Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
CRC	cis	rs4700695	0.841	rs251325	chr5:65269618	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.24	0.37	3.26e-12	Facial morphology (factor 19);
CRC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.61	-6.97	-0.36	1.76e-11	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.81	11.35	0.53	2.08e-25	Height;
CRC	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg16358738	chr2:241808595	AGXT	-0.41	-7.06	-0.36	9.73e-12	Urinary metabolites;
CRC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.76	0.3	1.92e-8	Ulcerative colitis;
CRC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg20885578	chr2:198174922	NA	-0.43	-6.83	-0.35	4.03e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.33e-9	Heart rate;
CRC	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg18827107	chr12:86230957	RASSF9	0.37	5.81	0.3	1.5e-8	Major depressive disorder;
CRC	cis	rs73206853	0.841	rs55741511	chr12:110880613	G/T	cg12870014	chr12:110450643	ANKRD13A	0.75	6.53	0.34	2.44e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs77633900	0.772	rs387321	chr15:76743565	A/G	cg21673338	chr15:77095150	SCAPER	-0.69	-6.07	-0.32	3.6e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.83	-9.31	-0.46	1.86e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6681460	0.898	rs536527	chr1:67193793	A/C	cg02459107	chr1:67143332	SGIP1	0.37	6.47	0.34	3.62e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.37	6.28e-12	Reticulocyte fraction of red cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11021810	chr14:89720620	FOXN3	-0.38	-6.41	-0.33	5.07e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.78	-8.85	-0.44	5.46e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.53	-7.72	-0.39	1.44e-13	Monocyte count;
CRC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg12927641	chr6:109611667	NA	-0.37	-6.71	-0.35	8.55e-11	Reticulocyte fraction of red cells;
CRC	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.32	-5.74	-0.3	2.19e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.37	-6.07	-0.32	3.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.2	14.06	0.61	1.69e-35	Uric acid levels;
CRC	cis	rs7274811	0.711	rs291689	chr20:32003974	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.38	5.81	0.3	1.51e-8	Height;
CRC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.51	-0.38	5.64e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.61	-7.98	-0.4	2.42e-14	Extraversion;
CRC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.92	-15.68	-0.65	8.93e-42	Height;
CRC	cis	rs4731207	0.698	rs886704	chr7:124422266	C/T	cg23710748	chr7:124431027	NA	-0.37	-5.85	-0.31	1.16e-8	Cutaneous malignant melanoma;
CRC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-1.03	-20.89	-0.76	2.86e-62	Headache;
CRC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.54	8.76	0.44	1.02e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg11887960	chr12:57824829	NA	0.66	7.1	0.36	7.76e-12	Obesity-related traits;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.67	7.86	0.4	5.71e-14	Body mass index;
CRC	cis	rs4965359	0.643	rs2924846	chr15:101598522	A/G	cg01350081	chr15:101592003	LRRK1	-0.35	-5.96	-0.31	6.48e-9	Central corneal thickness;
CRC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg23071808	chr14:103021642	NA	-0.64	-7.19	-0.37	4.38e-12	Platelet count;
CRC	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg00919237	chr7:87102261	ABCB4	-0.54	-7.09	-0.36	8.37e-12	Gallbladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20140173	chr1:155036019	EFNA4	0.44	6.17	0.32	2.05e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16369786	chr1:63153804	DOCK7	0.46	6.43	0.33	4.4e-10	Response to antipsychotic treatment;
CRC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.79	8.44	0.42	1.05e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg08501292	chr6:25962987	TRIM38	0.84	7.76	0.39	1.1e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2811415	0.597	rs1042907	chr3:127789172	G/C	cg13719885	chr3:127795394	NA	-0.4	-6.05	-0.32	3.83e-9	Lung function (FEV1/FVC);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01637218	chr1:29063669	YTHDF2	0.42	5.99	0.31	5.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.75	9.38	0.46	1.07e-18	Type 2 diabetes;
CRC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.33	-0.33	8.09e-10	Schizophrenia;
CRC	cis	rs4523957	0.928	rs8066372	chr17:2180968	A/G	cg16513277	chr17:2031491	SMG6	-0.54	-9.12	-0.45	7.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.45	-0.5	2.99e-22	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7671189	0.522	rs13113451	chr4:11744920	A/G	cg18054620	chr5:111191530	C5orf13	-0.3	-5.99	-0.31	5.43e-9	Obesity-related traits;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07491357	chr18:9914943	VAPA	0.46	6.04	0.32	4.22e-9	Survival in pancreatic cancer;
CRC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.3	6.2	0.32	1.71e-9	Homoarginine levels;
CRC	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.76	-10.46	-0.5	2.65e-22	White matter hyperintensity burden;
CRC	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg24046110	chr8:143859143	LYNX1	-0.37	-6.38	-0.33	6.16e-10	Urinary tract infection frequency;
CRC	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.55	9.47	0.46	5.8e-19	Schizophrenia;
CRC	cis	rs2346160	0.867	rs206975	chr6:167690356	A/G	cg27333441	chr6:167680455	NA	-0.38	-6.43	-0.33	4.4e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg16797656	chr11:68205561	LRP5	0.38	6.07	0.32	3.52e-9	Total body bone mineral density;
CRC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.85	15.68	0.65	9.21e-42	Lewy body disease;
CRC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.94	-0.36	2.06e-11	IgG glycosylation;
CRC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg20302533	chr7:39170763	POU6F2	0.41	5.66	0.3	3.38e-8	IgG glycosylation;
CRC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-10.37	-0.5	5.62e-22	Schizophrenia;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.45	-0.38	8.45e-13	Breast cancer;
CRC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.82	10.28	0.49	1.08e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.42	-0.33	4.73e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.53	-8.53	-0.43	5.37e-16	Aortic root size;
CRC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.62	-0.47	1.86e-19	Monocyte count;
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg25164649	chr6:28176230	NA	0.57	6.12	0.32	2.72e-9	Depression;
CRC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.89	-14.05	-0.61	1.85e-35	Height;
CRC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-17.13	-0.69	1.81e-47	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-6.86	-0.35	3.35e-11	HDL cholesterol;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg24829313	chr11:63684597	RCOR2	0.35	5.99	0.31	5.39e-9	Body mass index;
CRC	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.94	-14.98	-0.64	4.65e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs995000	0.868	rs1007205	chr1:62936912	T/C	cg19896129	chr1:63156450	NA	-0.44	-6.75	-0.35	6.68e-11	Triglyceride levels;
CRC	cis	rs3996993	0.724	rs2749029	chr6:52631188	A/G	cg20803780	chr6:52668592	GSTA1	-0.33	-5.9	-0.31	8.79e-9	Hemoglobin concentration;
CRC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.81	-0.55	4.64e-27	Type 2 diabetes;
CRC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.64	-10.4	-0.5	4.17e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg07718321	chr6:96025334	MANEA	0.49	5.81	0.3	1.51e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg09455208	chr3:40491958	NA	0.34	6.98	0.36	1.63e-11	Renal cell carcinoma;
CRC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.2	-0.37	4.19e-12	Morning vs. evening chronotype;
CRC	cis	rs17092148	0.887	rs6059919	chr20:33151545	G/T	cg08999081	chr20:33150536	PIGU	0.52	6.34	0.33	7.61e-10	Neuroticism;
CRC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg00734567	chr1:86172782	ZNHIT6	-0.48	-7.3	-0.37	2.21e-12	Urate levels in overweight individuals;
CRC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13198984	chr17:80129470	CCDC57	0.45	7.89	0.4	4.6e-14	Life satisfaction;
CRC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.38	-7.09	-0.36	8.02e-12	Mean corpuscular volume;
CRC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.7	-13.48	-0.6	2.8e-33	Prudent dietary pattern;
CRC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg17958423	chr11:6947583	ZNF215	0.53	5.63	0.3	3.81e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23375783	chr17:73008576	ICT1	0.39	6.3	0.33	9.7e-10	Obesity-related traits;
CRC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.73	-8.33	-0.42	2.18e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.32	5.64	0.3	3.72e-8	Erythrocyte sedimentation rate;
CRC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	7.29	0.37	2.32e-12	Menarche (age at onset);
CRC	cis	rs7712401	0.791	rs6887101	chr5:122109207	C/T	cg18764291	chr5:122110994	SNX2	-0.41	-6.44	-0.33	4.16e-10	Mean platelet volume;
CRC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.71	-0.39	1.47e-13	Hemoglobin concentration;
CRC	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg11887960	chr12:57824829	NA	0.59	6.73	0.35	7.55e-11	Obesity-related traits;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg25164649	chr6:28176230	NA	0.72	9.0	0.44	1.82e-17	Depression;
CRC	trans	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.12	-0.32	2.7e-9	Educational attainment (years of education);
CRC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.92	17.22	0.69	8.15e-48	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.63	9.66	0.47	1.3e-19	Testicular germ cell tumor;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18591801	chr3:52553433	STAB1	-0.31	-5.91	-0.31	8.35e-9	Electroencephalogram traits;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.65	-0.39	2.23e-13	Breast cancer;
CRC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.62	-10.82	-0.51	1.5e-23	Calcium levels;
CRC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.48	-8.24	-0.41	4.17e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg03030879	chr14:75389066	RPS6KL1	-0.5	-8.07	-0.41	1.3e-14	Caffeine consumption;
CRC	cis	rs7527798	0.592	rs10863461	chr1:207840776	C/T	cg09232269	chr1:207846808	CR1L	-0.51	-8.33	-0.42	2.2e-15	Erythrocyte sedimentation rate;
CRC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.01	-0.31	4.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.43	6.38	0.33	6.11e-10	Red blood cell count;
CRC	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg22182287	chr2:3452347	TTC15	0.38	5.96	0.31	6.57e-9	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.75	0.39	1.14e-13	Menopause (age at onset);
CRC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.08	20.35	0.75	3.48e-60	Triglycerides;
CRC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg21747405	chr11:67723411	NA	-0.44	-6.26	-0.33	1.23e-9	Blood pressure (smoking interaction);
CRC	cis	rs7113874	0.524	rs9734055	chr11:8577236	C/A	cg02811074	chr11:8615871	STK33	-0.34	-5.87	-0.31	1.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04045327	chr4:905805	GAK	0.44	7.67	0.39	1.94e-13	Systemic sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00846248	chr7:86849067	C7orf23	0.38	6.0	0.31	5.09e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05307864	chr6:160559487	SLC22A1	0.39	6.04	0.32	4.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.75	12.66	0.57	3.36e-30	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.7	9.47	0.46	5.57e-19	Platelet count;
CRC	cis	rs4903604	0.581	rs41347855	chr14:78037909	C/T	cg18872420	chr14:78023429	SPTLC2	0.35	6.06	0.32	3.63e-9	Gut microbiome composition (winter);
CRC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.39	6.08	0.32	3.37e-9	Crohn's disease;
CRC	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.51	-8.0	-0.4	2.11e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.51	6.66	0.34	1.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs3741151	0.773	rs7934218	chr11:73206729	C/T	cg17517138	chr11:73019481	ARHGEF17	0.55	5.84	0.31	1.25e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg08075719	chr14:103021372	NA	-0.61	-7.48	-0.38	6.67e-13	Platelet count;
CRC	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg19338460	chr6:170058176	WDR27	-0.76	-8.3	-0.42	2.78e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4664293	0.625	rs6722715	chr2:160525026	T/C	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.67e-10	Monocyte percentage of white cells;
CRC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.94	-17.28	-0.69	4.54e-48	Height;
CRC	cis	rs7527798	0.592	rs960086	chr1:207827069	A/G	cg09232269	chr1:207846808	CR1L	-0.45	-7.31	-0.37	2.02e-12	Erythrocyte sedimentation rate;
CRC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.42	6.91	0.36	2.49e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.31	0.33	8.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15803122	chr17:75277207	SEPT9	0.44	6.29	0.33	9.84e-10	Anxiety disorder;
CRC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.83	14.18	0.62	6.16e-36	Blood protein levels;
CRC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.43	0.46	7.76e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11725182	chr1:5968678	NPHP4	-0.38	-6.32	-0.33	8.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg05304507	chr6:116381966	FRK	0.29	6.52	0.34	2.61e-10	Total cholesterol levels;
CRC	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg26893134	chr6:116381904	FRK	0.25	6.14	0.32	2.33e-9	Total cholesterol levels;
CRC	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg18335740	chr13:41363409	SLC25A15	0.53	7.94	0.4	3.22e-14	Lewy body disease;
CRC	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg09344028	chr17:70110421	NA	0.43	6.63	0.34	1.41e-10	Thyroid hormone levels;
CRC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.71	-0.3	2.49e-8	Daytime sleep phenotypes;
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11645453	chr3:52864694	ITIH4	0.38	6.62	0.34	1.47e-10	Bipolar disorder;
CRC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg22535103	chr8:58192502	C8orf71	-0.44	-6.15	-0.32	2.23e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.57	5.99	0.31	5.47e-9	Initial pursuit acceleration;
CRC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08462924	chr1:41848221	NA	0.45	7.03	0.36	1.2e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	1.14	11.5	0.54	5.77e-26	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.63	7.0	0.36	1.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.68	11.48	0.53	6.86e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg02560186	chr11:3602584	NA	-0.44	-6.06	-0.32	3.72e-9	Blood pressure (smoking interaction);
CRC	cis	rs12580194	0.593	rs57050414	chr12:55776926	G/A	cg19537932	chr12:55886519	OR6C68	-0.75	-9.21	-0.45	3.8e-18	Cancer;
CRC	trans	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg13565492	chr6:43139072	SRF	-0.71	-7.12	-0.37	7.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10865541	0.967	rs6755448	chr2:3397359	T/C	cg22182287	chr2:3452347	TTC15	0.38	5.92	0.31	7.9e-9	Obesity-related traits;
CRC	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.61	-0.34	1.58e-10	Monocyte count;
CRC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.73	7.61	0.39	2.93e-13	Gut microbiome composition (summer);
CRC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.37	5.64	0.3	3.62e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.72	7.36	0.38	1.52e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.34	-6.59	-0.34	1.78e-10	Breast cancer;
CRC	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.83	0.35	4.05e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.68	10.18	0.49	2.4e-21	Menarche (age at onset);
CRC	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.16e-10	Obesity-related traits;
CRC	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs427941	0.632	rs201478	chr7:101746964	G/C	cg06246474	chr7:101738831	CUX1	0.43	6.62	0.34	1.45e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg09184832	chr6:79620586	NA	-0.46	-8.02	-0.4	1.93e-14	Intelligence (multi-trait analysis);
CRC	cis	rs8067545	1.000	rs7218708	chr17:19926836	A/G	cg13482628	chr17:19912719	NA	0.52	8.08	0.41	1.24e-14	Schizophrenia;
CRC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.83	10.98	0.52	4.16e-24	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.861	rs918299	chr11:65927607	C/T	cg16950941	chr11:66035639	RAB1B	-0.58	-7.24	-0.37	3.27e-12	Electroencephalogram traits;
CRC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.63	-9.96	-0.48	1.31e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.9	-13.43	-0.6	4.19e-33	Gut microbiome composition (summer);
CRC	trans	rs2303319	0.504	rs12467662	chr2:162386784	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Cognitive function;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg25164649	chr6:28176230	NA	0.67	9.19	0.45	4.68e-18	Parkinson's disease;
CRC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.28	-0.46	2.37e-18	Morning vs. evening chronotype;
CRC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.36	0.53	1.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.1	26.81	0.83	9.1200000000000006e-85	Testicular germ cell tumor;
CRC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg01849466	chr14:104193079	ZFYVE21	0.35	5.72	0.3	2.37e-8	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06805572	chr2:10444432	HPCAL1	0.47	6.55	0.34	2.24e-10	Response to antipsychotic treatment;
CRC	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.38	-6.54	-0.34	2.29e-10	Vitamin D levels;
CRC	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.66	10.21	0.49	1.98e-21	Itch intensity from mosquito bite;
CRC	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg17640201	chr16:30407289	ZNF48	0.44	6.44	0.33	4.16e-10	Tonsillectomy;
CRC	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg25856811	chr1:152973957	SPRR3	-0.21	-5.66	-0.3	3.22e-8	Inflammatory skin disease;
CRC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.44	6.72	0.35	8.13e-11	Mean platelet volume;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg21769114	chr3:32726526	CNOT10	-0.45	-6.6	-0.34	1.64e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2327429	0.541	rs12193973	chr6:134151297	A/G	cg06296503	chr6:134217401	NA	-0.37	-5.81	-0.31	1.47e-8	Coronary artery disease;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg07217954	chr7:1067459	C7orf50	0.56	5.75	0.3	2e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.33	-0.33	7.93e-10	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01258499	chr20:30540016	PDRG1	0.41	6.02	0.31	4.7e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05951993	chr19:49496864	GYS1;RUVBL2	0.46	6.62	0.34	1.45e-10	Response to antipsychotic treatment;
CRC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.64	8.87	0.44	4.91e-17	Coronary artery disease;
CRC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.55	0.34	2.19e-10	Schizophrenia;
CRC	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	7.84	0.4	6.23e-14	Menarche (age at onset);
CRC	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.52	7.01	0.36	1.4e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg02683197	chr6:28174875	NA	0.6	8.08	0.41	1.25e-14	Parkinson's disease;
CRC	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.74	7.49	0.38	6.43e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg26061582	chr7:22766209	IL6	0.53	8.03	0.4	1.77e-14	Lung cancer;
CRC	cis	rs4280164	0.945	rs2281472	chr14:24775846	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.58	6.95	0.36	1.97e-11	Parent of origin effect on language impairment (paternal);
CRC	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.63	-8.3	-0.42	2.64e-15	Malaria;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.44	-6.33	-0.33	8.19e-10	Parkinson's disease;
CRC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.52	0.46	3.83e-19	Monocyte percentage of white cells;
CRC	cis	rs3026445	0.926	rs28609096	chr12:110815922	A/G	cg12870014	chr12:110450643	ANKRD13A	0.37	5.76	0.3	1.96e-8	QT interval;
CRC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.47	6.5	0.34	2.97e-10	Eosinophil percentage of white cells;
CRC	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.57	-8.68	-0.43	1.81e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	11.19	0.52	7.86e-25	Bone mineral density;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg08584628	chr5:178286875	ZNF354B	0.48	6.27	0.33	1.16e-9	Hip circumference;
CRC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.81	-0.51	1.7e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.44	0.38	8.72e-13	Breast cancer;
CRC	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg25019722	chr6:37503610	NA	-0.47	-8.76	-0.43	1.05e-16	Cognitive performance;
CRC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg10589385	chr1:150898437	SETDB1	0.33	6.98	0.36	1.68e-11	Melanoma;
CRC	cis	rs9914988	0.576	rs67777803	chr17:27323322	G/T	cg16670446	chr17:27188758	MIR451;MIR144	0.47	6.45	0.34	3.97e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.7	7.38	0.38	1.31e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Corneal astigmatism;
CRC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.6	8.0	0.4	2.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-6.69	-0.35	9.54e-11	Systemic lupus erythematosus;
CRC	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.97	-0.44	2.34e-17	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs9469578	1.000	rs60447213	chr6:33715159	G/T	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.67e-18	Parkinson's disease;
CRC	trans	rs1607741	1.000	rs10005014	chr4:72712010	C/T	cg06437464	chr6:127441704	RSPO3	-0.29	-6.13	-0.32	2.48e-9	Vitamin D levels;
CRC	cis	rs6788895	1.000	rs6803830	chr3:150510579	A/G	cg09723797	chr3:150481914	SIAH2	0.89	5.93	0.31	7.58e-9	Breast cancer;
CRC	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.6	8.79	0.44	8.19e-17	Multiple myeloma (IgH translocation);
CRC	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.71	-8.17	-0.41	6.71e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.51	-6.31	-0.33	8.78e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.94	-0.55	1.47e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg21251018	chr6:28226885	NKAPL	0.43	6.18	0.32	1.86e-9	Parkinson's disease;
CRC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg13390004	chr1:15929781	NA	0.5	7.06	0.36	1.02e-11	Systolic blood pressure;
CRC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg03030879	chr14:75389066	RPS6KL1	0.46	7.2	0.37	4.2e-12	Height;
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg12516270	chr8:143859308	LYNX1	0.43	7.46	0.38	7.89e-13	Urinary tract infection frequency;
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02359409	chr6:42947317	PEX6	-0.58	-9.23	-0.45	3.46e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg03013999	chr17:37608204	MED1	0.47	7.21	0.37	3.76e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.59	-0.34	1.72e-10	Cognitive function;
CRC	cis	rs9463078	0.505	rs2038556	chr6:44740568	A/G	cg25276700	chr6:44698697	NA	0.3	7.76	0.39	1.09e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg09829573	chr1:144692074	NBPF9	-0.4	-6.05	-0.32	3.87e-9	Hip geometry;
CRC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg00976097	chr5:421733	AHRR	-0.45	-6.08	-0.32	3.28e-9	Cystic fibrosis severity;
CRC	cis	rs4654899	0.861	rs10916876	chr1:21169996	T/C	cg02927042	chr1:21476669	EIF4G3	0.42	6.7	0.35	8.96e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg00469287	chr7:23338798	C7orf30	0.43	5.82	0.31	1.42e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	11.09	0.52	1.78e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6700896	0.966	rs3790439	chr1:66085574	T/A	cg04111102	chr1:66153794	NA	0.33	5.95	0.31	6.81e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.16	0.49	2.93e-21	Heart rate;
CRC	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.4	-7.12	-0.37	6.65e-12	Rheumatoid arthritis;
CRC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.64	-11.32	-0.53	2.6e-25	Coronary artery disease;
CRC	cis	rs10242455	0.702	rs6977165	chr7:99269397	T/C	cg18809830	chr7:99032528	PTCD1	-1.04	-7.41	-0.38	1.05e-12	Blood metabolite levels;
CRC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.39	6.23	0.32	1.46e-9	Total body bone mineral density;
CRC	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	0.96	8.96	0.44	2.53e-17	Pulse pressure;
CRC	cis	rs3857067	1.000	rs1904094	chr4:95012459	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.46	-7.09	-0.36	8.36e-12	Coronary artery disease;
CRC	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.42	6.63	0.34	1.39e-10	Glucocorticoid-induced osteonecrosis (age 10 years and older);
CRC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.81	-0.31	1.47e-8	Total body bone mineral density;
CRC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.48	-7.26	-0.37	2.88e-12	Total body bone mineral density;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg05370988	chr3:186500739	EIF4A2	-0.45	-6.13	-0.32	2.53e-9	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs13201294	1	rs13201294	chr6:27556141	A/T	cg26958806	chr6:27640298	NA	0.84	6.41	0.33	5.07e-10	Squamous cell lung carcinoma;
CRC	trans	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.42	-0.38	1.01e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.81	0.31	1.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs17807624	0.780	rs11250152	chr8:11454200	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.1	-0.32	2.91e-9	Systemic lupus erythematosus;
CRC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.62	-10.19	-0.49	2.18e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg02254261	chr7:158964346	NA	-0.53	-6.0	-0.31	5.3300000000000004e-09	Myopia (pathological);
CRC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.54	-8.11	-0.41	1e-14	Blood protein levels;
CRC	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.55	-8.99	-0.44	2.04e-17	Congenital heart disease (maternal effect);
CRC	cis	rs12024301	0.557	rs10797901	chr1:183663303	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.52	-0.34	2.59e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.9	-0.31	8.93e-9	Total body bone mineral density;
CRC	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.62	7.7	0.39	1.58e-13	Intelligence (multi-trait analysis);
CRC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-1.18	-11.7	-0.54	1.1e-26	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg00343986	chr7:65444356	GUSB	0.45	6.65	0.34	1.25e-10	Aortic root size;
CRC	trans	rs7690467	0.794	rs1875024	chr4:133395895	C/T	cg05523500	chr3:73046033	PPP4R2	-0.45	-6.16	-0.32	2.13e-9	Eating disorders;
CRC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.69	11.78	0.54	5.97e-27	Mean corpuscular volume;
CRC	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.85	-0.31	1.16e-8	Blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00052422	chr3:41240987	CTNNB1	0.44	6.67	0.35	1.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6761276	0.932	rs10186133	chr2:113836944	G/T	cg09040174	chr2:113837401	NA	0.65	9.8	0.48	4.48e-20	Protein quantitative trait loci;
CRC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.5	-7.08	-0.36	8.57e-12	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23350889	chr12:133100618	FBRSL1	0.45	6.15	0.32	2.19e-9	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04784101	chr11:66824465	RHOD	0.38	6.19	0.32	1.75e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9287719	0.578	rs10175555	chr2:10703233	T/C	cg00105475	chr2:10696890	NA	0.48	7.25	0.37	2.99e-12	Prostate cancer;
CRC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.6	8.84	0.44	5.75e-17	Morning vs. evening chronotype;
CRC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg02175503	chr12:58329896	NA	0.5	5.99	0.31	5.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.59	7.13	0.37	6.35e-12	Carotid intima media thickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08269949	chr6:26538502	HMGN4	0.53	7.06	0.36	9.99e-12	Thyroid stimulating hormone;
CRC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-14.41	-0.62	8.04e-37	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.45e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg20744362	chr22:50050164	C22orf34	0.32	5.82	0.31	1.38e-8	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg06494592	chr3:125709126	NA	-0.58	-6.89	-0.35	2.9100000000000002e-11	Blood pressure (smoking interaction);
CRC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.54	8.53	0.43	5.26e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2882667	0.690	rs700629	chr5:138123994	T/G	cg09476006	chr5:138032270	NA	-0.59	-10.75	-0.51	2.69e-23	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg20203395	chr5:56204925	C5orf35	-0.69	-8.24	-0.41	4.19e-15	Initial pursuit acceleration;
CRC	trans	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg18288967	chr1:45987694	PRDX1	0.62	6.87	0.35	3.27e-11	Obesity-related traits;
CRC	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14119001	chr9:139324193	INPP5E	-0.44	-6.18	-0.32	1.91e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.62	-0.34	1.48e-10	Neuroticism;
CRC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-6.59	-0.34	1.73e-10	Bipolar disorder;
CRC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.38	6.57	0.34	1.99e-10	NT-proBNP levels in acute coronary syndrome;
CRC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.71	10.96	0.52	5.0600000000000004e-24	Corneal astigmatism;
CRC	cis	rs17767392	1.000	rs34524083	chr14:71858372	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17219203	chr10:38645113	HSD17B7P2	0.41	5.98	0.31	5.92e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7605827	0.930	rs4410258	chr2:15594984	A/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.14e-9	Educational attainment (years of education);
CRC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	5.87	0.31	1.05e-8	Response to antipsychotic treatment;
CRC	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.32	-5.98	-0.31	5.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-7.88	-0.4	4.8e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-15.07	-0.64	2.12e-39	Blood metabolite levels;
CRC	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.74	-10.24	-0.49	1.52e-21	Smoking behavior;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg06781209	chr11:61594997	FADS2	-0.77	-8.84	-0.44	6.1e-17	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.1	-0.36	7.96e-12	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10513480	chr14:21852135	SUPT16H	0.41	6.33	0.33	8.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.67	9.42	0.46	8.41e-19	Multiple sclerosis;
CRC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg11292332	chr7:45801988	SEPT13	-0.38	-6.81	-0.35	4.75e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-7.76	-0.39	1.1e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.66	10.34	0.5	7.03e-22	Gestational age at birth (maternal effect);
CRC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.43	6.58	0.34	1.81e-10	Longevity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09584155	chr16:25026271	ARHGAP17	0.41	6.08	0.32	3.4e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02996269	chr4:106394692	PPA2	0.43	6.38	0.33	6.11e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg20387954	chr3:183756860	HTR3D	0.37	6.35	0.33	7.1e-10	Anterior chamber depth;
CRC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.65	10.59	0.5	9.77e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg20203395	chr5:56204925	C5orf35	0.73	8.94	0.44	2.85e-17	Initial pursuit acceleration;
CRC	cis	rs2108622	0.701	rs3093209	chr19:15988420	G/C	cg13772218	chr19:15982569	NA	0.48	6.75	0.35	6.72e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.45	-6.39	-0.33	5.8e-10	Mean platelet volume;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg24046110	chr8:143859143	LYNX1	-0.43	-6.55	-0.34	2.2e-10	Urinary tract infection frequency;
CRC	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.56	-9.14	-0.45	6.57e-18	Schizophrenia;
CRC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.48	8.45	0.42	9.35e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.11e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-5.87	-0.31	1.05e-8	Arsenic metabolism;
CRC	cis	rs9463078	0.605	rs9472409	chr6:44926431	A/G	cg25276700	chr6:44698697	NA	0.25	6.2	0.32	1.69e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.26	0.33	1.23e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.64e-9	Bipolar disorder;
CRC	trans	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.95	-0.31	6.71e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.81	-0.4	7.92e-14	Aortic root size;
CRC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-13.31	-0.59	1.28e-32	Vitiligo;
CRC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.58	8.76	0.43	1.04e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9658691	0.920	rs36206197	chr10:90748602	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-6.3	-0.33	9.41e-10	Mosquito bite size;
CRC	cis	rs524281	0.814	rs1055615	chr11:65846922	C/G	cg14036092	chr11:66035641	RAB1B	-0.5	-6.25	-0.33	1.24e-9	Electroencephalogram traits;
CRC	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.32	-0.33	8.72e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-5.62	-0.3	4.13e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7739232	0.749	rs76994901	chr6:53528523	T/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.55	9.36	0.46	1.24e-18	Dupuytren's disease;
CRC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.44	-9.91	-0.48	1.93e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-0.98	-21.12	-0.76	3.63e-63	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.39	6.31	0.33	9.19e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg10876282	chr6:28092338	ZSCAN16	0.5	6.72	0.35	7.89e-11	Cardiac Troponin-T levels;
CRC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.42	6.33e-16	Prostate cancer;
CRC	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-12.18	-0.56	2e-28	Chronic sinus infection;
CRC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.5	7.08	0.36	8.97e-12	Cognitive ability;
CRC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.53	-7.16	-0.37	5.31e-12	DNA methylation (variation);
CRC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-0.9	-10.29	-0.49	1.01e-21	Breast cancer;
CRC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.45	-7.48	-0.38	6.79e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg16141378	chr3:129829833	LOC729375	-0.51	-7.81	-0.4	7.99e-14	Mood instability;
CRC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-0.95	-9.33	-0.46	1.66e-18	Breast cancer;
CRC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.58	9.01	0.44	1.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg27398640	chr15:77910606	LINGO1	0.44	7.64	0.39	2.35e-13	Type 2 diabetes;
CRC	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg25797454	chr6:150327115	RAET1K	0.37	6.45	0.34	3.96e-10	Alopecia areata;
CRC	cis	rs10152831	1	rs10152831	chr15:91059190	C/T	cg04176472	chr15:90893244	GABARAPL3	0.55	7.88	0.4	4.85e-14	Neutrophil percentage of white cells;
CRC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.02	0.32	4.59e-9	Rheumatoid arthritis;
CRC	cis	rs7932354	0.502	rs7118546	chr11:47087128	C/G	cg03339077	chr11:47165057	C11orf49	0.44	6.16	0.32	2.18e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.83	18.32	0.71	3.53e-52	Breast cancer;
CRC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg02993699	chr4:3415135	RGS12	-0.4	-6.61	-0.34	1.52e-10	Serum sulfate level;
CRC	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg21918786	chr6:109611834	NA	-0.35	-5.93	-0.31	7.65e-9	Reticulocyte fraction of red cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19978540	chr12:3409405	NA	0.41	6.08	0.32	3.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.53	0.54	4.61e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.67	11.54	0.54	4.41e-26	White blood cell count (basophil);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00098112	chr12:42631803	YAF2	0.45	6.08	0.32	3.25e-9	Anxiety disorder;
CRC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg12046867	chr14:103022105	NA	-0.83	-11.62	-0.54	2.25e-26	Platelet count;
CRC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-9.06	-0.45	1.15e-17	Menarche (age at onset);
CRC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.81	-11.32	-0.53	2.64e-25	Parkinson's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07312579	chr9:35096654	PIGO	0.4	6.04	0.32	4.21e-9	Interleukin-6 levels;
CRC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.84	-10.05	-0.48	6.63e-21	Bronchopulmonary dysplasia;
CRC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg02869306	chr7:64672164	INTS4L1	0.34	5.63	0.3	3.96e-8	Calcium levels;
CRC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.32	-0.71	3.68e-52	Height;
CRC	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.54	6.76	0.35	6.34e-11	Pulse pressure;
CRC	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	6.8	0.35	4.99e-11	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.72	8.25	0.41	3.88e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.08	14.62	0.63	1.25e-37	Vitiligo;
CRC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg11189052	chr15:85197271	WDR73	0.6	8.54	0.43	5.17e-16	Schizophrenia;
CRC	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02598441	chr17:62777298	LOC146880	0.53	7.09	0.36	8.29e-12	QT interval;
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18758796	chr5:131593413	PDLIM4	0.44	8.13	0.41	8.61e-15	Breast cancer;
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg06713098	chr7:45960367	IGFBP3	0.42	6.69	0.35	9.85e-11	Sitting height ratio;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.17	-0.32	2.04e-9	Total body bone mineral density;
CRC	cis	rs9549328	0.565	rs36145949	chr13:113616608	T/C	cg25790453	chr13:113633590	MCF2L	0.43	7.55	0.38	4.25e-13	Systolic blood pressure;
CRC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24308560	chr3:49941425	MST1R	-0.45	-7.06	-0.36	9.94e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7215564	0.818	rs1471790	chr17:78670565	C/A	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.09e-9	Myopia (pathological);
CRC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg10570241	chr7:158785291	NA	0.41	7.25	0.37	3.09e-12	Facial morphology (factor 20);
CRC	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg10517650	chr3:113235015	CCDC52	-0.4	-6.95	-0.36	1.98e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg03938978	chr2:103052716	IL18RAP	0.4	6.24	0.33	1.34e-9	Blood protein levels;
CRC	cis	rs294883	0.858	rs2879864	chr6:159712848	A/G	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg18876405	chr7:65276391	NA	-0.46	-6.32	-0.33	8.27e-10	Aortic root size;
CRC	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06307176	chr5:131281290	NA	0.45	6.45	0.34	3.91e-10	Life satisfaction;
CRC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.4	-6.7	-0.35	8.83e-11	Testicular germ cell tumor;
CRC	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg18200150	chr17:30822561	MYO1D	0.44	8.61	0.43	3.07e-16	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12667521	chr19:29218732	NA	-0.42	-5.71	-0.3	2.57e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs10128264	0.841	rs2790766	chr10:80960616	A/G	cg20744163	chr10:80999841	ZMIZ1	0.42	7.81	0.4	7.99e-14	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.69	9.97	0.48	1.28e-20	Body mass index;
CRC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.54	-8.06	-0.41	1.45e-14	Aortic root size;
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.5	6.78	0.35	5.6e-11	Height;
CRC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.49	-0.46	4.87e-19	Platelet count;
CRC	cis	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg18809830	chr7:99032528	PTCD1	0.92	6.98	0.36	1.66e-11	Blood metabolite levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02096607	chr11:27493868	LGR4	0.33	6.11	0.32	2.83e-9	Interleukin-6 levels;
CRC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg15848620	chr12:58087721	OS9	-0.63	-8.94	-0.44	2.88e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs728616	0.867	rs17096197	chr10:81808184	T/C	cg11900509	chr10:81946545	ANXA11	-0.57	-6.19	-0.32	1.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs2303319	0.504	rs55782047	chr2:162440255	A/C	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.42e-9	Cognitive function;
CRC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.68	-10.19	-0.49	2.27e-21	Menarche (age at onset);
CRC	cis	rs3018066	0.748	rs12510966	chr4:106983604	A/G	cg01869342	chr4:106983673	TBCK	0.46	6.76	0.35	6.35e-11	Cancer;
CRC	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.54	-8.23	-0.41	4.31e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.17	-13.55	-0.6	1.59e-33	Diabetic kidney disease;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg16606324	chr3:10149918	C3orf24	0.62	7.1	0.36	7.6e-12	Alzheimer's disease;
CRC	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.46	-5.79	-0.3	1.65e-8	Aortic root size;
CRC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.68	10.54	0.5	1.45e-22	Corneal astigmatism;
CRC	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.41	7.12	0.37	6.97e-12	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg03623178	chr6:28175578	NA	0.75	6.63	0.34	1.39e-10	Depression;
CRC	trans	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg18288967	chr1:45987694	PRDX1	0.67	7.43	0.38	9.3e-13	Obesity-related traits;
CRC	cis	rs17155006	0.655	rs448742	chr7:107733993	C/T	cg05962710	chr7:107745446	LAMB4	0.36	6.14	0.32	2.38e-9	Pneumococcal bacteremia;
CRC	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-5.83	-0.31	1.36e-8	Height;
CRC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.69	-7.76	-0.39	1.08e-13	Body mass index;
CRC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.64	-8.84	-0.44	5.78e-17	Coronary artery disease;
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-9.74	-0.47	7.31e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9648716	1.000	rs1267634	chr7:140490382	C/T	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.1e-8	Type 2 diabetes;
CRC	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.51	-7.12	-0.37	6.68e-12	Tuberculosis;
CRC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.53	-7.26	-0.37	2.82e-12	DNA methylation (variation);
CRC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.49	7.86	0.4	5.61e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.46	-7.12	-0.37	6.83e-12	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22715954	chr12:58146426	CDK4	0.46	6.79	0.35	5.31e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7487075	0.619	rs12822345	chr12:46834677	G/C	cg22049899	chr12:47219821	SLC38A4	0.32	5.78	0.3	1.77e-8	Itch intensity from mosquito bite;
CRC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.65e-9	Aortic root size;
CRC	trans	rs948562	0.947	rs11541682	chr11:58385752	T/C	cg26660744	chr1:1573181	CDK11B	0.54	6.1	0.32	2.94e-9	Lymphoma;
CRC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.66	9.21	0.45	3.84e-18	Neuroblastoma;
CRC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.56	6.15	0.32	2.29e-9	Initial pursuit acceleration;
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg22687807	chr8:143858763	LYNX1	0.49	8.92	0.44	3.32e-17	Urinary tract infection frequency;
CRC	cis	rs10512697	0.655	rs13171097	chr5:3512130	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs10426930	0.752	rs56249413	chr19:5036730	G/A	cg18473234	chr19:5097819	KDM4B	0.47	5.84	0.31	1.22e-8	Monocyte percentage of white cells;
CRC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.36	6.61	0.34	1.58e-10	Blood protein levels;
CRC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.5	0.6	2.46e-33	Schizophrenia;
CRC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.64	9.87	0.48	2.67e-20	Colorectal cancer;
CRC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.33e-10	Childhood ear infection;
CRC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.85	0.35	3.66e-11	Neutrophil percentage of white cells;
CRC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.15	0.41	7.93e-15	Lung cancer;
CRC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	trans	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg26043149	chr18:55253948	FECH	0.55	8.26	0.41	3.67e-15	Bone mineral density;
CRC	cis	rs4964805	0.594	rs4981036	chr12:104164344	C/G	cg02344784	chr12:104178138	NT5DC3	0.47	7.2	0.37	4.06e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	14.05	0.61	1.83e-35	Platelet count;
CRC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.66	-10.75	-0.51	2.65e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.68	10.89	0.51	8.31e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-0.89	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.61	-7.5	-0.38	6e-13	Bronchopulmonary dysplasia;
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg15786705	chr6:28176104	NA	0.7	10.11	0.49	4.3e-21	Parkinson's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04590956	chr2:70057467	GMCL1	-0.5	-6.02	-0.31	4.55e-9	Diisocyanate-induced asthma;
CRC	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg12908607	chr1:44402522	ARTN	-0.42	-6.85	-0.35	3.64e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.55	8.68	0.43	1.88e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.77	-12.6	-0.57	5.8e-30	Obesity-related traits;
CRC	cis	rs7849270	0.879	rs7859344	chr9:131848382	T/A	cg13538475	chr9:131942899	NA	-0.3	-5.76	-0.3	1.97e-8	Blood metabolite ratios;
CRC	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg02158880	chr13:53174818	NA	0.45	6.34	0.33	7.77e-10	Lewy body disease;
CRC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.41	6.58	0.34	1.81e-10	Mood instability;
CRC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg21153622	chr11:89784906	NA	-0.37	-5.97	-0.31	6.05e-9	Height;
CRC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.65	7.3	0.37	2.16e-12	Body mass index;
CRC	cis	rs17095355	1.000	rs752584	chr10:111682934	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.54	-6.17	-0.32	1.97e-9	Biliary atresia;
CRC	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.2	-0.32	1.7e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.45	6.79	0.35	5.3e-11	Obesity-related traits;
CRC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.94	16.95	0.68	9.02e-47	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17095355	1.000	rs2419313	chr10:111750851	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.75	-0.39	1.12e-13	Biliary atresia;
CRC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.91	-0.31	8.68e-9	Reticulocyte count;
CRC	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg04586622	chr2:25135609	ADCY3	-0.57	-9.65	-0.47	1.41e-19	Body mass index;
CRC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.77	-12.84	-0.58	7.46e-31	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02010776	chr16:18938091	SMG1	0.44	6.24	0.33	1.37e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg18187862	chr3:45730750	SACM1L	0.46	6.58	0.34	1.83e-10	Primary sclerosing cholangitis;
CRC	cis	rs12620999	0.555	rs10199274	chr2:238111864	G/C	cg23555395	chr2:238036564	NA	-0.37	-5.77	-0.3	1.84e-8	Systemic lupus erythematosus;
CRC	cis	rs938554	0.784	rs1071988	chr4:9974638	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.63	-0.3	3.78e-8	Blood metabolite levels;
CRC	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	15.32	0.65	2.24e-40	Mean corpuscular hemoglobin;
CRC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.03e-9	Bladder cancer;
CRC	trans	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.94	0.36	2.11e-11	Mean corpuscular volume;
CRC	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg02466173	chr16:30829666	NA	-0.71	-8.71	-0.43	1.52e-16	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24508409	chr1:112298175	DDX20;C1orf183	0.41	6.71	0.35	8.69e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg26102564	chr10:131424627	MGMT	0.37	5.67	0.3	3.19e-8	Response to temozolomide;
CRC	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.38	-6.15	-0.32	2.21e-9	Type 2 diabetes;
CRC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.42	6.82	0.35	4.41e-11	Obesity-related traits;
CRC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg05754148	chr16:3507555	NAT15	-0.71	-6.78	-0.35	5.61e-11	Tuberculosis;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg22687807	chr8:143858763	LYNX1	-0.45	-7.45	-0.38	8.23e-13	Urinary tract infection frequency;
CRC	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.49	-9.19	-0.45	4.59e-18	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-6.13	-0.32	2.48e-9	Longevity;Endometriosis;
CRC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg16606324	chr3:10149918	C3orf24	-0.45	-6.9	-0.36	2.63e-11	Alzheimer's disease;
CRC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg06470822	chr6:28175283	NA	0.62	9.21	0.45	3.81e-18	Pubertal anthropometrics;
CRC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg23071808	chr14:103021642	NA	-0.64	-7.27	-0.37	2.72e-12	Platelet count;
CRC	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.52	9.14	0.45	6.57e-18	Common traits (Other);
CRC	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.51	9.61	0.47	1.93e-19	Educational attainment (years of education);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03311606	chr2:173292277	ITGA6	0.48	6.11	0.32	2.89e-9	Thyroid stimulating hormone;
CRC	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.49	-8.73	-0.43	1.28e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.87	-16.91	-0.68	1.34e-46	Body mass index;
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg15145296	chr3:125709740	NA	-0.6	-7.07	-0.36	9.42e-12	Blood pressure (smoking interaction);
CRC	cis	rs727479	0.543	rs6493488	chr15:51513922	G/C	cg19946085	chr15:51559439	CYP19A1	-0.29	-5.73	-0.3	2.29e-8	Estradiol levels;
CRC	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.54	8.42	0.42	1.15e-15	Diastolic blood pressure;
CRC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.95	0.4	3.07e-14	Mean corpuscular volume;
CRC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg02772935	chr3:125709198	NA	-0.5	-5.81	-0.3	1.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.08	18.6	0.72	2.69e-53	Cognitive function;
CRC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	7.12	0.37	6.79e-12	Motion sickness;
CRC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.54	8.69	0.43	1.78e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	0.56	8.8	0.44	7.83e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg19635926	chr16:89946313	TCF25	0.64	6.43	0.33	4.43e-10	Skin colour saturation;
CRC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.54	6.1	0.32	2.99e-9	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs12473497	chr2:162433766	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.24	-0.33	1.33e-9	Cognitive function;
CRC	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg03162506	chr22:38580953	NA	0.26	5.68	0.3	2.93e-8	Melanoma;
CRC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.31	-0.33	9.17e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs6544773	0.587	rs341580	chr2:45056311	C/G	cg10208897	chr5:178548229	ADAMTS2	0.35	6.04	0.32	4.12e-9	Mosquito bite size;
CRC	cis	rs71403859	0.504	rs35203704	chr16:71959661	G/A	cg03805757	chr16:71968109	PKD1L3	-0.65	-5.65	-0.3	3.48e-8	Post bronchodilator FEV1;
CRC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	0.93	8.92	0.44	3.4e-17	Granulocyte percentage of myeloid white cells;
CRC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.55	-7.4	-0.38	1.13e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.83	-0.4	6.59e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.62	8.34	0.42	2.14e-15	Alzheimer's disease;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg10217327	chr6:118973057	C6orf204	0.51	5.81	0.3	1.5e-8	Diastolic blood pressure;
CRC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.74	6.66	0.34	1.14e-10	Diabetic kidney disease;
CRC	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg06271696	chr7:157225062	NA	-0.39	-6.72	-0.35	8.08e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg23996704	chr18:44553084	KATNAL2	-0.36	-7.33	-0.37	1.79e-12	Personality dimensions;
CRC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.44	-7.5	-0.38	6.09e-13	Hypertriglyceridemia;
CRC	cis	rs4731207	0.564	rs10270051	chr7:124649393	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	2.04e-9	Cutaneous malignant melanoma;
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs9311676	0.656	rs56198078	chr3:58392224	G/C	cg06643156	chr3:58380774	PXK	0.41	6.22	0.32	1.55e-9	Systemic lupus erythematosus;
CRC	cis	rs1867631	0.585	rs9787219	chr1:67080159	G/C	cg02459107	chr1:67143332	SGIP1	0.34	6.18	0.32	1.95e-9	Menopause (age at onset);
CRC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg20742385	chr13:113633654	MCF2L	-0.71	-12.39	-0.56	3.47e-29	Systolic blood pressure;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg03623178	chr6:28175578	NA	0.8	11.88	0.55	2.41e-27	Cardiac Troponin-T levels;
CRC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.63	8.71	0.43	1.51e-16	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg01766193	chr7:157202248	DNAJB6	-0.35	-5.72	-0.3	2.39e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs7692995	1.000	rs73100947	chr4:18021307	C/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg00343986	chr7:65444356	GUSB	0.45	6.2	0.32	1.68e-9	Aortic root size;
CRC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.45	5.62	0.3	4e-8	Aortic root size;
CRC	cis	rs10901296	0.660	rs2855199	chr9:133765044	T/C	cg01000188	chr9:133769184	QRFP	0.68	8.55	0.43	4.68e-16	Bilirubin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12639422	chr2:64069082	UGP2	0.45	6.4	0.33	5.29e-10	Response to antipsychotic treatment;
CRC	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.7	-0.3	2.64e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CRC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.49	6.89	0.35	2.9100000000000002e-11	Response to temozolomide;
CRC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	6.4	0.33	5.26e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg16797656	chr11:68205561	LRP5	0.39	6.17	0.32	2.02e-9	Total body bone mineral density (age 0-15);
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.42	6.58	0.34	1.82e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.6	-0.34	1.62e-10	Red cell distribution width;
CRC	cis	rs9903692	0.954	rs10853094	chr17:46176062	T/C	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs11212617	0.967	rs228592	chr11:108123189	C/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.37	0.33	6.24e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg16447950	chr5:562315	NA	-0.84	-13.05	-0.58	1.22e-31	Obesity-related traits;
CRC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.56	8.07	0.41	1.37e-14	Melanoma;
CRC	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.52	7.65	0.39	2.23e-13	Glioblastoma;Glioma;
CRC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg12855166	chr17:30846586	MYO1D	-0.35	-5.78	-0.3	1.7e-8	Schizophrenia;
CRC	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.54e-21	Asthma;
CRC	cis	rs6662572	0.737	rs11584814	chr1:46504389	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.94	0.31	7.27e-9	Blood protein levels;
CRC	cis	rs7312933	0.558	rs11181403	chr12:42682902	G/A	cg19980929	chr12:42632907	YAF2	0.46	6.94	0.36	2.13e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs587242	1.000	rs7551466	chr1:96892427	G/T	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.15	10.62	0.51	7.84e-23	Opioid sensitivity;
CRC	cis	rs9648716	0.872	rs6964937	chr7:140609690	C/G	cg10747023	chr7:140774559	NA	0.49	6.3	0.33	9.42e-10	Type 2 diabetes;
CRC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.48	-6.61	-0.34	1.59e-10	Fibrinogen levels;
CRC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg10298567	chr3:47292165	KIF9	0.37	5.8	0.3	1.58e-8	Colorectal cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07709635	chr12:3000034	TULP3	0.47	6.3	0.33	9.46e-10	Anxiety disorder;
CRC	trans	rs9528384	0.724	rs7987007	chr13:62247488	T/C	cg08375866	chr1:50799151	NA	-0.32	-5.96	-0.31	6.47e-9	Verbal declarative memory;
CRC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Bladder cancer;
CRC	cis	rs17065868	0.764	rs9533852	chr13:45019918	C/T	cg10246903	chr13:45222710	NA	-0.59	-6.48	-0.34	3.37e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-18.33	-0.71	3.41e-52	Height;
CRC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg01483505	chr11:975446	AP2A2	0.46	7.67	0.39	2.02e-13	Alzheimer's disease (late onset);
CRC	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.69	-0.3	2.81e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.73	-0.3	2.31e-8	Breast cancer;
CRC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.81	13.39	0.59	6.42e-33	Coronary artery disease;
CRC	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.38	5.92	0.31	7.94e-9	Endometrial cancer;
CRC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs16936870	0.571	rs7017499	chr8:71083453	A/G	cg14232793	chr8:71155543	NCOA2	-0.48	-5.69	-0.3	2.75e-8	QT interval;
CRC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs11105468	1.000	rs10858937	chr12:90274437	G/A	cg23572944	chr11:60720130	SLC15A3	-0.43	-6.04	-0.32	4.15e-9	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs6028335	0.674	rs61213966	chr20:37621906	A/G	cg16355469	chr20:37678765	NA	0.46	5.61	0.3	4.34e-8	Alcohol and nicotine co-dependence;
CRC	trans	rs559356	0.561	rs44338	chr3:34834586	G/A	cg18960307	chr17:4699574	PSMB6	0.4	6.08	0.32	3.24e-9	Cognitive function;
CRC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.14	-0.32	2.37e-9	Menopause (age at onset);
CRC	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01591470	chr14:39736043	CTAGE5	0.42	6.9	0.36	2.65e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.47	-5.73	-0.3	2.31e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7264396	0.778	rs6120959	chr20:34077848	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.53	-0.34	2.44e-10	Total cholesterol levels;
CRC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.43	-6.92	-0.36	2.36e-11	Resting heart rate;
CRC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.49	7.02	0.36	1.28e-11	Colorectal cancer;
CRC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg03609598	chr5:56110824	MAP3K1	-0.57	-7.74	-0.39	1.27e-13	Coronary artery disease;
CRC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	14.15	0.62	7.6e-36	Electrocardiographic conduction measures;
CRC	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg21251018	chr6:28226885	NKAPL	0.44	7.06	0.36	1e-11	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.26e-26	Prudent dietary pattern;
CRC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg15123519	chr2:136567270	LCT	0.34	6.57	0.34	1.94e-10	Mosquito bite size;
CRC	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg06076350	chr7:157294107	NA	0.35	6.44	0.33	4.3e-10	Inattentive symptoms;
CRC	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.39	-6.62	-0.34	1.42e-10	Hip circumference;Waist circumference;
CRC	cis	rs10450586	0.863	rs10835150	chr11:27301061	C/G	cg10370305	chr11:27303972	NA	-0.38	-6.11	-0.32	2.83e-9	Total body bone mineral density;
CRC	cis	rs6545883	0.507	rs2123111	chr2:61450454	A/G	cg10580144	chr2:61372316	C2orf74	-0.35	-7.86	-0.4	5.56e-14	Tuberculosis;
CRC	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg06102954	chr21:42741788	MX2	-0.39	-6.06	-0.32	3.81e-9	Melanoma;
CRC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.31	0.33	9.12e-10	Mean platelet volume;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-9.66	-0.47	1.36e-19	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00305188	chr1:205649794	SLC45A3	0.4	6.09	0.32	3.21e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16447950	chr5:562315	NA	-0.74	-9.73	-0.47	7.89e-20	Obesity-related traits;
CRC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.37	-7.45	-0.38	8.13e-13	Arsenic metabolism;
CRC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.46	6.87	0.35	3.17e-11	Colorectal cancer;
CRC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.39	6.79	0.35	5.22e-11	Sudden cardiac arrest;
CRC	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.81	12.03	0.55	7.25e-28	Obesity-related traits;
CRC	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.61	9.43	0.46	7.82e-19	Monocyte count;
CRC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.69	-7.86	-0.4	5.64e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62188153	chr2:162313036	G/T	cg19471553	chr17:41393123	NA	-0.7	-6.07	-0.32	3.48e-9	Cognitive function;
CRC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg25600027	chr14:23388339	RBM23	-0.53	-8.33	-0.42	2.26e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs758324	0.812	rs7709934	chr5:131145210	C/T	cg25547332	chr5:131281432	NA	0.35	5.61	0.3	4.31e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.4	-5.93	-0.31	7.7e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.05	-16.83	-0.68	2.85e-46	Schizophrenia;
CRC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.44	6.61e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9311676	0.656	rs56097407	chr3:58378079	G/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.9	0.31	8.9e-9	Hemoglobin concentration;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg06361278	chr17:25783929	NA	-0.4	-5.97	-0.31	6.27e-9	Brain structure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25667490	chr4:72052924	SLC4A4	0.42	7.32	0.37	1.96e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10924970	0.967	rs4481838	chr1:235442626	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.84e-9	Asthma;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg12273811	chr6:28175739	NA	0.57	8.38	0.42	1.59e-15	Parkinson's disease;
CRC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.6	8.54	0.43	5.12e-16	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17533455	chr5:130599827	CDC42SE2	0.35	6.02	0.31	4.76e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03227456	chr1:8878193	RERE	0.46	6.33	0.33	8.16e-10	Response to antipsychotic treatment;
CRC	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.88	16.87	0.68	1.83e-46	Hip circumference;
CRC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.9	16.42	0.67	1.13e-44	Intelligence (multi-trait analysis);
CRC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.61	-8.3	-0.42	2.67e-15	DNA methylation (variation);
CRC	cis	rs7781557	0.640	rs17135916	chr7:102552997	A/C	cg18108683	chr7:102477205	FBXL13	-0.48	-5.67	-0.3	3.21e-8	Colorectal adenoma (advanced);
CRC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg07713946	chr22:31675144	LIMK2	-0.39	-5.62	-0.3	4e-8	Colorectal cancer;
CRC	cis	rs4666002	0.956	rs10179872	chr2:27778572	G/A	cg27432699	chr2:27873401	GPN1	0.45	5.87	0.31	1.05e-8	Phospholipid levels (plasma);
CRC	cis	rs4731207	0.596	rs12112909	chr7:124584834	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.34e-9	Cutaneous malignant melanoma;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg07919197	chr1:32646027	TXLNA	0.59	6.47	0.34	3.51e-10	Body mass index;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.61	-0.3	4.2e-8	Electroencephalogram traits;
CRC	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.83	9.73	0.47	8.14e-20	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.61	-9.68	-0.47	1.18e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.67	8.53	0.43	5.47e-16	Gastritis;
CRC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.61	-0.39	2.9e-13	Height;
CRC	cis	rs10849893	0.538	rs10744762	chr12:121839701	A/C	cg01154721	chr12:121881891	KDM2B	0.44	6.69	0.35	9.59e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg12172441	chr6:28176163	NA	0.45	6.55	0.34	2.25e-10	Cardiac Troponin-T levels;
CRC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-12.95	-0.58	2.8e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11958404	0.929	rs60700182	chr5:157438376	A/G	cg05962755	chr5:157440814	NA	0.95	12.34	0.56	5.17e-29	IgG glycosylation;
CRC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.51	-9.28	-0.46	2.35e-18	Longevity;
CRC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21972741	chr5:435613	AHRR	0.54	7.37	0.38	1.39e-12	Cystic fibrosis severity;
CRC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-7.91	-0.4	4.05e-14	Body mass index;
CRC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg12193833	chr17:30244370	NA	-0.75	-8.72	-0.43	1.4e-16	Hip circumference adjusted for BMI;
CRC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg22963979	chr7:1858916	MAD1L1	0.74	11.37	0.53	1.77e-25	Bipolar disorder and schizophrenia;
CRC	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg21153622	chr11:89784906	NA	-0.44	-7.33	-0.37	1.84e-12	Coronary artery disease;
CRC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.38	0.46	1.15e-18	Lymphocyte counts;
CRC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.81	13.08	0.59	8.74e-32	Cognitive function;
CRC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.59	9.34	0.46	1.55e-18	Aortic root size;
CRC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg03929089	chr4:120376271	NA	0.56	7.25	0.37	2.95e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.32	0.46	1.72e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	11.46	0.53	8.01e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg06470822	chr6:28175283	NA	0.71	8.4	0.42	1.39e-15	Depression;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-7.02	-0.36	1.29e-11	Blood metabolite levels;
CRC	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.47	7.13	0.37	6.49e-12	HDL cholesterol;
CRC	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.52	-6.35	-0.33	7.3e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.62	9.94	0.48	1.56e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg21153622	chr11:89784906	NA	-0.43	-6.75	-0.35	6.5500000000000006e-11	Height;
CRC	cis	rs11212617	0.934	rs172896	chr11:108217049	T/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.34	0.33	7.46e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.64	10.68	0.51	4.51e-23	Vitiligo;
CRC	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.64	-9.9	-0.48	2.14e-20	Testicular germ cell tumor;
CRC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.33	-6.02	-0.32	4.59e-9	Menarche (age at onset);
CRC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.45	0.42	9.68e-16	Rheumatoid arthritis;
CRC	cis	rs7113874	0.524	rs9704586	chr11:8578530	T/G	cg02811074	chr11:8615871	STK33	-0.34	-5.87	-0.31	1.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00801512	chr17:28996047	NA	0.53	6.04	0.32	4.22e-9	Hip circumference adjusted for BMI;
CRC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	8.62	0.43	2.94e-16	Response to antipsychotic treatment;
CRC	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.16e-10	Obesity-related traits;
CRC	cis	rs847649	0.692	rs10271184	chr7:102477176	A/G	cg18108683	chr7:102477205	FBXL13	-0.67	-11.28	-0.53	3.62e-25	Morning vs. evening chronotype;
CRC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.21	5.95	0.31	6.84e-9	Urinary metabolites;
CRC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.94	10.72	0.51	3.35e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.41	0.42	1.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.29	-0.37	2.26e-12	Response to antipsychotic treatment;
CRC	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg07828340	chr4:882639	GAK	1.12	10.94	0.52	5.82e-24	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.74	-0.51	2.89e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.63	9.58	0.47	2.42e-19	Dementia with Lewy bodies;
CRC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.33	0.33	8.25e-10	Renal cell carcinoma;
CRC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.27	-6.61	-0.34	1.57e-10	Urate levels in overweight individuals;
CRC	trans	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg10756647	chr7:56101905	PSPH	0.62	6.58	0.34	1.8e-10	Diabetic kidney disease;
CRC	cis	rs12024301	0.557	rs6699033	chr1:183622450	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.99	0.36	1.53e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg11003573	chr3:44754125	ZNF502	-0.37	-6.29	-0.33	1.03e-9	Depressive symptoms;
CRC	cis	rs4865169	0.560	rs1277311	chr4:57902761	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.63	-0.3	3.89e-8	Breast cancer;
CRC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.74	10.1	0.49	4.64e-21	Systemic lupus erythematosus;
CRC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.54	-7.63	-0.39	2.52e-13	Prostate cancer;
CRC	cis	rs68149176	0.772	rs997762	chr16:87879562	C/A	cg03553613	chr16:87879502	SLC7A5	-0.56	-7.47	-0.38	7.46e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.52	7.76	0.39	1.07e-13	Lymphocyte counts;
CRC	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg16558208	chr1:156270281	VHLL	0.58	9.09	0.45	9.51e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.43	-8.49	-0.42	7.07e-16	Alcohol dependence;
CRC	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.19	0.59	3.46e-32	Hip circumference;
CRC	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg02466173	chr16:30829666	NA	0.45	6.13	0.32	2.51e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.52e-15	Height;
CRC	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06771106	chr2:113671356	IL1F7	0.43	6.16	0.32	2.14e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg14139581	chr11:64358342	SLC22A12	-0.39	-6.19	-0.32	1.81e-9	Urate levels in obese individuals;
CRC	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg00919237	chr7:87102261	ABCB4	-0.54	-7.15	-0.37	5.78e-12	Gallbladder cancer;
CRC	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.4	-6.85	-0.35	3.65e-11	Vitamin D levels;
CRC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.32	-0.33	8.39e-10	Reticulocyte fraction of red cells;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg26358599	chr1:24018029	RPL11	-0.74	-6.02	-0.31	4.71e-9	Cognitive function;
CRC	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.54	7.1	0.36	7.85e-12	Alzheimer's disease (survival time);
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.77	-0.51	2.31e-23	Alzheimer's disease;
CRC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.55	-8.65	-0.43	2.36e-16	Aortic root size;
CRC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-0.91	-10.56	-0.5	1.22e-22	Breast cancer;
CRC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.21	-0.32	1.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.67	8.88	0.44	4.41e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-8.76	-0.44	1.02e-16	Platelet count;
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.28	-0.42	3.09e-15	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23653712	chr4:52904379	SGCB	0.46	7.69	0.39	1.69e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg07998479	chr3:129830310	LOC729375	0.4	5.99	0.31	5.37e-9	Retinal vascular caliber;
CRC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.66	0.43	2.2e-16	Menopause (age at onset);
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg12564285	chr5:131593104	PDLIM4	0.45	7.53	0.38	5.05e-13	Breast cancer;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06384952	chr3:183602746	PARL	-0.4	-6.23	-0.32	1.39e-9	Obesity-related traits;
CRC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.53	-0.38	4.84e-13	Aortic root size;
CRC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.93	0.31	7.71e-9	Renal function-related traits (BUN);
CRC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.96	-0.4	2.87e-14	Gut microbiome composition (summer);
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.49	7.28	0.37	2.52e-12	Longevity;Endometriosis;
CRC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.42	-6.24	-0.33	1.32e-9	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg21251018	chr6:28226885	NKAPL	-0.44	-6.44	-0.33	4.2e-10	Parkinson's disease;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.6	-11.22	-0.53	5.92e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.45	6.62	0.34	1.42e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs417013	0.668	rs201519	chr7:101770505	G/A	cg06246474	chr7:101738831	CUX1	0.37	5.66	0.3	3.27e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-7.71	-0.39	1.49e-13	Menopause (age at onset);
CRC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-16.16	-0.67	1.19e-43	Electrocardiographic conduction measures;
CRC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.51	-6.86	-0.35	3.48e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.61	-9.55	-0.47	3e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00495681	chr13:53174319	NA	-0.56	-7.88	-0.4	4.95e-14	Lewy body disease;
CRC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.42	-7.07	-0.36	9.14e-12	Eye color traits;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs2122752	0.527	rs10187244	chr2:98816010	A/T	cg17915676	chr2:98928898	VWA3B	-0.32	-5.66	-0.3	3.24e-8	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12588279	chr6:26043732	HIST1H2BB	0.42	6.08	0.32	3.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2179367	0.959	rs540538	chr6:149647944	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.15	-0.32	2.23e-9	Dupuytren's disease;
CRC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.36	-0.56	4.3e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.38	-6.56	-0.34	2.09e-10	Reticulocyte fraction of red cells;
CRC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.38	0.33	5.97e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.47	-0.46	5.61e-19	Capecitabine sensitivity;
CRC	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.65	-0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.49	-7.52	-0.38	5.23e-13	Type 2 diabetes;
CRC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.64	0.39	2.43e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg12273811	chr6:28175739	NA	0.61	8.8	0.44	8.09e-17	Cardiac Troponin-T levels;
CRC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03711348	chr7:22862508	TOMM7	0.38	6.13	0.32	2.44e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.69	9.26	0.45	2.7e-18	Platelet count;
CRC	cis	rs6011002	0.550	rs6010634	chr20:62363838	T/C	cg01176363	chr20:62369445	LIME1	-0.72	-5.67	-0.3	3.14e-8	Dental caries;
CRC	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.6	0.34	1.62e-10	Morning vs. evening chronotype;
CRC	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.77	-10.24	-0.49	1.47e-21	Blood pressure (smoking interaction);
CRC	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg22687807	chr8:143858763	LYNX1	-0.38	-6.67	-0.35	1.1e-10	Urinary tract infection frequency;
CRC	cis	rs7580658	0.857	rs11890187	chr2:128083738	T/C	cg09760422	chr2:128146352	NA	-0.3	-5.8	-0.3	1.58e-8	Protein C levels;
CRC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg13722127	chr7:150037890	RARRES2	0.39	5.69	0.3	2.86e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg21856205	chr7:94953877	PON1	-0.5	-6.49	-0.34	3.25e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.53	-8.61	-0.43	3.09e-16	Neurofibrillary tangles;
CRC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.54	0.38	4.77e-13	Aortic root size;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.46	6.91	0.36	2.53e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg26353448	chr1:248524236	OR2T4	-0.35	-6.68	-0.35	1.02e-10	Common traits (Other);
CRC	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg02158880	chr13:53174818	NA	0.4	5.63	0.3	3.91e-8	Lewy body disease;
CRC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.02	-0.55	7.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg18876405	chr7:65276391	NA	-0.48	-6.51	-0.34	2.88e-10	Aortic root size;
CRC	cis	rs4728302	0.934	rs10258052	chr7:133635874	T/C	cg10665199	chr7:133106180	EXOC4	-0.39	-6.14	-0.32	2.34e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.0	0.44	1.83e-17	Lung cancer;
CRC	cis	rs747650	0.961	rs7945315	chr11:47110652	A/C	cg03339077	chr11:47165057	C11orf49	0.45	6.31	0.33	8.83e-10	Acne (severe);
CRC	trans	rs6472235	0.837	rs2357569	chr8:66917137	A/G	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.12	-0.32	2.62e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg16606324	chr3:10149918	C3orf24	0.69	8.08	0.41	1.2e-14	Alzheimer's disease;
CRC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.62	7.52	0.38	5.43e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2462686	0.930	rs2462687	chr7:45982306	C/T	cg23193639	chr7:45961078	IGFBP3	-0.39	-6.16	-0.32	2.14e-9	Major depressive disorder;
CRC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.55	8.29	0.42	2.97e-15	Aortic root size;
CRC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20092199	chr4:1342459	KIAA1530	0.35	5.91	0.31	8.62e-9	Obesity-related traits;
CRC	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-0.98	-9.67	-0.47	1.26e-19	Post bronchodilator FEV1;
CRC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.62	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg24416660	chr17:73865998	NA	-0.4	-6.08	-0.32	3.34e-9	Psoriasis;
CRC	cis	rs9906695	0.898	rs113274498	chr17:32566488	T/C	cg12698626	chr17:32581466	CCL2	0.42	5.8	0.3	1.57e-8	Monocyte percentage of white cells;
CRC	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-5.73	-0.3	2.25e-8	Schizophrenia;
CRC	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg23254163	chr1:152506842	NA	0.45	8.8	0.44	8e-17	Hair morphology;
CRC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.51	-8.27	-0.41	3.46e-15	Body mass index;
CRC	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.28	-0.42	3.05e-15	Brugada syndrome;
CRC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07701084	chr6:150067640	NUP43	-0.55	-7.53	-0.38	4.87e-13	Lung cancer;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.55	6.53	0.34	2.44e-10	Renal function-related traits (BUN);
CRC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.7	0.39	1.62e-13	Major depressive disorder;
CRC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg21153622	chr11:89784906	NA	-0.51	-8.52	-0.43	6.01e-16	HDL cholesterol;
CRC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.47	-6.72	-0.35	8.16e-11	Lymphocyte counts;
CRC	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.6	8.69	0.43	1.75e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.46	0.34	3.88e-10	Tonsillectomy;
CRC	cis	rs6496667	1.000	rs1452408	chr15:90891117	A/C	cg04176472	chr15:90893244	GABARAPL3	0.55	8.56	0.43	4.4e-16	Rheumatoid arthritis;
CRC	cis	rs7731657	0.537	rs4705995	chr5:130350688	G/A	cg08523029	chr5:130500466	HINT1	-0.45	-5.77	-0.3	1.85e-8	Fasting plasma glucose;
CRC	trans	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg05376469	chr2:102649931	NA	0.39	6.38	0.33	6.05e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21434440	chr6:47446198	CD2AP	0.48	6.83	0.35	4.09e-11	Response to antipsychotic treatment;
CRC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.59	8.92	0.44	3.42e-17	Vitiligo;
CRC	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg18646521	chr2:111875858	NA	0.4	6.31	0.33	9.12e-10	Chronic lymphocytic leukemia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10309340	chr10:102747329	C10orf2;MRPL43	0.38	6.19	0.32	1.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.56	-8.5	-0.42	6.87e-16	Asthma;
CRC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg23815491	chr16:72088622	HP	-0.46	-6.94	-0.36	2.05e-11	Fibrinogen levels;
CRC	cis	rs891088	0.695	rs28695870	chr19:7197988	C/T	cg00428638	chr19:7224713	INSR	-0.6	-7.55	-0.38	4.25e-13	Hip circumference adjusted for BMI;Height;
CRC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg10589385	chr1:150898437	SETDB1	0.34	6.83	0.35	4.03e-11	Melanoma;
CRC	cis	rs4664293	0.667	rs2042782	chr2:160646292	G/A	cg08347373	chr2:160653686	CD302	0.51	8.74	0.43	1.21e-16	Monocyte percentage of white cells;
CRC	cis	rs317865	0.737	rs73234644	chr4:16190661	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	5.71	0.3	2.58e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.48	-0.34	3.29e-10	Body mass index;
CRC	cis	rs7781266	0.790	rs6467492	chr7:133139713	C/T	cg03336402	chr7:133662267	EXOC4	0.46	5.65	0.3	3.5e-8	Educational attainment (college completion);
CRC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.43	-6.53	-0.34	2.54e-10	N-glycan levels;
CRC	cis	rs4499344	0.633	rs259246	chr19:33146154	G/C	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg12516270	chr8:143859308	LYNX1	-0.41	-6.38	-0.33	5.92e-10	Urinary tract infection frequency;
CRC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-15.54	-0.65	3.08e-41	Electrocardiographic conduction measures;
CRC	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.64	9.83	0.48	3.73e-20	White blood cell count (basophil);
CRC	cis	rs10878977	0.542	rs9645828	chr12:69814792	G/A	cg20891283	chr12:69753455	YEATS4	-0.59	-5.77	-0.3	1.83e-8	Colorectal cancer;
CRC	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.74	11.06	0.52	2.2e-24	Neutrophil percentage of white cells;
CRC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	11.48	0.53	7.14e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9323205	0.677	rs61987261	chr14:51723879	G/A	cg23942311	chr14:51606299	NA	-0.53	-6.24	-0.33	1.36e-9	Cancer;
CRC	cis	rs62432291	0.681	rs423533	chr6:159664516	G/T	cg14500486	chr6:159655392	FNDC1	-0.76	-10.03	-0.48	7.86e-21	Joint mobility (Beighton score);
CRC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-8.96	-0.44	2.55e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.48	7.3	0.37	2.2e-12	Corneal astigmatism;
CRC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.78	0.39	9.16e-14	Aortic root size;
CRC	cis	rs7259376	0.936	rs1865073	chr19:22554980	T/G	cg02657401	chr19:22469223	NA	-0.31	-6.77	-0.35	5.96e-11	Menopause (age at onset);
CRC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.59	-0.34	1.79e-10	Bipolar disorder;
CRC	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg22495460	chr2:25135724	ADCY3	-0.88	-14.99	-0.64	4.29e-39	Body mass index;
CRC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg22974920	chr21:40686053	BRWD1	0.41	5.68	0.3	2.91e-8	Cognitive function;
CRC	cis	rs9659323	1.000	rs6680737	chr1:119521631	G/A	cg26570165	chr1:119541833	NA	-0.39	-6.46	-0.34	3.76e-10	Body mass index;
CRC	cis	rs860295	0.812	rs12407800	chr1:155760742	A/C	cg02153340	chr1:155202674	NA	-0.51	-6.27	-0.33	1.15e-9	Body mass index;
CRC	cis	rs2013441	1.000	rs2703806	chr17:20108239	A/T	cg13482628	chr17:19912719	NA	-0.42	-6.57	-0.34	1.95e-10	Obesity-related traits;
CRC	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg18783429	chr5:92414398	NA	0.26	5.65	0.3	3.54e-8	Migraine;
CRC	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg16898833	chr6:26189333	HIST1H4D	0.8	6.56	0.34	2.08e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9463078	0.764	rs1576382	chr6:44957553	G/A	cg25276700	chr6:44698697	NA	-0.28	-6.88	-0.35	3.1e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1992660	0.523	rs7707395	chr5:40343533	G/C	cg09067459	chr5:40385259	NA	0.44	7.46	0.38	7.53e-13	Crohn's disease;
CRC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.47	0.34	3.64e-10	Lung cancer;
CRC	cis	rs4731207	0.698	rs4731217	chr7:124471889	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9463078	0.625	rs1891412	chr6:44760642	T/C	cg25276700	chr6:44698697	NA	0.28	6.78	0.35	5.7e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01897823	chr17:76356232	SOCS3	0.44	6.4	0.33	5.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.35	0.46	1.35e-18	Bladder cancer;
CRC	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-1.08	-13.72	-0.6	3.4e-34	Blood pressure (smoking interaction);
CRC	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.61	-8.54	-0.43	4.92e-16	Coronary artery disease;
CRC	cis	rs6445525	1.000	rs4688631	chr3:65994050	C/T	cg06109867	chr3:66002991	MAGI1	-0.38	-6.17	-0.32	2.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.45	-6.62	-0.34	1.43e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg05187965	chr10:45406764	TMEM72	-0.34	-6.99	-0.36	1.58e-11	Mean corpuscular volume;
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.5	7.37	0.38	1.43e-12	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.16	-0.32	2.08e-9	Total body bone mineral density;
CRC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.45	5.81	0.3	1.49e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg09491104	chr22:46646882	C22orf40	-0.38	-5.84	-0.31	1.25e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23708337	chr7:1209742	NA	0.39	5.82	0.31	1.36e-8	Longevity;Endometriosis;
CRC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.45	-0.34	4e-10	Electroencephalogram traits;
CRC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	10.98	0.52	4.29e-24	Platelet count;
CRC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04221910	chr5:616842	CEP72	0.4	6.54	0.34	2.39e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.68	10.64	0.51	6.45e-23	Coronary artery disease;
CRC	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.02	-0.31	4.78e-9	Bipolar disorder;
CRC	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-8.68	-0.43	1.83e-16	Blood protein levels;
CRC	cis	rs4664293	0.801	rs7607143	chr2:160584761	T/C	cg08347373	chr2:160653686	CD302	-0.35	-5.61	-0.3	4.36e-8	Monocyte percentage of white cells;
CRC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.46	-7.39	-0.38	1.26e-12	Monocyte count;
CRC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.83	14.44	0.62	5.96e-37	Breast cancer;
CRC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.37	-0.38	1.36e-12	Aortic root size;
CRC	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.44	-6.58	-0.34	1.88e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.39	6.64	0.34	1.27e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.7	-9.92	-0.48	1.87e-20	Alzheimer's disease;
CRC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.26	0.33	1.19e-9	IgG glycosylation;
CRC	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg01993067	chr11:68851601	TPCN2	0.56	6.31	0.33	9.23e-10	Blond vs. brown hair color;
CRC	cis	rs4731207	0.596	rs2219953	chr7:124671915	A/C	cg23710748	chr7:124431027	NA	-0.43	-6.68	-0.35	1.01e-10	Cutaneous malignant melanoma;
CRC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg06470822	chr6:28175283	NA	0.72	10.34	0.5	6.75e-22	Parkinson's disease;
CRC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.39	-0.33	5.8e-10	Systolic blood pressure;
CRC	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.61	-6.7	-0.35	9.26e-11	Coronary artery disease;
CRC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.84	-0.35	3.9e-11	Retinal vascular caliber;
CRC	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.71	-11.88	-0.55	2.51e-27	Itch intensity from mosquito bite;
CRC	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.84	10.71	0.51	3.63e-23	Height;
CRC	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.5	-0.38	6.15e-13	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.22	-0.32	1.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg09165964	chr15:75287851	SCAMP5	0.56	8.96	0.44	2.51e-17	Breast cancer;
CRC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	7.48	0.38	6.61e-13	Total body bone mineral density;
CRC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	8.78	0.44	9.3e-17	Lymphocyte counts;
CRC	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	1.05	12.53	0.57	1.03e-29	Diisocyanate-induced asthma;
CRC	cis	rs13144136	0.687	rs61796835	chr4:10656807	C/A	cg10242279	chr4:10666415	CLNK	-0.38	-6.5	-0.34	2.93e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.42	-6.69	-0.35	9.49e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.42	6.65	0.34	1.25e-10	Blood metabolite levels;
CRC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02161503	chr7:157955692	PTPRN2	0.42	7.29	0.37	2.29e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.64	6.79	0.35	5.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs317865	0.737	rs28483204	chr4:16205098	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.6	5.65	0.3	3.41e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.94	0.36	2.1e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.5	7.02	0.36	1.3e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.51	7.73	0.39	1.33e-13	Menopause (age at onset);
CRC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.14	-0.32	2.33e-9	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13301069	chr11:6624877	ILK;RRP8	0.36	6.28	0.33	1.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.74	11.92	0.55	1.86e-27	Plateletcrit;Platelet count;
CRC	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg15282417	chr9:129245246	FAM125B	0.47	8.7	0.43	1.57e-16	Intraocular pressure;
CRC	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg19418318	chr19:17219073	MYO9B	0.51	8.79	0.44	8.54e-17	Reticulocyte fraction of red cells;
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.12	-0.49	3.99e-21	Bipolar disorder;
CRC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.57e-9	Bladder cancer;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg26608667	chr7:1196370	ZFAND2A	0.4	6.56	0.34	2.1e-10	Longevity;Endometriosis;
CRC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg12573674	chr2:1569213	NA	-0.77	-8.03	-0.4	1.76e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg04969067	chr8:143858791	LYNX1	-0.73	-13.05	-0.58	1.17e-31	Urinary tract infection frequency;
CRC	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs911119	0.818	rs56077567	chr20:23591087	T/C	cg16589663	chr20:23618590	CST3	0.45	6.3	0.33	9.76e-10	Chronic kidney disease;
CRC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.75	-0.6	2.69e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs2737618	1.000	rs2737618	chr1:200107425	C/T	cg21825944	chr1:200113062	NR5A2	-0.44	-5.62	-0.3	4.16e-8	Uric acid levels;
CRC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.54	6.66	0.34	1.12e-10	Bipolar disorder (body mass index interaction);
CRC	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg00791764	chr4:53727839	RASL11B	-0.39	-5.8	-0.3	1.55e-8	Optic nerve measurement (cup area);
CRC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.76	-0.39	1.1e-13	Schizophrenia;
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg08888203	chr3:10149979	C3orf24	0.66	7.81	0.4	7.74e-14	Alzheimer's disease;
CRC	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.96	9.8	0.48	4.58e-20	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg05784532	chr1:230284198	GALNT2	0.48	6.54	0.34	2.4e-10	Coronary artery disease;
CRC	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.44	-6.95	-0.36	1.99e-11	Asthma;
CRC	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.62	8.5	0.42	6.85e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.51	7.27	0.37	2.68e-12	Colorectal cancer;
CRC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.53	-6.56	-0.34	2.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3956705	0.798	rs1045530	chr7:32908135	C/G	cg05721444	chr7:32995514	FKBP9	-0.46	-6.77	-0.35	6.04e-11	Red cell distribution width;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg16606324	chr3:10149918	C3orf24	0.55	6.51	0.34	2.74e-10	Alzheimer's disease;
CRC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.51	6.82	0.35	4.3e-11	Height;
CRC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.39	-6.74	-0.35	7.25e-11	Schizophrenia;
CRC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs60871478	0.786	rs12532534	chr7:831891	G/A	cg05535760	chr7:792225	HEATR2	-1.02	-12.73	-0.57	1.84e-30	Cerebrospinal P-tau181p levels;
CRC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.48	7.96	0.4	2.86e-14	Coronary artery disease;
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg00063174	chr2:228736253	WDR69	-0.51	-6.9	-0.36	2.6e-11	Blood pressure;
CRC	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg09476006	chr5:138032270	NA	0.42	6.4	0.33	5.43e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.37	6.08	0.32	3.37e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	-0.67	-7.55	-0.38	4.25e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.43	-6.28	-0.33	1.04e-9	Motion sickness;
CRC	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg03469862	chr11:68924853	NA	0.46	5.85	0.31	1.17e-8	Blond vs. brown hair color;
CRC	cis	rs6662572	0.578	rs6662307	chr1:46287287	G/T	cg08644498	chr1:46502608	NA	0.44	6.91	0.36	2.59e-11	Blood protein levels;
CRC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg02659138	chr7:134003124	SLC35B4	0.39	6.6	0.34	1.69e-10	Mean platelet volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11721769	chr6:24495264	ALDH5A1	0.47	6.65	0.34	1.22e-10	Anxiety disorder;
CRC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.5	7.02	0.36	1.28e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00166722	chr3:10149974	C3orf24	0.62	8.67	0.43	1.99e-16	Alzheimer's disease;
CRC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.02	0.36	1.29e-11	Rheumatoid arthritis;
CRC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.58e-10	Bladder cancer;
CRC	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.32	-6.61	-0.34	1.58e-10	Cutaneous nevi;
CRC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg25456477	chr12:86230367	RASSF9	0.38	6.43	0.33	4.41e-10	Major depressive disorder;
CRC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg15448220	chr1:150897856	SETDB1	0.41	6.05	0.32	3.94e-9	Tonsillectomy;
CRC	cis	rs7224737	0.750	rs13380830	chr17:40297658	C/G	cg20291162	chr17:40259547	DHX58	-0.44	-5.69	-0.3	2.87e-8	Fibrinogen levels;
CRC	cis	rs13063635	0.831	rs13433997	chr3:46049765	T/C	cg12691230	chr3:46064611	XCR1	-0.57	-6.23	-0.32	1.43e-9	Eosinophil percentage of granulocytes;
CRC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg15763984	chr4:1342303	KIAA1530	0.36	6.12	0.32	2.65e-9	Longevity;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs6681460	1.000	rs6588207	chr1:67066555	A/G	cg02459107	chr1:67143332	SGIP1	0.46	8.17	0.41	6.53e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.52	-0.34	2.6200000000000003e-10	Alzheimer's disease (late onset);
CRC	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.61	7.18	0.37	4.7e-12	Bipolar disorder;
CRC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02950623	chr16:14379524	NA	0.37	6.19	0.32	1.76e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg19622623	chr12:86230825	RASSF9	-0.4	-6.26	-0.33	1.18e-9	Major depressive disorder;
CRC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.4	6.22	0.32	1.47e-9	HDL cholesterol levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17128646	chr2:198363565	HSPD1;HSPE1	0.46	6.09	0.32	3.13e-9	Anxiety disorder;
CRC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	6.2	0.32	1.7e-9	Mean platelet volume;
CRC	cis	rs2380220	0.808	rs2263180	chr6:95902309	G/A	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.24	0.33	1.34e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.74	11.41	0.53	1.27e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.55	-8.29	-0.42	2.85e-15	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02296128	chr13:45694882	GTF2F2	0.44	6.1	0.32	3e-9	Response to antipsychotic treatment;
CRC	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.77	-12.18	-0.56	2.08e-28	Tonsillectomy;
CRC	cis	rs12505749	0.542	rs66858948	chr4:57334142	C/G	cg06922635	chr4:57371607	ARL9	-0.52	-5.63	-0.3	3.83e-8	Airflow obstruction;
CRC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg05313129	chr8:58192883	C8orf71	-0.4	-5.89	-0.31	9.72e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.05	-0.32	3.98e-9	Reticulocyte count;
CRC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.77	12.14	0.56	2.73e-28	Blood metabolite levels;
CRC	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg25025879	chr12:53359317	NA	-0.84	-7.97	-0.4	2.62e-14	Prostate cancer;
CRC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.94	0.48	1.52e-20	Cognitive test performance;
CRC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.52	8.82	0.44	6.7e-17	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.45	-8.92	-0.44	3.38e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.53	-8.23	-0.41	4.4e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.4	-0.38	1.12e-12	Colorectal cancer;
CRC	trans	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg19894588	chr14:64061835	NA	-0.58	-8.46	-0.42	8.74e-16	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.93	10.45	0.5	2.97e-22	Iron status biomarkers;
CRC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	9.08	0.45	1.02e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.84	15.43	0.65	8.51e-41	Multiple myeloma;
CRC	cis	rs4746091	0.951	rs1868006	chr10:73403324	C/T	cg22763136	chr10:73395000	CDH23	0.41	6.03	0.32	4.32e-9	Selective IgA deficiency;
CRC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.6	-9.24	-0.45	3.19e-18	Aortic root size;
CRC	cis	rs17152411	0.895	rs7080330	chr10:126585673	A/G	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.74	7.54	0.38	4.59e-13	Diabetic retinopathy;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.36	0.65	1.59e-40	Bipolar disorder;
CRC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg05585544	chr11:47624801	NA	-0.54	-9.51	-0.46	4.15e-19	Subjective well-being;
CRC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.55	-7.79	-0.39	8.77e-14	Menarche (age at onset);
CRC	cis	rs7725052	0.609	rs11957215	chr5:40445681	A/G	cg09067459	chr5:40385259	NA	-0.4	-6.71	-0.35	8.37e-11	Pediatric autoimmune diseases;
CRC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg19622623	chr12:86230825	RASSF9	-0.38	-6.11	-0.32	2.89e-9	Major depressive disorder;
CRC	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.03	0.32	4.34e-9	Vitamin D levels;
CRC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg21155852	chr7:2048760	MAD1L1	-0.53	-7.16	-0.37	5.38e-12	Bipolar disorder;
CRC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.99	0.55	9.92e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.25	-0.41	3.94e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11403890	chr1:41708077	SCMH1	0.45	6.17	0.32	2.05e-9	Anxiety disorder;
CRC	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.55	8.34	0.42	2.08e-15	Lewy body disease;
CRC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-5.83	-0.31	1.31e-8	Arsenic metabolism;
CRC	cis	rs11212617	0.869	rs4754299	chr11:108025214	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.84	0.31	1.27e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.31	-0.67	2.94e-44	Hip circumference;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15809230	chr15:75743753	SIN3A	0.45	6.17	0.32	2.03e-9	Anxiety disorder;
CRC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.94	-0.36	2.15e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.44	6.12	0.32	2.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.29	-0.71	4.7e-52	Height;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.49	-6.85	-0.35	3.73e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.12	10.53	0.5	1.51e-22	Diabetic retinopathy;
CRC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24702147	chr12:7071814	MIR141;MIR200C	0.24	6.15	0.32	2.2e-9	Response to antipsychotic treatment;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.38	-9.07	-0.45	1.1e-17	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.49	7.67	0.39	2e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03672602	chr19:19754555	GMIP	0.48	6.1	0.32	2.95e-9	Thyroid stimulating hormone;
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07685180	chr8:600429	NA	-0.54	-6.11	-0.32	2.83e-9	IgG glycosylation;
CRC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06028605	chr16:24865363	SLC5A11	0.44	7.98	0.4	2.42e-14	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-11.59	-0.54	2.71e-26	Height;
CRC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs57920188	0.537	rs4440829	chr1:4080780	A/G	cg10510935	chr1:4059661	NA	-0.38	-5.99	-0.31	5.6e-9	Interleukin-17 levels;
CRC	cis	rs2280630	0.529	rs6599274	chr3:39013948	T/C	cg01426195	chr3:39028469	NA	-0.43	-7.14	-0.37	5.92e-12	Verbal declarative memory;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg23161317	chr6:28129485	ZNF389	0.44	6.04	0.32	4.22e-9	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16554516	chr1:206680868	RASSF5	0.39	6.59	0.34	1.72e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg11707556	chr5:10655725	ANKRD33B	0.47	7.56	0.38	4.01e-13	Coronary artery disease;
CRC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.46	-0.34	3.7e-10	Electroencephalogram traits;
CRC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	11.23	0.53	5.44e-25	Motion sickness;
CRC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.69	-0.43	1.73e-16	Bone mineral density;
CRC	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-10.95	-0.52	5.15e-24	Colorectal cancer;
CRC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.26	0.45	2.71e-18	Personality dimensions;
CRC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.54	-9.4	-0.46	9.33e-19	Migraine;
CRC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.25	11.62	0.54	2.11e-26	Alzheimer's disease (late onset);
CRC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-0.56	-5.8	-0.3	1.53e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg27535305	chr1:53392650	SCP2	0.36	6.44	0.33	4.31e-10	Monocyte count;
CRC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.52	8.18	0.41	6.29e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.74	-10.25	-0.49	1.45e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	0.9	6.33	0.33	7.82e-10	Height;
CRC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.36	-5.96	-0.31	6.66e-9	Childhood ear infection;
CRC	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.14e-9	Hair morphology;
CRC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.58	9.04	0.45	1.36e-17	Aortic root size;
CRC	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.4	-0.42	1.34e-15	Total cholesterol levels;
CRC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg16989719	chr2:238392110	NA	-0.39	-6.43	-0.33	4.48e-10	Prostate cancer;
CRC	trans	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg10756647	chr7:56101905	PSPH	0.68	7.3	0.37	2.14e-12	Diabetic kidney disease;
CRC	cis	rs731174	0.722	rs553888	chr1:38152509	C/G	cg06917450	chr1:38156652	C1orf109	-0.5	-7.16	-0.37	5.37e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs394563	0.625	rs394526	chr6:149796975	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.55	-0.34	2.25e-10	Dupuytren's disease;
CRC	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.72	8.89	0.44	4.1e-17	Dialysis-related mortality;
CRC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg00071950	chr4:10020882	SLC2A9	0.49	6.84	0.35	3.78e-11	Blood metabolite levels;
CRC	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg24848437	chr7:2645542	IQCE	0.58	6.14	0.32	2.43e-9	Urate levels in lean individuals;
CRC	cis	rs798766	1.000	rs798744	chr4:1714684	C/A	cg25714306	chr4:1656736	FAM53A	-0.33	-5.84	-0.31	1.23e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs10208940	0.920	rs12713643	chr2:68724129	C/G	cg12452813	chr2:68675892	NA	0.51	6.35	0.33	7.33e-10	Urate levels in lean individuals;
CRC	trans	rs3758141	0.527	rs13273408	chr8:18700405	G/A	cg08576827	chr20:9075493	PLCB4	-0.76	-6.18	-0.32	1.91e-9	Body mass index (change over time) in gastrointestinal cancer;
CRC	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-5.82	-0.31	1.37e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.49	6.71	0.35	8.69e-11	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.38	-6.42	-0.33	4.69e-10	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24450365	chr7:89874355	C7orf63	0.44	6.55	0.34	2.2e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs57419108	chr2:162311357	G/C	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.27	-0.33	1.13e-9	Cognitive function;
CRC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.4	-0.33	5.21e-10	Arsenic metabolism;
CRC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.39	5.71	0.3	2.59e-8	Renal cell carcinoma;
CRC	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-5.93	-0.31	7.47e-9	Daytime sleep phenotypes;
CRC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.6	8.96	0.44	2.38e-17	Methadone dose in opioid dependence;
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg16060761	chr17:80687452	NA	-0.47	-6.29	-0.33	9.95e-10	Glycated hemoglobin levels;
CRC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.5	7.93	0.4	3.44e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.1	-0.36	7.92e-12	Bipolar disorder;
CRC	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.46	6.79	0.35	5.3e-11	Asthma;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg10876282	chr6:28092338	ZSCAN16	0.5	6.71	0.35	8.65e-11	Cardiac Troponin-T levels;
CRC	cis	rs7932354	0.583	rs7934421	chr11:46852753	T/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.54	-0.34	2.31e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.37	-6.58	-0.34	1.87e-10	Menarche (age at onset);
CRC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.22	-0.32	1.55e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.52	8.23	0.41	4.52e-15	Red blood cell count;
CRC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.3	-0.33	9.32e-10	Schizophrenia;
CRC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg19622623	chr12:86230825	RASSF9	-0.4	-6.55	-0.34	2.24e-10	Major depressive disorder;
CRC	cis	rs863345	0.604	rs11264984	chr1:158464990	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	9.9e-10	Pneumococcal bacteremia;
CRC	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.35	7.47	0.38	7.46e-13	Migraine;
CRC	cis	rs12044355	0.927	rs61835382	chr1:231833225	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	6.09	0.32	3.2e-9	Alzheimer's disease;
CRC	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg18761221	chr20:60518478	NA	-0.53	-8.29	-0.42	2.9e-15	Body mass index;
CRC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.5	7.39	0.38	1.23e-12	Asthma;
CRC	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.13	11.95	0.55	1.43e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-5.98	-0.31	5.91e-9	Bipolar disorder;
CRC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-9.07	-0.45	1.1e-17	Bone mineral density;
CRC	cis	rs2811415	0.597	rs6796874	chr3:127801198	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.85	-0.31	1.17e-8	Lung function (FEV1/FVC);
CRC	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg00319359	chr11:70116639	PPFIA1	0.55	5.68	0.3	2.93e-8	Coronary artery disease;
CRC	cis	rs612683	0.536	rs1855797	chr1:101027126	A/G	cg06223162	chr1:101003688	GPR88	0.36	6.5	0.34	2.9e-10	Breast cancer;
CRC	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.52	7.98	0.4	2.49e-14	Coronary artery disease;
CRC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.48	6.98	0.36	1.59e-11	Colorectal cancer;
CRC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg00745463	chr17:30367425	LRRC37B	-0.54	-6.72	-0.35	8.17e-11	Hip circumference adjusted for BMI;
CRC	cis	rs4662945	0.762	rs28510974	chr2:130215288	G/A	cg05903289	chr2:130345205	NA	-0.31	-6.01	-0.31	5.05e-9	Response to cytidine analogues (gemcitabine);
CRC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.18	0.45	5.03e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24249390	chr15:90295951	MESP1	-0.6	-9.49	-0.46	4.94e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.55	7.18	0.37	4.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.64	9.45	0.46	6.35e-19	Blood protein levels;
CRC	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.37	-5.9	-0.31	8.89e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.53	8.45	0.42	9.86e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg12590608	chr7:158785262	NA	0.39	6.84	0.35	3.86e-11	Facial morphology (factor 20);
CRC	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-6.13	-0.32	2.58e-9	Height;
CRC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17848003	chr1:3704513	LRRC47	0.4	5.7	0.3	2.66e-8	Red cell distribution width;
CRC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.57	0.47	2.7e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg06896663	chr8:82754093	SNX16	-0.69	-6.06	-0.32	3.82e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09242721	chr3:3168535	TRNT1	0.36	6.28	0.33	1.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.4	5.84	0.31	1.28e-8	Morning vs. evening chronotype;
CRC	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.47	6.79	0.35	5.13e-11	Coronary heart disease;
CRC	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.68	-10.63	-0.51	7.23e-23	Neurofibrillary tangles;
CRC	trans	rs6693295	0.729	rs6680996	chr1:246214432	C/T	cg03680032	chr11:94965610	SESN3	0.49	6.16	0.32	2.13e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.59	9.55	0.47	3.11e-19	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-6.04	-0.32	4.2e-9	Vitiligo;
CRC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.73e-30	Blood trace element (Zn levels);
CRC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.47	6.13	0.32	2.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1916521	0.519	rs11004952	chr10:57424125	T/C	cg16731318	chr1:94313343	NA	-0.43	-6.08	-0.32	3.35e-9	Cardiac hypertrophy;
CRC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.75	12.06	0.55	5.49e-28	Neuroticism;
CRC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg13777783	chr17:79615861	NA	0.3	5.64	0.3	3.71e-8	Eye color traits;
CRC	cis	rs12541635	0.771	rs12155864	chr8:107105491	C/T	cg10147462	chr8:107024639	NA	-0.39	-6.05	-0.32	3.92e-9	Age of smoking initiation;
CRC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.36	0.46	1.32e-18	Lung cancer in ever smokers;
CRC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg20503657	chr10:835505	NA	-0.42	-6.09	-0.32	3.18e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.4	-6.21	-0.32	1.56e-9	Recombination rate (males);
CRC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg06494592	chr3:125709126	NA	-0.5	-6.12	-0.32	2.61e-9	Blood pressure (smoking interaction);
CRC	cis	rs1656402	1.000	rs3021411	chr2:233425224	G/A	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg09877947	chr5:131593287	PDLIM4	0.43	7.04	0.36	1.13e-11	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25441200	chr7:156742235	NOM1	-0.5	-6.18	-0.32	1.89e-9	Diisocyanate-induced asthma;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.89	-20.28	-0.75	6.76e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2160860	0.773	rs11786337	chr8:39797764	G/T	cg11363097	chr8:39792086	IDO2	-0.43	-7.26	-0.37	2.77e-12	Blood metabolite levels;
CRC	cis	rs12286929	0.839	rs12421648	chr11:115013447	G/A	cg04055981	chr11:115044050	NA	0.36	5.85	0.31	1.22e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.47	6.22	0.32	1.5e-9	Gut microbiome composition (summer);
CRC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.42	-0.33	4.63e-10	Aortic root size;
CRC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.6	-11.46	-0.53	7.9e-26	Intelligence (multi-trait analysis);
CRC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg18375707	chr11:64034959	PLCB3	0.48	5.6	0.3	4.49e-8	Mean platelet volume;
CRC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.03	-22.54	-0.78	1.1e-68	Myeloid white cell count;
CRC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.98	0.55	1.09e-27	Bone mineral density;
CRC	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg09127314	chr1:152161683	NA	0.49	6.29	0.33	1.01e-9	Atopic dermatitis;
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg15511327	chr8:143859410	LYNX1	-0.33	-5.72	-0.3	2.34e-8	Urinary tract infection frequency;
CRC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.82	-10.55	-0.5	1.37e-22	Initial pursuit acceleration;
CRC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.6	10.78	0.51	2.04e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.36	-0.46	1.31e-18	Urate levels in obese individuals;
CRC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg01529538	chr14:23388837	RBM23	0.39	6.02	0.32	4.56e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.77	7.1	0.36	7.61e-12	Type 2 diabetes;
CRC	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.89	-0.36	2.82e-11	Response to antipsychotic treatment;
CRC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg03013636	chr16:1946785	NA	0.57	6.99	0.36	1.54e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg08210727	chr20:33865349	NA	0.43	5.88	0.31	1.03e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.97	0.36	1.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7692995	1.000	rs7698644	chr4:18019572	C/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.16	-0.32	2.16e-9	Aortic root size;
CRC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg15845792	chr6:28175446	NA	0.73	6.16	0.32	2.13e-9	Depression;
CRC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg25347419	chr2:177043501	NA	0.58	9.12	0.45	7.55e-18	IgG glycosylation;
CRC	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.48	8.08	0.41	1.24e-14	Common traits (Other);
CRC	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.67	10.7	0.51	4.01e-23	Breast cancer;
CRC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.39	0.46	1e-18	Monocyte percentage of white cells;
CRC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19717773	chr7:2847554	GNA12	-0.4	-5.83	-0.31	1.35e-8	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12315590	chr3:128997497	C3orf37	0.48	6.58	0.34	1.86e-10	Thyroid stimulating hormone;
CRC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.7	10.23	0.49	1.68e-21	Corneal astigmatism;
CRC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg27661571	chr11:113659931	NA	-0.89	-10.32	-0.49	8.03e-22	Hip circumference adjusted for BMI;
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.82	0.31	1.38e-8	Electroencephalogram traits;
CRC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	14.68	0.63	6.92e-38	Smoking behavior;
CRC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg04450456	chr4:17643702	FAM184B	0.41	6.65	0.34	1.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.57	-8.42	-0.42	1.17e-15	Bone mineral density;
CRC	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.37e-11	Prostate cancer;
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13198984	chr17:80129470	CCDC57	0.46	8.24	0.41	4.11e-15	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25617285	chr1:211431773	RCOR3	0.4	6.23	0.32	1.45e-9	Response to antipsychotic treatment;
CRC	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg03469862	chr11:68924853	NA	0.46	5.91	0.31	8.56e-9	Blond vs. brown hair color;
CRC	cis	rs9549328	0.700	rs3011474	chr13:113617865	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.36	0.46	1.32e-18	Systolic blood pressure;
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg27635394	chr6:26043820	HIST1H2BB	0.45	6.49	0.34	3.25e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-15.74	-0.66	5.06e-42	Intelligence (multi-trait analysis);
CRC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.37	-7.73	-0.39	1.33e-13	Schizophrenia;
CRC	cis	rs12044355	0.892	rs10429979	chr1:231843569	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.95	0.31	6.93e-9	Alzheimer's disease;
CRC	cis	rs2737618	0.674	rs2816973	chr1:200084743	C/G	cg21825944	chr1:200113062	NR5A2	0.48	6.95	0.36	1.96e-11	Uric acid levels;
CRC	trans	rs9693857	0.520	rs4557706	chr8:9357369	G/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.3	0.33	9.52e-10	Systolic blood pressure;
CRC	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.49	-0.34	3.11e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.81	13.53	0.6	1.85e-33	Menopause (age at onset);
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.77	11.67	0.54	1.44e-26	Menarche (age at onset);
CRC	cis	rs883565	0.740	rs6796837	chr3:39076188	C/T	cg01426195	chr3:39028469	NA	-0.53	-8.53	-0.43	5.57e-16	Handedness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17059624	chr11:85358760	TMEM126A	0.48	6.33	0.33	8.01e-10	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg02389323	chr16:88786976	FAM38A	0.98	9.0	0.44	1.86e-17	Plateletcrit;
CRC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.56	7.56	0.38	3.93e-13	Menopause (age at onset);
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg27615366	chr5:131592974	PDLIM4	0.34	6.43	0.33	4.61e-10	Blood metabolite levels;
CRC	cis	rs12024301	0.557	rs74341654	chr1:183642852	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.82	6.81	0.35	4.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.06	0.55	5.43e-28	Chronic sinus infection;
CRC	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg15571903	chr15:79123663	NA	0.31	6.13	0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15773716	chr6:44355950	CDC5L	0.4	6.49	0.34	3.24e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg20203395	chr5:56204925	C5orf35	-0.54	-7.43	-0.38	9.48e-13	Coronary artery disease;
CRC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-1.05	-13.77	-0.6	2.13e-34	Initial pursuit acceleration;
CRC	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.56e-8	Electroencephalogram traits;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.84	0.55	3.64e-27	Bone mineral density;
CRC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-9.22	-0.45	3.58e-18	Cognitive function;
CRC	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg12964065	chr18:77638022	KCNG2	0.68	6.8	0.35	4.94e-11	Opioid sensitivity;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg20933634	chr6:27740509	NA	0.42	5.85	0.31	1.21e-8	Parkinson's disease;
CRC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.4	-5.65	-0.3	3.47e-8	Parkinson's disease;
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg20848291	chr7:100343083	ZAN	-0.54	-6.69	-0.35	9.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02290350	chr8:58132656	NA	-0.56	-7.69	-0.39	1.76e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg05935833	chr10:81318306	SFTPA2	-0.73	-8.0	-0.4	2.14e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.58	-8.88	-0.44	4.43e-17	Bone mineral density;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	8.09e-9	Prudent dietary pattern;
CRC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.63	-0.34	1.41e-10	Total body bone mineral density;
CRC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.46	-6.27	-0.33	1.11e-9	Red blood cell count;
CRC	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.72	-11.75	-0.54	7.37e-27	Plateletcrit;Platelet count;
CRC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.26e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg00373020	chr1:21041521	KIF17	0.36	5.83	0.31	1.3e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.74e-9	Breast cancer;
CRC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.58	-8.46	-0.42	9.21e-16	Longevity;
CRC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.43	-7.35	-0.38	1.53e-12	Height;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg21251018	chr6:28226885	NKAPL	0.48	7.65	0.39	2.18e-13	Parkinson's disease;
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02359409	chr6:42947317	PEX6	-0.56	-8.68	-0.43	1.9e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4665630	0.522	rs75866363	chr2:24046426	G/A	cg07265300	chr2:24346000	PFN4;LOC375190	0.81	6.34	0.33	7.39e-10	Hypertension;
CRC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg20291162	chr17:40259547	DHX58	-0.55	-7.98	-0.4	2.46e-14	Fibrinogen levels;
CRC	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.66	-11.19	-0.53	7.53e-25	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.42	-5.69	-0.3	2.78e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.54	6.37	0.33	6.49e-10	Blood pressure (smoking interaction);
CRC	cis	rs7605827	0.930	rs11689686	chr2:15527659	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg13919466	chr1:32135498	COL16A1	-0.31	-5.91	-0.31	8.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.43	5.77	0.3	1.8e-8	Schizophrenia;
CRC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.39	7.44	0.38	9.12e-13	Mean corpuscular volume;
CRC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.66	7.44	0.38	8.84e-13	Vitiligo;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15471812	chr17:38599763	IGFBP4	0.44	6.02	0.31	4.75e-9	Hip circumference;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg07507251	chr3:52567010	NT5DC2	-0.42	-6.24	-0.33	1.32e-9	Bipolar disorder;
CRC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.69	11.34	0.53	2.24e-25	Mean platelet volume;
CRC	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg07322936	chr10:88137208	NA	0.63	8.82	0.44	6.67e-17	Schizophrenia;
CRC	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg23750338	chr8:142222470	SLC45A4	0.4	6.14	0.32	2.33e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg22561889	chr6:118971681	C6orf204	0.46	5.97	0.31	6.29e-9	Diastolic blood pressure;
CRC	cis	rs2015599	0.549	rs7972032	chr12:29444284	G/A	cg09582351	chr12:29534625	ERGIC2	-0.26	-5.71	-0.3	2.47e-8	Mean platelet volume;Platelet count;
CRC	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg26353448	chr1:248524236	OR2T4	-0.32	-6.04	-0.32	4.21e-9	Common traits (Other);
CRC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.78e-24	Bone mineral density;
CRC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.47	-7.47	-0.38	7.3e-13	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06361278	chr17:25783929	NA	0.5	7.84	0.4	6.34e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.32e-10	Electroencephalogram traits;
CRC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg06204229	chr3:52865917	ITIH4	0.54	6.28	0.33	1.07e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07327202	chr20:5107451	CDS2;PCNA	0.41	6.08	0.32	3.29e-9	Response to antipsychotic treatment;
CRC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-19.38	-0.73	2.35e-56	Ulcerative colitis;
CRC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg10729496	chr3:10149963	C3orf24	0.48	5.63	0.3	3.81e-8	Alzheimer's disease;
CRC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.4	5.98	0.31	5.9e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12463550	chr7:65579703	CRCP	-0.73	-6.56	-0.34	2.1e-10	Diabetic kidney disease;
CRC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg10494973	chr17:80897199	TBCD	-0.37	-5.67	-0.3	3.11e-8	Breast cancer;
CRC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06656553	chr16:89960601	TCF25	-0.68	-5.66	-0.3	3.31e-8	Skin colour saturation;
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg15382696	chr6:118971807	C6orf204	0.59	7.64	0.39	2.45e-13	Diastolic blood pressure;
CRC	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.42	6.7	0.35	9.12e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg06223162	chr1:101003688	GPR88	-0.34	-5.79	-0.3	1.68e-8	Monocyte count;
CRC	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg24289452	chr6:170231220	NA	-0.57	-6.21	-0.32	1.58e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.36	0.33	6.59e-10	Renal cell carcinoma;
CRC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg08999081	chr20:33150536	PIGU	0.43	5.89	0.31	9.38e-9	Protein C levels;
CRC	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg00666640	chr1:248458726	OR2T12	0.47	8.01	0.4	1.99e-14	Common traits (Other);
CRC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.76	16.49	0.67	5.94e-45	Breast cancer;
CRC	cis	rs1124376	1.000	rs1124376	chr3:20108546	A/G	cg05072819	chr3:20081367	KAT2B	-0.57	-6.88	-0.35	3.01e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg21153622	chr11:89784906	NA	-0.45	-7.23	-0.37	3.31e-12	HDL cholesterol;
CRC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	9.86	0.48	2.96e-20	Hip circumference adjusted for BMI;
CRC	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02598441	chr17:62777298	LOC146880	-0.53	-7.41	-0.38	1.1e-12	QT interval;
CRC	cis	rs7527798	0.571	rs7531923	chr1:207833336	T/G	cg21110645	chr1:207815933	NA	-0.44	-6.97	-0.36	1.76e-11	Erythrocyte sedimentation rate;
CRC	cis	rs4683142	0.518	rs7653682	chr3:46029271	A/G	cg08033130	chr3:45983597	CXCR6;FYCO1	0.42	5.72	0.3	2.46e-8	Methadone dose in opioid dependence;
CRC	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.46	-6.2	-0.32	1.68e-9	Diisocyanate-induced asthma;
CRC	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.63	-9.19	-0.45	4.64e-18	Blood pressure (smoking interaction);
CRC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg26248373	chr2:1572462	NA	-0.65	-7.15	-0.37	5.76e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.51e-8	Total body bone mineral density;
CRC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-5.88	-0.31	9.83e-9	Migraine;Coronary artery disease;
CRC	cis	rs4400599	1.000	rs3001363	chr1:154125067	C/T	cg05139571	chr1:154127138	NUP210L	-0.42	-6.43	-0.33	4.56e-10	Platelet distribution width;
CRC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.6	-11.46	-0.53	7.9e-26	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.66	12.27	0.56	9.73e-29	Aortic root size;
CRC	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-6.92	-0.36	2.43e-11	Coronary artery disease;
CRC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.5	-0.34	2.99e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06197006	chr17:1359813	CRK	0.44	6.18	0.32	1.93e-9	Response to antipsychotic treatment;
CRC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.68	9.47	0.46	5.71e-19	Gestational age at birth (maternal effect);
CRC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.65	-8.28	-0.42	3.04e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-11.03	-0.52	2.81e-24	Platelet distribution width;
CRC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.37	0.56	4.08e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-1.0	-22.68	-0.78	3.05e-69	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg15848620	chr12:58087721	OS9	0.57	7.69	0.39	1.74e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg24596898	chr1:41849189	NA	0.35	5.77	0.3	1.83e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg02527881	chr3:46936655	PTH1R	-0.36	-6.68	-0.35	1.04e-10	Colorectal cancer;
CRC	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg05925327	chr15:68127851	NA	0.29	5.65	0.3	3.53e-8	Restless legs syndrome;
CRC	cis	rs519973	1.000	rs2378351	chr3:187635979	A/G	cg10168494	chr3:187635183	NA	0.51	8.94	0.44	2.95e-17	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs9584850	0.574	rs60492361	chr13:99172653	T/C	cg20487152	chr13:99095054	FARP1	0.43	5.69	0.3	2.75e-8	Neuroticism;
CRC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg25834613	chr7:1915315	MAD1L1	-0.41	-5.72	-0.3	2.36e-8	Neuroticism;
CRC	cis	rs6969780	1.000	rs1801085	chr7:27168590	A/G	cg26364809	chr7:27145159	NA	-0.73	-6.78	-0.35	5.46e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.86	14.07	0.61	1.65e-35	Blood metabolite levels;
CRC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22029157	chr1:209979665	IRF6	0.61	6.79	0.35	5.21e-11	Cleft lip with or without cleft palate;
CRC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg11245181	chr6:149772854	ZC3H12D	0.53	9.34	0.46	1.46e-18	Dupuytren's disease;
CRC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.32	-0.33	8.43e-10	Bipolar disorder;
CRC	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg08222913	chr3:52553049	STAB1	-0.32	-6.16	-0.32	2.1e-9	Electroencephalogram traits;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.37	-5.96	-0.31	6.44e-9	Total body bone mineral density;
CRC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.63	7.06	0.36	1.02e-11	Lymphocyte counts;
CRC	cis	rs883565	0.569	rs784513	chr3:39164915	G/A	cg01426195	chr3:39028469	NA	0.42	6.99	0.36	1.56e-11	Handedness;
CRC	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21659725	chr3:3221576	CRBN	-0.68	-9.33	-0.46	1.64e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2179367	0.959	rs536203	chr6:149651264	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.03	-0.32	4.4e-9	Dupuytren's disease;
CRC	cis	rs72772090	0.539	rs11748328	chr5:96169916	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.38	-0.33	6.17e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.42	-6.19	-0.32	1.75e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg04850286	chr10:81895943	PLAC9	0.36	6.3	0.33	9.47e-10	Sarcoidosis;
CRC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.82	8.98	0.44	2.19e-17	Breast cancer;
CRC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.49	7.58	0.39	3.63e-13	Corneal astigmatism;
CRC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg25956985	chr22:39795188	MAP3K7IP1	0.47	7.02	0.36	1.28e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.8	-10.52	-0.5	1.6400000000000001e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs35883536	1.000	rs3861733	chr1:101111807	G/A	cg14515779	chr1:101123966	NA	-0.43	-8.29	-0.42	2.9e-15	Monocyte count;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg02683197	chr6:28174875	NA	0.6	7.89	0.4	4.56e-14	Parkinson's disease;
CRC	cis	rs294883	0.858	rs9365037	chr6:159704003	C/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.03	-0.45	1.43e-17	Brugada syndrome;
CRC	cis	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg27432699	chr2:27873401	GPN1	0.65	8.54	0.43	5.09e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs13253111	1.000	rs62500888	chr8:28061823	A/G	cg26534493	chr8:28060551	NA	0.48	8.48	0.42	7.61e-16	Childhood body mass index;
CRC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg00938859	chr5:1591904	SDHAP3	-0.62	-6.72	-0.35	8.19e-11	Breast cancer;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.56	-0.43	4.5e-16	Electroencephalogram traits;
CRC	cis	rs6662572	0.723	rs72677543	chr1:46565329	A/T	cg08644498	chr1:46502608	NA	0.46	7.28	0.37	2.42e-12	Blood protein levels;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.41	9.04	0.45	1.35e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-6.85	-0.35	3.54e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg27342122	chr8:133787442	PHF20L1	-0.71	-6.02	-0.31	4.6e-9	Cognitive function;
CRC	cis	rs7538876	0.903	rs1324367	chr1:17752451	C/G	cg01904812	chr1:17746340	RCC2	0.38	6.23	0.32	1.41e-9	Basal cell carcinoma;
CRC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.25	-0.41	3.89e-15	Chronic sinus infection;
CRC	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.19	0.32	1.74e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.55	7.68	0.39	1.83e-13	Testicular germ cell tumor;
CRC	cis	rs9322817	0.691	rs2400071	chr6:105344075	C/T	cg02098413	chr6:105308735	HACE1	0.46	9.14	0.45	6.64e-18	Thyroid stimulating hormone;
CRC	cis	rs1434579	0.966	rs1062093	chr19:44931995	C/G	cg15540054	chr19:45004280	ZNF180	0.5	6.36	0.33	6.63e-10	Tuberculosis;
CRC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg25347419	chr2:177043501	NA	-0.48	-6.43	-0.33	4.54e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.11	-0.56	3.76e-28	Coffee consumption (cups per day);
CRC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.68	-11.79	-0.54	5.45e-27	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08502759	chr11:10562853	RNF141	0.43	7.11	0.36	7.2e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.4	-6.23	-0.32	1.46e-9	Blood metabolite levels;
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.8	15.25	0.64	4.21e-40	Prudent dietary pattern;
CRC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg05585544	chr11:47624801	NA	-0.61	-10.81	-0.51	1.66e-23	Subjective well-being;
CRC	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg10820045	chr2:198174542	NA	0.43	7.48	0.38	6.87e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.43	6.05	0.32	3.91e-9	Primary tooth development (time to first tooth eruption);
CRC	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.38	-0.42	1.58e-15	Asthma (sex interaction);
CRC	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.94	-0.36	2.12e-11	Inflammatory skin disease;
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.81	-0.58	9.35e-31	Alzheimer's disease;
CRC	cis	rs11239930	1.000	rs11239930	chr1:146560564	C/T	cg11655389	chr1:146548469	NA	-0.32	-5.76	-0.3	1.93e-8	AIDS progression;
CRC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.78	11.13	0.52	1.28e-24	Breast cancer;
CRC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-12.05	-0.55	6.24e-28	Platelet count;
CRC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25517755	chr10:38738941	LOC399744	-0.43	-6.11	-0.32	2.88e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.79	0.61	1.92e-34	Schizophrenia;
CRC	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.61	8.28	0.42	3.08e-15	Coronary artery disease;
CRC	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg17182837	chr8:41585554	ANK1	-0.38	-5.99	-0.31	5.65e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg03037974	chr15:76606532	NA	0.53	8.12	0.41	9.26e-15	Blood metabolite levels;
CRC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.48	-0.46	5.41e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg14671364	chr1:107599128	PRMT6	-0.57	-7.78	-0.39	9.76e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.06	0.32	3.69e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.65	8.48	0.42	7.95e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.84	13.5	0.6	2.35e-33	Menarche (age at onset);
CRC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.6	7.72	0.39	1.42e-13	Bipolar disorder;
CRC	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.67	9.41	0.46	8.59e-19	Body mass index;
CRC	cis	rs72730918	0.564	rs28408214	chr15:51867574	A/T	cg14296394	chr15:51910925	DMXL2	-0.45	-5.95	-0.31	6.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.7	10.0	0.48	9.84e-21	Body mass index;
CRC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.59	8.71	0.43	1.52e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg07507251	chr3:52567010	NT5DC2	0.41	5.84	0.31	1.27e-8	Bipolar disorder;
CRC	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	11.03	0.52	2.86e-24	Platelet count;
CRC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.2	-0.32	1.72e-9	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.87	0.51	9.87e-24	Motion sickness;
CRC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg16102536	chr7:156981717	UBE3C	0.41	6.79	0.35	5.35e-11	Body mass index;
CRC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg15744005	chr10:104629667	AS3MT	-0.35	-6.42	-0.33	4.67e-10	Arsenic metabolism;
CRC	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg02353165	chr6:42928485	GNMT	0.54	6.91	0.36	2.57e-11	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23784313	chr12:15942613	EPS8	0.45	6.05	0.32	4.01e-9	Thyroid stimulating hormone;
CRC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg19077165	chr18:44547161	KATNAL2	0.43	6.71	0.35	8.7e-11	Personality dimensions;
CRC	cis	rs4731207	0.698	rs10261610	chr7:124450577	G/A	cg23710748	chr7:124431027	NA	0.38	6.03	0.32	4.49e-9	Cutaneous malignant melanoma;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.42	0.42	1.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg05139728	chr16:28306816	SBK1	-0.38	-6.23	-0.32	1.41e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg18830697	chr6:72922368	RIMS1	-0.39	-7.92	-0.4	3.81e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02725872	chr8:58115012	NA	-0.39	-6.78	-0.35	5.63e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs231513	0.954	rs231493	chr17:41976998	G/C	cg26893861	chr17:41843967	DUSP3	-0.62	-6.27	-0.33	1.11e-9	Cognitive function;
CRC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	0.98	16.66	0.68	1.26e-45	Total cholesterol levels;
CRC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.32	0.33	8.62e-10	Cognitive ability;
CRC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.78	-12.26	-0.56	9.94e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.68	-9.85	-0.48	3.17e-20	Monocyte count;
CRC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-8.35	-0.42	1.86e-15	Uric acid levels;
CRC	cis	rs9584850	0.789	rs7988345	chr13:99117685	A/G	cg07423050	chr13:99094983	FARP1	0.44	6.08	0.32	3.39e-9	Neuroticism;
CRC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.66	-9.3	-0.46	1.95e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Dilated cardiomyopathy;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22233523	chr18:44497604	PIAS2	0.41	6.82	0.35	4.3e-11	Obesity-related traits;
CRC	cis	rs834811	0.563	rs834801	chr7:135871355	A/G	cg01726295	chr7:135938950	NA	0.38	6.5	0.34	2.92e-10	Post-traumatic stress disorder;
CRC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.41	5.88	0.31	1.01e-8	Renal cell carcinoma;
CRC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.95	0.36	2.01e-11	Neuroticism;
CRC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.33	6.7	0.35	8.99e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.63e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04732357	chr2:96658324	NA	0.44	6.61	0.34	1.56e-10	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.21e-15	Bipolar disorder;
CRC	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.4	-6.68	-0.35	1.03e-10	Vitamin D levels;
CRC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg12046867	chr14:103022105	NA	0.77	8.98	0.44	2.14e-17	Platelet count;
CRC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.6	8.99	0.44	2.05e-17	Subjective well-being;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23708337	chr7:1209742	NA	0.51	7.9	0.4	4.34e-14	Longevity;Endometriosis;
CRC	cis	rs9903692	0.954	rs7212202	chr17:46132723	G/C	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05353131	chr15:64995641	OAZ2	0.46	6.88	0.35	3.11e-11	Intelligence (multi-trait analysis);
CRC	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg12870014	chr12:110450643	ANKRD13A	0.8	9.34	0.46	1.47e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7605827	0.897	rs13022830	chr2:15696542	T/C	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.52	-0.75	7.88e-61	Primary sclerosing cholangitis;
CRC	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	1.07	9.58	0.47	2.5e-19	Type 2 diabetes nephropathy;
CRC	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-6.0	-0.31	5.08e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	7.97	0.4	2.67e-14	Menarche (age at onset);
CRC	cis	rs12230513	0.793	rs1896045	chr12:55953568	A/G	cg19537932	chr12:55886519	OR6C68	-0.42	-5.65	-0.3	3.56e-8	Contrast sensitivity;
CRC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.6	9.85	0.48	3.25e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.5	7.74	0.39	1.26e-13	Corneal astigmatism;
CRC	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.11e-12	HDL cholesterol;
CRC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	7.97	0.4	2.71e-14	Schizophrenia;
CRC	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg27398640	chr15:77910606	LINGO1	0.46	8.16	0.41	6.94e-15	Type 2 diabetes;
CRC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.62	8.48	0.42	7.59e-16	Height;
CRC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.58	0.7	2.92e-49	Platelet count;
CRC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.86	13.14	0.59	5.44e-32	Cognitive function;
CRC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-14.31	-0.62	1.87e-36	Longevity;
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.74	-0.3	2.19e-8	Life satisfaction;
CRC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.12	-0.41	9.55e-15	Mood instability;
CRC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs34311866	0.656	rs11731377	chr4:971266	T/G	cg07828340	chr4:882639	GAK	0.75	7.18	0.37	4.81e-12	Parkinson's disease;
CRC	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.46	-0.38	7.65e-13	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs1190552	0.894	rs4906203	chr14:102928991	C/T	cg18135206	chr14:102964638	TECPR2	0.49	5.93	0.31	7.6e-9	Blood protein levels;
CRC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.89	-15.95	-0.66	7.68e-43	Height;
CRC	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg09659197	chr4:152720779	NA	0.42	8.83	0.44	6.15e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6479527	0.806	rs7867253	chr9:96750794	C/T	cg14459158	chr9:96720562	NA	0.41	7.52	0.38	5.11e-13	Esophageal adenocarcinoma;
CRC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.85	0.31	1.21e-8	Prudent dietary pattern;
CRC	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg20936604	chr3:58311152	NA	-0.75	-6.89	-0.35	2.9100000000000002e-11	Cholesterol, total;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg04518342	chr5:131593106	PDLIM4	0.36	6.72	0.35	7.83e-11	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14349843	chr17:16284098	UBB	0.46	6.45	0.34	4.04e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.7	-9.26	-0.45	2.68e-18	Alzheimer's disease;
CRC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.57	-0.43	4.12e-16	Chronic sinus infection;
CRC	cis	rs7113874	0.544	rs9704807	chr11:8578771	G/C	cg17679104	chr11:8615758	STK33	-0.35	-5.9	-0.31	8.88e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04402633	chr11:2907113	CDKN1C	0.37	6.01	0.31	4.91e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	10.18	0.49	2.44e-21	Alzheimer's disease (late onset);
CRC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.72	-0.35	8.25e-11	Aortic root size;
CRC	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.4	6.16	0.32	2.15e-9	Endometrial cancer;
CRC	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg20636351	chr8:55087400	NA	-0.33	-5.86	-0.31	1.1e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.98	-18.35	-0.71	2.72e-52	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs73200209	0.744	rs1865787	chr12:116429689	A/G	cg01776926	chr12:116560359	MED13L	-0.66	-7.66	-0.39	2.11e-13	Total body bone mineral density;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg02683197	chr6:28174875	NA	0.72	8.85	0.44	5.44e-17	Parkinson's disease;
CRC	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.76	-0.3	1.93e-8	Subjective well-being;
CRC	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.44	-6.31	-0.33	8.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg25856811	chr1:152973957	SPRR3	-0.21	-5.69	-0.3	2.87e-8	Inflammatory skin disease;
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.72	9.59	0.47	2.2e-19	Alzheimer's disease;
CRC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg07274523	chr3:49395745	GPX1	0.48	6.26	0.33	1.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3213961	0.529	rs6708	chr2:33789534	A/G	cg04131969	chr2:33951647	MYADML	0.44	6.14	0.32	2.34e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg11946769	chr3:48343235	NME6	-0.45	-6.07	-0.32	3.55e-9	Educational attainment (years of education);
CRC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.08	-0.41	1.22e-14	Monocyte count;
CRC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.57	10.33	0.49	7.36e-22	Total body bone mineral density;
CRC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	5.69	0.3	2.83e-8	Joint mobility (Beighton score);
CRC	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg14593290	chr7:50529359	DDC	-0.52	-7.21	-0.37	3.96e-12	Malaria;
CRC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.44	-6.53	-0.34	2.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18144860	chr5:130970833	RAPGEF6	0.4	6.33	0.33	8.14e-10	Schizophrenia;
CRC	cis	rs3996993	0.809	rs10948723	chr6:52666405	C/T	cg20803780	chr6:52668592	GSTA1	-0.35	-6.29	-0.33	1.02e-9	Hemoglobin concentration;
CRC	cis	rs73200209	0.701	rs11609930	chr12:116644670	A/G	cg01776926	chr12:116560359	MED13L	-0.61	-7.08	-0.36	8.97e-12	Total body bone mineral density;
CRC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.62	10.64	0.51	6.58e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs995000	0.931	rs1627591	chr1:62989807	C/T	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.56e-11	Triglyceride levels;
CRC	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg00531865	chr16:30841666	NA	-0.46	-6.45	-0.34	3.99e-10	Dementia with Lewy bodies;
CRC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.62	-9.23	-0.45	3.44e-18	Menarche (age at onset);
CRC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.74	-7.67	-0.39	1.9e-13	Diabetic retinopathy;
CRC	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	18.07	0.71	3.52e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19500275	chr17:80737654	TBCD	0.49	6.47	0.34	3.54e-10	Glycated hemoglobin levels;
CRC	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.45	-0.34	4e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg08992911	chr2:238395768	MLPH	0.52	6.09	0.32	3.17e-9	Prostate cancer;
CRC	cis	rs7113874	0.569	rs9300093	chr11:8590825	T/G	cg02811074	chr11:8615871	STK33	-0.34	-5.83	-0.31	1.35e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.53	7.6	0.39	3.15e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg11833968	chr6:79620685	NA	-0.37	-6.48	-0.34	3.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg22495460	chr2:25135724	ADCY3	-0.89	-17.5	-0.69	6.3e-49	Body mass index;
CRC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.16	0.37	5.28e-12	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg02683197	chr6:28174875	NA	0.63	8.77	0.44	1e-16	Parkinson's disease;
CRC	cis	rs939584	1.000	rs4854349	chr2:647861	T/C	cg03610516	chr2:642275	NA	0.41	5.93	0.31	7.83e-9	Body mass index;
CRC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02018176	chr4:1364513	KIAA1530	0.48	7.94	0.4	3.22e-14	Obesity-related traits;
CRC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	6.93	0.36	2.19e-11	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.62	11.42	0.53	1.13e-25	Immature fraction of reticulocytes;
CRC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg25456477	chr12:86230367	RASSF9	0.39	6.56	0.34	2.04e-10	Major depressive disorder;
CRC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-7.35	-0.38	1.54e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.6	8.76	0.43	1.05e-16	Schizophrenia;
CRC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.41	-6.57	-0.34	1.96e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg20041105	chr8:143859282	LYNX1	0.43	7.8	0.4	8.09e-14	Urinary tract infection frequency;
CRC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg25985355	chr7:65971099	NA	0.32	5.73	0.3	2.3e-8	Aortic root size;
CRC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.99	0.4	2.28e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg17848003	chr1:3704513	LRRC47	0.41	6.06	0.32	3.71e-9	Red cell distribution width;
CRC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg12855166	chr17:30846586	MYO1D	-0.56	-8.76	-0.43	1.05e-16	Schizophrenia;
CRC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg05941027	chr17:61774174	LIMD2	0.35	5.94	0.31	7.4e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg01738593	chr5:133860282	NA	0.57	7.27	0.37	2.65e-12	Resistin levels;
CRC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13198984	chr17:80129470	CCDC57	-0.47	-8.23	-0.41	4.43e-15	Life satisfaction;
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.17	-0.56	2.25e-28	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07362569	chr17:61921086	SMARCD2	0.36	5.6	0.3	4.41e-8	Prudent dietary pattern;
CRC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04880052	chr2:219191631	PNKD	-0.42	-6.64	-0.34	1.3100000000000001e-10	Colorectal cancer;
CRC	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg13385794	chr1:248469461	NA	-0.34	-6.31	-0.33	8.92e-10	Common traits (Other);
CRC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.55	9.24	0.45	3.09e-18	Eye color traits;
CRC	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg04586622	chr2:25135609	ADCY3	-0.55	-9.27	-0.46	2.52e-18	Body mass index;
CRC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	7.57	0.38	3.91e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.33	-0.42	2.17e-15	Type 2 diabetes;
CRC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.33	-0.42	2.26e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg04110750	chr16:69646130	NFAT5	-0.59	-8.08	-0.41	1.25e-14	IgE levels;
CRC	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.43	6.89	0.36	2.84e-11	Sitting height ratio;
CRC	cis	rs3015497	0.616	rs34061700	chr14:51084860	G/A	cg09863266	chr14:51125203	SAV1	-0.31	-5.89	-0.31	9.3e-9	Mean platelet volume;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg25164649	chr6:28176230	NA	0.65	8.79	0.44	8.45e-17	Parkinson's disease;
CRC	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg16068336	chr17:48637367	CACNA1G	-0.48	-6.94	-0.36	2.11e-11	Type 2 diabetes;
CRC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg20534287	chr10:135191450	PAOX	0.77	6.03	0.32	4.32e-9	Lifespan;
CRC	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg04110750	chr16:69646130	NFAT5	-0.56	-7.6	-0.39	3.05e-13	IgE levels;
CRC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.76	-0.35	6.4e-11	Platelet distribution width;
CRC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.53	-7.87	-0.4	5.27e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg20936604	chr3:58311152	NA	-0.62	-6.16	-0.32	2.08e-9	Cholesterol, total;
CRC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.91	-0.31	8.68e-9	Reticulocyte count;
CRC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22133161	chr19:49891603	CCDC155	0.46	5.87	0.31	1.04e-8	Multiple sclerosis;
CRC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg16110827	chr15:48056943	SEMA6D	-0.53	-8.15	-0.41	7.77e-15	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.97	15.64	0.65	1.34e-41	Parkinson's disease;
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.08	-0.32	3.36e-9	Total body bone mineral density;
CRC	cis	rs7113874	0.610	rs7947670	chr11:8525531	A/C	cg17679104	chr11:8615758	STK33	-0.37	-6.07	-0.32	3.45e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.61	-8.91	-0.44	3.65e-17	Menarche (age at onset);
CRC	cis	rs4601821	0.895	rs7130431	chr11:113238223	A/C	cg14159747	chr11:113255604	NA	0.5	9.42	0.46	8.33e-19	Alcoholic chronic pancreatitis;
CRC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.53	-0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.56	9.76	0.47	6.35e-20	Bipolar disorder;
CRC	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg20363699	chr7:23626180	CLK2P	0.35	6.15	0.32	2.27e-9	Schizophrenia;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05237023	chr16:75182837	ZFP1	0.39	6.37	0.33	6.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs995000	0.965	rs11207980	chr1:62992749	T/C	cg19896129	chr1:63156450	NA	0.4	5.91	0.31	8.43e-9	Triglyceride levels;
CRC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.64	-8.58	-0.43	3.92e-16	Malaria;
CRC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	9.55	0.47	3.1400000000000002e-19	Bipolar disorder and schizophrenia;
CRC	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg21153622	chr11:89784906	NA	-0.4	-6.34	-0.33	7.52e-10	Coronary artery disease;
CRC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-7.82	-0.4	7.16e-14	Colorectal cancer;
CRC	cis	rs11229555	0.645	rs7946522	chr11:58197905	G/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.71	-7.95	-0.4	3.01e-14	Body mass index;
CRC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.61	10.47	0.5	2.51e-22	Mean corpuscular volume;
CRC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg07090678	chr1:91966139	CDC7	0.42	6.95	0.36	1.93e-11	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20777956	chr18:60987812	BCL2	0.39	6.24	0.33	1.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.65	11.34	0.53	2.2e-25	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26272228	chr1:95538484	ALG14	0.42	6.92	0.36	2.42e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4700695	0.764	rs251277	chr5:65390177	A/G	cg21114390	chr5:65439923	SFRS12	-0.62	-6.72	-0.35	8.15e-11	Facial morphology (factor 19);
CRC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.56	8.5	0.42	6.77e-16	High light scatter reticulocyte count;
CRC	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.76	13.58	0.6	1.2e-33	Oral cavity cancer;
CRC	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	15.99	0.66	5.43e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg17321639	chr7:2759063	NA	-0.4	-5.99	-0.31	5.51e-9	Height;
CRC	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg05110241	chr16:68378359	PRMT7	-0.71	-6.64	-0.34	1.33e-10	Magnesium levels;
CRC	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.46	6.55	0.34	2.23e-10	Response to bleomycin (chromatid breaks);
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.48	-7.91	-0.4	4.02e-14	Testicular germ cell tumor;
CRC	trans	rs1973993	0.745	rs6683508	chr1:96955038	T/C	cg10631902	chr5:14652156	NA	-0.42	-7.0	-0.36	1.47e-11	Weight;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26342734	chr17:7211307	EIF5A	0.51	6.96	0.36	1.87e-11	Hip circumference;
CRC	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.78	-11.33	-0.53	2.4e-25	Multiple sclerosis;
CRC	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.28	-0.33	1.05e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.6	-12.04	-0.55	6.81e-28	Asthma (sex interaction);
CRC	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.11	13.43	0.6	4.2e-33	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.81	-16.93	-0.68	1.06e-46	Prostate cancer;
CRC	trans	rs10021731	0.668	rs11722201	chr4:115411733	C/T	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.21	-0.37	3.99e-12	Hemoglobin concentration;
CRC	cis	rs3764400	0.564	rs1452663	chr17:46293386	C/G	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.8	-13.58	-0.6	1.14e-33	Menopause (age at onset);
CRC	cis	rs9463078	0.625	rs500773	chr6:44888464	C/T	cg25276700	chr6:44698697	NA	-0.25	-6.11	-0.32	2.77e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg27001607	chr7:76178636	LOC100133091	0.49	6.01	0.31	4.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	trans	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	7.07	0.36	9.44e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.49	0.38	6.33e-13	Motion sickness;
CRC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg12560992	chr17:57184187	TRIM37	0.44	5.83	0.31	1.35e-8	Cognitive test performance;
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg11657817	chr20:23433608	CST11	0.53	8.65	0.43	2.24e-16	Facial morphology (factor 15, philtrum width);
CRC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.56	-6.95	-0.36	2.03e-11	Response to diuretic therapy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10724491	chr3:112738377	C3orf17	0.45	6.02	0.31	4.73e-9	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04352944	chr11:8932751	C11orf17;ST5	0.46	6.26	0.33	1.23e-9	Anxiety disorder;
CRC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	0.71	6.48	0.34	3.37e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg02466173	chr16:30829666	NA	0.62	9.32	0.46	1.78e-18	Dementia with Lewy bodies;
CRC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.41	6.49	0.34	3.21e-10	Monocyte count;
CRC	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.6	-9.6	-0.47	2.04e-19	Breast cancer;
CRC	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.45	6.75	0.35	6.76e-11	Neutrophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03289602	chr19:11708437	ZNF627	0.41	6.7	0.35	9.29e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs7302981	0.510	rs860698	chr12:50486322	T/C	cg18430156	chr2:187558795	FAM171B	-0.36	-5.98	-0.31	5.83e-9	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg12639453	chr1:2035780	PRKCZ	-0.33	-5.61	-0.3	4.38e-8	Height;
CRC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.71	-0.3	2.57e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02772935	chr3:125709198	NA	-0.52	-6.11	-0.32	2.89e-9	Blood pressure (smoking interaction);
CRC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg01420254	chr6:26195488	NA	0.84	8.64	0.43	2.44e-16	Gout;Renal underexcretion gout;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10343723	chr19:55919467	UBE2S	0.38	6.06	0.32	3.7e-9	Schizophrenia;
CRC	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg14593290	chr7:50529359	DDC	-0.63	-8.39	-0.42	1.48e-15	Malaria;
CRC	cis	rs117623576	0.715	rs11008755	chr10:32360053	C/T	cg03047570	chr10:32398778	NA	0.54	6.06	0.32	3.64e-9	Anti-saccade response;
CRC	cis	rs4664293	0.805	rs6432559	chr2:160607160	A/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.41	0.53	1.25e-25	Prudent dietary pattern;
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg21620606	chr4:1342894	KIAA1530	0.51	8.19	0.41	5.83e-15	Obesity-related traits;
CRC	cis	rs7129220	0.925	rs7108385	chr11:10337640	T/C	cg23875677	chr11:10229755	SBF2	-0.61	-5.6	-0.3	4.42e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg00490450	chr3:139108681	COPB2	0.43	6.43	0.33	4.53e-10	Obesity-related traits;
CRC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.82	-10.15	-0.49	2.98e-21	Initial pursuit acceleration;
CRC	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.83	0.63	1.82e-38	Exhaled nitric oxide output;
CRC	cis	rs3857067	0.806	rs9307137	chr4:95135712	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-6.24	-0.33	1.33e-9	QT interval;
CRC	cis	rs457287	0.772	rs844511	chr9:4822521	C/G	cg14182974	chr9:4791918	RCL1	0.39	5.85	0.31	1.19e-8	Platelet count;
CRC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg11212589	chr17:38028394	ZPBP2	0.42	7.7	0.39	1.59e-13	Self-reported allergy;
CRC	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.55	8.51	0.42	6.47e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.83	-0.4	6.72e-14	Caffeine consumption;
CRC	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.27	6.31	0.33	8.88e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg24463073	chr6:118973353	C6orf204	0.55	7.11	0.36	7.38e-12	Diastolic blood pressure;
CRC	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.46	-7.44	-0.38	8.91e-13	Refractive error;
CRC	cis	rs2223471	0.837	rs2817357	chr6:50762018	C/T	cg03432817	chr6:50765336	NA	-0.37	-5.95	-0.31	6.68e-9	Subcutaneous adipose tissue;
CRC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.62	9.57	0.47	2.66e-19	Corneal astigmatism;
CRC	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.49	8.37	0.42	1.68e-15	Common traits (Other);
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-13.64	-0.6	7.19e-34	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13402217	chr1:151584375	SNX27	0.41	6.38	0.33	6.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7107174	0.688	rs3740677	chr11:77928036	A/C	cg02023728	chr11:77925099	USP35	0.34	5.76	0.3	1.92e-8	Testicular germ cell tumor;
CRC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg22117107	chr15:45993392	NA	-0.44	-9.02	-0.45	1.58e-17	Waist circumference;Weight;
CRC	cis	rs12928939	0.911	rs11645725	chr16:71826883	C/T	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.05	-0.32	4.04e-9	Post bronchodilator FEV1;
CRC	cis	rs7737355	0.699	rs7711311	chr5:130781339	G/A	cg25547332	chr5:131281432	NA	-0.36	-5.74	-0.3	2.11e-8	Life satisfaction;
CRC	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.5	7.63	0.39	2.59e-13	Testicular germ cell tumor;
CRC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.85	0.31	1.19e-8	Bladder cancer;
CRC	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg06307176	chr5:131281290	NA	-0.4	-6.07	-0.32	3.6e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.47	-6.84	-0.35	3.92e-11	Longevity;Endometriosis;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg19041857	chr6:27730383	NA	-0.43	-6.05	-0.32	3.9e-9	Parkinson's disease;
CRC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.35	-6.08	-0.32	3.31e-9	Erythrocyte sedimentation rate;
CRC	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11578532	chr1:161008127	TSTD1	0.32	6.65	0.34	1.25e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg15832292	chr6:96025679	MANEA	0.6	6.53	0.34	2.43e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.57	-7.86	-0.4	5.59e-14	Lymphocyte percentage of white cells;
CRC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg14828511	chr1:107599125	PRMT6	0.47	6.52	0.34	2.67e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg11038491	chr20:34638489	LOC647979	-0.55	-6.23	-0.32	1.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.0	-0.31	5.06e-9	Gout;Renal underexcretion gout;
CRC	cis	rs12431939	0.626	rs8015848	chr14:51715021	G/A	cg23942311	chr14:51606299	NA	0.54	6.98	0.36	1.6e-11	Cancer;
CRC	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1320333	0.685	rs6710875	chr2:699976	A/G	cg20966539	chr2:681320	NA	-0.58	-5.92	-0.31	7.89e-9	Obesity-related traits;
CRC	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.08e-11	Common traits (Other);
CRC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.12	-14.83	-0.63	1.91e-38	Vitiligo;
CRC	cis	rs12931792	0.748	rs11150585	chr16:30184286	A/G	cg17640201	chr16:30407289	ZNF48	0.44	6.36	0.33	6.89e-10	Tonsillectomy;
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg16060761	chr17:80687452	NA	-0.45	-5.91	-0.31	8.41e-9	Glycated hemoglobin levels;
CRC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.43e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg03030879	chr14:75389066	RPS6KL1	0.44	6.69	0.35	9.82e-11	Height;
CRC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg13010199	chr12:38710504	ALG10B	0.43	6.2	0.32	1.71e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10735211	chr4:4310922	ZNF509	0.42	6.13	0.32	2.44e-9	Myopia (pathological);
CRC	cis	rs7945718	0.592	rs6416153	chr11:12684263	A/G	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.92e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.81	-13.15	-0.59	5.06e-32	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24903794	chr1:220220036	EPRS	0.43	6.03	0.32	4.46e-9	Response to antipsychotic treatment;
CRC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg16102536	chr7:156981717	UBE3C	-0.39	-6.8	-0.35	4.96e-11	Body mass index;
CRC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.08	0.36	8.73e-12	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08219700	chr8:58056026	NA	0.57	6.64	0.34	1.27e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1030268	0.608	rs12707106	chr7:133311350	A/T	cg10665199	chr7:133106180	EXOC4	0.64	7.71	0.39	1.48e-13	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg02466173	chr16:30829666	NA	-0.61	-9.25	-0.45	2.95e-18	Dementia with Lewy bodies;
CRC	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.44	-0.46	7.3e-19	Migraine;Coronary artery disease;
CRC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg08314208	chr16:67682810	RLTPR	-0.63	-7.22	-0.37	3.59e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.7	-7.86	-0.4	5.44e-14	Obesity-related traits;
CRC	trans	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-6.73	-0.35	7.62e-11	Monocyte count;
CRC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.22	-0.37	3.66e-12	Morning vs. evening chronotype;
CRC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.42	5.96	0.31	6.41e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.24	-0.37	3.23e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg14541582	chr5:601475	NA	-0.36	-7.29	-0.37	2.3e-12	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg10756647	chr7:56101905	PSPH	0.76	7.89	0.4	4.47e-14	Diabetic kidney disease;
CRC	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.49	-8.11	-0.41	1.04e-14	Bipolar disorder;
CRC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	7.83	0.4	6.94e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.9	0.52	7.71e-24	Diabetic retinopathy;
CRC	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-12.29	-0.56	8.04e-29	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09900105	chr16:74700924	RFWD3	0.48	6.65	0.34	1.23e-10	Response to antipsychotic treatment;
CRC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.57	7.01	0.36	1.33e-11	Mean platelet volume;
CRC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.51	-7.09	-0.36	8.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17065868	1.000	rs9533911	chr13:45138096	C/A	cg10246903	chr13:45222710	NA	0.52	5.99	0.31	5.56e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.59	-8.21	-0.41	5.01e-15	Urate levels in lean individuals;
CRC	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.62	8.78	0.44	8.87e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.42	-6.57	-0.34	1.95e-10	Blood metabolite levels;
CRC	cis	rs10950821	0.505	rs6949755	chr7:20688042	C/G	cg02470904	chr7:20686108	ABCB5	0.31	5.69	0.3	2.86e-8	Response to statin therapy;
CRC	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg20936604	chr3:58311152	NA	-0.76	-7.13	-0.37	6.48e-12	Cholesterol, total;
CRC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.51	6.42	0.33	4.9e-10	Tonsillectomy;
CRC	cis	rs6504950	0.790	rs8076984	chr17:53035428	T/C	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.49	-9.07	-0.45	1.13e-17	Intelligence (multi-trait analysis);
CRC	trans	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg06219351	chr7:158114137	PTPRN2	-0.6	-9.53	-0.47	3.61e-19	Calcium levels;
CRC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg16235748	chr6:149772707	ZC3H12D	0.36	6.45	0.33	4.08e-10	Dupuytren's disease;
CRC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.74	-0.35	7.28e-11	Major depressive disorder;
CRC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.72	8.23	0.41	4.28e-15	Obesity-related traits;
CRC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.21	-0.37	3.83e-12	Mean platelet volume;
CRC	trans	rs9826463	0.757	rs73240309	chr3:142240223	A/G	cg13928417	chr9:124498782	DAB2IP	-0.53	-5.97	-0.31	6.09e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	9.05	0.45	1.31e-17	Ulcerative colitis;
CRC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.54	0.34	2.39e-10	Axial length;
CRC	cis	rs939584	1.000	rs7569210	chr2:631462	G/A	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	0.94	13.05	0.58	1.21e-31	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs17767392	0.918	rs61991202	chr14:71766675	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.68	-10.05	-0.48	6.87e-21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7671266	0.622	rs11943276	chr4:10403545	A/G	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.63	-0.3	3.95e-8	Cardiovascular disease risk factors;
CRC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.71	11.67	0.54	1.47e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.97	-17.26	-0.69	5.67e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7605827	0.897	rs2178238	chr2:15533520	C/T	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.39	5.93	0.31	7.46e-9	Red blood cell count;
CRC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13606994	chr1:44402422	ARTN	0.33	5.66	0.3	3.35e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg04850286	chr10:81895943	PLAC9	-0.36	-6.5	-0.34	3.02e-10	Sarcoidosis;
CRC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.61	-10.95	-0.52	5.42e-24	Aortic root size;
CRC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.7	-0.39	1.59e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs8064024	0.538	rs11076854	chr16:4929269	A/G	cg19252218	chr17:41477271	ARL4D	-0.41	-6.07	-0.32	3.47e-9	Cancer;
CRC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.77	10.66	0.51	5.37e-23	Orofacial clefts;
CRC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg08999081	chr20:33150536	PIGU	0.46	5.98	0.31	5.87e-9	Protein C levels;
CRC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg01388757	chr2:102091195	RFX8	-0.62	-8.5	-0.42	6.8e-16	Chronic rhinosinusitis with nasal polyps;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27614038	chr3:28390080	AZI2	0.45	6.44	0.33	4.14e-10	Response to antipsychotic treatment;
CRC	cis	rs9491140	0.539	rs10872283	chr6:124685919	G/A	cg19267163	chr6:125004984	NKAIN2	0.45	6.13	0.32	2.52e-9	Neuroticism;
CRC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg07395648	chr5:131743802	NA	0.42	6.3	0.33	9.59e-10	Blood metabolite levels;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.43	-7.05	-0.36	1.06e-11	Weight;
CRC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.68	-7.01	-0.36	1.34e-11	Systemic lupus erythematosus;
CRC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16447950	chr5:562315	NA	-0.81	-9.9	-0.48	2.14e-20	Lung disease severity in cystic fibrosis;
CRC	trans	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.56	0.34	2.07e-10	Schizophrenia;
CRC	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg26165608	chr6:5261829	LYRM4;FARS2	-0.45	-5.78	-0.3	1.7e-8	Height;
CRC	cis	rs6586163	1.000	rs6586163	chr10:90752018	A/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.51	-7.45	-0.38	8.36e-13	Chronic lymphocytic leukemia;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg05486825	chr12:130710349	NA	0.5	6.08	0.32	3.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma;
CRC	cis	rs9287719	0.614	rs12622053	chr2:10722140	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg27427491	chr17:78079615	GAA	-0.37	-5.91	-0.31	8.59e-9	Yeast infection;
CRC	cis	rs2811415	0.597	rs1044843	chr3:127783698	A/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-10.8	-0.51	1.72e-23	Glomerular filtration rate (creatinine);
CRC	trans	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg10756647	chr7:56101905	PSPH	0.73	8.05	0.41	1.58e-14	Diabetic kidney disease;
CRC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-10.24	-0.49	1.58e-21	Intelligence (multi-trait analysis);
CRC	cis	rs12541635	0.639	rs6469030	chr8:107030321	C/T	cg10147462	chr8:107024639	NA	0.6	10.22	0.49	1.83e-21	Age of smoking initiation;
CRC	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.98	-0.36	1.6e-11	Menopause (age at onset);
CRC	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg17545662	chr6:170176663	C6orf70	0.53	5.86	0.31	1.12e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.45	-7.7	-0.39	1.56e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11088226	0.581	rs2016103	chr21:33878030	G/A	cg09050820	chr6:167586206	TCP10L2	0.57	7.92	0.4	3.76e-14	Gastritis;
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg15763984	chr4:1342303	KIAA1530	0.47	7.43	0.38	9.18e-13	Obesity-related traits;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg12273811	chr6:28175739	NA	0.56	7.88	0.4	4.8e-14	Parkinson's disease;
CRC	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg16898833	chr6:26189333	HIST1H4D	0.69	5.66	0.3	3.23e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.77	-0.35	6.02e-11	Bipolar disorder;
CRC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.9	-0.31	9.04e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg09877947	chr5:131593287	PDLIM4	0.53	9.94	0.48	1.53e-20	Acylcarnitine levels;
CRC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.44	-7.29	-0.37	2.34e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	6.41	0.33	4.92e-10	Menarche (age at onset);
CRC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.1	0.52	1.55e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.42	6.22	0.32	1.48e-9	Life satisfaction;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg27366882	chr3:133540807	NA	0.55	7.48	0.38	7.04e-13	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg09476006	chr5:138032270	NA	-0.42	-6.5	-0.34	3.01e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.2	-0.41	5.63e-15	Schizophrenia;
CRC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-7.51	-0.38	5.74e-13	Headache;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18297960	chr7:1142765	C7orf50	-0.44	-5.9	-0.31	8.97e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.72	-0.35	7.89e-11	Major depressive disorder;
CRC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.16	25.31	0.81	3.42e-79	IgG glycosylation;
CRC	cis	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.93	-0.31	7.79e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg04731861	chr2:219085781	ARPC2	0.31	6.36	0.33	6.89e-10	Colorectal cancer;
CRC	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.5	-7.37	-0.38	1.38e-12	Uric acid levels;
CRC	cis	rs4660214	0.666	rs4660550	chr1:39688459	A/T	cg11070191	chr1:39582205	MACF1	0.36	5.61	0.3	4.28e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-6.52	-0.34	2.61e-10	Bipolar disorder;
CRC	cis	rs9891119	0.965	rs3736161	chr17:40497835	C/G	cg06270615	chr17:40516068	STAT3	-0.27	-5.9	-0.31	8.79e-9	Multiple sclerosis;Crohn's disease;
CRC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.49	6.68	0.35	1.02e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.62	9.32	0.46	1.79e-18	Breast cancer;
CRC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-6.5	-0.34	2.89e-10	Arsenic metabolism;
CRC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.41	6.69	0.35	9.75e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-0.56	-7.62	-0.39	2.74e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.67	-10.59	-0.5	9.77e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12445461	chr9:6681608	NA	-0.5	-6.09	-0.32	3.14e-9	Diisocyanate-induced asthma;
CRC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.23	0.49	1.61e-21	Heart rate;
CRC	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg14191688	chr11:70257035	CTTN	0.59	7.19	0.37	4.29e-12	Coronary artery disease;
CRC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.4	-0.46	9.64e-19	Heart rate;
CRC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.63	8.78	0.44	9e-17	Height;
CRC	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.43	-5.97	-0.31	6.04e-9	Crohn's disease and psoriasis;
CRC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.52	-9.83	-0.48	3.65e-20	Birth weight;
CRC	cis	rs7487075	0.930	rs6582656	chr12:46843416	A/G	cg22049899	chr12:47219821	SLC38A4	0.32	6.33	0.33	8.1e-10	Itch intensity from mosquito bite;
CRC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.02	0.72	6.2e-55	Prudent dietary pattern;
CRC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.82	-0.35	4.43e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.9	-0.31	9.11e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03923535	chr7:1197113	ZFAND2A	0.53	7.6	0.39	3.1e-13	Longevity;Endometriosis;
CRC	cis	rs9649465	0.967	rs3779261	chr7:123315174	A/G	cg03229431	chr7:123269106	ASB15	-0.36	-5.74	-0.3	2.13e-8	Migraine;
CRC	cis	rs728616	0.614	rs59806247	chr10:82097974	T/C	cg05935833	chr10:81318306	SFTPA2	-0.48	-6.57	-0.34	1.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11212617	0.967	rs1003624	chr11:108152645	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.12	0.32	2.71e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-8.81	-0.44	7.12e-17	Platelet count;
CRC	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.55	9.38	0.46	1.1e-18	Common traits (Other);
CRC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	8.94	0.44	2.86e-17	Height;
CRC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg05941027	chr17:61774174	LIMD2	0.35	6.32	0.33	8.46e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.05	-14.58	-0.63	1.67e-37	Exhaled nitric oxide output;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.91	0.44	3.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18252515	chr7:66147081	NA	-0.4	-5.82	-0.31	1.4e-8	Aortic root size;
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.78	0.44	9.09e-17	Alzheimer's disease;
CRC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4.12e-17	Bipolar disorder;
CRC	cis	rs1712517	0.844	rs1163081	chr10:105029840	G/C	cg05636881	chr10:105038444	INA	0.48	8.64	0.43	2.41e-16	Migraine;
CRC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.85	-14.72	-0.63	4.99e-38	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.83	14.87	0.63	1.25e-38	Breast cancer;
CRC	cis	rs4731207	0.596	rs12539580	chr7:124619404	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg15269541	chr15:43626905	ADAL	0.43	5.76	0.3	1.93e-8	Lung cancer in ever smokers;
CRC	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.63	-10.74	-0.51	2.99e-23	Gout;
CRC	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg21064579	chr19:49206444	FUT2	0.5	8.63	0.43	2.58e-16	Dietary macronutrient intake;
CRC	cis	rs7129220	0.512	rs1867136	chr11:10228843	C/T	cg23875677	chr11:10229755	SBF2	-0.53	-5.97	-0.31	6.29e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg27661571	chr11:113659931	NA	-0.77	-9.59	-0.47	2.24e-19	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25456515	chr11:125439230	EI24	0.41	6.38	0.33	6.04e-10	Intelligence (multi-trait analysis);
CRC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg09218773	chr11:619014	MUPCDH	-0.42	-5.95	-0.31	6.73e-9	Systemic lupus erythematosus;
CRC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.47	8.17	0.41	6.84e-15	Schizophrenia;
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg21251018	chr6:28226885	NKAPL	0.47	7.46	0.38	7.96e-13	Parkinson's disease;
CRC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.51	0.34	2.88e-10	Morning vs. evening chronotype;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg26304593	chr6:42947056	PEX6	-0.46	-6.78	-0.35	5.65e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.42	-0.5	3.7e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11466653	1.000	rs9996228	chr4:38777517	A/C	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06128509	chr10:91461539	KIF20B	0.48	6.52	0.34	2.69e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.42	6.3	0.33	9.56e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06866400	chr6:143771904	ADAT2;PEX3	0.41	6.54	0.34	2.37e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.72e-20	Eye color traits;
CRC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	6.42	0.33	4.85e-10	IgG glycosylation;
CRC	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg25019722	chr6:37503610	NA	-0.41	-7.37	-0.38	1.4e-12	Cognitive performance;
CRC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20696051	chr7:158649028	WDR60	0.51	6.55	0.34	2.18e-10	Thyroid stimulating hormone;
CRC	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.92	-0.31	8.1e-9	Orofacial clefts;
CRC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.81	-0.4	7.99e-14	Personality dimensions;
CRC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.85	-0.35	3.63e-11	Systemic lupus erythematosus;
CRC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg27382691	chr15:76552771	ETFA;TYRO3P	0.51	6.4	0.33	5.33e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.22	-0.37	3.61e-12	Gut microbiome composition (summer);
CRC	cis	rs10746514	1.000	rs12129814	chr1:232251730	C/A	cg09506761	chr1:232265262	NA	0.43	5.63	0.3	3.79e-8	Response to statin therapy;
CRC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg15845792	chr6:28175446	NA	0.78	6.24	0.33	1.31e-9	Depression;
CRC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.3	0.62	2.11e-36	Chronic sinus infection;
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.56	8.36	0.42	1.79e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-14.16	-0.62	7.04e-36	Longevity;
CRC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg23018236	chr17:30244563	NA	-0.67	-8.02	-0.4	1.83e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs73200209	0.744	rs56911341	chr12:116682872	A/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.27	-0.37	2.66e-12	Total body bone mineral density;
CRC	cis	rs17767392	0.881	rs8017775	chr14:72029436	A/G	cg13720639	chr14:72061746	SIPA1L1	0.53	6.51	0.34	2.87e-10	Mitral valve prolapse;
CRC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.43	6.47	0.34	3.62e-10	Coronary artery disease;
CRC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.49	0.42	7.38e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.52	8.15	0.41	7.57e-15	Colorectal cancer;
CRC	cis	rs3767633	0.858	rs6698065	chr1:161891528	G/A	cg09175582	chr1:161736000	ATF6	0.65	6.17	0.32	1.95e-9	IgG glycosylation;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13530292	chr19:42721476	DEDD2	0.42	6.17	0.32	2.01e-9	Schizophrenia;
CRC	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.76	11.46	0.53	7.94e-26	Chronic lymphocytic leukemia;
CRC	trans	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.46	-0.34	3.83e-10	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg21839984	chr17:30846986	MYO1D	-0.36	-6.06	-0.32	3.64e-9	Schizophrenia;
CRC	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.12	17.14	0.69	1.66e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.71	0.35	8.52e-11	Hip circumference adjusted for BMI;
CRC	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg15226275	chr6:116381976	FRK	0.32	7.68	0.39	1.78e-13	Total cholesterol levels;
CRC	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	cg04338863	chr8:33670619	NA	0.44	6.55	0.34	2.28e-10	Body mass index;
CRC	cis	rs7259376	0.936	rs10404998	chr19:22608374	T/C	cg02657401	chr19:22469223	NA	0.31	6.68	0.35	1.01e-10	Menopause (age at onset);
CRC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.41	6.3	0.33	9.75e-10	Pulse pressure;
CRC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Bladder cancer;
CRC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.18	0.37	4.79e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.75	11.07	0.52	2e-24	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25179170	chr1:93427589	FAM69A	0.44	6.35	0.33	7.06e-10	Response to antipsychotic treatment;
CRC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.44	-5.84	-0.31	1.24e-8	Pulse pressure;
CRC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.07	-0.41	1.29e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.51	8.66	0.43	2.08e-16	Dupuytren's disease;
CRC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12474983	chr10:43903196	HNRNPF	0.4	6.01	0.31	5.04e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.43	-20.16	-0.74	1.97e-59	Hip circumference adjusted for BMI;
CRC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.66	12.3	0.56	7.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg19052272	chr2:3704530	ALLC	-0.5	-7.13	-0.37	6.48e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg12935359	chr14:103987150	CKB	-0.37	-6.14	-0.32	2.44e-9	Body mass index;
CRC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.83	10.63	0.51	6.75e-23	Gut microbiome composition (summer);
CRC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.34	-0.71	3.01e-52	Height;
CRC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg02741985	chr17:80059408	CCDC57	-0.42	-5.64	-0.3	3.6e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.09	20.25	0.74	8.92e-60	Exhaled nitric oxide output;
CRC	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg14352298	chr13:112236639	NA	0.29	6.63	0.34	1.38e-10	Hepatitis;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg09877947	chr5:131593287	PDLIM4	0.53	9.94	0.48	1.53e-20	Acylcarnitine levels;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02359409	chr6:42947317	PEX6	-0.69	-11.68	-0.54	1.36e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.82	14.0	0.61	3.05e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.44	6.39	0.33	5.54e-10	Height;
CRC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.6	0.39	3.04e-13	Vitiligo;
CRC	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.65e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.47	7.86	0.4	5.36e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.57	7.98	0.4	2.54e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.47	0.34	3.47e-10	Aortic root size;
CRC	cis	rs216026	0.689	rs4765701	chr12:2770891	C/T	cg19945202	chr12:2788847	CACNA1C	0.45	6.48	0.34	3.42e-10	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.52	8.11	0.41	9.83e-15	Temperament;
CRC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg25876840	chr17:41920477	NA	0.56	7.59	0.39	3.26e-13	Triglycerides;
CRC	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.87	-0.58	5.39e-31	White blood cell count (basophil);
CRC	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg09455208	chr3:40491958	NA	0.31	6.34	0.33	7.75e-10	Renal cell carcinoma;
CRC	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.56	-8.27	-0.41	3.44e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.52	-8.16	-0.41	6.97e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg19223190	chr17:80058835	NA	-0.41	-6.54	-0.34	2.36e-10	Life satisfaction;
CRC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.59	-0.6	1.05e-33	Blood metabolite levels;
CRC	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg14664628	chr15:75095509	CSK	0.52	6.08	0.32	3.34e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg15786705	chr6:28176104	NA	-0.67	-6.63	-0.34	1.37e-10	Depression;
CRC	trans	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-6.07	-0.32	3.52e-9	Menarche (age at onset);
CRC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg15382696	chr6:118971807	C6orf204	-0.56	-6.76	-0.35	6.22e-11	Diastolic blood pressure;
CRC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.81	-0.51	1.58e-23	Aortic root size;
CRC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.89	-0.31	9.3e-9	Arsenic metabolism;
CRC	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.12	0.32	2.67e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.57	-8.41	-0.42	1.29e-15	Mean platelet volume;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg15786705	chr6:28176104	NA	0.74	9.57	0.47	2.68e-19	Depression;
CRC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg27205649	chr11:78285834	NARS2	0.52	6.68	0.35	1.02e-10	Alzheimer's disease (survival time);
CRC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.54	-0.34	2.41e-10	Reticulocyte fraction of red cells;
CRC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.82	9.47	0.46	5.73e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs2108622	0.727	rs62106157	chr19:15980448	G/A	cg13772218	chr19:15982569	NA	0.48	6.82	0.35	4.37e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	8.12	0.41	9.28e-15	Iron status biomarkers;
CRC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.48	6.48	0.34	3.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.44	0.57	2.13e-29	Electrocardiographic conduction measures;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10833826	chr17:76837038	USP36	0.38	6.39	0.33	5.75e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.64	10.33	0.49	7.39e-22	Eosinophil percentage of white cells;
CRC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg00343986	chr7:65444356	GUSB	0.44	6.39	0.33	5.77e-10	Aortic root size;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg22638593	chr5:131593259	PDLIM4	-0.51	-9.63	-0.47	1.65e-19	Acylcarnitine levels;
CRC	cis	rs4737010	1.000	rs4737010	chr8:41630447	G/A	cg17182837	chr8:41585554	ANK1	0.5	6.76	0.35	6.19e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23946709	chr14:23527317	CDH24	0.37	6.03	0.32	4.51e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.38	0.56	3.79e-29	Height;
CRC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg03959625	chr15:84868606	LOC388152	0.4	5.78	0.3	1.74e-8	Bipolar disorder lithium response (categorical) or schizophrenia;
CRC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg08896387	chr1:24191740	FUCA1	0.54	6.92	0.36	2.35e-11	Immature fraction of reticulocytes;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg06470822	chr6:28175283	NA	-1.05	-14.24	-0.62	3.6e-36	Depression;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg25433682	chr16:30407049	ZNF48	0.43	6.2	0.32	1.73e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.75	15.17	0.64	9.02e-40	Leprosy;
CRC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.82	-13.11	-0.59	6.96e-32	Cognitive function;
CRC	cis	rs910187	0.532	rs6066209	chr20:45762795	G/T	cg27589058	chr20:45804311	EYA2	-0.36	-6.6	-0.34	1.68e-10	Migraine;
CRC	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg05585544	chr11:47624801	NA	-0.4	-6.35	-0.33	7.06e-10	Mean corpuscular hemoglobin;
CRC	trans	rs2303319	0.504	rs12467279	chr2:162544744	A/G	cg03757145	chr4:76555832	CDKL2	-0.66	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.73	9.36	0.46	1.33e-18	Iron status biomarkers;
CRC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg16486109	chr11:613632	IRF7	0.68	10.82	0.51	1.46e-23	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.95	-0.36	1.94e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11810498	chr9:130477698	PTRH1;TTC16	0.5	6.99	0.36	1.49e-11	Response to antipsychotic treatment;
CRC	cis	rs2346160	0.899	rs206980	chr6:167691798	A/G	cg04673565	chr6:167680447	NA	0.36	5.8	0.3	1.53e-8	Parental extreme longevity (95 years and older);
CRC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.62	9.73	0.47	7.67e-20	Prostate cancer;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.02	-0.31	4.78e-9	Bipolar disorder;
CRC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00700412	chr12:58011837	NA	-0.42	-6.6	-0.34	1.66e-10	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07355551	chr20:2489285	ZNF343	0.52	7.54	0.38	4.54e-13	Response to antipsychotic treatment;
CRC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.55	-7.43	-0.38	9.62e-13	IgG glycosylation;
CRC	cis	rs9908102	0.740	rs59287437	chr17:12912727	C/G	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg09659197	chr4:152720779	NA	0.4	8.32	0.42	2.29e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg18016565	chr1:150552671	MCL1	0.43	5.95	0.31	6.7e-9	Melanoma;
CRC	cis	rs863345	0.504	rs2022386	chr1:158563076	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-7.17	-0.37	4.96e-12	Pneumococcal bacteremia;
CRC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.74	-0.39	1.25e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4926298	0.926	rs8111617	chr19:13191461	C/T	cg11738485	chr19:12877000	HOOK2	-0.44	-6.07	-0.32	3.59e-9	Bipolar disorder;
CRC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.9	-0.31	9.25e-9	Lung cancer;
CRC	cis	rs524281	0.861	rs10896085	chr11:65913832	A/T	cg16950941	chr11:66035639	RAB1B	-0.61	-7.5	-0.38	5.99e-13	Electroencephalogram traits;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.87	-0.4	5.23e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.09	0.36	8.26e-12	Joint mobility (Beighton score);
CRC	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.43	6.58	0.34	1.88e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	trans	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg01505111	chr6:125621795	HDDC2	0.39	6.23	0.32	1.4e-9	DNA methylation (variation);
CRC	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg20356878	chr3:121714668	ILDR1	-0.46	-6.13	-0.32	2.48e-9	Multiple sclerosis;
CRC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.53	-7.35	-0.38	1.59e-12	Dental caries;
CRC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.55	6.19	0.32	1.82e-9	Vitiligo;
CRC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.31	5.13e-9	Hemoglobin concentration;
CRC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.46	7.0	0.36	1.42e-11	Menopause (age at onset);
CRC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg21238619	chr17:78079768	GAA	0.32	6.19	0.32	1.76e-9	Yeast infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24849812	chr5:95998671	CAST	0.4	6.2	0.32	1.66e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.55	-8.22	-0.41	4.88e-15	Mean platelet volume;
CRC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23903597	chr17:61704154	MAP3K3	-0.45	-6.22	-0.32	1.48e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-6.1	-0.32	3.02e-9	Carotid intima media thickness;
CRC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.62	9.48	0.46	5.3e-19	Birth weight;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.59e-10	Depression;
CRC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg25876840	chr17:41920477	NA	0.53	7.92	0.4	3.77e-14	Triglycerides;
CRC	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs9545047	0.716	rs8002838	chr13:79995816	G/A	cg07061582	chr15:90234082	PEX11A;WDR93	0.41	5.97	0.31	6.15e-9	Schizophrenia;
CRC	cis	rs11679072	1.000	rs7592764	chr2:240448167	A/C	cg03276489	chr2:240449683	NA	-0.76	-8.11	-0.41	1.03e-14	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-6.94	-0.36	2.12e-11	Aortic root size;
CRC	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.71	0.43	1.55e-16	Mean corpuscular volume;
CRC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.47	-7.3	-0.37	2.2e-12	Testicular germ cell tumor;
CRC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.74	7.61	0.39	3e-13	Diabetic retinopathy;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12172441	chr6:28176163	NA	0.59	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.39	5.66	0.3	3.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.76	0.35	6.39e-11	Body mass index;
CRC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg12193833	chr17:30244370	NA	-0.62	-7.98	-0.4	2.46e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10046574	0.519	rs7799873	chr7:135214030	C/T	cg27474649	chr7:135195673	CNOT4	0.6	5.88	0.31	1.01e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg02033258	chr5:131593261	PDLIM4	0.38	6.36	0.33	6.76e-10	Breast cancer;
CRC	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.51	7.57	0.39	3.68e-13	Corneal astigmatism;
CRC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.33	-6.76	-0.35	6.25e-11	Alzheimer's disease (late onset);
CRC	cis	rs73206853	0.764	rs3026447	chr12:110724272	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	8.22	0.41	4.85e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7605827	0.930	rs2049720	chr2:15514982	T/C	cg19274914	chr2:15703543	NA	0.4	6.03	0.32	4.33e-9	Educational attainment (years of education);
CRC	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.61	9.93	0.48	1.69e-20	Itch intensity from mosquito bite;
CRC	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.1	-0.32	3.04e-9	Blood pressure;
CRC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg13722127	chr7:150037890	RARRES2	0.52	8.1	0.41	1.09e-14	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg20935933	chr6:143382018	AIG1	0.54	6.96	0.36	1.86e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14526843	chr3:122233584	KPNA1	0.47	6.94	0.36	2.13e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.54	-0.47	3.4e-19	Migraine;Coronary artery disease;
CRC	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-6.84	-0.35	3.86e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27127705	chr8:56685527	TMEM68;TGS1	0.44	6.13	0.32	2.48e-9	Anxiety disorder;
CRC	cis	rs7901135	0.924	rs4627022	chr10:60563952	T/C	cg23799393	chr10:60588674	BICC1	0.37	5.66	0.3	3.22e-8	Morning vs. evening chronotype;
CRC	cis	rs55788414	1.000	rs55788414	chr16:81184939	C/T	cg06400318	chr16:81190750	PKD1L2	-0.69	-6.7	-0.35	8.92e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.83	-11.62	-0.54	2.25e-26	Asthma;
CRC	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg15382696	chr6:118971807	C6orf204	0.6	7.57	0.39	3.76e-13	Diastolic blood pressure;
CRC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.97	-0.31	6.01e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18802567	chr5:171433913	FBXW11	0.45	6.18	0.32	1.92e-9	Survival in pancreatic cancer;
CRC	trans	rs8177876	0.908	rs80187824	chr16:81118680	T/C	cg09779152	chr17:73205364	NUP85	0.61	5.99	0.31	5.57e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.75	-8.6	-0.43	3.29e-16	Breast cancer;
CRC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.98	0.4	2.46e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	9.82	0.48	3.87e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05628496	chr17:17991167	DRG2	-0.55	-6.77	-0.35	5.89e-11	Diisocyanate-induced asthma;
CRC	cis	rs2108622	0.683	rs6512067	chr19:15982951	G/T	cg13772218	chr19:15982569	NA	0.46	6.71	0.35	8.35e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.5	7.8	0.39	8.51e-14	Height;
CRC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.06	0.32	3.69e-9	Obesity-related traits;
CRC	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.62	-9.21	-0.45	4.02e-18	Dementia with Lewy bodies;
CRC	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.61	-6.82	-0.35	4.4e-11	Osteoarthritis;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg25164649	chr6:28176230	NA	0.47	5.63	0.3	3.95e-8	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs752010	0.756	rs943374	chr1:42056194	A/G	cg06885757	chr1:42089581	HIVEP3	0.34	5.99	0.31	5.63e-9	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.73	-0.39	1.28e-13	Cholesterol, total;
CRC	trans	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg03800765	chr3:11313984	ATG7	-0.41	-6.06	-0.32	3.73e-9	Inflammatory skin disease;
CRC	cis	rs7731657	0.518	rs7706328	chr5:130218943	G/C	cg08523029	chr5:130500466	HINT1	-0.41	-5.63	-0.3	3.87e-8	Fasting plasma glucose;
CRC	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.75	12.67	0.57	3.08e-30	Idiopathic membranous nephropathy;
CRC	cis	rs2842126	0.518	rs2813305	chr10:52007969	A/G	cg13488930	chr10:51784648	NA	-0.43	-5.89	-0.31	9.38e-9	Blood protein levels;
CRC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.97e-9	Life satisfaction;
CRC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg13722127	chr7:150037890	RARRES2	0.39	5.63	0.3	3.95e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-6.93	-0.36	2.26e-11	Prudent dietary pattern;
CRC	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.47	8.53	0.43	5.38e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs6956675	1.000	rs4718791	chr7:62577991	G/C	cg01314568	chr7:57830625	NA	-0.68	-9.35	-0.46	1.39e-18	Obesity-related traits;
CRC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg06462663	chr19:18546047	ISYNA1	0.46	7.04	0.36	1.15e-11	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18159230	chr1:169076004	ATP1B1	0.39	6.37	0.33	6.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.46	7.96	0.4	2.9e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs7725052	0.609	rs6872742	chr5:40470086	C/T	cg09067459	chr5:40385259	NA	0.43	7.11	0.36	7.43e-12	Pediatric autoimmune diseases;
CRC	cis	rs17095355	1.000	rs9988702	chr10:111703389	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.02	-0.4	1.84e-14	Biliary atresia;
CRC	trans	rs7619427	0.544	rs9821661	chr3:44031551	G/A	cg09408571	chr1:101003634	GPR88	0.45	6.25	0.33	1.24e-9	Schizophrenia;
CRC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13844804	chr7:814759	HEATR2	-0.55	-5.87	-0.31	1.06e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.31	-5.8	-0.3	1.55e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3825932	1.000	rs3825932	chr15:79235446	A/G	cg25744700	chr15:79237217	CTSH	0.39	6.04	0.32	4.13e-9	Type 1 diabetes;
CRC	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.65	9.75	0.47	6.76e-20	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.59e-14	HDL cholesterol;
CRC	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg21153622	chr11:89784906	NA	-0.38	-6.04	-0.32	4.27e-9	Height;
CRC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	7.56	0.38	3.99e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.35	0.5	6.61e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.62	0.3	4e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.41	8.56	0.43	4.41e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.97	-0.36	1.7e-11	Total cholesterol levels;
CRC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.4	6.74	0.35	6.98e-11	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
CRC	cis	rs7932354	0.583	rs2306026	chr11:46889713	T/C	cg19486271	chr11:47235900	DDB2	-0.42	-6.34	-0.33	7.49e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.43	-0.33	4.46e-10	Total cholesterol levels;
CRC	cis	rs2257205	0.667	rs9909763	chr17:56629640	C/T	cg25885038	chr17:56607967	SEPT4	-0.54	-6.17	-0.32	1.99e-9	Pancreatic cancer;
CRC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg03037974	chr15:76606532	NA	-0.56	-8.51	-0.42	6.38e-16	Blood metabolite levels;
CRC	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.37	6.25	0.33	1.26e-9	Sitting height ratio;
CRC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg13798912	chr7:905769	UNC84A	-0.62	-6.36	-0.33	6.71e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.66	-11.47	-0.53	7.74e-26	Type 2 diabetes;
CRC	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.18	-0.37	4.57e-12	IgG glycosylation;
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.31	0.37	2.04e-12	Alzheimer's disease;
CRC	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.56	-0.43	4.5e-16	Biliary atresia;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg18719198	chr14:55369460	GCH1	-0.44	-6.5	-0.34	2.91e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12417590	chr20:42086612	SFRS6	0.47	7.96	0.4	2.79e-14	Obesity-related traits;
CRC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.6	7.28	0.37	2.53e-12	Mean platelet volume;
CRC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.59	-0.34	1.72e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.89	-15.31	-0.65	2.45e-40	Height;
CRC	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.45	6.17	0.32	1.95e-9	Height;
CRC	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg16011679	chr1:85725395	C1orf52	0.49	6.29	0.33	1.03e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg13385521	chr17:29058706	SUZ12P	0.64	7.72	0.39	1.39e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg23127183	chr11:57508653	C11orf31	0.53	7.41	0.38	1.09e-12	Schizophrenia;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg21620606	chr4:1342894	KIAA1530	0.53	9.59	0.47	2.32e-19	Longevity;
CRC	cis	rs10886503	0.920	rs3009907	chr10:121262454	G/T	cg17804342	chr10:121271663	RGS10	-0.82	-7.77	-0.39	1.03e-13	Obstetric antiphospholipid syndrome;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.17	-0.32	1.97e-9	Total body bone mineral density;
CRC	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.58	6.36	0.33	6.73e-10	Schizophrenia;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.62	9.74	0.47	7.5e-20	Longevity;Endometriosis;
CRC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.53	10.92	0.52	6.76e-24	Alcohol dependence;
CRC	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.5	8.99	0.44	1.97e-17	Age-related hearing impairment;
CRC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg25985355	chr7:65971099	NA	-0.51	-5.87	-0.31	1.05e-8	Diabetic kidney disease;
CRC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.62	-8.01	-0.4	2.04e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg12273811	chr6:28175739	NA	0.61	8.16	0.41	7.15e-15	Parkinson's disease;
CRC	cis	rs9928842	0.882	rs9319481	chr16:75259478	T/C	cg08657710	chr16:75258780	CTRB1	-0.55	-6.35	-0.33	7.27e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg04117972	chr1:227635322	NA	0.64	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs2735413	0.875	rs4888737	chr16:78083819	A/G	cg04733911	chr16:78082701	NA	-0.45	-7.54	-0.38	4.5e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs11225569	0.539	rs7932706	chr11:103340376	A/T	cg01615333	chr12:127765195	NA	-0.64	-6.03	-0.32	4.37e-9	Diisocyanate-induced asthma;
CRC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg16060761	chr17:80687452	NA	-0.41	-5.9	-0.31	8.96e-9	Breast cancer;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.61	9.66	0.47	1.37e-19	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg17903999	chr18:56338584	MALT1	0.43	6.85	0.35	3.73e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13161895	0.938	rs594202	chr5:179417335	C/T	cg02702477	chr5:179499311	RNF130	0.55	6.4	0.33	5.21e-10	LDL cholesterol;
CRC	cis	rs294883	0.858	rs9457583	chr6:159722182	A/G	cg14500486	chr6:159655392	FNDC1	0.35	5.83	0.31	1.36e-8	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.59	10.1	0.49	4.39e-21	Prudent dietary pattern;
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02290350	chr8:58132656	NA	-0.5	-5.71	-0.3	2.54e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.33	5.67	0.3	3.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.33	-0.53	2.45e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-6.08	-0.32	3.39e-9	Major depressive disorder;
CRC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.48	-7.58	-0.39	3.5e-13	Neurofibrillary tangles;
CRC	cis	rs7703744	0.681	rs17145294	chr5:118701433	G/T	cg02283238	chr5:118691126	TNFAIP8	0.46	6.27	0.33	1.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg08314208	chr16:67682810	RLTPR	-0.54	-5.94	-0.31	7.18e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg06238570	chr21:40685208	BRWD1	0.75	10.23	0.49	1.63e-21	Cognitive function;
CRC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.37	0.33	6.31e-10	Bladder cancer;
CRC	cis	rs7487075	0.823	rs34472481	chr12:46836348	C/G	cg17501823	chr12:47219793	SLC38A4	0.32	5.94	0.31	7.11e-9	Itch intensity from mosquito bite;
CRC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg24675056	chr1:15929824	NA	0.49	6.83	0.35	4.15e-11	Systolic blood pressure;
CRC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.47	5.9	0.31	8.88e-9	Aortic root size;
CRC	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg11993925	chr19:44307056	LYPD5	-0.37	-6.16	-0.32	2.18e-9	Breast cancer;
CRC	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg08027265	chr7:2291960	NA	-0.41	-6.25	-0.33	1.24e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.38	7.22	0.37	3.72e-12	Mean corpuscular volume;
CRC	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.66	8.69	0.43	1.74e-16	Uric acid levels;
CRC	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg24154853	chr7:158122151	PTPRN2	0.58	9.62	0.47	1.76e-19	Calcium levels;
CRC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg21770322	chr7:97807741	LMTK2	0.53	8.6	0.43	3.35e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg18833306	chr6:118973337	C6orf204	0.45	5.81	0.3	1.49e-8	Diastolic blood pressure;
CRC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg08501292	chr6:25962987	TRIM38	0.83	6.43	0.33	4.44e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.58	7.84	0.4	6.3e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.77	-0.3	1.81e-8	Breast cancer;
CRC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.54	6.88	0.35	2.99e-11	Morning vs. evening chronotype;
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs7215564	0.908	rs34384177	chr17:78667040	A/T	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.19e-9	Myopia (pathological);
CRC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.55	-9.08	-0.45	1.03e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-10.34	-0.5	6.98e-22	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01711073	chr1:37980396	MEAF6	0.41	6.18	0.32	1.89e-9	Response to antipsychotic treatment;
CRC	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.52	-0.34	2.59e-10	Inflammatory skin disease;
CRC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16447950	chr5:562315	NA	-0.74	-9.76	-0.47	6.14e-20	Obesity-related traits;
CRC	cis	rs3849570	0.555	rs4481177	chr3:81996817	A/T	cg07356753	chr3:81810745	GBE1	0.51	7.08	0.36	8.94e-12	Waist circumference;Body mass index;
CRC	cis	rs4731207	0.646	rs7783781	chr7:124454413	T/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.5	7.19	0.37	4.45e-12	Pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11342046	chr2:242641489	ING5	0.47	6.76	0.35	6.43e-11	Response to antipsychotic treatment;
CRC	cis	rs1532331	0.898	rs6876746	chr5:43173085	A/T	cg09164108	chr5:43007320	NA	0.38	5.79	0.3	1.63e-8	Menarche (age at onset);
CRC	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.54	7.1	0.36	7.95e-12	Alzheimer's disease (survival time);
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg14122633	chr5:456516	EXOC3	-0.4	-7.1	-0.36	7.82e-12	Cystic fibrosis severity;
CRC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.58	-8.03	-0.4	1.76e-14	Gastritis;
CRC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.65	7.81	0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.18	0.52	7.89e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.61	9.59	0.47	2.34e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.79	10.97	0.52	4.45e-24	Cognitive function;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.69	7.79	0.39	8.55e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs7604735	0.824	rs6747275	chr2:145819922	A/G	cg26010734	chr19:15344046	EPHX3	-0.35	-6.12	-0.32	2.68e-9	Coronary artery disease;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg12273811	chr6:28175739	NA	0.56	7.93	0.4	3.5e-14	Parkinson's disease;
CRC	cis	rs8060686	0.925	rs13336189	chr16:67814152	C/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-11.36	-0.53	1.83e-25	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg27395922	chr11:50257633	LOC441601	0.48	6.05	0.32	3.87e-9	Axial length;
CRC	trans	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg09045935	chr12:6379348	NA	0.95	7.05	0.36	1.08e-11	Blood metabolite levels;
CRC	cis	rs4975616	1.000	rs4975616	chr5:1315660	G/A	cg06550200	chr5:1325588	CLPTM1L	0.63	9.24	0.45	3.04e-18	Lung cancer;
CRC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg19052272	chr2:3704530	ALLC	-0.5	-7.22	-0.37	3.64e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg14550653	chr6:52149695	MCM3	-0.36	-5.97	-0.31	6.26e-9	Aortic root size;
CRC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.54	-0.38	4.61e-13	Colorectal cancer;
CRC	cis	rs524281	0.773	rs2017969	chr11:66039032	G/A	cg16950941	chr11:66035639	RAB1B	-0.72	-8.1	-0.41	1.09e-14	Electroencephalogram traits;
CRC	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	0.88	11.16	0.52	9.85e-25	Red blood cell traits;
CRC	cis	rs7692995	1.000	rs6853216	chr4:17970655	C/T	cg08925142	chr4:18023851	LCORL	-0.5	-5.65	-0.3	3.39e-8	Height;
CRC	cis	rs9928842	0.882	rs9927264	chr16:75260241	T/C	cg08657710	chr16:75258780	CTRB1	-0.53	-6.12	-0.32	2.72e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	6.44	0.33	4.13e-10	Diabetic retinopathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26003386	chr19:14116507	RFX1	0.42	6.12	0.32	2.61e-9	Response to antipsychotic treatment;
CRC	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	trans	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.63	0.39	2.59e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.14e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2033908	0.558	rs6486064	chr11:12869509	T/C	cg25843174	chr11:12811716	TEAD1	-0.39	-6.84	-0.35	3.9e-11	Sitting height ratio;
CRC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg18490616	chr2:88469792	THNSL2	0.57	5.71	0.3	2.46e-8	Plasma clusterin levels;
CRC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg15845792	chr6:28175446	NA	-0.73	-6.99	-0.36	1.5e-11	Depression;
CRC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.56	-8.01	-0.4	1.94e-14	Response to temozolomide;
CRC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.68	-12.01	-0.55	8.36e-28	Asthma;
CRC	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg00691999	chr4:55094011	PDGFRA	0.43	5.91	0.31	8.51e-9	Corneal astigmatism;
CRC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg08314208	chr16:67682810	RLTPR	-0.65	-6.8	-0.35	4.91e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00338735	chr4:53728038	RASL11B	0.48	6.51	0.34	2.8e-10	Optic nerve measurement (cup area);
CRC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-7.76	-0.39	1.1e-13	Gut microbiome composition (summer);
CRC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.85	0.31	1.19e-8	Tonsillectomy;
CRC	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-11.15	-0.52	1.08e-24	Coffee consumption (cups per day);
CRC	cis	rs524281	0.773	rs7951079	chr11:65980550	C/T	cg16950941	chr11:66035639	RAB1B	-0.72	-8.05	-0.41	1.49e-14	Electroencephalogram traits;
CRC	cis	rs12745968	0.589	rs1059267	chr1:92975262	C/A	cg17283838	chr1:93427260	FAM69A	-0.48	-6.49	-0.34	3.16e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.62	-6.91	-0.36	2.51e-11	Breast cancer;
CRC	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg01426195	chr3:39028469	NA	-0.39	-5.62	-0.3	4.04e-8	Handedness;
CRC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.66	-9.38	-0.46	1.11e-18	Lung cancer;
CRC	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.46	6.32	0.33	8.43e-10	Cholesterol, total;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg22677401	chr17:46026860	NA	-0.7	-6.05	-0.32	3.89e-9	Cognitive function;
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg13957321	chr17:43675089	NA	0.5	6.27	0.33	1.13e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.58	0.54	2.96e-26	Bone mineral density;
CRC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.75	-0.35	6.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.64	7.71	0.39	1.47e-13	Behavioural disinhibition (generation interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16632661	chr19:45251986	BCL3	0.4	6.02	0.31	4.69e-9	Schizophrenia;
CRC	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg13491945	chr12:107078410	RFX4	0.35	6.16	0.32	2.11e-9	Heart rate;
CRC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg04545296	chr12:48745243	ZNF641	0.33	5.9	0.31	9.23e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17472796	chr11:72406685	ARAP1	-0.38	-6.35	-0.33	7.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.47	-8.73	-0.43	1.26e-16	Educational attainment (years of education);
CRC	cis	rs62229266	0.633	rs743420	chr21:37387402	A/G	cg08632701	chr21:37451849	NA	-0.38	-5.95	-0.31	6.99e-9	Mitral valve prolapse;
CRC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.6	-8.76	-0.43	1.04e-16	Menarche (age at onset);
CRC	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.43	-6.76	-0.35	6.21e-11	C-reactive protein levels;
CRC	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.87	-0.35	3.25e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.74	-0.47	7.14e-20	Height;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg15845792	chr6:28175446	NA	0.97	13.03	0.58	1.43e-31	Depression;
CRC	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.49	-8.0	-0.4	2.14e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg20243544	chr17:37824526	PNMT	0.57	9.04	0.45	1.33e-17	Asthma;
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.81	8.22	0.41	4.67e-15	IgG glycosylation;
CRC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg21709803	chr11:61594965	FADS2	-0.46	-5.87	-0.31	1.09e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg08213375	chr14:104286397	PPP1R13B	0.37	5.81	0.31	1.46e-8	Reticulocyte count;
CRC	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg23032129	chr1:109941072	SORT1	0.28	6.05	0.32	3.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.48	8.35	0.42	1.86e-15	Lung cancer;
CRC	cis	rs2252790	0.794	rs1204808	chr6:116550917	A/G	cg18764771	chr6:116381957	FRK	-0.21	-5.63	-0.3	3.93e-8	Fast beta electroencephalogram;
CRC	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01213331	chr16:15069449	PDXDC1	0.44	6.01	0.31	4.97e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.83	15.67	0.65	9.99e-42	Hip circumference;
CRC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.3	4.23e-8	Hemoglobin concentration;
CRC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg23463467	chr20:60627584	TAF4	0.41	7.83	0.4	6.7e-14	Body mass index;
CRC	cis	rs11229555	0.645	rs11229549	chr11:58395914	T/C	cg15696309	chr11:58395628	NA	-0.87	-9.15	-0.45	6.24e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.87	0.35	3.28e-11	Diabetic retinopathy;
CRC	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg18232548	chr7:50535776	DDC	0.44	6.2	0.32	1.7e-9	Malaria;
CRC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg17330251	chr7:94953956	PON1	-0.52	-6.68	-0.35	9.94e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	6.32	0.33	8.46e-10	Mean corpuscular volume;
CRC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.8	10.66	0.51	5.61e-23	Cerebrospinal P-tau181p levels;
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg00280220	chr17:61926910	NA	-0.34	-5.67	-0.3	3.05e-8	Prudent dietary pattern;
CRC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-5.91	-0.31	8.34e-9	Gout;
CRC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg15358701	chr1:161410459	NA	0.65	6.8	0.35	4.98e-11	Rheumatoid arthritis;
CRC	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.59	11.42	0.53	1.19e-25	Information processing speed;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12413365	chr12:12510412	LOH12CR1;LOH12CR2	0.48	6.16	0.32	2.16e-9	Thyroid stimulating hormone;
CRC	cis	rs9462846	0.845	rs9471964	chr6:42885664	C/A	cg21280719	chr6:42927975	GNMT	-0.35	-6.66	-0.34	1.16e-10	Blood protein levels;
CRC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.52	7.88	0.4	4.99e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.45	6.86	0.35	3.47e-11	Asthma;
CRC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.45	6.77	0.35	6.01e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.74	-0.39	1.26e-13	HDL cholesterol;
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.44	6.58	0.34	1.88e-10	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02947222	chr12:76425514	PHLDA1	0.43	6.03	0.32	4.33e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg03623178	chr6:28175578	NA	0.48	6.61	0.34	1.54e-10	Depression;
CRC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.3	3.18e-8	Diabetic retinopathy;
CRC	cis	rs7517126	0.541	rs9427656	chr1:196943020	A/T	cg13682187	chr1:196946512	CFHR5	-0.46	-6.83	-0.35	4.06e-11	Blood protein levels;
CRC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	1.95e-33	Vitiligo;
CRC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.14	-0.37	6.07e-12	Aortic root size;
CRC	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg20636351	chr8:55087400	NA	-0.34	-6.0	-0.31	5.17e-9	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02480104	chr20:35808036	C20orf132;RPN2	0.47	6.48	0.34	3.36e-10	Anxiety disorder;
CRC	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.74	12.56	0.57	7.83e-30	Adiposity;
CRC	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg23815491	chr16:72088622	HP	0.65	8.43	0.42	1.08e-15	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09665592	chr9:130699885	DPM2	0.43	6.16	0.32	2.09e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00822591	chr3:16306489	DPH3;OXNAD1	0.39	6.24	0.33	1.38e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17023223	0.537	rs2645301	chr1:119590420	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-6.29	-0.33	1.01e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg00318322	chr16:67708822	GFOD2	-0.31	-5.92	-0.31	8.03e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.23	-0.53	5.5e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	9.06	0.45	1.16e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg06172871	chr16:72088244	HP	0.4	5.82	0.31	1.39e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg14352298	chr13:112236639	NA	0.29	6.59	0.34	1.74e-10	Hepatitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00455883	chr3:73046007	PPP4R2	0.43	6.91	0.36	2.44e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg08314208	chr16:67682810	RLTPR	-0.58	-6.23	-0.32	1.47e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.79	8.7	0.43	1.64e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-7.06	-0.36	9.89e-12	Bipolar disorder;
CRC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.45	5.7	0.3	2.67e-8	Aortic root size;
CRC	cis	rs4692589	0.803	rs4145964	chr4:170985398	C/T	cg19918862	chr4:170955249	NA	-0.34	-5.68	-0.3	2.95e-8	Anxiety disorder;
CRC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg06494592	chr3:125709126	NA	-0.58	-6.85	-0.35	3.57e-11	Blood pressure (smoking interaction);
CRC	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.51	-9.59	-0.47	2.29e-19	Hip circumference;Waist circumference;
CRC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.68	9.36	0.46	1.27e-18	Breast cancer;
CRC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.62	0.54	2.22e-26	Hip circumference adjusted for BMI;
CRC	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.43	-0.38	9.16e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	6.4	0.33	5.37e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs11671005	0.610	rs8103813	chr19:59072684	C/T	cg22037779	chr5:139682734	PFDN1	-0.54	-6.38	-0.33	5.98e-10	Mean platelet volume;
CRC	cis	rs6758955	0.850	rs60661460	chr2:10478239	A/G	cg15773312	chr2:10472214	HPCAL1	-0.81	-9.63	-0.47	1.73e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg14458575	chr2:238380390	NA	0.48	6.45	0.34	3.96e-10	Prostate cancer;
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg07507251	chr3:52567010	NT5DC2	0.44	6.39	0.33	5.81e-10	Bipolar disorder;
CRC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.84	-0.31	1.25e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2179367	0.887	rs2789492	chr6:149747379	A/G	cg11245181	chr6:149772854	ZC3H12D	0.37	5.87	0.31	1.06e-8	Dupuytren's disease;
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-8.34	-0.42	2.06e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.98	19.96	0.74	1.28e-58	Alcohol dependence;
CRC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.86	-11.14	-0.52	1.12e-24	Gut microbiome composition (summer);
CRC	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-7.21	-0.37	3.82e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg14008862	chr17:28927542	LRRC37B2	0.55	5.76	0.3	1.98e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05472934	chr7:22766657	IL6	0.77	12.5	0.57	1.37e-29	Lung cancer;
CRC	cis	rs61160187	0.582	rs67858932	chr5:60143251	A/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.77	-0.3	1.78e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	9.62	0.47	1.8e-19	Body mass index (adult);
CRC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.47	7.02	0.36	1.26e-11	Asthma;
CRC	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.52	-7.92	-0.4	3.77e-14	Corneal astigmatism;
CRC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.39	0.42	1.43e-15	Body mass index;
CRC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg09264619	chr17:80180166	NA	0.35	5.82	0.31	1.37e-8	Life satisfaction;
CRC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	7.12	0.37	6.93e-12	Schizophrenia;
CRC	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.46	6.17	0.32	2.05e-9	Breast cancer;
CRC	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	18.35	0.71	2.74e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg17182837	chr8:41585554	ANK1	-0.52	-6.91	-0.36	2.53e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg10398005	chr11:117014888	PAFAH1B2	-0.45	-6.77	-0.35	5.76e-11	Blood protein levels;
CRC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.68	0.35	9.99e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs7712401	0.655	rs6884312	chr5:122103977	A/C	cg18764291	chr5:122110994	SNX2	0.37	5.91	0.31	8.74e-9	Mean platelet volume;
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.61	0.34	1.54e-10	Bipolar disorder;
CRC	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26240231	chr7:1148101	C7orf50	-0.42	-5.98	-0.31	5.96e-9	Bronchopulmonary dysplasia;
CRC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.46	-7.58	-0.39	3.62e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.55	7.95	0.4	3.04e-14	Testicular germ cell tumor;
CRC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Bone mineral density;
CRC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg17948913	chr5:572064	NA	0.55	6.34	0.33	7.56e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs6908034	0.607	rs73376655	chr6:19805664	C/T	cg02682789	chr6:19804855	NA	0.8	6.74	0.35	6.9e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg18753928	chr3:113234510	CCDC52	0.46	7.39	0.38	1.21e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs35000415	0.938	rs13239597	chr7:128695983	C/A	cg19972273	chr7:128594194	NA	0.71	6.15	0.32	2.2e-9	Systemic lupus erythematosus;
CRC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs55788414	1.000	rs67345347	chr16:81185125	G/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.87	-0.35	3.27e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.71	7.58	0.39	3.45e-13	Breast cancer;
CRC	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg22256960	chr15:77711686	NA	-0.55	-8.36	-0.42	1.73e-15	Type 2 diabetes;
CRC	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.04	-27.49	-0.83	3.05e-87	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.6	9.22	0.45	3.61e-18	Aortic root size;
CRC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.56	-0.34	2.05e-10	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-11.92	-0.55	1.85e-27	Extrinsic epigenetic age acceleration;
CRC	cis	rs12928939	0.911	rs77823468	chr16:71828616	C/T	cg08717414	chr16:71523259	ZNF19	-0.5	-6.19	-0.32	1.75e-9	Post bronchodilator FEV1;
CRC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.24	0.33	1.32e-9	Diabetic kidney disease;
CRC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.47	-6.83	-0.35	4.2e-11	Lymphocyte counts;
CRC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-10.26	-0.49	1.32e-21	Prudent dietary pattern;
CRC	cis	rs863345	0.584	rs11265018	chr1:158506409	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	trans	rs6462411	0.938	rs6968948	chr7:3912319	C/T	cg17780657	chr19:45971055	FOSB	0.52	6.33	0.33	8.09e-10	Quantitative traits;
CRC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-12.45	-0.57	2.05e-29	Schizophrenia;
CRC	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg15382696	chr6:118971807	C6orf204	-0.33	-5.61	-0.3	4.31e-8	Electrocardiographic conduction measures;
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.44	-0.42	1.05e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs35520189	0.591	rs12995439	chr2:113703646	T/C	cg12858261	chr2:113808755	IL1F8	0.46	6.0	0.31	5.15e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.57	8.88	0.44	4.4e-17	Colorectal cancer;
CRC	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg09873164	chr1:152488093	CRCT1	0.39	6.58	0.34	1.84e-10	Hair morphology;
CRC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.38	0.38	1.34e-12	Lung cancer;
CRC	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.92	-21.24	-0.76	1.24e-63	Longevity;
CRC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.66	-8.49	-0.42	7.36e-16	Body mass index;
CRC	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.48	7.59	0.39	3.34e-13	Red blood cell count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12713848	chr20:35401901	DSN1	0.44	6.51	0.34	2.74e-10	Anxiety disorder;
CRC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.82	-17.04	-0.68	4.16e-47	Prostate cancer;
CRC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.15	0.37	5.68e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.89	-15.95	-0.66	7.68e-43	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09845946	chr2:204192806	ABI2	0.43	6.08	0.32	3.35e-9	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.38	6.11	0.32	2.84e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg23298862	chr7:158159286	PTPRN2	-0.49	-8.05	-0.41	1.52e-14	Calcium levels;
CRC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg22777020	chr22:31556080	RNF185	-0.52	-6.0	-0.31	5.18e-9	Colorectal cancer;
CRC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.41	6.83	0.35	4.23e-11	Schizophrenia;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg12273811	chr6:28175739	NA	0.56	8.01	0.4	2.05e-14	Parkinson's disease;
CRC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06544989	chr22:39130855	UNC84B	-0.48	-7.85	-0.4	5.73e-14	Menopause (age at onset);
CRC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.45	0.53	8.93e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6600671	0.934	rs12131379	chr1:121293437	T/C	cg09829573	chr1:144692074	NBPF9	-0.42	-6.32	-0.33	8.74e-10	Hip geometry;
CRC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.56	-0.57	8.18e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10991814	1.000	rs17579908	chr9:93948636	G/C	cg14446406	chr9:93919335	NA	0.56	6.39	0.33	5.7e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.09	24.21	0.8	4.5e-75	Platelet distribution width;
CRC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.81	14.04	0.61	2.06e-35	Metabolic syndrome;
CRC	cis	rs9491140	0.539	rs12204076	chr6:124693493	A/G	cg19267163	chr6:125004984	NKAIN2	0.47	6.08	0.32	3.38e-9	Neuroticism;
CRC	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg27661571	chr11:113659931	NA	0.58	7.02	0.36	1.26e-11	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg21620606	chr4:1342894	KIAA1530	-0.43	-7.81	-0.4	7.76e-14	Obesity-related traits;
CRC	cis	rs2292864	1.000	rs2292864	chr17:45367681	C/T	cg18085866	chr17:45331354	ITGB3	-0.59	-5.94	-0.31	7.4e-9	Left atrial antero-posterior diameter;
CRC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.69	0.54	1.18e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg14003231	chr6:33640908	ITPR3	0.51	8.26	0.41	3.71e-15	Plateletcrit;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg03623178	chr6:28175578	NA	0.73	8.67	0.43	2.02e-16	Depression;
CRC	cis	rs2249694	0.960	rs2515642	chr10:135352013	C/T	cg16964102	chr10:135390573	NA	-0.38	-6.21	-0.32	1.57e-9	Obesity-related traits;
CRC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.5	-0.38	5.93e-13	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16176301	chr11:8933372	ST5;C11orf17	0.44	6.12	0.32	2.61e-9	Response to antipsychotic treatment;
CRC	cis	rs12044355	0.929	rs6667123	chr1:231851991	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.24	0.33	1.32e-9	Alzheimer's disease;
CRC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.59e-13	Diabetic retinopathy;
CRC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.67	11.85	0.55	3.1e-27	Prostate cancer;
CRC	trans	rs4745216	0.643	rs2795116	chr9:75773161	A/G	cg11926456	chr2:211432972	CPS1	0.56	6.09	0.32	3.14e-9	Blood protein levels;
CRC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-7.07	-0.36	9.09e-12	Colorectal cancer;
CRC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.49	-9.0	-0.44	1.8e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.69	-0.54	1.2e-26	Mean platelet volume;Platelet distribution width;
CRC	trans	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.42	-0.33	4.79e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04047710	chr21:34143336	C21orf66;C21orf49	-0.57	-6.86	-0.35	3.4e-11	Diisocyanate-induced asthma;
CRC	trans	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.68	0.35	1.02e-10	Mean corpuscular volume;
CRC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.2	-0.32	1.7e-9	Tonsillectomy;
CRC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.37	-5.69	-0.3	2.78e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.4	-6.36	-0.33	6.86e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg24209194	chr3:40518798	ZNF619	0.43	6.64	0.34	1.27e-10	Renal cell carcinoma;
CRC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.69	-9.07	-0.45	1.1e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	8.62	0.43	2.9e-16	Lung function (FEV1/FVC);
CRC	trans	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.68	-0.3	2.9e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.51	7.26	0.37	2.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-5.84	-0.31	1.28e-8	Body mass index (adult);
CRC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.36	6.11	0.32	2.77e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg04731861	chr2:219085781	ARPC2	-0.3	-6.0	-0.31	5.24e-9	Colorectal cancer;
CRC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	0.98	10.23	0.49	1.63e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7605827	0.930	rs13024104	chr2:15603346	T/C	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.47e-9	Educational attainment (years of education);
CRC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.61	6.21	0.32	1.57e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11098699	0.821	rs4833891	chr4:124231454	A/G	cg09941581	chr4:124220074	SPATA5	0.4	5.88	0.31	1.02e-8	Mosquito bite size;
CRC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14008862	chr17:28927542	LRRC37B2	0.59	5.77	0.3	1.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg14844989	chr11:31128820	NA	0.36	6.29	0.33	1.01e-9	Red blood cell count;
CRC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.49	-7.38	-0.38	1.29e-12	Menarche (age at onset);
CRC	cis	rs7113874	0.524	rs10743076	chr11:8560571	C/A	cg20771178	chr11:8615675	STK33	-0.35	-5.85	-0.31	1.18e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg05342945	chr12:48394962	COL2A1	-0.46	-6.41	-0.33	5.14e-10	Lung cancer;
CRC	cis	rs6496667	0.779	rs16944518	chr15:91035084	A/C	cg04176472	chr15:90893244	GABARAPL3	0.51	7.41	0.38	1.08e-12	Rheumatoid arthritis;
CRC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.83e-13	Educational attainment;
CRC	cis	rs773506	0.628	rs4743820	chr9:93928416	C/T	cg14446406	chr9:93919335	NA	-0.45	-7.71	-0.39	1.49e-13	Type 2 diabetes nephropathy;
CRC	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.95	-0.31	7.01e-9	Response to antipsychotic treatment;
CRC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg17321639	chr7:2759063	NA	-0.53	-7.09	-0.36	8.15e-12	Height;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01861096	chr22:19279212	CLTCL1	0.39	6.17	0.32	1.99e-9	Obesity-related traits;
CRC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.62	13.76	0.6	2.39e-34	Airflow obstruction;
CRC	trans	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	7.96	0.4	2.76e-14	Personality dimensions;
CRC	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	1.04	8.62	0.43	2.85e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg18721089	chr20:30220636	NA	-0.37	-5.92	-0.31	8.24e-9	Monocyte count;
CRC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg04731861	chr2:219085781	ARPC2	-0.3	-6.23	-0.32	1.46e-9	Colorectal cancer;
CRC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.65	-10.46	-0.5	2.67e-22	Blood pressure (smoking interaction);
CRC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg21138405	chr5:131827807	IRF1	0.32	5.69	0.3	2.87e-8	Blood metabolite levels;
CRC	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.62	-7.19	-0.37	4.34e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg22256960	chr15:77711686	NA	0.61	7.29	0.37	2.3e-12	Type 2 diabetes;
CRC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19904058	chr10:135279010	LOC619207	-0.35	-6.81	-0.35	4.71e-11	Systemic lupus erythematosus;
CRC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.53	-11.95	-0.55	1.4e-27	Urate levels in overweight individuals;
CRC	cis	rs2257205	0.667	rs6503884	chr17:56940026	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.43e-8	Pancreatic cancer;
CRC	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	0.96	18.06	0.71	3.96e-51	Eosinophil percentage of white cells;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg02683197	chr6:28174875	NA	0.8	10.0	0.48	9.7e-21	Depression;
CRC	cis	rs10901296	0.660	rs11789055	chr9:133766295	T/C	cg01000188	chr9:133769184	QRFP	0.72	9.15	0.45	5.92e-18	Bilirubin levels;
CRC	cis	rs13064447	0.874	rs9310408	chr3:12757726	T/C	cg07775309	chr3:12595852	NA	-0.36	-5.8	-0.3	1.53e-8	Major depression and alcohol dependence;
CRC	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.62	-6.81	-0.35	4.67e-11	Coronary artery disease;
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg22687807	chr8:143858763	LYNX1	-0.54	-9.74	-0.47	7.17e-20	Urinary tract infection frequency;
CRC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.91	-0.31	8.47e-9	Body mass index;
CRC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.68	11.31	0.53	2.82e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16007680	chr8:144349898	GLI4	0.42	6.17	0.32	1.95e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.61	-5.83	-0.31	1.34e-8	Schizophrenia;
CRC	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.43	0.5	3.37e-22	Corneal astigmatism;
CRC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg14671364	chr1:107599128	PRMT6	-0.58	-7.88	-0.4	4.99e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4731207	0.596	rs6466968	chr7:124583357	C/T	cg23710748	chr7:124431027	NA	0.39	6.37	0.33	6.5e-10	Cutaneous malignant melanoma;
CRC	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.48e-17	Dupuytren's disease;
CRC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.86	-13.74	-0.6	2.76e-34	Blood metabolite levels;
CRC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.48	7.61	0.39	2.98e-13	Eye color traits;
CRC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-11.1	-0.52	1.52e-24	Systemic lupus erythematosus;
CRC	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg05044414	chr3:183734942	ABCC5	0.47	7.52	0.38	5.17e-13	Anterior chamber depth;
CRC	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg00603274	chr11:61596626	FADS2	-0.46	-6.65	-0.34	1.2e-10	Trans fatty acid levels;
CRC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04731861	chr2:219085781	ARPC2	0.33	6.95	0.36	2.01e-11	Colorectal cancer;
CRC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg14427527	chr5:176793960	RGS14	0.38	5.64	0.3	3.75e-8	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.51	9.2	0.45	4.18e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.32	-6.28	-0.33	1.07e-9	Breast cancer;
CRC	cis	rs1465370	0.533	rs10239342	chr7:130009312	T/G	cg03229158	chr7:130009420	NA	0.5	7.16	0.37	5.23e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.8	8.79	0.44	8.31e-17	Gout;Renal underexcretion gout;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg27094323	chr7:1216898	NA	-0.4	-6.39	-0.33	5.71e-10	Longevity;Endometriosis;
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14290451	chr6:35436136	RPL10A	-0.44	-6.46	-0.34	3.73e-10	Daytime sleep phenotypes;
CRC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.0	0.48	1.02e-20	Platelet count;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01171360	chr6:293285	DUSP22	-0.45	-6.49	-0.34	3.17e-10	Menopause (age at onset);
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg12218747	chr21:37451666	NA	-0.41	-7.14	-0.37	5.85e-12	Mitral valve prolapse;
CRC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.85	-0.31	1.22e-8	Gout;Renal underexcretion gout;
CRC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg21877656	chr19:58662188	ZNF329	0.66	7.2	0.37	4.23e-12	Cholesterol, total;
CRC	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.88	-0.35	3.05e-11	Response to antipsychotic treatment;
CRC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.57	7.95	0.4	3.07e-14	Alcohol dependence;
CRC	trans	rs6693295	0.729	rs2185073	chr1:246213341	G/A	cg08881680	chr11:94965469	SESN3	0.49	6.02	0.31	4.7e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.68	0.3	3.02e-8	Protein C levels;
CRC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.09	-0.36	7.99e-12	Joint mobility (Beighton score);
CRC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	1.28	14.22	0.62	4.24e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1030268	0.962	rs12707122	chr7:133517309	A/C	cg03336402	chr7:133662267	EXOC4	-0.51	-6.77	-0.35	5.75e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg25856811	chr1:152973957	SPRR3	-0.23	-6.16	-0.32	2.13e-9	Inflammatory skin disease;
CRC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.86	-0.48	2.94e-20	Total cholesterol levels;
CRC	cis	rs4658101	0.700	rs6604045	chr1:92051755	C/T	cg24006770	chr1:92056542	NA	0.45	6.61	0.34	1.53e-10	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.95	11.45	0.53	8.78e-26	Eosinophil percentage of granulocytes;
CRC	trans	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg02560186	chr11:3602584	NA	-0.56	-7.1	-0.36	7.58e-12	Blood pressure (smoking interaction);
CRC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12516959	chr21:47718080	NA	-0.34	-5.68	-0.3	3.03e-8	Testicular germ cell tumor;
CRC	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.43	-6.2	-0.32	1.72e-9	Response to antineoplastic agents;
CRC	cis	rs9992667	0.955	rs6819274	chr4:38615927	A/G	cg19726192	chr4:38663646	FLJ13197	-0.57	-7.33	-0.37	1.81e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.29	-0.33	9.82e-10	Body mass index;
CRC	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg01422370	chr2:73384389	NA	0.37	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.0	-14.82	-0.63	1.99e-38	Colorectal cancer;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7209700	0.547	rs11657517	chr17:45343713	C/T	cg17185639	chr17:45330862	ITGB3	0.4	6.0	0.31	5.34e-9	IgG glycosylation;
CRC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06505273	chr16:24850292	NA	0.49	6.17	0.32	1.98e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs10858396	1.000	rs11789484	chr9:138275572	G/T	cg26979339	chr12:107168153	RIC8B	0.46	6.02	0.31	4.71e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.13	0.41	8.68e-15	Menarche (age at onset);
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11645453	chr3:52864694	ITIH4	0.36	6.49	0.34	3.17e-10	Bipolar disorder;
CRC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg11833968	chr6:79620685	NA	-0.35	-6.07	-0.32	3.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg15147215	chr3:52552868	STAB1	-0.65	-11.12	-0.52	1.31e-24	Bipolar disorder;
CRC	cis	rs9533799	1.000	rs7999059	chr13:44807194	C/A	cg19190762	chr13:44806055	NA	0.62	9.49	0.46	4.7e-19	Amyotrophic lateral sclerosis;
CRC	cis	rs2811415	0.597	rs3774797	chr3:127772793	G/A	cg13719885	chr3:127795394	NA	-0.4	-6.05	-0.32	3.83e-9	Lung function (FEV1/FVC);
CRC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	16.92	0.68	1.24e-46	Platelet count;
CRC	cis	rs6676180	0.555	rs12060730	chr1:119770702	A/G	cg05756136	chr1:119680316	WARS2	-0.44	-6.61	-0.34	1.57e-10	Monobrow;
CRC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.93	0.31	7.47e-9	Self-reported allergy;
CRC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17507749	chr15:85114479	UBE2QP1	0.65	9.55	0.47	2.98e-19	Schizophrenia;
CRC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.45	-7.16	-0.37	5.45e-12	Obesity-related traits;
CRC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.6	8.62	0.43	2.93e-16	Monobrow;
CRC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-13.75	-0.6	2.73e-34	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-7.47	-0.38	7.31e-13	Major depressive disorder;
CRC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.52	7.16	0.37	5.15e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9287719	0.649	rs7589694	chr2:10700874	T/C	cg00105475	chr2:10696890	NA	0.45	7.04	0.36	1.15e-11	Prostate cancer;
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.56	6.82	0.35	4.43e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs72956618	1.000	rs28564588	chr2:207496342	G/A	cg20754261	chr2:468330	NA	-0.64	-6.09	-0.32	3.09e-9	Tonsillectomy;
CRC	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-8.29	-0.42	2.97e-15	Schizophrenia;
CRC	cis	rs370915	0.578	rs1367934	chr4:187776396	A/G	cg12892747	chr4:187813459	NA	-0.55	-7.92	-0.4	3.77e-14	Gout;
CRC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.31	5.73	0.3	2.29e-8	Menarche (age at onset);
CRC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg19635926	chr16:89946313	TCF25	0.68	6.15	0.32	2.2e-9	Skin colour saturation;
CRC	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.48	-8.31	-0.42	2.46e-15	Response to cytidine analogues (gemcitabine);
CRC	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.9	-11.24	-0.53	5.03e-25	Hair shape;
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.09	-0.49	4.78e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.23	0.32	1.4e-9	Red blood cell count;
CRC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.52	-8.21	-0.41	5.21e-15	Intelligence (multi-trait analysis);
CRC	cis	rs96067	0.711	rs737381	chr1:36621186	G/C	cg25304816	chr1:36627734	MAP7D1	0.47	6.85	0.35	3.74e-11	Corneal structure;
CRC	cis	rs2882667	0.931	rs10077796	chr5:138356775	A/C	cg09476006	chr5:138032270	NA	-0.45	-7.33	-0.37	1.79e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10512697	1.000	rs35237876	chr5:3546147	A/T	cg19473799	chr5:3511975	NA	-0.76	-5.94	-0.31	7.41e-9	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.57	7.97	0.4	2.69e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.43	6.38	0.33	6.1e-10	Body mass index;
CRC	cis	rs9311676	0.656	rs62258081	chr3:58367705	A/C	cg06643156	chr3:58380774	PXK	0.42	6.55	0.34	2.25e-10	Systemic lupus erythematosus;
CRC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.95	11.66	0.54	1.57e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs863345	0.604	rs10797020	chr1:158490324	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg19318889	chr4:1322082	MAEA	0.43	6.56	0.34	2.06e-10	Obesity-related traits;
CRC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.86	11.56	0.54	3.73e-26	Gut microbiome composition (summer);
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg21268650	chr7:45961089	IGFBP3	0.36	6.16	0.32	2.06e-9	Sitting height ratio;
CRC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg19812747	chr11:111475976	SIK2	0.44	6.33	0.33	7.9e-10	Primary sclerosing cholangitis;
CRC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg13628971	chr7:2884303	GNA12	0.41	6.31	0.33	9.14e-10	Height;
CRC	trans	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.66	8.27	0.41	3.29e-15	Menarche (age at onset);
CRC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg15147215	chr3:52552868	STAB1	-0.41	-5.64	-0.3	3.61e-8	Schizophrenia;
CRC	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.86	-0.31	1.14e-8	Protein biomarker;
CRC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.37	5.71	0.3	2.49e-8	Crohn's disease;
CRC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.39	-0.38	1.19e-12	Self-reported allergy;
CRC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.45	6.78	0.35	5.62e-11	Colorectal cancer;
CRC	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.61	8.33	0.42	2.16e-15	Menopause (age at onset);
CRC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.86	-13.72	-0.6	3.39e-34	Cognitive function;
CRC	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.73	-8.34	-0.42	2.11e-15	Systolic blood pressure;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.47	-10.34	-0.5	6.76e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.47	-7.63	-0.39	2.6e-13	Body mass index;
CRC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg13206674	chr6:150067644	NUP43	0.48	6.95	0.36	1.93e-11	Testicular germ cell tumor;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20361001	chr2:9563570	ITGB1BP1;CPSF3	0.46	6.01	0.31	4.89e-9	Anxiety disorder;
CRC	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg05540913	chr6:167530185	CCR6	-0.37	-6.77	-0.35	5.76e-11	Rheumatoid arthritis;
CRC	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.72	0.35	7.92e-11	Coronary artery disease;
CRC	cis	rs8099014	0.814	rs7227488	chr18:56113233	A/G	cg12907477	chr18:56117327	MIR122	0.47	5.95	0.31	6.74e-9	Platelet count;
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.44	-6.58	-0.34	1.89e-10	Height;
CRC	trans	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.7	-0.35	8.99e-11	Depression;
CRC	cis	rs1883415	0.750	rs2076317	chr6:24490147	A/G	cg20631270	chr6:24437470	GPLD1	0.39	5.7	0.3	2.73e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.51	-7.7	-0.39	1.62e-13	Schizophrenia;
CRC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.82	13.53	0.6	1.81e-33	Cognitive function;
CRC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.6	-8.12	-0.41	9.79e-15	Gastritis;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg27094323	chr7:1216898	NA	-0.43	-7.33	-0.37	1.82e-12	Longevity;Endometriosis;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg11271282	chr2:238384023	NA	0.47	5.74	0.3	2.14e-8	Prostate cancer;
CRC	cis	rs2474619	0.562	rs2501721	chr6:90845036	A/G	cg06866423	chr6:90926672	BACH2	0.45	7.57	0.38	3.91e-13	Celiac disease;
CRC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg23463467	chr20:60627584	TAF4	0.44	8.34	0.42	2.05e-15	Body mass index;
CRC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg12193833	chr17:30244370	NA	-0.74	-8.72	-0.43	1.45e-16	Hip circumference adjusted for BMI;
CRC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.58	-7.95	-0.4	2.96e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1468498	0.588	rs7350409	chr10:116054585	C/G	cg10063575	chr12:53822143	AMHR2	-0.46	-6.0	-0.31	5.24e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg21681030	chr2:46777652	RHOQ	0.42	6.32	0.33	8.3e-10	Height;
CRC	cis	rs965469	0.779	rs2236121	chr20:3304320	A/G	cg25506879	chr20:3388711	C20orf194	-0.4	-5.74	-0.3	2.17e-8	IFN-related cytopenia;
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.52	7.83	0.4	6.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.69	11.05	0.52	2.28e-24	Longevity;Endometriosis;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg24284087	chr3:184033015	EIF4G1	-0.41	-6.04	-0.32	4.27e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.19	-0.53	7.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg11503833	chr11:492997	NA	0.44	5.66	0.3	3.31e-8	Systemic lupus erythematosus;
CRC	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg09127314	chr1:152161683	NA	0.49	6.15	0.32	2.29e-9	Atopic dermatitis;
CRC	cis	rs9931543	0.504	rs4784650	chr16:56306640	A/G	cg02433656	chr16:56322654	GNAO1	0.47	7.15	0.37	5.5e-12	Subjective well-being;
CRC	cis	rs11628318	0.515	rs9324049	chr14:103096352	T/C	cg12046867	chr14:103022105	NA	-0.41	-5.62	-0.3	4.02e-8	Platelet count;
CRC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.62	10.24	0.49	1.49e-21	Personality dimensions;
CRC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.92	0.31	7.88e-9	Self-reported allergy;
CRC	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.97	11.38	0.53	1.58e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg03732007	chr1:2071316	PRKCZ	-0.36	-5.72	-0.3	2.39e-8	Height;
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.64	6.79	0.35	5.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6496667	0.779	rs719473	chr15:90998064	A/G	cg04176472	chr15:90893244	GABARAPL3	0.58	8.3	0.42	2.82e-15	Rheumatoid arthritis;
CRC	cis	rs6840360	0.582	rs4696259	chr4:152310788	A/G	cg09659197	chr4:152720779	NA	0.31	5.96	0.31	6.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.5	6.49	0.34	3.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	9.8	0.48	4.71e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs939584	1.000	rs13415094	chr2:653093	T/C	cg03610516	chr2:642275	NA	-0.43	-5.93	-0.31	7.78e-9	Body mass index;
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg04025307	chr7:1156635	C7orf50	0.64	6.66	0.34	1.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg08314208	chr16:67682810	RLTPR	-0.54	-5.94	-0.31	7.18e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg27535305	chr1:53392650	SCP2	-0.34	-6.08	-0.32	3.26e-9	Monocyte count;
CRC	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg02927042	chr1:21476669	EIF4G3	-0.5	-8.1	-0.41	1.09e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.74	11.19	0.53	7.61e-25	Hemoglobin concentration;Hematocrit;
CRC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-7.42	-0.38	1.02e-12	Total body bone mineral density;
CRC	cis	rs9303542	0.559	rs12939811	chr17:46607958	A/T	cg04904318	chr17:46607828	HOXB1	-0.55	-6.55	-0.34	2.2e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg18683604	chr14:51561293	TRIM9	0.29	5.66	0.3	3.25e-8	Cancer;
CRC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.47	6.44	0.33	4.21e-10	Height;
CRC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.71	11.04	0.52	2.62e-24	Corneal astigmatism;
CRC	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg03929089	chr4:120376271	NA	-0.67	-7.18	-0.37	4.75e-12	D-dimer levels;
CRC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	0.93	18.14	0.71	1.87e-51	Height;
CRC	cis	rs289828	0.868	rs289832	chr2:152134405	G/C	cg06191203	chr2:152266755	RIF1	-0.4	-5.68	-0.3	2.91e-8	Blood protein levels;
CRC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	10.67	0.51	5.17e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.94	0.64	6.99e-39	Platelet count;
CRC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.46	-0.34	3.79e-10	Glycated hemoglobin levels;
CRC	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.49	0.38	6.38e-13	Lung cancer;
CRC	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.52	8.21	0.41	5.21e-15	Coronary artery disease;
CRC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.66	-11.45	-0.53	8.91e-26	Brugada syndrome;
CRC	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.89	8.49	0.42	7.16e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.54	7.9	0.4	4.36e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.76	-12.21	-0.56	1.58e-28	Height;
CRC	cis	rs6662572	0.737	rs56295206	chr1:46551026	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.94	0.31	7.26e-9	Blood protein levels;
CRC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.42	-6.17	-0.32	2.04e-9	Ulcerative colitis;
CRC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.34e-11	Menopause (age at onset);
CRC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.61	10.51	0.5	1.86e-22	Body mass index;
CRC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-6.21	-0.32	1.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12667521	chr19:29218732	NA	0.52	7.16	0.37	5.18e-12	Methadone dose in opioid dependence;
CRC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg04362960	chr10:104952993	NT5C2	-0.44	-5.88	-0.31	9.86e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.57	0.39	3.74e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.41	-6.84	-0.35	3.96e-11	Coronary artery disease;
CRC	cis	rs7626444	0.584	rs7633044	chr3:196490643	A/G	cg12930392	chr3:196481615	PAK2	0.38	6.82	0.35	4.44e-11	Monocyte count;
CRC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	1.01	20.06	0.74	5.16e-59	Headache;
CRC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.04e-15	Menopause (age at onset);
CRC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg15445000	chr17:37608096	MED1	-0.42	-8.53	-0.43	5.46e-16	Glomerular filtration rate (creatinine);
CRC	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.95	-13.65	-0.6	6.37e-34	Colorectal cancer;
CRC	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg16898833	chr6:26189333	HIST1H4D	0.78	6.52	0.34	2.64e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.04	-0.55	6.79e-28	Coffee consumption (cups per day);
CRC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg27068330	chr11:65405492	SIPA1	-0.48	-6.55	-0.34	2.24e-10	Breast cancer;
CRC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.38	5.71	0.3	2.54e-8	HDL cholesterol levels;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg15786705	chr6:28176104	NA	0.59	8.66	0.43	2.17e-16	Parkinson's disease;
CRC	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.52	-6.02	-0.31	4.73e-9	Body mass index;
CRC	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.68	-0.39	1.79e-13	Neuroticism;
CRC	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	1.1	12.97	0.58	2.42e-31	Obesity-related traits;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.69	-10.75	-0.51	2.57e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg19683494	chr5:74908142	NA	0.48	6.2	0.32	1.74e-9	Age-related disease endophenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12998533	chr5:43514915	C5orf34	0.45	6.26	0.33	1.22e-9	Response to antipsychotic treatment;
CRC	cis	rs2530545	0.762	rs10245143	chr7:34667302	C/T	cg14401837	chr7:34697493	NPSR1	0.42	6.09	0.32	3.13e-9	IgG glycosylation;
CRC	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	1.04	8.83	0.44	6.15e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.75	-12.3	-0.56	7.55e-29	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.44	7.06	0.36	9.87e-12	Resting heart rate;
CRC	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-12.18	-0.56	1.96e-28	Colorectal cancer;
CRC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.53	-6.9	-0.36	2.63e-11	Blood metabolite levels;
CRC	cis	rs847649	0.731	rs7785272	chr7:102671023	A/G	cg18108683	chr7:102477205	FBXL13	-0.51	-7.85	-0.4	5.94e-14	Morning vs. evening chronotype;
CRC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg06935464	chr4:38784597	TLR10	0.55	5.69	0.3	2.78e-8	Breast cancer;
CRC	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg20488157	chr14:104394430	TDRD9	-0.68	-9.68	-0.47	1.16e-19	Bipolar disorder;
CRC	cis	rs10450586	0.829	rs7478918	chr11:27295428	G/A	cg10370305	chr11:27303972	NA	0.38	6.25	0.33	1.29e-9	Total body bone mineral density;
CRC	trans	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.63	9.17	0.45	5.19e-18	Obesity-related traits;
CRC	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.54	7.9	0.4	4.19e-14	Platelet count;
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.27	5.63	0.3	3.78e-8	Alcohol dependence;
CRC	cis	rs13253111	0.624	rs4732844	chr8:28104473	A/G	cg26534493	chr8:28060551	NA	-0.43	-7.25	-0.37	3.04e-12	Childhood body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00108277	chr3:49840710	C3orf54	0.46	6.33	0.33	7.85e-10	Anxiety disorder;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.56	8.17	0.41	6.94e-15	Lymphocyte counts;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.93	15.46	0.65	6.71e-41	Menarche (age at onset);
CRC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg21475434	chr5:93447410	FAM172A	-0.46	-5.64	-0.3	3.6e-8	Diabetic retinopathy;
CRC	cis	rs6479527	0.840	rs1411860	chr9:96763932	T/G	cg14459158	chr9:96720562	NA	0.41	7.51	0.38	5.64e-13	Esophageal adenocarcinoma;
CRC	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg19688584	chr6:167529678	CCR6	-0.36	-6.45	-0.34	3.92e-10	Primary biliary cholangitis;
CRC	cis	rs7487075	0.930	rs4768121	chr12:46829852	A/G	cg22049899	chr12:47219821	SLC38A4	0.31	6.09	0.32	3.12e-9	Itch intensity from mosquito bite;
CRC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10053473	chr17:62856997	LRRC37A3	-0.73	-8.36	-0.42	1.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13057196	chr4:8442503	ACOX3	0.39	6.2	0.32	1.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.52	-6.96	-0.36	1.85e-11	Caudate activity during reward;
CRC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg13607699	chr17:42295918	UBTF	-0.46	-5.94	-0.31	7.08e-9	Total body bone mineral density;
CRC	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg10437265	chr15:77819839	NA	-0.48	-8.38	-0.42	1.51e-15	Type 2 diabetes;
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.03	-0.32	4.29e-9	Bipolar disorder;
CRC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg20203395	chr5:56204925	C5orf35	-0.57	-7.69	-0.39	1.78e-13	Initial pursuit acceleration;
CRC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.89	12.86	0.58	5.87e-31	Triglycerides;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06937829	chr11:554920	C11orf35	0.42	6.02	0.31	4.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.47	-0.34	3.52e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.51	-5.83	-0.31	1.33e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19713609	chr11:819941	PNPLA2	0.36	5.98	0.31	5.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.74	0.3	2.18e-8	IgG glycosylation;
CRC	cis	rs1223397	1.000	rs1223397	chr6:13270945	C/G	cg07912922	chr6:13274314	PHACTR1	0.44	5.66	0.3	3.26e-8	Blood pressure;
CRC	cis	rs1223397	0.938	rs20499	chr6:13295004	C/T	cg07912922	chr6:13274314	PHACTR1	0.47	5.83	0.31	1.35e-8	Blood pressure;
CRC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	8.95	0.44	2.71e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg06470822	chr6:28175283	NA	0.67	8.98	0.44	2.07e-17	Parkinson's disease;
CRC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.06	-0.49	6.04e-21	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12866938	chr5:145583408	RBM27	0.42	6.06	0.32	3.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.49	7.19	0.37	4.5e-12	Coronary artery disease;
CRC	trans	rs7604735	0.824	rs35462154	chr2:145821133	C/A	cg26010734	chr19:15344046	EPHX3	-0.35	-6.06	-0.32	3.78e-9	Coronary artery disease;
CRC	cis	rs17767392	0.958	rs4899398	chr14:72083441	A/G	cg13720639	chr14:72061746	SIPA1L1	0.56	7.05	0.36	1.07e-11	Mitral valve prolapse;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg21827969	chr4:56212299	SRD5A3	-0.48	-6.59	-0.34	1.74e-10	Protein C levels;
CRC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.71	-7.19	-0.37	4.26e-12	Lung cancer in ever smokers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18030105	chr11:3396237	ZNF195	-0.38	-6.22	-0.32	1.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.04	0.32	4.06e-9	Resting heart rate;
CRC	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg24097872	chr10:5724021	NA	-0.45	-6.05	-0.32	3.89e-9	Childhood ear infection;
CRC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg27523141	chr10:43048294	ZNF37B	0.5	7.34	0.38	1.73e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9303280	0.618	rs4065986	chr17:38102641	G/A	cg24910161	chr17:38119198	GSDMA	-0.33	-5.8	-0.3	1.59e-8	Self-reported allergy;
CRC	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg04850286	chr10:81895943	PLAC9	0.37	6.92	0.36	2.35e-11	Sarcoidosis;
CRC	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.67	7.26	0.37	2.77e-12	Childhood ear infection;
CRC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.54	6.85	0.35	3.62e-11	Morning vs. evening chronotype;
CRC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.37	6.18	0.32	1.87e-9	Vitiligo;
CRC	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.57	-8.08	-0.41	1.29e-14	Carotid intima media thickness;
CRC	trans	rs11847697	1.000	rs60186497	chr14:30479220	C/T	cg01202639	chr12:100898608	NR1H4	0.46	6.11	0.32	2.74e-9	Body mass index;
CRC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.9	-11.19	-0.52	7.73e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg10760299	chr15:45669010	GATM	0.51	8.02	0.4	1.93e-14	Homoarginine levels;
CRC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg18230493	chr5:56204884	C5orf35	-0.38	-5.64	-0.3	3.75e-8	Coronary artery disease;
CRC	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.51	-7.59	-0.39	3.24e-13	Coronary heart disease;
CRC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-7.87	-0.4	5.27e-14	Lung function (FEV1);
CRC	cis	rs7945718	0.621	rs7481252	chr11:12681682	A/G	cg25843174	chr11:12811716	TEAD1	0.39	7.07	0.36	9.43e-12	Educational attainment (years of education);
CRC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.58	-6.97	-0.36	1.76e-11	Menarche (age at onset);
CRC	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.68	9.18	0.45	4.87e-18	Coronary artery disease;
CRC	cis	rs995000	0.931	rs10889347	chr1:63075826	G/A	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.72	0.65	6.39e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3793917	0.948	rs3750846	chr10:124215565	T/C	cg24884230	chr10:124216658	ARMS2	0.36	5.69	0.3	2.88e-8	Age-related macular degeneration;
CRC	cis	rs2179367	0.959	rs4897125	chr6:149766208	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.43	-6.76	-0.35	6.39e-11	Dupuytren's disease;
CRC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.68	0.39	1.82e-13	Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10440450	chr16:66642627	CMTM3	0.44	6.3	0.33	9.66e-10	Anxiety disorder;
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.04e-15	Bipolar disorder;
CRC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.56	-7.67	-0.39	1.9e-13	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.66	-0.3	3.38e-8	Life satisfaction;
CRC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg10494257	chr1:16342123	HSPB7	0.4	5.65	0.3	3.51e-8	Systolic blood pressure;
CRC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.86	10.94	0.52	5.82e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs11212617	0.967	rs7395528	chr11:108056708	A/C	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.29	0.33	1.02e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.95	-0.31	7e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.7	-0.43	1.63e-16	Aortic root size;
CRC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.03	16.54	0.67	3.73e-45	Schizophrenia;
CRC	trans	rs11661542	0.967	rs11082043	chr18:20222985	C/G	cg21092177	chr17:73128031	NT5C	-0.43	-6.22	-0.32	1.55e-9	Intracranial aneurysm;
CRC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg19318889	chr4:1322082	MAEA	0.4	5.68	0.3	2.94e-8	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20488244	chr18:57026141	LMAN1	0.45	6.15	0.32	2.19e-9	Thyroid stimulating hormone;
CRC	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	8.13	0.41	8.85e-15	HIV-1 control;
CRC	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	6.06e-14	Homocysteine levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21515243	chr18:21033072	RIOK3	0.52	6.98	0.36	1.59e-11	Thyroid stimulating hormone;
CRC	cis	rs17095355	0.901	rs17126938	chr10:111761351	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.5	-5.98	-0.31	5.84e-9	Biliary atresia;
CRC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-11.28	-0.53	3.61e-25	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.38	-6.08	-0.32	3.36e-9	Gout;Renal underexcretion gout;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11388507	chr10:102027143	CWF19L1	0.48	6.39	0.33	5.74e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.42	-8.79	-0.44	8.25e-17	Bipolar disorder;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.62	-0.34	1.44e-10	Bipolar disorder;
CRC	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.34	-0.33	7.6e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.39e-9	Prudent dietary pattern;
CRC	trans	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs755249	0.567	rs41270811	chr1:39815344	G/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06307176	chr5:131281290	NA	0.45	6.53	0.34	2.55e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg18653534	chr16:772142	FAM173A	-0.39	-6.11	-0.32	2.8e-9	Height;
CRC	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.43	-0.33	4.55e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs4746003	0.752	rs9919438	chr10:71533042	G/A	cg10166889	chr5:61028374	NA	0.4	6.12	0.32	2.63e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.37	-0.38	1.42e-12	Gut microbiome composition (summer);
CRC	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg02158880	chr13:53174818	NA	-0.43	-6.54	-0.34	2.29e-10	Lewy body disease;
CRC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03901462	chr11:62572874	NXF1	0.38	6.17	0.32	1.96e-9	Obesity-related traits;
CRC	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg27534772	chr1:16042836	PLEKHM2	0.45	7.5	0.38	6.07e-13	Systolic blood pressure;
CRC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.34	-0.42	2.08e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.29	-0.37	2.4e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs62458065	0.850	rs7785999	chr7:32461262	G/T	cg20159608	chr7:32802032	NA	-0.56	-6.94	-0.36	2.05e-11	Metabolite levels (HVA/MHPG ratio);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20541753	chr11:34938014	PDHX;APIP	0.45	6.38	0.33	6e-10	Anxiety disorder;
CRC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.89	8.73	0.43	1.32e-16	Lymphocyte counts;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.67	-10.53	-0.5	1.55e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9783347	1.000	rs1140047	chr11:18327684	G/T	cg15585147	chr11:18324498	HPS5	0.42	5.9	0.31	8.87e-9	Pancreatic cancer;
CRC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg17724175	chr1:150552817	MCL1	0.44	6.55	0.34	2.27e-10	Melanoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23330034	chr19:41770021	HNRNPUL1	0.52	6.77	0.35	5.83e-11	Thyroid stimulating hormone;
CRC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg02033258	chr5:131593261	PDLIM4	0.35	6.16	0.32	2.12e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.69	9.24	0.45	3.22e-18	Platelet count;
CRC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.62	10.44	0.5	3.03e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg11168104	chr5:1857477	NA	-0.39	-6.72	-0.35	7.83e-11	Cardiovascular disease risk factors;
CRC	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg08999081	chr20:33150536	PIGU	0.46	5.68	0.3	2.99e-8	Neuroticism;
CRC	cis	rs2898681	0.614	rs11947787	chr4:53705225	C/A	cg00338735	chr4:53728038	RASL11B	0.42	6.3	0.33	9.57e-10	Optic nerve measurement (cup area);
CRC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.39	-0.56	3.32e-29	Type 2 diabetes;
CRC	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.87	16.39	0.67	1.5e-44	Hip circumference;
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.98	-19.36	-0.73	2.81e-56	Height;
CRC	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.72	8.93	0.44	3.01e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.18	29.14	0.85	3.73e-93	Colorectal cancer;
CRC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	8.46	0.42	8.91e-16	Height;
CRC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.46	7.35	0.38	1.62e-12	Uric acid clearance;
CRC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg04362960	chr10:104952993	NT5C2	0.55	6.48	0.34	3.34e-10	Waist circumference;Hip circumference;
CRC	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.35	5.66	0.3	3.38e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3126085	0.515	rs10788837	chr1:152351487	A/G	cg09127314	chr1:152161683	NA	-0.44	-5.73	-0.3	2.23e-8	Atopic dermatitis;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13645767	chr9:97766849	C9orf3	0.42	6.24	0.33	1.36e-9	Myopia (pathological);
CRC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.63	-10.0	-0.48	9.88e-21	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.65	8.78	0.44	9.01e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4252707	1	rs4252707	chr1:204508147	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.57	-8.01	-0.4	2.07e-14	Glioma;Non-glioblastoma glioma;
CRC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	9.49	0.46	4.91e-19	Bone mineral density;
CRC	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.59	0.39	3.36e-13	Mean platelet volume;
CRC	cis	rs3996993	0.809	rs62412906	chr6:52736685	T/C	cg20803780	chr6:52668592	GSTA1	0.37	6.84	0.35	3.84e-11	Hemoglobin concentration;
CRC	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-1.0	-15.67	-0.65	9.85e-42	Gout;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03489495	chr6:33588875	ITPR3	0.45	6.29	0.33	9.86e-10	Response to antipsychotic treatment;
CRC	cis	rs1179624	0.679	rs4731235	chr7:75265277	C/G	cg05145297	chr7:75264568	HIP1	0.6	8.2	0.41	5.44e-15	Age-related nuclear cataracts;
CRC	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.46	-6.34	-0.33	7.46e-10	Caudate activity during reward;
CRC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.61	9.23	0.45	3.43e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.68	-11.51	-0.54	5.35e-26	White blood cell count (basophil);
CRC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.42	-6.41	-0.33	5.13e-10	Body mass index;
CRC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.76	0.35	6.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.33	-0.37	1.83e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00157456	chr16:72042372	DHODH	0.45	6.04	0.32	4.27e-9	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25148255	chr8:17941568	ASAH1	0.45	6.0	0.31	5.19e-9	Anxiety disorder;
CRC	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg17133734	chr15:86042851	AKAP13	-0.38	-6.17	-0.32	2e-9	Interstitial lung disease;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.4	-6.69	-0.35	9.83e-11	Prostate cancer;
CRC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.69	-11.14	-0.52	1.16e-24	Urate levels;
CRC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.8	9.37	0.46	1.17e-18	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01420088	chr10:101491661	CUTC;COX15	0.54	7.6	0.39	3.16e-13	Response to antipsychotic treatment;
CRC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.21	0.32	1.61e-9	Prudent dietary pattern;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13360871	chr11:64013991	PPP1R14B	0.4	6.04	0.32	4.19e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15260365	chr11:67771606	UNC93B1	0.4	6.62	0.34	1.47e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.92	0.55	1.86e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.73	-12.51	-0.57	1.24e-29	Multiple myeloma;
CRC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.8	-0.39	8.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg22723502	chr6:26240528	HIST1H4F	0.37	5.65	0.3	3.46e-8	Gout;Renal underexcretion gout;
CRC	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.93	-0.31	7.53e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CRC	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.47	5.92	0.31	8.03e-9	Metabolite levels;
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.68	9.81	0.48	4.35e-20	Alzheimer's disease;
CRC	trans	rs1864729	1.000	rs2451113	chr8:98273448	G/A	cg08679828	chr8:102218111	ZNF706	-0.58	-6.99	-0.36	1.56e-11	Estradiol plasma levels (breast cancer);
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.71	-11.39	-0.53	1.51e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg06470822	chr6:28175283	NA	0.59	6.9	0.36	2.62e-11	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg18827107	chr12:86230957	RASSF9	-0.39	-6.01	-0.31	4.81e-9	Major depressive disorder;
CRC	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.78	-0.3	1.73e-8	Neuroticism;
CRC	cis	rs755249	0.567	rs66727439	chr1:39711930	C/T	cg18385671	chr1:39797026	MACF1	-0.44	-6.09	-0.32	3.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs875971	0.545	rs801199	chr7:66025273	A/G	cg02869306	chr7:64672164	INTS4L1	0.44	6.39	0.33	5.74e-10	Aortic root size;
CRC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	12.73	0.57	1.89e-30	Electrocardiographic conduction measures;
CRC	trans	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.77	-0.35	5.83e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23300289	chr9:132146083	NA	0.44	6.26	0.33	1.18e-9	Response to antipsychotic treatment;
CRC	cis	rs6076065	0.723	rs2275788	chr20:23338694	G/A	cg11657817	chr20:23433608	CST11	0.46	6.77	0.35	5.86e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	cis	rs7517126	1.000	rs12240148	chr1:196845307	T/C	cg13682187	chr1:196946512	CFHR5	-0.38	-5.89	-0.31	9.4e-9	Blood protein levels;
CRC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.7	0.51	3.88e-23	Cognitive function;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg08942682	chr3:197409980	KIAA0226	-0.46	-6.35	-0.33	7.06e-10	Lung cancer;
CRC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.9	-0.31	8.95e-9	Alcohol dependence;
CRC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.2	-0.32	1.68e-9	Height;
CRC	trans	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg25214090	chr10:38739885	LOC399744	0.41	6.3	0.33	9.7e-10	Diastolic blood pressure;
CRC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.45	5.83	0.31	1.33e-8	Schizophrenia;
CRC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.14	-0.37	6.13e-12	Reticulocyte fraction of red cells;
CRC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg14847009	chr1:175162515	KIAA0040	-0.28	-5.99	-0.31	5.56e-9	Alcohol dependence;
CRC	cis	rs7923609	0.841	rs10822186	chr10:65350383	A/G	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.73	-0.3	2.22e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg01422370	chr2:73384389	NA	0.37	5.63	0.3	3.86e-8	Intelligence (multi-trait analysis);
CRC	cis	rs62432291	0.681	rs386818	chr6:159660255	T/C	cg14500486	chr6:159655392	FNDC1	-0.76	-10.24	-0.49	1.49e-21	Joint mobility (Beighton score);
CRC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.37	-8.66	-0.43	2.21e-16	Multiple system atrophy;
CRC	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.83	-14.63	-0.63	1.07e-37	Lewy body disease;
CRC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg24879335	chr3:133465180	TF	0.37	6.92	0.36	2.36e-11	Iron status biomarkers;
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.74	10.97	0.52	4.67e-24	Menarche (age at onset);
CRC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg03037974	chr15:76606532	NA	0.73	13.13	0.59	5.83e-32	Blood metabolite levels;
CRC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.64	10.22	0.49	1.76e-21	Aortic root size;
CRC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg24289452	chr6:170231220	NA	-0.83	-7.15	-0.37	5.53e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.64	0.34	1.3e-10	Bipolar disorder;
CRC	cis	rs4731207	0.698	rs4552839	chr7:124499514	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.14	-0.32	2.36e-9	Cutaneous malignant melanoma;
CRC	trans	rs9914544	0.628	rs4924924	chr17:18677774	C/G	cg04702396	chr17:15466718	FAM18B2	0.57	9.2	0.45	4.27e-18	Educational attainment (years of education);
CRC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.47	8.58	0.43	3.91e-16	Childhood ear infection;
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg24046110	chr8:143859143	LYNX1	-0.76	-14.45	-0.62	5.36e-37	Urinary tract infection frequency;
CRC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.47	-8.55	-0.43	4.81e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.74	12.65	0.57	3.54e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.5	6.96	0.36	1.83e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7089973	1.000	rs7089973	chr10:116569565	A/C	cg23260525	chr10:116636907	FAM160B1	-0.33	-7.23	-0.37	3.43e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg17775713	chr3:133465469	TF	0.33	5.85	0.31	1.19e-8	Iron status biomarkers;
CRC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.64	10.08	0.49	5.26e-21	Prostate cancer;
CRC	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg09344028	chr17:70110421	NA	0.44	6.65	0.34	1.2e-10	Thyroid hormone levels;
CRC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg18230493	chr5:56204884	C5orf35	-0.42	-6.38	-0.33	6.14e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.72	10.49	0.5	2.11e-22	Menarche (age at onset);
CRC	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.62	9.82	0.48	3.99e-20	Lewy body disease;
CRC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.48	7.49	0.38	6.33e-13	Mean platelet volume;
CRC	cis	rs914615	0.508	rs4971079	chr1:155130391	C/T	cg02153340	chr1:155202674	NA	-0.39	-5.63	-0.3	3.85e-8	Urinary albumin-to-creatinine ratio;
CRC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.65	0.39	2.31e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.59	9.47	0.46	5.5e-19	Tonsillectomy;
CRC	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg17133734	chr15:86042851	AKAP13	0.42	6.78	0.35	5.75e-11	Interstitial lung disease;
CRC	cis	rs9826463	0.757	rs66597875	chr3:142264782	T/C	cg20824294	chr3:142316082	PLS1	0.4	6.79	0.35	5.33e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.49	7.0	0.36	1.46e-11	Schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03578541	chr16:72128063	TXNL4B;DHX38	-0.58	-7.04	-0.36	1.13e-11	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01027365	chr2:191184571	HIBCH	0.4	6.18	0.32	1.92e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-20.67	-0.75	2.07e-61	Hemostatic factors and hematological phenotypes;
CRC	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-15.19	-0.64	7.37e-40	Body mass index;
CRC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.73	13.96	0.61	4.04e-35	Body mass index;
CRC	cis	rs9303542	0.625	rs62065846	chr17:46592858	G/A	cg04904318	chr17:46607828	HOXB1	-0.54	-6.41	-0.33	4.95e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04731861	chr2:219085781	ARPC2	0.33	6.94	0.36	2.14e-11	Colorectal cancer;
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Blood osmolality (transformed sodium);
CRC	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg00666640	chr1:248458726	OR2T12	0.34	6.4	0.33	5.42e-10	Common traits (Other);
CRC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs7705042	0.793	rs10463348	chr5:141502035	G/T	cg07392085	chr5:141489673	NDFIP1	0.47	7.42	0.38	1.03e-12	Asthma;
CRC	trans	rs12200782	0.649	rs7775720	chr6:26381357	A/C	cg25800765	chr12:85673347	ALX1	0.26	5.98	0.31	5.95e-9	Small cell lung carcinoma;
CRC	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.39	-0.38	1.24e-12	QT interval;
CRC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.24	0.45	3.19e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.52	-9.85	-0.48	3.14e-20	Alcoholic chronic pancreatitis;
CRC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.48	-7.96	-0.4	2.88e-14	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.28e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6496667	0.779	rs62020734	chr15:90998430	G/C	cg04176472	chr15:90893244	GABARAPL3	0.59	8.29	0.42	2.95e-15	Rheumatoid arthritis;
CRC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.27	14.66	0.63	8.59e-38	Diabetic kidney disease;
CRC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	0.63	7.15	0.37	5.73e-12	LDL cholesterol;Cholesterol, total;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02466711	chr8:102218365	ZNF706	0.44	6.21	0.32	1.57e-9	Anxiety disorder;
CRC	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.47	0.42	8.11e-16	Coronary artery disease;
CRC	cis	rs6700896	0.931	rs11208715	chr1:66154414	G/T	cg04111102	chr1:66153794	NA	0.35	6.07	0.32	3.47e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.15	0.45	6.16e-18	Bladder cancer;
CRC	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00489730	chr2:29118113	WDR43	0.44	6.16	0.32	2.08e-9	Response to antipsychotic treatment;
CRC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg21747405	chr11:67723411	NA	-0.44	-6.26	-0.33	1.23e-9	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08299045	chr1:228296964	MRPL55	0.43	6.04	0.32	4.25e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg01721255	chr8:58191610	C8orf71	0.47	6.02	0.31	4.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21440829	chr7:100808893	VGF	0.48	6.58	0.34	1.91e-10	Anxiety disorder;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22078572	chr18:61033618	KDSR	0.55	6.13	0.32	2.48e-9	Interleukin-4 levels;
CRC	cis	rs2084637	1.000	rs10892855	chr11:122396173	C/A	cg21585512	chr11:122030076	LOC399959	-0.41	-7.49	-0.38	6.44e-13	Stroke;
CRC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.66	7.37	0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.66	-0.39	2.11e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.63	11.0	0.52	3.49e-24	Type 2 diabetes;
CRC	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.79	-11.7	-0.54	1.13e-26	Pubertal anthropometrics;
CRC	cis	rs13144136	0.687	rs4235336	chr4:10663850	C/T	cg10242279	chr4:10666415	CLNK	-0.39	-6.59	-0.34	1.78e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.49	7.44	0.38	8.82e-13	Mean platelet volume;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg23161317	chr6:28129485	ZNF389	0.45	6.46	0.34	3.87e-10	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05989775	chr11:2906934	CDKN1C	0.41	6.51	0.34	2.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.7	10.6	0.5	8.8e-23	Menopause (age at onset);
CRC	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.01	-19.29	-0.73	5.44e-56	Schizophrenia;
CRC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg15448220	chr1:150897856	SETDB1	0.49	7.02	0.36	1.24e-11	Tonsillectomy;
CRC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.22	-16.68	-0.68	1.07e-45	Breast cancer;
CRC	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg23710748	chr7:124431027	NA	-0.8	-14.25	-0.62	3.27e-36	Lewy body disease;
CRC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18867708	chr6:26865862	GUSBL1	0.41	6.15	0.32	2.31e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.39	5.99	0.31	5.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.74	-11.92	-0.55	1.81e-27	Mean platelet volume;
CRC	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.58	-7.03	-0.36	1.18e-11	Obesity (extreme);
CRC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.74	13.04	0.58	1.23e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs281302	0.621	rs281243	chr15:47737043	C/T	cg13159054	chr15:47721715	NA	0.44	6.51	0.34	2.81e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.45	6.01	0.31	4.87e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.48	-0.38	6.84e-13	Morning vs. evening chronotype;
CRC	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.4	0.46	9.63e-19	Corneal astigmatism;
CRC	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.32	0.46	1.8e-18	Dupuytren's disease;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-8.72	-0.43	1.37e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg03623178	chr6:28175578	NA	-0.67	-6.82	-0.35	4.28e-11	Depression;
CRC	cis	rs7632954	0.669	rs7647092	chr3:8528431	A/G	cg03495237	chr3:8533978	NA	0.36	6.64	0.34	1.33e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.51	6.4	0.33	5.34e-10	Systolic blood pressure;
CRC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	14.06	0.61	1.8e-35	Platelet count;
CRC	cis	rs501120	0.584	rs7902040	chr10:44695308	A/G	cg09554077	chr10:44749378	NA	0.69	8.09	0.41	1.15e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg00490450	chr3:139108681	COPB2	0.45	6.65	0.34	1.19e-10	Obesity-related traits;
CRC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.64	10.58	0.5	1e-22	Breast cancer;
CRC	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg24519413	chr1:26490540	NA	0.37	6.27	0.33	1.14e-9	Height;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg03623178	chr6:28175578	NA	0.64	8.51	0.42	6.36e-16	Parkinson's disease;
CRC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.64	-9.58	-0.47	2.38e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg26398791	chr1:38455867	SF3A3	-0.44	-5.92	-0.31	7.94e-9	Coronary artery disease;
CRC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.97	-17.26	-0.69	5.61e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.22	-0.37	3.61e-12	Gut microbiome composition (summer);
CRC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg11189052	chr15:85197271	WDR73	0.58	8.32	0.42	2.37e-15	Schizophrenia;
CRC	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.17e-9	Coronary artery disease;
CRC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg18016565	chr1:150552671	MCL1	0.44	6.08	0.32	3.42e-9	Melanoma;
CRC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.22	0.37	3.69e-12	Rheumatoid arthritis;
CRC	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.43	-7.49	-0.38	6.43e-13	Type 1 diabetes;
CRC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.65	-7.56	-0.38	3.94e-13	Diabetic retinopathy;
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.67	7.75	0.39	1.18e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00024790	chr16:22385412	CDR2	0.48	7.18	0.37	4.8e-12	Intelligence (multi-trait analysis);
CRC	cis	rs245880	0.740	rs245890	chr7:29190720	T/C	cg17163760	chr7:29186267	CPVL	-0.39	-6.74	-0.35	7.06e-11	Warfarin maintenance dose;
CRC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	11.64	0.54	1.91e-26	Bone mineral density;
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg06494592	chr3:125709126	NA	-0.55	-6.58	-0.34	1.88e-10	Blood pressure (smoking interaction);
CRC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.75	12.3	0.56	7.01e-29	Selective IgA deficiency;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16456337	chr5:112312164	DCP2	0.45	6.96	0.36	1.83e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.22e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-12.09	-0.55	4.31e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.42	-0.33	4.74e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs889398	0.651	rs1566455	chr16:69900164	G/T	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.3	-0.33	9.79e-10	Body mass index;
CRC	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.38	6.0	0.31	5.22e-9	IFN-related cytopenia;
CRC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg20092199	chr4:1342459	KIAA1530	0.46	7.21	0.37	3.87e-12	Obesity-related traits;
CRC	trans	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg18288967	chr1:45987694	PRDX1	0.65	7.38	0.38	1.31e-12	Obesity-related traits;
CRC	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg00277334	chr10:82204260	NA	-0.45	-5.86	-0.31	1.09e-8	Post bronchodilator FEV1;
CRC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08026144	chr9:78505312	PCSK5	0.45	6.65	0.34	1.25e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	17.24	0.69	6.62e-48	Prudent dietary pattern;
CRC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24308560	chr3:49941425	MST1R	0.44	6.86	0.35	3.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg25767906	chr1:53392781	SCP2	-0.49	-7.9	-0.4	4.29e-14	Monocyte count;
CRC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg24562669	chr7:97807699	LMTK2	-0.63	-11.56	-0.54	3.56e-26	Breast cancer;
CRC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.42	8.41	0.42	1.31e-15	Bipolar disorder;
CRC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.8	-0.35	4.86e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg22079747	chr2:228736145	WDR69	-0.44	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.46	-6.76	-0.35	6.2e-11	Crohn's disease;
CRC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg27068330	chr11:65405492	SIPA1	0.44	6.55	0.34	2.26e-10	Acne (severe);
CRC	cis	rs9361491	0.657	rs9361426	chr6:79457550	G/T	cg05283184	chr6:79620031	NA	-0.38	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9976767	0.792	rs2839508	chr21:43845294	A/G	cg23042151	chr21:43824109	UBASH3A	-0.35	-6.19	-0.32	1.79e-9	Type 1 diabetes;
CRC	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.52	6.18	0.32	1.88e-9	Blood protein levels;
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg24560729	chr4:1342394	KIAA1530	-0.31	-5.66	-0.3	3.25e-8	Obesity-related traits;
CRC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg22687807	chr8:143858763	LYNX1	-0.44	-6.86	-0.35	3.4e-11	Urinary tract infection frequency;
CRC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.41	-7.35	-0.38	1.63e-12	Prostate cancer;
CRC	cis	rs9649465	1.000	rs10238422	chr7:123353708	G/C	cg03229431	chr7:123269106	ASB15	-0.37	-5.69	-0.3	2.82e-8	Migraine;
CRC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.36	-6.05	-0.32	4.02e-9	Blood metabolite levels;
CRC	cis	rs9463078	0.656	rs227843	chr6:44691703	A/G	cg25276700	chr6:44698697	NA	0.25	5.93	0.31	7.62e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.31	-6.03	-0.32	4.39e-9	Renal function-related traits (BUN);
CRC	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg17145862	chr1:211918768	LPGAT1	-0.49	-8.18	-0.41	6.32e-15	Leprosy;
CRC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg13334819	chr7:99746414	C7orf59	0.57	6.78	0.35	5.45e-11	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg15786705	chr6:28176104	NA	0.59	8.42	0.42	1.21e-15	Parkinson's disease;
CRC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg14008862	chr17:28927542	LRRC37B2	0.53	5.64	0.3	3.61e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg15511327	chr8:143859410	LYNX1	0.39	6.97	0.36	1.79e-11	Urinary tract infection frequency;
CRC	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	0.52	5.75	0.3	2.04e-8	Insulin-like growth factors;
CRC	cis	rs6741819	0.955	rs4669124	chr2:7149737	A/G	cg27144453	chr2:7172511	RNF144A	-0.43	-6.43	-0.33	4.48e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.5	-6.27	-0.33	1.16e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17234274	0.644	rs1947940	chr11:23221511	A/C	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.03e-8	Cancer;
CRC	cis	rs910873	0.505	rs6059961	chr20:33231490	T/C	cg08999081	chr20:33150536	PIGU	0.5	6.15	0.32	2.22e-9	Melanoma;
CRC	cis	rs6604026	0.656	rs9439948	chr1:93370800	A/G	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16563178	chr3:50358443	HYAL2	0.4	6.08	0.32	3.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg21285383	chr16:89894308	SPIRE2	0.35	6.01	0.31	4.92e-9	Vitiligo;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg10729496	chr3:10149963	C3orf24	0.48	5.63	0.3	3.81e-8	Alzheimer's disease;
CRC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.51	-7.84	-0.4	6.16e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.6	9.2	0.45	4.2e-18	Asthma (sex interaction);
CRC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	trans	rs735172	0.765	rs16837649	chr4:5756362	C/T	cg10228456	chr14:30680170	NA	-0.41	-5.97	-0.31	6.1e-9	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.17	-0.41	6.55e-15	Calcium levels;
CRC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.64e-17	Prostate cancer;
CRC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.67	-9.56	-0.47	2.87e-19	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05744073	chr17:1953268	MIR132	0.52	7.5	0.38	5.86e-13	Response to antipsychotic treatment;
CRC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.5	9.46	0.46	6.14e-19	Reticulocyte fraction of red cells;
CRC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.69	10.11	0.49	4.32e-21	Longevity;
CRC	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.14e-26	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10926516	chr16:84151109	MBTPS1	0.43	6.03	0.32	4.52e-9	Response to antipsychotic treatment;
CRC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.08	14.74	0.63	4.15e-38	Orofacial clefts;
CRC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.81	-0.3	1.51e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06544989	chr22:39130855	UNC84B	-0.47	-7.39	-0.38	1.26e-12	Menopause (age at onset);
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg15845792	chr6:28175446	NA	0.8	8.48	0.42	7.73e-16	Lung cancer in ever smokers;
CRC	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg23425280	chr12:56401806	NA	0.44	5.61	0.3	4.19e-8	Cancer;
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11446398	chr5:77624930	NA	-0.48	-6.71	-0.35	8.57e-11	Triglycerides;
CRC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg04121214	chr22:50244548	NA	0.42	5.87	0.31	1.05e-8	Schizophrenia;
CRC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.43	-6.0	-0.31	5.06e-9	Breast cancer;
CRC	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.69	8.63	0.43	2.57e-16	Iron status biomarkers;
CRC	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg23425280	chr12:56401806	NA	0.47	6.02	0.31	4.68e-9	Cancer;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg02007433	chr3:129722099	NA	-0.61	-9.12	-0.45	7.74e-18	Blood pressure (smoking interaction);
CRC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg16558177	chr4:4109446	NA	-0.48	-6.23	-0.32	1.41e-9	Blood pressure (smoking interaction);
CRC	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.15e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.68	10.74	0.51	2.95e-23	Hemoglobin concentration;
CRC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.47	0.42	8.41e-16	Menarche (age at onset);
CRC	cis	rs9326248	0.731	rs90192	chr11:117059347	C/T	cg26566898	chr11:117069891	TAGLN	0.35	5.96	0.31	6.57e-9	Blood protein levels;
CRC	cis	rs9826463	0.582	rs116196326	chr3:142059684	A/T	cg20824294	chr3:142316082	PLS1	0.35	5.67	0.3	3.1e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs3018066	0.666	rs28765420	chr4:107034766	T/C	cg01869342	chr4:106983673	TBCK	0.42	5.66	0.3	3.38e-8	Cancer;
CRC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.83	-6.72	-0.35	7.97e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.23	6.45	0.34	3.97e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.09	-0.32	3.14e-9	Gout;Renal underexcretion gout;
CRC	trans	rs9630182	0.561	rs1562436	chr11:13462056	G/A	cg13741668	chr9:85679694	NA	0.38	6.19	0.32	1.78e-9	Bone mineral density;
CRC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.87	-17.28	-0.69	4.41e-48	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg05044414	chr3:183734942	ABCC5	0.43	7.35	0.38	1.62e-12	Anterior chamber depth;
CRC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.23	-0.32	1.46e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.51	8.08	0.41	1.25e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	0.98	14.38	0.62	9.93e-37	Breast cancer;
CRC	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9372498	0.764	rs9489372	chr6:118726243	T/C	cg18833306	chr6:118973337	C6orf204	0.46	5.64	0.3	3.57e-8	Diastolic blood pressure;
CRC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.79	13.89	0.61	7.72e-35	Metabolic syndrome;
CRC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-0.93	-17.22	-0.69	7.71e-48	Height;
CRC	cis	rs10901296	0.660	rs2696141	chr9:133754099	G/T	cg01000188	chr9:133769184	QRFP	0.57	6.6	0.34	1.67e-10	Bilirubin levels;
CRC	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	1.09	10.36	0.5	5.71e-22	Arsenic metabolism;
CRC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.55	9.13	0.45	7.21e-18	Total body bone mineral density;
CRC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.51	-8.33	-0.42	2.24e-15	Testicular germ cell tumor;
CRC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.06	-0.52	2.19e-24	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.75	12.24	0.56	1.19e-28	Blood protein levels;
CRC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg02254774	chr11:50257496	LOC441601	0.55	6.06	0.32	3.77e-9	Axial length;
CRC	cis	rs6968419	0.642	rs67251819	chr7:115905586	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.49	-0.34	3.18e-10	Intraocular pressure;
CRC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg11861562	chr11:117069780	TAGLN	0.26	5.81	0.3	1.51e-8	Blood protein levels;
CRC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.49	-6.9	-0.36	2.73e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.78	0.68	4.47e-46	Chronic sinus infection;
CRC	cis	rs1656402	0.906	rs1190435	chr2:233424106	A/G	cg03852847	chr2:233439513	NA	0.46	7.87	0.4	5.19e-14	Non-small cell lung cancer (survival);
CRC	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.49	8.1	0.41	1.06e-14	Endometriosis;
CRC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.56	-8.16	-0.41	7.16e-15	Menarche (age at onset);
CRC	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.73	8.61	0.43	3.13e-16	Eotaxin levels;
CRC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg18230493	chr5:56204884	C5orf35	-0.39	-5.84	-0.31	1.27e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg07636037	chr3:49044803	WDR6	0.65	6.7	0.35	8.98e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs16975963	0.644	rs1478462	chr19:38147025	A/G	cg15135657	chr19:38346511	NA	-0.47	-6.56	-0.34	2.09e-10	Longevity;
CRC	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg14593290	chr7:50529359	DDC	0.55	7.64	0.39	2.35e-13	Malaria;
CRC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.5	-8.41	-0.42	1.3e-15	Type 2 diabetes;
CRC	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-7.13	-0.37	6.51e-12	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.72	-0.43	1.38e-16	Aortic root size;
CRC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.5	5.76	0.3	1.89e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.78	-0.39	9.24e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg00507830	chr2:103233733	NA	0.55	6.16	0.32	2.07e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs6433857	0.627	rs1406259	chr2:181522879	T/G	cg23363182	chr2:181467187	NA	-0.48	-7.38	-0.38	1.29e-12	Body mass index;
CRC	cis	rs6445967	1.000	rs13325699	chr3:58286870	T/C	cg23715586	chr3:58305044	RPP14	0.36	6.1	0.32	3.04e-9	Platelet count;
CRC	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.54	-8.65	-0.43	2.34e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs1572438	0.899	rs9392198	chr6:860561	T/G	cg13447295	chr6:887704	NA	-0.46	-6.5	-0.34	2.98e-10	Aging;
CRC	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-5.96	-0.31	6.6e-9	Daytime sleep phenotypes;
CRC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.34	-0.46	1.52e-18	Intelligence (multi-trait analysis);
CRC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-21.13	-0.76	3.29e-63	Hemostatic factors and hematological phenotypes;
CRC	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.97	-0.44	2.23e-17	Bipolar disorder;
CRC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.62	9.46	0.46	5.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs10919791	0.501	rs4915189	chr1:199916450	C/A	cg07208853	chr1:200005219	NR5A2	0.23	5.94	0.31	7.18e-9	Pancreatic cancer;
CRC	cis	rs4664293	0.867	rs7566802	chr2:160584991	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	9.23	0.45	3.34e-18	Menarche (age at onset);
CRC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06734816	chr6:116422381	NT5DC1	0.47	6.7	0.35	9.06e-11	Response to antipsychotic treatment;
CRC	trans	rs4785204	1.000	rs13339262	chr16:50091383	C/A	cg01860778	chr20:26189510	MIR663	0.47	5.98	0.31	5.74e-9	Esophageal cancer (squamous cell);
CRC	cis	rs10128264	0.902	rs1250584	chr10:80976442	G/T	cg18737081	chr10:80999807	ZMIZ1	-0.36	-6.29	-0.33	1.04e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.16	0.45	5.67e-18	Hip circumference adjusted for BMI;
CRC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.57	-8.14	-0.41	8.42e-15	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11371493	chr20:30795352	POFUT1;PLAGL2	0.43	6.28	0.33	1.04e-9	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg03037974	chr15:76606532	NA	0.82	16.47	0.67	7.08e-45	Blood metabolite levels;
CRC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.7	9.05	0.45	1.31e-17	Psoriasis;
CRC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.47	-6.98	-0.36	1.59e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CRC	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg04990556	chr1:26633338	UBXN11	0.55	5.93	0.31	7.84e-9	Obesity-related traits;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg25164649	chr6:28176230	NA	-0.61	-7.98	-0.4	2.43e-14	Parkinson's disease;
CRC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	1.01	8.33	0.42	2.18e-15	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7527798	0.571	rs7531923	chr1:207833336	T/G	cg09232269	chr1:207846808	CR1L	-0.52	-8.65	-0.43	2.26e-16	Erythrocyte sedimentation rate;
CRC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.51	-0.38	5.57e-13	Neuroticism;
CRC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.37	6.29	0.33	1.02e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.63	7.14	0.37	6.12e-12	Chronic lymphocytic leukemia;
CRC	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.56	-10.39	-0.5	4.84e-22	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.66	0.3	3.23e-8	Prudent dietary pattern;
CRC	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg10556349	chr10:835070	NA	-0.34	-6.47	-0.34	3.52e-10	Survival in rectal cancer;
CRC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.49	-8.76	-0.43	1.06e-16	Prostate cancer;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg21784768	chr11:537496	LRRC56	-0.69	-6.56	-0.34	2.11e-10	Body mass index;
CRC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.98	-0.31	5.68e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg14844989	chr11:31128820	NA	-0.34	-5.92	-0.31	8.08e-9	Red blood cell count;
CRC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg23136738	chr11:925521	AP2A2	-0.52	-8.51	-0.42	6.44e-16	Alzheimer's disease (late onset);
CRC	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.58	-6.03	-0.32	4.43e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.81	14.42	0.62	6.85e-37	Total body bone mineral density;
CRC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.68	0.3	2.89e-8	Tonsillectomy;
CRC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.91	-0.4	3.86e-14	Gut microbiome composition (summer);
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg10217327	chr6:118973057	C6orf204	0.52	5.92	0.31	8.31e-9	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06530028	chr7:143078179	ZYX	0.45	6.2	0.32	1.69e-9	Response to antipsychotic treatment;
CRC	cis	rs243505	0.559	rs2072408	chr7:148508197	A/G	cg09806900	chr7:148480153	CUL1	0.58	8.22	0.41	4.75e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.27	-0.33	1.16e-9	Aortic root size;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg26587870	chr6:27730563	NA	-0.46	-7.09	-0.36	8.03e-12	Parkinson's disease;
CRC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.56	-8.78	-0.44	9.34e-17	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	trans	rs8089364	0.917	rs12957325	chr18:57884616	T/C	cg05871254	chr17:14213225	HS3ST3B1	-0.43	-5.97	-0.31	6.12e-9	Type 2 diabetes;Body mass index;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg23123621	chr4:1343375	KIAA1530	0.37	6.35	0.33	7.32e-10	Longevity;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22879676	chr17:81009871	B3GNTL1	0.4	6.15	0.32	2.22e-9	Myopia (pathological);
CRC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.93	-0.4	3.41e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.51	8.56	0.43	4.28e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg23071808	chr14:103021642	NA	0.63	7.04	0.36	1.14e-11	Platelet count;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.14e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.51	8.17	0.41	6.61e-15	Methadone dose in opioid dependence;
CRC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg16898833	chr6:26189333	HIST1H4D	0.73	6.15	0.32	2.21e-9	Urinary tract infection frequency;
CRC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.42	-5.99	-0.31	5.51e-9	Asthma;
CRC	cis	rs6676180	0.555	rs871665	chr1:119772663	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-6.59	-0.34	1.73e-10	Monobrow;
CRC	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.83	-0.35	4.02e-11	Coronary artery disease;
CRC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.54	8.03	0.4	1.73e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.51	-6.34	-0.33	7.53e-10	Recombination rate (females);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08306513	chr11:120040083	NA	0.42	6.02	0.31	4.58e-9	Response to antipsychotic treatment;
CRC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.38	5.86	0.31	1.11e-8	Red blood cell count;
CRC	trans	rs2303319	0.504	rs12473497	chr2:162433766	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.14	-0.32	2.36e-9	Cognitive function;
CRC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg03623178	chr6:28175578	NA	0.41	5.66	0.3	3.35e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17021463	0.807	rs6847989	chr4:95277099	A/C	cg11021082	chr4:95130006	SMARCAD1	0.49	7.12	0.37	6.77e-12	Testicular germ cell tumor;
CRC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.54	-0.34	2.3e-10	Tonsillectomy;
CRC	cis	rs28493229	0.881	rs59459325	chr19:41175390	C/T	cg21869046	chr19:41225005	ITPKC	0.44	6.47	0.34	3.57e-10	Kawasaki disease;
CRC	trans	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg10756647	chr7:56101905	PSPH	0.72	7.69	0.39	1.71e-13	Diabetic kidney disease;
CRC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.56	8.48	0.42	7.8e-16	Diastolic blood pressure;
CRC	cis	rs1534696	1.000	rs1534696	chr7:26397239	A/C	cg12965553	chr7:26403802	SNX10	-0.36	-5.94	-0.31	7.06e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg00734567	chr1:86172782	ZNHIT6	-0.4	-5.65	-0.3	3.47e-8	Urate levels in overweight individuals;
CRC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.06	0.41	1.43e-14	Cystic fibrosis severity;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	0.57	8.32	0.42	2.31e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.8	0.3	1.53e-8	Prudent dietary pattern;
CRC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg19682013	chr15:45996608	NA	0.32	6.53	0.34	2.51e-10	Waist circumference;Weight;
CRC	cis	rs501120	0.584	rs2804031	chr10:44702928	T/G	cg09554077	chr10:44749378	NA	0.67	7.47	0.38	7.27e-13	Coronary artery disease;Coronary heart disease;
CRC	trans	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg19894588	chr14:64061835	NA	0.59	8.83	0.44	6.54e-17	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.47	6.47	0.34	3.49e-10	Mean corpuscular volume;
CRC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.39	7.22	0.37	3.59e-12	Mean corpuscular volume;
CRC	cis	rs3736485	0.844	rs28415556	chr15:51760474	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.5	-0.34	2.95e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10352719	chr14:24769404	DHRS1;C14orf21	0.48	6.41	0.33	5.16e-10	Thyroid stimulating hormone;
CRC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.27	-0.37	2.6e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg19812747	chr11:111475976	SIK2	0.42	6.07	0.32	3.53e-9	Primary sclerosing cholangitis;
CRC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.37	8.88	0.44	4.48e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-6.85	-0.35	3.59e-11	Height;
CRC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.36	-0.59	8.31e-33	Systemic lupus erythematosus;
CRC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.5	-0.34	2.96e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.39e-11	Lung cancer;
CRC	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06307176	chr5:131281290	NA	0.42	6.27	0.33	1.11e-9	Life satisfaction;
CRC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.6	9.45	0.46	6.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg20933634	chr6:27740509	NA	0.58	6.81	0.35	4.67e-11	Depression;
CRC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg04673462	chr1:38461896	NA	-0.38	-6.13	-0.32	2.52e-9	Coronary artery disease;
CRC	cis	rs12745968	0.620	rs7514156	chr1:92970209	A/G	cg17283838	chr1:93427260	FAM69A	-0.44	-6.24	-0.33	1.32e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg18404041	chr3:52824283	ITIH1	-0.35	-6.17	-0.32	2.01e-9	Schizophrenia;
CRC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg24562669	chr7:97807699	LMTK2	-0.43	-7.14	-0.37	6.11e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg00343986	chr7:65444356	GUSB	0.54	8.18	0.41	6.38e-15	Aortic root size;
CRC	trans	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg13679164	chr6:161258479	NA	-0.42	-6.58	-0.34	1.88e-10	Gut microbiome composition (summer and winter);
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03647317	chr4:187891568	NA	-0.54	-9.78	-0.47	5.18e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg03361068	chr14:51561562	TRIM9	0.28	5.88	0.31	9.87e-9	Cancer;
CRC	cis	rs17767392	0.918	rs2108707	chr14:71791170	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.83	-0.35	4.17e-11	Mitral valve prolapse;
CRC	trans	rs2012709	0.934	rs35508346	chr5:32577772	C/T	cg03755955	chr8:6424269	MCPH1	0.4	6.0	0.31	5.3300000000000004e-09	Breast cancer;
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs17234274	0.607	rs10833975	chr11:23221973	T/C	cg05245346	chr11:23248277	NA	0.36	5.85	0.31	1.22e-8	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11027325	chr2:239148674	HES6	0.38	6.23	0.32	1.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs245880	0.740	rs245885	chr7:29188554	A/G	cg17163760	chr7:29186267	CPVL	-0.38	-6.66	-0.34	1.17e-10	Warfarin maintenance dose;
CRC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	8.52	0.43	5.85e-16	Electrocardiographic conduction measures;
CRC	cis	rs6141769	0.542	rs28548540	chr20:31294655	A/G	cg13636640	chr20:31349939	DNMT3B	-0.4	-6.12	-0.32	2.61e-9	Subjective well-being;
CRC	cis	rs2336384	1.000	rs2103876	chr1:12053100	C/T	cg13216073	chr1:12042593	MFN2	0.49	7.22	0.37	3.74e-12	Platelet count;
CRC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg01941586	chr1:40203715	PPIE	-0.46	-6.34	-0.33	7.56e-10	Blood protein levels;
CRC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-12.99	-0.58	1.92e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg02336364	chr1:24764700	NIPAL3	-0.46	-8.17	-0.41	6.63e-15	Response to interferon beta in multiple sclerosis;
CRC	cis	rs12898370	0.561	rs8028830	chr15:77508046	A/G	cg05673287	chr15:77411982	SGK269	-0.5	-5.61	-0.3	4.33e-8	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.03	-0.36	1.23e-11	Bipolar disorder;
CRC	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.46	6.1	0.32	3.06e-9	Recombination rate (females);
CRC	cis	rs476633	0.573	rs2099652	chr15:41528745	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-8.79	-0.44	8.55e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.62	14.27	0.62	2.79e-36	Airflow obstruction;
CRC	trans	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg01134436	chr17:81009848	B3GNTL1	0.74	6.97	0.36	1.7e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg04611788	chr3:186434169	KNG1	-0.6	-8.83	-0.44	6.23e-17	Blood protein levels;
CRC	cis	rs7904985	1.000	rs7084928	chr10:88122516	C/T	cg07322936	chr10:88137208	NA	-0.45	-6.11	-0.32	2.83e-9	Barrett's esophagus;
CRC	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.08	0.32	3.36e-9	Blood protein levels;
CRC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.59	-0.34	1.78e-10	Fibrinogen levels;
CRC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-5.98	-0.31	5.88e-9	Axial length;
CRC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.69	10.36	0.5	5.83e-22	Menopause (age at onset);
CRC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.68	8.53	0.43	5.4e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.47	0.34	3.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4700695	0.925	rs796728	chr5:65382500	C/T	cg21114390	chr5:65439923	SFRS12	-0.54	-6.76	-0.35	6.32e-11	Facial morphology (factor 19);
CRC	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg06606381	chr12:133084897	FBRSL1	0.82	6.32	0.33	8.52e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.39	-5.73	-0.3	2.3e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs12936587	0.601	rs7212538	chr17:17554587	T/G	cg04398451	chr17:18023971	MYO15A	0.36	6.0	0.31	5.2e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg10431340	chr1:161279108	MPZ	-0.56	-7.42	-0.38	1.04e-12	Rheumatoid arthritis;
CRC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-17.96	-0.7	9.13e-51	Height;
CRC	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg16898833	chr6:26189333	HIST1H4D	1.0	8.11	0.41	1.03e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg10589385	chr1:150898437	SETDB1	-0.27	-5.88	-0.31	9.98e-9	Melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07236925	chr15:91498269	RCCD1	0.45	6.4	0.33	5.44e-10	Response to antipsychotic treatment;
CRC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.83	0.55	3.87e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6662572	0.737	rs7530480	chr1:46399655	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.76	-0.3	1.98e-8	Blood protein levels;
CRC	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.61	-10.5	-0.5	1.9e-22	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	8.79	0.44	8.38e-17	Prudent dietary pattern;
CRC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	1.02	9.93	0.48	1.65e-20	Lymphocyte counts;
CRC	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.27	5.85	0.31	1.22e-8	Educational attainment (years of education);
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.5	6.75	0.35	6.54e-11	Height;
CRC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07701084	chr6:150067640	NUP43	0.49	6.79	0.35	5.34e-11	Lung cancer;
CRC	cis	rs13064447	0.874	rs13058951	chr3:12752381	C/T	cg07775309	chr3:12595852	NA	-0.35	-5.78	-0.3	1.78e-8	Major depression and alcohol dependence;
CRC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.79	-14.17	-0.62	6.42e-36	Lewy body disease;
CRC	cis	rs4073416	0.542	rs2411820	chr14:65946744	C/T	cg03016385	chr14:66212404	NA	-0.43	-5.93	-0.31	7.47e-9	N-glycan levels;
CRC	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.54	8.28	0.42	3.21e-15	Testicular germ cell tumor;
CRC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg23205692	chr1:25664452	TMEM50A	0.42	5.91	0.31	8.46e-9	Erythrocyte sedimentation rate;
CRC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.6	7.9	0.4	4.3e-14	Multiple sclerosis;
CRC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.54	-8.08	-0.41	1.26e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.82	-0.4	7.48e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08181479	chr10:81838760	LOC219347;C10orf57	-0.46	-6.84	-0.35	3.87e-11	Myopia (pathological);
CRC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.24	0.33	1.34e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg13844804	chr7:814759	HEATR2	0.68	7.43	0.38	9.18e-13	Cerebrospinal P-tau181p levels;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.85	15.11	0.64	1.46e-39	Breast cancer;
CRC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs4716602	0.596	rs10265482	chr7:156160655	C/G	cg16983916	chr7:156159713	NA	-0.39	-6.88	-0.35	3.1e-11	Anti-saccade response;
CRC	cis	rs12980942	0.591	rs4591267	chr19:41765407	A/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.39	0.33	5.58e-10	Coronary artery disease;
CRC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.68	-8.92	-0.44	3.4e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.5	9.73	0.47	7.8500000000000006e-20	Breast cancer;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	6.15	0.32	2.21e-9	Electroencephalogram traits;
CRC	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.97	17.9	0.7	1.69e-50	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03064167	chr17:38279234	MSL1	0.44	6.07	0.32	3.58e-9	Response to antipsychotic treatment;
CRC	cis	rs4964805	1.000	rs1866295	chr12:104186946	G/T	cg02344784	chr12:104178138	NT5DC3	0.57	8.68	0.43	1.86e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs2346177	0.875	rs6726089	chr2:46645480	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.67	-0.39	1.92e-13	HDL cholesterol;
CRC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.67	-9.91	-0.48	2.02e-20	Total body bone mineral density;
CRC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg12046867	chr14:103022105	NA	0.76	8.98	0.44	2.2e-17	Platelet count;
CRC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.61	8.73	0.43	1.33e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.4	7.23	0.37	3.42e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg14847009	chr1:175162515	KIAA0040	0.3	6.66	0.34	1.18e-10	Alcohol dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06216926	chr14:92572917	ATXN3	0.5	7.09	0.36	8.37e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg08125733	chr17:73851984	WBP2	-0.47	-6.27	-0.33	1.1e-9	White matter hyperintensity burden;
CRC	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.48	7.29	0.37	2.38e-12	Carotid intima media thickness;
CRC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg17321639	chr7:2759063	NA	-0.37	-5.65	-0.3	3.54e-8	Height;
CRC	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.49	8.29	0.42	3.01e-15	Common traits (Other);
CRC	cis	rs2289328	0.825	rs35777573	chr15:40644246	T/A	cg13931752	chr15:40660718	DISP2	0.57	5.79	0.3	1.66e-8	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.37	5.64	0.3	3.7e-8	Height;
CRC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.81	0.51	1.64e-23	Platelet count;
CRC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.24	0.37	3.25e-12	Life satisfaction;
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs12024301	0.557	rs78714242	chr1:183609310	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.83	0.35	4.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-5.83	-0.31	1.32e-8	Mean corpuscular volume;
CRC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg24011408	chr12:48396354	COL2A1	0.43	6.18	0.32	1.87e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16040186	chr17:57298050	GDPD1	0.42	6.11	0.32	2.85e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.6	7.34	0.38	1.69e-12	Renal function-related traits (BUN);
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.7	8.33	0.42	2.21e-15	Alzheimer's disease;
CRC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg02018176	chr4:1364513	KIAA1530	0.48	7.72	0.39	1.37e-13	Obesity-related traits;
CRC	cis	rs6534441	0.727	rs6848373	chr4:125426113	T/C	cg21609808	chr4:125404261	NA	0.39	5.64	0.3	3.67e-8	Major depressive disorder;
CRC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.66	-9.63	-0.47	1.63e-19	Vitiligo;
CRC	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.61	-0.3	4.38e-8	Coronary artery disease;
CRC	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.93e-14	Height;
CRC	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg12315302	chr6:26189340	HIST1H4D	0.89	6.86	0.35	3.44e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg12365402	chr11:9010492	NRIP3	-0.53	-9.43	-0.46	7.39e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13047869	chr3:10149882	C3orf24	0.58	7.77	0.39	9.84e-14	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	8.54	0.43	5.13e-16	Cognitive test performance;
CRC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.55	-7.72	-0.39	1.42e-13	Corneal structure;
CRC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.49	8.48	0.42	7.95e-16	Primary biliary cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13495574	chr1:173793781	CENPL;DARS2	0.44	7.28	0.37	2.51e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.61	-7.99	-0.4	2.32e-14	Neuroticism;
CRC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.63	9.29	0.46	2.1e-18	Lung cancer;
CRC	cis	rs910187	0.537	rs6122556	chr20:45763924	T/A	cg27589058	chr20:45804311	EYA2	-0.35	-6.15	-0.32	2.2e-9	Migraine;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.44	6.17	0.32	1.98e-9	Response to antipsychotic treatment;
CRC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02527881	chr3:46936655	PTH1R	0.39	7.29	0.37	2.39e-12	Colorectal cancer;
CRC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.65	-7.15	-0.37	5.49e-12	Initial pursuit acceleration;
CRC	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.28	-0.37	2.42e-12	Neuroticism;
CRC	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.7	0.47	9.94e-20	Blood protein levels;
CRC	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.29	0.46	2.18e-18	Iron status biomarkers;
CRC	trans	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg02674126	chr19:40336878	FBL	0.43	6.91	0.36	2.58e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.85	-0.35	3.65e-11	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg18478394	chr8:109455254	TTC35	0.37	5.71	0.3	2.5e-8	Dupuytren's disease;
CRC	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg01475377	chr6:109611718	NA	-0.34	-5.86	-0.31	1.15e-8	Reticulocyte fraction of red cells;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15947007	chr7:64023509	ZNF680	0.42	6.44	0.33	4.12e-10	Interleukin-6 levels;
CRC	cis	rs4073416	0.542	rs7144971	chr14:66120650	A/G	cg03016385	chr14:66212404	NA	0.4	5.63	0.3	3.85e-8	N-glycan levels;
CRC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg25809561	chr17:30822961	MYO1D	0.53	9.21	0.45	3.82e-18	Schizophrenia;
CRC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.5	-0.34	2.98e-10	Response to antipsychotic treatment;
CRC	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg14003231	chr6:33640908	ITPR3	0.46	7.36	0.38	1.5e-12	Height;
CRC	cis	rs62458065	0.850	rs10273165	chr7:32460840	G/A	cg20159608	chr7:32802032	NA	-0.54	-6.64	-0.34	1.26e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6479527	0.840	rs1854835	chr9:96768337	A/G	cg14459158	chr9:96720562	NA	0.39	7.02	0.36	1.24e-11	Esophageal adenocarcinoma;
CRC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.63	-0.47	1.69e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg04518342	chr5:131593106	PDLIM4	0.38	6.9	0.36	2.73e-11	Blood metabolite levels;
CRC	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.47	8.43	0.42	1.08e-15	Blood metabolite ratios;
CRC	cis	rs4731207	0.564	rs10954060	chr7:124626037	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	trans	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg26043149	chr18:55253948	FECH	-0.48	-7.33	-0.37	1.83e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07165851	chr6:158734300	TULP4	-0.59	-7.59	-0.39	3.38e-13	Height;
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.78	-0.39	9.36e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2425143	0.908	rs6060632	chr20:34422601	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.97	-0.31	6.04e-9	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12232852	chr3:69129018	UBA3	0.47	6.18	0.32	1.89e-9	Anxiety disorder;
CRC	cis	rs3018066	0.867	rs28467469	chr4:107036627	T/C	cg01869342	chr4:106983673	TBCK	0.36	5.66	0.3	3.26e-8	Cancer;
CRC	trans	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg20935933	chr6:143382018	AIG1	0.53	6.72	0.35	7.86e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.79	0.44	8.21e-17	Coffee consumption (cups per day);
CRC	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.21	-0.32	1.59e-9	Arsenic metabolism;
CRC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg02269571	chr22:50332266	NA	-0.82	-8.7	-0.43	1.66e-16	Mean platelet volume;
CRC	cis	rs7113874	0.531	rs7934396	chr11:8615632	C/G	cg17679104	chr11:8615758	STK33	0.38	6.4	0.33	5.31e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs427943	0.750	rs8126726	chr21:46609115	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	5.92	0.31	7.91e-9	Body mass index;
CRC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg00343986	chr7:65444356	GUSB	0.47	7.04	0.36	1.15e-11	Aortic root size;
CRC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.82	-10.55	-0.5	1.33e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	trans	rs76662990	0.665	rs7356676	chr5:73917301	A/G	cg04396288	chr16:27279887	NSMCE1	0.59	5.96	0.31	6.45e-9	Residual cognition;
CRC	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg00666640	chr1:248458726	OR2T12	0.48	8.36	0.42	1.85e-15	Common traits (Other);
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.13	-0.32	2.54e-9	Bipolar disorder;
CRC	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg22961107	chr3:194096808	NA	0.3	6.2	0.32	1.73e-9	Platelet distribution width;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg05683857	chr10:124030795	BTBD16	0.32	5.82	0.31	1.39e-8	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18387085	chr18:72922610	ZADH2;TSHZ1	0.41	6.17	0.32	1.99e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg21153622	chr11:89784906	NA	-0.46	-7.23	-0.37	3.45e-12	HDL cholesterol;
CRC	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.48	-0.34	3.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg20542592	chr8:11973495	FAM66D	0.33	5.72	0.3	2.34e-8	Retinal vascular caliber;
CRC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.18e-35	Mean platelet volume;
CRC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.18	0.45	4.89e-18	Parkinson's disease;
CRC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.43	6.52	0.34	2.58e-10	Menarche (age at onset);
CRC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg05941027	chr17:61774174	LIMD2	0.36	6.25	0.33	1.24e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.56	7.85	0.4	6.06e-14	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2411233	1.000	rs11635288	chr15:39270328	G/C	cg23129342	chr15:39283510	NA	0.31	5.64	0.3	3.69e-8	Platelet count;
CRC	trans	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg17903999	chr18:56338584	MALT1	0.41	6.9	0.36	2.61e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.64	8.75	0.43	1.12e-16	Arsenic metabolism;
CRC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg14008862	chr17:28927542	LRRC37B2	0.5	5.76	0.3	1.98e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-6.65	-0.34	1.26e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1223397	0.938	rs35549743	chr6:13294354	C/T	cg06879394	chr6:13274151	PHACTR1	0.53	6.18	0.32	1.87e-9	Blood pressure;
CRC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg23205692	chr1:25664452	TMEM50A	0.43	6.21	0.32	1.57e-9	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.54	8.61	0.43	3.01e-16	Coronary artery disease;
CRC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg19875578	chr6:126661172	C6orf173	0.42	5.99	0.31	5.54e-9	Male-pattern baldness;
CRC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.7	9.22	0.45	3.67e-18	High light scatter reticulocyte count;
CRC	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.08	-0.36	8.9e-12	Schizophrenia;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.7e-9	Bipolar disorder;
CRC	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.67	-0.35	1.05e-10	Longevity;Endometriosis;
CRC	cis	rs2565722	0.622	rs1937480	chr6:161304323	C/T	cg03159191	chr6:161285451	NA	-0.45	-6.22	-0.32	1.48e-9	Blood protein levels;
CRC	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg07929629	chr2:241523174	NA	0.63	8.35	0.42	1.87e-15	Bipolar disorder;
CRC	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.47	-8.39	-0.42	1.5e-15	Post-traumatic stress disorder;
CRC	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg12458913	chr13:53173898	NA	-0.51	-8.12	-0.41	9.43e-15	Lewy body disease;
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg15845792	chr6:28175446	NA	0.63	9.46	0.46	6.31e-19	Cardiac Troponin-T levels;
CRC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg04539111	chr16:67997858	SLC12A4	-0.51	-5.91	-0.31	8.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg15845792	chr6:28175446	NA	0.82	12.18	0.56	1.94e-28	Cardiac Troponin-T levels;
CRC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg19223190	chr17:80058835	NA	0.43	6.72	0.35	8.23e-11	Life satisfaction;
CRC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.73	10.84	0.51	1.26e-23	Tonsillectomy;
CRC	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.04	-14.64	-0.63	1.02e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg04727332	chr7:45960243	IGFBP3	0.42	6.41	0.33	5.01e-10	Sitting height ratio;
CRC	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg20356878	chr3:121714668	ILDR1	0.48	7.13	0.37	6.22e-12	Multiple sclerosis;
CRC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.55	-0.38	4.43e-13	Blood metabolite levels;
CRC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.61	9.48	0.46	5.4e-19	Aortic root size;
CRC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg22532475	chr10:104410764	TRIM8	-0.38	-6.77	-0.35	5.93e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.39	-0.46	1e-18	Platelet count;
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg15147215	chr3:52552868	STAB1	0.43	6.92	0.36	2.4e-11	Body mass index;
CRC	cis	rs728616	0.558	rs61859215	chr10:82151148	G/A	cg11900509	chr10:81946545	ANXA11	-0.56	-6.24	-0.33	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs3996993	0.809	rs9474334	chr6:52733458	A/G	cg20803780	chr6:52668592	GSTA1	-0.36	-6.83	-0.35	4.1e-11	Hemoglobin concentration;
CRC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.44	0.33	4.12e-10	Lung cancer;
CRC	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg01987224	chr1:201084466	NA	0.41	5.68	0.3	3.01e-8	Permanent tooth development;
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.9	-0.31	8.99e-9	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07077115	chr13:28024429	MTIF3	0.48	6.14	0.32	2.39e-9	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg21251018	chr6:28226885	NKAPL	0.42	6.02	0.32	4.53e-9	Parkinson's disease;
CRC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.25	-0.37	2.94e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg25164649	chr6:28176230	NA	-0.68	-7.65	-0.39	2.2e-13	Parkinson's disease;
CRC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.31e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.7	10.07	0.49	5.94e-21	Alzheimer's disease;
CRC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.54	-0.43	5.19e-16	Colorectal cancer;
CRC	trans	rs11023787	1.000	rs10458876	chr11:15939080	A/G	cg00338749	chr11:1036677	MUC6	-0.52	-5.97	-0.31	6.27e-9	Bone mineral density (wrist);
CRC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	14.46	0.62	4.93e-37	Platelet count;
CRC	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.8	9.85	0.48	3.23e-20	Blood protein levels;
CRC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.41	-0.33	5.1e-10	Breast cancer;
CRC	cis	rs747650	0.532	rs10838658	chr11:47130778	G/A	cg19486271	chr11:47235900	DDB2	0.46	6.13	0.32	2.47e-9	Acne (severe);
CRC	cis	rs9846480	0.598	rs7639850	chr3:138073564	G/A	cg25476813	chr3:138050155	TXNDC6	-0.38	-5.63	-0.3	3.95e-8	Whole-brain volume (Alzheimer's disease interaction);
CRC	trans	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg17903999	chr18:56338584	MALT1	-0.38	-6.26	-0.33	1.18e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs711830	0.576	rs72916141	chr2:177069364	G/T	cg13092806	chr2:177043255	NA	-0.61	-6.93	-0.36	2.29e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.2	-0.37	4.11e-12	Bipolar disorder;
CRC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg00129232	chr17:37814104	STARD3	-0.59	-7.28	-0.37	2.45e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.28	0.33	1.06e-9	IgG glycosylation;
CRC	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.6	8.46	0.42	9.15e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg03623178	chr6:28175578	NA	0.71	7.89	0.4	4.45e-14	Parkinson's disease;
CRC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.33	0.56	5.61e-29	Menopause (age at onset);
CRC	cis	rs7091068	0.671	rs1096025	chr10:95404701	T/C	cg20715218	chr10:95462985	C10orf4	-0.48	-5.66	-0.3	3.38e-8	Urinary tract infection frequency;
CRC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.32e-11	Total body bone mineral density;
CRC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.78	-0.35	5.53e-11	Alzheimer's disease (late onset);
CRC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.26	-0.37	2.76e-12	Morning vs. evening chronotype;
CRC	cis	rs4692589	1.000	rs17546378	chr4:170935854	G/A	cg19918862	chr4:170955249	NA	0.38	6.22	0.32	1.53e-9	Anxiety disorder;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg19041857	chr6:27730383	NA	-0.46	-6.25	-0.33	1.28e-9	Parkinson's disease;
CRC	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.6	6.21	0.32	1.62e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.69	0.35	9.7e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg02007433	chr3:129722099	NA	-0.51	-6.2	-0.32	1.72e-9	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-8.39	-0.42	1.42e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs9341835	0.740	rs9294198	chr6:64136993	T/C	cg13657004	chr13:50234944	EBPL	-0.36	-6.03	-0.32	4.42e-9	Schizophrenia;
CRC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.61	-7.94	-0.4	3.13e-14	Schizophrenia;
CRC	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.84	0.31	1.22e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.64	6.79	0.35	5.19e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg14646075	chr2:228736089	WDR69	-0.46	-6.22	-0.32	1.51e-9	Blood pressure;
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.46	0.42	9.07e-16	Life satisfaction;
CRC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.57	-0.39	3.68e-13	Bipolar disorder;
CRC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.58	5.99	0.31	5.36e-9	Cognitive function;
CRC	cis	rs863345	0.504	rs857698	chr1:158561166	A/T	cg12129480	chr1:158549410	OR10X1	-0.34	-7.17	-0.37	4.96e-12	Pneumococcal bacteremia;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.83	0.31	1.34e-8	Bipolar disorder;
CRC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.66	7.95	0.4	2.99e-14	Menarche (age at onset);
CRC	trans	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg16141378	chr3:129829833	LOC729375	0.44	6.73	0.35	7.69e-11	Mood instability;
CRC	cis	rs972578	1.000	rs6002997	chr22:43392264	A/G	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.96e-14	Mean platelet volume;
CRC	cis	rs1215050	0.744	rs966380	chr4:98435389	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.29	0.33	1.03e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7904985	0.961	rs12355013	chr10:88114538	A/G	cg07322936	chr10:88137208	NA	0.46	6.28	0.33	1.05e-9	Barrett's esophagus;
CRC	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.64	10.27	0.49	1.24e-21	Myopia (pathological);
CRC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.7	-11.39	-0.53	1.47e-25	Age at first birth;
CRC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-14.8	-0.63	2.43e-38	Blood metabolite levels;
CRC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.69	11.87	0.55	2.67e-27	Resting heart rate;
CRC	cis	rs1823874	0.720	rs7162911	chr15:100355050	A/G	cg16400843	chr15:100339927	C15orf51	0.31	5.71	0.3	2.53e-8	IgG glycosylation;
CRC	cis	rs2070677	0.736	rs6537612	chr10:135336717	A/T	cg20169779	chr10:135381914	SYCE1	-0.7	-6.61	-0.34	1.58e-10	Gout;
CRC	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg11887960	chr12:57824829	NA	0.63	6.89	0.36	2.93e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.16	-11.79	-0.54	5.48e-27	Breast cancer;
CRC	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.47	7.3	0.37	2.17e-12	Capecitabine sensitivity;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.74	11.53	0.54	4.71e-26	Intelligence (multi-trait analysis);
CRC	cis	rs12760731	0.623	rs10798608	chr1:178386753	A/G	cg00404053	chr1:178313656	RASAL2	0.73	9.02	0.45	1.62e-17	Obesity-related traits;
CRC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.06	-0.36	9.85e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25372275	chr1:161102558	DEDD	0.36	5.97	0.31	6.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs67981189	0.570	rs67188216	chr14:71509324	T/A	cg15910301	chr14:71632612	NA	0.31	6.14	0.32	2.41e-9	Schizophrenia;
CRC	trans	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg25214090	chr10:38739885	LOC399744	-0.42	-6.47	-0.34	3.48e-10	Plateletcrit;
CRC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.63	8.51	0.42	6.14e-16	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.74	-0.51	2.95e-23	Bipolar disorder;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg04518342	chr5:131593106	PDLIM4	0.36	6.72	0.35	8.18e-11	Blood metabolite levels;
CRC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.56	6.67	0.34	1.11e-10	Bipolar disorder;
CRC	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.51	5.9	0.31	8.87e-9	Blood protein levels;
CRC	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg03929089	chr4:120376271	NA	-0.53	-6.13	-0.32	2.47e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.3	6.44	0.33	4.23e-10	Alcohol dependence;
CRC	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.09	-15.35	-0.65	1.82e-40	Exhaled nitric oxide output;
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg02725872	chr8:58115012	NA	-0.56	-7.24	-0.37	3.15e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.53	8.31	0.42	2.56e-15	Corneal astigmatism;
CRC	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg09040174	chr2:113837401	NA	0.67	10.7	0.51	4.04e-23	Protein quantitative trait loci;
CRC	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.55	8.05	0.41	1.57e-14	Multiple myeloma (IgH translocation);
CRC	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg11887960	chr12:57824829	NA	0.58	6.5	0.34	3.04e-10	Obesity-related traits;
CRC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.85	15.86	0.66	1.72e-42	Menopause (age at onset);
CRC	cis	rs7202877	0.706	rs11149812	chr16:75323645	T/C	cg03315344	chr16:75512273	CHST6	0.49	5.61	0.3	4.28e-8	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.62	8.16	0.41	7.21e-15	Coronary artery disease;
CRC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg14008862	chr17:28927542	LRRC37B2	0.56	5.93	0.31	7.65e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.69	12.02	0.55	7.72e-28	Resting heart rate;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Depression;
CRC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg25985355	chr7:65971099	NA	-0.52	-6.0	-0.31	5.12e-9	Diabetic kidney disease;
CRC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.55	-6.86	-0.35	3.34e-11	Body mass index;
CRC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.09	-0.32	3.12e-9	Axial length;
CRC	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.52	0.38	5.35e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg07617317	chr6:118971624	C6orf204	0.47	5.69	0.3	2.79e-8	Diastolic blood pressure;
CRC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	6.1	0.32	2.99e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-10.39	-0.5	4.54e-22	Colorectal cancer;
CRC	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.8	-11.58	-0.54	2.97e-26	Pubertal anthropometrics;
CRC	cis	rs4731207	0.506	rs12531282	chr7:124625462	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.5	6.39	0.33	5.61e-10	Recombination rate (females);
CRC	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg24998770	chr7:37888106	TXNDC3	0.39	6.15	0.32	2.31e-9	Alzheimer's disease (late onset);
CRC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	6.62	0.34	1.46e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.97	12.24	0.56	1.17e-28	Exhaled nitric oxide levels;
CRC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	2.98e-9	Heart rate;
CRC	trans	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-6.96	-0.36	1.83e-11	Menarche (age at onset);
CRC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.94	0.31	7.33e-9	Aortic root size;
CRC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.17	-0.32	2.06e-9	Daytime sleep phenotypes;
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.43	0.42	1.09e-15	Life satisfaction;
CRC	cis	rs995000	0.899	rs12136083	chr1:63163073	T/C	cg19896129	chr1:63156450	NA	0.4	5.92	0.31	8.23e-9	Triglyceride levels;
CRC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.55	-8.81	-0.44	7.36e-17	Huntington's disease progression;
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.54	-9.6	-0.47	2.19e-19	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07017275	chr14:55738748	FBXO34	0.36	6.05	0.32	4.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16262614	chr3:133464971	TF	0.33	5.92	0.31	7.97e-9	Iron status biomarkers;
CRC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.17	0.45	5.45e-18	Bladder cancer;
CRC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	0.96	12.99	0.58	2.02e-31	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.4	6.05	0.32	3.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg11130432	chr3:121712080	ILDR1	-0.51	-6.08	-0.32	3.37e-9	Multiple sclerosis;
CRC	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.52	-7.87	-0.4	5.3e-14	Ovarian reserve;
CRC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-9.25	-0.45	2.91e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.36	-5.79	-0.3	1.67e-8	Ulcerative colitis;
CRC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.66	-0.3	3.22e-8	Life satisfaction;
CRC	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-5.62	-0.3	4e-8	Alzheimer's disease (survival time);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24306779	chr16:58060336	MMP15	-0.58	-7.26	-0.37	2.75e-12	Diisocyanate-induced asthma;
CRC	cis	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15342139	chr6:170124938	PHF10	0.34	5.7	0.3	2.6e-8	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-7.01	-0.36	1.33e-11	Blood metabolite levels;
CRC	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg08501292	chr6:25962987	TRIM38	0.93	9.06	0.45	1.19e-17	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.02	-25.23	-0.81	6.66e-79	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.47	6.93	0.36	2.2e-11	Total body bone mineral density;
CRC	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.4	-5.86	-0.31	1.1e-8	Adiposity;
CRC	cis	rs2811415	0.627	rs1549873	chr3:127769599	G/A	cg13719885	chr3:127795394	NA	-0.4	-6.05	-0.32	3.99e-9	Lung function (FEV1/FVC);
CRC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2530545	0.851	rs60341215	chr7:34680796	G/A	cg14401837	chr7:34697493	NPSR1	0.41	5.61	0.3	4.23e-8	IgG glycosylation;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg04362960	chr10:104952993	NT5C2	-0.5	-6.01	-0.31	4.8e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-6.62	-0.34	1.45e-10	Schizophrenia;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02684603	chr4:89445054	PIGY	0.47	6.07	0.32	3.53e-9	Hip circumference;
CRC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg02290350	chr8:58132656	NA	-0.43	-5.64	-0.3	3.68e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg21747405	chr11:67723411	NA	-0.58	-9.13	-0.45	6.88e-18	Blood pressure (smoking interaction);
CRC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.76	11.67	0.54	1.41e-26	Intelligence (multi-trait analysis);
CRC	cis	rs80207740	0.941	rs2076940	chr8:21836020	A/G	cg25597362	chr8:21767310	DOK2	-0.56	-6.25	-0.33	1.28e-9	Mean corpuscular hemoglobin;
CRC	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.51	9.38	0.46	1.15e-18	Neuroticism;
CRC	cis	rs4073416	0.508	rs11844682	chr14:65910844	G/C	cg03016385	chr14:66212404	NA	-0.42	-5.69	-0.3	2.86e-8	N-glycan levels;
CRC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.61	8.1	0.41	1.08e-14	Mean platelet volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15356674	chr10:79471309	NA	0.44	5.98	0.31	5.75e-9	Thyroid stimulating hormone;
CRC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg17724175	chr1:150552817	MCL1	-0.46	-7.22	-0.37	3.54e-12	Tonsillectomy;
CRC	cis	rs9467160	0.644	rs62400468	chr6:24457358	C/T	cg20631270	chr6:24437470	GPLD1	0.48	5.9	0.31	8.8e-9	Liver enzyme levels;
CRC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.47	-8.0	-0.4	2.12e-14	Height;
CRC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg14828511	chr1:107599125	PRMT6	-0.53	-7.62	-0.39	2.79e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.51	7.41	0.38	1.11e-12	Macular telangiectasia type 2;
CRC	cis	rs7635838	0.892	rs66974661	chr3:11482729	A/G	cg00170343	chr3:11313890	ATG7	0.42	6.46	0.34	3.82e-10	HDL cholesterol;
CRC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.19	-0.37	4.32e-12	Mean corpuscular volume;
CRC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.77	0.39	1.03e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.48	-7.13	-0.37	6.3e-12	N-glycan levels;
CRC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06505273	chr16:24850292	NA	-0.39	-5.71	-0.3	2.59e-8	Intelligence (multi-trait analysis);
CRC	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.45	-0.34	3.9e-10	Obesity-related traits;
CRC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.43	0.33	4.57e-10	Tonsillectomy;
CRC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg11292332	chr7:45801988	SEPT13	-0.35	-6.25	-0.33	1.3e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.67	-7.59	-0.39	3.41e-13	Vitiligo;
CRC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg21153622	chr11:89784906	NA	-0.37	-5.97	-0.31	6.05e-9	Height;
CRC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg20243544	chr17:37824526	PNMT	0.56	8.6	0.43	3.35e-16	Asthma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15877295	chr7:138915876	UBN2	-0.53	-6.49	-0.34	3.21e-10	Diisocyanate-induced asthma;
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.83	-0.31	1.36e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.51e-12	Motion sickness;
CRC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	8.11	0.41	1.04e-14	Aortic root size;
CRC	trans	rs12200782	0.577	rs12208220	chr6:26382635	C/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.78	-0.3	1.76e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.19e-8	Lung cancer;
CRC	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.75	-10.02	-0.48	8.31e-21	White matter hyperintensity burden;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg26873254	chr8:144332526	ZFP41	-0.39	-6.11	-0.32	2.84e-9	Body mass index;
CRC	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg13175173	chr14:55914753	NA	-0.52	-9.9	-0.48	2.06e-20	Pediatric bone mineral content (femoral neck);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02189786	chr16:67875959	THAP11;CENPT	0.42	6.3	0.33	9.37e-10	Response to antipsychotic treatment;
CRC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.56	7.52	0.38	5.12e-13	Height;
CRC	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg20041105	chr8:143859282	LYNX1	-0.32	-5.7	-0.3	2.64e-8	Urinary tract infection frequency;
CRC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg23750338	chr8:142222470	SLC45A4	-0.45	-7.85	-0.4	6.07e-14	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.6	-8.65	-0.43	2.37e-16	Coronary artery disease;
CRC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.75	-0.47	6.71e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.37	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.9	-15.52	-0.65	3.9e-41	Height;
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.37	1.72e-12	Alzheimer's disease;
CRC	cis	rs17767392	0.834	rs61991190	chr14:71737278	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.56	-0.34	2.1e-10	Mitral valve prolapse;
CRC	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.83	-0.44	6.18e-17	Coffee consumption (cups per day);
CRC	cis	rs11212617	0.967	rs186594	chr11:108265854	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.64	0.34	1.3e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.36	-6.05	-0.32	4.01e-9	Sitting height ratio;
CRC	cis	rs17155006	0.676	rs424866	chr7:107722869	T/C	cg05962710	chr7:107745446	LAMB4	-0.36	-5.85	-0.31	1.17e-8	Pneumococcal bacteremia;
CRC	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.5	7.35	0.38	1.54e-12	Coronary heart disease;
CRC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.44	0.62	5.96e-37	Chronic sinus infection;
CRC	trans	rs587242	1.000	rs2011693	chr1:96884287	G/A	cg10631902	chr5:14652156	NA	0.45	7.01	0.36	1.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.01	-10.5	-0.5	2e-22	Body mass index;
CRC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.34	8.28	0.42	3.1e-15	Diastolic blood pressure;
CRC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.44	7.61	0.39	3.01e-13	Mean corpuscular volume;
CRC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg23283495	chr1:209979779	IRF6	0.48	6.81	0.35	4.66e-11	Cleft lip with or without cleft palate;
CRC	cis	rs2969070	0.898	rs2906165	chr7:2508177	T/C	cg03277898	chr7:2518824	NA	-0.41	-5.89	-0.31	9.75e-9	Diastolic blood pressure;
CRC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24308560	chr3:49941425	MST1R	0.48	7.6	0.39	3.19e-13	Intelligence (multi-trait analysis);
CRC	cis	rs174479	0.677	rs1000778	chr11:61655305	A/G	cg01500311	chr11:61656094	FADS3	0.35	5.66	0.3	3.27e-8	Sphingolipid levels;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg18811860	chr17:31264143	TMEM98	0.37	6.19	0.32	1.82e-9	Myopia;
CRC	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.79	-0.44	8.24e-17	Coffee consumption (cups per day);
CRC	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.91	-0.36	2.5e-11	Response to antipsychotic treatment;
CRC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.56	-8.33	-0.42	2.21e-15	IgG glycosylation;
CRC	cis	rs10128264	0.902	rs1250587	chr10:80978021	A/G	cg20744163	chr10:80999841	ZMIZ1	-0.43	-7.39	-0.38	1.19e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.07	-0.32	3.47e-9	Height;
CRC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-5.77	-0.3	1.86e-8	Menopause (age at onset);
CRC	trans	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg06791473	chr12:49259579	RND1	0.61	5.99	0.31	5.45e-9	Blood protein levels;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg26958806	chr6:27640298	NA	0.67	5.87	0.31	1.05e-8	Breast cancer;
CRC	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.1	-0.41	1.07e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs11989122	0.517	rs10955831	chr8:118809805	G/T	cg02216535	chr4:85308929	NA	-0.39	-6.41	-0.33	5.02e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13713052	chr3:122102218	FAM162A;CCDC58	0.45	6.48	0.34	3.33e-10	Response to antipsychotic treatment;
CRC	cis	rs863345	0.604	rs12122663	chr1:158506724	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs7546094	1.000	rs6537743	chr1:113092527	A/G	cg22162597	chr1:113214053	CAPZA1	0.42	5.84	0.31	1.27e-8	Platelet distribution width;
CRC	cis	rs9400239	0.622	rs1268165	chr6:109008378	A/G	cg11073813	chr6:109029018	NA	-0.39	-6.21	-0.32	1.59e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.52	7.68	0.39	1.82e-13	Blood protein levels;
CRC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.5	-7.71	-0.39	1.53e-13	Coronary artery disease;
CRC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	7.23	0.37	3.36e-12	Parkinson's disease;
CRC	trans	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg03060546	chr3:49711283	APEH	-0.57	-6.1	-0.32	3.01e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.77	-8.41	-0.42	1.29e-15	Tuberculosis;
CRC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg18171855	chr10:2543474	NA	0.36	5.84	0.31	1.24e-8	Age-related hearing impairment;
CRC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.66	-9.58	-0.47	2.46e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.51	-8.36	-0.42	1.8e-15	Crohn's disease;
CRC	cis	rs728616	0.558	rs2343302	chr10:82163186	A/G	cg11900509	chr10:81946545	ANXA11	-0.56	-6.24	-0.33	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6585424	1.000	rs61860035	chr10:81932453	C/G	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.81	-14.21	-0.62	4.64e-36	Lewy body disease;
CRC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.54	6.64	0.34	1.32e-10	Psoriasis;
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.57	-0.34	1.97e-10	Lymphocyte counts;
CRC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg25344623	chr2:136566232	LCT	0.32	5.81	0.31	1.47e-8	Mosquito bite size;
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	0.7	9.43	0.46	7.84e-19	Alzheimer's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27629044	chr12:132628994	DDX51;NOC4L	-0.4	-6.1	-0.32	2.93e-9	Myopia (pathological);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06034874	chr16:75285194	BCAR1	-0.43	-5.99	-0.31	5.36e-9	Myopia (pathological);
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.66	7.17	0.37	4.94e-12	Inflammatory bowel disease;
CRC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.49	-8.98	-0.44	2.2e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	6.03e-10	Red blood cell count;
CRC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.56	-6.44	-0.33	4.36e-10	Bronchopulmonary dysplasia;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.04	0.36	1.13e-11	Parkinson's disease;
CRC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg13844804	chr7:814759	HEATR2	-0.6	-8.03	-0.4	1.81e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs7113874	0.569	rs11041999	chr11:8605739	T/C	cg17679104	chr11:8615758	STK33	0.35	5.93	0.31	7.48e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg21153622	chr11:89784906	NA	0.46	7.31	0.37	2.09e-12	HDL cholesterol;
CRC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-9.63	-0.47	1.65e-19	Morning vs. evening chronotype;
CRC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg21153622	chr11:89784906	NA	-0.41	-6.78	-0.35	5.45e-11	Coronary artery disease;
CRC	cis	rs7259376	0.936	rs8110854	chr19:22549453	C/T	cg02657401	chr19:22469223	NA	-0.31	-6.76	-0.35	6.13e-11	Menopause (age at onset);
CRC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.45	-5.97	-0.31	6.09e-9	Gut microbiome composition (summer);
CRC	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg04990556	chr1:26633338	UBXN11	0.52	5.68	0.3	3.04e-8	Obesity-related traits;
CRC	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.03	-22.03	-0.77	1.02e-66	Myeloid white cell count;
CRC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.61	-7.69	-0.39	1.72e-13	Obesity (extreme);
CRC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.42	6.35	0.33	7.08e-10	Platelet distribution width;
CRC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg08075719	chr14:103021372	NA	-0.68	-7.91	-0.4	3.94e-14	Platelet count;
CRC	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.75	13.68	0.6	4.93e-34	Lewy body disease;
CRC	cis	rs10221833	0.602	rs355884	chr2:165633933	C/A	cg03182029	chr2:165697222	COBLL1	0.5	5.83	0.31	1.35e-8	Response to statin therapy;
CRC	trans	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg20935933	chr6:143382018	AIG1	0.5	6.46	0.34	3.68e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg16141378	chr3:129829833	LOC729375	0.46	6.55	0.34	2.21e-10	Triglycerides;
CRC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	6.72	0.35	7.83e-11	Menopause (age at onset);
CRC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg16358738	chr2:241808595	AGXT	-0.38	-5.8	-0.3	1.53e-8	Urinary metabolites;
CRC	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.68	-8.67	-0.43	1.98e-16	Blood protein levels;
CRC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.67	10.99	0.52	3.98e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.54	-0.34	2.28e-10	Menopause (age at onset);
CRC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.42	-0.33	4.69e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg15704280	chr7:45808275	SEPT13	0.57	5.97	0.31	6.21e-9	Intraocular pressure;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg02683197	chr6:28174875	NA	-0.66	-9.22	-0.45	3.54e-18	Parkinson's disease;
CRC	cis	rs4664293	0.585	rs11893106	chr2:160540805	A/G	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.67e-10	Monocyte percentage of white cells;
CRC	cis	rs3751196	0.901	rs61748068	chr12:104186995	G/A	cg02344784	chr12:104178138	NT5DC3	0.7	7.14	0.37	6.12e-12	Sense of smell;
CRC	cis	rs75422866	0.510	rs73105819	chr12:48120973	C/T	cg14736327	chr12:48174669	SLC48A1	-0.73	-5.92	-0.31	8e-9	Pneumonia;
CRC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.65	15.16	0.64	1.01e-39	Airflow obstruction;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.3	0.33	9.46e-10	Electroencephalogram traits;
CRC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg19812747	chr11:111475976	SIK2	0.54	8.47	0.42	8.21e-16	Primary sclerosing cholangitis;
CRC	cis	rs449789	0.524	rs3904936	chr6:159777942	G/A	cg14500486	chr6:159655392	FNDC1	-0.45	-6.78	-0.35	5.65e-11	Pulse pressure;
CRC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.64	-9.16	-0.45	5.52e-18	Menarche (age at onset);
CRC	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg24046110	chr8:143859143	LYNX1	-0.36	-6.26	-0.33	1.23e-9	Urinary tract infection frequency;
CRC	cis	rs10503871	0.685	rs7824823	chr8:30322735	G/T	cg26383811	chr8:30366931	RBPMS	-0.47	-7.52	-0.38	5.16e-13	Metabolite levels  (X-11787);
CRC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg13957321	chr17:43675089	NA	0.53	6.31	0.33	8.92e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-7.44	-0.38	8.69e-13	Primary sclerosing cholangitis;
CRC	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07513332	chr6:167530253	CCR6	0.37	5.96	0.31	6.42e-9	Primary biliary cholangitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07238657	chr1:154973705	ZBTB7B	0.43	6.17	0.32	1.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00166722	chr3:10149974	C3orf24	0.66	9.23	0.45	3.41e-18	Alzheimer's disease;
CRC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg19812747	chr11:111475976	SIK2	-0.56	-9.73	-0.47	7.59e-20	Primary sclerosing cholangitis;
CRC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg05044414	chr3:183734942	ABCC5	0.48	8.33	0.42	2.22e-15	Anterior chamber depth;
CRC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.09	18.64	0.72	1.93e-53	Cognitive function;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.69	10.95	0.52	5.15e-24	Corneal astigmatism;
CRC	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14119001	chr9:139324193	INPP5E	-0.43	-6.37	-0.33	6.49e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.36	-10.44	-0.5	3.11e-22	Mean corpuscular volume;
CRC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.17	0.32	2e-9	Asthma;
CRC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.38	-0.53	1.57e-25	Migraine;Coronary artery disease;
CRC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg25985355	chr7:65971099	NA	-0.53	-6.02	-0.31	4.7e-9	Diabetic kidney disease;
CRC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.95	0.48	1.51e-20	Cognitive test performance;
CRC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg20203395	chr5:56204925	C5orf35	0.57	7.96	0.4	2.91e-14	Initial pursuit acceleration;
CRC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg07636037	chr3:49044803	WDR6	-0.67	-5.8	-0.3	1.53e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.74	0.43	1.17e-16	Lymphocyte counts;
CRC	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.34	-0.33	7.37e-10	Body mass index;
CRC	cis	rs7712401	0.755	rs10071705	chr5:122132725	T/C	cg18764291	chr5:122110994	SNX2	0.42	6.76	0.35	6.39e-11	Mean platelet volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19850565	chr19:35168394	ZNF302	0.47	6.36	0.33	6.86e-10	Thyroid stimulating hormone;
CRC	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.72	-12.62	-0.57	4.62e-30	White blood cell count (basophil);
CRC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.09	0.72	3.29e-55	Parkinson's disease;
CRC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg07636037	chr3:49044803	WDR6	-0.67	-5.8	-0.3	1.59e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00791764	chr4:53727839	RASL11B	0.57	6.09	0.32	3.09e-9	Optic nerve measurement (cup area);
CRC	cis	rs11031096	0.542	rs10835390	chr11:3981488	A/G	cg18678763	chr11:4115507	RRM1	-0.39	-6.72	-0.35	7.82e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.91	17.77	0.7	5.22e-50	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04456666	chr15:40615783	NA	0.37	6.04	0.32	4.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg02683197	chr6:28174875	NA	0.7	9.66	0.47	1.31e-19	Parkinson's disease;
CRC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.62	-10.58	-0.5	1.07e-22	Coronary artery disease;
CRC	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg11886554	chr3:170076028	SKIL	-0.93	-9.46	-0.46	5.98e-19	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg19622623	chr12:86230825	RASSF9	-0.39	-6.19	-0.32	1.77e-9	Major depressive disorder;
CRC	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg06581033	chr10:766294	NA	-0.51	-5.77	-0.3	1.88e-8	Uric acid levels;
CRC	cis	rs2179367	0.920	rs638407	chr6:149738350	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.05	-0.32	4.05e-9	Dupuytren's disease;
CRC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.68	-0.35	1.04e-10	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.38	-0.33	6.03e-10	Blood metabolite levels;
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.83	-0.35	3.99e-11	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.59	-9.24	-0.45	3.23e-18	Corneal astigmatism;
CRC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.77	12.62	0.57	4.9e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.62	-11.3	-0.53	3.03e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.58	9.35	0.46	1.41e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs3849570	0.673	rs9877408	chr3:81974558	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-6.43	-0.33	4.52e-10	Waist circumference;Body mass index;
CRC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg23136738	chr11:925521	AP2A2	-0.4	-6.56	-0.34	2.04e-10	Alzheimer's disease (late onset);
CRC	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.65	-10.27	-0.49	1.16e-21	Corneal astigmatism;
CRC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg12273811	chr6:28175739	NA	0.4	5.97	0.31	6.21e-9	Pubertal anthropometrics;
CRC	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg18830697	chr6:72922368	RIMS1	0.41	8.01	0.4	2.02e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16024904	chr19:17905718	B3GNT3	0.39	6.1	0.32	2.92e-9	Tumor biomarkers;
CRC	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.46	-6.4	-0.33	5.5e-10	Obesity-related traits;
CRC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg15193198	chr20:60906057	LAMA5	0.41	6.19	0.32	1.8e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24796471	chr19:6737389	GPR108	0.42	6.41	0.33	5.18e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.45	6.55	0.34	2.16e-10	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	-0.66	-7.27	-0.37	2.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.39	0.33	5.69e-10	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs12618769	0.652	rs2230388	chr2:99193496	C/T	cg18455616	chr2:99124870	INPP4A	0.36	5.91	0.31	8.57e-9	Bipolar disorder;
CRC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.07	0.32	3.46e-9	Crohn's disease;
CRC	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg27422857	chr2:105853526	NA	-0.38	-6.99	-0.36	1.55e-11	Type 2 diabetes;
CRC	cis	rs11031096	0.563	rs12281849	chr11:4224832	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-6.16	-0.32	2.07e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.16	-0.32	2.07e-9	Aortic root size;
CRC	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.88	-0.31	1.02e-8	Type 2 diabetes;
CRC	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg27205649	chr11:78285834	NARS2	-0.47	-5.79	-0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg26587870	chr6:27730563	NA	-0.47	-6.99	-0.36	1.53e-11	Parkinson's disease;
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02772935	chr3:125709198	NA	-0.46	-5.94	-0.31	7.44e-9	Blood pressure (smoking interaction);
CRC	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-6.4	-0.33	5.37e-10	Schizophrenia;
CRC	cis	rs7605827	0.930	rs12692263	chr2:15539206	G/A	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-13.61	-0.6	9.01e-34	Blood metabolite levels;
CRC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.43	7.0	0.36	1.48e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7113874	0.524	rs10743076	chr11:8560571	C/A	cg02811074	chr11:8615871	STK33	-0.36	-6.09	-0.32	3.13e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08417425	chr5:153784856	GALNT10	0.37	6.2	0.32	1.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.96	-17.49	-0.69	7.06e-49	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25517755	chr10:38738941	LOC399744	0.45	6.56	0.34	2.07e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.42	-0.46	8.28e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.6	10.52	0.5	1.68e-22	Body mass index;
CRC	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.29	10.83	0.51	1.4e-23	Psoriasis vulgaris;
CRC	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg08501292	chr6:25962987	TRIM38	0.64	6.68	0.35	1.04e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06052471	chr11:61130074	TMEM138;CYBASC3	0.48	6.76	0.35	6.33e-11	Response to antipsychotic treatment;
CRC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.72	11.71	0.54	1.05e-26	Osteoporosis;
CRC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.48	-6.71	-0.35	8.61e-11	Inflammatory bowel disease;
CRC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.89	-0.51	8.4e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-5.81	-0.3	1.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.64	-0.34	1.3e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.42	6.69	0.35	9.85e-11	Major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15716185	chr18:60190644	ZCCHC2	0.4	5.99	0.31	5.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4654899	0.897	rs7548649	chr1:21090081	A/G	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.67	-0.35	1.1e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.06	-12.35	-0.56	4.92e-29	Diabetic kidney disease;
CRC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.59	10.53	0.5	1.57e-22	Aortic root size;
CRC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.53	-8.24	-0.41	4.06e-15	Corneal astigmatism;
CRC	cis	rs7605827	0.897	rs10084390	chr2:15597662	C/A	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.51e-9	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03383661	chr6:42714115	TBCC	0.44	6.27	0.33	1.14e-9	Response to antipsychotic treatment;
CRC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.45	-6.47	-0.34	3.48e-10	Asthma;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg15786705	chr6:28176104	NA	0.48	6.39	0.33	5.74e-10	Parkinson's disease;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.45	5.82	0.31	1.39e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs16867321	0.951	rs61289394	chr2:181354915	T/G	cg23363182	chr2:181467187	NA	-0.48	-5.89	-0.31	9.54e-9	Obesity;
CRC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.49	7.62	0.39	2.72e-13	Corneal astigmatism;
CRC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-0.99	-11.95	-0.55	1.37e-27	Height;
CRC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg12963866	chr19:57752005	ZNF805	-0.42	-6.22	-0.32	1.5e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs9549328	0.700	rs4907570	chr13:113617651	T/C	cg25790453	chr13:113633590	MCF2L	0.44	7.65	0.39	2.22e-13	Systolic blood pressure;
CRC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.6	7.74	0.39	1.23e-13	Mean platelet volume;
CRC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.74	-0.72	7.61e-54	Height;
CRC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.25	-0.62	3.35e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.36	-7.7	-0.39	1.61e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg19875535	chr5:140030758	IK	0.42	6.5	0.34	3.04e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg09184832	chr6:79620586	NA	-0.44	-7.49	-0.38	6.26e-13	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.64	-9.9	-0.48	2.21e-20	Breast cancer;
CRC	trans	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-8.08	-0.41	1.21e-14	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	5.7	0.3	2.71e-8	Electroencephalogram traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03669052	chr18:72164002	CNDP2	0.5	7.04	0.36	1.14e-11	Response to antipsychotic treatment;
CRC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.57	8.33	0.42	2.29e-15	Tuberculosis;
CRC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.21	0.32	1.63e-9	Aortic root size;
CRC	cis	rs6504622	1.000	rs12940071	chr17:45028052	C/T	cg16759221	chr17:45003025	GOSR2	0.45	7.17	0.37	4.83e-12	Orofacial clefts;
CRC	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg11788234	chr13:29393811	NA	-0.52	-9.13	-0.45	7.11e-18	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.37	-6.04	-0.32	4.08e-9	Ulcerative colitis;
CRC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.49	8.43	0.42	1.09e-15	Hypertriglyceridemia;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.59	-0.34	1.8e-10	Breast cancer;
CRC	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg02353165	chr6:42928485	GNMT	-0.46	-6.29	-0.33	1e-9	Blood protein levels;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg06470822	chr6:28175283	NA	0.64	9.21	0.45	3.97e-18	Hepatitis A;
CRC	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg02927042	chr1:21476669	EIF4G3	-0.53	-8.43	-0.42	1.08e-15	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02854695	chr19:50832032	KCNC3	0.36	6.09	0.32	3.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.4	-5.73	-0.3	2.32e-8	Blood pressure (smoking interaction);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16924120	chr12:118814149	SUDS3	0.45	6.52	0.34	2.68e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.51	8.45	0.42	9.22e-16	Uric acid clearance;
CRC	trans	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg10756647	chr7:56101905	PSPH	0.72	7.98	0.4	2.39e-14	Diabetic kidney disease;
CRC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.41	-6.37	-0.33	6.43e-10	Crohn's disease;
CRC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.38e-14	Colorectal cancer;
CRC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.54	-6.61	-0.34	1.58e-10	Bronchopulmonary dysplasia;
CRC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.77	14.61	0.63	1.28e-37	Body mass index;
CRC	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.59	-7.42	-0.38	1.03e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	12.7	0.57	2.34e-30	Hip circumference;
CRC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg08687515	chr19:58661962	ZNF329	0.8	8.74	0.43	1.23e-16	Cholesterol, total;
CRC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-9.53	-0.47	3.62e-19	Alcohol dependence;
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	trans	rs9341835	0.772	rs9294206	chr6:64141201	A/G	cg13657004	chr13:50234944	EBPL	-0.36	-6.06	-0.32	3.78e-9	Schizophrenia;
CRC	cis	rs4728302	0.838	rs2042453	chr7:133580730	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.99	0.31	5.51e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4547160	0.962	rs12229749	chr12:63503447	C/T	cg26727693	chr12:63544175	AVPR1A	-0.4	-7.87	-0.4	5.28e-14	Morning vs. evening chronotype;
CRC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg25985355	chr7:65971099	NA	0.32	5.7	0.3	2.62e-8	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18788524	chr1:145096602	SEC22B	0.39	6.4	0.33	5.5e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.62	-9.61	-0.47	1.92e-19	Corneal astigmatism;
CRC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg12365402	chr11:9010492	NRIP3	0.5	8.43	0.42	1.08e-15	Tonsillectomy;
CRC	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.65	9.92	0.48	1.87e-20	Bipolar disorder;
CRC	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg25797454	chr6:150327115	RAET1K	0.38	6.51	0.34	2.8e-10	Alopecia areata;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg26587870	chr6:27730563	NA	-0.42	-6.3	-0.33	9.41e-10	Parkinson's disease;
CRC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.6	8.46	0.42	8.73e-16	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01584448	chr16:50099761	HEATR3	0.44	7.06	0.36	1e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.6	8.7	0.43	1.65e-16	Lung cancer;
CRC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.52	0.46	3.81e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.5	-6.92	-0.36	2.41e-11	Inhibitory control;
CRC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.68	13.18	0.59	3.99e-32	Age-related hearing impairment;
CRC	cis	rs7932354	0.528	rs1965952	chr11:47181040	G/A	cg03339077	chr11:47165057	C11orf49	-0.46	-6.28	-0.33	1.06e-9	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg06834434	chr14:75079333	LTBP2	0.52	6.03	0.32	4.31e-9	Obesity-related traits;
CRC	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.16	-0.32	2.15e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7680126	0.633	rs4698040	chr4:10352550	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.36	-0.33	6.74e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	12.39	0.56	3.38e-29	Alzheimer's disease;
CRC	cis	rs282587	0.569	rs7987238	chr13:113409944	G/A	cg04656015	chr13:113407548	ATP11A	0.65	8.12	0.41	9.52e-15	Glycated hemoglobin levels;
CRC	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-7.32	-0.37	1.86e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	12.66	0.57	3.33e-30	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg15786705	chr6:28176104	NA	0.74	9.43	0.46	7.64e-19	Depression;
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-6.53	-0.34	2.42e-10	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15617548	chr2:171785815	GORASP2	0.45	6.97	0.36	1.72e-11	Interleukin-6 levels;
CRC	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.76	-13.35	-0.59	9.04e-33	Metabolite levels;
CRC	cis	rs9287719	0.601	rs10084172	chr2:10771228	A/C	cg00105475	chr2:10696890	NA	0.46	7.06	0.36	1.02e-11	Prostate cancer;
CRC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.64	-9.0	-0.44	1.81e-17	DNA methylation (variation);
CRC	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.55	0.43	4.76e-16	Coffee consumption (cups per day);
CRC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.53	-8.59	-0.43	3.44e-16	Aortic root size;
CRC	trans	rs1353394	0.617	rs11129904	chr3:41465657	A/G	cg08437403	chr11:1669832	HCCA2	-0.44	-6.09	-0.32	3.2e-9	Gut microbiota (functional units);
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg15845792	chr6:28175446	NA	0.77	11.42	0.53	1.13e-25	Cardiac Troponin-T levels;
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg27635394	chr6:26043820	HIST1H2BB	0.44	6.42	0.33	4.63e-10	Intelligence (multi-trait analysis);
CRC	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.1	-0.45	8.67e-18	Brugada syndrome;
CRC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.5	7.2	0.37	4.16e-12	Pancreatic cancer;
CRC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.53	0.34	2.5e-10	Rheumatoid arthritis;
CRC	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.84	-14.43	-0.62	6.81e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.87	-19.82	-0.74	4.43e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8105895	0.935	rs7247147	chr19:22249858	G/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs3087591	0.600	rs2952975	chr17:29490992	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	8.58	0.43	3.9e-16	Hip circumference;
CRC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.63	10.26	0.49	1.26e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.6	-6.94	-0.36	2.09e-11	Vitiligo;
CRC	trans	rs12189452	0.507	rs4957723	chr5:107157011	C/T	cg09163005	chr12:14926986	H2AFJ	0.39	6.1	0.32	2.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg27053337	chr8:124217698	FAM83A	0.45	6.82	0.35	4.48e-11	Urinary uromodulin levels;
CRC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.89	0.4	4.39e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.66	-0.3	3.24e-8	Asthma;
CRC	cis	rs7614311	0.552	rs73117078	chr3:63942084	G/A	cg22134162	chr3:63841271	THOC7	-0.57	-5.76	-0.3	1.89e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.66	8.8	0.44	7.85e-17	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg05376469	chr2:102649931	NA	-0.37	-6.28	-0.33	1.04e-9	Prostate cancer;
CRC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg08314208	chr16:67682810	RLTPR	-0.65	-7.41	-0.38	1.08e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg00531865	chr16:30841666	NA	0.47	6.78	0.35	5.6e-11	Dementia with Lewy bodies;
CRC	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg20356878	chr3:121714668	ILDR1	0.5	7.87	0.4	5.23e-14	Cognitive performance;
CRC	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.62	-8.37	-0.42	1.71e-15	Blood pressure (smoking interaction);
CRC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7264396	0.887	rs6060442	chr20:34093757	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.62	-0.34	1.44e-10	Total cholesterol levels;
CRC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-1.07	-12.71	-0.57	2.22e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-7.17	-0.37	4.95e-12	Neuroticism;
CRC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7113874	0.550	rs11042002	chr11:8616646	T/C	cg17679104	chr11:8615758	STK33	0.38	6.41	0.33	5.17e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.61	9.47	0.46	5.44e-19	Corneal astigmatism;
CRC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.85	0.31	1.16e-8	Tonsillectomy;
CRC	cis	rs8070740	1.000	rs8080400	chr17:5328633	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.98	0.36	1.65e-11	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs17234274	0.644	rs10833970	chr11:23219417	A/G	cg05245346	chr11:23248277	NA	0.36	5.92	0.31	8.22e-9	Cancer;
CRC	cis	rs10878977	0.542	rs11177662	chr12:69818480	C/T	cg20891283	chr12:69753455	YEATS4	-0.58	-5.65	-0.3	3.4e-8	Colorectal cancer;
CRC	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.42	6.45	0.34	3.93e-10	Capecitabine sensitivity;
CRC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.72	-0.47	8.53e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.25	-0.37	2.92e-12	Type 2 diabetes;
CRC	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg04117972	chr1:227635322	NA	0.6	6.51	0.34	2.82e-10	Major depressive disorder;
CRC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.59	10.16	0.49	2.9e-21	Aortic root size;
CRC	cis	rs11212617	1.000	rs227093	chr11:108233939	T/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.03	0.32	4.32e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16143763	chr17:41116517	AARSD1	-0.38	-6.01	-0.31	4.81e-9	Myopia (pathological);
CRC	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.73	-6.47	-0.34	3.48e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.08	16.82	0.68	3.12e-46	Testicular germ cell tumor;
CRC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg20243544	chr17:37824526	PNMT	0.47	5.61	0.3	4.22e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg07952391	chr2:88470173	THNSL2	-0.41	-6.0	-0.31	5.12e-9	Response to metformin (IC50);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06766273	chr11:62521983	ZBTB3	0.53	7.63	0.39	2.48e-13	Response to antipsychotic treatment;
CRC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg17085576	chr10:5658249	NA	-0.43	-6.19	-0.32	1.78e-9	Breast cancer;
CRC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.68e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20307385	chr11:47447363	PSMC3	-0.54	-7.56	-0.38	4.13e-13	Subjective well-being;
CRC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.4	0.71	1.71e-52	Cognitive ability;
CRC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.74e-9	Breast cancer;
CRC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.4	-7.47	-0.38	7.06e-13	Multiple sclerosis;
CRC	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.55	6.07	0.32	3.52e-9	Coronary artery disease;
CRC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.74	-12.73	-0.57	1.85e-30	Body mass index;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.45	-7.85	-0.4	6.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg14711859	chr11:8959438	ASCL3	-0.58	-11.14	-0.52	1.12e-24	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.56	10.01	0.48	9.4e-21	HDL cholesterol levels;
CRC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.8	-10.12	-0.49	3.78e-21	Bronchopulmonary dysplasia;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.82	-11.23	-0.53	5.37e-25	Intelligence (multi-trait analysis);
CRC	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg25019722	chr6:37503610	NA	-0.47	-8.74	-0.43	1.24e-16	Cognitive performance;
CRC	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg23100626	chr2:96804247	ASTL	0.26	6.87	0.35	3.22e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.64	9.04	0.45	1.33e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.02	0.48	8.79e-21	Corneal astigmatism;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg17084751	chr11:6953558	ZNF215	-0.51	-5.81	-0.31	1.47e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10899768	chr8:102506635	GRHL2	0.32	6.14	0.32	2.44e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs354033	0.959	rs735120	chr7:149313811	C/T	cg24335155	chr7:149193227	ZNF746	0.38	5.98	0.31	5.78e-9	Multiple sclerosis;
CRC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg14844989	chr11:31128820	NA	-0.34	-6.11	-0.32	2.88e-9	Red blood cell count;
CRC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.56	6.19	0.32	1.75e-9	Vitiligo;
CRC	trans	rs746629	0.528	rs4899811	chr14:83241901	A/G	cg04246003	chr19:47987151	KPTN	-0.45	-6.0	-0.31	5.29e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	13.99	0.61	3.3e-35	Colorectal cancer;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12172441	chr6:28176163	NA	0.57	7.25	0.37	2.99e-12	Parkinson's disease;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg10596483	chr8:143751796	JRK	-0.45	-6.37	-0.33	6.4e-10	Urinary tract infection frequency;
CRC	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg13385794	chr1:248469461	NA	0.41	7.34	0.38	1.66e-12	Common traits (Other);
CRC	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg21918786	chr6:109611834	NA	-0.33	-5.63	-0.3	3.82e-8	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.89	-0.44	4e-17	Alzheimer's disease;
CRC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.94	10.72	0.51	3.35e-23	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03509813	chr4:17812473	NCAPG;DCAF16	0.37	6.1	0.32	3.05e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.7	-0.39	1.62e-13	Morning vs. evening chronotype;
CRC	cis	rs11212617	0.902	rs641312	chr11:108148265	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.86	0.31	1.1e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.59	6.55	0.34	2.25e-10	Bipolar disorder;
CRC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.92	-0.31	8.02e-9	Gout;Renal underexcretion gout;
CRC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.43	-6.68	-0.35	1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg06470822	chr6:28175283	NA	0.53	6.33	0.33	8.16e-10	Breast cancer;
CRC	trans	rs2303319	0.504	rs62187652	chr2:162468033	C/G	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.43e-9	Cognitive function;
CRC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.45	-7.42	-0.38	1.02e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.52	-0.75	7.88e-61	Primary sclerosing cholangitis;
CRC	trans	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg17903999	chr18:56338584	MALT1	0.42	6.93	0.36	2.17e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg20936604	chr3:58311152	NA	-0.75	-6.88	-0.35	3.02e-11	Cholesterol, total;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg20092199	chr4:1342459	KIAA1530	0.33	5.61	0.3	4.32e-8	Obesity-related traits;
CRC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.31	-0.42	2.53e-15	Bone mineral density;
CRC	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.64	-10.17	-0.49	2.67e-21	Mean platelet volume;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.59	8.51	0.42	6.14e-16	Parkinson's disease;
CRC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg09835421	chr16:68378352	PRMT7	-0.8	-8.3	-0.42	2.67e-15	Schizophrenia;
CRC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	6.03	0.32	4.46e-9	Menarche (age at onset);
CRC	trans	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg07817883	chr1:32538562	TMEM39B	-0.63	-7.9	-0.4	4.1e-14	Monocyte percentage of white cells;
CRC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.46	-5.79	-0.3	1.65e-8	Aortic root size;
CRC	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg22182287	chr2:3452347	TTC15	0.42	6.7	0.35	9.14e-11	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01510332	chr19:59087201	MGC2752	0.49	6.32	0.33	8.61e-10	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	13.28	0.59	1.59e-32	Menopause (age at onset);
CRC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.29	6.09	0.32	3.07e-9	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13950210	chr1:45452319	EIF2B3	0.44	6.17	0.32	2e-9	Anxiety disorder;
CRC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg25767906	chr1:53392781	SCP2	0.42	6.65	0.34	1.24e-10	Monocyte count;
CRC	cis	rs755249	0.567	rs41270807	chr1:39801815	A/C	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.93	9.98	0.48	1.11e-20	Inflammatory bowel disease;
CRC	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg19300414	chr2:1746591	PXDN	0.44	7.37	0.38	1.39e-12	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.81	11.76	0.54	6.78e-27	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02659854	chr13:24824078	SPATA13	0.3	6.77	0.35	6.1e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs115344852	0.575	rs1015811	chr6:28448086	A/G	cg06470822	chr6:28175283	NA	0.49	5.81	0.31	1.45e-8	Epithelial ovarian cancer;
CRC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.49	8.19	0.41	5.85e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	7.93	0.4	3.43e-14	Obesity-related traits;
CRC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.36	-0.33	6.84e-10	Monocyte percentage of white cells;
CRC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.99	-0.31	5.38e-9	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00209424	chr2:55277876	RTN4	0.39	6.27	0.33	1.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg01639898	chr1:32083012	HCRTR1	0.28	5.64	0.3	3.57e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12516959	chr21:47718080	NA	-0.32	-5.7	-0.3	2.67e-8	Testicular germ cell tumor;
CRC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-8.27	-0.41	3.3e-15	Gut microbiome composition (summer);
CRC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.49	-7.01	-0.36	1.38e-11	Height;
CRC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.52	5.75	0.3	2.02e-8	Bipolar disorder;
CRC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.43	-7.11	-0.36	7.35e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg05313129	chr8:58192883	C8orf71	-0.45	-6.27	-0.33	1.12e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	7.96	0.4	2.76e-14	Breast cancer;
CRC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.39	-5.73	-0.3	2.3e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.52	7.37	0.38	1.36e-12	Corneal astigmatism;
CRC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	10.09	0.49	4.95e-21	Longevity;
CRC	cis	rs11212617	0.934	rs11212551	chr11:108078693	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.48	0.34	3.33e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9937943	0.615	rs12925346	chr16:74492495	G/C	cg01733217	chr16:74700730	RFWD3	0.71	7.9	0.4	4.16e-14	Neutrophil percentage of white cells;
CRC	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg06469542	chr14:77965869	ISM2	0.48	5.92	0.31	8.1e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.6	0.3	4.53e-8	Putamen volume;
CRC	cis	rs28493229	0.708	rs10408309	chr19:41161189	T/G	cg21869046	chr19:41225005	ITPKC	0.41	6.15	0.32	2.26e-9	Kawasaki disease;
CRC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.46	0.57	1.8e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg10483660	chr13:112241077	NA	0.37	5.94	0.31	7.28e-9	Menarche (age at onset);
CRC	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-6.16	-0.32	2.14e-9	Post bronchodilator FEV1;
CRC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.63	-0.39	2.58e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg01262667	chr19:19385393	TM6SF2	0.37	6.05	0.32	3.94e-9	Tonsillectomy;
CRC	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-1.05	-9.88	-0.48	2.54e-20	Post bronchodilator FEV1;
CRC	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.47	-6.85	-0.35	3.66e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10450586	0.863	rs7126943	chr11:27303937	A/G	cg10370305	chr11:27303972	NA	-0.39	-6.38	-0.33	6.18e-10	Total body bone mineral density;
CRC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.17	24.85	0.81	1.79e-77	IgG glycosylation;
CRC	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.47	7.56	0.38	4.01e-13	Fat distribution (HIV);
CRC	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg07299736	chr8:135490787	ZFAT	-0.38	-6.42	-0.33	4.65e-10	Hypertension (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.35	5.63	0.3	3.93e-8	Sitting height ratio;
CRC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.27	-0.59	1.76e-32	Systemic lupus erythematosus;
CRC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.86	-10.93	-0.52	6.42e-24	Obesity-related traits;
CRC	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.91	11.15	0.52	1.08e-24	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.81	-0.61	1.61e-34	Hypospadias;
CRC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.38	8.73	0.43	1.29e-16	Multiple system atrophy;
CRC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.01	18.64	0.72	1.9e-53	Primary sclerosing cholangitis;
CRC	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.48	-5.79	-0.3	1.6e-8	Coronary artery calcification;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13265437	chr11:32851260	PRRG4	0.45	6.42	0.33	4.88e-10	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.45	-5.81	-0.3	1.51e-8	Crohn's disease;
CRC	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs3751196	0.615	rs17034620	chr12:104211278	C/A	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00622580	chr2:62082097	FAM161A	0.42	6.25	0.33	1.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg04586622	chr2:25135609	ADCY3	0.59	10.06	0.49	6.15e-21	Body mass index;
CRC	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg12856521	chr11:46389249	DGKZ	-0.44	-6.98	-0.36	1.61e-11	Leprosy;
CRC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.66	11.83	0.55	3.94e-27	Eye color traits;
CRC	cis	rs231513	0.954	rs231510	chr17:41966470	T/C	cg26893861	chr17:41843967	DUSP3	-0.63	-6.41	-0.33	5.01e-10	Cognitive function;
CRC	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.72	-0.3	2.35e-8	Menarche (age at onset);
CRC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.62	-9.73	-0.47	7.88e-20	Intelligence (multi-trait analysis);
CRC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.44	7.39	0.38	1.26e-12	Educational attainment;
CRC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.59	-8.98	-0.44	2.16e-17	Psychosis in Alzheimer's disease;
CRC	cis	rs7120118	0.517	rs12575157	chr11:47272746	A/G	cg25783544	chr11:47291846	MADD	0.61	5.61	0.3	4.24e-8	HDL cholesterol;
CRC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.49	-7.72	-0.39	1.41e-13	Monocyte count;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg02683197	chr6:28174875	NA	0.79	9.73	0.47	8.12e-20	Depression;
CRC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.46	0.69	8.98e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.78	-6.45	-0.33	4.05e-10	Recalcitrant atopic dermatitis;
CRC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.45e-17	Morning vs. evening chronotype;
CRC	cis	rs77633900	0.772	rs283799	chr15:76752834	A/C	cg21673338	chr15:77095150	SCAPER	-0.68	-6.22	-0.32	1.54e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.51e-34	Menopause (age at onset);
CRC	cis	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg16589663	chr20:23618590	CST3	-0.59	-7.46	-0.38	8.03e-13	Chronic kidney disease;
CRC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg16447950	chr5:562315	NA	-0.81	-10.49	-0.5	2.1e-22	Obesity-related traits;
CRC	cis	rs12476592	0.571	rs7584404	chr2:63794342	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.24	0.45	3.19e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.3	-0.42	2.66e-15	Bipolar disorder;
CRC	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-8.16	-0.41	7.28e-15	Homocysteine levels;
CRC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.83	-13.07	-0.58	9.83e-32	Cognitive function;
CRC	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg27205649	chr11:78285834	NARS2	0.49	5.94	0.31	7.3e-9	Alzheimer's disease (survival time);
CRC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.4	5.65	0.3	3.54e-8	Renal cell carcinoma;
CRC	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.61	8.64	0.43	2.43e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg24644049	chr4:85504048	CDS1	0.7	7.01	0.36	1.4e-11	Skin colour saturation;
CRC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.38	7.27	0.37	2.67e-12	Tonsillectomy;
CRC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.3e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2006209	0.536	rs10414640	chr19:42097086	A/G	cg10389454	chr19:42083748	CEACAM21	-0.47	-5.72	-0.3	2.34e-8	Lung adenocarcinoma;
CRC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.46	6.33	0.33	8.07e-10	Red blood cell count;
CRC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg15845792	chr6:28175446	NA	0.78	6.33	0.33	7.82e-10	Depression;
CRC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg17401720	chr7:158221031	PTPRN2	0.46	7.64	0.39	2.35e-13	Obesity-related traits;
CRC	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg12935359	chr14:103987150	CKB	-0.69	-9.25	-0.45	2.84e-18	Body mass index;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg27432699	chr2:27873401	GPN1	-0.5	-7.66	-0.39	2.06e-13	Total body bone mineral density;
CRC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.55	0.38	4.42e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2949837	0.581	rs2960436	chr7:45977282	G/A	cg06713098	chr7:45960367	IGFBP3	0.42	6.71	0.35	8.43e-11	Sitting height ratio;
CRC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07701084	chr6:150067640	NUP43	0.54	7.4	0.38	1.16e-12	Lung cancer;
CRC	trans	rs4378999	0.668	rs9864443	chr3:51656376	C/G	cg22768531	chr19:49403500	NUCB1	-0.51	-6.16	-0.32	2.17e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.74	-0.43	1.21e-16	Aortic root size;
CRC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.33	-0.33	7.89e-10	Tonsillectomy;
CRC	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.65	7.42	0.38	1.01e-12	Colorectal cancer;
CRC	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg10756647	chr7:56101905	PSPH	0.77	8.03	0.4	1.78e-14	Diabetic kidney disease;
CRC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-14.98	-0.64	4.86e-39	Schizophrenia;
CRC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	11.43	0.53	1.02e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24014487	chr20:36793744	TGM2	0.42	5.98	0.31	5.79e-9	Anxiety disorder;
CRC	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.51	8.25	0.41	3.81e-15	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23463467	chr20:60627584	TAF4	-0.42	-8.45	-0.42	9.49e-16	Body mass index;
CRC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.55	9.58	0.47	2.51e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00166722	chr3:10149974	C3orf24	0.7	8.12	0.41	9.45e-15	Alzheimer's disease;
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg08222913	chr3:52553049	STAB1	-0.39	-7.65	-0.39	2.29e-13	Bipolar disorder;
CRC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg02993699	chr4:3415135	RGS12	-0.38	-6.27	-0.33	1.14e-9	Serum sulfate level;
CRC	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	6.15	0.32	2.23e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7572644	0.603	rs4666013	chr2:28019106	C/T	cg27432699	chr2:27873401	GPN1	0.46	5.67	0.3	3.07e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.61	-9.64	-0.47	1.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.33	1.01e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg00495681	chr13:53174319	NA	-0.6	-9.08	-0.45	9.96e-18	Lewy body disease;
CRC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg26061582	chr7:22766209	IL6	0.55	8.33	0.42	2.19e-15	Lung cancer;
CRC	cis	rs71403859	0.667	rs12149264	chr16:71720921	T/G	cg08717414	chr16:71523259	ZNF19	-0.98	-9.09	-0.45	9.46e-18	Post bronchodilator FEV1;
CRC	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.76	10.01	0.48	9.4e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.89	11.13	0.52	1.21e-24	Obesity-related traits;
CRC	cis	rs9969804	0.682	rs10761168	chr9:95505560	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.94	-0.31	7.16e-9	Height;
CRC	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.75	-0.43	1.1e-16	Coffee consumption (cups per day);
CRC	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg01557791	chr16:72042693	DHODH	-0.53	-5.69	-0.3	2.78e-8	Coronary artery disease;
CRC	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg03909863	chr11:638404	DRD4	-0.47	-6.1	-0.32	3.04e-9	Systemic lupus erythematosus;
CRC	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.65	-0.34	1.2e-10	Breast cancer;
CRC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.52	8.92	0.44	3.2e-17	Aortic root size;
CRC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.54	0.43	5.11e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg12856521	chr11:46389249	DGKZ	0.62	9.28	0.46	2.32e-18	Crohn's disease;
CRC	trans	rs2172802	0.693	rs7660566	chr4:62481231	G/T	cg01233948	chr15:31318495	TRPM1	0.44	6.02	0.31	4.68e-9	Partial epilepsies;
CRC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.48e-24	Motion sickness;
CRC	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg24140574	chr1:16342155	HSPB7	0.44	6.14	0.32	2.34e-9	Dilated cardiomyopathy;
CRC	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg11130432	chr3:121712080	ILDR1	-0.47	-6.12	-0.32	2.69e-9	Multiple sclerosis;
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.55	7.31	0.37	2.11e-12	Alzheimer's disease;
CRC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.48	7.51	0.38	5.47e-13	Corneal astigmatism;
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg10729496	chr3:10149963	C3orf24	0.51	5.86	0.31	1.13e-8	Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.11e-22	Prudent dietary pattern;
CRC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.59	-9.15	-0.45	6.2e-18	Monocyte count;
CRC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.82	0.4	7.23e-14	Schizophrenia;
CRC	cis	rs970548	0.954	rs11239549	chr10:46018831	A/G	cg15590007	chr10:45870220	ALOX5	0.51	6.38	0.33	5.98e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-11.34	-0.53	2.17e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs12745968	0.653	rs2107519	chr1:93192870	T/G	cg17283838	chr1:93427260	FAM69A	-0.47	-6.38	-0.33	6.1e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16263701	chr12:48213605	HDAC7	0.46	6.48	0.34	3.28e-10	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.99	0.52	3.81e-24	Motion sickness;
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg10729496	chr3:10149963	C3orf24	0.58	7.52	0.38	5.23e-13	Alzheimer's disease;
CRC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.55	-0.38	4.39e-13	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.47	6.95	0.36	1.94e-11	Menopause (age at onset);
CRC	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.46	-7.36	-0.38	1.44e-12	Schizophrenia;
CRC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.43	9.22	0.45	3.77e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.6	-8.86	-0.44	5.08e-17	Primary sclerosing cholangitis;
CRC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	9.24	0.45	3.11e-18	Alzheimer's disease;
CRC	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg23167259	chr10:102495509	NA	-0.47	-6.35	-0.33	6.97e-10	Alzheimer's disease;
CRC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.39	6.6	0.34	1.68e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs9771228	0.965	rs1014242	chr7:32272305	C/T	cg02979224	chr7:93204462	CALCR	0.34	5.96	0.31	6.43e-9	Cognitive ability;Verbal-numerical reasoning;
CRC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.67	8.14	0.41	8.16e-15	Obesity (extreme);
CRC	cis	rs1552172	0.853	rs1471630	chr1:145707297	A/G	cg11743829	chr1:145714124	CD160	-0.41	-6.06	-0.32	3.68e-9	Breast cancer;
CRC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.73	11.61	0.54	2.43e-26	Intelligence (multi-trait analysis);
CRC	cis	rs7394190	0.688	rs76033784	chr10:75535970	A/G	cg07699608	chr10:75541558	CHCHD1	0.61	6.38	0.33	5.99e-10	Incident atrial fibrillation;
CRC	cis	rs3736485	0.844	rs12101858	chr15:51783981	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.3	-0.33	9.39e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12023718	0.588	rs12042226	chr1:178589105	C/T	cg00404053	chr1:178313656	RASAL2	0.61	7.47	0.38	7.13e-13	Obesity-related traits;
CRC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	11.98	0.55	1.12e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11723261	0.546	rs57839456	chr4:148289	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	6.83	0.35	4.04e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.52	7.15	0.37	5.69e-12	Schizophrenia;
CRC	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg21169611	chr9:106856078	SMC2	0.41	5.8	0.3	1.6e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.07	-0.41	1.36e-14	IgG glycosylation;
CRC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.23	6.44	0.33	4.12e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg20243544	chr17:37824526	PNMT	0.42	6.57	0.34	2.02e-10	Self-reported allergy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22064942	chr4:110355472	SEC24B	0.48	6.73	0.35	7.62e-11	Response to antipsychotic treatment;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg06470822	chr6:28175283	NA	0.66	10.14	0.49	3.46e-21	Cardiac Troponin-T levels;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.62	-8.61	-0.43	3.11e-16	Intelligence (multi-trait analysis);
CRC	trans	rs6066835	1.000	rs4455220	chr20:47335017	A/G	cg21109867	chr19:55897418	RPL28	-0.69	-6.03	-0.32	4.38e-9	Multiple myeloma;
CRC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-15.9	-0.66	1.24e-42	Body mass index;
CRC	cis	rs8105895	0.935	rs28374572	chr19:22276478	A/C	cg02657401	chr19:22469223	NA	-0.35	-5.67	-0.3	3.06e-8	Body mass index (change over time);
CRC	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg00691999	chr4:55094011	PDGFRA	0.43	6.28	0.33	1.06e-9	Corneal astigmatism;
CRC	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.56	7.54	0.38	4.6e-13	Urinary tract infection frequency;
CRC	cis	rs7781266	0.842	rs17656452	chr7:133193425	G/A	cg03336402	chr7:133662267	EXOC4	0.49	5.81	0.31	1.46e-8	Educational attainment (college completion);
CRC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg10589385	chr1:150898437	SETDB1	-0.3	-6.25	-0.33	1.29e-9	Melanoma;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg02683197	chr6:28174875	NA	0.66	9.03	0.45	1.49e-17	Parkinson's disease;
CRC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.63	11.1	0.52	1.63e-24	Schizophrenia;
CRC	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25809561	chr17:30822961	MYO1D	-0.51	-9.0	-0.44	1.88e-17	Schizophrenia;
CRC	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.69	-8.69	-0.43	1.68e-16	Blood protein levels;
CRC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	-0.45	-5.84	-0.31	1.27e-8	Resistin levels;
CRC	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.57	7.88	0.4	4.78e-14	Coronary artery disease;
CRC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.77	-13.29	-0.59	1.49e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.2	-0.41	5.62e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.89	-15.19	-0.64	7.1e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg08798685	chr6:27730294	NA	-0.49	-6.88	-0.35	3.05e-11	Parkinson's disease;
CRC	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg15654264	chr1:150340011	RPRD2	0.43	6.41	0.33	5.06e-10	Migraine;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01664130	chr13:99740155	DOCK9	0.47	6.06	0.32	3.74e-9	Thyroid stimulating hormone;
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.53	7.4	0.38	1.18e-12	Alzheimer's disease;
CRC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg03037974	chr15:76606532	NA	0.84	16.86	0.68	2.06e-46	Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs6705287	chr2:15529368	A/C	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.49	8.46	0.42	8.65e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.52	7.08	0.36	8.71e-12	Caudate activity during reward;
CRC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.35	-0.42	1.95e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.51	8.25	0.41	3.87e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.7	7.83	0.4	6.8e-14	Body mass index;
CRC	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-5.86	-0.31	1.11e-8	Blood protein levels;
CRC	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.52	-6.03	-0.32	4.4e-9	Post bronchodilator FEV1;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.47	-0.38	7.39e-13	Acylcarnitine levels;
CRC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.9	-11.55	-0.54	3.86e-26	Initial pursuit acceleration;
CRC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.44	-6.39	-0.33	5.8e-10	Response to metformin (IC50);
CRC	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg05784532	chr1:230284198	GALNT2	0.46	6.29	0.33	1.04e-9	Coronary artery disease;
CRC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	0.98	15.07	0.64	2.23e-39	Cognitive function;
CRC	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	1.21	10.67	0.51	5.18e-23	Arsenic metabolism;
CRC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.54	9.05	0.45	1.24e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.58	0.54	3.17e-26	Bipolar disorder;
CRC	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.8	-8.7	-0.43	1.58e-16	Obesity-related traits;
CRC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.41	8.02	0.4	1.88e-14	Mean corpuscular volume;
CRC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.97	-16.92	-0.68	1.24e-46	Headache;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09092311	chr3:49142581	QARS	0.39	5.68	0.3	2.93e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4290604	0.665	rs4316893	chr2:238089767	T/C	cg23555395	chr2:238036564	NA	-0.6	-6.07	-0.32	3.57e-9	Asthma;
CRC	cis	rs9322817	1.000	rs6900902	chr6:105235757	A/G	cg02098413	chr6:105308735	HACE1	-0.33	-5.97	-0.31	6.17e-9	Thyroid stimulating hormone;
CRC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-6.64	-0.34	1.32e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg25347419	chr2:177043501	NA	0.47	6.69	0.35	9.63e-11	IgG glycosylation;
CRC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.52e-15	Height;
CRC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.66	-0.47	1.38e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg18268547	chr17:79615552	TSPAN10	0.33	8.01	0.4	1.96e-14	Myopia;
CRC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24003225	chr3:184870891	C3orf70	0.44	6.04	0.32	4.06e-9	Survival in pancreatic cancer;
CRC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.77	-11.12	-0.52	1.29e-24	Mean platelet volume;Platelet distribution width;
CRC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.67	8.81	0.44	7.35e-17	Morning vs. evening chronotype;
CRC	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.52	7.37	0.38	1.36e-12	Autism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09434832	chr19:52642515	ZNF616	0.39	6.05	0.32	3.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.76	-0.3	1.89e-8	Breast cancer;
CRC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.48	-0.62	4.1e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	17.16	0.69	1.33e-47	Smoking behavior;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07080067	chr5:68514103	MRPS36	-0.53	-6.31	-0.33	8.84e-10	Monocyte percentage of white cells;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg03035921	chr2:122407209	CLASP1	-0.43	-5.98	-0.31	5.73e-9	Protein C levels;
CRC	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.52	-0.54	4.95e-26	Idiopathic membranous nephropathy;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg26762873	chr11:5879799	OR52E8	-0.45	-6.69	-0.35	9.75e-11	DNA methylation (variation);
CRC	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.06	0.36	1e-11	Red blood cell count;
CRC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	0.84	7.64	0.39	2.34e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07238657	chr1:154973705	ZBTB7B	0.48	6.69	0.35	9.56e-11	Response to antipsychotic treatment;
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22988483	chr14:93581567	ITPK1	0.39	6.48	0.34	3.37e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10486722	0.651	rs4724070	chr7:41783359	T/C	cg22138096	chr7:41772439	LOC285954	0.62	7.31	0.37	2.06e-12	Pit-and-Fissure caries;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg25164649	chr6:28176230	NA	0.73	9.32	0.46	1.74e-18	Depression;
CRC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.78	13.76	0.6	2.43e-34	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01140101	chr1:202113040	ARL8A	0.48	6.37	0.33	6.23e-10	Thyroid stimulating hormone;
CRC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.58	0.43	3.88e-16	Lymphocyte counts;
CRC	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.67	-0.35	1.06e-10	Educational attainment;
CRC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg27490568	chr2:178487706	NA	0.61	7.33	0.37	1.85e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg25972092	chr12:117363249	FBXW8	0.53	6.38	0.33	6.02e-10	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.48	7.12	0.37	7.01e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg13126279	chr21:47581558	C21orf56	-0.39	-5.92	-0.31	7.89e-9	Testicular germ cell tumor;
CRC	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg21153622	chr11:89784906	NA	-0.45	-7.11	-0.36	7.19e-12	HDL cholesterol;
CRC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.9	0.4	4.09e-14	Height;
CRC	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg09659197	chr4:152720779	NA	0.41	8.6	0.43	3.34e-16	Intelligence (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25175469	chr15:59063261	FAM63B	0.38	6.03	0.32	4.45e-9	Schizophrenia;
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.48	6.59	0.34	1.79e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg15147215	chr3:52552868	STAB1	-0.53	-7.72	-0.39	1.38e-13	Bipolar disorder;
CRC	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg26394196	chr10:1453818	ADARB2	-0.33	-5.94	-0.31	7.13e-9	Radiation response;
CRC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.98	21.04	0.76	6.92e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4688759	0.764	rs11716961	chr3:49908338	G/A	cg07636037	chr3:49044803	WDR6	-0.86	-5.7	-0.3	2.7e-8	Blood protein levels;
CRC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.59	-0.47	2.23e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-6.92	-0.36	2.34e-11	Aortic root size;
CRC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.6	7.45	0.38	8.07e-13	Menarche (age at onset);
CRC	cis	rs3823572	0.564	rs2953621	chr7:133662403	C/G	cg03336402	chr7:133662267	EXOC4	-0.67	-10.38	-0.5	5.03e-22	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.71	10.79	0.51	1.95e-23	Platelet distribution width;
CRC	trans	rs6058526	1.000	rs12479832	chr20:30733863	A/G	cg13674914	chr7:14429205	DGKB	-0.52	-6.11	-0.32	2.88e-9	Chronic obstructive pulmonary disease;
CRC	trans	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg16141378	chr3:129829833	LOC729375	0.43	6.22	0.32	1.48e-9	Mood instability;
CRC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.46	-6.72	-0.35	7.99e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.57	7.87	0.4	5.3e-14	Lung cancer;
CRC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.18	0.45	5.05e-18	Alzheimer's disease (late onset);
CRC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg00814883	chr7:100076585	TSC22D4	-0.5	-6.04	-0.32	4.14e-9	Lung function (FEV1/FVC);
CRC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.43	6.88	0.35	3.03e-11	High light scatter reticulocyte count;
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg22561889	chr6:118971681	C6orf204	0.52	6.7	0.35	9.08e-11	Diastolic blood pressure;
CRC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.49	-0.38	6.49e-13	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11251499	chr4:57774202	REST	0.41	6.06	0.32	3.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg04725166	chr1:7887271	PER3	-0.45	-5.66	-0.3	3.31e-8	Crohn's disease;
CRC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs11212617	0.967	rs228589	chr11:108093208	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.35	0.33	7.01e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.41	6.82	0.35	4.41e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.11	0.52	1.4e-24	Prudent dietary pattern;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24506149	chr1:39339048	MYCBP	0.44	6.23	0.32	1.42e-9	Anxiety disorder;
CRC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.34	0.33	7.63e-10	Lung cancer;
CRC	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg08071915	chr8:12219732	FAM66A	0.35	5.99	0.31	5.48e-9	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.37	5.82	0.31	1.38e-8	Mean corpuscular volume;
CRC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	8.95	0.44	2.58e-17	Bone mineral density;
CRC	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.48	6.07	0.32	3.43e-9	Coronary artery disease;
CRC	cis	rs911119	0.913	rs6036463	chr20:23578940	A/T	cg16589663	chr20:23618590	CST3	-0.41	-5.74	-0.3	2.21e-8	Chronic kidney disease;
CRC	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.35	5.85	0.31	1.21e-8	Menopause (age at onset);
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg10729496	chr3:10149963	C3orf24	0.46	6.07	0.32	3.58e-9	Alzheimer's disease;
CRC	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.49	7.64	0.39	2.43e-13	Red blood cell count;
CRC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg19812747	chr11:111475976	SIK2	0.54	8.48	0.42	7.7e-16	Primary sclerosing cholangitis;
CRC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg25767906	chr1:53392781	SCP2	0.47	7.49	0.38	6.24e-13	Monocyte count;
CRC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.18	0.32	1.94e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10914544	chr1:94374370	GCLM	0.43	6.58	0.34	1.86e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg14541582	chr5:601475	NA	-0.36	-7.37	-0.38	1.42e-12	Obesity-related traits;
CRC	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg15192750	chr16:69999425	NA	0.55	7.36	0.38	1.44e-12	IgE levels;
CRC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.47	5.96	0.31	6.37e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.45	-6.65	-0.34	1.21e-10	Height;
CRC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	5.86	0.31	1.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.59	6.93	0.36	2.19e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg20573242	chr4:122745356	CCNA2	0.4	6.01	0.31	4.92e-9	Type 2 diabetes;
CRC	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.6	9.71	0.47	9.23e-20	Itch intensity from mosquito bite;
CRC	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.67	0.35	1.05e-10	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.23	14.8	0.63	2.42e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs783540	0.809	rs3970696	chr15:83263756	A/T	cg18393722	chr15:85113863	UBE2QP1	0.34	6.19	0.32	1.83e-9	Schizophrenia;
CRC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.12e-9	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg14593290	chr7:50529359	DDC	-0.61	-8.0	-0.4	2.14e-14	Malaria;
CRC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.5	-9.33	-0.46	1.57e-18	Longevity;
CRC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.61	8.48	0.42	7.82e-16	Arsenic metabolism;
CRC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.67	7.13	0.37	6.42e-12	Inflammatory bowel disease;
CRC	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg15654264	chr1:150340011	RPRD2	0.43	6.52	0.34	2.68e-10	Migraine;
CRC	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-7.03	-0.36	1.21e-11	Menarche (age at onset);
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.27	-0.33	1.11e-9	Lymphocyte counts;
CRC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.25	-14.86	-0.63	1.46e-38	Diabetic kidney disease;
CRC	cis	rs883565	0.582	rs811969	chr3:39180162	A/C	cg01426195	chr3:39028469	NA	0.41	6.61	0.34	1.6e-10	Handedness;
CRC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.77	-11.46	-0.53	8.14e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.51	-5.8	-0.3	1.55e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg01420254	chr6:26195488	NA	0.67	6.0	0.31	5.2e-9	Iron status biomarkers (total iron binding capacity);
CRC	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg08017880	chr11:407180	SIGIRR	-0.44	-6.2	-0.32	1.65e-9	Total cholesterol levels;
CRC	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg11130432	chr3:121712080	ILDR1	-0.49	-6.04	-0.32	4.1e-9	Multiple sclerosis;
CRC	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.68	-9.86	-0.48	2.95e-20	Blood protein levels;
CRC	cis	rs9311676	0.656	rs55711525	chr3:58397775	C/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.67	10.41	0.5	3.9e-22	Gestational age at birth (maternal effect);
CRC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.15	25.75	0.82	7.73e-81	IgG glycosylation;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg26608667	chr7:1196370	ZFAND2A	0.36	5.7	0.3	2.66e-8	Longevity;Endometriosis;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.73	-0.51	3.19e-23	Alzheimer's disease;
CRC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg01262667	chr19:19385393	TM6SF2	0.38	6.24	0.33	1.36e-9	Tonsillectomy;
CRC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.63	9.96	0.48	1.38e-20	Blood protein levels;
CRC	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg18850127	chr7:39170497	POU6F2	0.5	6.43	0.33	4.42e-10	IgG glycosylation;
CRC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg15445000	chr17:37608096	MED1	0.39	8.38	0.42	1.52e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs4679956	0.511	rs55686028	chr3:151688903	C/T	cg05484920	chr19:49588520	SNRNP70	0.45	6.03	0.32	4.31e-9	Male-pattern baldness;
CRC	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.4	-6.68	-0.35	1.03e-10	Vitamin D levels;
CRC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.38	-7.76	-0.39	1.1e-13	Cutaneous nevi;
CRC	trans	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.28	0.33	1.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg19318889	chr4:1322082	MAEA	0.39	5.92	0.31	8.1e-9	Obesity-related traits;
CRC	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.7	11.58	0.54	3.02e-26	Itch intensity from mosquito bite;
CRC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.46	-8.34	-0.42	2.09e-15	Immature fraction of reticulocytes;
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.58	7.8	0.39	8.47e-14	Alzheimer's disease;
CRC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.73	8.42	0.42	1.22e-15	Obesity-related traits;
CRC	trans	rs10021731	0.718	rs7671026	chr4:115408892	C/A	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.26	-0.41	3.52e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.9	0.31	8.97e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.53	-0.38	5e-13	Bipolar disorder;
CRC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.54	11.42	0.53	1.19e-25	Bone mineral density;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.63	6.74	0.35	6.94e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.49	-6.38	-0.33	5.92e-10	Biliary atresia;
CRC	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg07636037	chr3:49044803	WDR6	-0.61	-5.73	-0.3	2.29e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.35	6.08	0.32	3.31e-9	Erythrocyte sedimentation rate;
CRC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.46	0.42	9.02e-16	Homoarginine levels;
CRC	cis	rs3812762	0.871	rs11603335	chr11:8809844	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.39	6.52	0.34	2.7e-10	Hypospadias;
CRC	cis	rs858239	0.965	rs156429	chr7:23306020	A/G	cg00469287	chr7:23338798	C7orf30	0.45	6.14	0.32	2.41e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg09264619	chr17:80180166	NA	0.39	6.5	0.34	3.04e-10	Life satisfaction;
CRC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.51	0.5	1.77e-22	Corneal astigmatism;
CRC	cis	rs2882667	0.628	rs13171173	chr5:138042464	A/C	cg09476006	chr5:138032270	NA	-0.59	-9.79	-0.48	4.92e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.25	0.37	2.99e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.56	-0.47	2.92e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1545257	0.505	rs13016195	chr2:24634942	T/C	cg06627628	chr2:24431161	ITSN2	-0.45	-6.64	-0.34	1.29e-10	Sjögren's syndrome;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs17666963	0.568	rs768733	chr10:125214716	C/T	cg00049729	chr5:55776345	NA	0.69	6.04	0.32	4.16e-9	Cardiac Troponin-T levels;
CRC	cis	rs9311676	0.609	rs55646457	chr3:58415263	T/A	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.39e-10	Systemic lupus erythematosus;
CRC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.59	-0.39	3.22e-13	Neuroticism;
CRC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.84	-14.44	-0.62	5.88e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.75	-11.78	-0.54	5.96e-27	Metabolic syndrome;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg08798685	chr6:27730294	NA	-0.57	-6.29	-0.33	9.95e-10	Lung cancer in ever smokers;
CRC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg17545662	chr6:170176663	C6orf70	0.56	6.45	0.34	3.94e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.6	-8.9	-0.44	3.81e-17	Acne (severe);
CRC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.56	9.11	0.45	8.32e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.91	0.31	8.58e-9	Diastolic blood pressure;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	cis	rs2742417	1.000	rs2673036	chr3:45752471	C/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.53	7.43	0.38	9.64e-13	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01900965	chr4:2471727	RNF4	0.42	6.29	0.33	1.02e-9	Interleukin-6 levels;
CRC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.73	0.3	2.33e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6088813	0.961	rs1886691	chr20:33986271	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.74	-0.3	2.12e-8	Height;
CRC	cis	rs7605827	0.930	rs12692260	chr2:15511809	A/G	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg21153622	chr11:89784906	NA	-0.53	-8.82	-0.44	6.77e-17	HDL cholesterol;
CRC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.52	7.07	0.36	9.11e-12	Gut microbiome composition (summer);
CRC	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.61	7.94	0.4	3.13e-14	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06061645	chr5:86708854	CCNH	0.43	6.36	0.33	6.93e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg00254258	chr1:3105189	PRDM16	-0.57	-9.51	-0.46	4.07e-19	Migraine;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27095527	chr3:12329080	PPARG	0.4	6.18	0.32	1.85e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17554472	chr22:41940697	POLR3H	-0.55	-5.78	-0.3	1.77e-8	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03892937	chr1:67395684	MIER1	0.44	6.42	0.33	4.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.64	10.8	0.51	1.78e-23	Platelet count;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18758796	chr5:131593413	PDLIM4	0.45	8.23	0.41	4.3e-15	Breast cancer;
CRC	trans	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.85	0.35	3.65e-11	Mean corpuscular volume;
CRC	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.76	-0.35	6.44e-11	Metabolite levels;
CRC	cis	rs9903692	0.954	rs12450620	chr17:46130254	G/T	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.72	8.14	0.41	8.31e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.62e-12	Inflammatory skin disease;
CRC	cis	rs2233152	0.611	rs28660501	chr19:41300277	G/T	cg21869046	chr19:41225005	ITPKC	0.35	5.67	0.3	3.07e-8	Kawasaki disease;
CRC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.57	-10.11	-0.49	4.18e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15434853	chr3:52570586	NT5DC2;LOC440957	-0.38	-6.15	-0.32	2.24e-9	Obesity-related traits;
CRC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.61	-9.11	-0.45	8.15e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12143943	0.866	rs10458588	chr1:204505487	T/C	cg17419461	chr1:204415978	PIK3C2B	0.39	5.99	0.31	5.43e-9	Cognitive performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02931271	chr19:49947035	NA	0.41	5.97	0.31	6.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg02466173	chr16:30829666	NA	-0.59	-8.92	-0.44	3.29e-17	Dementia with Lewy bodies;
CRC	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.22	-0.32	1.53e-9	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg15660573	chr17:549704	VPS53	-0.7	-12.31	-0.56	6.51e-29	Prostate cancer;
CRC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg03037974	chr15:76606532	NA	0.81	15.83	0.66	2.33e-42	Blood metabolite levels;
CRC	cis	rs11030122	0.547	rs10767723	chr11:3955026	G/T	cg18678763	chr11:4115507	RRM1	-0.39	-6.61	-0.34	1.59e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.43	0.33	4.47e-10	Tonsillectomy;
CRC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg03030879	chr14:75389066	RPS6KL1	0.45	7.16	0.37	5.34e-12	Height;
CRC	cis	rs653465	0.739	rs1522151	chr3:27165174	C/T	cg02860705	chr3:27208620	NA	0.35	5.67	0.3	3.19e-8	Breast cancer (early onset);
CRC	cis	rs3750082	0.889	rs7785065	chr7:32915204	C/A	cg05721444	chr7:32995514	FKBP9	0.51	7.87	0.4	5.33e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02998992	chr17:19265610	B9D1	0.4	6.21	0.32	1.57e-9	Intelligence (multi-trait analysis);
CRC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04221910	chr5:616842	CEP72	-0.4	-6.61	-0.34	1.57e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01494303	chr16:3508002	NAT15	0.44	6.25	0.33	1.27e-9	Anxiety disorder;
CRC	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg23740940	chr11:68924746	NA	0.44	5.65	0.3	3.48e-8	Blond vs. brown hair color;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19654209	chr19:13976743	NA	0.45	6.29	0.33	1.01e-9	Anxiety disorder;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg02683197	chr6:28174875	NA	0.72	8.85	0.44	5.44e-17	Parkinson's disease;
CRC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.82	13.89	0.61	7.63e-35	Menopause (age at onset);
CRC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	7.09	0.36	8.14e-12	Eye color traits;
CRC	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg06606381	chr12:133084897	FBRSL1	-0.88	-6.69	-0.35	9.64e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.5	5.93	0.31	7.51e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.82	-11.83	-0.55	3.93e-27	Response to antineoplastic agents;
CRC	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg22561889	chr6:118971681	C6orf204	0.51	6.29	0.33	1.04e-9	Diastolic blood pressure;
CRC	cis	rs55702914	0.742	rs34555121	chr2:198166053	C/T	cg10820045	chr2:198174542	NA	0.47	8.79	0.44	8.67e-17	Major depression and alcohol dependence;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg02683197	chr6:28174875	NA	0.47	6.61	0.34	1.53e-10	Cardiac Troponin-T levels;
CRC	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg16989719	chr2:238392110	NA	-0.34	-5.87	-0.31	1.06e-8	Prostate cancer;
CRC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg09264619	chr17:80180166	NA	0.51	7.31	0.37	1.99e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-12.22	-0.56	1.44e-28	Refractive error;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg15845792	chr6:28175446	NA	0.69	8.58	0.43	3.72e-16	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg25164649	chr6:28176230	NA	0.78	9.65	0.47	1.48e-19	Depression;
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.55	8.04	0.41	1.64e-14	Melanoma;
CRC	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.47	8.99	0.44	2.03e-17	Renal cell carcinoma;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.65	-0.39	2.17e-13	Breast cancer;
CRC	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07951519	chr17:4607306	PELP1	0.49	6.9	0.36	2.62e-11	Response to antipsychotic treatment;
CRC	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.71	11.59	0.54	2.9e-26	Mean platelet volume;
CRC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg07507251	chr3:52567010	NT5DC2	-0.39	-6.17	-0.32	1.99e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg13611204	chr9:139324423	INPP5E	-0.42	-5.87	-0.31	1.08e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg23387468	chr7:139079360	LUC7L2	-0.41	-7.02	-0.36	1.28e-11	Diisocyanate-induced asthma;
CRC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.93	14.17	0.62	6.79e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs447	1.000	rs7783472	chr7:83751882	G/A	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.79	-0.39	8.91e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04626574	chr22:26879726	HPS4;SRRD	0.47	6.1	0.32	2.99e-9	Thyroid stimulating hormone;
CRC	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg05709478	chr1:6581295	PLEKHG5	0.67	5.73	0.3	2.23e-8	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08616681	chr16:718778	RHOT2	0.45	6.19	0.32	1.75e-9	Thyroid stimulating hormone;
CRC	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	7.58	0.39	3.47e-13	Diisocyanate-induced asthma;
CRC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.9	0.51	8.28e-24	Prostate cancer;
CRC	cis	rs4713675	0.525	rs622917	chr6:33702869	C/T	cg14003231	chr6:33640908	ITPR3	-0.36	-5.92	-0.31	8.27e-9	Plateletcrit;
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.75	-0.3	1.99e-8	Total body bone mineral density;
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg24046110	chr8:143859143	LYNX1	0.46	7.97	0.4	2.7e-14	Urinary tract infection frequency;
CRC	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.66	-10.06	-0.49	6.11e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20390613	chr1:12678355	DHRS3	0.46	6.54	0.34	2.38e-10	Response to antipsychotic treatment;
CRC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.75	-14.96	-0.64	5.77e-39	Prostate cancer;
CRC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.57	9.02	0.45	1.58e-17	Aortic root size;
CRC	trans	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg17712092	chr4:129076599	LARP1B	-0.52	-7.97	-0.4	2.61e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	1.17	10.78	0.51	2.08e-23	Arsenic metabolism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16003301	chr12:56521951	ESYT1	0.45	6.15	0.32	2.22e-9	Anxiety disorder;
CRC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg12193833	chr17:30244370	NA	-0.72	-8.27	-0.41	3.45e-15	Hip circumference adjusted for BMI;
CRC	cis	rs6973256	0.637	rs12539993	chr7:133418799	C/T	cg10665199	chr7:133106180	EXOC4	0.46	7.32	0.37	1.97e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06307176	chr5:131281290	NA	0.44	6.45	0.34	3.9e-10	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02760007	chr6:43139670	SRF	0.4	6.17	0.32	2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.44	-7.7	-0.39	1.58e-13	Reticulocyte fraction of red cells;
CRC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.71	-11.69	-0.54	1.18e-26	Hip circumference adjusted for BMI;
CRC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.83e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg18187862	chr3:45730750	SACM1L	0.43	5.97	0.31	6.29e-9	Primary sclerosing cholangitis;
CRC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20237707	chr13:111719772	NA	0.43	7.38	0.38	1.31e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg15654264	chr1:150340011	RPRD2	0.41	6.1	0.32	3.03e-9	Migraine;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg05972502	chr5:132073061	KIF3A	-0.7	-6.01	-0.31	5.01e-9	Cognitive function;
CRC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.51	-0.42	6.05e-16	Hemoglobin concentration;
CRC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.75	9.14	0.45	6.52e-18	Body mass index;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg20615401	chr6:28092323	ZSCAN16	0.42	5.61	0.3	4.21e-8	Cardiac Troponin-T levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04108127	chr1:222885781	AIDA;C1orf58	0.42	6.08	0.32	3.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg06632207	chr12:54070931	ATP5G2	0.39	6.58	0.34	1.82e-10	Height;
CRC	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.65	-8.88	-0.44	4.48e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs12286929	0.802	rs12787954	chr11:115020328	T/C	cg04055981	chr11:115044050	NA	0.38	6.14	0.32	2.33e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	7.31	0.37	2.1e-12	Breast cancer;
CRC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.39	6.1	0.32	2.93e-9	Crohn's disease;
CRC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.51	8.22	0.41	4.63e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg15382696	chr6:118971807	C6orf204	0.61	8.01	0.4	2.07e-14	Diastolic blood pressure;
CRC	cis	rs10911390	0.793	rs12041487	chr1:183591550	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Systemic lupus erythematosus;
CRC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-20.53	-0.75	7.34e-61	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22633390	chr7:100964966	RABL5	0.38	6.15	0.32	2.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.44	-7.11	-0.37	7.05e-12	Coronary artery disease;
CRC	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.66	10.32	0.49	7.91e-22	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.39	0.33	5.69e-10	Platelet count;
CRC	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg13086574	chr8:135490821	ZFAT	-0.37	-6.26	-0.33	1.19e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.23	-0.32	1.41e-9	Arsenic metabolism;
CRC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-18.01	-0.7	5.8e-51	Height;
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.75	11.16	0.52	9.55e-25	Breast cancer;
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs1624802	0.966	rs1707933	chr12:130497813	T/G	cg15444478	chr12:130494697	NA	-0.29	-5.98	-0.31	5.85e-9	Obesity-related traits;
CRC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg04121214	chr22:50244548	NA	-0.42	-6.11	-0.32	2.84e-9	Schizophrenia;
CRC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg13108601	chr6:41748242	FRS3;PRICKLE4	-0.54	-6.63	-0.34	1.41e-10	Diisocyanate-induced asthma;
CRC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.39	6.18	0.32	1.87e-9	Platelet distribution width;
CRC	cis	rs2398668	0.570	rs4721548	chr7:2330496	A/G	cg08027265	chr7:2291960	NA	-0.42	-6.85	-0.35	3.63e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.53	-6.07	-0.32	3.43e-9	Vitiligo;
CRC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.76	10.4	0.5	4.3e-22	Coronary artery disease;
CRC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-12.89	-0.58	4.62e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6141769	0.542	rs6057630	chr20:31318737	A/G	cg13636640	chr20:31349939	DNMT3B	-0.37	-5.73	-0.3	2.32e-8	Subjective well-being;
CRC	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.48	7.28	0.37	2.46e-12	Carotid intima media thickness;
CRC	cis	rs2398893	1.000	rs12004383	chr9:96826239	G/T	cg14459158	chr9:96720562	NA	0.48	7.59	0.39	3.23e-13	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg18288967	chr1:45987694	PRDX1	0.56	6.39	0.33	5.51e-10	Obesity-related traits;
CRC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.87	14.08	0.61	1.47e-35	Multiple system atrophy;
CRC	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.54	7.15	0.37	5.81e-12	Non-substance related behavioral disinhibition;
CRC	cis	rs10769945	0.834	rs217207	chr11:1974831	G/A	cg23202291	chr11:1979235	NA	-0.45	-6.57	-0.34	1.96e-10	DNA methylation (variation);
CRC	cis	rs6988985	0.765	rs62525057	chr8:143976023	T/C	cg10324643	chr8:143916377	GML	0.38	6.24	0.33	1.38e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.57	8.72	0.43	1.43e-16	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.92	0.58	3.51e-31	Alzheimer's disease;
CRC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-12.6	-0.57	5.83e-30	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13603510	chr19:3626908	C19orf29	0.38	6.08	0.32	3.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.66	9.25	0.45	2.92e-18	Neuroblastoma;
CRC	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.52	-0.38	5.14e-13	Brugada syndrome;
CRC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.54	-7.37	-0.38	1.4e-12	Corneal structure;
CRC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg22777020	chr22:31556080	RNF185	-0.51	-5.76	-0.3	1.92e-8	Colorectal cancer;
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg01874867	chr7:94954059	PON1	-0.49	-6.25	-0.33	1.27e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg23018236	chr17:30244563	NA	-0.46	-6.2	-0.32	1.68e-9	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09133386	chr6:20404188	E2F3	0.48	6.81	0.35	4.77e-11	Response to antipsychotic treatment;
CRC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg24675056	chr1:15929824	NA	0.52	7.06	0.36	9.92e-12	Systolic blood pressure;
CRC	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg16670446	chr17:27188758	MIR451;MIR144	-0.59	-10.38	-0.5	4.89e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg09029085	chr17:47094198	IGF2BP1	0.3	5.66	0.3	3.31e-8	Intelligence (multi-trait analysis);Body fat percentage;
CRC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg25985355	chr7:65971099	NA	0.32	5.69	0.3	2.76e-8	Aortic root size;
CRC	cis	rs6840360	0.642	rs1470280	chr4:152431770	C/T	cg09659197	chr4:152720779	NA	0.33	6.69	0.35	9.61e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.62	8.22	0.41	4.83e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12980942	0.872	rs11879562	chr19:41804976	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.45	5.61	0.3	4.39e-8	Coronary artery disease;
CRC	cis	rs7923609	0.740	rs10761784	chr10:65308750	A/T	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.71	-0.3	2.58e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg21251018	chr6:28226885	NKAPL	-0.4	-6.27	-0.33	1.11e-9	Systemic lupus erythematosus;
CRC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.57	-0.75	5.09e-61	Height;
CRC	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-7.09	-0.36	8.06e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg26248373	chr2:1572462	NA	-0.61	-6.42	-0.33	4.84e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg15145174	chr5:6755386	POLS	-0.45	-6.45	-0.33	4.1e-10	Menopause (age at onset);
CRC	cis	rs4073416	0.542	rs4902404	chr14:66047022	T/C	cg03016385	chr14:66212404	NA	-0.46	-6.25	-0.33	1.29e-9	N-glycan levels;
CRC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.36	5.73	0.3	2.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.69	7.95	0.4	3.05e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg25835954	chr13:50160062	RCBTB1	0.54	8.01	0.4	1.99e-14	Cortisol levels (saliva);
CRC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-13.15	-0.59	4.81e-32	Vitiligo;
CRC	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.57	9.92	0.48	1.8e-20	Leprosy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18737971	chr15:43941642	CATSPER2	-0.41	-6.74	-0.35	7.29e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	trans	rs1590305	0.786	rs3764077	chr13:38059067	A/G	cg03965764	chr11:45248109	NA	-0.59	-6.05	-0.32	3.96e-9	Hip geometry;
CRC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg04562611	chr16:615315	C16orf11	0.38	6.49	0.34	3.23e-10	Height;
CRC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.4	-7.26	-0.37	2.73e-12	Height;
CRC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16447950	chr5:562315	NA	-0.83	-10.81	-0.51	1.71e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.48	0.42	7.81e-16	Vitiligo;
CRC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.42	6.63	0.34	1.41e-10	Dupuytren's disease;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg22638593	chr5:131593259	PDLIM4	0.39	6.47	0.34	3.47e-10	Breast cancer;
CRC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.09	0.49	4.78e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs780094	0.500	rs1919127	chr2:27801493	T/C	cg27432699	chr2:27873401	GPN1	0.47	6.03	0.32	4.47e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.2	-30.69	-0.86	1.43e-98	Colorectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20614940	chr2:191273670	MFSD6	0.5	6.41	0.33	5.11e-10	Thyroid stimulating hormone;
CRC	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.18	-0.32	1.93e-9	Adiposity;
CRC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.45	7.93	0.4	3.34e-14	Systemic lupus erythematosus;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg19764421	chr1:228783274	DUSP5P	0.4	6.11	0.32	2.75e-9	Body mass index;
CRC	cis	rs10208940	0.764	rs34744266	chr2:68782606	G/A	cg12452813	chr2:68675892	NA	0.47	5.9	0.31	9.19e-9	Urate levels in lean individuals;
CRC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.3e-40	Prostate cancer;
CRC	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg26182253	chr13:112236782	NA	0.31	6.28	0.33	1.07e-9	Hepatitis;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.41	-5.78	-0.3	1.77e-8	Longevity;Endometriosis;
CRC	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.59	11.57	0.54	3.37e-26	Neuroticism;
CRC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-7.11	-0.36	7.44e-12	Colorectal cancer;
CRC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.72	-10.28	-0.49	1.07e-21	Vitiligo;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19784910	chr11:101785671	KIAA1377;ANGPTL5	0.43	5.99	0.31	5.44e-9	Anxiety disorder;
CRC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.33	5.82	0.31	1.37e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg04586622	chr2:25135609	ADCY3	-0.44	-7.82	-0.4	7.26e-14	Body mass index in non-asthmatics;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23507024	chr3:14166481	TMEM43;CHCHD4	0.46	6.48	0.34	3.3e-10	Response to antipsychotic treatment;
CRC	cis	rs2252790	1.000	rs1204853	chr6:116577113	A/G	cg18764771	chr6:116381957	FRK	0.22	5.81	0.31	1.48e-8	Fast beta electroencephalogram;
CRC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg21153622	chr11:89784906	NA	-0.53	-8.8	-0.44	8.03e-17	HDL cholesterol;
CRC	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.62	-7.4	-0.38	1.14e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00280220	chr17:61926910	NA	0.33	5.64	0.3	3.6e-8	Prudent dietary pattern;
CRC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	11.93	0.55	1.68e-27	Menopause (age at onset);
CRC	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.62	10.47	0.5	2.39e-22	Blood protein levels;
CRC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.48	0.53	7.17e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12366118	chr12:62860687	MON2	0.48	7.07	0.36	9.31e-12	Response to antipsychotic treatment;
CRC	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21659725	chr3:3221576	CRBN	-0.63	-7.19	-0.37	4.36e-12	Menarche (age at onset);
CRC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.64	10.06	0.48	6.41e-21	Colorectal cancer;
CRC	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.75	5.61	0.3	4.32e-8	Obesity (early onset extreme);
CRC	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg04880052	chr2:219191631	PNKD	0.4	6.1	0.32	3.01e-9	Colorectal cancer;
CRC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.79	0.39	8.62e-14	Lung cancer;
CRC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg17764715	chr19:33622953	WDR88	0.45	6.45	0.33	4.02e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs7737355	0.773	rs31239	chr5:130813377	G/T	cg25547332	chr5:131281432	NA	-0.36	-5.88	-0.31	1.02e-8	Life satisfaction;
CRC	cis	rs12505749	0.542	rs12646890	chr4:57355262	T/C	cg06922635	chr4:57371607	ARL9	-0.54	-5.7	-0.3	2.66e-8	Airflow obstruction;
CRC	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.34	-5.9	-0.31	9.12e-9	Airway imaging phenotypes;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.6	10.28	0.49	1.13e-21	Prudent dietary pattern;
CRC	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	9.36	0.46	1.24e-18	Fuchs's corneal dystrophy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24984818	chr19:7600102	PNPLA6	0.44	6.07	0.32	3.53e-9	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg02569458	chr12:86230093	RASSF9	0.39	6.61	0.34	1.6e-10	Major depressive disorder;
CRC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.56	8.11	0.41	1.04e-14	Lung cancer;
CRC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.27	0.49	1.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	11.55	0.54	3.83e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg21028142	chr17:79581711	NPLOC4	-0.34	-6.15	-0.32	2.23e-9	Eye color traits;
CRC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.54	-8.75	-0.43	1.09e-16	Coronary artery disease;
CRC	cis	rs863345	0.565	rs2220633	chr1:158445272	A/G	cg12129480	chr1:158549410	OR10X1	-0.28	-5.85	-0.31	1.17e-8	Pneumococcal bacteremia;
CRC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.64	7.32	0.37	1.94e-12	Vitiligo;
CRC	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg06156847	chr2:113672199	IL1F7	-0.4	-6.03	-0.32	4.46e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.61	-9.32	-0.46	1.8e-18	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs62187652	chr2:162468033	C/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10964577	chr17:15160725	PMP22	0.4	6.18	0.32	1.91e-9	Myopia (pathological);
CRC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.34	2.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12760731	0.720	rs12047646	chr1:178274083	G/A	cg00404053	chr1:178313656	RASAL2	1.11	11.41	0.53	1.29e-25	Obesity-related traits;
CRC	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.01	0.64	3.85e-39	Bipolar disorder;
CRC	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg14352298	chr13:112236639	NA	0.29	6.64	0.34	1.3100000000000001e-10	Hepatitis;
CRC	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.55	8.68	0.43	1.91e-16	Schizophrenia;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.46	7.09	0.36	8.3e-12	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-5.62	-0.3	4.16e-8	Height;
CRC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.39	-5.77	-0.3	1.87e-8	Mean corpuscular volume;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg20933634	chr6:27740509	NA	0.57	8.08	0.41	1.24e-14	Parkinson's disease;
CRC	cis	rs501120	0.584	rs11238889	chr10:44668724	G/A	cg09554077	chr10:44749378	NA	0.73	8.06	0.41	1.38e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg26893861	chr17:41843967	DUSP3	-0.7	-6.36	-0.33	6.72e-10	Cognitive function;
CRC	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg16898833	chr6:26189333	HIST1H4D	0.72	6.45	0.34	4.06e-10	Depression;
CRC	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.74	-0.35	7.09e-11	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18452149	chr3:108308268	KIAA1524;DZIP3	0.4	6.85	0.35	3.74e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg10978503	chr1:24200527	CNR2	0.44	7.45	0.38	8.06e-13	Immature fraction of reticulocytes;
CRC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.55	-8.34	-0.42	2.11e-15	Calcium levels;
CRC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.65	0.43	2.36e-16	Prostate cancer;
CRC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg21153622	chr11:89784906	NA	-0.55	-9.21	-0.45	4.02e-18	HDL cholesterol;
CRC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	6.33	0.33	8.19e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.45	-7.1	-0.36	7.95e-12	Obesity-related traits;
CRC	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.08	-19.92	-0.74	1.81e-58	Exhaled nitric oxide output;
CRC	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.46	-8.18	-0.41	6.32e-15	Testicular germ cell tumor;
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg16606324	chr3:10149918	C3orf24	0.59	7.13	0.37	6.53e-12	Alzheimer's disease;
CRC	cis	rs3857067	0.967	rs1355240	chr4:95019353	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.06	-0.32	3.63e-9	QT interval;
CRC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.0	0.55	9.22e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.45	8.98	0.44	2.08e-17	Renal cell carcinoma;
CRC	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs117623576	0.941	rs7924082	chr10:32429126	A/G	cg03047570	chr10:32398778	NA	0.64	6.39	0.33	5.75e-10	Anti-saccade response;
CRC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.47	-0.34	3.64e-10	Schizophrenia;
CRC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs7554547	0.765	rs6541010	chr1:11973842	A/G	cg13216073	chr1:12042593	MFN2	0.4	5.76	0.3	1.89e-8	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.39	6.0	0.31	5.21e-9	Obesity;
CRC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.1	26.81	0.83	9.1200000000000006e-85	Testicular germ cell tumor;
CRC	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.79	-12.87	-0.58	5.35e-31	Hypospadias;
CRC	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg08080985	chr9:77703079	C9orf95;OSTF1	0.46	6.49	0.34	3.12e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg06470822	chr6:28175283	NA	0.81	12.09	0.55	4.31e-28	Cardiac Troponin-T levels;
CRC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-0.62	-10.81	-0.51	1.63e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg00666640	chr1:248458726	OR2T12	0.43	7.64	0.39	2.34e-13	Common traits (Other);
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.71	9.42	0.46	7.95e-19	Alzheimer's disease;
CRC	cis	rs7539542	0.556	rs10732292	chr1:202891366	T/C	cg19681188	chr1:202830198	LOC148709	0.45	6.57	0.34	1.94e-10	Mean platelet volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25756398	chr11:93474621	C11orf54;TAF1D	0.43	6.78	0.35	5.42e-11	Obesity-related traits;
CRC	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	cg04338863	chr8:33670619	NA	0.45	6.6	0.34	1.63e-10	Body mass index;
CRC	trans	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg11430096	chr6:110968061	CDK19	0.67	5.98	0.31	5.74e-9	Prostate cancer;
CRC	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.75	-0.3	1.99e-8	Coronary artery disease;
CRC	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.5	8.42	0.42	1.19e-15	Airway imaging phenotypes;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg11503833	chr11:492997	NA	0.56	5.89	0.31	9.64e-9	Body mass index;
CRC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg02319466	chr17:76381040	PGS1	0.38	5.96	0.31	6.53e-9	HDL cholesterol levels;
CRC	cis	rs2013441	1.000	rs2703815	chr17:20118499	C/T	cg13482628	chr17:19912719	NA	0.39	5.94	0.31	7.2e-9	Obesity-related traits;
CRC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.81	14.2	0.62	4.88e-36	Breast cancer;
CRC	cis	rs3087591	0.639	rs734403	chr17:29723346	T/C	cg24425628	chr17:29625626	OMG;NF1	0.68	12.15	0.56	2.62e-28	Hip circumference;
CRC	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.13	0.32	2.5e-9	Ovarian reserve;
CRC	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg01422370	chr2:73384389	NA	-0.39	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7289126	1.000	rs5756986	chr22:38640841	A/G	cg25457927	chr22:38595422	NA	-0.33	-6.39	-0.33	5.6e-10	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs9925964	0.967	rs1549293	chr16:31141993	C/T	cg10396673	chr16:31104726	VKORC1	0.34	5.64	0.3	3.76e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.56	8.86	0.44	5.26e-17	Colorectal cancer;
CRC	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.84	10.74	0.51	2.84e-23	Diisocyanate-induced asthma;
CRC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-7.04	-0.36	1.11e-11	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27537453	chr16:2732578	KCTD5	0.46	6.67	0.35	1.11e-10	Response to antipsychotic treatment;
CRC	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.81	-13.96	-0.61	4.07e-35	Lewy body disease;
CRC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg12365402	chr11:9010492	NRIP3	-0.49	-8.3	-0.42	2.69e-15	Hemoglobin concentration;
CRC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.68	-0.39	1.89e-13	Vitiligo;
CRC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg23758597	chr6:163146217	PARK2	-0.66	-6.66	-0.34	1.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.37	0.56	3.93e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg22431228	chr1:16359049	CLCNKA	-0.32	-6.34	-0.33	7.37e-10	Dilated cardiomyopathy;
CRC	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.4	-6.36	-0.33	6.93e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.16	11.02	0.52	3.04e-24	Skin colour saturation;
CRC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg23262073	chr20:60523788	NA	-0.45	-7.07	-0.36	9.51e-12	Body mass index;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg10802521	chr3:52805072	NEK4	-0.4	-6.32	-0.33	8.46e-10	Electroencephalogram traits;
CRC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg23071808	chr14:103021642	NA	-0.64	-7.25	-0.37	2.99e-12	Platelet count;
CRC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.55	7.36	0.38	1.5e-12	Alcohol dependence;
CRC	cis	rs4731207	0.698	rs1904975	chr7:124552802	C/T	cg23710748	chr7:124431027	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Cutaneous malignant melanoma;
CRC	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.64	9.28	0.46	2.39e-18	Schizophrenia;
CRC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.68	9.29	0.46	2.23e-18	Gestational age at birth (maternal effect);
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.62	0.34	1.47e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg16964102	chr10:135390573	NA	0.53	7.44	0.38	8.92e-13	Gout;
CRC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg08761264	chr16:28874980	SH2B1	-0.42	-5.64	-0.3	3.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.8	0.35	5.05e-11	Lung cancer;
CRC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.47	7.63	0.39	2.5e-13	Obesity-related traits;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg06470822	chr6:28175283	NA	0.97	13.12	0.59	6.28e-32	Parkinson's disease;
CRC	cis	rs4363385	0.747	rs1415962	chr1:152958731	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.28	-0.37	2.43e-12	Inflammatory skin disease;
CRC	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.48	6.64	0.34	1.3100000000000001e-10	Coronary artery disease;
CRC	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.69	9.24	0.45	3.18e-18	Platelet count;
CRC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.48	7.3	0.37	2.22e-12	Corneal astigmatism;
CRC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.38	-0.33	6.16e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16515820	chr3:114866447	ZBTB20	0.42	6.25	0.33	1.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.11	-0.32	2.75e-9	Reticulocyte count;
CRC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17554472	chr22:41940697	POLR3H	-0.56	-5.73	-0.3	2.23e-8	Vitiligo;
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.63	-0.43	2.75e-16	Total body bone mineral density;
CRC	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.73	10.64	0.51	6.62e-23	Pulse pressure;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.95	-22.1	-0.77	5.46e-67	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg09998033	chr7:158218633	PTPRN2	-0.55	-7.44	-0.38	8.78e-13	Obesity-related traits;
CRC	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg27534772	chr1:16042836	PLEKHM2	0.42	6.71	0.35	8.76e-11	Systolic blood pressure;
CRC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.96	11.57	0.54	3.29e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg27432699	chr2:27873401	GPN1	-0.61	-9.15	-0.45	5.97e-18	Total body bone mineral density;
CRC	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-9.36	-0.46	1.27e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg20041105	chr8:143859282	LYNX1	0.57	10.07	0.49	5.65e-21	Urinary tract infection frequency;
CRC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.55	8.26	0.41	3.49e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16739845	chr14:92040772	C14orf184	0.42	5.96	0.31	6.5e-9	Anxiety disorder;
CRC	cis	rs4700695	0.841	rs27569	chr5:65373419	C/T	cg21114390	chr5:65439923	SFRS12	-0.48	-6.15	-0.32	2.19e-9	Facial morphology (factor 19);
CRC	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.56	-10.56	-0.5	1.25e-22	Schizophrenia;
CRC	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg00042356	chr1:8021962	PARK7	0.68	8.35	0.42	1.98e-15	Inflammatory bowel disease;
CRC	cis	rs73206853	0.764	rs57033697	chr12:110550992	G/A	cg12870014	chr12:110450643	ANKRD13A	0.83	10.65	0.51	5.74e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6662572	0.737	rs7413189	chr1:46254330	G/A	cg08644498	chr1:46502608	NA	-0.45	-7.22	-0.37	3.58e-12	Blood protein levels;
CRC	cis	rs728616	0.510	rs12411989	chr10:81937850	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.35	-0.46	1.42e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.47	6.53	0.34	2.55e-10	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs7517126	1.000	rs35155714	chr1:196838929	C/A	cg13682187	chr1:196946512	CFHR5	-0.36	-5.91	-0.31	8.52e-9	Blood protein levels;
CRC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.68	8.2	0.41	5.37e-15	Menarche (age at onset);
CRC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.7	-0.35	9.3e-11	Monocyte count;
CRC	cis	rs12760731	0.720	rs12021983	chr1:178323800	C/T	cg00404053	chr1:178313656	RASAL2	0.85	10.33	0.49	7.65e-22	Obesity-related traits;
CRC	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-6.0	-0.31	5.11e-9	Intelligence;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.81	10.84	0.51	1.25e-23	Alzheimer's disease;
CRC	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg02353165	chr6:42928485	GNMT	0.57	7.19	0.37	4.37e-12	Blood protein levels;
CRC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06636001	chr8:8085503	FLJ10661	0.44	5.75	0.3	2.06e-8	Obesity-related traits;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.75	9.54	0.47	3.22e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.14	-0.41	8.18e-15	Bladder cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14195377	chr11:60928647	VPS37C	0.41	6.8	0.35	4.96e-11	Obesity-related traits;
CRC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.88	-0.48	2.55e-20	Body mass index;
CRC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.45	0.53	8.76e-26	Tonsillectomy;
CRC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01400952	chr12:122460473	BCL7A	0.48	6.58	0.34	1.81e-10	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22491225	chr15:41136499	SPINT1	0.45	6.16	0.32	2.11e-9	Anxiety disorder;
CRC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-5.98	-0.31	5.75e-9	Monocyte count;
CRC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.49	-9.14	-0.45	6.82e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg14003231	chr6:33640908	ITPR3	0.47	7.41	0.38	1.09e-12	Plateletcrit;
CRC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.66	0.57	3.53e-30	Platelet count;
CRC	cis	rs4731207	0.724	rs6953168	chr7:124506341	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.59	7.85	0.4	5.72e-14	Mean platelet volume;
CRC	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg27205649	chr11:78285834	NARS2	0.49	6.4	0.33	5.23e-10	Alzheimer's disease (survival time);
CRC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg20203395	chr5:56204925	C5orf35	-0.73	-8.6	-0.43	3.41e-16	Initial pursuit acceleration;
CRC	cis	rs12580194	0.593	rs3935215	chr12:55792401	T/A	cg19537932	chr12:55886519	OR6C68	-0.72	-9.22	-0.45	3.64e-18	Cancer;
CRC	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg04990556	chr1:26633338	UBXN11	0.53	5.8	0.3	1.57e-8	Obesity-related traits;
CRC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.84	14.79	0.63	2.58e-38	Blood protein levels;
CRC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg25876840	chr17:41920477	NA	0.62	8.91	0.44	3.57e-17	Triglycerides;
CRC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg25456477	chr12:86230367	RASSF9	0.37	6.16	0.32	2.13e-9	Major depressive disorder;
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.32	0.42	2.36e-15	Alzheimer's disease;
CRC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg05304507	chr6:116381966	FRK	0.31	8.38	0.42	1.56e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6460942	0.591	rs62451461	chr7:12355480	G/A	cg06484146	chr7:12443880	VWDE	-0.56	-5.82	-0.31	1.39e-8	Coronary artery disease;
CRC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.56	7.84	0.4	6.48e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9463078	0.691	rs9296458	chr6:45267183	T/C	cg25276700	chr6:44698697	NA	-0.25	-6.01	-0.31	4.91e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.33	5.88	0.31	1.01e-8	Erythrocyte sedimentation rate;
CRC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.44	-0.38	9.01e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg03623178	chr6:28175578	NA	0.93	12.17	0.56	2.25e-28	Depression;
CRC	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg16898833	chr6:26189333	HIST1H4D	1.05	7.54	0.38	4.49e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.02	10.31	0.49	8.6e-22	Diabetic retinopathy;
CRC	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.68	0.3	3e-8	Rheumatoid arthritis;
CRC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.77	14.43	0.62	6.45e-37	Prudent dietary pattern;
CRC	cis	rs7605827	0.930	rs2160693	chr2:15654669	A/T	cg19274914	chr2:15703543	NA	0.4	6.0	0.31	5.16e-9	Educational attainment (years of education);
CRC	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.72	-0.35	7.91e-11	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	15.38	0.65	1.37e-40	Subjective well-being;
CRC	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg13736514	chr6:26305472	NA	-0.43	-7.18	-0.37	4.6e-12	Educational attainment;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23591125	chr1:178481898	C1orf49	0.36	6.12	0.32	2.64e-9	Aortic root size;
CRC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg01721255	chr8:58191610	C8orf71	0.49	6.16	0.32	2.18e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.25	-0.56	1.09e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-9.09	-0.45	9.34e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg10578991	chr7:12443926	VWDE	-0.5	-5.95	-0.31	6.95e-9	Coronary artery disease;
CRC	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.81	15.07	0.64	2.14e-39	Ulcerative colitis;
CRC	cis	rs720844	0.628	rs12468186	chr2:149297624	C/T	cg09247360	chr2:149335327	NA	-0.56	-5.83	-0.31	1.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.65	7.94	0.4	3.25e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19403339	chr2:183580841	DNAJC10	0.39	6.54	0.34	2.36e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.54	0.38	4.63e-13	Mean platelet volume;
CRC	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg01639898	chr1:32083012	HCRTR1	0.28	5.6	0.3	4.47e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg25804541	chr17:80189381	SLC16A3	0.3	5.81	0.31	1.47e-8	Life satisfaction;
CRC	cis	rs10097731	0.908	rs28550260	chr8:82025584	T/C	cg25230327	chr8:82042993	NA	-0.78	-10.85	-0.51	1.21e-23	Serum total protein level;
CRC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.42	-8.07	-0.41	1.3e-14	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17986463	chr6:150326316	RAET1K	0.39	6.11	0.32	2.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg22431228	chr1:16359049	CLCNKA	0.35	5.92	0.31	7.99e-9	Dilated cardiomyopathy;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg06470822	chr6:28175283	NA	-0.81	-9.21	-0.45	3.91e-18	Parkinson's disease;
CRC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.48	6.14	0.32	2.41e-9	Obesity-related traits;
CRC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg22496339	chr2:162101262	NA	-0.54	-7.29	-0.37	2.26e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	5.05e-15	Red blood cell count;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg02683197	chr6:28174875	NA	0.8	10.0	0.48	9.7e-21	Depression;
CRC	cis	rs8058578	0.614	rs2878304	chr16:30878366	C/T	cg02466173	chr16:30829666	NA	0.66	8.48	0.42	7.78e-16	Multiple myeloma;
CRC	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.47	-6.79	-0.35	5.1e-11	Squamous cell lung carcinoma;
CRC	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg00601450	chr5:74908170	NA	0.49	6.08	0.32	3.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6504622	0.791	rs758392	chr17:45017859	C/T	cg16759221	chr17:45003025	GOSR2	0.48	7.32	0.37	1.88e-12	Orofacial clefts;
CRC	cis	rs35343117	1	rs35343117	chr15:86079115	C/G	cg10818794	chr15:86012489	AKAP13	-0.44	-6.37	-0.33	6.53e-10	Psoriasis;
CRC	cis	rs7760949	0.852	rs9349847	chr6:13927711	T/C	cg27413430	chr6:13925136	RNF182	0.34	5.84	0.31	1.25e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg09597638	chr17:3907349	NA	-0.45	-5.79	-0.3	1.68e-8	Type 2 diabetes;
CRC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg07713946	chr22:31675144	LIMK2	-0.4	-5.7	-0.3	2.61e-8	Colorectal cancer;
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg12172441	chr6:28176163	NA	0.52	7.23	0.37	3.42e-12	Parkinson's disease;
CRC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg15786705	chr6:28176104	NA	0.59	8.5	0.42	6.86e-16	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02830438	chr14:93651416	C14orf109;MOAP1	0.41	5.98	0.31	5.69e-9	Intelligence (multi-trait analysis);
CRC	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.81	6.92	0.36	2.36e-11	LDL cholesterol;
CRC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.51	-6.38	-0.33	6.11e-10	Recombination rate (females);
CRC	cis	rs7605827	0.897	rs4140714	chr2:15515723	T/A	cg19274914	chr2:15703543	NA	0.4	6.03	0.32	4.33e-9	Educational attainment (years of education);
CRC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-14.67	-0.63	7.63e-38	Height;
CRC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.6	10.35	0.5	6.46e-22	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08692210	chr3:52188851	WDR51A	0.48	7.8	0.4	8.22e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.47e-12	Eye color traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00926192	chr17:42297085	UBTF	-0.38	-5.99	-0.31	5.4e-9	Myopia (pathological);
CRC	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg16070123	chr10:51489643	NA	-0.35	-5.8	-0.3	1.54e-8	Prostate-specific antigen levels;
CRC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.14	-0.37	6.01e-12	Hemoglobin concentration;
CRC	trans	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg26043149	chr18:55253948	FECH	0.54	7.59	0.39	3.38e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.48	-7.76	-0.39	1.11e-13	Body mass index;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.59	9.97	0.48	1.2e-20	Prudent dietary pattern;
CRC	cis	rs4654899	0.802	rs7519685	chr1:21192623	G/A	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.83	-0.4	6.62e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.49	6.49	0.34	3.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.69	0.39	1.77e-13	Motion sickness;
CRC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg22777020	chr22:31556080	RNF185	0.5	5.99	0.31	5.4e-9	Colorectal cancer;
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.73	0.3	2.24e-8	Electroencephalogram traits;
CRC	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.6	8.19	0.41	5.65e-15	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs17133277	0.702	rs7786415	chr7:3500105	T/G	cg25123566	chr12:47610734	FAM113B;LOC100233209	-0.55	-5.99	-0.31	5.44e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12721145	chr4:109571876	OSTC	0.5	8.02	0.4	1.93e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.26	0.37	2.79e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.78	10.39	0.5	4.59e-22	Vitiligo;
CRC	trans	rs7976838	0.908	rs35755432	chr12:60142506	G/A	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.34	-5.66	-0.3	3.35e-8	Menopause (age at onset);
CRC	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.65	-9.33	-0.46	1.56e-18	Type 2 diabetes;
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03647317	chr4:187891568	NA	-0.52	-9.44	-0.46	6.84e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.78	-0.3	1.72e-8	Longevity;Endometriosis;
CRC	cis	rs11264799	0.598	rs72708402	chr1:157719073	C/T	cg11810135	chr1:157771971	FCRL1	0.37	5.8	0.3	1.59e-8	IgA nephropathy;
CRC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	trans	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.81	8.07	0.41	1.32e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg06494592	chr3:125709126	NA	-0.53	-6.9	-0.36	2.61e-11	Blood pressure (smoking interaction);
CRC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg04553112	chr3:125709451	NA	-0.54	-6.17	-0.32	1.97e-9	Blood pressure (smoking interaction);
CRC	cis	rs4862307	0.754	rs6846007	chr4:184991604	A/G	cg06737308	chr4:185021514	ENPP6	-0.45	-6.89	-0.35	2.92e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	trans	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg26043149	chr18:55253948	FECH	0.53	8.11	0.41	9.94e-15	Bone mineral density;
CRC	cis	rs4716602	0.596	rs12386682	chr7:156158265	C/T	cg16983916	chr7:156159713	NA	-0.39	-6.92	-0.36	2.42e-11	Anti-saccade response;
CRC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.69	10.78	0.51	2.15e-23	Selective IgA deficiency;
CRC	cis	rs6988985	0.693	rs6395	chr8:143956808	A/C	cg10324643	chr8:143916377	GML	0.36	6.16	0.32	2.08e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27480539	chr19:16770792	TMEM38A;C19orf42	0.47	6.69	0.35	9.75e-11	Response to antipsychotic treatment;
CRC	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg00852783	chr1:26633632	UBXN11	-0.49	-5.81	-0.31	1.45e-8	Obesity-related traits;
CRC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.5	0.38	5.91e-13	Schizophrenia;
CRC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.07	0.49	5.64e-21	Heart rate;
CRC	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	0.98	10.96	0.52	4.8e-24	Gut microbiota (bacterial taxa);
CRC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.53	-9.8	-0.48	4.47e-20	Longevity;
CRC	cis	rs11229555	0.645	rs12785578	chr11:58206432	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.44	7.03	0.36	1.18e-11	Dupuytren's disease;
CRC	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.57	-8.76	-0.43	1.04e-16	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.84	-11.98	-0.55	1.05e-27	Gut microbiome composition (summer);
CRC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg16892393	chr17:41919603	NA	0.49	7.55	0.38	4.32e-13	Triglycerides;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22627950	chr7:44622302	TMED4	0.43	6.01	0.31	5.03e-9	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.46	6.75	0.35	6.69e-11	Menopause (age at onset);
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	7.17	0.37	4.96e-12	Acylcarnitine levels;
CRC	cis	rs490234	0.702	rs13285587	chr9:128233058	G/T	cg14078157	chr9:128172775	NA	-0.39	-6.47	-0.34	3.59e-10	Mean arterial pressure;
CRC	cis	rs501120	0.929	rs2576354	chr10:44750393	G/A	cg09554077	chr10:44749378	NA	0.87	11.81	0.55	4.65e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10486722	0.583	rs2108174	chr7:41762747	T/C	cg22138096	chr7:41772439	LOC285954	0.39	5.92	0.31	8.24e-9	Pit-and-Fissure caries;
CRC	cis	rs7215564	0.818	rs36034584	chr17:78671478	A/G	cg09596252	chr17:78655493	RPTOR	0.57	6.17	0.32	2.02e-9	Myopia (pathological);
CRC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.6	0.73	3.2e-57	Prudent dietary pattern;
CRC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.07	16.9	0.68	1.41e-46	Testicular germ cell tumor;
CRC	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.83	13.39	0.59	5.99e-33	Alcohol dependence;
CRC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs929596	0.564	rs2741028	chr2:234518914	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.7	-0.3	2.62e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg03804128	chr16:635623	NA	0.31	7.36	0.38	1.53e-12	Height;
CRC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.86	-14.75	-0.63	3.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7215564	0.908	rs2315923	chr17:78693678	A/G	cg09596252	chr17:78655493	RPTOR	0.62	6.6	0.34	1.65e-10	Myopia (pathological);
CRC	cis	rs4757319	0.515	rs7116542	chr11:15436304	A/G	cg03245590	chr11:15329459	NA	0.53	9.19	0.45	4.56e-18	Breast cancer;
CRC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.56	9.13	0.45	7.33e-18	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg02018176	chr4:1364513	KIAA1530	-0.48	-8.17	-0.41	6.61e-15	Obesity-related traits;
CRC	cis	rs6840360	0.642	rs7680236	chr4:152409601	A/G	cg09659197	chr4:152720779	NA	0.33	6.52	0.34	2.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg16898833	chr6:26189333	HIST1H4D	1.12	8.21	0.41	5.22e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.6	7.38	0.38	1.3e-12	Body mass index;
CRC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.5	-8.04	-0.41	1.6e-14	Monocyte count;
CRC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.57	7.66	0.39	2.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.57	-8.31	-0.42	2.46e-15	IgG glycosylation;
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-7.99	-0.4	2.33e-14	Bipolar disorder;
CRC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg05623727	chr3:50126028	RBM5	0.45	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.56	10.26	0.49	1.35e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.46	6.75	0.35	6.5500000000000006e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.78	-0.3	1.76e-8	Ulcerative colitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04270274	chr16:58662988	CNOT1	0.47	6.0	0.31	5.24e-9	Thyroid stimulating hormone;
CRC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg23262073	chr20:60523788	NA	-0.41	-7.0	-0.36	1.49e-11	Body mass index;
CRC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.78	0.39	9.69e-14	Resting heart rate;
CRC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.77	0.3	1.82e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.67	0.39	1.95e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg16482183	chr6:26056742	HIST1H1C	0.73	9.03	0.45	1.46e-17	Iron status biomarkers;
CRC	cis	rs11212617	1.000	rs680113	chr11:108165406	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.16	0.32	2.08e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05447486	chr1:112162367	RAP1A	0.41	6.23	0.32	1.46e-9	Interleukin-6 levels;
CRC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-9.0	-0.44	1.84e-17	Schizophrenia;
CRC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.88	0.4	4.67e-14	Lung cancer;
CRC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg21970626	chr13:21893289	NA	0.42	5.67	0.3	3.18e-8	White matter hyperintensity burden;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg11843238	chr5:131593191	PDLIM4	0.43	7.29	0.37	2.38e-12	Breast cancer;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.44	5.7	0.3	2.61e-8	Intelligence (multi-trait analysis);
CRC	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.53	-10.11	-0.49	4.05e-21	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.81	11.08	0.52	1.81e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg13390004	chr1:15929781	NA	0.43	5.76	0.3	1.92e-8	Systolic blood pressure;
CRC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.07	0.36	9.39e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	10.37	0.5	5.51e-22	Bone mineral density;
CRC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs9462027	0.606	rs205260	chr6:34563958	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.08	-0.32	3.35e-9	Systemic lupus erythematosus;
CRC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.72	-9.39	-0.46	1.07e-18	Vitiligo;
CRC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.57	8.54	0.43	5.08e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.5	8.07	0.41	1.37e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.58	7.89	0.4	4.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg21153622	chr11:89784906	NA	-0.5	-8.43	-0.42	1.09e-15	HDL cholesterol;
CRC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.81	12.34	0.56	5e-29	Cognitive function;
CRC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16767297	chr16:279223	LUC7L	0.45	6.2	0.32	1.69e-9	Anxiety disorder;
CRC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg26805224	chr10:79626177	DLG5	0.55	8.16	0.41	6.95e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	8.94	0.44	2.79e-17	Ulcerative colitis;
CRC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.71	8.47	0.42	8.32e-16	Lung function (FEV1/FVC);
CRC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.65	-9.58	-0.47	2.46e-19	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.1	-0.32	3.02e-9	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	0.43	5.99	0.31	5.49e-9	Response to antipsychotic treatment;
CRC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg23957660	chr17:17878224	LRRC48	0.37	6.48	0.34	3.28e-10	Total body bone mineral density;
CRC	cis	rs4750440	0.706	rs61837399	chr10:14016047	G/A	cg00551146	chr10:14014579	FRMD4A	0.36	5.71	0.3	2.55e-8	Adiponectin levels;
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs7259376	0.905	rs114170435	chr19:22562522	C/A	cg02657401	chr19:22469223	NA	-0.32	-7.01	-0.36	1.35e-11	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05164022	chr11:112160734	NA	0.47	5.96	0.31	6.53e-9	Thyroid stimulating hormone;
CRC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg13072238	chr3:49761600	GMPPB	0.48	5.63	0.3	3.77e-8	Menarche (age at onset);
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg15786705	chr6:28176104	NA	0.54	7.03	0.36	1.23e-11	Parkinson's disease;
CRC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.95	-18.43	-0.71	1.27e-52	Height;
CRC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	8.78	0.44	8.95e-17	Total cholesterol levels;
CRC	cis	rs4727963	0.846	rs1608829	chr7:122707613	A/G	cg03640110	chr7:122635026	TAS2R16	0.33	5.9	0.31	8.95e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.62	13.91	0.61	6.76e-35	Airflow obstruction;
CRC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.24	-0.41	4.19e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20092199	chr4:1342459	KIAA1530	-0.42	-7.71	-0.39	1.54e-13	Obesity-related traits;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg15786705	chr6:28176104	NA	0.62	8.75	0.43	1.12e-16	Cardiac Troponin-T levels;
CRC	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.69	10.69	0.51	4.34e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs863345	0.565	rs59188837	chr1:158500636	C/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	0.93	10.01	0.48	9.11e-21	Atopic dermatitis;
CRC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.63	-0.47	1.7e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.95	11.66	0.54	1.57e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.66	10.9	0.52	7.82e-24	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.85	0.51	1.18e-23	Bipolar disorder;
CRC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.53	9.8	0.48	4.52e-20	Eye color traits;
CRC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	9.14	0.45	6.79e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.31	-0.33	9.2e-10	Aortic root size;
CRC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.42	-5.69	-0.3	2.81e-8	Cognitive function;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21575187	chr5:177558253	RMND5B	0.4	6.03	0.32	4.47e-9	Myopia (pathological);
CRC	trans	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.27	-0.37	2.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg17949981	chr6:28129498	ZNF389	0.4	5.6	0.3	4.43e-8	Cardiac Troponin-T levels;
CRC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.77	0.3	1.79e-8	Lymphocyte counts;
CRC	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg13615338	chr4:55094005	PDGFRA	0.41	5.95	0.31	6.88e-9	Corneal astigmatism;
CRC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	14.55	0.63	2.29e-37	Mean platelet volume;
CRC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-6.98	-0.36	1.68e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04004882	chr2:215674386	BARD1	0.62	7.52	0.38	5.09e-13	Neuroblastoma;
CRC	cis	rs3026101	0.671	rs57406064	chr17:5300183	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg12458913	chr13:53173898	NA	-0.51	-8.14	-0.41	8.23e-15	Lewy body disease;
CRC	cis	rs6977940	0.730	rs11770451	chr7:2887990	G/T	cg19731401	chr7:2775893	GNA12	0.58	5.65	0.3	3.46e-8	White matter integrity;
CRC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.62	9.44	0.46	6.96e-19	Obesity-related traits;
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.05	-0.36	1.03e-11	Total body bone mineral density;
CRC	cis	rs2969070	0.831	rs886627	chr7:2498054	C/T	cg03277898	chr7:2518824	NA	-0.43	-6.21	-0.32	1.57e-9	Diastolic blood pressure;
CRC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.42	-0.33	4.63e-10	Aortic root size;
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.5	7.42	0.38	1.01e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19882132	chr14:106167949	NA	-0.42	-6.26	-0.33	1.23e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00704288	chr1:44172956	ST3GAL3	0.53	7.45	0.38	8.09e-13	Response to antipsychotic treatment;
CRC	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg20041105	chr8:143859282	LYNX1	-0.32	-5.62	-0.3	4.01e-8	Urinary tract infection frequency;
CRC	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.74e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg25547332	chr5:131281432	NA	-0.38	-5.7	-0.3	2.7e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.53	7.43	0.38	9.67e-13	Triglycerides;
CRC	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg01422370	chr2:73384389	NA	0.37	5.68	0.3	3.03e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-5.87	-0.31	1.07e-8	Body mass index;
CRC	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg27534772	chr1:16042836	PLEKHM2	0.42	6.69	0.35	9.69e-11	Systolic blood pressure;
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.34	-7.09	-0.36	8.37e-12	Electroencephalogram traits;
CRC	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.57	9.2	0.45	4.33e-18	Testicular germ cell tumor;
CRC	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.95	-12.85	-0.58	6.88e-31	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs863345	0.625	rs10908655	chr1:158460899	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.07	-0.32	3.49e-9	Pneumococcal bacteremia;
CRC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-9.0	-0.44	1.8e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.96	-0.31	6.54e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.62	-10.29	-0.49	1.04e-21	Schizophrenia;
CRC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.19	0.37	4.51e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg10596483	chr8:143751796	JRK	-0.46	-6.6	-0.34	1.64e-10	Urinary tract infection frequency;
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.49	-6.46	-0.34	3.7e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.77	10.76	0.51	2.48e-23	Heart rate;
CRC	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg03929089	chr4:120376271	NA	0.53	6.36	0.33	6.95e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-15.0	-0.64	3.94e-39	Vitiligo;
CRC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.55	-6.86	-0.35	3.34e-11	Body mass index;
CRC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg11189052	chr15:85197271	WDR73	0.59	8.69	0.43	1.78e-16	Schizophrenia;
CRC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.62	9.6	0.47	2.18e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs73206853	0.841	rs61663407	chr12:111055128	A/G	cg12870014	chr12:110450643	ANKRD13A	0.77	7.23	0.37	3.44e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg23018236	chr17:30244563	NA	0.52	6.72	0.35	7.81e-11	Hip circumference adjusted for BMI;
CRC	cis	rs12044355	0.929	rs6696914	chr1:231853480	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.06	0.32	3.72e-9	Alzheimer's disease;
CRC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.63	-8.31	-0.42	2.57e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11239544	1	rs11239544	chr10:46007533	C/T	cg15590007	chr10:45870220	ALOX5	0.48	6.07	0.32	3.55e-9	Cholesterol, total;
CRC	cis	rs2013441	1.000	rs2013441	chr17:20023099	G/A	cg13482628	chr17:19912719	NA	0.41	6.39	0.33	5.67e-10	Obesity-related traits;
CRC	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg27053337	chr8:124217698	FAM83A	0.46	6.83	0.35	4.1e-11	Urinary uromodulin levels;
CRC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.53	7.96	0.4	2.76e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs13178541	0.551	rs4315919	chr5:135108794	G/A	cg07516956	chr5:134915085	CXCL14	-0.38	-6.63	-0.34	1.39e-10	IgG glycosylation;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.72	11.75	0.54	7.22e-27	Longevity;Endometriosis;
CRC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.94	-0.4	3.18e-14	Bipolar disorder;
CRC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25517755	chr10:38738941	LOC399744	-0.42	-6.03	-0.32	4.45e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.54	8.06	0.41	1.39e-14	Alzheimer's disease (cognitive decline);
CRC	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.78	12.91	0.58	4.1e-31	Alcohol dependence;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg15786705	chr6:28176104	NA	-0.52	-7.31	-0.37	2.07e-12	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.76	-0.39	1.05e-13	Breast cancer;
CRC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6694672	0.850	rs1412632	chr1:197036868	G/A	cg13682187	chr1:196946512	CFHR5	0.48	7.42	0.38	9.89e-13	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16593646	chr5:71616216	PTCD2;MRPS27	0.39	6.54	0.34	2.29e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.95	-0.31	7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.89	-0.51	8.73e-24	Eye color traits;
CRC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.47	6.86	0.35	3.34e-11	Cleft lip with or without cleft palate;
CRC	cis	rs9649465	1.000	rs3958047	chr7:123327936	G/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.15	-0.37	5.83e-12	Total cholesterol levels;
CRC	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.57	7.92	0.4	3.6e-14	Coronary artery disease;
CRC	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.66e-9	Corneal astigmatism;
CRC	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.61	-8.88	-0.44	4.52e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg02466173	chr16:30829666	NA	0.66	9.9	0.48	2.12e-20	Dementia with Lewy bodies;
CRC	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg23254163	chr1:152506842	NA	0.46	9.23	0.45	3.42e-18	Hair morphology;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.59	-8.47	-0.42	8.21e-16	Menopause (age at onset);
CRC	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.54	7.79	0.39	8.71e-14	Primary sclerosing cholangitis;
CRC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.86	16.3	0.67	3.4e-44	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.6	-0.43	3.35e-16	Uric acid levels;
CRC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.78	12.8	0.58	9.92e-31	Coronary artery disease;
CRC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.59	-9.1	-0.45	8.78e-18	Intelligence (multi-trait analysis);
CRC	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg03934865	chr2:198174659	NA	-0.39	-6.0	-0.31	5.32e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg25344623	chr2:136566232	LCT	0.33	5.98	0.31	5.97e-9	Mosquito bite size;
CRC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.68	-0.63	7.19e-38	Height;
CRC	trans	rs6749447	0.848	rs10170391	chr2:169009426	A/C	cg01878807	chr14:24422368	DHRS4;C14orf167	0.4	6.01	0.31	5.04e-9	Blood pressure;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-8.19	-0.41	5.78e-15	Longevity;Endometriosis;
CRC	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg16898833	chr6:26189333	HIST1H4D	0.77	6.42	0.33	4.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs932541	1.000	rs6043989	chr20:16455389	C/G	cg17003395	chr20:16555519	KIF16B	0.41	5.73	0.3	2.25e-8	Intelligence;
CRC	trans	rs1200821	0.704	rs9888115	chr10:37658351	C/T	cg25427524	chr10:38739819	LOC399744	0.42	6.25	0.33	1.25e-9	Hemostatic factors and hematological phenotypes;
CRC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.53	0.54	4.43e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-1.07	-17.84	-0.7	2.94e-50	Blood pressure (smoking interaction);
CRC	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.73	-12.93	-0.58	3.24e-31	Prostate cancer;
CRC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.45	-0.42	9.73e-16	Intelligence (multi-trait analysis);
CRC	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.68	12.89	0.58	4.89e-31	Bone mineral density;
CRC	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs939584	0.825	rs7564708	chr2:639055	T/C	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.67e-8	Body mass index;
CRC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.67	11.91	0.55	2.01e-27	Eye color traits;
CRC	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.81	-13.03	-0.58	1.44e-31	Plateletcrit;Platelet count;
CRC	cis	rs847649	1.000	rs12537977	chr7:102539230	C/T	cg18108683	chr7:102477205	FBXL13	-0.57	-9.16	-0.45	5.71e-18	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.47	7.09	0.36	8.31e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.14	-0.37	5.85e-12	Bipolar disorder;
CRC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.4	-6.76	-0.35	6.24e-11	Blood metabolite levels;
CRC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.66	0.3	3.25e-8	Menarche (age at onset);
CRC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-7.13	-0.37	6.43e-12	Dental caries;
CRC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.97	0.31	6.32e-9	Height;
CRC	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Hypertriglyceridemia;
CRC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg03013999	chr17:37608204	MED1	-0.49	-7.54	-0.38	4.7e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.58	7.75	0.39	1.13e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.39	0.33	5.83e-10	Renal cell carcinoma;
CRC	cis	rs12431939	1.000	rs67113863	chr14:51653103	G/C	cg23942311	chr14:51606299	NA	-0.54	-6.15	-0.32	2.26e-9	Cancer;
CRC	cis	rs972578	1.000	rs9611984	chr22:43408562	C/T	cg01576275	chr22:43409880	NA	-0.46	-7.29	-0.37	2.34e-12	Mean platelet volume;
CRC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.48	5.81	0.31	1.45e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg10756647	chr7:56101905	PSPH	-0.78	-8.05	-0.41	1.55e-14	Diabetic kidney disease;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.45	5.81	0.3	1.51e-8	Intelligence (multi-trait analysis);
CRC	trans	rs800082	0.516	rs9813164	chr3:144227590	A/G	cg24215973	chr2:240111563	HDAC4	0.48	6.65	0.34	1.26e-10	Smoking behavior;
CRC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-12.98	-0.58	2.23e-31	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12841375	chr6:52929709	FBXO9	0.45	6.25	0.33	1.29e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.98	-0.36	1.6e-11	Aortic root size;
CRC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.33	0.37	1.8e-12	Neuroticism;
CRC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.61	8.81	0.44	7.5e-17	Hepatocellular carcinoma;
CRC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.71e-21	Aortic root size;
CRC	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.6	7.82	0.4	7.06e-14	Mammographic density (dense area);
CRC	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.46	0.42	8.61e-16	Corneal astigmatism;
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-6.46	-0.34	3.74e-10	Renal function-related traits (BUN);
CRC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.37	6.31	0.33	9e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.73	11.95	0.55	1.35e-27	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.47	-5.96	-0.31	6.48e-9	DNA methylation (variation);
CRC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.49	6.24	0.33	1.38e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6988985	0.678	rs10087214	chr8:143999726	G/A	cg10324643	chr8:143916377	GML	0.39	6.54	0.34	2.34e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs741668	1.000	rs2806923	chr13:46518570	T/C	cg06018095	chr13:46550134	ZC3H13	-0.4	-5.81	-0.31	1.46e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs12630931	0.798	rs9816495	chr3:31989374	C/G	cg21375017	chr3:31988082	OSBPL10	-0.42	-6.09	-0.32	3.21e-9	Periodontal disease-related phenotypes;
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-0.65	-11.14	-0.52	1.14e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg17948913	chr5:572064	NA	0.55	6.33	0.33	7.93e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.14	-0.37	6.2e-12	Red blood cell count;
CRC	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg27398640	chr15:77910606	LINGO1	0.44	7.39	0.38	1.19e-12	Type 2 diabetes;
CRC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.39	-6.99	-0.36	1.54e-11	Reticulocyte fraction of red cells;
CRC	cis	rs1105228	0.921	rs479273	chr6:165715006	A/G	cg20535254	chr6:165714960	C6orf118	0.29	5.99	0.31	5.56e-9	Number of pregnancies;Number of children;
CRC	cis	rs4731207	0.596	rs12111660	chr7:124584795	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.12	-11.64	-0.54	1.86e-26	Atopic dermatitis;
CRC	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg00603274	chr11:61596626	FADS2	-0.44	-6.31	-0.33	9.15e-10	Trans fatty acid levels;
CRC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg06145435	chr7:1022769	CYP2W1	0.4	5.67	0.3	3.13e-8	Bronchopulmonary dysplasia;
CRC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.82	11.39	0.53	1.41e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.48	7.23	0.37	3.49e-12	Menopause (age at onset);
CRC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.66	6.47	0.34	3.48e-10	Plasma clusterin levels;
CRC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg23996704	chr18:44553084	KATNAL2	0.4	7.81	0.4	7.66e-14	Personality dimensions;
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.59	0.39	3.29e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.45	7.49	0.38	6.26e-13	Type 2 diabetes;
CRC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.22e-13	QT interval;
CRC	cis	rs4731207	0.698	rs4728011	chr7:124481712	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.51	10.13	0.49	3.65e-21	Renal cell carcinoma;
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.57	-0.34	1.94e-10	Lymphocyte counts;
CRC	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.79	0.44	8.21e-17	Coffee consumption (cups per day);
CRC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.85	0.4	5.97e-14	Plateletcrit;
CRC	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.68	7.94	0.4	3.27e-14	Phospholipid levels (plasma);
CRC	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg25019722	chr6:37503610	NA	-0.38	-6.69	-0.35	9.34e-11	Cognitive performance;
CRC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.44	-6.73	-0.35	7.72e-11	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06080793	chr6:1625457	GMDS	0.22	6.16	0.32	2.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg25164649	chr6:28176230	NA	0.59	8.37	0.42	1.63e-15	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07688604	chr12:133065928	FBRSL1	0.45	6.24	0.33	1.38e-9	Anxiety disorder;
CRC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.19	-0.32	1.77e-9	Alzheimer's disease (late onset);
CRC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.71	10.85	0.51	1.23e-23	Corneal astigmatism;
CRC	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.7	0.47	1.01e-19	Corneal astigmatism;
CRC	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg00086871	chr4:6988644	TBC1D14	1.01	7.58	0.39	3.49e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.59	7.73	0.39	1.3e-13	RR interval (heart rate);
CRC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.67	0.34	1.11e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.43	0.38	9.25e-13	Motion sickness;
CRC	trans	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.71	11.6	0.54	2.58e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.18	-17.36	-0.69	2.24e-48	Hip circumference adjusted for BMI;
CRC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.49	-8.0	-0.4	2.15e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.61	9.08	0.45	1.01e-17	Methadone dose in opioid dependence;
CRC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.6	10.33	0.49	7.46e-22	Body mass index;
CRC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg14541582	chr5:601475	NA	-0.33	-6.59	-0.34	1.73e-10	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11907102	chr2:201936469	NDUFB3;FAM126B	0.44	6.17	0.32	2.03e-9	Response to antipsychotic treatment;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20470467	chr16:30886130	NA	-0.41	-5.98	-0.31	5.71e-9	Daytime sleep phenotypes;
CRC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg03233332	chr7:66118400	NA	0.44	6.14	0.32	2.44e-9	Aortic root size;
CRC	cis	rs282587	0.569	rs408826	chr13:113415268	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.72	0.39	1.37e-13	Glycated hemoglobin levels;
CRC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.98	-0.4	2.38e-14	Hemoglobin concentration;
CRC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.6	-6.36	-0.33	6.71e-10	Schizophrenia;
CRC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Bladder cancer;
CRC	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.41	-6.38	-0.33	6.17e-10	Recombination rate (males);
CRC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-17.0	-0.68	5.6e-47	Height;
CRC	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg11130432	chr3:121712080	ILDR1	-0.47	-5.86	-0.31	1.12e-8	Multiple sclerosis;
CRC	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.49	8.03	0.4	1.73e-14	Coronary artery disease;
CRC	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg15083037	chr5:83017644	HAPLN1	-0.53	-6.88	-0.35	3.06e-11	Prostate cancer;
CRC	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg21851534	chr17:3907994	ZZEF1	0.38	6.7	0.35	9.06e-11	Type 2 diabetes;
CRC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.51	7.7	0.39	1.59e-13	Morning vs. evening chronotype;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg21208545	chr3:11851506	C3orf31	-0.53	-6.02	-0.31	4.53e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs7527798	0.637	rs7515149	chr1:207838352	T/G	cg09232269	chr1:207846808	CR1L	-0.53	-8.62	-0.43	2.78e-16	Erythrocyte sedimentation rate;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg12963866	chr19:57752005	ZNF805	-0.41	-6.01	-0.31	4.96e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.68	12.48	0.57	1.58e-29	Hip circumference;
CRC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	6.76	0.35	6.43e-11	Platelet count;
CRC	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.48	7.55	0.38	4.35e-13	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09033691	chr11:10829409	EIF4G2	0.44	6.64	0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.07	-0.32	3.43e-9	Diabetic kidney disease;
CRC	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06544989	chr22:39130855	UNC84B	-0.44	-6.75	-0.35	6.76e-11	Menopause (age at onset);
CRC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg11608241	chr8:8085544	FLJ10661	0.39	5.74	0.3	2.17e-8	Mood instability;
CRC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.2	-0.45	4.16e-18	Subjective well-being;
CRC	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.6e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.24e-37	Hypertriglyceridemia;
CRC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.42	7.13	0.37	6.33e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.33	-0.46	1.65e-18	Joint mobility (Beighton score);
CRC	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg02023728	chr11:77925099	USP35	-0.36	-6.06	-0.32	3.72e-9	Alzheimer's disease (survival time);
CRC	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg09127314	chr1:152161683	NA	0.49	6.28	0.33	1.07e-9	Atopic dermatitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04244535	chr14:23236155	OXA1L	0.48	7.02	0.36	1.26e-11	Intelligence (multi-trait analysis);
CRC	trans	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.67	-0.39	1.92e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.08	0.32	3.39e-9	Morning vs. evening chronotype;
CRC	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg26741380	chr15:41871084	TYRO3	-0.41	-6.22	-0.32	1.49e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.57	-9.38	-0.46	1.09e-18	Neuroticism;
CRC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg02023728	chr11:77925099	USP35	-0.34	-5.77	-0.3	1.84e-8	Alzheimer's disease (survival time);
CRC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.67	11.47	0.53	7.77e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs754466	0.561	rs67332822	chr10:79706118	G/A	cg17075019	chr10:79541650	NA	-0.6	-6.8	-0.35	4.82e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.4	7.69	0.39	1.74e-13	Subjective well-being;
CRC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.7	-0.3	2.71e-8	Monocyte percentage of white cells;
CRC	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-8.67	-0.43	1.93e-16	HDL cholesterol;
CRC	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.85	-0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.62	7.61	0.39	2.98e-13	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.99	-0.4	2.25e-14	Gut microbiome composition (summer);
CRC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	7.47	0.38	7.06e-13	Aortic root size;
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.48	6.75	0.35	6.74e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23463467	chr20:60627584	TAF4	0.36	6.39	0.33	5.67e-10	Body mass index;
CRC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.98	0.4	2.45e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs447	0.887	rs6467988	chr7:83756500	C/T	cg22846510	chr7:83753280	SEMA3A	-0.61	-7.79	-0.39	8.85e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.68	-9.96	-0.48	1.31e-20	Blood protein levels;
CRC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.46	6.14	0.32	2.35e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg21523564	chr15:75251491	NA	0.42	6.12	0.32	2.65e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4654899	0.931	rs1152998	chr1:21124290	C/T	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.87	-0.35	3.24e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg03623178	chr6:28175578	NA	0.81	11.99	0.55	1.02e-27	Cardiac Troponin-T levels;
CRC	trans	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg18335740	chr13:41363409	SLC25A15	-0.5	-7.84	-0.4	6.12e-14	Lewy body disease;
CRC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg10494257	chr1:16342123	HSPB7	0.45	6.0	0.31	5.3e-9	Dilated cardiomyopathy;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.22	-0.56	1.48e-28	Alzheimer's disease;
CRC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09740319	chr1:231004641	C1orf198	0.48	7.01	0.36	1.38e-11	Intelligence (multi-trait analysis);
CRC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg00603274	chr11:61596626	FADS2	-0.56	-7.53	-0.38	4.9e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.62	9.35	0.46	1.43e-18	Breast cancer;
CRC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.45	7.22	0.37	3.72e-12	Menopause (age at onset);
CRC	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.1	-15.04	-0.64	2.83e-39	Exhaled nitric oxide output;
CRC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.56	7.12	0.37	6.76e-12	Morning vs. evening chronotype;
CRC	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg14631576	chr9:95140430	CENPP	-0.41	-7.34	-0.37	1.73e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg23093090	chr10:104574429	C10orf26	0.4	6.74	0.35	7.25e-11	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.71	-0.3	2.47e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.47	6.69	0.35	9.37e-11	Morning vs. evening chronotype;
CRC	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg08501292	chr6:25962987	TRIM38	0.84	7.97	0.4	2.63e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg17469321	chr7:55412551	NA	0.71	10.69	0.51	4.22e-23	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3790455	0.610	rs1171548	chr1:156471998	G/T	cg14087168	chr1:156450669	MEF2D	-0.35	-5.89	-0.31	9.79e-9	Migraine;
CRC	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.82	13.1	0.59	7.63e-32	Testicular germ cell tumor;
CRC	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.87	-0.35	3.28e-11	Neuroticism;
CRC	cis	rs4711350	0.862	rs487835	chr6:33710933	G/A	cg07979401	chr6:33739406	LEMD2	0.48	6.0	0.31	5.1e-9	Schizophrenia;
CRC	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.75	9.36	0.46	1.31e-18	Type 2 diabetes;
CRC	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.47	-6.58	-0.34	1.88e-10	Pulmonary function decline;
CRC	cis	rs12760731	0.565	rs2095133	chr1:178198612	C/G	cg00404053	chr1:178313656	RASAL2	1.05	10.9	0.52	7.84e-24	Obesity-related traits;
CRC	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg20542592	chr8:11973495	FAM66D	0.32	5.69	0.3	2.76e-8	Retinal vascular caliber;
CRC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.76	0.3	1.92e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.71	-9.11	-0.45	7.97e-18	Psoriasis;
CRC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.48	6.9	0.36	2.75e-11	Lymphocyte counts;
CRC	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14470647	chr9:107690075	ABCA1	0.38	5.7	0.3	2.62e-8	Intraocular pressure;
CRC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg20203395	chr5:56204925	C5orf35	0.4	5.65	0.3	3.49e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.16	-0.37	5.33e-12	Self-reported allergy;
CRC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.45	-6.35	-0.33	7.09e-10	DNA methylation (variation);
CRC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.65	9.5	0.46	4.35e-19	Menopause (age at onset);
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.13	-0.45	7.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg22777020	chr22:31556080	RNF185	0.54	6.3	0.33	9.52e-10	Colorectal cancer;
CRC	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-8.23	-0.41	4.41e-15	Subjective well-being;
CRC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg10911889	chr6:126070802	HEY2	0.39	5.94	0.31	7.15e-9	Brugada syndrome;
CRC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg03233332	chr7:66118400	NA	0.43	5.98	0.31	5.79e-9	Aortic root size;
CRC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24308560	chr3:49941425	MST1R	-0.41	-6.3	-0.33	9.49e-10	Body mass index;
CRC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs12760731	0.582	rs9803679	chr1:178410425	T/C	cg00404053	chr1:178313656	RASAL2	0.75	9.35	0.46	1.4e-18	Obesity-related traits;
CRC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	16.33	0.67	2.62e-44	Lymphocyte percentage of white cells;
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.56	-7.93	-0.4	3.35e-14	Alzheimer's disease;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg15786705	chr6:28176104	NA	0.81	11.6	0.54	2.52e-26	Depression;
CRC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.66	-8.52	-0.43	5.76e-16	Mean platelet volume;
CRC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg25174290	chr11:3078921	CARS	-0.42	-5.77	-0.3	1.87e-8	Calcium levels;
CRC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.57	6.18	0.32	1.9e-9	Initial pursuit acceleration;
CRC	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.48	-8.85	-0.44	5.68e-17	Hip circumference;Waist circumference;
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.65e-9	Bipolar disorder;
CRC	cis	rs868943	0.554	rs34362666	chr6:116472705	C/T	cg15226275	chr6:116381976	FRK	0.26	6.08	0.32	3.33e-9	Total cholesterol levels;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.53	8.07	0.41	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.2	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.87	-0.35	3.27e-11	HDL cholesterol;
CRC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.58	-0.39	3.51e-13	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg25164649	chr6:28176230	NA	0.77	9.56	0.47	2.78e-19	Depression;
CRC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.86	13.26	0.59	1.98e-32	Multiple sclerosis;
CRC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-13.53	-0.6	1.77e-33	Blood metabolite levels;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26894523	chr4:107725	ZNF718	0.27	6.41	0.33	4.98e-10	Myopia (pathological);
CRC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg24375607	chr4:120327624	NA	0.47	7.15	0.37	5.66e-12	Corneal astigmatism;
CRC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.69	10.57	0.5	1.09e-22	Corneal astigmatism;
CRC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.52	-8.11	-0.41	1e-14	Total body bone mineral density;
CRC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg26893134	chr6:116381904	FRK	0.26	7.6	0.39	3.03e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.47	-0.38	7.21e-13	Headache;
CRC	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.91	10.96	0.52	4.99e-24	Neuroticism (multi-trait analysis);Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21890848	chr21:27107814	ATP5J;GABPA	0.39	6.35	0.33	7.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.7	9.17	0.45	5.23e-18	Alzheimer's disease;
CRC	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.65	-9.12	-0.45	7.48e-18	Autism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10989441	chr1:231347308	TRIM67	0.52	7.4	0.38	1.17e-12	Response to antipsychotic treatment;
CRC	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4731207	0.596	rs6466963	chr7:124572288	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.57	-9.94	-0.48	1.57e-20	Iron status biomarkers;
CRC	cis	rs17713451	0.593	rs79901758	chr7:151268963	A/G	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01626569	chr16:20911881	LYRM1;DCUN1D3	0.39	6.24	0.33	1.34e-9	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14706579	chr2:203736710	ICA1L	0.39	5.99	0.31	5.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.43	-6.4	-0.33	5.39e-10	Body mass index;
CRC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.63	-6.96	-0.36	1.9e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.73	9.2	0.45	4.16e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.87	12.21	0.56	1.52e-28	Triglycerides;
CRC	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.51	6.22	0.32	1.49e-9	Bipolar disorder;
CRC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.49e-10	Melanoma;
CRC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.63	-0.47	1.66e-19	Morning vs. evening chronotype;
CRC	cis	rs2013441	1.000	rs2703818	chr17:20119976	T/A	cg13482628	chr17:19912719	NA	-0.41	-6.45	-0.34	3.99e-10	Obesity-related traits;
CRC	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg00495681	chr13:53174319	NA	0.56	7.34	0.38	1.69e-12	Lewy body disease;
CRC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.47	-7.08	-0.36	8.67e-12	Colorectal cancer;
CRC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.43	5.81	0.31	1.44e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg16447950	chr5:562315	NA	-0.81	-10.62	-0.51	7.76e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs6735179	0.755	rs13421140	chr2:1774009	C/T	cg26137290	chr2:1776737	NA	-0.45	-5.98	-0.31	5.93e-9	Response to antipsychotic treatment;
CRC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.41	-5.91	-0.31	8.61e-9	Temperament;
CRC	cis	rs10229583	0.527	rs73450923	chr7:127305809	G/C	cg01233922	chr7:127693937	SND1	-0.47	-7.09	-0.36	8.25e-12	Type 2 diabetes;
CRC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg00074818	chr8:8560427	CLDN23	0.4	7.2	0.37	4.04e-12	Obesity-related traits;
CRC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10284973	chr10:77163397	C10orf41	0.49	6.27	0.33	1.1e-9	Migraine with aura;
CRC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.62	-9.42	-0.46	8.2e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.81e-8	Major depressive disorder;
CRC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.8e-16	Eye color traits;
CRC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.35	-5.81	-0.3	1.49e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2333194	0.772	rs8009466	chr14:73832313	C/T	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.39	-5.83	-0.31	1.33e-8	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs7781266	0.790	rs62472378	chr7:133108979	T/C	cg03336402	chr7:133662267	EXOC4	0.49	5.81	0.3	1.5e-8	Educational attainment (college completion);
CRC	trans	rs10504390	0.519	rs75342066	chr8:66644963	T/G	cg26403416	chr21:43771339	TFF2	0.53	6.04	0.32	4.25e-9	IgG glycosylation;
CRC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg05896524	chr21:47604654	C21orf56	0.46	6.9	0.36	2.73e-11	Testicular germ cell tumor;
CRC	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.84	-12.52	-0.57	1.11e-29	Blood metabolite levels;
CRC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.9	12.86	0.58	6.12e-31	Breast cancer;
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg08200582	chr11:442649	ANO9	-0.68	-7.63	-0.39	2.56e-13	Body mass index;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16925090	chr11:101785516	KIAA1377;ANGPTL5	-0.5	-6.27	-0.33	1.13e-9	Diisocyanate-induced asthma;
CRC	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20848291	chr7:100343083	ZAN	0.48	7.44	0.38	9.12e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.6	0.43	3.33e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.76	10.26	0.49	1.32e-21	Platelet count;
CRC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23463467	chr20:60627584	TAF4	0.34	5.71	0.3	2.49e-8	Body mass index;
CRC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.82	13.33	0.59	1e-32	Menopause (age at onset);
CRC	cis	rs17767392	0.881	rs35866366	chr14:71849185	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.48	-6.12	-0.32	2.72e-9	Mitral valve prolapse;
CRC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-6.07	-0.32	3.55e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.77	9.64	0.47	1.6e-19	Obesity-related traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23104227	chr2:70781287	TGFA	0.39	6.15	0.32	2.25e-9	Schizophrenia;
CRC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.56	-0.43	4.4e-16	Chronic sinus infection;
CRC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.31	-0.46	1.84e-18	Aortic root size;
CRC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg26762873	chr11:5879799	OR52E8	-0.48	-7.25	-0.37	2.95e-12	DNA methylation (variation);
CRC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.48	-7.44	-0.38	8.69e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9992667	0.910	rs10019144	chr4:38686405	C/T	cg19726192	chr4:38663646	FLJ13197	-0.68	-8.78	-0.44	9.27e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg21972741	chr5:435613	AHRR	0.56	7.66	0.39	2.03e-13	Cystic fibrosis severity;
CRC	cis	rs4731207	0.698	rs7782340	chr7:124506025	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18591801	chr3:52553433	STAB1	-0.32	-6.15	-0.32	2.21e-9	Electroencephalogram traits;
CRC	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.56	9.58	0.47	2.43e-19	Dupuytren's disease;
CRC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg18479299	chr3:125709523	NA	-0.55	-6.58	-0.34	1.86e-10	Blood pressure (smoking interaction);
CRC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.35	0.33	7.03e-10	Height;
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.46	6.84	0.35	3.9e-11	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03543731	chr15:50474621	SLC27A2	0.45	6.3	0.33	9.73e-10	Response to antipsychotic treatment;
CRC	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.91	-17.05	-0.68	3.72e-47	Longevity;
CRC	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg17885191	chr8:135476712	NA	0.53	7.27	0.37	2.61e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.85	-0.4	6.1e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-12.06	-0.55	5.5e-28	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.1	-0.32	3.03e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg12463550	chr7:65579703	CRCP	0.65	6.2	0.32	1.67e-9	Diabetic kidney disease;
CRC	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg22561889	chr6:118971681	C6orf204	0.44	6.1	0.32	2.9e-9	Renal cell carcinoma;
CRC	trans	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.56	0.38	3.95e-13	Endometrial cancer;
CRC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg24585782	chr17:78113791	EIF4A3	-0.52	-7.11	-0.37	7.06e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.63	0.34	1.38e-10	Mean corpuscular volume;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.53e-18	Parkinson's disease;
CRC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.21	-0.32	1.56e-9	Bipolar disorder;
CRC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.8	14.61	0.63	1.34e-37	Anterior chamber depth;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg12273811	chr6:28175739	NA	0.54	7.59	0.39	3.36e-13	Parkinson's disease;
CRC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.76	-9.41	-0.46	9.04e-19	Initial pursuit acceleration;
CRC	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg13491945	chr12:107078410	RFX4	0.36	6.16	0.32	2.18e-9	Heart rate;
CRC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.66	10.92	0.52	6.95e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs1515182	chr2:162436934	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.01	-0.31	4.93e-9	Cognitive function;
CRC	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.34	5.74	0.3	2.12e-8	Menopause (age at onset);
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.37	-6.07	-0.32	3.43e-9	Total body bone mineral density;
CRC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.49	-0.34	3.23e-10	Breast cancer;
CRC	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.85	-0.31	1.16e-8	Height;
CRC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-7.69	-0.39	1.73e-13	Aortic root size;
CRC	cis	rs1223397	0.651	rs2496145	chr6:13312293	C/T	cg07912922	chr6:13274314	PHACTR1	-0.38	-5.97	-0.31	6.18e-9	Blood pressure;
CRC	cis	rs9463078	0.677	rs6458423	chr6:45140645	C/T	cg25276700	chr6:44698697	NA	-0.24	-5.91	-0.31	8.45e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.55	8.26	0.41	3.58e-15	Blood protein levels;
CRC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg21770322	chr7:97807741	LMTK2	-0.49	-8.0	-0.4	2.19e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.59	8.49	0.42	7.05e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg19223190	chr17:80058835	NA	-0.46	-7.35	-0.38	1.57e-12	Life satisfaction;
CRC	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.4	6.78	0.35	5.49e-11	Schizophrenia;
CRC	cis	rs4684776	0.676	rs35975472	chr3:11292653	T/G	cg00170343	chr3:11313890	ATG7	-0.5	-5.89	-0.31	9.55e-9	Small vessel stroke;
CRC	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.49	7.86	0.4	5.42e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.47	6.98	0.36	1.61e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-10.52	-0.5	1.63e-22	Longevity;Endometriosis;
CRC	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.43	0.33	4.43e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.03	9.91	0.48	2.04e-20	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07572592	chr17:73937177	FBF1	0.44	6.1	0.32	2.91e-9	Response to antipsychotic treatment;
CRC	trans	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg20935933	chr6:143382018	AIG1	0.52	6.73	0.35	7.57e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.5	8.01	0.4	1.96e-14	Calcium levels;
CRC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg10298567	chr3:47292165	KIF9	0.37	6.05	0.32	3.93e-9	Colorectal cancer;
CRC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12292205	chr6:26970375	C6orf41	0.5	6.73	0.35	7.65e-11	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18724032	chr3:171758176	FNDC3B	-0.37	-6.16	-0.32	2.11e-9	Myopia (pathological);
CRC	cis	rs3101457	0.515	rs4658628	chr1:244516090	T/C	cg09033006	chr1:244517177	C1orf100	-0.44	-6.26	-0.33	1.2e-9	Smoking behavior;
CRC	cis	rs713477	0.505	rs4901561	chr14:55888578	T/C	cg13175173	chr14:55914753	NA	-0.46	-7.3	-0.37	2.24e-12	Pediatric bone mineral content (femoral neck);
CRC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.1	13.26	0.59	1.87e-32	Sexual dysfunction (female);
CRC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.42	6.63	0.34	1.36e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.77	-0.39	1e-13	HDL cholesterol;
CRC	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs6961069	0.806	rs11770907	chr7:80258630	G/A	cg04458919	chr7:80252533	CD36	0.34	5.98	0.31	5.72e-9	Platelet count;
CRC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg26248373	chr2:1572462	NA	-0.66	-7.19	-0.37	4.36e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.45	-6.59	-0.34	1.7e-10	Height;
CRC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.47	-7.02	-0.36	1.24e-11	Obesity-related traits;
CRC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.56	9.42	0.46	8.08e-19	Schizophrenia;
CRC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.65	-8.86	-0.44	5.21e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.76	-9.59	-0.47	2.32e-19	Monocyte percentage of white cells;
CRC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.58	10.59	0.5	9.48e-23	Aortic root size;
CRC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg14825688	chr5:132208181	LEAP2	-0.38	-5.91	-0.31	8.62e-9	Apolipoprotein A-IV levels;
CRC	trans	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg01134436	chr17:81009848	B3GNTL1	0.72	6.57	0.34	1.97e-10	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg11887960	chr12:57824829	NA	0.59	6.68	0.35	1.01e-10	Obesity-related traits;
CRC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.15	14.73	0.63	4.62e-38	Uric acid levels;
CRC	cis	rs11679072	1.000	rs56986149	chr2:240450869	T/G	cg03276489	chr2:240449683	NA	-0.91	-8.95	-0.44	2.69e-17	Blood pressure (smoking interaction);
CRC	cis	rs7932354	0.583	rs10742784	chr11:46899282	G/A	cg19486271	chr11:47235900	DDB2	-0.42	-6.35	-0.33	7.28e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg27205649	chr11:78285834	NARS2	0.51	6.59	0.34	1.76e-10	Alzheimer's disease (survival time);
CRC	cis	rs4700695	0.841	rs152994	chr5:65262989	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.49	9.71	0.47	9.45e-20	Renal cell carcinoma;
CRC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.41	-7.19	-0.37	4.36e-12	Hepatitis;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.05	-0.32	4.02e-9	Cognitive function;
CRC	trans	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg09872104	chr7:134855509	C7orf49	-0.87	-8.4	-0.42	1.33e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.46	6.64	0.34	1.33e-10	Schizophrenia;
CRC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.35	6.26	0.33	1.2e-9	Alopecia areata;
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.29	-0.33	1.02e-9	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04565464	chr8:145669602	NFKBIL2	0.41	6.68	0.35	9.97e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	1.99e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	0.67	10.89	0.51	8.9e-24	Cognitive test performance;
CRC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.42	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
CRC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.64	-9.5	-0.46	4.39e-19	Acne (severe);
CRC	cis	rs17065868	0.764	rs9533864	chr13:45037165	A/G	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs501120	0.564	rs12415866	chr10:44686664	A/G	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg10729496	chr3:10149963	C3orf24	-0.5	-5.96	-0.31	6.38e-9	Alzheimer's disease;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg20512303	chr5:131592959	PDLIM4	0.38	7.0	0.36	1.45e-11	Blood metabolite levels;
CRC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg02421172	chr7:1938701	MAD1L1	0.43	5.87	0.31	1.09e-8	Bipolar disorder;
CRC	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.51	-6.0	-0.31	5.31e-9	Prion diseases;
CRC	cis	rs501120	0.564	rs11238907	chr10:44687780	T/G	cg09554077	chr10:44749378	NA	0.5	6.86	0.35	3.5e-11	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg21466736	chr12:48725269	NA	0.46	7.12	0.37	6.72e-12	Glycated hemoglobin levels;
CRC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg11887960	chr12:57824829	NA	0.58	6.45	0.34	3.94e-10	Lung disease severity in cystic fibrosis;
CRC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.69	8.15e-49	Height;
CRC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.39	6.09	0.32	3.22e-9	Crohn's disease;
CRC	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.23	0.37	3.41e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.32	0.42	2.37e-15	Rheumatoid arthritis;
CRC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.09	-0.32	3.22e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs17092148	0.887	rs2889849	chr20:33164277	A/G	cg08999081	chr20:33150536	PIGU	0.48	5.92	0.31	8.25e-9	Neuroticism;
CRC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.48	6.46	0.34	3.79e-10	Methadone dose in opioid dependence;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg07121733	chr10:123734241	NSMCE4A	0.38	6.07	0.32	3.56e-9	Myopia;
CRC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.86	-14.62	-0.63	1.26e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.06e-32	Vitiligo;
CRC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg17724175	chr1:150552817	MCL1	-0.52	-8.46	-0.42	8.99e-16	Tonsillectomy;
CRC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.26	-0.33	1.17e-9	Type 2 diabetes;
CRC	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.47	0.67	7.29e-45	Electrocardiographic conduction measures;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.68	0.3	2.9e-8	Depression;
CRC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.06e-32	Vitiligo;
CRC	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg07423050	chr13:99094983	FARP1	-0.57	-8.05	-0.41	1.53e-14	Neuroticism;
CRC	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg15382696	chr6:118971807	C6orf204	0.59	7.43	0.38	9.32e-13	Diastolic blood pressure;
CRC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.42	-9.13	-0.45	7.24e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg18709589	chr6:96969512	KIAA0776	-0.48	-6.8	-0.35	5.03e-11	Headache;
CRC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.47	-6.54	-0.34	2.29e-10	Platelet distribution width;
CRC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.62	-12.2	-0.56	1.65e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Depression;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg04053776	chr11:6947353	ZNF215	0.49	6.56	0.34	2.12e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6834538	0.894	rs34712587	chr4:113485894	A/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.46	-6.46	-0.34	3.69e-10	Free thyroxine concentration;
CRC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.71	0.39	1.51e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.79	0.39	8.88e-14	Menopause (age at onset);
CRC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.48	-9.16	-0.45	5.86e-18	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg21153622	chr11:89784906	NA	-0.44	-7.1	-0.36	7.56e-12	HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08451598	chr22:50220343	NA	0.45	6.09	0.32	3.19e-9	Anxiety disorder;
CRC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.47	7.06	0.36	9.72e-12	Testicular germ cell tumor;
CRC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.52	-8.46	-0.42	8.8e-16	Testicular germ cell tumor;
CRC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.72	11.38	0.53	1.64e-25	Colorectal cancer;
CRC	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg02398342	chr17:80708632	TBCD;FN3K	-0.6	-6.82	-0.35	4.25e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs3760982	1.000	rs4803658	chr19:44290013	T/A	cg11993925	chr19:44307056	LYPD5	0.47	7.72	0.39	1.4e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg04586622	chr2:25135609	ADCY3	-0.53	-9.82	-0.48	4.06e-20	Body mass index;
CRC	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg08795948	chr3:128337044	NA	0.35	6.09	0.32	3.15e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.61	10.78	0.51	2.14e-23	Immature fraction of reticulocytes;
CRC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg01483505	chr11:975446	AP2A2	-0.38	-5.69	-0.3	2.78e-8	Alzheimer's disease (late onset);
CRC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg16141378	chr3:129829833	LOC729375	0.41	5.99	0.31	5.62e-9	Myopia (pathological);
CRC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.6	-0.34	1.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.71	8.88	0.44	4.56e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.13	22.84	0.78	7.36e-70	Schizophrenia;
CRC	trans	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg10756647	chr7:56101905	PSPH	0.74	7.77	0.39	9.91e-14	Diabetic kidney disease;
CRC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.58	0.39	3.45e-13	Lung cancer in ever smokers;
CRC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.38	-0.33	6.11e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs12495832	0.778	rs56270789	chr3:147912859	G/A	cg10221266	chr7:153579447	NA	0.57	6.17	0.32	2.05e-9	Chin dimples;
CRC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg23461800	chr14:103021989	NA	-0.71	-8.08	-0.41	1.28e-14	Platelet count;
CRC	cis	rs7849270	1.000	rs7869804	chr9:131913144	C/T	cg13538475	chr9:131942899	NA	-0.29	-5.75	-0.3	2e-8	Blood metabolite ratios;
CRC	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.51	6.06	0.32	3.72e-9	Renal function-related traits (BUN);
CRC	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.49	7.5	0.38	6.06e-13	Corneal astigmatism;
CRC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-9.18	-0.45	5.01e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10208940	0.920	rs13417100	chr2:68821725	C/T	cg12452813	chr2:68675892	NA	-0.45	-5.64	-0.3	3.75e-8	Urate levels in lean individuals;
CRC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.72	0.35	7.79e-11	Dupuytren's disease;
CRC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg19980929	chr12:42632907	YAF2	0.42	6.35	0.33	7.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7104764	0.507	rs7121085	chr11:258523	A/G	cg00562011	chr11:252351	PSMD13	-0.54	-6.33	-0.33	8.18e-10	Menarche (age at onset);
CRC	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.98	17.95	0.7	1.01e-50	Gut microbiome composition (winter);
CRC	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg09873164	chr1:152488093	CRCT1	0.38	6.34	0.33	7.77e-10	Hair morphology;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01334186	chr1:151372572	PSMB4	0.53	7.06	0.36	9.77e-12	Thyroid stimulating hormone;
CRC	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-11.28	-0.53	3.66e-25	Exhaled nitric oxide output;
CRC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.46	-0.38	7.89e-13	Morning vs. evening chronotype;
CRC	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.13	-0.37	6.55e-12	Type 2 diabetes;
CRC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.29	0.46	2.14e-18	Cognitive test performance;
CRC	cis	rs2084637	1.000	rs11605335	chr11:122390754	C/A	cg21585512	chr11:122030076	LOC399959	-0.38	-6.74	-0.35	7e-11	Stroke;
CRC	cis	rs7605827	0.930	rs4668918	chr2:15661992	A/T	cg19274914	chr2:15703543	NA	0.39	5.91	0.31	8.66e-9	Educational attainment (years of education);
CRC	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.12	17.34	0.69	2.69e-48	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.58	-5.85	-0.31	1.18e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-7.77	-0.39	1.01e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg23136738	chr11:925521	AP2A2	-0.43	-7.2	-0.37	4.09e-12	Alzheimer's disease (late onset);
CRC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg02421172	chr7:1938701	MAD1L1	0.44	6.0	0.31	5.23e-9	Bipolar disorder;
CRC	cis	rs62007496	0.520	rs73358643	chr14:103612707	C/T	cg09274347	chr14:103599552	TNFAIP2	0.54	5.81	0.31	1.45e-8	Language performance in older adults (adjusted for episodic memory);
CRC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.3	6.41	0.33	5.02e-10	Diastolic blood pressure;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22944662	chr1:178062847	LOC100302401;RASAL2	0.34	6.16	0.32	2.08e-9	Obesity-related traits;
CRC	trans	rs2294025	0.833	rs4736434	chr8:134121121	C/T	cg19857114	chr3:176741225	TBL1XR1	-0.38	-6.06	-0.32	3.68e-9	Graves' disease;
CRC	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.35	5.62	0.3	4.17e-8	Height;
CRC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.51	-8.07	-0.41	1.37e-14	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12273811	chr6:28175739	NA	0.71	9.2	0.45	4.28e-18	Depression;
CRC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg00383909	chr3:49044727	WDR6	0.46	5.63	0.3	3.86e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17377491	chr11:112096999	PTS	0.47	6.64	0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg24560729	chr4:1342394	KIAA1530	0.41	6.78	0.35	5.57e-11	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23629415	chr14:54955474	GMFB	0.41	6.04	0.32	4.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12618769	0.652	rs3754877	chr2:99184019	A/G	cg18455616	chr2:99124870	INPP4A	0.36	5.83	0.31	1.31e-8	Bipolar disorder;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg15845792	chr6:28175446	NA	0.51	5.92	0.31	8.03e-9	Breast cancer;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00802000	chr16:706648	WDR90	-0.43	-6.31	-0.33	9.1e-10	Height;
CRC	cis	rs12534701	1.000	rs13232266	chr7:154681363	A/T	cg24255201	chr7:154684926	DPP6	0.58	8.38	0.42	1.53e-15	Colorectal cancer (diet interaction);
CRC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	11.11	0.52	1.48e-24	Motion sickness;
CRC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.56	-7.53	-0.38	4.95e-13	Schizophrenia;
CRC	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg13736514	chr6:26305472	NA	-0.36	-6.17	-0.32	1.99e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	13.49	0.6	2.5e-33	Menopause (age at onset);
CRC	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg25797454	chr6:150327115	RAET1K	0.36	6.22	0.32	1.49e-9	Alopecia areata;
CRC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.95	-0.4	2.96e-14	Gut microbiome composition (summer);
CRC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	6.15	0.32	2.25e-9	Menarche (age at onset);
CRC	cis	rs4654899	0.772	rs12145203	chr1:21086127	C/T	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.22	-0.37	3.74e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.67	-9.87	-0.48	2.79e-20	Multiple myeloma;
CRC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg00246817	chr9:123691163	NA	-0.46	-5.86	-0.31	1.13e-8	Rheumatoid arthritis;
CRC	trans	rs10242455	1.000	rs17161692	chr7:98953863	A/G	cg09045935	chr12:6379348	NA	-0.71	-7.09	-0.36	8.04e-12	Blood metabolite levels;
CRC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18912574	chr7:65842487	NCRNA00174	0.33	5.62	0.3	4.06e-8	Aortic root size;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg04025307	chr7:1156635	C7orf50	0.64	6.76	0.35	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.5	7.27	0.37	2.58e-12	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20566942	chr11:28129866	METT5D1;KIF18A	0.39	6.14	0.32	2.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-7.55	-0.38	4.24e-13	Dilated cardiomyopathy;
CRC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.56	-7.76	-0.39	1.1e-13	DNA methylation (variation);
CRC	trans	rs4955793	0.585	rs61796591	chr3:178648302	T/G	cg11644478	chr21:40555479	PSMG1	0.66	6.06	0.32	3.69e-9	Post-traumatic stress disorder (asjusted for relatedness);
CRC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.57	-8.53	-0.43	5.27e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	10.49	0.5	2.16e-22	Schizophrenia;
CRC	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg12458913	chr13:53173898	NA	0.76	14.23	0.62	3.93e-36	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07067521	chr19:41196729	NUMBL	0.46	6.53	0.34	2.48e-10	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg22974920	chr21:40686053	BRWD1	0.45	6.13	0.32	2.48e-9	Cognitive function;
CRC	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.78	-11.79	-0.54	5.4e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs7731657	0.537	rs17621442	chr5:130205555	T/C	cg08523029	chr5:130500466	HINT1	-0.49	-6.03	-0.32	4.4e-9	Fasting plasma glucose;
CRC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg06204229	chr3:52865917	ITIH4	0.52	5.85	0.31	1.19e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7712401	0.686	rs154511	chr5:122195554	T/A	cg18764291	chr5:122110994	SNX2	0.36	5.73	0.3	2.23e-8	Mean platelet volume;
CRC	cis	rs6545883	0.507	rs12478192	chr2:61591175	A/G	cg10580144	chr2:61372316	C2orf74	-0.35	-7.89	-0.4	4.41e-14	Tuberculosis;
CRC	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.34	-7.95	-0.4	3.12e-14	Corneal astigmatism;
CRC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.58	8.25	0.41	3.76e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg15786705	chr6:28176104	NA	-0.69	-9.04	-0.45	1.4e-17	Parkinson's disease;
CRC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.8	0.44	8.02e-17	Parkinson's disease;
CRC	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.41	6.16	0.32	2.09e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.47	0.46	5.71e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.63	9.1	0.45	8.84e-18	Schizophrenia;
CRC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.64	7.9	0.4	4.09e-14	Menarche (age at onset);
CRC	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	21.56	0.77	6.84e-65	Colorectal cancer;
CRC	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.46	7.77	0.39	1.03e-13	Testicular germ cell tumor;
CRC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.74	7.56	0.38	4.17e-13	Diabetic retinopathy;
CRC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.34	0.42	2.09e-15	Menopause (age at onset);
CRC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg26248373	chr2:1572462	NA	-0.66	-7.1	-0.36	7.65e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs16937	0.662	rs11588199	chr1:205164580	C/T	cg00857998	chr1:205179979	DSTYK	0.41	5.65	0.3	3.49e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10706266	chr8:66546233	ARMC1	0.5	7.21	0.37	3.93e-12	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.11	19.18	0.73	1.39e-55	Cognitive function;
CRC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.49	9.28	0.46	2.29e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9463078	0.605	rs3799981	chr6:44882380	T/A	cg25276700	chr6:44698697	NA	0.25	6.04	0.32	4.21e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9969804	0.837	rs6479424	chr9:95297077	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.88	-0.31	1.03e-8	Height;
CRC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.9	-0.44	3.92e-17	Aortic root size;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg25856811	chr1:152973957	SPRR3	-0.23	-6.16	-0.32	2.09e-9	Inflammatory skin disease;
CRC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg03938978	chr2:103052716	IL18RAP	0.36	5.89	0.31	9.54e-9	Asthma;
CRC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.3	-0.33	9.66e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10229583	0.527	rs7778413	chr7:127357716	T/C	cg01233922	chr7:127693937	SND1	-0.49	-7.49	-0.38	6.23e-13	Type 2 diabetes;
CRC	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05645997	chr2:108443466	LOC729121;RGPD4	-0.39	-6.71	-0.35	8.51e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.56	8.07	0.41	1.35e-14	Mean platelet volume;
CRC	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.95	-13.35	-0.59	8.41e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06779604	chr7:122526572	CADPS2	0.4	6.49	0.34	3.24e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11212617	1.000	rs645485	chr11:108168863	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.83	0.31	1.35e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs372883	0.600	rs2832291	chr21:30734388	C/T	cg08807101	chr21:30365312	RNF160	0.52	7.27	0.37	2.59e-12	Pancreatic cancer;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg01426195	chr3:39028469	NA	-0.54	-8.69	-0.43	1.7e-16	Handedness;
CRC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.67	-9.98	-0.48	1.16e-20	DNA methylation (variation);
CRC	cis	rs427941	0.668	rs201459	chr7:101741502	G/A	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-5.98	-0.31	5.75e-9	Menopause (age at onset);
CRC	cis	rs2289328	0.882	rs7164581	chr15:40645098	C/G	cg13931752	chr15:40660718	DISP2	-0.55	-6.56	-0.34	2.14e-10	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg09232269	chr1:207846808	CR1L	-0.48	-7.79	-0.39	8.9e-14	Erythrocyte sedimentation rate;
CRC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.47	6.54	0.34	2.3e-10	Aortic root size;
CRC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.45	-8.11	-0.41	1.04e-14	Monocyte count;
CRC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg27534772	chr1:16042836	PLEKHM2	0.55	10.53	0.5	1.54e-22	Systolic blood pressure;
CRC	cis	rs73206853	0.563	rs7968913	chr12:111138558	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	6.05	0.32	3.96e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	0.51	8.24	0.41	4.21e-15	Intelligence (multi-trait analysis);
CRC	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.67	10.89	0.51	8.36e-24	Cognitive test performance;
CRC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-7.27	-0.37	2.56e-12	Morning vs. evening chronotype;
CRC	trans	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg10756647	chr7:56101905	PSPH	-0.78	-7.93	-0.4	3.35e-14	Diabetic kidney disease;
CRC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14895029	chr7:2775587	GNA12	-0.45	-6.52	-0.34	2.67e-10	Height;
CRC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.83	12.6	0.57	5.51e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg23625390	chr15:77176239	SCAPER	0.39	5.67	0.3	3.08e-8	Blood metabolite levels;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg12273811	chr6:28175739	NA	0.63	8.87	0.44	4.79e-17	Parkinson's disease;
CRC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	trans	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg16141378	chr3:129829833	LOC729375	0.41	6.02	0.31	4.76e-9	Joint mobility (Beighton score);
CRC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.54	9.48	0.46	5.06e-19	Coronary artery disease;
CRC	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs9847710	0.967	rs2564934	chr3:53024580	G/A	cg04503182	chr3:53078218	SFMBT1	0.41	6.19	0.32	1.75e-9	Ulcerative colitis;
CRC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.69	-10.7	-0.51	4.05e-23	Mean corpuscular hemoglobin;
CRC	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.39	-7.06	-0.36	1.01e-11	Breast cancer;
CRC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg12458913	chr13:53173898	NA	0.92	16.64	0.68	1.57e-45	Lewy body disease;
CRC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-8.87	-0.44	4.84e-17	Bipolar disorder;
CRC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.98	-0.31	5.86e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.95	13.75	0.6	2.59e-34	Breast cancer;
CRC	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.59	7.41	0.38	1.09e-12	RR interval (heart rate);
CRC	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-7.44	-0.38	8.59e-13	Hepatocellular carcinoma;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg25164649	chr6:28176230	NA	0.62	8.82	0.44	6.67e-17	Parkinson's disease;
CRC	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.5	8.55	0.43	4.83e-16	Dupuytren's disease;
CRC	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	10.89	0.51	8.38e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12172441	chr6:28176163	NA	0.55	6.96	0.36	1.83e-11	Parkinson's disease;
CRC	cis	rs7605827	0.930	rs1852751	chr2:15557320	C/T	cg19274914	chr2:15703543	NA	0.39	5.91	0.31	8.33e-9	Educational attainment (years of education);
CRC	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg12560992	chr17:57184187	TRIM37	0.54	7.38	0.38	1.33e-12	Testicular germ cell tumor;
CRC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.73	11.0	0.52	3.52e-24	Corneal astigmatism;
CRC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.54	-0.34	2.4e-10	Blood metabolite levels;
CRC	cis	rs12594515	0.591	rs35554150	chr15:45990298	G/A	cg06207120	chr15:45996521	NA	0.31	6.19	0.32	1.83e-9	Waist circumference;Weight;
CRC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg08888203	chr3:10149979	C3orf24	0.45	7.19	0.37	4.45e-12	Alzheimer's disease;
CRC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.68	7.79	0.39	8.9e-14	Gut microbiome composition (summer);
CRC	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	10.46	0.5	2.68e-22	Schizophrenia;
CRC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.6	0.63	1.43e-37	Mean platelet volume;
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	7.95e-11	Blood pressure (smoking interaction);
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.17	-0.32	2e-9	Total body bone mineral density;
CRC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.51	8.38	0.42	1.6e-15	Height;
CRC	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg13385794	chr1:248469461	NA	0.38	6.63	0.34	1.36e-10	Common traits (Other);
CRC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg02527881	chr3:46936655	PTH1R	0.41	7.48	0.38	6.71e-13	Colorectal cancer;
CRC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.68	10.96	0.52	5.0600000000000004e-24	Cognitive function;
CRC	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	10.32	0.49	7.93e-22	Schizophrenia;
CRC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg20684491	chr1:25596433	NA	0.41	7.27	0.37	2.6e-12	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.38	6.18	0.32	1.91e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.75	12.9	0.58	4.34e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-9.06	-0.45	1.2e-17	Hemoglobin concentration;
CRC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.57	7.61	0.39	2.94e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-13.1	-0.59	7.64e-32	Alzheimer's disease;
CRC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.3	-0.37	2.24e-12	Schizophrenia;
CRC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg20744362	chr22:50050164	C22orf34	0.34	6.2	0.32	1.69e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs6738485	0.557	rs12988865	chr2:106854386	G/A	cg16099169	chr2:106886729	NA	-0.35	-5.98	-0.31	5.73e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.78	-11.01	-0.52	3.34e-24	Coronary artery disease;
CRC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.63	0.3	3.9e-8	Cystic fibrosis severity;
CRC	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.67	8.94	0.44	2.86e-17	Uric acid levels;
CRC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.5	7.04	0.36	1.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg14979609	chr8:8086686	FLJ10661	0.37	5.99	0.31	5.42e-9	Neuroticism;
CRC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.39	7.09	0.36	8.1e-12	Obesity-related traits;
CRC	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.45	7.02	0.36	1.27e-11	C-reactive protein levels;
CRC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg26603656	chr10:5671107	NA	0.45	7.55	0.38	4.39e-13	Breast cancer;
CRC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.27	-0.33	1.12e-9	Aortic root size;
CRC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg21856205	chr7:94953877	PON1	-0.46	-5.81	-0.31	1.48e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.61	0.43	3.09e-16	Homoarginine levels;
CRC	cis	rs9467603	0.858	rs1937126	chr6:25769608	G/C	cg08501292	chr6:25962987	TRIM38	-0.67	-6.29	-0.33	1.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.53	-8.68	-0.43	1.86e-16	Type 2 diabetes;
CRC	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.7	12.37	0.56	3.99e-29	Longevity;
CRC	cis	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.92	-9.42	-0.46	8.4e-19	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.75	-0.3	1.99e-8	Total body bone mineral density;
CRC	trans	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.41	-0.33	5.12e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.98	-0.36	1.6e-11	Neuroticism;
CRC	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg02772935	chr3:125709198	NA	-0.5	-5.81	-0.3	1.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs6662572	1.000	rs7517111	chr1:46122140	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.86	0.31	1.12e-8	Blood protein levels;
CRC	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.47	6.38	0.33	6.16e-10	Cholesterol, total;
CRC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.17	-0.52	9.01e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.59	-9.34	-0.46	1.49e-18	Lewy body disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11688874	chr10:28822482	WAC	0.48	6.41	0.33	5.15e-10	Thyroid stimulating hormone;
CRC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.03	-0.32	4.37e-9	Menarche (age at onset);
CRC	cis	rs755249	0.567	rs41270799	chr1:39748662	G/A	cg18385671	chr1:39797026	MACF1	-0.42	-5.85	-0.31	1.2e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1006703	0.544	rs10153291	chr17:3833740	G/A	cg06463185	chr17:3833770	ATP2A3	-0.67	-7.29	-0.37	2.26e-12	Glucose homeostasis traits;
CRC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.33	-5.91	-0.31	8.76e-9	Menarche (age at onset);
CRC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.29e-24	Motion sickness;
CRC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.43	9.45	0.46	6.4e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg02569458	chr12:86230093	RASSF9	0.48	8.13	0.41	8.91e-15	Major depressive disorder;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg11235426	chr6:292522	DUSP22	-0.54	-7.79	-0.39	8.74e-14	Menopause (age at onset);
CRC	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.47	-0.34	3.6e-10	Retinal vascular caliber;
CRC	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg11693508	chr17:37793320	STARD3	0.55	7.41	0.38	1.08e-12	Bipolar disorder;
CRC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.42	-6.38	-0.33	5.93e-10	Height;
CRC	cis	rs9311676	0.656	rs7647078	chr3:58369912	C/T	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.95	15.69	0.65	8.13e-42	Menarche (age at onset);
CRC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	7.23	0.37	3.34e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.69	9.68	0.47	1.15e-19	Alzheimer's disease;
CRC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.59	-6.06	-0.32	3.74e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.55	9.74	0.47	7.5e-20	Body mass index;
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.63e-11	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04534726	chr3:23987467	NR1D2	0.47	6.72	0.35	8.1e-11	Anxiety disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06936779	chr1:151171405	PIP5K1A	-0.45	-6.46	-0.34	3.71e-10	Myopia (pathological);
CRC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.46	6.76	0.35	6.3e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg06470822	chr6:28175283	NA	0.67	10.27	0.49	1.2e-21	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14293776	chr19:12371199	NA	0.44	6.67	0.35	1.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs56307353	0.513	rs2041120	chr19:1961474	C/T	cg05502645	chr19:1971281	CSNK1G2	0.51	7.96	0.4	2.82e-14	Coronary artery disease;
CRC	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg23032129	chr1:109941072	SORT1	-0.28	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-9.12	-0.45	7.41e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.7	13.47	0.6	3.13e-33	Body mass index;
CRC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.43	-0.33	4.61e-10	Coronary artery disease;
CRC	cis	rs12760731	0.920	rs10913562	chr1:178481750	A/C	cg00404053	chr1:178313656	RASAL2	-0.69	-7.6	-0.39	3.17e-13	Obesity-related traits;
CRC	cis	rs2252790	1.000	rs12203516	chr6:116638619	A/G	cg18764771	chr6:116381957	FRK	0.22	5.75	0.3	2e-8	Fast beta electroencephalogram;
CRC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.42	0.33	4.88e-10	Tonsillectomy;
CRC	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.74	11.44	0.53	9.4e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.42	6.37	0.33	6.55e-10	Monocyte count;
CRC	cis	rs11650494	0.710	rs74619404	chr17:47484445	C/T	cg08112188	chr17:47440006	ZNF652	0.95	7.43	0.38	9.72e-13	Prostate cancer;
CRC	cis	rs6586163	0.872	rs1800682	chr10:90749963	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.48	-6.86	-0.35	3.44e-11	Chronic lymphocytic leukemia;
CRC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.57	-0.39	3.86e-13	Joint mobility (Beighton score);
CRC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.75	-0.35	6.77e-11	Triglycerides;
CRC	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-7.43	-0.38	9.67e-13	Primary sclerosing cholangitis;
CRC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.71	0.35	8.69e-11	Mean platelet volume;
CRC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg09796270	chr17:17721594	SREBF1	0.46	7.62	0.39	2.75e-13	Total body bone mineral density;
CRC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16786661	chr2:234160315	ATG16L1	0.37	6.09	0.32	3.12e-9	Obesity-related traits;
CRC	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg04880052	chr2:219191631	PNKD	0.4	6.1	0.32	3.01e-9	Colorectal cancer;
CRC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.69	-13.6	-0.6	9.99e-34	Educational attainment;
CRC	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.82	-0.35	4.37e-11	Coronary artery disease;
CRC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.55	-8.29	-0.42	2.92e-15	Calcium levels;
CRC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg18876405	chr7:65276391	NA	-0.44	-6.21	-0.32	1.57e-9	Aortic root size;
CRC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08219700	chr8:58056026	NA	0.56	5.81	0.3	1.48e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.61	7.7	0.39	1.59e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs7428	1.000	rs7428	chr2:85545490	C/T	cg24342717	chr2:85555507	TGOLN2	0.49	6.97	0.36	1.75e-11	Ear protrusion;
CRC	cis	rs9549328	0.565	rs35988856	chr13:113617427	T/C	cg20742385	chr13:113633654	MCF2L	0.56	9.5	0.46	4.54e-19	Systolic blood pressure;
CRC	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.46	-7.44	-0.38	8.69e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.65e-24	Motion sickness;
CRC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-5.93	-0.31	7.68e-9	Lymphocyte counts;
CRC	cis	rs11203032	0.831	rs11203022	chr10:90954068	G/A	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23084309	chr19:6280164	MLLT1	0.43	7.26	0.37	2.9e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9463078	0.625	rs6926370	chr6:44947280	G/C	cg25276700	chr6:44698697	NA	-0.25	-6.21	-0.32	1.56e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs17401966	0.540	rs6541094	chr1:10467074	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-7.76	-0.39	1.1e-13	Hepatocellular carcinoma;
CRC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.04	-0.45	1.37e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.5	-7.88	-0.4	4.98e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2292864	0.764	rs3892085	chr17:45340480	A/G	cg18085866	chr17:45331354	ITGB3	-0.61	-6.02	-0.31	4.73e-9	Left atrial antero-posterior diameter;
CRC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.82	0.4	7.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.54	6.9	0.36	2.76e-11	Morning vs. evening chronotype;
CRC	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.86	-0.35	3.37e-11	HDL cholesterol;
CRC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	17.46	0.69	9.05e-49	Primary sclerosing cholangitis;
CRC	cis	rs12476592	0.516	rs7558796	chr2:63597108	T/A	cg10828910	chr2:63850056	LOC388955	0.47	5.83	0.31	1.34e-8	Childhood ear infection;
CRC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.17	0.32	2.02e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.27	-0.37	2.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.45	6.12	0.32	2.72e-9	Aortic root size;
CRC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg07870213	chr5:140052090	DND1	-0.63	-8.23	-0.41	4.3e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24917945	chr10:120514927	C10orf46	0.46	6.08	0.32	3.4e-9	Thyroid stimulating hormone;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25007351	chr3:160118866	SMC4	0.46	6.75	0.35	6.77e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21482969	chr3:57261456	APPL1	0.43	6.2	0.32	1.69e-9	Response to antipsychotic treatment;
CRC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg17948913	chr5:572064	NA	0.51	5.89	0.31	9.53e-9	Obesity-related traits;
CRC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.96	-0.31	6.46e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2737618	0.722	rs2737676	chr1:200086839	T/C	cg21825944	chr1:200113062	NR5A2	-0.49	-6.95	-0.36	1.91e-11	Uric acid levels;
CRC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13606994	chr1:44402422	ARTN	-0.34	-5.69	-0.3	2.78e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.76	-9.55	-0.47	3.07e-19	Blood protein levels;
CRC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.87	0.35	3.15e-11	Morning vs. evening chronotype;
CRC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.65	9.52	0.46	3.76e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.14	9.22	0.45	3.66e-18	Mitochondrial DNA levels;
CRC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg07274523	chr3:49395745	GPX1	0.48	6.32	0.33	8.48e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.04	-0.41	1.65e-14	Height;
CRC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-6.7	-0.35	8.91e-11	Renal cell carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22476645	chr16:15150025	NTAN1	0.43	5.98	0.31	5.97e-9	Response to antipsychotic treatment;
CRC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.47	-7.66	-0.39	2.11e-13	Type 2 diabetes;
CRC	cis	rs7072216	0.587	rs2296435	chr10:100182285	C/T	cg26618903	chr10:100175079	PYROXD2	0.4	6.09	0.32	3.14e-9	Metabolite levels;
CRC	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg13736514	chr6:26305472	NA	-0.37	-6.22	-0.32	1.49e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg00745463	chr17:30367425	LRRC37B	-0.58	-7.43	-0.38	9.46e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.32	-6.87	-0.35	3.32e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.64	9.6	0.47	2.14e-19	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.93	0.44	3.16e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.58	9.44	0.46	7.07e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg24209194	chr3:40518798	ZNF619	0.42	6.5	0.34	2.97e-10	Renal cell carcinoma;
CRC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-11.98	-0.55	1.08e-27	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.67	-11.23	-0.53	5.29e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-6.12	-0.32	2.65e-9	Major depressive disorder;
CRC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.74	12.06	0.55	5.62e-28	Blood protein levels;
CRC	cis	rs4363385	0.747	rs4240866	chr1:152954875	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.09e-13	Inflammatory skin disease;
CRC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-1.23	-11.18	-0.52	8.11e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-6.06	-0.32	3.74e-9	Menarche (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22704915	chr10:73079101	SLC29A3	-0.4	-6.48	-0.34	3.43e-10	Myopia (pathological);
CRC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg09473613	chr1:24152604	HMGCL	0.36	6.12	0.32	2.59e-9	Immature fraction of reticulocytes;
CRC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg26597838	chr10:835615	NA	-0.51	-7.08	-0.36	8.53e-12	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.56	-0.38	4.07e-13	Cystic fibrosis severity;
CRC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.51	-7.13	-0.37	6.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9928842	0.824	rs12924999	chr16:75262425	T/G	cg08657710	chr16:75258780	CTRB1	-0.57	-6.45	-0.34	3.9e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00495681	chr13:53174319	NA	0.62	9.4	0.46	9.79e-19	Lewy body disease;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg20918563	chr3:196263520	NA	-0.47	-6.55	-0.34	2.16e-10	Lung cancer;
CRC	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.78	-6.36	-0.33	6.56e-10	Non-glioblastoma glioma;Glioma;
CRC	trans	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg07393940	chr7:158741817	NA	-0.52	-7.54	-0.38	4.67e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.4	0.33	5.42e-10	Diabetic kidney disease;
CRC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.57	0.39	3.8e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg05552183	chr6:42928497	GNMT	0.48	6.36	0.33	6.69e-10	Blood protein levels;
CRC	cis	rs7115242	0.920	rs6589574	chr11:116730638	A/G	cg26566898	chr11:117069891	TAGLN	0.5	5.79	0.3	1.68e-8	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CRC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.56	9.76	0.47	6.33e-20	Schizophrenia;
CRC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.15	0.32	2.24e-9	Rheumatoid arthritis;
CRC	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.55	5.92	0.31	7.93e-9	Blood protein levels;
CRC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.83	8.1	0.41	1.1e-14	Diabetic retinopathy;
CRC	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg09163369	chr1:210001066	C1orf107	-0.52	-7.01	-0.36	1.34e-11	Orofacial clefts;
CRC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.71	-11.41	-0.53	1.2e-25	Dental caries;
CRC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.52	-9.16	-0.45	5.53e-18	Sense of smell;
CRC	cis	rs6691722	1.000	rs6691722	chr1:24673866	A/G	cg18323236	chr1:24743029	NIPAL3	0.37	5.82	0.31	1.37e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00166722	chr3:10149974	C3orf24	0.63	8.78	0.44	9.09e-17	Alzheimer's disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06120528	chr15:78800245	AGPHD1	0.41	6.08	0.32	3.33e-9	Schizophrenia;
CRC	cis	rs10046574	0.517	rs7782727	chr7:135200299	A/G	cg27474649	chr7:135195673	CNOT4	0.67	6.29	0.33	9.88e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg23229016	chr1:26872525	RPS6KA1	0.3	7.29	0.37	2.39e-12	Glucose homeostasis traits;
CRC	cis	rs12580194	0.593	rs12581916	chr12:55764409	A/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.12	-0.45	7.84e-18	Cancer;
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26610681	chr1:87380186	HS2ST1;SEP15	0.39	6.12	0.32	2.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg24879335	chr3:133465180	TF	0.37	6.81	0.35	4.56e-11	Iron status biomarkers;
CRC	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11547950	chr5:77652471	NA	-0.51	-7.63	-0.39	2.59e-13	Triglycerides;
CRC	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	6.0	0.31	5.08e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.06	-0.32	3.66e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.62	9.25	0.45	2.97e-18	Blood protein levels;
CRC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.72	0.39	1.44e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs17021463	0.676	rs17311887	chr4:95313228	T/C	cg11021082	chr4:95130006	SMARCAD1	0.42	5.94	0.31	7.06e-9	Testicular germ cell tumor;
CRC	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.71	-8.3	-0.42	2.69e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.9	-12.65	-0.57	3.79e-30	Vitiligo;
CRC	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.75	11.01	0.52	3.3e-24	Neutrophil percentage of white cells;
CRC	cis	rs1712517	0.844	rs1163075	chr10:105021263	A/G	cg05636881	chr10:105038444	INA	-0.47	-8.42	-0.42	1.19e-15	Migraine;
CRC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.34	-6.39	-0.33	5.53e-10	Monocyte percentage of white cells;
CRC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.53	0.38	5.05e-13	Blood metabolite levels;
CRC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.72	10.02	0.48	8.33e-21	Blood metabolite levels;
CRC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg11707556	chr5:10655725	ANKRD33B	0.38	7.05	0.36	1.09e-11	Coronary artery disease;
CRC	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.71	5.95	0.31	6.99e-9	Body mass index;
CRC	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.18	-16.78	-0.68	4.35e-46	Breast cancer;
CRC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-8.22	-0.41	4.69e-15	Personality dimensions;
CRC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.4	-0.33	5.35e-10	Cognitive function;
CRC	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.52	-6.34	-0.33	7.68e-10	Glioblastoma;
CRC	trans	rs10242455	0.702	rs116671616	chr7:98954558	C/T	cg09045935	chr12:6379348	NA	0.92	7.02	0.36	1.25e-11	Blood metabolite levels;
CRC	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.46	-0.38	7.65e-13	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs10411161	0.702	rs11878583	chr19:52388546	C/T	cg22319618	chr22:45562946	NUP50	0.58	6.71	0.35	8.62e-11	Breast cancer;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.03	-23.79	-0.8	1.75e-73	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.64	11.46	0.53	8.39e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg03030879	chr14:75389066	RPS6KL1	0.5	7.65	0.39	2.2e-13	Height;
CRC	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.14	-0.32	2.37e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.64	-9.72	-0.47	8.59e-20	Testicular germ cell tumor;
CRC	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.52	-0.38	5.14e-13	Height;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg08989290	chr16:615782	NHLRC4	0.48	9.19	0.45	4.61e-18	Height;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg08200582	chr11:442649	ANO9	-0.73	-7.61	-0.39	2.84e-13	Body mass index;
CRC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.4	6.03	0.32	4.41e-9	Coronary artery disease;
CRC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg24503407	chr1:205819492	PM20D1	0.44	6.02	0.32	4.61e-9	Parkinson's disease;
CRC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.49	7.95	0.4	3.06e-14	Height;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.94	-0.31	7.43e-9	Depression;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09117826	chr6:86303884	SNX14	0.4	5.96	0.31	6.49e-9	Interleukin-6 levels;
CRC	cis	rs669446	0.562	rs11210907	chr1:44191759	C/T	cg12908607	chr1:44402522	ARTN	-0.34	-5.81	-0.3	1.51e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg21747405	chr11:67723411	NA	-0.43	-6.1	-0.32	2.97e-9	Blood pressure (smoking interaction);
CRC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.88	0.35	3.12e-11	Educational attainment;
CRC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.9	16.62	0.68	1.89e-45	Intelligence (multi-trait analysis);
CRC	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg13160058	chr8:26243215	BNIP3L	0.44	7.77	0.39	9.95e-14	Height;
CRC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-7.75	-0.39	1.14e-13	Pulmonary function;
CRC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.54	-8.07	-0.41	1.37e-14	Facial morphology (factor 23);
CRC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.25	15.0	0.64	4.06e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs6681460	0.625	rs4488004	chr1:67073314	T/C	cg02459107	chr1:67143332	SGIP1	0.35	6.31	0.33	8.78e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.39	-6.3	-0.33	9.34e-10	Total body bone mineral density;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg07395648	chr5:131743802	NA	0.42	5.8	0.3	1.58e-8	Acylcarnitine levels;
CRC	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg13736514	chr6:26305472	NA	-0.46	-7.23	-0.37	3.45e-12	Height;
CRC	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg02527881	chr3:46936655	PTH1R	0.35	5.98	0.31	5.85e-9	Colorectal cancer;
CRC	cis	rs4731207	0.596	rs13234368	chr7:124676054	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.1	-0.32	2.98e-9	Cutaneous malignant melanoma;
CRC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-8.08	-0.41	1.22e-14	Vitiligo;
CRC	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.53	6.38	0.33	6e-10	Cognitive test performance;
CRC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.94	13.01	0.58	1.66e-31	Initial pursuit acceleration;
CRC	cis	rs11958404	0.517	rs17679725	chr5:157221489	A/G	cg05962755	chr5:157440814	NA	0.75	8.89	0.44	4.15e-17	IgG glycosylation;
CRC	cis	rs9928842	0.882	rs3169330	chr16:75269267	A/G	cg09066997	chr16:75300724	BCAR1	0.69	6.63	0.34	1.4e-10	Alcoholic chronic pancreatitis;
CRC	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	7.0	0.36	1.48e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06307176	chr5:131281290	NA	-0.39	-5.91	-0.31	8.68e-9	Life satisfaction;
CRC	cis	rs524281	0.861	rs2177054	chr11:65944612	C/A	cg16950941	chr11:66035639	RAB1B	-0.61	-7.45	-0.38	8.09e-13	Electroencephalogram traits;
CRC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.9	-0.48	2.2e-20	Height;
CRC	cis	rs9567406	0.588	rs7981614	chr13:44847936	G/T	cg19190762	chr13:44806055	NA	-0.5	-5.62	-0.3	4.12e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	0.63	7.14	0.37	5.85e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg00343986	chr7:65444356	GUSB	0.42	5.84	0.31	1.27e-8	Calcium levels;
CRC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.99	-0.74	9.26e-59	Primary sclerosing cholangitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26496372	chr5:37379396	WDR70	0.44	6.02	0.31	4.61e-9	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-8.58	-0.43	3.77e-16	Total body bone mineral density;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.65	-0.43	2.35e-16	Bipolar disorder;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg27615366	chr5:131592974	PDLIM4	0.32	5.73	0.3	2.22e-8	Breast cancer;
CRC	cis	rs28655083	0.529	rs285022	chr16:77099730	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.81	0.35	4.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2652834	1.000	rs2729784	chr15:63402735	T/C	cg05507819	chr15:63340323	TPM1	0.44	5.61	0.3	4.19e-8	HDL cholesterol;
CRC	cis	rs1624802	1.000	rs1707934	chr12:130497611	C/T	cg15444478	chr12:130494697	NA	0.29	6.07	0.32	3.6e-9	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.44	-6.41	-0.33	5.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.98	16.17	0.67	1.12e-43	Parkinson's disease;
CRC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.67	9.93	0.48	1.65e-20	Menopause (age at onset);
CRC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.95	10.61	0.5	8.04e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg02741985	chr17:80059408	CCDC57	0.42	6.91	0.36	2.53e-11	Life satisfaction;
CRC	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.85	-12.91	-0.58	3.9e-31	Response to temozolomide;
CRC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg03013999	chr17:37608204	MED1	0.45	6.82	0.35	4.29e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg02421172	chr7:1938701	MAD1L1	0.43	5.8	0.3	1.56e-8	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	12.28	0.56	8.31e-29	Prudent dietary pattern;
CRC	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg21747405	chr11:67723411	NA	-0.59	-6.09	-0.32	3.09e-9	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-6.71	-0.35	8.76e-11	Longevity;Endometriosis;
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg02683197	chr6:28174875	NA	0.71	9.78	0.47	5.23e-20	Parkinson's disease;
CRC	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg25190513	chr12:123201362	GPR109B	-0.49	-6.2	-0.32	1.73e-9	Adiponectin levels;
CRC	trans	rs10242455	0.702	rs73711293	chr7:99081595	C/T	cg09045935	chr12:6379348	NA	1.1	7.89	0.4	4.41e-14	Blood metabolite levels;
CRC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.07	-0.32	3.54e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.46	-5.89	-0.31	9.74e-9	Serum thyroid-stimulating hormone levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20614940	chr2:191273670	MFSD6	-0.44	-6.5	-0.34	2.99e-10	Daytime sleep phenotypes;
CRC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.98	-12.78	-0.58	1.22e-30	Triglycerides;
CRC	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.44	-6.86	-0.35	3.33e-11	Asperger disorder;
CRC	cis	rs7463659	1.000	rs7463659	chr8:135432140	T/C	cg17885191	chr8:135476712	NA	-0.44	-6.57	-0.34	1.98e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-10.02	-0.48	8.5e-21	Initial pursuit acceleration;
CRC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.92	13.52	0.6	2.02e-33	Triglycerides;
CRC	cis	rs9928842	0.882	rs1107593	chr16:75261329	G/C	cg08657710	chr16:75258780	CTRB1	-0.57	-6.45	-0.34	3.9e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.54	-0.6	1.67e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg23136738	chr11:925521	AP2A2	-0.51	-8.36	-0.42	1.78e-15	Alzheimer's disease (late onset);
CRC	cis	rs7605827	0.930	rs1125534	chr2:15618339	G/A	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg23254163	chr1:152506842	NA	0.45	9.13	0.45	6.92e-18	Hair morphology;
CRC	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.94	0.31	7.35e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.38	-0.42	1.53e-15	Mean platelet volume;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-8.95	-0.44	2.69e-17	Bipolar disorder;
CRC	cis	rs755249	0.567	rs61783378	chr1:39777159	G/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.84	-0.31	1.22e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg11766577	chr21:47581405	C21orf56	-0.41	-6.34	-0.33	7.36e-10	Testicular germ cell tumor;
CRC	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.44	-8.01	-0.4	1.98e-14	Educational attainment (years of education);
CRC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.56	8.87	0.44	4.61e-17	Motion sickness;
CRC	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.97	-0.31	6.14e-9	Subjective well-being;
CRC	cis	rs534126	0.813	rs526867	chr7:142904427	G/A	cg04182207	chr7:143013161	CLCN1	-0.32	-5.81	-0.31	1.46e-8	Cancer;
CRC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.53	11.13	0.52	1.27e-24	Alcohol dependence;
CRC	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg26805224	chr10:79626177	DLG5	-0.56	-8.34	-0.42	2.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg17330251	chr7:94953956	PON1	-0.56	-7.14	-0.37	6.03e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.44	-7.45	-0.38	8.31e-13	Schizophrenia;
CRC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.93	0.64	7.26e-39	Lymphocyte percentage of white cells;
CRC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	7.01	0.36	1.34e-11	Educational attainment;
CRC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.58	9.22	0.45	3.73e-18	Schizophrenia;
CRC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.32	-0.37	1.95e-12	Coronary artery disease;
CRC	cis	rs10865541	0.869	rs13020433	chr2:3417577	G/A	cg22182287	chr2:3452347	TTC15	0.37	5.76	0.3	1.98e-8	Obesity-related traits;
CRC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.5	6.65	0.34	1.21e-10	IgG glycosylation;
CRC	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.48	-8.88	-0.44	4.58e-17	Educational attainment (years of education);
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg11064797	chr5:141016628	RELL2;HDAC3	0.5	6.15	0.32	2.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9969804	0.905	rs4744142	chr9:95391288	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.72	-0.3	2.45e-8	Height;
CRC	cis	rs9648716	1.000	rs7800472	chr7:140600134	T/C	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.22e-9	Diastolic blood pressure;
CRC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.55	8.09	0.41	1.14e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.32	-6.71	-0.35	8.58e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg05585544	chr11:47624801	NA	0.5	8.89	0.44	3.99e-17	Subjective well-being;
CRC	cis	rs17155006	0.664	rs1735499	chr7:107738882	G/A	cg05962710	chr7:107745446	LAMB4	-0.43	-7.53	-0.38	4.79e-13	Pneumococcal bacteremia;
CRC	cis	rs4731207	0.564	rs6466964	chr7:124572400	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs7539542	0.577	rs6662398	chr1:202888456	T/G	cg19681188	chr1:202830198	LOC148709	0.45	6.51	0.34	2.81e-10	Mean platelet volume;
CRC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.75	12.45	0.57	2e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.76	-12.11	-0.56	3.77e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs8105895	0.799	rs6511327	chr19:22286899	T/A	cg02912127	chr19:22235281	ZNF257	-0.38	-5.63	-0.3	3.9e-8	Body mass index (change over time);
CRC	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.33e-10	Vitamin D levels;
CRC	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	6.41	0.33	4.92e-10	Refractive astigmatism;
CRC	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.65e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1456896	0.835	rs921913	chr7:50311099	G/A	cg02134594	chr1:3632713	TP73	0.38	6.27	0.33	1.14e-9	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00777555	chr3:57583074	ARF4	0.52	7.36	0.38	1.45e-12	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.53	6.37	0.33	6.54e-10	Lymphocyte counts;
CRC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.36	-6.37	-0.33	6.48e-10	Reticulocyte fraction of red cells;
CRC	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.71	12.7	0.57	2.34e-30	Hip circumference;
CRC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14008862	chr17:28927542	LRRC37B2	0.59	5.82	0.31	1.4e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.5e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6499129	1.000	rs8063771	chr16:67506115	C/T	cg26727032	chr16:67993705	SLC12A4	-0.6	-7.16	-0.37	5.31e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.3	6.15	0.32	2.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.75	-10.61	-0.5	8.15e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.39	-8.62	-0.43	2.89e-16	Eye color traits;
CRC	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.69	-8.78	-0.44	9.07e-17	Multiple sclerosis;
CRC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.01	0.31	4.84e-9	Heart rate;
CRC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg08222913	chr3:52553049	STAB1	-0.37	-6.99	-0.36	1.56e-11	Electroencephalogram traits;
CRC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.57	-9.85	-0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.1	-0.45	9.11e-18	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06522697	chr10:121356224	TIAL1	0.47	7.35	0.38	1.54e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg16434002	chr17:42200994	HDAC5	-0.45	-6.0	-0.31	5.1e-9	Total body bone mineral density;
CRC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15433164	chr3:25824899	NGLY1	0.32	6.07	0.32	3.58e-9	Interleukin-6 levels;
CRC	cis	rs11229555	0.645	rs56228632	chr11:58187444	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.87	0.35	3.18e-11	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg19223190	chr17:80058835	NA	0.41	6.7	0.35	8.79e-11	Life satisfaction;
CRC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.44	7.56	0.38	4.08e-13	Hypertriglyceridemia;
CRC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	14.63	0.63	1.06e-37	Platelet count;
CRC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.53	7.44	0.38	8.75e-13	Height;
CRC	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg01666796	chr15:70364327	TLE3	-0.71	-5.61	-0.3	4.2e-8	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg08314208	chr16:67682810	RLTPR	-0.55	-5.96	-0.31	6.57e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs564309	0.681	rs1188473	chr1:228612444	A/G	cg20905516	chr11:106889364	GUCY1A2	0.58	6.15	0.32	2.26e-9	Hip circumference (psychosocial stress interaction);
CRC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg08027265	chr7:2291960	NA	-0.34	-5.93	-0.31	7.58e-9	Schizophrenia;
CRC	trans	rs13067260	1.000	rs6438827	chr3:123796759	C/T	cg18317531	chr1:225688425	ENAH	-0.58	-5.99	-0.31	5.57e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs216303	1.000	rs216299	chr12:6156635	A/G	cg19878637	chr12:6148451	VWF	-0.54	-6.34	-0.33	7.41e-10	Low vWF levels;
CRC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg22532475	chr10:104410764	TRIM8	-0.37	-6.95	-0.36	1.99e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg05192639	chr6:26864778	GUSBL1	0.34	6.16	0.32	2.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.11	-0.37	7.2e-12	Aortic root size;
CRC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.6	0.43	3.4e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg20243544	chr17:37824526	PNMT	0.54	8.73	0.43	1.33e-16	Asthma;
CRC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.39	-0.33	5.51e-10	Daytime sleep phenotypes;
CRC	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.38	0.33	6.09e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg04518342	chr5:131593106	PDLIM4	0.32	5.68	0.3	2.95e-8	Blood metabolite levels;
CRC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.32	4.53e-9	Gut microbiome composition (summer);
CRC	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg10820045	chr2:198174542	NA	0.38	6.25	0.33	1.29e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg16102536	chr7:156981717	UBE3C	-0.4	-6.8	-0.35	4.8e-11	Body mass index;
CRC	trans	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg17903999	chr18:56338584	MALT1	-0.42	-7.09	-0.36	8.4e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg18721089	chr20:30220636	NA	-0.36	-5.86	-0.31	1.12e-8	Mean corpuscular hemoglobin;
CRC	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	cis	rs4716602	0.542	rs10261485	chr7:156159775	C/T	cg16983916	chr7:156159713	NA	-0.4	-6.92	-0.36	2.41e-11	Anti-saccade response;
CRC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg15786705	chr6:28176104	NA	0.51	6.67	0.35	1.06e-10	Parkinson's disease;
CRC	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg22687807	chr8:143858763	LYNX1	-0.36	-6.17	-0.32	2.02e-9	Urinary tract infection frequency;
CRC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.64	9.27	0.46	2.53e-18	Multiple sclerosis;
CRC	cis	rs501120	0.564	rs10899999	chr10:44690185	A/G	cg09554077	chr10:44749378	NA	0.58	8.13	0.41	8.75e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.84	-0.63	1.63e-38	Diabetic kidney disease;
CRC	cis	rs7487075	0.578	rs1492895	chr12:46808755	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs7725052	0.609	rs4957295	chr5:40447997	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.64	-0.34	1.3100000000000001e-10	Pediatric autoimmune diseases;
CRC	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.24e-37	Hypertriglyceridemia;
CRC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-6.28	-0.33	1.06e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2275731	0.525	rs7922050	chr10:16479007	C/G	cg04254609	chr10:16479192	PTER	-0.58	-8.65	-0.43	2.23e-16	Bone fracture in osteoporosis;
CRC	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.46	6.89	0.36	2.82e-11	Carotid intima media thickness;
CRC	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg21153622	chr11:89784906	NA	-0.45	-7.17	-0.37	5.09e-12	HDL cholesterol;
CRC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.04	0.32	4.12e-9	Aortic root size;
CRC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.82	9.16	0.45	5.68e-18	Breast cancer;
CRC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg10760299	chr15:45669010	GATM	0.48	7.58	0.39	3.6e-13	Homoarginine levels;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg02683197	chr6:28174875	NA	0.78	9.5	0.46	4.55e-19	Depression;
CRC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.94	11.83	0.55	3.85e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs17767392	0.958	rs61989373	chr14:71935156	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.17	-0.37	5.11e-12	Mitral valve prolapse;
CRC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.85	0.61	1.11e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.41	5.91	0.31	8.71e-9	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01638175	chr3:49171179	LAMB2	0.41	6.27	0.33	1.13e-9	Response to antipsychotic treatment;
CRC	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.68	10.69	0.51	4.28e-23	Intelligence (multi-trait analysis);
CRC	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.09	-0.45	9.27e-18	Prevalent atrial fibrillation;
CRC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04731861	chr2:219085781	ARPC2	0.32	6.72	0.35	8.11e-11	Colorectal cancer;
CRC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.4	-0.56	3.1e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3804749	0.966	rs4677875	chr3:122841062	G/A	cg26084141	chr3:122786895	PDIA5	0.22	6.0	0.31	5.19e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs11958404	0.932	rs72816540	chr5:157414500	T/C	cg05962755	chr5:157440814	NA	0.74	10.37	0.5	5.47e-22	IgG glycosylation;
CRC	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg24555670	chr8:18244502	NA	0.49	5.62	0.3	4.05e-8	Blood metabolite levels;
CRC	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg09596252	chr17:78655493	RPTOR	-0.58	-6.07	-0.32	3.43e-9	Myopia (pathological);
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25220896	chr1:11004296	NA	0.42	6.63	0.34	1.42e-10	Response to antipsychotic treatment;
CRC	cis	rs908922	0.566	rs12144049	chr1:152440910	C/T	cg09873164	chr1:152488093	CRCT1	0.38	5.79	0.3	1.62e-8	Hair morphology;
CRC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-11.66	-0.54	1.52e-26	Asthma;
CRC	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.7	7.68	0.39	1.9e-13	Inflammatory bowel disease;
CRC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.54	-8.3	-0.42	2.71e-15	Aortic root size;
CRC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg21784768	chr11:537496	LRRC56	-0.66	-6.13	-0.32	2.48e-9	Body mass index;
CRC	cis	rs10486722	0.624	rs4724069	chr7:41775278	C/T	cg22138096	chr7:41772439	LOC285954	-0.38	-5.83	-0.31	1.35e-8	Pit-and-Fissure caries;
CRC	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.72	0.54	9.5e-27	Coffee consumption (cups per day);
CRC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.52	7.4	0.38	1.17e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10128264	0.967	rs942794	chr10:80965109	T/C	cg20744163	chr10:80999841	ZMIZ1	-0.37	-6.7	-0.35	9.08e-11	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.52	-8.03	-0.4	1.78e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg00042356	chr1:8021962	PARK7	0.72	7.53	0.38	4.8e-13	Inflammatory bowel disease;
CRC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.66	-0.47	1.38e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg14631576	chr9:95140430	CENPP	-0.32	-6.1	-0.32	3.02e-9	Height;
CRC	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.53	7.49	0.38	6.52e-13	Testicular germ cell tumor;
CRC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.44	6.04	0.32	4.14e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9462027	0.628	rs7776219	chr6:34784667	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.06	-0.32	3.62e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3018066	0.666	rs28507027	chr4:107035423	C/A	cg01869342	chr4:106983673	TBCK	0.46	6.03	0.32	4.52e-9	Cancer;
CRC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.17	-0.49	2.57e-21	Monocyte count;
CRC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.87	0.4	5.25e-14	Aortic root size;
CRC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.97	-0.4	2.66e-14	Height;
CRC	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg09876464	chr15:85330779	ZNF592	0.46	7.58	0.39	3.47e-13	P wave terminal force;
CRC	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.25	-0.41	3.85e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs6694672	1.000	rs2336597	chr1:196993339	C/T	cg13682187	chr1:196946512	CFHR5	-0.49	-7.68	-0.39	1.88e-13	Asthma;
CRC	cis	rs17162190	0.698	rs7539320	chr1:26850665	C/T	cg17456097	chr1:26900765	RPS6KA1	0.42	5.94	0.31	7.38e-9	Mean corpuscular volume;
CRC	cis	rs6445525	0.967	rs6782159	chr3:65993782	C/G	cg06109867	chr3:66002991	MAGI1	-0.38	-6.23	-0.32	1.46e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9908102	0.740	rs73981621	chr17:12914832	C/T	cg26162695	chr17:12921313	ELAC2	0.44	5.91	0.31	8.44e-9	Schizophrenia;
CRC	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.44	-0.46	7.3e-19	Migraine;Coronary artery disease;
CRC	cis	rs394563	0.517	rs377454	chr6:149791093	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.49	-7.94	-0.4	3.26e-14	Dupuytren's disease;
CRC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.14	26.32	0.82	5.65e-83	Testicular germ cell tumor;
CRC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.41	5.71	0.3	2.47e-8	Lymphocyte counts;
CRC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.07	13.98	0.61	3.39e-35	Night sleep phenotypes;
CRC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg11189052	chr15:85197271	WDR73	0.59	8.26	0.41	3.66e-15	Schizophrenia;
CRC	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg00300879	chr1:26503847	CNKSR1	0.29	5.83	0.31	1.31e-8	QRS complex (12-leadsum);
CRC	cis	rs939584	0.935	rs11127490	chr2:646110	C/T	cg03610516	chr2:642275	NA	0.42	5.87	0.31	1.06e-8	Body mass index;
CRC	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg23293999	chr7:106826042	HBP1	-0.5	-5.81	-0.31	1.46e-8	Coronary artery disease;
CRC	cis	rs10242455	0.702	rs917152	chr7:99004497	T/C	cg18809830	chr7:99032528	PTCD1	-1.08	-7.96	-0.4	2.89e-14	Blood metabolite levels;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.67	-9.58	-0.47	2.43e-19	DNA methylation (variation);
CRC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-9.37	-0.46	1.17e-18	Hemoglobin concentration;
CRC	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.43	6.82	0.35	4.36e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2811415	0.597	rs67786346	chr3:127794654	C/G	cg13719885	chr3:127795394	NA	-0.39	-5.84	-0.31	1.27e-8	Lung function (FEV1/FVC);
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg02033258	chr5:131593261	PDLIM4	0.38	6.41	0.33	5.01e-10	Breast cancer;
CRC	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.35	-6.45	-0.34	4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg20615401	chr6:28092323	ZSCAN16	0.45	5.89	0.31	9.65e-9	Cardiac Troponin-T levels;
CRC	trans	rs6479874	0.831	rs2245543	chr10:52745148	C/A	cg15483030	chr1:5935144	NPHP4	-0.71	-6.34	-0.33	7.64e-10	Migraine;
CRC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.35	-0.38	1.58e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.53	7.66	0.39	2.04e-13	Colorectal cancer;
CRC	trans	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg10756647	chr7:56101905	PSPH	0.7	7.47	0.38	7.51e-13	Diabetic kidney disease;
CRC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.44	-8.06	-0.41	1.45e-14	Reticulocyte fraction of red cells;
CRC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.28e-13	Heart rate;
CRC	trans	rs10090774	0.760	rs6993266	chr8:141762659	G/A	cg14360659	chr9:137029702	RNU6ATAC	-0.47	-6.15	-0.32	2.23e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg18490616	chr2:88469792	THNSL2	0.61	6.1	0.32	2.9e-9	Plasma clusterin levels;
CRC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.44	9.68	0.47	1.12e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9584850	0.834	rs17574378	chr13:99116384	T/C	cg07423050	chr13:99094983	FARP1	0.42	6.03	0.32	4.33e-9	Neuroticism;
CRC	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg23461800	chr14:103021989	NA	0.57	6.53	0.34	2.47e-10	Platelet count;
CRC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4728302	0.643	rs2346442	chr7:133705907	A/G	cg10665199	chr7:133106180	EXOC4	-0.36	-5.71	-0.3	2.53e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-6.19	-0.32	1.81e-9	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg18288967	chr1:45987694	PRDX1	0.65	6.58	0.34	1.82e-10	Obesity-related traits;
CRC	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.66	-0.34	1.12e-10	IgG glycosylation;
CRC	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00114008	chr1:27114423	PIGV	0.37	6.28	0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1403694	1.000	rs1656911	chr3:186439373	T/C	cg04611788	chr3:186434169	KNG1	-0.45	-6.96	-0.36	1.83e-11	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21886851	chr18:47340405	SCARNA17;ACAA2	0.4	6.32	0.33	8.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg19554555	chr3:13937349	NA	0.43	6.19	0.32	1.81e-9	Ovarian reserve;
CRC	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.58	9.87	0.48	2.63e-20	Asthma;
CRC	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg24851651	chr11:66362959	CCS	-0.4	-6.94	-0.36	2.08e-11	Educational attainment (years of education);
CRC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.66	8.75	0.43	1.14e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg21918786	chr6:109611834	NA	-0.33	-5.63	-0.3	3.82e-8	Reticulocyte fraction of red cells;
CRC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg02811702	chr13:24901961	NA	0.45	6.22	0.32	1.53e-9	Obesity-related traits;
CRC	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.75	-7.61	-0.39	2.89e-13	Inflammatory biomarkers;
CRC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.47	-7.57	-0.39	3.68e-13	Testicular germ cell tumor;
CRC	cis	rs9463078	0.608	rs608941	chr6:44888740	C/T	cg25276700	chr6:44698697	NA	-0.25	-6.06	-0.32	3.71e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg15412446	chr2:106886593	NA	-0.5	-6.97	-0.36	1.7e-11	Facial morphology (factor 23);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg13468249	chr17:7154818	DULLARD;C17orf81	0.42	6.59	0.34	1.76e-10	Interleukin-6 levels;
CRC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.69	-10.73	-0.51	3.19e-23	Blood protein levels;
CRC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg16670446	chr17:27188758	MIR451;MIR144	-0.52	-8.54	-0.43	5.19e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg04611788	chr3:186434169	KNG1	-0.58	-8.36	-0.42	1.79e-15	Adiponectin levels;
CRC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg18721089	chr20:30220636	NA	-0.36	-6.06	-0.32	3.71e-9	Mean corpuscular hemoglobin;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14750263	chr11:10324369	NA	0.41	5.96	0.31	6.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg08989290	chr16:615782	NHLRC4	0.43	8.26	0.41	3.56e-15	Height;
CRC	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.02	0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.39	-5.88	-0.31	1.01e-8	P wave terminal force;
CRC	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-7.13	-0.37	6.43e-12	Tuberculosis;
CRC	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.83	-13.43	-0.6	4.27e-33	Hypospadias;
CRC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.94	-17.88	-0.7	2e-50	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg21153622	chr11:89784906	NA	-0.44	-7.1	-0.36	7.56e-12	HDL cholesterol;
CRC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	1.02	10.37	0.5	5.29e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-6.29	-0.33	1.03e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg02228815	chr15:31685131	NA	-0.43	-5.98	-0.31	5.89e-9	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03087334	chr18:33077969	INO80C	0.48	6.18	0.32	1.87e-9	Thyroid stimulating hormone;
CRC	cis	rs4731207	0.535	rs1552120	chr7:124639238	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.27e-9	Cutaneous malignant melanoma;
CRC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.67	-7.67	-0.39	1.98e-13	Vitiligo;
CRC	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg24519413	chr1:26490540	NA	0.38	6.35	0.33	7.05e-10	Height;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg20512303	chr5:131592959	PDLIM4	0.41	7.12	0.37	7e-12	Acylcarnitine levels;
CRC	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg10263370	chr3:44754102	ZNF502	-0.36	-5.86	-0.31	1.09e-8	Depressive symptoms;
CRC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg04317338	chr11:64019027	PLCB3	0.61	5.98	0.31	5.71e-9	Mean platelet volume;
CRC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.12	-0.32	2.67e-9	Eosinophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06096824	chr1:51443952	NA	0.36	5.97	0.31	6.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.89e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	18.38	0.71	2.05e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.82	11.06	0.52	2.2e-24	Cerebrospinal P-tau181p levels;
CRC	cis	rs7487075	0.578	rs2897951	chr12:46809206	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.52	6.36	0.33	6.59e-10	Cognitive test performance;
CRC	cis	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg02972257	chr16:68554789	NA	-0.56	-6.99	-0.36	1.51e-11	Ulcerative colitis;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg15511327	chr8:143859410	LYNX1	-0.39	-6.52	-0.34	2.65e-10	Urinary tract infection frequency;
CRC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.14	-0.41	8.09e-15	Response to amphetamines;
CRC	cis	rs6504622	0.905	rs9889741	chr17:45026333	G/A	cg16759221	chr17:45003025	GOSR2	-0.52	-8.3	-0.42	2.69e-15	Orofacial clefts;
CRC	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.64	-0.39	2.44e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.93	0.52	6.24e-24	Motion sickness;
CRC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg23996704	chr18:44553084	KATNAL2	-0.31	-6.17	-0.32	1.98e-9	Personality dimensions;
CRC	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.53	8.81	0.44	7.17e-17	Dupuytren's disease;
CRC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg03609598	chr5:56110824	MAP3K1	0.59	7.99	0.4	2.34e-14	Initial pursuit acceleration;
CRC	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg09659197	chr4:152720779	NA	0.32	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.71	-0.43	1.49e-16	Monocyte count;
CRC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.22	-0.49	1.81e-21	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12445461	chr9:6681608	NA	0.54	7.13	0.37	6.23e-12	Thyroid stimulating hormone;
CRC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.64	10.09	0.49	4.73e-21	Cognitive ability;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg15845792	chr6:28175446	NA	0.75	11.09	0.52	1.64e-24	Parkinson's disease;
CRC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.25e-10	Alzheimer's disease;
CRC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg15786705	chr6:28176104	NA	0.7	5.88	0.31	1e-8	Depression;
CRC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.19	0.32	1.79e-9	Diabetic kidney disease;
CRC	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.5	6.49	0.34	3.17e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.34	7.41	0.38	1.1e-12	Total body bone mineral density;
CRC	cis	rs73195822	0.667	rs7967386	chr12:111239162	G/A	cg12870014	chr12:110450643	ANKRD13A	0.58	5.92	0.31	8.15e-9	Itch intensity from mosquito bite;
CRC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	7.85	0.4	6.04e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.24	0.37	3.14e-12	Calcium levels;
CRC	trans	rs9561329	0.800	rs1408208	chr13:94034934	G/A	cg23072629	chr2:239195537	PER2	0.32	6.01	0.31	5.03e-9	Neuroticism (age interaction);
CRC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.54	-0.43	5.12e-16	Gut microbiome composition (summer);
CRC	cis	rs4964805	0.954	rs10861105	chr12:104189999	C/T	cg02344784	chr12:104178138	NT5DC3	0.56	8.5	0.42	6.72e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs6977955	1.000	rs4722760	chr7:28172183	C/T	cg23620719	chr7:28220237	JAZF1	-0.43	-5.61	-0.3	4.4e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08580838	chr8:104427696	DCAF13;SLC25A32	0.38	5.98	0.31	5.82e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6546324	0.580	rs6724133	chr2:67858671	A/G	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.23	-0.32	1.44e-9	Endometriosis;
CRC	cis	rs55788414	0.932	rs34110030	chr16:81185211	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.87	-0.35	3.27e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg05194412	chr2:137003533	NA	0.44	6.89	0.35	2.9e-11	Colorectal cancer;
CRC	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.06	0.52	2.21e-24	Exhaled nitric oxide output;
CRC	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.71	-9.12	-0.45	7.86e-18	Dementia with Lewy bodies;
CRC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.55	9.95	0.48	1.4e-20	Lung cancer;
CRC	cis	rs7703744	0.634	rs17145248	chr5:118685011	C/T	cg02283238	chr5:118691126	TNFAIP8	0.46	6.15	0.32	2.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1887596	0.705	rs1697223	chr13:27216940	A/T	cg01312412	chr13:27282625	NA	-0.42	-5.85	-0.31	1.2e-8	Facial morphology (factor 3, length of philtrum);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08377569	chr16:30538014	ZNF768	0.38	6.47	0.34	3.47e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06814637	chr1:36554277	ADPRHL2	0.42	6.0	0.31	5.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg13844804	chr7:814759	HEATR2	0.65	8.51	0.42	6.2e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs7428	1.000	rs72840063	chr2:85550396	T/A	cg24342717	chr2:85555507	TGOLN2	-0.5	-6.93	-0.36	2.29e-11	Ear protrusion;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg25164649	chr6:28176230	NA	0.48	6.96	0.36	1.88e-11	Cardiac Troponin-T levels;
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs758324	0.812	rs10045303	chr5:131202801	C/T	cg25547332	chr5:131281432	NA	-0.36	-5.7	-0.3	2.61e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9463078	0.838	rs1924662	chr6:45140332	T/A	cg25276700	chr6:44698697	NA	-0.29	-6.82	-0.35	4.28e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.65	-9.56	-0.47	2.82e-19	Height;
CRC	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.49	-7.55	-0.38	4.41e-13	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg06238570	chr21:40685208	BRWD1	0.71	10.02	0.48	8.55e-21	Cognitive function;
CRC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg08807892	chr2:162101083	NA	-0.43	-5.67	-0.3	3.16e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06886078	chr10:126480477	METTL10	0.37	6.39	0.33	5.74e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9786986	0.764	rs210036	chr1:235694741	C/T	cg08848088	chr1:235714526	GNG4	0.49	5.76	0.3	1.94e-8	Body mass index;
CRC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.55	6.11	0.32	2.79e-9	Initial pursuit acceleration;
CRC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.5	-7.03	-0.36	1.23e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg07884673	chr3:53033167	SFMBT1	0.69	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.7	0.35	9.26e-11	Tonsillectomy;
CRC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.57	11.37	0.53	1.67e-25	Asthma (sex interaction);
CRC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-13.97	-0.61	3.74e-35	Lymphocyte percentage of white cells;
CRC	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg26875233	chr11:93583750	C11orf90	0.37	7.17	0.37	4.82e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.78e-15	Life satisfaction;
CRC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg23018236	chr17:30244563	NA	-0.58	-7.7	-0.39	1.64e-13	Hip circumference adjusted for BMI;
CRC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg02560186	chr11:3602584	NA	-0.47	-6.3	-0.33	9.55e-10	Blood pressure (smoking interaction);
CRC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg17948913	chr5:572064	NA	0.51	6.14	0.32	2.43e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.56	-5.73	-0.3	2.25e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.8	-0.35	4.92e-11	Aortic root size;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg25164649	chr6:28176230	NA	0.63	8.31	0.42	2.62e-15	Parkinson's disease;
CRC	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12144309	0.554	rs1217375	chr1:114346904	G/A	cg03325407	chr1:114423726	BCL2L15	0.35	6.52	0.34	2.63e-10	Coronary artery disease;
CRC	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.69	-8.69	-0.43	1.68e-16	Blood protein levels;
CRC	cis	rs539514	0.690	rs4885345	chr13:76318453	C/T	cg04757411	chr13:76259545	LMO7	0.35	5.95	0.31	6.73e-9	Type 1 diabetes;
CRC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	0.84	13.39	0.59	6.15e-33	Cognitive function;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg06470822	chr6:28175283	NA	0.58	6.84	0.35	3.81e-11	Breast cancer;
CRC	cis	rs9847710	0.967	rs2564934	chr3:53024580	G/A	cg18404041	chr3:52824283	ITIH1	0.3	5.94	0.31	7.34e-9	Ulcerative colitis;
CRC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.32	6.96	0.36	1.81e-11	Psoriasis;
CRC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-5.9	-0.31	8.85e-9	Major depressive disorder;
CRC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.84	14.85	0.63	1.52e-38	Breast cancer;
CRC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.44	-0.33	4.21e-10	Aortic root size;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg20467896	chr19:6361623	CLPP	-0.55	-5.97	-0.31	6e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg18551225	chr6:44695536	NA	-0.41	-6.04	-0.32	4.17e-9	Total body bone mineral density;
CRC	cis	rs939584	0.696	rs62105306	chr2:633660	C/T	cg03610516	chr2:642275	NA	0.42	5.65	0.3	3.49e-8	Body mass index;
CRC	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.61	-11.27	-0.53	3.78e-25	Educational attainment;
CRC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.15	-0.32	2.27e-9	Gut microbiome composition (summer);
CRC	cis	rs10208940	0.841	rs10172125	chr2:68787191	T/G	cg12452813	chr2:68675892	NA	0.47	5.93	0.31	7.57e-9	Urate levels in lean individuals;
CRC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg05540913	chr6:167530185	CCR6	-0.41	-7.36	-0.38	1.44e-12	Primary biliary cholangitis;
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.59	-0.34	1.71e-10	Height;
CRC	trans	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg07393940	chr7:158741817	NA	0.51	7.22	0.37	3.52e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg09264619	chr17:80180166	NA	-0.5	-7.28	-0.37	2.49e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.79	-14.18	-0.62	6.07e-36	Lewy body disease;
CRC	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg02659138	chr7:134003124	SLC35B4	0.43	7.49	0.38	6.58e-13	Mean platelet volume;
CRC	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg14844989	chr11:31128820	NA	0.33	5.73	0.3	2.22e-8	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24155668	chr6:36098398	MAPK13	0.43	6.13	0.32	2.46e-9	Response to antipsychotic treatment;
CRC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg10760299	chr15:45669010	GATM	-0.44	-6.82	-0.35	4.48e-11	Homoarginine levels;
CRC	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg26364809	chr7:27145159	NA	-0.72	-6.71	-0.35	8.56e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg15790184	chr11:494944	RNH1	0.61	6.24	0.33	1.35e-9	Body mass index;
CRC	cis	rs78761021	0.514	rs4791906	chr17:9795452	A/G	cg26853458	chr17:9805074	RCVRN	-0.28	-6.01	-0.31	5e-9	Type 2 diabetes;
CRC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.71	-0.35	8.67e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10130860	chr1:43124230	PPIH	0.44	6.54	0.34	2.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6479527	0.875	rs4744308	chr9:96798762	C/T	cg14459158	chr9:96720562	NA	0.38	6.71	0.35	8.37e-11	Esophageal adenocarcinoma;
CRC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.43	-5.74	-0.3	2.21e-8	Platelet distribution width;
CRC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.46	9.21	0.45	3.9e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	5.67	0.3	3.1e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.46	-7.67	-0.39	1.95e-13	Educational attainment;
CRC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg26260408	chr4:53727979	RASL11B	0.41	5.86	0.31	1.12e-8	Optic nerve measurement (cup area);
CRC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.72	12.01	0.55	8.26e-28	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg03623178	chr6:28175578	NA	0.48	6.37	0.33	6.37e-10	Myopia;
CRC	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-8.41	-0.42	1.25e-15	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.5	6.36	0.33	6.68e-10	Systolic blood pressure;
CRC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.56	-7.46	-0.38	7.53e-13	Multiple sclerosis;
CRC	cis	rs1178968	1.000	rs4717751	chr7:72750627	G/A	cg25889504	chr7:72793014	NA	0.53	6.04	0.32	4.16e-9	Triglyceride levels;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg17346650	chr17:80929145	B3GNTL1	0.49	7.12	0.37	6.93e-12	Glycated hemoglobin levels;
CRC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.5	9.13	0.45	6.91e-18	Longevity;
CRC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	6.02	0.31	4.74e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg04796162	chr7:45961102	IGFBP3	-0.43	-7.26	-0.37	2.88e-12	Sitting height ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11342046	chr2:242641489	ING5	0.46	6.03	0.32	4.32e-9	Thyroid stimulating hormone;
CRC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg02569458	chr12:86230093	RASSF9	0.37	6.46	0.34	3.67e-10	Major depressive disorder;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg01900965	chr4:2471727	RNF4	-0.51	-5.96	-0.31	6.39e-9	Type 1 diabetes;
CRC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg19193384	chr17:30244184	NA	-0.49	-6.75	-0.35	6.88e-11	Hip circumference adjusted for BMI;
CRC	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.45	7.4	0.38	1.14e-12	Refractive error;
CRC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg19980929	chr12:42632907	YAF2	0.48	7.3	0.37	2.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.12	-0.37	6.98e-12	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg19223190	chr17:80058835	NA	0.41	6.5	0.34	3e-10	Life satisfaction;
CRC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	5.73	0.3	2.27e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg23815491	chr16:72088622	HP	0.64	8.0	0.4	2.15e-14	Blood protein levels;
CRC	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-9.21	-0.45	3.94e-18	Exhaled nitric oxide output;
CRC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg21425842	chr6:26240939	HIST1H4F	-0.34	-5.72	-0.3	2.45e-8	Gout;Renal underexcretion gout;
CRC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.59	10.44	0.5	3.1e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-17.75	-0.7	6.67e-50	Height;
CRC	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.61	11.29	0.53	3.27e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs9463078	0.753	rs10948186	chr6:44903248	C/T	cg25276700	chr6:44698697	NA	-0.28	-6.74	-0.35	7.27e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg25356066	chr3:128598488	ACAD9	0.39	5.67	0.3	3.06e-8	IgG glycosylation;
CRC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg21294424	chr19:58662284	ZNF329	0.83	9.28	0.46	2.31e-18	Cholesterol, total;
CRC	cis	rs4938330	0.723	rs7931398	chr11:116879676	T/C	cg20608306	chr11:116969690	SIK3	-0.31	-5.9	-0.31	8.8e-9	Blood protein levels;
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg24046110	chr8:143859143	LYNX1	0.49	8.52	0.43	5.77e-16	Urinary tract infection frequency;
CRC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.19	0.32	1.75e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-9.71	-0.47	9.15e-20	Total cholesterol levels;
CRC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.42	-0.5	3.58e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.58	0.47	2.52e-19	Cognitive test performance;
CRC	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg09659197	chr4:152720779	NA	0.4	7.93	0.4	3.4e-14	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	ch.5.67026991F	chr5:66991235	NA	0.4	5.99	0.31	5.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.83	14.72	0.63	5.16e-38	Breast cancer;
CRC	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.42	-5.71	-0.3	2.5e-8	Diisocyanate-induced asthma;
CRC	cis	rs55702914	0.809	rs6738721	chr2:198182334	A/G	cg03934865	chr2:198174659	NA	-0.41	-7.11	-0.36	7.41e-12	Major depression and alcohol dependence;
CRC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.44	5.92	0.31	8.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.94	-9.7	-0.47	1.01e-19	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.32	-0.37	1.87e-12	Bipolar disorder;
CRC	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg19025524	chr12:109796872	NA	-0.49	-7.37	-0.38	1.36e-12	Neuroticism;
CRC	cis	rs17443541	0.564	rs1450570	chr2:200442061	G/T	cg03741458	chr2:200468445	NA	0.37	5.81	0.31	1.47e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg17294928	chr15:75287854	SCAMP5	-0.42	-6.4	-0.33	5.39e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg10596483	chr8:143751796	JRK	-0.5	-6.82	-0.35	4.5e-11	Urinary tract infection frequency;
CRC	trans	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg17903999	chr18:56338584	MALT1	0.42	7.05	0.36	1.08e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.46	-0.42	9.03e-16	Bipolar disorder;
CRC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.76	-10.35	-0.5	6.54e-22	Coronary artery disease;
CRC	trans	rs58810682	0.662	rs12164144	chr8:43701112	C/T	cg20651681	chr7:50861418	GRB10	-0.46	-5.99	-0.31	5.37e-9	Response to amphetamines;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.56	8.36	0.42	1.84e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17520203	chr4:47465732	COMMD8	0.44	6.16	0.32	2.12e-9	Response to antipsychotic treatment;
CRC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.24	0.37	3.19e-12	Hip circumference adjusted for BMI;
CRC	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg27068330	chr11:65405492	SIPA1	0.45	6.69	0.35	9.62e-11	Acne (severe);
CRC	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.39	-0.33	5.62e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.88	0.4	4.89e-14	Breast cancer;
CRC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.29	-0.46	2.11e-18	Dupuytren's disease;
CRC	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.53	-7.25	-0.37	2.96e-12	Triglycerides;
CRC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	ch.11.42038R	chr11:967971	AP2A2	0.58	9.18	0.45	5.03e-18	Alzheimer's disease (late onset);
CRC	cis	rs12519773	0.526	rs4242240	chr5:92517203	A/G	cg18783429	chr5:92414398	NA	0.26	5.62	0.3	4.07e-8	Migraine;
CRC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg24879335	chr3:133465180	TF	0.31	5.67	0.3	3.11e-8	Iron status biomarkers;
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.7	9.21	0.45	3.89e-18	Alzheimer's disease;
CRC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.33	-0.33	8.17e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.74	-9.21	-0.45	3.87e-18	Body mass index;
CRC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.36	-8.39	-0.42	1.5e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.45	-7.04	-0.36	1.13e-11	HDL cholesterol;
CRC	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.75	0.47	6.73e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg18653534	chr16:772142	FAM173A	-0.37	-5.84	-0.31	1.26e-8	Height;
CRC	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.67	10.77	0.51	2.32e-23	Pulmonary function decline;
CRC	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.44	6.49	0.34	3.1e-10	Social autistic-like traits;
CRC	cis	rs6854137	1.000	rs6854137	chr4:169728236	T/G	cg20607169	chr4:169750834	PALLD	0.39	6.09	0.32	3.14e-9	Vein graft stenosis in coronary artery bypass grafting;
CRC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.47	6.4	0.33	5.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs731174	0.797	rs586252	chr1:38155265	G/C	cg06917450	chr1:38156652	C1orf109	-0.51	-7.22	-0.37	3.61e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.49	7.14	0.37	5.85e-12	Blood metabolite levels;
CRC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.51	7.86	0.4	5.64e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.98	0.31	5.94e-9	Aortic root size;
CRC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg15226275	chr6:116381976	FRK	0.29	8.27	0.41	3.3e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.49	7.22	0.37	3.68e-12	Blood metabolite levels;
CRC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.6	-9.19	-0.45	4.6e-18	Body mass index;
CRC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.75	11.76	0.54	7.11e-27	Schizophrenia;
CRC	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.63	9.92	0.48	1.8899999999999998e-20	Gestational age at birth (maternal effect);
CRC	cis	rs972578	1.000	rs5751404	chr22:43358737	G/T	cg01576275	chr22:43409880	NA	-0.45	-7.25	-0.37	3.08e-12	Mean platelet volume;
CRC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.55	-8.81	-0.44	7.39e-17	Prostate cancer;
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.78	0.44	9.09e-17	Alzheimer's disease;
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02807482	chr3:125708958	NA	-0.46	-5.9	-0.31	9.13e-9	Blood pressure (smoking interaction);
CRC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-8.58	-0.43	3.84e-16	Coronary artery disease;
CRC	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg05283184	chr6:79620031	NA	-0.45	-6.45	-0.34	4.01e-10	Intelligence (multi-trait analysis);
CRC	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.76	8.65	0.43	2.26e-16	Inflammatory bowel disease;
CRC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg08314208	chr16:67682810	RLTPR	-0.58	-6.22	-0.32	1.53e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg27534772	chr1:16042836	PLEKHM2	0.43	7.21	0.37	3.93e-12	Systolic blood pressure;
CRC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.61	-9.73	-0.47	7.7e-20	Monocyte count;
CRC	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.56	8.18	0.41	6.18e-15	Childhood ear infection;
CRC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.97	-16.92	-0.68	1.24e-46	Headache;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16157821	chr3:58419758	PDHB	0.49	6.87	0.35	3.13e-11	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.43	-0.33	4.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.53	6.66	0.34	1.18e-10	Methadone dose in opioid dependence;
CRC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.9	-0.31	8.99e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.45	-6.06	-0.32	3.79e-9	Gut microbiome composition (summer);
CRC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.21	-26.26	-0.82	9.61e-83	Triglycerides;
CRC	trans	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg01134436	chr17:81009848	B3GNTL1	0.76	7.09	0.36	8.43e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.62	9.26	0.45	2.68e-18	Lewy body disease;
CRC	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.61	9.46	0.46	5.96e-19	Blood protein levels;
CRC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.49	-5.79	-0.3	1.65e-8	Hip geometry;
CRC	cis	rs12523822	0.957	rs9479915	chr6:154960735	T/G	cg20019720	chr6:154832845	CNKSR3	0.26	5.66	0.3	3.37e-8	Diabetic kidney disease;
CRC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.78	-12.98	-0.58	2.25e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg01543582	chr4:190862539	FRG1	-0.31	-5.99	-0.31	5.57e-9	Brain structure;
CRC	trans	rs7546	0.505	rs760118	chr16:4940994	A/G	cg19252218	chr17:41477271	ARL4D	-0.43	-6.33	-0.33	8.08e-10	Cancer;
CRC	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg20356878	chr3:121714668	ILDR1	-0.42	-5.9	-0.31	8.81e-9	Multiple sclerosis;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg15269541	chr15:43626905	ADAL	-0.37	-5.72	-0.3	2.43e-8	Lung cancer;
CRC	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.71	-0.35	8.65e-11	Coronary artery disease;
CRC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.47	-7.06	-0.36	1.01e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg07090678	chr1:91966139	CDC7	0.37	5.85	0.31	1.19e-8	Breast cancer;
CRC	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.48	7.33	0.37	1.82e-12	Testicular germ cell tumor;
CRC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.91	0.31	8.58e-9	Renal function-related traits (BUN);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19355881	chr6:34759549	UHRF1BP1	0.38	6.08	0.32	3.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12431939	1.000	rs67065973	chr14:51656225	T/C	cg23942311	chr14:51606299	NA	-0.53	-6.4	-0.33	5.41e-10	Cancer;
CRC	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.14	-9.47	-0.46	5.64e-19	Mitochondrial DNA levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25652642	chr19:10514370	MIR1181;CDC37	0.48	6.57	0.34	1.94e-10	Anxiety disorder;
CRC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.43	5.9	0.31	9.08e-9	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13365641	chr2:211036230	C2orf67	0.38	6.29	0.33	9.95e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs55726902	0.761	rs2544030	chr12:48195451	G/A	cg14736327	chr12:48174669	SLC48A1	-0.48	-6.33	-0.33	7.9e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs73200209	0.744	rs17498802	chr12:116642212	T/G	cg01776926	chr12:116560359	MED13L	-0.61	-7.08	-0.36	8.97e-12	Total body bone mineral density;
CRC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.65	7.06	0.36	1.01e-11	Axial length;
CRC	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg00490450	chr3:139108681	COPB2	0.44	6.53	0.34	2.57e-10	Obesity-related traits;
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg27432699	chr2:27873401	GPN1	-0.5	-7.58	-0.39	3.5e-13	Total body bone mineral density;
CRC	cis	rs501120	0.564	rs2804036	chr10:44680405	A/G	cg09554077	chr10:44749378	NA	0.49	6.79	0.35	5.23e-11	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg22687807	chr8:143858763	LYNX1	-0.42	-6.34	-0.33	7.43e-10	Urinary tract infection frequency;
CRC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.5	-6.81	-0.35	4.68e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11098699	0.821	rs6830258	chr4:124230345	A/G	cg09941581	chr4:124220074	SPATA5	-0.4	-5.94	-0.31	7.44e-9	Mosquito bite size;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11446398	chr5:77624930	NA	0.43	6.24	0.33	1.37e-9	Triglycerides;
CRC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg19193384	chr17:30244184	NA	-0.51	-6.45	-0.33	4.05e-10	Hip circumference adjusted for BMI;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16304302	chr12:27486485	ARNTL2	0.45	6.52	0.34	2.65e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.37	0.33	6.21e-10	Tonsillectomy;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg06470822	chr6:28175283	NA	0.76	8.05	0.41	1.49e-14	Depression;
CRC	cis	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg01904812	chr1:17746340	RCC2	0.36	5.93	0.31	7.49e-9	Basal cell carcinoma;
CRC	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg03934865	chr2:198174659	NA	-0.39	-5.81	-0.31	1.47e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.74	-0.35	6.99e-11	Coronary artery disease;
CRC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg12927641	chr6:109611667	NA	-0.38	-6.74	-0.35	7.22e-11	Reticulocyte fraction of red cells;
CRC	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.73	0.51	3.22e-23	Bipolar disorder;
CRC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg15786705	chr6:28176104	NA	-0.57	-7.3	-0.37	2.16e-12	Parkinson's disease;
CRC	trans	rs10253216	0.684	rs10245233	chr7:16860089	G/C	cg00402074	chr6:46889742	GPR116	0.33	6.14	0.32	2.43e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
CRC	cis	rs2929278	0.617	rs11070410	chr15:44057045	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-5.92	-0.31	8.07e-9	Schizophrenia;
CRC	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11446398	chr5:77624930	NA	0.43	6.33	0.33	8.01e-10	Triglycerides;
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg22687807	chr8:143858763	LYNX1	0.49	8.79	0.44	8.36e-17	Urinary tract infection frequency;
CRC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg08755490	chr11:65554678	OVOL1	0.4	5.79	0.3	1.66e-8	Acne (severe);
CRC	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.66	8.79	0.44	8.27e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.7	-8.88	-0.44	4.55e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2070433	0.534	rs2839269	chr21:47891491	A/G	cg19571106	chr8:9762850	NA	-0.32	-6.28	-0.33	1.09e-9	Lymphocyte counts;
CRC	cis	rs6604026	0.740	rs7536563	chr1:93349046	A/G	cg17283838	chr1:93427260	FAM69A	-0.47	-6.33	-0.33	7.8e-10	Multiple sclerosis;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg12856521	chr11:46389249	DGKZ	-0.42	-6.77	-0.35	5.85e-11	Leprosy;
CRC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg07884673	chr3:53033167	SFMBT1	0.69	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg09658497	chr7:2847517	GNA12	-0.38	-6.31	-0.33	9.14e-10	Height;
CRC	cis	rs7487075	0.786	rs7980775	chr12:46674873	A/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.02	0.32	4.59e-9	Itch intensity from mosquito bite;
CRC	cis	rs12286929	0.839	rs12790574	chr11:115009145	C/T	cg04055981	chr11:115044050	NA	0.36	5.67	0.3	3.14e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg19622623	chr12:86230825	RASSF9	-0.37	-5.8	-0.3	1.57e-8	Major depressive disorder;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.34	-6.3	-0.33	9.3e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.94	8.71	0.43	1.54e-16	Mitochondrial DNA levels;
CRC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.75	12.76	0.58	1.4e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.58	-8.69	-0.43	1.71e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.95	12.2	0.56	1.64e-28	Triglycerides;
CRC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.08	-0.49	5.11e-21	Primary sclerosing cholangitis;
CRC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg26384229	chr12:38710491	ALG10B	0.46	6.47	0.34	3.64e-10	Morning vs. evening chronotype;
CRC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg08314208	chr16:67682810	RLTPR	-0.65	-6.67	-0.34	1.11e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg26741380	chr15:41871084	TYRO3	0.45	6.2	0.32	1.73e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.69	-0.3	2.82e-8	Coronary artery disease;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.67	10.68	0.51	4.82e-23	Longevity;Endometriosis;
CRC	cis	rs11690256	1.000	rs11690256	chr2:129542767	A/G	cg16353174	chr2:129543148	NA	0.43	6.07	0.32	3.46e-9	Symmetrical dimethylarginine levels;
CRC	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.7	-7.5	-0.38	6e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.51	6.97	0.36	1.75e-11	Triglycerides;
CRC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg24011408	chr12:48396354	COL2A1	0.45	6.63	0.34	1.34e-10	Glycated hemoglobin levels;
CRC	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.57	9.66	0.47	1.33e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.22e-12	Bipolar disorder;
CRC	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg09127314	chr1:152161683	NA	0.48	6.22	0.32	1.49e-9	Atopic dermatitis;
CRC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-9.53	-0.47	3.6e-19	Body mass index;
CRC	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-8.2	-0.41	5.6e-15	Waist circumference;Body mass index;
CRC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.76	12.15	0.56	2.61e-28	Breast cancer;
CRC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg14979609	chr8:8086686	FLJ10661	0.36	5.82	0.31	1.44e-8	Joint mobility (Beighton score);
CRC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.59	8.23	0.41	4.41e-15	Bipolar disorder;
CRC	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.64	6.49	0.34	3.15e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.79	-8.63	-0.43	2.67e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg26816564	chr1:7831052	VAMP3	-0.48	-5.79	-0.3	1.67e-8	Inflammatory bowel disease;
CRC	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg27523141	chr10:43048294	ZNF37B	0.43	6.04	0.32	4.19e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.71	-9.21	-0.45	4.06e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.44	5.88	0.31	1.01e-8	Schizophrenia;
CRC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.58	-0.43	3.7e-16	Aortic root size;
CRC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.69	-0.35	9.33e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.92	-0.31	7.95e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg16486109	chr11:613632	IRF7	0.63	11.05	0.52	2.33e-24	Systemic lupus erythematosus;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10075436	chr19:59084928	MZF1;LOC100131691	0.5	6.43	0.33	4.54e-10	Thyroid stimulating hormone;
CRC	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.59	8.83	0.44	6.54e-17	Autism;
CRC	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg14631576	chr9:95140430	CENPP	-0.38	-6.63	-0.34	1.38e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.83e-9	Life satisfaction;
CRC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.86	-0.58	6.14e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.56	6.48	0.34	3.3e-10	Vitiligo;
CRC	cis	rs9491140	0.539	rs10872285	chr6:124689145	C/T	cg22366943	chr6:124882293	NKAIN2	0.59	8.33	0.42	2.17e-15	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05739825	chr11:125439882	EI24	0.48	6.77	0.35	6e-11	Response to antipsychotic treatment;
CRC	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.48	6.38	0.33	6.04e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg10724054	chr17:3904396	NA	-0.46	-7.5	-0.38	5.99e-13	Type 2 diabetes;
CRC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs972578	1.000	rs5759078	chr22:43393042	G/C	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.97e-14	Mean platelet volume;
CRC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.67	9.45	0.46	6.69e-19	Neuroblastoma;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12172441	chr6:28176163	NA	0.59	7.18	0.37	4.72e-12	Parkinson's disease;
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg18479299	chr3:125709523	NA	-0.53	-6.36	-0.33	6.78e-10	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.43	9.48	0.46	5.3e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg18288967	chr1:45987694	PRDX1	0.61	6.7	0.35	8.83e-11	Obesity-related traits;
CRC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.06	-15.36	-0.65	1.63e-40	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00960509	chr1:21671908	ECE1	0.38	6.15	0.32	2.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02290350	chr8:58132656	NA	-0.43	-6.12	-0.32	2.64e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.52	0.43	5.72e-16	Corneal astigmatism;
CRC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.61	-11.33	-0.53	2.31e-25	Educational attainment;
CRC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.79	8.04	0.41	1.68e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg03037974	chr15:76606532	NA	-0.7	-12.23	-0.56	1.33e-28	Blood metabolite levels;
CRC	cis	rs1322512	1.000	rs1727054	chr6:152947742	A/G	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06175075	chr4:146055261	OTUD4	-0.38	-6.31	-0.33	8.94e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg02007433	chr3:129722099	NA	-0.51	-6.26	-0.33	1.19e-9	Blood pressure (smoking interaction);
CRC	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.62	9.45	0.46	6.77e-19	Night sleep phenotypes;
CRC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.03	0.32	4.38e-9	Diabetic retinopathy;
CRC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.39e-11	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12443622	chr17:42219154	C17orf53	0.51	7.2	0.37	4.16e-12	Response to antipsychotic treatment;
CRC	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12292205	chr6:26970375	C6orf41	-0.76	-8.08	-0.41	1.29e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7113874	0.610	rs1446462	chr11:8566343	C/T	cg17679104	chr11:8615758	STK33	-0.36	-6.01	-0.31	4.87e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23600533	chr11:64885249	ZNHIT2	-0.4	-5.98	-0.31	5.84e-9	Myopia (pathological);
CRC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.99	-0.4	2.36e-14	Life satisfaction;
CRC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.58	-0.34	1.85e-10	Coronary artery disease;
CRC	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.49	8.76	0.43	1.04e-16	Weight;
CRC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.22	0.37	3.53e-12	Aortic root size;
CRC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.47	-0.42	8.1e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.11	-0.45	8.2e-18	Neuroticism;
CRC	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.48	7.56	0.38	4.03e-13	Red blood cell count;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg07414643	chr4:187882934	NA	0.37	6.32	0.33	8.36e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg22495460	chr2:25135724	ADCY3	0.67	11.12	0.52	1.38e-24	Body mass index in non-asthmatics;
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.47	6.56	0.34	2.06e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.67	6.82	0.35	4.47e-11	Pediatric areal bone mineral density (radius);
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.5	-6.72	-0.35	8.02e-11	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11912956	chr7:73588697	EIF4H	0.44	5.97	0.31	6.12e-9	Thyroid stimulating hormone;
CRC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.83	-14.42	-0.62	7.17e-37	Height;
CRC	cis	rs10782582	0.609	rs946163	chr1:76383049	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.43	-5.65	-0.3	3.43e-8	Daytime sleep phenotypes;
CRC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg04586622	chr2:25135609	ADCY3	-0.56	-10.33	-0.49	7.53e-22	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10473508	chr5:172068142	NEURL1B	0.49	7.02	0.36	1.25e-11	Response to antipsychotic treatment;
CRC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26850624	chr5:429559	AHRR	-0.51	-8.54	-0.43	4.91e-16	Cystic fibrosis severity;
CRC	trans	rs28411352	0.922	rs12116786	chr1:38247095	A/G	cg19525872	chr12:130934808	RIMBP2	-0.41	-6.06	-0.32	3.72e-9	Rheumatoid arthritis;
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg20041105	chr8:143859282	LYNX1	0.57	10.09	0.49	4.91e-21	Urinary tract infection frequency;
CRC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg15763984	chr4:1342303	KIAA1530	0.34	5.82	0.31	1.4e-8	Longevity;
CRC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.37	0.53	1.67e-25	Asthma (sex interaction);
CRC	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs62408225	1.000	rs2325291	chr6:90986686	G/A	cg06866423	chr6:90926672	BACH2	0.5	8.22	0.41	4.88e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-9.58	-0.47	2.38e-19	Monocyte count;
CRC	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg04165759	chr1:150448943	RPRD2	0.34	5.66	0.3	3.21e-8	Migraine;
CRC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.6	-8.77	-0.44	9.96e-17	Menarche (age at onset);
CRC	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.96	-0.31	6.61e-9	Subjective well-being;
CRC	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg00564723	chr10:75632066	CAMK2G	-0.37	-8.77	-0.44	9.6e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.72	12.45	0.57	2e-29	Mosquito bite size;
CRC	cis	rs7804356	1.000	rs73069507	chr7:26877536	A/G	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.1e-8	Type 1 diabetes;
CRC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-17.22	-0.69	7.75e-48	Coronary artery disease;
CRC	cis	rs12230513	0.732	rs12582120	chr12:55830064	A/G	cg19537932	chr12:55886519	OR6C68	-0.73	-9.44	-0.46	7.02e-19	Contrast sensitivity;
CRC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.0	0.31	5.32e-9	Aortic root size;
CRC	cis	rs807029	0.533	rs67813203	chr10:102738551	A/G	cg04662943	chr10:102668895	NA	0.63	7.57	0.39	3.74e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.35	-0.33	7.08e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg24304309	chr1:154577895	ADAR	-0.37	-6.14	-0.32	2.42e-9	Blood protein levels;
CRC	cis	rs2857891	1.000	rs2595500	chr11:6963165	C/T	cg22096450	chr11:6947773	ZNF215	-0.57	-6.35	-0.33	6.98e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.22	-0.32	1.54e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg17724175	chr1:150552817	MCL1	-0.48	-7.12	-0.37	6.96e-12	Melanoma;
CRC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.03e-9	Bladder cancer;
CRC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.68	10.25	0.49	1.37e-21	Monocyte count;
CRC	trans	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg26043149	chr18:55253948	FECH	0.5	7.46	0.38	7.59e-13	Bone mineral density;
CRC	cis	rs12620999	0.887	rs6723783	chr2:237963572	C/A	cg23555395	chr2:238036564	NA	0.45	6.72	0.35	7.96e-11	Systemic lupus erythematosus;
CRC	trans	rs55675132	0.548	rs3911879	chr1:115378032	C/T	cg25493687	chr8:27288214	PTK2B	0.51	6.43	0.33	4.62e-10	Schizophrenia;
CRC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg11632617	chr15:75315747	PPCDC	-0.56	-7.96	-0.4	2.86e-14	Blood trace element (Zn levels);
CRC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.05	-0.32	3.98e-9	Reticulocyte count;
CRC	cis	rs2982552	0.873	rs1999807	chr6:152064199	C/G	cg22157087	chr6:152012887	ESR1	0.38	5.83	0.31	1.3e-8	Bone properties (heel);
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.23	0.45	3.46e-18	Lung cancer;
CRC	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.35	6.36	0.33	6.58e-10	Panic disorder;
CRC	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg18761221	chr20:60518478	NA	0.45	7.21	0.37	3.8e-12	Body mass index;
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg16060761	chr17:80687452	NA	-0.46	-6.05	-0.32	3.84e-9	Glycated hemoglobin levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27018013	chr16:2524149	TBC1D24	0.46	6.21	0.32	1.6e-9	Anxiety disorder;
CRC	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.47	-8.33	-0.42	2.18e-15	Testicular germ cell tumor;
CRC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg21153622	chr11:89784906	NA	0.41	6.27	0.33	1.15e-9	Coronary artery disease;
CRC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.45	0.46	6.57e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.45	5.94	0.31	7.09e-9	Gut microbiome composition (summer);
CRC	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.49	-6.43	-0.33	4.43e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs3751196	0.803	rs74625467	chr12:104185164	C/A	cg02344784	chr12:104178138	NT5DC3	0.7	7.14	0.37	6.12e-12	Sense of smell;
CRC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.5	-7.72	-0.39	1.39e-13	Body mass index;
CRC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04740679	chr13:114016140	GRTP1	0.34	7.04	0.36	1.16e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.34e-36	Colorectal cancer;
CRC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.73e-20	Bladder cancer;
CRC	cis	rs10888329	0.707	rs4916106	chr1:248353537	G/A	cg00666640	chr1:248458726	OR2T12	0.43	7.46	0.38	7.92e-13	Autism spectrum disorder;
CRC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg25072359	chr17:41440525	NA	0.44	5.93	0.31	7.79e-9	Menopause (age at onset);
CRC	cis	rs10924970	0.687	rs4553178	chr1:235364543	T/C	cg09010748	chr1:235293032	TOMM20	-0.4	-5.64	-0.3	3.72e-8	Asthma;
CRC	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg09659197	chr4:152720779	NA	0.5	10.59	0.5	9.76e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.38	-0.38	1.27e-12	Monocyte percentage of white cells;
CRC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.13	0.64	1.23e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	5.84	0.31	1.27e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.44	6.04	0.32	4.18e-9	Obesity-related traits;
CRC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.91	16.65	0.68	1.38e-45	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.82	-16.09	-0.66	2.26e-43	Prostate cancer;
CRC	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.93	10.43	0.5	3.2800000000000002e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23235142	chr7:45066841	CCM2	0.37	8.97	0.44	2.25e-17	Liver disease severity in Alagille syndrome;
CRC	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.85	0.35	3.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.02	-0.52	2.92e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.46	-0.34	3.74e-10	Response to antipsychotic treatment;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18402987	chr7:1209562	NA	0.46	6.78	0.35	5.47e-11	Longevity;Endometriosis;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg08034379	chr2:228736324	WDR69	-0.48	-6.91	-0.36	2.56e-11	Blood pressure;
CRC	cis	rs6763159	0.566	rs35166137	chr3:59643114	C/T	cg07069742	chr3:59644285	NA	-0.44	-8.71	-0.43	1.51e-16	Conotruncal heart defects;
CRC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.1	-12.3	-0.56	7.15e-29	Diabetic kidney disease;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01442958	chr1:222817780	MIA3	0.47	6.34	0.33	7.69e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg09324608	chr17:30823087	MYO1D	0.33	5.64	0.3	3.73e-8	Schizophrenia;
CRC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16447950	chr5:562315	NA	-0.83	-11.08	-0.52	1.83e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg27535305	chr1:53392650	SCP2	0.36	6.44	0.33	4.31e-10	Monocyte count;
CRC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.61	-0.3	4.34e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg21204522	chr6:27730016	NA	-0.67	-5.89	-0.31	9.79e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg03037974	chr15:76606532	NA	-0.57	-8.7	-0.43	1.64e-16	Blood metabolite levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17114192	chr19:2061553	NA	0.45	6.83	0.35	4.09e-11	Schizophrenia;
CRC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.54	-7.32	-0.37	1.89e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg09491104	chr22:46646882	C22orf40	-0.45	-5.66	-0.3	3.34e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.91	-17.22	-0.69	7.9e-48	Obesity-related traits;
CRC	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.83	-13.73	-0.6	3.07e-34	Hypospadias;
CRC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.46	6.91	0.36	2.52e-11	Menopause (age at onset);
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Parkinson's disease;
CRC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg03948781	chr1:205179583	DSTYK	0.43	6.13	0.32	2.56e-9	Red blood cell count;
CRC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.35	-0.33	7.02e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.87	0.35	3.28e-11	Mood instability;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.72	7.47	0.38	7.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs804280	0.564	rs4639	chr8:11644751	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.03	0.32	4.43e-9	Myopia (pathological);
CRC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.61	9.44	0.46	6.9e-19	Methadone dose in opioid dependence;
CRC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.41	6.13	0.32	2.47e-9	Type 2 diabetes;
CRC	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.64	8.54	0.43	4.93e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg09655341	chr17:79618100	PDE6G	-0.38	-6.84	-0.35	3.77e-11	Eye color traits;
CRC	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.54	7.27	0.37	2.69e-12	Itch intensity from mosquito bite;
CRC	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg11645453	chr3:52864694	ITIH4	-0.4	-7.47	-0.38	7.52e-13	Body mass index;
CRC	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg12855166	chr17:30846586	MYO1D	-0.37	-6.02	-0.32	4.54e-9	Schizophrenia;
CRC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.51	-9.74	-0.47	7.02e-20	Intelligence (multi-trait analysis);
CRC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.4	-7.93	-0.4	3.39e-14	Schizophrenia;
CRC	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	7.05	0.36	1.05e-11	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1223397	1.000	rs1223397	chr6:13270945	C/G	cg06879394	chr6:13274151	PHACTR1	0.49	6.18	0.32	1.87e-9	Blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20362559	chr2:96931853	TMEM127;CIAO1	0.48	6.67	0.35	1.06e-10	Anxiety disorder;
CRC	cis	rs73206853	0.841	rs2339511	chr12:110789372	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	6.77	0.35	6.05e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-9.11	-0.45	7.96e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg21770322	chr7:97807741	LMTK2	0.52	8.48	0.42	7.75e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1405069	0.809	rs1063021	chr6:36932327	A/G	cg26433444	chr6:36932349	PI16	0.38	6.78	0.35	5.68e-11	Chemerin levels;
CRC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.48	8.38	0.42	1.57e-15	Primary biliary cholangitis;
CRC	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.72	-10.3	-0.49	9.63e-22	Blood protein levels;
CRC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.77	-13.08	-0.58	9.14e-32	Blood protein levels;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg18108499	chr4:106629741	INTS12;GSTCD	-0.57	-5.98	-0.31	5.72e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.45	-7.29	-0.37	2.35e-12	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg02037503	chr14:23540729	ACIN1	0.39	6.12	0.32	2.67e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.34	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.46	0.34	3.84e-10	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23100370	chr2:109336342	RANBP2	0.42	6.86	0.35	3.47e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.63	-0.3	3.77e-8	Breast cancer;
CRC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg11522145	chr4:3412961	RGS12	-0.37	-6.19	-0.32	1.79e-9	Parental longevity (mother's age at death);
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.54	7.53	0.38	4.82e-13	Alzheimer's disease;
CRC	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.23	6.29	0.33	1.03e-9	Type 2 diabetes;
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg01216370	chr2:228736459	WDR69	-0.45	-5.7	-0.3	2.68e-8	Blood pressure;
CRC	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg22687807	chr8:143858763	LYNX1	-0.37	-6.43	-0.33	4.41e-10	Urinary tract infection frequency;
CRC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg14541582	chr5:601475	NA	-0.36	-7.3	-0.37	2.21e-12	Obesity-related traits;
CRC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.11	19.05	0.72	4.69e-55	Cognitive function;
CRC	cis	rs6743376	0.532	rs2515403	chr2:113820732	T/C	cg24553058	chr2:113831203	IL1F10	0.44	7.18	0.37	4.61e-12	Inflammatory biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07210839	chr7:150595735	NA	0.5	6.96	0.36	1.81e-11	Response to antipsychotic treatment;
CRC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.49	-7.91	-0.4	3.95e-14	Body mass index;
CRC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.3	-0.42	2.79e-15	Type 2 diabetes;
CRC	cis	rs737008	0.922	rs1559394	chr16:11369205	A/G	cg00044050	chr16:11439710	C16orf75	-0.5	-6.79	-0.35	5.23e-11	Obesity-related traits;
CRC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03885332	chr11:832357	CD151	-0.43	-6.41	-0.33	4.96e-10	Mean platelet volume;
CRC	cis	rs3736485	0.966	rs62016017	chr15:51897402	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.38	-0.33	6.01e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.75	-11.01	-0.52	3.14e-24	Platelet distribution width;
CRC	cis	rs7849270	0.959	rs7032712	chr9:131893087	C/T	cg13538475	chr9:131942899	NA	-0.29	-5.87	-0.31	1.08e-8	Blood metabolite ratios;
CRC	trans	rs587242	0.956	rs602272	chr1:96893914	G/A	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09302729	chr15:91565883	VPS33B	0.43	6.17	0.32	2.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.45	-5.91	-0.31	8.44e-9	Lung cancer;
CRC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg04586622	chr2:25135609	ADCY3	0.54	10.12	0.49	4.01e-21	Body mass index;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg19386303	chr19:47104863	CALM3	-0.42	-6.13	-0.32	2.58e-9	Birth weight;Height;
CRC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	12.38	0.56	3.72e-29	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13068082	chr3:9834448	ARPC4;TADA3	0.53	7.51	0.38	5.79e-13	Response to antipsychotic treatment;
CRC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.55e-18	Parkinson's disease;
CRC	cis	rs9462846	0.959	rs9462843	chr6:42856499	T/G	cg02353165	chr6:42928485	GNMT	0.47	5.67	0.3	3.13e-8	Blood protein levels;
CRC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.66	-10.08	-0.49	5.33e-21	Corneal astigmatism;
CRC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg19847866	chr10:1019161	NA	0.41	5.9	0.31	8.99e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.45	6.01	0.31	4.87e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07388806	chr6:7108895	RREB1	0.47	6.37	0.33	6.25e-10	Response to antipsychotic treatment;
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.55	-7.99	-0.4	2.32e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9648716	1.000	rs7792984	chr7:140566243	G/A	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.15e-8	Type 2 diabetes;
CRC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20135002	chr11:47629003	NA	0.34	5.69	0.3	2.83e-8	Subjective well-being;
CRC	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.56	-0.38	3.93e-13	Coronary artery disease;
CRC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.63	8.43	0.42	1.09e-15	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.55e-27	Cognitive function;
CRC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.59	0.39	3.38e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs783540	0.967	rs783526	chr15:83285795	C/A	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.15	-0.32	2.21e-9	Schizophrenia;
CRC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-6.98	-0.36	1.61e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.46	-6.54	-0.34	2.31e-10	Bladder cancer;
CRC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.91	-16.67	-0.68	1.17e-45	Body mass index;
CRC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg10760299	chr15:45669010	GATM	0.5	7.73	0.39	1.29e-13	Homoarginine levels;
CRC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.75	-12.29	-0.56	7.82e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg15192750	chr16:69999425	NA	0.57	7.37	0.38	1.39e-12	IgE levels;
CRC	cis	rs77633900	0.772	rs157760	chr15:76800260	A/G	cg21673338	chr15:77095150	SCAPER	-0.74	-6.93	-0.36	2.25e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-7.99	-0.4	2.25e-14	Hepatocellular carcinoma;
CRC	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.0	-0.31	5.16e-9	Neuroticism;
CRC	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.65	6.92	0.36	2.38e-11	Breast cancer;
CRC	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg20356878	chr3:121714668	ILDR1	-0.47	-6.84	-0.35	3.92e-11	Multiple sclerosis;
CRC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.22	-0.45	3.68e-18	Intelligence (multi-trait analysis);
CRC	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	18.15	0.71	1.63e-51	Smoking behavior;
CRC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.63	-0.39	2.6e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.81	-0.35	4.6e-11	Body mass index;
CRC	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg23740940	chr11:68924746	NA	0.43	5.64	0.3	3.71e-8	Blond vs. brown hair color;
CRC	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg00490450	chr3:139108681	COPB2	-0.43	-6.42	-0.33	4.72e-10	Obesity-related traits;
CRC	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg14092571	chr14:90743983	NA	0.39	5.98	0.31	5.81e-9	Mortality in heart failure;
CRC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.23	0.53	5.36e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.83	11.17	0.52	9.27e-25	Cisplatin-induced ototoxicity;
CRC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg15396367	chr9:139972779	UAP1L1	-0.56	-8.85	-0.44	5.66e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.79	12.03	0.55	7.39e-28	Cognitive function;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg03623178	chr6:28175578	NA	0.75	8.28	0.42	3.23e-15	Parkinson's disease;
CRC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg07952391	chr2:88470173	THNSL2	-0.44	-6.44	-0.33	4.27e-10	Response to metformin (IC50);
CRC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.36e-9	Coronary artery disease;
CRC	trans	rs2055729	0.710	rs10104236	chr8:9740292	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.54	-0.34	2.32e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.76e-10	Life satisfaction;
CRC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.35	5.66	0.3	3.34e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.5	-0.34	2.91e-10	Mean corpuscular volume;
CRC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.74e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3018066	0.867	rs6836198	chr4:107052107	G/A	cg01869342	chr4:106983673	TBCK	0.37	5.72	0.3	2.4e-8	Cancer;
CRC	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg02023728	chr11:77925099	USP35	0.36	5.84	0.31	1.23e-8	Alzheimer's disease (survival time);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27006027	chr19:33165562	ANKRD27;RGS9BP	0.41	6.22	0.32	1.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg02527881	chr3:46936655	PTH1R	0.34	6.14	0.32	2.42e-9	Colorectal cancer;
CRC	cis	rs713477	0.524	rs2341538	chr14:55895174	C/G	cg13175173	chr14:55914753	NA	0.47	7.56	0.38	4.02e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.51	0.5	1.77e-22	Heart rate;
CRC	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg16486109	chr11:613632	IRF7	0.69	11.44	0.53	9.43e-26	Systemic lupus erythematosus;
CRC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.91	-0.52	7.55e-24	Bipolar disorder;
CRC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.68	-0.35	1.02e-10	Breast cancer;
CRC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.63	0.47	1.74e-19	Cognitive test performance;
CRC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg05623727	chr3:50126028	RBM5	-0.44	-7.52	-0.38	5.3e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.61	-9.64	-0.47	1.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs10450586	0.863	rs7937389	chr11:27298451	C/T	cg10370305	chr11:27303972	NA	0.38	6.23	0.32	1.42e-9	Total body bone mineral density;
CRC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.59	8.46	0.42	9.13e-16	Pancreatic cancer;
CRC	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	7.13	0.37	6.26e-12	Bipolar disorder;
CRC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.7	10.0	0.48	9.94e-21	Immature fraction of reticulocytes;
CRC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	16.37	0.67	1.82e-44	Platelet count;
CRC	cis	rs281302	0.621	rs12439443	chr15:47733445	G/A	cg13159054	chr15:47721715	NA	-0.43	-6.68	-0.35	1.01e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg27572855	chr1:25598939	RHD	0.36	6.57	0.34	1.94e-10	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.64	8.16	0.41	7.15e-15	Arsenic metabolism;
CRC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.51	7.15	0.37	5.8e-12	Bronchopulmonary dysplasia;
CRC	cis	rs73195822	0.614	rs55680931	chr12:111218297	A/T	cg12870014	chr12:110450643	ANKRD13A	0.7	5.71	0.3	2.52e-8	Itch intensity from mosquito bite;
CRC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.81	-10.97	-0.52	4.69e-24	Initial pursuit acceleration;
CRC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.9	-0.4	4.09e-14	Cystic fibrosis severity;
CRC	trans	rs3793917	0.901	rs58077526	chr10:124230024	A/C	cg14854287	chr5:423894	AHRR	-0.4	-6.13	-0.32	2.57e-9	Age-related macular degeneration;
CRC	cis	rs12476592	0.602	rs262479	chr2:63872479	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.88e-9	Childhood ear infection;
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25229157	chr1:51426110	FAF1	0.48	7.07	0.36	9.34e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-9.02	-0.45	1.59e-17	Hemoglobin concentration;
CRC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.66	12.16	0.56	2.29e-28	Bone mineral density;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11781535	chr10:38893821	NA	0.47	6.6	0.34	1.63e-10	Survival in pancreatic cancer;
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.71	-11.35	-0.53	2.02e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.52	0.57	1.08e-29	Alzheimer's disease;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg10876282	chr6:28092338	ZSCAN16	0.4	5.81	0.31	1.47e-8	Cardiac Troponin-T levels;
CRC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg22907277	chr7:1156413	C7orf50	0.43	6.18	0.32	1.85e-9	Longevity;Endometriosis;
CRC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.72	-0.39	1.37e-13	Gut microbiome composition (summer);
CRC	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.53	9.35	0.46	1.43e-18	Blood metabolite ratios;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23161317	chr6:28129485	ZNF389	0.46	6.02	0.31	4.79e-9	Depression;
CRC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.83	11.51	0.54	5.3e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg19590445	chr5:174155345	MSX2	0.46	6.32	0.33	8.48e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg02158880	chr13:53174818	NA	0.48	6.31	0.33	8.93e-10	Lewy body disease;
CRC	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.68	6.97	0.36	1.77e-11	Non-glioblastoma glioma;Glioma;
CRC	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.67	-0.39	2.02e-13	HDL cholesterol;
CRC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.19e-8	Bladder cancer;
CRC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.92	18.38	0.71	2.04e-52	Bone mineral density;
CRC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.42	-5.63	-0.3	3.86e-8	Gut microbiome composition (summer);
CRC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg17724175	chr1:150552817	MCL1	0.47	7.0	0.36	1.46e-11	Melanoma;
CRC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg26816564	chr1:7831052	VAMP3	0.58	6.32	0.33	8.47e-10	Inflammatory bowel disease;
CRC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg23758597	chr6:163146217	PARK2	-0.54	-6.34	-0.33	7.48e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.4	5.71	0.3	2.52e-8	Aortic root size;
CRC	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg16576597	chr16:28551801	NUPR1	0.53	7.76	0.39	1.05e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.52	8.88	0.44	4.42e-17	Acylcarnitine levels;
CRC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.11	-0.32	2.88e-9	Monocyte percentage of white cells;
CRC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg00734567	chr1:86172782	ZNHIT6	-0.49	-7.41	-0.38	1.08e-12	Urate levels in overweight individuals;
CRC	cis	rs305851	0.875	rs74335065	chr6:39759083	T/C	cg02386599	chr6:39769542	DAAM2	0.37	5.83	0.31	1.36e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.54	5.71	0.3	2.49e-8	Schizophrenia;
CRC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg14671364	chr1:107599128	PRMT6	-0.56	-7.89	-0.4	4.42e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.78	-0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg22495460	chr2:25135724	ADCY3	-0.77	-12.75	-0.58	1.5e-30	Body mass index;
CRC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	1.1	10.48	0.5	2.33e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.7	-9.41	-0.46	9.11e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg24531977	chr5:56204891	C5orf35	-0.45	-7.11	-0.36	7.23e-12	Coronary artery disease;
CRC	cis	rs73206853	0.841	rs56076213	chr12:110572913	G/A	cg12870014	chr12:110450643	ANKRD13A	0.79	8.0	0.4	2.21e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg24011408	chr12:48396354	COL2A1	0.45	6.24	0.33	1.34e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-13.69	-0.6	4.34e-34	Vitiligo;
CRC	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.63	9.77	0.47	5.88e-20	Corneal astigmatism;
CRC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg09796270	chr17:17721594	SREBF1	0.55	9.46	0.46	6e-19	Total body bone mineral density;
CRC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	8.49	0.42	7.32e-16	Rheumatoid arthritis;
CRC	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.21	-0.37	3.97e-12	Putamen volume;
CRC	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.11	-0.41	1.03e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.11	-0.41	1.01e-14	Schizophrenia;
CRC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.99	0.4	2.27e-14	Height;
CRC	cis	rs6840360	0.607	rs1561918	chr4:152446832	T/A	cg09659197	chr4:152720779	NA	0.33	6.67	0.35	1.08e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.44	-6.19	-0.32	1.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.6	-11.25	-0.53	4.69e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.59	8.85	0.44	5.39e-17	Schizophrenia;
CRC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.63	-7.19	-0.37	4.38e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6499255	0.951	rs689455	chr16:69761661	T/G	cg15192750	chr16:69999425	NA	0.57	7.57	0.39	3.84e-13	IgE levels;
CRC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2486012	1.000	rs2906463	chr1:44330048	A/G	cg12908607	chr1:44402522	ARTN	-0.42	-5.7	-0.3	2.66e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.603	rs755209	chr9:95489671	G/A	cg14631576	chr9:95140430	CENPP	-0.34	-5.72	-0.3	2.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg06223162	chr1:101003688	GPR88	0.35	6.42	0.33	4.76e-10	Monocyte count;
CRC	cis	rs870825	0.655	rs6844929	chr4:185653809	C/G	cg04058563	chr4:185651563	MLF1IP	-0.76	-9.02	-0.45	1.62e-17	Blood protein levels;
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.26	-0.33	1.18e-9	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.79	0.63	2.66e-38	Prudent dietary pattern;
CRC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg15107132	chr11:63991130	FERMT3	-0.37	-6.07	-0.32	3.46e-9	Platelet count;
CRC	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg14458575	chr2:238380390	NA	0.52	7.08	0.36	8.63e-12	Prostate cancer;
CRC	cis	rs4917300	0.605	rs4917279	chr8:143095690	C/T	cg25363559	chr8:143086065	NA	-0.33	-6.11	-0.32	2.82e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg21851534	chr17:3907994	ZZEF1	-0.39	-6.48	-0.34	3.36e-10	Type 2 diabetes;
CRC	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg22495460	chr2:25135724	ADCY3	-0.83	-13.86	-0.61	1.02e-34	Body mass index;
CRC	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.59	0.47	2.22e-19	Common traits (Other);
CRC	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg15654264	chr1:150340011	RPRD2	0.42	6.25	0.33	1.29e-9	Migraine;
CRC	cis	rs9469578	1.000	rs16869458	chr6:33714639	C/T	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs9847710	0.967	rs2564931	chr3:53020559	G/A	cg18404041	chr3:52824283	ITIH1	0.31	6.09	0.32	3.1e-9	Ulcerative colitis;
CRC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-6.02	-0.31	4.73e-9	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12857488	chr7:149195092	ZNF746	0.36	6.01	0.31	4.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs56283067	0.810	rs10948155	chr6:44687957	T/C	cg18551225	chr6:44695536	NA	-0.4	-5.79	-0.3	1.63e-8	Total body bone mineral density;
CRC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.54	0.34	2.32e-10	Parkinson's disease;
CRC	trans	rs7448080	0.702	rs2088903	chr5:123299735	G/C	cg23202058	chr4:185139648	ENPP6	0.63	6.49	0.34	3.21e-10	Alcohol dependence (age at onset);
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.73	9.99	0.48	1.03e-20	Alzheimer's disease;
CRC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02450064	chr17:40260053	DHX58	0.42	6.08	0.32	3.31e-9	Fibrinogen levels;
CRC	cis	rs4523957	0.579	rs2270478	chr17:2089848	G/A	cg16513277	chr17:2031491	SMG6	-0.59	-9.87	-0.48	2.66e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg19682013	chr15:45996608	NA	0.33	6.83	0.35	4.04e-11	Waist circumference;Weight;
CRC	cis	rs4731207	0.596	rs6959632	chr7:124691046	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg18057887	chr11:133800913	IGSF9B	0.45	5.6	0.3	4.43e-8	Parkinson's disease;
CRC	cis	rs812925	0.537	rs10865324	chr2:61621307	G/A	cg10580144	chr2:61372316	C2orf74	-0.33	-7.18	-0.37	4.79e-12	Immature fraction of reticulocytes;
CRC	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg16141378	chr3:129829833	LOC729375	0.42	6.15	0.32	2.25e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	trans	rs62295889	0.602	rs62293665	chr4:12538601	T/A	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg23123621	chr4:1343375	KIAA1530	-0.36	-5.85	-0.31	1.19e-8	Obesity-related traits;
CRC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.33	0.33	8.22e-10	Tonsillectomy;
CRC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.59e-18	Platelet count;
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.65	7.42	0.38	1.03e-12	Body mass index;
CRC	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21582582	chr3:182698605	DCUN1D1	0.49	6.26	0.33	1.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg00769240	chr8:12517080	NA	-0.66	-7.28	-0.37	2.51e-12	Blood pressure (smoking interaction);
CRC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.72	-12.64	-0.57	3.92e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.81	0.58	9.33e-31	Mean platelet volume;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.95	-0.31	6.68e-9	Longevity;Endometriosis;
CRC	cis	rs9908158	1	rs9908158	chr17:33890083	T/C	cg05299278	chr17:33885742	SLFN14	-0.42	-6.33	-0.33	7.95e-10	Platelet count;Platelet distribution width;
CRC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg03013999	chr17:37608204	MED1	-0.46	-7.02	-0.36	1.25e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.7	-9.71	-0.47	8.86e-20	Coronary artery disease;
CRC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.63	-11.07	-0.52	1.95e-24	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	0.94	18.63	0.72	2.21e-53	Height;
CRC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.51	7.41	0.38	1.06e-12	Height;
CRC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.6	9.96	0.48	1.33e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg00769240	chr8:12517080	NA	-0.74	-10.23	-0.49	1.64e-21	Blood pressure (smoking interaction);
CRC	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.52	8.53	0.43	5.43e-16	Lymphocyte counts;
CRC	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.64	8.66	0.43	2.14e-16	Uric acid levels;
CRC	cis	rs6743376	0.556	rs2515402	chr2:113820580	C/A	cg24553058	chr2:113831203	IL1F10	0.44	7.18	0.37	4.61e-12	Inflammatory biomarkers;
CRC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg02527881	chr3:46936655	PTH1R	-0.34	-5.91	-0.31	8.59e-9	Colorectal cancer;
CRC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.24	0.45	3.1e-18	Heart rate;
CRC	cis	rs12024301	0.557	rs76792069	chr1:183654011	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg02683197	chr6:28174875	NA	-0.54	-7.51	-0.38	5.63e-13	Systemic lupus erythematosus;
CRC	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.5	7.21	0.37	3.91e-12	Ovarian reserve;
CRC	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-9.9	-0.48	2.13e-20	Coronary artery disease;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.31	-7.3	-0.37	2.23e-12	Lymphocyte counts;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg26587870	chr6:27730563	NA	-0.42	-6.29	-0.33	1.01e-9	Parkinson's disease;
CRC	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg13385794	chr1:248469461	NA	0.38	6.61	0.34	1.55e-10	Common traits (Other);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg16975973	chr12:77459865	E2F7	-0.41	-6.12	-0.32	2.72e-9	Daytime sleep phenotypes;
CRC	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.65	-11.21	-0.53	6.44e-25	Iron status biomarkers;
CRC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.59	-10.25	-0.49	1.43e-21	Schizophrenia;
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.16	-0.32	2.08e-9	Total body bone mineral density;
CRC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg14671364	chr1:107599128	PRMT6	0.49	6.92	0.36	2.36e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.45	-7.34	-0.38	1.72e-12	Lung function (FVC);
CRC	cis	rs4731207	0.565	rs6977613	chr7:124681791	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12066438	chr12:98909292	TMPO;LOC100128191	0.4	6.03	0.32	4.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10924970	0.934	rs2891026	chr1:235429907	A/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.75	0.3	2.06e-8	Asthma;
CRC	cis	rs17592366	0.517	rs10148967	chr14:35283744	G/A	cg09327582	chr14:35236912	BAZ1A	0.46	6.46	0.34	3.78e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.6	9.34	0.46	1.51e-18	Longevity;Endometriosis;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.69	-0.3	2.77e-8	Breast cancer;
CRC	cis	rs2882667	0.931	rs13153618	chr5:138352776	C/A	cg04439458	chr5:138467593	SIL1	-0.33	-5.91	-0.31	8.35e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18758796	chr5:131593413	PDLIM4	0.44	8.17	0.41	6.87e-15	Breast cancer;
CRC	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.17	-0.37	4.91e-12	Carotid intima media thickness;
CRC	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.58	7.34	0.38	1.65e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	11.96	0.55	1.33e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2333194	0.707	rs10134224	chr14:73781943	G/T	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.42	-6.28	-0.33	1.05e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.77	8.62	0.43	2.84e-16	Neuroticism;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg21784768	chr11:537496	LRRC56	-0.64	-6.09	-0.32	3.21e-9	Body mass index;
CRC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.03	-0.4	1.77e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg21770322	chr7:97807741	LMTK2	-0.54	-9.14	-0.45	6.73e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.25	0.33	1.31e-9	Bladder cancer;
CRC	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg20737812	chr15:86336631	KLHL25	-0.34	-5.62	-0.3	4.13e-8	Coronary artery disease;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.16	10.95	0.52	5.2e-24	Skin colour saturation;
CRC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.61	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg05084668	chr3:125655381	ALG1L	-0.44	-6.16	-0.32	2.09e-9	Blood pressure (smoking interaction);
CRC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg19980929	chr12:42632907	YAF2	0.45	6.51	0.34	2.86e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.46	6.53	0.34	2.54e-10	Menarche (age at onset);
CRC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.36	0.38	1.46e-12	Height;
CRC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.59e-10	Blood metabolite levels;
CRC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.68	10.35	0.5	6.48e-22	Lung cancer;
CRC	cis	rs7712401	0.755	rs27740	chr5:122204772	A/T	cg18764291	chr5:122110994	SNX2	-0.41	-6.52	-0.34	2.7e-10	Mean platelet volume;
CRC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg10862848	chr6:42927986	GNMT	-0.29	-6.02	-0.32	4.54e-9	Blood protein levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15617548	chr2:171785815	GORASP2	0.4	6.34	0.33	7.36e-10	Obesity-related traits;
CRC	cis	rs4253772	0.626	rs113658408	chr22:46646019	C/G	cg09491104	chr22:46646882	C22orf40	-0.48	-5.77	-0.3	1.79e-8	LDL cholesterol;Cholesterol, total;
CRC	trans	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg17903999	chr18:56338584	MALT1	0.41	6.61	0.34	1.59e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-13.83	-0.61	1.33e-34	Blood metabolite levels;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg03623178	chr6:28175578	NA	0.91	12.82	0.58	8.85e-31	Parkinson's disease;
CRC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.52	8.58	0.43	3.77e-16	Calcium levels;
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4844614	0.904	rs6686325	chr1:207833357	G/A	cg17822947	chr1:207842917	CR1L	-0.35	-5.7	-0.3	2.64e-8	LDL cholesterol;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.63	10.12	0.49	3.85e-21	Height;
CRC	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.36	-6.03	-0.32	4.34e-9	Menopause (age at onset);
CRC	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg04611788	chr3:186434169	KNG1	-0.58	-8.34	-0.42	2.04e-15	Adiponectin levels;
CRC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg02527881	chr3:46936655	PTH1R	0.35	6.11	0.32	2.83e-9	Colorectal cancer;
CRC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg06219103	chr11:63990595	FERMT3	-0.44	-6.93	-0.36	2.25e-11	Platelet count;
CRC	cis	rs9322817	0.902	rs9391238	chr6:105197874	A/G	cg02098413	chr6:105308735	HACE1	-0.36	-6.58	-0.34	1.9e-10	Thyroid stimulating hormone;
CRC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.06	-0.32	3.73e-9	Mean corpuscular volume;
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.75	10.83	0.51	1.45e-23	Longevity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22041707	chr1:24127812	GALE	0.39	5.97	0.31	6.11e-9	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.74	11.29	0.53	3.43e-25	Corneal astigmatism;
CRC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.17	0.37	5.11e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.67	8.11	0.41	9.86e-15	Eotaxin levels;
CRC	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg12163867	chr12:51592794	POU6F1	-0.4	-6.26	-0.33	1.19e-9	Cisplatin-induced ototoxicity;
CRC	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg23920097	chr1:209922102	NA	0.53	6.56	0.34	2.1e-10	Red blood cell count;
CRC	trans	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.18	0.37	4.57e-12	Endometrial cancer;
CRC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.7	-10.69	-0.51	4.45e-23	Calcium levels;
CRC	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	8.29	0.42	2.83e-15	Eotaxin levels;
CRC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.46	-7.69	-0.39	1.72e-13	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg06636001	chr8:8085503	FLJ10661	0.45	6.55	0.34	2.27e-10	Retinal vascular caliber;
CRC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.7	-0.43	1.62e-16	Aortic root size;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg21251018	chr6:28226885	NKAPL	0.42	5.91	0.31	8.46e-9	Parkinson's disease;
CRC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg10760299	chr15:45669010	GATM	0.5	7.9	0.4	4.16e-14	Homoarginine levels;
CRC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.81	-14.29	-0.62	2.27e-36	Height;
CRC	cis	rs10221833	0.636	rs355877	chr2:165632910	G/A	cg03182029	chr2:165697222	COBLL1	0.49	5.68	0.3	3e-8	Response to statin therapy;
CRC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.52	7.16	0.37	5.17e-12	Schizophrenia;
CRC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg19223190	chr17:80058835	NA	-0.45	-7.18	-0.37	4.78e-12	Life satisfaction;
CRC	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg20636351	chr8:55087400	NA	-0.32	-5.7	-0.3	2.69e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.52	6.13	0.32	2.47e-9	Renal function-related traits (BUN);
CRC	cis	rs7074356	0.704	rs1417220	chr10:82168154	G/A	cg05935833	chr10:81318306	SFTPA2	-0.45	-6.53	-0.34	2.55e-10	Borderline personality disorder;
CRC	cis	rs10097731	0.901	rs10464931	chr8:82042664	A/G	cg25230327	chr8:82042993	NA	0.88	13.7	0.6	4.26e-34	Serum total protein level;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.21	-0.56	1.54e-28	Idiopathic membranous nephropathy;
CRC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg19193384	chr17:30244184	NA	-0.59	-7.01	-0.36	1.38e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg21211367	chr2:162094118	NA	-0.38	-6.16	-0.32	2.12e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs12024301	0.557	rs10911398	chr1:183646886	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.71	-6.24	-0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg17691542	chr6:26056736	HIST1H1C	0.69	8.69	0.43	1.7e-16	Height;
CRC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.93	-17.93	-0.7	1.28e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9311676	0.656	rs12496906	chr3:58390490	A/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-13.29	-0.59	1.52e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs9487051	0.724	rs11966072	chr6:109634828	A/G	cg01475377	chr6:109611718	NA	-0.4	-6.0	-0.31	5.22e-9	Reticulocyte fraction of red cells;
CRC	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.39	-0.38	1.23e-12	Metabolite levels;
CRC	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.56	-8.23	-0.41	4.38e-15	Vitiligo;
CRC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.33	0.46	1.61e-18	Heart rate;
CRC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-18.09	-0.71	3.01e-51	Schizophrenia;
CRC	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.51	6.49	0.34	3.24e-10	Systolic blood pressure;
CRC	cis	rs1971762	0.527	rs1247956	chr12:53963814	G/T	cg06632207	chr12:54070931	ATP5G2	-0.49	-8.29	-0.42	2.89e-15	Height;
CRC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.58	6.47	0.34	3.47e-10	Bipolar disorder;
CRC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.54	-0.34	2.34e-10	Eosinophil percentage of white cells;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg00280220	chr17:61926910	NA	0.35	5.74	0.3	2.18e-8	Prudent dietary pattern;
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg22687807	chr8:143858763	LYNX1	-0.44	-6.86	-0.35	3.4e-11	Urinary tract infection frequency;
CRC	cis	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg15786705	chr6:28176104	NA	0.73	6.04	0.32	4.18e-9	Depression;
CRC	cis	rs8099014	0.859	rs11152072	chr18:56098912	A/G	cg12907477	chr18:56117327	MIR122	0.49	6.22	0.32	1.5e-9	Platelet count;
CRC	cis	rs447	1.000	rs7793598	chr7:83759108	C/T	cg22846510	chr7:83753280	SEMA3A	-0.61	-7.79	-0.39	8.85e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.53	7.4	0.38	1.15e-12	Longevity;Endometriosis;
CRC	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.52	-5.9	-0.31	9.09e-9	Coronary artery calcification;
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg03623178	chr6:28175578	NA	-0.43	-5.72	-0.3	2.44e-8	Systemic lupus erythematosus;
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.84	0.31	1.25e-8	Prudent dietary pattern;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25365794	chr17:8022404	ALOXE3	0.52	6.83	0.35	4.12e-11	Thyroid stimulating hormone;
CRC	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg13385794	chr1:248469461	NA	0.41	7.17	0.37	4.84e-12	Common traits (Other);
CRC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24308560	chr3:49941425	MST1R	-0.44	-6.64	-0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3736485	0.932	rs2124879	chr15:51916833	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.39	-0.33	5.54e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	15.59	0.65	1.96e-41	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg24977027	chr2:88469347	THNSL2	0.49	5.91	0.31	8.4e-9	Plasma clusterin levels;
CRC	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	0.81	7.28	0.37	2.42e-12	Economic and political preferences (immigration/crime);
CRC	cis	rs9297145	0.673	rs62473003	chr7:98725660	A/G	cg05967295	chr7:98741636	SMURF1	1.1	15.62	0.65	1.61e-41	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	6.65	0.34	1.22e-10	Reticulocyte count;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.7	11.28	0.53	3.48e-25	Osteoporosis;
CRC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg09127314	chr1:152161683	NA	0.52	6.58	0.34	1.87e-10	Atopic dermatitis;
CRC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.54	-9.09	-0.45	9.57e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg13880726	chr7:1868755	MAD1L1	-0.44	-5.9	-0.31	9.07e-9	Bipolar disorder;
CRC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.57	9.96	0.48	1.37e-20	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24926775	chr1:151584391	SNX27	0.47	6.65	0.34	1.25e-10	Response to antipsychotic treatment;
CRC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.68	-11.18	-0.52	8.33e-25	Electrocardiographic conduction measures;
CRC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg22535103	chr8:58192502	C8orf71	-0.44	-5.85	-0.31	1.21e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08882271	chr5:61708404	IPO11	0.43	6.15	0.32	2.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg15205204	chr1:6545172	PLEKHG5	0.39	5.67	0.3	3.12e-8	Body mass index;
CRC	cis	rs12541635	0.966	rs7819327	chr8:106986003	A/C	cg10147462	chr8:107024639	NA	0.45	7.34	0.38	1.65e-12	Age of smoking initiation;
CRC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg17133734	chr15:86042851	AKAP13	0.45	7.19	0.37	4.29e-12	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06648271	chr10:126432949	FAM53B	0.44	6.57	0.34	2.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg07125278	chr16:67683757	RLTPR	0.63	7.37	0.38	1.4e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.28	-0.33	1.1e-9	Electroencephalogram traits;
CRC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg07636037	chr3:49044803	WDR6	-0.7	-6.07	-0.32	3.56e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.68	-10.85	-0.51	1.24e-23	Neurofibrillary tangles;
CRC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.48	-0.71	8.77e-53	Height;
CRC	cis	rs9287719	0.649	rs10166765	chr2:10725673	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg09877947	chr5:131593287	PDLIM4	-0.45	-7.47	-0.38	7.26e-13	Breast cancer;
CRC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.59	-10.21	-0.49	1.99e-21	Iron status biomarkers;
CRC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg19223190	chr17:80058835	NA	0.41	6.6	0.34	1.61e-10	Life satisfaction;
CRC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.02	-20.21	-0.74	1.24e-59	Primary sclerosing cholangitis;
CRC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.92	-0.31	8.11e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg02135003	chr7:105160482	PUS7	-0.95	-12.58	-0.57	6.68e-30	Bipolar disorder (body mass index interaction);
CRC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.23	-0.53	5.57e-25	Chronic sinus infection;
CRC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-13.5	-0.6	2.35e-33	Blood metabolite levels;
CRC	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.59	8.34	0.42	2.06e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.72	7.66	0.39	2.14e-13	Recalcitrant atopic dermatitis;
CRC	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.65	0.34	1.19e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg03973167	chr4:185394988	IRF2	-0.46	-6.53	-0.34	2.52e-10	Schizophrenia;
CRC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.85	0.31	1.18e-8	Major depressive disorder;
CRC	cis	rs6763159	1.000	rs6763159	chr3:59649521	T/C	cg07069742	chr3:59644285	NA	-0.33	-6.55	-0.34	2.27e-10	Conotruncal heart defects;
CRC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg16342193	chr10:102329863	NA	-0.36	-5.86	-0.31	1.14e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07173973	chr19:45596087	NA	0.45	6.15	0.32	2.28e-9	Response to antipsychotic treatment;
CRC	cis	rs8105895	0.867	rs62111037	chr19:22286563	C/T	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17554472	chr22:41940697	POLR3H	-0.56	-6.01	-0.31	4.84e-9	Vitiligo;
CRC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg05044414	chr3:183734942	ABCC5	0.48	8.34	0.42	2.1e-15	Anterior chamber depth;
CRC	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg23387468	chr7:139079360	LUC7L2	0.4	6.96	0.36	1.9e-11	Diisocyanate-induced asthma;
CRC	cis	rs7572644	0.639	rs74429612	chr2:27993843	C/T	cg27432699	chr2:27873401	GPN1	0.47	5.73	0.3	2.27e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg20387954	chr3:183756860	HTR3D	0.44	7.41	0.38	1.06e-12	Anterior chamber depth;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26744078	chr19:57752172	ZNF805	0.44	5.96	0.31	6.5e-9	Anxiety disorder;
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg19913688	chr11:428466	ANO9	-0.59	-6.26	-0.33	1.23e-9	Body mass index;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.65	10.87	0.51	1.03e-23	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg10217327	chr6:118973057	C6orf204	0.51	5.78	0.3	1.73e-8	Diastolic blood pressure;
CRC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.41	6.79	0.35	5.15e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6504950	0.705	rs9899602	chr17:52986908	C/T	cg26251398	chr17:52985966	TOM1L1	-0.42	-6.2	-0.32	1.69e-9	Breast cancer;
CRC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.67	-0.72	1.46e-53	Primary sclerosing cholangitis;
CRC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.16	-0.32	2.17e-9	Schizophrenia;
CRC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.93	-0.31	7.87e-9	Lung cancer;
CRC	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	1.06	11.38	0.53	1.62e-25	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg23229984	chr5:148520753	ABLIM3	0.49	6.8	0.35	4.85e-11	Breast cancer;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg12172441	chr6:28176163	NA	0.5	6.74	0.35	7.17e-11	Parkinson's disease;
CRC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.5	-7.98	-0.4	2.39e-14	Menopause (age at onset);
CRC	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	1.07	18.04	0.71	4.67e-51	Schizophrenia;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.71	0.3	2.57e-8	Parkinson's disease;
CRC	cis	rs4803480	0.873	rs1476770	chr19:42084385	C/G	cg08478046	chr19:42093086	CEACAM21	-0.33	-5.88	-0.31	1.01e-8	Schizophrenia;
CRC	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg16670446	chr17:27188758	MIR451;MIR144	-0.61	-10.36	-0.5	5.96e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1863824	0.625	rs10887599	chr10:88168780	G/A	cg07322936	chr10:88137208	NA	-0.64	-8.66	-0.43	2.11e-16	Schizophrenia;
CRC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg18230493	chr5:56204884	C5orf35	-0.39	-5.61	-0.3	4.21e-8	Coronary artery disease;
CRC	cis	rs2223471	0.719	rs17608920	chr6:50773860	G/A	cg03432817	chr6:50765336	NA	0.39	6.26	0.33	1.19e-9	Subcutaneous adipose tissue;
CRC	trans	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg11693508	chr17:37793320	STARD3	0.47	6.44	0.33	4.22e-10	Neuroticism;
CRC	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02756545	chr1:94884060	ABCD3	-0.62	-6.16	-0.32	2.13e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.56	10.04	0.48	7.37e-21	HDL cholesterol levels;
CRC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.69	0.39	1.73e-13	Colorectal cancer;
CRC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.56	6.42	0.33	4.68e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.53	8.87	0.44	4.83e-17	Schizophrenia;
CRC	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.86	16.76	0.68	5.38e-46	Hip circumference;
CRC	cis	rs12024301	0.557	rs60156786	chr1:183596905	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs216303	1.000	rs216303	chr12:6159045	C/T	cg19878637	chr12:6148451	VWF	-0.55	-6.08	-0.32	3.35e-9	Low vWF levels;
CRC	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg00373020	chr1:21041521	KIF17	0.4	6.17	0.32	2.04e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.3	0.37	2.14e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg08999081	chr20:33150536	PIGU	0.45	5.79	0.3	1.65e-8	Protein C levels;
CRC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.56	-8.54	-0.43	5.17e-16	Schizophrenia;
CRC	cis	rs17767392	0.958	rs34169215	chr14:72011148	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.3	-0.37	2.25e-12	Mitral valve prolapse;
CRC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.74	11.79	0.55	5.27e-27	Cognitive function;
CRC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.38	-6.13	-0.32	2.5e-9	Bone mineral density (spine);
CRC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.49	-9.82	-0.48	4.02e-20	Intelligence (multi-trait analysis);
CRC	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.61	8.72	0.43	1.36e-16	Uric acid levels;
CRC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg08200770	chr17:80723486	TBCD	-0.5	-7.67	-0.39	1.95e-13	Glycated hemoglobin levels;
CRC	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.58	-0.39	3.44e-13	Bipolar disorder;
CRC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.33	1.01e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.47	-0.46	5.71e-19	Breast cancer;
CRC	cis	rs3743266	0.613	rs1869485	chr15:60746605	G/A	cg21667061	chr15:60772094	NARG2	-0.28	-5.74	-0.3	2.11e-8	Menarche (age at onset);
CRC	cis	rs59104589	0.617	rs3755400	chr2:242379795	A/C	cg19488206	chr2:242435732	STK25	-0.51	-7.25	-0.37	2.97e-12	Fibrinogen levels;
CRC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	1.01	10.66	0.51	5.36e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.71	-0.43	1.52e-16	Bipolar disorder;
CRC	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.5	0.38	6.05e-13	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08292968	chr12:111020671	PPTC7	0.41	6.62	0.34	1.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.5	-7.4	-0.38	1.13e-12	Sum neutrophil eosinophil counts;
CRC	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.59	-6.35	-0.33	7.14e-10	Coronary artery disease;
CRC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06505273	chr16:24850292	NA	0.54	7.04	0.36	1.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg21620606	chr4:1342894	KIAA1530	0.34	5.65	0.3	3.53e-8	Obesity-related traits;
CRC	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.59	9.61	0.47	1.94e-19	Tourette's syndrome or obsessive-compulsive disorder;
CRC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.08	-0.32	3.33e-9	Height;
CRC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.39	-5.64	-0.3	3.74e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs10986311	0.832	rs9695388	chr9:127141727	C/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.39	-5.72	-0.3	2.38e-8	Vitiligo;
CRC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg13390004	chr1:15929781	NA	0.53	7.23	0.37	3.46e-12	Systolic blood pressure;
CRC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.37	0.33	6.41e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3736485	0.934	rs4143721	chr15:51866781	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.64	-0.34	1.29e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs711830	1.000	rs1549334	chr2:177039197	G/A	cg13092806	chr2:177043255	NA	0.72	9.04	0.45	1.39e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.88	8.93	0.44	3.07e-17	Lymphocyte counts;
CRC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.31	5.93	0.31	7.77e-9	Blood protein levels;
CRC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg03037974	chr15:76606532	NA	-0.52	-7.84	-0.4	6.23e-14	Blood metabolite levels;
CRC	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg13385794	chr1:248469461	NA	0.39	6.95	0.36	2.03e-11	Common traits (Other);
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.12	0.41	9.42e-15	Life satisfaction;
CRC	trans	rs12699921	0.632	rs2691597	chr7:17870340	C/T	cg15753394	chr6:17282781	RBM24	-0.36	-6.11	-0.32	2.81e-9	Fibrinogen levels;
CRC	trans	rs10411161	0.702	rs79180893	chr19:52395615	A/G	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.24	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.92	17.13	0.69	1.78e-47	Intelligence (multi-trait analysis);
CRC	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.36	0.65	1.59e-40	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.68	-10.06	-0.49	6.04e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25360663	chr11:66035791	RAB1B	0.44	6.23	0.32	1.42e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13309018	chr9:130965761	CIZ1;DNM1	0.49	6.49	0.34	3.17e-10	Thyroid stimulating hormone;
CRC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg23996704	chr18:44553084	KATNAL2	-0.34	-7.0	-0.36	1.4e-11	Personality dimensions;
CRC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.9	11.64	0.54	1.83e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9491140	0.539	rs11154221	chr6:124675246	C/T	cg05308643	chr6:124982296	NKAIN2	0.45	6.28	0.33	1.09e-9	Neuroticism;
CRC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	5.91	0.31	8.45e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	6.72	0.35	7.82e-11	Rheumatoid arthritis;
CRC	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg07921184	chr16:71880281	ATXN1L	-0.48	-6.05	-0.32	3.97e-9	Intelligence (multi-trait analysis);
CRC	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.2	18.64	0.72	2.04e-53	Atopic dermatitis;
CRC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.63	-9.22	-0.45	3.56e-18	Menarche (age at onset);
CRC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.42	-6.25	-0.33	1.26e-9	Pulse pressure;
CRC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.58	8.23	0.41	4.55e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg23283495	chr1:209979779	IRF6	0.4	6.64	0.34	1.27e-10	Cleft lip with or without cleft palate;
CRC	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.65	-10.75	-0.51	2.65e-23	Hepatocellular carcinoma;
CRC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg03037974	chr15:76606532	NA	0.71	12.58	0.57	6.58e-30	Blood metabolite levels;
CRC	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg21153622	chr11:89784906	NA	-0.47	-7.87	-0.4	5.04e-14	Height;
CRC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg11189052	chr15:85197271	WDR73	0.58	8.41	0.42	1.23e-15	Schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06788803	chr1:45805948	MUTYH;TOE1	0.4	6.17	0.32	1.95e-9	Schizophrenia;
CRC	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.41	-6.93	-0.36	2.29e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CRC	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg12908607	chr1:44402522	ARTN	-0.35	-6.04	-0.32	4.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-11.71	-0.54	1.03e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.09	12.84	0.58	7.37e-31	Sexual dysfunction (female);
CRC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.43	7.06	0.36	9.77e-12	Resting heart rate;
CRC	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-7.76	-0.39	1.06e-13	Hepatocellular carcinoma;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.38	-0.33	6.13e-10	Bipolar disorder;
CRC	trans	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.91	0.36	2.58e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9463078	0.547	rs4711798	chr6:44750777	A/G	cg25276700	chr6:44698697	NA	-0.31	-7.78	-0.39	9.37e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.67	-0.35	1.09e-10	Total body bone mineral density;
CRC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.5	6.19	0.32	1.8e-9	Bipolar disorder;
CRC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.44	6.33	0.33	8.22e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22133161	chr19:49891603	CCDC155	0.51	6.65	0.34	1.21e-10	Multiple sclerosis;
CRC	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg17640201	chr16:30407289	ZNF48	0.8	12.68	0.57	2.84e-30	Tonsillectomy;
CRC	cis	rs939584	1.000	rs10865550	chr2:641718	T/G	cg03610516	chr2:642275	NA	0.41	5.77	0.3	1.83e-8	Body mass index;
CRC	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg07701084	chr6:150067640	NUP43	0.47	5.78	0.3	1.73e-8	Lung cancer;
CRC	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.36	0.62	1.26e-36	Hypertriglyceridemia;
CRC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.21	0.41	4.99e-15	Platelet count;
CRC	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.27e-25	White blood cell count (basophil);
CRC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.44	-9.87	-0.48	2.68e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21659725	chr3:3221576	CRBN	-0.69	-7.14	-0.37	6.11e-12	Menarche (age at onset);
CRC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg13334819	chr7:99746414	C7orf59	-0.46	-6.31	-0.33	9.18e-10	Coronary artery disease;
CRC	cis	rs524281	0.731	rs11227439	chr11:66025679	G/A	cg16950941	chr11:66035639	RAB1B	-0.72	-8.08	-0.41	1.24e-14	Electroencephalogram traits;
CRC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.42	0.42	1.15e-15	Cognitive test performance;
CRC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.41	-5.84	-0.31	1.24e-8	DNA methylation (variation);
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg27048067	chr8:674560	ERICH1	0.5	5.92	0.31	8.01e-9	IgG glycosylation;
CRC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.71	11.72	0.54	9.78e-27	Body mass index;
CRC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	8.24e-11	Colorectal cancer;
CRC	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg13856295	chr9:139396418	NOTCH1	-0.38	-5.64	-0.3	3.57e-8	Monocyte percentage of white cells;
CRC	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	5.8	0.3	1.56e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs652260	0.967	rs569175	chr19:7901160	T/G	cg26014689	chr19:7917955	EVI5L	-0.54	-8.83	-0.44	6.37e-17	Menarche (age at onset);
CRC	cis	rs72627123	0.867	rs73301475	chr14:74462868	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.02	0.31	4.74e-9	Morning vs. evening chronotype;
CRC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg06219103	chr11:63990595	FERMT3	0.37	5.7	0.3	2.71e-8	Platelet count;
CRC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.52	-7.81	-0.4	7.53e-14	Systemic sclerosis;
CRC	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.87	16.75	0.68	5.73e-46	Hip circumference;
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.79	9.82	0.48	4.06e-20	Lung function (FEV1/FVC);
CRC	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg16540259	chr10:75572220	NDST2	0.51	7.96	0.4	2.82e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.24	-0.37	3.16e-12	Height;
CRC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.45	-7.19	-0.37	4.52e-12	Lung cancer;
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.97	-20.93	-0.76	1.86e-62	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.93	11.27	0.53	3.8e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.1	20.48	0.75	1.1e-60	Exhaled nitric oxide output;
CRC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg03684893	chr10:554711	DIP2C	0.32	5.6	0.3	4.42e-8	Psychosis in Alzheimer's disease;
CRC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.16	-0.45	5.49e-18	Height;
CRC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.56	8.15	0.41	7.95e-15	Uric acid levels;
CRC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.74	-0.39	1.27e-13	Vitiligo;
CRC	cis	rs6496667	0.779	rs8041764	chr15:90968264	G/A	cg04176472	chr15:90893244	GABARAPL3	0.61	8.51	0.42	6.23e-16	Rheumatoid arthritis;
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg08546805	chr12:8549446	NA	-0.4	-6.12	-0.32	2.67e-9	Blood pressure (smoking interaction);
CRC	cis	rs2882667	0.690	rs825747	chr5:138136585	C/T	cg09476006	chr5:138032270	NA	-0.54	-8.88	-0.44	4.48e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.43	-20.28	-0.75	6.84e-60	Hip circumference adjusted for BMI;
CRC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.52	-8.67	-0.43	2.04e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.82	-0.44	6.9e-17	Urinary metabolites;
CRC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.0	14.8	0.63	2.32e-38	Breast cancer;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg02683197	chr6:28174875	NA	0.65	9.03	0.45	1.48e-17	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.76	0.43	1.05e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.15	0.41	7.66e-15	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg21918786	chr6:109611834	NA	-0.35	-6.05	-0.32	3.9e-9	Reticulocyte fraction of red cells;
CRC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg06470822	chr6:28175283	NA	0.64	6.5	0.34	2.98e-10	Depression;
CRC	cis	rs6076065	0.755	rs6076071	chr20:23406380	A/C	cg11657817	chr20:23433608	CST11	0.43	6.32	0.33	8.59e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.52	8.87	0.44	4.61e-17	Systemic lupus erythematosus;
CRC	cis	rs2811415	0.597	rs10934847	chr3:127788955	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.98	-0.31	5.78e-9	Lung function (FEV1/FVC);
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27181079	chr12:10766103	MAGOHB	0.47	7.38	0.38	1.32e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	0.97	18.25	0.71	6.72e-52	Height;
CRC	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg09659197	chr4:152720779	NA	0.49	10.42	0.5	3.75e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6743376	0.556	rs2515401	chr2:113820476	C/T	cg09040174	chr2:113837401	NA	-0.41	-5.91	-0.31	8.59e-9	Inflammatory biomarkers;
CRC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg14673194	chr17:80132900	CCDC57	-0.51	-6.79	-0.35	5.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.89	-0.48	2.34e-20	Primary sclerosing cholangitis;
CRC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.57	8.47	0.42	8.25e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.73	-12.63	-0.57	4.31e-30	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.44	5.84	0.31	1.26e-8	Platelet distribution width;
CRC	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg18876405	chr7:65276391	NA	0.46	6.49	0.34	3.24e-10	Aortic root size;
CRC	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg14593290	chr7:50529359	DDC	-0.49	-7.14	-0.37	6.02e-12	Systemic sclerosis;
CRC	cis	rs1570884	0.857	rs4942848	chr13:50141345	A/G	cg08779649	chr13:50194554	NA	-0.31	-6.1	-0.32	3.01e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs5756813	0.903	rs13054052	chr22:38130385	A/C	cg19894588	chr14:64061835	NA	0.53	7.84	0.4	6.13e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.55	9.06	0.45	1.21e-17	Schizophrenia;
CRC	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.66	-9.54	-0.47	3.38e-19	Type 2 diabetes;
CRC	cis	rs6433857	0.594	rs736019	chr2:181526568	A/C	cg23363182	chr2:181467187	NA	0.44	6.75	0.35	6.65e-11	Body mass index;
CRC	cis	rs9648716	1.000	rs7793758	chr7:140603996	T/C	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs17095355	1.000	rs2122517	chr10:111754787	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.56	-0.43	4.38e-16	Biliary atresia;
CRC	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg14711859	chr11:8959438	ASCL3	-0.59	-11.44	-0.53	9.37e-26	Hematocrit;
CRC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.75	10.75	0.51	2.64e-23	High light scatter reticulocyte count;
CRC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.33e-9	Heart rate;
CRC	cis	rs10071761	0.513	rs12514900	chr5:40363876	A/G	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs2880765	0.546	rs36098649	chr15:86056807	C/T	cg10818794	chr15:86012489	AKAP13	-0.43	-6.2	-0.32	1.71e-9	Coronary artery disease;
CRC	cis	rs6973256	0.897	rs2991242	chr7:133336459	A/T	cg10665199	chr7:133106180	EXOC4	-0.37	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.4	-6.41	-0.33	5.17e-10	Reticulocyte count;
CRC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.68	9.59	0.47	2.28e-19	Bladder cancer;
CRC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg23018236	chr17:30244563	NA	-0.58	-7.7	-0.39	1.64e-13	Hip circumference adjusted for BMI;
CRC	cis	rs17767392	0.958	rs61989367	chr14:71907295	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.55	-7.05	-0.36	1.07e-11	Mitral valve prolapse;
CRC	cis	rs2062225	1.000	rs1384796	chr2:111771873	C/T	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg25600027	chr14:23388339	RBM23	-0.53	-8.3	-0.42	2.72e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs17095355	1.000	rs7067604	chr10:111734665	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.63	-0.39	2.52e-13	Biliary atresia;
CRC	cis	rs75422866	0.510	rs75424057	chr12:48131077	G/A	cg14736327	chr12:48174669	SLC48A1	-0.77	-6.25	-0.33	1.29e-9	Pneumonia;
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.37	0.56	4.13e-29	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24293976	chr12:111843567	SH2B3	0.38	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.47	7.19	0.37	4.26e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.8	14.27	0.62	2.79e-36	Breast cancer;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	10.51	0.5	1.82e-22	Lymphocyte counts;
CRC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg05585544	chr11:47624801	NA	-0.43	-6.8	-0.35	4.98e-11	Mean corpuscular hemoglobin;
CRC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.03	18.47	0.71	9.49e-53	Parkinson's disease;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.32	-0.46	1.73e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2979489	0.891	rs16877096	chr8:30364388	T/C	cg26383811	chr8:30366931	RBPMS	-0.76	-11.65	-0.54	1.66e-26	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg26587870	chr6:27730563	NA	-0.44	-6.75	-0.35	6.5e-11	Parkinson's disease;
CRC	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24385694	chr6:4282346	NA	0.38	6.11	0.32	2.84e-9	Pancreatic cancer;
CRC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.14e-8	Bladder cancer;
CRC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg23719950	chr11:63933701	MACROD1	-0.57	-6.09	-0.32	3.11e-9	Mean platelet volume;
CRC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg07636037	chr3:49044803	WDR6	-0.84	-6.02	-0.32	4.57e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.46	0.34	3.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg01420254	chr6:26195488	NA	0.81	8.55	0.43	4.7e-16	Gout;Renal underexcretion gout;
CRC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg19847866	chr10:1019161	NA	-0.42	-6.0	-0.31	5.08e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg12870014	chr12:110450643	ANKRD13A	0.83	10.4	0.5	4.37e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-7.18	-0.37	4.76e-12	Dental caries;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg02683197	chr6:28174875	NA	0.62	8.46	0.42	8.99e-16	Cardiac Troponin-T levels;
CRC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.77	0.39	1.01e-13	Motion sickness;
CRC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg26752003	chr8:145688521	CYHR1	-0.57	-9.33	-0.46	1.59e-18	Age at first birth;
CRC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg16576597	chr16:28551801	NUPR1	0.46	6.96	0.36	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.42	0.33	4.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg06470822	chr6:28175283	NA	0.91	13.28	0.59	1.54e-32	Parkinson's disease;
CRC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs7737355	0.853	rs7730810	chr5:130781179	T/C	cg25547332	chr5:131281432	NA	-0.36	-5.74	-0.3	2.11e-8	Life satisfaction;
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	1.0	18.47	0.71	9.02e-53	Gut microbiome composition (winter);
CRC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.59	7.17	0.37	5.01e-12	Resting heart rate;
CRC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg12751644	chr20:60527061	NA	-0.39	-6.09	-0.32	3.15e-9	Body mass index;
CRC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.44	6.74	0.35	6.94e-11	Monocyte count;
CRC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg22117107	chr15:45993392	NA	0.44	8.7	0.43	1.66e-16	Waist circumference;Weight;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg05872234	chr4:48390346	SLAIN2	-0.54	-6.04	-0.32	4.24e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.32	-0.49	8.33e-22	Chronic sinus infection;
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.36	-7.75	-0.39	1.13e-13	Total body bone mineral density;
CRC	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg20503657	chr10:835505	NA	0.52	7.25	0.37	3.04e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg16268157	chr7:99778414	STAG3	-0.43	-5.69	-0.3	2.74e-8	Lung function (FEV1/FVC);
CRC	trans	rs1550115	0.524	rs113939247	chr2:25029179	G/A	cg08894410	chr5:99715943	LOC100133050	0.48	6.27	0.33	1.12e-9	Coronary artery disease;
CRC	cis	rs6123683	0.711	rs2180783	chr20:55827144	C/A	cg13236649	chr20:55835020	BMP7	0.48	7.46	0.38	7.84e-13	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs1062746	0.544	rs3762182	chr16:87326113	A/G	cg02258303	chr16:87377426	FBXO31	0.49	7.03	0.36	1.19e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg08645402	chr16:4508243	NA	0.53	7.4	0.38	1.18e-12	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04094107	chr15:73976560	CD276	0.38	6.47	0.34	3.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.44	6.61e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649465	0.967	rs7791183	chr7:123343719	A/G	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs16975963	0.843	rs112628349	chr19:38268238	G/C	cg15135657	chr19:38346511	NA	-0.44	-5.9	-0.31	9.09e-9	Longevity;
CRC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.56	8.04	0.41	1.61e-14	Coronary artery disease;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg22713327	chr12:120703336	PXN	-0.39	-6.0	-0.31	5.26e-9	Protein C levels;
CRC	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg25809561	chr17:30822961	MYO1D	0.52	9.15	0.45	5.97e-18	Schizophrenia;
CRC	trans	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.31	-0.37	2.03e-12	Menarche (age at onset);
CRC	trans	rs6928289	0.527	rs9321597	chr6:137672746	A/G	cg24169820	chr12:121711996	CAMKK2	-0.39	-6.0	-0.31	5.32e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2072510	0.593	rs2540498	chr12:96400569	T/A	cg15438951	chr12:96389694	HAL	-0.49	-6.23	-0.33	1.39e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg00603274	chr11:61596626	FADS2	-0.85	-9.45	-0.46	6.65e-19	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs989128	0.614	rs1132414	chr17:48628092	A/G	cg16068336	chr17:48637367	CACNA1G	-0.54	-7.73	-0.39	1.36e-13	Type 2 diabetes;
CRC	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg03929089	chr4:120376271	NA	0.63	6.14	0.32	2.43e-9	Axial length;
CRC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg21466736	chr12:48725269	NA	-0.58	-8.54	-0.43	4.88e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.4	3.78e-14	Lung cancer in ever smokers;
CRC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.47	6.93	0.36	2.28e-11	Blood metabolite levels;
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-6.24	-0.33	1.37e-9	Menopause (age at onset);
CRC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.54	6.96	0.36	1.79e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05663122	chr19:59055778	TRIM28	0.47	6.71	0.35	8.3e-11	Anxiety disorder;
CRC	cis	rs9292777	0.720	rs57970171	chr5:40401030	A/T	cg09067459	chr5:40385259	NA	-0.54	-8.98	-0.44	2.1e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.51	-8.1	-0.41	1.12e-14	Type 2 diabetes;
CRC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg13390004	chr1:15929781	NA	0.5	7.07	0.36	9.19e-12	Systolic blood pressure;
CRC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	trans	rs55675132	0.548	rs10494169	chr1:115363532	T/C	cg25493687	chr8:27288214	PTK2B	0.47	6.04	0.32	4.08e-9	Schizophrenia;
CRC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg11189052	chr15:85197271	WDR73	0.62	8.85	0.44	5.51e-17	Schizophrenia;
CRC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.07	0.32	3.6e-9	Aortic root size;
CRC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.61	0.47	1.92e-19	Cognitive test performance;
CRC	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg04176472	chr15:90893244	GABARAPL3	0.34	5.85	0.31	1.2e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.75	-0.51	2.71e-23	Alzheimer's disease;
CRC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg15440763	chr7:158190612	PTPRN2	0.47	7.56	0.38	4.05e-13	Obesity-related traits;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10841076	chr16:3174662	NA	0.47	6.78	0.35	5.63e-11	Response to antipsychotic treatment;
CRC	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.66	7.06	0.36	1.02e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.9	-20.37	-0.75	2.89e-60	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.52	7.0	0.36	1.45e-11	Methadone dose in opioid dependence;
CRC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.83	-0.48	3.55e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.53	6.12	0.32	2.59e-9	Coronary artery disease;
CRC	trans	rs4256159	1.000	rs75407508	chr3:18825612	G/A	cg01763821	chr15:59397510	CCNB2	-0.63	-5.98	-0.31	5.76e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.56	-0.38	4e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs3760982	1.000	rs4802200	chr19:44289518	G/A	cg11993925	chr19:44307056	LYPD5	0.49	8.14	0.41	8.12e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg19554555	chr3:13937349	NA	0.44	6.61	0.34	1.58e-10	Ovarian reserve;
CRC	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg09184832	chr6:79620586	NA	-0.46	-7.82	-0.4	7.32e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.77	-0.35	5.83e-11	Bipolar disorder;
CRC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg03037974	chr15:76606532	NA	0.7	12.39	0.56	3.28e-29	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.53	0.46	3.72e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.2	0.49	2.14e-21	Asthma (childhood onset);
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	7.56	0.38	4.03e-13	Obesity-related traits;
CRC	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg10263370	chr3:44754102	ZNF502	-0.36	-5.96	-0.31	6.46e-9	Depressive symptoms;
CRC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg15534755	chr11:117069859	TAGLN	-0.34	-6.29	-0.33	9.86e-10	Blood protein levels;
CRC	trans	rs10403021	0.855	rs4805433	chr19:30069763	C/T	cg22044635	chr17:76557109	DNAH17	0.43	5.99	0.31	5.47e-9	Diabetic retinopathy;
CRC	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg08314208	chr16:67682810	RLTPR	-0.54	-5.88	-0.31	9.91e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg25482853	chr8:67687455	SGK3	1.16	13.2	0.59	3.15e-32	Obesity-related traits;
CRC	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg25182066	chr10:30743637	MAP3K8	-0.41	-5.97	-0.31	6.06e-9	Inflammatory bowel disease;
CRC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg14979609	chr8:8086686	FLJ10661	0.38	5.95	0.31	6.87e-9	Mood instability;
CRC	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.95	-16.9	-0.68	1.41e-46	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.41	-5.81	-0.3	1.5e-8	Aortic root size;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs12476592	0.602	rs4671508	chr2:63654140	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.22	0.32	1.54e-9	Childhood ear infection;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg20647610	chr2:228736258	WDR69	-0.47	-6.46	-0.34	3.75e-10	Blood pressure;
CRC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.37	5.62	0.3	4.12e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07157834	chr1:205819609	PM20D1	0.44	6.03	0.32	4.34e-9	Parkinson's disease;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.02	-24.87	-0.81	1.52e-77	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg15107132	chr11:63991130	FERMT3	0.45	7.73	0.39	1.34e-13	Platelet count;
CRC	cis	rs2411233	1.000	rs12910426	chr15:39278738	A/G	cg23129342	chr15:39283510	NA	0.33	6.02	0.32	4.6e-9	Platelet count;
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg12516270	chr8:143859308	LYNX1	0.44	7.74	0.39	1.2e-13	Urinary tract infection frequency;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12103840	chr6:108582260	SNX3	0.5	7.23	0.37	3.34e-12	Anxiety disorder;
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg19913688	chr11:428466	ANO9	-0.65	-6.58	-0.34	1.83e-10	Body mass index;
CRC	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.7	9.69	0.47	1.09e-19	Hair shape;
CRC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-13.51	-0.6	2.11e-33	Systemic lupus erythematosus;
CRC	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.72	-0.3	2.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg07274523	chr3:49395745	GPX1	0.47	6.41	0.33	5.15e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.55	-8.42	-0.42	1.15e-15	Bipolar disorder;
CRC	cis	rs2579500	0.844	rs2708975	chr2:97184160	G/A	cg23100626	chr2:96804247	ASTL	0.24	5.72	0.3	2.43e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg06470822	chr6:28175283	NA	0.69	6.51	0.34	2.85e-10	Depression;
CRC	cis	rs6445967	0.932	rs13093235	chr3:58296706	A/T	cg23715586	chr3:58305044	RPP14	0.37	5.96	0.31	6.33e-9	Platelet count;
CRC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg18612461	chr15:75251733	NA	-0.39	-6.06	-0.32	3.69e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4757319	0.512	rs4360688	chr11:15441149	A/G	cg03245590	chr11:15329459	NA	0.39	6.82	0.35	4.51e-11	Breast cancer;
CRC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-5.83	-0.31	1.33e-8	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24763869	chr17:3572311	TMEM93;TAX1BP3	0.41	6.08	0.32	3.33e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.45	5.62	0.3	4.06e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10865541	1.000	rs11692425	chr2:3395383	A/G	cg22182287	chr2:3452347	TTC15	0.38	5.9	0.31	9.02e-9	Obesity-related traits;
CRC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.6	0.39	3.17e-13	Alzheimer's disease (late onset);
CRC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.36	-6.68	-0.35	1.03e-10	Height;
CRC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.62	-9.89	-0.48	2.39e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg03623178	chr6:28175578	NA	0.75	5.94	0.31	7.17e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	4.01e-16	Life satisfaction;
CRC	cis	rs11191205	0.686	rs12358045	chr10:103399708	C/T	cg15320455	chr10:103880129	LDB1	0.56	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Parkinson's disease;
CRC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.44	-7.73	-0.39	1.31e-13	Reticulocyte fraction of red cells;
CRC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.49	7.34	0.38	1.68e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4757319	0.515	rs58697209	chr11:15431540	C/T	cg03245590	chr11:15329459	NA	0.53	9.26	0.45	2.75e-18	Breast cancer;
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00166722	chr3:10149974	C3orf24	0.66	9.23	0.45	3.41e-18	Alzheimer's disease;
CRC	cis	rs4664293	0.805	rs7593273	chr2:160605860	T/G	cg08347373	chr2:160653686	CD302	-0.47	-7.44	-0.38	9.06e-13	Monocyte percentage of white cells;
CRC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg16745616	chr19:8428856	ANGPTL4	-0.45	-7.04	-0.36	1.16e-11	HDL cholesterol;
CRC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	9.62	0.47	1.82e-19	Body mass index (adult);
CRC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.18	25.25	0.81	5.58e-79	IgG glycosylation;
CRC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.19	-0.37	4.33e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21028142	chr17:79581711	NPLOC4	0.34	7.16	0.37	5.16e-12	Eye color traits;
CRC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25517755	chr10:38738941	LOC399744	-0.41	-6.1	-0.32	3.04e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg00255919	chr5:131827918	IRF1	-0.6	-11.88	-0.55	2.59e-27	Asthma (sex interaction);
CRC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.46	-7.07	-0.36	9.56e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.25	15.65	0.65	1.15e-41	Lung disease severity in cystic fibrosis;
CRC	cis	rs7487075	0.619	rs7486495	chr12:46826336	A/G	cg22049899	chr12:47219821	SLC38A4	0.31	5.69	0.3	2.89e-8	Itch intensity from mosquito bite;
CRC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.37	5.61	0.3	4.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.45	-7.62	-0.39	2.79e-13	Schizophrenia;
CRC	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.04	0.32	4.27e-9	Asthma;
CRC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg03037974	chr15:76606532	NA	0.53	8.39	0.42	1.5e-15	Blood metabolite levels;
CRC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-1.06	-17.79	-0.7	4.45e-50	Blood pressure (smoking interaction);
CRC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.45	0.38	8.2e-13	Motion sickness;
CRC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg17948913	chr5:572064	NA	0.55	6.33	0.33	7.93e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	trans	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.98	0.31	5.9e-9	Metabolite levels;
CRC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.7	9.18	0.45	5.08e-18	High light scatter reticulocyte count;
CRC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.46	-0.34	3.86e-10	Monocyte percentage of white cells;
CRC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.7	8.63	0.43	2.69e-16	Prostate cancer;
CRC	cis	rs4728302	0.871	rs10259686	chr7:133633152	A/G	cg10665199	chr7:133106180	EXOC4	-0.38	-5.8	-0.3	1.54e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs972578	0.905	rs60752002	chr22:43371628	C/T	cg01576275	chr22:43409880	NA	-0.46	-7.36	-0.38	1.52e-12	Mean platelet volume;
CRC	cis	rs501120	0.810	rs513391	chr10:44749708	A/C	cg09554077	chr10:44749378	NA	0.89	13.21	0.59	3.04e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12463550	chr7:65579703	CRCP	0.69	6.4	0.33	5.48e-10	Diabetic kidney disease;
CRC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.42	7.01	0.36	1.32e-11	Diastolic blood pressure;
CRC	cis	rs7113874	0.543	rs7935708	chr11:8478545	C/A	cg20771178	chr11:8615675	STK33	-0.34	-5.61	-0.3	4.31e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg02972257	chr16:68554789	NA	0.44	5.61	0.3	4.28e-8	Colorectal cancer;
CRC	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg23627948	chr7:2760692	NA	0.48	5.73	0.3	2.23e-8	Childhood ear infection;
CRC	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.41	6.66	0.34	1.18e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	0.96	8.96	0.44	2.53e-17	Pulse pressure;
CRC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.26	-0.33	1.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.43	5.8	0.3	1.57e-8	Schizophrenia;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg18721089	chr20:30220636	NA	-0.35	-5.86	-0.31	1.1e-8	Mean corpuscular hemoglobin;
CRC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.95	-0.4	2.96e-14	Gut microbiome composition (summer);
CRC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.66	-9.71	-0.47	9.35e-20	DNA methylation (variation);
CRC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg17321639	chr7:2759063	NA	-0.38	-5.85	-0.31	1.21e-8	Height;
CRC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg12311346	chr5:56204834	C5orf35	-0.47	-7.24	-0.37	3.14e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.55	-9.72	-0.47	8.33e-20	Educational attainment;
CRC	cis	rs10971721	0.731	rs72725402	chr9:33878356	G/C	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.59	10.09	0.49	5.02e-21	Prudent dietary pattern;
CRC	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.52	-8.06	-0.41	1.46e-14	Vitiligo;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19737664	chr11:537435	LRRC56	-0.51	-6.01	-0.31	4.92e-9	Diisocyanate-induced asthma;
CRC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.8	-0.35	5.09e-11	Monocyte percentage of white cells;
CRC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg13837822	chr10:26931731	LOC731789	0.58	8.69	0.43	1.72e-16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.4	-7.17	-0.37	5.11e-12	Primary biliary cholangitis;
CRC	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg26597838	chr10:835615	NA	0.72	8.21	0.41	5.26e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-6.48	-0.34	3.3e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.25	0.45	2.97e-18	Migraine;Coronary artery disease;
CRC	cis	rs12024301	0.557	rs16861414	chr1:183620393	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.5	-7.68	-0.39	1.8e-13	Red blood cell count;
CRC	cis	rs2252521	0.583	rs320088	chr7:29083262	C/T	cg11728747	chr7:29037910	CPVL	-0.47	-6.68	-0.35	1.02e-10	Cognitive performance;
CRC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	8.18	0.41	6.09e-15	Axial length;
CRC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-8.42	-0.42	1.15e-15	Response to bleomycin (chromatid breaks);
CRC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.46	-0.38	7.88e-13	Type 2 diabetes;
CRC	cis	rs863345	0.604	rs7555174	chr1:158487426	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-6.03	-0.32	4.52e-9	Pneumococcal bacteremia;
CRC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-12.39	-0.56	3.29e-29	Dental caries;
CRC	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg24642844	chr7:1081250	C7orf50	-0.65	-6.93	-0.36	2.23e-11	Longevity;Endometriosis;
CRC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.45	0.42	9.3e-16	Height;
CRC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.6	-11.06	-0.52	2.26e-24	Hematocrit;
CRC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.51	-9.64	-0.47	1.59e-19	Longevity;
CRC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.76	12.14	0.56	2.92e-28	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg26116260	chr4:7069785	GRPEL1	-0.58	-5.76	-0.3	1.94e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9494145	0.680	rs9389269	chr6:135427159	T/C	cg22676075	chr6:135203613	NA	0.57	7.3	0.37	2.24e-12	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg20354231	chr13:53171401	NA	-0.43	-6.86	-0.35	3.51e-11	Lewy body disease;
CRC	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.56	-8.94	-0.44	2.89e-17	Schizophrenia;
CRC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.64	10.86	0.51	1.06e-23	Prostate cancer;
CRC	trans	rs16957091	0.528	rs72713784	chr15:43115936	A/G	cg07673103	chr8:74277181	NA	0.56	6.13	0.32	2.56e-9	MGMT methylation in smokers;
CRC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.53	7.99	0.4	2.27e-14	Axial length;
CRC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.39	6.08	0.32	3.32e-9	Height;
CRC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.5	8.15	0.41	7.48e-15	Lipoprotein (a) levels;
CRC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg09218773	chr11:619014	MUPCDH	-0.42	-6.08	-0.32	3.35e-9	Systemic lupus erythematosus;
CRC	cis	rs9847710	0.708	rs2581811	chr3:53085801	T/C	cg18099408	chr3:52552593	STAB1	0.41	6.14	0.32	2.44e-9	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17820247	chr12:6579852	VAMP1	0.36	6.6	0.34	1.62e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13260133	chr10:104626808	NA	0.43	6.86	0.35	3.51e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg16558177	chr4:4109446	NA	-0.62	-8.88	-0.44	4.49e-17	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-7.71	-0.39	1.49e-13	Longevity;Endometriosis;
CRC	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	8.29	0.42	2.86e-15	Recombination measurement;
CRC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.69	-0.35	9.69e-11	Vitiligo;
CRC	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.35	5.7	0.3	2.69e-8	Sitting height ratio;
CRC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.39	6.08	0.32	3.37e-9	Crohn's disease;
CRC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.05	-0.45	1.24e-17	Brugada syndrome;
CRC	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.88	0.35	3.11e-11	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg02683197	chr6:28174875	NA	0.63	8.49	0.42	7.22e-16	Parkinson's disease;
CRC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.91	17.35	0.69	2.44e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs16852403	0.619	rs10913513	chr1:178135941	A/G	cg00404053	chr1:178313656	RASAL2	0.6	7.59	0.39	3.27e-13	Childhood ear infection;
CRC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.44	6.31	0.33	9.07e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.76	-0.39	1.05e-13	Superior frontal gyrus grey matter volume;
CRC	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.33	16.07	0.66	2.6e-43	Uric acid levels;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01516881	chr6:292596	DUSP22	-0.56	-8.07	-0.41	1.33e-14	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg16606324	chr3:10149918	C3orf24	0.69	9.36	0.46	1.3e-18	Alzheimer's disease;
CRC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.35	-0.62	1.33e-36	Height;
CRC	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.37	-6.52	-0.34	2.69e-10	Sarcoidosis;
CRC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.22	0.32	1.51e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg19582491	chr16:67682965	RLTPR	-0.57	-6.53	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg02811702	chr13:24901961	NA	0.46	6.31	0.33	9.03e-10	Obesity-related traits;
CRC	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.53	8.16	0.41	7.19e-15	Testicular germ cell tumor;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.33	0.33	7.97e-10	Parkinson's disease;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	8.08e-10	Depression;
CRC	cis	rs643506	0.967	rs2850248	chr11:111644824	C/A	cg09085632	chr11:111637200	PPP2R1B	0.5	6.42	0.33	4.64e-10	Breast cancer;
CRC	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.36	0.5	6.04e-22	Corneal astigmatism;
CRC	cis	rs7534824	0.543	rs6577221	chr1:101420406	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.77	0.3	1.79e-8	Refractive astigmatism;
CRC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.88	-0.31	9.99e-9	Gut microbiome composition (summer);
CRC	cis	rs6604026	0.656	rs2811600	chr1:93334138	C/T	cg17283838	chr1:93427260	FAM69A	-0.42	-5.62	-0.3	4.1e-8	Multiple sclerosis;
CRC	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.56	9.92	0.48	1.87e-20	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg18833306	chr6:118973337	C6orf204	0.45	5.82	0.31	1.44e-8	Diastolic blood pressure;
CRC	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg16898833	chr6:26189333	HIST1H4D	0.69	6.06	0.32	3.64e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.82	-0.35	4.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg00383909	chr3:49044727	WDR6	0.5	6.2	0.32	1.72e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14298966	chr12:49393226	DDN	0.43	6.03	0.32	4.5e-9	Anxiety disorder;
CRC	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.5	5.95	0.31	6.95e-9	QRS duration;
CRC	trans	rs12310399	0.772	rs6538602	chr12:95525641	C/A	cg09150239	chr1:204347429	NA	0.43	6.15	0.32	2.27e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CRC	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.32	0.42	2.41e-15	Corneal astigmatism;
CRC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.31	-0.49	8.94e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg08071915	chr8:12219732	FAM66A	0.32	5.74	0.3	2.13e-8	Retinal vascular caliber;
CRC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.5	6.65	0.34	1.24e-10	Height;
CRC	cis	rs11229555	0.645	rs7926682	chr11:58189495	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.61	9.41	0.46	8.85e-19	Schizophrenia;
CRC	trans	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg13565492	chr6:43139072	SRF	-0.86	-6.29	-0.33	1.03e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg07617317	chr6:118971624	C6orf204	0.5	5.91	0.31	8.47e-9	Diastolic blood pressure;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.51	-8.26	-0.41	3.56e-15	Paraoxonase activity;
CRC	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg06307176	chr5:131281290	NA	0.41	5.94	0.31	7.3e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg21770322	chr7:97807741	LMTK2	0.53	8.59	0.43	3.59e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.61	9.3	0.46	2.03e-18	Menopause (age at onset);
CRC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	6.35	0.33	6.98e-10	Height;
CRC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg05941027	chr17:61774174	LIMD2	0.36	6.63	0.34	1.41e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.48	6.49	0.34	3.12e-10	Mean corpuscular volume;
CRC	cis	rs7901135	0.962	rs4293075	chr10:60561751	A/G	cg23799393	chr10:60588674	BICC1	0.39	5.94	0.31	7.18e-9	Morning vs. evening chronotype;
CRC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.62	11.13	0.52	1.22e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01200585	chr1:228362443	C1orf69	0.39	5.73	0.3	2.22e-8	Diastolic blood pressure;
CRC	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.88	0.4	4.89e-14	Breast cancer;
CRC	cis	rs3026101	0.671	rs12602061	chr17:5302645	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14119001	chr9:139324193	INPP5E	-0.44	-6.23	-0.32	1.46e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg16141378	chr3:129829833	LOC729375	0.41	6.13	0.32	2.45e-9	Joint mobility (Beighton score);
CRC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.47	9.02	0.45	1.61e-17	Smoking initiation;
CRC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.6	8.84	0.44	5.91e-17	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg12639453	chr1:2035780	PRKCZ	0.31	5.74	0.3	2.2e-8	Height;
CRC	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.65	-9.43	-0.46	7.66e-19	Type 2 diabetes;
CRC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.48	7.29	0.37	2.38e-12	Corneal astigmatism;
CRC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.85	16.24	0.67	6e-44	Metabolic syndrome;
CRC	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.39	6.44	0.33	4.31e-10	Mean arterial pressure;
CRC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg04315214	chr1:2043799	PRKCZ	-0.36	-6.2	-0.32	1.7e-9	Height;
CRC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.03	23.18	0.79	3.67e-71	Multiple system atrophy;
CRC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.67	0.6	5.48e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.73	0.3	2.27e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	0.92	13.95	0.61	4.4e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg15845792	chr6:28175446	NA	0.96	13.94	0.61	5.17e-35	Parkinson's disease;
CRC	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg21918786	chr6:109611834	NA	0.37	6.43	0.33	4.58e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7725052	0.609	rs7725387	chr5:40459749	G/C	cg09067459	chr5:40385259	NA	0.39	6.43	0.33	4.42e-10	Pediatric autoimmune diseases;
CRC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.71	0.65	6.73e-42	Chronic sinus infection;
CRC	trans	rs9650657	0.644	rs3808603	chr8:10698218	T/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.08	-0.32	3.34e-9	Neuroticism;
CRC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg23100626	chr2:96804247	ASTL	0.29	7.03	0.36	1.19e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.2	-0.41	5.62e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs11166629	1.000	rs3739423	chr8:135614705	A/G	cg27224718	chr8:135614730	ZFAT	0.53	7.8	0.4	8.33e-14	Smoking quantity;
CRC	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.89	0.83	4.7e-85	Schizophrenia;
CRC	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	trans	rs10411161	0.702	rs10402630	chr19:52384570	G/A	cg22319618	chr22:45562946	NUP50	-0.69	-7.57	-0.39	3.9e-13	Breast cancer;
CRC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-9.29	-0.46	2.18e-18	Type 2 diabetes;
CRC	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.61	10.95	0.52	5.42e-24	Aortic root size;
CRC	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.42	6.63	0.34	1.4e-10	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07177681	chr21:33105032	SFRS15	0.42	6.09	0.32	3.11e-9	Response to antipsychotic treatment;
CRC	trans	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg17903999	chr18:56338584	MALT1	0.4	6.69	0.35	9.66e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs12660387	1.000	rs10498824	chr6:65259197	T/C	cg13393512	chr9:135749454	C9orf98	0.53	6.13	0.32	2.49e-9	Schizophrenia;
CRC	trans	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.38	-0.33	6.05e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg24562669	chr7:97807699	LMTK2	0.78	17.53	0.7	4.54e-49	Breast cancer;
CRC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg17724175	chr1:150552817	MCL1	-0.47	-7.39	-0.38	1.19e-12	Tonsillectomy;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg15786705	chr6:28176104	NA	0.55	7.6	0.39	3.15e-13	Parkinson's disease;
CRC	cis	rs73206853	0.843	rs12320025	chr12:110742991	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	8.39	0.42	1.41e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.48	7.43	0.38	9.7e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.1	-0.32	2.97e-9	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20332865	chr2:206177247	PARD3B	0.41	6.45	0.34	3.97e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.28	-0.37	2.51e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg09597638	chr17:3907349	NA	0.46	7.07	0.36	9.35e-12	Type 2 diabetes;
CRC	cis	rs10905065	0.804	rs2380202	chr10:5823397	C/T	cg11519256	chr10:5708881	ASB13	-0.44	-6.33	-0.33	8.11e-10	Menopause (age at onset);
CRC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.57	-0.34	1.97e-10	Coronary artery disease;
CRC	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg23100626	chr2:96804247	ASTL	0.27	7.09	0.36	8.15e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-1.03	-10.44	-0.5	3.16e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg12573674	chr2:1569213	NA	-0.77	-8.05	-0.41	1.51e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.33	-5.99	-0.31	5.59e-9	Longevity;Endometriosis;
CRC	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg12856521	chr11:46389249	DGKZ	0.43	6.85	0.35	3.69e-11	Leprosy;
CRC	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.65	-0.3	3.46e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2898857	0.524	rs2960172	chr17:47379581	G/A	cg08112188	chr17:47440006	ZNF652	0.42	5.62	0.3	4.04e-8	Cancer;
CRC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04476341	chr5:669733	TPPP	0.42	6.88	0.35	3.1e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-8.15	-0.41	7.92e-15	Axial length;
CRC	trans	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs524281	0.731	rs11227439	chr11:66025679	G/A	cg14036092	chr11:66035641	RAB1B	-0.55	-6.02	-0.32	4.64e-9	Electroencephalogram traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06140764	chr6:30539234	ABCF1	0.48	6.81	0.35	4.68e-11	Anxiety disorder;
CRC	cis	rs77861329	0.748	rs747343	chr3:52109407	T/C	cg08692210	chr3:52188851	WDR51A	0.55	6.26	0.33	1.17e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs13418455	0.619	rs1401263	chr2:181188035	G/T	cg23363182	chr2:181467187	NA	0.39	5.62	0.3	4.14e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26933359	chr14:20937370	PNP	0.44	6.42	0.33	4.83e-10	Intelligence (multi-trait analysis);
CRC	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg00507830	chr2:103233733	NA	0.5	5.63	0.3	3.86e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.59	7.95	0.4	2.94e-14	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19733847	chr19:8571072	NA	0.43	6.35	0.33	7.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-6.88	-0.35	2.95e-11	Putamen volume;
CRC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	14.9	0.63	9.84e-39	Mean platelet volume;
CRC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.21	-0.37	3.96e-12	Mean platelet volume;
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.38	6.28	0.33	1.07e-9	Sitting height ratio;
CRC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.95	0.31	6.97e-9	Menopause (age at onset);
CRC	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.75	8.73	0.43	1.33e-16	Eosinophilic esophagitis;
CRC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.81	14.18	0.62	5.98e-36	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.52	7.5	0.38	5.96e-13	Response to antipsychotic treatment;
CRC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.68	13.43	0.6	4.32e-33	Coronary artery disease;
CRC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13085065	chr19:41769941	HNRNPUL1	0.5	6.37	0.33	6.43e-10	Thyroid stimulating hormone;
CRC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg11189052	chr15:85197271	WDR73	0.61	9.03	0.45	1.46e-17	Schizophrenia;
CRC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.29	0.46	2.14e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.9	16.5	0.67	5.49e-45	Intelligence (multi-trait analysis);
CRC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.44	7.28	0.37	2.52e-12	Total cholesterol levels;
CRC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.64	-12.79	-0.58	1.08e-30	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.56	7.33	0.37	1.8e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.83	0.35	4.13e-11	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09670790	chr13:76056027	TBC1D4	0.44	6.12	0.32	2.65e-9	Anxiety disorder;
CRC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.19	0.45	4.47e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.97	12.26	0.56	1.03e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.44	5.69	0.3	2.83e-8	Gut microbiome composition (summer);
CRC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg02659138	chr7:134003124	SLC35B4	0.42	7.36	0.38	1.49e-12	Mean platelet volume;
CRC	cis	rs3020333	0.875	rs2982572	chr6:152010561	C/T	cg22157087	chr6:152012887	ESR1	0.52	7.81	0.4	7.96e-14	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16917406	chr15:85114159	UBE2QP1	0.45	6.37	0.33	6.33e-10	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs4964805	0.641	rs11111755	chr12:104159667	G/A	cg02344784	chr12:104178138	NT5DC3	0.49	7.66	0.39	2.17e-13	Attention deficit hyperactivity disorder;
CRC	trans	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg17903999	chr18:56338584	MALT1	0.42	7.02	0.36	1.25e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.64	0.51	6.45e-23	Hip circumference adjusted for BMI;
CRC	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg12855166	chr17:30846586	MYO1D	-0.39	-6.59	-0.34	1.8e-10	Schizophrenia;
CRC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.66	10.86	0.51	1.07e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.58	7.28	0.37	2.55e-12	RR interval (heart rate);
CRC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.95	11.25	0.53	4.64e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.18	0.32	1.93e-9	Depression;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg03623178	chr6:28175578	NA	0.88	12.69	0.57	2.62e-30	Parkinson's disease;
CRC	cis	rs6076065	0.723	rs2424548	chr20:23394456	A/C	cg11657817	chr20:23433608	CST11	0.44	6.29	0.33	9.83e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02725872	chr8:58115012	NA	-0.59	-9.17	-0.45	5.24e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs11203032	0.831	rs2863216	chr10:90941937	C/T	cg16672925	chr10:90967113	CH25H	0.44	5.7	0.3	2.6e-8	Heart failure;
CRC	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.64	-8.98	-0.44	2.1e-17	Menopause (age at onset);
CRC	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.5	6.12	0.32	2.6e-9	Neutrophil percentage of white cells;
CRC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.86	0.31	1.11e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8141797	0.901	rs2330722	chr22:24491488	C/G	cg20894457	chr22:24584366	SUSD2	-0.66	-6.86	-0.35	3.51e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.71	0.51	3.81e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs3018066	0.738	rs12639678	chr4:106952765	A/T	cg02609279	chr2:182325952	ITGA4	-0.44	-6.05	-0.32	3.91e-9	Cancer;
CRC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.7	9.81	0.48	4.41e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	0.66	7.15	0.37	5.74e-12	Prostate cancer;
CRC	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg26043149	chr18:55253948	FECH	-0.53	-8.31	-0.42	2.56e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs4363385	0.818	rs12085426	chr1:153003074	C/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.28	-0.37	2.52e-12	Inflammatory skin disease;
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg12516270	chr8:143859308	LYNX1	0.43	7.43	0.38	9.19e-13	Urinary tract infection frequency;
CRC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.06	-17.31	-0.69	3.46e-48	Dilated cardiomyopathy;
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg02811702	chr13:24901961	NA	0.47	6.49	0.34	3.07e-10	Obesity-related traits;
CRC	cis	rs863345	0.604	rs1342952	chr1:158464430	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.32	-0.33	8.42e-10	Pneumococcal bacteremia;
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg12516270	chr8:143859308	LYNX1	0.42	7.54	0.38	4.55e-13	Urinary tract infection frequency;
CRC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.75	-0.3	2.01e-8	Mean platelet volume;
CRC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.92	12.43	0.57	2.34e-29	Glomerular filtration rate (creatinine);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg02641420	chr17:65688720	PITPNC1	-0.37	-6.36	-0.33	6.87e-10	HDL cholesterol;
CRC	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.44	6.59	0.34	1.76e-10	Neutrophil percentage of white cells;
CRC	trans	rs12699921	0.573	rs2723562	chr7:17846620	C/G	cg15753394	chr6:17282781	RBM24	-0.36	-6.03	-0.32	4.44e-9	Fibrinogen levels;
CRC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.49	0.54	6.51e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs863345	0.584	rs6657638	chr1:158497184	C/G	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	trans	rs853679	0.760	rs967005	chr6:28210688	C/T	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.7	-0.35	8.99e-11	Depression;
CRC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg11212589	chr17:38028394	ZPBP2	0.34	6.02	0.32	4.65e-9	Asthma;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Blood metabolite levels;
CRC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	0.77	7.52	0.38	5.15e-13	Type 2 diabetes nephropathy;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.38	0.33	5.96e-10	Alzheimer's disease;
CRC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.29	-5.83	-0.31	1.32e-8	Lung cancer;
CRC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.75	-11.89	-0.55	2.27e-27	Dilated cardiomyopathy;
CRC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.44	5.86	0.31	1.1e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg25182066	chr10:30743637	MAP3K8	-0.41	-5.96	-0.31	6.64e-9	Inflammatory bowel disease;
CRC	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.37	6.09	0.32	3.1e-9	Pelvic organ prolapse;
CRC	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg26727032	chr16:67993705	SLC12A4	-0.65	-9.8	-0.48	4.59e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.38	-6.59	-0.34	1.73e-10	Reticulocyte fraction of red cells;
CRC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.53	-8.33	-0.42	2.26e-15	Schizophrenia;
CRC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.38	7.39	0.38	1.22e-12	Intelligence (multi-trait analysis);
CRC	trans	rs8012941	0.593	rs4902190	chr14:63314591	A/G	cg17602776	chr5:178977377	RUFY1	0.4	6.11	0.32	2.76e-9	Major depressive disorder;
CRC	cis	rs6728302	0.557	rs73002000	chr2:233254052	C/T	cg14418609	chr2:233286870	NA	-0.69	-5.86	-0.31	1.14e-8	Height;
CRC	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.49	7.13	0.37	6.33e-12	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04848196	chr16:75657359	ADAT1	0.44	6.11	0.32	2.84e-9	Response to antipsychotic treatment;
CRC	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg19773385	chr1:10388646	KIF1B	-0.57	-7.94	-0.4	3.3e-14	Hepatocellular carcinoma;
CRC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg27068330	chr11:65405492	SIPA1	0.48	7.0	0.36	1.45e-11	Acne (severe);
CRC	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-7.8	-0.4	8.12e-14	Extraversion;
CRC	trans	rs62295889	0.602	rs73096518	chr4:12536943	T/G	cg03490839	chr16:73082051	ZFHX3	0.57	5.97	0.31	6.26e-9	Obesity-related traits;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.72	-0.3	2.4e-8	Longevity;Endometriosis;
CRC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.86	14.58	0.63	1.72e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.52	6.48	0.34	3.38e-10	White matter hyperintensity burden;
CRC	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg02023728	chr11:77925099	USP35	0.37	6.21	0.32	1.64e-9	Alzheimer's disease (survival time);
CRC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.8	11.44	0.53	9.38e-26	Initial pursuit acceleration;
CRC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.36	-0.42	1.74e-15	Monocyte percentage of white cells;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg27112062	chr3:48456733	PLXNB1	-0.45	-6.38	-0.33	6.04e-10	Lung cancer;
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.97	10.23	0.49	1.66e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg13385794	chr1:248469461	NA	0.38	6.72	0.35	7.94e-11	Common traits (Other);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg09712606	chr19:50169182	IRF3;BCL2L12	-0.41	-5.98	-0.31	5.89e-9	Daytime sleep phenotypes;
CRC	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg20608306	chr11:116969690	SIK3	-0.32	-5.82	-0.31	1.41e-8	Subjective well-being;
CRC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.66	-0.3	3.28e-8	Breast cancer;
CRC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg23463467	chr20:60627584	TAF4	0.38	6.55	0.34	2.19e-10	Body mass index;
CRC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.65	9.66	0.47	1.37e-19	Heart rate;
CRC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.81	0.3	1.51e-8	Breast cancer;
CRC	trans	rs6534347	0.788	rs56267605	chr4:123363109	A/C	cg21129976	chr7:100421502	EPHB4	0.39	6.0	0.31	5.35e-9	Type 1 diabetes;
CRC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.0	-0.31	5.22e-9	Obesity-related traits;
CRC	cis	rs62408225	1.000	rs11752685	chr6:90966415	A/C	cg06866423	chr6:90926672	BACH2	0.49	8.16	0.41	7.32e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg08231274	chr14:57735852	MUDENG;EXOC5	-0.58	-6.05	-0.32	3.98e-9	Longevity (90 years and older);
CRC	cis	rs7078219	0.714	rs11190139	chr10:101288099	C/G	cg10506844	chr10:101281203	NA	-0.3	-5.64	-0.3	3.63e-8	Dental caries;
CRC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg03690763	chr11:133734501	NA	-0.35	-5.86	-0.31	1.13e-8	Childhood ear infection;
CRC	trans	rs12432203	1.000	rs3935981	chr14:51730283	T/C	cg14592830	chr9:122318704	NA	0.59	6.12	0.32	2.62e-9	Cancer;
CRC	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.7	11.75	0.54	7.42e-27	Eosinophil percentage of white cells;
CRC	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg15192750	chr16:69999425	NA	0.62	7.85	0.4	5.93e-14	IgE levels;
CRC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24308560	chr3:49941425	MST1R	0.45	7.16	0.37	5.47e-12	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.29	0.53	3.26e-25	Prudent dietary pattern;
CRC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg16447950	chr5:562315	NA	-0.86	-13.15	-0.59	5.1e-32	Lung disease severity in cystic fibrosis;
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg21138405	chr5:131827807	IRF1	-0.34	-5.88	-0.31	1e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.34	-6.24	-0.33	1.35e-9	Gout;Renal underexcretion gout;
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.45	7.0	0.36	1.44e-11	Large artery stroke;
CRC	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.67	-9.35	-0.46	1.4e-18	Exhaled nitric oxide output;
CRC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg02659138	chr7:134003124	SLC35B4	0.4	6.91	0.36	2.47e-11	Mean platelet volume;
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.71	9.52	0.46	3.79e-19	Alzheimer's disease;
CRC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.44	7.45	0.38	8.44e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg20615401	chr6:28092323	ZSCAN16	0.44	5.9	0.31	8.92e-9	Parkinson's disease;
CRC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.32	-0.49	8.22e-22	Total cholesterol levels;
CRC	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	0.57	8.58	0.43	3.74e-16	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26306683	chr17:18585705	ZNF286B	0.5	6.93	0.36	2.28e-11	Educational attainment (years of education);
CRC	cis	rs4728302	0.869	rs10224683	chr7:133590937	A/G	cg10665199	chr7:133106180	EXOC4	-0.4	-6.07	-0.32	3.43e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.48	-0.46	5.17e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg20243544	chr17:37824526	PNMT	0.56	8.97	0.44	2.35e-17	Asthma;
CRC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.48	6.25	0.33	1.25e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.79	14.22	0.62	4.06e-36	Oral cavity cancer;
CRC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.47e-12	Eye color traits;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.39	-0.33	5.53e-10	Breast cancer;
CRC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg06028605	chr16:24865363	SLC5A11	0.37	6.87	0.35	3.24e-11	Intelligence (multi-trait analysis);
CRC	cis	rs939584	1.000	rs10193244	chr2:647580	T/C	cg03610516	chr2:642275	NA	0.41	5.93	0.31	7.83e-9	Body mass index;
CRC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg24110177	chr3:50126178	RBM5	0.43	5.98	0.31	5.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg19223190	chr17:80058835	NA	0.4	6.32	0.33	8.48e-10	Life satisfaction;
CRC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.61	0.3	4.31e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4731207	0.596	rs10258873	chr7:124650489	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg16476235	chr8:21771668	DOK2	0.39	6.52	0.34	2.65e-10	Mean corpuscular volume;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.62	-9.64	-0.47	1.52e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.45	7.7	0.39	1.63e-13	Childhood ear infection;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25789201	chr7:72395803	POM121	0.5	6.41	0.33	5.19e-10	Thyroid stimulating hormone;
CRC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg10911889	chr6:126070802	HEY2	-0.37	-5.61	-0.3	4.28e-8	Brugada syndrome;
CRC	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.33e-29	Prostate cancer;
CRC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	0.66	7.87	0.4	5.08e-14	Lymphocyte counts;
CRC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.4	0.56	3.08e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.5	7.72	0.39	1.41e-13	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07936430	chr16:30538244	ZNF768	0.41	6.16	0.32	2.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg10760299	chr15:45669010	GATM	0.51	7.87	0.4	5.05e-14	Homoarginine levels;
CRC	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg06935464	chr4:38784597	TLR10	0.56	5.79	0.3	1.6e-8	Breast cancer;
CRC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg25303599	chr11:61595807	FADS2	-0.48	-5.95	-0.31	6.97e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11528995	chr1:117210575	IGSF3	0.39	6.56	0.34	2.13e-10	Obesity-related traits;
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg15147215	chr3:52552868	STAB1	-0.61	-10.05	-0.48	6.91e-21	Bipolar disorder;
CRC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	14.77	0.63	3.1e-38	Electrocardiographic conduction measures;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.61	9.57	0.47	2.64e-19	Breast cancer;
CRC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.7	-0.39	1.61e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.84	13.62	0.6	8.16e-34	Menarche (age at onset);
CRC	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.5	0.34	3.01e-10	Homocysteine levels;
CRC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg27523141	chr10:43048294	ZNF37B	0.45	6.47	0.34	3.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02290350	chr8:58132656	NA	-0.57	-7.6	-0.39	3.18e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.57	9.24	0.45	3.19e-18	Gout;
CRC	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.13	22.51	0.78	1.39e-68	Triglycerides;
CRC	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.44	8.58	0.43	3.85e-16	Schizophrenia;
CRC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.49	-0.38	6.59e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02157667	chr16:85722621	GINS2	-0.53	-6.04	-0.32	4.27e-9	Monocyte percentage of white cells;
CRC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.16	10.93	0.52	6.45e-24	Skin colour saturation;
CRC	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.44	6.46	0.34	3.74e-10	Body mass index;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13198984	chr17:80129470	CCDC57	0.47	8.43	0.42	1.09e-15	Life satisfaction;
CRC	cis	rs17065868	0.764	rs9533850	chr13:45011699	C/T	cg10246903	chr13:45222710	NA	0.58	5.65	0.3	3.45e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.57	6.77	0.35	5.77e-11	Pediatric autoimmune diseases;
CRC	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.48	9.62	0.47	1.82e-19	Schizophrenia;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg12273811	chr6:28175739	NA	0.61	8.44	0.42	1.02e-15	Parkinson's disease;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-7.82	-0.4	7.11e-14	Total body bone mineral density;
CRC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.88	17.33	0.69	2.92e-48	Metabolic syndrome;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26819140	chr22:36925319	EIF3D	-0.39	-6.1	-0.32	2.99e-9	Obesity-related traits;
CRC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.38	7.86	0.4	5.5e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20092199	chr4:1342459	KIAA1530	0.33	5.81	0.3	1.5e-8	Longevity;
CRC	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg07125278	chr16:67683757	RLTPR	-0.49	-6.54	-0.34	2.31e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg21747405	chr11:67723411	NA	-0.43	-6.1	-0.32	2.97e-9	Blood pressure (smoking interaction);
CRC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.53	0.54	4.6e-26	Prudent dietary pattern;
CRC	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.52	-7.41	-0.38	1.05e-12	Caudate activity during reward;
CRC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.06	-0.32	3.75e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9908102	0.756	rs7210890	chr17:12917134	A/G	cg26162695	chr17:12921313	ELAC2	0.42	5.63	0.3	3.93e-8	Schizophrenia;
CRC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-6.61	-0.34	1.59e-10	Bipolar disorder;
CRC	cis	rs6142102	0.886	rs6142098	chr20:32688294	A/C	cg08999081	chr20:33150536	PIGU	0.36	5.62	0.3	4.17e-8	Skin pigmentation;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.57	-9.87	-0.48	2.62e-20	Age at first birth;
CRC	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs9443189	0.762	rs2748944	chr6:76436106	A/G	cg01950844	chr6:76311363	SENP6	0.65	8.62	0.43	2.94e-16	Prostate cancer;
CRC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.99	-0.36	1.51e-11	IgG glycosylation;
CRC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.41	7.82	0.4	7.36e-14	Mean corpuscular volume;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.62	0.3	4.11e-8	Parkinson's disease;
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.71	-0.39	1.48e-13	Bipolar disorder;
CRC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-6.16	-0.32	2.11e-9	Lung cancer;
CRC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg07701084	chr6:150067640	NUP43	0.54	7.8	0.4	8.21e-14	Lung cancer;
CRC	cis	rs12024301	0.557	rs115625135	chr1:183644493	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.85	0.35	3.67e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs3812111	0.609	rs549332	chr6:116454588	C/T	cg25858983	chr17:42295711	UBTF	0.4	5.99	0.31	5.35e-9	Age-related macular degeneration;
CRC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.96	14.2	0.62	5.23e-36	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26859586	chr10:104953231	NT5C2	0.37	6.08	0.32	3.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.72e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	9.37	0.46	1.21e-18	Lymphocyte counts;
CRC	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg04239558	chr2:103089729	SLC9A4	-0.38	-6.73	-0.35	7.76e-11	Blood protein levels;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27367768	chr5:171615456	STK10	0.42	6.13	0.32	2.57e-9	Hip circumference;
CRC	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg13491945	chr12:107078410	RFX4	-0.34	-5.81	-0.31	1.45e-8	Heart rate;
CRC	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.41	5.76	0.3	1.9e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	17.29	0.69	4.24e-48	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.45	0.62	5.37e-37	Platelet count;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.64	-10.07	-0.49	5.93e-21	Longevity;Endometriosis;
CRC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg23957660	chr17:17878224	LRRC48	-0.39	-6.91	-0.36	2.5e-11	Total body bone mineral density;
CRC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.61	-9.66	-0.47	1.39e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.53	-8.07	-0.41	1.33e-14	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.35	5.63	0.3	3.92e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.94	-17.84	-0.7	2.87e-50	Height;
CRC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.48	6.31	0.33	8.87e-10	Bladder cancer;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg25164649	chr6:28176230	NA	-0.61	-8.1	-0.41	1.05e-14	Parkinson's disease;
CRC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.96	-18.34	-0.71	3.01e-52	Height;
CRC	cis	rs9462846	0.853	rs7765132	chr6:42872829	G/A	cg21280719	chr6:42927975	GNMT	-0.33	-6.47	-0.34	3.65e-10	Blood protein levels;
CRC	cis	rs7605827	0.897	rs2241238	chr2:15656560	T/C	cg19274914	chr2:15703543	NA	0.4	6.0	0.31	5.16e-9	Educational attainment (years of education);
CRC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.81	-0.35	4.6e-11	Cutaneous nevi;
CRC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.66	-0.63	8.15e-38	Height;
CRC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.05	0.68	3.65e-47	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10046574	0.831	rs17403220	chr7:135191705	A/G	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10392504	chr7:5464594	TNRC18	0.51	7.29	0.37	2.39e-12	Response to antipsychotic treatment;
CRC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg21521518	chr4:53727714	RASL11B	0.4	5.86	0.31	1.12e-8	Optic nerve measurement (cup area);
CRC	cis	rs7605827	0.930	rs13026732	chr2:15695429	G/A	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.63	5.89	0.31	9.72e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.79	0.35	5.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg18232548	chr7:50535776	DDC	-0.43	-5.73	-0.3	2.31e-8	Malaria;
CRC	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.51	6.72	0.35	8.19e-11	Migraine;
CRC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	0.66	6.47	0.34	3.6e-10	Fat distribution (HIV);
CRC	cis	rs728616	0.614	rs35395602	chr10:81906770	A/G	cg11900509	chr10:81946545	ANXA11	-0.71	-8.0	-0.4	2.21e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-10.29	-0.49	1.06e-21	Heart rate;
CRC	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.51	7.4	0.38	1.12e-12	Testicular germ cell tumor;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.7	-11.35	-0.53	2.05e-25	Monocyte percentage of white cells;
CRC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.7	7.77	0.39	1.03e-13	Vitiligo;
CRC	cis	rs10242455	0.850	rs57367781	chr7:99116819	G/A	cg18809830	chr7:99032528	PTCD1	-1.2	-8.64	-0.43	2.46e-16	Blood metabolite levels;
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	9.23	0.45	3.3e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-11.98	-0.55	1.05e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg07195577	chr17:27052828	TLCD1	0.42	6.16	0.32	2.09e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6728642	0.519	rs59131346	chr2:97566768	C/T	cg26665480	chr2:98280029	ACTR1B	-0.54	-5.9	-0.31	9.2e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg01262667	chr19:19385393	TM6SF2	0.35	5.91	0.31	8.35e-9	Tonsillectomy;
CRC	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.33	7.23	0.37	3.41e-12	Hip circumference adjusted for BMI;
CRC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg08314208	chr16:67682810	RLTPR	-0.64	-6.87	-0.35	3.23e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.72	0.54	9.53e-27	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06643102	chr19:8455567	RAB11B	0.43	6.66	0.34	1.15e-10	Interleukin-6 levels;
CRC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.46	7.05	0.36	1.06e-11	Dupuytren's disease;
CRC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.65	-0.3	3.44e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.94	0.44	2.78e-17	Schizophrenia;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.72	12.29	0.56	7.76e-29	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.07	-0.41	1.32e-14	Monocyte percentage of white cells;
CRC	cis	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-6.67	-0.35	1.1e-10	Colorectal or endometrial cancer;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg21251018	chr6:28226885	NKAPL	0.47	7.26	0.37	2.86e-12	Cardiac Troponin-T levels;
CRC	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg20488157	chr14:104394430	TDRD9	0.69	8.52	0.43	5.94e-16	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	7.53	0.38	5.06e-13	Response to antipsychotic treatment;
CRC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.55	7.22	0.37	3.67e-12	Breast cancer;
CRC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.69	-8.23	-0.41	4.32e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9814567	0.574	rs1391695	chr3:134171376	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-8.29	-0.42	2.91e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00287636	chr16:49892218	NA	0.35	6.48	0.34	3.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	9.02	0.45	1.58e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.14	0.49	3.26e-21	Heart rate;
CRC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.19	-0.32	1.76e-9	Dupuytren's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06329143	chr18:48556512	SMAD4	0.48	6.13	0.32	2.54e-9	Anxiety disorder;
CRC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.25	0.49	1.36e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-10.28	-0.49	1.1e-21	Breast cancer;
CRC	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.33	-5.62	-0.3	4.15e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs2346160	0.899	rs206974	chr6:167690300	G/A	cg04673565	chr6:167680447	NA	-0.41	-6.85	-0.35	3.72e-11	Parental extreme longevity (95 years and older);
CRC	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.49	-5.79	-0.3	1.68e-8	Coronary artery calcification;
CRC	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.56	-6.27	-0.33	1.14e-9	Type 2 diabetes;
CRC	trans	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.09	0.32	3.12e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.92	-11.43	-0.53	1.04e-25	Exhaled nitric oxide output;
CRC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg13844804	chr7:814759	HEATR2	0.65	8.47	0.42	8.48e-16	Cerebrospinal P-tau181p levels;
CRC	trans	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg23009290	chr3:125982568	NA	-0.35	-6.25	-0.33	1.27e-9	Migraine;
CRC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.49	6.63	0.34	1.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.47	-5.67	-0.3	3.06e-8	Body mass index (adult);
CRC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.38	-6.51	-0.34	2.81e-10	Reticulocyte fraction of red cells;
CRC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.64	0.3	3.59e-8	Tonsillectomy;
CRC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.55	-0.38	4.43e-13	Blood metabolite levels;
CRC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.47	8.54	0.43	5.02e-16	Immature fraction of reticulocytes;
CRC	cis	rs6076065	0.683	rs2424557	chr20:23422159	C/G	cg11657817	chr20:23433608	CST11	-0.44	-6.63	-0.34	1.4e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.34	-5.65	-0.3	3.45e-8	Body mass index;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg06361278	chr17:25783929	NA	0.48	6.11	0.32	2.86e-9	Hip circumference;
CRC	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.54	9.38	0.46	1.08e-18	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.38	5.91	0.31	8.64e-9	HDL cholesterol levels;
CRC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg03948781	chr1:205179583	DSTYK	0.43	6.13	0.32	2.56e-9	Red blood cell count;
CRC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.61	9.12	0.45	7.78e-18	Methadone dose in opioid dependence;
CRC	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.86	-20.97	-0.76	1.37e-62	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.59	8.35	0.42	1.89e-15	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg18335740	chr13:41363409	SLC25A15	0.56	8.81	0.44	7.2e-17	Lewy body disease;
CRC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.18	-0.32	1.86e-9	Cognitive function;
CRC	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg26875233	chr11:93583750	C11orf90	0.3	6.05	0.32	4.05e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	1.08	9.34	0.46	1.51e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.38	-6.22	-0.32	1.49e-9	Menopause (age at onset);
CRC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.39	-7.02	-0.36	1.25e-11	Dupuytren's disease;
CRC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	0.71	8.88	0.44	4.41e-17	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.84	-18.03	-0.71	4.84e-51	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg09264619	chr17:80180166	NA	0.52	7.44	0.38	8.67e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.62	-10.01	-0.48	9.3e-21	P wave terminal force;
CRC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg15962314	chr1:44399869	ARTN	0.29	5.74	0.3	2.17e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg03013999	chr17:37608204	MED1	0.45	6.83	0.35	4.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs3764400	0.567	rs4995899	chr17:46150730	G/A	cg10706073	chr17:46328419	SKAP1	-0.62	-6.71	-0.35	8.77e-11	Body mass index;
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.31	-0.37	2e-12	Bipolar disorder;
CRC	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.49	7.89	0.4	4.47e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.54	0.43	5.11e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.41	-6.17	-0.32	2.01e-9	Neutrophil percentage of white cells;
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs989128	0.614	rs8077587	chr17:48626575	C/T	cg16068336	chr17:48637367	CACNA1G	-0.54	-7.73	-0.39	1.3e-13	Type 2 diabetes;
CRC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-8.4	-0.42	1.31e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg13385521	chr17:29058706	SUZ12P	0.46	5.95	0.31	6.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-6.77	-0.35	5.81e-11	Lymphocyte counts;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg15763984	chr4:1342303	KIAA1530	-0.38	-5.97	-0.31	6.08e-9	Obesity-related traits;
CRC	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-7.53	-0.38	4.91e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00051782	chr3:193859210	NA	0.45	6.4	0.33	5.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.19	-0.49	2.18e-21	Total cholesterol levels;
CRC	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.45	8.21	0.41	4.98e-15	Blood metabolite ratios;
CRC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.37	5.85	0.31	1.2e-8	Blood metabolite levels;
CRC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg03934865	chr2:198174659	NA	-0.44	-8.05	-0.41	1.48e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.71	12.11	0.56	3.69e-28	Gout;
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	6.2	0.32	1.68e-9	Bipolar disorder;
CRC	cis	rs3736485	0.934	rs1902592	chr15:51881980	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.04	12.91	0.58	3.83e-31	Vitiligo;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12273811	chr6:28175739	NA	0.62	8.29	0.42	2.87e-15	Parkinson's disease;
CRC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg10431340	chr1:161279108	MPZ	-0.56	-7.42	-0.38	1.04e-12	Rheumatoid arthritis;
CRC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg05623727	chr3:50126028	RBM5	0.53	6.86	0.35	3.52e-11	Menarche (age at onset);
CRC	cis	rs6499255	0.904	rs7190652	chr16:69616292	C/G	cg15192750	chr16:69999425	NA	0.59	7.79	0.39	8.66e-14	IgE levels;
CRC	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg06781209	chr11:61594997	FADS2	-0.39	-5.96	-0.31	6.66e-9	Trans fatty acid levels;
CRC	cis	rs7605827	0.930	rs12692273	chr2:15688834	G/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.16e-9	Educational attainment (years of education);
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-7.0	-0.36	1.44e-11	Metabolite levels;
CRC	cis	rs9649465	0.934	rs7799354	chr7:123269819	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-6.37	-0.33	6.52e-10	Migraine;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg03013999	chr17:37608204	MED1	0.46	6.98	0.36	1.66e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.14	-12.02	-0.55	7.44e-28	Breast cancer;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg25164649	chr6:28176230	NA	0.49	7.0	0.36	1.46e-11	Cardiac Troponin-T levels;
CRC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-5.89	-0.31	9.55e-9	Lung cancer;
CRC	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	0.66	6.9	0.36	2.6e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs17767392	0.915	rs1990241	chr14:71774052	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.9	-0.36	2.71e-11	Mitral valve prolapse;
CRC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.44	-7.65	-0.39	2.29e-13	Height;
CRC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.97	-0.36	1.69e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.64	-0.34	1.33e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.89	-19.86	-0.74	3e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.64	10.25	0.49	1.38e-21	White blood cell count (basophil);
CRC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.53	-7.31	-0.37	2.04e-12	DNA methylation (variation);
CRC	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.73	-9.89	-0.48	2.39e-20	Coronary artery disease;
CRC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.19	-0.41	6.01e-15	Neuroticism;
CRC	cis	rs7487075	0.820	rs7304622	chr12:46698860	G/A	cg22049899	chr12:47219821	SLC38A4	0.33	6.13	0.32	2.48e-9	Itch intensity from mosquito bite;
CRC	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.43	-6.36	-0.33	6.68e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.89	0.44	4.18e-17	Schizophrenia;
CRC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.31	0.53	2.84e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.38	-0.38	1.31e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9292777	0.834	rs1992660	chr5:40415067	C/T	cg09067459	chr5:40385259	NA	0.53	9.31	0.46	1.8e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.57	8.66	0.43	2.16e-16	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.57	8.11	0.41	9.85e-15	Coronary heart disease;
CRC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.92	14.2	0.62	4.86e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.53	7.56	0.38	4.13e-13	Longevity;
CRC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.81	-0.4	7.72e-14	Response to antipsychotic treatment;
CRC	cis	rs9928842	1.000	rs9928842	chr16:75242867	T/C	cg08657710	chr16:75258780	CTRB1	-0.59	-6.82	-0.35	4.37e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.57	7.15	0.37	5.56e-12	Alzheimer's disease;
CRC	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.21	0.45	3.84e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.6	10.29	0.49	1.01e-21	Prudent dietary pattern;
CRC	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.52	-0.34	2.67e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.16	0.41	7.3e-15	Alzheimer's disease;
CRC	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.74	-0.3	2.13e-8	Electroencephalogram traits;
CRC	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.58	11.42	0.53	1.13e-25	Weight;
CRC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.39	-0.33	5.7e-10	Aortic root size;
CRC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.77	10.68	0.51	4.51e-23	Orofacial clefts;
CRC	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.82	10.85	0.51	1.21e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs12024301	0.557	rs16861243	chr1:183589382	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.76	-7.03	-0.36	1.21e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.39	-0.42	1.42e-15	Height;
CRC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg13722127	chr7:150037890	RARRES2	0.5	7.84	0.4	6.35e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs948562	0.647	rs71486418	chr11:58240133	C/T	cg15696309	chr11:58395628	NA	-0.57	-8.73	-0.43	1.3e-16	Lymphoma;
CRC	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.67	-6.26	-0.33	1.2e-9	Obesity;Body mass index;
CRC	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.53	0.34	2.47e-10	Coronary artery disease;
CRC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.74	10.88	0.51	9.48e-24	Breast cancer;
CRC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.7	-10.23	-0.49	1.65e-21	Blood metabolite levels;
CRC	cis	rs62432291	0.681	rs420054	chr6:159655084	C/G	cg14500486	chr6:159655392	FNDC1	-0.76	-10.41	-0.5	4.01e-22	Joint mobility (Beighton score);
CRC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.8	0.3	1.52e-8	Bladder cancer;
CRC	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.37	4.05e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.91	0.36	2.5e-11	Platelet count;
CRC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg20534287	chr10:135191450	PAOX	0.76	5.9	0.31	9.19e-9	Lifespan;
CRC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.64	-9.58	-0.47	2.42e-19	Obesity-related traits;
CRC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg21770322	chr7:97807741	LMTK2	0.55	9.2	0.45	4.12e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.56	9.33	0.46	1.59e-18	Schizophrenia;
CRC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.47	7.13	0.37	6.29e-12	Eye color traits;
CRC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.34	-7.16	-0.37	5.41e-12	Cutaneous nevi;
CRC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.31	0.33	9.21e-10	Morning vs. evening chronotype;
CRC	cis	rs16975963	0.843	rs113690074	chr19:38375393	G/A	cg15135657	chr19:38346511	NA	-0.43	-5.76	-0.3	1.96e-8	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13551243	chr8:146052742	ZNF7	0.4	5.98	0.31	5.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg16964102	chr10:135390573	NA	-0.41	-6.76	-0.35	6.47e-11	Obesity-related traits;
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg05569086	chr8:143859399	LYNX1	0.37	6.33	0.33	8e-10	Urinary tract infection frequency;
CRC	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg19025524	chr12:109796872	NA	-0.47	-6.75	-0.35	6.8e-11	Neuroticism;
CRC	trans	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.1	0.36	7.97e-12	Ulcerative colitis;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg19041857	chr6:27730383	NA	0.73	7.06	0.36	9.84e-12	Depression;
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs4964805	0.954	rs10861104	chr12:104189923	A/C	cg02344784	chr12:104178138	NT5DC3	0.51	7.21	0.37	3.89e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg18479299	chr3:125709523	NA	-0.55	-6.44	-0.33	4.23e-10	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02632015	chr17:19551762	ALDH3A2	0.4	6.48	0.34	3.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3736485	0.844	rs17603116	chr15:51786877	G/A	cg08986416	chr15:51914746	DMXL2	-0.44	-6.26	-0.33	1.19e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg12193833	chr17:30244370	NA	-0.6	-7.88	-0.4	4.8e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.64	8.48	0.42	8e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.65	7.04	0.36	1.13e-11	Axial length;
CRC	cis	rs7394190	0.748	rs3843939	chr10:75578948	T/C	cg07699608	chr10:75541558	CHCHD1	0.59	6.01	0.31	5.03e-9	Incident atrial fibrillation;
CRC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.56	-8.48	-0.42	7.99e-16	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg12437481	chr16:420112	MRPL28	-0.66	-9.91	-0.48	1.97e-20	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.49	7.46	0.38	7.86e-13	Corneal astigmatism;
CRC	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.49	-6.26	-0.33	1.22e-9	Body mass index;
CRC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.74	11.89	0.55	2.31e-27	Blood protein levels;
CRC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg02428538	chr16:24856791	SLC5A11	0.56	6.66	0.34	1.16e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.71	0.3	2.52e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.37	5.85	0.31	1.16e-8	Height;
CRC	cis	rs4481887	0.504	rs12117067	chr1:248363568	A/G	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.72	-7.86	-0.4	5.55e-14	Major depressive disorder;
CRC	cis	rs11212617	0.967	rs113995	chr11:108256837	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.49	0.34	3.21e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.65	7.25	0.37	3.04e-12	Gut microbiome composition (summer);
CRC	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.56	-8.84	-0.44	5.89e-17	Breast cancer;
CRC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.55	0.43	4.83e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6460942	0.908	rs967126	chr7:12237300	G/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.15	-0.32	2.29e-9	Coronary artery disease;
CRC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.54	8.23	0.41	4.43e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4917300	0.586	rs1352949	chr8:143096253	G/C	cg25363559	chr8:143086065	NA	-0.34	-6.35	-0.33	6.98e-10	Amyotrophic lateral sclerosis;
CRC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.67	9.93	0.48	1.67e-20	Body mass index;
CRC	cis	rs3772130	0.583	rs7618041	chr3:121566481	G/A	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	cis	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg17459225	chr2:239074497	NA	0.45	7.81	0.4	7.49e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.34	5.64	0.3	3.7e-8	Childhood ear infection;
CRC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.68	-12.21	-0.56	1.6e-28	Lewy body disease;
CRC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.62	-8.35	-0.42	1.86e-15	Obesity-related traits;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.48	-8.8	-0.44	8.16e-17	Hip circumference;Waist circumference;
CRC	trans	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.31	0.33	9.26e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.51	-8.44	-0.42	1.05e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	9.29	0.46	2.19e-18	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg15848620	chr12:58087721	OS9	-0.61	-8.29	-0.42	3.02e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg02033258	chr5:131593261	PDLIM4	0.34	5.98	0.31	5.71e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.44	6.68	0.35	1.03e-10	Coronary artery disease;
CRC	cis	rs10888329	0.744	rs7518603	chr1:248349904	A/T	cg00666640	chr1:248458726	OR2T12	0.43	6.82	0.35	4.41e-11	Autism spectrum disorder;
CRC	cis	rs3850699	0.683	rs67481356	chr10:104317811	C/A	cg04362960	chr10:104952993	NT5C2	0.49	6.05	0.32	3.93e-9	Prostate cancer;
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.46	5.92	0.31	8.02e-9	HDL cholesterol;
CRC	cis	rs7605827	0.866	rs13016989	chr2:15514338	T/A	cg19274914	chr2:15703543	NA	0.4	6.06	0.32	3.78e-9	Educational attainment (years of education);
CRC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.18	-0.32	1.86e-9	Menopause (age at onset);
CRC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.64	7.91	0.4	4.06e-14	Menarche (age at onset);
CRC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg02869306	chr7:64672164	INTS4L1	-0.34	-5.8	-0.3	1.59e-8	Aortic root size;
CRC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.31e-9	Morning vs. evening chronotype;
CRC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg16342193	chr10:102329863	NA	-0.38	-6.16	-0.32	2.11e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.39	-5.6	-0.3	4.51e-8	Ovarian reserve;
CRC	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.84	0.35	3.82e-11	Mean corpuscular volume;
CRC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.73	10.76	0.51	2.53e-23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
CRC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.87	-0.31	1.05e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12476592	0.602	rs6736029	chr2:63789170	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.55	5.98	0.31	5.82e-9	RR interval (heart rate);
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg20933634	chr6:27740509	NA	0.46	6.56	0.34	2.08e-10	Parkinson's disease;
CRC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.79	-0.3	1.6e-8	Lung cancer;
CRC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg08213375	chr14:104286397	PPP1R13B	0.41	6.35	0.33	7.33e-10	Reticulocyte count;
CRC	trans	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg11704114	chr12:21509398	SLCO1A2	-0.31	-5.99	-0.31	5.56e-9	Tuberculosis;
CRC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.52	8.75	0.43	1.16e-16	Coronary artery disease;
CRC	cis	rs7487075	0.930	rs4076248	chr12:46833605	C/T	cg17501823	chr12:47219793	SLC38A4	0.32	5.9	0.31	8.98e-9	Itch intensity from mosquito bite;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.83	12.96	0.58	2.59e-31	Menarche (age at onset);
CRC	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.66	-10.39	-0.5	4.56e-22	Adiposity;
CRC	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.9	-0.4	4.25e-14	Caffeine consumption;
CRC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg25459000	chr22:39777742	SYNGR1	0.33	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg21138405	chr5:131827807	IRF1	-0.34	-5.83	-0.31	1.36e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs17767392	0.958	rs3825719	chr14:72053097	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.22	-0.37	3.6e-12	Mitral valve prolapse;
CRC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.67	9.02	0.45	1.59e-17	Breast cancer;
CRC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16262614	chr3:133464971	TF	0.34	6.05	0.32	4.04e-9	Iron status biomarkers;
CRC	cis	rs12580194	1.000	rs12579030	chr12:55689194	T/C	cg19537932	chr12:55886519	OR6C68	-0.6	-8.37	-0.42	1.68e-15	Cancer;
CRC	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-1.25	-15.87	-0.66	1.56e-42	Lung disease severity in cystic fibrosis;
CRC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.69	0.39	1.7e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4493873	1.000	rs4493873	chr8:92075643	A/C	cg16814680	chr8:91681699	NA	0.41	5.83	0.31	1.3e-8	Migraine - clinic-based;
CRC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.49	8.29	0.42	2.89e-15	Lipoprotein (a) levels;
CRC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12463550	chr7:65579703	CRCP	0.69	6.4	0.33	5.42e-10	Diabetic kidney disease;
CRC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg24289452	chr6:170231220	NA	-0.94	-7.59	-0.39	3.43e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10960135	chr3:121264538	POLQ	0.37	5.98	0.31	5.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg19773385	chr1:10388646	KIF1B	-0.46	-7.22	-0.37	3.72e-12	Hepatocellular carcinoma;
CRC	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg20744362	chr22:50050164	C22orf34	0.34	6.32	0.33	8.57e-10	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.66	-0.34	1.15e-10	Morning vs. evening chronotype;
CRC	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.43	7.92	0.4	3.67e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.95	-0.44	2.67e-17	Electroencephalogram traits;
CRC	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg25885038	chr17:56607967	SEPT4	-0.51	-7.7	-0.39	1.63e-13	Vitamin D levels;
CRC	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg22089800	chr15:90895588	ZNF774	-0.42	-5.87	-0.31	1.04e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	7.02	0.36	1.28e-11	Mean platelet volume;
CRC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-6.7	-0.35	9.23e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.35	0.56	4.64e-29	Menopause (age at onset);
CRC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg10760299	chr15:45669010	GATM	0.52	8.29	0.42	2.96e-15	Homoarginine levels;
CRC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.43	-6.05	-0.32	3.84e-9	Cognitive ability;
CRC	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-17.64	-0.7	1.7e-49	Ulcerative colitis;
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	13.32	0.59	1.17e-32	Alzheimer's disease;
CRC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.4	-5.78	-0.3	1.72e-8	Aortic root size;
CRC	cis	rs6687487	1.000	rs28455953	chr1:23060951	A/G	cg05266663	chr1:23061564	EPHB2	-0.65	-5.95	-0.31	6.99e-9	Blood protein levels;
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.77	11.27	0.53	3.99e-25	Menarche (age at onset);
CRC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg10578991	chr7:12443926	VWDE	-0.47	-5.66	-0.3	3.24e-8	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08120044	chr21:42539440	BACE2	0.4	6.41	0.33	5.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.49	-5.98	-0.31	5.9e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CRC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.22	-0.32	1.54e-9	Aortic root size;
CRC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.88	-0.48	2.52e-20	Personality dimensions;
CRC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.39	-6.89	-0.36	2.77e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.51	-6.25	-0.33	1.29e-9	Diastolic blood pressure;
CRC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.84	11.74	0.54	7.85e-27	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg20615401	chr6:28092323	ZSCAN16	0.47	6.25	0.33	1.28e-9	Parkinson's disease;
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg03909863	chr11:638404	DRD4	-0.53	-7.16	-0.37	5.39e-12	Systemic lupus erythematosus;
CRC	cis	rs12024301	0.557	rs79546878	chr1:183609492	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.83	0.35	4.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.97	-0.31	6.15e-9	Metabolite levels;
CRC	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.68	-10.27	-0.49	1.17e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.53	8.05	0.41	1.56e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg16724585	chr3:197361211	NA	-0.47	-7.0	-0.36	1.49e-11	Pancreatic cancer;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg25164649	chr6:28176230	NA	0.63	9.03	0.45	1.43e-17	Parkinson's disease;
CRC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg09165964	chr15:75287851	SCAMP5	0.5	7.79	0.39	9e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.54	-8.27	-0.41	3.34e-15	Eosinophil percentage of white cells;
CRC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.93	-0.31	7.62e-9	Cognitive function;
CRC	cis	rs12620999	0.941	rs62183343	chr2:237979163	T/C	cg23555395	chr2:238036564	NA	0.54	8.35	0.42	1.91e-15	Systemic lupus erythematosus;
CRC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.37	-5.86	-0.31	1.15e-8	Blood metabolite levels;
CRC	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	0.92	10.07	0.49	5.72e-21	Gut microbiota (bacterial taxa);
CRC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg20673091	chr1:2541236	MMEL1	0.36	5.82	0.31	1.43e-8	Ulcerative colitis;
CRC	cis	rs7605827	0.930	rs12692262	chr2:15539084	A/G	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.09e-8	Educational attainment (years of education);
CRC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg14530993	chr4:882597	GAK	0.82	7.7	0.39	1.64e-13	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02290575	chr7:100964799	RABL5	0.42	7.05	0.36	1.04e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.64	-9.29	-0.46	2.24e-18	Height;
CRC	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06307176	chr5:131281290	NA	0.42	6.09	0.32	3.08e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9462027	0.628	rs2764208	chr6:34714322	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.12e-8	Systemic lupus erythematosus;
CRC	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.14	0.56	2.94e-28	Coffee consumption (cups per day);
CRC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.53	-7.19	-0.37	4.49e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.96e-13	Lung cancer in ever smokers;
CRC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.51	-0.38	5.7e-13	Coronary artery disease;
CRC	cis	rs7259376	0.807	rs11669254	chr19:22544805	A/G	cg02657401	chr19:22469223	NA	-0.29	-6.05	-0.32	3.94e-9	Menopause (age at onset);
CRC	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.62	0.39	2.68e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg10437265	chr15:77819839	NA	-0.45	-7.96	-0.4	2.86e-14	Type 2 diabetes;
CRC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.82	0.35	4.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-8.35	-0.42	1.95e-15	Mean platelet volume;Platelet distribution width;
CRC	trans	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg16724585	chr3:197361211	NA	-0.5	-6.54	-0.34	2.3e-10	Pancreatic cancer;
CRC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg22117107	chr15:45993392	NA	-0.41	-8.16	-0.41	7.15e-15	Waist circumference;Weight;
CRC	cis	rs860295	0.756	rs7546258	chr1:155698645	T/A	cg02153340	chr1:155202674	NA	-0.51	-6.25	-0.33	1.25e-9	Body mass index;
CRC	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg20542592	chr8:11973495	FAM66D	0.33	5.8	0.3	1.6e-8	Retinal vascular caliber;
CRC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.55	9.08	0.45	1.06e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.37	-6.04	-0.32	4.14e-9	Coronary artery disease;
CRC	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg03146154	chr1:46216737	IPP	-0.44	-5.71	-0.3	2.48e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6909279	0.933	rs9479068	chr6:151872448	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.38	-5.82	-0.31	1.39e-8	Bone mineral density;
CRC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.64	8.99	0.44	1.96e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.59	6.58	0.34	1.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6662572	0.737	rs4434876	chr1:46270129	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-6.08	-0.32	3.36e-9	Blood protein levels;
CRC	trans	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg14791747	chr16:20752902	THUMPD1	0.55	6.83	0.35	4.09e-11	Cognitive test performance;
CRC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg05585544	chr11:47624801	NA	-0.62	-11.41	-0.53	1.22e-25	Subjective well-being;
CRC	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-7.01	-0.36	1.35e-11	Tuberculosis;
CRC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.66	7.53	0.38	4.88e-13	Vitiligo;
CRC	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.94e-9	Corneal astigmatism;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.62	0.6	8.27e-34	Prudent dietary pattern;
CRC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-8.26	-0.41	3.56e-15	Hemoglobin concentration;
CRC	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs7705042	0.865	rs7733850	chr5:141515564	C/T	cg07392085	chr5:141489673	NDFIP1	0.45	7.26	0.37	2.75e-12	Asthma;
CRC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.69	-9.08	-0.45	1.06e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7258465	0.931	rs11673604	chr19:18540988	T/C	cg06462663	chr19:18546047	ISYNA1	0.5	7.33	0.37	1.82e-12	Breast cancer;
CRC	cis	rs3736485	0.966	rs11633713	chr15:51908052	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.45	-0.34	3.97e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12044355	0.929	rs11122323	chr1:231848933	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.07	0.32	3.43e-9	Alzheimer's disease;
CRC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.4	-6.53	-0.34	2.5e-10	Huntington's disease progression;
CRC	cis	rs834811	0.583	rs12539683	chr7:135891486	A/T	cg01726295	chr7:135938950	NA	0.35	6.01	0.31	5e-9	Post-traumatic stress disorder;
CRC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.2	-0.41	5.41e-15	Chronic sinus infection;
CRC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	9.27	0.45	2.56e-18	Cognitive test performance;
CRC	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.82	-0.31	1.43e-8	Pulmonary function;
CRC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg00129232	chr17:37814104	STARD3	-0.44	-6.91	-0.36	2.58e-11	Self-reported allergy;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg20933634	chr6:27740509	NA	0.5	7.17	0.37	4.9e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.05	0.55	6.15e-28	Chronic sinus infection;
CRC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.57	9.1	0.45	8.82e-18	Vitiligo;
CRC	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	0.55	6.0	0.31	5.18e-9	Coronary artery disease;
CRC	cis	rs1124376	1.000	rs61457790	chr3:20136186	G/A	cg05072819	chr3:20081367	KAT2B	0.54	6.2	0.32	1.66e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs28655083	0.956	rs4088757	chr16:77071545	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.5	7.12	0.37	6.61e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.62	0.6	8.2e-34	Chronic sinus infection;
CRC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.85	-12.49	-0.57	1.49e-29	Platelet distribution width;
CRC	cis	rs17023223	0.537	rs17023171	chr1:119593268	A/C	cg05756136	chr1:119680316	WARS2	-0.44	-5.86	-0.31	1.15e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.48	-9.25	-0.45	2.91e-18	Schizophrenia;
CRC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06462663	chr19:18546047	ISYNA1	0.49	7.31	0.37	1.98e-12	Breast cancer;
CRC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.98	-0.48	1.12e-20	Height;
CRC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg18721089	chr20:30220636	NA	-0.36	-5.86	-0.31	1.12e-8	Mean corpuscular hemoglobin;
CRC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.77	-0.44	9.46e-17	Total cholesterol levels;
CRC	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	0.64	6.83	0.35	4.08e-11	Prostate cancer;
CRC	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg17788362	chr6:86352627	SYNCRIP	-0.47	-6.41	-0.33	5.19e-10	Smooth-surface caries;
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.55	6.72	0.35	7.98e-11	Vitiligo;
CRC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg07090678	chr1:91966139	CDC7	0.44	7.15	0.37	5.48e-12	Breast cancer;
CRC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	11.41	0.53	1.2e-25	High light scatter reticulocyte count;
CRC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.85	-0.35	3.75e-11	Hemoglobin concentration;
CRC	cis	rs9292777	0.897	rs1445004	chr5:40414419	C/T	cg09067459	chr5:40385259	NA	0.51	8.76	0.43	1.05e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg15790184	chr11:494944	RNH1	0.66	6.4	0.33	5.31e-10	Body mass index;
CRC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg04990556	chr1:26633338	UBXN11	-0.48	-6.15	-0.32	2.31e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg25456477	chr12:86230367	RASSF9	-0.34	-5.87	-0.31	1.04e-8	Major depressive disorder;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg15511327	chr8:143859410	LYNX1	-0.4	-6.19	-0.32	1.81e-9	Urinary tract infection frequency;
CRC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	10.79	0.51	1.93e-23	Nonalcoholic fatty liver disease;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12963246	chr6:28129442	ZNF389	0.5	5.76	0.3	1.88e-8	Depression;
CRC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.6	-9.61	-0.47	1.9e-19	Intelligence (multi-trait analysis);
CRC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg06028605	chr16:24865363	SLC5A11	0.44	7.87	0.4	5.09e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg04450456	chr4:17643702	FAM184B	0.39	6.22	0.32	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg25173405	chr17:45401733	C17orf57	-0.45	-6.89	-0.36	2.87e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.64	-17.41	-0.69	1.47e-48	Urate levels in overweight individuals;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23161317	chr6:28129485	ZNF389	0.53	6.55	0.34	2.21e-10	Depression;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg16558177	chr4:4109446	NA	-0.62	-8.74	-0.43	1.23e-16	Blood pressure (smoking interaction);
CRC	cis	rs12476592	0.602	rs11125977	chr2:63809549	C/T	cg10828910	chr2:63850056	LOC388955	-0.46	-5.73	-0.3	2.22e-8	Childhood ear infection;
CRC	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-1.02	-10.27	-0.49	1.16e-21	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6662572	0.737	rs4573476	chr1:46346721	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.78	0.3	1.77e-8	Blood protein levels;
CRC	cis	rs7923609	0.967	rs2393986	chr10:65320006	A/T	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.72	-0.3	2.42e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg27094323	chr7:1216898	NA	-0.33	-5.61	-0.3	4.34e-8	Longevity;Endometriosis;
CRC	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg08501292	chr6:25962987	TRIM38	0.85	5.77	0.3	1.79e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-6.63	-0.34	1.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.65	-11.17	-0.52	8.86e-25	Brugada syndrome;
CRC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.92	-16.19	-0.67	9.15e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.62	10.19	0.49	2.17e-21	Calcium levels;
CRC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.21	0.64	6.22e-40	Primary sclerosing cholangitis;
CRC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.7	10.01	0.48	9.23e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.74	-10.65	-0.51	6.16e-23	Platelet distribution width;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg08798685	chr6:27730294	NA	-0.58	-6.44	-0.33	4.18e-10	Lung cancer in ever smokers;
CRC	cis	rs6663390	0.831	rs3754171	chr1:208086939	T/C	cg03990033	chr1:208084030	CD34	0.5	6.89	0.35	2.9100000000000002e-11	Facial morphology (factor 18);
CRC	cis	rs6504622	0.721	rs8077021	chr17:45139303	T/C	cg16759221	chr17:45003025	GOSR2	0.45	6.93	0.36	2.23e-11	Orofacial clefts;
CRC	cis	rs10971721	0.908	rs10971728	chr9:33834633	G/T	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.71	-8.54	-0.43	4.91e-16	Hemostatic factors and hematological phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10494556	chr7:1199936	ZFAND2A	0.36	6.07	0.32	3.61e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.82	12.67	0.57	3.15e-30	Cognitive function;
CRC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.76	-12.99	-0.58	2.03e-31	Breast cancer;
CRC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.84	-13.92	-0.61	6.1e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21908638	chr3:101497982	FAM55C	0.38	6.2	0.32	1.73e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg11292332	chr7:45801988	SEPT13	-0.39	-7.04	-0.36	1.12e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg05313129	chr8:58192883	C8orf71	-0.4	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4478858	0.684	rs1546375	chr1:31765968	C/T	cg00250761	chr1:31883323	NA	-0.4	-7.69	-0.39	1.76e-13	Alcohol dependence;
CRC	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.12	11.82	0.55	4.19e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12580194	0.593	rs61957946	chr12:55755778	T/C	cg23425280	chr12:56401806	NA	0.47	5.78	0.3	1.76e-8	Cancer;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg12172441	chr6:28176163	NA	0.59	8.41	0.42	1.23e-15	Cardiac Troponin-T levels;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.75	12.25	0.56	1.12e-28	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg18811423	chr2:55921094	PNPT1	0.6	8.76	0.43	1.03e-16	Metabolic syndrome;
CRC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.6	10.93	0.52	6.45e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.63	-11.86	-0.55	2.88e-27	Educational attainment;
CRC	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.49	8.26	0.41	3.48e-15	Testicular germ cell tumor;
CRC	trans	rs7088591	0.558	rs57910753	chr10:59819531	T/C	cg21239940	chr8:68870412	PREX2	0.54	6.01	0.31	4.93e-9	Blood pressure;
CRC	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.51	6.8	0.35	4.95e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14019695	chr9:139328340	INPP5E	0.38	5.8	0.3	1.57e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.66	-8.53	-0.43	5.51e-16	Mean platelet volume;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.7	9.98	0.48	1.16e-20	Cleft lip with or without cleft palate;
CRC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	8.73	0.43	1.3e-16	Colorectal cancer;
CRC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.07	0.45	1.07e-17	Alzheimer's disease;
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg01339444	chr6:118972232	C6orf204	0.55	6.2	0.32	1.69e-9	Diastolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26486702	chr1:161129448	USP21	0.46	6.73	0.35	7.69e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.73	-11.27	-0.53	3.95e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.32	-7.01	-0.36	1.32e-11	IgG glycosylation;
CRC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.5	-0.38	5.84e-13	Coronary artery disease;
CRC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	trans	rs4785204	1.000	rs4785202	chr16:50095995	C/T	cg07960154	chr17:37760198	NEUROD2	-0.64	-6.03	-0.32	4.47e-9	Esophageal cancer (squamous cell);
CRC	cis	rs600626	0.636	rs10899110	chr11:75452342	C/G	cg24262691	chr11:75473276	NA	0.55	7.61	0.39	2.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.45	7.78	0.39	9.63e-14	Migraine;
CRC	cis	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.23	0.37	3.48e-12	Asthma;
CRC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.44	-0.38	8.9e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.61	9.88	0.48	2.49e-20	Tonsillectomy;
CRC	cis	rs73206853	0.841	rs28404862	chr12:110850241	C/G	cg12870014	chr12:110450643	ANKRD13A	0.76	8.38	0.42	1.53e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.56	8.48	0.42	7.76e-16	Longevity;Endometriosis;
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg21251018	chr6:28226885	NKAPL	-0.41	-6.31	-0.33	8.88e-10	Systemic lupus erythematosus;
CRC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.94	-0.31	7.22e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg08514558	chr10:81106712	PPIF	0.36	5.77	0.3	1.88e-8	Height;
CRC	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-7.54	-0.38	4.48e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg10729496	chr3:10149963	C3orf24	0.49	6.52	0.34	2.67e-10	Alzheimer's disease;
CRC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg05347473	chr6:146136440	FBXO30	0.37	5.81	0.31	1.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.73	-0.35	7.69e-11	Major depressive disorder;
CRC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg23298862	chr7:158159286	PTPRN2	0.38	5.99	0.31	5.49e-9	Calcium levels;
CRC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.89	-16.43	-0.67	1.01e-44	Height;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.09	0.32	3.1e-9	Depression;
CRC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-6.03	-0.32	4.3e-9	IgG glycosylation;
CRC	cis	rs394563	0.517	rs385303	chr6:149779064	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.44	-7.15	-0.37	5.79e-12	Dupuytren's disease;
CRC	cis	rs17092148	0.887	rs2068474	chr20:33231079	A/G	cg08999081	chr20:33150536	PIGU	0.5	6.16	0.32	2.1e-9	Neuroticism;
CRC	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.52	-8.53	-0.43	5.27e-16	Schizophrenia;
CRC	trans	rs17570583	1.000	rs17570583	chr5:171559531	A/G	cg08920628	chr10:48354911	ZNF488	0.6	5.99	0.31	5.56e-9	Migraine - clinic-based;
CRC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs10242455	0.702	rs76702117	chr7:98916779	A/G	cg09045935	chr12:6379348	NA	0.98	7.27	0.37	2.66e-12	Blood metabolite levels;
CRC	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg09040174	chr2:113837401	NA	0.64	10.17	0.49	2.63e-21	Protein quantitative trait loci;
CRC	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.34e-36	Colorectal cancer;
CRC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg02007433	chr3:129722099	NA	0.49	6.24	0.33	1.35e-9	Blood pressure (smoking interaction);
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	14.07	0.61	1.53e-35	Alzheimer's disease;
CRC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.43	5.89	0.31	9.34e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-5.72	-0.3	2.38e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.43	-0.38	9.36e-13	Bipolar disorder;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12273811	chr6:28175739	NA	0.75	10.18	0.49	2.5e-21	Depression;
CRC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.83	0.35	4.07e-11	Neuroticism;
CRC	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.72	14.34	0.62	1.46e-36	Leprosy;
CRC	cis	rs17023223	0.537	rs2765532	chr1:119591546	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-6.26	-0.33	1.18e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	8.94	0.44	2.83e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7781557	0.640	rs6955064	chr7:102579571	T/C	cg18108683	chr7:102477205	FBXL13	-0.49	-5.69	-0.3	2.86e-8	Colorectal adenoma (advanced);
CRC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.66	7.21	0.37	3.94e-12	Inflammatory bowel disease;
CRC	cis	rs2274471	0.660	rs10974948	chr9:5075255	C/T	cg03390472	chr9:5043263	JAK2	-0.58	-6.41	-0.33	4.97e-10	Crohn's disease;
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.55	6.88	0.35	2.97e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.63	-0.39	2.54e-13	Morning vs. evening chronotype;
CRC	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.5	-6.19	-0.32	1.76e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CRC	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg21918786	chr6:109611834	NA	-0.33	-5.73	-0.3	2.3e-8	Reticulocyte fraction of red cells;
CRC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-7.24	-0.37	3.14e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs6534441	0.824	rs6836758	chr4:125458226	G/A	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.58	-8.78	-0.44	9.23e-17	Uric acid levels;
CRC	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg23032129	chr1:109941072	SORT1	-0.28	-6.04	-0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.9	0.44	3.69e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg06219351	chr7:158114137	PTPRN2	-0.52	-7.86	-0.4	5.7e-14	Calcium levels;
CRC	cis	rs6545883	0.507	rs12617371	chr2:61569134	A/G	cg10580144	chr2:61372316	C2orf74	-0.34	-7.55	-0.38	4.37e-13	Tuberculosis;
CRC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.82	-0.44	6.89e-17	Alcohol dependence;
CRC	cis	rs1322512	1.000	rs2250514	chr6:153010920	C/T	cg03415253	chr6:152958462	SYNE1	0.39	5.86	0.31	1.1e-8	Tonometry;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.74	0.3	2.14e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.59	-9.33	-0.46	1.59e-18	Breast cancer;
CRC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.86	16.76	0.68	5.07e-46	White blood cell count;
CRC	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.41	7.74	0.39	1.25e-13	Alcohol dependence;
CRC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.35	-0.33	7.11e-10	Schizophrenia;
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.76	14.24	0.62	3.62e-36	Prudent dietary pattern;
CRC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.71	11.08	0.52	1.87e-24	Menopause (age at onset);
CRC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg25767906	chr1:53392781	SCP2	-0.39	-6.2	-0.32	1.72e-9	Monocyte count;
CRC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.45	-6.62	-0.34	1.47e-10	Breast size;
CRC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg16928487	chr17:17741425	SREBF1	0.55	9.89	0.48	2.29e-20	Body mass index;
CRC	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.9	0.48	2.09e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.49	7.51	0.38	5.6e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.88	0.31	1.01e-8	Hemoglobin concentration;
CRC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg02269571	chr22:50332266	NA	-0.59	-7.67	-0.39	1.96e-13	Schizophrenia;
CRC	trans	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.52	9.46	0.46	6.3e-19	HDL cholesterol levels;
CRC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.6	-9.37	-0.46	1.19e-18	Colorectal cancer;
CRC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg11212589	chr17:38028394	ZPBP2	0.43	7.93	0.4	3.39e-14	Self-reported allergy;
CRC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.67	7.77	0.39	9.93e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg23136738	chr11:925521	AP2A2	-0.38	-5.89	-0.31	9.65e-9	Alzheimer's disease (late onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04485844	chr17:56296718	MKS1	0.44	6.39	0.33	5.83e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.56	-9.13	-0.45	6.9e-18	Pursuit maintenance gain;
CRC	cis	rs524281	0.773	rs2282568	chr11:66052832	C/G	cg14036092	chr11:66035641	RAB1B	-0.54	-5.97	-0.31	6.14e-9	Electroencephalogram traits;
CRC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg02421172	chr7:1938701	MAD1L1	0.49	6.61	0.34	1.59e-10	Bipolar disorder;
CRC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-6.33	-0.33	8e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	10.69	0.51	4.23e-23	Prudent dietary pattern;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg03623178	chr6:28175578	NA	0.61	8.65	0.43	2.32e-16	Parkinson's disease;
CRC	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.63	-7.95	-0.4	3.08e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.84	9.9	0.48	2.08e-20	Psoriasis;
CRC	cis	rs12980942	0.872	rs7257583	chr19:41788117	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.44	5.62	0.3	4.08e-8	Coronary artery disease;
CRC	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg14668889	chr17:73230827	NUP85	-0.52	-7.57	-0.39	3.79e-13	Systemic lupus erythematosus;
CRC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg04586622	chr2:25135609	ADCY3	-0.56	-10.45	-0.5	3.03e-22	Body mass index;
CRC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.59	6.72	0.35	7.95e-11	Bipolar disorder;
CRC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.41	-6.33	-0.33	7.9e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.54	8.4	0.42	1.39e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1011108	0.561	rs1053807	chr2:26800422	G/A	cg18742855	chr2:26800399	C2orf70	0.63	11.11	0.52	1.41e-24	Periodontal microbiota;
CRC	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.48	6.96	0.36	1.91e-11	Primary sclerosing cholangitis;
CRC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.17	-0.32	2e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19591439	chr19:11708747	ZNF627	0.42	6.24	0.33	1.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.65	5.74	0.3	2.15e-8	Yeast infection;
CRC	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.52	7.59	0.39	3.32e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg09876464	chr15:85330779	ZNF592	0.44	7.31	0.37	2e-12	P wave terminal force;
CRC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.42	6.86	0.35	3.4e-11	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.42	7.21	0.37	3.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs2462686	1.000	rs1525828	chr7:46002078	T/A	cg23193639	chr7:45961078	IGFBP3	-0.38	-5.86	-0.31	1.14e-8	Major depressive disorder;
CRC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.48	7.31	0.37	2.07e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.81	13.76	0.6	2.44e-34	Menopause (age at onset);
CRC	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg20742385	chr13:113633654	MCF2L	-0.64	-10.78	-0.51	2.13e-23	Systolic blood pressure;
CRC	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg21483461	chr5:81570383	RPS23	-0.37	-5.86	-0.31	1.1e-8	Breast cancer;
CRC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-14.94	-0.64	6.9e-39	Electrocardiographic conduction measures;
CRC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.62	-9.02	-0.45	1.64e-17	Subjective well-being;
CRC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs4731207	0.596	rs12538171	chr7:124645570	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.88	-10.57	-0.5	1.13e-22	Monocyte percentage of white cells;
CRC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.34	-6.07	-0.32	3.47e-9	Rheumatoid arthritis;
CRC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.67	0.54	1.42e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.54	-10.06	-0.49	6.03e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg25164649	chr6:28176230	NA	0.77	9.53	0.46	3.69e-19	Depression;
CRC	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.64	10.64	0.51	6.33e-23	Hip circumference;
CRC	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	9.22	0.45	3.56e-18	Type 2 diabetes;
CRC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.55	-0.38	4.19e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg22687807	chr8:143858763	LYNX1	0.49	8.69	0.43	1.68e-16	Urinary tract infection frequency;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17609050	chr7:92861606	CCDC132	0.48	6.18	0.32	1.89e-9	Thyroid stimulating hormone;
CRC	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.42	-6.08	-0.32	3.41e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg10978503	chr1:24200527	CNR2	-0.44	-6.55	-0.34	2.24e-10	Immature fraction of reticulocytes;
CRC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.61	-9.5	-0.46	4.42e-19	Body mass index;
CRC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.55	11.79	0.54	5.49e-27	Bone mineral density;
CRC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg15468180	chr1:107600409	PRMT6	-0.44	-6.42	-0.33	4.72e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg00666640	chr1:248458726	OR2T12	0.37	6.84	0.35	3.88e-11	Common traits (Other);
CRC	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.24	-0.37	3.22e-12	Inflammatory skin disease;
CRC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.42	6.37	0.33	6.5e-10	Mean platelet volume;
CRC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg00601486	chr12:48723148	H1FNT	0.34	6.54	0.34	2.33e-10	Glycated hemoglobin levels;
CRC	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.43	-7.18	-0.37	4.72e-12	Metabolite levels;
CRC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg05929019	chr1:183155154	LAMC2	-0.38	-6.95	-0.36	1.93e-11	Hypertriglyceridemia;
CRC	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg12908607	chr1:44402522	ARTN	-0.34	-5.94	-0.31	7.2e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg14671364	chr1:107599128	PRMT6	-0.57	-7.78	-0.39	9.76e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs6671200	0.920	rs11165339	chr1:95674064	T/C	cg04454259	chr21:37507390	CBR3	-0.63	-6.02	-0.31	4.74e-9	Stearic acid (18:0) levels;
CRC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.65	0.47	1.44e-19	Birth weight;
CRC	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg00531865	chr16:30841666	NA	0.5	7.03	0.36	1.2e-11	Dementia with Lewy bodies;
CRC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.76	12.25	0.56	1.11e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg08717414	chr16:71523259	ZNF19	-0.46	-5.83	-0.31	1.3e-8	Post bronchodilator FEV1;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg23161317	chr6:28129485	ZNF389	0.47	6.08	0.32	3.3e-9	Parkinson's disease;
CRC	cis	rs7072216	0.881	rs11189591	chr10:100155296	T/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-6.16	-0.32	2.14e-9	Metabolite levels;
CRC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.58	8.01	0.4	1.95e-14	Menopause (age at onset);
CRC	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.7	-9.19	-0.45	4.47e-18	IgG glycosylation;
CRC	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.88	17.16	0.69	1.37e-47	Hip circumference;
CRC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg23815491	chr16:72088622	HP	0.48	7.0	0.36	1.42e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.55	7.45	0.38	8.25e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.7	-0.3	2.7e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.51	7.8	0.39	8.42e-14	Corneal astigmatism;
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg21724239	chr8:58056113	NA	0.39	5.6	0.3	4.43e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04593550	chr5:56206289	C5orf35	0.37	6.05	0.32	3.89e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.57	-9.14	-0.45	6.81e-18	Motion sickness;
CRC	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.62	12.44	0.57	2.14e-29	Weight;
CRC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg18478394	chr8:109455254	TTC35	0.38	5.82	0.31	1.38e-8	Dupuytren's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19858671	chr8:130951373	FAM49B	-0.39	-6.18	-0.32	1.93e-9	Aortic root size;
CRC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.55	-0.34	2.16e-10	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
CRC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.67	-8.02	-0.4	1.87e-14	Menarche (age at onset);
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg26566898	chr11:117069891	TAGLN	0.39	7.02	0.36	1.24e-11	Blood protein levels;
CRC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.55	8.06	0.41	1.42e-14	Resting heart rate;
CRC	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.83	-12.65	-0.57	3.64e-30	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.28	0.46	2.4e-18	Blood protein levels;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11587400	0.679	rs12090305	chr1:115109441	G/A	cg12756093	chr1:115239321	AMPD1	0.43	5.9	0.31	9.27e-9	Autism;
CRC	trans	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg26043149	chr18:55253948	FECH	0.53	8.1	0.41	1.11e-14	Bone mineral density;
CRC	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	9.22	0.45	3.56e-18	Type 2 diabetes;
CRC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-6.55	-0.34	2.17e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs360798	0.512	rs9973612	chr2:63019815	G/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.16	-0.32	2.07e-9	Coronary artery disease;
CRC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.26	-5.63	-0.3	3.79e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.66	11.77	0.54	6.24e-27	Height;
CRC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.71	8.22	0.41	4.82e-15	Body mass index;
CRC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.53	0.47	3.56e-19	Colorectal cancer;
CRC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.67	11.13	0.52	1.28e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7312933	0.509	rs1920685	chr12:42428674	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.18	0.32	1.88e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3823572	0.542	rs2346269	chr7:133643066	C/T	cg03336402	chr7:133662267	EXOC4	-0.68	-10.48	-0.5	2.32e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.76	-0.35	6.36e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.99	0.4	2.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Depression;
CRC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.74	-0.43	1.21e-16	Aortic root size;
CRC	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.3	0.33	9.8e-10	Systemic lupus erythematosus;
CRC	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.71	0.3	2.59e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.54	0.57	9.25e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.2	-0.64	6.61e-40	Gut microbiome composition (summer);
CRC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.08	0.32	3.33e-9	Tonsillectomy;
CRC	trans	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg18187862	chr3:45730750	SACM1L	-0.58	-7.46	-0.38	7.69e-13	Primary sclerosing cholangitis;
CRC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02290350	chr8:58132656	NA	-0.41	-5.88	-0.31	1.03e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-9.96	-0.48	1.35e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	7.87	0.4	5.07e-14	Lymphocyte counts;Red cell distribution width;
CRC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg13010199	chr12:38710504	ALG10B	0.45	6.51	0.34	2.88e-10	Morning vs. evening chronotype;
CRC	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.62	-9.38	-0.46	1.12e-18	Obesity;
CRC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.75	11.11	0.52	1.42e-24	Breast cancer;
CRC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg02869306	chr7:64672164	INTS4L1	0.44	6.17	0.32	1.98e-9	Aortic root size;
CRC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.6	-8.71	-0.43	1.53e-16	Menarche (age at onset);
CRC	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.63	8.48	0.42	7.67e-16	Facial morphology (factor 19);
CRC	cis	rs62458065	1.000	rs10231294	chr7:32465357	C/T	cg20159608	chr7:32802032	NA	-0.5	-6.31	-0.33	8.83e-10	Metabolite levels (HVA/MHPG ratio);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09655822	chr6:146136083	FBXO30	-0.4	-6.01	-0.31	5.05e-9	Myopia (pathological);
CRC	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.02	14.75	0.63	3.74e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg04586622	chr2:25135609	ADCY3	-0.55	-10.26	-0.49	1.26e-21	Body mass index;
CRC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.42	-7.25	-0.37	3.04e-12	Blood metabolite levels;
CRC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.99	7.68	0.39	1.79e-13	Psoriasis;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg21251018	chr6:28226885	NKAPL	0.49	7.72	0.39	1.44e-13	Cardiac Troponin-T levels;
CRC	cis	rs6988985	0.728	rs5017238	chr8:143954769	G/A	cg10324643	chr8:143916377	GML	0.35	5.8	0.3	1.53e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-14.69	-0.63	6.48e-38	Prostate cancer;
CRC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.63	10.1	0.49	4.59e-21	Height;
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.04	0.32	4.16e-9	Prudent dietary pattern;
CRC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.75	0.35	6.87e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs4234798	0.588	rs4689640	chr4:7214066	G/A	cg18431297	chr4:7219810	SORCS2	0.51	7.99	0.4	2.27e-14	Insulin-like growth factors;
CRC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg03233332	chr7:66118400	NA	-0.43	-5.84	-0.31	1.28e-8	Aortic root size;
CRC	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.33	-0.33	8.12e-10	Total cholesterol levels;
CRC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg05585544	chr11:47624801	NA	0.49	8.92	0.44	3.21e-17	Subjective well-being;
CRC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg14530993	chr4:882597	GAK	-0.74	-7.58	-0.39	3.56e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.63	9.16	0.45	5.64e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.42	7.44	0.38	8.72e-13	Obesity-related traits;
CRC	cis	rs7894051	0.764	rs11101725	chr10:135194608	A/G	cg20534287	chr10:135191450	PAOX	-0.82	-7.17	-0.37	5.12e-12	Lifespan;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.2	0.62	5.17e-36	Prudent dietary pattern;
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg16558177	chr4:4109446	NA	-0.62	-8.92	-0.44	3.38e-17	Blood pressure (smoking interaction);
CRC	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.44	-6.58	-0.34	1.86e-10	Neutrophil percentage of white cells;
CRC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.51	9.07	0.45	1.11e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3789045	0.560	rs4553256	chr1:204411144	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.81	-10.84	-0.51	1.31e-23	Educational attainment (college completion);
CRC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	7.29	0.37	2.37e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.49	-0.34	3.23e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.78	-13.17	-0.59	4.04e-32	Ear protrusion;
CRC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.69	8.52	0.43	5.85e-16	Body mass index;
CRC	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-7.83	-0.4	6.63e-14	Mood instability;
CRC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	trans	rs6413860	0.688	rs10802434	chr1:246859182	G/T	cg25623271	chr1:240656217	GREM2	0.44	6.21	0.32	1.59e-9	Gut microbiome composition (summer);
CRC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.25	0.33	1.26e-9	Aortic root size;
CRC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.47	7.83	0.4	6.69e-14	Primary biliary cholangitis;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.66	0.34	1.18e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.46	6.33	0.33	8.15e-10	Obesity-related traits;
CRC	cis	rs4240897	0.935	rs2236055	chr1:12042261	A/G	cg13216073	chr1:12042593	MFN2	0.65	10.92	0.52	6.97e-24	Tuberculosis;
CRC	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.83	-0.4	6.72e-14	Caffeine consumption;
CRC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg04553112	chr3:125709451	NA	-0.53	-6.06	-0.32	3.68e-9	Blood pressure (smoking interaction);
CRC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	15.83	0.66	2.26e-42	Platelet count;
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.68	-11.34	-0.53	2.15e-25	Age at first birth;
CRC	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg25797454	chr6:150327115	RAET1K	0.38	6.47	0.34	3.48e-10	Alopecia areata;
CRC	cis	rs6066835	0.867	rs6095271	chr20:47356176	C/G	cg18078177	chr20:47281410	PREX1	0.63	5.93	0.31	7.49e-9	Multiple myeloma;
CRC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg00717180	chr2:96193071	NA	-0.36	-6.0	-0.31	5.3e-9	HDL cholesterol;
CRC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.69	-11.41	-0.53	1.24e-25	Lung cancer;
CRC	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg11130432	chr3:121712080	ILDR1	-0.52	-6.5	-0.34	3.03e-10	Multiple sclerosis;
CRC	trans	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg10756647	chr7:56101905	PSPH	0.69	7.1	0.36	7.8e-12	Diabetic kidney disease;
CRC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.35	-6.08	-0.32	3.31e-9	Erythrocyte sedimentation rate;
CRC	cis	rs2298450	0.550	rs7280997	chr21:37658509	C/T	cg02919814	chr21:37666008	DOPEY2	-0.4	-5.94	-0.31	7.28e-9	Schizophrenia;
CRC	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.52	7.96	0.4	2.72e-14	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-6.16	-0.32	2.16e-9	Diabetic retinopathy;
CRC	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.24	-0.41	4.22e-15	Metabolite levels;
CRC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg19847866	chr10:1019161	NA	0.39	5.74	0.3	2.11e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-10.21	-0.49	1.88e-21	Hepatocellular carcinoma;
CRC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	9.09	0.45	9.67e-18	Cognitive test performance;
CRC	cis	rs11191205	0.686	rs11191067	chr10:103379882	G/T	cg15320455	chr10:103880129	LDB1	0.54	5.98	0.31	5.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.68	10.39	0.5	4.69e-22	Lung cancer;
CRC	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02315113	chr1:173684045	KLHL20	0.54	7.16	0.37	5.34e-12	Thyroid stimulating hormone;
CRC	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.74	7.43	0.38	9.15e-13	Recalcitrant atopic dermatitis;
CRC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.57	0.57	7.49e-30	Height;
CRC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.9	0.48	2.16e-20	Cognitive test performance;
CRC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg22495460	chr2:25135724	ADCY3	-0.85	-16.22	-0.67	7.02e-44	Body mass index;
CRC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.48	6.77	0.35	6.07e-11	Lung cancer;
CRC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg12193833	chr17:30244370	NA	-0.57	-8.01	-0.4	2.07e-14	Hip circumference adjusted for BMI;
CRC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg27661571	chr11:113659931	NA	-0.71	-8.91	-0.44	3.49e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg13072238	chr3:49761600	GMPPB	-0.51	-5.81	-0.3	1.5e-8	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	0.49	7.04	0.36	1.14e-11	Response to antipsychotic treatment;
CRC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.25	5.78	0.3	1.72e-8	Psoriasis;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg27635394	chr6:26043820	HIST1H2BB	-0.44	-6.43	-0.33	4.44e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03193349	chr6:139309610	REPS1	0.51	7.28	0.37	2.41e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg15763984	chr4:1342303	KIAA1530	0.35	6.0	0.31	5.28e-9	Longevity;
CRC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.49	-7.26	-0.37	2.89e-12	Morning vs. evening chronotype;
CRC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg02018176	chr4:1364513	KIAA1530	0.47	7.66	0.39	2.07e-13	Obesity-related traits;
CRC	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg10523679	chr1:76189770	ACADM	0.41	5.79	0.3	1.64e-8	Daytime sleep phenotypes;
CRC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.62e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.5	6.97	0.36	1.74e-11	Urate levels;
CRC	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg16558208	chr1:156270281	VHLL	0.59	9.15	0.45	6.25e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs264943	0.600	rs11677228	chr2:104096243	G/A	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.8e-9	HIV-1 viral setpoint;
CRC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	8.63	0.43	2.75e-16	Lung function (FEV1/FVC);
CRC	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.57	-0.34	1.92e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.29	-0.33	9.91e-10	Aortic root size;
CRC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.6	-0.34	1.65e-10	Body mass index;
CRC	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.55	8.06	0.41	1.42e-14	Resting heart rate;
CRC	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1336149	0.901	rs822430	chr1:156902259	A/G	cg06374307	chr1:156893873	C1orf92	-0.25	-5.64	-0.3	3.72e-8	Chin dimples;
CRC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs3823572	0.542	rs62470443	chr7:133627499	G/A	cg03336402	chr7:133662267	EXOC4	0.67	10.11	0.49	4.31e-21	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.15	23.41	0.79	5.01e-72	IgG glycosylation;
CRC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15369054	chr17:80825471	TBCD	-0.35	-5.9	-0.31	8.9e-9	Breast cancer;
CRC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.54	5.62	0.3	4.1e-8	Fat distribution (HIV);
CRC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.56	7.86	0.4	5.57e-14	Lung cancer;
CRC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.61	10.35	0.5	6.37e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-5.66	-0.3	3.3e-8	Aortic root size;
CRC	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14097577	chr3:25824924	NGLY1	0.41	6.22	0.32	1.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.49	7.68	0.39	1.82e-13	Red blood cell count;
CRC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.56	9.16	0.45	5.74e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.24	5.61	0.3	4.41e-8	Psoriasis;
CRC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.58	9.48	0.46	5.15e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.93	-17.08	-0.69	2.88e-47	Height;
CRC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.44	8.79	0.44	8.17e-17	Renal cell carcinoma;
CRC	trans	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.43e-13	HDL cholesterol;
CRC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg27523141	chr10:43048294	ZNF37B	0.5	7.25	0.37	3.04e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.57	-8.07	-0.41	1.31e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.56	-0.34	2.09e-10	Reticulocyte fraction of red cells;
CRC	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg10820045	chr2:198174542	NA	0.38	6.24	0.33	1.34e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12760731	0.545	rs12032055	chr1:178567934	G/A	cg00404053	chr1:178313656	RASAL2	0.56	6.82	0.35	4.45e-11	Obesity-related traits;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg02033258	chr5:131593261	PDLIM4	0.38	6.44	0.33	4.21e-10	Breast cancer;
CRC	cis	rs12760731	0.623	rs11584977	chr1:178387283	A/G	cg00404053	chr1:178313656	RASAL2	0.74	9.19	0.45	4.56e-18	Obesity-related traits;
CRC	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.02	-0.36	1.26e-11	Breast cancer;
CRC	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.6	9.11	0.45	8.09e-18	Corneal astigmatism;
CRC	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03672933	chr12:100661444	SCYL2;DEPDC4	0.39	6.37	0.33	6.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.22e-37	Hypertriglyceridemia;
CRC	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.84	-14.29	-0.62	2.28e-36	Gut microbiome composition (winter);
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.42	8.49	0.42	7.06e-16	Bipolar disorder;
CRC	cis	rs62045849	0.557	rs12927059	chr16:89199205	G/A	cg08015503	chr16:89190385	ACSF3	0.99	6.02	0.32	4.58e-9	Red blood cell count;
CRC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.24	-0.37	3.23e-12	Myopia (pathological);
CRC	cis	rs11212617	0.935	rs664143	chr11:108225661	C/T	cg14761454	chr11:108092087	ATM;NPAT	-0.39	-5.69	-0.3	2.82e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg00246817	chr9:123691163	NA	-0.47	-6.0	-0.31	5.19e-9	Rheumatoid arthritis;
CRC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	11.11	0.52	1.48e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.85	0.35	3.65e-11	Aortic root size;
CRC	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.47	5.9	0.31	9.21e-9	Recombination rate (females);
CRC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg23136738	chr11:925521	AP2A2	-0.48	-7.63	-0.39	2.49e-13	Alzheimer's disease (late onset);
CRC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg26248373	chr2:1572462	NA	-0.8	-11.01	-0.52	3.36e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.03	12.95	0.58	2.89e-31	Vitiligo;
CRC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.03	0.32	4.45e-9	Diabetic retinopathy;
CRC	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg12573674	chr2:1569213	NA	-0.67	-7.74	-0.39	1.27e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23378565	chr7:2036160	MAD1L1	-0.47	-6.62	-0.34	1.45e-10	Bipolar disorder;
CRC	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.93	12.29	0.56	8.22e-29	Uric acid levels;
CRC	cis	rs11250464	0.517	rs2387668	chr10:1432003	C/T	cg02408697	chr10:1416920	ADARB2	0.39	5.61	0.3	4.21e-8	Radiation response;
CRC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg18099408	chr3:52552593	STAB1	0.35	6.04	0.32	4.2e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.51	-7.09	-0.36	8.3e-12	Schizophrenia;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12172441	chr6:28176163	NA	0.55	7.14	0.37	5.94e-12	Parkinson's disease;
CRC	cis	rs3785888	0.553	rs10853086	chr17:45006109	A/G	cg16759221	chr17:45003025	GOSR2	0.6	9.01	0.44	1.71e-17	Cleft lip with or without cleft palate;
CRC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg04362960	chr10:104952993	NT5C2	-0.4	-5.6	-0.3	4.46e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg23161317	chr6:28129485	ZNF389	0.47	6.64	0.34	1.28e-10	Parkinson's disease;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg08798685	chr6:27730294	NA	-0.43	-6.33	-0.33	8.06e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.75	-0.3	2.07e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	8.9	0.44	3.95e-17	Cognitive test performance;
CRC	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg11271282	chr2:238384023	NA	0.45	5.63	0.3	3.85e-8	Prostate cancer;
CRC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg05639522	chr1:247681581	NA	0.49	7.09	0.36	8.43e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.44	-6.54	-0.34	2.31e-10	Cerebrospinal P-tau181p levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg03558408	chr5:134181967	C5orf24	0.37	6.29	0.33	1.02e-9	Interleukin-6 levels;
CRC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	1.13	10.63	0.51	6.83e-23	Arsenic metabolism;
CRC	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg00086871	chr4:6988644	TBC1D14	0.83	6.46	0.34	3.68e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg20542592	chr8:11973495	FAM66D	0.35	5.72	0.3	2.34e-8	Triglycerides;
CRC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14828511	chr1:107599125	PRMT6	-0.57	-7.83	-0.4	6.95e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2493151	1.000	rs2493151	chr1:230878561	G/A	cg07502417	chr1:230849801	AGT	0.29	5.9	0.31	8.83e-9	Blood protein levels;
CRC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.37	6.19	0.32	1.75e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.45	6.62	0.34	1.42e-10	Mean platelet volume;
CRC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.67	-10.24	-0.49	1.56e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg15654264	chr1:150340011	RPRD2	0.43	6.46	0.34	3.87e-10	Migraine;
CRC	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.34	6.39	0.33	5.68e-10	Ulcerative colitis;
CRC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.56	-8.25	-0.41	3.8e-15	Type 1 diabetes;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	7.25	0.37	3.07e-12	Breast cancer;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg15845792	chr6:28175446	NA	0.74	10.98	0.52	4.05e-24	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.76	0.51	2.49e-23	Motion sickness;
CRC	cis	rs6585424	1.000	rs34162901	chr10:81946856	A/C	cg11900509	chr10:81946545	ANXA11	-0.76	-9.15	-0.45	6.21e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	6.25	0.33	1.24e-9	Asthma;
CRC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.73	-0.66	5.59e-42	Intelligence (multi-trait analysis);
CRC	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	trans	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.35	-6.58	-0.34	1.86e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs2070997	1.000	rs6597645	chr9:133745487	A/G	cg01000188	chr9:133769184	QRFP	0.55	7.08	0.36	8.55e-12	Response to amphetamines;
CRC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg10790698	chr19:18539756	SSBP4	-0.46	-8.76	-0.43	1.06e-16	Breast cancer;
CRC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg15192750	chr16:69999425	NA	0.61	8.09	0.41	1.15e-14	IgE levels;
CRC	cis	rs6499129	1.000	rs7185709	chr16:67529349	T/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.49	6.08	0.32	3.24e-9	Bipolar disorder;
CRC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg20354231	chr13:53171401	NA	-0.42	-6.69	-0.35	9.65e-11	Lewy body disease;
CRC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.05	0.41	1.52e-14	Height;
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.63	8.25	0.41	3.83e-15	Alzheimer's disease;
CRC	cis	rs7692995	1.000	rs16896236	chr4:18003812	T/C	cg08925142	chr4:18023851	LCORL	-0.54	-6.03	-0.32	4.31e-9	Height;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs73200209	0.744	rs2392967	chr12:116531742	T/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.27	-0.37	2.72e-12	Total body bone mineral density;
CRC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.9	10.71	0.51	3.79e-23	Body mass index;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01668174	chr2:106810661	UXS1	-0.57	-6.9	-0.36	2.62e-11	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24487784	chr11:696252	TMEM80;DEAF1	0.54	7.53	0.38	4.94e-13	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg13047869	chr3:10149882	C3orf24	0.38	5.97	0.31	6.27e-9	Alzheimer's disease;
CRC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-12.51	-0.57	1.25e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.44	6.34	0.33	7.37e-10	Menarche (age at onset);
CRC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg24920358	chr1:40204285	PPIE	0.56	8.37	0.42	1.62e-15	Blood protein levels;
CRC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.56	9.99	0.48	1.03e-20	HDL cholesterol levels;
CRC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.35	-0.38	1.62e-12	QT interval;
CRC	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.56	0.54	3.48e-26	Coffee consumption (cups per day);
CRC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.48	-10.64	-0.51	6.2e-23	Rheumatoid arthritis;
CRC	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.37	-0.38	1.43e-12	Capecitabine sensitivity;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.74	7.87	0.4	5.03e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.94	-0.36	2.03e-11	Mean corpuscular volume;
CRC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg15465823	chr12:48382534	COL2A1	0.37	6.16	0.32	2.12e-9	Glycated hemoglobin levels;
CRC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	0.99	9.38	0.46	1.1e-18	Diabetic retinopathy;
CRC	trans	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.08	-0.32	3.25e-9	Tuberculosis;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.37	-6.08	-0.32	3.27e-9	Total body bone mineral density;
CRC	cis	rs4666002	0.956	rs34502053	chr2:27854524	G/A	cg27432699	chr2:27873401	GPN1	0.44	5.66	0.3	3.38e-8	Phospholipid levels (plasma);
CRC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.78	-10.6	-0.5	8.77e-23	Initial pursuit acceleration;
CRC	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	cis	rs1572438	0.868	rs9378518	chr6:861084	A/G	cg13447295	chr6:887704	NA	-0.45	-6.68	-0.35	1.01e-10	Aging;
CRC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-12.2	-0.56	1.64e-28	Height;
CRC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.76	10.06	0.49	6.06e-21	Systolic blood pressure;
CRC	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.49	0.38	6.35e-13	Lung cancer in ever smokers;
CRC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.75	-11.75	-0.54	7.28e-27	Metabolic syndrome;
CRC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.39	5.88	0.31	1.03e-8	Mean corpuscular volume;
CRC	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg05585544	chr11:47624801	NA	0.41	6.23	0.33	1.4e-9	Mean corpuscular hemoglobin;
CRC	cis	rs3218092	0.872	rs16895128	chr6:41924369	G/A	cg17623882	chr6:41773611	USP49	0.49	5.95	0.31	6.95e-9	Red cell distribution width;
CRC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.43	-7.02	-0.36	1.27e-11	Height;
CRC	cis	rs7527798	0.614	rs11118253	chr1:207825469	G/C	cg09232269	chr1:207846808	CR1L	-0.45	-7.31	-0.37	2.02e-12	Erythrocyte sedimentation rate;
CRC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.23	16.47	0.67	7.5e-45	Breast cancer;
CRC	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.44	-8.36	-0.42	1.75e-15	Alcohol dependence;
CRC	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.53	11.8	0.55	4.99e-27	Cutaneous nevi;
CRC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.96e-9	Gut microbiome composition (summer);
CRC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.78	8.25	0.41	3.88e-15	Diabetic retinopathy;
CRC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.38	-6.97	-0.36	1.78e-11	Reticulocyte fraction of red cells;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg06470822	chr6:28175283	NA	0.93	13.59	0.6	1.05e-33	Parkinson's disease;
CRC	trans	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.02	-0.31	4.74e-9	Educational attainment (years of education);
CRC	cis	rs4509693	0.765	rs10786604	chr10:102495302	C/G	cg23167259	chr10:102495509	NA	-0.47	-5.87	-0.31	1.06e-8	Alzheimer's disease;
CRC	cis	rs9322817	0.691	rs2486136	chr6:105285759	C/T	cg02098413	chr6:105308735	HACE1	0.44	8.72	0.43	1.41e-16	Thyroid stimulating hormone;
CRC	cis	rs6076065	0.723	rs2144381	chr20:23369940	C/T	cg11657817	chr20:23433608	CST11	0.44	6.63	0.34	1.37e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.67	7.69	0.39	1.77e-13	Cleft lip with or without cleft palate;
CRC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg25985355	chr7:65971099	NA	-0.32	-5.62	-0.3	4.12e-8	Aortic root size;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02772935	chr3:125709198	NA	-0.5	-5.71	-0.3	2.53e-8	Blood pressure (smoking interaction);
CRC	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.42	6.09	0.32	3.23e-9	Diastolic blood pressure;
CRC	cis	rs13315871	1.000	rs35792042	chr3:58409668	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.2	-0.37	4.22e-12	Cholesterol, total;
CRC	cis	rs10046574	0.831	rs7810503	chr7:135142285	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.72	0.3	2.41e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.41	5.71	0.3	2.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.54	7.95	0.4	2.99e-14	Schizophrenia;
CRC	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.67	7.28	0.37	2.51e-12	Gut microbiota (bacterial taxa);
CRC	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.74	9.84	0.48	3.41e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs13144136	0.687	rs12499294	chr4:10654086	T/C	cg10242279	chr4:10666415	CLNK	-0.37	-6.29	-0.33	1.02e-9	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	6.18	0.32	1.95e-9	Lung cancer;
CRC	cis	rs853679	1.000	rs853676	chr6:28299687	C/T	cg03623178	chr6:28175578	NA	0.69	7.04	0.36	1.11e-11	Depression;
CRC	cis	rs72627123	1.000	rs17093141	chr14:74326903	G/T	cg19860245	chr14:74300557	NA	-0.51	-5.61	-0.3	4.36e-8	Morning vs. evening chronotype;
CRC	cis	rs11212617	1.000	rs2884030	chr11:108281903	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.63	0.34	1.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg03013999	chr17:37608204	MED1	-0.48	-7.47	-0.38	7.5e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03923535	chr7:1197113	ZFAND2A	0.53	7.6	0.39	3.03e-13	Longevity;Endometriosis;
CRC	cis	rs2569991	0.588	rs14191	chr3:12940346	G/A	cg22481960	chr3:13008800	IQSEC1	-0.5	-6.25	-0.33	1.26e-9	Periodontitis (DPAL);
CRC	cis	rs747650	0.504	rs7114683	chr11:47077246	T/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.86	-0.31	1.11e-8	Acne (severe);
CRC	trans	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.95	-0.36	1.97e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.54	-9.85	-0.48	3.21e-20	Lung cancer;
CRC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.87	10.25	0.49	1.43e-21	Psoriasis;
CRC	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.75	8.98	0.44	2.09e-17	Eosinophilic esophagitis;
CRC	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg10756647	chr7:56101905	PSPH	0.76	7.92	0.4	3.72e-14	Diabetic kidney disease;
CRC	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.66	-0.54	1.59e-26	Idiopathic membranous nephropathy;
CRC	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.67	10.41	0.5	4.15e-22	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.14	0.32	2.34e-9	Monocyte percentage of white cells;
CRC	cis	rs143985986	1	rs143985986	chr3:58399886	TC/T	cg06643156	chr3:58380774	PXK	0.41	5.92	0.31	7.96e-9	Hematocrit;
CRC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.82	-0.44	6.89e-17	Alcohol dependence;
CRC	cis	rs4237845	0.611	rs4583019	chr12:58316745	T/C	cg02175503	chr12:58329896	NA	0.81	13.25	0.59	2.02e-32	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25020728	chr12:123011538	RSRC2;KNTC1	0.48	6.05	0.32	3.88e-9	Thyroid stimulating hormone;
CRC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg23378565	chr7:2036160	MAD1L1	-0.44	-6.49	-0.34	3.12e-10	Neuroticism;
CRC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.15	0.45	6.28e-18	Alzheimer's disease (late onset);
CRC	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg00738113	chr16:70207722	CLEC18C	-0.38	-5.62	-0.3	4.13e-8	IgE levels;
CRC	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.56	-7.47	-0.38	7.34e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg24562669	chr7:97807699	LMTK2	0.79	17.7	0.7	1.05e-49	Breast cancer;
CRC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.83	0.4	6.98e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg18165381	chr3:44552316	NA	-0.38	-5.69	-0.3	2.8e-8	Depressive symptoms;
CRC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg23533926	chr12:111358616	MYL2	-0.44	-6.45	-0.34	3.98e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-7.17	-0.37	4.88e-12	Pancreatic cancer;
CRC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.42	-7.26	-0.37	2.79e-12	Height;
CRC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.48	-0.34	3.4e-10	Total body bone mineral density;
CRC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-7.11	-0.36	7.31e-12	Obesity (extreme);
CRC	cis	rs3018066	0.867	rs7693448	chr4:107156635	T/C	cg01869342	chr4:106983673	TBCK	-0.36	-5.65	-0.3	3.45e-8	Cancer;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.55	9.85	0.48	3.11e-20	Lung cancer;
CRC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg09659197	chr4:152720779	NA	0.54	11.69	0.54	1.24e-26	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12273811	chr6:28175739	NA	0.72	9.03	0.45	1.47e-17	Depression;
CRC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21972741	chr5:435613	AHRR	0.54	7.37	0.38	1.39e-12	Cystic fibrosis severity;
CRC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.89	-15.09	-0.64	1.77e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.8	-0.55	4.81e-27	Colorectal cancer;
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.55	6.15	0.32	2.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs4077468	0.700	rs4951030	chr1:205913747	T/A	cg13172432	chr1:205912842	SLC26A9	-0.34	-6.04	-0.32	4.25e-9	Cystic fibrosis-related diabetes;
CRC	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.54	8.59	0.43	3.49e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.87	0.31	1.05e-8	Rheumatoid arthritis;
CRC	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.6	-8.31	-0.42	2.48e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.72	0.43	1.39e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.43	0.42	1.07e-15	Height;
CRC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg17321639	chr7:2759063	NA	-0.55	-7.55	-0.38	4.29e-13	Height;
CRC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg10877050	chr13:100741041	PCCA	-0.44	-6.46	-0.34	3.79e-10	Daytime sleep phenotypes;
CRC	cis	rs12024301	0.557	rs10911413	chr1:183662791	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg07395648	chr5:131743802	NA	0.4	5.74	0.3	2.19e-8	Breast cancer;
CRC	trans	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-6.16	-0.32	2.1e-9	Breast cancer;
CRC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg19635926	chr16:89946313	TCF25	0.67	6.88	0.35	3.12e-11	Skin colour saturation;
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.4	-5.84	-0.31	1.28e-8	IFN-related cytopenia;
CRC	cis	rs6840360	0.693	rs28622593	chr4:152374080	A/G	cg09659197	chr4:152720779	NA	0.33	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.84e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.82	12.64	0.57	4.02e-30	Menarche (age at onset);
CRC	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg15382696	chr6:118971807	C6orf204	0.59	7.43	0.38	9.32e-13	Diastolic blood pressure;
CRC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.62	7.69	0.39	1.67e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.8	-0.4	8.25e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs10878977	0.542	rs11177653	chr12:69802927	C/T	cg20891283	chr12:69753455	YEATS4	-0.57	-5.81	-0.3	1.5e-8	Colorectal cancer;
CRC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.37	6.19	0.32	1.8e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs3736485	0.816	rs8038341	chr15:51870748	G/C	cg08986416	chr15:51914746	DMXL2	-0.48	-6.96	-0.36	1.88e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4731207	0.570	rs10954055	chr7:124589232	C/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.76	12.45	0.57	2e-29	Gut microbiome composition (winter);
CRC	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21659725	chr3:3221576	CRBN	-0.69	-7.14	-0.37	6.11e-12	Menarche (age at onset);
CRC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.67	-8.27	-0.41	3.3e-15	Initial pursuit acceleration;
CRC	cis	rs12913538	0.513	rs12441930	chr15:62889367	C/G	cg09983546	chr15:62884068	NA	0.42	5.89	0.31	9.62e-9	Sleep depth;
CRC	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.63	5.71	0.3	2.48e-8	Schizophrenia;
CRC	cis	rs17189216	1.000	rs17189216	chr8:120448932	C/T	cg27215916	chr8:120218354	NA	0.67	5.82	0.31	1.37e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.46	0.65	6.33e-41	Fuchs's corneal dystrophy;
CRC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-7.91	-0.4	4.04e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.68	11.6	0.54	2.51e-26	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs427941	0.703	rs201450	chr7:101739441	A/T	cg06246474	chr7:101738831	CUX1	-0.46	-7.3	-0.37	2.18e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.71e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.83	7.49	0.38	6.51e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.68	7.3	0.37	2.2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2160860	0.773	rs6474194	chr8:39800944	C/A	cg11363097	chr8:39792086	IDO2	-0.45	-7.63	-0.39	2.55e-13	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21989094	chr19:39421295	MRPS12;SARS2	0.56	7.54	0.38	4.55e-13	Thyroid stimulating hormone;
CRC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-10.53	-0.5	1.57e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.2	-0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.62	11.22	0.53	5.75e-25	Schizophrenia;
CRC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg13798780	chr7:105162888	PUS7	0.68	8.02	0.4	1.87e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg10130564	chr11:117069849	TAGLN	0.35	5.86	0.31	1.11e-8	Blood protein levels;
CRC	cis	rs6893807	0.778	rs13174131	chr5:87959538	T/G	cg09002922	chr5:87956389	LOC645323	-0.44	-5.65	-0.3	3.53e-8	Body mass index;
CRC	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg10820045	chr2:198174542	NA	0.38	6.38	0.33	6.03e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.35	-6.01	-0.31	5.03e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.53	-7.17	-0.37	4.9e-12	Triglycerides;
CRC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg10305451	chr2:177043427	NA	0.71	11.34	0.53	2.24e-25	IgG glycosylation;
CRC	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	6.5	0.34	3e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg12311346	chr5:56204834	C5orf35	-0.49	-7.72	-0.39	1.45e-13	Coronary artery disease;
CRC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.46	7.41	0.38	1.07e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.62	-10.38	-0.5	5.13e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg15962314	chr1:44399869	ARTN	0.32	6.26	0.33	1.2e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	7.73	0.39	1.3e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6681460	0.899	rs499263	chr1:67179937	T/C	cg02459107	chr1:67143332	SGIP1	0.36	6.06	0.32	3.76e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg08314208	chr16:67682810	RLTPR	-0.55	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs3736485	0.934	rs8036904	chr15:51861438	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.56	9.43	0.46	7.65e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs6545883	0.542	rs2593628	chr2:61573287	T/A	cg10580144	chr2:61372316	C2orf74	-0.35	-7.81	-0.4	7.8500000000000006e-14	Tuberculosis;
CRC	cis	rs11229555	0.645	rs12290089	chr11:58176849	A/G	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.49	7.67	0.39	1.92e-13	Red blood cell count;
CRC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg21238619	chr17:78079768	GAA	0.43	6.99	0.36	1.58e-11	Yeast infection;
CRC	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.62e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.39	5.93	0.31	7.87e-9	Hemoglobin concentration;
CRC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.85	0.44	5.65e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06295308	chr2:232575555	PTMA	0.43	6.04	0.32	4.26e-9	Response to antipsychotic treatment;
CRC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg03030879	chr14:75389066	RPS6KL1	0.44	6.88	0.35	3.04e-11	Height;
CRC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.68	0.39	1.88e-13	Red blood cell count;
CRC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg19635926	chr16:89946313	TCF25	0.65	6.09	0.32	3.17e-9	Skin colour saturation;
CRC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.73	11.32	0.53	2.66e-25	Tonsillectomy;
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.25e-36	Prudent dietary pattern;
CRC	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg27382691	chr15:76552771	ETFA;TYRO3P	0.42	6.09	0.32	3.2e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.61	-9.62	-0.47	1.84e-19	Motion sickness;
CRC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.59	-7.45	-0.38	8.39e-13	Obesity (extreme);
CRC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg12564285	chr5:131593104	PDLIM4	-0.33	-5.88	-0.31	9.97e-9	Blood metabolite levels;
CRC	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg02158880	chr13:53174818	NA	0.45	6.74	0.35	6.93e-11	Lewy body disease;
CRC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg23018236	chr17:30244563	NA	-0.66	-7.83	-0.4	6.59e-14	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg00343986	chr7:65444356	GUSB	-0.5	-7.43	-0.38	9.64e-13	Aortic root size;
CRC	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.66	-7.61	-0.39	2.93e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9990333	1.000	rs9990333	chr3:195827205	C/T	cg12923728	chr3:195709715	SDHAP1	0.51	7.41	0.38	1.1e-12	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
CRC	trans	rs264943	0.600	rs1836054	chr2:104095980	T/C	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.8e-9	HIV-1 viral setpoint;
CRC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.41	7.68	0.39	1.79e-13	Ulcerative colitis;
CRC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg01420254	chr6:26195488	NA	0.75	8.46	0.42	9.1e-16	Gout;Renal underexcretion gout;
CRC	cis	rs4789693	0.938	rs8078595	chr17:80426988	G/T	cg04308225	chr17:80449738	NA	0.52	6.96	0.36	1.87e-11	Glucocorticoid-induced osteonecrosis;
CRC	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-9.21	-0.45	3.84e-18	Blood protein levels;
CRC	cis	rs2280381	0.510	rs1474176	chr16:86008814	A/G	cg08215318	chr16:86016387	NA	0.42	6.62	0.34	1.44e-10	Rheumatoid arthritis;
CRC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.98	-0.31	5.81e-9	Migraine;Coronary artery disease;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg16239906	chr20:35724590	RBL1	0.45	6.96	0.36	1.83e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.63	-0.47	1.67e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.75	-13.27	-0.59	1.71e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.56	-8.74	-0.43	1.2e-16	Vitiligo;
CRC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg18827107	chr12:86230957	RASSF9	0.44	6.96	0.36	1.88e-11	Major depressive disorder;
CRC	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg09796270	chr17:17721594	SREBF1	0.41	6.88	0.35	3.12e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg16576597	chr16:28551801	NUPR1	0.49	7.07	0.36	9.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.53	-8.41	-0.42	1.28e-15	Monocyte count;
CRC	cis	rs9303280	0.806	rs9303279	chr17:38073968	G/C	cg17467752	chr17:38218738	THRA	0.41	5.9	0.31	9e-9	Self-reported allergy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26858605	chr17:45771108	NA	0.52	7.52	0.38	5.14e-13	Response to antipsychotic treatment;
CRC	trans	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.19	0.37	4.3e-12	Menarche (age at onset);
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.48	8.1	0.41	1.09e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg08761264	chr16:28874980	SH2B1	-0.43	-5.72	-0.3	2.4e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.35	-0.38	1.57e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.43	-0.33	4.41e-10	Longevity;Endometriosis;
CRC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.46	7.33	0.37	1.81e-12	Eye color traits;
CRC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.82	-0.35	4.48e-11	QT interval;
CRC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.72	0.39	1.42e-13	Axial length;
CRC	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.07	-15.45	-0.65	6.9e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4908760	0.965	rs10864356	chr1:8569871	A/T	cg20416874	chr1:8611966	RERE	-0.45	-6.45	-0.33	4.03e-10	Vitiligo;
CRC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.31e-12	Motion sickness;
CRC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.69	10.33	0.5	7.26e-22	Corneal astigmatism;
CRC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.64	6.95	0.36	1.95e-11	Prostate cancer;
CRC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.5	6.39	0.33	5.83e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg18131467	chr2:239335373	ASB1	-0.65	-5.67	-0.3	3.2e-8	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.64	0.39	2.39e-13	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00166722	chr3:10149974	C3orf24	0.42	6.26	0.33	1.22e-9	Alzheimer's disease;
CRC	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg11861562	chr11:117069780	TAGLN	0.33	6.23	0.32	1.45e-9	Blood protein levels;
CRC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.52	6.89	0.36	2.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.84	-0.48	3.48e-20	Total cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23396974	chr7:45151349	TBRG4	0.36	6.13	0.32	2.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2267708	0.506	rs1842616	chr7:124582172	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.25e-9	Chronic lymphocytic leukemia;
CRC	cis	rs7804356	0.906	rs73069540	chr7:26904770	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-5.93	-0.31	7.6e-9	Type 1 diabetes;
CRC	trans	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg10756647	chr7:56101905	PSPH	0.78	8.03	0.4	1.75e-14	Diabetic kidney disease;
CRC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg02725872	chr8:58115012	NA	-0.43	-6.37	-0.33	6.2e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.86	0.35	3.5e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.98	-0.4	2.39e-14	Homoarginine levels;
CRC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg03609598	chr5:56110824	MAP3K1	-0.62	-6.01	-0.31	4.85e-9	Type 2 diabetes;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.37	-6.37	-0.33	6.47e-10	Longevity;Endometriosis;
CRC	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.48	-6.84	-0.35	3.95e-11	Coronary artery disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15198335	chr15:66586003	DIS3L	0.38	6.0	0.31	5.25e-9	Interleukin-6 levels;
CRC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.73	-0.3	2.23e-8	Blood protein levels;
CRC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.55	7.98	0.4	2.47e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.91	17.38	0.69	1.84e-48	Blood protein levels;
CRC	cis	rs7619833	0.512	rs7653795	chr3:27217080	G/A	cg02860705	chr3:27208620	NA	0.39	5.99	0.31	5.54e-9	Breast cancer;
CRC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs728616	0.717	rs12414332	chr10:81840955	C/T	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.55	-0.34	2.18e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.43	-6.57	-0.34	2e-10	Endometrial cancer;
CRC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.68	-8.4	-0.42	1.35e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.23e-9	Obesity-related traits;
CRC	cis	rs7635838	0.892	rs9836167	chr3:11493392	C/T	cg00170343	chr3:11313890	ATG7	0.43	6.61	0.34	1.55e-10	HDL cholesterol;
CRC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.46	-0.38	7.81e-13	Alzheimer's disease;
CRC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.85	10.74	0.51	3e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13198984	chr17:80129470	CCDC57	-0.49	-8.7	-0.43	1.67e-16	Life satisfaction;
CRC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.62	-8.67	-0.43	1.94e-16	DNA methylation (variation);
CRC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12463550	chr7:65579703	CRCP	0.68	6.55	0.34	2.22e-10	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18865796	chr19:11457210	TMEM205;CCDC159	0.44	7.05	0.36	1.03e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.38	-5.65	-0.3	3.55e-8	Systolic blood pressure;
CRC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.43	6.12	0.32	2.6e-9	HIV-1 control;
CRC	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.72	-9.2	-0.45	4.26e-18	Blood pressure (smoking interaction);
CRC	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.14	0.37	6.12e-12	Diisocyanate-induced asthma;
CRC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg19812747	chr11:111475976	SIK2	0.47	7.82	0.4	7.26e-14	Primary sclerosing cholangitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00455883	chr3:73046007	PPP4R2	-0.45	-6.65	-0.34	1.19e-10	Myopia (pathological);
CRC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.9	-0.52	8e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.82	0.31	1.4e-8	IgG glycosylation;
CRC	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.58	0.39	3.56e-13	Eye color traits;
CRC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg12064134	chr16:90016061	DEF8	0.62	9.68	0.47	1.16e-19	Squamous cell carcinoma;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.38	6.68	0.35	9.92e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg02741985	chr17:80059408	CCDC57	-0.45	-7.43	-0.38	9.56e-13	Life satisfaction;
CRC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.37	8.5	0.42	6.58e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg05376469	chr2:102649931	NA	0.37	6.03	0.32	4.36e-9	Coronary artery disease;
CRC	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg02569458	chr12:86230093	RASSF9	0.36	6.15	0.32	2.21e-9	Major depressive disorder;
CRC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.61	8.77	0.44	9.8e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.8e-27	Asthma (sex interaction);
CRC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.44	6.62	0.34	1.49e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg13319975	chr6:146136371	FBXO30	0.38	5.65	0.3	3.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg23758597	chr6:163146217	PARK2	-0.51	-5.9	-0.31	8.81e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg23880581	chr15:78912387	CHRNA3	0.33	5.63	0.3	3.92e-8	Sudden cardiac arrest;
CRC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs12467279	chr2:162544744	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.16	-0.32	2.13e-9	Cognitive function;
CRC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.94	-16.46	-0.67	8.07e-45	Total cholesterol levels;
CRC	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg05519781	chr21:40033154	ERG	-0.42	-5.73	-0.3	2.21e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg02741985	chr17:80059408	CCDC57	-0.47	-7.61	-0.39	2.86e-13	Life satisfaction;
CRC	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.9	-0.4	4.22e-14	Schizophrenia;
CRC	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.45	7.01	0.36	1.37e-11	C-reactive protein levels;
CRC	trans	rs1899951	1.000	rs1899951	chr3:12394840	A/G	cg04083076	chr1:169452126	SLC19A2	0.47	6.08	0.32	3.42e-9	Body mass index;
CRC	cis	rs4664293	0.967	rs12999124	chr2:160531328	A/G	cg08347373	chr2:160653686	CD302	-0.44	-7.1	-0.36	7.75e-12	Monocyte percentage of white cells;
CRC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07513332	chr6:167530253	CCR6	-0.37	-6.1	-0.32	2.94e-9	Primary biliary cholangitis;
CRC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.3	0.33	9.48e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.52	7.75	0.39	1.16e-13	Lymphocyte counts;
CRC	cis	rs9786986	0.764	rs10925930	chr1:235696940	A/G	cg08848088	chr1:235714526	GNG4	0.5	5.84	0.31	1.24e-8	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00530939	chr1:51425360	FAF1	0.41	6.44	0.33	4.34e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg23123621	chr4:1343375	KIAA1530	0.38	6.43	0.33	4.55e-10	Longevity;
CRC	cis	rs2415984	0.600	rs72672853	chr14:46932920	T/G	cg14871534	chr14:47121158	RPL10L	-0.42	-5.97	-0.31	6.01e-9	Number of children ever born;
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.82	17.75	0.7	6.42e-50	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.12	-0.37	6.69e-12	Inflammatory skin disease;
CRC	trans	rs12210905	1.000	rs9368494	chr6:27237301	C/T	cg05005425	chr1:167687389	NA	0.62	6.33	0.33	8.22e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.24	0.37	3.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7932354	0.528	rs7937950	chr11:47098445	A/C	cg19486271	chr11:47235900	DDB2	-0.45	-6.57	-0.34	2.02e-10	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs4378999	0.528	rs4485709	chr3:50776497	G/T	cg12383621	chr7:7735611	RPA3	-0.48	-6.05	-0.32	3.92e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.34	-6.95	-0.36	1.98e-11	Alzheimer's disease (late onset);
CRC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.01	0.31	4.91e-9	Heart rate;
CRC	cis	rs7945705	0.902	rs11042088	chr11:8843515	T/A	cg14711859	chr11:8959438	ASCL3	-0.45	-7.01	-0.36	1.38e-11	Hemoglobin concentration;
CRC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg21856205	chr7:94953877	PON1	-0.45	-5.81	-0.31	1.47e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.07	23.95	0.8	4.29e-74	Multiple myeloma;
CRC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg23758597	chr6:163146217	PARK2	-0.59	-5.91	-0.31	8.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg00745463	chr17:30367425	LRRC37B	-0.68	-8.26	-0.41	3.61e-15	Hip circumference adjusted for BMI;
CRC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.53	-7.25	-0.37	2.99e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.51	7.62	0.39	2.66e-13	Eosinophil percentage of white cells;
CRC	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.5	7.57	0.39	3.7e-13	Testicular germ cell tumor;
CRC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.68	10.17	0.49	2.69e-21	Corneal astigmatism;
CRC	cis	rs9287719	0.614	rs10929681	chr2:10723283	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg23387468	chr7:139079360	LUC7L2	0.4	7.04	0.36	1.16e-11	Diisocyanate-induced asthma;
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.99	13.53	0.6	1.81e-33	Orofacial clefts;
CRC	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg21095983	chr6:86352623	SYNCRIP	0.52	7.59	0.39	3.26e-13	Smooth-surface caries;
CRC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	8.47	0.42	8.18e-16	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03216991	chr17:2415620	METT10D	0.37	6.05	0.32	3.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg00280220	chr17:61926910	NA	-0.33	-5.67	-0.3	3.16e-8	Prudent dietary pattern;
CRC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.8	10.54	0.5	1.38e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.26	-0.41	3.66e-15	Alzheimer's disease (late onset);
CRC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs3736485	0.873	rs12101920	chr15:51820909	T/C	cg08986416	chr15:51914746	DMXL2	-0.48	-6.94	-0.36	2.14e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.38	-0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.73	-14.1	-0.61	1.17e-35	Breast cancer;
CRC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.71	11.25	0.53	4.59e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.43	-5.77	-0.3	1.8e-8	Height;
CRC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.24	-5.85	-0.31	1.21e-8	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-10.66	-0.51	5.56e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25756398	chr11:93474621	C11orf54;TAF1D	0.4	6.24	0.33	1.38e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.41	-0.38	1.11e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	8.18	0.41	6.32e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg15763984	chr4:1342303	KIAA1530	0.45	6.83	0.35	4.02e-11	Obesity-related traits;
CRC	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.67	-10.29	-0.49	1.02e-21	Psoriasis;
CRC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.39	-5.64	-0.3	3.74e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg22732515	chr19:44031385	ETHE1	0.61	9.1	0.45	9.18e-18	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02825527	chr7:2087843	MAD1L1	-0.51	-6.04	-0.32	4.14e-9	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06341202	chr17:78010343	CCDC40;TBC1D16	0.48	6.54	0.34	2.34e-10	Anxiety disorder;
CRC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.49	7.82	0.4	7.35e-14	Resting heart rate;
CRC	cis	rs9311676	0.632	rs6774577	chr3:58361716	A/G	cg06643156	chr3:58380774	PXK	0.43	6.64	0.34	1.3100000000000001e-10	Systemic lupus erythematosus;
CRC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05654483	chr10:122610929	WDR11	0.43	6.78	0.35	5.55e-11	Obesity-related traits;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg27094323	chr7:1216898	NA	-0.37	-5.91	-0.31	8.47e-9	Longevity;Endometriosis;
CRC	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg14631576	chr9:95140430	CENPP	-0.33	-6.05	-0.32	3.94e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.68	0.51	4.61e-23	Motion sickness;
CRC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22133161	chr19:49891603	CCDC155	0.5	6.52	0.34	2.69e-10	Multiple sclerosis;
CRC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.84	0.4	6.26e-14	Menopause (age at onset);
CRC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-7.76	-0.39	1.06e-13	IgG glycosylation;
CRC	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.63	-9.65	-0.47	1.42e-19	Tuberculosis;
CRC	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.83	16.28	0.67	3.95e-44	Hip circumference;
CRC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.45	0.42	9.3e-16	Height;
CRC	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.44	-6.18	-0.32	1.87e-9	Eye color traits;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02290350	chr8:58132656	NA	-0.61	-7.12	-0.37	6.7e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4589502	0.841	rs75991095	chr15:67123224	C/G	cg12317470	chr15:67143691	NA	0.73	5.75	0.3	2.08e-8	Lung cancer (smoking interaction);
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg12262378	chr17:6899522	ALOX12	0.55	10.46	0.5	2.77e-22	Tonsillectomy;
CRC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.56	8.54	0.43	4.98e-16	Aortic root size;
CRC	cis	rs6908034	0.607	rs75110577	chr6:19814523	C/T	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg11693508	chr17:37793320	STARD3	0.6	6.99	0.36	1.58e-11	Neuroticism;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg21251018	chr6:28226885	NKAPL	0.48	7.51	0.38	5.5e-13	Parkinson's disease;
CRC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.72	-10.54	-0.5	1.39e-22	Refractive error;
CRC	trans	rs587242	0.955	rs35251373	chr1:96970538	C/T	cg10631902	chr5:14652156	NA	0.4	6.08	0.32	3.27e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-6.69	-0.35	9.49e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17155006	0.563	rs451416	chr7:107738531	A/G	cg05962710	chr7:107745446	LAMB4	-0.43	-7.53	-0.38	4.79e-13	Pneumococcal bacteremia;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.58	-0.34	1.89e-10	Total body bone mineral density;
CRC	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg25834613	chr7:1915315	MAD1L1	-0.5	-7.85	-0.4	6.08e-14	Bipolar disorder;
CRC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.29	-0.33	1.01e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.78	-0.39	9.71e-14	Hemoglobin concentration;
CRC	cis	rs4731207	0.596	rs10954050	chr7:124577901	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg25985355	chr7:65971099	NA	-0.51	-6.04	-0.32	4.25e-9	Diabetic kidney disease;
CRC	cis	rs8105895	0.935	rs10406119	chr19:22245009	C/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.44	6.1	0.32	2.99e-9	Parkinson's disease;
CRC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg18827107	chr12:86230957	RASSF9	-0.39	-6.41	-0.33	5.07e-10	Major depressive disorder;
CRC	trans	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.11	0.32	2.76e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg12564285	chr5:131593104	PDLIM4	0.41	7.37	0.38	1.35e-12	Blood metabolite levels;
CRC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg24163568	chr5:669837	TPPP	0.43	6.83	0.35	4.09e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.7	-9.42	-0.46	8.35e-19	Coronary artery disease;
CRC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.85	-12.49	-0.57	1.49e-29	Platelet distribution width;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	ch.4.185006926F	chr4:184769932	NA	0.41	6.04	0.32	4.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2462686	0.932	rs2471557	chr7:46000595	G/C	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.86	-0.31	1.11e-8	Major depressive disorder;
CRC	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.96	-0.4	2.9e-14	Homocysteine levels;
CRC	cis	rs12580194	0.593	rs61956291	chr12:55797964	G/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.09	-0.45	9.43e-18	Cancer;
CRC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.49	0.34	3.12e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.54	-8.43	-0.42	1.07e-15	Itch intensity from mosquito bite;
CRC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.47	5.97	0.31	5.99e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06435639	chr8:37756942	RAB11FIP1	0.46	6.43	0.33	4.59e-10	Response to antipsychotic treatment;
CRC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.94	0.4	3.21e-14	Colorectal cancer;
CRC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg26805224	chr10:79626177	DLG5	-0.48	-7.22	-0.37	3.65e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.52	8.01	0.4	2e-14	Corneal astigmatism;
CRC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.45	8.47	0.42	8.05e-16	Childhood ear infection;
CRC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.67	9.99	0.48	1.1e-20	Corneal astigmatism;
CRC	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.89	0.36	2.83e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.94	16.35	0.67	2.16e-44	Menarche (age at onset);
CRC	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06307176	chr5:131281290	NA	-0.4	-6.05	-0.32	3.94e-9	Life satisfaction;
CRC	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.77	0.3	1.82e-8	Educational attainment;
CRC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.54	7.26	0.37	2.81e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.73	-9.99	-0.48	1.09e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.48	-0.34	3.29e-10	Monocyte percentage of white cells;
CRC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.59	-10.6	-0.5	8.55e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-5.95	-0.31	6.9e-9	Coronary artery disease;
CRC	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.95	-12.73	-0.57	1.82e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.75	-0.3	2.07e-8	Daytime sleep phenotypes;
CRC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-12.4	-0.56	3.17e-29	Extrinsic epigenetic age acceleration;
CRC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg18709589	chr6:96969512	KIAA0776	0.52	5.72	0.3	2.38e-8	Migraine;Coronary artery disease;
CRC	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg22482690	chr17:47019901	SNF8	0.49	8.16	0.41	7.35e-15	Type 2 diabetes;
CRC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg19338460	chr6:170058176	WDR27	-0.67	-7.38	-0.38	1.27e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg24675056	chr1:15929824	NA	0.5	6.81	0.35	4.53e-11	Systolic blood pressure;
CRC	cis	rs965469	1.000	rs8123289	chr20:3253831	T/C	cg25506879	chr20:3388711	C20orf194	-0.39	-5.63	-0.3	3.88e-8	IFN-related cytopenia;
CRC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg16670446	chr17:27188758	MIR451;MIR144	0.54	8.31	0.42	2.48e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.38	-0.67	1.69e-44	Intelligence (multi-trait analysis);
CRC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.87	-11.46	-0.53	8.01e-26	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.41	-8.05	-0.41	1.49e-14	Subjective well-being;
CRC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.61	8.37	0.42	1.65e-15	Obesity-related traits;
CRC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.67	8.69	0.43	1.78e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs2015599	0.549	rs6487799	chr12:29444020	A/G	cg09582351	chr12:29534625	ERGIC2	-0.26	-5.71	-0.3	2.47e-8	Mean platelet volume;Platelet count;
CRC	cis	rs17443541	0.507	rs1823488	chr2:200463830	G/A	cg03741458	chr2:200468445	NA	-0.36	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	7.24	0.37	3.29e-12	Rheumatoid arthritis;
CRC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.42	-0.38	1e-12	Aortic root size;
CRC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg26116260	chr4:7069785	GRPEL1	-0.59	-5.68	-0.3	3.01e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg05527609	chr1:210001259	C1orf107	0.55	6.32	0.33	8.32e-10	Red blood cell count;
CRC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.49	-7.31	-0.37	2.05e-12	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10776493	chr7:16684321	BZW2;ANKMY2	0.49	6.48	0.34	3.38e-10	Thyroid stimulating hormone;
CRC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.97	11.68	0.54	1.3e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.46	-6.05	-0.32	3.92e-9	Type 2 diabetes;
CRC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg15269541	chr15:43626905	ADAL	-0.51	-5.62	-0.3	4.11e-8	Lung cancer in ever smokers;
CRC	trans	rs820077	0.609	rs9469955	chr6:35142235	T/A	cg23173586	chr14:20945319	PNP	-0.29	-6.03	-0.32	4.43e-9	Systemic lupus erythematosus;
CRC	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.55	-9.65	-0.47	1.43e-19	Common traits (Other);
CRC	cis	rs2415984	0.579	rs1494097	chr14:46960552	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.91	0.31	8.5e-9	Number of children ever born;
CRC	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.66e-12	Inflammatory skin disease;
CRC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg05623727	chr3:50126028	RBM5	0.46	7.55	0.38	4.29e-13	Intelligence (multi-trait analysis);
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg07404485	chr7:94953653	PON1	-0.6	-9.84	-0.48	3.32e-20	Paraoxonase activity;
CRC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg02390115	chr1:21767211	NBPF3	0.55	8.34	0.42	2.13e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.44	6.18	0.32	1.87e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.53	-8.91	-0.44	3.61e-17	Type 2 diabetes;
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg20041105	chr8:143859282	LYNX1	-0.34	-5.86	-0.31	1.11e-8	Urinary tract infection frequency;
CRC	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg06307176	chr5:131281290	NA	-0.43	-6.36	-0.33	6.6e-10	Life satisfaction;
CRC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	cis	rs2730260	0.537	rs55683317	chr7:158878599	C/T	cg02254261	chr7:158964346	NA	-0.55	-6.28	-0.33	1.08e-9	Myopia (pathological);
CRC	cis	rs72627123	0.867	rs73301485	chr14:74468643	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.92	0.31	8.3e-9	Morning vs. evening chronotype;
CRC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.28e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.55	-9.48	-0.46	5.19e-19	Schizophrenia;
CRC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14671364	chr1:107599128	PRMT6	-0.62	-8.27	-0.41	3.36e-15	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.42	-20.23	-0.74	1.03e-59	Hip circumference adjusted for BMI;
CRC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.49	9.9	0.48	2.21e-20	Ulcerative colitis;
CRC	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg20636351	chr8:55087400	NA	-0.33	-5.99	-0.31	5.59e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.89	0.44	4.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.33	-0.42	2.24e-15	Height;
CRC	cis	rs7692995	1.000	rs7694606	chr4:18028987	G/A	cg08925142	chr4:18023851	LCORL	-0.53	-5.86	-0.31	1.13e-8	Height;
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.6	11.07	0.52	1.99e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.72	-10.88	-0.51	9.35e-24	Platelet distribution width;
CRC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.1	0.64	1.72e-39	Platelet count;
CRC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.88	16.48	0.67	6.71e-45	Primary sclerosing cholangitis;
CRC	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.67	-0.47	1.26e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.79	-11.33	-0.53	2.46e-25	Pulse pressure;
CRC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	cis	rs4692589	0.606	rs34752946	chr4:170951738	G/T	cg19918862	chr4:170955249	NA	0.55	6.84	0.35	3.94e-11	Anxiety disorder;
CRC	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.6	7.64	0.39	2.33e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.3	6.17	0.32	2.05e-9	Lung cancer;
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.6	0.39	3.2e-13	Height;
CRC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg14711859	chr11:8959438	ASCL3	0.46	7.66	0.39	2.12e-13	Hemoglobin concentration;
CRC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.43	8.61	0.43	2.99e-16	IgG glycosylation;
CRC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg02659138	chr7:134003124	SLC35B4	0.4	7.09	0.36	8.11e-12	Mean platelet volume;
CRC	cis	rs732505	1.000	rs4807790	chr19:5584614	A/G	cg26242866	chr19:5711310	LONP1	0.54	5.67	0.3	3.18e-8	vWF and FVIII levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23943013	chr5:79551904	SERINC5	0.48	8.12	0.41	9.5e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs6563739	0.616	rs12017722	chr13:40224401	C/T	cg00026919	chr13:40226031	NA	0.5	6.41	0.33	4.98e-10	Menarche (age at onset);
CRC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.39	0.46	9.94e-19	Migraine;Coronary artery disease;
CRC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.57	-8.51	-0.42	6.07e-16	Response to temozolomide;
CRC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.61	0.6	9.34e-34	Menarche (age at onset);
CRC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg12311346	chr5:56204834	C5orf35	-0.53	-8.19	-0.41	5.85e-15	Coronary artery disease;
CRC	cis	rs4789693	0.938	rs4789694	chr17:80428099	A/C	cg04308225	chr17:80449738	NA	-0.54	-7.41	-0.38	1.08e-12	Glucocorticoid-induced osteonecrosis;
CRC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.42	7.18	0.37	4.65e-12	Attention deficit hyperactivity disorder;
CRC	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.64	8.24	0.41	4.16e-15	Bipolar disorder;
CRC	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg00250761	chr1:31883323	NA	-0.38	-7.23	-0.37	3.44e-12	Alcohol dependence;
CRC	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.62	-8.63	-0.43	2.61e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7572644	0.680	rs12465012	chr2:28028191	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.18	0.32	1.87e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg14092571	chr14:90743983	NA	0.39	5.89	0.31	9.54e-9	Mortality in heart failure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07121733	chr10:123734241	NSMCE4A	0.47	6.88	0.35	2.96e-11	Intelligence (multi-trait analysis);
CRC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg08514558	chr10:81106712	PPIF	0.36	5.8	0.3	1.52e-8	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02664216	chr12:19592651	AEBP2	0.44	6.21	0.32	1.62e-9	Response to antipsychotic treatment;
CRC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	7.9e-11	Colorectal cancer;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.38	-6.64	-0.34	1.28e-10	Systemic lupus erythematosus;
CRC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.46	-6.9	-0.36	2.68e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.45	-6.43	-0.33	4.49e-10	Intelligence (multi-trait analysis);
CRC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.67	0.34	1.11e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs939317	0.635	rs865809	chr3:183997735	C/T	cg09405238	chr3:183994500	ECE2	-0.49	-5.93	-0.31	7.66e-9	Menarche (age at onset);
CRC	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18357526	chr6:26021779	HIST1H4A	0.42	5.95	0.31	7.03e-9	Height;
CRC	cis	rs3731896	0.898	rs7596956	chr2:220152359	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.46	-5.77	-0.3	1.85e-8	Educational attainment;
CRC	cis	rs11664298	0.606	rs11081564	chr18:77551586	A/G	cg24058013	chr18:77568902	NA	-0.35	-5.63	-0.3	3.77e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.49	7.16	0.37	5.24e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg08501292	chr6:25962987	TRIM38	-0.99	-8.58	-0.43	3.89e-16	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg10876282	chr6:28092338	ZSCAN16	0.48	6.53	0.34	2.51e-10	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13227691	chr12:72233472	TBC1D15	0.38	6.04	0.32	4.25e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg06766450	chr1:16766999	NECAP2	-0.42	-6.15	-0.32	2.29e-9	Daytime sleep phenotypes;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.3	5.99	0.31	5.45e-9	Depression;
CRC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.69	-0.3	2.75e-8	Lung cancer;
CRC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.47	6.17	0.32	2.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.59	-5.79	-0.3	1.65e-8	White matter integrity;
CRC	cis	rs12983728	0.536	rs34380569	chr19:58648528	A/G	cg21294424	chr19:58662284	ZNF329	0.52	6.6	0.34	1.63e-10	Cholesterol, total;
CRC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg23234261	chr14:55582407	NA	-0.29	-5.67	-0.3	3.15e-8	Protein biomarker;
CRC	trans	rs1200821	0.738	rs1926128	chr10:37654620	C/T	cg25427524	chr10:38739819	LOC399744	0.42	6.25	0.33	1.25e-9	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.5	-7.51	-0.38	5.49e-13	Menarche (age at onset);
CRC	cis	rs4731207	0.698	rs4319000	chr7:124528055	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.09	-0.32	3.13e-9	Cutaneous malignant melanoma;
CRC	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.72	-0.3	2.33e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg09659197	chr4:152720779	NA	-0.5	-10.38	-0.5	5.01e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.6	0.34	1.62e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg12273811	chr6:28175739	NA	0.5	6.72	0.35	8.08e-11	Parkinson's disease;
CRC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.67	7.61	0.39	2.99e-13	Vitiligo;
CRC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.44	6.65	0.34	1.19e-10	Pancreatic cancer;
CRC	cis	rs7113874	0.589	rs9705253	chr11:8596483	A/T	cg17679104	chr11:8615758	STK33	-0.36	-5.99	-0.31	5.52e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04436714	chr1:90309218	LRRC8D	0.52	6.77	0.35	5.85e-11	Thyroid stimulating hormone;
CRC	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg25019722	chr6:37503610	NA	-0.5	-9.29	-0.46	2.17e-18	Cognitive performance;
CRC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.49	9.91	0.48	2.04e-20	Inflammatory bowel disease;Ulcerative colitis;
CRC	trans	rs35094601	0.959	rs11690254	chr2:139225035	C/A	cg25299176	chr17:1303341	YWHAE	-0.47	-6.7	-0.35	9.16e-11	Schizophrenia;
CRC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.44	-6.53	-0.34	2.56e-10	Menarche (age at onset);
CRC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.92	-15.98	-0.66	6.18e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	0.75	7.44	0.38	8.72e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg19418318	chr19:17219073	MYO9B	-0.48	-7.91	-0.4	3.89e-14	Reticulocyte fraction of red cells;
CRC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-18.86	-0.72	2.59e-54	Height;
CRC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.47	-0.34	3.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.56	5.68	0.3	2.94e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.52	-6.9	-0.36	2.72e-11	Caudate activity during reward;
CRC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.44	-8.96	-0.44	2.44e-17	Renal cell carcinoma;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.76	15.4	0.65	1.08e-40	Ulcerative colitis;
CRC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.76	16.53	0.67	4.35e-45	Breast cancer;
CRC	cis	rs7901135	1.000	rs7901135	chr10:60586506	G/A	cg23799393	chr10:60588674	BICC1	0.36	5.66	0.3	3.33e-8	Morning vs. evening chronotype;
CRC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.81	11.46	0.53	8.52e-26	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg21033440	chr11:65409861	SIPA1	-0.52	-5.87	-0.31	1.04e-8	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.57	-8.46	-0.42	8.9e-16	Schizophrenia;
CRC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.91	10.86	0.51	1.08e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg20607287	chr7:12443886	VWDE	-0.56	-6.15	-0.32	2.21e-9	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05284652	chr8:70746191	SLCO5A1	0.44	6.57	0.34	2e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.74	11.31	0.53	2.74e-25	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg20307385	chr11:47447363	PSMC3	0.48	5.98	0.31	5.86e-9	Migraine - clinic-based;
CRC	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg08632701	chr21:37451849	NA	-0.44	-6.8	-0.35	4.92e-11	Mitral valve prolapse;
CRC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg21770322	chr7:97807741	LMTK2	0.85	19.42	0.73	1.66e-56	Breast cancer;
CRC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.76	9.44	0.46	7.24e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg11189052	chr15:85197271	WDR73	0.6	8.83	0.44	6.13e-17	Schizophrenia;
CRC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg18016565	chr1:150552671	MCL1	0.42	5.96	0.31	6.51e-9	Melanoma;
CRC	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.31	0.42	2.48e-15	Type 2 diabetes;
CRC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.11	0.32	2.75e-9	Mean platelet volume;
CRC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.56	8.27	0.41	3.47e-15	Melanoma;
CRC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.45	6.95	0.36	1.91e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.07	-14.34	-0.62	1.5e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.46	6.9	0.36	2.74e-11	Menopause (age at onset);
CRC	cis	rs9292777	0.649	rs348601	chr5:40320006	T/C	cg09067459	chr5:40385259	NA	-0.56	-9.56	-0.47	2.92e-19	Crohn's disease;Multiple sclerosis;
CRC	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.46	-6.0	-0.31	5.27e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22943782	chr6:3157966	TUBB2A	0.44	6.31	0.33	9.25e-10	Response to antipsychotic treatment;
CRC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg15269541	chr15:43626905	ADAL	-0.59	-5.75	-0.3	2.04e-8	Lung cancer in ever smokers;
CRC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg02683197	chr6:28174875	NA	0.65	9.03	0.45	1.48e-17	Parkinson's disease;
CRC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg19193384	chr17:30244184	NA	-0.49	-6.6	-0.34	1.66e-10	Hip circumference adjusted for BMI;
CRC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg07713946	chr22:31675144	LIMK2	-0.39	-5.72	-0.3	2.45e-8	Colorectal cancer;
CRC	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-5.71	-0.3	2.56e-8	Coronary artery disease;
CRC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-0.75	-7.75	-0.39	1.14e-13	Magnesium levels;
CRC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.59e-10	Menopause (age at onset);
CRC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	trans	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg16141378	chr3:129829833	LOC729375	0.43	6.42	0.33	4.68e-10	Joint mobility (Beighton score);
CRC	cis	rs17155006	0.711	rs377007	chr7:107750446	T/A	cg05962710	chr7:107745446	LAMB4	-0.41	-7.32	-0.37	1.97e-12	Pneumococcal bacteremia;
CRC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg02175503	chr12:58329896	NA	0.49	6.11	0.32	2.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	0.96	11.2	0.53	6.88e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg21251018	chr6:28226885	NKAPL	0.4	6.09	0.32	3.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg19624444	chr7:2048497	MAD1L1	0.32	5.8	0.3	1.57e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.44	6.77	0.35	5.94e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg07212818	chr11:638076	DRD4	-0.44	-5.78	-0.3	1.73e-8	Systemic lupus erythematosus;
CRC	trans	rs10411161	0.702	rs11879436	chr19:52397815	T/A	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	cis	rs10946940	0.896	rs12208078	chr6:27498581	G/A	cg08798685	chr6:27730294	NA	0.38	5.72	0.3	2.38e-8	Systemic lupus erythematosus;
CRC	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg02175503	chr12:58329896	NA	0.6	8.99	0.44	1.98e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg27523141	chr10:43048294	ZNF37B	0.41	6.04	0.32	4.06e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.97	-0.36	1.72e-11	Educational attainment;
CRC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.27	-0.49	1.2e-21	Initial pursuit acceleration;
CRC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	1.1	10.99	0.52	3.93e-24	Parkinson's disease;
CRC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.62	-10.55	-0.5	1.3e-22	Calcium levels;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.4	0.38	1.14e-12	Height;
CRC	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.75	0.54	7.56e-27	Exhaled nitric oxide levels;
CRC	cis	rs10924970	1.000	rs12095653	chr1:235327138	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.74	0.3	2.12e-8	Asthma;
CRC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.22	0.41	4.68e-15	Red blood cell count;
CRC	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.04	-0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg10494973	chr17:80897199	TBCD	-0.37	-5.85	-0.31	1.16e-8	Breast cancer;
CRC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.87	-0.4	5.01e-14	Intelligence (multi-trait analysis);
CRC	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg25011176	chr20:3776985	CDC25B	-0.43	-5.77	-0.3	1.86e-8	Bipolar disorder;
CRC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg03013999	chr17:37608204	MED1	0.43	6.6	0.34	1.68e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.36	-0.56	4.45e-29	Type 2 diabetes;
CRC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-5.73	-0.3	2.26e-8	Longevity;
CRC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg10589385	chr1:150898437	SETDB1	0.33	6.76	0.35	6.15e-11	Melanoma;
CRC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg25985355	chr7:65971099	NA	-0.49	-5.66	-0.3	3.29e-8	Diabetic kidney disease;
CRC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.34	-0.33	7.58e-10	Monocyte percentage of white cells;
CRC	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.26	-0.33	1.18e-9	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.07	-0.49	5.69e-21	Bipolar disorder;
CRC	trans	rs10411161	0.702	rs10420224	chr19:52398955	A/G	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.62	8.16	0.41	7.34e-15	Smoking initiation;
CRC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.61	-0.47	1.97e-19	Subjective well-being;
CRC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.13e-13	Motion sickness;
CRC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.84	-13.92	-0.61	6.1e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg23018236	chr17:30244563	NA	-0.67	-7.93	-0.4	3.48e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9287719	0.649	rs12618726	chr2:10728375	C/G	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.39	5.68	0.3	3.03e-8	Growth-regulated protein alpha levels;
CRC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.02	0.52	3.04e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.41	-0.38	1.07e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.53	8.07	0.41	1.36e-14	Testicular germ cell tumor;
CRC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.4	-6.09	-0.32	3.1e-9	Monocyte count;
CRC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.77	10.7	0.51	4.09e-23	Orofacial clefts;
CRC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.4	-6.5	-0.34	2.93e-10	Hemoglobin concentration;
CRC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.77	-11.41	-0.53	1.28e-25	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02740969	chr7:139477893	TBXAS1;HIPK2	0.4	6.31	0.33	9.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.19	-0.32	1.77e-9	Alzheimer's disease (late onset);
CRC	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.71	-8.93	-0.44	3.03e-17	Prostate cancer;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.51	8.77	0.44	9.57e-17	Hypertriglyceridemia;
CRC	trans	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg26043149	chr18:55253948	FECH	-0.52	-7.78	-0.39	9.21e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.07	-0.45	1.11e-17	Type 2 diabetes;
CRC	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.62	-0.43	2.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg12884169	chr21:40033163	ERG	0.35	7.34	0.37	1.72e-12	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.5	-7.88	-0.4	4.98e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.46	-6.61	-0.34	1.56e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1941687	0.702	rs1493924	chr18:31314721	T/C	cg27147174	chr7:100797783	AP1S1	-0.39	-6.52	-0.34	2.65e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.98	-19.25	-0.73	7.43e-56	Height;
CRC	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	cg04338863	chr8:33670619	NA	0.41	6.74	0.35	7e-11	Body mass index;
CRC	trans	rs12940923	1.000	rs35433894	chr17:56376042	A/G	cg16900910	chr15:72789182	ARIH1	0.53	6.04	0.32	4.19e-9	Circulating myeloperoxidase levels (plasma);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg03757145	chr4:76555832	CDKL2	-0.65	-6.0	-0.31	5.07e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00722097	chr6:111195976	AMD1	0.41	6.27	0.33	1.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg04850286	chr10:81895943	PLAC9	0.37	6.56	0.34	2.12e-10	Sarcoidosis;
CRC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.66	9.12	0.45	7.64e-18	Eosinophil percentage of granulocytes;
CRC	cis	rs2734839	0.964	rs7131440	chr11:113299910	A/G	cg14159747	chr11:113255604	NA	-0.46	-8.1	-0.41	1.11e-14	Information processing speed;
CRC	cis	rs17592366	0.540	rs7145614	chr14:35290846	C/T	cg09327582	chr14:35236912	BAZ1A	-0.48	-6.93	-0.36	2.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs117623576	0.941	rs7912584	chr10:32416623	C/T	cg03047570	chr10:32398778	NA	-0.85	-9.07	-0.45	1.11e-17	Anti-saccade response;
CRC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.46	-5.78	-0.3	1.69e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2933343	1.000	rs6785869	chr3:128643144	G/A	cg11901034	chr3:128598214	ACAD9	-0.52	-6.3	-0.33	9.3e-10	IgG glycosylation;
CRC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.97	-0.31	6.26e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13198984	chr17:80129470	CCDC57	0.47	8.43	0.42	1.09e-15	Life satisfaction;
CRC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.81	12.26	0.56	1.05e-28	Response to antineoplastic agents;
CRC	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.46	7.76	0.39	1.08e-13	Testicular germ cell tumor;
CRC	cis	rs9322817	0.691	rs1455935	chr6:105230312	C/G	cg02098413	chr6:105308735	HACE1	-0.44	-8.55	-0.43	4.67e-16	Thyroid stimulating hormone;
CRC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.87	-15.14	-0.64	1.12e-39	Intelligence (multi-trait analysis);
CRC	cis	rs2252790	0.548	rs114094955	chr6:116521164	G/T	cg18764771	chr6:116381957	FRK	0.25	5.77	0.3	1.81e-8	Fast beta electroencephalogram;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-8.07	-0.41	1.29e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs9462027	0.628	rs9462023	chr6:34769410	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.47e-9	Systemic lupus erythematosus;
CRC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg20608306	chr11:116969690	SIK3	0.34	6.97	0.36	1.75e-11	Blood protein levels;
CRC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.31	9.81e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.26	0.45	2.71e-18	Height;
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg04969067	chr8:143858791	LYNX1	-0.55	-9.64	-0.47	1.53e-19	Urinary tract infection frequency;
CRC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg12463550	chr7:65579703	CRCP	0.46	6.48	0.34	3.34e-10	Aortic root size;
CRC	cis	rs2179367	0.881	rs2744432	chr6:149743871	A/C	cg07828024	chr6:149772892	ZC3H12D	0.38	6.02	0.32	4.56e-9	Dupuytren's disease;
CRC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18357526	chr6:26021779	HIST1H4A	0.41	5.74	0.3	2.12e-8	Height;
CRC	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.47	6.74	0.35	7.31e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.51	7.93	0.4	3.43e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg03013636	chr16:1946785	NA	0.56	6.79	0.35	5.16e-11	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg19660720	chr22:25960296	ADRBK2	-0.42	-5.97	-0.31	6.16e-9	Hirschsprung disease;
CRC	cis	rs2252521	0.553	rs1603907	chr7:29096263	A/G	cg11728747	chr7:29037910	CPVL	-0.49	-6.92	-0.36	2.3e-11	Cognitive performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08547432	chr19:50143419	RRAS	0.5	6.92	0.36	2.34e-11	Response to antipsychotic treatment;
CRC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg03030879	chr14:75389066	RPS6KL1	0.43	6.51	0.34	2.78e-10	Height;
CRC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.83	-0.44	6.31e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.55	9.53	0.47	3.53e-19	Common traits (Other);
CRC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	12.09	0.55	4.33e-28	Platelet count;
CRC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.46	6.9	0.36	2.64e-11	Menopause (age at onset);
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.91	0.31	8.32e-9	Electroencephalogram traits;
CRC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.84	15.61	0.65	1.72e-41	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13244260	chr10:112632027	LOC282997;PDCD4	0.5	6.44	0.33	4.14e-10	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18045461	chr22:29601862	EMID1	0.35	6.61	0.34	1.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.49	6.73	0.35	7.77e-11	Diastolic blood pressure;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg21856205	chr7:94953877	PON1	-0.5	-6.46	-0.34	3.73e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.42	5.83	0.31	1.31e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.59	-0.43	3.67e-16	Response to antipsychotic treatment;
CRC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.72	0.35	7.98e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs863345	0.625	rs7534112	chr1:158532065	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.29	-0.37	2.38e-12	Pneumococcal bacteremia;
CRC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.63	7.58	0.39	3.5e-13	Mean platelet volume;
CRC	cis	rs972578	1.000	rs5759059	chr22:43358492	G/A	cg01576275	chr22:43409880	NA	-0.45	-7.25	-0.37	3.08e-12	Mean platelet volume;
CRC	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.44	-6.27	-0.33	1.13e-9	Glioblastoma;Glioma;
CRC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg07125278	chr16:67683757	RLTPR	-0.63	-6.85	-0.35	3.56e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.39	0.38	1.19e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs231513	0.954	rs231497	chr17:41975947	A/G	cg26893861	chr17:41843967	DUSP3	-0.62	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg14593290	chr7:50529359	DDC	0.55	7.7	0.39	1.65e-13	Malaria;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.02	-0.4	1.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg01304814	chr3:48885189	PRKAR2A	0.87	6.31	0.33	8.86e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2195987	0.668	rs4533408	chr19:24153804	A/G	cg00460763	chr19:23944615	RPSAP58	0.55	5.98	0.31	5.71e-9	Testicular germ cell tumor;
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg12516270	chr8:143859308	LYNX1	-0.42	-7.01	-0.36	1.34e-11	Urinary tract infection frequency;
CRC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.58	6.44	0.33	4.15e-10	Initial pursuit acceleration;
CRC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00166722	chr3:10149974	C3orf24	0.42	6.3	0.33	9.75e-10	Alzheimer's disease;
CRC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.63	10.66	0.51	5.61e-23	Prostate cancer;
CRC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-7.07	-0.36	9.33e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.14	-11.99	-0.55	1.03e-27	Breast cancer;
CRC	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg12026095	chr19:49468461	FTL	-0.49	-6.1	-0.32	2.99e-9	Colorectal cancer;
CRC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.52	6.7	0.35	9.12e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.55	8.49	0.42	7.44e-16	Breast cancer;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg16060761	chr17:80687452	NA	-0.43	-5.74	-0.3	2.17e-8	Glycated hemoglobin levels;
CRC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg27523141	chr10:43048294	ZNF37B	0.48	6.99	0.36	1.56e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs10106298	0.846	rs2436940	chr8:103678521	A/C	cg10187029	chr8:103597600	NA	0.42	5.9	0.31	8.81e-9	Schizophrenia;
CRC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.09	0.45	9.67e-18	Bladder cancer;
CRC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.14	0.32	2.4e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg13565492	chr6:43139072	SRF	-0.73	-7.52	-0.38	5.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.31	-0.42	2.48e-15	Electroencephalogram traits;
CRC	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg14515779	chr1:101123966	NA	-0.35	-6.36	-0.33	6.74e-10	Monocyte count;
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.76	-0.43	1.08e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-7.6	-0.39	3.04e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg27615366	chr5:131592974	PDLIM4	0.34	5.96	0.31	6.55e-9	Breast cancer;
CRC	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.38	-5.65	-0.3	3.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs12702919	0.615	rs4427078	chr7:9556688	C/T	cg15597424	chr4:24472487	NA	-0.38	-6.01	-0.31	4.88e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.53	-7.57	-0.39	3.69e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg02702477	chr5:179499311	RNF130	0.54	6.22	0.32	1.52e-9	LDL cholesterol;
CRC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.48	6.84	0.35	3.96e-11	Colorectal cancer;
CRC	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.55	-6.15	-0.32	2.27e-9	Neuroticism;
CRC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg27432699	chr2:27873401	GPN1	-0.64	-9.82	-0.48	4e-20	Total body bone mineral density;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg10876282	chr6:28092338	ZSCAN16	0.49	6.61	0.34	1.56e-10	Parkinson's disease;
CRC	trans	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg14318858	chr19:50204862	CPT1C	-0.37	-6.09	-0.32	3.21e-9	Schizophrenia;
CRC	cis	rs858239	0.730	rs10255155	chr7:23402147	A/T	cg00469287	chr7:23338798	C7orf30	-0.48	-6.38	-0.33	5.91e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg05623727	chr3:50126028	RBM5	-0.44	-7.36	-0.38	1.52e-12	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg01262667	chr19:19385393	TM6SF2	0.37	6.05	0.32	3.94e-9	Tonsillectomy;
CRC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	9.31	0.46	1.89e-18	Multiple sclerosis;
CRC	cis	rs4073416	0.508	rs6573619	chr14:66061560	T/C	cg03016385	chr14:66212404	NA	-0.46	-6.31	-0.33	9e-10	N-glycan levels;
CRC	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg27053337	chr8:124217698	FAM83A	-0.4	-6.42	-0.33	4.84e-10	Urinary uromodulin levels;
CRC	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.55	7.68	0.39	1.78e-13	Triglycerides;
CRC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.96	14.47	0.62	4.59e-37	IgG glycosylation;
CRC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.58	7.81	0.4	7.99e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg03623178	chr6:28175578	NA	0.79	6.91	0.36	2.6e-11	Breast cancer;
CRC	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg03929089	chr4:120376271	NA	0.71	6.93	0.36	2.26e-11	Axial length;
CRC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg05625103	chr10:2543513	NA	0.38	6.02	0.31	4.78e-9	Age-related hearing impairment;
CRC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.7	8.16	0.41	7.37e-15	Hip circumference adjusted for BMI;
CRC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.29	-0.49	1.06e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.43	6.33	0.33	8.21e-10	Coronary artery disease;
CRC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg13835894	chr2:219148914	PNKD;TMBIM1	0.29	5.69	0.3	2.75e-8	Colorectal cancer;
CRC	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-0.66	-9.82	-0.48	3.93e-20	Acne (severe);
CRC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.4	-0.33	5.38e-10	Aortic root size;
CRC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.63	0.47	1.63e-19	Cognitive test performance;
CRC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg27661571	chr11:113659931	NA	-0.77	-9.59	-0.47	2.24e-19	Hip circumference adjusted for BMI;
CRC	trans	rs1120787	0.793	rs1153634	chr18:55014457	A/G	cg19077231	chr7:100484514	SRRT	0.55	6.03	0.32	4.45e-9	HIV-1 control;
CRC	cis	rs12760731	0.565	rs10913516	chr1:178169493	G/A	cg00404053	chr1:178313656	RASAL2	1.11	11.5	0.54	6.02e-26	Obesity-related traits;
CRC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.58	-0.34	1.82e-10	Lung cancer;
CRC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.51	7.77	0.39	9.98e-14	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs12024301	0.557	rs12039168	chr1:183638854	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21440829	chr7:100808893	VGF	0.43	6.74	0.35	6.99e-11	Schizophrenia;
CRC	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.65	10.46	0.5	2.74e-22	Corneal astigmatism;
CRC	cis	rs6988985	0.693	rs7822986	chr8:143957856	G/A	cg10324643	chr8:143916377	GML	0.36	5.98	0.31	5.66e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.4	5.62	0.3	4e-8	Renal cell carcinoma;
CRC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.58	-6.14	-0.32	2.32e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg10517650	chr3:113235015	CCDC52	-0.38	-6.04	-0.32	4.08e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.19	0.71	1.2e-51	Cognitive ability;
CRC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.98	0.4	2.46e-14	Motion sickness;
CRC	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.89	-0.31	9.54e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.82	9.46	0.46	6.06e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.35	-5.8	-0.3	1.52e-8	IgG glycosylation;
CRC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.38	6.09	0.32	3.22e-9	Testicular germ cell tumor;
CRC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-13.57	-0.6	1.23e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.77	12.55	0.57	8.76e-30	Height;
CRC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg19318889	chr4:1322082	MAEA	0.41	6.18	0.32	1.92e-9	Longevity;
CRC	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.55	-6.52	-0.34	2.63e-10	Coronary artery calcification;
CRC	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.49	-7.44	-0.38	8.77e-13	Blood protein levels;
CRC	cis	rs4073416	0.504	rs1953418	chr14:65915226	G/A	cg03016385	chr14:66212404	NA	-0.42	-5.78	-0.3	1.77e-8	N-glycan levels;
CRC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg05304507	chr6:116381966	FRK	0.3	8.06	0.41	1.45e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-7.85	-0.4	5.87e-14	Facial morphology (factor 19);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17589079	chr11:67806437	TCIRG1	0.45	6.5	0.34	3.02e-10	Response to antipsychotic treatment;
CRC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.34	-0.38	1.71e-12	Reticulocyte fraction of red cells;
CRC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.57	-5.87	-0.31	1.07e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.49	7.48	0.38	6.89e-13	Coronary artery disease;
CRC	cis	rs6496667	0.779	rs7175476	chr15:91027184	G/C	cg04176472	chr15:90893244	GABARAPL3	0.53	7.8	0.39	8.38e-14	Rheumatoid arthritis;
CRC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	9.35	0.46	1.38e-18	Alzheimer's disease;
CRC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.78	-0.35	5.73e-11	Aortic root size;
CRC	cis	rs6691722	0.503	rs12135404	chr1:24704263	C/T	cg02336364	chr1:24764700	NIPAL3	-0.37	-5.95	-0.31	6.93e-9	Response to interferon beta in multiple sclerosis;
CRC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	2.98e-9	Heart rate;
CRC	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.5	-6.04	-0.32	4.18e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.04	18.25	0.71	7.09e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.08	-0.66	2.34e-43	Blood protein levels;
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg10677697	chr7:45961126	IGFBP3	0.34	6.01	0.31	5.03e-9	Sitting height ratio;
CRC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.22	-0.41	4.65e-15	Bone mineral density;
CRC	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg16898833	chr6:26189333	HIST1H4D	0.73	6.37	0.33	6.51e-10	Depression;
CRC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg08314208	chr16:67682810	RLTPR	-0.59	-6.28	-0.33	1.08e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg06470822	chr6:28175283	NA	0.68	8.91	0.44	3.6e-17	Parkinson's disease;
CRC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.1	-0.52	1.53e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg15845792	chr6:28175446	NA	-0.48	-6.57	-0.34	2e-10	Systemic lupus erythematosus;
CRC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs7849270	1.000	rs7868408	chr9:131917864	G/A	cg13538475	chr9:131942899	NA	-0.3	-5.78	-0.3	1.73e-8	Blood metabolite ratios;
CRC	cis	rs3812762	0.783	rs34524863	chr11:8777408	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.18	-0.32	1.95e-9	Hypospadias;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20959894	chr7:27779871	TAX1BP1	0.38	6.47	0.34	3.54e-10	Obesity-related traits;
CRC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.59	-0.34	1.75e-10	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.53	6.77	0.35	5.85e-11	Morning vs. evening chronotype;
CRC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg23109721	chr2:106886537	NA	-0.47	-7.39	-0.38	1.22e-12	Facial morphology (factor 23);
CRC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg05754148	chr16:3507555	NAT15	-0.7	-6.75	-0.35	6.7e-11	Tuberculosis;
CRC	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03364015	chr11:69454423	CCND1	0.47	6.04	0.32	4.26e-9	Anxiety disorder;
CRC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.14	0.56	2.91e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.48	6.71	0.35	8.54e-11	Cognitive function;
CRC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.42	-6.93	-0.36	2.27e-11	Weight;
CRC	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.8	-13.03	-0.58	1.37e-31	Hypospadias;
CRC	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.72	-0.35	7.81e-11	Putamen volume;
CRC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg15786705	chr6:28176104	NA	0.73	6.17	0.32	2.03e-9	Depression;
CRC	cis	rs6743226	0.934	rs6705421	chr2:242212672	A/G	cg10021735	chr2:242295487	FARP2	0.47	6.96	0.36	1.89e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.66	-10.14	-0.49	3.23e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	0.56	8.76	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.64	7.34	0.38	1.63e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	7.66	0.39	2.09e-13	Platelet count;
CRC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.09	0.41	1.2e-14	Menopause (age at onset);
CRC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.07	0.41	1.33e-14	Menopause (age at onset);
CRC	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.45	-6.46	-0.34	3.82e-10	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.4	19.03	0.72	5.7e-55	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg26838691	chr2:24397539	C2orf84	0.41	5.72	0.3	2.34e-8	Asthma;
CRC	cis	rs4727963	0.792	rs6466853	chr7:122719094	C/A	cg03640110	chr7:122635026	TAS2R16	-0.32	-5.92	-0.31	8.31e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23109191	chr11:78128445	GAB2	-0.39	-6.0	-0.31	5.32e-9	Aortic root size;
CRC	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.4	-5.82	-0.31	1.41e-8	Tonsillectomy;
CRC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	8.66	0.43	2.14e-16	Colorectal cancer;
CRC	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.09	-0.36	8.28e-12	Capecitabine sensitivity;
CRC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	7.23	0.37	3.42e-12	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.74e-9	Depression;
CRC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.69	-0.35	9.41e-11	Menopause (age at onset);
CRC	cis	rs883565	0.740	rs6780772	chr3:39087764	A/G	cg01426195	chr3:39028469	NA	-0.53	-8.54	-0.43	4.97e-16	Handedness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10117518	chr2:29117384	WDR43	0.39	6.15	0.32	2.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg04362960	chr10:104952993	NT5C2	0.46	6.11	0.32	2.84e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21687924	chr11:3400496	ZNF195	0.42	6.2	0.32	1.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.91	11.11	0.52	1.41e-24	Eosinophil percentage of granulocytes;
CRC	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.7	-11.27	-0.53	3.86e-25	Coronary artery disease;
CRC	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.57	8.26	0.41	3.65e-15	Testicular germ cell tumor;
CRC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.78	-10.78	-0.51	2.15e-23	Initial pursuit acceleration;
CRC	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.69	8.09	0.41	1.15e-14	Eotaxin levels;
CRC	cis	rs75422866	0.510	rs73105829	chr12:48127945	A/C	cg14736327	chr12:48174669	SLC48A1	-0.77	-6.26	-0.33	1.22e-9	Pneumonia;
CRC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg25767906	chr1:53392781	SCP2	0.37	5.86	0.31	1.12e-8	Monocyte count;
CRC	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.52	9.23	0.45	3.37e-18	Blood metabolite ratios;
CRC	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg00012203	chr2:219082015	ARPC2	-0.38	-5.73	-0.3	2.22e-8	Ulcerative colitis;
CRC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-7.33	-0.37	1.81e-12	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg18404039	chr20:3184938	DDRGK1	0.52	6.22	0.32	1.48e-9	Kashin-Beck disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11039072	chr15:35280907	ZNF770	0.51	6.68	0.35	1.04e-10	Thyroid stimulating hormone;
CRC	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.63	-8.71	-0.43	1.52e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.75	0.54	7.66e-27	Prudent dietary pattern;
CRC	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.54	8.06	0.41	1.39e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.73	0.3	2.33e-8	Bladder cancer;
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.64	8.64	0.43	2.5e-16	Alzheimer's disease;
CRC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg23461800	chr14:103021989	NA	-0.68	-7.91	-0.4	3.86e-14	Platelet count;
CRC	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg12458913	chr13:53173898	NA	0.46	6.81	0.35	4.53e-11	Lewy body disease;
CRC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg21535247	chr6:8435926	SLC35B3	-0.41	-6.0	-0.31	5.22e-9	Motion sickness;
CRC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg19622623	chr12:86230825	RASSF9	-0.4	-6.31	-0.33	9.21e-10	Major depressive disorder;
CRC	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	cis	rs13098911	0.540	rs13074382	chr3:46061840	A/G	cg12691230	chr3:46064611	XCR1	-0.52	-5.82	-0.31	1.41e-8	Celiac disease;
CRC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.41	5.66	0.3	3.22e-8	Multiple sclerosis;
CRC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.74	0.35	7.02e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.6	9.3	0.46	2.03e-18	Aortic root size;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.52	7.28	0.37	2.51e-12	Longevity;Endometriosis;
CRC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.7	9.2	0.45	4.3e-18	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg01339444	chr6:118972232	C6orf204	0.53	6.03	0.32	4.29e-9	Diastolic blood pressure;
CRC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.39	5.99	0.31	5.36e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.63	11.52	0.54	5.02e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9463078	0.683	rs1342640	chr6:44743516	T/C	cg25276700	chr6:44698697	NA	0.25	5.95	0.31	6.9e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.43	8.2	0.41	5.48e-15	Bone mineral density;
CRC	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21368352	chr6:424126	NA	-0.4	-6.04	-0.32	4.12e-9	Pancreatic cancer;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02359409	chr6:42947317	PEX6	-0.65	-10.33	-0.49	7.58e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg19913688	chr11:428466	ANO9	-0.65	-6.58	-0.34	1.83e-10	Body mass index;
CRC	cis	rs4660306	0.614	rs12032658	chr1:45923851	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	6.76	0.35	6.49e-11	Homocysteine levels;
CRC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-6.05	-0.32	3.99e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.6	9.93	0.48	1.68e-20	Mean corpuscular volume;
CRC	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.61	6.6	0.34	1.63e-10	Blood protein levels;
CRC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-7.45	-0.38	8.43e-13	Colorectal cancer;
CRC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.31	0.46	1.84e-18	Tonsillectomy;
CRC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg15445000	chr17:37608096	MED1	0.39	8.36	0.42	1.79e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.92	0.31	7.91e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-6.93	-0.36	2.28e-11	Osteoarthritis;
CRC	trans	rs9987353	0.840	rs41436744	chr8:9123324	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.45	-0.34	4.06e-10	Recombination measurement;
CRC	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg22356347	chr1:167427500	CD247	-0.4	-6.08	-0.32	3.28e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg15571903	chr15:79123663	NA	0.31	6.14	0.32	2.38e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.79	-0.68	3.96e-46	Height;
CRC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg11212589	chr17:38028394	ZPBP2	0.34	6.02	0.32	4.62e-9	Asthma;
CRC	cis	rs2949837	0.603	rs1542818	chr7:45977656	G/T	cg15898840	chr7:45960834	IGFBP3	0.45	7.4	0.38	1.12e-12	Sitting height ratio;
CRC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.59	10.51	0.5	1.75e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.62	-9.4	-0.46	9.91e-19	Dementia with Lewy bodies;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.73	9.61	0.47	1.95e-19	Alzheimer's disease;
CRC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg25356066	chr3:128598488	ACAD9	0.39	5.66	0.3	3.22e-8	IgG glycosylation;
CRC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.77	-11.56	-0.54	3.52e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg03623178	chr6:28175578	NA	0.88	12.69	0.57	2.62e-30	Parkinson's disease;
CRC	trans	rs8064024	0.538	rs12596053	chr16:4946794	A/C	cg19252218	chr17:41477271	ARL4D	-0.41	-6.05	-0.32	3.93e-9	Cancer;
CRC	cis	rs9292777	0.805	rs6880778	chr5:40399096	A/G	cg09067459	chr5:40385259	NA	0.54	9.47	0.46	5.67e-19	Crohn's disease;Multiple sclerosis;
CRC	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.67	-9.29	-0.46	2.13e-18	Blood pressure (smoking interaction);
CRC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-9.24	-0.45	3.2e-18	Bipolar disorder;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg03623178	chr6:28175578	NA	0.65	9.04	0.45	1.34e-17	Parkinson's disease;
CRC	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg06204229	chr3:52865917	ITIH4	-0.47	-5.87	-0.31	1.05e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg23071808	chr14:103021642	NA	-0.7	-8.95	-0.44	2.72e-17	Platelet count;
CRC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04722249	chr2:97617061	FAM178B	0.4	6.34	0.33	7.74e-10	Myopia (pathological);
CRC	cis	rs970548	0.908	rs11239538	chr10:45994596	G/C	cg15590007	chr10:45870220	ALOX5	0.48	6.04	0.32	4.24e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.5	8.37	0.42	1.72e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg26132723	chr8:70041827	NA	-0.35	-5.61	-0.3	4.27e-8	Dupuytren's disease;
CRC	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg23112188	chr14:24563095	PCK2	-0.35	-6.46	-0.34	3.7e-10	IgG glycosylation;
CRC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.41	5.86	0.31	1.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.72	-12.14	-0.56	2.83e-28	Asthma;
CRC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.57	8.38	0.42	1.54e-15	Resting heart rate;
CRC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.39	-0.33	5.66e-10	Aortic root size;
CRC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg02421172	chr7:1938701	MAD1L1	0.44	5.71	0.3	2.5e-8	Bipolar disorder;
CRC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg13798912	chr7:905769	UNC84A	-0.5	-5.67	-0.3	3.11e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.63	-9.83	-0.48	3.57e-20	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26959990	chr15:23034449	NIPA2	0.44	6.59	0.34	1.78e-10	Schizophrenia;
CRC	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg11993925	chr19:44307056	LYPD5	0.47	7.74	0.39	1.24e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-6.09	-0.32	3.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.64	0.39	2.33e-13	Schizophrenia;
CRC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.48	6.76	0.35	6.41e-11	Granulocyte percentage of myeloid white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24664570	chr2:159825143	TANC1	0.41	6.81	0.35	4.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs113123495	0.609	rs2436502	chr19:5645444	G/A	cg26242866	chr19:5711310	LONP1	0.75	6.14	0.32	2.36e-9	Obsessive-compulsive symptoms;
CRC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06462663	chr19:18546047	ISYNA1	0.48	7.22	0.37	3.58e-12	Breast cancer;
CRC	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg16141378	chr3:129829833	LOC729375	0.42	5.98	0.31	5.8e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg22535103	chr8:58192502	C8orf71	-0.43	-5.75	-0.3	2e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg13722127	chr7:150037890	RARRES2	0.48	7.48	0.38	6.81e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.47	-8.67	-0.43	1.97e-16	Hepatitis;
CRC	cis	rs7605827	0.930	rs1019359	chr2:15524615	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-7.24	-0.37	3.21e-12	Metabolite levels;
CRC	cis	rs17162190	0.590	rs7524421	chr1:26810612	C/G	cg17456097	chr1:26900765	RPS6KA1	0.44	6.36	0.33	6.79e-10	Mean corpuscular volume;
CRC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	8.25	0.41	3.95e-15	Personality dimensions;
CRC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.98	-0.31	5.81e-9	Migraine;Coronary artery disease;
CRC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg03929089	chr4:120376271	NA	-0.46	-6.53	-0.34	2.55e-10	Height;
CRC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg24562669	chr7:97807699	LMTK2	0.42	6.95	0.36	2.01e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg00677455	chr12:58241039	CTDSP2	0.39	5.67	0.3	3.12e-8	Intelligence (multi-trait analysis);
CRC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.53	6.78	0.35	5.57e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17767392	0.595	rs4902918	chr14:71656732	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.48	-6.15	-0.32	2.24e-9	Mitral valve prolapse;
CRC	trans	rs679582	0.864	rs4896469	chr6:139843787	A/G	cg24871798	chr6:50817450	NA	-0.36	-6.29	-0.33	1.01e-9	Blood trace element (Se levels);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06396948	chr16:67193897	FBXL8;TRADD	0.45	6.58	0.34	1.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg04165759	chr1:150448943	RPRD2	0.36	5.87	0.31	1.06e-8	Migraine;
CRC	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.37	-5.68	-0.3	2.93e-8	Type 1 diabetes;
CRC	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg13385794	chr1:248469461	NA	-0.4	-6.87	-0.35	3.19e-11	Common traits (Other);
CRC	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs11229555	0.645	rs11229428	chr11:58180382	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.29	-0.49	1.02e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.85	-11.58	-0.54	3.01e-26	Asthma;
CRC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg23018236	chr17:30244563	NA	-0.47	-6.63	-0.34	1.42e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2730260	0.500	rs73169244	chr7:158887293	T/C	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.75	-12.27	-0.56	9.78e-29	Blood metabolite levels;
CRC	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg23071808	chr14:103021642	NA	-0.68	-8.71	-0.43	1.55e-16	Platelet count;
CRC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.62	0.34	1.47e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11239930	0.934	rs10900313	chr1:146560747	T/A	cg11655389	chr1:146548469	NA	-0.32	-5.72	-0.3	2.41e-8	AIDS progression;
CRC	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs10924970	1.000	rs10924501	chr1:235351447	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.76	0.3	1.92e-8	Asthma;
CRC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg21770322	chr7:97807741	LMTK2	0.53	8.63	0.43	2.63e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg21153622	chr11:89784906	NA	-0.45	-7.13	-0.37	6.32e-12	HDL cholesterol;
CRC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.16	-0.56	2.46e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg01412321	chr7:36429799	ANLN;KIAA0895	0.57	6.14	0.32	2.36e-9	Body mass index;
CRC	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.44	5.81	0.31	1.47e-8	Coronary artery disease;
CRC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.69	11.86	0.55	2.88e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.52	-8.38	-0.42	1.6e-15	Aortic root size;
CRC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.33	-5.92	-0.31	8.17e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs245880	0.740	rs245889	chr7:29190626	C/T	cg17163760	chr7:29186267	CPVL	-0.39	-6.89	-0.35	2.9100000000000002e-11	Warfarin maintenance dose;
CRC	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg09163369	chr1:210001066	C1orf107	0.56	7.59	0.39	3.41e-13	Orofacial clefts;
CRC	cis	rs703980	0.967	rs703972	chr10:80952826	G/C	cg20744163	chr10:80999841	ZMIZ1	0.31	5.74	0.3	2.16e-8	Type 2 diabetes;
CRC	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.5	-7.47	-0.38	7.38e-13	Schizophrenia;
CRC	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg19683494	chr5:74908142	NA	0.51	6.46	0.34	3.67e-10	Age-related disease endophenotypes;
CRC	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-0.52	-6.05	-0.32	3.96e-9	Opioid sensitivity;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.08	-0.32	3.27e-9	Total body bone mineral density;
CRC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg21466736	chr12:48725269	NA	-0.53	-8.06	-0.41	1.47e-14	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.65	10.3	0.49	9.16e-22	Intelligence (multi-trait analysis);
CRC	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-5.99	-0.31	5.51e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg22687807	chr8:143858763	LYNX1	0.51	9.08	0.45	1e-17	Urinary tract infection frequency;
CRC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.27e-46	Breast cancer;
CRC	cis	rs7731657	0.537	rs4705924	chr5:130210792	G/A	cg08523029	chr5:130500466	HINT1	-0.48	-6.14	-0.32	2.44e-9	Fasting plasma glucose;
CRC	cis	rs2882667	0.728	rs7722413	chr5:138278251	T/C	cg09476006	chr5:138032270	NA	0.58	10.02	0.48	8.25e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.3	-0.42	2.68e-15	Bone mineral density;
CRC	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11117896	chr2:220094984	ANKZF1;ATG9A	0.55	7.2	0.37	4.07e-12	Thyroid stimulating hormone;
CRC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg18301423	chr5:131593218	PDLIM4	0.41	6.79	0.35	5.39e-11	Breast cancer;
CRC	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg21153622	chr11:89784906	NA	-0.44	-7.1	-0.36	7.56e-12	HDL cholesterol;
CRC	cis	rs354033	1.000	rs354042	chr7:149297104	A/G	cg24335155	chr7:149193227	ZNF746	0.37	5.84	0.31	1.29e-8	Multiple sclerosis;
CRC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.01	-0.36	1.33e-11	Colorectal cancer;
CRC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.62	0.3	3.97e-8	Monocyte percentage of white cells;
CRC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.52	-9.03	-0.45	1.44e-17	Aortic root size;
CRC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	1.99e-11	Morning vs. evening chronotype;
CRC	cis	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg06470822	chr6:28175283	NA	0.81	6.57	0.34	2.03e-10	Depression;
CRC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg01262667	chr19:19385393	TM6SF2	0.37	6.17	0.32	2.05e-9	Tonsillectomy;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.63	-8.68	-0.43	1.82e-16	Obesity-related traits;
CRC	cis	rs8062405	0.540	rs480400	chr16:28574615	A/G	cg05139728	chr16:28306816	SBK1	-0.32	-5.74	-0.3	2.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.23	0.37	3.49e-12	Hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20859525	chr6:80714300	TTK	0.44	6.27	0.33	1.12e-9	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg19318889	chr4:1322082	MAEA	0.42	6.43	0.33	4.45e-10	Obesity-related traits;
CRC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.59	-8.7	-0.43	1.59e-16	Multiple sclerosis;
CRC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.55	-7.96	-0.4	2.88e-14	Resting heart rate;
CRC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.68	-0.43	1.83e-16	IgG glycosylation;
CRC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.32	0.37	1.97e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg12682573	chr17:27188876	MIR451;MIR144	0.6	8.88	0.44	4.38e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04731861	chr2:219085781	ARPC2	0.37	7.99	0.4	2.37e-14	Colorectal cancer;
CRC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg01626995	chr9:139526017	NA	-0.43	-6.81	-0.35	4.67e-11	Aortic root size;
CRC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.91	13.53	0.6	1.84e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg27274463	chr12:110338238	TCHP	0.39	6.45	0.34	3.88e-10	Obesity-related traits;
CRC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg24154853	chr7:158122151	PTPRN2	0.61	9.89	0.48	2.36e-20	Calcium levels;
CRC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.55	7.71	0.39	1.49e-13	Height;
CRC	cis	rs77861329	1.000	rs123681	chr3:52209320	A/G	cg08692210	chr3:52188851	WDR51A	0.83	7.81	0.4	7.57e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg12564285	chr5:131593104	PDLIM4	-0.39	-7.48	-0.38	6.88e-13	Breast cancer;
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg04662943	chr10:102668895	NA	0.59	7.25	0.37	3.07e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7113874	0.569	rs11041985	chr11:8582684	A/G	cg02811074	chr11:8615871	STK33	-0.34	-5.87	-0.31	1.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs45544231	0.569	rs9302556	chr16:52543645	C/A	cg09051775	chr16:52580266	TOX3	-0.38	-6.16	-0.32	2.15e-9	Restless legs syndrome;
CRC	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.47	8.89	0.44	4.16e-17	Hepatitis;
CRC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.63	-10.14	-0.49	3.25e-21	Corneal structure;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04639396	chr7:27190539	NA	-0.5	-6.06	-0.32	3.64e-9	Diisocyanate-induced asthma;
CRC	cis	rs10760158	0.769	rs10985200	chr9:124043867	C/T	cg14417974	chr9:124058376	GSN	-0.33	-5.63	-0.3	3.83e-8	Pulse pressure;
CRC	cis	rs11098699	0.821	rs904712	chr4:124225337	T/C	cg09941581	chr4:124220074	SPATA5	0.43	6.33	0.33	7.98e-10	Mosquito bite size;
CRC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.54	-7.89	-0.4	4.67e-14	Tuberculosis;
CRC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg10589385	chr1:150898437	SETDB1	-0.3	-6.2	-0.32	1.65e-9	Melanoma;
CRC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.95e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg14541582	chr5:601475	NA	-0.34	-6.64	-0.34	1.33e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-5.71	-0.3	2.58e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.55	7.66	0.39	2.05e-13	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.65	-0.51	5.95e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.8	13.45	0.6	3.64e-33	Menopause (age at onset);
CRC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.28	0.33	1.09e-9	Bladder cancer;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg22561889	chr6:118971681	C6orf204	0.51	6.83	0.35	4.04e-11	Diastolic blood pressure;
CRC	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-6.94	-0.36	2.13e-11	Menarche (age at onset);
CRC	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.74	-10.25	-0.49	1.45e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04977983	chr14:39572202	SEC23A	-0.4	-6.25	-0.33	1.27e-9	Myopia (pathological);
CRC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.12e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17095355	1.000	rs17126931	chr10:111754633	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.52	-5.89	-0.31	9.74e-9	Biliary atresia;
CRC	cis	rs939584	1.000	rs10192350	chr2:652607	T/C	cg03610516	chr2:642275	NA	-0.43	-5.93	-0.31	7.78e-9	Body mass index;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg21620606	chr4:1342894	KIAA1530	0.4	6.94	0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21638063	chr5:107717975	FBXL17	0.4	6.12	0.32	2.71e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.51	9.12	0.45	7.72e-18	Common traits (Other);
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg15786705	chr6:28176104	NA	0.62	6.67	0.34	1.11e-10	Depression;
CRC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3015497	0.616	rs6572678	chr14:51090115	T/G	cg09863266	chr14:51125203	SAV1	-0.3	-5.76	-0.3	1.93e-8	Mean platelet volume;
CRC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg25344623	chr2:136566232	LCT	-0.32	-5.85	-0.31	1.17e-8	Mosquito bite size;
CRC	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-7.11	-0.36	7.42e-12	Response to antipsychotic treatment;
CRC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg01216370	chr2:228736459	WDR69	-0.45	-5.7	-0.3	2.68e-8	Blood pressure;
CRC	trans	rs11581859	0.950	rs55842403	chr1:99358542	C/T	cg12183875	chr3:169587454	LRRC31	0.25	5.99	0.31	5.39e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.8	0.4	8.53e-14	Skin colour saturation;
CRC	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.6	-8.63	-0.43	2.63e-16	Coronary artery disease;
CRC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg27534772	chr1:16042836	PLEKHM2	0.55	10.85	0.51	1.21e-23	Systolic blood pressure;
CRC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.72	0.35	8.19e-11	Lung cancer;
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.82	10.57	0.5	1.09e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12745968	0.589	rs3903212	chr1:92984055	A/G	cg17283838	chr1:93427260	FAM69A	-0.45	-6.19	-0.32	1.74e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg02269571	chr22:50332266	NA	-0.61	-7.52	-0.38	5.19e-13	Schizophrenia;
CRC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.68	7.96	0.4	2.79e-14	Hemostatic factors and hematological phenotypes;
CRC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs6976053	0.935	rs4727469	chr7:100509163	C/T	cg10426581	chr7:100472382	SRRT	0.38	5.79	0.3	1.62e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs4731207	0.536	rs34630567	chr7:124630663	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.34	-0.33	7.73e-10	Cutaneous malignant melanoma;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.02	-0.45	1.55e-17	Bipolar disorder;
CRC	cis	rs3736485	0.966	rs6493510	chr15:51900651	T/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.6	-0.34	1.67e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04073608	chr11:65268100	MALAT1	0.45	6.05	0.32	3.86e-9	Thyroid stimulating hormone;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg10876282	chr6:28092338	ZSCAN16	0.48	6.38	0.33	5.96e-10	Cardiac Troponin-T levels;
CRC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg05874882	chr4:1763078	NA	-0.36	-6.7	-0.35	8.92e-11	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06194421	chr17:33570128	SLFN5	0.42	6.42	0.33	4.8e-10	Myopia (pathological);
CRC	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg27398640	chr15:77910606	LINGO1	-0.4	-7.11	-0.36	7.26e-12	Type 2 diabetes;
CRC	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg05049329	chr1:226924846	ITPKB	0.39	8.81	0.44	7.52e-17	Parkinson's disease;
CRC	cis	rs243505	0.691	rs243480	chr7:148452905	G/T	cg09806900	chr7:148480153	CUL1	-0.6	-7.73	-0.39	1.34e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.38	0.38	1.32e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.62	-0.39	2.68e-13	Breast cancer;
CRC	trans	rs6472235	0.837	rs4317552	chr8:66914293	G/T	cg07884673	chr3:53033167	SFMBT1	-0.46	-6.34	-0.33	7.48e-10	Myopia (pathological);Plateletcrit;
CRC	trans	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg14063357	chr9:79793314	VPS13A;LOC100286938	0.6	6.19	0.32	1.83e-9	Iron status biomarkers;
CRC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.56	-9.52	-0.46	3.98e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs12024301	0.557	rs77398368	chr1:183645845	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.73	6.43	0.33	4.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23052081	chr20:50808205	ZFP64	0.53	7.68	0.39	1.81e-13	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg18761221	chr20:60518478	NA	0.47	7.52	0.38	5.36e-13	Body mass index;
CRC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.6	8.34	0.42	2.01e-15	Height;
CRC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	0.99	15.5	0.65	4.7e-41	Cognitive function;
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.8	-0.3	1.58e-8	Life satisfaction;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12975295	chr9:86571409	C9orf64	0.43	6.5	0.34	3.04e-10	Schizophrenia;
CRC	cis	rs12922317	0.538	rs442234	chr16:12072161	A/G	cg09319797	chr16:12061715	TNFRSF17	0.35	5.92	0.31	7.98e-9	Schizophrenia;
CRC	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg07478791	chr1:31886160	SERINC2	-0.41	-5.68	-0.3	2.89e-8	Alcohol dependence;
CRC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg02766259	chr12:125626809	AACS	-0.43	-7.22	-0.37	3.54e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.19	0.32	1.8e-9	Lung cancer;
CRC	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg23100626	chr2:96804247	ASTL	0.28	7.41	0.38	1.11e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg16342193	chr10:102329863	NA	-0.33	-5.71	-0.3	2.59e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.9	-0.48	2.08e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.71	10.29	0.49	1.04e-21	Menarche (age at onset);
CRC	trans	rs2898857	0.524	rs2119931	chr17:47429834	A/G	cg11430096	chr6:110968061	CDK19	-0.48	-7.48	-0.38	6.89e-13	Cancer;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg11843238	chr5:131593191	PDLIM4	0.45	7.63	0.39	2.59e-13	Breast cancer;
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.45	-0.42	9.79e-16	Electroencephalogram traits;
CRC	cis	rs3750082	0.817	rs3750078	chr7:32969489	G/A	cg05721444	chr7:32995514	FKBP9	-0.51	-7.75	-0.39	1.14e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg21169611	chr9:106856078	SMC2	0.4	5.67	0.3	3.12e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs11212617	0.902	rs599406	chr11:108118234	T/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.26	0.33	1.22e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.42	6.36	0.33	6.58e-10	Mean platelet volume;
CRC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.8	-0.3	1.53e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7605827	0.897	rs13014906	chr2:15614404	T/C	cg19274914	chr2:15703543	NA	0.39	5.94	0.31	7.43e-9	Educational attainment (years of education);
CRC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.67	0.35	1.08e-10	Heart rate;
CRC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-8.97	-0.44	2.31e-17	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg00745463	chr17:30367425	LRRC37B	-0.44	-5.88	-0.31	9.89e-9	Hip circumference adjusted for BMI;
CRC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.77	-14.67	-0.63	7.87e-38	Body mass index;
CRC	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg07856975	chr6:36356162	ETV7	0.47	5.87	0.31	1.06e-8	Platelet distribution width;
CRC	cis	rs747650	0.892	rs7111764	chr11:47233209	G/A	cg03339077	chr11:47165057	C11orf49	0.45	6.37	0.33	6.55e-10	Acne (severe);
CRC	cis	rs6743376	0.556	rs1530553	chr2:113818171	G/A	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.43	-6.11	-0.32	2.86e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.72	9.54	0.47	3.38e-19	Cleft lip with or without cleft palate;
CRC	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg12963866	chr19:57752005	ZNF805	-0.41	-6.09	-0.32	3.15e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.06e-22	Corneal astigmatism;
CRC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg02428538	chr16:24856791	SLC5A11	0.55	6.6	0.34	1.68e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.55	9.2	0.45	4.2e-18	Systemic lupus erythematosus;
CRC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg14979609	chr8:8086686	FLJ10661	-0.35	-5.89	-0.31	9.71e-9	Mood instability;
CRC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.46	7.02	0.36	1.29e-11	Menopause (age at onset);
CRC	trans	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.66	8.76	0.43	1.09e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.36	-0.33	6.72e-10	Life satisfaction;
CRC	cis	rs7487075	0.786	rs7965629	chr12:46675066	G/C	cg22049899	chr12:47219821	SLC38A4	0.32	5.77	0.3	1.84e-8	Itch intensity from mosquito bite;
CRC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.52	-7.91	-0.4	3.94e-14	Lymphocyte counts;
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs539514	0.690	rs2328953	chr13:76317459	T/G	cg04757411	chr13:76259545	LMO7	-0.34	-5.7	-0.3	2.67e-8	Type 1 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22776125	chr6:167041314	RPS6KA2	0.51	6.69	0.35	9.75e-11	Thyroid stimulating hormone;
CRC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.36	5.62	0.3	4.02e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2737618	0.674	rs2737683	chr1:200092448	G/A	cg21825944	chr1:200113062	NR5A2	-0.5	-7.36	-0.38	1.45e-12	Uric acid levels;
CRC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg05044414	chr3:183734942	ABCC5	0.48	8.29	0.42	3.02e-15	Anterior chamber depth;
CRC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.68	9.58	0.47	2.55e-19	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.5	5.78	0.3	1.75e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg18876405	chr7:65276391	NA	0.46	6.44	0.33	4.29e-10	Aortic root size;
CRC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg06882758	chr19:58662330	ZNF329	0.77	8.08	0.41	1.24e-14	Cholesterol, total;
CRC	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.32	0.42	2.41e-15	Corneal astigmatism;
CRC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.56	8.47	0.42	8.43e-16	Calcium levels;
CRC	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg08999081	chr20:33150536	PIGU	0.46	5.73	0.3	2.24e-8	Neuroticism;
CRC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.59	7.32	0.37	1.94e-12	Obesity (extreme);
CRC	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg11861562	chr11:117069780	TAGLN	0.32	6.13	0.32	2.5e-9	Blood protein levels;
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.71	-13.09	-0.59	8.66e-32	Bipolar disorder;
CRC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.36	5.81	0.31	1.47e-8	Total body bone mineral density;
CRC	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.53	-7.93	-0.4	3.55e-14	Blood protein levels;
CRC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.65	-0.47	1.46e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.86	0.44	4.97e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	9.63	0.47	1.68e-19	Mood instability;
CRC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.96	13.35	0.59	8.56e-33	Breast cancer;
CRC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.72	0.35	8.23e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.37	5.7	0.3	2.7e-8	Electroencephalogram traits;
CRC	trans	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.27	-0.37	2.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs883565	0.606	rs6763607	chr3:39091596	C/G	cg01426195	chr3:39028469	NA	-0.47	-8.01	-0.4	2e-14	Handedness;
CRC	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.73	13.3	0.59	1.33e-32	Hip circumference;
CRC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.5	7.31	0.37	2.05e-12	Lymphocyte counts;
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.53	-7.1	-0.36	7.53e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.43	-8.49	-0.42	7.13e-16	Alcohol dependence;
CRC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg01518246	chr11:63870912	FLRT1;MACROD1	0.44	6.09	0.32	3.17e-9	Mean platelet volume;
CRC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg20203395	chr5:56204925	C5orf35	-0.55	-7.46	-0.38	7.64e-13	Coronary artery disease;
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.95	-0.44	2.62e-17	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.37	0.46	1.21e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.05	-0.32	4.02e-9	Cognitive function;
CRC	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.4e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.73	-8.07	-0.41	1.33e-14	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg20203395	chr5:56204925	C5orf35	-0.59	-6.9	-0.36	2.63e-11	Initial pursuit acceleration;
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.91	0.44	3.61e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.52	-0.46	4e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.54	7.8	0.4	8.32e-14	Birth weight;
CRC	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg09873164	chr1:152488093	CRCT1	-0.35	-6.0	-0.31	5.22e-9	Hair morphology;
CRC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg19318889	chr4:1322082	MAEA	0.46	6.83	0.35	4.18e-11	Longevity;
CRC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.91	11.2	0.53	6.77e-25	Tuberculosis;
CRC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.47	5.9	0.31	9.21e-9	Aortic root size;
CRC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.47	-6.24	-0.33	1.37e-9	Carotid intima media thickness;
CRC	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.48	6.59	0.34	1.77e-10	Response to antidepressants and depression;
CRC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.5	-8.31	-0.42	2.49e-15	Aortic root size;
CRC	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg12218747	chr21:37451666	NA	-0.38	-6.3	-0.33	9.37e-10	Mitral valve prolapse;
CRC	cis	rs7932354	0.537	rs2290884	chr11:46890388	C/G	cg19486271	chr11:47235900	DDB2	-0.41	-6.39	-0.33	5.67e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.94	16.26	0.67	4.86e-44	Cognitive ability;
CRC	cis	rs2227564	0.649	rs2242258	chr10:75607168	T/C	cg00564723	chr10:75632066	CAMK2G	0.36	8.63	0.43	2.72e-16	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.95	-12.37	-0.56	4.11e-29	Exhaled nitric oxide output;
CRC	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.31	0.37	2.05e-12	Lung cancer;
CRC	cis	rs4780401	0.933	rs1592572	chr16:11810382	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.61	-0.3	4.4e-8	Rheumatoid arthritis;
CRC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.97	0.4	2.71e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00495681	chr13:53174319	NA	0.57	8.15	0.41	7.67e-15	Lewy body disease;
CRC	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg06818126	chr11:68850279	TPCN2	-0.52	-7.35	-0.38	1.58e-12	Hair color;
CRC	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.87	-16.83	-0.68	2.79e-46	Hip circumference;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19683962	chr4:108852534	CYP2U1	0.37	6.16	0.32	2.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.68	8.55	0.43	4.71e-16	Skin colour saturation;
CRC	trans	rs2303319	0.504	rs12467279	chr2:162544744	A/G	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.55e-9	Cognitive function;
CRC	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg05540913	chr6:167530185	CCR6	-0.38	-6.99	-0.36	1.54e-11	Primary biliary cholangitis;
CRC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.4	-5.82	-0.31	1.4e-8	Aortic root size;
CRC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.34e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg06204229	chr3:52865917	ITIH4	0.58	7.91	0.4	3.9e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.79	-11.73	-0.54	8.56e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.43	-6.18	-0.32	1.88e-9	Blood pressure (smoking interaction);
CRC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.46	-6.83	-0.35	4e-11	Menarche (age at onset);
CRC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.93	13.93	0.61	5.22e-35	Systemic lupus erythematosus;
CRC	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00495681	chr13:53174319	NA	0.55	8.04	0.41	1.64e-14	Lewy body disease;
CRC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.97	21.36	0.76	3.91e-64	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.19	0.56	1.93e-28	Exhaled nitric oxide levels;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.42	1.07e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.29	0.56	7.65e-29	Menopause (age at onset);
CRC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.21	-0.41	5.15e-15	Hip circumference adjusted for BMI;
CRC	cis	rs9462846	0.919	rs12202901	chr6:42828550	A/T	cg02353165	chr6:42928485	GNMT	0.45	5.92	0.31	8.1e-9	Blood protein levels;
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg21620606	chr4:1342894	KIAA1530	0.37	5.69	0.3	2.75e-8	Longevity;
CRC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.39	5.86	0.31	1.1e-8	Schizophrenia;
CRC	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg25547332	chr5:131281432	NA	0.39	5.68	0.3	2.93e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs728616	0.764	rs56196124	chr10:81902655	A/T	cg18543242	chr14:23290393	SLC7A7	0.45	6.01	0.31	4.96e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs7142881	0.662	rs12885598	chr14:32071665	G/A	cg07250515	chr12:56618133	OBFC2B	-0.39	-6.1	-0.32	3.01e-9	Response to iloperidone treatment (QT prolongation);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13995117	chr16:1402058	GNPTG;C16orf42	0.46	6.36	0.33	6.85e-10	Anxiety disorder;
CRC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.55	8.82	0.44	6.79e-17	Intelligence (multi-trait analysis);
CRC	cis	rs62432291	0.681	rs402388	chr6:159654994	A/C	cg14500486	chr6:159655392	FNDC1	-0.76	-10.4	-0.5	4.17e-22	Joint mobility (Beighton score);
CRC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg21132104	chr15:45694354	SPATA5L1	0.4	5.83	0.31	1.33e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19447636	chr7:126894250	NA	0.47	6.72	0.35	7.89e-11	Intelligence (multi-trait analysis);
CRC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.57	7.54	0.38	4.59e-13	Mean platelet volume;
CRC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.38e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs62432291	0.681	rs404461	chr6:159640709	T/C	cg14500486	chr6:159655392	FNDC1	0.75	10.13	0.49	3.54e-21	Joint mobility (Beighton score);
CRC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.14	0.32	2.32e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.98	0.55	1.05e-27	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4664293	0.867	rs11681565	chr2:160616873	C/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.4	0.46	9.6e-19	Height;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg06470822	chr6:28175283	NA	0.77	10.5	0.5	1.99e-22	Parkinson's disease;
CRC	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg03013999	chr17:37608204	MED1	-0.49	-7.1	-0.36	7.8e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.44	0.38	8.95e-13	Eye color traits;
CRC	cis	rs17155006	0.664	rs440938	chr7:107741092	C/G	cg05962710	chr7:107745446	LAMB4	-0.43	-7.57	-0.39	3.74e-13	Pneumococcal bacteremia;
CRC	trans	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.82	-0.35	4.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg27534772	chr1:16042836	PLEKHM2	0.51	8.95	0.44	2.69e-17	Systolic blood pressure;
CRC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.52	-8.02	-0.4	1.83e-14	Body mass index;
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg16060761	chr17:80687452	NA	-0.45	-5.8	-0.3	1.52e-8	Glycated hemoglobin levels;
CRC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.5	8.23	0.41	4.35e-15	Coronary artery disease;
CRC	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg09218773	chr11:619014	MUPCDH	-0.35	-5.65	-0.3	3.51e-8	Systemic lupus erythematosus;
CRC	cis	rs10979	0.562	rs9399446	chr6:143874639	G/C	cg25407410	chr6:143891975	LOC285740	-0.51	-7.22	-0.37	3.69e-12	Hypospadias;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.46	-6.55	-0.34	2.18e-10	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12172441	chr6:28176163	NA	0.63	7.42	0.38	1.02e-12	Depression;
CRC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.1	0.32	3.01e-9	Menopause (age at onset);
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.02	0.32	4.62e-9	Bipolar disorder;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18758796	chr5:131593413	PDLIM4	-0.5	-9.25	-0.45	2.94e-18	Acylcarnitine levels;
CRC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg16102536	chr7:156981717	UBE3C	-0.41	-6.91	-0.36	2.55e-11	Body mass index;
CRC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.85e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.03	-0.32	4.35e-9	Heart rate;
CRC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.31	-6.91	-0.36	2.47e-11	IgG glycosylation;
CRC	trans	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg26043149	chr18:55253948	FECH	0.55	8.29	0.42	2.92e-15	Bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07886860	chr3:40566285	ZNF621	0.45	6.2	0.32	1.73e-9	Anxiety disorder;
CRC	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg10483660	chr13:112241077	NA	0.36	5.82	0.31	1.39e-8	Menarche (age at onset);
CRC	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.75	10.29	0.49	9.9e-22	Coronary artery disease;
CRC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.45	-6.71	-0.35	8.73e-11	Coronary artery disease;
CRC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.93	14.1	0.61	1.23e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.54	-6.7	-0.35	8.85e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.43	5.92	0.31	8.12e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg19683494	chr5:74908142	NA	0.5	6.36	0.33	6.94e-10	Age-related disease endophenotypes;
CRC	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg23100626	chr2:96804247	ASTL	0.32	8.74	0.43	1.24e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.57	-8.06	-0.41	1.43e-14	Rheumatoid arthritis;
CRC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-0.93	-16.5	-0.67	5.24e-45	Height;
CRC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.47	0.75	1.25e-60	Headache;
CRC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.46	-5.84	-0.31	1.24e-8	Menopause (age at onset);
CRC	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg01388757	chr2:102091195	RFX8	0.65	8.7	0.43	1.61e-16	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs73206853	0.610	rs73194020	chr12:111131366	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	6.07	0.32	3.62e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.29	-0.71	4.59e-52	Height;
CRC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg15123519	chr2:136567270	LCT	0.3	5.65	0.3	3.53e-8	Mosquito bite size;
CRC	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.42	5.92	0.31	8.02e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg16540259	chr10:75572220	NDST2	0.37	5.88	0.31	1.03e-8	Inflammatory bowel disease;
CRC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.5	6.78	0.35	5.47e-11	Total body bone mineral density;
CRC	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg15147215	chr3:52552868	STAB1	0.43	6.98	0.36	1.59e-11	Body mass index;
CRC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.63	9.17	0.45	5.28e-18	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6479527	0.840	rs1590969	chr9:96756436	G/T	cg14459158	chr9:96720562	NA	0.41	7.64	0.39	2.36e-13	Esophageal adenocarcinoma;
CRC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg00343986	chr7:65444356	GUSB	0.43	6.21	0.32	1.61e-9	Aortic root size;
CRC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg20790798	chr5:1857306	NA	-0.45	-6.95	-0.36	1.96e-11	Cardiovascular disease risk factors;
CRC	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	0.97	17.92	0.7	1.37e-50	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg02527881	chr3:46936655	PTH1R	-0.34	-5.91	-0.31	8.74e-9	Colorectal cancer;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg15845792	chr6:28175446	NA	0.65	9.78	0.47	5.56e-20	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.12	-0.32	2.72e-9	Neuroticism;
CRC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15171982	chr2:183903302	NCKAP1	0.46	7.88	0.4	4.78e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs7626444	0.625	rs7638090	chr3:196476836	A/G	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	cis	rs12580194	0.958	rs7974512	chr12:55713606	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-7.54	-0.38	4.53e-13	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10332296	chr1:42928798	NA	0.49	6.97	0.36	1.71e-11	Response to antipsychotic treatment;
CRC	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.61	-8.59	-0.43	3.52e-16	Coronary artery disease;
CRC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.56	6.3	0.33	9.81e-10	Vitiligo;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg02683197	chr6:28174875	NA	0.86	10.64	0.51	6.2e-23	Depression;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg05535760	chr7:792225	HEATR2	-0.44	-5.78	-0.3	1.73e-8	Perceived unattractiveness to mosquitoes;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg24671245	chr10:76585406	MYST4	0.58	6.44	0.33	4.36e-10	Body mass index;
CRC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.44	-5.89	-0.31	9.43e-9	Gut microbiome composition (summer);
CRC	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg05935833	chr10:81318306	SFTPA2	-0.73	-7.99	-0.4	2.28e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	6.02	0.31	4.7e-9	Homoarginine levels;
CRC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.68	-11.42	-0.53	1.18e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08722720	chr15:34331557	AVEN;CHRM5	0.49	7.26	0.37	2.9e-12	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg03037974	chr15:76606532	NA	-0.51	-7.16	-0.37	5.14e-12	Blood metabolite levels;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg03623178	chr6:28175578	NA	0.87	12.53	0.57	1.06e-29	Parkinson's disease;
CRC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.68	10.2	0.49	2.03e-21	Corneal astigmatism;
CRC	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.46	7.07	0.36	9.55e-12	HDL cholesterol;
CRC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg22777020	chr22:31556080	RNF185	-0.51	-5.86	-0.31	1.15e-8	Colorectal cancer;
CRC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg07636037	chr3:49044803	WDR6	0.58	6.16	0.32	2.07e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24375607	chr4:120327624	NA	0.42	6.49	0.34	3.2e-10	Corneal astigmatism;
CRC	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	8.16	0.41	7.36e-15	Exhaled nitric oxide output;
CRC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg02135003	chr7:105160482	PUS7	0.86	12.08	0.55	4.74e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.41	7.83	0.4	6.66e-14	Ulcerative colitis;
CRC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg10978503	chr1:24200527	CNR2	0.62	11.22	0.53	6.02e-25	Immature fraction of reticulocytes;
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg05569086	chr8:143859399	LYNX1	0.38	6.61	0.34	1.58e-10	Urinary tract infection frequency;
CRC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	9.14	0.45	6.81e-18	Lymphocyte counts;
CRC	cis	rs1223397	0.651	rs2458309	chr6:13312086	G/A	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.51	6.68	0.35	1.01e-10	Alzheimer's disease (survival time);
CRC	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-7.49	-0.38	6.55e-13	Self-reported allergy;
CRC	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-17.37	-0.69	2.07e-48	Body mass index in non-asthmatics;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg26043149	chr18:55253948	FECH	0.52	8.11	0.41	9.94e-15	Bone mineral density;
CRC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	7.03	0.36	1.21e-11	Mean platelet volume;
CRC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg24375607	chr4:120327624	NA	0.49	7.34	0.38	1.67e-12	Corneal astigmatism;
CRC	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.67	0.47	1.21e-19	Corneal astigmatism;
CRC	cis	rs10484885	0.553	rs2182864	chr6:90235552	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.54	-6.07	-0.32	3.43e-9	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.59	10.88	0.51	9.05e-24	Total body bone mineral density;
CRC	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-8.73	-0.43	1.32e-16	IgG glycosylation;
CRC	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.82	0.31	1.39e-8	Ovarian reserve;
CRC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.8	-12.53	-0.57	1.05e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13333054	0.950	rs68143182	chr16:86005838	C/T	cg04454285	chr16:86016317	NA	0.76	10.76	0.51	2.48e-23	Multiple sclerosis;
CRC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.75	-0.3	2.05e-8	Morning vs. evening chronotype;
CRC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.61	8.8	0.44	7.89e-17	Lymphocyte counts;
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.41	5.96	0.31	6.45e-9	Longevity;Endometriosis;
CRC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.04	0.32	4.17e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	6.92	0.36	2.33e-11	Schizophrenia;
CRC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Body mass index;
CRC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.03	-0.32	4.34e-9	Triglycerides;
CRC	cis	rs3857067	1.000	rs1588382	chr4:95017589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	trans	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg00419564	chr1:153508860	S100A6	0.47	6.1	0.32	2.93e-9	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23729963	chr8:94753249	RBM12B	0.43	6.23	0.32	1.45e-9	Response to antipsychotic treatment;
CRC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.24	5.61	0.3	4.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.79	-0.35	5.2e-11	Aortic root size;
CRC	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.45	-6.06	-0.32	3.81e-9	Height;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.41	-6.2	-0.32	1.66e-9	Lymphocyte counts;
CRC	cis	rs16852403	0.519	rs421767	chr1:178096922	C/T	cg00404053	chr1:178313656	RASAL2	-0.49	-6.58	-0.34	1.87e-10	Childhood ear infection;
CRC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17507749	chr15:85114479	UBE2QP1	0.66	8.77	0.44	9.86e-17	Schizophrenia;
CRC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg11326919	chr17:43324904	LOC100133991	-0.65	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg09877947	chr5:131593287	PDLIM4	-0.45	-7.33	-0.37	1.79e-12	Breast cancer;
CRC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg03060546	chr3:49711283	APEH	0.44	6.38	0.33	5.97e-10	Menarche (age at onset);
CRC	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.8	-0.3	1.57e-8	Alzheimer's disease (survival time);
CRC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.41	5.71	0.3	2.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	15.39	0.65	1.24e-40	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-8.73	-0.43	1.29e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12143943	0.966	rs3747632	chr1:204587240	G/A	cg17419461	chr1:204415978	PIK3C2B	0.42	6.34	0.33	7.51e-10	Cognitive performance;
CRC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.33	-0.33	8.11e-10	Diabetic kidney disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20552752	chr15:90895281	ZNF774	-0.4	-6.02	-0.31	4.63e-9	Daytime sleep phenotypes;
CRC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.54	-0.34	2.39e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.86e-9	Diabetic kidney disease;
CRC	cis	rs4926298	1.000	rs8104231	chr19:13159569	A/T	cg23899408	chr19:12877188	HOOK2	-0.45	-6.26	-0.33	1.21e-9	Bipolar disorder;
CRC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.94	13.66	0.6	6.02e-34	Breast cancer;
CRC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.39	6.51	0.34	2.76e-10	Alopecia areata;
CRC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg06287003	chr12:125626642	AACS	0.55	7.28	0.37	2.5e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.59	8.6	0.43	3.41e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.81	0.48	4.12e-20	Bladder cancer;
CRC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.09	-0.36	8.23e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-11.82	-0.55	3.99e-27	Monocyte percentage of white cells;
CRC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.49	5.9	0.31	9.16e-9	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg24560729	chr4:1342394	KIAA1530	0.44	7.45	0.38	8.23e-13	Obesity-related traits;
CRC	cis	rs9491140	1.000	rs12192208	chr6:124693764	C/A	cg22366943	chr6:124882293	NKAIN2	0.35	5.64	0.3	3.71e-8	Neuroticism;
CRC	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg12856521	chr11:46389249	DGKZ	0.41	6.77	0.35	6.03e-11	Leprosy;
CRC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-15.34	-0.65	1.99e-40	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg09876464	chr15:85330779	ZNF592	0.46	8.06	0.41	1.38e-14	P wave terminal force;
CRC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.73	-11.84	-0.55	3.64e-27	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4676482	0.541	rs17735402	chr3:39205176	C/T	cg02254461	chr3:39195904	CSRNP1	0.68	7.27	0.37	2.7e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg16576597	chr16:28551801	NUPR1	0.46	6.96	0.36	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.19	0.45	4.44e-18	Bladder cancer;
CRC	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.72	0.35	7.82e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-1.04	-13.68	-0.6	4.68e-34	Bronchopulmonary dysplasia;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.56e-19	Depression;
CRC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.68	-11.65	-0.54	1.64e-26	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1256061	0.603	rs928554	chr14:64694195	C/T	cg23250157	chr14:64679961	SYNE2	0.48	7.44	0.38	8.79e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.62	9.66	0.47	1.37e-19	Corneal astigmatism;
CRC	cis	rs17067123	0.614	rs35522192	chr4:180064376	C/A	cg26610307	chr4:180072759	NA	-0.55	-6.57	-0.34	1.97e-10	Response to hepatitis C treatment;
CRC	cis	rs6504950	0.745	rs12603899	chr17:53010098	T/C	cg26251398	chr17:52985966	TOM1L1	0.37	5.69	0.3	2.8e-8	Breast cancer;
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg10217327	chr6:118973057	C6orf204	0.51	5.86	0.31	1.12e-8	Diastolic blood pressure;
CRC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.57	7.46	0.38	7.56e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg19338460	chr6:170058176	WDR27	-1.24	-10.25	-0.49	1.46e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.21	-0.32	1.62e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.99	-0.31	5.54e-9	Bladder cancer;
CRC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg21251018	chr6:28226885	NKAPL	0.41	6.26	0.33	1.19e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg20307385	chr11:47447363	PSMC3	0.47	5.8	0.3	1.52e-8	Migraine - clinic-based;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg08798685	chr6:27730294	NA	-0.62	-6.06	-0.32	3.82e-9	Breast cancer;
CRC	cis	rs4073416	0.518	rs7141536	chr14:65987312	T/A	cg03016385	chr14:66212404	NA	-0.44	-6.1	-0.32	2.93e-9	N-glycan levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26366360	chr17:79895491	PYCR1	0.43	6.2	0.32	1.71e-9	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.67	-11.43	-0.53	1.05e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg25164649	chr6:28176230	NA	0.61	7.68	0.39	1.87e-13	Parkinson's disease;
CRC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.56	-0.34	2.11e-10	Aortic root size;
CRC	cis	rs9534288	0.577	rs2897029	chr13:46682821	T/C	cg15192986	chr13:46630673	CPB2	-0.58	-7.65	-0.39	2.22e-13	Blood protein levels;
CRC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg05995172	chr11:57434667	ZDHHC5	-0.51	-6.01	-0.31	4.82e-9	Type 1 diabetes;
CRC	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.86	-0.48	2.81e-20	Blood protein levels;
CRC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg26850624	chr5:429559	AHRR	-0.73	-9.57	-0.47	2.68e-19	Cystic fibrosis severity;
CRC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-8.25	-0.41	3.91e-15	Type 2 diabetes;
CRC	cis	rs3106136	0.901	rs17376488	chr4:95226548	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.36	1.33e-11	Capecitabine sensitivity;
CRC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.63	8.73	0.43	1.31e-16	Coronary artery disease;
CRC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	8.3	0.42	2.65e-15	Lymphocyte counts;
CRC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.59	-8.56	-0.43	4.45e-16	Menarche (age at onset);
CRC	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.48	-8.18	-0.41	6.12e-15	Response to cytidine analogues (gemcitabine);
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24426209	chr7:92157939	PEX1;C7orf64	-0.38	-6.44	-0.33	4.2e-10	Obesity-related traits;
CRC	trans	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	6.44	0.33	4.15e-10	Mean corpuscular volume;
CRC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.47	6.78	0.35	5.53e-11	Colorectal cancer;
CRC	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.85	-0.31	1.18e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.01	-0.31	4.92e-9	Life satisfaction;
CRC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg10911889	chr6:126070802	HEY2	0.39	5.94	0.31	7.2e-9	Brugada syndrome;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.42	1.07e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6681460	1.000	rs1562217	chr1:67073566	C/T	cg02459107	chr1:67143332	SGIP1	-0.45	-7.8	-0.4	8.06e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.25	-0.33	1.29e-9	Tonsillectomy;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg14830952	chr8:86089500	E2F5	-0.41	-6.27	-0.33	1.14e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg16358738	chr2:241808595	AGXT	-0.39	-6.73	-0.35	7.43e-11	Urinary metabolites;
CRC	cis	rs11212617	0.934	rs10890834	chr11:108286443	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.34	0.33	7.39e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.56	-9.86	-0.48	2.97e-20	Huntington's disease progression;
CRC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.57	0.34	1.99e-10	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg25482853	chr8:67687455	SGK3	1.16	13.2	0.59	3.15e-32	Obesity-related traits;
CRC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg22495460	chr2:25135724	ADCY3	0.84	15.85	0.66	2e-42	Body mass index;
CRC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25517755	chr10:38738941	LOC399744	-0.4	-5.62	-0.3	4.01e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.86e-12	Major depressive disorder;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.4	6.17	0.32	2.03e-9	Electroencephalogram traits;
CRC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.42	7.34	0.37	1.73e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.76	10.05	0.48	6.73e-21	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.65	-0.43	2.35e-16	Bipolar disorder;
CRC	cis	rs12143943	0.966	rs12135707	chr1:204556223	C/T	cg17419461	chr1:204415978	PIK3C2B	0.42	6.35	0.33	7.03e-10	Cognitive performance;
CRC	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.5	-7.47	-0.38	7.38e-13	Schizophrenia;
CRC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.64	9.83	0.48	3.73e-20	Birth weight;
CRC	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.65	9.13	0.45	6.87e-18	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.43	6.89	0.35	2.93e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg15845792	chr6:28175446	NA	0.77	11.44	0.53	9.43e-26	Parkinson's disease;
CRC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	10.21	0.49	1.89e-21	Schizophrenia;
CRC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.74	-8.22	-0.41	4.9e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7635838	0.892	rs9874535	chr3:11463730	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.24	0.33	1.32e-9	HDL cholesterol;
CRC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg13798780	chr7:105162888	PUS7	0.68	8.05	0.41	1.55e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs243505	0.691	rs243483	chr7:148449163	A/G	cg09806900	chr7:148480153	CUL1	-0.59	-7.39	-0.38	1.23e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-5.86	-0.31	1.12e-8	Metabolite levels;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.42	-8.75	-0.43	1.14e-16	Bipolar disorder;
CRC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.37	-6.15	-0.32	2.22e-9	Blood metabolite levels;
CRC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg21523564	chr15:75251491	NA	0.41	6.07	0.32	3.48e-9	Breast cancer;
CRC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	1.01	8.46	0.42	8.84e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg24058013	chr18:77568902	NA	-0.44	-6.96	-0.36	1.83e-11	Schizophrenia;
CRC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg12856521	chr11:46389249	DGKZ	-0.42	-6.63	-0.34	1.41e-10	Leprosy;
CRC	cis	rs737337	0.623	rs3826815	chr19:11332505	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.8	8.84	0.44	5.7e-17	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.25	-0.45	2.91e-18	Metabolite levels;
CRC	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg17145862	chr1:211918768	LPGAT1	0.59	10.1	0.49	4.48e-21	Leprosy;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.34	0.62	1.44e-36	Mean platelet volume;
CRC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03605463	chr16:89740564	NA	0.42	6.06	0.32	3.72e-9	Vitiligo;
CRC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.26	-0.73	6.71e-56	Height;
CRC	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.41	-5.81	-0.3	1.51e-8	Height;
CRC	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.68	8.63	0.43	2.72e-16	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16458507	chr12:113376293	OAS3	0.41	6.72	0.35	8.06e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24677501	chr11:64008407	FKBP2	0.46	6.54	0.34	2.38e-10	Response to antipsychotic treatment;
CRC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg11843238	chr5:131593191	PDLIM4	-0.33	-6.08	-0.32	3.42e-9	Blood metabolite levels;
CRC	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg13385794	chr1:248469461	NA	0.39	6.7	0.35	9.32e-11	Common traits (Other);
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg20041105	chr8:143859282	LYNX1	-0.43	-6.69	-0.35	9.5e-11	Urinary tract infection frequency;
CRC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-19.54	-0.73	5.49e-57	Height;
CRC	cis	rs13144136	0.775	rs13136927	chr4:10669522	A/C	cg10242279	chr4:10666415	CLNK	-0.33	-5.62	-0.3	3.98e-8	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.6	-8.93	-0.44	3.13e-17	Aortic root size;
CRC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.58	9.34	0.46	1.45e-18	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg11292332	chr7:45801988	SEPT13	-0.38	-7.02	-0.36	1.26e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg13482628	chr17:19912719	NA	-0.4	-6.19	-0.32	1.75e-9	Obesity-related traits;
CRC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.41	5.72	0.3	2.34e-8	Aortic root size;
CRC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.21	-0.37	3.87e-12	Self-reported allergy;
CRC	cis	rs747650	0.504	rs11601798	chr11:47158392	A/G	cg19486271	chr11:47235900	DDB2	0.45	5.97	0.31	6.24e-9	Acne (severe);
CRC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.87	0.55	2.69e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.37	5.71	0.3	2.47e-8	Height;
CRC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	5.7	0.3	2.61e-8	Mean platelet volume;
CRC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg23463467	chr20:60627584	TAF4	0.33	5.79	0.3	1.61e-8	Body mass index;
CRC	cis	rs6681460	1.000	rs9662943	chr1:67121132	A/G	cg02459107	chr1:67143332	SGIP1	-0.46	-7.59	-0.39	3.27e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	10.75	0.51	2.73e-23	Menarche (age at onset);
CRC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-9.21	-0.45	4.06e-18	Initial pursuit acceleration;
CRC	cis	rs6142102	0.961	rs8119937	chr20:32645551	C/T	cg08999081	chr20:33150536	PIGU	0.39	6.11	0.32	2.77e-9	Skin pigmentation;
CRC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.69	-0.3	2.75e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	trans	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg00953403	chr17:74099816	EXOC7	-0.48	-7.28	-0.37	2.53e-12	Psychosis in Alzheimer's disease;
CRC	trans	rs17444059	0.925	rs17528473	chr5:58559042	C/T	cg01818579	chr20:55982315	RBM38	-0.54	-5.97	-0.31	6.29e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.72	9.39	0.46	1.05e-18	Initial pursuit acceleration;
CRC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg00339695	chr16:24857497	SLC5A11	0.26	6.16	0.32	2.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg25876840	chr17:41920477	NA	0.41	6.46	0.34	3.83e-10	Triglycerides;
CRC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.41	-6.17	-0.32	1.99e-9	Monocyte count;
CRC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.89	-0.31	9.79e-9	Bipolar disorder;
CRC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.46	-6.45	-0.33	4.08e-10	DNA methylation (variation);
CRC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.73	8.14	0.41	8.46e-15	Vitiligo;
CRC	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.46	-6.5	-0.34	2.96e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg08533674	chr1:46993347	NA	-0.78	-10.48	-0.5	2.36e-22	Monobrow;
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg08222913	chr3:52553049	STAB1	0.33	6.14	0.32	2.39e-9	Bipolar disorder;
CRC	cis	rs1564271	1.000	rs1197422	chr10:27012078	A/G	cg13837822	chr10:26931731	LOC731789	0.47	6.5	0.34	2.9e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs6546324	0.625	rs6546325	chr2:67861901	C/A	cg15745817	chr2:67799979	NA	-0.55	-9.56	-0.47	2.8e-19	Endometriosis;
CRC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.68e-19	Corneal astigmatism;
CRC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.72	-7.86	-0.4	5.63e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.53	-8.41	-0.42	1.23e-15	Corneal astigmatism;
CRC	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.6	-9.08	-0.45	1.04e-17	Cancer;
CRC	cis	rs9326248	0.530	rs1242229	chr11:117062370	A/G	cg26566898	chr11:117069891	TAGLN	0.4	5.65	0.3	3.53e-8	Blood protein levels;
CRC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.87	10.5	0.5	2e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-7.09	-0.36	8.05e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25517755	chr10:38738941	LOC399744	0.41	5.91	0.31	8.44e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.61	9.45	0.46	6.66e-19	Aortic root size;
CRC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.52	7.0	0.36	1.4e-11	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg18833306	chr6:118973337	C6orf204	0.44	5.64	0.3	3.68e-8	Diastolic blood pressure;
CRC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.77	-13.72	-0.6	3.43e-34	Breast cancer;
CRC	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	trans	rs12495832	0.841	rs76286406	chr3:147898445	T/C	cg10221266	chr7:153579447	NA	0.55	6.06	0.32	3.81e-9	Chin dimples;
CRC	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg11693508	chr17:37793320	STARD3	0.62	7.08	0.36	8.79e-12	Neuroticism;
CRC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.59	-11.77	-0.54	6.37e-27	Asthma (sex interaction);
CRC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg14074117	chr16:1909714	C16orf73	-0.46	-6.55	-0.34	2.23e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs12476592	0.714	rs262491	chr2:63841113	A/G	cg10828910	chr2:63850056	LOC388955	0.56	6.84	0.35	3.86e-11	Childhood ear infection;
CRC	cis	rs4660531	0.890	rs61229336	chr1:41834935	C/T	cg19619003	chr1:41846758	NA	-0.38	-5.75	-0.3	2.09e-8	Bipolar disorder;
CRC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.72	11.27	0.53	3.82e-25	Cognitive ability;
CRC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.01	0.31	5.06e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg03623178	chr6:28175578	NA	0.62	9.52	0.46	3.87e-19	Pubertal anthropometrics;
CRC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.63	0.54	2.04e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg15534755	chr11:117069859	TAGLN	0.35	6.78	0.35	5.48e-11	Blood protein levels;
CRC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.75	-0.3	2.04e-8	Bladder cancer;
CRC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg23262073	chr20:60523788	NA	-0.47	-7.26	-0.37	2.87e-12	Body mass index;
CRC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg17346650	chr17:80929145	B3GNTL1	0.34	5.66	0.3	3.28e-8	Breast cancer;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.2	0.32	1.66e-9	Prudent dietary pattern;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.6	-0.34	1.68e-10	Total body bone mineral density;
CRC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg03030879	chr14:75389066	RPS6KL1	0.45	7.17	0.37	5.12e-12	Height;
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.82	-12.66	-0.57	3.39e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.56	0.7	3.65e-49	Platelet count;
CRC	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg12292205	chr6:26970375	C6orf41	-0.51	-6.46	-0.34	3.85e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11650494	0.710	rs73987294	chr17:47474730	T/C	cg08112188	chr17:47440006	ZNF652	0.69	6.28	0.33	1.05e-9	Prostate cancer;
CRC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.39	7.06	0.36	1.02e-11	Colorectal cancer;
CRC	trans	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg17712092	chr4:129076599	LARP1B	0.45	6.13	0.32	2.47e-9	Breast cancer;
CRC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.78	-11.93	-0.55	1.63e-27	Cognitive function;
CRC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.68	-10.66	-0.51	5.47e-23	Huntington's disease progression;
CRC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16447950	chr5:562315	NA	-0.7	-10.02	-0.48	8.41e-21	Obesity-related traits;
CRC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.4	-0.46	9.56e-19	Body mass index;
CRC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.85	8.57	0.43	4.15e-16	Cognitive function;
CRC	cis	rs929596	0.564	rs2741027	chr2:234518011	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.7	-0.3	2.62e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg02574844	chr11:5959923	NA	-0.44	-6.15	-0.32	2.25e-9	DNA methylation (variation);
CRC	cis	rs7737355	0.812	rs4705890	chr5:130855000	A/G	cg25547332	chr5:131281432	NA	0.36	5.87	0.31	1.07e-8	Life satisfaction;
CRC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.6	8.43	0.42	1.1e-15	Uric acid levels;
CRC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.59	9.95	0.48	1.51e-20	Prudent dietary pattern;
CRC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.3	-6.5	-0.34	2.98e-10	IgG glycosylation;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05492810	chr11:78129288	GAB2	0.45	6.18	0.32	1.88e-9	Survival in pancreatic cancer;
CRC	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.41	-6.82	-0.35	4.38e-11	Mean arterial pressure;
CRC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.53	-7.45	-0.38	8.23e-13	Longevity;
CRC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg15448220	chr1:150897856	SETDB1	-0.47	-6.73	-0.35	7.53e-11	Tonsillectomy;
CRC	cis	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg08501292	chr6:25962987	TRIM38	-0.94	-8.19	-0.41	5.94e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.48	0.34	3.28e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs889398	0.741	rs7193038	chr16:69926134	T/G	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.81	-0.3	1.49e-8	Body mass index;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.59	9.33	0.46	1.55e-18	Glycated hemoglobin levels;
CRC	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg05393297	chr12:53359155	NA	-1.06	-10.23	-0.49	1.6e-21	Prostate cancer;
CRC	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.81	-0.3	1.49e-8	Height;
CRC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg15147215	chr3:52552868	STAB1	-0.54	-7.88	-0.4	4.89e-14	Bipolar disorder;
CRC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.84	-0.35	3.77e-11	Urate levels in overweight individuals;
CRC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.47	-6.54	-0.34	2.36e-10	Fibrinogen levels;
CRC	cis	rs73200209	0.744	rs17498760	chr12:116636803	C/G	cg01776926	chr12:116560359	MED13L	-0.61	-7.0	-0.36	1.41e-11	Total body bone mineral density;
CRC	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg11547950	chr5:77652471	NA	0.45	6.44	0.33	4.35e-10	Triglycerides;
CRC	cis	rs11209185	0.509	rs12142271	chr1:68446837	A/G	cg22082780	chr1:68452167	NA	0.41	6.17	0.32	2.05e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	7.24	0.37	3.17e-12	Electroencephalogram traits;
CRC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	12.44	0.57	2.21e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs11098699	0.821	rs2099955	chr4:124214160	C/T	cg09941581	chr4:124220074	SPATA5	0.4	5.78	0.3	1.75e-8	Mosquito bite size;
CRC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.34e-9	Major depressive disorder;
CRC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.44	-6.53	-0.34	2.43e-10	Body mass index;
CRC	trans	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg08231274	chr14:57735852	MUDENG;EXOC5	-0.54	-5.98	-0.31	5.74e-9	Longevity (90 years and older);
CRC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.48	-6.36	-0.33	6.68e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg25985355	chr7:65971099	NA	-0.55	-6.23	-0.32	1.41e-9	Diabetic kidney disease;
CRC	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.38	-6.14	-0.32	2.31e-9	Intelligence (multi-trait analysis);Body fat percentage;
CRC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.39	7.22	0.37	3.59e-12	Mean corpuscular volume;
CRC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25517755	chr10:38738941	LOC399744	0.42	5.98	0.31	5.86e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg00587665	chr15:100533223	ADAMTS17	0.46	7.91	0.4	4.03e-14	Height;
CRC	trans	rs783540	0.867	rs11855735	chr15:83296545	A/T	cg18393722	chr15:85113863	UBE2QP1	0.4	7.15	0.37	5.66e-12	Schizophrenia;
CRC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.74	10.29	0.49	1.02e-21	Cognitive function;
CRC	cis	rs7215564	0.730	rs1125587	chr17:78581696	A/G	cg09596252	chr17:78655493	RPTOR	0.62	6.47	0.34	3.64e-10	Myopia (pathological);
CRC	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg01422370	chr2:73384389	NA	0.37	5.83	0.31	1.35e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4664293	0.867	rs7579206	chr2:160572503	A/C	cg08347373	chr2:160653686	CD302	-0.44	-6.9	-0.36	2.63e-11	Monocyte percentage of white cells;
CRC	cis	rs10924970	0.687	rs4433382	chr1:235364993	C/A	cg09010748	chr1:235293032	TOMM20	-0.41	-5.76	-0.3	1.95e-8	Asthma;
CRC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.36	0.38	1.44e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	1.03	20.52	0.75	7.72e-61	Headache;
CRC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.09e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.08	10.84	0.51	1.29e-23	Diabetic retinopathy;
CRC	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg16898833	chr6:26189333	HIST1H4D	0.72	6.45	0.34	4.08e-10	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21536585	chr5:133801528	NA	0.39	6.07	0.32	3.56e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg01666796	chr15:70364327	TLE3	0.48	5.83	0.31	1.33e-8	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs7209700	0.962	rs56327427	chr17:45354746	C/T	cg08085267	chr17:45401833	C17orf57	0.44	6.26	0.33	1.2e-9	IgG glycosylation;
CRC	trans	rs1864729	0.892	rs1821134	chr8:98266824	C/T	cg08679828	chr8:102218111	ZNF706	0.62	7.56	0.38	4.04e-13	Estradiol plasma levels (breast cancer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18784586	chr12:13044401	GPRC5A	0.43	6.2	0.32	1.71e-9	Response to antipsychotic treatment;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20032723	chr11:126174041	DCPS	-0.41	-6.1	-0.32	3.04e-9	Daytime sleep phenotypes;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg23161317	chr6:28129485	ZNF389	0.45	6.5	0.34	3.01e-10	Parkinson's disease;
CRC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.59	9.48	0.46	5.17e-19	Tonsillectomy;
CRC	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs6681460	1.000	rs7521111	chr1:67121634	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.38	0.42	1.54e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs2274273	0.624	rs8005450	chr14:55799165	A/T	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.74	-0.3	2.21e-8	Protein biomarker;
CRC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.57	0.39	3.83e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.18e-13	Motion sickness;
CRC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg19824325	chr16:58548873	SETD6	0.9	6.09	0.32	3.09e-9	Schizophrenia;
CRC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	13.28	0.59	1.6e-32	Cognitive ability;
CRC	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg07978099	chr16:83986941	OSGIN1	0.54	6.55	0.34	2.17e-10	Pursuit maintenance gain;
CRC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.22	0.41	4.66e-15	Arsenic metabolism;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg19913688	chr11:428466	ANO9	-0.7	-7.19	-0.37	4.26e-12	Body mass index;
CRC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-8.14	-0.41	8.37e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.54	-7.56	-0.38	4.07e-13	Body mass index;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.06e-10	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15492422	chr19:2328553	SPPL2B;LSM7	0.43	6.06	0.32	3.7e-9	Anxiety disorder;
CRC	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg04132472	chr17:19861366	AKAP10	0.43	6.66	0.34	1.15e-10	Schizophrenia;
CRC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.67	-10.94	-0.52	5.85e-24	Hepatocellular carcinoma;
CRC	cis	rs305851	0.818	rs1504328	chr6:39753352	G/A	cg02386599	chr6:39769542	DAAM2	0.39	6.16	0.32	2.15e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.68	-11.38	-0.53	1.63e-25	Blood protein levels;
CRC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.89	-0.51	8.94e-24	Total cholesterol levels;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-7.25	-0.37	2.94e-12	Life satisfaction;
CRC	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.75	-0.43	1.12e-16	Coffee consumption (cups per day);
CRC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.94	0.31	7.25e-9	Depression;
CRC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.35	6.41	0.33	5.15e-10	Dupuytren's disease;
CRC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.68	9.8	0.48	4.49e-20	Vitamin D levels;
CRC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	7.61	0.39	2.9e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.39	-7.02	-0.36	1.25e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13959152	chr12:100535986	UHRF1BP1L	0.47	6.1	0.32	3e-9	Thyroid stimulating hormone;
CRC	cis	rs9303280	0.559	rs4795408	chr17:38107627	G/A	cg24910161	chr17:38119198	GSDMA	-0.36	-6.2	-0.32	1.74e-9	Self-reported allergy;
CRC	cis	rs7894051	0.867	rs10466127	chr10:135188519	A/G	cg20534287	chr10:135191450	PAOX	-0.73	-5.91	-0.31	8.32e-9	Lifespan;
CRC	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg00325661	chr8:49890786	NA	0.37	5.78	0.3	1.77e-8	Sudden cardiac arrest;
CRC	cis	rs7259376	0.967	rs808369	chr19:22474282	C/T	cg02657401	chr19:22469223	NA	0.38	8.68	0.43	1.82e-16	Menopause (age at onset);
CRC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.57	-8.2	-0.41	5.57e-15	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01911186	chr12:12765398	CREBL2	0.5	6.58	0.34	1.88e-10	Thyroid stimulating hormone;
CRC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.85	0.35	3.62e-11	Morning vs. evening chronotype;
CRC	cis	rs6585424	1.000	rs34749786	chr10:81924390	C/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.45	-0.38	8.41e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs17443541	0.507	rs10196195	chr2:200456620	C/T	cg03741458	chr2:200468445	NA	-0.36	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.1	7.42	0.38	9.96e-13	Age-related hearing impairment;
CRC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg00343986	chr7:65444356	GUSB	-0.5	-7.43	-0.38	9.64e-13	Aortic root size;
CRC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.86	16.5	0.67	5.46e-45	White blood cell count;
CRC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-6.2	-0.32	1.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.73	-0.35	7.47e-11	Multiple sclerosis;
CRC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.06	-0.32	3.74e-9	Bladder cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03613717	chr10:121356708	TIAL1	0.51	6.59	0.34	1.8e-10	Thyroid stimulating hormone;
CRC	cis	rs1887596	0.705	rs9553874	chr13:27189883	C/T	cg01312412	chr13:27282625	NA	0.45	5.93	0.31	7.54e-9	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.38	-5.82	-0.31	1.37e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.39	-6.84	-0.35	3.78e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9434723	0.920	rs2239560	chr1:9304731	C/T	cg04199779	chr1:9294473	H6PD	0.48	5.75	0.3	2.04e-8	Height;
CRC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.67	7.69	0.39	1.77e-13	Cleft lip with or without cleft palate;
CRC	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.5	7.21	0.37	3.95e-12	Pulmonary function decline;
CRC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.43	5.71	0.3	2.47e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg02527881	chr3:46936655	PTH1R	0.39	7.31	0.37	2.07e-12	Colorectal cancer;
CRC	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg20129853	chr10:51489980	NA	-0.35	-5.69	-0.3	2.77e-8	Prostate-specific antigen levels;
CRC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.65	9.61	0.47	1.95e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2898681	0.581	rs730246	chr4:53680719	T/C	cg00338735	chr4:53728038	RASL11B	0.38	5.87	0.31	1.06e-8	Optic nerve measurement (cup area);
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.38	-6.24	-0.33	1.37e-9	Total body bone mineral density;
CRC	trans	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg26043149	chr18:55253948	FECH	0.51	7.92	0.4	3.79e-14	Bone mineral density;
CRC	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.44	-6.5	-0.34	3.03e-10	Body mass index;
CRC	cis	rs6496667	0.738	rs58438191	chr15:91045751	G/A	cg04176472	chr15:90893244	GABARAPL3	0.56	7.99	0.4	2.3e-14	Rheumatoid arthritis;
CRC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.43	-0.42	1.12e-15	Height;
CRC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.63	11.52	0.54	4.85e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	9.62	0.47	1.82e-19	Psoriasis;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-7.82	-0.4	7.41e-14	Total body bone mineral density;
CRC	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg19875578	chr6:126661172	C6orf173	0.42	5.84	0.31	1.26e-8	Male-pattern baldness;
CRC	cis	rs16975963	0.644	rs111319455	chr19:38162647	A/C	cg15135657	chr19:38346511	NA	-0.47	-6.56	-0.34	2.15e-10	Longevity;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg08888203	chr3:10149979	C3orf24	0.6	8.47	0.42	8.55e-16	Alzheimer's disease;
CRC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg13047869	chr3:10149882	C3orf24	0.39	5.95	0.31	6.8e-9	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08924777	chr16:48278166	LONP2	0.43	6.22	0.32	1.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg18876405	chr7:65276391	NA	0.43	7.76	0.39	1.08e-13	Aortic root size;
CRC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.78	7.8	0.39	8.44e-14	Type 2 diabetes nephropathy;
CRC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	10.54	0.5	1.4e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.16	25.97	0.82	1.16e-81	IgG glycosylation;
CRC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg24209194	chr3:40518798	ZNF619	0.38	5.69	0.3	2.89e-8	Renal cell carcinoma;
CRC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs501120	0.564	rs1626459	chr10:44691548	T/C	cg09554077	chr10:44749378	NA	0.58	8.13	0.41	8.75e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7572644	0.699	rs12465000	chr2:28199424	G/A	cg27432699	chr2:27873401	GPN1	-0.4	-5.61	-0.3	4.22e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.27	-0.37	2.64e-12	Height;
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.66	-0.39	2.06e-13	Bipolar disorder;
CRC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.86	-11.71	-0.54	1.02e-26	Asthma;
CRC	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.68	10.24	0.49	1.57e-21	Schizophrenia;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11645453	chr3:52864694	ITIH4	0.35	6.14	0.32	2.31e-9	Bipolar disorder;
CRC	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.49	-7.97	-0.4	2.68e-14	Metabolite levels;
CRC	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.98	11.64	0.54	1.87e-26	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg14458575	chr2:238380390	NA	0.52	6.86	0.35	3.51e-11	Prostate cancer;
CRC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.73	0.35	7.57e-11	HIV-1 control;
CRC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg19337854	chr7:99768885	GPC2	0.39	5.81	0.31	1.46e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.81	-0.31	1.47e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.47	6.82	0.35	4.42e-11	Methadone dose in opioid dependence;
CRC	trans	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg10756647	chr7:56101905	PSPH	0.74	7.72	0.39	1.37e-13	Diabetic kidney disease;
CRC	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.15	0.32	2.21e-9	Hair morphology;
CRC	cis	rs6743376	0.556	rs1800930	chr2:113820530	A/G	cg09040174	chr2:113837401	NA	0.4	5.84	0.31	1.22e-8	Inflammatory biomarkers;
CRC	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.7	-0.35	9.12e-11	Gallbladder cancer;
CRC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.29	16.27	0.67	4.48e-44	Uric acid levels;
CRC	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	7.82	0.4	7.3e-14	Bipolar disorder;
CRC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.48	-7.93	-0.4	3.49e-14	Coronary artery disease;
CRC	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.43	6.4	0.33	5.5e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg12963866	chr19:57752005	ZNF805	-0.39	-5.84	-0.31	1.23e-8	Hyperactive-impulsive symptoms;
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.63	-9.83	-0.48	3.69e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.52	8.41	0.42	1.3e-15	Aortic root size;
CRC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.38	8.86	0.44	5.17e-17	Multiple system atrophy;
CRC	trans	rs11105468	1.000	rs11105442	chr12:90260348	G/C	cg23572944	chr11:60720130	SLC15A3	-0.45	-6.33	-0.33	7.82e-10	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg15786705	chr6:28176104	NA	0.81	11.64	0.54	1.84e-26	Depression;
CRC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7605827	0.930	rs10207209	chr2:15512701	A/G	cg19274914	chr2:15703543	NA	0.39	5.76	0.3	1.89e-8	Educational attainment (years of education);
CRC	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.3	1.75e-8	Response to antipsychotic treatment;
CRC	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.18	-0.37	4.78e-12	Inflammatory skin disease;
CRC	cis	rs1178968	1.000	rs7802062	chr7:72757812	T/C	cg25889504	chr7:72793014	NA	0.53	5.93	0.31	7.73e-9	Triglyceride levels;
CRC	cis	rs9462027	0.562	rs2814946	chr6:34651180	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.29e-9	Systemic lupus erythematosus;
CRC	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg00042356	chr1:8021962	PARK7	-0.5	-5.84	-0.31	1.25e-8	Inflammatory bowel disease;
CRC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.46	6.73	0.35	7.35e-11	Emphysema distribution in smoking;
CRC	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.62	11.34	0.53	2.29e-25	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg26816564	chr1:7831052	VAMP3	0.56	6.08	0.32	3.35e-9	Inflammatory bowel disease;
CRC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg13628971	chr7:2884303	GNA12	0.4	5.74	0.3	2.12e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg09127314	chr1:152161683	NA	0.53	6.87	0.35	3.25e-11	Atopic dermatitis;
CRC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.36	6.03	0.32	4.51e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg19131313	chr8:1704013	NA	-0.49	-6.08	-0.32	3.42e-9	Systolic blood pressure;
CRC	cis	rs4731207	0.570	rs1600738	chr7:124639549	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.2	-0.32	1.68e-9	Cutaneous malignant melanoma;
CRC	cis	rs3015497	0.752	rs6572682	chr14:51144800	A/T	cg09863266	chr14:51125203	SAV1	-0.33	-6.23	-0.32	1.44e-9	Mean platelet volume;
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg24046110	chr8:143859143	LYNX1	0.4	6.83	0.35	4.19e-11	Urinary tract infection frequency;
CRC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.39	6.19	0.32	1.78e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.69	-0.39	1.69e-13	Bladder cancer;
CRC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.17e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg21153622	chr11:89784906	NA	-0.38	-6.09	-0.32	3.2e-9	Height;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg25164649	chr6:28176230	NA	0.6	8.89	0.44	4.25e-17	Parkinson's disease;
CRC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.6	0.47	2.07e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg06238570	chr21:40685208	BRWD1	0.76	10.29	0.49	9.94e-22	Cognitive function;
CRC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg06505273	chr16:24850292	NA	0.39	5.97	0.31	6.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	9.23	0.45	3.29e-18	Mean corpuscular hemoglobin;
CRC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.64	-9.62	-0.47	1.82e-19	Ulcerative colitis;
CRC	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg20129853	chr10:51489980	NA	-0.35	-5.73	-0.3	2.26e-8	Prostate-specific antigen levels;
CRC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.77	-13.6	-0.6	1e-33	Body mass index;
CRC	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg25547332	chr5:131281432	NA	0.4	6.1	0.32	3e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.98	-0.52	4.16e-24	Hepatocellular carcinoma;
CRC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg00106254	chr7:1943704	MAD1L1	-0.37	-5.75	-0.3	1.99e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs9463078	0.625	rs12190136	chr6:44767072	A/G	cg25276700	chr6:44698697	NA	-0.26	-6.39	-0.33	5.82e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg23161317	chr6:28129485	ZNF389	0.45	6.5	0.34	3.05e-10	Parkinson's disease;
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs294883	0.739	rs962338	chr6:159729355	G/A	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs6479527	0.840	rs7033481	chr9:96752329	A/C	cg14459158	chr9:96720562	NA	0.41	7.64	0.39	2.36e-13	Esophageal adenocarcinoma;
CRC	trans	rs6015450	1.000	rs78872658	chr20:57754390	G/A	cg22122715	chr13:96086023	CLDN10	-0.55	-6.16	-0.32	2.11e-9	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.82	-0.4	7.01e-14	QT interval;
CRC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg03013999	chr17:37608204	MED1	0.47	7.35	0.38	1.58e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.44	-0.33	4.29e-10	Metabolite levels;
CRC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.46	7.45	0.38	8.3e-13	Obesity-related traits;
CRC	trans	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.05	0.36	1.08e-11	Ulcerative colitis;
CRC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.73	-0.35	7.35e-11	Total body bone mineral density;
CRC	cis	rs7680126	0.586	rs7689060	chr4:10305463	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	6.33	0.33	8.07e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.28	-0.46	2.39e-18	Migraine;Coronary artery disease;
CRC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-10.0	-0.48	9.83e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg12564285	chr5:131593104	PDLIM4	0.38	7.44	0.38	8.91e-13	Blood metabolite levels;
CRC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	10.1	0.49	4.65e-21	HIV-1 control;
CRC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg11632617	chr15:75315747	PPCDC	-0.56	-8.05	-0.41	1.57e-14	Blood trace element (Zn levels);
CRC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg14541582	chr5:601475	NA	-0.36	-7.37	-0.38	1.42e-12	Obesity-related traits;
CRC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.58	0.34	1.85e-10	Testicular germ cell tumor;
CRC	cis	rs7605827	0.930	rs7568678	chr2:15596203	C/T	cg19274914	chr2:15703543	NA	0.39	5.76	0.3	1.97e-8	Educational attainment (years of education);
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg07423050	chr13:99094983	FARP1	0.4	6.45	0.34	3.9e-10	Longevity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22468868	chr17:58042029	RNFT1	0.43	6.5	0.34	3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.64	8.65	0.43	2.28e-16	Urate levels in lean individuals;
CRC	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02290350	chr8:58132656	NA	-0.42	-6.03	-0.32	4.52e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg16898833	chr6:26189333	HIST1H4D	0.74	6.18	0.32	1.94e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg12516270	chr8:143859308	LYNX1	0.56	9.86	0.48	3.01e-20	Urinary tract infection frequency;
CRC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.26	-0.33	1.23e-9	Aortic root size;
CRC	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.6	-10.83	-0.51	1.4e-23	Aortic root size;
CRC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.85	10.08	0.49	5.15e-21	Psoriasis;
CRC	cis	rs9372498	0.764	rs9489371	chr6:118725368	T/C	cg18833306	chr6:118973337	C6orf204	0.47	5.86	0.31	1.11e-8	Diastolic blood pressure;
CRC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.93	-17.87	-0.7	2.11e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.81	-7.58	-0.39	3.47e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.41	0.38	1.1e-12	Motion sickness;
CRC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.61	-0.39	2.9e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg22117107	chr15:45993392	NA	-0.44	-9.02	-0.45	1.58e-17	Waist circumference;Weight;
CRC	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg11130432	chr3:121712080	ILDR1	-0.51	-6.65	-0.34	1.19e-10	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13622657	chr9:34620508	DCTN3	0.5	7.17	0.37	5.09e-12	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg08125733	chr17:73851984	WBP2	0.72	9.09	0.45	9.41e-18	Psoriasis;
CRC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.46	0.34	3.77e-10	Lung cancer;
CRC	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg09873164	chr1:152488093	CRCT1	0.37	6.22	0.32	1.49e-9	Hair morphology;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.98	-0.31	5.78e-9	Menopause (age at onset);
CRC	cis	rs10971721	0.643	rs41315997	chr9:33798838	T/C	cg13495928	chr9:33750294	PRSS3	0.63	5.65	0.3	3.53e-8	Body mass index;
CRC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.44	-7.41	-0.38	1.07e-12	Height;
CRC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.47	6.97	0.36	1.75e-11	Asthma;
CRC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.02	0.48	8.56e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3789045	1.000	rs3789044	chr1:204589101	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.49	-7.0	-0.36	1.45e-11	Educational attainment (college completion);
CRC	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg12856521	chr11:46389249	DGKZ	-0.41	-6.53	-0.34	2.56e-10	Leprosy;
CRC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.54	8.26	0.41	3.49e-15	Aortic root size;
CRC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18252515	chr7:66147081	NA	0.39	5.7	0.3	2.72e-8	Aortic root size;
CRC	cis	rs6840360	0.642	rs4696092	chr4:152412603	T/C	cg09659197	chr4:152720779	NA	0.33	6.52	0.34	2.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-0.69	-6.72	-0.35	8.13e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.45	-7.33	-0.37	1.75e-12	Monocyte count;
CRC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.12	0.74	2.81e-59	Prudent dietary pattern;
CRC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.27e-11	Menopause (age at onset);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01708711	chr7:75959031	YWHAG	0.45	6.16	0.32	2.18e-9	Survival in pancreatic cancer;
CRC	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg09915433	chr19:53449742	NA	-0.43	-6.0	-0.31	5.1e-9	Psoriasis;
CRC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg21251018	chr6:28226885	NKAPL	0.39	5.81	0.31	1.48e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3026101	0.671	rs58832024	chr17:5306536	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg14515779	chr1:101123966	NA	-0.43	-8.33	-0.42	2.17e-15	Monocyte count;
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.62	-0.39	2.67e-13	Breast cancer;
CRC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg20487152	chr13:99095054	FARP1	-0.45	-6.55	-0.34	2.2e-10	Longevity;
CRC	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.84	-0.31	1.25e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	6.6	0.34	1.64e-10	Menopause (age at onset);
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg02820901	chr13:113351484	ATP11A	0.62	6.77	0.35	5.83e-11	Glycated hemoglobin levels;
CRC	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg13385794	chr1:248469461	NA	0.4	6.83	0.35	4.13e-11	Common traits (Other);
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.03e-10	Bipolar disorder;
CRC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.64	12.0	0.55	9.43e-28	Coronary artery disease;
CRC	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg00603274	chr11:61596626	FADS2	-0.45	-6.63	-0.34	1.4e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs10911390	0.744	rs115167874	chr1:183652721	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Systemic lupus erythematosus;
CRC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	11.69	0.54	1.24e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.43	-7.09	-0.36	8.09e-12	Type 2 diabetes;
CRC	cis	rs11212617	1.000	rs227087	chr11:108244114	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.64	0.34	1.27e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg15848620	chr12:58087721	OS9	0.59	7.95	0.4	3.07e-14	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg27523141	chr10:43048294	ZNF37B	0.47	6.74	0.35	7.02e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs740160	0.558	rs12538893	chr7:98908497	G/A	cg24650262	chr7:98904301	NA	0.56	6.06	0.32	3.73e-9	Dehydroepiandrosterone sulphate levels;
CRC	trans	rs57590327	0.503	rs9880844	chr3:81507217	C/T	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-6.0	-0.31	5.25e-9	Extraversion;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg12255352	chr13:24375209	MIPEP	-0.37	-6.06	-0.32	3.62e-9	HDL cholesterol;
CRC	cis	rs6662572	0.737	rs55765474	chr1:46401170	G/T	cg08644498	chr1:46502608	NA	0.44	6.89	0.36	2.77e-11	Blood protein levels;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg22627826	chr19:1240265	ATP5D	-0.72	-6.18	-0.32	1.86e-9	Cognitive function;
CRC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.62	9.19	0.45	4.62e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.57	7.63	0.39	2.63e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.72	13.15	0.59	4.91e-32	Iron status biomarkers;
CRC	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.64	9.99	0.48	1.03e-20	Corneal astigmatism;
CRC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.36	6.38	0.33	6.18e-10	Crohn's disease;
CRC	cis	rs6558530	0.965	rs730377	chr8:1707951	G/A	cg19131313	chr8:1704013	NA	-0.45	-6.12	-0.32	2.65e-9	Systolic blood pressure;
CRC	cis	rs9409565	0.559	rs62581187	chr9:97242284	T/G	cg04523069	chr9:97136363	HIATL1	0.43	5.88	0.31	9.92e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg06505273	chr16:24850292	NA	0.37	5.68	0.3	3.02e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.527	rs1683151	chr12:53946219	C/G	cg06632207	chr12:54070931	ATP5G2	-0.49	-8.37	-0.42	1.63e-15	Height;
CRC	cis	rs231513	0.911	rs231521	chr17:41955158	A/G	cg26893861	chr17:41843967	DUSP3	-0.7	-6.46	-0.34	3.69e-10	Cognitive function;
CRC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.71e-11	Menopause (age at onset);
CRC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg15654264	chr1:150340011	RPRD2	-0.4	-5.91	-0.31	8.48e-9	Migraine;
CRC	cis	rs10737909	0.510	rs12025158	chr1:15539259	A/G	cg21012057	chr1:15538911	TMEM51	0.39	5.61	0.3	4.24e-8	Migraine;
CRC	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg19773385	chr1:10388646	KIF1B	-0.56	-7.83	-0.4	6.65e-14	Hepatocellular carcinoma;
CRC	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.22	28.81	0.85	5.44e-92	Schizophrenia;
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg22638593	chr5:131593259	PDLIM4	-0.36	-6.61	-0.34	1.57e-10	Blood metabolite levels;
CRC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.3	-0.37	2.24e-12	Colorectal cancer;
CRC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg00343986	chr7:65444356	GUSB	-0.5	-7.43	-0.38	9.64e-13	Aortic root size;
CRC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.42	7.94	0.4	3.13e-14	Multiple sclerosis;
CRC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21028142	chr17:79581711	NPLOC4	-0.33	-6.98	-0.36	1.64e-11	Eye color traits;
CRC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.75	0.66	4.84e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.52	9.14	0.45	6.5e-18	Blood metabolite ratios;
CRC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.6e-12	Gut microbiome composition (summer);
CRC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.62	0.54	2.1e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg22561889	chr6:118971681	C6orf204	0.47	5.9	0.31	8.96e-9	Renal cell carcinoma;
CRC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg00129232	chr17:37814104	STARD3	0.54	7.34	0.38	1.68e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg25427524	chr10:38739819	LOC399744	0.54	8.6	0.43	3.41e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12760731	0.565	rs35926996	chr1:178075351	A/G	cg00404053	chr1:178313656	RASAL2	1.06	11.28	0.53	3.67e-25	Obesity-related traits;
CRC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.76e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs71386933	0.543	rs36114735	chr16:72017683	C/T	cg08717414	chr16:71523259	ZNF19	-0.87	-7.18	-0.37	4.62e-12	Post bronchodilator FEV1;
CRC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg05110241	chr16:68378359	PRMT7	-0.6	-7.21	-0.37	3.85e-12	Schizophrenia;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.68	-0.43	1.87e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.2	-0.37	4.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs812925	0.512	rs1729674	chr2:61389737	T/G	cg10580144	chr2:61372316	C2orf74	0.36	8.07	0.41	1.34e-14	Immature fraction of reticulocytes;
CRC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.58	9.5	0.46	4.41e-19	Type 2 diabetes;
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.45	-0.34	3.92e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg13606994	chr1:44402422	ARTN	-0.34	-5.86	-0.31	1.12e-8	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.38	-0.33	6.15e-10	Daytime sleep phenotypes;
CRC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg04545296	chr12:48745243	ZNF641	0.36	6.22	0.32	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.6	10.66	0.51	5.32e-23	Schizophrenia;
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.45	6.05	0.32	3.85e-9	Morning vs. evening chronotype;
CRC	cis	rs12980942	0.872	rs10421990	chr19:41797099	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.44	5.66	0.3	3.24e-8	Coronary artery disease;
CRC	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.66	-10.66	-0.51	5.35e-23	Hepatocellular carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05663122	chr19:59055778	TRIM28	0.37	6.0	0.31	5.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg04025307	chr7:1156635	C7orf50	0.66	7.07	0.36	9.23e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.61	-0.34	1.54e-10	Systemic lupus erythematosus;
CRC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.49	9.0	0.44	1.87e-17	Total body bone mineral density;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.73	8.87	0.44	4.88e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg17182837	chr8:41585554	ANK1	-0.55	-7.75	-0.39	1.17e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.65	10.05	0.48	6.52e-21	Height;
CRC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg00745463	chr17:30367425	LRRC37B	-0.45	-5.99	-0.31	5.61e-9	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs1322512	1.000	rs2800625	chr6:153006016	A/G	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.18e-9	Tonometry;
CRC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-5.91	-0.31	8.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg16141378	chr3:129829833	LOC729375	0.42	5.98	0.31	5.78e-9	Neuroticism;
CRC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.53	8.26	0.41	3.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg26384229	chr12:38710491	ALG10B	0.45	6.31	0.33	9.05e-10	Morning vs. evening chronotype;
CRC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.95	-17.95	-0.7	1e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg12317470	chr15:67143691	NA	-0.51	-6.03	-0.32	4.31e-9	Lung cancer (smoking interaction);
CRC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.54	-0.34	2.37e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	1.03e-13	Intelligence (multi-trait analysis);
CRC	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06210969	chr3:120067732	LRRC58	0.42	6.0	0.31	5.22e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.89	-0.31	9.67e-9	Colorectal cancer;
CRC	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg04969067	chr8:143858791	LYNX1	-0.34	-5.82	-0.31	1.38e-8	Urinary tract infection frequency;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg13490827	chr1:46269305	MAST2	-0.7	-6.28	-0.33	1.09e-9	Blood osmolality (transformed sodium);
CRC	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg00531865	chr16:30841666	NA	0.49	7.0	0.36	1.48e-11	Dementia with Lewy bodies;
CRC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.75	-0.47	6.56e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.71	-0.35	8.56e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs1864729	1.000	rs2583504	chr8:98283404	G/C	cg08679828	chr8:102218111	ZNF706	-0.59	-7.13	-0.37	6.34e-12	Estradiol plasma levels (breast cancer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14850412	chr1:200860682	C1orf106	0.42	6.24	0.33	1.38e-9	Response to antipsychotic treatment;
CRC	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg04662943	chr10:102668895	NA	0.59	7.25	0.37	3.07e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06655377	chr16:56553780	BBS2	0.42	5.97	0.31	6.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.33	-0.37	1.8e-12	Height;
CRC	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.4	-6.28	-0.33	1.09e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.46	6.94	0.36	2.11e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg15271348	chr13:114292740	TFDP1	-0.38	-6.04	-0.32	4.15e-9	HDL cholesterol;
CRC	trans	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg24644049	chr4:85504048	CDS1	0.92	7.64	0.39	2.42e-13	Skin colour saturation;
CRC	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg10437265	chr15:77819839	NA	-0.52	-8.53	-0.43	5.37e-16	Type 2 diabetes;
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.67	9.92	0.48	1.8e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-9.18	-0.45	4.8e-18	Initial pursuit acceleration;
CRC	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.86	-13.96	-0.61	4.27e-35	Alcohol dependence;
CRC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1880529	0.830	rs6533687	chr4:114365275	C/T	cg05422836	chr8:81806286	NA	-0.4	-6.01	-0.31	5.02e-9	White matter integrity (bipolar disorder risk interaction);
CRC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.29	6.05	0.32	3.94e-9	Lung cancer;
CRC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.69	9.12	0.45	7.51e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.53	9.32	0.46	1.72e-18	Common traits (Other);
CRC	cis	rs863345	0.604	rs879635	chr1:158462908	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.31	-0.33	8.84e-10	Pneumococcal bacteremia;
CRC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.52	7.79	0.39	8.6e-14	Corneal astigmatism;
CRC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.35	6.19	0.32	1.8e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.02	-0.36	1.26e-11	Eye color traits;
CRC	trans	rs2797369	0.824	rs1149271	chr6:101608851	A/G	cg26346621	chr12:6873348	NA	-0.39	-6.14	-0.32	2.44e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.33	0.69	2.88e-48	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20400718	chr8:42940792	FNTA	-0.37	-6.22	-0.32	1.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg06287003	chr12:125626642	AACS	-0.58	-7.49	-0.38	6.42e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs11212617	0.902	rs61913892	chr11:108340216	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.15	0.32	2.21e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21531444	chr3:178961439	KCNMB3	-0.39	-6.06	-0.32	3.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs534126	0.744	rs10248147	chr7:142941023	C/G	cg04039957	chr7:143013207	CLCN1	-0.34	-5.64	-0.3	3.71e-8	Cancer;
CRC	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6499255	0.951	rs689455	chr16:69761661	T/G	cg04110750	chr16:69646130	NFAT5	-0.54	-7.35	-0.38	1.63e-12	IgE levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27481254	chr8:94753071	RBM12B	0.48	6.38	0.33	6.18e-10	Thyroid stimulating hormone;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg07507251	chr3:52567010	NT5DC2	0.45	6.39	0.33	5.82e-10	Bipolar disorder;
CRC	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg14074117	chr16:1909714	C16orf73	-0.34	-5.81	-0.31	1.44e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg14003231	chr6:33640908	ITPR3	0.49	7.82	0.4	7.19e-14	Plateletcrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23037918	chr19:7600138	PNPLA6	0.43	6.11	0.32	2.78e-9	Response to antipsychotic treatment;
CRC	cis	rs449789	0.857	rs10806706	chr6:159721945	G/T	cg14500486	chr6:159655392	FNDC1	0.48	7.38	0.38	1.3e-12	Pulse pressure;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg24998145	chr1:150550761	MCL1	-0.43	-6.82	-0.35	4.38e-11	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12648201	chr2:27665141	KRTCAP3	0.32	6.83	0.35	4e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg08896387	chr1:24191740	FUCA1	0.52	7.01	0.36	1.32e-11	Immature fraction of reticulocytes;
CRC	trans	rs2540226	0.527	rs11124695	chr2:40026583	G/A	cg05727001	chr11:66718583	PC	0.41	6.01	0.31	4.91e-9	Personality dimensions;
CRC	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg09218773	chr11:619014	MUPCDH	-0.36	-5.66	-0.3	3.29e-8	Systemic lupus erythematosus;
CRC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-7.19	-0.37	4.43e-12	Fibrinogen levels;
CRC	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.44	9.19	0.45	4.44e-18	Bone mineral density;
CRC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg15848620	chr12:58087721	OS9	-0.65	-9.38	-0.46	1.15e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.62	8.79	0.44	8.3e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.58	8.57	0.43	4.13e-16	Morning vs. evening chronotype;
CRC	cis	rs6586163	1.000	rs6586165	chr10:90755056	T/A	cg13456138	chr10:90753195	FAS	-0.43	-6.62	-0.34	1.5e-10	Chronic lymphocytic leukemia;
CRC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	13.12	0.59	6.43e-32	Menopause (age at onset);
CRC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg24209194	chr3:40518798	ZNF619	0.41	6.02	0.31	4.67e-9	Renal cell carcinoma;
CRC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.57	8.52	0.43	5.82e-16	High light scatter reticulocyte count;
CRC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.76	8.59	0.43	3.53e-16	Tuberculosis;
CRC	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.26	0.45	2.73e-18	Blood protein levels;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg21620606	chr4:1342894	KIAA1530	0.52	9.57	0.47	2.74e-19	Longevity;
CRC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.84	-14.71	-0.63	5.44e-38	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg12046867	chr14:103022105	NA	0.76	8.97	0.44	2.22e-17	Platelet count;
CRC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.92e-30	Blood trace element (Zn levels);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10601761	chr19:4930780	UHRF1	-0.42	-5.98	-0.31	5.86e-9	Anxiety disorder;
CRC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg23071808	chr14:103021642	NA	-0.6	-6.92	-0.36	2.35e-11	Platelet count;
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs12580194	0.593	rs7314118	chr12:55737403	A/C	cg23425280	chr12:56401806	NA	0.47	5.97	0.31	6.21e-9	Cancer;
CRC	cis	rs2411233	1.000	rs2117207	chr15:39289254	C/T	cg23129342	chr15:39283510	NA	0.33	6.19	0.32	1.78e-9	Platelet count;
CRC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.3	0.46	2.03e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg02158880	chr13:53174818	NA	0.44	6.65	0.34	1.19e-10	Lewy body disease;
CRC	cis	rs2735413	0.837	rs12920830	chr16:78083149	A/C	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.66	-10.16	-0.49	2.91e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg08200582	chr11:442649	ANO9	-0.69	-7.21	-0.37	3.75e-12	Body mass index;
CRC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.81	-0.31	1.48e-8	Life satisfaction;
CRC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.47	7.07	0.36	9.21e-12	Testicular germ cell tumor;
CRC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.4	6.33	0.33	8.1e-10	Monocyte count;
CRC	cis	rs9648716	1.000	rs7801086	chr7:140454973	G/T	cg10747023	chr7:140774559	NA	0.45	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.66	10.1	0.49	4.4e-21	Monocyte count;
CRC	cis	rs7259376	0.837	rs1368476	chr19:22586192	A/G	cg02657401	chr19:22469223	NA	0.32	6.81	0.35	4.66e-11	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs12980942	0.872	rs12976536	chr19:41799886	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.52	6.02	0.31	4.73e-9	Coronary artery disease;
CRC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg23758597	chr6:163146217	PARK2	-0.6	-6.68	-0.35	1.04e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.54	-8.19	-0.41	5.69e-15	Male sexual orientation;
CRC	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg00801512	chr17:28996047	NA	-0.6	-6.1	-0.32	2.91e-9	Height;
CRC	cis	rs2073499	1.000	rs2301639	chr3:50380661	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.67	5.85	0.31	1.16e-8	Schizophrenia;
CRC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.4	5.21e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	5.92	0.31	8.07e-9	Aortic root size;
CRC	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg22495460	chr2:25135724	ADCY3	-0.9	-14.95	-0.64	6.53e-39	Body mass index;
CRC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg18764771	chr6:116381957	FRK	0.25	7.04	0.36	1.1e-11	Cholesterol, total;LDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05263682	chr6:89673273	RNGTT	0.43	6.08	0.32	3.38e-9	Response to antipsychotic treatment;
CRC	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.48	-8.34	-0.42	2.09e-15	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7605827	0.930	rs13006997	chr2:15700872	T/C	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.45	5.81	0.3	1.49e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.92	15.29	0.64	2.9e-40	Dupuytren's disease;
CRC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg00334542	chr7:100209784	MOSPD3	-0.51	-6.59	-0.34	1.76e-10	Other erythrocyte phenotypes;
CRC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.43	7.09	0.36	8.17e-12	Resting heart rate;
CRC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.91	13.82	0.61	1.42e-34	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.68	9.27	0.46	2.46e-18	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.96	0.4	2.85e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.53	7.54	0.38	4.71e-13	Longevity;
CRC	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.14	0.41	8.34e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9549328	0.700	rs4907570	chr13:113617651	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.24e-19	Systolic blood pressure;
CRC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.67	7.39	0.38	1.22e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.83	0.44	6.4e-17	Hip circumference adjusted for BMI;
CRC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.71	0.57	2.19e-30	Menopause (age at onset);
CRC	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.6	10.82	0.51	1.56e-23	Blood metabolite ratios;
CRC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.85	16.14	0.66	1.48e-43	Dental caries;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03324947	chr7:42971765	PSMA2;MRPL32	0.39	6.56	0.34	2.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs863345	0.604	rs1342946	chr1:158453187	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.99	-0.31	5.56e-9	Pneumococcal bacteremia;
CRC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.88	11.41	0.53	1.21e-25	Triglycerides;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg06470822	chr6:28175283	NA	0.9	13.82	0.61	1.49e-34	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg13047869	chr3:10149882	C3orf24	0.51	7.07	0.36	9.31e-12	Alzheimer's disease;
CRC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg10130564	chr11:117069849	TAGLN	-0.37	-6.73	-0.35	7.77e-11	Blood protein levels;
CRC	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.88	-0.31	1.02e-8	Pulmonary function;
CRC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.4	6.89	0.36	2.8e-11	Skin aging (microtopography measurement);
CRC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.9	-0.52	7.9e-24	Pancreatic cancer;
CRC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs12024301	0.557	rs10797895	chr1:183589625	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-8.93	-0.44	3.04e-17	Total body bone mineral density;
CRC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.49	-7.32	-0.37	1.9e-12	Height;
CRC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.52	7.87	0.4	5.22e-14	Calcium levels;
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg20041105	chr8:143859282	LYNX1	0.46	8.2	0.41	5.51e-15	Urinary tract infection frequency;
CRC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.67e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs939584	0.932	rs1320336	chr2:650012	G/A	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg15448220	chr1:150897856	SETDB1	0.49	6.82	0.35	4.3e-11	Urate levels;
CRC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.63	0.47	1.63e-19	Cognitive test performance;
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.23	0.32	1.46e-9	Prudent dietary pattern;
CRC	cis	rs1524976	1.000	rs2030732	chr3:65465766	T/C	cg16238336	chr3:65465873	MAGI1	0.5	7.22	0.37	3.64e-12	PR interval;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.74	7.77	0.39	9.78e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.76	-7.7	-0.39	1.56e-13	Diabetic retinopathy;
CRC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.73	-0.43	1.33e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.78	7.86	0.4	5.41e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.47	0.46	5.58e-19	Coffee consumption (cups per day);
CRC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.55	-8.55	-0.43	4.64e-16	Vitiligo;
CRC	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.54	-6.01	-0.31	4.83e-9	Blood protein levels;
CRC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.65	0.63	9.4e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.48	6.94	0.36	2.12e-11	Subjective well-being;
CRC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg16989086	chr20:62203971	PRIC285	0.48	6.21	0.32	1.57e-9	Glioblastoma;
CRC	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.48	6.05	0.32	3.93e-9	Systolic blood pressure;
CRC	cis	rs12541635	0.966	rs56352125	chr8:107041831	G/T	cg10147462	chr8:107024639	NA	0.47	7.7	0.39	1.59e-13	Age of smoking initiation;
CRC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-6.6	-0.34	1.69e-10	Height;
CRC	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs11255291	1.000	rs10905219	chr10:7738411	C/T	cg00997801	chr10:7671259	ITIH5	0.46	6.67	0.35	1.06e-10	Ovarian reserve;
CRC	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.46	5.83	0.31	1.35e-8	Metabolite levels;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24415082	chr16:74700811	RFWD3	0.56	6.24	0.33	1.38e-9	Interleukin-4 levels;
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg15511327	chr8:143859410	LYNX1	0.42	7.31	0.37	1.98e-12	Urinary tract infection frequency;
CRC	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-0.69	-6.73	-0.35	7.77e-11	Cannabis dependence symptom count;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg22687807	chr8:143858763	LYNX1	-0.45	-6.98	-0.36	1.68e-11	Urinary tract infection frequency;
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.39	0.46	1.02e-18	Alzheimer's disease;
CRC	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.5	7.99	0.4	2.23e-14	Monocyte percentage of white cells;
CRC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg24209194	chr3:40518798	ZNF619	0.41	6.04	0.32	4.22e-9	Renal cell carcinoma;
CRC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg08200582	chr11:442649	ANO9	-0.68	-6.49	-0.34	3.09e-10	Body mass index;
CRC	cis	rs7923609	1.000	rs7070296	chr10:65070438	T/A	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.94	-0.31	7.07e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.39	8.73	0.43	1.3e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	7.01	0.36	1.39e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg10729496	chr3:10149963	C3orf24	0.5	6.81	0.35	4.67e-11	Alzheimer's disease;
CRC	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00495681	chr13:53174319	NA	-0.53	-8.13	-0.41	9e-15	Lewy body disease;
CRC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg24879335	chr3:133465180	TF	0.37	6.84	0.35	3.9e-11	Iron status biomarkers;
CRC	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg25811766	chr13:21894605	NA	-0.58	-5.95	-0.31	6.86e-9	White matter hyperintensity burden;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04622074	chr17:62657955	SMURF2	0.42	6.41	0.33	4.98e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.6	-6.28	-0.33	1.05e-9	Pursuit maintenance gain;
CRC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.16	0.45	5.58e-18	Tonsillectomy;
CRC	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg19773385	chr1:10388646	KIF1B	-0.58	-8.21	-0.41	5.22e-15	Hepatocellular carcinoma;
CRC	cis	rs17401966	0.577	rs6661326	chr1:10242231	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-7.25	-0.37	2.92e-12	Hepatocellular carcinoma;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15190599	chr6:26156487	HIST1H1E	0.44	6.31	0.33	9.08e-10	Survival in pancreatic cancer;
CRC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.68	-11.19	-0.52	7.82e-25	Hepatocellular carcinoma;
CRC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.24	6.83	0.35	4.19e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg16235748	chr6:149772707	ZC3H12D	0.38	6.95	0.36	1.94e-11	Dupuytren's disease;
CRC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15541040	chr2:3486749	NA	0.42	6.53	0.34	2.44e-10	Neurofibrillary tangles;
CRC	trans	rs4853036	0.586	rs2312551	chr2:70007357	C/T	cg14633329	chr9:139640053	LCN6	-0.39	-6.42	-0.33	4.63e-10	Colorectal or endometrial cancer;
CRC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs6479527	0.904	rs1418251	chr9:96848077	T/C	cg14459158	chr9:96720562	NA	0.42	7.2	0.37	4.15e-12	Esophageal adenocarcinoma;
CRC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.38e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02725872	chr8:58115012	NA	-0.39	-6.66	-0.34	1.14e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.46	-5.97	-0.31	5.98e-9	Heschl's gyrus morphology;
CRC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.63	-6.96	-0.36	1.88e-11	Coronary artery disease;
CRC	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg21155852	chr7:2048760	MAD1L1	-0.44	-5.83	-0.31	1.3e-8	Neuroticism;
CRC	cis	rs7173389	0.560	rs7174643	chr15:73680301	A/C	cg01796676	chr15:73680284	NA	0.55	8.62	0.43	2.79e-16	Resting heart rate;
CRC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg00531865	chr16:30841666	NA	-0.46	-6.0	-0.31	5.11e-9	Multiple myeloma;
CRC	cis	rs17767392	0.958	rs35051046	chr14:71849308	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.91	-0.36	2.6e-11	Mitral valve prolapse;
CRC	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.66	6.72	0.35	7.79e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8023845	1.000	rs3759843	chr15:40453075	A/G	cg20259534	chr15:40453036	BUB1B	-0.52	-6.03	-0.32	4.36e-9	Chronic lymphocytic leukemia;
CRC	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.77	15.93	0.66	9.13e-43	Leprosy;
CRC	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.34e-11	Response to antipsychotic treatment;
CRC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.54	-8.43	-0.42	1.07e-15	Dental caries;
CRC	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-6.23	-0.32	1.45e-9	Inflammatory biomarkers;
CRC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.62	6.34	0.33	7.55e-10	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.44	6.94	0.36	2.1e-11	Response to radiotherapy in cancer (late toxicity);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23397278	chr11:64051699	GPR137;BAD	-0.47	-5.97	-0.31	6.08e-9	Diisocyanate-induced asthma;
CRC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg05585544	chr11:47624801	NA	-0.62	-11.41	-0.53	1.22e-25	Subjective well-being;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04402966	chr7:87505783	SLC25A40;DBF4	0.42	6.09	0.32	3.2e-9	Anxiety disorder;
CRC	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.83	0.35	4.16e-11	Neutrophil percentage of white cells;
CRC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg11212589	chr17:38028394	ZPBP2	-0.35	-6.28	-0.33	1.07e-9	Self-reported allergy;
CRC	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07513332	chr6:167530253	CCR6	0.42	7.57	0.39	3.78e-13	Primary biliary cholangitis;
CRC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15204119	chr19:10613180	KEAP1	0.42	6.72	0.35	8.24e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.57	-7.57	-0.38	3.88e-13	Bipolar disorder;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg24874828	chr4:187887005	NA	-0.37	-6.39	-0.33	5.82e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.38	6.3	0.33	9.39e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs11212617	0.840	rs228599	chr11:108107660	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.89	0.31	9.33e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06481639	chr22:41940642	POLR3H	0.56	6.12	0.32	2.68e-9	Vitiligo;
CRC	cis	rs7487637	0.529	rs11168244	chr12:48202941	C/T	cg14736327	chr12:48174669	SLC48A1	-0.58	-7.77	-0.39	9.85e-14	Mononucleosis;
CRC	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg15147215	chr3:52552868	STAB1	0.43	6.98	0.36	1.59e-11	Body mass index;
CRC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.37	6.35e-12	Lung disease severity in cystic fibrosis;
CRC	trans	rs963731	0.649	rs10172714	chr2:39197543	C/G	cg13401531	chr11:70333281	SHANK2	0.72	6.09	0.32	3.08e-9	Corticobasal degeneration;
CRC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.62	9.8	0.48	4.65e-20	Gestational age at birth (maternal effect);
CRC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg18016565	chr1:150552671	MCL1	-0.47	-7.04	-0.36	1.12e-11	Tonsillectomy;
CRC	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.35	-0.42	1.89e-15	Body mass index;
CRC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.61	8.83	0.44	6.14e-17	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.82	-7.24	-0.37	3.19e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	9.14	0.45	6.81e-18	Lymphocyte counts;
CRC	cis	rs4700695	0.841	rs251306	chr5:65252453	C/T	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.43	-7.32	-0.37	1.96e-12	Lung cancer;
CRC	trans	rs1864729	0.591	rs2635139	chr8:98301557	A/G	cg08679828	chr8:102218111	ZNF706	-0.48	-6.18	-0.32	1.91e-9	Estradiol plasma levels (breast cancer);
CRC	cis	rs7940866	0.809	rs2324317	chr11:130877142	T/C	cg12179176	chr11:130786555	SNX19	0.58	8.33	0.42	2.27e-15	Schizophrenia;
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-6.72	-0.35	8.06e-11	Coronary artery disease;
CRC	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg00631329	chr6:26305371	NA	-0.54	-9.36	-0.46	1.26e-18	Educational attainment;
CRC	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg24519413	chr1:26490540	NA	0.36	5.93	0.31	7.53e-9	Height;
CRC	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.35	5.63	0.3	3.93e-8	Sitting height ratio;
CRC	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg02770688	chr6:168491649	NA	0.61	8.73	0.43	1.27e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg21851534	chr17:3907994	ZZEF1	0.37	6.31	0.33	9.02e-10	Type 2 diabetes;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg03623178	chr6:28175578	NA	0.88	12.69	0.57	2.62e-30	Parkinson's disease;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg25164649	chr6:28176230	NA	0.73	9.22	0.45	3.66e-18	Depression;
CRC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.95	-14.15	-0.62	7.69e-36	Systemic lupus erythematosus;
CRC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.41	0.42	1.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23706441	chr14:104181929	XRCC3;ZFYVE21	0.44	6.06	0.32	3.63e-9	Response to antipsychotic treatment;
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg25834613	chr7:1915315	MAD1L1	-0.42	-6.1	-0.32	3.06e-9	Bipolar disorder;
CRC	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg17958423	chr11:6947583	ZNF215	0.53	5.63	0.3	3.81e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.3e-9	Prudent dietary pattern;
CRC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.61	-11.07	-0.52	1.96e-24	Aortic root size;
CRC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	9.16	0.45	5.52e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-9.57	-0.47	2.56e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.57	7.73	0.39	1.31e-13	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg03013999	chr17:37608204	MED1	-0.48	-7.48	-0.38	6.82e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11446398	chr5:77624930	NA	0.47	6.29	0.33	1.03e-9	Triglycerides;
CRC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.84	14.73	0.63	4.33e-38	Breast cancer;
CRC	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg23229984	chr5:148520753	ABLIM3	0.52	6.71	0.35	8.42e-11	Breast cancer;
CRC	cis	rs858239	1.000	rs199351	chr7:23300049	A/C	cg00469287	chr7:23338798	C7orf30	0.46	6.2	0.32	1.69e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.26	0.37	2.77e-12	Hip circumference adjusted for BMI;
CRC	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg04439458	chr5:138467593	SIL1	0.35	6.03	0.32	4.33e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg08213375	chr14:104286397	PPP1R13B	0.43	6.83	0.35	4.21e-11	Reticulocyte count;
CRC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.48	5.99	0.31	5.51e-9	Bipolar disorder;
CRC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.05	10.89	0.51	8.72e-24	Diabetic retinopathy;
CRC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.58	-0.34	1.82e-10	Blood pressure (smoking interaction);
CRC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12315302	chr6:26189340	HIST1H4D	0.81	6.23	0.32	1.45e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.45	-7.77	-0.39	9.99e-14	Eye color traits;
CRC	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.1	-0.32	3.01e-9	Menopause (age at onset);
CRC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.8	-0.48	4.63e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg05044414	chr3:183734942	ABCC5	0.46	8.03	0.4	1.72e-14	Anterior chamber depth;
CRC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	19.76	0.74	7.57e-58	Prudent dietary pattern;
CRC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.39	-5.71	-0.3	2.53e-8	Neurofibrillary tangles;
CRC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.08	-0.32	3.27e-9	Bladder cancer;
CRC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg17652424	chr22:38574118	PLA2G6	0.21	6.68	0.35	1.01e-10	Cutaneous nevi;
CRC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg24562669	chr7:97807699	LMTK2	0.47	7.88	0.4	4.83e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10450586	0.863	rs10437623	chr11:27307247	C/T	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18099408	chr3:52552593	STAB1	0.44	7.0	0.36	1.48e-11	Bipolar disorder;
CRC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.7	-13.04	-0.58	1.34e-31	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10800280	chr6:36646508	CDKN1A	0.39	6.21	0.32	1.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.14	0.61	8.51e-36	Fuchs's corneal dystrophy;
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.38	-5.91	-0.31	8.35e-9	Breast cancer;
CRC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.84	0.48	3.41e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg04146151	chr16:2155961	PKD1	-0.47	-6.26	-0.33	1.17e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg05627522	chr15:75251581	NA	0.38	5.83	0.31	1.33e-8	Breast cancer;
CRC	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-0.38	-6.53	-0.34	2.49e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg18232548	chr7:50535776	DDC	-0.43	-5.67	-0.3	3.18e-8	Malaria;
CRC	cis	rs9992667	0.744	rs7657152	chr4:38641936	G/T	cg19726192	chr4:38663646	FLJ13197	-0.67	-8.73	-0.43	1.31e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg02869306	chr7:64672164	INTS4L1	0.43	6.23	0.32	1.43e-9	Aortic root size;
CRC	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.14	0.45	6.58e-18	Coffee consumption (cups per day);
CRC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.54	-6.7	-0.35	9.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	7.94	0.4	3.33e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.41	6.2	0.32	1.66e-9	Endometrial cancer;
CRC	trans	rs2303319	0.582	rs16845851	chr2:162295623	A/C	cg26623550	chr1:112281629	C1orf183	-0.81	-6.06	-0.32	3.73e-9	Cognitive function;
CRC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg17031739	chr1:67600172	NA	-0.4	-6.46	-0.34	3.69e-10	Psoriasis;
CRC	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.99	-10.78	-0.51	2.03e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.49	8.07	0.41	1.3e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.85	16.3	0.67	3.43e-44	White blood cell count (neutrophil);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20183778	chr7:102105344	ALKBH4;LRWD1	0.51	7.12	0.37	6.99e-12	Anxiety disorder;
CRC	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.83	0.31	1.35e-8	Corneal astigmatism;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.67	0.3	3.09e-8	Cardiac Troponin-T levels;
CRC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg26116260	chr4:7069785	GRPEL1	-0.59	-5.65	-0.3	3.54e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.55	-8.95	-0.44	2.69e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg04218760	chr10:45406644	TMEM72	-0.3	-7.37	-0.38	1.43e-12	Mean corpuscular volume;
CRC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.66	-0.43	2.21e-16	Schizophrenia;
CRC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.38	5.83	0.31	1.35e-8	Height;
CRC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.48	-7.39	-0.38	1.18e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.29	-0.46	2.22e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.01	-0.31	4.82e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg07125278	chr16:67683757	RLTPR	-0.46	-5.95	-0.31	6.69e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.25	-15.27	-0.64	3.51e-40	Gout;
CRC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.6	11.33	0.53	2.35e-25	Bone mineral density;
CRC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.03	-22.36	-0.78	5.29e-68	Myeloid white cell count;
CRC	cis	rs7619833	0.512	rs7634574	chr3:27223319	C/A	cg02860705	chr3:27208620	NA	0.38	5.91	0.31	8.51e-9	Breast cancer;
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.41	-0.38	1.09e-12	Lymphocyte counts;
CRC	cis	rs2857891	0.817	rs2638096	chr11:6977916	T/A	cg04053776	chr11:6947353	ZNF215	0.41	5.88	0.31	1.01e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.51	6.44	0.33	4.32e-10	White matter hyperintensity burden;
CRC	cis	rs2179367	0.959	rs514839	chr6:149648440	A/T	cg07828024	chr6:149772892	ZC3H12D	-0.37	-5.9	-0.31	9.13e-9	Dupuytren's disease;
CRC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	9.76	0.47	6.28e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg05625103	chr10:2543513	NA	-0.41	-6.47	-0.34	3.61e-10	Age-related hearing impairment;
CRC	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg02023728	chr11:77925099	USP35	-0.37	-6.3	-0.33	9.63e-10	Alzheimer's disease (survival time);
CRC	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07165851	chr6:158734300	TULP4	0.63	7.94	0.4	3.14e-14	Height;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08492707	chr21:34696952	IFNAR1	0.43	6.74	0.35	7.21e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg11211951	chr8:145729740	GPT	0.41	7.07	0.36	9.33e-12	Age at first birth;
CRC	cis	rs2249694	1.000	rs1952467	chr10:135353499	T/G	cg16964102	chr10:135390573	NA	-0.38	-6.21	-0.32	1.57e-9	Obesity-related traits;
CRC	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.81	-0.31	1.45e-8	Tuberculosis;
CRC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.39	-0.33	5.67e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-6.71	-0.35	8.44e-11	Alzheimer's disease (late onset);
CRC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12580194	1.000	rs4262806	chr12:55711562	T/A	cg19537932	chr12:55886519	OR6C68	-0.6	-8.23	-0.41	4.29e-15	Cancer;
CRC	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.5	6.47	0.34	3.52e-10	Alzheimer's disease (survival time);
CRC	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.83	0.4	6.61e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18043455	chr3:127771761	SEC61A1	0.43	6.2	0.32	1.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.91	-14.66	-0.63	8.16e-38	Response to temozolomide;
CRC	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-7.67	-0.39	2.02e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.24	-14.68	-0.63	7.09e-38	Diabetic kidney disease;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg02683197	chr6:28174875	NA	0.65	7.61	0.39	2.87e-13	Parkinson's disease;
CRC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg23018236	chr17:30244563	NA	-0.67	-7.99	-0.4	2.35e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.75	-0.35	6.53e-11	Monocyte percentage of white cells;
CRC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.43	6.94	0.36	2.11e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.52	9.22	0.45	3.57e-18	Common traits (Other);
CRC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg20129853	chr10:51489980	NA	-0.43	-7.17	-0.37	4.92e-12	Prostate-specific antigen levels;
CRC	cis	rs6662572	0.737	rs6700322	chr1:46409176	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.82	-0.31	1.42e-8	Blood protein levels;
CRC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.28	-0.33	1.05e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg19223190	chr17:80058835	NA	0.39	6.29	0.33	1e-9	Life satisfaction;
CRC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.8	-0.3	1.58e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18099408	chr3:52552593	STAB1	-0.48	-8.31	-0.42	2.48e-15	Electroencephalogram traits;
CRC	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg12315302	chr6:26189340	HIST1H4D	0.96	6.61	0.34	1.58e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.78	0.35	5.46e-11	Lymphocyte counts;
CRC	cis	rs45544231	0.521	rs1477074	chr16:52578548	T/C	cg09051775	chr16:52580266	TOX3	-0.4	-6.51	-0.34	2.87e-10	Restless legs syndrome;
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	cis	rs12534701	0.904	rs3817518	chr7:154672809	C/T	cg24255201	chr7:154684926	DPP6	0.59	8.68	0.43	1.81e-16	Colorectal cancer (diet interaction);
CRC	trans	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.18	0.37	4.75e-12	Endometrial cancer;
CRC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-6.49	-0.34	3.21e-10	Ulcerative colitis;
CRC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.31	0.56	6.9e-29	Height;
CRC	cis	rs7605827	0.930	rs1035247	chr2:15617846	T/A	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	trans	rs1864585	0.520	rs73208789	chr8:10679187	A/G	cg26278703	chr11:58910052	FAM111A	0.55	6.38	0.33	5.95e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.53	-0.47	3.63e-19	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15042806	chr16:23652268	DCTN5;PALB2	0.45	6.38	0.33	5.98e-10	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26250143	chr17:3627045	ITGAE;GSG2	0.4	6.37	0.33	6.38e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4130344	0.935	rs4234923	chr4:159688477	A/C	cg01113538	chr6:53658866	LRRC1	0.4	5.98	0.31	5.92e-9	Intelligence (multi-trait analysis);
CRC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.76	10.68	0.51	4.7e-23	High light scatter reticulocyte count;
CRC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg00255919	chr5:131827918	IRF1	-0.38	-6.43	-0.33	4.57e-10	Breast cancer;Mosquito bite size;
CRC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.54	7.98	0.4	2.43e-14	Intelligence (multi-trait analysis);
CRC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.78	-0.35	5.43e-11	Breast cancer;
CRC	cis	rs6840360	0.642	rs2053566	chr4:152445831	A/C	cg09659197	chr4:152720779	NA	0.33	6.67	0.35	1.08e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.33	12.69	0.57	2.61e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg02869364	chr7:1081709	C7orf50	-0.48	-6.6	-0.34	1.63e-10	Bronchopulmonary dysplasia;
CRC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg25834613	chr7:1915315	MAD1L1	-0.48	-6.76	-0.35	6.3e-11	Bipolar disorder;
CRC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.76	-10.97	-0.52	4.65e-24	Neutrophil percentage of white cells;
CRC	cis	rs17095355	1.000	rs13377169	chr10:111729414	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.27	-0.42	3.27e-15	Biliary atresia;
CRC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.76	12.95	0.58	2.82e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-7.21	-0.37	3.82e-12	Response to bleomycin (chromatid breaks);
CRC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.76	-8.77	-0.44	9.63e-17	Cerebrospinal P-tau181p levels;
CRC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.69	-0.39	1.74e-13	Bladder cancer;
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.71	-11.45	-0.53	9.16e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26918792	chr6:26402310	BTN3A1	-0.39	-6.28	-0.33	1.04e-9	Aortic root size;
CRC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg18282456	chr14:51561492	TRIM9	0.29	5.71	0.3	2.48e-8	Cancer;
CRC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.01e-12	Alzheimer's disease (late onset);
CRC	cis	rs501120	1.000	rs607760	chr10:44756236	A/G	cg09554077	chr10:44749378	NA	0.89	13.28	0.59	1.58e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.61	9.64	0.47	1.62e-19	Mean corpuscular hemoglobin concentration;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18604876	chr3:5164258	ARL8B	-0.45	-6.52	-0.34	2.66e-10	Myopia (pathological);
CRC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.49	-0.38	6.34e-13	Aortic root size;
CRC	cis	rs4731207	0.651	rs28710776	chr7:124614472	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	6.06	0.32	3.76e-9	Axial length;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05139434	chr1:41328180	CITED4	0.38	6.24	0.33	1.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.46	7.01	0.36	1.37e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01341218	chr17:43662625	NA	0.76	8.08	0.41	1.22e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	8.26	0.41	3.67e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.61	7.23	0.37	3.34e-12	White matter hyperintensity burden;
CRC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.41	0.38	1.08e-12	Heart rate;
CRC	cis	rs6496044	1.000	rs6496044	chr15:86067306	G/A	cg17133734	chr15:86042851	AKAP13	0.39	5.93	0.31	7.51e-9	Interstitial lung disease;
CRC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg06238570	chr21:40685208	BRWD1	0.78	10.83	0.51	1.36e-23	Cognitive function;
CRC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.94	-15.38	-0.65	1.29e-40	Gut microbiota (bacterial taxa);
CRC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-8.46	-0.42	9.01e-16	Total body bone mineral density;
CRC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.55e-18	Parkinson's disease;
CRC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.66	11.83	0.55	3.94e-27	Eye color traits;
CRC	cis	rs539514	0.690	rs607095	chr13:76316165	A/T	cg04757411	chr13:76259545	LMO7	-0.36	-6.08	-0.32	3.29e-9	Type 1 diabetes;
CRC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.02	12.72	0.57	1.98e-30	Uric acid levels;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.22	-0.41	4.71e-15	Total body bone mineral density;
CRC	cis	rs975722	0.638	rs718829	chr7:117207860	C/A	cg09181792	chr7:117119393	CFTR	0.29	6.04	0.32	4.28e-9	Coronary artery disease;
CRC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.37	0.33	6.35e-10	Height;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg19318889	chr4:1322082	MAEA	-0.4	-5.95	-0.31	6.8e-9	Obesity-related traits;
CRC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.47	-5.98	-0.31	5.79e-9	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg25547332	chr5:131281432	NA	0.4	5.6	0.3	4.43e-8	Life satisfaction;
CRC	cis	rs863345	0.526	rs857724	chr1:158607372	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg03929089	chr4:120376271	NA	-0.54	-6.67	-0.35	1.09e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.92	-0.44	3.42e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.65	-8.14	-0.41	8.31e-15	Menarche (age at onset);
CRC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02290350	chr8:58132656	NA	-0.59	-8.33	-0.42	2.25e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg22110888	chr17:80059540	CCDC57	0.39	6.14	0.32	2.34e-9	Life satisfaction;
CRC	cis	rs11021065	0.720	rs11021083	chr11:94952391	G/A	cg08881680	chr11:94965469	SESN3	-0.4	-5.63	-0.3	3.83e-8	Common carotid intima-media thickness in HIV infection;Common carotid intima-media thickness;
CRC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.2	-0.37	4.04e-12	Hemoglobin concentration;
CRC	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg00631329	chr6:26305371	NA	-0.4	-6.89	-0.36	2.86e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20094282	chr17:79369258	NA	0.4	5.96	0.31	6.56e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19522332	chr3:178866004	PIK3CA	0.5	6.48	0.34	3.3e-10	Thyroid stimulating hormone;
CRC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.67	-5.93	-0.31	7.56e-9	Diabetic retinopathy;
CRC	cis	rs7680126	0.596	rs12510549	chr4:10276467	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.94	-0.31	7.08e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.09	13.47	0.6	3.05e-33	Vitiligo;
CRC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg10802521	chr3:52805072	NEK4	0.48	6.45	0.34	3.96e-10	Schizophrenia;
CRC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.35	-6.6	-0.34	1.66e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.32	6.69	0.35	9.39e-11	Electroencephalogram traits;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.56	-8.93	-0.44	2.97e-17	Breast cancer;
CRC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	8.51	0.42	6.17e-16	Homoarginine levels;
CRC	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg22495460	chr2:25135724	ADCY3	-0.83	-13.94	-0.61	5.1e-35	Body mass index;
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	0.98	10.05	0.48	6.69e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg02569458	chr12:86230093	RASSF9	0.47	8.0	0.4	2.15e-14	Major depressive disorder;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.58	10.15	0.49	3.07e-21	Asthma;
CRC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg21747405	chr11:67723411	NA	-0.45	-6.33	-0.33	8.16e-10	Blood pressure (smoking interaction);
CRC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.44	-5.86	-0.31	1.15e-8	Gut microbiome composition (summer);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21826008	chr12:54674368	HNRPA1L-2;HNRNPA1;CBX5	0.47	6.25	0.33	1.25e-9	Thyroid stimulating hormone;
CRC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.49	-9.34	-0.46	1.52e-18	Reticulocyte fraction of red cells;
CRC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.55	0.43	4.71e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.89	-15.36	-0.65	1.55e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg03152288	chr2:177042942	NA	-0.57	-7.37	-0.38	1.4e-12	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.25	0.53	4.55e-25	Prudent dietary pattern;
CRC	cis	rs4728302	0.869	rs10156088	chr7:133592544	G/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.56	-0.34	2.04e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg25164649	chr6:28176230	NA	0.63	8.83	0.44	6.21e-17	Parkinson's disease;
CRC	cis	rs524281	0.731	rs10791840	chr11:65803383	T/C	cg16950941	chr11:66035639	RAB1B	-0.53	-5.81	-0.31	1.45e-8	Electroencephalogram traits;
CRC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.06	-0.32	3.72e-9	Diabetic kidney disease;
CRC	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27309920	chr12:6798957	ZNF384	0.51	7.48	0.38	7.02e-13	Response to antipsychotic treatment;
CRC	cis	rs73206853	0.841	rs73191834	chr12:110963841	T/G	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.67e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg14139581	chr11:64358342	SLC22A12	-0.38	-6.1	-0.32	3.01e-9	Urate levels in obese individuals;
CRC	cis	rs4728302	0.869	rs7792546	chr7:133595502	G/T	cg10665199	chr7:133106180	EXOC4	0.4	6.03	0.32	4.33e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.47	-6.72	-0.35	8.22e-11	Uric acid clearance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02444243	chr1:61516135	NA	0.44	6.4	0.33	5.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.8	13.44	0.6	3.93e-33	Menopause (age at onset);
CRC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-6.37	-0.33	6.51e-10	Menarche (age at onset);
CRC	cis	rs9463078	0.605	rs9472416	chr6:44950963	T/C	cg25276700	chr6:44698697	NA	0.26	6.31	0.33	9.21e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.86	-0.48	2.94e-20	Schizophrenia;
CRC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.23	-0.32	1.41e-9	Arsenic metabolism;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg19176530	chr2:71295334	NAGK	0.49	6.27	0.33	1.16e-9	Resistin levels;
CRC	cis	rs10267593	0.516	rs62435159	chr7:1911281	G/A	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.47	-0.34	3.62e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10638605	chr10:69991197	ATOH7	0.45	6.32	0.33	8.57e-10	Response to antipsychotic treatment;
CRC	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.54	-0.34	2.32e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.4	-6.89	-0.35	2.9e-11	Reticulocyte fraction of red cells;
CRC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.82	-13.88	-0.61	8.55e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.01	-0.48	9.28e-21	Height;
CRC	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.55	8.77	0.44	9.97e-17	Mean corpuscular volume;
CRC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.75	0.47	6.62e-20	Platelet count;
CRC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg19041857	chr6:27730383	NA	-0.7	-6.61	-0.34	1.51e-10	Breast cancer;
CRC	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg21452805	chr1:244014465	NA	0.48	6.44	0.33	4.2e-10	RR interval (heart rate);
CRC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.81	13.63	0.6	7.36e-34	Menopause (age at onset);
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg08200770	chr17:80723486	TBCD	-0.5	-7.54	-0.38	4.57e-13	Glycated hemoglobin levels;
CRC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.78	11.83	0.55	3.97e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.71	-0.35	8.73e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.17	25.84	0.82	3.41e-81	IgG glycosylation;
CRC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.46	-6.63	-0.34	1.34e-10	Uric acid clearance;
CRC	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.07	-0.32	3.5e-9	Heart rate;
CRC	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.92	15.29	0.64	2.9e-40	Dupuytren's disease;
CRC	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg03339077	chr11:47165057	C11orf49	0.51	7.31	0.37	2.01e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.52	-5.99	-0.31	5.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.44	6.43	0.33	4.48e-10	Resting heart rate;
CRC	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.4	-5.68	-0.3	2.93e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.6	-0.43	3.21e-16	Hemoglobin concentration;
CRC	cis	rs17065868	0.649	rs56317250	chr13:45034046	T/C	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.98	12.42	0.56	2.73e-29	Orofacial clefts;
CRC	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.37	-0.33	6.45e-10	Height;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26230658	chr17:5372445	DHX33	0.39	5.97	0.31	6.16e-9	Myopia (pathological);
CRC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg03162506	chr22:38580953	NA	0.27	5.77	0.3	1.81e-8	Cutaneous nevi;
CRC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg15193198	chr20:60906057	LAMA5	-0.43	-6.16	-0.32	2.07e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg21155852	chr7:2048760	MAD1L1	-0.44	-5.8	-0.3	1.59e-8	Neuroticism;
CRC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg23463467	chr20:60627584	TAF4	0.39	7.67	0.39	1.9e-13	Body mass index;
CRC	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg00857998	chr1:205179979	DSTYK	0.41	5.76	0.3	1.96e-8	Red blood cell count;
CRC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-6.84	-0.35	3.77e-11	HDL cholesterol;
CRC	cis	rs7572644	0.640	rs4665392	chr2:28029649	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.18	0.32	1.87e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.08	-12.43	-0.57	2.49e-29	Atopic dermatitis;
CRC	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.63	9.19	0.45	4.56e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.37	0.33	6.37e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13606994	chr1:44402422	ARTN	-0.35	-5.93	-0.31	7.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.68	-10.63	-0.51	7.18e-23	Plateletcrit;Platelet count;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04110283	chr11:17373108	DKFZp686O24166	-0.47	-6.09	-0.32	3.2e-9	Diisocyanate-induced asthma;
CRC	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg10820045	chr2:198174542	NA	0.46	8.12	0.41	9.32e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.71	0.3	2.48e-8	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.75	-0.3	2.06e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.48	6.59	0.34	1.79e-10	Lymphocyte counts;
CRC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg19812747	chr11:111475976	SIK2	-0.56	-9.52	-0.46	3.81e-19	Primary sclerosing cholangitis;
CRC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	1.03	17.63	0.7	1.83e-49	Parkinson's disease;
CRC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.58	-0.34	1.87e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.77	-10.49	-0.5	2.11e-22	White matter hyperintensity burden;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg04518342	chr5:131593106	PDLIM4	0.43	6.98	0.36	1.62e-11	Blood metabolite levels;
CRC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.79	-0.44	8.46e-17	Schizophrenia;
CRC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.07	0.32	3.47e-9	Calcium levels;
CRC	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg06470822	chr6:28175283	NA	0.77	6.93	0.36	2.26e-11	Depression;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg21251018	chr6:28226885	NKAPL	0.57	9.86	0.48	2.99e-20	Cardiac Troponin-T levels;
CRC	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg12072164	chr19:44306565	LYPD5	0.37	5.79	0.3	1.68e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs10971721	0.554	rs55917897	chr9:33795950	C/T	cg13495928	chr9:33750294	PRSS3	0.67	5.94	0.31	7.14e-9	Body mass index;
CRC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.85	0.44	5.65e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.9	0.48	2.16e-20	Cognitive test performance;
CRC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.95	13.64	0.6	7.03e-34	Breast cancer;
CRC	cis	rs9400239	0.622	rs1268167	chr6:109008183	A/G	cg11073813	chr6:109029018	NA	0.41	6.46	0.34	3.67e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.5	6.92	0.36	2.32e-11	Lymphocyte counts;
CRC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg04586622	chr2:25135609	ADCY3	-0.56	-10.49	-0.5	2.11e-22	Body mass index in non-asthmatics;
CRC	cis	rs6988985	0.678	rs7831617	chr8:144002283	G/T	cg10324643	chr8:143916377	GML	0.38	6.32	0.33	8.57e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.68	-12.27	-0.56	9.04e-29	Lewy body disease;
CRC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	11.65	0.54	1.73e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.7e-8	Lung cancer;
CRC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg11887960	chr12:57824829	NA	0.6	6.78	0.35	5.74e-11	Lung disease severity in cystic fibrosis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04592976	chr16:89984572	MC1R	0.48	5.98	0.31	5.81e-9	Thyroid stimulating hormone;
CRC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg16892393	chr17:41919603	NA	-0.38	-5.94	-0.31	7.23e-9	Triglycerides;
CRC	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.87	-0.35	3.31e-11	Putamen volume;
CRC	cis	rs939584	1.000	rs74676797	chr2:633063	G/A	cg03610516	chr2:642275	NA	0.42	5.65	0.3	3.49e-8	Body mass index;
CRC	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg04611788	chr3:186434169	KNG1	-0.58	-8.37	-0.42	1.66e-15	Blood protein levels;
CRC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg00255919	chr5:131827918	IRF1	-0.36	-6.12	-0.32	2.69e-9	Breast cancer;Mosquito bite size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05654483	chr10:122610929	WDR11	0.4	6.15	0.32	2.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg25834613	chr7:1915315	MAD1L1	-0.35	-5.86	-0.31	1.1e-8	Neuroticism;
CRC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.46	6.67	0.35	1.06e-10	Cognitive test performance;
CRC	cis	rs9928842	0.823	rs8061356	chr16:75294232	G/A	cg08657710	chr16:75258780	CTRB1	-0.53	-6.3	-0.33	9.65e-10	Alcoholic chronic pancreatitis;
CRC	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	14.22	0.62	4.24e-36	Exhaled nitric oxide output;
CRC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.59	-0.34	1.78e-10	Mean corpuscular volume;
CRC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.4	6.52	0.34	2.61e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.82e-16	Prostate cancer;
CRC	cis	rs17155006	0.655	rs378641	chr7:107722149	C/T	cg05962710	chr7:107745446	LAMB4	0.35	5.88	0.31	1.01e-8	Pneumococcal bacteremia;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12273811	chr6:28175739	NA	0.74	9.46	0.46	6.29e-19	Depression;
CRC	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-5.71	-0.3	2.51e-8	Breast cancer;
CRC	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	1.11	10.44	0.5	3.09e-22	Arsenic metabolism;
CRC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.3	-7.15	-0.37	5.55e-12	Lymphocyte counts;
CRC	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.54	-8.08	-0.41	1.23e-14	Diisocyanate-induced asthma;
CRC	cis	rs7224737	0.673	rs11079035	chr17:40289012	C/T	cg20291162	chr17:40259547	DHX58	-0.45	-6.01	-0.31	4.98e-9	Fibrinogen levels;
CRC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.83	0.35	4.13e-11	Joint mobility (Beighton score);
CRC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.49	7.02	0.36	1.28e-11	Breast cancer;
CRC	cis	rs2565722	0.583	rs2465874	chr6:161298592	G/T	cg03159191	chr6:161285451	NA	-0.38	-5.87	-0.31	1.07e-8	Blood protein levels;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg09264619	chr17:80180166	NA	-0.35	-5.97	-0.31	5.98e-9	Life satisfaction;
CRC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg16141378	chr3:129829833	LOC729375	-0.42	-6.11	-0.32	2.79e-9	Triglycerides;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg20512303	chr5:131592959	PDLIM4	0.29	5.68	0.3	2.97e-8	Blood metabolite levels;
CRC	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.68	11.33	0.53	2.49e-25	Alzheimer's disease (late onset);
CRC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.63	-0.34	1.4e-10	Aortic root size;
CRC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-6.25	-0.33	1.29e-9	Vitiligo;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.52	7.98	0.4	2.54e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.53	7.88	0.4	4.97e-14	Response to temozolomide;
CRC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg17948913	chr5:572064	NA	0.56	6.29	0.33	1e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.5	5.62	0.3	3.98e-8	Menarche (age at onset);
CRC	cis	rs4523957	0.890	rs8076939	chr17:2099931	C/A	cg16513277	chr17:2031491	SMG6	-0.56	-9.35	-0.46	1.4e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	1.11	13.02	0.58	1.5e-31	Obesity-related traits;
CRC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.51	-10.6	-0.5	8.6e-23	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.35	-6.03	-0.32	4.52e-9	Aortic root size;
CRC	cis	rs6499244	0.510	rs68039170	chr16:69886089	T/C	cg15192750	chr16:69999425	NA	0.39	5.73	0.3	2.22e-8	Menarche (age at onset);
CRC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.49	6.62	0.34	1.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs993804	0.527	rs7630907	chr3:25122044	G/C	cg12730826	chr1:205179972	DSTYK	-0.47	-6.02	-0.31	4.75e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg12273811	chr6:28175739	NA	0.55	8.14	0.41	8.09e-15	Parkinson's disease;
CRC	cis	rs6840360	0.642	rs7684462	chr4:152348422	T/G	cg09659197	chr4:152720779	NA	0.34	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.44	6.8	0.35	5.03e-11	Height;
CRC	cis	rs3814231	0.589	rs12357967	chr10:115469710	G/A	cg24846397	chr10:115438155	CASP7	-0.35	-5.68	-0.3	2.9e-8	Vitiligo;
CRC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg15445000	chr17:37608096	MED1	-0.34	-6.04	-0.32	4.2e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg18165381	chr3:44552316	NA	-0.39	-5.88	-0.31	1.02e-8	Depressive symptoms;
CRC	trans	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg17903999	chr18:56338584	MALT1	0.43	7.08	0.36	8.61e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.43	-6.6	-0.34	1.65e-10	Endometrial cancer;
CRC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.6	9.95	0.48	1.44e-20	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.69	0.65	8.17e-42	Platelet count;
CRC	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.57	7.59	0.39	3.38e-13	Serum parathyroid hormone levels;
CRC	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.29	-0.42	2.98e-15	Biliary atresia;
CRC	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg21699342	chr2:239360505	ASB1	0.48	7.59	0.39	3.38e-13	Multiple system atrophy;
CRC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.37	-6.72	-0.35	8.01e-11	Reticulocyte fraction of red cells;
CRC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.08	0.32	3.33e-9	Tonsillectomy;
CRC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.39e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs747334	0.818	rs3981165	chr10:92704909	C/T	cg19856520	chr1:39696676	MACF1	-0.32	-5.99	-0.31	5.45e-9	Fibroblast growth factor basic levels;
CRC	cis	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg00291366	chr1:12616550	NA	0.6	10.86	0.51	1.1e-23	Optic cup area;
CRC	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg10263370	chr3:44754102	ZNF502	-0.37	-6.04	-0.32	4.08e-9	Depressive symptoms;
CRC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06634786	chr22:41940651	POLR3H	0.42	5.71	0.3	2.54e-8	Vitiligo;
CRC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.66	-9.62	-0.47	1.89e-19	Cognitive function;
CRC	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.61	-5.77	-0.3	1.85e-8	IgG glycosylation;
CRC	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg26805224	chr10:79626177	DLG5	-0.56	-8.34	-0.42	2.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs747650	0.504	rs7108822	chr11:47044355	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.9	-0.31	9.01e-9	Acne (severe);
CRC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.6	-8.61	-0.43	3.02e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.71	-9.84	-0.48	3.41e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-6.56	-0.34	2.11e-10	Major depressive disorder;
CRC	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs629535	0.773	rs630235	chr8:70033529	T/G	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.55	10.01	0.48	8.86e-21	HDL cholesterol levels;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.46	-6.2	-0.32	1.69e-9	Longevity;Endometriosis;
CRC	cis	rs6691722	0.503	rs1064842	chr1:24706269	A/G	cg02336364	chr1:24764700	NIPAL3	0.38	6.34	0.33	7.51e-10	Response to interferon beta in multiple sclerosis;
CRC	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	8.17	0.41	6.68e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.66	-9.84	-0.48	3.34e-20	Pancreatic cancer;
CRC	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.71	-7.28	-0.37	2.54e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg26762873	chr11:5879799	OR52E8	-0.46	-6.53	-0.34	2.46e-10	DNA methylation (variation);
CRC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.55	7.63	0.39	2.5e-13	Pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16551665	chr17:30814028	CDK5R1	0.46	6.56	0.34	2.05e-10	Response to antipsychotic treatment;
CRC	cis	rs11203032	0.831	rs11203028	chr10:90956550	C/T	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.96	-0.31	6.44e-9	Life satisfaction;
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg04969067	chr8:143858791	LYNX1	0.44	7.43	0.38	9.31e-13	Urinary tract infection frequency;
CRC	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.56	-8.96	-0.44	2.44e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs773506	0.628	rs10733739	chr9:93929515	C/T	cg14446406	chr9:93919335	NA	-0.45	-7.71	-0.39	1.49e-13	Type 2 diabetes nephropathy;
CRC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-5.8	-0.3	1.59e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg15845792	chr6:28175446	NA	0.92	9.45	0.46	6.58e-19	Depression;
CRC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg05585544	chr11:47624801	NA	0.47	8.2	0.41	5.54e-15	Subjective well-being;
CRC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.6	9.37	0.46	1.21e-18	Aortic root size;
CRC	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg14758556	chr20:62440591	NA	0.41	6.15	0.32	2.23e-9	Atopic dermatitis;
CRC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	5.97	0.31	6.22e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.65	0.63	9e-38	Hypertriglyceridemia;
CRC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg05540913	chr6:167530185	CCR6	-0.34	-5.85	-0.31	1.2e-8	Primary biliary cholangitis;
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.1	-0.41	1.06e-14	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04622074	chr17:62657955	SMURF2	0.45	6.13	0.32	2.52e-9	Anxiety disorder;
CRC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.7	10.72	0.51	3.35e-23	Tonsillectomy;
CRC	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.85e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs11212617	0.967	rs227066	chr11:108209199	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.6	0.3	4.44e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11507343	chr20:18447757	C20orf12;POLR3F	0.42	5.96	0.31	6.43e-9	Response to antipsychotic treatment;
CRC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	11.35	0.53	1.96e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9891119	0.965	rs8072391	chr17:40495390	G/A	cg06270615	chr17:40516068	STAT3	-0.26	-5.75	-0.3	2.04e-8	Multiple sclerosis;Crohn's disease;
CRC	cis	rs863345	0.604	rs4276920	chr1:158504972	G/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.3e-9	Pneumococcal bacteremia;
CRC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.38	-0.33	5.89e-10	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09254969	chr5:141303622	KIAA0141	0.37	6.04	0.32	4.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.15e-10	Mean platelet volume;
CRC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg11833968	chr6:79620685	NA	-0.35	-6.05	-0.32	3.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg00106254	chr7:1943704	MAD1L1	-0.37	-5.81	-0.31	1.46e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7605827	0.930	rs6715487	chr2:15540579	T/C	cg19274914	chr2:15703543	NA	0.39	5.93	0.31	7.81e-9	Educational attainment (years of education);
CRC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.49	6.64	0.34	1.27e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg17885791	chr6:149771845	ZC3H12D	0.32	5.87	0.31	1.04e-8	Dupuytren's disease;
CRC	cis	rs6662572	0.737	rs74523130	chr1:46599619	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.24	0.33	1.32e-9	Blood protein levels;
CRC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.39	5.84	0.31	1.26e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11212617	0.934	rs595747	chr11:108194073	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.91	0.31	8.63e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.54	7.92	0.4	3.75e-14	Testicular germ cell tumor;
CRC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.72	11.24	0.53	5.13e-25	Corneal astigmatism;
CRC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.58	-8.48	-0.42	7.96e-16	Menarche (age at onset);
CRC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg07195577	chr17:27052828	TLCD1	0.39	5.63	0.3	3.87e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.94	0.48	1.55e-20	Bladder cancer;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.44	-6.15	-0.32	2.3e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.88	-0.55	2.58e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg27284194	chr4:1044797	NA	0.5	6.1	0.32	2.99e-9	Recombination rate (females);
CRC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.75	-0.35	6.76e-11	Aortic root size;
CRC	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26306683	chr17:18585705	ZNF286B	0.49	7.0	0.36	1.47e-11	Educational attainment (years of education);
CRC	cis	rs12692738	0.526	rs355846	chr2:165624586	C/T	cg03182029	chr2:165697222	COBLL1	-0.5	-5.81	-0.31	1.45e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg26893134	chr6:116381904	FRK	0.27	6.5	0.34	3.06e-10	Total cholesterol levels;
CRC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.63	11.16	0.52	9.56e-25	Schizophrenia;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.78	0.44	9.31e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.58	8.64	0.43	2.56e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.57	-0.39	3.73e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	11.16	0.52	9.91e-25	Bone mineral density;
CRC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg08772003	chr10:104629869	AS3MT	-0.35	-5.81	-0.31	1.48e-8	Arsenic metabolism;
CRC	cis	rs6695640	0.854	rs1075535	chr1:17739820	T/C	cg10329579	chr1:17754830	RCC2	-0.31	-5.73	-0.3	2.26e-8	Mean platelet volume;
CRC	cis	rs2882667	0.898	rs10038121	chr5:138389602	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-6.13	-0.32	2.45e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	cis	rs7605827	0.930	rs4668905	chr2:15543776	C/A	cg19274914	chr2:15703543	NA	0.4	5.92	0.31	8.18e-9	Educational attainment (years of education);
CRC	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg27534772	chr1:16042836	PLEKHM2	0.43	7.07	0.36	9.17e-12	Systolic blood pressure;
CRC	cis	rs2108622	0.559	rs7252638	chr19:15981025	G/C	cg13772218	chr19:15982569	NA	0.48	6.81	0.35	4.52e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	4.89e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7692995	0.920	rs35613046	chr4:18005966	A/G	cg08925142	chr4:18023851	LCORL	-0.55	-6.06	-0.32	3.73e-9	Height;
CRC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg00343986	chr7:65444356	GUSB	0.43	5.78	0.3	1.7e-8	Corneal structure;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg12564285	chr5:131593104	PDLIM4	0.45	7.35	0.38	1.61e-12	Breast cancer;
CRC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.57	-0.39	3.75e-13	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27343303	chr11:34380546	NA	0.46	6.2	0.32	1.65e-9	Thyroid stimulating hormone;
CRC	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg19131313	chr8:1704013	NA	-0.49	-6.05	-0.32	3.98e-9	Systolic blood pressure;
CRC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.37	5.71	0.3	2.55e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-13.76	-0.6	2.34e-34	Vitiligo;
CRC	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.62	5.64	0.3	3.66e-8	Schizophrenia;
CRC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg19257562	chr1:2043853	PRKCZ	0.38	6.42	0.33	4.67e-10	Height;
CRC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	7.99	0.4	2.36e-14	Colorectal cancer;
CRC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.67	10.61	0.51	7.91e-23	Breast cancer;
CRC	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.66	10.3	0.49	9.66e-22	Lewy body disease;
CRC	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.07	20.49	0.75	9.97e-61	Triglycerides;
CRC	cis	rs58799304	0.531	rs74965833	chr1:156054119	C/T	cg15685922	chr1:156045208	MEX3A	-0.52	-8.65	-0.43	2.38e-16	Ischemic stroke;
CRC	trans	rs1864585	0.520	rs17774398	chr8:10632496	A/G	cg26278703	chr11:58910052	FAM111A	-0.49	-6.39	-0.33	5.72e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.42	6.63	0.34	1.39e-10	Electroencephalogram traits;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg19041857	chr6:27730383	NA	-0.41	-5.96	-0.31	6.46e-9	Parkinson's disease;
CRC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg06462663	chr19:18546047	ISYNA1	-0.46	-6.97	-0.36	1.77e-11	Breast cancer;
CRC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	10.55	0.5	1.36e-22	Motion sickness;
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg15845792	chr6:28175446	NA	0.76	7.99	0.4	2.34e-14	Depression;
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02018176	chr4:1364513	KIAA1530	0.39	6.56	0.34	2.07e-10	Obesity-related traits;
CRC	cis	rs6076065	0.723	rs6137922	chr20:23363773	G/A	cg11657817	chr20:23433608	CST11	0.46	6.82	0.35	4.42e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.51	-0.71	6.56e-53	Schizophrenia;
CRC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.95	-0.36	2.01e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.33	0.33	7.91e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2.09e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.23	15.06	0.64	2.44e-39	Uric acid levels;
CRC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	1.03	13.47	0.6	2.98e-33	Cerebrospinal P-tau181p levels;
CRC	trans	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg26043149	chr18:55253948	FECH	-0.43	-6.12	-0.32	2.71e-9	Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg04586622	chr2:25135609	ADCY3	0.35	6.05	0.32	3.95e-9	Body mass index in non-asthmatics;
CRC	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.85	16.59	0.67	2.5e-45	Hip circumference;
CRC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.91	17.31	0.69	3.58e-48	Bone mineral density;
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.6	6.83	0.35	4.16e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.78	-9.85	-0.48	3.07e-20	Body mass index;
CRC	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.62	0.47	1.8e-19	Type 2 diabetes;
CRC	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.57	6.97	0.36	1.79e-11	Insulin-like growth factors;
CRC	cis	rs902774	0.818	rs73110471	chr12:53316821	G/A	cg14581129	chr12:53358946	NA	-0.51	-5.7	-0.3	2.62e-8	Prostate cancer;
CRC	trans	rs596169	0.764	rs715685	chr1:219127037	G/C	cg09853702	chr12:47665230	NA	0.77	6.43	0.33	4.58e-10	Intraocular pressure;
CRC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.41	-5.62	-0.3	4.07e-8	Corneal structure;
CRC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.57	-7.85	-0.4	5.91e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	6.74	0.35	7.23e-11	Cystic fibrosis severity;
CRC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg06238570	chr21:40685208	BRWD1	0.72	9.45	0.46	6.57e-19	Cognitive function;
CRC	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.83	0.63	1.82e-38	Exhaled nitric oxide output;
CRC	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.84	-13.71	-0.6	3.9e-34	Hypospadias;
CRC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.53	8.26	0.41	3.69e-15	Breast cancer;
CRC	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg12315302	chr6:26189340	HIST1H4D	0.73	5.8	0.3	1.6e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.49	6.6	0.34	1.68e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg27615366	chr5:131592974	PDLIM4	0.33	5.85	0.31	1.16e-8	Acylcarnitine levels;
CRC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.59	8.33	0.42	2.14e-15	Lung cancer;
CRC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.66	8.6	0.43	3.3e-16	Gestational age at birth (maternal effect);
CRC	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.7	8.28	0.42	3.13e-15	Eotaxin levels;
CRC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.47	-7.79	-0.39	8.57e-14	Type 2 diabetes;
CRC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.49	8.47	0.42	8.25e-16	Primary biliary cholangitis;
CRC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.29	-0.37	2.31e-12	Bipolar disorder;
CRC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.72	-8.11	-0.41	9.84e-15	Obesity-related traits;
CRC	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.47	-8.45	-0.42	9.64e-16	Psychosis in Alzheimer's disease;
CRC	cis	rs629535	0.783	rs658407	chr8:70035247	T/C	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.78	-0.35	5.73e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg14196790	chr5:131705035	SLC22A5	-0.37	-6.23	-0.32	1.41e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.83	17.53	0.69	4.82e-49	Cancer;
CRC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.9	-0.51	8.21e-24	Hepatocellular carcinoma;
CRC	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.33	-6.43	-0.33	4.51e-10	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg02683197	chr6:28174875	NA	-0.54	-7.43	-0.38	9.17e-13	Systemic lupus erythematosus;
CRC	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg25876840	chr17:41920477	NA	0.42	6.79	0.35	5.19e-11	Triglycerides;
CRC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.64	-0.43	2.49e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg02269571	chr22:50332266	NA	0.46	6.39	0.33	5.77e-10	Schizophrenia;
CRC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.66	9.0	0.44	1.79e-17	Schizophrenia;
CRC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-9.24	-0.45	3.24e-18	Subjective well-being;
CRC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.44	7.41	0.38	1.11e-12	Crohn's disease;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg15147215	chr3:52552868	STAB1	0.6	9.93	0.48	1.75e-20	Bipolar disorder;
CRC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.55	-9.21	-0.45	4.05e-18	Platelet count;
CRC	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg18827107	chr12:86230957	RASSF9	-0.37	-5.85	-0.31	1.21e-8	Major depressive disorder;
CRC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg12639453	chr1:2035780	PRKCZ	-0.38	-7.44	-0.38	8.82e-13	Height;
CRC	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg23234261	chr14:55582407	NA	-0.3	-5.8	-0.3	1.59e-8	Protein biomarker;
CRC	cis	rs12983728	0.505	rs12460050	chr19:58666109	G/A	cg24884572	chr19:58661833	ZNF329	0.45	5.69	0.3	2.76e-8	Cholesterol, total;
CRC	cis	rs17767392	0.958	rs35231795	chr14:71987374	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.29	-0.37	2.29e-12	Mitral valve prolapse;
CRC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.51	-6.27	-0.33	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg04202892	chr2:111875749	ACOXL	0.4	6.44	0.33	4.2e-10	Chronic lymphocytic leukemia;
CRC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg03013999	chr17:37608204	MED1	-0.48	-7.44	-0.38	8.77e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs6694672	1.000	rs7554757	chr1:196973054	A/T	cg13682187	chr1:196946512	CFHR5	0.53	7.26	0.37	2.86e-12	Asthma;
CRC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg12927641	chr6:109611667	NA	0.35	6.08	0.32	3.34e-9	Reticulocyte fraction of red cells;
CRC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.87e-12	Aortic root size;
CRC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	5.72	0.3	2.37e-8	IgG glycosylation;
CRC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.68	7.77	0.39	1.02e-13	Cleft lip with or without cleft palate;
CRC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.86	-0.31	1.12e-8	Monocyte count;
CRC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.43	6.78	0.35	5.71e-11	Corneal astigmatism;
CRC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	trans	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg05874882	chr4:1763078	NA	-0.35	-6.49	-0.34	3.07e-10	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg11887960	chr12:57824829	NA	0.63	6.43	0.33	4.4e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.8e-13	Colorectal cancer;
CRC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.24	-0.56	1.24e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-6.89	-0.36	2.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.68	7.4	0.38	1.17e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.42	9.26	0.45	2.62e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24739457	chr1:205821442	NA	0.44	6.42	0.33	4.82e-10	Menarche (age at onset);
CRC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	27.61	0.84	1.1e-87	Testicular germ cell tumor;
CRC	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.81	-0.3	1.51e-8	Blood protein levels;
CRC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg05623727	chr3:50126028	RBM5	-0.59	-10.0	-0.48	9.64e-21	Body mass index;
CRC	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg09876464	chr15:85330779	ZNF592	0.46	7.57	0.39	3.84e-13	P wave terminal force;
CRC	cis	rs2415984	0.579	rs2415999	chr14:46966224	T/C	cg14871534	chr14:47121158	RPL10L	-0.4	-6.01	-0.31	5.05e-9	Number of children ever born;
CRC	cis	rs972578	0.535	rs3091364	chr22:43414330	A/G	cg01576275	chr22:43409880	NA	0.38	5.85	0.31	1.21e-8	Mean platelet volume;
CRC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg12751644	chr20:60527061	NA	-0.38	-5.98	-0.31	5.71e-9	Body mass index;
CRC	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.02	-0.36	1.28e-11	Coronary artery disease;
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.53	7.09	0.36	8.22e-12	Alzheimer's disease;
CRC	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg01475377	chr6:109611718	NA	-0.35	-6.11	-0.32	2.87e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.74	-12.35	-0.56	4.66e-29	Height;
CRC	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.34	5.75	0.3	2.09e-8	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.42	6.97	0.36	1.7e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.83	10.94	0.52	5.81e-24	Prostate cancer;
CRC	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.65	-10.79	-0.51	1.95e-23	Hepatocellular carcinoma;
CRC	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.28	6.02	0.32	4.6e-9	Educational attainment (years of education);
CRC	cis	rs3126085	0.515	rs10788835	chr1:152330945	T/C	cg09127314	chr1:152161683	NA	-0.43	-5.66	-0.3	3.38e-8	Atopic dermatitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04652621	chr7:150671807	KCNH2	0.43	6.73	0.35	7.5e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.54	7.6	0.39	3.18e-13	Testicular germ cell tumor;
CRC	cis	rs11031096	0.535	rs10767886	chr11:4218391	T/C	cg18678763	chr11:4115507	RRM1	-0.35	-5.71	-0.3	2.55e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs863345	0.584	rs1117125	chr1:158509396	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.3e-9	Pneumococcal bacteremia;
CRC	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg02158880	chr13:53174818	NA	0.48	7.18	0.37	4.61e-12	Lewy body disease;
CRC	cis	rs7487075	0.820	rs10467213	chr12:46720263	T/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.18	0.32	1.91e-9	Itch intensity from mosquito bite;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.4	-0.42	1.36e-15	Bipolar disorder;
CRC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.41	-6.23	-0.32	1.42e-9	Migraine;
CRC	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.9	0.36	2.69e-11	Systolic blood pressure;
CRC	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg21452805	chr1:244014465	NA	0.5	6.84	0.35	3.85e-11	RR interval (heart rate);
CRC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.74	0.39	1.27e-13	Platelet count;
CRC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	6.12	0.32	2.7e-9	Mean platelet volume;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12760041	chr2:211036890	C2orf67	-0.4	-5.96	-0.31	6.42e-9	Interleukin-6 levels;
CRC	cis	rs7113874	0.569	rs2289921	chr11:8496611	G/C	cg20771178	chr11:8615675	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4478137	0.899	rs10857354	chr4:164239841	A/G	cg06758707	chr4:164254230	NPY1R	0.39	6.01	0.31	4.89e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg07074390	chr21:40555500	PSMG1	-0.43	-5.68	-0.3	2.91e-8	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12074093	chr17:16256568	CENPV	0.42	6.81	0.35	4.53e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg08314208	chr16:67682810	RLTPR	-0.61	-6.26	-0.33	1.2e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.83	0.35	4e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.72	11.63	0.54	1.95e-26	Dental caries;
CRC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.52	-6.04	-0.32	4.2e-9	Vitiligo;
CRC	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	6.53	0.34	2.43e-10	Blood protein levels;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.67	-10.93	-0.52	6.5e-24	Neurofibrillary tangles;
CRC	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.41	0.5	4.05e-22	Corneal astigmatism;
CRC	cis	rs6921919	0.789	rs11970439	chr6:28303464	C/G	cg21251018	chr6:28226885	NKAPL	0.41	5.92	0.31	8.14e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.6	-7.08	-0.36	8.62e-12	Blood protein levels;
CRC	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg00666640	chr1:248458726	OR2T12	0.4	7.28	0.37	2.49e-12	Common traits (Other);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg23300289	chr9:132146083	NA	-0.4	-6.07	-0.32	3.43e-9	Daytime sleep phenotypes;
CRC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg27661571	chr11:113659931	NA	-0.87	-10.28	-0.49	1.09e-21	Hip circumference adjusted for BMI;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17839278	chr11:47664375	MTCH2	0.5	6.27	0.33	1.12e-9	Thyroid stimulating hormone;
CRC	cis	rs2333194	0.844	rs17182286	chr14:73748908	C/T	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.4	-5.86	-0.31	1.13e-8	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.41	-7.39	-0.38	1.24e-12	Reticulocyte fraction of red cells;
CRC	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.57	8.52	0.43	5.7e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.65	-0.34	1.25e-10	Cutaneous nevi;
CRC	cis	rs7916697	0.947	rs4745950	chr10:69996455	A/G	cg06988349	chr10:69991859	ATOH7	-0.34	-6.13	-0.32	2.49e-9	Optic disc area;
CRC	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.71	13.8	0.61	1.74e-34	Mean corpuscular hemoglobin;
CRC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.41	-0.56	2.84e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.6	0.39	3.22e-13	Mean corpuscular hemoglobin;
CRC	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg02023728	chr11:77925099	USP35	0.36	6.12	0.32	2.67e-9	Alzheimer's disease (survival time);
CRC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.28e-19	Morning vs. evening chronotype;
CRC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg26805224	chr10:79626177	DLG5	-0.43	-6.33	-0.33	7.82e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.22	-0.32	1.53e-9	Aortic root size;
CRC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.55	-8.0	-0.4	2.15e-14	Colorectal cancer;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.64	6.55	0.34	2.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15672675	chr1:40507006	CAP1	-0.52	-6.56	-0.34	2.08e-10	Monocyte percentage of white cells;
CRC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.59	8.9	0.44	3.73e-17	Asthma;
CRC	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11446398	chr5:77624930	NA	-0.47	-6.55	-0.34	2.15e-10	Triglycerides;
CRC	trans	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg21153622	chr11:89784906	NA	-0.44	-6.79	-0.35	5.17e-11	Height;
CRC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.66	-0.34	1.13e-10	Monocyte percentage of white cells;
CRC	cis	rs8028182	0.636	rs4886707	chr15:75755467	C/T	cg20655648	chr15:75932815	IMP3	0.42	6.01	0.31	5.06e-9	Sudden cardiac arrest;
CRC	cis	rs13315871	1.000	rs71311858	chr3:58323793	G/C	cg20936604	chr3:58311152	NA	-0.78	-7.38	-0.38	1.34e-12	Cholesterol, total;
CRC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg13206674	chr6:150067644	NUP43	0.63	9.28	0.46	2.36e-18	Lung cancer;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-12.31	-0.56	6.7e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.63	-0.34	1.4e-10	Metabolite levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11563264	chr4:190862026	FRG1	-0.45	-7.12	-0.37	6.94e-12	Myopia (pathological);
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg23161317	chr6:28129485	ZNF389	0.47	6.62	0.34	1.48e-10	Cardiac Troponin-T levels;
CRC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.39	-8.62	-0.43	2.89e-16	Eye color traits;
CRC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg18876405	chr7:65276391	NA	0.47	6.49	0.34	3.08e-10	Aortic root size;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg15786705	chr6:28176104	NA	0.72	9.36	0.46	1.33e-18	Parkinson's disease;
CRC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg00769240	chr8:12517080	NA	-0.65	-7.34	-0.38	1.67e-12	Blood pressure (smoking interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11820993	chr17:79633565	CCDC137;C17orf90	0.39	5.98	0.31	5.86e-9	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg04269497	chr6:167369491	RNASET2	-0.74	-6.05	-0.32	3.85e-9	Cognitive function;
CRC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg16506815	chr2:162101123	NA	-0.38	-5.63	-0.3	3.85e-8	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05661282	chr19:58220370	ZNF154	0.24	6.5	0.34	2.9e-10	Diisocyanate-induced asthma;
CRC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.56	-7.81	-0.4	7.54e-14	Blood trace element (Cu levels);
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg06470822	chr6:28175283	NA	-1.01	-13.68	-0.6	4.92e-34	Depression;
CRC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg22723502	chr6:26240528	HIST1H4F	-0.35	-5.82	-0.31	1.4e-8	Gout;Renal underexcretion gout;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg00306905	chr10:121356070	TIAL1	0.43	6.03	0.32	4.32e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6585424	1.000	rs11201972	chr10:81932680	C/T	cg11900509	chr10:81946545	ANXA11	-0.72	-8.84	-0.44	5.72e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg20647610	chr2:228736258	WDR69	-0.5	-6.76	-0.35	6.37e-11	Blood pressure;
CRC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.5	-8.04	-0.41	1.62e-14	Monocyte count;
CRC	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.38	5.94	0.31	7.06e-9	Reticulocyte fraction of red cells;
CRC	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.95	-0.36	1.97e-11	Inflammatory skin disease;
CRC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg07718321	chr6:96025334	MANEA	-0.58	-7.22	-0.37	3.52e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs12024301	0.557	rs79082707	chr1:183620572	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.36	6.18	0.32	1.9e-9	Height;
CRC	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.47	-6.68	-0.35	9.93e-11	Vitamin D levels;
CRC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.42	-7.44	-0.38	8.63e-13	Reticulocyte fraction of red cells;
CRC	cis	rs1322512	1.000	rs2250006	chr6:153006401	T/A	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.18e-9	Tonometry;
CRC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-7.61	-0.39	2.97e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.82	12.72	0.57	2.08e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg12516270	chr8:143859308	LYNX1	-0.39	-6.44	-0.33	4.17e-10	Urinary tract infection frequency;
CRC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.51	0.57	1.22e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13300549	chr12:10365696	GABARAPL1	0.4	6.38	0.33	6.15e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.58	-9.13	-0.45	7.2e-18	Intelligence (multi-trait analysis);
CRC	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.06	-12.35	-0.56	4.92e-29	Diabetic kidney disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25355076	chr5:39074677	RICTOR	0.41	5.99	0.31	5.39e-9	Anxiety disorder;
CRC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.49	0.38	6.24e-13	Lung cancer in ever smokers;
CRC	cis	rs73206853	0.620	rs112599609	chr12:111147643	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.48	0.34	3.4e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg03623178	chr6:28175578	NA	0.73	6.88	0.35	3.12e-11	Depression;
CRC	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.52	7.7	0.39	1.58e-13	Coronary artery disease;
CRC	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.85	16.13	0.66	1.59e-43	Hip circumference;
CRC	cis	rs6479527	0.875	rs9299414	chr9:96805568	C/T	cg14459158	chr9:96720562	NA	0.38	6.71	0.35	8.37e-11	Esophageal adenocarcinoma;
CRC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12311346	chr5:56204834	C5orf35	0.46	7.25	0.37	2.91e-12	Coronary artery disease;
CRC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.49	-0.75	9.84e-61	Height;
CRC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.31	-0.42	2.57e-15	Chronic sinus infection;
CRC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.77	0.3	1.82e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg07217954	chr7:1067459	C7orf50	0.56	5.85	0.31	1.21e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg18612461	chr15:75251733	NA	-0.39	-6.1	-0.32	2.9e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4973397	0.810	rs12999051	chr2:232276992	T/A	cg13347044	chr2:232276743	NA	0.52	7.49	0.38	6.2e-13	Anti-saccade response;
CRC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-7.5	-0.38	5.96e-13	Vitiligo;
CRC	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg16670446	chr17:27188758	MIR451;MIR144	-0.6	-10.42	-0.5	3.64e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.09	-0.45	9.31e-18	Neuroticism;
CRC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg00343986	chr7:65444356	GUSB	0.5	7.44	0.38	8.9e-13	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-9.54	-0.47	3.45e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg09127314	chr1:152161683	NA	0.53	6.69	0.35	9.52e-11	Atopic dermatitis;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.64	10.23	0.49	1.66e-21	Longevity;Endometriosis;
CRC	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	8.51	0.42	6.2e-16	Alzheimer's disease (late onset);
CRC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg26211634	chr5:139558579	C5orf32	0.44	7.69	0.39	1.74e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3804749	0.934	rs13314114	chr3:122836000	T/C	cg26084141	chr3:122786895	PDIA5	0.24	6.68	0.35	1.05e-10	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	trans	rs4955793	0.585	rs61796578	chr3:178615072	G/A	cg11644478	chr21:40555479	PSMG1	0.65	6.06	0.32	3.83e-9	Post-traumatic stress disorder (asjusted for relatedness);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01021423	chr3:48541507	SHISA5	-0.43	-6.59	-0.34	1.79e-10	Myopia (pathological);
CRC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23378565	chr7:2036160	MAD1L1	-0.45	-6.79	-0.35	5.26e-11	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03859306	chr9:131452634	SET	0.42	6.04	0.32	4.07e-9	Response to antipsychotic treatment;
CRC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-6.42	-0.33	4.68e-10	Body mass index;
CRC	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.75	9.48	0.46	5.09e-19	Iron status biomarkers;
CRC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.49	6.91	0.36	2.53e-11	Type 1 diabetes nephropathy;
CRC	cis	rs365302	1.000	rs371023	chr6:159618397	C/T	cg14500486	chr6:159655392	FNDC1	0.53	7.76	0.39	1.05e-13	Coronary heart disease;
CRC	cis	rs3751196	0.808	rs80023709	chr12:104213192	A/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.44	-0.33	4.21e-10	Lymphocyte counts;
CRC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.59	-9.85	-0.48	3.17e-20	Dupuytren's disease;
CRC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-6.94	-0.36	2.15e-11	Axial length;
CRC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.56	6.12	0.32	2.64e-9	Initial pursuit acceleration;
CRC	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg16898833	chr6:26189333	HIST1H4D	1.12	8.21	0.41	5.22e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12541635	1.000	rs2881037	chr8:107090901	C/T	cg10147462	chr8:107024639	NA	-0.37	-6.2	-0.32	1.69e-9	Age of smoking initiation;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg16703956	chr5:1446217	SLC6A3	-0.28	-6.2	-0.32	1.7e-9	Type 1 diabetes;
CRC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24308560	chr3:49941425	MST1R	0.5	8.31	0.42	2.46e-15	Intelligence (multi-trait analysis);
CRC	cis	rs911119	0.955	rs7270413	chr20:23593821	C/G	cg16589663	chr20:23618590	CST3	0.42	5.73	0.3	2.3e-8	Chronic kidney disease;
CRC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg26248373	chr2:1572462	NA	-0.65	-7.15	-0.37	5.76e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.25	-0.41	3.91e-15	Morning vs. evening chronotype;
CRC	cis	rs6694672	1.000	rs7516700	chr1:197110331	T/G	cg13682187	chr1:196946512	CFHR5	0.46	7.37	0.38	1.38e-12	Asthma;
CRC	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg01843034	chr6:37503916	NA	-0.38	-6.8	-0.35	4.85e-11	Cognitive performance;
CRC	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.64	-0.3	3.71e-8	Pulmonary function;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.96	-0.31	6.58e-9	Longevity;Endometriosis;
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	3.99e-16	Life satisfaction;
CRC	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg03623178	chr6:28175578	NA	0.96	13.39	0.59	6.04e-33	Depression;
CRC	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg06935464	chr4:38784597	TLR10	0.55	5.74	0.3	2.12e-8	Breast cancer;
CRC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg00531865	chr16:30841666	NA	-0.45	-6.13	-0.32	2.58e-9	Multiple myeloma;
CRC	cis	rs31872	1.000	rs31872	chr5:140372222	A/G	cg19650706	chr5:140594406	PCDHB13	-0.46	-6.85	-0.35	3.73e-11	Visceral adipose tissue adjusted for BMI;
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.25e-10	Alzheimer's disease;
CRC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.82	14.46	0.62	5.12e-37	Breast cancer;
CRC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.53	-7.45	-0.38	8.23e-13	Longevity;
CRC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.42	6.71	0.35	8.44e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg00666640	chr1:248458726	OR2T12	0.49	8.32	0.42	2.42e-15	Common traits (Other);
CRC	cis	rs2252790	0.859	rs2157321	chr6:116683788	C/T	cg18764771	chr6:116381957	FRK	-0.23	-6.14	-0.32	2.4e-9	Fast beta electroencephalogram;
CRC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.94	0.52	5.64e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.6	7.69	0.39	1.69e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg04176472	chr15:90893244	GABARAPL3	0.34	5.84	0.31	1.28e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg12463550	chr7:65579703	CRCP	0.64	6.15	0.32	2.27e-9	Diabetic kidney disease;
CRC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg02560186	chr11:3602584	NA	-0.56	-7.23	-0.37	3.41e-12	Blood pressure (smoking interaction);
CRC	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.65	5.99	0.31	5.64e-9	IgG glycosylation;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.38	-9.13	-0.45	6.96e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg20041105	chr8:143859282	LYNX1	0.46	8.27	0.41	3.45e-15	Urinary tract infection frequency;
CRC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.0	9.49	0.46	4.89e-19	Diabetic retinopathy;
CRC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	9.3	0.46	2.09e-18	Cognitive test performance;
CRC	cis	rs7680126	0.596	rs10939723	chr4:10139105	G/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.77	-0.3	1.79e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.63	0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg25174290	chr11:3078921	CARS	-0.41	-5.72	-0.3	2.44e-8	Calcium levels;
CRC	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg12573674	chr2:1569213	NA	-0.73	-7.37	-0.38	1.42e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2415984	0.600	rs61993299	chr14:46944880	A/C	cg14871534	chr14:47121158	RPL10L	-0.44	-6.2	-0.32	1.66e-9	Number of children ever born;
CRC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.16	0.32	2.13e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20307385	chr11:47447363	PSMC3	0.54	7.62	0.39	2.66e-13	Subjective well-being;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg10729496	chr3:10149963	C3orf24	0.54	6.97	0.36	1.71e-11	Alzheimer's disease;
CRC	cis	rs4731207	0.698	rs10085793	chr7:124484166	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.6e-9	Aortic root size;
CRC	cis	rs73206853	0.841	rs73206870	chr12:110819953	T/C	cg12870014	chr12:110450643	ANKRD13A	0.84	8.74	0.43	1.24e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.84	0.31	1.28e-8	Hemoglobin concentration;
CRC	cis	rs12745968	0.653	rs7418336	chr1:93163385	A/G	cg17283838	chr1:93427260	FAM69A	-0.45	-6.09	-0.32	3.16e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg03894339	chr8:19674705	INTS10	-0.42	-5.77	-0.3	1.85e-8	Breast cancer;
CRC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.46	-0.5	2.69e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-9.95	-0.48	1.48e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-25.23	-0.81	6.72e-79	Exhaled nitric oxide output;
CRC	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.6	13.21	0.59	2.89e-32	Airflow obstruction;
CRC	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.73	-0.43	1.28e-16	Metabolite levels;
CRC	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg01557791	chr16:72042693	DHODH	-0.55	-5.64	-0.3	3.6e-8	Coronary artery disease;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg15845792	chr6:28175446	NA	0.5	7.04	0.36	1.09e-11	Parkinson's disease;
CRC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.4	5.98	0.31	5.84e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16447950	chr5:562315	NA	-0.74	-9.76	-0.47	6.14e-20	Obesity-related traits;
CRC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.68	9.61	0.47	2e-19	Vitamin D levels;
CRC	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.64	-10.25	-0.49	1.43e-21	Lewy body disease;
CRC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg26608667	chr7:1196370	ZFAND2A	0.46	7.38	0.38	1.29e-12	Longevity;Endometriosis;
CRC	cis	rs2302190	0.882	rs12942018	chr17:56613277	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-7.88	-0.4	4.84e-14	Vitamin D levels;
CRC	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg10263370	chr3:44754102	ZNF502	-0.36	-5.95	-0.31	6.83e-9	Depressive symptoms;
CRC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	17.22	0.69	8.1e-48	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs995000	0.931	rs1168018	chr1:63001120	A/C	cg19896129	chr1:63156450	NA	-0.45	-6.98	-0.36	1.65e-11	Triglyceride levels;
CRC	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.69	5.66	0.3	3.36e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2811415	0.597	rs10934840	chr3:127746083	G/C	cg13719885	chr3:127795394	NA	-0.37	-5.64	-0.3	3.69e-8	Lung function (FEV1/FVC);
CRC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-10.5	-0.5	2.01e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs6433857	0.505	rs16867320	chr2:181362312	A/G	cg23363182	chr2:181467187	NA	0.54	7.73	0.39	1.35e-13	Body mass index;
CRC	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.48	6.57	0.34	1.92e-10	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08229018	chr4:119274133	PRSS12	0.41	7.25	0.37	3.05e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-0.72	-7.66	-0.39	2.15e-13	Schizophrenia;
CRC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.66	-9.86	-0.48	2.96e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg23815491	chr16:72088622	HP	0.56	6.11	0.32	2.74e-9	Coronary artery disease;
CRC	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs7626444	0.625	rs2686596	chr3:196475119	T/C	cg12930392	chr3:196481615	PAK2	0.41	7.3	0.37	2.23e-12	Monocyte count;
CRC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.76e-24	Bone mineral density;
CRC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.67	-7.97	-0.4	2.61e-14	Vitiligo;
CRC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.92	0.31	7.96e-9	Tonsillectomy;
CRC	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.64	-10.11	-0.49	4.21e-21	Lewy body disease;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.41	-6.0	-0.31	5.13e-9	Lymphocyte counts;
CRC	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.82	-15.23	-0.64	5.11e-40	Hip circumference;
CRC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg22495460	chr2:25135724	ADCY3	-0.87	-16.43	-0.67	1.04e-44	Body mass index in non-asthmatics;
CRC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	0.94	18.35	0.71	2.73e-52	Height;
CRC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.17	-0.37	5.07e-12	Mean corpuscular volume;
CRC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.65	-0.34	1.22e-10	Total body bone mineral density;
CRC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.61	-9.74	-0.47	7.11e-20	Total body bone mineral density;
CRC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.5	6.78	0.35	5.7e-11	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14534967	chr7:73153139	ABHD11	0.45	6.38	0.33	5.89e-10	Response to antipsychotic treatment;
CRC	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg15282417	chr9:129245246	FAM125B	0.44	8.2	0.41	5.43e-15	Intraocular pressure;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg10695429	chr3:185542769	IGF2BP2	0.42	6.12	0.32	2.69e-9	Body mass index;
CRC	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	0.61	9.64	0.47	1.58e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg27089200	chr19:41531976	NA	0.34	6.29	0.33	9.96e-10	DDT metabolite (p,p'-DDE levels);
CRC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.47	6.9	0.36	2.68e-11	Cognitive function;
CRC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.88	-0.31	9.96e-9	Mean corpuscular volume;
CRC	cis	rs6976053	0.868	rs3087504	chr7:100486088	C/T	cg10426581	chr7:100472382	SRRT	0.38	5.78	0.3	1.74e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	9.34	0.46	1.5e-18	Platelet count;
CRC	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg00601450	chr5:74908170	NA	0.39	5.61	0.3	4.34e-8	Age-related disease endophenotypes;
CRC	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg24596788	chr1:163392923	NA	-0.54	-8.45	-0.42	9.67e-16	Motion sickness;
CRC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.64	9.49	0.46	4.86e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.99	11.61	0.54	2.39e-26	Nonalcoholic fatty liver disease;
CRC	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.32	-0.33	8.44e-10	Coronary artery disease;
CRC	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.08	-24.46	-0.8	5.03e-76	Platelet distribution width;
CRC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.79	-8.66	-0.43	2.2e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs73198271	0.531	rs17154756	chr8:8652394	C/T	cg01851573	chr8:8652454	MFHAS1	0.55	6.84	0.35	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.85	-0.4	5.72e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16262614	chr3:133464971	TF	0.34	6.06	0.32	3.66e-9	Iron status biomarkers;
CRC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.77	0.74	6.66e-58	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.07	-0.36	9.15e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27447557	chr1:165796797	UCK2	0.44	6.37	0.33	6.5e-10	Anxiety disorder;
CRC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg06219103	chr11:63990595	FERMT3	-0.43	-6.78	-0.35	5.6e-11	Platelet count;
CRC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.6	-8.92	-0.44	3.27e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2013441	1.000	rs2703816	chr17:20118887	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.46	-0.34	3.67e-10	Obesity-related traits;
CRC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg23229984	chr5:148520753	ABLIM3	0.51	6.68	0.35	1.01e-10	Breast cancer;
CRC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	9.52	0.46	3.73e-19	Psoriasis;
CRC	trans	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08382705	chr11:45687319	CHST1	-0.44	-8.08	-0.41	1.24e-14	Height;
CRC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.43	6.7	0.35	8.89e-11	Hemoglobin concentration;
CRC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.84	-9.73	-0.47	7.72e-20	Breast cancer;
CRC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.72	-8.86	-0.44	5.29e-17	Mean platelet volume;
CRC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.63	9.45	0.46	6.58e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.4	7.1	0.36	7.63e-12	Obesity-related traits;
CRC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	9.64	0.47	1.61e-19	Body mass index (adult);
CRC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg12273811	chr6:28175739	NA	0.69	5.8	0.3	1.53e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	trans	rs867371	0.519	rs1566560	chr15:82524457	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.08	-0.32	3.32e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs9311676	0.609	rs1126551	chr3:58416535	C/T	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.39e-10	Systemic lupus erythematosus;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.59	6.44	0.33	4.31e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.18	-0.37	4.7e-12	Total body bone mineral density;
CRC	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.86	-0.31	1.11e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs860295	0.702	rs3851912	chr1:155586444	T/G	cg02153340	chr1:155202674	NA	-0.51	-6.43	-0.33	4.4e-10	Body mass index;
CRC	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.5	8.14	0.41	8e-15	Endometrial cancer;
CRC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	-0.65	-7.56	-0.38	4.17e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.44	6.68	0.35	1.04e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg03315344	chr16:75512273	CHST6	-0.53	-6.13	-0.32	2.55e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs6076065	0.723	rs6137905	chr20:23340938	G/A	cg11657817	chr20:23433608	CST11	0.45	6.57	0.34	2e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.84	0.44	5.75e-17	Schizophrenia;
CRC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg21153622	chr11:89784906	NA	-0.51	-8.52	-0.43	5.87e-16	HDL cholesterol;
CRC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	8.15	0.41	7.75e-15	Insulin-like growth factors;
CRC	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.11	-9.49	-0.46	4.7e-19	Mitochondrial DNA levels;
CRC	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.43	-7.44	-0.38	8.89e-13	Venous thromboembolism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03426840	chr11:118661678	DDX6	0.48	7.66	0.39	2.07e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7731657	0.537	rs10076495	chr5:130362953	A/C	cg08523029	chr5:130500466	HINT1	-0.47	-6.08	-0.32	3.32e-9	Fasting plasma glucose;
CRC	trans	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg25214090	chr10:38739885	LOC399744	0.41	6.34	0.33	7.8e-10	Diastolic blood pressure;
CRC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.55	10.01	0.48	9.44e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.85	14.73	0.63	4.51e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.69	0.35	9.43e-11	Hemoglobin concentration;
CRC	cis	rs9783347	1.000	rs4150641	chr11:18370739	C/A	cg15585147	chr11:18324498	HPS5	0.43	6.09	0.32	3.12e-9	Pancreatic cancer;
CRC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.48	7.02	0.36	1.28e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.15	-0.49	3.01e-21	Bipolar disorder;
CRC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.63	-0.39	2.48e-13	Gut microbiome composition (summer);
CRC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.85	16.06	0.66	2.81e-43	Dental caries;
CRC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.7	12.51	0.57	1.19e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg03609598	chr5:56110824	MAP3K1	0.59	7.89	0.4	4.64e-14	Initial pursuit acceleration;
CRC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.47	8.29	0.42	2.91e-15	Systemic lupus erythematosus;
CRC	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-5.87	-0.31	1.04e-8	Eosinophil percentage of white cells;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.74	-10.54	-0.5	1.45e-22	Menopause (age at onset);
CRC	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.51e-19	Systemic lupus erythematosus;
CRC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg21466736	chr12:48725269	NA	-0.52	-7.89	-0.4	4.64e-14	Glycated hemoglobin levels;
CRC	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.45	7.07	0.36	9.36e-12	Platelet count;
CRC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.29	-0.33	1.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg18478394	chr8:109455254	TTC35	0.38	5.94	0.31	7.24e-9	Dupuytren's disease;
CRC	cis	rs7113874	0.524	rs10769925	chr11:8623585	C/T	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg03340356	chr1:67600835	NA	0.24	5.78	0.3	1.71e-8	Psoriasis;
CRC	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.43	-6.56	-0.34	2.1e-10	Obesity-related traits;
CRC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.39	-7.53	-0.38	5.08e-13	Abdominal aortic aneurysm;
CRC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15738916	chr2:102314495	MAP4K4	-0.53	-6.47	-0.34	3.54e-10	Diisocyanate-induced asthma;
CRC	cis	rs459193	1.000	rs465002	chr5:55808475	C/T	cg18302225	chr5:55776401	NA	0.44	6.11	0.32	2.83e-9	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.41	6.02	0.32	4.58e-9	Electroencephalogram traits;
CRC	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg13844804	chr7:814759	HEATR2	0.68	7.43	0.38	9.32e-13	Cerebrospinal P-tau181p levels;
CRC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.95	11.2	0.53	6.98e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.87	-0.35	3.31e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.24	11.59	0.54	2.8e-26	Granulocyte percentage of myeloid white cells;
CRC	cis	rs501120	0.564	rs1704231	chr10:44691543	C/T	cg09554077	chr10:44749378	NA	0.49	6.29	0.33	1.04e-9	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg09085632	chr11:111637200	PPP2R1B	0.49	6.5	0.34	2.95e-10	Primary sclerosing cholangitis;
CRC	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.49	-6.7	-0.35	8.83e-11	Tanning;
CRC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs7487075	0.780	rs10785620	chr12:46737252	G/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.39	0.33	5.57e-10	Itch intensity from mosquito bite;
CRC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.47	-7.61	-0.39	2.9e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1950626	0.623	rs2295657	chr14:101430620	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.74	11.52	0.54	5.13e-26	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02725872	chr8:58115012	NA	-0.52	-7.23	-0.37	3.46e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05821866	chr1:167905319	DCAF6;BRP44	0.48	6.8	0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg16591659	chr17:78472290	NA	0.39	5.69	0.3	2.85e-8	Fractional excretion of uric acid;
CRC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.52	-8.06	-0.41	1.42e-14	Fibrinogen levels;
CRC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.58	8.89	0.44	4.26e-17	Coronary artery disease;
CRC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06505273	chr16:24850292	NA	0.41	6.29	0.33	9.86e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.73	11.54	0.54	4.22e-26	Colorectal cancer;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg06470822	chr6:28175283	NA	0.98	13.34	0.59	9.69e-33	Depression;
CRC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg19812747	chr11:111475976	SIK2	-0.58	-10.06	-0.49	6.12e-21	Primary sclerosing cholangitis;
CRC	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs2257205	0.667	rs8080281	chr17:56938558	A/G	cg25885038	chr17:56607967	SEPT4	0.53	5.82	0.31	1.43e-8	Pancreatic cancer;
CRC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.48	6.96	0.36	1.81e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.99	-0.31	5.41e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.47	7.43	0.38	9.7e-13	Inflammatory skin disease;
CRC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.7	-0.35	9.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	8.99	0.44	2.01e-17	Height;
CRC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg02560186	chr11:3602584	NA	-0.46	-6.25	-0.33	1.3e-9	Blood pressure (smoking interaction);
CRC	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg26353448	chr1:248524236	OR2T4	-0.34	-7.04	-0.36	1.1e-11	Common traits (Other);
CRC	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.71	8.44	0.42	1.03e-15	Eotaxin levels;
CRC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.4	6.14	0.32	2.43e-9	Mean corpuscular volume;
CRC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.63	-0.39	2.56e-13	Blood metabolite levels;
CRC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs11203032	0.614	rs11203025	chr10:90955474	A/C	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.8	-11.58	-0.54	2.97e-26	Pubertal anthropometrics;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg18864399	chr15:73345368	NEO1	-0.42	-6.23	-0.32	1.41e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.8	15.26	0.64	4.12e-40	Prudent dietary pattern;
CRC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	4.04e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg19041857	chr6:27730383	NA	-0.43	-6.01	-0.31	4.81e-9	Parkinson's disease;
CRC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.88	-14.83	-0.63	1.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg25131818	chr5:173000177	NA	0.58	6.12	0.32	2.7e-9	Airway imaging phenotypes;
CRC	cis	rs35883536	1.000	rs4907918	chr1:101094609	A/G	cg14515779	chr1:101123966	NA	0.44	8.57	0.43	3.97e-16	Monocyte count;
CRC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00376283	chr12:123451042	ABCB9	-0.51	-6.54	-0.34	2.32e-10	Neutrophil percentage of white cells;
CRC	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg17845761	chr1:175162550	KIAA0040	0.29	5.99	0.31	5.36e-9	Alcohol dependence;
CRC	cis	rs11628318	0.515	rs2093259	chr14:103145646	T/A	cg12046867	chr14:103022105	NA	0.41	5.83	0.31	1.29e-8	Platelet count;
CRC	cis	rs375066	0.623	rs1549959	chr19:44354486	G/A	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.48	7.96	0.4	2.74e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs2175142	chr2:162450124	T/C	cg15664909	chr17:685709	GLOD4;RNMTL1	-0.67	-5.96	-0.31	6.48e-9	Cognitive function;
CRC	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.86	15.83	0.66	2.29e-42	Hip circumference;
CRC	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.79	13.13	0.59	5.83e-32	Height;
CRC	cis	rs449789	0.857	rs606833	chr6:159717776	T/A	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg02683197	chr6:28174875	NA	0.89	10.93	0.52	6.43e-24	Depression;
CRC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.72	-0.35	8.23e-11	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs501120	0.584	rs629213	chr10:44736784	C/T	cg09554077	chr10:44749378	NA	0.76	8.38	0.42	1.59e-15	Coronary artery disease;Coronary heart disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg21192376	chr14:53020168	GPR137C;TXNDC16	0.37	6.15	0.32	2.23e-9	Interleukin-6 levels;
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-0.65	-11.13	-0.52	1.27e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg09127314	chr1:152161683	NA	0.5	6.36	0.33	6.76e-10	Atopic dermatitis;
CRC	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg25019722	chr6:37503610	NA	-0.47	-8.66	-0.43	2.1e-16	Cognitive performance;
CRC	cis	rs4711350	0.749	rs7752348	chr6:33718252	C/G	cg07979401	chr6:33739406	LEMD2	-0.43	-5.67	-0.3	3.1e-8	Schizophrenia;
CRC	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg23254163	chr1:152506842	NA	0.43	8.07	0.41	1.33e-14	Hair morphology;
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg22110888	chr17:80059540	CCDC57	0.39	6.23	0.32	1.41e-9	Life satisfaction;
CRC	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.57	0.43	4.07e-16	Corneal astigmatism;
CRC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	8.35	0.42	1.92e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg20291162	chr17:40259547	DHX58	-0.52	-7.06	-0.36	9.65e-12	Fibrinogen levels;
CRC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.47	9.1	0.45	8.66e-18	Renal cell carcinoma;
CRC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.15	-0.32	2.28e-9	Aortic root size;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.77	14.61	0.63	1.28e-37	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17491185	chr1:23811274	ASAP3	0.39	5.99	0.31	5.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.1	-0.32	2.94e-9	Neuroticism;
CRC	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.62	-0.43	2.94e-16	Brugada syndrome;
CRC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00166722	chr3:10149974	C3orf24	0.66	9.13	0.45	7.29e-18	Alzheimer's disease;
CRC	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg01843034	chr6:37503916	NA	-0.48	-8.8	-0.44	7.73e-17	Cognitive performance;
CRC	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.53	0.43	5.29e-16	Endometrial cancer;
CRC	trans	rs11031096	0.702	rs34356743	chr11:4153891	T/C	cg22978087	chr8:24814126	NEFL	0.33	6.08	0.32	3.37e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-15.06	-0.64	2.38e-39	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs860295	0.702	rs10908465	chr1:155389688	C/T	cg02153340	chr1:155202674	NA	-0.57	-6.77	-0.35	5.96e-11	Body mass index;
CRC	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg09695851	chr17:3907499	NA	0.74	13.31	0.59	1.25e-32	Type 2 diabetes;
CRC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.48	-0.42	7.78e-16	Monocyte count;
CRC	cis	rs6445967	0.695	rs2292675	chr3:58235727	T/C	cg23715586	chr3:58305044	RPP14	0.38	5.89	0.31	9.79e-9	Platelet count;
CRC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg03037974	chr15:76606532	NA	-0.43	-6.61	-0.34	1.51e-10	Blood metabolite levels;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg08888203	chr3:10149979	C3orf24	0.71	8.58	0.43	3.91e-16	Alzheimer's disease;
CRC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.62	-9.12	-0.45	7.68e-18	Diastolic blood pressure;
CRC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg07153921	chr17:41440717	NA	-0.38	-5.74	-0.3	2.13e-8	Menopause (age at onset);
CRC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.6e-12	Motion sickness;
CRC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.19	-0.71	1.21e-51	Height;
CRC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.5	-7.37	-0.38	1.38e-12	Longevity;
CRC	cis	rs294883	0.821	rs294899	chr6:159672455	C/T	cg14500486	chr6:159655392	FNDC1	-0.37	-6.15	-0.32	2.27e-9	Coronary artery disease;
CRC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-5.62	-0.3	4.06e-8	Joint mobility (Beighton score);
CRC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07294406	chr7:64700536	NA	0.37	6.0	0.31	5.1e-9	Calcium levels;
CRC	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.96	-0.72	1.04e-54	Schizophrenia;
CRC	cis	rs243505	0.898	rs243532	chr7:148412371	A/G	cg09806900	chr7:148480153	CUL1	-0.43	-5.95	-0.31	7.02e-9	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20237707	chr13:111719772	NA	-0.42	-6.66	-0.34	1.15e-10	Myopia (pathological);
CRC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg01843034	chr6:37503916	NA	-0.39	-7.12	-0.37	6.8e-12	Cognitive performance;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12609600	chr11:1595974	HCCA2;LOC338651	0.36	6.04	0.32	4.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04880052	chr2:219191631	PNKD	-0.44	-6.95	-0.36	2e-11	Colorectal cancer;
CRC	cis	rs9359856	0.564	rs17735590	chr6:90330268	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.85	-0.4	5.97e-14	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs62187646	chr2:162445488	T/C	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	trans	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg07393940	chr7:158741817	NA	0.51	7.23	0.37	3.3e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs372883	0.869	rs2027605	chr21:30726773	A/G	cg24692254	chr21:30365293	RNF160	0.39	5.94	0.31	7.35e-9	Pancreatic cancer;
CRC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg24209194	chr3:40518798	ZNF619	0.41	6.28	0.33	1.08e-9	Renal cell carcinoma;
CRC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02290350	chr8:58132656	NA	-0.41	-5.74	-0.3	2.21e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.7	8.59	0.43	3.49e-16	Mean platelet volume;
CRC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	9.71	0.47	8.87e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg00769240	chr8:12517080	NA	-0.74	-10.38	-0.5	5.02e-22	Blood pressure (smoking interaction);
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg20933634	chr6:27740509	NA	0.51	7.28	0.37	2.46e-12	Parkinson's disease;
CRC	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg22561889	chr6:118971681	C6orf204	0.45	5.95	0.31	6.93e-9	Diastolic blood pressure;
CRC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.97	13.53	0.6	1.75e-33	Breast cancer;
CRC	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg09040174	chr2:113837401	NA	0.64	10.17	0.49	2.58e-21	Protein quantitative trait loci;
CRC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.21e-10	Alzheimer's disease;
CRC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg24130564	chr14:104152367	KLC1	-0.4	-5.73	-0.3	2.33e-8	Body mass index;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-6.18	-0.32	1.9e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg04719120	chr6:96025338	MANEA	0.61	6.99	0.36	1.58e-11	Behavioural disinhibition (generation interaction);
CRC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg16476235	chr8:21771668	DOK2	0.35	6.0	0.31	5.3e-9	Mean corpuscular volume;
CRC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.46	-0.34	3.86e-10	Tonsillectomy;
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	0.8	8.79	0.44	8.31e-17	Gout;Renal underexcretion gout;
CRC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg12927641	chr6:109611667	NA	-0.38	-6.75	-0.35	6.72e-11	Reticulocyte fraction of red cells;
CRC	cis	rs672059	0.967	rs514183	chr1:183163174	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	7.35	0.38	1.55e-12	Hypertriglyceridemia;
CRC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.6	-9.16	-0.45	5.57e-18	Body mass index;
CRC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.48	0.38	6.73e-13	Motion sickness;
CRC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.02	-0.31	4.75e-9	Parkinson's disease;
CRC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg24300038	chr13:113819356	PROZ	-0.47	-5.89	-0.31	9.4e-9	Platelet distribution width;
CRC	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.71	8.98	0.44	2.08e-17	Iron status biomarkers;
CRC	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg02820901	chr13:113351484	ATP11A	0.71	7.44	0.38	9.05e-13	Glycated hemoglobin levels;
CRC	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	trans	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg10756647	chr7:56101905	PSPH	0.69	7.49	0.38	6.21e-13	Diabetic kidney disease;
CRC	cis	rs7493	0.516	rs13233527	chr7:95068795	T/C	cg19678392	chr7:94953810	PON1	-0.43	-5.87	-0.31	1.06e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	11.65	0.54	1.73e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.15	0.49	2.98e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs965469	0.779	rs1884563	chr20:3335540	T/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.94e-8	IFN-related cytopenia;
CRC	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20646317	chr12:50794494	LARP4	0.47	6.02	0.31	4.58e-9	Thyroid stimulating hormone;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00415497	chr22:50329860	NA	0.44	6.2	0.32	1.65e-9	Response to antipsychotic treatment;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg19913688	chr11:428466	ANO9	-0.69	-7.03	-0.36	1.22e-11	Body mass index;
CRC	trans	rs2303319	0.504	rs62187597	chr2:162398263	A/T	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.61	-0.39	2.85e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs4363385	0.755	rs516198	chr1:153026196	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.13e-13	Inflammatory skin disease;
CRC	trans	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	6.55	0.34	2.18e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03676636	chr4:99064102	C4orf37	0.2	5.81	0.31	1.45e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.78	13.83	0.61	1.26e-34	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg00250761	chr1:31883323	NA	-0.4	-7.41	-0.38	1.08e-12	Alcohol dependence;
CRC	cis	rs4803480	0.872	rs2058149	chr19:42086665	C/G	cg08478046	chr19:42093086	CEACAM21	-0.31	-5.61	-0.3	4.28e-8	Schizophrenia;
CRC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg09218773	chr11:619014	MUPCDH	-0.42	-5.93	-0.31	7.54e-9	Systemic lupus erythematosus;
CRC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.24	-16.6	-0.68	2.3e-45	Breast cancer;
CRC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	13.6	0.6	9.75e-34	Menopause (age at onset);
CRC	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg18232548	chr7:50535776	DDC	-0.39	-5.9	-0.31	9.13e-9	Body mass index;
CRC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.77	-7.65	-0.39	2.2e-13	Coronary artery disease;
CRC	cis	rs6586163	0.872	rs1926201	chr10:90746360	G/C	cg13456138	chr10:90753195	FAS	-0.43	-6.44	-0.33	4.19e-10	Chronic lymphocytic leukemia;
CRC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.39e-17	Morning vs. evening chronotype;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs1971762	0.527	rs6580958	chr12:54073483	A/G	cg06632207	chr12:54070931	ATP5G2	0.45	7.69	0.39	1.74e-13	Height;
CRC	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.77	7.69	0.39	1.77e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs863345	0.584	rs10797024	chr1:158497163	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.57	8.09	0.41	1.16e-14	Obesity-related traits;
CRC	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.4	-6.83	-0.35	4.13e-11	Hip circumference;Waist circumference;
CRC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.37	5.91	0.31	8.45e-9	Total body bone mineral density;
CRC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.29	-5.64	-0.3	3.59e-8	Personality dimensions;
CRC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.46	6.18	0.32	1.88e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg17724175	chr1:150552817	MCL1	0.43	6.55	0.34	2.19e-10	Melanoma;
CRC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.61	9.02	0.45	1.59e-17	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07042827	chr14:90849692	NA	0.47	6.62	0.34	1.48e-10	Response to antipsychotic treatment;
CRC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.54	7.99	0.4	2.35e-14	Resting heart rate;
CRC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.46	6.9	0.36	2.64e-11	Menopause (age at onset);
CRC	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg18833306	chr6:118973337	C6orf204	0.46	5.88	0.31	1.01e-8	Diastolic blood pressure;
CRC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.45	0.46	6.6e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.98	-0.31	5.88e-9	Bladder cancer;
CRC	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.63	-8.31	-0.42	2.63e-15	Malaria;
CRC	cis	rs7781266	0.640	rs62472376	chr7:133100276	T/C	cg03336402	chr7:133662267	EXOC4	0.51	5.98	0.31	5.89e-9	Educational attainment (college completion);
CRC	trans	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	5.02e-9	Breast cancer;
CRC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.4	6.22	0.32	1.53e-9	HDL cholesterol levels;
CRC	cis	rs3736485	0.934	rs2899475	chr15:51883051	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg21153622	chr11:89784906	NA	-0.4	-6.14	-0.32	2.34e-9	Height;
CRC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg05044414	chr3:183734942	ABCC5	0.48	8.29	0.42	2.89e-15	Anterior chamber depth;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21071989	chr15:31508272	NA	0.42	6.24	0.33	1.36e-9	Myopia (pathological);
CRC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.26	0.37	2.78e-12	Motion sickness;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	10.34	0.5	7.2e-22	Lymphocyte counts;
CRC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg19223190	chr17:80058835	NA	-0.49	-7.8	-0.4	8.33e-14	Life satisfaction;
CRC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg23758597	chr6:163146217	PARK2	-0.66	-6.48	-0.34	3.28e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.05	0.45	1.29e-17	Bladder cancer;
CRC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs12580194	0.593	rs11171431	chr12:55757609	G/T	cg19537932	chr12:55886519	OR6C68	-0.67	-8.83	-0.44	6.47e-17	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07582382	chr10:15001273	MEIG1	0.5	6.9	0.36	2.76e-11	Response to antipsychotic treatment;
CRC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.37	6.21	0.32	1.55e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.51	-7.1	-0.36	7.78e-12	Tuberculosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18462141	chr11:49872414	NA	-0.33	-6.06	-0.32	3.71e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.63	10.05	0.48	6.71e-21	Monocyte count;
CRC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	1.06	12.73	0.57	1.91e-30	Iron status biomarkers;
CRC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.44	6.51	0.34	2.73e-10	Calcium levels;
CRC	cis	rs9648716	1.000	rs10232600	chr7:140619317	A/C	cg10747023	chr7:140774559	NA	0.46	6.03	0.32	4.51e-9	Type 2 diabetes;
CRC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.46e-13	Schizophrenia;
CRC	cis	rs4964805	0.865	rs3935416	chr12:104206955	C/G	cg02344784	chr12:104178138	NT5DC3	0.53	8.07	0.41	1.29e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg08075719	chr14:103021372	NA	0.65	7.55	0.38	4.22e-13	Platelet count;
CRC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.75	10.96	0.52	4.91e-24	Longevity;
CRC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.77	-12.97	-0.58	2.46e-31	Breast cancer;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.67	10.93	0.52	6.36e-24	Height;
CRC	trans	rs12699921	0.632	rs2691601	chr7:17875431	C/T	cg02066331	chr6:17282778	RBM24	-0.37	-6.41	-0.33	5.08e-10	Fibrinogen levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26814432	chr1:114302134	PHTF1	0.42	6.11	0.32	2.79e-9	Response to antipsychotic treatment;
CRC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.47	0.5	2.42e-22	Diabetic retinopathy;
CRC	cis	rs16867321	0.507	rs2013577	chr2:181370505	C/T	cg23363182	chr2:181467187	NA	-0.54	-7.97	-0.4	2.7e-14	Obesity;
CRC	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.72	-10.09	-0.49	4.82e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg08288130	chr8:21771540	DOK2	0.3	6.04	0.32	4.15e-9	Mean corpuscular volume;
CRC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26879891	chr1:152191343	HRNR	-0.31	-5.99	-0.31	5.48e-9	Inflammatory skin disease;
CRC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.41	6.49	0.34	3.21e-10	Monocyte count;
CRC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.42	-6.14	-0.32	2.37e-9	Aortic root size;
CRC	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	9.05	0.45	1.26e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7605827	0.930	rs7578787	chr2:15655119	T/C	cg19274914	chr2:15703543	NA	0.4	6.0	0.31	5.16e-9	Educational attainment (years of education);
CRC	cis	rs62229266	0.659	rs2255734	chr21:37411909	T/C	cg12218747	chr21:37451666	NA	-0.36	-6.21	-0.32	1.63e-9	Mitral valve prolapse;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12051359	chr8:120886151	DEPDC6	0.44	6.32	0.33	8.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.46	-6.53	-0.34	2.44e-10	Blood pressure (smoking interaction);
CRC	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.46	0.53	7.91e-26	Exhaled nitric oxide output;
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg04727332	chr7:45960243	IGFBP3	0.36	5.73	0.3	2.28e-8	Sitting height ratio;
CRC	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.73	0.35	7.73e-11	Lymphocyte counts;
CRC	cis	rs2310173	0.612	rs3819369	chr2:102632582	T/A	cg20856504	chr2:102616538	IL1R2	0.39	6.18	0.32	1.92e-9	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	cis	rs9467773	0.572	rs9467737	chr6:26381630	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.81	-0.3	1.5e-8	Gut microbiome composition (summer);
CRC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg07636037	chr3:49044803	WDR6	-0.82	-6.75	-0.35	6.8e-11	Cognitive function;
CRC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.26	0.33	1.19e-9	IgG glycosylation;
CRC	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.94	0.48	1.6e-20	Fuchs's corneal dystrophy;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	6.1	0.32	3.05e-9	Life satisfaction;
CRC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg23625390	chr15:77176239	SCAPER	0.41	5.9	0.31	9.18e-9	Blood metabolite levels;
CRC	cis	rs7916697	0.540	rs4551651	chr10:70024529	A/G	cg06988349	chr10:69991859	ATOH7	0.38	7.1	0.36	7.84e-12	Optic disc area;
CRC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.5	7.91	0.4	3.91e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.53	8.15	0.41	7.66e-15	Longevity;Endometriosis;
CRC	trans	rs2413583	0.591	rs12483879	chr22:39719148	C/G	cg09612413	chr10:12085555	UPF2	-0.55	-6.06	-0.32	3.77e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg02560186	chr11:3602584	NA	-0.56	-6.92	-0.36	2.39e-11	Blood pressure (smoking interaction);
CRC	cis	rs755249	0.567	rs67020650	chr1:39668015	T/C	cg18385671	chr1:39797026	MACF1	-0.41	-5.93	-0.31	7.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.85	-0.44	5.5e-17	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.42	6.09	0.32	3.08e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg17470449	chr10:769945	NA	0.5	7.06	0.36	9.9e-12	Uric acid levels;
CRC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.9	0.4	4.36e-14	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.62	10.48	0.5	2.23e-22	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01772115	chr1:90460555	ZNF326;LOC492303	0.46	7.51	0.38	5.56e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg12790874	chr13:100310405	CLYBL	0.61	6.3	0.33	9.58e-10	Breast cancer;
CRC	trans	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.62	-0.3	4.11e-8	Life satisfaction;
CRC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.54	7.84	0.4	6.5e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs1456896	0.835	rs921914	chr7:50310728	T/G	cg02134594	chr1:3632713	TP73	0.38	6.27	0.33	1.11e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.88	-15.78	-0.66	3.79e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.65	10.76	0.51	2.5e-23	Iron status biomarkers;
CRC	cis	rs4478137	0.931	rs12509756	chr4:164237464	A/T	cg06758707	chr4:164254230	NPY1R	0.39	5.95	0.31	6.76e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.53	-8.69	-0.43	1.75e-16	Schizophrenia;
CRC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.26	-0.37	2.78e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-11.72	-0.54	9.36e-27	Asthma;
CRC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg26043149	chr18:55253948	FECH	0.49	7.42	0.38	9.93e-13	Bone mineral density;
CRC	cis	rs62408225	0.722	rs1319433	chr6:90921988	G/A	cg06866423	chr6:90926672	BACH2	0.67	12.55	0.57	8.4000000000000007e-30	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.47	7.23	0.37	3.36e-12	Age at first birth;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg02683197	chr6:28174875	NA	0.69	7.44	0.38	8.81e-13	Parkinson's disease;
CRC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg23627948	chr7:2760692	NA	0.3	5.65	0.3	3.51e-8	Loneliness (linear analysis);
CRC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4728302	0.869	rs10155909	chr7:133593036	A/G	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.25e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.47	6.83	0.35	4.2e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.82	18.29	0.71	4.59e-52	Breast cancer;
CRC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg18683604	chr14:51561293	TRIM9	0.29	6.0	0.31	5.11e-9	Cancer;
CRC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg23625390	chr15:77176239	SCAPER	0.47	6.9	0.36	2.72e-11	Blood metabolite levels;
CRC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.45	6.52	0.34	2.7e-10	Obesity-related traits;
CRC	cis	rs501120	0.584	rs673354	chr10:44733816	C/A	cg09554077	chr10:44749378	NA	0.64	7.06	0.36	9.84e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.72	-8.15	-0.41	7.69e-15	Obesity-related traits;
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.28	-0.42	3.04e-15	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05585758	chr2:43037627	NA	0.4	5.97	0.31	6.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12273811	chr6:28175739	NA	0.71	9.07	0.45	1.08e-17	Depression;
CRC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.36	0.59	7.69e-33	Electrocardiographic conduction measures;
CRC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg03013636	chr16:1946785	NA	0.53	6.56	0.34	2.03e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.68	0.47	1.13e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.6	-0.3	4.53e-8	Parkinson's disease;
CRC	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.38	-6.38	-0.33	6.11e-10	Vitamin D levels;
CRC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.97	0.31	6.09e-9	Lung cancer;
CRC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg23463467	chr20:60627584	TAF4	0.36	6.37	0.33	6.21e-10	Body mass index;
CRC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.55	9.41	0.46	8.65e-19	Iron status biomarkers;
CRC	cis	rs3772130	0.583	rs6767409	chr3:121564989	G/A	cg20356878	chr3:121714668	ILDR1	0.37	6.1	0.32	2.91e-9	Cognitive performance;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.68e-17	Bipolar disorder;
CRC	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg06636001	chr8:8085503	FLJ10661	0.43	6.18	0.32	1.89e-9	Retinal vascular caliber;
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.39	0.56	3.27e-29	Alzheimer's disease;
CRC	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.43	6.87	0.35	3.17e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg16342193	chr10:102329863	NA	-0.34	-5.79	-0.3	1.67e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.51	6.78	0.35	5.48e-11	Coronary artery disease;
CRC	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg14631576	chr9:95140430	CENPP	-0.4	-7.13	-0.37	6.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.59	-8.2	-0.41	5.44e-15	Menopause (age at onset);
CRC	cis	rs3812762	0.871	rs2173999	chr11:8778077	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.37	6.09	0.32	3.15e-9	Hypospadias;
CRC	trans	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg17903999	chr18:56338584	MALT1	0.41	6.91	0.36	2.56e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.58	6.39	0.33	5.62e-10	Initial pursuit acceleration;
CRC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.75	9.83	0.48	3.62e-20	Alzheimer's disease;
CRC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg23463467	chr20:60627584	TAF4	0.39	7.06	0.36	9.79e-12	Body mass index;
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg12516270	chr8:143859308	LYNX1	0.44	7.79	0.39	8.89e-14	Urinary tract infection frequency;
CRC	cis	rs910187	0.678	rs3818006	chr20:45816328	A/G	cg27589058	chr20:45804311	EYA2	-0.39	-7.52	-0.38	5.4e-13	Migraine;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11866396	chr17:5322940	RPAIN;NUP88	0.41	6.69	0.35	9.33e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.94e-10	Lung cancer;
CRC	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.72	8.27	0.41	3.42e-15	Educational attainment;
CRC	trans	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg04077850	chr5:125800366	GRAMD3	0.36	6.13	0.32	2.47e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg23438505	chr17:78489298	NA	-0.45	-6.3	-0.33	9.8e-10	Parkinson's disease;
CRC	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg18764771	chr6:116381957	FRK	0.26	6.36	0.33	6.92e-10	Total cholesterol levels;
CRC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.49	8.45	0.42	9.51e-16	Facial morphology (factor 20);
CRC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.77	11.13	0.52	1.25e-24	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.99	0.66	5.77e-43	Intelligence (multi-trait analysis);
CRC	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.57	7.65	0.39	2.17e-13	Height;
CRC	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.66	-7.01	-0.36	1.4e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.72	-10.94	-0.52	5.62e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.08	-0.32	3.3e-9	Schizophrenia;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg21251018	chr6:28226885	NKAPL	-0.48	-6.38	-0.33	6.16e-10	Depression;
CRC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg20487152	chr13:99095054	FARP1	-0.44	-6.43	-0.33	4.54e-10	Longevity;
CRC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	8.3	0.42	2.81e-15	Eosinophilic esophagitis;
CRC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg17545662	chr6:170176663	C6orf70	0.48	5.72	0.3	2.37e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.19	-0.41	5.98e-15	Type 2 diabetes;
CRC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg21294424	chr19:58662284	ZNF329	0.85	9.53	0.47	3.54e-19	Cholesterol, total;
CRC	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg25885038	chr17:56607967	SEPT4	-0.51	-7.61	-0.39	2.96e-13	Vitamin D levels;
CRC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	0.71	6.49	0.34	3.11e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	6.13	0.32	2.48e-9	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00881440	chr7:2595255	C7orf27	0.48	7.7	0.39	1.5700000000000001e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-16.42	-0.67	1.1e-44	Height;
CRC	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.64	10.32	0.49	8.44e-22	Corneal astigmatism;
CRC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg15468180	chr1:107600409	PRMT6	-0.45	-6.73	-0.35	7.76e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6662572	0.737	rs9429184	chr1:46524739	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.37	0.33	6.29e-10	Blood protein levels;
CRC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.58	-8.09	-0.41	1.12e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg13385794	chr1:248469461	NA	0.38	6.56	0.34	2.08e-10	Common traits (Other);
CRC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.92	-0.44	3.42e-17	Urinary metabolites;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01754155	chr3:98620518	DCBLD2	0.39	6.29	0.33	1.03e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	9.53	0.47	3.55e-19	Cognitive test performance;
CRC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg05639522	chr1:247681581	NA	-0.52	-8.74	-0.43	1.18e-16	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs9378357	0.702	rs4383859	chr6:3280241	C/G	cg00226545	chr16:54320225	IRX3	0.76	6.2	0.32	1.72e-9	Obesity-related traits;
CRC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.11	-0.37	7.14e-12	Aortic root size;
CRC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.51	-8.22	-0.41	4.59e-15	Obesity-related traits;
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg11503833	chr11:492997	NA	0.56	5.89	0.31	9.64e-9	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20331612	chr10:3282311	NA	0.4	5.99	0.31	5.48e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04402184	chr1:193028837	TROVE2;UCHL5	0.47	6.79	0.35	5.4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7705042	0.828	rs6580224	chr5:141489306	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.2	0.37	4.04e-12	Asthma;
CRC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg01304814	chr3:48885189	PRKAR2A	0.86	6.24	0.33	1.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs11661542	0.967	rs11082043	chr18:20222985	C/G	cg20497554	chr1:28908371	SNHG12;SNORA44;SNORA16A	-0.45	-6.37	-0.33	6.26e-10	Intracranial aneurysm;
CRC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.23	0.45	3.48e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs8105895	0.935	rs10420019	chr19:22251905	T/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs73206853	0.764	rs56123836	chr12:110999032	G/A	cg12870014	chr12:110450643	ANKRD13A	0.81	9.34	0.46	1.45e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.43	-6.41	-0.33	4.99e-10	Cerebrospinal P-tau181p levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03500911	chr18:48556576	SMAD4	0.47	6.45	0.34	4.04e-10	Anxiety disorder;
CRC	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.29e-11	Morning vs. evening chronotype;
CRC	cis	rs12024301	0.557	rs10911389	chr1:183616805	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.86	0.35	3.41e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.79	10.33	0.49	7.59e-22	Bone mineral density;
CRC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg08999081	chr20:33150536	PIGU	0.44	5.72	0.3	2.39e-8	Protein C levels;
CRC	cis	rs2795502	0.564	rs11239826	chr10:43403097	T/C	cg20628663	chr10:43360327	NA	0.55	6.21	0.32	1.59e-9	Blood protein levels;
CRC	trans	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg18288967	chr1:45987694	PRDX1	0.58	6.36	0.33	6.58e-10	Obesity-related traits;
CRC	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg20936604	chr3:58311152	NA	-0.76	-7.13	-0.37	6.48e-12	Cholesterol, total;
CRC	cis	rs12143943	1.000	rs12143943	chr1:204572071	G/A	cg17419461	chr1:204415978	PIK3C2B	0.37	5.71	0.3	2.59e-8	Cognitive performance;
CRC	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.65	-9.44	-0.46	7.16e-19	Bipolar disorder;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.03	-26.55	-0.83	8.54e-84	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7301826	0.651	rs4759521	chr12:131297313	C/T	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.76	8.52	0.43	5.88e-16	Neuroticism;
CRC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.56	8.64	0.43	2.53e-16	Height;
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg22110888	chr17:80059540	CCDC57	0.39	6.2	0.32	1.71e-9	Life satisfaction;
CRC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.51	5.89	0.31	9.38e-9	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22537964	chr8:54755419	ATP6V1H	0.41	6.04	0.32	4.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.9	-0.31	9.28e-9	Life satisfaction;
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.71	9.76	0.47	6.26e-20	Alzheimer's disease;
CRC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg09163369	chr1:210001066	C1orf107	0.4	5.75	0.3	2.08e-8	Orofacial clefts;
CRC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg02466173	chr16:30829666	NA	0.66	9.94	0.48	1.6e-20	Dementia with Lewy bodies;
CRC	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.75	-12.1	-0.55	3.92e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs965469	1.000	rs6051806	chr20:3350319	C/T	cg25506879	chr20:3388711	C20orf194	-0.39	-5.63	-0.3	3.97e-8	IFN-related cytopenia;
CRC	cis	rs9287719	0.674	rs12622551	chr2:10720443	G/A	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs834811	0.583	rs10954517	chr7:135871947	T/C	cg01726295	chr7:135938950	NA	0.37	6.43	0.33	4.4e-10	Post-traumatic stress disorder;
CRC	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg00666640	chr1:248458726	OR2T12	0.41	7.43	0.38	9.52e-13	Common traits (Other);
CRC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-18.15	-0.71	1.75e-51	Schizophrenia;
CRC	trans	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs7572644	0.608	rs75429814	chr2:27961614	T/C	cg27432699	chr2:27873401	GPN1	0.51	5.74	0.3	2.13e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg27398640	chr15:77910606	LINGO1	-0.48	-8.88	-0.44	4.28e-17	Type 2 diabetes;
CRC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.68	9.3	0.46	1.98e-18	Multiple sclerosis;
CRC	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.6	5.89	0.31	9.38e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.4	7.64	0.39	2.32e-13	Ulcerative colitis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg22819135	chr5:41920822	C5orf51	-0.4	-6.02	-0.31	4.53e-9	HDL cholesterol;
CRC	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-7.58	-0.39	3.46e-13	Homocysteine levels;
CRC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	6.03	0.32	4.39e-9	Cognitive test performance;
CRC	cis	rs2270875	1.000	rs78340057	chr8:132927607	T/G	cg24184792	chr8:132919238	EFR3A	-0.68	-6.92	-0.36	2.39e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg05655116	chr2:37899435	CDC42EP3	-0.42	-6.16	-0.32	2.14e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.63	-7.22	-0.37	3.53e-12	Hip circumference adjusted for BMI;
CRC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.49	-6.81	-0.35	4.74e-11	Blood metabolite levels;
CRC	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.61	9.86	0.48	2.85e-20	Dupuytren's disease;
CRC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.59	-0.34	1.7e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.56	7.6	0.39	3.07e-13	Alzheimer's disease;
CRC	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.76	6.22	0.32	1.51e-9	Major depressive disorder;
CRC	trans	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg20742385	chr13:113633654	MCF2L	-0.69	-12.1	-0.55	4.02e-28	Systolic blood pressure;
CRC	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.72	-11.66	-0.54	1.57e-26	Neurofibrillary tangles;
CRC	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Parkinson's disease;
CRC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.4	6.14	0.32	2.35e-9	HDL cholesterol levels;
CRC	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg25019722	chr6:37503610	NA	-0.47	-8.79	-0.44	8.43e-17	Cognitive performance;
CRC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	7.46	0.38	7.74e-13	Menarche (age at onset);
CRC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.37	0.69	2.02e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg12273811	chr6:28175739	NA	0.46	6.63	0.34	1.41e-10	Cardiac Troponin-T levels;
CRC	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.5	-0.54	5.89e-26	Colorectal cancer;
CRC	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg10820045	chr2:198174542	NA	-0.39	-6.77	-0.35	5.97e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13150400	chr6:135819157	C6orf217;AHI1	0.39	6.42	0.33	4.77e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.59	10.66	0.51	5.37e-23	Blood metabolite ratios;
CRC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.81	11.47	0.53	7.41e-26	Cognitive function;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg12172441	chr6:28176163	NA	0.54	7.02	0.36	1.31e-11	Parkinson's disease;
CRC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	8.16e-11	Blood pressure (smoking interaction);
CRC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg03929089	chr4:120376271	NA	-0.47	-6.62	-0.34	1.44e-10	HDL cholesterol;
CRC	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.66	11.4	0.53	1.36e-25	Type 2 diabetes;
CRC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.71	-0.39	1.47e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs775227	0.574	rs13068107	chr3:113029530	A/C	cg18753928	chr3:113234510	CCDC52	-0.53	-6.56	-0.34	2.07e-10	Dental caries;
CRC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.46	-8.72	-0.43	1.45e-16	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.61e-9	Height;
CRC	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.51	-6.42	-0.33	4.84e-10	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg21268650	chr7:45961089	IGFBP3	0.38	6.38	0.33	5.94e-10	Sitting height ratio;
CRC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.43	-0.33	4.51e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs965469	0.744	rs6139093	chr20:3334838	A/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.77	-0.3	1.84e-8	IFN-related cytopenia;
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3750082	0.632	rs35165932	chr7:32926260	T/G	cg05721444	chr7:32995514	FKBP9	0.52	6.65	0.34	1.22e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs17767392	0.681	rs7146169	chr14:71684656	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.72	-0.35	7.83e-11	Mitral valve prolapse;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.35	-6.59	-0.34	1.8e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg02560186	chr11:3602584	NA	-0.46	-6.23	-0.32	1.42e-9	Blood pressure (smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05563107	chr19:50528575	VRK3;ZNF473	0.51	6.51	0.34	2.81e-10	Thyroid stimulating hormone;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01337508	chr17:40540572	STAT3	0.48	6.92	0.36	2.42e-11	Response to antipsychotic treatment;
CRC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg16476235	chr8:21771668	DOK2	-0.36	-6.02	-0.31	4.76e-9	Mean corpuscular volume;
CRC	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.57	6.84	0.35	3.98e-11	Ulcerative colitis;
CRC	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg14345882	chr6:26364793	BTN3A2	0.78	6.31	0.33	8.91e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.43	-7.21	-0.37	3.76e-12	Prostate-specific antigen levels;
CRC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.66	7.83	0.4	6.69e-14	Lymphocyte counts;
CRC	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.91	-0.36	2.54e-11	Inflammatory skin disease;
CRC	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.93	-0.44	3.03e-17	Intelligence (multi-trait analysis);Educational attainment (years of education);
CRC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.78	10.66	0.51	5.39e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.56	8.02	0.4	1.88e-14	Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00704953	chr11:96123144	CCDC82;JRKL	0.42	6.32	0.33	8.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.96	-0.36	1.87e-11	Lung cancer;
CRC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.77	-0.35	5.89e-11	Height;
CRC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg25173405	chr17:45401733	C17orf57	-0.39	-5.99	-0.31	5.58e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.69	9.42	0.46	8.11e-19	Breast cancer;
CRC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.53	-0.34	2.43e-10	Aortic root size;
CRC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-6.25	-0.33	1.3e-9	Subjective well-being;
CRC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-7.21	-0.37	3.84e-12	Neutrophil percentage of white cells;
CRC	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.78	-10.81	-0.51	1.6e-23	Blood pressure (smoking interaction);
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.35	-0.38	1.62e-12	Bipolar disorder;
CRC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.49	6.68	0.35	1.02e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg10431340	chr1:161279108	MPZ	-0.53	-6.98	-0.36	1.59e-11	Rheumatoid arthritis;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg25164649	chr6:28176230	NA	0.65	9.43	0.46	7.83e-19	Parkinson's disease;
CRC	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg12034943	chr19:18811790	CRTC1	-0.44	-5.71	-0.3	2.49e-8	Menarche (age at onset);
CRC	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.9	0.55	2.04e-27	Exhaled nitric oxide levels;
CRC	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.75	-0.39	1.15e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-9.9	-0.48	2.1e-20	Blood protein levels;
CRC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.59	-7.56	-0.38	4.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg18551225	chr6:44695536	NA	-0.41	-5.8	-0.3	1.53e-8	Total body bone mineral density;
CRC	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.37	-5.76	-0.3	1.9e-8	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.21	-0.53	6.46e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.95	11.45	0.53	8.78e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.53	0.47	3.62e-19	Monocyte percentage of white cells;
CRC	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-6.25	-0.33	1.26e-9	Endometrial cancer;
CRC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.99	21.43	0.76	2.12e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg25767906	chr1:53392781	SCP2	-0.39	-5.91	-0.31	8.37e-9	Monocyte count;
CRC	trans	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg27398640	chr15:77910606	LINGO1	0.42	8.03	0.4	1.7e-14	Type 2 diabetes;
CRC	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.6	6.77	0.35	5.85e-11	Glioblastoma;
CRC	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.26	-0.33	1.23e-9	Height;
CRC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.37	-5.66	-0.3	3.25e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.4	5.64	0.3	3.62e-8	Daytime sleep phenotypes;
CRC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.07	0.32	3.57e-9	Bladder cancer;
CRC	cis	rs3750082	0.780	rs9638884	chr7:32913612	T/C	cg05721444	chr7:32995514	FKBP9	0.51	7.87	0.4	5.33e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.76	-0.3	1.93e-8	Total body bone mineral density;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.71	12.08	0.55	4.8e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-15.62	-0.65	1.57e-41	Prostate cancer;
CRC	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.31	0.37	2.11e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.59	6.69	0.35	9.34e-11	Lymphocyte counts;
CRC	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg25025879	chr12:53359317	NA	-0.84	-7.95	-0.4	2.97e-14	Prostate cancer;
CRC	cis	rs10450586	0.863	rs7115157	chr11:27301586	G/A	cg10370305	chr11:27303972	NA	0.37	6.08	0.32	3.41e-9	Total body bone mineral density;
CRC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.49	7.54	0.38	4.75e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs13315871	1.000	rs9869576	chr3:58401262	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg13010199	chr12:38710504	ALG10B	0.43	6.24	0.33	1.37e-9	Morning vs. evening chronotype;
CRC	cis	rs6961069	0.745	rs3212160	chr7:80273308	A/C	cg04458919	chr7:80252533	CD36	0.36	6.29	0.33	1.04e-9	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09993119	chr22:41601085	L3MBTL2	0.49	6.91	0.36	2.58e-11	Response to antipsychotic treatment;
CRC	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.92	-11.36	-0.53	1.94e-25	Hair shape;
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.9	-10.91	-0.52	7.16e-24	Alzheimer's disease;
CRC	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.35	0.38	1.57e-12	Testicular germ cell tumor;
CRC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.73	7.74	0.39	1.25e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02290350	chr8:58132656	NA	-0.53	-7.79	-0.39	9.03e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.73	-12.42	-0.56	2.69e-29	Ulcerative colitis;
CRC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg26608667	chr7:1196370	ZFAND2A	0.45	7.5	0.38	6.02e-13	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26480543	chr19:55629279	PPP1R12C	0.46	6.64	0.34	1.28e-10	Response to antipsychotic treatment;
CRC	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg20750642	chr13:99100586	FARP1	0.41	5.87	0.31	1.06e-8	Neuroticism;
CRC	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.08	14.73	0.63	4.38e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg02733842	chr7:1102375	C7orf50	-0.71	-8.35	-0.42	1.93e-15	Bronchopulmonary dysplasia;
CRC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.52	5.9	0.31	9.19e-9	Cannabis dependence symptom count;
CRC	cis	rs365302	1.000	rs433308	chr6:159619866	A/G	cg14500486	chr6:159655392	FNDC1	-0.48	-6.98	-0.36	1.64e-11	Coronary heart disease;
CRC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.01	-0.31	5.06e-9	Monocyte percentage of white cells;
CRC	cis	rs4478858	0.746	rs7520439	chr1:31688721	G/C	cg00250761	chr1:31883323	NA	0.31	5.82	0.31	1.4e-8	Alcohol dependence;
CRC	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.59	6.7	0.35	9.17e-11	Coronary artery disease;
CRC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg03013636	chr16:1946785	NA	-0.59	-7.34	-0.37	1.74e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.0	-0.31	5.29e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.52	-6.7	-0.35	8.81e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.61	-11.09	-0.52	1.75e-24	Aortic root size;
CRC	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.34	-0.53	2.17e-25	Colorectal cancer;
CRC	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.63e-9	Arsenic metabolism;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.96	16.43	0.67	9.94e-45	Menarche (age at onset);
CRC	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg23254163	chr1:152506842	NA	0.45	9.15	0.45	6.31e-18	Hair morphology;
CRC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.19	0.32	1.8e-9	Lung cancer;
CRC	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.45	5.99	0.31	5.65e-9	Tuberculosis;
CRC	cis	rs7215564	0.908	rs7501659	chr17:78662061	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.03	0.32	4.39e-9	Myopia (pathological);
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg10513866	chr5:139070639	NA	0.54	8.39	0.42	1.42e-15	Schizophrenia;
CRC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg23815491	chr16:72088622	HP	0.57	7.32	0.37	1.9e-12	Blood protein levels;
CRC	cis	rs294883	0.739	rs1394236	chr6:159728679	T/G	cg14500486	chr6:159655392	FNDC1	-0.34	-5.94	-0.31	7.37e-9	Coronary artery disease;
CRC	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.07	-0.36	9.12e-12	Menarche (age at onset);
CRC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.48	6.68	0.35	1e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg14541582	chr5:601475	NA	-0.36	-7.26	-0.37	2.87e-12	Obesity-related traits;
CRC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.52	0.6	2.03e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.52	-8.69	-0.43	1.79e-16	Dupuytren's disease;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.57	9.23	0.45	3.51e-18	Coronary artery disease;
CRC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09469663	chr15:74908191	CLK3	0.4	6.27	0.33	1.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.61	0.54	2.33e-26	Alzheimer's disease;
CRC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23903597	chr17:61704154	MAP3K3	-0.44	-6.05	-0.32	3.99e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.24	-0.41	4.08e-15	Brugada syndrome;
CRC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg05552183	chr6:42928497	GNMT	0.47	6.58	0.34	1.83e-10	Blood protein levels;
CRC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs1760803	0.754	rs9803857	chr1:154191791	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.34	5.89	0.31	9.31e-9	Nicotine dependence;
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.23e-12	Bipolar disorder;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02290350	chr8:58132656	NA	-0.51	-6.38	-0.33	5.84e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9928842	0.823	rs8061356	chr16:75294232	G/A	cg09066997	chr16:75300724	BCAR1	0.61	6.04	0.32	4.17e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs11212617	0.967	rs371406	chr11:108221482	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.67	0.3	3.21e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.45	-5.69	-0.3	2.87e-8	Bipolar disorder;
CRC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.71	-9.09	-0.45	9.28e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.6	-8.89	-0.44	4e-17	Crohn's disease;
CRC	cis	rs4728142	0.604	rs13242262	chr7:128591364	A/T	cg06630958	chr7:128577819	IRF5	-0.35	-5.79	-0.3	1.68e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.65	10.61	0.5	8.49e-23	Platelet count;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23642001	chr8:67025419	NA	0.4	5.96	0.31	6.42e-9	Myopia (pathological);
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.5	-7.95	-0.4	3.08e-14	Blood pressure (smoking interaction);
CRC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.75	-0.3	2e-8	Cardiac Troponin-T levels;
CRC	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.69	9.69	0.47	1.04e-19	Alzheimer's disease;
CRC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.46	7.0	0.36	1.43e-11	Menopause (age at onset);
CRC	cis	rs9462027	0.606	rs205258	chr6:34564243	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.99	-0.31	5.63e-9	Systemic lupus erythematosus;
CRC	cis	rs12024301	0.557	rs10911416	chr1:183665120	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13606994	chr1:44402422	ARTN	-0.34	-5.82	-0.31	1.4e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg22638593	chr5:131593259	PDLIM4	-0.32	-5.86	-0.31	1.15e-8	Blood metabolite levels;
CRC	trans	rs264943	0.805	rs4851030	chr2:104160261	G/A	cg08628431	chr5:14506972	TRIO	0.42	6.02	0.31	4.63e-9	HIV-1 viral setpoint;
CRC	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.47	-7.58	-0.39	3.64e-13	Schizophrenia;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01490821	chr2:170684022	UBR3	-0.43	-6.32	-0.33	8.41e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg14593290	chr7:50529359	DDC	0.55	7.7	0.39	1.65e-13	Malaria;
CRC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.83	-0.31	1.34e-8	Skin colour saturation;
CRC	cis	rs17152411	1.000	rs61873263	chr10:126589202	G/A	cg07906193	chr10:126599966	NA	0.58	6.54	0.34	2.33e-10	Height;
CRC	cis	rs4478858	0.735	rs12734617	chr1:31823446	G/T	cg00250761	chr1:31883323	NA	-0.41	-7.7	-0.39	1.61e-13	Alcohol dependence;
CRC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg11833968	chr6:79620685	NA	-0.34	-5.97	-0.31	6.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.83	11.94	0.55	1.5e-27	Cognitive function;
CRC	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.75	13.61	0.6	8.94e-34	Anterior chamber depth;
CRC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	0.98	14.93	0.64	7.78e-39	Monocyte percentage of white cells;
CRC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.13	-0.52	1.21e-24	Chronic sinus infection;
CRC	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.05	-0.36	1.06e-11	Coronary artery disease;
CRC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.3	-0.33	9.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-6.98	-0.36	1.63e-11	Body mass index (adult);
CRC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg27523141	chr10:43048294	ZNF37B	0.45	6.46	0.34	3.73e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.88	0.31	1.02e-8	Total body bone mineral density;
CRC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.45	0.69	9.8e-49	Platelet count;
CRC	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg01639898	chr1:32083012	HCRTR1	0.3	6.07	0.32	3.49e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.83	-10.57	-0.5	1.16e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.45	-8.17	-0.41	6.55e-15	Monocyte count;
CRC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.44	6.33	0.33	8.22e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.58	-9.04	-0.45	1.41e-17	Asthma (sex interaction);
CRC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.69	-11.62	-0.54	2.25e-26	Asthma;
CRC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.52	-8.83	-0.44	6.32e-17	Orofacial clefts;
CRC	cis	rs427941	0.668	rs201438	chr7:101735236	G/A	cg06246474	chr7:101738831	CUX1	0.45	7.08	0.36	8.53e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs4824093	0.535	rs9627797	chr22:50317569	G/A	cg09872104	chr7:134855509	C7orf49	-0.75	-6.93	-0.36	2.25e-11	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.95	-10.98	-0.52	4.14e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg09436375	chr6:42928200	GNMT	-0.34	-6.24	-0.33	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg24289452	chr6:170231220	NA	-0.78	-6.96	-0.36	1.86e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.4	5.78	0.3	1.74e-8	Obesity-related traits;
CRC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.39	0.46	1e-18	Cognitive test performance;
CRC	trans	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24308560	chr3:49941425	MST1R	0.45	7.16	0.37	5.47e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg10494257	chr1:16342123	HSPB7	0.45	6.33	0.33	7.97e-10	Dilated cardiomyopathy;
CRC	cis	rs12760731	0.622	rs12743256	chr1:178576505	T/C	cg00404053	chr1:178313656	RASAL2	0.65	6.95	0.36	2.03e-11	Obesity-related traits;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg01708711	chr7:75959031	YWHAG	-0.44	-6.01	-0.31	4.84e-9	Lung cancer;
CRC	cis	rs6433857	0.594	rs34526919	chr2:181522678	T/A	cg23363182	chr2:181467187	NA	-0.47	-7.28	-0.37	2.42e-12	Body mass index;
CRC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.44	9.44	0.46	6.99e-19	Blood protein levels;
CRC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.35	-6.43	-0.33	4.38e-10	Iron status biomarkers;
CRC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg05585544	chr11:47624801	NA	-0.45	-8.12	-0.41	9.44e-15	Subjective well-being;
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg22687807	chr8:143858763	LYNX1	0.51	9.11	0.45	8.37e-18	Urinary tract infection frequency;
CRC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.67	-8.57	-0.43	3.98e-16	Gut microbiome composition (summer);
CRC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.33	0.37	1.82e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4481887	0.504	rs6587432	chr1:248355130	C/T	cg00666640	chr1:248458726	OR2T12	0.43	7.05	0.36	1.05e-11	Common traits (Other);
CRC	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.6	-8.61	-0.43	3.12e-16	Plateletcrit;Platelet count;
CRC	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg14664628	chr15:75095509	CSK	-0.44	-6.29	-0.33	1.04e-9	Systemic lupus erythematosus;
CRC	cis	rs4731207	0.596	rs10264210	chr7:124611594	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.16	-0.32	2.1e-9	Cutaneous malignant melanoma;
CRC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-6.19	-0.32	1.79e-9	Longevity;Endometriosis;
CRC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg01629716	chr15:45996671	NA	0.41	8.51	0.42	6.27e-16	Waist circumference;Weight;
CRC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg14119001	chr9:139324193	INPP5E	-0.44	-5.9	-0.31	8.91e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg03929089	chr4:120376271	NA	0.62	6.09	0.32	3.17e-9	Axial length;
CRC	cis	rs7705042	0.828	rs1036209	chr5:141498632	T/A	cg07392085	chr5:141489673	NDFIP1	0.47	7.41	0.38	1.07e-12	Asthma;
CRC	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.91	13.9	0.61	6.8000000000000005e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.45	7.68	0.39	1.84e-13	Major depressive disorder;
CRC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg00129232	chr17:37814104	STARD3	0.56	6.98	0.36	1.67e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2742417	1.000	rs9829631	chr3:45740558	T/C	cg04837898	chr3:45731254	SACM1L	-0.36	-5.87	-0.31	1.09e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	8.53	0.43	5.49e-16	Iron status biomarkers;
CRC	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.92	-0.55	1.85e-27	Colorectal cancer;
CRC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.56	8.26	0.41	3.67e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg14593290	chr7:50529359	DDC	-0.48	-6.95	-0.36	1.95e-11	Systemic sclerosis;
CRC	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.65	6.68	0.35	9.97e-11	Pediatric areal bone mineral density (radius);
CRC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.66	10.95	0.52	5.38e-24	Age at first birth;
CRC	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg04110750	chr16:69646130	NFAT5	-0.56	-7.56	-0.38	4.18e-13	IgE levels;
CRC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg08923669	chr16:420230	MRPL28	-0.59	-7.97	-0.4	2.7e-14	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.71	-7.96	-0.4	2.76e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7212590	0.655	rs8067568	chr17:57999215	A/G	cg10252138	chr17:58120427	NA	-0.52	-5.76	-0.3	1.89e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg15145174	chr5:6755386	POLS	-0.46	-6.43	-0.33	4.4e-10	Menopause (age at onset);
CRC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.41	7.96	0.4	2.75e-14	Mean corpuscular volume;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg07005513	chr11:61595956	FADS2	-0.51	-6.54	-0.34	2.34e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12463550	chr7:65579703	CRCP	0.62	5.97	0.31	6.12e-9	Diabetic kidney disease;
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.56	-7.25	-0.37	3.02e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.37	6.23	0.32	1.43e-9	Sitting height ratio;
CRC	cis	rs12760731	0.565	rs12037925	chr1:178160268	C/T	cg00404053	chr1:178313656	RASAL2	1.04	10.92	0.52	6.54e-24	Obesity-related traits;
CRC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.6	-0.34	1.62e-10	Red cell distribution width;
CRC	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-7.72	-0.39	1.43e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02450064	chr17:40260053	DHX58	-0.42	-6.13	-0.32	2.54e-9	Fibrinogen levels;
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg15845792	chr6:28175446	NA	0.5	7.39	0.38	1.22e-12	Pubertal anthropometrics;
CRC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg07865391	chr16:88106882	BANP	0.46	6.05	0.32	3.86e-9	Menopause (age at onset);
CRC	cis	rs4290604	0.667	rs62183332	chr2:237952535	G/T	cg23555395	chr2:238036564	NA	0.64	6.38	0.33	5.96e-10	Asthma;
CRC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-15.52	-0.65	3.69e-41	Prostate cancer;
CRC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-5.69	-0.3	2.83e-8	Body mass index;
CRC	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg14458575	chr2:238380390	NA	0.57	7.91	0.4	3.84e-14	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08120389	chr17:19881268	AKAP10	0.46	7.38	0.38	1.33e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.67	-9.51	-0.46	4.3e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.48	7.07	0.36	9.08e-12	Breast cancer;
CRC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.45	-8.29	-0.42	2.86e-15	Reticulocyte fraction of red cells;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg06896663	chr8:82754093	SNX16	-0.69	-6.06	-0.32	3.82e-9	Cognitive function;
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg19223190	chr17:80058835	NA	0.39	6.29	0.33	1e-9	Life satisfaction;
CRC	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-8.97	-0.44	2.3e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg15786705	chr6:28176104	NA	0.74	9.41	0.46	8.75e-19	Depression;
CRC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.59	-8.06	-0.41	1.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4692589	1.000	rs4692785	chr4:170938593	C/T	cg19918862	chr4:170955249	NA	0.39	6.29	0.33	9.93e-10	Anxiety disorder;
CRC	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.73	-7.61	-0.39	2.83e-13	Inflammatory biomarkers;
CRC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	9.0	0.44	1.83e-17	Ulcerative colitis;
CRC	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.59	-8.47	-0.42	8.15e-16	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.0	0.55	9.22e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs6678914	1.000	rs12129456	chr1:202189087	T/G	cg19977628	chr5:1262072	TERT	0.43	6.2	0.32	1.65e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.34	5.75	0.3	2.01e-8	Menopause (age at onset);
CRC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.41	-6.47	-0.34	3.47e-10	Blood metabolite levels;
CRC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.39	5.85	0.31	1.16e-8	Colorectal cancer;
CRC	cis	rs13161895	1.000	rs12656814	chr5:179471556	G/A	cg02702477	chr5:179499311	RNF130	0.55	6.26	0.33	1.18e-9	LDL cholesterol;
CRC	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg08501292	chr6:25962987	TRIM38	1.15	9.94	0.48	1.63e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg23260525	chr10:116636907	FAM160B1	0.34	7.82	0.4	7.31e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.47	-0.46	5.54e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.42	5.8	0.3	1.58e-8	Height;
CRC	trans	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg07838205	chr1:110091179	GNAI3	-0.48	-5.98	-0.31	5.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02290350	chr8:58132656	NA	-0.56	-7.55	-0.38	4.44e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg25985355	chr7:65971099	NA	-0.47	-5.61	-0.3	4.34e-8	Diabetic kidney disease;
CRC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs1165668	0.727	rs2722176	chr12:104313943	T/C	cg21863207	chr12:104234989	NT5DC3	0.48	7.16	0.37	5.39e-12	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg14593290	chr7:50529359	DDC	0.52	7.17	0.37	4.97e-12	Malaria;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg25164649	chr6:28176230	NA	0.78	9.69	0.47	1.04e-19	Depression;
CRC	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg25338242	chr13:114786047	RASA3	0.39	6.05	0.32	4.04e-9	Facial morphology (factor 14, intercanthal width);
CRC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.91	0.36	2.53e-11	Menopause (age at onset);
CRC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.82	14.48	0.62	4.27e-37	Coronary artery disease;
CRC	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.08	0.32	3.38e-9	Hair morphology;
CRC	cis	rs11212617	1.000	rs7108522	chr11:108281004	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.58	0.34	1.82e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.05	-0.36	1.07e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.89	-0.36	2.78e-11	Mean corpuscular volume;
CRC	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.43	6.19	0.32	1.8e-9	Asthma;
CRC	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.67	-10.65	-0.51	5.71e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.42	-7.55	-0.38	4.2e-13	Monocyte count;
CRC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg19196414	chr17:27188595	MIR451;MIR144	0.4	5.84	0.31	1.28e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.2	-0.32	1.65e-9	Breast cancer;
CRC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-17.32	-0.69	3.07e-48	Intelligence (multi-trait analysis);
CRC	cis	rs2270875	0.935	rs10505583	chr8:132981421	C/T	cg24184792	chr8:132919238	EFR3A	-0.65	-6.37	-0.33	6.26e-10	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.87	-0.31	1.04e-8	Calcium levels;
CRC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.62	8.18	0.41	6.13e-15	Coronary artery disease;
CRC	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.96	16.54	0.67	3.79e-45	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.58	-5.94	-0.31	7.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.32	-0.37	1.86e-12	Bladder cancer;
CRC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.49	6.26	0.33	1.22e-9	Obesity-related traits;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.17	-0.32	2.03e-9	Total body bone mineral density;
CRC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-10.07	-0.49	5.64e-21	Schizophrenia;
CRC	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.47	0.65	5.89e-41	Bipolar disorder;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.48	-8.08	-0.41	1.23e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.49	7.17	0.37	5.12e-12	Body mass index;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	trans	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg18288967	chr1:45987694	PRDX1	0.68	7.53	0.38	4.99e-13	Obesity-related traits;
CRC	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	0.94	11.07	0.52	2e-24	Height;
CRC	cis	rs9287719	0.649	rs6720112	chr2:10725719	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.46	7.97	0.4	2.59e-14	Common traits (Other);
CRC	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.65	-8.89	-0.44	4.25e-17	Extraversion;
CRC	cis	rs7605827	0.893	rs1024871	chr2:15626162	C/T	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	8.14e-9	Educational attainment (years of education);
CRC	cis	rs501120	0.584	rs11592445	chr10:44732945	G/T	cg09554077	chr10:44749378	NA	0.64	7.06	0.36	9.84e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7703744	0.634	rs3797340	chr5:118691737	C/G	cg23917399	chr5:118691751	TNFAIP8	0.41	5.67	0.3	3.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg03030879	chr14:75389066	RPS6KL1	0.43	6.83	0.35	4.03e-11	Height;
CRC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.53	0.57	9.97e-30	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.59	-7.39	-0.38	1.2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg26893861	chr17:41843967	DUSP3	-0.69	-6.32	-0.33	8.59e-10	Cognitive function;
CRC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-9.66	-0.47	1.3e-19	Monocyte count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00331096	chr20:22564947	FOXA2	0.44	6.49	0.34	3.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-7.41	-0.38	1.08e-12	Eye color traits;
CRC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.72	11.04	0.52	2.59e-24	Neutrophil percentage of white cells;
CRC	trans	rs1864585	0.520	rs17776622	chr8:10676497	T/C	cg26278703	chr11:58910052	FAM111A	0.54	6.3	0.33	9.29e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.0	0.44	1.87e-17	Monocyte count;
CRC	cis	rs9467603	0.925	rs1892251	chr6:25769349	T/C	cg08501292	chr6:25962987	TRIM38	-0.65	-6.11	-0.32	2.76e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7849782	0.604	rs10121600	chr9:104378003	C/T	cg26072213	chr5:52095705	ITGA1;PELO	0.49	6.38	0.33	6.18e-10	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Bladder cancer;
CRC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.7	0.47	9.7e-20	Cognitive test performance;
CRC	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.57	8.39	0.42	1.48e-15	Autism;
CRC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.76	0.35	6.43e-11	Morning vs. evening chronotype;
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg23378565	chr7:2036160	MAD1L1	-0.43	-5.86	-0.31	1.13e-8	Neuroticism;
CRC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.81	-11.22	-0.53	5.83e-25	Asthma;
CRC	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg03929089	chr4:120376271	NA	-0.48	-6.73	-0.35	7.56e-11	Height;
CRC	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07513332	chr6:167530253	CCR6	0.36	5.87	0.31	1.05e-8	Primary biliary cholangitis;
CRC	cis	rs4664293	0.669	rs2042778	chr2:160528630	A/G	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.67e-10	Monocyte percentage of white cells;
CRC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.81	11.14	0.52	1.17e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.22	0.32	1.53e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg01472538	chr16:58549086	SETD6	1.2	7.61	0.39	2.9e-13	Schizophrenia;
CRC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.47	-0.57	1.67e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.59	-6.91	-0.36	2.54e-11	Ulcerative colitis;
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-13.07	-0.58	9.78e-32	Alzheimer's disease;
CRC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg13880726	chr7:1868755	MAD1L1	-0.45	-5.65	-0.3	3.53e-8	Bipolar disorder;
CRC	cis	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.77	-0.3	1.87e-8	Asthma;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg27534772	chr1:16042836	PLEKHM2	0.51	9.33	0.46	1.56e-18	Systolic blood pressure;
CRC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.69	0.47	1.09e-19	Bladder cancer;
CRC	cis	rs10991814	0.920	rs10512211	chr9:94104260	C/G	cg14446406	chr9:93919335	NA	0.56	6.29	0.33	1.03e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg22638593	chr5:131593259	PDLIM4	0.39	7.22	0.37	3.7e-12	Breast cancer;
CRC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.48	7.02	0.36	1.24e-11	Cognitive function;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder;
CRC	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg01475377	chr6:109611718	NA	-0.35	-6.1	-0.32	3e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18357526	chr6:26021779	HIST1H4A	0.41	5.98	0.31	5.92e-9	Height;
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.83	-15.22	-0.64	5.73e-40	Tonsillectomy;
CRC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.54	7.3	0.37	2.18e-12	Height;
CRC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.83	14.57	0.63	1.95e-37	Breast cancer;
CRC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg26373071	chr5:1325741	CLPTM1L	0.55	9.97	0.48	1.23e-20	Lung cancer;
CRC	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.11	-0.32	2.74e-9	Aortic root size;
CRC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-10.11	-0.49	4.29e-21	HDL cholesterol;
CRC	cis	rs75804782	0.935	rs61332075	chr2:239316560	G/C	cg18131467	chr2:239335373	ASB1	-0.67	-5.71	-0.3	2.57e-8	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-5.97	-0.31	6.24e-9	Bipolar disorder;
CRC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.73	0.39	1.3e-13	Colorectal cancer;
CRC	cis	rs77861329	1.000	rs59890038	chr3:52147850	A/G	cg08692210	chr3:52188851	WDR51A	0.82	7.44	0.38	8.9e-13	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.61	-9.26	-0.45	2.71e-18	Body mass index;
CRC	trans	rs73162807	0.655	rs73160972	chr3:146422109	C/T	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs9427116	1.000	rs9330261	chr1:154634998	T/A	cg17218026	chr1:154582156	ADAR	0.43	6.54	0.34	2.39e-10	Blood protein levels;
CRC	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg00343986	chr7:65444356	GUSB	0.45	6.27	0.33	1.12e-9	Aortic root size;
CRC	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.47	7.83	0.4	6.92e-14	Alcohol dependence (age at onset);
CRC	cis	rs2860975	1.000	rs12781471	chr10:96765362	T/C	cg09036531	chr10:96991505	NA	-0.42	-5.79	-0.3	1.65e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg13172432	chr1:205912842	SLC26A9	-0.35	-6.11	-0.32	2.76e-9	Cystic fibrosis-related diabetes;
CRC	cis	rs17532515	0.628	rs6840266	chr4:141479999	T/C	cg09181644	chr4:141490428	UCP1	0.32	5.78	0.3	1.71e-8	Select biomarker traits;
CRC	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.69	8.15	0.41	7.44e-15	Eotaxin levels;
CRC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.33e-10	Childhood ear infection;
CRC	trans	rs9341835	0.740	rs9294215	chr6:64151771	C/G	cg13657004	chr13:50234944	EBPL	-0.36	-6.08	-0.32	3.38e-9	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00516597	chr3:25824837	NGLY1	0.48	6.76	0.35	6.18e-11	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03689054	chr17:81037743	METRNL	0.38	6.0	0.31	5.19e-9	Obesity-related traits;
CRC	cis	rs281302	0.621	rs12591490	chr15:47732441	C/T	cg13159054	chr15:47721715	NA	-0.43	-6.58	-0.34	1.84e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs2072510	0.593	rs2540499	chr12:96399869	A/C	cg09636302	chr12:96389483	HAL	0.5	6.48	0.34	3.42e-10	Metabolite levels (small molecules and protein measures);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07628558	chr20:56964831	VAPB	-0.5	-6.29	-0.33	1.03e-9	Diisocyanate-induced asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18959139	chr7:72993101	TBL2	0.41	6.2	0.32	1.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.47	-0.38	7.34e-13	Major depressive disorder;
CRC	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg24046110	chr8:143859143	LYNX1	-0.38	-6.6	-0.34	1.65e-10	Urinary tract infection frequency;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.46	5.75	0.3	2.05e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.69	-0.35	9.81e-11	Putamen volume;
CRC	cis	rs11098699	0.821	rs6811630	chr4:124222254	G/A	cg09941581	chr4:124220074	SPATA5	0.43	6.39	0.33	5.51e-10	Mosquito bite size;
CRC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.39	0.33	5.66e-10	Aortic root size;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg02683197	chr6:28174875	NA	0.7	9.9	0.48	2.16e-20	Parkinson's disease;
CRC	cis	rs1322512	1.000	rs2758816	chr6:152968338	A/T	cg03415253	chr6:152958462	SYNE1	-0.44	-6.76	-0.35	6.31e-11	Tonometry;
CRC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.67	10.27	0.49	1.24e-21	Corneal astigmatism;
CRC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.9	11.1	0.52	1.6e-24	Tuberculosis;
CRC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.49	0.34	3.18e-10	Rheumatoid arthritis;
CRC	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.45	6.23	0.32	1.43e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.2	0.32	1.67e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10436540	chr17:4047319	ZZEF1;CYB5D2	0.49	7.09	0.36	8.47e-12	Response to antipsychotic treatment;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg02683197	chr6:28174875	NA	0.6	6.33	0.33	7.97e-10	Depression;
CRC	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.85	15.55	0.65	2.87e-41	Multiple myeloma;
CRC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.68	12.22	0.56	1.46e-28	Age at first birth;
CRC	cis	rs7680126	0.633	rs2024280	chr4:10291813	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.8	-0.35	5.03e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.69	10.77	0.51	2.19e-23	Immature fraction of reticulocytes;
CRC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.68	11.51	0.54	5.56e-26	Alzheimer's disease (late onset);
CRC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.47	6.83	0.35	4.12e-11	Cleft lip with or without cleft palate;
CRC	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg11887960	chr12:57824829	NA	0.59	6.58	0.34	1.89e-10	Obesity-related traits;
CRC	cis	rs3764400	0.567	rs8071879	chr17:46217457	G/A	cg10706073	chr17:46328419	SKAP1	0.59	6.36	0.33	6.7e-10	Body mass index;
CRC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg17633681	chr16:88106987	BANP	0.87	16.24	0.67	5.81e-44	Menopause (age at onset);
CRC	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.08	0.32	3.36e-9	Blood protein levels;
CRC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-6.59	-0.34	1.7e-10	Diabetic retinopathy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05300939	chr11:44587523	CD82	0.41	6.24	0.33	1.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg06223162	chr1:101003688	GPR88	0.37	6.69	0.35	9.55e-11	Breast cancer;
CRC	cis	rs2179367	0.920	rs560051	chr6:149666977	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.35	-0.33	7.18e-10	Dupuytren's disease;
CRC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.54	8.05	0.41	1.51e-14	Obesity-related traits;
CRC	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07165851	chr6:158734300	TULP4	0.62	7.76	0.39	1.11e-13	Height;
CRC	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg23815491	chr16:72088622	HP	0.49	7.09	0.36	8.15e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg27523141	chr10:43048294	ZNF37B	0.5	7.32	0.37	1.98e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4731207	0.596	rs10081336	chr7:124575945	A/G	cg23710748	chr7:124431027	NA	-0.44	-6.94	-0.36	2.09e-11	Cutaneous malignant melanoma;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.86	15.05	0.64	2.49e-39	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	7.1	0.36	7.8e-12	Mood instability;
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.93	0.31	7.84e-9	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24317988	chr10:33247433	ITGB1	0.42	7.08	0.36	9.04e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.63	-0.34	1.35e-10	Headache;
CRC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Educational attainment;
CRC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	11.27	0.53	3.92e-25	Monocyte percentage of white cells;
CRC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg15147215	chr3:52552868	STAB1	0.42	6.73	0.35	7.78e-11	Body mass index;
CRC	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg05540913	chr6:167530185	CCR6	0.33	5.83	0.31	1.3e-8	Primary biliary cholangitis;
CRC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg09835421	chr16:68378352	PRMT7	-0.78	-8.22	-0.41	4.62e-15	Schizophrenia;
CRC	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.65	6.68	0.35	1.02e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11866815	0.649	rs56355849	chr16:380641	T/C	cg00101154	chr16:420108	MRPL28	0.53	5.71	0.3	2.5e-8	Body mass index;
CRC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.74	-10.54	-0.5	1.38e-22	Platelet distribution width;
CRC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	8.15	0.41	7.56e-15	Cognitive test performance;
CRC	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.8	9.27	0.46	2.53e-18	Uric acid levels;
CRC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.17	0.52	9.08e-25	Prudent dietary pattern;
CRC	cis	rs427941	0.632	rs201502	chr7:101759561	C/T	cg06246474	chr7:101738831	CUX1	-0.4	-6.21	-0.32	1.63e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs2321882	0.834	rs17682784	chr13:59459934	C/T	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-6.89	-0.36	2.83e-11	Cognitive function;
CRC	cis	rs997295	0.570	rs7170299	chr15:67872718	A/G	cg24247231	chr15:67904302	MAP2K5	-0.33	-5.62	-0.3	4.16e-8	Motion sickness;
CRC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.67	-0.35	1.09e-10	Aortic root size;
CRC	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Systolic blood pressure;
CRC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.8	12.18	0.56	2.05e-28	Cognitive function;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.44	7.06	0.36	1e-11	Schizophrenia;
CRC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.76	10.12	0.49	3.85e-21	Coronary artery disease;
CRC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.54	-7.17	-0.37	4.93e-12	Gut microbiome composition (summer);
CRC	cis	rs6427782	0.602	rs4915390	chr1:199824908	G/C	cg07208853	chr1:200005219	NR5A2	0.23	5.94	0.31	7.33e-9	Menarche (age at onset);
CRC	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.46	6.83	0.35	4.11e-11	Testicular germ cell tumor;
CRC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.78	0.66	3.78e-42	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.41	5.71	0.3	2.58e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.28	5.77	0.3	1.82e-8	Personality dimensions;
CRC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg23750338	chr8:142222470	SLC45A4	0.44	7.51	0.38	5.5e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Alcohol dependence;
CRC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.69	7.91	0.4	4.03e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg23565292	chr14:50234668	KLHDC2	-0.45	-6.34	-0.33	7.51e-10	Carotid intima media thickness;
CRC	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg26816564	chr1:7831052	VAMP3	-0.53	-6.19	-0.32	1.78e-9	Inflammatory bowel disease;
CRC	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.58	-7.95	-0.4	2.93e-14	Caudate activity during reward;
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.52	-7.34	-0.38	1.67e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.54	-5.65	-0.3	3.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg25856811	chr1:152973957	SPRR3	-0.22	-6.08	-0.32	3.4e-9	Inflammatory skin disease;
CRC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.27	-14.62	-0.63	1.25e-37	Diabetic kidney disease;
CRC	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.83	7.42	0.38	9.79e-13	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg20512303	chr5:131592959	PDLIM4	0.37	6.89	0.36	2.8e-11	Breast cancer;
CRC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.64	8.61	0.43	3.15e-16	Multiple sclerosis;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12273811	chr6:28175739	NA	0.62	8.29	0.42	2.87e-15	Parkinson's disease;
CRC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.8	-12.22	-0.56	1.4e-28	Uric acid levels;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg21856205	chr7:94953877	PON1	-0.54	-6.77	-0.35	6.07e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg14201387	chr1:221737206	NA	-0.44	-6.41	-0.33	4.99e-10	Lung cancer;
CRC	trans	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg19188899	chr13:112838565	NA	-0.42	-6.31	-0.33	8.84e-10	Systemic lupus erythematosus;
CRC	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-16.47	-0.67	7.23e-45	Electrocardiographic conduction measures;
CRC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.3	-0.42	2.69e-15	Type 2 diabetes;
CRC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	8.79	0.44	8.47e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.44	7.7	0.39	1.62e-13	HDL cholesterol;
CRC	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg10437265	chr15:77819839	NA	-0.48	-8.06	-0.41	1.42e-14	Type 2 diabetes;
CRC	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg08999081	chr20:33150536	PIGU	-0.42	-5.62	-0.3	4.16e-8	Neuroticism;
CRC	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg01843034	chr6:37503916	NA	-0.34	-5.62	-0.3	4.05e-8	Cognitive performance;
CRC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg04731861	chr2:219085781	ARPC2	0.33	6.4	0.33	5.45e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-5.83	-0.31	1.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.44	5.82	0.31	1.36e-8	Cognitive ability;
CRC	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg11657817	chr20:23433608	CST11	0.52	8.55	0.43	4.69e-16	Facial morphology (factor 15, philtrum width);
CRC	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	1.06	14.77	0.63	3.26e-38	Exhaled nitric oxide output;
CRC	cis	rs9648716	1.000	rs9648715	chr7:140611845	C/T	cg10747023	chr7:140774559	NA	0.47	6.11	0.32	2.74e-9	Type 2 diabetes;
CRC	cis	rs9491140	0.539	rs10872284	chr6:124685928	G/A	cg22366943	chr6:124882293	NKAIN2	0.56	8.42	0.42	1.18e-15	Neuroticism;
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.74	11.54	0.54	4.36e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.52	9.32	0.46	1.78e-18	Huntington's disease progression;
CRC	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg20737812	chr15:86336631	KLHL25	-0.43	-7.01	-0.36	1.33e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.69	8.89	0.44	4.14e-17	Psoriasis;
CRC	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.57	8.02	0.4	1.91e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	11.56	0.54	3.68e-26	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg04551154	chr10:95462393	C10orf4	-0.75	-6.36	-0.33	6.93e-10	Cognitive function;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.5	5.82	0.31	1.38e-8	Parkinson's disease;
CRC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02725872	chr8:58115012	NA	-0.54	-7.07	-0.36	9.5e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg13880726	chr7:1868755	MAD1L1	-0.43	-5.75	-0.3	2.03e-8	Bipolar disorder;
CRC	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.71	-9.4	-0.46	9.34e-19	Blood pressure (smoking interaction);
CRC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.74	0.35	7.29e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg08027265	chr7:2291960	NA	-0.37	-5.8	-0.3	1.54e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.64	9.44	0.46	6.94e-19	QT interval;
CRC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.8	-0.44	7.92e-17	Morning vs. evening chronotype;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg08132177	chr1:856685	NA	-0.68	-6.0	-0.31	5.29e-9	Cognitive function;
CRC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	13.39	0.59	6.1e-33	Cognitive ability;
CRC	cis	rs4728302	0.869	rs7779370	chr7:133595702	T/C	cg10665199	chr7:133106180	EXOC4	0.38	5.79	0.3	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1223397	1.000	rs1223403	chr6:13271812	G/A	cg00460589	chr6:13274354	PHACTR1	0.49	6.02	0.31	4.68e-9	Blood pressure;
CRC	cis	rs7517126	1.000	rs7517587	chr1:196840765	A/G	cg13682187	chr1:196946512	CFHR5	-0.36	-5.87	-0.31	1.06e-8	Blood protein levels;
CRC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.51	-7.77	-0.39	1.01e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.61	9.6	0.47	2.08e-19	Gestational age at birth (maternal effect);
CRC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.42	7.11	0.36	7.22e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20385686	chr1:27024451	ARID1A	0.43	7.13	0.37	6.46e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg23758597	chr6:163146217	PARK2	-0.56	-5.7	-0.3	2.69e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg02702477	chr5:179499311	RNF130	0.69	7.58	0.39	3.54e-13	LDL cholesterol;
CRC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.92	0.44	3.3e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.5	6.95	0.36	1.98e-11	Huntington's disease progression;
CRC	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg15412446	chr2:106886593	NA	-0.39	-6.25	-0.33	1.29e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.91	-0.36	2.47e-11	Self-reported allergy;
CRC	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.66	-0.39	2.05e-13	Biliary atresia;
CRC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.18	0.32	1.87e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.15	25.79	0.82	5.51e-81	IgG glycosylation;
CRC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg14711859	chr11:8959438	ASCL3	-0.42	-6.69	-0.35	9.85e-11	Hemoglobin concentration;
CRC	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07165851	chr6:158734300	TULP4	0.62	7.89	0.4	4.38e-14	Height;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.23	0.32	1.41e-9	Bipolar disorder;
CRC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.49	-6.22	-0.32	1.49e-9	Blood pressure (smoking interaction);
CRC	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.35	-0.69	2.37e-48	Schizophrenia;
CRC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg04450456	chr4:17643702	FAM184B	0.39	6.22	0.32	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-16.76	-0.68	5.2e-46	Height;
CRC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.6	-6.36	-0.33	6.71e-10	Schizophrenia;
CRC	cis	rs12024301	0.557	rs16828981	chr1:183608658	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.97	0.36	1.75e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg01339444	chr6:118972232	C6orf204	0.52	5.74	0.3	2.11e-8	Diastolic blood pressure;
CRC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg23461800	chr14:103021989	NA	-0.68	-7.83	-0.4	6.62e-14	Platelet count;
CRC	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	1.09	14.13	0.61	9.25e-36	Exhaled nitric oxide output;
CRC	cis	rs728616	0.867	rs1983775	chr10:81663575	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.74	-0.39	1.21e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.4	-6.12	-0.32	2.64e-9	Menopause (age at onset);
CRC	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg21918786	chr6:109611834	NA	-0.33	-5.72	-0.3	2.33e-8	Reticulocyte fraction of red cells;
CRC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.89	9.29	0.46	2.11e-18	Arsenic metabolism;
CRC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.53	6.55	0.34	2.21e-10	Diastolic blood pressure;
CRC	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.83	0.63	1.82e-38	Exhaled nitric oxide output;
CRC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.7	12.27	0.56	9.25e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3026101	0.578	rs55747983	chr17:5297742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.79	0.35	5.16e-11	Body mass index;
CRC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	0.7	8.71	0.43	1.56e-16	Breast cancer;
CRC	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.64	-12.89	-0.58	4.84e-31	Menarche (age at onset);
CRC	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.91	15.9	0.66	1.21e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.77	0.35	5.98e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.19	0.45	4.67e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg15571903	chr15:79123663	NA	0.31	6.13	0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	7.25	0.37	3.09e-12	Lung cancer in ever smokers;
CRC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	0.84	8.08	0.41	1.22e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg26260408	chr4:53727979	RASL11B	0.41	5.74	0.3	2.11e-8	Optic nerve measurement (cup area);
CRC	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg23032129	chr1:109941072	SORT1	-0.28	-5.98	-0.31	5.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6499129	1.000	rs9922624	chr16:67478976	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.87	-0.31	1.07e-8	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.61	8.77	0.44	9.63e-17	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg24531977	chr5:56204891	C5orf35	-0.44	-6.69	-0.35	9.73e-11	Breast cancer;Breast cancer (early onset);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg02310562	chr12:117348663	FBXW8	-0.5	-6.03	-0.32	4.31e-9	Type 1 diabetes;
CRC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg06462663	chr19:18546047	ISYNA1	-0.5	-7.53	-0.38	4.98e-13	Breast cancer;
CRC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.79	0.47	5.14e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.32	-0.37	1.87e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6700896	0.931	rs12021623	chr1:66153586	A/C	cg04111102	chr1:66153794	NA	0.35	6.07	0.32	3.47e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg18478394	chr8:109455254	TTC35	0.39	6.03	0.32	4.51e-9	Dupuytren's disease;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg22922770	chr7:98923339	ARPC1A	-0.69	-6.19	-0.32	1.77e-9	Cognitive function;
CRC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.47	5.9	0.31	9.01e-9	Aortic root size;
CRC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.27	0.49	1.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.33	-0.42	2.21e-15	Mean platelet volume;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.46	-6.5	-0.34	2.97e-10	Lymphocyte counts;
CRC	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.51	6.79	0.35	5.1e-11	Breast cancer;
CRC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg21747405	chr11:67723411	NA	-0.49	-6.36	-0.33	6.71e-10	Blood pressure (smoking interaction);
CRC	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.41	6.33	0.33	7.93e-10	Obesity;
CRC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.61	0.34	1.53e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20014284	chr12:112563241	TRAFD1	0.41	6.02	0.31	4.73e-9	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05454975	chr4:141445769	ELMOD2	0.47	6.6	0.34	1.6e-10	Response to antipsychotic treatment;
CRC	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.43	6.9	0.36	2.64e-11	Sitting height ratio;
CRC	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.89	-10.01	-0.48	9.22e-21	Uric acid levels;
CRC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg21251018	chr6:28226885	NKAPL	0.41	6.24	0.33	1.35e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg16099169	chr2:106886729	NA	-0.39	-6.7	-0.35	8.85e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.16	26.82	0.83	8.27e-85	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09926380	chr3:10052611	LOC401052	0.42	6.34	0.33	7.5e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg19812747	chr11:111475976	SIK2	0.43	6.11	0.32	2.76e-9	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.8	11.44	0.53	9.8e-26	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg11764359	chr7:65958608	NA	-0.58	-8.85	-0.44	5.59e-17	Aortic root size;
CRC	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg00507830	chr2:103233733	NA	0.51	5.7	0.3	2.73e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11645453	chr3:52864694	ITIH4	0.33	5.89	0.31	9.65e-9	Electroencephalogram traits;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.07	-0.55	4.89e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6804368	0.553	rs2888258	chr3:30765115	C/T	cg06106510	chr3:30762233	NA	0.37	6.08	0.32	3.4e-9	Blood metabolite levels;
CRC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.46	-8.22	-0.41	4.86e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11547950	chr5:77652471	NA	-0.48	-7.03	-0.36	1.17e-11	Triglycerides;
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg15845792	chr6:28175446	NA	0.75	8.1	0.41	1.06e-14	Depression;
CRC	cis	rs6694672	1.000	rs9726778	chr1:197116754	G/C	cg13682187	chr1:196946512	CFHR5	0.42	6.65	0.34	1.24e-10	Asthma;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs8105895	0.799	rs10426159	chr19:22267324	G/A	cg02657401	chr19:22469223	NA	-0.35	-5.75	-0.3	2.05e-8	Body mass index (change over time);
CRC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.57	-7.65	-0.39	2.22e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.77	0.3	1.88e-8	Homoarginine levels;
CRC	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg01843034	chr6:37503916	NA	-0.43	-7.95	-0.4	3.03e-14	Cognitive performance;
CRC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.01	0.44	1.77e-17	Bladder cancer;
CRC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	8.16	0.41	7.07e-15	Height;
CRC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.53	6.62	0.34	1.49e-10	Methadone dose in opioid dependence;
CRC	cis	rs4664293	1.000	rs10193402	chr2:160507782	A/G	cg08347373	chr2:160653686	CD302	-0.38	-6.24	-0.33	1.38e-9	Monocyte percentage of white cells;
CRC	cis	rs9463078	0.625	rs1360197	chr6:44949630	T/C	cg25276700	chr6:44698697	NA	-0.23	-5.73	-0.3	2.27e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-14.87	-0.63	1.27e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-10.77	-0.51	2.27e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg09659197	chr4:152720779	NA	-0.42	-8.51	-0.42	6.07e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.64	9.53	0.47	3.51e-19	Lung cancer;
CRC	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.81	-0.44	7.52e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.6	8.57	0.43	4.21e-16	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24666733	chr2:242089739	PPP1R7;PASK	0.44	6.04	0.32	4.1e-9	Anxiety disorder;
CRC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.26	-15.13	-0.64	1.25e-39	Gout;
CRC	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg10761708	chr20:43804764	PI3	0.48	5.62	0.3	4.06e-8	Blood protein levels;
CRC	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg03929089	chr4:120376271	NA	-0.67	-7.27	-0.37	2.56e-12	D-dimer levels;
CRC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.3	-0.33	9.6e-10	Tonsillectomy;
CRC	cis	rs7172809	0.607	rs79590310	chr15:77842095	A/G	cg10437265	chr15:77819839	NA	-0.36	-5.91	-0.31	8.67e-9	Glucose homeostasis traits;
CRC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg25347419	chr2:177043501	NA	0.54	8.34	0.42	2e-15	IgG glycosylation;
CRC	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.49	8.27	0.42	3.25e-15	Endometriosis;
CRC	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg03932441	chr10:102415297	NA	-0.33	-5.7	-0.3	2.71e-8	Body mass index;
CRC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.42	-7.4	-0.38	1.13e-12	Reticulocyte fraction of red cells;
CRC	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg03929089	chr4:120376271	NA	0.51	6.74	0.35	6.93e-11	Intraocular pressure;
CRC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.43	6.32	0.33	8.56e-10	Diastolic blood pressure;
CRC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg12751644	chr20:60527061	NA	-0.38	-5.77	-0.3	1.82e-8	Body mass index;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.4	-5.63	-0.3	3.79e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4731207	0.507	rs10954052	chr7:124586811	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.34e-9	Cutaneous malignant melanoma;
CRC	trans	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg11693508	chr17:37793320	STARD3	0.56	6.95	0.36	2.01e-11	Bipolar disorder;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.65	-13.03	-0.58	1.37e-31	Tonsillectomy;
CRC	cis	rs55702914	0.746	rs4850425	chr2:198152786	T/C	cg03934865	chr2:198174659	NA	-0.44	-7.68	-0.39	1.8e-13	Major depression and alcohol dependence;
CRC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.52	7.67	0.39	2e-13	Calcium levels;
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.8	-0.3	1.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6968419	0.755	rs3807981	chr7:115896716	G/A	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.48e-10	Intraocular pressure;
CRC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.43	-0.33	4.59e-10	Reticulocyte fraction of red cells;
CRC	cis	rs1223397	0.938	rs35511719	chr6:13282442	T/C	cg06879394	chr6:13274151	PHACTR1	0.53	6.32	0.33	8.4e-10	Blood pressure;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.64	-10.45	-0.5	3.03e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.67	-0.35	1.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.59	-6.99	-0.36	1.58e-11	Lung function (FEV1/FVC);
CRC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.4	7.67	0.39	2e-13	Ulcerative colitis;
CRC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg21425842	chr6:26240939	HIST1H4F	0.34	5.73	0.3	2.22e-8	Gout;Renal underexcretion gout;
CRC	cis	rs4954585	0.593	rs12691881	chr2:137029668	A/G	cg05194412	chr2:137003533	NA	0.44	6.85	0.35	3.57e-11	Colorectal cancer;
CRC	trans	rs66573146	0.803	rs59809420	chr4:6969928	G/T	cg07817883	chr1:32538562	TMEM39B	1.74	14.27	0.62	2.8e-36	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.45	0.34	3.96e-10	Alzheimer's disease;
CRC	cis	rs9462846	0.881	rs34498470	chr6:42879551	C/T	cg21280719	chr6:42927975	GNMT	-0.34	-6.03	-0.32	4.32e-9	Blood protein levels;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01598046	chr3:49894152	TRAIP	0.4	5.92	0.31	8.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.25e-10	Alzheimer's disease (late onset);
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.88e-9	Hemoglobin concentration;
CRC	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.49	-5.8	-0.3	1.55e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	1.09	10.29	0.49	1.04e-21	Arsenic metabolism;
CRC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg13390004	chr1:15929781	NA	0.53	7.43	0.38	9.43e-13	Systolic blood pressure;
CRC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.33	0.33	8.13e-10	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg03623178	chr6:28175578	NA	0.83	10.78	0.51	2.17e-23	Parkinson's disease;
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.08	-0.36	8.79e-12	Total body bone mineral density;
CRC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.52	7.72	0.39	1.43e-13	Blood protein levels;
CRC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg13902645	chr11:5959945	NA	-0.53	-6.7	-0.35	8.88e-11	DNA methylation (variation);
CRC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-9.98	-0.48	1.17e-20	Monocyte percentage of white cells;
CRC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.49	5.79	0.3	1.64e-8	Vitiligo;
CRC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-8.97	-0.44	2.32e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	0.75	7.51	0.38	5.74e-13	Severe influenza A (H1N1) infection;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23138817	chr14:105864896	NA	0.39	5.99	0.31	5.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg04562611	chr16:615315	C16orf11	0.36	5.98	0.31	5.93e-9	Height;
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11645453	chr3:52864694	ITIH4	0.37	6.59	0.34	1.78e-10	Bipolar disorder;
CRC	cis	rs9361491	0.657	rs9343798	chr6:79455282	A/G	cg05283184	chr6:79620031	NA	-0.38	-5.77	-0.3	1.78e-8	Intelligence (multi-trait analysis);
CRC	trans	rs11088226	0.758	rs2833864	chr21:33888393	A/C	cg09050820	chr6:167586206	TCP10L2	0.57	6.31	0.33	8.76e-10	Gastritis;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.65	-10.62	-0.51	7.32e-23	Height;
CRC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.76	9.66	0.47	1.38e-19	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg04611788	chr3:186434169	KNG1	-0.61	-9.09	-0.45	9.52e-18	Blood protein levels;
CRC	trans	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg11693508	chr17:37793320	STARD3	0.45	6.1	0.32	2.92e-9	Neuroticism;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-0.83	-11.41	-0.53	1.19e-25	Intelligence (multi-trait analysis);
CRC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.57	9.4	0.46	9.87e-19	Schizophrenia;
CRC	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.72	-9.7	-0.47	9.79e-20	Blood pressure (smoking interaction);
CRC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg01420254	chr6:26195488	NA	-0.76	-8.77	-0.44	9.69e-17	Gout;Renal underexcretion gout;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.69	-0.3	2.87e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg11946769	chr3:48343235	NME6	-0.44	-5.88	-0.31	1.02e-8	Educational attainment (years of education);
CRC	trans	rs587242	1.000	rs12030271	chr1:96892099	A/G	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01200585	chr1:228362443	C1orf69	0.39	5.73	0.3	2.22e-8	Diastolic blood pressure;
CRC	trans	rs2857891	0.695	rs2468986	chr11:6986027	G/C	cg17499358	chr1:24476861	NA	0.3	6.16	0.32	2.07e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.49	-8.99	-0.44	1.91e-17	Hip circumference;Waist circumference;
CRC	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.41	5.85	0.31	1.16e-8	Blood metabolite levels;
CRC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.65	8.57	0.43	4.22e-16	Gut microbiome composition (summer);
CRC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg18764771	chr6:116381957	FRK	0.26	7.07	0.36	9.08e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6840360	0.642	rs2724571	chr4:152376795	T/C	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.36	-0.56	4.47e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-7.51	-0.38	5.56e-13	Vitiligo;
CRC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	17.02	0.68	4.77e-47	Smoking behavior;
CRC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.48	6.49	0.34	3.23e-10	Schizophrenia;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20092199	chr4:1342459	KIAA1530	-0.38	-6.73	-0.35	7.45e-11	Obesity-related traits;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg27094323	chr7:1216898	NA	-0.37	-5.77	-0.3	1.83e-8	Longevity;Endometriosis;
CRC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.56	0.43	4.5e-16	Gut microbiome composition (summer);
CRC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.0	-0.48	9.78e-21	Initial pursuit acceleration;
CRC	cis	rs889398	0.683	rs8047682	chr16:69913446	G/A	cg00738113	chr16:70207722	CLEC18C	-0.33	-5.7	-0.3	2.68e-8	Body mass index;
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14863265	chr7:2801509	GNA12	-0.41	-5.78	-0.3	1.78e-8	Height;
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.7	10.09	0.49	4.75e-21	Menarche (age at onset);
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.74	0.35	7.23e-11	Alzheimer's disease;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.56	-0.43	4.4e-16	Chronic sinus infection;
CRC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.22	-0.32	1.55e-9	Aortic root size;
CRC	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg21854759	chr1:92012499	NA	0.5	5.84	0.31	1.28e-8	Eosinophil percentage of white cells;
CRC	cis	rs116248771	0.549	rs1548013	chr3:158431070	C/T	cg16708174	chr3:158430962	RARRES1	0.45	6.05	0.32	4.04e-9	diarrhoeal disease at age 2;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.66	10.84	0.51	1.29e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23903597	chr17:61704154	MAP3K3	-0.45	-6.22	-0.32	1.48e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.45	-5.8	-0.3	1.58e-8	Putamen volume;
CRC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.66	-7.92	-0.4	3.72e-14	Vitamin D levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24497270	chr17:42401753	SLC25A39	0.46	6.46	0.34	3.75e-10	Anxiety disorder;
CRC	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs6545883	0.894	rs6734628	chr2:61451260	T/C	cg15711740	chr2:61764176	XPO1	0.43	5.78	0.3	1.72e-8	Tuberculosis;
CRC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg15440763	chr7:158190612	PTPRN2	0.41	6.44	0.33	4.16e-10	Obesity-related traits;
CRC	cis	rs4757319	0.515	rs6486237	chr11:15334740	G/A	cg03245590	chr11:15329459	NA	-0.53	-9.42	-0.46	8.16e-19	Breast cancer;
CRC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.63	-0.34	1.35e-10	Lung cancer;
CRC	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.6	-8.96	-0.44	2.5e-17	Testicular germ cell tumor;
CRC	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.67	-0.47	1.26e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs7180079	0.686	rs11071801	chr15:64883884	C/T	cg02770814	chr5:137368293	FAM13B	-0.6	-6.05	-0.32	4.02e-9	Monocyte count;
CRC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.37	6.02	0.31	4.78e-9	Ulcerative colitis;
CRC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.58	6.39	0.33	5.61e-10	Bipolar disorder;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.09	0.32	3.1e-9	Depression;
CRC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.84	0.31	1.26e-8	Hemoglobin concentration;
CRC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14909376	chr20:43588988	TOMM34	0.42	6.01	0.31	4.83e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.2	-0.32	1.65e-9	Blood metabolite levels;
CRC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.48	-7.79	-0.39	8.91e-14	Schizophrenia;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.98	14.61	0.63	1.29e-37	Breast cancer;
CRC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.73	-0.3	2.31e-8	Gout;Renal underexcretion gout;
CRC	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.62	10.6	0.5	8.85e-23	Platelet distribution width;
CRC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.24	-0.33	1.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.71	7.9	0.4	4.14e-14	Eotaxin levels;
CRC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	7.16	0.37	5.32e-12	Headache;
CRC	cis	rs72799341	0.706	rs11865499	chr16:31132250	A/G	cg02466173	chr16:30829666	NA	-0.42	-5.67	-0.3	3.17e-8	Diastolic blood pressure;
CRC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.41	-6.09	-0.32	3.18e-9	HDL cholesterol;
CRC	cis	rs728616	0.867	rs17886286	chr10:81703852	C/G	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.88	-0.4	4.76e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	7.17	0.37	5.05e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.42	7.79	0.39	8.85e-14	Lung cancer;
CRC	cis	rs12024301	0.557	rs11804313	chr1:183647803	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs758324	0.812	rs30159	chr5:131306535	T/C	cg25547332	chr5:131281432	NA	-0.36	-5.78	-0.3	1.74e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	17.83	0.7	2.97e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4481887	0.504	rs4390205	chr1:248358273	C/A	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.4e-9	Prudent dietary pattern;
CRC	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.73	11.68	0.54	1.33e-26	Eosinophil percentage of white cells;
CRC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.47	7.58	0.39	3.67e-13	Crohn's disease;
CRC	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.75	-9.35	-0.46	1.34e-18	Blood protein levels;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11645453	chr3:52864694	ITIH4	0.33	6.01	0.31	4.79e-9	Cognitive function;
CRC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.61	10.32	0.49	8.14e-22	Schizophrenia;
CRC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.56	-0.6	1.36e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs939584	0.935	rs7579427	chr2:631183	C/A	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.54	-8.44	-0.42	9.91e-16	Schizophrenia;
CRC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg15832292	chr6:96025679	MANEA	0.56	5.73	0.3	2.25e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs938554	0.779	rs9998811	chr4:9966477	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.04	-0.32	4.26e-9	Blood metabolite levels;
CRC	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.68	6.56	0.34	2.07e-10	Intraocular pressure;
CRC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.58	8.39	0.42	1.44e-15	Pancreatic cancer;
CRC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-8.21	-0.41	5e-15	Personality dimensions;
CRC	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg04920474	chr2:44395004	PPM1B	0.41	5.91	0.31	8.49e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.34	-5.71	-0.3	2.54e-8	Menopause (age at onset);
CRC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.8	-11.1	-0.52	1.61e-24	Platelet distribution width;
CRC	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	cg04338863	chr8:33670619	NA	0.39	6.88	0.35	2.97e-11	Body mass index;
CRC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg23758597	chr6:163146217	PARK2	-0.54	-6.18	-0.32	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.54	8.56	0.43	4.31e-16	Lewy body disease;
CRC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.45	-7.26	-0.37	2.85e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.74e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.73	-7.3	-0.37	2.12e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.59	0.34	1.78e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg18288967	chr1:45987694	PRDX1	0.64	7.81	0.4	7.56e-14	Obesity-related traits;
CRC	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.58	10.01	0.48	9.19e-21	Leprosy;
CRC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg21970626	chr13:21893289	NA	0.42	5.62	0.3	4.06e-8	White matter hyperintensity burden;
CRC	cis	rs4664293	0.647	rs1863686	chr2:160504049	C/T	cg08347373	chr2:160653686	CD302	-0.38	-6.55	-0.34	2.16e-10	Monocyte percentage of white cells;
CRC	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.49	0.38	6.44e-13	Eye color traits;
CRC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg11887960	chr12:57824829	NA	0.64	7.14	0.37	5.9e-12	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22833292	chr11:64126806	RPS6KA4	0.47	6.99	0.36	1.55e-11	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg00343986	chr7:65444356	GUSB	0.47	6.69	0.35	9.4e-11	Aortic root size;
CRC	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.44	6.79	0.35	5.15e-11	Schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02065795	chr15:64673455	KIAA0101	-0.51	-6.12	-0.32	2.62e-9	Diisocyanate-induced asthma;
CRC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-7.03	-0.36	1.21e-11	Monocyte percentage of white cells;
CRC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.54	7.47	0.38	7.43e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg13834844	chr10:102415320	NA	-0.36	-5.96	-0.31	6.6e-9	Body mass index;
CRC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.38	7.17	0.37	5.05e-12	Mean corpuscular volume;
CRC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.39	-0.33	5.71e-10	Blood metabolite levels;
CRC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.66	-8.28	-0.42	3.15e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg11266682	chr4:10021025	SLC2A9	0.43	7.18	0.37	4.76e-12	Blood metabolite levels;
CRC	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-7.24	-0.37	3.29e-12	Coronary artery disease;
CRC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg05709478	chr1:6581295	PLEKHG5	0.66	7.36	0.38	1.47e-12	Body mass index;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.89	-19.78	-0.74	6.16e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.57	7.4	0.38	1.15e-12	Body mass index;
CRC	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg07166546	chr14:35805898	NA	0.29	5.9	0.31	9.05e-9	Hip circumference adjusted for BMI;
CRC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	0.76	6.17	0.32	1.98e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.78	11.47	0.53	7.55e-26	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.05	-0.32	3.87e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.73	-0.39	1.28e-13	QT interval;
CRC	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg15664640	chr17:80829946	TBCD	-0.56	-6.11	-0.32	2.87e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.56	7.39	0.38	1.19e-12	Monocyte percentage of white cells;
CRC	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.54	8.59	0.43	3.49e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.52	6.71	0.35	8.42e-11	Longevity;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.76	9.41	0.46	8.87e-19	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20774722	chr17:19551893	ALDH3A2	0.4	7.05	0.36	1.05e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.48	-7.2	-0.37	4.23e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.39	6.04	0.32	4.2e-9	Capecitabine sensitivity;
CRC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg17724175	chr1:150552817	MCL1	-0.39	-6.01	-0.31	4.94e-9	Melanoma;
CRC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg20885578	chr2:198174922	NA	-0.41	-6.94	-0.36	2.16e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11212617	1.000	rs227087	chr11:108244114	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.76	0.35	6.12e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg11833968	chr6:79620685	NA	-0.37	-6.48	-0.34	3.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.68	-9.02	-0.45	1.63e-17	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.27	-0.71	5.69e-52	Height;
CRC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg02527881	chr3:46936655	PTH1R	0.33	5.75	0.3	2.04e-8	Colorectal cancer;
CRC	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg02135003	chr7:105160482	PUS7	-0.52	-8.11	-0.41	1.01e-14	Bipolar disorder (body mass index interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09031165	chr17:17586474	RAI1	0.5	6.42	0.33	4.89e-10	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg06470822	chr6:28175283	NA	0.94	12.8	0.58	1.0500000000000001e-30	Parkinson's disease;
CRC	trans	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg26043149	chr18:55253948	FECH	0.49	7.49	0.38	6.48e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4662945	0.688	rs12993231	chr2:130206377	A/G	cg05962382	chr2:130345044	NA	-0.33	-5.65	-0.3	3.55e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg25985355	chr7:65971099	NA	0.54	6.13	0.32	2.57e-9	Diabetic kidney disease;
CRC	cis	rs11958404	0.860	rs72818114	chr5:157440207	A/C	cg05962755	chr5:157440814	NA	0.96	12.14	0.56	2.72e-28	IgG glycosylation;
CRC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.1	10.9	0.52	7.71e-24	Diabetic retinopathy;
CRC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.66	7.29	0.37	2.38e-12	Gut microbiome composition (summer);
CRC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.18	-0.49	2.41e-21	Chronic sinus infection;
CRC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.7	11.02	0.52	2.99e-24	Corneal astigmatism;
CRC	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.43	6.12	0.32	2.65e-9	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10005894	chr3:186649165	ST6GAL1	0.43	5.99	0.31	5.44e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7781266	0.741	rs62469960	chr7:133141695	A/G	cg03336402	chr7:133662267	EXOC4	0.49	5.89	0.31	9.55e-9	Educational attainment (college completion);
CRC	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.69	-0.39	1.71e-13	Vitamin D levels;
CRC	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg15083037	chr5:83017644	HAPLN1	-0.53	-6.91	-0.36	2.45e-11	Prostate cancer;
CRC	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.42	6.88	0.35	2.99e-11	Menopause (age at onset);
CRC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg13072238	chr3:49761600	GMPPB	-0.51	-5.81	-0.3	1.5e-8	Menarche (age at onset);
CRC	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.46	7.93	0.4	3.55e-14	Common traits (Other);
CRC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.79	11.99	0.55	1.01e-27	Cognitive function;
CRC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg15440763	chr7:158190612	PTPRN2	0.47	7.63	0.39	2.52e-13	Obesity-related traits;
CRC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-10.25	-0.49	1.41e-21	Breast cancer;
CRC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.52	-8.62	-0.43	2.96e-16	Sense of smell;
CRC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.88	13.1	0.59	7.43e-32	Diastolic blood pressure;
CRC	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg09760422	chr2:128146352	NA	-0.36	-6.9	-0.36	2.6e-11	Protein C levels;
CRC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg12458913	chr13:53173898	NA	0.56	8.82	0.44	7.02e-17	Lewy body disease;
CRC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg12046867	chr14:103022105	NA	-0.73	-8.67	-0.43	2.07e-16	Platelet count;
CRC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.53	5.75	0.3	2.01e-8	Schizophrenia;
CRC	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg09654669	chr8:57350985	NA	-0.44	-5.93	-0.31	7.85e-9	Obesity-related traits;
CRC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.87	-10.18	-0.49	2.47e-21	Initial pursuit acceleration;
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg07217954	chr7:1067459	C7orf50	0.55	5.68	0.3	3.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12476592	0.543	rs2604615	chr2:63898428	T/C	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.55	8.44	0.42	1.06e-15	Diastolic blood pressure;
CRC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.67	7.13	0.37	6.42e-12	Inflammatory bowel disease;
CRC	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.38	-0.33	5.86e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.35	6.19	0.32	1.79e-9	Atrioventricular conduction;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	6.88	0.35	3.04e-11	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02139671	chr12:123237174	DENR	0.49	6.22	0.32	1.51e-9	Thyroid stimulating hormone;
CRC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-9.76	-0.47	6.03e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00006032	chr14:66974439	GPHN	0.51	6.64	0.34	1.29e-10	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.32	0.33	8.64e-10	Life satisfaction;
CRC	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.54	11.64	0.54	1.78e-26	Alcohol dependence;
CRC	cis	rs4604732	0.603	rs10802512	chr1:247633730	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.61	0.34	1.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.17	-0.45	5.17e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg18240062	chr17:79603768	NPLOC4	-0.42	-5.69	-0.3	2.81e-8	Eye color traits;
CRC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg10589385	chr1:150898437	SETDB1	0.33	6.79	0.35	5.17e-11	Melanoma;
CRC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.42	-5.93	-0.31	7.79e-9	Aortic root size;
CRC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.27	0.33	1.16e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs17234274	0.622	rs10833981	chr11:23232602	C/A	cg05245346	chr11:23248277	NA	0.36	5.84	0.31	1.23e-8	Cancer;
CRC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.43	8.85	0.44	5.67e-17	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.02	10.38	0.5	4.9e-22	Diabetic retinopathy;
CRC	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.88	8.82	0.44	7.02e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg02683197	chr6:28174875	NA	0.67	6.91	0.36	2.55e-11	Depression;
CRC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	6.03	0.32	4.37e-9	IgG glycosylation;
CRC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.7	0.3	2.63e-8	Obesity-related traits;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Depression;
CRC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.57	-0.72	3.59e-53	Primary sclerosing cholangitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16186051	chr20:40247245	CHD6	0.49	7.3	0.37	2.13e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.6	-9.23	-0.45	3.3e-18	Breast cancer;
CRC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.39	-7.85	-0.4	6.11e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7086803	1.000	rs12217440	chr10:114502218	G/A	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg07507251	chr3:52567010	NT5DC2	-0.39	-6.12	-0.32	2.61e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06307176	chr5:131281290	NA	0.43	6.34	0.33	7.7e-10	Life satisfaction;
CRC	trans	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.95	-0.36	1.98e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-1.18	-10.81	-0.51	1.7e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	6.02	0.32	4.61e-9	Resistin levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10800280	chr6:36646508	CDKN1A	0.44	7.2	0.37	4.2e-12	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs55841284	chr2:162560011	A/G	cg12500891	chr11:57225987	NA	-0.66	-6.09	-0.32	3.19e-9	Cognitive function;
CRC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.91	-0.31	8.34e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.26	-0.37	2.9e-12	Acylcarnitine levels;
CRC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.57	0.39	3.85e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.53	8.18	0.41	6.29e-15	Colorectal cancer;
CRC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.7	-0.47	1.02e-19	Schizophrenia;
CRC	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-0.7	-8.65	-0.43	2.27e-16	Blood protein levels;
CRC	cis	rs6504622	0.935	rs740617	chr17:45028001	C/T	cg16759221	chr17:45003025	GOSR2	-0.53	-8.49	-0.42	7.23e-16	Orofacial clefts;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.93	16.02	0.66	4.17e-43	Menarche (age at onset);
CRC	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.37	3.87e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.37	6.28e-12	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.73	-0.3	2.33e-8	Schizophrenia;
CRC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.8	0.48	4.54e-20	Cognitive test performance;
CRC	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	cg04338863	chr8:33670619	NA	0.41	6.18	0.32	1.86e-9	Body mass index;
CRC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	10.46	0.5	2.64e-22	Bone mineral density;
CRC	cis	rs4660214	0.724	rs10788933	chr1:39695155	A/G	cg11070191	chr1:39582205	MACF1	0.36	5.67	0.3	3.09e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19500275	chr17:80737654	TBCD	0.5	6.85	0.35	3.67e-11	Glycated hemoglobin levels;
CRC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.92	0.4	3.77e-14	Motion sickness;
CRC	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.34	-0.38	1.63e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg21505886	chr4:1724428	TMEM129;TACC3	-0.39	-5.6	-0.3	4.46e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.74	11.38	0.53	1.54e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg27523141	chr10:43048294	ZNF37B	-0.49	-7.35	-0.38	1.61e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg14008862	chr17:28927542	LRRC37B2	-0.57	-5.97	-0.31	6.08e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1883415	0.530	rs3765311	chr6:24503862	G/T	cg20631270	chr6:24437470	GPLD1	-0.38	-5.83	-0.31	1.32e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg23387468	chr7:139079360	LUC7L2	-0.42	-7.31	-0.37	2.02e-12	Diisocyanate-induced asthma;
CRC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg04166393	chr7:2884313	GNA12	0.38	5.79	0.3	1.64e-8	Height;
CRC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.57	11.33	0.53	2.39e-25	Asthma (sex interaction);
CRC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.8	-0.3	1.52e-8	Calcium levels;
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4716602	0.596	rs34977094	chr7:156160864	C/T	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.65e-11	Anti-saccade response;
CRC	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.42	0.46	8.12e-19	Ileal carcinoids;
CRC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.6	9.6	0.47	2.08e-19	Colorectal cancer;
CRC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.89	0.51	8.67e-24	Prudent dietary pattern;
CRC	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.63	6.59	0.34	1.71e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs73206853	0.841	rs73206894	chr12:110876328	C/T	cg12870014	chr12:110450643	ANKRD13A	0.75	8.18	0.41	6.45e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07308232	chr7:1071921	C7orf50	-0.42	-5.72	-0.3	2.36e-8	Longevity;Endometriosis;
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.6	10.33	0.49	7.77e-22	Prudent dietary pattern;
CRC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.86	-10.19	-0.49	2.29e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg20617676	chr7:123389167	WASL	0.38	6.28	0.33	1.08e-9	Interleukin-6 levels;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.78	-12.84	-0.58	7.49e-31	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg23093090	chr10:104574429	C10orf26	0.35	5.67	0.3	3.15e-8	Waist circumference;Hip circumference;
CRC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.48	-7.28	-0.37	2.43e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg22586996	chr5:158523907	EBF1	-0.34	-5.97	-0.31	6.02e-9	Cognitive performance;
CRC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.34	-0.33	7.59e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05977147	chr6:88182533	SLC35A1	0.41	6.41	0.33	5e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs642858	1.000	rs9403133	chr6:140301947	A/G	cg27524944	chr6:140295369	NA	-0.36	-5.97	-0.31	6.17e-9	Type 2 diabetes;
CRC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.58	9.65	0.47	1.5e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.03e-9	Bladder cancer;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	7.98	0.4	2.47e-14	Breast cancer;
CRC	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.45	6.63	0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs17209837	1.000	rs17149647	chr7:87086931	T/C	cg00919237	chr7:87102261	ABCB4	-0.47	-5.8	-0.3	1.54e-8	Gallbladder cancer;
CRC	cis	rs17767392	0.914	rs7147668	chr14:71857427	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.42	6.51	0.34	2.76e-10	Monocyte count;
CRC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.54	7.37	0.38	1.37e-12	Total body bone mineral density;
CRC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.59	0.43	3.46e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.7	12.46	0.57	1.81e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-1.25	-10.26	-0.49	1.27e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6496667	0.821	rs4412956	chr15:90885717	G/T	cg04176472	chr15:90893244	GABARAPL3	-0.59	-6.93	-0.36	2.2e-11	Rheumatoid arthritis;
CRC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.89	0.36	2.87e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.72	-0.35	8.23e-11	Menopause (age at onset);
CRC	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg03315344	chr16:75512273	CHST6	0.48	5.8	0.3	1.59e-8	Advanced age-related macular degeneration;
CRC	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg15654264	chr1:150340011	RPRD2	-0.4	-5.83	-0.31	1.29e-8	Migraine;
CRC	cis	rs1178968	0.901	rs7783232	chr7:72765171	C/G	cg25889504	chr7:72793014	NA	0.54	6.17	0.32	2.06e-9	Triglyceride levels;
CRC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.45	-5.63	-0.3	3.8e-8	Bipolar disorder;
CRC	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs4731207	0.698	rs7799938	chr7:124521391	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.65	9.8	0.48	4.58e-20	Lung cancer;
CRC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg03934865	chr2:198174659	NA	-0.48	-8.92	-0.44	3.26e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg10978503	chr1:24200527	CNR2	-0.5	-8.8	-0.44	8.16e-17	Immature fraction of reticulocytes;
CRC	cis	rs2415984	0.600	rs61993295	chr14:46932614	T/C	cg14871534	chr14:47121158	RPL10L	-0.42	-5.97	-0.31	6.01e-9	Number of children ever born;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg00769240	chr8:12517080	NA	-0.73	-10.15	-0.49	3.08e-21	Blood pressure (smoking interaction);
CRC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg05192639	chr6:26864778	GUSBL1	0.35	6.44	0.33	4.29e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.6	0.34	1.63e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg09127314	chr1:152161683	NA	-0.45	-5.61	-0.3	4.29e-8	Atopic dermatitis;
CRC	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg09344028	chr17:70110421	NA	0.51	8.27	0.41	3.46e-15	Thyroid hormone levels;
CRC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.38	-0.53	1.57e-25	Migraine;Coronary artery disease;
CRC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.53	-9.16	-0.45	5.7e-18	Type 2 diabetes;
CRC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.63	8.31	0.42	2.62e-15	Coronary artery disease;
CRC	cis	rs7209700	0.638	rs4629025	chr17:45337435	A/T	cg08085267	chr17:45401833	C17orf57	0.48	6.98	0.36	1.59e-11	IgG glycosylation;
CRC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.61	-0.39	2.96e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.48	-6.23	-0.32	1.44e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.45	6.49	0.34	3.23e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.59	8.48	0.42	7.65e-16	Smooth-surface caries;
CRC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.19	14.3	0.62	2.14e-36	Diabetic kidney disease;
CRC	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.72	-0.35	8.09e-11	Metabolic traits;
CRC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.9	0.44	3.69e-17	Hip circumference adjusted for BMI;
CRC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.73	-13.35	-0.59	8.95e-33	Body mass index;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg15147215	chr3:52552868	STAB1	0.64	10.59	0.5	9.25e-23	Bipolar disorder;
CRC	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.46	7.56	0.38	3.99e-13	Refractive error;
CRC	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.47	-5.73	-0.3	2.21e-8	Lymphocyte percentage of white cells;
CRC	cis	rs9682041	0.561	rs7616830	chr3:170146445	A/G	cg11886554	chr3:170076028	SKIL	0.68	7.65	0.39	2.28e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.47	6.27	0.33	1.11e-9	Obesity-related traits;
CRC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.26	0.33	1.21e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.97	-18.51	-0.71	6.19e-53	Height;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	7.27	0.37	2.58e-12	Electroencephalogram traits;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.54	10.41	0.5	3.98e-22	Acylcarnitine levels;
CRC	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg02158880	chr13:53174818	NA	0.43	6.44	0.33	4.24e-10	Lewy body disease;
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.6	7.33	0.37	1.82e-12	Alzheimer's disease;
CRC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs519973	0.775	rs12638043	chr3:187635232	C/T	cg10168494	chr3:187635183	NA	0.5	8.65	0.43	2.26e-16	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg07952391	chr2:88470173	THNSL2	0.65	6.63	0.34	1.4e-10	Plasma clusterin levels;
CRC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.49	7.86	0.4	5.56e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.61	8.51	0.42	6.45e-16	Arsenic metabolism;
CRC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.44	-6.59	-0.34	1.77e-10	Systemic lupus erythematosus;
CRC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.72	-0.47	8.53e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg24046110	chr8:143859143	LYNX1	0.48	8.24	0.41	4.26e-15	Urinary tract infection frequency;
CRC	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	cg04338863	chr8:33670619	NA	0.39	6.84	0.35	3.92e-11	Body mass index;
CRC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.77	-11.51	-0.54	5.29e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs66569888	0.607	rs11687271	chr2:106727456	G/A	cg16099169	chr2:106886729	NA	-0.37	-5.67	-0.3	3.16e-8	Facial morphology (factor 23);
CRC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-1.12	-10.69	-0.51	4.43e-23	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.62	-0.34	1.49e-10	Alzheimer's disease (late onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09484009	chr8:97274693	MTERFD1;PTDSS1	-0.41	-5.96	-0.31	6.52e-9	Interleukin-6 levels;
CRC	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.68	-7.42	-0.38	9.81e-13	Axial length;
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg21138405	chr5:131827807	IRF1	0.32	5.76	0.3	1.91e-8	Blood metabolite levels;
CRC	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.95	-13.36	-0.59	7.99e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	0.58	6.82	0.35	4.34e-11	Prostate cancer;
CRC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1656402	1.000	rs1656400	chr2:233427783	A/G	cg03852847	chr2:233439513	NA	-0.34	-6.33	-0.33	8.16e-10	Non-small cell lung cancer (survival);
CRC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.47	-7.78	-0.39	9.5e-14	Monocyte count;
CRC	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg13319975	chr6:146136371	FBXO30	0.41	6.18	0.32	1.9e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-10.71	-0.51	3.59e-23	Longevity;Endometriosis;
CRC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.98	-0.31	5.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.5	8.67	0.43	2.02e-16	Hypertriglyceridemia;
CRC	cis	rs4700695	0.841	rs417074	chr5:65314894	C/T	cg21114390	chr5:65439923	SFRS12	0.64	6.6	0.34	1.61e-10	Facial morphology (factor 19);
CRC	cis	rs11166629	1.000	rs6577713	chr8:135645592	C/A	cg27224718	chr8:135614730	ZFAT	0.52	7.62	0.39	2.7e-13	Smoking quantity;
CRC	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.73	-12.82	-0.58	8.7e-31	White blood cell count (basophil);
CRC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.87e-12	Aortic root size;
CRC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.79	0.47	5.14e-20	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.69	-0.3	2.88e-8	Electroencephalogram traits;
CRC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.51	6.21	0.32	1.61e-9	Diastolic blood pressure;
CRC	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg21155852	chr7:2048760	MAD1L1	-0.44	-6.26	-0.33	1.2e-9	Neuroticism;
CRC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg17948913	chr5:572064	NA	0.56	6.29	0.33	1e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-8.09	-0.41	1.18e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.21	-0.37	3.78e-12	Capecitabine sensitivity;
CRC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.68	8.63	0.43	2.76e-16	Psoriasis;
CRC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.47	6.03	0.32	4.46e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2252521	0.524	rs2529480	chr7:29043120	G/A	cg11728747	chr7:29037910	CPVL	-0.49	-7.03	-0.36	1.2e-11	Cognitive performance;
CRC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg22777020	chr22:31556080	RNF185	-0.53	-6.07	-0.32	3.45e-9	Colorectal cancer;
CRC	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.17	-0.32	1.98e-9	Breast cancer;
CRC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.84	0.31	1.25e-8	Tonsillectomy;
CRC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.48	7.36	0.38	1.51e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs6561151	1.000	rs6561151	chr13:44484706	G/A	cg12856521	chr11:46389249	DGKZ	0.63	9.38	0.46	1.1e-18	Crohn's disease;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg22638593	chr5:131593259	PDLIM4	0.36	6.9	0.36	2.73e-11	Blood metabolite levels;
CRC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg14979609	chr8:8086686	FLJ10661	0.38	6.25	0.33	1.26e-9	Joint mobility (Beighton score);
CRC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.58	-10.01	-0.48	9.42e-21	Developmental language disorder (linguistic errors);
CRC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.9	-11.33	-0.53	2.46e-25	Monocyte percentage of white cells;
CRC	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.57	7.61	0.39	2.85e-13	Coronary artery disease;
CRC	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.74	-13.42	-0.59	4.69e-33	Coronary artery disease;
CRC	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	1.11	12.99	0.58	2.06e-31	Obesity-related traits;
CRC	trans	rs10411161	1.000	rs2867318	chr19:52363472	T/C	cg22319618	chr22:45562946	NUP50	-0.52	-6.03	-0.32	4.4e-9	Breast cancer;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.77	-0.35	5.85e-11	Inflammatory skin disease;
CRC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.62	-10.84	-0.51	1.34e-23	Type 2 diabetes;
CRC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.63	7.36	0.38	1.48e-12	Cleft lip with or without cleft palate;
CRC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	8.19	0.41	5.88e-15	LDL cholesterol;Cholesterol, total;
CRC	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	14.05	0.61	1.94e-35	Exhaled nitric oxide output;
CRC	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg26893134	chr6:116381904	FRK	0.27	6.45	0.33	4.07e-10	Total cholesterol levels;
CRC	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	0.99	7.81	0.4	7.63e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.71	-10.05	-0.48	6.59e-21	Blood metabolite levels;
CRC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.51	5.62	0.3	4.01e-8	Vitiligo;
CRC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-10.35	-0.5	6.21e-22	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01952724	chr19:51611733	CTU1	0.46	6.41	0.33	4.94e-10	Response to antipsychotic treatment;
CRC	cis	rs12580194	0.593	rs66516917	chr12:55749131	T/G	cg19537932	chr12:55886519	OR6C68	-0.68	-8.88	-0.44	4.57e-17	Cancer;
CRC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg08075719	chr14:103021372	NA	-0.69	-9.22	-0.45	3.67e-18	Platelet count;
CRC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg26587870	chr6:27730563	NA	-0.57	-6.27	-0.33	1.12e-9	Depression;
CRC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg02175503	chr12:58329896	NA	0.52	7.48	0.38	6.61e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.0	0.4	2.12e-14	Menarche (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10780647	chr20:3800838	C20orf29	0.42	5.98	0.31	5.9e-9	Anxiety disorder;
CRC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg21399703	chr1:247681439	NA	-0.55	-9.98	-0.48	1.14e-20	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13606994	chr1:44402422	ARTN	-0.34	-5.79	-0.3	1.65e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-10.77	-0.51	2.21e-23	Personality dimensions;
CRC	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-6.09	-0.32	3.16e-9	Axial length;
CRC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.1	0.71	2.67e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg09264619	chr17:80180166	NA	-0.37	-6.32	-0.33	8.43e-10	Life satisfaction;
CRC	cis	rs4728302	0.869	rs12707130	chr7:133616739	G/T	cg10665199	chr7:133106180	EXOC4	0.4	6.05	0.32	3.92e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.62	-0.54	2.13e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg25164649	chr6:28176230	NA	-0.41	-5.79	-0.3	1.63e-8	Systemic lupus erythematosus;
CRC	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.67	6.91	0.36	2.58e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.5	1.25e-22	Heart rate;
CRC	cis	rs2249694	0.922	rs8192780	chr10:135354125	T/G	cg20169779	chr10:135381914	SYCE1	0.54	8.62	0.43	2.79e-16	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07835289	chr1:236030215	LYST	0.38	6.05	0.32	3.98e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg23533926	chr12:111358616	MYL2	0.44	6.54	0.34	2.36e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.42	0.42	1.15e-15	Cognitive test performance;
CRC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.55	9.2	0.45	4.2e-18	Systemic lupus erythematosus;
CRC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg11212589	chr17:38028394	ZPBP2	0.41	7.42	0.38	1.03e-12	Self-reported allergy;
CRC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg17724175	chr1:150552817	MCL1	0.5	7.49	0.38	6.23e-13	Melanoma;
CRC	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.58	-5.71	-0.3	2.54e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.64	12.01	0.55	8.66e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs418053	0.648	rs204228	chr6:13680776	A/G	cg02206980	chr6:13574034	SIRT5	-0.38	-6.19	-0.32	1.77e-9	Breast cancer;
CRC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.93	17.75	0.7	6.21e-50	Height;
CRC	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	7.98	0.4	2.39e-14	Bipolar disorder;
CRC	cis	rs9463078	0.691	rs10948229	chr6:45306371	A/G	cg25276700	chr6:44698697	NA	0.25	6.11	0.32	2.89e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.49	7.01	0.36	1.33e-11	Height;
CRC	cis	rs7951870	0.645	rs10769205	chr11:46723603	A/G	cg19486271	chr11:47235900	DDB2	0.47	7.2	0.37	4.07e-12	Schizophrenia;
CRC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.05	0.68	3.65e-47	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.87e-11	Bipolar disorder;
CRC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.43	7.78	0.39	9.33e-14	Reticulocyte fraction of red cells;
CRC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.69	-0.47	1.05e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Blood protein levels;
CRC	cis	rs6681460	0.649	rs967325	chr1:67003722	C/T	cg02459107	chr1:67143332	SGIP1	0.39	6.06	0.32	3.78e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg03948781	chr1:205179583	DSTYK	0.41	5.84	0.31	1.25e-8	Red blood cell count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23141096	chr10:98347050	TM9SF3	0.42	6.22	0.32	1.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.61	8.92	0.44	3.39e-17	Adiposity;
CRC	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.67	-0.35	1.07e-10	Response to antipsychotic treatment;
CRC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg05501817	chr11:14380813	RRAS2	-0.46	-6.04	-0.32	4.12e-9	Sense of smell;
CRC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg11271282	chr2:238384023	NA	0.45	5.7	0.3	2.72e-8	Prostate cancer;
CRC	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.58	8.22	0.41	4.63e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-10.29	-0.49	1e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.42	-7.06	-0.36	1.01e-11	Breast cancer;
CRC	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-8.56	-0.43	4.28e-16	Coronary artery disease;
CRC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.48	7.39	0.38	1.24e-12	Mean platelet volume;
CRC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg06987292	chr12:125626746	AACS	-0.37	-5.76	-0.3	1.95e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17885091	chr1:68299057	GNG12	0.37	6.08	0.32	3.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.36	0.62	1.21e-36	Chronic sinus infection;
CRC	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg19041857	chr6:27730383	NA	-0.59	-5.78	-0.3	1.71e-8	Depression;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg03623178	chr6:28175578	NA	0.57	6.72	0.35	8.03e-11	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.26	-0.33	1.22e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7705042	0.865	rs6580225	chr5:141489381	G/C	cg07392085	chr5:141489673	NDFIP1	0.46	7.2	0.37	4.04e-12	Asthma;
CRC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-8.18	-0.41	6.31e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.41	-0.38	1.1e-12	Inflammatory skin disease;
CRC	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg13491945	chr12:107078410	RFX4	0.35	5.92	0.31	7.88e-9	Heart rate;
CRC	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-7.96	-0.4	2.72e-14	Coronary artery disease;
CRC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.67	-0.47	1.25e-19	Height;
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg23625390	chr15:77176239	SCAPER	0.55	8.4	0.42	1.37e-15	Blood metabolite levels;
CRC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.48e-17	Bladder cancer;
CRC	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-0.7	-10.8	-0.51	1.76e-23	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs4920343	0.698	rs591009	chr1:19086869	A/G	cg19637330	chr1:19110922	NA	0.39	5.82	0.31	1.39e-8	Knee osteoarthritis;
CRC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.45	6.75	0.35	6.77e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.51	-6.19	-0.32	1.76e-9	Body mass index;
CRC	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.66	-9.21	-0.45	3.82e-18	Autism;
CRC	cis	rs9463078	0.527	rs2040032	chr6:44743009	C/T	cg25276700	chr6:44698697	NA	0.3	7.76	0.39	1.09e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.63	11.84	0.55	3.3699999999999996e-27	Schizophrenia;
CRC	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.38	-5.69	-0.3	2.83e-8	Intelligence;
CRC	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg23032129	chr1:109941072	SORT1	-0.29	-5.88	-0.31	1.03e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.0	0.31	5.2e-9	Bipolar disorder;
CRC	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.67	-0.39	2.02e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.79	-11.85	-0.55	3.23e-27	Multiple sclerosis;
CRC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg03030879	chr14:75389066	RPS6KL1	0.41	6.41	0.33	5.09e-10	Height;
CRC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg12564285	chr5:131593104	PDLIM4	-0.33	-5.76	-0.3	1.9e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.41	6.03	0.32	4.47e-9	Pulse pressure;
CRC	cis	rs12024301	0.557	rs6692924	chr1:183624098	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg09127314	chr1:152161683	NA	-0.51	-5.91	-0.31	8.47e-9	Atopic dermatitis;
CRC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.22	0.49	1.85e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6123683	1.000	rs6123683	chr20:55824509	A/G	cg13236649	chr20:55835020	BMP7	0.43	6.14	0.32	2.4e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.63	0.7	1.96e-49	Platelet count;
CRC	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.43	5.76	0.3	1.91e-8	Coronary artery disease;
CRC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.74	-8.44	-0.42	1.05e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.52	0.34	2.61e-10	Hip circumference adjusted for BMI;
CRC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-8.42	-0.42	1.2e-15	Colorectal cancer;
CRC	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.44	-5.79	-0.3	1.6e-8	Waist circumference;Body mass index;
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs807029	0.533	rs67692077	chr10:102740271	T/C	cg04662943	chr10:102668895	NA	0.65	7.5	0.38	6.11e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs55702914	0.935	rs56116936	chr2:198219217	C/A	cg10820045	chr2:198174542	NA	0.36	6.38	0.33	5.99e-10	Major depression and alcohol dependence;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-7.43	-0.38	9.17e-13	Longevity;Endometriosis;
CRC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15369054	chr17:80825471	TBCD	0.52	6.19	0.32	1.76e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.37	7.19e-12	Menopause (age at onset);
CRC	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.46	6.86	0.35	3.48e-11	Crohn's disease;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.61	-11.57	-0.54	3.41e-26	Tonsillectomy;
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.21	-0.32	1.63e-9	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs995000	0.965	rs1979722	chr1:62940097	G/A	cg19896129	chr1:63156450	NA	0.4	5.84	0.31	1.28e-8	Triglyceride levels;
CRC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg13072238	chr3:49761600	GMPPB	-0.52	-5.92	-0.31	8.06e-9	Menarche (age at onset);
CRC	trans	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg07504079	chr7:72649617	NCF1B	-0.45	-7.01	-0.36	1.39e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.47	-6.15	-0.32	2.26e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg19046167	chr17:80928561	B3GNTL1	0.44	7.46	0.38	7.74e-13	Breast cancer;
CRC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-6.91	-0.36	2.54e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2486012	0.850	rs2906462	chr1:44332084	G/A	cg12908607	chr1:44402522	ARTN	-0.42	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg19318889	chr4:1322082	MAEA	0.4	5.72	0.3	2.39e-8	Obesity-related traits;
CRC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.28	-0.33	1.05e-9	Gout;Renal underexcretion gout;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.37	5.92	0.31	8.18e-9	Lung cancer;
CRC	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.47	9.49	0.46	4.77e-19	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6893807	0.667	rs1477290	chr5:87988934	T/C	cg09002922	chr5:87956389	LOC645323	-0.43	-5.61	-0.3	4.23e-8	Body mass index;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg05569086	chr8:143859399	LYNX1	-0.39	-6.39	-0.33	5.59e-10	Urinary tract infection frequency;
CRC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg09003973	chr2:102972529	NA	0.53	6.67	0.35	1.1e-10	Blood protein levels;
CRC	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.61	0.65	1.71e-41	Fuchs's corneal dystrophy;
CRC	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.39	6.4	0.33	5.2e-10	Sitting height ratio;
CRC	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg14352298	chr13:112236639	NA	0.29	6.49	0.34	3.25e-10	Hepatitis;
CRC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.14e-9	Crohn's disease;
CRC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg15704280	chr7:45808275	SEPT13	-0.48	-6.83	-0.35	4.14e-11	HDL cholesterol;
CRC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg07809909	chr20:30433512	FOXS1	0.35	5.7	0.3	2.6e-8	Mean corpuscular hemoglobin;
CRC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.32	0.53	2.57e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.57	8.59	0.43	3.61e-16	Monobrow;
CRC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.37	6.66	0.34	1.17e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2882667	0.898	rs6867343	chr5:138374428	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-5.98	-0.31	5.91e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6662572	0.737	rs6680647	chr1:46345478	C/T	cg08644498	chr1:46502608	NA	0.45	7.07	0.36	9.47e-12	Blood protein levels;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.61	9.26	0.45	2.63e-18	Longevity;Endometriosis;
CRC	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.67	-11.12	-0.52	1.34e-24	Type 2 diabetes;
CRC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.57	9.75	0.47	6.71e-20	Iron status biomarkers;
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg15147215	chr3:52552868	STAB1	-0.68	-12.03	-0.55	7.29e-28	Electroencephalogram traits;
CRC	cis	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg05299278	chr17:33885742	SLFN14	0.41	6.12	0.32	2.7e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg09877947	chr5:131593287	PDLIM4	0.52	9.52	0.46	3.88e-19	Blood metabolite levels;
CRC	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.66	8.97	0.44	2.28e-17	White matter hyperintensity burden;
CRC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg02903104	chr8:1507517	DLGAP2	0.35	6.13	0.32	2.46e-9	Lung cancer;
CRC	cis	rs6432018	1.000	rs10210225	chr2:9739225	A/G	cg12832956	chr2:9616023	IAH1	-0.38	-5.69	-0.3	2.8e-8	Heart rate variability traits;
CRC	cis	rs776905	0.598	rs491098	chr13:113769346	C/G	cg09069900	chr13:113776964	F10	0.4	6.52	0.34	2.7e-10	Blood protein levels;
CRC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.71	12.49	0.57	1.42e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.34	5.88	0.31	1.01e-8	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16467105	chr14:74959227	NPC2;ISCA2	0.48	6.71	0.35	8.41e-11	Thyroid stimulating hormone;
CRC	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg15382696	chr6:118971807	C6orf204	0.61	8.02	0.4	1.92e-14	Diastolic blood pressure;
CRC	cis	rs365302	0.628	rs409096	chr6:159610904	T/C	cg14500486	chr6:159655392	FNDC1	0.59	8.5	0.42	6.63e-16	Coronary heart disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05193570	chr5:893022	TRIP13;BRD9	0.39	6.02	0.31	4.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7553864	0.518	rs10747341	chr1:87627331	G/A	cg02083836	chr1:87617350	LOC339524	0.63	10.98	0.52	4.33e-24	Smoking behavior;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	6.41	0.33	5.07e-10	Obesity-related traits;
CRC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.51	7.43	0.38	9.14e-13	Dementia with Lewy bodies;
CRC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg26028573	chr6:26043587	HIST1H2BB	0.46	6.94	0.36	2.11e-11	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Depression;
CRC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.65	6.55	0.34	2.28e-10	Inflammatory bowel disease;
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg01874867	chr7:94954059	PON1	-0.52	-6.46	-0.34	3.79e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg09659197	chr4:152720779	NA	0.5	10.93	0.52	6.33e-24	Intelligence (multi-trait analysis);
CRC	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg25482853	chr8:67687455	SGK3	0.71	8.91	0.44	3.53e-17	Obesity-related traits;
CRC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.54	0.43	5.04e-16	Morning vs. evening chronotype;
CRC	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg24375607	chr4:120327624	NA	0.47	7.66	0.39	2.13e-13	Corneal astigmatism;
CRC	cis	rs6694672	0.867	rs518149	chr1:197188664	A/G	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.36	2.31e-11	Asthma;
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.78	14.07	0.61	1.52e-35	Prudent dietary pattern;
CRC	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.4	-5.9	-0.31	9.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg04586622	chr2:25135609	ADCY3	-0.58	-9.95	-0.48	1.42e-20	Body mass index;
CRC	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg18196295	chr10:418757	DIP2C	-0.67	-9.32	-0.46	1.7e-18	Psychosis in Alzheimer's disease;
CRC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg01879757	chr17:41196368	BRCA1	-0.42	-6.33	-0.33	7.99e-10	Menopause (age at onset);
CRC	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	1.0	18.87	0.72	2.33e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.65	12.06	0.55	5.61e-28	Aortic root size;
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg04969067	chr8:143858791	LYNX1	0.44	7.43	0.38	9.31e-13	Urinary tract infection frequency;
CRC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.19	-0.32	1.76e-9	Type 2 diabetes;
CRC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-13.02	-0.58	1.57e-31	Blood metabolite levels;
CRC	cis	rs758324	0.773	rs13174385	chr5:131160187	T/G	cg25547332	chr5:131281432	NA	0.37	5.93	0.31	7.56e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.2e-25	Prostate cancer;
CRC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg12590608	chr7:158785262	NA	-0.44	-7.91	-0.4	4e-14	Facial morphology (factor 20);
CRC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.05	-0.48	6.65e-21	Chronic sinus infection;
CRC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.09	-15.06	-0.64	2.3e-39	Exhaled nitric oxide output;
CRC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.78	-0.35	5.53e-11	Alzheimer's disease (late onset);
CRC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	8.4	0.42	1.39e-15	Cognitive test performance;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg06395988	chr2:242041550	MTERFD2	-0.42	-6.06	-0.32	3.82e-9	Daytime sleep phenotypes;
CRC	cis	rs863345	0.604	rs6670343	chr1:158497258	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.36	-6.15	-0.32	2.24e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.4	-6.35	-0.33	7.35e-10	Testicular germ cell tumor;
CRC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.47	-6.59	-0.34	1.76e-10	Fibrinogen levels;
CRC	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg07299736	chr8:135490787	ZFAT	-0.37	-6.19	-0.32	1.81e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-5.88	-0.31	1.01e-8	Red blood cell count;
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07067904	chr2:74425934	MTHFD2	0.38	6.19	0.32	1.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg16558208	chr1:156270281	VHLL	0.57	8.94	0.44	2.95e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.62	9.09	0.45	9.79e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.29	-0.42	2.89e-15	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13393195	chr12:113659153	TPCN1;IQCD	0.43	6.02	0.31	4.6e-9	Response to antipsychotic treatment;
CRC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.22	0.59	2.6e-32	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg15733309	chr7:157513707	PTPRN2	0.42	6.85	0.35	3.69e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.63	0.34	1.41e-10	Mean platelet volume;
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.62	-0.54	2.14e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg09654669	chr8:57350985	NA	-0.42	-5.9	-0.31	8.98e-9	Obesity-related traits;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.9	-0.4	4.23e-14	Longevity;Endometriosis;
CRC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.84e-10	Breast cancer;
CRC	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.56	8.37	0.42	1.68e-15	Schizophrenia;
CRC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.44	-6.31	-0.33	9.13e-10	Uric acid clearance;
CRC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.58	-8.97	-0.44	2.3e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.68	8.09	0.41	1.19e-14	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg10756647	chr7:56101905	PSPH	-0.77	-7.87	-0.4	5.06e-14	Diabetic kidney disease;
CRC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg12927641	chr6:109611667	NA	-0.36	-6.38	-0.33	6.1e-10	Reticulocyte fraction of red cells;
CRC	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.66	-8.38	-0.42	1.51e-15	Schizophrenia;
CRC	trans	rs7765175	0.547	rs1066296	chr6:113572558	A/C	cg10503028	chr9:127615433	WDR38	0.46	6.13	0.32	2.45e-9	Coronary artery calcification;
CRC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg02569458	chr12:86230093	RASSF9	0.39	6.32	0.33	8.64e-10	Major depressive disorder;
CRC	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	17.88	0.7	1.96e-50	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg27499820	chr13:21296301	IL17D	0.41	5.91	0.31	8.36e-9	Dental caries;
CRC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.52	0.38	5.16e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.52	-8.69	-0.43	1.76e-16	Menarche (age at onset);
CRC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.45	-7.39	-0.38	1.21e-12	Type 2 diabetes;
CRC	trans	rs17641971	0.862	rs341829	chr8:50005758	T/C	cg18784943	chr17:79371681	NA	0.41	6.4	0.33	5.27e-10	Blood metabolite levels;
CRC	trans	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-6.37	-0.33	6.25e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg18758796	chr5:131593413	PDLIM4	0.39	6.3	0.33	9.75e-10	Breast cancer;
CRC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg18232548	chr7:50535776	DDC	0.44	6.33	0.33	8.03e-10	Malaria;
CRC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.52e-15	Height;
CRC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.09	0.45	9.25e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs720844	0.748	rs35076661	chr2:149319685	T/G	cg09247360	chr2:149335327	NA	-0.55	-6.03	-0.32	4.29e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.39	-0.33	5.78e-10	Aortic root size;
CRC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg23625390	chr15:77176239	SCAPER	0.48	6.93	0.36	2.28e-11	Blood metabolite levels;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg12172441	chr6:28176163	NA	0.49	6.42	0.33	4.77e-10	Parkinson's disease;
CRC	cis	rs995000	0.931	rs1748199	chr1:63057136	T/C	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	17.8	0.7	4.17e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg24505167	chr7:1915268	MAD1L1	-0.43	-6.02	-0.31	4.68e-9	Bipolar disorder;
CRC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.66	-8.89	-0.44	4.02e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.58	8.14	0.41	8.5e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.89e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	8.1	0.41	1.05e-14	Body mass index;
CRC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	10.31	0.49	8.97e-22	Bone mineral density;
CRC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.5	-6.44	-0.33	4.24e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.84	-0.44	6.02e-17	Hemoglobin concentration;
CRC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.51	0.69	5.94e-49	Platelet count;
CRC	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg02927042	chr1:21476669	EIF4G3	-0.45	-7.23	-0.37	3.33e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs73206853	0.686	rs73194039	chr12:111179153	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	6.29	0.33	1.01e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg14004847	chr7:1930337	MAD1L1	0.44	6.35	0.33	7.29e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.6	10.33	0.49	7.37e-22	Prudent dietary pattern;
CRC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.53	7.84	0.4	6.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.64	-9.02	-0.45	1.57e-17	Multiple sclerosis;
CRC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.47	-0.38	7.35e-13	Psoriasis;
CRC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.47	8.19	0.41	5.8e-15	Height;
CRC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.8	-0.3	1.54e-8	Gut microbiome composition (summer);
CRC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.59	9.61	0.47	2.03e-19	Tonsillectomy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00492233	chr7:135242493	NUP205	0.49	6.15	0.32	2.24e-9	Thyroid stimulating hormone;
CRC	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.76	8.66	0.43	2.15e-16	Neuroticism;
CRC	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	5.01e-17	Coffee consumption (cups per day);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03442064	chr6:41515050	FOXP4	-0.52	-6.2	-0.32	1.7e-9	Diisocyanate-induced asthma;
CRC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19856771	chr13:42780042	DGKH	-0.39	-5.97	-0.31	6.17e-9	Smoking initiation;
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02290350	chr8:58132656	NA	-0.6	-7.22	-0.37	3.54e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg07817883	chr1:32538562	TMEM39B	-0.59	-7.64	-0.39	2.37e-13	Monocyte percentage of white cells;
CRC	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.33	12.86	0.58	6.21e-31	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24308560	chr3:49941425	MST1R	0.43	6.59	0.34	1.78e-10	Body mass index;
CRC	cis	rs7333181	1.000	rs12866444	chr13:112239743	C/T	cg27543320	chr13:112200689	NA	0.49	6.22	0.32	1.51e-9	Menopause (age at onset);
CRC	cis	rs6662572	0.774	rs6696284	chr1:46571684	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.27	0.33	1.13e-9	Blood protein levels;
CRC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.49	0.54	6.29e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg11900509	chr10:81946545	ANXA11	-0.68	-6.96	-0.36	1.91e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.59	-0.34	1.75e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.43	6.54	0.34	2.36e-10	Endometrial cancer;
CRC	trans	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.12	-0.32	2.7e-9	Educational attainment (years of education);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07740911	chr16:8768488	ABAT	0.44	6.27	0.33	1.13e-9	Anxiety disorder;
CRC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg00074818	chr8:8560427	CLDN23	0.42	7.66	0.39	2.09e-13	Obesity-related traits;
CRC	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.74	-12.13	-0.56	3.05e-28	Gut microbiome composition (winter);
CRC	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.4	5.79	0.3	1.66e-8	Body mass index;
CRC	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg05579598	chr16:88989069	CBFA2T3	0.36	7.29	0.37	2.39e-12	Social autistic-like traits;
CRC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.84	-0.4	6.38e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	1.22	14.45	0.62	5.36e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.34	-0.38	1.65e-12	Bipolar disorder;
CRC	trans	rs1901167	1.000	rs1901167	chr5:40961164	A/G	cg07701837	chr2:210516795	MAP2	0.37	5.98	0.31	5.85e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.54	8.87	0.44	4.65e-17	Mean corpuscular volume;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.61	0.57	5.01e-30	Platelet count;
CRC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.44	-5.71	-0.3	2.51e-8	Height;
CRC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg25164649	chr6:28176230	NA	0.64	8.67	0.43	1.95e-16	Parkinson's disease;
CRC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.89	-15.26	-0.64	3.82e-40	Height;
CRC	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.31	0.46	1.84e-18	Blood protein levels;
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.39	-0.38	1.24e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg21770322	chr7:97807741	LMTK2	0.53	8.59	0.43	3.62e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.36	5.62	0.3	4.08e-8	Educational attainment;
CRC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg04731861	chr2:219085781	ARPC2	-0.31	-6.74	-0.35	7.21e-11	Colorectal cancer;
CRC	cis	rs6504622	0.905	rs197926	chr17:45012087	A/G	cg16759221	chr17:45003025	GOSR2	-0.53	-8.59	-0.43	3.58e-16	Orofacial clefts;
CRC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.98	0.4	2.45e-14	Colorectal cancer;
CRC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg22495460	chr2:25135724	ADCY3	-0.87	-16.98	-0.68	6.95e-47	Body mass index;
CRC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	6.87	0.35	3.32e-11	Coronary artery disease;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.24	0.41	4.11e-15	Life satisfaction;
CRC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.95	18.1	0.71	2.76e-51	Height;
CRC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg06462663	chr19:18546047	ISYNA1	0.51	7.73	0.39	1.32e-13	Breast cancer;
CRC	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.95e-8	Coronary artery calcification;
CRC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.43	6.12	0.32	2.62e-9	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04914231	chr16:30006637	INO80E;HIRIP3	0.39	6.24	0.33	1.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.53	-8.91	-0.44	3.61e-17	Type 2 diabetes;
CRC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.83	-13.08	-0.58	9.46e-32	Blood metabolite levels;
CRC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	9.32	0.46	1.76e-18	Eye color traits;
CRC	cis	rs501120	0.657	rs1704222	chr10:44710465	T/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	5.74	0.3	2.2e-8	Aortic root size;
CRC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.34	6.42	0.33	4.8e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.12	0.49	3.81e-21	Menopause (age at onset);
CRC	cis	rs35883536	0.875	rs1970227	chr1:101140723	G/A	cg14515779	chr1:101123966	NA	0.36	6.61	0.34	1.57e-10	Monocyte count;
CRC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.85	8.82	0.44	6.92e-17	Skin colour saturation;
CRC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg10298567	chr3:47292165	KIF9	-0.39	-6.59	-0.34	1.74e-10	Colorectal cancer;
CRC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.16	-13.54	-0.6	1.73e-33	Diabetic kidney disease;
CRC	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg07322936	chr10:88137208	NA	-0.63	-8.64	-0.43	2.45e-16	Schizophrenia;
CRC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.44	-6.23	-0.32	1.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.12	10.78	0.51	2.04e-23	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-10.61	-0.51	8e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-6.74	-0.35	7.18e-11	Endometrial cancer;
CRC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.4	0.33	5.46e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.58	10.41	0.5	4.15e-22	Coronary artery disease;
CRC	cis	rs5744897	1.000	rs5744897	chr12:133226831	C/T	cg26621607	chr12:133180238	NA	0.44	6.13	0.32	2.57e-9	Urate levels in overweight individuals;
CRC	cis	rs4660531	1.000	rs4660532	chr1:41840197	C/T	cg00290994	chr1:41848739	NA	0.44	6.35	0.33	7.15e-10	Bipolar disorder;
CRC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-7.07	-0.36	9.19e-12	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.45	0.46	6.59e-19	Corneal astigmatism;
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.37	5.78	0.3	1.75e-8	Height;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg20933634	chr6:27740509	NA	0.65	9.13	0.45	7.01e-18	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs9323205	0.765	rs12232228	chr14:51658072	A/G	cg23942311	chr14:51606299	NA	0.57	8.73	0.43	1.33e-16	Cancer;
CRC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	8.85	0.44	5.43e-17	Schizophrenia;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg15845792	chr6:28175446	NA	1.0	13.06	0.58	1.11e-31	Depression;
CRC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg01339444	chr6:118972232	C6orf204	0.53	5.92	0.31	8.19e-9	Renal cell carcinoma;
CRC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.86	-0.31	1.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.59	8.5	0.42	6.91e-16	Breast cancer;
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.63	6.48	0.34	3.26e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09021643	chr7:30635214	GARS	0.43	6.08	0.32	3.29e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04959837	chr3:145968389	PLSCR4	0.44	6.33	0.33	8.11e-10	Response to antipsychotic treatment;
CRC	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg21106136	chr3:194405973	FAM43A	-0.44	-6.51	-0.34	2.74e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg12172441	chr6:28176163	NA	0.44	6.39	0.33	5.72e-10	Cardiac Troponin-T levels;
CRC	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.34	-0.33	7.63e-10	Triglycerides;
CRC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-6.0	-0.31	5.27e-9	Gut microbiome composition (summer);
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg06713098	chr7:45960367	IGFBP3	0.41	6.54	0.34	2.35e-10	Sitting height ratio;
CRC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.64	-6.99	-0.36	1.54e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.29	0.33	1.02e-9	Height;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg15845792	chr6:28175446	NA	-1.01	-15.62	-0.65	1.58e-41	Depression;
CRC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.75	7.65	0.39	2.18e-13	Diabetic retinopathy;
CRC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.51	9.74	0.47	7.27e-20	Acylcarnitine levels;
CRC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.53	7.49	0.38	6.54e-13	Testicular germ cell tumor;
CRC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.47	-6.75	-0.35	6.54e-11	HDL cholesterol;
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2274273	0.588	rs2297816	chr14:55833038	A/G	cg10130446	chr14:55658398	DLGAP5	-0.44	-6.2	-0.32	1.73e-9	Protein biomarker;
CRC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.7	10.55	0.5	1.34e-22	Corneal astigmatism;
CRC	cis	rs863345	0.564	rs7515245	chr1:158494110	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	7e-9	Pneumococcal bacteremia;
CRC	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.82	15.8	0.66	3.09e-42	Hip circumference;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22081084	chr1:89990230	LRRC8B	0.45	6.5	0.34	2.98e-10	Response to antipsychotic treatment;
CRC	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.62	10.19	0.49	2.31e-21	Subjective well-being (multi-trait analysis);
CRC	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21659725	chr3:3221576	CRBN	-0.66	-7.5	-0.38	5.88e-13	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02360337	chr11:65627185	MUS81;CFL1	0.56	7.13	0.37	6.37e-12	Thyroid stimulating hormone;
CRC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.66	-0.39	2.11e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.73	-0.3	2.23e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.67	-7.46	-0.38	8.02e-13	Bone mineral density;
CRC	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-12.98	-0.58	2.17e-31	Blood metabolite levels;
CRC	cis	rs699	0.583	rs2493150	chr1:230868427	C/T	cg07502417	chr1:230849801	AGT	0.31	6.11	0.32	2.86e-9	Coronary artery disease;
CRC	cis	rs231513	0.954	rs11654245	chr17:41992650	T/C	cg26893861	chr17:41843967	DUSP3	0.72	6.13	0.32	2.45e-9	Cognitive function;
CRC	cis	rs7572644	0.640	rs34181670	chr2:28019856	T/C	cg27432699	chr2:27873401	GPN1	0.45	5.62	0.3	4.03e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.85	-0.63	1.59e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21058506	chr12:66524791	LLPH	0.57	8.29	0.42	2.87e-15	Response to antipsychotic treatment;
CRC	cis	rs10426930	0.621	rs72990138	chr19:5018217	T/A	cg18473234	chr19:5097819	KDM4B	0.59	6.31	0.33	9.18e-10	Monocyte percentage of white cells;
CRC	trans	rs16846053	0.792	rs62188983	chr2:162513959	G/C	cg12500891	chr11:57225987	NA	-0.67	-6.12	-0.32	2.62e-9	Blood osmolality (transformed sodium);
CRC	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.94	-12.2	-0.56	1.65e-28	Exhaled nitric oxide output;
CRC	trans	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg11887960	chr12:57824829	NA	0.55	6.1	0.32	3.02e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7923609	0.967	rs3999089	chr10:65203808	C/T	cg08743896	chr10:65200160	JMJD1C	0.43	6.14	0.32	2.41e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14029663	chr14:50582909	C14orf138	-0.46	-6.78	-0.35	5.72e-11	Myopia (pathological);
CRC	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg07617317	chr6:118971624	C6orf204	0.53	6.14	0.32	2.33e-9	Diastolic blood pressure;
CRC	cis	rs72634501	0.540	rs16826036	chr1:39757799	G/C	cg18385671	chr1:39797026	MACF1	-0.42	-5.98	-0.31	5.94e-9	HDL cholesterol;
CRC	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.55	7.78	0.39	9.51e-14	Uric acid levels;
CRC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.62	10.4	0.5	4.48e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.57	7.11	0.36	7.42e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10503871	0.657	rs13248936	chr8:30316162	C/T	cg26383811	chr8:30366931	RBPMS	-0.48	-7.72	-0.39	1.41e-13	Metabolite levels  (X-11787);
CRC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.37	-6.06	-0.32	3.63e-9	Platelet distribution width;
CRC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.67	11.06	0.52	2.13e-24	Platelet count;
CRC	cis	rs12612619	0.732	rs11679681	chr2:27298479	C/A	cg00617064	chr2:27272375	NA	-0.38	-6.46	-0.34	3.85e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg13482628	chr17:19912719	NA	0.55	8.76	0.43	1.05e-16	Schizophrenia;
CRC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.13	-0.32	2.58e-9	Diabetic kidney disease;
CRC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02850689	chr1:2391347	NA	-0.35	-5.73	-0.3	2.27e-8	Schizophrenia;
CRC	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg02491457	chr7:128862824	NA	0.53	7.73	0.39	1.36e-13	White matter hyperintensity burden;
CRC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.48	7.15	0.37	5.57e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.59	9.69	0.47	1.11e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12476592	0.602	rs1446564	chr2:63731682	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.12	0.32	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	0.97	10.42	0.5	3.8e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.55	8.29	0.42	2.97e-15	Vitiligo;
CRC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg16342193	chr10:102329863	NA	0.34	5.75	0.3	2.04e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.55	0.38	4.28e-13	Motion sickness;
CRC	trans	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg21302420	chr1:112162376	RAP1A	0.65	6.53	0.34	2.45e-10	Skin colour saturation;
CRC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08071915	chr8:12219732	FAM66A	-0.37	-6.64	-0.34	1.32e-10	Retinal vascular caliber;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19500275	chr17:80737654	TBCD	0.53	7.2	0.37	4.19e-12	Glycated hemoglobin levels;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.53	-0.34	2.48e-10	Alzheimer's disease (late onset);
CRC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.17e-8	Lung cancer;
CRC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.45e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.49	6.09	0.32	3.11e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg07217954	chr7:1067459	C7orf50	0.56	5.69	0.3	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-5.63	-0.3	3.81e-8	Major depressive disorder;
CRC	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.63	-5.88	-0.31	1.03e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9287719	0.649	rs10190774	chr2:10718746	T/A	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.42	-0.42	1.22e-15	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14806103	chr8:121457329	MTBP;MRPL13	0.4	6.12	0.32	2.67e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19212674	chr4:71571625	RUFY3	0.46	6.05	0.32	4.03e-9	Thyroid stimulating hormone;
CRC	cis	rs3857067	0.967	rs1509942	chr4:95013440	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.57	6.78	0.35	5.67e-11	Type 2 diabetes nephropathy;
CRC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.91	0.31	8.46e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg06470822	chr6:28175283	NA	0.92	11.69	0.54	1.26e-26	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg14541582	chr5:601475	NA	-0.37	-7.17	-0.37	5.13e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.37	5.83	0.31	1.33e-8	Ulcerative colitis;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg06470822	chr6:28175283	NA	0.8	12.0	0.55	9.29e-28	Parkinson's disease;
CRC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.02	10.15	0.49	3.07e-21	Diabetic retinopathy;
CRC	cis	rs7246967	0.736	rs398945	chr19:22997116	A/T	cg23217946	chr19:22817039	ZNF492	-0.4	-5.74	-0.3	2.18e-8	Bronchopulmonary dysplasia;
CRC	cis	rs1863824	0.625	rs12354988	chr10:88155204	G/A	cg07322936	chr10:88137208	NA	-0.63	-8.76	-0.44	1.03e-16	Schizophrenia;
CRC	cis	rs9914988	0.619	rs34580233	chr17:27317935	A/T	cg16670446	chr17:27188758	MIR451;MIR144	0.48	6.63	0.34	1.35e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg15468180	chr1:107600409	PRMT6	-0.42	-6.36	-0.33	6.79e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg25834613	chr7:1915315	MAD1L1	-0.45	-6.36	-0.33	6.83e-10	Neuroticism;
CRC	trans	rs2294025	0.899	rs7836457	chr8:134164920	T/C	cg19857114	chr3:176741225	TBL1XR1	-0.39	-6.13	-0.32	2.51e-9	Graves' disease;
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.07e-10	Life satisfaction;
CRC	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.49	9.13	0.45	6.88e-18	Common traits (Other);
CRC	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	8.29	0.42	2.94e-15	Iron status biomarkers;
CRC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.53	-0.34	2.44e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06762403	chr12:56325867	DGKA	0.44	6.03	0.32	4.51e-9	Anxiety disorder;
CRC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.68	9.7	0.47	9.65e-20	Body mass index;
CRC	cis	rs4727963	0.792	rs1525469	chr7:122718038	A/G	cg03640110	chr7:122635026	TAS2R16	0.35	6.29	0.33	1.04e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg16950941	chr11:66035639	RAB1B	0.62	8.65	0.43	2.31e-16	Electroencephalogram traits;
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-8.6	-0.43	3.38e-16	Bipolar disorder;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg09877947	chr5:131593287	PDLIM4	0.44	7.14	0.37	5.98e-12	Breast cancer;
CRC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.82	-0.35	4.28e-11	QT interval;
CRC	trans	rs4785204	1.000	rs4785203	chr16:50096065	C/T	cg07960154	chr17:37760198	NEUROD2	-0.64	-6.03	-0.32	4.47e-9	Esophageal cancer (squamous cell);
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs9323205	0.723	rs61987304	chr14:51741213	A/G	cg23942311	chr14:51606299	NA	-0.51	-5.74	-0.3	2.2e-8	Cancer;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg03623178	chr6:28175578	NA	0.8	11.78	0.54	5.62e-27	Cardiac Troponin-T levels;
CRC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg09491104	chr22:46646882	C22orf40	-0.45	-7.15	-0.37	5.8e-12	LDL cholesterol;Cholesterol, total;
CRC	trans	rs7324845	0.624	rs7328262	chr13:46708731	C/A	cg15277906	chr8:97170364	GDF6	0.59	6.0	0.31	5.3e-9	Non-alcoholic fatty liver disease histology (other);
CRC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.64	-10.15	-0.49	3.19e-21	Cognitive function;
CRC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg21770322	chr7:97807741	LMTK2	0.52	8.54	0.43	5.11e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4481887	0.504	rs11204610	chr1:248363324	C/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	trans	rs6956675	0.915	rs4285375	chr7:62650353	C/T	cg01314568	chr7:57830625	NA	-0.63	-8.94	-0.44	2.87e-17	Obesity-related traits;
CRC	cis	rs11191205	0.686	rs10786640	chr10:103392633	A/T	cg15320455	chr10:103880129	LDB1	0.55	6.13	0.32	2.52e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00347280	chr1:45477834	HECTD3;UROD	0.44	6.32	0.33	8.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg27068330	chr11:65405492	SIPA1	0.48	7.0	0.36	1.45e-11	Acne (severe);
CRC	cis	rs2742417	1.000	rs1609554	chr3:45735192	A/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.95e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs17021463	0.643	rs17311521	chr4:95298060	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-6.06	-0.32	3.78e-9	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11611950	chr6:24667276	ACOT13;TTRAP	0.39	6.09	0.32	3.12e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19761014	chr17:28927070	LRRC37B2	0.42	6.29	0.33	1.02e-9	Response to antipsychotic treatment;
CRC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg04880052	chr2:219191631	PNKD	-0.45	-7.04	-0.36	1.15e-11	Colorectal cancer;
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.68e-12	Life satisfaction;
CRC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.64	-0.47	1.58e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4478858	0.684	rs12135540	chr1:31764693	G/A	cg00250761	chr1:31883323	NA	-0.4	-7.65	-0.39	2.23e-13	Alcohol dependence;
CRC	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg20583945	chr8:144636462	GSDMD	0.47	5.82	0.31	1.43e-8	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.38	-5.69	-0.3	2.79e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.43	6.47	0.34	3.47e-10	Blood metabolite levels;
CRC	cis	rs12580194	0.593	rs7311751	chr12:55748847	A/G	cg19537932	chr12:55886519	OR6C68	-0.69	-8.94	-0.44	2.82e-17	Cancer;
CRC	trans	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.99	0.31	5.47e-9	Metabolite levels;
CRC	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.63	9.8	0.48	4.73e-20	Testicular germ cell tumor;
CRC	cis	rs17767392	0.958	rs12892512	chr14:71983296	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.26	-0.37	2.77e-12	Mitral valve prolapse;
CRC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.82	13.11	0.59	7.16e-32	Cognitive function;
CRC	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.5	6.3	0.33	9.65e-10	Recombination rate (females);
CRC	cis	rs2108622	0.727	rs7256877	chr19:15980683	T/C	cg13772218	chr19:15982569	NA	0.48	6.81	0.35	4.67e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-0.66	-10.93	-0.52	6.16e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg16342193	chr10:102329863	NA	-0.4	-6.48	-0.34	3.33e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs995000	0.965	rs10889333	chr1:62957030	G/A	cg19896129	chr1:63156450	NA	0.4	5.88	0.31	1.01e-8	Triglyceride levels;
CRC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.64	-9.27	-0.46	2.45e-18	Cognitive function;
CRC	cis	rs12143943	0.866	rs35666383	chr1:204492784	T/C	cg17419461	chr1:204415978	PIK3C2B	0.39	6.04	0.32	4.22e-9	Cognitive performance;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.37	-6.66	-0.34	1.15e-10	Lymphocyte counts;
CRC	trans	rs4745216	0.643	rs1050305	chr9:75775235	A/G	cg11926456	chr2:211432972	CPS1	0.56	6.09	0.32	3.14e-9	Blood protein levels;
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.26	-0.56	1.05e-28	Alzheimer's disease;
CRC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.46	-7.45	-0.38	8.25e-13	Obesity-related traits;
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg07404485	chr7:94953653	PON1	-0.47	-6.18	-0.32	1.86e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.49	-7.59	-0.39	3.23e-13	Type 2 diabetes;
CRC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.95	11.88	0.55	2.53e-27	Cerebrospinal P-tau181p levels;
CRC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.69	-0.47	1.05e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.56	8.1	0.41	1.11e-14	Iron status biomarkers;
CRC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.62	8.2	0.41	5.52e-15	Coronary artery disease;
CRC	cis	rs1519814	0.956	rs7016388	chr8:121101865	A/G	cg22335954	chr8:121166405	COL14A1	-0.51	-6.09	-0.32	3.08e-9	Breast cancer;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.46	6.34	0.33	7.42e-10	Height;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02353165	chr6:42928485	GNMT	0.84	15.09	0.64	1.82e-39	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg08992911	chr2:238395768	MLPH	0.47	5.75	0.3	2.04e-8	Prostate cancer;
CRC	cis	rs4844614	0.951	rs17049197	chr1:207874704	G/A	cg17822947	chr1:207842917	CR1L	-0.36	-5.79	-0.3	1.63e-8	LDL cholesterol;
CRC	cis	rs868943	0.511	rs12204724	chr6:116532430	C/T	cg18764771	chr6:116381957	FRK	0.23	5.63	0.3	3.89e-8	Total cholesterol levels;
CRC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg21155852	chr7:2048760	MAD1L1	-0.49	-6.69	-0.35	9.76e-11	Bipolar disorder;
CRC	cis	rs10242455	0.702	rs74552228	chr7:98977046	C/T	cg18809830	chr7:99032528	PTCD1	-1.09	-7.78	-0.39	9.4e-14	Blood metabolite levels;
CRC	cis	rs2625529	0.526	rs11634622	chr15:72562327	G/A	cg16672083	chr15:72433130	SENP8	0.45	6.88	0.35	2.95e-11	Red blood cell count;
CRC	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.02	-0.31	4.78e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	9.35	0.46	1.35e-18	Exhaled nitric oxide levels;
CRC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.47	-7.45	-0.38	8.39e-13	Coronary artery disease;
CRC	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.65	0.34	1.24e-10	Morning vs. evening chronotype;
CRC	cis	rs1868673	1.000	rs16862651	chr3:150157388	C/T	cg04908077	chr3:150187338	NA	-0.33	-5.64	-0.3	3.58e-8	Waist circumference;
CRC	cis	rs7517126	1.000	rs34673990	chr1:196838757	G/A	cg13682187	chr1:196946512	CFHR5	-0.36	-5.91	-0.31	8.52e-9	Blood protein levels;
CRC	cis	rs3018066	0.666	rs4323181	chr4:107029515	A/G	cg01869342	chr4:106983673	TBCK	0.45	5.93	0.31	7.73e-9	Cancer;
CRC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.95	-18.15	-0.71	1.64e-51	Height;
CRC	cis	rs4700695	0.925	rs12657113	chr5:65396959	A/C	cg21114390	chr5:65439923	SFRS12	-0.49	-6.35	-0.33	7.17e-10	Facial morphology (factor 19);
CRC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.96e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6840360	0.606	rs2724550	chr4:152358986	C/T	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05671585	chr4:186064123	SLC25A4	0.41	6.6	0.34	1.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.61	9.47	0.46	5.59e-19	Colorectal cancer;
CRC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.52	8.3	0.42	2.69e-15	Menopause (age at onset);
CRC	trans	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.81	0.35	4.59e-11	Ulcerative colitis;
CRC	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg13491945	chr12:107078410	RFX4	0.34	5.93	0.31	7.87e-9	Heart rate;
CRC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.63	-8.86	-0.44	5.09e-17	Vitiligo;
CRC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.54	6.04	0.32	4.22e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg16102536	chr7:156981717	UBE3C	0.4	6.78	0.35	5.54e-11	Body mass index;
CRC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.49	-9.71	-0.47	9.31e-20	Subjective well-being;
CRC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.56	8.82	0.44	7.03e-17	Tonsillectomy;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07362569	chr17:61921086	SMARCD2	-0.36	-5.64	-0.3	3.63e-8	Prudent dietary pattern;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.65	-9.36	-0.46	1.29e-18	Obesity-related traits;
CRC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.87	-16.13	-0.66	1.53e-43	Intelligence (multi-trait analysis);
CRC	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.4	-6.12	-0.32	2.64e-9	Menopause (age at onset);
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg07617317	chr6:118971624	C6orf204	0.49	6.06	0.32	3.7e-9	Diastolic blood pressure;
CRC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.68	10.44	0.5	3.19e-22	Diastolic blood pressure;
CRC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	7.73	0.39	1.31e-13	Menarche (age at onset);
CRC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg14671364	chr1:107599128	PRMT6	0.61	8.29	0.42	2.92e-15	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.11	0.41	9.94e-15	Height;
CRC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.52	-0.34	2.6200000000000003e-10	Alzheimer's disease (late onset);
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.27	-0.46	2.46e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-5.93	-0.31	7.66e-9	Alzheimer's disease (late onset);
CRC	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.71	-8.3	-0.42	2.69e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg23461800	chr14:103021989	NA	0.68	7.74	0.39	1.23e-13	Platelet count;
CRC	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg07741184	chr6:167504864	NA	-0.33	-5.68	-0.3	2.97e-8	Primary biliary cholangitis;
CRC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	trans	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.01	0.31	4.84e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.4	5.78	0.3	1.72e-8	Aortic root size;
CRC	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg08717414	chr16:71523259	ZNF19	-0.48	-5.89	-0.31	9.38e-9	Post bronchodilator FEV1;
CRC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.59e-14	Corneal astigmatism;
CRC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg05941027	chr17:61774174	LIMD2	0.34	5.96	0.31	6.36e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20789954	chr3:132441258	NCRNA00119;NPHP3	0.4	6.46	0.34	3.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7712401	0.791	rs1870559	chr5:122116706	G/C	cg18764291	chr5:122110994	SNX2	0.42	6.8	0.35	4.89e-11	Mean platelet volume;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.34	7.0	0.36	1.47e-11	Electroencephalogram traits;
CRC	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.45	-8.17	-0.41	6.65e-15	Intelligence (multi-trait analysis);
CRC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.5	8.21	0.41	5.03e-15	Lipoprotein (a) levels;
CRC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.49	-6.83	-0.35	4.12e-11	Gut microbiome composition (summer);
CRC	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg05527609	chr1:210001259	C1orf107	-0.55	-6.03	-0.32	4.39e-9	Red blood cell count;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.55	-9.85	-0.48	3.04e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg17633681	chr16:88106987	BANP	0.87	16.24	0.67	5.81e-44	Menopause (age at onset);
CRC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.39	6.91	0.36	2.54e-11	Primary biliary cholangitis;
CRC	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.69	-7.71	-0.39	1.54e-13	Bone mineral density;
CRC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.49	5.73	0.3	2.32e-8	Vitiligo;
CRC	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.59	-9.53	-0.47	3.63e-19	Schizophrenia;
CRC	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.98	18.26	0.71	6.01e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.64	10.3	0.49	9.79e-22	Height;
CRC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.6	-0.34	1.6e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.38	-0.56	3.73e-29	Type 2 diabetes;
CRC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg16342193	chr10:102329863	NA	-0.4	-6.48	-0.34	3.33e-10	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs587242	1.000	rs61786494	chr1:96905987	A/G	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.37	6.51	0.34	2.83e-10	Cardiovascular disease risk factors;
CRC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.48	-6.17	-0.32	2.01e-9	Body mass index;
CRC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.42	6.14	0.32	2.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.63	-6.97	-0.36	1.74e-11	Cerebrospinal P-tau181p levels;
CRC	trans	rs1864585	0.520	rs10503409	chr8:10669654	C/G	cg26278703	chr11:58910052	FAM111A	-0.52	-6.25	-0.33	1.28e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.58	-9.1	-0.45	8.9e-18	Survival in rectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05377417	chr17:59940892	BRIP1	-0.39	-6.18	-0.32	1.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg11833968	chr6:79620685	NA	-0.35	-6.12	-0.32	2.69e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.02	19.21	0.73	1.07e-55	Primary sclerosing cholangitis;
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.06	0.41	1.46e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg05192639	chr6:26864778	GUSBL1	0.33	6.02	0.32	4.64e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-11.99	-0.55	9.61e-28	Monocyte percentage of white cells;
CRC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.71	-0.39	1.51e-13	Height;
CRC	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.49	7.07	0.36	9.29e-12	Pulmonary function decline;
CRC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.43	5.67	0.3	3.16e-8	Menarche (age at onset);
CRC	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.42	-11.61	-0.54	2.3e-26	Psoriasis vulgaris;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10346511	chr11:30344563	C11orf46	0.38	5.97	0.31	6.11e-9	Interleukin-6 levels;
CRC	cis	rs965469	1.000	rs6051808	chr20:3350697	A/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.83	-0.31	1.35e-8	IFN-related cytopenia;
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.83	13.17	0.59	4.18e-32	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.77	7.56	0.38	4.08e-13	Diabetic retinopathy;
CRC	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12884169	chr21:40033163	ERG	-0.38	-8.35	-0.42	1.94e-15	Coronary artery disease;
CRC	cis	rs1572438	0.760	rs7740748	chr6:869509	T/C	cg13447295	chr6:887704	NA	-0.49	-7.11	-0.36	7.39e-12	Aging;
CRC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.69	-0.35	9.41e-11	Menopause (age at onset);
CRC	trans	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg14222797	chr10:16859974	RSU1	-0.63	-6.36	-0.33	6.72e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.42	5.78	0.3	1.77e-8	Response to amphetamines;
CRC	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg04053776	chr11:6947353	ZNF215	0.52	7.08	0.36	8.52e-12	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg07404485	chr7:94953653	PON1	-0.45	-5.94	-0.31	7.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7113874	0.544	rs9704807	chr11:8578771	G/C	cg02811074	chr11:8615871	STK33	-0.34	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6988985	0.728	rs10103405	chr8:143968631	T/C	cg10324643	chr8:143916377	GML	0.39	6.4	0.33	5.45e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg11579758	chr4:1086637	RNF212	0.41	6.67	0.34	1.11e-10	Recombination rate (males);
CRC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.57	-6.62	-0.34	1.45e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg09184832	chr6:79620586	NA	-0.45	-7.74	-0.39	1.27e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg02972257	chr16:68554789	NA	0.44	5.61	0.3	4.28e-8	Colorectal cancer;
CRC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg09455208	chr3:40491958	NA	0.33	6.66	0.34	1.13e-10	Renal cell carcinoma;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.61	-9.84	-0.48	3.48e-20	Obesity-related traits;
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.69	-0.39	1.7e-13	Total body bone mineral density;
CRC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	9.0	0.44	1.86e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.18	0.41	6.42e-15	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.77	0.63	3.05e-38	Exhaled nitric oxide output;
CRC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.34	7.32	0.37	1.9e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03738959	chr9:37904295	MCART1	0.42	6.03	0.32	4.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg00531865	chr16:30841666	NA	0.49	6.86	0.35	3.47e-11	Dementia with Lewy bodies;
CRC	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.15	24.79	0.81	2.88e-77	Exhaled nitric oxide output;
CRC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.49	7.77	0.39	1e-13	Height;
CRC	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.05	0.45	1.24e-17	Dupuytren's disease;
CRC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg26805224	chr10:79626177	DLG5	-0.5	-7.09	-0.36	8.28e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.46	7.21	0.37	3.89e-12	Corneal astigmatism;
CRC	trans	rs800082	0.516	rs1178893	chr3:144239246	A/C	cg24215973	chr2:240111563	HDAC4	0.45	6.29	0.33	1.01e-9	Smoking behavior;
CRC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.52	6.47	0.34	3.54e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7264396	0.887	rs1570841	chr20:34048161	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.07	-0.32	3.48e-9	Total cholesterol levels;
CRC	cis	rs9462027	0.628	rs2814959	chr6:34705947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.48	6.09	0.32	3.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg04450456	chr4:17643702	FAM184B	0.39	6.03	0.32	4.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16471585	chr12:118199103	KSR2	-0.39	-6.26	-0.33	1.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs989128	0.642	rs7214956	chr17:48627148	G/C	cg24438145	chr17:48624694	SPATA20	0.51	7.37	0.38	1.35e-12	Type 2 diabetes;
CRC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg06462663	chr19:18546047	ISYNA1	0.5	7.64	0.39	2.45e-13	Breast cancer;
CRC	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg23356831	chr14:105996513	TMEM121	-0.42	-7.23	-0.37	3.42e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.7	-11.4	-0.53	1.35e-25	Cognitive function;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06307176	chr5:131281290	NA	0.41	6.15	0.32	2.22e-9	Life satisfaction;
CRC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.61	9.23	0.45	3.45e-18	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06307176	chr5:131281290	NA	-0.39	-5.91	-0.31	8.68e-9	Life satisfaction;
CRC	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.66	-8.06	-0.41	1.44e-14	Obesity (extreme);
CRC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.66	9.83	0.48	3.67e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg23244877	chr17:73518230	TSEN54	0.44	6.97	0.36	1.74e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00731619	chr6:158981954	TMEM181	0.47	6.96	0.36	1.9e-11	Response to antipsychotic treatment;
CRC	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.89	-0.31	9.31e-9	Height;
CRC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	10.89	0.51	8.67e-24	Neutrophil percentage of white cells;
CRC	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.43	7.59	0.39	3.33e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg15654264	chr1:150340011	RPRD2	0.43	6.42	0.33	4.74e-10	Migraine;
CRC	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg05418105	chr22:50981406	NA	-0.53	-7.18	-0.37	4.78e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9463078	0.845	rs1329713	chr6:45004028	A/C	cg25276700	chr6:44698697	NA	-0.28	-6.72	-0.35	8.09e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-9.27	-0.45	2.6e-18	Platelet count;
CRC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.3	0.33	9.4e-10	Bladder cancer;
CRC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.61	-9.17	-0.45	5.16e-18	Body mass index;
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg24560729	chr4:1342394	KIAA1530	0.38	6.13	0.32	2.53e-9	Obesity-related traits;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.07	-0.32	3.49e-9	Parkinson's disease;
CRC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.58	9.8	0.48	4.47e-20	Gestational age at birth (maternal effect);
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg03844506	chr4:4109441	NA	-0.51	-7.58	-0.39	3.65e-13	Blood pressure (smoking interaction);
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.71	11.6	0.54	2.58e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.06e-10	Hepatitis;
CRC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-0.72	-8.17	-0.41	6.78e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.16	0.56	2.46e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.8	0.44	8.09e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg18232548	chr7:50535776	DDC	-0.4	-6.18	-0.32	1.92e-9	Body mass index;
CRC	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.25	0.41	3.9e-15	Mean corpuscular volume;
CRC	cis	rs3772130	0.962	rs4311252	chr3:121514161	A/G	cg20356878	chr3:121714668	ILDR1	0.5	7.83	0.4	6.85e-14	Cognitive performance;
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04062187	chr1:167424664	CD247	0.44	6.04	0.32	4.1e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.5e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.59	9.33	0.46	1.66e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.52	9.3	0.46	1.98e-18	Blood metabolite ratios;
CRC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.53	8.89	0.44	4.14e-17	Dupuytren's disease;
CRC	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	7.45	0.38	8.11e-13	Breast cancer;
CRC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	17.63	0.7	1.85e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs783540	1.000	rs698500	chr15:83237769	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.53	-0.34	2.5e-10	Schizophrenia;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.6	10.33	0.49	7.77e-22	Prudent dietary pattern;
CRC	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-6.83	-0.35	4.04e-11	Putamen volume;
CRC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg07636037	chr3:49044803	WDR6	-0.84	-6.32	-0.33	8.46e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.59	9.17	0.45	5.34e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7605827	0.897	rs7586068	chr2:15596747	T/A	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	8.31e-9	Educational attainment (years of education);
CRC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.46	0.34	3.76e-10	Morning vs. evening chronotype;
CRC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg06740227	chr12:86229804	RASSF9	-0.38	-5.78	-0.3	1.74e-8	Major depressive disorder;
CRC	cis	rs2233152	0.610	rs10405596	chr19:41314720	C/T	cg21869046	chr19:41225005	ITPKC	0.37	5.73	0.3	2.21e-8	Kawasaki disease;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02018176	chr4:1364513	KIAA1530	0.43	7.25	0.37	3.07e-12	Obesity-related traits;
CRC	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.56	0.38	4e-13	Corneal astigmatism;
CRC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg11941060	chr3:133502564	NA	0.43	7.21	0.37	3.81e-12	Iron status biomarkers;
CRC	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg12728517	chr11:6947552	ZNF215	0.55	5.81	0.31	1.48e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.48	-8.43	-0.42	1.07e-15	Dupuytren's disease;
CRC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg09597638	chr17:3907349	NA	0.44	5.61	0.3	4.26e-8	Type 2 diabetes;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12273811	chr6:28175739	NA	0.61	8.39	0.42	1.45e-15	Parkinson's disease;
CRC	cis	rs6496667	0.697	rs62020725	chr15:90980980	C/T	cg04176472	chr15:90893244	GABARAPL3	0.6	6.54	0.34	2.42e-10	Rheumatoid arthritis;
CRC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg13798912	chr7:905769	UNC84A	0.52	6.12	0.32	2.66e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg02869306	chr7:64672164	INTS4L1	-0.47	-8.14	-0.41	8.41e-15	Calcium levels;
CRC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg03395651	chr16:88107091	BANP	0.54	7.2	0.37	4.2e-12	Menopause (age at onset);
CRC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	8.14	0.41	8.34e-15	Lymphocyte counts;
CRC	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-11.11	-0.52	1.45e-24	Hepatocellular carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24669129	chr7:155089712	INSIG1	0.42	6.65	0.34	1.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.94	-14.4	-0.62	8.52e-37	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06307176	chr5:131281290	NA	0.42	6.23	0.32	1.45e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-7.99	-0.4	2.22e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.05	-0.32	3.87e-9	Adiposity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19545258	chr7:73703601	CLIP2	0.36	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6496667	0.779	rs28408607	chr15:90919000	T/C	cg04176472	chr15:90893244	GABARAPL3	0.57	7.88	0.4	4.93e-14	Rheumatoid arthritis;
CRC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	8.03	0.41	1.69e-14	Personality dimensions;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg22638593	chr5:131593259	PDLIM4	0.38	6.24	0.33	1.33e-9	Breast cancer;
CRC	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.76	-12.67	-0.57	3.03e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.9	-0.4	4.2e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.71	-0.35	8.4e-11	Menopause (age at onset);
CRC	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma (childhood onset);
CRC	trans	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg25164649	chr6:28176230	NA	0.7	8.93	0.44	3.12e-17	Parkinson's disease;
CRC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.43e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg11887960	chr12:57824829	NA	0.64	7.2	0.37	4.1e-12	Obesity-related traits;
CRC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg10645314	chr2:3704589	ALLC	0.5	6.82	0.35	4.37e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.7	10.8	0.51	1.74e-23	Corneal astigmatism;
CRC	cis	rs524281	0.861	rs10896085	chr11:65913832	A/T	cg14036092	chr11:66035641	RAB1B	-0.46	-5.65	-0.3	3.43e-8	Electroencephalogram traits;
CRC	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.67	11.13	0.52	1.24e-24	Cancer;
CRC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.28	0.49	1.15e-21	Hemoglobin concentration;
CRC	cis	rs7113874	0.569	rs10160430	chr11:8599876	G/T	cg17679104	chr11:8615758	STK33	0.36	6.01	0.31	5.06e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg27432699	chr2:27873401	GPN1	-0.62	-9.48	-0.46	5.39e-19	Total body bone mineral density;
CRC	cis	rs12024301	0.557	rs12048457	chr1:183625491	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04709655	chr2:122513098	TSN	0.46	6.68	0.35	9.97e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg02033258	chr5:131593261	PDLIM4	0.32	5.68	0.3	2.99e-8	Blood metabolite levels;
CRC	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.41	0.46	8.68e-19	Coffee consumption (cups per day);
CRC	cis	rs4692589	0.965	rs7657455	chr4:170958843	C/G	cg19918862	chr4:170955249	NA	0.39	6.22	0.32	1.5e-9	Anxiety disorder;
CRC	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg17710535	chr19:10819994	QTRT1	0.45	6.56	0.34	2.06e-10	Inflammatory skin disease;
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.83	13.48	0.6	2.7e-33	Menarche (age at onset);
CRC	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.75	-10.24	-0.49	1.5e-21	Coronary artery disease;
CRC	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg20744362	chr22:50050164	C22orf34	0.33	5.96	0.31	6.37e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-8.32	-0.42	2.39e-15	Bladder cancer;
CRC	cis	rs11212617	0.837	rs2070661	chr11:108043988	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.23	0.32	1.42e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg04415270	chr2:102091202	RFX8	0.35	6.01	0.31	4.82e-9	Chronic rhinosinusitis with nasal polyps;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg21972741	chr5:435613	AHRR	0.5	6.99	0.36	1.51e-11	Cystic fibrosis severity;
CRC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg19812747	chr11:111475976	SIK2	0.42	6.24	0.33	1.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.66	9.83	0.48	3.8e-20	Autism;
CRC	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg00086871	chr4:6988644	TBC1D14	1.02	7.68	0.39	1.81e-13	Granulocyte percentage of myeloid white cells;
CRC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs7215564	0.730	rs4889877	chr17:78662459	A/C	cg09596252	chr17:78655493	RPTOR	0.54	6.08	0.32	3.41e-9	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22929104	chr3:101396044	ZBTB11;LOC100009676	0.46	6.76	0.35	6.4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.69	-0.35	9.47e-11	Total body bone mineral density;
CRC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg14895029	chr7:2775587	GNA12	-0.41	-6.14	-0.32	2.34e-9	Height;
CRC	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.5	7.46	0.38	7.86e-13	HDL cholesterol;
CRC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.75	8.2	0.41	5.31e-15	Tuberculosis;
CRC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.49	-0.42	7.3e-16	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20592700	chr7:5230083	WIPI2	0.45	7.12	0.37	6.98e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg26727032	chr16:67993705	SLC12A4	-0.69	-11.2	-0.53	7.17e-25	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-6.18	-0.32	1.91e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.7	7.16	0.37	5.26e-12	Initial pursuit acceleration;
CRC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.56	-7.32	-0.37	1.93e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.69	0.3	2.8e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs9462846	0.887	rs7758576	chr6:42871056	G/A	cg21280719	chr6:42927975	GNMT	-0.33	-6.47	-0.34	3.65e-10	Blood protein levels;
CRC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg01483505	chr11:975446	AP2A2	0.42	6.81	0.35	4.75e-11	Alzheimer's disease (late onset);
CRC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.69	-9.33	-0.46	1.64e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06505273	chr16:24850292	NA	0.53	6.93	0.36	2.21e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg14979609	chr8:8086686	FLJ10661	-0.36	-5.78	-0.3	1.77e-8	Mood instability;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.7	10.07	0.49	5.94e-21	Alzheimer's disease;
CRC	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.93	-0.4	3.57e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg10729496	chr3:10149963	C3orf24	0.57	7.26	0.37	2.75e-12	Alzheimer's disease;
CRC	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.62e-12	Inflammatory skin disease;
CRC	cis	rs11098699	0.821	rs4833886	chr4:124206263	A/C	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg21153622	chr11:89784906	NA	-0.45	-7.23	-0.37	3.3e-12	HDL cholesterol;
CRC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg10978503	chr1:24200527	CNR2	0.62	11.34	0.53	2.2e-25	Immature fraction of reticulocytes;
CRC	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg18232548	chr7:50535776	DDC	-0.44	-5.73	-0.3	2.27e-8	Malaria;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07159286	chr12:133779169	ZNF268	-0.42	-6.88	-0.35	2.99e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01742826	chr19:47104737	CALM3	0.45	6.06	0.32	3.8e-9	Survival in pancreatic cancer;
CRC	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	8.93	0.44	3.04e-17	Ulcerative colitis;
CRC	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.19	-0.45	4.63e-18	Prevalent atrial fibrillation;
CRC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	0.8	8.79	0.44	8.58e-17	Gout;Renal underexcretion gout;
CRC	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg23167259	chr10:102495509	NA	-0.46	-6.23	-0.32	1.41e-9	Alzheimer's disease;
CRC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg16342193	chr10:102329863	NA	-0.35	-6.02	-0.31	4.7e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg25193742	chr10:104614220	C10orf32	-0.76	-6.42	-0.33	4.8e-10	Cognitive function;
CRC	cis	rs7107770	0.663	rs1078531	chr11:125073396	G/A	cg27629782	chr11:125073726	PKNOX2	0.51	7.34	0.38	1.66e-12	Photic sneeze reflex;
CRC	cis	rs995000	0.931	rs598253	chr1:62911341	T/C	cg19896129	chr1:63156450	NA	0.44	6.8	0.35	4.87e-11	Triglyceride levels;
CRC	trans	rs73162807	0.655	rs73160981	chr3:146428795	C/T	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg16342193	chr10:102329863	NA	-0.37	-6.11	-0.32	2.82e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.74	-12.52	-0.57	1.09e-29	Hemoglobin concentration;
CRC	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	20.55	0.75	6.22e-61	Exhaled nitric oxide output;
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.53	0.38	4.87e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.55	-9.61	-0.47	1.97e-19	Alzheimer's disease (late onset);
CRC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.48	-7.78	-0.39	9.72e-14	Testicular germ cell tumor;
CRC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.6	10.13	0.49	3.48e-21	Prudent dietary pattern;
CRC	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg14593290	chr7:50529359	DDC	0.63	8.52	0.43	5.96e-16	Malaria;
CRC	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.72e-12	Inflammatory skin disease;
CRC	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.67	-7.78	-0.39	9.5e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg16476235	chr8:21771668	DOK2	0.39	6.5	0.34	2.94e-10	Mean corpuscular volume;
CRC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg27534772	chr1:16042836	PLEKHM2	0.55	10.93	0.52	6.22e-24	Systolic blood pressure;
CRC	cis	rs4727963	0.792	rs1525468	chr7:122716911	A/C	cg03640110	chr7:122635026	TAS2R16	0.34	6.23	0.32	1.46e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg14844989	chr11:31128820	NA	0.35	6.19	0.32	1.79e-9	Red blood cell count;
CRC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.36	0.46	1.31e-18	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.12	0.52	1.36e-24	Prudent dietary pattern;
CRC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.35	6.32	0.33	8.58e-10	Crohn's disease;
CRC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.59	-7.59	-0.39	3.22e-13	Neuroticism;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.36	0.53	1.81e-25	Alzheimer's disease;
CRC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.54	-8.7	-0.43	1.58e-16	Neurofibrillary tangles;
CRC	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg06223162	chr1:101003688	GPR88	0.38	6.95	0.36	1.92e-11	Breast cancer;
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.81	0.61	1.49e-34	Alzheimer's disease;
CRC	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	7.33	0.37	1.79e-12	Blood protein levels;
CRC	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg04439458	chr5:138467593	SIL1	-0.35	-5.91	-0.31	8.54e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.1	-12.3	-0.56	7.15e-29	Diabetic kidney disease;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.1	-0.32	3.04e-9	Total body bone mineral density;
CRC	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.5	-7.16	-0.37	5.23e-12	Cognitive test performance;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04582424	chr1:203764710	ZC3H11A	0.46	7.25	0.37	3.03e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg09873164	chr1:152488093	CRCT1	0.38	6.24	0.33	1.35e-9	Hair morphology;
CRC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24308560	chr3:49941425	MST1R	0.45	7.06	0.36	9.95e-12	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03341697	chr11:94277138	FUT4	-0.52	-6.33	-0.33	8.09e-10	Diisocyanate-induced asthma;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg12273811	chr6:28175739	NA	0.55	7.79	0.39	8.91e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg16342193	chr10:102329863	NA	-0.34	-5.82	-0.31	1.37e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.12	0.41	9.56e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg21132104	chr15:45694354	SPATA5L1	0.39	5.64	0.3	3.73e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.82	8.04	0.41	1.63e-14	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20840177	chr12:68042558	DYRK2	0.44	6.23	0.32	1.41e-9	Anxiety disorder;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg21251018	chr6:28226885	NKAPL	0.45	6.8	0.35	4.83e-11	Parkinson's disease;
CRC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.53	7.5	0.38	5.95e-13	Menarche (age at onset);
CRC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg02659138	chr7:134003124	SLC35B4	0.37	6.21	0.32	1.62e-9	Mean platelet volume;
CRC	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.47	7.55	0.38	4.39e-13	Refractive error;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg21194723	chr11:60681294	TMEM109	0.42	5.99	0.31	5.42e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.83	12.57	0.57	7.29e-30	Multiple sclerosis;
CRC	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.43	6.13	0.32	2.55e-9	Diastolic blood pressure;
CRC	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.5	8.12	0.41	9.57e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs3764400	0.567	rs208011	chr17:46258345	A/G	cg10706073	chr17:46328419	SKAP1	0.59	6.55	0.34	2.21e-10	Body mass index;
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23422044	chr7:1970798	MAD1L1	0.56	6.96	0.36	1.85e-11	Bipolar disorder;
CRC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.74	-10.55	-0.5	1.34e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.55	-9.13	-0.45	7.21e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	18.87	0.72	2.33e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.53	-5.97	-0.31	6.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.53	-8.19	-0.41	5.93e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs2322633	0.515	rs1892474	chr6:80862349	G/A	cg08355045	chr6:80787529	NA	0.36	5.74	0.3	2.14e-8	Height;
CRC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.33e-10	Childhood ear infection;
CRC	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg08314208	chr16:67682810	RLTPR	-0.51	-6.04	-0.32	4.13e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.07e-25	Hip circumference adjusted for BMI;
CRC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.39	-5.92	-0.31	8.19e-9	Crohn's disease;
CRC	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.02	-0.32	4.61e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.64	-10.73	-0.51	3.05e-23	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9826463	0.582	rs73238130	chr3:142004004	G/A	cg20824294	chr3:142316082	PLS1	0.36	5.72	0.3	2.38e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.17	-0.41	6.79e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9903692	0.505	rs208005	chr17:46239985	A/G	cg10706073	chr17:46328419	SKAP1	0.6	6.5	0.34	3.05e-10	Pulse pressure;
CRC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.6	-6.22	-0.32	1.53e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.62	0.57	4.92e-30	Body mass index;
CRC	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.44	6.37	0.33	6.53e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.74	-11.81	-0.55	4.43e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16262614	chr3:133464971	TF	0.33	5.84	0.31	1.24e-8	Iron status biomarkers;
CRC	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg03938978	chr2:103052716	IL18RAP	0.38	6.29	0.33	9.85e-10	Asthma;
CRC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg15226275	chr6:116381976	FRK	0.27	7.27	0.37	2.69e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs12449964	0.524	rs4925092	chr17:17568931	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.37	5.62	0.3	4.05e-8	Coronary artery disease or ischemic stroke;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg17589124	chr1:6546732	PLEKHG5	-0.39	-6.0	-0.31	5.17e-9	HDL cholesterol;
CRC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.6e-12	Motion sickness;
CRC	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.69	12.73	0.57	1.87e-30	Hip circumference;
CRC	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg13385794	chr1:248469461	NA	0.34	5.87	0.31	1.07e-8	Common traits (Other);
CRC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg00101154	chr16:420108	MRPL28	-0.56	-8.03	-0.41	1.7e-14	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06544989	chr22:39130855	UNC84B	0.47	7.58	0.39	3.51e-13	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01199328	chr20:5107611	CDS2;PCNA	0.43	6.07	0.32	3.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg04415270	chr2:102091202	RFX8	0.62	8.71	0.43	1.54e-16	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11645453	chr3:52864694	ITIH4	0.47	8.38	0.42	1.59e-15	Bipolar disorder;
CRC	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg09127314	chr1:152161683	NA	0.45	5.86	0.31	1.14e-8	Atopic dermatitis;
CRC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.64	7.54	0.38	4.52e-13	Menarche (age at onset);
CRC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.54	7.34	0.38	1.65e-12	Resting heart rate;
CRC	trans	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs1158570	0.521	rs10089819	chr8:131172968	C/T	cg15707833	chr8:131455276	NA	-0.38	-5.72	-0.3	2.35e-8	Platelet count;
CRC	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg02158880	chr13:53174818	NA	0.46	6.91	0.36	2.57e-11	Lewy body disease;
CRC	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg14228332	chr4:119757509	SEC24D	0.74	5.67	0.3	3.13e-8	Cannabis dependence symptom count;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg16402443	chr7:2598526	IQCE	0.43	6.06	0.32	3.65e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26742440	chr11:73472391	RAB6A	0.49	7.17	0.37	5.12e-12	Response to antipsychotic treatment;
CRC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.74	-9.44	-0.46	6.91e-19	Bone mineral density;
CRC	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.89	-11.31	-0.53	2.94e-25	Hair shape;
CRC	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.65	8.05	0.41	1.58e-14	Obesity (extreme);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19345165	chr11:47600677	NDUFS3;KBTBD4	0.39	5.98	0.31	5.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg14074117	chr16:1909714	C16orf73	0.49	6.52	0.34	2.59e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg11632617	chr15:75315747	PPCDC	-0.57	-7.85	-0.4	5.77e-14	Blood trace element (Zn levels);
CRC	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-5.74	-0.3	2.11e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.57	8.76	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg26805224	chr10:79626177	DLG5	-0.53	-7.91	-0.4	3.92e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg07212818	chr11:638076	DRD4	-0.46	-5.85	-0.31	1.19e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	11.77	0.54	6.55e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.76	-0.35	6.22e-11	Colorectal cancer;
CRC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg01483505	chr11:975446	AP2A2	0.47	7.72	0.39	1.42e-13	Alzheimer's disease (late onset);
CRC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.89	-16.45	-0.67	8.22e-45	Height;
CRC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.58	-7.35	-0.38	1.58e-12	Migraine;
CRC	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.87	15.54	0.65	3.24e-41	Dupuytren's disease;
CRC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-7.53	-0.38	4.85e-13	Coronary artery disease;
CRC	cis	rs198813	0.611	rs198823	chr6:26122933	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.48	-6.84	-0.35	3.93e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12936587	0.569	rs8073683	chr17:17555596	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.38	-5.82	-0.31	1.37e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.61	10.39	0.5	4.83e-22	Resting heart rate;
CRC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.74	-10.5	-0.5	1.94e-22	Platelet distribution width;
CRC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.83	-11.34	-0.53	2.26e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.5	-0.34	2.91e-10	Total body bone mineral density;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06522697	chr10:121356224	TIAL1	0.4	6.01	0.31	4.86e-9	Interleukin-6 levels;
CRC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-20.67	-0.75	2.07e-61	Hemostatic factors and hematological phenotypes;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg15786705	chr6:28176104	NA	0.68	10.33	0.49	7.66e-22	Cardiac Troponin-T levels;
CRC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.96	18.55	0.71	4.63e-53	Height;
CRC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.72	9.6	0.47	2.12e-19	Coronary artery disease;
CRC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.51	-8.99	-0.44	1.97e-17	Facial morphology (factor 20);
CRC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg21153622	chr11:89784906	NA	-0.38	-6.05	-0.32	3.92e-9	Height;
CRC	cis	rs7572644	0.723	rs12473400	chr2:28024024	G/T	cg27432699	chr2:27873401	GPN1	0.45	5.66	0.3	3.27e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-12.8	-0.58	1.04e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs2310173	0.575	rs757918	chr2:102613299	C/T	cg20856504	chr2:102616538	IL1R2	0.36	5.69	0.3	2.74e-8	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.45	-6.53	-0.34	2.46e-10	Macular telangiectasia type 2;
CRC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg02158880	chr13:53174818	NA	0.55	8.7	0.43	1.66e-16	Lewy body disease;
CRC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.9	0.31	9.15e-9	Rheumatoid arthritis;
CRC	trans	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg21302420	chr1:112162376	RAP1A	0.73	5.98	0.31	5.83e-9	Skin colour saturation;
CRC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.95	-0.58	2.89e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.81	0.4	7.74e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7781557	1.000	rs11496066	chr7:102486254	T/C	cg18108683	chr7:102477205	FBXL13	-0.55	-6.97	-0.36	1.75e-11	Colorectal adenoma (advanced);
CRC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.71	-11.38	-0.53	1.57e-25	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15045943	chr5:171614719	STK10	-0.54	-6.63	-0.34	1.39e-10	Diisocyanate-induced asthma;
CRC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-12.64	-0.57	3.92e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4938330	0.600	rs2239010	chr11:117089006	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.04	-0.32	4.26e-9	Blood protein levels;
CRC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.9	-0.31	8.82e-9	Heart rate;
CRC	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.77	11.86	0.55	2.99e-27	Type 2 diabetes;
CRC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.08	-0.32	3.39e-9	Menopause (age at onset);
CRC	cis	rs2282802	0.685	rs4913079	chr5:139683029	A/G	cg26211634	chr5:139558579	C5orf32	0.44	7.75	0.39	1.18e-13	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-11.1	-0.52	1.53e-24	Hepatocellular carcinoma;
CRC	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.34	-0.59	9.15e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.46	6.03	0.32	4.29e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.42	6.72	0.35	8.02e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.49	0.42	7.34e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7558233	0.614	rs763456	chr2:23675180	A/G	cg00747342	chr2:23700632	KLHL29	0.58	6.08	0.32	3.33e-9	Cannabis use (initiation);
CRC	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	0.98	8.49	0.42	7.39e-16	Blood protein levels;
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.19	0.32	1.75e-9	Prudent dietary pattern;
CRC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.12	0.32	2.72e-9	Aortic root size;
CRC	cis	rs6565681	1.000	rs6565681	chr17:78348494	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.53	-5.98	-0.31	5.92e-9	Moyamoya disease;
CRC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.46	7.4	0.38	1.13e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.03e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.49	-6.98	-0.36	1.59e-11	Height;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.06	26.73	0.83	1.79e-84	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7705042	0.865	rs2043280	chr5:141513691	C/G	cg07392085	chr5:141489673	NDFIP1	-0.46	-7.32	-0.37	1.87e-12	Asthma;
CRC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg25036284	chr2:26402008	FAM59B	0.54	6.41	0.33	5.04e-10	Gut microbiome composition (summer);
CRC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.47	8.53	0.43	5.33e-16	Monocyte count;
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.6	10.88	0.51	9.1e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.09	-0.32	3.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg15997130	chr1:24165203	NA	0.5	6.7	0.35	9.13e-11	Immature fraction of reticulocytes;
CRC	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.3	5.67	0.3	3.1e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg25459000	chr22:39777742	SYNGR1	-0.33	-6.06	-0.32	3.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	17.35	0.69	2.41e-48	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.38	5.65	0.3	3.47e-8	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06529459	chr11:67397595	NUDT8	0.37	6.1	0.32	3.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.81	-0.4	7.84e-14	Electroencephalogram traits;
CRC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.58	5.73	0.3	2.25e-8	Fat distribution (HIV);
CRC	cis	rs7264396	0.887	rs224360	chr20:34059675	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	6.76	0.35	6.12e-11	Total cholesterol levels;
CRC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.52	7.82	0.4	7.41e-14	Corneal astigmatism;
CRC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.52	-7.26	-0.37	2.86e-12	Corneal structure;
CRC	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	5.68	0.3	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg25547332	chr5:131281432	NA	0.37	5.73	0.3	2.28e-8	Life satisfaction;
CRC	cis	rs2857891	0.817	rs1491829	chr11:6968941	T/A	cg04053776	chr11:6947353	ZNF215	0.38	5.6	0.3	4.5e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.02	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg12218747	chr21:37451666	NA	-0.41	-7.0	-0.36	1.46e-11	Mitral valve prolapse;
CRC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	12.3	0.56	7.55e-29	Electrocardiographic conduction measures;
CRC	cis	rs12618769	0.652	rs3820941	chr2:99233781	C/T	cg18455616	chr2:99124870	INPP4A	0.36	5.91	0.31	8.32e-9	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01965872	chr20:33291894	TP53INP2	0.45	5.96	0.31	6.43e-9	Anxiety disorder;
CRC	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg08729031	chr10:102416179	NA	0.43	7.58	0.39	3.6e-13	Body mass index;
CRC	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.77	-6.56	-0.34	2.03e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.7	9.49	0.46	4.97e-19	Alzheimer's disease;
CRC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.72e-9	Aortic root size;
CRC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs600626	0.636	rs10793125	chr11:75452364	C/T	cg24262691	chr11:75473276	NA	-0.47	-6.92	-0.36	2.33e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9826463	0.582	rs73238155	chr3:142073145	G/A	cg20824294	chr3:142316082	PLS1	0.35	5.7	0.3	2.72e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.5	-0.5	1.92e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.64	-0.57	4.19e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.69	0.35	9.39e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs73206853	0.841	rs73206883	chr12:110849549	A/G	cg12870014	chr12:110450643	ANKRD13A	0.77	8.56	0.43	4.24e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.43	-6.1	-0.32	3.02e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.91	17.77	0.7	5.22e-50	Intelligence (multi-trait analysis);
CRC	cis	rs16852403	0.583	rs12071903	chr1:178095804	C/T	cg00404053	chr1:178313656	RASAL2	0.6	7.55	0.38	4.22e-13	Childhood ear infection;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg25164649	chr6:28176230	NA	0.59	8.13	0.41	8.77e-15	Parkinson's disease;
CRC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.5	7.67	0.39	1.93e-13	Corneal astigmatism;
CRC	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.56	-7.02	-0.36	1.29e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.43	6.69	0.35	9.56e-11	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.56	6.75	0.35	6.57e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg11168104	chr5:1857477	NA	-0.37	-6.42	-0.33	4.8e-10	Cardiovascular disease risk factors;
CRC	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg08795948	chr3:128337044	NA	0.36	6.22	0.32	1.53e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg14008862	chr17:28927542	LRRC37B2	0.54	5.68	0.3	2.91e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	cg04338863	chr8:33670619	NA	0.39	6.18	0.32	1.88e-9	Body mass index;
CRC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg25174290	chr11:3078921	CARS	-0.41	-5.65	-0.3	3.48e-8	Calcium levels;
CRC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.47	-7.91	-0.4	3.92e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg04553112	chr3:125709451	NA	-0.51	-5.85	-0.31	1.17e-8	Blood pressure (smoking interaction);
CRC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.44	6.21	0.32	1.64e-9	Aortic root size;
CRC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.42	-8.49	-0.42	6.95e-16	Renal cell carcinoma;
CRC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.46	6.2	0.32	1.69e-9	Aortic root size;
CRC	trans	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg21153622	chr11:89784906	NA	-0.48	-7.7	-0.39	1.66e-13	HDL cholesterol;
CRC	cis	rs863345	0.604	rs11265010	chr1:158498853	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg23815491	chr16:72088622	HP	-0.43	-6.49	-0.34	3.13e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.45	-6.57	-0.34	2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs17234274	0.644	rs1482746	chr11:23225003	T/C	cg05245346	chr11:23248277	NA	0.35	5.72	0.3	2.38e-8	Cancer;
CRC	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.74	7.95	0.4	3.03e-14	Breast cancer;
CRC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.03	12.92	0.58	3.76e-31	Vitiligo;
CRC	cis	rs12541635	0.934	rs10955407	chr8:107020648	G/A	cg10147462	chr8:107024639	NA	0.42	6.99	0.36	1.57e-11	Age of smoking initiation;
CRC	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.96	-15.45	-0.65	7.15e-41	Gout;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.49	8.91	0.44	3.52e-17	Acylcarnitine levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09525523	chr12:16064153	DERA	0.44	6.05	0.32	4.04e-9	Anxiety disorder;
CRC	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	0.79	6.47	0.34	3.55e-10	Economic and political preferences (immigration/crime);
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg15147215	chr3:52552868	STAB1	-0.65	-11.12	-0.52	1.31e-24	Bipolar disorder;
CRC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.24	0.33	1.38e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.5	-5.66	-0.3	3.31e-8	Vitiligo;
CRC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg20243544	chr17:37824526	PNMT	-0.44	-5.61	-0.3	4.2e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg00255919	chr5:131827918	IRF1	-0.34	-5.81	-0.3	1.51e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg16476235	chr8:21771668	DOK2	0.41	7.05	0.36	1.07e-11	Mean corpuscular volume;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg01874867	chr7:94954059	PON1	-0.49	-6.36	-0.33	6.6e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg21153622	chr11:89784906	NA	-0.44	-7.15	-0.37	5.73e-12	Coronary artery disease;
CRC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.05	-0.32	3.93e-9	Gout;Renal underexcretion gout;
CRC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-5.94	-0.31	7.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2530545	0.651	rs10261506	chr7:34662042	T/C	cg14401837	chr7:34697493	NPSR1	0.42	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09525994	chr12:48512905	PFKM	0.43	6.67	0.35	1.06e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.67	10.34	0.5	6.87e-22	Breast cancer;
CRC	cis	rs653465	0.621	rs11719250	chr3:27174261	G/T	cg02860705	chr3:27208620	NA	-0.38	-5.91	-0.31	8.66e-9	Breast cancer (early onset);
CRC	cis	rs12529935	0.609	rs12526057	chr6:90895994	C/G	cg06866423	chr6:90926672	BACH2	0.71	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
CRC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg14664628	chr15:75095509	CSK	0.47	6.97	0.36	1.77e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg14459158	chr9:96720562	NA	0.45	8.28	0.42	3.08e-15	Esophageal adenocarcinoma;
CRC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.9	-17.43	-0.69	1.19e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.71	-0.35	8.63e-11	Coronary artery disease;
CRC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg21095983	chr6:86352623	SYNCRIP	0.56	8.07	0.41	1.35e-14	Smooth-surface caries;
CRC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.5	-7.79	-0.39	8.56e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.63	9.8	0.48	4.66e-20	Schizophrenia;
CRC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg24324837	chr19:49891574	CCDC155	0.53	7.0	0.36	1.45e-11	Multiple sclerosis;
CRC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.58	-9.72	-0.47	8.63e-20	Total body bone mineral density;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02807482	chr3:125708958	NA	-0.45	-5.82	-0.31	1.37e-8	Blood pressure (smoking interaction);
CRC	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.43	-7.32	-0.37	1.94e-12	Mitral valve prolapse;
CRC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg12463550	chr7:65579703	CRCP	0.65	5.98	0.31	5.9e-9	Diabetic kidney disease;
CRC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.09	13.47	0.6	3.05e-33	Vitiligo;
CRC	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.62	-10.12	-0.49	3.93e-21	Neuroticism;
CRC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.16e-13	Corneal astigmatism;
CRC	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg00255919	chr5:131827918	IRF1	0.34	5.67	0.3	3.19e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs11615274	0.527	rs10879550	chr12:73502964	C/T	cg06707406	chr2:50570407	NRXN1	0.41	5.96	0.31	6.47e-9	Body mass index and cholesterol (psychopharmacological treatment);
CRC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	0.92	17.33	0.69	2.9e-48	Height;
CRC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.4	0.42	1.33e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg14329157	chr2:228736135	WDR69	-0.47	-6.53	-0.34	2.48e-10	Blood pressure;
CRC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.04	-0.48	7.33e-21	Chronic sinus infection;
CRC	cis	rs10924970	0.967	rs6688441	chr1:235489184	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.4	-6.1	-0.32	2.97e-9	Asthma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11407514	chr10:99094219	FRAT2	-0.53	-6.41	-0.33	4.93e-10	Diisocyanate-induced asthma;
CRC	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.37	-5.72	-0.3	2.33e-8	Height;
CRC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg15352829	chr14:105391018	PLD4	0.5	10.68	0.51	4.86e-23	Rheumatoid arthritis;
CRC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-10.84	-0.51	1.29e-23	Vitiligo;
CRC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg10512202	chr3:45649293	LIMD1	0.4	5.82	0.31	1.4e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs7604735	0.635	rs1830319	chr2:145821597	C/T	cg26010734	chr19:15344046	EPHX3	-0.34	-6.29	-0.33	1.02e-9	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg07617317	chr6:118971624	C6orf204	0.46	5.64	0.3	3.6e-8	Diastolic blood pressure;
CRC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-7.16	-0.37	5.3e-12	Adiposity;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	1.02	18.51	0.71	6.31e-53	Menarche (age at onset);
CRC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg10760299	chr15:45669010	GATM	-0.51	-8.14	-0.41	8.3e-15	Homoarginine levels;
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.42e-10	Electroencephalogram traits;
CRC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.07	-0.32	3.44e-9	Coronary artery disease;
CRC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.03	-0.32	4.47e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05889321	chr10:97416837	ALDH18A1	-0.51	-6.46	-0.34	3.84e-10	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.8	0.44	7.8e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.5	6.36	0.33	6.9e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.78	7.6	0.39	3.03e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.49	-9.83	-0.48	3.7799999999999997e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.84	0.51	1.31e-23	Prudent dietary pattern;
CRC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg06634786	chr22:41940651	POLR3H	-0.51	-6.33	-0.33	7.99e-10	Neuroticism;
CRC	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	0.58	8.92	0.44	3.2e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg27534772	chr1:16042836	PLEKHM2	0.43	7.24	0.37	3.13e-12	Systolic blood pressure;
CRC	cis	rs7429990	0.930	rs71323371	chr3:47945817	A/T	cg11946769	chr3:48343235	NME6	0.45	5.77	0.3	1.81e-8	Educational attainment (years of education);
CRC	cis	rs3823572	0.542	rs2953636	chr7:133637904	A/G	cg03336402	chr7:133662267	EXOC4	0.65	10.11	0.49	4.07e-21	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg01444801	chr10:135216882	MTG1	-0.55	-7.82	-0.4	7.4e-14	Systemic lupus erythematosus;
CRC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.63	8.39	0.42	1.42e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.25	0.41	3.86e-15	Height;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.33	0.33	8.26e-10	Bipolar disorder;
CRC	cis	rs9467603	0.925	rs6910549	chr6:25780811	A/G	cg08501292	chr6:25962987	TRIM38	-0.62	-5.76	-0.3	1.93e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs77861329	1.000	rs17051977	chr3:52182944	A/G	cg08692210	chr3:52188851	WDR51A	0.79	7.63	0.39	2.52e-13	Macrophage inflammatory protein 1b levels;
CRC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.47	-8.05	-0.41	1.56e-14	Height;
CRC	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.61	8.71	0.43	1.46e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg05192639	chr6:26864778	GUSBL1	-0.34	-6.08	-0.32	3.29e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.45	-6.55	-0.34	2.25e-10	Body mass index;
CRC	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg12560992	chr17:57184187	TRIM37	0.54	7.35	0.38	1.58e-12	Testicular germ cell tumor;
CRC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg11279151	chr3:101281821	RG9MTD1	0.51	6.93	0.36	2.24e-11	Colorectal cancer;
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg13880726	chr7:1868755	MAD1L1	-0.5	-5.81	-0.31	1.44e-8	Bipolar disorder;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.59e-14	Bipolar disorder;
CRC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg16141378	chr3:129829833	LOC729375	0.42	6.54	0.34	2.38e-10	Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18163118	chr11:67250585	AIP	-0.4	-6.02	-0.31	4.77e-9	Myopia (pathological);
CRC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.3	0.49	9.15e-22	Alzheimer's disease (late onset);
CRC	cis	rs6496667	1.000	rs58436485	chr15:90900633	G/A	cg04176472	chr15:90893244	GABARAPL3	0.61	8.26	0.41	3.64e-15	Rheumatoid arthritis;
CRC	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg14711859	chr11:8959438	ASCL3	-0.37	-5.72	-0.3	2.35e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.51	8.07	0.41	1.29e-14	Methadone dose in opioid dependence;
CRC	cis	rs6969780	1.000	rs6948297	chr7:27149404	A/G	cg26364809	chr7:27145159	NA	-0.78	-7.53	-0.38	4.81e-13	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	trans	rs2303319	0.504	rs62189003	chr2:162548104	T/A	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.55	-8.2	-0.41	5.53e-15	Mean platelet volume;
CRC	cis	rs6445967	1.000	rs12688	chr3:58305079	T/C	cg23715586	chr3:58305044	RPP14	0.34	5.75	0.3	2.03e-8	Platelet count;
CRC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.24	0.41	4.27e-15	Platelet count;
CRC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-9.06	-0.45	1.21e-17	Schizophrenia;
CRC	cis	rs4880487	0.505	rs4880778	chr10:1205810	C/G	cg10055817	chr10:1229050	ADARB2	0.4	6.66	0.34	1.14e-10	Migraine;
CRC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.82	-0.31	1.37e-8	Arsenic metabolism;
CRC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.51	0.42	6.27e-16	Platelet count;
CRC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.94	14.66	0.63	8.11e-38	Monocyte percentage of white cells;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	8.15	0.41	7.94e-15	Menarche (age at onset);
CRC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.84e-12	Prostate cancer;
CRC	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	1.01	16.24	0.67	5.94e-44	Testicular germ cell tumor;
CRC	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.59	-0.47	2.35e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6743226	0.870	rs12624197	chr2:242254737	G/C	cg10021735	chr2:242295487	FARP2	0.47	6.9	0.36	2.66e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.8	8.86	0.44	5.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg10589385	chr1:150898437	SETDB1	0.29	6.2	0.32	1.7e-9	Tonsillectomy;
CRC	trans	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg02674126	chr19:40336878	FBL	0.41	6.61	0.34	1.56e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.73	10.82	0.51	1.5e-23	Breast cancer;
CRC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg23018236	chr17:30244563	NA	-0.67	-8.02	-0.4	1.83e-14	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs2708240	0.666	rs2710117	chr7:147601772	T/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.44	-6.42	-0.33	4.87e-10	QT interval (drug interaction);
CRC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.86	-0.48	3e-20	P wave terminal force;
CRC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.83	-11.41	-0.53	1.28e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.76	17.11	0.69	2.17e-47	Breast cancer;
CRC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.51	8.37	0.42	1.62e-15	Colorectal cancer;
CRC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg04155289	chr7:94953770	PON1	-0.59	-7.29	-0.37	2.26e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg15269541	chr15:43626905	ADAL	-0.39	-6.0	-0.31	5.1e-9	Lung cancer;
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.72	9.31	0.46	1.83e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.53	-11.96	-0.55	1.24e-27	Cutaneous nevi;
CRC	cis	rs7113874	0.569	rs1446463	chr11:8566329	G/A	cg02811074	chr11:8615871	STK33	-0.36	-6.14	-0.32	2.44e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.67	-0.3	3.13e-8	Erythrocyte sedimentation rate;
CRC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg23018236	chr17:30244563	NA	-0.67	-7.98	-0.4	2.51e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.42	-9.22	-0.45	3.61e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg03623178	chr6:28175578	NA	0.94	12.29	0.56	7.67e-29	Depression;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05445914	chr16:30134068	MAPK3	0.38	6.38	0.33	5.91e-10	Obesity-related traits;
CRC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.2	-0.32	1.65e-9	Schizophrenia;
CRC	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-7.26	-0.37	2.89e-12	Morning vs. evening chronotype;
CRC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.92	17.34	0.69	2.55e-48	Obesity-related traits;
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg21856205	chr7:94953877	PON1	-0.48	-6.23	-0.32	1.46e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2033908	0.620	rs1992334	chr11:12851645	C/T	cg25843174	chr11:12811716	TEAD1	-0.4	-7.12	-0.37	7.03e-12	Sitting height ratio;
CRC	trans	rs9341835	0.618	rs1779747	chr6:64141100	C/T	cg13657004	chr13:50234944	EBPL	0.38	6.63	0.34	1.39e-10	Schizophrenia;
CRC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17554472	chr22:41940697	POLR3H	-0.55	-5.82	-0.31	1.4e-8	Vitiligo;
CRC	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg18753928	chr3:113234510	CCDC52	-0.48	-7.67	-0.39	2.01e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.48	-6.38	-0.33	5.87e-10	Height;
CRC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.48	7.47	0.38	7.42e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.69	9.71	0.47	9.43e-20	Bladder cancer;
CRC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.74	-12.26	-0.56	1.02e-28	Height;
CRC	cis	rs883565	0.568	rs6599004	chr3:39095678	C/T	cg01426195	chr3:39028469	NA	-0.54	-8.77	-0.44	9.85e-17	Handedness;
CRC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg10589385	chr1:150898437	SETDB1	0.28	6.07	0.32	3.43e-9	Melanoma;
CRC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	8.05	0.41	1.52e-14	Axial length;
CRC	cis	rs62458065	1.000	rs1450868	chr7:32463666	G/A	cg20159608	chr7:32802032	NA	-0.49	-6.07	-0.32	3.53e-9	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.0	-0.31	5.15e-9	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.47	-0.57	1.78e-29	Idiopathic membranous nephropathy;
CRC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.08	-0.55	4.67e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs797680	0.856	rs6541404	chr1:93743434	A/T	cg09807536	chr1:203457686	PRELP	0.43	6.48	0.34	3.36e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CRC	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg07862535	chr7:139043722	LUC7L2	0.54	7.03	0.36	1.18e-11	Diisocyanate-induced asthma;
CRC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.63	-9.69	-0.47	1.11e-19	Cognitive function;
CRC	trans	rs4140564	0.730	rs7554410	chr1:186767992	T/G	cg01619416	chr16:1110991	NA	-0.44	-6.02	-0.31	4.59e-9	Knee osteoarthritis;
CRC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg17633681	chr16:88106987	BANP	0.88	16.15	0.66	1.35e-43	Menopause (age at onset);
CRC	cis	rs7212590	0.748	rs8073489	chr17:57861794	A/C	cg10252138	chr17:58120427	NA	-0.55	-5.87	-0.31	1.09e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg09491104	chr22:46646882	C22orf40	-0.46	-7.0	-0.36	1.41e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.49	7.75	0.39	1.12e-13	Schizophrenia;
CRC	cis	rs6504340	0.600	rs2325946	chr17:46584631	G/C	cg04904318	chr17:46607828	HOXB1	0.45	5.95	0.31	6.86e-9	Primary tooth development (number of teeth);
CRC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg12792011	chr19:58661915	ZNF329	0.72	7.86	0.4	5.5e-14	Cholesterol, total;
CRC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.93	-0.31	7.72e-9	Alzheimer's disease (late onset);
CRC	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg18323236	chr1:24743029	NIPAL3	0.39	5.72	0.3	2.37e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	cg04338863	chr8:33670619	NA	0.41	6.92	0.36	2.37e-11	Body mass index;
CRC	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.48	7.38	0.38	1.32e-12	Testicular germ cell tumor;
CRC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg21153622	chr11:89784906	NA	0.39	6.15	0.32	2.2e-9	Coronary artery disease;
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.62	0.54	2.28e-26	Alzheimer's disease;
CRC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg18230493	chr5:56204884	C5orf35	0.55	8.26	0.41	3.66e-15	Initial pursuit acceleration;
CRC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-5.78	-0.3	1.77e-8	Schizophrenia;
CRC	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg01639898	chr1:32083012	HCRTR1	0.32	6.67	0.35	1.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.47	7.21	0.37	3.8e-12	Red blood cell count;
CRC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg04880052	chr2:219191631	PNKD	0.42	6.76	0.35	6.16e-11	Colorectal cancer;
CRC	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.5	7.05	0.36	1.06e-11	Glioblastoma;Glioma;
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg18833306	chr6:118973337	C6orf204	0.44	5.71	0.3	2.54e-8	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10922530	chr12:124457083	CCDC92;ZNF664	0.4	7.51	0.38	5.44e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.63	-10.64	-0.51	6.55e-23	Depressive symptoms (multi-trait analysis);
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.16	0.52	9.37e-25	Prudent dietary pattern;
CRC	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.64	0.3	3.65e-8	Heart rate;
CRC	cis	rs365302	1.000	rs294923	chr6:159620925	G/A	cg14500486	chr6:159655392	FNDC1	0.51	7.53	0.38	4.94e-13	Coronary heart disease;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02290350	chr8:58132656	NA	-0.51	-6.39	-0.33	5.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4658101	0.700	rs12048543	chr1:92050356	C/T	cg24006770	chr1:92056542	NA	0.46	6.91	0.36	2.56e-11	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.39	7.04	0.36	1.12e-11	Mean corpuscular volume;
CRC	cis	rs713587	0.520	rs493090	chr2:25303772	G/A	cg22495460	chr2:25135724	ADCY3	0.44	6.61	0.34	1.54e-10	Body mass index in non-asthmatics;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10556830	chr5:68462986	CCNB1	0.45	6.44	0.33	4.35e-10	Response to antipsychotic treatment;
CRC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg07274523	chr3:49395745	GPX1	0.47	5.98	0.31	5.79e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg02033258	chr5:131593261	PDLIM4	-0.31	-5.75	-0.3	2.08e-8	Blood metabolite levels;
CRC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-8.66	-0.43	2.12e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.78	-8.76	-0.44	1.02e-16	Neuroticism;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg15145296	chr3:125709740	NA	-0.57	-6.5	-0.34	2.98e-10	Blood pressure (smoking interaction);
CRC	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.54	7.76	0.39	1.09e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.13	0.52	1.23e-24	Prudent dietary pattern;
CRC	cis	rs7178572	0.633	rs7162637	chr15:77843365	A/G	cg22256960	chr15:77711686	NA	-0.63	-8.87	-0.44	4.77e-17	Type 2 diabetes;
CRC	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg24304309	chr1:154577895	ADAR	0.34	5.69	0.3	2.87e-8	Blood protein levels;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg20041105	chr8:143859282	LYNX1	-0.41	-6.78	-0.35	5.61e-11	Urinary tract infection frequency;
CRC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.98	-0.52	4.16e-24	Hepatocellular carcinoma;
CRC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg18612461	chr15:75251733	NA	0.48	7.26	0.37	2.88e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.11	0.69	2.18e-47	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.83	-0.35	4.14e-11	HDL cholesterol;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09741240	chr6:3000097	NQO2	0.46	5.96	0.31	6.51e-9	Hip circumference;
CRC	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.27	-0.37	2.69e-12	Cholesterol, total;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.48	6.62	0.34	1.45e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.41	6.26	0.33	1.23e-9	Red blood cell count;
CRC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.89	-0.35	2.9e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg06970220	chr1:156163860	SLC25A44	-0.49	-7.09	-0.36	8.05e-12	Testicular germ cell tumor;
CRC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.49	-7.03	-0.36	1.19e-11	Height;
CRC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.65	-9.2	-0.45	4.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.63	11.29	0.53	3.27e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-11.75	-0.54	7.36e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.49	6.01	0.31	5.05e-9	Lymphocyte counts;
CRC	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg09127314	chr1:152161683	NA	0.49	6.02	0.31	4.77e-9	Atopic dermatitis;
CRC	cis	rs6747952	0.899	rs2121404	chr2:239083826	A/G	cg17459225	chr2:239074497	NA	0.45	7.7	0.39	1.63e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.41	6.31	0.33	8.77e-10	Recombination rate (males);
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18758796	chr5:131593413	PDLIM4	0.46	8.51	0.42	6.45e-16	Breast cancer;
CRC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	16.12	0.66	1.63e-43	Lymphocyte percentage of white cells;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08989290	chr16:615782	NHLRC4	0.48	9.48	0.46	5.37e-19	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08413153	chr17:46185283	SNX11	0.44	6.1	0.32	3e-9	Response to antipsychotic treatment;
CRC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	8.87	0.44	4.89e-17	Height;
CRC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg07274523	chr3:49395745	GPX1	0.45	6.05	0.32	4.03e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.36	5.76	0.3	1.89e-8	Huntington's disease progression;
CRC	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs540254	0.647	rs474918	chr1:160771197	C/T	cg20255094	chr1:160771763	LY9	-0.5	-6.52	-0.34	2.64e-10	Blood protein levels;
CRC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.39	0.33	5.7e-10	Triglycerides;
CRC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.55	-7.63	-0.39	2.5e-13	Systemic lupus erythematosus;
CRC	cis	rs4380275	1.000	rs6548253	chr2:773655	A/G	cg27237671	chr2:676223	TMEM18	-0.43	-6.11	-0.32	2.76e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.01	16.04	0.66	3.63e-43	Cognitive function;
CRC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.24	-14.68	-0.63	7.09e-38	Diabetic kidney disease;
CRC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg10398005	chr11:117014888	PAFAH1B2	-0.39	-5.84	-0.31	1.27e-8	Blood protein levels;
CRC	cis	rs11212617	0.967	rs227040	chr11:108223391	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.43	0.33	4.52e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.93	15.04	0.64	2.76e-39	Migraine;
CRC	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.53	8.86	0.44	4.94e-17	Menarche (age at onset);
CRC	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.71	9.55	0.47	3.2e-19	Coronary artery disease;
CRC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.85	15.94	0.66	8.64e-43	Dental caries;
CRC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg19812747	chr11:111475976	SIK2	-0.58	-9.93	-0.48	1.68e-20	Primary sclerosing cholangitis;
CRC	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	1.01	8.32	0.42	2.41e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.79	0.35	5.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.87	0.31	1.08e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.81	-0.31	1.48e-8	Height;
CRC	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.49	-6.78	-0.35	5.63e-11	Superior crus of antihelix expression;
CRC	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.67	6.96	0.36	1.82e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-7.49	-0.38	6.52e-13	Colorectal cancer;
CRC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg19812747	chr11:111475976	SIK2	0.43	6.3	0.33	9.57e-10	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.69	10.53	0.5	1.56e-22	Corneal astigmatism;
CRC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.54	11.96	0.55	1.3e-27	Alcohol dependence;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	8.59	0.43	3.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4731207	0.596	rs1600741	chr7:124692292	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.16	0.37	5.26e-12	Myopia (pathological);
CRC	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.67	-7.83	-0.4	6.92e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs7703744	0.634	rs6884061	chr5:118683431	C/T	cg23985447	chr5:118691066	TNFAIP8	0.45	6.6	0.34	1.64e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.71	-11.5	-0.54	6.13e-26	Neurofibrillary tangles;
CRC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17467752	chr17:38218738	THRA	0.4	5.81	0.31	1.45e-8	Asthma;
CRC	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.53	9.08	0.45	1e-17	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg06470822	chr6:28175283	NA	0.98	13.17	0.59	4.07e-32	Depression;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04260516	chr14:24630327	IRF9	-0.49	-6.1	-0.32	3.04e-9	Diisocyanate-induced asthma;
CRC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-8.76	-0.43	1.03e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7680126	0.596	rs4698031	chr4:10315921	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.99	-0.31	5.53e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.32	5.7	0.3	2.7e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.78	0.35	5.48e-11	Subjective well-being;
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01947930	chr5:141016379	RELL2;HDAC3	0.39	6.26	0.33	1.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	7.05	0.36	1.09e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg04455712	chr21:45112962	RRP1B	-0.34	-5.87	-0.31	1.07e-8	Mean corpuscular hemoglobin;
CRC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.48	7.1	0.36	7.89e-12	Obesity-related traits;
CRC	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg19025524	chr12:109796872	NA	-0.47	-5.93	-0.31	7.57e-9	Neuroticism;
CRC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-5.84	-0.31	1.22e-8	Height;
CRC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.56	-8.85	-0.44	5.59e-17	Colorectal cancer;
CRC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-8.59	-0.43	3.56e-16	Gut microbiome composition (summer);
CRC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg12590608	chr7:158785262	NA	0.35	6.3	0.33	9.45e-10	Facial morphology (factor 20);
CRC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.79	10.38	0.5	5.05e-22	Cerebrospinal P-tau181p levels;
CRC	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.52	-0.43	5.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.37	5.78	0.3	1.75e-8	Height;
CRC	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg00318322	chr16:67708822	GFOD2	0.32	5.91	0.31	8.34e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.89	-15.97	-0.66	6.36e-43	IgG glycosylation;
CRC	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.73	16.26	0.67	4.86e-44	Intelligence (multi-trait analysis);
CRC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.51	-7.86	-0.4	5.48e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.67	-0.35	1.08e-10	IgG glycosylation;
CRC	trans	rs7142002	0.892	rs8005273	chr14:102364006	G/C	cg24202123	chr3:36422093	STAC	-0.48	-6.36	-0.33	6.64e-10	Autism;
CRC	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.55	8.47	0.42	8.17e-16	Diastolic blood pressure;
CRC	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg23920097	chr1:209922102	NA	-0.49	-6.17	-0.32	1.98e-9	Red blood cell count;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.05	-0.32	3.94e-9	Bipolar disorder;
CRC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg26597838	chr10:835615	NA	-0.49	-7.42	-0.38	1.04e-12	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-0.81	-6.31	-0.33	8.98e-10	Depression;
CRC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.42	6.87	0.35	3.3e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-6.29	-0.33	1.02e-9	Plateletcrit;
CRC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.41	6.43	0.33	4.46e-10	Monocyte count;
CRC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.41	-6.06	-0.32	3.69e-9	Aortic root size;
CRC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg12223502	chr10:5658492	NA	-0.37	-5.89	-0.31	9.57e-9	Breast cancer;
CRC	cis	rs4594175	0.926	rs11624975	chr14:51628347	T/C	cg23942311	chr14:51606299	NA	0.61	9.7	0.47	9.55e-20	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13294780	chr4:140005756	ELF2	0.38	6.36	0.33	6.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg01879757	chr17:41196368	BRCA1	-0.39	-5.82	-0.31	1.36e-8	Menopause (age at onset);
CRC	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.37	-5.9	-0.31	8.89e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.09	0.41	1.14e-14	Resting heart rate;
CRC	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.57	-9.14	-0.45	6.4e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg01420254	chr6:26195488	NA	0.69	7.54	0.38	4.73e-13	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.19	-0.32	1.76e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg21174375	chr14:64681225	SYNE2	0.4	6.48	0.34	3.43e-10	Atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04640194	chr12:56754023	STAT2	0.57	8.3	0.42	2.82e-15	Response to antipsychotic treatment;
CRC	trans	rs11581859	0.950	rs72728532	chr1:99297822	C/A	cg12183875	chr3:169587454	LRRC31	0.27	6.27	0.33	1.13e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.43	-20.28	-0.75	6.91e-60	Hip circumference adjusted for BMI;
CRC	cis	rs2882667	0.690	rs7709789	chr5:138274451	C/T	cg09476006	chr5:138032270	NA	0.58	9.89	0.48	2.25e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.56	8.05	0.41	1.57e-14	Mean corpuscular hemoglobin;
CRC	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.62	8.51	0.42	6.44e-16	Coronary artery disease;
CRC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg10978503	chr1:24200527	CNR2	-0.44	-6.84	-0.35	3.85e-11	Immature fraction of reticulocytes;
CRC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04880052	chr2:219191631	PNKD	-0.42	-6.64	-0.34	1.3100000000000001e-10	Colorectal cancer;
CRC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg15110403	chr19:17392923	ANKLE1	0.36	5.94	0.31	7.18e-9	Systemic lupus erythematosus;
CRC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.54	-8.37	-0.42	1.73e-15	Aortic root size;
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-6.0	-0.31	5.13e-9	Life satisfaction;
CRC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.71	-0.35	8.54e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.52	7.39	0.38	1.23e-12	Birth weight;
CRC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.41	5.76	0.3	1.96e-8	Aortic root size;
CRC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	9.16	0.45	5.52e-18	Migraine;Coronary artery disease;
CRC	cis	rs1223397	0.651	rs2496144	chr6:13311941	A/G	cg20827128	chr6:13274284	PHACTR1	0.37	5.66	0.3	3.32e-8	Blood pressure;
CRC	cis	rs4908760	0.965	rs1884352	chr1:8537289	G/A	cg20416874	chr1:8611966	RERE	-0.46	-6.7	-0.35	8.82e-11	Vitiligo;
CRC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.56	0.34	2.1e-10	Cognitive test performance;
CRC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg12573674	chr2:1569213	NA	-0.76	-7.84	-0.4	6.48e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg25019722	chr6:37503610	NA	-0.38	-6.77	-0.35	6.05e-11	Cognitive performance;
CRC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10208940	0.841	rs7581931	chr2:68791641	A/G	cg12452813	chr2:68675892	NA	0.47	5.95	0.31	6.88e-9	Urate levels in lean individuals;
CRC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.52	7.42	0.38	1.01e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.51	-7.52	-0.38	5.22e-13	Asthma;
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg20119798	chr7:94954144	PON1	-0.49	-6.2	-0.32	1.72e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.51	8.0	0.4	2.21e-14	Coronary artery disease;
CRC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.3	-0.33	9.52e-10	Mean corpuscular volume;
CRC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.51	7.22	0.37	3.57e-12	Alzheimer's disease (late onset);
CRC	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.5	9.51	0.46	4.2e-19	Hip circumference;Waist circumference;
CRC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.37	-6.01	-0.31	4.79e-9	Diastolic blood pressure;
CRC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg26528668	chr16:1614120	IFT140	-0.36	-5.64	-0.3	3.58e-8	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg03929089	chr4:120376271	NA	-0.62	-6.14	-0.32	2.33e-9	Axial length;
CRC	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.75	-10.2	-0.49	2.05e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02290350	chr8:58132656	NA	-0.59	-8.01	-0.4	1.96e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg20169779	chr10:135381914	SYCE1	-0.77	-10.64	-0.51	6.34e-23	Gout;
CRC	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg23514324	chr3:12329213	PPARG	0.57	7.23	0.37	3.34e-12	LDL cholesterol;
CRC	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.65	9.27	0.46	2.53e-18	Schizophrenia;
CRC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	9.08e-17	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26179948	chr7:28220645	JAZF1	0.42	6.23	0.32	1.41e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.55	7.6	0.39	3.16e-13	Resting heart rate;
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.24	0.41	4.11e-15	Life satisfaction;
CRC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg13206674	chr6:150067644	NUP43	0.48	6.95	0.36	1.93e-11	Testicular germ cell tumor;
CRC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	3.95e-13	Motion sickness;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.87	-19.83	-0.74	4.13e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	1.14	10.04	0.48	7.37e-21	Mitochondrial DNA levels;
CRC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.36	0.56	4.51e-29	Menopause (age at onset);
CRC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.6	-9.22	-0.45	3.56e-18	Body mass index;
CRC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	ch.11.42038R	chr11:967971	AP2A2	0.57	9.75	0.47	6.98e-20	Alzheimer's disease (late onset);
CRC	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs526821	0.553	rs519637	chr11:55295935	A/T	cg04317927	chr11:55418816	OR4S2	0.41	6.87	0.35	3.14e-11	Pediatric bone mineral density (spine);
CRC	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.07	0.45	1.11e-17	Fuchs's corneal dystrophy;
CRC	trans	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	10.57	0.5	1.15e-22	Coronary artery disease;
CRC	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11547950	chr5:77652471	NA	-0.5	-7.43	-0.38	9.69e-13	Triglycerides;
CRC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.36	-0.46	1.29e-18	Subjective well-being;
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.73	9.93	0.48	1.7e-20	Cognitive function;
CRC	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.62	9.52	0.46	3.85e-19	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.47	7.78	0.39	9.77e-14	Major depressive disorder;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg22103414	chr8:6638082	NA	0.31	6.0	0.31	5.21e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.59	9.22	0.45	3.55e-18	Body mass index;
CRC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	17.16	0.69	1.33e-47	Smoking behavior;
CRC	cis	rs2084637	1.000	rs9633953	chr11:122419642	C/T	cg21585512	chr11:122030076	LOC399959	-0.37	-6.62	-0.34	1.5e-10	Stroke;
CRC	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.54	7.31	0.37	2.01e-12	Metabolite levels;
CRC	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg00601486	chr12:48723148	H1FNT	-0.33	-6.16	-0.32	2.09e-9	Glycated hemoglobin levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08576880	chr16:1359158	UBE2I	0.45	5.97	0.31	6.2e-9	Anxiety disorder;
CRC	cis	rs3824347	0.771	rs10746968	chr9:77579976	A/G	cg01251476	chr9:77566080	C9orf40	0.38	5.83	0.31	1.35e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.74	0.63	4.18e-38	Exhaled nitric oxide output;
CRC	cis	rs672059	1.000	rs1760621	chr1:183156006	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.13	0.37	6.58e-12	Hypertriglyceridemia;
CRC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.4	5.95	0.31	6.89e-9	Heart rate;
CRC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.93	0.44	3.08e-17	Menarche (age at onset);
CRC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg24562669	chr7:97807699	LMTK2	0.42	7.04	0.36	1.1e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6973256	0.569	rs9649595	chr7:133385921	G/C	cg10665199	chr7:133106180	EXOC4	0.5	7.95	0.4	2.94e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.79	-14.53	-0.63	2.68e-37	Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05863116	chr5:133562407	PPP2CA	0.39	6.13	0.32	2.49e-9	Interleukin-6 levels;
CRC	cis	rs12745968	0.685	rs11164807	chr1:93234095	G/C	cg17283838	chr1:93427260	FAM69A	-0.43	-5.8	-0.3	1.58e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.6	8.45	0.42	9.37e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7894051	1.000	rs11101724	chr10:135192153	G/A	cg24905316	chr10:135186343	ECHS1	0.59	6.1	0.32	2.98e-9	Lifespan;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11897279	chr19:13044638	FARSA	0.48	7.11	0.36	7.22e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9362426	0.551	rs6912282	chr6:88103000	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	6.4	0.33	5.4e-10	Depressive episodes in bipolar disorder;
CRC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.59	11.9	0.55	2.21e-27	Asthma (sex interaction);
CRC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.52	-0.5	1.73e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs6496667	0.908	rs8039446	chr15:90853061	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.49	-7.1	-0.36	7.91e-12	Rheumatoid arthritis;
CRC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg26666090	chr16:58549219	SETD6	0.94	6.29	0.33	9.91e-10	Schizophrenia;
CRC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.55	6.9	0.36	2.66e-11	Psoriasis;
CRC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.36	0.5	5.71e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg15848620	chr12:58087721	OS9	0.54	6.3	0.33	9.35e-10	Multiple sclerosis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11117765	chr4:7044873	CCDC96;TADA2B	0.45	6.91	0.36	2.48e-11	Schizophrenia;
CRC	cis	rs728616	0.510	rs12768957	chr10:82187293	G/A	cg05935833	chr10:81318306	SFTPA2	-0.54	-6.33	-0.33	8e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12913538	0.855	rs11071677	chr15:62896909	T/A	cg09983546	chr15:62884068	NA	0.58	8.94	0.44	2.81e-17	Sleep depth;
CRC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.45	-6.64	-0.34	1.33e-10	Body mass index;
CRC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Bone mineral density;
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs2274273	0.624	rs7151754	chr14:55788501	C/T	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.78	-0.3	1.72e-8	Protein biomarker;
CRC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.43	7.02	0.36	1.31e-11	Obesity-related traits;
CRC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	1.03e-17	Bladder cancer;
CRC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg00769240	chr8:12517080	NA	-0.65	-7.34	-0.38	1.67e-12	Blood pressure (smoking interaction);
CRC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	11.49	0.54	6.5e-26	High light scatter reticulocyte count;
CRC	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg09659197	chr4:152720779	NA	0.31	5.69	0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.41	-6.06	-0.32	3.74e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.38	-6.53	-0.34	2.54e-10	Height;
CRC	cis	rs2072510	0.569	rs7134860	chr12:96390358	C/A	cg09636302	chr12:96389483	HAL	-0.52	-6.5	-0.34	3.02e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg23018236	chr17:30244563	NA	-0.57	-7.55	-0.38	4.27e-13	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00586365	chr5:132948251	FSTL4	0.3	6.01	0.31	4.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg01629716	chr15:45996671	NA	0.4	8.3	0.42	2.79e-15	Waist circumference;Weight;
CRC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	5.97	0.31	5.99e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs534126	0.778	rs10256011	chr7:142936243	G/A	cg04039957	chr7:143013207	CLCN1	0.34	5.7	0.3	2.69e-8	Cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21054179	chr12:49412581	PRKAG1	0.42	6.03	0.32	4.52e-9	Anxiety disorder;
CRC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.65	-10.66	-0.51	5.67e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.48	7.96	0.4	2.8e-14	Major depressive disorder;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18269826	chr15:101459483	LRRK1	0.37	6.12	0.32	2.6e-9	Interleukin-6 levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23376446	chr14:100752258	NA	0.42	6.13	0.32	2.48e-9	Response to antipsychotic treatment;
CRC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.44	5.92	0.31	8.12e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.64	0.51	6.45e-23	Hip circumference adjusted for BMI;
CRC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-11.6	-0.54	2.55e-26	Ulcerative colitis;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.48	5.7	0.3	2.72e-8	Depression;
CRC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15687855	chr3:44754131	ZNF502	-0.37	-6.19	-0.32	1.79e-9	Depressive symptoms;
CRC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.1	-0.36	7.58e-12	Joint mobility (Beighton score);
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg10729496	chr3:10149963	C3orf24	0.53	6.92	0.36	2.3e-11	Alzheimer's disease;
CRC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	1e-8	Life satisfaction;
CRC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.43	6.87	0.35	3.26e-11	Vitiligo;
CRC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	15.49	0.65	4.88e-41	Smoking behavior;
CRC	cis	rs970548	0.865	rs12246131	chr10:45993782	A/T	cg15590007	chr10:45870220	ALOX5	0.48	6.04	0.32	4.24e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.05	18.91	0.72	1.63e-54	Schizophrenia;
CRC	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.44	-6.26	-0.33	1.18e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	6.09	0.32	3.07e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.28	6.05	0.32	3.98e-9	Educational attainment (years of education);
CRC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.16	-0.49	2.85e-21	Monocyte count;
CRC	trans	rs12200782	0.649	rs9467742	chr6:26386363	A/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.62	7.56	0.38	4.02e-13	Response to hepatitis C treatment;
CRC	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.69	-0.35	9.66e-11	Educational attainment (years of education);
CRC	cis	rs972578	0.837	rs4820496	chr22:43320301	A/G	cg01576275	chr22:43409880	NA	-0.38	-5.89	-0.31	9.6e-9	Mean platelet volume;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18588052	chr6:111408752	SLC16A10	0.36	6.05	0.32	3.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg11245181	chr6:149772854	ZC3H12D	0.52	9.12	0.45	7.83e-18	Dupuytren's disease;
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg13047869	chr3:10149882	C3orf24	0.52	7.13	0.37	6.56e-12	Alzheimer's disease;
CRC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.08	-10.41	-0.5	4.14e-22	Diabetic retinopathy;
CRC	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	6.93	0.36	2.26e-11	Blood metabolite levels;
CRC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4722166	0.598	rs4722179	chr7:22803861	C/A	cg05472934	chr7:22766657	IL6	0.65	10.59	0.5	9.6e-23	Lung cancer;
CRC	cis	rs9462027	0.675	rs13206387	chr6:34696792	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.38e-9	Systemic lupus erythematosus;
CRC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-7.12	-0.37	6.88e-12	Neuroticism;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg06470822	chr6:28175283	NA	0.82	8.57	0.43	3.96e-16	Lung cancer in ever smokers;
CRC	cis	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg16814680	chr8:91681699	NA	0.65	10.49	0.5	2.18e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.24	18.66	0.72	1.65e-53	Mitochondrial DNA levels;
CRC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.55	6.38	0.33	6.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.3	3.81e-8	Hemoglobin concentration;
CRC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg05585544	chr11:47624801	NA	-0.6	-10.53	-0.5	1.5e-22	Subjective well-being;
CRC	cis	rs7129220	0.512	rs1867137	chr11:10228809	G/A	cg23875677	chr11:10229755	SBF2	-0.53	-5.97	-0.31	6.29e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.76	13.58	0.6	1.2e-33	Oral cavity cancer;
CRC	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.38	6.87	0.35	3.3e-11	Breast cancer;
CRC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.55	6.58	0.34	1.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02696742	chr7:106810147	HBP1	0.47	7.53	0.38	4.87e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.3	-0.37	2.19e-12	Bipolar disorder;
CRC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.54	8.61	0.43	3.13e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.63	-9.71	-0.47	9.35e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-0.74	-8.19	-0.41	5.95e-15	Post bronchodilator FEV1;
CRC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg00129232	chr17:37814104	STARD3	0.5	8.19	0.41	5.85e-15	Self-reported allergy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24991452	chr6:35996059	MAPK14	0.43	6.08	0.32	3.4e-9	Response to antipsychotic treatment;
CRC	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	15.0	0.64	4.09e-39	Primary sclerosing cholangitis;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09188016	chr12:64798414	XPOT	-0.41	-6.38	-0.33	6.15e-10	Brain structure;
CRC	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg21399703	chr1:247681439	NA	0.51	5.75	0.3	2e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.81	-0.3	1.51e-8	Skin colour saturation;
CRC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.38	0.38	1.3e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.98	0.31	5.72e-9	Electroencephalogram traits;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.49	-0.34	3.17e-10	Longevity;Endometriosis;
CRC	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05962382	chr2:130345044	NA	-0.45	-7.72	-0.39	1.38e-13	Response to cytidine analogues (gemcitabine);
CRC	trans	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.58	-0.34	1.82e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.87	16.65	0.68	1.45e-45	Hip circumference;
CRC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.35	9.85e-11	Lung cancer;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20092199	chr4:1342459	KIAA1530	0.38	6.67	0.35	1.06e-10	Obesity-related traits;
CRC	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.63	8.39	0.42	1.48e-15	Alzheimer's disease;
CRC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.59	8.59	0.43	3.53e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.55	7.55	0.38	4.35e-13	Longevity;Endometriosis;
CRC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.47	7.93	0.4	3.37e-14	Breast cancer;
CRC	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg16898833	chr6:26189333	HIST1H4D	0.78	6.46	0.34	3.78e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg03152288	chr2:177042942	NA	0.81	13.04	0.58	1.27e-31	IgG glycosylation;
CRC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.71	12.56	0.57	7.85e-30	Dental caries;
CRC	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.88	16.62	0.68	1.76e-45	Lewy body disease;
CRC	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg09003973	chr2:102972529	NA	0.68	7.56	0.38	3.99e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.83	13.04	0.58	1.3e-31	Menarche (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24285721	chr7:44046988	SPDYE1;POLR2J4	-0.38	-6.44	-0.33	4.22e-10	Obesity-related traits;
CRC	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.72	-12.56	-0.57	8.2e-30	White blood cell count (basophil);
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.15	-0.32	2.22e-9	Total body bone mineral density;
CRC	cis	rs4547160	0.821	rs951359	chr12:63482309	G/A	cg26727693	chr12:63544175	AVPR1A	-0.44	-7.96	-0.4	2.73e-14	Morning vs. evening chronotype;
CRC	cis	rs6088813	1.000	rs4911494	chr20:33971914	C/T	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg09695851	chr17:3907499	NA	0.83	16.4	0.67	1.33e-44	Type 2 diabetes;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00300859	chr18:55289375	NARS	0.54	5.96	0.31	6.36e-9	Interleukin-4 levels;
CRC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg05341575	chr12:125625032	AACS	-0.35	-5.74	-0.3	2.18e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.78	-0.35	5.63e-11	Breast cancer;
CRC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.53	0.54	4.57e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.86	-0.31	1.12e-8	Total body bone mineral density;
CRC	cis	rs12024301	0.557	rs10911412	chr1:183662429	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9649465	0.967	rs768680	chr7:123364127	T/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.67	-0.3	3.21e-8	Migraine;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19514765	chr6:27805693	HIST1H2BN;HIST1H2AK	0.55	7.14	0.37	5.83e-12	Thyroid stimulating hormone;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21790657	chr18:77675478	PQLC1	0.44	6.38	0.33	6.02e-10	Survival in pancreatic cancer;
CRC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.44	-6.47	-0.34	3.56e-10	Ulcerative colitis;
CRC	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.42	7.98	0.4	2.44e-14	Alcohol dependence;
CRC	cis	rs7739232	0.920	rs75728990	chr6:53528375	C/T	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs4481887	0.504	rs4916110	chr1:248360783	T/C	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs6988985	0.678	rs28491316	chr8:143992661	C/T	cg10324643	chr8:143916377	GML	0.35	5.71	0.3	2.57e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	14.23	0.62	3.93e-36	Hip circumference adjusted for BMI;
CRC	cis	rs3857067	0.901	rs4693368	chr4:95046907	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.73	-0.3	2.27e-8	QT interval;
CRC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-8.28	-0.42	3.15e-15	Mean platelet volume;
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.53	7.05	0.36	1.03e-11	Alzheimer's disease;
CRC	cis	rs922182	0.557	rs7161764	chr15:64202744	C/T	cg01859228	chr15:64208452	DAPK2	0.37	5.61	0.3	4.2e-8	Blood protein levels;
CRC	cis	rs1572438	0.811	rs6916756	chr6:880467	G/A	cg13447295	chr6:887704	NA	0.55	8.4	0.42	1.4e-15	Aging;
CRC	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.51	-9.64	-0.47	1.62e-19	Pediatric bone mineral content (femoral neck);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25535838	chr15:30917991	ARHGAP11B	0.39	6.4	0.33	5.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6968419	0.747	rs2030977	chr7:115875359	G/C	cg02561103	chr7:115862891	TES	-0.42	-6.24	-0.33	1.32e-9	Intraocular pressure;
CRC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.88	0.55	2.54e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-8.09	-0.41	1.15e-14	Personality dimensions;
CRC	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg07636037	chr3:49044803	WDR6	-0.63	-6.35	-0.33	7.27e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.47	8.01	0.4	1.96e-14	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07088328	chr8:38089161	DDHD2	0.44	6.77	0.35	5.83e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4750440	0.702	rs7917296	chr10:14029639	G/A	cg00551146	chr10:14014579	FRMD4A	0.39	6.33	0.33	7.99e-10	Adiponectin levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg23957850	chr13:103528318	ERCC5	-0.39	-6.23	-0.32	1.47e-9	HDL cholesterol;
CRC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-7.69	-0.39	1.73e-13	Aortic root size;
CRC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg13390004	chr1:15929781	NA	0.52	7.01	0.36	1.32e-11	Systolic blood pressure;
CRC	trans	rs587242	0.911	rs80336582	chr1:96901001	G/A	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.53	-7.6	-0.39	3.04e-13	Response to temozolomide;
CRC	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg10761708	chr20:43804764	PI3	0.48	5.62	0.3	4.06e-8	Blood protein levels;
CRC	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.62e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs501120	0.584	rs11238898	chr10:44679016	T/A	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6840360	0.573	rs11099807	chr4:152269228	C/T	cg09659197	chr4:152720779	NA	0.33	6.36	0.33	6.58e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.9	0.31	8.85e-9	Self-reported allergy;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.63	-8.72	-0.43	1.36e-16	Menopause (age at onset);
CRC	cis	rs2282802	0.685	rs1529693	chr5:139678213	A/G	cg26211634	chr5:139558579	C5orf32	0.42	7.28	0.37	2.47e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.06	0.41	1.38e-14	Menopause (age at onset);
CRC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-9.07	-0.45	1.1e-17	Bone mineral density;
CRC	cis	rs7932354	0.550	rs10734549	chr11:46822686	C/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.48	-0.34	3.3e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.43	5.89	0.31	9.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.58	9.12	0.45	7.84e-18	Longevity;Endometriosis;
CRC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-0.96	-19.15	-0.73	1.84e-55	Myeloid white cell count;
CRC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg06660174	chr16:19892831	GPRC5B	-0.41	-6.26	-0.33	1.22e-9	HDL cholesterol;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg06470822	chr6:28175283	NA	0.79	12.11	0.56	3.54e-28	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24515799	chr6:149867235	PPIL4	0.41	6.64	0.34	1.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg14558114	chr2:88469736	THNSL2	-0.46	-6.68	-0.35	1.05e-10	Response to metformin (IC50);
CRC	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.98	20.12	0.74	2.92e-59	Metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18720285	chr11:15096341	CALCB	0.36	6.01	0.31	4.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg03676636	chr4:99064102	C4orf37	0.25	5.63	0.3	3.93e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6896969	0.510	rs7730306	chr5:40423257	C/A	cg09067459	chr5:40385259	NA	0.46	7.97	0.4	2.69e-14	Multiple sclerosis;
CRC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-7.59	-0.39	3.23e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.46	0.65	6.33e-41	Colorectal cancer;
CRC	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg06076350	chr7:157294107	NA	0.32	5.78	0.3	1.78e-8	Inattentive symptoms;
CRC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20307385	chr11:47447363	PSMC3	-0.59	-8.15	-0.41	7.74e-15	Subjective well-being;
CRC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.5	-0.38	6.03e-13	Coronary artery disease;
CRC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.37	-6.33	-0.33	8.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22846949	chr16:14723829	PARN	0.44	6.17	0.32	2.02e-9	Response to antipsychotic treatment;
CRC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.77	-0.35	5.81e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.2	0.32	1.72e-9	Rheumatoid arthritis;
CRC	cis	rs55702914	0.628	rs3849362	chr2:198308260	A/G	cg10820045	chr2:198174542	NA	-0.33	-5.74	-0.3	2.11e-8	Major depression and alcohol dependence;
CRC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.92	0.31	7.97e-9	Personality dimensions;
CRC	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.53	-8.67	-0.43	2.01e-16	Thyroid hormone levels;
CRC	cis	rs7091068	0.671	rs604489	chr10:95405408	T/C	cg20715218	chr10:95462985	C10orf4	-0.47	-5.65	-0.3	3.4e-8	Urinary tract infection frequency;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.58	-8.04	-0.41	1.68e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Parkinson's disease;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.36	8.64	0.43	2.49e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg10729496	chr3:10149963	C3orf24	0.5	6.49	0.34	3.18e-10	Alzheimer's disease;
CRC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg18721089	chr20:30220636	NA	-0.34	-5.71	-0.3	2.5e-8	Mean corpuscular hemoglobin;
CRC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.6	7.13	0.37	6.33e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.11	0.45	8.53e-18	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09317632	chr19:58838370	ZSCAN22	0.4	6.53	0.34	2.54e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg20512303	chr5:131592959	PDLIM4	0.34	6.33	0.33	7.86e-10	Breast cancer;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.72	10.48	0.5	2.26e-22	Menarche (age at onset);
CRC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg03030879	chr14:75389066	RPS6KL1	0.42	6.37	0.33	6.2e-10	Height;
CRC	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg22495460	chr2:25135724	ADCY3	-0.85	-16.16	-0.67	1.15e-43	Body mass index in non-asthmatics;
CRC	cis	rs55788414	0.651	rs2317121	chr16:81182826	T/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.82	-0.35	4.38e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs2296342	0.652	rs2296338	chr6:33630816	G/A	cg14003231	chr6:33640908	ITPR3	0.36	5.91	0.31	8.45e-9	Schizophrenia;
CRC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06877462	chr1:205807181	PM20D1	0.38	6.0	0.31	5.31e-9	Menarche (age at onset);
CRC	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg09324608	chr17:30823087	MYO1D	0.36	6.31	0.33	9.25e-10	Schizophrenia;
CRC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.37	-6.63	-0.34	1.36e-10	Menarche (age at onset);
CRC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.6	-8.39	-0.42	1.48e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.64	9.81	0.48	4.32e-20	Itch intensity from mosquito bite;
CRC	cis	rs9491140	0.539	rs980658	chr6:124690371	G/A	cg05308643	chr6:124982296	NKAIN2	0.48	6.74	0.35	7.01e-11	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23049307	chr1:55353163	DHCR24	0.44	6.96	0.36	1.82e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3026101	0.671	rs57774467	chr17:5300205	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs12476592	0.516	rs6717060	chr2:63568608	G/A	cg10828910	chr2:63850056	LOC388955	0.45	5.79	0.3	1.62e-8	Childhood ear infection;
CRC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.65	0.63	8.94e-38	Breast cancer;
CRC	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.21	0.41	5.11e-15	Cognitive performance;
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-5.96	-0.31	6.47e-9	Bipolar disorder;
CRC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.4	-7.56	-0.38	4.12e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.47	-6.4	-0.33	5.4e-10	Pulse pressure;
CRC	trans	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg13565492	chr6:43139072	SRF	-0.71	-7.27	-0.37	2.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25802399	chr20:61847276	YTHDF1	0.39	6.39	0.33	5.65e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.94	16.6	0.68	2.23e-45	IgG glycosylation;
CRC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.04	12.91	0.58	3.83e-31	Vitiligo;
CRC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.7	12.46	0.57	1.8e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg07699608	chr10:75541558	CHCHD1	0.59	6.14	0.32	2.38e-9	Incident atrial fibrillation;
CRC	cis	rs4731207	0.596	rs1994023	chr7:124580670	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.09	-0.32	3.18e-9	Cutaneous malignant melanoma;
CRC	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.98	18.34	0.71	2.87e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.5	7.32	0.37	1.9e-12	Height;
CRC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.82	-0.31	1.42e-8	Lung cancer;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.78	-0.39	9.32e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.49	7.74	0.39	1.21e-13	Red blood cell count;
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.74	9.41	0.46	8.98e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg14631576	chr9:95140430	CENPP	0.4	7.07	0.36	9.24e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg24519413	chr1:26490540	NA	0.38	6.37	0.33	6.44e-10	Height;
CRC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.65	-7.81	-0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.94	-17.12	-0.69	1.97e-47	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-11.67	-0.54	1.49e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.56	-0.34	2.04e-10	Subjective well-being;
CRC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg08896387	chr1:24191740	FUCA1	0.53	7.0	0.36	1.45e-11	Immature fraction of reticulocytes;
CRC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs720844	1.000	rs6761549	chr2:149352262	T/A	cg09247360	chr2:149335327	NA	-0.63	-7.74	-0.39	1.21e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.38	-5.72	-0.3	2.41e-8	Testicular germ cell tumor;
CRC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.33e-12	Life satisfaction;
CRC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg26398791	chr1:38455867	SF3A3	-0.44	-5.89	-0.31	9.39e-9	Coronary artery disease;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02359409	chr6:42947317	PEX6	-0.7	-11.83	-0.55	3.96e-27	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.49	-0.71	7.45e-53	Height;
CRC	cis	rs9463078	0.702	rs929614	chr6:44771934	C/A	cg25276700	chr6:44698697	NA	-0.27	-6.81	-0.35	4.71e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg18761221	chr20:60518478	NA	0.47	7.72	0.39	1.37e-13	Body mass index;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.17	-0.32	1.98e-9	Bipolar disorder;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg18758796	chr5:131593413	PDLIM4	0.4	6.32	0.33	8.41e-10	Blood metabolite levels;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg18301423	chr5:131593218	PDLIM4	-0.41	-7.02	-0.36	1.3e-11	Breast cancer;
CRC	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg00105475	chr2:10696890	NA	0.44	7.14	0.37	6.13e-12	Prostate cancer;
CRC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.48	7.69	0.39	1.76e-13	Schizophrenia;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg21854759	chr1:92012499	NA	0.51	6.07	0.32	3.52e-9	Eosinophil percentage of white cells;
CRC	cis	rs9659323	1.000	rs6700415	chr1:119516174	A/T	cg26570165	chr1:119541833	NA	-0.38	-6.42	-0.33	4.75e-10	Body mass index;
CRC	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg00105475	chr2:10696890	NA	0.47	7.53	0.38	4.96e-13	Prostate cancer;
CRC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg20487152	chr13:99095054	FARP1	-0.46	-6.7	-0.35	8.95e-11	Longevity;
CRC	cis	rs3790844	0.613	rs12030331	chr1:200001547	G/A	cg13229857	chr1:200006247	NR5A2	0.52	7.48	0.38	6.7e-13	Pancreatic cancer;
CRC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-7.83	-0.4	6.78e-14	Aortic root size;
CRC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.25	0.45	2.87e-18	Personality dimensions;
CRC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.98	18.05	0.71	4.09e-51	Headache;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Parkinson's disease;
CRC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.61	-11.46	-0.53	8.56e-26	Educational attainment;
CRC	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-0.57	-6.12	-0.32	2.72e-9	Breast cancer (early onset);
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg12273811	chr6:28175739	NA	0.52	7.15	0.37	5.76e-12	Parkinson's disease;
CRC	cis	rs7113874	0.610	rs12576736	chr11:8512281	A/C	cg20771178	chr11:8615675	STK33	-0.35	-5.75	-0.3	2.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15395842	chr19:489248	NA	0.44	6.22	0.32	1.49e-9	Response to antipsychotic treatment;
CRC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg13390004	chr1:15929781	NA	0.5	7.16	0.37	5.45e-12	Systolic blood pressure;
CRC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.41	8.89	0.44	4.13e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg21466736	chr12:48725269	NA	-0.49	-7.71	-0.39	1.46e-13	Plateletcrit;
CRC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg02569458	chr12:86230093	RASSF9	0.35	5.84	0.31	1.25e-8	Major depressive disorder;
CRC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.31	0.42	2.47e-15	Lung cancer;
CRC	cis	rs860295	0.702	rs12047756	chr1:155624944	G/A	cg02153340	chr1:155202674	NA	-0.57	-6.94	-0.36	2.1e-11	Body mass index;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg21251018	chr6:28226885	NKAPL	0.55	8.9	0.44	3.96e-17	Parkinson's disease;
CRC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.67	8.05	0.41	1.51e-14	Hip circumference adjusted for BMI;
CRC	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	6.87	0.35	3.26e-11	Lymphocyte counts;
CRC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	0.93	11.07	0.52	1.96e-24	Red blood cell traits;
CRC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.59	-8.06	-0.41	1.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7932354	0.528	rs747650	chr11:47176005	C/T	cg03339077	chr11:47165057	C11orf49	-0.46	-6.54	-0.34	2.4e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.45	-6.6	-0.34	1.64e-10	Uric acid clearance;
CRC	cis	rs939584	0.778	rs12992154	chr2:632300	G/T	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.58e-8	Body mass index;
CRC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.38	6.4	0.33	5.44e-10	Major depressive disorder;
CRC	trans	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.83e-14	HDL cholesterol;
CRC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.94	-17.8	-0.7	4.15e-50	Height;
CRC	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.62	-7.62	-0.39	2.81e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.74	11.12	0.52	1.29e-24	Menarche (age at onset);
CRC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.41	-7.81	-0.4	7.67e-14	Ulcerative colitis;
CRC	trans	rs11466653	0.661	rs11466619	chr4:38780431	T/G	cg11403706	chr22:49042600	FAM19A5	0.62	6.09	0.32	3.16e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.45	0.38	8.38e-13	Blood metabolite levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25834275	chr19:3359809	NFIC	0.44	6.67	0.35	1.11e-10	Schizophrenia;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg23123621	chr4:1343375	KIAA1530	0.38	6.89	0.35	2.9e-11	Longevity;
CRC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg22532475	chr10:104410764	TRIM8	0.33	5.62	0.3	4e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.46	0.42	9.11e-16	Rheumatoid arthritis;
CRC	cis	rs6496667	0.600	rs3902286	chr15:91075375	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.5	-7.51	-0.38	5.47e-13	Rheumatoid arthritis;
CRC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.77	-13.0	-0.58	1.76e-31	Breast cancer;
CRC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.28	0.53	3.76e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.61	8.56	0.43	4.26e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26373071	chr5:1325741	CLPTM1L	0.47	8.35	0.42	1.87e-15	Lung cancer;
CRC	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg20933634	chr6:27740509	NA	0.59	7.05	0.36	1.05e-11	Parkinson's disease;
CRC	cis	rs6076065	0.683	rs1419010	chr20:23365254	G/C	cg11657817	chr20:23433608	CST11	0.47	6.9	0.36	2.64e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-11.03	-0.52	2.75e-24	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.2	-18.39	-0.71	1.85e-52	Blood pressure (smoking interaction);
CRC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.56	-9.71	-0.47	8.83e-20	Menarche (age at onset);
CRC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.86	14.88	0.63	1.18e-38	Coronary artery disease;
CRC	trans	rs4586057	0.812	rs12256605	chr10:92621473	G/C	cg26894278	chr13:21016241	CRYL1	0.38	6.29	0.33	9.83e-10	Economic and political preferences (time);
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.52	6.38	0.33	6.02e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.6	-8.53	-0.43	5.57e-16	Inflammatory bowel disease;
CRC	cis	rs6758955	1.000	rs1558628	chr2:10478422	C/T	cg15773312	chr2:10472214	HPCAL1	0.66	8.62	0.43	2.79e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.52	9.66	0.47	1.37e-19	Acylcarnitine levels;
CRC	cis	rs12444156	1	rs12444156	chr16:71841257	C/T	cg08717414	chr16:71523259	ZNF19	-0.99	-9.24	-0.45	3.21e-18	Post bronchodilator FEV1;
CRC	cis	rs954108	0.809	rs1792023	chr13:29368502	G/A	cg11788234	chr13:29393811	NA	-0.42	-6.6	-0.34	1.64e-10	Obesity-related traits;
CRC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	10.04	0.48	6.97e-21	Monocyte percentage of white cells;
CRC	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.58e-11	Inflammatory skin disease;
CRC	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.63	0.43	2.65e-16	Coffee consumption (cups per day);
CRC	cis	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.52	-8.27	-0.41	3.34e-15	Corneal structure;
CRC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.58	-9.51	-0.46	4.07e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.13	-0.32	2.56e-9	Lung cancer;
CRC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10924970	0.578	rs12025973	chr1:235463888	G/A	cg09010748	chr1:235293032	TOMM20	-0.43	-5.92	-0.31	8.25e-9	Asthma;
CRC	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.76	-8.49	-0.42	7.21e-16	Blood pressure (smoking interaction);
CRC	cis	rs2811415	0.597	rs56380765	chr3:127768878	C/A	cg13719885	chr3:127795394	NA	-0.37	-5.65	-0.3	3.49e-8	Lung function (FEV1/FVC);
CRC	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.49	8.04	0.41	1.61e-14	Testicular germ cell tumor;
CRC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg26260408	chr4:53727979	RASL11B	0.41	5.96	0.31	6.67e-9	Optic nerve measurement (cup area);
CRC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.43	6.91	0.36	2.44e-11	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04875709	chr12:12870463	CDKN1B	0.45	6.14	0.32	2.34e-9	Anxiety disorder;
CRC	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.46	-6.4	-0.33	5.37e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs449789	0.857	rs625284	chr6:159703373	G/T	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs1887596	0.639	rs11149445	chr13:27162727	A/G	cg01312412	chr13:27282625	NA	0.43	5.66	0.3	3.29e-8	Facial morphology (factor 3, length of philtrum);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21210124	chr9:92219187	GADD45G	0.43	6.03	0.32	4.51e-9	Response to antipsychotic treatment;
CRC	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg26554054	chr8:600488	NA	0.56	6.26	0.33	1.18e-9	IgG glycosylation;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg06470822	chr6:28175283	NA	0.67	10.27	0.49	1.2e-21	Cardiac Troponin-T levels;
CRC	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.48e-17	Dupuytren's disease;
CRC	cis	rs10450586	0.863	rs6484283	chr11:27298776	C/G	cg10370305	chr11:27303972	NA	0.38	6.23	0.32	1.42e-9	Total body bone mineral density;
CRC	cis	rs3751196	0.808	rs12423889	chr12:104206092	G/A	cg02344784	chr12:104178138	NT5DC3	0.7	7.16	0.37	5.43e-12	Sense of smell;
CRC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.49	-7.88	-0.4	4.88e-14	Aortic root size;
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg26304593	chr6:42947056	PEX6	-0.44	-6.25	-0.33	1.26e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.51	0.38	5.6e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg16745616	chr19:8428856	ANGPTL4	-0.47	-7.58	-0.39	3.54e-13	HDL cholesterol;
CRC	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.51	7.03	0.36	1.21e-11	Eosinophil percentage of white cells;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg06994813	chr7:82792357	PCLO	-0.39	-6.41	-0.33	4.92e-10	Underweight status;
CRC	trans	rs7142881	0.508	rs7147510	chr14:32115400	G/C	cg10453823	chr2:190539512	ANKAR	0.4	5.98	0.31	5.83e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg09655341	chr17:79618100	PDE6G	0.57	6.83	0.35	4.23e-11	Dental caries;
CRC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.74	-0.39	1.24e-13	Gut microbiome composition (summer);
CRC	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.93	-0.58	3.26e-31	Brugada syndrome;
CRC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.67	9.56	0.47	2.97e-19	Lung cancer;
CRC	cis	rs1519814	0.956	rs4133251	chr8:121166993	A/G	cg22335954	chr8:121166405	COL14A1	-0.59	-6.84	-0.35	3.81e-11	Breast cancer;
CRC	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.78	9.66	0.47	1.3e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg19318889	chr4:1322082	MAEA	0.41	5.73	0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.43	6.32	0.33	8.69e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	6.26	0.33	1.22e-9	Diabetic retinopathy;
CRC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	7.56	0.38	4.04e-13	Obesity-related traits;
CRC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.25	-16.79	-0.68	3.81e-46	Breast cancer;
CRC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg18230493	chr5:56204884	C5orf35	-0.39	-5.89	-0.31	9.44e-9	Coronary artery disease;
CRC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.41	5.76	0.3	1.94e-8	Aortic root size;
CRC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.43	-0.42	1.1e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg00074818	chr8:8560427	CLDN23	0.41	7.36	0.38	1.45e-12	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.65	9.59	0.47	2.27e-19	Menopause (age at onset);
CRC	cis	rs720844	0.748	rs16828954	chr2:149330915	T/A	cg09247360	chr2:149335327	NA	-0.56	-6.04	-0.32	4.27e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.57	-9.18	-0.45	5.08e-18	Vitiligo;
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.73	10.15	0.49	3.03e-21	Alzheimer's disease;
CRC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.5	0.38	6.01e-13	Calcium levels;
CRC	cis	rs7429990	0.965	rs9854454	chr3:48012797	A/G	cg11946769	chr3:48343235	NME6	-0.44	-5.72	-0.3	2.34e-8	Educational attainment (years of education);
CRC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg10298567	chr3:47292165	KIF9	-0.37	-5.91	-0.31	8.32e-9	Colorectal cancer;
CRC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg19318889	chr4:1322082	MAEA	0.4	5.71	0.3	2.55e-8	Obesity-related traits;
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	0.94	10.28	0.49	1.14e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.51	-0.62	3.13e-37	Body mass index;
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs1528435	1.000	rs1406256	chr2:181528663	T/C	cg23363182	chr2:181467187	NA	-0.35	-5.68	-0.3	3e-8	Body mass index;
CRC	cis	rs11212617	0.967	rs6589019	chr11:108324961	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.67	0.3	3.09e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03428813	chr2:62115351	CCT4	0.5	7.01	0.36	1.34e-11	Response to antipsychotic treatment;
CRC	cis	rs7264396	0.887	rs750487	chr20:34066645	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.2	-0.32	1.68e-9	Total cholesterol levels;
CRC	cis	rs4700695	0.841	rs251304	chr5:65249700	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg10554839	chr10:27529782	ACBD5	0.42	6.54	0.34	2.29e-10	Body mass index;
CRC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.69	-0.39	1.76e-13	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02276793	chr3:169685131	LOC100128164;SEC62	0.52	7.47	0.38	7.52e-13	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.46	0.46	6.1e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.78	-9.79	-0.47	5.01e-20	Platelet count;
CRC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-9.6	-0.47	2.13e-19	Platelet count;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.76	8.07	0.41	1.31e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs791888	0.965	rs791877	chr10:89406863	A/G	cg13926569	chr10:89418898	PAPSS2	0.44	6.48	0.34	3.26e-10	Magnesium levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10988288	chr7:150780510	TMUB1	0.39	6.24	0.33	1.34e-9	Schizophrenia;
CRC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.6	10.48	0.5	2.39e-22	Aortic root size;
CRC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg13844804	chr7:814759	HEATR2	0.65	8.51	0.42	6.2e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-5.86	-0.31	1.12e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.54	9.05	0.45	1.24e-17	Systemic lupus erythematosus;
CRC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.61	9.52	0.46	3.91e-19	Neuroticism;Neuroticism (multi-trait analysis);
CRC	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg15192750	chr16:69999425	NA	0.56	7.54	0.38	4.63e-13	IgE levels;
CRC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.53	-0.46	3.71e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	8.9	0.44	3.71e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.28	14.87	0.63	1.28e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg03233332	chr7:66118400	NA	-0.42	-5.66	-0.3	3.27e-8	Aortic root size;
CRC	cis	rs9463078	0.764	rs3799971	chr6:44819319	G/C	cg25276700	chr6:44698697	NA	-0.27	-6.48	-0.34	3.43e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-15.74	-0.66	5.05e-42	Intelligence (multi-trait analysis);
CRC	trans	rs564309	0.681	rs1150918	chr1:228608689	T/C	cg20905516	chr11:106889364	GUCY1A2	0.58	6.11	0.32	2.8e-9	Hip circumference (psychosocial stress interaction);
CRC	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.69	8.29	0.42	3.01e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg09184832	chr6:79620586	NA	-0.47	-8.46	-0.42	8.66e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9976767	0.932	rs7283281	chr21:43825519	C/G	cg23042151	chr21:43824109	UBASH3A	-0.35	-6.31	-0.33	9.26e-10	Type 1 diabetes;
CRC	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.8	12.1	0.56	3.83e-28	Testicular germ cell tumor;
CRC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.92	-0.36	2.32e-11	Lung cancer;
CRC	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.79	13.32	0.59	1.13e-32	Hip circumference;
CRC	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.66	-9.15	-0.45	6.14e-18	Autism;
CRC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.14	-0.32	2.32e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.41	5.74	0.3	2.11e-8	Renal cell carcinoma;
CRC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.19	0.56	1.79e-28	Hip circumference adjusted for BMI;
CRC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-6.57	-0.34	2.01e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.79	-9.35	-0.46	1.4e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.68	0.54	1.36e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.38	0.33	6.13e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.4	-5.69	-0.3	2.74e-8	Rheumatoid arthritis;
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg24192786	chr5:122917781	CSNK1G3	0.4	6.04	0.32	4.17e-9	Monocyte count;
CRC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.57	8.23	0.41	4.34e-15	Multiple sclerosis;
CRC	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.52	7.95	0.4	2.98e-14	Testicular germ cell tumor;
CRC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg18230493	chr5:56204884	C5orf35	0.59	8.69	0.43	1.69e-16	Initial pursuit acceleration;
CRC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.83	0.31	1.36e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.65	9.5	0.46	4.63e-19	Schizophrenia;
CRC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg21681030	chr2:46777652	RHOQ	0.42	5.71	0.3	2.52e-8	Height;
CRC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs8105895	0.935	rs10413784	chr19:22246191	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.79	-0.35	5.15e-11	Retinal vascular caliber;
CRC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.63	8.06	0.41	1.4e-14	Response to diuretic therapy;
CRC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.97	-0.44	2.25e-17	Urinary metabolites;
CRC	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-10.35	-0.5	6.36e-22	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05617927	chr15:83654886	FAM103A1	0.52	6.66	0.34	1.14e-10	Thyroid stimulating hormone;
CRC	cis	rs9549328	0.670	rs2993344	chr13:113617022	C/T	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.12e-19	Systolic blood pressure;
CRC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.4	7.85	0.4	6.03e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3857067	1.000	rs1585652	chr4:95014313	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6942756	0.747	rs691435	chr7:129097352	C/T	cg02491457	chr7:128862824	NA	0.6	8.13	0.41	8.56e-15	White matter hyperintensity burden;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05800723	chr4:79103126	FRAS1	0.48	8.14	0.41	8.53e-15	Liver disease severity in Alagille syndrome;
CRC	trans	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg09872104	chr7:134855509	C7orf49	-0.82	-7.2	-0.37	4e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.61	11.04	0.52	2.59e-24	Schizophrenia;
CRC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.79	9.04	0.45	1.33e-17	Breast cancer;
CRC	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.16	-0.37	5.36e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	7.02	0.36	1.26e-11	Homocysteine levels;
CRC	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg16141378	chr3:129829833	LOC729375	0.43	6.43	0.33	4.6e-10	Neuroticism;
CRC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.95	-0.31	6.96e-9	Arsenic metabolism;
CRC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg09127314	chr1:152161683	NA	0.49	6.18	0.32	1.88e-9	Atopic dermatitis;
CRC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.21	0.37	3.99e-12	Colorectal cancer;
CRC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.55	8.26	0.41	3.56e-15	Red cell distribution width;
CRC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.82	7.84	0.4	6.37e-14	Diabetic retinopathy;
CRC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.84	-0.4	6.33e-14	Heart rate;
CRC	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.85	12.68	0.57	2.82e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.37	6.21	0.32	1.56e-9	Cardiovascular disease risk factors;
CRC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.89	-0.4	4.37e-14	Gut microbiome composition (summer);
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6496667	1.000	rs7162175	chr15:90897473	A/G	cg04176472	chr15:90893244	GABARAPL3	0.61	8.47	0.42	8.02e-16	Rheumatoid arthritis;
CRC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg02135003	chr7:105160482	PUS7	-0.68	-10.13	-0.49	3.59e-21	Bipolar disorder (body mass index interaction);
CRC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.79	13.38	0.59	6.71e-33	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.18	-0.32	1.85e-9	Diabetic kidney disease;
CRC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.63	-6.96	-0.36	1.9e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-6.17	-0.32	1.96e-9	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07970400	chr15:40650285	DISP2	0.42	6.8	0.35	5.08e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg13482628	chr17:19912719	NA	0.54	8.59	0.43	3.6e-16	Schizophrenia;
CRC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg22495460	chr2:25135724	ADCY3	-0.88	-17.4	-0.69	1.56e-48	Body mass index;
CRC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.82	-13.06	-0.58	1.11e-31	Cognitive function;
CRC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg13844804	chr7:814759	HEATR2	0.68	8.0	0.4	2.15e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.51	5.89	0.31	9.38e-9	Vitiligo;
CRC	cis	rs2882667	0.690	rs160401	chr5:138061341	C/T	cg09476006	chr5:138032270	NA	-0.53	-9.04	-0.45	1.33e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.51	-0.38	5.57e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.57	9.64	0.47	1.54e-19	Eye color traits;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Parkinson's disease;
CRC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.67	12.3	0.56	7.37e-29	Body mass index;
CRC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24308560	chr3:49941425	MST1R	-0.45	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg02683197	chr6:28174875	NA	0.65	9.03	0.45	1.48e-17	Parkinson's disease;
CRC	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.73	-6.21	-0.32	1.56e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.86	-0.48	2.86e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg22079747	chr2:228736145	WDR69	-0.44	-5.91	-0.31	8.76e-9	Blood pressure;
CRC	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.79	10.82	0.51	1.57e-23	IgG glycosylation;
CRC	cis	rs9462027	0.628	rs9469914	chr6:34827693	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.19	-0.32	1.82e-9	Systemic lupus erythematosus;
CRC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.41	6.82	0.35	4.46e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.44	-6.53	-0.34	2.56e-10	Menarche (age at onset);
CRC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.26	-6.43	-0.33	4.38e-10	Iron status biomarkers;
CRC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.73	-0.66	5.59e-42	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.38	0.42	1.6e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg26043149	chr18:55253948	FECH	0.53	8.27	0.41	3.26e-15	Bone mineral density;
CRC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Corneal astigmatism;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03352830	chr11:487213	PTDSS2	0.65	7.33	0.37	1.75e-12	Body mass index;
CRC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06544989	chr22:39130855	UNC84B	0.44	6.62	0.34	1.44e-10	Menopause (age at onset);
CRC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.57	-9.23	-0.45	3.35e-18	Dupuytren's disease;
CRC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-6.44	-0.33	4.18e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg12564285	chr5:131593104	PDLIM4	0.38	7.44	0.38	8.85e-13	Blood metabolite levels;
CRC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg18230493	chr5:56204884	C5orf35	0.6	8.95	0.44	2.64e-17	Initial pursuit acceleration;
CRC	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.63	-10.53	-0.5	1.53e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.44	8.95	0.44	2.58e-17	Renal cell carcinoma;
CRC	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg00383909	chr3:49044727	WDR6	0.44	5.68	0.3	2.91e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12172441	chr6:28176163	NA	0.67	8.41	0.42	1.25e-15	Depression;
CRC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.36	6.41	0.33	5.02e-10	Reticulocyte fraction of red cells;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs728616	0.867	rs56000427	chr10:81986946	A/G	cg05935833	chr10:81318306	SFTPA2	-0.79	-8.12	-0.41	9.2e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg13198984	chr17:80129470	CCDC57	0.42	7.33	0.37	1.77e-12	Life satisfaction;
CRC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.42	9.06	0.45	1.23e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.67	-11.45	-0.53	9.28e-26	Vitiligo;
CRC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.46	9.25	0.45	2.91e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.78	12.0	0.55	9.33e-28	Menarche (age at onset);
CRC	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg00738113	chr16:70207722	CLEC18C	-0.41	-5.93	-0.31	7.84e-9	IgE levels;
CRC	trans	rs783540	0.846	rs783539	chr15:83254070	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.14	-0.32	2.31e-9	Schizophrenia;
CRC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg08213375	chr14:104286397	PPP1R13B	0.43	6.83	0.35	4.21e-11	Reticulocyte count;
CRC	cis	rs7703744	0.634	rs6883657	chr5:118683346	C/G	cg02283238	chr5:118691126	TNFAIP8	0.46	6.2	0.32	1.67e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.4	7.6	0.39	3.18e-13	Ulcerative colitis;
CRC	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.47	9.03	0.45	1.52e-17	Educational attainment (years of education);
CRC	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg09873164	chr1:152488093	CRCT1	0.36	6.13	0.32	2.48e-9	Hair morphology;
CRC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg27068330	chr11:65405492	SIPA1	0.48	7.0	0.36	1.45e-11	Acne (severe);
CRC	cis	rs4973397	0.883	rs4973392	chr2:232286552	G/A	cg13347044	chr2:232276743	NA	0.52	7.12	0.37	6.82e-12	Anti-saccade response;
CRC	cis	rs4731207	0.698	rs7796015	chr7:124521146	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.1	-0.32	2.96e-9	Cutaneous malignant melanoma;
CRC	cis	rs7605827	0.930	rs13002869	chr2:15674389	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.45	7.54	0.38	4.47e-13	Alcohol dependence;
CRC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg06470822	chr6:28175283	NA	0.42	5.72	0.3	2.42e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.37	-0.46	1.21e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.54	8.76	0.44	1.03e-16	Coronary artery disease;
CRC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06634786	chr22:41940651	POLR3H	-0.43	-5.61	-0.3	4.36e-8	Vitiligo;
CRC	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg12458913	chr13:53173898	NA	0.58	9.27	0.46	2.54e-18	Lewy body disease;
CRC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.44	-6.49	-0.34	3.07e-10	Menarche (age at onset);
CRC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.49	0.42	6.97e-16	Height;
CRC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	7.61	0.39	2.95e-13	Gut microbiome composition (summer);
CRC	cis	rs972578	1.000	rs972577	chr22:43387645	C/T	cg01576275	chr22:43409880	NA	-0.49	-7.76	-0.39	1.06e-13	Mean platelet volume;
CRC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.6	6.38	0.33	5.99e-10	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12564526	chr7:66767603	PMS2L4;STAG3L4	0.54	9.24	0.45	3.11e-18	Liver disease severity in Alagille syndrome;
CRC	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.32	0.37	1.92e-12	Lung cancer;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.66	0.34	1.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg04731861	chr2:219085781	ARPC2	-0.33	-6.77	-0.35	5.85e-11	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	trans	rs6011368	0.765	rs7270745	chr20:62892756	C/G	cg13869341	chr1:15865	WASH5P	-0.4	-6.05	-0.32	3.84e-9	Clozapine-induced cytotoxicity;
CRC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg10760299	chr15:45669010	GATM	-0.38	-6.06	-0.32	3.63e-9	Response to fenofibrate (adiponectin levels);
CRC	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.87	-0.35	3.25e-11	Intelligence (multi-trait analysis);
CRC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.43	-5.63	-0.3	3.77e-8	Response to diuretic therapy;
CRC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.44	-7.13	-0.37	6.54e-12	Obesity-related traits;
CRC	trans	rs7027930	0.524	rs3812527	chr9:608683	A/C	cg27061366	chr19:13044373	FARSA	0.48	6.07	0.32	3.45e-9	Pulmonary function decline;
CRC	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.98	0.44	2.15e-17	Fuchs's corneal dystrophy;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06666157	chr19:4791552	FEM1A	-0.56	-6.9	-0.36	2.68e-11	Diisocyanate-induced asthma;
CRC	cis	rs8105895	0.935	rs10411275	chr19:22259469	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.77	-0.35	5.76e-11	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.54	7.54	0.38	4.64e-13	Pulmonary function decline;
CRC	trans	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.87	-0.35	3.25e-11	Primary sclerosing cholangitis;
CRC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.81	-10.94	-0.52	5.99e-24	Initial pursuit acceleration;
CRC	cis	rs2811415	0.597	rs9882664	chr3:127766058	A/C	cg13719885	chr3:127795394	NA	0.4	6.02	0.31	4.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.78	14.34	0.62	1.47e-36	Hip circumference;
CRC	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11547950	chr5:77652471	NA	-0.5	-7.41	-0.38	1.05e-12	Triglycerides;
CRC	cis	rs6804368	0.553	rs9839109	chr3:30770605	C/T	cg06106510	chr3:30762233	NA	-0.37	-6.05	-0.32	4.04e-9	Blood metabolite levels;
CRC	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg23229984	chr5:148520753	ABLIM3	-0.47	-6.5	-0.34	2.93e-10	Breast cancer;
CRC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.57	7.63	0.39	2.49e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs7503807	0.515	rs12944407	chr17:78691979	C/T	cg00549398	chr17:78725201	RPTOR	0.43	5.7	0.3	2.72e-8	Obesity;
CRC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.87	11.62	0.54	2.24e-26	Triglycerides;
CRC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.91	16.17	0.67	1.13e-43	Cognitive function;
CRC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.17	-0.41	6.83e-15	Bone mineral density;
CRC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.45	-0.38	8.12e-13	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00995911	chr19:45004602	ZNF180	0.39	6.18	0.32	1.92e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg21251018	chr6:28226885	NKAPL	0.5	5.8	0.3	1.56e-8	Depression;
CRC	trans	rs4915077	0.773	rs12564672	chr1:108287028	A/T	cg00331283	chr11:133917072	NA	-0.54	-6.07	-0.32	3.52e-9	Hypothyroidism;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg27615366	chr5:131592974	PDLIM4	-0.34	-6.23	-0.33	1.39e-9	Breast cancer;
CRC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.56	-0.43	4.41e-16	Hemoglobin concentration;
CRC	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.84	-0.35	3.82e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs9826463	0.757	rs79576118	chr3:142244645	A/C	cg20824294	chr3:142316082	PLS1	0.4	6.69	0.35	9.6e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg15845792	chr6:28175446	NA	0.76	6.85	0.35	3.65e-11	Depression;
CRC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.31	-0.56	6.46e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23708337	chr7:1209742	NA	0.47	6.98	0.36	1.59e-11	Longevity;Endometriosis;
CRC	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.58	8.08	0.41	1.26e-14	Monobrow;
CRC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.37	-7.19	-0.37	4.37e-12	Hypertriglyceridemia;
CRC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg09473613	chr1:24152604	HMGCL	0.34	5.63	0.3	3.83e-8	Immature fraction of reticulocytes;
CRC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.42	6.02	0.32	4.56e-9	Height;
CRC	cis	rs60871478	0.838	rs12530859	chr7:835034	G/A	cg13844804	chr7:814759	HEATR2	-0.65	-7.35	-0.38	1.59e-12	Cerebrospinal P-tau181p levels;
CRC	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-6.72	-0.35	8.03e-11	Menopause (age at onset);
CRC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.98	0.31	5.9e-9	Diabetic retinopathy;
CRC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.67	0.47	1.21e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg19131313	chr8:1704013	NA	0.5	6.3	0.33	9.38e-10	Systolic blood pressure;
CRC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.22	0.32	1.49e-9	Rheumatoid arthritis;
CRC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.92	0.52	6.61e-24	Prostate cancer;
CRC	trans	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg26043149	chr18:55253948	FECH	-0.54	-8.2	-0.41	5.38e-15	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21117584	chr1:38019997	SNIP1	0.41	5.97	0.31	6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.58	-6.76	-0.35	6.18e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs10237067	0.581	rs10271980	chr7:68345599	A/G	cg25628286	chr3:111396827	PLCXD2	0.38	5.98	0.31	5.73e-9	Lifetime average cigarettes per day in chronic obstructive pulmonary disease;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.45	6.34	0.33	7.42e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.41	5.71	0.3	2.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-19.18	-0.73	1.47e-55	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12541635	0.966	rs7839195	chr8:107020193	G/A	cg10147462	chr8:107024639	NA	0.41	6.84	0.35	3.94e-11	Age of smoking initiation;
CRC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.62	0.43	2.95e-16	Menopause (age at onset);
CRC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg10723962	chr6:26240782	HIST1H4F	0.39	6.53	0.34	2.48e-10	Gout;Renal underexcretion gout;
CRC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg20495365	chr4:3371291	RGS12	-0.33	-5.72	-0.3	2.38e-8	Serum sulfate level;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.64	11.6	0.54	2.48e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9648716	1.000	rs59055264	chr7:140604873	T/C	cg10747023	chr7:140774559	NA	0.45	5.89	0.31	9.29e-9	Type 2 diabetes;
CRC	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.54	-8.87	-0.44	4.79e-17	Metabolite levels;
CRC	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg06634786	chr22:41940651	POLR3H	-0.42	-5.94	-0.31	7.1e-9	Neuroticism;
CRC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg17321639	chr7:2759063	NA	-0.47	-6.16	-0.32	2.07e-9	Height;
CRC	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.86	11.59	0.54	2.89e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.92	-0.55	1.77e-27	Exhaled nitric oxide output;
CRC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.57	-8.25	-0.41	3.98e-15	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.63	-9.33	-0.46	1.66e-18	Menarche (age at onset);
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg23123621	chr4:1343375	KIAA1530	0.32	5.64	0.3	3.65e-8	Obesity-related traits;
CRC	trans	rs11654801	0.812	rs8080233	chr17:20866854	A/C	cg23759823	chr7:139672531	TBXAS1	-0.38	-6.21	-0.32	1.56e-9	Mosquito bite size;
CRC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.49	6.64	0.34	1.26e-10	Height;
CRC	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.23	-0.32	1.41e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.82	12.33	0.56	5.48e-29	Blood trace element (Zn levels);
CRC	cis	rs2179367	0.959	rs537354	chr6:149665937	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.13	-0.32	2.48e-9	Dupuytren's disease;
CRC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg03316587	chr8:142245164	NA	-0.4	-6.02	-0.32	4.58e-9	Immature fraction of reticulocytes;
CRC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg02135003	chr7:105160482	PUS7	-0.73	-10.37	-0.5	5.48e-22	Bipolar disorder (body mass index interaction);
CRC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.71	10.1	0.49	4.6e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.4	-5.62	-0.3	3.97e-8	Cognitive test performance;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg15845792	chr6:28175446	NA	0.77	11.52	0.54	5.21e-26	Cardiac Troponin-T levels;
CRC	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.64	8.98	0.44	2.19e-17	Platelet count;
CRC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg12100956	chr17:78086420	GAA	-0.39	-6.1	-0.32	2.97e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20092199	chr4:1342459	KIAA1530	0.41	7.61	0.39	2.85e-13	Obesity-related traits;
CRC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg27661571	chr11:113659931	NA	-0.96	-11.16	-0.52	9.58e-25	Hip circumference adjusted for BMI;
CRC	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.79	-13.9	-0.61	6.97e-35	Lewy body disease;
CRC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg23298862	chr7:158159286	PTPRN2	-0.5	-8.21	-0.41	4.93e-15	Calcium levels;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23161317	chr6:28129485	ZNF389	0.54	6.6	0.34	1.64e-10	Depression;
CRC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.48	7.45	0.38	8.51e-13	Corneal astigmatism;
CRC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.82	0.4	7.07e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.76	12.1	0.55	4.05e-28	Mean platelet volume;
CRC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.67	9.35	0.46	1.43e-18	Neuroblastoma;
CRC	trans	rs10139154	0.824	rs229222	chr14:31004351	T/A	cg18753625	chr19:36705707	ZNF565;ZNF146	-0.42	-6.01	-0.31	4.93e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.48	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.94	0.36	2.08e-11	Mean platelet volume;
CRC	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	16.19	0.67	9.46e-44	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.42	6.84	0.35	3.87e-11	Obesity-related traits;
CRC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.32e-10	Alzheimer's disease;
CRC	cis	rs6961069	0.745	rs3211839	chr7:80280462	G/A	cg04458919	chr7:80252533	CD36	-0.33	-5.68	-0.3	3.03e-8	Platelet count;
CRC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.87	-0.4	5.09e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs12745968	0.653	rs11164791	chr1:93119634	C/T	cg17283838	chr1:93427260	FAM69A	-0.46	-6.2	-0.32	1.73e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4780401	0.703	rs8191295	chr16:11766905	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.73	-0.3	2.28e-8	Rheumatoid arthritis;
CRC	cis	rs7835763	0.692	rs2514744	chr8:119104321	A/G	cg11592677	chr8:119110466	EXT1	0.38	6.25	0.33	1.29e-9	Autism spectrum disorder;
CRC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.49	-0.34	3.24e-10	Menopause (age at onset);
CRC	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.51	8.33	0.42	2.21e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.48	-0.5	2.3e-22	Total cholesterol levels;
CRC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.24	15.65	0.65	1.15e-41	Lung disease severity in cystic fibrosis;
CRC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.81	-12.91	-0.58	4.11e-31	Cognitive function;
CRC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.48	7.45	0.38	8.51e-13	Corneal astigmatism;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.44	-9.68	-0.47	1.17e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.49	6.45	0.33	4.04e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.48	-5.96	-0.31	6.36e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1223397	0.938	rs3817741	chr6:13279507	A/G	cg06879394	chr6:13274151	PHACTR1	-0.51	-6.38	-0.33	5.86e-10	Blood pressure;
CRC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.71	11.52	0.54	5.04e-26	Mean platelet volume;
CRC	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg17507749	chr15:85114479	UBE2QP1	0.52	6.89	0.36	2.8e-11	Alzheimer's disease (age of onset);
CRC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.86	15.73	0.66	5.56e-42	Lewy body disease;
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg04969067	chr8:143858791	LYNX1	0.45	7.67	0.39	1.97e-13	Urinary tract infection frequency;
CRC	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.54	-8.95	-0.44	2.75e-17	Metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16342149	chr9:86238535	C9orf103	0.46	6.5	0.34	2.96e-10	Response to antipsychotic treatment;
CRC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.9	10.55	0.5	1.36e-22	Psoriasis;
CRC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.6	8.84	0.44	5.75e-17	Morning vs. evening chronotype;
CRC	cis	rs2227564	0.649	rs2242258	chr10:75607168	T/C	cg16540259	chr10:75572220	NDST2	-0.45	-6.46	-0.34	3.74e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.53	-7.08	-0.36	8.6e-12	Platelet distribution width;
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.63	10.64	0.51	6.2e-23	Prudent dietary pattern;
CRC	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.28	-0.42	3.2e-15	Biliary atresia;
CRC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.76	11.29	0.53	3.32e-25	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-13.97	-0.61	3.8e-35	Gut microbiome composition (summer);
CRC	cis	rs2336384	1.000	rs873457	chr1:12046334	C/G	cg13216073	chr1:12042593	MFN2	0.48	7.2	0.37	4.14e-12	Platelet count;
CRC	cis	rs3731896	1.000	rs3731896	chr2:220146402	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.52	6.04	0.32	4.21e-9	Educational attainment;
CRC	cis	rs4363385	0.747	rs11205151	chr1:152961496	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.29	-0.37	2.3e-12	Inflammatory skin disease;
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.94	0.44	2.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.74	-11.89	-0.55	2.26e-27	Lung cancer;
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-9.23	-0.45	3.36e-18	Subjective well-being;
CRC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.72	10.96	0.52	4.79e-24	Immature fraction of reticulocytes;
CRC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.66	-8.04	-0.41	1.68e-14	Menarche (age at onset);
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg06470822	chr6:28175283	NA	0.79	8.6	0.43	3.24e-16	Depression;
CRC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.28	-0.53	3.57e-25	Platelet distribution width;
CRC	cis	rs9469578	0.681	rs78748610	chr6:33714412	T/C	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.41	0.46	8.67e-19	Height;
CRC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.71	-0.35	8.6e-11	Major depressive disorder;
CRC	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	6.03	0.32	4.53e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6460942	0.544	rs17650302	chr7:12143138	C/T	cg06484146	chr7:12443880	VWDE	-0.56	-6.18	-0.32	1.87e-9	Coronary artery disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01398415	chr1:226309536	NA	-0.41	-5.97	-0.31	6.24e-9	Daytime sleep phenotypes;
CRC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.75	12.28	0.56	8.33e-29	Lung cancer;
CRC	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.42	-8.55	-0.43	4.74e-16	Migraine;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19281693	chr22:42666674	NA	0.45	6.66	0.34	1.12e-10	Intelligence (multi-trait analysis);
CRC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg00814883	chr7:100076585	TSC22D4	-0.52	-5.87	-0.31	1.07e-8	Lung function (FEV1/FVC);
CRC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	7.76	0.39	1.1e-13	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.03	-0.4	1.72e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.19	0.67	9.15e-44	Electrocardiographic conduction measures;
CRC	trans	rs2163503	0.666	rs481940	chr1:71442457	C/T	cg23933503	chr22:44255884	SULT4A1	0.37	6.24	0.33	1.38e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg10272801	chr16:14013773	ERCC4	-0.69	-6.06	-0.32	3.8e-9	Cognitive function;
CRC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.39	0.53	1.52e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-0.58	-8.11	-0.41	1.03e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg09659197	chr4:152720779	NA	-0.44	-8.97	-0.44	2.3e-17	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.09	-0.49	5.03e-21	Colorectal cancer;
CRC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.73	0.3	2.26e-8	Self-reported allergy;
CRC	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.51	-0.38	5.58e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.73	6.6	0.34	1.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.55	9.33	0.46	1.62e-18	Dupuytren's disease;
CRC	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.98	0.31	5.91e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg05272587	chr13:111038400	COL4A2	0.41	6.27	0.33	1.11e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	6.2	0.32	1.73e-9	Systemic lupus erythematosus;
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.22	-0.56	1.48e-28	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25454755	chr9:102584145	NR4A3	0.47	6.01	0.31	4.84e-9	Thyroid stimulating hormone;
CRC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.65	-0.39	2.28e-13	Breast cancer;
CRC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg18016565	chr1:150552671	MCL1	0.46	6.63	0.34	1.41e-10	Tonsillectomy;
CRC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-6.13	-0.32	2.56e-9	Menarche (age at onset);
CRC	trans	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg19894588	chr14:64061835	NA	-0.57	-7.82	-0.4	7.26e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.53	7.92	0.4	3.7e-14	Monocyte count;
CRC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.39	-0.38	1.25e-12	Headache;
CRC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.91	-0.44	3.5e-17	Chronic sinus infection;
CRC	trans	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs2652834	0.904	rs8032506	chr15:63371644	G/A	cg05507819	chr15:63340323	TPM1	-0.45	-5.71	-0.3	2.58e-8	HDL cholesterol;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg08222913	chr3:52553049	STAB1	0.34	6.13	0.32	2.45e-9	Bipolar disorder;
CRC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.75	-0.3	2.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16140449	chr1:178511703	C1orf220	0.49	7.06	0.36	1.01e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.25	-0.33	1.25e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.87	12.63	0.57	4.37e-30	Triglycerides;
CRC	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.54	7.92	0.4	3.75e-14	Testicular germ cell tumor;
CRC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.63	10.33	0.49	7.54e-22	Menarche (age at onset);
CRC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.48	-0.71	8.12e-53	Height;
CRC	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.6	7.4	0.38	1.16e-12	Cocaine dependence;
CRC	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg20203395	chr5:56204925	C5orf35	-0.41	-5.81	-0.3	1.5e-8	Coronary artery disease;
CRC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg05585544	chr11:47624801	NA	-0.46	-8.12	-0.41	9.43e-15	Subjective well-being;
CRC	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.41	1.5e-14	Cognitive performance;
CRC	cis	rs4750440	0.670	rs7917314	chr10:14029682	G/A	cg00551146	chr10:14014579	FRMD4A	0.36	5.85	0.31	1.19e-8	Adiponectin levels;
CRC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg21251018	chr6:28226885	NKAPL	0.56	9.68	0.47	1.19e-19	Pulmonary function;
CRC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.16	0.37	5.24e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg15845792	chr6:28175446	NA	0.8	6.52	0.34	2.67e-10	Depression;
CRC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.4	5.62	0.3	4e-8	Renal cell carcinoma;
CRC	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	7.03	0.36	1.2e-11	Blood protein levels;
CRC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-5.71	-0.3	2.57e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.89	15.26	0.64	3.92e-40	Phospholipid levels (plasma);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13627451	chr15:52043674	TMOD2;LYSMD2	0.37	6.05	0.32	3.92e-9	Obesity-related traits;
CRC	trans	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg02869306	chr7:64672164	INTS4L1	-0.41	-6.01	-0.31	4.91e-9	Aortic root size;
CRC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.56	-8.68	-0.43	1.93e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.73	-0.39	1.3e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.59	-8.31	-0.42	2.46e-15	Monobrow;
CRC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.98	0.55	1.13e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg25456477	chr12:86230367	RASSF9	-0.36	-6.14	-0.32	2.31e-9	Major depressive disorder;
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.19	-0.45	4.45e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.65	6.68	0.35	1.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs490234	0.812	rs13292924	chr9:128409728	C/T	cg14078157	chr9:128172775	NA	-0.43	-6.71	-0.35	8.71e-11	Mean arterial pressure;
CRC	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg07862535	chr7:139043722	LUC7L2	0.58	7.32	0.37	1.87e-12	Diisocyanate-induced asthma;
CRC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.03	-0.36	1.17e-11	IgG glycosylation;
CRC	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg04586622	chr2:25135609	ADCY3	-0.55	-9.36	-0.46	1.32e-18	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04779191	chr16:69166964	CHTF8;CIRH1A	0.5	6.43	0.33	4.51e-10	Thyroid stimulating hormone;
CRC	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.63	-10.0	-0.48	9.58e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-5.82	-0.31	1.39e-8	Blood metabolite levels;
CRC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.83	0.44	6.35e-17	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24787081	chr4:184365198	CDKN2AIP	0.47	6.77	0.35	5.8e-11	Response to antipsychotic treatment;
CRC	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.44	-7.1	-0.36	7.68e-12	Refractive error;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg23161317	chr6:28129485	ZNF389	0.45	6.42	0.33	4.64e-10	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10425946	chr17:3571430	TMEM93;TAX1BP3	0.43	6.55	0.34	2.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs354033	1.000	rs354031	chr7:149285921	A/G	cg24335155	chr7:149193227	ZNF746	0.37	5.78	0.3	1.72e-8	Multiple sclerosis;
CRC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.56	-9.9	-0.48	2.19e-20	Height;
CRC	cis	rs10971721	0.822	rs72725374	chr9:33840649	T/C	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	trans	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg04702396	chr17:15466718	FAM18B2	-0.44	-6.21	-0.32	1.56e-9	Educational attainment (years of education);
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.55	-9.91	-0.48	1.97e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.39	6.2	0.32	1.7e-9	Coronary artery disease;
CRC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.52	7.01	0.36	1.38e-11	Tourette syndrome;
CRC	cis	rs73200209	0.744	rs17498452	chr12:116538854	C/T	cg01776926	chr12:116560359	MED13L	0.6	7.19	0.37	4.29e-12	Total body bone mineral density;
CRC	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.59	-8.28	-0.42	3.11e-15	Personality dimensions;
CRC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg21155852	chr7:2048760	MAD1L1	-0.52	-7.01	-0.36	1.33e-11	Bipolar disorder;
CRC	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.65e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg10756647	chr7:56101905	PSPH	0.73	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.7	9.81	0.48	4.43e-20	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11234017	chr17:42767172	CCDC43	0.45	6.45	0.34	4.04e-10	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.78	-13.21	-0.59	3e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.92	11.26	0.53	4.21e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.45	-0.34	4.02e-10	Triglycerides;
CRC	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.52	8.63	0.43	2.73e-16	Testicular germ cell tumor;
CRC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	7.7	0.39	1.63e-13	Height;
CRC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.5	-7.97	-0.4	2.64e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.46	8.49	0.42	7.01e-16	Intraocular pressure;
CRC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg24884572	chr19:58661833	ZNF329	0.79	8.67	0.43	1.97e-16	Cholesterol, total;
CRC	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.82	12.56	0.57	7.98e-30	Chronic lymphocytic leukemia;
CRC	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg04837898	chr3:45731254	SACM1L	-0.34	-5.69	-0.3	2.81e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4234798	0.933	rs7678751	chr4:7219035	A/G	cg18431297	chr4:7219810	SORCS2	0.56	10.06	0.48	6.31e-21	Insulin-like growth factors;
CRC	trans	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg13092806	chr2:177043255	NA	0.8	13.0	0.58	1.74e-31	IgG glycosylation;
CRC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.35	6.3	0.33	9.33e-10	Crohn's disease;
CRC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg12463550	chr7:65579703	CRCP	0.71	6.53	0.34	2.52e-10	Diabetic kidney disease;
CRC	trans	rs72991	0.644	rs297486	chr11:121257399	G/A	cg27192990	chr6:129479024	LAMA2	-0.36	-5.99	-0.31	5.5e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg08807892	chr2:162101083	NA	0.45	6.63	0.34	1.35e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	7.56	0.38	4.17e-13	Homocysteine levels;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg22096450	chr11:6947773	ZNF215	0.58	6.01	0.31	4.99e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.61	10.43	0.5	3.51e-22	Lung cancer in ever smokers;
CRC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.63	7.69	0.39	1.76e-13	Type 2 diabetes nephropathy;
CRC	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg06581033	chr10:766294	NA	-0.51	-5.8	-0.3	1.59e-8	Uric acid levels;
CRC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.99	21.36	0.76	4.12e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.14	0.45	6.75e-18	Bladder cancer;
CRC	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg11693508	chr17:37793320	STARD3	-0.63	-8.03	-0.4	1.77e-14	Bipolar disorder;
CRC	cis	rs12618769	0.543	rs2278211	chr2:99149946	G/A	cg18455616	chr2:99124870	INPP4A	0.35	5.69	0.3	2.8e-8	Bipolar disorder;
CRC	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.75	13.3	0.59	1.39e-32	Insulin-like growth factors;
CRC	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	7.3	0.37	2.24e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg19500275	chr17:80737654	TBCD	0.49	6.52	0.34	2.68e-10	Glycated hemoglobin levels;
CRC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.61	8.0	0.4	2.1e-14	Orofacial clefts;
CRC	trans	rs1973993	0.745	rs6593602	chr1:96951281	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.82	-0.35	4.39e-11	Weight;
CRC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg10130564	chr11:117069849	TAGLN	-0.38	-7.0	-0.36	1.49e-11	Blood protein levels;
CRC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.36	0.46	1.25e-18	Hip circumference adjusted for BMI;
CRC	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg11212589	chr17:38028394	ZPBP2	0.39	7.02	0.36	1.32e-11	Self-reported allergy;
CRC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.63	10.64	0.51	6.56e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg15448220	chr1:150897856	SETDB1	-0.45	-6.39	-0.33	5.62e-10	Tonsillectomy;
CRC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.51	7.91	0.4	4.03e-14	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11744295	chr1:161283833	SDHC;LOC642502	0.41	6.25	0.33	1.24e-9	Response to antipsychotic treatment;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23708337	chr7:1209742	NA	0.44	6.51	0.34	2.78e-10	Longevity;Endometriosis;
CRC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.63	13.29	0.59	1.49e-32	Schizophrenia;
CRC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-6.92	-0.36	2.31e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.44	6.46	0.34	3.77e-10	Renal cell carcinoma;
CRC	trans	rs17136627	0.661	rs4705669	chr5:113823916	A/T	cg24528350	chr1:77384892	ST6GALNAC5	-0.48	-6.0	-0.31	5.2e-9	Coronary arterial lesions in patients with Kawasaki disease;
CRC	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.62	5.64	0.3	3.66e-8	Schizophrenia;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg07414643	chr4:187882934	NA	0.37	6.33	0.33	8.1e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.4	-5.72	-0.3	2.37e-8	Asthma;
CRC	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg18412871	chr13:95254051	GPR180	-0.55	-7.71	-0.39	1.52e-13	Triglyceride levels;
CRC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.14	-11.87	-0.55	2.78e-27	Breast cancer;
CRC	cis	rs10901296	0.588	rs12003046	chr9:133741626	T/C	cg01000188	chr9:133769184	QRFP	0.6	7.43	0.38	9.44e-13	Bilirubin levels;
CRC	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.49	-6.63	-0.34	1.39e-10	Neuroblastoma;
CRC	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.48	-8.99	-0.44	2.01e-17	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.52	-7.99	-0.4	2.33e-14	Aortic root size;
CRC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.58	8.11	0.41	1.04e-14	Arsenic metabolism;
CRC	cis	rs6988985	0.728	rs5303	chr8:143955095	A/G	cg10324643	chr8:143916377	GML	0.37	6.08	0.32	3.29e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg16102536	chr7:156981717	UBE3C	-0.37	-6.26	-0.33	1.21e-9	Body mass index;
CRC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.71	-0.47	9.26e-20	Heart rate;
CRC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.23	-0.37	3.38e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.46	-6.11	-0.32	2.85e-9	Gut microbiome composition (summer);
CRC	cis	rs10971721	0.822	rs72727336	chr9:33931793	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs8040855	0.579	rs6496797	chr15:85726855	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.19	0.32	1.83e-9	Bulimia nervosa;
CRC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.45	-5.73	-0.3	2.22e-8	Gut microbiome composition (summer);
CRC	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00938859	chr5:1591904	SDHAP3	0.73	7.76	0.39	1.07e-13	Breast cancer;
CRC	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.04	14.64	0.63	1.04e-37	Exhaled nitric oxide output;
CRC	cis	rs807029	0.533	rs12571302	chr10:102742763	C/A	cg04662943	chr10:102668895	NA	0.65	7.45	0.38	8.54e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.56	10.82	0.51	1.49e-23	Neuroticism;
CRC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.41	-6.17	-0.32	2.02e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg02659138	chr7:134003124	SLC35B4	0.39	6.85	0.35	3.59e-11	Mean platelet volume;
CRC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg25304816	chr1:36627734	MAP7D1	0.42	6.71	0.35	8.53e-11	Schizophrenia;
CRC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg15848620	chr12:58087721	OS9	0.53	6.16	0.32	2.08e-9	Multiple sclerosis;
CRC	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.58	-5.9	-0.31	8.93e-9	Vitamin D levels;
CRC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.71	9.7	0.47	9.66e-20	Cognitive function;
CRC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg06462663	chr19:18546047	ISYNA1	0.45	6.61	0.34	1.53e-10	Breast cancer;
CRC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.82	11.35	0.53	2.04e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg14458575	chr2:238380390	NA	0.44	6.3	0.33	9.77e-10	Prostate cancer;
CRC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.06	-0.32	3.76e-9	Blood metabolite levels;
CRC	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg00490450	chr3:139108681	COPB2	0.44	6.59	0.34	1.79e-10	Obesity-related traits;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg27532560	chr4:187881888	NA	-0.55	-10.12	-0.49	3.82e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07190229	chr8:142377361	GPR20	0.46	6.31	0.33	9.21e-10	Thyroid stimulating hormone;
CRC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.74	0.47	7.25e-20	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.57	9.13	0.45	7.16e-18	Neuroticism;
CRC	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg06042504	chr8:55087323	NA	-0.36	-5.72	-0.3	2.45e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg18016565	chr1:150552671	MCL1	-0.49	-7.78	-0.39	9.4e-14	Tonsillectomy;
CRC	trans	rs1737890	0.778	rs6119241	chr20:30929095	G/T	cg05428433	chr16:3614067	NLRC3	0.39	5.97	0.31	6.08e-9	Chronic obstructive pulmonary disease;
CRC	trans	rs6788895	1.000	rs6769917	chr3:150509604	A/T	cg03041920	chr13:100310311	CLYBL	0.62	5.97	0.31	6.12e-9	Breast cancer;
CRC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-6.71	-0.35	8.64e-11	Menarche (age at onset);
CRC	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-6.8	-0.35	4.91e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.79	-11.79	-0.55	5.24e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.59	10.72	0.51	3.35e-23	Tonsillectomy;
CRC	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg12458913	chr13:53173898	NA	0.48	7.16	0.37	5.41e-12	Lewy body disease;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18099408	chr3:52552593	STAB1	-0.42	-6.41	-0.33	4.95e-10	Bipolar disorder;
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.47	6.91	0.36	2.45e-11	Autism;
CRC	trans	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.99	0.31	5.47e-9	Metabolite levels;
CRC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg24578937	chr1:2090814	PRKCZ	0.44	7.83	0.4	6.99e-14	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.75	-9.83	-0.48	3.67e-20	Initial pursuit acceleration;
CRC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg24851651	chr11:66362959	CCS	-0.35	-6.03	-0.32	4.45e-9	Educational attainment (years of education);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-6.24	-0.33	1.35e-9	Longevity;Endometriosis;
CRC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14895029	chr7:2775587	GNA12	-0.44	-6.45	-0.34	3.95e-10	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10354764	chr16:3285464	ZNF200	0.49	6.4	0.33	5.46e-10	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg03623178	chr6:28175578	NA	0.75	11.35	0.53	2.11e-25	Parkinson's disease;
CRC	cis	rs11608355	0.538	rs12228876	chr12:109796799	C/A	cg19025524	chr12:109796872	NA	-0.62	-10.1	-0.49	4.61e-21	Neuroticism;
CRC	cis	rs10971721	0.822	rs10971755	chr9:33872005	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs11212617	0.967	rs11212635	chr11:108310702	T/A	cg01991180	chr11:108092276	ATM;NPAT	-0.4	-5.77	-0.3	1.8e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.5	8.21	0.41	5.03e-15	Lipoprotein (a) levels;
CRC	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.46	-7.45	-0.38	8.4e-13	Refractive error;
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.3	-0.33	9.69e-10	Total body bone mineral density;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02807482	chr3:125708958	NA	-0.46	-5.95	-0.31	6.78e-9	Blood pressure (smoking interaction);
CRC	cis	rs4750440	0.736	rs4748070	chr10:14031388	G/A	cg00551146	chr10:14014579	FRMD4A	0.37	5.96	0.31	6.63e-9	Adiponectin levels;
CRC	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.62	-6.83	-0.35	4.17e-11	Coronary artery disease;
CRC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.15	0.45	6.17e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1816752	0.819	rs4769349	chr13:24982832	A/G	cg02811702	chr13:24901961	NA	-0.4	-5.63	-0.3	3.86e-8	Obesity-related traits;
CRC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg19980929	chr12:42632907	YAF2	0.45	6.6	0.34	1.63e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.63	10.74	0.51	2.96e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg07052231	chr12:7363540	PEX5	-0.48	-7.82	-0.4	7.42e-14	IgG glycosylation;
CRC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg05192639	chr6:26864778	GUSBL1	-0.33	-5.77	-0.3	1.82e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg11833968	chr6:79620685	NA	-0.36	-6.26	-0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg10217327	chr6:118973057	C6orf204	0.52	5.9	0.31	9e-9	Diastolic blood pressure;
CRC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.58	0.43	3.78e-16	Morning vs. evening chronotype;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.51	-6.87	-0.35	3.19e-11	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05596267	chr15:34331198	CHRM5;AVEN	0.38	6.33	0.33	8.07e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.69	10.37	0.5	5.49e-22	Nonalcoholic fatty liver disease;
CRC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.49	-0.34	3.14e-10	Axial length;
CRC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg13390004	chr1:15929781	NA	0.5	7.11	0.37	7.21e-12	Systolic blood pressure;
CRC	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg03037974	chr15:76606532	NA	-0.51	-7.27	-0.37	2.71e-12	Blood metabolite levels;
CRC	trans	rs4853036	0.586	rs7558899	chr2:70010351	T/C	cg14633329	chr9:139640053	LCN6	-0.39	-6.44	-0.33	4.31e-10	Colorectal or endometrial cancer;
CRC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg23533926	chr12:111358616	MYL2	0.46	6.67	0.35	1.1e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.71	11.88	0.55	2.45e-27	Selective IgA deficiency;
CRC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-10.34	-0.5	7.13e-22	Ileal carcinoids;
CRC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg27535305	chr1:53392650	SCP2	-0.38	-6.74	-0.35	6.95e-11	Monocyte count;
CRC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.29	-0.37	2.35e-12	Personality dimensions;
CRC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs72730918	0.564	rs6493511	chr15:51901605	A/G	cg14296394	chr15:51910925	DMXL2	-0.46	-6.0	-0.31	5.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.899	rs1168032	chr1:62967747	A/G	cg19896129	chr1:63156450	NA	-0.39	-6.08	-0.32	3.29e-9	Triglyceride levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10403048	chr19:15490832	AKAP8	0.49	6.29	0.33	1.01e-9	Thyroid stimulating hormone;
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.81	0.61	1.49e-34	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17408923	chr2:109335769	RANBP2	0.44	6.37	0.33	6.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.61	8.87	0.44	4.71e-17	Sudden cardiac arrest;
CRC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.66	-9.34	-0.46	1.53e-18	DNA methylation (variation);
CRC	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.68	-7.81	-0.4	7.5e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.71	-9.34	-0.46	1.48e-18	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.42e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.39	-0.33	5.79e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.66	11.33	0.53	2.44e-25	Height;
CRC	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg15192750	chr16:69999425	NA	-0.47	-6.4	-0.33	5.38e-10	IgE levels;
CRC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.44	6.09	0.32	3.24e-9	Cholesterol, total;
CRC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	0.98	12.83	0.58	7.84e-31	Diabetic kidney disease;
CRC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.5	-8.29	-0.42	2.87e-15	Aortic root size;
CRC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.46	6.85	0.35	3.63e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.48	6.6	0.34	1.65e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.99	0.31	5.36e-9	Height;
CRC	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.74	-0.3	2.18e-8	Subjective well-being;
CRC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.53	7.69	0.39	1.72e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.53	9.5	0.46	4.66e-19	Blood metabolite ratios;
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.5	-0.5	1.96e-22	Bipolar disorder;
CRC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.65	8.78	0.44	9.01e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.52	7.15	0.37	5.69e-12	Schizophrenia;
CRC	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg13385794	chr1:248469461	NA	-0.38	-6.87	-0.35	3.27e-11	Common traits (Other);
CRC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg26666090	chr16:58549219	SETD6	0.95	6.49	0.34	3.24e-10	Schizophrenia;
CRC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.69	-0.57	2.61e-30	Ulcerative colitis;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg15845792	chr6:28175446	NA	0.95	13.94	0.61	5.13e-35	Parkinson's disease;
CRC	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg11204139	chr17:3907470	NA	0.75	14.31	0.62	1.86e-36	Type 2 diabetes;
CRC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.91	17.74	0.7	6.87e-50	Cerebrospinal fluid biomarker levels;
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	13.41	0.59	4.99e-33	Menopause (age at onset);
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg20512303	chr5:131592959	PDLIM4	0.29	5.83	0.31	1.35e-8	Blood metabolite levels;
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.17	-13.55	-0.6	1.59e-33	Diabetic kidney disease;
CRC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.4	9.35	0.46	1.38e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.41	6.7	0.35	8.99e-11	Resting heart rate;
CRC	cis	rs4728302	0.869	rs2042455	chr7:133580545	A/G	cg03336402	chr7:133662267	EXOC4	-0.43	-6.15	-0.32	2.23e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	0.64	6.84	0.35	3.88e-11	Prostate cancer;
CRC	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.78	12.38	0.56	3.84e-29	Mean platelet volume;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.37	-6.28	-0.33	1.09e-9	Longevity;Endometriosis;
CRC	cis	rs12760731	0.623	rs6688546	chr1:178332511	A/G	cg00404053	chr1:178313656	RASAL2	0.75	9.45	0.46	6.51e-19	Obesity-related traits;
CRC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.67	-0.35	1.06e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.21	-0.32	1.58e-9	Gout;Renal underexcretion gout;
CRC	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.76	-0.39	1.09e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.52	-7.16	-0.37	5.28e-12	Tuberculosis;
CRC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21028142	chr17:79581711	NPLOC4	0.33	6.97	0.36	1.77e-11	Eye color traits;
CRC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg10298567	chr3:47292165	KIF9	-0.39	-6.59	-0.34	1.73e-10	Colorectal cancer;
CRC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.52	8.4	0.42	1.38e-15	Body mass index;
CRC	cis	rs62408225	0.894	rs62408218	chr6:90931858	C/T	cg06866423	chr6:90926672	BACH2	0.45	7.16	0.37	5.23e-12	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	8.74	0.43	1.21e-16	Adiposity;
CRC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.43	0.38	9.58e-13	Obesity-related traits;
CRC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs537930	0.560	rs2431151	chr5:134348225	G/T	cg24576358	chr5:134350122	NA	0.32	5.64	0.3	3.58e-8	Height;
CRC	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg04239558	chr2:103089729	SLC9A4	0.38	6.65	0.34	1.25e-10	Blood protein levels;
CRC	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg04969067	chr8:143858791	LYNX1	-0.36	-6.08	-0.32	3.39e-9	Urinary tract infection frequency;
CRC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.8	-0.48	4.62e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.13e-12	Life satisfaction;
CRC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	1.12	13.12	0.59	6.41e-32	Obesity-related traits;
CRC	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg24289452	chr6:170231220	NA	-0.94	-7.59	-0.39	3.43e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.44	-7.0	-0.36	1.49e-11	Type 2 diabetes;
CRC	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.53	7.04	0.36	1.15e-11	Plateletcrit;
CRC	cis	rs4478858	0.602	rs4949370	chr1:31723889	G/C	cg00250761	chr1:31883323	NA	-0.33	-6.14	-0.32	2.4e-9	Alcohol dependence;
CRC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.99	-0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.06	-0.45	1.22e-17	Rheumatoid arthritis;
CRC	trans	rs2163503	0.691	rs847734	chr1:71438092	T/A	cg23933503	chr22:44255884	SULT4A1	-0.42	-6.19	-0.32	1.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.48	0.38	6.67e-13	Motion sickness;
CRC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.41	5.96	0.31	6.57e-9	Red cell distribution width;Reticulocyte count;
CRC	cis	rs7605827	0.930	rs6749663	chr2:15529705	T/G	cg19274914	chr2:15703543	NA	0.38	5.75	0.3	2.01e-8	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06766450	chr1:16766999	NECAP2	0.49	6.94	0.36	2.07e-11	Response to antipsychotic treatment;
CRC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.83	8.32	0.42	2.36e-15	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.43e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.53	-0.47	3.64e-19	Capecitabine sensitivity;
CRC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg23018236	chr17:30244563	NA	-0.65	-7.78	-0.39	9.41e-14	Hip circumference adjusted for BMI;
CRC	cis	rs582297	1	rs582297	chr11:108165407	C/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.07	0.32	3.56e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09696331	chr12:510665	CCDC77	0.46	6.91	0.36	2.6e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-9.19	-0.45	4.55e-18	Alzheimer's disease;
CRC	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.62	8.17	0.41	6.6e-15	Iron status biomarkers;
CRC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg15445000	chr17:37608096	MED1	0.27	5.95	0.31	7.05e-9	Asthma;
CRC	cis	rs9292777	0.814	rs6873829	chr5:40418264	T/G	cg09067459	chr5:40385259	NA	0.53	9.25	0.45	3.02e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs698833	0.859	rs786612	chr2:44600819	G/C	cg04920474	chr2:44395004	PPM1B	0.42	6.11	0.32	2.79e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.5	-6.94	-0.36	2.06e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2305707	0.544	rs34080711	chr15:51561456	G/A	cg02146857	chr19:18901748	COMP	0.5	5.97	0.31	6.03e-9	Height;
CRC	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg15654264	chr1:150340011	RPRD2	0.42	6.4	0.33	5.48e-10	Migraine;
CRC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.63	9.09	0.45	9.45e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14019695	chr9:139328340	INPP5E	0.42	6.18	0.32	1.91e-9	Monocyte percentage of white cells;
CRC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.41	8.88	0.44	4.53e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs9826463	0.818	rs9858204	chr3:142299855	C/T	cg20824294	chr3:142316082	PLS1	0.32	5.78	0.3	1.71e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg20356878	chr3:121714668	ILDR1	-0.47	-7.49	-0.38	6.34e-13	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18789337	chr6:114180353	MARCKS	0.47	6.76	0.35	6.15e-11	Response to antipsychotic treatment;
CRC	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.52	-9.86	-0.48	2.91e-20	Hip circumference;Waist circumference;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02092906	chr6:83903419	PGM3;RWDD2A	0.45	6.15	0.32	2.22e-9	Survival in pancreatic cancer;
CRC	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg18830697	chr6:72922368	RIMS1	0.41	8.25	0.41	3.95e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs972578	0.806	rs738397	chr22:43295271	C/T	cg01576275	chr22:43409880	NA	-0.42	-6.58	-0.34	1.91e-10	Mean platelet volume;
CRC	cis	rs12476592	0.571	rs10865341	chr2:63824050	A/T	cg10828910	chr2:63850056	LOC388955	0.48	5.86	0.31	1.15e-8	Childhood ear infection;
CRC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.04	-0.36	1.14e-11	Colorectal cancer;
CRC	trans	rs4942242	1.000	rs9594987	chr13:44230994	C/T	cg19169023	chr15:41853346	TYRO3	0.53	7.96	0.4	2.73e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs4936891	0.577	rs12225469	chr11:123902719	G/A	cg22125253	chr11:123886957	OR10G4	-0.33	-5.79	-0.3	1.63e-8	Male fertility;
CRC	cis	rs6743376	0.556	rs3820738	chr2:113819439	A/G	cg09040174	chr2:113837401	NA	0.38	5.75	0.3	2.02e-8	Inflammatory biomarkers;
CRC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg18016565	chr1:150552671	MCL1	-0.46	-7.06	-0.36	1.01e-11	Tonsillectomy;
CRC	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.24	6.53	0.34	2.46e-10	Type 2 diabetes;
CRC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	0.98	14.42	0.62	6.85e-37	Breast cancer;
CRC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg12407791	chr17:73824354	UNC13D	0.28	6.37	0.33	6.3e-10	White matter hyperintensity burden;
CRC	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.54	9.1	0.45	9e-18	Facial morphology (factor 15, philtrum width);
CRC	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.64	-0.3	3.69e-8	Type 2 diabetes;
CRC	cis	rs6694672	1.000	rs9427662	chr1:196946775	T/C	cg13682187	chr1:196946512	CFHR5	-0.51	-8.08	-0.41	1.21e-14	Asthma;
CRC	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.6	-0.3	4.47e-8	Blood pressure;
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.77e-9	Life satisfaction;
CRC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg21770322	chr7:97807741	LMTK2	0.53	8.62	0.43	2.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg21854759	chr1:92012499	NA	-0.47	-6.68	-0.35	9.97e-11	Eosinophil percentage of white cells;
CRC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02228675	chr17:40259724	DHX58	0.44	6.07	0.32	3.45e-9	Fibrinogen levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14032529	chr10:114712217	TCF7L2	-0.41	-6.16	-0.32	2.13e-9	Myopia (pathological);
CRC	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.93	-10.98	-0.52	4.09e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.64	10.48	0.5	2.35e-22	Motion sickness;
CRC	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.57	9.81	0.48	4.2e-20	Common traits (Other);
CRC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg10298567	chr3:47292165	KIF9	-0.38	-6.22	-0.32	1.47e-9	Colorectal cancer;
CRC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04476341	chr5:669733	TPPP	0.42	6.88	0.35	3.1e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	14.84	0.63	1.66e-38	Smoking behavior;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12588279	chr6:26043732	HIST1H2BB	0.42	5.86	0.31	1.12e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.61	-0.34	1.52e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.62	-8.05	-0.41	1.56e-14	Body mass index;
CRC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.6	7.36	0.38	1.45e-12	Mean platelet volume;
CRC	cis	rs1158570	0.564	rs2791343	chr8:131316030	C/T	cg26053073	chr8:131455383	NA	0.4	6.21	0.32	1.59e-9	Platelet count;
CRC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.46	6.72	0.35	8.25e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.7	-0.3	2.72e-8	Tonsillectomy;
CRC	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.83	13.79	0.61	1.88e-34	Height;
CRC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.48	0.34	3.45e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg19678392	chr7:94953810	PON1	-0.56	-7.06	-0.36	9.89e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9311676	0.632	rs11923181	chr3:58380569	A/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.7	-11.25	-0.53	4.5e-25	Personality dimensions;
CRC	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.78	-13.69	-0.6	4.3e-34	Lewy body disease;
CRC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg11262906	chr1:85462892	MCOLN2	0.49	7.01	0.36	1.32e-11	Serum sulfate level;
CRC	cis	rs17767392	0.813	rs36052007	chr14:71984705	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.4	-0.33	5.31e-10	Mitral valve prolapse;
CRC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-0.86	-10.3	-0.49	9.82e-22	Monocyte percentage of white cells;
CRC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.49	-7.12	-0.37	6.86e-12	Height;
CRC	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg02741985	chr17:80059408	CCDC57	-0.43	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-7.56	-0.38	4.01e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg16606324	chr3:10149918	C3orf24	0.7	9.64	0.47	1.61e-19	Alzheimer's disease;
CRC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.32	-0.59	1.12e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.56	8.43	0.42	1.12e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23151374	chr4:164415611	C4orf43	0.44	6.23	0.32	1.44e-9	Response to antipsychotic treatment;
CRC	cis	rs12760731	0.582	rs4433354	chr1:178532484	C/T	cg00404053	chr1:178313656	RASAL2	-0.69	-7.64	-0.39	2.42e-13	Obesity-related traits;
CRC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6604026	0.671	rs6697543	chr1:93312295	C/A	cg17283838	chr1:93427260	FAM69A	-0.48	-6.86	-0.35	3.37e-11	Multiple sclerosis;
CRC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.88	0.35	3.1e-11	Morning vs. evening chronotype;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.87	-19.96	-0.74	1.28e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.8	-0.4	8.23e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg22495460	chr2:25135724	ADCY3	-0.72	-11.6	-0.54	2.51e-26	Body mass index;
CRC	cis	rs4740619	0.619	rs4741560	chr9:16043170	C/T	cg14451791	chr9:16040625	NA	0.23	5.69	0.3	2.86e-8	Body mass index;
CRC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-0.93	-10.56	-0.5	1.18e-22	Breast cancer;
CRC	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.81	-13.96	-0.61	4.09e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-9.73	-0.47	7.99e-20	Menarche (age at onset);
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23708337	chr7:1209742	NA	0.39	5.9	0.31	8.79e-9	Longevity;Endometriosis;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg02683197	chr6:28174875	NA	0.79	9.62	0.47	1.8e-19	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26145502	chr1:8939074	ENO1	0.37	6.15	0.32	2.26e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.44	6.37	0.33	6.55e-10	Body mass index;
CRC	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	21.85	0.77	5.07e-66	Colorectal cancer;
CRC	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24249390	chr15:90295951	MESP1	-0.59	-9.58	-0.47	2.51e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg03160526	chr17:80928410	B3GNTL1	0.49	8.05	0.41	1.52e-14	Breast cancer;
CRC	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.85	13.75	0.6	2.63e-34	Multiple myeloma;
CRC	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.23	-0.37	3.34e-12	Capecitabine sensitivity;
CRC	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.74	11.72	0.54	9.84e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg04165759	chr1:150448943	RPRD2	0.36	5.87	0.31	1.05e-8	Migraine;
CRC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.13	0.32	2.57e-9	Tonsillectomy;
CRC	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.83	-7.54	-0.38	4.63e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.45	-6.25	-0.33	1.27e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg24560729	chr4:1342394	KIAA1530	0.34	6.27	0.33	1.1e-9	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25671651	chr2:203776787	ALS2CR8;WDR12	0.48	6.29	0.33	1.01e-9	Thyroid stimulating hormone;
CRC	cis	rs727505	0.826	rs11532793	chr7:124747952	A/G	cg23710748	chr7:124431027	NA	-0.72	-11.95	-0.55	1.45e-27	Lewy body disease;
CRC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.68	0.3	3.01e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.81	13.55	0.6	1.51e-33	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.77	-7.8	-0.4	8.22e-14	Obesity;Body mass index;
CRC	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg16558208	chr1:156270281	VHLL	0.58	9.08	0.45	1.03e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.56	8.62	0.43	2.78e-16	Diastolic blood pressure;
CRC	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.58	-8.13	-0.41	8.78e-15	Carotid intima media thickness;
CRC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.41	5.72	0.3	2.33e-8	Renal cell carcinoma;
CRC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.57	9.54	0.47	3.41e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.76	16.13	0.66	1.56e-43	Age-related hearing impairment;
CRC	cis	rs3020333	1.000	rs3020333	chr6:152010254	A/G	cg22157087	chr6:152012887	ESR1	0.51	7.55	0.38	4.21e-13	Total body bone mineral density;
CRC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.72	9.71	0.47	9.39e-20	Cognitive function;
CRC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.62	-0.3	4.17e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.98	-0.31	5.9e-9	Height;
CRC	cis	rs2070997	0.756	rs3824400	chr9:133734075	A/G	cg01000188	chr9:133769184	QRFP	-0.52	-6.13	-0.32	2.53e-9	Response to amphetamines;
CRC	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg14664628	chr15:75095509	CSK	0.44	6.18	0.32	1.9e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.67	10.83	0.51	1.46e-23	Cognitive test performance;
CRC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.49e-12	Life satisfaction;
CRC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.44	6.72	0.35	8.13e-11	Mean platelet volume;
CRC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-14.52	-0.62	3.04e-37	Prostate cancer;
CRC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.68	-8.5	-0.42	6.71e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-9.1	-0.45	8.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.62	-8.62	-0.43	2.77e-16	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10178094	0.528	rs62175963	chr2:161339964	T/C	cg03641300	chr2:160917029	PLA2R1	-0.45	-6.11	-0.32	2.77e-9	White blood cell count;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.49e-10	Depression;
CRC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.42	-6.43	-0.33	4.42e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.32	5.68	0.3	2.94e-8	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.53e-8	Blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27054308	chr14:20922865	APEX1;OSGEP	0.49	7.17	0.37	4.91e-12	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00495681	chr13:53174319	NA	0.62	9.28	0.46	2.26e-18	Lewy body disease;
CRC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg22535103	chr8:58192502	C8orf71	-0.52	-6.32	-0.33	8.67e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.17	-0.32	2.03e-9	Daytime sleep phenotypes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15312298	chr8:127570908	FAM84B	0.41	6.15	0.32	2.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg07404485	chr7:94953653	PON1	-0.45	-5.93	-0.31	7.79e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.48	-0.42	7.77e-16	Monocyte count;
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg15105011	chr4:940614	TMEM175	0.55	9.11	0.45	8.44e-18	Sjögren's syndrome;
CRC	cis	rs2062225	1.000	rs1157455	chr2:111760081	G/A	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg21839984	chr17:30846986	MYO1D	0.34	5.7	0.3	2.6e-8	Schizophrenia;
CRC	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg01557791	chr16:72042693	DHODH	-0.55	-5.9	-0.31	8.98e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs6445525	1.000	rs4416407	chr3:65995747	T/C	cg06109867	chr3:66002991	MAGI1	-0.39	-6.41	-0.33	5e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.15	-0.32	2.19e-9	Alzheimer's disease (late onset);
CRC	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.38	-0.71	2.03e-52	Schizophrenia;
CRC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.63	-0.34	1.36e-10	Coronary artery disease;
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg03623178	chr6:28175578	NA	0.79	6.96	0.36	1.89e-11	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18318636	chr17:56591750	MTMR4	0.46	6.75	0.35	6.68e-11	Response to antipsychotic treatment;
CRC	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg20737812	chr15:86336631	KLHL25	-0.49	-7.34	-0.38	1.66e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.94	-0.31	7.07e-9	Calcium levels;
CRC	cis	rs1511802	0.666	rs4862662	chr4:187118662	A/C	cg24794857	chr4:187113578	CYP4V2	-0.39	-5.79	-0.3	1.62e-8	Blood protein levels;
CRC	cis	rs8141797	0.901	rs76376425	chr22:24523177	C/T	cg20894457	chr22:24584366	SUSD2	0.65	6.83	0.35	4.08e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.32	-0.37	1.96e-12	Major depressive disorder;
CRC	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg08890418	chr1:21044141	KIF17	-0.33	-6.17	-0.32	2.04e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg06484146	chr7:12443880	VWDE	-0.75	-6.47	-0.34	3.48e-10	Coronary artery disease;
CRC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20782850	chr6:117002205	KPNA5	0.44	5.96	0.31	6.48e-9	Survival in pancreatic cancer;
CRC	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.55	7.34	0.38	1.67e-12	Adiposity;
CRC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg23262073	chr20:60523788	NA	-0.4	-6.88	-0.35	2.98e-11	Body mass index;
CRC	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.44	6.47	0.34	3.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9322817	0.691	rs6907016	chr6:105211360	G/A	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.37e-16	Thyroid stimulating hormone;
CRC	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.09	0.41	1.14e-14	Corneal astigmatism;
CRC	cis	rs2859741	0.565	rs12023397	chr1:37507739	G/A	cg09363841	chr1:37513479	NA	-0.48	-7.46	-0.38	7.6e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.82	9.94	0.48	1.53e-20	Iron status biomarkers;
CRC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07165851	chr6:158734300	TULP4	0.61	7.76	0.39	1.11e-13	Height;
CRC	cis	rs9925964	0.967	rs889548	chr16:31137712	A/G	cg10396673	chr16:31104726	VKORC1	-0.34	-5.61	-0.3	4.24e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.84	-0.4	6.24e-14	Total cholesterol levels;
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg22561889	chr6:118971681	C6orf204	0.51	6.58	0.34	1.84e-10	Renal cell carcinoma;
CRC	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg25382214	chr1:3105252	PRDM16	0.42	6.85	0.35	3.74e-11	Migraine;
CRC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.86	-14.45	-0.62	5.68e-37	Body mass index;
CRC	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg04202892	chr2:111875749	ACOXL	0.48	7.88	0.4	4.69e-14	Chronic lymphocytic leukemia;
CRC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.63	9.22	0.45	3.58e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg23565292	chr14:50234668	KLHDC2	-0.43	-6.16	-0.32	2.14e-9	Carotid intima media thickness;
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg07332563	chr6:291687	DUSP22	-0.49	-6.99	-0.36	1.57e-11	Menopause (age at onset);
CRC	trans	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg07393940	chr7:158741817	NA	-0.52	-7.43	-0.38	9.26e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24677674	chr10:113943468	GPAM	0.45	6.24	0.33	1.31e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.79	-0.3	1.65e-8	Life satisfaction;
CRC	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg14074117	chr16:1909714	C16orf73	0.35	6.02	0.32	4.53e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg15147215	chr3:52552868	STAB1	-0.61	-10.04	-0.48	7.46e-21	Bipolar disorder;
CRC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.58	8.18	0.41	6.07e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.48	7.64	0.39	2.37e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.32	0.33	8.69e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8060686	0.623	rs255049	chr16:68013471	T/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-10.45	-0.5	2.85e-22	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg19508488	chr2:152266495	RIF1	0.49	6.2	0.32	1.68e-9	Squamous cell lung carcinoma;
CRC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.55	-8.22	-0.41	4.78e-15	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24218995	chr18:67873134	RTTN	0.41	6.07	0.32	3.52e-9	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.62	7.76	0.39	1.12e-13	Gut microbiome composition (summer);
CRC	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.63	-8.54	-0.43	4.95e-16	Extraversion;
CRC	trans	rs2303319	0.582	rs12464282	chr2:162448855	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.17	-0.32	2.06e-9	Cognitive function;
CRC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-0.67	-7.14	-0.37	6.12e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg10760299	chr15:45669010	GATM	0.49	7.79	0.39	8.71e-14	Homoarginine levels;
CRC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg15448220	chr1:150897856	SETDB1	-0.44	-6.29	-0.33	1.04e-9	Blood protein levels;
CRC	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.79	8.48	0.42	7.89e-16	Migraine;Coronary artery disease;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02290350	chr8:58132656	NA	-0.5	-6.18	-0.32	1.95e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg00852783	chr1:26633632	UBXN11	-0.45	-5.89	-0.31	9.65e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12760731	0.920	rs9658883	chr1:178480315	A/G	cg00404053	chr1:178313656	RASAL2	0.57	6.85	0.35	3.65e-11	Obesity-related traits;
CRC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.69	-8.26	-0.41	3.72e-15	Initial pursuit acceleration;
CRC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.99	12.45	0.57	1.96e-29	Cerebrospinal P-tau181p levels;
CRC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg16141378	chr3:129829833	LOC729375	0.49	7.48	0.38	6.65e-13	Neuroticism;
CRC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.58	-8.79	-0.44	8.58e-17	Body mass index;
CRC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.63	7.89	0.4	4.52e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.89	-0.48	2.23e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.68	-12.18	-0.56	1.93e-28	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26301297	chr10:123734889	NSMCE4A	0.51	7.52	0.38	5.35e-13	Response to antipsychotic treatment;
CRC	trans	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg24644049	chr4:85504048	CDS1	-0.68	-7.04	-0.36	1.16e-11	Skin colour saturation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10243787	chr22:19419481	HIRA;MRPL40	0.45	6.47	0.34	3.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08219700	chr8:58056026	NA	0.58	6.69	0.35	9.52e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12273811	chr6:28175739	NA	0.7	8.79	0.44	8.29e-17	Depression;
CRC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.61	10.33	0.49	7.69e-22	Resting heart rate;
CRC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs72772090	0.539	rs11742261	chr5:96167608	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.88	-0.31	1.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10991814	0.844	rs58307373	chr9:94070782	T/C	cg14446406	chr9:93919335	NA	0.5	5.94	0.31	7.43e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.45	-0.34	3.95e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23161317	chr6:28129485	ZNF389	-0.46	-6.03	-0.32	4.44e-9	Depression;
CRC	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.72	-0.3	2.38e-8	Coronary artery disease;
CRC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.84	-0.31	1.25e-8	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07833644	chr2:27440142	CAD	0.46	6.64	0.34	1.3e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.23	-0.53	5.45e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.9	0.55	2.04e-27	Exhaled nitric oxide levels;
CRC	cis	rs16936870	0.571	rs7003804	chr8:71089631	T/C	cg14232793	chr8:71155543	NCOA2	-0.47	-5.64	-0.3	3.76e-8	QT interval;
CRC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25533220	chr19:2328480	SPPL2B;LSM7	0.48	6.18	0.32	1.94e-9	Thyroid stimulating hormone;
CRC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg19622623	chr12:86230825	RASSF9	-0.37	-5.73	-0.3	2.33e-8	Major depressive disorder;
CRC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.75	0.35	6.87e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.09	13.49	0.6	2.65e-33	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07394347	chr3:37285773	GOLGA4	0.45	6.68	0.35	9.92e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26850624	chr5:429559	AHRR	-0.77	-12.55	-0.57	8.53e-30	Cystic fibrosis severity;
CRC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.67	8.8	0.44	7.66e-17	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00242285	chr3:124480225	NA	0.45	6.62	0.34	1.43e-10	Response to antipsychotic treatment;
CRC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.42	-0.46	8.15e-19	Monocyte count;
CRC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.48	8.9	0.44	3.69e-17	Common traits (Other);
CRC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.36	12.67	0.57	3e-30	Cognitive function;
CRC	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	0.89	8.7	0.43	1.67e-16	Arsenic metabolism;
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	5.96	0.31	6.34e-9	Prudent dietary pattern;
CRC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg11189052	chr15:85197271	WDR73	0.58	7.58	0.39	3.65e-13	Schizophrenia;
CRC	cis	rs11583043	0.546	rs35363849	chr1:101591293	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.79	0.3	1.68e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs282587	0.569	rs390657	chr13:113415085	A/G	cg04656015	chr13:113407548	ATP11A	0.59	7.56	0.38	3.96e-13	Glycated hemoglobin levels;
CRC	cis	rs3857067	0.934	rs2865336	chr4:95029357	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.66	-0.3	3.27e-8	QT interval;
CRC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.37	6.58	0.34	1.86e-10	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs9649465	0.806	rs6971297	chr7:123293342	A/T	cg03229431	chr7:123269106	ASB15	-0.38	-5.77	-0.3	1.86e-8	Migraine;
CRC	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	0.95	7.08	0.36	8.73e-12	Plateletcrit;
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg06074448	chr4:187884817	NA	-0.59	-10.72	-0.51	3.34e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.56	-8.18	-0.41	6.15e-15	Longevity;
CRC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg08648136	chr8:956695	NA	0.3	6.03	0.32	4.3e-9	Schizophrenia;
CRC	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg10217327	chr6:118973057	C6orf204	0.46	5.66	0.3	3.34e-8	Renal cell carcinoma;
CRC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg15123519	chr2:136567270	LCT	0.3	5.74	0.3	2.12e-8	Corneal structure;
CRC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.38	-6.53	-0.34	2.44e-10	Reticulocyte fraction of red cells;
CRC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.53	11.5	0.54	5.83e-26	Alcohol dependence;
CRC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	0.84	7.63	0.39	2.54e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	10.04	0.48	7.27e-21	Systolic blood pressure;
CRC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.65	-7.6	-0.39	3.09e-13	Diabetic retinopathy;
CRC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg24375607	chr4:120327624	NA	0.49	7.83	0.4	6.9e-14	Corneal astigmatism;
CRC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.4	0.38	1.15e-12	Lung cancer;
CRC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg13072238	chr3:49761600	GMPPB	-0.52	-5.92	-0.31	8.06e-9	Menarche (age at onset);
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	cis	rs17767392	0.881	rs7152674	chr14:72016613	G/T	cg13720639	chr14:72061746	SIPA1L1	0.51	6.64	0.34	1.3100000000000001e-10	Mitral valve prolapse;
CRC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-6.73	-0.35	7.37e-11	Schizophrenia;
CRC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.59	-9.09	-0.45	9.28e-18	Body mass index;
CRC	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.02	-20.96	-0.76	1.47e-62	Primary sclerosing cholangitis;
CRC	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.69	-0.43	1.72e-16	Coronary artery disease;
CRC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.46	6.98	0.36	1.64e-11	Corneal astigmatism;
CRC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg21770322	chr7:97807741	LMTK2	0.68	12.1	0.55	3.94e-28	Breast cancer;
CRC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.78	11.44	0.53	9.89e-26	Neutrophil percentage of white cells;
CRC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.38	6.1	0.32	2.91e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg16476235	chr8:21771668	DOK2	0.37	6.25	0.33	1.29e-9	Mean corpuscular volume;
CRC	trans	rs10789207	0.531	rs20354	chr1:67071356	G/T	cg12612336	chr17:74350433	PRPSAP1	0.59	5.96	0.31	6.5e-9	Resting heart rate;
CRC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.37	-5.94	-0.31	7.1e-9	Iron status biomarkers;
CRC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.91	14.15	0.62	7.73e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg13043300	chr11:71146211	DHCR7	-0.43	-5.82	-0.31	1.36e-8	Vitamin D levels;
CRC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.42	0.46	8.44e-19	Parkinson's disease;
CRC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg15845792	chr6:28175446	NA	0.54	7.78	0.39	9.25e-14	Pubertal anthropometrics;
CRC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg21972741	chr5:435613	AHRR	0.46	6.1	0.32	3.01e-9	Cystic fibrosis severity;
CRC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg07884673	chr3:53033167	SFMBT1	0.76	6.13	0.32	2.45e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.7	0.35	8.89e-11	Lung cancer;
CRC	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.72	-12.91	-0.58	3.97e-31	White blood cell count (basophil);
CRC	cis	rs10971721	0.749	rs72725375	chr9:33840704	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09300324	chr12:132568690	EP400NL	-0.37	-6.12	-0.32	2.72e-9	Obesity-related traits;
CRC	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg03929089	chr4:120376271	NA	0.63	6.15	0.32	2.29e-9	Axial length;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08263226	chr1:23881409	NA	0.39	6.22	0.32	1.54e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.7	-0.39	1.65e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs294883	0.826	rs447615	chr6:159698751	G/T	cg14500486	chr6:159655392	FNDC1	-0.36	-5.82	-0.31	1.4e-8	Coronary artery disease;
CRC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.54	8.39	0.42	1.5e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg23996704	chr18:44553084	KATNAL2	0.41	7.85	0.4	5.84e-14	Personality dimensions;
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.53	8.01	0.4	1.99e-14	Educational attainment;
CRC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.37	-6.97	-0.36	1.73e-11	Mean corpuscular volume;
CRC	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-6.57	-0.34	1.99e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.8	-11.79	-0.54	5.51e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.03	0.36	1.19e-11	Obesity-related traits;
CRC	trans	rs6956675	1.000	rs10231112	chr7:62601257	A/G	cg01314568	chr7:57830625	NA	-0.7	-9.59	-0.47	2.31e-19	Obesity-related traits;
CRC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.06	9.98	0.48	1.12e-20	Opioid sensitivity;
CRC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg00316803	chr15:76480434	C15orf27	-0.36	-5.82	-0.31	1.39e-8	Blood metabolite levels;
CRC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.9	-0.4	4.09e-14	Cystic fibrosis severity;
CRC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.09e-15	Platelet count;
CRC	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.42	-5.89	-0.31	9.39e-9	Diastolic blood pressure;
CRC	cis	rs6496667	0.779	rs7163632	chr15:91039020	C/T	cg04176472	chr15:90893244	GABARAPL3	0.53	7.64	0.39	2.33e-13	Rheumatoid arthritis;
CRC	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.49	7.69	0.39	1.73e-13	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-7.41	-0.38	1.1e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.57	-6.24	-0.33	1.33e-9	Coronary artery disease;
CRC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.61	-10.98	-0.52	4.01e-24	Schizophrenia;
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg09264619	chr17:80180166	NA	-0.36	-5.99	-0.31	5.51e-9	Life satisfaction;
CRC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.47	6.51	0.34	2.78e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg17724175	chr1:150552817	MCL1	-0.38	-5.77	-0.3	1.8e-8	Tonsillectomy;
CRC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.61	-8.22	-0.41	4.74e-15	Menarche (age at onset);
CRC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg05501817	chr11:14380813	RRAS2	-0.43	-5.84	-0.31	1.28e-8	Sense of smell;
CRC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-9.55	-0.47	3.07e-19	Hip circumference adjusted for BMI;
CRC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.9	16.65	0.68	1.38e-45	Intelligence (multi-trait analysis);
CRC	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg06781209	chr11:61594997	FADS2	-0.38	-5.7	-0.3	2.61e-8	Trans fatty acid levels;
CRC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-13.29	-0.59	1.49e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg11189052	chr15:85197271	WDR73	0.64	9.3	0.46	1.97e-18	Schizophrenia;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg03315344	chr16:75512273	CHST6	-0.5	-6.05	-0.32	3.99e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.66	-9.72	-0.47	8.53e-20	DNA methylation (variation);
CRC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.39	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg19894588	chr14:64061835	NA	0.41	5.99	0.31	5.52e-9	Glioblastoma;Glioma;
CRC	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.08	14.73	0.63	4.38e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg23920097	chr1:209922102	NA	-0.52	-6.59	-0.34	1.72e-10	Red blood cell count;
CRC	cis	rs4731207	0.735	rs720616	chr7:124452961	A/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg12908607	chr1:44402522	ARTN	-0.35	-5.99	-0.31	5.56e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-7.67	-0.39	1.98e-13	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12982440	chr20:36661586	RPRD1B;KIAA0406	0.5	6.48	0.34	3.27e-10	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.43	6.89	0.36	2.79e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9463078	0.838	rs9357470	chr6:45065613	C/T	cg25276700	chr6:44698697	NA	-0.29	-6.99	-0.36	1.55e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg15382696	chr6:118971807	C6orf204	0.6	7.72	0.39	1.38e-13	Diastolic blood pressure;
CRC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs728616	1.000	rs728615	chr10:81848089	G/A	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.55	-0.34	2.18e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg16235748	chr6:149772707	ZC3H12D	0.35	6.23	0.33	1.39e-9	Dupuytren's disease;
CRC	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg21466736	chr12:48725269	NA	0.45	6.99	0.36	1.54e-11	Plateletcrit;
CRC	trans	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.66	0.34	1.14e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.32	-6.6	-0.34	1.6e-10	Cutaneous nevi;
CRC	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.55	-6.28	-0.33	1.07e-9	Post bronchodilator FEV1;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.41	6.37	0.33	6.34e-10	Electroencephalogram traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02273166	chr14:105487914	CDCA4	0.43	6.15	0.32	2.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.72	-11.79	-0.54	5.33e-27	Breast cancer;
CRC	trans	rs2303319	0.582	rs62187614	chr2:162436285	C/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.0	-0.31	5.13e-9	Cognitive function;
CRC	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.76	-6.72	-0.35	8.2e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11212617	0.935	rs227055	chr11:108261261	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.33	0.33	7.86e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg23942311	chr14:51606299	NA	0.84	17.26	0.69	5.3e-48	Cancer;
CRC	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.78	-0.3	1.77e-8	Type 2 diabetes;
CRC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.06	0.48	6.25e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.37	0.33	6.35e-10	Height;
CRC	cis	rs16852403	0.517	rs12733805	chr1:178249853	C/A	cg00404053	chr1:178313656	RASAL2	0.48	6.12	0.32	2.7e-9	Childhood ear infection;
CRC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg10589385	chr1:150898437	SETDB1	0.31	6.47	0.34	3.52e-10	Melanoma;
CRC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.1	0.41	1.06e-14	Menopause (age at onset);
CRC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.35	-0.38	1.59e-12	Total body bone mineral density;
CRC	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg07166546	chr14:35805898	NA	-0.3	-6.04	-0.32	4.1e-9	Hip circumference adjusted for BMI;
CRC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg03609598	chr5:56110824	MAP3K1	0.67	7.88	0.4	4.91e-14	Initial pursuit acceleration;
CRC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-14.37	-0.62	1.14e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.52	-6.83	-0.35	4.13e-11	Coronary artery disease;
CRC	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.67	7.4	0.38	1.18e-12	Inflammatory bowel disease;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs2257205	0.667	rs7211439	chr17:56847832	A/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.52	-5.76	-0.3	1.96e-8	Schizophrenia;
CRC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.08	0.45	1.04e-17	Menarche (age at onset);
CRC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	cis	rs4664293	0.867	rs13415025	chr2:160586310	C/T	cg08347373	chr2:160653686	CD302	-0.47	-7.52	-0.38	5.31e-13	Monocyte percentage of white cells;
CRC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	cis	rs883565	0.502	rs4374473	chr3:38942618	C/T	cg01426195	chr3:39028469	NA	0.38	6.37	0.33	6.34e-10	Handedness;
CRC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.72	-0.43	1.37e-16	Hemoglobin concentration;
CRC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg23815491	chr16:72088622	HP	0.51	7.9	0.4	4.32e-14	Fibrinogen levels;
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.48	-7.08	-0.36	8.88e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.47	-0.34	3.52e-10	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg14008862	chr17:28927542	LRRC37B2	0.5	6.08	0.32	3.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07822143	chr4:146019674	ABCE1;ANAPC10	0.42	6.16	0.32	2.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.37	-5.84	-0.31	1.26e-8	Inflammatory bowel disease;
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	13.32	0.59	1.17e-32	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg25985355	chr7:65971099	NA	-0.49	-5.87	-0.31	1.05e-8	Diabetic kidney disease;
CRC	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.51	8.65	0.43	2.36e-16	Dupuytren's disease;
CRC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	8.06	0.41	1.44e-14	Cognitive test performance;
CRC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.48	-0.71	8.63e-53	Height;
CRC	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.08	-9.67	-0.47	1.28e-19	Mitochondrial DNA levels;
CRC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.72	8.69	0.43	1.76e-16	Type 2 diabetes nephropathy;
CRC	cis	rs3812111	0.524	rs12193094	chr6:116540395	C/T	cg18764771	chr6:116381957	FRK	0.25	5.89	0.31	9.61e-9	Age-related macular degeneration;
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.56	0.38	4.01e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.65	7.68	0.39	1.79e-13	Ulcerative colitis;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg20615401	chr6:28092323	ZSCAN16	0.46	6.07	0.32	3.55e-9	Cardiac Troponin-T levels;
CRC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.69	11.56	0.54	3.73e-26	Alzheimer's disease (late onset);
CRC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.73e-9	Colorectal cancer;
CRC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.86	-15.13	-0.64	1.24e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg20542592	chr8:11973495	FAM66D	0.33	5.79	0.3	1.6e-8	Retinal vascular caliber;
CRC	cis	rs7917772	0.715	rs7077678	chr10:104438565	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.71	0.39	1.55e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04004882	chr2:215674386	BARD1	0.48	6.31	0.33	9.24e-10	Neuroblastoma;
CRC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.52	0.34	2.6e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.61	9.23	0.45	3.43e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.69	-0.35	9.81e-11	Coronary artery disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12277888	chr11:35723985	TRIM44	-0.42	-6.88	-0.35	2.95e-11	Interleukin-6 levels;
CRC	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.82	0.44	6.72e-17	Coffee consumption (cups per day);
CRC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.59	9.84	0.48	3.36e-20	Mean corpuscular volume;
CRC	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg06917450	chr1:38156652	C1orf109	0.46	6.67	0.35	1.06e-10	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg10589385	chr1:150898437	SETDB1	0.31	6.31	0.33	9.16e-10	Melanoma;
CRC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.76	0.35	6.43e-11	Morning vs. evening chronotype;
CRC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg14541582	chr5:601475	NA	-0.37	-7.19	-0.37	4.49e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg24562669	chr7:97807699	LMTK2	0.45	7.63	0.39	2.6e-13	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	ch.1.4829111R	chr1:242658279	PLD5	0.4	5.97	0.31	6.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.55	8.11	0.41	1.05e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.45	-6.74	-0.35	7.17e-11	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg07507251	chr3:52567010	NT5DC2	0.39	5.73	0.3	2.31e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.52	-0.34	2.68e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg08501292	chr6:25962987	TRIM38	1.08	9.05	0.45	1.3e-17	Autism spectrum disorder or schizophrenia;
CRC	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.61	-0.34	1.58e-10	Vitamin D levels;
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg13047869	chr3:10149882	C3orf24	0.53	7.61	0.39	2.93e-13	Alzheimer's disease;
CRC	cis	rs6589219	0.908	rs7103178	chr11:111165009	C/T	cg25129781	chr11:111156908	C11orf53	-0.31	-5.82	-0.31	1.41e-8	Colorectal cancer;
CRC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.64e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.52	-9.73	-0.47	8.06e-20	Schizophrenia;
CRC	trans	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg17903999	chr18:56338584	MALT1	0.42	7.01	0.36	1.37e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.34	-0.38	1.7e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs12286929	0.780	rs2187986	chr11:115001410	C/T	cg04055981	chr11:115044050	NA	0.37	5.8	0.3	1.54e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg13540147	chr9:140131233	NA	0.41	6.02	0.31	4.56e-9	Interleukin-6 levels;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.82	13.01	0.58	1.61e-31	Menarche (age at onset);
CRC	cis	rs7605827	0.930	rs10929375	chr2:15684483	A/G	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.65	-10.41	-0.5	3.86e-22	Monocyte percentage of white cells;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.42	-5.92	-0.31	8.23e-9	Longevity;Endometriosis;
CRC	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-7.03	-0.36	1.23e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.48	-6.77	-0.35	6.05e-11	Height;
CRC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg23229984	chr5:148520753	ABLIM3	0.5	6.83	0.35	4.04e-11	Breast cancer;
CRC	cis	rs28493229	0.708	rs111410535	chr19:41158441	C/T	cg21869046	chr19:41225005	ITPKC	0.42	6.39	0.33	5.78e-10	Kawasaki disease;
CRC	cis	rs6763159	0.566	rs9876719	chr3:59654569	G/A	cg07069742	chr3:59644285	NA	-0.46	-8.63	-0.43	2.65e-16	Conotruncal heart defects;
CRC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-5.91	-0.31	8.49e-9	IgG glycosylation;
CRC	cis	rs3932549	1	rs3932549	chr9:97073588	A/C	cg04523069	chr9:97136363	HIATL1	-0.37	-5.63	-0.3	3.95e-8	Body mass index;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg01842685	chr12:56123602	CD63	-0.45	-6.42	-0.33	4.87e-10	Schizophrenia;
CRC	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.47	6.43	0.33	4.37e-10	Menarche (age at onset);
CRC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23463467	chr20:60627584	TAF4	0.36	6.4	0.33	5.45e-10	Body mass index;
CRC	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	8.79	0.44	8.6e-17	Pulse pressure;
CRC	trans	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg22545385	chr10:131989303	NA	-0.43	-6.3	-0.33	9.34e-10	Coronary artery disease;
CRC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.17	0.45	5.14e-18	Lymphocyte counts;
CRC	cis	rs3790844	0.613	rs12030331	chr1:200001547	G/A	cg07208853	chr1:200005219	NR5A2	0.35	8.82	0.44	6.67e-17	Pancreatic cancer;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg00603274	chr11:61596626	FADS2	-0.86	-10.31	-0.49	9.08e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs62432291	0.681	rs404435	chr6:159654487	G/T	cg14500486	chr6:159655392	FNDC1	-0.77	-10.45	-0.5	3.02e-22	Joint mobility (Beighton score);
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.22e-9	Life satisfaction;
CRC	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-6.17	-0.32	2.01e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4731207	0.596	rs10256218	chr7:124609982	C/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg09877947	chr5:131593287	PDLIM4	0.44	7.22	0.37	3.68e-12	Acylcarnitine levels;
CRC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.68	-8.56	-0.43	4.35e-16	Mean platelet volume;
CRC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.36	6.09	0.32	3.1e-9	Major depressive disorder;
CRC	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg01951491	chr16:67709440	GFOD2	-0.45	-5.66	-0.3	3.36e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.54	7.76	0.39	1.11e-13	Lung cancer;
CRC	cis	rs10746514	0.804	rs1854822	chr1:232262270	G/C	cg09506761	chr1:232265262	NA	-0.46	-6.67	-0.34	1.11e-10	Response to statin therapy;
CRC	cis	rs7932354	0.528	rs4752957	chr11:47125632	T/G	cg03339077	chr11:47165057	C11orf49	0.45	6.31	0.33	8.83e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.52	9.27	0.45	2.57e-18	Blood metabolite ratios;
CRC	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.21	-0.37	3.98e-12	HDL cholesterol;
CRC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg26566898	chr11:117069891	TAGLN	0.27	5.85	0.31	1.2e-8	Blood protein levels;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24910938	chr20:47835804	DDX27	-0.48	-6.56	-0.34	2.13e-10	Monocyte percentage of white cells;
CRC	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.66	9.15	0.45	6.11e-18	Systemic lupus erythematosus;
CRC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.01	-0.48	9.28e-21	Height;
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.54	-7.95	-0.4	3.04e-14	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.61	8.23	0.41	4.33e-15	Coronary artery disease;
CRC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	11.1	0.52	1.55e-24	Monocyte percentage of white cells;
CRC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.59	9.01	0.45	1.66e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg14008862	chr17:28927542	LRRC37B2	0.56	5.8	0.3	1.6e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9925964	0.933	rs749671	chr16:31088347	G/A	cg03418659	chr16:31128414	MYST1	0.5	6.94	0.36	2.07e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4903604	0.581	rs12879719	chr14:78035253	C/A	cg18872420	chr14:78023429	SPTLC2	0.34	5.92	0.31	7.9e-9	Gut microbiome composition (winter);
CRC	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg15212455	chr7:39170539	POU6F2	0.45	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs6952808	0.724	rs7792631	chr7:1982779	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.02	-0.36	1.25e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.38	-5.69	-0.3	2.85e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	trans	rs4714291	0.775	rs2949019	chr6:40051200	C/T	cg02267698	chr19:7991119	CTXN1	-0.51	-7.05	-0.36	1.05e-11	Strep throat;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15665968	chr21:44527764	U2AF1	0.46	6.49	0.34	3.21e-10	Anxiety disorder;
CRC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg15445000	chr17:37608096	MED1	-0.36	-6.33	-0.33	7.84e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04733989	chr22:42467013	NAGA	0.41	5.69	0.3	2.86e-8	Cognitive function;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.53	7.15	0.37	5.67e-12	Alzheimer's disease;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg12172441	chr6:28176163	NA	0.55	6.55	0.34	2.16e-10	Parkinson's disease;
CRC	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.69	7.2	0.37	4.09e-12	Blood protein levels;
CRC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg10802521	chr3:52805072	NEK4	-0.47	-6.25	-0.33	1.28e-9	Schizophrenia;
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-10.94	-0.52	5.89e-24	Alzheimer's disease;
CRC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.67	-8.76	-0.43	1.05e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.51	-6.43	-0.33	4.53e-10	Body mass index;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg23161317	chr6:28129485	ZNF389	0.43	6.06	0.32	3.76e-9	Cardiac Troponin-T levels;
CRC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.25	-0.37	3.03e-12	Bladder cancer;
CRC	cis	rs501120	0.564	rs2802482	chr10:44675851	A/G	cg09554077	chr10:44749378	NA	0.5	6.91	0.36	2.6e-11	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.18	-0.37	4.55e-12	Life satisfaction;
CRC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg25962774	chr5:176831364	F12	0.42	5.99	0.31	5.61e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.53	5.74	0.3	2.2e-8	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01525597	chr12:1739061	WNT5B	0.47	6.9	0.36	2.61e-11	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.81	-13.15	-0.59	4.86e-32	Height;
CRC	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.47	7.65	0.39	2.24e-13	Schizophrenia;
CRC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg09779027	chr19:7224513	INSR	1.0	21.42	0.76	2.46e-64	Hypothyroidism;
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.13e-22	Prudent dietary pattern;
CRC	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.44	6.68	0.35	1.05e-10	HDL cholesterol;
CRC	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	10.06	0.49	6.18e-21	Monocyte count;
CRC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02228675	chr17:40259724	DHX58	-0.5	-7.01	-0.36	1.38e-11	Fibrinogen levels;
CRC	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.3	1.75e-8	Response to antipsychotic treatment;
CRC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg07404485	chr7:94953653	PON1	-0.43	-5.64	-0.3	3.62e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06880365	chr19:36870044	NA	0.4	6.57	0.34	1.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.59	10.5	0.5	1.88e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg25214090	chr10:38739885	LOC399744	0.4	6.06	0.32	3.72e-9	Diastolic blood pressure;
CRC	cis	rs524281	0.773	rs11227448	chr11:66048491	G/A	cg16950941	chr11:66035639	RAB1B	-0.73	-8.15	-0.41	7.81e-15	Electroencephalogram traits;
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.61	0.39	2.93e-13	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26605046	chr4:2439731	NA	-0.41	-7.28	-0.37	2.49e-12	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03132935	chr11:118901768	SLC37A4	0.45	6.3	0.33	9.6e-10	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg19812747	chr11:111475976	SIK2	0.49	8.28	0.42	3.03e-15	Primary sclerosing cholangitis;
CRC	trans	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg25482853	chr8:67687455	SGK3	1.01	10.95	0.52	5.47e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12273811	chr6:28175739	NA	0.71	9.14	0.45	6.45e-18	Depression;
CRC	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg06627628	chr2:24431161	ITSN2	-0.43	-6.37	-0.33	6.52e-10	Sjögren's syndrome;
CRC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.71	-12.05	-0.55	5.95e-28	Personality dimensions;
CRC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg10802521	chr3:52805072	NEK4	-0.45	-6.1	-0.32	3.05e-9	Schizophrenia;
CRC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.6	8.8	0.44	7.87e-17	Longevity;
CRC	cis	rs4743820	0.651	rs10739912	chr9:93929115	A/G	cg14446406	chr9:93919335	NA	-0.76	-13.62	-0.6	8.32e-34	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.51	0.34	2.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.68e-9	Diabetic kidney disease;
CRC	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.43	-6.04	-0.32	4.12e-9	Macular telangiectasia type 2;
CRC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.66	-10.21	-0.49	1.9e-21	Huntington's disease progression;
CRC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.96	-18.34	-0.71	3.01e-52	Height;
CRC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.31	-0.42	2.58e-15	Schizophrenia;
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg02033258	chr5:131593261	PDLIM4	0.41	7.78	0.39	9.25e-14	Breast cancer;
CRC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.44	6.42	0.33	4.86e-10	Menopause (age at onset);
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg08222913	chr3:52553049	STAB1	-0.37	-7.14	-0.37	6.08e-12	Electroencephalogram traits;
CRC	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.12	-0.37	6.66e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.06	0.55	5.41e-28	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg15845792	chr6:28175446	NA	0.85	8.72	0.43	1.38e-16	Lung cancer in ever smokers;
CRC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.75	0.47	6.92e-20	Bladder cancer;
CRC	cis	rs1545257	0.514	rs2584940	chr2:24641639	A/C	cg06627628	chr2:24431161	ITSN2	-0.43	-6.41	-0.33	5.05e-10	Sjögren's syndrome;
CRC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.49	7.55	0.38	4.23e-13	Red blood cell count;
CRC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.63	10.14	0.49	3.31e-21	Height;
CRC	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.86	-9.43	-0.46	7.7e-19	Obesity-related traits;
CRC	cis	rs12484776	0.786	rs17323591	chr22:40534211	T/A	cg21771250	chr22:40406049	FAM83F	0.34	6.18	0.32	1.87e-9	Uterine fibroids;
CRC	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.58	-9.14	-0.45	6.77e-18	Breast cancer;
CRC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.46	-0.42	8.86e-16	Monocyte count;
CRC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.13	10.98	0.52	4.02e-24	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.01	-0.31	4.86e-9	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.57	-8.55	-0.43	4.8e-16	Aortic root size;
CRC	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.76	-9.45	-0.46	6.53e-19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.51	8.22	0.41	4.77e-15	Body mass index;
CRC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.69	-10.32	-0.49	8.04e-22	Other erythrocyte phenotypes;
CRC	cis	rs9990333	0.687	rs62285383	chr3:195813923	T/G	cg01351295	chr3:195700735	SDHAP1	-0.4	-5.65	-0.3	3.48e-8	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
CRC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.93	0.48	1.65e-20	Cognitive test performance;
CRC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.27	-0.33	1.16e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.41	5.91	0.31	8.46e-9	Obesity-related traits;
CRC	cis	rs16924133	0.793	rs16923839	chr11:33142361	T/C	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg09904177	chr6:26538194	HMGN4	0.55	6.57	0.34	1.95e-10	Small cell lung carcinoma;
CRC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.65	8.88	0.44	4.57e-17	Asthma;
CRC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	8.62	0.43	2.77e-16	Ileal carcinoids;
CRC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.56	-0.43	4.51e-16	Hemoglobin concentration;
CRC	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.82	0.48	3.92e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23588161	chr11:65729143	SART1	0.39	5.98	0.31	5.77e-9	Interleukin-6 levels;
CRC	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.39	-6.62	-0.34	1.42e-10	Hip circumference;Waist circumference;
CRC	cis	rs365302	1.000	rs374973	chr6:159645562	A/C	cg14500486	chr6:159655392	FNDC1	0.43	6.6	0.34	1.68e-10	Coronary heart disease;
CRC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.71	9.29	0.46	2.11e-18	Iron status biomarkers;
CRC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.83	13.31	0.59	1.29e-32	Cognitive function;
CRC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg16989719	chr2:238392110	NA	-0.44	-7.56	-0.38	4.12e-13	Prostate cancer;
CRC	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg23815491	chr16:72088622	HP	0.47	6.63	0.34	1.39e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06467769	chr19:37808668	NA	0.36	5.99	0.31	5.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg15845792	chr6:28175446	NA	-0.64	-7.78	-0.39	9.73e-14	Parkinson's disease;
CRC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.12	-0.32	2.62e-9	Alzheimer's disease (late onset);
CRC	cis	rs12476592	0.543	rs1900303	chr2:63897260	C/T	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	cis	rs2077654	0.556	rs2299640	chr11:17441228	A/G	cg25308976	chr11:17434268	ABCC8	0.62	6.85	0.35	3.74e-11	Gout;
CRC	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.95	0.52	5.53e-24	Bipolar disorder;
CRC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg11189052	chr15:85197271	WDR73	0.61	8.85	0.44	5.62e-17	Schizophrenia;
CRC	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.76	8.5	0.42	6.78e-16	Neuroticism;
CRC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg26695010	chr11:65641043	EFEMP2	-0.54	-5.67	-0.3	3.13e-8	Crohn's disease;
CRC	cis	rs6460942	0.908	rs112049544	chr7:12242551	A/G	cg06484146	chr7:12443880	VWDE	-0.68	-6.58	-0.34	1.82e-10	Coronary artery disease;
CRC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs10788264	0.504	rs7069328	chr10:124030741	G/C	cg09507567	chr10:124027408	NA	0.37	8.17	0.41	6.71e-15	Total body bone mineral density;
CRC	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.64	-9.4	-0.46	9.62e-19	Type 2 diabetes;
CRC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.55	8.06	0.41	1.39e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.46	6.75	0.35	6.52e-11	Asthma;
CRC	trans	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg13565492	chr6:43139072	SRF	-0.7	-7.11	-0.36	7.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.83	0.44	6.2e-17	Rheumatoid arthritis;
CRC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg20885578	chr2:198174922	NA	-0.37	-6.43	-0.33	4.61e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9322817	0.691	rs4946648	chr6:105329422	G/T	cg02098413	chr6:105308735	HACE1	0.43	8.49	0.42	7.27e-16	Thyroid stimulating hormone;
CRC	cis	rs1545257	0.537	rs2249387	chr2:24649801	C/G	cg06627628	chr2:24431161	ITSN2	0.45	6.63	0.34	1.37e-10	Sjögren's syndrome;
CRC	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg03623178	chr6:28175578	NA	0.68	7.32	0.37	1.98e-12	Depression;
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg16606324	chr3:10149918	C3orf24	0.64	8.37	0.42	1.67e-15	Alzheimer's disease;
CRC	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg02811702	chr13:24901961	NA	0.43	5.97	0.31	5.99e-9	Obesity-related traits;
CRC	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg02023728	chr11:77925099	USP35	0.4	7.14	0.37	5.98e-12	Testicular germ cell tumor;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00166722	chr3:10149974	C3orf24	0.59	7.68	0.39	1.87e-13	Alzheimer's disease;
CRC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.12	-0.32	2.69e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg21856205	chr7:94953877	PON1	-0.48	-6.28	-0.33	1.1e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.71	-0.72	1.05e-53	Height;
CRC	trans	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.25	0.41	3.96e-15	Lewy body disease;
CRC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.46	0.38	7.85e-13	Motion sickness;
CRC	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.87	-0.35	3.25e-11	Intelligence (multi-trait analysis);
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg18950002	chr17:79673969	MRPL12	-0.48	-6.64	-0.34	1.33e-10	Lung cancer;
CRC	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.53	6.85	0.35	3.63e-11	Alzheimer's disease (survival time);
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg09877947	chr5:131593287	PDLIM4	0.47	7.62	0.39	2.72e-13	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08424427	chr5:180670815	SNORD95;GNB2L1	0.39	6.52	0.34	2.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.23	-0.32	1.4e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.6	8.44	0.42	1.05e-15	Alcohol dependence;
CRC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.85	-9.81	-0.48	4.13e-20	Breast cancer;
CRC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.44	6.3	0.33	9.53e-10	Tonsillectomy;
CRC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.67	13.38	0.59	6.78e-33	Bone mineral density;
CRC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg01268866	chr2:3683757	COLEC11	-0.58	-8.12	-0.41	9.51e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24739457	chr1:205821442	NA	0.42	5.89	0.31	9.53e-9	Menarche (age at onset);
CRC	trans	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08382705	chr11:45687319	CHST1	-0.43	-7.96	-0.4	2.91e-14	Height;
CRC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.72	9.66	0.47	1.31e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10512697	1.000	rs34988275	chr5:3549238	C/T	cg19473799	chr5:3511975	NA	-0.72	-5.66	-0.3	3.22e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.75	7.47	0.38	7.27e-13	Diabetic retinopathy;
CRC	cis	rs12936587	0.601	rs8068296	chr17:17554563	A/C	cg04398451	chr17:18023971	MYO15A	0.36	6.05	0.32	3.93e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.15	0.49	3.01e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18402987	chr7:1209562	NA	0.44	6.56	0.34	2.07e-10	Longevity;Endometriosis;
CRC	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg08027265	chr7:2291960	NA	-0.34	-5.74	-0.3	2.1e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.17	-0.32	1.96e-9	Alzheimer's disease (late onset);
CRC	trans	rs12495832	0.778	rs12633861	chr3:147919557	C/T	cg10221266	chr7:153579447	NA	0.56	6.13	0.32	2.54e-9	Chin dimples;
CRC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.81	-0.4	7.64e-14	Cystic fibrosis severity;
CRC	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2895526	0.580	rs11257930	chr10:12696120	A/G	cg00115178	chr10:12648176	CAMK1D	0.36	5.91	0.31	8.66e-9	Headache;
CRC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg20573242	chr4:122745356	CCNA2	0.42	6.27	0.33	1.12e-9	Type 2 diabetes;
CRC	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg09003973	chr2:102972529	NA	0.68	7.54	0.38	4.74e-13	Gut microbiota (bacterial taxa);
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.46	0.42	9.06e-16	Menopause (age at onset);
CRC	cis	rs59104589	0.920	rs59916403	chr2:242370751	G/T	cg10021735	chr2:242295487	FARP2	0.47	6.58	0.34	1.89e-10	Fibrinogen levels;
CRC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.61	9.61	0.47	1.93e-19	Corneal astigmatism;
CRC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	8.45	0.42	9.86e-16	Schizophrenia;
CRC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg03013636	chr16:1946785	NA	0.59	7.18	0.37	4.7e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.45	7.54	0.38	4.51e-13	Total cholesterol levels;
CRC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.51	7.34	0.37	1.72e-12	Height;
CRC	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.22	-5.89	-0.31	9.29e-9	Type 2 diabetes;
CRC	trans	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg17903999	chr18:56338584	MALT1	0.41	6.83	0.35	4.19e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1465370	0.760	rs10263705	chr7:130027633	C/T	cg03229158	chr7:130009420	NA	-0.46	-6.66	-0.34	1.14e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs4237845	0.611	rs4272820	chr12:58330541	G/A	cg00677455	chr12:58241039	CTDSP2	0.4	5.71	0.3	2.51e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.14	14.67	0.63	7.68e-38	Uric acid levels;
CRC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.87	-12.88	-0.58	5.33e-31	Response to antineoplastic agents;
CRC	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.38	5.84	0.31	1.25e-8	Red blood cell count;
CRC	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-5.63	-0.3	3.82e-8	Blood metabolite levels;
CRC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.57	-8.03	-0.41	1.69e-14	Platelet distribution width;
CRC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.5	10.92	0.52	6.7e-24	Alcohol dependence;
CRC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.85	-0.31	1.17e-8	Life satisfaction;
CRC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	11.19	0.53	7.45e-25	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.35	5.67	0.3	3.08e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.13	0.32	2.55e-9	Height;
CRC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.32	5.61	0.3	4.31e-8	Schizophrenia;
CRC	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.71	7.58	0.39	3.45e-13	Breast cancer;
CRC	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.76	-0.35	6.15e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs56313388	0.751	rs8057553	chr16:56334990	A/G	cg02433656	chr16:56322654	GNAO1	0.52	7.84	0.4	6.43e-14	Pulse pressure;
CRC	cis	rs2565722	0.609	rs9365227	chr6:161297925	G/T	cg03159191	chr6:161285451	NA	-0.46	-6.4	-0.33	5.47e-10	Blood protein levels;
CRC	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.58e-11	Opioid sensitivity;
CRC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg24209194	chr3:40518798	ZNF619	0.42	6.36	0.33	6.56e-10	Renal cell carcinoma;
CRC	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg12856521	chr11:46389249	DGKZ	-0.43	-6.78	-0.35	5.53e-11	Leprosy;
CRC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-7.53	-0.38	4.86e-13	Coronary artery disease;
CRC	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg18827107	chr12:86230957	RASSF9	0.36	5.69	0.3	2.79e-8	Major depressive disorder;
CRC	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg25885038	chr17:56607967	SEPT4	-0.51	-7.61	-0.39	2.96e-13	Vitamin D levels;
CRC	trans	rs587242	1.000	rs1830868	chr1:96895906	G/A	cg10631902	chr5:14652156	NA	0.44	6.81	0.35	4.51e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13784889	chr4:89513377	HERC3	0.46	6.64	0.34	1.26e-10	Response to antipsychotic treatment;
CRC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	7.39	0.38	1.24e-12	Height;
CRC	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.76	-12.32	-0.56	6.03e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.61	9.57	0.47	2.61e-19	Aortic root size;
CRC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.88	-0.44	4.47e-17	Personality dimensions;
CRC	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.74	0.39	1.26e-13	Platelet count;
CRC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.54	-7.48	-0.38	6.94e-13	Corneal structure;
CRC	cis	rs12760731	0.582	rs35302804	chr1:178513342	G/A	cg00404053	chr1:178313656	RASAL2	0.71	7.82	0.4	7.09e-14	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04886448	chr17:27224035	FLOT2	0.41	5.98	0.31	5.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.69	0.3	2.8e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.01	-21.75	-0.77	1.22e-65	Myeloid white cell count;
CRC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.34	0.42	2.13e-15	Height;
CRC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.77	9.75	0.47	6.59e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs11212617	1.000	rs600931	chr11:108117335	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.26	0.33	1.22e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3790844	0.667	rs3790843	chr1:200010824	A/G	cg07208853	chr1:200005219	NR5A2	-0.34	-8.67	-0.43	2.06e-16	Pancreatic cancer;
CRC	cis	rs9341808	0.667	rs2490251	chr6:80895164	A/G	cg08355045	chr6:80787529	NA	0.33	5.65	0.3	3.52e-8	Sitting height ratio;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.88	0.31	1.01e-8	Depression;
CRC	cis	rs860295	0.702	rs12067371	chr1:155437669	C/T	cg02153340	chr1:155202674	NA	-0.53	-6.97	-0.36	1.73e-11	Body mass index;
CRC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.65	8.7	0.43	1.65e-16	Alcohol dependence;
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.95	-0.36	2.01e-11	Bipolar disorder;
CRC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.74	0.35	7.02e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.45	6.89	0.35	2.9e-11	Cleft lip with or without cleft palate;
CRC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg02549819	chr16:58548995	SETD6	1.2	7.97	0.4	2.72e-14	Schizophrenia;
CRC	cis	rs9322817	0.583	rs10782363	chr6:105149713	C/G	cg02098413	chr6:105308735	HACE1	0.43	8.51	0.42	6.15e-16	Thyroid stimulating hormone;
CRC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg27535305	chr1:53392650	SCP2	-0.34	-6.08	-0.32	3.26e-9	Monocyte count;
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.1	-0.32	2.93e-9	Life satisfaction;
CRC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	19.76	0.74	7.57e-58	Prudent dietary pattern;
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.9e-11	Electroencephalogram traits;
CRC	trans	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg04077850	chr5:125800366	GRAMD3	0.38	6.2	0.32	1.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.48	7.21	0.37	3.85e-12	Testicular germ cell tumor;
CRC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10446143	chr21:44394730	PKNOX1	0.48	6.83	0.35	4.17e-11	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-8.98	-0.44	2.18e-17	Prudent dietary pattern;
CRC	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg26182253	chr13:112236782	NA	0.31	6.24	0.33	1.35e-9	Hepatitis;
CRC	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Parkinson's disease;
CRC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.43	7.7	0.39	1.56e-13	Perceived unattractiveness to mosquitoes;
CRC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.5	7.53	0.38	5e-13	Emphysema distribution in smoking;
CRC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.43	4.1e-16	Aortic root size;
CRC	trans	rs28735056	0.509	rs4799094	chr18:77621727	T/C	cg08586216	chr6:35612351	FKBP5	0.4	6.22	0.32	1.52e-9	Schizophrenia;
CRC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23903597	chr17:61704154	MAP3K3	-0.44	-6.0	-0.31	5.31e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg06494592	chr3:125709126	NA	-0.54	-6.42	-0.33	4.71e-10	Blood pressure (smoking interaction);
CRC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg20243544	chr17:37824526	PNMT	0.58	9.05	0.45	1.28e-17	Asthma;
CRC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg20243544	chr17:37824526	PNMT	0.55	8.95	0.44	2.66e-17	Asthma;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.48	7.33	0.37	1.79e-12	Testicular germ cell tumor;
CRC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg24675056	chr1:15929824	NA	0.47	6.24	0.33	1.33e-9	Systolic blood pressure;
CRC	cis	rs10512697	0.655	rs13156164	chr5:3509083	C/T	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs449789	0.857	rs578714	chr6:159715118	G/T	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-6.87	-0.35	3.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.69	9.78	0.47	5.55e-20	Alzheimer's disease;
CRC	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg04239558	chr2:103089729	SLC9A4	0.37	6.59	0.34	1.72e-10	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16565161	chr1:155292726	RUSC1;C1orf104	0.42	6.06	0.32	3.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.6	7.94	0.4	3.25e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.55	9.68	0.47	1.19e-19	Lung cancer;
CRC	cis	rs11212617	0.935	rs1607476	chr11:108075161	A/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.03	0.32	4.37e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18301423	chr5:131593218	PDLIM4	0.37	6.87	0.35	3.16e-11	Breast cancer;
CRC	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.52	8.02	0.4	1.94e-14	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.21	-0.41	5.01e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg20615401	chr6:28092323	ZSCAN16	0.46	6.23	0.32	1.45e-9	Parkinson's disease;
CRC	cis	rs6988985	0.765	rs7011830	chr8:143982392	G/T	cg10324643	chr8:143916377	GML	-0.37	-6.15	-0.32	2.25e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg01262667	chr19:19385393	TM6SF2	-0.37	-5.99	-0.31	5.56e-9	Tonsillectomy;
CRC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.77	-0.44	9.89e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	8.06	0.41	1.44e-14	Height;
CRC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.0	0.31	5.12e-9	Morning vs. evening chronotype;
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.77	-0.39	1.02e-13	Total body bone mineral density;
CRC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.2	0.53	7.19e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg08314208	chr16:67682810	RLTPR	-0.55	-5.96	-0.31	6.57e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.62	0.3	4.14e-8	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04219625	chr11:66247798	DPP3	0.45	6.0	0.31	5.08e-9	Anxiety disorder;
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg02152992	chr13:48877591	RB1	-0.43	-6.11	-0.32	2.89e-9	Total body bone mineral density;
CRC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg19318889	chr4:1322082	MAEA	0.4	5.71	0.3	2.57e-8	Obesity-related traits;
CRC	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.43	5.68	0.3	2.92e-8	Tuberculosis;
CRC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03437924	chr16:25123326	LCMT1	0.39	6.16	0.32	2.18e-9	Obesity-related traits;
CRC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.56	-7.61	-0.39	2.85e-13	Coronary artery disease;
CRC	cis	rs6961069	0.806	rs1761665	chr7:80242079	A/G	cg04458919	chr7:80252533	CD36	-0.35	-6.34	-0.33	7.45e-10	Platelet count;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.43	5.67	0.3	3.12e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg04989706	chr14:50066350	PPIL5	-0.56	-7.71	-0.39	1.48e-13	Carotid intima media thickness;
CRC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.76	11.19	0.52	7.79e-25	Menopause (age at onset);
CRC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg19792802	chr11:65647270	CTSW	0.61	7.34	0.38	1.66e-12	Crohn's disease;
CRC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.44	-6.73	-0.35	7.45e-11	Psychosis in Alzheimer's disease;
CRC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.6	-0.39	3.15e-13	Body mass index;
CRC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.66	8.76	0.43	1.09e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-8.08	-0.41	1.26e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-6.02	-0.32	4.57e-9	Longevity;Endometriosis;
CRC	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg26248373	chr2:1572462	NA	-0.68	-8.52	-0.43	5.83e-16	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03804568	chr22:39548919	CBX7	0.41	6.06	0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg12193833	chr17:30244370	NA	-0.62	-8.01	-0.4	2e-14	Hip circumference adjusted for BMI;
CRC	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg24851651	chr11:66362959	CCS	-0.37	-6.41	-0.33	5.18e-10	Educational attainment (years of education);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01086389	chr3:150321178	SELT	0.42	6.02	0.31	4.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg09264619	chr17:80180166	NA	0.52	7.28	0.37	2.55e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.29	-0.33	9.87e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg09659197	chr4:152720779	NA	-0.52	-10.87	-0.51	1.02e-23	Intelligence (multi-trait analysis);
CRC	cis	rs41005	0.967	rs1974696	chr2:8115782	A/G	cg03155496	chr2:8117019	LOC339788	0.4	7.25	0.37	3.02e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.05e-30	Bone mineral density;
CRC	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg14345882	chr6:26364793	BTN3A2	0.4	6.23	0.32	1.42e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04554905	chr3:172428857	NCEH1	-0.51	-6.09	-0.32	3.1e-9	Diisocyanate-induced asthma;
CRC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.62	7.22	0.37	3.61e-12	Vitiligo;
CRC	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.64	8.98	0.44	2.09e-17	Lung cancer;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.47	-8.34	-0.42	2.04e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09626274	chr15:77224230	RCN2	0.42	6.51	0.34	2.85e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg15145296	chr3:125709740	NA	-0.57	-7.35	-0.38	1.59e-12	Blood pressure (smoking interaction);
CRC	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-6.26	-0.33	1.22e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.77	0.35	5.88e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs938554	0.737	rs10939637	chr4:9977577	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	5.64	0.3	3.62e-8	Blood metabolite levels;
CRC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg05941027	chr17:61774174	LIMD2	0.34	5.74	0.3	2.2e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.42	-0.53	1.16e-25	Electrocardiographic conduction measures;
CRC	trans	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg05623727	chr3:50126028	RBM5	-0.4	-6.08	-0.32	3.36e-9	Intelligence (multi-trait analysis);
CRC	trans	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg15744005	chr10:104629667	AS3MT	0.31	6.18	0.32	1.86e-9	Arsenic metabolism;
CRC	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg19169023	chr15:41853346	TYRO3	-0.51	-7.77	-0.39	1.04e-13	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	9.34	0.46	1.49e-18	Joint mobility (Beighton score);
CRC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	9.4	0.46	9.71e-19	Cognitive test performance;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07203134	chr3:171178176	TNIK	-0.45	-6.92	-0.36	2.44e-11	Aortic root size;
CRC	cis	rs9648716	1.000	rs10261732	chr7:140570145	C/T	cg10747023	chr7:140774559	NA	0.44	5.62	0.3	4.04e-8	Type 2 diabetes;
CRC	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.62	8.46	0.42	8.62e-16	Menopause (age at onset);
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.6	-0.3	4.51e-8	Life satisfaction;
CRC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.49	-0.5	2.14e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.51	5.89	0.31	9.43e-9	Dental caries;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg14329157	chr2:228736135	WDR69	-0.45	-6.22	-0.32	1.52e-9	Blood pressure;
CRC	cis	rs9322817	0.691	rs2400072	chr6:105344116	C/T	cg02098413	chr6:105308735	HACE1	0.46	9.14	0.45	6.64e-18	Thyroid stimulating hormone;
CRC	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.72	11.3	0.53	3.17e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Hypertriglyceridemia;
CRC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.57	8.55	0.43	4.79e-16	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24327803	chr21:27108210	ATP5J;GABPA	0.46	6.41	0.33	4.96e-10	Response to antipsychotic treatment;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.51	0.38	5.7e-13	Lymphocyte counts;
CRC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.67	10.12	0.49	4.01e-21	Lung cancer;
CRC	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.55	0.43	4.65e-16	Electrocardiographic conduction measures;
CRC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg15147215	chr3:52552868	STAB1	0.45	7.5	0.38	6.17e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.82	-14.36	-0.62	1.23e-36	Breast cancer;
CRC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg18721089	chr20:30220636	NA	-0.34	-5.63	-0.3	3.77e-8	Mean corpuscular hemoglobin;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09305948	chr7:5254072	WIPI2	-0.37	-6.06	-0.32	3.82e-9	Interleukin-6 levels;
CRC	cis	rs972578	0.806	rs5759008	chr22:43274367	A/T	cg01576275	chr22:43409880	NA	-0.41	-6.45	-0.33	4.05e-10	Mean platelet volume;
CRC	cis	rs4557101	0.526	rs7627890	chr3:73532069	C/T	cg24173753	chr3:73529447	PDZRN3	-0.36	-5.78	-0.3	1.73e-8	QT interval;
CRC	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06307176	chr5:131281290	NA	-0.43	-6.43	-0.33	4.55e-10	Life satisfaction;
CRC	cis	rs12024301	0.557	rs4325101	chr1:183644070	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.99	0.36	1.52e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.21	0.37	3.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg06494592	chr3:125709126	NA	-0.55	-6.58	-0.34	1.88e-10	Blood pressure (smoking interaction);
CRC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.51	-0.38	5.46e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg12639453	chr1:2035780	PRKCZ	-0.38	-7.31	-0.37	2e-12	Height;
CRC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.42	7.73	0.39	1.34e-13	Monocyte count;
CRC	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg09659197	chr4:152720779	NA	-0.42	-8.69	-0.43	1.79e-16	Intelligence (multi-trait analysis);
CRC	trans	rs4902562	0.838	rs6573823	chr14:68733632	A/G	cg00520622	chr21:27107799	ATP5J;GABPA	0.47	6.01	0.31	4.82e-9	Systemic lupus erythematosus;
CRC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.78e-13	Hip circumference adjusted for BMI;
CRC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg10544611	chr16:67998164	SLC12A4	-0.53	-5.64	-0.3	3.66e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3736485	0.609	rs744039	chr15:51973373	T/C	cg08986416	chr15:51914746	DMXL2	-0.39	-5.65	-0.3	3.54e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	9.81e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.45	7.05	0.36	1.07e-11	Schizophrenia;
CRC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.13	0.32	2.56e-9	Height;
CRC	cis	rs73200209	0.744	rs55837280	chr12:116645483	A/G	cg01776926	chr12:116560359	MED13L	-0.61	-7.08	-0.36	8.97e-12	Total body bone mineral density;
CRC	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg01339444	chr6:118972232	C6orf204	0.53	5.94	0.31	7.25e-9	Diastolic blood pressure;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg04518342	chr5:131593106	PDLIM4	0.51	9.27	0.46	2.44e-18	Blood metabolite levels;
CRC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.39	6.38	0.33	5.88e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg05304507	chr6:116381966	FRK	0.3	8.06	0.41	1.45e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.62	11.35	0.53	2.04e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.53	-0.34	2.56e-10	Dupuytren's disease;
CRC	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	1.11	9.39	0.46	1.06e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg13957321	chr17:43675089	NA	0.53	6.32	0.33	8.34e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.75	-0.3	1.99e-8	Total body bone mineral density;
CRC	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	cg04338863	chr8:33670619	NA	0.4	6.84	0.35	3.8e-11	Body mass index;
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.73	12.46	0.57	1.94e-29	Systemic lupus erythematosus;
CRC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg00290607	chr11:67383545	NA	0.33	5.71	0.3	2.48e-8	Mean corpuscular volume;
CRC	cis	rs9908102	0.740	rs8079600	chr17:12910706	T/C	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.67	10.02	0.48	8.25e-21	Corneal astigmatism;
CRC	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg22134325	chr11:66188745	NPAS4	0.28	5.65	0.3	3.39e-8	Airway imaging phenotypes;
CRC	cis	rs7246967	0.551	rs8103204	chr19:22936517	T/A	cg08271804	chr19:22816896	ZNF492	0.38	5.86	0.31	1.11e-8	Bronchopulmonary dysplasia;
CRC	cis	rs7804356	1.000	rs10272190	chr7:26887942	T/A	cg03456212	chr7:26904342	SKAP2	-0.49	-5.63	-0.3	3.89e-8	Type 1 diabetes;
CRC	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	1.01	12.23	0.56	1.32e-28	Obesity-related traits;
CRC	cis	rs7113874	0.550	rs4929949	chr11:8604593	T/C	cg17679104	chr11:8615758	STK33	0.36	6.02	0.32	4.6e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.17	0.56	2.25e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.1	-0.36	7.56e-12	IgG glycosylation;
CRC	cis	rs972578	1.000	rs4822244	chr22:43389028	C/T	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.96e-14	Mean platelet volume;
CRC	cis	rs1545257	0.514	rs7581577	chr2:24638107	C/T	cg06627628	chr2:24431161	ITSN2	-0.47	-7.02	-0.36	1.27e-11	Sjögren's syndrome;
CRC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg14558114	chr2:88469736	THNSL2	-0.39	-6.03	-0.32	4.46e-9	Response to metformin (IC50);
CRC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.61	8.45	0.42	9.8e-16	Platelet count;
CRC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	0.76	8.36	0.42	1.81e-15	Gout;Renal underexcretion gout;
CRC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.41	-6.08	-0.32	3.4e-9	Breast size;
CRC	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	9.38	0.46	1.13e-18	Platelet distribution width;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12172441	chr6:28176163	NA	-0.61	-7.31	-0.37	2.1e-12	Depression;
CRC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
CRC	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg12458913	chr13:53173898	NA	0.45	6.55	0.34	2.19e-10	Lewy body disease;
CRC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9443189	1.000	rs1280044	chr6:76522602	A/G	cg01950844	chr6:76311363	SENP6	-0.54	-6.4	-0.33	5.34e-10	Prostate cancer;
CRC	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg12179176	chr11:130786555	SNX19	0.6	8.82	0.44	6.9e-17	Schizophrenia;
CRC	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.4	0.33	5.42e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs3106136	0.872	rs10030713	chr4:95238536	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-6.6	-0.34	1.63e-10	Capecitabine sensitivity;
CRC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg11189052	chr15:85197271	WDR73	0.58	8.43	0.42	1.1e-15	Schizophrenia;
CRC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-7.06	-0.36	9.65e-12	Height;
CRC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.65	-10.4	-0.5	4.43e-22	Urinary electrolytes (magnesium/calcium ratio);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05421101	chr16:23568813	UBFD1;EARS2	0.47	6.5	0.34	2.99e-10	Anxiety disorder;
CRC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	7.71	0.39	1.51e-13	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16703956	chr5:1446217	SLC6A3	0.21	6.06	0.32	3.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg23254163	chr1:152506842	NA	0.5	10.05	0.48	6.51e-21	Hair morphology;
CRC	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg14345882	chr6:26364793	BTN3A2	-0.38	-6.1	-0.32	3.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg04362960	chr10:104952993	NT5C2	0.58	8.22	0.41	4.66e-15	Arsenic metabolism;
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.46	-6.0	-0.31	5.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.36e-24	Prudent dietary pattern;
CRC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.5	10.93	0.52	6.28e-24	Alcohol dependence;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26125625	chr3:124860871	SLC12A8	0.2	6.06	0.32	3.82e-9	Schizophrenia;
CRC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	8.96	0.44	2.45e-17	Cognitive test performance;
CRC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.73	11.23	0.53	5.33e-25	Corneal astigmatism;
CRC	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.53	0.43	5.29e-16	Endometrial cancer;
CRC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.82	10.26	0.49	1.31e-21	Eosinophil percentage of granulocytes;
CRC	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.55	-0.5	1.37e-22	Colorectal cancer;
CRC	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-6.73	-0.35	7.76e-11	Homocysteine levels;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg15383120	chr6:291909	DUSP22	-0.51	-7.27	-0.37	2.71e-12	Menopause (age at onset);
CRC	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.58	-7.78	-0.39	9.14e-14	Mammographic density (dense area);
CRC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.14	0.32	2.4e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25291941	chr8:99129319	POP1;HRSP12	0.51	8.37	0.42	1.72e-15	Liver disease severity in Alagille syndrome;
CRC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.06	9.98	0.48	1.12e-20	Opioid sensitivity;
CRC	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs3015497	0.586	rs12587842	chr14:51092562	A/G	cg09863266	chr14:51125203	SAV1	-0.3	-5.76	-0.3	1.92e-8	Mean platelet volume;
CRC	cis	rs11191205	0.686	rs11191091	chr10:103448649	C/A	cg15320455	chr10:103880129	LDB1	0.57	6.21	0.32	1.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.8	-9.78	-0.47	5.31e-20	Initial pursuit acceleration;
CRC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.75	-0.43	1.12e-16	Aortic root size;
CRC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.56	7.75	0.39	1.17e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.78	0.44	8.78e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg09323728	chr8:95962352	TP53INP1	-0.37	-6.01	-0.31	4.9e-9	Type 2 diabetes;
CRC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg03934865	chr2:198174659	NA	0.36	5.81	0.31	1.44e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.34	-0.42	2e-15	Neuroticism;
CRC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg21153622	chr11:89784906	NA	0.44	7.19	0.37	4.26e-12	Coronary artery disease;
CRC	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.19	9.37	0.46	1.17e-18	Economic and political preferences (immigration/crime);
CRC	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-8.98	-0.44	2.15e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.85	12.8	0.58	9.97e-31	Cognitive function;
CRC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.54	-0.34	2.38e-10	Life satisfaction;
CRC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06544989	chr22:39130855	UNC84B	-0.47	-7.65	-0.39	2.31e-13	Menopause (age at onset);
CRC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.67	9.98	0.48	1.19e-20	Diastolic blood pressure;
CRC	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.53	-10.0	-0.48	9.74e-21	Hip circumference;Waist circumference;
CRC	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.44	6.93	0.36	2.28e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.65	7.73	0.39	1.28e-13	Gut microbiome composition (summer);
CRC	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.39	-0.33	5.62e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11688275	chr8:128750871	MYC	0.41	5.99	0.31	5.35e-9	Response to antipsychotic treatment;
CRC	cis	rs3751196	0.808	rs74503365	chr12:104212665	G/A	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs2692947	0.667	rs4144055	chr2:96647856	G/T	cg23100626	chr2:96804247	ASTL	0.26	6.95	0.36	2.01e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24859228	chr10:12391835	CAMK1D	-0.51	-6.09	-0.32	3.23e-9	Diisocyanate-induced asthma;
CRC	cis	rs17152411	0.895	rs7914206	chr10:126585397	G/A	cg07906193	chr10:126599966	NA	0.57	6.28	0.33	1.06e-9	Height;
CRC	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.67	11.08	0.52	1.89e-24	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs2735413	0.881	rs12918547	chr16:78082746	G/A	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.25	-0.56	1.09e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10924970	0.625	rs10802624	chr1:235494971	A/G	cg09010748	chr1:235293032	TOMM20	-0.46	-6.27	-0.33	1.15e-9	Asthma;
CRC	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-9.88	-0.48	2.52e-20	Blood protein levels;
CRC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13198984	chr17:80129470	CCDC57	-0.5	-8.77	-0.44	1.01e-16	Life satisfaction;
CRC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-5.77	-0.3	1.79e-8	Mean corpuscular volume;
CRC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.13	-0.59	5.84e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.38	-6.77	-0.35	6.05e-11	Reticulocyte fraction of red cells;
CRC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg21699342	chr2:239360505	ASB1	0.54	9.56	0.47	2.85e-19	Multiple system atrophy;
CRC	cis	rs3736485	0.932	rs4775966	chr15:51913788	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-6.27	-0.33	1.12e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.07	-28.34	-0.84	2.74e-90	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2462686	0.932	rs2471557	chr7:46000595	G/C	cg23193639	chr7:45961078	IGFBP3	-0.38	-5.86	-0.31	1.14e-8	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23186422	chr6:139013826	NA	0.47	6.71	0.35	8.41e-11	Anxiety disorder;
CRC	cis	rs2160860	0.736	rs10958573	chr8:39797955	G/A	cg11363097	chr8:39792086	IDO2	-0.42	-7.24	-0.37	3.23e-12	Blood metabolite levels;
CRC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.52	6.39	0.33	5.69e-10	White matter hyperintensity burden;
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg24046110	chr8:143859143	LYNX1	0.48	8.34	0.42	2.11e-15	Urinary tract infection frequency;
CRC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-15.43	-0.65	8.48e-41	Schizophrenia;
CRC	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg06042504	chr8:55087323	NA	-0.42	-6.5	-0.34	2.97e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	12.99	0.58	1.9e-31	Alzheimer's disease;
CRC	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.65	-7.89	-0.4	4.42e-14	Menarche (age at onset);
CRC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.43	0.5	3.54e-22	Systolic blood pressure;
CRC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.61	-12.15	-0.56	2.6e-28	Asthma (sex interaction);
CRC	cis	rs6479527	0.904	rs1418251	chr9:96848077	T/C	cg13460858	chr9:96720652	NA	0.31	5.7	0.3	2.62e-8	Esophageal adenocarcinoma;
CRC	cis	rs9525927	0.625	rs4941488	chr13:44817758	T/C	cg19190762	chr13:44806055	NA	0.54	6.37	0.33	6.22e-10	Dupuytren's disease;
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg06713098	chr7:45960367	IGFBP3	0.42	6.67	0.35	1.05e-10	Sitting height ratio;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg06470822	chr6:28175283	NA	1.02	13.67	0.6	5.35e-34	Depression;
CRC	cis	rs728616	0.867	rs41302709	chr10:81807278	G/A	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.88	-0.31	9.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs995000	0.931	rs1781195	chr1:62988972	T/C	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.56e-11	Triglyceride levels;
CRC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.03	0.66	3.98e-43	Chronic sinus infection;
CRC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.56	8.82	0.44	6.8e-17	Vitiligo;
CRC	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.76	12.85	0.58	6.69e-31	Adiposity;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.72	-0.3	2.36e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-13.33	-0.59	1.08e-32	Ulcerative colitis;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg25164649	chr6:28176230	NA	0.72	9.1	0.45	9.16e-18	Depression;
CRC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.66	0.3	3.31e-8	Educational attainment;
CRC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-11.58	-0.54	3.01e-26	Asthma;
CRC	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg08632701	chr21:37451849	NA	-0.45	-7.09	-0.36	8.4e-12	Mitral valve prolapse;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	3.04e-10	Fibrinogen levels;
CRC	trans	rs6937795	0.898	rs6913178	chr6:137294204	G/A	cg04282530	chr11:128530479	NA	-0.39	-5.96	-0.31	6.44e-9	Type 2 diabetes;
CRC	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.61	8.37	0.42	1.71e-15	Arsenic metabolism;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00632778	chr13:50422122	NA	-0.46	-6.09	-0.32	3.22e-9	Monocyte percentage of white cells;
CRC	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.75	0.54	7.28e-27	Exhaled nitric oxide levels;
CRC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.74	-11.38	-0.53	1.55e-25	Prudent dietary pattern;
CRC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.36	-0.56	4.47e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.72	0.3	2.37e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.51	7.74	0.39	1.21e-13	Red blood cell count;
CRC	cis	rs77861329	0.800	rs6777340	chr3:52188308	T/C	cg08692210	chr3:52188851	WDR51A	0.5	5.91	0.31	8.42e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.78	-11.57	-0.54	3.32e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.1e-16	Alcohol dependence;
CRC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.39	-6.72	-0.35	8.04e-11	Reticulocyte fraction of red cells;
CRC	cis	rs8020095	0.571	rs7156852	chr14:67340549	T/G	cg00791868	chr14:66963628	C14orf53	0.45	5.75	0.3	2.09e-8	Depression (quantitative trait);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08857478	chr17:74722826	JMJD6;C17orf95	0.53	6.76	0.35	6.14e-11	Thyroid stimulating hormone;
CRC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-9.83	-0.48	3.62e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.46	7.15	0.37	5.82e-12	Eye color traits;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.95	0.31	7.04e-9	Depression;
CRC	cis	rs457287	0.772	rs415719	chr9:4823007	G/T	cg14182974	chr9:4791918	RCL1	0.4	6.21	0.32	1.55e-9	Platelet count;
CRC	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg09179987	chr1:167433047	CD247	0.49	7.68	0.39	1.85e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17851730	chr1:19229128	ALDH4A1	0.47	6.56	0.34	2.05e-10	Response to antipsychotic treatment;
CRC	cis	rs11212617	0.967	rs186594	chr11:108265854	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.5	0.34	3.04e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06307176	chr5:131281290	NA	0.43	6.35	0.33	7.09e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.46	7.03	0.36	1.22e-11	Dupuytren's disease;
CRC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.67	-9.88	-0.48	2.58e-20	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg00255919	chr5:131827918	IRF1	-0.31	-5.66	-0.3	3.37e-8	Blood metabolite levels;
CRC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg20203395	chr5:56204925	C5orf35	0.41	5.98	0.31	5.81e-9	Coronary artery disease;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.85	-0.31	1.18e-8	Total body bone mineral density;
CRC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg11189052	chr15:85197271	WDR73	0.62	8.86	0.44	4.93e-17	Schizophrenia;
CRC	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.66	8.93	0.44	3.13e-17	White matter hyperintensity burden;
CRC	cis	rs755249	0.567	rs16826009	chr1:39716902	A/G	cg18385671	chr1:39797026	MACF1	-0.42	-5.99	-0.31	5.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18520411	chr19:19516967	GATAD2A	0.47	6.08	0.32	3.31e-9	Thyroid stimulating hormone;
CRC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.64	-9.58	-0.47	2.44e-19	Menarche (age at onset);
CRC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	13.5	0.6	2.43e-33	Smoking behavior;
CRC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.75	12.12	0.56	3.32e-28	Blood protein levels;
CRC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg27661571	chr11:113659931	NA	-0.95	-11.06	-0.52	2.1e-24	Hip circumference adjusted for BMI;
CRC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.54	7.33	0.37	1.81e-12	Height;
CRC	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.31	6.35	0.33	7.18e-10	Cutaneous nevi;
CRC	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.68	11.03	0.52	2.88e-24	Cognitive test performance;
CRC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.65	-0.39	2.3e-13	Cystic fibrosis severity;
CRC	cis	rs501120	0.584	rs617019	chr10:44737246	A/G	cg09554077	chr10:44749378	NA	-0.7	-7.83	-0.4	6.87e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg13206674	chr6:150067644	NUP43	-0.48	-6.99	-0.36	1.52e-11	Testicular germ cell tumor;
CRC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg25171089	chr10:5708825	ASB13	0.41	5.75	0.3	2.04e-8	Menopause (age at onset);
CRC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.76	0.39	1.08e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.36	0.56	4.4e-29	Chronic sinus infection;
CRC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.43	6.34	0.33	7.37e-10	Menopause (age at onset);
CRC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.69	9.61	0.47	1.9e-19	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-18.23	-0.71	8.31e-52	Ulcerative colitis;
CRC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.51	-6.34	-0.33	7.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.84	-0.35	3.91e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs4964805	0.657	rs4964813	chr12:104189554	T/C	cg02344784	chr12:104178138	NT5DC3	0.79	14.97	0.64	5.11e-39	Attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02852436	chr20:2821472	FAM113A;VPS16	0.37	5.97	0.31	6.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg13414629	chr9:132935646	FREQ	0.44	6.35	0.33	7.06e-10	Alzheimer's disease (cognitive decline);
CRC	cis	rs2944591	0.505	rs747462	chr2:233790171	A/C	cg11972305	chr2:233791962	NGEF	-0.39	-6.03	-0.32	4.41e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg22723502	chr6:26240528	HIST1H4F	0.36	5.99	0.31	5.43e-9	Gout;Renal underexcretion gout;
CRC	cis	rs2227564	0.794	rs2633320	chr10:75693306	A/G	cg00564723	chr10:75632066	CAMK2G	-0.28	-6.54	-0.34	2.39e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.46	-0.38	7.65e-13	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.45	-8.2	-0.41	5.37e-15	Urate levels in overweight individuals;
CRC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg08999081	chr20:33150536	PIGU	0.46	5.8	0.3	1.58e-8	Protein C levels;
CRC	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.54	7.14	0.37	6.03e-12	Mammographic density (dense area);
CRC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.54	7.32	0.37	1.93e-12	Height;
CRC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-9.68	-0.47	1.18e-19	Menarche (age at onset);
CRC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.39	-8.05	-0.41	1.53e-14	Renal cell carcinoma;
CRC	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.72	-0.35	8.25e-11	Schizophrenia;
CRC	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.9	0.44	3.77e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.7	-10.98	-0.52	4.09e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.38	5.69	0.3	2.79e-8	Menarche (age at onset);
CRC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.42	5.7	0.3	2.74e-8	IgG glycosylation;
CRC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.94	0.31	7.07e-9	Monocyte percentage of white cells;
CRC	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg00631329	chr6:26305371	NA	-0.53	-9.1	-0.45	8.92e-18	Educational attainment;
CRC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.98	-0.31	5.97e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg08755490	chr11:65554678	OVOL1	0.4	5.85	0.31	1.19e-8	Acne (severe);
CRC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	0.87	7.24	0.37	3.25e-12	Type 2 diabetes nephropathy;
CRC	cis	rs1223397	0.651	rs2458314	chr6:13309224	C/T	cg00460589	chr6:13274354	PHACTR1	0.38	6.08	0.32	3.26e-9	Blood pressure;
CRC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.67	10.34	0.5	6.89e-22	Corneal astigmatism;
CRC	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.6	6.17	0.32	2.03e-9	Putamen volume;
CRC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg13010199	chr12:38710504	ALG10B	0.43	6.26	0.33	1.19e-9	Morning vs. evening chronotype;
CRC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.43	6.96	0.36	1.86e-11	Resting heart rate;
CRC	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg10724054	chr17:3904396	NA	-0.47	-7.96	-0.4	2.75e-14	Type 2 diabetes;
CRC	trans	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg18288967	chr1:45987694	PRDX1	0.6	7.0	0.36	1.46e-11	Obesity-related traits;
CRC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.4	-5.83	-0.31	1.29e-8	Response to metformin (IC50);
CRC	cis	rs6743376	0.556	rs2515401	chr2:113820476	C/T	cg24553058	chr2:113831203	IL1F10	-0.42	-6.89	-0.35	2.92e-11	Inflammatory biomarkers;
CRC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.52	8.46	0.42	8.72e-16	Body mass index;
CRC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg18490616	chr2:88469792	THNSL2	0.5	5.66	0.3	3.24e-8	Plasma clusterin levels;
CRC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16447950	chr5:562315	NA	0.78	10.6	0.5	9.08e-23	Obesity-related traits;
CRC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.9	-0.36	2.69e-11	Calcium levels;
CRC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg22777020	chr22:31556080	RNF185	-0.51	-5.82	-0.31	1.42e-8	Colorectal cancer;
CRC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg00310523	chr12:86230176	RASSF9	0.43	7.22	0.37	3.68e-12	Major depressive disorder;
CRC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.56	7.12	0.37	6.82e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.44	-6.94	-0.36	2.04e-11	HDL cholesterol;
CRC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	6.1	0.32	3.04e-9	Axial length;
CRC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.66	-8.02	-0.4	1.89e-14	Menarche (age at onset);
CRC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg15226275	chr6:116381976	FRK	0.3	8.43	0.42	1.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg05540913	chr6:167530185	CCR6	-0.35	-6.41	-0.33	5.17e-10	Rheumatoid arthritis;
CRC	cis	rs7932354	0.528	rs2018527	chr11:47175809	A/G	cg03339077	chr11:47165057	C11orf49	-0.48	-6.8	-0.35	5.08e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg03623178	chr6:28175578	NA	0.7	6.28	0.33	1.08e-9	Breast cancer;
CRC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg14196790	chr5:131705035	SLC22A5	-0.35	-5.62	-0.3	3.98e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00938859	chr5:1591904	SDHAP3	0.73	7.76	0.39	1.05e-13	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17157516	chr1:35332203	DLGAP3	-0.52	-6.45	-0.34	3.96e-10	Diisocyanate-induced asthma;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg26587870	chr6:27730563	NA	-0.37	-5.64	-0.3	3.62e-8	Cardiac Troponin-T levels;
CRC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg18876405	chr7:65276391	NA	-0.46	-6.33	-0.33	8.06e-10	Aortic root size;
CRC	cis	rs4790333	0.813	rs2005029	chr17:2255138	G/T	cg02569219	chr17:2266849	SGSM2	-0.52	-9.04	-0.45	1.37e-17	Proinsulin levels;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9462846	0.841	rs13206802	chr6:42871148	G/A	cg21280719	chr6:42927975	GNMT	-0.33	-6.47	-0.34	3.65e-10	Blood protein levels;
CRC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.44	0.46	6.89e-19	Cognitive test performance;
CRC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.54	-5.88	-0.31	9.87e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg27532560	chr4:187881888	NA	-0.56	-10.22	-0.49	1.79e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.44	-6.18	-0.32	1.9e-9	Daytime sleep phenotypes;
CRC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs9648716	0.580	rs801098	chr7:140655727	A/G	cg10747023	chr7:140774559	NA	0.42	5.79	0.3	1.67e-8	Type 2 diabetes;
CRC	cis	rs10486722	0.624	rs10224857	chr7:41765978	T/G	cg22138096	chr7:41772439	LOC285954	0.38	5.64	0.3	3.57e-8	Pit-and-Fissure caries;
CRC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.42	6.64	0.34	1.3100000000000001e-10	Dupuytren's disease;
CRC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.31	0.46	1.85e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.92	0.31	8.07e-9	Monocyte percentage of white cells;
CRC	cis	rs7129556	1.000	rs7129556	chr11:77300048	A/G	cg12586386	chr11:77299805	AQP11	-0.42	-5.89	-0.31	9.66e-9	Weight loss (gastric bypass surgery);
CRC	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg15226275	chr6:116381976	FRK	0.31	7.36	0.38	1.45e-12	Total cholesterol levels;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg10876282	chr6:28092338	ZSCAN16	0.48	6.55	0.34	2.21e-10	Parkinson's disease;
CRC	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg05784532	chr1:230284198	GALNT2	0.42	5.87	0.31	1.08e-8	Coronary artery disease;
CRC	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.68	-10.91	-0.52	7.49e-24	Motion sickness;
CRC	cis	rs1223397	0.938	rs35511719	chr6:13282442	T/C	cg20827128	chr6:13274284	PHACTR1	0.55	6.55	0.34	2.27e-10	Blood pressure;
CRC	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg16691251	chr5:66510806	NA	-0.44	-7.88	-0.4	4.84e-14	Breast cancer;
CRC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.68e-21	Aortic root size;
CRC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	7.33	0.37	1.83e-12	Motion sickness;
CRC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.54	7.36	0.38	1.44e-12	Tuberculosis;
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.46	6.42	0.33	4.79e-10	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08300164	chr4:56815263	CEP135	0.48	6.64	0.34	1.29e-10	Response to antipsychotic treatment;
CRC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.63	9.72	0.47	8.42e-20	Pancreatic cancer;
CRC	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.27	-0.37	2.69e-12	Cholesterol, total;
CRC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00612595	chr21:47717864	NA	-0.39	-6.25	-0.33	1.28e-9	Testicular germ cell tumor;
CRC	trans	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs7527798	0.592	rs4097398	chr1:207857760	C/T	cg09232269	chr1:207846808	CR1L	-0.45	-7.33	-0.37	1.84e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg22110888	chr17:80059540	CCDC57	0.38	6.07	0.32	3.61e-9	Life satisfaction;
CRC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-7.06	-0.36	9.89e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	trans	rs4879656	0.525	rs10971406	chr9:33099668	A/G	cg22174844	chr1:39570747	MACF1	-0.46	-6.28	-0.33	1.06e-9	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03193417	chr12:56583536	SMARCC2	0.49	6.19	0.32	1.83e-9	Thyroid stimulating hormone;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg04969067	chr8:143858791	LYNX1	-0.42	-6.64	-0.34	1.28e-10	Urinary tract infection frequency;
CRC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.79	11.88	0.55	2.48e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.39	-7.37	-0.38	1.37e-12	Iron status biomarkers;
CRC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.34	-5.96	-0.31	6.56e-9	Menarche (age at onset);
CRC	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.52	9.22	0.45	3.57e-18	Common traits (Other);
CRC	cis	rs995000	0.965	rs4587594	chr1:63133930	G/A	cg19896129	chr1:63156450	NA	0.4	5.94	0.31	7.29e-9	Triglyceride levels;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg04969067	chr8:143858791	LYNX1	0.44	7.47	0.38	7.38e-13	Urinary tract infection frequency;
CRC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.45	-0.34	3.9e-10	Tonsillectomy;
CRC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.48	0.34	3.35e-10	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24249390	chr15:90295951	MESP1	-0.59	-9.61	-0.47	1.93e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg23982607	chr1:1823379	GNB1	0.41	5.78	0.3	1.72e-8	Body mass index;
CRC	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	trans	rs7690467	0.794	rs1875024	chr4:133395895	C/T	cg19296258	chr17:78878799	RPTOR	-0.49	-6.61	-0.34	1.51e-10	Eating disorders;
CRC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.66	9.42	0.46	8.32e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7487075	0.619	rs2408498	chr12:46796900	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.88	0.31	9.88e-9	Itch intensity from mosquito bite;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg19223190	chr17:80058835	NA	0.38	6.18	0.32	1.94e-9	Life satisfaction;
CRC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.88	-0.4	4.76e-14	Gut microbiome composition (summer);
CRC	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-10.36	-0.5	5.94e-22	Blood protein levels;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg10876282	chr6:28092338	ZSCAN16	0.49	6.71	0.35	8.48e-11	Cardiac Troponin-T levels;
CRC	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg04110750	chr16:69646130	NFAT5	-0.52	-6.92	-0.36	2.3e-11	IgE levels;
CRC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.93e-18	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.4	6.07	0.32	3.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4731207	0.698	rs6466954	chr7:124515346	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.78	-0.3	1.71e-8	Blood pressure;
CRC	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg03037974	chr15:76606532	NA	-0.5	-7.1	-0.36	7.9e-12	Blood metabolite levels;
CRC	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.56	9.51	0.46	4.26e-19	Dupuytren's disease;
CRC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.58	-7.57	-0.39	3.69e-13	Schizophrenia;
CRC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs995000	0.931	rs1168015	chr1:62996046	C/G	cg19896129	chr1:63156450	NA	-0.45	-6.97	-0.36	1.75e-11	Triglyceride levels;
CRC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.83	-0.72	3.41e-54	Height;
CRC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.61	-8.05	-0.41	1.57e-14	Gut microbiome composition (summer);
CRC	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	17.67	0.7	1.31e-49	Platelet count;
CRC	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.24	0.49	1.56e-21	Corneal astigmatism;
CRC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.6	-6.09	-0.32	3.2e-9	Tuberculosis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18088653	chr15:71407757	CT62	0.39	6.15	0.32	2.19e-9	Schizophrenia;
CRC	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.44	-6.7	-0.35	9.29e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.63	11.4	0.53	1.32e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg15786705	chr6:28176104	NA	0.78	9.63	0.47	1.65e-19	Depression;
CRC	cis	rs9925964	0.933	rs9929899	chr16:31062701	C/A	cg03418659	chr16:31128414	MYST1	0.46	6.83	0.35	4.23e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.39	0.38	1.24e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.53	0.43	5.53e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs995000	0.931	rs2479464	chr1:63130991	G/A	cg19896129	chr1:63156450	NA	-0.42	-6.45	-0.34	3.99e-10	Triglyceride levels;
CRC	cis	rs7932354	0.528	rs7103581	chr11:47072805	G/T	cg03339077	chr11:47165057	C11orf49	0.44	6.23	0.32	1.44e-9	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg12500891	chr11:57225987	NA	-0.69	-6.06	-0.32	3.82e-9	Cognitive function;
CRC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.52	7.51	0.38	5.64e-13	Alzheimer's disease (late onset);
CRC	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-5.77	-0.3	1.85e-8	Asthma (bronchodilator response);
CRC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.61	11.04	0.52	2.48e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19590290	chr4:104119639	CENPE	0.44	6.17	0.32	2.03e-9	Anxiety disorder;
CRC	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.33	16.07	0.66	2.6e-43	Uric acid levels;
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.59	-9.06	-0.45	1.17e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg18335740	chr13:41363409	SLC25A15	-0.52	-7.78	-0.39	9.41e-14	Lewy body disease;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg21251018	chr6:28226885	NKAPL	0.46	7.14	0.37	6.07e-12	Cardiac Troponin-T levels;
CRC	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.78	-7.42	-0.38	9.94e-13	Non-glioblastoma glioma;Glioma;
CRC	cis	rs72627123	0.867	rs73301477	chr14:74463560	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.0	0.31	5.3300000000000004e-09	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23161317	chr6:28129485	ZNF389	0.54	6.52	0.34	2.61e-10	Depression;
CRC	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.61	8.05	0.41	1.53e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00402069	chr5:89770788	POLR3G;MBLAC2	0.42	6.53	0.34	2.46e-10	Obesity-related traits;
CRC	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg26875233	chr11:93583750	C11orf90	-0.33	-6.48	-0.34	3.36e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.72	11.15	0.52	1.02e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.59	0.43	3.61e-16	Mean corpuscular volume;
CRC	trans	rs473651	0.837	rs563458	chr2:239345613	T/A	cg13521940	chr21:36262239	RUNX1	-0.4	-5.97	-0.31	6.29e-9	Multiple system atrophy;
CRC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.45	6.94	0.36	2.08e-11	Monocyte count;
CRC	cis	rs6604026	0.740	rs10874747	chr1:93352491	A/G	cg17283838	chr1:93427260	FAM69A	-0.5	-6.89	-0.35	2.9e-11	Multiple sclerosis;
CRC	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg03037974	chr15:76606532	NA	-0.44	-6.19	-0.32	1.76e-9	Blood metabolite levels;
CRC	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg17545662	chr6:170176663	C6orf70	0.53	5.82	0.31	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs863345	0.604	rs6699473	chr1:158495209	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.77	-11.18	-0.52	8.1e-25	Menarche (age at onset);
CRC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg20608306	chr11:116969690	SIK3	-0.29	-5.82	-0.31	1.38e-8	Blood protein levels;
CRC	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.38	-5.62	-0.3	4.11e-8	IFN-related cytopenia;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg21620606	chr4:1342894	KIAA1530	0.4	7.22	0.37	3.59e-12	Obesity-related traits;
CRC	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.01	-0.31	4.84e-9	Coronary artery disease;
CRC	trans	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg26043149	chr18:55253948	FECH	-0.53	-8.2	-0.41	5.61e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.61	0.34	1.52e-10	Subjective well-being;
CRC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.51	8.13	0.41	8.98e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg13385794	chr1:248469461	NA	0.38	6.66	0.34	1.14e-10	Common traits (Other);
CRC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-8.76	-0.43	1.06e-16	Type 2 diabetes;
CRC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg11833968	chr6:79620685	NA	-0.36	-6.26	-0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	0.84	7.67	0.39	2.02e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg23193639	chr7:45961078	IGFBP3	0.38	6.52	0.34	2.73e-10	Sitting height ratio;
CRC	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.42	6.74	0.35	7.19e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg07217954	chr7:1067459	C7orf50	0.55	5.73	0.3	2.26e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25752527	chr2:136499146	UBXN4	0.43	6.38	0.33	6.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.5	8.91	0.44	3.64e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg11212589	chr17:38028394	ZPBP2	0.42	7.55	0.38	4.22e-13	Self-reported allergy;
CRC	trans	rs56052703	0.702	rs76893841	chr19:13432778	G/A	cg07875759	chr21:43639080	ABCG1	-0.49	-6.08	-0.32	3.33e-9	Proteinuria and chronic kidney disease;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg12172441	chr6:28176163	NA	0.59	7.37	0.38	1.43e-12	Parkinson's disease;
CRC	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg14631576	chr9:95140430	CENPP	-0.33	-5.97	-0.31	6.26e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18247177	chr17:7745472	KDM6B	0.42	6.02	0.31	4.77e-9	Response to antipsychotic treatment;
CRC	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.32	-0.33	8.67e-10	Body mass index;
CRC	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.48	8.47	0.42	8.2e-16	Blood metabolite ratios;
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.98	-0.44	2.21e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.61	-11.25	-0.53	4.46e-25	Immature fraction of reticulocytes;
CRC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.7	-0.3	2.64e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26790897	chr7:56147772	SUMF2	0.37	6.08	0.32	3.29e-9	Myopia (pathological);
CRC	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg12856521	chr11:46389249	DGKZ	-0.44	-6.98	-0.36	1.67e-11	Leprosy;
CRC	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg06818126	chr11:68850279	TPCN2	0.43	5.85	0.31	1.18e-8	Hair color;
CRC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-1.12	-19.3	-0.73	5.07e-56	Blood pressure (smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12557235	chr12:122242600	SETD1B;LOC338799	0.45	6.22	0.32	1.48e-9	Anxiety disorder;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23713156	chr17:80606235	WDR45L	0.38	6.05	0.32	3.84e-9	Obesity-related traits;
CRC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-7.75	-0.39	1.16e-13	Menarche (age at onset);
CRC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.41	0.5	4.01e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9914544	0.545	rs9914914	chr17:18787780	G/A	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.1	-0.32	2.93e-9	Educational attainment (years of education);
CRC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg11632617	chr15:75315747	PPCDC	-0.56	-7.74	-0.39	1.23e-13	Blood trace element (Zn levels);
CRC	cis	rs812925	0.519	rs1186706	chr2:61673394	G/T	cg10580144	chr2:61372316	C2orf74	0.31	6.71	0.35	8.71e-11	Immature fraction of reticulocytes;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg18758796	chr5:131593413	PDLIM4	0.35	6.36	0.33	6.6e-10	Blood metabolite levels;
CRC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.55	-6.36	-0.33	6.6e-10	Bipolar disorder;
CRC	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.46	-6.04	-0.32	4.13e-9	Post bronchodilator FEV1;
CRC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.43	-6.34	-0.33	7.56e-10	Electroencephalogram traits;
CRC	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-7.42	-0.38	1.01e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg02569458	chr12:86230093	RASSF9	0.48	8.01	0.4	2.05e-14	Major depressive disorder;
CRC	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.75	0.35	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg04202892	chr2:111875749	ACOXL	0.35	5.68	0.3	3.01e-8	Chronic lymphocytic leukemia;
CRC	cis	rs1800978	0.925	rs2244278	chr9:107661129	C/A	cg14313833	chr9:107666037	ABCA1	-0.58	-5.96	-0.31	6.33e-9	Coronary artery disease;
CRC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.72	-13.08	-0.58	9.07e-32	Iron status biomarkers;
CRC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.55	0.54	3.78e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg10483660	chr13:112241077	NA	0.36	5.82	0.31	1.39e-8	Menarche (age at onset);
CRC	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.88	15.8	0.66	3.14e-42	Obesity (extreme);
CRC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.5	-7.22	-0.37	3.55e-12	White blood cell count;
CRC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.37	-0.33	6.52e-10	Dupuytren's disease;
CRC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.33	1.04e-9	Heart rate;
CRC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.44	-6.38	-0.33	6.11e-10	Cerebrospinal P-tau181p levels;
CRC	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.21	0.49	1.9e-21	Corneal astigmatism;
CRC	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.38	6.4	0.33	5.43e-10	Sitting height ratio;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.6	-11.3	-0.53	3.13e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.31	-5.91	-0.31	8.55e-9	Cutaneous nevi;
CRC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.34	0.33	7.54e-10	Aortic root size;
CRC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.7	9.94	0.48	1.62e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs7804356	1.000	rs73069510	chr7:26877567	T/C	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.1e-8	Type 1 diabetes;
CRC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.42	6.59	0.34	1.8e-10	Red blood cell count;
CRC	cis	rs4880487	0.888	rs35341304	chr10:1252526	T/C	cg03183215	chr10:1252341	ADARB2	-0.3	-6.32	-0.33	8.35e-10	Migraine;
CRC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.63	11.1	0.52	1.63e-24	Schizophrenia;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.86	-19.5	-0.73	8.09e-57	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg12172441	chr6:28176163	NA	0.57	7.93	0.4	3.39e-14	Parkinson's disease;
CRC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg22495460	chr2:25135724	ADCY3	-0.87	-17.43	-0.69	1.16e-48	Body mass index;
CRC	cis	rs13226913	0.643	rs7780273	chr7:7250449	A/C	cg04827551	chr7:7268805	C1GALT1	-0.4	-6.08	-0.32	3.33e-9	Serum galactose-deficient IgA1 levels;
CRC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.32	0.42	2.38e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.76e-9	Life satisfaction;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-0.56	-7.63	-0.39	2.61e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.58	9.7	0.47	9.81e-20	Menopause (age at onset);
CRC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.58	-6.03	-0.32	4.43e-9	Lung function (FVC);Lung function (FEV1);
CRC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg25985355	chr7:65971099	NA	0.32	5.69	0.3	2.81e-8	Aortic root size;
CRC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.37	6.23	0.32	1.45e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg03006477	chr6:74432658	CD109	0.36	6.31	0.33	9.1e-10	Blood protein levels;Calcium levels;
CRC	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg04439458	chr5:138467593	SIL1	-0.35	-5.98	-0.31	5.95e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg13206674	chr6:150067644	NUP43	0.45	5.69	0.3	2.85e-8	Lung cancer;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05665937	chr4:1216051	CTBP1	-0.39	-5.99	-0.31	5.58e-9	Obesity-related traits;
CRC	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.6	9.36	0.46	1.32e-18	Proinsulin levels;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg24874828	chr4:187887005	NA	-0.34	-5.92	-0.31	8.26e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.56	9.39	0.46	1.03e-18	Menopause (age at onset);
CRC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.04	-9.95	-0.48	1.45e-20	Alzheimer's disease (late onset);
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.71	9.42	0.46	7.95e-19	Alzheimer's disease;
CRC	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07513332	chr6:167530253	CCR6	0.43	7.76	0.39	1.08e-13	Primary biliary cholangitis;
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	trans	rs800082	0.516	rs1178896	chr3:144240689	A/T	cg24215973	chr2:240111563	HDAC4	0.45	6.36	0.33	6.88e-10	Smoking behavior;
CRC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.7	10.79	0.51	1.95e-23	Corneal astigmatism;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07355693	chr12:125667907	NA	0.42	6.44	0.33	4.15e-10	Myopia (pathological);
CRC	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05585630	chr7:157510462	PTPRN2	-0.43	-6.86	-0.35	3.39e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.5	7.24	0.37	3.16e-12	Vitiligo;
CRC	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg16989086	chr20:62203971	PRIC285	0.52	6.75	0.35	6.8e-11	Atopic dermatitis;
CRC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.76	-9.26	-0.45	2.65e-18	Initial pursuit acceleration;
CRC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.04	0.32	4.12e-9	Personality dimensions;
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.58	8.32	0.42	2.39e-15	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04767442	chr6:49817519	CRISP1	0.39	5.97	0.31	6.17e-9	Response to antipsychotic treatment;
CRC	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.34	-0.38	1.63e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	trans	rs12495832	0.778	rs76846626	chr3:147907283	C/T	cg10221266	chr7:153579447	NA	0.56	6.13	0.32	2.54e-9	Chin dimples;
CRC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.19	-16.52	-0.67	4.72e-45	Breast cancer;
CRC	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.84	-11.03	-0.52	2.86e-24	Gut microbiome composition (summer);
CRC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.14	-0.32	2.37e-9	Height;
CRC	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-0.62	-7.02	-0.36	1.27e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs7259376	0.902	rs12610462	chr19:22551462	C/T	cg02657401	chr19:22469223	NA	-0.32	-7.0	-0.36	1.44e-11	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03145124	chr4:76649546	USO1	0.54	7.6	0.39	3.19e-13	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20760063	chr17:41277580	NBR2;BRCA1	0.42	6.3	0.33	9.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.41e-18	Lymphocyte counts;
CRC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-6.28	-0.33	1.06e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.5	10.11	0.49	4.27e-21	Ulcerative colitis;
CRC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg26805224	chr10:79626177	DLG5	-0.48	-6.93	-0.36	2.18e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	0.87	8.08	0.41	1.23e-14	Plateletcrit;
CRC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.02	-0.4	1.93e-14	Gut microbiome composition (summer);
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg14003231	chr6:33640908	ITPR3	0.43	7.04	0.36	1.16e-11	Height;
CRC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg24881330	chr22:46731750	TRMU	0.56	6.6	0.34	1.61e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.24	-0.37	3.24e-12	IgG glycosylation;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg14577476	chr17:49337432	MBTD1;UTP18	-0.37	-6.07	-0.32	3.57e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.47	-6.75	-0.35	6.52e-11	Breast cancer;
CRC	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.63	6.62	0.34	1.43e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.62	9.61	0.47	1.96e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12550646	0.600	rs10110994	chr8:41671503	A/G	cg12180191	chr8:41686706	ANK1	-0.48	-7.08	-0.36	8.59e-12	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg23650765	chr1:12612165	NA	0.3	5.75	0.3	2.03e-8	Optic cup area;
CRC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg03037974	chr15:76606532	NA	-0.5	-7.07	-0.36	9.6e-12	Blood metabolite levels;
CRC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.61	8.47	0.42	8.03e-16	Coronary artery disease;
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.44	-9.1	-0.45	8.91e-18	Bipolar disorder;
CRC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-7.14	-0.37	5.95e-12	Hemostatic factors and hematological phenotypes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12128893	chr10:75255807	PPP3CB	0.5	6.69	0.35	9.6e-11	Thyroid stimulating hormone;
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg04155289	chr7:94953770	PON1	-0.62	-7.74	-0.39	1.23e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.73	-13.14	-0.59	5.49e-32	Oral cavity cancer;
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.8	14.2	0.62	5.1e-36	Breast cancer;
CRC	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg13628971	chr7:2884303	GNA12	0.41	6.12	0.32	2.61e-9	Height;
CRC	trans	rs2303319	0.504	rs62189003	chr2:162548104	T/A	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.95	-0.31	6.8e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg00603274	chr11:61596626	FADS2	-0.82	-9.73	-0.47	7.78e-20	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs16937	0.662	rs11240376	chr1:205146460	A/G	cg00857998	chr1:205179979	DSTYK	0.41	5.68	0.3	2.94e-8	Schizophrenia;
CRC	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.61	7.32	0.37	1.88e-12	Carotid intima media thickness;
CRC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.74	-0.43	1.19e-16	Uric acid levels;
CRC	cis	rs2857891	0.695	rs1907609	chr11:6991389	G/A	cg04053776	chr11:6947353	ZNF215	0.43	6.68	0.35	1.03e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg23100626	chr2:96804247	ASTL	0.28	7.08	0.36	8.68e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg07423050	chr13:99094983	FARP1	0.43	6.54	0.34	2.41e-10	Longevity;
CRC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.57	-8.81	-0.44	7.2e-17	Height;
CRC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.61	7.18	0.37	4.57e-12	Lymphocyte counts;
CRC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.29	-0.37	2.31e-12	Colorectal cancer;
CRC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg10935138	chr17:73851978	WBP2	0.64	7.49	0.38	6.19e-13	Psoriasis;
CRC	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.63	8.26	0.41	3.61e-15	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg03037974	chr15:76606532	NA	0.69	12.34	0.56	5.33e-29	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.73	9.87	0.48	2.75e-20	Alzheimer's disease;
CRC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.5	6.71	0.35	8.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-7.49	-0.38	6.2800000000000005e-13	Extraversion;
CRC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.64	-12.22	-0.56	1.49e-28	Systolic blood pressure;
CRC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg11189052	chr15:85197271	WDR73	0.56	7.53	0.38	5.02e-13	Schizophrenia;
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg27535305	chr1:53392650	SCP2	0.39	6.97	0.36	1.72e-11	Monocyte count;
CRC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg03885332	chr11:832357	CD151	-0.42	-6.18	-0.32	1.88e-9	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08951903	chr10:44070173	ZNF239	0.4	5.97	0.31	6.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg26028573	chr6:26043587	HIST1H2BB	-0.44	-6.37	-0.33	6.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.52	8.16	0.41	7.11e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg27398640	chr15:77910606	LINGO1	0.38	6.9	0.36	2.66e-11	Type 2 diabetes;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12958836	chr12:8185024	FOXJ2	0.49	6.77	0.35	5.88e-11	Survival in pancreatic cancer;
CRC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg12193833	chr17:30244370	NA	-0.75	-8.76	-0.44	1.01e-16	Hip circumference adjusted for BMI;
CRC	cis	rs13315871	0.929	rs9854438	chr3:58277327	G/A	cg20936604	chr3:58311152	NA	-0.61	-5.83	-0.31	1.35e-8	Cholesterol, total;
CRC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-12.66	-0.57	3.45e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.74	-0.39	1.2e-13	Vitamin D levels;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.9	-0.4	4.33e-14	Longevity;Endometriosis;
CRC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.63	11.28	0.53	3.55e-25	Schizophrenia;
CRC	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg18830697	chr6:72922368	RIMS1	0.4	7.69	0.39	1.7e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs7572644	0.699	rs7577342	chr2:28205581	A/G	cg27432699	chr2:27873401	GPN1	0.41	5.67	0.3	3.12e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19793034	chr4:1284190	MAEA	0.49	6.34	0.33	7.42e-10	Thyroid stimulating hormone;
CRC	cis	rs7113874	0.610	rs10840055	chr11:8494345	C/T	cg20771178	chr11:8615675	STK33	0.34	5.67	0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg15898840	chr7:45960834	IGFBP3	0.45	7.4	0.38	1.14e-12	Sitting height ratio;
CRC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.66	9.24	0.45	3.06e-18	Vitiligo;
CRC	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.55	7.04	0.36	1.1e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.45	-7.28	-0.37	2.49e-12	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.36	8.17	0.41	6.49e-15	Multiple system atrophy;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.56	6.65	0.34	1.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs11098699	0.821	rs6811839	chr4:124222326	G/A	cg09941581	chr4:124220074	SPATA5	0.43	6.39	0.33	5.51e-10	Mosquito bite size;
CRC	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.48	7.56	0.38	3.94e-13	Red blood cell count;
CRC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.94	0.36	2.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.53	-0.34	2.49e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.6	0.43	3.34e-16	Rheumatoid arthritis;
CRC	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg09003973	chr2:102972529	NA	0.72	7.95	0.4	2.96e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.07	0.32	3.46e-9	Crohn's disease;
CRC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-12.61	-0.57	5.17e-30	Prostate cancer;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg21620606	chr4:1342894	KIAA1530	0.53	9.54	0.47	3.33e-19	Longevity;
CRC	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.46	-6.45	-0.34	4.01e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.7	9.46	0.46	5.93e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.42	6.81	0.35	4.67e-11	Sitting height ratio;
CRC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg00579200	chr11:133705235	NA	-0.41	-5.96	-0.31	6.32e-9	Childhood ear infection;
CRC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg08888203	chr3:10149979	C3orf24	0.48	7.18	0.37	4.64e-12	Alzheimer's disease;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg21251018	chr6:28226885	NKAPL	0.47	7.36	0.38	1.44e-12	Cardiac Troponin-T levels;
CRC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19825600	chr2:3704501	ALLC	-0.53	-6.37	-0.33	6.52e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7894051	1.000	rs2185746	chr10:135195332	A/G	cg20534287	chr10:135191450	PAOX	-0.68	-6.53	-0.34	2.43e-10	Lifespan;
CRC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.51	7.31	0.37	2.02e-12	Height;
CRC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.21	-0.37	3.97e-12	Coronary artery disease;
CRC	cis	rs73200209	0.704	rs56258518	chr12:116596371	G/A	cg01776926	chr12:116560359	MED13L	-0.62	-7.21	-0.37	3.98e-12	Total body bone mineral density;
CRC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg18479299	chr3:125709523	NA	-0.54	-6.28	-0.33	1.04e-9	Blood pressure (smoking interaction);
CRC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.5	-0.34	2.94e-10	Triglycerides;
CRC	cis	rs1387259	0.698	rs4579969	chr12:48779562	C/T	cg21466736	chr12:48725269	NA	0.38	5.85	0.31	1.22e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg07424746	chr4:185654737	MLF1IP	-0.63	-5.97	-0.31	6.28e-9	Blood protein levels;
CRC	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg17633681	chr16:88106987	BANP	0.81	13.65	0.6	6.22e-34	Menopause (age at onset);
CRC	cis	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg11143507	chr3:125485238	NA	-0.58	-7.46	-0.38	7.69e-13	Blood pressure (smoking interaction);
CRC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg16822035	chr13:113633379	MCF2L	-0.29	-6.07	-0.32	3.61e-9	Systolic blood pressure;
CRC	cis	rs2969070	0.831	rs7799266	chr7:2506595	G/A	cg03277898	chr7:2518824	NA	-0.43	-6.16	-0.32	2.13e-9	Diastolic blood pressure;
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg22687807	chr8:143858763	LYNX1	0.51	8.97	0.44	2.24e-17	Urinary tract infection frequency;
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg02560186	chr11:3602584	NA	-0.63	-9.54	-0.47	3.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.4	-5.93	-0.31	7.5e-9	Lung cancer;
CRC	trans	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg10756647	chr7:56101905	PSPH	-0.7	-7.52	-0.38	5.25e-13	Diabetic kidney disease;
CRC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	9.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.66	-0.34	1.18e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.74	11.65	0.54	1.64e-26	Anterior chamber depth;
CRC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.66	0.68	1.34e-45	Platelet count;
CRC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05317630	chr4:184366047	CDKN2AIP	0.45	6.08	0.32	3.34e-9	Anxiety disorder;
CRC	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.59	-8.25	-0.41	3.8e-15	Waist circumference;Body mass index;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg24311251	chr13:44453387	CCDC122;C13orf31	-0.42	-6.68	-0.35	1.02e-10	Brain structure;
CRC	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	0.59	6.69	0.35	9.74e-11	Prostate cancer;
CRC	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg23032129	chr1:109941072	SORT1	-0.27	-5.79	-0.3	1.65e-8	Intelligence (multi-trait analysis);
CRC	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.45	8.99	0.44	1.99e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs61160187	0.582	rs1021005	chr5:60191460	A/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs457287	0.892	rs461130	chr9:4834597	C/T	cg14182974	chr9:4791918	RCL1	0.37	6.02	0.32	4.54e-9	Platelet count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09378497	chr16:1525169	CLCN7	0.45	6.4	0.33	5.32e-10	Anxiety disorder;
CRC	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg03805757	chr16:71968109	PKD1L3	-0.47	-5.95	-0.31	6.74e-9	Post bronchodilator FEV1;
CRC	cis	rs4380275	1.000	rs73143802	chr2:773826	T/C	cg27237671	chr2:676223	TMEM18	-0.43	-6.11	-0.32	2.76e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.27	0.56	9.02e-29	Platelet count;
CRC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Body mass index;
CRC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg15445000	chr17:37608096	MED1	0.41	8.93	0.44	2.96e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg17420585	chr12:42539391	GXYLT1	-0.44	-6.37	-0.33	6.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-6.12	-0.32	2.63e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.91	-0.52	7.62e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	1.03	20.74	0.75	1.06e-61	Lewy body disease;
CRC	cis	rs12044355	0.929	rs1954175	chr1:231855410	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.03	0.32	4.5e-9	Alzheimer's disease;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg21251018	chr6:28226885	NKAPL	0.48	6.64	0.34	1.29e-10	Parkinson's disease;
CRC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.16	-16.31	-0.67	2.94e-44	Breast cancer;
CRC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.82	-11.49	-0.54	6.46e-26	Platelet distribution width;
CRC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12884169	chr21:40033163	ERG	0.34	7.54	0.38	4.71e-13	Coronary artery disease;
CRC	trans	rs2078087	1.000	rs11577151	chr1:183381795	A/G	cg01099024	chr14:70347833	SMOC1	-0.48	-6.1	-0.32	2.98e-9	Obesity-related traits;
CRC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-15.9	-0.66	1.28e-42	Body mass index;
CRC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg16558177	chr4:4109446	NA	-0.47	-6.09	-0.32	3.21e-9	Blood pressure (smoking interaction);
CRC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg13390004	chr1:15929781	NA	0.52	7.25	0.37	2.93e-12	Systolic blood pressure;
CRC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.36	6.17	0.32	2.04e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg15445000	chr17:37608096	MED1	-0.35	-6.12	-0.32	2.59e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.72	12.82	0.58	8.71e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.71	0.3	2.56e-8	Hemoglobin concentration;
CRC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.73	10.47	0.5	2.51e-22	Cognitive function;
CRC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.74	10.51	0.5	1.78e-22	Schizophrenia;
CRC	cis	rs55894132	1	rs55894132	chr14:23408837	C/G	cg25600027	chr14:23388339	RBM23	-0.43	-6.38	-0.33	5.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg07274523	chr3:49395745	GPX1	0.47	6.02	0.31	4.71e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.96	0.44	2.49e-17	Intelligence (multi-trait analysis);
CRC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	trans	rs2303319	0.504	rs12469302	chr2:162433831	G/T	cg10498984	chr16:28874827	SH2B1	-0.73	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.31	-5.64	-0.3	3.64e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg21251018	chr6:28226885	NKAPL	0.4	6.06	0.32	3.66e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.47	-5.79	-0.3	1.62e-8	Gut microbiome composition (summer);
CRC	trans	rs204595	0.896	rs28579261	chr7:20896148	C/G	cg02372745	chr13:50365574	KPNA3	-0.45	-5.97	-0.31	6.04e-9	Depressive symptoms (stressful life events interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02113521	chr15:22892956	CYFIP1	0.43	7.16	0.37	5.43e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.49	6.09	0.32	3.14e-9	Body mass index (adult);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12600378	chr5:52405361	MOCS2	0.41	6.39	0.33	5.52e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg21659725	chr3:3221576	CRBN	0.66	6.72	0.35	8.1e-11	Menarche (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26726589	chr20:306364	SOX12	0.38	6.31	0.33	8.86e-10	Obesity-related traits;
CRC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.39	5.63	0.3	3.8e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.93	12.59	0.57	6e-30	Height;
CRC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg12193833	chr17:30244370	NA	0.55	6.82	0.35	4.32e-11	Hip circumference adjusted for BMI;
CRC	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.71	-10.88	-0.51	9.71e-24	Response to temozolomide;
CRC	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15369054	chr17:80825471	TBCD	-0.52	-8.23	-0.41	4.34e-15	Breast cancer;
CRC	cis	rs117623576	0.941	rs111864818	chr10:32426613	G/A	cg03047570	chr10:32398778	NA	-0.7	-6.99	-0.36	1.57e-11	Anti-saccade response;
CRC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.75e-11	Body mass index;
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.38	-0.38	1.27e-12	Menopause (age at onset);
CRC	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg09455208	chr3:40491958	NA	0.32	6.65	0.34	1.24e-10	Renal cell carcinoma;
CRC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.47	7.22	0.37	3.65e-12	Corneal astigmatism;
CRC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	0.93	11.02	0.52	3.11e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg09835421	chr16:68378352	PRMT7	-0.76	-8.1	-0.41	1.12e-14	Schizophrenia;
CRC	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs12024301	0.557	rs16861451	chr1:183646306	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.73	6.43	0.33	4.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-6.81	-0.35	4.6e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs863345	0.604	rs12078065	chr1:158465063	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.35	-0.33	7.19e-10	Pneumococcal bacteremia;
CRC	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.66	-7.85	-0.4	5.91e-14	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.46	-7.33	-0.37	1.79e-12	Schizophrenia;
CRC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg17330251	chr7:94953956	PON1	-0.59	-7.65	-0.39	2.27e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.6	9.38	0.46	1.12e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2929278	0.617	rs524908	chr15:44187991	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-6.14	-0.32	2.39e-9	Schizophrenia;
CRC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg26721908	chr21:47610096	LSS	0.45	7.39	0.38	1.21e-12	Testicular germ cell tumor;
CRC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.77	9.75	0.47	6.59e-20	Eosinophil percentage of granulocytes;
CRC	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg03929089	chr4:120376271	NA	0.66	6.31	0.33	9.22e-10	Axial length;
CRC	cis	rs2530545	0.851	rs10276755	chr7:34679959	C/T	cg14401837	chr7:34697493	NPSR1	0.41	5.68	0.3	2.96e-8	IgG glycosylation;
CRC	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.32	-0.33	8.45e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg04731861	chr2:219085781	ARPC2	0.31	6.36	0.33	6.94e-10	Colorectal cancer;
CRC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	7.58	0.39	3.49e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.63	9.82	0.48	3.9e-20	Initial pursuit acceleration;
CRC	trans	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg11693508	chr17:37793320	STARD3	0.51	6.74	0.35	6.9e-11	Neuroticism;
CRC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.6	0.63	1.48e-37	Fuchs's corneal dystrophy;
CRC	cis	rs4731207	0.596	rs7790975	chr7:124577944	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg19824325	chr16:58548873	SETD6	0.87	5.81	0.31	1.44e-8	Schizophrenia;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.81	0.31	1.47e-8	Obesity-related traits;
CRC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg22777020	chr22:31556080	RNF185	-0.53	-6.2	-0.32	1.72e-9	Colorectal cancer;
CRC	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06156847	chr2:113672199	IL1F7	-0.45	-6.78	-0.35	5.59e-11	Pulmonary function;
CRC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg23517279	chr6:96025343	MANEA	0.55	6.38	0.33	6.07e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.34	-0.33	7.37e-10	Eye color traits;
CRC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.79	-0.47	5.04e-20	Primary sclerosing cholangitis;
CRC	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.13	-0.37	6.34e-12	Capecitabine sensitivity;
CRC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.47	7.72	0.39	1.42e-13	Major depressive disorder;
CRC	cis	rs6988985	0.560	rs2078674	chr8:143928233	G/T	cg10324643	chr8:143916377	GML	0.37	6.23	0.32	1.45e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.51	9.03	0.45	1.45e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	8.73	0.43	1.3e-16	Menarche (age at onset);
CRC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.53	-5.61	-0.3	4.28e-8	Vitamin D levels;
CRC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.58	0.34	1.83e-10	Morning vs. evening chronotype;
CRC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.78	-15.94	-0.66	8.46e-43	Prostate cancer;
CRC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.24	-16.52	-0.67	4.4e-45	Breast cancer;
CRC	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg01843034	chr6:37503916	NA	-0.43	-8.08	-0.41	1.21e-14	Cognitive performance;
CRC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.56	5.68	0.3	2.94e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg03623178	chr6:28175578	NA	0.94	12.33	0.56	5.52e-29	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05504270	chr16:72130759	DHX38	-0.38	-6.3	-0.33	9.33e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.1	0.32	2.98e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.96	15.57	0.65	2.37e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.82	-10.92	-0.52	6.85e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg23100626	chr2:96804247	ASTL	-0.28	-7.76	-0.39	1.09e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs995000	0.868	rs9787151	chr1:63179138	C/T	cg19896129	chr1:63156450	NA	-0.43	-6.52	-0.34	2.67e-10	Triglyceride levels;
CRC	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.79	7.84	0.4	6.36e-14	Major depressive disorder;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg20933634	chr6:27740509	NA	0.62	8.02	0.4	1.86e-14	Breast cancer;
CRC	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg23815491	chr16:72088622	HP	0.58	6.2	0.32	1.73e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-1.02	-11.01	-0.52	3.24e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.53	7.96	0.4	2.76e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.24	0.33	1.37e-9	Aortic root size;
CRC	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.11	-0.37	7.16e-12	QT interval;
CRC	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg23032129	chr1:109941072	SORT1	-0.28	-5.82	-0.31	1.37e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2769264	0.593	rs4971040	chr1:151366494	A/C	cg18801370	chr1:151430492	POGZ	0.52	5.95	0.31	6.72e-9	Blood trace element (Cu levels);
CRC	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg26353448	chr1:248524236	OR2T4	-0.34	-6.9	-0.36	2.75e-11	Common traits (Other);
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26761047	chr1:15944228	DDI2	0.56	6.12	0.32	2.72e-9	Interleukin-4 levels;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-9.64	-0.47	1.56e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25397718	chr9:140317786	EXD3;NOXA1	0.45	6.17	0.32	1.99e-9	Response to antipsychotic treatment;
CRC	trans	rs1864585	0.520	rs73208781	chr8:10677498	A/C	cg26278703	chr11:58910052	FAM111A	0.55	6.35	0.33	7.34e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg03804128	chr16:635623	NA	0.31	7.12	0.37	6.91e-12	Height;
CRC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.82	-10.96	-0.52	4.91e-24	Initial pursuit acceleration;
CRC	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.42	-0.65	9.24e-41	Exhaled nitric oxide output;
CRC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg27121462	chr16:89883253	FANCA	-0.39	-5.71	-0.3	2.55e-8	Vitiligo;
CRC	cis	rs9549328	0.616	rs35086993	chr13:113617305	G/A	cg20742385	chr13:113633654	MCF2L	0.56	9.53	0.46	3.7e-19	Systolic blood pressure;
CRC	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg23684204	chr15:91497937	RCCD1	0.43	6.49	0.34	3.13e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.8	-0.48	4.44e-20	Monocyte count;
CRC	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.65	-10.46	-0.5	2.71e-22	Post bronchodilator FEV1;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12933314	chr7:4815160	KIAA0415	0.45	6.4	0.33	5.29e-10	Response to antipsychotic treatment;
CRC	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.85	-20.99	-0.76	1.09e-62	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs3849570	0.555	rs6790351	chr3:82008988	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-6.92	-0.36	2.39e-11	Waist circumference;Body mass index;
CRC	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg09184832	chr6:79620586	NA	-0.45	-7.7	-0.39	1.58e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg14593290	chr7:50529359	DDC	0.53	7.37	0.38	1.36e-12	Malaria;
CRC	cis	rs501120	0.584	rs61855740	chr10:44679810	A/G	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.6	10.74	0.51	2.85e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23679662	chr1:26633288	UBXN11	0.38	6.0	0.31	5.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098699	0.718	rs13116874	chr4:124212211	T/C	cg09941581	chr4:124220074	SPATA5	0.4	5.78	0.3	1.75e-8	Mosquito bite size;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.7	10.07	0.49	5.94e-21	Alzheimer's disease;
CRC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.46	-7.02	-0.36	1.26e-11	Mean platelet volume;
CRC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.43	0.46	7.56e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.43	6.86	0.35	3.49e-11	Dupuytren's disease;
CRC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg17321639	chr7:2759063	NA	-0.39	-5.6	-0.3	4.49e-8	Height;
CRC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.41	0.38	1.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.64	-8.58	-0.43	3.92e-16	Malaria;
CRC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.72	-0.3	2.44e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.65	-7.89	-0.4	4.42e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.5	7.1	0.36	7.98e-12	Prostate cancer;
CRC	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.51e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.4	-7.52	-0.38	5.37e-13	Ulcerative colitis;
CRC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.57	8.41	0.42	1.23e-15	Cognitive test performance;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02290350	chr8:58132656	NA	-0.59	-6.84	-0.35	3.91e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg03469862	chr11:68924853	NA	0.46	5.91	0.31	8.56e-9	Blond vs. brown hair color;
CRC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.25	-0.41	3.93e-15	Monocyte percentage of white cells;
CRC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg19980929	chr12:42632907	YAF2	0.38	5.92	0.31	8e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg09010904	chr3:51573036	NA	0.4	6.19	0.32	1.83e-9	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg25985355	chr7:65971099	NA	-0.52	-6.0	-0.31	5.15e-9	Diabetic kidney disease;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg12172441	chr6:28176163	NA	0.52	7.1	0.36	7.87e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.7	-0.35	9.01e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Parkinson's disease;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg02683197	chr6:28174875	NA	0.83	11.13	0.52	1.19e-24	Depression;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg15147215	chr3:52552868	STAB1	-0.65	-11.41	-0.53	1.28e-25	Electroencephalogram traits;
CRC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.9	-0.31	8.81e-9	Life satisfaction;
CRC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg12927641	chr6:109611667	NA	-0.32	-5.62	-0.3	3.97e-8	Reticulocyte fraction of red cells;
CRC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.65	10.21	0.49	1.97e-21	Sudden cardiac arrest;
CRC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.61	-11.07	-0.52	1.96e-24	Aortic root size;
CRC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.85	-0.44	5.66e-17	Menarche (age at onset);
CRC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.61	11.12	0.52	1.31e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6662572	0.737	rs56047133	chr1:46517228	C/T	cg08644498	chr1:46502608	NA	0.47	7.43	0.38	9.19e-13	Blood protein levels;
CRC	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg09232269	chr1:207846808	CR1L	-0.47	-7.66	-0.39	2.12e-13	Erythrocyte sedimentation rate;
CRC	cis	rs2273669	0.915	rs10872028	chr6:109313728	A/G	cg05315195	chr6:109294784	ARMC2	0.49	5.65	0.3	3.55e-8	Prostate cancer;
CRC	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-9.8	-0.48	4.66e-20	HDL cholesterol;
CRC	trans	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-7.36	-0.38	1.46e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg15110403	chr19:17392923	ANKLE1	-0.36	-5.75	-0.3	1.99e-8	Systemic lupus erythematosus;
CRC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.6	8.47	0.42	8.52e-16	Homoarginine levels;
CRC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.03	0.68	4.35e-47	Electrocardiographic conduction measures;
CRC	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	7.76e-17	Dupuytren's disease;
CRC	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.72	-10.71	-0.51	3.76e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-13.78	-0.61	1.99e-34	Prostate cancer;
CRC	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	6.45	0.34	4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg06470822	chr6:28175283	NA	0.8	11.94	0.55	1.56e-27	Parkinson's disease;
CRC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg23463467	chr20:60627584	TAF4	0.33	5.71	0.3	2.53e-8	Body mass index;
CRC	cis	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg05299278	chr17:33885742	SLFN14	0.4	6.06	0.32	3.73e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg25767906	chr1:53392781	SCP2	0.41	6.75	0.35	6.6e-11	Monocyte count;
CRC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.92	-0.4	3.69e-14	Intelligence (multi-trait analysis);
CRC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.73	9.39	0.46	1.04e-18	Psoriasis;
CRC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg07713946	chr22:31675144	LIMK2	-0.39	-5.6	-0.3	4.42e-8	Colorectal cancer;
CRC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.57	8.04	0.41	1.6e-14	Height;
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg27535305	chr1:53392650	SCP2	0.39	7.01	0.36	1.34e-11	Monocyte count;
CRC	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg18232548	chr7:50535776	DDC	0.47	6.1	0.32	3e-9	Malaria;
CRC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.17	0.37	5.11e-12	Menopause (age at onset);
CRC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.52	5.71	0.3	2.54e-8	Schizophrenia;
CRC	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.5	7.54	0.38	4.52e-13	Night sleep phenotypes;
CRC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.58	6.08	0.32	3.27e-9	Blood protein levels;
CRC	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg10978503	chr1:24200527	CNR2	-0.51	-9.08	-0.45	9.99e-18	Immature fraction of reticulocytes;
CRC	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-0.73	-7.66	-0.39	2.04e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.83	8.24	0.41	4.04e-15	Diabetic retinopathy;
CRC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg11632617	chr15:75315747	PPCDC	-0.57	-7.79	-0.39	8.82e-14	Blood trace element (Zn levels);
CRC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg21839984	chr17:30846986	MYO1D	-0.34	-5.89	-0.31	9.69e-9	Schizophrenia;
CRC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg13390004	chr1:15929781	NA	0.45	6.47	0.34	3.61e-10	Systolic blood pressure;
CRC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.18	-0.32	1.87e-9	Axial length;
CRC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.48	-7.02	-0.36	1.28e-11	Total body bone mineral density;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg18833306	chr6:118973337	C6orf204	0.45	5.95	0.31	6.95e-9	Diastolic blood pressure;
CRC	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg20169779	chr10:135381914	SYCE1	-0.62	-10.38	-0.5	4.87e-22	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26307797	chr11:130446613	NA	0.38	6.14	0.32	2.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2274273	0.638	rs67416413	chr14:55702263	A/G	cg10130446	chr14:55658398	DLGAP5	-0.44	-5.87	-0.31	1.06e-8	Protein biomarker;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg21251018	chr6:28226885	NKAPL	-0.46	-5.85	-0.31	1.19e-8	Depression;
CRC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-10.06	-0.49	6.09e-21	Personality dimensions;
CRC	cis	rs9818941	1.000	rs7429574	chr3:157703589	G/A	cg08654915	chr3:157813417	NA	-0.32	-5.98	-0.31	5.73e-9	Height;
CRC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.23	0.37	3.4e-12	Diabetic retinopathy;
CRC	cis	rs10512697	0.655	rs35573920	chr5:3486281	C/T	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs1992660	0.528	rs12655827	chr5:40412335	C/T	cg09067459	chr5:40385259	NA	-0.42	-7.09	-0.36	8.27e-12	Crohn's disease;
CRC	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.71	13.57	0.6	1.23e-33	Mean corpuscular hemoglobin;
CRC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.26	-0.37	2.89e-12	Type 2 diabetes;
CRC	cis	rs10888329	0.819	rs7521717	chr1:248370463	T/A	cg00666640	chr1:248458726	OR2T12	0.43	6.83	0.35	4e-11	Autism spectrum disorder;
CRC	cis	rs7215564	0.730	rs76584516	chr17:78549237	A/G	cg09596252	chr17:78655493	RPTOR	0.61	5.79	0.3	1.68e-8	Myopia (pathological);
CRC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.45	-6.24	-0.33	1.33e-9	Height;
CRC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-8.81	-0.44	7.55e-17	Menarche (age at onset);
CRC	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.34	-0.65	1.9e-40	Schizophrenia;
CRC	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg08890418	chr1:21044141	KIF17	0.33	5.91	0.31	8.65e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.24e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg18827107	chr12:86230957	RASSF9	-0.37	-5.88	-0.31	1.01e-8	Major depressive disorder;
CRC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.69	9.18	0.45	4.98e-18	Reticulocyte fraction of red cells;
CRC	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.24	-0.41	4.12e-15	Biliary atresia;
CRC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg19622623	chr12:86230825	RASSF9	0.38	5.81	0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.78e-24	Bone mineral density;
CRC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg17724175	chr1:150552817	MCL1	0.49	7.15	0.37	5.51e-12	Urate levels;
CRC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.72	0.35	8.03e-11	Educational attainment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09485063	chr2:75107440	HK2	-0.37	-5.98	-0.31	5.91e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06606381	chr12:133084897	FBRSL1	0.75	6.49	0.34	3.15e-10	Depression;
CRC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-8.46	-0.42	9.03e-16	Height;
CRC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.26	0.33	1.2e-9	Diabetic kidney disease;
CRC	cis	rs10971721	0.822	rs10971794	chr9:33924312	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.89	-14.85	-0.63	1.6e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	6.15	0.32	2.26e-9	Asthma;
CRC	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.59	6.6	0.34	1.64e-10	Lung function (FEV1/FVC);
CRC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg10589385	chr1:150898437	SETDB1	-0.29	-6.16	-0.32	2.18e-9	Tonsillectomy;
CRC	cis	rs11166629	1.000	rs6992668	chr8:135645129	T/C	cg27224718	chr8:135614730	ZFAT	0.53	7.77	0.39	1.02e-13	Smoking quantity;
CRC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.72	-8.76	-0.43	1.07e-16	Body mass index;
CRC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-9.29	-0.46	2.24e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-7.34	-0.38	1.68e-12	Blood protein levels;
CRC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	5.79	0.3	1.69e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.38	-0.42	1.6e-15	Response to antipsychotic treatment;
CRC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.5	6.39	0.33	5.67e-10	Blood metabolite levels;
CRC	cis	rs1572438	0.862	rs9406075	chr6:856361	A/G	cg13447295	chr6:887704	NA	-0.42	-6.12	-0.32	2.6e-9	Aging;
CRC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.51	7.89	0.4	4.64e-14	Intelligence (multi-trait analysis);
CRC	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.58	-9.03	-0.45	1.52e-17	Eosinophil percentage of white cells;
CRC	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs6546324	0.625	rs6730286	chr2:67848054	C/T	cg15745817	chr2:67799979	NA	-0.55	-9.5	-0.46	4.36e-19	Endometriosis;
CRC	cis	rs17152411	0.947	rs55674450	chr10:126592153	G/T	cg07906193	chr10:126599966	NA	0.59	6.74	0.35	6.98e-11	Height;
CRC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg03678062	chr6:149772716	ZC3H12D	0.35	6.34	0.33	7.43e-10	Dupuytren's disease;
CRC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg25456477	chr12:86230367	RASSF9	0.34	5.71	0.3	2.5e-8	Major depressive disorder;
CRC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-7.42	-0.38	1.01e-12	Chronic sinus infection;
CRC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.85	0.55	3.25e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg02466173	chr16:30829666	NA	0.66	10.0	0.48	1.02e-20	Dementia with Lewy bodies;
CRC	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.48	-6.94	-0.36	2.13e-11	Large artery stroke;
CRC	cis	rs10208940	0.920	rs10211211	chr2:68718191	G/C	cg12452813	chr2:68675892	NA	0.51	6.35	0.33	7.33e-10	Urate levels in lean individuals;
CRC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.77	-0.35	5.99e-11	Monocyte count;
CRC	trans	rs2303319	0.582	rs62187614	chr2:162436285	C/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.01	-0.31	5.03e-9	Cognitive function;
CRC	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg12870014	chr12:110450643	ANKRD13A	0.87	10.08	0.49	5.28e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs62432291	0.681	rs436277	chr6:159634142	G/A	cg14500486	chr6:159655392	FNDC1	0.8	10.62	0.51	7.3e-23	Joint mobility (Beighton score);
CRC	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg15660573	chr17:549704	VPS53	-0.87	-15.78	-0.66	3.72e-42	Prostate cancer;
CRC	cis	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.78	-0.3	1.72e-8	Blood trace element (Cu levels);
CRC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.8	-14.82	-0.63	1.98e-38	Body mass index;
CRC	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.52	-7.06	-0.36	9.84e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	14.67	0.63	7.5e-38	Mean corpuscular hemoglobin;
CRC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	1.01	15.86	0.66	1.73e-42	Primary sclerosing cholangitis;
CRC	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.74	-11.74	-0.54	8.38e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg00564723	chr10:75632066	CAMK2G	-0.22	-5.66	-0.3	3.32e-8	Inflammatory bowel disease;
CRC	cis	rs10046574	0.561	rs13438700	chr7:135207626	C/A	cg27474649	chr7:135195673	CNOT4	0.61	5.95	0.31	7.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	9.59	0.47	2.2e-19	Height;
CRC	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.65	9.35	0.46	1.42e-18	Schizophrenia;
CRC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1472360	0.505	rs1496527	chr8:86273696	G/A	cg21346043	chr8:86351067	CA3	-0.38	-6.28	-0.33	1.1e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.43	6.94	0.36	2.11e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg08798685	chr6:27730294	NA	-0.48	-6.66	-0.34	1.12e-10	Parkinson's disease;
CRC	cis	rs17065868	0.764	rs41425048	chr13:45026729	C/T	cg10246903	chr13:45222710	NA	-0.54	-5.81	-0.3	1.51e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg16540259	chr10:75572220	NDST2	0.51	7.81	0.4	7.58e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4920343	0.698	rs573966	chr1:19087828	A/G	cg19637330	chr1:19110922	NA	0.39	5.85	0.31	1.21e-8	Knee osteoarthritis;
CRC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg10760299	chr15:45669010	GATM	0.52	8.29	0.42	2.96e-15	Homoarginine levels;
CRC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.71	-7.19	-0.37	4.26e-12	Systemic lupus erythematosus;
CRC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.4	6.6	0.34	1.62e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg12273811	chr6:28175739	NA	0.58	5.98	0.31	5.69e-9	Lung cancer in ever smokers;
CRC	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.68	11.62	0.54	2.22e-26	Subjective well-being (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.61	7.19	0.37	4.29e-12	Major depressive disorder;
CRC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.05	-0.32	4.05e-9	Eosinophil percentage of white cells;
CRC	cis	rs524281	0.773	rs10750781	chr11:66037270	A/G	cg14036092	chr11:66035641	RAB1B	-0.56	-6.13	-0.32	2.56e-9	Electroencephalogram traits;
CRC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.01	-0.52	3.24e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg23758597	chr6:163146217	PARK2	-0.65	-6.74	-0.35	6.95e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg16540259	chr10:75572220	NDST2	0.38	5.91	0.31	8.5e-9	Inflammatory bowel disease;
CRC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg24154853	chr7:158122151	PTPRN2	0.65	10.75	0.51	2.67e-23	Calcium levels;
CRC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	9.79	0.48	4.91e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg23262073	chr20:60523788	NA	-0.41	-6.91	-0.36	2.47e-11	Body mass index;
CRC	cis	rs812925	0.502	rs6545868	chr2:61655365	T/C	cg10580144	chr2:61372316	C2orf74	-0.31	-6.59	-0.34	1.73e-10	Immature fraction of reticulocytes;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.45	-0.42	9.43e-16	Height;
CRC	cis	rs294883	0.739	rs62438586	chr6:159730272	C/T	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.4	0.33	5.21e-10	Depression;
CRC	trans	rs4087296	0.502	rs2906804	chr16:82335001	C/T	cg09652807	chr17:2652918	MIR1253	0.54	5.99	0.31	5.51e-9	Bone mineral density;
CRC	cis	rs1178968	0.901	rs1178970	chr7:72750345	G/A	cg25889504	chr7:72793014	NA	0.51	5.93	0.31	7.62e-9	Triglyceride levels;
CRC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg03605463	chr16:89740564	NA	-0.42	-6.24	-0.33	1.31e-9	Vitiligo;
CRC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11212617	0.805	rs10890821	chr11:108022061	A/T	cg01883757	chr16:56815826	NUP93	0.39	6.11	0.32	2.87e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24249390	chr15:90295951	MESP1	-0.6	-9.49	-0.46	4.94e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.73	12.88	0.58	5.32e-31	Body mass index;
CRC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg06470822	chr6:28175283	NA	0.72	6.95	0.36	1.92e-11	Depression;
CRC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.2	-0.32	1.71e-9	IgG glycosylation;
CRC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.4	6.89	0.36	2.77e-11	Coronary artery disease;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg19678392	chr7:94953810	PON1	-0.57	-7.2	-0.37	4.21e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.91	17.35	0.69	2.44e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg00631329	chr6:26305371	NA	-0.48	-7.56	-0.38	4.03e-13	Height;
CRC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg27565382	chr3:53032988	SFMBT1	0.67	5.97	0.31	6.2e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.28	-0.53	3.63e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.67	9.13	0.45	7.3e-18	Breast cancer;
CRC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg02527881	chr3:46936655	PTH1R	0.34	5.88	0.31	1.03e-8	Colorectal cancer;
CRC	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg21153622	chr11:89784906	NA	-0.44	-7.1	-0.36	7.5e-12	HDL cholesterol;
CRC	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg05527609	chr1:210001259	C1orf107	-0.55	-6.0	-0.31	5.1e-9	Red blood cell count;
CRC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.66	-8.12	-0.41	9.74e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs847649	0.699	rs10271157	chr7:102527591	A/G	cg18108683	chr7:102477205	FBXL13	-0.63	-11.01	-0.52	3.37e-24	Morning vs. evening chronotype;
CRC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg19610905	chr11:61596333	FADS2	-0.44	-5.69	-0.3	2.84e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg01656853	chr19:49199172	FUT2	0.23	5.68	0.3	2.89e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs10896135	0.554	rs3741364	chr11:66451178	C/T	cg24851651	chr11:66362959	CCS	0.42	5.85	0.31	1.2e-8	Bipolar disorder;
CRC	cis	rs9847710	0.733	rs9818819	chr3:53076755	T/G	cg18099408	chr3:52552593	STAB1	0.39	5.83	0.31	1.3e-8	Ulcerative colitis;
CRC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.09	-0.41	1.17e-14	Monocyte count;
CRC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.78	7.82	0.4	7.47e-14	Diabetic retinopathy;
CRC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.66	0.43	2.19e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	12.29	0.56	7.8e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg18764771	chr6:116381957	FRK	0.26	7.44	0.38	8.76e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7300001	0.538	rs7968848	chr12:110941059	T/A	cg12870014	chr12:110450643	ANKRD13A	0.84	9.83	0.48	3.66e-20	Headache;
CRC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.53	-9.17	-0.45	5.48e-18	Aortic root size;
CRC	trans	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.63	10.68	0.51	4.75e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09116932	chr22:31477245	SMTN	0.41	6.21	0.32	1.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg14530993	chr4:882597	GAK	0.82	7.82	0.4	7.42e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.46	7.02	0.36	1.28e-11	Cleft lip with or without cleft palate;
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.72e-11	Alzheimer's disease;
CRC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.7	0.43	1.67e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg25956985	chr22:39795188	MAP3K7IP1	0.44	6.33	0.33	8.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs35520189	0.591	rs12465526	chr2:113699981	A/G	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg04450456	chr4:17643702	FAM184B	0.42	6.72	0.35	8.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg15147215	chr3:52552868	STAB1	0.4	6.27	0.33	1.13e-9	Body mass index;
CRC	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg10556349	chr10:835070	NA	-0.36	-6.67	-0.35	1.07e-10	Survival in rectal cancer;
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg04518342	chr5:131593106	PDLIM4	0.37	6.79	0.35	5.38e-11	Blood metabolite levels;
CRC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.75	10.75	0.51	2.72e-23	High light scatter reticulocyte count;
CRC	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06307176	chr5:131281290	NA	0.42	6.08	0.32	3.35e-9	Life satisfaction;
CRC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg25456477	chr12:86230367	RASSF9	0.4	6.78	0.35	5.42e-11	Major depressive disorder;
CRC	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg07166546	chr14:35805898	NA	-0.3	-5.84	-0.31	1.27e-8	Psoriasis;
CRC	cis	rs4654899	0.897	rs6679753	chr1:21066634	G/C	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.8	-0.35	5.08e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-11.19	-0.52	7.71e-25	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.68	-0.39	1.83e-13	Cholesterol, total;
CRC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.87	-0.78	5.86e-70	Myeloid white cell count;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg05562828	chr17:3906858	NA	-0.67	-11.74	-0.54	8.03e-27	Type 2 diabetes;
CRC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg02549819	chr16:58548995	SETD6	1.22	7.92	0.4	3.82e-14	Schizophrenia;
CRC	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg18551225	chr6:44695536	NA	-0.41	-5.96	-0.31	6.36e-9	Total body bone mineral density;
CRC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.78	-0.3	1.72e-8	Daytime sleep phenotypes;
CRC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg02007433	chr3:129722099	NA	-0.46	-6.0	-0.31	5.27e-9	Blood pressure (smoking interaction);
CRC	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg13385794	chr1:248469461	NA	0.38	6.68	0.35	1.01e-10	Common traits (Other);
CRC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg10298567	chr3:47292165	KIF9	0.41	6.3	0.33	9.73e-10	Colorectal cancer;
CRC	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg27411982	chr8:10470053	RP1L1	0.36	5.65	0.3	3.56e-8	Neuroticism;
CRC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg04518342	chr5:131593106	PDLIM4	0.43	6.96	0.36	1.81e-11	Breast cancer;
CRC	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-6.5	-0.34	3.02e-10	QRS duration;
CRC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg15145296	chr3:125709740	NA	-0.57	-6.75	-0.35	6.67e-11	Blood pressure (smoking interaction);
CRC	cis	rs9783347	0.961	rs4150653	chr11:18374782	G/A	cg15585147	chr11:18324498	HPS5	0.44	6.13	0.32	2.51e-9	Pancreatic cancer;
CRC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.64	-8.68	-0.43	1.81e-16	Refractive error;
CRC	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.71	-12.1	-0.55	3.99e-28	Idiopathic membranous nephropathy;
CRC	cis	rs6961069	0.935	rs819435	chr7:80224372	T/G	cg04458919	chr7:80252533	CD36	-0.33	-5.88	-0.31	1e-8	Platelet count;
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.55	0.54	3.91e-26	Prudent dietary pattern;
CRC	cis	rs3772130	1.000	rs34086988	chr3:121352745	G/C	cg20356878	chr3:121714668	ILDR1	0.49	7.59	0.39	3.23e-13	Cognitive performance;
CRC	cis	rs11212617	1.000	rs641605	chr11:108101919	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.21	0.32	1.57e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.43	6.4	0.33	5.5e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.33	-5.75	-0.3	2.08e-8	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg06243866	chr13:111019493	COL4A2	0.36	5.68	0.3	2.97e-8	White matter hyperintensity burden;
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	7.05	0.36	1.06e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7173389	0.551	rs11638264	chr15:73656307	G/A	cg01796676	chr15:73680284	NA	0.62	5.9	0.31	8.94e-9	Resting heart rate;
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-7.26	-0.37	2.8e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.82	13.72	0.6	3.47e-34	Coronary artery disease;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg25164649	chr6:28176230	NA	-0.47	-6.86	-0.35	3.53e-11	Cardiac Troponin-T levels;
CRC	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.46	-6.18	-0.32	1.88e-9	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.14	-0.37	5.93e-12	Total cholesterol levels;
CRC	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg24899294	chr7:1481343	MICALL2	-0.67	-6.92	-0.36	2.43e-11	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CRC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg24289452	chr6:170231220	NA	-0.54	-6.01	-0.31	5.05e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.79	7.99	0.4	2.36e-14	IgG glycosylation;
CRC	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.57	7.92	0.4	3.6e-14	Coronary artery disease;
CRC	cis	rs17767392	0.781	rs14030	chr14:71956141	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.46	-6.08	-0.32	3.38e-9	Mitral valve prolapse;
CRC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.47	-0.34	3.49e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg03790207	chr6:42947109	PEX6	-0.52	-7.66	-0.39	2.06e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg10431340	chr1:161279108	MPZ	-0.52	-7.02	-0.36	1.28e-11	Rheumatoid arthritis;
CRC	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.1	0.45	8.81e-18	Blood protein levels;
CRC	cis	rs9359856	0.518	rs10485242	chr6:90183389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.51	-5.62	-0.3	4.04e-8	Bipolar disorder;
CRC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg17948913	chr5:572064	NA	0.46	5.72	0.3	2.46e-8	Obesity-related traits;
CRC	cis	rs7429990	0.965	rs184388	chr3:47939626	G/A	cg11946769	chr3:48343235	NME6	0.46	5.9	0.31	8.99e-9	Educational attainment (years of education);
CRC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg20684491	chr1:25596433	NA	0.42	7.23	0.37	3.41e-12	Erythrocyte sedimentation rate;
CRC	cis	rs17713451	0.593	rs79994029	chr7:151268774	A/G	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.22	-0.32	1.5e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12760731	0.720	rs10913535	chr1:178302914	C/A	cg00404053	chr1:178313656	RASAL2	0.92	9.63	0.47	1.74e-19	Obesity-related traits;
CRC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg04545296	chr12:48745243	ZNF641	0.35	6.1	0.32	2.96e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg05585544	chr11:47624801	NA	-0.57	-10.26	-0.49	1.31e-21	Subjective well-being;
CRC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg13390004	chr1:15929781	NA	0.5	6.93	0.36	2.16e-11	Systolic blood pressure;
CRC	cis	rs6663390	0.510	rs1932819	chr1:208078238	C/T	cg03990033	chr1:208084030	CD34	0.44	6.26	0.33	1.21e-9	Facial morphology (factor 18);
CRC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.27	-0.33	1.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.5	7.63	0.39	2.59e-13	Corneal astigmatism;
CRC	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.73	-8.14	-0.41	8.25e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg15448220	chr1:150897856	SETDB1	-0.48	-6.76	-0.35	6.35e-11	Urate levels;
CRC	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.49	9.94	0.48	1.58e-20	Hand grip strength;
CRC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg10589385	chr1:150898437	SETDB1	-0.32	-6.82	-0.35	4.43e-11	Urate levels;
CRC	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg16141378	chr3:129829833	LOC729375	0.43	5.97	0.31	6.28e-9	Neuroticism;
CRC	trans	rs12249377	0.748	rs10881834	chr10:92581244	G/A	cg26894278	chr13:21016241	CRYL1	0.4	5.98	0.31	5.89e-9	White matter microstructure (global fractional anisotropy);
CRC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg22676075	chr6:135203613	NA	0.41	6.39	0.33	5.63e-10	Red blood cell count;
CRC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.51	-6.83	-0.35	4.16e-11	Dialysis-related mortality;
CRC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.8	8.79	0.44	8.31e-17	Gout;Renal underexcretion gout;
CRC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg03037974	chr15:76606532	NA	0.69	12.16	0.56	2.4e-28	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.41	0.38	1.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.55	-9.37	-0.46	1.18e-18	Paraoxonase activity;
CRC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.56	10.91	0.52	7.29e-24	Pursuit maintenance gain;
CRC	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.7	-9.64	-0.47	1.56e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.67	0.63	7.94e-38	Chronic sinus infection;
CRC	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
CRC	cis	rs1322512	1.000	rs7765586	chr6:152949109	C/T	cg03415253	chr6:152958462	SYNE1	0.42	6.41	0.33	5.06e-10	Tonometry;
CRC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.63	-9.8	-0.48	4.73e-20	Cognitive function;
CRC	trans	rs9581094	1.000	rs73154395	chr13:25081803	T/G	ch.10.2420334F	chr10:115122200	NA	0.62	6.08	0.32	3.24e-9	Sudden cardiac arrest;
CRC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.5	-9.89	-0.48	2.36e-20	Prostate cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25934771	chr12:66696354	HELB	0.43	6.27	0.33	1.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs440932	0.747	rs330946	chr8:9022177	A/C	cg06636001	chr8:8085503	FLJ10661	0.61	8.67	0.43	2e-16	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.63	7.18	0.37	4.79e-12	Type 2 diabetes nephropathy;
CRC	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.44	0.69	1.05e-48	Intelligence (multi-trait analysis);
CRC	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.03	0.52	2.83e-24	Bipolar disorder;
CRC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg19418318	chr19:17219073	MYO9B	0.44	7.0	0.36	1.45e-11	Reticulocyte fraction of red cells;
CRC	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg13919466	chr1:32135498	COL16A1	0.3	5.68	0.3	2.94e-8	Intelligence (multi-trait analysis);
CRC	cis	rs501120	0.584	rs11238894	chr10:44671851	T/C	cg09554077	chr10:44749378	NA	0.74	8.38	0.42	1.58e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.67	10.05	0.48	6.96e-21	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26434988	chr14:50999636	MAP4K5;ATL1	0.43	6.2	0.32	1.71e-9	Response to antipsychotic treatment;
CRC	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg22189786	chr22:42395067	WBP2NL	-0.42	-5.96	-0.31	6.37e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.41	-6.25	-0.33	1.29e-9	Menopause (age at onset);
CRC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.66	-9.94	-0.48	1.6e-20	Initial pursuit acceleration;
CRC	trans	rs2303319	0.582	rs62187608	chr2:162431138	T/G	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.19	-0.32	1.77e-9	Cognitive function;
CRC	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.49	-7.64	-0.39	2.46e-13	Schizophrenia;
CRC	cis	rs1223397	0.702	rs13191897	chr6:13288428	G/A	cg21538684	chr6:13274180	PHACTR1	0.48	5.66	0.3	3.3e-8	Blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24658452	chr6:133134754	RPS12	0.38	6.07	0.32	3.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9847710	1.000	rs6770152	chr3:53100214	A/C	cg04503182	chr3:53078218	SFMBT1	0.4	6.17	0.32	2.04e-9	Ulcerative colitis;
CRC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.27	0.45	2.59e-18	Lymphocyte counts;
CRC	cis	rs6834538	1.000	rs2171280	chr4:113472637	A/G	cg10021238	chr4:113569128	MIR367;LARP7	0.42	6.04	0.32	4.12e-9	Free thyroxine concentration;
CRC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg00129232	chr17:37814104	STARD3	0.58	7.09	0.36	8.09e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14442939	chr10:27389572	ANKRD26	0.65	6.98	0.36	1.59e-11	Breast cancer;
CRC	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-0.95	-11.38	-0.53	1.64e-25	Hip circumference adjusted for BMI;
CRC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.18	-0.52	8.22e-25	Ulcerative colitis;
CRC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg24375607	chr4:120327624	NA	-0.47	-7.77	-0.39	1.02e-13	Corneal astigmatism;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.77	11.28	0.53	3.66e-25	Menarche (age at onset);
CRC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg24562669	chr7:97807699	LMTK2	0.44	7.27	0.37	2.71e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs6893807	1.000	rs13163336	chr5:87943710	C/A	cg09002922	chr5:87956389	LOC645323	-0.42	-6.05	-0.32	3.83e-9	Body mass index;
CRC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	2.92e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.48	7.7	0.39	1.58e-13	Bronchopulmonary dysplasia;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18912574	chr7:65842487	NCRNA00174	0.33	5.62	0.3	4.16e-8	Calcium levels;
CRC	cis	rs6700896	0.931	rs4420065	chr1:66161461	T/C	cg04111102	chr1:66153794	NA	-0.33	-5.75	-0.3	2.01e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg12193833	chr17:30244370	NA	0.44	6.14	0.32	2.35e-9	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	8.93	0.44	3.03e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg02421172	chr7:1938701	MAD1L1	0.44	6.03	0.32	4.46e-9	Bipolar disorder;
CRC	cis	rs3741151	0.686	rs11823913	chr11:73141627	C/G	cg17517138	chr11:73019481	ARHGEF17	0.57	6.04	0.32	4.18e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.86	0.44	5.13e-17	Bladder cancer;
CRC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg03428951	chr5:177434336	FAM153C	-0.4	-6.46	-0.34	3.7e-10	Methadone dose in opioid dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09741240	chr6:3000097	NQO2	0.39	6.03	0.32	4.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg17133734	chr15:86042851	AKAP13	0.42	6.76	0.35	6.41e-11	Coronary artery disease;
CRC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.04	-0.36	1.12e-11	Lung cancer;
CRC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.79	13.75	0.6	2.71e-34	Birth weight;
CRC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.6	-9.59	-0.47	2.34e-19	Aortic root size;
CRC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.4	-6.7	-0.35	9.32e-11	Testicular germ cell tumor;
CRC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06028605	chr16:24865363	SLC5A11	-0.37	-7.08	-0.36	8.66e-12	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg03013636	chr16:1946785	NA	0.54	6.79	0.35	5.4e-11	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.92	-0.48	1.85e-20	Height;
CRC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.5	-7.0	-0.36	1.45e-11	Gut microbiome composition (summer);
CRC	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.71	8.75	0.43	1.16e-16	Neuroticism (multi-trait analysis);Neuroticism;
CRC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.65	6.72	0.35	8.14e-11	Axial length;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15739944	chr9:99212660	HABP4	0.44	6.34	0.33	7.62e-10	Response to antipsychotic treatment;
CRC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg07713946	chr22:31675144	LIMK2	0.38	5.84	0.31	1.23e-8	Colorectal cancer;
CRC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.66	-8.21	-0.41	4.94e-15	Schizophrenia;
CRC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.02	0.32	4.62e-9	Prudent dietary pattern;
CRC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.88	-14.62	-0.63	1.25e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.7	8.86	0.44	5.04e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.7	-0.3	2.64e-8	Blood trace element (Cu levels);
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.49	-7.72	-0.39	1.44e-13	Bipolar disorder;
CRC	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.65	-11.04	-0.52	2.59e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.55	-7.55	-0.38	4.41e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.19	-0.53	7.42e-25	Eye color traits;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg02527881	chr3:46936655	PTH1R	0.35	6.16	0.32	2.11e-9	Colorectal cancer;
CRC	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.94	14.04	0.61	2.01e-35	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.81	-9.7	-0.47	9.66e-20	Initial pursuit acceleration;
CRC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.48	-6.54	-0.34	2.37e-10	Tonsillectomy;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4664293	0.625	rs11903816	chr2:160531858	T/C	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.67e-10	Monocyte percentage of white cells;
CRC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.62	9.59	0.47	2.31e-19	Corneal astigmatism;
CRC	cis	rs6546324	0.625	rs1430792	chr2:67864744	A/C	cg15745817	chr2:67799979	NA	-0.53	-9.25	-0.45	2.87e-18	Endometriosis;
CRC	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg22495460	chr2:25135724	ADCY3	0.67	11.12	0.52	1.38e-24	Body mass index in non-asthmatics;
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg05569086	chr8:143859399	LYNX1	-0.38	-5.85	-0.31	1.17e-8	Urinary tract infection frequency;
CRC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.48	6.2	0.32	1.73e-9	Obesity-related traits;
CRC	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg06484146	chr7:12443880	VWDE	-0.64	-6.75	-0.35	6.64e-11	Coronary artery disease;
CRC	cis	rs4731207	0.698	rs4463363	chr7:124513770	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7605827	0.930	rs6710456	chr2:15669939	C/T	cg19274914	chr2:15703543	NA	-0.37	-5.66	-0.3	3.27e-8	Educational attainment (years of education);
CRC	cis	rs2637266	0.538	rs11001787	chr10:78221963	A/T	cg18941641	chr10:78392320	NA	-0.36	-6.23	-0.32	1.41e-9	Pulmonary function;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.79	-0.35	5.4e-11	Breast cancer;
CRC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	9.07	0.45	1.14e-17	Monocyte percentage of white cells;
CRC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.68	11.57	0.54	3.22e-26	Alzheimer's disease (late onset);
CRC	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.56	-7.96	-0.4	2.81e-14	Vitiligo;
CRC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.83	10.52	0.5	1.73e-22	Obesity-related traits;
CRC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.42	-5.69	-0.3	2.81e-8	Cognitive function;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg04553112	chr3:125709451	NA	-0.52	-5.97	-0.31	6.27e-9	Blood pressure (smoking interaction);
CRC	cis	rs7680126	0.596	rs74778870	chr4:10298583	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.78	-0.3	1.71e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg12193833	chr17:30244370	NA	-0.56	-7.4	-0.38	1.15e-12	Hip circumference adjusted for BMI;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.35	-6.49	-0.34	3.23e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.6	0.63	1.48e-37	Fuchs's corneal dystrophy;
CRC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.12	10.46	0.5	2.76e-22	Skin colour saturation;
CRC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.54	-8.71	-0.43	1.5e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs3790844	0.746	rs3790850	chr1:200005193	C/G	cg13229857	chr1:200006247	NR5A2	0.54	7.61	0.39	2.83e-13	Pancreatic cancer;
CRC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.46	-6.66	-0.34	1.18e-10	Daytime sleep phenotypes;
CRC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12630931	1.000	rs35133414	chr3:31974182	G/C	cg21375017	chr3:31988082	OSBPL10	0.43	5.97	0.31	6.2e-9	Periodontal disease-related phenotypes;
CRC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.85	-0.7	2.65e-50	Height;
CRC	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg12046867	chr14:103022105	NA	0.42	6.13	0.32	2.54e-9	Platelet count;
CRC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg16102536	chr7:156981717	UBE3C	-0.37	-6.32	-0.33	8.36e-10	Body mass index;
CRC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21525449	chr1:156571403	GPATCH4	0.43	6.03	0.32	4.36e-9	Response to antipsychotic treatment;
CRC	trans	rs10411161	0.702	rs10424202	chr19:52387297	G/A	cg22319618	chr22:45562946	NUP50	-0.66	-7.28	-0.37	2.41e-12	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06604058	chr11:63448992	RTN3	0.42	6.43	0.33	4.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2811415	0.597	rs55662362	chr3:127774723	A/C	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.17e-8	Lung function (FEV1/FVC);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19980912	chr5:133304180	C5orf15	0.42	6.94	0.36	2.04e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.56	-0.43	4.45e-16	Aortic root size;
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg21620606	chr4:1342894	KIAA1530	-0.38	-5.89	-0.31	9.75e-9	Longevity;
CRC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.57	7.93	0.4	3.45e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.54	-8.63	-0.43	2.62e-16	Monocyte count;
CRC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg04025307	chr7:1156635	C7orf50	0.48	6.01	0.31	4.85e-9	Bronchopulmonary dysplasia;
CRC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.58	-8.83	-0.44	6.38e-17	Aortic root size;
CRC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.24	6.77	0.35	6.11e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17219203	chr10:38645113	HSD17B7P2	0.41	5.72	0.3	2.39e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs9463078	0.754	rs9349309	chr6:45025814	G/T	cg25276700	chr6:44698697	NA	-0.24	-5.79	-0.3	1.63e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg27661571	chr11:113659931	NA	-0.69	-8.61	-0.43	3.11e-16	Hip circumference adjusted for BMI;
CRC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.02	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg11833968	chr6:79620685	NA	-0.35	-6.21	-0.32	1.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.25	-0.49	1.43e-21	Electroencephalogram traits;
CRC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg02766259	chr12:125626809	AACS	-0.45	-8.51	-0.42	6.05e-16	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9322817	0.902	rs7773123	chr6:105173726	A/G	cg02098413	chr6:105308735	HACE1	0.37	6.81	0.35	4.67e-11	Thyroid stimulating hormone;
CRC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.57	-6.82	-0.35	4.37e-11	HIV-1 control;
CRC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg05132306	chr1:1846340	CALML6	-0.5	-7.74	-0.39	1.22e-13	Body mass index;
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg10729496	chr3:10149963	C3orf24	0.49	6.38	0.33	5.96e-10	Alzheimer's disease;
CRC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.47	-7.13	-0.37	6.31e-12	Colorectal cancer;
CRC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.58	-7.7	-0.39	1.61e-13	Mean platelet volume;
CRC	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.52	-7.47	-0.38	7.07e-13	Caudate activity during reward;
CRC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs4757319	0.532	rs6486245	chr11:15438256	G/A	cg03245590	chr11:15329459	NA	0.43	7.34	0.38	1.7e-12	Breast cancer;
CRC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.73	-0.39	1.35e-13	Height;
CRC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	6.72	0.35	8.06e-11	Hip circumference adjusted for BMI;
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.15	0.74	2.13e-59	Prudent dietary pattern;
CRC	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.59	-6.66	-0.34	1.14e-10	Osteoarthritis;
CRC	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.38	5.94	0.31	7.06e-9	Reticulocyte fraction of red cells;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.1	-0.41	1.1e-14	Height;
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg07404485	chr7:94953653	PON1	-0.45	-5.92	-0.31	7.97e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs11229555	0.645	rs11229443	chr11:58197188	G/C	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1383484	0.606	rs9329364	chr15:84643242	G/A	cg11189052	chr15:85197271	WDR73	-0.48	-6.03	-0.32	4.4e-9	Height;
CRC	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg27050936	chr6:887821	NA	0.34	5.61	0.3	4.29e-8	Aging;
CRC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.7	-11.86	-0.55	3.01e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-7.62	-0.39	2.8e-13	Height;
CRC	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.34	-0.38	1.68e-12	Capecitabine sensitivity;
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg04727332	chr7:45960243	IGFBP3	0.36	5.74	0.3	2.18e-8	Sitting height ratio;
CRC	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg25547332	chr5:131281432	NA	0.4	5.65	0.3	3.41e-8	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg13490827	chr1:46269305	MAST2	-0.72	-6.21	-0.32	1.56e-9	Cognitive function;
CRC	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.34	-0.33	7.6e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.45	-6.78	-0.35	5.65e-11	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23237339	chr1:171283153	FMO4	-0.38	-6.12	-0.32	2.71e-9	Aortic root size;
CRC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.38	-5.76	-0.3	1.96e-8	Ulcerative colitis;
CRC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.42	9.3	0.46	2.03e-18	Blood protein levels;
CRC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.55	8.02	0.4	1.84e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.15	-0.37	5.58e-12	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22911074	chr5:6632973	NSUN2;SRD5A1	0.39	6.68	0.35	1.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg09655341	chr17:79618100	PDE6G	-0.36	-6.13	-0.32	2.53e-9	Eye color traits;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg03623178	chr6:28175578	NA	-0.94	-12.89	-0.58	4.59e-31	Depression;
CRC	cis	rs2013441	1.000	rs2526460	chr17:20086352	G/A	cg13482628	chr17:19912719	NA	-0.39	-5.96	-0.31	6.54e-9	Obesity-related traits;
CRC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.64	5.81	0.31	1.44e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs909002	0.925	rs10798882	chr1:32108547	C/G	cg13919466	chr1:32135498	COL16A1	0.3	5.76	0.3	1.91e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg21251018	chr6:28226885	NKAPL	0.41	6.24	0.33	1.35e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs7737355	0.773	rs31589	chr5:131004646	G/A	cg25547332	chr5:131281432	NA	0.36	5.63	0.3	3.82e-8	Life satisfaction;
CRC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.3	0.37	2.16e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.53	-0.54	4.56e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg08795948	chr3:128337044	NA	0.35	6.01	0.31	5e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.48	-7.05	-0.36	1.07e-11	Pulse pressure;
CRC	cis	rs9549328	0.565	rs36145949	chr13:113616608	T/C	cg08614441	chr13:113633676	MCF2L	0.4	6.97	0.36	1.69e-11	Systolic blood pressure;
CRC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.74	-12.92	-0.58	3.58e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.61	-0.34	1.51e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.65	8.95	0.44	2.6e-17	Bronchopulmonary dysplasia;
CRC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.69	10.12	0.49	3.9e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7215564	0.818	rs4889878	chr17:78662479	G/T	cg09596252	chr17:78655493	RPTOR	0.54	6.09	0.32	3.17e-9	Myopia (pathological);
CRC	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg11446398	chr5:77624930	NA	0.41	5.89	0.31	9.63e-9	Triglycerides;
CRC	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.66	10.56	0.5	1.18e-22	Corneal astigmatism;
CRC	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.53	9.6	0.47	2.06e-19	Common traits (Other);
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg06470822	chr6:28175283	NA	0.79	10.17	0.49	2.72e-21	Parkinson's disease;
CRC	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-7.87	-0.4	5.12e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-9.68	-0.47	1.16e-19	Dental caries;
CRC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg21851534	chr17:3907994	ZZEF1	-0.35	-5.93	-0.31	7.85e-9	Type 2 diabetes;
CRC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.39	6.09	0.32	3.17e-9	Endometrial cancer;
CRC	cis	rs3857067	1.000	rs899134	chr4:95019675	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg12855166	chr17:30846586	MYO1D	-0.37	-5.88	-0.31	9.92e-9	Schizophrenia;
CRC	cis	rs9462027	0.628	rs2814992	chr6:34617144	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.29	-0.33	1e-9	Systemic lupus erythematosus;
CRC	cis	rs12580194	0.593	rs60774348	chr12:55757717	A/G	cg19537932	chr12:55886519	OR6C68	-0.72	-9.07	-0.45	1.12e-17	Cancer;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.55	-0.47	3.11e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg26666090	chr16:58549219	SETD6	0.92	6.25	0.33	1.26e-9	Schizophrenia;
CRC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg19635926	chr16:89946313	TCF25	0.69	6.92	0.36	2.41e-11	Skin colour saturation;
CRC	cis	rs9463078	0.845	rs1023090	chr6:45012381	T/C	cg25276700	chr6:44698697	NA	-0.28	-6.73	-0.35	7.76e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.48	-10.06	-0.48	6.45e-21	Rheumatoid arthritis;
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12463550	chr7:65579703	CRCP	0.67	6.4	0.33	5.29e-10	Diabetic kidney disease;
CRC	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.49	6.39	0.33	5.8e-10	Alzheimer's disease (survival time);
CRC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.95	-0.31	6.85e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.4	5.88	0.31	9.81e-9	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.69	-0.3	2.75e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs3824347	0.839	rs10781258	chr9:77618438	C/A	cg01251476	chr9:77566080	C9orf40	0.36	5.67	0.3	3.21e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg22638593	chr5:131593259	PDLIM4	-0.41	-7.7	-0.39	1.66e-13	Breast cancer;
CRC	cis	rs7572733	0.592	rs17731449	chr2:198465840	T/C	cg10820045	chr2:198174542	NA	0.35	6.29	0.33	1.01e-9	Dermatomyositis;
CRC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.54	-7.91	-0.4	3.95e-14	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.94	11.85	0.55	3.1e-27	Exhaled nitric oxide levels;
CRC	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.52	7.86	0.4	5.44e-14	Corneal astigmatism;
CRC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.41	5.75	0.3	2.03e-8	Corneal structure;
CRC	cis	rs4478858	0.602	rs7515867	chr1:31724744	C/T	cg00250761	chr1:31883323	NA	0.32	5.95	0.31	6.84e-9	Alcohol dependence;
CRC	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg13491945	chr12:107078410	RFX4	0.34	5.84	0.31	1.26e-8	Heart rate;
CRC	trans	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg18335740	chr13:41363409	SLC25A15	0.53	7.89	0.4	4.58e-14	Lewy body disease;
CRC	cis	rs62408225	1.000	rs905670	chr6:90958502	G/A	cg06866423	chr6:90926672	BACH2	0.49	8.06	0.41	1.42e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.66	-10.65	-0.51	6.15e-23	Motion sickness;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg10729496	chr3:10149963	C3orf24	0.56	7.26	0.37	2.89e-12	Alzheimer's disease;
CRC	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg05507819	chr15:63340323	TPM1	0.46	6.05	0.32	3.88e-9	HDL cholesterol;
CRC	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.33	-0.33	8.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg06470822	chr6:28175283	NA	-0.74	-9.99	-0.48	1.07e-20	Parkinson's disease;
CRC	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.81	0.3	1.5e-8	Corneal astigmatism;
CRC	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.64	-8.93	-0.44	3.18e-17	Pulmonary function decline;
CRC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.7	0.57	2.49e-30	Platelet count;
CRC	cis	rs6741819	0.740	rs700943	chr2:7126569	G/A	cg27144453	chr2:7172511	RNF144A	-0.41	-5.88	-0.31	9.83e-9	Response to antipsychotic treatment;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg03790207	chr6:42947109	PEX6	-0.49	-6.91	-0.36	2.51e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03437924	chr16:25123326	LCMT1	0.47	7.62	0.39	2.67e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.8	15.25	0.64	4.41e-40	Prudent dietary pattern;
CRC	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.32	7.34	0.37	1.73e-12	Corneal astigmatism;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.62	6.47	0.34	3.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06877462	chr1:205807181	PM20D1	0.38	5.91	0.31	8.48e-9	Menarche (age at onset);
CRC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.34	0.42	2.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08817171	chr15:69706672	KIF23	0.52	7.77	0.39	1.03e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg19223190	chr17:80058835	NA	-0.38	-6.04	-0.32	4.07e-9	Life satisfaction;
CRC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.35	-5.91	-0.31	8.79e-9	Personality dimensions;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.93	0.74	1.63e-58	Prudent dietary pattern;
CRC	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.39	5.87	0.31	1.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.46	6.66	0.34	1.14e-10	Longevity;Endometriosis;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg06470822	chr6:28175283	NA	0.75	8.32	0.42	2.38e-15	Depression;
CRC	cis	rs7605827	0.930	rs2052439	chr2:15702029	C/G	cg19274914	chr2:15703543	NA	0.39	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.16	-0.32	2.09e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00338735	chr4:53728038	RASL11B	0.41	6.49	0.34	3.2e-10	Optic nerve measurement (cup area);
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.42	5.89	0.31	9.71e-9	Menarche (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00012762	chr17:72744649	SLC9A3R1	-0.42	-6.34	-0.33	7.76e-10	Myopia (pathological);
CRC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	cis	rs364477	0.818	rs279886	chr9:979585	G/T	cg13952963	chr9:998547	NA	0.5	6.25	0.33	1.29e-9	Major depressive disorder;
CRC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg24253500	chr15:84953950	NA	0.4	6.3	0.33	9.53e-10	Schizophrenia;
CRC	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.54	-9.35	-0.46	1.44e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.57	8.37	0.42	1.69e-15	Longevity;Endometriosis;
CRC	cis	rs7605827	0.930	rs4133515	chr2:15696655	A/G	cg19274914	chr2:15703543	NA	0.39	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.02	0.48	8.39e-21	Alzheimer's disease (late onset);
CRC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.75	7.5	0.38	5.89e-13	Pulse pressure;
CRC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg23262073	chr20:60523788	NA	-0.37	-5.7	-0.3	2.65e-8	Body mass index;
CRC	cis	rs7113874	0.589	rs6578968	chr11:8480719	G/T	cg17679104	chr11:8615758	STK33	-0.34	-5.67	-0.3	3.1e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.5	-7.54	-0.38	4.66e-13	Motion sickness;
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg07404485	chr7:94953653	PON1	-0.45	-5.94	-0.31	7.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.59	9.98	0.48	1.13e-20	Menopause (age at onset);
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg23590916	chr17:43697445	MGC57346	0.69	6.65	0.34	1.2e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	0.92	13.23	0.59	2.47e-32	Breast cancer;
CRC	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.1	-0.32	3.05e-9	Systemic lupus erythematosus;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg02683197	chr6:28174875	NA	0.66	7.99	0.4	2.37e-14	Parkinson's disease;
CRC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.19	-0.37	4.36e-12	QT interval;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg04562611	chr16:615315	C16orf11	0.38	6.47	0.34	3.56e-10	Height;
CRC	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg12935359	chr14:103987150	CKB	-0.53	-9.18	-0.45	4.97e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.47	6.92	0.36	2.33e-11	Schizophrenia;
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.68	-8.76	-0.43	1.08e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.63	-0.39	2.6e-13	Thrombosis;
CRC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.49	0.34	3.18e-10	Cognitive ability;
CRC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg19980929	chr12:42632907	YAF2	0.41	6.27	0.33	1.11e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.29	-0.37	2.26e-12	Mean corpuscular volume;
CRC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.5	-0.34	2.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11645453	chr3:52864694	ITIH4	0.37	6.4	0.33	5.48e-10	Bipolar disorder;
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.74	-0.3	2.2e-8	Total body bone mineral density;
CRC	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.66	0.3	3.36e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg18478394	chr8:109455254	TTC35	0.38	5.83	0.31	1.31e-8	Dupuytren's disease;
CRC	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.69	0.47	1.09e-19	Fuchs's corneal dystrophy;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.74	-0.51	2.95e-23	Bipolar disorder;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg03623178	chr6:28175578	NA	0.6	7.82	0.4	7.2e-14	Parkinson's disease;
CRC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg23461800	chr14:103021989	NA	-0.64	-7.41	-0.38	1.07e-12	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20779414	chr12:57505882	STAT6	0.43	6.05	0.32	4.05e-9	Response to antipsychotic treatment;
CRC	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg23254163	chr1:152506842	NA	0.5	10.11	0.49	4.05e-21	Hair morphology;
CRC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg08213375	chr14:104286397	PPP1R13B	0.4	6.34	0.33	7.5e-10	Reticulocyte count;
CRC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg01879757	chr17:41196368	BRCA1	-0.42	-6.29	-0.33	1.02e-9	Menopause (age at onset);
CRC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg15226275	chr6:116381976	FRK	0.3	8.47	0.42	8.36e-16	Cholesterol, total;LDL cholesterol;
CRC	trans	rs1933755	0.541	rs11154595	chr6:130916665	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.88	6.55	0.34	2.16e-10	Colorectal cancer (calcium intake interaction);
CRC	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-7.12	-0.37	6.98e-12	Major depressive disorder;
CRC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.39	-6.25	-0.33	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-7.04	-0.36	1.12e-11	Schizophrenia;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15539395	chr19:59086703	MGC2752	0.47	6.63	0.34	1.38e-10	Response to antipsychotic treatment;
CRC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.92	17.0	0.68	6.03e-47	Intelligence (multi-trait analysis);
CRC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg03684893	chr10:554711	DIP2C	0.34	5.67	0.3	3.16e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg25838818	chr2:108905173	SULT1C2	-0.37	-5.98	-0.31	5.88e-9	Blood pressure;
CRC	trans	rs3851050	0.757	rs12778754	chr10:81869642	G/A	cg04055819	chr10:13749602	FRMD4A	0.44	6.04	0.32	4.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.74	-9.21	-0.45	3.91e-18	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25522312	chr4:120988417	MAD2L1	0.46	6.8	0.35	4.88e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20047235	chr7:150755417	CDK5;SLC4A2	-0.46	-6.22	-0.32	1.52e-9	Energy expenditure (24h);
CRC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	8.12	0.41	9.28e-15	Iron status biomarkers;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg25164649	chr6:28176230	NA	0.62	8.95	0.44	2.58e-17	Parkinson's disease;
CRC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.46	-6.95	-0.36	2.03e-11	Psoriasis;
CRC	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg10556349	chr10:835070	NA	-0.38	-7.52	-0.38	5.43e-13	Survival in rectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07923305	chr1:46598507	PIK3R3	0.56	7.59	0.39	3.23e-13	Thyroid stimulating hormone;
CRC	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs755249	0.567	rs2036464	chr1:39688242	A/G	cg18385671	chr1:39797026	MACF1	-0.43	-6.13	-0.32	2.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg11271282	chr2:238384023	NA	0.43	5.88	0.31	9.83e-9	Prostate cancer;
CRC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.3	0.33	9.59e-10	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21144587	chr2:27851409	GPN1;CCDC121	0.44	7.05	0.36	1.08e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg21577049	chr2:228736449	WDR69	-0.47	-6.22	-0.32	1.5e-9	Blood pressure;
CRC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg25804541	chr17:80189381	SLC16A3	0.33	6.29	0.33	1.02e-9	Life satisfaction;
CRC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.46	-6.8	-0.35	5.03e-11	Systemic lupus erythematosus;
CRC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.14	-0.41	8.48e-15	Type 2 diabetes;
CRC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-11.38	-0.53	1.54e-25	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.04	-0.36	1.15e-11	Total cholesterol levels;
CRC	cis	rs9826463	0.582	rs73238140	chr3:142046665	T/G	cg20824294	chr3:142316082	PLS1	0.35	5.72	0.3	2.41e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.11e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.4	6.25	0.33	1.27e-9	Reticulocyte count;High light scatter reticulocyte count;
CRC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.65	7.33	0.37	1.83e-12	Body mass index;
CRC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06505273	chr16:24850292	NA	-0.48	-5.81	-0.31	1.48e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1950626	0.827	rs35829821	chr14:101409763	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.98	0.66	6.18e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7113874	0.524	rs4612809	chr11:8620038	T/C	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3018066	0.666	rs75318236	chr4:106960346	T/A	cg01869342	chr4:106983673	TBCK	0.5	6.44	0.33	4.28e-10	Cancer;
CRC	cis	rs282587	0.569	rs432522	chr13:113400015	A/G	cg04656015	chr13:113407548	ATP11A	0.62	7.97	0.4	2.63e-14	Glycated hemoglobin levels;
CRC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg21466736	chr12:48725269	NA	-0.58	-8.59	-0.43	3.46e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs35883536	1.000	rs2282253	chr1:101094383	C/G	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg20933634	chr6:27740509	NA	0.53	6.54	0.34	2.38e-10	Parkinson's disease;
CRC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.91	10.01	0.48	9.31e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.25	5.97	0.31	6.07e-9	Coronary artery disease;
CRC	cis	rs6968419	0.650	rs1881287	chr7:115866354	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.45	-0.33	4.1e-10	Intraocular pressure;
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11098699	0.821	rs2083935	chr4:124214338	A/C	cg09941581	chr4:124220074	SPATA5	0.42	6.28	0.33	1.05e-9	Mosquito bite size;
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.84	14.44	0.62	5.8e-37	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.45	-6.59	-0.34	1.72e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.85	9.13	0.45	7.32e-18	Gastritis;
CRC	cis	rs2249694	1.000	rs8192781	chr10:135354251	T/G	cg20169779	chr10:135381914	SYCE1	0.54	8.63	0.43	2.68e-16	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25759457	chr1:172502420	C1orf9	0.46	5.98	0.31	5.81e-9	Thyroid stimulating hormone;
CRC	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg17470449	chr10:769945	NA	0.57	8.02	0.4	1.89e-14	Uric acid levels;
CRC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.41	0.38	1.08e-12	Lung cancer in ever smokers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14729455	chr14:53019147	TXNDC16;GPR137C	0.47	6.71	0.35	8.52e-11	Response to antipsychotic treatment;
CRC	cis	rs2979489	0.891	rs17551512	chr8:30330109	A/G	cg26383811	chr8:30366931	RBPMS	-0.7	-9.77	-0.47	5.95e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-0.7	-7.62	-0.39	2.82e-13	Schizophrenia;
CRC	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg02927042	chr1:21476669	EIF4G3	-0.44	-6.98	-0.36	1.6e-11	Superior frontal gyrus grey matter volume;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg00894870	chr1:19578612	MRTO4;KIAA0090	-0.41	-6.04	-0.32	4.18e-9	Daytime sleep phenotypes;
CRC	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.41	5.99	0.31	5.39e-9	Platelet distribution width;
CRC	trans	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg14791747	chr16:20752902	THUMPD1	-0.53	-6.52	-0.34	2.68e-10	Cognitive test performance;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg08798685	chr6:27730294	NA	-0.42	-6.04	-0.32	4.07e-9	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	11.56	0.54	3.74e-26	Bone mineral density;
CRC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.58	0.47	2.51e-19	Cognitive test performance;
CRC	cis	rs2811415	0.597	rs9834124	chr3:127741260	C/G	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.49	-8.54	-0.43	5.08e-16	Response to cytidine analogues (gemcitabine);
CRC	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg23425280	chr12:56401806	NA	0.48	5.93	0.31	7.76e-9	Cancer;
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	5.9	0.31	8.8e-9	Hip circumference adjusted for BMI;
CRC	cis	rs501120	0.584	rs1704226	chr10:44678387	C/A	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.46	0.5	2.69e-22	Heart rate;
CRC	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.8	9.87	0.48	2.64e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.52	9.67	0.47	1.28e-19	Alcoholic chronic pancreatitis;
CRC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.48e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.6	-9.34	-0.46	1.54e-18	Body mass index;
CRC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg15309053	chr8:964076	NA	0.41	7.93	0.4	3.36e-14	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07355551	chr20:2489285	ZNF343	0.41	6.01	0.31	4.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.38	-5.7	-0.3	2.64e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg12458913	chr13:53173898	NA	0.52	7.93	0.4	3.56e-14	Lewy body disease;
CRC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25517755	chr10:38738941	LOC399744	0.45	6.6	0.34	1.62e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg03623178	chr6:28175578	NA	0.7	9.8	0.48	4.67e-20	Parkinson's disease;
CRC	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.54	8.24	0.41	4.1e-15	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs1847505	0.609	rs9317154	chr13:61560533	A/G	cg14094164	chr13:61491000	NA	0.33	6.22	0.32	1.47e-9	Polychlorinated biphenyl levels;
CRC	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	0.95	10.52	0.5	1.72e-22	Atopic dermatitis;
CRC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg22117107	chr15:45993392	NA	-0.44	-8.91	-0.44	3.43e-17	Waist circumference;Weight;
CRC	trans	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg18187862	chr3:45730750	SACM1L	0.47	6.78	0.35	5.68e-11	Primary sclerosing cholangitis;
CRC	trans	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg18543242	chr14:23290393	SLC7A7	0.43	5.98	0.31	5.79e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6074578	0.902	rs6033484	chr20:185926	A/G	cg16931068	chr20:139680	DEFB127	-0.29	-5.63	-0.3	3.8e-8	Hirschsprung disease;
CRC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg16898833	chr6:26189333	HIST1H4D	0.83	7.12	0.37	6.74e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.67	8.87	0.44	4.81e-17	Alzheimer's disease;
CRC	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-7.81	-0.4	7.97e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06377221	chr19:18111739	ARRDC2	0.47	6.3	0.33	9.78e-10	Thyroid stimulating hormone;
CRC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.52	7.78	0.39	9.18e-14	Resting heart rate;
CRC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.72	11.53	0.54	4.64e-26	Dental caries;
CRC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.51	0.54	5.3e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.72	-13.42	-0.59	4.73e-33	Educational attainment;
CRC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg02527881	chr3:46936655	PTH1R	0.37	6.79	0.35	5.21e-11	Colorectal cancer;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg21251018	chr6:28226885	NKAPL	0.38	5.83	0.31	1.35e-8	Parkinson's disease;
CRC	cis	rs117623576	0.941	rs72778716	chr10:32370541	G/A	cg03047570	chr10:32398778	NA	-0.74	-7.11	-0.37	7.1e-12	Anti-saccade response;
CRC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.91	-15.65	-0.65	1.2e-41	Height;
CRC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.33	6.0	0.31	5.24e-9	Huntington's disease progression;
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.07e-10	Life satisfaction;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg03757145	chr4:76555832	CDKL2	-0.68	-6.04	-0.32	4.06e-9	Cognitive function;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10819733	chr22:24237672	NA	-0.37	-6.39	-0.33	5.62e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	10.77	0.51	2.23e-23	Alzheimer's disease;
CRC	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg11204139	chr17:3907470	NA	0.75	14.23	0.62	3.77e-36	Type 2 diabetes;
CRC	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.81	0.4	7.84e-14	Height;
CRC	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg02353165	chr6:42928485	GNMT	0.47	6.42	0.33	4.81e-10	Blood protein levels;
CRC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.38	11.14	0.52	1.16e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19318450	chr21:34852305	TMEM50B	0.41	7.17	0.37	5.12e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.51	7.51	0.38	5.58e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	5.67	0.3	3.1e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	6.15	0.32	2.26e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	0.85	7.07	0.36	9.24e-12	Fat distribution (HIV);
CRC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	5.9	0.31	8.88e-9	Coronary artery disease;
CRC	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg23202291	chr11:1979235	NA	0.48	6.73	0.35	7.48e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.64	-0.34	1.26e-10	Height;
CRC	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg02023728	chr11:77925099	USP35	-0.37	-6.27	-0.33	1.15e-9	Alzheimer's disease (survival time);
CRC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.97	-0.4	2.68e-14	Monocyte percentage of white cells;
CRC	cis	rs365302	1.000	rs2782552	chr6:159643696	G/T	cg14500486	chr6:159655392	FNDC1	0.44	6.61	0.34	1.54e-10	Coronary heart disease;
CRC	cis	rs965469	1.000	rs6051762	chr20:3321590	T/C	cg25506879	chr20:3388711	C20orf194	-0.4	-5.74	-0.3	2.17e-8	IFN-related cytopenia;
CRC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.15	0.32	2.3e-9	Diabetic kidney disease;
CRC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.81	-0.4	7.86e-14	Response to antipsychotic treatment;
CRC	cis	rs4363385	0.510	rs11488175	chr1:153039778	A/G	cg25856811	chr1:152973957	SPRR3	0.23	6.29	0.33	1.04e-9	Inflammatory skin disease;
CRC	cis	rs10045504	0.502	rs17456635	chr5:38745456	G/A	cg15396434	chr5:38725168	NA	-0.6	-6.01	-0.31	4.86e-9	Night sleep phenotypes;
CRC	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.67	9.49	0.46	4.9e-19	Body mass index;
CRC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.0	0.61	2.81e-35	Mean platelet volume;
CRC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg03929089	chr4:120376271	NA	0.56	6.51	0.34	2.73e-10	Intraocular pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01855760	chr4:68567075	LOC550112;UBA6	0.47	6.05	0.32	3.92e-9	Thyroid stimulating hormone;
CRC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.04	-0.32	4.21e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	5.84	0.31	1.22e-8	Hemoglobin concentration;
CRC	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg12856521	chr11:46389249	DGKZ	0.44	7.23	0.37	3.31e-12	Leprosy;
CRC	cis	rs4132509	0.895	rs6674314	chr1:243920895	A/G	cg21452805	chr1:244014465	NA	0.48	6.62	0.34	1.48e-10	RR interval (heart rate);
CRC	cis	rs3087591	0.683	rs2525564	chr17:29652531	A/G	cg24425628	chr17:29625626	OMG;NF1	0.74	13.21	0.59	2.86e-32	Hip circumference;
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-7.69	-0.39	1.77e-13	Vitiligo;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg14587446	chr7:150672364	KCNH2	0.39	6.26	0.33	1.17e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg13798780	chr7:105162888	PUS7	0.65	7.41	0.38	1.1e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg18758796	chr5:131593413	PDLIM4	-0.34	-6.2	-0.32	1.73e-9	Breast cancer;
CRC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	1.01	13.45	0.6	3.76e-33	Vitiligo;
CRC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.17	-14.11	-0.61	1.14e-35	Mitochondrial DNA levels;
CRC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	11.07	0.52	2.09e-24	Neutrophil percentage of white cells;
CRC	cis	rs9992667	0.955	rs60029573	chr4:38663863	T/C	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.02	-0.45	1.62e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs3764400	0.567	rs3897789	chr17:46312777	C/T	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg19688584	chr6:167529678	CCR6	0.33	6.13	0.32	2.56e-9	Primary biliary cholangitis;
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.98	0.31	5.83e-9	Prudent dietary pattern;
CRC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-9.83	-0.48	3.71e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.85	16.24	0.67	6e-44	Metabolic syndrome;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-11.26	-0.53	4.42e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.55	8.26	0.41	3.49e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.8	10.05	0.48	6.61e-21	Prostate cancer;
CRC	cis	rs9658691	0.920	rs2234768	chr10:90749943	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-6.3	-0.33	9.41e-10	Mosquito bite size;
CRC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.12	-0.41	9.38e-15	Bone mineral density;
CRC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.44	-7.36	-0.38	1.46e-12	Facial morphology (factor 20);
CRC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.78	0.3	1.74e-8	Lung cancer;
CRC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg13072238	chr3:49761600	GMPPB	0.48	5.63	0.3	3.86e-8	Menarche (age at onset);
CRC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-8.08	-0.41	1.26e-14	Uric acid levels;
CRC	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.51	7.84	0.4	6.42e-14	Corneal astigmatism;
CRC	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.08	-0.55	4.63e-28	Coffee consumption (cups per day);
CRC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.51	7.06	0.36	1.01e-11	Obesity-related traits;
CRC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.66	12.54	0.57	9.6e-30	Bone mineral density;
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.04	0.55	6.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16975973	chr12:77459865	E2F7	0.47	6.94	0.36	2.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg17724175	chr1:150552817	MCL1	0.45	6.93	0.36	2.17e-11	Melanoma;
CRC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-9.04	-0.45	1.33e-17	Body mass index (adult);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26379672	chr3:4534954	ITPR1	0.46	6.06	0.32	3.7e-9	Anxiety disorder;
CRC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg25456477	chr12:86230367	RASSF9	-0.35	-5.9	-0.31	8.88e-9	Major depressive disorder;
CRC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.58	-9.5	-0.46	4.46e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg00042356	chr1:8021962	PARK7	0.73	7.64	0.39	2.36e-13	Inflammatory bowel disease;
CRC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.61	-9.36	-0.46	1.25e-18	Height;
CRC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.5	7.61	0.39	2.84e-13	Corneal astigmatism;
CRC	cis	rs703970	0.560	rs2802361	chr10:80971640	G/C	cg20744163	chr10:80999841	ZMIZ1	-0.37	-6.04	-0.32	4.12e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg12273811	chr6:28175739	NA	0.45	6.56	0.34	2.06e-10	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg12564285	chr5:131593104	PDLIM4	0.48	7.98	0.4	2.45e-14	Breast cancer;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.64	-8.99	-0.44	1.97e-17	Menopause (age at onset);
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg06470822	chr6:28175283	NA	0.81	11.77	0.54	6.35e-27	Cardiac Troponin-T levels;
CRC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.48	-0.38	6.64e-13	Mean corpuscular volume;
CRC	trans	rs507080	0.922	rs654792	chr11:118552996	A/C	cg17272795	chr10:38382849	ZNF37A	0.41	5.97	0.31	6.08e-9	Serum metabolite levels;
CRC	cis	rs17065868	1.000	rs9533920	chr13:45157394	G/A	cg10246903	chr13:45222710	NA	0.53	5.95	0.31	6.84e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06717492	chr7:65447339	GUSB	0.42	6.89	0.36	2.9100000000000002e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.68	-6.07	-0.32	3.43e-9	Diabetic kidney disease;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.6	7.09	0.36	8.33e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.5	-9.12	-0.45	7.86e-18	Intelligence (multi-trait analysis);
CRC	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.46	6.86	0.35	3.49e-11	Crohn's disease;
CRC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.01	0.31	4.91e-9	Heart rate;
CRC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	8.61	0.43	3.02e-16	Eosinophil percentage of white cells;
CRC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.25	0.37	2.95e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16856342	chr1:67895909	SERBP1	0.4	6.57	0.34	1.98e-10	Interleukin-6 levels;
CRC	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg16850897	chr7:100343110	ZAN	0.45	6.72	0.35	7.97e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg14196790	chr5:131705035	SLC22A5	0.35	5.61	0.3	4.37e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.44	6.61e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.46	9.53	0.47	3.52e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.67	-0.3	3.09e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-0.92	-8.27	-0.41	3.43e-15	Mitochondrial DNA levels;
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.39	0.33	5.63e-10	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg20935933	chr6:143382018	AIG1	0.51	6.64	0.34	1.3e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.67	-9.92	-0.48	1.81e-20	Acne (severe);
CRC	cis	rs3825932	0.961	rs2870085	chr15:79234268	T/C	cg25744700	chr15:79237217	CTSH	0.39	6.08	0.32	3.42e-9	Type 1 diabetes;
CRC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.64	9.8	0.48	4.75e-20	Platelet count;
CRC	cis	rs7781266	0.847	rs889824	chr7:133596581	A/G	cg03336402	chr7:133662267	EXOC4	-0.59	-7.76	-0.39	1.08e-13	Educational attainment (college completion);
CRC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.56	9.43	0.46	7.82e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.69e-21	Prudent dietary pattern;
CRC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	13.73	0.6	3.2e-34	Schizophrenia;
CRC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg12193833	chr17:30244370	NA	-0.74	-8.7	-0.43	1.61e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17554472	chr22:41940697	POLR3H	-0.52	-5.6	-0.3	4.42e-8	Vitiligo;
CRC	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	1.05	12.55	0.57	8.75e-30	Diisocyanate-induced asthma;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20887711	chr4:1340912	KIAA1530	0.42	6.14	0.32	2.4e-9	Obesity-related traits;
CRC	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-6.36	-0.33	6.71e-10	Coronary artery disease;
CRC	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg21169611	chr9:106856078	SMC2	0.42	5.83	0.31	1.31e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.54	7.06	0.36	1.03e-11	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.56	8.41	0.42	1.28e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.79	11.88	0.55	2.48e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.57	-6.38	-0.33	6.07e-10	Red blood cell count;
CRC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	0.85	9.64	0.47	1.51e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06544989	chr22:39130855	UNC84B	0.42	6.17	0.32	2.03e-9	Menopause (age at onset);
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08989290	chr16:615782	NHLRC4	0.5	9.9	0.48	2.1e-20	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26329349	chr8:67974458	COPS5	0.42	5.96	0.31	6.48e-9	Response to antipsychotic treatment;
CRC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg18016565	chr1:150552671	MCL1	-0.42	-6.26	-0.33	1.22e-9	Lymphocyte counts;
CRC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.22	-0.37	3.58e-12	Mean platelet volume;
CRC	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.72	-9.22	-0.45	3.61e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.26	0.41	3.61e-15	Height;
CRC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.55	-8.6	-0.43	3.21e-16	Aortic root size;
CRC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.33	-0.33	7.89e-10	Tonsillectomy;
CRC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.55	8.22	0.41	4.61e-15	Morning vs. evening chronotype;
CRC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.6	11.29	0.53	3.36e-25	Bone mineral density;
CRC	cis	rs41005	1.000	rs41008	chr2:8108588	G/T	cg03155496	chr2:8117019	LOC339788	0.42	7.45	0.38	8.06e-13	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs4664293	0.867	rs10204867	chr2:160589185	C/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg26061582	chr7:22766209	IL6	0.55	8.34	0.42	2.03e-15	Lung cancer;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg03623178	chr6:28175578	NA	0.89	11.72	0.54	9.49e-27	Parkinson's disease;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24268822	chr3:49059985	NDUFAF3	0.44	6.19	0.32	1.77e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg27661571	chr11:113659931	NA	-0.95	-11.08	-0.52	1.91e-24	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.47	0.46	5.78e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2223471	0.905	rs2817414	chr6:50748813	G/A	cg03432817	chr6:50765336	NA	0.37	5.8	0.3	1.52e-8	Subcutaneous adipose tissue;
CRC	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.45	-7.44	-0.38	8.84e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.52	7.32	0.37	1.86e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.73	10.92	0.52	6.54e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.59	9.45	0.46	6.76e-19	Schizophrenia;
CRC	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.03	-0.32	4.46e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.43	6.25	0.33	1.28e-9	Obesity-related traits;
CRC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	10.27	0.49	1.2e-21	Migraine;Coronary artery disease;
CRC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	6.8	0.35	5.07e-11	Parkinson's disease;
CRC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg00919237	chr7:87102261	ABCB4	-0.53	-7.07	-0.36	9.33e-12	Gallbladder cancer;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs4499344	0.633	rs259260	chr19:33153261	G/A	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.04	0.32	4.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.54	-8.65	-0.43	2.26e-16	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08039281	chr14:35761689	PSMA6	0.47	6.05	0.32	3.88e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.63	-10.05	-0.48	6.6e-21	Aortic root size;
CRC	cis	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg15786705	chr6:28176104	NA	-0.58	-5.96	-0.31	6.43e-9	Depression;
CRC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20652235	chr19:47747597	NA	0.46	6.16	0.32	2.1e-9	Anxiety disorder;
CRC	cis	rs6662572	0.542	rs72677553	chr1:46592278	C/T	cg08644498	chr1:46502608	NA	0.46	7.31	0.37	2.11e-12	Blood protein levels;
CRC	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.45	0.5	2.84e-22	Corneal astigmatism;
CRC	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg10556349	chr10:835070	NA	-0.38	-7.44	-0.38	8.7e-13	Survival in rectal cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01581637	chr12:49463804	RHEBL1	0.47	6.69	0.35	9.83e-11	Anxiety disorder;
CRC	cis	rs375066	0.623	rs6509120	chr19:44350205	C/T	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs73195822	0.614	rs73194061	chr12:111221941	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	6.98	0.36	1.61e-11	Itch intensity from mosquito bite;
CRC	cis	rs737008	0.922	rs2550475	chr16:11371986	C/T	cg00044050	chr16:11439710	C16orf75	0.51	6.76	0.35	6.4e-11	Obesity-related traits;
CRC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.55	7.53	0.38	4.84e-13	Height;
CRC	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg16141378	chr3:129829833	LOC729375	0.41	6.35	0.33	7.24e-10	Triglycerides;
CRC	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.2e-12	Prostate cancer;
CRC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.43	-5.65	-0.3	3.56e-8	Protein C levels;
CRC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg14671364	chr1:107599128	PRMT6	0.48	6.81	0.35	4.79e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9462027	0.606	rs7768759	chr6:34795685	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.13	-0.32	2.45e-9	Systemic lupus erythematosus;
CRC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.39	5.81	0.3	1.5e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.75	-10.27	-0.49	1.17e-21	Height;
CRC	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.98	11.6	0.54	2.54e-26	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.64	8.39	0.42	1.46e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg05627522	chr15:75251581	NA	0.37	5.71	0.3	2.55e-8	Breast cancer;
CRC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg09655341	chr17:79618100	PDE6G	-0.36	-6.16	-0.32	2.15e-9	Eye color traits;
CRC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.58	8.57	0.43	4.07e-16	Intelligence (multi-trait analysis);
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.68	-9.93	-0.48	1.69e-20	Menopause (age at onset);
CRC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.48	6.13	0.32	2.58e-9	Schizophrenia;
CRC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.65	9.22	0.45	3.53e-18	Vitamin D levels;
CRC	cis	rs67981189	0.529	rs17108808	chr14:71441552	T/C	cg15910301	chr14:71632612	NA	0.28	5.67	0.3	3.11e-8	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03113121	chr19:46366686	FOXA3;SYMPK	0.47	6.84	0.35	3.97e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.29	0.33	1.03e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-5.97	-0.31	6.23e-9	Inflammatory skin disease;
CRC	cis	rs9463078	0.605	rs9472407	chr6:44908800	T/C	cg25276700	chr6:44698697	NA	0.25	6.06	0.32	3.74e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.43	-6.03	-0.32	4.49e-9	Calcium levels;
CRC	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.61	0.39	2.99e-13	Systolic blood pressure;
CRC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.65e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00147160	chr1:26503991	CNKSR1	0.3	6.24	0.33	1.35e-9	Height;
CRC	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg27398640	chr15:77910606	LINGO1	-0.44	-7.66	-0.39	2.12e-13	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.51	-6.63	-0.34	1.39e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.5	8.04	0.41	1.65e-14	Body mass index;
CRC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.72	-0.35	8.1e-11	Alzheimer's disease (late onset);
CRC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.45	5.86	0.31	1.15e-8	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.55	-8.02	-0.4	1.84e-14	Cognitive test performance;
CRC	cis	rs4664293	0.867	rs12623283	chr2:160593470	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.53	7.53	0.38	5e-13	Alzheimer's disease;
CRC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-7.05	-0.36	1.04e-11	Homoarginine levels;
CRC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.44	-0.62	6.1e-37	Height;
CRC	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.39	5.63	0.3	3.83e-8	Asthma (bronchodilator response);
CRC	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.54	9.02	0.45	1.65e-17	Dupuytren's disease;
CRC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.51	0.34	2.81e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2411233	1.000	rs8026431	chr15:39274261	C/A	cg23129342	chr15:39283510	NA	0.32	5.91	0.31	8.53e-9	Platelet count;
CRC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg00383909	chr3:49044727	WDR6	0.47	5.89	0.31	9.58e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	10.05	0.48	6.91e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg23378565	chr7:2036160	MAD1L1	-0.36	-6.13	-0.32	2.57e-9	Bipolar disorder;
CRC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg19812747	chr11:111475976	SIK2	0.54	8.54	0.43	5.03e-16	Primary sclerosing cholangitis;
CRC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.55	8.17	0.41	6.61e-15	Fibrinogen levels;
CRC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg18230493	chr5:56204884	C5orf35	0.6	8.72	0.43	1.39e-16	Initial pursuit acceleration;
CRC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg09835421	chr16:68378352	PRMT7	-0.78	-8.1	-0.41	1.12e-14	Schizophrenia;
CRC	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.37	6.23	0.33	1.39e-9	IgG glycosylation;
CRC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.62	7.11	0.36	7.24e-12	Resting heart rate;
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg12172441	chr6:28176163	NA	0.47	6.53	0.34	2.44e-10	Parkinson's disease;
CRC	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.62	8.74	0.43	1.17e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.83	0.35	4.15e-11	Reticulocyte fraction of red cells;
CRC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.47	6.45	0.33	4.03e-10	Aortic root size;
CRC	cis	rs4700695	0.841	rs251300	chr5:65299715	C/G	cg21114390	chr5:65439923	SFRS12	-0.57	-7.02	-0.36	1.28e-11	Facial morphology (factor 19);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00090800	chr16:27325237	IL4R	0.38	6.06	0.32	3.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg15448220	chr1:150897856	SETDB1	-0.44	-6.24	-0.33	1.34e-9	Urate levels;
CRC	cis	rs1681630	0.545	rs12790666	chr11:47983477	G/A	cg05585544	chr11:47624801	NA	-0.43	-7.24	-0.37	3.27e-12	Height;
CRC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.56	-7.53	-0.38	4.95e-13	Schizophrenia;
CRC	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	6.87	0.35	3.28e-11	Lung cancer;
CRC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.69	-8.9	-0.44	3.93e-17	Initial pursuit acceleration;
CRC	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.41	0.46	8.79e-19	Fuchs's corneal dystrophy;
CRC	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.67	6.81	0.35	4.78e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.82	-0.35	4.36e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.4	6.04	0.32	4.26e-9	Hemoglobin concentration;
CRC	cis	rs4731207	0.564	rs6960622	chr7:124654080	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.24	-0.33	1.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-7.03	-0.36	1.19e-11	Total body bone mineral density;
CRC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg15147215	chr3:52552868	STAB1	0.54	9.47	0.46	5.65e-19	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg24163568	chr5:669837	TPPP	-0.42	-6.71	-0.35	8.41e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs11212617	0.934	rs609557	chr11:108084513	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.4	6.15	0.32	2.2e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.72	-0.35	7.95e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg24463073	chr6:118973353	C6orf204	0.5	6.41	0.33	4.91e-10	Diastolic blood pressure;
CRC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg20684491	chr1:25596433	NA	0.42	7.54	0.38	4.7e-13	Erythrocyte sedimentation rate;
CRC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs7259376	0.905	rs7258446	chr19:22550341	A/T	cg02657401	chr19:22469223	NA	-0.33	-7.19	-0.37	4.28e-12	Menopause (age at onset);
CRC	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg07423050	chr13:99094983	FARP1	0.41	6.57	0.34	1.93e-10	Longevity;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.63e-9	Life satisfaction;
CRC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg18478394	chr8:109455254	TTC35	0.38	5.81	0.31	1.46e-8	Dupuytren's disease;
CRC	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg06818126	chr11:68850279	TPCN2	-0.47	-6.64	-0.34	1.26e-10	Hair color;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg15845792	chr6:28175446	NA	0.6	7.95	0.4	3.01e-14	Parkinson's disease;
CRC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.62	14.21	0.62	4.69e-36	Airflow obstruction;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12273811	chr6:28175739	NA	-0.76	-11.04	-0.52	2.59e-24	Depression;
CRC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	0.94	13.54	0.6	1.62e-33	Breast cancer;
CRC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg09218773	chr11:619014	MUPCDH	-0.41	-6.16	-0.32	2.16e-9	Systemic lupus erythematosus;
CRC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	12.94	0.58	3.18e-31	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg06028605	chr16:24865363	SLC5A11	0.37	6.87	0.35	3.21e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4728302	0.869	rs10224575	chr7:133590875	G/A	cg03336402	chr7:133662267	EXOC4	-0.44	-6.41	-0.33	4.91e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs972578	1.000	rs972578	chr22:43387695	G/T	cg01576275	chr22:43409880	NA	-0.49	-7.89	-0.4	4.45e-14	Mean platelet volume;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg04155289	chr7:94953770	PON1	0.6	7.55	0.38	4.39e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.04	0.32	4.19e-9	Ovarian reserve;
CRC	cis	rs9549328	0.564	rs34556022	chr13:113617437	G/A	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.7e-13	Systolic blood pressure;
CRC	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14119001	chr9:139324193	INPP5E	-0.44	-6.19	-0.32	1.75e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg09659197	chr4:152720779	NA	-0.41	-8.78	-0.44	9.31e-17	Intelligence (multi-trait analysis);
CRC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg08773314	chr2:239334832	ASB1	0.37	7.76	0.39	1.11e-13	Multiple system atrophy;
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.73	7.69	0.39	1.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.55	-5.7	-0.3	2.72e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.92	16.75	0.68	5.53e-46	Intelligence (multi-trait analysis);
CRC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.45e-9	Ulcerative colitis;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.83	-0.44	6.13e-17	Bipolar disorder;
CRC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	12.36	0.56	4.47e-29	Lymphocyte percentage of white cells;
CRC	cis	rs4731207	0.596	rs10247349	chr7:124607495	C/T	cg23710748	chr7:124431027	NA	-0.43	-6.81	-0.35	4.56e-11	Cutaneous malignant melanoma;
CRC	cis	rs17234274	0.644	rs7949855	chr11:23222449	C/T	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.02e-8	Cancer;
CRC	cis	rs7781557	1.000	rs2041094	chr7:102495434	C/T	cg18108683	chr7:102477205	FBXL13	-0.54	-6.86	-0.35	3.43e-11	Colorectal adenoma (advanced);
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.51	-6.94	-0.36	2.16e-11	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26126750	chr3:195809198	TFRC	0.43	6.11	0.32	2.77e-9	Anxiety disorder;
CRC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.9	-0.31	8.86e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs35000415	0.745	rs117944677	chr7:128698185	A/T	cg19972273	chr7:128594194	NA	0.71	6.15	0.32	2.2e-9	Systemic lupus erythematosus;
CRC	trans	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg13565492	chr6:43139072	SRF	-0.69	-7.13	-0.37	6.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg15382696	chr6:118971807	C6orf204	0.47	6.51	0.34	2.88e-10	Renal cell carcinoma;
CRC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.63	-9.34	-0.46	1.51e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg13491945	chr12:107078410	RFX4	0.36	6.23	0.32	1.42e-9	Heart rate;
CRC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.45	7.47	0.38	7.14e-13	Major depressive disorder;
CRC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.54	9.06	0.45	1.19e-17	Systemic lupus erythematosus;
CRC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.7	-0.51	4.12e-23	Monocyte count;
CRC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18642567	chr14:21755798	RPGRIP1	-0.42	-7.07	-0.36	9.05e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.54	6.43	0.33	4.45e-10	Obesity-related traits;
CRC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.06	0.32	3.76e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13315871	1.000	rs13063504	chr3:58409854	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg12311346	chr5:56204834	C5orf35	-0.46	-7.04	-0.36	1.16e-11	Coronary artery disease;
CRC	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg14092571	chr14:90743983	NA	0.38	5.8	0.3	1.6e-8	Mortality in heart failure;
CRC	cis	rs10221833	0.602	rs355886	chr2:165634156	G/A	cg03182029	chr2:165697222	COBLL1	0.48	5.66	0.3	3.26e-8	Response to statin therapy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04053862	chr2:179345017	MIR548N;PLEKHA3	0.42	5.99	0.31	5.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	14.14	0.61	8.29e-36	Platelet count;
CRC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.8	-0.51	1.81e-23	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03398387	chr6:160114178	SOD2	0.45	6.29	0.33	9.86e-10	Response to antipsychotic treatment;
CRC	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06307176	chr5:131281290	NA	0.41	6.15	0.32	2.22e-9	Life satisfaction;
CRC	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.5	-7.31	-0.37	2.11e-12	Magnesium levels;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg22638593	chr5:131593259	PDLIM4	0.36	5.76	0.3	1.89e-8	Breast cancer;
CRC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	15.1	0.64	1.64e-39	Mean platelet volume;
CRC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg09655341	chr17:79618100	PDE6G	-0.35	-6.03	-0.32	4.46e-9	Eye color traits;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg23123621	chr4:1343375	KIAA1530	0.32	5.69	0.3	2.84e-8	Obesity-related traits;
CRC	cis	rs79387448	0.745	rs72993760	chr2:103151704	G/A	cg09003973	chr2:102972529	NA	0.73	8.14	0.41	8.53e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg07274523	chr3:49395745	GPX1	0.46	6.02	0.31	4.74e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg20608306	chr11:116969690	SIK3	-0.33	-6.4	-0.33	5.32e-10	Subjective well-being;
CRC	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.67	-8.78	-0.44	9.1e-17	Hypospadias;
CRC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.52	7.8	0.4	8.17e-14	Blood protein levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17910969	chr17:73521755	LLGL2	0.44	6.77	0.35	5.9e-11	Schizophrenia;
CRC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg20400248	chr8:9005257	PPP1R3B	-0.37	-5.82	-0.31	1.4e-8	Joint mobility (Beighton score);
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg15786705	chr6:28176104	NA	0.81	11.69	0.54	1.25e-26	Depression;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg03623178	chr6:28175578	NA	0.83	12.47	0.57	1.76e-29	Parkinson's disease;
CRC	cis	rs17681684	0.565	rs12150149	chr17:9764039	A/C	cg26853458	chr17:9805074	RCVRN	-0.5	-9.04	-0.45	1.38e-17	GIP levels in response to oral glucose tolerance test (fasting);
CRC	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg07741184	chr6:167504864	NA	0.33	5.94	0.31	7.32e-9	Primary biliary cholangitis;
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg25922969	chr5:176793941	RGS14	0.39	5.76	0.3	1.93e-8	Hemoglobin concentration;Hematocrit;
CRC	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.27	-0.33	1.13e-9	Body mass index;
CRC	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	6.68	0.35	1.01e-10	Body mass index;
CRC	cis	rs7605827	0.930	rs3954894	chr2:15517656	T/C	cg19274914	chr2:15703543	NA	0.38	5.66	0.3	3.29e-8	Educational attainment (years of education);
CRC	cis	rs61160187	0.582	rs4642318	chr5:60292758	A/G	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.76	-0.3	1.95e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.14	-0.45	6.43e-18	Intelligence (multi-trait analysis);
CRC	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.64	11.05	0.52	2.38e-24	Metabolite levels;
CRC	cis	rs995000	0.899	rs1002687	chr1:62963737	G/A	cg19896129	chr1:63156450	NA	-0.39	-6.01	-0.31	4.99e-9	Triglyceride levels;
CRC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs2386661	0.523	rs61832677	chr10:5652477	A/G	cg26603656	chr10:5671107	NA	0.4	7.28	0.37	2.47e-12	Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14780845	chr17:41323115	NBR1	0.38	6.0	0.31	5.31e-9	Interleukin-6 levels;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg25164649	chr6:28176230	NA	0.61	8.85	0.44	5.43e-17	Cardiac Troponin-T levels;
CRC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg24209194	chr3:40518798	ZNF619	0.41	6.1	0.32	2.94e-9	Renal cell carcinoma;
CRC	cis	rs9372498	0.764	rs9489369	chr6:118720704	A/C	cg18833306	chr6:118973337	C6orf204	-0.5	-6.41	-0.33	5.15e-10	Diastolic blood pressure;
CRC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.46	-6.97	-0.36	1.76e-11	Blood metabolite levels;
CRC	trans	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.19	-0.32	1.79e-9	Tuberculosis;
CRC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg04731861	chr2:219085781	ARPC2	0.32	6.5	0.34	2.93e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26964202	chr12:63328896	PPM1H	0.45	6.41	0.33	5.02e-10	Anxiety disorder;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.3	-6.28	-0.33	1.1e-9	Bipolar disorder;
CRC	trans	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg13565492	chr6:43139072	SRF	-0.65	-6.68	-0.35	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.57	8.79	0.44	8.78e-17	Educational attainment;
CRC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	1.02	8.54	0.43	4.99e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.61	-0.3	4.38e-8	Coronary artery disease;
CRC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg06970220	chr1:156163860	SLC25A44	0.49	7.16	0.37	5.18e-12	Testicular germ cell tumor;
CRC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg11189052	chr15:85197271	WDR73	-0.63	-8.95	-0.44	2.7e-17	Schizophrenia;
CRC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.62	7.93	0.4	3.57e-14	Iron status biomarkers;
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18402987	chr7:1209562	NA	0.43	6.32	0.33	8.37e-10	Longevity;Endometriosis;
CRC	cis	rs6662572	1.000	rs7517111	chr1:46122140	A/G	cg08644498	chr1:46502608	NA	0.48	7.04	0.36	1.13e-11	Blood protein levels;
CRC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.31	-6.09	-0.32	3.15e-9	Blood metabolite levels;
CRC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.41	8.95	0.44	2.73e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs501120	0.564	rs2246891	chr10:44680591	A/G	cg09554077	chr10:44749378	NA	0.5	6.98	0.36	1.62e-11	Coronary artery disease;Coronary heart disease;
CRC	cis	rs12143943	0.966	rs4951410	chr1:204563817	G/A	cg17419461	chr1:204415978	PIK3C2B	0.4	6.04	0.32	4.28e-9	Cognitive performance;
CRC	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.13	-0.32	2.46e-9	Schizophrenia;
CRC	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.27	-0.33	1.16e-9	Metabolite levels;
CRC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.54	6.28	0.33	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-18.34	-0.71	3.01e-52	Height;
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18297960	chr7:1142765	C7orf50	-0.43	-5.79	-0.3	1.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-6.05	-0.32	3.96e-9	Monocyte count;
CRC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.61	-0.43	3.09e-16	Aortic root size;
CRC	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.52	-7.55	-0.38	4.39e-13	Schizophrenia;
CRC	cis	rs4731207	0.596	rs11763920	chr7:124640880	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.38	-0.42	1.6e-15	Aortic root size;
CRC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.75	14.08	0.61	1.43e-35	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.67	0.3	3.18e-8	Depression;
CRC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.82	-0.4	7.28e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-17.43	-0.69	1.23e-48	Height;
CRC	cis	rs9467160	0.871	rs9467168	chr6:24449036	A/G	cg20631270	chr6:24437470	GPLD1	0.48	6.66	0.34	1.16e-10	Liver enzyme levels;
CRC	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg05049329	chr1:226924846	ITPKB	0.39	8.71	0.43	1.46e-16	Parkinson's disease;
CRC	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg11901034	chr3:128598214	ACAD9	-0.5	-6.23	-0.32	1.44e-9	IgG glycosylation;
CRC	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.45	-7.91	-0.4	3.99e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs12580194	0.593	rs115471673	chr12:55766516	A/G	cg19537932	chr12:55886519	OR6C68	-0.73	-9.2	-0.45	4.32e-18	Cancer;
CRC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.01e-12	Rheumatoid arthritis;
CRC	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.06	-0.45	1.19e-17	Triglycerides;
CRC	cis	rs1403694	0.695	rs11924390	chr3:186433099	T/C	cg04611788	chr3:186434169	KNG1	-0.59	-8.81	-0.44	7.08e-17	Blood protein levels;
CRC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.58	-8.29	-0.42	2.84e-15	Breast cancer;
CRC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg23229984	chr5:148520753	ABLIM3	0.48	6.59	0.34	1.79e-10	Breast cancer;
CRC	cis	rs4824093	0.610	rs9627799	chr22:50317989	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-8.7	-0.43	1.57e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg21251018	chr6:28226885	NKAPL	0.49	7.16	0.37	5.42e-12	Parkinson's disease;
CRC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs4290604	0.748	rs4549025	chr2:238052911	C/T	cg23555395	chr2:238036564	NA	0.63	6.53	0.34	2.51e-10	Asthma;
CRC	cis	rs3996993	0.809	rs72938170	chr6:52736385	C/T	cg20803780	chr6:52668592	GSTA1	0.37	6.85	0.35	3.6e-11	Hemoglobin concentration;
CRC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.92	-0.36	2.38e-11	QT interval;
CRC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.85	14.77	0.63	3.2e-38	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20092199	chr4:1342459	KIAA1530	0.34	5.95	0.31	6.85e-9	Obesity-related traits;
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	10.73	0.51	3.21e-23	Prudent dietary pattern;
CRC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.0	0.31	5.12e-9	Dupuytren's disease;
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.6	9.4	0.46	9.3e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.47	-6.24	-0.33	1.33e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.21	-0.32	1.6e-9	Monocyte percentage of white cells;
CRC	cis	rs9487051	0.646	rs11153165	chr6:109622159	G/A	cg01475377	chr6:109611718	NA	-0.36	-5.65	-0.3	3.45e-8	Reticulocyte fraction of red cells;
CRC	trans	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.16	0.41	7.12e-15	Educational attainment;
CRC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.51	8.74	0.43	1.23e-16	Hypertriglyceridemia;
CRC	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.41	6.74	0.35	7.28e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.88	-0.35	2.98e-11	Total body bone mineral density;
CRC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg13798780	chr7:105162888	PUS7	0.66	7.39	0.38	1.19e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.51	0.38	5.67e-13	Lung cancer in ever smokers;
CRC	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg02820901	chr13:113351484	ATP11A	0.64	7.02	0.36	1.3e-11	Glycated hemoglobin levels;
CRC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.67	-7.85	-0.4	5.96e-14	Rheumatoid arthritis;
CRC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg00129232	chr17:37814104	STARD3	-0.45	-7.21	-0.37	3.98e-12	Self-reported allergy;
CRC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-7.86	-0.4	5.4e-14	Total body bone mineral density;
CRC	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg15382696	chr6:118971807	C6orf204	0.57	7.06	0.36	1.02e-11	Diastolic blood pressure;
CRC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.29	-0.42	2.97e-15	Type 2 diabetes;
CRC	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.44	6.94	0.36	2.1e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Urate levels;
CRC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.06	0.32	3.8e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.8	-0.44	7.65e-17	Aortic root size;
CRC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg27661571	chr11:113659931	NA	0.62	7.33	0.37	1.75e-12	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.38	-0.42	1.55e-15	Aortic root size;
CRC	trans	rs2547917	0.947	rs2702376	chr5:58707592	C/G	cg15920655	chr2:129025795	HS6ST1	0.58	6.19	0.32	1.82e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	6.16	0.32	2.13e-9	Breast cancer;
CRC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs720844	1.000	rs4972383	chr2:149345062	G/A	cg09247360	chr2:149335327	NA	-0.62	-7.8	-0.39	8.45e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.37	6.14	0.32	2.38e-9	Cardiovascular disease risk factors;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg27635394	chr6:26043820	HIST1H2BB	0.46	6.56	0.34	2.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg06875740	chr19:51307921	C19orf48	-0.66	-6.03	-0.32	4.5e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.71	10.14	0.49	3.35e-21	Cognitive function;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg26587870	chr6:27730563	NA	-0.43	-6.69	-0.35	9.86e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg13722127	chr7:150037890	RARRES2	0.47	7.94	0.4	3.32e-14	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg18187862	chr3:45730750	SACM1L	0.47	6.78	0.35	5.68e-11	Primary sclerosing cholangitis;
CRC	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	14.9	0.63	1.01e-38	Hypertriglyceridemia;
CRC	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.39	-0.62	9.26e-37	Colorectal cancer;
CRC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.93	-14.35	-0.62	1.31e-36	Systemic lupus erythematosus;
CRC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg00129232	chr17:37814104	STARD3	-0.49	-7.65	-0.39	2.22e-13	Self-reported allergy;
CRC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.39	-5.94	-0.31	7.22e-9	Type 1 diabetes;
CRC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg04155289	chr7:94953770	PON1	0.56	7.15	0.37	5.69e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2160860	0.773	rs10755980	chr8:39798322	C/G	cg11363097	chr8:39792086	IDO2	-0.42	-7.24	-0.37	3.23e-12	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00531750	chr3:66551802	LRIG1	0.43	6.12	0.32	2.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6141769	0.518	rs28378056	chr20:31298317	G/C	cg13636640	chr20:31349939	DNMT3B	-0.4	-6.14	-0.32	2.43e-9	Subjective well-being;
CRC	cis	rs6743376	0.556	rs4849146	chr2:113824840	A/T	cg09040174	chr2:113837401	NA	0.4	5.86	0.31	1.13e-8	Inflammatory biomarkers;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03480535	chr4:87856849	AFF1	0.53	7.1	0.36	7.81e-12	Thyroid stimulating hormone;
CRC	cis	rs889398	0.617	rs4985450	chr16:69901106	A/T	cg00738113	chr16:70207722	CLEC18C	0.37	6.56	0.34	2.15e-10	Body mass index;
CRC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.72	-0.35	8.03e-11	Aortic root size;
CRC	cis	rs11229555	0.645	rs11229442	chr11:58196790	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.62	0.43	2.89e-16	Neuroticism;
CRC	cis	rs6496667	0.514	rs62019353	chr15:90933683	T/C	cg22089800	chr15:90895588	ZNF774	0.47	5.93	0.31	7.56e-9	Rheumatoid arthritis;
CRC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.56	-9.87	-0.48	2.65e-20	Huntington's disease progression;
CRC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.75	12.57	0.57	7.16e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg25809561	chr17:30822961	MYO1D	0.52	9.2	0.45	4.24e-18	Schizophrenia;
CRC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.93e-9	Height;
CRC	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg18827107	chr12:86230957	RASSF9	-0.36	-5.67	-0.3	3.05e-8	Major depressive disorder;
CRC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg24011408	chr12:48396354	COL2A1	0.46	6.35	0.33	7.23e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Body mass index;
CRC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg05756136	chr1:119680316	WARS2	-0.52	-7.03	-0.36	1.19e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.46	-0.5	2.59e-22	Alzheimer's disease;
CRC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.61	7.55	0.38	4.37e-13	Mean platelet volume;
CRC	cis	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg04317927	chr11:55418816	OR4S2	0.38	6.49	0.34	3.24e-10	Pediatric bone mineral density (spine);
CRC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.58	-8.81	-0.44	7.37e-17	Body mass index;
CRC	cis	rs834811	0.863	rs834821	chr7:135895713	A/T	cg01726295	chr7:135938950	NA	0.4	6.92	0.36	2.31e-11	Post-traumatic stress disorder;
CRC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.36	0.62	1.24e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg21153622	chr11:89784906	NA	-0.52	-8.77	-0.44	9.87e-17	HDL cholesterol;
CRC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.94	14.42	0.62	6.86e-37	Monocyte percentage of white cells;
CRC	cis	rs7737355	0.842	rs7731001	chr5:130781338	T/C	cg25547332	chr5:131281432	NA	-0.36	-5.74	-0.3	2.11e-8	Life satisfaction;
CRC	cis	rs4780355	0.918	rs243318	chr16:11358018	G/A	cg00044050	chr16:11439710	C16orf75	0.42	5.97	0.31	6.09e-9	Crohn's disease and psoriasis;
CRC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.69	9.16	0.45	5.52e-18	Bronchopulmonary dysplasia;
CRC	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.16	-9.44	-0.46	7.24e-19	Mitochondrial DNA levels;
CRC	trans	rs67073037	0.955	rs12465258	chr2:29162904	G/T	cg13899017	chr1:159158444	CADM3	-0.37	-6.14	-0.32	2.4e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	trans	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.02	-0.31	4.6e-9	Educational attainment (years of education);
CRC	cis	rs7212590	0.748	rs73315252	chr17:57854855	A/G	cg10252138	chr17:58120427	NA	-0.55	-5.87	-0.31	1.09e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.87	-16.16	-0.67	1.17e-43	Dementia with Lewy bodies;
CRC	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.71	6.65	0.34	1.23e-10	Coronary artery disease;
CRC	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	5.84	0.31	1.24e-8	Diastolic blood pressure;
CRC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.09	18.67	0.72	1.44e-53	Cognitive function;
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg10760299	chr15:45669010	GATM	0.35	5.62	0.3	4.17e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21789229	chr4:54232186	SCFD2	0.39	6.23	0.32	1.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.41	5.62	0.3	4.12e-8	Lymphocyte counts;
CRC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17023223	0.537	rs2645302	chr1:119590398	A/C	cg05756136	chr1:119680316	WARS2	-0.46	-6.21	-0.32	1.61e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.9	0.48	2.16e-20	Cognitive test performance;
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg04969067	chr8:143858791	LYNX1	0.44	7.47	0.38	7.38e-13	Urinary tract infection frequency;
CRC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.87	-0.35	3.29e-11	Total body bone mineral density;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.3	-5.98	-0.31	5.92e-9	Breast cancer;
CRC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.57	7.16	0.37	5.41e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.6	-11.93	-0.55	1.7e-27	Asthma (sex interaction);
CRC	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg21601837	chr3:125900065	ALDH1L1	0.35	5.77	0.3	1.86e-8	Metabolite levels;
CRC	cis	rs728616	0.558	rs12772945	chr10:82154496	C/T	cg11900509	chr10:81946545	ANXA11	-0.56	-6.24	-0.33	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.38	-6.81	-0.35	4.75e-11	Obesity-related traits;
CRC	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.44	-0.33	4.29e-10	Blood metabolite levels;
CRC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg25456477	chr12:86230367	RASSF9	0.4	6.76	0.35	6.23e-11	Major depressive disorder;
CRC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.84	-13.81	-0.61	1.5e-34	Height;
CRC	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.45	5.68	0.3	3e-8	Metabolite levels;
CRC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.87	-0.31	1.04e-8	Gout;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg10876282	chr6:28092338	ZSCAN16	0.47	6.41	0.33	5.18e-10	Parkinson's disease;
CRC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.52	7.76	0.39	1.11e-13	Resting heart rate;
CRC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.66	10.35	0.5	6.58e-22	Gestational age at birth (maternal effect);
CRC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg00129232	chr17:37814104	STARD3	0.46	7.44	0.38	8.92e-13	Self-reported allergy;
CRC	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.1	-15.25	-0.64	4.44e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg06238570	chr21:40685208	BRWD1	-0.67	-9.01	-0.44	1.76e-17	Cognitive function;
CRC	cis	rs2795502	0.630	rs2282443	chr10:43474169	A/G	cg08461752	chr10:43522343	NA	-0.85	-7.59	-0.39	3.41e-13	Blood protein levels;
CRC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.46	8.08	0.41	1.23e-14	Coronary artery disease;
CRC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg22029157	chr1:209979665	IRF6	0.59	6.94	0.36	2.1e-11	Coronary artery disease;
CRC	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.56	-0.38	4.02e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.05	-0.32	4.04e-9	Monocyte percentage of white cells;
CRC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-0.83	-12.5	-0.57	1.34e-29	IgG glycosylation;
CRC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.79	-0.3	1.67e-8	Diabetic kidney disease;
CRC	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-1.09	-11.5	-0.54	6.13e-26	Blood pressure (smoking interaction);
CRC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.64	-11.97	-0.55	1.23e-27	Breast cancer;
CRC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs427941	0.655	rs2529095	chr7:101749663	C/T	cg06246474	chr7:101738831	CUX1	0.44	6.72	0.35	8.09e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs699	0.698	rs2478527	chr1:230863398	A/C	cg07502417	chr1:230849801	AGT	0.29	5.94	0.31	7.11e-9	Coronary artery disease;
CRC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-9.92	-0.48	1.82e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg04117972	chr1:227635322	NA	0.65	6.07	0.32	3.57e-9	Major depressive disorder;
CRC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg24375607	chr4:120327624	NA	0.43	6.64	0.34	1.28e-10	Corneal astigmatism;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg15845792	chr6:28175446	NA	1.02	15.66	0.65	1.12e-41	Depression;
CRC	trans	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg10756647	chr7:56101905	PSPH	0.77	8.22	0.41	4.72e-15	Diabetic kidney disease;
CRC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.67	9.79	0.48	4.89e-20	Lung cancer;
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg22638593	chr5:131593259	PDLIM4	0.42	7.8	0.4	8.11e-14	Breast cancer;
CRC	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.63	8.98	0.44	2.18e-17	Uric acid levels;
CRC	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	0.59	6.86	0.35	3.34e-11	Blood trace element (Cu levels);
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg03623178	chr6:28175578	NA	0.64	8.51	0.42	6.36e-16	Parkinson's disease;
CRC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.76	0.3	1.91e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7705042	0.686	rs62381975	chr5:141513018	G/A	cg07392085	chr5:141489673	NDFIP1	-0.41	-5.96	-0.31	6.36e-9	Asthma;
CRC	trans	rs12257178	0.532	rs12263857	chr10:113006704	A/G	cg02683314	chr19:4182606	SIRT6;ANKRD24	-0.47	-6.73	-0.35	7.52e-11	Longitudinal alcohol consumption;
CRC	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.64	-6.71	-0.35	8.65e-11	Incident atrial fibrillation;
CRC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg14847009	chr1:175162515	KIAA0040	0.29	6.46	0.34	3.67e-10	Alcohol dependence;
CRC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-8.89	-0.44	4.07e-17	Intelligence (multi-trait analysis);
CRC	trans	rs800082	0.531	rs2204603	chr3:144258720	T/A	cg24215973	chr2:240111563	HDAC4	0.44	6.19	0.32	1.82e-9	Smoking behavior;
CRC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.61	-0.43	3.1e-16	Aortic root size;
CRC	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.67	-7.69	-0.39	1.77e-13	Psoriasis;
CRC	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.43	6.79	0.35	5.35e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3823572	0.526	rs2971967	chr7:133642595	A/G	cg03336402	chr7:133662267	EXOC4	-0.68	-10.48	-0.5	2.23e-22	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-8.71	-0.43	1.55e-16	Type 2 diabetes;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg22638593	chr5:131593259	PDLIM4	-0.38	-6.32	-0.33	8.61e-10	Blood metabolite levels;
CRC	cis	rs3790844	0.876	rs3790847	chr1:200006217	G/T	cg13229857	chr1:200006247	NR5A2	0.54	7.6	0.39	3.04e-13	Pancreatic cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01920373	chr16:66968627	FAM96B;CES2	0.41	6.2	0.32	1.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg20916646	chr4:852691	GAK	0.4	5.92	0.31	8.25e-9	Systemic sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25504222	chr19:4639508	TNFAIP8L1	0.43	6.29	0.33	1.03e-9	Response to antipsychotic treatment;
CRC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.12	-0.45	7.75e-18	Migraine;Coronary artery disease;
CRC	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg24505167	chr7:1915268	MAD1L1	-0.34	-5.6	-0.3	4.45e-8	Bipolar disorder;
CRC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.54	-7.78	-0.39	9.55e-14	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs427941	0.703	rs201452	chr7:101739663	C/T	cg06246474	chr7:101738831	CUX1	0.46	7.23	0.37	3.35e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg09659197	chr4:152720779	NA	0.52	11.28	0.53	3.6e-25	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.38	-6.53	-0.34	2.54e-10	Height;
CRC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg11941060	chr3:133502564	NA	-0.41	-6.79	-0.35	5.25e-11	Iron status biomarkers;
CRC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg10589385	chr1:150898437	SETDB1	0.29	6.13	0.32	2.47e-9	Tonsillectomy;
CRC	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.61	-7.13	-0.37	6.51e-12	Bipolar disorder;
CRC	cis	rs12541635	0.902	rs59123253	chr8:107006365	C/T	cg10147462	chr8:107024639	NA	0.42	6.94	0.36	2.09e-11	Age of smoking initiation;
CRC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.77	0.3	1.79e-8	Eosinophil percentage of white cells;
CRC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.46e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.04	0.45	1.36e-17	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23387220	chr4:53578496	SNORA26;KIAA0114	0.42	6.35	0.33	7.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.52	-7.71	-0.39	1.52e-13	Mean platelet volume;
CRC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.92	18.8	0.72	4.57e-54	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24689099	chr15:66084495	DENND4A	0.46	6.29	0.33	1.02e-9	Anxiety disorder;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.58	0.39	3.5e-13	Lymphocyte counts;
CRC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.47	6.13	0.32	2.47e-9	Aortic root size;
CRC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg17724175	chr1:150552817	MCL1	0.49	7.34	0.38	1.7e-12	Melanoma;
CRC	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	0.69	5.78	0.3	1.78e-8	Major depressive disorder;
CRC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.5	-6.7	-0.35	9.27e-11	Glioblastoma;
CRC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.46	-0.6	3.28e-33	Blood trace element (Zn levels);
CRC	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.59	7.86	0.4	5.36e-14	Mammographic density (dense area);
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg22687807	chr8:143858763	LYNX1	0.52	9.2	0.45	4.34e-18	Urinary tract infection frequency;
CRC	trans	rs17126268	0.502	rs1340395	chr1:102890127	C/T	cg18468354	chr14:36993517	NA	0.38	6.12	0.32	2.65e-9	Glomerular filtration rate;
CRC	cis	rs6743376	0.509	rs3180234	chr2:113820655	A/T	cg09040174	chr2:113837401	NA	0.4	5.84	0.31	1.22e-8	Inflammatory biomarkers;
CRC	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.28	6.14	0.32	2.43e-9	Educational attainment (years of education);
CRC	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg21169611	chr9:106856078	SMC2	0.4	5.66	0.3	3.22e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.09	18.57	0.72	3.71e-53	Cognitive function;
CRC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.64	-9.88	-0.48	2.57e-20	Height;
CRC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg18230493	chr5:56204884	C5orf35	-0.46	-6.69	-0.35	9.61e-11	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg19223190	chr17:80058835	NA	0.42	6.77	0.35	5.88e-11	Life satisfaction;
CRC	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.5	-9.44	-0.46	7.1e-19	Hip circumference;Waist circumference;
CRC	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.5	6.33	0.33	7.93e-10	White matter hyperintensity burden;
CRC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.58	-0.6	1.19e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.56	-8.54	-0.43	4.98e-16	Height;
CRC	cis	rs10242455	0.702	rs78218664	chr7:99154381	C/A	cg18809830	chr7:99032528	PTCD1	-1.32	-9.14	-0.45	6.74e-18	Blood metabolite levels;
CRC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg24130564	chr14:104152367	KLC1	-0.47	-7.16	-0.37	5.18e-12	Body mass index;
CRC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.53	7.16	0.37	5.37e-12	Height;
CRC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6496667	0.865	rs12594934	chr15:90887750	G/T	cg04176472	chr15:90893244	GABARAPL3	0.58	6.84	0.35	3.94e-11	Rheumatoid arthritis;
CRC	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.54	-8.57	-0.43	4.1e-16	Metabolite levels (Pyroglutamine);
CRC	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.68	-0.3	2.92e-8	Pulmonary function;
CRC	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg12728517	chr11:6947552	ZNF215	0.57	6.14	0.32	2.38e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-7.94	-0.4	3.33e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs643506	1.000	rs4936675	chr11:111623088	T/A	cg09085632	chr11:111637200	PPP2R1B	0.5	6.51	0.34	2.88e-10	Breast cancer;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg12273811	chr6:28175739	NA	0.6	8.82	0.44	7e-17	Parkinson's disease;
CRC	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	27.0	0.83	1.83e-85	Schizophrenia;
CRC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.58	6.64	0.34	1.29e-10	Bronchopulmonary dysplasia;
CRC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.34	-9.55	-0.47	3.04e-19	Mean corpuscular volume;
CRC	cis	rs4660214	0.724	rs11205695	chr1:39620957	A/C	cg11070191	chr1:39582205	MACF1	0.35	5.69	0.3	2.82e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.66	-7.89	-0.4	4.55e-14	Ulcerative colitis;
CRC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.78	-12.85	-0.58	6.42e-31	Intelligence (multi-trait analysis);
CRC	cis	rs2415984	0.538	rs4595715	chr14:46967541	C/T	cg14871534	chr14:47121158	RPL10L	-0.43	-6.26	-0.33	1.21e-9	Number of children ever born;
CRC	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.73	0.35	7.5e-11	Mean corpuscular volume;
CRC	trans	rs7546	0.504	rs2075636	chr16:4938321	A/T	cg19252218	chr17:41477271	ARL4D	-0.44	-6.52	-0.34	2.71e-10	Cancer;
CRC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg03013999	chr17:37608204	MED1	0.48	7.33	0.37	1.79e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs375066	0.623	rs2217669	chr19:44353080	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.65	-0.34	1.23e-10	Eye color traits;
CRC	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg23254163	chr1:152506842	NA	0.47	9.11	0.45	8.35e-18	Hair morphology;
CRC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11645453	chr3:52864694	ITIH4	0.38	6.83	0.35	4.05e-11	Bipolar disorder;
CRC	cis	rs73206853	1.000	rs73206853	chr12:110708746	A/C	cg12870014	chr12:110450643	ANKRD13A	0.56	6.53	0.34	2.54e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00979634	chr1:16011290	PLEKHM2	0.48	6.82	0.35	4.27e-11	Response to antipsychotic treatment;
CRC	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-7.16	-0.37	5.31e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-7.99	-0.4	2.32e-14	Initial pursuit acceleration;
CRC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg13092806	chr2:177043255	NA	0.79	12.4	0.56	3.04e-29	IgG glycosylation;
CRC	cis	rs6968419	0.674	rs1918911	chr7:115906748	G/T	cg02561103	chr7:115862891	TES	-0.44	-6.64	-0.34	1.3e-10	Intraocular pressure;
CRC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.46	0.53	7.99e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	7.67	0.39	1.96e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.83	-0.35	4.01e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23679333	chr2:53995338	LOC100302652;ASB3;CHAC2	0.42	6.12	0.32	2.69e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.04	0.32	4.15e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.43	-6.02	-0.32	4.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.11e-22	Prudent dietary pattern;
CRC	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg07423050	chr13:99094983	FARP1	0.4	6.35	0.33	7.27e-10	Longevity;
CRC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg15902774	chr15:75289873	SCAMP5	-0.49	-5.8	-0.3	1.55e-8	Lung cancer;
CRC	trans	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg17903999	chr18:56338584	MALT1	-0.43	-7.26	-0.37	2.86e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg11189052	chr15:85197271	WDR73	0.57	8.17	0.41	6.61e-15	Schizophrenia;
CRC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.17	-0.32	2.04e-9	Height;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg12273811	chr6:28175739	NA	0.59	7.68	0.39	1.8e-13	Depression;
CRC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.58	0.43	3.79e-16	Menopause (age at onset);
CRC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.05	-0.41	1.5e-14	Height;
CRC	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg09655341	chr17:79618100	PDE6G	0.59	6.92	0.36	2.37e-11	Dental caries;
CRC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.88	-0.44	4.51e-17	Alcohol dependence;
CRC	cis	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg24254488	chr7:25991654	NA	0.3	6.32	0.33	8.48e-10	Triglyceride levels;
CRC	cis	rs2486012	1.000	rs1766968	chr1:44403042	T/C	cg12908607	chr1:44402522	ARTN	0.46	5.91	0.31	8.59e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18880390	chr1:175162128	KIAA0040	0.47	6.67	0.35	1.11e-10	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.18	-0.41	6.31e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.69	-9.68	-0.47	1.11e-19	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00852783	chr1:26633632	UBXN11	0.48	6.89	0.35	2.89e-11	Granulocyte percentage of myeloid white cells;
CRC	trans	rs6956675	0.915	rs7795023	chr7:62652291	C/T	cg01314568	chr7:57830625	NA	-0.63	-8.98	-0.44	2.13e-17	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18622001	chr10:126150304	LHPP	0.4	6.52	0.34	2.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.74	0.43	1.23e-16	Homoarginine levels;
CRC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.45	-6.1	-0.32	3e-9	Aortic root size;
CRC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.77	-10.37	-0.5	5.36e-22	Height;
CRC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.52	-7.0	-0.36	1.42e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.49	7.1	0.36	7.93e-12	Height;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg10876282	chr6:28092338	ZSCAN16	0.5	6.6	0.34	1.61e-10	Cardiac Troponin-T levels;
CRC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.48	-9.49	-0.46	4.71e-19	Renal cell carcinoma;
CRC	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.79	-9.92	-0.48	1.81e-20	Gut microbiome composition (winter);
CRC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.47	6.29	0.33	9.85e-10	Methadone dose in opioid dependence;
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg19635926	chr16:89946313	TCF25	0.57	5.94	0.31	7.24e-9	Skin colour saturation;
CRC	cis	rs1178968	0.818	rs2262777	chr7:72786490	A/T	cg25889504	chr7:72793014	NA	0.52	5.9	0.31	9.14e-9	Triglyceride levels;
CRC	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1e-22	Iron status biomarkers;
CRC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg27366882	chr3:133540807	NA	-0.6	-9.04	-0.45	1.4e-17	Alcohol consumption (transferrin glycosylation);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17080073	chr3:39447926	RPSA	0.41	5.97	0.31	6.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.84	-0.44	6.01e-17	IgG glycosylation;
CRC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.46	6.98	0.36	1.67e-11	Menopause (age at onset);
CRC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.82	-12.54	-0.57	9.86e-30	Cognitive function;
CRC	cis	rs7705042	0.828	rs1835966	chr5:141501508	C/T	cg08523384	chr5:141488047	NDFIP1	-0.35	-6.09	-0.32	3.17e-9	Asthma;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.97	-0.4	2.71e-14	Total body bone mineral density;
CRC	cis	rs755249	0.567	rs3818806	chr1:39748271	G/A	cg18385671	chr1:39797026	MACF1	-0.42	-5.85	-0.31	1.2e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.6	9.67	0.47	1.21e-19	Migraine;
CRC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.09	0.45	9.67e-18	Bladder cancer;
CRC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.97	-0.31	6.25e-9	Vitiligo;
CRC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.48	6.43	0.33	4.48e-10	Height;
CRC	cis	rs1347297	0.774	rs9973732	chr2:179281435	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.4	-5.76	-0.3	1.93e-8	Alzheimer disease and age of onset;
CRC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-5.83	-0.31	1.36e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26684574	chr20:48532295	SPATA2	0.42	6.61	0.34	1.55e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26770187	chr3:14693171	C3orf19	0.5	6.5	0.34	3.02e-10	Thyroid stimulating hormone;
CRC	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.81	-0.31	1.45e-8	Endometrial cancer;
CRC	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.43	6.23	0.33	1.4e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg20607798	chr8:58055168	NA	0.52	5.67	0.3	3.12e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.48	-7.65	-0.39	2.24e-13	HDL cholesterol;
CRC	cis	rs9648716	0.577	rs11769042	chr7:140460169	T/C	cg10747023	chr7:140774559	NA	0.42	5.68	0.3	3.01e-8	Type 2 diabetes;
CRC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg26805224	chr10:79626177	DLG5	-0.5	-7.36	-0.38	1.44e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.63	-9.66	-0.47	1.37e-19	Hepatocellular carcinoma;
CRC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.62	-9.2	-0.45	4.33e-18	Diastolic blood pressure;
CRC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02290350	chr8:58132656	NA	-0.56	-7.32	-0.37	1.93e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21556389	chr17:1957370	HIC1	0.35	6.47	0.34	3.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg15147215	chr3:52552868	STAB1	-0.53	-7.92	-0.4	3.81e-14	Bipolar disorder;
CRC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg14673194	chr17:80132900	CCDC57	0.49	6.3	0.33	9.59e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg08888203	chr3:10149979	C3orf24	0.73	8.59	0.43	3.52e-16	Alzheimer's disease;
CRC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg24011408	chr12:48396354	COL2A1	0.46	6.49	0.34	3.13e-10	Glycated hemoglobin levels;
CRC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.95	-9.42	-0.46	8.46e-19	Breast cancer;
CRC	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.71	7.97	0.4	2.59e-14	Systolic blood pressure;
CRC	cis	rs4731207	0.570	rs7784614	chr7:124677191	C/G	cg23710748	chr7:124431027	NA	-0.39	-6.11	-0.32	2.83e-9	Cutaneous malignant melanoma;
CRC	trans	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01098771	chr19:4969087	KDM4B	0.4	6.21	0.32	1.63e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.76	10.03	0.48	7.78e-21	Coronary artery disease;
CRC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg00343986	chr7:65444356	GUSB	-0.47	-7.02	-0.36	1.26e-11	Aortic root size;
CRC	cis	rs10512697	0.803	rs62333968	chr5:3579447	A/C	cg19473799	chr5:3511975	NA	-0.72	-5.67	-0.3	3.1e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.83	-0.35	4.18e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg10790698	chr19:18539756	SSBP4	-0.45	-8.71	-0.43	1.5e-16	Breast cancer;
CRC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.52e-15	Height;
CRC	cis	rs6432018	0.964	rs7565646	chr2:9728879	A/G	cg12832956	chr2:9616023	IAH1	-0.38	-5.64	-0.3	3.73e-8	Heart rate variability traits;
CRC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	16.32	0.67	2.7e-44	Testicular germ cell tumor;
CRC	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.22	30.69	0.86	1.43e-98	Colorectal cancer;
CRC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.51	8.18	0.41	6.32e-15	Uric acid clearance;
CRC	cis	rs10946940	0.864	rs13201411	chr6:27498217	G/C	cg06470822	chr6:28175283	NA	-0.52	-7.08	-0.36	8.63e-12	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.24	-0.37	3.25e-12	Body mass index;
CRC	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg12315302	chr6:26189340	HIST1H4D	0.85	6.61	0.34	1.59e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.83	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg11245181	chr6:149772854	ZC3H12D	0.53	9.22	0.45	3.64e-18	Dupuytren's disease;
CRC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.58	9.03	0.45	1.49e-17	Mood instability;
CRC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.19	0.32	1.78e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg03013636	chr16:1946785	NA	0.4	5.75	0.3	2.09e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18912574	chr7:65842487	NCRNA00174	0.32	5.63	0.3	3.78e-8	Aortic root size;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg20615401	chr6:28092323	ZSCAN16	0.43	5.66	0.3	3.35e-8	Cardiac Troponin-T levels;
CRC	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.55	8.7	0.43	1.58e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	0.66	6.46	0.34	3.75e-10	Fat distribution (HIV);
CRC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2307022	0.586	rs4783557	chr16:68403945	T/C	cg02226672	chr16:68398533	SMPD3	0.29	5.68	0.3	2.98e-8	Body mass index;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg15786705	chr6:28176104	NA	-0.68	-9.6	-0.47	2.11e-19	Parkinson's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25998860	chr5:126853954	PRRC1	-0.55	-6.72	-0.35	7.89e-11	Diisocyanate-induced asthma;
CRC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg13010199	chr12:38710504	ALG10B	0.43	6.05	0.32	3.86e-9	Morning vs. evening chronotype;
CRC	cis	rs4660214	0.666	rs7538300	chr1:39652764	C/A	cg11070191	chr1:39582205	MACF1	0.36	5.76	0.3	1.9e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12476592	0.571	rs262518	chr2:63891335	A/G	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.7	-0.54	1.11e-26	Alzheimer's disease;
CRC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.6	-9.26	-0.45	2.74e-18	Platelet count;
CRC	cis	rs847649	0.731	rs10808120	chr7:102672234	A/G	cg18108683	chr7:102477205	FBXL13	-0.5	-7.83	-0.4	6.81e-14	Morning vs. evening chronotype;
CRC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.44	5.6	0.3	4.49e-8	Aortic root size;
CRC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg12564285	chr5:131593104	PDLIM4	0.34	6.07	0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg04553112	chr3:125709451	NA	-0.51	-6.0	-0.31	5.07e-9	Blood pressure (smoking interaction);
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.24	-5.98	-0.31	5.96e-9	Lymphocyte counts;
CRC	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.56	6.0	0.31	5.35e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.69	8.63	0.43	2.57e-16	Iron status biomarkers;
CRC	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.45	7.64	0.39	2.4e-13	Testicular germ cell tumor;
CRC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.81	13.71	0.6	3.69e-34	Lung cancer;
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.48	6.45	0.34	3.9e-10	Height;
CRC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-8.93	-0.44	3.16e-17	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.99	-0.55	1.01e-27	Body mass index;
CRC	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg26816564	chr1:7831052	VAMP3	-0.46	-5.63	-0.3	3.89e-8	Inflammatory bowel disease;
CRC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.67	0.43	2.04e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.45	6.3	0.33	9.74e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs11885103	0.543	rs2724925	chr2:562458	G/A	cg12228919	chr15:44955936	SPG11	-0.46	-6.84	-0.35	3.98e-11	Heschl's gyrus morphology;
CRC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.68	10.31	0.49	8.56e-22	Gestational age at birth (maternal effect);
CRC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25598908	chr1:100731592	RTCD1	0.4	5.98	0.31	5.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.35	0.38	1.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg20935933	chr6:143382018	AIG1	0.5	6.46	0.34	3.66e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.86	-0.35	3.42e-11	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.78	-10.3	-0.49	9.48e-22	Initial pursuit acceleration;
CRC	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg13606994	chr1:44402422	ARTN	-0.36	-6.05	-0.32	3.84e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11602459	chr20:39765965	PLCG1	0.46	6.65	0.34	1.21e-10	Anxiety disorder;
CRC	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg12315302	chr6:26189340	HIST1H4D	0.96	6.62	0.34	1.43e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4654899	0.680	rs2305463	chr1:21180181	C/T	cg02927042	chr1:21476669	EIF4G3	0.36	5.61	0.3	4.39e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.62	-11.14	-0.52	1.17e-24	Aortic root size;
CRC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.41	-7.56	-0.38	3.95e-13	Height;
CRC	cis	rs7113874	0.524	rs10840083	chr11:8608636	C/T	cg02811074	chr11:8615871	STK33	0.34	5.88	0.31	1.02e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg17031739	chr1:67600172	NA	-0.51	-8.03	-0.4	1.7e-14	Psoriasis;
CRC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.54	6.12	0.32	2.6e-9	Menarche (age at onset);
CRC	cis	rs10746514	0.833	rs12039526	chr1:232272599	C/T	cg09506761	chr1:232265262	NA	-0.45	-6.39	-0.33	5.68e-10	Response to statin therapy;
CRC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg01612440	chr4:3296283	NA	0.41	5.93	0.31	7.47e-9	Serum sulfate level;
CRC	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg19773385	chr1:10388646	KIF1B	-0.62	-9.57	-0.47	2.56e-19	Hepatocellular carcinoma;
CRC	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg14471455	chr9:80332956	NA	-0.39	-6.2	-0.32	1.64e-9	Parkinson's disease;
CRC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12463550	chr7:65579703	CRCP	0.63	6.11	0.32	2.82e-9	Diabetic kidney disease;
CRC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.5	-5.73	-0.3	2.21e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.68	9.05	0.45	1.32e-17	Multiple sclerosis;
CRC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.31	6.31	0.33	8.83e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.35	-0.56	4.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.68	-8.05	-0.41	1.5e-14	Alzheimer's disease;
CRC	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg08999081	chr20:33150536	PIGU	0.47	5.83	0.31	1.33e-8	Neuroticism;
CRC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.65	6.72	0.35	8.06e-11	Axial length;
CRC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.51	0.38	5.59e-13	Motion sickness;
CRC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.59	9.12	0.45	7.77e-18	Blood protein levels;
CRC	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg27398640	chr15:77910606	LINGO1	-0.42	-6.85	-0.35	3.62e-11	Type 2 diabetes;
CRC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.11	-0.41	1.01e-14	Hemoglobin concentration;
CRC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	0.64	6.18	0.32	1.86e-9	Fat distribution (HIV);
CRC	cis	rs9463078	0.764	rs6923519	chr6:44864152	A/G	cg25276700	chr6:44698697	NA	-0.27	-6.59	-0.34	1.71e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4728302	0.869	rs10954434	chr7:133597864	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.5	-0.34	2.97e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs8099014	0.814	rs9966765	chr18:56116790	C/G	cg12907477	chr18:56117327	MIR122	0.48	5.86	0.31	1.1e-8	Platelet count;
CRC	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg00250761	chr1:31883323	NA	-0.4	-7.53	-0.38	4.98e-13	Alcohol dependence;
CRC	cis	rs7264396	0.887	rs224344	chr20:34036865	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.98	-0.36	1.63e-11	Total cholesterol levels;
CRC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	8.13	0.41	9.02e-15	Menarche (age at onset);
CRC	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg21251018	chr6:28226885	NKAPL	0.4	6.11	0.32	2.88e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.75	12.95	0.58	2.77e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg11887960	chr12:57824829	NA	0.65	7.31	0.37	2.02e-12	Obesity-related traits;
CRC	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg07713946	chr22:31675144	LIMK2	-0.39	-5.62	-0.3	4e-8	Colorectal cancer;
CRC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.76	-11.02	-0.52	2.95e-24	Mean platelet volume;Platelet distribution width;
CRC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.7	-7.6	-0.39	3.08e-13	Schizophrenia;
CRC	cis	rs2274273	0.710	rs67395212	chr14:55591939	T/A	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.71	-0.3	2.58e-8	Protein biomarker;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06552368	chr11:118972898	DPAGT1	0.44	6.46	0.34	3.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6445525	1.000	rs4688259	chr3:65995266	T/C	cg06109867	chr3:66002991	MAGI1	-0.39	-6.46	-0.34	3.66e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs35123781	1.000	rs34510678	chr5:139064835	C/T	cg10513866	chr5:139070639	NA	0.45	7.19	0.37	4.27e-12	Schizophrenia;
CRC	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.89	0.31	9.73e-9	Height;
CRC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.49	7.18	0.37	4.8e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.41	-0.33	5.17e-10	Coronary artery disease;
CRC	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.65	0.57	3.7e-30	Height;
CRC	cis	rs1033849	0.507	rs9507259	chr13:24722809	C/G	cg14860438	chr13:24731302	NA	-0.36	-6.04	-0.32	4.27e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg24874828	chr4:187887005	NA	-0.33	-5.66	-0.3	3.26e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	13.42	0.59	4.92e-33	Colorectal cancer;
CRC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.77	-10.55	-0.5	1.34e-22	White matter hyperintensity burden;
CRC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.64	6.79	0.35	5.19e-11	Chronic lymphocytic leukemia;
CRC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg05540913	chr6:167530185	CCR6	-0.34	-6.22	-0.32	1.51e-9	Primary biliary cholangitis;
CRC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.84	9.07	0.45	1.07e-17	Breast cancer;
CRC	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg11204139	chr17:3907470	NA	0.42	5.88	0.31	1.01e-8	Type 2 diabetes;
CRC	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.11	-0.32	2.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.19	-0.32	1.76e-9	Axial length;
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.3	-0.37	2.24e-12	Total body bone mineral density;
CRC	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg19077165	chr18:44547161	KATNAL2	0.38	5.71	0.3	2.54e-8	Educational attainment (years of education);
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg03623178	chr6:28175578	NA	0.89	11.83	0.55	3.94e-27	Parkinson's disease;
CRC	cis	rs6504622	0.537	rs197919	chr17:45003675	C/T	cg16759221	chr17:45003025	GOSR2	-0.64	-10.57	-0.5	1.15e-22	Orofacial clefts;
CRC	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg21153622	chr11:89784906	NA	0.44	7.09	0.36	8.08e-12	HDL cholesterol;
CRC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10820045	chr2:198174542	NA	-0.52	-10.23	-0.49	1.68e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.53	-0.5	1.5e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.83	14.8	0.63	2.43e-38	Intelligence (multi-trait analysis);
CRC	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg24159697	chr1:205181237	DSTYK	-0.34	-6.29	-0.33	1e-9	Red cell distribution width;
CRC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg00343986	chr7:65444356	GUSB	-0.48	-7.11	-0.36	7.48e-12	Aortic root size;
CRC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.93	0.36	2.24e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg22182287	chr2:3452347	TTC15	0.38	6.06	0.32	3.71e-9	Obesity-related traits;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.57	-0.39	3.77e-13	Eye color traits;
CRC	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.05	0.58	1.15e-31	Hip circumference;
CRC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg26587870	chr6:27730563	NA	-0.6	-5.91	-0.31	8.73e-9	Depression;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.61	-0.39	2.98e-13	Blood trace element (Zn levels);
CRC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.51	-0.34	2.88e-10	Breast cancer;
CRC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.04	0.55	6.41e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.92	-16.25	-0.67	5.39e-44	Cognitive function;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg10868875	chr11:61596307	FADS2	-0.49	-6.09	-0.32	3.13e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg19773385	chr1:10388646	KIF1B	-0.48	-7.44	-0.38	8.95e-13	Hepatocellular carcinoma;
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	7.91e-9	Prudent dietary pattern;
CRC	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.82	-0.4	7.14e-14	Biliary atresia;
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.12	0.32	2.71e-9	Bipolar disorder;
CRC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg26248373	chr2:1572462	NA	-0.65	-7.15	-0.37	5.76e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg10820045	chr2:198174542	NA	-0.55	-9.25	-0.45	2.82e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.63	9.67	0.47	1.23e-19	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.69	-12.17	-0.56	2.27e-28	Asthma;
CRC	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.55	7.52	0.38	5.38e-13	Uric acid levels;
CRC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	0.92	7.35	0.38	1.59e-12	Type 2 diabetes nephropathy;
CRC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.88	-0.31	1.03e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.83	11.03	0.52	2.88e-24	IgG glycosylation;
CRC	cis	rs72627123	1.000	rs45559033	chr14:74341124	G/A	cg19860245	chr14:74300557	NA	-0.51	-5.63	-0.3	3.82e-8	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.19	0.37	4.26e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs73200209	0.744	rs11615595	chr12:116470876	T/C	cg01776926	chr12:116560359	MED13L	-0.64	-7.57	-0.39	3.78e-13	Total body bone mineral density;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg08546805	chr12:8549446	NA	-0.43	-6.55	-0.34	2.26e-10	Blood pressure (smoking interaction);
CRC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg12935359	chr14:103987150	CKB	-0.49	-7.99	-0.4	2.27e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7725052	0.609	rs10043846	chr5:40442902	A/G	cg09067459	chr5:40385259	NA	0.39	6.41	0.33	4.92e-10	Pediatric autoimmune diseases;
CRC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg16141378	chr3:129829833	LOC729375	0.47	7.33	0.37	1.79e-12	Neuroticism;
CRC	cis	rs10986311	0.832	rs10123514	chr9:127142878	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.39	-5.67	-0.3	3.16e-8	Vitiligo;
CRC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg21153622	chr11:89784906	NA	-0.49	-8.16	-0.41	7.26e-15	HDL cholesterol;
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg19913688	chr11:428466	ANO9	-0.68	-6.93	-0.36	2.17e-11	Body mass index;
CRC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.22	-0.32	1.51e-9	Tonsillectomy;
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.53	-7.52	-0.38	5.11e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.18	0.45	4.79e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.96	-0.36	1.86e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg08648136	chr8:956695	NA	0.31	6.02	0.31	4.66e-9	Schizophrenia;
CRC	trans	rs10411161	1.000	rs6509581	chr19:52363882	T/C	cg22319618	chr22:45562946	NUP50	-0.52	-6.03	-0.32	4.4e-9	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25215340	chr11:2907127	CDKN1C	0.46	5.97	0.31	5.98e-9	Thyroid stimulating hormone;
CRC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.84	-12.98	-0.58	2.21e-31	Blood metabolite levels;
CRC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg18016565	chr1:150552671	MCL1	0.44	6.29	0.33	1.01e-9	Melanoma;
CRC	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs3751196	0.808	rs56123042	chr12:104220257	C/T	cg02344784	chr12:104178138	NT5DC3	0.71	7.25	0.37	3.05e-12	Sense of smell;
CRC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.42	0.46	8.43e-19	Monocyte percentage of white cells;
CRC	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.72	-9.73	-0.47	7.79e-20	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17913451	chr14:58619030	C14orf37	0.49	7.21	0.37	3.8e-12	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.62e-12	Inflammatory skin disease;
CRC	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.48	6.21	0.32	1.56e-9	Cholesterol, total;
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg17330251	chr7:94953956	PON1	-0.6	-7.52	-0.38	5.11e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.86	-9.85	-0.48	3.16e-20	Breast cancer;
CRC	trans	rs473651	0.904	rs508274	chr2:239337723	G/A	cg13521940	chr21:36262239	RUNX1	-0.41	-6.18	-0.32	1.94e-9	Multiple system atrophy;
CRC	cis	rs4780401	0.632	rs8059262	chr16:11784129	G/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.72	-0.3	2.4e-8	Rheumatoid arthritis;
CRC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg13722127	chr7:150037890	RARRES2	0.53	7.89	0.4	4.48e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg13919466	chr1:32135498	COL16A1	-0.31	-5.88	-0.31	9.98e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.53	7.43	0.38	9.5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg02158880	chr13:53174818	NA	0.5	7.51	0.38	5.74e-13	Lewy body disease;
CRC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg26721908	chr21:47610096	LSS	-0.45	-7.21	-0.37	3.84e-12	Testicular germ cell tumor;
CRC	cis	rs17152411	1.000	rs7083336	chr10:126590771	T/C	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08273200	chr1:39338480	MYCBP	0.44	6.13	0.32	2.5e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg05044414	chr3:183734942	ABCC5	0.48	8.28	0.42	3.17e-15	Anterior chamber depth;
CRC	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg09659197	chr4:152720779	NA	0.52	11.29	0.53	3.31e-25	Intelligence (multi-trait analysis);
CRC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-0.83	-12.5	-0.57	1.34e-29	IgG glycosylation;
CRC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	10.68	0.51	4.59e-23	Coronary artery disease;
CRC	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-6.65	-0.34	1.22e-10	Coronary artery disease;
CRC	cis	rs4731207	0.698	rs2402753	chr7:124448259	A/G	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.73	13.55	0.6	1.55e-33	Prudent dietary pattern;
CRC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-5.9	-0.31	8.87e-9	Cognitive function;
CRC	cis	rs773506	0.602	rs10761110	chr9:93929884	A/G	cg14446406	chr9:93919335	NA	-0.47	-8.15	-0.41	7.53e-15	Type 2 diabetes nephropathy;
CRC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.75	0.47	6.87e-20	Cognitive test performance;
CRC	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg10279832	chr4:154682576	RNF175	0.38	5.79	0.3	1.65e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-8.75	-0.43	1.13e-16	Bipolar disorder;
CRC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.87	-15.08	-0.64	1.97e-39	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg20933634	chr6:27740509	NA	0.57	7.9	0.4	4.13e-14	Parkinson's disease;
CRC	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg01097406	chr16:89675127	NA	0.52	9.55	0.47	3.07e-19	Vitiligo;
CRC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.96	-18.56	-0.72	3.92e-53	Height;
CRC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-8.42	-0.42	1.14e-15	Chronic sinus infection;
CRC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.63	-9.96	-0.48	1.36e-20	Motion sickness;
CRC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg15845792	chr6:28175446	NA	0.47	6.43	0.33	4.4e-10	Depression;
CRC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg11887960	chr12:57824829	NA	0.64	7.18	0.37	4.66e-12	Obesity-related traits;
CRC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	1.14	11.5	0.54	5.77e-26	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg24675056	chr1:15929824	NA	0.49	6.76	0.35	6.2e-11	Systolic blood pressure;
CRC	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.34	0.42	2.13e-15	Schizophrenia;
CRC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg20243544	chr17:37824526	PNMT	0.39	5.84	0.31	1.24e-8	Self-reported allergy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19336883	chr11:64085465	PRDX5;TRMT112	0.41	6.44	0.33	4.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg02336364	chr1:24764700	NIPAL3	0.44	7.42	0.38	1.01e-12	Response to interferon beta in multiple sclerosis;
CRC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg10570241	chr7:158785291	NA	-0.41	-6.96	-0.36	1.9e-11	Facial morphology (factor 20);
CRC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.27	0.41	3.37e-15	Lung cancer;
CRC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.8	-0.35	4.92e-11	Breast cancer;
CRC	cis	rs17023223	0.537	rs12086	chr1:119573860	T/C	cg05756136	chr1:119680316	WARS2	-0.52	-6.4	-0.33	5.35e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg20673091	chr1:2541236	MMEL1	-0.38	-5.85	-0.31	1.16e-8	Ulcerative colitis;
CRC	cis	rs10924970	0.625	rs12757645	chr1:235497804	T/C	cg09010748	chr1:235293032	TOMM20	-0.41	-5.76	-0.3	1.98e-8	Asthma;
CRC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.74	13.18	0.59	3.7e-32	Oral cavity cancer;
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.98	0.31	5.71e-9	Life satisfaction;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg23161317	chr6:28129485	ZNF389	-0.38	-5.7	-0.3	2.6e-8	Cardiac Troponin-T levels;
CRC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg22676075	chr6:135203613	NA	0.45	6.94	0.36	2.09e-11	High light scatter reticulocyte percentage of red cells;
CRC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.15	14.73	0.63	4.62e-38	Uric acid levels;
CRC	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg25547332	chr5:131281432	NA	0.41	5.72	0.3	2.42e-8	Life satisfaction;
CRC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg24375607	chr4:120327624	NA	-0.47	-7.69	-0.39	1.67e-13	Corneal astigmatism;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg03623178	chr6:28175578	NA	0.73	9.66	0.47	1.31e-19	Parkinson's disease;
CRC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.53	11.35	0.53	2.08e-25	Alcohol dependence;
CRC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.62	-7.65	-0.39	2.28e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.12	0.41	9.29e-15	Monocyte count;
CRC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.43	-0.79	4.22e-72	Myeloid white cell count;
CRC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.87	-9.52	-0.46	3.79e-19	Hip circumference adjusted for BMI;
CRC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.81	-12.83	-0.58	7.91e-31	Cognitive function;
CRC	cis	rs9891119	0.896	rs35950888	chr17:40499198	A/G	cg06270615	chr17:40516068	STAT3	-0.27	-5.94	-0.31	7.32e-9	Multiple sclerosis;Crohn's disease;
CRC	cis	rs11212617	1.000	rs2356801	chr11:108281999	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.2	0.32	1.66e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3751196	0.808	rs79928071	chr12:104220071	T/C	cg02344784	chr12:104178138	NT5DC3	0.71	7.25	0.37	3.05e-12	Sense of smell;
CRC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.49	-7.79	-0.39	8.6e-14	Red blood cell count;
CRC	cis	rs4665630	0.522	rs114382704	chr2:23951810	G/T	cg08063864	chr2:24346004	PFN4;LOC375190	0.96	7.52	0.38	5.32e-13	Hypertension;
CRC	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.64	-8.6	-0.43	3.35e-16	Cocaine dependence;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg21251018	chr6:28226885	NKAPL	0.45	6.51	0.34	2.73e-10	Parkinson's disease;
CRC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.35	5.66	0.3	3.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg06470822	chr6:28175283	NA	0.98	13.17	0.59	4.07e-32	Depression;
CRC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.73	-0.3	2.27e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs427941	0.703	rs201435	chr7:101732865	G/C	cg06246474	chr7:101738831	CUX1	0.46	7.13	0.37	6.52e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.4	0.33	5.42e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.21	-0.41	5.18e-15	Chronic sinus infection;
CRC	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg22495460	chr2:25135724	ADCY3	-0.66	-11.1	-0.52	1.62e-24	Body mass index in non-asthmatics;
CRC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.8	-11.92	-0.55	1.75e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg24011408	chr12:48396354	COL2A1	0.45	6.39	0.33	5.56e-10	Glycated hemoglobin levels;
CRC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-10.07	-0.49	5.67e-21	Schizophrenia;
CRC	cis	rs3812762	0.833	rs10500707	chr11:8817580	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.4	6.53	0.34	2.43e-10	Hypospadias;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.13	-0.37	6.47e-12	Bipolar disorder;
CRC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.68	8.94	0.44	2.78e-17	Multiple sclerosis;
CRC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.7	-0.43	1.64e-16	Intelligence (multi-trait analysis);
CRC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.54	-7.23	-0.37	3.4e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg10818794	chr15:86012489	AKAP13	-0.45	-6.58	-0.34	1.81e-10	Coronary artery disease;
CRC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg15534755	chr11:117069859	TAGLN	0.35	6.64	0.34	1.32e-10	Blood protein levels;
CRC	cis	rs501120	1.000	rs504799	chr10:44753456	C/T	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg10190698	chr14:50154770	POLE2	0.43	6.42	0.33	4.64e-10	Body mass index;
CRC	cis	rs6088813	1.000	rs6141548	chr20:33971085	A/G	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.61	-9.27	-0.45	2.56e-18	Cognitive function;
CRC	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.56	8.41	0.42	1.22e-15	Corneal astigmatism;
CRC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.72	11.22	0.53	5.76e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.73	0.35	7.48e-11	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.08	-0.32	3.24e-9	Life satisfaction;
CRC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.91	-17.1	-0.69	2.31e-47	Intelligence (multi-trait analysis);
CRC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.44	5.73	0.3	2.31e-8	Daytime sleep phenotypes;
CRC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	6.03	0.32	4.35e-9	Schizophrenia;
CRC	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.85	20.71	0.75	1.39e-61	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg01472538	chr16:58549086	SETD6	1.12	7.38	0.38	1.28e-12	Schizophrenia;
CRC	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg01426195	chr3:39028469	NA	-0.45	-7.57	-0.39	3.81e-13	Handedness;
CRC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg00343986	chr7:65444356	GUSB	0.45	6.17	0.32	2.05e-9	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19626500	chr19:17445531	ANO8	0.42	6.03	0.32	4.41e-9	Anxiety disorder;
CRC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg23463467	chr20:60627584	TAF4	0.44	8.31	0.42	2.47e-15	Body mass index;
CRC	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.28	0.49	1.15e-21	Ileal carcinoids;
CRC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-7.95	-0.4	3.07e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.49	0.42	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9463078	0.739	rs1293457	chr6:44758098	T/C	cg25276700	chr6:44698697	NA	0.29	7.03	0.36	1.23e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11976233	chr4:56719715	EXOC1	0.41	7.11	0.36	7.18e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.49	-8.35	-0.42	1.95e-15	Huntington's disease progression;
CRC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01171360	chr6:293285	DUSP22	-0.48	-6.72	-0.35	7.85e-11	Menopause (age at onset);
CRC	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg16576597	chr16:28551801	NUPR1	0.46	7.11	0.36	7.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	7.09	0.36	8.27e-12	Obesity-related traits;
CRC	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg02811702	chr13:24901961	NA	0.43	6.0	0.31	5.17e-9	Obesity-related traits;
CRC	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg23254163	chr1:152506842	NA	0.45	9.15	0.45	6.31e-18	Hair morphology;
CRC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.31	-0.33	9.14e-10	Aortic root size;
CRC	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg17182837	chr8:41585554	ANK1	-0.56	-7.82	-0.4	7.46e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs3924048	0.559	rs4580	chr1:12628188	T/C	cg00291366	chr1:12616550	NA	0.52	8.92	0.44	3.21e-17	Optic cup area;
CRC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.81	11.92	0.55	1.84e-27	Response to antineoplastic agents;
CRC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.71	11.97	0.55	1.22e-27	Gout;
CRC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.93	0.4	3.54e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.62	-8.27	-0.41	3.47e-15	White matter hyperintensity burden;
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.85e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17127169	0.536	rs112625995	chr1:65496627	A/G	cg13853591	chr1:65468921	NA	0.81	5.67	0.3	3.06e-8	Sitting height ratio;
CRC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.52	0.38	5.42e-13	Motion sickness;
CRC	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-6.52	-0.34	2.67e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.72	-11.12	-0.52	1.36e-24	Colorectal cancer;
CRC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg18876405	chr7:65276391	NA	-0.51	-8.39	-0.42	1.44e-15	Aortic root size;
CRC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.61	10.87	0.51	1e-23	Schizophrenia;
CRC	cis	rs3996993	0.809	rs55815585	chr6:52697601	T/G	cg20803780	chr6:52668592	GSTA1	0.36	6.56	0.34	2.07e-10	Hemoglobin concentration;
CRC	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.98	-0.48	1.13e-20	Colorectal cancer;
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg21620606	chr4:1342894	KIAA1530	-0.4	-7.2	-0.37	4.07e-12	Obesity-related traits;
CRC	cis	rs6662572	1.000	rs28433203	chr1:46196813	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.92	0.31	8.32e-9	Blood protein levels;
CRC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.47	-0.57	1.6800000000000001e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.63	-0.43	2.76e-16	Bipolar disorder;
CRC	cis	rs7632954	0.605	rs6790631	chr3:8521605	G/T	cg03495237	chr3:8533978	NA	0.37	6.76	0.35	6.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	7.69	0.39	1.75e-13	Mean platelet volume;
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.14e-9	Prudent dietary pattern;
CRC	cis	rs17253792	0.545	rs3742571	chr14:56016704	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-6.45	-0.33	4.09e-10	Putamen volume;
CRC	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg11887960	chr12:57824829	NA	0.63	6.79	0.35	5.32e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.96	0.4	2.82e-14	Menopause (age at onset);
CRC	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.39	6.92	0.36	2.38e-11	Coronary artery disease;
CRC	trans	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.42	-6.68	-0.35	1.02e-10	Mean corpuscular volume;
CRC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.58	8.1	0.41	1.11e-14	Alcohol dependence;
CRC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-7.44	-0.38	9.09e-13	Chronic sinus infection;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17808901	chr3:39093368	WDR48	-0.5	-6.34	-0.33	7.76e-10	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.43	6.14	0.32	2.42e-9	Aortic root size;
CRC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	6.81	0.35	4.75e-11	Lung function (FEV1/FVC);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11809094	chr4:159593519	ETFDH;C4orf46	0.46	6.67	0.35	1.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6700896	0.931	rs4655743	chr1:66087301	G/C	cg04111102	chr1:66153794	NA	0.33	5.94	0.31	7.41e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg25342872	chr17:79175132	AZI1	0.44	7.89	0.4	4.61e-14	Frontotemporal dementia;
CRC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	14.71	0.63	5.4e-38	Platelet count;
CRC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.94	11.22	0.53	6.04e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg00042356	chr1:8021962	PARK7	0.72	7.51	0.38	5.59e-13	Inflammatory bowel disease;
CRC	cis	rs457287	0.685	rs466547	chr9:4834034	C/T	cg14182974	chr9:4791918	RCL1	-0.41	-6.24	-0.33	1.35e-9	Platelet count;
CRC	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	0.87	10.75	0.51	2.69e-23	Breast cancer;
CRC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	5.65	0.3	3.44e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.47	7.76	0.39	1.06e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.74	-11.92	-0.55	1.85e-27	Autism spectrum disorder or schizophrenia;
CRC	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.49	-0.34	3.2e-10	Coronary artery disease;
CRC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.1	0.32	2.95e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs4276421	0.837	rs6451807	chr5:45534423	C/G	cg04793272	chr11:119020941	ABCG4	-0.37	-6.07	-0.32	3.48e-9	P wave duration;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.9	-9.45	-0.46	6.64e-19	Blood protein levels;
CRC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.4	5.76	0.3	1.91e-8	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14360659	chr9:137029702	RNU6ATAC	0.44	6.09	0.32	3.14e-9	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.49	-0.38	6.21e-13	Bladder cancer;
CRC	cis	rs6662572	0.686	rs72692639	chr1:46446096	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.64	0.3	3.59e-8	Blood protein levels;
CRC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.84	0.4	6.25e-14	Motion sickness;
CRC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg03037974	chr15:76606532	NA	0.54	8.05	0.41	1.54e-14	Blood metabolite levels;
CRC	cis	rs6700896	0.966	rs11208689	chr1:66083197	G/A	cg04111102	chr1:66153794	NA	0.35	6.21	0.32	1.56e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11992992	chr3:71633216	FOXP1	0.45	6.78	0.35	5.61e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.46	5.8	0.3	1.55e-8	Metabolite levels;
CRC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.38	-6.57	-0.34	1.97e-10	Systemic lupus erythematosus;
CRC	cis	rs1050631	0.564	rs1785931	chr18:33722107	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.68	0.3	2.96e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.47	6.61	0.34	1.51e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs294883	0.858	rs4709289	chr6:159720529	C/T	cg14500486	chr6:159655392	FNDC1	-0.34	-5.63	-0.3	3.89e-8	Coronary artery disease;
CRC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.05	16.19	0.67	8.71e-44	Testicular germ cell tumor;
CRC	trans	rs783540	0.746	rs7165125	chr15:83297936	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.34	-5.97	-0.31	6.24e-9	Schizophrenia;
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00166722	chr3:10149974	C3orf24	0.66	9.0	0.44	1.85e-17	Alzheimer's disease;
CRC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-6.13	-0.32	2.56e-9	Lung cancer;
CRC	cis	rs6496667	0.779	rs113212493	chr15:90960293	T/A	cg04176472	chr15:90893244	GABARAPL3	0.67	8.31	0.42	2.47e-15	Rheumatoid arthritis;
CRC	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.46	-5.89	-0.31	9.51e-9	Neuroticism;
CRC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg26695010	chr11:65641043	EFEMP2	0.44	6.28	0.33	1.05e-9	DNA methylation (variation);
CRC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.6	-5.94	-0.31	7.2e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.14	-0.37	5.9e-12	Total body bone mineral density;
CRC	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg17507749	chr15:85114479	UBE2QP1	0.75	10.72	0.51	3.44e-23	Schizophrenia;
CRC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	14.69	0.63	6.34e-38	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12820999	chr7:5821320	RNF216	0.45	6.5	0.34	2.94e-10	Response to antipsychotic treatment;
CRC	cis	rs2811415	0.531	rs2116674	chr3:127759664	C/A	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.1e-8	Lung function (FEV1/FVC);
CRC	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg03315344	chr16:75512273	CHST6	-0.55	-6.38	-0.33	6.16e-10	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9462027	0.628	rs9296129	chr6:34774414	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.19	0.32	1.83e-9	Systemic lupus erythematosus;
CRC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.51	-0.38	5.7e-13	HDL cholesterol;
CRC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.84	-0.48	3.38e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.73	11.54	0.54	4.4e-26	Plateletcrit;Platelet count;
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-7.86	-0.4	5.46e-14	Renal function-related traits (BUN);
CRC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.24	0.33	1.35e-9	IgG glycosylation;
CRC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.35	-7.4	-0.38	1.12e-12	Urinary metabolites;
CRC	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg18477163	chr1:228402036	OBSCN	0.42	7.04	0.36	1.13e-11	Diastolic blood pressure;
CRC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.9	16.49	0.67	5.75e-45	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	11.25	0.53	4.73e-25	Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03901462	chr11:62572874	NXF1	0.46	7.46	0.38	7.7e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg19897017	chr7:2163380	MAD1L1	0.38	5.74	0.3	2.09e-8	Schizophrenia;
CRC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg17545662	chr6:170176663	C6orf70	0.57	6.55	0.34	2.26e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg07138768	chr7:917805	C7orf20	0.3	5.81	0.31	1.45e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.73	0.39	1.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-7.38	-0.38	1.34e-12	Menarche (age at onset);
CRC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg25767906	chr1:53392781	SCP2	-0.44	-6.89	-0.35	2.9100000000000002e-11	Monocyte count;
CRC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.89	-0.48	2.34e-20	Primary sclerosing cholangitis;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.51	7.05	0.36	1.07e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.14	0.49	3.34e-21	Asthma (childhood onset);
CRC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.31	0.33	9.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.43	-7.25	-0.37	2.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg20608306	chr11:116969690	SIK3	-0.3	-5.61	-0.3	4.26e-8	Blood protein levels;
CRC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.53e-12	Menopause (age at onset);
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.44	-5.94	-0.31	7.37e-9	Parkinson's disease;
CRC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg21466736	chr12:48725269	NA	-0.52	-8.08	-0.41	1.23e-14	Platelet count;
CRC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.59	7.97	0.4	2.56e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg18761221	chr20:60518478	NA	0.39	6.87	0.35	3.19e-11	Body mass index;
CRC	cis	rs9491140	0.539	rs10872284	chr6:124685928	G/A	cg05308643	chr6:124982296	NKAIN2	0.48	6.64	0.34	1.26e-10	Neuroticism;
CRC	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.6	-9.42	-0.46	8.47e-19	Ulcerative colitis;
CRC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg14979609	chr8:8086686	FLJ10661	0.35	5.7	0.3	2.68e-8	Joint mobility (Beighton score);
CRC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.51	6.85	0.35	3.65e-11	Obesity-related traits;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.63	7.24	0.37	3.25e-12	Body mass index;
CRC	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg26805224	chr10:79626177	DLG5	-0.49	-7.29	-0.37	2.37e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.53	-7.24	-0.37	3.19e-12	DNA methylation (variation);
CRC	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.8	-0.3	1.55e-8	Arsenic metabolism;
CRC	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.57	8.83	0.44	6.39e-17	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01623627	chr12:56473229	ERBB3	0.39	6.25	0.33	1.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg00246817	chr9:123691163	NA	-0.47	-6.04	-0.32	4.11e-9	Rheumatoid arthritis;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-9.1	-0.45	8.89e-18	Bipolar disorder;
CRC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg23262073	chr20:60523788	NA	-0.39	-6.34	-0.33	7.37e-10	Body mass index;
CRC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16909824	chr1:151299438	PI4KB	0.48	6.8	0.35	4.87e-11	Response to antipsychotic treatment;
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09695851	chr17:3907499	NA	-0.78	-14.33	-0.62	1.65e-36	Type 2 diabetes;
CRC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg00074818	chr8:8560427	CLDN23	0.41	7.54	0.38	4.61e-13	Obesity-related traits;
CRC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-7.11	-0.36	7.49e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg02772935	chr3:125709198	NA	-0.5	-5.81	-0.3	1.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg18876405	chr7:65276391	NA	0.45	6.35	0.33	7.13e-10	Aortic root size;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.9	0.36	2.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7178572	0.633	rs4886875	chr15:77838419	C/T	cg22256960	chr15:77711686	NA	0.64	9.39	0.46	1.04e-18	Type 2 diabetes;
CRC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.49	-0.38	6.6e-13	Educational attainment;
CRC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.3	0.42	2.76e-15	Coffee consumption (cups per day);
CRC	cis	rs4728302	0.574	rs7804463	chr7:133447651	T/C	cg10665199	chr7:133106180	EXOC4	0.44	6.92	0.36	2.35e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.63	-0.47	1.69e-19	Primary sclerosing cholangitis;
CRC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.84	13.11	0.59	7.23e-32	Menarche (age at onset);
CRC	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg18646521	chr2:111875858	NA	0.4	6.36	0.33	6.66e-10	Chronic lymphocytic leukemia;
CRC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.68	0.35	1.02e-10	Schizophrenia;
CRC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-6.45	-0.34	3.88e-10	Reticulocyte count;
CRC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-7.87	-0.4	5.31e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.5	7.64	0.39	2.38e-13	Corneal astigmatism;
CRC	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.9	-0.63	9.49e-39	Exhaled nitric oxide output;
CRC	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.41	-6.02	-0.32	4.64e-9	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19183932	chr6:27791712	HIST1H4J	0.48	7.46	0.38	7.74e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.41	0.46	8.79e-19	Fuchs's corneal dystrophy;
CRC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.65	-0.6	6.24e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.52	0.38	5.22e-13	Mean corpuscular volume;
CRC	cis	rs9400239	0.584	rs1268174	chr6:109018859	A/G	cg11073813	chr6:109029018	NA	-0.38	-5.99	-0.31	5.61e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14616479	chr3:155588124	GMPS	-0.41	-6.01	-0.31	5e-9	Daytime sleep phenotypes;
CRC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.69	11.11	0.52	1.49e-24	Colorectal cancer;
CRC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13198984	chr17:80129470	CCDC57	0.48	8.45	0.42	9.35e-16	Life satisfaction;
CRC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.92	-0.52	6.61e-24	Blood trace element (Zn levels);
CRC	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg05562828	chr17:3906858	NA	0.49	6.18	0.32	1.92e-9	Type 2 diabetes;
CRC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.58	0.7	2.92e-49	Platelet count;
CRC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.38	-7.11	-0.36	7.47e-12	Lymphocyte counts;
CRC	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10888329	0.819	rs4546956	chr1:248358953	G/A	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Autism spectrum disorder;
CRC	cis	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg11900509	chr10:81946545	ANXA11	-0.72	-8.54	-0.43	4.91e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7539542	0.556	rs1539357	chr1:202878454	T/A	cg19681188	chr1:202830198	LOC148709	0.46	6.55	0.34	2.18e-10	Mean platelet volume;
CRC	cis	rs1975031	1	rs1975031	chr19:7217601	G/A	cg00428638	chr19:7224713	INSR	-0.79	-9.94	-0.48	1.62e-20	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg06713675	chr4:122721982	EXOSC9	-0.39	-6.38	-0.33	6.01e-10	Type 2 diabetes;
CRC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.55	-0.47	3.01e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.44	7.04	0.36	1.1e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.19	-0.69	1.07e-47	Height;
CRC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.43	8.67	0.43	2.01e-16	Renal cell carcinoma;
CRC	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.92	15.72	0.65	6.46e-42	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-6.77	-0.35	5.99e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.76	-10.29	-0.49	1.06e-21	White matter hyperintensity burden;
CRC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.72	8.0	0.4	2.21e-14	Vitiligo;
CRC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg18612461	chr15:75251733	NA	0.38	5.92	0.31	7.95e-9	Breast cancer;
CRC	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg00691999	chr4:55094011	PDGFRA	0.4	5.93	0.31	7.46e-9	Corneal astigmatism;
CRC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.63	0.39	2.52e-13	Mean platelet volume;
CRC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg14541582	chr5:601475	NA	-0.36	-7.11	-0.36	7.3e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg11189052	chr15:85197271	WDR73	0.65	9.53	0.47	3.47e-19	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06417831	chr6:43596987	MAD2L1BP;GTPBP2	0.45	6.01	0.31	5.04e-9	Anxiety disorder;
CRC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg03233332	chr7:66118400	NA	0.45	6.24	0.33	1.36e-9	Aortic root size;
CRC	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.59	8.48	0.42	7.66e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-7.75	-0.39	1.19e-13	Subjective well-being;
CRC	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg01843034	chr6:37503916	NA	0.38	6.31	0.33	9.05e-10	Cognitive performance;
CRC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	0.94	13.54	0.6	1.62e-33	Breast cancer;
CRC	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg15786705	chr6:28176104	NA	-0.56	-6.08	-0.32	3.38e-9	Depression;
CRC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg24375607	chr4:120327624	NA	0.44	6.83	0.35	4.17e-11	Corneal astigmatism;
CRC	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.64	-9.05	-0.45	1.24e-17	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg10437265	chr15:77819839	NA	0.6	10.69	0.51	4.18e-23	Type 2 diabetes;
CRC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16035780	chr5:759353	NA	0.36	5.75	0.3	2.03e-8	Obesity-related traits;
CRC	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.26	0.33	1.18e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6968419	0.674	rs17138528	chr7:115907289	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.22	-0.32	1.48e-9	Intraocular pressure;
CRC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg01612440	chr4:3296283	NA	0.43	6.03	0.32	4.4e-9	Serum sulfate level;
CRC	cis	rs7849270	0.851	rs7861663	chr9:131880946	G/A	cg13538475	chr9:131942899	NA	-0.29	-5.89	-0.31	9.75e-9	Blood metabolite ratios;
CRC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.46	6.87	0.35	3.17e-11	Longevity;Endometriosis;
CRC	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.53	-7.26	-0.37	2.88e-12	Tuberculosis;
CRC	cis	rs9463078	0.790	rs1324531	chr6:45136224	T/C	cg25276700	chr6:44698697	NA	-0.28	-6.71	-0.35	8.36e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.63	-9.07	-0.45	1.08e-17	Systolic blood pressure;
CRC	cis	rs9462027	0.628	rs2395604	chr6:34787976	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.17	-0.32	2e-9	Systemic lupus erythematosus;
CRC	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.49	8.59	0.43	3.6e-16	Weight;
CRC	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.44	-7.34	-0.37	1.73e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg04969067	chr8:143858791	LYNX1	0.43	6.58	0.34	1.84e-10	Urinary tract infection frequency;
CRC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.63	9.85	0.48	3.18e-20	Corneal astigmatism;
CRC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.67	11.83	0.55	3.91e-27	Height;
CRC	trans	rs2407314	0.595	rs10094300	chr8:4087295	C/T	cg01356198	chr3:187929513	LPP	-0.39	-6.08	-0.32	3.33e-9	Insulin resistance/response;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13791713	chr21:40720916	HMGN1	0.41	6.25	0.33	1.28e-9	Myopia (pathological);
CRC	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.74	-10.46	-0.5	2.76e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.49e-12	Motion sickness;
CRC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.92	-17.68	-0.7	1.24e-49	Cognitive ability;
CRC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg20607287	chr7:12443886	VWDE	-0.67	-6.68	-0.35	1.01e-10	Coronary artery disease;
CRC	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.48	-5.78	-0.3	1.77e-8	Coronary artery calcification;
CRC	cis	rs2971970	0.519	rs2346272	chr7:133654830	T/C	cg03336402	chr7:133662267	EXOC4	-0.67	-10.43	-0.5	3.51e-22	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.48	7.67	0.39	2e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.47	6.22	0.32	1.47e-9	Morning vs. evening chronotype;
CRC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.54	7.6	0.39	3.15e-13	Response to temozolomide;
CRC	cis	rs524281	0.817	rs10791859	chr11:65978453	C/T	cg16950941	chr11:66035639	RAB1B	-0.66	-7.87	-0.4	5.28e-14	Electroencephalogram traits;
CRC	cis	rs853679	1.000	rs853679	chr6:28296863	C/A	cg06470822	chr6:28175283	NA	0.59	6.14	0.32	2.39e-9	Depression;
CRC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.75	10.86	0.51	1.12e-23	Longevity;
CRC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	17.17	0.69	1.2e-47	Electrocardiographic conduction measures;
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-6.67	-0.35	1.07e-10	Lymphocyte counts;
CRC	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.56	-8.6	-0.43	3.34e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.45	-6.7	-0.35	9.28e-11	Cognitive test performance;
CRC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.51	7.22	0.37	3.6e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.7	9.33	0.46	1.65e-18	Initial pursuit acceleration;
CRC	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.48	-6.85	-0.35	3.57e-11	Schizophrenia;
CRC	cis	rs7605827	0.626	rs2031011	chr2:15548390	A/G	cg19274914	chr2:15703543	NA	0.38	5.65	0.3	3.56e-8	Educational attainment (years of education);
CRC	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.44	-6.69	-0.35	9.69e-11	Bone mineral density;
CRC	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.96	-16.27	-0.67	4.46e-44	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.33	-0.53	2.45e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg02033258	chr5:131593261	PDLIM4	-0.39	-6.76	-0.35	6.12e-11	Blood metabolite levels;
CRC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg19318889	chr4:1322082	MAEA	0.4	5.65	0.3	3.41e-8	Obesity-related traits;
CRC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21467203	chr3:49911342	NA	0.24	5.93	0.31	7.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg16476235	chr8:21771668	DOK2	0.37	6.22	0.32	1.48e-9	Mean corpuscular volume;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg06470822	chr6:28175283	NA	0.67	9.13	0.45	6.85e-18	Parkinson's disease;
CRC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.15	0.71	1.69e-51	Parkinson's disease;
CRC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02850689	chr1:2391347	NA	-0.39	-6.4	-0.33	5.22e-10	Non-obstructive azoospermia;
CRC	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.61	-10.29	-0.49	1.06e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs11229555	0.645	rs11229431	chr11:58181253	A/G	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.92	13.17	0.59	4.28e-32	Breast cancer;
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.29	-6.19	-0.32	1.81e-9	Total body bone mineral density;
CRC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.68	8.3	0.42	2.76e-15	Gut microbiome composition (summer);
CRC	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg26695010	chr11:65641043	EFEMP2	0.46	6.82	0.35	4.43e-11	Eosinophil percentage of white cells;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.7	-0.43	1.62e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-5.91	-0.31	8.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-7.21	-0.37	3.91e-12	Aortic root size;
CRC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg20302533	chr7:39170763	POU6F2	0.41	5.66	0.3	3.38e-8	IgG glycosylation;
CRC	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	7.68e-17	Dupuytren's disease;
CRC	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs7605827	0.930	rs4668925	chr2:15703576	C/T	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.79e-9	Educational attainment (years of education);
CRC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.61	9.1	0.45	8.91e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg04611788	chr3:186434169	KNG1	-0.59	-8.78	-0.44	8.92e-17	Blood protein levels;
CRC	cis	rs12476592	0.602	rs1255	chr2:63825934	T/C	cg10828910	chr2:63850056	LOC388955	0.5	6.13	0.32	2.54e-9	Childhood ear infection;
CRC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-9.01	-0.44	1.76e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.83e-9	Life satisfaction;
CRC	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.67	-10.99	-0.52	3.83e-24	Hepatocellular carcinoma;
CRC	cis	rs7192380	0.893	rs12921782	chr16:69780022	C/T	cg00738113	chr16:70207722	CLEC18C	0.37	6.43	0.33	4.4e-10	Sjögren's syndrome;
CRC	cis	rs891088	0.622	rs11670932	chr19:7206790	A/G	cg09779027	chr19:7224513	INSR	-0.62	-7.54	-0.38	4.72e-13	Hip circumference adjusted for BMI;Height;
CRC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.52	-0.5	1.73e-22	Extrinsic epigenetic age acceleration;
CRC	trans	rs1590305	0.786	rs61946576	chr13:38060134	T/C	cg03965764	chr11:45248109	NA	-0.6	-6.15	-0.32	2.31e-9	Hip geometry;
CRC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg09650180	chr20:62225654	GMEB2	-0.52	-6.91	-0.36	2.51e-11	Glioblastoma;
CRC	trans	rs10504390	0.656	rs17394294	chr8:66512767	T/C	cg26403416	chr21:43771339	TFF2	0.6	6.22	0.32	1.47e-9	IgG glycosylation;
CRC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.58	7.94	0.4	3.29e-14	Lung cancer;
CRC	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.17	-0.37	4.93e-12	Inflammatory skin disease;
CRC	cis	rs2625529	0.689	rs8178	chr15:72114747	G/A	cg16672083	chr15:72433130	SENP8	-0.45	-6.54	-0.34	2.38e-10	Red blood cell count;
CRC	cis	rs16852403	0.517	rs1319918	chr1:178243524	A/G	cg00404053	chr1:178313656	RASAL2	0.48	6.12	0.32	2.7e-9	Childhood ear infection;
CRC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.36	5.88	0.31	1.03e-8	Height;
CRC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg20203395	chr5:56204925	C5orf35	-0.58	-6.86	-0.35	3.42e-11	Initial pursuit acceleration;
CRC	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.5	0.42	6.5e-16	Corneal astigmatism;
CRC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06636001	chr8:8085503	FLJ10661	0.44	5.77	0.3	1.86e-8	Obesity-related traits;
CRC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.51	0.38	5.67e-13	Lung cancer in ever smokers;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07308232	chr7:1071921	C7orf50	-0.47	-6.26	-0.33	1.22e-9	Longevity;Endometriosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07754938	chr3:48885314	PRKAR2A	0.42	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.09	-0.32	3.1e-9	Total body bone mineral density;
CRC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.83	-0.48	3.67e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg25164649	chr6:28176230	NA	0.58	8.04	0.41	1.65e-14	Parkinson's disease;
CRC	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.76	-0.39	1.08e-13	Triglycerides;
CRC	cis	rs6988985	0.728	rs56400819	chr8:143925374	A/G	cg10324643	chr8:143916377	GML	0.35	5.67	0.3	3.16e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	17.32	0.69	3.19e-48	Electrocardiographic conduction measures;
CRC	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg03315344	chr16:75512273	CHST6	-0.56	-6.64	-0.34	1.3100000000000001e-10	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.5	7.27	0.37	2.58e-12	Height;
CRC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg13628971	chr7:2884303	GNA12	0.4	6.27	0.33	1.14e-9	Height;
CRC	cis	rs727479	0.502	rs2899471	chr15:51506553	G/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.08	-0.32	3.36e-9	Estradiol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25946952	chr7:143059218	FAM131B	0.38	6.39	0.33	5.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.36	5.69	0.3	2.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.55	-6.27	-0.33	1.15e-9	Vitiligo;
CRC	cis	rs7605827	0.930	rs7580672	chr2:15586646	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.89e-9	Educational attainment (years of education);
CRC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19904058	chr10:135279010	LOC619207	-0.38	-7.25	-0.37	2.94e-12	Systemic lupus erythematosus;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.48	6.75	0.35	6.68e-11	Height;
CRC	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	1.17	11.08	0.52	1.78e-24	Prostate cancer;
CRC	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.39	6.05	0.32	3.83e-9	Testicular germ cell tumor;
CRC	cis	rs2617583	0.509	rs2937650	chr5:1458018	C/T	cg07148919	chr5:1466943	LPCAT1	0.45	6.02	0.31	4.69e-9	Breast cancer;
CRC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg03395651	chr16:88107091	BANP	0.53	6.91	0.36	2.53e-11	Menopause (age at onset);
CRC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21963583	chr11:68658836	MRPL21	0.62	11.31	0.53	2.92e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4920343	0.698	rs578988	chr1:19077291	T/C	cg26220594	chr1:19110978	NA	0.36	5.63	0.3	3.85e-8	Knee osteoarthritis;
CRC	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.95	-0.36	1.97e-11	Inflammatory skin disease;
CRC	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.68	-9.39	-0.46	1.02e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.54	10.41	0.5	3.98e-22	Acylcarnitine levels;
CRC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-8.98	-0.44	2.14e-17	Monocyte percentage of white cells;
CRC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.68	-0.35	1.02e-10	IgG glycosylation;
CRC	cis	rs1403694	0.966	rs9869244	chr3:186437554	A/T	cg04611788	chr3:186434169	KNG1	-0.45	-6.96	-0.36	1.84e-11	Blood protein levels;
CRC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.59	8.45	0.42	9.59e-16	Breast cancer;
CRC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	9.44	0.46	7.03e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs1472147	1.000	rs6970221	chr7:128511024	A/G	cg00260937	chr7:128520193	KCP	0.48	7.26	0.37	2.77e-12	Calcium levels;
CRC	cis	rs17767392	0.813	rs61991243	chr14:71847117	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.71	-0.3	2.53e-8	Mitral valve prolapse;
CRC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18252515	chr7:66147081	NA	0.39	5.68	0.3	2.99e-8	Aortic root size;
CRC	cis	rs965469	0.901	rs6037563	chr20:3326568	G/A	cg25506879	chr20:3388711	C20orf194	-0.37	-5.6	-0.3	4.41e-8	IFN-related cytopenia;
CRC	cis	rs17234274	0.622	rs10767021	chr11:23238782	G/T	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg19025524	chr12:109796872	NA	-0.46	-6.17	-0.32	2.01e-9	Neuroticism;
CRC	cis	rs1639906	1.000	rs1639906	chr7:2219966	T/C	cg19897017	chr7:2163380	MAD1L1	0.43	6.63	0.34	1.4e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.74	10.59	0.5	9.5e-23	Obesity-related traits;
CRC	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg26875233	chr11:93583750	C11orf90	0.35	6.9	0.36	2.67e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg16558177	chr4:4109446	NA	-0.48	-6.22	-0.32	1.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs9341808	0.652	rs2505940	chr6:80851191	T/C	cg08355045	chr6:80787529	NA	0.34	5.82	0.31	1.36e-8	Sitting height ratio;
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg11833968	chr6:79620685	NA	-0.37	-6.4	-0.33	5.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-10.87	-0.51	1.03e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	11.84	0.55	3.55e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.46	6.87	0.35	3.32e-11	Breast cancer;
CRC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.53e-10	Response to antipsychotic treatment;
CRC	cis	rs12144309	0.608	rs1217408	chr1:114396280	T/C	cg03325407	chr1:114423726	BCL2L15	0.35	6.54	0.34	2.3e-10	Coronary artery disease;
CRC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.66	7.29	0.37	2.28e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.95	18.13	0.71	2.1e-51	Height;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03923535	chr7:1197113	ZFAND2A	0.74	11.26	0.53	4.14e-25	Longevity;Endometriosis;
CRC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.58	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.41	-6.64	-0.34	1.28e-10	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.49	8.81	0.44	7.36e-17	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23963351	chr1:43834180	ELOVL1	0.45	6.31	0.33	9.11e-10	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	12.7	0.57	2.34e-30	Coffee consumption (cups per day);
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.57	0.34	1.92e-10	Parkinson's disease;
CRC	cis	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg26132723	chr8:70041827	NA	-0.35	-5.63	-0.3	3.87e-8	Dupuytren's disease;
CRC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.76	14.26	0.62	2.86e-36	Prudent dietary pattern;
CRC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg19847866	chr10:1019161	NA	0.4	5.82	0.31	1.43e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.48	6.43	0.33	4.56e-10	Resistin levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05886006	chr1:161359784	NA	-0.49	-5.96	-0.31	6.47e-9	Diisocyanate-induced asthma;
CRC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-9.63	-0.47	1.7e-19	Alcohol dependence;
CRC	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.28	-0.42	3.05e-15	Brugada syndrome;
CRC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.43	0.38	9.65e-13	Blood metabolite levels;
CRC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.28	-15.37	-0.65	1.5e-40	Diabetic kidney disease;
CRC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg06634786	chr22:41940651	POLR3H	-0.46	-5.88	-0.31	1.02e-8	Neuroticism;
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02290350	chr8:58132656	NA	-0.54	-6.4	-0.33	5.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg17775713	chr3:133465469	TF	0.33	5.85	0.31	1.19e-8	Iron status biomarkers;
CRC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.53	-0.34	2.56e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17554472	chr22:41940697	POLR3H	0.52	5.62	0.3	4.16e-8	Vitiligo;
CRC	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.34	5.88	0.31	1.01e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.13	0.37	6.46e-12	Rheumatoid arthritis;
CRC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.03	-0.32	4.31e-9	Menarche (age at onset);
CRC	cis	rs216303	0.570	rs216339	chr12:6149284	T/C	cg19878637	chr12:6148451	VWF	-0.6	-5.94	-0.31	7.1e-9	Low vWF levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08077726	chr17:74734280	SFRS2;MFSD11	-0.52	-6.09	-0.32	3.07e-9	Diisocyanate-induced asthma;
CRC	cis	rs2077654	0.908	rs7926934	chr11:17433088	A/C	cg25308976	chr11:17434268	ABCC8	0.8	8.33	0.42	2.26e-15	Gout;
CRC	trans	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.42	0.42	1.14e-15	Lewy body disease;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.08e-9	Life satisfaction;
CRC	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg20169779	chr10:135381914	SYCE1	0.63	10.42	0.5	3.72e-22	Obesity-related traits;
CRC	cis	rs3018066	0.836	rs13114479	chr4:107172679	C/T	cg01869342	chr4:106983673	TBCK	-0.36	-5.63	-0.3	3.82e-8	Cancer;
CRC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg05299278	chr17:33885742	SLFN14	-0.41	-6.26	-0.33	1.22e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg17298326	chr8:142245477	NA	0.42	6.28	0.33	1.04e-9	Immature fraction of reticulocytes;
CRC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg10760299	chr15:45669010	GATM	0.52	7.85	0.4	6.09e-14	Homoarginine levels;
CRC	cis	rs2179367	0.959	rs628488	chr6:149719400	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.18	-0.32	1.93e-9	Dupuytren's disease;
CRC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.25	-0.45	2.97e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.68	11.27	0.53	4.04e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.8	14.58	0.63	1.67e-37	Anterior chamber depth;
CRC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.42	6.66	0.34	1.12e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg00325661	chr8:49890786	NA	-0.35	-6.0	-0.31	5.25e-9	Sudden cardiac arrest;
CRC	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.42	6.63	0.34	1.39e-10	Electroencephalogram traits;
CRC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.76	-12.9	-0.58	4.36e-31	Body mass index;
CRC	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg10724054	chr17:3904396	NA	-0.45	-7.54	-0.38	4.61e-13	Type 2 diabetes;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg07404485	chr7:94953653	PON1	-0.45	-6.04	-0.32	4.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.66	10.54	0.5	1.46e-22	Corneal astigmatism;
CRC	trans	rs1161463	0.789	rs1027416	chr13:29429051	T/G	cg16311697	chr3:124249497	KALRN	-0.45	-6.12	-0.32	2.6e-9	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
CRC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.58	10.42	0.5	3.71e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.46	-0.42	8.81e-16	Bipolar disorder;
CRC	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.09	0.36	8.48e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg00666640	chr1:248458726	OR2T12	0.48	7.78	0.39	9.44e-14	Common traits (Other);
CRC	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.51	8.11	0.41	9.81e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.54	5.89	0.31	9.47e-9	Initial pursuit acceleration;
CRC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg19622623	chr12:86230825	RASSF9	-0.37	-5.93	-0.31	7.48e-9	Major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26182254	chr15:57210406	LOC145783;TCF12	0.38	6.2	0.32	1.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg20194872	chr6:41519635	FOXP4	-0.39	-5.68	-0.3	3.01e-8	Prostate cancer;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	1.03	19.83	0.74	3.98e-58	Menarche (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	-0.52	-6.3	-0.33	9.41e-10	Diisocyanate-induced asthma;
CRC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.8	14.35	0.62	1.28e-36	Breast cancer;
CRC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.36	-6.82	-0.35	4.44e-11	Colorectal cancer;
CRC	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg17710535	chr19:10819994	QTRT1	0.44	6.54	0.34	2.3e-10	Inflammatory skin disease;
CRC	cis	rs995000	0.931	rs634341	chr1:62921422	T/C	cg19896129	chr1:63156450	NA	0.44	6.78	0.35	5.59e-11	Triglyceride levels;
CRC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.73	9.57	0.47	2.65e-19	Cleft lip with or without cleft palate;
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.67	8.87	0.44	4.81e-17	Alzheimer's disease;
CRC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-9.16	-0.45	5.63e-18	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.8	-11.2	-0.53	6.83e-25	Uric acid levels;
CRC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.81	-0.72	4.3e-54	Height;
CRC	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.35	6.53	0.34	2.49e-10	Panic disorder;
CRC	cis	rs3026101	0.624	rs60116755	chr17:5303215	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	6.93	0.36	2.22e-11	Body mass index;
CRC	trans	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	20.28	0.75	6.6e-60	Headache;
CRC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.51	6.67	0.35	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg02659138	chr7:134003124	SLC35B4	0.37	6.38	0.33	6e-10	Mean platelet volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10030417	chr3:11102607	NA	0.45	6.05	0.32	3.88e-9	Anxiety disorder;
CRC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.47	-8.48	-0.42	7.49e-16	Intelligence (multi-trait analysis);
CRC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg11245181	chr6:149772854	ZC3H12D	0.52	9.12	0.45	7.83e-18	Dupuytren's disease;
CRC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9463078	0.753	rs3778507	chr6:44896803	G/A	cg25276700	chr6:44698697	NA	-0.28	-6.73	-0.35	7.44e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs995000	0.931	rs116405518	chr1:63036807	G/A	cg19896129	chr1:63156450	NA	-0.44	-6.85	-0.35	3.55e-11	Triglyceride levels;
CRC	cis	rs10924970	0.874	rs6681842	chr1:235332555	G/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.8	0.3	1.58e-8	Asthma;
CRC	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.66	-8.36	-0.42	1.81e-15	Waist circumference adjusted for body mass index;
CRC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.57	6.39	0.33	5.75e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.44	6.13	0.32	2.53e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg17298326	chr8:142245477	NA	-0.37	-5.63	-0.3	3.96e-8	Immature fraction of reticulocytes;
CRC	cis	rs11958404	0.860	rs11135023	chr5:157420082	G/T	cg05962755	chr5:157440814	NA	0.77	11.37	0.53	1.74e-25	IgG glycosylation;
CRC	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.53	6.15	0.32	2.21e-9	Blood protein levels;
CRC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.71	10.9	0.51	8.17e-24	Corneal astigmatism;
CRC	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg25457927	chr22:38595422	NA	-0.32	-6.25	-0.33	1.28e-9	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg15445000	chr17:37608096	MED1	0.32	5.67	0.3	3.06e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs4664293	0.867	rs34795915	chr2:160588931	A/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg22349387	chr12:9600060	DDX12	-0.36	-5.66	-0.3	3.26e-8	Breast size;
CRC	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg18646521	chr2:111875858	NA	0.37	5.85	0.31	1.19e-8	Chronic lymphocytic leukemia;
CRC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg10431340	chr1:161279108	MPZ	-0.52	-6.78	-0.35	5.55e-11	Rheumatoid arthritis;
CRC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-12.24	-0.56	1.17e-28	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg21747405	chr11:67723411	NA	-0.49	-6.32	-0.33	8.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-8.2	-0.41	5.32e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.77	-9.05	-0.45	1.31e-17	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.74	10.47	0.5	2.54e-22	Blood metabolite levels;
CRC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.76	12.12	0.56	3.36e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg15468180	chr1:107600409	PRMT6	-0.38	-5.99	-0.31	5.44e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-10.9	-0.51	8.16e-24	Motion sickness;
CRC	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1572438	0.811	rs6916756	chr6:880467	G/A	cg21062780	chr6:887772	NA	0.41	6.67	0.35	1.09e-10	Aging;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21126573	chr17:7755257	KDM6B	0.44	6.15	0.32	2.25e-9	Response to antipsychotic treatment;
CRC	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.5	-0.34	3.05e-10	Coronary artery disease;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg12172441	chr6:28176163	NA	0.45	6.55	0.34	2.16e-10	Cardiac Troponin-T levels;
CRC	cis	rs10503871	0.967	rs2294085	chr8:30436779	C/T	cg26383811	chr8:30366931	RBPMS	0.45	7.39	0.38	1.24e-12	Metabolite levels  (X-11787);
CRC	trans	rs2303319	0.504	rs16846047	chr2:162561946	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.64	8.83	0.44	6.42e-17	Uric acid levels;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg15786705	chr6:28176104	NA	0.49	7.03	0.36	1.18e-11	Parkinson's disease;
CRC	cis	rs2179367	0.959	rs237034	chr6:149711862	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.0	-0.31	5.23e-9	Dupuytren's disease;
CRC	cis	rs41271951	0.512	rs12058128	chr1:151106113	C/T	cg11822372	chr1:151115635	SEMA6C	-0.72	-5.81	-0.31	1.46e-8	Blood protein levels;
CRC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.62	-0.34	1.47e-10	Schizophrenia;
CRC	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.31	0.37	2.07e-12	Lymphocyte percentage of white cells;
CRC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg25456477	chr12:86230367	RASSF9	0.32	5.63	0.3	3.86e-8	Major depressive disorder;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08219700	chr8:58056026	NA	0.53	6.09	0.32	3.21e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7243821	0.847	rs2187412	chr18:52704561	C/T	cg16669619	chr18:52630472	NA	-0.43	-6.4	-0.33	5.2e-10	Chin dimples;
CRC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	trans	rs4276421	0.806	rs6414906	chr5:45406321	T/C	cg04793272	chr11:119020941	ABCG4	-0.37	-6.03	-0.32	4.31e-9	P wave duration;
CRC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.27	0.49	1.24e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.94	0.4	3.26e-14	Height;
CRC	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.2	-0.37	4.18e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs534126	0.813	rs526867	chr7:142904427	G/A	cg04039957	chr7:143013207	CLCN1	0.35	6.07	0.32	3.58e-9	Cancer;
CRC	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg18646521	chr2:111875858	NA	0.38	5.99	0.31	5.36e-9	Chronic lymphocytic leukemia;
CRC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.51	8.11	0.41	1.01e-14	Red blood cell count;
CRC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.7	0.54	1.16e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg15786705	chr6:28176104	NA	0.47	6.9	0.36	2.66e-11	Cardiac Troponin-T levels;
CRC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.57	-6.62	-0.34	1.5e-10	Vitiligo;
CRC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.33	1.26e-9	Heart rate;
CRC	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.46	7.55	0.38	4.46e-13	Schizophrenia;
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.59e-9	Bipolar disorder;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg25164649	chr6:28176230	NA	0.79	11.08	0.52	1.9e-24	Depression;
CRC	cis	rs2013441	0.866	rs12947950	chr17:20045176	C/T	cg13482628	chr17:19912719	NA	0.4	5.76	0.3	1.92e-8	Obesity-related traits;
CRC	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg01422370	chr2:73384389	NA	0.37	5.8	0.3	1.57e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg08501292	chr6:25962987	TRIM38	0.79	6.17	0.32	2e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6761276	0.649	rs10181720	chr2:113838608	A/G	cg09040174	chr2:113837401	NA	0.6	9.43	0.46	7.69e-19	Protein quantitative trait loci;
CRC	cis	rs7932354	0.537	rs3816614	chr11:46890165	C/T	cg19486271	chr11:47235900	DDB2	-0.42	-6.34	-0.33	7.49e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9891119	0.602	rs1905340	chr17:40520390	C/A	cg06270615	chr17:40516068	STAT3	-0.34	-7.18	-0.37	4.65e-12	Multiple sclerosis;Crohn's disease;
CRC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.41	6.75	0.35	6.67e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.32	-5.62	-0.3	4.17e-8	Pneumonia;
CRC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.13	-0.71	2e-51	Height;
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.47	-6.59	-0.34	1.73e-10	Height;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg15845792	chr6:28175446	NA	0.97	13.03	0.58	1.43e-31	Depression;
CRC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg01941586	chr1:40203715	PPIE	-0.45	-6.21	-0.32	1.59e-9	Blood protein levels;
CRC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.97	-0.44	2.35e-17	Aortic root size;
CRC	cis	rs62432291	0.614	rs452112	chr6:159658028	A/G	cg14500486	chr6:159655392	FNDC1	-0.75	-10.12	-0.49	3.83e-21	Joint mobility (Beighton score);
CRC	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.19	0.59	3.46e-32	Hip circumference;
CRC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.51	5.63	0.3	3.96e-8	Vitiligo;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg15383120	chr6:291909	DUSP22	-0.5	-7.04	-0.36	1.15e-11	Menopause (age at onset);
CRC	cis	rs720844	0.748	rs6746352	chr2:149352353	A/G	cg09247360	chr2:149335327	NA	0.57	6.42	0.33	4.65e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg05585544	chr11:47624801	NA	-0.53	-9.45	-0.46	6.77e-19	Subjective well-being;
CRC	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg19418318	chr19:17219073	MYO9B	0.51	8.79	0.44	8.54e-17	Reticulocyte fraction of red cells;
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.72	-0.51	3.45e-23	Intelligence (multi-trait analysis);
CRC	cis	rs926938	0.557	rs6667218	chr1:115238982	G/A	cg12756093	chr1:115239321	AMPD1	-0.67	-9.77	-0.47	5.62e-20	Autism;
CRC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.62	-0.39	2.82e-13	Neuroticism;
CRC	cis	rs3824347	0.839	rs7857510	chr9:77625711	A/G	cg01251476	chr9:77566080	C9orf40	0.36	5.61	0.3	4.25e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs7707921	0.881	rs2407153	chr5:81555328	T/G	cg17942617	chr5:81327376	ATG10	-0.38	-5.71	-0.3	2.55e-8	Breast cancer;
CRC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.51	7.38	0.38	1.32e-12	Primary sclerosing cholangitis;
CRC	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.98	0.31	5.94e-9	Aortic root size;
CRC	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.38	-5.84	-0.31	1.27e-8	Cardiovascular disease risk factors;
CRC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.79	-0.35	5.16e-11	Type 2 diabetes;
CRC	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.68	-7.45	-0.38	8.34e-13	Axial length;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19483816	chr5:180670343	GNB2L1;SNORD95;SNORD96A	0.43	5.97	0.31	6.23e-9	Survival in pancreatic cancer;
CRC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.15	0.32	2.19e-9	Hair morphology;
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.99	-0.4	2.25e-14	Total body bone mineral density;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg02683197	chr6:28174875	NA	0.88	12.35	0.56	4.59e-29	Depression;
CRC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg02741985	chr17:80059408	CCDC57	0.44	7.17	0.37	5.01e-12	Life satisfaction;
CRC	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	8.25	0.41	3.96e-15	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.82	-0.4	7.04e-14	Gut microbiome composition (summer);
CRC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.61	0.57	5.01e-30	Platelet count;
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg22687807	chr8:143858763	LYNX1	0.51	9.17	0.45	5.35e-18	Urinary tract infection frequency;
CRC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.55	7.6	0.39	3.08e-13	Bronchopulmonary dysplasia;
CRC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.66e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14287603	chr2:120771169	EPB41L5	0.44	6.58	0.34	1.83e-10	Response to antipsychotic treatment;
CRC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.58	7.57	0.39	3.82e-13	Multiple sclerosis;
CRC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.47e-10	Prostate cancer;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg06872519	chr11:6947619	ZNF215	0.58	5.79	0.3	1.68e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.42	-8.07	-0.41	1.3e-14	Ulcerative colitis;
CRC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.51	7.43	0.38	9.67e-13	Blood protein levels;
CRC	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg08823186	chr16:347294	AXIN1	0.49	7.57	0.39	3.72e-13	Morning vs. evening chronotype;
CRC	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.85	0.35	3.61e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.46	-6.34	-0.33	7.78e-10	Red blood cell count;
CRC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.9	-0.36	2.69e-11	Morning vs. evening chronotype;
CRC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	10.72	0.51	3.48e-23	Motion sickness;
CRC	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.33	6.64	0.34	1.29e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CRC	trans	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg02936872	chr9:99801550	CTSL2	0.48	6.18	0.32	1.85e-9	Iron status biomarkers;
CRC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.09	-0.36	8.06e-12	Life satisfaction;
CRC	cis	rs1124376	1.000	rs9828701	chr3:20149203	A/G	cg05072819	chr3:20081367	KAT2B	0.48	5.8	0.3	1.57e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.57e-16	Chronic sinus infection;
CRC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.45	-0.34	3.88e-10	Morning vs. evening chronotype;
CRC	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg09873164	chr1:152488093	CRCT1	0.37	6.04	0.32	4.17e-9	Hair morphology;
CRC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.45	-6.37	-0.33	6.54e-10	Platelet distribution width;
CRC	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.63	7.62	0.39	2.71e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.95	-0.52	5.2e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12172441	chr6:28176163	NA	0.54	6.99	0.36	1.58e-11	Parkinson's disease;
CRC	cis	rs7705042	0.865	rs12655465	chr5:141522213	C/T	cg08523384	chr5:141488047	NDFIP1	-0.31	-5.66	-0.3	3.27e-8	Asthma;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg15786705	chr6:28176104	NA	0.62	8.87	0.44	4.89e-17	Parkinson's disease;
CRC	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg20636351	chr8:55087400	NA	-0.33	-5.86	-0.31	1.11e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg05585544	chr11:47624801	NA	-0.61	-10.85	-0.51	1.22e-23	Subjective well-being;
CRC	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.4	-6.18	-0.32	1.86e-9	Menopause (age at onset);
CRC	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.53	0.34	2.45e-10	Neuroticism;
CRC	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg20885578	chr2:198174922	NA	-0.39	-6.28	-0.33	1.09e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2415984	0.622	rs61993294	chr14:46932466	C/G	cg14871534	chr14:47121158	RPL10L	-0.43	-6.15	-0.32	2.22e-9	Number of children ever born;
CRC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.2	-0.32	1.68e-9	Alzheimer's disease (late onset);
CRC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.62	7.6	0.39	3.21e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	7.15	0.37	5.79e-12	Lymphocyte counts;
CRC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.59	8.09	0.41	1.16e-14	Lung cancer;
CRC	cis	rs2282802	0.685	rs6580515	chr5:139698110	A/C	cg26211634	chr5:139558579	C5orf32	-0.43	-7.11	-0.36	7.38e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.54	0.6	1.63e-33	Menarche (age at onset);
CRC	cis	rs2625529	0.775	rs16956273	chr15:72117102	C/T	cg16672083	chr15:72433130	SENP8	-0.44	-6.32	-0.33	8.57e-10	Red blood cell count;
CRC	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	21.5	0.76	1.18e-64	Colorectal cancer;
CRC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	10.74	0.51	2.78e-23	Motion sickness;
CRC	cis	rs883565	0.684	rs811971	chr3:39168283	C/T	cg01426195	chr3:39028469	NA	-0.4	-5.94	-0.31	7.06e-9	Handedness;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-8.48	-0.42	7.63e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.68	7.24	0.37	3.18e-12	Axial length;
CRC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.61	-11.54	-0.54	4.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.39	5.75	0.3	2.01e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs59104589	0.617	rs62186409	chr2:242235710	C/A	cg19488206	chr2:242435732	STK25	0.47	6.43	0.33	4.43e-10	Fibrinogen levels;
CRC	cis	rs282587	0.569	rs282601	chr13:113392619	A/G	cg04656015	chr13:113407548	ATP11A	0.63	7.79	0.39	8.78e-14	Glycated hemoglobin levels;
CRC	cis	rs73206853	0.841	rs73206845	chr12:110660556	T/C	cg12870014	chr12:110450643	ANKRD13A	0.8	7.8	0.39	8.42e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.46	6.8	0.35	4.81e-11	Crohn's disease;
CRC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	10.95	0.52	5.48e-24	Mean corpuscular hemoglobin;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04529602	chr19:14228303	PRKACA	0.43	6.21	0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.43	6.19	0.32	1.79e-9	Body mass index;
CRC	cis	rs9311676	0.656	rs4399910	chr3:58389809	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg13385794	chr1:248469461	NA	-0.34	-5.84	-0.31	1.24e-8	Common traits (Other);
CRC	cis	rs2708240	0.689	rs2710114	chr7:147598021	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.41	-5.99	-0.31	5.52e-9	QT interval (drug interaction);
CRC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.7	12.13	0.56	3.16e-28	Cancer;
CRC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.84	0.63	1.66e-38	Lymphocyte percentage of white cells;
CRC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.68	-0.47	1.13e-19	Intelligence (multi-trait analysis);
CRC	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg27395922	chr11:50257633	LOC441601	0.48	6.15	0.32	2.26e-9	Intraocular pressure;
CRC	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg23650765	chr1:12612165	NA	0.31	5.95	0.31	6.91e-9	Optic cup area;
CRC	trans	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg17903999	chr18:56338584	MALT1	-0.4	-6.69	-0.35	9.69e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.99	21.36	0.76	4.12e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-5.67	-0.3	3.16e-8	Obesity (extreme);
CRC	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.34	-6.92	-0.36	2.4e-11	Cutaneous nevi;
CRC	trans	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg26043149	chr18:55253948	FECH	-0.55	-7.79	-0.39	8.98e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs10411161	1.000	rs8108477	chr19:52364902	C/T	cg22319618	chr22:45562946	NUP50	-0.52	-6.05	-0.32	3.84e-9	Breast cancer;
CRC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22133161	chr19:49891603	CCDC155	0.53	7.17	0.37	4.85e-12	Multiple sclerosis;
CRC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.43	6.52	0.34	2.58e-10	Menarche (age at onset);
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg00042356	chr1:8021962	PARK7	-0.53	-6.21	-0.32	1.63e-9	Inflammatory bowel disease;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg20512303	chr5:131592959	PDLIM4	0.42	7.23	0.37	3.37e-12	Breast cancer;
CRC	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.68	-0.39	1.89e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.31	0.33	9.14e-10	Tonsillectomy;
CRC	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.28	6.07	0.32	3.46e-9	Educational attainment (years of education);
CRC	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	5.75	0.3	2.08e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.5	6.64	0.34	1.29e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.95	0.31	6.86e-9	Renal function-related traits (BUN);
CRC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.68e-17	Aortic root size;
CRC	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg11887960	chr12:57824829	NA	0.68	7.14	0.37	6.05e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	13.76	0.6	2.48e-34	Smoking behavior;
CRC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg00933542	chr6:150070202	PCMT1	-0.32	-6.18	-0.32	1.94e-9	Lung cancer;
CRC	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.48	0.38	6.8e-13	Coffee consumption (cups per day);
CRC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.69	9.01	0.44	1.75e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg02106180	chr16:845767	CHTF18	0.57	9.13	0.45	7.36e-18	Mean corpuscular volume;
CRC	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	9.6	0.47	2.17e-19	Fuchs's corneal dystrophy;
CRC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg16102536	chr7:156981717	UBE3C	-0.4	-6.8	-0.35	4.8e-11	Body mass index;
CRC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.52	7.47	0.38	7.14e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs55788414	0.932	rs9921748	chr16:81181783	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs2292864	0.764	rs1969269	chr17:45335537	C/A	cg18085866	chr17:45331354	ITGB3	-0.64	-6.08	-0.32	3.3e-9	Left atrial antero-posterior diameter;
CRC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.78	0.47	5.53e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg18016565	chr1:150552671	MCL1	-0.47	-7.2	-0.37	4.11e-12	Tonsillectomy;
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg20607798	chr8:58055168	NA	0.5	5.77	0.3	1.84e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.68	11.07	0.52	1.95e-24	Prudent dietary pattern;
CRC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg11843238	chr5:131593191	PDLIM4	0.35	5.61	0.3	4.3e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.07	0.71	3.39e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg26762873	chr11:5879799	OR52E8	0.38	6.1	0.32	2.91e-9	DNA methylation (variation);
CRC	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.6	-6.4	-0.33	5.25e-10	Coronary artery disease;
CRC	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.73	-10.84	-0.51	1.26e-23	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.43	6.87	0.35	3.18e-11	Resting heart rate;
CRC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.53	-8.62	-0.43	2.95e-16	Huntington's disease progression;
CRC	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.59	0.47	2.32e-19	Type 2 diabetes;
CRC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.54	-8.12	-0.41	9.54e-15	Blood protein levels;
CRC	cis	rs6735179	0.688	rs2382564	chr2:1763701	A/G	cg19300414	chr2:1746591	PXDN	0.35	6.15	0.32	2.22e-9	Response to antipsychotic treatment;
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.34	-0.33	7.78e-10	Total body bone mineral density;
CRC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.49	-9.29	-0.46	2.13e-18	Reticulocyte fraction of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00006032	chr14:66974439	GPHN	0.44	6.25	0.33	1.29e-9	Response to antipsychotic treatment;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg08989290	chr16:615782	NHLRC4	0.48	9.21	0.45	3.88e-18	Height;
CRC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-1.02	-13.01	-0.58	1.61e-31	Vitiligo;
CRC	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg09476006	chr5:138032270	NA	0.43	6.5	0.34	3.03e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11212617	0.905	rs425538	chr11:108219339	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.92	0.31	8.19e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs802075	1.000	rs802070	chr6:49656358	A/G	cg20364632	chr6:49636226	NA	-0.37	-5.95	-0.31	6.7e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg26587870	chr6:27730563	NA	-0.6	-5.98	-0.31	5.78e-9	Breast cancer;
CRC	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-7.2	-0.37	4.1e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.65	-0.3	3.44e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.65	8.29	0.42	2.83e-15	Nonalcoholic fatty liver disease;
CRC	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	15.31	0.65	2.51e-40	Mean corpuscular hemoglobin;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.48	-9.42	-0.46	8.17e-19	Longevity;Endometriosis;
CRC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.66	11.38	0.53	1.62e-25	Brugada syndrome;
CRC	cis	rs4363385	0.747	rs1611759	chr1:152957439	T/G	cg25856811	chr1:152973957	SPRR3	-0.28	-7.65	-0.39	2.18e-13	Inflammatory skin disease;
CRC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.6	8.84	0.44	5.75e-17	Morning vs. evening chronotype;
CRC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.42	-0.5	3.73e-22	Chronic sinus infection;
CRC	cis	rs35000415	0.938	rs12539476	chr7:128657483	T/C	cg19972273	chr7:128594194	NA	0.68	6.32	0.33	8.52e-10	Systemic lupus erythematosus;
CRC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.61	9.04	0.45	1.41e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.91	-18.14	-0.71	1.81e-51	Height;
CRC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg14458575	chr2:238380390	NA	0.54	7.09	0.36	8.5e-12	Prostate cancer;
CRC	cis	rs11212617	0.967	rs4237579	chr11:108279201	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.67	0.35	1.07e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.89	-0.36	2.82e-11	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.63	10.79	0.51	1.96e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.39	-0.33	5.58e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.67	9.7	0.47	9.69e-20	Menarche (age at onset);
CRC	cis	rs6564851	0.545	rs12149068	chr16:81252903	T/G	cg00908271	chr16:81254010	PKD1L2	-0.37	-5.96	-0.31	6.32e-9	Carotenoid and tocopherol levels;
CRC	cis	rs9462027	0.628	rs1125340	chr6:34786408	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	16.4	0.67	1.4e-44	Lymphocyte percentage of white cells;
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.79	-0.58	1.13e-30	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21411757	chr12:93771484	NUDT4;NUDT4P1	0.48	6.17	0.32	1.99e-9	Thyroid stimulating hormone;
CRC	trans	rs10242455	0.571	rs45532337	chr7:99310319	A/G	cg09045935	chr12:6379348	NA	0.78	6.48	0.34	3.42e-10	Blood metabolite levels;
CRC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.35	7.08	0.36	8.53e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg22834771	chr12:69754056	YEATS4	-0.41	-5.9	-0.31	9.25e-9	Blood protein levels;
CRC	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.53	8.51	0.42	6.44e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.95	0.4	3e-14	Platelet count;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12273811	chr6:28175739	NA	0.63	8.63	0.43	2.64e-16	Parkinson's disease;
CRC	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-6.89	-0.36	2.92e-11	Body mass index;
CRC	cis	rs12044355	0.927	rs17748239	chr1:231834901	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.81	-0.35	4.68e-11	Alzheimer's disease;
CRC	trans	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.11	-0.32	2.88e-9	Aortic root size;
CRC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.45	-6.16	-0.32	2.13e-9	Gut microbiome composition (summer);
CRC	cis	rs910187	0.678	rs3818008	chr20:45816488	C/T	cg27589058	chr20:45804311	EYA2	-0.37	-7.12	-0.37	6.7e-12	Migraine;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg25164649	chr6:28176230	NA	0.67	7.56	0.38	4.17e-13	Parkinson's disease;
CRC	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-7.35	-0.38	1.62e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.73	11.26	0.53	4.43e-25	Intelligence (multi-trait analysis);
CRC	cis	rs2257205	0.667	rs8070007	chr17:56709169	A/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.79	-0.3	1.62e-8	Pancreatic cancer;
CRC	cis	rs7680126	0.633	rs2868937	chr4:10303081	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.58	-0.34	1.82e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.84	-0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	13.81	0.61	1.55e-34	Platelet count;
CRC	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.69	-9.02	-0.45	1.65e-17	Blood pressure (smoking interaction);
CRC	trans	rs4869931	0.929	rs59466561	chr6:151005119	C/T	cg01367992	chr1:160766535	LY9	0.37	6.03	0.32	4.38e-9	Systolic blood pressure in sickle cell anemia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05002732	chr11:19262474	E2F8	0.42	6.03	0.32	4.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.52	9.19	0.45	4.43e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.45	19.88	0.74	2.43e-58	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg13468214	chr4:1046988	NA	0.34	5.78	0.3	1.72e-8	Recombination rate (males);
CRC	cis	rs13064447	0.817	rs73022939	chr3:12762264	G/A	cg07775309	chr3:12595852	NA	0.37	5.94	0.31	7.18e-9	Major depression and alcohol dependence;
CRC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.02	0.4	1.83e-14	Platelet count;
CRC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.95	0.44	2.58e-17	Lymphocyte counts;
CRC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.45	-8.24	-0.41	4.21e-15	Reticulocyte fraction of red cells;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13906749	chr12:120933893	DYNLL1	-0.42	-6.31	-0.33	8.95e-10	Myopia (pathological);
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg02683197	chr6:28174875	NA	0.75	11.02	0.52	3.04e-24	Cardiac Troponin-T levels;
CRC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg13798780	chr7:105162888	PUS7	0.42	5.67	0.3	3.15e-8	Bipolar disorder (body mass index interaction);
CRC	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.73	9.69	0.47	1.03e-19	Coronary artery disease;
CRC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.93	13.32	0.59	1.11e-32	Breast cancer;
CRC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.56	8.02	0.4	1.87e-14	Melanoma;
CRC	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.45	-6.43	-0.33	4.49e-10	Intelligence (multi-trait analysis);
CRC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.65	-8.41	-0.42	1.28e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.98	-0.31	5.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6973256	0.637	rs1362739	chr7:133430934	C/A	cg10665199	chr7:133106180	EXOC4	0.45	7.09	0.36	8.05e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.67	9.13	0.45	7.3e-18	Breast cancer;
CRC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.64	-6.57	-0.34	1.97e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg17321639	chr7:2759063	NA	-0.51	-6.7	-0.35	9.26e-11	Height;
CRC	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.57	-8.06	-0.41	1.43e-14	Triglycerides;
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg20295408	chr7:1910781	MAD1L1	-0.37	-5.62	-0.3	3.99e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg08314208	chr16:67682810	RLTPR	-0.69	-7.43	-0.38	9.17e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-7.92	-0.4	3.61e-14	Major depressive disorder;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg01843034	chr6:37503916	NA	-0.46	-8.54	-0.43	4.93e-16	Cognitive performance;
CRC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.57	-7.86	-0.4	5.37e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg14530993	chr4:882597	GAK	0.75	6.88	0.35	3.02e-11	Parkinson's disease;
CRC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.49	-7.33	-0.37	1.81e-12	Height;
CRC	cis	rs883565	0.569	rs7638329	chr3:39020408	T/C	cg01426195	chr3:39028469	NA	-0.44	-7.27	-0.37	2.58e-12	Handedness;
CRC	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.56	8.35	0.42	1.97e-15	Blood protein levels;
CRC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg11766577	chr21:47581405	C21orf56	0.39	5.88	0.31	1.03e-8	Testicular germ cell tumor;
CRC	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.43	5.93	0.31	7.58e-9	Response to bleomycin (chromatid breaks);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19875216	chr3:133524841	SRPRB	0.49	6.9	0.36	2.61e-11	Response to antipsychotic treatment;
CRC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg19635926	chr16:89946313	TCF25	0.65	6.21	0.32	1.55e-9	Skin colour saturation;
CRC	cis	rs524281	0.731	rs10791838	chr11:65789854	T/G	cg16950941	chr11:66035639	RAB1B	-0.54	-5.96	-0.31	6.59e-9	Electroencephalogram traits;
CRC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.61e-20	Eye color traits;
CRC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.57	9.61	0.47	2.02e-19	Tumor biomarkers;
CRC	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.75	-7.68	-0.39	1.83e-13	Cholesterol, total;
CRC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg15269541	chr15:43626905	ADAL	-0.49	-5.9	-0.31	9.27e-9	Lung cancer in ever smokers;
CRC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg10253484	chr15:75165896	SCAMP2	-0.41	-5.93	-0.31	7.78e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.13	-0.37	6.43e-12	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-13.38	-0.59	6.93e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.44	-6.32	-0.33	8.53e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs2982552	0.844	rs3020343	chr6:152054363	C/T	cg22157087	chr6:152012887	ESR1	0.38	5.86	0.31	1.15e-8	Bone properties (heel);
CRC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.45	0.5	2.86e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.65	-0.34	1.26e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	7.69	0.39	1.71e-13	Intelligence (multi-trait analysis);
CRC	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.58	-7.34	-0.38	1.7e-12	Platelet distribution width;
CRC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.5	-9.15	-0.45	6.08e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg18833306	chr6:118973337	C6orf204	0.44	5.66	0.3	3.38e-8	Diastolic blood pressure;
CRC	cis	rs9359856	0.957	rs9362666	chr6:90310345	T/C	cg13799429	chr6:90582589	CASP8AP2	0.42	6.01	0.31	5.04e-9	Bipolar disorder;
CRC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg03609598	chr5:56110824	MAP3K1	-0.76	-8.73	-0.43	1.31e-16	Initial pursuit acceleration;
CRC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.72	-11.45	-0.53	8.76e-26	Tonsillectomy;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.45	6.77	0.35	5.78e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg06470822	chr6:28175283	NA	0.77	8.09	0.41	1.18e-14	Depression;
CRC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg07507251	chr3:52567010	NT5DC2	0.4	6.22	0.32	1.53e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg25356066	chr3:128598488	ACAD9	0.39	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg12273811	chr6:28175739	NA	0.67	10.11	0.49	4.27e-21	Cardiac Troponin-T levels;
CRC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-16.27	-0.67	4.42e-44	Height;
CRC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.47	-7.66	-0.39	2.05e-13	Iron status biomarkers;
CRC	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg09659197	chr4:152720779	NA	0.35	6.19	0.32	1.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg06494592	chr3:125709126	NA	-0.57	-6.67	-0.35	1.08e-10	Blood pressure (smoking interaction);
CRC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.09	13.45	0.6	3.5e-33	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-1.04	-20.43	-0.75	1.71e-60	Headache;
CRC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06505273	chr16:24850292	NA	-0.52	-6.68	-0.35	1.01e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg24505687	chr6:33548425	BAK1	0.3	5.91	0.31	8.73e-9	Platelet count;
CRC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs4728302	0.594	rs12533206	chr7:133700251	C/T	cg03336402	chr7:133662267	EXOC4	-0.51	-8.06	-0.41	1.44e-14	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.55	-7.66	-0.39	2.1e-13	Corneal structure;
CRC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.36	0.38	1.5e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.55	7.59	0.39	3.25e-13	Longevity;Endometriosis;
CRC	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.42	6.06	0.32	3.66e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02018176	chr4:1364513	KIAA1530	0.47	7.68	0.39	1.78e-13	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.68	-0.43	1.85e-16	Aortic root size;
CRC	cis	rs7945718	0.622	rs4643058	chr11:12689454	C/T	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.95e-12	Educational attainment (years of education);
CRC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.61e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	8.35	0.42	1.93e-15	Lewy body disease;
CRC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.4	-0.42	1.33e-15	Monocyte count;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.7	9.56	0.47	2.77e-19	Menarche (age at onset);
CRC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.48	-7.91	-0.4	3.85e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg05623727	chr3:50126028	RBM5	-0.44	-7.39	-0.38	1.23e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.61	9.79	0.48	4.91e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.53	8.76	0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.49	-7.85	-0.4	6e-14	Monocyte count;
CRC	cis	rs970548	0.955	rs10900223	chr10:46021631	T/C	cg15590007	chr10:45870220	ALOX5	0.5	6.38	0.33	6.07e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg26870460	chr11:6947759	ZNF215	0.58	6.05	0.32	3.85e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.48	-6.74	-0.35	7.05e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.56	8.27	0.41	3.46e-15	Schizophrenia;
CRC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.52	-0.38	5.33e-13	Height;
CRC	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg09141835	chr16:88988174	CBFA2T3	-0.27	-5.9	-0.31	8.91e-9	Social autistic-like traits;
CRC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg06882758	chr19:58662330	ZNF329	0.74	7.78	0.39	9.17e-14	Cholesterol, total;
CRC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-7.72	-0.39	1.43e-13	Total body bone mineral density;
CRC	cis	rs7246967	0.673	rs7247191	chr19:22899585	C/T	cg08271804	chr19:22816896	ZNF492	0.36	5.66	0.3	3.23e-8	Bronchopulmonary dysplasia;
CRC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19046167	chr17:80928561	B3GNTL1	0.48	6.75	0.35	6.84e-11	Glycated hemoglobin levels;
CRC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.82	-0.31	1.4e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg23112188	chr14:24563095	PCK2	-0.36	-7.02	-0.36	1.29e-11	IgG glycosylation;
CRC	cis	rs10795061	0.576	rs12219804	chr10:3710626	C/T	cg22632523	chr10:3711048	NA	0.45	6.24	0.33	1.35e-9	Subjective well-being;
CRC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.18	-0.32	1.92e-9	IgG glycosylation;
CRC	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.75	-9.37	-0.46	1.18e-18	Blood protein levels;
CRC	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.59	8.33	0.42	2.27e-15	Osteoporosis;
CRC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.88	-14.91	-0.63	9.26e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg00646200	chr1:148855367	NA	-0.35	-6.38	-0.33	5.95e-10	Hip geometry;
CRC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.3	0.37	2.17e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.53	0.34	2.57e-10	Bipolar disorder;
CRC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.58	-8.26	-0.41	3.67e-15	Height;
CRC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.51	7.92	0.4	3.71e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg08888203	chr3:10149979	C3orf24	0.71	8.58	0.43	3.91e-16	Alzheimer's disease;
CRC	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.43	-6.33	-0.33	7.96e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg04545296	chr12:48745243	ZNF641	0.36	6.19	0.32	1.81e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.5	7.09	0.36	8.42e-12	Schizophrenia;
CRC	trans	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.87	-0.35	3.17e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6123683	0.702	rs1998190	chr20:55822649	A/C	cg13236649	chr20:55835020	BMP7	-0.45	-7.05	-0.36	1.08e-11	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.97	-0.36	1.69e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.98	-19.36	-0.73	2.81e-56	Height;
CRC	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.6	10.39	0.5	4.55e-22	Asthma (childhood onset);
CRC	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.07e-8	Type 2 diabetes;
CRC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.43	5.93	0.31	7.62e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-5.74	-0.3	2.17e-8	Yeast infection;
CRC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.46	-0.34	3.86e-10	Tonsillectomy;
CRC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.67	-0.39	2e-13	Total body bone mineral density;
CRC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.65	7.81	0.4	7.91e-14	Behavioural disinhibition (generation interaction);
CRC	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.64	-0.47	1.61e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.83	-0.31	1.32e-8	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg11693508	chr17:37793320	STARD3	0.54	7.06	0.36	1.02e-11	Neuroticism;
CRC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.57	9.15	0.45	6.06e-18	Height;
CRC	cis	rs4664293	0.867	rs3863924	chr2:160614758	A/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	trans	rs12699921	0.632	rs2723572	chr7:17888587	T/C	cg15753394	chr6:17282781	RBM24	-0.37	-6.17	-0.32	1.96e-9	Fibrinogen levels;
CRC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg00553149	chr7:99775558	STAG3;GPC2	0.25	5.89	0.31	9.29e-9	Coronary artery disease;
CRC	cis	rs10208940	0.764	rs7583649	chr2:68830939	T/C	cg12452813	chr2:68675892	NA	0.49	6.09	0.32	3.2e-9	Urate levels in lean individuals;
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg02475695	chr16:616220	NHLRC4	0.47	7.87	0.4	5.3e-14	Height;
CRC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.18	0.45	5.08e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.75	-13.79	-0.61	1.84e-34	Prostate cancer;
CRC	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.64	-9.35	-0.46	1.38e-18	Blood protein levels;
CRC	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.34	-5.86	-0.31	1.13e-8	Pneumonia;
CRC	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.72	-7.05	-0.36	1.07e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg26587870	chr6:27730563	NA	-0.5	-6.87	-0.35	3.14e-11	Breast cancer;
CRC	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.89	-11.6	-0.54	2.61e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6681460	1.000	rs10789210	chr1:67066030	G/A	cg02459107	chr1:67143332	SGIP1	0.47	8.18	0.41	6.4e-15	Presence of antiphospholipid antibodies;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17517709	chr10:18999145	NA	0.44	7.0	0.36	1.47e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.39	-0.46	1.02e-18	Prevalent atrial fibrillation;
CRC	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	19.99	0.74	9.58e-59	Metabolite levels;
CRC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.52	-8.36	-0.42	1.78e-15	Caffeine consumption;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg13770153	chr20:60521292	NA	-0.41	-6.17	-0.32	2.04e-9	Body mass index;
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10819733	chr22:24237672	NA	-0.35	-6.12	-0.32	2.63e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.46	6.68	0.35	1.02e-10	Menarche (age at onset);
CRC	cis	rs13315871	0.929	rs35007301	chr3:58230352	G/A	cg20936604	chr3:58311152	NA	-0.68	-6.59	-0.34	1.75e-10	Cholesterol, total;
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg02683197	chr6:28174875	NA	0.46	6.38	0.33	6.1e-10	Cardiac Troponin-T levels;
CRC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	0.94	11.39	0.53	1.51e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg17710535	chr19:10819994	QTRT1	0.44	6.54	0.34	2.3e-10	Inflammatory skin disease;
CRC	cis	rs4453791	0.769	rs4676585	chr3:38951040	A/T	cg02254461	chr3:39195904	CSRNP1	0.45	5.74	0.3	2.16e-8	Social communication problems;
CRC	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.49	6.85	0.35	3.61e-11	Coronary artery disease;
CRC	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.22	32.66	0.87	3.02e-105	Colorectal cancer;
CRC	cis	rs16852403	0.583	rs964993	chr1:178062359	G/A	cg00404053	chr1:178313656	RASAL2	0.62	7.93	0.4	3.56e-14	Childhood ear infection;
CRC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg04586622	chr2:25135609	ADCY3	0.55	10.34	0.5	6.73e-22	Body mass index;
CRC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg05623727	chr3:50126028	RBM5	0.45	7.6	0.39	3.11e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg13047869	chr3:10149882	C3orf24	0.52	7.37	0.38	1.35e-12	Alzheimer's disease;
CRC	cis	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg03623178	chr6:28175578	NA	0.79	6.36	0.33	6.62e-10	Depression;
CRC	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.75	-0.3	2.01e-8	Electroencephalogram traits;
CRC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.41	-5.95	-0.31	6.76e-9	Motion sickness;
CRC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.37	5.66	0.3	3.34e-8	Height;
CRC	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.08	-0.32	3.42e-9	Diastolic blood pressure;
CRC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.82	0.48	3.87e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg20936604	chr3:58311152	NA	-0.73	-7.0	-0.36	1.46e-11	Cholesterol, total;
CRC	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg16141378	chr3:129829833	LOC729375	0.4	6.09	0.32	3.07e-9	Joint mobility (Beighton score);
CRC	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg03805757	chr16:71968109	PKD1L3	-0.47	-5.97	-0.31	6.25e-9	Post bronchodilator FEV1;
CRC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg13119609	chr19:45449297	APOC2	0.31	5.81	0.3	1.5e-8	Blood protein levels;
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16400469	chr20:62339231	ARFRP1;ZGPAT	0.46	6.43	0.33	4.41e-10	Anxiety disorder;
CRC	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.53	-8.05	-0.41	1.56e-14	HDL cholesterol;
CRC	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg12046867	chr14:103022105	NA	0.42	6.16	0.32	2.16e-9	Platelet count;
CRC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.74e-21	Alzheimer's disease (late onset);
CRC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.71	10.91	0.52	7.37e-24	Corneal astigmatism;
CRC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12292205	chr6:26970375	C6orf41	-0.61	-6.9	-0.36	2.75e-11	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23812393	chr1:92949959	GFI1	0.39	6.29	0.33	1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg12365402	chr11:9010492	NRIP3	0.49	7.95	0.4	3.07e-14	Hemoglobin concentration;
CRC	cis	rs6534441	0.727	rs77899971	chr4:125419177	C/G	cg21609808	chr4:125404261	NA	0.45	6.38	0.33	6.04e-10	Major depressive disorder;
CRC	cis	rs6662572	0.737	rs56140667	chr1:46411715	T/C	cg08644498	chr1:46502608	NA	0.43	6.76	0.35	6.27e-11	Blood protein levels;
CRC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg04025307	chr7:1156635	C7orf50	0.67	7.14	0.37	5.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg00246817	chr9:123691163	NA	0.49	6.23	0.32	1.45e-9	Rheumatoid arthritis;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.42	-0.33	4.81e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.85	0.55	3.29e-27	Bone mineral density;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.29	-0.33	1.02e-9	Cognitive function;
CRC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.66	8.76	0.43	1.08e-16	Initial pursuit acceleration;
CRC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg01629716	chr15:45996671	NA	0.4	8.25	0.41	3.97e-15	Waist circumference;Weight;
CRC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg25985355	chr7:65971099	NA	0.5	5.84	0.31	1.28e-8	Diabetic kidney disease;
CRC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	6.05	0.32	3.84e-9	Renal function-related traits (BUN);
CRC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-5.62	-0.3	3.99e-8	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09936566	chr1:163292020	NUF2	0.45	6.29	0.33	1.01e-9	Response to antipsychotic treatment;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18301423	chr5:131593218	PDLIM4	0.45	8.33	0.42	2.22e-15	Acylcarnitine levels;
CRC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg03340356	chr1:67600835	NA	0.29	6.53	0.34	2.56e-10	Psoriasis;
CRC	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.55	7.51	0.38	5.44e-13	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.47	6.81	0.35	4.55e-11	Tonsillectomy;
CRC	trans	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.9	0.36	2.74e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.66	0.34	1.18e-10	Subjective well-being;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15598511	chr20:1447287	NSFL1C	0.43	6.0	0.31	5.14e-9	Anxiety disorder;
CRC	cis	rs12403795	0.527	rs17648533	chr1:150316576	A/G	cg17724175	chr1:150552817	MCL1	0.63	5.96	0.31	6.5e-9	Illicit drug use;
CRC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.48	-7.16	-0.37	5.17e-12	Morning vs. evening chronotype;
CRC	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-8.02	-0.4	1.91e-14	D-dimer levels;
CRC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.38	0.33	6.13e-10	Diabetic retinopathy;
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg04731861	chr2:219085781	ARPC2	-0.27	-5.81	-0.31	1.47e-8	Colorectal cancer;
CRC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.49	6.63	0.34	1.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.56	9.04	0.45	1.33e-17	Coronary artery disease;
CRC	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.22	-0.37	3.72e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.31	0.37	2.08e-12	Lung cancer;
CRC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg23609528	chr2:113191194	RGPD5;RGPD8	0.63	5.62	0.3	4.01e-8	Yeast infection;
CRC	cis	rs9303280	0.806	rs9303279	chr17:38073968	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.39	-6.17	-0.32	1.96e-9	Self-reported allergy;
CRC	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.63	7.83	0.4	6.75e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs728616	0.717	rs116884206	chr10:81990546	A/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-7.86	-0.4	5.42e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.83	-0.35	4.07e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.24	-0.33	1.32e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.93	0.36	2.18e-11	Height;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23161317	chr6:28129485	ZNF389	-0.44	-5.82	-0.31	1.38e-8	Depression;
CRC	cis	rs9648716	0.766	rs801158	chr7:140780955	A/G	cg10747023	chr7:140774559	NA	-0.46	-6.09	-0.32	3.1e-9	Type 2 diabetes;
CRC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.58	-8.91	-0.44	3.55e-17	Uric acid levels;
CRC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.29	-6.06	-0.32	3.63e-9	Homoarginine levels;
CRC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg08270630	chr22:50330655	NA	-0.41	-5.98	-0.31	5.85e-9	Schizophrenia;
CRC	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	10.38	0.5	4.9e-22	Exhaled nitric oxide output;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11297934	chr3:12705869	RAF1	-0.42	-6.33	-0.33	8.01e-10	Myopia (pathological);
CRC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.62	9.36	0.46	1.28e-18	Pancreatic cancer;
CRC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.88	-15.57	-0.65	2.54e-41	Body mass index;
CRC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.17	-0.45	5.32e-18	Alcohol dependence;
CRC	cis	rs10208712	0.505	rs4553834	chr2:4048065	A/G	cg00217080	chr2:4050767	NA	0.26	6.48	0.34	3.44e-10	Restless legs syndrome;
CRC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.5	-6.71	-0.35	8.75e-11	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13198984	chr17:80129470	CCDC57	0.43	7.61	0.39	2.95e-13	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06913287	chr2:18742029	RDH14	0.4	6.27	0.33	1.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.18	0.52	7.91e-25	Tonsillectomy;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.47	0.34	3.52e-10	Monocyte count;
CRC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.01	-0.31	4.81e-9	QT interval;
CRC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-7.52	-0.38	5.24e-13	Colorectal cancer;
CRC	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.22	-5.92	-0.31	7.94e-9	Type 2 diabetes;
CRC	cis	rs4728302	0.869	rs10253633	chr7:133590869	A/G	cg03336402	chr7:133662267	EXOC4	-0.44	-6.41	-0.33	4.91e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7804356	1.000	rs3801816	chr7:26881177	G/A	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.1e-8	Type 1 diabetes;
CRC	cis	rs4750440	0.637	rs2447010	chr10:14032115	T/C	cg00551146	chr10:14014579	FRMD4A	0.45	8.06	0.41	1.4e-14	Adiponectin levels;
CRC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.95	10.61	0.5	8.04e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.54	-8.98	-0.44	2.2e-17	Prudent dietary pattern;
CRC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.48	8.51	0.42	6.09e-16	Blood metabolite levels;
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg12326244	chr17:78078995	GAA	-0.38	-5.77	-0.3	1.87e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.52	7.77	0.39	1.02e-13	Coronary heart disease;
CRC	cis	rs9463078	0.715	rs9357459	chr6:44782562	C/T	cg25276700	chr6:44698697	NA	-0.27	-6.4	-0.33	5.22e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2398893	0.924	rs1539282	chr9:96827424	T/C	cg14459158	chr9:96720562	NA	0.43	7.18	0.37	4.71e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.7	10.81	0.51	1.71e-23	Corneal astigmatism;
CRC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.52	8.55	0.43	4.66e-16	Aortic root size;
CRC	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.63	-8.81	-0.44	7.29e-17	Type 2 diabetes;
CRC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg04731861	chr2:219085781	ARPC2	-0.3	-6.22	-0.32	1.47e-9	Colorectal cancer;
CRC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-16.78	-0.68	4.34e-46	Cognitive function;
CRC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	8.04e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02097616	chr17:62675921	NA	0.47	5.74	0.3	2.18e-8	QT interval;
CRC	cis	rs12936587	0.777	rs12951347	chr17:17534513	C/G	cg09796270	chr17:17721594	SREBF1	-0.42	-5.97	-0.31	6.09e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.07e-11	Common traits (Other);
CRC	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	13.6	0.6	9.52e-34	Colorectal cancer;
CRC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.48	-7.15	-0.37	5.52e-12	Motion sickness;
CRC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.57	10.33	0.49	7.36e-22	Total body bone mineral density;
CRC	cis	rs7605827	0.930	rs2111458	chr2:15598039	T/A	cg19274914	chr2:15703543	NA	0.4	5.97	0.31	6.3e-9	Educational attainment (years of education);
CRC	trans	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.12	-0.41	9.21e-15	Alcohol dependence;
CRC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.71	8.51	0.42	6.03e-16	Bipolar disorder;
CRC	cis	rs1528435	1.000	rs6727573	chr2:181522783	T/C	cg23363182	chr2:181467187	NA	-0.35	-5.66	-0.3	3.22e-8	Body mass index;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.61	-0.5	8.25e-23	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17094688	chr17:17380209	MED9	0.39	7.03	0.36	1.23e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.52	6.31	0.33	8.8e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-7.99	-0.4	2.38e-14	IgG glycosylation;
CRC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.66e-23	Aortic root size;
CRC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.66	-9.18	-0.45	4.99e-18	DNA methylation (variation);
CRC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg15147215	chr3:52552868	STAB1	-0.51	-8.24	-0.41	4.04e-15	Electroencephalogram traits;
CRC	cis	rs501120	0.925	rs1746049	chr10:44776310	C/T	cg09554077	chr10:44749378	NA	0.74	11.02	0.52	2.91e-24	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04763192	chr1:111889241	C1orf88	0.4	6.31	0.33	9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.15	-0.41	7.95e-15	Schizophrenia;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15560884	chr1:710097	NA	-0.38	-6.8	-0.35	4.91e-11	Interleukin-6 levels;
CRC	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.52	8.69	0.43	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg14074117	chr16:1909714	C16orf73	0.36	6.2	0.32	1.65e-9	Insulin-like growth factors;
CRC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.71	-10.15	-0.49	3.02e-21	Other erythrocyte phenotypes;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.65	10.53	0.5	1.5e-22	Height;
CRC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.61	-0.34	1.51e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.52	8.96	0.44	2.51e-17	Iron status biomarkers;
CRC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-5.78	-0.3	1.77e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.13	-0.32	2.52e-9	Alzheimer's disease (late onset);
CRC	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.38	-0.33	5.99e-10	Obesity-related traits;
CRC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.66	8.73	0.43	1.33e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.42	-8.02	-0.4	1.89e-14	Mean corpuscular volume;
CRC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.79	0.44	8.4e-17	Height;
CRC	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.78	13.78	0.6	2.06e-34	Multiple myeloma;
CRC	cis	rs6867913	0.951	rs4912799	chr5:141453720	G/C	cg08523384	chr5:141488047	NDFIP1	0.45	6.47	0.34	3.55e-10	Asthma;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg04969067	chr8:143858791	LYNX1	-0.41	-6.18	-0.32	1.9e-9	Urinary tract infection frequency;
CRC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.44	6.5	0.34	2.96e-10	Menopause (age at onset);
CRC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.67	-8.03	-0.4	1.7e-14	Menarche (age at onset);
CRC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.07	-0.72	3.93e-55	Height;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg08888203	chr3:10149979	C3orf24	0.55	6.75	0.35	6.79e-11	Alzheimer's disease;
CRC	cis	rs61996546	0.622	rs12900771	chr15:26835235	G/A	cg15066197	chr15:26874202	GABRB3	-0.41	-6.16	-0.32	2.07e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.32	5.91	0.31	8.45e-9	Pulse pressure;
CRC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.5	-7.63	-0.39	2.51e-13	Aortic root size;
CRC	cis	rs10751667	0.677	rs11246386	chr11:1044938	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.51	-6.72	-0.35	7.96e-11	Alzheimer's disease (late onset);
CRC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg18827107	chr12:86230957	RASSF9	0.45	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-18.9	-0.72	1.86e-54	Schizophrenia;
CRC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.76e-9	Multiple sclerosis;
CRC	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.69	-10.64	-0.51	6.41e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.52	7.14	0.37	6.06e-12	Schizophrenia;
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-9.75	-0.47	6.74e-20	Migraine;Coronary artery disease;
CRC	cis	rs6988985	0.626	rs6392	chr8:143956925	T/C	cg10324643	chr8:143916377	GML	0.4	6.62	0.34	1.46e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03792199	chr7:27702785	HIBADH	0.44	6.25	0.33	1.31e-9	Response to antipsychotic treatment;
CRC	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.37	0.38	1.39e-12	Calcium levels;
CRC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.6	7.26	0.37	2.73e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11904759	chr17:80656664	RAB40B	0.47	6.92	0.36	2.36e-11	Response to antipsychotic treatment;
CRC	cis	rs9427116	0.740	rs11264230	chr1:154608418	G/T	cg17218026	chr1:154582156	ADAR	0.63	10.22	0.49	1.74e-21	Blood protein levels;
CRC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.62	9.42	0.46	8.45e-19	Corneal astigmatism;
CRC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.65	0.47	1.4e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.44	5.83	0.31	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.44	0.46	7.12e-19	Cognitive test performance;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.69	-8.31	-0.42	2.49e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg25173405	chr17:45401733	C17orf57	-0.42	-6.22	-0.32	1.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.7	0.43	1.6e-16	Endometrial cancer;
CRC	cis	rs9925964	0.933	rs2359612	chr16:31103796	A/G	cg02466173	chr16:30829666	NA	-0.42	-5.75	-0.3	2.07e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11098699	0.821	rs13120866	chr4:124199293	A/G	cg09941581	chr4:124220074	SPATA5	0.41	5.95	0.31	6.87e-9	Mosquito bite size;
CRC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.69	8.13	0.41	9.09e-15	Hip circumference adjusted for BMI;
CRC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.82	0.51	1.51e-23	Motion sickness;
CRC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg27534772	chr1:16042836	PLEKHM2	0.52	10.5	0.5	2e-22	Systolic blood pressure;
CRC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.4	-0.33	5.29e-10	Aortic root size;
CRC	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.62	-10.51	-0.5	1.88e-22	Colorectal cancer;
CRC	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.36	-0.42	1.75e-15	Alcohol dependence;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg23750338	chr8:142222470	SLC45A4	0.36	6.05	0.32	4.03e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7215564	0.908	rs35918698	chr17:78683533	G/A	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.26e-9	Myopia (pathological);
CRC	trans	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg03041920	chr13:100310311	CLYBL	0.6	6.12	0.32	2.63e-9	Breast cancer;
CRC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.61e-11	Aortic root size;
CRC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg10756647	chr7:56101905	PSPH	0.73	7.68	0.39	1.79e-13	Diabetic kidney disease;
CRC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg23461800	chr14:103021989	NA	-0.7	-8.05	-0.41	1.57e-14	Platelet count;
CRC	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.63	0.43	2.76e-16	Mean corpuscular volume;
CRC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.44e-9	Homoarginine levels;
CRC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.62	9.32	0.46	1.75e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.44e-9	Homoarginine levels;
CRC	cis	rs35520189	0.591	rs6705432	chr2:113701824	C/T	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	8.87	0.44	4.91e-17	Schizophrenia;
CRC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.48	0.34	3.28e-10	Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21783428	chr6:3118692	BPHL	0.41	6.64	0.34	1.34e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.59	8.11	0.41	9.88e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9649465	0.902	rs10253850	chr7:123273095	T/C	cg03229431	chr7:123269106	ASB15	-0.43	-6.59	-0.34	1.72e-10	Migraine;
CRC	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.42	6.54	0.34	2.34e-10	Body mass index (alcohol intake interaction);
CRC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.69	0.63	6.23e-38	Lymphocyte percentage of white cells;
CRC	cis	rs834811	1.000	rs834811	chr7:135884571	A/G	cg01726295	chr7:135938950	NA	0.4	6.85	0.35	3.55e-11	Post-traumatic stress disorder;
CRC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg00343986	chr7:65444356	GUSB	0.43	6.26	0.33	1.21e-9	Aortic root size;
CRC	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.32	5.63	0.3	3.78e-8	Heart rate;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12172441	chr6:28176163	NA	0.69	9.19	0.45	4.69e-18	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03634887	chr16:66730948	CMTM4	0.49	6.85	0.35	3.75e-11	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg15845792	chr6:28175446	NA	1.0	13.28	0.59	1.67e-32	Depression;
CRC	cis	rs10046574	0.831	rs10227931	chr7:135084601	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.65	-0.34	1.23e-10	Eye color traits;
CRC	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.78	11.13	0.52	1.26e-24	Gout;
CRC	cis	rs12476592	1.000	rs12476592	chr2:63850098	G/C	cg10828910	chr2:63850056	LOC388955	-0.54	-6.26	-0.33	1.19e-9	Childhood ear infection;
CRC	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg12756093	chr1:115239321	AMPD1	0.56	8.32	0.42	2.42e-15	Autism;
CRC	cis	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg16876255	chr19:9731953	ZNF561	0.68	5.71	0.3	2.5e-8	Pursuit maintenance gain;
CRC	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.46	-6.66	-0.34	1.17e-10	Lung cancer;
CRC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16262614	chr3:133464971	TF	0.34	6.0	0.31	5.15e-9	Iron status biomarkers;
CRC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg25456477	chr12:86230367	RASSF9	-0.39	-6.54	-0.34	2.36e-10	Major depressive disorder;
CRC	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg26566898	chr11:117069891	TAGLN	0.39	6.99	0.36	1.51e-11	Blood protein levels;
CRC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg15269541	chr15:43626905	ADAL	-0.53	-5.8	-0.3	1.59e-8	Lung cancer in ever smokers;
CRC	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg05623727	chr3:50126028	RBM5	0.52	6.81	0.35	4.67e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.67	-7.47	-0.38	7.12e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.71	-0.35	8.37e-11	Total body bone mineral density;
CRC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.66	10.91	0.52	7.27e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	7.02	0.36	1.3e-11	Mean platelet volume;
CRC	trans	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.56	6.67	0.35	1.1e-10	Ulcerative colitis;
CRC	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.37	2.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.04	0.32	4.14e-9	Aortic root size;
CRC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.61	10.2	0.49	2.05e-21	Prudent dietary pattern;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.53	-9.62	-0.47	1.82e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.1e-16	Waist circumference;Weight;
CRC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.58	8.96	0.44	2.52e-17	Colorectal cancer;
CRC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
CRC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.13	14.52	0.62	2.9e-37	Uric acid levels;
CRC	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.36	6.67	0.35	1.09e-10	Panic disorder;
CRC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.61	9.13	0.45	7.15e-18	Acne (severe);
CRC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg05623727	chr3:50126028	RBM5	0.45	7.52	0.38	5.18e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03734322	chr17:1532856	SLC43A2	0.44	6.19	0.32	1.8e-9	Response to antipsychotic treatment;
CRC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg12573674	chr2:1569213	NA	-0.77	-8.03	-0.4	1.78e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.58	8.03	0.4	1.72e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg26061582	chr7:22766209	IL6	0.54	8.29	0.42	2.92e-15	Lung cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18231159	chr7:99214508	ZNF498	-0.4	-6.01	-0.31	4.87e-9	Myopia (pathological);
CRC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg24253500	chr15:84953950	NA	0.38	6.44	0.33	4.32e-10	Schizophrenia;
CRC	cis	rs9549328	0.643	rs4907567	chr13:113617533	C/T	cg17524180	chr13:113633600	MCF2L	0.52	9.5	0.46	4.44e-19	Systolic blood pressure;
CRC	cis	rs1552172	0.853	rs9728345	chr1:145597417	C/A	cg11743829	chr1:145714124	CD160	-0.4	-5.9	-0.31	9.1e-9	Breast cancer;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Depression;
CRC	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.26e-9	Red blood cell count;
CRC	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.52	7.55	0.38	4.27e-13	White matter hyperintensity burden;
CRC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.55	9.8	0.48	4.7e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9323205	0.765	rs2999386	chr14:51652628	G/T	cg23942311	chr14:51606299	NA	0.62	9.92	0.48	1.79e-20	Cancer;
CRC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.85	-0.35	3.64e-11	HDL cholesterol;
CRC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.49e-9	Blood metabolite levels;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg06470822	chr6:28175283	NA	0.8	11.88	0.55	2.48e-27	Parkinson's disease;
CRC	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.44	6.77	0.35	6.03e-11	Red blood cell count;
CRC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs972578	0.967	rs9623737	chr22:43406680	G/T	cg01576275	chr22:43409880	NA	-0.5	-8.19	-0.41	5.69e-15	Mean platelet volume;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.11	10.62	0.51	7.72e-23	Diabetic retinopathy;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg15382696	chr6:118971807	C6orf204	0.59	7.63	0.39	2.54e-13	Diastolic blood pressure;
CRC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.48	7.19	0.37	4.29e-12	Corneal astigmatism;
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg15845792	chr6:28175446	NA	0.74	7.78	0.39	9.45e-14	Depression;
CRC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.3	0.33	9.57e-10	Primary sclerosing cholangitis;
CRC	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.39	5.73	0.3	2.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.43	-0.79	4.22e-72	Myeloid white cell count;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg18301423	chr5:131593218	PDLIM4	0.37	6.25	0.33	1.27e-9	Breast cancer;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg02683197	chr6:28174875	NA	0.81	9.98	0.48	1.15e-20	Depression;
CRC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg18230493	chr5:56204884	C5orf35	0.42	6.27	0.33	1.15e-9	Coronary artery disease;
CRC	cis	rs2072510	0.569	rs17677343	chr12:96397081	T/A	cg15438951	chr12:96389694	HAL	-0.49	-5.94	-0.31	7.38e-9	Metabolite levels (small molecules and protein measures);
CRC	trans	rs800082	0.966	rs2575192	chr3:144281170	C/T	cg24215973	chr2:240111563	HDAC4	0.52	6.94	0.36	2.1e-11	Smoking behavior;
CRC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.55	-0.5	1.36e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg05341575	chr12:125625032	AACS	-0.4	-5.81	-0.31	1.47e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.47	6.81	0.35	4.62e-11	Type 2 diabetes;
CRC	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.49	7.24	0.37	3.29e-12	Testicular germ cell tumor;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07682937	chr12:56546305	MYL6B	0.42	6.35	0.33	7.02e-10	Interleukin-6 levels;
CRC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	0.91	10.96	0.52	4.95e-24	Red blood cell traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06476606	chr10:91061728	IFIT2	0.41	6.0	0.31	5.07e-9	Intelligence (multi-trait analysis);
CRC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12273811	chr6:28175739	NA	0.72	9.03	0.45	1.47e-17	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02853322	chr7:39989723	CDK13	0.38	5.98	0.31	5.9e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11031096	0.677	rs11031043	chr11:4145385	G/T	cg22978087	chr8:24814126	NEFL	0.33	6.08	0.32	3.36e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs3087591	0.573	rs731758	chr17:29723000	C/G	cg24425628	chr17:29625626	OMG;NF1	0.6	10.24	0.49	1.56e-21	Hip circumference;
CRC	trans	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.41	-0.33	5.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg15733309	chr7:157513707	PTPRN2	0.4	6.57	0.34	1.96e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.7	-9.75	-0.47	6.64e-20	Platelet count;
CRC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.68	0.51	4.61e-23	Ileal carcinoids;
CRC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.96	13.46	0.6	3.28e-33	Breast cancer;
CRC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.64	9.16	0.45	5.72e-18	Coronary artery disease;
CRC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg10820045	chr2:198174542	NA	0.4	6.64	0.34	1.3e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12791968	0.527	rs4755300	chr11:45013421	C/T	cg11846598	chr11:44996168	LOC221122	0.48	6.15	0.32	2.28e-9	Inhibitory control;
CRC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.49	7.38	0.38	1.32e-12	Corneal astigmatism;
CRC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23378565	chr7:2036160	MAD1L1	-0.49	-6.96	-0.36	1.8e-11	Bipolar disorder;
CRC	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.79e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.62e-9	Life satisfaction;
CRC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs3736485	0.934	rs17609666	chr15:51858038	G/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	-0.51	-8.36	-0.42	1.83e-15	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.05	-0.45	1.3e-17	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.28	0.53	3.77e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15557168	chr22:42548783	NA	-0.34	-5.68	-0.3	2.9e-8	Cognitive function;
CRC	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.61	-10.02	-0.48	8.4e-21	Neuroticism;
CRC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.72	-11.85	-0.55	3.15e-27	Height;
CRC	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.5	7.07	0.36	9.63e-12	Testicular germ cell tumor;
CRC	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg27205649	chr11:78285834	NARS2	0.47	5.79	0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.5	6.65	0.34	1.21e-10	IgG glycosylation;
CRC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.71	-0.39	1.54e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.53	7.91	0.4	3.96e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs10021731	0.718	rs1460772	chr4:115408184	C/T	cg25927708	chr2:119603813	EN1	-0.32	-6.05	-0.32	3.96e-9	Optic disc area;
CRC	cis	rs6662572	0.737	rs72677530	chr1:46529677	G/A	cg08644498	chr1:46502608	NA	0.45	7.25	0.37	3.09e-12	Blood protein levels;
CRC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.89	-0.55	2.37e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.13	17.37	0.69	1.99e-48	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-11.24	-0.53	5.05e-25	Prostate cancer;
CRC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.29	-0.42	2.97e-15	Type 2 diabetes;
CRC	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.68	-6.63	-0.34	1.36e-10	Inflammatory biomarkers;
CRC	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-10.67	-0.51	5.19e-23	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg03623178	chr6:28175578	NA	0.9	7.35	0.38	1.55e-12	Depression;
CRC	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-6.38	-0.33	5.93e-10	Eye color traits;
CRC	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg22482690	chr17:47019901	SNF8	0.46	7.65	0.39	2.26e-13	Type 2 diabetes;
CRC	trans	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.57	0.34	1.97e-10	Diastolic blood pressure;
CRC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	11.4	0.53	1.31e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.69	7.51	0.38	5.74e-13	Eosinophilic esophagitis;
CRC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.51	7.55	0.38	4.29e-13	Mean platelet volume;
CRC	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.57	-0.39	3.77e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg06632207	chr12:54070931	ATP5G2	0.46	7.82	0.4	7.18e-14	Height;
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg02776659	chr21:47717406	C21orf57	-0.38	-6.17	-0.32	1.99e-9	Testicular germ cell tumor;
CRC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.45	6.93	0.36	2.29e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg02659138	chr7:134003124	SLC35B4	0.36	5.74	0.3	2.16e-8	Mean platelet volume;
CRC	cis	rs73206853	0.841	rs56379265	chr12:110956370	G/A	cg12870014	chr12:110450643	ANKRD13A	0.71	7.68	0.39	1.86e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.73	-0.39	1.3e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.51	-8.8	-0.44	7.93e-17	Height;
CRC	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.59	-8.08	-0.41	1.21e-14	Adiposity;
CRC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.66	0.57	3.42e-30	Platelet count;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-9.13	-0.45	6.95e-18	Intelligence (multi-trait analysis);
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg21548813	chr6:291882	DUSP22	-0.52	-7.24	-0.37	3.21e-12	Menopause (age at onset);
CRC	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	8.2	0.41	5.33e-15	Mean corpuscular volume;
CRC	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg04672837	chr16:48644449	N4BP1	0.42	6.0	0.31	5.26e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20488697	chr17:79885644	LOC92659;MAFG	0.43	6.0	0.31	5.15e-9	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06458679	chr21:46974866	NA	0.38	6.05	0.32	4.02e-9	Obesity-related traits;
CRC	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg11833968	chr6:79620685	NA	-0.35	-6.24	-0.33	1.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.55	8.77	0.44	9.97e-17	Mean corpuscular volume;
CRC	cis	rs7703744	0.597	rs73237297	chr5:118691121	G/T	cg02283238	chr5:118691126	TNFAIP8	0.46	6.49	0.34	3.07e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-7.67	-0.39	2.01e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs4942242	1.000	rs9562501	chr13:44205683	C/T	cg19169023	chr15:41853346	TYRO3	-0.5	-7.73	-0.39	1.36e-13	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.28	6.05	0.32	3.93e-9	Educational attainment (years of education);
CRC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.79	10.86	0.51	1.11e-23	Cognitive function;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.66	-8.5	-0.42	6.91e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4731207	0.698	rs9886177	chr7:124513450	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs4746091	1.000	rs61463062	chr10:73398844	G/A	cg22763136	chr10:73395000	CDH23	0.4	5.74	0.3	2.11e-8	Selective IgA deficiency;
CRC	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.56	7.78	0.39	9.7e-14	Coronary artery disease;
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg11843238	chr5:131593191	PDLIM4	0.43	8.18	0.41	6.34e-15	Breast cancer;
CRC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.68	-0.68	1.07e-45	Height;
CRC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.5	0.38	6.18e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg20387954	chr3:183756860	HTR3D	0.46	7.91	0.4	3.89e-14	Anterior chamber depth;
CRC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.5	9.45	0.46	6.59e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.61	0.34	1.55e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.61	-9.72	-0.47	8.35e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07157834	chr1:205819609	PM20D1	0.43	5.82	0.31	1.41e-8	Parkinson's disease;
CRC	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.86	-0.35	3.51e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.51	-8.09	-0.41	1.13e-14	Coronary artery disease;
CRC	cis	rs73200209	0.744	rs17498543	chr12:116581796	T/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.21	-0.37	3.98e-12	Total body bone mineral density;
CRC	cis	rs6076065	0.723	rs2253924	chr20:23388020	G/A	cg11657817	chr20:23433608	CST11	0.43	6.42	0.33	4.86e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11645453	chr3:52864694	ITIH4	0.35	6.15	0.32	2.25e-9	Bipolar disorder;
CRC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.74	0.51	2.95e-23	Psoriasis;
CRC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.62	-0.3	4.05e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg10756647	chr7:56101905	PSPH	0.76	7.88	0.4	4.86e-14	Diabetic kidney disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03087334	chr18:33077969	INO80C	0.49	6.96	0.36	1.83e-11	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.54	6.94	0.36	2.04e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.58	8.74	0.43	1.21e-16	Schizophrenia;
CRC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.75	-12.98	-0.58	2.18e-31	Body mass index;
CRC	cis	rs7503807	0.515	rs12945216	chr17:78670642	C/T	cg00549398	chr17:78725201	RPTOR	0.43	5.65	0.3	3.41e-8	Obesity;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg19041857	chr6:27730383	NA	0.48	6.62	0.34	1.46e-10	Parkinson's disease;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00802000	chr16:706648	WDR90	-0.42	-6.01	-0.31	4.83e-9	Height;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg23161317	chr6:28129485	ZNF389	0.47	6.84	0.35	3.86e-11	Cardiac Troponin-T levels;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.47	-7.21	-0.37	3.91e-12	Obesity-related traits;
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg23193639	chr7:45961078	IGFBP3	0.37	6.31	0.33	9.19e-10	Sitting height ratio;
CRC	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg09184832	chr6:79620586	NA	-0.47	-8.22	-0.41	4.67e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.39	-6.15	-0.32	2.28e-9	Blood metabolite levels;
CRC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.6	-10.89	-0.51	8.91e-24	Facial morphology (factor 23);
CRC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.44	6.59	0.34	1.77e-10	Ulcerative colitis;
CRC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg13206674	chr6:150067644	NUP43	0.49	7.03	0.36	1.22e-11	Testicular germ cell tumor;
CRC	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.63	5.94	0.31	7.12e-9	Schizophrenia;
CRC	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg14593290	chr7:50529359	DDC	0.64	8.51	0.42	6.25e-16	Malaria;
CRC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.83	15.03	0.64	3.12e-39	Vitiligo;
CRC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg21466736	chr12:48725269	NA	-0.56	-8.32	-0.42	2.36e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.35	6.0	0.31	5.08e-9	Major depressive disorder;
CRC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.92	-0.4	3.58e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.92	12.42	0.56	2.67e-29	Monocyte percentage of white cells;
CRC	trans	rs2303319	0.504	rs62190168	chr2:162322012	A/G	cg19471553	chr17:41393123	NA	-0.7	-6.07	-0.32	3.48e-9	Cognitive function;
CRC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.74	10.15	0.49	3.08e-21	Coronary artery disease;
CRC	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg26769984	chr7:1090371	C7orf50	0.58	7.38	0.38	1.31e-12	Bronchopulmonary dysplasia;
CRC	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.97	-19.43	-0.73	1.47e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.46	7.24	0.37	3.27e-12	Platelet count;
CRC	cis	rs35000415	0.938	rs35188261	chr7:128683539	G/A	cg19972273	chr7:128594194	NA	0.69	6.28	0.33	1.05e-9	Systemic lupus erythematosus;
CRC	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.62	-0.43	2.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11212617	1.000	rs2884030	chr11:108281903	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.45	6.89	0.36	2.79e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs539514	0.516	rs2273996	chr13:76410725	A/G	cg04757411	chr13:76259545	LMO7	0.34	5.68	0.3	3e-8	Type 1 diabetes;
CRC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg12573674	chr2:1569213	NA	-0.74	-7.89	-0.4	4.59e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs10504390	0.585	rs80151640	chr8:66537841	C/T	cg26403416	chr21:43771339	TFF2	0.6	6.14	0.32	2.38e-9	IgG glycosylation;
CRC	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg07617317	chr6:118971624	C6orf204	0.47	5.68	0.3	2.91e-8	Diastolic blood pressure;
CRC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.51	7.31	0.37	2.06e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.6	-0.3	4.43e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.23	-0.37	3.32e-12	Lymphocyte counts;
CRC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.82	-14.07	-0.61	1.56e-35	Intelligence (multi-trait analysis);
CRC	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.39	5.97	0.31	6.09e-9	Red blood cell count;
CRC	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-9.16	-0.45	5.88e-18	Hyperactive-impulsive symptoms;
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-8.01	-0.4	1.96e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs747650	0.532	rs3922684	chr11:47121176	T/C	cg19486271	chr11:47235900	DDB2	0.44	5.89	0.31	9.76e-9	Acne (severe);
CRC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.28	0.53	3.51e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg19635926	chr16:89946313	TCF25	0.65	6.09	0.32	3.17e-9	Skin colour saturation;
CRC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg18478394	chr8:109455254	TTC35	0.4	6.24	0.33	1.34e-9	Dupuytren's disease;
CRC	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.58	-0.39	3.44e-13	Bipolar disorder;
CRC	cis	rs8105895	0.935	rs7252547	chr19:22305481	T/C	cg02912127	chr19:22235281	ZNF257	-0.42	-5.74	-0.3	2.21e-8	Body mass index (change over time);
CRC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg16342193	chr10:102329863	NA	-0.36	-5.91	-0.31	8.37e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	6.96e-16	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07151637	chr22:32149913	DEPDC5	0.36	6.32	0.33	8.61e-10	Obesity-related traits;
CRC	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.48	8.14	0.41	7.98e-15	Common traits (Other);
CRC	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.96	-0.55	1.28e-27	Exhaled nitric oxide output;
CRC	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.54	8.2	0.41	5.55e-15	Testicular germ cell tumor;
CRC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.84	13.94	0.61	4.86e-35	Tonsillectomy;
CRC	cis	rs4819852	1.000	rs4819852	chr22:19988167	G/A	cg07821417	chr22:19972146	ARVCF	0.45	5.82	0.31	1.38e-8	Pulse pressure;
CRC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.77	-0.39	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg10570241	chr7:158785291	NA	0.45	7.75	0.39	1.16e-13	Facial morphology (factor 20);
CRC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	9.43	0.46	7.75e-19	Eye color traits;
CRC	cis	rs16975963	0.793	rs56672492	chr19:38448231	T/C	cg15135657	chr19:38346511	NA	-0.42	-5.65	-0.3	3.55e-8	Longevity;
CRC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.81	-10.01	-0.48	8.99e-21	Initial pursuit acceleration;
CRC	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg20041105	chr8:143859282	LYNX1	-0.32	-5.66	-0.3	3.28e-8	Urinary tract infection frequency;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-8.38	-0.42	1.52e-15	Longevity;Endometriosis;
CRC	cis	rs16852403	0.548	rs543452	chr1:178220878	A/G	cg00404053	chr1:178313656	RASAL2	-0.5	-6.49	-0.34	3.08e-10	Childhood ear infection;
CRC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg01721255	chr8:58191610	C8orf71	0.5	6.18	0.32	1.87e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.57	0.57	7.49e-30	Height;
CRC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-11.09	-0.52	1.74e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg25246084	chr19:4971487	KDM4B	-0.34	-5.77	-0.3	1.81e-8	Monocyte percentage of white cells;
CRC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.81	0.31	1.47e-8	Rheumatoid arthritis;
CRC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.45	-7.79	-0.39	8.81e-14	Eye color traits;
CRC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.54	-8.68	-0.43	1.81e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-7.41	-0.38	1.1e-12	Neuroticism;
CRC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg25281562	chr12:121454272	C12orf43	0.43	6.03	0.32	4.41e-9	N-glycan levels;
CRC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg25204440	chr1:209979598	IRF6	0.47	5.79	0.3	1.62e-8	Cleft lip with or without cleft palate;
CRC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.68	0.39	1.79e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg15110403	chr19:17392923	ANKLE1	0.36	5.85	0.31	1.21e-8	Systemic lupus erythematosus;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg19041857	chr6:27730383	NA	-0.77	-6.87	-0.35	3.3e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.47	-0.38	7.35e-13	Psoriasis;
CRC	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.64	9.77	0.47	5.94e-20	Corneal astigmatism;
CRC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.38	6.11	0.32	2.84e-9	Major depressive disorder;
CRC	cis	rs2710642	0.925	rs72807578	chr2:63008044	G/A	cg17519650	chr2:63277830	OTX1	-0.49	-6.59	-0.34	1.75e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.46	6.61	0.34	1.52e-10	Subjective well-being;
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg20119798	chr7:94954144	PON1	-0.49	-6.26	-0.33	1.21e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	0.98	8.39	0.42	1.44e-15	Blood protein levels;
CRC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.53	7.25	0.37	3.02e-12	Height;
CRC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg01483505	chr11:975446	AP2A2	0.4	6.02	0.31	4.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg05072774	chr3:49840536	C3orf54	-0.44	-5.68	-0.3	2.95e-8	Resting heart rate;
CRC	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.49	7.42	0.38	1.01e-12	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21721210	chr19:39574878	PAPL	0.33	6.42	0.33	4.69e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.6	-8.78	-0.44	8.92e-17	Menarche (age at onset);
CRC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.16	-0.32	2.09e-9	Morning vs. evening chronotype;
CRC	cis	rs2013441	1.000	rs4924809	chr17:20044673	C/T	cg13482628	chr17:19912719	NA	0.41	6.33	0.33	7.87e-10	Obesity-related traits;
CRC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg15440763	chr7:158190612	PTPRN2	0.53	8.42	0.42	1.14e-15	Obesity-related traits;
CRC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.45	6.75	0.35	6.77e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11229555	0.645	rs7116847	chr11:58178478	C/A	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.39e-17	Bipolar disorder;
CRC	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.65	8.91	0.44	3.55e-17	Menarche (age at onset);
CRC	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.52	8.3	0.42	2.66e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-11.66	-0.54	1.52e-26	Asthma;
CRC	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.65	-10.84	-0.51	1.31e-23	Type 2 diabetes;
CRC	cis	rs3764400	0.508	rs55696440	chr17:46271146	G/A	cg10706073	chr17:46328419	SKAP1	-0.64	-6.83	-0.35	4.21e-11	Body mass index;
CRC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.42	-7.0	-0.36	1.47e-11	Height;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg03623178	chr6:28175578	NA	0.79	11.55	0.54	3.91e-26	Parkinson's disease;
CRC	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg20487152	chr13:99095054	FARP1	0.35	5.93	0.31	7.59e-9	Longevity;
CRC	trans	rs2303319	0.504	rs56407015	chr2:162455625	G/A	cg27113153	chr11:123612418	ZNF202	-0.7	-6.15	-0.32	2.28e-9	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06884548	chr6:34856897	ANKS1A;TAF11	0.43	6.19	0.32	1.74e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-6.27	-0.33	1.13e-9	IgG glycosylation;
CRC	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg21851534	chr17:3907994	ZZEF1	0.37	6.41	0.33	5.16e-10	Type 2 diabetes;
CRC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg07134254	chr20:33865797	NA	0.45	5.73	0.3	2.32e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.41	-0.38	1.05e-12	Caudate activity during reward;
CRC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.48	7.39	0.38	1.26e-12	Longevity;
CRC	cis	rs12760731	0.720	rs12022185	chr1:178279653	A/G	cg00404053	chr1:178313656	RASAL2	1.13	11.48	0.53	6.77e-26	Obesity-related traits;
CRC	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.44	6.53	0.34	2.44e-10	Body mass index;
CRC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg06634786	chr22:41940651	POLR3H	-0.47	-6.13	-0.32	2.44e-9	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05798107	chr17:40761563	FAM134C;TUBG1	0.46	6.89	0.36	2.84e-11	Intelligence (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.58	-0.34	1.83e-10	Coronary artery disease;
CRC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-6.49	-0.34	3.25e-10	Menarche (age at onset);
CRC	cis	rs9400239	0.622	rs1268164	chr6:109008416	C/T	cg11073813	chr6:109029018	NA	0.4	6.44	0.33	4.23e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8070740	0.898	rs9896735	chr17:5325808	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.43	-6.85	-0.35	3.54e-11	Menopause (age at onset);
CRC	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.5	-7.48	-0.38	6.68e-13	Menopause (age at onset);
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg12564526	chr7:66767603	PMS2L4;STAG3L4	0.38	6.08	0.32	3.28e-9	Age-related macular degeneration;
CRC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.94	-0.36	2.05e-11	Platelet distribution width;
CRC	cis	rs4728302	0.869	rs6955707	chr7:133612188	G/A	cg03336402	chr7:133662267	EXOC4	-0.43	-6.3	-0.33	9.56e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7539542	0.556	rs10753928	chr1:202891045	A/C	cg19681188	chr1:202830198	LOC148709	-0.43	-6.31	-0.33	9.14e-10	Mean platelet volume;
CRC	cis	rs523516	0.645	rs520054	chr17:37321538	G/A	cg20555674	chr17:37321631	ARL5C	0.39	7.98	0.4	2.44e-14	IgG glycosylation;
CRC	cis	rs2252790	0.548	rs114094955	chr6:116521164	G/T	cg26893134	chr6:116381904	FRK	0.25	5.74	0.3	2.16e-8	Fast beta electroencephalogram;
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.09	-0.32	3.23e-9	Total body bone mineral density;
CRC	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.58	-6.54	-0.34	2.39e-10	Blood protein levels;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg02683197	chr6:28174875	NA	0.78	9.5	0.46	4.55e-19	Depression;
CRC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg17294928	chr15:75287854	SCAMP5	0.5	7.69	0.39	1.76e-13	Breast cancer;
CRC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.41	7.83	0.4	6.79e-14	Mean corpuscular volume;
CRC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.49	-0.34	3.2e-10	Type 2 diabetes;
CRC	trans	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.3	0.37	2.11e-12	Endometrial cancer;
CRC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg23298862	chr7:158159286	PTPRN2	0.38	5.92	0.31	7.95e-9	Calcium levels;
CRC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-14.93	-0.64	7.75e-39	Vitiligo;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18758796	chr5:131593413	PDLIM4	0.44	8.09	0.41	1.19e-14	Breast cancer;
CRC	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg15845792	chr6:28175446	NA	0.72	6.19	0.32	1.8e-9	Depression;
CRC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.74	-12.26	-0.56	1.05e-28	Gut microbiota (bacterial taxa);
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-0.98	-21.93	-0.77	2.58e-66	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.3	0.49	9.6e-22	Menopause (age at onset);
CRC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg14673194	chr17:80132900	CCDC57	0.49	6.35	0.33	7.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.34	-9.79	-0.48	4.92e-20	Mean corpuscular volume;
CRC	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg21851534	chr17:3907994	ZZEF1	0.38	6.49	0.34	3.19e-10	Type 2 diabetes;
CRC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg12564285	chr5:131593104	PDLIM4	-0.36	-6.67	-0.35	1.09e-10	Blood metabolite levels;
CRC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.47	6.02	0.32	4.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2882667	0.898	rs2116789	chr5:138394262	G/T	cg04439458	chr5:138467593	SIL1	-0.33	-6.11	-0.32	2.77e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.05e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg11579758	chr4:1086637	RNF212	0.42	6.96	0.36	1.9e-11	Recombination rate (males);
CRC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg16606324	chr3:10149918	C3orf24	0.45	6.82	0.35	4.25e-11	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg03623178	chr6:28175578	NA	-0.96	-12.59	-0.57	5.92e-30	Depression;
CRC	trans	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-7.02	-0.36	1.3e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg27068330	chr11:65405492	SIPA1	0.44	5.79	0.3	1.63e-8	Urate levels;
CRC	cis	rs892085	0.681	rs7246673	chr19:10876841	T/G	cg17710535	chr19:10819994	QTRT1	0.38	5.86	0.31	1.11e-8	Psoriasis vulgaris;Psoriasis;
CRC	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.79	-0.35	5.1e-11	Coronary artery disease;
CRC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.35	0.33	6.99e-10	Body mass index;
CRC	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.46	7.24	0.37	3.27e-12	Platelet count;
CRC	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.75	8.73	0.43	1.31e-16	Inflammatory bowel disease;
CRC	cis	rs1943345	0.556	rs528703	chr11:82926035	G/A	cg07047830	chr11:82868014	PCF11	0.45	6.42	0.33	4.74e-10	Obesity-related traits;
CRC	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg09796270	chr17:17721594	SREBF1	-0.4	-6.41	-0.33	5.18e-10	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg12935359	chr14:103987150	CKB	-0.36	-6.02	-0.31	4.75e-9	Body mass index;
CRC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg21856205	chr7:94953877	PON1	-0.47	-5.99	-0.31	5.45e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.39	-6.27	-0.33	1.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.78e-13	Hip circumference adjusted for BMI;
CRC	cis	rs12476592	0.602	rs7608470	chr2:63691478	T/C	cg10828910	chr2:63850056	LOC388955	0.46	5.64	0.3	3.64e-8	Childhood ear infection;
CRC	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.43	-7.51	-0.38	5.75e-13	Venous thromboembolism;
CRC	trans	rs12048904	0.504	rs12039319	chr1:101340134	C/T	cg01303055	chr11:11265429	NA	-0.36	-6.0	-0.31	5.21e-9	Multiple sclerosis;
CRC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.81	12.33	0.56	5.83e-29	Cognitive function;
CRC	cis	rs7781557	1.000	rs12113073	chr7:102482527	T/C	cg18108683	chr7:102477205	FBXL13	-0.57	-7.22	-0.37	3.61e-12	Colorectal adenoma (advanced);
CRC	cis	rs6585424	0.850	rs75804987	chr10:81932509	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.6	9.13	0.45	7.26e-18	Longevity;Endometriosis;
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.56	-7.25	-0.37	3.02e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg06606381	chr12:133084897	FBRSL1	-0.88	-7.08	-0.36	8.82e-12	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.43	-8.33	-0.42	2.18e-15	Systolic blood pressure;
CRC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg08071915	chr8:12219732	FAM66A	0.33	6.03	0.32	4.3e-9	Retinal vascular caliber;
CRC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg24375607	chr4:120327624	NA	-0.46	-7.73	-0.39	1.31e-13	Corneal astigmatism;
CRC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg08222913	chr3:52553049	STAB1	-0.35	-6.53	-0.34	2.49e-10	Electroencephalogram traits;
CRC	trans	rs6472235	0.837	rs11997658	chr8:66920756	C/T	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.07	-0.32	3.54e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs11645898	0.574	rs17604349	chr16:72210865	C/T	cg14768367	chr16:72042858	DHODH	-0.52	-6.15	-0.32	2.23e-9	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22081084	chr1:89990230	LRRC8B	0.49	6.61	0.34	1.58e-10	Thyroid stimulating hormone;
CRC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.52	-6.81	-0.35	4.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.92e-30	Blood trace element (Zn levels);
CRC	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.98	20.12	0.74	2.92e-59	Metabolite levels;
CRC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg23262073	chr20:60523788	NA	-0.45	-6.99	-0.36	1.52e-11	Body mass index;
CRC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg00343986	chr7:65444356	GUSB	-0.47	-6.52	-0.34	2.69e-10	Aortic root size;
CRC	trans	rs1602565	1.000	rs1907605	chr11:29158507	A/G	cg10961700	chr1:150898620	SETDB1	-0.59	-6.07	-0.32	3.61e-9	Schizophrenia;
CRC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.82	-14.08	-0.61	1.44e-35	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.89	0.55	2.36e-27	Alzheimer's disease;
CRC	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg10818794	chr15:86012489	AKAP13	0.41	6.4	0.33	5.3e-10	Bulimia nervosa;
CRC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.43	0.57	2.44e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg09873164	chr1:152488093	CRCT1	0.39	6.58	0.34	1.84e-10	Hair morphology;
CRC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.45	0.42	9.23e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg11619707	chr19:22235551	ZNF257	-0.28	-5.82	-0.31	1.36e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CRC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.77	-0.58	1.27e-30	Bipolar disorder and schizophrenia;
CRC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.05	-0.41	1.48e-14	Height;
CRC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.38	0.38	1.31e-12	Aortic root size;
CRC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.0	-0.44	1.88e-17	Mood instability;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.47	7.01	0.36	1.32e-11	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25552655	chr19:33864476	CEBPG	0.5	6.97	0.36	1.75e-11	Anxiety disorder;
CRC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.74	8.89	0.44	4.07e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-12.82	-0.58	8.45e-31	Cognitive function;
CRC	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.1	0.32	3.01e-9	Asthma;
CRC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.23	-0.32	1.44e-9	Aortic root size;
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.41	0.5	3.88e-22	Alzheimer's disease;
CRC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.43	6.18	0.32	1.9e-9	Aortic root size;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg21866596	chr11:93474724	C11orf54;TAF1D	0.39	6.07	0.32	3.49e-9	Interleukin-6 levels;
CRC	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg08800497	chr19:1970008	CSNK1G2	0.57	8.96	0.44	2.53e-17	Coronary artery disease;
CRC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.43	5.7	0.3	2.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg18016565	chr1:150552671	MCL1	0.42	6.0	0.31	5.18e-9	Melanoma;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg25164649	chr6:28176230	NA	0.8	9.96	0.48	1.34e-20	Depression;
CRC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.73	-12.88	-0.58	5.02e-31	Hemoglobin concentration;
CRC	trans	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg26043149	chr18:55253948	FECH	-0.46	-6.94	-0.36	2.07e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16944820	chr13:45492071	NA	0.41	6.17	0.32	1.97e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.7	-11.46	-0.53	8.13e-26	Hepatocellular carcinoma;
CRC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-6.86	-0.35	3.4e-11	Headache;
CRC	trans	rs1325195	0.507	rs10798652	chr1:179061427	A/G	cg11624085	chr17:8464688	MYH10	0.41	6.18	0.32	1.92e-9	IgE grass sensitization;
CRC	trans	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg05679027	chr9:99775184	HIATL2	-0.4	-6.05	-0.32	3.91e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.19	0.64	7.56e-40	Hypertriglyceridemia;
CRC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.74	-0.43	1.21e-16	Aortic root size;
CRC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg27395922	chr11:50257633	LOC441601	0.35	5.71	0.3	2.58e-8	Coronary artery disease;
CRC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.49	7.61	0.39	2.99e-13	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11744777	chr6:27799370	HIST1H4K	0.47	7.24	0.37	3.28e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg13385521	chr17:29058706	SUZ12P	0.55	7.36	0.38	1.53e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.48	6.92	0.36	2.36e-11	Heart rate;
CRC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.48	-7.82	-0.4	7.46e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.43	0.42	1.08e-15	Height;
CRC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.92	0.48	1.84e-20	Lung cancer;
CRC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.83	-13.36	-0.59	8.28e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg17145862	chr1:211918768	LPGAT1	0.49	6.31	0.33	8.95e-10	Crohn's disease;
CRC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg15445000	chr17:37608096	MED1	0.27	5.98	0.31	5.91e-9	Asthma;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.05	-0.32	3.84e-9	Longevity;Endometriosis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26084319	chr14:21905280	CHD8	0.47	6.17	0.32	2.02e-9	Thyroid stimulating hormone;
CRC	cis	rs73206853	0.764	rs55887805	chr12:110597246	T/C	cg12870014	chr12:110450643	ANKRD13A	0.83	10.65	0.51	5.74e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.65	13.79	0.61	1.92e-34	Schizophrenia;
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg13198984	chr17:80129470	CCDC57	0.43	7.68	0.39	1.89e-13	Life satisfaction;
CRC	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.67	-11.02	-0.52	3.09e-24	Hepatocellular carcinoma;
CRC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.18	0.37	4.6e-12	Life satisfaction;
CRC	trans	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg10756647	chr7:56101905	PSPH	-0.75	-8.14	-0.41	8.07e-15	Diabetic kidney disease;
CRC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg05569086	chr8:143859399	LYNX1	-0.32	-5.63	-0.3	3.93e-8	Urinary tract infection frequency;
CRC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.38	-5.63	-0.3	3.94e-8	Aortic root size;
CRC	cis	rs1847505	0.609	rs9539004	chr13:61587049	T/C	cg14094164	chr13:61491000	NA	0.31	5.94	0.31	7.19e-9	Polychlorinated biphenyl levels;
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.39	5.98	0.31	5.67e-9	Monocyte count;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg27615366	chr5:131592974	PDLIM4	0.33	5.78	0.3	1.7e-8	Breast cancer;
CRC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg14541582	chr5:601475	NA	-0.37	-7.19	-0.37	4.49e-12	Lung disease severity in cystic fibrosis;
CRC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.61	7.75	0.39	1.13e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg18755114	chr2:209119030	IDH1	-0.4	-6.17	-0.32	2.05e-9	Blood protein levels;
CRC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.38	0.42	1.58e-15	Schizophrenia;
CRC	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.62	10.13	0.49	3.53e-21	Subjective well-being (multi-trait analysis);
CRC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg03609598	chr5:56110824	MAP3K1	0.75	8.73	0.43	1.31e-16	Initial pursuit acceleration;
CRC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg04362960	chr10:104952993	NT5C2	-0.43	-6.11	-0.32	2.8e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4654899	0.609	rs12128470	chr1:21534055	T/C	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.16	-0.37	5.25e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.35	5.62	0.3	4.12e-8	Survival in rectal cancer;
CRC	cis	rs883565	0.655	rs6778963	chr3:39091812	T/G	cg01426195	chr3:39028469	NA	-0.54	-8.77	-0.44	9.85e-17	Handedness;
CRC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.79	14.03	0.61	2.24e-35	Vitiligo;
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.73	-8.63	-0.43	2.64e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.43	-0.46	7.78e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg04110750	chr16:69646130	NFAT5	-0.46	-6.21	-0.32	1.57e-9	IgE levels;
CRC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-8.68	-0.43	1.91e-16	Bipolar disorder and schizophrenia;
CRC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.51	0.34	2.88e-10	Morning vs. evening chronotype;
CRC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.68	-0.35	1.04e-10	Bipolar disorder;
CRC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.57	8.92	0.44	3.29e-17	Mean corpuscular hemoglobin concentration;
CRC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg05501817	chr11:14380813	RRAS2	-0.45	-5.96	-0.31	6.67e-9	Sense of smell;
CRC	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg09655341	chr17:79618100	PDE6G	0.58	6.92	0.36	2.44e-11	Dental caries;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06643102	chr19:8455567	RAB11B	0.46	7.51	0.38	5.72e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg26741380	chr15:41871084	TYRO3	-0.48	-6.75	-0.35	6.5500000000000006e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.42	6.35	0.33	6.97e-10	Mean platelet volume;
CRC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.54	-8.3	-0.42	2.71e-15	Aortic root size;
CRC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.4	7.16	0.37	5.37e-12	Iron status biomarkers;
CRC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.84	-0.4	6.15e-14	Chronic sinus infection;
CRC	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.37	-6.75	-0.35	6.71e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.62	11.01	0.52	3.36e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg05968270	chr1:65533502	NA	0.57	6.82	0.35	4.47e-11	Kashin-Beck disease;
CRC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.64	-0.34	1.29e-10	Body mass index;
CRC	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg21174375	chr14:64681225	SYNE2	0.41	6.53	0.34	2.54e-10	Atrial fibrillation;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.37	6.48	0.34	3.29e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.44	-6.32	-0.33	8.55e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.47e-10	Prostate cancer;
CRC	cis	rs72627123	0.867	rs113768127	chr14:74467839	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.92	0.31	8.3e-9	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg12273811	chr6:28175739	NA	0.61	8.68	0.43	1.89e-16	Parkinson's disease;
CRC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.81	0.4	7.95e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.95	10.15	0.49	3.16e-21	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05137146	chr16:30103511	TBX6	0.4	6.36	0.33	6.78e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.54	-6.7	-0.35	8.85e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17067123	0.614	rs56749262	chr4:180067592	C/A	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	6.94e-11	Response to hepatitis C treatment;
CRC	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	6.66	0.34	1.18e-10	Caffeine consumption;
CRC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.76	0.47	6.42e-20	Bladder cancer;
CRC	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.53	10.29	0.49	1.03e-21	Urate levels in lean individuals;
CRC	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.51	-0.34	2.76e-10	Metabolite levels;
CRC	cis	rs7487075	0.859	rs7960147	chr12:46751454	C/T	cg22049899	chr12:47219821	SLC38A4	0.32	5.88	0.31	1.03e-8	Itch intensity from mosquito bite;
CRC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg11707556	chr5:10655725	ANKRD33B	0.39	6.32	0.33	8.46e-10	Coronary artery disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07225547	chr2:211035530	C2orf67	-0.43	-6.54	-0.34	2.29e-10	Aortic root size;
CRC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	7.35	0.38	1.6e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-8.33	-0.42	2.15e-15	Self-reported allergy;
CRC	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.49	7.24	0.37	3.1e-12	Triglycerides;
CRC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.11	0.49	4.19e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.23	-0.33	1.4e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.39	-6.36	-0.33	6.58e-10	Blood metabolite levels;
CRC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg25876840	chr17:41920477	NA	-0.52	-7.02	-0.36	1.24e-11	Triglycerides;
CRC	trans	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.11	0.36	7.27e-12	Mean corpuscular volume;
CRC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.94	13.59	0.6	1.08e-33	Breast cancer;
CRC	trans	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg15845792	chr6:28175446	NA	0.67	6.48	0.34	3.34e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.23	-0.32	1.42e-9	Total body bone mineral density;
CRC	cis	rs9487051	0.646	rs11153167	chr6:109622582	A/T	cg01475377	chr6:109611718	NA	0.37	5.92	0.31	8.07e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.5	6.2	0.32	1.73e-9	Obesity (extreme);
CRC	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.47	-6.66	-0.34	1.17e-10	Mammographic density (dense area);
CRC	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.29	-0.37	2.28e-12	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.92	0.36	2.41e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-9.18	-0.45	4.97e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.23	6.15	0.32	2.26e-9	Type 2 diabetes;
CRC	cis	rs12580194	0.593	rs7313465	chr12:55736863	C/T	cg19537932	chr12:55886519	OR6C68	-0.65	-8.42	-0.42	1.16e-15	Cancer;
CRC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.5	5.63	0.3	3.89e-8	Menarche (age at onset);
CRC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg11632617	chr15:75315747	PPCDC	-0.55	-7.91	-0.4	4e-14	Blood trace element (Zn levels);
CRC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg19680485	chr15:31195859	MTMR15	0.47	6.6	0.34	1.68e-10	Huntington's disease progression;
CRC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.82	11.71	0.54	1.08e-26	Cognitive function;
CRC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-15.56	-0.65	2.56e-41	Prostate cancer;
CRC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.7	-10.64	-0.51	6.45e-23	Acne (severe);
CRC	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	6.28	0.33	1.08e-9	Response to antipsychotic treatment;
CRC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.91	-17.78	-0.7	5.08e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07234876	chr8:600039	NA	0.99	9.35	0.46	1.37e-18	IgG glycosylation;
CRC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.17	0.32	2e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.76	8.87	0.44	4.84e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.16	-28.76	-0.85	8.51e-92	Testicular germ cell tumor;
CRC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.54	-8.95	-0.44	2.57e-17	Total body bone mineral density;
CRC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.7	9.73	0.47	8.02e-20	Cleft lip with or without cleft palate;
CRC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.41	-0.5	3.93e-22	Total cholesterol levels;
CRC	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg08501292	chr6:25962987	TRIM38	1.11	9.98	0.48	1.13e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7113874	0.569	rs9737401	chr11:8595652	C/T	cg20771178	chr11:8615675	STK33	-0.35	-5.72	-0.3	2.42e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7301826	0.651	rs10848206	chr12:131281471	G/C	cg11011512	chr12:131303247	STX2	0.38	5.73	0.3	2.25e-8	Plasma plasminogen activator levels;
CRC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	9.29	0.46	2.18e-18	Cognitive test performance;
CRC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.71	10.87	0.51	1.04e-23	Immature fraction of reticulocytes;
CRC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.71e-21	Aortic root size;
CRC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.35	-5.68	-0.3	3e-8	High light scatter reticulocyte count;
CRC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.09	-0.32	3.14e-9	Bipolar disorder;
CRC	cis	rs6700896	0.866	rs6588158	chr1:66160621	T/C	cg04111102	chr1:66153794	NA	-0.34	-5.89	-0.31	9.43e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.42	0.5	3.83e-22	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.24	-0.33	1.31e-9	Aortic root size;
CRC	cis	rs12760731	0.623	rs10913536	chr1:178315257	G/A	cg00404053	chr1:178313656	RASAL2	0.74	9.2	0.45	4.23e-18	Obesity-related traits;
CRC	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg08501292	chr6:25962987	TRIM38	0.64	6.69	0.35	9.65e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.92	-21.53	-0.76	8.7e-65	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2982552	0.967	rs2982558	chr6:152056146	A/G	cg22157087	chr6:152012887	ESR1	0.4	6.25	0.33	1.29e-9	Bone properties (heel);
CRC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg00343986	chr7:65444356	GUSB	-0.4	-5.68	-0.3	2.97e-8	Aortic root size;
CRC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.71	-10.7	-0.51	3.98e-23	Platelet distribution width;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03760483	chr17:6899297	ALOX12	-0.61	-11.25	-0.53	4.57e-25	Tonsillectomy;
CRC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg03146154	chr1:46216737	IPP	0.56	5.75	0.3	2.07e-8	Platelet count;
CRC	cis	rs2486012	0.826	rs3011229	chr1:44328017	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-5.65	-0.3	3.48e-8	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg17507749	chr15:85114479	UBE2QP1	0.53	7.07	0.36	9.07e-12	Alzheimer's disease (age of onset);
CRC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg02725872	chr8:58115012	NA	-0.4	-6.62	-0.34	1.49e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.58	-8.47	-0.42	8.41e-16	Longevity;
CRC	cis	rs889398	0.802	rs12919094	chr16:69843357	A/G	cg00738113	chr16:70207722	CLEC18C	0.36	6.17	0.32	2.04e-9	Body mass index;
CRC	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg09165964	chr15:75287851	SCAMP5	-0.5	-7.6	-0.39	3.08e-13	Caffeine consumption;
CRC	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg01339444	chr6:118972232	C6orf204	0.58	6.22	0.32	1.48e-9	Diastolic blood pressure;
CRC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg16989719	chr2:238392110	NA	-0.45	-7.68	-0.39	1.81e-13	Prostate cancer;
CRC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	-0.42	-6.47	-0.34	3.54e-10	Menopause (age at onset);
CRC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	0.94	9.67	0.47	1.24e-19	Skin colour saturation;
CRC	cis	rs9525927	0.521	rs4942298	chr13:44798622	G/A	cg19190762	chr13:44806055	NA	0.52	6.56	0.34	2.05e-10	Dupuytren's disease;
CRC	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.75	14.08	0.61	1.45e-35	Ulcerative colitis;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20092199	chr4:1342459	KIAA1530	0.35	6.0	0.31	5.12e-9	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg24046110	chr8:143859143	LYNX1	0.49	8.65	0.43	2.37e-16	Urinary tract infection frequency;
CRC	trans	rs2303319	1.000	rs12471336	chr2:162265189	A/C	cg11875773	chr22:50468633	TTLL8	0.72	6.04	0.32	4.16e-9	Cognitive function;
CRC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	16.13	0.66	1.56e-43	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15650240	chr1:15736530	EFHD2	0.37	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg15382696	chr6:118971807	C6orf204	-0.33	-5.61	-0.3	4.31e-8	Electrocardiographic conduction measures;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Depression;
CRC	trans	rs12960119	0.764	rs2169000	chr18:23605526	A/G	cg14546394	chr8:72756863	MSC	-0.32	-5.97	-0.31	5.99e-9	Rhegmatogenous retinal detachment;
CRC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg26893134	chr6:116381904	FRK	0.26	7.72	0.39	1.39e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg07636037	chr3:49044803	WDR6	-0.84	-6.09	-0.32	3.22e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6761276	0.727	rs6743376	chr2:113832333	C/A	cg24553058	chr2:113831203	IL1F10	0.42	6.42	0.33	4.87e-10	Protein quantitative trait loci;
CRC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-7.2	-0.37	4.1e-12	Lung cancer in ever smokers;
CRC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.82	-9.18	-0.45	5.02e-18	Breast cancer;
CRC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.5	-0.34	2.97e-10	Total body bone mineral density;
CRC	cis	rs889398	0.594	rs7202233	chr16:69894432	A/G	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.9	-0.31	8.8e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17256253	chr4:968603	DGKQ	-0.37	-6.37	-0.33	6.5e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.2	0.37	4.06e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07165851	chr6:158734300	TULP4	0.6	7.59	0.39	3.38e-13	Height;
CRC	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.64	9.22	0.45	3.69e-18	Arsenic metabolism;
CRC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.55	8.02	0.4	1.89e-14	Melanoma;
CRC	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg23010048	chr19:52391257	ZNF577	0.49	5.88	0.31	1.03e-8	Breast cancer;
CRC	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.6	-8.31	-0.42	2.48e-15	Eosinophil percentage of white cells;
CRC	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06544989	chr22:39130855	UNC84B	0.42	6.23	0.32	1.44e-9	Menopause (age at onset);
CRC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.69	-8.55	-0.43	4.81e-16	Coronary artery disease;
CRC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs9311676	0.656	rs68021431	chr3:58403136	A/G	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.71e-10	Systemic lupus erythematosus;
CRC	cis	rs6499129	1.000	rs55966046	chr16:67466726	C/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.87	-0.31	1.07e-8	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.56	7.78	0.39	9.2e-14	Alcohol dependence;
CRC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.64	13.04	0.58	1.3e-31	Schizophrenia;
CRC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg27068330	chr11:65405492	SIPA1	0.44	6.55	0.34	2.26e-10	Acne (severe);
CRC	cis	rs7705042	0.659	rs11743029	chr5:141509282	G/A	cg07392085	chr5:141489673	NDFIP1	-0.41	-5.94	-0.31	7.23e-9	Asthma;
CRC	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.87	13.27	0.59	1.74e-32	Ulcerative colitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25745773	chr20:33264905	PIGU	0.45	6.36	0.33	6.89e-10	Anxiety disorder;
CRC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.51	-7.96	-0.4	2.81e-14	Multiple myeloma (IgH translocation);
CRC	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.72	14.34	0.62	1.46e-36	Leprosy;
CRC	cis	rs6764363	0.504	rs4684333	chr3:278661	A/C	cg02057681	chr3:285234	CHL1	0.41	6.89	0.36	2.79e-11	Sudden cardiac arrest;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01368133	chr4:89513561	HERC3	0.48	6.4	0.33	5.31e-10	Anxiety disorder;
CRC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.57	8.71	0.43	1.47e-16	Blood metabolite levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25580254	chr12:8088937	SLC2A3	-0.49	-7.5	-0.38	6.11e-13	Interleukin-6 levels;
CRC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg16342193	chr10:102329863	NA	-0.4	-6.45	-0.34	3.91e-10	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-19.1	-0.73	2.9e-55	Height;
CRC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg03572133	chr10:126482885	NA	-0.38	-5.98	-0.31	5.7e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
CRC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg18099408	chr3:52552593	STAB1	0.34	5.76	0.3	1.95e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg18764771	chr6:116381957	FRK	0.27	7.7	0.39	1.61e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.47	6.82	0.35	4.33e-11	Tonsillectomy;
CRC	cis	rs2735413	0.958	rs7192416	chr16:78063143	C/T	cg04733911	chr16:78082701	NA	-0.36	-6.01	-0.31	4.97e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.8e-13	Colorectal cancer;
CRC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.6	9.96	0.48	1.33e-20	Lung cancer in ever smokers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12314527	chr22:19110193	DGCR2	0.39	6.93	0.36	2.19e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg11861562	chr11:117069780	TAGLN	0.35	6.47	0.34	3.57e-10	Blood protein levels;
CRC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.81	14.19	0.62	5.71e-36	Breast cancer;
CRC	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.52	7.53	0.38	4.78e-13	Corneal astigmatism;
CRC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.56	-8.3	-0.42	2.77e-15	Longevity;
CRC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.48	6.14	0.32	2.41e-9	Obesity-related traits;
CRC	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.12	0.37	6.81e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26630792	chr5:137515009	BRD8;KIF20A	0.45	6.23	0.32	1.41e-9	Response to antipsychotic treatment;
CRC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg24300038	chr13:113819356	PROZ	0.5	6.61	0.34	1.52e-10	Platelet distribution width;
CRC	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma;
CRC	cis	rs1572438	0.831	rs4960373	chr6:855764	A/C	cg13447295	chr6:887704	NA	-0.43	-6.52	-0.34	2.71e-10	Aging;
CRC	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07234876	chr8:600039	NA	0.73	7.64	0.39	2.37e-13	IgG glycosylation;
CRC	cis	rs3736485	0.844	rs28680710	chr15:51788991	G/C	cg08986416	chr15:51914746	DMXL2	-0.44	-6.21	-0.32	1.61e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.19	0.32	1.8e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg13722127	chr7:150037890	RARRES2	0.49	7.68	0.39	1.82e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.6	9.72	0.47	8.36e-20	Itch intensity from mosquito bite;
CRC	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg23533926	chr12:111358616	MYL2	-0.42	-6.25	-0.33	1.27e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.85	0.4	5.81e-14	Morning vs. evening chronotype;
CRC	cis	rs2280630	0.529	rs784505	chr3:39168757	G/A	cg01426195	chr3:39028469	NA	0.42	7.12	0.37	6.89e-12	Verbal declarative memory;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.63	6.54	0.34	2.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg02896835	chr1:92012615	NA	0.43	5.9	0.31	8.97e-9	Eosinophil percentage of white cells;
CRC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.86	-14.36	-0.62	1.23e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg26304593	chr6:42947056	PEX6	-0.41	-5.87	-0.31	1.08e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.57	-9.12	-0.45	7.48e-18	P wave terminal force;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg27588902	chr6:42928151	GNMT	-0.37	-6.59	-0.34	1.71e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.48	7.49	0.38	6.31e-13	Corneal astigmatism;
CRC	trans	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg13565492	chr6:43139072	SRF	-0.86	-6.3	-0.33	9.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.49	7.69	0.39	1.77e-13	Corneal astigmatism;
CRC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.41	5.67	0.3	3.2e-8	Multiple sclerosis;
CRC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.59	-10.2	-0.49	2.16e-21	Iron status biomarkers;
CRC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.47	6.66	0.34	1.17e-10	Blood metabolite levels;
CRC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.39	5.89	0.31	9.46e-9	Pulse pressure;
CRC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.92	17.24	0.69	6.7e-48	Intelligence (multi-trait analysis);
CRC	trans	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg09045935	chr12:6379348	NA	1.13	9.23	0.45	3.42e-18	Blood metabolite levels;
CRC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.15	23.79	0.8	1.82e-73	IgG glycosylation;
CRC	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.0	-0.31	5.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	15.72	0.65	6.34e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.48	7.75	0.39	1.18e-13	Schizophrenia;
CRC	cis	rs6504622	1.000	rs2003539	chr17:45025319	A/G	cg16759221	chr17:45003025	GOSR2	0.44	6.93	0.36	2.27e-11	Orofacial clefts;
CRC	cis	rs12295403	0.723	rs12787397	chr11:18687025	C/T	cg07538406	chr11:18686895	NA	-0.47	-5.93	-0.31	7.61e-9	Ovarian reserve;
CRC	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.58	9.45	0.46	6.48e-19	Mean corpuscular volume;
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg18758796	chr5:131593413	PDLIM4	0.36	6.63	0.34	1.37e-10	Blood metabolite levels;
CRC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg18827107	chr12:86230957	RASSF9	-0.43	-6.85	-0.35	3.64e-11	Major depressive disorder;
CRC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.81	-0.72	4.3e-54	Height;
CRC	cis	rs3789045	0.837	rs57450685	chr1:204580832	A/T	cg17419461	chr1:204415978	PIK3C2B	-0.52	-7.43	-0.38	9.72e-13	Educational attainment (college completion);
CRC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.18	-0.45	4.77e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.77	-0.3	1.88e-8	Daytime sleep phenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23191292	chr6:157099924	ARID1B	0.47	6.57	0.34	2.01e-10	Response to antipsychotic treatment;
CRC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg22681709	chr2:178499509	PDE11A	-0.35	-6.38	-0.33	6.15e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.62	-10.38	-0.5	5.18e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10891025	chr15:44828937	EIF3J	0.42	6.09	0.32	3.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2836754	1.000	rs2836754	chr21:40291740	C/T	cg02119577	chr21:40195074	ETS2	0.36	6.33	0.33	8.23e-10	Crohn's disease;Body mass index;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg07245980	chr10:52390973	NA	-0.58	-6.59	-0.34	1.78e-10	Optic disc area;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23729963	chr8:94753249	RBM12B	0.44	6.64	0.34	1.28e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg18876405	chr7:65276391	NA	0.46	6.42	0.33	4.74e-10	Aortic root size;
CRC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.53	0.73	5.78e-57	Prudent dietary pattern;
CRC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	7.27	0.37	2.64e-12	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11970458	chr16:31213481	PYCARD	0.48	6.9	0.36	2.65e-11	Response to antipsychotic treatment;
CRC	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.64	6.56	0.34	2.11e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.4	0.33	5.42e-10	Depressive episodes in bipolar disorder;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg04969067	chr8:143858791	LYNX1	-0.41	-6.12	-0.32	2.64e-9	Urinary tract infection frequency;
CRC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg26805224	chr10:79626177	DLG5	-0.49	-7.3	-0.37	2.13e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.42	-0.38	9.88e-13	Type 2 diabetes;
CRC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-0.95	-9.33	-0.46	1.66e-18	Breast cancer;
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.84	-0.35	3.87e-11	Bipolar disorder;
CRC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg25452165	chr22:42524984	CYP2D6	0.4	6.04	0.32	4.11e-9	Schizophrenia;
CRC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.33e-15	Type 2 diabetes;
CRC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg10483660	chr13:112241077	NA	0.36	5.78	0.3	1.74e-8	Menarche (age at onset);
CRC	cis	rs12530845	0.943	rs60858457	chr7:135336918	T/C	cg23117316	chr7:135346802	PL-5283	-0.41	-5.82	-0.31	1.37e-8	Red blood cell traits;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg12273811	chr6:28175739	NA	0.59	8.64	0.43	2.56e-16	Cardiac Troponin-T levels;
CRC	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg23254163	chr1:152506842	NA	0.44	8.57	0.43	4.11e-16	Hair morphology;
CRC	cis	rs4974559	0.739	rs59810282	chr4:1320968	A/G	cg02980000	chr4:1222292	CTBP1	0.72	8.01	0.4	1.94e-14	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13524873	chr10:104953185	NT5C2	0.38	6.19	0.32	1.81e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg21153622	chr11:89784906	NA	0.47	7.44	0.38	8.86e-13	HDL cholesterol;
CRC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	11.12	0.52	1.37e-24	Motion sickness;
CRC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg03233332	chr7:66118400	NA	-0.43	-5.87	-0.31	1.05e-8	Aortic root size;
CRC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.67	9.76	0.47	6.49e-20	DNA methylation (variation);
CRC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.48	-9.1	-0.45	8.71e-18	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.59	8.37	0.42	1.66e-15	Longevity;
CRC	cis	rs737337	0.623	rs12974173	chr19:11333359	A/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.8	8.84	0.44	5.7e-17	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg06484146	chr7:12443880	VWDE	-0.75	-7.42	-0.38	9.99e-13	Coronary artery disease;
CRC	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	9.09	0.45	9.43e-18	Type 2 diabetes;
CRC	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.65	7.87	0.4	5.09e-14	Eotaxin levels;
CRC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.71	-12.41	-0.56	2.75e-29	Hemoglobin concentration;
CRC	trans	rs6678914	1.000	rs12132085	chr1:202188932	A/G	cg19977628	chr5:1262072	TERT	0.43	6.2	0.32	1.65e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.73	-7.59	-0.39	3.41e-13	Inflammatory biomarkers;
CRC	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg09835421	chr16:68378352	PRMT7	-0.78	-8.17	-0.41	6.92e-15	Schizophrenia;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.68	-10.05	-0.48	6.7e-21	Menopause (age at onset);
CRC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-18.06	-0.71	3.66e-51	Coronary artery disease;
CRC	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.47	-7.96	-0.4	2.84e-14	Airway imaging phenotypes;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.62	9.49	0.46	4.92e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6694672	0.867	rs7554802	chr1:197148599	T/C	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.73e-11	Asthma;
CRC	cis	rs9303542	0.625	rs8073963	chr17:46609918	G/A	cg04904318	chr17:46607828	HOXB1	0.44	5.9	0.31	8.83e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs4363385	0.818	rs2787629	chr1:153011966	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg00105475	chr2:10696890	NA	0.45	7.19	0.37	4.48e-12	Prostate cancer;
CRC	trans	rs17607347	0.738	rs17669912	chr16:72346595	T/C	cg27230510	chr3:50404023	CACNA2D2	-0.53	-6.11	-0.32	2.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.51	6.48	0.34	3.41e-10	Recombination rate (females);
CRC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.64	11.48	0.53	7.03e-26	Schizophrenia;
CRC	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg16606324	chr3:10149918	C3orf24	-0.73	-10.16	-0.49	2.82e-21	Alzheimer's disease;
CRC	cis	rs365302	1.000	rs449385	chr6:159644318	A/G	cg14500486	chr6:159655392	FNDC1	0.44	6.61	0.34	1.59e-10	Coronary heart disease;
CRC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	0.72	6.79	0.35	5.36e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05607246	chr6:139695661	CITED2	-0.41	-6.47	-0.34	3.55e-10	Obesity-related traits;
CRC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.48	0.38	6.79e-13	Calcium levels;
CRC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.17	10.87	0.51	1.05e-23	Alzheimer's disease (late onset);
CRC	cis	rs6432018	1.000	rs6745213	chr2:9741546	A/G	cg12832956	chr2:9616023	IAH1	-0.37	-5.65	-0.3	3.48e-8	Heart rate variability traits;
CRC	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.34	6.19	0.32	1.83e-9	Neuroticism;
CRC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.75	-0.3	2e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs4973397	0.810	rs12993290	chr2:232279687	G/A	cg13347044	chr2:232276743	NA	0.5	7.1	0.36	7.82e-12	Anti-saccade response;
CRC	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg06632207	chr12:54070931	ATP5G2	0.41	7.07	0.36	9.17e-12	Height;
CRC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.66	0.57	3.42e-30	Platelet count;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.57	8.34	0.42	2.07e-15	Lymphocyte counts;
CRC	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg17145862	chr1:211918768	LPGAT1	-0.51	-8.49	-0.42	7.05e-16	Leprosy;
CRC	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg21918786	chr6:109611834	NA	-0.33	-5.7	-0.3	2.65e-8	Reticulocyte fraction of red cells;
CRC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.61	0.34	1.57e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10924970	0.649	rs4659656	chr1:235384114	A/G	cg09010748	chr1:235293032	TOMM20	-0.4	-5.82	-0.31	1.39e-8	Asthma;
CRC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	8.49	0.42	7.43e-16	Total body bone mineral density;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg09877947	chr5:131593287	PDLIM4	0.58	10.21	0.49	1.93e-21	Acylcarnitine levels;
CRC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.64	6.46	0.34	3.68e-10	Axial length;
CRC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg01629716	chr15:45996671	NA	0.41	8.41	0.42	1.29e-15	Waist circumference;Weight;
CRC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.61	-8.95	-0.44	2.72e-17	Systolic blood pressure;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg02683197	chr6:28174875	NA	0.75	9.8	0.48	4.46e-20	Parkinson's disease;
CRC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg12458913	chr13:53173898	NA	0.8	14.88	0.63	1.15e-38	Lewy body disease;
CRC	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.85	-14.62	-0.63	1.17e-37	Longevity;
CRC	cis	rs6504622	0.935	rs62075889	chr17:45028037	A/T	cg16759221	chr17:45003025	GOSR2	0.45	7.17	0.37	4.83e-12	Orofacial clefts;
CRC	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg09659197	chr4:152720779	NA	0.52	11.28	0.53	3.52e-25	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.97	-0.4	2.62e-14	Chronic sinus infection;
CRC	cis	rs10512697	0.803	rs11739180	chr5:3580077	C/A	cg19473799	chr5:3511975	NA	-0.72	-5.69	-0.3	2.81e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg16447950	chr5:562315	NA	-0.84	-11.5	-0.54	6.14e-26	Lung disease severity in cystic fibrosis;
CRC	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.07	-15.45	-0.65	6.9e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.96	11.85	0.55	3.3e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.5	8.06	0.41	1.45e-14	Height;
CRC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-1.04	-13.4	-0.59	5.46e-33	Cerebrospinal P-tau181p levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02700172	chr2:241377874	GPC1	0.41	6.01	0.31	5.04e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15015892	chr1:151810887	C2CD4D;LOC100132111	0.2	6.02	0.31	4.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10888329	0.744	rs6587433	chr1:248355279	G/A	cg00666640	chr1:248458726	OR2T12	0.43	7.05	0.36	1.05e-11	Autism spectrum disorder;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.75	10.69	0.51	4.33e-23	Menarche (age at onset);
CRC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.82e-8	Major depressive disorder;
CRC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.51	-0.38	5.61e-13	Alzheimer's disease;
CRC	cis	rs863345	0.604	rs1894038	chr1:158455947	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.07	-0.32	3.47e-9	Pneumococcal bacteremia;
CRC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.6	11.31	0.53	2.93e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.89	-15.02	-0.64	3.48e-39	Gut microbiota (bacterial taxa);
CRC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.51	0.38	5.7e-13	Neuroticism;
CRC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.52	8.33	0.42	2.24e-15	Menopause (age at onset);
CRC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg02569458	chr12:86230093	RASSF9	0.38	6.57	0.34	1.99e-10	Major depressive disorder;
CRC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.49	-7.43	-0.38	9.24e-13	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.42	5.93	0.31	7.86e-9	Renal cell carcinoma;
CRC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.56	10.73	0.51	3.25e-23	Asthma (sex interaction);
CRC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg12193833	chr17:30244370	NA	-0.63	-8.23	-0.41	4.38e-15	Hip circumference adjusted for BMI;
CRC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.34	-5.66	-0.3	3.31e-8	Gout;Renal underexcretion gout;
CRC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg21747405	chr11:67723411	NA	-0.44	-6.21	-0.32	1.6e-9	Blood pressure (smoking interaction);
CRC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.54	0.38	4.76e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg18016565	chr1:150552671	MCL1	0.42	6.02	0.31	4.66e-9	Melanoma;
CRC	cis	rs477692	0.569	rs10764884	chr10:131308370	G/C	cg05714579	chr10:131428358	MGMT	0.53	7.71	0.39	1.49e-13	Response to temozolomide;
CRC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.58	7.67	0.39	1.97e-13	Arsenic metabolism;
CRC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.49	-0.34	3.21e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg13057898	chr1:3703894	LRRC47	0.43	5.83	0.31	1.35e-8	Red cell distribution width;
CRC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.57	-0.39	3.84e-13	Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13265914	chr8:21999630	REEP4	0.51	7.58	0.39	3.48e-13	Response to antipsychotic treatment;
CRC	trans	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg20935933	chr6:143382018	AIG1	0.52	6.73	0.35	7.57e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg20487152	chr13:99095054	FARP1	-0.45	-6.71	-0.35	8.71e-11	Longevity;
CRC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	8.2	0.41	5.52e-15	Cognitive test performance;
CRC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.61	8.53	0.43	5.32e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24308560	chr3:49941425	MST1R	0.45	7.01	0.36	1.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.6	8.58	0.43	3.83e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.35	-0.46	1.39e-18	HDL cholesterol;
CRC	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.65	-9.98	-0.48	1.2e-20	Dementia with Lewy bodies;
CRC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.96	-18.43	-0.71	1.31e-52	Myeloid white cell count;
CRC	cis	rs9969804	0.905	rs1111047	chr9:95397418	C/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.85	-0.31	1.19e-8	Height;
CRC	trans	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg18288967	chr1:45987694	PRDX1	0.66	7.7	0.39	1.64e-13	Obesity-related traits;
CRC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.76e-24	Bone mineral density;
CRC	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.31	5.7	0.3	2.7e-8	QRS complex (12-leadsum);
CRC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.62	-0.34	1.47e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg16898833	chr6:26189333	HIST1H4D	0.97	7.92	0.4	3.81e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs77861329	0.748	rs731684	chr3:52109841	T/C	cg08692210	chr3:52188851	WDR51A	0.51	5.77	0.3	1.85e-8	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6445967	0.689	rs11714574	chr3:58380465	A/T	cg23715586	chr3:58305044	RPP14	0.34	6.12	0.32	2.64e-9	Platelet count;
CRC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.63	-9.31	-0.46	1.84e-18	Mean platelet volume;Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04799181	chr3:46037014	FYCO1	0.45	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.09e-12	Rheumatoid arthritis;
CRC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.85	0.31	1.16e-8	Renal function-related traits (BUN);
CRC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-6.52	-0.34	2.64e-10	Bladder cancer;
CRC	cis	rs12760731	0.720	rs10798607	chr1:178373110	C/T	cg00404053	chr1:178313656	RASAL2	1.16	11.74	0.54	8.13e-27	Obesity-related traits;
CRC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.37	0.38	1.43e-12	Total body bone mineral density;
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.57	-8.87	-0.44	4.74e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7072216	0.555	rs2296433	chr10:100184062	C/A	cg26618903	chr10:100175079	PYROXD2	-0.49	-7.34	-0.38	1.67e-12	Metabolite levels;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg24634471	chr8:143751801	JRK	-0.45	-6.38	-0.33	5.86e-10	Urinary tract infection frequency;
CRC	cis	rs4150161	0.591	rs1056616	chr16:84211718	C/T	cg10106505	chr16:84220380	TAF1C	-0.66	-6.61	-0.34	1.56e-10	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.28	-0.33	1.09e-9	Alzheimer's disease (late onset);
CRC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.84	-11.5	-0.54	6.02e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.49	-0.38	6.57e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs35123781	1.000	rs2336880	chr5:139063728	A/G	cg10513866	chr5:139070639	NA	-0.44	-7.13	-0.37	6.36e-12	Schizophrenia;
CRC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg14673194	chr17:80132900	CCDC57	-0.5	-6.59	-0.34	1.7e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.99	-17.95	-0.7	1.05e-50	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs3018066	0.748	rs12509366	chr4:107003343	A/G	cg01869342	chr4:106983673	TBCK	0.46	6.79	0.35	5.15e-11	Cancer;
CRC	cis	rs1619661	0.591	rs605414	chr10:44744110	C/T	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	QT interval (ambient particulate matter interaction);
CRC	trans	rs10411161	0.702	rs7251755	chr19:52388948	G/A	cg22319618	chr22:45562946	NUP50	-0.65	-7.22	-0.37	3.63e-12	Breast cancer;
CRC	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg16989719	chr2:238392110	NA	-0.4	-7.86	-0.4	5.57e-14	Prostate cancer;
CRC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.09	-0.45	9.8e-18	Hip circumference adjusted for BMI;
CRC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.48	-5.93	-0.31	7.63e-9	Systemic lupus erythematosus;
CRC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.65	-0.3	3.39e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.39	0.33	5.68e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6534441	0.727	rs56149912	chr4:125440131	G/A	cg21609808	chr4:125404261	NA	0.39	5.63	0.3	3.77e-8	Major depressive disorder;
CRC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	9.79	0.47	5.06e-20	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23422044	chr7:1970798	MAD1L1	-0.44	-6.22	-0.32	1.55e-9	Neuroticism;
CRC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg23625390	chr15:77176239	SCAPER	0.4	5.94	0.31	7.34e-9	Blood metabolite levels;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg04518342	chr5:131593106	PDLIM4	0.41	6.88	0.35	3.03e-11	Blood metabolite levels;
CRC	cis	rs727505	0.607	rs67673811	chr7:124802694	C/G	cg23710748	chr7:124431027	NA	-0.63	-10.25	-0.49	1.4e-21	Lewy body disease;
CRC	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg16558208	chr1:156270281	VHLL	0.58	9.08	0.45	1.03e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7113874	0.524	rs10769926	chr11:8623674	C/A	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14599714	chr12:31226825	DDX11	0.43	5.99	0.31	5.63e-9	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg20607287	chr7:12443886	VWDE	-0.56	-6.15	-0.32	2.21e-9	Coronary artery disease;
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.88	0.31	9.94e-9	Prudent dietary pattern;
CRC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.51	-0.42	6.2e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7503807	0.515	rs12452916	chr17:78664655	C/T	cg00549398	chr17:78725201	RPTOR	0.43	5.61	0.3	4.29e-8	Obesity;
CRC	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.47	-6.56	-0.34	2.04e-10	Superior crus of antihelix expression;
CRC	cis	rs9584850	0.834	rs745639	chr13:99119279	C/T	cg20487152	chr13:99095054	FARP1	0.41	6.08	0.32	3.34e-9	Neuroticism;
CRC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.58	6.84	0.35	3.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07681084	chr7:156685826	LMBR1	0.39	6.0	0.31	5.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg06917450	chr1:38156652	C1orf109	-0.51	-7.27	-0.37	2.69e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg27053337	chr8:124217698	FAM83A	0.48	7.1	0.36	7.74e-12	Urinary uromodulin levels;
CRC	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	1.0	11.4	0.53	1.34e-25	Diisocyanate-induced asthma;
CRC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-7.47	-0.38	7.42e-13	Colorectal cancer;
CRC	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-6.87	-0.35	3.14e-11	Menopause (age at onset);
CRC	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs7572644	0.509	rs13001060	chr2:28025061	T/C	cg27432699	chr2:27873401	GPN1	0.45	5.73	0.3	2.24e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.98	0.44	2.15e-17	Fuchs's corneal dystrophy;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25111554	chr5:74348903	NA	0.4	6.54	0.34	2.34e-10	Schizophrenia;
CRC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.48	-0.34	3.42e-10	Systemic lupus erythematosus;
CRC	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg16898833	chr6:26189333	HIST1H4D	0.87	7.3	0.37	2.2e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.86	10.37	0.5	5.69e-22	Menarche (age at onset);
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg04493422	chr21:48055366	PRMT2	0.5	6.01	0.31	5.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4728302	0.869	rs6969899	chr7:133597490	A/G	cg03336402	chr7:133662267	EXOC4	-0.44	-6.42	-0.33	4.78e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	0.99	14.36	0.62	1.17e-36	Breast cancer;
CRC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.6	-8.61	-0.43	3.1e-16	Subjective well-being;
CRC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.67	9.5	0.46	4.55e-19	Vitiligo;
CRC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.06	-0.41	1.44e-14	Brugada syndrome;
CRC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.27e-20	Hip circumference adjusted for BMI;
CRC	cis	rs904251	0.686	rs2776911	chr6:37439950	T/A	cg25019722	chr6:37503610	NA	-0.42	-6.09	-0.32	3.12e-9	Cognitive performance;
CRC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.14	-0.32	2.42e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.01	-0.48	9.09e-21	Menarche (age at onset);
CRC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.81	-8.56	-0.43	4.49e-16	Coronary artery disease;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.64	-10.04	-0.48	7.15e-21	Lymphocyte counts;
CRC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg10589385	chr1:150898437	SETDB1	0.28	5.97	0.31	6.08e-9	Tonsillectomy;
CRC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.62	9.5	0.46	4.43e-19	Corneal astigmatism;
CRC	trans	rs6544773	0.529	rs341588	chr2:45047870	T/C	cg10208897	chr5:178548229	ADAMTS2	0.34	6.07	0.32	3.62e-9	Mosquito bite size;
CRC	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.44	-6.95	-0.36	1.91e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.74	7.56	0.38	4.17e-13	Diabetic retinopathy;
CRC	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.61	7.51	0.38	5.72e-13	Post bronchodilator FEV1;
CRC	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.36	-0.53	1.89e-25	Platelet distribution width;
CRC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.75e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.9	0.55	2.04e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.07	-0.32	3.51e-9	Aortic root size;
CRC	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.17	-0.37	4.83e-12	Tuberculosis;
CRC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg16989719	chr2:238392110	NA	-0.46	-7.88	-0.4	4.73e-14	Prostate cancer;
CRC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.49	6.68	0.35	1.04e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.23e-8	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.38	5.95	0.31	6.73e-9	Height;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg17346650	chr17:80929145	B3GNTL1	0.39	5.82	0.31	1.42e-8	Glycated hemoglobin levels;
CRC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.06	10.59	0.5	9.22e-23	Diabetic retinopathy;
CRC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.42	6.51	0.34	2.76e-10	Monocyte count;
CRC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.64	9.39	0.46	1.01e-18	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.83	0.44	6.45e-17	Rheumatoid arthritis;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.82	9.11	0.45	8.01e-18	Breast cancer;
CRC	trans	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.23e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg07713946	chr22:31675144	LIMK2	-0.39	-5.62	-0.3	4.12e-8	Colorectal cancer;
CRC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg09658497	chr7:2847517	GNA12	0.41	5.65	0.3	3.48e-8	Height;
CRC	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06745235	chr1:180471494	ACBD6	-0.5	-6.0	-0.31	5.25e-9	Diisocyanate-induced asthma;
CRC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.66	11.27	0.53	3.8e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.0	-0.36	1.47e-11	Bipolar disorder;
CRC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.57	-8.44	-0.42	1.01e-15	Migraine;Coronary artery disease;
CRC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.41	0.38	1.08e-12	Colorectal cancer;
CRC	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22601191	chr20:60968625	CABLES2	0.54	8.83	0.44	6.51e-17	Colorectal cancer;
CRC	cis	rs7731657	0.537	rs10066004	chr5:130304689	G/A	cg08523029	chr5:130500466	HINT1	-0.48	-6.15	-0.32	2.2e-9	Fasting plasma glucose;
CRC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.74	-9.34	-0.46	1.45e-18	Body mass index;
CRC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.6	-9.69	-0.47	1.03e-19	Anterior chamber depth;
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg21851534	chr17:3907994	ZZEF1	0.36	6.34	0.33	7.65e-10	Type 2 diabetes;
CRC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-12.44	-0.57	2.25e-29	Extrinsic epigenetic age acceleration;
CRC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg21153622	chr11:89784906	NA	-0.43	-7.04	-0.36	1.15e-11	Height;
CRC	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.22	-6.17	-0.32	2.05e-9	Urinary metabolites;
CRC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg09655341	chr17:79618100	PDE6G	0.54	6.56	0.34	2.05e-10	Dental caries;
CRC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.96	-18.51	-0.71	6.54e-53	Height;
CRC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.9	16.6	0.68	2.13e-45	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg12046867	chr14:103022105	NA	-0.82	-11.79	-0.55	5.13e-27	Platelet count;
CRC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.74	0.57	1.73e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.06	9.98	0.48	1.12e-20	Opioid sensitivity;
CRC	cis	rs9463078	0.774	rs9296457	chr6:45264687	A/G	cg25276700	chr6:44698697	NA	-0.28	-6.72	-0.35	8.12e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-6.33	-0.33	7.99e-10	Menopause (age at onset);
CRC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19346786	chr7:2764209	NA	-0.36	-6.25	-0.33	1.25e-9	Height;
CRC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg02659138	chr7:134003124	SLC35B4	0.36	6.24	0.33	1.33e-9	Mean platelet volume;
CRC	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg07699608	chr10:75541558	CHCHD1	0.61	6.37	0.33	6.53e-10	Incident atrial fibrillation;
CRC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg20607287	chr7:12443886	VWDE	-0.68	-7.33	-0.37	1.84e-12	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg12172441	chr6:28176163	NA	0.52	7.34	0.38	1.64e-12	Parkinson's disease;
CRC	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg16540259	chr10:75572220	NDST2	0.52	7.65	0.39	2.22e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7300001	0.504	rs12318462	chr12:110504717	C/A	cg12870014	chr12:110450643	ANKRD13A	0.89	7.48	0.38	6.96e-13	Headache;
CRC	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.65	10.13	0.49	3.5e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.56	8.39	0.42	1.41e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.81	14.44	0.62	5.85e-37	Vitiligo;
CRC	cis	rs4731207	0.596	rs1013754	chr7:124642047	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.27e-9	Cutaneous malignant melanoma;
CRC	cis	rs16867335	1.000	rs16867335	chr2:181458934	C/T	cg23363182	chr2:181467187	NA	-0.49	-6.62	-0.34	1.45e-10	Survival in rectal cancer;
CRC	cis	rs9549328	0.700	rs3011474	chr13:113617865	T/C	cg08614441	chr13:113633676	MCF2L	0.4	7.04	0.36	1.13e-11	Systolic blood pressure;
CRC	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg12856521	chr11:46389249	DGKZ	0.44	7.26	0.37	2.78e-12	Leprosy;
CRC	trans	rs11654801	0.947	rs11656662	chr17:20921837	G/C	cg23759823	chr7:139672531	TBXAS1	-0.45	-6.42	-0.33	4.71e-10	Mosquito bite size;
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.37	-5.77	-0.3	1.87e-8	Platelet count;
CRC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.35	0.42	1.89e-15	Homoarginine levels;
CRC	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg19875578	chr6:126661172	C6orf173	0.4	5.63	0.3	3.94e-8	Male-pattern baldness;
CRC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.64	6.33	0.33	7.87e-10	Diabetic retinopathy;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg12273811	chr6:28175739	NA	0.58	7.29	0.37	2.36e-12	Parkinson's disease;
CRC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.28	0.33	1.05e-9	Heart rate;
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg02549819	chr16:58548995	SETD6	1.29	8.25	0.41	3.97e-15	Schizophrenia;
CRC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg02741985	chr17:80059408	CCDC57	0.44	7.03	0.36	1.17e-11	Life satisfaction;
CRC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.33	5.67	0.3	3.18e-8	Schizophrenia;
CRC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-8.07	-0.41	1.33e-14	IgG glycosylation;
CRC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.66	-0.34	1.18e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg00603274	chr11:61596626	FADS2	-0.43	-6.3	-0.33	9.63e-10	Trans fatty acid levels;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01171360	chr6:293285	DUSP22	-0.47	-6.66	-0.34	1.16e-10	Menopause (age at onset);
CRC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.12	10.36	0.5	5.96e-22	Diabetic retinopathy;
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.33	-0.42	2.28e-15	Electroencephalogram traits;
CRC	cis	rs11212617	1.000	rs11212579	chr11:108150664	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.14	0.32	2.42e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.66	-6.2	-0.32	1.68e-9	Tuberculosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00301775	chr5:40798454	PRKAA1	-0.43	-6.5	-0.34	2.94e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg19824325	chr16:58548873	SETD6	0.98	6.47	0.34	3.47e-10	Schizophrenia;
CRC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.43	-6.43	-0.33	4.49e-10	Ulcerative colitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04616222	chr10:99078965	FRAT1	0.44	5.97	0.31	6.31e-9	Anxiety disorder;
CRC	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.65	-10.3	-0.49	9.19e-22	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22066877	chr1:160175701	PEA15	0.43	6.29	0.33	9.95e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg00666640	chr1:248458726	OR2T12	0.46	8.34	0.42	2.05e-15	Common traits (Other);
CRC	cis	rs9463078	0.653	rs6899378	chr6:45080368	C/T	cg25276700	chr6:44698697	NA	-0.24	-5.8	-0.3	1.6e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-7.09	-0.36	8.36e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs7147624	1.000	rs10083363	chr14:66200768	G/A	cg03016385	chr14:66212404	NA	-1.03	-10.36	-0.5	5.94e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.6	10.69	0.51	4.26e-23	Aortic root size;
CRC	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.62	-10.29	-0.49	1.01e-21	Breast cancer;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.45	5.66	0.3	3.37e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs2518564	0.541	rs2814764	chr1:159064568	A/T	cg03710481	chr6:122931605	PKIB	0.52	6.11	0.32	2.79e-9	White blood cell count;
CRC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.34	-0.38	1.68e-12	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.35	0.53	2.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg00999904	chr2:3704751	ALLC	-0.53	-6.7	-0.35	9.16e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-10.84	-0.51	1.32e-23	Platelet distribution width;
CRC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.68	10.49	0.5	2.06e-22	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12045430	chr1:29407	WASH5P	0.37	7.28	0.37	2.45e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.6	-8.82	-0.44	6.62e-17	Response to bleomycin (chromatid breaks);
CRC	cis	rs10905065	1.000	rs10795488	chr10:5755207	C/A	cg11519256	chr10:5708881	ASB13	0.44	6.19	0.32	1.77e-9	Menopause (age at onset);
CRC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.56	6.16	0.32	2.09e-9	Vitiligo;
CRC	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg23032129	chr1:109941072	SORT1	-0.27	-5.84	-0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.56	7.47	0.38	7.35e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.79	8.19	0.41	5.73e-15	Diabetic retinopathy;
CRC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.63	11.7	0.54	1.12e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.65	7.08	0.36	8.92e-12	Cannabis dependence symptom count;
CRC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg05501817	chr11:14380813	RRAS2	-0.42	-5.85	-0.31	1.2e-8	Sense of smell;
CRC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.24	-0.37	3.29e-12	Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg21770322	chr7:97807741	LMTK2	0.52	8.48	0.42	7.61e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03432641	chr12:49760606	SPATS2	0.44	6.1	0.32	2.91e-9	Anxiety disorder;
CRC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.22	0.45	3.69e-18	Cognitive test performance;
CRC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.44	7.54	0.38	4.6e-13	Alcohol dependence;
CRC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.81	-0.4	7.9e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.31	-5.75	-0.3	2.01e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.96	-17.86	-0.7	2.34e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg00953403	chr17:74099816	EXOC7	-0.46	-6.25	-0.33	1.26e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg24324837	chr19:49891574	CCDC155	-0.52	-6.8	-0.35	4.8e-11	Multiple sclerosis;
CRC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.65	-0.57	3.69e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg23815491	chr16:72088622	HP	0.5	7.33	0.37	1.77e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs11212617	1.000	rs599558	chr11:108177538	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.21	0.32	1.59e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.53	9.93	0.48	1.64e-20	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg11441379	chr12:63026424	NA	0.54	5.67	0.3	3.09e-8	IgG glycosylation;
CRC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.45	6.63	0.34	1.4e-10	Menopause (age at onset);
CRC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg20092199	chr4:1342459	KIAA1530	0.49	8.22	0.41	4.68e-15	Obesity-related traits;
CRC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.46	6.86	0.35	3.39e-11	Uric acid clearance;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg10217327	chr6:118973057	C6orf204	0.52	5.94	0.31	7.42e-9	Diastolic blood pressure;
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg27068330	chr11:65405492	SIPA1	-0.63	-9.46	-0.46	5.9e-19	Acne (severe);
CRC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.64	-13.26	-0.59	1.86e-32	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03205495	chr19:14640249	TECR;MIR639	0.45	6.11	0.32	2.79e-9	Response to antipsychotic treatment;
CRC	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.71	0.3	2.58e-8	Heart rate;
CRC	cis	rs6738825	0.547	rs67616109	chr2:198409490	G/A	cg10820045	chr2:198174542	NA	0.34	6.06	0.32	3.83e-9	Crohn's disease;
CRC	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.6	-9.69	-0.47	1.09e-19	Itch intensity from mosquito bite;
CRC	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.38	5.98	0.31	5.72e-9	Reticulocyte fraction of red cells;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg21251018	chr6:28226885	NKAPL	0.52	7.36	0.38	1.52e-12	Depression;
CRC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg20503657	chr10:835505	NA	0.66	8.82	0.44	6.86e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.61	-8.79	-0.44	8.67e-17	Testicular germ cell tumor;
CRC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg09325506	chr2:243030735	LOC728323	-0.44	-6.0	-0.31	5.28e-9	Select biomarker traits;
CRC	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg20487152	chr13:99095054	FARP1	0.36	5.93	0.31	7.65e-9	Longevity;
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.84	-0.58	7.52e-31	Alzheimer's disease;
CRC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.51	7.69	0.39	1.75e-13	Corneal astigmatism;
CRC	trans	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg26043149	chr18:55253948	FECH	-0.48	-7.48	-0.38	6.96e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3996993	0.597	rs12529923	chr6:52736056	C/T	cg20803780	chr6:52668592	GSTA1	0.39	6.61	0.34	1.57e-10	Hemoglobin concentration;
CRC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.63	-9.28	-0.46	2.33e-18	Cognitive function;
CRC	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg15704280	chr7:45808275	SEPT13	0.65	6.22	0.32	1.49e-9	Axial length;
CRC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.58	-6.97	-0.36	1.78e-11	Tuberculosis;
CRC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg22834771	chr12:69754056	YEATS4	-0.41	-5.9	-0.31	9.25e-9	Blood protein levels;
CRC	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg04731861	chr2:219085781	ARPC2	0.29	6.01	0.31	4.97e-9	Ulcerative colitis;
CRC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg00999904	chr2:3704751	ALLC	-0.53	-6.7	-0.35	9.16e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.18	-0.37	4.56e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.98	-0.31	5.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg01639898	chr1:32083012	HCRTR1	0.29	5.93	0.31	7.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs939584	1.000	rs7559018	chr2:645203	C/T	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.61	-0.43	3.02e-16	Bipolar disorder;
CRC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.4	-0.46	9.56e-19	Body mass index;
CRC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.75e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.97	-0.31	5.98e-9	Life satisfaction;
CRC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.24	-0.33	1.36e-9	Bipolar disorder;
CRC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.1	-0.36	7.58e-12	Joint mobility (Beighton score);
CRC	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg11579758	chr4:1086637	RNF212	-0.4	-6.59	-0.34	1.77e-10	Recombination rate (males);
CRC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.22	-0.32	1.52e-9	Life satisfaction;
CRC	cis	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg15845792	chr6:28175446	NA	0.89	5.71	0.3	2.56e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg19875578	chr6:126661172	C6orf173	0.43	5.87	0.31	1.09e-8	Male-pattern baldness;
CRC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.47	-6.6	-0.34	1.68e-10	Schizophrenia;
CRC	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg12573674	chr2:1569213	NA	-0.74	-7.3	-0.37	2.21e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.61	10.87	0.51	1e-23	Schizophrenia;
CRC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.63	11.52	0.54	5.02e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17914881	chr12:121838395	RNF34	0.42	6.44	0.33	4.32e-10	Schizophrenia;
CRC	cis	rs10924970	0.649	rs4659492	chr1:235482207	T/G	cg09010748	chr1:235293032	TOMM20	-0.4	-5.65	-0.3	3.57e-8	Asthma;
CRC	cis	rs6662572	0.737	rs75490316	chr1:46553785	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.96	0.31	6.59e-9	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23508591	chr15:75871807	PTPN9	0.42	6.85	0.35	3.59e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.31	-0.42	2.53e-15	Morning vs. evening chronotype;
CRC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.39	-0.5	4.64e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs672059	1.000	rs660602	chr1:183162774	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.48	6.88	0.35	3.1e-11	Hypertriglyceridemia;
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs4660306	0.614	rs1007859	chr1:45911906	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.64	0.34	1.32e-10	Homocysteine levels;
CRC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg23298862	chr7:158159286	PTPRN2	0.39	5.99	0.31	5.39e-9	Calcium levels;
CRC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.46	6.69	0.35	9.68e-11	Cognitive function;
CRC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22878388	chr2:105853796	NA	-0.34	-6.54	-0.34	2.41e-10	Type 2 diabetes;
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.56	-7.12	-0.37	6.68e-12	Blood pressure (smoking interaction);
CRC	cis	rs4654899	0.802	rs1530946	chr1:21182540	A/G	cg02927042	chr1:21476669	EIF4G3	0.45	7.22	0.37	3.68e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg26618903	chr10:100175079	PYROXD2	-0.42	-6.42	-0.33	4.89e-10	Metabolite levels;
CRC	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.09	-0.32	3.14e-9	Inflammatory bowel disease;
CRC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.73	-11.31	-0.53	2.88e-25	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	trans	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.27	0.46	2.55e-18	Mean corpuscular volume;
CRC	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg13086574	chr8:135490821	ZFAT	-0.35	-6.06	-0.32	3.63e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs910187	0.641	rs6018327	chr20:45813126	C/T	cg27589058	chr20:45804311	EYA2	-0.39	-7.36	-0.38	1.49e-12	Migraine;
CRC	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.43	7.23	0.37	3.5e-12	Total cholesterol levels;
CRC	cis	rs10971721	0.822	rs41314578	chr9:33933941	T/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.57	-10.77	-0.51	2.23e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.47	-7.91	-0.4	3.83e-14	Life satisfaction;
CRC	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.36e-11	Prostate cancer;
CRC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg06028605	chr16:24865363	SLC5A11	-0.33	-6.35	-0.33	7.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.24	0.67	5.52e-44	Chronic sinus infection;
CRC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg10253484	chr15:75165896	SCAMP2	-0.37	-5.84	-0.31	1.23e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg15786705	chr6:28176104	NA	0.74	9.35	0.46	1.41e-18	Depression;
CRC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg21251018	chr6:28226885	NKAPL	0.45	6.51	0.34	2.73e-10	Parkinson's disease;
CRC	cis	rs7192750	0.535	rs152826	chr16:72126180	A/G	cg14768367	chr16:72042858	DHODH	0.85	6.44	0.33	4.18e-10	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs4731207	0.623	rs1600744	chr7:124585960	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs860295	0.702	rs10908479	chr1:155643403	C/T	cg02153340	chr1:155202674	NA	-0.53	-6.88	-0.35	3.1e-11	Body mass index;
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg10729496	chr3:10149963	C3orf24	0.51	6.6	0.34	1.68e-10	Alzheimer's disease;
CRC	cis	rs7107770	0.663	rs6590135	chr11:125073667	A/G	cg27629782	chr11:125073726	PKNOX2	0.5	7.18	0.37	4.78e-12	Photic sneeze reflex;
CRC	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.55	8.63	0.43	2.71e-16	Motion sickness;
CRC	cis	rs4731207	0.671	rs6466949	chr7:124444900	T/C	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg24675056	chr1:15929824	NA	0.46	6.32	0.33	8.53e-10	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25937884	chr5:180674133	NA	0.4	5.98	0.31	5.96e-9	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01481784	chr1:161369725	NA	0.4	6.17	0.32	2e-9	Schizophrenia;
CRC	cis	rs10229583	0.527	rs6943385	chr7:127308428	C/G	cg01233922	chr7:127693937	SND1	0.45	6.72	0.35	7.86e-11	Type 2 diabetes;
CRC	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.8	-0.35	4.85e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.79	13.98	0.61	3.42e-35	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.71	-0.3	2.5e-8	Blood trace element (Cu levels);
CRC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.17e-8	Skin colour saturation;
CRC	cis	rs3751196	0.711	rs78345851	chr12:104226206	C/T	cg02344784	chr12:104178138	NT5DC3	0.7	7.16	0.37	5.32e-12	Sense of smell;
CRC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg07636037	chr3:49044803	WDR6	-0.68	-6.53	-0.34	2.57e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	9.51	0.46	4.05e-19	Lymphocyte counts;
CRC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.67e-9	Menopause (age at onset);
CRC	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11547950	chr5:77652471	NA	-0.48	-7.03	-0.36	1.19e-11	Triglycerides;
CRC	trans	rs7179994	0.579	rs111884664	chr15:28300834	C/A	cg05237436	chr5:138533428	SIL1	0.71	6.29	0.33	1.03e-9	Shingles;
CRC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.72	11.63	0.54	2.02e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg14092571	chr14:90743983	NA	0.38	5.89	0.31	9.61e-9	Mortality in heart failure;
CRC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.56	8.6	0.43	3.21e-16	Breast cancer;
CRC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.82	0.35	4.46e-11	Obesity-related traits;
CRC	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	2.09e-8	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14264380	chr17:79651103	ARL16;HGS	0.44	6.31	0.33	8.93e-10	Anxiety disorder;
CRC	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.67	0.3	3.16e-8	Putamen volume;
CRC	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg18646521	chr2:111875858	NA	0.39	6.2	0.32	1.64e-9	Chronic lymphocytic leukemia;
CRC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.19	-0.32	1.74e-9	Reticulocyte count;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22478328	chr22:32340140	C22orf24;YWHAH	-0.53	-6.43	-0.33	4.39e-10	Diisocyanate-induced asthma;
CRC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.47	-0.38	7.17e-13	Colorectal cancer;
CRC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.29	-0.59	1.49e-32	Extrinsic epigenetic age acceleration;
CRC	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg12856521	chr11:46389249	DGKZ	-0.5	-8.27	-0.41	3.26e-15	Leprosy;
CRC	trans	rs587242	1.000	rs12758621	chr1:96898421	C/T	cg10631902	chr5:14652156	NA	0.44	6.83	0.35	4.06e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.88	-14.83	-0.63	1.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.32	8.07	0.41	1.31e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg06988349	chr10:69991859	ATOH7	0.36	5.71	0.3	2.59e-8	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
CRC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.42	6.18	0.32	1.85e-9	Renal cell carcinoma;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg19296258	chr17:78878799	RPTOR	0.4	6.05	0.32	3.87e-9	Menarche (age at onset);
CRC	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.55	-8.12	-0.41	9.58e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg25408707	chr6:160393049	IGF2R	-0.55	-6.1	-0.32	2.94e-9	Lymphocyte counts;
CRC	trans	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg10756647	chr7:56101905	PSPH	0.78	8.32	0.42	2.42e-15	Diabetic kidney disease;
CRC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.75	-0.35	6.82e-11	Total cholesterol levels;
CRC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.68	6.91	0.36	2.53e-11	Plasma clusterin levels;
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg13092806	chr2:177043255	NA	0.77	12.53	0.57	1.03e-29	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00408597	chr11:9685941	SWAP70	0.39	5.98	0.31	5.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01334186	chr1:151372572	PSMB4	-0.5	-6.18	-0.32	1.88e-9	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22522509	chr21:16436121	NRIP1	0.39	6.32	0.33	8.66e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg03340356	chr1:67600835	NA	0.26	5.87	0.31	1.09e-8	Psoriasis;
CRC	cis	rs8105895	0.935	rs9653142	chr19:22249596	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.46	9.49	0.46	4.98e-19	Renal cell carcinoma;
CRC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.79	-11.34	-0.53	2.19e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.67	8.93	0.44	3.04e-17	Bladder cancer;
CRC	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.72	-11.84	-0.55	3.54e-27	Idiopathic membranous nephropathy;
CRC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.19	0.41	5.91e-15	Resting heart rate;
CRC	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg26805224	chr10:79626177	DLG5	-0.5	-7.34	-0.38	1.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04483163	chr1:147806437	NA	-0.41	-6.59	-0.34	1.75e-10	Aortic root size;
CRC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.12	0.32	2.62e-9	Endometrial cancer;
CRC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg17321639	chr7:2759063	NA	-0.4	-6.07	-0.32	3.5e-9	Height;
CRC	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg07862535	chr7:139043722	LUC7L2	0.58	7.38	0.38	1.3e-12	Diisocyanate-induced asthma;
CRC	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.46	0.65	6.33e-41	Fuchs's corneal dystrophy;
CRC	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg25173405	chr17:45401733	C17orf57	-0.44	-6.82	-0.35	4.28e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.46	6.17	0.32	1.96e-9	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs727479	0.543	rs8023263	chr15:51517597	G/T	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.06	-0.32	3.76e-9	Estradiol levels;
CRC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg17333051	chr19:2783644	SGTA	0.47	6.9	0.36	2.69e-11	Total cholesterol levels;
CRC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.44	7.52	0.38	5.43e-13	Childhood ear infection;
CRC	cis	rs9463078	0.803	rs2396380	chr6:45043557	T/A	cg25276700	chr6:44698697	NA	-0.28	-6.71	-0.35	8.49e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.5	-5.61	-0.3	4.27e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00376283	chr12:123451042	ABCB9	-0.54	-6.14	-0.32	2.42e-9	Neutrophil percentage of white cells;
CRC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg04731861	chr2:219085781	ARPC2	0.31	6.36	0.33	6.89e-10	Colorectal cancer;
CRC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.65	-9.59	-0.47	2.22e-19	Cognitive function;
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.21e-15	Bipolar disorder;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg09844983	chr1:28240714	RPA2	0.4	6.02	0.31	4.62e-9	Crohn's disease;
CRC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg01620082	chr3:125678407	NA	-0.74	-6.23	-0.32	1.47e-9	Depression;
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.94	-0.31	7.33e-9	Menopause (age at onset);
CRC	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.81	-14.15	-0.62	7.86e-36	Lewy body disease;
CRC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.37	0.69	2.02e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.62	8.41	0.42	1.3e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.08	-0.32	3.39e-9	Menopause (age at onset);
CRC	cis	rs965469	0.947	rs6037578	chr20:3345911	T/C	cg25506879	chr20:3388711	C20orf194	-0.4	-5.77	-0.3	1.81e-8	IFN-related cytopenia;
CRC	cis	rs6988985	0.765	rs4736317	chr8:143982753	A/G	cg10324643	chr8:143916377	GML	0.38	6.17	0.32	2.01e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs10924970	0.649	rs1933247	chr1:235432767	A/G	cg09010748	chr1:235293032	TOMM20	-0.42	-5.77	-0.3	1.8e-8	Asthma;
CRC	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.18	-0.32	1.93e-9	Blood protein levels;
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-10.53	-0.5	1.57e-22	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.35	-5.88	-0.31	9.96e-9	Mean platelet volume;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg27048067	chr8:674560	ERICH1	-0.53	-5.84	-0.31	1.26e-8	IgG glycosylation;
CRC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg08200582	chr11:442649	ANO9	-0.66	-6.33	-0.33	7.93e-10	Body mass index;
CRC	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.67	-0.3	3.17e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg22903471	chr2:27725779	GCKR	-0.34	-5.63	-0.3	3.91e-8	Oral cavity cancer;
CRC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs4478858	0.684	rs12403136	chr1:31728920	A/G	cg00250761	chr1:31883323	NA	-0.41	-7.84	-0.4	6.13e-14	Alcohol dependence;
CRC	trans	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.59	-0.34	1.73e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06866400	chr6:143771904	ADAT2;PEX3	0.38	6.0	0.31	5.23e-9	Obesity-related traits;
CRC	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.52	-7.11	-0.36	7.28e-12	DNA methylation (variation);
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg21153622	chr11:89784906	NA	-0.51	-8.48	-0.42	7.88e-16	HDL cholesterol;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05360402	chr5:110848191	STARD4	-0.52	-6.33	-0.33	7.9e-10	Diisocyanate-induced asthma;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14331148	chr19:47551893	TMEM160	0.44	6.27	0.33	1.12e-9	Survival in pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13237843	chr11:6640720	TPP1	0.47	6.7	0.35	8.85e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21889078	chr8:56675203	TMEM68	-0.39	-6.56	-0.34	2.1e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6445525	0.935	rs6806075	chr3:66000650	G/T	cg06109867	chr3:66002991	MAGI1	-0.4	-6.55	-0.34	2.21e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26618056	chr16:25043323	NA	0.4	6.64	0.34	1.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.25	0.37	2.97e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.9	9.49	0.46	4.71e-19	Arsenic metabolism;
CRC	cis	rs6076065	0.723	rs1419009	chr20:23365094	G/A	cg11657817	chr20:23433608	CST11	0.47	6.9	0.36	2.64e-11	Facial morphology (factor 15, philtrum width);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18141918	chr10:89622539	PTEN;KILLIN	0.38	6.07	0.32	3.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.28	13.03	0.58	1.36e-31	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18462168	chr15:22892545	CYFIP1	0.45	6.34	0.33	7.52e-10	Response to antipsychotic treatment;
CRC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg24300038	chr13:113819356	PROZ	0.42	5.73	0.3	2.28e-8	Platelet distribution width;
CRC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-12.25	-0.56	1.07e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-7.95	-0.4	3.06e-14	Extraversion;
CRC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.57	-7.52	-0.38	5.3e-13	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.61	-0.43	3.04e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs9549260	0.564	rs12184871	chr13:41291928	C/A	cg21288729	chr13:41239152	FOXO1	0.43	6.73	0.35	7.66e-11	Red blood cell count;
CRC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.39	6.66	0.34	1.17e-10	Crohn's disease;
CRC	cis	rs4716602	0.633	rs10249382	chr7:156159349	G/T	cg16983916	chr7:156159713	NA	-0.41	-7.2	-0.37	4.03e-12	Anti-saccade response;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg09877947	chr5:131593287	PDLIM4	0.44	7.14	0.37	5.89e-12	Breast cancer;
CRC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg20387954	chr3:183756860	HTR3D	0.44	7.55	0.38	4.43e-13	Anterior chamber depth;
CRC	cis	rs3823572	0.542	rs2971974	chr7:133644598	C/T	cg03336402	chr7:133662267	EXOC4	0.68	10.57	0.5	1.1e-22	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg06740227	chr12:86229804	RASSF9	-0.38	-5.78	-0.3	1.74e-8	Major depressive disorder;
CRC	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00495681	chr13:53174319	NA	0.62	9.28	0.46	2.27e-18	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00660251	chr1:89991016	LRRC8B	0.4	6.28	0.33	1.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.96e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-5.92	-0.31	7.92e-9	Total body bone mineral density;
CRC	cis	rs7209700	0.889	rs16941801	chr17:45354543	G/C	cg17185639	chr17:45330862	ITGB3	0.35	5.84	0.31	1.27e-8	IgG glycosylation;
CRC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg13206674	chr6:150067644	NUP43	0.52	7.22	0.37	3.67e-12	Testicular germ cell tumor;
CRC	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.88	7.43	0.38	9.29e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg10517650	chr3:113235015	CCDC52	-0.39	-5.63	-0.3	3.88e-8	Dental caries;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg10596483	chr8:143751796	JRK	-0.49	-6.84	-0.35	3.88e-11	Urinary tract infection frequency;
CRC	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	17.41	0.69	1.38e-48	Electrocardiographic conduction measures;
CRC	cis	rs73200209	0.912	rs2288134	chr12:116441395	G/T	cg01776926	chr12:116560359	MED13L	-0.53	-6.47	-0.34	3.58e-10	Total body bone mineral density;
CRC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.79	-0.39	8.63e-14	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04720665	chr1:245028075	HNRNPU	0.48	6.86	0.35	3.33e-11	Response to antipsychotic treatment;
CRC	trans	rs728616	0.681	rs34816332	chr10:81907967	G/A	cg18543242	chr14:23290393	SLC7A7	0.48	6.47	0.34	3.58e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg13447295	chr6:887704	NA	-0.55	-7.39	-0.38	1.22e-12	Aging;
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg02683197	chr6:28174875	NA	0.64	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg00614641	chr11:61596405	FADS2	-0.57	-6.6	-0.34	1.63e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.57	0.34	1.97e-10	Depression;
CRC	trans	rs7594321	0.931	rs4973193	chr2:230230104	A/G	ch.3.5198520F	chr3:5223520	NA	0.41	5.96	0.31	6.54e-9	Pulmonary function (smoking interaction);
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.63	9.74	0.47	7.22e-20	Response to diuretic therapy;
CRC	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.42	6.35	0.33	7.28e-10	Neutrophil percentage of white cells;
CRC	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	0.9	6.76	0.35	6.12e-11	Fat distribution (HIV);
CRC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.93	-0.36	2.17e-11	Lung cancer;
CRC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg15786705	chr6:28176104	NA	0.62	8.75	0.43	1.12e-16	Cardiac Troponin-T levels;
CRC	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	0.99	18.28	0.71	5.27e-52	Schizophrenia;
CRC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.81	-0.3	1.51e-8	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15045943	chr5:171614719	STK10	0.47	6.69	0.35	9.9e-11	Response to antipsychotic treatment;
CRC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-12.96	-0.58	2.57e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.44	-5.9	-0.31	8.98e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02290350	chr8:58132656	NA	-0.5	-6.19	-0.32	1.75e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.92	13.49	0.6	2.49e-33	Alzheimer's disease;
CRC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.53	7.19	0.37	4.35e-12	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.54	6.9	0.36	2.74e-11	Obesity-related traits;
CRC	trans	rs1916521	0.519	rs7914545	chr10:57420576	C/A	cg16731318	chr1:94313343	NA	-0.43	-6.01	-0.31	4.85e-9	Cardiac hypertrophy;
CRC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.94	-0.4	3.24e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.61	-8.53	-0.43	5.28e-16	Intelligence (multi-trait analysis);
CRC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.61	8.31	0.42	2.62e-15	Menopause (age at onset);
CRC	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.52	6.74	0.35	7.02e-11	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04139300	chr20:40247070	CHD6	0.5	6.68	0.35	1.01e-10	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg03037974	chr15:76606532	NA	-0.5	-7.46	-0.38	7.86e-13	Blood metabolite levels;
CRC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.68	-9.22	-0.45	3.53e-18	Cleft lip with or without cleft palate;
CRC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-6.34	-0.33	7.45e-10	Menarche (age at onset);
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg24046110	chr8:143859143	LYNX1	0.49	8.61	0.43	3.15e-16	Urinary tract infection frequency;
CRC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg15147215	chr3:52552868	STAB1	-0.65	-11.31	-0.53	2.8e-25	Electroencephalogram traits;
CRC	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.69	-10.65	-0.51	5.92e-23	Type 2 diabetes;
CRC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.65	-7.54	-0.38	4.59e-13	Vitiligo;
CRC	trans	rs57590327	0.503	rs1461611	chr3:81512061	C/A	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-6.0	-0.31	5.25e-9	Extraversion;
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.18	-0.32	1.89e-9	QT interval;
CRC	cis	rs728616	0.867	rs28365998	chr10:81965436	C/A	cg11900509	chr10:81946545	ANXA11	-0.77	-7.17	-0.37	5.08e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.43	6.21	0.32	1.62e-9	HIV-1 control;
CRC	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.56	-9.01	-0.44	1.74e-17	Neuroticism;
CRC	cis	rs9309413	0.679	rs6717329	chr2:68555700	C/T	cg21581504	chr2:68545960	CNRIP1	-0.33	-6.09	-0.32	3.13e-9	Metabolite levels;
CRC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg08772003	chr10:104629869	AS3MT	-0.4	-6.7	-0.35	9.14e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg01483505	chr11:975446	AP2A2	0.46	7.59	0.39	3.23e-13	Alzheimer's disease (late onset);
CRC	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.01	0.4	2.01e-14	Coffee consumption (cups per day);
CRC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg12935359	chr14:103987150	CKB	-0.37	-6.19	-0.32	1.83e-9	Body mass index;
CRC	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg07617317	chr6:118971624	C6orf204	0.51	5.88	0.31	1.02e-8	Renal cell carcinoma;
CRC	trans	rs6546324	0.625	rs2861695	chr2:67846727	A/G	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.14	-0.32	2.38e-9	Endometriosis;
CRC	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.88	-0.31	9.84e-9	Height;
CRC	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.62	8.6	0.43	3.36e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-9.44	-0.46	7.22e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.67	10.62	0.51	7.51e-23	Sudden cardiac arrest;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs449789	0.857	rs687314	chr6:159716262	G/C	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.68	9.02	0.45	1.57e-17	Bronchopulmonary dysplasia;
CRC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg21155852	chr7:2048760	MAD1L1	0.42	6.1	0.32	3.02e-9	Bipolar disorder;
CRC	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.54	-7.63	-0.39	2.52e-13	Prostate cancer;
CRC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.62	7.95	0.4	2.92e-14	Gut microbiome composition (summer);
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23708337	chr7:1209742	NA	-0.42	-6.33	-0.33	7.88e-10	Longevity;Endometriosis;
CRC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.82	-0.58	8.34e-31	Ulcerative colitis;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg04518342	chr5:131593106	PDLIM4	0.43	6.82	0.35	4.33e-11	Blood metabolite levels;
CRC	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.7	-0.3	2.61e-8	Blood protein levels;
CRC	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg00105475	chr2:10696890	NA	0.45	7.12	0.37	6.81e-12	Prostate cancer;
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg10217327	chr6:118973057	C6orf204	0.51	5.81	0.3	1.5e-8	Renal cell carcinoma;
CRC	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg17948913	chr5:572064	NA	0.51	5.87	0.31	1.07e-8	Obesity-related traits;
CRC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.74	-8.39	-0.42	1.42e-15	Obesity-related traits;
CRC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	8.1	0.41	1.05e-14	Body mass index;
CRC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.4	5.97	0.31	6.29e-9	Height;
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.75	-0.35	6.85e-11	Total body bone mineral density;
CRC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.56	8.19	0.41	6.03e-15	Melanoma;
CRC	trans	rs728616	0.681	rs35420115	chr10:81908188	A/G	cg18543242	chr14:23290393	SLC7A7	0.48	6.52	0.34	2.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12588279	chr6:26043732	HIST1H2BB	0.43	6.09	0.32	3.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9462846	0.853	rs2395940	chr6:42860467	C/G	cg21280719	chr6:42927975	GNMT	-0.34	-6.53	-0.34	2.49e-10	Blood protein levels;
CRC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.57	-9.61	-0.47	1.97e-19	Menarche (age at onset);
CRC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.37	0.38	1.41e-12	Height;
CRC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.67	10.08	0.49	5.26e-21	Menopause (age at onset);
CRC	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.28	-0.33	1.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.85	14.48	0.62	4.06e-37	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.74	-10.65	-0.51	6.16e-23	Platelet distribution width;
CRC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.57	9.64	0.47	1.54e-19	Prostate cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15761814	chr2:109403565	CCDC138	0.42	6.09	0.32	3.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.64	9.32	0.46	1.76e-18	Menopause (age at onset);
CRC	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg07617317	chr6:118971624	C6orf204	0.47	5.66	0.3	3.25e-8	Diastolic blood pressure;
CRC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.78	0.35	5.54e-11	Body mass index;
CRC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.87	0.35	3.18e-11	Platelet count;
CRC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.63	11.78	0.54	5.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.27	-5.62	-0.3	4.05e-8	Homoarginine levels;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg22110888	chr17:80059540	CCDC57	0.4	6.36	0.33	6.76e-10	Life satisfaction;
CRC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-6.77	-0.35	5.84e-11	Itch intensity from mosquito bite;
CRC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-15.58	-0.65	2.19e-41	Prostate cancer;
CRC	cis	rs6479527	0.875	rs10429603	chr9:96805627	A/G	cg14459158	chr9:96720562	NA	0.39	6.95	0.36	1.96e-11	Esophageal adenocarcinoma;
CRC	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.56	0.47	2.92e-19	Coffee consumption (cups per day);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18822411	chr15:40075102	FSIP1	0.36	5.98	0.31	5.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00612595	chr21:47717864	NA	-0.4	-6.36	-0.33	6.91e-10	Testicular germ cell tumor;
CRC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.43	6.89	0.36	2.79e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.67	8.9	0.44	3.94e-17	Coronary artery disease;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg21784768	chr11:537496	LRRC56	-0.69	-6.56	-0.34	2.11e-10	Body mass index;
CRC	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg09597638	chr17:3907349	NA	0.71	13.27	0.59	1.72e-32	Type 2 diabetes;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.6	-10.94	-0.52	5.67e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-6.9	-0.36	2.61e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00399650	chr7:141402322	KIAA1147	0.49	6.22	0.32	1.53e-9	Thyroid stimulating hormone;
CRC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	8.06	0.41	1.46e-14	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15057251	chr18:32621312	MAPRE2	0.4	6.05	0.32	3.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg10820045	chr2:198174542	NA	0.39	6.41	0.33	4.94e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg23254163	chr1:152506842	NA	0.39	6.65	0.34	1.21e-10	Hair morphology;
CRC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg00343986	chr7:65444356	GUSB	0.44	6.48	0.34	3.42e-10	Aortic root size;
CRC	cis	rs6681460	0.932	rs659291	chr1:67180746	A/C	cg02459107	chr1:67143332	SGIP1	0.35	6.1	0.32	2.94e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg03030879	chr14:75389066	RPS6KL1	0.54	8.83	0.44	6.45e-17	Caffeine consumption;
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.65	11.79	0.54	5.52e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.36	-6.74	-0.35	7.31e-11	Iron status biomarkers;
CRC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.21	-0.53	6.28e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg01612440	chr4:3296283	NA	0.4	5.62	0.3	4.11e-8	Serum sulfate level;
CRC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.82	-11.21	-0.53	6.68e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg24463073	chr6:118973353	C6orf204	0.51	6.9	0.36	2.68e-11	Diastolic blood pressure;
CRC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg16342193	chr10:102329863	NA	-0.38	-6.2	-0.32	1.66e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	8.25	0.41	3.79e-15	Total body bone mineral density;
CRC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs3751196	0.808	rs56403068	chr12:104220743	T/C	cg02344784	chr12:104178138	NT5DC3	0.71	7.28	0.37	2.55e-12	Sense of smell;
CRC	cis	rs73206853	0.841	rs17187412	chr12:110766767	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.8	-7.95	-0.4	3.1e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.52	8.65	0.43	2.34e-16	Type 2 diabetes;
CRC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.45	-6.75	-0.35	6.79e-11	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22302626	chr19:10196930	C19orf66	0.46	7.44	0.38	9.07e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg11843238	chr5:131593191	PDLIM4	0.34	6.6	0.34	1.68e-10	Blood metabolite levels;
CRC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.38	0.38	1.29e-12	Blood metabolite levels;
CRC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.57	-0.34	1.94e-10	Life satisfaction;
CRC	cis	rs75422866	0.541	rs12425816	chr12:48125202	G/T	cg14736327	chr12:48174669	SLC48A1	-0.77	-6.26	-0.33	1.22e-9	Pneumonia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03552472	chr10:51623769	TIMM23	0.37	6.18	0.32	1.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg06207120	chr15:45996521	NA	0.31	7.54	0.38	4.48e-13	Waist circumference;Weight;
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.32	0.37	1.98e-12	Alzheimer's disease;
CRC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.56	-6.64	-0.34	1.33e-10	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.55	9.0	0.44	1.84e-17	Corneal astigmatism;
CRC	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.81	-0.3	1.51e-8	Blood protein levels;
CRC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg09127314	chr1:152161683	NA	0.52	6.81	0.35	4.79e-11	Atopic dermatitis;
CRC	cis	rs35520189	0.591	rs6733003	chr2:113701452	G/A	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.52	9.2	0.45	4.1e-18	Common traits (Other);
CRC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-5.73	-0.3	2.24e-8	Major depressive disorder;
CRC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.48	-7.26	-0.37	2.83e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs4728302	0.869	rs6467510	chr7:133607968	A/G	cg03336402	chr7:133662267	EXOC4	-0.44	-6.35	-0.33	7.31e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.17	27.42	0.83	5.34e-87	IgG glycosylation;
CRC	cis	rs501120	0.657	rs10899998	chr10:44688524	G/C	cg09554077	chr10:44749378	NA	0.57	6.55	0.34	2.2e-10	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	0.84	13.43	0.6	4.32e-33	Cognitive function;
CRC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.65	-0.34	1.21e-10	Lung cancer;
CRC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.9	-16.84	-0.68	2.61e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.05	10.39	0.5	4.7e-22	Diabetic retinopathy;
CRC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-18.13	-0.71	2.01e-51	Schizophrenia;
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.88	-0.35	3.08e-11	Response to antipsychotic treatment;
CRC	cis	rs6969780	1.000	rs6969780	chr7:27159136	G/C	cg26364809	chr7:27145159	NA	-0.72	-6.69	-0.35	9.6e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.5	8.22	0.41	4.69e-15	Major depressive disorder;
CRC	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.7	-7.95	-0.4	2.96e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg19875578	chr6:126661172	C6orf173	0.43	5.97	0.31	6.11e-9	Male-pattern baldness;
CRC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-17.1	-0.69	2.31e-47	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg15845792	chr6:28175446	NA	1.02	15.66	0.65	1.12e-41	Depression;
CRC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.44	5.71	0.3	2.54e-8	Response to diuretic therapy;
CRC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.58	8.25	0.41	3.97e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg05562828	chr17:3906858	NA	0.63	11.4	0.53	1.4e-25	Type 2 diabetes;
CRC	cis	rs225245	1.000	rs225245	chr17:33946107	A/G	cg05299278	chr17:33885742	SLFN14	0.44	7.07	0.36	9.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.63	8.34	0.42	2.12e-15	Orofacial clefts;
CRC	cis	rs6445525	1.000	rs6805139	chr3:66005660	G/A	cg06109867	chr3:66002991	MAGI1	-0.4	-6.49	-0.34	3.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06544989	chr22:39130855	UNC84B	0.48	7.6	0.39	3.18e-13	Menopause (age at onset);
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg16606324	chr3:10149918	C3orf24	0.66	7.77	0.39	9.99e-14	Alzheimer's disease;
CRC	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg00495681	chr13:53174319	NA	0.59	8.92	0.44	3.42e-17	Lewy body disease;
CRC	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs10208940	0.920	rs35002937	chr2:68753240	T/A	cg12452813	chr2:68675892	NA	0.48	6.05	0.32	4.01e-9	Urate levels in lean individuals;
CRC	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg14325436	chr19:17404977	ABHD8	-0.35	-5.7	-0.3	2.69e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg03563238	chr19:33554763	RHPN2	-0.31	-5.63	-0.3	3.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.7	0.47	9.55e-20	Fuchs's corneal dystrophy;
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07167872	chr1:205819463	PM20D1	0.42	5.83	0.31	1.34e-8	Parkinson's disease;
CRC	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.08	11.38	0.53	1.56e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg17775713	chr3:133465469	TF	0.37	6.67	0.35	1.09e-10	Iron status biomarkers (transferrin levels);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00677811	chr7:45040321	CCM2	0.45	6.17	0.32	2e-9	Response to antipsychotic treatment;
CRC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.65	-7.64	-0.39	2.46e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg26918954	chr5:179728553	GFPT2	-0.42	-6.88	-0.35	2.95e-11	Height;
CRC	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg14352298	chr13:112236639	NA	0.29	6.59	0.34	1.74e-10	Hepatitis;
CRC	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg13514129	chr1:39547527	MACF1	0.68	10.35	0.5	6.3e-22	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg16745616	chr19:8428856	ANGPTL4	-0.45	-6.94	-0.36	2.1e-11	HDL cholesterol;
CRC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.58	-8.73	-0.43	1.29e-16	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03352830	chr11:487213	PTDSS2	0.65	7.33	0.37	1.75e-12	Body mass index;
CRC	trans	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg14520829	chr3:18390388	SATB1	0.44	6.67	0.35	1.11e-10	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4664293	0.967	rs7597488	chr2:160547096	T/G	cg08347373	chr2:160653686	CD302	-0.38	-6.18	-0.32	1.9e-9	Monocyte percentage of white cells;
CRC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.89	0.31	9.38e-9	Rheumatoid arthritis;
CRC	cis	rs11212617	0.967	rs172895	chr11:108265876	C/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.07	0.32	3.46e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg13206674	chr6:150067644	NUP43	-0.65	-9.12	-0.45	7.85e-18	Lung cancer;
CRC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg03678062	chr6:149772716	ZC3H12D	0.34	6.21	0.32	1.64e-9	Dupuytren's disease;
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg06092702	chr1:163392909	NA	-0.39	-6.01	-0.31	4.84e-9	Motion sickness;
CRC	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg06632207	chr12:54070931	ATP5G2	0.39	6.59	0.34	1.75e-10	Height;
CRC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg00343986	chr7:65444356	GUSB	0.42	5.84	0.31	1.26e-8	Aortic root size;
CRC	trans	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg08231274	chr14:57735852	MUDENG;EXOC5	-0.58	-6.07	-0.32	3.52e-9	Longevity (90 years and older);
CRC	cis	rs4654899	0.643	rs589755	chr1:21099846	A/G	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.9	-0.31	8.85e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.64	-10.21	-0.49	1.95e-21	Dementia with Lewy bodies;
CRC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.19	0.52	7.85e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1853665	0.580	rs12524576	chr6:150271944	G/A	cg16301758	chr6:150275521	NA	-0.39	-5.77	-0.3	1.85e-8	Radiation response;
CRC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg04450456	chr4:17643702	FAM184B	0.41	6.59	0.34	1.79e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.81	-11.3	-0.53	3.02e-25	Asthma;
CRC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.55	0.63	2.26e-37	Chronic sinus infection;
CRC	trans	rs11712655	0.961	rs3937966	chr3:135226700	C/T	cg14625040	chr2:6214447	NA	-0.41	-6.09	-0.32	3.21e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.84	-16.96	-0.68	8.63e-47	Post bronchodilator FEV1;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs2882667	0.690	rs288040	chr5:138204894	A/T	cg09476006	chr5:138032270	NA	0.54	8.92	0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.59	-8.59	-0.43	3.52e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.69	6.19	0.32	1.78e-9	Lifespan;
CRC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.53	-8.22	-0.41	4.75e-15	Body mass index;
CRC	cis	rs9976767	0.932	rs9978717	chr21:43827765	A/G	cg23042151	chr21:43824109	UBASH3A	-0.37	-6.41	-0.33	4.98e-10	Type 1 diabetes;
CRC	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg16486109	chr11:613632	IRF7	0.59	10.42	0.5	3.57e-22	Systemic lupus erythematosus;
CRC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.67	-0.43	2.07e-16	Coronary artery disease;
CRC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg12437481	chr16:420112	MRPL28	-0.62	-7.97	-0.4	2.61e-14	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.12	0.41	9.27e-15	Monocyte count;
CRC	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.81	-0.35	4.67e-11	Inflammatory skin disease;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9826463	0.582	rs114066728	chr3:142022265	T/C	cg20824294	chr3:142316082	PLS1	0.36	5.72	0.3	2.38e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.59	10.14	0.49	3.45e-21	Body mass index;
CRC	cis	rs1760803	0.754	rs12062977	chr1:154211516	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-5.94	-0.31	7.2e-9	Nicotine dependence;
CRC	cis	rs6604026	0.740	rs10782946	chr1:93352669	G/A	cg17283838	chr1:93427260	FAM69A	-0.5	-6.89	-0.35	2.9e-11	Multiple sclerosis;
CRC	cis	rs8005677	0.828	rs8016027	chr14:23420153	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.2	-0.32	1.7e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs281302	0.621	rs406196	chr15:47731245	A/G	cg13159054	chr15:47721715	NA	-0.43	-6.45	-0.34	3.93e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg16591659	chr17:78472290	NA	0.42	6.12	0.32	2.64e-9	Fractional excretion of uric acid;
CRC	cis	rs7487075	0.786	rs12298619	chr12:46673501	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.77	0.3	1.84e-8	Itch intensity from mosquito bite;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12273811	chr6:28175739	NA	-0.72	-9.19	-0.45	4.49e-18	Depression;
CRC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg24140574	chr1:16342155	HSPB7	0.44	6.31	0.33	9.2e-10	Systolic blood pressure;
CRC	cis	rs6997458	0.742	rs10111039	chr8:86396656	G/A	cg21346043	chr8:86351067	CA3	-0.28	-6.14	-0.32	2.43e-9	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg03258749	chr1:151040405	MLLT11	-0.47	-7.28	-0.37	2.55e-12	Childhood ear infection;
CRC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.47	8.16	0.41	7.34e-15	Systemic lupus erythematosus;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16794633	chr3:143690145	C3orf58	0.45	6.38	0.33	5.96e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg25456477	chr12:86230367	RASSF9	0.34	5.81	0.31	1.48e-8	Major depressive disorder;
CRC	cis	rs669446	0.562	rs4660260	chr1:44195353	A/G	cg12908607	chr1:44402522	ARTN	-0.33	-5.79	-0.3	1.61e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg20933634	chr6:27740509	NA	-0.63	-8.56	-0.43	4.35e-16	Parkinson's disease;
CRC	cis	rs939574	0.512	rs10194278	chr2:220138408	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.48	5.69	0.3	2.75e-8	Platelet distribution width;
CRC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.66	-0.3	3.23e-8	Height;
CRC	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.52	-7.75	-0.39	1.13e-13	Lewy body disease;
CRC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17507749	chr15:85114479	UBE2QP1	0.53	7.76	0.39	1.06e-13	Schizophrenia;
CRC	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.69	-9.96	-0.48	1.32e-20	Bronchopulmonary dysplasia;
CRC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.65	-0.34	1.25e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg14311320	chr7:124405732	GPR37	-0.38	-5.65	-0.3	3.56e-8	Lewy body disease;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.82	-0.35	4.3e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4731207	0.698	rs4311608	chr7:124519707	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.77	0.39	1.01e-13	Breast cancer;
CRC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.4	5.86	0.31	1.12e-8	Cognitive ability;
CRC	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	0.73	6.82	0.35	4.32e-11	Mean corpuscular volume;
CRC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.68	-13.44	-0.6	3.92e-33	Educational attainment;
CRC	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.36	6.67	0.35	1.09e-10	Panic disorder;
CRC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.77	-0.35	5.99e-11	Monocyte count;
CRC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg10760299	chr15:45669010	GATM	0.51	8.16	0.41	7.22e-15	Homoarginine levels;
CRC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.81	8.3	0.42	2.64e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7517126	1.000	rs7547477	chr1:196839292	C/T	cg13682187	chr1:196946512	CFHR5	-0.36	-5.92	-0.31	7.89e-9	Blood protein levels;
CRC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.48	-7.74	-0.39	1.23e-13	Post bronchodilator FEV1;
CRC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.5	6.62	0.34	1.5e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26634140	chr19:9938264	UBL5	0.43	5.98	0.31	5.73e-9	Response to antipsychotic treatment;
CRC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.52	-8.5	-0.42	6.54e-16	Schizophrenia;
CRC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	20.92	0.76	2.16e-62	Testicular germ cell tumor;
CRC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.8	13.67	0.6	5.4400000000000004e-34	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10651300	chr12:53661859	ESPL1	0.55	7.24	0.37	3.16e-12	Thyroid stimulating hormone;
CRC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg27523141	chr10:43048294	ZNF37B	0.45	6.59	0.34	1.7e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.58	5.85	0.31	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.65	8.51	0.42	6.25e-16	Uric acid levels;
CRC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg19041857	chr6:27730383	NA	-0.71	-6.81	-0.35	4.66e-11	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09667226	chr13:73632762	KLF5	0.43	6.26	0.33	1.18e-9	Response to antipsychotic treatment;
CRC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.44	6.72	0.35	7.92e-11	Blood metabolite levels;
CRC	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.61	8.64	0.43	2.43e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.39	-5.84	-0.31	1.26e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07513332	chr6:167530253	CCR6	-0.44	-8.11	-0.41	1.04e-14	Rheumatoid arthritis;
CRC	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.58	5.82	0.31	1.42e-8	Yeast infection;
CRC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06505273	chr16:24850292	NA	0.39	6.01	0.31	5.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.58	9.32	0.46	1.8e-18	Vitiligo;
CRC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.59	-9.01	-0.44	1.74e-17	Colorectal cancer;
CRC	cis	rs6961069	0.837	rs1722505	chr7:80240689	T/C	cg04458919	chr7:80252533	CD36	-0.36	-6.4	-0.33	5.28e-10	Platelet count;
CRC	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg13390004	chr1:15929781	NA	0.5	7.09	0.36	8.36e-12	Systolic blood pressure;
CRC	cis	rs12024301	0.557	rs2231240	chr1:183599638	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.01	10.23	0.49	1.67e-21	Diabetic retinopathy;
CRC	cis	rs932541	0.955	rs6105611	chr20:16457351	C/T	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.66	10.17	0.49	2.56e-21	Lymphocyte counts;
CRC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.33	5.71	0.3	2.48e-8	Total body bone mineral density;
CRC	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.77	0.3	1.82e-8	Coronary artery disease;
CRC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-5.67	-0.3	3.17e-8	Lung cancer;
CRC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.37	-0.71	2.25e-52	Height;
CRC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg14844989	chr11:31128820	NA	-0.34	-6.0	-0.31	5.16e-9	Red blood cell count;
CRC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg21851534	chr17:3907994	ZZEF1	-0.38	-6.57	-0.34	1.93e-10	Type 2 diabetes;
CRC	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg00531865	chr16:30841666	NA	0.47	6.77	0.35	5.97e-11	Dementia with Lewy bodies;
CRC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg00343986	chr7:65444356	GUSB	-0.41	-5.87	-0.31	1.06e-8	Aortic root size;
CRC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg19635926	chr16:89946313	TCF25	0.68	6.13	0.32	2.57e-9	Skin colour saturation;
CRC	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.8	-14.11	-0.61	1.15e-35	Lewy body disease;
CRC	cis	rs698813	0.724	rs1067364	chr2:44655734	A/G	cg04920474	chr2:44395004	PPM1B	0.44	6.03	0.32	4.29e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CRC	trans	rs12566888	1	rs12566888	chr1:156869047	G/T	cg00735843	chr14:57735967	MUDENG;EXOC5	0.54	5.97	0.31	6.31e-9	Platelet aggregation;
CRC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg03160526	chr17:80928410	B3GNTL1	0.45	6.62	0.34	1.45e-10	Breast cancer;
CRC	cis	rs9292777	0.720	rs4957286	chr5:40418521	A/G	cg09067459	chr5:40385259	NA	-0.55	-8.93	-0.44	3.12e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg12311346	chr5:56204834	C5orf35	-0.44	-6.86	-0.35	3.47e-11	Coronary artery disease;
CRC	cis	rs863345	0.535	rs12064570	chr1:158499631	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.18	-0.32	1.88e-9	Pneumococcal bacteremia;
CRC	cis	rs4722166	0.532	rs1880242	chr7:22759607	A/C	cg05472934	chr7:22766657	IL6	-0.64	-10.01	-0.48	9.1e-21	Lung cancer;
CRC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.6	8.99	0.44	2.05e-17	Subjective well-being;
CRC	trans	rs4386084	1.000	rs62020967	chr15:50256059	T/C	cg02453146	chr1:53068587	GPX7	-0.34	-5.97	-0.31	6.13e-9	Basophil percentage of white cells;Basophil percentage of granulocytes;
CRC	cis	rs1256061	0.624	rs7229	chr14:64692825	G/A	cg23250157	chr14:64679961	SYNE2	0.45	7.04	0.36	1.14e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08151832	chr16:66835414	CCDC79	-0.37	-6.2	-0.32	1.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg23018236	chr17:30244563	NA	-0.65	-7.74	-0.39	1.21e-13	Hip circumference adjusted for BMI;
CRC	cis	rs883565	0.527	rs11715262	chr3:39003853	A/T	cg01426195	chr3:39028469	NA	-0.41	-6.87	-0.35	3.31e-11	Handedness;
CRC	cis	rs2882667	0.894	rs10054478	chr5:138354075	G/A	cg09476006	chr5:138032270	NA	0.41	6.86	0.35	3.4e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg23100626	chr2:96804247	ASTL	0.28	7.1	0.36	7.68e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2882667	0.627	rs1549203	chr5:138468344	A/G	cg04439458	chr5:138467593	SIL1	0.35	6.44	0.33	4.13e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.6	8.7	0.43	1.64e-16	Uric acid levels;
CRC	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg02770688	chr6:168491649	NA	0.62	9.14	0.45	6.49e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	7.61	0.39	2.93e-13	Total body bone mineral density;
CRC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.28	0.42	3.05e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.92	-18.74	-0.72	7.88e-54	Urate levels in lean individuals;
CRC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.16	14.75	0.63	3.65e-38	Uric acid levels;
CRC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg23461800	chr14:103021989	NA	-0.7	-7.99	-0.4	2.27e-14	Platelet count;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.13	-0.41	9.08e-15	Total body bone mineral density;
CRC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.5	8.49	0.42	7.27e-16	Coronary artery disease;
CRC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.6	0.43	3.33e-16	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.39	-6.42	-0.33	4.67e-10	HDL cholesterol;
CRC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.5	-7.21	-0.37	3.96e-12	Pulse pressure;
CRC	cis	rs9928842	0.823	rs11149811	chr16:75300708	C/G	cg09066997	chr16:75300724	BCAR1	0.64	5.91	0.31	8.68e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg25588852	chr2:216877276	MREG	-0.35	-6.86	-0.35	3.45e-11	Alcohol dependence;
CRC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-11.56	-0.54	3.46e-26	Asthma;
CRC	cis	rs12630931	1.000	rs12630931	chr3:31981767	T/C	cg21375017	chr3:31988082	OSBPL10	0.42	5.8	0.3	1.52e-8	Periodontal disease-related phenotypes;
CRC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.43	6.18	0.32	1.85e-9	Aortic root size;
CRC	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.44	-0.38	8.6e-13	Inflammatory bowel disease;
CRC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg20203395	chr5:56204925	C5orf35	-0.44	-5.98	-0.31	5.78e-9	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.88	17.21	0.69	8.34e-48	Hip circumference;
CRC	cis	rs11581903	0.568	rs11590859	chr1:53073838	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.71	5.65	0.3	3.42e-8	Joint mobility (Beighton score);
CRC	cis	rs7932354	0.583	rs7101374	chr11:46824241	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-6.53	-0.34	2.54e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	27.61	0.84	1.1e-87	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.77	-7.65	-0.39	2.2e-13	Coronary artery disease;
CRC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.79	13.29	0.59	1.53e-32	Blood protein levels;
CRC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	12.45	0.57	2.06e-29	Menarche (age at onset);
CRC	cis	rs747650	0.892	rs7111764	chr11:47233209	G/A	cg19486271	chr11:47235900	DDB2	-0.51	-7.79	-0.39	8.91e-14	Acne (severe);
CRC	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.49	7.63	0.39	2.49e-13	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10522587	chr1:120166026	ZNF697	-0.4	-6.58	-0.34	1.81e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.69	-0.3	2.78e-8	Tonsillectomy;
CRC	cis	rs9462027	0.583	rs912716	chr6:34715761	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg21918786	chr6:109611834	NA	0.33	5.78	0.3	1.69e-8	Reticulocyte fraction of red cells;
CRC	trans	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.98	0.36	1.63e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg19318889	chr4:1322082	MAEA	0.41	5.95	0.31	6.97e-9	Obesity-related traits;
CRC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.4	7.71	0.39	1.49e-13	Renal cell carcinoma;
CRC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-7.66	-0.39	2.13e-13	Total body bone mineral density;
CRC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-12.0	-0.55	9.29e-28	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07068998	chr1:115259668	NRAS;CSDE1	0.47	7.56	0.38	4.01e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg18288967	chr1:45987694	PRDX1	0.65	6.99	0.36	1.57e-11	Obesity-related traits;
CRC	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-5.86	-0.31	1.1e-8	Brugada syndrome;
CRC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-7.26	-0.37	2.84e-12	Pulmonary function;
CRC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.46	-0.34	3.75e-10	Aortic root size;
CRC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.92	0.31	8.24e-9	Diabetic retinopathy;
CRC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.71	9.99	0.48	1.04e-20	Cleft lip with or without cleft palate;
CRC	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg12218747	chr21:37451666	NA	-0.43	-7.44	-0.38	8.61e-13	Mitral valve prolapse;
CRC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.67	-8.49	-0.42	7.3e-16	Gut microbiome composition (summer);
CRC	cis	rs10503871	0.545	rs6468436	chr8:30469293	T/A	cg26383811	chr8:30366931	RBPMS	0.39	5.62	0.3	4.05e-8	Metabolite levels  (X-11787);
CRC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg22495460	chr2:25135724	ADCY3	-0.81	-13.5	-0.6	2.36e-33	Body mass index;
CRC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.21	0.32	1.56e-9	Aortic root size;
CRC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	18.49	0.71	7.66e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs73200209	0.744	rs41452748	chr12:116509432	A/T	cg01776926	chr12:116560359	MED13L	-0.67	-7.77	-0.39	1.03e-13	Total body bone mineral density;
CRC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.9	0.4	4.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.66	-0.39	2.05e-13	Gut microbiome composition (summer);
CRC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.63	9.78	0.47	5.41e-20	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg08501292	chr6:25962987	TRIM38	1.0	9.67	0.47	1.2e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.32	5.71	0.3	2.52e-8	Erythrocyte sedimentation rate;
CRC	cis	rs12431939	0.626	rs3924306	chr14:51715566	C/A	cg23942311	chr14:51606299	NA	0.48	6.29	0.33	1.02e-9	Cancer;
CRC	cis	rs720844	0.554	rs16828790	chr2:149296762	G/A	cg09247360	chr2:149335327	NA	-0.42	-5.7	-0.3	2.62e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.44	-6.17	-0.32	2e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.49	7.17	0.37	4.88e-12	Alcohol dependence;
CRC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.39	-5.93	-0.31	7.76e-9	Mean corpuscular volume;
CRC	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.7	-0.39	1.6e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23463467	chr20:60627584	TAF4	0.42	7.74	0.39	1.25e-13	Body mass index;
CRC	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.08	0.64	1.92e-39	Bipolar disorder;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.61	-0.34	1.53e-10	Blood metabolite levels;
CRC	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.6	8.49	0.42	7.42e-16	Intelligence (multi-trait analysis);
CRC	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.91	-11.54	-0.54	4.09e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.62	-7.8	-0.39	8.5e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10971721	0.822	rs117687546	chr9:33864929	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs863345	0.967	rs10908685	chr1:158524436	T/A	cg12129480	chr1:158549410	OR10X1	-0.26	-5.68	-0.3	2.9e-8	Pneumococcal bacteremia;
CRC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs4731207	0.698	rs720615	chr7:124452706	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	1.05	11.43	0.53	1.1e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.54	9.36	0.46	1.32e-18	Common traits (Other);
CRC	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg08477640	chr19:41863820	B9D2	0.56	7.84	0.4	6.5e-14	Colorectal cancer;
CRC	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.74	-0.3	2.16e-8	Coronary artery disease;
CRC	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg10724054	chr17:3904396	NA	-0.48	-8.12	-0.41	9.44e-15	Type 2 diabetes;
CRC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.61	9.02	0.45	1.64e-17	Obesity-related traits;
CRC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg05941027	chr17:61774174	LIMD2	0.36	6.36	0.33	6.71e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.69	-0.54	1.2e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.5	-0.34	2.97e-10	Total body bone mineral density;
CRC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.45	-6.9	-0.36	2.72e-11	Monocyte count;
CRC	cis	rs12144094	0.882	rs55806106	chr1:120232539	T/A	cg20995928	chr1:120229863	NA	0.47	6.47	0.34	3.56e-10	Height;
CRC	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.3	-6.45	-0.33	4.11e-10	Educational attainment (years of education);
CRC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.84	-0.44	6.02e-17	Hemoglobin concentration;
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.82	8.43	0.42	1.07e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.55	8.59	0.43	3.54e-16	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs501120	0.584	rs11238891	chr10:44670992	A/C	cg09554077	chr10:44749378	NA	-0.73	-8.09	-0.41	1.14e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7712401	0.755	rs3756362	chr5:122108890	C/G	cg18764291	chr5:122110994	SNX2	0.37	5.98	0.31	5.88e-9	Mean platelet volume;
CRC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.12	0.49	3.78e-21	Systolic blood pressure;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	cis	rs4731207	0.698	rs34014883	chr7:124480577	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.43	-0.38	9.69e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg19025524	chr12:109796872	NA	-0.48	-6.87	-0.35	3.25e-11	Neuroticism;
CRC	cis	rs7692995	1.000	rs6840868	chr4:17939331	C/T	cg08925142	chr4:18023851	LCORL	-0.52	-5.81	-0.31	1.45e-8	Height;
CRC	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg00691999	chr4:55094011	PDGFRA	0.4	5.73	0.3	2.28e-8	Corneal astigmatism;
CRC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.89	-0.31	9.29e-9	Lung cancer;
CRC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg16060761	chr17:80687452	NA	0.42	6.06	0.32	3.64e-9	Breast cancer;
CRC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-1.11	-13.08	-0.58	8.83e-32	Obesity-related traits;
CRC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.57	-6.61	-0.34	1.59e-10	Breast cancer;
CRC	cis	rs4731207	0.596	rs9332427	chr7:124576958	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg04287289	chr16:89883240	FANCA	0.54	8.5	0.42	6.67e-16	Vitiligo;
CRC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.95	-0.4	3.05e-14	Height;
CRC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-8.97	-0.44	2.35e-17	Subjective well-being;
CRC	cis	rs4547160	0.788	rs12227007	chr12:63484710	G/T	cg26727693	chr12:63544175	AVPR1A	-0.44	-8.32	-0.42	2.37e-15	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19747357	chr1:61547866	NFIA	0.5	7.16	0.37	5.39e-12	Response to antipsychotic treatment;
CRC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.53	-8.51	-0.42	6.32e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.85	-0.35	3.58e-11	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.72	-9.18	-0.45	4.91e-18	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs6499255	0.951	rs11075728	chr16:69611582	A/G	cg04110750	chr16:69646130	NFAT5	-0.56	-7.57	-0.39	3.75e-13	IgE levels;
CRC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.52	7.48	0.38	6.75e-13	Alzheimer's disease;
CRC	trans	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg02674126	chr19:40336878	FBL	-0.41	-6.39	-0.33	5.6e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg21138405	chr5:131827807	IRF1	-0.38	-6.58	-0.34	1.84e-10	Breast cancer;Mosquito bite size;
CRC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.62	10.35	0.5	6.4e-22	Colorectal cancer;
CRC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg02049041	chr17:27085579	C17orf63	-0.45	-5.75	-0.3	1.99e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.96	0.31	6.36e-9	IgG glycosylation;
CRC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.82e-9	Tonsillectomy;
CRC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.82	12.89	0.58	4.5e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.49	7.3	0.37	2.17e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg21452805	chr1:244014465	NA	-0.49	-6.86	-0.35	3.47e-11	RR interval (heart rate);
CRC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.82	-0.4	7.45e-14	Hemoglobin concentration;
CRC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.47	-7.99	-0.4	2.28e-14	Height;
CRC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.57	6.82	0.35	4.48e-11	Diastolic blood pressure;
CRC	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-7.07	-0.36	9.14e-12	Menarche (age at onset);
CRC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg23071808	chr14:103021642	NA	0.59	7.73	0.39	1.3e-13	Platelet count;
CRC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.8	13.44	0.6	3.93e-33	Menopause (age at onset);
CRC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.91	16.63	0.68	1.66e-45	Intelligence (multi-trait analysis);
CRC	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.84	-13.82	-0.61	1.45e-34	Hypospadias;
CRC	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.66	-8.7	-0.43	1.6e-16	Cocaine dependence;
CRC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.48	-6.64	-0.34	1.3e-10	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs10411161	0.702	rs10423838	chr19:52387283	C/T	cg22319618	chr22:45562946	NUP50	-0.57	-6.75	-0.35	6.83e-11	Breast cancer;
CRC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg03233332	chr7:66118400	NA	-0.43	-5.85	-0.31	1.18e-8	Aortic root size;
CRC	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-7.9	-0.4	4.3e-14	Prevalent atrial fibrillation;
CRC	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg08071915	chr8:12219732	FAM66A	0.31	5.65	0.3	3.47e-8	Retinal vascular caliber;
CRC	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg24553058	chr2:113831203	IL1F10	0.39	6.26	0.33	1.18e-9	Protein quantitative trait loci;
CRC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.7	7.77	0.39	1.03e-13	Vitiligo;
CRC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg06740227	chr12:86229804	RASSF9	0.37	5.71	0.3	2.47e-8	Major depressive disorder;
CRC	cis	rs7932354	0.550	rs2035068	chr11:46915993	T/C	cg19486271	chr11:47235900	DDB2	-0.42	-6.38	-0.33	6.1e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	11.69	0.54	1.28e-26	Electrocardiographic conduction measures;
CRC	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.57	-0.39	3.79e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.87	0.48	2.66e-20	Migraine;Coronary artery disease;
CRC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.49	9.46	0.46	6.05e-19	Renal cell carcinoma;
CRC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.6	10.29	0.49	1.01e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17127169	0.536	rs74860172	chr1:65497547	T/A	cg15583014	chr1:65468659	NA	0.89	6.12	0.32	2.71e-9	Sitting height ratio;
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg27635394	chr6:26043820	HIST1H2BB	0.44	6.31	0.33	8.96e-10	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.39	0.5	4.71e-22	Corneal astigmatism;
CRC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.38	5.97	0.31	6.08e-9	Crohn's disease;
CRC	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.67	9.77	0.47	5.75e-20	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg25985355	chr7:65971099	NA	-0.49	-5.85	-0.31	1.19e-8	Diabetic kidney disease;
CRC	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.74	0.43	1.17e-16	Coffee consumption (cups per day);
CRC	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.39	-0.42	1.48e-15	Idiopathic membranous nephropathy;
CRC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.81	13.55	0.6	1.47e-33	Menopause (age at onset);
CRC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg14711859	chr11:8959438	ASCL3	-0.51	-8.24	-0.41	4.27e-15	Hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23162967	chr3:105587981	CBLB	0.38	6.34	0.33	7.43e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4918814	0.955	rs7090401	chr10:115107328	C/T	cg25339052	chr2:196399403	NA	-0.38	-5.99	-0.31	5.52e-9	Neuroticism (multi-trait analysis);
CRC	trans	rs9545047	0.716	rs586219	chr13:79999312	T/C	cg07061582	chr15:90234082	PEX11A;WDR93	-0.41	-5.97	-0.31	6.15e-9	Schizophrenia;
CRC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.65e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg15845792	chr6:28175446	NA	0.65	6.49	0.34	3.17e-10	Depression;
CRC	cis	rs4929949	0.932	rs10840087	chr11:8616255	G/A	cg20771178	chr11:8615675	STK33	0.35	5.77	0.3	1.81e-8	Body mass index;
CRC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.94	-0.44	2.84e-17	Schizophrenia;
CRC	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.57	8.8	0.44	8.08e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg01339444	chr6:118972232	C6orf204	0.52	5.87	0.31	1.08e-8	Diastolic blood pressure;
CRC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12516959	chr21:47718080	NA	0.35	6.0	0.31	5.11e-9	Testicular germ cell tumor;
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12463550	chr7:65579703	CRCP	0.68	6.55	0.34	2.22e-10	Diabetic kidney disease;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-8.4	-0.42	1.36e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9308731	0.583	rs2165107	chr2:111931350	C/G	cg04202892	chr2:111875749	ACOXL	0.42	6.73	0.35	7.37e-11	Chronic lymphocytic leukemia;
CRC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.33	-5.78	-0.3	1.7e-8	Menarche (age at onset);
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.57	-0.39	3.76e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.77	-0.35	6.03e-11	Monocyte count;
CRC	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg21496419	chr19:44306685	LYPD5	0.34	6.47	0.34	3.65e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.62	-11.06	-0.52	2.11e-24	Schizophrenia;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg03623178	chr6:28175578	NA	0.97	12.38	0.56	3.55e-29	Depression;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.18	-0.32	1.88e-9	Total body bone mineral density;
CRC	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg12064134	chr16:90016061	DEF8	-0.53	-8.17	-0.41	6.73e-15	Squamous cell carcinoma;
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg10729496	chr3:10149963	C3orf24	0.51	6.64	0.34	1.27e-10	Alzheimer's disease;
CRC	cis	rs12505749	0.542	rs55915354	chr4:57370023	G/T	cg06922635	chr4:57371607	ARL9	-0.54	-5.71	-0.3	2.54e-8	Airflow obstruction;
CRC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.14	-0.32	2.41e-9	Menopause (age at onset);
CRC	cis	rs9434723	1.000	rs9434723	chr1:9292282	C/T	cg04199779	chr1:9294473	H6PD	0.54	6.21	0.32	1.6e-9	Height;
CRC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.29	0.33	1.04e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg13491945	chr12:107078410	RFX4	0.35	5.98	0.31	5.87e-9	Heart rate;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11566939	chr17:7155231	DULLARD;C17orf81	0.43	6.24	0.33	1.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.48	7.31	0.37	2e-12	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.94	16.05	0.66	3.3e-43	IgG glycosylation;
CRC	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-6.23	-0.32	1.43e-9	Carotid intima media thickness;
CRC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.92	-15.85	-0.66	1.93e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg00531865	chr16:30841666	NA	-0.46	-6.45	-0.34	3.88e-10	Dementia with Lewy bodies;
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.89	-0.31	9.4e-9	Life satisfaction;
CRC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.79	9.8	0.48	4.47e-20	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.87	0.48	2.6e-20	Cognitive test performance;
CRC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg17724175	chr1:150552817	MCL1	0.47	7.0	0.36	1.46e-11	Melanoma;
CRC	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.4	0.33	5.33e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.65	-10.88	-0.51	9.23e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg10570241	chr7:158785291	NA	0.38	6.45	0.33	4.1e-10	Facial morphology (factor 20);
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-8.89	-0.44	3.97e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg07865391	chr16:88106882	BANP	0.47	6.02	0.31	4.75e-9	Menopause (age at onset);
CRC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg23533926	chr12:111358616	MYL2	-0.54	-8.21	-0.41	5e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs17067123	0.614	rs11723608	chr4:180077492	A/C	cg26610307	chr4:180072759	NA	-0.5	-5.71	-0.3	2.55e-8	Response to hepatitis C treatment;
CRC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.51	6.99	0.36	1.51e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg17710535	chr19:10819994	QTRT1	0.47	7.21	0.37	3.81e-12	Inflammatory skin disease;
CRC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.4	7.55	0.38	4.39e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	5.72	0.3	2.35e-8	Ovarian reserve;
CRC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.74	-0.3	2.16e-8	Bladder cancer;
CRC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.88	12.1	0.55	3.97e-28	Height;
CRC	cis	rs6763159	0.566	rs12493090	chr3:59641065	A/C	cg07069742	chr3:59644285	NA	-0.44	-8.82	-0.44	6.62e-17	Conotruncal heart defects;
CRC	trans	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.22	-0.32	1.52e-9	Neuroticism;
CRC	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.42	-6.92	-0.36	2.37e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg02927042	chr1:21476669	EIF4G3	-0.38	-6.01	-0.31	4.81e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.14	-0.45	6.55e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.53	-8.07	-0.41	1.29e-14	Aortic root size;
CRC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.36	-0.46	1.27e-18	Subjective well-being;
CRC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.66	8.11	0.41	1.03e-14	Obesity (extreme);
CRC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.79	0.44	8.39e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.85	10.82	0.51	1.51e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.39	-5.89	-0.31	9.73e-9	Crohn's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23300289	chr9:132146083	NA	-0.51	-6.34	-0.33	7.57e-10	Diisocyanate-induced asthma;
CRC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg12193833	chr17:30244370	NA	-0.76	-8.89	-0.44	4.24e-17	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10728060	chr13:53029403	CKAP2	0.48	6.99	0.36	1.57e-11	Response to antipsychotic treatment;
CRC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.85	-0.31	1.2e-8	Alzheimer's disease (late onset);
CRC	cis	rs9311474	0.841	rs352139	chr3:52258372	T/C	cg08222913	chr3:52553049	STAB1	-0.35	-6.61	-0.34	1.53e-10	Electroencephalogram traits;
CRC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.83	-13.42	-0.59	4.88e-33	Blood metabolite levels;
CRC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg13319975	chr6:146136371	FBXO30	0.4	5.87	0.31	1.05e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg13047869	chr3:10149882	C3orf24	0.58	6.91	0.36	2.56e-11	Alzheimer's disease;
CRC	cis	rs7212590	0.618	rs56142307	chr17:57878149	A/G	cg10252138	chr17:58120427	NA	-0.54	-5.67	-0.3	3.07e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg23758597	chr6:163146217	PARK2	-0.72	-7.28	-0.37	2.49e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.76	0.47	6.05e-20	Cognitive test performance;
CRC	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.41	1.53e-14	Cognitive performance;
CRC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-10.8	-0.51	1.76e-23	Systemic lupus erythematosus;
CRC	trans	rs11885103	0.519	rs2685263	chr2:549873	C/G	cg12228919	chr15:44955936	SPG11	0.45	6.97	0.36	1.74e-11	Heschl's gyrus morphology;
CRC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg22638593	chr5:131593259	PDLIM4	0.41	7.54	0.38	4.58e-13	Breast cancer;
CRC	cis	rs7254114	0.578	rs7246614	chr19:11310538	C/T	cg02815516	chr19:11306319	KANK2	-0.35	-6.46	-0.34	3.87e-10	Immature fraction of reticulocytes;
CRC	cis	rs601339	1.000	rs507525	chr12:123181581	T/C	cg25190513	chr12:123201362	GPR109B	-0.48	-5.9	-0.31	9.24e-9	Adiponectin levels;
CRC	cis	rs3015497	0.594	rs35637875	chr14:51132533	T/G	cg09863266	chr14:51125203	SAV1	-0.31	-5.85	-0.31	1.2e-8	Mean platelet volume;
CRC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	-0.51	-8.22	-0.41	4.87e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg13047869	chr3:10149882	C3orf24	0.55	6.01	0.31	4.98e-9	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01375172	chr16:23464338	COG7	0.44	6.09	0.32	3.11e-9	Response to antipsychotic treatment;
CRC	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg09597638	chr17:3907349	NA	-0.68	-11.92	-0.55	1.86e-27	Type 2 diabetes;
CRC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-1.07	-17.86	-0.7	2.45e-50	Blood pressure (smoking interaction);
CRC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.83	-14.06	-0.61	1.78e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs12760731	0.720	rs12022646	chr1:178355821	A/G	cg00404053	chr1:178313656	RASAL2	0.94	9.65	0.47	1.46e-19	Obesity-related traits;
CRC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.37	-7.22	-0.37	3.58e-12	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03199721	chr4:75023540	MTHFD2L	0.49	6.84	0.35	3.82e-11	Response to antipsychotic treatment;
CRC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.82	-17.5	-0.69	6.01e-49	Prostate cancer;
CRC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.84	-11.16	-0.52	9.37e-25	Initial pursuit acceleration;
CRC	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg05562828	chr17:3906858	NA	0.47	6.03	0.32	4.36e-9	Type 2 diabetes;
CRC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.38	6.13	0.32	2.51e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg24550644	chr17:30846204	MYO1D	-0.4	-6.68	-0.35	1.01e-10	Schizophrenia;
CRC	cis	rs3018066	0.640	rs28787305	chr4:107034947	C/A	cg01869342	chr4:106983673	TBCK	0.46	6.03	0.32	4.52e-9	Cancer;
CRC	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.85	9.79	0.48	4.94e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16313264	chr11:57103491	SSRP1	0.43	6.14	0.32	2.32e-9	Response to antipsychotic treatment;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg12516270	chr8:143859308	LYNX1	-0.42	-6.55	-0.34	2.18e-10	Urinary tract infection frequency;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12273811	chr6:28175739	NA	0.69	8.81	0.44	7.29e-17	Depression;
CRC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg23625390	chr15:77176239	SCAPER	0.49	7.26	0.37	2.76e-12	Blood metabolite levels;
CRC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.45	-7.33	-0.37	1.84e-12	Body mass index;
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.96	0.4	2.85e-14	Iron status biomarkers;
CRC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.05	-0.36	1.06e-11	Mean corpuscular volume;
CRC	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.6	0.47	2.14e-19	Cognitive test performance;
CRC	cis	rs3099143	0.901	rs76101229	chr15:77134975	C/T	cg21673338	chr15:77095150	SCAPER	-0.78	-6.5	-0.34	3.05e-10	Recalcitrant atopic dermatitis;
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.55	-0.43	4.72e-16	Life satisfaction;
CRC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.53	7.0	0.36	1.45e-11	Multiple sclerosis;
CRC	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.17	0.64	8.69e-40	Colorectal cancer;
CRC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.12	-0.41	9.38e-15	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06995624	chr17:73043174	ATP5H;KCTD2	0.43	6.41	0.33	5.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19828298	chr1:3713105	LRRC47	-0.6	-7.55	-0.38	4.28e-13	Diisocyanate-induced asthma;
CRC	cis	rs72730918	0.564	rs1902595	chr15:51905715	T/C	cg14296394	chr15:51910925	DMXL2	-0.45	-5.87	-0.31	1.04e-8	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg15786705	chr6:28176104	NA	0.64	7.1	0.36	7.64e-12	Depression;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg12273811	chr6:28175739	NA	0.5	6.63	0.34	1.38e-10	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16618282	chr3:47018402	CCDC12	-0.46	-6.96	-0.36	1.9e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.27	0.56	9.74e-29	Platelet count;
CRC	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg00105475	chr2:10696890	NA	-0.47	-7.16	-0.37	5.43e-12	Prostate cancer;
CRC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.67	9.72	0.47	8.8e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg17294928	chr15:75287854	SCAMP5	0.52	8.06	0.41	1.43e-14	Breast cancer;
CRC	cis	rs3864277	0.510	rs31478	chr5:131423475	T/C	cg18758796	chr5:131593413	PDLIM4	0.36	6.32	0.33	8.63e-10	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg17470449	chr10:769945	NA	0.64	8.39	0.42	1.42e-15	Uric acid levels;
CRC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.15	-0.74	2.29e-59	Primary sclerosing cholangitis;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.09	0.32	3.24e-9	Cardiac Troponin-T levels;
CRC	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.39	-6.7	-0.35	9.06e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.04	0.32	4.14e-9	Heart rate;
CRC	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg17903999	chr18:56338584	MALT1	0.37	6.13	0.32	2.45e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg12046867	chr14:103022105	NA	0.42	6.1	0.32	2.94e-9	Platelet count;
CRC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.36e-9	Red blood cell count;
CRC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.14	0.41	8.01e-15	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.03	0.32	4.5e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg20933634	chr6:27740509	NA	0.65	9.14	0.45	6.66e-18	Parkinson's disease;
CRC	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg06781209	chr11:61594997	FADS2	-0.39	-5.66	-0.3	3.27e-8	Trans fatty acid levels;
CRC	cis	rs10208940	0.920	rs34366735	chr2:68771995	A/G	cg12452813	chr2:68675892	NA	0.46	5.77	0.3	1.79e-8	Urate levels in lean individuals;
CRC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.5	-9.27	-0.46	2.53e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	15.72	0.66	6.04e-42	Mean corpuscular hemoglobin;
CRC	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.66	-9.26	-0.45	2.66e-18	Body mass index;
CRC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg14558114	chr2:88469736	THNSL2	-0.47	-6.79	-0.35	5.36e-11	Response to metformin (IC50);
CRC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	1.02	17.91	0.7	1.45e-50	Parkinson's disease;
CRC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.45	-7.13	-0.37	6.28e-12	Monocyte count;
CRC	cis	rs73206853	0.841	rs57216167	chr12:110940748	C/T	cg12870014	chr12:110450643	ANKRD13A	0.82	8.53	0.43	5.39e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02294249	chr13:34392492	RFC3	0.53	6.76	0.35	6.25e-11	Thyroid stimulating hormone;
CRC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.48	-9.36	-0.46	1.29e-18	Subjective well-being;
CRC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs832540	0.866	rs252894	chr5:56224339	A/C	cg12311346	chr5:56204834	C5orf35	0.45	6.5	0.34	2.9e-10	Coronary artery disease;
CRC	cis	rs2179367	0.959	rs9377212	chr6:149704901	G/C	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.5	-0.34	2.9e-10	Dupuytren's disease;
CRC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg22495460	chr2:25135724	ADCY3	-0.8	-14.63	-0.63	1.09e-37	Body mass index in non-asthmatics;
CRC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.35	-5.61	-0.3	4.24e-8	Ulcerative colitis;
CRC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.13	0.41	9.08e-15	Lung cancer in ever smokers;
CRC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.46	-5.72	-0.3	2.37e-8	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22744680	chr16:3014898	KREMEN2	0.49	6.8	0.35	5e-11	Response to antipsychotic treatment;
CRC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg15962314	chr1:44399869	ARTN	-0.3	-5.84	-0.31	1.23e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.46	5.97	0.31	5.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg23071808	chr14:103021642	NA	-0.68	-8.91	-0.44	3.44e-17	Platelet count;
CRC	cis	rs12024301	0.557	rs10911414	chr1:183663149	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.7	6.23	0.32	1.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.68	12.44	0.57	2.18e-29	Hip circumference;
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	0.97	10.57	0.5	1.1e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-7.56	-0.38	4.12e-13	Coronary artery disease;
CRC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.42	-0.38	9.95e-13	Aortic root size;
CRC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01402409	chr4:78978133	FRAS1	0.4	6.19	0.32	1.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.61	-0.3	4.31e-8	Metabolite levels;
CRC	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg27398640	chr15:77910606	LINGO1	-0.42	-7.26	-0.37	2.87e-12	Type 2 diabetes;
CRC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.5	7.55	0.38	4.25e-13	Methadone dose in opioid dependence;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg15017067	chr4:17643749	FAM184B	0.36	5.73	0.3	2.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.34	0.46	1.49e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.49	-0.34	3.25e-10	Reticulocyte fraction of red cells;
CRC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg10398005	chr11:117014888	PAFAH1B2	0.4	5.64	0.3	3.6e-8	Blood protein levels;
CRC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg04043695	chr12:129287642	SLC15A4	0.38	5.74	0.3	2.11e-8	Systemic lupus erythematosus;
CRC	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg10820045	chr2:198174542	NA	0.41	6.94	0.36	2.09e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.85	11.44	0.53	9.59e-26	IgG glycosylation;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg15309264	chr2:58274034	VRK2	0.42	6.17	0.32	2.03e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg23127183	chr11:57508653	C11orf31	0.53	7.39	0.38	1.22e-12	Schizophrenia;
CRC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.7	-0.3	2.73e-8	Response to bleomycin (chromatid breaks);
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.79	-0.3	1.62e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.36	5.66	0.3	3.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg20041105	chr8:143859282	LYNX1	0.43	7.8	0.4	8.17e-14	Urinary tract infection frequency;
CRC	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.93	15.89	0.66	1.37e-42	Parkinson's disease;
CRC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.56e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.56	7.48	0.38	6.89e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg08314208	chr16:67682810	RLTPR	-0.61	-7.0	-0.36	1.48e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.64	10.4	0.5	4.47e-22	Motion sickness;
CRC	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.4	-5.83	-0.31	1.35e-8	Alzheimer's disease;
CRC	cis	rs1050631	0.592	rs9958282	chr18:33710440	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.38	-5.92	-0.31	8.25e-9	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.68	-0.3	3.04e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.75	-12.16	-0.56	2.34e-28	Lung cancer;
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg21784768	chr11:537496	LRRC56	-0.69	-6.14	-0.32	2.41e-9	Body mass index;
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.08	-0.45	1.05e-17	Bipolar disorder;
CRC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.68	8.94	0.44	2.95e-17	Multiple sclerosis;
CRC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg25985355	chr7:65971099	NA	0.32	5.71	0.3	2.54e-8	Aortic root size;
CRC	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.38	-5.85	-0.31	1.16e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg15654264	chr1:150340011	RPRD2	0.43	6.41	0.33	5.06e-10	Migraine;
CRC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg15448220	chr1:150897856	SETDB1	-0.44	-6.16	-0.32	2.14e-9	Blood protein levels;
CRC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg15848620	chr12:58087721	OS9	-0.6	-8.15	-0.41	7.76e-15	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04903157	chr22:35795952	MCM5	0.44	6.5	0.34	3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.26	-0.33	1.24e-9	Menopause (age at onset);
CRC	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.53	-6.26	-0.33	1.21e-9	Body mass index;
CRC	cis	rs6968419	0.692	rs10500060	chr7:115900686	C/T	cg02561103	chr7:115862891	TES	-0.44	-6.53	-0.34	2.51e-10	Intraocular pressure;
CRC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.57	8.1	0.41	1.1e-14	Inflammatory bowel disease;
CRC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.61	-9.59	-0.47	2.25e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.69	-0.3	2.79e-8	Migraine;Coronary artery disease;
CRC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.56	-0.34	2.05e-10	Type 2 diabetes;
CRC	cis	rs9925964	0.967	rs9936329	chr16:31140799	G/T	cg10396673	chr16:31104726	VKORC1	0.34	5.64	0.3	3.76e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg15786705	chr6:28176104	NA	-0.56	-5.82	-0.31	1.43e-8	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07344955	chr3:50374863	RASSF1	0.47	6.41	0.33	5.04e-10	Anxiety disorder;
CRC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg02869306	chr7:64672164	INTS4L1	-0.34	-5.77	-0.3	1.83e-8	Calcium levels;
CRC	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.61	5.81	0.31	1.48e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.34	-0.46	1.5e-18	Heart rate;
CRC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.19e-13	Colorectal cancer;
CRC	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-6.92	-0.36	2.3e-11	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11088931	chr19:6460274	SLC25A23	0.45	6.65	0.34	1.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.11	10.26	0.49	1.31e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
CRC	cis	rs11212617	0.967	rs599164	chr11:108120439	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.85	0.31	1.17e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6804368	0.649	rs9835412	chr3:30764596	T/A	cg06106510	chr3:30762233	NA	0.41	7.29	0.37	2.29e-12	Blood metabolite levels;
CRC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.91	-17.84	-0.7	2.75e-50	Intelligence (multi-trait analysis);
CRC	trans	rs1404872	0.717	rs73049438	chr7:3329418	G/A	cg25123566	chr12:47610734	FAM113B;LOC100233209	-0.52	-6.0	-0.31	5.16e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg15660573	chr17:549704	VPS53	-0.87	-15.83	-0.66	2.25e-42	Prostate cancer;
CRC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.83	-13.1	-0.59	7.97e-32	Blood metabolite levels;
CRC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg05861140	chr6:150128134	PCMT1	0.39	6.29	0.33	9.85e-10	Lung cancer;
CRC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.59	10.18	0.49	2.36e-21	Mean corpuscular volume;
CRC	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg12218747	chr21:37451666	NA	0.44	7.54	0.38	4.56e-13	Mitral valve prolapse;
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg12516270	chr8:143859308	LYNX1	-0.33	-5.66	-0.3	3.36e-8	Urinary tract infection frequency;
CRC	cis	rs294883	0.686	rs9456391	chr6:159732998	G/A	cg14500486	chr6:159655392	FNDC1	-0.35	-6.04	-0.32	4.11e-9	Coronary artery disease;
CRC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.97	-0.4	2.58e-14	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00573140	chr1:121141934	NA	0.46	7.15	0.37	5.62e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.71	-0.51	3.76e-23	Alzheimer's disease;
CRC	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.2	-0.37	4.21e-12	Morning vs. evening chronotype;
CRC	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-14.4	-0.62	8.86e-37	Lymphocyte percentage of white cells;
CRC	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg14458575	chr2:238380390	NA	0.69	9.02	0.45	1.59e-17	Prostate cancer;
CRC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.69	-9.22	-0.45	3.55e-18	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10377451	chr4:140375014	RAB33B	0.44	6.1	0.32	3.04e-9	Response to antipsychotic treatment;
CRC	cis	rs995000	0.931	rs10889350	chr1:63085266	C/T	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-9.43	-0.46	7.85e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6460942	0.908	rs75704904	chr7:12233583	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	cis	rs6973256	0.583	rs6955530	chr7:133339511	T/C	cg10665199	chr7:133106180	EXOC4	0.46	7.18	0.37	4.58e-12	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg01262667	chr19:19385393	TM6SF2	0.37	6.2	0.32	1.7e-9	Tonsillectomy;
CRC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.87	0.4	5.26e-14	Cognitive ability;
CRC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.56	-8.23	-0.41	4.52e-15	Colorectal cancer;
CRC	cis	rs9462027	0.628	rs1125341	chr6:34786305	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.7	-0.35	9.11e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16655837	chr10:32636197	EPC1	0.44	6.25	0.33	1.26e-9	Anxiety disorder;
CRC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.74	11.87	0.55	2.63e-27	Neuroticism;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.65	6.84	0.35	3.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.84	13.86	0.61	1e-34	Menarche (age at onset);
CRC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.99	-18.12	-0.71	2.27e-51	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.47	5.85	0.31	1.17e-8	Metabolite levels;
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.61	9.49	0.46	4.93e-19	Monocyte percentage of white cells;
CRC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg15226275	chr6:116381976	FRK	0.3	8.52	0.42	6e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg20203395	chr5:56204925	C5orf35	-0.46	-6.35	-0.33	7.36e-10	Coronary artery disease;
CRC	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.46	-5.93	-0.31	7.51e-9	Tuberculosis;
CRC	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg20628663	chr10:43360327	NA	-0.52	-5.65	-0.3	3.46e-8	Pediatric bone mineral content (radius);
CRC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs995000	0.899	rs1168027	chr1:62970184	T/C	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.5e-11	Triglyceride levels;
CRC	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.59	-6.93	-0.36	2.26e-11	Post bronchodilator FEV1;
CRC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.59	0.5	9.79e-23	Coronary artery disease;
CRC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.88	-16.77	-0.68	4.53e-46	Cerebrospinal fluid biomarker levels;
CRC	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	0.78	15.73	0.66	5.98e-42	Leprosy;
CRC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	12.76	0.58	1.44e-30	Platelet count;
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.93	-0.44	2.97e-17	Bipolar disorder;
CRC	cis	rs10046574	0.516	rs7802453	chr7:135200638	T/C	cg27474649	chr7:135195673	CNOT4	0.67	6.29	0.33	9.88e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.41	6.02	0.31	4.75e-9	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	1.08	12.84	0.58	6.96e-31	Obesity-related traits;
CRC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.23	-0.32	1.4e-9	Menopause (age at onset);
CRC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-7.06	-0.36	1e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.49	7.35	0.38	1.61e-12	Corneal astigmatism;
CRC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.43	0.38	9.15e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg01475377	chr6:109611718	NA	-0.35	-6.09	-0.32	3.18e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-0.74	-7.65	-0.39	2.23e-13	Blood protein levels;
CRC	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg11901034	chr3:128598214	ACAD9	-0.49	-6.09	-0.32	3.11e-9	IgG glycosylation;
CRC	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.54	-8.85	-0.44	5.38e-17	Mean corpuscular volume;
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.62	10.21	0.49	1.99e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.46	-6.39	-0.33	5.56e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.98	-0.44	2.11e-17	Bipolar disorder;
CRC	cis	rs1223397	0.938	rs35549743	chr6:13294354	C/T	cg21538684	chr6:13274180	PHACTR1	0.47	5.6	0.3	4.42e-8	Blood pressure;
CRC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-5.88	-0.31	1.01e-8	Height;
CRC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.46	7.2	0.37	4.18e-12	Monobrow;
CRC	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.69	-0.35	9.35e-11	Total body bone mineral density;
CRC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.49	-7.46	-0.38	8.02e-13	Corneal astigmatism;
CRC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.27	0.46	2.53e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.32	-0.37	1.89e-12	Bipolar disorder;
CRC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.86	-0.35	3.35e-11	Total body bone mineral density;
CRC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.84	10.24	0.49	1.58e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.57	-9.51	-0.46	4.26e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06656553	chr16:89960601	TCF25	-0.7	-5.77	-0.3	1.82e-8	Skin colour saturation;
CRC	cis	rs1190552	0.846	rs1061924	chr14:102975655	C/T	cg18135206	chr14:102964638	TECPR2	0.52	6.19	0.32	1.81e-9	Blood protein levels;
CRC	cis	rs2949837	0.603	rs1542818	chr7:45977656	G/T	cg04796162	chr7:45961102	IGFBP3	0.4	6.83	0.35	4.07e-11	Sitting height ratio;
CRC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg24253500	chr15:84953950	NA	0.37	6.28	0.33	1.1e-9	Schizophrenia;
CRC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg03037974	chr15:76606532	NA	0.72	12.63	0.57	4.47e-30	Blood metabolite levels;
CRC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00791764	chr4:53727839	RASL11B	0.59	6.39	0.33	5.8e-10	Optic nerve measurement (cup area);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg10684905	chr12:2999782	TULP3	0.41	5.99	0.31	5.49e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.61	-0.3	4.21e-8	Life satisfaction;
CRC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg14530993	chr4:882597	GAK	0.82	7.93	0.4	3.4e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.81	7.89	0.4	4.67e-14	Body mass index;
CRC	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.51	6.23	0.33	1.39e-9	Recombination rate (females);
CRC	cis	rs524281	0.861	rs3862386	chr11:65894424	G/C	cg16950941	chr11:66035639	RAB1B	-0.62	-7.51	-0.38	5.54e-13	Electroencephalogram traits;
CRC	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg08461752	chr10:43522343	NA	0.82	7.5	0.38	6.04e-13	Blood protein levels;
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.53	-7.39	-0.38	1.23e-12	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07789552	chr1:36851195	STK40	0.42	5.98	0.31	5.93e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.6	9.38	0.46	1.09e-18	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.54	-8.33	-0.42	2.19e-15	Aortic root size;
CRC	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.8	-0.44	8.12e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.72	0.35	7.98e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.44e-10	Cognitive ability;
CRC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg07828024	chr6:149772892	ZC3H12D	-0.53	-10.07	-0.49	5.53e-21	Dupuytren's disease;
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg06074448	chr4:187884817	NA	-0.59	-10.95	-0.52	5.1900000000000004e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.27	-0.33	1.15e-9	Gout;Renal underexcretion gout;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg04043695	chr12:129287642	SLC15A4	0.37	5.66	0.3	3.32e-8	Systemic lupus erythematosus;
CRC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg21620606	chr4:1342894	KIAA1530	0.51	8.23	0.41	4.33e-15	Obesity-related traits;
CRC	trans	rs7800418	0.753	rs730558	chr7:26588153	A/C	cg14387656	chr2:233470847	EFHD1	0.46	6.37	0.33	6.36e-10	Cognitive function;
CRC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg25164649	chr6:28176230	NA	0.55	5.75	0.3	2e-8	Depression;
CRC	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.56	-10.69	-0.51	4.47e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.68	10.77	0.51	2.29e-23	Mean corpuscular hemoglobin;
CRC	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.69	-6.1	-0.32	2.91e-9	Yeast infection;
CRC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.46	-6.99	-0.36	1.58e-11	Breast size;
CRC	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.71	0.3	2.57e-8	Educational attainment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12097945	chr11:10562746	RNF141	0.45	6.3	0.33	9.74e-10	Anxiety disorder;
CRC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.44	-9.75	-0.47	6.95e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.43	-0.38	9.53e-13	Life satisfaction;
CRC	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.45	-6.54	-0.34	2.29e-10	Body mass index;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg03623178	chr6:28175578	NA	0.92	13.02	0.58	1.52e-31	Parkinson's disease;
CRC	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg11130432	chr3:121712080	ILDR1	0.55	7.26	0.37	2.86e-12	Multiple sclerosis;
CRC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.67	9.81	0.48	4.26e-20	Corneal astigmatism;
CRC	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg12560992	chr17:57184187	TRIM37	0.56	7.78	0.39	9.44e-14	Testicular germ cell tumor;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05351267	chr16:1877388	HAGH;FAHD1	0.47	6.35	0.33	7.15e-10	Anxiety disorder;
CRC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.77	-0.35	5.8e-11	Response to antipsychotic treatment;
CRC	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg04415270	chr2:102091202	RFX8	-0.36	-5.99	-0.31	5.65e-9	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.45	0.34	3.99e-10	Renal cell carcinoma;
CRC	cis	rs8105895	0.935	rs10406485	chr19:22245002	G/T	cg02657401	chr19:22469223	NA	-0.34	-5.63	-0.3	3.83e-8	Body mass index (change over time);
CRC	cis	rs938554	0.876	rs6449139	chr4:9934111	A/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-5.63	-0.3	3.94e-8	Blood metabolite levels;
CRC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.4	-6.02	-0.32	4.56e-9	Breast cancer;
CRC	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.82	-10.94	-0.52	5.91e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs17155006	0.655	rs389486	chr7:107727804	C/G	cg05962710	chr7:107745446	LAMB4	-0.35	-5.87	-0.31	1.04e-8	Pneumococcal bacteremia;
CRC	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.52	8.4	0.42	1.37e-15	Endometrial cancer;
CRC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-5.8	-0.3	1.59e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.71	9.59	0.47	2.25e-19	Coronary artery disease;
CRC	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.73	13.45	0.6	3.52e-33	Hip circumference;
CRC	cis	rs4664293	0.605	rs890095	chr2:160461219	A/G	cg08347373	chr2:160653686	CD302	0.36	5.88	0.31	9.85e-9	Monocyte percentage of white cells;
CRC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg13390004	chr1:15929781	NA	0.5	7.2	0.37	4.18e-12	Systolic blood pressure;
CRC	trans	rs17192198	0.613	rs73196656	chr12:89996381	C/T	cg17836913	chr1:54723679	SSBP3	-0.49	-6.19	-0.32	1.82e-9	Diastolic blood pressure;
CRC	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.64	6.58	0.34	1.81e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.75	0.43	1.12e-16	Schizophrenia;
CRC	cis	rs7264396	0.887	rs736032	chr20:34048661	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.41	-0.33	5.12e-10	Total cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23193153	chr6:34192178	NA	0.43	6.15	0.32	2.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.18	-0.41	6.23e-15	Electroencephalogram traits;
CRC	trans	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg24644049	chr4:85504048	CDS1	0.92	7.13	0.37	6.52e-12	Skin colour saturation;
CRC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.64	-9.04	-0.45	1.42e-17	Body mass index;
CRC	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg27532560	chr4:187881888	NA	-0.55	-10.06	-0.48	6.26e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-8.36	-0.42	1.78e-15	Uric acid levels;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg14458575	chr2:238380390	NA	0.51	6.78	0.35	5.68e-11	Prostate cancer;
CRC	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg23254163	chr1:152506842	NA	0.45	9.13	0.45	6.92e-18	Hair morphology;
CRC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-11.21	-0.53	6.38e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.73	0.39	1.35e-13	Schizophrenia;
CRC	trans	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg21153622	chr11:89784906	NA	-0.47	-7.58	-0.39	3.59e-13	HDL cholesterol;
CRC	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.89e-8	Prostate cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04036462	chr19:55691490	SYT5	-0.4	-6.15	-0.32	2.3e-9	Aortic root size;
CRC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-8.08	-0.41	1.26e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.96	-0.36	1.83e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs34043159	0.898	rs7594775	chr2:102300940	T/C	cg23013864	chr6:17393396	CAP2	0.41	6.06	0.32	3.8e-9	Parkinson's disease;
CRC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	9.26	0.45	2.68e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg16005559	chr11:120040616	NA	-0.55	-7.62	-0.39	2.68e-13	Stroke (pediatric);
CRC	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.73	11.71	0.54	1.03e-26	Plateletcrit;Platelet count;
CRC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.38	-5.85	-0.31	1.19e-8	Breast cancer;
CRC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.42	7.51	0.38	5.5e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11587400	0.574	rs2268696	chr1:115219083	T/A	cg12756093	chr1:115239321	AMPD1	-0.45	-6.08	-0.32	3.26e-9	Autism;
CRC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.49	6.93	0.36	2.27e-11	Alzheimer's disease;
CRC	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.72	-0.3	2.38e-8	Coronary artery disease;
CRC	trans	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg17903999	chr18:56338584	MALT1	0.43	7.12	0.37	6.83e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs185694	1.000	rs595449	chr13:30896852	T/C	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.29	-0.33	9.97e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.67	-10.23	-0.49	1.7e-21	Ulcerative colitis;
CRC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.67	0.6	5.46e-34	Vitiligo;
CRC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg16141378	chr3:129829833	LOC729375	0.43	6.63	0.34	1.39e-10	Neuroticism;
CRC	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg15465823	chr12:48382534	COL2A1	-0.34	-5.62	-0.3	3.97e-8	Plateletcrit;
CRC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.43	6.64	0.34	1.28e-10	Red blood cell count;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg07369507	chr6:28304287	ZNF323	0.5	6.41	0.33	5.04e-10	Hip circumference;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.66	10.62	0.51	7.39e-23	Height;
CRC	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-5.97	-0.31	6.02e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.46	0.69	8.83e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs501120	0.584	rs556434	chr10:44732519	T/A	cg09554077	chr10:44749378	NA	0.64	7.06	0.36	9.82e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.94	0.52	5.59e-24	Systolic blood pressure;
CRC	cis	rs698833	0.859	rs1302175	chr2:44657024	G/C	cg04920474	chr2:44395004	PPM1B	0.39	5.7	0.3	2.74e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs9322817	0.583	rs6941988	chr6:105146656	C/T	cg02098413	chr6:105308735	HACE1	0.44	8.78	0.44	9.23e-17	Thyroid stimulating hormone;
CRC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.32	-6.34	-0.33	7.41e-10	Schizophrenia;
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.26	5.68	0.3	2.96e-8	Total body bone mineral density;
CRC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.63	8.4	0.42	1.39e-15	Methadone dose in opioid dependence;
CRC	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.77	0.3	1.85e-8	Tonsillectomy;
CRC	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.89	-15.31	-0.65	2.53e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7517126	0.920	rs6428365	chr1:196844131	C/A	cg13682187	chr1:196946512	CFHR5	-0.37	-6.08	-0.32	3.39e-9	Blood protein levels;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.48	5.7	0.3	2.72e-8	Depression;
CRC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	10.21	0.49	1.97e-21	Lung cancer;
CRC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.57	-7.56	-0.38	4.01e-13	Initial pursuit acceleration;
CRC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.67	10.37	0.5	5.31e-22	Monocyte count;
CRC	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.92	11.38	0.53	1.56e-25	Exhaled nitric oxide output;
CRC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	9.92	0.48	1.86e-20	Cognitive test performance;
CRC	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-6.16	-0.32	2.14e-9	Yeast infection;
CRC	cis	rs7680126	0.596	rs11722185	chr4:10317482	C/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.37	-0.33	6.38e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.73	0.39	1.35e-13	Colorectal cancer;
CRC	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg20607287	chr7:12443886	VWDE	-0.55	-5.98	-0.31	5.94e-9	Coronary artery disease;
CRC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	8.62	0.43	2.78e-16	Cognitive test performance;
CRC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.69	0.57	2.66e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.29	0.56	7.69e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.9	-17.21	-0.69	8.44e-48	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08614771	chr6:157100981	ARID1B	0.39	6.13	0.32	2.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22878388	chr2:105853796	NA	-0.31	-5.96	-0.31	6.51e-9	Type 2 diabetes;
CRC	cis	rs753274	0.650	rs72998945	chr19:14418441	C/A	cg25450033	chr19:14444658	NA	0.35	6.11	0.32	2.8e-9	Tumor necrosis factor beta levels;
CRC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.46	6.96	0.36	1.87e-11	Menopause (age at onset);
CRC	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.59	7.66	0.39	2.12e-13	Body mass index;
CRC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.45	6.44	0.33	4.17e-10	Height;
CRC	cis	rs847649	1.000	rs28856331	chr7:102543763	T/G	cg18108683	chr7:102477205	FBXL13	-0.57	-9.26	-0.45	2.8e-18	Morning vs. evening chronotype;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg15845792	chr6:28175446	NA	0.74	7.78	0.39	9.45e-14	Depression;
CRC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.31	6.51	0.34	2.81e-10	Alcohol dependence;
CRC	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.54	-9.55	-0.47	3.08e-19	Lung function (FVC);
CRC	cis	rs988712	0.622	rs10767664	chr11:27725986	T/A	cg10635145	chr11:27742435	BDNF	0.42	6.28	0.33	1.08e-9	Obesity;
CRC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg00074818	chr8:8560427	CLDN23	0.36	6.43	0.33	4.59e-10	Obesity-related traits;
CRC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-6.88	-0.35	2.99e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.45	0.33	4.08e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11212617	0.967	rs113995	chr11:108256837	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.59	0.34	1.74e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.53	-5.6	-0.3	4.45e-8	Neuroticism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12502759	chr12:99039019	APAF1;IKBIP	0.46	6.28	0.33	1.09e-9	Anxiety disorder;
CRC	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg10724054	chr17:3904396	NA	-0.46	-7.57	-0.39	3.71e-13	Type 2 diabetes;
CRC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.41	6.94	0.36	2.04e-11	Height;
CRC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg15848620	chr12:58087721	OS9	-0.62	-8.68	-0.43	1.91e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.29	-0.56	7.62e-29	Idiopathic membranous nephropathy;
CRC	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.55	-9.12	-0.45	7.52e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	0.84	7.59	0.39	3.31e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.88	-0.31	9.9e-9	Educational attainment;
CRC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.56	-8.41	-0.42	1.24e-15	Height;
CRC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.81	-0.4	7.9e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs17767392	0.881	rs7157241	chr14:72001296	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.19	-0.37	4.45e-12	Mitral valve prolapse;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg21577049	chr2:228736449	WDR69	-0.45	-5.98	-0.31	5.87e-9	Blood pressure;
CRC	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg09873164	chr1:152488093	CRCT1	0.4	6.72	0.35	8.09e-11	Hair morphology;
CRC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg25790453	chr13:113633590	MCF2L	-0.57	-9.93	-0.48	1.73e-20	Systolic blood pressure;
CRC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.37	-6.14	-0.32	2.32e-9	Vitiligo;
CRC	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.16	-0.32	2.16e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.79	-0.3	1.64e-8	Inflammatory bowel disease;
CRC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23463467	chr20:60627584	TAF4	0.33	5.61	0.3	4.27e-8	Body mass index;
CRC	cis	rs9462846	0.881	rs113433755	chr6:42887558	A/G	cg21280719	chr6:42927975	GNMT	-0.35	-6.58	-0.34	1.88e-10	Blood protein levels;
CRC	cis	rs34164109	1	rs34164109	chr6:135421176	C/T	cg22676075	chr6:135203613	NA	0.52	6.6	0.34	1.62e-10	Red blood cell count;Reticulocyte fraction of red cells;
CRC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg05585544	chr11:47624801	NA	-0.54	-9.69	-0.47	1.08e-19	Subjective well-being;
CRC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	trans	rs6011368	0.840	rs2427638	chr20:62900717	C/T	cg13869341	chr1:15865	WASH5P	0.52	8.06	0.41	1.39e-14	Clozapine-induced cytotoxicity;
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg13264159	chr8:625131	ERICH1	-0.77	-7.22	-0.37	3.52e-12	IgG glycosylation;
CRC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.66	-0.3	3.25e-8	Erythrocyte sedimentation rate;
CRC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.56	0.43	4.37e-16	Menopause (age at onset);
CRC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.69	-0.47	1.04e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.92	0.36	2.36e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	16.05	0.66	3.27e-43	Platelet count;
CRC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.02	16.12	0.66	1.65e-43	Cognitive function;
CRC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.8	-13.18	-0.59	3.72e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.63	-0.34	1.36e-10	Mean platelet volume;
CRC	cis	rs10208940	0.777	rs4513330	chr2:68850921	C/T	cg12452813	chr2:68675892	NA	-0.48	-6.11	-0.32	2.86e-9	Urate levels in lean individuals;
CRC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	6.06	0.32	3.77e-9	Putamen volume;
CRC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	10.19	0.49	2.26e-21	Calcium levels;
CRC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.81	-0.3	1.5e-8	Aortic root size;
CRC	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.19	-0.37	4.5e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg04110750	chr16:69646130	NFAT5	-0.49	-6.77	-0.35	5.77e-11	IgE levels;
CRC	cis	rs2795502	0.630	rs3004257	chr10:43480529	C/T	cg20628663	chr10:43360327	NA	0.61	6.94	0.36	2.13e-11	Blood protein levels;
CRC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.51	6.96	0.36	1.83e-11	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-19.1	-0.73	2.93e-55	Height;
CRC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg10589385	chr1:150898437	SETDB1	0.31	6.49	0.34	3.08e-10	Melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15214069	chr9:139333582	INPP5E	0.44	6.33	0.33	8.05e-10	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.69	-0.35	9.43e-11	Total body bone mineral density;
CRC	cis	rs6479527	0.875	rs10435922	chr9:96781419	G/A	cg14459158	chr9:96720562	NA	0.36	6.49	0.34	3.12e-10	Esophageal adenocarcinoma;
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs11650494	0.634	rs8072520	chr17:47466640	T/G	cg08112188	chr17:47440006	ZNF652	0.71	6.32	0.33	8.54e-10	Prostate cancer;
CRC	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.55	-9.11	-0.45	8.03e-18	Depressive symptoms (multi-trait analysis);
CRC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.71	0.57	2.19e-30	Menopause (age at onset);
CRC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.23	0.45	3.48e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.65	9.17	0.45	5.22e-18	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14932796	chr17:55038330	COIL	0.49	6.36	0.33	6.9e-10	Thyroid stimulating hormone;
CRC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg22777020	chr22:31556080	RNF185	-0.53	-6.2	-0.32	1.72e-9	Colorectal cancer;
CRC	cis	rs995000	0.931	rs6678483	chr1:63074442	C/A	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.8	-0.3	1.54e-8	Coronary artery disease;
CRC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg08798685	chr6:27730294	NA	-0.68	-6.06	-0.32	3.83e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.94	-0.36	2.06e-11	Metabolite levels (Pyroglutamine);
CRC	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg10862848	chr6:42927986	GNMT	-0.3	-5.64	-0.3	3.75e-8	Blood protein levels;
CRC	cis	rs4731207	0.535	rs28820311	chr7:124598989	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg18479299	chr3:125709523	NA	-0.55	-6.62	-0.34	1.45e-10	Blood pressure (smoking interaction);
CRC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20307385	chr11:47447363	PSMC3	-0.51	-6.77	-0.35	6.01e-11	Subjective well-being;
CRC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	17.64	0.7	1.78e-49	Smoking behavior;
CRC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.63	-0.47	1.69e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	8.51	0.42	6.25e-16	Migraine;Coronary artery disease;
CRC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.65	9.72	0.47	8.55e-20	Initial pursuit acceleration;
CRC	cis	rs6973256	0.568	rs7800126	chr7:133521356	A/C	cg10665199	chr7:133106180	EXOC4	0.45	6.81	0.35	4.56e-11	Intelligence (multi-trait analysis);
CRC	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.35	16.39	0.67	1.43e-44	Uric acid levels;
CRC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Educational attainment;
CRC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.48	7.29	0.37	2.31e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg18196295	chr10:418757	DIP2C	-0.45	-6.05	-0.32	3.86e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.97	18.89	0.72	1.98e-54	Height;
CRC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg23533926	chr12:111358616	MYL2	-0.44	-6.45	-0.34	3.95e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1347297	0.666	rs10204497	chr2:179266127	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.42	-5.92	-0.31	8.1e-9	Alzheimer disease and age of onset;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg24560729	chr4:1342394	KIAA1530	0.33	6.19	0.32	1.78e-9	Obesity-related traits;
CRC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.8	-10.8	-0.51	1.79e-23	Initial pursuit acceleration;
CRC	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.63	-0.3	3.92e-8	Tuberculosis;
CRC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg23018236	chr17:30244563	NA	-0.58	-7.53	-0.38	5e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4731207	0.596	rs922713	chr7:124607059	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.16	-0.32	2.14e-9	Cutaneous malignant melanoma;
CRC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-6.64	-0.34	1.28e-10	Subjective well-being;
CRC	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.48	-8.78	-0.44	9.05e-17	Total body bone mineral density;
CRC	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.14	10.07	0.49	5.8e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.5	-7.72	-0.39	1.45e-13	Diastolic blood pressure;
CRC	trans	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg24644049	chr4:85504048	CDS1	0.83	7.0	0.36	1.47e-11	Skin colour saturation;
CRC	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.3	-0.67	3.4e-44	Hip circumference;
CRC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.78	-10.48	-0.5	2.37e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2380220	0.872	rs2613529	chr6:95945036	C/T	cg04719120	chr6:96025338	MANEA	-0.55	-6.04	-0.32	4.15e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg27534772	chr1:16042836	PLEKHM2	0.55	10.87	0.51	9.78e-24	Systolic blood pressure;
CRC	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.12	9.63	0.47	1.74e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.64	6.74	0.35	7.14e-11	Chronic lymphocytic leukemia;
CRC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.59	-8.68	-0.43	1.91e-16	Aortic root size;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.68e-17	Bipolar disorder;
CRC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg04239562	chr7:158767014	NA	0.36	5.68	0.3	2.96e-8	Facial morphology (factor 20);
CRC	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.74	-12.41	-0.56	2.86e-29	Bipolar disorder;
CRC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.06	0.69	3.53e-47	Platelet count;
CRC	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.6	-9.12	-0.45	7.49e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.5	8.4	0.42	1.36e-15	Hypertriglyceridemia;
CRC	trans	rs9341835	0.642	rs1723535	chr6:64136886	A/G	cg13657004	chr13:50234944	EBPL	-0.36	-6.17	-0.32	2.03e-9	Schizophrenia;
CRC	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg27083787	chr2:113543245	IL1A	0.45	6.38	0.33	5.89e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs11212617	1.000	rs609429	chr11:108196509	G/C	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.43	0.33	4.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.87	-0.31	1.06e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg09873164	chr1:152488093	CRCT1	0.39	6.58	0.34	1.84e-10	Hair morphology;
CRC	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	cg04338863	chr8:33670619	NA	0.43	6.92	0.36	2.3e-11	Body mass index;
CRC	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.4	-6.63	-0.34	1.34e-10	Mean arterial pressure;
CRC	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.36	-5.6	-0.3	4.47e-8	Myeloid white cell count;
CRC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.06	-0.32	3.79e-9	Mean corpuscular volume;
CRC	cis	rs3018066	0.692	rs28822186	chr4:107009482	G/A	cg01869342	chr4:106983673	TBCK	0.44	6.7	0.35	9.19e-11	Cancer;
CRC	trans	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg13565492	chr6:43139072	SRF	-0.7	-7.21	-0.37	3.77e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg19223190	chr17:80058835	NA	0.38	6.18	0.32	1.94e-9	Life satisfaction;
CRC	cis	rs7212590	0.655	rs62081824	chr17:57907950	A/G	cg10252138	chr17:58120427	NA	-0.54	-5.65	-0.3	3.51e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.43	6.56	0.34	2.15e-10	Social autistic-like traits;
CRC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg23136738	chr11:925521	AP2A2	-0.48	-7.63	-0.39	2.52e-13	Alzheimer's disease (late onset);
CRC	cis	rs9469578	1.000	rs16869456	chr6:33714622	G/A	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	0.99	14.57	0.63	1.87e-37	Breast cancer;
CRC	cis	rs938554	0.736	rs11734219	chr4:9977154	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.65	0.34	1.21e-10	Blood metabolite levels;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.74	-10.54	-0.5	1.42e-22	Menopause (age at onset);
CRC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.57	-9.44	-0.46	6.97e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.28	-6.92	-0.36	2.41e-11	Lymphocyte counts;
CRC	cis	rs7274811	0.625	rs293723	chr20:31927706	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.43	-5.81	-0.3	1.49e-8	Height;
CRC	cis	rs8105895	0.935	rs2043319	chr19:22274595	A/G	cg02657401	chr19:22469223	NA	-0.35	-5.6	-0.3	4.44e-8	Body mass index (change over time);
CRC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.82	9.97	0.48	1.25e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs12580194	0.593	rs4448777	chr12:55724981	T/C	cg19537932	chr12:55886519	OR6C68	-0.7	-8.73	-0.43	1.31e-16	Cancer;
CRC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg10589385	chr1:150898437	SETDB1	0.28	6.05	0.32	4.05e-9	Tonsillectomy;
CRC	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.51	-7.27	-0.37	2.63e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	1.02	9.92	0.48	1.78e-20	Lymphocyte counts;
CRC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.38	5.92	0.31	8.06e-9	HDL cholesterol levels;
CRC	cis	rs1322512	0.959	rs2758798	chr6:152943980	A/G	cg03415253	chr6:152958462	SYNE1	-0.41	-6.38	-0.33	6.06e-10	Tonometry;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24594295	chr1:151966792	S100A10	0.41	6.02	0.31	4.75e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23181591	chr8:123793873	ZHX2	-0.5	-5.99	-0.31	5.52e-9	Diisocyanate-induced asthma;
CRC	cis	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg27395922	chr11:50257633	LOC441601	-0.37	-5.69	-0.3	2.87e-8	Coronary artery disease;
CRC	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.15	-0.32	2.24e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.0	-0.48	9.6e-21	Bipolar disorder;
CRC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12172441	chr6:28176163	NA	0.63	7.43	0.38	9.41e-13	Depression;
CRC	cis	rs7259376	0.902	rs11669270	chr19:22604816	G/A	cg02657401	chr19:22469223	NA	0.3	6.54	0.34	2.3e-10	Menopause (age at onset);
CRC	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-1.06	-10.11	-0.49	4.16e-21	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg23161317	chr6:28129485	ZNF389	0.42	6.02	0.32	4.55e-9	Cardiac Troponin-T levels;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg12172441	chr6:28176163	NA	0.54	6.99	0.36	1.49e-11	Parkinson's disease;
CRC	cis	rs4731207	0.596	rs1481327	chr7:124628282	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.33	-0.33	7.94e-10	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.13	-0.32	2.57e-9	Height;
CRC	cis	rs7113874	0.610	rs1446462	chr11:8566343	C/T	cg20771178	chr11:8615675	STK33	-0.36	-5.89	-0.31	9.43e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg23260525	chr10:116636907	FAM160B1	0.31	5.97	0.31	6.17e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.23	0.53	5.36e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.38	6.0	0.31	5.25e-9	Height;
CRC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-7.06	-0.36	9.9e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7739232	0.920	rs78684814	chr6:53527508	T/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.2	-0.32	1.68e-9	Cognitive function;
CRC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.35	5.68	0.3	3.01e-8	Height;
CRC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.67	-11.75	-0.54	7.56e-27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	0.51	8.19	0.41	5.85e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg18827107	chr12:86230957	RASSF9	0.39	5.98	0.31	5.76e-9	Major depressive disorder;
CRC	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6988985	0.678	rs1799998	chr8:143999600	A/G	cg10324643	chr8:143916377	GML	0.39	6.54	0.34	2.34e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.67	6.87	0.35	3.17e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	cg22592108	chr5:53304441	ARL15	0.48	6.0	0.31	5.23e-9	Migraine;
CRC	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg02466173	chr16:30829666	NA	-0.73	-8.96	-0.44	2.48e-17	Diastolic blood pressure;
CRC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg09324608	chr17:30823087	MYO1D	0.4	6.75	0.35	6.5500000000000006e-11	Schizophrenia;
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg12172441	chr6:28176163	NA	0.65	6.23	0.32	1.45e-9	Depression;
CRC	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg11887960	chr12:57824829	NA	0.63	6.89	0.36	2.93e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg02702477	chr5:179499311	RNF130	0.64	7.06	0.36	9.81e-12	LDL cholesterol;
CRC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.45	-6.64	-0.34	1.28e-10	Subjective well-being;
CRC	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.93	11.85	0.55	3.31e-27	Migraine;
CRC	cis	rs741668	0.931	rs61953332	chr13:46590274	G/C	cg06018095	chr13:46550134	ZC3H13	0.41	5.75	0.3	2.01e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.49	6.69	0.35	9.46e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.56	-7.25	-0.37	3.02e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.43	6.81	0.35	4.57e-11	Height;
CRC	cis	rs8010715	0.816	rs6573573	chr14:24599257	T/C	cg23112188	chr14:24563095	PCK2	-0.36	-7.23	-0.37	3.41e-12	IgG glycosylation;
CRC	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.67	10.01	0.48	9.03e-21	Psoriasis;
CRC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.36	-6.45	-0.34	3.95e-10	Reticulocyte fraction of red cells;
CRC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.89	-15.12	-0.64	1.43e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21028142	chr17:79581711	NPLOC4	0.32	6.86	0.35	3.43e-11	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00866667	chr19:40031046	EID2	0.44	5.97	0.31	6.05e-9	Response to antipsychotic treatment;
CRC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.72	-11.42	-0.53	1.15e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg10298567	chr3:47292165	KIF9	0.4	6.28	0.33	1.08e-9	Colorectal cancer;
CRC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.4	5.61	0.3	4.27e-8	Uric acid clearance;
CRC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.56	-9.76	-0.47	6.48e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg02158880	chr13:53174818	NA	0.42	6.06	0.32	3.63e-9	Lewy body disease;
CRC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.47	0.38	7.49e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.58	0.39	3.52e-13	Endometrial cancer;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.58	-7.52	-0.38	5.39e-13	Gut microbiome composition (summer);
CRC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg01483505	chr11:975446	AP2A2	-0.44	-7.29	-0.37	2.31e-12	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03262694	chr11:64684810	ATG2A	0.48	6.84	0.35	3.93e-11	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.76	-0.47	6.37e-20	Height;
CRC	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg25547332	chr5:131281432	NA	0.38	5.93	0.31	7.75e-9	Life satisfaction;
CRC	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg16591659	chr17:78472290	NA	-0.45	-6.72	-0.35	8.05e-11	Fractional excretion of uric acid;
CRC	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg13385794	chr1:248469461	NA	0.39	6.65	0.34	1.23e-10	Common traits (Other);
CRC	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg09760422	chr2:128146352	NA	-0.36	-6.93	-0.36	2.27e-11	Protein C levels;
CRC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.67	9.71	0.47	8.93e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.18	-0.37	4.82e-12	Inflammatory skin disease;
CRC	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-7.04	-0.36	1.12e-11	Schizophrenia;
CRC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.53	8.27	0.42	3.26e-15	Height;
CRC	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.52	7.88	0.4	4.94e-14	Corneal astigmatism;
CRC	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg14311320	chr7:124405732	GPR37	-0.37	-5.61	-0.3	4.3e-8	Lewy body disease;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg22638593	chr5:131593259	PDLIM4	0.48	8.84	0.44	5.99e-17	Blood metabolite levels;
CRC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.51	-10.18	-0.49	2.38e-21	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.72	9.97	0.48	1.26e-20	Alzheimer's disease;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18402987	chr7:1209562	NA	0.41	6.16	0.32	2.16e-9	Longevity;Endometriosis;
CRC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.68	-0.57	2.79e-30	Ulcerative colitis;
CRC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.64	-0.43	2.42e-16	Hemoglobin concentration;
CRC	cis	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg07965774	chr1:17746286	RCC2	0.32	6.15	0.32	2.22e-9	Basal cell carcinoma;
CRC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg22110888	chr17:80059540	CCDC57	-0.43	-6.55	-0.34	2.27e-10	Life satisfaction;
CRC	cis	rs11628318	0.515	rs11850580	chr14:103156586	C/T	cg12046867	chr14:103022105	NA	0.4	5.62	0.3	3.99e-8	Platelet count;
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.78	0.44	9.31e-17	Lymphocyte counts;
CRC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.27	0.64	3.72e-40	Platelet count;
CRC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-15.23	-0.64	5.13e-40	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10884662	chr15:75871802	PTPN9	0.42	6.97	0.36	1.73e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.47	7.5	0.38	6.01e-13	Calcium levels;
CRC	cis	rs2530545	0.762	rs17169924	chr7:34667565	G/T	cg14401837	chr7:34697493	NPSR1	0.43	6.34	0.33	7.68e-10	IgG glycosylation;
CRC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg04969067	chr8:143858791	LYNX1	-0.34	-5.84	-0.31	1.28e-8	Urinary tract infection frequency;
CRC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg04731861	chr2:219085781	ARPC2	0.3	5.72	0.3	2.41e-8	Colorectal cancer;
CRC	cis	rs970548	0.954	rs10466245	chr10:46031747	G/A	cg15590007	chr10:45870220	ALOX5	0.48	6.17	0.32	2.04e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.71	-0.35	8.58e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.55	-8.89	-0.44	4.23e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.36	6.2	0.32	1.66e-9	Systemic lupus erythematosus;
CRC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.42	6.48	0.34	3.41e-10	Hemoglobin concentration;
CRC	cis	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11326485	chr3:87275983	CHMP2B	-0.38	-5.73	-0.3	2.26e-8	Myopia (pathological);
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.77	-0.35	5.8200000000000003e-11	Electroencephalogram traits;
CRC	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.67	11.75	0.54	7.17e-27	Aortic root size;
CRC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.6	-9.07	-0.45	1.13e-17	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.72	-0.43	1.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.64	8.66	0.43	2.14e-16	Multiple sclerosis;
CRC	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.49	-9.14	-0.45	6.73e-18	Hip circumference;Waist circumference;
CRC	cis	rs524281	0.861	rs7937281	chr11:65950074	T/C	cg16950941	chr11:66035639	RAB1B	-0.57	-7.14	-0.37	5.84e-12	Electroencephalogram traits;
CRC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.48	-7.03	-0.36	1.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.36	-6.34	-0.33	7.58e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg00579200	chr11:133705235	NA	-0.41	-5.93	-0.31	7.52e-9	Childhood ear infection;
CRC	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg27565382	chr3:53032988	SFMBT1	0.75	6.04	0.32	4.11e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg21106136	chr3:194405973	FAM43A	-0.5	-7.49	-0.38	6.53e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.99	-0.31	5.54e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.09	0.41	1.15e-14	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16800975	chr8:17434541	PDGFRL	0.51	8.27	0.41	3.25e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs75422866	0.867	rs73104155	chr12:48094573	T/C	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-13.13	-0.59	5.94e-32	Blood metabolite levels;
CRC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg05207973	chr5:176823642	SLC34A1	0.35	5.94	0.31	7.08e-9	Hemoglobin concentration;Hematocrit;
CRC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.66	8.26	0.41	3.7e-15	Subcortical brain region volumes;Hippocampal volume;
CRC	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg13047869	chr3:10149882	C3orf24	0.39	5.95	0.31	6.8e-9	Alzheimer's disease;
CRC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg22495460	chr2:25135724	ADCY3	-0.84	-15.95	-0.66	7.89e-43	Body mass index in non-asthmatics;
CRC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.7	-0.3	2.61e-8	Type 2 diabetes;
CRC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.64	9.75	0.47	6.66e-20	Fibrinogen levels;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg19958696	chr11:107992251	ACAT1	-0.55	-6.0	-0.31	5.16e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.73	-0.3	2.27e-8	Obesity-related traits;
CRC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.63	10.19	0.49	2.25e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.78	-9.66	-0.47	1.3e-19	Platelet count;
CRC	cis	rs9549328	0.670	rs61963562	chr13:113616523	T/G	cg08614441	chr13:113633676	MCF2L	0.4	6.97	0.36	1.69e-11	Systolic blood pressure;
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg26304593	chr6:42947056	PEX6	-0.41	-5.84	-0.31	1.23e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-8.83	-0.44	6.51e-17	Urinary metabolites;
CRC	cis	rs10484885	0.571	rs76955220	chr6:90252030	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.56	-6.32	-0.33	8.43e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00108277	chr3:49840710	C3orf54	0.42	6.72	0.35	8.2e-11	Schizophrenia;
CRC	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg25856811	chr1:152973957	SPRR3	0.25	7.01	0.36	1.38e-11	Inflammatory skin disease;
CRC	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-14.39	-0.62	9.71e-37	Colorectal cancer;
CRC	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg04586622	chr2:25135609	ADCY3	-0.5	-8.4	-0.42	1.39e-15	Body mass index;
CRC	cis	rs2342406	0.825	rs1026061	chr2:45142011	C/G	cg23424933	chr2:45157613	NA	0.43	5.71	0.3	2.57e-8	Myopia;
CRC	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.8	-0.35	4.84e-11	Metabolite levels;
CRC	cis	rs7731657	0.537	rs4705976	chr5:130286160	T/C	cg08523029	chr5:130500466	HINT1	0.43	5.69	0.3	2.74e-8	Fasting plasma glucose;
CRC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.71	9.34	0.46	1.55e-18	High light scatter reticulocyte count;
CRC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	1.02	18.92	0.72	1.55e-54	Primary sclerosing cholangitis;
CRC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg23283495	chr1:209979779	IRF6	0.46	6.63	0.34	1.4e-10	Cleft lip with or without cleft palate;
CRC	cis	rs4731207	0.698	rs11978628	chr7:124449897	C/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.31	-6.64	-0.34	1.33e-10	Schizophrenia;
CRC	cis	rs4654899	0.931	rs3767241	chr1:21166144	C/T	cg02927042	chr1:21476669	EIF4G3	0.41	6.55	0.34	2.24e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.12	-0.32	2.59e-9	Lung cancer;
CRC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.71	11.66	0.54	1.53e-26	Monocyte count;
CRC	cis	rs4964805	0.773	rs4964623	chr12:104222742	G/A	cg02344784	chr12:104178138	NT5DC3	0.48	6.66	0.34	1.18e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.93	-11.32	-0.53	2.62e-25	Glomerular filtration rate (creatinine);
CRC	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.58	0.63	1.79e-37	Exhaled nitric oxide output;
CRC	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.77	10.67	0.51	5.19e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.71	9.34	0.46	1.55e-18	High light scatter reticulocyte count;
CRC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.62	8.85	0.44	5.57e-17	DNA methylation (variation);
CRC	cis	rs2885135	0.559	rs1148455	chr1:13914230	A/G	cg04886857	chr1:13914270	PDPN	0.31	6.11	0.32	2.83e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg18335740	chr13:41363409	SLC25A15	0.56	9.03	0.45	1.5e-17	Lewy body disease;
CRC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg05941027	chr17:61774174	LIMD2	0.36	6.47	0.34	3.52e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.5	6.8	0.35	5.08e-11	Schizophrenia;
CRC	cis	rs9549328	0.611	rs72661939	chr13:113617498	C/T	cg17524180	chr13:113633600	MCF2L	0.52	9.5	0.46	4.44e-19	Systolic blood pressure;
CRC	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg20194872	chr6:41519635	FOXP4	0.41	5.98	0.31	5.72e-9	Prostate cancer;
CRC	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.7	-11.3	-0.53	2.99e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.82	0.35	4.25e-11	Mean platelet volume;
CRC	cis	rs6840360	0.582	rs7691601	chr4:152321631	A/G	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.66	-10.56	-0.5	1.2e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.06	13.2	0.59	3.23e-32	Vitiligo;
CRC	cis	rs6793245	0.810	rs9843500	chr3:38588095	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-8.48	-0.42	7.65e-16	QT interval;
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.65	0.54	1.65e-26	Prudent dietary pattern;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16478012	chr16:87425779	FBXO31;MAP1LC3B	0.38	6.11	0.32	2.82e-9	Schizophrenia;
CRC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	11.5	0.54	6.07e-26	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20749283	chr15:69755176	NA	0.39	6.27	0.33	1.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.03	0.32	4.52e-9	Glioblastoma;
CRC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.8	-0.4	8.08e-14	Caffeine consumption;
CRC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	11.97	0.55	1.17e-27	Platelet count;
CRC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg10431340	chr1:161279108	MPZ	-0.52	-6.96	-0.36	1.84e-11	Rheumatoid arthritis;
CRC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.69	-10.63	-0.51	7.04e-23	Blood protein levels;
CRC	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.43	5.78	0.3	1.73e-8	Recombination rate (females);
CRC	cis	rs11212617	0.967	rs227074	chr11:108215095	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.35	0.33	7.28e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg18595228	chr15:67193261	NA	-0.46	-6.6	-0.34	1.68e-10	Lung cancer (smoking interaction);
CRC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.39	0.46	1.04e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.8	-12.35	-0.56	4.75e-29	Menarche (age at onset);
CRC	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.54	7.05	0.36	1.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12273811	chr6:28175739	NA	0.69	8.83	0.44	6.17e-17	Depression;
CRC	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	1.12	10.16	0.49	2.88e-21	Arsenic metabolism;
CRC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg21620606	chr4:1342894	KIAA1530	0.35	5.76	0.3	1.9e-8	Obesity-related traits;
CRC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.69	-11.47	-0.53	7.63e-26	Breast cancer;
CRC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg18016565	chr1:150552671	MCL1	0.44	6.19	0.32	1.8e-9	Melanoma;
CRC	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12315302	chr6:26189340	HIST1H4D	0.75	6.33	0.33	7.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.66	-9.18	-0.45	4.99e-18	DNA methylation (variation);
CRC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg05501817	chr11:14380813	RRAS2	-0.46	-6.06	-0.32	3.7e-9	Sense of smell;
CRC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.6	-0.3	4.44e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg10589385	chr1:150898437	SETDB1	0.27	5.9	0.31	8.95e-9	Tonsillectomy;
CRC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.36	5.8	0.3	1.54e-8	Height;
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg08222913	chr3:52553049	STAB1	-0.37	-6.99	-0.36	1.51e-11	Electroencephalogram traits;
CRC	cis	rs17767392	0.914	rs28859432	chr14:72010693	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-6.93	-0.36	2.28e-11	Mitral valve prolapse;
CRC	trans	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.41	-5.86	-0.31	1.13e-8	Red blood cell count;
CRC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.56	-8.5	-0.42	6.56e-16	Aortic root size;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg20468365	chr15:83419170	NA	0.4	6.1	0.32	3.02e-9	Schizophrenia;
CRC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg17724175	chr1:150552817	MCL1	0.47	6.91	0.36	2.47e-11	Melanoma;
CRC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-5.9	-0.31	9.1e-9	Inflammatory bowel disease;
CRC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg02659138	chr7:134003124	SLC35B4	0.38	6.47	0.34	3.54e-10	Mean platelet volume;
CRC	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.52	-8.19	-0.41	5.73e-15	Hyperactive-impulsive symptoms;
CRC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg27661571	chr11:113659931	NA	-0.77	-9.65	-0.47	1.43e-19	Hip circumference adjusted for BMI;
CRC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.48	0.38	6.66e-13	Height;
CRC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.95	-15.19	-0.64	7.44e-40	Longevity;
CRC	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg17517138	chr11:73019481	ARHGEF17	0.52	5.66	0.3	3.36e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs800082	0.516	rs12486882	chr3:144228481	A/G	cg24215973	chr2:240111563	HDAC4	0.46	6.44	0.33	4.18e-10	Smoking behavior;
CRC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.6	0.39	3.04e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-12.7	-0.57	2.36e-30	Vitiligo;
CRC	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.77	-0.35	5.83e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.48	7.36	0.38	1.51e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg20243544	chr17:37824526	PNMT	0.47	5.61	0.3	4.22e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg12273811	chr6:28175739	NA	0.52	6.83	0.35	4.08e-11	Parkinson's disease;
CRC	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.47	-6.81	-0.35	4.69e-11	Breast cancer;
CRC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.27e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.79	-6.69	-0.35	9.4e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.6	-0.39	3.08e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12074057	chr3:124605640	ITGB5	0.43	6.11	0.32	2.88e-9	Response to antipsychotic treatment;
CRC	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.97	17.98	0.7	7.97e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.11	18.13	0.71	2e-51	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.28	-0.33	1.07e-9	Alzheimer's disease (late onset);
CRC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	8.9	0.44	3.84e-17	Mean platelet volume;
CRC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg18016565	chr1:150552671	MCL1	-0.39	-5.65	-0.3	3.42e-8	Tonsillectomy;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-6.17	-0.32	1.99e-9	Lymphocyte counts;
CRC	cis	rs6662572	0.855	rs7517418	chr1:46252418	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-6.12	-0.32	2.69e-9	Blood protein levels;
CRC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.78	-10.48	-0.5	2.37e-22	IgG glycosylation;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17050602	chr7:4681478	NA	0.45	6.09	0.32	3.12e-9	Anxiety disorder;
CRC	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.87	9.7	0.47	9.91e-20	Uric acid levels;
CRC	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg09873164	chr1:152488093	CRCT1	0.39	6.41	0.33	5.17e-10	Hair morphology;
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.33	-0.46	1.62e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.41	5.88	0.31	9.87e-9	Daytime sleep phenotypes;
CRC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.61	10.25	0.49	1.43e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.2	0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg03790207	chr6:42947109	PEX6	-0.45	-6.34	-0.33	7.56e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.1	-19.24	-0.73	8.63e-56	Dilated cardiomyopathy;
CRC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	0.66	6.44	0.33	4.17e-10	Fat distribution (HIV);
CRC	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.32	-6.07	-0.32	3.5e-9	Cutaneous nevi;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg01182386	chr15:75182373	MPI	0.49	6.25	0.33	1.28e-9	Plasma plasminogen activator levels;
CRC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.49	7.9	0.4	4.35e-14	Height;
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg10729496	chr3:10149963	C3orf24	0.49	6.47	0.34	3.6e-10	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20456276	chr12:51157683	ATF1	0.46	6.52	0.34	2.66e-10	Anxiety disorder;
CRC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.76e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.6	-8.16	-0.41	7.31e-15	Facial morphology (factor 19);
CRC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.62	9.59	0.47	2.31e-19	Corneal astigmatism;
CRC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-13.54	-0.6	1.67e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.32	0.65	2.28e-40	Fuchs's corneal dystrophy;
CRC	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg14191688	chr11:70257035	CTTN	0.42	5.85	0.31	1.18e-8	Coronary artery disease;
CRC	cis	rs2635047	0.542	rs1512235	chr18:44781569	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.32	-0.33	8.32e-10	Educational attainment;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.72	9.5	0.46	4.68e-19	Alzheimer's disease;
CRC	cis	rs1891275	0.508	rs2096079	chr10:93496667	C/G	cg07889827	chr10:93443413	NA	-0.39	-6.46	-0.34	3.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.58	6.08	0.32	3.27e-9	Blood protein levels;
CRC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.83	-12.41	-0.56	2.76e-29	Blood metabolite levels;
CRC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg23298862	chr7:158159286	PTPRN2	0.38	5.98	0.31	5.8e-9	Calcium levels;
CRC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.89	-0.4	4.6e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.39	-5.89	-0.31	9.33e-9	Gout;Renal underexcretion gout;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg15786705	chr6:28176104	NA	0.68	10.39	0.5	4.62e-22	Cardiac Troponin-T levels;
CRC	cis	rs7527798	0.592	rs6667118	chr1:207822724	G/T	cg21110645	chr1:207815933	NA	-0.41	-6.45	-0.34	3.95e-10	Erythrocyte sedimentation rate;
CRC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.91	-0.4	4.08e-14	Gut microbiome composition (summer);
CRC	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.97	7.95	0.4	2.97e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg02659138	chr7:134003124	SLC35B4	-0.42	-7.37	-0.38	1.42e-12	Mean platelet volume;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.89	11.67	0.54	1.42e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.68	0.51	4.61e-23	Ileal carcinoids;
CRC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.45	7.49	0.38	6.6e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	trans	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.53	-8.91	-0.44	3.61e-17	Type 2 diabetes;
CRC	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.74	0.43	1.22e-16	Coffee consumption (cups per day);
CRC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg16558177	chr4:4109446	NA	-0.56	-6.77	-0.35	5.77e-11	Blood pressure (smoking interaction);
CRC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg23920097	chr1:209922102	NA	-0.54	-6.71	-0.35	8.67e-11	Red blood cell count;
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.64	0.34	1.28e-10	Alzheimer's disease;
CRC	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg10437265	chr15:77819839	NA	0.69	12.91	0.58	3.94e-31	Type 2 diabetes;
CRC	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07165851	chr6:158734300	TULP4	0.61	7.54	0.38	4.53e-13	Height;
CRC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.37	-6.91	-0.36	2.49e-11	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03467813	chr6:3851047	FAM50B	0.39	6.24	0.33	1.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12711979	0.513	rs4849991	chr2:3840545	T/G	cg17052675	chr2:3827356	NA	-0.35	-5.99	-0.31	5.6e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.43	4.17e-16	Aortic root size;
CRC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.61	-8.7	-0.43	1.61e-16	Other erythrocyte phenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01019362	chr1:53163908	C1orf163	0.5	7.02	0.36	1.24e-11	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.45	6.63	0.34	1.39e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.17	-0.37	5.14e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.46	9.68	0.47	1.14e-19	Vitiligo;
CRC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.35	6.1	0.32	3.04e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg02725872	chr8:58115012	NA	-0.53	-7.23	-0.37	3.39e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg07414643	chr4:187882934	NA	-0.35	-5.94	-0.31	7.39e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07685180	chr8:600429	NA	0.85	8.61	0.43	3.03e-16	IgG glycosylation;
CRC	cis	rs995000	0.931	rs2131926	chr1:63026011	C/T	cg19896129	chr1:63156450	NA	-0.43	-6.67	-0.35	1.06e-10	Triglyceride levels;
CRC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00829269	chr20:44065852	NA	0.34	5.97	0.31	6.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.47	-7.74	-0.39	1.2e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.61	0.39	3e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.24	-0.33	1.39e-9	Blood pressure;
CRC	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg21153622	chr11:89784906	NA	-0.46	-7.31	-0.37	2.1e-12	HDL cholesterol;
CRC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.89	17.16	0.69	1.43e-47	Obesity-related traits;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg22638593	chr5:131593259	PDLIM4	0.38	6.24	0.33	1.37e-9	Breast cancer;
CRC	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-11.2	-0.53	6.79e-25	Colorectal cancer;
CRC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.5	-7.25	-0.37	3.08e-12	Morning vs. evening chronotype;
CRC	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg27398640	chr15:77910606	LINGO1	0.39	7.06	0.36	9.95e-12	Type 2 diabetes;
CRC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.82	15.11	0.64	1.57e-39	Mean platelet volume;
CRC	cis	rs4750440	0.702	rs4748066	chr10:14029313	A/T	cg00551146	chr10:14014579	FRMD4A	-0.36	-5.74	-0.3	2.16e-8	Adiponectin levels;
CRC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.37	0.33	6.54e-10	Diastolic blood pressure;
CRC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.65	-8.89	-0.44	4.04e-17	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs755249	0.567	rs4660214	chr1:39731550	T/C	cg18385671	chr1:39797026	MACF1	-0.42	-5.96	-0.31	6.35e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-10.33	-0.49	7.53e-22	Neuroticism;
CRC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.83e-9	Hemoglobin concentration;
CRC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.91	0.36	2.57e-11	Cognitive ability;
CRC	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.61	0.43	3.06e-16	Coffee consumption (cups per day);
CRC	cis	rs2882667	0.722	rs2011462	chr5:138162772	G/A	cg09476006	chr5:138032270	NA	-0.59	-10.72	-0.51	3.27e-23	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11229555	0.645	rs12802960	chr11:58174775	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.95e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.81	14.47	0.62	4.55e-37	Vitiligo;
CRC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.22e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.49	7.33	0.37	1.78e-12	Intelligence (multi-trait analysis);
CRC	cis	rs3736485	0.966	rs7176044	chr15:51895343	T/C	cg08986416	chr15:51914746	DMXL2	-0.47	-6.7	-0.35	9e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.48	7.6	0.39	3.11e-13	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg13490827	chr1:46269305	MAST2	-0.71	-6.33	-0.33	7.97e-10	Cognitive function;
CRC	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg14345882	chr6:26364793	BTN3A2	0.76	6.22	0.32	1.53e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg17133734	chr15:86042851	AKAP13	0.4	6.49	0.34	3.21e-10	Interstitial lung disease;
CRC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.56	8.23	0.41	4.4e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs6973256	0.897	rs4731970	chr7:133326602	C/T	cg10665199	chr7:133106180	EXOC4	-0.37	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg05376469	chr2:102649931	NA	0.37	6.13	0.32	2.51e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.52	8.08	0.41	1.22e-14	Colorectal cancer;
CRC	cis	rs365302	0.951	rs439251	chr6:159644198	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.67	0.35	1.06e-10	Coronary heart disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20257372	chr17:1945152	OVCA2;DPH1	0.39	6.55	0.34	2.26e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg16681516	chr19:46297285	DMWD	0.35	5.8	0.3	1.54e-8	Coronary artery disease;
CRC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg24324837	chr19:49891574	CCDC155	0.53	6.94	0.36	2.13e-11	Multiple sclerosis;
CRC	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	1.07	22.87	0.78	5.93e-70	Multiple myeloma;
CRC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg00769240	chr8:12517080	NA	-0.67	-7.82	-0.4	7.4e-14	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	6.06	0.32	3.71e-9	Height;
CRC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.39	7.42	0.38	9.77e-13	Subjective well-being;
CRC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg25287198	chr4:183728479	NA	0.56	6.83	0.35	4.1e-11	Pediatric autoimmune diseases;
CRC	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg09344028	chr17:70110421	NA	0.44	6.76	0.35	6.41e-11	Thyroid hormone levels;
CRC	cis	rs7605827	0.930	rs10176967	chr2:15686086	G/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.67	-0.39	2e-13	Waist circumference;Hip circumference;
CRC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.67	-10.06	-0.48	6.29e-21	Bronchopulmonary dysplasia;
CRC	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg06935464	chr4:38784597	TLR10	0.55	5.69	0.3	2.78e-8	Breast cancer;
CRC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg07636037	chr3:49044803	WDR6	-0.61	-6.24	-0.33	1.35e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg27205649	chr11:78285834	NARS2	0.52	6.66	0.34	1.13e-10	Alzheimer's disease (survival time);
CRC	cis	rs17092148	0.836	rs6059910	chr20:33142107	T/C	cg08999081	chr20:33150536	PIGU	0.51	6.51	0.34	2.85e-10	Neuroticism;
CRC	cis	rs9818941	0.824	rs1123115	chr3:157813401	C/T	cg08654915	chr3:157813417	NA	0.31	5.85	0.31	1.17e-8	Height;
CRC	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.61	-9.71	-0.47	8.96e-20	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg04990556	chr1:26633338	UBXN11	0.55	5.86	0.31	1.15e-8	Obesity-related traits;
CRC	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.53	6.98	0.36	1.61e-11	Coronary artery disease;
CRC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg27565382	chr3:53032988	SFMBT1	0.8	6.32	0.33	8.4e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg18653534	chr16:772142	FAM173A	-0.35	-5.63	-0.3	3.96e-8	Height;
CRC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21028142	chr17:79581711	NPLOC4	0.32	6.85	0.35	3.68e-11	Eye color traits;
CRC	cis	rs17065868	0.764	rs9533869	chr13:45040702	T/C	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.63	-11.46	-0.53	8.3e-26	Breast cancer;
CRC	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.31	7.24	0.37	3.17e-12	Corneal astigmatism;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.33	-0.42	2.18e-15	Electroencephalogram traits;
CRC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	6.04	0.32	4.26e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24308560	chr3:49941425	MST1R	-0.45	-7.28	-0.37	2.5e-12	Intelligence (multi-trait analysis);
CRC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.38	8.67	0.43	1.98e-16	Multiple system atrophy;
CRC	trans	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg26043149	chr18:55253948	FECH	-0.5	-7.78	-0.39	9.21e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg21747405	chr11:67723411	NA	0.42	5.97	0.31	6.1e-9	Blood pressure (smoking interaction);
CRC	cis	rs282587	0.502	rs408476	chr13:113400056	A/C	cg04656015	chr13:113407548	ATP11A	0.62	7.97	0.4	2.63e-14	Glycated hemoglobin levels;
CRC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.45	-6.13	-0.32	2.48e-9	Diastolic blood pressure;
CRC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.51	10.49	0.5	2.06e-22	Alcohol dependence;
CRC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.39	-6.87	-0.35	3.21e-11	Dilated cardiomyopathy;
CRC	cis	rs727479	0.502	rs10046	chr15:51502986	G/A	cg19946085	chr15:51559439	CYP19A1	-0.29	-5.83	-0.31	1.31e-8	Estradiol levels;
CRC	cis	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg06470822	chr6:28175283	NA	0.67	6.62	0.34	1.48e-10	Depression;
CRC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.84	11.58	0.54	3.13e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.84	15.55	0.65	3.02e-41	Vitiligo;
CRC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg22110888	chr17:80059540	CCDC57	0.41	6.44	0.33	4.27e-10	Life satisfaction;
CRC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.6	-9.06	-0.45	1.2e-17	Breast cancer;
CRC	cis	rs938554	0.784	rs16868246	chr4:9978305	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	6.45	0.34	3.98e-10	Blood metabolite levels;
CRC	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg24759859	chr6:86352639	SYNCRIP	0.48	6.75	0.35	6.54e-11	Smooth-surface caries;
CRC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg11833968	chr6:79620685	NA	-0.37	-6.27	-0.33	1.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.52	5.89	0.31	9.36e-9	Vitiligo;
CRC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg09417038	chr21:47716443	C21orf57	-0.52	-8.69	-0.43	1.7e-16	Testicular germ cell tumor;
CRC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.7e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.71	-9.33	-0.46	1.56e-18	Alcohol dependence;
CRC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg06470822	chr6:28175283	NA	0.49	6.55	0.34	2.16e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg09898070	chr2:48009866	MSH6	0.45	7.15	0.37	5.51e-12	Body mass index;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03923535	chr7:1197113	ZFAND2A	0.64	9.19	0.45	4.6e-18	Longevity;Endometriosis;
CRC	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06307176	chr5:131281290	NA	0.48	6.77	0.35	5.94e-11	Life satisfaction;
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg21155852	chr7:2048760	MAD1L1	-0.45	-5.88	-0.31	1e-8	Neuroticism;
CRC	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.62	9.76	0.47	6.12e-20	Testicular germ cell tumor;
CRC	cis	rs7274811	0.688	rs6141400	chr20:32056087	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.41	-5.88	-0.31	1e-8	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01285435	chr8:145654565	VPS28;NFKBIL2	0.38	7.05	0.36	1.04e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs59104589	0.583	rs73002176	chr2:242332438	T/C	cg19488206	chr2:242435732	STK25	0.48	6.78	0.35	5.73e-11	Fibrinogen levels;
CRC	cis	rs60594510	1	rs60594510	chr12:110594503	C/T	cg12870014	chr12:110450643	ANKRD13A	0.83	10.65	0.51	5.74e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.43e-17	Bipolar disorder;
CRC	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.61	-0.47	1.96e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg25664220	chr3:72788482	NA	-0.39	-5.92	-0.31	8.18e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.96	-12.72	-0.57	1.96e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12431939	0.948	rs12435916	chr14:51665858	T/G	cg23942311	chr14:51606299	NA	-0.51	-6.19	-0.32	1.77e-9	Cancer;
CRC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-7.59	-0.39	3.34e-13	Longevity;
CRC	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs8029989	0.869	rs8039162	chr15:38740829	A/G	cg11248668	chr11:45826493	SLC35C1	0.38	5.96	0.31	6.35e-9	Psychosis (atypical);
CRC	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg16482183	chr6:26056742	HIST1H1C	-0.5	-6.77	-0.35	5.86e-11	Blood metabolite levels;
CRC	cis	rs62432291	0.681	rs435521	chr6:159662638	C/T	cg14500486	chr6:159655392	FNDC1	0.74	9.75	0.47	6.82e-20	Joint mobility (Beighton score);
CRC	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.53e-11	Common traits (Other);
CRC	cis	rs9399186	1.000	rs12176346	chr6:136732664	C/T	cg11114242	chr6:136756541	MAP7	0.48	6.62	0.34	1.45e-10	Pursuit maintenance gain;
CRC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.34e-11	Menopause (age at onset);
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg04025307	chr7:1156635	C7orf50	0.55	5.93	0.31	7.65e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.56	8.43	0.42	1.12e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.66	10.27	0.49	1.24e-21	Initial pursuit acceleration;
CRC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06873352	chr17:61820015	STRADA	0.5	7.76	0.39	1.06e-13	Height;
CRC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.59	8.69	0.43	1.72e-16	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06620762	chr15:76136437	UBE2Q2	0.53	7.01	0.36	1.37e-11	Thyroid stimulating hormone;
CRC	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg19537932	chr12:55886519	OR6C68	-0.66	-8.56	-0.43	4.26e-16	Cancer;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.48	8.82	0.44	7.04e-17	Acylcarnitine levels;
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.62	8.75	0.43	1.11e-16	Blood protein levels;
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.13	0.49	3.71e-21	Corneal astigmatism;
CRC	cis	rs600806	0.854	rs11102974	chr1:109886371	G/A	cg23032129	chr1:109941072	SORT1	-0.27	-5.79	-0.3	1.64e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.37	5.94	0.31	7.21e-9	Height;
CRC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.18	-16.13	-0.66	1.55e-43	Breast cancer;
CRC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg22687807	chr8:143858763	LYNX1	0.48	8.58	0.43	3.68e-16	Urinary tract infection frequency;
CRC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	7.09	0.36	8.14e-12	Eye color traits;
CRC	cis	rs1712517	0.771	rs7074749	chr10:105116056	C/T	cg05636881	chr10:105038444	INA	0.47	8.08	0.41	1.2e-14	Migraine;
CRC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg10760299	chr15:45669010	GATM	0.52	8.29	0.42	2.96e-15	Homoarginine levels;
CRC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.88	16.37	0.67	1.71e-44	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.95	17.39	0.69	1.66e-48	IgG glycosylation;
CRC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg01472538	chr16:58549086	SETD6	1.12	7.38	0.38	1.28e-12	Schizophrenia;
CRC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.54	-9.36	-0.46	1.32e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2303319	0.504	rs12469052	chr2:162319353	T/C	cg19471553	chr17:41393123	NA	-0.7	-6.07	-0.32	3.48e-9	Cognitive function;
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg10295955	chr4:187884368	NA	-0.97	-21.38	-0.76	3.42e-64	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	6.89	0.36	2.77e-11	Reticulocyte count;
CRC	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.6	5.76	0.3	1.93e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00837765	chr8:74884459	TCEB1	0.37	6.14	0.32	2.39e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg22456192	chr18:71959684	CYB5A	0.59	6.28	0.33	1.09e-9	Airway imaging phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04867738	chr17:42298359	UBTF	0.4	6.47	0.34	3.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.71	12.56	0.57	8.05e-30	P wave terminal force;
CRC	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg25885038	chr17:56607967	SEPT4	-0.46	-7.14	-0.37	5.86e-12	Vitamin D levels;
CRC	cis	rs2421770	0.530	rs10836375	chr11:35353842	C/T	cg13971030	chr11:35366721	SLC1A2	-0.37	-6.17	-0.32	1.98e-9	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.52	7.6	0.39	3.21e-13	Corneal astigmatism;
CRC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs2062225	0.935	rs1384795	chr2:111771647	A/G	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg09659197	chr4:152720779	NA	0.31	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.58	-0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	-0.54	-7.64	-0.39	2.36e-13	Cystic fibrosis severity;
CRC	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.18	-0.37	4.69e-12	Neuroticism;
CRC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.7	-0.3	2.71e-8	Type 2 diabetes;
CRC	cis	rs6141769	0.542	rs28456361	chr20:31299597	T/C	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.84	-0.31	1.27e-8	Subjective well-being;
CRC	cis	rs1005224	0.963	rs2302592	chr14:76129287	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.46	6.41	0.33	5.05e-10	Large artery stroke;
CRC	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.39	-6.43	-0.33	4.51e-10	Refractive error;
CRC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.72	7.73	0.39	1.31e-13	Diabetic retinopathy;
CRC	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs741668	0.931	rs7317990	chr13:46568497	C/T	cg06018095	chr13:46550134	ZC3H13	0.41	5.73	0.3	2.21e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.43	-9.34	-0.46	1.49e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00166722	chr3:10149974	C3orf24	0.66	9.0	0.44	1.85e-17	Alzheimer's disease;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg16416152	chr16:67193901	FBXL8;TRADD	0.4	5.97	0.31	6.17e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg05535760	chr7:792225	HEATR2	1.01	11.95	0.55	1.34e-27	Cerebrospinal P-tau181p levels;
CRC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	1.11	13.07	0.58	9.93e-32	Obesity-related traits;
CRC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.57	0.39	3.69e-13	Educational attainment;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg27635394	chr6:26043820	HIST1H2BB	0.42	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.69	-11.44	-0.53	9.78e-26	Hepatocellular carcinoma;
CRC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.6	10.66	0.51	5.32e-23	Schizophrenia;
CRC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.54	0.47	3.22e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.76	-12.49	-0.57	1.45e-29	Menarche (age at onset);
CRC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-10.11	-0.49	4.17e-21	Total cholesterol levels;
CRC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.76	11.47	0.53	7.62e-26	Acne (severe);
CRC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.35	0.69	2.37e-48	Platelet count;
CRC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.79	-0.48	4.8e-20	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg15786705	chr6:28176104	NA	0.58	8.28	0.42	3.04e-15	Parkinson's disease;
CRC	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg09654669	chr8:57350985	NA	-0.39	-5.65	-0.3	3.47e-8	Obesity-related traits;
CRC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg24253500	chr15:84953950	NA	0.37	6.25	0.33	1.24e-9	Schizophrenia;
CRC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.66	-0.39	2.09e-13	Psoriasis;
CRC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.75	8.68	0.43	1.88e-16	Eosinophilic esophagitis;
CRC	cis	rs728616	0.681	rs12413174	chr10:82062404	G/A	cg11900509	chr10:81946545	ANXA11	-0.54	-5.94	-0.31	7.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.25	-0.33	1.31e-9	Aortic root size;
CRC	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg04362960	chr10:104952993	NT5C2	-0.47	-6.24	-0.33	1.34e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.73	-0.51	3.06e-23	Monocyte count;
CRC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.83	13.49	0.6	2.63e-33	Blood metabolite levels;
CRC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.12e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4731207	0.565	rs6466978	chr7:124643786	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09805055	chr2:208634004	FZD5	0.46	6.35	0.33	7.13e-10	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.31	4.69e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02725872	chr8:58115012	NA	-0.38	-6.45	-0.33	4.06e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.6	-8.47	-0.42	8.04e-16	Squamous cell lung carcinoma;
CRC	cis	rs12983728	0.536	rs34380569	chr19:58648528	A/G	cg08687515	chr19:58661962	ZNF329	0.51	6.32	0.33	8.48e-10	Cholesterol, total;
CRC	cis	rs10503871	0.584	rs7831616	chr8:30449536	A/G	cg26383811	chr8:30366931	RBPMS	-0.39	-5.8	-0.3	1.53e-8	Metabolite levels  (X-11787);
CRC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.5	7.14	0.37	6.16e-12	Aortic root size;
CRC	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.42	5.66	0.3	3.22e-8	Height;
CRC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.3	0.56	7.27e-29	Height;
CRC	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.81	14.29	0.62	2.3e-36	Intelligence (multi-trait analysis);
CRC	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg15192750	chr16:69999425	NA	0.47	6.34	0.33	7.63e-10	IgE levels;
CRC	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.61	9.65	0.47	1.47e-19	Systemic lupus erythematosus;
CRC	trans	rs2303319	0.582	rs62187614	chr2:162436285	C/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.01	-0.31	4.93e-9	Cognitive function;
CRC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.91	0.44	3.44e-17	Hip circumference adjusted for BMI;
CRC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.33	-0.53	2.33e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.39	-5.91	-0.31	8.48e-9	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12013492	chr11:46143011	PHF21A	0.42	6.72	0.35	7.95e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg25767906	chr1:53392781	SCP2	0.42	6.67	0.35	1.09e-10	Monocyte count;
CRC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	1.01	20.08	0.74	4.1e-59	Headache;
CRC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.17e-13	Colorectal cancer;
CRC	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.77	0.54	6.24e-27	Coffee consumption (cups per day);
CRC	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.63	-8.39	-0.42	1.5e-15	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-7.92	-0.4	3.82e-14	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.56	-7.89	-0.4	4.61e-14	Lung cancer;
CRC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.69	9.21	0.45	3.87e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg16898833	chr6:26189333	HIST1H4D	0.83	7.22	0.37	3.65e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12541635	0.966	rs6469023	chr8:106989558	T/C	cg10147462	chr8:107024639	NA	0.45	7.34	0.38	1.65e-12	Age of smoking initiation;
CRC	cis	rs10971721	0.554	rs10971712	chr9:33820938	C/T	cg13495928	chr9:33750294	PRSS3	0.55	5.89	0.31	9.66e-9	Body mass index;
CRC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.51	8.22	0.41	4.88e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.42	-0.75	2e-60	Hip circumference adjusted for BMI;
CRC	cis	rs55702914	1.000	rs56234206	chr2:198215995	T/A	cg10820045	chr2:198174542	NA	0.34	6.09	0.32	3.07e-9	Major depression and alcohol dependence;
CRC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.57	7.53	0.38	4.84e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.35	0.56	4.64e-29	Menopause (age at onset);
CRC	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.47	6.86	0.35	3.43e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg25985355	chr7:65971099	NA	0.45	6.07	0.32	3.52e-9	Diabetic kidney disease;
CRC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs7705042	0.826	rs6883827	chr5:141504991	A/G	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.85	-0.31	1.19e-8	Asthma;
CRC	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.52	-8.33	-0.42	2.22e-15	Corneal astigmatism;
CRC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg00246817	chr9:123691163	NA	-0.47	-5.99	-0.31	5.38e-9	Rheumatoid arthritis;
CRC	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg02659138	chr7:134003124	SLC35B4	0.36	5.89	0.31	9.4e-9	Mean platelet volume;
CRC	cis	rs16867321	0.806	rs16867314	chr2:181336471	C/A	cg23363182	chr2:181467187	NA	-0.52	-6.14	-0.32	2.31e-9	Obesity;
CRC	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg15571903	chr15:79123663	NA	-0.31	-6.08	-0.32	3.34e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs6589219	0.954	rs10789823	chr11:111172403	T/C	cg25129781	chr11:111156908	C11orf53	-0.32	-5.7	-0.3	2.62e-8	Colorectal cancer;
CRC	cis	rs863345	0.604	rs11265021	chr1:158511810	A/T	cg12129480	chr1:158549410	OR10X1	0.29	6.32	0.33	8.33e-10	Pneumococcal bacteremia;
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.06	-25.5	-0.81	6.2e-80	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12024301	0.557	rs78730917	chr1:183609966	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.58	10.43	0.5	3.29e-22	Blood metabolite ratios;
CRC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg10820045	chr2:198174542	NA	0.47	8.46	0.42	8.94e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.62	9.56	0.47	2.82e-19	Fibrinogen levels;
CRC	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.95e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9879311	0.966	rs7619385	chr3:10414909	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.36	5.63	0.3	3.89e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg24375607	chr4:120327624	NA	0.44	6.86	0.35	3.46e-11	Corneal astigmatism;
CRC	cis	rs4731207	0.565	rs7777126	chr7:124599742	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.74	-0.3	2.16e-8	Gout;Renal underexcretion gout;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.58	-8.77	-0.44	9.45e-17	Body mass index;
CRC	cis	rs891088	0.626	rs12982656	chr19:7194609	C/T	cg00428638	chr19:7224713	INSR	-0.63	-7.75	-0.39	1.18e-13	Hip circumference adjusted for BMI;Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20988798	chr7:75677766	MDH2;STYXL1	0.45	6.53	0.34	2.49e-10	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.65	9.54	0.47	3.3e-19	Menopause (age at onset);
CRC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg15848620	chr12:58087721	OS9	-0.65	-9.21	-0.45	3.84e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs972578	0.776	rs3827363	chr22:43327587	G/A	cg01576275	chr22:43409880	NA	-0.36	-5.77	-0.3	1.83e-8	Mean platelet volume;
CRC	cis	rs1030268	0.620	rs2160746	chr7:133478204	G/C	cg10665199	chr7:133106180	EXOC4	0.54	6.1	0.32	2.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.36	-6.63	-0.34	1.38e-10	Dupuytren's disease;
CRC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.48	5.89	0.31	9.46e-9	Lymphocyte counts;
CRC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.33	0.37	1.76e-12	Life satisfaction;
CRC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.88e-9	Hemoglobin concentration;
CRC	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg14191688	chr11:70257035	CTTN	0.42	5.77	0.3	1.84e-8	Coronary artery disease;
CRC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.39	6.6	0.34	1.67e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.54	-6.61	-0.34	1.53e-10	Platelet distribution width;
CRC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.59	-9.62	-0.47	1.88e-19	Monocyte count;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.43	6.2	0.32	1.65e-9	Obesity-related traits;
CRC	cis	rs11212617	0.967	rs3781869	chr11:108059000	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.89	0.31	9.49e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg02410480	chr12:132819930	GALNT9	-0.35	-5.85	-0.31	1.2e-8	Anti-saccade response;
CRC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.88	-11.73	-0.54	8.51e-27	Triglycerides;
CRC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-10.79	-0.51	1.91e-23	Gut microbiome composition (summer);
CRC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.93	-16.32	-0.67	2.74e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.48	6.75	0.35	6.67e-11	Lung cancer;
CRC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.81	12.33	0.56	5.83e-29	Cognitive function;
CRC	cis	rs6691722	0.503	rs4140519	chr1:24708304	C/T	cg18323236	chr1:24743029	NIPAL3	0.39	5.83	0.31	1.33e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg23093090	chr10:104574429	C10orf26	0.37	6.01	0.31	5.05e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.8	-0.35	5.05e-11	Total body bone mineral density;
CRC	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg27398640	chr15:77910606	LINGO1	0.43	7.22	0.37	3.74e-12	Type 2 diabetes;
CRC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.69	0.39	1.71e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.2	0.37	4.08e-12	Life satisfaction;
CRC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16405210	chr4:1374714	KIAA1530	0.43	6.01	0.31	4.87e-9	Obesity-related traits;
CRC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.85	-10.62	-0.51	7.59e-23	Psoriasis;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg04518342	chr5:131593106	PDLIM4	0.44	7.12	0.37	6.71e-12	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25485084	chr12:118809325	TAOK3	0.44	6.03	0.32	4.52e-9	Thyroid stimulating hormone;
CRC	trans	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg20935933	chr6:143382018	AIG1	0.53	6.74	0.35	6.96e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.69	-12.52	-0.57	1.09e-29	Leprosy;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg22096450	chr11:6947773	ZNF215	0.6	6.14	0.32	2.41e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg15440763	chr7:158190612	PTPRN2	0.56	8.97	0.44	2.33e-17	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01626569	chr16:20911881	LYRM1;DCUN1D3	0.41	6.48	0.34	3.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg26587870	chr6:27730563	NA	-0.48	-6.54	-0.34	2.3e-10	Breast cancer;
CRC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.2	0.32	1.65e-9	Lung cancer;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.6	8.88	0.44	4.45e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.67	7.71	0.39	1.48e-13	Body mass index;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg02033258	chr5:131593261	PDLIM4	0.4	7.5	0.38	6.11e-13	Breast cancer;
CRC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.41	-0.33	5.14e-10	Aortic root size;
CRC	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.39	-7.16	-0.37	5.26e-12	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.8	-6.48	-0.34	3.35e-10	Cognitive function;
CRC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.69	-11.01	-0.52	3.26e-24	Hemoglobin concentration;
CRC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1109861	0.663	rs658469	chr10:11221366	C/T	cg24910943	chr10:11206320	CUGBP2	-0.34	-9.54	-0.47	3.32e-19	Urinary albumin-to-creatinine ratio;
CRC	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.41	-6.92	-0.36	2.35e-11	Endometriosis;
CRC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.61	11.47	0.53	7.56e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs3018066	0.692	rs7658011	chr4:106961023	A/G	cg01869342	chr4:106983673	TBCK	0.5	6.42	0.33	4.8e-10	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12592908	chr6:36954170	MTCH1	0.35	5.97	0.31	6.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.82e-15	Mean platelet volume;
CRC	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26264429	chr14:45603676	FKBP3;FANCM	0.39	5.97	0.31	5.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg10911889	chr6:126070802	HEY2	0.38	5.75	0.3	2.05e-8	Brugada syndrome;
CRC	cis	rs2882667	0.861	rs10043676	chr5:138389561	C/T	cg04439458	chr5:138467593	SIL1	-0.34	-6.13	-0.32	2.45e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12172441	chr6:28176163	NA	0.51	7.1	0.36	7.58e-12	Parkinson's disease;
CRC	cis	rs16867321	0.950	rs12472841	chr2:181491840	C/A	cg23363182	chr2:181467187	NA	-0.53	-6.88	-0.35	2.94e-11	Obesity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25898425	chr17:7137333	DVL2	0.41	6.02	0.31	4.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg02158880	chr13:53174818	NA	0.48	7.18	0.37	4.8e-12	Lewy body disease;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	5.78	0.3	1.77e-8	Lung function (FEV1/FVC);
CRC	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.25	11.73	0.54	8.73e-27	Prostate cancer;
CRC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.69	0.35	9.6e-11	Lung cancer;
CRC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.51	8.46	0.42	9.04e-16	Schizophrenia;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.03e-10	Bipolar disorder;
CRC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg15763984	chr4:1342303	KIAA1530	0.47	7.42	0.38	9.84e-13	Obesity-related traits;
CRC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.4	-5.99	-0.31	5.36e-9	Pulse pressure;
CRC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg10978503	chr1:24200527	CNR2	-0.55	-10.05	-0.48	6.73e-21	Immature fraction of reticulocytes;
CRC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg12193833	chr17:30244370	NA	-0.45	-6.19	-0.32	1.77e-9	Hip circumference adjusted for BMI;
CRC	trans	rs9341835	0.709	rs9359467	chr6:64154975	G/C	cg13657004	chr13:50234944	EBPL	-0.37	-6.18	-0.32	1.92e-9	Schizophrenia;
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg18833306	chr6:118973337	C6orf204	0.44	5.74	0.3	2.12e-8	Diastolic blood pressure;
CRC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02450064	chr17:40260053	DHX58	-0.43	-6.13	-0.32	2.55e-9	Fibrinogen levels;
CRC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.61	0.43	3.07e-16	Hip circumference adjusted for BMI;
CRC	cis	rs11212617	0.967	rs227076	chr11:108218905	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.02	0.31	4.79e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg25214090	chr10:38739885	LOC399744	-0.41	-6.38	-0.33	6.13e-10	Diastolic blood pressure;
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs995000	0.839	rs1168010	chr1:62943979	G/A	cg19896129	chr1:63156450	NA	-0.39	-6.02	-0.31	4.78e-9	Triglyceride levels;
CRC	trans	rs12495832	0.778	rs12635568	chr3:147938960	A/G	cg10221266	chr7:153579447	NA	0.53	5.97	0.31	6.06e-9	Chin dimples;
CRC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg05623727	chr3:50126028	RBM5	-0.43	-7.33	-0.37	1.84e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg16476235	chr8:21771668	DOK2	0.4	6.73	0.35	7.42e-11	Mean corpuscular volume;
CRC	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.0	9.37	0.46	1.18e-18	Severe influenza A (H1N1) infection;
CRC	trans	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg21302420	chr1:112162376	RAP1A	0.69	6.15	0.32	2.28e-9	Skin colour saturation;
CRC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs77861329	1.000	rs9817653	chr3:52148233	T/G	cg08692210	chr3:52188851	WDR51A	0.85	7.76	0.39	1.05e-13	Macrophage inflammatory protein 1b levels;
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.79	-0.35	5.35e-11	Bipolar disorder;
CRC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg02659138	chr7:134003124	SLC35B4	0.42	7.35	0.38	1.57e-12	Mean platelet volume;
CRC	cis	rs7113874	0.569	rs1446463	chr11:8566329	G/A	cg17679104	chr11:8615758	STK33	-0.36	-6.01	-0.31	4.87e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg15845792	chr6:28175446	NA	0.78	11.44	0.53	9.8e-26	Parkinson's disease;
CRC	cis	rs4867766	0.585	rs6878032	chr5:173950070	A/G	cg20434911	chr5:173954559	NA	0.64	7.09	0.36	8e-12	Stroke;
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.33e-9	Prudent dietary pattern;
CRC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.44	-0.46	6.9e-19	Aortic root size;
CRC	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.46	0.53	8.54e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.1	0.49	4.6e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.05	0.45	1.29e-17	Mean platelet volume;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg15383719	chr1:100316030	AGL	0.55	6.22	0.32	1.48e-9	Body mass index;
CRC	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg23996704	chr18:44553084	KATNAL2	-0.29	-5.66	-0.3	3.29e-8	Educational attainment;
CRC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.99	18.01	0.7	5.77e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.51	-7.53	-0.38	4.88e-13	White blood cell count;
CRC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.61	-9.19	-0.45	4.58e-18	Hip circumference adjusted for BMI;
CRC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.27e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.48	6.46	0.34	3.84e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg09658497	chr7:2847517	GNA12	-0.42	-5.65	-0.3	3.55e-8	Height;
CRC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg01483505	chr11:975446	AP2A2	0.45	7.39	0.38	1.24e-12	Alzheimer's disease (late onset);
CRC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.38	-0.42	1.58e-15	Asthma (sex interaction);
CRC	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.47	7.78	0.39	9.77e-14	Major depressive disorder;
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.38	-9.07	-0.45	1.11e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10865541	0.902	rs7558487	chr2:3425514	G/C	cg22182287	chr2:3452347	TTC15	0.39	6.25	0.33	1.24e-9	Obesity-related traits;
CRC	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg19847866	chr10:1019161	NA	0.42	6.13	0.32	2.53e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs1158570	0.500	rs2670890	chr8:131314923	G/A	cg26053073	chr8:131455383	NA	0.42	6.27	0.33	1.11e-9	Platelet count;
CRC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg00106254	chr7:1943704	MAD1L1	-0.37	-5.84	-0.31	1.22e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs12760731	0.565	rs10913519	chr1:178196094	A/T	cg00404053	chr1:178313656	RASAL2	1.11	11.45	0.53	8.75e-26	Obesity-related traits;
CRC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.93	0.44	3.1e-17	Bladder cancer;
CRC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	7.85	0.4	5.87e-14	Schizophrenia;
CRC	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.53	-7.19	-0.37	4.51e-12	Tuberculosis;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg15845792	chr6:28175446	NA	0.79	11.71	0.54	1.05e-26	Cardiac Troponin-T levels;
CRC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.91	-0.36	2.54e-11	Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08862778	chr1:11322643	MTOR	0.45	6.5	0.34	2.93e-10	Response to antipsychotic treatment;
CRC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.13	-0.49	3.57e-21	Total cholesterol levels;
CRC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.09	-0.36	8.46e-12	Height;
CRC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.79	13.08	0.58	8.99e-32	Blood protein levels;
CRC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.54	-11.29	-0.53	3.41e-25	Alcohol dependence;
CRC	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg07166546	chr14:35805898	NA	-0.3	-5.84	-0.31	1.27e-8	Psoriasis;
CRC	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.27	-0.33	1.14e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.65	10.41	0.5	3.96e-22	Myopia (pathological);
CRC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg15123519	chr2:136567270	LCT	0.33	6.41	0.33	5.07e-10	Mosquito bite size;
CRC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs17601876	0.807	rs10519299	chr15:51551346	C/G	cg19946085	chr15:51559439	CYP19A1	-0.32	-6.55	-0.34	2.28e-10	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs1322512	1.000	rs7744697	chr6:152948986	G/A	cg03415253	chr6:152958462	SYNE1	-0.42	-6.43	-0.33	4.53e-10	Tonometry;
CRC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.64e-9	Bipolar disorder;
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg19337854	chr7:99768885	GPC2	0.48	6.38	0.33	6e-10	Lung function (FEV1/FVC);
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.77	-9.96	-0.48	1.3e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	9.25	0.45	2.88e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-5.77	-0.3	1.81e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg13456138	chr10:90753195	FAS	0.42	5.87	0.31	1.07e-8	Chronic lymphocytic leukemia;
CRC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.32	5.83	0.31	1.32e-8	Huntington's disease progression;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.79	-13.02	-0.58	1.52e-31	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14184786	chr14:94547643	IFI27L1;DDX24	0.46	6.01	0.31	4.89e-9	Thyroid stimulating hormone;
CRC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg17724175	chr1:150552817	MCL1	0.44	6.59	0.34	1.73e-10	Melanoma;
CRC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg27523141	chr10:43048294	ZNF37B	0.49	7.14	0.37	6.19e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.31	6.56	0.34	2.1e-10	Corneal astigmatism;
CRC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	16.22	0.67	6.93e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.44	-0.38	9.1e-13	Blood metabolite levels;
CRC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.4	-0.33	5.48e-10	Glycated hemoglobin levels;
CRC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.59	-6.29	-0.33	1.04e-9	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.81	-0.31	1.48e-8	Life satisfaction;
CRC	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.48	-6.09	-0.32	3.2e-9	Orofacial clefts;
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs12143943	0.866	rs12032618	chr1:204532659	C/T	cg17419461	chr1:204415978	PIK3C2B	0.4	6.28	0.33	1.05e-9	Cognitive performance;
CRC	trans	rs732528	1.000	rs2847577	chr18:48364819	A/G	cg15540507	chr19:3676403	PIP5K1C	0.46	6.11	0.32	2.84e-9	Entorhinal cortical thickness;
CRC	cis	rs3743266	0.613	rs4775273	chr15:60738566	T/G	cg21667061	chr15:60772094	NARG2	-0.28	-5.73	-0.3	2.23e-8	Menarche (age at onset);
CRC	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.62	-0.34	1.46e-10	Metabolite levels;
CRC	cis	rs16852403	0.517	rs2902217	chr1:178248162	T/C	cg00404053	chr1:178313656	RASAL2	0.48	6.12	0.32	2.6e-9	Childhood ear infection;
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02290350	chr8:58132656	NA	-0.57	-7.91	-0.4	4.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7725052	0.609	rs4507534	chr5:40453033	C/T	cg09067459	chr5:40385259	NA	-0.4	-6.67	-0.35	1.09e-10	Pediatric autoimmune diseases;
CRC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg24881330	chr22:46731750	TRMU	0.59	7.03	0.36	1.24e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg06042504	chr8:55087323	NA	-0.36	-5.67	-0.3	3.08e-8	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg04479987	chr5:180649488	TRIM41	-0.43	-6.17	-0.32	2.01e-9	Schizophrenia;
CRC	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.72	9.69	0.47	1.05e-19	Coronary artery disease;
CRC	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg00105475	chr2:10696890	NA	0.48	7.27	0.37	2.72e-12	Prostate cancer;
CRC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25517755	chr10:38738941	LOC399744	-0.41	-6.09	-0.32	3.13e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs77972916	0.518	rs55877805	chr2:43557597	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.93	-0.31	7.64e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.0	0.36	1.44e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.6	8.49	0.42	7.08e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3026101	0.671	rs2407	chr17:5289028	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.39	6.4	0.33	5.43e-10	Body mass index;
CRC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.43	5.72	0.3	2.36e-8	Gut microbiome composition (summer);
CRC	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg13611204	chr9:139324423	INPP5E	-0.45	-6.35	-0.33	7.3e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.8	11.38	0.53	1.62e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg15147215	chr3:52552868	STAB1	-0.64	-11.07	-0.52	1.98e-24	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21149286	chr12:65153070	GNS	0.41	6.33	0.33	8.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs863345	0.604	rs7518808	chr1:158491820	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.24	-0.33	1.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg07217954	chr7:1067459	C7orf50	0.57	5.93	0.31	7.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.58	-8.16	-0.41	7.4e-15	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.56	10.72	0.51	3.38e-23	Acylcarnitine levels;
CRC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	cis	rs6681460	0.584	rs7528182	chr1:67067369	C/T	cg02459107	chr1:67143332	SGIP1	0.36	6.59	0.34	1.77e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs12760731	0.720	rs10798606	chr1:178372965	G/A	cg00404053	chr1:178313656	RASAL2	0.87	10.43	0.5	3.29e-22	Obesity-related traits;
CRC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs534126	1.000	rs557797	chr7:142921509	T/C	cg04039957	chr7:143013207	CLCN1	0.37	6.51	0.34	2.8e-10	Cancer;
CRC	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.83	-13.73	-0.6	3.07e-34	Hypospadias;
CRC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.52	-0.46	3.76e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.86	16.13	0.66	1.54e-43	Dental caries;
CRC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.41	0.33	4.98e-10	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.25	0.53	4.64e-25	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15418287	chr17:40706385	HSD17B1	0.45	6.5	0.34	2.93e-10	Response to antipsychotic treatment;
CRC	cis	rs2992756	0.663	rs2992735	chr1:18800387	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.4	-5.68	-0.3	3.03e-8	Breast cancer;
CRC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.18	-0.37	4.78e-12	Educational attainment;
CRC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-6.88	-0.35	2.96e-11	Response to antipsychotic treatment;
CRC	cis	rs4731207	0.698	rs7795492	chr7:124524131	C/T	cg23710748	chr7:124431027	NA	-0.37	-5.91	-0.31	8.41e-9	Cutaneous malignant melanoma;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-0.99	-23.51	-0.79	1.98e-72	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg25019722	chr6:37503610	NA	0.48	8.92	0.44	3.21e-17	Cognitive performance;
CRC	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.79	9.55	0.47	3.07e-19	Inflammatory bowel disease;
CRC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.16	-12.06	-0.55	5.41e-28	Breast cancer;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.6	-0.3	4.53e-8	Parkinson's disease;
CRC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.65	7.93	0.4	3.54e-14	Initial pursuit acceleration;
CRC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.52	-8.29	-0.42	2.83e-15	Neurofibrillary tangles;
CRC	cis	rs9322817	0.625	rs2499655	chr6:105307435	G/A	cg02098413	chr6:105308735	HACE1	0.43	8.54	0.43	5.22e-16	Thyroid stimulating hormone;
CRC	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg06038358	chr2:128176007	PROC	0.33	5.66	0.3	3.28e-8	Self-rated health;
CRC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.62	8.83	0.44	6.45e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs863345	0.625	rs12063360	chr1:158499494	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	trans	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs370915	0.578	rs1367932	chr4:187776654	A/G	cg12892747	chr4:187813459	NA	-0.56	-8.12	-0.41	9.57e-15	Gout;
CRC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.23	0.45	3.34e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.32	-0.33	8.67e-10	Body mass index;
CRC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.69	-10.8	-0.51	1.83e-23	Blood protein levels;
CRC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg21251018	chr6:28226885	NKAPL	0.55	9.45	0.46	6.36e-19	Pulmonary function;
CRC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.51	-6.76	-0.35	6.44e-11	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.66	-10.74	-0.51	2.8e-23	Breast cancer;
CRC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.71	-11.91	-0.55	1.95e-27	Cognitive function;
CRC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.49	6.28	0.33	1.1e-9	Obesity-related traits;
CRC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.73	11.44	0.53	9.82e-26	Colorectal cancer;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.05	0.32	3.85e-9	Depression;
CRC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.3	6.77	0.35	5.96e-11	IgG glycosylation;
CRC	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.4	5.87	0.31	1.08e-8	Obesity-related traits;
CRC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.71	-0.3	2.51e-8	Response to diuretic therapy;
CRC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg00647820	chr17:40259828	DHX58	-0.46	-6.55	-0.34	2.18e-10	Fibrinogen levels;
CRC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg25600027	chr14:23388339	RBM23	-0.51	-7.93	-0.4	3.4e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.57	-10.62	-0.51	7.25e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19717773	chr7:2847554	GNA12	-0.48	-6.93	-0.36	2.2e-11	Height;
CRC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg15382696	chr6:118971807	C6orf204	0.59	7.47	0.38	7.36e-13	Renal cell carcinoma;
CRC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.92	-17.52	-0.69	5.41e-49	Coronary artery disease;
CRC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	8.64	0.43	2.53e-16	Chronic sinus infection;
CRC	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.02	0.31	4.58e-9	Axial length;
CRC	cis	rs60871478	0.786	rs12536056	chr7:831351	T/A	cg13798912	chr7:905769	UNC84A	-0.52	-5.84	-0.31	1.25e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg18512352	chr11:47633146	NA	0.36	7.13	0.37	6.5e-12	Subjective well-being;
CRC	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.7	10.6	0.5	8.79e-23	Schizophrenia;
CRC	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg18809830	chr7:99032528	PTCD1	-1.2	-8.73	-0.43	1.27e-16	Blood metabolite levels;
CRC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.21	-0.32	1.62e-9	Alzheimer's disease (late onset);
CRC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.68	-11.59	-0.54	2.87e-26	Neuroticism;
CRC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.55	0.34	2.27e-10	Morning vs. evening chronotype;
CRC	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.61	-8.75	-0.43	1.17e-16	Coronary artery disease;
CRC	trans	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg18335740	chr13:41363409	SLC25A15	0.56	9.0	0.44	1.91e-17	Lewy body disease;
CRC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.25	-0.45	2.86e-18	Height;
CRC	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.82	10.36	0.5	5.73e-22	Prostate cancer;
CRC	trans	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.51	0.38	5.69e-13	Endometrial cancer;
CRC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.25	0.49	1.36e-21	Personality dimensions;
CRC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg19257562	chr1:2043853	PRKCZ	0.37	6.24	0.33	1.31e-9	Height;
CRC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.23	-0.32	1.41e-9	Diabetic kidney disease;
CRC	trans	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.09	-0.32	3.09e-9	Educational attainment (years of education);
CRC	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg14003231	chr6:33640908	ITPR3	0.49	8.02	0.4	1.85e-14	Plateletcrit;
CRC	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.8	-0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10971721	0.643	rs12375483	chr9:33784908	C/A	cg13495928	chr9:33750294	PRSS3	0.66	5.92	0.31	8.05e-9	Body mass index;
CRC	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.53	-8.19	-0.41	5.93e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.63	10.64	0.51	6.32e-23	Prudent dietary pattern;
CRC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.29	0.37	2.35e-12	Blood metabolite levels;
CRC	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.56	9.25	0.45	2.96e-18	Mean corpuscular volume;
CRC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.59	-10.34	-0.5	6.79e-22	Schizophrenia;
CRC	cis	rs8040855	0.599	rs4577058	chr15:85726458	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.37	5.7	0.3	2.71e-8	Bulimia nervosa;
CRC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.93e-11	Body mass index;
CRC	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg02336364	chr1:24764700	NIPAL3	0.38	6.35	0.33	7e-10	Response to interferon beta in multiple sclerosis;
CRC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg06346307	chr22:19949965	COMT	0.28	6.9	0.36	2.72e-11	Blood metabolite levels;
CRC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.51	7.19	0.37	4.25e-12	Melanoma;
CRC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.7	-0.3	2.62e-8	Coronary artery disease;
CRC	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.68	-9.09	-0.45	9.33e-18	Blood pressure (smoking interaction);
CRC	cis	rs6681460	1.000	rs6696927	chr1:67070381	A/G	cg02459107	chr1:67143332	SGIP1	0.43	7.61	0.39	2.94e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg25287198	chr4:183728479	NA	0.52	5.85	0.31	1.21e-8	Pediatric autoimmune diseases;
CRC	cis	rs2637266	0.519	rs1907328	chr10:78253135	C/T	cg18941641	chr10:78392320	NA	-0.35	-5.81	-0.3	1.5e-8	Pulmonary function;
CRC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg01612440	chr4:3296283	NA	0.41	5.8	0.3	1.52e-8	Serum sulfate level;
CRC	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	1.01	12.13	0.56	3.07e-28	Obesity-related traits;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.67	-9.83	-0.48	3.68e-20	Menopause (age at onset);
CRC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-5.82	-0.31	1.39e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg16486109	chr11:613632	IRF7	0.72	11.71	0.54	9.99e-27	Systemic lupus erythematosus;
CRC	trans	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg07817883	chr1:32538562	TMEM39B	1.49	12.21	0.56	1.59e-28	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg22974920	chr21:40686053	BRWD1	0.44	5.98	0.31	5.85e-9	Cognitive function;
CRC	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.39	-0.38	1.23e-12	Electroencephalogram traits;
CRC	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.33	0.46	1.67e-18	Blood protein levels;
CRC	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg20742385	chr13:113633654	MCF2L	0.55	9.23	0.45	3.35e-18	Systolic blood pressure;
CRC	cis	rs911119	1.000	rs2016161	chr20:23621174	G/T	cg16589663	chr20:23618590	CST3	-0.61	-8.34	-0.42	2.05e-15	Chronic kidney disease;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.76	14.25	0.62	3.29e-36	Prudent dietary pattern;
CRC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg11070056	chr1:107600091	PRMT6	-0.4	-6.16	-0.32	2.16e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg03037974	chr15:76606532	NA	-0.51	-7.24	-0.37	3.14e-12	Blood metabolite levels;
CRC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg18478394	chr8:109455254	TTC35	0.41	6.09	0.32	3.19e-9	Dupuytren's disease;
CRC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04239562	chr7:158767014	NA	0.4	6.29	0.33	1.02e-9	Facial morphology (factor 20);
CRC	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.57	-8.36	-0.42	1.82e-15	Schizophrenia;
CRC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	13.48	0.6	2.75e-33	Platelet count;
CRC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.65	-12.98	-0.58	2.23e-31	Educational attainment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18652453	chr5:68665041	TAF9;RAD17	0.41	6.21	0.32	1.6e-9	Intelligence (multi-trait analysis);
CRC	trans	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	6.25	0.33	1.29e-9	Mean corpuscular volume;
CRC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg12573674	chr2:1569213	NA	-0.68	-7.74	-0.39	1.22e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg00086871	chr4:6988644	TBC1D14	1.02	7.86	0.4	5.66e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	0.3	5.87	0.31	1.05e-8	Colorectal cancer;
CRC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.43	7.27	0.37	2.56e-12	Major depressive disorder;
CRC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg16060761	chr17:80687452	NA	0.46	6.64	0.34	1.33e-10	Breast cancer;
CRC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg22117107	chr15:45993392	NA	-0.43	-8.69	-0.43	1.73e-16	Waist circumference;Weight;
CRC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.75	-0.43	1.13e-16	Aortic root size;
CRC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg23202291	chr11:1979235	NA	0.48	6.59	0.34	1.78e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs11233250	0.502	rs11233268	chr11:82405067	A/G	cg17391194	chr11:82401662	NA	0.42	6.39	0.33	5.75e-10	Glioblastoma;Glioma;
CRC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.54	8.07	0.41	1.37e-14	Morning vs. evening chronotype;
CRC	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg09904177	chr6:26538194	HMGN4	-0.47	-6.71	-0.35	8.69e-11	Intelligence (multi-trait analysis);
CRC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg15269541	chr15:43626905	ADAL	-0.37	-5.94	-0.31	7.1e-9	Lung cancer;
CRC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.4	6.62	0.34	1.45e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	12.11	0.56	3.61e-28	Alzheimer's disease;
CRC	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.6	-8.82	-0.44	6.96e-17	Blood pressure (smoking interaction);
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg21856205	chr7:94953877	PON1	-0.48	-6.28	-0.33	1.1e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	8.29	0.42	2.88e-15	Total body bone mineral density;
CRC	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg08614441	chr13:113633676	MCF2L	0.39	6.87	0.35	3.19e-11	Systolic blood pressure;
CRC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.55	-8.3	-0.42	2.75e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.99e-9	Aortic root size;
CRC	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg09873164	chr1:152488093	CRCT1	-0.36	-6.06	-0.32	3.69e-9	Hair morphology;
CRC	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.86	-17.36	-0.69	2.26e-48	Longevity;
CRC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg04166393	chr7:2884313	GNA12	0.41	6.34	0.33	7.48e-10	Height;
CRC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.42	6.25	0.33	1.27e-9	Testicular germ cell tumor;
CRC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.82	11.28	0.53	3.58e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.61	10.75	0.51	2.7e-23	Aortic root size;
CRC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg18876405	chr7:65276391	NA	0.45	6.22	0.32	1.51e-9	Aortic root size;
CRC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.52	8.05	0.41	1.49e-14	Coronary artery disease;
CRC	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	6.39	0.33	5.79e-10	Height;
CRC	cis	rs11212617	0.967	rs5023001	chr11:108335538	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.79	0.3	1.61e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-6.33	-0.33	7.9e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.48	6.71	0.35	8.38e-11	Huntington's disease progression;
CRC	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg00631329	chr6:26305371	NA	-0.52	-8.72	-0.43	1.42e-16	Educational attainment;
CRC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.89	0.36	2.84e-11	Rheumatoid arthritis;
CRC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.52	-7.52	-0.38	5.39e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg02353165	chr6:42928485	GNMT	0.54	6.91	0.36	2.57e-11	Blood protein levels;
CRC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	10.77	0.51	2.2e-23	Mean corpuscular hemoglobin;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20607513	chr21:46708029	POFUT2;LOC642852	0.37	6.05	0.32	3.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg24531977	chr5:56204891	C5orf35	-0.45	-6.83	-0.35	4.08e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2274471	0.645	rs55787634	chr9:5116064	T/A	cg03390472	chr9:5043263	JAK2	-0.55	-6.32	-0.33	8.31e-10	Crohn's disease;
CRC	trans	rs6693295	0.793	rs2788021	chr1:246248704	A/G	cg03680032	chr11:94965610	SESN3	0.47	6.02	0.31	4.76e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.37	-0.46	1.19e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.51	-6.73	-0.35	7.63e-11	Glioblastoma;
CRC	cis	rs2274273	0.588	rs7155054	chr14:55750662	A/G	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.89	-0.31	9.37e-9	Protein biomarker;
CRC	trans	rs596169	0.541	rs6667536	chr1:219215137	G/A	cg09853702	chr12:47665230	NA	0.82	6.39	0.33	5.67e-10	Intraocular pressure;
CRC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg11212589	chr17:38028394	ZPBP2	0.44	8.27	0.41	3.34e-15	Self-reported allergy;
CRC	cis	rs12137294	0.866	rs896320	chr1:205205347	T/C	cg24159697	chr1:205181237	DSTYK	-0.34	-6.22	-0.32	1.54e-9	Red cell distribution width;
CRC	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07165851	chr6:158734300	TULP4	0.62	7.88	0.4	4.67e-14	Height;
CRC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.09	-0.32	3.07e-9	Acne (severe);
CRC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg27661571	chr11:113659931	NA	-0.7	-8.72	-0.43	1.43e-16	Hip circumference adjusted for BMI;
CRC	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.34	0.42	2e-15	Corneal astigmatism;
CRC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs2933343	1.000	rs2933343	chr3:128658492	G/A	cg11901034	chr3:128598214	ACAD9	-0.52	-6.33	-0.33	8.23e-10	IgG glycosylation;
CRC	cis	rs2333194	0.875	rs10220356	chr14:73809476	C/T	cg19682024	chr14:74008259	HEATR4;ACOT1	0.41	6.13	0.32	2.45e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	5.05e-15	Reticulocyte count;High light scatter reticulocyte count;
CRC	cis	rs17065868	0.764	rs73188731	chr13:45031494	A/C	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.09	21.23	0.76	1.34e-63	Schizophrenia;
CRC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.61	-8.43	-0.42	1.13e-15	DNA methylation (variation);
CRC	cis	rs17767392	0.918	rs34533948	chr14:71772727	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.85	13.15	0.59	4.99e-32	Menarche (age at onset);
CRC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.46	6.32	0.33	8.5e-10	Morning vs. evening chronotype;
CRC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.8	-10.79	-0.51	1.93e-23	Platelet distribution width;
CRC	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.63	10.24	0.49	1.54e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4474465	0.790	rs12363982	chr11:78229167	C/T	cg27205649	chr11:78285834	NARS2	0.48	6.04	0.32	4.28e-9	Alzheimer's disease (survival time);
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.66	-0.39	2.03e-13	Total body bone mineral density;
CRC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.6	12.22	0.56	1.4e-28	Schizophrenia;
CRC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.44	6.81	0.35	4.58e-11	Longevity;Endometriosis;
CRC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.67	-6.8	-0.35	4.92e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.53	8.0	0.4	2.18e-14	Methadone dose in opioid dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25940730	chr4:16228647	TAPT1;FLJ39653	0.49	7.87	0.4	5.31e-14	Liver disease severity in Alagille syndrome;
CRC	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.7	9.9	0.48	2.1e-20	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.63	9.67	0.47	1.28e-19	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18036573	chr7:92219856	FAM133B	0.44	6.13	0.32	2.48e-9	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.65	9.78	0.47	5.29e-20	Lung cancer;
CRC	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.65	10.37	0.5	5.64e-22	Corneal astigmatism;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.39	0.42	1.41e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.71	-0.57	2.16e-30	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg00769240	chr8:12517080	NA	-0.54	-6.71	-0.35	8.78e-11	Blood pressure (smoking interaction);
CRC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.51	7.29	0.37	2.27e-12	Colorectal cancer;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg25164649	chr6:28176230	NA	0.58	7.43	0.38	9.73e-13	Parkinson's disease;
CRC	cis	rs1322512	0.761	rs1631293	chr6:152939886	T/C	cg03415253	chr6:152958462	SYNE1	-0.41	-6.36	-0.33	6.67e-10	Tonometry;
CRC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg12311346	chr5:56204834	C5orf35	-0.48	-7.38	-0.38	1.3e-12	Breast cancer;Breast cancer (early onset);
CRC	trans	rs1117324	1.000	rs1117324	chr2:21840093	C/T	cg07470598	chr14:107239068	NA	-0.56	-6.02	-0.31	4.56e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22564599	chr17:15466921	FAM18B2	0.4	6.31	0.33	8.89e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.51	-9.76	-0.47	6.34e-20	Schizophrenia;
CRC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg19907964	chr20:61473305	TCFL5	-0.47	-6.14	-0.32	2.33e-9	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17712202	chr19:13261217	IER2;STX10	0.5	7.3	0.37	2.18e-12	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23303782	chr10:120967744	GRK5	0.43	6.01	0.31	5.01e-9	Response to antipsychotic treatment;
CRC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg12639453	chr1:2035780	PRKCZ	-0.34	-6.39	-0.33	5.76e-10	Height;
CRC	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	6.32	0.33	8.68e-10	Schizophrenia;
CRC	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs11229555	0.645	rs11229462	chr11:58209931	A/T	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg16102536	chr7:156981717	UBE3C	-0.39	-6.65	-0.34	1.24e-10	Body mass index;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.89	16.98	0.68	6.74e-47	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7605827	0.930	rs1549017	chr2:15617017	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg02683197	chr6:28174875	NA	-0.47	-6.59	-0.34	1.72e-10	Cardiac Troponin-T levels;
CRC	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg19508488	chr2:152266495	RIF1	-0.48	-6.92	-0.36	2.42e-11	Squamous cell lung carcinoma;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg26587870	chr6:27730563	NA	-0.39	-5.86	-0.31	1.13e-8	Cardiac Troponin-T levels;
CRC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.9	-0.52	8e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.97	0.52	4.68e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.8	0.3	1.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs477692	0.637	rs7098619	chr10:131315856	C/T	cg05714579	chr10:131428358	MGMT	0.5	6.99	0.36	1.5e-11	Response to temozolomide;
CRC	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg11901034	chr3:128598214	ACAD9	-0.5	-6.19	-0.32	1.8e-9	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.65	11.91	0.55	2e-27	Bone mineral density;
CRC	cis	rs73200209	0.912	rs11609898	chr12:116638445	G/T	cg01776926	chr12:116560359	MED13L	0.47	5.77	0.3	1.82e-8	Total body bone mineral density;
CRC	trans	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.16	0.41	7.12e-15	Educational attainment;
CRC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg23587288	chr2:27483067	SLC30A3	-0.43	-6.29	-0.33	1.01e-9	Blood metabolite levels;
CRC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.65	11.35	0.53	1.97e-25	Prostate cancer;
CRC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.43	-7.03	-0.36	1.18e-11	Refractive error;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.1e-10	Hepatitis;
CRC	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg08890418	chr1:21044141	KIF17	0.32	5.75	0.3	2.02e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	trans	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.73	12.41	0.56	2.89e-29	Systemic lupus erythematosus;
CRC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02228675	chr17:40259724	DHX58	-0.5	-7.01	-0.36	1.38e-11	Fibrinogen levels;
CRC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.7	-7.87	-0.4	5.06e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.66	5.67	0.3	3.17e-8	Depression;
CRC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg25834613	chr7:1915315	MAD1L1	-0.42	-6.04	-0.32	4.14e-9	Bipolar disorder;
CRC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.47	6.76	0.35	6.2e-11	Aortic root size;
CRC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.71	10.46	0.5	2.79e-22	Immature fraction of reticulocytes;
CRC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.4	-0.59	5.88e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.32	5.8	0.3	1.58e-8	Menarche (age at onset);
CRC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	9.87	0.48	2.63e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06505273	chr16:24850292	NA	0.53	6.86	0.35	3.5e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12936587	0.576	rs8073975	chr17:17555631	G/T	cg04398451	chr17:18023971	MYO15A	0.36	5.93	0.31	7.68e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg09179987	chr1:167433047	CD247	0.56	8.84	0.44	5.94e-17	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg13565492	chr6:43139072	SRF	-0.83	-6.14	-0.32	2.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg03037974	chr15:76606532	NA	-0.5	-7.12	-0.37	6.62e-12	Blood metabolite levels;
CRC	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg07617317	chr6:118971624	C6orf204	0.47	5.68	0.3	2.91e-8	Diastolic blood pressure;
CRC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.02	-0.4	1.84e-14	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.62	10.01	0.48	9.08e-21	Aortic root size;
CRC	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.58	-7.72	-0.39	1.37e-13	Malaria;
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg10729496	chr3:10149963	C3orf24	0.56	7.23	0.37	3.32e-12	Alzheimer's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07474652	chr3:47823067	SMARCC1	-0.41	-6.35	-0.33	7.09e-10	Myopia (pathological);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14866419	chr14:100704911	YY1	0.43	5.96	0.31	6.4e-9	Anxiety disorder;
CRC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg09876464	chr15:85330779	ZNF592	0.44	7.3	0.37	2.22e-12	P wave terminal force;
CRC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.63	-8.9	-0.44	3.86e-17	DNA methylation (variation);
CRC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.33	0.33	7.8e-10	Rheumatoid arthritis;
CRC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg27535305	chr1:53392650	SCP2	0.38	7.3	0.37	2.22e-12	Monocyte count;
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04155289	chr7:94953770	PON1	0.59	7.42	0.38	1.02e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg02725872	chr8:58115012	NA	-0.44	-6.61	-0.34	1.51e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9462027	0.628	rs10807141	chr6:34693111	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.07	0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs6751744	0.513	rs7563368	chr2:160457075	C/T	cg08347373	chr2:160653686	CD302	0.36	5.99	0.31	5.53e-9	Dysphagia;
CRC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.53	7.84	0.4	6.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.59	-10.13	-0.49	3.5e-21	Alzheimer's disease (late onset);
CRC	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg18646521	chr2:111875858	NA	0.36	5.7	0.3	2.69e-8	Chronic lymphocytic leukemia;
CRC	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg25885038	chr17:56607967	SEPT4	-0.41	-6.66	-0.34	1.15e-10	Vitamin D levels;
CRC	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.09	0.41	1.2e-14	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19284510	chr4:128886615	MFSD8;C4orf29	0.4	6.02	0.31	4.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	13.74	0.6	2.92e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg13319975	chr6:146136371	FBXO30	0.39	5.84	0.31	1.24e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.84	18.44	0.71	1.18e-52	Breast cancer;
CRC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.59	9.41	0.46	8.98e-19	Tonsillectomy;
CRC	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.52	7.57	0.38	3.9e-13	Corneal astigmatism;
CRC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.79	-13.18	-0.59	3.98e-32	Colorectal cancer;
CRC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg25204440	chr1:209979598	IRF6	0.5	7.08	0.36	8.78e-12	Cleft lip with or without cleft palate;
CRC	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.58	-7.91	-0.4	3.86e-14	Extraversion;
CRC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg26805224	chr10:79626177	DLG5	0.57	8.45	0.42	9.46e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.56	7.31	0.37	2.03e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.13	21.2	0.76	1.69e-63	Cognitive function;
CRC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.51	0.34	2.77e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	0.88	8.11	0.41	1.03e-14	Thyroid stimulating hormone;
CRC	cis	rs57590327	0.528	rs7642112	chr3:81674927	C/T	cg07356753	chr3:81810745	GBE1	-0.66	-8.51	-0.42	6.32e-16	Extraversion;
CRC	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.49	7.99	0.4	2.31e-14	Coronary artery disease;
CRC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.6	0.34	1.62e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.41	6.33	0.33	8.21e-10	Type 2 diabetes;
CRC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.5	6.81	0.35	4.54e-11	Type 1 diabetes nephropathy;
CRC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.41	0.5	3.99e-22	Heart rate;
CRC	trans	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg26043149	chr18:55253948	FECH	0.52	7.66	0.39	2.12e-13	Bone mineral density;
CRC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.67	14.1	0.61	1.21e-35	Schizophrenia;
CRC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.75	12.24	0.56	1.19e-28	Blood protein levels;
CRC	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.65	8.47	0.42	8.37e-16	Cisplatin-induced ototoxicity;
CRC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.04	0.32	4.14e-9	Heart rate;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00232805	chr2:97779565	ANKRD36	0.51	6.55	0.34	2.24e-10	Thyroid stimulating hormone;
CRC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.92	-19.57	-0.73	4.36e-57	Urate levels in lean individuals;
CRC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.02	22.78	0.78	1.34e-69	Multiple system atrophy;
CRC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.44	-5.9	-0.31	8.9e-9	Gut microbiome composition (summer);
CRC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.13	0.56	3.14e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03399598	chr4:174091002	GALNT7	0.5	6.49	0.34	3.09e-10	Thyroid stimulating hormone;
CRC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg13072238	chr3:49761600	GMPPB	-0.51	-5.92	-0.31	7.96e-9	Menarche (age at onset);
CRC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.65	0.39	2.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg08027265	chr7:2291960	NA	-0.38	-6.37	-0.33	6.47e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7538876	0.787	rs57142672	chr1:17744536	A/G	cg01904812	chr1:17746340	RCC2	0.37	6.05	0.32	3.93e-9	Basal cell carcinoma;
CRC	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.58	-0.34	1.83e-10	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11951449	chr1:116519025	SLC22A15	0.4	7.14	0.37	5.88e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07355551	chr20:2489285	ZNF343	0.5	6.52	0.34	2.7e-10	Thyroid stimulating hormone;
CRC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	9.49	0.46	4.86e-19	Multiple sclerosis;
CRC	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.76	-8.33	-0.42	2.24e-15	Atopic dermatitis;
CRC	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.56	-0.34	2.09e-10	Multiple sclerosis;
CRC	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.6	10.4	0.5	4.44e-22	Asthma;
CRC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	10.75	0.51	2.56e-23	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg12172441	chr6:28176163	NA	0.45	6.52	0.34	2.58e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.29	-0.33	1.03e-9	Alzheimer's disease (late onset);
CRC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.38e-14	Colorectal cancer;
CRC	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.76	0.35	6.22e-11	Coronary artery disease;
CRC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.21	-0.32	1.58e-9	Gout;Renal underexcretion gout;
CRC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-9.81	-0.48	4.26e-20	Body mass index (adult);
CRC	cis	rs6076065	0.676	rs4813490	chr20:23325150	A/G	cg11657817	chr20:23433608	CST11	0.44	6.63	0.34	1.35e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.63	8.88	0.44	4.29e-17	Height;
CRC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-7.87	-0.4	5.1e-14	Fibrinogen levels;
CRC	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.52	9.66	0.47	1.35e-19	Menarche (age at onset);
CRC	cis	rs9322817	0.715	rs6918700	chr6:105244526	A/T	cg02098413	chr6:105308735	HACE1	-0.43	-8.46	-0.42	8.65e-16	Thyroid stimulating hormone;
CRC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg10356904	chr22:49881777	NA	-0.32	-6.0	-0.31	5.11e-9	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.0	0.36	1.46e-11	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05470809	chr4:175205489	KIAA1712;FBXO8	0.48	6.79	0.35	5.19e-11	Response to antipsychotic treatment;
CRC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.74	-12.25	-0.56	1.1e-28	Breast cancer;
CRC	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.58	10.01	0.48	9.02e-21	Liver enzyme levels;
CRC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.97	12.04	0.55	6.75e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.02	0.58	1.55e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.18	0.32	1.9e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.5	-7.6	-0.39	3.08e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.93	17.41	0.69	1.36e-48	Lewy body disease;
CRC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.65	-9.91	-0.48	1.94e-20	Menarche (age at onset);
CRC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.74	9.62	0.47	1.75e-19	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00236302	chr12:69004867	RAP1B	-0.43	-6.14	-0.32	2.43e-9	Myopia (pathological);
CRC	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11446398	chr5:77624930	NA	0.43	6.12	0.32	2.59e-9	Triglycerides;
CRC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg03233332	chr7:66118400	NA	-0.44	-6.11	-0.32	2.78e-9	Aortic root size;
CRC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg06671706	chr8:8559999	CLDN23	0.49	7.22	0.37	3.7e-12	Obesity-related traits;
CRC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg07195577	chr17:27052828	TLCD1	0.41	5.79	0.3	1.66e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.65e-9	Aortic root size;
CRC	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg15485101	chr11:133734466	NA	0.39	7.16	0.37	5.45e-12	Childhood ear infection;
CRC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg25382214	chr1:3105252	PRDM16	-0.44	-7.13	-0.37	6.48e-12	Migraine;
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.68	-0.35	1.02e-10	Lymphocyte counts;
CRC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.85	10.08	0.49	5.15e-21	Psoriasis;
CRC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg10298567	chr3:47292165	KIF9	-0.39	-6.21	-0.32	1.56e-9	Colorectal cancer;
CRC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22133161	chr19:49891603	CCDC155	0.51	6.65	0.34	1.21e-10	Multiple sclerosis;
CRC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-5.91	-0.31	8.45e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2882667	0.931	rs10075951	chr5:138355963	G/T	cg04439458	chr5:138467593	SIL1	-0.32	-5.82	-0.31	1.37e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.75	11.63	0.54	1.97e-26	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.47	-6.67	-0.35	1.08e-10	Diastolic blood pressure;
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg14196790	chr5:131705035	SLC22A5	0.35	5.72	0.3	2.42e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs4700695	1.000	rs153319	chr5:65419423	C/T	cg21114390	chr5:65439923	SFRS12	-0.51	-6.0	-0.31	5.13e-9	Facial morphology (factor 19);
CRC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.64	10.14	0.49	3.2e-21	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.41	0.42	1.24e-15	Corneal astigmatism;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.79	-11.86	-0.55	3.05e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.7	10.11	0.49	4.35e-21	Inflammatory bowel disease;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.13	-0.37	6.36e-12	Bipolar disorder;
CRC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg11212589	chr17:38028394	ZPBP2	-0.37	-6.76	-0.35	6.45e-11	Self-reported allergy;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg25164649	chr6:28176230	NA	0.59	8.43	0.42	1.14e-15	Parkinson's disease;
CRC	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.56	10.76	0.51	2.48e-23	Cognitive performance;
CRC	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.48	7.35	0.38	1.55e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg25547332	chr5:131281432	NA	0.38	5.75	0.3	2.01e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-7.49	-0.38	6.29e-13	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07556773	chr1:155294010	RUSC1;C1orf104	0.4	6.12	0.32	2.63e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.41	-8.99	-0.44	2.02e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs2179367	0.959	rs489551	chr6:149689457	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.16	-0.32	2.06e-9	Dupuytren's disease;
CRC	cis	rs2415984	0.622	rs61993302	chr14:46949684	C/T	cg14871534	chr14:47121158	RPL10L	-0.45	-6.37	-0.33	6.21e-10	Number of children ever born;
CRC	cis	rs12760731	0.641	rs11590951	chr1:178322757	C/T	cg00404053	chr1:178313656	RASAL2	0.94	9.89	0.48	2.37e-20	Obesity-related traits;
CRC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	0.85	8.96	0.44	2.4e-17	Gout;Renal underexcretion gout;
CRC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg10589385	chr1:150898437	SETDB1	0.28	6.07	0.32	3.43e-9	Melanoma;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg03623178	chr6:28175578	NA	0.67	9.51	0.46	4.25e-19	Parkinson's disease;
CRC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.68	-11.51	-0.54	5.59e-26	P wave terminal force;
CRC	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.69	11.49	0.54	6.25e-26	Subjective well-being (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.63	7.31	0.37	2.02e-12	Diabetic retinopathy;
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.97	-0.36	1.69e-11	Bipolar disorder;
CRC	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.52	-6.69	-0.35	9.32e-11	Systolic blood pressure;
CRC	trans	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg03037974	chr15:76606532	NA	0.57	9.58	0.47	2.41e-19	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13770088	chr11:32851361	PRRG4	0.45	6.89	0.36	2.84e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg01426195	chr3:39028469	NA	-0.53	-8.56	-0.43	4.39e-16	Handedness;
CRC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.42	-6.62	-0.34	1.5e-10	Longevity;Endometriosis;
CRC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.38	5.61	0.3	4.26e-8	Menarche (age at onset);
CRC	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.51	7.18	0.37	4.61e-12	Metabolite levels;
CRC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.76	0.39	1.11e-13	Motion sickness;
CRC	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg04850286	chr10:81895943	PLAC9	-0.37	-6.67	-0.35	1.06e-10	Sarcoidosis;
CRC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.66	0.47	1.3e-19	Lung cancer;
CRC	cis	rs9992667	0.955	rs73232881	chr4:38664131	T/C	cg19726192	chr4:38663646	FLJ13197	-0.71	-8.79	-0.44	8.56e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.18	-0.49	2.47e-21	Schizophrenia;
CRC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.61	-8.04	-0.41	1.59e-14	Mean platelet volume;
CRC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.55	8.31	0.42	2.5e-15	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18876457	chr1:160071037	NA	-0.53	-6.47	-0.34	3.6e-10	Diisocyanate-induced asthma;
CRC	cis	rs9467603	0.925	rs1892253	chr6:25782314	G/T	cg08501292	chr6:25962987	TRIM38	0.61	5.9	0.31	9.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.45	7.13	0.37	6.23e-12	Height;
CRC	trans	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg19894588	chr14:64061835	NA	-0.54	-7.2	-0.37	4.07e-12	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	ch.11.42038R	chr11:967971	AP2A2	0.54	8.69	0.43	1.74e-16	Alzheimer's disease (late onset);
CRC	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21659725	chr3:3221576	CRBN	0.62	6.51	0.34	2.86e-10	Menarche (age at onset);
CRC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.68	-0.3	2.94e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	5.99	0.31	5.59e-9	Prudent dietary pattern;
CRC	cis	rs4728302	0.643	rs6966335	chr7:133702217	C/T	cg03336402	chr7:133662267	EXOC4	-0.44	-6.76	-0.35	6.25e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04117832	chr2:152685230	ARL5A	0.41	6.63	0.34	1.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg07574458	chr4:17513646	QDPR	0.37	6.04	0.32	4.26e-9	Body mass index;
CRC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.44	-0.38	8.74e-13	Bladder cancer;
CRC	trans	rs10411161	0.810	rs17778711	chr19:52385300	A/G	cg22319618	chr22:45562946	NUP50	-0.67	-6.21	-0.32	1.63e-9	Breast cancer;
CRC	cis	rs2268241	0.938	rs28653198	chr21:34782395	A/C	cg14850771	chr21:34775459	IFNGR2	0.77	9.64	0.47	1.6e-19	Obesity-related traits;
CRC	cis	rs755249	0.567	rs72661927	chr1:39675322	A/G	cg18385671	chr1:39797026	MACF1	-0.44	-6.34	-0.33	7.8e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.3	0.33	9.68e-10	Obesity-related traits;
CRC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.61	-9.12	-0.45	7.57e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-15.86	-0.66	1.71e-42	Prostate cancer;
CRC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.51	7.2	0.37	4.11e-12	High light scatter reticulocyte count;
CRC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.8	-0.35	4.82e-11	Monocyte count;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg15786705	chr6:28176104	NA	0.62	6.67	0.34	1.11e-10	Depression;
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-7.07	-0.36	9.11e-12	Lymphocyte counts;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05367824	chr21:40817657	SH3BGR	0.44	6.26	0.33	1.18e-9	Anxiety disorder;
CRC	cis	rs911119	0.913	rs13038990	chr20:23589053	C/T	cg16589663	chr20:23618590	CST3	0.44	6.29	0.33	9.89e-10	Chronic kidney disease;
CRC	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.82	-13.57	-0.6	1.26e-33	Bipolar disorder;
CRC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.27	0.64	3.58e-40	Platelet count;
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.88	0.35	3.08e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.56	-8.4	-0.42	1.38e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs939584	0.825	rs4423631	chr2:648758	T/C	cg03610516	chr2:642275	NA	0.42	5.85	0.31	1.2e-8	Body mass index;
CRC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.5	7.53	0.38	5e-13	Emphysema distribution in smoking;
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg22638593	chr5:131593259	PDLIM4	0.39	7.71	0.39	1.49e-13	Blood metabolite levels;
CRC	trans	rs2413583	0.591	rs76449672	chr22:39696482	G/A	cg09612413	chr10:12085555	UPF2	-0.56	-6.21	-0.32	1.58e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.47	6.83	0.35	4.19e-11	Lymphocyte counts;
CRC	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg26875233	chr11:93583750	C11orf90	-0.33	-6.54	-0.34	2.33e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs62408225	1.000	rs943689	chr6:90984035	C/T	cg06866423	chr6:90926672	BACH2	0.48	8.03	0.4	1.74e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg21335942	chr16:58549945	SETD6	0.86	5.72	0.3	2.39e-8	Schizophrenia;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.38	6.77	0.35	5.91e-11	Lung cancer;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg22638593	chr5:131593259	PDLIM4	0.35	6.79	0.35	5.38e-11	Blood metabolite levels;
CRC	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.68	12.17	0.56	2.11e-28	Leprosy;
CRC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg11887960	chr12:57824829	NA	0.61	6.72	0.35	7.84e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg08213375	chr14:104286397	PPP1R13B	0.58	11.91	0.55	1.87e-27	Schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23978161	chr4:77870897	SEPT11	-0.41	-6.15	-0.32	2.2e-9	Myopia (pathological);
CRC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.87	-14.92	-0.64	8.13e-39	Height;
CRC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.41	-5.64	-0.3	3.58e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs12431939	0.948	rs12433249	chr14:51669661	T/C	cg23942311	chr14:51606299	NA	-0.5	-6.36	-0.33	6.9e-10	Cancer;
CRC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.31	6.41	0.33	5.11e-10	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.6	0.47	2.17e-19	Corneal astigmatism;
CRC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-9.54	-0.47	3.37e-19	Coronary artery disease;
CRC	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg08600765	chr20:34638493	LOC647979	-0.62	-7.47	-0.38	7.09e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2898681	0.739	rs1047959	chr4:53739856	C/G	cg00338735	chr4:53728038	RASL11B	0.37	5.62	0.3	4.04e-8	Optic nerve measurement (cup area);
CRC	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	7.02	0.36	1.29e-11	Body mass index (adult);
CRC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.81	14.84	0.63	1.62e-38	Mean platelet volume;
CRC	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg14593290	chr7:50529359	DDC	-0.52	-7.72	-0.39	1.37e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-15.19	-0.64	7.27e-40	Body mass index;
CRC	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.81	0.68	3.44e-46	Electrocardiographic conduction measures;
CRC	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.66	7.94	0.4	3.13e-14	Eotaxin levels;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg20933634	chr6:27740509	NA	0.62	8.21	0.41	5.17e-15	Parkinson's disease;
CRC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.33	1.26e-9	Heart rate;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg02683197	chr6:28174875	NA	0.47	6.65	0.34	1.24e-10	Cardiac Troponin-T levels;
CRC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.77	-0.3	1.79e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.56	8.96	0.44	2.43e-17	Neuroticism;
CRC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg14673194	chr17:80132900	CCDC57	0.49	6.42	0.33	4.73e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.64	0.57	3.9e-30	Menopause (age at onset);
CRC	cis	rs9463078	0.691	rs12194311	chr6:45329048	C/A	cg25276700	chr6:44698697	NA	0.24	5.84	0.31	1.26e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.24	0.45	3.04e-18	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.33e-11	Morning vs. evening chronotype;
CRC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.34e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.37	-0.5	5.27e-22	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07822613	chr19:1875079	NA	0.44	6.43	0.33	4.41e-10	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg01951491	chr16:67709440	GFOD2	-0.45	-5.94	-0.31	7.37e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.43	6.89	0.36	2.82e-11	Monocyte count;
CRC	cis	rs12898370	0.561	rs34129891	chr15:77481210	T/C	cg05673287	chr15:77411982	SGK269	-0.54	-5.81	-0.31	1.46e-8	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg07507251	chr3:52567010	NT5DC2	-0.45	-6.36	-0.33	6.94e-10	Bipolar disorder;
CRC	cis	rs972578	1.000	rs2016623	chr22:43370549	A/G	cg01576275	chr22:43409880	NA	-0.45	-7.28	-0.37	2.47e-12	Mean platelet volume;
CRC	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg14593290	chr7:50529359	DDC	0.49	6.92	0.36	2.42e-11	Malaria;
CRC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.1	0.36	7.8e-12	Colorectal cancer;
CRC	cis	rs6499255	0.951	rs57488237	chr16:69741571	T/C	cg15192750	chr16:69999425	NA	0.55	7.49	0.38	6.37e-13	IgE levels;
CRC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.54	0.34	2.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09068198	chr2:65357064	RAB1A	0.44	5.99	0.31	5.53e-9	Response to antipsychotic treatment;
CRC	cis	rs7572644	0.640	rs9678336	chr2:28065404	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.11	0.32	2.79e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.03	0.32	4.45e-9	Diabetic retinopathy;
CRC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.61	-9.68	-0.47	1.15e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.93	-0.36	2.19e-11	Metabolite levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14677014	chr10:15001504	MEIG1	-0.39	-6.05	-0.32	3.85e-9	Myopia (pathological);
CRC	cis	rs7705042	0.897	rs4912807	chr5:141519296	G/C	cg07392085	chr5:141489673	NDFIP1	0.45	7.25	0.37	2.94e-12	Asthma;
CRC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.66	0.3	3.33e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.55	9.99	0.48	1.07e-20	HDL cholesterol levels;
CRC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-10.12	-0.49	4e-21	Menarche (age at onset);
CRC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg25456477	chr12:86230367	RASSF9	0.39	6.56	0.34	2.13e-10	Major depressive disorder;
CRC	cis	rs7705042	0.727	rs1062158	chr5:141523000	C/T	cg08523384	chr5:141488047	NDFIP1	-0.31	-5.68	-0.3	3.02e-8	Asthma;
CRC	cis	rs4731207	0.596	rs10274513	chr7:124650537	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.44	-6.14	-0.32	2.44e-9	Schizophrenia;
CRC	trans	rs7809615	0.581	rs57980352	chr7:98985408	G/A	cg19809667	chr19:54401945	PRKCG	0.6	5.99	0.31	5.43e-9	Blood metabolite ratios;
CRC	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg16950941	chr11:66035639	RAB1B	-0.6	-7.44	-0.38	8.67e-13	Electroencephalogram traits;
CRC	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.87	-8.37	-0.42	1.63e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.46	7.28	0.37	2.55e-12	Height;
CRC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
CRC	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg09163369	chr1:210001066	C1orf107	0.6	7.47	0.38	7.22e-13	Orofacial clefts;
CRC	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg23254163	chr1:152506842	NA	0.44	8.57	0.43	4.11e-16	Hair morphology;
CRC	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg14345882	chr6:26364793	BTN3A2	0.71	6.06	0.32	3.68e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	0.94	18.74	0.72	8.14e-54	Height;
CRC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.33	0.37	1.85e-12	Educational attainment;
CRC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.58	6.3	0.33	9.76e-10	Schizophrenia;
CRC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.37	-0.33	6.54e-10	Platelet distribution width;
CRC	cis	rs4750440	0.540	rs11258766	chr10:14016196	G/A	cg00551146	chr10:14014579	FRMD4A	0.44	6.96	0.36	1.91e-11	Adiponectin levels;
CRC	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.51	9.72	0.47	8.52e-20	HIV-1 susceptibility;
CRC	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg20608306	chr11:116969690	SIK3	-0.32	-6.12	-0.32	2.69e-9	Subjective well-being;
CRC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.99	12.39	0.56	3.48e-29	Vitiligo;
CRC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs55702914	0.650	rs6715690	chr2:198148371	C/T	cg10820045	chr2:198174542	NA	-0.38	-6.88	-0.35	3.04e-11	Major depression and alcohol dependence;
CRC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg19223190	chr17:80058835	NA	-0.43	-6.77	-0.35	6.1e-11	Life satisfaction;
CRC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.98	-0.31	5.88e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.89	21.04	0.76	7.18e-63	Longevity;
CRC	cis	rs6969780	1.000	rs73071550	chr7:27149099	T/C	cg26364809	chr7:27145159	NA	-0.72	-6.71	-0.35	8.56e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.49	6.8	0.35	5.04e-11	Height;
CRC	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg26875233	chr11:93583750	C11orf90	-0.35	-6.71	-0.35	8.35e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4363385	0.818	rs12195	chr1:153004983	C/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.34	-0.33	7.66e-10	Inflammatory skin disease;
CRC	cis	rs7635838	0.892	rs6442252	chr3:11451416	T/C	cg00170343	chr3:11313890	ATG7	0.38	5.75	0.3	2.04e-8	HDL cholesterol;
CRC	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.65	-9.51	-0.46	4.2e-19	Waist circumference;Body mass index;
CRC	cis	rs6662572	0.737	rs7525281	chr1:46267923	A/G	cg08644498	chr1:46502608	NA	-0.44	-7.0	-0.36	1.4e-11	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07150538	chr10:111970028	MXI1	0.47	6.01	0.31	4.87e-9	Thyroid stimulating hormone;
CRC	trans	rs2313132	0.722	rs7434478	chr4:138598984	A/G	cg16556111	chr5:92918829	NR2F1	-0.57	-6.01	-0.31	4.93e-9	Systemic lupus erythematosus;
CRC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.5	7.33	0.37	1.85e-12	Coronary artery disease;
CRC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg21770322	chr7:97807741	LMTK2	0.58	9.54	0.47	3.29e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.93	-0.31	7.62e-9	Lung cancer;
CRC	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.2	-0.32	1.71e-9	IgE levels;
CRC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg12273811	chr6:28175739	NA	0.64	6.4	0.33	5.26e-10	Depression;
CRC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.53	-8.86	-0.44	5e-17	Systemic lupus erythematosus;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg02869364	chr7:1081709	C7orf50	-0.42	-6.83	-0.35	4.11e-11	Longevity;Endometriosis;
CRC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.73	-0.39	1.32e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	10.61	0.5	8.45e-23	Motion sickness;
CRC	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.15	-0.45	6.31e-18	Migraine;Coronary artery disease;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg21747405	chr11:67723411	NA	-0.58	-8.99	-0.44	2e-17	Blood pressure (smoking interaction);
CRC	cis	rs1519814	1.000	rs4271006	chr8:121146640	T/G	cg22335954	chr8:121166405	COL14A1	-0.56	-6.44	-0.33	4.13e-10	Breast cancer;
CRC	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	15.91	0.66	1.15e-42	Mean corpuscular hemoglobin;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	9.61	0.47	2.01e-19	Lymphocyte counts;
CRC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.77	10.96	0.52	4.9299999999999996e-24	Neutrophil percentage of white cells;
CRC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.48	7.78	0.39	9.35e-14	Huntington's disease progression;
CRC	cis	rs17767392	0.670	rs17767386	chr14:71748353	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.66	-0.3	3.27e-8	Mitral valve prolapse;
CRC	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.77	-0.35	5.92e-11	Rheumatoid arthritis;
CRC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.54	-7.88	-0.4	4.91e-14	Lung cancer;
CRC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.49	6.43	0.33	4.52e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.03	23.4	0.79	5.63e-72	Multiple system atrophy;
CRC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.38	6.3	0.33	9.56e-10	Major depressive disorder;
CRC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.23	-0.53	5.45e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.72	7.85	0.4	6.07e-14	Diabetic retinopathy;
CRC	trans	rs2303319	0.504	rs56152608	chr2:162283469	G/A	cg21546874	chr1:9294571	H6PD	-0.76	-6.01	-0.31	4.89e-9	Cognitive function;
CRC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg03623178	chr6:28175578	NA	0.83	6.72	0.35	7.91e-11	Depression;
CRC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg16235748	chr6:149772707	ZC3H12D	0.38	6.97	0.36	1.78e-11	Dupuytren's disease;
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02290350	chr8:58132656	NA	-0.57	-7.91	-0.4	4.05e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs55821334	chr2:162452014	A/G	cg27113153	chr11:123612418	ZNF202	-0.7	-6.15	-0.32	2.28e-9	Cognitive function;
CRC	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg09655341	chr17:79618100	PDE6G	0.5	5.83	0.31	1.35e-8	Dental caries;
CRC	trans	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.61	-0.39	2.94e-13	Endometrial cancer;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.45	7.25	0.37	2.94e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.46	-7.46	-0.38	7.97e-13	Non-obstructive azoospermia;
CRC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.22	-0.37	3.66e-12	Chronic sinus infection;
CRC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.64	8.43	0.42	1.11e-15	High light scatter reticulocyte count;
CRC	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05142140	chr3:49055321	DALRD3	0.42	6.16	0.32	2.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.42	7.83	0.4	6.9e-14	Monocyte count;
CRC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.6	-9.16	-0.45	5.57e-18	Body mass index;
CRC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	8.49	0.42	7.26e-16	Electrocardiographic conduction measures;
CRC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	16.26	0.67	4.86e-44	Smoking behavior;
CRC	cis	rs11098699	0.821	rs6835952	chr4:124230974	A/C	cg09941581	chr4:124220074	SPATA5	0.4	5.86	0.31	1.15e-8	Mosquito bite size;
CRC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.19	-0.32	1.74e-9	Aortic root size;
CRC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.45	5.62	0.3	4.01e-8	Aortic root size;
CRC	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.75	-13.14	-0.59	5.6199999999999995e-32	Tonsillectomy;
CRC	cis	rs7932354	0.502	rs10769244	chr11:47182368	A/G	cg19486271	chr11:47235900	DDB2	0.47	6.73	0.35	7.35e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.66	10.27	0.49	1.24e-21	Initial pursuit acceleration;
CRC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.08	-0.41	1.24e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.67	0.3	3.1e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.66	8.86	0.44	5.13e-17	Iron status biomarkers;
CRC	cis	rs1552172	0.853	rs11591191	chr1:145675931	T/C	cg11743829	chr1:145714124	CD160	-0.41	-6.18	-0.32	1.91e-9	Breast cancer;
CRC	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg20356878	chr3:121714668	ILDR1	0.51	7.75	0.39	1.19e-13	Cognitive performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18342900	chr16:46865048	C16orf87	0.5	7.39	0.38	1.19e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08219700	chr8:58056026	NA	0.54	6.15	0.32	2.27e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.54	-8.1	-0.41	1.05e-14	Red cell distribution width;Reticulocyte count;
CRC	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg06470822	chr6:28175283	NA	-0.6	-6.3	-0.33	9.67e-10	Depression;
CRC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg18827107	chr12:86230957	RASSF9	-0.37	-6.13	-0.32	2.49e-9	Major depressive disorder;
CRC	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.66	0.39	2.03e-13	Breast cancer;
CRC	cis	rs59104589	0.583	rs12618809	chr2:242249122	G/A	cg19488206	chr2:242435732	STK25	0.48	6.72	0.35	7.88e-11	Fibrinogen levels;
CRC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.74	9.61	0.47	1.93e-19	Platelet count;
CRC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.51	9.44	0.46	7.33e-19	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg10298567	chr3:47292165	KIF9	0.4	6.26	0.33	1.19e-9	Colorectal cancer;
CRC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.26	0.37	2.9e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.42	0.33	4.73e-10	Diastolic blood pressure;
CRC	trans	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg10756647	chr7:56101905	PSPH	0.69	7.34	0.38	1.66e-12	Diabetic kidney disease;
CRC	trans	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg18335740	chr13:41363409	SLC25A15	0.61	9.69	0.47	1.1e-19	Lewy body disease;
CRC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg04586622	chr2:25135609	ADCY3	0.54	9.91	0.48	1.99e-20	Body mass index;
CRC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.01	0.31	4.85e-9	Life satisfaction;
CRC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.55	-8.46	-0.42	8.7e-16	Schizophrenia;
CRC	cis	rs4731207	0.596	rs7791399	chr7:124577972	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs6662572	0.737	rs1355641	chr1:46599143	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.24	0.33	1.32e-9	Blood protein levels;
CRC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.37	5.99	0.31	5.42e-9	Reticulocyte count;
CRC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.14	-0.32	2.34e-9	Mean corpuscular volume;
CRC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg27535305	chr1:53392650	SCP2	-0.36	-6.63	-0.34	1.37e-10	Monocyte count;
CRC	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.35	-0.33	7.18e-10	Diastolic blood pressure;
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.64	-0.3	3.61e-8	Life satisfaction;
CRC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.89	10.52	0.5	1.62e-22	Gut microbiome composition (summer);
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg21153622	chr11:89784906	NA	-0.53	-8.82	-0.44	6.69e-17	HDL cholesterol;
CRC	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.42	6.18	0.32	1.92e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs62229266	0.659	rs2835242	chr21:37413532	A/C	cg08632701	chr21:37451849	NA	-0.41	-6.39	-0.33	5.8e-10	Mitral valve prolapse;
CRC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00612595	chr21:47717864	NA	-0.39	-6.19	-0.32	1.76e-9	Testicular germ cell tumor;
CRC	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg21280719	chr6:42927975	GNMT	-0.33	-5.86	-0.31	1.11e-8	Blood protein levels;
CRC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg10589385	chr1:150898437	SETDB1	0.32	6.51	0.34	2.73e-10	Melanoma;
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.47	-0.38	7.46e-13	Lymphocyte counts;
CRC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.2	0.32	1.65e-9	Total body bone mineral density;
CRC	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.4	5.78	0.3	1.71e-8	Height;
CRC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.38	-7.46	-0.38	7.61e-13	Mean corpuscular volume;
CRC	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg19486271	chr11:47235900	DDB2	-0.49	-7.56	-0.38	4.17e-13	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	ch.11.42038R	chr11:967971	AP2A2	0.57	9.75	0.47	6.98e-20	Alzheimer's disease (late onset);
CRC	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.96	12.36	0.56	4.54e-29	Triglycerides;
CRC	cis	rs9549328	0.700	rs34890317	chr13:113617245	G/C	cg08614441	chr13:113633676	MCF2L	0.4	7.08	0.36	8.63e-12	Systolic blood pressure;
CRC	cis	rs76993477	0.666	rs12142587	chr1:169716214	G/A	cg03211132	chr1:169703751	SELE	0.61	5.83	0.31	1.32e-8	Tonsillectomy;
CRC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.24	-16.67	-0.68	1.18e-45	Breast cancer;
CRC	cis	rs4964805	0.865	rs11111796	chr12:104205928	C/T	cg02344784	chr12:104178138	NT5DC3	0.47	6.78	0.35	5.56e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.85e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	cis	rs989128	0.642	rs8077323	chr17:48626398	C/T	cg24438145	chr17:48624694	SPATA20	0.52	7.41	0.38	1.04e-12	Type 2 diabetes;
CRC	cis	rs16975963	0.843	rs3848624	chr19:38262816	C/T	cg15135657	chr19:38346511	NA	-0.45	-5.92	-0.31	7.95e-9	Longevity;
CRC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.43	7.04	0.36	1.15e-11	Resting heart rate;
CRC	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.5	8.73	0.43	1.3e-16	Dietary macronutrient intake;
CRC	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.45	7.24	0.37	3.18e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11446398	chr5:77624930	NA	-0.4	-5.92	-0.31	8.19e-9	Triglycerides;
CRC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs12476592	0.602	rs7563623	chr2:63720210	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.07	-15.1	-0.64	1.63e-39	Exhaled nitric oxide output;
CRC	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-8.74	-0.43	1.26e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-6.9	-0.36	2.66e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg00601450	chr5:74908170	NA	0.48	5.91	0.31	8.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg20628663	chr10:43360327	NA	0.57	6.85	0.35	3.55e-11	Blood protein levels;
CRC	cis	rs3789045	0.528	rs61817953	chr1:204462612	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.78	-0.39	9.73e-14	Educational attainment (college completion);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02076939	chr11:118042561	SCN2B	0.42	6.0	0.31	5.31e-9	Response to antipsychotic treatment;
CRC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg15269541	chr15:43626905	ADAL	0.46	6.13	0.32	2.56e-9	Lung cancer in ever smokers;
CRC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.55	7.31	0.37	2.05e-12	Multiple sclerosis;
CRC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.7	-12.43	-0.57	2.31e-29	Prostate cancer;
CRC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg09998033	chr7:158218633	PTPRN2	-0.46	-6.54	-0.34	2.41e-10	Obesity-related traits;
CRC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.55	7.83	0.4	6.61e-14	Alcohol dependence;
CRC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.46	-0.38	7.91e-13	Reticulocyte fraction of red cells;
CRC	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.9	0.36	2.61e-11	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.76	0.3	1.89e-8	Prudent dietary pattern;
CRC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.47	6.43	0.33	4.6e-10	Bladder cancer;
CRC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.79	-9.35	-0.46	1.4e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9549328	0.670	rs61963562	chr13:113616523	T/G	cg24588162	chr13:113633484	MCF2L	0.36	6.43	0.33	4.47e-10	Systolic blood pressure;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg18758796	chr5:131593413	PDLIM4	0.4	6.46	0.34	3.74e-10	Breast cancer;
CRC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg04731861	chr2:219085781	ARPC2	0.28	5.97	0.31	6.18e-9	Ulcerative colitis;
CRC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.38	-0.38	1.34e-12	Height;
CRC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.51	8.48	0.42	7.61e-16	Coronary artery disease;
CRC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.67	11.75	0.54	7.17e-27	Calcium levels;
CRC	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.28	-0.33	1.1e-9	QT interval;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg09491104	chr22:46646882	C22orf40	-0.41	-5.66	-0.3	3.33e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg15845792	chr6:28175446	NA	1.04	13.9	0.61	6.84e-35	Depression;
CRC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.1	-0.32	2.91e-9	Obesity-related traits;
CRC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg20203395	chr5:56204925	C5orf35	-0.54	-7.44	-0.38	9.1e-13	Coronary artery disease;
CRC	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.69	-0.3	2.88e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg04731861	chr2:219085781	ARPC2	-0.29	-6.05	-0.32	3.84e-9	Colorectal cancer;
CRC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	1.12	13.08	0.58	8.83e-32	Obesity-related traits;
CRC	trans	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.41	-6.69	-0.35	9.38e-11	Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.34	5.89	0.31	9.39e-9	Sitting height ratio;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg15845792	chr6:28175446	NA	0.77	11.37	0.53	1.74e-25	Parkinson's disease;
CRC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.36	-6.2	-0.32	1.7e-9	Schizophrenia;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.92	-0.31	8.17e-9	Life satisfaction;
CRC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.32	-5.62	-0.3	3.99e-8	Iron status biomarkers;
CRC	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-1.17	-9.98	-0.48	1.17e-20	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.25	-0.33	1.3e-9	Daytime sleep phenotypes;
CRC	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.23	-0.32	1.43e-9	Fractional excretion of uric acid;
CRC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.71	10.09	0.49	4.9e-21	Cognitive function;
CRC	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.88	0.35	3.12e-11	Mean corpuscular volume;
CRC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.49	-7.24	-0.37	3.29e-12	Colorectal cancer;
CRC	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.38e-25	White blood cell count (basophil);
CRC	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.59	-5.62	-0.3	4.09e-8	IgG glycosylation;
CRC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.64	7.83	0.4	6.74e-14	Vitiligo;
CRC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg21153622	chr11:89784906	NA	-0.38	-6.2	-0.32	1.74e-9	Height;
CRC	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.22	-0.37	3.66e-12	Intelligence (multi-trait analysis);
CRC	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	1.09	12.84	0.58	7.36e-31	Obesity-related traits;
CRC	cis	rs7539542	0.556	rs4950889	chr1:202874786	T/C	cg19681188	chr1:202830198	LOC148709	0.46	6.67	0.35	1.09e-10	Mean platelet volume;
CRC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.39	6.32	0.33	8.54e-10	Monocyte count;
CRC	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.76	-6.69	-0.35	9.69e-11	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02359409	chr6:42947317	PEX6	0.58	8.88	0.44	4.33e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg22535103	chr8:58192502	C8orf71	-0.44	-5.8	-0.3	1.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.49	-9.68	-0.47	1.12e-19	Urate levels in overweight individuals;
CRC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.99	0.4	2.3e-14	Triglycerides;
CRC	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.44	6.69	0.35	9.83e-11	Neutrophil percentage of white cells;
CRC	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg08632701	chr21:37451849	NA	-0.45	-7.15	-0.37	5.77e-12	Mitral valve prolapse;
CRC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.61	8.42	0.42	1.18e-15	Neutrophil percentage of white cells;
CRC	cis	rs12476592	0.602	rs2604613	chr2:63832776	G/A	cg10828910	chr2:63850056	LOC388955	0.5	6.13	0.32	2.54e-9	Childhood ear infection;
CRC	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.92	-8.25	-0.41	3.95e-15	Putamen volume;
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	trans	rs12635820	0.504	rs79853094	chr3:80385001	G/A	cg23627948	chr7:2760692	NA	0.41	6.11	0.32	2.74e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg24881330	chr22:46731750	TRMU	0.67	5.71	0.3	2.56e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1519814	0.956	rs4369033	chr8:121138921	C/A	cg22335954	chr8:121166405	COL14A1	-0.56	-6.44	-0.33	4.13e-10	Breast cancer;
CRC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg15147215	chr3:52552868	STAB1	0.43	7.18	0.37	4.63e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.22	-5.82	-0.31	1.39e-8	Type 2 diabetes;
CRC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg07195577	chr17:27052828	TLCD1	0.41	5.9	0.31	9.27e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg24028381	chr8:145133668	EXOSC4	-0.42	-6.28	-0.33	1.04e-9	Myopia (pathological);
CRC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	9.67	0.47	1.28e-19	Alzheimer's disease;
CRC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	7.08	0.36	8.57e-12	Breast cancer;
CRC	cis	rs4731207	0.698	rs7793258	chr7:124448012	G/A	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19845159	chr8:146012669	ZNF34	0.44	6.14	0.32	2.44e-9	Anxiety disorder;
CRC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.62	-0.3	4.18e-8	Schizophrenia;
CRC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg26893134	chr6:116381904	FRK	0.27	7.79	0.39	8.83e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg15590007	chr10:45870220	ALOX5	-0.55	-5.64	-0.3	3.76e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg10820045	chr2:198174542	NA	0.41	6.81	0.35	4.64e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg09659197	chr4:152720779	NA	0.49	10.37	0.5	5.37e-22	Intelligence (multi-trait analysis);
CRC	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-11.0	-0.52	3.44e-24	Hepatocellular carcinoma;
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg13264159	chr8:625131	ERICH1	-0.63	-6.4	-0.33	5.5e-10	IgG glycosylation;
CRC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.73	7.5	0.38	5.96e-13	Plasma clusterin levels;
CRC	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.55	-9.21	-0.45	3.79e-18	Dupuytren's disease;
CRC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	10.52	0.5	1.65e-22	Schizophrenia;
CRC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.62	-9.5	-0.46	4.66e-19	Cognitive function;
CRC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg08999081	chr20:33150536	PIGU	0.44	5.72	0.3	2.39e-8	Protein C levels;
CRC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs965469	1.000	rs6037562	chr20:3326141	A/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.6	-0.3	4.41e-8	IFN-related cytopenia;
CRC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.43	-7.76	-0.39	1.07e-13	Monocyte count;
CRC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg19337854	chr7:99768885	GPC2	0.48	6.42	0.33	4.73e-10	Lung function (FEV1/FVC);
CRC	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.35	-0.69	2.4e-48	Schizophrenia;
CRC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg18230493	chr5:56204884	C5orf35	0.59	8.77	0.44	1.01e-16	Initial pursuit acceleration;
CRC	trans	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-7.59	-0.39	3.29e-13	Neuroticism;
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg18479299	chr3:125709523	NA	-0.52	-6.36	-0.33	6.72e-10	Blood pressure (smoking interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02664216	chr12:19592651	AEBP2	-0.61	-7.63	-0.39	2.63e-13	Diisocyanate-induced asthma;
CRC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.35	0.33	7.21e-10	Prudent dietary pattern;
CRC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.62	-11.53	-0.54	4.55e-26	Educational attainment;
CRC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.44	0.57	2.23e-29	Body mass index;
CRC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.67	9.2	0.45	4.12e-18	Breast cancer;
CRC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00234608	chr9:139702971	C9orf86;LOC100131193	0.4	6.52	0.34	2.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7201929	1.000	rs8061877	chr16:28856819	C/T	cg10436792	chr16:28889110	ATP2A1	0.41	5.64	0.3	3.61e-8	QT interval;
CRC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.54	8.19	0.41	5.95e-15	Height;
CRC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.73	11.48	0.53	6.77e-26	Tonsillectomy;
CRC	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg17218026	chr1:154582156	ADAR	-0.54	-9.21	-0.45	3.9e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.68	-0.3	2.9e-8	Tuberculosis;
CRC	cis	rs17767392	0.958	rs34957192	chr14:71752336	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.49	-0.34	3.22e-10	Mitral valve prolapse;
CRC	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg20936604	chr3:58311152	NA	-0.72	-7.15	-0.37	5.58e-12	Cholesterol, total;
CRC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.08	0.36	8.64e-12	Neuroticism;
CRC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg18279126	chr7:2041391	MAD1L1	0.39	5.78	0.3	1.76e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	8.42	0.42	1.14e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg03351412	chr1:154909251	PMVK	0.51	7.22	0.37	3.73e-12	Prostate cancer;
CRC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.95	-0.31	6.71e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6496667	0.865	rs7171617	chr15:90904858	G/A	cg04176472	chr15:90893244	GABARAPL3	0.51	7.67	0.39	1.91e-13	Rheumatoid arthritis;
CRC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.87	-16.07	-0.66	2.67e-43	Coronary artery disease;
CRC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.28	16.09	0.66	2.14e-43	Uric acid levels;
CRC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg23234261	chr14:55582407	NA	-0.28	-5.74	-0.3	2.15e-8	Protein biomarker;
CRC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.62	10.1	0.49	4.48e-21	Breast cancer;
CRC	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.47	-7.37	-0.38	1.42e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg18200150	chr17:30822561	MYO1D	0.44	8.58	0.43	3.85e-16	Schizophrenia;
CRC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.62	7.77	0.39	1.04e-13	Dilated cardiomyopathy;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg10729496	chr3:10149963	C3orf24	0.57	7.29	0.37	2.39e-12	Alzheimer's disease;
CRC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg15465823	chr12:48382534	COL2A1	-0.36	-5.9	-0.31	9.14e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.55	8.2	0.41	5.47e-15	Tuberculosis;
CRC	cis	rs965469	0.779	rs6515810	chr20:3370861	T/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.96e-8	IFN-related cytopenia;
CRC	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg09760422	chr2:128146352	NA	-0.37	-7.27	-0.37	2.72e-12	Protein C levels;
CRC	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg01843034	chr6:37503916	NA	-0.35	-5.66	-0.3	3.3e-8	Cognitive performance;
CRC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.85	9.91	0.48	2.03e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.54	-8.98	-0.44	2.17e-17	Prudent dietary pattern;
CRC	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg11579758	chr4:1086637	RNF212	0.41	6.74	0.35	7.01e-11	Recombination rate (males);
CRC	cis	rs17152411	1.000	rs17152381	chr10:126592903	T/G	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.28	6.09	0.32	3.19e-9	Schizophrenia;
CRC	cis	rs77861329	0.748	rs893055	chr3:52177348	T/C	cg08692210	chr3:52188851	WDR51A	0.51	5.92	0.31	7.96e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.65	10.49	0.5	2.1e-22	Colorectal cancer;
CRC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.25	-0.41	3.97e-15	Bladder cancer;
CRC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.57	-6.96	-0.36	1.89e-11	Body mass index;
CRC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg05132306	chr1:1846340	CALML6	-0.51	-7.92	-0.4	3.77e-14	Body mass index;
CRC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-7.75	-0.39	1.14e-13	Total body bone mineral density;
CRC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.12	-0.41	9.35e-15	Height;
CRC	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg00750074	chr16:89608354	SPG7	-0.45	-6.67	-0.35	1.05e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs1572438	0.811	rs6916781	chr6:880493	G/A	cg21062780	chr6:887772	NA	0.41	6.67	0.35	1.09e-10	Aging;
CRC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	12.02	0.55	7.58e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7503807	0.515	rs12450876	chr17:78682630	A/G	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.86e-8	Obesity;
CRC	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg05874882	chr4:1763078	NA	-0.38	-7.12	-0.37	6.66e-12	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs62577244	0.645	rs111342974	chr9:138434448	G/A	cg14582108	chr9:138439003	OBP2A	0.53	8.19	0.41	5.83e-15	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
CRC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-0.71	-8.13	-0.41	8.56e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.32	0.42	2.38e-15	Lung cancer;
CRC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.61	0.3	4.31e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	1.01	17.0	0.68	5.91e-47	Parkinson's disease;
CRC	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg18404041	chr3:52824283	ITIH1	0.35	6.38	0.33	6.17e-10	Schizophrenia;
CRC	cis	rs4713675	0.565	rs4711343	chr6:33714548	G/A	cg14003231	chr6:33640908	ITPR3	0.45	7.43	0.38	9.44e-13	Plateletcrit;
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.5	-6.95	-0.36	1.99e-11	Gut microbiome composition (summer);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19238398	chr5:138775248	DNAJC18	-0.39	-6.04	-0.32	4.22e-9	Myopia (pathological);
CRC	cis	rs2380220	0.810	rs66524640	chr6:95956566	T/C	cg04719120	chr6:96025338	MANEA	-0.55	-6.04	-0.32	4.15e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.59	-6.54	-0.34	2.29e-10	Coronary artery disease;
CRC	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23194596	chr7:36193344	EEPD1	0.36	6.03	0.32	4.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg06581033	chr10:766294	NA	-0.47	-5.71	-0.3	2.58e-8	Uric acid levels;
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.93	-21.97	-0.77	1.75e-66	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.32	-0.69	3.26e-48	Height;
CRC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.64	0.51	6.51e-23	Hip circumference adjusted for BMI;
CRC	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.56	5.98	0.31	5.78e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.99	-0.36	1.55e-11	Lung cancer;
CRC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg15269541	chr15:43626905	ADAL	-0.58	-6.1	-0.32	2.92e-9	Lung cancer in ever smokers;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.43	6.47	0.34	3.51e-10	Red blood cell count;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg12564285	chr5:131593104	PDLIM4	0.36	6.67	0.35	1.1e-10	Lung function (FEV1/FVC);
CRC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.53	5.75	0.3	2.03e-8	Schizophrenia;
CRC	cis	rs73200209	0.744	rs2392968	chr12:116533861	A/C	cg01776926	chr12:116560359	MED13L	-0.63	-7.65	-0.39	2.3e-13	Total body bone mineral density;
CRC	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.57	-0.34	1.95e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg10790698	chr19:18539756	SSBP4	-0.47	-8.71	-0.43	1.53e-16	Breast cancer;
CRC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg14673194	chr17:80132900	CCDC57	0.48	6.23	0.32	1.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.68	10.13	0.49	3.65e-21	Corneal astigmatism;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg20615401	chr6:28092323	ZSCAN16	0.47	6.36	0.33	6.89e-10	Parkinson's disease;
CRC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.69	-11.98	-0.55	1.08e-27	Body mass index;
CRC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.12	-0.37	6.71e-12	Morning vs. evening chronotype;
CRC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.32	0.46	1.78e-18	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23585910	chr11:134123368	THYN1;ACAD8	0.48	7.05	0.36	1.08e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9427116	1.000	rs9427117	chr1:154632231	C/G	cg17218026	chr1:154582156	ADAR	0.42	6.49	0.34	3.12e-10	Blood protein levels;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03923535	chr7:1197113	ZFAND2A	0.69	10.34	0.5	7.18e-22	Longevity;Endometriosis;
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg26668828	chr6:292823	DUSP22	-0.59	-8.55	-0.43	4.8e-16	Menopause (age at onset);
CRC	cis	rs720844	1.000	rs1031290	chr2:149367295	T/C	cg09247360	chr2:149335327	NA	-0.53	-6.78	-0.35	5.62e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.8	8.33	0.42	2.23e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg22431228	chr1:16359049	CLCNKA	0.35	5.92	0.31	7.99e-9	Dilated cardiomyopathy;
CRC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg00277769	chr7:97922759	BAIAP2L1	0.61	10.67	0.51	4.89e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg05874882	chr4:1763078	NA	-0.39	-7.16	-0.37	5.26e-12	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.45	-7.98	-0.4	2.4e-14	Reticulocyte fraction of red cells;
CRC	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.64	-8.73	-0.43	1.32e-16	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.18	0.52	8.32e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	9.5	0.46	4.52e-19	Blood protein levels;
CRC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.82	-0.31	1.41e-8	Life satisfaction;
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.98	16.93	0.68	1.13e-46	Menarche (age at onset);
CRC	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.54	9.57	0.47	2.69e-19	Common traits (Other);
CRC	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.43	-5.87	-0.31	1.05e-8	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CRC	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg04117972	chr1:227635322	NA	0.76	6.59	0.34	1.73e-10	Major depressive disorder;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11050527	chr8:54755511	ATP6V1H	-0.52	-6.26	-0.33	1.18e-9	Diisocyanate-induced asthma;
CRC	cis	rs2070997	0.702	rs3780284	chr9:133733961	A/G	cg01000188	chr9:133769184	QRFP	0.48	6.01	0.31	5e-9	Response to amphetamines;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02523617	chr4:39699380	UBE2K	0.46	7.0	0.36	1.41e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	0.62	6.12	0.32	2.71e-9	Prostate cancer;
CRC	trans	rs1973993	0.689	rs17375929	chr1:96962246	A/T	cg10631902	chr5:14652156	NA	-0.4	-6.72	-0.35	7.89e-11	Weight;
CRC	cis	rs3126085	0.515	rs1923506	chr1:152359700	A/T	cg09127314	chr1:152161683	NA	-0.44	-5.86	-0.31	1.13e-8	Atopic dermatitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13425637	chr14:61788328	PRKCH	0.44	7.25	0.37	2.99e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.63	-11.11	-0.52	1.41e-24	Breast cancer;
CRC	cis	rs6662572	0.737	rs56316933	chr1:46266725	C/T	cg08644498	chr1:46502608	NA	0.44	6.64	0.34	1.28e-10	Blood protein levels;
CRC	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.68	0.3	3.03e-8	Breast cancer;
CRC	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg10437265	chr15:77819839	NA	0.67	11.9	0.55	2.1e-27	Type 2 diabetes;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg05972000	chr8:67525501	MYBL1	-0.48	-5.96	-0.31	6.52e-9	Type 1 diabetes;
CRC	trans	rs3018066	0.518	rs12648091	chr4:107291528	G/C	cg07070047	chr13:25497298	CENPJ	-0.62	-5.96	-0.31	6.39e-9	Cancer;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.22	0.32	1.53e-9	Hemoglobin concentration;
CRC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05175466	chr13:52586483	ALG11;ATP7B	0.46	6.55	0.34	2.23e-10	Response to antipsychotic treatment;
CRC	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Educational attainment;
CRC	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-16.64	-0.68	1.57e-45	Electrocardiographic conduction measures;
CRC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.54	8.05	0.41	1.49e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7402982	0.525	rs11247361	chr15:99207392	C/G	cg03437748	chr15:99193247	IGF1R	-0.46	-6.05	-0.32	3.97e-9	Birth weight;
CRC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg25767906	chr1:53392781	SCP2	0.45	7.22	0.37	3.55e-12	Monocyte count;
CRC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.52	0.57	1.07e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.98	-0.4	2.49e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.93	-14.35	-0.62	1.31e-36	Systemic lupus erythematosus;
CRC	cis	rs7605827	0.930	rs9287661	chr2:15595901	G/A	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.51e-9	Educational attainment (years of education);
CRC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.64	7.85	0.4	5.9e-14	Arsenic metabolism;
CRC	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.69	-11.16	-0.52	1.01e-24	Idiopathic membranous nephropathy;
CRC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.48	-7.58	-0.39	3.52e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9549328	0.614	rs34306822	chr13:113616499	G/A	cg17524180	chr13:113633600	MCF2L	0.52	9.39	0.46	1e-18	Systolic blood pressure;
CRC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg10494257	chr1:16342123	HSPB7	0.44	5.95	0.31	7.02e-9	Dilated cardiomyopathy;
CRC	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.68	8.51	0.42	6.14e-16	Iron status biomarkers;
CRC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.42	-8.25	-0.41	3.81e-15	Vitiligo;
CRC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.63	-9.23	-0.45	3.51e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.4	7.43	0.38	9.36e-13	Body mass index;
CRC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-7.24	-0.37	3.14e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg23587288	chr2:27483067	SLC30A3	-0.32	-5.64	-0.3	3.58e-8	Blood metabolite levels;
CRC	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.72	8.21	0.41	5.14e-15	Neuroticism;
CRC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	9.98	0.48	1.16e-20	Schizophrenia;
CRC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.06	0.32	3.69e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs747650	0.504	rs34340483	chr11:46953154	T/G	cg19486271	chr11:47235900	DDB2	-0.44	-6.69	-0.35	9.4e-11	Acne (severe);
CRC	cis	rs447	1.000	rs10263314	chr7:83776972	C/T	cg22846510	chr7:83753280	SEMA3A	-0.55	-6.81	-0.35	4.68e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg26666090	chr16:58549219	SETD6	0.9	6.11	0.32	2.86e-9	Schizophrenia;
CRC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.65	10.06	0.48	6.34e-21	Birth weight;
CRC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg26587870	chr6:27730563	NA	-0.63	-6.65	-0.34	1.19e-10	Breast cancer;
CRC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.25	-0.33	1.24e-9	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05720666	chr2:69969591	ANXA4	0.46	6.68	0.35	1.01e-10	Response to antipsychotic treatment;
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg21784768	chr11:537496	LRRC56	-0.69	-6.56	-0.34	2.11e-10	Body mass index;
CRC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.49	7.12	0.37	7e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.7	-8.89	-0.44	4.01e-17	Blood pressure (smoking interaction);
CRC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.52	-7.25	-0.37	2.98e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.52	8.86	0.44	5.26e-17	Dupuytren's disease;
CRC	cis	rs7705042	0.865	rs413214	chr5:141530157	G/A	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.48e-8	Asthma;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg20933634	chr6:27740509	NA	0.57	8.07	0.41	1.38e-14	Parkinson's disease;
CRC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.62	8.89	0.44	4.01e-17	Selective IgA deficiency;
CRC	trans	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg26043149	chr18:55253948	FECH	-0.53	-8.0	-0.4	2.12e-14	Bone mineral density;
CRC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.59	7.32	0.37	1.94e-12	Obesity (extreme);
CRC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.8	8.74	0.43	1.23e-16	Breast cancer;
CRC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.45	6.73	0.35	7.51e-11	Type 2 diabetes;
CRC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00801512	chr17:28996047	NA	0.56	6.68	0.35	1.04e-10	Hip circumference adjusted for BMI;
CRC	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg12573674	chr2:1569213	NA	-0.75	-7.58	-0.39	3.52e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7692995	1.000	rs16896312	chr4:18030853	C/T	cg08925142	chr4:18023851	LCORL	-0.53	-5.86	-0.31	1.13e-8	Height;
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.95	-0.36	1.93e-11	Bipolar disorder;
CRC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.47	9.56	0.47	2.81e-19	Schizophrenia;
CRC	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg10523679	chr1:76189770	ACADM	-0.4	-5.71	-0.3	2.56e-8	Daytime sleep phenotypes;
CRC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.36	0.33	6.86e-10	Cognitive ability;
CRC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.42	-5.84	-0.31	1.23e-8	DNA methylation (variation);
CRC	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg11887960	chr12:57824829	NA	0.63	6.79	0.35	5.32e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.43	0.53	1.09e-25	Bone mineral density;
CRC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.55	7.93	0.4	3.5e-14	Corneal astigmatism;
CRC	cis	rs11212617	1.000	rs2884030	chr11:108281903	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.51	0.34	2.74e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.37	-6.93	-0.36	2.28e-11	Panic disorder;
CRC	cis	rs6743376	0.532	rs2251872	chr2:113818632	G/A	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6504622	0.537	rs1618989	chr17:44993708	T/C	cg16759221	chr17:45003025	GOSR2	-0.71	-11.36	-0.53	1.91e-25	Orofacial clefts;
CRC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.17	-0.32	1.99e-9	Arsenic metabolism;
CRC	cis	rs7707921	1.000	rs1019806	chr5:81551659	G/A	cg17942617	chr5:81327376	ATG10	-0.39	-5.85	-0.31	1.2e-8	Breast cancer;
CRC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg17971929	chr21:40555470	PSMG1	-0.47	-6.09	-0.32	3.18e-9	Menarche (age at onset);
CRC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.63	-8.78	-0.44	8.96e-17	DNA methylation (variation);
CRC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.48	-8.71	-0.43	1.53e-16	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1624802	0.638	rs1696431	chr12:130498408	C/T	cg15444478	chr12:130494697	NA	0.31	6.13	0.32	2.53e-9	Obesity-related traits;
CRC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.49	7.57	0.39	3.72e-13	Red blood cell count;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.92	-17.3	-0.69	3.99e-48	Coronary artery disease;
CRC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.44	6.72	0.35	8.13e-11	Mean platelet volume;
CRC	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.43	-0.6	4.41e-33	Educational attainment;
CRC	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.56	-9.37	-0.46	1.22e-18	Prostate cancer;
CRC	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.89	0.31	9.67e-9	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.45	6.82	0.35	4.26e-11	Menopause (age at onset);
CRC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.43	0.62	6.73e-37	Chronic sinus infection;
CRC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.59	8.62	0.43	2.93e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg21115391	chr11:93143810	CCDC67	-0.38	-5.7	-0.3	2.74e-8	Pulmonary function decline;
CRC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.47	-0.38	7.49e-13	Coronary artery disease;
CRC	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.91	7.98	0.4	2.38e-14	Pediatric areal bone mineral density (radius);
CRC	trans	rs2303319	0.582	rs62187608	chr2:162431138	T/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.12	-0.32	2.66e-9	Cognitive function;
CRC	trans	rs7845127	0.535	rs7815626	chr8:18171218	C/T	cg07676709	chr17:46673442	LOC404266;HOXB6	-0.41	-5.99	-0.31	5.44e-9	Night sleep phenotypes;
CRC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.41	-0.33	5.18e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	1.11	9.62	0.47	1.8e-19	Mitochondrial DNA levels;
CRC	cis	rs911119	0.955	rs67997662	chr20:23592864	G/A	cg16589663	chr20:23618590	CST3	0.45	6.3	0.33	9.76e-10	Chronic kidney disease;
CRC	trans	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.71	-0.35	8.45e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.07e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.44e-13	Motion sickness;
CRC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	1.06	10.05	0.48	6.48e-21	Lymphocyte counts;
CRC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg26597838	chr10:835615	NA	-0.43	-5.75	-0.3	2e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.68	0.43	1.86e-16	Coffee consumption (cups per day);
CRC	trans	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.51	-6.47	-0.34	3.65e-10	Red blood cell traits;
CRC	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.89	-0.31	9.78e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	6.2	0.32	1.67e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.67	9.84	0.48	3.29e-20	Longevity;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23708337	chr7:1209742	NA	0.42	6.15	0.32	2.21e-9	Longevity;Endometriosis;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21954346	chr16:68271489	ESRP2	0.43	6.04	0.32	4.07e-9	Response to antipsychotic treatment;
CRC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.49e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12463550	chr7:65579703	CRCP	0.62	5.63	0.3	3.93e-8	Gout;
CRC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg02741985	chr17:80059408	CCDC57	0.42	7.04	0.36	1.16e-11	Life satisfaction;
CRC	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.53	7.74	0.39	1.27e-13	Platelet distribution width;
CRC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg03689076	chr20:33865952	NA	-0.57	-7.66	-0.39	2.11e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.73	0.3	2.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.82	-13.85	-0.61	1.11e-34	Coronary artery disease;
CRC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg19761014	chr17:28927070	LRRC37B2	0.52	6.13	0.32	2.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.57	9.97	0.48	1.29e-20	Age of smoking initiation;
CRC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.81	-12.7	-0.57	2.36e-30	Multiple myeloma;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17822314	chr2:54198336	PSME4	0.42	6.51	0.34	2.83e-10	Schizophrenia;
CRC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.62	-0.39	2.8e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.38	6.21	0.32	1.62e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg27649806	chr9:35101217	STOML2	-0.38	-6.07	-0.32	3.44e-9	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2274273	0.624	rs7140628	chr14:55760681	A/C	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.66	-0.3	3.28e-8	Protein biomarker;
CRC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.5	10.97	0.52	4.61e-24	Alcohol dependence;
CRC	cis	rs13098911	0.540	rs9824651	chr3:46108285	C/T	cg12691230	chr3:46064611	XCR1	-0.53	-6.09	-0.32	3.17e-9	Celiac disease;
CRC	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	5.7	0.3	2.69e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg20936604	chr3:58311152	NA	-0.71	-7.58	-0.39	3.55e-13	Cholesterol, total;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.97	-0.44	2.23e-17	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.7	-10.99	-0.52	3.78e-24	Prudent dietary pattern;
CRC	cis	rs4144027	0.967	rs10133399	chr14:104361843	A/T	cg08213375	chr14:104286397	PPP1R13B	0.38	6.73	0.35	7.61e-11	Blood metabolite levels;
CRC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.67	10.37	0.5	5.41e-22	Birth weight;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06659009	chr4:95129138	SMARCAD1	0.4	6.62	0.34	1.42e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06569271	chr3:186501246	EIF4A2;SNORD2	0.42	6.04	0.32	4.22e-9	Interleukin-6 levels;
CRC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.52	-5.89	-0.31	9.53e-9	Vitiligo;
CRC	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg13175173	chr14:55914753	NA	-0.52	-9.94	-0.48	1.57e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs3020333	0.875	rs3020331	chr6:152008780	C/T	cg22157087	chr6:152012887	ESR1	0.52	7.76	0.39	1.08e-13	Total body bone mineral density;
CRC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.54	8.12	0.41	9.26e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.72	0.35	8.12e-11	Morning vs. evening chronotype;
CRC	trans	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.18	0.37	4.57e-12	Endometrial cancer;
CRC	cis	rs17209837	1.000	rs45593435	chr7:87088772	A/G	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.83	-0.44	6.34e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.57	-8.94	-0.44	2.76e-17	Height;
CRC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.73	-10.92	-0.52	6.68e-24	Platelet distribution width;
CRC	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.61	-0.34	1.58e-10	Vitamin D levels;
CRC	cis	rs73206853	0.764	rs17682012	chr12:111094454	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.8	-7.93	-0.4	3.42e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.67	-0.3	3.07e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg05623727	chr3:50126028	RBM5	-0.43	-7.3	-0.37	2.21e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.73	12.52	0.57	1.14e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.54	7.12	0.37	6.74e-12	Alzheimer's disease (survival time);
CRC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.63	0.3	3.87e-8	Bladder cancer;
CRC	cis	rs12580194	0.593	rs61956272	chr12:55779559	A/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.11	-0.45	7.95e-18	Cancer;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.45	-0.33	4.07e-10	Breast cancer;
CRC	cis	rs6840360	0.606	rs2709814	chr4:152360870	T/C	cg09659197	chr4:152720779	NA	0.33	6.47	0.34	3.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.32	6.77	0.35	5.89e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg19223190	chr17:80058835	NA	0.42	6.68	0.35	1.01e-10	Life satisfaction;
CRC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.61	9.02	0.45	1.55e-17	Cisplatin-induced ototoxicity;
CRC	trans	rs783540	0.967	rs783523	chr15:83283555	A/G	cg18393722	chr15:85113863	UBE2QP1	0.37	6.19	0.32	1.82e-9	Schizophrenia;
CRC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-18.42	-0.71	1.42e-52	Hemostatic factors and hematological phenotypes;
CRC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg00579200	chr11:133705235	NA	-0.4	-5.77	-0.3	1.82e-8	Childhood ear infection;
CRC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg00601486	chr12:48723148	H1FNT	0.33	6.09	0.32	3.08e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs17155006	0.655	rs94604	chr7:107733856	C/T	cg05962710	chr7:107745446	LAMB4	-0.35	-5.85	-0.31	1.18e-8	Pneumococcal bacteremia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06334988	chr2:220095083	ANKZF1;ATG9A	0.48	6.84	0.35	3.85e-11	Anxiety disorder;
CRC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-9.3	-0.46	2.03e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.74	12.52	0.57	1.13e-29	Cognitive function;
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12588279	chr6:26043732	HIST1H2BB	-0.4	-5.66	-0.3	3.35e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.41	5.77	0.3	1.86e-8	Aortic root size;
CRC	cis	rs720844	0.684	rs13029692	chr2:149299202	C/G	cg09247360	chr2:149335327	NA	-0.58	-6.02	-0.32	4.55e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.69	-9.09	-0.45	9.31e-18	Blood pressure (smoking interaction);
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.54	-9.67	-0.47	1.26e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.73	-9.44	-0.46	7.16e-19	Blood protein levels;
CRC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	8.47	0.42	8.52e-16	Schizophrenia;
CRC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.8	14.3	0.62	2.04e-36	Breast cancer;
CRC	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg16482183	chr6:26056742	HIST1H1C	0.75	9.51	0.46	4.09e-19	Iron status biomarkers;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09916155	chr16:1728187	HN1L	0.41	6.15	0.32	2.31e-9	Schizophrenia;
CRC	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.55	8.2	0.41	5.56e-15	Blood protein levels;
CRC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.59	7.91	0.4	4.02e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg15660573	chr17:549704	VPS53	0.86	15.87	0.66	1.61e-42	Prostate cancer;
CRC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.22	-0.32	1.49e-9	Acylcarnitine levels;
CRC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg03934865	chr2:198174659	NA	0.34	5.66	0.3	3.34e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.07	0.32	3.48e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.64	-14.92	-0.64	8.42e-39	Airflow obstruction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16211334	chr6:10695274	C6orf52;PAK1IP1	0.42	7.02	0.36	1.27e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.56	0.6	1.38e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.57	9.23	0.45	3.38e-18	Gout;
CRC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.52	8.95	0.44	2.64e-17	Acylcarnitine levels;
CRC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg01262667	chr19:19385393	TM6SF2	0.38	6.39	0.33	5.6e-10	Tonsillectomy;
CRC	cis	rs733592	0.599	rs12819124	chr12:48409054	G/T	cg15465823	chr12:48382534	COL2A1	0.37	6.3	0.33	9.66e-10	Plateletcrit;
CRC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.66	-9.52	-0.46	3.99e-19	Blood trace element (Zn levels);
CRC	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg25856811	chr1:152973957	SPRR3	-0.27	-7.35	-0.38	1.57e-12	Inflammatory skin disease;
CRC	cis	rs863345	0.604	rs11265015	chr1:158503252	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.28	-0.33	1.09e-9	Pneumococcal bacteremia;
CRC	cis	rs6662572	0.737	rs11587648	chr1:46585418	G/A	cg08644498	chr1:46502608	NA	0.43	7.01	0.36	1.32e-11	Blood protein levels;
CRC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.69	10.28	0.49	1.13e-21	Tonometry;
CRC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.4	-6.69	-0.35	9.55e-11	Prostate cancer;
CRC	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.61	-6.72	-0.35	8e-11	Osteoarthritis;
CRC	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.67	11.04	0.52	2.64e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3790455	0.610	rs1185700	chr1:156450719	G/A	cg14087168	chr1:156450669	MEF2D	-0.38	-6.56	-0.34	2.06e-10	Migraine;
CRC	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	7.91	0.4	4.01e-14	Response to antipsychotic treatment;
CRC	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg03340356	chr1:67600835	NA	0.29	6.44	0.33	4.34e-10	Psoriasis;
CRC	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.34	-0.33	7.79e-10	Breast cancer;
CRC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg10431340	chr1:161279108	MPZ	0.56	7.28	0.37	2.52e-12	Rheumatoid arthritis;
CRC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.75	-14.78	-0.63	2.78e-38	Prostate cancer;
CRC	cis	rs449789	0.857	rs579533	chr6:159715203	C/T	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.44	-6.71	-0.35	8.56e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03758392	chr3:184870408	C3orf70	0.43	6.13	0.32	2.46e-9	Response to antipsychotic treatment;
CRC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.64	10.92	0.52	7.04e-24	Resting heart rate;
CRC	cis	rs7259376	0.936	rs11085524	chr19:22536422	G/C	cg02657401	chr19:22469223	NA	-0.33	-7.46	-0.38	7.6e-13	Menopause (age at onset);
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg12172441	chr6:28176163	NA	0.52	7.26	0.37	2.77e-12	Parkinson's disease;
CRC	trans	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg21153622	chr11:89784906	NA	-0.48	-7.67	-0.39	1.95e-13	HDL cholesterol;
CRC	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.76	7.63	0.39	2.48e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.75	-0.47	6.59e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs4728142	0.604	rs6969930	chr7:128630313	T/C	cg06630958	chr7:128577819	IRF5	-0.35	-5.65	-0.3	3.39e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs59104589	0.550	rs12612038	chr2:242369685	A/G	cg19488206	chr2:242435732	STK25	0.48	7.05	0.36	1.04e-11	Fibrinogen levels;
CRC	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.66	-10.78	-0.51	2.04e-23	Hepatocellular carcinoma;
CRC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.29	-0.53	3.37e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg13390004	chr1:15929781	NA	0.52	7.28	0.37	2.49e-12	Systolic blood pressure;
CRC	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-5.72	-0.3	2.46e-8	Height;
CRC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg24905316	chr10:135186343	ECHS1	0.74	6.63	0.34	1.37e-10	Lifespan;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24786579	chr12:32832461	DNM1L	0.45	6.23	0.32	1.41e-9	Anxiety disorder;
CRC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-1.27	-12.38	-0.56	3.83e-29	Acne (severe);
CRC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.73	9.49	0.46	4.87e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2084637	0.965	rs12223035	chr11:122410565	G/C	cg21585512	chr11:122030076	LOC399959	-0.38	-6.73	-0.35	7.6e-11	Stroke;
CRC	cis	rs910187	0.571	rs3746490	chr20:45801712	G/A	cg27589058	chr20:45804311	EYA2	-0.44	-8.54	-0.43	5.18e-16	Migraine;
CRC	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.13	-0.37	6.35e-12	Triglycerides;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.38	-5.93	-0.31	7.46e-9	Endometrial cancer;
CRC	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg05507819	chr15:63340323	TPM1	0.47	5.97	0.31	6.31e-9	HDL cholesterol;
CRC	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg08896387	chr1:24191740	FUCA1	0.45	5.67	0.3	3.18e-8	Immature fraction of reticulocytes;
CRC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.77	-13.4	-0.59	5.84e-33	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3736485	0.966	rs8042840	chr15:51908498	C/T	cg08986416	chr15:51914746	DMXL2	-0.49	-6.93	-0.36	2.23e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.52	-9.44	-0.46	7.16e-19	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.58	9.1	0.45	9.09e-18	Aortic root size;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12172441	chr6:28176163	NA	0.65	8.59	0.43	3.46e-16	Depression;
CRC	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.34	-0.42	2.08e-15	Waist circumference adjusted for body mass index;
CRC	cis	rs7487075	0.859	rs7974529	chr12:46751388	A/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.76	0.35	6.13e-11	Itch intensity from mosquito bite;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01802975	chr1:67519155	SLC35D1	0.37	6.04	0.32	4.25e-9	Obesity-related traits;
CRC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.93	0.4	3.53e-14	Aortic root size;
CRC	cis	rs7215564	0.908	rs2873060	chr17:78663497	A/C	cg09596252	chr17:78655493	RPTOR	0.54	6.08	0.32	3.26e-9	Myopia (pathological);
CRC	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.58	-8.86	-0.44	5.15e-17	Schizophrenia;
CRC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.36	5.85	0.31	1.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.59	-11.92	-0.55	1.83e-27	Schizophrenia;
CRC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.63	11.1	0.52	1.59e-24	Schizophrenia;
CRC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.87	0.31	1.07e-8	Homoarginine levels;
CRC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg25173405	chr17:45401733	C17orf57	0.41	6.3	0.33	9.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg10263370	chr3:44754102	ZNF502	-0.36	-6.05	-0.32	3.97e-9	Depressive symptoms;
CRC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.05	0.32	3.93e-9	Hemoglobin concentration;
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.99	-0.44	2.05e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.67	8.83	0.44	6.26e-17	Morning vs. evening chronotype;
CRC	cis	rs16867321	0.806	rs1453060	chr2:181330763	C/A	cg23363182	chr2:181467187	NA	-0.51	-5.93	-0.31	7.64e-9	Obesity;
CRC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.12	-0.45	7.52e-18	Mean corpuscular hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04691425	chr12:96252524	SNRPF	0.49	6.88	0.35	2.95e-11	Response to antipsychotic treatment;
CRC	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	7.15	0.37	5.82e-12	Blood protein levels;
CRC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.63	0.3	3.86e-8	Bladder cancer;
CRC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg25204440	chr1:209979598	IRF6	0.48	5.77	0.3	1.82e-8	Cleft lip with or without cleft palate;
CRC	cis	rs863345	0.647	rs923663	chr1:158507732	A/T	cg12129480	chr1:158549410	OR10X1	0.3	6.27	0.33	1.13e-9	Pneumococcal bacteremia;
CRC	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.99	0.48	1.07e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.51	6.28	0.33	1.1e-9	Vitiligo;
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg09877947	chr5:131593287	PDLIM4	0.36	6.59	0.34	1.71e-10	Blood metabolite levels;
CRC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.55	-0.75	6.02e-61	Height;
CRC	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.44	-6.84	-0.35	3.81e-11	Asthma;
CRC	cis	rs7301826	0.651	rs10848210	chr12:131312020	G/A	cg11011512	chr12:131303247	STX2	0.38	5.7	0.3	2.69e-8	Plasma plasminogen activator levels;
CRC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg06470822	chr6:28175283	NA	0.45	5.98	0.31	5.71e-9	Myopia;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	1.06	10.83	0.51	1.44e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.4	-6.97	-0.36	1.75e-11	Hip circumference;Waist circumference;
CRC	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.77	14.78	0.63	2.79e-38	Itch intensity from mosquito bite;
CRC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.8	-0.3	1.59e-8	Heart rate;
CRC	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg02258303	chr16:87377426	FBXO31	-0.53	-8.18	-0.41	6.43e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.67e-19	Migraine;Coronary artery disease;
CRC	trans	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25373372	chr6:82462656	FAM46A	-0.39	-6.09	-0.32	3.24e-9	Obesity-related traits;
CRC	cis	rs7605827	0.729	rs35131126	chr2:15537730	A/G	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.59	8.65	0.43	2.26e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg24289452	chr6:170231220	NA	-0.57	-6.21	-0.32	1.6e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.81	12.99	0.58	1.94e-31	Menarche (age at onset);
CRC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.47	-0.38	7.3e-13	Hemoglobin concentration;
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.67	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs2067615	0.899	rs4964188	chr12:107100717	T/C	cg13491945	chr12:107078410	RFX4	0.33	5.62	0.3	4.18e-8	Heart rate;
CRC	cis	rs3812762	0.912	rs4929936	chr11:8792622	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-5.93	-0.31	7.57e-9	Hypospadias;
CRC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.9	0.44	3.83e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg03877680	chr5:178157825	ZNF354A	0.8	11.39	0.53	1.43e-25	Neutrophil percentage of white cells;
CRC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.51	-9.28	-0.46	2.3e-18	Intelligence (multi-trait analysis);
CRC	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.07	-0.36	9.09e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.75	10.86	0.51	1.08e-23	Longevity;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.7	0.35	8.98e-11	Subjective well-being;
CRC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.5	8.22	0.41	4.87e-15	Coronary artery disease;
CRC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.4	5.66	0.3	3.36e-8	Aortic root size;
CRC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg01849466	chr14:104193079	ZFYVE21	0.44	6.9	0.36	2.71e-11	Body mass index;
CRC	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg03689076	chr20:33865952	NA	0.43	6.02	0.32	4.62e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.47	-9.3	-0.46	2.02e-18	Renal cell carcinoma;
CRC	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg03929089	chr4:120376271	NA	0.52	7.04	0.36	1.1e-11	Intraocular pressure;
CRC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.85	0.66	1.93e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08724901	chr15:89089781	DET1	0.47	6.09	0.32	3.14e-9	Thyroid stimulating hormone;
CRC	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.81	-0.31	1.45e-8	Tuberculosis;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	1.03	19.83	0.74	3.98e-58	Menarche (age at onset);
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24739457	chr1:205821442	NA	-0.38	-5.71	-0.3	2.58e-8	Menarche (age at onset);
CRC	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.6	8.61	0.43	3.08e-16	Coronary artery disease;
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.46	0.53	8.44e-26	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01250046	chr11:6704297	MRPL17	0.52	7.47	0.38	7.08e-13	Response to antipsychotic treatment;
CRC	trans	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg21153622	chr11:89784906	NA	-0.42	-6.57	-0.34	1.97e-10	HDL cholesterol;
CRC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.82	-0.31	1.39e-8	Ulcerative colitis;
CRC	cis	rs12760731	0.720	rs6702625	chr1:178339206	G/A	cg00404053	chr1:178313656	RASAL2	0.85	10.34	0.5	6.68e-22	Obesity-related traits;
CRC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg03013999	chr17:37608204	MED1	0.47	7.15	0.37	5.71e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.16	-0.49	2.82e-21	Height;
CRC	cis	rs2302190	0.882	rs11650105	chr17:56588072	C/T	cg25885038	chr17:56607967	SEPT4	-0.53	-8.17	-0.41	6.75e-15	Vitamin D levels;
CRC	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.64	0.34	1.32e-10	Homocysteine levels;
CRC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.4	6.08	0.32	3.37e-9	Hemoglobin concentration;
CRC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.9	0.48	2.16e-20	Cognitive test performance;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07131166	chr7:138089188	NA	-0.42	-7.1	-0.36	7.77e-12	Obesity-related traits;
CRC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	6.53	0.34	2.55e-10	Platelet count;
CRC	cis	rs2252521	0.689	rs989851	chr7:29081849	G/C	cg11728747	chr7:29037910	CPVL	-0.33	-6.16	-0.32	2.12e-9	Cognitive performance;
CRC	cis	rs9549328	0.670	rs2993344	chr13:113617022	C/T	cg20742385	chr13:113633654	MCF2L	0.56	9.56	0.47	2.94e-19	Systolic blood pressure;
CRC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.66	7.37	0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-1.2	-11.23	-0.53	5.58e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs863345	0.526	rs857718	chr1:158595142	T/A	cg12129480	chr1:158549410	OR10X1	-0.29	-6.31	-0.33	8.95e-10	Pneumococcal bacteremia;
CRC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.78	-0.3	1.74e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7209700	0.662	rs8074094	chr17:45348021	T/C	cg08085267	chr17:45401833	C17orf57	0.44	5.97	0.31	6.01e-9	IgG glycosylation;
CRC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.69e-12	Obesity-related traits;
CRC	cis	rs12431939	0.626	rs7350715	chr14:51717060	C/A	cg23942311	chr14:51606299	NA	0.54	6.95	0.36	1.93e-11	Cancer;
CRC	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.79	10.97	0.52	4.35e-24	Obesity;Body mass index;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10902427	chr5:176944034	DDX41	0.38	6.14	0.32	2.4e-9	Interleukin-6 levels;
CRC	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg14711859	chr11:8959438	ASCL3	0.38	6.4	0.33	5.21e-10	Hemoglobin concentration;
CRC	cis	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg10589385	chr1:150898437	SETDB1	0.32	6.87	0.35	3.16e-11	Melanoma;
CRC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.61	-9.35	-0.46	1.35e-18	Aortic root size;
CRC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.84	-0.35	3.78e-11	Bipolar disorder;
CRC	cis	rs11574514	1.000	rs8058835	chr16:67814865	C/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.04	-0.32	4.14e-9	Crohn's disease;
CRC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.77	10.32	0.49	7.81e-22	Initial pursuit acceleration;
CRC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg19338460	chr6:170058176	WDR27	-0.71	-7.8	-0.4	8.04e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.69	-0.39	1.76e-13	Cystic fibrosis severity;
CRC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.59	8.07	0.41	1.32e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-7.82	-0.4	7.25e-14	Vitamin D levels;
CRC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg20159608	chr7:32802032	NA	-0.51	-5.92	-0.31	8.19e-9	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg01721255	chr8:58191610	C8orf71	0.49	6.07	0.32	3.59e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.05	-0.32	3.87e-9	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04295991	chr13:21348012	N6AMT2	0.53	6.79	0.35	5.31e-11	Thyroid stimulating hormone;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg18301423	chr5:131593218	PDLIM4	0.38	6.39	0.33	5.7e-10	Acylcarnitine levels;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg02033258	chr5:131593261	PDLIM4	0.38	6.47	0.34	3.5e-10	Blood metabolite levels;
CRC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.95	0.44	2.57e-17	Bladder cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20733500	chr12:89747474	DUSP6	0.39	5.99	0.31	5.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10924970	1.000	rs10157739	chr1:235354555	C/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.97	0.31	6.28e-9	Asthma;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg11843238	chr5:131593191	PDLIM4	-0.41	-7.06	-0.36	1.01e-11	Breast cancer;
CRC	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.53	7.95	0.4	2.94e-14	Breast size;
CRC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.04	10.15	0.49	2.97e-21	Lymphocyte counts;
CRC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.53	9.21	0.45	4.05e-18	Huntington's disease progression;
CRC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.75	10.44	0.5	3.06e-22	Heart rate;
CRC	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs457287	0.772	rs17718266	chr9:4827541	T/C	cg14182974	chr9:4791918	RCL1	-0.42	-5.77	-0.3	1.79e-8	Platelet count;
CRC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg10298567	chr3:47292165	KIF9	-0.44	-7.03	-0.36	1.19e-11	Colorectal cancer;
CRC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	6.07	0.32	3.45e-9	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03570976	chr16:66968476	FAM96B;CES2	0.43	6.25	0.33	1.25e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.56	0.5	1.25e-22	Corneal astigmatism;
CRC	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.87	-0.48	2.65e-20	Hip circumference adjusted for BMI;
CRC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-9.9	-0.48	2.07e-20	Personality dimensions;
CRC	cis	rs6741819	1.000	rs6741819	chr2:7147973	A/G	cg27144453	chr2:7172511	RNF144A	0.42	6.23	0.32	1.41e-9	Response to antipsychotic treatment;
CRC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-8.35	-0.42	1.95e-15	Coronary artery disease;
CRC	trans	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.95	-0.36	1.98e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.88	0.4	4.94e-14	Corneal astigmatism;
CRC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.64	-11.47	-0.53	7.77e-26	Bone mineral density;
CRC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg17652424	chr22:38574118	PLA2G6	0.21	6.25	0.33	1.28e-9	Cutaneous nevi;
CRC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.64	-9.52	-0.46	4.01e-19	Lung cancer;
CRC	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.02	-0.32	4.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg12365402	chr11:9010492	NRIP3	-0.51	-9.01	-0.44	1.76e-17	Hemoglobin concentration;
CRC	cis	rs4664293	0.647	rs357022	chr2:160489444	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.74	-0.35	7.15e-11	Monocyte percentage of white cells;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.62	-0.39	2.68e-13	Total body bone mineral density;
CRC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.48	6.49	0.34	3.15e-10	IgG glycosylation;
CRC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.68	6.55	0.34	2.22e-10	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18222961	chr2:48009935	MSH6	0.39	6.23	0.32	1.4e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6499255	0.951	rs60472033	chr16:69677709	A/G	cg15192750	chr16:69999425	NA	0.57	7.65	0.39	2.24e-13	IgE levels;
CRC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	7.26	0.37	2.84e-12	Schizophrenia;
CRC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.79	13.36	0.59	8e-33	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.42	6.29	0.33	9.97e-10	Obesity-related traits;
CRC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00815214	chr21:47717953	NA	-0.33	-5.6	-0.3	4.49e-8	Testicular germ cell tumor;
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1971762	0.545	rs10876466	chr12:53981426	G/C	cg06632207	chr12:54070931	ATP5G2	0.39	6.47	0.34	3.47e-10	Height;
CRC	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.42	5.91	0.31	8.76e-9	Leprosy;
CRC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	6.63	0.34	1.37e-10	Mean platelet volume;
CRC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	9.41	0.46	9.17e-19	Body mass index (adult);
CRC	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-8.41	-0.42	1.25e-15	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.48	6.58	0.34	1.87e-10	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15051221	chr5:177434457	FAM153C	-0.35	-6.22	-0.32	1.47e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.91	-0.4	3.91e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.47	-6.87	-0.35	3.15e-11	Height;
CRC	trans	rs67073037	0.955	rs12611829	chr2:29144456	T/C	cg13899017	chr1:159158444	CADM3	-0.36	-6.09	-0.32	3.16e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs2062225	1.000	rs6733497	chr2:111773488	A/G	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs3812049	0.532	rs251389	chr5:127541877	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	8.23	0.41	4.37e-15	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs4400599	0.608	rs4845609	chr1:154181954	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.65	-0.3	3.48e-8	Platelet distribution width;
CRC	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg19875535	chr5:140030758	IK	0.39	6.0	0.31	5.23e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs1326986	0.702	rs7910815	chr10:19832047	C/G	cg27614309	chr16:85478580	NA	-0.46	-6.14	-0.32	2.37e-9	Ankylosing spondylitis;
CRC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg23957660	chr17:17878224	LRRC48	-0.41	-7.15	-0.37	5.65e-12	Total body bone mineral density;
CRC	cis	rs13144136	0.664	rs17267821	chr4:10653402	A/G	cg10242279	chr4:10666415	CLNK	-0.37	-6.32	-0.33	8.56e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-6.07	-0.32	3.54e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs427941	0.632	rs201522	chr7:101771546	C/T	cg06246474	chr7:101738831	CUX1	0.38	5.87	0.31	1.08e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-17.74	-0.7	7.17e-50	Coronary artery disease;
CRC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.48	6.9	0.36	2.68e-11	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25671651	chr2:203776787	ALS2CR8;WDR12	0.45	6.63	0.34	1.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.73	11.32	0.53	2.67e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.88	-13.83	-0.61	1.3600000000000001e-34	Intelligence (multi-trait analysis);
CRC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.68	-10.64	-0.51	6.3e-23	Huntington's disease progression;
CRC	trans	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-7.44	-0.38	8.69e-13	Menarche (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03894033	chr22:20850168	KLHL22	-0.42	-6.32	-0.33	8.72e-10	Myopia (pathological);
CRC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.75	0.7	6.43e-50	Platelet count;
CRC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg20684491	chr1:25596433	NA	0.45	7.96	0.4	2.75e-14	Erythrocyte sedimentation rate;
CRC	cis	rs5751901	0.929	rs2330805	chr22:24998619	A/G	cg15363607	chr22:24998974	GGT1	-0.42	-6.72	-0.35	7.86e-11	Protein quantitative trait loci;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13904018	chr4:1340886	KIAA1530	0.43	6.0	0.31	5.23e-9	Anxiety disorder;
CRC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.79	-12.13	-0.56	3.16e-28	Cognitive function;
CRC	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.54	6.86	0.35	3.46e-11	Systolic blood pressure;
CRC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.55	-10.33	-0.49	7.58e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs13315871	1.000	rs3196769	chr3:58409361	A/T	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	trans	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg10756647	chr7:56101905	PSPH	0.67	7.06	0.36	9.88e-12	Diabetic kidney disease;
CRC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.54	-9.61	-0.47	2.02e-19	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg08075719	chr14:103021372	NA	-0.69	-9.18	-0.45	4.94e-18	Platelet count;
CRC	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	12.25	0.56	1.07e-28	Coffee consumption (cups per day);
CRC	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.65	11.68	0.54	1.34e-26	Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08925066	chr14:39572669	SEC23A	0.39	6.55	0.34	2.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.89	0.4	4.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg24505167	chr7:1915268	MAD1L1	-0.47	-6.17	-0.32	2e-9	Bipolar disorder;
CRC	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.4	-6.63	-0.34	1.34e-10	Mean arterial pressure;
CRC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13198984	chr17:80129470	CCDC57	0.45	7.89	0.4	4.46e-14	Life satisfaction;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg16606324	chr3:10149918	C3orf24	0.6	8.18	0.41	6.05e-15	Alzheimer's disease;
CRC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg21625146	chr5:486483	SLC9A3	0.37	5.69	0.3	2.86e-8	Cystic fibrosis severity;
CRC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.72	-8.16	-0.41	7.16e-15	Obesity-related traits;
CRC	cis	rs7707921	0.958	rs4703870	chr5:81492643	G/A	cg17942617	chr5:81327376	ATG10	-0.4	-6.02	-0.32	4.6e-9	Breast cancer;
CRC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.73	10.46	0.5	2.7e-22	Height;
CRC	trans	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg18335740	chr13:41363409	SLC25A15	0.53	7.91	0.4	3.86e-14	Lewy body disease;
CRC	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg07168214	chr17:7380112	ZBTB4	-0.4	-5.77	-0.3	1.82e-8	Androgen levels;
CRC	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.13	0.32	2.45e-9	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09813219	chr15:38365138	NA	0.39	6.26	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg15654264	chr1:150340011	RPRD2	0.43	6.48	0.34	3.27e-10	Migraine;
CRC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg18232548	chr7:50535776	DDC	-0.43	-6.0	-0.31	5.35e-9	Systemic sclerosis;
CRC	cis	rs1158570	0.500	rs2791342	chr8:131314429	C/T	cg21674704	chr8:131455249	NA	0.39	5.94	0.31	7.15e-9	Platelet count;
CRC	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.98	-19.23	-0.73	8.84e-56	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.02	9.71	0.47	9.35e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
CRC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.96	0.31	6.49e-9	Tonsillectomy;
CRC	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg23425280	chr12:56401806	NA	0.46	5.65	0.3	3.39e-8	Cancer;
CRC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-10.31	-0.49	8.47e-22	Neuroticism;
CRC	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg00919237	chr7:87102261	ABCB4	-0.55	-7.24	-0.37	3.16e-12	Gallbladder cancer;
CRC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.53	-7.93	-0.4	3.45e-14	Height;
CRC	trans	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg12726277	chr7:973190	ADAP1	-0.4	-6.21	-0.32	1.61e-9	Systemic lupus erythematosus;
CRC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	11.31	0.53	2.93e-25	Neutrophil percentage of white cells;
CRC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.44	-0.46	7.08e-19	Total cholesterol levels;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-8.69	-0.43	1.72e-16	Blood pressure (smoking interaction);
CRC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg15147215	chr3:52552868	STAB1	0.38	5.81	0.31	1.44e-8	Schizophrenia;
CRC	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg15123519	chr2:136567270	LCT	0.34	6.57	0.34	1.94e-10	Mosquito bite size;
CRC	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.39	-0.46	1.02e-18	Prevalent atrial fibrillation;
CRC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.2	-0.41	5.41e-15	Hip circumference adjusted for BMI;
CRC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.53	-0.38	4.86e-13	Chronic sinus infection;
CRC	cis	rs7712401	0.791	rs9327279	chr5:122122160	T/G	cg18764291	chr5:122110994	SNX2	0.42	6.87	0.35	3.17e-11	Mean platelet volume;
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg04518342	chr5:131593106	PDLIM4	0.45	8.39	0.42	1.4e-15	Breast cancer;
CRC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.9	10.55	0.5	1.36e-22	Psoriasis;
CRC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg04990556	chr1:26633338	UBXN11	-0.48	-6.19	-0.32	1.74e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.49	7.1	0.36	7.66e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg03609598	chr5:56110824	MAP3K1	0.59	7.96	0.4	2.85e-14	Initial pursuit acceleration;
CRC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.55	8.52	0.43	5.79e-16	Aortic root size;
CRC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg11262906	chr1:85462892	MCOLN2	0.54	6.65	0.34	1.19e-10	Serum sulfate level;
CRC	cis	rs9287719	0.649	rs10198971	chr2:10718699	G/C	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	1.01e-11	Prostate cancer;
CRC	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.99	-0.4	2.36e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.19	-15.3	-0.64	2.73e-40	Breast cancer;
CRC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.38	-5.83	-0.31	1.33e-8	Mean corpuscular volume;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.83	-0.35	3.99e-11	Bipolar disorder;
CRC	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.55	8.82	0.44	7.01e-17	Mean corpuscular volume;
CRC	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-6.82	-0.35	4.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.59	0.54	2.85e-26	Menarche (age at onset);
CRC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg07195577	chr17:27052828	TLCD1	0.38	5.65	0.3	3.53e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	trans	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg06206626	chr22:26825900	ASPHD2	0.41	5.98	0.31	5.82e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25355226	chr3:150320980	SELT	0.56	8.24	0.41	4.01e-15	Response to antipsychotic treatment;
CRC	cis	rs8177179	0.503	rs9985395	chr3:133413119	A/G	cg24879335	chr3:133465180	TF	-0.32	-6.02	-0.31	4.72e-9	Iron status biomarkers (transferrin levels);
CRC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.71	12.72	0.57	2.06e-30	Prostate cancer;
CRC	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg23254163	chr1:152506842	NA	-0.4	-8.05	-0.41	1.57e-14	Hair morphology;
CRC	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg09476006	chr5:138032270	NA	0.42	6.32	0.33	8.53e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.59	6.76	0.35	6.28e-11	Coronary artery disease;
CRC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.5	7.14	0.37	6.16e-12	Aortic root size;
CRC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.81	10.57	0.5	1.1e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg21951975	chr1:209979733	IRF6	0.49	6.64	0.34	1.3100000000000001e-10	Cleft lip with or without cleft palate;
CRC	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.6	8.71	0.43	1.5e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg26043149	chr18:55253948	FECH	0.55	8.65	0.43	2.37e-16	Bone mineral density;
CRC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs526821	0.553	rs295597	chr11:55470003	T/C	cg04317927	chr11:55418816	OR4S2	0.41	6.77	0.35	6.09e-11	Pediatric bone mineral density (spine);
CRC	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg20628663	chr10:43360327	NA	0.72	7.32	0.37	1.93e-12	Pediatric bone mineral content (radius);
CRC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg03732007	chr1:2071316	PRKCZ	-0.36	-5.69	-0.3	2.77e-8	Height;
CRC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.39	-5.65	-0.3	3.45e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.59	-8.72	-0.43	1.43e-16	Diastolic blood pressure;
CRC	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg09066997	chr16:75300724	BCAR1	0.69	6.8	0.35	4.96e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg05861140	chr6:150128134	PCMT1	-0.39	-6.39	-0.33	5.67e-10	Lung cancer;
CRC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg18764771	chr6:116381957	FRK	0.24	6.96	0.36	1.81e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.79	10.82	0.51	1.57e-23	IgG glycosylation;
CRC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs7212590	1.000	rs73315284	chr17:57884868	A/G	cg10252138	chr17:58120427	NA	-0.54	-5.73	-0.3	2.32e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.63	10.45	0.5	2.8e-22	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg14664628	chr15:75095509	CSK	0.41	6.0	0.31	5.14e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg09127314	chr1:152161683	NA	0.52	6.62	0.34	1.5e-10	Atopic dermatitis;
CRC	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg14515779	chr1:101123966	NA	0.38	6.91	0.36	2.57e-11	Monocyte count;
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg10729496	chr3:10149963	C3orf24	-0.51	-6.81	-0.35	4.73e-11	Alzheimer's disease;
CRC	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.45	-7.32	-0.37	1.87e-12	Lung function (FVC);
CRC	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.38	-6.42	-0.33	4.66e-10	Obesity-related traits;
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.57	8.76	0.43	1.05e-16	Longevity;Endometriosis;
CRC	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.54	6.41	0.33	5.11e-10	Lymphocyte counts;
CRC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-11.19	-0.52	7.82e-25	Hepatocellular carcinoma;
CRC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg24675056	chr1:15929824	NA	0.5	6.81	0.35	4.53e-11	Systolic blood pressure;
CRC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.6	7.28	0.37	2.53e-12	Mean platelet volume;
CRC	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.75	-0.39	1.17e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.05	13.07	0.58	1.02e-31	Vitiligo;
CRC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-5.94	-0.31	7.16e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg27523141	chr10:43048294	ZNF37B	0.47	6.88	0.35	3.11e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg07424746	chr4:185654737	MLF1IP	0.56	5.65	0.3	3.49e-8	Blood protein levels;
CRC	cis	rs6662572	0.737	rs6673894	chr1:46301182	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.09	-0.32	3.11e-9	Blood protein levels;
CRC	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11547950	chr5:77652471	NA	-0.5	-7.19	-0.37	4.46e-12	Triglycerides;
CRC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.52	0.42	6.03e-16	Homoarginine levels;
CRC	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.63	8.43	0.42	1.11e-15	Uric acid levels;
CRC	cis	rs11625487	0.609	rs78371022	chr14:77971029	G/A	cg20045696	chr14:77926864	AHSA1	-0.72	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg18131467	chr2:239335373	ASB1	-0.7	-6.06	-0.32	3.7e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06544989	chr22:39130855	UNC84B	0.48	7.65	0.39	2.25e-13	Menopause (age at onset);
CRC	trans	rs2303319	0.582	rs72870248	chr2:162435849	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.02	-0.31	4.57e-9	Cognitive function;
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.89	-0.36	2.81e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1950626	0.577	rs61991118	chr14:101441974	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.75	12.12	0.56	3.4e-28	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.91	14.41	0.62	7.47e-37	Diastolic blood pressure;
CRC	cis	rs4237845	0.611	rs4373979	chr12:58332386	C/G	cg02175503	chr12:58329896	NA	0.79	12.42	0.56	2.73e-29	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.69	10.52	0.5	1.66e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-8.05	-0.41	1.54e-14	Hepatocellular carcinoma;
CRC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.68	-10.62	-0.51	7.54e-23	Huntington's disease progression;
CRC	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg04239558	chr2:103089729	SLC9A4	0.35	6.07	0.32	3.58e-9	Blood protein levels;
CRC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-9.0	-0.44	1.81e-17	Hemoglobin concentration;
CRC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.74	-10.07	-0.49	5.92e-21	White matter hyperintensity burden;
CRC	cis	rs1124376	0.810	rs6807771	chr3:20160634	C/A	cg05072819	chr3:20081367	KAT2B	0.5	6.03	0.32	4.46e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg03623178	chr6:28175578	NA	0.94	11.9	0.55	2.08e-27	Depression;
CRC	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.79	-0.35	5.09e-11	Coronary artery disease;
CRC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.42	6.51	0.34	2.84e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.92	-11.86	-0.55	2.95e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg27661571	chr11:113659931	NA	-0.71	-8.89	-0.44	4.22e-17	Hip circumference adjusted for BMI;
CRC	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	12.25	0.56	1.09e-28	Coffee consumption (cups per day);
CRC	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg01843034	chr6:37503916	NA	-0.4	-5.78	-0.3	1.77e-8	Cognitive performance;
CRC	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.72	7.34	0.38	1.71e-12	Inflammatory biomarkers;
CRC	cis	rs17234274	0.644	rs10833973	chr11:23220064	A/T	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.03e-8	Cancer;
CRC	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.49	-7.46	-0.38	7.7e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16714605	chr19:10765132	ILF3;LOC147727	0.39	6.81	0.35	4.55e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.51e-12	Motion sickness;
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs9287719	0.649	rs10182589	chr2:10720664	C/T	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.53e-12	Menopause (age at onset);
CRC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.46	0.34	3.88e-10	Tonsillectomy;
CRC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-8.23	-0.41	4.46e-15	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.764	rs79529820	chr10:81820529	A/T	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.81	-0.35	4.73e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19500275	chr17:80737654	TBCD	0.49	6.47	0.34	3.55e-10	Glycated hemoglobin levels;
CRC	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.4	5.94	0.31	7.16e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12430567	chr5:159848786	PTTG1	0.43	6.13	0.32	2.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg26587870	chr6:27730563	NA	-0.43	-6.77	-0.35	6.04e-11	Parkinson's disease;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg19318889	chr4:1322082	MAEA	0.41	5.98	0.31	5.74e-9	Obesity-related traits;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21956150	chr19:1438388	RPS15	0.42	6.74	0.35	6.92e-11	Obesity-related traits;
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg12516270	chr8:143859308	LYNX1	0.4	6.93	0.36	2.24e-11	Urinary tract infection frequency;
CRC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg18876405	chr7:65276391	NA	-0.45	-6.24	-0.33	1.35e-9	Aortic root size;
CRC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24308560	chr3:49941425	MST1R	0.52	8.44	0.42	1e-15	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg15786705	chr6:28176104	NA	0.67	6.41	0.33	5.07e-10	Depression;
CRC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg11212589	chr17:38028394	ZPBP2	0.42	7.64	0.39	2.4e-13	Self-reported allergy;
CRC	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.73	-8.35	-0.42	1.94e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg25985355	chr7:65971099	NA	-0.52	-6.17	-0.32	2e-9	Diabetic kidney disease;
CRC	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.34	5.74	0.3	2.19e-8	Menopause (age at onset);
CRC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.79	0.44	8.46e-17	Schizophrenia;
CRC	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg02023728	chr11:77925099	USP35	-0.36	-6.14	-0.32	2.41e-9	Alzheimer's disease (survival time);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11071762	chr1:111746640	NA	0.46	6.43	0.33	4.46e-10	Response to antipsychotic treatment;
CRC	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg06636001	chr8:8085503	FLJ10661	0.44	6.17	0.32	2.02e-9	Neuroticism;
CRC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.41	6.54	0.34	2.3e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg14458575	chr2:238380390	NA	0.43	6.22	0.32	1.51e-9	Prostate cancer;
CRC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.82	9.16	0.45	5.68e-18	Breast cancer;
CRC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg18478394	chr8:109455254	TTC35	0.38	5.73	0.3	2.33e-8	Dupuytren's disease;
CRC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-1.14	-10.98	-0.52	4.1e-24	Post bronchodilator FEV1;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	-0.28	-6.86	-0.35	3.36e-11	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16211055	chr1:228594250	TRIM11	0.5	7.14	0.37	5.91e-12	Response to antipsychotic treatment;
CRC	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg22089800	chr15:90895588	ZNF774	0.49	7.8	0.4	8.01e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.77	8.64	0.43	2.48e-16	Neuroticism;
CRC	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg08992911	chr2:238395768	MLPH	0.63	6.13	0.32	2.45e-9	Prostate cancer;
CRC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.36	7.0	0.36	1.42e-11	Renal cell carcinoma;
CRC	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.21	0.32	1.63e-9	Mean corpuscular hemoglobin concentration;
CRC	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.27	10.57	0.5	1.09e-22	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs2252521	0.614	rs317703	chr7:29087226	G/C	cg11728747	chr7:29037910	CPVL	-0.47	-6.68	-0.35	1.02e-10	Cognitive performance;
CRC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg18876405	chr7:65276391	NA	0.44	6.22	0.32	1.49e-9	Aortic root size;
CRC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-7.68	-0.39	1.83e-13	Schizophrenia;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.68	-0.35	1.01e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.88	11.35	0.53	2.1e-25	Vitiligo;
CRC	cis	rs2302190	0.882	rs12939703	chr17:56611090	G/C	cg12560992	chr17:57184187	TRIM37	0.5	5.89	0.31	9.67e-9	Vitamin D levels;
CRC	cis	rs6534441	0.727	rs7675285	chr4:125422463	G/A	cg21609808	chr4:125404261	NA	0.46	6.45	0.34	3.97e-10	Major depressive disorder;
CRC	cis	rs972578	0.837	rs1018448	chr22:43206950	A/C	cg01576275	chr22:43409880	NA	-0.4	-6.29	-0.33	1.03e-9	Mean platelet volume;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15216925	chr5:179921655	CNOT6	0.45	7.46	0.38	7.73e-13	Interleukin-6 levels;
CRC	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.52	7.71	0.39	1.49e-13	Corneal astigmatism;
CRC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg15147215	chr3:52552868	STAB1	-0.48	-6.52	-0.34	2.59e-10	Schizophrenia;
CRC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg03030879	chr14:75389066	RPS6KL1	0.39	5.94	0.31	7.3e-9	Height;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg04497992	chr16:616212	NHLRC4	0.42	6.68	0.35	9.92e-11	Height;
CRC	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.45	6.79	0.35	5.18e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	10.07	0.49	5.69e-21	Ileal carcinoids;
CRC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.48	-6.0	-0.31	5.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg09232269	chr1:207846808	CR1L	-0.48	-7.78	-0.39	9.29e-14	Erythrocyte sedimentation rate;
CRC	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg13611204	chr9:139324423	INPP5E	-0.41	-5.7	-0.3	2.63e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg13753209	chr17:57696993	CLTC	0.45	5.88	0.31	9.94e-9	Hemoglobin concentration;
CRC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.71	8.01	0.4	2.05e-14	Blood protein levels;
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg21268650	chr7:45961089	IGFBP3	0.38	6.5	0.34	2.92e-10	Sitting height ratio;
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18402987	chr7:1209562	NA	0.4	5.83	0.31	1.29e-8	Longevity;Endometriosis;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg11284414	chr2:232573146	PTMA	-0.41	-6.11	-0.32	2.77e-9	Birth weight;Height;
CRC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.48	7.24	0.37	3.13e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-6.37	-0.33	6.31e-10	Schizophrenia;
CRC	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg27205649	chr11:78285834	NARS2	0.46	5.69	0.3	2.75e-8	Alzheimer's disease (survival time);
CRC	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg11130432	chr3:121712080	ILDR1	-0.43	-5.66	-0.3	3.32e-8	Multiple sclerosis;
CRC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg21153622	chr11:89784906	NA	-0.52	-8.68	-0.43	1.92e-16	HDL cholesterol;
CRC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.42e-12	Colorectal cancer;
CRC	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.05	-0.32	3.86e-9	Breast cancer;
CRC	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.6	7.79	0.39	9.1e-14	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg06917634	chr15:78832804	PSMA4	0.45	6.6	0.34	1.63e-10	Sudden cardiac arrest;
CRC	cis	rs4666002	0.636	rs13023194	chr2:27967260	G/C	cg27432699	chr2:27873401	GPN1	0.54	6.19	0.32	1.8e-9	Phospholipid levels (plasma);
CRC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.55	-7.49	-0.38	6.41e-13	DNA methylation (variation);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15839751	chr8:146126984	ZNF250	0.42	6.29	0.33	9.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12760731	0.565	rs12034657	chr1:178099354	A/C	cg00404053	chr1:178313656	RASAL2	-0.99	-10.21	-0.49	1.97e-21	Obesity-related traits;
CRC	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg19683494	chr5:74908142	NA	0.49	6.26	0.33	1.23e-9	Age-related disease endophenotypes;
CRC	cis	rs17155006	0.746	rs425623	chr7:107747465	C/T	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg24046110	chr8:143859143	LYNX1	-0.43	-6.9	-0.36	2.67e-11	Urinary tract infection frequency;
CRC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.98	0.31	5.9e-9	Diabetic retinopathy;
CRC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.58	7.91	0.4	4.06e-14	Lung cancer;
CRC	trans	rs728616	0.681	rs36023925	chr10:81906846	T/C	cg18543242	chr14:23290393	SLC7A7	0.45	6.08	0.32	3.29e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.51	7.19	0.37	4.25e-12	Melanoma;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23161317	chr6:28129485	ZNF389	0.44	5.76	0.3	1.96e-8	Parkinson's disease;
CRC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg06238570	chr21:40685208	BRWD1	0.76	10.24	0.49	1.53e-21	Cognitive function;
CRC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.79	-0.75	6.66e-62	Height;
CRC	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg03623178	chr6:28175578	NA	0.76	6.07	0.32	3.43e-9	Depression;
CRC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.57	-0.39	3.77e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg01448155	chr10:3564782	NA	-0.5	-6.03	-0.32	4.43e-9	Lymphocyte percentage of white cells;
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.54	-7.03	-0.36	1.19e-11	Blood pressure (smoking interaction);
CRC	cis	rs2274471	0.678	rs7867965	chr9:5104574	G/T	cg03390472	chr9:5043263	JAK2	-0.54	-6.29	-0.33	9.83e-10	Crohn's disease;
CRC	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.59	7.19	0.37	4.35e-12	Alzheimer's disease;
CRC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs73206853	0.925	rs61106808	chr12:110876009	C/G	cg12870014	chr12:110450643	ANKRD13A	0.71	8.83	0.44	6.5e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.7	-0.39	1.56e-13	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-8.65	-0.43	2.35e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.08	-0.36	8.58e-12	Pulmonary function;
CRC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.14	25.38	0.81	1.74e-79	IgG glycosylation;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.48	6.7	0.35	9.11e-11	Menarche (age at onset);
CRC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg22676075	chr6:135203613	NA	0.41	6.3	0.33	9.69e-10	Red blood cell count;
CRC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs8099014	1.000	rs11152073	chr18:56108266	A/T	cg12907477	chr18:56117327	MIR122	0.41	5.97	0.31	6.04e-9	Platelet count;
CRC	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.4	-6.18	-0.32	1.93e-9	Endometrial cancer;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26089074	chr17:17184578	COPS3	-0.35	-5.98	-0.31	5.91e-9	Obesity-related traits;
CRC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg23018236	chr17:30244563	NA	-0.65	-7.78	-0.39	9.41e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1178968	1.000	rs12534600	chr7:72762721	C/T	cg25889504	chr7:72793014	NA	-0.54	-6.12	-0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs2257205	0.667	rs9899893	chr17:56754597	T/C	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.87e-8	Pancreatic cancer;
CRC	cis	rs910873	0.505	rs6059969	chr20:33245284	T/C	cg08999081	chr20:33150536	PIGU	0.49	6.04	0.32	4.21e-9	Melanoma;
CRC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg15448220	chr1:150897856	SETDB1	0.49	6.99	0.36	1.53e-11	Tonsillectomy;
CRC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.48	8.47	0.42	8.52e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.49e-16	Metabolite levels (small molecules and protein measures);
CRC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.83	-0.35	4.05e-11	Mean corpuscular volume;
CRC	cis	rs9992667	1.000	rs9992667	chr4:38680186	C/T	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.0	-0.44	1.79e-17	Eosinophil percentage of granulocytes;
CRC	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg02475695	chr16:616220	NHLRC4	0.46	7.54	0.38	4.54e-13	Height;
CRC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17507749	chr15:85114479	UBE2QP1	0.6	8.47	0.42	8.24e-16	Schizophrenia;
CRC	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.48	6.74	0.35	7.26e-11	Corneal astigmatism;
CRC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.64	-0.3	3.72e-8	Colorectal cancer;
CRC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.54	-8.07	-0.41	1.37e-14	Facial morphology (factor 23);
CRC	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg05754148	chr16:3507555	NAT15	-0.65	-5.69	-0.3	2.79e-8	Tuberculosis;
CRC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.82e-9	Gut microbiome composition (summer);
CRC	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.05	-0.36	1.08e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs860295	0.702	rs2025669	chr1:155357609	G/A	cg02153340	chr1:155202674	NA	-0.57	-6.77	-0.35	5.96e-11	Body mass index;
CRC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.71	10.06	0.49	6.12e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.71	-9.2	-0.45	4.39e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.76	-10.63	-0.51	7.01e-23	Vitiligo;
CRC	trans	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg17903999	chr18:56338584	MALT1	0.41	6.68	0.35	1.05e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.51	-7.73	-0.39	1.36e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.57	-8.73	-0.43	1.27e-16	Height;
CRC	cis	rs4750440	0.614	rs898718	chr10:14027235	C/T	cg00551146	chr10:14014579	FRMD4A	0.44	7.09	0.36	8.28e-12	Adiponectin levels;
CRC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.24	-16.13	-0.66	1.57e-43	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12793864	chr3:14693121	C3orf19	0.44	6.11	0.32	2.81e-9	Response to antipsychotic treatment;
CRC	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.58	8.5	0.42	6.79e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	0.87	10.45	0.5	2.96e-22	Left atrial antero-posterior diameter;
CRC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.64	-9.34	-0.46	1.53e-18	Lung cancer;
CRC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.61	10.75	0.51	2.65e-23	Aortic root size;
CRC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg18016565	chr1:150552671	MCL1	0.44	6.17	0.32	2.03e-9	Melanoma;
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.18	-0.32	1.9e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06156847	chr2:113672199	IL1F7	-0.45	-6.78	-0.35	5.59e-11	Pulmonary function;
CRC	trans	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg26043149	chr18:55253948	FECH	-0.48	-7.44	-0.38	8.74e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.06	-12.41	-0.56	2.93e-29	Diabetic kidney disease;
CRC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.69	-8.55	-0.43	4.81e-16	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg06470822	chr6:28175283	NA	-0.63	-6.25	-0.33	1.24e-9	Depression;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg15511327	chr8:143859410	LYNX1	0.42	7.01	0.36	1.34e-11	Urinary tract infection frequency;
CRC	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg05784532	chr1:230284198	GALNT2	0.43	6.01	0.31	4.79e-9	Coronary artery disease;
CRC	cis	rs7487075	0.930	rs12814298	chr12:46837624	T/G	cg22049899	chr12:47219821	SLC38A4	0.31	6.11	0.32	2.83e-9	Itch intensity from mosquito bite;
CRC	trans	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg18187862	chr3:45730750	SACM1L	0.46	6.62	0.34	1.43e-10	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13361393	chr22:24114971	MMP11	0.4	6.77	0.35	5.9e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.44	-6.11	-0.32	2.75e-9	Height;
CRC	trans	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06834434	chr14:75079333	LTBP2	0.55	6.83	0.35	4.23e-11	Obesity-related traits;
CRC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.63	-0.3	3.92e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.67	-10.85	-0.51	1.19e-23	Sudden cardiac arrest;
CRC	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.29	6.04	0.32	4.1e-9	Height;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg14911242	chr14:105892412	MTA1	-0.55	-6.41	-0.33	4.9e-10	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13896783	chr2:159313876	CCDC148;PKP4	0.43	7.0	0.36	1.42e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.74	-0.35	7.09e-11	Response to antipsychotic treatment;
CRC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.95	18.04	0.71	4.61e-51	Intelligence (multi-trait analysis);
CRC	cis	rs800160	0.777	rs2521283	chr11:2341572	A/G	cg09785033	chr11:2336066	TSPAN32	-0.47	-5.7	-0.3	2.62e-8	Bacteremia;
CRC	cis	rs2742417	1.000	rs1877933	chr3:45753487	C/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.64	-0.3	3.76e-8	Lung cancer;
CRC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.53	0.47	3.56e-19	Colorectal cancer;
CRC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg02094049	chr14:103021097	NA	-0.53	-6.86	-0.35	3.49e-11	Platelet count;
CRC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.68	-0.35	1.03e-10	Aortic root size;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-0.57	-7.96	-0.4	2.76e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25517755	chr10:38738941	LOC399744	-0.45	-6.49	-0.34	3.24e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg12172441	chr6:28176163	NA	0.46	6.5	0.34	2.97e-10	Cardiac Troponin-T levels;
CRC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06544989	chr22:39130855	UNC84B	0.46	7.32	0.37	1.97e-12	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.64	-0.3	3.64e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg21153622	chr11:89784906	NA	0.42	7.02	0.36	1.31e-11	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg09264619	chr17:80180166	NA	-0.36	-5.99	-0.31	5.64e-9	Life satisfaction;
CRC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-12.58	-0.57	6.96e-30	Body mass index;
CRC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.47	-7.46	-0.38	7.77e-13	Ankle injury;
CRC	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.41	-0.42	1.28e-15	Coronary artery disease;
CRC	cis	rs7781557	1.000	rs10487284	chr7:102470275	G/A	cg18108683	chr7:102477205	FBXL13	-0.51	-6.65	-0.34	1.21e-10	Colorectal adenoma (advanced);
CRC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12699921	0.599	rs2723554	chr7:17841652	C/T	cg02066331	chr6:17282778	RBM24	-0.35	-5.96	-0.31	6.43e-9	Fibrinogen levels;
CRC	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg18198730	chr1:247681584	NA	0.63	6.91	0.36	2.52e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.49	-5.8	-0.3	1.58e-8	Vitiligo;
CRC	cis	rs9648716	1.000	rs10251380	chr7:140586895	C/T	cg10747023	chr7:140774559	NA	0.44	5.88	0.31	9.82e-9	Type 2 diabetes;
CRC	cis	rs7255374	0.566	rs11666982	chr19:41531368	T/G	cg20630647	chr19:41531805	NA	0.36	5.92	0.31	8.3e-9	DDT metabolite (p,p'-DDE levels);
CRC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	8.85	0.44	5.59e-17	Mean platelet volume;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12172441	chr6:28176163	NA	0.61	7.3	0.37	2.21e-12	Depression;
CRC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.57	11.33	0.53	2.39e-25	Asthma (sex interaction);
CRC	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg25856811	chr1:152973957	SPRR3	-0.27	-7.42	-0.38	1.03e-12	Inflammatory skin disease;
CRC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.43	6.23	0.32	1.44e-9	Aortic root size;
CRC	cis	rs932541	1.000	rs6111154	chr20:16456201	T/C	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.66	8.7	0.43	1.63e-16	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22233093	chr11:65381871	MAP3K11	0.44	6.13	0.32	2.46e-9	Response to antipsychotic treatment;
CRC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.44	0.42	9.97e-16	Arsenic metabolism;
CRC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.57	7.47	0.38	7.29e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1178968	0.818	rs4717086	chr7:72777049	A/G	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.5	7.16	0.37	5.46e-12	Primary sclerosing cholangitis;
CRC	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.41	6.22	0.32	1.5e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs3760982	0.967	rs12463346	chr19:44292244	A/G	cg12072164	chr19:44306565	LYPD5	0.4	6.24	0.33	1.37e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs427943	0.778	rs28782181	chr21:46588817	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.43	-5.71	-0.3	2.59e-8	Body mass index;
CRC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.14	0.32	2.4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg18764771	chr6:116381957	FRK	0.26	6.34	0.33	7.74e-10	Total cholesterol levels;
CRC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	0.92	7.35	0.38	1.56e-12	Type 2 diabetes nephropathy;
CRC	cis	rs6604026	0.740	rs6700585	chr1:93364156	T/G	cg17283838	chr1:93427260	FAM69A	-0.5	-6.92	-0.36	2.36e-11	Multiple sclerosis;
CRC	cis	rs938554	0.737	rs10939637	chr4:9977577	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.65	0.34	1.21e-10	Blood metabolite levels;
CRC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.56	9.77	0.47	5.87e-20	Bipolar disorder;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	9.1	0.45	8.68e-18	Lymphocyte counts;
CRC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.73	11.19	0.52	7.66e-25	Cognitive function;
CRC	cis	rs7605827	0.930	rs11889160	chr2:15605509	C/T	cg19274914	chr2:15703543	NA	0.39	6.02	0.32	4.65e-9	Educational attainment (years of education);
CRC	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg09003973	chr2:102972529	NA	0.41	5.68	0.3	2.96e-8	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23323627	chr1:153895881	GATAD2B	0.5	7.27	0.37	2.67e-12	Response to antipsychotic treatment;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.57	-11.02	-0.52	2.95e-24	Acylcarnitine levels;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.64	9.13	0.45	7.25e-18	Parkinson's disease;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	7.71	0.39	1.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7894051	0.764	rs12242667	chr10:135192346	G/C	cg20534287	chr10:135191450	PAOX	-0.81	-7.28	-0.37	2.43e-12	Lifespan;
CRC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.65	7.81	0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.74	10.24	0.49	1.47e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg06238570	chr21:40685208	BRWD1	0.43	5.9	0.31	9.24e-9	Cognitive function;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12028816	chr17:7232827	NEURL4	0.39	6.09	0.32	3.13e-9	Interleukin-6 levels;
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg04025307	chr7:1156635	C7orf50	0.48	5.9	0.31	9.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.7	-8.86	-0.44	5.25e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.51	8.73	0.43	1.29e-16	Type 2 diabetes;
CRC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.82	14.42	0.62	7.03e-37	Breast cancer;
CRC	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg21038819	chr17:73507788	CASKIN2	-0.41	-5.76	-0.3	1.89e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs965469	1.000	rs6051779	chr20:3333449	A/G	cg25506879	chr20:3388711	C20orf194	-0.39	-5.81	-0.31	1.44e-8	IFN-related cytopenia;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-7.01	-0.36	1.37e-11	Longevity;Endometriosis;
CRC	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.45	-7.08	-0.36	8.72e-12	Red blood cell count;
CRC	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg25182066	chr10:30743637	MAP3K8	0.44	6.14	0.32	2.39e-9	Inflammatory bowel disease;
CRC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.45	0.6	3.81e-33	Platelet count;
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.87	-19.51	-0.73	7.12e-57	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7945404	0.548	rs4936618	chr11:121223996	G/T	cg27192990	chr6:129479024	LAMA2	0.43	6.04	0.32	4.11e-9	QT interval;
CRC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.9	16.1	0.66	2.05e-43	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.89	-0.4	4.58e-14	Height;
CRC	cis	rs1656402	1.000	rs2573217	chr2:233427015	G/A	cg03852847	chr2:233439513	NA	0.45	7.66	0.39	2.1e-13	Non-small cell lung cancer (survival);
CRC	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.77	7.67	0.39	1.98e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.38	0.59	6.83e-33	Chronic sinus infection;
CRC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	1.1	10.4	0.5	4.45e-22	Parkinson's disease;
CRC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg23205692	chr1:25664452	TMEM50A	0.4	5.68	0.3	2.93e-8	Erythrocyte sedimentation rate;
CRC	trans	rs991639	0.654	rs17019429	chr3:80797	A/T	cg08213608	chr4:3748254	NA	0.47	6.07	0.32	3.6e-9	Problematic alcohol use in trauma-exposed individuals;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg04155289	chr7:94953770	PON1	-0.61	-7.58	-0.39	3.56e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.19	-0.41	5.7e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.72	8.94	0.44	2.96e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg15131784	chr3:139108705	COPB2	0.39	5.63	0.3	3.79e-8	Obesity-related traits;
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.79	0.55	5.3e-27	Prudent dietary pattern;
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.64	-0.39	2.46e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-5.89	-0.31	9.69e-9	Reticulocyte count;
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.44	5.7	0.3	2.64e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.43	8.9	0.44	3.69e-17	Renal cell carcinoma;
CRC	trans	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg10756647	chr7:56101905	PSPH	0.71	7.6	0.39	3.2e-13	Diabetic kidney disease;
CRC	cis	rs55788414	0.860	rs9929059	chr16:81182117	G/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.77	-0.35	6.02e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12963246	chr6:28129442	ZNF389	0.5	5.75	0.3	2e-8	Depression;
CRC	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.39	6.15	0.32	2.3e-9	C-reactive protein levels;
CRC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.11	19.05	0.72	4.69e-55	Cognitive function;
CRC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg18709589	chr6:96969512	KIAA0776	-0.41	-5.99	-0.31	5.64e-9	Headache;
CRC	trans	rs75246769	0.706	rs77271013	chr7:145692412	G/A	cg21982490	chr5:124845866	NA	-0.69	-5.98	-0.31	5.89e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs11601602	0.531	rs35031414	chr11:28545563	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	6.99	0.36	1.57e-11	Obesity-related traits;
CRC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.57	8.23	0.41	4.57e-15	Lymphocyte counts;
CRC	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.95	15.98	0.66	5.8e-43	Dupuytren's disease;
CRC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.48	-7.54	-0.38	4.6e-13	Testicular germ cell tumor;
CRC	cis	rs17767392	0.958	rs34480562	chr14:71979724	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.26	-0.37	2.77e-12	Mitral valve prolapse;
CRC	cis	rs9908102	0.637	rs8078508	chr17:12910523	G/A	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.46	7.35	0.38	1.62e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.88	-0.48	2.46e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg14711859	chr11:8959438	ASCL3	0.33	5.61	0.3	4.36e-8	Hemoglobin concentration;
CRC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07338698	chr17:79895532	PYCR1	0.43	6.25	0.33	1.24e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg17903999	chr18:56338584	MALT1	0.43	7.12	0.37	6.83e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.59	-10.64	-0.51	6.42e-23	Tonsillectomy;
CRC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.86	0.66	1.86e-42	Intelligence (multi-trait analysis);
CRC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg27534772	chr1:16042836	PLEKHM2	0.56	10.93	0.52	6.06e-24	Systolic blood pressure;
CRC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.71	10.09	0.49	5.05e-21	Platelet count;
CRC	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.58	-7.2	-0.37	4.05e-12	Obesity (extreme);
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.71	-11.63	-0.54	1.96e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg05562828	chr17:3906858	NA	-0.66	-11.48	-0.53	7.1e-26	Type 2 diabetes;
CRC	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-6.79	-0.35	5.11e-11	Axial length;
CRC	cis	rs7487075	0.820	rs4768113	chr12:46708036	T/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.54	0.34	2.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.81	-0.35	4.64e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.79	-10.09	-0.49	5.03e-21	Height;
CRC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.45	6.22	0.32	1.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.51	13.37	0.59	7.39e-33	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.69	0.43	1.69e-16	Menopause (age at onset);
CRC	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.7	-8.78	-0.44	9.03e-17	Multiple sclerosis;
CRC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.58	9.45	0.46	6.7e-19	IgG glycosylation;
CRC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22133161	chr19:49891603	CCDC155	0.48	6.79	0.35	5.23e-11	Multiple sclerosis;
CRC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.57	9.0	0.44	1.85e-17	Aortic root size;
CRC	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg01788221	chr16:89496183	ANKRD11	-0.46	-7.06	-0.36	9.9e-12	Multiple myeloma (IgH translocation);
CRC	trans	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.19	0.41	5.85e-15	Ulcerative colitis;
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg15511327	chr8:143859410	LYNX1	-0.62	-11.17	-0.52	8.8e-25	Urinary tract infection frequency;
CRC	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg21285383	chr16:89894308	SPIRE2	-0.33	-5.66	-0.3	3.38e-8	Vitiligo;
CRC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg25767906	chr1:53392781	SCP2	0.42	6.66	0.34	1.15e-10	Monocyte count;
CRC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.98	-0.48	1.19e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.55	-8.05	-0.41	1.5e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.87	12.73	0.57	1.86e-30	Diastolic blood pressure;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14577476	chr17:49337432	MBTD1;UTP18	0.42	6.19	0.32	1.81e-9	Survival in pancreatic cancer;
CRC	cis	rs12024301	0.557	rs12048186	chr1:183611003	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.58	8.39	0.42	1.44e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.6	9.5	0.46	4.63e-19	Anterior chamber depth;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg12273811	chr6:28175739	NA	0.5	6.66	0.34	1.18e-10	Parkinson's disease;
CRC	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg25124228	chr12:125621409	AACS	-0.56	-6.72	-0.35	7.79e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6973256	0.828	rs9649046	chr7:133433402	C/T	cg10665199	chr7:133106180	EXOC4	-0.38	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
CRC	cis	rs755249	0.567	rs61779274	chr1:39816941	C/G	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.52	-7.64	-0.39	2.4e-13	Urate levels;
CRC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	1.0	12.88	0.58	5.14e-31	Psoriasis;
CRC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.27	-0.49	1.2e-21	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02415717	chr17:45727607	KPNB1	0.37	6.13	0.32	2.52e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg00938859	chr5:1591904	SDHAP3	0.7	7.5	0.38	6.13e-13	Breast cancer;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.42	-6.01	-0.31	4.92e-9	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg16950941	chr11:66035639	RAB1B	-0.61	-7.57	-0.39	3.88e-13	Electroencephalogram traits;
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg15845792	chr6:28175446	NA	0.8	11.59	0.54	2.82e-26	Cardiac Troponin-T levels;
CRC	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.87	7.11	0.36	7.44e-12	Alzheimer's disease (late onset);
CRC	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.49	-7.28	-0.37	2.46e-12	Large artery stroke;
CRC	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-1.14	-10.91	-0.52	7.62e-24	Post bronchodilator FEV1;
CRC	cis	rs4380275	1.000	rs4380275	chr2:773278	C/T	cg27237671	chr2:676223	TMEM18	-0.43	-6.11	-0.32	2.76e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.64	7.74	0.39	1.24e-13	Arsenic metabolism;
CRC	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18252515	chr7:66147081	NA	0.39	5.69	0.3	2.85e-8	Aortic root size;
CRC	trans	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg10756647	chr7:56101905	PSPH	0.69	7.1	0.36	7.8e-12	Diabetic kidney disease;
CRC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.61	8.53	0.43	5.25e-16	Arsenic metabolism;
CRC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-15.12	-0.64	1.43e-39	Vitiligo;
CRC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.65	-8.21	-0.41	5.22e-15	Body mass index;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.56	7.98	0.4	2.49e-14	Menarche (age at onset);
CRC	cis	rs939584	1.000	rs1320337	chr2:649867	A/T	cg03610516	chr2:642275	NA	-0.42	-5.91	-0.31	8.4e-9	Body mass index;
CRC	cis	rs6534441	0.759	rs28756446	chr4:125461021	T/C	cg21609808	chr4:125404261	NA	0.4	5.75	0.3	2.01e-8	Major depressive disorder;
CRC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.51	7.91	0.4	3.83e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.44	-9.91	-0.48	1.93e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs6694672	0.867	rs510135	chr1:197187779	C/T	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.36	2.31e-11	Asthma;
CRC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.43	6.14	0.32	2.35e-9	Aortic root size;
CRC	cis	rs2270875	1.000	rs1553270	chr8:132996059	T/G	cg24184792	chr8:132919238	EFR3A	-0.61	-5.9	-0.31	9.02e-9	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs3736485	0.934	rs17609791	chr15:51874824	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.63	7.03	0.36	1.19e-11	Inflammatory bowel disease;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18301423	chr5:131593218	PDLIM4	0.36	6.81	0.35	4.71e-11	Breast cancer;
CRC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23378565	chr7:2036160	MAD1L1	-0.46	-6.65	-0.34	1.23e-10	Bipolar disorder;
CRC	trans	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg19688584	chr6:167529678	CCR6	0.33	6.09	0.32	3.1e-9	Primary biliary cholangitis;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11777782	chr19:18284937	IFI30	0.41	6.23	0.32	1.45e-9	Myopia (pathological);
CRC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg01721255	chr8:58191610	C8orf71	0.45	5.78	0.3	1.75e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.66	-11.85	-0.55	3.23e-27	Lewy body disease;
CRC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.2	-0.53	7.25e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs2108622	0.727	rs7254940	chr19:15984508	C/T	cg13772218	chr19:15982569	NA	0.48	6.85	0.35	3.56e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg17321639	chr7:2759063	NA	-0.4	-6.09	-0.32	3.15e-9	Height;
CRC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.52	7.56	0.38	4.08e-13	Uric acid levels;
CRC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.43	-6.38	-0.33	5.9e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.97	-0.31	6.01e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7932354	0.528	rs10769234	chr11:47084061	G/C	cg03339077	chr11:47165057	C11orf49	0.43	5.95	0.31	6.94e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.66	-8.6	-0.43	3.25e-16	Initial pursuit acceleration;
CRC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.45	-0.5	2.91e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15664640	chr17:80829946	TBCD	0.48	5.6	0.3	4.45e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.91	-0.31	8.73e-9	Depression;
CRC	trans	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06834434	chr14:75079333	LTBP2	0.54	7.07	0.36	9.32e-12	Obesity-related traits;
CRC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.56	-7.26	-0.37	2.8e-12	Mean platelet volume;
CRC	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.65	-9.01	-0.45	1.66e-17	Cocaine dependence;
CRC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.66	-10.22	-0.49	1.81e-21	Huntington's disease progression;
CRC	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg16141378	chr3:129829833	LOC729375	0.45	6.87	0.35	3.28e-11	Neuroticism;
CRC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.3	0.33	9.36e-10	Cognitive ability;
CRC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.47	8.21	0.41	4.96e-15	Anterior chamber depth;
CRC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.11	0.59	6.77e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12900413	0.687	rs28465116	chr15:90310152	T/C	cg24249390	chr15:90295951	MESP1	-0.58	-9.33	-0.46	1.56e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs889398	0.771	rs1500337	chr16:69901884	C/T	cg00738113	chr16:70207722	CLEC18C	0.35	5.81	0.3	1.51e-8	Body mass index;
CRC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.33	-0.33	7.9e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.69	-8.89	-0.44	4.26e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg18232548	chr7:50535776	DDC	-0.43	-5.67	-0.3	3.11e-8	Malaria;
CRC	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.52	7.21	0.37	3.83e-12	DNA methylation (variation);
CRC	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.88	-10.8	-0.51	1.85e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs113123495	0.609	rs2485275	chr19:5636672	A/T	cg26242866	chr19:5711310	LONP1	0.7	5.76	0.3	1.88e-8	Obsessive-compulsive symptoms;
CRC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.87	12.03	0.55	6.99e-28	Initial pursuit acceleration;
CRC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Bone mineral density;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg11645453	chr3:52864694	ITIH4	0.34	6.43	0.33	4.6e-10	Hemoglobin concentration;
CRC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.42	-7.98	-0.4	2.48e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CRC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.79	0.39	8.74e-14	Height;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12172441	chr6:28176163	NA	0.53	7.17	0.37	5.02e-12	Cardiac Troponin-T levels;
CRC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.62	-8.99	-0.44	2.04e-17	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00760200	chr1:115053833	TRIM33	0.47	7.58	0.39	3.44e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg15845792	chr6:28175446	NA	0.77	11.38	0.53	1.58e-25	Parkinson's disease;
CRC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.34	-9.68	-0.47	1.17e-19	Mean corpuscular volume;
CRC	cis	rs2411233	1.000	rs8028719	chr15:39270782	C/T	cg23129342	chr15:39283510	NA	0.31	5.64	0.3	3.68e-8	Platelet count;
CRC	cis	rs7605827	0.930	rs4668450	chr2:15675011	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.57	7.32	0.37	1.89e-12	Urate levels in lean individuals;
CRC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.38	8.65	0.43	2.26e-16	Multiple system atrophy;
CRC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg03909863	chr11:638404	DRD4	-0.42	-6.11	-0.32	2.82e-9	Systemic lupus erythematosus;
CRC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg16342193	chr10:102329863	NA	-0.33	-5.7	-0.3	2.65e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.59	6.59	0.34	1.74e-10	Gastritis;
CRC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.66	7.21	0.37	3.85e-12	Axial length;
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.38	6.51	0.34	2.86e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.42	9.57	0.47	2.61e-19	Coronary artery disease;
CRC	cis	rs6460942	0.908	rs73301032	chr7:12256799	C/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.8	-0.3	1.58e-8	Coronary artery disease;
CRC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.46	6.43	0.33	4.37e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.54	7.49	0.38	6.22e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3750082	0.889	rs6963831	chr7:32934827	G/T	cg05721444	chr7:32995514	FKBP9	0.49	7.51	0.38	5.49e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg04454285	chr16:86016317	NA	-0.77	-11.18	-0.52	8.46e-25	Multiple sclerosis;
CRC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.78	0.47	5.43e-20	Cognitive test performance;
CRC	cis	rs6681460	0.576	rs2859914	chr1:66989840	A/G	cg02459107	chr1:67143332	SGIP1	0.38	5.76	0.3	1.97e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg08200582	chr11:442649	ANO9	-0.67	-6.39	-0.33	5.74e-10	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26912688	chr1:176176562	RFWD2	0.55	7.53	0.38	4.81e-13	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.53	7.9	0.4	4.12e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17767392	0.958	rs8010616	chr14:72019108	A/G	cg13720639	chr14:72061746	SIPA1L1	0.56	7.14	0.37	6.03e-12	Mitral valve prolapse;
CRC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.81	-8.91	-0.44	3.59e-17	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22228043	chr1:11159903	EXOSC10	0.44	6.72	0.35	8.08e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.46	6.62	0.34	1.48e-10	Emphysema distribution in smoking;
CRC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg00310523	chr12:86230176	RASSF9	0.44	7.42	0.38	1.02e-12	Major depressive disorder;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg24560729	chr4:1342394	KIAA1530	0.33	5.79	0.3	1.6e-8	Obesity-related traits;
CRC	cis	rs1320333	0.772	rs2903491	chr2:686688	T/A	cg00500140	chr2:691012	NA	0.63	6.93	0.36	2.19e-11	Obesity-related traits;
CRC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg19635926	chr16:89946313	TCF25	0.68	6.13	0.32	2.57e-9	Skin colour saturation;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04131734	chr11:102323536	TMEM123	0.43	6.64	0.34	1.27e-10	Interleukin-6 levels;
CRC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg07718321	chr6:96025334	MANEA	0.52	6.11	0.32	2.82e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg02741985	chr17:80059408	CCDC57	0.42	6.99	0.36	1.53e-11	Life satisfaction;
CRC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.63	-9.65	-0.47	1.4e-19	Diastolic blood pressure;
CRC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs243505	0.660	rs10274535	chr7:148543525	A/G	cg09806900	chr7:148480153	CUL1	0.52	6.63	0.34	1.38e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.49	8.43	0.42	1.14e-15	Testicular germ cell tumor;
CRC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg26587870	chr6:27730563	NA	-0.6	-5.98	-0.31	5.78e-9	Breast cancer;
CRC	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg20936604	chr3:58311152	NA	-0.74	-7.76	-0.39	1.05e-13	Cholesterol, total;
CRC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9648716	1.000	rs6947950	chr7:140539665	A/G	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg17544762	chr6:151300474	MTHFD1L	0.43	6.24	0.33	1.32e-9	Interleukin-6 levels;
CRC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.03	-12.21	-0.56	1.55e-28	Diabetic kidney disease;
CRC	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg18646521	chr2:111875858	NA	0.36	5.63	0.3	3.77e-8	Chronic lymphocytic leukemia;
CRC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.07	-0.45	1.14e-17	Joint mobility (Beighton score);
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg21251018	chr6:28226885	NKAPL	0.41	5.88	0.31	1.02e-8	Parkinson's disease;
CRC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-21.25	-0.76	1.1e-63	Myeloid white cell count;
CRC	cis	rs17162190	0.698	rs4659442	chr1:26823580	T/G	cg17456097	chr1:26900765	RPS6KA1	0.42	6.15	0.32	2.25e-9	Mean corpuscular volume;
CRC	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.49	-7.14	-0.37	5.95e-12	Height;
CRC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg13722127	chr7:150037890	RARRES2	0.41	6.27	0.33	1.12e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs77861329	1.000	rs9882775	chr3:52149649	C/T	cg08692210	chr3:52188851	WDR51A	0.81	6.74	0.35	7.03e-11	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.17	0.52	9.08e-25	Prudent dietary pattern;
CRC	cis	rs7113874	0.589	rs10769907	chr11:8457237	G/A	cg02811074	chr11:8615871	STK33	-0.35	-5.91	-0.31	8.76e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.62	-0.39	2.65e-13	Inflammatory bowel disease;
CRC	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg08999081	chr20:33150536	PIGU	0.47	5.84	0.31	1.24e-8	Neuroticism;
CRC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	trans	rs587242	1.000	rs7543671	chr1:96892268	T/C	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.89	-9.25	-0.45	2.83e-18	Gastritis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05950833	chr1:32688296	C1orf91;EIF3I	0.47	6.83	0.35	4.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4290604	0.667	rs80185012	chr2:237958643	T/C	cg23555395	chr2:238036564	NA	0.67	6.59	0.34	1.71e-10	Asthma;
CRC	cis	rs4743820	0.620	rs7848226	chr9:93920117	C/G	cg14446406	chr9:93919335	NA	0.82	15.22	0.64	5.85e-40	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg23687437	chr15:64125745	HERC1	-0.58	-6.19	-0.32	1.84e-9	Lung adenocarcinoma;
CRC	trans	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19894588	chr14:64061835	NA	0.43	6.25	0.33	1.24e-9	Glioblastoma;Glioma;
CRC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03923535	chr7:1197113	ZFAND2A	0.53	7.7	0.39	1.64e-13	Longevity;Endometriosis;
CRC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg23996704	chr18:44553084	KATNAL2	0.32	6.22	0.32	1.48e-9	Personality dimensions;
CRC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.32	-5.73	-0.3	2.31e-8	Longevity;Endometriosis;
CRC	cis	rs2274273	0.638	rs17672364	chr14:55705904	G/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.71	-0.3	2.53e-8	Protein biomarker;
CRC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.79	9.05	0.45	1.29e-17	Breast cancer;
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.24	-0.33	1.34e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.67	-9.39	-0.46	1.07e-18	Coronary artery disease;
CRC	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.38	-0.33	5.85e-10	Coronary artery disease;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.5	8.59	0.43	3.63e-16	Hypertriglyceridemia;
CRC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	cis	rs1656402	0.911	rs2880817	chr2:233453705	G/A	cg03852847	chr2:233439513	NA	-0.42	-7.26	-0.37	2.83e-12	Non-small cell lung cancer (survival);
CRC	trans	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg21153622	chr11:89784906	NA	-0.44	-7.01	-0.36	1.38e-11	HDL cholesterol;
CRC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.68	10.01	0.48	8.88e-21	Menopause (age at onset);
CRC	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.43	6.0	0.31	5.25e-9	Superior crus of antihelix expression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23897067	chr9:140100305	TMEM203;NDOR1	0.44	6.36	0.33	6.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg15269541	chr15:43626905	ADAL	-0.62	-6.38	-0.33	6.11e-10	Lung cancer in ever smokers;
CRC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.36	6.55	0.34	2.19e-10	Erythrocyte sedimentation rate;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg10876282	chr6:28092338	ZSCAN16	0.43	5.7	0.3	2.64e-8	Parkinson's disease;
CRC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.2	0.67	8.61e-44	Chronic sinus infection;
CRC	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.48	6.07	0.32	3.51e-9	Recombination rate (females);
CRC	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg18850127	chr7:39170497	POU6F2	0.44	5.71	0.3	2.53e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg06935464	chr4:38784597	TLR10	0.57	5.69	0.3	2.8e-8	Breast cancer;
CRC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg02733842	chr7:1102375	C7orf50	-0.69	-8.48	-0.42	7.78e-16	Bronchopulmonary dysplasia;
CRC	cis	rs3736485	0.868	rs1531155	chr15:51932133	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.51	-0.34	2.88e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg06781209	chr11:61594997	FADS2	-0.39	-5.78	-0.3	1.69e-8	Trans fatty acid levels;
CRC	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.43	8.37	0.42	1.63e-15	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.41	-7.03	-0.36	1.21e-11	Lung cancer;
CRC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.67	-7.49	-0.38	6.53e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CRC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.02	-0.45	1.61e-17	Neuroticism;
CRC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.75	8.27	0.41	3.31e-15	Tuberculosis;
CRC	cis	rs9682041	0.627	rs3772173	chr3:170078232	C/T	cg11886554	chr3:170076028	SKIL	0.67	8.22	0.41	4.9e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg05585544	chr11:47624801	NA	-0.57	-10.41	-0.5	3.89e-22	Subjective well-being;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01603508	chr16:30937154	FBXL19	-0.38	-6.11	-0.32	2.87e-9	Interleukin-6 levels;
CRC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.74	0.47	7.34e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.46	9.45	0.46	6.61e-19	Hand grip strength;
CRC	cis	rs1223397	1.000	rs1232392	chr6:13272671	C/G	cg20827128	chr6:13274284	PHACTR1	0.56	6.78	0.35	5.42e-11	Blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13904018	chr4:1340886	KIAA1530	0.41	6.36	0.33	6.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12292205	chr6:26970375	C6orf41	-0.49	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.747	rs1611753	chr1:152956381	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.58e-12	Inflammatory skin disease;
CRC	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg11266682	chr4:10021025	SLC2A9	0.34	6.1	0.32	2.89e-9	Blood metabolite levels;
CRC	cis	rs834811	0.602	rs17243556	chr7:135886489	T/A	cg01726295	chr7:135938950	NA	0.36	6.11	0.32	2.74e-9	Post-traumatic stress disorder;
CRC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.22	-16.66	-0.68	1.26e-45	Breast cancer;
CRC	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.51	6.03	0.32	4.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03075736	chr3:52444632	PHF7;BAP1	0.39	6.27	0.33	1.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2013441	0.965	rs2703808	chr17:20109665	A/C	cg13482628	chr17:19912719	NA	-0.42	-6.57	-0.34	1.95e-10	Obesity-related traits;
CRC	cis	rs2735413	0.958	rs2735401	chr16:78057103	A/C	cg04733911	chr16:78082701	NA	0.35	5.68	0.3	2.95e-8	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs12692738	0.526	rs391915	chr2:165623811	A/G	cg03182029	chr2:165697222	COBLL1	0.5	5.88	0.31	1.02e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2303319	0.582	rs62187608	chr2:162431138	T/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.17	-0.32	2.05e-9	Cognitive function;
CRC	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.47	5.88	0.31	1.02e-8	Bladder cancer;
CRC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.64e-17	Prostate cancer;
CRC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.49	5.61	0.3	4.24e-8	Vitiligo;
CRC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24308560	chr3:49941425	MST1R	-0.5	-7.74	-0.39	1.26e-13	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.47	-5.92	-0.31	8.3e-9	Aortic root size;
CRC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.43e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg21620606	chr4:1342894	KIAA1530	0.41	7.49	0.38	6.45e-13	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	10.6	0.5	9.1e-23	Prudent dietary pattern;
CRC	trans	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.44	6.46	0.34	3.83e-10	Menopause (age at onset);
CRC	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg00666640	chr1:248458726	OR2T12	0.42	7.59	0.39	3.32e-13	Common traits (Other);
CRC	cis	rs2737618	0.722	rs1986405	chr1:200095935	C/G	cg21825944	chr1:200113062	NR5A2	-0.52	-7.61	-0.39	2.92e-13	Uric acid levels;
CRC	cis	rs1355223	1.000	rs35365094	chr11:34767790	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.53	-0.34	2.53e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-7.07	-0.36	9.33e-12	Lung cancer;
CRC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg18827107	chr12:86230957	RASSF9	-0.38	-6.2	-0.32	1.71e-9	Major depressive disorder;
CRC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.43	-0.33	4.54e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg25164649	chr6:28176230	NA	0.64	8.97	0.44	2.29e-17	Cardiac Troponin-T levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24892074	chr4:89444835	PIGY	0.43	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg19046167	chr17:80928561	B3GNTL1	0.51	7.33	0.37	1.82e-12	Glycated hemoglobin levels;
CRC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.59	10.38	0.5	4.93e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3764400	0.508	rs757353	chr17:46122270	A/G	cg10706073	chr17:46328419	SKAP1	-0.68	-7.29	-0.37	2.26e-12	Body mass index;
CRC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.38	-5.87	-0.31	1.05e-8	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00251738	chr7:77428046	PHTF2;TMEM60	0.48	6.72	0.35	8.04e-11	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	0.89	10.1	0.49	4.57e-21	Inflammatory bowel disease;
CRC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.49	7.22	0.37	3.73e-12	Chronic sinus infection;
CRC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-8.97	-0.44	2.29e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.71	-0.35	8.46e-11	Electroencephalogram traits;
CRC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	10.77	0.51	2.2e-23	Mean corpuscular hemoglobin;
CRC	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6867913	0.951	rs4912799	chr5:141453720	G/C	cg23435118	chr5:141488016	NDFIP1	0.42	5.81	0.31	1.47e-8	Asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17967426	chr5:168006763	PANK3	0.43	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-8.43	-0.42	1.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.31	0.37	2.09e-12	Motion sickness;
CRC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg25304816	chr1:36627734	MAP7D1	-0.48	-7.32	-0.37	1.91e-12	Corneal structure;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg04518342	chr5:131593106	PDLIM4	0.54	9.05	0.45	1.24e-17	Acylcarnitine levels;
CRC	cis	rs995000	0.931	rs638305	chr1:62906537	G/T	cg19896129	chr1:63156450	NA	0.44	6.84	0.35	3.76e-11	Triglyceride levels;
CRC	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13844804	chr7:814759	HEATR2	-0.57	-6.07	-0.32	3.62e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs4731207	0.596	rs10252798	chr7:124637211	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.18	-0.32	1.87e-9	Cutaneous malignant melanoma;
CRC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg03934865	chr2:198174659	NA	-0.43	-7.63	-0.39	2.64e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs12541902	0.696	rs4299991	chr8:60641321	G/T	cg07441319	chr10:8117467	NA	0.38	6.09	0.32	3.2e-9	Obesity-related traits;
CRC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.9	16.15	0.67	1.25e-43	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg15205204	chr1:6545172	PLEKHG5	0.38	5.63	0.3	3.81e-8	Body mass index;
CRC	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.39	6.09	0.32	3.2e-9	Obesity;
CRC	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg04110750	chr16:69646130	NFAT5	-0.49	-6.5	-0.34	2.99e-10	IgE levels;
CRC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg22532475	chr10:104410764	TRIM8	0.33	5.62	0.3	4e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9549328	0.614	rs34306822	chr13:113616499	G/A	cg20742385	chr13:113633654	MCF2L	0.55	9.39	0.46	1.01e-18	Systolic blood pressure;
CRC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.23	0.45	3.48e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg24011408	chr12:48396354	COL2A1	0.48	6.62	0.34	1.44e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg09003973	chr2:102972529	NA	0.41	5.96	0.31	6.62e-9	Blood protein levels;
CRC	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.5	-7.97	-0.4	2.68e-14	Neuroticism;
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.33e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	1.06	10.0	0.48	1.01e-20	Prostate cancer;
CRC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.9	14.49	0.62	3.98e-37	Ewing sarcoma;
CRC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.34	-0.33	7.66e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.58	8.55	0.43	4.6e-16	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11094694	chr3:38206939	OXSR1	0.45	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.4	0.33	5.21e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg02527881	chr3:46936655	PTH1R	0.33	5.71	0.3	2.51e-8	Colorectal cancer;
CRC	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg00587665	chr15:100533223	ADAMTS17	0.34	6.01	0.31	4.8e-9	Height;
CRC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.64	10.88	0.51	9.41e-24	Platelet count;
CRC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	cis	rs7072216	0.843	rs2296441	chr10:100144782	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.93	-0.31	7.55e-9	Metabolite levels;
CRC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.28	15.26	0.64	3.9e-40	Uric acid levels;
CRC	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.89	13.9	0.61	7.07e-35	Blood metabolite levels;
CRC	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	0.56	8.76	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-8.03	-0.4	1.77e-14	Body mass index;
CRC	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg13385794	chr1:248469461	NA	0.39	6.68	0.35	9.97e-11	Common traits (Other);
CRC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg02376097	chr19:46275166	DMPK	0.37	5.83	0.31	1.33e-8	Coronary artery disease;
CRC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.24	-0.45	3.09e-18	Breast cancer;
CRC	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	23.97	0.8	3.83e-74	Schizophrenia;
CRC	cis	rs4731207	0.565	rs1994025	chr7:124663859	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.11	-0.32	2.87e-9	Cutaneous malignant melanoma;
CRC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg15468180	chr1:107600409	PRMT6	-0.42	-6.29	-0.33	9.93e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7120118	0.517	rs56168519	chr11:47317987	T/C	cg25783544	chr11:47291846	MADD	0.62	5.71	0.3	2.47e-8	HDL cholesterol;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg23123621	chr4:1343375	KIAA1530	-0.36	-6.72	-0.35	8.11e-11	Obesity-related traits;
CRC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg04731861	chr2:219085781	ARPC2	-0.29	-6.15	-0.32	2.27e-9	Colorectal cancer;
CRC	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.74	-9.02	-0.45	1.64e-17	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03057164	chr11:17099458	RPS13	0.44	6.14	0.32	2.31e-9	Response to antipsychotic treatment;
CRC	cis	rs4594175	0.926	rs72688717	chr14:51614493	C/T	cg23942311	chr14:51606299	NA	0.64	9.62	0.47	1.81e-19	Cancer;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg25164649	chr6:28176230	NA	0.77	9.45	0.46	6.39e-19	Parkinson's disease;
CRC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg23018236	chr17:30244563	NA	-0.66	-7.99	-0.4	2.32e-14	Hip circumference adjusted for BMI;
CRC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.48	-9.12	-0.45	7.58e-18	Intelligence (multi-trait analysis);
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg25834613	chr7:1915315	MAD1L1	-0.42	-5.94	-0.31	7.09e-9	Neuroticism;
CRC	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.5	0.42	6.89e-16	Corneal astigmatism;
CRC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg19338460	chr6:170058176	WDR27	-0.67	-7.38	-0.38	1.32e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	1.02	18.4	0.71	1.8e-52	Menarche (age at onset);
CRC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	0.72	7.75	0.39	1.18e-13	Gout;Renal underexcretion gout;
CRC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.45	9.66	0.47	1.31e-19	Blood protein levels;
CRC	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.61	9.68	0.47	1.12e-19	Crohn's disease;
CRC	cis	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg05299278	chr17:33885742	SLFN14	-0.41	-6.24	-0.33	1.33e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.44	5.98	0.31	5.96e-9	Pulse pressure;
CRC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg00246817	chr9:123691163	NA	-0.47	-6.0	-0.31	5.19e-9	Rheumatoid arthritis;
CRC	cis	rs6662572	0.737	rs11587648	chr1:46585418	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.3	0.33	9.58e-10	Blood protein levels;
CRC	cis	rs7849270	1.000	rs7036236	chr9:131899299	G/A	cg13538475	chr9:131942899	NA	-0.32	-6.36	-0.33	6.65e-10	Blood metabolite ratios;
CRC	cis	rs12692738	0.526	rs355850	chr2:165626043	C/T	cg03182029	chr2:165697222	COBLL1	0.51	6.07	0.32	3.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg12273811	chr6:28175739	NA	0.64	8.85	0.44	5.61e-17	Parkinson's disease;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.62	-8.24	-0.41	4.02e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.48	6.78	0.35	5.71e-11	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11256290	chr10:32734912	CCDC7	0.41	6.64	0.34	1.3e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.71	-0.7	8.92e-50	Height;
CRC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.48	6.44	0.33	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.47	5.82	0.31	1.42e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg22777020	chr22:31556080	RNF185	-0.51	-5.93	-0.31	7.76e-9	Colorectal cancer;
CRC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.27	-0.46	2.46e-18	Body mass index;
CRC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.16	-0.49	2.85e-21	Monocyte count;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16717773	chr1:155211079	GBA	-0.39	-5.99	-0.31	5.48e-9	Aortic root size;
CRC	trans	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg15704280	chr7:45808275	SEPT13	0.67	6.0	0.31	5.12e-9	Axial length;
CRC	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.96	-0.31	6.39e-9	Endometrial cancer;
CRC	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg16342193	chr10:102329863	NA	-0.33	-5.62	-0.3	4.16e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.07	-0.49	5.58e-21	Bipolar disorder;
CRC	cis	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg15786705	chr6:28176104	NA	0.59	6.05	0.32	3.84e-9	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11614622	chr11:66623681	LRFN4;PC	0.47	7.37	0.38	1.37e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10486722	0.638	rs10951659	chr7:41792345	T/G	cg22138096	chr7:41772439	LOC285954	0.45	5.68	0.3	2.97e-8	Pit-and-Fissure caries;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02290350	chr8:58132656	NA	-0.55	-6.73	-0.35	7.4e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg08992911	chr2:238395768	MLPH	0.59	6.11	0.32	2.82e-9	Prostate cancer;
CRC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.54	0.34	2.36e-10	Schizophrenia;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.46	6.84	0.35	3.94e-11	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21866054	chr4:103748674	UBE2D3	0.45	6.4	0.33	5.27e-10	Response to antipsychotic treatment;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg16924120	chr12:118814149	SUDS3	0.4	6.02	0.31	4.57e-9	Crohn's disease;
CRC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg08200582	chr11:442649	ANO9	-0.68	-6.42	-0.33	4.65e-10	Body mass index;
CRC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.3	6.17	0.32	2.01e-9	Homoarginine levels;
CRC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg25809561	chr17:30822961	MYO1D	0.57	10.52	0.5	1.65e-22	Schizophrenia;
CRC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.45	5.69	0.3	2.8e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.77	12.05	0.55	6.12e-28	Body mass index;
CRC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.59	8.04	0.41	1.68e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.4	6.04	0.32	4.1e-9	Obesity-related traits;
CRC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg12590608	chr7:158785262	NA	-0.33	-5.7	-0.3	2.73e-8	Facial morphology (factor 20);
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg00597713	chr6:42947103	PEX6	-0.42	-5.92	-0.31	7.89e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.47	-0.34	3.6e-10	Coronary artery disease;
CRC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.37	6.79	0.35	5.18e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg03623178	chr6:28175578	NA	0.64	8.29	0.42	2.88e-15	Parkinson's disease;
CRC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs1760803	0.754	rs10158820	chr1:154217763	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-5.94	-0.31	7.2e-9	Nicotine dependence;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.97	16.82	0.68	2.99e-46	Menarche (age at onset);
CRC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.86	-13.22	-0.59	2.6e-32	Platelet distribution width;
CRC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.88	9.76	0.47	6.36e-20	Skin colour saturation;
CRC	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg16591659	chr17:78472290	NA	0.42	6.04	0.32	4.07e-9	Fractional excretion of uric acid;
CRC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.72	-8.15	-0.41	7.69e-15	Obesity-related traits;
CRC	cis	rs77633900	0.772	rs284905	chr15:76743345	C/T	cg21673338	chr15:77095150	SCAPER	-0.7	-6.06	-0.32	3.79e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.67	8.53	0.43	5.51e-16	Mean platelet volume;
CRC	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg20203395	chr5:56204925	C5orf35	-0.68	-8.34	-0.42	2.04e-15	Type 2 diabetes;
CRC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg10790698	chr19:18539756	SSBP4	-0.46	-8.96	-0.44	2.49e-17	Breast cancer;
CRC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	8.77	0.44	9.87e-17	Bone mineral density;
CRC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.42	-7.36	-0.38	1.51e-12	Height;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg20615401	chr6:28092323	ZSCAN16	0.46	6.19	0.32	1.75e-9	Cardiac Troponin-T levels;
CRC	cis	rs4731207	0.564	rs10234592	chr7:124611656	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.51	-7.34	-0.38	1.67e-12	Caudate activity during reward;
CRC	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.78	15.75	0.66	4.75e-42	Leprosy;
CRC	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.24	12.08	0.55	4.79e-28	Granulocyte percentage of myeloid white cells;
CRC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg25173405	chr17:45401733	C17orf57	0.39	5.81	0.3	1.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	9.17	0.45	5.19e-18	Cognitive test performance;
CRC	trans	rs12200782	0.510	rs9467738	chr6:26382181	T/C	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs1465370	0.711	rs4731689	chr7:130009839	C/T	cg03229158	chr7:130009420	NA	0.49	6.88	0.35	3.01e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.51	-8.4	-0.42	1.32e-15	Type 2 diabetes;
CRC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg09650180	chr20:62225654	GMEB2	-0.5	-6.7	-0.35	9.27e-11	Glioblastoma;
CRC	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg23254163	chr1:152506842	NA	0.45	9.13	0.45	6.92e-18	Hair morphology;
CRC	cis	rs12940626	0.674	rs11867297	chr17:66433493	C/T	cg02501334	chr17:66508232	PRKAR1A	0.4	5.62	0.3	4.06e-8	Red cell distribution width;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-7.88	-0.4	4.8e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg25164649	chr6:28176230	NA	0.73	9.16	0.45	5.49e-18	Depression;
CRC	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg23555395	chr2:238036564	NA	-0.63	-9.93	-0.48	1.71e-20	Systemic lupus erythematosus;
CRC	cis	rs73206853	0.841	rs17625767	chr12:111102627	A/C	cg12870014	chr12:110450643	ANKRD13A	0.69	6.82	0.35	4.41e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24249390	chr15:90295951	MESP1	-0.62	-9.76	-0.47	6.44e-20	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21768436	chr8:67341108	RRS1	0.35	6.04	0.32	4.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-10.83	-0.51	1.43e-23	Bipolar disorder;
CRC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.32	5.69	0.3	2.78e-8	Erythrocyte sedimentation rate;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.32	-5.77	-0.3	1.86e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.07	-0.32	3.55e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg08999081	chr20:33150536	PIGU	0.44	5.71	0.3	2.52e-8	Protein C levels;
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg10729496	chr3:10149963	C3orf24	-0.49	-6.61	-0.34	1.57e-10	Alzheimer's disease;
CRC	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.53	7.05	0.36	1.04e-11	Carotid intima media thickness;
CRC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.96	-0.36	1.83e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg25182066	chr10:30743637	MAP3K8	0.39	5.77	0.3	1.8e-8	Inflammatory bowel disease;
CRC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	12.02	0.55	7.97e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg19041857	chr6:27730383	NA	-0.44	-6.08	-0.32	3.38e-9	Parkinson's disease;
CRC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.42	-7.19	-0.37	4.51e-12	Height;
CRC	cis	rs3106136	0.837	rs2289186	chr4:95255637	T/G	cg11021082	chr4:95130006	SMARCAD1	0.43	6.47	0.34	3.58e-10	Capecitabine sensitivity;
CRC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.61	8.4	0.42	1.37e-15	Arsenic metabolism;
CRC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.5	7.68	0.39	1.88e-13	Osteoporosis;
CRC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg14949292	chr17:78079608	GAA	-0.43	-6.15	-0.32	2.23e-9	Yeast infection;
CRC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.52	8.07	0.41	1.35e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6743376	0.556	rs1530550	chr2:113817513	A/T	cg24553058	chr2:113831203	IL1F10	0.43	7.0	0.36	1.47e-11	Inflammatory biomarkers;
CRC	trans	rs67073037	0.955	rs4666141	chr2:29164022	G/T	cg13899017	chr1:159158444	CADM3	-0.37	-6.17	-0.32	1.98e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22159483	chr17:1588198	PRPF8	0.43	6.04	0.32	4.26e-9	Response to antipsychotic treatment;
CRC	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg14844989	chr11:31128820	NA	-0.34	-5.97	-0.31	6.13e-9	Red blood cell count;
CRC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg23262073	chr20:60523788	NA	0.4	7.04	0.36	1.15e-11	Body mass index;
CRC	cis	rs10486722	0.606	rs10807910	chr7:41796992	A/G	cg22138096	chr7:41772439	LOC285954	0.45	5.64	0.3	3.67e-8	Pit-and-Fissure caries;
CRC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.49	-8.38	-0.42	1.59e-15	P wave terminal force;
CRC	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg08501292	chr6:25962987	TRIM38	0.84	8.08	0.41	1.25e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg23587288	chr2:27483067	SLC30A3	-0.42	-6.08	-0.32	3.37e-9	Blood metabolite levels;
CRC	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg09659197	chr4:152720779	NA	-0.51	-11.19	-0.53	7.49e-25	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.59	-0.34	1.79e-10	Menopause (age at onset);
CRC	cis	rs2652834	1.000	rs2134265	chr15:63398196	G/A	cg05507819	chr15:63340323	TPM1	0.47	5.98	0.31	5.87e-9	HDL cholesterol;
CRC	cis	rs7113874	0.589	rs7939731	chr11:8510299	T/G	cg02811074	chr11:8615871	STK33	-0.36	-6.17	-0.32	1.95e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.46	-0.34	3.75e-10	Aortic root size;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg12172441	chr6:28176163	NA	0.6	6.59	0.34	1.71e-10	Parkinson's disease;
CRC	cis	rs4290604	0.679	rs4663700	chr2:238036764	T/C	cg23555395	chr2:238036564	NA	-0.54	-6.94	-0.36	2.14e-11	Asthma;
CRC	cis	rs11098699	0.769	rs13136692	chr4:124229169	G/A	cg09941581	chr4:124220074	SPATA5	0.39	5.81	0.3	1.49e-8	Mosquito bite size;
CRC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.15	0.45	5.95e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg05585544	chr11:47624801	NA	-0.46	-8.26	-0.41	3.69e-15	Subjective well-being;
CRC	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.51	8.2	0.41	5.27e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs11679072	1.000	rs6735368	chr2:240448748	C/T	cg03276489	chr2:240449683	NA	-0.93	-9.41	-0.46	8.71e-19	Blood pressure (smoking interaction);
CRC	trans	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg21153622	chr11:89784906	NA	-0.45	-6.96	-0.36	1.8e-11	HDL cholesterol;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.62e-9	Bipolar disorder;
CRC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.09	10.42	0.5	3.56e-22	Opioid sensitivity;
CRC	cis	rs117623576	0.941	rs17230172	chr10:32438490	G/T	cg03047570	chr10:32398778	NA	-0.69	-6.86	-0.35	3.45e-11	Anti-saccade response;
CRC	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.12	0.45	7.93e-18	Blood protein levels;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.95e-9	Body mass index;
CRC	cis	rs7487075	0.619	rs4768717	chr12:46831561	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.74	0.3	2.12e-8	Itch intensity from mosquito bite;
CRC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.37	-0.56	4.1e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4692589	1.000	rs7666219	chr4:170932739	T/C	cg19918862	chr4:170955249	NA	0.4	6.53	0.34	2.51e-10	Anxiety disorder;
CRC	cis	rs76793172	0.588	rs8110017	chr19:46289392	G/C	cg11657440	chr19:46296263	DMWD	0.58	6.03	0.32	4.52e-9	Eosinophil counts;
CRC	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg23417306	chr2:180868811	CWC22	0.42	5.63	0.3	3.91e-8	Schizophrenia;
CRC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.15	0.45	6.27e-18	Parkinson's disease;
CRC	cis	rs427943	0.750	rs8130224	chr21:46616441	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.44	5.97	0.31	6.09e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02096607	chr11:27493868	LGR4	0.37	7.13	0.37	6.31e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23001456	chr17:2615074	KIAA0664	0.37	5.99	0.31	5.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.71	-11.43	-0.53	1.03e-25	Mean platelet volume;
CRC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg08270630	chr22:50330655	NA	-0.57	-5.79	-0.3	1.68e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16944159	chr2:62132759	COMMD1	0.5	7.22	0.37	3.74e-12	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg18827107	chr12:86230957	RASSF9	-0.38	-6.25	-0.33	1.3e-9	Major depressive disorder;
CRC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-5.73	-0.3	2.32e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	9.49	0.46	4.72e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Parkinson's disease;
CRC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.52	7.39	0.38	1.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg08112188	chr17:47440006	ZNF652	-0.82	-7.21	-0.37	3.85e-12	Prostate cancer;
CRC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.41	-0.46	8.67e-19	HDL cholesterol;
CRC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg24675056	chr1:15929824	NA	0.53	7.18	0.37	4.76e-12	Systolic blood pressure;
CRC	trans	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	8.66	0.43	2.18e-16	Ulcerative colitis;
CRC	cis	rs1223397	0.938	rs3817741	chr6:13279507	A/G	cg20827128	chr6:13274284	PHACTR1	-0.5	-6.32	-0.33	8.48e-10	Blood pressure;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.13	-0.32	2.54e-9	Bipolar disorder;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg15845792	chr6:28175446	NA	1.04	13.88	0.61	8.66e-35	Depression;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	8.55	0.43	4.65e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg07005513	chr11:61595956	FADS2	-0.5	-6.31	-0.33	9.09e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.98	-0.36	1.68e-11	Mean corpuscular volume;
CRC	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.72	-6.9	-0.36	2.63e-11	Putamen volume;
CRC	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.63	6.94	0.36	2.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7901135	0.962	rs6481438	chr10:60559603	A/G	cg23799393	chr10:60588674	BICC1	0.39	6.0	0.31	5.22e-9	Morning vs. evening chronotype;
CRC	cis	rs17253792	0.822	rs78432811	chr14:56051545	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.81	-0.35	4.51e-11	Putamen volume;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg14196790	chr5:131705035	SLC22A5	0.36	6.2	0.32	1.72e-9	Blood metabolite levels;
CRC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs7731657	0.538	rs2107335	chr5:130292853	C/A	cg08523029	chr5:130500466	HINT1	-0.49	-6.19	-0.32	1.83e-9	Fasting plasma glucose;
CRC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.46	6.02	0.32	4.53e-9	Pulse pressure;
CRC	cis	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg27395922	chr11:50257633	LOC441601	-0.34	-5.6	-0.3	4.52e-8	Coronary artery disease;
CRC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.49	7.44	0.38	8.67e-13	Corneal astigmatism;
CRC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.24	0.37	3.15e-12	Aortic root size;
CRC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.57	-6.71	-0.35	8.67e-11	Birth weight;
CRC	cis	rs2971970	0.519	rs10230628	chr7:133633133	G/A	cg03336402	chr7:133662267	EXOC4	0.63	9.63	0.47	1.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2880765	0.546	rs35316253	chr15:86065560	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-6.54	-0.34	2.39e-10	Coronary artery disease;
CRC	cis	rs75422866	0.510	rs35784744	chr12:48123429	T/G	cg14736327	chr12:48174669	SLC48A1	-0.75	-6.17	-0.32	1.99e-9	Pneumonia;
CRC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg02175503	chr12:58329896	NA	0.45	5.73	0.3	2.27e-8	Multiple sclerosis;
CRC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg07884673	chr3:53033167	SFMBT1	0.7	6.15	0.32	2.23e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg10820045	chr2:198174542	NA	0.54	10.65	0.51	5.87e-23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.44	-7.19	-0.37	4.4e-12	Type 2 diabetes;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg07404485	chr7:94953653	PON1	-0.48	-6.03	-0.32	4.44e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.59	10.4	0.5	4.23e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4750440	0.712	rs11258776	chr10:14031709	G/T	cg00551146	chr10:14014579	FRMD4A	0.42	6.9	0.36	2.67e-11	Adiponectin levels;
CRC	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-8.24	-0.41	4.03e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg19773385	chr1:10388646	KIF1B	0.45	6.96	0.36	1.86e-11	Hepatocellular carcinoma;
CRC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.5	-0.34	2.96e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs16852403	0.548	rs6685012	chr1:178175301	C/A	cg00404053	chr1:178313656	RASAL2	0.5	6.58	0.34	1.88e-10	Childhood ear infection;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12721145	chr4:109571876	OSTC	0.4	6.2	0.32	1.66e-9	Interleukin-6 levels;
CRC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg18833306	chr6:118973337	C6orf204	0.43	5.63	0.3	3.92e-8	Renal cell carcinoma;
CRC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	0.92	13.64	0.6	6.69e-34	Cognitive function;
CRC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.42	-7.51	-0.38	5.79e-13	Monocyte count;
CRC	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg03162506	chr22:38580953	NA	0.27	5.83	0.31	1.3e-8	Cutaneous nevi;
CRC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Alcohol dependence;
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.54	6.2	0.32	1.68e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs34638657	0.500	rs12446210	chr16:82185762	G/A	cg07918374	chr16:82182319	MPHOSPH6	0.4	5.66	0.3	3.33e-8	Lung adenocarcinoma;
CRC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21963583	chr11:68658836	MRPL21	0.63	11.58	0.54	3.15e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.46	-6.45	-0.33	4.08e-10	DNA methylation (variation);
CRC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.39	-0.5	4.81e-22	Chronic sinus infection;
CRC	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.36	5.62	0.3	4.04e-8	Pubertal anthropometrics;
CRC	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.47	7.23	0.37	3.47e-12	HDL cholesterol;
CRC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	6.83	0.35	4.22e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.12	-19.25	-0.73	7.48e-56	Ulcerative colitis;
CRC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.56	-9.34	-0.46	1.47e-18	Iron status biomarkers;
CRC	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.45	6.43	0.33	4.45e-10	Height;
CRC	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-0.9	-9.39	-0.46	1.06e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.83	-13.4	-0.59	5.47e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12692738	0.526	rs355832	chr2:165616833	C/T	cg03182029	chr2:165697222	COBLL1	0.48	5.66	0.3	3.32e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg10298567	chr3:47292165	KIF9	0.38	6.09	0.32	3.06e-9	Colorectal cancer;
CRC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.92	-15.93	-0.66	9.45e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.81	13.48	0.6	2.74e-33	Monocyte count;
CRC	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.51	-7.88	-0.4	4.68e-14	Diastolic blood pressure;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09781304	chr17:80887954	TBCD	0.42	5.97	0.31	6.12e-9	Survival in pancreatic cancer;
CRC	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.01	0.52	3.28e-24	Exhaled nitric oxide output;
CRC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg18876405	chr7:65276391	NA	-0.44	-6.14	-0.32	2.41e-9	Aortic root size;
CRC	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.64	-10.72	-0.51	3.44e-23	Tuberculosis;
CRC	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.43	-5.86	-0.31	1.15e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg09873164	chr1:152488093	CRCT1	0.4	6.72	0.35	7.83e-11	Hair morphology;
CRC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg02527881	chr3:46936655	PTH1R	-0.34	-5.87	-0.31	1.05e-8	Colorectal cancer;
CRC	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg11645453	chr3:52864694	ITIH4	-0.4	-7.43	-0.38	9.61e-13	Body mass index;
CRC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.47	6.75	0.35	6.84e-11	Lymphocyte counts;
CRC	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	cg04338863	chr8:33670619	NA	0.42	6.75	0.35	6.5e-11	Body mass index;
CRC	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07165851	chr6:158734300	TULP4	0.61	7.72	0.39	1.37e-13	Height;
CRC	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg00071950	chr4:10020882	SLC2A9	0.41	6.48	0.34	3.4e-10	Blood metabolite levels;
CRC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg02527881	chr3:46936655	PTH1R	-0.37	-6.94	-0.36	2.13e-11	Colorectal cancer;
CRC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg12100956	chr17:78086420	GAA	0.39	6.27	0.33	1.12e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.31	-0.33	8.9e-10	Aortic root size;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg03188948	chr7:1209495	NA	0.43	6.09	0.32	3.18e-9	Longevity;Endometriosis;
CRC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg23172400	chr8:95962367	TP53INP1	0.4	6.57	0.34	1.95e-10	Type 2 diabetes;
CRC	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.55	8.16	0.41	7.03e-15	Schizophrenia;
CRC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.42	0.53	1.19e-25	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24103979	chr1:155829285	SYT11	0.42	6.04	0.32	4.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.48	-6.78	-0.35	5.64e-11	Headache;
CRC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	15.93	0.66	9.42e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs4523957	0.928	rs6502155	chr17:2176964	A/G	cg16513277	chr17:2031491	SMG6	-0.54	-9.12	-0.45	7.71e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11556929	chr2:240323605	HDAC4	0.39	6.09	0.32	3.16e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06614563	chr5:89770451	MBLAC2;POLR3G	0.42	6.15	0.32	2.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.44	-6.77	-0.35	6.08e-11	Body mass index;
CRC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg26666090	chr16:58549219	SETD6	0.84	5.65	0.3	3.55e-8	Schizophrenia;
CRC	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.41	6.23	0.32	1.45e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.55	-0.5	1.36e-22	Alzheimer's disease;
CRC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.7	-0.35	9.01e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs77861329	1.000	rs9809977	chr3:52166147	T/C	cg08692210	chr3:52188851	WDR51A	0.86	7.84	0.4	6.46e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.59	-10.15	-0.49	3.05e-21	Body mass index;
CRC	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.42	-0.46	8.39e-19	Testicular germ cell tumor;
CRC	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg16540259	chr10:75572220	NDST2	0.38	6.29	0.33	1.02e-9	Inflammatory bowel disease;
CRC	cis	rs4666002	0.956	rs2384656	chr2:27832055	A/G	cg27432699	chr2:27873401	GPN1	0.49	6.45	0.33	4.09e-10	Phospholipid levels (plasma);
CRC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.24	-0.33	1.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg27532560	chr4:187881888	NA	-0.54	-9.79	-0.47	4.95e-20	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	ch.8.34907260F	chr8:34787718	NA	0.75	6.65	0.34	1.24e-10	Temperament (bipolar disorder);
CRC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.37	-0.46	1.17e-18	HDL cholesterol;
CRC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.19	-0.41	5.81e-15	Calcium levels;
CRC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.93	0.31	7.62e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg20243544	chr17:37824526	PNMT	0.55	8.85	0.44	5.62e-17	Asthma;
CRC	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg06636001	chr8:8085503	FLJ10661	0.5	6.52	0.34	2.69e-10	Obesity-related traits;
CRC	cis	rs12024301	0.557	rs57403433	chr1:183622951	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07610776	chr16:1832675	SPSB3;NUBP2	0.45	6.22	0.32	1.54e-9	Response to antipsychotic treatment;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.84	13.37	0.59	7.39e-33	Menarche (age at onset);
CRC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.65	9.25	0.45	2.83e-18	Vitamin D levels;
CRC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	0.98	9.51	0.46	4.15e-19	Lymphocyte counts;
CRC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg20573242	chr4:122745356	CCNA2	0.41	6.15	0.32	2.27e-9	Type 2 diabetes;
CRC	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.17	-0.32	1.99e-9	Schizophrenia;
CRC	trans	rs1459104	0.778	rs17149846	chr11:55793788	T/C	cg03313212	chr12:104850718	CHST11	-0.5	-5.99	-0.31	5.37e-9	Body mass index;
CRC	cis	rs6957923	0.967	rs35133514	chr7:23501808	C/T	cg20265043	chr7:23510089	IGF2BP3	0.37	5.68	0.3	3.03e-8	Height;
CRC	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg16691251	chr5:66510806	NA	-0.61	-11.36	-0.53	1.85e-25	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14843989	chr17:10600751	C17orf48;SCO1	0.38	6.08	0.32	3.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2415984	0.622	rs2123126	chr14:46926609	C/T	cg14871534	chr14:47121158	RPL10L	-0.43	-6.19	-0.32	1.8e-9	Number of children ever born;
CRC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.23	15.11	0.64	1.55e-39	Uric acid levels;
CRC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.53	-10.07	-0.49	5.92e-21	Height;
CRC	cis	rs728616	0.867	rs12414877	chr10:81780708	A/G	cg11900509	chr10:81946545	ANXA11	-0.68	-6.75	-0.35	6.81e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg14664628	chr15:75095509	CSK	-0.48	-7.18	-0.37	4.54e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs7572644	0.679	rs6745545	chr2:28021845	C/G	cg27432699	chr2:27873401	GPN1	0.47	6.15	0.32	2.27e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.13	0.32	2.58e-9	Bipolar disorder;
CRC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.51e-11	Monocyte count;
CRC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	15.5	0.65	4.39e-41	Smoking behavior;
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg04155289	chr7:94953770	PON1	-0.59	-7.53	-0.38	5.06e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.68	-0.3	2.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7527798	0.592	rs2025372	chr1:207829653	T/G	cg21110645	chr1:207815933	NA	-0.39	-6.18	-0.32	1.9e-9	Erythrocyte sedimentation rate;
CRC	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg11130432	chr3:121712080	ILDR1	-0.5	-6.61	-0.34	1.56e-10	Multiple sclerosis;
CRC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg04450456	chr4:17643702	FAM184B	0.41	6.72	0.35	8.23e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1871744	1.000	rs1871744	chr4:89039629	C/T	cg04322572	chr10:43447618	NA	-0.35	-6.08	-0.32	3.36e-9	Renal underexcretion gout;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12273811	chr6:28175739	NA	0.6	8.03	0.4	1.74e-14	Parkinson's disease;
CRC	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg25304816	chr1:36627734	MAP7D1	0.45	7.03	0.36	1.21e-11	Schizophrenia;
CRC	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.48	6.06	0.32	3.76e-9	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14640751	chr11:111636595	PPP2R1B	0.47	6.83	0.35	4.06e-11	Response to antipsychotic treatment;
CRC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.51	8.99	0.44	1.94e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.33	-0.53	2.36e-25	Alzheimer's disease;
CRC	cis	rs4692589	0.758	rs6823836	chr4:170933159	T/C	cg19918862	chr4:170955249	NA	0.35	5.69	0.3	2.78e-8	Anxiety disorder;
CRC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.0	0.31	5.3300000000000004e-09	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.55	7.88	0.4	4.99e-14	Lung cancer;
CRC	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.74	-11.93	-0.55	1.66e-27	Neurofibrillary tangles;
CRC	trans	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg18187862	chr3:45730750	SACM1L	0.48	6.91	0.36	2.54e-11	Primary sclerosing cholangitis;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.39	0.33	5.52e-10	Alzheimer's disease;
CRC	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.37	3.87e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05634287	chr5:148931071	CSNK1A1	0.45	6.12	0.32	2.66e-9	Anxiety disorder;
CRC	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.19	-0.67	8.76e-44	Hip circumference;
CRC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.53	6.68	0.35	1.05e-10	White matter hyperintensity burden;
CRC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.47	7.24	0.37	3.26e-12	Capecitabine sensitivity;
CRC	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg14664628	chr15:75095509	CSK	-0.67	-10.65	-0.51	6.04e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg14003231	chr6:33640908	ITPR3	0.5	7.27	0.37	2.59e-12	Platelet count;
CRC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.63	9.96	0.48	1.35e-20	Colorectal cancer;
CRC	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.6	-6.01	-0.31	4.86e-9	Night sleep phenotypes;
CRC	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg24726965	chr2:63606136	C2orf86	-0.37	-5.71	-0.3	2.54e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.95	0.31	6.72e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.78	-8.67	-0.43	1.99e-16	Non-glioblastoma glioma;Glioma;
CRC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.75	10.78	0.51	2.06e-23	Blood metabolite levels;
CRC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.43	-6.03	-0.32	4.31e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12553538	chr17:8191987	RANGRF;SLC25A35	0.37	6.0	0.31	5.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3789045	1.000	rs61817485	chr1:204595592	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.45	-7.01	-0.36	1.34e-11	Educational attainment (college completion);
CRC	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg18232548	chr7:50535776	DDC	-0.46	-6.54	-0.34	2.31e-10	Malaria;
CRC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.48	-6.91	-0.36	2.48e-11	Height;
CRC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg09876464	chr15:85330779	ZNF592	0.47	7.95	0.4	2.97e-14	P wave terminal force;
CRC	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg02336364	chr1:24764700	NIPAL3	0.37	6.15	0.32	2.19e-9	Response to interferon beta in multiple sclerosis;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg05788437	chr3:197476880	FYTTD1;KIAA0226	-0.44	-6.7	-0.35	8.87e-11	Birth weight;Height;
CRC	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg19683494	chr5:74908142	NA	0.5	6.28	0.33	1.06e-9	Age-related disease endophenotypes;
CRC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.81	10.08	0.49	5.3e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg05941027	chr17:61774174	LIMD2	0.33	5.75	0.3	1.99e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg18827107	chr12:86230957	RASSF9	-0.39	-6.34	-0.33	7.39e-10	Major depressive disorder;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg10272801	chr16:14013773	ERCC4	-0.69	-6.22	-0.32	1.49e-9	Cognitive function;
CRC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.93	-0.31	7.58e-9	Lung cancer;
CRC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg00310523	chr12:86230176	RASSF9	-0.37	-6.06	-0.32	3.82e-9	Major depressive disorder;
CRC	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg06935464	chr4:38784597	TLR10	0.55	5.74	0.3	2.12e-8	Breast cancer;
CRC	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg03641300	chr2:160917029	PLA2R1	-0.45	-6.44	-0.33	4.3e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.88	-0.4	4.7e-14	Body mass index;
CRC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg11189052	chr15:85197271	WDR73	0.6	8.9	0.44	3.69e-17	Schizophrenia;
CRC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.72	-9.04	-0.45	1.42e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.61	-8.86	-0.44	4.98e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs58799304	0.590	rs3738593	chr1:156045973	C/T	cg15685922	chr1:156045208	MEX3A	-0.48	-7.97	-0.4	2.64e-14	Ischemic stroke;
CRC	cis	rs2745967	0.715	rs1474740	chr1:208069741	A/G	cg09788693	chr1:208063733	CD34	0.45	6.74	0.35	7.14e-11	Resting heart rate;
CRC	cis	rs754466	0.706	rs7099526	chr10:79657705	C/G	cg26805224	chr10:79626177	DLG5	-0.52	-7.32	-0.37	1.92e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18358588	chr6:26660131	ZNF322A	0.47	7.54	0.38	4.71e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.36	5.79	0.3	1.68e-8	Resting heart rate;
CRC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.43	-7.81	-0.4	7.77e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04880052	chr2:219191631	PNKD	-0.42	-6.73	-0.35	7.33e-11	Colorectal cancer;
CRC	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.1e-10	Hepatitis;
CRC	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.63	11.56	0.54	3.61e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs3026101	0.671	rs9789002	chr17:5298792	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.8e-11	Body mass index;
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-0.64	-11.45	-0.53	8.66e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06994090	chr5:76011849	F2R	0.39	6.52	0.34	2.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg18232548	chr7:50535776	DDC	-0.44	-5.76	-0.3	1.9e-8	Malaria;
CRC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.51	8.67	0.43	2e-16	Hypertriglyceridemia;
CRC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.42	7.2	0.37	4.01e-12	Major depressive disorder;
CRC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.77	-13.05	-0.58	1.19e-31	Body mass index;
CRC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg02527881	chr3:46936655	PTH1R	0.37	6.84	0.35	3.78e-11	Colorectal cancer;
CRC	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.74	-16.15	-0.66	1.3e-43	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8.04e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg13514129	chr1:39547527	MACF1	0.66	10.12	0.49	3.84e-21	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg17401720	chr7:158221031	PTPRN2	0.44	7.4	0.38	1.16e-12	Obesity-related traits;
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg02951883	chr7:2050386	MAD1L1	-0.57	-9.64	-0.47	1.6e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg21251018	chr6:28226885	NKAPL	0.48	6.29	0.33	9.93e-10	Depression;
CRC	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.6	-10.37	-0.5	5.61e-22	Asthma;
CRC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.66	-10.1	-0.49	4.67e-21	Corneal astigmatism;
CRC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.52	7.75	0.39	1.14e-13	High light scatter reticulocyte count;
CRC	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg06581033	chr10:766294	NA	-0.51	-5.78	-0.3	1.76e-8	Uric acid levels;
CRC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.44	7.45	0.38	8.14e-13	Crohn's disease;
CRC	trans	rs2303319	0.504	rs16845997	chr2:162521046	C/A	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.23	0.49	1.65e-21	Hemoglobin concentration;
CRC	cis	rs3790645	1.000	rs188158	chr1:26898142	A/G	cg17456097	chr1:26900765	RPS6KA1	0.44	6.63	0.34	1.41e-10	Glucose homeostasis traits;
CRC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg25347419	chr2:177043501	NA	0.58	9.0	0.44	1.88e-17	IgG glycosylation;
CRC	cis	rs789852	0.867	rs1773175	chr3:194317732	G/A	cg21106136	chr3:194405973	FAM43A	-0.73	-5.98	-0.31	5.77e-9	QT interval;
CRC	cis	rs4700695	0.841	rs433773	chr5:65309609	G/C	cg21114390	chr5:65439923	SFRS12	0.62	6.54	0.34	2.32e-10	Facial morphology (factor 19);
CRC	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg02023728	chr11:77925099	USP35	-0.37	-6.26	-0.33	1.19e-9	Alzheimer's disease (survival time);
CRC	cis	rs61160187	0.582	rs67490467	chr5:60263818	G/C	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.74	-0.3	2.15e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs728616	0.867	rs1537835	chr10:81830152	C/G	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.93	-0.31	7.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.53	7.69	0.39	1.71e-13	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.27	0.41	3.37e-15	Lung cancer;
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg19913688	chr11:428466	ANO9	-0.7	-7.19	-0.37	4.26e-12	Body mass index;
CRC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg06287003	chr12:125626642	AACS	0.52	7.07	0.36	9.62e-12	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg17903999	chr18:56338584	MALT1	-0.45	-7.38	-0.38	1.27e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	8.35	0.42	1.87e-15	Hemoglobin concentration;
CRC	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.92	-0.31	8.07e-9	Cardiovascular disease risk factors;
CRC	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg24531977	chr5:56204891	C5orf35	0.48	7.65	0.39	2.28e-13	Coronary artery disease;
CRC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.58	-5.99	-0.31	5.56e-9	White matter hyperintensity burden;
CRC	cis	rs6662572	0.774	rs9429188	chr1:46570879	A/T	cg08644498	chr1:46502608	NA	0.46	7.36	0.38	1.45e-12	Blood protein levels;
CRC	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg25164649	chr6:28176230	NA	0.67	10.08	0.49	5.35e-21	Cardiac Troponin-T levels;
CRC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	17.5	0.69	6.15e-49	Body mass index (adult);
CRC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.52	8.21	0.41	5.22e-15	Multiple system atrophy;
CRC	cis	rs10242455	0.702	rs17161700	chr7:98977067	A/G	cg18809830	chr7:99032528	PTCD1	-0.95	-7.04	-0.36	1.1e-11	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.69	-8.31	-0.42	2.49e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.69	9.08	0.45	1.03e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7113874	0.569	rs10769915	chr11:8597449	C/G	cg02811074	chr11:8615871	STK33	-0.36	-6.11	-0.32	2.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg03013999	chr17:37608204	MED1	0.45	6.77	0.35	5.76e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07007050	chr12:31882290	AMN1	0.38	6.01	0.31	4.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs6546324	0.625	rs4533457	chr2:67787348	T/G	cg15745817	chr2:67799979	NA	-0.53	-8.45	-0.42	9.22e-16	Endometriosis;
CRC	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.57	-7.77	-0.39	9.98e-14	Extraversion;
CRC	trans	rs529967	0.757	rs687487	chr3:124166908	A/T	cg01377916	chr16:46654868	SHCBP1	0.48	6.16	0.32	2.18e-9	Acute graft versus host disease in bone marrow transplantation (donor effect);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09455096	chr2:61765470	XPO1	0.51	6.57	0.34	1.92e-10	Thyroid stimulating hormone;
CRC	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.55	8.4	0.42	1.31e-15	Diastolic blood pressure;
CRC	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg19683494	chr5:74908142	NA	0.5	6.26	0.33	1.22e-9	Age-related disease endophenotypes;
CRC	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.12e-18	Blood protein levels;
CRC	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg12700464	chr11:78128424	GAB2	-0.47	-5.66	-0.3	3.38e-8	Testicular germ cell tumor;
CRC	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg20936604	chr3:58311152	NA	-0.74	-6.94	-0.36	2.05e-11	Cholesterol, total;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07119616	chr9:129452879	LMX1B	0.43	6.03	0.32	4.39e-9	Thyroid stimulating hormone;
CRC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.66	-0.57	3.26e-30	Bipolar disorder and schizophrenia;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02567788	chr10:71992279	PPA1	-0.45	-6.62	-0.34	1.48e-10	Daytime sleep phenotypes;
CRC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.74	-12.12	-0.56	3.27e-28	Colorectal cancer;
CRC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.09e-12	Headache;
CRC	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.57	-7.93	-0.4	3.36e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg08222913	chr3:52553049	STAB1	-0.35	-6.55	-0.34	2.17e-10	Bipolar disorder;
CRC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.49	-9.39	-0.46	1.03e-18	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-6.69	-0.35	9.49e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.12	0.41	9.29e-15	Monocyte count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06713297	chr1:242011104	EXO1	0.46	6.06	0.32	3.78e-9	Thyroid stimulating hormone;
CRC	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.7	-7.3	-0.37	2.15e-12	Recalcitrant atopic dermatitis;
CRC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07513332	chr6:167530253	CCR6	0.38	6.34	0.33	7.46e-10	Primary biliary cholangitis;
CRC	cis	rs519973	0.554	rs13069721	chr3:187669234	C/A	cg10168494	chr3:187635183	NA	0.39	5.71	0.3	2.57e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg03609598	chr5:56110824	MAP3K1	0.57	7.71	0.39	1.5e-13	Initial pursuit acceleration;
CRC	cis	rs1840108	0.529	rs35192399	chr2:181492583	T/C	cg23363182	chr2:181467187	NA	-0.48	-6.51	-0.34	2.8e-10	Anti-saccade response;
CRC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.55	-7.83	-0.4	6.97e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.76	-9.19	-0.45	4.53e-18	Initial pursuit acceleration;
CRC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg11833968	chr6:79620685	NA	-0.36	-6.1	-0.32	2.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.51	6.95	0.36	1.95e-11	Aortic root size;
CRC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.44	0.38	9e-13	Mean platelet volume;
CRC	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.44	5.91	0.31	8.59e-9	Tuberculosis;
CRC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.41	7.43	0.38	9.56e-13	Childhood ear infection;
CRC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.74	10.08	0.49	5.11e-21	Platelet count;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02073318	chr1:41708081	SCMH1	-0.41	-6.06	-0.32	3.77e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.8	13.18	0.59	3.73e-32	Height;
CRC	cis	rs972578	0.967	rs5759091	chr22:43407464	C/T	cg01576275	chr22:43409880	NA	-0.47	-7.47	-0.38	7.06e-13	Mean platelet volume;
CRC	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.31	-0.33	8.99e-10	Arsenic metabolism;
CRC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.68	-11.48	-0.53	7.08e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.45	5.67	0.3	3.19e-8	Aortic root size;
CRC	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.63	-9.77	-0.47	5.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg14433983	chr11:636460	DRD4	-0.44	-5.61	-0.3	4.26e-8	Systemic lupus erythematosus;
CRC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg19046167	chr17:80928561	B3GNTL1	0.5	7.1	0.36	7.65e-12	Glycated hemoglobin levels;
CRC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.16	-0.41	7.34e-15	Chronic sinus infection;
CRC	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.62	-8.27	-0.41	3.35e-15	Blood pressure (smoking interaction);
CRC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07395648	chr5:131743802	NA	-0.39	-5.67	-0.3	3.15e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg18827107	chr12:86230957	RASSF9	-0.36	-5.7	-0.3	2.65e-8	Major depressive disorder;
CRC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.48	6.31	0.33	9.13e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	7.96	0.4	2.77e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	8.14	0.41	8.5e-15	Lung cancer in ever smokers;
CRC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.67e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg02741985	chr17:80059408	CCDC57	0.43	7.14	0.37	5.9e-12	Life satisfaction;
CRC	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg23100626	chr2:96804247	ASTL	-0.28	-7.14	-0.37	6.1e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	-0.54	-9.04	-0.45	1.34e-17	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.52	8.12	0.41	9.33e-15	Menopause (age at onset);
CRC	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.63	-0.3	3.93e-8	Blood pressure;
CRC	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.41	-6.44	-0.33	4.29e-10	Testicular germ cell tumor;
CRC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg23262073	chr20:60523788	NA	-0.46	-7.11	-0.36	7.38e-12	Body mass index;
CRC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.46e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg21970626	chr13:21893289	NA	0.46	5.94	0.31	7.09e-9	White matter hyperintensity burden;
CRC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.34	-0.33	7.75e-10	Menarche (age at onset);
CRC	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.79	0.35	5.28e-11	Lymphocyte counts;
CRC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.05	-0.45	1.3e-17	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02018176	chr4:1364513	KIAA1530	0.4	6.73	0.35	7.47e-11	Obesity-related traits;
CRC	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.0	0.31	5.23e-9	Axial length;
CRC	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.66	7.27	0.37	2.68e-12	Breast cancer;
CRC	cis	rs742115	0.510	rs9468839	chr6:11308035	A/T	cg25250968	chr6:11318770	NEDD9	0.38	7.27	0.37	2.63e-12	Coronary artery disease;
CRC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.61	8.13	0.41	9.02e-15	Height;
CRC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.04	14.1	0.61	1.17e-35	Orofacial clefts;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.83	-18.14	-0.71	1.79e-51	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg18301423	chr5:131593218	PDLIM4	0.39	6.46	0.34	3.77e-10	Breast cancer;
CRC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.89	0.55	2.32e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.21	-0.32	1.63e-9	Bipolar disorder;
CRC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.44	8.82	0.44	6.83e-17	Renal cell carcinoma;
CRC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.71	-10.34	-0.5	7.19e-22	Platelet distribution width;
CRC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.67	10.36	0.5	5.72e-22	Schizophrenia;
CRC	cis	rs9039	1.000	rs17652208	chr16:9196463	C/T	cg08831531	chr16:9218945	NA	-0.56	-6.66	-0.34	1.13e-10	Menopause (age at onset);
CRC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.7	-0.51	4.06e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.21	-6.03	-0.32	4.52e-9	Urinary metabolites;
CRC	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg18742855	chr2:26800399	C2orf70	-0.48	-7.28	-0.37	2.42e-12	Periodontal microbiota;
CRC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.29	-0.37	2.37e-12	Vitiligo;
CRC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-8.29	-0.42	2.94e-15	Uric acid levels;
CRC	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg24849736	chr1:201084428	NA	-0.61	-11.23	-0.53	5.39e-25	Permanent tooth development;
CRC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.39	5.98	0.31	5.67e-9	Crohn's disease;
CRC	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg17410650	chr12:54324560	NA	-0.37	-6.69	-0.35	9.45e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.51	0.69	5.94e-49	Platelet count;
CRC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.67	-11.67	-0.54	1.46e-26	Refractive error;
CRC	cis	rs7680126	0.633	rs11729318	chr4:10336919	G/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.11	-0.32	2.78e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg26587870	chr6:27730563	NA	-0.46	-6.82	-0.35	4.26e-11	Parkinson's disease;
CRC	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.62	11.34	0.53	2.27e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.57	-8.95	-0.44	2.75e-17	Height;
CRC	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.67	-0.3	3.18e-8	Tuberculosis;
CRC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.53	-7.58	-0.39	3.44e-13	Migraine;
CRC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-11.47	-0.53	7.71e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.75	-0.39	1.12e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.5	8.79	0.44	8.61e-17	Testicular germ cell tumor;
CRC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.82	13.45	0.6	3.74e-33	Menopause (age at onset);
CRC	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.79	-0.68	4.09e-46	Hip circumference;
CRC	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg03929089	chr4:120376271	NA	-0.47	-6.7	-0.35	9.18e-11	Height;
CRC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg05207973	chr5:176823642	SLC34A1	0.34	5.87	0.31	1.08e-8	Hemoglobin concentration;Hematocrit;
CRC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.59	13.49	0.6	2.67e-33	Breast size;
CRC	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-0.85	-12.89	-0.58	4.77e-31	Platelet distribution width;
CRC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg23996704	chr18:44553084	KATNAL2	0.41	8.2	0.41	5.47e-15	Personality dimensions;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg15845792	chr6:28175446	NA	0.86	13.37	0.59	7.62e-33	Cardiac Troponin-T levels;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.37	-5.77	-0.3	1.86e-8	Platelet count;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.9	-0.36	2.69e-11	Schizophrenia;
CRC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg11632617	chr15:75315747	PPCDC	-0.56	-7.9	-0.4	4.2e-14	Blood trace element (Zn levels);
CRC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	0.68	6.1	0.32	3.04e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.74	12.19	0.56	1.84e-28	Selective IgA deficiency;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg19545348	chr1:211434133	RCOR3	-0.4	-5.96	-0.31	6.43e-9	Daytime sleep phenotypes;
CRC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.78	0.3	1.69e-8	Major depressive disorder;
CRC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.3	-0.37	2.23e-12	Morning vs. evening chronotype;
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.43	-6.13	-0.32	2.52e-9	Lymphocyte counts;
CRC	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg11887960	chr12:57824829	NA	0.59	6.68	0.35	1.01e-10	Obesity-related traits;
CRC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.54	-8.04	-0.41	1.69e-14	Menarche (age at onset);
CRC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg19223190	chr17:80058835	NA	0.4	6.31	0.33	8.92e-10	Life satisfaction;
CRC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg09163369	chr1:210001066	C1orf107	0.44	6.4	0.33	5.35e-10	Orofacial clefts;
CRC	cis	rs990171	0.955	rs6761825	chr2:103075561	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.87	0.31	1.09e-8	Lymphocyte counts;
CRC	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg27398640	chr15:77910606	LINGO1	-0.44	-7.61	-0.39	2.96e-13	Type 2 diabetes;
CRC	cis	rs4604732	0.754	rs12080212	chr1:247631606	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.39	6.42	0.33	4.63e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.7	-6.51	-0.34	2.89e-10	Inflammatory biomarkers;
CRC	cis	rs883565	0.569	rs704959	chr3:39180263	G/A	cg01426195	chr3:39028469	NA	0.41	6.7	0.35	9.13e-11	Handedness;
CRC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.44	-19.26	-0.73	6.97e-56	Hip circumference adjusted for BMI;
CRC	trans	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg10756647	chr7:56101905	PSPH	-0.77	-7.87	-0.4	5.06e-14	Diabetic kidney disease;
CRC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.64	7.54	0.38	4.52e-13	Menarche (age at onset);
CRC	cis	rs7605827	0.930	rs4668919	chr2:15662171	C/T	cg19274914	chr2:15703543	NA	0.37	5.71	0.3	2.52e-8	Educational attainment (years of education);
CRC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-12.65	-0.57	3.73e-30	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.59	9.2	0.45	4.28e-18	Facial morphology (factor 23);
CRC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg11887960	chr12:57824829	NA	0.58	6.5	0.34	3.04e-10	Obesity-related traits;
CRC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.68	-12.62	-0.57	4.58e-30	Breast cancer;
CRC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.5	9.49	0.46	4.72e-19	Smoking initiation;
CRC	cis	rs17162190	0.698	rs6693662	chr1:26821230	A/G	cg17456097	chr1:26900765	RPS6KA1	0.45	6.51	0.34	2.79e-10	Mean corpuscular volume;
CRC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.56	-0.47	2.8e-19	Migraine;Coronary artery disease;
CRC	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg14458575	chr2:238380390	NA	0.52	6.86	0.35	3.51e-11	Prostate cancer;
CRC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.59	7.33	0.37	1.8e-12	Ulcerative colitis;
CRC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.48	5.92	0.31	8.01e-9	Renal function-related traits (BUN);
CRC	trans	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg26043149	chr18:55253948	FECH	0.54	8.27	0.41	3.27e-15	Bone mineral density;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.66	-10.63	-0.51	6.76e-23	Motion sickness;
CRC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg02007433	chr3:129722099	NA	0.46	6.55	0.34	2.28e-10	Blood pressure (smoking interaction);
CRC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg07636037	chr3:49044803	WDR6	-0.82	-6.67	-0.35	1.06e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.81	13.64	0.6	7.09e-34	Menopause (age at onset);
CRC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.65	-8.84	-0.44	5.89e-17	Alcohol dependence;
CRC	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.38	5.74	0.3	2.12e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.49	0.34	3.18e-10	Rheumatoid arthritis;
CRC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg19812747	chr11:111475976	SIK2	-0.58	-9.92	-0.48	1.8e-20	Primary sclerosing cholangitis;
CRC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.43	-0.42	1.12e-15	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.59	-9.11	-0.45	8.18e-18	Colorectal cancer;
CRC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.5	0.57	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.91	11.32	0.53	2.52e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs12699921	0.632	rs2691594	chr7:17864816	C/G	cg02066331	chr6:17282778	RBM24	-0.36	-6.09	-0.32	3.23e-9	Fibrinogen levels;
CRC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.54	-8.25	-0.41	3.88e-15	Aortic root size;
CRC	cis	rs7605827	0.930	rs4668900	chr2:15511740	T/C	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs6735179	1.000	rs6735179	chr2:1777150	A/G	cg19300414	chr2:1746591	PXDN	0.36	6.28	0.33	1.05e-9	Response to antipsychotic treatment;
CRC	cis	rs524281	0.861	rs11227426	chr11:65971951	T/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.3	-0.37	2.21e-12	Electroencephalogram traits;
CRC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.5e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg02023728	chr11:77925099	USP35	0.32	5.62	0.3	4e-8	Alzheimer's disease (survival time);
CRC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.38	6.79	0.35	5.25e-11	Cardiovascular disease risk factors;
CRC	cis	rs1840108	0.543	rs13020426	chr2:181345771	T/C	cg23363182	chr2:181467187	NA	-0.56	-6.59	-0.34	1.72e-10	Anti-saccade response;
CRC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.32	4.57e-9	Gut microbiome composition (summer);
CRC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.63	-9.98	-0.48	1.17e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.58	8.17	0.41	6.65e-15	Lung cancer;
CRC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg10589385	chr1:150898437	SETDB1	0.3	6.16	0.32	2.14e-9	Melanoma;
CRC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.7	7.85	0.4	6.01e-14	Vitiligo;
CRC	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.59	-10.45	-0.5	2.81e-22	Educational attainment;
CRC	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.39	6.04	0.32	4.14e-9	Endometrial cancer;
CRC	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg01426195	chr3:39028469	NA	-0.52	-8.34	-0.42	2.13e-15	Handedness;
CRC	cis	rs6896969	0.510	rs1899982	chr5:40425045	C/T	cg09067459	chr5:40385259	NA	0.47	7.9	0.4	4.19e-14	Multiple sclerosis;
CRC	trans	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg26043149	chr18:55253948	FECH	0.49	7.77	0.39	9.81e-14	Bone mineral density;
CRC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg21681030	chr2:46777652	RHOQ	0.45	6.05	0.32	3.98e-9	Height;
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs7705042	0.826	rs13184323	chr5:141494719	T/G	cg07392085	chr5:141489673	NDFIP1	0.47	7.41	0.38	1.06e-12	Asthma;
CRC	trans	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg21302420	chr1:112162376	RAP1A	-0.71	-6.0	-0.31	5.24e-9	Skin colour saturation;
CRC	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	5.72	0.3	2.37e-8	Refractive astigmatism;
CRC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.43	5.96	0.31	6.64e-9	Resistin levels;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.77	11.31	0.53	2.93e-25	Menarche (age at onset);
CRC	trans	rs263156	0.727	rs7740440	chr6:142972917	A/G	cg26361513	chr14:105821007	PACS2	0.4	6.11	0.32	2.82e-9	Ear morphology;Lobe size;Lobe attachment;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.58	8.51	0.42	6.24e-16	Lymphocyte counts;
CRC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.14e-10	Lung cancer;
CRC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.44	6.66	0.34	1.13e-10	Type 2 diabetes;
CRC	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.36	-5.65	-0.3	3.48e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.42	-0.33	4.7e-10	Menarche (age at onset);
CRC	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.36	-5.99	-0.31	5.5e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs890448	0.896	rs9884436	chr4:102413271	A/G	cg24678611	chr1:3567732	TP73;WDR8	-0.28	-6.01	-0.31	4.84e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg07212818	chr11:638076	DRD4	-0.43	-5.61	-0.3	4.24e-8	Systemic lupus erythematosus;
CRC	cis	rs10512697	0.803	rs13173352	chr5:3578681	A/G	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg04110750	chr16:69646130	NFAT5	0.54	7.86	0.4	5.64e-14	IgE levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06477881	chr10:72142520	LRRC20	0.41	6.22	0.32	1.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-7.76	-0.39	1.09e-13	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.78	-0.39	9.34e-14	Biliary atresia;
CRC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.4	-0.33	5.26e-10	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg19223190	chr17:80058835	NA	0.38	6.17	0.32	1.97e-9	Life satisfaction;
CRC	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.68	-11.49	-0.54	6.43e-26	White blood cell count (basophil);
CRC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.62	-9.05	-0.45	1.28e-17	Menarche (age at onset);
CRC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.1	0.32	2.99e-9	Obesity-related traits;
CRC	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg01843034	chr6:37503916	NA	-0.44	-8.26	-0.41	3.64e-15	Cognitive performance;
CRC	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg26875233	chr11:93583750	C11orf90	-0.34	-6.59	-0.34	1.7e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.75	9.79	0.48	4.94e-20	Platelet count;
CRC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-6.3	-0.33	9.82e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.95	10.61	0.5	8.04e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-7.34	-0.38	1.7e-12	Putamen volume;
CRC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.58	7.22	0.37	3.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.89	-11.28	-0.53	3.61e-25	Hair shape;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00546594	chr21:35287829	ATP5O	0.4	6.09	0.32	3.08e-9	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11044724	chr2:7005733	CMPK2	0.44	6.58	0.34	1.81e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4824093	0.610	rs73443986	chr22:50321193	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-9.16	-0.45	5.66e-18	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs9822411	0.623	rs17016187	chr3:25364289	A/G	cg18451114	chr1:38511677	POU3F1	0.5	6.46	0.34	3.69e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.72	0.35	8.19e-11	Lung cancer;
CRC	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.42	-11.61	-0.54	2.3e-26	Psoriasis vulgaris;
CRC	cis	rs10905065	0.827	rs7089100	chr10:5849877	C/G	cg11519256	chr10:5708881	ASB13	0.46	6.76	0.35	6.38e-11	Menopause (age at onset);
CRC	trans	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.33	-0.33	7.99e-10	Aortic root size;
CRC	cis	rs4728302	0.869	rs6978170	chr7:133603838	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.67	0.3	3.13e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.88	10.71	0.51	3.7e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.17	-0.49	2.64e-21	Bipolar disorder;
CRC	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.44	6.02	0.31	4.78e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs728616	0.510	rs7074356	chr10:82191334	C/T	cg05935833	chr10:81318306	SFTPA2	-0.43	-6.05	-0.32	4.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.96	-0.31	6.5e-9	Metabolite levels;
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg18301423	chr5:131593218	PDLIM4	0.31	5.93	0.31	7.79e-9	Blood metabolite levels;
CRC	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.54	-7.95	-0.4	3.04e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.76	-11.88	-0.55	2.4200000000000002e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.97	-0.31	5.99e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.66	0.57	3.42e-30	Platelet count;
CRC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs9914544	0.564	rs7223173	chr17:18805887	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.04	-0.32	4.16e-9	Educational attainment (years of education);
CRC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-9.98	-0.48	1.14e-20	Breast cancer;
CRC	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.68	-0.35	1.03e-10	Eye color traits;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg15382696	chr6:118971807	C6orf204	0.62	8.05	0.41	1.53e-14	Diastolic blood pressure;
CRC	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	cg04338863	chr8:33670619	NA	0.42	6.33	0.33	7.99e-10	Body mass index;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg18301423	chr5:131593218	PDLIM4	-0.41	-7.02	-0.36	1.3e-11	Blood metabolite levels;
CRC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.39	-5.74	-0.3	2.19e-8	Lung cancer;
CRC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.82	12.72	0.57	2.08e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Educational attainment;
CRC	cis	rs1712517	0.771	rs61871160	chr10:105144288	C/T	cg05636881	chr10:105038444	INA	0.47	8.11	0.41	1.04e-14	Migraine;
CRC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.45	7.41	0.38	1.07e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.56	0.6	1.36e-33	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.86	-0.31	1.13e-8	Lung cancer;
CRC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg24209194	chr3:40518798	ZNF619	0.45	6.78	0.35	5.61e-11	Renal cell carcinoma;
CRC	cis	rs3736485	0.966	rs2414113	chr15:51903896	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.53	-0.34	2.56e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg16077055	chr2:106428750	NCK2	0.39	5.61	0.3	4.38e-8	Addiction;
CRC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.75	11.11	0.52	1.49e-24	Cisplatin-induced ototoxicity;
CRC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.34	6.46	0.34	3.7e-10	Iron status biomarkers;
CRC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs17067123	0.614	rs72712851	chr4:180066258	A/G	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	7.28e-11	Response to hepatitis C treatment;
CRC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-5.61	-0.3	4.32e-8	Schizophrenia;
CRC	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.61	-7.5	-0.38	5.93e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.85	0.44	5.32e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.31	-0.33	9.14e-10	Aortic root size;
CRC	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg04239558	chr2:103089729	SLC9A4	-0.36	-6.05	-0.32	3.88e-9	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00106211	chr6:36514552	STK38	0.46	6.51	0.34	2.77e-10	Response to antipsychotic treatment;
CRC	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg14631576	chr9:95140430	CENPP	-0.3	-5.62	-0.3	4.08e-8	Height;
CRC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.62	-7.6	-0.39	3.05e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03176143	chr19:4066940	ZBTB7A	0.52	7.3	0.37	2.25e-12	Anxiety disorder;
CRC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.68	7.7	0.39	1.62e-13	Major depressive disorder;
CRC	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.37	5.92	0.31	8.15e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg19318889	chr4:1322082	MAEA	0.39	5.64	0.3	3.73e-8	Obesity-related traits;
CRC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.52	7.16	0.37	5.17e-12	Response to temozolomide;
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	7.35	0.38	1.6e-12	Menarche (age at onset);
CRC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg20243544	chr17:37824526	PNMT	0.56	9.0	0.44	1.86e-17	Asthma;
CRC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg11189052	chr15:85197271	WDR73	0.64	8.98	0.44	2.11e-17	Schizophrenia;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10819733	chr22:24237672	NA	-0.37	-6.29	-0.33	1.02e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.48	-7.06	-0.36	9.82e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03143033	chr16:75032853	ZNRF1	0.39	6.16	0.32	2.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg03804128	chr16:635623	NA	0.28	6.49	0.34	3.24e-10	Height;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.56	9.16	0.45	5.85e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.86	13.21	0.59	2.95e-32	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04213235	chr1:145826932	GPR89A	0.52	7.25	0.37	2.99e-12	Response to antipsychotic treatment;
CRC	cis	rs6700896	0.931	rs4655574	chr1:66135328	T/A	cg04111102	chr1:66153794	NA	0.35	6.14	0.32	2.32e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.98	18.08	0.71	3.2e-51	IgG glycosylation;
CRC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.57	8.4	0.42	1.37e-15	Type 2 diabetes;
CRC	cis	rs4964805	1.000	rs34307072	chr12:104196304	G/A	cg02344784	chr12:104178138	NT5DC3	0.54	7.99	0.4	2.36e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg08888203	chr3:10149979	C3orf24	0.48	7.28	0.37	2.52e-12	Alzheimer's disease;
CRC	trans	rs9528384	0.750	rs12865693	chr13:62256485	A/C	cg08375866	chr1:50799151	NA	-0.32	-6.0	-0.31	5.08e-9	Verbal declarative memory;
CRC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.49	0.34	3.1e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.48	-0.42	7.77e-16	Monocyte count;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-8.98	-0.44	2.11e-17	Bipolar disorder;
CRC	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg00666640	chr1:248458726	OR2T12	0.4	7.31	0.37	2e-12	Common traits (Other);
CRC	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg24476569	chr13:95954382	ABCC4	-0.39	-5.81	-0.31	1.44e-8	Blood metabolite levels;
CRC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.47	7.78	0.39	9.77e-14	Major depressive disorder;
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.25	-0.33	1.27e-9	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24931592	chr11:105948506	AASDHPPT;KBTBD3	0.46	6.5	0.34	2.93e-10	Response to antipsychotic treatment;
CRC	cis	rs9462027	0.628	rs7739003	chr6:34800329	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.4e-9	Systemic lupus erythematosus;
CRC	cis	rs17155006	0.655	rs426812	chr7:107728512	T/C	cg05962710	chr7:107745446	LAMB4	-0.38	-6.28	-0.33	1.08e-9	Pneumococcal bacteremia;
CRC	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.38	5.77	0.3	1.84e-8	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
CRC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg22110888	chr17:80059540	CCDC57	-0.37	-5.93	-0.31	7.8e-9	Life satisfaction;
CRC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-16.03	-0.66	3.99e-43	Schizophrenia;
CRC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-6.09	-0.32	3.07e-9	Monocyte percentage of white cells;
CRC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs4728302	0.869	rs7792546	chr7:133595502	G/T	cg03336402	chr7:133662267	EXOC4	-0.43	-6.16	-0.32	2.13e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.0	-0.31	5.12e-9	Retinal vascular caliber;
CRC	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.66	10.88	0.51	9.19e-24	Hepatocellular carcinoma;
CRC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.69	10.92	0.52	6.62e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.77	11.26	0.53	4.18e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-6.24	-0.33	1.34e-9	Height;
CRC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg04450456	chr4:17643702	FAM184B	0.39	6.03	0.32	4.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.81	14.02	0.61	2.5e-35	Height;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg19041857	chr6:27730383	NA	-0.41	-5.96	-0.31	6.46e-9	Parkinson's disease;
CRC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.6	10.27	0.49	1.18e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.71	-0.35	8.71e-11	Response to antipsychotic treatment;
CRC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg13753209	chr17:57696993	CLTC	0.44	5.85	0.31	1.19e-8	Hemoglobin concentration;
CRC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg08222618	chr4:941054	TMEM175	0.75	15.05	0.64	2.57e-39	Sjögren's syndrome;
CRC	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.62	0.3	3.97e-8	Corneal astigmatism;
CRC	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.51	7.97	0.4	2.66e-14	Anxiety disorder;
CRC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.41	-5.63	-0.3	3.79e-8	Parkinson's disease;
CRC	cis	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg15105060	chr4:7024189	TBC1D14	-0.74	-5.67	-0.3	3.19e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12745968	0.620	rs4847267	chr1:93155347	A/G	cg17283838	chr1:93427260	FAM69A	0.47	6.33	0.33	7.89e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	16.13	0.66	1.55e-43	Platelet count;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24689420	chr5:179126339	CANX	-0.54	-6.58	-0.34	1.8e-10	Diisocyanate-induced asthma;
CRC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.64	9.67	0.47	1.27e-19	Hemoglobin concentration;
CRC	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.46	6.66	0.34	1.18e-10	Subjective well-being;
CRC	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.91	0.31	8.35e-9	Axial length;
CRC	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg13385794	chr1:248469461	NA	0.34	6.19	0.32	1.75e-9	Common traits (Other);
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-12.25	-0.56	1.1e-28	Asthma;
CRC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.29	-0.33	1.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.65	10.82	0.51	1.54e-23	Iron status biomarkers;
CRC	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-5.69	-0.3	2.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg11212589	chr17:38028394	ZPBP2	0.34	6.01	0.31	4.8e-9	Self-reported allergy;
CRC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.65	9.39	0.46	1.02e-18	Menopause (age at onset);
CRC	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.2	10.77	0.51	2.33e-23	Prostate cancer;
CRC	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.88	0.31	9.91e-9	Protein C levels;
CRC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12516959	chr21:47718080	NA	-0.33	-5.72	-0.3	2.38e-8	Testicular germ cell tumor;
CRC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg27284194	chr4:1044797	NA	0.48	5.84	0.31	1.25e-8	Recombination rate (females);
CRC	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.49e-16	Homoarginine levels;
CRC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg03037974	chr15:76606532	NA	0.78	15.79	0.66	3.49e-42	Blood metabolite levels;
CRC	cis	rs9584850	0.794	rs17470961	chr13:99135314	A/G	cg07423050	chr13:99094983	FARP1	0.46	6.45	0.33	4.07e-10	Neuroticism;
CRC	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.83	-14.62	-0.63	1.16e-37	Lewy body disease;
CRC	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg26741380	chr15:41871084	TYRO3	0.45	6.2	0.32	1.73e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.55	7.53	0.38	4.93e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.49	-7.65	-0.39	2.27e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs6076065	0.723	rs2424534	chr20:23378866	A/G	cg11657817	chr20:23433608	CST11	-0.42	-6.28	-0.33	1.08e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.68	0.35	1.02e-10	Schizophrenia;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg03623178	chr6:28175578	NA	0.64	9.66	0.47	1.3e-19	Cardiac Troponin-T levels;
CRC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-6.33	-0.33	7.81e-10	Vitiligo;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg04553112	chr3:125709451	NA	-0.51	-5.71	-0.3	2.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.44	-5.94	-0.31	7.23e-9	Gut microbiome composition (summer);
CRC	cis	rs1223397	0.938	rs3817737	chr6:13279082	A/G	cg20827128	chr6:13274284	PHACTR1	0.54	6.36	0.33	6.6e-10	Blood pressure;
CRC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.47	-0.38	7.52e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	6.34	0.33	7.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.86	-0.48	2.88e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.48	-7.46	-0.38	7.92e-13	Coronary artery disease;
CRC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.67	-0.35	1.09e-10	Daytime sleep phenotypes;
CRC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.35	0.56	4.59e-29	Coronary artery disease;
CRC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.51	8.05	0.41	1.48e-14	Psychosis in Alzheimer's disease;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Depression;
CRC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16447950	chr5:562315	NA	-0.74	-9.76	-0.47	6.14e-20	Obesity-related traits;
CRC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.52	7.81	0.4	7.83e-14	Cognitive function;
CRC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg00717180	chr2:96193071	NA	-0.39	-6.47	-0.34	3.53e-10	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06538998	chr16:28503160	CLN3	0.4	6.19	0.32	1.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg16342193	chr10:102329863	NA	-0.39	-6.32	-0.33	8.56e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg00738113	chr16:70207722	CLEC18C	-0.41	-5.86	-0.31	1.12e-8	IgE levels;
CRC	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.61	0.39	2.84e-13	Iron status biomarkers;
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.74	11.28	0.53	3.63e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg02811702	chr13:24901961	NA	0.47	6.47	0.34	3.6e-10	Obesity-related traits;
CRC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg17724175	chr1:150552817	MCL1	0.45	6.68	0.35	1.03e-10	Melanoma;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg21620606	chr4:1342894	KIAA1530	0.4	6.94	0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.23	0.32	1.43e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg10802521	chr3:52805072	NEK4	-0.47	-6.15	-0.32	2.19e-9	Schizophrenia;
CRC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg18827107	chr12:86230957	RASSF9	-0.38	-5.84	-0.31	1.26e-8	Major depressive disorder;
CRC	cis	rs3741151	0.686	rs12291233	chr11:73272946	T/G	cg17517138	chr11:73019481	ARHGEF17	0.55	5.62	0.3	4.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg21251018	chr6:28226885	NKAPL	0.57	10.06	0.49	6.1e-21	Cardiac Troponin-T levels;
CRC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.82	0.31	1.37e-8	Systemic lupus erythematosus;
CRC	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.52	9.95	0.48	1.42e-20	HIV-1 susceptibility;
CRC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg16060761	chr17:80687452	NA	-0.46	-6.04	-0.32	4.28e-9	Glycated hemoglobin levels;
CRC	cis	rs12476592	0.602	rs262530	chr2:63904274	A/T	cg10828910	chr2:63850056	LOC388955	0.51	6.33	0.33	7.99e-10	Childhood ear infection;
CRC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg20542592	chr8:11973495	FAM66D	-0.34	-5.96	-0.31	6.63e-9	Retinal vascular caliber;
CRC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.68	-0.39	1.81e-13	Gut microbiome composition (summer);
CRC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.25	-0.45	2.96e-18	Alcohol dependence;
CRC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	9.37	0.46	1.19e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.75	6.95	0.36	1.93e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.935	rs227070	chr11:108211412	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.91	0.31	8.7e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.54	-6.73	-0.35	7.68e-11	Ulcerative colitis;
CRC	cis	rs4363385	0.765	rs11205165	chr1:152986928	G/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.65e-12	Inflammatory skin disease;
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg12273811	chr6:28175739	NA	-0.52	-5.83	-0.31	1.32e-8	Parkinson's disease;
CRC	cis	rs4908768	0.501	rs12061328	chr1:8531963	C/T	cg20416874	chr1:8611966	RERE	-0.43	-6.13	-0.32	2.55e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.59	7.29	0.37	2.37e-12	Response to diuretic therapy;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.67	11.11	0.52	1.42e-24	Height;
CRC	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.65	10.1	0.49	4.61e-21	Corneal astigmatism;
CRC	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.79	11.97	0.55	1.22e-27	Testicular germ cell tumor;
CRC	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs12476592	0.602	rs262487	chr2:63880517	G/T	cg10828910	chr2:63850056	LOC388955	-0.47	-5.95	-0.31	6.74e-9	Childhood ear infection;
CRC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.18	-0.41	6.32e-15	Morning vs. evening chronotype;
CRC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	4.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	9.49	0.46	4.91e-19	Personality dimensions;
CRC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.67	9.02	0.45	1.59e-17	Breast cancer;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg23100626	chr2:96804247	ASTL	0.27	7.01	0.36	1.34e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-6.17	-0.32	2.02e-9	Schizophrenia;
CRC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	1.04e-10	Menopause (age at onset);
CRC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg16797656	chr11:68205561	LRP5	0.36	5.75	0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs11203032	0.831	rs10887925	chr10:90938902	G/T	cg16672925	chr10:90967113	CH25H	0.45	5.7	0.3	2.64e-8	Heart failure;
CRC	cis	rs7635838	0.892	rs4684775	chr3:11436413	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.28	0.33	1.08e-9	HDL cholesterol;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg21251018	chr6:28226885	NKAPL	0.42	6.06	0.32	3.81e-9	Parkinson's disease;
CRC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.56	-0.34	2.04e-10	Subjective well-being;
CRC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg23071808	chr14:103021642	NA	-0.67	-8.67	-0.43	2.07e-16	Platelet count;
CRC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.46	7.83e-19	Bladder cancer;
CRC	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.69	-11.91	-0.55	1.95e-27	White blood cell count (basophil);
CRC	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.43	-6.76	-0.35	6.25e-11	Caffeine consumption;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg06151567	chr1:17765735	RCC2	-0.61	-6.07	-0.32	3.46e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.6e-9	Major depressive disorder;
CRC	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg13736514	chr6:26305472	NA	-0.46	-7.55	-0.38	4.45e-13	Educational attainment;
CRC	trans	rs2055729	0.677	rs6601393	chr8:9741035	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.02	-0.31	4.63e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	7.34	0.37	1.72e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.75	-8.31	-0.42	2.55e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg19678392	chr7:94953810	PON1	-0.56	-7.07	-0.36	9.28e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.16	-11.98	-0.55	1.13e-27	Breast cancer;
CRC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.73	-13.06	-0.58	1.05e-31	Body mass index;
CRC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	1.1	10.82	0.51	1.56e-23	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.901	rs2083707	chr11:108066130	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.39	5.76	0.3	1.94e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg20935368	chr5:178288625	ZNF354B	0.43	7.01	0.36	1.32e-11	Sleep duration;
CRC	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.04	0.45	1.36e-17	Dupuytren's disease;
CRC	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.56	-0.38	4.1e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.36	-5.84	-0.31	1.28e-8	High light scatter reticulocyte count;
CRC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg23880581	chr15:78912387	CHRNA3	0.33	5.62	0.3	4e-8	Sudden cardiac arrest;
CRC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg15845792	chr6:28175446	NA	0.72	6.15	0.32	2.24e-9	Breast cancer;
CRC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.41	-7.71	-0.39	1.47e-13	Huntington's disease progression;
CRC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg23815491	chr16:72088622	HP	0.51	7.78	0.39	9.45e-14	Fibrinogen levels;
CRC	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg00691999	chr4:55094011	PDGFRA	0.4	5.93	0.31	7.46e-9	Corneal astigmatism;
CRC	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.62	9.71	0.47	9.26e-20	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25179170	chr1:93427589	FAM69A	0.41	6.13	0.32	2.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12024301	0.557	rs10157799	chr1:183655121	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.67	6.13	0.32	2.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	5.84	0.31	1.26e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.37	-6.89	-0.36	2.86e-11	Iron status biomarkers;
CRC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.65	-9.93	-0.48	1.64e-20	Body mass index;
CRC	cis	rs995000	0.899	rs1781221	chr1:63006842	A/C	cg19896129	chr1:63156450	NA	-0.44	-6.88	-0.35	3.04e-11	Triglyceride levels;
CRC	cis	rs972578	1.000	rs714003	chr22:43369766	T/C	cg01576275	chr22:43409880	NA	-0.45	-7.28	-0.37	2.47e-12	Mean platelet volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16043990	chr14:104314434	PPP1R13B	0.46	6.38	0.33	5.95e-10	Anxiety disorder;
CRC	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20092199	chr4:1342459	KIAA1530	-0.37	-6.68	-0.35	9.98e-11	Obesity-related traits;
CRC	cis	rs6694672	0.717	rs12039586	chr1:196997452	C/G	cg13682187	chr1:196946512	CFHR5	0.48	7.58	0.39	3.64e-13	Asthma;
CRC	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs10229583	0.527	rs10239440	chr7:127406049	T/C	cg01233922	chr7:127693937	SND1	-0.55	-8.13	-0.41	8.83e-15	Type 2 diabetes;
CRC	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg05925327	chr15:68127851	NA	-0.3	-5.87	-0.31	1.04e-8	Restless legs syndrome;
CRC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.55	-8.63	-0.43	2.66e-16	Aortic root size;
CRC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg21918786	chr6:109611834	NA	0.39	6.94	0.36	2.07e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg12365402	chr11:9010492	NRIP3	-0.37	-6.37	-0.33	6.28e-10	Hemoglobin concentration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08063013	chr11:63742144	COX8A	0.42	5.98	0.31	5.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg18478394	chr8:109455254	TTC35	0.37	5.73	0.3	2.22e-8	Dupuytren's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11256290	chr10:32734912	CCDC7	0.38	6.24	0.33	1.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg11833968	chr6:79620685	NA	-0.37	-6.4	-0.33	5.44e-10	Intelligence (multi-trait analysis);
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg24463073	chr6:118973353	C6orf204	0.51	6.85	0.35	3.7e-11	Renal cell carcinoma;
CRC	cis	rs863345	0.565	rs10908671	chr1:158502160	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg12193833	chr17:30244370	NA	-0.62	-7.94	-0.4	3.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.9	-0.36	2.63e-11	Dilated cardiomyopathy;
CRC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.67	0.63	7.4e-38	Platelet count;
CRC	cis	rs2072510	1.000	rs2540492	chr12:96417659	C/T	cg22491680	chr12:96389547	HAL	-0.38	-5.95	-0.31	6.7e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.68	-0.39	1.85e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg05527609	chr1:210001259	C1orf107	-0.5	-6.86	-0.35	3.53e-11	Monobrow;
CRC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	11.25	0.53	4.79e-25	Immature fraction of reticulocytes;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.46	-0.34	3.8e-10	Lymphocyte counts;
CRC	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg07807695	chr5:81608485	ATP6AP1L	0.46	7.3	0.37	2.14e-12	Breast cancer;
CRC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.81	-14.46	-0.62	5.09e-37	Total body bone mineral density;
CRC	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.66	0.51	5.39e-23	Iron status biomarkers;
CRC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.63	10.79	0.51	1.87e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8170	1.000	rs34084277	chr19:17387176	A/G	cg04749549	chr19:17459798	NA	-0.42	-5.94	-0.31	7.07e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.42	-5.97	-0.31	6.24e-9	Asthma;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.59	-8.15	-0.41	7.57e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg20243544	chr17:37824526	PNMT	0.5	7.53	0.38	4.86e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.65	-7.42	-0.38	9.79e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg24759859	chr6:86352639	SYNCRIP	0.47	6.4	0.33	5.23e-10	Smooth-surface caries;
CRC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.6	0.47	2.07e-19	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs9840812	0.953	rs4678322	chr3:135812523	G/T	cg17080335	chr12:131030206	NA	0.41	6.2	0.32	1.65e-9	Fibrinogen levels;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.47	-0.57	1.73e-29	Leprosy;
CRC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.48	-8.99	-0.44	2.02e-17	Reticulocyte fraction of red cells;
CRC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.81	14.79	0.63	2.55e-38	Metabolic syndrome;
CRC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.56	-7.68	-0.39	1.82e-13	Coronary artery disease;
CRC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.4	5.79	0.3	1.63e-8	Aortic root size;
CRC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	1.0	14.76	0.63	3.57e-38	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg22482690	chr17:47019901	SNF8	0.47	7.81	0.4	7.67e-14	Type 2 diabetes;
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg15845792	chr6:28175446	NA	-0.65	-7.02	-0.36	1.25e-11	Parkinson's disease;
CRC	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg00564723	chr10:75632066	CAMK2G	0.29	6.96	0.36	1.84e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.52	-9.84	-0.48	3.33e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs55788414	0.932	rs729265	chr16:81183600	G/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.76	-0.39	1.11e-13	Psoriasis;
CRC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00677455	chr12:58241039	CTDSP2	-0.41	-5.91	-0.31	8.43e-9	Multiple sclerosis;
CRC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg15845792	chr6:28175446	NA	0.71	6.75	0.35	6.81e-11	Depression;
CRC	cis	rs1209950	0.536	rs468057	chr21:40217306	T/G	cg02119577	chr21:40195074	ETS2	-0.36	-5.77	-0.3	1.79e-8	Non-small cell lung cancer (survival);
CRC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg04450456	chr4:17643702	FAM184B	-0.38	-6.05	-0.32	3.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.92	-16.24	-0.67	5.77e-44	Cognitive function;
CRC	cis	rs6691722	0.503	rs4140519	chr1:24708304	C/T	cg02336364	chr1:24764700	NIPAL3	0.38	6.31	0.33	9.18e-10	Response to interferon beta in multiple sclerosis;
CRC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.4	7.35	0.38	1.54e-12	Schizophrenia;
CRC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.6	0.34	1.61e-10	Intraocular pressure;
CRC	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg24463073	chr6:118973353	C6orf204	0.55	7.11	0.36	7.38e-12	Diastolic blood pressure;
CRC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.87	-0.35	3.16e-11	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24043236	chr3:98312515	CPOX	0.39	6.32	0.33	8.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg07274523	chr3:49395745	GPX1	0.47	6.07	0.32	3.48e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.56	-0.34	2.15e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg25304816	chr1:36627734	MAP7D1	0.61	10.06	0.48	6.41e-21	Corneal structure;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.5	-6.38	-0.33	6.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7394190	0.748	rs11000728	chr10:75404300	C/G	cg07699608	chr10:75541558	CHCHD1	0.61	6.21	0.32	1.63e-9	Incident atrial fibrillation;
CRC	cis	rs7707921	0.767	rs6880209	chr5:81574182	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.5	7.79	0.39	8.55e-14	Breast cancer;
CRC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-7.65	-0.39	2.18e-13	Menarche (age at onset);
CRC	cis	rs12476592	0.543	rs262470	chr2:63830559	C/T	cg10828910	chr2:63850056	LOC388955	0.5	6.13	0.32	2.54e-9	Childhood ear infection;
CRC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.17	-0.37	4.84e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.5	-8.1	-0.41	1.05e-14	Menarche (age at onset);
CRC	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12928939	0.911	rs8051878	chr16:71818431	C/G	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.06	-0.32	3.75e-9	Post bronchodilator FEV1;
CRC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.31	-0.33	9.12e-10	Menarche (age at onset);
CRC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg21153622	chr11:89784906	NA	-0.5	-8.07	-0.41	1.34e-14	Height;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg02683197	chr6:28174875	NA	0.68	9.38	0.46	1.09e-18	Cardiac Troponin-T levels;
CRC	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.81	-0.31	1.45e-8	Tuberculosis;
CRC	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.46	-6.86	-0.35	3.42e-11	Red blood cell count;
CRC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.82	-0.31	1.43e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg10760299	chr15:45669010	GATM	0.49	7.65	0.39	2.19e-13	Homoarginine levels;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg16975973	chr12:77459865	E2F7	0.37	6.02	0.31	4.74e-9	Myopia;
CRC	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	trans	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg16141378	chr3:129829833	LOC729375	0.4	6.13	0.32	2.57e-9	Myopia;Myopia (pathological);
CRC	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg20487152	chr13:99095054	FARP1	0.36	5.9	0.31	8.88e-9	Longevity;
CRC	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.12	0.45	7.64e-18	Coffee consumption (cups per day);
CRC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.58	8.68	0.43	1.85e-16	Aortic root size;
CRC	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	cg04338863	chr8:33670619	NA	0.39	6.76	0.35	6.31e-11	Body mass index;
CRC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.57	7.94	0.4	3.15e-14	Lung cancer;
CRC	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.45	-7.51	-0.38	5.46e-13	Refractive error;
CRC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.53	6.88	0.35	2.99e-11	Schizophrenia;
CRC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.5e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12612619	0.704	rs2119026	chr2:27310393	A/G	cg00617064	chr2:27272375	NA	0.35	5.79	0.3	1.62e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.44	5.91	0.31	8.39e-9	IgG glycosylation;
CRC	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.66	6.74	0.35	7.01e-11	Pediatric areal bone mineral density (radius);
CRC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.36	5.69	0.3	2.83e-8	Life satisfaction;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg03188948	chr7:1209495	NA	0.56	6.49	0.34	3.19e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg06074448	chr4:187884817	NA	-0.59	-10.72	-0.51	3.34e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg20041105	chr8:143859282	LYNX1	0.43	7.85	0.4	5.73e-14	Urinary tract infection frequency;
CRC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.45	6.2	0.32	1.7e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg17691542	chr6:26056736	HIST1H1C	0.43	6.03	0.32	4.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.44	-0.5	3.05e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg09476006	chr5:138032270	NA	-0.47	-7.35	-0.38	1.61e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg16141378	chr3:129829833	LOC729375	0.41	6.02	0.31	4.75e-9	Neuroticism;
CRC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg03361068	chr14:51561562	TRIM9	0.28	5.73	0.3	2.23e-8	Cancer;
CRC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs10971721	0.822	rs10971754	chr9:33871712	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.48	7.04	0.36	1.16e-11	Testicular germ cell tumor;
CRC	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg18404041	chr3:52824283	ITIH1	0.32	6.32	0.33	8.59e-10	Schizophrenia;
CRC	trans	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.91	-0.36	2.54e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02725872	chr8:58115012	NA	-0.39	-6.78	-0.35	5.63e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18426487	chr10:35379348	CUL2	-0.39	-6.13	-0.32	2.46e-9	Myopia (pathological);
CRC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.45	0.46	6.57e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg23958373	chr8:599963	NA	0.66	6.92	0.36	2.37e-11	IgG glycosylation;
CRC	trans	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.45	-6.03	-0.32	4.51e-9	Extraversion;
CRC	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	cis	rs9296095	0.554	rs12214883	chr6:33513968	A/G	cg14003231	chr6:33640908	ITPR3	0.55	8.08	0.41	1.25e-14	Platelet count;
CRC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg22687807	chr8:143858763	LYNX1	0.51	9.1	0.45	8.56e-18	Urinary tract infection frequency;
CRC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.44	-6.53	-0.34	2.44e-10	Tonsillectomy;
CRC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	16.18	0.67	1e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs282587	0.597	rs408247	chr13:113405738	C/A	cg04656015	chr13:113407548	ATP11A	0.6	7.31	0.37	2.04e-12	Glycated hemoglobin levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22857567	chr1:33116716	RBBP4;ZBTB8OS	-0.39	-5.97	-0.31	6.02e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05815920	chr10:103880348	LDB1	0.39	6.68	0.35	1e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18320648	chr2:152266336	RIF1	0.41	6.52	0.34	2.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4964805	0.865	rs4964780	chr12:104206859	A/G	cg02344784	chr12:104178138	NT5DC3	0.49	6.9	0.36	2.6e-11	Attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06646493	chr1:116519019	SLC22A15	0.39	6.8	0.35	4.86e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg12590608	chr7:158785262	NA	0.33	5.85	0.31	1.2e-8	Facial morphology (factor 20);
CRC	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg21452805	chr1:244014465	NA	0.54	7.02	0.36	1.28e-11	RR interval (heart rate);
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg04025307	chr7:1156635	C7orf50	0.57	6.12	0.32	2.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-6.97	-0.36	1.78e-11	Gut microbiome composition (summer);
CRC	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.78	-0.6	1.95e-34	Exhaled nitric oxide output;
CRC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.77	-0.35	6.03e-11	Total cholesterol levels;
CRC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.53	8.55	0.43	4.62e-16	Prostate cancer;
CRC	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg16691251	chr5:66510806	NA	0.44	7.76	0.39	1.05e-13	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23889391	chr6:46138699	ENPP5	0.44	6.3	0.33	9.76e-10	Anxiety disorder;
CRC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.61	8.35	0.42	1.93e-15	Obesity-related traits;
CRC	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.51	8.79	0.44	8.65e-17	Aortic root size;
CRC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.78	-0.3	1.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.93	-13.42	-0.59	4.77e-33	Dupuytren's disease;
CRC	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.14	17.46	0.69	9.11e-49	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs10155981	0.510	rs4722157	chr7:22583941	G/A	cg05062323	chr7:22590069	NA	-0.61	-6.81	-0.35	4.59e-11	Bilirubin levels;
CRC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.62	-0.34	1.51e-10	Menopause (age at onset);
CRC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg16892393	chr17:41919603	NA	0.57	8.35	0.42	1.9e-15	Triglycerides;
CRC	trans	rs11031096	0.714	rs3794049	chr11:4145658	A/G	cg22978087	chr8:24814126	NEFL	0.33	6.08	0.32	3.36e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg21251018	chr6:28226885	NKAPL	-0.46	-6.48	-0.34	3.3e-10	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26980138	chr12:68726465	MDM1	0.51	7.19	0.37	4.28e-12	Response to antipsychotic treatment;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg07507251	chr3:52567010	NT5DC2	0.49	7.84	0.4	6.13e-14	Electroencephalogram traits;
CRC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg01304814	chr3:48885189	PRKAR2A	0.89	6.57	0.34	1.92e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10046574	0.519	rs10265128	chr7:135211446	A/G	cg27474649	chr7:135195673	CNOT4	0.61	5.95	0.31	7.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00744199	chr3:150479830	SIAH2	0.42	6.16	0.32	2.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg25856811	chr1:152973957	SPRR3	-0.21	-5.69	-0.3	2.74e-8	Inflammatory skin disease;
CRC	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.44	-7.14	-0.37	6.12e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg15848620	chr12:58087721	OS9	-0.59	-8.27	-0.41	3.31e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.64	8.53	0.43	5.5e-16	Gut microbiome composition (summer);
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.21	-0.32	1.59e-9	Acylcarnitine levels;
CRC	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg09873164	chr1:152488093	CRCT1	0.37	6.19	0.32	1.81e-9	Hair morphology;
CRC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.41	0.42	1.25e-15	Height;
CRC	cis	rs728616	0.510	rs12416084	chr10:81749215	A/G	cg05935833	chr10:81318306	SFTPA2	-0.53	-6.97	-0.36	1.72e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg20935933	chr6:143382018	AIG1	0.53	6.95	0.36	2.01e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.56	-0.34	2.11e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.47	8.31	0.42	2.53e-15	Testicular germ cell tumor;
CRC	cis	rs9462027	0.628	rs2477508	chr6:34703695	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.33	5.81	0.3	1.49e-8	Systemic lupus erythematosus;
CRC	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.62	-8.2	-0.41	5.53e-15	Malaria;
CRC	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg20469991	chr17:27169893	C17orf63	0.47	5.88	0.31	1.01e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.43	6.33	0.33	8.21e-10	Coronary artery disease;
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.6	-7.59	-0.39	3.35e-13	Alzheimer's disease;
CRC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.4	6.22	0.32	1.5e-9	Red blood cell count;
CRC	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg08847533	chr14:75593920	NEK9	0.83	12.94	0.58	3.07e-31	Height;
CRC	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.87	-0.35	3.3e-11	Height;
CRC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.49	-0.38	6.52e-13	Colorectal cancer;
CRC	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg25547332	chr5:131281432	NA	-0.37	-5.62	-0.3	4.04e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg12870014	chr12:110450643	ANKRD13A	0.81	9.1	0.45	8.98e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.82	-9.93	-0.48	1.76e-20	Initial pursuit acceleration;
CRC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.98	-0.44	2.17e-17	Alcohol dependence;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.49	-6.8	-0.35	5.01e-11	Obesity-related traits;
CRC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.34	-0.38	1.7e-12	Type 2 diabetes;
CRC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.75	9.79	0.48	4.94e-20	Platelet count;
CRC	cis	rs7804356	1.000	rs3801805	chr7:26897640	A/G	cg03456212	chr7:26904342	SKAP2	-0.5	-5.69	-0.3	2.77e-8	Type 1 diabetes;
CRC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20503657	chr10:835505	NA	-0.53	-8.31	-0.42	2.53e-15	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.73	-10.5	-0.5	1.98e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2282802	0.711	rs1864970	chr5:139633042	T/C	cg26211634	chr5:139558579	C5orf32	0.44	7.61	0.39	2.97e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.51e-34	Menopause (age at onset);
CRC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.52	6.23	0.32	1.47e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23598254	chr1:15736141	EFHD2	0.43	6.09	0.32	3.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg15845792	chr6:28175446	NA	0.79	10.3	0.49	9.39e-22	Parkinson's disease;
CRC	cis	rs7605827	0.866	rs35237017	chr2:15615704	T/C	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.61	-8.92	-0.44	3.38e-17	Menarche (age at onset);
CRC	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg14844989	chr11:31128820	NA	0.36	6.53	0.34	2.46e-10	Red blood cell count;
CRC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.42	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg23136738	chr11:925521	AP2A2	-0.4	-6.24	-0.33	1.34e-9	Alzheimer's disease (late onset);
CRC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.65	-9.79	-0.48	4.89e-20	Cognitive function;
CRC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.73	-12.1	-0.55	4.12e-28	Breast cancer;
CRC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg20243544	chr17:37824526	PNMT	0.59	9.14	0.45	6.54e-18	Asthma;
CRC	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg09695851	chr17:3907499	NA	-0.78	-14.06	-0.61	1.71e-35	Type 2 diabetes;
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.41	8.59	0.43	3.5e-16	Bipolar disorder;
CRC	cis	rs6504622	1.000	rs6504622	chr17:45019731	C/T	cg16759221	chr17:45003025	GOSR2	-0.45	-7.12	-0.37	6.76e-12	Orofacial clefts;
CRC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg12573674	chr2:1569213	NA	-0.77	-7.94	-0.4	3.17e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg10756647	chr7:56101905	PSPH	-0.76	-7.72	-0.39	1.4e-13	Diabetic kidney disease;
CRC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-5.94	-0.31	7.23e-9	Aortic root size;
CRC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.24	-0.33	1.37e-9	Menopause (age at onset);
CRC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg13198984	chr17:80129470	CCDC57	0.43	7.56	0.38	3.92e-13	Life satisfaction;
CRC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-6.58	-0.34	1.82e-10	Eosinophil percentage of white cells;
CRC	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg16892393	chr17:41919603	NA	-0.53	-5.66	-0.3	3.3e-8	Cognitive function;
CRC	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.67	-0.35	1.08e-10	Inflammatory skin disease;
CRC	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.41	6.01	0.31	5.02e-9	Red blood cell count;
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg22687807	chr8:143858763	LYNX1	0.47	8.39	0.42	1.45e-15	Urinary tract infection frequency;
CRC	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg25741118	chr1:54482237	LDLRAD1	0.21	5.89	0.31	9.63e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18278596	chr14:105915860	MTA1	-0.39	-6.12	-0.32	2.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs61996546	0.622	rs11639008	chr15:26842107	C/G	cg15066197	chr15:26874202	GABRB3	-0.39	-5.89	-0.31	9.47e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.53	-8.61	-0.43	3.09e-16	Neurofibrillary tangles;
CRC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg23018236	chr17:30244563	NA	-0.46	-6.46	-0.34	3.7e-10	Hip circumference adjusted for BMI;
CRC	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg04110750	chr16:69646130	NFAT5	-0.56	-7.71	-0.39	1.48e-13	IgE levels;
CRC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.92	12.98	0.58	2.1e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.46	7.72	0.39	1.4e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12760731	0.720	rs7537811	chr1:178276421	A/T	cg00404053	chr1:178313656	RASAL2	0.81	9.47	0.46	5.85e-19	Obesity-related traits;
CRC	cis	rs2072510	0.593	rs2660838	chr12:96416383	T/C	cg22491680	chr12:96389547	HAL	-0.46	-5.73	-0.3	2.23e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.45e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg21433313	chr16:3507492	NAT15	-0.69	-6.25	-0.33	1.26e-9	Tuberculosis;
CRC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.78	11.71	0.54	1.02e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg23071808	chr14:103021642	NA	0.63	7.04	0.36	1.14e-11	Platelet count;
CRC	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.52	-7.31	-0.37	1.98e-12	Schizophrenia;
CRC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.61	11.45	0.53	9.05e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.57	-0.34	1.97e-10	Monocyte count;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.87	-0.44	4.88e-17	Bipolar disorder;
CRC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg19812747	chr11:111475976	SIK2	0.44	6.34	0.33	7.7e-10	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.51	-9.6	-0.47	2.04e-19	Alcohol dependence;
CRC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.4	-0.38	1.14e-12	Aortic root size;
CRC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg18827107	chr12:86230957	RASSF9	-0.46	-7.54	-0.38	4.63e-13	Major depressive disorder;
CRC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.38	0.38	1.32e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04703844	chr8:74207197	RPL7;RDH10	-0.39	-6.03	-0.32	4.31e-9	Aortic root size;
CRC	cis	rs453193	0.726	rs443997	chr2:8448422	G/A	cg12167548	chr2:8464763	NA	0.29	5.76	0.3	1.98e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.63	-8.26	-0.41	3.64e-15	Cocaine dependence;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17585343	chr11:43702103	HSD17B12	0.39	5.99	0.31	5.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg22117107	chr15:45993392	NA	-0.44	-8.99	-0.44	2.05e-17	Waist circumference;Weight;
CRC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.32	6.62	0.34	1.5e-10	Lung cancer;
CRC	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg21918786	chr6:109611834	NA	0.36	6.28	0.33	1.07e-9	Reticulocyte fraction of red cells;
CRC	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg12458913	chr13:53173898	NA	0.52	7.91	0.4	3.88e-14	Lewy body disease;
CRC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.76	13.4	0.59	5.88e-33	Oral cavity cancer;
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg11105980	chr13:37393381	RFXAP	0.38	5.99	0.31	5.41e-9	Age-related macular degeneration;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg18061543	chr17:80864463	TBCD	-0.43	-6.59	-0.34	1.77e-10	HDL cholesterol;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg20129853	chr10:51489980	NA	-0.35	-5.73	-0.3	2.26e-8	Prostate-specific antigen levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23901904	chr1:10855062	CASZ1	0.46	6.04	0.32	4.27e-9	Thyroid stimulating hormone;
CRC	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.77	-0.3	1.79e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.56	10.19	0.49	2.29e-21	Cognitive performance;
CRC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.81	-0.44	7.23e-17	Neuroticism;
CRC	trans	rs6600671	0.902	rs2222371	chr1:121289118	T/C	cg00646200	chr1:148855367	NA	-0.34	-6.09	-0.32	3.07e-9	Hip geometry;
CRC	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.5	0.65	4.51e-41	Colorectal cancer;
CRC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg07713946	chr22:31675144	LIMK2	0.42	6.29	0.33	1.02e-9	Colorectal cancer;
CRC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.8	-12.49	-0.57	1.43e-29	Body mass index (adult);
CRC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg20399509	chr21:47717575	C21orf57	-0.36	-5.74	-0.3	2.1e-8	Testicular germ cell tumor;
CRC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.53	0.38	5.08e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg04166393	chr7:2884313	GNA12	0.45	6.06	0.32	3.65e-9	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20503117	chr3:5164013	ARL8B	0.52	6.61	0.34	1.51e-10	Thyroid stimulating hormone;
CRC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.51	8.47	0.42	8.21e-16	Aortic root size;
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	7.98	0.4	2.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	8.31	0.42	2.57e-15	Iron status biomarkers;
CRC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.65	9.7	0.47	9.98e-20	Initial pursuit acceleration;
CRC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.48	9.14	0.45	6.66e-18	Reticulocyte fraction of red cells;
CRC	cis	rs2227564	1	rs2227564	chr10:75673101	C/T	cg00564723	chr10:75632066	CAMK2G	0.28	6.26	0.33	1.23e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg03315344	chr16:75512273	CHST6	-0.54	-6.2	-0.32	1.72e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg12935359	chr14:103987150	CKB	-0.37	-6.18	-0.32	1.88e-9	Body mass index;
CRC	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.35	7.53	0.38	5e-13	Total body bone mineral density;
CRC	cis	rs7428	0.962	rs3637	chr2:85549874	A/G	cg24342717	chr2:85555507	TGOLN2	-0.49	-6.91	-0.36	2.52e-11	Ear protrusion;
CRC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg25809561	chr17:30822961	MYO1D	0.58	10.54	0.5	1.44e-22	Schizophrenia;
CRC	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.39	-0.38	1.21e-12	Schizophrenia;
CRC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.73	0.43	1.35e-16	Prostate cancer;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23708337	chr7:1209742	NA	0.43	6.46	0.34	3.68e-10	Longevity;Endometriosis;
CRC	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	24.06	0.8	1.68e-74	Schizophrenia;
CRC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.75	9.77	0.47	5.96e-20	Platelet count;
CRC	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	7.85	0.4	5.91e-14	Adiposity;
CRC	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.75	-12.09	-0.55	4.23e-28	Plateletcrit;Platelet count;
CRC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.37	5.94	0.31	7.18e-9	Ulcerative colitis;
CRC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.63	-0.47	1.67e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg03929089	chr4:120376271	NA	-0.46	-6.45	-0.34	3.93e-10	Height;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg15763984	chr4:1342303	KIAA1530	-0.38	-5.98	-0.31	5.86e-9	Obesity-related traits;
CRC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg03844506	chr4:4109441	NA	-0.51	-7.57	-0.39	3.88e-13	Blood pressure (smoking interaction);
CRC	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg21836586	chr14:55907198	TBPL2	0.31	5.62	0.3	4.1e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.58	-9.39	-0.46	1.04e-18	Aortic root size;
CRC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.61	-0.34	1.57e-10	Reticulocyte fraction of red cells;
CRC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg10802521	chr3:52805072	NEK4	-0.47	-6.33	-0.33	8.18e-10	Bipolar disorder;
CRC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.76e-12	Extrinsic epigenetic age acceleration;
CRC	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-1.09	-12.99	-0.58	2e-31	Blood pressure (smoking interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18222582	chr1:232765331	NA	-0.48	-6.06	-0.32	3.65e-9	Diisocyanate-induced asthma;
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	1.04	11.25	0.53	4.81e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.34	7.05	0.36	1.06e-11	Lung cancer;
CRC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.87	-0.48	2.65e-20	Hip circumference adjusted for BMI;
CRC	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.31	-0.37	2.03e-12	Menarche (age at onset);
CRC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.0	-0.31	5.3e-9	Monocyte percentage of white cells;
CRC	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.03	-0.32	4.3e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg05139728	chr16:28306816	SBK1	-0.37	-6.12	-0.32	2.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.55	-0.34	2.2e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs73206853	0.534	rs13313219	chr12:110509461	G/A	cg12870014	chr12:110450643	ANKRD13A	0.86	8.88	0.44	4.53e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg07862535	chr7:139043722	LUC7L2	-0.56	-7.23	-0.37	3.49e-12	Diisocyanate-induced asthma;
CRC	cis	rs55702914	0.805	rs11888760	chr2:198243749	A/T	cg10820045	chr2:198174542	NA	-0.36	-6.5	-0.34	3.04e-10	Major depression and alcohol dependence;
CRC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs6076065	0.692	rs6083092	chr20:23348836	T/C	cg11657817	chr20:23433608	CST11	0.43	6.19	0.32	1.75e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg20302533	chr7:39170763	POU6F2	0.41	5.66	0.3	3.38e-8	IgG glycosylation;
CRC	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	9.65	0.47	1.5e-19	Blood protein levels;
CRC	trans	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.41	-0.38	1.1e-12	Menarche (age at onset);
CRC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.43	-0.33	4.52e-10	Reticulocyte fraction of red cells;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.74	9.41	0.46	8.98e-19	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02865447	chr6:90062469	UBE2J1	0.47	6.37	0.33	6.28e-10	Anxiety disorder;
CRC	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg11130432	chr3:121712080	ILDR1	0.51	6.62	0.34	1.48e-10	Multiple sclerosis;
CRC	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg09264619	chr17:80180166	NA	0.52	7.45	0.38	8.22e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.83	-0.35	4.04e-11	HDL cholesterol;
CRC	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.1	13.51	0.6	2.16e-33	Vitiligo;
CRC	cis	rs12612619	0.667	rs7605526	chr2:27345484	A/G	cg00617064	chr2:27272375	NA	-0.4	-6.44	-0.33	4.3e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg07617317	chr6:118971624	C6orf204	0.52	6.4	0.33	5.29e-10	Diastolic blood pressure;
CRC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.77	9.41	0.46	9.09e-19	Body mass index;
CRC	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg15147215	chr3:52552868	STAB1	0.43	6.93	0.36	2.18e-11	Body mass index;
CRC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.76	-10.31	-0.49	8.86e-22	Coronary artery disease;
CRC	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.37	-7.03	-0.36	1.23e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.74	-0.43	1.22e-16	Aortic root size;
CRC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.38	5.86	0.31	1.11e-8	Red blood cell count;
CRC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-7.74	-0.39	1.26e-13	Aortic root size;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg09496464	chr2:208904568	NA	-0.39	-6.0	-0.31	5.17e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-8.88	-0.44	4.44e-17	Alzheimer's disease;
CRC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg24209194	chr3:40518798	ZNF619	0.39	5.74	0.3	2.17e-8	Renal cell carcinoma;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.66	-10.25	-0.49	1.41e-21	Platelet count;
CRC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.46	6.32	0.33	8.48e-10	Aortic root size;
CRC	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.21	0.41	5.11e-15	Cognitive performance;
CRC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.31	12.49	0.57	1.46e-29	Cognitive function;
CRC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.5	0.34	3.05e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-9.1	-0.45	9.11e-18	Breast cancer;
CRC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.69	9.07	0.45	1.08e-17	High light scatter reticulocyte count;
CRC	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.72	-0.35	8.19e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.07	-0.55	5.16e-28	Primary sclerosing cholangitis;
CRC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.53	7.59	0.39	3.37e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.89	0.55	2.36e-27	Alzheimer's disease;
CRC	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.82	9.54	0.47	3.22e-19	Obesity-related traits;
CRC	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg16068336	chr17:48637367	CACNA1G	-0.49	-7.1	-0.36	7.82e-12	Type 2 diabetes;
CRC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg07274523	chr3:49395745	GPX1	0.46	6.21	0.32	1.61e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.07e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24877558	chr1:42801138	FOXJ3	0.36	6.12	0.32	2.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg04518342	chr5:131593106	PDLIM4	0.44	7.12	0.37	7e-12	Breast cancer;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg01339444	chr6:118972232	C6orf204	0.55	6.2	0.32	1.69e-9	Diastolic blood pressure;
CRC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg09877947	chr5:131593287	PDLIM4	0.57	9.98	0.48	1.17e-20	Acylcarnitine levels;
CRC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.78	10.91	0.52	7.6e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg05569086	chr8:143859399	LYNX1	-0.43	-7.01	-0.36	1.35e-11	Urinary tract infection frequency;
CRC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.52	-6.32	-0.33	8.72e-10	Tuberculosis;
CRC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.14	-13.85	-0.61	1.06e-34	Diabetic kidney disease;
CRC	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-0.85	-9.83	-0.48	3.6e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6684428	0.706	rs10493187	chr1:56320969	C/T	cg11651538	chr1:56320950	NA	-0.44	-5.65	-0.3	3.39e-8	Airflow obstruction;
CRC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.52	-6.93	-0.36	2.29e-11	Total body bone mineral density;
CRC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.84	-15.27	-0.64	3.52e-40	Menopause (age at onset);
CRC	cis	rs7333181	0.649	rs914030	chr13:112240131	T/C	cg27543320	chr13:112200689	NA	-0.56	-9.42	-0.46	8.49e-19	Menopause (age at onset);
CRC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06544989	chr22:39130855	UNC84B	0.49	7.78	0.39	9.51e-14	Menopause (age at onset);
CRC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.33	-5.61	-0.3	4.22e-8	Mean platelet volume;
CRC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg09654669	chr8:57350985	NA	-0.43	-5.83	-0.31	1.3e-8	Obesity-related traits;
CRC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg02527881	chr3:46936655	PTH1R	-0.37	-6.96	-0.36	1.87e-11	Colorectal cancer;
CRC	cis	rs6479527	1.000	rs6479528	chr9:96858429	G/A	cg14459158	chr9:96720562	NA	0.43	7.52	0.38	5.31e-13	Esophageal adenocarcinoma;
CRC	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg03258749	chr1:151040405	MLLT11	-0.46	-7.19	-0.37	4.32e-12	Childhood ear infection;
CRC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.15	-0.41	7.66e-15	Menarche (age at onset);
CRC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.7	-11.91	-0.55	2.01e-27	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs501120	0.584	rs61855739	chr10:44679603	G/A	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.81	-0.35	4.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg12964065	chr18:77638022	KCNG2	0.68	7.02	0.36	1.29e-11	Opioid sensitivity;
CRC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.02	-0.36	1.3e-11	Lung cancer;
CRC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-5.85	-0.31	1.17e-8	Electroencephalogram traits;
CRC	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg02248941	chr16:2239361	CASKIN1	0.63	11.66	0.54	1.59e-26	Height;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25867694	chr22:31503597	SELM	0.4	6.72	0.35	8e-11	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15198335	chr15:66586003	DIS3L	0.38	6.05	0.32	4.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg11843238	chr5:131593191	PDLIM4	0.43	7.3	0.37	2.22e-12	Breast cancer;
CRC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.98	0.31	5.84e-9	Lung cancer;
CRC	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26714650	chr12:56694279	CS	-1.4	-10.71	-0.51	3.56e-23	Psoriasis vulgaris;
CRC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.63	0.39	2.64e-13	Height;
CRC	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.47	-6.63	-0.34	1.35e-10	Schizophrenia;
CRC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg05313129	chr8:58192883	C8orf71	-0.4	-5.89	-0.31	9.72e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg12072164	chr19:44306565	LYPD5	-0.41	-6.42	-0.33	4.86e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg10113582	chr4:905918	GAK	-0.47	-6.98	-0.36	1.68e-11	Systemic sclerosis;
CRC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-5.74	-0.3	2.12e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.5	8.81	0.44	7.15e-17	Hypertriglyceridemia;
CRC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	9.44	0.46	6.91e-19	Body mass index (adult);
CRC	cis	rs10128264	0.902	rs2802360	chr10:80971196	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.44	-7.71	-0.39	1.47e-13	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.71	-9.09	-0.45	9.73e-18	Blood protein levels;
CRC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg16681516	chr19:46297285	DMWD	0.36	5.84	0.31	1.26e-8	Coronary artery disease;
CRC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.95	0.31	6.82e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-9.16	-0.45	5.87e-18	Urinary metabolites;
CRC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg16476235	chr8:21771668	DOK2	-0.37	-6.19	-0.32	1.82e-9	Lung cancer in ever smokers;
CRC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.56	9.08	0.45	1.03e-17	Menopause (age at onset);
CRC	cis	rs55702914	0.746	rs4850425	chr2:198152786	T/C	cg10820045	chr2:198174542	NA	-0.48	-9.0	-0.44	1.78e-17	Major depression and alcohol dependence;
CRC	cis	rs2406342	1.000	rs2406342	chr18:74488280	G/T	cg16472389	chr18:74514291	NA	0.37	5.69	0.3	2.78e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
CRC	cis	rs28655083	0.956	rs35848061	chr16:77101327	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-7.77	-0.39	1.02e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg20356878	chr3:121714668	ILDR1	-0.5	-7.34	-0.37	1.72e-12	Multiple sclerosis;
CRC	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.74	-11.74	-0.54	8.38e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9903692	0.908	rs7222136	chr17:46199592	C/G	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	3.09e-14	Pulse pressure;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg22638593	chr5:131593259	PDLIM4	0.35	6.88	0.35	2.97e-11	Blood metabolite levels;
CRC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.78	11.38	0.53	1.56e-25	Gestational age at birth (maternal effect);
CRC	cis	rs739496	0.542	rs12423926	chr12:111781055	C/T	cg10833066	chr12:111807467	FAM109A	-0.53	-6.97	-0.36	1.78e-11	Platelet count;
CRC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg13072238	chr3:49761600	GMPPB	0.56	6.02	0.31	4.71e-9	Menarche (age at onset);
CRC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.09	13.45	0.6	3.5e-33	Vitiligo;
CRC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.53	-0.34	2.43e-10	Aortic root size;
CRC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.67	-11.09	-0.52	1.73e-24	Electrocardiographic conduction measures;
CRC	cis	rs11229555	0.598	rs11229426	chr11:58180063	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.68	7.29	0.37	2.33e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
CRC	cis	rs4237845	0.611	rs4760346	chr12:58334743	A/G	cg02175503	chr12:58329896	NA	0.78	12.46	0.57	1.9e-29	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg21620606	chr4:1342894	KIAA1530	0.36	5.89	0.31	9.62e-9	Obesity-related traits;
CRC	trans	rs10077885	0.967	rs2974505	chr5:114431917	G/A	cg08634079	chr15:65478037	CLPX	-0.38	-6.09	-0.32	3.13e-9	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.45	6.73	0.35	7.51e-11	Type 2 diabetes;
CRC	cis	rs2944755	1.000	rs2944755	chr8:141574194	A/G	cg07466463	chr8:141574207	EIF2C2	-0.4	-5.94	-0.31	7.18e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs11466653	1.000	rs11466643	chr4:38778241	G/A	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg00531865	chr16:30841666	NA	-0.4	-5.64	-0.3	3.71e-8	Response to metformin (IC50);
CRC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.39	-7.41	-0.38	1.06e-12	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.46	-8.04	-0.41	1.66e-14	Intelligence (multi-trait analysis);
CRC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg03609598	chr5:56110824	MAP3K1	-0.44	-5.91	-0.31	8.78e-9	Coronary artery disease;
CRC	cis	rs3018066	0.666	rs7671145	chr4:107033675	C/T	cg01869342	chr4:106983673	TBCK	0.44	5.73	0.3	2.29e-8	Cancer;
CRC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03885332	chr11:832357	CD151	-0.42	-6.4	-0.33	5.25e-10	Mean platelet volume;
CRC	cis	rs77861329	1.000	rs28659792	chr3:52107966	G/C	cg08692210	chr3:52188851	WDR51A	0.84	7.14	0.37	5.98e-12	Macrophage inflammatory protein 1b levels;
CRC	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.98	19.9	0.74	2.05e-58	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.9	17.43	0.69	1.19e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.16	-0.32	2.09e-9	Subjective well-being;
CRC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg09264619	chr17:80180166	NA	0.49	7.02	0.36	1.26e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.73	-9.09	-0.45	9.32e-18	Blood protein levels;
CRC	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.5	-7.21	-0.37	3.93e-12	Cocaine dependence;
CRC	cis	rs9847710	1.000	rs2564956	chr3:53070462	C/T	cg04503182	chr3:53078218	SFMBT1	0.43	6.92	0.36	2.35e-11	Ulcerative colitis;
CRC	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.53	-9.51	-0.46	4.29e-19	Schizophrenia;
CRC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.3	1.56e-8	Diabetic retinopathy;
CRC	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	cis	rs8141797	0.792	rs3752497	chr22:24581207	C/T	cg20894457	chr22:24584366	SUSD2	0.64	7.39	0.38	1.26e-12	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.67	-7.71	-0.39	1.56e-13	Opioid sensitivity;
CRC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.67	0.3	3.13e-8	Self-reported allergy;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg15845792	chr6:28175446	NA	1.01	15.4	0.65	1.16e-40	Depression;
CRC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.73e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22152050	chr18:60987904	BCL2	0.44	6.16	0.32	2.14e-9	Hip circumference;
CRC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.49	-0.5	2.17e-22	Breast cancer;
CRC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	13.85	0.61	1.09e-34	Platelet count;
CRC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.72	-10.94	-0.52	5.62e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg00601486	chr12:48723148	H1FNT	-0.36	-6.65	-0.34	1.23e-10	Glycated hemoglobin levels;
CRC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.72	-11.01	-0.52	3.27e-24	Corneal astigmatism;
CRC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.83	14.49	0.62	3.84e-37	Breast cancer;
CRC	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.56	6.1	0.32	2.93e-9	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.82	14.71	0.63	5.17e-38	Metabolic syndrome;
CRC	cis	rs990171	1.000	rs2110735	chr2:103050925	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	5.8	0.3	1.53e-8	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04266864	chr17:27224823	FLOT2;DHRS13	0.43	6.42	0.33	4.79e-10	Intelligence (multi-trait analysis);
CRC	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.56	7.96	0.4	2.88e-14	Kawasaki disease;
CRC	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-1.39	-13.18	-0.59	3.89e-32	Plateletcrit;
CRC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.45	-6.1	-0.32	2.92e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.73	-0.35	7.37e-11	Bipolar disorder;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.01	-0.31	5.01e-9	Total body bone mineral density;
CRC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.14	-11.87	-0.55	2.78e-27	Breast cancer;
CRC	trans	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg11693508	chr17:37793320	STARD3	0.55	7.76	0.39	1.06e-13	Bipolar disorder;
CRC	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.43	5.67	0.3	3.16e-8	Platelet distribution width;
CRC	cis	rs6142102	0.961	rs2284389	chr20:32656841	C/G	cg08999081	chr20:33150536	PIGU	0.38	5.95	0.31	6.75e-9	Skin pigmentation;
CRC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	14.44	0.62	5.83e-37	Platelet count;
CRC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.53	7.63	0.39	2.49e-13	Mean platelet volume;
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.28	-0.33	1.08e-9	Electroencephalogram traits;
CRC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.99	-0.44	1.95e-17	Bipolar disorder;
CRC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.6	9.31	0.46	1.86e-18	Aortic root size;
CRC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg07090678	chr1:91966139	CDC7	0.42	6.95	0.36	1.93e-11	Breast cancer;
CRC	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.61	7.38	0.38	1.29e-12	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.63	9.77	0.47	5.88e-20	Corneal astigmatism;
CRC	cis	rs73206853	0.841	rs55634798	chr12:110833748	G/T	cg12870014	chr12:110450643	ANKRD13A	0.78	8.4	0.42	1.35e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.8	-7.36	-0.38	1.5e-12	Putamen volume;
CRC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.72	0.47	8.75e-20	Cognitive test performance;
CRC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.6	9.78	0.47	5.3e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg02683197	chr6:28174875	NA	0.47	6.68	0.35	1.04e-10	Cardiac Troponin-T levels;
CRC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.41	5.73	0.3	2.26e-8	Aortic root size;
CRC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.47	6.26	0.33	1.17e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2270875	1.000	rs10435560	chr8:132937397	G/A	cg24184792	chr8:132919238	EFR3A	-0.67	-6.7	-0.35	9.08e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.4	-0.42	1.36e-15	Bipolar disorder;
CRC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.67	10.01	0.48	9.15e-21	Lung cancer;
CRC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg00597713	chr6:42947103	PEX6	-0.4	-5.68	-0.3	3.04e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2282802	0.685	rs2436391	chr5:139557385	C/T	cg26211634	chr5:139558579	C5orf32	-0.44	-7.73	-0.39	1.32e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26240231	chr7:1148101	C7orf50	0.46	6.16	0.32	2.08e-9	Bronchopulmonary dysplasia;
CRC	cis	rs62007496	0.520	rs8008679	chr14:103605707	T/C	cg09274347	chr14:103599552	TNFAIP2	0.51	5.83	0.31	1.33e-8	Language performance in older adults (adjusted for episodic memory);
CRC	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.49	6.66	0.34	1.14e-10	Urinary tract infection frequency;
CRC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.72	-0.47	8.52e-20	Hip circumference adjusted for BMI;
CRC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.76	-12.22	-0.56	1.46e-28	Blood protein levels;
CRC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.41	7.97	0.4	2.57e-14	Mean corpuscular volume;
CRC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.63	-6.34	-0.33	7.42e-10	QRS complex (12-leadsum);
CRC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-5.78	-0.3	1.72e-8	Lung cancer;
CRC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.25	0.33	1.27e-9	Diabetic kidney disease;
CRC	trans	rs6472235	0.837	rs7017618	chr8:66930392	A/C	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.68e-17	Bipolar disorder;
CRC	cis	rs4728302	0.643	rs2346440	chr7:133685512	G/C	cg03336402	chr7:133662267	EXOC4	-0.45	-6.95	-0.36	1.93e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6838801	0.857	rs17002148	chr4:77580240	A/G	cg17476223	chr4:77663285	SHROOM3	-0.41	-5.7	-0.3	2.63e-8	Cleft lip with or without cleft palate;
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg17321639	chr7:2759063	NA	0.54	7.59	0.39	3.25e-13	Height;
CRC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.38	0.38	1.27e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.29	-0.33	1.02e-9	Cognitive function;
CRC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg03623178	chr6:28175578	NA	0.78	6.64	0.34	1.27e-10	Breast cancer;
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.61	8.37	0.42	1.7e-15	Iron status biomarkers;
CRC	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs77861329	0.920	rs9846049	chr3:52120214	A/G	cg08692210	chr3:52188851	WDR51A	0.85	8.07	0.41	1.31e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17219203	chr10:38645113	HSD17B7P2	0.4	5.61	0.3	4.31e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.69	10.17	0.49	2.72e-21	Menopause (age at onset);
CRC	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.64	0.3	3.63e-8	Putamen volume;
CRC	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg13385794	chr1:248469461	NA	0.4	7.09	0.36	8.35e-12	Common traits (Other);
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg16355271	chr7:27283528	EVX1	-0.4	-5.96	-0.31	6.37e-9	Parkinson's disease;
CRC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg27565382	chr3:53032988	SFMBT1	0.78	6.24	0.33	1.33e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	7.17	0.37	5.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.3	-0.33	9.71e-10	Aortic root size;
CRC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.38	-0.38	1.32e-12	Major depressive disorder;
CRC	trans	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg15704280	chr7:45808275	SEPT13	-0.45	-6.09	-0.32	3.1e-9	Height;
CRC	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg10437265	chr15:77819839	NA	0.68	12.43	0.57	2.41e-29	Type 2 diabetes;
CRC	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg21153622	chr11:89784906	NA	0.46	7.28	0.37	2.48e-12	HDL cholesterol;
CRC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	8.01	0.4	2.03e-14	Schizophrenia;
CRC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.19	-0.32	1.74e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-8.31	-0.42	2.48e-15	Electroencephalogram traits;
CRC	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.68	7.5	0.38	6.05e-13	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	cis	rs4731207	0.698	rs10260227	chr7:124446486	T/C	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.78	-0.63	3.02e-38	Exhaled nitric oxide output;
CRC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.68	-0.54	1.33e-26	Platelet distribution width;
CRC	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.44	6.43	0.33	4.45e-10	Body mass index;
CRC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg03909863	chr11:638404	DRD4	-0.52	-7.13	-0.37	6.36e-12	Systemic lupus erythematosus;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11361691	chr3:57993876	FLNB	-0.4	-6.34	-0.33	7.66e-10	Myopia (pathological);
CRC	cis	rs35493131	0.557	rs7251466	chr19:42576952	C/G	cg22273452	chr19:42578905	ZNF574	0.56	5.64	0.3	3.58e-8	Monocyte count;
CRC	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.83	-10.53	-0.5	1.5e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	7.77	0.39	9.85e-14	Blood metabolite levels;
CRC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.88	0.4	4.82e-14	Menopause (age at onset);
CRC	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.43	-8.2	-0.41	5.39e-15	Alcohol dependence;
CRC	cis	rs629535	0.814	rs674429	chr8:70069942	G/A	cg26132723	chr8:70041827	NA	0.35	5.77	0.3	1.8e-8	Dupuytren's disease;
CRC	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.61	-9.13	-0.45	6.96e-18	Dementia with Lewy bodies;
CRC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.52	6.91	0.36	2.51e-11	Obesity-related traits;
CRC	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg12856521	chr11:46389249	DGKZ	-0.43	-6.72	-0.35	7.85e-11	Leprosy;
CRC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg27523141	chr10:43048294	ZNF37B	0.47	6.89	0.36	2.87e-11	Extrinsic epigenetic age acceleration;
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg13490827	chr1:46269305	MAST2	-0.7	-6.28	-0.33	1.09e-9	Cognitive function;
CRC	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg18827107	chr12:86230957	RASSF9	-0.36	-5.98	-0.31	5.85e-9	Major depressive disorder;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg03623178	chr6:28175578	NA	0.93	12.26	0.56	9.88e-29	Depression;
CRC	cis	rs17331151	0.505	rs79979130	chr3:52551010	C/T	cg07884673	chr3:53033167	SFMBT1	0.87	6.46	0.34	3.82e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg27432699	chr2:27873401	GPN1	0.64	8.48	0.42	7.75e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.72	9.03	0.45	1.52e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg14791747	chr16:20752902	THUMPD1	-0.56	-7.6	-0.39	3.17e-13	Cognitive test performance;
CRC	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.86	-14.97	-0.64	5.18e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.45	5.89	0.31	9.42e-9	Response to diuretic therapy;
CRC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.91e-9	Hemoglobin concentration;
CRC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.43	6.22	0.32	1.49e-9	Emphysema distribution in smoking;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14310890	chr6:108881016	FOXO3	0.54	6.96	0.36	1.84e-11	Thyroid stimulating hormone;
CRC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.4	-0.33	5.28e-10	Reticulocyte fraction of red cells;
CRC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg03030879	chr14:75389066	RPS6KL1	0.38	5.66	0.3	3.28e-8	Height;
CRC	trans	rs2303319	0.504	rs62188984	chr2:162514518	G/A	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-7.44	-0.38	8.94e-13	Coronary artery disease;
CRC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.58	8.91	0.44	3.49e-17	Blood protein levels;
CRC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.48	-7.6	-0.39	3.02e-13	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg27661571	chr11:113659931	NA	-0.67	-7.54	-0.38	4.55e-13	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08744769	chr2:70142523	MXD1	0.44	6.19	0.32	1.8e-9	Response to antipsychotic treatment;
CRC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg06028605	chr16:24865363	SLC5A11	0.44	8.07	0.41	1.33e-14	Intelligence (multi-trait analysis);
CRC	cis	rs75059851	1.000	rs75059851	chr11:133822569	A/G	cg17703048	chr11:133852993	NA	-0.45	-5.82	-0.31	1.38e-8	Schizophrenia;
CRC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.36	-0.33	6.79e-10	Alzheimer's disease (late onset);
CRC	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg27534772	chr1:16042836	PLEKHM2	0.5	8.98	0.44	2.12e-17	Systolic blood pressure;
CRC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.45	-7.88	-0.4	4.89e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg04586622	chr2:25135609	ADCY3	-0.55	-9.36	-0.46	1.32e-18	Body mass index;
CRC	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.64	6.97	0.36	1.79e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.03e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.5	-0.34	2.98e-10	Triglycerides;
CRC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.06	0.36	9.81e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg23262073	chr20:60523788	NA	-0.37	-5.87	-0.31	1.05e-8	Body mass index;
CRC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.58	-9.95	-0.48	1.4e-20	Coronary artery disease;
CRC	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08462924	chr1:41848221	NA	0.43	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.84	-0.31	1.26e-8	Subjective well-being;
CRC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.42	7.21	0.37	3.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.17	0.32	2.03e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg02659138	chr7:134003124	SLC35B4	0.38	6.51	0.34	2.73e-10	Mean platelet volume;
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.83	-0.31	1.3e-8	Total body bone mineral density;
CRC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.52	8.83	0.44	6.38e-17	Aortic root size;
CRC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.77	-0.47	5.9e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.82	-9.5	-0.46	4.38e-19	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.06	-12.27	-0.56	9.34e-29	Diabetic kidney disease;
CRC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.38	-0.42	1.53e-15	Platelet count;
CRC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg09127314	chr1:152161683	NA	0.49	6.25	0.33	1.26e-9	Atopic dermatitis;
CRC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18297960	chr7:1142765	C7orf50	-0.43	-5.91	-0.31	8.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.49	-6.99	-0.36	1.55e-11	Coronary artery disease;
CRC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.85	11.71	0.54	9.97e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23616842	chr20:4129483	SMOX	0.38	6.14	0.32	2.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.51	-7.91	-0.4	3.87e-14	Motion sickness;
CRC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.23	11.76	0.54	6.79e-27	Cognitive function;
CRC	trans	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg09045935	chr12:6379348	NA	1.13	9.23	0.45	3.42e-18	Blood metabolite levels;
CRC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	11.48	0.53	6.79e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-9.23	-0.45	3.47e-18	Subjective well-being;
CRC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs4965359	0.808	rs1598492	chr15:101577534	A/G	cg01350081	chr15:101592003	LRRK1	0.37	6.27	0.33	1.14e-9	Central corneal thickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01720705	chr1:231175557	FAM89A	0.41	6.52	0.34	2.6e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.42	5.86	0.31	1.13e-8	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs2072510	0.593	rs2540498	chr12:96400569	T/A	cg09636302	chr12:96389483	HAL	-0.5	-6.42	-0.33	4.89e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-7.66	-0.39	2.13e-13	Total body bone mineral density;
CRC	cis	rs1062746	0.528	rs12149622	chr16:87340235	A/G	cg02258303	chr16:87377426	FBXO31	-0.51	-7.33	-0.37	1.75e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.39	6.6	0.34	1.63e-10	IgG glycosylation;
CRC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.29	-0.46	2.15e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-6.42	-0.33	4.66e-10	Eye color traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13713052	chr3:122102218	FAM162A;CCDC58	0.52	6.87	0.35	3.23e-11	Thyroid stimulating hormone;
CRC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg15660573	chr17:549704	VPS53	-0.87	-15.78	-0.66	3.72e-42	Prostate cancer;
CRC	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.37	-7.67	-0.39	1.91e-13	Cutaneous nevi;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02569759	chr3:10052551	LOC401052	0.49	7.74	0.39	1.26e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.51	8.61	0.43	3.12e-16	Hypertriglyceridemia;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.58	-0.34	1.81e-10	Bipolar disorder;
CRC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.93	10.53	0.5	1.51e-22	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23388714	chr18:51750950	MBD2	0.38	5.99	0.31	5.44e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6463739	0.965	rs7795244	chr7:7902588	T/C	cg09417038	chr21:47716443	C21orf57	0.4	6.09	0.32	3.12e-9	Small cell lung carcinoma;
CRC	cis	rs8070740	0.838	rs1050390	chr17:5336058	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.85	0.31	1.2e-8	Menopause (age at onset);
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.72	12.13	0.56	3.18e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.36	-5.79	-0.3	1.65e-8	Blood metabolite levels;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.48	6.89	0.36	2.87e-11	Longevity;
CRC	trans	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg26043149	chr18:55253948	FECH	0.53	7.84	0.4	6.27e-14	Bone mineral density;
CRC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-10.21	-0.49	1.93e-21	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24158363	chr17:73401717	GRB2	0.37	6.43	0.33	4.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.74	-9.91	-0.48	1.95e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.76	0.35	6.27e-11	Rheumatoid arthritis;
CRC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.28	0.53	3.51e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg19894588	chr14:64061835	NA	0.42	6.26	0.33	1.22e-9	Glioblastoma;Glioma;
CRC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.69	0.39	1.76e-13	Menopause (age at onset);
CRC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.45	-0.33	4.06e-10	Platelet distribution width;
CRC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24308560	chr3:49941425	MST1R	-0.45	-7.21	-0.37	3.87e-12	Intelligence (multi-trait analysis);
CRC	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg17145862	chr1:211918768	LPGAT1	0.49	6.4	0.33	5.47e-10	Crohn's disease;
CRC	cis	rs4073416	0.542	rs3825639	chr14:66028505	T/C	cg03016385	chr14:66212404	NA	-0.44	-6.12	-0.32	2.62e-9	N-glycan levels;
CRC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.22	-16.01	-0.66	4.73e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.53	7.97	0.4	2.65e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.04	-0.32	4.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg06484146	chr7:12443880	VWDE	-0.6	-6.33	-0.33	8.08e-10	Coronary artery disease;
CRC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2e-14	Type 2 diabetes;
CRC	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.75	-7.97	-0.4	2.71e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.97	13.56	0.6	1.39e-33	Exhaled nitric oxide output;
CRC	cis	rs7259376	0.902	rs11669356	chr19:22605120	G/T	cg02657401	chr19:22469223	NA	0.3	6.42	0.33	4.68e-10	Menopause (age at onset);
CRC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.54	6.65	0.34	1.22e-10	Diastolic blood pressure;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg01008941	chr4:39046077	KLHL5	-0.45	-6.94	-0.36	2.06e-11	Aortic root size;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.41	-7.27	-0.37	2.66e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4363385	0.818	rs1334849	chr1:153004652	A/G	cg25856811	chr1:152973957	SPRR3	0.23	6.29	0.33	1.02e-9	Inflammatory skin disease;
CRC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg06671706	chr8:8559999	CLDN23	-0.57	-8.09	-0.41	1.19e-14	Obesity-related traits;
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg01339444	chr6:118972232	C6orf204	0.52	5.89	0.31	9.54e-9	Renal cell carcinoma;
CRC	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.51	7.48	0.38	7.03e-13	Testicular germ cell tumor;
CRC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.93	-0.36	2.23e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.58	10.82	0.51	1.52e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12980942	0.872	rs12985339	chr19:41801756	A/T	cg25627403	chr19:41769009	HNRNPUL1	-0.48	-5.7	-0.3	2.74e-8	Coronary artery disease;
CRC	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.42	-9.25	-0.45	2.82e-18	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10663655	chr7:66309627	LOC729156	0.51	7.25	0.37	3.03e-12	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.89	-0.36	2.82e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg21724239	chr8:58056113	NA	0.39	5.6	0.3	4.43e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.5	-9.4	-0.46	9.53e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.31	-6.8	-0.35	4.93e-11	Psoriasis;
CRC	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg24463073	chr6:118973353	C6orf204	0.42	6.03	0.32	4.4e-9	Renal cell carcinoma;
CRC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs9908102	0.740	rs60713770	chr17:12912385	A/G	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs789852	0.764	rs1773184	chr3:194313832	T/C	cg21106136	chr3:194405973	FAM43A	-0.71	-5.82	-0.31	1.43e-8	QT interval;
CRC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg24343755	chr10:26987087	PDSS1	-0.5	-6.66	-0.34	1.14e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs7113874	0.550	rs10840084	chr11:8609274	G/A	cg02811074	chr11:8615871	STK33	0.34	5.86	0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.65	6.96	0.36	1.83e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08991297	chr3:49967416	MON1A	0.41	5.78	0.3	1.7e-8	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	5.7	0.3	2.72e-8	Obesity-related traits;
CRC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg24977027	chr2:88469347	THNSL2	0.62	7.41	0.38	1.08e-12	Plasma clusterin levels;
CRC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.93	0.31	7.49e-9	Hemoglobin concentration;
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.49	-8.34	-0.42	2.13e-15	Bipolar disorder;
CRC	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg14458575	chr2:238380390	NA	0.52	7.08	0.36	8.63e-12	Prostate cancer;
CRC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.96	0.44	2.49e-17	Morning vs. evening chronotype;
CRC	cis	rs243505	0.762	rs933436	chr7:148487329	A/C	cg09806900	chr7:148480153	CUL1	-0.5	-7.59	-0.39	3.44e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg22687807	chr8:143858763	LYNX1	0.36	6.49	0.34	3.22e-10	Urinary tract infection frequency;
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.23	-0.41	4.34e-15	Bipolar disorder;
CRC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg20573242	chr4:122745356	CCNA2	0.42	6.25	0.33	1.25e-9	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.73	11.63	0.54	2e-26	Colorectal cancer;
CRC	cis	rs10751667	0.661	rs6597946	chr11:1037888	A/G	ch.11.42038R	chr11:967971	AP2A2	0.54	6.93	0.36	2.24e-11	Alzheimer's disease (late onset);
CRC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.75	-0.3	2.07e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.06	0.61	1.76e-35	Prudent dietary pattern;
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.47	7.49	0.38	6.27e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11645453	chr3:52864694	ITIH4	0.34	6.14	0.32	2.35e-9	Bipolar disorder;
CRC	cis	rs9311676	0.632	rs11719192	chr3:58431817	C/G	cg06643156	chr3:58380774	PXK	0.43	6.56	0.34	2.06e-10	Systemic lupus erythematosus;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs10208940	0.619	rs7567869	chr2:68865293	G/A	cg12452813	chr2:68675892	NA	0.54	6.65	0.34	1.2e-10	Urate levels in lean individuals;
CRC	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg00738113	chr16:70207722	CLEC18C	-0.39	-5.82	-0.31	1.39e-8	IgE levels;
CRC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	8.7	0.43	1.63e-16	Height;
CRC	cis	rs672059	0.966	rs689375	chr1:183160973	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.28	0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg12172441	chr6:28176163	NA	0.51	6.98	0.36	1.65e-11	Parkinson's disease;
CRC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.1	10.9	0.52	7.71e-24	Diabetic retinopathy;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg06781209	chr11:61594997	FADS2	-0.73	-8.78	-0.44	9.17e-17	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg07537917	chr2:241836409	C2orf54	-0.21	-5.66	-0.3	3.27e-8	Urinary metabolites;
CRC	trans	rs7030480	0.606	rs113196649	chr9:71658436	G/A	cg07563180	chr1:208452792	NA	0.5	6.12	0.32	2.71e-9	Night sleep phenotypes;
CRC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.52	7.09	0.36	8.45e-12	Iron status biomarkers;
CRC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg07636037	chr3:49044803	WDR6	-0.67	-5.79	-0.3	1.64e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg20512303	chr5:131592959	PDLIM4	-0.37	-7.2	-0.37	4e-12	Breast cancer;
CRC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.44	8.97	0.44	2.27e-17	IgG glycosylation;
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10944051	chr3:42632258	SS18L2	0.47	6.45	0.34	4.05e-10	Anxiety disorder;
CRC	cis	rs11233250	0.502	rs11233278	chr11:82412597	C/G	cg17391194	chr11:82401662	NA	0.39	6.03	0.32	4.39e-9	Glioblastoma;Glioma;
CRC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg06470822	chr6:28175283	NA	0.81	8.33	0.42	2.26e-15	Parkinson's disease;
CRC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.08	-0.45	1.01e-17	Prostate cancer;
CRC	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg21169611	chr9:106856078	SMC2	0.42	5.95	0.31	7.05e-9	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.4	-7.05	-0.36	1.04e-11	Height;
CRC	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg15786705	chr6:28176104	NA	0.69	9.45	0.46	6.46e-19	Parkinson's disease;
CRC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.66	-0.3	3.35e-8	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08329777	chr17:79885590	LOC92659;MAFG	0.43	6.14	0.32	2.34e-9	Response to antipsychotic treatment;
CRC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.53	-8.37	-0.42	1.73e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.67	9.32	0.46	1.7e-18	Lung cancer;
CRC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.56	8.09	0.41	1.15e-14	Intelligence (multi-trait analysis);
CRC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.69	-0.35	9.45e-11	Triglycerides;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10729317	chr20:2821390	FAM113A;VPS16	0.4	6.4	0.33	5.2e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9837602	0.935	rs9860290	chr3:99839106	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.82	-0.31	1.4e-8	Breast cancer;
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.48	8.39	0.42	1.41e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.76	-0.47	6.15e-20	Hemoglobin concentration;
CRC	cis	rs7517126	1.000	rs28413658	chr1:196843400	G/T	cg13682187	chr1:196946512	CFHR5	-0.38	-6.16	-0.32	2.09e-9	Blood protein levels;
CRC	cis	rs7605827	0.930	rs2160692	chr2:15637496	C/G	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	8.87	0.44	4.63e-17	Breast cancer;
CRC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.74	-11.24	-0.53	4.83e-25	Platelet distribution width;
CRC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.14	25.93	0.82	1.68e-81	IgG glycosylation;
CRC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.34	-0.38	1.71e-12	Type 2 diabetes;
CRC	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	1.12	9.78	0.47	5.23e-20	Arsenic metabolism;
CRC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg27490568	chr2:178487706	NA	0.62	7.37	0.38	1.37e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg15845792	chr6:28175446	NA	0.67	6.22	0.32	1.52e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.71	-8.92	-0.44	3.39e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.28	-0.42	3.11e-15	Alzheimer's disease (late onset);
CRC	trans	rs4308415	0.623	rs1390070	chr4:67802169	A/C	cg19648955	chr2:177134095	MTX2	-0.41	-5.99	-0.31	5.44e-9	Educational attainment (years of education);
CRC	cis	rs10046574	0.831	rs7785527	chr7:135063685	C/T	cg27474649	chr7:135195673	CNOT4	0.68	5.72	0.3	2.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.04	-0.32	4.27e-9	Morning vs. evening chronotype;
CRC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-1.02	-13.24	-0.59	2.32e-32	Vitiligo;
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.36	-5.84	-0.31	1.27e-8	Glycated hemoglobin levels;
CRC	cis	rs7113874	0.610	rs12576736	chr11:8512281	A/C	cg02811074	chr11:8615871	STK33	-0.36	-6.17	-0.32	1.95e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.85	14.49	0.62	3.83e-37	Intelligence (multi-trait analysis);
CRC	cis	rs427941	0.632	rs201475	chr7:101745883	G/T	cg06246474	chr7:101738831	CUX1	0.44	6.78	0.35	5.45e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.17	-0.32	1.98e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-10.09	-0.49	4.97e-21	P wave terminal force;
CRC	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.79	-11.4	-0.53	1.32e-25	Platelet distribution width;
CRC	cis	rs4728302	0.838	rs10225454	chr7:133591535	G/C	cg03336402	chr7:133662267	EXOC4	-0.45	-6.56	-0.34	2.04e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.67	9.74	0.47	7.45e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	1.02	8.54	0.43	4.99e-16	Granulocyte percentage of myeloid white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15617548	chr2:171785815	GORASP2	0.53	8.69	0.43	1.74e-16	Liver disease severity in Alagille syndrome;
CRC	cis	rs929596	0.564	rs2741038	chr2:234563998	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-6.13	-0.32	2.49e-9	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg15448220	chr1:150897856	SETDB1	-0.38	-5.76	-0.3	1.89e-8	Tonsillectomy;
CRC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.44	-7.13	-0.37	6.23e-12	Menopause (age at onset);
CRC	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg22561889	chr6:118971681	C6orf204	0.48	5.92	0.31	8.26e-9	Diastolic blood pressure;
CRC	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg26248373	chr2:1572462	NA	-0.83	-11.59	-0.54	2.92e-26	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	3.01e-11	Glioblastoma;
CRC	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.6	9.54	0.47	3.45e-19	Anterior chamber depth;
CRC	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.55	-8.27	-0.41	3.34e-15	Ulcerative colitis;
CRC	cis	rs2072510	0.569	rs61937881	chr12:96393587	C/T	cg15438951	chr12:96389694	HAL	-0.49	-5.93	-0.31	7.65e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	6.22	0.32	1.5e-9	Mean platelet volume;
CRC	cis	rs7680126	0.596	rs10939835	chr4:10313750	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-7.25	-0.37	2.95e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.39	5.67	0.3	3.19e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1808579	0.904	rs2960578	chr18:21143739	A/C	cg14672496	chr18:21087552	C18orf8	0.37	6.25	0.33	1.28e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-7.04	-0.36	1.16e-11	Breast cancer;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg22638593	chr5:131593259	PDLIM4	0.39	6.36	0.33	6.64e-10	Breast cancer;
CRC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.3	-0.71	4.39e-52	Schizophrenia;
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14895029	chr7:2775587	GNA12	-0.45	-6.52	-0.34	2.59e-10	Height;
CRC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.73	11.97	0.55	1.17e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-13.76	-0.6	2.33e-34	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.37	-5.96	-0.31	6.65e-9	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18527133	chr12:71834707	LGR5	0.51	7.81	0.4	7.73e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.6e-12	Gut microbiome composition (summer);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03183882	chr3:15373315	SH3BP5	0.47	6.65	0.34	1.25e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg18187862	chr3:45730750	SACM1L	0.5	7.12	0.37	6.79e-12	Primary sclerosing cholangitis;
CRC	cis	rs1223397	0.938	rs13205692	chr6:13291560	C/T	cg21538684	chr6:13274180	PHACTR1	0.48	5.63	0.3	3.89e-8	Blood pressure;
CRC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg04450456	chr4:17643702	FAM184B	0.42	6.74	0.35	7.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.48	8.65e-21	Lung cancer;
CRC	trans	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg17903999	chr18:56338584	MALT1	-0.42	-7.0	-0.36	1.41e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.85	9.81	0.48	4.4e-20	Psoriasis;
CRC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg04545659	chr9:139973827	UAP1L1	-0.49	-7.95	-0.4	3e-14	Cerebrospinal fluid biomarker levels;
CRC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg00507830	chr2:103233733	NA	0.6	5.95	0.31	6.78e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs524281	0.817	rs10896092	chr11:65958046	A/C	cg14036092	chr11:66035641	RAB1B	-0.45	-5.61	-0.3	4.26e-8	Electroencephalogram traits;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	trans	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.29	-0.37	2.26e-12	HDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17727989	chr9:27529519	MOBKL2B	0.41	5.97	0.31	6.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.05	0.32	4e-9	Axial length;
CRC	cis	rs6840360	0.642	rs2709817	chr4:152382050	A/G	cg09659197	chr4:152720779	NA	0.33	6.57	0.34	1.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg23815491	chr16:72088622	HP	0.52	7.62	0.39	2.66e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04607442	chr13:21872219	NA	-0.41	-6.02	-0.31	4.75e-9	Myopia (pathological);
CRC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.82	12.72	0.57	2.08e-30	Glomerular filtration rate (creatinine);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04232674	chr1:150601743	ENSA	0.5	6.31	0.33	8.97e-10	Thyroid stimulating hormone;
CRC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.62	9.57	0.47	2.57e-19	Methadone dose in opioid dependence;
CRC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.71	9.35	0.46	1.44e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg09351035	chr11:748060	TALDO1	0.46	6.68	0.35	1.02e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11309891	chr11:73388802	RAB6A	-0.43	-7.02	-0.36	1.27e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg24519413	chr1:26490540	NA	0.45	7.36	0.38	1.51e-12	Height;
CRC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg08075719	chr14:103021372	NA	-0.68	-7.93	-0.4	3.47e-14	Platelet count;
CRC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.4	6.54	0.34	2.36e-10	Height;
CRC	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.63	6.49	0.34	3.1e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg24675056	chr1:15929824	NA	0.54	7.31	0.37	2.07e-12	Systolic blood pressure;
CRC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.69	-0.47	1.11e-19	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09123307	chr7:6746650	ZNF12	0.37	6.26	0.33	1.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.86	-0.48	2.94e-20	Total cholesterol levels;
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg07617317	chr6:118971624	C6orf204	0.49	6.07	0.32	3.58e-9	Diastolic blood pressure;
CRC	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg04662943	chr10:102668895	NA	0.66	7.74	0.39	1.27e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.6	-13.64	-0.6	7.19e-34	Longevity;Endometriosis;
CRC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03193349	chr6:139309610	REPS1	0.45	6.61	0.34	1.59e-10	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.94	-0.31	7.42e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.41	-0.5	4.13e-22	Breast cancer;
CRC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.77	-9.16	-0.45	5.8e-18	HIV-1 control;
CRC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.45	5.8	0.3	1.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg15786705	chr6:28176104	NA	0.76	9.45	0.46	6.35e-19	Depression;
CRC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.66	7.14	0.37	5.94e-12	Eosinophilic esophagitis;
CRC	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-9.24	-0.45	3.13e-18	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.71	-8.28	-0.42	3.22e-15	Vitiligo;
CRC	cis	rs9311676	0.632	rs67904096	chr3:58365508	T/A	cg06643156	chr3:58380774	PXK	0.42	6.55	0.34	2.17e-10	Systemic lupus erythematosus;
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.71	-0.43	1.54e-16	Bipolar disorder;
CRC	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg12512039	chr7:65958832	NA	-0.36	-5.64	-0.3	3.65e-8	Aortic root size;
CRC	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	6.55	0.34	2.25e-10	Blood protein levels;
CRC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.66	0.47	1.29e-19	Bladder cancer;
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-8.75	-0.43	1.14e-16	Bipolar disorder;
CRC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.81	-0.35	4.59e-11	Colorectal cancer;
CRC	cis	rs11696501	0.694	rs4812943	chr20:44260966	G/C	cg11783356	chr20:44313418	WFDC10B	-0.37	-5.65	-0.3	3.41e-8	Brain structure;
CRC	cis	rs2342371	0.720	rs61345811	chr3:196143030	C/T	cg15048948	chr3:196158458	UBXN7	0.5	6.18	0.32	1.93e-9	Fat distribution (HIV);
CRC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.94	-0.31	7.28e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg10911889	chr6:126070802	HEY2	-0.38	-5.94	-0.31	7.29e-9	Brugada syndrome;
CRC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.64	-0.47	1.58e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg21155852	chr7:2048760	MAD1L1	-0.52	-6.87	-0.35	3.24e-11	Bipolar disorder;
CRC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg03959625	chr15:84868606	LOC388152	0.42	6.14	0.32	2.34e-9	Schizophrenia;
CRC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.55	7.74	0.39	1.22e-13	Melanoma;
CRC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-6.2	-0.32	1.66e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.11	-0.41	1.05e-14	Morning vs. evening chronotype;
CRC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.77	11.31	0.53	2.78e-25	High light scatter reticulocyte count;
CRC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-9.04	-0.45	1.37e-17	Asthma;
CRC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.45	0.38	8.34e-13	Motion sickness;
CRC	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.57	6.93	0.36	2.18e-11	Lymphocyte counts;
CRC	cis	rs10486722	0.607	rs6463036	chr7:41753786	G/A	cg22138096	chr7:41772439	LOC285954	0.53	6.73	0.35	7.76e-11	Pit-and-Fissure caries;
CRC	trans	rs12517041	0.935	rs36035239	chr5:23294107	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.73	9.61	0.47	1.98e-19	Alzheimer's disease;
CRC	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.64	0.54	1.78e-26	Exhaled nitric oxide levels;
CRC	cis	rs2227564	0.597	rs2633305	chr10:75652123	A/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.63	-0.39	2.58e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7129220	0.512	rs2119991	chr11:10226268	A/G	cg23875677	chr11:10229755	SBF2	-0.52	-5.9	-0.31	8.91e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.61	-10.12	-0.49	3.97e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg01639898	chr1:32083012	HCRTR1	0.31	6.23	0.33	1.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	1.01	8.98	0.44	2.13e-17	Pulse pressure;
CRC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-0.83	-9.45	-0.46	6.4e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg10437265	chr15:77819839	NA	0.67	11.67	0.54	1.48e-26	Type 2 diabetes;
CRC	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	8.96	0.44	2.42e-17	Migraine;Coronary artery disease;
CRC	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.68	0.47	1.12e-19	Cognitive test performance;
CRC	cis	rs460214	0.564	rs9979888	chr21:40022099	A/G	cg05519781	chr21:40033154	ERG	0.41	5.85	0.31	1.2e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.65	-9.77	-0.47	5.83e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.61	9.79	0.47	5.09e-20	Systemic lupus erythematosus;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg04562611	chr16:615315	C16orf11	0.35	5.85	0.31	1.21e-8	Height;
CRC	cis	rs9297145	0.673	rs12531875	chr7:98724730	C/T	cg05967295	chr7:98741636	SMURF1	1.1	15.62	0.65	1.55e-41	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14329673	chr8:95732141	DPY19L4	0.36	6.03	0.32	4.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-7.29	-0.37	2.36e-12	Response to antipsychotic treatment;
CRC	cis	rs787274	0.850	rs10759604	chr9:115639748	G/A	cg13803584	chr9:115635662	SNX30	-0.66	-5.97	-0.31	6.04e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg09626299	chr10:82213104	TSPAN14	-0.36	-5.97	-0.31	6.25e-9	Post bronchodilator FEV1;
CRC	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-5.63	-0.3	3.81e-8	Inflammatory bowel disease;
CRC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	7.21	0.37	3.79e-12	Neuroticism;
CRC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg00246817	chr9:123691163	NA	-0.47	-5.97	-0.31	6.26e-9	Rheumatoid arthritis;
CRC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.3	-0.46	2.07e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.08	18.6	0.72	2.69e-53	Cognitive function;
CRC	cis	rs2730260	0.537	rs3793222	chr7:158863536	A/C	cg02254261	chr7:158964346	NA	0.45	5.67	0.3	3.08e-8	Myopia (pathological);
CRC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg24375607	chr4:120327624	NA	0.49	7.67	0.39	1.96e-13	Corneal astigmatism;
CRC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg11292332	chr7:45801988	SEPT13	-0.38	-6.77	-0.35	5.83e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.58	8.36	0.42	1.82e-15	Multiple sclerosis;
CRC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.24	-0.33	1.37e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.62	-9.62	-0.47	1.85e-19	Corneal astigmatism;
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13198984	chr17:80129470	CCDC57	-0.5	-8.89	-0.44	4.15e-17	Life satisfaction;
CRC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg05501817	chr11:14380813	RRAS2	-0.45	-5.92	-0.31	7.92e-9	Sense of smell;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg04025307	chr7:1156635	C7orf50	0.58	7.0	0.36	1.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.38	-7.64	-0.39	2.33e-13	Lung cancer;
CRC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	7.84	0.4	6.25e-14	Obesity-related traits;
CRC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.13	-20.54	-0.75	6.64e-61	Ulcerative colitis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg20466045	chr21:30445936	CCT8	-0.41	-6.08	-0.32	3.32e-9	HDL cholesterol;
CRC	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.74	-0.51	2.89e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17554472	chr22:41940697	POLR3H	0.55	5.66	0.3	3.31e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs802075	0.967	rs802068	chr6:49657330	C/T	cg20364632	chr6:49636226	NA	-0.36	-5.88	-0.31	9.95e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg08798685	chr6:27730294	NA	-0.49	-6.91	-0.36	2.59e-11	Parkinson's disease;
CRC	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.57	6.23	0.32	1.43e-9	Coronary artery disease;
CRC	cis	rs7584330	0.666	rs6760963	chr2:238398268	C/T	cg14458575	chr2:238380390	NA	-0.58	-7.83	-0.4	6.96e-14	Prostate cancer;
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg19678392	chr7:94953810	PON1	-0.57	-7.2	-0.37	4.21e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg20203395	chr5:56204925	C5orf35	-0.69	-8.47	-0.42	8.19e-16	Initial pursuit acceleration;
CRC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.07	-0.32	3.55e-9	Inflammatory bowel disease;
CRC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-7.75	-0.39	1.12e-13	Type 2 diabetes;
CRC	cis	rs11997175	0.568	rs4733169	chr8:33581855	T/C	ch.8.33884649F	chr8:33765107	NA	0.36	5.6	0.3	4.44e-8	Body mass index;
CRC	cis	rs4803480	0.766	rs723902	chr19:42084182	G/C	cg08478046	chr19:42093086	CEACAM21	-0.31	-6.21	-0.32	1.61e-9	Schizophrenia;
CRC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg06494592	chr3:125709126	NA	-0.58	-6.85	-0.35	3.57e-11	Blood pressure (smoking interaction);
CRC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg18225595	chr11:63971243	STIP1	0.59	6.24	0.33	1.35e-9	Mean platelet volume;
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23708337	chr7:1209742	NA	0.39	5.79	0.3	1.69e-8	Longevity;Endometriosis;
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.72	-0.43	1.39e-16	Bipolar disorder;
CRC	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-0.66	-7.02	-0.36	1.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-9.19	-0.45	4.55e-18	Blood trace element (Cu levels);
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg04969067	chr8:143858791	LYNX1	-0.41	-6.12	-0.32	2.64e-9	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23123679	chr12:49351256	ARF3	0.44	6.17	0.32	2.05e-9	Response to antipsychotic treatment;
CRC	cis	rs7259376	0.601	rs7251483	chr19:22494136	G/A	cg02657401	chr19:22469223	NA	-0.31	-6.63	-0.34	1.41e-10	Menopause (age at onset);
CRC	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	8.94	0.44	2.86e-17	Ulcerative colitis;
CRC	cis	rs4728302	0.869	rs6955240	chr7:133581873	G/A	cg03336402	chr7:133662267	EXOC4	-0.43	-6.28	-0.33	1.05e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs939584	1.000	rs11127488	chr2:646061	T/C	cg03610516	chr2:642275	NA	0.42	5.87	0.31	1.06e-8	Body mass index;
CRC	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.5	7.85	0.4	5.87e-14	Carotid intima media thickness;
CRC	cis	rs231513	0.911	rs537165	chr17:41976736	C/T	cg26893861	chr17:41843967	DUSP3	-0.63	-6.36	-0.33	6.63e-10	Cognitive function;
CRC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.43	0.38	9.54e-13	Menopause (age at onset);
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg02007433	chr3:129722099	NA	-0.61	-9.36	-0.46	1.32e-18	Blood pressure (smoking interaction);
CRC	trans	rs10050311	0.698	rs10516778	chr4:87636051	G/A	cg00004207	chr2:38977301	SFRS7	0.5	6.07	0.32	3.56e-9	Insulin-related traits;
CRC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.5	-6.87	-0.35	3.12e-11	Colorectal cancer;
CRC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg05874882	chr4:1763078	NA	-0.38	-7.18	-0.37	4.67e-12	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.7	-9.38	-0.46	1.09e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.28	-0.33	1.07e-9	Tonsillectomy;
CRC	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.6	8.69	0.43	1.69e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg02007433	chr3:129722099	NA	-0.44	-6.02	-0.31	4.6e-9	Blood pressure (smoking interaction);
CRC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg11657440	chr19:46296263	DMWD	-0.49	-6.85	-0.35	3.61e-11	Coronary artery disease;
CRC	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg09659197	chr4:152720779	NA	0.52	11.48	0.53	6.71e-26	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.53	5.98	0.31	5.81e-9	Gut microbiome composition (summer);
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-8.39	-0.42	1.44e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9283706	0.608	rs12523505	chr5:66334631	C/T	cg11590213	chr5:66331682	MAST4	0.4	5.62	0.3	4.06e-8	Coronary artery disease;
CRC	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.56	6.51	0.34	2.88e-10	Neutrophil percentage of white cells;
CRC	cis	rs3812762	0.879	rs10769959	chr11:8818833	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.38	5.92	0.31	8.12e-9	Hypospadias;
CRC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg15147215	chr3:52552868	STAB1	0.51	8.74	0.43	1.26e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.42	-0.38	9.84e-13	Inflammatory bowel disease;
CRC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg09264619	chr17:80180166	NA	0.37	6.02	0.32	4.6e-9	Life satisfaction;
CRC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.88	-0.35	3e-11	Total body bone mineral density;
CRC	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg18833306	chr6:118973337	C6orf204	0.45	5.72	0.3	2.35e-8	Diastolic blood pressure;
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg20119798	chr7:94954144	PON1	-0.49	-6.43	-0.33	4.48e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs35000415	0.938	rs17339836	chr7:128681062	C/T	cg19972273	chr7:128594194	NA	0.68	6.25	0.33	1.27e-9	Systemic lupus erythematosus;
CRC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-6.43	-0.33	4.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9296736	0.961	rs9370260	chr6:53921674	T/C	cg04374786	chr6:53939321	C6orf142	0.45	7.21	0.37	3.97e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg02033258	chr5:131593261	PDLIM4	0.41	7.82	0.4	7.08e-14	Breast cancer;
CRC	cis	rs2530545	0.619	rs6955901	chr7:34662400	C/T	cg14401837	chr7:34697493	NPSR1	0.42	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10325398	chr1:45476990	HECTD3;UROD	0.45	5.98	0.31	5.91e-9	Anxiety disorder;
CRC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.8	14.24	0.62	3.57e-36	Breast cancer;
CRC	cis	rs10512697	0.772	rs62336077	chr5:3516458	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs447	1.000	rs2158566	chr7:83755276	A/C	cg22846510	chr7:83753280	SEMA3A	-0.61	-7.79	-0.39	8.85e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05585630	chr7:157510462	PTPRN2	-0.39	-6.18	-0.32	1.91e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg10760299	chr15:45669010	GATM	0.51	7.78	0.39	9.59e-14	Homoarginine levels;
CRC	trans	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg10756647	chr7:56101905	PSPH	0.66	7.83	0.4	6.57e-14	Diabetic kidney disease;
CRC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.79	-12.46	-0.57	1.82e-29	Blood trace element (Zn levels);
CRC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.52e-10	Aortic root size;
CRC	cis	rs7113874	0.610	rs7947670	chr11:8525531	A/C	cg02811074	chr11:8615871	STK33	-0.36	-6.22	-0.32	1.54e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.35	-0.75	3.67e-60	Height;
CRC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg18764771	chr6:116381957	FRK	0.24	6.97	0.36	1.77e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.42	8.32	0.42	2.39e-15	Mean corpuscular volume;
CRC	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg10862848	chr6:42927986	GNMT	-0.3	-5.64	-0.3	3.75e-8	Blood protein levels;
CRC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-15.4	-0.65	1.13e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16128701	chr8:82193449	FABP5	0.4	6.41	0.33	5.01e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg11887960	chr12:57824829	NA	0.6	6.68	0.35	1.01e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.47	-8.1	-0.41	1.11e-14	Vitamin D levels;
CRC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.4	5.94	0.31	7.29e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg23136738	chr11:925521	AP2A2	-0.45	-6.74	-0.35	7.19e-11	Alzheimer's disease (late onset);
CRC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-7.64	-0.39	2.45e-13	Headache;
CRC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.36	5.93	0.31	7.84e-9	Prostate-specific antigen levels;
CRC	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg23254163	chr1:152506842	NA	0.44	8.81	0.44	7.45e-17	Hair morphology;
CRC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg15468180	chr1:107600409	PRMT6	0.43	6.4	0.33	5.43e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg13722127	chr7:150037890	RARRES2	0.46	7.39	0.38	1.2e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.9	-0.36	2.74e-11	Response to antipsychotic treatment;
CRC	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-6.62	-0.34	1.44e-10	Breast cancer;
CRC	cis	rs4478858	0.684	rs11578407	chr1:31728543	A/G	cg00250761	chr1:31883323	NA	-0.41	-7.85	-0.4	5.83e-14	Alcohol dependence;
CRC	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.57	-5.9	-0.31	8.9e-9	Coronary artery disease;
CRC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.57	7.08	0.36	8.83e-12	Body mass index (adult);
CRC	cis	rs2249694	0.586	rs9418987	chr10:135324409	A/G	cg20169779	chr10:135381914	SYCE1	0.63	9.64	0.47	1.51e-19	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-11.87	-0.55	2.79e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.65	11.05	0.52	2.41e-24	Resting heart rate;
CRC	cis	rs6793245	0.960	rs7373779	chr3:38593943	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-7.88	-0.4	4.71e-14	QT interval;
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.29e-11	Alzheimer's disease;
CRC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.58	-8.38	-0.42	1.52e-15	Obesity-related traits;
CRC	cis	rs4363385	0.740	rs1338181	chr1:153010301	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.11	-0.32	2.79e-9	Menopause (age at onset);
CRC	cis	rs889398	0.769	rs12927052	chr16:69857043	A/G	cg00738113	chr16:70207722	CLEC18C	0.33	5.62	0.3	4.04e-8	Body mass index;
CRC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	0.5	8.14	0.41	8.11e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02290350	chr8:58132656	NA	-0.51	-5.89	-0.31	9.42e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.73	-8.33	-0.42	2.18e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.69	0.35	9.5e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26376749	chr17:30677620	ZNF207	0.48	6.64	0.34	1.34e-10	Response to antipsychotic treatment;
CRC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg21918786	chr6:109611834	NA	-0.4	-7.03	-0.36	1.21e-11	Reticulocyte fraction of red cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22817719	chr11:130068300	ST14	-0.41	-6.98	-0.36	1.64e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7259376	0.777	rs7247735	chr19:22575488	C/T	cg02657401	chr19:22469223	NA	0.31	6.78	0.35	5.73e-11	Menopause (age at onset);
CRC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.69	0.43	1.78e-16	Coffee consumption (cups per day);
CRC	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-8.01	-0.4	1.97e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.97	13.51	0.6	2.11e-33	Breast cancer;
CRC	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.61	-0.39	2.93e-13	QT interval;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15398448	chr19:50353971	PTOV1	0.48	6.66	0.34	1.12e-10	Response to antipsychotic treatment;
CRC	cis	rs758324	0.947	rs173812	chr5:131319460	A/G	cg06307176	chr5:131281290	NA	-0.37	-5.78	-0.3	1.72e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.38	5.79	0.3	1.63e-8	Hemoglobin concentration;
CRC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.41	5.76	0.3	1.94e-8	Aortic root size;
CRC	cis	rs669446	0.562	rs4660259	chr1:44194534	A/G	cg12908607	chr1:44402522	ARTN	-0.34	-5.91	-0.31	8.5e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.52	-7.41	-0.38	1.08e-12	Pancreatic cancer;
CRC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.52	8.58	0.43	3.92e-16	Coronary artery disease;
CRC	cis	rs13063635	0.831	rs36040135	chr3:46061304	A/G	cg12691230	chr3:46064611	XCR1	-0.53	-5.77	-0.3	1.83e-8	Eosinophil percentage of granulocytes;
CRC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	13.22	0.59	2.65e-32	Chronic sinus infection;
CRC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg18230493	chr5:56204884	C5orf35	-0.4	-5.77	-0.3	1.86e-8	Coronary artery disease;
CRC	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-6.04	-0.32	4.15e-9	Coronary artery disease;
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.73	-0.51	3.15e-23	Body mass index;
CRC	trans	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.24	-0.59	2.25e-32	Alzheimer's disease;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.71	0.35	8.61e-11	Bipolar disorder;
CRC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.92	0.48	1.81e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg15382696	chr6:118971807	C6orf204	0.6	7.67	0.39	1.9e-13	Diastolic blood pressure;
CRC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.68	0.3	3.01e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1030268	0.667	rs12707111	chr7:133330144	C/T	cg10665199	chr7:133106180	EXOC4	0.64	7.73	0.39	1.32e-13	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2.09e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs4478147	0.591	rs56009992	chr4:87459669	G/A	cg01215037	chr19:50083917	PRRG2;NOSIP	0.49	6.46	0.34	3.68e-10	Migraine - clinic-based;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.31	0.33	9.2e-10	Alzheimer's disease;
CRC	cis	rs12541635	0.677	rs7846149	chr8:107053417	T/C	cg10147462	chr8:107024639	NA	0.61	11.08	0.52	1.93e-24	Age of smoking initiation;
CRC	cis	rs12760731	0.720	rs10913560	chr1:178452629	A/G	cg00404053	chr1:178313656	RASAL2	1.06	11.12	0.52	1.37e-24	Obesity-related traits;
CRC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.78	-9.65	-0.47	1.46e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg10820045	chr2:198174542	NA	0.41	7.01	0.36	1.33e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg07700843	chr1:2391317	NA	-0.49	-7.7	-0.39	1.62e-13	Non-obstructive azoospermia;
CRC	cis	rs1223397	0.938	rs3817737	chr6:13279082	A/G	cg06879394	chr6:13274151	PHACTR1	0.51	6.03	0.32	4.38e-9	Blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16901519	chr22:18560646	PEX26	0.35	6.1	0.32	3.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	6.55	0.34	2.28e-10	Rheumatoid arthritis;
CRC	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.69	-10.61	-0.51	7.96e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.72	-0.3	2.4e-8	Tonsillectomy;
CRC	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.55	7.92	0.4	3.63e-14	Bone mineral density;
CRC	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg04611788	chr3:186434169	KNG1	0.59	8.76	0.44	1.03e-16	Blood protein levels;
CRC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.46	-6.17	-0.32	1.98e-9	Diastolic blood pressure;
CRC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg19812747	chr11:111475976	SIK2	0.45	6.68	0.35	1.04e-10	Primary sclerosing cholangitis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26706201	chr11:57103334	SSRP1	0.43	5.96	0.31	6.52e-9	Survival in pancreatic cancer;
CRC	cis	rs4908768	0.501	rs1463051	chr1:8596893	A/T	cg20416874	chr1:8611966	RERE	0.43	6.27	0.33	1.13e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg08347473	chr17:78092826	GAA	0.35	6.04	0.32	4.11e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.14	0.45	6.75e-18	Bladder cancer;
CRC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.55	-0.38	4.24e-13	Myopia (pathological);
CRC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg10570241	chr7:158785291	NA	0.38	6.54	0.34	2.29e-10	Facial morphology (factor 20);
CRC	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg21970626	chr13:21893289	NA	0.46	5.94	0.31	7.09e-9	White matter hyperintensity burden;
CRC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.22	-0.32	1.52e-9	Life satisfaction;
CRC	trans	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg10756647	chr7:56101905	PSPH	0.73	8.14	0.41	8.01e-15	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12277888	chr11:35723985	TRIM44	-0.41	-6.71	-0.35	8.67e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs783540	0.846	rs2099259	chr15:83323688	C/T	cg18393722	chr15:85113863	UBE2QP1	0.37	6.49	0.34	3.11e-10	Schizophrenia;
CRC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.82	12.37	0.56	4.11e-29	Menarche (age at onset);
CRC	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg01475377	chr6:109611718	NA	-0.34	-5.81	-0.31	1.45e-8	Reticulocyte fraction of red cells;
CRC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.57e-9	Colorectal cancer;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg06470822	chr6:28175283	NA	0.82	12.11	0.56	3.71e-28	Parkinson's disease;
CRC	cis	rs698833	0.859	rs17580340	chr2:44602554	C/G	cg04920474	chr2:44395004	PPM1B	0.41	6.14	0.32	2.35e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.66	9.98	0.48	1.19e-20	Menopause (age at onset);
CRC	trans	rs16846053	0.786	rs115562071	chr2:162493241	C/T	cg12500891	chr11:57225987	NA	-0.69	-6.13	-0.32	2.48e-9	Blood osmolality (transformed sodium);
CRC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg15468180	chr1:107600409	PRMT6	0.35	5.61	0.3	4.38e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.54	-7.81	-0.4	7.74e-14	Rheumatoid arthritis;
CRC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.36	-5.82	-0.31	1.39e-8	Ulcerative colitis;
CRC	cis	rs10512697	0.685	rs11741304	chr5:3577245	C/T	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg23123621	chr4:1343375	KIAA1530	0.38	6.72	0.35	8.1e-11	Longevity;
CRC	cis	rs8170	1.000	rs61634114	chr19:17387254	G/A	cg04749549	chr19:17459798	NA	-0.42	-5.63	-0.3	3.77e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.44e-9	Coronary artery disease;
CRC	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg09659197	chr4:152720779	NA	0.51	10.57	0.5	1.12e-22	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.4	-7.36	-0.38	1.48e-12	Bipolar disorder;
CRC	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.58	-6.72	-0.35	7.93e-11	Major depressive disorder;
CRC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	11.56	0.54	3.64e-26	Mean platelet volume;
CRC	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01575614	chr17:40169693	DNAJC7;NKIRAS2	-0.49	-5.96	-0.31	6.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.64	9.29	0.46	2.09e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7215564	0.908	rs2316060	chr17:78663728	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg07507251	chr3:52567010	NT5DC2	-0.37	-5.61	-0.3	4.28e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.45	-6.77	-0.35	6.01e-11	Cognitive test performance;
CRC	cis	rs6681460	0.932	rs2146904	chr1:67160336	C/T	cg02459107	chr1:67143332	SGIP1	-0.4	-6.76	-0.35	6.3e-11	Presence of antiphospholipid antibodies;
CRC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.72	12.57	0.57	7.07e-30	DNA methylation (variation);
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.06	-0.32	3.74e-9	Life satisfaction;
CRC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	0.71	6.48	0.34	3.37e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.99	0.44	2.03e-17	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.25	5.67	0.3	3.19e-8	Height;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.46	-0.34	3.69e-10	Breast cancer;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.74	-12.01	-0.55	8.16e-28	Mean platelet volume;
CRC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg20673091	chr1:2541236	MMEL1	0.37	5.88	0.31	1.03e-8	Ulcerative colitis;
CRC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21028142	chr17:79581711	NPLOC4	0.33	6.97	0.36	1.77e-11	Eye color traits;
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.75	11.01	0.52	3.39e-24	Blood metabolite levels;
CRC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2223471	0.727	rs2206272	chr6:50765352	C/T	cg03432817	chr6:50765336	NA	-0.42	-6.81	-0.35	4.69e-11	Subcutaneous adipose tissue;
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.57	6.89	0.36	2.77e-11	Post bronchodilator FEV1;
CRC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.58	-9.91	-0.48	1.95e-20	Calcium levels;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.96	-0.44	2.53e-17	Bipolar disorder;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13198984	chr17:80129470	CCDC57	-0.39	-6.54	-0.34	2.32e-10	Life satisfaction;
CRC	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.05	0.41	1.49e-14	Cognitive performance;
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.57	7.05	0.36	1.04e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.62	9.14	0.45	6.71e-18	Obesity-related traits;
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.51	0.34	2.81e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.72	11.2	0.53	6.82e-25	Intelligence (multi-trait analysis);
CRC	cis	rs1838105	0.556	rs34710835	chr17:45146717	C/T	cg16759221	chr17:45003025	GOSR2	0.52	8.07	0.41	1.32e-14	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg13047869	chr3:10149882	C3orf24	0.48	6.78	0.35	5.47e-11	Alzheimer's disease;
CRC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.58	6.79	0.35	5.15e-11	Neutrophil percentage of white cells;
CRC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21956150	chr19:1438388	RPS15	0.46	6.03	0.32	4.52e-9	Hip circumference;
CRC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg26028573	chr6:26043587	HIST1H2BB	0.46	6.68	0.35	1.04e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.43	-6.41	-0.33	5.01e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs2274471	0.699	rs10974985	chr9:5156061	C/T	cg03390472	chr9:5043263	JAK2	0.53	5.73	0.3	2.31e-8	Crohn's disease;
CRC	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.52	8.36	0.42	1.76e-15	Resting heart rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14877741	chr9:125703099	RABGAP1	0.43	6.0	0.31	5.3e-9	Response to antipsychotic treatment;
CRC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg01262667	chr19:19385393	TM6SF2	0.38	6.22	0.32	1.5e-9	Tonsillectomy;
CRC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.98	-14.4	-0.62	8.87e-37	Hip circumference adjusted for BMI;
CRC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.31	0.46	1.9e-18	Migraine;Coronary artery disease;
CRC	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.73	-10.88	-0.51	9.4e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg07299736	chr8:135490787	ZFAT	-0.38	-6.19	-0.32	1.82e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.79	13.25	0.59	2.13e-32	Menopause (age at onset);
CRC	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg14844989	chr11:31128820	NA	-0.34	-6.14	-0.32	2.33e-9	Red blood cell count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16836995	chr17:43662488	NA	0.49	6.16	0.32	2.07e-9	Thyroid stimulating hormone;
CRC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.62	7.69	0.39	1.67e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.82	9.46	0.46	6.06e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.21	-0.32	1.61e-9	Endometrial cancer;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.64	9.13	0.45	7.25e-18	Parkinson's disease;
CRC	trans	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg11693508	chr17:37793320	STARD3	0.57	7.08	0.36	8.78e-12	Bipolar disorder;
CRC	cis	rs863345	0.565	rs12403685	chr1:158452399	C/T	cg12129480	chr1:158549410	OR10X1	0.29	6.04	0.32	4.2e-9	Pneumococcal bacteremia;
CRC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.91	-0.44	3.58e-17	Type 2 diabetes;
CRC	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.26	0.37	2.79e-12	Retinal vascular caliber;
CRC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	8.98	0.44	2.09e-17	Hip circumference adjusted for BMI;
CRC	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21659725	chr3:3221576	CRBN	-0.43	-6.62	-0.34	1.5e-10	Menarche (age at onset);
CRC	cis	rs7538876	1.000	rs4920603	chr1:17727379	C/G	cg07965774	chr1:17746286	RCC2	-0.33	-6.41	-0.33	5.18e-10	Basal cell carcinoma;
CRC	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg17182837	chr8:41585554	ANK1	-0.52	-6.91	-0.36	2.54e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.49	-8.04	-0.41	1.66e-14	Aortic root size;
CRC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg21153622	chr11:89784906	NA	0.4	6.5	0.34	2.91e-10	Coronary artery disease;
CRC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-6.08	-0.32	3.34e-9	Breast cancer;
CRC	trans	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg05376469	chr2:102649931	NA	-0.38	-6.28	-0.33	1.09e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg17321639	chr7:2759063	NA	-0.55	-7.79	-0.39	8.65e-14	Height;
CRC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.7	-10.84	-0.51	1.31e-23	Lung cancer;
CRC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.74	-0.54	7.83e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.37	-7.0	-0.36	1.42e-11	Colorectal cancer;
CRC	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.86	-0.35	3.36e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg10523679	chr1:76189770	ACADM	-0.4	-5.7	-0.3	2.7e-8	Daytime sleep phenotypes;
CRC	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg20936604	chr3:58311152	NA	0.71	6.64	0.34	1.29e-10	Cholesterol, total;
CRC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.44	-0.53	9.35e-26	Ulcerative colitis;
CRC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg08888203	chr3:10149979	C3orf24	0.58	8.44	0.42	1.03e-15	Alzheimer's disease;
CRC	cis	rs4926298	0.926	rs8111617	chr19:13191461	C/T	cg04657146	chr19:12876947	HOOK2	-0.44	-5.89	-0.31	9.56e-9	Bipolar disorder;
CRC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg04545659	chr9:139973827	UAP1L1	0.49	8.14	0.41	8.38e-15	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2302190	0.882	rs12942018	chr17:56613277	C/T	cg12560992	chr17:57184187	TRIM37	0.51	5.99	0.31	5.48e-9	Vitamin D levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00983485	chr15:31284262	MTMR10	0.44	6.35	0.33	7.21e-10	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14090510	chr7:64839023	ZNF92	0.39	6.29	0.33	1.02e-9	Obesity-related traits;
CRC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg27661571	chr11:113659931	NA	-0.78	-9.61	-0.47	1.89e-19	Hip circumference adjusted for BMI;
CRC	cis	rs294883	0.858	rs4708818	chr6:159723503	C/G	cg14500486	chr6:159655392	FNDC1	0.35	5.81	0.31	1.44e-8	Coronary artery disease;
CRC	cis	rs2857891	0.817	rs2638094	chr11:6981488	A/G	cg04053776	chr11:6947353	ZNF215	0.5	6.63	0.34	1.34e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.13	-0.37	6.35e-12	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs9925964	0.933	rs10871454	chr16:31048079	C/T	cg02466173	chr16:30829666	NA	0.44	5.96	0.31	6.65e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg09165964	chr15:75287851	SCAMP5	0.56	8.89	0.44	4.11e-17	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01038479	chr17:35767307	TADA2A;ACACA	0.47	6.81	0.35	4.74e-11	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23161317	chr6:28129485	ZNF389	-0.5	-6.01	-0.31	5e-9	Depression;
CRC	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.55	7.67	0.39	2e-13	Schizophrenia;
CRC	trans	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.4	5.91	0.31	8.33e-9	Breast cancer;
CRC	cis	rs6700896	0.931	rs2889195	chr1:66156730	C/T	cg04111102	chr1:66153794	NA	0.32	5.68	0.3	2.92e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg00343986	chr7:65444356	GUSB	-0.5	-7.44	-0.38	8.9e-13	Aortic root size;
CRC	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.59	8.71	0.43	1.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg21452805	chr1:244014465	NA	0.53	6.27	0.33	1.14e-9	RR interval (heart rate);
CRC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.95	-0.52	5.49e-24	Chronic sinus infection;
CRC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg03885332	chr11:832357	CD151	-0.42	-6.23	-0.32	1.46e-9	Mean platelet volume;
CRC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.4	5.82	0.31	1.41e-8	Longevity;Endometriosis;
CRC	cis	rs4654899	0.827	rs12564330	chr1:21207495	A/C	cg02927042	chr1:21476669	EIF4G3	0.4	6.48	0.34	3.39e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.29	-6.82	-0.35	4.29e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.53	-8.74	-0.43	1.18e-16	Total body bone mineral density;
CRC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.29	6.06	0.32	3.68e-9	Lung cancer;
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.39	5.95	0.31	6.98e-9	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-8.88	-0.44	4.32e-17	Menarche (age at onset);
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg15845792	chr6:28175446	NA	0.66	9.22	0.45	3.55e-18	Parkinson's disease;
CRC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.1	13.26	0.59	1.87e-32	Sexual dysfunction (female);
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00166722	chr3:10149974	C3orf24	-0.66	-8.96	-0.44	2.55e-17	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11361691	chr3:57993876	FLNB	0.37	6.2	0.32	1.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6564851	0.506	rs11648145	chr16:81257977	T/C	cg05274606	chr16:81253692	PKD1L2	-0.36	-5.81	-0.31	1.45e-8	Carotenoid and tocopherol levels;
CRC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.54e-33	Menopause (age at onset);
CRC	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.69	5.93	0.31	7.85e-9	Schizophrenia;
CRC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12648201	chr2:27665141	KRTCAP3	0.3	5.95	0.31	6.96e-9	Total body bone mineral density;
CRC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	0.49	6.47	0.34	3.51e-10	Blood protein levels;
CRC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-0.98	-14.41	-0.62	7.74e-37	Hip circumference adjusted for BMI;
CRC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.48	7.32	0.37	1.91e-12	Corneal astigmatism;
CRC	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	11.32	0.53	2.66e-25	Tonsillectomy;
CRC	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.52	-7.54	-0.38	4.65e-13	Body mass index;
CRC	cis	rs365302	1.000	rs418902	chr6:159648864	T/A	cg14500486	chr6:159655392	FNDC1	0.44	6.87	0.35	3.15e-11	Coronary heart disease;
CRC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.78	0.35	5.68e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12699921	0.632	rs2723501	chr7:17854532	A/C	cg02066331	chr6:17282778	RBM24	0.36	6.36	0.33	6.86e-10	Fibrinogen levels;
CRC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg06028605	chr16:24865363	SLC5A11	0.39	7.26	0.37	2.9e-12	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.98	0.31	5.83e-9	Prudent dietary pattern;
CRC	cis	rs7705042	0.865	rs4912805	chr5:141493685	A/G	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.9	-0.31	9e-9	Asthma;
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.2	0.59	3.17e-32	Alzheimer's disease;
CRC	trans	rs7821565	0.904	rs1370443	chr8:52164230	A/G	cg09187163	chr7:72721838	NSUN5	-0.41	-5.98	-0.31	5.79e-9	Tuberculosis;
CRC	cis	rs860295	0.639	rs10908469	chr1:155468732	A/C	cg02153340	chr1:155202674	NA	-0.53	-6.69	-0.35	9.55e-11	Body mass index;
CRC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg15676542	chr6:26421231	BTN2A3	0.32	5.61	0.3	4.3e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg20469991	chr17:27169893	C17orf63	0.47	5.87	0.31	1.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs72627123	0.737	rs77361581	chr14:74465290	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.0	0.31	5.3300000000000004e-09	Morning vs. evening chronotype;
CRC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.48	-6.97	-0.36	1.72e-11	Colorectal cancer;
CRC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.61	11.47	0.53	7.48e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.48	-7.87	-0.4	5.07e-14	Iron status biomarkers;
CRC	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg16540259	chr10:75572220	NDST2	0.44	6.38	0.33	6.07e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.69	11.25	0.53	4.6e-25	Monocyte percentage of white cells;
CRC	cis	rs6694672	0.867	rs4915378	chr1:197161212	T/G	cg13682187	chr1:196946512	CFHR5	0.44	7.13	0.37	6.61e-12	Asthma;
CRC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.42	0.33	4.73e-10	Diastolic blood pressure;
CRC	cis	rs6662572	0.737	rs7532388	chr1:46472734	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.87	0.31	1.09e-8	Blood protein levels;
CRC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.63	-9.55	-0.47	3.13e-19	Corneal astigmatism;
CRC	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.41	-5.75	-0.3	2.02e-8	Neuroticism;
CRC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.78	-9.98	-0.48	1.14e-20	Cognitive test performance;
CRC	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.66	10.86	0.51	1.12e-23	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
CRC	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.17	-9.75	-0.47	6.94e-20	Mitochondrial DNA levels;
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.17	0.37	4.89e-12	Lung cancer in ever smokers;
CRC	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.1	0.32	3.01e-9	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16063989	chr7:139929855	NA	0.42	6.54	0.34	2.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg07195577	chr17:27052828	TLCD1	0.42	5.99	0.31	5.62e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-6.8	-0.35	4.83e-11	Coronary artery disease;
CRC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg22532475	chr10:104410764	TRIM8	-0.37	-6.8	-0.35	4.94e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.56	-7.03	-0.36	1.2e-11	Vitiligo;
CRC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.2	-0.32	1.72e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg19812747	chr11:111475976	SIK2	-0.57	-9.67	-0.47	1.21e-19	Primary sclerosing cholangitis;
CRC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.51	6.67	0.35	1.1e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.52	5.7	0.3	2.61e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.29	-0.37	2.27e-12	Schizophrenia;
CRC	cis	rs524281	0.861	rs12049852	chr11:65884702	T/C	cg16950941	chr11:66035639	RAB1B	-0.57	-7.35	-0.38	1.61e-12	Electroencephalogram traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08806348	chr19:14201154	SAMD1	0.44	6.15	0.32	2.25e-9	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.01	0.44	1.77e-17	Bladder cancer;
CRC	trans	rs4398173	1.000	rs4398173	chr18:6941108	A/G	cg11797573	chr7:158219200	PTPRN2	0.35	6.0	0.31	5.22e-9	Response to citalopram treatment;
CRC	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg19688584	chr6:167529678	CCR6	-0.34	-6.16	-0.32	2.09e-9	Primary biliary cholangitis;
CRC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.52	0.38	5.18e-13	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.38	-0.33	6.11e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg16670446	chr17:27188758	MIR451;MIR144	-0.54	-8.45	-0.42	9.38e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01656856	chr2:170551263	PHOSPHO2;KLHL23;C2orf77	0.48	7.39	0.38	1.21e-12	Schizophrenia;
CRC	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg08992911	chr2:238395768	MLPH	0.64	6.48	0.34	3.43e-10	Prostate cancer;
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg20811857	chr17:78079795	GAA	-0.46	-6.72	-0.35	8.06e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg15763984	chr4:1342303	KIAA1530	-0.35	-6.08	-0.32	3.29e-9	Obesity-related traits;
CRC	cis	rs9468199	1.000	rs9468199	chr6:27681215	G/A	cg20933634	chr6:27740509	NA	0.46	5.92	0.31	8.13e-9	Parkinson's disease;
CRC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg02766259	chr12:125626809	AACS	-0.43	-8.18	-0.41	6.23e-15	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.52	9.09	0.45	9.28e-18	Schizophrenia;
CRC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1639906	0.708	rs3779013	chr7:2210844	A/G	cg19897017	chr7:2163380	MAD1L1	0.65	9.21	0.45	4.03e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg07507251	chr3:52567010	NT5DC2	0.43	6.15	0.32	2.19e-9	Bipolar disorder;
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg26587870	chr6:27730563	NA	-0.66	-6.83	-0.35	4.21e-11	Breast cancer;
CRC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.38	0.53	1.55e-25	Bone mineral density;
CRC	trans	rs1117324	1.000	rs1117324	chr2:21840093	C/T	cg15889231	chr14:107239010	NA	-0.56	-6.37	-0.33	6.43e-10	Response to antipsychotic treatment;
CRC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.63	-0.39	2.57e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg04165759	chr1:150448943	RPRD2	-0.35	-5.73	-0.3	2.27e-8	Migraine;
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg27432699	chr2:27873401	GPN1	-0.62	-9.48	-0.46	5.39e-19	Total body bone mineral density;
CRC	cis	rs540254	0.647	rs12405457	chr1:160759052	A/G	cg20255094	chr1:160771763	LY9	0.49	6.14	0.32	2.34e-9	Blood protein levels;
CRC	cis	rs4363385	0.818	rs532773	chr1:153011750	T/A	cg25856811	chr1:152973957	SPRR3	-0.25	-7.0	-0.36	1.49e-11	Inflammatory skin disease;
CRC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	ch.11.42038R	chr11:967971	AP2A2	0.57	9.77	0.47	5.76e-20	Alzheimer's disease (late onset);
CRC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.44	8.82	0.44	6.83e-17	Renal cell carcinoma;
CRC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg10760299	chr15:45669010	GATM	-0.41	-6.28	-0.33	1.09e-9	Homoarginine levels;
CRC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-7.39	-0.38	1.21e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08409687	chr2:201936025	NDUFB3;FAM126B	0.53	6.98	0.36	1.64e-11	Thyroid stimulating hormone;
CRC	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.54	0.5	1.46e-22	Corneal astigmatism;
CRC	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.91	11.09	0.52	1.75e-24	Exhaled nitric oxide output;
CRC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg09659197	chr4:152720779	NA	-0.42	-8.73	-0.43	1.26e-16	Intelligence (multi-trait analysis);
CRC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.46	6.61	0.34	1.51e-10	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25867694	chr22:31503597	SELM	0.41	6.82	0.35	4.42e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06834434	chr14:75079333	LTBP2	0.51	6.03	0.32	4.48e-9	Obesity-related traits;
CRC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-12.38	-0.56	3.73e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.75	13.47	0.6	3e-33	Lewy body disease;
CRC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg20684491	chr1:25596433	NA	-0.43	-7.39	-0.38	1.23e-12	Erythrocyte sedimentation rate;
CRC	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.55	8.17	0.41	6.9e-15	Night sleep phenotypes;
CRC	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs3790844	0.876	rs61486545	chr1:200008337	G/A	cg07208853	chr1:200005219	NR5A2	0.34	8.28	0.42	3.14e-15	Pancreatic cancer;
CRC	cis	rs8067545	0.532	rs35915823	chr17:19973397	A/G	cg13482628	chr17:19912719	NA	0.42	6.0	0.31	5.07e-9	Schizophrenia;
CRC	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg20354231	chr13:53171401	NA	-0.44	-7.17	-0.37	4.88e-12	Lewy body disease;
CRC	cis	rs2898681	0.837	rs2017237	chr4:53748515	A/G	cg00338735	chr4:53728038	RASL11B	0.36	5.68	0.3	3.01e-8	Optic nerve measurement (cup area);
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg00597713	chr6:42947103	PEX6	-0.41	-5.71	-0.3	2.51e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.45	5.66	0.3	3.38e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06589507	chr5:179234594	SQSTM1;MGAT4B	0.5	6.64	0.34	1.3100000000000001e-10	Thyroid stimulating hormone;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.56	-7.33	-0.37	1.76e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg02741985	chr17:80059408	CCDC57	0.44	7.34	0.38	1.68e-12	Life satisfaction;
CRC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg10589385	chr1:150898437	SETDB1	0.31	6.48	0.34	3.32e-10	Tonsillectomy;
CRC	trans	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg16141378	chr3:129829833	LOC729375	0.4	6.11	0.32	2.85e-9	Joint mobility (Beighton score);
CRC	cis	rs6557786	0.636	rs2445940	chr8:24787201	C/G	cg19677607	chr8:24772270	NEFM	0.37	5.88	0.31	1.03e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.68	8.43	0.42	1.13e-15	Body mass index;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.94	0.44	2.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg16989719	chr2:238392110	NA	-0.34	-5.87	-0.31	1.06e-8	Prostate cancer;
CRC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg21010569	chr2:103233596	NA	0.6	6.67	0.34	1.11e-10	Gut microbiota (bacterial taxa);
CRC	trans	rs73162807	0.655	rs73160990	chr3:146434154	A/T	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.99	-0.36	1.5e-11	Colorectal cancer;
CRC	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg02880119	chr16:3481970	NA	0.47	6.59	0.34	1.73e-10	Body mass index (adult);
CRC	trans	rs9581094	1.000	rs73154401	chr13:25085667	C/A	ch.10.2420334F	chr10:115122200	NA	0.61	6.01	0.31	4.94e-9	Sudden cardiac arrest;
CRC	cis	rs13333054	1.000	rs13333054	chr16:86011033	C/T	cg04454285	chr16:86016317	NA	0.81	11.58	0.54	3.17e-26	Multiple sclerosis;
CRC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.56	8.89	0.44	3.99e-17	Vitiligo;
CRC	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg05527609	chr1:210001259	C1orf107	-0.56	-5.88	-0.31	1.01e-8	Red blood cell count;
CRC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.61	8.65	0.43	2.31e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg16892393	chr17:41919603	NA	0.5	7.58	0.39	3.55e-13	Triglycerides;
CRC	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.93	0.55	1.69e-27	Coffee consumption (cups per day);
CRC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.75	-13.52	-0.6	1.94e-33	Menarche (age at onset);
CRC	cis	rs12476592	0.602	rs262521	chr2:63892485	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.33	0.33	7.85e-10	Childhood ear infection;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.83	13.16	0.59	4.52e-32	Menarche (age at onset);
CRC	cis	rs3996993	0.573	rs11759734	chr6:52724146	A/G	cg20803780	chr6:52668592	GSTA1	0.39	6.6	0.34	1.62e-10	Hemoglobin concentration;
CRC	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg11887960	chr12:57824829	NA	0.59	6.4	0.33	5.2400000000000005e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23708337	chr7:1209742	NA	0.4	6.0	0.31	5.23e-9	Longevity;Endometriosis;
CRC	cis	rs12024301	0.557	rs10797896	chr1:183589800	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.92	0.36	2.41e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.38	0.33	6.15e-10	Tonsillectomy;
CRC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.39	5.8	0.3	1.53e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00615892	chr16:69166530	CHTF8;CIRH1A	0.42	6.48	0.34	3.41e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.3	6.93	0.36	2.18e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7274811	0.711	rs291697	chr20:31985248	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.77	0.3	1.87e-8	Height;
CRC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.8	13.22	0.59	2.77e-32	Menopause (age at onset);
CRC	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg16691251	chr5:66510806	NA	0.56	11.17	0.52	8.69e-25	Breast cancer;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.47e-8	Prudent dietary pattern;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17216071	chr19:18392551	JUND	0.4	6.31	0.33	8.99e-10	Schizophrenia;
CRC	cis	rs2677744	0.626	rs11857545	chr15:91489705	G/A	cg23684204	chr15:91497937	RCCD1	0.42	6.34	0.33	7.4e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.68	0.47	1.13e-19	Menopause (age at onset);
CRC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.55	8.6	0.43	3.37e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.54	-7.48	-0.38	6.77e-13	DNA methylation (variation);
CRC	trans	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18876405	chr7:65276391	NA	0.4	6.15	0.32	2.25e-9	Corneal structure;
CRC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg24675056	chr1:15929824	NA	0.49	6.72	0.35	8.13e-11	Systolic blood pressure;
CRC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg15832292	chr6:96025679	MANEA	0.58	6.33	0.33	7.84e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg00343986	chr7:65444356	GUSB	-0.51	-7.62	-0.39	2.66e-13	Aortic root size;
CRC	cis	rs2227564	0.700	rs2675677	chr10:75648249	C/A	cg00564723	chr10:75632066	CAMK2G	-0.3	-6.89	-0.36	2.87e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.78	0.39	9.23e-14	Height;
CRC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.37	7.07	0.36	9.28e-12	Iron status biomarkers;
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.31	0.33	8.84e-10	Bipolar disorder;
CRC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg04731861	chr2:219085781	ARPC2	-0.32	-6.81	-0.35	4.61e-11	Colorectal cancer;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg15845792	chr6:28175446	NA	0.96	13.94	0.61	5.17e-35	Parkinson's disease;
CRC	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg03934865	chr2:198174659	NA	-0.4	-6.39	-0.33	5.71e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg16898833	chr6:26189333	HIST1H4D	0.66	6.19	0.32	1.83e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07549269	chr21:33765057	C21orf119;URB1	0.4	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.4	7.81	0.4	7.68e-14	Mean corpuscular volume;
CRC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.57	9.65	0.47	1.47e-19	Menopause (age at onset);
CRC	cis	rs7731657	0.537	rs4705850	chr5:130220358	A/G	cg08523029	chr5:130500466	HINT1	-0.49	-6.39	-0.33	5.71e-10	Fasting plasma glucose;
CRC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.74	11.71	0.54	1.03e-26	Platelet distribution width;
CRC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg19193384	chr17:30244184	NA	-0.53	-6.66	-0.34	1.15e-10	Hip circumference adjusted for BMI;
CRC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg13777783	chr17:79615861	NA	-0.3	-5.71	-0.3	2.54e-8	Eye color traits;
CRC	cis	rs4936891	0.557	rs55954258	chr11:123914759	A/G	cg22125253	chr11:123886957	OR10G4	-0.34	-6.13	-0.32	2.49e-9	Male fertility;
CRC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.48	6.59	0.34	1.79e-10	Lymphocyte counts;
CRC	cis	rs6499255	0.904	rs12595927	chr16:69716338	C/G	cg04110750	chr16:69646130	NFAT5	-0.6	-7.9	-0.4	4.16e-14	IgE levels;
CRC	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.74	-7.76	-0.39	1.06e-13	Type 2 diabetes;
CRC	cis	rs6694672	1.000	rs928440	chr1:196950350	G/A	cg13682187	chr1:196946512	CFHR5	-0.48	-7.61	-0.39	2.83e-13	Asthma;
CRC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.61	9.62	0.47	1.84e-19	Height;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg00769240	chr8:12517080	NA	-0.72	-9.89	-0.48	2.24e-20	Blood pressure (smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09951048	chr8:21966736	NUDT18	0.38	6.02	0.31	4.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Hypertriglyceridemia;
CRC	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg12458913	chr13:53173898	NA	0.48	7.23	0.37	3.5e-12	Lewy body disease;
CRC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg11062466	chr8:58055876	NA	0.52	5.61	0.3	4.25e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.63e-12	Lung cancer;
CRC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.52	8.81	0.44	7.46e-17	Coronary artery disease;
CRC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	9.11	0.45	8.37e-18	Cognitive test performance;
CRC	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.86	-8.13	-0.41	9.08e-15	Height;
CRC	cis	rs4743820	0.503	rs10820835	chr9:93921227	C/T	cg14446406	chr9:93919335	NA	0.49	8.76	0.44	1.02e-16	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg12218747	chr21:37451666	NA	-0.43	-7.41	-0.38	1.09e-12	Mitral valve prolapse;
CRC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg17948913	chr5:572064	NA	0.5	5.73	0.3	2.26e-8	Obesity-related traits;
CRC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg00769240	chr8:12517080	NA	-0.65	-7.34	-0.38	1.67e-12	Blood pressure (smoking interaction);
CRC	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.8	10.93	0.52	6.36e-24	Migraine;Coronary artery disease;
CRC	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	0.93	9.99	0.48	1.08e-20	Atopic dermatitis;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02290350	chr8:58132656	NA	0.55	6.57	0.34	1.94e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15703646	chr7:100209939	MOSPD3	0.41	6.01	0.31	4.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg18301423	chr5:131593218	PDLIM4	0.31	5.6	0.3	4.51e-8	Blood metabolite levels;
CRC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.41	-7.02	-0.36	1.28e-11	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23181138	chr9:88356705	AGTPBP1	0.43	5.99	0.31	5.48e-9	Response to antipsychotic treatment;
CRC	cis	rs2336384	1.000	rs1810563	chr1:12054030	A/G	cg13216073	chr1:12042593	MFN2	-0.52	-7.16	-0.37	5.22e-12	Platelet count;
CRC	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07165851	chr6:158734300	TULP4	0.62	7.76	0.39	1.07e-13	Height;
CRC	trans	rs17111396	0.627	rs59741121	chr14:81502778	T/C	cg22745369	chr6:3517953	NA	-0.43	-6.15	-0.32	2.19e-9	Uric acid levels;
CRC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg00601450	chr5:74908170	NA	-0.46	-6.01	-0.31	4.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg13057898	chr1:3703894	LRRC47	0.53	6.99	0.36	1.53e-11	Red cell distribution width;
CRC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.5	0.34	2.91e-10	Aortic root size;
CRC	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg13385794	chr1:248469461	NA	0.37	6.58	0.34	1.88e-10	Common traits (Other);
CRC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.83	-14.26	-0.62	3.02e-36	Height;
CRC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	trans	rs10411161	0.580	rs12151288	chr19:52381552	A/G	cg22319618	chr22:45562946	NUP50	-0.48	-6.49	-0.34	3.23e-10	Breast cancer;
CRC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg24375607	chr4:120327624	NA	0.47	7.59	0.39	3.42e-13	Corneal astigmatism;
CRC	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.76	8.12	0.41	9.6e-15	Migraine;Coronary artery disease;
CRC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	10.06	0.49	6e-21	Alzheimer's disease (late onset);
CRC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.76	-0.47	6.07e-20	Total cholesterol levels;
CRC	cis	rs11958404	1.000	rs11958404	chr5:157410278	A/T	cg05962755	chr5:157440814	NA	0.83	10.82	0.51	1.57e-23	IgG glycosylation;
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg10217327	chr6:118973057	C6orf204	0.51	5.71	0.3	2.55e-8	Renal cell carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20824237	chr3:99979579	TBC1D23	0.5	7.05	0.36	1.08e-11	Response to antipsychotic treatment;
CRC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg19688584	chr6:167529678	CCR6	-0.33	-6.09	-0.32	3.24e-9	Primary biliary cholangitis;
CRC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.52	-9.14	-0.45	6.61e-18	Sense of smell;
CRC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.88	-14.93	-0.64	7.65e-39	Blood metabolite levels;
CRC	cis	rs7626444	0.625	rs2931210	chr3:196476676	G/C	cg12930392	chr3:196481615	PAK2	0.39	6.97	0.36	1.69e-11	Monocyte count;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.04	0.36	1.13e-11	Cardiac Troponin-T levels;
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg06713098	chr7:45960367	IGFBP3	0.43	6.83	0.35	4.05e-11	Sitting height ratio;
CRC	trans	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19894588	chr14:64061835	NA	0.43	6.11	0.32	2.86e-9	Glioblastoma;Glioma;
CRC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.93	17.67	0.7	1.28e-49	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.27	-0.33	1.13e-9	Aortic root size;
CRC	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg05562828	chr17:3906858	NA	-0.44	-5.76	-0.3	1.95e-8	Type 2 diabetes;
CRC	cis	rs8005677	0.798	rs4982713	chr14:23404102	C/T	cg25600027	chr14:23388339	RBM23	-0.43	-6.34	-0.33	7.59e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.52	7.99	0.4	2.25e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18143863	chr3:25706824	TOP2B	0.49	6.9	0.36	2.62e-11	Response to antipsychotic treatment;
CRC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg01733459	chr4:1388830	CRIPAK	0.5	5.79	0.3	1.68e-8	Systolic blood pressure;
CRC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-6.61	-0.34	1.54e-10	Body mass index;
CRC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.53e-46	Breast cancer;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.71	-0.43	1.54e-16	Bipolar disorder;
CRC	trans	rs16957091	0.528	rs72713784	chr15:43115936	A/G	cg15973384	chr6:168817498	NA	0.53	6.06	0.32	3.64e-9	MGMT methylation in smokers;
CRC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg10790698	chr19:18539756	SSBP4	-0.46	-8.72	-0.43	1.44e-16	Breast cancer;
CRC	cis	rs2274273	0.638	rs9919921	chr14:55695505	A/G	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.75	-0.3	2.04e-8	Protein biomarker;
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.7	-0.54	1.12e-26	Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg07507251	chr3:52567010	NT5DC2	0.44	6.39	0.33	5.81e-10	Bipolar disorder;
CRC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	10.55	0.5	1.3e-22	Body mass index;
CRC	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg13390004	chr1:15929781	NA	0.55	7.43	0.38	9.37e-13	Systolic blood pressure;
CRC	cis	rs7202877	0.561	rs4888369	chr16:75307277	T/C	cg03315344	chr16:75512273	CHST6	0.52	5.89	0.31	9.66e-9	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13537857	chr3:133293460	CDV3	0.41	6.23	0.32	1.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.84	0.35	3.85e-11	Renal cell carcinoma;
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg10130564	chr11:117069849	TAGLN	0.31	5.95	0.31	6.71e-9	Blood protein levels;
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.7	-6.45	-0.34	3.96e-10	Inflammatory biomarkers;
CRC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.74	-11.14	-0.52	1.14e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg26587870	chr6:27730563	NA	-0.37	-5.76	-0.3	1.96e-8	Cardiac Troponin-T levels;
CRC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg19318889	chr4:1322082	MAEA	0.4	5.72	0.3	2.39e-8	Obesity-related traits;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24739457	chr1:205821442	NA	0.44	6.44	0.33	4.18e-10	Menarche (age at onset);
CRC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.65	7.83	0.4	6.68e-14	Diabetic retinopathy;
CRC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.48	8.0	0.4	2.1e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg10570241	chr7:158785291	NA	-0.47	-8.21	-0.41	5.09e-15	Facial morphology (factor 20);
CRC	cis	rs13064447	0.817	rs73022951	chr3:12767557	G/A	cg07775309	chr3:12595852	NA	0.35	5.7	0.3	2.63e-8	Major depression and alcohol dependence;
CRC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.77	-0.44	9.89e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg23860436	chr12:58378763	NA	0.37	5.97	0.31	6.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	9.59	0.47	2.2e-19	Height;
CRC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg02683197	chr6:28174875	NA	0.62	8.43	0.42	1.14e-15	Parkinson's disease;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.77	-0.35	6.02e-11	Bipolar disorder;
CRC	cis	rs2072510	0.593	rs2540497	chr12:96404275	A/T	cg09636302	chr12:96389483	HAL	-0.51	-6.4	-0.33	5.42e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.56	8.87	0.44	4.87e-17	Coronary artery disease;
CRC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.89	16.32	0.67	2.73e-44	Prostate cancer;
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg22561889	chr6:118971681	C6orf204	0.54	6.92	0.36	2.31e-11	Renal cell carcinoma;
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.36	0.33	6.79e-10	Life satisfaction;
CRC	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg16540259	chr10:75572220	NDST2	0.38	5.8	0.3	1.59e-8	Inflammatory bowel disease;
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	0.92	9.76	0.47	6.41e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.44	-6.36	-0.33	6.91e-10	Macular telangiectasia type 2;
CRC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.57	-7.66	-0.39	2.07e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6546324	0.625	rs11126138	chr2:67794476	C/T	cg15745817	chr2:67799979	NA	-0.54	-9.09	-0.45	9.4e-18	Endometriosis;
CRC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.15	0.32	2.3e-9	Lung cancer;
CRC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.09	-0.32	3.11e-9	Lung cancer;
CRC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.23	-0.45	3.34e-18	Alcohol dependence;
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg09877947	chr5:131593287	PDLIM4	0.37	6.38	0.33	6.08e-10	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16104446	chr8:48873951	MCM4;PRKDC	0.48	6.18	0.32	1.91e-9	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg23161317	chr6:28129485	ZNF389	0.47	6.62	0.34	1.48e-10	Cardiac Troponin-T levels;
CRC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg16077055	chr2:106428750	NCK2	0.4	5.73	0.3	2.23e-8	Addiction;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00802000	chr16:706648	WDR90	-0.41	-5.84	-0.31	1.22e-8	Height;
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg10729496	chr3:10149963	C3orf24	0.53	6.96	0.36	1.8e-11	Alzheimer's disease;
CRC	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg27411982	chr8:10470053	RP1L1	-0.35	-5.68	-0.3	2.99e-8	Neuroticism;
CRC	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-6.27	-0.33	1.13e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.31	-0.53	2.93e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.14	0.64	1.16e-39	Lymphocyte percentage of white cells;
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs9491140	1.000	rs12204812	chr6:124681503	C/A	cg19267163	chr6:125004984	NKAIN2	0.36	5.66	0.3	3.24e-8	Neuroticism;
CRC	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg02811702	chr13:24901961	NA	0.48	6.6	0.34	1.69e-10	Obesity-related traits;
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.66	-0.39	2.15e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12194463	chr7:32982580	RP9P	0.48	6.43	0.33	4.61e-10	Anxiety disorder;
CRC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg24768116	chr2:27665128	KRTCAP3	0.3	6.61	0.34	1.55e-10	Total body bone mineral density;
CRC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.69	11.02	0.52	3.05e-24	Motion sickness;
CRC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.59	-0.34	1.7e-10	Major depressive disorder;
CRC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.64	-11.51	-0.54	5.4e-26	Aortic root size;
CRC	cis	rs4290604	0.748	rs80326134	chr2:237982015	T/C	cg23555395	chr2:238036564	NA	0.68	6.92	0.36	2.36e-11	Asthma;
CRC	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.99	-0.55	9.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg15147215	chr3:52552868	STAB1	-0.53	-9.29	-0.46	2.18e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.8	13.44	0.6	3.93e-33	Menopause (age at onset);
CRC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg02560186	chr11:3602584	NA	-0.57	-6.97	-0.36	1.73e-11	Blood pressure (smoking interaction);
CRC	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg27205649	chr11:78285834	NARS2	0.48	5.8	0.3	1.56e-8	Alzheimer's disease (survival time);
CRC	cis	rs11191205	0.686	rs10883671	chr10:103413862	G/T	cg15320455	chr10:103880129	LDB1	0.57	6.49	0.34	3.23e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg16141378	chr3:129829833	LOC729375	-0.45	-6.88	-0.35	3e-11	Triglycerides;
CRC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg25347419	chr2:177043501	NA	0.58	8.89	0.44	4e-17	IgG glycosylation;
CRC	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg16141378	chr3:129829833	LOC729375	0.42	6.25	0.33	1.25e-9	Mood instability;
CRC	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg23417306	chr2:180868811	CWC22	-0.43	-5.92	-0.31	7.89e-9	Schizophrenia;
CRC	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.53	6.85	0.35	3.63e-11	Alzheimer's disease (survival time);
CRC	cis	rs7259376	0.934	rs7253315	chr19:22594439	C/T	cg02657401	chr19:22469223	NA	0.31	6.82	0.35	4.25e-11	Menopause (age at onset);
CRC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	10.31	0.49	8.65e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.47	8.16	0.41	7.34e-15	Systemic lupus erythematosus;
CRC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg02683197	chr6:28174875	NA	0.88	12.35	0.56	4.59e-29	Depression;
CRC	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg09127314	chr1:152161683	NA	-0.47	-6.05	-0.32	3.84e-9	Atopic dermatitis;
CRC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03676636	chr4:99064102	C4orf37	0.22	6.19	0.32	1.83e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4547160	0.821	rs877898	chr12:63483535	G/A	cg26727693	chr12:63544175	AVPR1A	-0.41	-7.45	-0.38	8.23e-13	Morning vs. evening chronotype;
CRC	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg14254433	chr6:34482411	PACSIN1	-0.45	-5.63	-0.3	3.9e-8	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg24562669	chr7:97807699	LMTK2	0.46	7.58	0.39	3.61e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg16482183	chr6:26056742	HIST1H1C	0.82	10.46	0.5	2.62e-22	Iron status biomarkers;
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg05569086	chr8:143859399	LYNX1	0.52	8.95	0.44	2.69e-17	Urinary tract infection frequency;
CRC	cis	rs12612619	0.732	rs11126836	chr2:27273128	C/T	cg00617064	chr2:27272375	NA	-0.39	-6.46	-0.34	3.71e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.59	-6.23	-0.32	1.41e-9	Schizophrenia;
CRC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.23	-0.41	4.32e-15	Response to amphetamines;
CRC	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg12573674	chr2:1569213	NA	-0.73	-7.36	-0.38	1.5e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2072510	0.569	rs7306086	chr12:96390502	T/C	cg09636302	chr12:96389483	HAL	-0.52	-6.5	-0.34	3.02e-10	Metabolite levels (small molecules and protein measures);
CRC	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-11.22	-0.53	6.06e-25	Prudent dietary pattern;
CRC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg10645314	chr2:3704589	ALLC	-0.54	-6.39	-0.33	5.78e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.87	-0.31	1.05e-8	Pulmonary function;
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg14988396	chr8:25316392	CDCA2;KCTD9	0.44	5.88	0.31	1.02e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.51	11.53	0.54	4.46e-26	Cutaneous nevi;
CRC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg04155289	chr7:94953770	PON1	-0.57	-7.1	-0.36	7.66e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-7.76	-0.39	1.05e-13	Hepatocellular carcinoma;
CRC	trans	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.68	6.74	0.35	7.29e-11	Fat distribution (HIV);
CRC	cis	rs7528419	0.617	rs4970834	chr1:109814880	C/T	cg00908766	chr1:109817496	CELSR2	-0.33	-5.83	-0.31	1.33e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.39	-0.33	5.59e-10	Breast cancer;
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.66	9.66	0.47	1.33e-19	Menopause (age at onset);
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg11843238	chr5:131593191	PDLIM4	0.43	8.18	0.41	6.26e-15	Breast cancer;
CRC	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg00042356	chr1:8021962	PARK7	-0.54	-6.27	-0.33	1.14e-9	Inflammatory bowel disease;
CRC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.71	10.96	0.52	5.0600000000000004e-24	Corneal astigmatism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00960509	chr1:21671908	ECE1	-0.45	-6.82	-0.35	4.26e-11	Myopia (pathological);
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.85	-19.37	-0.73	2.52e-56	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	11.2	0.53	6.88e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg18404041	chr3:52824283	ITIH1	-0.32	-5.66	-0.3	3.23e-8	Schizophrenia;
CRC	trans	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg00938859	chr5:1591904	SDHAP3	-0.57	-6.22	-0.32	1.51e-9	Breast cancer;
CRC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.1	-0.32	2.99e-9	Type 2 diabetes;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.77	-10.3	-0.49	9.87e-22	Smoking behavior;
CRC	trans	rs8175379	0.521	rs10037109	chr5:46328445	C/G	cg11378101	chr11:94826095	ENDOD1	-0.21	-6.07	-0.32	3.56e-9	Interleukin-7 levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19482049	chr3:30647725	TGFBR2	0.38	6.81	0.35	4.6e-11	Intelligence (multi-trait analysis);
CRC	cis	rs672059	1.000	rs479994	chr1:183161729	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.28	0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg10217327	chr6:118973057	C6orf204	0.52	5.87	0.31	1.08e-8	Diastolic blood pressure;
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2160860	0.965	rs2543046	chr8:39819370	A/C	cg11363097	chr8:39792086	IDO2	-0.36	-5.75	-0.3	2.08e-8	Blood metabolite levels;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg05569086	chr8:143859399	LYNX1	-0.39	-6.11	-0.32	2.74e-9	Urinary tract infection frequency;
CRC	cis	rs11212617	0.934	rs623860	chr11:108106782	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.39	5.6	0.3	4.42e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg02927042	chr1:21476669	EIF4G3	0.38	5.68	0.3	2.98e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.83e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs16924631	0.769	rs13292799	chr9:6448764	A/G	cg18105767	chr19:41698548	CYP2S1	-0.46	-6.0	-0.31	5.18e-9	Periodontal microbiota;
CRC	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg12573674	chr2:1569213	NA	-0.71	-7.0	-0.36	1.41e-11	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	16.32	0.67	2.89e-44	Electrocardiographic conduction measures;
CRC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.41	-6.55	-0.34	2.28e-10	Bone mineral density (spine);
CRC	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	0.9	12.04	0.55	6.54e-28	Blood protein levels;
CRC	cis	rs7113874	0.589	rs7949017	chr11:8492127	C/T	cg20771178	chr11:8615675	STK33	0.34	5.67	0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg23254163	chr1:152506842	NA	0.52	10.37	0.5	5.45e-22	Hair morphology;
CRC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.71	7.01	0.36	1.38e-11	Type 2 diabetes;
CRC	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg19337854	chr7:99768885	GPC2	0.47	5.93	0.31	7.64e-9	Lung function (FEV1/FVC);
CRC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg26248373	chr2:1572462	NA	-0.67	-7.62	-0.39	2.8e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.76	10.04	0.48	7.3e-21	Height;
CRC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg26850624	chr5:429559	AHRR	-0.74	-12.46	-0.57	1.83e-29	Cystic fibrosis severity;
CRC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg03037974	chr15:76606532	NA	0.71	12.35	0.56	4.72e-29	Blood metabolite levels;
CRC	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg02702477	chr5:179499311	RNF130	0.61	6.95	0.36	1.95e-11	LDL cholesterol;
CRC	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.49	6.03	0.32	4.33e-9	Neuroticism;
CRC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.31e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.5	-8.26	-0.41	3.52e-15	Aortic root size;
CRC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.74	-11.13	-0.52	1.21e-24	Refractive error;
CRC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.28	-0.33	1.09e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg27411982	chr8:10470053	RP1L1	0.43	6.35	0.33	7.29e-10	Neuroticism;
CRC	trans	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24555065	chr12:6977392	TPI1	0.49	7.0	0.36	1.46e-11	Response to antipsychotic treatment;
CRC	cis	rs78523330	0.614	rs78443405	chr17:37072073	G/A	cg21637561	chr17:37074902	LASP1	-0.63	-5.74	-0.3	2.18e-8	Multiple system atrophy;
CRC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg24011408	chr12:48396354	COL2A1	0.46	6.48	0.34	3.4e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.67	-11.24	-0.53	5.04e-25	Urate levels;
CRC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.42	5.81	0.31	1.44e-8	Neuroticism;
CRC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg07865391	chr16:88106882	BANP	0.43	5.69	0.3	2.87e-8	Menopause (age at onset);
CRC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg27661571	chr11:113659931	NA	-0.96	-11.11	-0.52	1.42e-24	Hip circumference adjusted for BMI;
CRC	cis	rs2882667	0.898	rs6862393	chr5:138364698	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.45e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.69	8.94	0.44	2.94e-17	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg23485639	chr6:28045615	ZNF165	0.39	5.73	0.3	2.24e-8	Parkinson's disease;
CRC	cis	rs6691722	0.503	rs6656485	chr1:24707685	A/G	cg18323236	chr1:24743029	NIPAL3	0.39	5.68	0.3	2.96e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.62e-9	Life satisfaction;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg25164649	chr6:28176230	NA	0.64	8.67	0.43	1.95e-16	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15380588	chr6:144606480	NA	0.37	6.13	0.32	2.49e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.68	10.91	0.52	7.48e-24	Corneal astigmatism;
CRC	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs16975963	0.843	rs1056405	chr19:38313021	T/C	cg15135657	chr19:38346511	NA	-0.44	-5.94	-0.31	7.12e-9	Longevity;
CRC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.47	8.47	0.42	8.06e-16	Childhood ear infection;
CRC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs16975963	0.644	rs112666969	chr19:38047645	G/A	cg15135657	chr19:38346511	NA	-0.42	-5.98	-0.31	5.91e-9	Longevity;
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02711726	chr17:80685570	FN3KRP	-0.55	-7.35	-0.38	1.58e-12	Glycated hemoglobin levels;
CRC	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.97	-0.36	1.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08448040	chr3:13521693	HDAC11	0.48	6.19	0.32	1.82e-9	Thyroid stimulating hormone;
CRC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.11	-0.32	2.75e-9	IgG glycosylation;
CRC	cis	rs9786986	0.764	rs2492767	chr1:235695799	A/G	cg08848088	chr1:235714526	GNG4	0.49	5.91	0.31	8.35e-9	Body mass index;
CRC	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-8.96	-0.44	2.56e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10893370	chr17:30228961	UTP6	0.42	6.13	0.32	2.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.57	8.27	0.42	3.25e-15	Testicular germ cell tumor;
CRC	cis	rs55702914	0.809	rs2376407	chr2:198183465	A/G	cg03934865	chr2:198174659	NA	-0.4	-7.01	-0.36	1.35e-11	Major depression and alcohol dependence;
CRC	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg11130432	chr3:121712080	ILDR1	-0.48	-5.95	-0.31	6.91e-9	Multiple sclerosis;
CRC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21643547	chr1:205240462	TMCC2	-0.47	-7.8	-0.4	8.33e-14	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs10905065	0.829	rs6602278	chr10:5868361	A/G	cg11519256	chr10:5708881	ASB13	-0.47	-6.76	-0.35	6.15e-11	Menopause (age at onset);
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-8.15	-0.41	7.84e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2486012	1.000	rs2906459	chr1:44335657	A/C	cg12908607	chr1:44402522	ARTN	-0.42	-5.71	-0.3	2.53e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.67e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs294883	0.739	rs9457589	chr6:159733016	C/T	cg14500486	chr6:159655392	FNDC1	-0.37	-6.43	-0.33	4.47e-10	Coronary artery disease;
CRC	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9625935	0.518	rs9614086	chr22:30259608	A/C	cg01021169	chr22:30184971	ASCC2	0.37	5.68	0.3	2.92e-8	Tonsillectomy;
CRC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.24	0.33	1.31e-9	Obesity-related traits;
CRC	cis	rs2882667	0.898	rs13182437	chr5:138387149	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.47e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg09873164	chr1:152488093	CRCT1	0.37	6.26	0.33	1.19e-9	Hair morphology;
CRC	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.62	-8.57	-0.43	4.17e-16	Cocaine dependence;
CRC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.78	0.39	9.75e-14	Heart rate;
CRC	cis	rs2882667	0.931	rs11955952	chr5:138329119	A/G	cg09476006	chr5:138032270	NA	0.42	7.09	0.36	8.32e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg17800788	chr1:21766015	NBPF3	0.37	6.59	0.34	1.79e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.77	-0.39	1e-13	HDL cholesterol;
CRC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.62	10.23	0.49	1.67e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg08314208	chr16:67682810	RLTPR	-0.54	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg13957321	chr17:43675089	NA	0.53	6.32	0.33	8.34e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg16141378	chr3:129829833	LOC729375	0.45	6.49	0.34	3.17e-10	Mood instability;
CRC	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.79	10.86	0.51	1.08e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.44	-6.82	-0.35	4.31e-11	Monocyte count;
CRC	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.72	-0.39	1.45e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs7274811	0.625	rs293722	chr20:31927361	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.42	-5.61	-0.3	4.33e-8	Height;
CRC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.74	9.41	0.46	8.99e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.83	0.31	1.33e-8	HDL cholesterol;
CRC	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.46	-6.83	-0.35	4.19e-11	Body mass index;
CRC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.2	-0.37	4.18e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.3	-0.37	2.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6681460	0.866	rs996123	chr1:67025343	T/C	cg02459107	chr1:67143332	SGIP1	0.46	7.45	0.38	8.5e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.28	-0.46	2.42e-18	Bone mineral density;
CRC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg00383909	chr3:49044727	WDR6	0.44	5.68	0.3	2.91e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.01	-0.48	9.28e-21	Height;
CRC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.41	-7.1	-0.36	7.58e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.35	-0.38	1.55e-12	Type 2 diabetes;
CRC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.86	-0.31	1.11e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.38	-5.76	-0.3	1.97e-8	Height;
CRC	cis	rs35883536	1.000	rs34441740	chr1:101137046	C/G	cg14515779	chr1:101123966	NA	-0.41	-7.97	-0.4	2.69e-14	Monocyte count;
CRC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.46	-6.22	-0.32	1.49e-9	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.44	6.76	0.35	6.36e-11	Longevity;Endometriosis;
CRC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg03037974	chr15:76606532	NA	-0.53	-7.45	-0.38	8.14e-13	Blood metabolite levels;
CRC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12044889	chr6:3000430	NQO2	0.47	6.18	0.32	1.93e-9	Thyroid stimulating hormone;
CRC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.94	-0.36	2.06e-11	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs4731207	0.564	rs13234634	chr7:124676033	G/A	cg23710748	chr7:124431027	NA	-0.43	-6.72	-0.35	8e-11	Cutaneous malignant melanoma;
CRC	cis	rs7538876	0.903	rs1324367	chr1:17752451	C/G	cg07965774	chr1:17746286	RCC2	0.32	5.99	0.31	5.59e-9	Basal cell carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20633339	chr19:10196919	C19orf66	0.4	6.5	0.34	2.96e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-7.77	-0.39	1e-13	Dilated cardiomyopathy;
CRC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg24375607	chr4:120327624	NA	-0.46	-7.73	-0.39	1.31e-13	Corneal astigmatism;
CRC	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.54	8.05	0.41	1.52e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.49	7.29	0.37	2.4e-12	Vitiligo;
CRC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.46	6.74	0.35	7.11e-11	Pancreatic cancer;
CRC	cis	rs6988985	0.765	rs4483134	chr8:143978646	G/C	cg10324643	chr8:143916377	GML	0.38	6.27	0.33	1.15e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.81	-0.35	4.66e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-1.04	-13.84	-0.61	1.2e-34	Blood pressure (smoking interaction);
CRC	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg13385794	chr1:248469461	NA	0.4	6.9	0.36	2.64e-11	Common traits (Other);
CRC	cis	rs17767392	0.881	rs35680546	chr14:71940619	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.23	-0.37	3.46e-12	Mitral valve prolapse;
CRC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.51	0.42	6.42e-16	Mood instability;
CRC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg17321639	chr7:2759063	NA	-0.54	-7.52	-0.38	5.17e-13	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18002905	chr4:8442565	ACOX3	0.46	6.48	0.34	3.29e-10	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg12458913	chr13:53173898	NA	-0.4	-5.7	-0.3	2.7e-8	Lewy body disease;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.68	11.22	0.53	5.68e-25	Height;
CRC	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg13491945	chr12:107078410	RFX4	0.36	6.17	0.32	1.96e-9	Heart rate;
CRC	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.88	-0.44	4.54e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg18016565	chr1:150552671	MCL1	0.48	6.91	0.36	2.57e-11	Melanoma;
CRC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04880052	chr2:219191631	PNKD	-0.44	-6.96	-0.36	1.91e-11	Colorectal cancer;
CRC	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.18	-16.76	-0.68	5.1e-46	Hip circumference adjusted for BMI;
CRC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg03030879	chr14:75389066	RPS6KL1	0.39	5.94	0.31	7.3e-9	Height;
CRC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.99	0.4	2.27e-14	Height;
CRC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-10.57	-0.5	1.16e-22	Heart rate;
CRC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.25	-14.84	-0.63	1.63e-38	Diabetic kidney disease;
CRC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.65	0.57	3.56e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.42	5.93	0.31	7.79e-9	Aortic root size;
CRC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.17	0.52	9.08e-25	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2882667	0.690	rs906695	chr5:138139277	A/G	cg09476006	chr5:138032270	NA	0.5	8.63	0.43	2.67e-16	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.17	-0.32	1.96e-9	Arsenic metabolism;
CRC	cis	rs6840360	0.642	rs7657747	chr4:152394254	A/G	cg09659197	chr4:152720779	NA	0.34	6.64	0.34	1.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.42	0.38	9.93e-13	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16437679	chr6:146056419	EPM2A	0.4	6.32	0.33	8.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.71	-7.59	-0.39	3.23e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs5167	0.566	rs5120	chr19:45451620	T/A	cg09555818	chr19:45449301	APOC2	0.33	5.7	0.3	2.68e-8	Blood protein levels;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18099408	chr3:52552593	STAB1	0.43	7.08	0.36	8.77e-12	Bipolar disorder;
CRC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.64	0.3	3.57e-8	Neuroticism;
CRC	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.55	9.78	0.47	5.43e-20	Common traits (Other);
CRC	cis	rs6743226	0.934	rs4303713	chr2:242257859	G/A	cg10021735	chr2:242295487	FARP2	0.47	6.85	0.35	3.68e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.66	-0.3	3.37e-8	Rheumatoid arthritis;
CRC	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg02569219	chr17:2266849	SGSM2	0.58	9.86	0.48	2.84e-20	Proinsulin levels;
CRC	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-8.98	-0.44	2.17e-17	Bipolar disorder;
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg04553112	chr3:125709451	NA	-0.51	-6.43	-0.33	4.51e-10	Blood pressure (smoking interaction);
CRC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.14	-0.32	2.42e-9	Alzheimer's disease (late onset);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg19670317	chr17:8093380	C17orf59	0.45	6.47	0.34	3.65e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.41	-0.38	1.05e-12	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg11164639	chr15:91192950	NA	-0.36	-5.99	-0.31	5.46e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.51	6.35	0.33	7.31e-10	Recombination rate (females);
CRC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.54	8.91	0.44	3.45e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs7932354	0.583	rs964551	chr11:46897995	G/T	cg19486271	chr11:47235900	DDB2	-0.42	-6.35	-0.33	7.28e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs747650	0.504	rs7128193	chr11:46988983	A/C	cg19486271	chr11:47235900	DDB2	-0.43	-6.49	-0.34	3.11e-10	Acne (severe);
CRC	cis	rs7940866	0.838	rs7949071	chr11:130877478	T/C	cg12179176	chr11:130786555	SNX19	0.58	8.3	0.42	2.77e-15	Schizophrenia;
CRC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg26162295	chr17:38119207	GSDMA	-0.34	-5.67	-0.3	3.09e-8	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	6.87	0.35	3.2e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg03037974	chr15:76606532	NA	0.83	16.81	0.68	3.39e-46	Blood metabolite levels;
CRC	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.6	-9.64	-0.47	1.51e-19	Breast cancer;
CRC	trans	rs2547917	0.652	rs2591748	chr5:58677499	C/T	cg23342516	chr9:133538893	PRDM12	-0.32	-6.05	-0.32	3.99e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg27534772	chr1:16042836	PLEKHM2	0.55	10.98	0.52	4.27e-24	Systolic blood pressure;
CRC	cis	rs10946940	0.965	rs10946935	chr6:27501345	T/C	cg02683197	chr6:28174875	NA	-0.53	-7.25	-0.37	2.99e-12	Systemic lupus erythematosus;
CRC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.82	-10.14	-0.49	3.31e-21	Platelet count;
CRC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-7.88	-0.4	4.75e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.51	-8.17	-0.41	6.87e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.42	-7.68	-0.39	1.81e-13	Huntington's disease progression;
CRC	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg04239558	chr2:103089729	SLC9A4	0.37	6.61	0.34	1.51e-10	Blood protein levels;
CRC	trans	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.72	0.35	8.15e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.3	0.33	9.57e-10	Primary sclerosing cholangitis;
CRC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg24879335	chr3:133465180	TF	-0.32	-5.8	-0.3	1.54e-8	Iron status biomarkers;
CRC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg09835421	chr16:68378352	PRMT7	-0.6	-7.16	-0.37	5.31e-12	Schizophrenia;
CRC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.51	6.48	0.34	3.41e-10	Recombination rate (females);
CRC	cis	rs2527866	1.000	rs2527866	chr7:157090296	A/C	cg00552600	chr7:157091575	NA	-0.36	-5.63	-0.3	3.84e-8	Quantitative traits;
CRC	cis	rs4132509	0.895	rs12138168	chr1:244009113	A/G	cg21452805	chr1:244014465	NA	0.58	7.33	0.37	1.85e-12	RR interval (heart rate);
CRC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg14711859	chr11:8959438	ASCL3	-0.46	-7.45	-0.38	8.45e-13	Hemoglobin concentration;
CRC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg19041857	chr6:27730383	NA	-0.72	-6.75	-0.35	6.7e-11	Breast cancer;
CRC	cis	rs4731207	0.596	rs1404898	chr7:124694339	G/T	cg23710748	chr7:124431027	NA	-0.4	-6.3	-0.33	9.53e-10	Cutaneous malignant melanoma;
CRC	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.61	6.79	0.35	5.14e-11	Coronary artery disease;
CRC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.36	-7.73	-0.39	1.33e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.17	-0.41	6.79e-15	Type 2 diabetes;
CRC	cis	rs6496667	1.000	rs7178496	chr15:90896959	C/T	cg04176472	chr15:90893244	GABARAPL3	0.52	7.95	0.4	3.04e-14	Rheumatoid arthritis;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg01339444	chr6:118972232	C6orf204	0.52	5.87	0.31	1.08e-8	Diastolic blood pressure;
CRC	cis	rs35883536	0.933	rs1409419	chr1:101183396	T/C	cg14515779	chr1:101123966	NA	-0.35	-6.44	-0.33	4.32e-10	Monocyte count;
CRC	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg08501292	chr6:25962987	TRIM38	0.91	8.23	0.41	4.35e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.8	12.15	0.56	2.51e-28	Multiple sclerosis;
CRC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.83	-11.51	-0.54	5.41e-26	Gut microbiome composition (summer);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19842065	chr12:56660480	COQ10A	0.48	7.09	0.36	8.03e-12	Intelligence (multi-trait analysis);
CRC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg25876840	chr17:41920477	NA	0.53	7.92	0.4	3.77e-14	Triglycerides;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg15845792	chr6:28175446	NA	0.66	7.9	0.4	4.21e-14	Parkinson's disease;
CRC	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.8	-0.35	5.08e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg27053337	chr8:124217698	FAM83A	0.42	5.67	0.3	3.16e-8	Urinary uromodulin levels;
CRC	cis	rs9311676	0.632	rs62258139	chr3:58406836	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.55	13.07	0.58	9.6e-32	Breast size;
CRC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.42	-9.13	-0.45	7.24e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.51	-9.37	-0.46	1.24e-18	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.42	-6.59	-0.34	1.78e-10	C-reactive protein levels;
CRC	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.84	13.58	0.6	1.19e-33	Alcohol dependence;
CRC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg21251018	chr6:28226885	NKAPL	-0.62	-11.57	-0.54	3.19e-26	Pubertal anthropometrics;
CRC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.46	7.27	0.37	2.65e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.73	-0.35	7.77e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.3	-0.33	9.48e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.67	0.35	1.09e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.41	6.62	0.34	1.43e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg14844989	chr11:31128820	NA	0.35	6.3	0.33	9.75e-10	Red blood cell count;
CRC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.04	-0.41	1.67e-14	Schizophrenia;
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg07507251	chr3:52567010	NT5DC2	0.44	6.39	0.33	5.81e-10	Bipolar disorder;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg21251018	chr6:28226885	NKAPL	0.49	7.69	0.39	1.76e-13	Parkinson's disease;
CRC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.4	-7.57	-0.39	3.84e-13	Subjective well-being;
CRC	cis	rs7632954	0.935	rs6770049	chr3:8522388	C/T	cg03495237	chr3:8533978	NA	0.35	6.32	0.33	8.32e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.55	0.57	8.85e-30	Alzheimer's disease;
CRC	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg21095983	chr6:86352623	SYNCRIP	-0.46	-6.74	-0.35	6.9e-11	Smooth-surface caries;
CRC	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg20628663	chr10:43360327	NA	0.55	6.76	0.35	6.28e-11	Blood protein levels;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12273811	chr6:28175739	NA	-0.71	-9.06	-0.45	1.2e-17	Depression;
CRC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg13206674	chr6:150067644	NUP43	0.5	7.02	0.36	1.25e-11	Testicular germ cell tumor;
CRC	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.77	9.64	0.47	1.6e-19	Obesity-related traits;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg04518342	chr5:131593106	PDLIM4	0.37	6.6	0.34	1.67e-10	Blood metabolite levels;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg20092199	chr4:1342459	KIAA1530	0.45	7.32	0.37	1.95e-12	Obesity-related traits;
CRC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.56	-8.33	-0.42	2.28e-15	Body mass index;
CRC	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.46	5.82	0.31	1.42e-8	Alzheimer's disease (survival time);
CRC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	0.69	6.25	0.33	1.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs394563	0.556	rs398159	chr6:149792768	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.41	-6.7	-0.35	9.3e-11	Dupuytren's disease;
CRC	cis	rs7202877	0.656	rs6564245	chr16:75308899	A/G	cg03315344	chr16:75512273	CHST6	-0.49	-5.69	-0.3	2.82e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg21620606	chr4:1342894	KIAA1530	0.36	6.15	0.32	2.21e-9	Obesity-related traits;
CRC	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.6	8.76	0.43	1.06e-16	Crohn's disease;
CRC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.2	0.59	3.2e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24308560	chr3:49941425	MST1R	0.45	7.07	0.36	9.39e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs11212617	0.967	rs625120	chr11:108095220	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.25	0.33	1.25e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-7.69	-0.39	1.73e-13	Aortic root size;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23161317	chr6:28129485	ZNF389	0.44	5.71	0.3	2.49e-8	Parkinson's disease;
CRC	cis	rs12024301	0.557	rs61265590	chr1:183591790	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2898857	0.524	rs2906100	chr17:47372764	C/T	cg11430096	chr6:110968061	CDK19	0.54	8.14	0.41	8.21e-15	Cancer;
CRC	cis	rs4964805	0.865	rs67825151	chr12:104205444	C/T	cg02344784	chr12:104178138	NT5DC3	0.5	6.95	0.36	2e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs7605827	0.930	rs6735633	chr2:15706096	G/A	cg19274914	chr2:15703543	NA	0.39	5.98	0.31	5.9e-9	Educational attainment (years of education);
CRC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.58	-0.43	3.84e-16	Aortic root size;
CRC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.16	-0.45	5.56e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs6764363	0.506	rs13091018	chr3:277659	A/G	cg02057681	chr3:285234	CHL1	0.36	5.9	0.31	9.25e-9	Sudden cardiac arrest;
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg12270520	chr8:146023939	ZNF517	-0.42	-6.77	-0.35	5.79e-11	Age at first birth;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg06470822	chr6:28175283	NA	0.69	9.39	0.46	1.04e-18	Parkinson's disease;
CRC	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.72	7.76	0.39	1.08e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.18	-0.32	1.91e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg23815491	chr16:72088622	HP	0.49	7.51	0.38	5.77e-13	Fibrinogen levels;
CRC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.47	8.19e-20	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.39	-6.03	-0.32	4.46e-9	Monocyte count;
CRC	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.25	0.64	4.14e-40	Colorectal cancer;
CRC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	1.03	8.74	0.43	1.19e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12928939	0.723	rs28501298	chr16:71855133	C/G	cg03805757	chr16:71968109	PKD1L3	-0.53	-7.07	-0.36	9.19e-12	Post bronchodilator FEV1;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.76	-9.58	-0.47	2.4e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.77	-0.51	2.33e-23	Alzheimer's disease;
CRC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-9.63	-0.47	1.69e-19	Dental caries;
CRC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.6	-0.5	8.76e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg15358701	chr1:161410459	NA	-0.65	-6.94	-0.36	2.1e-11	Rheumatoid arthritis;
CRC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.69	11.21	0.53	6.51e-25	Tonsillectomy;
CRC	cis	rs501120	1.000	rs493874	chr10:44764077	C/T	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.87	-15.33	-0.65	2.2e-40	Intelligence (multi-trait analysis);
CRC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg14530993	chr4:882597	GAK	0.82	7.83	0.4	6.7e-14	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-11.38	-0.53	1.64e-25	Colorectal cancer;
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.3	-0.53	3.02e-25	Alzheimer's disease;
CRC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg00343986	chr7:65444356	GUSB	0.45	6.28	0.33	1.08e-9	Aortic root size;
CRC	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.51	-8.35	-0.42	1.95e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg10756647	chr7:56101905	PSPH	0.74	8.12	0.41	9.34e-15	Diabetic kidney disease;
CRC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.29	-0.33	9.98e-10	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg03623178	chr6:28175578	NA	-0.66	-8.03	-0.4	1.74e-14	Parkinson's disease;
CRC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	7.18	0.37	4.69e-12	Parkinson's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06753227	chr18:9475508	RALBP1	0.41	6.26	0.33	1.22e-9	Interleukin-6 levels;
CRC	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	7.76	0.39	1.11e-13	Response to antipsychotic treatment;
CRC	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.61	-8.89	-0.44	4.18e-17	Coronary artery disease;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.63	-9.7	-0.47	1.01e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.5	0.34	3.06e-10	Schizophrenia;
CRC	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.79	-0.48	4.89e-20	Blood protein levels;
CRC	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.51	7.64	0.39	2.39e-13	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09112790	chr10:127408004	C10orf137	0.46	6.4	0.33	5.47e-10	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.25e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg05756136	chr1:119680316	WARS2	-0.49	-6.73	-0.35	7.51e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.51	-0.34	2.82e-10	Coronary artery calcification;
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs9463078	0.774	rs6935398	chr6:45262427	G/A	cg25276700	chr6:44698697	NA	-0.28	-6.71	-0.35	8.5e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs863345	0.604	rs2873593	chr1:158504711	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.69	11.42	0.53	1.19e-25	Hepatocellular carcinoma;
CRC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg20203395	chr5:56204925	C5orf35	-0.39	-5.78	-0.3	1.72e-8	Coronary artery disease;
CRC	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.82	-0.31	1.39e-8	Rheumatoid arthritis;
CRC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg20487152	chr13:99095054	FARP1	-0.43	-6.28	-0.33	1.09e-9	Neuroticism;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	7.3	0.37	2.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg23942311	chr14:51606299	NA	0.84	17.26	0.69	5.3e-48	Cancer;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.46	-0.34	3.8e-10	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16418735	chr3:97483530	ARL6	0.55	7.2	0.37	4.14e-12	Thyroid stimulating hormone;
CRC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.73	-0.35	7.78e-11	Urate levels in overweight individuals;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.28	0.64	3.23e-40	Colorectal cancer;
CRC	cis	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg05299278	chr17:33885742	SLFN14	0.4	5.99	0.31	5.59e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg11941060	chr3:133502564	NA	-0.44	-7.21	-0.37	3.89e-12	Iron status biomarkers;
CRC	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg14458575	chr2:238380390	NA	0.45	7.75	0.39	1.13e-13	Prostate cancer;
CRC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.06e-32	Vitiligo;
CRC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg21970626	chr13:21893289	NA	0.44	5.8	0.3	1.59e-8	White matter hyperintensity burden;
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-8.17	-0.41	6.49e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg09650180	chr20:62225654	GMEB2	-0.51	-6.8	-0.35	4.98e-11	Glioblastoma;
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	trans	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.23	14.67	0.63	7.55e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg21747405	chr11:67723411	NA	-0.43	-6.13	-0.32	2.45e-9	Blood pressure (smoking interaction);
CRC	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs6973256	0.661	rs2550989	chr7:133500313	A/T	cg03336402	chr7:133662267	EXOC4	-0.55	-7.1	-0.36	7.96e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.47	7.48	0.38	6.76e-13	Gestational age at birth (maternal effect);
CRC	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.52	8.67	0.43	2.02e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.33	16.07	0.66	2.6e-43	Uric acid levels;
CRC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.44	-6.09	-0.32	3.19e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.34	5.7	0.3	2.64e-8	Emphysema distribution in smoking;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18402987	chr7:1209562	NA	0.44	6.48	0.34	3.28e-10	Longevity;Endometriosis;
CRC	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.47	8.22	0.41	4.8e-15	Migraine;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02057063	chr1:114354442	RSBN1	0.39	6.68	0.35	1.01e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05935360	chr19:11639865	ECSIT	0.4	6.3	0.33	9.44e-10	Schizophrenia;
CRC	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg09654669	chr8:57350985	NA	-0.41	-5.71	-0.3	2.54e-8	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22358856	chr18:12991346	CEP192	0.44	5.98	0.31	5.92e-9	Anxiety disorder;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg15763984	chr4:1342303	KIAA1530	-0.39	-6.07	-0.32	3.52e-9	Obesity-related traits;
CRC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs1519814	0.740	rs7845541	chr8:121044393	G/C	cg22335954	chr8:121166405	COL14A1	-0.53	-6.0	-0.31	5.17e-9	Breast cancer;
CRC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.63	-7.68	-0.39	1.86e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg09877947	chr5:131593287	PDLIM4	0.45	8.36	0.42	1.85e-15	Breast cancer;
CRC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	9.03	0.45	1.49e-17	Lymphocyte percentage of white cells;
CRC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.42	-6.35	-0.33	7.25e-10	Body mass index;
CRC	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.63	8.33	0.42	2.21e-15	Alzheimer's disease;
CRC	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.63	10.3	0.49	9.19e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg08501292	chr6:25962987	TRIM38	0.79	6.17	0.32	2e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	9.02	0.45	1.56e-17	Cognitive test performance;
CRC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg18016565	chr1:150552671	MCL1	0.44	6.07	0.32	3.53e-9	Melanoma;
CRC	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.61	8.68	0.43	1.84e-16	Breast cancer;
CRC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.71	-0.57	2.21e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg13385794	chr1:248469461	NA	0.38	6.55	0.34	2.23e-10	Common traits (Other);
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.47	6.28	0.33	1.08e-9	Menarche (age at onset);
CRC	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.56	-6.63	-0.34	1.39e-10	Body mass index;
CRC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	10.2	0.49	2.08e-21	Bone mineral density;
CRC	cis	rs231513	0.911	rs124721	chr17:41959808	T/C	cg26893861	chr17:41843967	DUSP3	-0.72	-6.5	-0.34	3.05e-10	Cognitive function;
CRC	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Colorectal cancer;
CRC	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.77	0.3	1.84e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.75	-11.85	-0.55	3.26e-27	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.49	5.98	0.31	5.67e-9	Neuroticism;
CRC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.72	13.66	0.6	5.96e-34	Body mass index;
CRC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-5.61	-0.3	4.35e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	8.79	0.44	8.4e-17	Height;
CRC	cis	rs10046574	0.764	rs28422979	chr7:135145924	C/T	cg27474649	chr7:135195673	CNOT4	0.71	5.82	0.31	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	13.91	0.61	6.75e-35	Hypertriglyceridemia;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.48	-7.41	-0.38	1.1e-12	Large artery stroke;
CRC	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.04	-0.32	4.16e-9	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12830839	chr6:170615752	FAM120B	0.45	6.0	0.31	5.32e-9	Anxiety disorder;
CRC	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	1.19	14.38	0.62	1e-36	Lung disease severity in cystic fibrosis;
CRC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.8	14.1	0.61	1.25e-35	Breast cancer;
CRC	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg16540259	chr10:75572220	NDST2	0.51	7.85	0.4	5.87e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg15845792	chr6:28175446	NA	0.72	6.14	0.32	2.36e-9	Depression;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	trans	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	9.81	0.48	4.36e-20	Exhaled nitric oxide output;
CRC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.37	0.56	3.95e-29	Menopause (age at onset);
CRC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg25164649	chr6:28176230	NA	-0.41	-5.68	-0.3	2.93e-8	Systemic lupus erythematosus;
CRC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-9.68	-0.47	1.16e-19	Dental caries;
CRC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02228675	chr17:40259724	DHX58	-0.48	-6.8	-0.35	5.05e-11	Fibrinogen levels;
CRC	cis	rs2000999	0.524	rs36125653	chr16:72190805	G/A	cg04254540	chr16:71951199	KIAA0174	-0.76	-6.26	-0.33	1.18e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.45	6.85	0.35	3.59e-11	Platelet count;
CRC	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.59	7.02	0.36	1.3e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.45	6.62	0.34	1.5e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.7	-0.3	2.63e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg11861562	chr11:117069780	TAGLN	0.41	9.3	0.46	1.96e-18	Blood protein levels;
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.28	-0.37	2.4e-12	Bipolar disorder;
CRC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.35	-6.77	-0.35	6.05e-11	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg09491104	chr22:46646882	C22orf40	-0.44	-6.67	-0.35	1.05e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs8105895	0.935	rs959908	chr19:22281893	A/C	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg02158880	chr13:53174818	NA	0.61	9.39	0.46	1.06e-18	Lewy body disease;
CRC	cis	rs3767633	0.858	rs4300199	chr1:161852057	A/G	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg12273811	chr6:28175739	NA	-0.5	-6.63	-0.34	1.42e-10	Parkinson's disease;
CRC	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg12964065	chr18:77638022	KCNG2	0.66	6.74	0.35	7.15e-11	Opioid sensitivity;
CRC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-7.25	-0.37	3.03e-12	Blood pressure (smoking interaction);
CRC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg02527881	chr3:46936655	PTH1R	-0.39	-7.46	-0.38	7.82e-13	Colorectal cancer;
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.26	-0.33	1.22e-9	Bipolar disorder;
CRC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	12.39	0.56	3.35e-29	Hip circumference adjusted for BMI;
CRC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.12	0.32	2.73e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2479724	0.870	rs7766960	chr6:41918190	T/G	cg17623882	chr6:41773611	USP49	-0.52	-8.32	-0.42	2.32e-15	Menarche (age at onset);
CRC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg18230493	chr5:56204884	C5orf35	-0.39	-5.76	-0.3	1.91e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.72	-9.06	-0.45	1.19e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16229364	chr3:47866611	DHX30	0.43	5.97	0.31	6.28e-9	Anxiety disorder;
CRC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.91	0.31	8.76e-9	Height;
CRC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.48	6.95	0.36	1.93e-11	Methadone dose in opioid dependence;
CRC	cis	rs10911390	0.744	rs116197881	chr1:183652657	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16041123	chr14:71373980	PCNX	0.41	6.35	0.33	7.06e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg02033258	chr5:131593261	PDLIM4	0.3	5.62	0.3	4.07e-8	Blood metabolite levels;
CRC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg24296786	chr1:45957014	TESK2	0.42	5.92	0.31	8.02e-9	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26687726	chr19:47220339	PRKD2	0.48	7.11	0.36	7.1e-12	Intelligence (multi-trait analysis);
CRC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.6	-10.65	-0.51	5.83e-23	Aortic root size;
CRC	cis	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg04267008	chr7:1944627	MAD1L1	0.54	7.79	0.39	8.7e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs2692947	0.550	rs12623771	chr2:96633504	A/G	cg23100626	chr2:96804247	ASTL	0.25	6.92	0.36	2.31e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.54	7.47	0.38	7.43e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-7.15	-0.37	5.76e-12	Type 2 diabetes;
CRC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.46	6.94	0.36	2.07e-11	Menopause (age at onset);
CRC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg15445000	chr17:37608096	MED1	0.32	5.64	0.3	3.58e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.32	16.18	0.67	1.01e-43	Uric acid levels;
CRC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg06287003	chr12:125626642	AACS	-0.57	-7.33	-0.37	1.76e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.79	14.28	0.62	2.55e-36	Anterior chamber depth;
CRC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg04545296	chr12:48745243	ZNF641	0.35	6.07	0.32	3.57e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.56	-6.26	-0.33	1.21e-9	Blood protein levels;
CRC	trans	rs6724465	0.714	rs2089035	chr2:219898076	C/T	cg26714650	chr12:56694279	CS	-0.56	-6.1	-0.32	2.91e-9	Height;
CRC	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.65	9.03	0.45	1.47e-17	Type 2 diabetes;
CRC	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.52	-8.31	-0.42	2.56e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.44	5.7	0.3	2.7e-8	Schizophrenia;
CRC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-9.43	-0.46	7.68e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.55e-9	Skin colour saturation;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg25164649	chr6:28176230	NA	0.8	10.74	0.51	2.84e-23	Depression;
CRC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.52	-6.72	-0.35	8.21e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.42	5.95	0.31	6.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-9.3	-0.46	1.98e-18	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.6	6.83	0.35	4.16e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.39	6.65	0.34	1.25e-10	Airway imaging phenotypes;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.45	-9.96	-0.48	1.31e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	7.96	0.4	2.74e-14	Height;
CRC	cis	rs2411233	1.000	rs1824493	chr15:39284663	A/T	cg23129342	chr15:39283510	NA	0.31	5.74	0.3	2.11e-8	Platelet count;
CRC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.6	9.86	0.48	2.94e-20	Colorectal cancer;
CRC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.98e-8	Bladder cancer;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg08798685	chr6:27730294	NA	-0.45	-5.89	-0.31	9.48e-9	Parkinson's disease;
CRC	trans	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg10756647	chr7:56101905	PSPH	0.74	7.77	0.39	9.91e-14	Diabetic kidney disease;
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.61	7.96	0.4	2.85e-14	Alzheimer's disease;
CRC	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.34	-0.38	1.71e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.49	-6.38	-0.33	5.99e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg20684491	chr1:25596433	NA	-0.43	-7.39	-0.38	1.23e-12	Erythrocyte sedimentation rate;
CRC	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg18232548	chr7:50535776	DDC	0.43	5.72	0.3	2.38e-8	Malaria;
CRC	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	7.3	0.37	2.18e-12	Mean corpuscular volume;
CRC	cis	rs883565	0.528	rs4676584	chr3:38965907	C/A	cg01426195	chr3:39028469	NA	0.42	7.07	0.36	9.39e-12	Handedness;
CRC	cis	rs868943	0.512	rs10456903	chr6:116541384	A/G	cg26893134	chr6:116381904	FRK	0.24	5.68	0.3	2.92e-8	Total cholesterol levels;
CRC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.43	6.91	0.36	2.56e-11	Body mass index;
CRC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.54	-7.36	-0.38	1.44e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.7	-0.39	1.59e-13	Breast cancer;
CRC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.54	8.25	0.41	3.77e-15	Aortic root size;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg02475695	chr16:616220	NHLRC4	0.46	7.79	0.39	8.66e-14	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08555112	chr17:48942811	TOB1	0.56	7.56	0.38	3.93e-13	Thyroid stimulating hormone;
CRC	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.24	6.57	0.34	2.02e-10	Type 2 diabetes;
CRC	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg23650765	chr1:12612165	NA	0.36	7.04	0.36	1.13e-11	Optic cup area;
CRC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-6.06	-0.32	3.65e-9	Lung cancer;
CRC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	7.11	0.37	7.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg05320533	chr16:89541815	ANKRD11	-0.47	-6.53	-0.34	2.54e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.73	0.35	7.74e-11	Body mass index;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23438505	chr17:78489298	NA	0.45	6.63	0.34	1.36e-10	Survival in pancreatic cancer;
CRC	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.4	6.2	0.32	1.66e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg17330251	chr7:94953956	PON1	-0.58	-7.48	-0.38	7.01e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.52	-0.34	2.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.54	-5.87	-0.31	1.04e-8	Schizophrenia;
CRC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg15744005	chr10:104629667	AS3MT	-0.35	-6.5	-0.34	2.89e-10	Arsenic metabolism;
CRC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12463550	chr7:65579703	CRCP	-0.61	-5.72	-0.3	2.41e-8	Diabetic kidney disease;
CRC	cis	rs6500395	0.735	rs2883641	chr16:48664446	T/C	cg04672837	chr16:48644449	N4BP1	0.41	5.87	0.31	1.09e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07080067	chr5:68514103	MRPS36	0.44	6.2	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	cis	rs10450586	0.897	rs6484288	chr11:27317367	T/C	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	6.05	0.32	4.01e-9	Aortic root size;
CRC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.51	7.53	0.38	4.86e-13	Corneal astigmatism;
CRC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg03037974	chr15:76606532	NA	0.57	9.55	0.47	3.03e-19	Blood metabolite levels;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg08497772	chr8:22407100	NA	0.27	6.34	0.33	7.61e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	10.21	0.49	1.87e-21	Menarche (age at onset);
CRC	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.6	-7.97	-0.4	2.63e-14	Post bronchodilator FEV1;
CRC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.2	-0.53	7.11e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg20933634	chr6:27740509	NA	0.65	9.13	0.45	7.01e-18	Parkinson's disease;
CRC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.68	11.27	0.53	4.04e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.97	-0.4	2.66e-14	Gut microbiome composition (summer);
CRC	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg09873164	chr1:152488093	CRCT1	0.4	6.74	0.35	7.22e-11	Hair morphology;
CRC	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.18	-0.37	4.78e-12	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
CRC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg16342193	chr10:102329863	NA	0.34	5.76	0.3	1.95e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg11070056	chr1:107600091	PRMT6	0.37	5.76	0.3	1.98e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.7	-0.47	9.82e-20	Primary sclerosing cholangitis;
CRC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	13.44	0.6	3.95e-33	Chronic sinus infection;
CRC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.57	-8.94	-0.44	2.94e-17	Corneal astigmatism;
CRC	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.5	7.98	0.4	2.39e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	11.36	0.53	1.87e-25	Height;
CRC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.72e-11	Menopause (age at onset);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg27499259	chr13:28400924	NA	-0.42	-6.17	-0.32	2e-9	Daytime sleep phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15947099	chr10:70481448	CCAR1	0.38	6.34	0.33	7.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-8.03	-0.4	1.71e-14	Height;
CRC	cis	rs57994353	0.570	rs10870139	chr9:139303269	G/A	cg14119001	chr9:139324193	INPP5E	-0.43	-5.6	-0.3	4.44e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg11214544	chr1:2391121	NA	-0.42	-6.59	-0.34	1.76e-10	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10878768	chr1:33430605	RNF19B	0.46	6.9	0.36	2.68e-11	Intelligence (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.51	9.87	0.48	2.76e-20	Renal cell carcinoma;
CRC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.59	9.4	0.46	9.34e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.48	-7.3	-0.37	2.19e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	1.1	10.4	0.5	4.45e-22	Parkinson's disease;
CRC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.6	-9.36	-0.46	1.25e-18	Aortic root size;
CRC	cis	rs4731207	0.698	rs4379394	chr7:124519627	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.64	-0.3	3.65e-8	Neuroticism;
CRC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.22	-0.41	4.86e-15	Height;
CRC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.58	6.87	0.35	3.15e-11	Type 2 diabetes nephropathy;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg02683197	chr6:28174875	NA	-0.64	-8.28	-0.42	3.07e-15	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.25	0.45	2.97e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12273811	chr6:28175739	NA	0.62	8.22	0.41	4.78e-15	Parkinson's disease;
CRC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.42e-22	Corneal astigmatism;
CRC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.06	0.32	3.66e-9	Lung cancer;
CRC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.02e-15	Menopause (age at onset);
CRC	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.55	-0.34	2.27e-10	Metabolite levels;
CRC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg23298862	chr7:158159286	PTPRN2	-0.5	-8.14	-0.41	8.27e-15	Calcium levels;
CRC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.61	-9.5	-0.46	4.63e-19	Non-obstructive azoospermia;
CRC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.67	-9.9	-0.48	2.18e-20	Primary sclerosing cholangitis;
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg21268650	chr7:45961089	IGFBP3	0.38	6.46	0.34	3.73e-10	Sitting height ratio;
CRC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.6	-8.85	-0.44	5.52e-17	Obesity-related traits;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.61	8.3	0.42	2.64e-15	Menarche (age at onset);
CRC	cis	rs3751196	1.000	rs12423912	chr12:104176295	G/A	cg02344784	chr12:104178138	NT5DC3	0.73	7.73	0.39	1.3e-13	Sense of smell;
CRC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.65	9.17	0.45	5.42e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.2	-0.32	1.72e-9	Blood metabolite levels;
CRC	cis	rs4766646	0.542	rs4766489	chr12:110306345	G/A	cg01252219	chr12:110302105	GLTP	0.4	5.84	0.31	1.26e-8	Metabolite levels (MHPG);
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg24046110	chr8:143859143	LYNX1	0.49	8.54	0.43	4.92e-16	Urinary tract infection frequency;
CRC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg23461800	chr14:103021989	NA	-0.7	-8.05	-0.41	1.57e-14	Platelet count;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.44	-5.94	-0.31	7.37e-9	Parkinson's disease;
CRC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	10.85	0.51	1.18e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.35	-0.38	1.54e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06312003	chr17:26662584	IFT20;TNFAIP1	0.4	6.05	0.32	3.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.861	rs10791856	chr11:65964650	T/C	cg16950941	chr11:66035639	RAB1B	-0.58	-7.22	-0.37	3.68e-12	Electroencephalogram traits;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.46	0.42	8.64e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19862616	chr7:65841803	NCRNA00174	0.46	6.22	0.32	1.49e-9	Eotaxin levels;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.67	-10.8	-0.51	1.74e-23	Paraoxonase activity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21294471	chr11:35639653	FJX1	0.37	6.2	0.32	1.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.75	-0.47	6.56e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4664293	0.647	rs4144512	chr2:160507519	G/A	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	11.09	0.52	1.73e-24	Personality dimensions;
CRC	cis	rs7586673	0.725	rs6757645	chr2:161891382	A/G	cg22496339	chr2:162101262	NA	0.48	7.0	0.36	1.43e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1178968	0.901	rs1178953	chr7:72781277	A/G	cg25889504	chr7:72793014	NA	0.54	6.05	0.32	4.01e-9	Triglyceride levels;
CRC	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg08501292	chr6:25962987	TRIM38	0.83	5.93	0.31	7.73e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg04518342	chr5:131593106	PDLIM4	-0.45	-7.54	-0.38	4.47e-13	Breast cancer;
CRC	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.48	-7.82	-0.4	7.05e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.5	6.53	0.34	2.53e-10	IgG glycosylation;
CRC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.57	8.31	0.42	2.59e-15	Testicular germ cell tumor;
CRC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.65	-0.3	3.39e-8	Type 2 diabetes;
CRC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.89	-0.31	9.55e-9	Diabetic kidney disease;
CRC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.56	-9.02	-0.45	1.62e-17	Intelligence (multi-trait analysis);
CRC	trans	rs8097070	0.661	rs9966711	chr18:23171413	C/G	cg21950287	chr19:54385441	PRKCG	0.55	6.05	0.32	3.88e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.82	-0.35	4.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.29	-0.53	3.23e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.73	-0.54	8.98e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs12541902	0.574	rs4504625	chr8:60641332	A/T	cg07441319	chr10:8117467	NA	0.38	6.09	0.32	3.2e-9	Obesity-related traits;
CRC	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07513332	chr6:167530253	CCR6	-0.4	-7.31	-0.37	2.04e-12	Rheumatoid arthritis;
CRC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.63	10.06	0.48	6.32e-21	Height;
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg24768116	chr2:27665128	KRTCAP3	0.32	7.17	0.37	5.09e-12	Total body bone mineral density;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.63	11.47	0.53	7.64e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg00857998	chr1:205179979	DSTYK	0.41	5.77	0.3	1.79e-8	Red blood cell count;
CRC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg26587870	chr6:27730563	NA	-0.63	-6.05	-0.32	4.04e-9	Depression;
CRC	cis	rs4731207	0.698	rs17147496	chr7:124449868	G/A	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02862674	chr6:44238426	TMEM151B	0.39	6.4	0.33	5.37e-10	Hip circumference;
CRC	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs2280630	0.529	rs6599010	chr3:39153222	C/T	cg01426195	chr3:39028469	NA	-0.42	-7.16	-0.37	5.35e-12	Verbal declarative memory;
CRC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.44	-6.9	-0.36	2.66e-11	Monocyte count;
CRC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	9.96	0.48	1.38e-20	Monocyte percentage of white cells;
CRC	cis	rs9905704	0.836	rs170024	chr17:56831887	T/C	cg12560992	chr17:57184187	TRIM37	0.55	7.92	0.4	3.66e-14	Testicular germ cell tumor;
CRC	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	0.63	8.67	0.43	1.93e-16	Type 2 diabetes;
CRC	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg12317470	chr15:67143691	NA	0.72	5.93	0.31	7.58e-9	Lung cancer (smoking interaction);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg14824382	chr8:144680115	EEF1D;TIGD5	0.37	5.98	0.31	5.75e-9	Body mass index;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg15786705	chr6:28176104	NA	-0.49	-6.97	-0.36	1.74e-11	Parkinson's disease;
CRC	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs812925	0.519	rs2694627	chr2:61625506	A/G	cg10580144	chr2:61372316	C2orf74	-0.33	-7.08	-0.36	8.84e-12	Immature fraction of reticulocytes;
CRC	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg17133734	chr15:86042851	AKAP13	0.39	6.31	0.33	9.23e-10	Interstitial lung disease;
CRC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.72	9.66	0.47	1.31e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.88	-0.31	1.01e-8	Daytime sleep phenotypes;
CRC	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.65	10.37	0.5	5.42e-22	Corneal astigmatism;
CRC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg02094049	chr14:103021097	NA	-0.53	-6.84	-0.35	3.9e-11	Platelet count;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg12172441	chr6:28176163	NA	0.54	7.43	0.38	9.55e-13	Parkinson's disease;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03923535	chr7:1197113	ZFAND2A	0.73	11.16	0.52	9.91e-25	Longevity;Endometriosis;
CRC	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.6	9.65	0.47	1.42e-19	Myeloid white cell count;
CRC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg04121214	chr22:50244548	NA	0.4	5.71	0.3	2.47e-8	Schizophrenia;
CRC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.58	-8.12	-0.41	9.37e-15	Prostate cancer;
CRC	cis	rs9533799	0.966	rs7999368	chr13:44807184	G/A	cg19190762	chr13:44806055	NA	0.62	9.49	0.46	4.7e-19	Amyotrophic lateral sclerosis;
CRC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg01483505	chr11:975446	AP2A2	0.46	7.62	0.39	2.78e-13	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20777176	chr1:231376761	GNPAT;C1orf131	0.44	6.09	0.32	3.14e-9	Response to antipsychotic treatment;
CRC	cis	rs6585424	1.000	rs35180576	chr10:81922971	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.29	-0.46	2.25e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.57	-9.16	-0.45	5.65e-18	Hyperactive-impulsive symptoms;
CRC	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.14	-9.47	-0.46	5.64e-19	Mitochondrial DNA levels;
CRC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.98	-0.31	5.92e-9	Lung cancer;
CRC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.37	-6.73	-0.35	7.39e-11	Reticulocyte fraction of red cells;
CRC	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.49	-7.22	-0.37	3.55e-12	Coronary heart disease;
CRC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.75	0.47	6.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.55	-7.54	-0.38	4.68e-13	Colorectal cancer;
CRC	cis	rs16975963	0.843	rs73041022	chr19:38272394	C/T	cg15135657	chr19:38346511	NA	-0.44	-5.89	-0.31	9.55e-9	Longevity;
CRC	cis	rs17767392	0.918	rs17178234	chr14:71900364	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg02135003	chr7:105160482	PUS7	-0.94	-12.5	-0.57	1.37e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.66	11.61	0.54	2.35e-26	Height;
CRC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.57	-7.37	-0.38	1.4e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg24463073	chr6:118973353	C6orf204	0.48	6.22	0.32	1.49e-9	Diastolic blood pressure;
CRC	cis	rs2179367	0.887	rs2789492	chr6:149747379	A/G	cg07828024	chr6:149772892	ZC3H12D	0.35	5.81	0.31	1.45e-8	Dupuytren's disease;
CRC	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg05283184	chr6:79620031	NA	-0.45	-6.45	-0.34	4.01e-10	Intelligence (multi-trait analysis);
CRC	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg26816564	chr1:7831052	VAMP3	0.49	5.86	0.31	1.1e-8	Inflammatory bowel disease;
CRC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg25456477	chr12:86230367	RASSF9	0.32	5.64	0.3	3.58e-8	Major depressive disorder;
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.89	0.31	9.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.37	6.8	0.35	5.05e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg22687807	chr8:143858763	LYNX1	0.51	9.17	0.45	5.35e-18	Urinary tract infection frequency;
CRC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.43	9.43	0.46	7.8e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs990171	1.000	rs6716784	chr2:103048467	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.9	0.31	9.09e-9	Lymphocyte counts;
CRC	cis	rs6694672	0.850	rs6428387	chr1:197061557	A/G	cg13682187	chr1:196946512	CFHR5	0.47	7.57	0.39	3.82e-13	Asthma;
CRC	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.64	-12.93	-0.58	3.39e-31	Menarche (age at onset);
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00166722	chr3:10149974	C3orf24	0.65	8.74	0.43	1.18e-16	Alzheimer's disease;
CRC	cis	rs995000	0.899	rs6696502	chr1:63039533	C/T	cg19896129	chr1:63156450	NA	-0.43	-6.7	-0.35	8.85e-11	Triglyceride levels;
CRC	cis	rs8105895	0.935	rs28894669	chr19:22243264	G/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.54	8.4	0.42	1.37e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11209185	0.509	rs12130147	chr1:68446944	G/A	cg22082780	chr1:68452167	NA	0.41	6.17	0.32	2.05e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg21251018	chr6:28226885	NKAPL	0.4	6.06	0.32	3.66e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.54	-0.71	4.67e-53	Schizophrenia;
CRC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2.04e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg10790698	chr19:18539756	SSBP4	-0.42	-7.94	-0.4	3.2e-14	Breast cancer;
CRC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.82	-0.48	3.92e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	7.99	0.4	2.37e-14	Breast cancer;
CRC	cis	rs9303542	0.592	rs34378400	chr17:46589265	A/G	cg04904318	chr17:46607828	HOXB1	-0.52	-6.27	-0.33	1.16e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg22535103	chr8:58192502	C8orf71	-0.44	-5.81	-0.3	1.49e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg01788221	chr16:89496183	ANKRD11	0.44	6.66	0.34	1.12e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.63	-5.92	-0.31	8.12e-9	Diabetic retinopathy;
CRC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.55	10.17	0.49	2.62e-21	HDL cholesterol levels;
CRC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg03037974	chr15:76606532	NA	-0.53	-7.42	-0.38	9.8e-13	Blood metabolite levels;
CRC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.76e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.21	-0.32	1.62e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.51	7.78	0.39	9.58e-14	Red blood cell count;
CRC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.45	-5.91	-0.31	8.59e-9	Tuberculosis;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.23e-26	Prudent dietary pattern;
CRC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg14541582	chr5:601475	NA	-0.33	-6.59	-0.34	1.73e-10	Obesity-related traits;
CRC	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.2	0.45	4.18e-18	Coffee consumption (cups per day);
CRC	cis	rs8105895	0.733	rs62111029	chr19:22276601	C/A	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	0.74	7.9	0.4	4.11e-14	IgG glycosylation;
CRC	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg17182837	chr8:41585554	ANK1	-0.54	-7.56	-0.38	4.02e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.45	-0.34	3.92e-10	Coronary artery disease;
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.43	-5.61	-0.3	4.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.63	-9.93	-0.48	1.71e-20	Systemic lupus erythematosus;
CRC	cis	rs2415984	0.622	rs1761027	chr14:46929611	G/A	cg14871534	chr14:47121158	RPL10L	0.4	5.82	0.31	1.42e-8	Number of children ever born;
CRC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.61e-11	Aortic root size;
CRC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg02659138	chr7:134003124	SLC35B4	0.35	6.09	0.32	3.18e-9	Mean platelet volume;
CRC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Bladder cancer;
CRC	cis	rs995000	0.931	rs10159255	chr1:63020816	C/A	cg19896129	chr1:63156450	NA	0.4	5.86	0.31	1.11e-8	Triglyceride levels;
CRC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg19223190	chr17:80058835	NA	-0.5	-7.93	-0.4	3.44e-14	Life satisfaction;
CRC	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.13	0.37	6.51e-12	Eye color traits;
CRC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.43	6.94	0.36	2.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-8.88	-0.44	4.52e-17	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.03	-0.36	1.21e-11	Major depressive disorder;
CRC	cis	rs6088813	0.922	rs4911493	chr20:33960799	A/G	cg14752227	chr20:34000481	UQCC	-0.37	-5.68	-0.3	2.98e-8	Height;
CRC	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg02158880	chr13:53174818	NA	-0.46	-7.02	-0.36	1.26e-11	Lewy body disease;
CRC	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.49	7.17	0.37	4.83e-12	Sudden cardiac arrest;
CRC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg12311346	chr5:56204834	C5orf35	0.46	7.27	0.37	2.68e-12	Coronary artery disease;
CRC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.05	13.01	0.58	1.6e-31	Vitiligo;
CRC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.4	7.5	0.38	5.86e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg25164649	chr6:28176230	NA	0.6	7.91	0.4	3.87e-14	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04056025	chr13:45694609	GTF2F2	0.45	6.12	0.32	2.7e-9	Anxiety disorder;
CRC	trans	rs62295889	0.602	rs73096514	chr4:12536931	G/A	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.58	-9.87	-0.48	2.64e-20	Calcium levels;
CRC	cis	rs6743376	0.556	rs4849146	chr2:113824840	A/T	cg24553058	chr2:113831203	IL1F10	0.43	7.09	0.36	8.4e-12	Inflammatory biomarkers;
CRC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.58	-9.16	-0.45	5.52e-18	Sudden cardiac arrest;
CRC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.74	-12.61	-0.57	5.09e-30	Body mass index;
CRC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.91	0.44	3.58e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02097616	chr17:62675921	NA	0.52	7.11	0.37	7.1e-12	Joint mobility (Beighton score);
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg16606324	chr3:10149918	C3orf24	0.69	9.36	0.46	1.3e-18	Alzheimer's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21788396	chr15:78423938	CIB2	-0.43	-6.57	-0.34	1.99e-10	Myopia (pathological);
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.62	-7.92	-0.4	3.68e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.55	9.19	0.45	4.64e-18	Tonsillectomy;
CRC	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.67	11.15	0.52	1.09e-24	Cancer;
CRC	cis	rs4824093	0.535	rs9627797	chr22:50317569	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-8.61	-0.43	2.99e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.78	-10.25	-0.49	1.42e-21	Orofacial clefts;
CRC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.82e-8	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2811415	0.531	rs9839861	chr3:127742405	G/T	cg13719885	chr3:127795394	NA	-0.37	-5.65	-0.3	3.49e-8	Lung function (FEV1/FVC);
CRC	trans	rs12517041	1.000	rs10052994	chr5:23292784	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.56	-6.34	-0.33	7.61e-10	Calcium levels;
CRC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.81	-13.07	-0.58	1.01e-31	Cognitive function;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg04497992	chr16:616212	NHLRC4	0.43	6.71	0.35	8.33e-11	Height;
CRC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.48	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1;
CRC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg14979609	chr8:8086686	FLJ10661	0.38	6.22	0.32	1.54e-9	Joint mobility (Beighton score);
CRC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg09555818	chr19:45449301	APOC2	-0.33	-5.69	-0.3	2.8e-8	Blood protein levels;
CRC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.75	12.98	0.58	2.16e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-8.74	-0.43	1.21e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg22777020	chr22:31556080	RNF185	-0.53	-5.9	-0.31	8.8e-9	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19872317	chr14:65346686	NA	0.5	7.13	0.37	6.35e-12	Response to antipsychotic treatment;
CRC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg01420254	chr6:26195488	NA	0.84	8.78	0.44	9.23e-17	Gout;Renal underexcretion gout;
CRC	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg00490450	chr3:139108681	COPB2	-0.45	-6.74	-0.35	7.09e-11	Obesity-related traits;
CRC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.83	-18.69	-0.72	1.29e-53	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.52	-0.34	2.66e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2929278	0.546	rs686666	chr15:44161550	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	6.63	0.34	1.35e-10	Schizophrenia;
CRC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg13722127	chr7:150037890	RARRES2	0.46	7.49	0.38	6.43e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.54	7.01	0.36	1.36e-11	DNA methylation (variation);
CRC	cis	rs1322512	0.920	rs1407487	chr6:152945846	T/C	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.68	-7.79	-0.39	8.58e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.49	6.31	0.33	9.24e-10	Cholesterol, total;
CRC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.7	-9.21	-0.45	4e-18	Bronchopulmonary dysplasia;
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg06470822	chr6:28175283	NA	0.62	9.27	0.46	2.45e-18	Pubertal anthropometrics;
CRC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-11.12	-0.52	1.31e-24	Cognitive function;
CRC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg13119609	chr19:45449297	APOC2	0.31	5.81	0.3	1.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.6	6.99	0.36	1.51e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.74	-12.95	-0.58	2.85e-31	Prostate cancer;
CRC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.09	-0.32	3.14e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg02033258	chr5:131593261	PDLIM4	0.38	6.3	0.33	9.51e-10	Breast cancer;
CRC	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg12560992	chr17:57184187	TRIM37	0.47	5.75	0.3	2.08e-8	Vitamin D levels;
CRC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg13390004	chr1:15929781	NA	0.51	7.21	0.37	3.91e-12	Systolic blood pressure;
CRC	cis	rs9925964	0.967	rs1978487	chr16:31129942	C/T	cg03418659	chr16:31128414	MYST1	-0.48	-7.01	-0.36	1.37e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23979971	chr5:138677953	PAIP2	0.37	6.06	0.32	3.63e-9	Obesity-related traits;
CRC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.27	0.41	3.35e-15	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.62	-0.47	1.85e-19	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs6066835	0.572	rs6066804	chr20:47262322	G/A	cg21109867	chr19:55897418	RPL28	-0.82	-6.21	-0.32	1.57e-9	Multiple myeloma;
CRC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.95	13.75	0.6	2.59e-34	Breast cancer;
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6076065	0.676	rs1419006	chr20:23336766	C/T	cg11657817	chr20:23433608	CST11	0.48	7.2	0.37	4.14e-12	Facial morphology (factor 15, philtrum width);
CRC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg25767906	chr1:53392781	SCP2	-0.41	-6.3	-0.33	9.68e-10	Monocyte count;
CRC	trans	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.37	0.33	6.35e-10	Height;
CRC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.37	3.53e-12	Blood metabolite levels;
CRC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.65	-0.39	2.25e-13	Schizophrenia;
CRC	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg15147215	chr3:52552868	STAB1	0.38	5.86	0.31	1.11e-8	Schizophrenia;
CRC	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.69	7.55	0.38	4.21e-13	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15664899	chr5:133450709	TCF7	0.45	7.07	0.36	9.22e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.52	-8.68	-0.43	1.88e-16	Breast cancer;
CRC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.46	-9.16	-0.45	5.58e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs972578	0.967	rs2038061	chr22:43397861	A/G	cg01576275	chr22:43409880	NA	-0.46	-6.96	-0.36	1.88e-11	Mean platelet volume;
CRC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17554472	chr22:41940697	POLR3H	-0.57	-6.09	-0.32	3.18e-9	Vitiligo;
CRC	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	13.18	0.59	3.89e-32	Hypertriglyceridemia;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.67	-0.35	1.09e-10	Electroencephalogram traits;
CRC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg15123519	chr2:136567270	LCT	0.34	6.57	0.34	1.94e-10	Mosquito bite size;
CRC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.64	-9.08	-0.45	1.06e-17	DNA methylation (variation);
CRC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.51	-0.42	6.43e-16	Monocyte percentage of white cells;
CRC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.98	0.36	1.62e-11	Mean platelet volume;
CRC	trans	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg19894588	chr14:64061835	NA	-0.6	-8.15	-0.41	7.58e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg09127314	chr1:152161683	NA	0.48	6.18	0.32	1.93e-9	Atopic dermatitis;
CRC	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.92	-11.51	-0.54	5.56e-26	Exhaled nitric oxide output;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20982606	chr12:109535391	UNG	0.43	6.01	0.31	5.04e-9	Survival in pancreatic cancer;
CRC	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-5.83	-0.31	1.3e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.58	0.43	3.85e-16	Schizophrenia;
CRC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.17	-0.32	1.99e-9	Life satisfaction;
CRC	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.88	-0.31	9.99e-9	Response to antipsychotic treatment;
CRC	cis	rs3015497	0.616	rs4901043	chr14:51083594	C/T	cg09863266	chr14:51125203	SAV1	0.3	5.69	0.3	2.85e-8	Mean platelet volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11901034	chr3:128598214	ACAD9	0.41	6.31	0.33	8.82e-10	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14878150	chr12:101673760	UTP20	0.51	7.33	0.37	1.83e-12	Response to antipsychotic treatment;
CRC	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.88	-0.35	3.08e-11	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	6.94	0.36	2.03e-11	Breast cancer;
CRC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.57	7.09	0.36	8.16e-12	IgG glycosylation;
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg22687807	chr8:143858763	LYNX1	0.51	9.19	0.45	4.69e-18	Urinary tract infection frequency;
CRC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.79	-13.27	-0.59	1.76e-32	Obesity-related traits;
CRC	cis	rs9463078	0.547	rs9472360	chr6:44747410	T/C	cg25276700	chr6:44698697	NA	0.3	7.76	0.39	1.09e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.51	8.11	0.41	9.81e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.62	-8.79	-0.44	8.52e-17	Coronary artery disease;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.12	0.32	2.72e-9	Alzheimer's disease;
CRC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	8.75	0.43	1.12e-16	Mean platelet volume;
CRC	cis	rs789859	0.611	rs1077729	chr3:194418126	A/G	cg21106136	chr3:194405973	FAM43A	0.44	6.29	0.33	1.03e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg13919466	chr1:32135498	COL16A1	-0.37	-7.08	-0.36	8.77e-12	Intelligence (multi-trait analysis);
CRC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	8.52	0.43	5.72e-16	Colorectal cancer;
CRC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.78	-0.35	5.73e-11	Aortic root size;
CRC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.69	-0.54	1.2e-26	Mean platelet volume;Platelet distribution width;
CRC	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.25	14.99	0.64	4.45e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg18721089	chr20:30220636	NA	-0.35	-5.85	-0.31	1.2e-8	Mean corpuscular hemoglobin;
CRC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	10.66	0.51	5.31e-23	Motion sickness;
CRC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.36	-0.46	1.28e-18	Heart rate;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15025054	chr1:212964885	TATDN3;NSL1	0.49	6.2	0.32	1.7e-9	Thyroid stimulating hormone;
CRC	cis	rs7705042	0.865	rs4385236	chr5:141513396	G/A	cg07392085	chr5:141489673	NDFIP1	0.45	7.26	0.37	2.75e-12	Asthma;
CRC	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-8.85	-0.44	5.43e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.53	-0.34	2.47e-10	Response to antipsychotic treatment;
CRC	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	17.05	0.68	3.76e-47	Ulcerative colitis;
CRC	cis	rs860295	0.651	rs6692183	chr1:155304327	T/G	cg02153340	chr1:155202674	NA	-0.5	-6.08	-0.32	3.35e-9	Body mass index;
CRC	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.57	8.91	0.44	3.63e-17	HDL cholesterol;
CRC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	1.03e-17	Bladder cancer;
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg06713098	chr7:45960367	IGFBP3	0.44	6.87	0.35	3.32e-11	Sitting height ratio;
CRC	trans	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.19	0.37	4.49e-12	Ulcerative colitis;
CRC	cis	rs939584	1.000	rs6719980	chr2:651507	T/C	cg03610516	chr2:642275	NA	-0.43	-5.94	-0.31	7.19e-9	Body mass index;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08279428	chr12:31479139	FAM60A	0.39	6.01	0.31	4.9e-9	Schizophrenia;
CRC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg14844989	chr11:31128820	NA	-0.34	-5.99	-0.31	5.5e-9	Red blood cell count;
CRC	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-10.72	-0.51	3.46e-23	Coronary artery disease;
CRC	cis	rs10991814	1.000	rs74508579	chr9:93959594	C/T	cg14446406	chr9:93919335	NA	0.56	6.05	0.32	4e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs3020333	0.846	rs3020335	chr6:152013223	G/T	cg22157087	chr6:152012887	ESR1	0.55	8.23	0.41	4.52e-15	Total body bone mineral density;
CRC	cis	rs6076065	0.723	rs2424532	chr20:23373877	G/A	cg11657817	chr20:23433608	CST11	0.45	6.68	0.35	1.01e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.73	-0.43	1.26e-16	Chronic sinus infection;
CRC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.87	-0.35	3.21e-11	Mood instability;
CRC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-9.25	-0.45	3e-18	Response to antipsychotic treatment;
CRC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg19824325	chr16:58548873	SETD6	0.91	6.09	0.32	3.08e-9	Schizophrenia;
CRC	cis	rs2481665	0.772	rs6661862	chr1:62534854	A/C	cg18591186	chr1:62594603	INADL	0.54	7.66	0.39	2.17e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg15511327	chr8:143859410	LYNX1	-0.32	-5.76	-0.3	1.92e-8	Urinary tract infection frequency;
CRC	cis	rs9903692	0.909	rs12952163	chr17:46159391	C/T	cg21215337	chr17:46176117	CBX1	0.42	7.71	0.39	1.5e-13	Pulse pressure;
CRC	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	6.9	0.36	2.76e-11	Diisocyanate-induced asthma;
CRC	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.5	0.38	5.94e-13	Multiple myeloma (hyperdiploidy);
CRC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg03929089	chr4:120376271	NA	0.6	6.13	0.32	2.51e-9	Axial length;
CRC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg26028573	chr6:26043587	HIST1H2BB	-0.39	-5.75	-0.3	2.09e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6028335	0.674	rs59072291	chr20:37622010	T/A	cg16355469	chr20:37678765	NA	0.46	5.61	0.3	4.34e-8	Alcohol and nicotine co-dependence;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg26608667	chr7:1196370	ZFAND2A	0.43	6.99	0.36	1.57e-11	Longevity;Endometriosis;
CRC	trans	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.37	-6.1	-0.32	2.95e-9	Mean corpuscular volume;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg20512303	chr5:131592959	PDLIM4	0.39	6.81	0.35	4.67e-11	Breast cancer;
CRC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.25e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9491140	0.539	rs980658	chr6:124690371	G/A	cg22366943	chr6:124882293	NKAIN2	0.53	7.98	0.4	2.46e-14	Neuroticism;
CRC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg23018236	chr17:30244563	NA	-0.65	-7.71	-0.39	1.48e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.52	6.94	0.36	2.04e-11	Methadone dose in opioid dependence;
CRC	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-13.92	-0.61	5.81e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15506890	chr2:3487001	NA	-0.58	-9.22	-0.45	3.56e-18	Neurofibrillary tangles;
CRC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.61	8.95	0.44	2.68e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs3857067	1.000	rs6532462	chr4:95026833	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.22	-0.32	1.55e-9	QT interval;
CRC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.66	-6.87	-0.35	3.26e-11	Type 2 diabetes;
CRC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.67	9.58	0.47	2.42e-19	Menopause (age at onset);
CRC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg27489772	chr12:121021490	NA	0.47	6.37	0.33	6.48e-10	Type 1 diabetes nephropathy;
CRC	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.67	7.55	0.38	4.29e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.38	-7.02	-0.36	1.29e-11	Lung cancer;
CRC	cis	rs1832871	0.521	rs62437409	chr6:158820221	G/C	cg14153777	chr6:158651016	NA	0.4	5.61	0.3	4.26e-8	Height;
CRC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-8.11	-0.41	1.01e-14	IgG glycosylation;
CRC	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg18232548	chr7:50535776	DDC	-0.44	-5.8	-0.3	1.57e-8	Malaria;
CRC	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.84	10.26	0.49	1.27e-21	Breast cancer;
CRC	cis	rs6604026	0.740	rs10782945	chr1:93304272	C/T	cg17283838	chr1:93427260	FAM69A	-0.49	-6.96	-0.36	1.8e-11	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04298196	chr4:120549256	PDE5A	0.39	5.96	0.31	6.33e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13906045	chr3:14166433	CHCHD4;TMEM43	0.42	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7565792	1.000	rs7565792	chr2:48649705	A/G	cg19646200	chr12:132886954	GALNT9	0.37	6.12	0.32	2.65e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.92	-0.31	8.11e-9	Bipolar disorder;
CRC	trans	rs2055729	0.677	rs6601393	chr8:9741035	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.79	-0.35	5.4e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.59	-9.43	-0.46	7.47e-19	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.64	0.3	3.63e-8	Eosinophil percentage of white cells;
CRC	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.6	-9.12	-0.45	7.49e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4731207	0.698	rs2402755	chr7:124448608	T/C	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg03623178	chr6:28175578	NA	0.58	6.39	0.33	5.76e-10	Depression;
CRC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg00734567	chr1:86172782	ZNHIT6	-0.38	-5.99	-0.31	5.55e-9	Urate levels in overweight individuals;
CRC	cis	rs4731207	0.662	rs7357296	chr7:124532716	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.54	0.75	6.37e-61	Prudent dietary pattern;
CRC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.15e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2930353	0.765	rs2975366	chr8:3720473	C/T	cg02274509	chr10:127407819	C10orf137	0.43	5.97	0.31	6.16e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.76	0.66	4.41e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	11.0	0.52	3.66e-24	Systolic blood pressure;
CRC	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.58	-9.22	-0.45	3.52e-18	Breast cancer;
CRC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.14	-0.32	2.43e-9	Alzheimer's disease (late onset);
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.7	-0.39	1.66e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6662572	0.737	rs6429593	chr1:46505235	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.84	0.31	1.27e-8	Blood protein levels;
CRC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.55	-8.52	-0.43	5.86e-16	Aortic root size;
CRC	cis	rs6076065	0.723	rs2424531	chr20:23372754	C/T	cg11657817	chr20:23433608	CST11	-0.44	-6.5	-0.34	2.92e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4838594	0.549	rs3888909	chr10:49687284	C/T	cg17291251	chr10:49678358	ARHGAP22	0.4	6.19	0.32	1.76e-9	Daytime sleep phenotypes;
CRC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.85	15.74	0.66	5.32e-42	Menopause (age at onset);
CRC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.41	-7.67	-0.39	2e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9491140	0.539	rs11154231	chr6:124687586	T/C	cg05308643	chr6:124982296	NKAIN2	0.48	6.67	0.35	1.09e-10	Neuroticism;
CRC	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg05562828	chr17:3906858	NA	0.47	7.59	0.39	3.41e-13	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05756109	chr10:103347662	POLL;RP11-529I10.4	0.42	6.08	0.32	3.41e-9	Response to antipsychotic treatment;
CRC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06656553	chr16:89960601	TCF25	-0.71	-6.22	-0.32	1.54e-9	Skin colour saturation;
CRC	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.49	-6.05	-0.32	3.93e-9	Coronary artery calcification;
CRC	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg08847533	chr14:75593920	NEK9	0.4	5.92	0.31	8.2e-9	Caffeine consumption;
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg07507251	chr3:52567010	NT5DC2	-0.43	-6.25	-0.33	1.27e-9	Bipolar disorder;
CRC	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.75	0.63	3.64e-38	Hypertriglyceridemia;
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.75	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs62458065	0.850	rs73096034	chr7:32472048	A/G	cg20159608	chr7:32802032	NA	-0.55	-6.56	-0.34	2.11e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg10183150	chr4:120222239	C4orf3	-0.33	-5.97	-0.31	6.13e-9	Educational attainment;
CRC	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.31	0.82	6.44e-83	Schizophrenia;
CRC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24308560	chr3:49941425	MST1R	-0.46	-6.93	-0.36	2.22e-11	Body mass index;
CRC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg17848003	chr1:3704513	LRRC47	0.4	5.7	0.3	2.66e-8	Red cell distribution width;
CRC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.29	0.56	8.24e-29	Mean platelet volume;
CRC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.69	-0.43	1.74e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.96	18.28	0.71	5.33e-52	Height;
CRC	cis	rs3785888	0.569	rs1838105	chr17:45008935	A/G	cg16759221	chr17:45003025	GOSR2	0.58	8.67	0.43	1.96e-16	Cleft lip with or without cleft palate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00082939	chr10:77165293	C10orf41	0.34	6.71	0.35	8.66e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.82	0.35	4.31e-11	Hip circumference adjusted for BMI;
CRC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.66	9.71	0.47	8.86e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	13.69	0.6	4.35e-34	Schizophrenia;
CRC	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-6.07	-0.32	3.57e-9	Blood pressure;
CRC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.75	-12.7	-0.57	2.35e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs12286929	0.661	rs7947402	chr11:115088420	T/C	cg04055981	chr11:115044050	NA	0.37	5.8	0.3	1.55e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1864585	0.520	rs73208791	chr8:10680338	T/C	cg26278703	chr11:58910052	FAM111A	0.56	6.55	0.34	2.24e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg18827107	chr12:86230957	RASSF9	0.39	6.08	0.32	3.3e-9	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.89	0.44	4.2e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.49	-7.28	-0.37	2.43e-12	Coronary artery disease;
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.93	-20.68	-0.75	1.89e-61	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg21601837	chr3:125900065	ALDH1L1	-0.42	-6.86	-0.35	3.52e-11	Metabolite levels;
CRC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.56	-8.16	-0.41	7.26e-15	Prudent dietary pattern;
CRC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.99e-24	Motion sickness;
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg15147215	chr3:52552868	STAB1	0.63	10.64	0.51	6.46e-23	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01704976	chr3:52273381	TWF2	0.44	6.24	0.33	1.36e-9	Survival in pancreatic cancer;
CRC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.55	-5.74	-0.3	2.15e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg27366882	chr3:133540807	NA	0.58	8.52	0.42	6e-16	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.16	0.32	2.15e-9	Rheumatoid arthritis;
CRC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg24253500	chr15:84953950	NA	0.38	6.44	0.33	4.32e-10	Schizophrenia;
CRC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.54	8.68	0.43	1.81e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.35	-5.85	-0.31	1.16e-8	Mean arterial pressure;
CRC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.06	-0.32	3.65e-9	High light scatter reticulocyte count;
CRC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.59	-10.94	-0.52	5.92e-24	Intelligence (multi-trait analysis);
CRC	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg09873164	chr1:152488093	CRCT1	0.36	6.13	0.32	2.48e-9	Hair morphology;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01600100	chr12:96794307	CDK17	0.37	6.14	0.32	2.36e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05147328	chr17:79849438	ANAPC11;THOC4	0.47	6.03	0.32	4.44e-9	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.45	-6.12	-0.32	2.63e-9	Longevity;Endometriosis;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.54	0.34	2.39e-10	Life satisfaction;
CRC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.45	-7.35	-0.38	1.54e-12	Monocyte count;
CRC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.55	7.52	0.38	5.22e-13	Schizophrenia;
CRC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16447950	chr5:562315	NA	-0.83	-10.81	-0.51	1.71e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	9.06e-9	Red blood cell count;
CRC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.41	-5.69	-0.3	2.87e-8	DNA methylation (variation);
CRC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19784903	chr17:45786737	TBKBP1	-0.35	-5.76	-0.3	1.91e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-1.12	-10.92	-0.52	7.06e-24	Body mass index;
CRC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.55	-8.08	-0.41	1.28e-14	Coronary artery disease;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21308919	chr4:140619560	MGST2	-0.43	-6.75	-0.35	6.67e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4692589	0.581	rs6821641	chr4:170960193	C/T	cg19918862	chr4:170955249	NA	0.55	7.26	0.37	2.73e-12	Anxiety disorder;
CRC	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.53	-7.32	-0.37	1.97e-12	Coronary artery disease;
CRC	cis	rs10924970	1.000	rs10924870	chr1:235359782	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.38	-5.72	-0.3	2.42e-8	Asthma;
CRC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.17	-0.49	2.58e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.09	18.64	0.72	1.93e-53	Cognitive function;
CRC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg03690763	chr11:133734501	NA	-0.36	-6.04	-0.32	4.16e-9	Childhood ear infection;
CRC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.4	0.33	5.33e-10	Acne (severe);
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.61	-10.86	-0.51	1.14e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.63	0.39	2.59e-13	Lymphocyte percentage of white cells;
CRC	cis	rs1223397	1.000	rs1223403	chr6:13271812	G/A	cg20827128	chr6:13274284	PHACTR1	0.57	6.96	0.36	1.8e-11	Blood pressure;
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-7.74	-0.39	1.23e-13	Renal function-related traits (BUN);
CRC	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg12682573	chr17:27188876	MIR451;MIR144	-0.6	-8.94	-0.44	2.83e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg00999904	chr2:3704751	ALLC	-0.53	-6.68	-0.35	1.04e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.46	0.42	8.88e-16	Lymphocyte counts;
CRC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg11861562	chr11:117069780	TAGLN	0.41	9.24	0.45	3.12e-18	Blood protein levels;
CRC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.05	-0.52	2.27e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.42	6.9	0.36	2.61e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.47	-7.01	-0.36	1.34e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	6.81	0.35	4.59e-11	Breast cancer;
CRC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.86	-10.97	-0.52	4.69e-24	Obesity-related traits;
CRC	cis	rs2857891	1.000	rs2638092	chr11:6961746	G/A	cg22096450	chr11:6947773	ZNF215	0.61	6.36	0.33	6.71e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11212617	0.935	rs621947	chr11:108165219	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.71	0.3	2.58e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.22	-0.49	1.73e-21	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg03037974	chr15:76606532	NA	0.72	12.89	0.58	4.86e-31	Blood metabolite levels;
CRC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg12700464	chr11:78128424	GAB2	-0.5	-5.91	-0.31	8.53e-9	Testicular germ cell tumor;
CRC	cis	rs863345	0.604	rs1157524	chr1:158457298	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.07	-0.32	3.49e-9	Pneumococcal bacteremia;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17429065	chr1:6453910	ACOT7	0.4	6.47	0.34	3.5e-10	Obesity-related traits;
CRC	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-6.95	-0.36	1.93e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.53	7.46	0.38	7.96e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07626433	chr4:141071632	MAML3	0.41	6.12	0.32	2.67e-9	Myopia (pathological);
CRC	cis	rs889398	0.802	rs12921407	chr16:69860933	T/C	cg00738113	chr16:70207722	CLEC18C	0.36	6.2	0.32	1.66e-9	Body mass index;
CRC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.54	-7.82	-0.4	7.26e-14	Menarche (age at onset);
CRC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.41	-5.82	-0.31	1.42e-8	DNA methylation (variation);
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.73	-11.89	-0.55	2.29e-27	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.46	0.42	8.8e-16	Rheumatoid arthritis;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg23161317	chr6:28129485	ZNF389	0.48	6.21	0.32	1.61e-9	Depression;
CRC	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg15131784	chr3:139108705	COPB2	0.41	5.93	0.31	7.87e-9	Obesity-related traits;
CRC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg25767906	chr1:53392781	SCP2	0.37	5.86	0.31	1.12e-8	Monocyte count;
CRC	cis	rs7680126	0.633	rs4698014	chr4:10286301	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.13	-0.32	2.51e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg00106254	chr7:1943704	MAD1L1	0.46	7.22	0.37	3.63e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg11704114	chr12:21509398	SLCO1A2	-0.33	-6.35	-0.33	7.22e-10	Tuberculosis;
CRC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.73	0.3	2.23e-8	Bladder cancer;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.7	0.3	2.7e-8	Depression;
CRC	cis	rs9649465	0.967	rs1005568	chr7:123306470	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-5.71	-0.3	2.56e-8	Migraine;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Parkinson's disease;
CRC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.63	9.57	0.47	2.58e-19	Menopause (age at onset);
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.53	-9.89	-0.48	2.27e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.21	-0.37	3.91e-12	Bipolar disorder;
CRC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.37	6.49	0.34	3.22e-10	Systemic lupus erythematosus;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02359409	chr6:42947317	PEX6	0.68	11.38	0.53	1.64e-25	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg21625146	chr5:486483	SLC9A3	0.37	5.76	0.3	1.9e-8	Cystic fibrosis severity;
CRC	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-5.79	-0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg25164649	chr6:28176230	NA	-0.77	-10.55	-0.5	1.27e-22	Depression;
CRC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg12046867	chr14:103022105	NA	0.65	8.07	0.41	1.29e-14	Platelet count;
CRC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-0.6	-8.35	-0.42	1.93e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.59	7.73	0.39	1.34e-13	Bipolar disorder;
CRC	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.68	-11.53	-0.54	4.57e-26	White blood cell count (basophil);
CRC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-18.17	-0.71	1.37e-51	Schizophrenia;
CRC	cis	rs10919791	0.539	rs10919786	chr1:199946176	A/G	cg07208853	chr1:200005219	NR5A2	0.26	6.57	0.34	2.01e-10	Pancreatic cancer;
CRC	cis	rs6761276	0.525	rs12711752	chr2:113837840	C/T	cg09040174	chr2:113837401	NA	-0.51	-7.81	-0.4	7.77e-14	Protein quantitative trait loci;
CRC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.49	6.19	0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.29	5.69	0.3	2.78e-8	Vitiligo;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg15993354	chr19:12912590	PRDX2	0.56	6.42	0.33	4.81e-10	Body mass index;
CRC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.69	-8.71	-0.43	1.54e-16	Dilated cardiomyopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13353472	chr19:39343117	HNRNPL	0.38	6.16	0.32	2.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.57	9.77	0.47	5.75e-20	Alzheimer's disease (late onset);
CRC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs17095355	0.605	rs58154613	chr10:111633966	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.78	-0.3	1.7e-8	Biliary atresia;
CRC	cis	rs17767392	0.958	rs6574016	chr14:72040525	G/A	cg13720639	chr14:72061746	SIPA1L1	0.56	6.88	0.35	2.96e-11	Mitral valve prolapse;
CRC	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	0.76	15.19	0.64	7.62e-40	Leprosy;
CRC	cis	rs728616	0.867	rs17096197	chr10:81808184	T/C	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.82	-0.35	4.41e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg02683197	chr6:28174875	NA	0.7	9.78	0.47	5.24e-20	Cardiac Troponin-T levels;
CRC	trans	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.01	-0.31	5.01e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.66	10.51	0.5	1.82e-22	Type 2 diabetes;
CRC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.72	-8.17	-0.41	6.66e-15	Psoriasis;
CRC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.55	-8.9	-0.44	3.78e-17	Pulse pressure;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07308232	chr7:1071921	C7orf50	-0.42	-5.76	-0.3	1.96e-8	Longevity;Endometriosis;
CRC	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.74	-11.09	-0.52	1.65e-24	Waist circumference;Body mass index;
CRC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.68	-9.24	-0.45	3.2e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg13722127	chr7:150037890	RARRES2	0.49	7.66	0.39	2.13e-13	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.73	8.5	0.42	6.78e-16	Eotaxin levels;
CRC	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.72	-11.87	-0.55	2.65e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	7.76	0.39	1.09e-13	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04190002	chr22:51113604	SHANK3	0.47	7.83	0.4	6.75e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg26608667	chr7:1196370	ZFAND2A	0.35	5.61	0.3	4.24e-8	Longevity;Endometriosis;
CRC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg13753209	chr17:57696993	CLTC	0.45	5.88	0.31	9.94e-9	Hemoglobin concentration;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg06557630	chr16:49889701	NA	0.4	6.06	0.32	3.72e-9	Hip circumference;
CRC	cis	rs9549328	0.565	rs35371379	chr13:113616715	T/C	cg08614441	chr13:113633676	MCF2L	0.39	6.92	0.36	2.31e-11	Systolic blood pressure;
CRC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.39	-0.38	1.23e-12	Aortic root size;
CRC	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.43	6.73	0.35	7.5e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.47	-6.23	-0.32	1.45e-9	Gut microbiome composition (summer);
CRC	trans	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.13	0.32	2.55e-9	Height;
CRC	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.72	-11.39	-0.53	1.49e-25	Mean platelet volume;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19853194	chr18:9913725	VAPA	-0.53	-6.49	-0.34	3.23e-10	Diisocyanate-induced asthma;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.8	-11.67	-0.54	1.43e-26	Pubertal anthropometrics;
CRC	cis	rs7429990	0.965	rs319692	chr3:47924317	G/C	cg11946769	chr3:48343235	NME6	0.43	5.62	0.3	4.11e-8	Educational attainment (years of education);
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg26587870	chr6:27730563	NA	-0.38	-5.73	-0.3	2.28e-8	Cardiac Troponin-T levels;
CRC	cis	rs2630709	0.521	rs2630745	chr2:8459919	C/T	cg12167548	chr2:8464763	NA	0.34	6.51	0.34	2.86e-10	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.6	-10.68	-0.51	4.52e-23	Breast cancer;
CRC	cis	rs6758955	1.000	rs1558629	chr2:10478364	C/T	cg15773312	chr2:10472214	HPCAL1	-0.7	-9.23	-0.45	3.46e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2084637	0.965	rs2370747	chr11:122407131	C/T	cg21585512	chr11:122030076	LOC399959	-0.4	-7.29	-0.37	2.4e-12	Stroke;
CRC	cis	rs2252790	0.605	rs12193974	chr6:116542500	T/C	cg15226275	chr6:116381976	FRK	0.26	6.11	0.32	2.86e-9	Fast beta electroencephalogram;
CRC	trans	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.43	-6.14	-0.32	2.33e-9	Monocyte count;
CRC	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.51	-8.11	-0.41	1.01e-14	Airway imaging phenotypes;
CRC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.37	6.2	0.32	1.66e-9	Cardiovascular disease risk factors;
CRC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-6.88	-0.35	3.07e-11	Coronary artery disease;
CRC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17554472	chr22:41940697	POLR3H	-0.56	-5.89	-0.31	9.38e-9	Vitiligo;
CRC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.6	-0.34	1.69e-10	Height;
CRC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.22	0.32	1.49e-9	Diabetic kidney disease;
CRC	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.39	-6.07	-0.32	3.51e-9	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11526405	chr9:131790894	SH3GLB2	0.43	6.06	0.32	3.65e-9	Response to antipsychotic treatment;
CRC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.6	8.86	0.44	5.02e-17	Homoarginine levels;
CRC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	14.87	0.63	1.3e-38	Platelet count;
CRC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg07713946	chr22:31675144	LIMK2	0.4	5.71	0.3	2.46e-8	Colorectal cancer;
CRC	cis	rs17095355	1.000	rs55717725	chr10:111666629	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.41	-0.38	1.08e-12	Biliary atresia;
CRC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.67	9.53	0.47	3.52e-19	Bladder cancer;
CRC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs11212617	0.934	rs694376	chr11:108119048	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.13	0.32	2.52e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.59	-8.7	-0.43	1.65e-16	Platelet count;
CRC	cis	rs7215564	0.908	rs35151535	chr17:78661695	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.14	0.32	2.41e-9	Myopia (pathological);
CRC	cis	rs7209700	0.778	rs3851807	chr17:45351519	C/G	cg08085267	chr17:45401833	C17orf57	0.44	6.37	0.33	6.21e-10	IgG glycosylation;
CRC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg19635926	chr16:89946313	TCF25	0.61	5.81	0.31	1.44e-8	Skin colour saturation;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg02033258	chr5:131593261	PDLIM4	-0.45	-7.92	-0.4	3.69e-14	Acylcarnitine levels;
CRC	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.4	5.8	0.3	1.57e-8	Growth-regulated protein alpha levels;
CRC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.81	-9.94	-0.48	1.61e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	0.96	7.03	0.36	1.2e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12024301	0.557	rs12040874	chr1:183615776	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.42	-6.91	-0.36	2.45e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.71	0.39	1.54e-13	Motion sickness;
CRC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.58	9.02	0.45	1.59e-17	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg24531977	chr5:56204891	C5orf35	-0.44	-6.68	-0.35	1e-10	Coronary artery disease;
CRC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg14593290	chr7:50529359	DDC	-0.5	-7.15	-0.37	5.52e-12	Systemic sclerosis;
CRC	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg19875578	chr6:126661172	C6orf173	0.41	5.68	0.3	2.98e-8	Male-pattern baldness;
CRC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	18.55	0.71	4.45e-53	Cognitive ability;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.46	0.6	3.42e-33	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15726318	chr8:71315757	NCOA2	0.34	6.11	0.32	2.78e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9952051	0.961	rs12717053	chr18:63264766	C/T	cg20240715	chr21:35828503	KCNE1	0.33	6.11	0.32	2.85e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.5	9.33	0.46	1.65e-18	Common traits (Other);
CRC	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg03929089	chr4:120376271	NA	0.63	6.1	0.32	3.03e-9	Axial length;
CRC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg10298567	chr3:47292165	KIF9	-0.38	-6.23	-0.32	1.44e-9	Colorectal cancer;
CRC	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg20487152	chr13:99095054	FARP1	-0.45	-6.43	-0.33	4.56e-10	Neuroticism;
CRC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.15	-0.37	5.79e-12	Body mass index;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-10.59	-0.5	9.28e-23	Longevity;Endometriosis;
CRC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.42	6.6	0.34	1.65e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.71	9.5	0.46	4.39e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4664293	0.715	rs13002625	chr2:160504625	T/C	cg08347373	chr2:160653686	CD302	0.45	7.79	0.39	8.83e-14	Monocyte percentage of white cells;
CRC	cis	rs6662572	1.000	rs41310432	chr1:46083706	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.68	0.3	3.02e-8	Blood protein levels;
CRC	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg08501292	chr6:25962987	TRIM38	0.98	9.07	0.45	1.09e-17	Autism spectrum disorder or schizophrenia;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg15845792	chr6:28175446	NA	0.64	9.63	0.47	1.66e-19	Cardiac Troponin-T levels;
CRC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.85	-11.05	-0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.69	-11.86	-0.55	3.08e-27	Resting heart rate;
CRC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.44	-6.57	-0.34	1.95e-10	Height;
CRC	cis	rs11229555	0.598	rs12289876	chr11:58185250	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.5	-8.49	-0.42	7.34e-16	Crohn's disease;
CRC	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs9526114	1.000	rs12430490	chr13:46411812	A/G	cg18557684	chr14:22362441	NA	0.39	5.97	0.31	6.2e-9	Pneumococcal bacteremia;
CRC	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg20885578	chr2:198174922	NA	-0.42	-6.69	-0.35	9.64e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1572438	0.760	rs7766714	chr6:869519	C/T	cg21062780	chr6:887772	NA	-0.38	-5.98	-0.31	5.78e-9	Aging;
CRC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.74	9.61	0.47	1.9e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	1.24	14.83	0.63	1.93e-38	Lung disease severity in cystic fibrosis;
CRC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg10578777	chr12:7781093	NA	-0.45	-6.08	-0.32	3.41e-9	HDL cholesterol levels;
CRC	cis	rs2276314	0.553	rs12964535	chr18:33611691	A/C	cg05985134	chr18:33552581	C18orf21	-0.37	-5.86	-0.31	1.1e-8	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg23245007	chr3:195682326	NA	-0.4	-5.63	-0.3	3.81e-8	Pancreatic cancer;
CRC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg16482183	chr6:26056742	HIST1H1C	0.67	8.6	0.43	3.39e-16	Iron status biomarkers;
CRC	cis	rs4713675	0.546	rs10947435	chr6:33718075	G/A	cg14003231	chr6:33640908	ITPR3	0.45	7.24	0.37	3.22e-12	Plateletcrit;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13197406	chr4:57687839	SPINK2	0.33	6.08	0.32	3.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg05623727	chr3:50126028	RBM5	-0.39	-6.6	-0.34	1.67e-10	Menarche (age at onset);
CRC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.33	0.42	2.16e-15	Arsenic metabolism;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg15786705	chr6:28176104	NA	0.77	9.78	0.47	5.51e-20	Depression;
CRC	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.39	-0.33	5.67e-10	Eye color traits;
CRC	cis	rs9467603	0.547	rs913455	chr6:25420344	C/G	cg16898833	chr6:26189333	HIST1H4D	-0.77	-5.86	-0.31	1.15e-8	Intelligence (multi-trait analysis);
CRC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	8.62	0.43	2.86e-16	Colorectal cancer;
CRC	cis	rs1832871	0.521	rs62437409	chr6:158820221	G/C	cg07165851	chr6:158734300	TULP4	0.45	5.83	0.31	1.3e-8	Height;
CRC	cis	rs10512697	0.803	rs35056798	chr5:3575747	A/G	cg19473799	chr5:3511975	NA	-0.72	-5.67	-0.3	3.12e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06544989	chr22:39130855	UNC84B	0.42	6.35	0.33	7.13e-10	Menopause (age at onset);
CRC	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.05	-0.32	3.91e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03956833	chr1:1051711	C1orf159	0.51	7.23	0.37	3.38e-12	Response to antipsychotic treatment;
CRC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.05	0.41	1.49e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg12193833	chr17:30244370	NA	0.57	6.54	0.34	2.39e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1190596	0.525	rs6575901	chr14:102691854	A/G	cg18135206	chr14:102964638	TECPR2	0.41	5.64	0.3	3.7e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.5	8.15	0.41	7.48e-15	Lipoprotein (a) levels;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-8.2	-0.41	5.37e-15	Longevity;Endometriosis;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.68	10.79	0.51	2e-23	Longevity;Endometriosis;
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg00063174	chr2:228736253	WDR69	-0.51	-6.86	-0.35	3.49e-11	Blood pressure;
CRC	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.51	8.04	0.41	1.62e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18411480	chr20:2082418	STK35	0.38	6.05	0.32	3.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.89	0.36	2.87e-11	Lymphocyte counts;
CRC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.48	-7.07	-0.36	9.63e-12	Menarche (age at onset);
CRC	cis	rs4666002	0.917	rs2068834	chr2:27839539	A/G	cg27432699	chr2:27873401	GPN1	0.43	5.71	0.3	2.48e-8	Phospholipid levels (plasma);
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg27532560	chr4:187881888	NA	-0.54	-9.81	-0.48	4.32e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.08	-0.32	3.28e-9	High light scatter reticulocyte count;
CRC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.13	0.52	1.19e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00102714	chr1:207925343	CD46	0.42	6.74	0.35	7.32e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00612595	chr21:47717864	NA	-0.37	-6.15	-0.32	2.22e-9	Testicular germ cell tumor;
CRC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.24	-0.37	3.15e-12	Aortic root size;
CRC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.47	9.03	0.45	1.53e-17	Iron status biomarkers;
CRC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg05941027	chr17:61774174	LIMD2	0.34	6.0	0.31	5.21e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg15168958	chr13:99100528	FARP1	0.39	6.41	0.33	4.9e-10	Educational attainment (years of education);
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.59	-10.52	-0.5	1.71e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.97	-14.43	-0.62	6.3e-37	Systemic lupus erythematosus;
CRC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg00343986	chr7:65444356	GUSB	0.43	5.97	0.31	6.08e-9	Aortic root size;
CRC	cis	rs9595066	0.715	rs9567366	chr13:44682973	A/C	cg04068111	chr13:44716778	NA	0.39	5.63	0.3	3.78e-8	Schizophrenia;
CRC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	16.07	0.66	2.59e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.41	6.01	0.31	5.04e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.6	10.9	0.52	7.96e-24	Age of smoking initiation;
CRC	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.63	6.92	0.36	2.34e-11	Height;
CRC	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.63	9.43	0.46	7.35e-19	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg26373071	chr5:1325741	CLPTM1L	0.48	8.42	0.42	1.17e-15	Lung cancer;
CRC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg12573674	chr2:1569213	NA	-0.76	-8.04	-0.41	1.69e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg25050447	chr17:78165522	CARD14	0.42	5.79	0.3	1.69e-8	Yeast infection;
CRC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.5	8.65	0.43	2.28e-16	Coronary artery disease;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg12273811	chr6:28175739	NA	0.54	7.55	0.38	4.19e-13	Parkinson's disease;
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.44	5.75	0.3	2.03e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7113874	0.569	rs2289921	chr11:8496611	G/C	cg17679104	chr11:8615758	STK33	0.34	5.66	0.3	3.28e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.51	6.02	0.32	4.55e-9	QRS duration;
CRC	cis	rs9462027	0.583	rs9469902	chr6:34793768	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.15	-0.32	2.28e-9	Systemic lupus erythematosus;
CRC	cis	rs7932354	0.554	rs6485721	chr11:47040854	A/G	cg03339077	chr11:47165057	C11orf49	0.44	6.18	0.32	1.91e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.41	6.43	0.33	4.42e-10	Blood metabolite levels;
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg10217327	chr6:118973057	C6orf204	0.51	5.66	0.3	3.27e-8	Diastolic blood pressure;
CRC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg06970220	chr1:156163860	SLC25A44	0.5	7.13	0.37	6.42e-12	Testicular germ cell tumor;
CRC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.98	-19.27	-0.73	6.62e-56	Height;
CRC	trans	rs783540	0.967	rs783527	chr15:83285847	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.15	-0.32	2.21e-9	Schizophrenia;
CRC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg10645314	chr2:3704589	ALLC	-0.55	-6.45	-0.34	4.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.38	6.01	0.31	4.92e-9	Height;
CRC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	7.47	0.38	7.35e-13	Aortic root size;
CRC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.8	-10.59	-0.5	9.88e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.59	-10.78	-0.51	2.13e-23	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.12	0.32	2.68e-9	Depression;
CRC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	10.09	0.49	4.96e-21	Hip circumference adjusted for BMI;
CRC	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg23815491	chr16:72088622	HP	-0.42	-6.44	-0.33	4.2e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg08222913	chr3:52553049	STAB1	0.33	6.26	0.33	1.22e-9	Electroencephalogram traits;
CRC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg14673194	chr17:80132900	CCDC57	-0.46	-5.86	-0.31	1.12e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.68	-0.54	1.36e-26	Migraine;Coronary artery disease;
CRC	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	6.3	0.33	9.78e-10	Diastolic blood pressure;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.97	0.52	4.54e-24	Exhaled nitric oxide output;
CRC	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.36	5.72	0.3	2.36e-8	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
CRC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg15147215	chr3:52552868	STAB1	0.63	10.36	0.5	6.06e-22	Bipolar disorder;
CRC	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg23234261	chr14:55582407	NA	-0.29	-5.65	-0.3	3.53e-8	Protein biomarker;
CRC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.68	10.55	0.5	1.34e-22	Diastolic blood pressure;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg10596483	chr8:143751796	JRK	0.46	6.31	0.33	8.88e-10	Urinary tract infection frequency;
CRC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.79	11.87	0.55	2.65e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg18279126	chr7:2041391	MAD1L1	0.44	6.68	0.35	1.04e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-11.1	-0.52	1.56e-24	Coronary artery disease;
CRC	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg00105475	chr2:10696890	NA	0.44	7.14	0.37	6.13e-12	Prostate cancer;
CRC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg25174290	chr11:3078921	CARS	-0.41	-5.71	-0.3	2.56e-8	Calcium levels;
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18758796	chr5:131593413	PDLIM4	0.44	8.12	0.41	9.72e-15	Breast cancer;
CRC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.84	0.51	1.33e-23	Coronary artery disease;
CRC	cis	rs17767392	0.881	rs9672060	chr14:72010126	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.55	-7.17	-0.37	4.95e-12	Mitral valve prolapse;
CRC	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.42	-7.51	-0.38	5.75e-13	Ulcerative colitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06443542	chr10:100206752	HPS1	-0.41	-6.05	-0.32	3.95e-9	Myopia (pathological);
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg07195197	chr16:1662150	IFT140	-0.7	-5.98	-0.31	5.91e-9	Cognitive function;
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.15	0.74	2.13e-59	Prudent dietary pattern;
CRC	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg23229984	chr5:148520753	ABLIM3	0.48	6.59	0.34	1.79e-10	Breast cancer;
CRC	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.42	6.5	0.34	2.95e-10	Monocyte count;
CRC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg16606324	chr3:10149918	C3orf24	0.69	9.75	0.47	6.97e-20	Alzheimer's disease;
CRC	cis	rs8105895	0.867	rs12151358	chr19:22282608	G/A	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs7725052	0.609	rs4957292	chr5:40446223	A/C	cg09067459	chr5:40385259	NA	-0.39	-6.57	-0.34	1.96e-10	Pediatric autoimmune diseases;
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg18833306	chr6:118973337	C6orf204	0.44	5.81	0.31	1.48e-8	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08983011	chr11:118774009	BCL9L	0.42	6.45	0.34	3.92e-10	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.71	-0.35	8.5e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-6.38	-0.33	5.85e-10	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14706950	chr10:93169801	HECTD2;LOC100188947	0.45	6.14	0.32	2.35e-9	Anxiety disorder;
CRC	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.86	-13.63	-0.6	7.74e-34	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.06e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.52	-7.15	-0.37	5.72e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.82	9.3	0.46	2.08e-18	Monocyte percentage of white cells;
CRC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.52	0.43	5.89e-16	Homoarginine levels;
CRC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.62	-0.3	3.99e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.44	-8.54	-0.43	5e-16	Schizophrenia;
CRC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.17	-9.73	-0.47	7.81e-20	Mitochondrial DNA levels;
CRC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg21466736	chr12:48725269	NA	-0.49	-7.57	-0.39	3.74e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.52	-8.3	-0.42	2.79e-15	Height;
CRC	cis	rs3736485	0.873	rs10851502	chr15:51890936	A/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.55	-0.34	2.22e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.81	9.42	0.46	7.93e-19	Inflammatory bowel disease;
CRC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.47	7.7	0.39	1.63e-13	Fat distribution (HIV);
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg09877947	chr5:131593287	PDLIM4	0.33	5.89	0.31	9.42e-9	Blood metabolite levels;
CRC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	14.54	0.63	2.38e-37	Platelet count;
CRC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.41	-0.33	4.97e-10	Alzheimer's disease (late onset);
CRC	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg00105475	chr2:10696890	NA	0.44	7.08	0.36	8.73e-12	Prostate cancer;
CRC	cis	rs2481665	0.765	rs2481679	chr1:62634303	T/A	cg18591186	chr1:62594603	INADL	-0.49	-6.84	-0.35	3.79e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg24505167	chr7:1915268	MAD1L1	-0.45	-6.32	-0.33	8.39e-10	Bipolar disorder;
CRC	cis	rs6893807	0.778	rs1501672	chr5:87963761	A/G	cg09002922	chr5:87956389	LOC645323	-0.44	-5.66	-0.3	3.23e-8	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08611430	chr5:137801033	EGR1	0.48	6.24	0.33	1.35e-9	Anxiety disorder;
CRC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg10760299	chr15:45669010	GATM	0.49	7.65	0.39	2.19e-13	Homoarginine levels;
CRC	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.46	8.23	0.41	4.37e-15	Blood metabolite ratios;
CRC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.81	-12.26	-0.56	1.01e-28	Cognitive function;
CRC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.57	-9.79	-0.48	4.84e-20	Menarche (age at onset);
CRC	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.15	-0.56	2.56e-28	Idiopathic membranous nephropathy;
CRC	trans	rs1147246	0.714	rs323848	chr12:125878240	G/A	cg23470196	chr14:102695671	RAGE	0.41	5.98	0.31	5.73e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.4	-7.52	-0.38	5.37e-13	Ulcerative colitis;
CRC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-6.42	-0.33	4.89e-10	Body mass index;
CRC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.44	-0.53	9.35e-26	Ulcerative colitis;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03923535	chr7:1197113	ZFAND2A	0.74	11.1	0.52	1.6e-24	Longevity;Endometriosis;
CRC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.48	-0.34	3.25e-10	Alzheimer's disease (late onset);
CRC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.58	8.87	0.44	4.65e-17	Vitiligo;
CRC	cis	rs6840360	0.642	rs2709834	chr4:152375424	T/G	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9549328	0.700	rs34890317	chr13:113617245	G/C	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.75e-13	Systolic blood pressure;
CRC	cis	rs995000	0.931	rs746735	chr1:63113511	C/A	cg19896129	chr1:63156450	NA	-0.41	-6.34	-0.33	7.66e-10	Triglyceride levels;
CRC	cis	rs3789045	0.774	rs898388	chr1:204500257	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.54	-7.56	-0.38	4.14e-13	Educational attainment (college completion);
CRC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.67	10.02	0.48	8.75e-21	Menopause (age at onset);
CRC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06634786	chr22:41940651	POLR3H	-0.44	-5.88	-0.31	1e-8	Vitiligo;
CRC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.92	0.4	3.59e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.61	-9.48	-0.46	5.18e-19	Coronary artery disease;
CRC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.57	8.4	0.42	1.34e-15	Longevity;
CRC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.21	0.32	1.56e-9	Heart rate;
CRC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6445525	0.967	rs2060022	chr3:65999755	A/G	cg06109867	chr3:66002991	MAGI1	-0.4	-6.69	-0.35	9.87e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.25	-0.45	3.02e-18	Alcohol dependence;
CRC	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg07856975	chr6:36356162	ETV7	0.48	6.01	0.31	4.83e-9	Platelet distribution width;
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.83	-0.31	1.34e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg25204440	chr1:209979598	IRF6	0.51	6.63	0.34	1.35e-10	Cleft lip with or without cleft palate;
CRC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.65	7.35	0.38	1.59e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.81	-0.35	4.6e-11	Cutaneous nevi;
CRC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.05	-0.32	3.98e-9	Menopause (age at onset);
CRC	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.62	8.67	0.43	1.95e-16	Lung cancer;
CRC	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg12183467	chr14:104352244	NA	-0.49	-6.76	-0.35	6.28e-11	Bipolar disorder;
CRC	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.74	-0.3	2.11e-8	Breast cancer;
CRC	cis	rs4523957	0.890	rs62069332	chr17:2112720	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-8.62	-0.43	2.82e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.58	8.12	0.41	9.52e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.73	-11.43	-0.53	1.02e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg26741380	chr15:41871084	TYRO3	-0.43	-6.57	-0.34	1.96e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.19	0.37	4.48e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-6.97	-0.36	1.72e-11	Body mass index;
CRC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.06	-18.13	-0.71	2.03e-51	Blood pressure (smoking interaction);
CRC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	6.24	0.33	1.37e-9	Lung cancer in ever smokers;
CRC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.43	-8.16	-0.41	7.21e-15	Colorectal cancer;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.6	8.13	0.41	8.68e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs13144136	0.664	rs6448177	chr4:10666272	C/T	cg10242279	chr4:10666415	CLNK	-0.39	-6.61	-0.34	1.56e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg23650765	chr1:12612165	NA	0.3	5.74	0.3	2.13e-8	Optic cup area;
CRC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.67	-0.34	1.11e-10	Schizophrenia;
CRC	cis	rs10046574	0.656	rs17403326	chr7:135194440	T/G	cg27474649	chr7:135195673	CNOT4	0.65	6.08	0.32	3.36e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-8.04	-0.41	1.58e-14	Hepatocellular carcinoma;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.66	0.57	3.43e-30	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg15845792	chr6:28175446	NA	1.0	13.01	0.58	1.62e-31	Depression;
CRC	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg12458913	chr13:53173898	NA	0.49	7.23	0.37	3.41e-12	Lewy body disease;
CRC	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.2	0.32	1.66e-9	Intelligence (multi-trait analysis);
CRC	trans	rs564309	1.000	rs493950	chr1:228606965	C/T	cg24066601	chr6:26271455	HIST1H3G	-0.55	-5.98	-0.31	5.88e-9	Hip circumference (psychosocial stress interaction);
CRC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg08288130	chr8:21771540	DOK2	0.29	5.88	0.31	9.88e-9	Lung cancer in ever smokers;
CRC	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg02398342	chr17:80708632	TBCD;FN3K	0.51	5.92	0.31	7.97e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.78	-0.47	5.21e-20	Hip circumference adjusted for BMI;
CRC	trans	rs7976838	0.908	rs12821998	chr12:60117371	T/C	cg16974014	chr22:22007515	MIR130B	0.49	5.97	0.31	6.13e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs2745967	0.740	rs2745955	chr1:208064341	G/A	cg09788693	chr1:208063733	CD34	0.44	6.45	0.33	4.04e-10	Resting heart rate;
CRC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.74	10.14	0.49	3.27e-21	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.64	10.2	0.49	2.12e-21	Myopia (pathological);
CRC	cis	rs1519814	0.696	rs2326434	chr8:121047798	A/C	cg22335954	chr8:121166405	COL14A1	-0.62	-7.11	-0.37	7.2e-12	Breast cancer;
CRC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.71	-0.35	8.38e-11	Menopause (age at onset);
CRC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10820045	chr2:198174542	NA	-0.55	-11.08	-0.52	1.79e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg03929089	chr4:120376271	NA	0.63	6.15	0.32	2.29e-9	Intraocular pressure;
CRC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.25	-0.33	1.25e-9	Aortic root size;
CRC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.74	12.67	0.57	3.12e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7212590	0.748	rs7213697	chr17:57903041	G/C	cg10252138	chr17:58120427	NA	-0.53	-5.61	-0.3	4.22e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg09163369	chr1:210001066	C1orf107	0.41	5.78	0.3	1.72e-8	Orofacial clefts;
CRC	cis	rs2276314	0.532	rs11081927	chr18:33614282	C/T	cg19628046	chr18:33552617	C18orf21	0.4	6.22	0.32	1.49e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg10978503	chr1:24200527	CNR2	-0.44	-6.67	-0.35	1.06e-10	Immature fraction of reticulocytes;
CRC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.94	-17.32	-0.69	3.26e-48	Height;
CRC	cis	rs4731207	0.662	rs10246553	chr7:124494934	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7626444	0.625	rs843530	chr3:196481024	A/G	cg12930392	chr3:196481615	PAK2	0.38	6.67	0.35	1.1e-10	Monocyte count;
CRC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.54	7.81	0.4	7.52e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg03037974	chr15:76606532	NA	-0.55	-8.23	-0.41	4.33e-15	Blood metabolite levels;
CRC	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg19193384	chr17:30244184	NA	-0.58	-7.03	-0.36	1.19e-11	Hip circumference adjusted for BMI;
CRC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg03030879	chr14:75389066	RPS6KL1	0.41	6.11	0.32	2.83e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24787076	chr5:40834616	RPL37	0.45	7.25	0.37	3e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.95	0.31	6.7e-9	Melanoma;
CRC	cis	rs9039	0.918	rs12933086	chr16:9225494	A/G	cg08831531	chr16:9218945	NA	-0.59	-6.92	-0.36	2.33e-11	Menopause (age at onset);
CRC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.56	8.44	0.42	1.02e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.33	-6.82	-0.35	4.42e-11	Renal cell carcinoma;
CRC	cis	rs73200209	0.744	rs10507269	chr12:116560327	A/T	cg01776926	chr12:116560359	MED13L	-0.6	-7.26	-0.37	2.75e-12	Total body bone mineral density;
CRC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.32	-6.83	-0.35	4.22e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.43	5.84	0.31	1.23e-8	Tuberculosis;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.87	-0.44	4.63e-17	Bipolar disorder;
CRC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg23136738	chr11:925521	AP2A2	-0.48	-7.63	-0.39	2.52e-13	Alzheimer's disease (late onset);
CRC	trans	rs4346635	0.528	rs6827369	chr4:81416967	C/T	cg13904968	chr20:56136012	PCK1	-0.19	-6.02	-0.31	4.64e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg10570241	chr7:158785291	NA	-0.43	-6.5	-0.34	2.92e-10	Facial morphology (factor 20);
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.79	0.55	5.3e-27	Prudent dietary pattern;
CRC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.72	11.91	0.55	1.97e-27	Body mass index;
CRC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.54	-0.34	2.33e-10	Schizophrenia;
CRC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.5	6.94	0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs4722166	0.567	rs62449490	chr7:22748491	T/G	cg05472934	chr7:22766657	IL6	0.41	6.05	0.32	3.88e-9	Lung cancer;
CRC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.6	-10.66	-0.51	5.65e-23	Dupuytren's disease;
CRC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.55	8.15	0.41	7.92e-15	Obesity-related traits;
CRC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg24289452	chr6:170231220	NA	-0.58	-6.58	-0.34	1.81e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.21	-0.32	1.6e-9	Breast cancer;
CRC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg01483505	chr11:975446	AP2A2	0.46	7.5	0.38	5.98e-13	Alzheimer's disease (late onset);
CRC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.23	0.45	3.48e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg25019722	chr6:37503610	NA	-0.47	-8.73	-0.43	1.28e-16	Cognitive performance;
CRC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-7.61	-0.39	2.85e-13	Coronary artery disease;
CRC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.46	-6.57	-0.34	2.01e-10	Mean platelet volume;
CRC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.23	-0.41	4.33e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	0.96	13.13	0.59	5.94e-32	Vitiligo;
CRC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg10589385	chr1:150898437	SETDB1	0.29	6.2	0.32	1.7e-9	Tonsillectomy;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12273811	chr6:28175739	NA	0.71	8.94	0.44	2.8e-17	Depression;
CRC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg08325383	chr11:65190187	NEAT1	-0.42	-6.16	-0.32	2.13e-9	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.34	-9.55	-0.47	3.15e-19	Mean corpuscular volume;
CRC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.18	-0.32	1.86e-9	Aortic root size;
CRC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.45	6.65	0.34	1.25e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9925964	0.933	rs9939417	chr16:31053467	C/T	cg03418659	chr16:31128414	MYST1	0.47	6.79	0.35	5.22e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.57	6.15	0.32	2.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg15744005	chr10:104629667	AS3MT	-0.35	-6.43	-0.33	4.37e-10	Arsenic metabolism;
CRC	cis	rs2637266	0.561	rs10824441	chr10:78490195	G/A	cg18941641	chr10:78392320	NA	-0.36	-6.03	-0.32	4.46e-9	Pulmonary function;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23161317	chr6:28129485	ZNF389	0.53	6.52	0.34	2.57e-10	Depression;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg12564285	chr5:131593104	PDLIM4	0.45	7.49	0.38	6.2800000000000005e-13	Breast cancer;
CRC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.94	17.29	0.69	4.4e-48	Intelligence (multi-trait analysis);
CRC	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg23100626	chr2:96804247	ASTL	-0.31	-8.53	-0.43	5.55e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	10.49	0.5	2.11e-22	Bone mineral density;
CRC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4716602	0.596	rs36013171	chr7:156160511	C/T	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.65e-11	Anti-saccade response;
CRC	cis	rs7246760	1.000	rs73507215	chr19:9887312	C/T	cg16876255	chr19:9731953	ZNF561	0.69	5.71	0.3	2.49e-8	Pursuit maintenance gain;
CRC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.55	8.19	0.41	5.84e-15	Breast cancer;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs7264396	0.887	rs2236161	chr20:34101631	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.47	-0.34	3.51e-10	Total cholesterol levels;
CRC	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.48	7.91	0.4	3.98e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.58	-8.49	-0.42	6.96e-16	Blood pressure (smoking interaction);
CRC	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg15282417	chr9:129245246	FAM125B	0.47	8.78	0.44	9.18e-17	Intraocular pressure;
CRC	cis	rs12760731	0.623	rs16852708	chr1:178308249	T/G	cg00404053	chr1:178313656	RASAL2	0.73	9.14	0.45	6.55e-18	Obesity-related traits;
CRC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.7	-8.84	-0.44	5.83e-17	Sitting height ratio;
CRC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06656553	chr16:89960601	TCF25	-0.69	-6.15	-0.32	2.21e-9	Skin colour saturation;
CRC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.08	0.32	3.28e-9	Diabetic kidney disease;
CRC	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.92	-0.31	7.98e-9	Pulmonary function;
CRC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.2	0.53	6.69e-25	Prudent dietary pattern;
CRC	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg09184832	chr6:79620586	NA	-0.46	-8.07	-0.41	1.32e-14	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06544376	chr20:18548101	LOC388789	0.39	6.37	0.33	6.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13198984	chr17:80129470	CCDC57	0.44	7.8	0.4	8.18e-14	Life satisfaction;
CRC	trans	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.3	0.37	2.11e-12	Endometrial cancer;
CRC	cis	rs7527798	0.592	rs10863437	chr1:207817612	T/C	cg21110645	chr1:207815933	NA	-0.39	-5.87	-0.31	1.08e-8	Erythrocyte sedimentation rate;
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.7	0.54	1.1e-26	Prudent dietary pattern;
CRC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg03609598	chr5:56110824	MAP3K1	-0.45	-6.15	-0.32	2.18e-9	Breast cancer;Breast cancer (early onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04950361	chr8:22552624	NA	0.45	6.35	0.33	7.11e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs2882667	0.690	rs274119	chr5:138064219	G/A	cg09476006	chr5:138032270	NA	0.58	10.42	0.5	3.74e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs36715	0.953	rs36700	chr5:127551273	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	7.35	0.38	1.59e-12	Breast cancer;
CRC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.3	0.33	9.47e-10	Monocyte count;
CRC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.69	7.82	0.4	7.23e-14	Major depressive disorder;
CRC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.6	8.59	0.43	3.61e-16	Arsenic metabolism;
CRC	cis	rs79387448	0.810	rs75218113	chr2:103239356	C/G	cg21010569	chr2:103233596	NA	0.58	6.2	0.32	1.67e-9	Gut microbiota (bacterial taxa);
CRC	trans	rs2303319	0.582	rs12464282	chr2:162448855	C/T	cg10272801	chr16:14013773	ERCC4	-0.68	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.65	9.73	0.47	8.13e-20	Cleft lip with or without cleft palate;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01940867	chr16:431543	TMEM8A;LOC100134368	0.42	6.15	0.32	2.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg26248373	chr2:1572462	NA	-0.61	-6.45	-0.34	3.98e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7605827	0.704	rs62120513	chr2:15537727	T/A	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.59	-8.5	-0.42	6.71e-16	Systolic blood pressure;
CRC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.63	0.3	3.87e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2303319	0.504	rs56153413	chr2:162440079	G/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.15	-0.32	2.18e-9	Cognitive function;
CRC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-7.09	-0.36	8.4e-12	Monocyte percentage of white cells;
CRC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-12.61	-0.57	5.17e-30	Prostate cancer;
CRC	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.14	18.98	0.72	8.64e-55	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.26	-0.33	1.17e-9	Depression;
CRC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg16102536	chr7:156981717	UBE3C	-0.4	-6.8	-0.35	4.8e-11	Body mass index;
CRC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.52	-7.52	-0.38	5.25e-13	Longevity;
CRC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.49	7.87	0.4	5.16e-14	Cystic fibrosis severity;
CRC	cis	rs9584850	0.794	rs17574433	chr13:99138057	A/G	cg07423050	chr13:99094983	FARP1	-0.42	-5.76	-0.3	1.97e-8	Neuroticism;
CRC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg27661571	chr11:113659931	NA	-0.95	-11.08	-0.52	1.91e-24	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.58	8.78	0.44	8.98e-17	Menopause (age at onset);
CRC	trans	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg13565492	chr6:43139072	SRF	-0.73	-8.04	-0.41	1.6e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.49	6.51	0.34	2.87e-10	Cleft lip with or without cleft palate;
CRC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg10298567	chr3:47292165	KIF9	-0.39	-6.59	-0.34	1.74e-10	Colorectal cancer;
CRC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.7	-12.19	-0.56	1.92e-28	Prostate cancer;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	6.6	0.34	1.61e-10	Cardiac Troponin-T levels;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg26608667	chr7:1196370	ZFAND2A	0.4	6.21	0.32	1.56e-9	Longevity;Endometriosis;
CRC	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg23229984	chr5:148520753	ABLIM3	-0.47	-6.32	-0.33	8.56e-10	Breast cancer;
CRC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.39	-6.16	-0.32	2.11e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22211233	chr3:182817584	MCCC1	0.48	6.6	0.34	1.61e-10	Thyroid stimulating hormone;
CRC	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.43	-6.74	-0.35	7.17e-11	Corneal astigmatism;
CRC	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.45	8.04	0.41	1.64e-14	Testicular germ cell tumor;
CRC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.96e-18	Lymphocyte counts;
CRC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.98	-0.31	5.86e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs58799304	0.618	rs3814314	chr1:156045183	T/A	cg15685922	chr1:156045208	MEX3A	-0.48	-8.07	-0.41	1.37e-14	Ischemic stroke;
CRC	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.5	6.93	0.36	2.29e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12172441	chr6:28176163	NA	0.63	7.45	0.38	8.22e-13	Depression;
CRC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg03948781	chr1:205179583	DSTYK	0.43	6.0	0.31	5.27e-9	Red blood cell count;
CRC	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.05	14.56	0.63	2.04e-37	Exhaled nitric oxide output;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17956079	chr11:73358572	PLEKHB1	-0.5	-6.38	-0.33	6.18e-10	Diisocyanate-induced asthma;
CRC	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg21153622	chr11:89784906	NA	0.47	7.41	0.38	1.08e-12	HDL cholesterol;
CRC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.57	-9.24	-0.45	3.22e-18	P wave terminal force;
CRC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.42	6.02	0.31	4.7e-9	Menarche (age at onset);
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.66	-0.34	1.14e-10	Breast cancer;
CRC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.59	10.28	0.49	1.14e-21	DNA methylation (variation);
CRC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg03037974	chr15:76606532	NA	0.83	16.99	0.68	6.28e-47	Blood metabolite levels;
CRC	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.85	10.95	0.52	5.53e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg23730037	chr7:158596552	ESYT2	-0.39	-5.63	-0.3	3.89e-8	Height;
CRC	cis	rs6961069	0.774	rs1413661	chr7:80243003	G/C	cg04458919	chr7:80252533	CD36	-0.36	-6.4	-0.33	5.29e-10	Platelet count;
CRC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.59	9.88	0.48	2.43e-20	Calcium levels;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg22738278	chr10:104220943	TMEM180	-0.42	-6.04	-0.32	4.07e-9	Protein C levels;
CRC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.41	-6.01	-0.31	4.85e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25517755	chr10:38738941	LOC399744	-0.45	-6.64	-0.34	1.27e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.9	0.31	9.13e-9	Personality dimensions;
CRC	cis	rs9462846	0.887	rs6458311	chr6:42866292	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-6.49	-0.34	3.09e-10	Blood protein levels;
CRC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg23625390	chr15:77176239	SCAPER	0.4	5.92	0.31	8.29e-9	Blood metabolite levels;
CRC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-6.78	-0.35	5.45e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.69	-12.89	-0.58	4.51e-31	Educational attainment;
CRC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.45	7.29	0.37	2.29e-12	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11970458	chr16:31213481	PYCARD	-0.55	-6.89	-0.36	2.81e-11	Diisocyanate-induced asthma;
CRC	cis	rs9398803	0.830	rs2039735	chr6:126745076	T/C	cg19875578	chr6:126661172	C6orf173	0.42	5.94	0.31	7.42e-9	Male-pattern baldness;
CRC	cis	rs12230513	0.732	rs55797706	chr12:55836585	G/A	cg19537932	chr12:55886519	OR6C68	-0.73	-9.49	-0.46	5.01e-19	Contrast sensitivity;
CRC	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.66	-0.34	1.14e-10	Osteoarthritis;
CRC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.59	7.01	0.36	1.33e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6738485	0.567	rs7598745	chr2:106848216	A/T	cg16099169	chr2:106886729	NA	0.33	5.71	0.3	2.58e-8	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	trans	rs8089364	0.917	rs2045439	chr18:57883801	C/T	cg05871254	chr17:14213225	HS3ST3B1	-0.44	-6.23	-0.32	1.46e-9	Type 2 diabetes;Body mass index;
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.31e-17	Bipolar disorder;
CRC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg20041105	chr8:143859282	LYNX1	0.45	7.4	0.38	1.12e-12	Urinary tract infection frequency;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.86	13.55	0.6	1.52e-33	Menarche (age at onset);
CRC	cis	rs4731207	0.596	rs4624966	chr7:124626471	C/A	cg23710748	chr7:124431027	NA	-0.4	-6.38	-0.33	6.15e-10	Cutaneous malignant melanoma;
CRC	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	1.11	12.97	0.58	2.45e-31	Obesity-related traits;
CRC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.57	0.43	4.13e-16	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12172441	chr6:28176163	NA	0.64	7.59	0.39	3.28e-13	Depression;
CRC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.64	8.38	0.42	1.6e-15	Arsenic metabolism;
CRC	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.52	-6.96	-0.36	1.89e-11	Caudate activity during reward;
CRC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.84	-0.48	3.48e-20	Total cholesterol levels;
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-6.11	-0.32	2.86e-9	Bipolar disorder;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.66	10.07	0.49	5.68e-21	Longevity;Endometriosis;
CRC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg07713946	chr22:31675144	LIMK2	0.37	5.74	0.3	2.18e-8	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05930162	chr1:46152207	GPBP1L1	0.48	6.81	0.35	4.65e-11	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.59	6.69	0.35	9.34e-11	Lymphocyte counts;
CRC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg07513332	chr6:167530253	CCR6	-0.46	-8.49	-0.42	7.24e-16	Primary biliary cholangitis;
CRC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	8.63	0.43	2.68e-16	Parkinson's disease;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.28	-0.49	1.15e-21	Bipolar disorder;
CRC	cis	rs6908034	0.607	rs62404179	chr6:19806272	T/C	cg02682789	chr6:19804855	NA	0.8	6.79	0.35	5.36e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg13385794	chr1:248469461	NA	-0.37	-6.56	-0.34	2.05e-10	Common traits (Other);
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.74	-0.43	1.21e-16	Bipolar disorder;
CRC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.34	0.33	7.4e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.8	0.3	1.54e-8	Prudent dietary pattern;
CRC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.97	0.44	2.37e-17	Morning vs. evening chronotype;
CRC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg19318889	chr4:1322082	MAEA	0.4	5.69	0.3	2.83e-8	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21815536	chr7:35840623	SEPT7	0.38	6.01	0.31	5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.78	11.9	0.55	2.15e-27	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-9.34	-0.46	1.49e-18	Chronic sinus infection;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg06470822	chr6:28175283	NA	0.74	10.0	0.48	9.56e-21	Parkinson's disease;
CRC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg07274523	chr3:49395745	GPX1	0.48	6.56	0.34	2.13e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.52	8.15	0.41	7.84e-15	Red blood cell count;
CRC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-8.97	-0.44	2.29e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.9	13.66	0.6	5.87e-34	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg12692199	chr17:7138010	DVL2	-0.45	-6.22	-0.32	1.55e-9	Protein C levels;
CRC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg15123519	chr2:136567270	LCT	0.33	6.39	0.33	5.65e-10	Mosquito bite size;
CRC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26240231	chr7:1148101	C7orf50	-0.43	-6.34	-0.33	7.51e-10	Bronchopulmonary dysplasia;
CRC	cis	rs10503871	1.000	rs10503872	chr8:30437031	C/G	cg26383811	chr8:30366931	RBPMS	-0.45	-7.3	-0.37	2.11e-12	Metabolite levels  (X-11787);
CRC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg16898833	chr6:26189333	HIST1H4D	0.89	7.28	0.37	2.4e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.95e-9	Depression;
CRC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.46	7.07	0.36	9.26e-12	Calcium levels;
CRC	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.58	-0.34	1.83e-10	Eye color traits;
CRC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.42	7.21	0.37	3.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.43	-0.38	9.18e-13	Height;
CRC	cis	rs290268	0.874	rs290995	chr9:93559477	C/A	cg02608019	chr9:93564028	SYK	0.44	6.93	0.36	2.17e-11	Platelet count;
CRC	cis	rs9296736	0.890	rs1325831	chr6:53904347	C/T	cg04374786	chr6:53939321	C6orf142	-0.42	-6.5	-0.34	3.04e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.39	6.24	0.33	1.37e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.22	-0.32	1.49e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	10.54	0.5	1.42e-22	Nonalcoholic fatty liver disease;
CRC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.48	8.02	0.4	1.82e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg02353165	chr6:42928485	GNMT	0.47	6.5	0.34	2.95e-10	Blood protein levels;
CRC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg16486109	chr11:613632	IRF7	0.72	11.75	0.54	7.45e-27	Systemic lupus erythematosus;
CRC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-8.17	-0.41	6.53e-15	Intelligence (multi-trait analysis);
CRC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg20409590	chr14:70655382	SLC8A3	-0.31	-6.21	-0.32	1.57e-9	Prostate cancer;
CRC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.39	-8.4	-0.42	1.37e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg11713064	chr6:33730089	NA	0.23	5.67	0.3	3.15e-8	Crohn's disease;
CRC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.3	0.71	4.39e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs117623576	0.941	rs72778753	chr10:32426579	A/T	cg03047570	chr10:32398778	NA	-0.69	-7.39	-0.38	1.19e-12	Anti-saccade response;
CRC	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.23e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3750082	0.582	rs3750079	chr7:32969419	G/A	cg05721444	chr7:32995514	FKBP9	0.61	8.79	0.44	8.64e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg15440763	chr7:158190612	PTPRN2	-0.39	-6.06	-0.32	3.72e-9	Obesity-related traits;
CRC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.29	0.42	2.96e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg02135003	chr7:105160482	PUS7	-0.68	-10.13	-0.49	3.59e-21	Bipolar disorder (body mass index interaction);
CRC	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg23229984	chr5:148520753	ABLIM3	-0.5	-6.92	-0.36	2.32e-11	Breast cancer;
CRC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs3823572	0.564	rs2346275	chr7:133662166	G/A	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01821126	chr16:70100199	PDXDC2	0.46	6.41	0.33	5.12e-10	Anxiety disorder;
CRC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.37	7.82	0.4	7.03e-14	Cutaneous nevi;
CRC	trans	rs855408	0.883	rs208990	chr6:62864433	A/G	cg21737066	chr3:72495901	RYBP	0.5	6.06	0.32	3.77e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.01	-23.38	-0.79	6.57e-72	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg26043149	chr18:55253948	FECH	0.54	8.53	0.43	5.51e-16	Bone mineral density;
CRC	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12292205	chr6:26970375	C6orf41	-0.67	-8.19	-0.41	5.9e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs216303	0.642	rs216335	chr12:6148005	T/C	cg19878637	chr12:6148451	VWF	-0.63	-6.91	-0.36	2.54e-11	Low vWF levels;
CRC	cis	rs6088813	0.885	rs6142353	chr20:33942685	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.73	-0.3	2.3e-8	Height;
CRC	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg26741380	chr15:41871084	TYRO3	-0.48	-7.08	-0.36	8.85e-12	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7572644	0.699	rs6738887	chr2:28268467	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-5.71	-0.3	2.51e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg20203395	chr5:56204925	C5orf35	-0.44	-6.13	-0.32	2.54e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-8.9	-0.44	3.86e-17	Menarche (age at onset);
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.95	-0.4	3.02e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15345369	chr2:10262827	RRM2	0.37	6.19	0.32	1.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-10.98	-0.52	4.04e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.41	6.03	0.32	4.45e-9	Renal cell carcinoma;
CRC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.56	-8.78	-0.44	8.88e-17	Asthma (sex interaction);
CRC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg01529538	chr14:23388837	RBM23	0.4	6.18	0.32	1.9e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.41	-5.69	-0.3	2.84e-8	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.5	0.34	2.91e-10	Menopause (age at onset);
CRC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.64	10.62	0.51	7.3e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	0.78	8.99	0.44	1.96e-17	Gout;Renal underexcretion gout;
CRC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	7.37	0.38	1.41e-12	Colorectal cancer;
CRC	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg10820045	chr2:198174542	NA	0.41	7.1	0.36	7.61e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg07274523	chr3:49395745	GPX1	0.45	6.01	0.31	4.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg10790698	chr19:18539756	SSBP4	-0.44	-8.44	-0.42	1e-15	Breast cancer;
CRC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.58	-0.34	1.86e-10	Menopause (age at onset);
CRC	cis	rs6968419	0.755	rs4710	chr7:115897392	G/C	cg02561103	chr7:115862891	TES	-0.43	-6.44	-0.33	4.17e-10	Intraocular pressure;
CRC	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21551185	chr12:65950729	NA	0.39	6.35	0.33	7.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg22638593	chr5:131593259	PDLIM4	0.37	7.07	0.36	9.45e-12	Blood metabolite levels;
CRC	cis	rs2882667	0.898	rs6890272	chr5:138371116	G/A	cg09476006	chr5:138032270	NA	0.44	7.41	0.38	1.09e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg21856205	chr7:94953877	PON1	-0.49	-6.55	-0.34	2.18e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	12.08	0.55	4.54e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.75	13.62	0.6	8.5e-34	Lewy body disease;
CRC	cis	rs370915	0.507	rs6835018	chr4:187794328	C/A	cg12892747	chr4:187813459	NA	-0.56	-8.05	-0.41	1.5e-14	Gout;
CRC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17772535	chr12:65153236	GNS	0.43	6.97	0.36	1.77e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.68	12.3	0.56	7.28e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7113874	0.569	rs7131358	chr11:8558333	G/C	cg17679104	chr11:8615758	STK33	-0.36	-5.96	-0.31	6.35e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.41	6.28	0.33	1.04e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.38	6.06	0.32	3.83e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg02033258	chr5:131593261	PDLIM4	-0.39	-6.61	-0.34	1.52e-10	Breast cancer;
CRC	cis	rs12630931	0.798	rs4073767	chr3:31988108	G/A	cg21375017	chr3:31988082	OSBPL10	0.49	6.28	0.33	1.05e-9	Periodontal disease-related phenotypes;
CRC	trans	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg10756647	chr7:56101905	PSPH	0.74	7.74	0.39	1.23e-13	Diabetic kidney disease;
CRC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.53	6.5	0.34	2.93e-10	Vitiligo;
CRC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	8.0	0.4	2.15e-14	Mean corpuscular hemoglobin;
CRC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.59	-7.94	-0.4	3.21e-14	Schizophrenia;
CRC	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.59	8.57	0.43	3.97e-16	Schizophrenia;
CRC	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg25173405	chr17:45401733	C17orf57	0.44	6.74	0.35	6.94e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-6.49	-0.34	3.17e-10	Red blood cell count;Reticulocyte count;
CRC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02807482	chr3:125708958	NA	-0.44	-5.8	-0.3	1.55e-8	Blood pressure (smoking interaction);
CRC	cis	rs7692995	1.000	rs6842114	chr4:18008199	A/C	cg08925142	chr4:18023851	LCORL	-0.53	-5.98	-0.31	5.78e-9	Height;
CRC	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs4294134	0.832	rs12707241	chr7:135259183	T/C	cg20392616	chr7:135392013	SLC13A4	0.51	5.78	0.3	1.71e-8	Paget's disease;
CRC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-5.9	-0.31	8.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.0	-0.31	5.31e-9	Arsenic metabolism;
CRC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.56	-9.01	-0.45	1.67e-17	Neurofibrillary tangles;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22194305	chr4:2264032	MXD4	0.51	7.43	0.38	9.16e-13	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.582	rs16845851	chr2:162295623	A/C	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.23	-0.32	1.43e-9	Cognitive function;
CRC	cis	rs6504622	0.537	rs1662597	chr17:44994855	T/C	cg16759221	chr17:45003025	GOSR2	-0.65	-10.52	-0.5	1.62e-22	Orofacial clefts;
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.49	-7.67	-0.39	1.96e-13	Bipolar disorder;
CRC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.18	0.45	5.02e-18	Bladder cancer;
CRC	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.1	-0.32	2.9e-9	Diastolic blood pressure;
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.61	-0.34	1.51e-10	Total body bone mineral density;
CRC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	6.24	0.33	1.33e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.7	-9.94	-0.48	1.59e-20	Hypospadias;
CRC	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.42	6.92	0.36	2.41e-11	Sitting height ratio;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26797661	chr1:151138516	LYSMD1;SCNM1	0.4	6.15	0.32	2.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.22	0.41	4.85e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.55	-0.43	4.83e-16	Electroencephalogram traits;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg15845792	chr6:28175446	NA	0.98	13.02	0.58	1.56e-31	Depression;
CRC	cis	rs941898	0.836	rs8016001	chr14:100598691	A/G	cg26002632	chr14:100625216	DEGS2	-0.39	-5.92	-0.31	8.31e-9	White matter hyperintensity burden;
CRC	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.79	8.48	0.42	7.89e-16	Migraine;Coronary artery disease;
CRC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg03013999	chr17:37608204	MED1	-0.48	-7.46	-0.38	7.7e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg02033258	chr5:131593261	PDLIM4	0.41	7.89	0.4	4.58e-14	Breast cancer;
CRC	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs6693567	0.874	rs698915	chr1:150388318	C/T	cg04165759	chr1:150448943	RPRD2	-0.37	-5.71	-0.3	2.58e-8	Migraine;
CRC	cis	rs10751667	0.677	rs9794921	chr11:1039867	T/G	ch.11.42038R	chr11:967971	AP2A2	0.54	7.1	0.36	7.87e-12	Alzheimer's disease (late onset);
CRC	trans	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg03623178	chr6:28175578	NA	0.5	7.4	0.38	1.15e-12	Pubertal anthropometrics;
CRC	cis	rs711830	1.000	rs2857540	chr2:177026698	G/T	cg13092806	chr2:177043255	NA	0.71	8.42	0.42	1.15e-15	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.61	-0.34	1.58e-10	Platelet distribution width;
CRC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.39	5.73	0.3	2.21e-8	Red cell distribution width;
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.24	-0.59	2.25e-32	Alzheimer's disease;
CRC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.42	0.33	4.81e-10	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-0.54	-5.93	-0.31	7.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.47	6.45	0.33	4.03e-10	Aortic root size;
CRC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.44	-6.82	-0.35	4.25e-11	Platelet count;
CRC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.53	6.82	0.35	4.29e-11	IgG glycosylation;
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.28e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.37	-6.02	-0.32	4.56e-9	Ulcerative colitis;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.23	5.62	0.3	4.16e-8	Parkinson's disease;
CRC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg27661571	chr11:113659931	NA	0.65	7.59	0.39	3.3e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7546094	1.000	rs1001494	chr1:113110619	T/C	cg22162597	chr1:113214053	CAPZA1	0.43	5.94	0.31	7.2e-9	Platelet distribution width;
CRC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg09655341	chr17:79618100	PDE6G	-0.36	-6.13	-0.32	2.53e-9	Eye color traits;
CRC	cis	rs7487075	1.000	rs10880966	chr12:46801782	C/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.53	0.34	2.53e-10	Itch intensity from mosquito bite;
CRC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.22	-6.14	-0.32	2.33e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04277470	chr13:41707106	KBTBD6	0.46	6.4	0.33	5.4e-10	Response to antipsychotic treatment;
CRC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.63	12.16	0.56	2.42e-28	Skin aging (microtopography measurement);
CRC	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.67	9.42	0.46	8.41e-19	Multiple sclerosis;
CRC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg21285383	chr16:89894308	SPIRE2	0.36	6.2	0.32	1.71e-9	Vitiligo;
CRC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	8.68	0.43	1.83e-16	Height;
CRC	trans	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg18288967	chr1:45987694	PRDX1	0.65	7.77	0.39	1.03e-13	Obesity-related traits;
CRC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.62	9.05	0.45	1.3e-17	Obesity-related traits;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg17956387	chr1:208418015	PLXNA2	-0.39	-5.96	-0.31	6.35e-9	HDL cholesterol;
CRC	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg02466173	chr16:30829666	NA	0.61	9.0	0.44	1.87e-17	Dementia with Lewy bodies;
CRC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg00343986	chr7:65444356	GUSB	0.48	7.0	0.36	1.48e-11	Calcium levels;
CRC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.77	0.44	9.58e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg00750074	chr16:89608354	SPG7	-0.5	-7.59	-0.39	3.29e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-5.72	-0.3	2.41e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.8	14.75	0.63	3.65e-38	Anterior chamber depth;
CRC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.45	6.31	0.33	9.01e-10	Fibrinogen levels;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg07217954	chr7:1067459	C7orf50	0.57	5.98	0.31	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12501888	chr15:85177176	SCAND2	-0.37	-6.16	-0.32	2.09e-9	P wave terminal force;
CRC	cis	rs79387448	0.810	rs75218113	chr2:103239356	C/G	cg00507830	chr2:103233733	NA	0.73	7.57	0.39	3.71e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.97	-0.36	1.77e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.51	7.6	0.39	3.1e-13	Subjective well-being;
CRC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.21	-5.7	-0.3	2.65e-8	Urinary metabolites;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11147586	chr5:170845829	FGF18	0.45	6.08	0.32	3.25e-9	Survival in pancreatic cancer;
CRC	cis	rs758970	0.523	rs741028	chr9:129186589	C/G	cg15282417	chr9:129245246	FAM125B	-0.35	-6.07	-0.32	3.59e-9	Obesity-related traits;
CRC	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.71	13.05	0.58	1.18e-31	Hip circumference;
CRC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.58	5.7	0.3	2.7e-8	Initial pursuit acceleration;
CRC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.79	13.09	0.59	8.5e-32	Obesity-related traits;
CRC	cis	rs11229555	0.645	rs12802819	chr11:58174747	T/G	cg15696309	chr11:58395628	NA	-0.81	-10.38	-0.5	5.2e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.34	6.93	0.36	2.26e-11	Renal cell carcinoma;
CRC	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.56	-6.7	-0.35	9.25e-11	Carotid intima media thickness;
CRC	cis	rs3790455	0.610	rs3790458	chr1:156459699	A/T	cg14087168	chr1:156450669	MEF2D	-0.37	-6.54	-0.34	2.3e-10	Migraine;
CRC	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.92	0.44	3.23e-17	Coffee consumption (cups per day);
CRC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.51	7.19	0.37	4.36e-12	Aortic root size;
CRC	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg06581033	chr10:766294	NA	-0.5	-5.76	-0.3	1.93e-8	Uric acid levels;
CRC	trans	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg18335740	chr13:41363409	SLC25A15	0.53	7.89	0.4	4.58e-14	Lewy body disease;
CRC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.97e-9	Life satisfaction;
CRC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.62	-7.18	-0.37	4.64e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.41	5.66	0.3	3.32e-8	Schizophrenia;
CRC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	7.12	0.37	6.79e-12	Motion sickness;
CRC	cis	rs2227564	0.678	rs2242257	chr10:75597605	A/G	cg00564723	chr10:75632066	CAMK2G	0.37	8.65	0.43	2.34e-16	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.35	5.7	0.3	2.66e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.67	12.13	0.56	3.12e-28	Aortic root size;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10162261	chr22:38598048	MAFF	0.39	6.24	0.33	1.34e-9	Schizophrenia;
CRC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.64	-0.7	1.77e-49	Height;
CRC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.72	12.75	0.57	1.61e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.91	-0.31	8.64e-9	Subjective well-being;
CRC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs16867321	0.853	rs58388320	chr2:181340490	C/T	cg23363182	chr2:181467187	NA	-0.51	-5.98	-0.31	5.76e-9	Obesity;
CRC	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.43	-0.38	9.25e-13	Neuroticism;
CRC	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.42	-0.65	9.24e-41	Exhaled nitric oxide output;
CRC	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.83	-0.31	1.3e-8	Migraine;Coronary artery disease;
CRC	cis	rs4664293	0.631	rs6714899	chr2:160449406	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.57	5.78	0.3	1.73e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12516959	chr21:47718080	NA	0.35	5.96	0.31	6.46e-9	Testicular germ cell tumor;
CRC	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.6	-0.47	2.04e-19	Breast cancer;
CRC	cis	rs2179367	0.959	rs540538	chr6:149647944	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.08	-0.32	3.27e-9	Dupuytren's disease;
CRC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg15786705	chr6:28176104	NA	0.67	6.36	0.33	6.67e-10	Depression;
CRC	cis	rs7605827	0.675	rs2111449	chr2:15616215	C/T	cg19274914	chr2:15703543	NA	0.39	5.64	0.3	3.6e-8	Educational attainment (years of education);
CRC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg00246817	chr9:123691163	NA	-0.47	-6.04	-0.32	4.11e-9	Rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg10760299	chr15:45669010	GATM	0.53	8.09	0.41	1.14e-14	Homoarginine levels;
CRC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-5.77	-0.3	1.8e-8	Tonsillectomy;
CRC	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.55	6.43	0.33	4.42e-10	Body mass index;
CRC	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg00490450	chr3:139108681	COPB2	-0.43	-6.41	-0.33	4.94e-10	Obesity-related traits;
CRC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.44	6.53	0.34	2.44e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.5	7.51	0.38	5.75e-13	Corneal astigmatism;
CRC	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.69	9.03	0.45	1.51e-17	Uric acid levels;
CRC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17756712	0.725	rs2294667	chr6:617523	A/T	cg16786516	chr6:604617	EXOC2	0.46	5.71	0.3	2.47e-8	Vertical cup-disc ratio;
CRC	cis	rs6546550	0.630	rs9309429	chr2:69995580	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.34	-0.33	7.79e-10	Prevalent atrial fibrillation;
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.72	-0.43	1.44e-16	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15688767	chr3:125093330	ZNF148	0.45	6.44	0.33	4.19e-10	Response to antipsychotic treatment;
CRC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.63	-8.37	-0.42	1.67e-15	Coronary artery disease;
CRC	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg19773385	chr1:10388646	KIF1B	-0.56	-7.63	-0.39	2.56e-13	Hepatocellular carcinoma;
CRC	cis	rs10242455	0.717	rs72494455	chr7:99336777	C/G	cg18809830	chr7:99032528	PTCD1	-0.8	-5.98	-0.31	5.96e-9	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.43	6.36	0.33	6.77e-10	Menopause (age at onset);
CRC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.7	-0.35	9.22e-11	Height;
CRC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.54	8.43	0.42	1.08e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.45	6.94	0.36	2.08e-11	Monocyte count;
CRC	trans	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg11693508	chr17:37793320	STARD3	0.51	6.3	0.33	9.7e-10	Bipolar disorder;
CRC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg07828340	chr4:882639	GAK	0.55	7.21	0.37	3.81e-12	Parkinson's disease;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19160555	chr6:143267454	HIVEP2	0.4	6.22	0.32	1.49e-9	Myopia (pathological);
CRC	cis	rs4964805	0.657	rs11111787	chr12:104189499	C/T	cg02344784	chr12:104178138	NT5DC3	0.79	14.94	0.64	6.83e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-6.0	-0.31	5.23e-9	Total body bone mineral density;
CRC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	15.81	0.66	2.92e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.7e-9	Bipolar disorder;
CRC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg02951883	chr7:2050386	MAD1L1	-0.55	-9.05	-0.45	1.32e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs73206853	0.764	rs55859138	chr12:110775610	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	7.71	0.39	1.55e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4743820	0.651	rs10733738	chr9:93929352	G/A	cg14446406	chr9:93919335	NA	-0.76	-13.38	-0.59	6.45e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs9303542	0.527	rs62066689	chr17:46609092	T/C	cg04904318	chr17:46607828	HOXB1	-0.54	-6.33	-0.33	7.85e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.46	-7.44	-0.38	8.86e-13	Aortic root size;
CRC	cis	rs540254	0.578	rs4656271	chr1:160782942	A/G	cg20255094	chr1:160771763	LY9	0.49	6.34	0.33	7.78e-10	Blood protein levels;
CRC	cis	rs12620038	0.525	rs7598661	chr2:47468955	C/T	cg13204236	chr2:47476732	NA	0.31	5.79	0.3	1.62e-8	Survival in pancreatic cancer;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Parkinson's disease;
CRC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.46	0.69	8.83e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9928842	0.823	rs11149811	chr16:75300708	C/G	cg08657710	chr16:75258780	CTRB1	-0.57	-6.48	-0.34	3.28e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.68	-8.4	-0.42	1.35e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.46	-0.42	9e-16	Bipolar disorder;
CRC	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.53	8.25	0.41	3.73e-15	Testicular germ cell tumor;
CRC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.45	6.95	0.36	1.94e-11	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17105206	chr16:67211972	KIAA0895L	0.45	7.59	0.39	3.26e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.67	10.31	0.49	8.52e-22	Initial pursuit acceleration;
CRC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg02569458	chr12:86230093	RASSF9	0.38	6.57	0.34	1.99e-10	Major depressive disorder;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg16060761	chr17:80687452	NA	0.53	8.12	0.41	9.73e-15	Glycated hemoglobin levels;
CRC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg05623727	chr3:50126028	RBM5	-0.4	-6.09	-0.32	3.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.46	6.78	0.35	5.6e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg05304507	chr6:116381966	FRK	0.3	6.71	0.35	8.67e-11	Total cholesterol levels;
CRC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.4	-7.67	-0.39	1.91e-13	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.41	-0.46	9.1e-19	Aortic root size;
CRC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-10.02	-0.48	8.3e-21	Dental caries;
CRC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.55	-7.84	-0.4	6.25e-14	Testicular germ cell tumor;
CRC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg16434002	chr17:42200994	HDAC5	0.45	6.03	0.32	4.4e-9	Total body bone mineral density;
CRC	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg14558114	chr2:88469736	THNSL2	-0.43	-6.35	-0.33	6.97e-10	Response to metformin (IC50);
CRC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.41e-9	Type 2 diabetes;
CRC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.52	8.33	0.42	2.23e-15	Colorectal cancer;
CRC	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.51	-0.38	5.56e-13	Type 2 diabetes;
CRC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg13607699	chr17:42295918	UBTF	-0.48	-6.23	-0.32	1.47e-9	Total body bone mineral density;
CRC	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.65	10.7	0.51	3.95e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12024301	0.557	rs6698036	chr1:183603017	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg00490450	chr3:139108681	COPB2	0.43	6.45	0.33	4.1e-10	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg07856975	chr6:36356162	ETV7	0.48	6.09	0.32	3.15e-9	Platelet distribution width;
CRC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.15	-0.37	5.81e-12	Capecitabine sensitivity;
CRC	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg04969067	chr8:143858791	LYNX1	-0.36	-6.12	-0.32	2.62e-9	Urinary tract infection frequency;
CRC	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.63	10.08	0.49	5.36e-21	Corneal astigmatism;
CRC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg10431340	chr1:161279108	MPZ	-0.52	-7.02	-0.36	1.28e-11	Rheumatoid arthritis;
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.66	-0.39	2.03e-13	Total body bone mineral density;
CRC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.71e-21	Aortic root size;
CRC	cis	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg07480446	chr2:239069576	NA	-0.37	-6.81	-0.35	4.59e-11	Mean corpuscular hemoglobin concentration;
CRC	trans	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.06	-0.36	1e-11	Menarche (age at onset);
CRC	cis	rs12692738	0.526	rs355830	chr2:165616503	C/G	cg03182029	chr2:165697222	COBLL1	0.51	6.09	0.32	3.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg27395922	chr11:50257633	LOC441601	0.36	5.78	0.3	1.71e-8	Coronary artery disease;
CRC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.82	9.2	0.45	4.12e-18	Breast cancer;
CRC	cis	rs77972916	0.609	rs72790903	chr2:43561985	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.67	-0.3	3.09e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-6.73	-0.35	7.65e-11	Lung cancer;
CRC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.47	-0.42	8.34e-16	Chronic sinus infection;
CRC	cis	rs11212617	0.837	rs4754298	chr11:108023284	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.64	0.34	1.32e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg01339444	chr6:118972232	C6orf204	0.54	5.98	0.31	5.97e-9	Diastolic blood pressure;
CRC	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg27171509	chr10:82033454	MAT1A	-0.47	-8.4	-0.42	1.35e-15	Borderline personality disorder;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.61	0.3	4.27e-8	Intelligence (multi-trait analysis);
CRC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg23229984	chr5:148520753	ABLIM3	0.57	7.51	0.38	5.45e-13	Breast cancer;
CRC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-5.94	-0.31	7.32e-9	Alzheimer's disease (late onset);
CRC	cis	rs883565	0.771	rs2056613	chr3:39125293	G/T	cg01426195	chr3:39028469	NA	-0.54	-8.3	-0.42	2.82e-15	Handedness;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12273811	chr6:28175739	NA	0.74	9.39	0.46	1.04e-18	Depression;
CRC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg23018236	chr17:30244563	NA	-0.57	-7.41	-0.38	1.09e-12	Hip circumference adjusted for BMI;
CRC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.08e-35	Uric acid levels;
CRC	cis	rs3106136	0.609	rs28696050	chr4:95136630	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.81	-0.35	4.72e-11	Capecitabine sensitivity;
CRC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-11.74	-0.54	8.09e-27	Bone mineral density;
CRC	trans	rs10021731	0.668	rs7698363	chr4:115413574	A/G	cg25927708	chr2:119603813	EN1	-0.33	-6.09	-0.32	3.21e-9	Optic disc area;
CRC	trans	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg05376469	chr2:102649931	NA	-0.36	-6.18	-0.32	1.86e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.9e-14	Obesity-related traits;
CRC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg21972741	chr5:435613	AHRR	0.45	5.95	0.31	6.89e-9	Cystic fibrosis severity;
CRC	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.31	-6.69	-0.35	9.46e-11	Educational attainment (years of education);
CRC	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.4	-6.0	-0.31	5.17e-9	P wave terminal force;
CRC	trans	rs4714291	0.802	rs7759622	chr6:40114735	C/T	cg02267698	chr19:7991119	CTXN1	-0.49	-6.67	-0.35	1.06e-10	Strep throat;
CRC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.54	8.25	0.41	3.77e-15	Aortic root size;
CRC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.39	5.91	0.31	8.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg12856521	chr11:46389249	DGKZ	0.47	7.62	0.39	2.74e-13	Leprosy;
CRC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	13.56	0.6	1.39e-33	Intelligence (multi-trait analysis);
CRC	cis	rs4716602	0.596	rs4997808	chr7:156158734	C/G	cg16983916	chr7:156159713	NA	-0.39	-6.87	-0.35	3.14e-11	Anti-saccade response;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg23123621	chr4:1343375	KIAA1530	0.32	5.7	0.3	2.7e-8	Obesity-related traits;
CRC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.75	12.18	0.56	1.93e-28	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg15845792	chr6:28175446	NA	0.86	12.44	0.57	2.24e-29	Parkinson's disease;
CRC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg12273811	chr6:28175739	NA	0.56	8.05	0.41	1.52e-14	Parkinson's disease;
CRC	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg02466173	chr16:30829666	NA	0.66	10.0	0.48	1.02e-20	Dementia with Lewy bodies;
CRC	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg00105475	chr2:10696890	NA	0.45	7.09	0.36	8.03e-12	Prostate cancer;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.11	-0.32	2.76e-9	Bipolar disorder;
CRC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg02094049	chr14:103021097	NA	-0.55	-7.38	-0.38	1.3e-12	Platelet count;
CRC	cis	rs2415984	0.579	rs754962	chr14:46962719	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.96	0.31	6.64e-9	Number of children ever born;
CRC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg06740227	chr12:86229804	RASSF9	0.38	5.83	0.31	1.31e-8	Major depressive disorder;
CRC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.06	-0.32	3.72e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.65	7.37	0.38	1.36e-12	Inflammatory bowel disease;
CRC	trans	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg20935933	chr6:143382018	AIG1	0.52	6.56	0.34	2.04e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg02033258	chr5:131593261	PDLIM4	0.38	6.34	0.33	7.76e-10	Breast cancer;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01947585	chr15:59225861	SLTM	0.43	6.22	0.32	1.53e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.65	10.8	0.51	1.79e-23	Subjective well-being (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.51	-6.9	-0.36	2.64e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.33	-0.33	7.89e-10	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.62	0.43	2.82e-16	Menopause (age at onset);
CRC	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.53	7.71	0.39	1.52e-13	Coronary heart disease;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.57	-7.91	-0.4	4.04e-14	Pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11550426	chr8:59465609	SDCBP	0.44	6.08	0.32	3.42e-9	Response to antipsychotic treatment;
CRC	cis	rs965469	1.000	rs6037567	chr20:3332160	C/A	cg25506879	chr20:3388711	C20orf194	-0.37	-5.6	-0.3	4.41e-8	IFN-related cytopenia;
CRC	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.86	-0.4	5.61e-14	Bipolar disorder;
CRC	trans	rs2908835	0.521	rs6488412	chr12:11612600	G/A	cg03979024	chr10:419189	DIP2C	-0.4	-6.28	-0.33	1.08e-9	Information processing speed;
CRC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.62	-8.76	-0.43	1.08e-16	Obesity-related traits;
CRC	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.92	-0.44	3.27e-17	Coffee consumption (cups per day);
CRC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.51	7.71	0.39	1.53e-13	Aortic root size;
CRC	cis	rs4731207	0.698	rs10228376	chr7:124493743	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg23093090	chr10:104574429	C10orf26	0.43	7.15	0.37	5.79e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs3767633	0.925	rs2298019	chr1:161736035	A/G	cg09175582	chr1:161736000	ATF6	0.68	6.03	0.32	4.36e-9	IgG glycosylation;
CRC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg20965017	chr5:231967	SDHA	0.53	5.88	0.31	1.02e-8	Breast cancer;
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-7.07	-0.36	9.28e-12	Lymphocyte counts;
CRC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.76	-12.1	-0.56	3.83e-28	Cognitive ability;
CRC	cis	rs11203032	0.831	rs10887929	chr10:90948864	T/C	cg16672925	chr10:90967113	CH25H	0.46	5.79	0.3	1.66e-8	Heart failure;
CRC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg25985355	chr7:65971099	NA	0.32	5.69	0.3	2.75e-8	Aortic root size;
CRC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.72	6.63	0.34	1.35e-10	Diabetic kidney disease;
CRC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.49	-8.45	-0.42	9.34e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg22687807	chr8:143858763	LYNX1	0.42	7.24	0.37	3.21e-12	Urinary tract infection frequency;
CRC	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.43	0.53	1.03e-25	Bipolar disorder;
CRC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.43	6.7	0.35	9.28e-11	Height;
CRC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.23	-14.38	-0.62	9.77e-37	Diabetic kidney disease;
CRC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.72	10.67	0.51	5.26e-23	Breast cancer;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.62	-9.42	-0.46	8.48e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	0.99	14.36	0.62	1.17e-36	Breast cancer;
CRC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-8.72	-0.43	1.43e-16	Bipolar disorder;
CRC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.35	0.46	1.37e-18	Lung cancer;
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg05569086	chr8:143859399	LYNX1	0.38	6.59	0.34	1.79e-10	Urinary tract infection frequency;
CRC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.75	0.68	5.43e-46	Chronic sinus infection;
CRC	cis	rs6586163	1.000	rs1926196	chr10:90753748	C/T	cg13456138	chr10:90753195	FAS	0.43	6.68	0.35	1.02e-10	Chronic lymphocytic leukemia;
CRC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg25767906	chr1:53392781	SCP2	0.36	5.82	0.31	1.39e-8	Monocyte count;
CRC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.55	-7.76	-0.39	1.06e-13	IgG glycosylation;
CRC	cis	rs12760731	0.565	rs16852576	chr1:178192371	C/T	cg00404053	chr1:178313656	RASAL2	1.05	10.9	0.52	7.99e-24	Obesity-related traits;
CRC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.87	0.35	3.29e-11	Cognitive test performance;
CRC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.77	-11.42	-0.53	1.11e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.65	8.5	0.42	6.78e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.65	-7.61	-0.39	2.85e-13	Iron status biomarkers;
CRC	cis	rs7301826	0.610	rs7957899	chr12:131279076	T/C	cg11011512	chr12:131303247	STX2	0.39	5.82	0.31	1.41e-8	Plasma plasminogen activator levels;
CRC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.92	-0.36	2.34e-11	Aortic root size;
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.56	-0.5	1.24e-22	Bipolar disorder;
CRC	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	cis	rs6662572	0.737	rs7413189	chr1:46254330	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.3	-0.33	9.58e-10	Blood protein levels;
CRC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.64	-8.7	-0.43	1.62e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17374227	chr4:140374776	RAB33B	0.51	7.33	0.37	1.82e-12	Response to antipsychotic treatment;
CRC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.7	-0.35	8.8e-11	Response to antipsychotic treatment;
CRC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.35	5.6	0.3	4.44e-8	Hemoglobin concentration;
CRC	trans	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg18288967	chr1:45987694	PRDX1	0.61	7.17	0.37	4.98e-12	Obesity-related traits;
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.5	6.85	0.35	3.67e-11	Glycated hemoglobin levels;
CRC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.96	-0.36	1.9e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.48	-10.64	-0.51	6.26e-23	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12273811	chr6:28175739	NA	0.69	8.83	0.44	6.17e-17	Depression;
CRC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.77	9.71	0.47	9.48e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2657888	0.628	rs2638334	chr12:56882528	A/C	cg23002907	chr12:56915593	RBMS2	0.39	6.04	0.32	4.2e-9	Adiponectin levels;
CRC	trans	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.45	-0.34	3.89e-10	Aortic root size;
CRC	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.71	-0.3	2.57e-8	Daytime sleep phenotypes;
CRC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.52	-0.34	2.59e-10	Colorectal cancer;
CRC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.65	7.34	0.37	1.74e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg24675056	chr1:15929824	NA	-0.49	-6.63	-0.34	1.35e-10	Systolic blood pressure;
CRC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg11518657	chr1:67396239	MIER1	-0.57	-6.07	-0.32	3.47e-9	Lymphocyte percentage of white cells;
CRC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.54	8.53	0.43	5.26e-16	Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.38	6.27	0.33	1.16e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	7.99	0.4	2.27e-14	Height;
CRC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg00129232	chr17:37814104	STARD3	0.57	7.01	0.36	1.35e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.68	-8.75	-0.43	1.11e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg05623727	chr3:50126028	RBM5	-0.43	-7.03	-0.36	1.17e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg04850286	chr10:81895943	PLAC9	0.37	6.71	0.35	8.44e-11	Sarcoidosis;
CRC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.47	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.01	0.31	4.88e-9	Lung cancer;
CRC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.65	-0.34	1.25e-10	Crohn's disease;
CRC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.36	5.73	0.3	2.29e-8	Neurofibrillary tangles;
CRC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.39	7.59	0.39	3.36e-13	Mean corpuscular volume;
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg17321639	chr7:2759063	NA	-0.48	-6.67	-0.35	1.09e-10	Height;
CRC	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg16898833	chr6:26189333	HIST1H4D	0.76	6.09	0.32	3.14e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.55	6.44	0.33	4.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs59901009	0.815	rs10500721	chr11:10203610	A/G	cg23875677	chr11:10229755	SBF2	-0.47	-5.91	-0.31	8.6e-9	Hematocrit;Hemoglobin concentration;
CRC	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-12.32	-0.56	6.22e-29	Colorectal cancer;
CRC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.69	10.31	0.49	8.57e-22	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg16447950	chr5:562315	NA	-0.81	-10.49	-0.5	2.1e-22	Obesity-related traits;
CRC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.63	-8.83	-0.44	6.29e-17	Other erythrocyte phenotypes;
CRC	cis	rs2992756	0.663	rs3007718	chr1:18808465	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.39	-5.78	-0.3	1.76e-8	Breast cancer;
CRC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg16102536	chr7:156981717	UBE3C	-0.4	-6.8	-0.35	4.8e-11	Body mass index;
CRC	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg25588852	chr2:216877276	MREG	-0.36	-7.01	-0.36	1.36e-11	Alcohol dependence;
CRC	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.54	-6.41	-0.33	5.19e-10	Coronary artery calcification;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.55	-8.85	-0.44	5.44e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.68	-10.29	-0.49	1.06e-21	Hair shape;
CRC	cis	rs7680126	0.596	rs28441463	chr4:10289577	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.0	-0.31	5.3300000000000004e-09	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.93	-21.91	-0.77	3.09e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7487075	0.619	rs12824565	chr12:46834693	A/G	cg22049899	chr12:47219821	SLC38A4	0.32	5.78	0.3	1.77e-8	Itch intensity from mosquito bite;
CRC	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.63	-6.14	-0.32	2.37e-9	Arsenic metabolism;
CRC	cis	rs12760731	0.720	rs7548163	chr1:178306695	G/A	cg00404053	chr1:178313656	RASAL2	0.92	9.63	0.47	1.74e-19	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15921587	chr2:73144353	EMX1	-0.39	-6.02	-0.31	4.57e-9	Myopia (pathological);
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg20041105	chr8:143859282	LYNX1	-0.42	-6.64	-0.34	1.28e-10	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05232067	chr8:26240888	BNIP3L	0.44	6.07	0.32	3.61e-9	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs891088	0.677	rs11670892	chr19:7185306	C/G	cg09779027	chr19:7224513	INSR	-0.59	-6.08	-0.32	3.32e-9	Hip circumference adjusted for BMI;Height;
CRC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.66	7.41	0.38	1.1e-12	Body mass index;
CRC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-12.51	-0.57	1.25e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.76	0.3	1.97e-8	Self-reported allergy;
CRC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg11965913	chr1:205819406	PM20D1	0.41	6.24	0.33	1.36e-9	Prostate cancer;
CRC	cis	rs17767392	0.881	rs35625243	chr14:71944937	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.78	-0.3	1.75e-8	Mitral valve prolapse;
CRC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.69	6.8	0.35	5.09e-11	Diabetic retinopathy;
CRC	cis	rs243505	0.762	rs2007404	chr7:148487395	A/G	cg09806900	chr7:148480153	CUL1	0.48	6.91	0.36	2.49e-11	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04197313	chr15:67547198	IQCH;AAGAB	0.42	5.96	0.31	6.53e-9	Anxiety disorder;
CRC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.67	8.6	0.43	3.25e-16	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12405341	chr2:233415195	TIGD1;EIF4E2	0.47	6.79	0.35	5.12e-11	Response to antipsychotic treatment;
CRC	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.37	-6.84	-0.35	3.98e-11	Breast cancer;
CRC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.8e-27	Asthma (sex interaction);
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.92	-11.99	-0.55	9.72e-28	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02228675	chr17:40259724	DHX58	-0.49	-6.9	-0.36	2.7e-11	Fibrinogen levels;
CRC	cis	rs501120	0.584	rs11517251	chr10:44724052	A/G	cg09554077	chr10:44749378	NA	0.65	7.32	0.37	1.9e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.13	-0.49	3.5e-21	Total cholesterol levels;
CRC	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg20607287	chr7:12443886	VWDE	-0.44	-6.51	-0.34	2.78e-10	Coronary artery disease;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-6.07	-0.32	3.47e-9	Obesity-related traits;
CRC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-6.75	-0.35	6.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.44	7.09	0.36	8.13e-12	Height;
CRC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.53	-7.28	-0.37	2.43e-12	DNA methylation (variation);
CRC	cis	rs4664293	1.000	rs10432413	chr2:160495754	T/A	cg08347373	chr2:160653686	CD302	-0.47	-7.51	-0.38	5.49e-13	Monocyte percentage of white cells;
CRC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.95	-0.52	5.2e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg02869306	chr7:64672164	INTS4L1	-0.47	-8.1	-0.41	1.06e-14	Calcium levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12876261	chr7:56119223	PSPH;CCT6A	0.37	6.14	0.32	2.34e-9	Obesity-related traits;
CRC	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.83	-0.55	3.79e-27	Coffee consumption (cups per day);
CRC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16262614	chr3:133464971	TF	0.33	5.91	0.31	8.53e-9	Iron status biomarkers;
CRC	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg04165759	chr1:150448943	RPRD2	0.36	5.86	0.31	1.15e-8	Migraine;
CRC	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-12.86	-0.58	5.86e-31	Idiopathic membranous nephropathy;
CRC	trans	rs1147246	0.714	rs323850	chr12:125878116	C/G	cg23470196	chr14:102695671	RAGE	0.41	5.96	0.31	6.4e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg09796270	chr17:17721594	SREBF1	-0.47	-8.0	-0.4	2.18e-14	Coronary artery disease or ischemic stroke;
CRC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.95e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg19678392	chr7:94953810	PON1	-0.53	-6.63	-0.34	1.39e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16543009	chr15:34331514	AVEN;CHRM5	0.4	6.18	0.32	1.91e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg09873164	chr1:152488093	CRCT1	0.37	6.26	0.33	1.18e-9	Hair morphology;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.41	0.38	1.08e-12	Longevity;
CRC	cis	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg09547119	chr19:52391367	ZNF577	-0.45	-5.63	-0.3	3.91e-8	Breast cancer;
CRC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg20933634	chr6:27740509	NA	0.56	7.04	0.36	1.12e-11	Breast cancer;
CRC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.7	-12.45	-0.57	2.01e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.56	7.72	0.39	1.42e-13	Lung cancer;
CRC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.73	-0.3	2.31e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.17	0.45	5.24e-18	Coffee consumption (cups per day);
CRC	cis	rs4973397	0.643	rs2034413	chr2:232288149	C/T	cg13347044	chr2:232276743	NA	0.39	5.78	0.3	1.77e-8	Anti-saccade response;
CRC	cis	rs995000	0.826	rs12023489	chr1:62923858	G/A	cg19896129	chr1:63156450	NA	0.41	6.15	0.32	2.24e-9	Triglyceride levels;
CRC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	10.79	0.51	1.93e-23	Nonalcoholic fatty liver disease;
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.38	-6.75	-0.35	6.73e-11	Height;
CRC	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.39	-0.33	5.82e-10	Systemic lupus erythematosus;
CRC	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06307176	chr5:131281290	NA	0.45	6.48	0.34	3.26e-10	Life satisfaction;
CRC	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.65	8.83	0.44	6.18e-17	Coronary artery disease;
CRC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-6.05	-0.32	3.98e-9	Schizophrenia;
CRC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.87	-0.35	3.13e-11	Lung cancer;
CRC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.86	-14.21	-0.62	4.56e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.33	6.48	0.34	3.36e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.42	6.98	0.36	1.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg24463073	chr6:118973353	C6orf204	0.52	6.95	0.36	2e-11	Diastolic blood pressure;
CRC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg00531865	chr16:30841666	NA	-0.44	-5.9	-0.31	8.96e-9	Multiple myeloma;
CRC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.84	15.45	0.65	7.41e-41	Metabolic syndrome;
CRC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.45	-8.29	-0.42	2.9e-15	Reticulocyte fraction of red cells;
CRC	cis	rs9903692	0.954	rs11651097	chr17:46147039	T/C	cg21215337	chr17:46176117	CBX1	0.42	7.78	0.39	9.36e-14	Pulse pressure;
CRC	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg12923728	chr3:195709715	SDHAP1	0.63	7.8	0.4	8.29e-14	Red cell distribution width;
CRC	cis	rs10991814	0.920	rs76309414	chr9:94104882	T/C	cg14446406	chr9:93919335	NA	0.59	6.61	0.34	1.51e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg06470822	chr6:28175283	NA	0.52	7.64	0.39	2.38e-13	Pubertal anthropometrics;
CRC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.85	-0.31	1.16e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06811360	chr17:8089327	NA	0.47	6.12	0.32	2.71e-9	Thyroid stimulating hormone;
CRC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg05139728	chr16:28306816	SBK1	-0.36	-5.72	-0.3	2.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.75	13.6	0.6	1.01e-33	Coronary artery disease;
CRC	cis	rs11212617	0.935	rs227070	chr11:108211412	T/G	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.6	0.3	4.48e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.65	-9.03	-0.45	1.43e-17	Refractive error;
CRC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.57	8.95	0.44	2.66e-17	Aortic root size;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg26289871	chr20:39969385	LPIN3	-0.38	-6.68	-0.35	1.01e-10	Interleukin-6 levels;
CRC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.48	6.71	0.35	8.71e-11	Tuberculosis;
CRC	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg03938978	chr2:103052716	IL18RAP	-0.41	-6.52	-0.34	2.61e-10	Blood protein levels;
CRC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg18764771	chr6:116381957	FRK	0.26	7.45	0.38	8.12e-13	Cholesterol, total;LDL cholesterol;
CRC	trans	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg10756647	chr7:56101905	PSPH	-0.71	-7.13	-0.37	6.57e-12	Diabetic kidney disease;
CRC	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.41	-0.38	1.1e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg20041105	chr8:143859282	LYNX1	-0.4	-6.16	-0.32	2.09e-9	Urinary tract infection frequency;
CRC	cis	rs3126085	0.515	rs11204995	chr1:152359168	C/T	cg09127314	chr1:152161683	NA	-0.44	-5.86	-0.31	1.13e-8	Atopic dermatitis;
CRC	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg00531865	chr16:30841666	NA	0.5	7.03	0.36	1.2e-11	Dementia with Lewy bodies;
CRC	cis	rs35000415	0.938	rs13227075	chr7:128643297	T/C	cg19972273	chr7:128594194	NA	0.68	6.31	0.33	8.75e-10	Systemic lupus erythematosus;
CRC	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	1.06	10.83	0.51	1.42e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg04727332	chr7:45960243	IGFBP3	0.36	5.8	0.3	1.59e-8	Sitting height ratio;
CRC	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	8.89	0.44	4.26e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-8.15	-0.41	7.73e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05759424	chr2:42721296	KCNG3	0.34	6.25	0.33	1.24e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.71	-10.84	-0.51	1.31e-23	Cognitive function;
CRC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.83	-0.31	1.35e-8	Heart rate;
CRC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs6076065	0.612	rs11905630	chr20:23326165	G/C	cg11657817	chr20:23433608	CST11	0.48	7.1	0.36	7.96e-12	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg00290994	chr1:41848739	NA	0.45	6.36	0.33	6.84e-10	Bipolar disorder;
CRC	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.39	-6.28	-0.33	1.08e-9	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg27523141	chr10:43048294	ZNF37B	0.45	6.41	0.33	4.97e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.41	-7.1	-0.36	7.86e-12	Obesity-related traits;
CRC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg09876464	chr15:85330779	ZNF592	0.47	8.14	0.41	8.19e-15	P wave terminal force;
CRC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.84	-10.82	-0.51	1.54e-23	Gut microbiome composition (summer);
CRC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg19812747	chr11:111475976	SIK2	0.42	6.08	0.32	3.39e-9	Primary sclerosing cholangitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05391628	chr12:49463937	RHEBL1	0.52	6.78	0.35	5.72e-11	Thyroid stimulating hormone;
CRC	cis	rs289828	0.868	rs3771888	chr2:152138789	A/G	cg06191203	chr2:152266755	RIF1	-0.4	-5.67	-0.3	3.05e-8	Blood protein levels;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.37	-8.7	-0.43	1.66e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.39	7.31	0.37	2.11e-12	Mean corpuscular volume;
CRC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg06494592	chr3:125709126	NA	-0.55	-6.52	-0.34	2.65e-10	Blood pressure (smoking interaction);
CRC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.49e-12	Motion sickness;
CRC	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.56	-8.67	-0.43	2.06e-16	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Depression;
CRC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg07274523	chr3:49395745	GPX1	0.46	5.93	0.31	7.77e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-8.58	-0.43	3.8e-16	Gut microbiome composition (summer);
CRC	cis	rs6952809	1.000	rs12671804	chr7:2449740	C/T	cg23289794	chr7:2394357	EIF3B	-0.42	-5.6	-0.3	4.45e-8	Multiple sclerosis;
CRC	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg00376283	chr12:123451042	ABCB9	-0.53	-6.55	-0.34	2.15e-10	Neutrophil percentage of white cells;
CRC	trans	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Depression;
CRC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.41	8.05	0.41	1.49e-14	Mean corpuscular volume;
CRC	cis	rs11229555	0.645	rs12800531	chr11:58180099	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg19046167	chr17:80928561	B3GNTL1	0.45	7.12	0.37	6.95e-12	Breast cancer;
CRC	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.78	-15.65	-0.65	1.19e-41	Nonalcoholic fatty liver disease;
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.55	-8.06	-0.41	1.41e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.72	-0.39	1.37e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2857891	0.817	rs2857885	chr11:6967187	G/A	cg04053776	chr11:6947353	ZNF215	0.41	5.86	0.31	1.14e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00338735	chr4:53728038	RASL11B	0.36	5.72	0.3	2.41e-8	Optic nerve measurement (cup area);
CRC	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.05	0.36	1.09e-11	Endometrial cancer;
CRC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.4	6.07	0.32	3.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.5	7.42	0.38	9.77e-13	Corneal astigmatism;
CRC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.81	12.56	0.57	7.87e-30	Menarche (age at onset);
CRC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.67	0.54	1.46e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.4	6.94	0.36	2.09e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.48	7.42	0.38	9.95e-13	Methadone dose in opioid dependence;
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg17724175	chr1:150552817	MCL1	0.49	7.23	0.37	3.34e-12	Melanoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02007493	chr14:105647510	NUDT14	0.47	6.19	0.32	1.8e-9	Anxiety disorder;
CRC	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg26182253	chr13:112236782	NA	0.31	6.25	0.33	1.26e-9	Hepatitis;
CRC	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.82	-0.44	6.77e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg20542592	chr8:11973495	FAM66D	0.33	5.8	0.3	1.58e-8	Retinal vascular caliber;
CRC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.82	18.07	0.71	3.4e-51	Breast cancer;
CRC	trans	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.06	-0.36	1e-11	Menarche (age at onset);
CRC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.85	-0.35	3.7e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.32	2.31e-9	Mean platelet volume;
CRC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.08	-0.55	4.87e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04238871	chr10:126431886	FAM53B	0.49	6.3	0.33	9.75e-10	Thyroid stimulating hormone;
CRC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg19812747	chr11:111475976	SIK2	0.51	7.96	0.4	2.78e-14	Primary sclerosing cholangitis;
CRC	trans	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg18335740	chr13:41363409	SLC25A15	0.53	7.91	0.4	3.82e-14	Lewy body disease;
CRC	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.13	23.68	0.79	4.75e-73	Schizophrenia;
CRC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.92	-0.4	3.58e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3736485	0.844	rs12438892	chr15:51755240	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.48	-0.34	3.38e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3750082	0.889	rs6462431	chr7:32935439	A/G	cg05721444	chr7:32995514	FKBP9	0.49	7.45	0.38	8.12e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg07636037	chr3:49044803	WDR6	-0.65	-6.72	-0.35	7.84e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7209700	0.742	rs7217710	chr17:45370582	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-5.93	-0.31	7.68e-9	IgG glycosylation;
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg03790207	chr6:42947109	PEX6	-0.43	-6.08	-0.32	3.27e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1539053	0.932	rs12038397	chr1:58108237	C/G	cg20292791	chr1:58089357	DAB1	-0.34	-5.85	-0.31	1.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg09085632	chr11:111637200	PPP2R1B	0.49	6.5	0.34	2.99e-10	Primary sclerosing cholangitis;
CRC	cis	rs73200209	0.744	rs61937384	chr12:116698606	G/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.27	-0.37	2.66e-12	Total body bone mineral density;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Parkinson's disease;
CRC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.66	12.04	0.55	6.66e-28	Aortic root size;
CRC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-10.47	-0.5	2.53e-22	Glomerular filtration rate (creatinine);
CRC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	7.44	0.38	9.02e-13	Height;
CRC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12977448	chr10:14920832	SUV39H2	0.45	6.11	0.32	2.81e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg00343986	chr7:65444356	GUSB	0.45	6.24	0.33	1.37e-9	Aortic root size;
CRC	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg25856811	chr1:152973957	SPRR3	-0.21	-5.66	-0.3	3.38e-8	Inflammatory skin disease;
CRC	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.66	-10.92	-0.52	6.61e-24	White blood cell count (basophil);
CRC	cis	rs12580194	0.593	rs61956272	chr12:55779559	A/T	cg23425280	chr12:56401806	NA	0.47	5.66	0.3	3.38e-8	Cancer;
CRC	cis	rs3889199	0.707	rs12402265	chr1:59690602	G/A	cg25881383	chr1:59680599	NA	-0.37	-5.99	-0.31	5.57e-9	Pulse pressure;
CRC	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	15.65	0.65	1.16e-41	Leprosy;
CRC	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Dilated cardiomyopathy;
CRC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21972741	chr5:435613	AHRR	0.54	7.39	0.38	1.21e-12	Cystic fibrosis severity;
CRC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.64	9.93	0.48	1.7e-20	Colonoscopy-negative controls vs population controls;
CRC	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg00531865	chr16:30841666	NA	-0.42	-5.95	-0.31	6.87e-9	Dementia with Lewy bodies;
CRC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-7.72	-0.39	1.38e-13	Aortic root size;
CRC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.67	7.17	0.37	5.14e-12	Axial length;
CRC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	7.24	0.37	3.29e-12	Rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.6	8.92	0.44	3.33e-17	Homoarginine levels;
CRC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.95	0.4	3.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-7.22	-0.37	3.55e-12	Lymphocyte counts;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02090014	chr7:156802340	MNX1	-0.45	-6.06	-0.32	3.7e-9	Diisocyanate-induced asthma;
CRC	cis	rs10242455	0.702	rs73711294	chr7:99088714	G/A	cg18809830	chr7:99032528	PTCD1	-1.32	-9.11	-0.45	8.29e-18	Blood metabolite levels;
CRC	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.01	13.92	0.61	5.81e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6066835	0.867	rs6095276	chr20:47363230	C/T	cg18078177	chr20:47281410	PREX1	0.64	5.84	0.31	1.27e-8	Multiple myeloma;
CRC	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.47	6.94	0.36	2.09e-11	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg06470822	chr6:28175283	NA	0.76	7.09	0.36	8.3e-12	Depression;
CRC	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg14515779	chr1:101123966	NA	-0.46	-8.73	-0.43	1.3e-16	Monocyte count;
CRC	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00376283	chr12:123451042	ABCB9	-0.55	-6.93	-0.36	2.25e-11	Neutrophil percentage of white cells;
CRC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.53	0.47	3.57e-19	Cognitive test performance;
CRC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.83	-0.31	1.3e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.59	-8.69	-0.43	1.69e-16	Alzheimer's disease biomarkers;
CRC	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	5.75	0.3	2.08e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7899719	0.744	rs2395293	chr10:77425125	A/C	cg24369728	chr10:77472158	NA	0.42	6.62	0.34	1.43e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
CRC	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	1.07	17.79	0.7	4.33e-50	Schizophrenia;
CRC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-6.61	-0.34	1.54e-10	Arsenic metabolism;
CRC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg16447950	chr5:562315	NA	-0.85	-12.55	-0.57	8.97e-30	Obesity-related traits;
CRC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg19622623	chr12:86230825	RASSF9	0.37	5.81	0.3	1.49e-8	Major depressive disorder;
CRC	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg24140574	chr1:16342155	HSPB7	0.47	6.67	0.34	1.12e-10	Dilated cardiomyopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14241323	chr18:13824002	NA	0.36	5.99	0.31	5.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1992660	0.504	rs10941505	chr5:40399246	G/A	cg09067459	chr5:40385259	NA	0.45	7.72	0.39	1.36e-13	Crohn's disease;
CRC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.89	9.04	0.45	1.4e-17	Lymphocyte counts;
CRC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg23957660	chr17:17878224	LRRC48	-0.36	-6.73	-0.35	7.6e-11	Total body bone mineral density;
CRC	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	7.98	0.4	2.52e-14	Breast cancer;
CRC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.93	14.19	0.62	5.6e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.44	-0.33	4.16e-10	Life satisfaction;
CRC	cis	rs9392556	0.734	rs648900	chr6:4109422	T/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.23	5.89	0.31	9.41e-9	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01255349	chr12:27676697	PPFIBP1	0.51	6.41	0.33	5.11e-10	Thyroid stimulating hormone;
CRC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.86	-15.66	-0.65	1.12e-41	Body mass index;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00402069	chr5:89770788	POLR3G;MBLAC2	0.42	6.17	0.32	1.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.83	0.4	6.87e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.73	12.26	0.56	9.98e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24971957	chr17:67323276	ABCA5	0.45	6.66	0.34	1.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-9.05	-0.45	1.26e-17	Bipolar disorder;
CRC	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.74	11.89	0.55	2.31e-27	Blood protein levels;
CRC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg10298567	chr3:47292165	KIF9	-0.35	-5.65	-0.3	3.52e-8	Colorectal cancer;
CRC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.42	-8.58	-0.43	3.73e-16	Renal cell carcinoma;
CRC	cis	rs12541635	0.966	rs16873989	chr8:106966381	C/T	cg10147462	chr8:107024639	NA	0.44	7.08	0.36	8.67e-12	Age of smoking initiation;
CRC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.58	9.22	0.45	3.63e-18	Urate levels;
CRC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg23461800	chr14:103021989	NA	0.68	7.6	0.39	3.07e-13	Platelet count;
CRC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg03929089	chr4:120376271	NA	-0.58	-7.41	-0.38	1.06e-12	Intraocular pressure;
CRC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.51	7.2	0.37	4.17e-12	Aortic root size;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg15845792	chr6:28175446	NA	0.95	13.73	0.6	3.05e-34	Parkinson's disease;
CRC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg25985355	chr7:65971099	NA	0.53	6.05	0.32	3.9e-9	Diabetic kidney disease;
CRC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.03	-12.2	-0.56	1.68e-28	Diabetic kidney disease;
CRC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg21620606	chr4:1342894	KIAA1530	0.36	5.91	0.31	8.57e-9	Obesity-related traits;
CRC	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.91	-0.31	8.42e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg12639453	chr1:2035780	PRKCZ	-0.33	-6.21	-0.32	1.59e-9	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18373552	chr10:76871314	SAMD8	0.4	6.34	0.33	7.4e-10	Schizophrenia;
CRC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	9.55	0.47	3.09e-19	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.24	-0.33	1.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg04202892	chr2:111875749	ACOXL	0.42	6.71	0.35	8.69e-11	Chronic lymphocytic leukemia;
CRC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.41	0.33	5.02e-10	IgG glycosylation;
CRC	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	9.49e-20	Hair morphology;
CRC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.44	-6.42	-0.33	4.68e-10	Metabolic traits;LDL cholesterol;
CRC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.37	-0.38	1.41e-12	Monocyte percentage of white cells;
CRC	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.56	-8.41	-0.42	1.29e-15	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.66	8.39	0.42	1.41e-15	Red blood cell traits;
CRC	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.85	-15.14	-0.64	1.15e-39	Colorectal cancer;
CRC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg26762873	chr11:5879799	OR52E8	-0.44	-6.37	-0.33	6.51e-10	DNA methylation (variation);
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.37	0.75	3.12e-60	Prudent dietary pattern;
CRC	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.87e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg14671364	chr1:107599128	PRMT6	0.54	7.22	0.37	3.54e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.46	-7.07	-0.36	9.36e-12	Response to antineoplastic agents;
CRC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg23758597	chr6:163146217	PARK2	-0.64	-6.36	-0.33	6.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.03	0.32	4.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.67	-8.04	-0.41	1.65e-14	Menarche (age at onset);
CRC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.59	7.52	0.38	5.28e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.47	6.72	0.35	8.25e-11	Colorectal cancer;
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg07617317	chr6:118971624	C6orf204	0.5	6.23	0.32	1.44e-9	Diastolic blood pressure;
CRC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.43	-8.39	-0.42	1.41e-15	Ulcerative colitis;
CRC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.52	7.2	0.37	4.22e-12	Response to antidepressants and depression;
CRC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.54e-13	Mean platelet volume;
CRC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.43	6.71	0.35	8.46e-11	Methadone dose in opioid dependence;
CRC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg27588902	chr6:42928151	GNMT	-0.34	-5.61	-0.3	4.2e-8	Blood protein levels;
CRC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.85e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg09003973	chr2:102972529	NA	-0.41	-5.93	-0.31	7.7e-9	Blood protein levels;
CRC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.52e-8	Aortic root size;
CRC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.54	-7.82	-0.4	7.12e-14	Resting heart rate;
CRC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.08e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.49	7.96	0.4	2.8e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.36	6.4	0.33	5.41e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.74	-0.51	2.87e-23	Aortic root size;
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-6.58	-0.34	1.84e-10	Lung function (FEV1/FVC);
CRC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg16141378	chr3:129829833	LOC729375	0.46	6.55	0.34	2.21e-10	Triglycerides;
CRC	cis	rs6691722	0.503	rs7546875	chr1:24703667	T/C	cg02336364	chr1:24764700	NIPAL3	0.37	6.19	0.32	1.74e-9	Response to interferon beta in multiple sclerosis;
CRC	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.43	-6.53	-0.34	2.46e-10	Body mass index;
CRC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.43	0.69	1.13e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.53	6.9	0.36	2.68e-11	Intelligence (multi-trait analysis);
CRC	cis	rs812925	0.559	rs2600667	chr2:61404931	A/T	cg10580144	chr2:61372316	C2orf74	0.36	7.38	0.38	1.28e-12	Immature fraction of reticulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19793034	chr4:1284190	MAEA	0.45	6.39	0.33	5.82e-10	Response to antipsychotic treatment;
CRC	cis	rs1223397	0.651	rs202023	chr6:13304658	C/T	cg07912922	chr6:13274314	PHACTR1	0.39	6.04	0.32	4.28e-9	Blood pressure;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg15845792	chr6:28175446	NA	0.85	8.81	0.44	7.07e-17	Lung cancer in ever smokers;
CRC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.74	-0.3	2.16e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.43	0.5	3.49e-22	Systolic blood pressure;
CRC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.63	-9.29	-0.46	2.2e-18	Menarche (age at onset);
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg01305625	chr5:131593812	PDLIM4	-0.34	-6.0	-0.31	5.15e-9	Acylcarnitine levels;
CRC	cis	rs9928842	0.882	rs4737	chr16:75238103	A/G	cg09066997	chr16:75300724	BCAR1	-0.54	-6.02	-0.32	4.61e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs8005677	0.828	rs2295680	chr14:23374435	A/G	cg25600027	chr14:23388339	RBM23	0.47	7.05	0.36	1.06e-11	Cognitive ability (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.51	0.5	1.81e-22	Menopause (age at onset);
CRC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.03	0.32	4.45e-9	Diabetic retinopathy;
CRC	cis	rs9463078	0.617	rs1359336	chr6:45071874	T/A	cg25276700	chr6:44698697	NA	-0.25	-5.92	-0.31	8.26e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	11.66	0.54	1.6e-26	Mean platelet volume;
CRC	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.21	16.46	0.67	7.76e-45	Mitochondrial DNA levels;
CRC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg15445000	chr17:37608096	MED1	0.36	6.28	0.33	1.08e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-6.48	-0.34	3.33e-10	Metabolite levels;
CRC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.54	7.98	0.4	2.44e-14	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.85	-14.46	-0.62	4.99e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs2084637	1.000	rs67890224	chr11:122400289	C/A	cg21585512	chr11:122030076	LOC399959	-0.4	-7.29	-0.37	2.39e-12	Stroke;
CRC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.58	7.1	0.36	7.7e-12	Response to diuretic therapy;
CRC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg00769240	chr8:12517080	NA	-0.57	-7.05	-0.36	1.04e-11	Blood pressure (smoking interaction);
CRC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.63	-8.94	-0.44	2.81e-17	Obesity-related traits;
CRC	cis	rs2652834	0.950	rs2652815	chr15:63401345	T/C	cg05507819	chr15:63340323	TPM1	0.45	5.76	0.3	1.89e-8	HDL cholesterol;
CRC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg21153622	chr11:89784906	NA	-0.53	-8.9	-0.44	3.8e-17	HDL cholesterol;
CRC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg21251018	chr6:28226885	NKAPL	0.38	5.63	0.3	3.95e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.3	-0.46	2.07e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.59	-7.45	-0.38	8.39e-13	Obesity (extreme);
CRC	cis	rs2579500	0.660	rs6711452	chr2:97139307	G/A	cg23100626	chr2:96804247	ASTL	0.25	6.13	0.32	2.55e-9	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg15468180	chr1:107600409	PRMT6	-0.44	-6.5	-0.34	2.96e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.5	8.73	0.43	1.33e-16	Hypertriglyceridemia;
CRC	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg14458575	chr2:238380390	NA	0.57	7.34	0.38	1.67e-12	Prostate cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20690303	chr4:17513834	QDPR	0.41	6.21	0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg03564338	chr16:50585384	NKD1	-0.54	-6.06	-0.32	3.75e-9	Body mass index;
CRC	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.96	17.67	0.7	1.34e-49	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.54e-21	Asthma;
CRC	cis	rs2811415	0.597	rs56143290	chr3:127737383	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.74	-0.3	2.17e-8	Lung function (FEV1/FVC);
CRC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg03160526	chr17:80928410	B3GNTL1	0.52	8.74	0.43	1.2e-16	Breast cancer;
CRC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.83	7.88	0.4	4.83e-14	Diabetic retinopathy;
CRC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.76	-0.47	6.07e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.95	17.6	0.7	2.43e-49	Cognitive ability;
CRC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg23815491	chr16:72088622	HP	0.51	7.65	0.39	2.3e-13	Fibrinogen levels;
CRC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.64	-9.97	-0.48	1.26e-20	Cognitive test performance;
CRC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.9	-0.36	2.62e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.58	8.7	0.43	1.66e-16	Menopause (age at onset);
CRC	cis	rs977987	0.864	rs37594	chr16:75496943	T/C	cg03315344	chr16:75512273	CHST6	-0.58	-9.62	-0.47	1.8e-19	Dupuytren's disease;
CRC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.16	25.19	0.81	8.85e-79	IgG glycosylation;
CRC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-9.38	-0.46	1.15e-18	Subjective well-being;
CRC	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.64	-6.61	-0.34	1.54e-10	Pediatric areal bone mineral density (radius);
CRC	cis	rs9928842	0.765	rs6564221	chr16:75224971	C/T	cg09066997	chr16:75300724	BCAR1	0.64	6.21	0.32	1.58e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg18827107	chr12:86230957	RASSF9	-0.47	-7.87	-0.4	5.15e-14	Major depressive disorder;
CRC	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-7.34	-0.37	1.73e-12	Response to antipsychotic treatment;
CRC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	0.8	7.17	0.37	4.9e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg03623178	chr6:28175578	NA	0.56	8.03	0.4	1.75e-14	Parkinson's disease;
CRC	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg27398640	chr15:77910606	LINGO1	-0.46	-8.2	-0.41	5.57e-15	Type 2 diabetes;
CRC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.82	-0.4	7.12e-14	Aortic root size;
CRC	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.73	-0.39	1.3e-13	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	7.87	0.4	5.06e-14	Mean corpuscular volume;
CRC	cis	rs4523957	0.928	rs170044	chr17:2197502	C/G	cg16513277	chr17:2031491	SMG6	-0.54	-9.17	-0.45	5.11e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12476592	0.602	rs262476	chr2:63870607	A/G	cg10828910	chr2:63850056	LOC388955	-0.51	-6.3	-0.33	9.67e-10	Childhood ear infection;
CRC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.79	-12.96	-0.58	2.47e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.42	-9.05	-0.45	1.25e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg24289452	chr6:170231220	NA	-0.58	-6.93	-0.36	2.23e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg21951975	chr1:209979733	IRF6	0.45	6.0	0.31	5.12e-9	Cleft lip with or without cleft palate;
CRC	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12431939	0.626	rs7161242	chr14:51716188	A/C	cg23942311	chr14:51606299	NA	0.47	6.26	0.33	1.19e-9	Cancer;
CRC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.35	-5.79	-0.3	1.67e-8	Iron status biomarkers;
CRC	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.5	6.88	0.35	3.12e-11	Venous thromboembolism (SNP x SNP interaction);
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg13957321	chr17:43675089	NA	0.52	6.21	0.32	1.62e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg23298862	chr7:158159286	PTPRN2	0.37	5.77	0.3	1.8e-8	Calcium levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04498971	chr17:56084468	SFRS1	0.43	5.98	0.31	5.89e-9	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.52	0.46	3.79e-19	Bladder cancer;
CRC	cis	rs698833	0.926	rs786620	chr2:44595803	C/T	cg04920474	chr2:44395004	PPM1B	0.42	6.24	0.33	1.37e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7671266	0.589	rs10938772	chr4:10375328	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.14	-0.32	2.34e-9	Cardiovascular disease risk factors;
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.99	0.36	1.51e-11	Renal cell carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17239761	chr22:21213665	SNAP29;PI4KA	0.41	6.27	0.33	1.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.5	-7.6	-0.39	3.1e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.57	-8.14	-0.41	8.35e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07513332	chr6:167530253	CCR6	0.4	7.21	0.37	3.86e-12	Crohn's disease;
CRC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.65	-10.2	-0.49	2.14e-21	Height;
CRC	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.42	-5.86	-0.31	1.14e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.42	-6.74	-0.35	7.25e-11	Type 1 diabetes;
CRC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg04498913	chr7:1135747	C7orf50	-0.51	-5.98	-0.31	5.81e-9	Bronchopulmonary dysplasia;
CRC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01200585	chr1:228362443	C1orf69	0.39	5.73	0.3	2.22e-8	Diastolic blood pressure;
CRC	cis	rs9311676	0.656	rs55783924	chr3:58403610	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg08755490	chr11:65554678	OVOL1	0.44	6.34	0.33	7.57e-10	Acne (severe);
CRC	trans	rs8078472	0.614	rs12950148	chr17:12872802	A/G	cg02659581	chr1:3467842	MEGF6	0.39	6.11	0.32	2.77e-9	Joint mobility (Beighton score);
CRC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.67	-0.43	2e-16	Uric acid levels;
CRC	cis	rs7546094	1.000	rs11102497	chr1:113109274	T/C	cg22162597	chr1:113214053	CAPZA1	0.43	5.94	0.31	7.2e-9	Platelet distribution width;
CRC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	15.56	0.65	2.69e-41	Smoking behavior;
CRC	trans	rs3819340	0.558	rs73162911	chr3:148629012	C/A	cg03707696	chr10:81075467	ZMIZ1	0.71	5.96	0.31	6.39e-9	LDL peak particle diameter (total fat intake interaction);
CRC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.69	11.33	0.53	2.39e-25	Menarche (age at onset);
CRC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.37	-8.49	-0.42	7.29e-16	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00441754	chr19:45394894	TOMM40	0.45	6.83	0.35	3.99e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.51	-8.21	-0.41	5.11e-15	Resting heart rate;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.03	-0.36	1.19e-11	Breast cancer;
CRC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.49	0.34	3.16e-10	Testicular germ cell tumor;
CRC	cis	rs6545883	0.507	rs6545855	chr2:61532860	G/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.65	-0.39	2.23e-13	Tuberculosis;
CRC	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.48	-0.38	6.8e-13	Caudate activity during reward;
CRC	trans	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg05679027	chr9:99775184	HIATL2	-0.43	-6.5	-0.34	2.91e-10	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg20607798	chr8:58055168	NA	0.55	5.91	0.31	8.36e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.28	-0.37	2.46e-12	Lymphocyte counts;
CRC	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-7.95	-0.4	2.92e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.18	0.74	1.67e-59	Prudent dietary pattern;
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13198984	chr17:80129470	CCDC57	0.47	8.31	0.42	2.54e-15	Life satisfaction;
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg10729496	chr3:10149963	C3orf24	0.51	6.89	0.35	2.92e-11	Alzheimer's disease;
CRC	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-6.82	-0.35	4.32e-11	Schizophrenia;
CRC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.49	-8.34	-0.42	2e-15	Facial morphology (factor 20);
CRC	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.62	12.56	0.57	7.84e-30	Weight;
CRC	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.49	-0.42	7.05e-16	Depression;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12273811	chr6:28175739	NA	0.62	8.22	0.41	4.78e-15	Parkinson's disease;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs983332	0.512	rs6428657	chr1:88212380	C/T	cg09221037	chr5:1523205	LPCAT1	-0.64	-6.05	-0.32	3.92e-9	Response to TNF antagonist treatment;
CRC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg17321639	chr7:2759063	NA	-0.44	-6.1	-0.32	2.96e-9	Height;
CRC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.99	-17.1	-0.69	2.36e-47	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.71	-0.3	2.47e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.74	0.39	1.26e-13	Cognitive ability;
CRC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.29	0.33	1.01e-9	Hip circumference adjusted for BMI;
CRC	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-0.8	-7.67	-0.39	2e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.76	-12.1	-0.55	4.09e-28	Multiple myeloma;
CRC	cis	rs2882667	0.898	rs12719519	chr5:138375687	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-6.04	-0.32	4.07e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg03030879	chr14:75389066	RPS6KL1	0.42	6.38	0.33	5.95e-10	Height;
CRC	cis	rs9903692	0.862	rs12943543	chr17:46181365	A/T	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg08772003	chr10:104629869	AS3MT	-0.36	-6.11	-0.32	2.84e-9	Arsenic metabolism;
CRC	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg08999081	chr20:33150536	PIGU	0.44	5.71	0.3	2.52e-8	Protein C levels;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.6	9.55	0.47	3.1e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs17166499	0.803	rs73070141	chr7:12897219	A/G	cg12945054	chr7:12841881	NA	0.49	6.06	0.32	3.75e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.64	7.93	0.4	3.38e-14	Cocaine dependence;
CRC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.71	-9.3	-0.46	1.95e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3996993	0.809	rs6932500	chr6:52665671	G/A	cg20803780	chr6:52668592	GSTA1	0.35	6.37	0.33	6.23e-10	Hemoglobin concentration;
CRC	cis	rs17234274	0.622	rs10833976	chr11:23221991	C/G	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.02e-8	Cancer;
CRC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	7.16	0.37	5.28e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.87	18.96	0.72	1.04e-54	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.43	6.22	0.32	1.5e-9	Height;
CRC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.56	6.27	0.33	1.15e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.37	5.62	0.3	4.11e-8	Height;
CRC	trans	rs10504390	0.585	rs117486340	chr8:66542077	G/A	cg26403416	chr21:43771339	TFF2	0.6	6.14	0.32	2.38e-9	IgG glycosylation;
CRC	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.86	-10.13	-0.49	3.56e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg23102388	chr7:1867652	MAD1L1	-0.31	-5.83	-0.31	1.34e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.88	11.92	0.55	1.84e-27	Initial pursuit acceleration;
CRC	cis	rs7705042	0.897	rs7718955	chr5:141521459	A/G	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.5e-8	Asthma;
CRC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.54	-8.85	-0.44	5.62e-17	Huntington's disease progression;
CRC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.22	0.32	1.48e-9	Hemoglobin concentration;
CRC	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg08645402	chr16:4508243	NA	0.49	6.45	0.34	3.89e-10	Schizophrenia;
CRC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.0	0.44	1.81e-17	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08621418	chr6:79944414	HMGN3	0.42	6.36	0.33	6.74e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	6.08	0.32	3.33e-9	Menarche (age at onset);
CRC	cis	rs629535	0.821	rs680993	chr8:70050247	G/A	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.59e-8	Dupuytren's disease;
CRC	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.39	-5.76	-0.3	1.95e-8	Metabolic traits;
CRC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-10.82	-0.51	1.51e-23	Body mass index;
CRC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.4	-0.33	5.48e-10	Aortic root size;
CRC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.57	-9.51	-0.46	4.26e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg11003573	chr3:44754125	ZNF502	-0.33	-5.71	-0.3	2.51e-8	Depressive symptoms;
CRC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	11.69	0.54	1.24e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg26608667	chr7:1196370	ZFAND2A	0.42	6.86	0.35	3.4e-11	Longevity;Endometriosis;
CRC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.49	-0.34	3.19e-10	Breast cancer;
CRC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-10.44	-0.5	3.25e-22	Personality dimensions;
CRC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.4	-6.31	-0.33	9.05e-10	Blood metabolite levels;
CRC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	8.68	0.43	1.83e-16	Height;
CRC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.75	-0.51	2.77e-23	Bipolar disorder;
CRC	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-0.88	-8.64	-0.43	2.48e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg02023728	chr11:77925099	USP35	-0.37	-6.24	-0.33	1.33e-9	Alzheimer's disease (survival time);
CRC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg05044414	chr3:183734942	ABCC5	0.37	6.15	0.32	2.23e-9	Anterior chamber depth;
CRC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.07	-0.49	5.62e-21	Monocyte count;
CRC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.51	8.45	0.42	9.69e-16	Aortic root size;
CRC	cis	rs6499129	0.558	rs16957489	chr16:67651879	G/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-7.89	-0.4	4.61e-14	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs4664293	0.582	rs1046496	chr2:160473399	A/T	cg08347373	chr2:160653686	CD302	-0.39	-6.54	-0.34	2.38e-10	Monocyte percentage of white cells;
CRC	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg10724054	chr17:3904396	NA	-0.37	-5.91	-0.31	8.32e-9	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.17	-0.32	2.06e-9	Daytime sleep phenotypes;
CRC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-7.83	-0.4	6.56e-14	Bipolar disorder;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.23	-0.37	3.32e-12	Lymphocyte counts;
CRC	trans	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	6.47	0.34	3.5e-10	Mean corpuscular volume;
CRC	cis	rs2033908	0.589	rs4757060	chr11:12842990	G/A	cg25843174	chr11:12811716	TEAD1	-0.38	-6.73	-0.35	7.55e-11	Sitting height ratio;
CRC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.8	-0.3	1.53e-8	Vitiligo;
CRC	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	cg04338863	chr8:33670619	NA	0.38	6.52	0.34	2.66e-10	Body mass index;
CRC	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.85	-15.13	-0.64	1.23e-39	Itch intensity from mosquito bite;
CRC	cis	rs7901135	1.000	rs2393502	chr10:60560334	G/C	cg23799393	chr10:60588674	BICC1	0.4	6.37	0.33	6.34e-10	Morning vs. evening chronotype;
CRC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.31	0.42	2.51e-15	Colorectal cancer;
CRC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02018176	chr4:1364513	KIAA1530	0.43	7.03	0.36	1.23e-11	Obesity-related traits;
CRC	cis	rs6662572	0.686	rs884443	chr1:46484421	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.9	0.31	8.81e-9	Blood protein levels;
CRC	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg14092571	chr14:90743983	NA	0.39	5.94	0.31	7.29e-9	Mortality in heart failure;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg21169611	chr9:106856078	SMC2	0.44	6.11	0.32	2.75e-9	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4930561	0.714	rs7126326	chr11:67947275	T/G	cg04465784	chr11:67976953	SUV420H1	-0.3	-6.16	-0.32	2.12e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg07195577	chr17:27052828	TLCD1	0.41	5.97	0.31	6.23e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.47	7.66	0.39	2.03e-13	Red cell distribution width;
CRC	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.82	10.85	0.51	1.21e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.95	-0.31	6.72e-9	Type 2 diabetes;
CRC	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.46	-6.56	-0.34	2.1e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.12	-0.41	9.45e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg13385794	chr1:248469461	NA	0.36	6.34	0.33	7.63e-10	Common traits (Other);
CRC	cis	rs9322817	0.691	rs12203954	chr6:105295647	C/T	cg02098413	chr6:105308735	HACE1	0.44	8.7	0.43	1.61e-16	Thyroid stimulating hormone;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg04518342	chr5:131593106	PDLIM4	0.38	7.1	0.36	7.78e-12	Blood metabolite levels;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg09226173	chr5:122111107	SNX2	0.4	6.05	0.32	3.98e-9	Crohn's disease;
CRC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.14	-0.45	6.51e-18	Schizophrenia;
CRC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.86	-0.58	6.05e-31	Ulcerative colitis;
CRC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg06204229	chr3:52865917	ITIH4	0.5	5.93	0.31	7.74e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.52	-9.14	-0.45	6.51e-18	Sense of smell;
CRC	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.68	-9.59	-0.47	2.37e-19	Personality dimensions;
CRC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg03233332	chr7:66118400	NA	-0.43	-5.95	-0.31	6.75e-9	Aortic root size;
CRC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.78	0.66	3.78e-42	Intelligence (multi-trait analysis);
CRC	cis	rs4664293	0.867	rs3732289	chr2:160585398	G/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	0.87	7.35	0.38	1.55e-12	Pediatric areal bone mineral density (radius);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12598007	chr11:68607069	CPT1A	0.43	6.13	0.32	2.53e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.55	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs812925	0.762	rs3213951	chr2:61622251	C/T	cg10580144	chr2:61372316	C2orf74	0.3	6.12	0.32	2.61e-9	Immature fraction of reticulocytes;
CRC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.58	7.74	0.39	1.27e-13	Response to diuretic therapy;
CRC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.6	9.25	0.45	2.97e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.81	-0.4	7.79e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg24562669	chr7:97807699	LMTK2	-0.44	-7.48	-0.38	6.94e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.59	10.91	0.52	7.16e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.53	8.12	0.41	9.16e-15	Axial length;
CRC	cis	rs7259376	0.840	rs8106611	chr19:22569618	G/A	cg02657401	chr19:22469223	NA	-0.31	-6.7	-0.35	9.22e-11	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01269469	chr7:155090211	INSIG1	0.44	6.0	0.31	5.3300000000000004e-09	Response to antipsychotic treatment;
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.65	10.27	0.49	1.16e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.31	0.46	1.85e-18	High light scatter reticulocyte count;
CRC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg24675056	chr1:15929824	NA	0.53	7.36	0.38	1.51e-12	Systolic blood pressure;
CRC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.43	-0.33	4.47e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.64	-0.34	1.28e-10	Major depressive disorder;
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	4.89e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.87	-12.19	-0.56	1.84e-28	Schizophrenia;
CRC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.86e-30	Blood trace element (Zn levels);
CRC	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.74	9.57	0.47	2.68e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs11574514	1.000	rs11861657	chr16:67824395	A/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-6.02	-0.32	4.59e-9	Crohn's disease;
CRC	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.9	-0.31	8.95e-9	Reticulocyte fraction of red cells;
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.8	0.3	1.53e-8	Prudent dietary pattern;
CRC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.99	0.31	5.38e-9	Height;
CRC	cis	rs3087591	0.708	rs10445402	chr17:29661340	G/T	cg24425628	chr17:29625626	OMG;NF1	0.73	13.21	0.59	3.03e-32	Hip circumference;
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.44	6.38	0.33	5.94e-10	Menarche (age at onset);
CRC	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.61	0.34	1.53e-10	Blood protein levels;
CRC	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.56	-8.57	-0.43	4.05e-16	HDL cholesterol;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg03623178	chr6:28175578	NA	0.92	12.19	0.56	1.91e-28	Depression;
CRC	trans	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg24628676	chr5:59189846	PDE4D	-0.3	-6.03	-0.32	4.44e-9	Urinary tract infection frequency;
CRC	trans	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg02869306	chr7:64672164	INTS4L1	0.42	6.01	0.31	4.85e-9	Aortic root size;
CRC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.53	7.62	0.39	2.65e-13	Type 2 diabetes;
CRC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.84	12.58	0.57	6.99e-30	Platelet distribution width;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.58	-9.8	-0.48	4.58e-20	Multiple sclerosis;Ankylosing spondylitis;
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.43e-10	Bipolar disorder;
CRC	cis	rs17234274	0.622	rs2170596	chr11:23234445	C/G	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.8e-8	Colorectal cancer;
CRC	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg06632207	chr12:54070931	ATP5G2	0.48	8.39	0.42	1.49e-15	Height;
CRC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg01949993	chr1:183155116	LAMC2	-0.33	-5.8	-0.3	1.59e-8	Hypertriglyceridemia;
CRC	cis	rs7605827	0.930	rs7608831	chr2:15605029	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs12983728	0.505	rs12460050	chr19:58666109	G/A	cg21294424	chr19:58662284	ZNF329	0.5	6.44	0.33	4.34e-10	Cholesterol, total;
CRC	trans	rs492478	0.892	rs11950510	chr5:3943222	T/A	cg09199442	chr11:28132951	METT5D1	-0.7	-6.1	-0.32	2.89e-9	Cognitive performance;
CRC	cis	rs6735179	1.000	rs1124200	chr2:1778558	A/G	cg19300414	chr2:1746591	PXDN	0.37	6.32	0.33	8.53e-10	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21083161	chr7:6388591	C7orf70	0.44	6.04	0.32	4.15e-9	Anxiety disorder;
CRC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.51	6.88	0.35	3.01e-11	Resistin levels;
CRC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.58	8.71	0.43	1.46e-16	Schizophrenia;
CRC	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg16141378	chr3:129829833	LOC729375	0.41	6.18	0.32	1.94e-9	Joint mobility (Beighton score);
CRC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.92	-0.4	3.81e-14	Educational attainment;
CRC	cis	rs7635838	0.859	rs9869977	chr3:11480081	C/A	cg00170343	chr3:11313890	ATG7	0.42	6.37	0.33	6.23e-10	HDL cholesterol;
CRC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.56	-6.61	-0.34	1.56e-10	Body mass index;
CRC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-6.25	-0.33	1.25e-9	Schizophrenia;
CRC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.68	-11.22	-0.53	5.94e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.54	7.38	0.38	1.28e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.19	-0.32	1.74e-9	Breast cancer;
CRC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg21285383	chr16:89894308	SPIRE2	0.34	5.72	0.3	2.4e-8	Vitiligo;
CRC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.53	-8.28	-0.42	3.1e-15	Corneal astigmatism;
CRC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.56	8.21	0.41	5.15e-15	Obesity-related traits;
CRC	trans	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg07817883	chr1:32538562	TMEM39B	-0.63	-7.9	-0.4	4.1e-14	Monocyte percentage of white cells;
CRC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	1.02	18.12	0.71	2.13e-51	Parkinson's disease;
CRC	trans	rs924135	0.634	rs171583	chr16:16132332	A/G	cg06794141	chr16:77535527	NA	0.41	6.12	0.32	2.65e-9	White blood cell count (basophil);Blood metabolite levels;
CRC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-6.83	-0.35	4.05e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10960666	chr17:33446614	RAD51L3	0.46	6.5	0.34	2.92e-10	Response to antipsychotic treatment;
CRC	cis	rs11229555	0.645	rs10466679	chr11:58188257	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.2	-0.49	2.15e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg12856521	chr11:46389249	DGKZ	0.46	7.55	0.38	4.22e-13	Leprosy;
CRC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.38	5.86	0.31	1.11e-8	Red blood cell count;
CRC	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.67	-0.3	3.18e-8	Tuberculosis;
CRC	cis	rs17362650	0.653	rs12474647	chr2:9554280	A/T	cg23886495	chr2:9695866	ADAM17	-0.47	-5.89	-0.31	9.69e-9	Alcohol dependence (age at onset);
CRC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.39	0.46	9.96e-19	IgG glycosylation;
CRC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg23533926	chr12:111358616	MYL2	0.47	6.83	0.35	4.16e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.51	6.89	0.36	2.89e-11	Morning vs. evening chronotype;
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.22e-9	Diastolic blood pressure;
CRC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.81	0.4	7.95e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.58	-7.98	-0.4	2.47e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.56	-0.47	2.8e-19	Migraine;Coronary artery disease;
CRC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg25356066	chr3:128598488	ACAD9	0.39	5.66	0.3	3.22e-8	IgG glycosylation;
CRC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	1.03	13.43	0.59	4.47e-33	Cerebrospinal P-tau181p levels;
CRC	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.54	-0.34	2.36e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.07	0.45	1.14e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.46	6.73	0.35	7.69e-11	Pulmonary function decline;
CRC	cis	rs11098699	0.821	rs11731898	chr4:124220979	C/A	cg09941581	chr4:124220074	SPATA5	0.43	6.39	0.33	5.51e-10	Mosquito bite size;
CRC	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.99	21.34	0.76	4.66e-64	Metabolite levels;
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg07617317	chr6:118971624	C6orf204	0.52	6.47	0.34	3.53e-10	Diastolic blood pressure;
CRC	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg07506560	chr2:240697449	NA	-0.36	-5.72	-0.3	2.38e-8	Obesity-related traits;
CRC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.59	-7.86	-0.4	5.58e-14	IgG glycosylation;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.41	-6.06	-0.32	3.78e-9	Electroencephalogram traits;
CRC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg25204440	chr1:209979598	IRF6	0.48	5.83	0.31	1.35e-8	Cleft lip with or without cleft palate;
CRC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.46	6.35	0.33	7.11e-10	Parkinson's disease;
CRC	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.52	7.45	0.38	8.21e-13	Ovarian reserve;
CRC	cis	rs9469890	0.604	rs76452512	chr6:34504388	G/C	cg17674042	chr6:34482479	PACSIN1	-0.66	-7.72	-0.39	1.4e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.55	6.18	0.32	1.85e-9	Obesity-related traits;
CRC	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.87	-13.23	-0.59	2.44e-32	Schizophrenia;
CRC	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	1.01	8.53	0.43	5.54e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg24910161	chr17:38119198	GSDMA	-0.37	-5.97	-0.31	6.2e-9	Asthma;
CRC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.02	-0.4	1.91e-14	Menarche (age at onset);
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.57	10.22	0.49	1.83e-21	Acylcarnitine levels;
CRC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.86	14.88	0.63	1.18e-38	Coronary artery disease;
CRC	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-0.74	-7.66	-0.39	2.13e-13	Blood protein levels;
CRC	cis	rs4728302	0.807	rs10226267	chr7:133601862	G/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.51	-0.34	2.84e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-6.42	-0.33	4.64e-10	Coronary artery disease;
CRC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.64	-13.32	-0.59	1.1e-32	Schizophrenia;
CRC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.56	0.34	2.04e-10	Lung cancer;
CRC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg09127314	chr1:152161683	NA	0.52	6.81	0.35	4.79e-11	Atopic dermatitis;
CRC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.49	-7.13	-0.37	6.36e-12	Schizophrenia;
CRC	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg23387468	chr7:139079360	LUC7L2	-0.42	-7.25	-0.37	2.96e-12	Diisocyanate-induced asthma;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.47	-0.46	5.62e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.38	5.72	0.3	2.44e-8	Menarche (age at onset);
CRC	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.52	8.63	0.43	2.58e-16	Aortic root size;
CRC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.82	13.67	0.6	5.17e-34	Menopause (age at onset);
CRC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.41	-9.01	-0.44	1.72e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs4481887	0.508	rs6695316	chr1:248394322	G/C	cg00666640	chr1:248458726	OR2T12	0.45	7.05	0.36	1.05e-11	Common traits (Other);
CRC	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg09455208	chr3:40491958	NA	-0.3	-6.06	-0.32	3.83e-9	Renal cell carcinoma;
CRC	cis	rs9462027	0.628	rs2492860	chr6:34705530	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.67	7.3	0.37	2.25e-12	Childhood ear infection;
CRC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg22110888	chr17:80059540	CCDC57	0.43	6.66	0.34	1.17e-10	Life satisfaction;
CRC	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.56	7.82	0.4	7.31e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6504622	0.875	rs4968250	chr17:45045351	C/G	cg16759221	chr17:45003025	GOSR2	-0.54	-8.49	-0.42	7.18e-16	Orofacial clefts;
CRC	cis	rs4731207	0.591	rs1471571	chr7:124650874	C/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg23202291	chr11:1979235	NA	0.48	6.59	0.34	1.78e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.53	9.0	0.44	1.89e-17	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.3	12.44	0.57	2.31e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.57	-9.03	-0.45	1.5e-17	Electroencephalogram traits;
CRC	trans	rs2676917	1.000	rs2676917	chr3:194737873	A/C	cg23928234	chr4:184235706	WWC2	0.39	6.16	0.32	2.12e-9	Metabolite levels (Pyroglutamine);
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg15147215	chr3:52552868	STAB1	-0.59	-9.36	-0.46	1.26e-18	Bipolar disorder;
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg23555395	chr2:238036564	NA	0.58	9.42	0.46	8.38e-19	Systemic lupus erythematosus;
CRC	cis	rs9969804	0.905	rs6479427	chr9:95428016	C/T	cg14631576	chr9:95140430	CENPP	0.33	6.12	0.32	2.73e-9	Height;
CRC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.62	10.57	0.5	1.11e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg18764771	chr6:116381957	FRK	0.26	7.45	0.38	8.21e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg12516270	chr8:143859308	LYNX1	-0.39	-6.44	-0.33	4.17e-10	Urinary tract infection frequency;
CRC	trans	rs10021731	0.692	rs10031142	chr4:115409589	G/A	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.39	-5.91	-0.31	8.48e-9	Monocyte count;
CRC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	13.46	0.6	3.28e-33	Chronic sinus infection;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg08200582	chr11:442649	ANO9	-0.69	-7.15	-0.37	5.65e-12	Body mass index;
CRC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-7.1	-0.36	7.59e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.27	-0.41	3.39e-15	Body mass index;
CRC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.73	-0.35	7.76e-11	Alzheimer's disease (late onset);
CRC	cis	rs6700896	0.931	rs11208711	chr1:66147846	G/T	cg04111102	chr1:66153794	NA	0.34	5.8	0.3	1.56e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.55	7.45	0.38	8.31e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.85	0.55	3.25e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04464465	chr12:123755775	CDK2AP1	0.43	5.97	0.31	6.28e-9	Response to antipsychotic treatment;
CRC	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.41	-7.4	-0.38	1.11e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg06346307	chr22:19949965	COMT	-0.23	-5.93	-0.31	7.67e-9	Blood metabolite levels;
CRC	cis	rs4663866	1.000	rs6741269	chr2:239179418	A/G	cg16914508	chr2:239161102	PER2	0.77	7.86	0.4	5.51e-14	Irritable bowel syndrome;
CRC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.14	0.37	5.86e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.58	-9.49	-0.46	5.01e-19	Body mass index;
CRC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	13.17	0.59	4.16e-32	Chronic sinus infection;
CRC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg11632617	chr15:75315747	PPCDC	-0.53	-7.1	-0.36	7.9e-12	Blood trace element (Zn levels);
CRC	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-5.67	-0.3	3.12e-8	Neuroticism;
CRC	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg26116260	chr4:7069785	GRPEL1	-0.6	-5.81	-0.31	1.48e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.08	0.36	8.98e-12	Rheumatoid arthritis;
CRC	cis	rs6694672	1.000	rs5997	chr1:197030201	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.51	0.38	5.72e-13	Asthma;
CRC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.8	11.81	0.55	4.58e-27	Cognitive function;
CRC	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.61	9.88	0.48	2.43e-20	Itch intensity from mosquito bite;
CRC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg12064134	chr16:90016061	DEF8	-0.6	-5.6	-0.3	4.47e-8	Skin colour saturation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21211866	chr9:35111727	KIAA1539	0.51	6.63	0.34	1.35e-10	Thyroid stimulating hormone;
CRC	cis	rs1192419	0.502	rs6681883	chr1:92054131	A/G	cg24006770	chr1:92056542	NA	0.56	9.39	0.46	1.05e-18	Optic disc area;Optic nerve measurement (cup-to-disc ratio);
CRC	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.67	-9.21	-0.45	3.84e-18	Vitiligo;
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.57e-12	Life satisfaction;
CRC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg20573242	chr4:122745356	CCNA2	0.4	6.0	0.31	5.17e-9	Type 2 diabetes;
CRC	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg18806716	chr10:30721971	MAP3K8	-0.54	-7.33	-0.37	1.85e-12	Itch intensity from mosquito bite;
CRC	cis	rs2735413	0.837	rs4888734	chr16:78083685	C/G	cg04733911	chr16:78082701	NA	-0.45	-7.42	-0.38	1.03e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.74	-0.39	1.24e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs3741151	0.892	rs7102787	chr11:73012614	A/G	cg17517138	chr11:73019481	ARHGEF17	0.69	7.28	0.37	2.48e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs1901167	1.000	rs3828509	chr5:40961873	A/G	cg07701837	chr2:210516795	MAP2	0.37	5.98	0.31	5.85e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.57	-9.14	-0.45	6.68e-18	Body mass index;
CRC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg03030879	chr14:75389066	RPS6KL1	0.43	6.54	0.34	2.35e-10	Height;
CRC	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.13	0.32	2.46e-9	Ovarian reserve;
CRC	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.74	13.39	0.59	5.98e-33	Coronary artery disease;
CRC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg08213375	chr14:104286397	PPP1R13B	0.37	5.79	0.3	1.66e-8	Reticulocyte count;
CRC	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg23555395	chr2:238036564	NA	0.44	7.19	0.37	4.34e-12	Systemic lupus erythematosus;
CRC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg05501817	chr11:14380813	RRAS2	-0.45	-5.94	-0.31	7.15e-9	Sense of smell;
CRC	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-5.79	-0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg05874882	chr4:1763078	NA	-0.36	-6.62	-0.34	1.5e-10	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.25	0.37	3.06e-12	Aortic root size;
CRC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.89	0.36	2.78e-11	Bone mineral density (spine);
CRC	cis	rs17095355	1.000	rs55683820	chr10:111665376	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.53	-6.07	-0.32	3.43e-9	Biliary atresia;
CRC	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg12072164	chr19:44306565	LYPD5	0.41	6.5	0.34	2.89e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.75	-0.43	1.1e-16	Hemoglobin concentration;
CRC	cis	rs2481665	0.740	rs2457831	chr1:62633581	C/T	cg18591186	chr1:62594603	INADL	0.45	6.45	0.33	4.02e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8170	1.000	rs73509996	chr19:17393449	T/G	cg04749549	chr19:17459798	NA	-0.46	-6.16	-0.32	2.13e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg00769240	chr8:12517080	NA	-0.57	-7.09	-0.36	8.4e-12	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18912574	chr7:65842487	NCRNA00174	0.35	5.87	0.31	1.05e-8	Aortic root size;
CRC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.78	-0.8	1.85e-73	Myeloid white cell count;
CRC	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.92	0.44	3.28e-17	Mean corpuscular volume;
CRC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.87	0.31	1.07e-8	Major depressive disorder;
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.22e-9	Life satisfaction;
CRC	cis	rs62408225	0.894	rs4707609	chr6:90946479	T/C	cg06866423	chr6:90926672	BACH2	0.44	7.12	0.37	6.97e-12	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.62	-8.3	-0.42	2.78e-15	Refractive error;
CRC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.77	-10.93	-0.52	6.36e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg25164649	chr6:28176230	NA	0.55	7.41	0.38	1.1e-12	Parkinson's disease;
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg23533926	chr12:111358616	MYL2	0.52	7.74	0.39	1.27e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.76	11.47	0.53	7.42e-26	Menarche (age at onset);
CRC	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7703744	0.634	rs73237292	chr5:118688520	A/T	cg17471836	chr5:118691007	TNFAIP8	0.42	5.91	0.31	8.71e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.818	rs61811862	chr1:152995668	G/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.73	-0.35	7.68e-11	Inflammatory skin disease;
CRC	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.94	11.8	0.55	5e-27	Exhaled nitric oxide levels;
CRC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg08807892	chr2:162101083	NA	0.45	6.64	0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.63	0.3	3.86e-8	Major depressive disorder;
CRC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.72	-0.47	8.69e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.4	-0.38	1.13e-12	Reticulocyte fraction of red cells;
CRC	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.36	5.73	0.3	2.24e-8	Educational attainment;
CRC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg04756853	chr17:38118787	GSDMA	-0.38	-5.81	-0.3	1.49e-8	Asthma;
CRC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg25767906	chr1:53392781	SCP2	-0.39	-6.17	-0.32	2.01e-9	Monocyte count;
CRC	cis	rs10888329	0.744	rs4916082	chr1:248367415	C/T	cg00666640	chr1:248458726	OR2T12	0.43	6.96	0.36	1.8e-11	Autism spectrum disorder;
CRC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg21155852	chr7:2048760	MAD1L1	0.42	5.89	0.31	9.57e-9	Bipolar disorder;
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.62e-9	Bipolar disorder;
CRC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg03351412	chr1:154909251	PMVK	0.51	7.22	0.37	3.73e-12	Prostate cancer;
CRC	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.92	7.7	0.39	1.63e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg06470822	chr6:28175283	NA	0.82	12.06	0.55	5.37e-28	Cardiac Troponin-T levels;
CRC	trans	rs12200782	0.649	rs9467743	chr6:26386506	T/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs7726414	1.000	rs115808154	chr5:133464275	A/G	cg11781344	chr5:133706657	UBE2B	0.68	6.92	0.36	2.41e-11	Systemic lupus erythematosus;
CRC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg00603274	chr11:61596626	FADS2	-0.44	-6.4	-0.33	5.33e-10	Trans fatty acid levels;
CRC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.16	-0.37	5.38e-12	Personality dimensions;
CRC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.82	13.6	0.6	9.77e-34	Menopause (age at onset);
CRC	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-8.65	-0.43	2.28e-16	Blood pressure (smoking interaction);
CRC	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg24375607	chr4:120327624	NA	0.48	7.28	0.37	2.43e-12	Corneal astigmatism;
CRC	cis	rs755249	0.567	rs16826093	chr1:39815143	T/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.45	-6.01	-0.31	4.94e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg22777020	chr22:31556080	RNF185	-0.52	-5.97	-0.31	6.27e-9	Colorectal cancer;
CRC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-11.59	-0.54	2.73e-26	Asthma;
CRC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg11189052	chr15:85197271	WDR73	0.62	9.12	0.45	7.59e-18	Schizophrenia;
CRC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.81	0.35	4.72e-11	Axial length;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02360337	chr11:65627185	MUS81;CFL1	0.48	6.6	0.34	1.68e-10	Response to antipsychotic treatment;
CRC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.72	-0.35	8.2e-11	Bipolar disorder;
CRC	cis	rs3789045	1.000	rs45501495	chr1:204596454	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-7.01	-0.36	1.34e-11	Educational attainment (college completion);
CRC	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.89	13.4	0.59	5.88e-33	Blood pressure (smoking interaction);
CRC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg15848620	chr12:58087721	OS9	-0.66	-9.19	-0.45	4.44e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs524281	0.814	rs1055615	chr11:65846922	C/G	cg16950941	chr11:66035639	RAB1B	-0.61	-7.65	-0.39	2.25e-13	Electroencephalogram traits;
CRC	cis	rs6586163	0.872	rs1800682	chr10:90749963	A/G	cg13456138	chr10:90753195	FAS	-0.4	-6.15	-0.32	2.19e-9	Chronic lymphocytic leukemia;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.37	0.38	1.37e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg04796162	chr7:45961102	IGFBP3	0.4	6.86	0.35	3.4e-11	Sitting height ratio;
CRC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.89	-10.02	-0.48	8.61e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.66	-0.39	2.09e-13	Gut microbiome composition (summer);
CRC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.6	11.12	0.52	1.31e-24	Immature fraction of reticulocytes;
CRC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.49e-16	Homoarginine levels;
CRC	trans	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs17095355	1.000	rs12571872	chr10:111676114	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.53	-6.03	-0.32	4.49e-9	Biliary atresia;
CRC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06544989	chr22:39130855	UNC84B	0.43	6.32	0.33	8.54e-10	Menopause (age at onset);
CRC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg21153622	chr11:89784906	NA	-0.37	-5.96	-0.31	6.37e-9	Coronary artery disease;
CRC	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg07699608	chr10:75541558	CHCHD1	0.59	6.08	0.32	3.34e-9	Incident atrial fibrillation;
CRC	cis	rs7932354	0.528	rs7479189	chr11:47057009	T/A	cg19486271	chr11:47235900	DDB2	-0.42	-6.22	-0.32	1.52e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.47	0.46	5.47e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg02135003	chr7:105160482	PUS7	-0.7	-10.33	-0.49	7.7e-22	Bipolar disorder (body mass index interaction);
CRC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.4	6.18	0.32	1.86e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg09877947	chr5:131593287	PDLIM4	0.38	7.21	0.37	3.96e-12	Blood metabolite levels;
CRC	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.28e-11	Body mass index;
CRC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-0.88	-10.39	-0.5	4.67e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2565722	0.714	rs78851647	chr6:161276950	C/T	cg03159191	chr6:161285451	NA	-0.46	-5.66	-0.3	3.36e-8	Blood protein levels;
CRC	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.66	-10.06	-0.49	6.04e-21	Autism;
CRC	cis	rs1223397	0.938	rs3817738	chr6:13279388	G/T	cg07912922	chr6:13274314	PHACTR1	0.56	6.53	0.34	2.46e-10	Blood pressure;
CRC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.24	-16.52	-0.67	4.4e-45	Breast cancer;
CRC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.51	6.06	0.32	3.79e-9	Vitiligo;
CRC	cis	rs2298450	0.717	rs2835328	chr21:37622915	A/C	cg02919814	chr21:37666008	DOPEY2	-0.49	-6.5	-0.34	2.96e-10	Schizophrenia;
CRC	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg25019722	chr6:37503610	NA	-0.4	-7.13	-0.37	6.42e-12	Cognitive performance;
CRC	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.83	0.31	1.29e-8	Height;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg21577049	chr2:228736449	WDR69	-0.44	-6.2	-0.32	1.65e-9	Blood pressure;
CRC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	8.62	0.43	2.79e-16	Eosinophil percentage of white cells;
CRC	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg02421172	chr7:1938701	MAD1L1	-0.44	-6.15	-0.32	2.29e-9	Bipolar disorder;
CRC	cis	rs12760731	0.641	rs12038910	chr1:178444907	C/T	cg00404053	chr1:178313656	RASAL2	0.87	9.36	0.46	1.27e-18	Obesity-related traits;
CRC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.52	8.33	0.42	2.24e-15	Menopause (age at onset);
CRC	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg12560992	chr17:57184187	TRIM37	0.53	7.29	0.37	2.33e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-7.26	-0.37	2.8e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg18099408	chr3:52552593	STAB1	0.34	5.87	0.31	1.06e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg15382696	chr6:118971807	C6orf204	0.58	7.38	0.38	1.32e-12	Diastolic blood pressure;
CRC	trans	rs62295889	0.673	rs62293666	chr4:12538889	G/C	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs73200209	0.912	rs57109552	chr12:116657460	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.78	-0.3	1.72e-8	Total body bone mineral density;
CRC	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.63	8.68	0.43	1.91e-16	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg04518342	chr5:131593106	PDLIM4	0.35	6.31	0.33	9.18e-10	Blood metabolite levels;
CRC	trans	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg26587870	chr6:27730563	NA	-0.44	-6.73	-0.35	7.39e-11	Parkinson's disease;
CRC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg25456477	chr12:86230367	RASSF9	0.4	6.61	0.34	1.51e-10	Major depressive disorder;
CRC	cis	rs12922317	0.589	rs7192491	chr16:12144026	T/C	cg02368508	chr16:12060182	TNFRSF17	-0.41	-6.04	-0.32	4.08e-9	Schizophrenia;
CRC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.38	6.35	0.33	7.15e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.79	-12.65	-0.57	3.72e-30	Body mass index;
CRC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg12590608	chr7:158785262	NA	0.37	6.47	0.34	3.56e-10	Facial morphology (factor 20);
CRC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-0.91	-15.7	-0.65	7.66e-42	Body mass index;
CRC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.81	11.93	0.55	1.61e-27	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03689120	chr13:20767179	GJB2	-0.4	-6.13	-0.32	2.55e-9	Myopia (pathological);
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg27094323	chr7:1216898	NA	-0.37	-5.86	-0.31	1.12e-8	Longevity;Endometriosis;
CRC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.71	-0.35	8.45e-11	Calcium levels;
CRC	cis	rs1109861	0.525	rs606139	chr10:11205719	A/G	cg24910943	chr10:11206320	CUGBP2	0.28	8.08	0.41	1.22e-14	Urinary albumin-to-creatinine ratio;
CRC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg19193384	chr17:30244184	NA	-0.63	-7.17	-0.37	4.91e-12	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14114033	chr7:105752648	SYPL1	0.4	6.32	0.33	8.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.53	6.44	0.33	4.19e-10	Bipolar disorder;
CRC	trans	rs596169	0.655	rs6697647	chr1:219159834	A/G	cg00778190	chr1:95068029	NA	0.74	6.38	0.33	5.97e-10	Intraocular pressure;
CRC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg05313129	chr8:58192883	C8orf71	-0.39	-5.88	-0.31	9.84e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg16506815	chr2:162101123	NA	-0.48	-7.93	-0.4	3.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.53	9.64	0.47	1.53e-19	Vitiligo;
CRC	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.81	-0.35	4.6e-11	Response to antipsychotic treatment;
CRC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg12193833	chr17:30244370	NA	-0.74	-8.65	-0.43	2.34e-16	Hip circumference adjusted for BMI;
CRC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg25985355	chr7:65971099	NA	-0.32	-5.62	-0.3	3.97e-8	Aortic root size;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.8e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.88	0.63	1.23e-38	Mean platelet volume;
CRC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg27426351	chr10:43362370	NA	0.47	5.87	0.31	1.08e-8	Blood protein levels;
CRC	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg19676328	chr12:49525230	TUBA1B	-0.45	-5.98	-0.31	5.71e-9	Total cholesterol levels;
CRC	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg19980929	chr12:42632907	YAF2	0.44	6.48	0.34	3.28e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10849893	0.576	rs7134248	chr12:121897052	T/C	cg01154721	chr12:121881891	KDM2B	-0.43	-6.23	-0.32	1.41e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg22110888	chr17:80059540	CCDC57	-0.41	-6.44	-0.33	4.12e-10	Life satisfaction;
CRC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.67	9.61	0.47	1.95e-19	Longevity;
CRC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg00677455	chr12:58241039	CTDSP2	0.66	8.71	0.43	1.56e-16	Multiple sclerosis;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.73	0.43	1.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs10504390	0.656	rs78912269	chr8:66511446	C/T	cg26403416	chr21:43771339	TFF2	0.64	6.54	0.34	2.37e-10	IgG glycosylation;
CRC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg23625390	chr15:77176239	SCAPER	0.48	6.92	0.36	2.34e-11	Blood metabolite levels;
CRC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21643547	chr1:205240462	TMCC2	-0.44	-7.6	-0.39	3.03e-13	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.41	0.38	1.08e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.56	0.6	1.38e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-11.25	-0.53	4.62e-25	Gut microbiome composition (summer);
CRC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.57	8.59	0.43	3.61e-16	Calcium levels;
CRC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg21770322	chr7:97807741	LMTK2	0.56	9.37	0.46	1.2e-18	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg12890291	chr7:22234163	RAPGEF5	-0.78	-7.0	-0.36	1.48e-11	Temperament (bipolar disorder);
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg12516270	chr8:143859308	LYNX1	0.4	7.1	0.36	7.66e-12	Urinary tract infection frequency;
CRC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg05072774	chr3:49840536	C3orf54	-0.43	-5.71	-0.3	2.58e-8	Resting heart rate;
CRC	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.5	7.91	0.4	3.85e-14	Height;
CRC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.43	6.35	0.33	6.97e-10	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.7	-9.7	-0.47	9.73e-20	Alzheimer's disease;
CRC	cis	rs1572438	1.000	rs873560	chr6:875559	A/G	cg13447295	chr6:887704	NA	-0.45	-6.42	-0.33	4.7e-10	Aging;
CRC	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg04586622	chr2:25135609	ADCY3	-0.56	-9.4	-0.46	9.79e-19	Body mass index;
CRC	cis	rs1552172	0.853	rs10752826	chr1:145602791	C/G	cg25221984	chr1:145714143	CD160	0.35	5.65	0.3	3.39e-8	Breast cancer;
CRC	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.34	-5.99	-0.31	5.51e-9	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg27398640	chr15:77910606	LINGO1	-0.45	-7.95	-0.4	2.94e-14	Type 2 diabetes;
CRC	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg11822372	chr1:151115635	SEMA6C	0.5	7.25	0.37	2.91e-12	Childhood ear infection;
CRC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	11.13	0.52	1.19e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-6.54	-0.34	2.35e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs11025559	0.631	rs11025571	chr11:20482801	C/G	cg19653624	chr11:20408972	PRMT3	0.59	6.34	0.33	7.43e-10	Pursuit maintenance gain;
CRC	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg14458575	chr2:238380390	NA	0.53	7.38	0.38	1.29e-12	Prostate cancer;
CRC	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.56	6.45	0.34	3.89e-10	Lymphocyte counts;
CRC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.47	6.83	0.35	4.02e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10534439	chr2:69969029	ANXA4	0.4	6.94	0.36	2.04e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs17592366	0.517	rs4982222	chr14:35301997	T/C	cg09327582	chr14:35236912	BAZ1A	0.48	6.85	0.35	3.69e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.8	13.3	0.59	1.3e-32	Blood protein levels;
CRC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.87	-0.35	3.17e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.38	-5.97	-0.31	6.2e-9	Mean corpuscular volume;
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-10.35	-0.5	6.66e-22	Bipolar disorder;
CRC	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg18764771	chr6:116381957	FRK	0.26	6.35	0.33	7.26e-10	Total cholesterol levels;
CRC	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.94	16.01	0.66	4.76e-43	Bipolar disorder;
CRC	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg25124228	chr12:125621409	AACS	-0.57	-6.41	-0.33	4.98e-10	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg14844989	chr11:31128820	NA	0.35	6.36	0.33	6.64e-10	Red blood cell count;
CRC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.75	13.29	0.59	1.43e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg22495460	chr2:25135724	ADCY3	-0.84	-14.02	-0.61	2.41e-35	Body mass index;
CRC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09329705	chr19:4909474	UHRF1	0.42	6.11	0.32	2.74e-9	Response to antipsychotic treatment;
CRC	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg05049329	chr1:226924846	ITPKB	0.4	8.86	0.44	5.05e-17	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14229688	chr14:77564380	KIAA1737	0.46	6.3	0.33	9.47e-10	Anxiety disorder;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg23123621	chr4:1343375	KIAA1530	-0.36	-5.84	-0.31	1.29e-8	Obesity-related traits;
CRC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg20573242	chr4:122745356	CCNA2	0.41	6.14	0.32	2.36e-9	Type 2 diabetes;
CRC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg12682573	chr17:27188876	MIR451;MIR144	0.56	7.48	0.38	6.64e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.64	8.98	0.44	2.13e-17	Gestational age at birth (maternal effect);
CRC	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-7.03	-0.36	1.21e-11	Menarche (age at onset);
CRC	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg17133734	chr15:86042851	AKAP13	0.42	7.02	0.36	1.28e-11	Interstitial lung disease;
CRC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.41	0.42	1.25e-15	Height;
CRC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	9.88e-10	Aortic root size;
CRC	cis	rs4880487	0.888	rs67699390	chr10:1252427	G/A	cg03183215	chr10:1252341	ADARB2	-0.3	-6.37	-0.33	6.38e-10	Migraine;
CRC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-6.35	-0.33	7.09e-10	Personality dimensions;
CRC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg01788221	chr16:89496183	ANKRD11	-0.4	-6.08	-0.32	3.37e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.77	-13.06	-0.58	1.11e-31	Idiopathic membranous nephropathy;
CRC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.42	7.01	0.36	1.34e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.53	0.46	3.72e-19	Ileal carcinoids;
CRC	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.75	12.23	0.56	1.36e-28	Height;
CRC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.6	-9.37	-0.46	1.19e-18	Colorectal cancer;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.84	-11.79	-0.55	5.24e-27	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.48	-6.71	-0.35	8.47e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23708337	chr7:1209742	NA	0.51	7.81	0.4	7.79e-14	Longevity;Endometriosis;
CRC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.47e-16	Aortic root size;
CRC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.57	6.3	0.33	9.68e-10	Initial pursuit acceleration;
CRC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg23730037	chr7:158596552	ESYT2	-0.43	-6.42	-0.33	4.83e-10	Height;
CRC	cis	rs9513627	0.833	rs4605005	chr13:100132471	T/C	cg15490075	chr13:100150979	NA	0.58	5.83	0.31	1.36e-8	Obesity-related traits;
CRC	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg09003973	chr2:102972529	NA	0.41	5.65	0.3	3.47e-8	Blood protein levels;
CRC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.41	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg00738113	chr16:70207722	CLEC18C	-0.42	-6.06	-0.32	3.64e-9	IgE levels;
CRC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg19635926	chr16:89946313	TCF25	0.67	6.25	0.33	1.25e-9	Skin colour saturation;
CRC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-11.11	-0.52	1.4e-24	Blood trace element (Zn levels);
CRC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg03934865	chr2:198174659	NA	-0.45	-8.07	-0.41	1.33e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.54	-8.36	-0.42	1.76e-15	Asthma (sex interaction);
CRC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.57	-8.78	-0.44	9.09e-17	Prudent dietary pattern;
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg07617317	chr6:118971624	C6orf204	0.52	6.52	0.34	2.68e-10	Diastolic blood pressure;
CRC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs2179367	0.959	rs9285519	chr6:149692935	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.34	-5.66	-0.3	3.22e-8	Dupuytren's disease;
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg15511327	chr8:143859410	LYNX1	0.5	8.8	0.44	7.87e-17	Urinary tract infection frequency;
CRC	cis	rs2179367	0.959	rs4895789	chr6:149764654	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.62	-0.34	1.44e-10	Dupuytren's disease;
CRC	cis	rs7259376	0.729	rs3867187	chr19:22570220	C/G	cg02657401	chr19:22469223	NA	-0.3	-6.44	-0.33	4.12e-10	Menopause (age at onset);
CRC	cis	rs8170	1.000	rs56028644	chr19:17388790	C/T	cg04749549	chr19:17459798	NA	-0.45	-6.11	-0.32	2.76e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.83	13.04	0.58	1.25e-31	Platelet distribution width;
CRC	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg10556349	chr10:835070	NA	-0.37	-7.37	-0.38	1.39e-12	Survival in rectal cancer;
CRC	cis	rs9462846	0.853	rs2395940	chr6:42860467	C/G	cg10862848	chr6:42927986	GNMT	-0.27	-5.7	-0.3	2.71e-8	Blood protein levels;
CRC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.64	9.65	0.47	1.42e-19	Corneal astigmatism;
CRC	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.98	0.36	1.67e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-7.47	-0.38	7.14e-13	Total body bone mineral density;
CRC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg15465823	chr12:48382534	COL2A1	-0.38	-6.34	-0.33	7.42e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.1	13.32	0.59	1.09e-32	Vitiligo;
CRC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.69	-0.35	9.58e-11	Monocyte percentage of white cells;
CRC	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.83	11.79	0.55	5.16e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-11.97	-0.55	1.23e-27	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg24562669	chr7:97807699	LMTK2	-0.5	-7.39	-0.38	1.23e-12	Breast cancer;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00802000	chr16:706648	WDR90	-0.43	-6.34	-0.33	7.74e-10	Height;
CRC	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg26182253	chr13:112236782	NA	0.31	6.27	0.33	1.12e-9	Hepatitis;
CRC	cis	rs2257205	0.667	rs7214805	chr17:56931895	C/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.43e-8	Pancreatic cancer;
CRC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.43	0.46	7.63e-19	Height;
CRC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg02094049	chr14:103021097	NA	-0.48	-5.61	-0.3	4.31e-8	Platelet count;
CRC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg10298567	chr3:47292165	KIF9	-0.35	-5.85	-0.31	1.17e-8	Colorectal cancer;
CRC	cis	rs713477	0.618	rs6573033	chr14:55919060	C/G	cg21836586	chr14:55907198	TBPL2	0.33	5.89	0.31	9.67e-9	Pediatric bone mineral content (femoral neck);
CRC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.17	13.98	0.61	3.58e-35	Uric acid levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13735691	chr19:36103707	HAUS5	0.44	6.09	0.32	3.12e-9	Anxiety disorder;
CRC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-6.3	-0.33	9.34e-10	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09974566	chr22:32150118	DEPDC5	0.43	6.22	0.32	1.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg19193384	chr17:30244184	NA	-0.59	-7.22	-0.37	3.57e-12	Hip circumference adjusted for BMI;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg09997638	chr19:17530742	FAM125A	-0.4	-5.96	-0.31	6.54e-9	Birth weight;Height;
CRC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.4	0.53	1.36e-25	Bone mineral density;
CRC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.6	-8.22	-0.41	4.88e-15	DNA methylation (variation);
CRC	cis	rs2882667	0.898	rs10058347	chr5:138361358	G/A	cg09476006	chr5:138032270	NA	0.44	7.36	0.38	1.52e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	9.42	0.46	8.35e-19	Monocyte count;
CRC	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg08795948	chr3:128337044	NA	0.36	6.15	0.32	2.24e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.52	-7.13	-0.37	6.28e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs1223397	0.589	rs364493	chr6:13297020	C/T	cg06879394	chr6:13274151	PHACTR1	-0.41	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg01392867	chr16:30410429	ZNF48	-0.39	-6.21	-0.32	1.58e-9	Tonsillectomy;
CRC	trans	rs6544773	0.668	rs341597	chr2:45066963	A/G	cg10208897	chr5:178548229	ADAMTS2	0.35	6.11	0.32	2.84e-9	Mosquito bite size;
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.59	10.1	0.49	4.39e-21	Prudent dietary pattern;
CRC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.44	-6.06	-0.32	3.68e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.34	0.46	1.48e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.78	10.7	0.51	3.88e-23	Cognitive function;
CRC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg16416165	chr4:3325029	RGS12	0.39	5.95	0.31	6.97e-9	Serum sulfate level;
CRC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.75	-11.26	-0.53	4.13e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.61	9.48	0.46	5.06e-19	Dental caries;
CRC	cis	rs6963495	0.510	rs56353563	chr7:105226698	G/C	cg02135003	chr7:105160482	PUS7	-0.71	-7.68	-0.39	1.88e-13	Bipolar disorder (body mass index interaction);
CRC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.93	-16.53	-0.67	4.09e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs741668	0.931	rs61953330	chr13:46588876	T/A	cg06018095	chr13:46550134	ZC3H13	0.41	5.73	0.3	2.21e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs2386661	0.956	rs10905489	chr10:5670541	G/C	cg26603656	chr10:5671107	NA	-0.48	-7.94	-0.4	3.14e-14	Breast cancer;
CRC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.56	6.35	0.33	7.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg24562669	chr7:97807699	LMTK2	0.42	7.02	0.36	1.3e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.47	7.45	0.38	8.47e-13	Schizophrenia;
CRC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.52	-8.32	-0.42	2.29e-15	Neurofibrillary tangles;
CRC	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.14	19.64	0.73	2.22e-57	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	1.13	13.26	0.59	1.97e-32	Obesity-related traits;
CRC	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	8.6	0.43	3.21e-16	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.61	11.3	0.53	3.08e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01743962	chr17:17686332	RAI1	0.41	5.97	0.31	6.1e-9	Response to antipsychotic treatment;
CRC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.33	6.71e-10	Heart rate;
CRC	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	0.94	16.8	0.68	3.46e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.76	-11.91	-0.55	2e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs4728302	0.838	rs6974143	chr7:133603550	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.67	0.3	3.13e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.64	-8.48	-0.42	7.72e-16	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg17903999	chr18:56338584	MALT1	0.43	6.85	0.35	3.73e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.12	0.52	1.33e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9826463	0.757	rs73238200	chr3:142204634	C/T	cg13928417	chr9:124498782	DAB2IP	-0.53	-6.04	-0.32	4.07e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg16060761	chr17:80687452	NA	-0.44	-6.23	-0.32	1.43e-9	Breast cancer;
CRC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.81	-0.3	1.49e-8	Daytime sleep phenotypes;
CRC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	1.02	18.3	0.71	4.38e-52	Parkinson's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26358659	chr3:60740074	FHIT	-0.37	-6.06	-0.32	3.68e-9	Aortic root size;
CRC	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg06581033	chr10:766294	NA	-0.51	-5.66	-0.3	3.34e-8	Uric acid levels;
CRC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.59	6.52	0.34	2.68e-10	Skin colour saturation;
CRC	trans	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	0.62	9.74	0.47	7.36e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg21869046	chr19:41225005	ITPKC	0.4	6.03	0.32	4.47e-9	Kawasaki disease;
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.84	0.35	3.88e-11	Bipolar disorder;
CRC	cis	rs2979489	0.945	rs34960391	chr8:30332723	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-9.77	-0.47	5.95e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-6.95	-0.36	1.94e-11	Glioblastoma;
CRC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg24140574	chr1:16342155	HSPB7	0.41	5.93	0.31	7.49e-9	Dilated cardiomyopathy;
CRC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18288967	chr1:45987694	PRDX1	0.64	7.86	0.4	5.4e-14	Obesity-related traits;
CRC	cis	rs11958404	0.860	rs7730844	chr5:157461208	C/T	cg05962755	chr5:157440814	NA	1.0	12.82	0.58	8.84e-31	IgG glycosylation;
CRC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.58	-6.01	-0.31	4.9e-9	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs10071761	0.597	rs116129874	chr5:40370481	A/G	cg09067459	chr5:40385259	NA	-0.52	-7.06	-0.36	9.82e-12	Selective IgA deficiency;
CRC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.72	-11.72	-0.54	9.3e-27	Obesity-related traits;
CRC	cis	rs758324	0.812	rs2088718	chr5:131179189	C/T	cg25547332	chr5:131281432	NA	0.35	5.61	0.3	4.25e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg06781209	chr11:61594997	FADS2	0.42	5.98	0.31	5.93e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.5	-0.38	6.11e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg18551225	chr6:44695536	NA	0.42	5.9	0.31	9.24e-9	Total body bone mineral density;
CRC	cis	rs12024301	0.557	rs12066802	chr1:183647316	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.67	-6.08	-0.32	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.77	0.63	3.05e-38	Exhaled nitric oxide output;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20390613	chr1:12678355	DHRS3	0.42	6.18	0.32	1.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.66	-11.45	-0.53	9e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.39	0.71	1.93e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18867708	chr6:26865862	GUSBL1	0.42	6.02	0.32	4.59e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	1.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.59	0.34	1.74e-10	Resistin levels;
CRC	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.62	9.84	0.48	3.5e-20	Crohn's disease;
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.34e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.59	9.61	0.47	2.02e-19	Prostate cancer;
CRC	cis	rs911119	0.955	rs8115417	chr20:23605223	T/A	cg16589663	chr20:23618590	CST3	0.45	6.35	0.33	7.25e-10	Chronic kidney disease;
CRC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.73	9.9	0.48	2.16e-20	Coronary artery disease;
CRC	cis	rs4731207	0.596	rs11981797	chr7:124579451	T/A	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.66	-0.39	2.12e-13	QT interval;
CRC	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.52	9.0	0.44	1.87e-17	Schizophrenia;
CRC	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.24	-0.49	1.49e-21	Bipolar disorder;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.54	-9.92	-0.48	1.82e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.58	10.64	0.51	6.5e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55788414	0.929	rs66463064	chr16:81180995	T/C	cg06400318	chr16:81190750	PKD1L2	-0.66	-6.45	-0.33	4.06e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04650786	chr6:108395545	OSTM1	-0.53	-6.55	-0.34	2.18e-10	Diisocyanate-induced asthma;
CRC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	9.22	0.45	3.55e-18	Body mass index (adult);
CRC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.68	8.46	0.42	8.72e-16	Bladder cancer;
CRC	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.5	-8.05	-0.41	1.55e-14	Metabolite levels (small molecules and protein measures);
CRC	trans	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs12476592	0.602	rs262504	chr2:63861235	C/G	cg10828910	chr2:63850056	LOC388955	0.49	6.04	0.32	4.23e-9	Childhood ear infection;
CRC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.64	-0.34	1.29e-10	Axial length;
CRC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	trans	rs16934284	0.764	rs58399611	chr9:119851764	C/A	cg16808373	chr11:122850140	BSX	-0.39	-6.14	-0.32	2.42e-9	Obesity-related traits;
CRC	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg26205652	chr12:48591994	NA	0.46	5.62	0.3	4.01e-8	Longevity (90 years and older);
CRC	trans	rs1376359	0.636	rs7533566	chr1:103123172	C/A	cg16220183	chr17:56609687	SEPT4	-0.47	-6.48	-0.34	3.34e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	8.12	0.41	9.71e-15	Mean corpuscular volume;
CRC	cis	rs17092148	0.887	rs6142199	chr20:33162298	G/C	cg08999081	chr20:33150536	PIGU	0.5	6.48	0.34	3.41e-10	Neuroticism;
CRC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg26805224	chr10:79626177	DLG5	-0.49	-7.0	-0.36	1.48e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.33	0.37	1.8e-12	Eotaxin levels;
CRC	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.39e-12	HDL cholesterol;
CRC	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg11519256	chr10:5708881	ASB13	-0.5	-7.53	-0.38	4.96e-13	Menopause (age at onset);
CRC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-6.92	-0.36	2.32e-11	Morning vs. evening chronotype;
CRC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.43	-6.27	-0.33	1.14e-9	Height;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg12273811	chr6:28175739	NA	-0.55	-7.25	-0.37	2.96e-12	Parkinson's disease;
CRC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.46	6.36	0.33	6.7e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06589161	chr5:180618230	NA	-0.41	-6.15	-0.32	2.23e-9	Myopia (pathological);
CRC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.56	2.94e-29	Prostate cancer;
CRC	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg04662943	chr10:102668895	NA	0.61	7.13	0.37	6.44e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg22495460	chr2:25135724	ADCY3	-0.84	-16.07	-0.66	2.73e-43	Body mass index;
CRC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	6.78	0.35	5.54e-11	Response to antipsychotic treatment;
CRC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06505273	chr16:24850292	NA	-0.52	-6.7	-0.35	9.01e-11	Intelligence (multi-trait analysis);
CRC	trans	rs8005150	0.737	rs8016427	chr14:88484544	T/C	cg25527770	chr19:1444892	NA	-0.56	-6.03	-0.32	4.36e-9	Hepatitis B;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg00597713	chr6:42947103	PEX6	-0.41	-5.83	-0.31	1.3e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.73	0.43	1.34e-16	Rheumatoid arthritis;
CRC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.32	-0.37	1.86e-12	Mean corpuscular volume;
CRC	cis	rs6764363	0.527	rs13078683	chr3:275511	T/G	cg02057681	chr3:285234	CHL1	0.4	6.68	0.35	1.01e-10	Sudden cardiac arrest;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05778739	chr2:96676295	LOC729234	0.42	6.13	0.32	2.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.9	16.44	0.67	9.58e-45	Coronary artery disease;
CRC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.4	-0.33	5.41e-10	Personality dimensions;
CRC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.63	9.12	0.45	7.53e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-5.73	-0.3	2.26e-8	Alzheimer's disease (late onset);
CRC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.72	10.69	0.51	4.31e-23	Immature fraction of reticulocytes;
CRC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.42	6.83	0.35	4.13e-11	Major depressive disorder;
CRC	trans	rs1376359	0.636	rs6669473	chr1:103114350	C/T	cg16220183	chr17:56609687	SEPT4	-0.48	-6.63	-0.34	1.36e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11604912	chr11:67163072	RAD9A	-0.4	-7.24	-0.37	3.18e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	7.43	0.38	9.73e-13	Height;
CRC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.42	-5.98	-0.31	5.82e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.98e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.15	27.07	0.83	1.05e-85	Testicular germ cell tumor;
CRC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.47	6.61	0.34	1.52e-10	Tuberculosis;
CRC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.25e-12	HDL cholesterol;
CRC	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	cg04338863	chr8:33670619	NA	0.44	6.52	0.34	2.67e-10	Body mass index;
CRC	trans	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg25214090	chr10:38739885	LOC399744	0.54	8.16	0.41	7.12e-15	Educational attainment;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg02683197	chr6:28174875	NA	0.64	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.46	-6.43	-0.33	4.53e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07355693	chr12:125667907	NA	0.43	6.32	0.33	8.44e-10	Response to antipsychotic treatment;
CRC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg14979609	chr8:8086686	FLJ10661	0.37	5.92	0.31	7.97e-9	Joint mobility (Beighton score);
CRC	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.68	-0.35	1.03e-10	Eye color traits;
CRC	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg09344028	chr17:70110421	NA	0.48	7.55	0.38	4.36e-13	Thyroid hormone levels;
CRC	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.41	6.94	0.36	2.15e-11	Intelligence (multi-trait analysis);
CRC	trans	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg26043149	chr18:55253948	FECH	0.49	7.76	0.39	1.05e-13	Bone mineral density;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs11212617	0.967	rs419716	chr11:108221099	G/T	cg12106634	chr11:108092400	ATM;NPAT	-0.42	-6.32	-0.33	8.45e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs800082	0.507	rs2717379	chr3:144256805	G/A	cg24215973	chr2:240111563	HDAC4	0.44	6.1	0.32	2.97e-9	Smoking behavior;
CRC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.94	0.36	2.05e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04254693	chr3:49727222	MST1;RNF123	0.46	6.02	0.31	4.75e-9	Thyroid stimulating hormone;
CRC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	14.72	0.63	5.16e-38	Primary sclerosing cholangitis;
CRC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg18479299	chr3:125709523	NA	-0.56	-6.64	-0.34	1.3e-10	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg01273802	chr8:10871371	XKR6	0.32	6.23	0.32	1.44e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.36	-0.33	6.75e-10	Breast cancer;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.66	-10.13	-0.49	3.48e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg20936604	chr3:58311152	NA	-0.72	-6.86	-0.35	3.51e-11	Cholesterol, total;
CRC	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.31	-0.42	2.6e-15	Gut microbiome composition (summer);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24413235	chr2:27851648	CCDC121;GPN1	0.42	6.3	0.33	9.81e-10	Myopia (pathological);
CRC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.08	0.32	3.41e-9	Bladder cancer;
CRC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.97	0.58	2.38e-31	Chronic sinus infection;
CRC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg13319975	chr6:146136371	FBXO30	0.43	6.45	0.34	3.96e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs364477	0.904	rs420061	chr9:957951	C/G	cg13952963	chr9:998547	NA	0.54	5.76	0.3	1.89e-8	Major depressive disorder;
CRC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.5	6.8	0.35	4.8e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.83	0.51	1.35e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs6662572	0.686	rs11805376	chr1:46559664	C/G	cg08644498	chr1:46502608	NA	0.46	7.36	0.38	1.45e-12	Blood protein levels;
CRC	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.53	5.62	0.3	4.18e-8	Type 2 diabetes;
CRC	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.02	0.31	4.77e-9	Ovarian reserve;
CRC	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.61	-9.48	-0.46	5.43e-19	Ulcerative colitis;
CRC	cis	rs71403859	0.504	rs12926413	chr16:71972325	T/C	cg08717414	chr16:71523259	ZNF19	-0.83	-7.11	-0.36	7.48e-12	Post bronchodilator FEV1;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10649384	chr7:87505489	SLC25A40;DBF4	0.36	6.06	0.32	3.75e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6496667	0.821	rs79731978	chr15:90876013	G/A	cg04176472	chr15:90893244	GABARAPL3	0.62	7.32	0.37	1.93e-12	Rheumatoid arthritis;
CRC	cis	rs12249377	0.519	rs11186320	chr10:92576448	C/T	cg14313238	chr10:92632228	RPP30	-0.44	-5.8	-0.3	1.54e-8	White matter microstructure (global fractional anisotropy);
CRC	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.7	-9.55	-0.47	3.18e-19	Coronary artery disease;
CRC	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg00277334	chr10:82204260	NA	0.37	5.91	0.31	8.4e-9	Sarcoidosis;
CRC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.34	-0.33	7.74e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.97	-0.31	5.98e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.67	7.26	0.37	2.84e-12	Childhood ear infection;
CRC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-6.77	-0.35	6.06e-11	Coronary artery disease;
CRC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.62	-11.54	-0.54	4.28e-26	Educational attainment;
CRC	cis	rs728616	0.867	rs61859022	chr10:81860799	G/A	cg05935833	chr10:81318306	SFTPA2	-0.61	-6.94	-0.36	2.15e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.66	10.22	0.49	1.74e-21	Initial pursuit acceleration;
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg07507251	chr3:52567010	NT5DC2	0.45	6.49	0.34	3.08e-10	Bipolar disorder;
CRC	cis	rs45544231	0.569	rs3095605	chr16:52583847	A/G	cg09051775	chr16:52580266	TOX3	-0.42	-6.59	-0.34	1.74e-10	Restless legs syndrome;
CRC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.8	-9.78	-0.47	5.44e-20	Initial pursuit acceleration;
CRC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.73	-0.3	2.24e-8	Gout;Renal underexcretion gout;
CRC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.55	0.43	4.83e-16	Menopause (age at onset);
CRC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.01	-0.4	1.96e-14	Monocyte percentage of white cells;
CRC	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.85	7.38	0.38	1.29e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg00343986	chr7:65444356	GUSB	0.48	7.33	0.37	1.79e-12	Aortic root size;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.75	-0.39	1.19e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg00071950	chr4:10020882	SLC2A9	0.48	6.6	0.34	1.63e-10	Blood metabolite levels;
CRC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.78	7.75	0.39	1.17e-13	Diabetic retinopathy;
CRC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.72	10.08	0.49	5.16e-21	Blood metabolite levels;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.73	9.89	0.48	2.26e-20	Alzheimer's disease;
CRC	cis	rs73200209	0.744	rs7314858	chr12:116565050	T/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.16	-0.37	5.26e-12	Total body bone mineral density;
CRC	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg06243866	chr13:111019493	COL4A2	-0.43	-6.53	-0.34	2.54e-10	White matter hyperintensity burden;
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg20512303	chr5:131592959	PDLIM4	0.39	6.76	0.35	6.38e-11	Breast cancer;
CRC	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.37	-5.82	-0.31	1.4e-8	C-reactive protein levels;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg20512303	chr5:131592959	PDLIM4	0.38	6.52	0.34	2.6e-10	Acylcarnitine levels;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg22638593	chr5:131593259	PDLIM4	0.49	9.08	0.45	1.05e-17	Acylcarnitine levels;
CRC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.47	7.15	0.37	5.75e-12	Obesity-related traits;
CRC	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	8.05	0.41	1.53e-14	Mean corpuscular volume;
CRC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.69	-10.57	-0.5	1.09e-22	Menopause (age at onset);
CRC	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg04202892	chr2:111875749	ACOXL	0.43	7.03	0.36	1.21e-11	Chronic lymphocytic leukemia;
CRC	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg06634786	chr22:41940651	POLR3H	-0.43	-5.77	-0.3	1.83e-8	Neuroticism;
CRC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	trans	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg25173405	chr17:45401733	C17orf57	0.47	7.39	0.38	1.2e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.43	7.67	0.39	1.95e-13	Height;
CRC	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg08798685	chr6:27730294	NA	-0.48	-6.64	-0.34	1.27e-10	Parkinson's disease;
CRC	cis	rs977987	0.864	rs37595	chr16:75496963	G/C	cg03315344	chr16:75512273	CHST6	-0.58	-9.62	-0.47	1.8e-19	Dupuytren's disease;
CRC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg08314208	chr16:67682810	RLTPR	-0.65	-7.38	-0.38	1.34e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg11993925	chr19:44307056	LYPD5	-0.38	-6.18	-0.32	1.9e-9	Breast cancer;
CRC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg24289452	chr6:170231220	NA	-0.77	-6.87	-0.35	3.18e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	13.66	0.6	5.9e-34	Smoking behavior;
CRC	cis	rs4728302	0.594	rs6978383	chr7:133721697	G/A	cg03336402	chr7:133662267	EXOC4	-0.43	-6.67	-0.34	1.11e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.8	-0.4	8.03e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7937682	0.593	rs1944117	chr11:111351184	T/C	cg09085632	chr11:111637200	PPP2R1B	0.42	5.84	0.31	1.28e-8	Primary sclerosing cholangitis;
CRC	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg23100626	chr2:96804247	ASTL	0.25	6.56	0.34	2.1e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.51	7.36	0.38	1.49e-12	Colorectal cancer;
CRC	cis	rs9649465	1.000	rs2109725	chr7:123325459	C/T	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg10298567	chr3:47292165	KIF9	0.38	6.01	0.31	4.81e-9	Colorectal cancer;
CRC	cis	rs10982256	0.875	rs1535962	chr9:117259062	T/C	cg13636371	chr9:117264095	DFNB31	0.41	7.72	0.39	1.44e-13	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-8.42	-0.42	1.2e-15	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg11130432	chr3:121712080	ILDR1	-0.5	-6.53	-0.34	2.48e-10	Multiple sclerosis;
CRC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	0.33	6.2	0.32	1.65e-9	Colorectal cancer;
CRC	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06307176	chr5:131281290	NA	0.45	6.44	0.33	4.35e-10	Life satisfaction;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg18479299	chr3:125709523	NA	-0.54	-6.28	-0.33	1.04e-9	Blood pressure (smoking interaction);
CRC	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.78	6.28	0.33	1.06e-9	Alzheimer's disease (late onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14824280	chr20:60718867	SS18L1;PSMA7	0.44	6.19	0.32	1.84e-9	Anxiety disorder;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07140808	chr4:78978772	FRAS1	-0.56	-6.9	-0.36	2.68e-11	Diisocyanate-induced asthma;
CRC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	11.12	0.52	1.29e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-9.76	-0.47	6.15e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.42	0.33	4.69e-10	Aortic root size;
CRC	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.17	0.32	1.99e-9	Endometrial cancer;
CRC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.83	-17.25	-0.69	5.83e-48	Post bronchodilator FEV1;
CRC	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg21153622	chr11:89784906	NA	0.44	7.1	0.36	7.65e-12	HDL cholesterol;
CRC	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.49	-7.7	-0.39	1.6e-13	Type 2 diabetes;
CRC	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	14.4	0.62	8.33e-37	Lewy body disease;
CRC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.49	-9.21	-0.45	3.86e-18	Reticulocyte fraction of red cells;
CRC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	7.9	0.4	4.19e-14	Chronic sinus infection;
CRC	trans	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg10756647	chr7:56101905	PSPH	0.73	8.14	0.41	8.01e-15	Diabetic kidney disease;
CRC	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg12564285	chr5:131593104	PDLIM4	0.36	6.93	0.36	2.21e-11	Blood metabolite levels;
CRC	trans	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.72e-15	Bone mineral density;
CRC	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg03315344	chr16:75512273	CHST6	0.55	9.29	0.46	2.16e-18	Coronary artery disease;
CRC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.47	9.12	0.45	7.63e-18	Breast cancer;Mosquito bite size;
CRC	cis	rs17767392	0.958	rs36072220	chr14:71980744	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.29	-0.37	2.34e-12	Mitral valve prolapse;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg20387954	chr3:183756860	HTR3D	-0.36	-6.12	-0.32	2.67e-9	Anterior chamber depth;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11224423	chr12:56136943	GDF11	0.46	6.14	0.32	2.35e-9	Hip circumference;
CRC	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14769373	chr6:40998127	UNC5CL	-0.51	-6.18	-0.32	1.9e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs117623576	0.941	rs17230152	chr10:32431969	A/G	cg03047570	chr10:32398778	NA	-0.68	-6.82	-0.35	4.3e-11	Anti-saccade response;
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.87	-0.55	2.77e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4731207	0.596	rs10244797	chr7:124571684	C/T	cg23710748	chr7:124431027	NA	-0.43	-6.69	-0.35	9.89e-11	Cutaneous malignant melanoma;
CRC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.54	8.62	0.43	2.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.6	7.91	0.4	3.86e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.61	7.43	0.38	9.64e-13	Lymphocyte counts;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg15845792	chr6:28175446	NA	-0.75	-6.47	-0.34	3.6e-10	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10016835	chr1:29557393	MECR	0.43	6.04	0.32	4.12e-9	Response to antipsychotic treatment;
CRC	cis	rs73206853	0.841	rs56209636	chr12:110841998	T/C	cg12870014	chr12:110450643	ANKRD13A	0.85	10.18	0.49	2.4e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.47	-0.46	5.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg02659138	chr7:134003124	SLC35B4	-0.42	-7.33	-0.37	1.74e-12	Mean platelet volume;
CRC	cis	rs6758955	0.850	rs6758633	chr2:10480201	T/C	cg15773312	chr2:10472214	HPCAL1	-0.82	-9.49	-0.46	5.01e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-7.97	-0.4	2.59e-14	Type 2 diabetes;
CRC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-10.1	-0.49	4.61e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.4	6.22	0.32	1.53e-9	HDL cholesterol levels;
CRC	trans	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg20936604	chr3:58311152	NA	-0.72	-7.67	-0.39	1.95e-13	Cholesterol, total;
CRC	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg11800794	chr20:31407338	MAPRE1	0.38	5.85	0.31	1.16e-8	Inflammatory bowel disease;
CRC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.8	14.16	0.62	6.84e-36	Breast cancer;
CRC	trans	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg21302420	chr1:112162376	RAP1A	0.73	5.98	0.31	5.83e-9	Skin colour saturation;
CRC	cis	rs9292777	1.000	rs9292777	chr5:40437948	C/T	cg09067459	chr5:40385259	NA	0.52	9.43	0.46	7.59e-19	Crohn's disease;Multiple sclerosis;
CRC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs2882667	0.690	rs288007	chr5:138230628	C/T	cg09476006	chr5:138032270	NA	0.54	8.88	0.44	4.42e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	16.55	0.67	3.38e-45	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.69	11.8	0.55	4.9e-27	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg22110888	chr17:80059540	CCDC57	0.41	6.38	0.33	6.11e-10	Life satisfaction;
CRC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.59	0.43	3.46e-16	Lymphocyte counts;
CRC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.64	10.02	0.48	8.38e-21	Corneal astigmatism;
CRC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-8.15	-0.41	7.47e-15	IgG glycosylation;
CRC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.87	-0.31	1.06e-8	Lung cancer;
CRC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg06462663	chr19:18546047	ISYNA1	0.46	6.9	0.36	2.62e-11	Breast cancer;
CRC	cis	rs35883536	1.000	rs1610387	chr1:101123943	T/G	cg14515779	chr1:101123966	NA	-0.44	-8.65	-0.43	2.35e-16	Monocyte count;
CRC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	12.71	0.57	2.12e-30	Coffee consumption (cups per day);
CRC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.72	-10.64	-0.51	6.3e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.49	0.34	3.24e-10	Bipolar disorder;
CRC	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	8.1	0.41	1.11e-14	Adiposity;
CRC	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.43	-5.61	-0.3	4.41e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2274471	0.645	rs73639261	chr9:5084215	G/A	cg03390472	chr9:5043263	JAK2	-0.56	-6.0	-0.31	5.08e-9	Crohn's disease;
CRC	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.83	10.95	0.52	5.52e-24	Lymphocyte counts;
CRC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.65	11.92	0.55	1.86e-27	Aortic root size;
CRC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.6	9.6	0.47	2.08e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.5	6.92	0.36	2.34e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.95	0.31	6.97e-9	Obesity-related traits;
CRC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.75	-14.78	-0.63	2.8e-38	Prostate cancer;
CRC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.03	0.32	4.52e-9	Glioblastoma;
CRC	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.71	7.58	0.39	3.66e-13	Inflammatory bowel disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06238426	chr17:71228473	C17orf80;FAM104A	0.42	6.23	0.32	1.44e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2257205	0.667	rs7208872	chr17:56777649	A/G	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.8e-8	Pancreatic cancer;
CRC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.02	-0.36	1.26e-11	Morning vs. evening chronotype;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg05886006	chr1:161359784	NA	0.59	6.35	0.33	7.25e-10	Airway imaging phenotypes;
CRC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.66	8.64	0.43	2.54e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg12845249	chr16:67876451	CENPT;THAP11	-0.39	-6.0	-0.31	5.07e-9	Aortic root size;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00802000	chr16:706648	WDR90	-0.41	-5.95	-0.31	6.78e-9	Height;
CRC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.11	21.27	0.76	9.49e-64	Cognitive function;
CRC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.53	-8.24	-0.41	4.02e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.42	9.34	0.46	1.45e-18	Glomerular filtration rate (creatinine);
CRC	trans	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg27327334	chr3:48484191	CCDC72	-0.35	-6.0	-0.31	5.31e-9	Endometriosis;
CRC	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg14664628	chr15:75095509	CSK	-0.47	-5.64	-0.3	3.69e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg03623178	chr6:28175578	NA	0.77	11.23	0.53	5.67e-25	Parkinson's disease;
CRC	cis	rs4731207	0.596	rs9969187	chr7:124661472	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.07	-0.32	3.58e-9	Cutaneous malignant melanoma;
CRC	cis	rs7113874	0.550	rs2044464	chr11:8559695	G/A	cg17679104	chr11:8615758	STK33	-0.36	-5.96	-0.31	6.52e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10760158	0.832	rs4837825	chr9:124015414	A/G	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-7.49	-0.38	6.49e-13	Vitiligo;
CRC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg05304507	chr6:116381966	FRK	0.31	8.44	0.42	1.03e-15	Cholesterol, total;LDL cholesterol;
CRC	trans	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg18288967	chr1:45987694	PRDX1	0.69	7.65	0.39	2.25e-13	Obesity-related traits;
CRC	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.3	0.64	2.7e-40	Fuchs's corneal dystrophy;
CRC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg13798912	chr7:905769	UNC84A	0.51	5.81	0.31	1.45e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06877462	chr1:205807181	PM20D1	0.38	5.9	0.31	8.85e-9	Menarche (age at onset);
CRC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.59	-8.25	-0.41	3.93e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg25214684	chr1:39457099	AKIRIN1	-0.56	-6.1	-0.32	2.93e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.82	-0.44	6.97e-17	Hemoglobin concentration;
CRC	cis	rs6504622	0.755	rs4074249	chr17:45149409	C/T	cg16759221	chr17:45003025	GOSR2	0.43	6.69	0.35	9.65e-11	Orofacial clefts;
CRC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03605463	chr16:89740564	NA	0.39	5.89	0.31	9.46e-9	Vitiligo;
CRC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.36	-5.9	-0.31	8.85e-9	Childhood ear infection;
CRC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.44	6.61	0.34	1.59e-10	Calcium levels;
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg04969067	chr8:143858791	LYNX1	-0.37	-6.22	-0.32	1.55e-9	Urinary tract infection frequency;
CRC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.42	6.52	0.34	2.61e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.26	-6.48	-0.34	3.39e-10	Lymphocyte counts;
CRC	cis	rs10760158	0.832	rs878691	chr9:124037607	C/T	cg14417974	chr9:124058376	GSN	-0.35	-5.89	-0.31	9.54e-9	Pulse pressure;
CRC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26207408	chr2:203500527	FAM117B	0.4	6.08	0.32	3.28e-9	Schizophrenia;
CRC	trans	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg15845792	chr6:28175446	NA	0.67	6.52	0.34	2.71e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	6.7	0.35	9.2e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.62	8.39	0.42	1.41e-15	High light scatter reticulocyte count;
CRC	trans	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.36	5.76	0.3	1.93e-8	Total body bone mineral density;
CRC	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg09476006	chr5:138032270	NA	0.46	7.27	0.37	2.62e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs12713404	1.000	rs2419061	chr2:60016819	G/A	cg03397442	chr10:128945079	DOCK1;FAM196A	-0.46	-5.99	-0.31	5.65e-9	Resting heart rate;
CRC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg13047869	chr3:10149882	C3orf24	0.36	5.7	0.3	2.73e-8	Alzheimer's disease;
CRC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg16898833	chr6:26189333	HIST1H4D	0.89	7.39	0.38	1.2e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23972301	chr1:117504011	PTGFRN	0.38	6.47	0.34	3.53e-10	Aortic root size;
CRC	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.53	-5.89	-0.31	9.69e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.29	-5.93	-0.31	7.62e-9	Total body bone mineral density;
CRC	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg00129232	chr17:37814104	STARD3	0.46	7.28	0.37	2.45e-12	Self-reported allergy;
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-9.28	-0.46	2.38e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg14631576	chr9:95140430	CENPP	-0.41	-7.32	-0.37	1.91e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.23	5.9	0.31	8.81e-9	Type 2 diabetes;
CRC	trans	rs2303319	0.582	rs72870248	chr2:162435849	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.06	-0.32	3.76e-9	Cognitive function;
CRC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.89	16.28	0.67	4.04e-44	Height;
CRC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.67	-10.1	-0.49	4.48e-21	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16299428	chr3:30648098	TGFBR2	0.44	6.13	0.32	2.48e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg16850897	chr7:100343110	ZAN	0.45	6.67	0.34	1.11e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs4478858	0.684	rs12725881	chr1:31736123	C/T	cg00250761	chr1:31883323	NA	0.37	7.19	0.37	4.43e-12	Alcohol dependence;
CRC	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs62045849	0.557	rs6500534	chr16:89190313	C/T	cg08015503	chr16:89190385	ACSF3	-0.93	-7.4	-0.38	1.18e-12	Red blood cell count;
CRC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.47	7.22	0.37	3.65e-12	Corneal astigmatism;
CRC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-11.01	-0.52	3.19e-24	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg25173405	chr17:45401733	C17orf57	0.47	7.47	0.38	7.26e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.77	-14.8	-0.63	2.33e-38	Prudent dietary pattern;
CRC	cis	rs501120	0.657	rs583489	chr10:44738688	C/G	cg09554077	chr10:44749378	NA	0.85	10.97	0.52	4.42e-24	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.46	-0.34	3.66e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.44	-8.52	-0.43	5.98e-16	Alcohol dependence;
CRC	cis	rs9311676	0.656	rs59643048	chr3:58390248	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.68	7.88	0.4	4.72e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4654899	0.627	rs637990	chr1:21047616	A/G	cg02927042	chr1:21476669	EIF4G3	0.43	6.54	0.34	2.34e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07701084	chr6:150067640	NUP43	0.53	7.51	0.38	5.51e-13	Testicular germ cell tumor;
CRC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.6	10.83	0.51	1.46e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg06470822	chr6:28175283	NA	0.42	5.73	0.3	2.27e-8	Pulmonary function;
CRC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.2	-0.32	1.68e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg20243544	chr17:37824526	PNMT	0.4	6.02	0.32	4.63e-9	Self-reported allergy;
CRC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	10.32	0.49	8.34e-22	Motion sickness;
CRC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg23229984	chr5:148520753	ABLIM3	0.48	6.64	0.34	1.33e-10	Breast cancer;
CRC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.74	0.43	1.19e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg04155289	chr7:94953770	PON1	-0.59	-7.54	-0.38	4.66e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.62	8.35	0.42	1.98e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs231513	0.954	rs231508	chr17:41967583	G/A	cg26893861	chr17:41843967	DUSP3	-0.62	-6.35	-0.33	7.21e-10	Cognitive function;
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg25834613	chr7:1915315	MAD1L1	-0.45	-6.34	-0.33	7.46e-10	Neuroticism;
CRC	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg13206674	chr6:150067644	NUP43	0.47	5.75	0.3	2.09e-8	Lung cancer;
CRC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg00999904	chr2:3704751	ALLC	-0.79	-9.75	-0.47	6.72e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.66	-9.77	-0.47	5.91e-20	Total body bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25682936	chr1:38455768	SF3A3	0.46	5.96	0.31	6.39e-9	Thyroid stimulating hormone;
CRC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.41	5.75	0.3	2.08e-8	Parkinson's disease;
CRC	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.14e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg13057898	chr1:3703894	LRRC47	-0.46	-6.23	-0.32	1.45e-9	Red cell distribution width;
CRC	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.78	-9.19	-0.45	4.69e-18	Multiple sclerosis;
CRC	trans	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg21153622	chr11:89784906	NA	0.46	7.32	0.37	1.92e-12	HDL cholesterol;
CRC	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg05925327	chr15:68127851	NA	-0.31	-6.01	-0.31	4.84e-9	Restless legs syndrome;
CRC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg12193833	chr17:30244370	NA	-0.58	-8.01	-0.4	1.96e-14	Hip circumference adjusted for BMI;
CRC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg06386533	chr2:46925753	SOCS5	0.45	5.74	0.3	2.09e-8	Height;
CRC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.37	-6.16	-0.32	2.1e-9	Blood metabolite levels;
CRC	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.37	5.92	0.31	8.09e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg27534772	chr1:16042836	PLEKHM2	0.42	7.01	0.36	1.32e-11	Systolic blood pressure;
CRC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.4	-6.26	-0.33	1.19e-9	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg05376469	chr2:102649931	NA	0.38	6.21	0.32	1.63e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs4665630	0.522	rs75866363	chr2:24046426	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	0.94	7.56	0.38	4.03e-13	Hypertension;
CRC	trans	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg18288967	chr1:45987694	PRDX1	0.66	6.64	0.34	1.26e-10	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.45	-6.32	-0.33	8.43e-10	Platelet distribution width;
CRC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.83	10.35	0.5	6.32e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3018066	0.831	rs10049933	chr4:107078887	T/C	cg01869342	chr4:106983673	TBCK	0.37	5.74	0.3	2.15e-8	Cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03346041	chr8:68255952	ARFGEF1	0.44	6.15	0.32	2.22e-9	Thyroid stimulating hormone;
CRC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.42	5.78	0.3	1.77e-8	Response to amphetamines;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg01860201	chr4:75720019	BTC	0.51	6.23	0.32	1.44e-9	Kashin-Beck disease;
CRC	cis	rs2745959	0.527	rs2473653	chr1:208101656	C/T	cg15031826	chr1:208136952	NA	0.36	5.65	0.3	3.52e-8	Resting heart rate;
CRC	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.28	0.42	3.2e-15	Mean corpuscular volume;
CRC	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.55	-8.38	-0.42	1.53e-15	Ulcerative colitis;
CRC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17507749	chr15:85114479	UBE2QP1	0.62	8.97	0.44	2.36e-17	Schizophrenia;
CRC	cis	rs1572438	1.000	rs1572438	chr6:858970	A/G	cg13447295	chr6:887704	NA	0.44	6.27	0.33	1.12e-9	Aging;
CRC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.44	0.33	4.36e-10	Renal cell carcinoma;
CRC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg21854759	chr1:92012499	NA	0.39	6.0	0.31	5.28e-9	Breast cancer;
CRC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg23071808	chr14:103021642	NA	0.53	6.33	0.33	7.82e-10	Platelet count;
CRC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.63	0.34	1.39e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs289828	0.868	rs3771886	chr2:152138522	T/C	cg06191203	chr2:152266755	RIF1	-0.4	-5.74	-0.3	2.11e-8	Blood protein levels;
CRC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.86	-0.35	3.41e-11	Cutaneous nevi;
CRC	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.48	-7.67	-0.39	1.97e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00166722	chr3:10149974	C3orf24	0.66	9.03	0.45	1.5e-17	Alzheimer's disease;
CRC	trans	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg18288967	chr1:45987694	PRDX1	-0.68	-7.74	-0.39	1.27e-13	Obesity-related traits;
CRC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.2e-25	Prostate cancer;
CRC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.51	7.98	0.4	2.44e-14	Longevity;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20887711	chr4:1340912	KIAA1530	0.41	5.85	0.31	1.19e-8	Obesity-related traits;
CRC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg18230493	chr5:56204884	C5orf35	0.39	5.86	0.31	1.11e-8	Breast cancer;Breast cancer (early onset);
CRC	trans	rs8005150	0.737	rs8003806	chr14:88463388	C/A	cg25527770	chr19:1444892	NA	-0.55	-6.04	-0.32	4.12e-9	Hepatitis B;
CRC	cis	rs7113874	0.524	rs10769922	chr11:8621752	G/A	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg11693508	chr17:37793320	STARD3	0.51	6.57	0.34	1.93e-10	Neuroticism;
CRC	cis	rs3857067	1.000	rs1509943	chr4:95013366	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.36	6.01	0.31	4.87e-9	Response to Dalcetrapib treatment in acute coronary syndrome;
CRC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.62	7.78	0.39	9.59e-14	Gut microbiome composition (summer);
CRC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg06484146	chr7:12443880	VWDE	-0.64	-6.83	-0.35	4.2e-11	Coronary artery disease;
CRC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg06238570	chr21:40685208	BRWD1	0.7	9.31	0.46	1.85e-18	Cognitive function;
CRC	cis	rs2257205	0.667	rs6503881	chr17:56911251	C/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.43e-8	Pancreatic cancer;
CRC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.71	0.65	6.73e-42	Chronic sinus infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26918957	chr8:22926800	TNFRSF10B	0.39	6.03	0.32	4.34e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01735101	chr19:19774554	ATP13A1	0.45	6.28	0.33	1.05e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.46	-6.5	-0.34	2.97e-10	Lymphocyte counts;
CRC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.47	-7.11	-0.37	7.1e-12	Colorectal cancer;
CRC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	7.38	0.38	1.28e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.57	0.43	4.19e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.63	-7.54	-0.38	4.75e-13	Blood protein levels;
CRC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.32	-0.42	2.31e-15	Type 2 diabetes;
CRC	cis	rs990171	0.955	rs4241210	chr2:103078740	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Lymphocyte counts;
CRC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.52	-0.34	2.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06544989	chr22:39130855	UNC84B	0.44	6.79	0.35	5.41e-11	Menopause (age at onset);
CRC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.82	14.76	0.63	3.49e-38	Mean platelet volume;
CRC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.85	-14.86	-0.63	1.48e-38	Body mass index;
CRC	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg11518657	chr1:67396239	MIER1	-0.57	-6.07	-0.32	3.47e-9	Lymphocyte percentage of white cells;
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg15511327	chr8:143859410	LYNX1	0.41	7.2	0.37	4.06e-12	Urinary tract infection frequency;
CRC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.53	7.19	0.37	4.26e-12	Obesity-related traits;
CRC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.54	0.34	2.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.34	-6.95	-0.36	1.91e-11	Cutaneous nevi;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg02683197	chr6:28174875	NA	0.68	7.33	0.37	1.81e-12	Parkinson's disease;
CRC	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg19025524	chr12:109796872	NA	-0.46	-6.5	-0.34	2.96e-10	Neuroticism;
CRC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.43	-0.38	9.75e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12999616	0.602	rs17489259	chr2:98392302	G/A	cg26665480	chr2:98280029	ACTR1B	0.55	6.3	0.33	9.69e-10	Colorectal cancer;
CRC	cis	rs2811415	0.597	rs10934843	chr3:127749605	C/T	cg13719885	chr3:127795394	NA	-0.38	-5.78	-0.3	1.71e-8	Lung function (FEV1/FVC);
CRC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.43	7.77	0.39	1e-13	Intelligence (multi-trait analysis);
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.56	-7.93	-0.4	3.51e-14	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.77	-14.7	-0.63	6.04e-38	Prudent dietary pattern;
CRC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.54	-0.38	4.68e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg00666640	chr1:248458726	OR2T12	0.4	7.28	0.37	2.49e-12	Common traits (Other);
CRC	cis	rs812925	0.502	rs778150	chr2:61608372	C/T	cg10580144	chr2:61372316	C2orf74	-0.33	-7.34	-0.38	1.66e-12	Immature fraction of reticulocytes;
CRC	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg17674042	chr6:34482479	PACSIN1	-0.63	-7.45	-0.38	8.35e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21570168	chr14:102226945	PPP2R5C	-0.49	-7.9	-0.4	4.14e-14	Myopia (pathological);
CRC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.65	6.56	0.34	2.11e-10	Axial length;
CRC	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg02033258	chr5:131593261	PDLIM4	0.32	5.84	0.31	1.24e-8	Blood metabolite levels;
CRC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.49	9.24	0.45	3.19e-18	Renal cell carcinoma;
CRC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.72	-12.28	-0.56	8.95e-29	Body mass index;
CRC	cis	rs3736594	0.513	rs62138964	chr2:27814438	C/T	cg27432699	chr2:27873401	GPN1	0.65	8.29	0.42	2.95e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.41	-0.33	4.9e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs3764400	0.508	rs72823528	chr17:46098944	C/T	cg10706073	chr17:46328419	SKAP1	-0.65	-6.85	-0.35	3.56e-11	Body mass index;
CRC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	0.31	5.92	0.31	7.97e-9	Colorectal cancer;
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	16.52	0.67	4.74e-45	Platelet count;
CRC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.64	8.65	0.43	2.31e-16	Multiple sclerosis;
CRC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.62	8.2	0.41	5.52e-15	Coronary artery disease;
CRC	cis	rs41005	0.967	rs193927	chr2:8108055	G/A	cg03155496	chr2:8117019	LOC339788	0.42	7.46	0.38	7.83e-13	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg18758796	chr5:131593413	PDLIM4	0.39	6.35	0.33	7.23e-10	Breast cancer;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg12500891	chr11:57225987	NA	-0.66	-6.1	-0.32	2.98e-9	Cognitive function;
CRC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.82	-12.98	-0.58	2.1e-31	Multiple sclerosis;
CRC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-5.85	-0.31	1.2e-8	Electroencephalogram traits;
CRC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.77	-10.21	-0.49	1.87e-21	Blood metabolite levels;
CRC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs939584	1.000	rs7571970	chr2:646849	T/C	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.41	-5.75	-0.3	2.07e-8	Neuroticism;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.75	-0.3	2.01e-8	Parkinson's disease;
CRC	cis	rs6564851	0.506	rs56053403	chr16:81259025	T/C	cg05274606	chr16:81253692	PKD1L2	-0.38	-6.28	-0.33	1.05e-9	Carotenoid and tocopherol levels;
CRC	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg09654669	chr8:57350985	NA	-0.38	-5.62	-0.3	4.05e-8	Obesity-related traits;
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.06e-32	Vitiligo;
CRC	trans	rs72956618	0.715	rs72933222	chr2:207319653	C/T	cg20754261	chr2:468330	NA	-0.61	-6.02	-0.31	4.57e-9	Tonsillectomy;
CRC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.96	0.36	1.88e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.28	-0.33	1.07e-9	Lymphocyte counts;
CRC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg02254774	chr11:50257496	LOC441601	0.57	6.03	0.32	4.46e-9	Intraocular pressure;
CRC	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.45	6.42	0.33	4.68e-10	Coronary artery disease;
CRC	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.48	-6.44	-0.33	4.16e-10	QRS duration;
CRC	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg06581033	chr10:766294	NA	-0.52	-5.77	-0.3	1.84e-8	Uric acid levels;
CRC	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg11887960	chr12:57824829	NA	0.62	6.76	0.35	6.26e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.95e-9	Body mass index;
CRC	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.71	9.56	0.47	2.97e-19	Cognitive function;
CRC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.1	-18.12	-0.71	2.23e-51	Ulcerative colitis;
CRC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.62	-0.39	2.82e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.1	13.33	0.59	1.08e-32	Vitiligo;
CRC	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.51	-7.09	-0.36	8.3e-12	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14524403	chr9:136325208	C9orf7	0.43	6.27	0.33	1.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.527	rs7311902	chr12:54015236	A/G	cg06632207	chr12:54070931	ATP5G2	0.45	7.67	0.39	1.98e-13	Height;
CRC	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.55	-0.47	3.18e-19	Prevalent atrial fibrillation;
CRC	cis	rs7487637	0.529	rs56389811	chr12:48205358	C/T	cg14736327	chr12:48174669	SLC48A1	-0.63	-7.86	-0.4	5.62e-14	Mononucleosis;
CRC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg11292332	chr7:45801988	SEPT13	-0.38	-6.81	-0.35	4.75e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9462846	0.811	rs6938994	chr6:42879326	C/T	cg21280719	chr6:42927975	GNMT	-0.34	-6.51	-0.34	2.75e-10	Blood protein levels;
CRC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.6	9.18	0.45	4.91e-18	Initial pursuit acceleration;
CRC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs990171	0.908	rs731628	chr2:103082571	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Lymphocyte counts;
CRC	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.58	6.3	0.33	9.27e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12760731	0.565	rs12049568	chr1:178154345	A/G	cg00404053	chr1:178313656	RASAL2	1.02	10.74	0.51	2.85e-23	Obesity-related traits;
CRC	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg24759859	chr6:86352639	SYNCRIP	0.49	6.7	0.35	9.16e-11	Smooth-surface caries;
CRC	trans	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.18	0.37	4.57e-12	Endometrial cancer;
CRC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.55	-8.3	-0.42	2.82e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg15848620	chr12:58087721	OS9	-0.65	-9.27	-0.45	2.57e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-8.49	-0.42	7.41e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs9992667	0.911	rs28360925	chr4:38617297	A/T	cg19726192	chr4:38663646	FLJ13197	-0.58	-7.49	-0.38	6.58e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24249390	chr15:90295951	MESP1	-0.59	-9.58	-0.47	2.51e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg27398640	chr15:77910606	LINGO1	0.46	8.45	0.42	9.61e-16	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06524757	chr13:72441523	DACH1	0.38	6.47	0.34	3.62e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.66	7.22	0.37	3.64e-12	Urinary 1,3-butadiene metabolite levels in smokers;
CRC	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.47	6.49	0.34	3.22e-10	White matter microstructure (global fractional anisotropy);
CRC	trans	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.1	-0.36	7.91e-12	Endometrial cancer;
CRC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.05	-0.32	4.03e-9	Bipolar disorder;
CRC	cis	rs860295	0.665	rs12079134	chr1:155466784	C/G	cg02153340	chr1:155202674	NA	-0.52	-6.49	-0.34	3.08e-10	Body mass index;
CRC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg03623178	chr6:28175578	NA	0.48	6.58	0.34	1.87e-10	Depression;
CRC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.43	-0.38	9.7e-13	Type 2 diabetes;
CRC	trans	rs6102059	0.748	rs6129648	chr20:39231118	A/G	cg05435295	chr11:125703230	PATE4	0.36	6.78	0.35	5.45e-11	LDL cholesterol;
CRC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg04545296	chr12:48745243	ZNF641	0.33	5.64	0.3	3.63e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.66	-7.93	-0.4	3.41e-14	Rheumatoid arthritis;
CRC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.41	5.65	0.3	3.53e-8	Emphysema distribution in smoking;
CRC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg03929089	chr4:120376271	NA	-0.49	-7.01	-0.36	1.36e-11	HDL cholesterol;
CRC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.52	8.11	0.41	9.98e-15	Intelligence (multi-trait analysis);
CRC	cis	rs354225	0.626	rs7608414	chr2:54844995	G/A	cg26097391	chr2:54893211	SPTBN1	0.38	5.67	0.3	3.2e-8	Schizophrenia;
CRC	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg07512295	chr2:234599026	UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.38	5.85	0.31	1.2e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg19046167	chr17:80928561	B3GNTL1	0.4	6.39	0.33	5.54e-10	Breast cancer;
CRC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	1.11	9.14	0.45	6.46e-18	Plateletcrit;
CRC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.6	-9.86	-0.48	2.83e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.53	-8.42	-0.42	1.14e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	6.23	0.32	1.4e-9	Lung cancer;
CRC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg09998033	chr7:158218633	PTPRN2	0.49	6.89	0.36	2.87e-11	Obesity-related traits;
CRC	cis	rs4664293	0.867	rs7565297	chr2:160572519	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.45	-0.38	8.04e-13	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.67	8.88	0.44	4.54e-17	Morning vs. evening chronotype;
CRC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.81	14.03	0.61	2.18e-35	Height;
CRC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.65	8.57	0.43	4.22e-16	Gut microbiome composition (summer);
CRC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.13	-0.32	2.56e-9	Height;
CRC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.57	-0.43	4.14e-16	Aortic root size;
CRC	trans	rs79464052	0.571	rs10491312	chr5:140940596	A/C	cg05255351	chr5:1503979	LPCAT1	-0.45	-6.07	-0.32	3.6e-9	Diffuse large B cell lymphoma;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg06470822	chr6:28175283	NA	0.68	8.91	0.44	3.6e-17	Parkinson's disease;
CRC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.37	10.36	0.5	5.82e-22	Mean corpuscular volume;
CRC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.1	-0.41	1.1e-14	Height;
CRC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.94	0.31	7.33e-9	Aortic root size;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.5	5.95	0.31	6.72e-9	Lung function (FEV1/FVC);
CRC	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.7	-0.3	2.67e-8	Pulmonary function;
CRC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg24675056	chr1:15929824	NA	0.51	7.04	0.36	1.14e-11	Systolic blood pressure;
CRC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.42	0.42	1.15e-15	Schizophrenia;
CRC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.78	0.44	9.26e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7756236	0.521	rs6907793	chr6:36625206	A/G	cg08179530	chr6:36648295	CDKN1A	0.38	5.63	0.3	3.85e-8	QRS duration;
CRC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg02527881	chr3:46936655	PTH1R	0.41	7.33	0.37	1.78e-12	Colorectal cancer;
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg23102388	chr7:1867652	MAD1L1	-0.33	-5.6	-0.3	4.46e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24044651	chr1:24105262	C1orf128	0.43	6.07	0.32	3.45e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.42	5.93	0.31	7.62e-9	Aortic root size;
CRC	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.66	-0.47	1.3e-19	Body mass index;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03452623	chr4:187889614	NA	-0.9	-20.05	-0.74	5.59e-59	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.58	11.35	0.53	2.05e-25	Information processing speed;
CRC	trans	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.18	0.37	4.57e-12	Endometrial cancer;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.35	-6.46	-0.34	3.67e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg22029157	chr1:209979665	IRF6	0.6	6.66	0.34	1.14e-10	Coronary artery disease;
CRC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg04850286	chr10:81895943	PLAC9	0.38	6.84	0.35	3.78e-11	Sarcoidosis;
CRC	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg26875233	chr11:93583750	C11orf90	0.3	5.92	0.31	7.97e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs17767392	0.595	rs8005615	chr14:71661187	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.47	-6.0	-0.31	5.16e-9	Mitral valve prolapse;
CRC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg00246817	chr9:123691163	NA	-0.47	-6.04	-0.32	4.11e-9	Rheumatoid arthritis;
CRC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg06096015	chr1:231504339	EGLN1	0.42	6.39	0.33	5.73e-10	Hemoglobin concentration;
CRC	trans	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg23996704	chr18:44553084	KATNAL2	-0.34	-7.06	-0.36	9.77e-12	Personality dimensions;
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg16606324	chr3:10149918	C3orf24	0.67	9.13	0.45	6.91e-18	Alzheimer's disease;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg12172441	chr6:28176163	NA	0.61	6.56	0.34	2.13e-10	Parkinson's disease;
CRC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.63	-0.47	1.66e-19	Heart rate;
CRC	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	0.8	9.67	0.47	1.21e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.74	8.23	0.41	4.5e-15	Neuroticism;
CRC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.54	8.31	0.42	2.57e-15	Aortic root size;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.68	-0.39	1.89e-13	Breast cancer;
CRC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12463550	chr7:65579703	CRCP	0.66	6.24	0.33	1.31e-9	Diabetic kidney disease;
CRC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg08888203	chr3:10149979	C3orf24	-0.47	-7.41	-0.38	1.08e-12	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22104487	chr8:42010424	AP3M2	0.47	6.62	0.34	1.44e-10	Response to antipsychotic treatment;
CRC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.61	0.34	1.58e-10	Bipolar disorder;
CRC	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	6.26	0.33	1.2e-9	Blood metabolite levels;
CRC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.79	0.44	8.21e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg08761264	chr16:28874980	SH2B1	0.44	5.81	0.3	1.5e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.59	10.36	0.5	6.13e-22	Age of smoking initiation;
CRC	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.63	8.32	0.42	2.39e-15	Body mass index;
CRC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.31e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.52	-5.62	-0.3	4.15e-8	Schizophrenia;
CRC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-8.69	-0.43	1.71e-16	Electroencephalogram traits;
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.24	0.53	5.12e-25	Prudent dietary pattern;
CRC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.63	7.28	0.37	2.42e-12	Vitiligo;
CRC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg03934865	chr2:198174659	NA	-0.43	-7.18	-0.37	4.67e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs9462027	0.628	rs9469857	chr6:34719793	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-6.6	-0.34	1.64e-10	Systemic lupus erythematosus;
CRC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.47	6.49	0.34	3.11e-10	Schizophrenia;
CRC	cis	rs13161895	1.000	rs27018	chr5:179405144	A/G	cg02702477	chr5:179499311	RNF130	0.54	6.28	0.33	1.08e-9	LDL cholesterol;
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.05	-0.41	1.58e-14	Bipolar disorder;
CRC	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.43	-8.41	-0.42	1.3e-15	Alcohol dependence;
CRC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.89	11.35	0.53	2.01e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.78	10.91	0.52	7.6e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.49	-6.37	-0.33	6.27e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg00601450	chr5:74908170	NA	-0.47	-5.61	-0.3	4.3e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg23262073	chr20:60523788	NA	-0.46	-7.2	-0.37	4.16e-12	Body mass index;
CRC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg03037974	chr15:76606532	NA	-0.5	-7.33	-0.37	1.84e-12	Blood metabolite levels;
CRC	cis	rs12431939	0.947	rs56026555	chr14:51649066	G/T	cg23942311	chr14:51606299	NA	-0.56	-6.38	-0.33	5.84e-10	Cancer;
CRC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg13206674	chr6:150067644	NUP43	0.62	8.6	0.43	3.24e-16	Lung cancer;
CRC	cis	rs4658101	0.815	rs12117800	chr1:92049014	C/T	cg24006770	chr1:92056542	NA	-0.45	-5.99	-0.31	5.5e-9	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02807482	chr3:125708958	NA	-0.46	-6.01	-0.31	4.92e-9	Blood pressure (smoking interaction);
CRC	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs60871478	0.735	rs10950455	chr7:831451	C/T	cg13844804	chr7:814759	HEATR2	-0.64	-6.89	-0.36	2.8e-11	Cerebrospinal P-tau181p levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19998654	chr2:37458983	CEBPZ;C2orf56	0.45	7.31	0.37	1.99e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.39	-6.12	-0.32	2.6e-9	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16629158	chr2:122042988	TFCP2L1	0.39	6.22	0.32	1.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.21	-0.41	5.18e-15	Chronic sinus infection;
CRC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg08888203	chr3:10149979	C3orf24	0.5	7.58	0.39	3.59e-13	Alzheimer's disease;
CRC	cis	rs4660531	1.000	rs61774746	chr1:41838561	T/G	cg00290994	chr1:41848739	NA	0.44	6.23	0.32	1.41e-9	Bipolar disorder;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.82	0.35	4.39e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.47	-8.29	-0.42	3e-15	Dupuytren's disease;
CRC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.67	11.31	0.53	2.84e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.67	-11.86	-0.55	2.99e-27	Asthma;
CRC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.87e-12	Aortic root size;
CRC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg19622623	chr12:86230825	RASSF9	-0.36	-5.81	-0.3	1.5e-8	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg24562669	chr7:97807699	LMTK2	-0.45	-7.46	-0.38	7.54e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10274279	1.000	rs2021742	chr7:157381671	T/A	cg26886268	chr7:157387156	PTPRN2	-0.48	-5.84	-0.31	1.23e-8	Myopia (pathological);
CRC	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.87	10.58	0.5	1.04e-22	Obesity-related traits;
CRC	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.07	0.36	9.42e-12	Menarche (age at onset);
CRC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.57	-8.74	-0.43	1.23e-16	Schizophrenia;
CRC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.7	-8.5	-0.42	6.92e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg24505167	chr7:1915268	MAD1L1	0.41	5.95	0.31	7.03e-9	Bipolar disorder;
CRC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg18876405	chr7:65276391	NA	-0.44	-6.01	-0.31	5.02e-9	Aortic root size;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20386580	chr10:105344807	NEURL	0.27	5.98	0.31	5.71e-9	Myopia (pathological);
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg06470822	chr6:28175283	NA	0.84	12.77	0.58	1.28e-30	Parkinson's disease;
CRC	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg26248373	chr2:1572462	NA	-0.81	-11.92	-0.55	1.74e-27	IgG glycosylation;
CRC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg24253500	chr15:84953950	NA	0.38	6.49	0.34	3.23e-10	Schizophrenia;
CRC	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.47	-7.78	-0.39	9.43e-14	Airway imaging phenotypes;
CRC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.37	6.77	0.35	5.76e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs62432291	0.681	rs438853	chr6:159630352	A/C	cg14500486	chr6:159655392	FNDC1	-0.72	-10.07	-0.49	5.9e-21	Joint mobility (Beighton score);
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.26	-6.47	-0.34	3.61e-10	Lymphocyte counts;
CRC	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.66	7.14	0.37	5.98e-12	Childhood ear infection;
CRC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.8	-11.46	-0.53	8.11e-26	Coronary artery disease;
CRC	cis	rs61160187	0.582	rs1460961	chr5:60411832	A/G	cg16298547	chr5:60138761	ELOVL7	-0.26	-5.66	-0.3	3.3e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs6427782	0.602	rs4915185	chr1:199822101	A/G	cg07208853	chr1:200005219	NR5A2	0.22	5.69	0.3	2.81e-8	Menarche (age at onset);
CRC	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.82	-0.4	7.06e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.61	6.58	0.34	1.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.46	-6.36	-0.33	6.58e-10	Lung cancer;
CRC	cis	rs972578	1.000	rs2413737	chr22:43361143	C/G	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs4780355	0.918	rs243323	chr16:11361202	A/G	cg00044050	chr16:11439710	C16orf75	0.42	5.87	0.31	1.07e-8	Crohn's disease and psoriasis;
CRC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs669446	0.529	rs6697354	chr1:44151015	T/G	cg12908607	chr1:44402522	ARTN	-0.34	-5.73	-0.3	2.21e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.66	-11.48	-0.53	6.95e-26	Brugada syndrome;
CRC	cis	rs7605827	0.930	rs4668449	chr2:15530141	T/C	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg21466736	chr12:48725269	NA	0.5	7.85	0.4	6.03e-14	Plateletcrit;
CRC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.83	8.23	0.41	4.37e-15	Diabetic retinopathy;
CRC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.49	7.77	0.39	1e-13	Height;
CRC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.87	-0.78	5.86e-70	Myeloid white cell count;
CRC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.5	7.72	0.39	1.38e-13	Prostate cancer;
CRC	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg25834613	chr7:1915315	MAD1L1	0.4	5.95	0.31	7.04e-9	Bipolar disorder;
CRC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.54	-0.43	5.09e-16	Monocyte count;
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg18827107	chr12:86230957	RASSF9	-0.4	-6.08	-0.32	3.34e-9	Major depressive disorder;
CRC	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	6.05	0.32	3.96e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs8108034	0.920	rs30480	chr19:39807213	A/G	cg00455333	chr1:45205373	KIF2C	-0.53	-6.19	-0.32	1.83e-9	Lung adenocarcinoma;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg16691251	chr5:66510806	NA	0.44	7.82	0.4	7.09e-14	Breast cancer;
CRC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	15.52	0.65	3.98e-41	Gut microbiome composition (summer);
CRC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg23996704	chr18:44553084	KATNAL2	-0.41	-8.23	-0.41	4.43e-15	Personality dimensions;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.16	0.32	2.18e-9	Bipolar disorder;
CRC	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.4	6.08	0.32	3.35e-9	Red blood cell count;
CRC	cis	rs1322512	1.000	rs2800630	chr6:153008261	A/G	cg03415253	chr6:152958462	SYNE1	0.38	5.72	0.3	2.4e-8	Tonometry;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg13206674	chr6:150067644	NUP43	0.57	7.82	0.4	7.26e-14	Lung cancer;
CRC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.37	0.38	1.38e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03056465	chr20:3026350	MRPS26;GNRH2	0.47	6.52	0.34	2.66e-10	Response to antipsychotic treatment;
CRC	cis	rs9469578	0.792	rs79297236	chr6:33713930	T/C	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.46	7.11	0.36	7.41e-12	Calcium levels;
CRC	cis	rs4700695	0.925	rs10069614	chr5:65396530	A/C	cg21114390	chr5:65439923	SFRS12	-0.57	-7.06	-0.36	1.02e-11	Facial morphology (factor 19);
CRC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.51	0.34	2.87e-10	Aortic root size;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg17321639	chr7:2759063	NA	-0.48	-6.66	-0.34	1.17e-10	Height;
CRC	trans	rs4853036	0.503	rs34198970	chr2:70012933	C/A	cg14633329	chr9:139640053	LCN6	-0.39	-6.44	-0.33	4.26e-10	Colorectal or endometrial cancer;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.56	-0.43	4.32e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.56	8.7	0.43	1.63e-16	Mean platelet volume;
CRC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.5	8.37	0.42	1.72e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg14844989	chr11:31128820	NA	-0.34	-5.95	-0.31	6.79e-9	Red blood cell count;
CRC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg22495460	chr2:25135724	ADCY3	0.88	17.77	0.7	5.57e-50	Body mass index;
CRC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.45	-7.5	-0.38	6.06e-13	Uric acid clearance;
CRC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.2	-0.73	1.2e-55	Primary sclerosing cholangitis;
CRC	cis	rs7605827	0.930	rs7602186	chr2:15510003	C/T	cg19274914	chr2:15703543	NA	0.38	5.76	0.3	1.97e-8	Educational attainment (years of education);
CRC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	5.92	0.31	8.16e-9	Asthma;
CRC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg12590608	chr7:158785262	NA	0.33	5.81	0.31	1.45e-8	Facial morphology (factor 20);
CRC	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.48	7.52	0.38	5.43e-13	Fat distribution (HIV);
CRC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.41	-8.79	-0.44	8.33e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.46e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg20041105	chr8:143859282	LYNX1	0.46	8.03	0.4	1.72e-14	Urinary tract infection frequency;
CRC	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.72	11.4	0.53	1.38e-25	Plateletcrit;Platelet count;
CRC	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.61	-8.37	-0.42	1.65e-15	Extraversion;
CRC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.5	0.34	2.94e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.74	10.46	0.5	2.8e-22	Blood metabolite levels;
CRC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.49	5.63	0.3	3.89e-8	Vitiligo;
CRC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg12639453	chr1:2035780	PRKCZ	-0.33	-6.17	-0.32	1.99e-9	Height;
CRC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21028142	chr17:79581711	NPLOC4	0.32	6.85	0.35	3.68e-11	Eye color traits;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03864326	chr16:67927170	PSKH1	0.42	6.0	0.31	5.18e-9	Survival in pancreatic cancer;
CRC	cis	rs3750082	0.855	rs12536402	chr7:32936419	C/G	cg05721444	chr7:32995514	FKBP9	-0.48	-7.29	-0.37	2.26e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.91	-15.77	-0.66	4.09e-42	Height;
CRC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.54e-15	Morning vs. evening chronotype;
CRC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.55	10.21	0.49	1.97e-21	Lung cancer;
CRC	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.39	6.0	0.31	5.13e-9	Height;
CRC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg19318889	chr4:1322082	MAEA	-0.42	-6.08	-0.32	3.36e-9	Obesity-related traits;
CRC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.44	-6.86	-0.35	3.36e-11	Coronary artery disease;
CRC	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.93	-0.4	3.45e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.55	8.4	0.42	1.39e-15	Intelligence (multi-trait analysis);
CRC	cis	rs926938	0.967	rs11587596	chr1:115241857	A/G	cg12756093	chr1:115239321	AMPD1	-0.72	-11.57	-0.54	3.27e-26	Autism;
CRC	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg04586622	chr2:25135609	ADCY3	-0.39	-6.68	-0.35	9.93e-11	Body mass index in non-asthmatics;
CRC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg22482690	chr17:47019901	SNF8	0.47	7.94	0.4	3.17e-14	Type 2 diabetes;
CRC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.52	-7.9	-0.4	4.13e-14	Aortic root size;
CRC	cis	rs4363385	0.693	rs689008	chr1:153047100	G/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.86e-10	Inflammatory skin disease;
CRC	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.67	8.34	0.42	2.07e-15	Iron status biomarkers;
CRC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.72	-9.45	-0.46	6.41e-19	Initial pursuit acceleration;
CRC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.77	-14.06	-0.61	1.68e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs76993477	0.610	rs115822670	chr1:169711885	T/C	cg03211132	chr1:169703751	SELE	0.58	5.7	0.3	2.72e-8	Tonsillectomy;
CRC	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.41	0.33	5.09e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.2	-0.37	4.22e-12	Educational attainment;
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.0	-0.4	2.22e-14	Bipolar disorder;
CRC	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.44	6.27	0.33	1.14e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.51	7.1	0.36	7.83e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.68	9.17	0.45	5.38e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg18761221	chr20:60518478	NA	0.46	7.36	0.38	1.53e-12	Body mass index;
CRC	cis	rs79387448	0.745	rs7587856	chr2:103144305	C/A	cg09003973	chr2:102972529	NA	0.73	8.14	0.41	8.53e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg00383909	chr3:49044727	WDR6	0.49	6.16	0.32	2.08e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.53	-8.82	-0.44	6.82e-17	Menarche (age at onset);
CRC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.21	-0.37	3.76e-12	Total cholesterol levels;
CRC	cis	rs1950626	0.623	rs34603287	chr14:101433831	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.75	12.07	0.55	5.21e-28	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs524281	0.861	rs10791858	chr11:65978396	A/G	cg16950941	chr11:66035639	RAB1B	-0.66	-7.87	-0.4	5.28e-14	Electroencephalogram traits;
CRC	cis	rs9659323	0.700	rs10923746	chr1:119616278	A/G	cg26570165	chr1:119541833	NA	-0.36	-5.91	-0.31	8.72e-9	Body mass index;
CRC	cis	rs2227564	0.672	rs2461864	chr10:75659872	A/T	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.14	-0.37	5.99e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.49	-7.26	-0.37	2.79e-12	Headache;
CRC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg03609598	chr5:56110824	MAP3K1	0.58	7.79	0.39	8.61e-14	Initial pursuit acceleration;
CRC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg06462663	chr19:18546047	ISYNA1	0.46	7.07	0.36	9.28e-12	Breast cancer;
CRC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.42	-6.63	-0.34	1.36e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24796471	chr19:6737389	GPR108	0.46	6.13	0.32	2.54e-9	Anxiety disorder;
CRC	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.32	6.39	0.33	5.73e-10	Ewing sarcoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10893140	chr3:49158297	USP19	0.45	6.45	0.34	3.94e-10	Anxiety disorder;
CRC	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.58	-9.46	-0.46	6.21e-19	Schizophrenia;
CRC	cis	rs883565	0.740	rs6763016	chr3:39098964	G/A	cg01426195	chr3:39028469	NA	-0.54	-8.66	-0.43	2.15e-16	Handedness;
CRC	trans	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg21302420	chr1:112162376	RAP1A	0.65	6.41	0.33	5.02e-10	Skin colour saturation;
CRC	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.47	-0.42	8.32e-16	High light scatter reticulocyte count;
CRC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-8.49	-0.42	7.04e-16	Vitamin D levels;
CRC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.04	17.67	0.7	1.35e-49	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.33	-0.42	2.17e-15	Longevity;Endometriosis;
CRC	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg04110750	chr16:69646130	NFAT5	-0.51	-7.22	-0.37	3.59e-12	IgE levels;
CRC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg24289452	chr6:170231220	NA	-0.81	-7.11	-0.36	7.23e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-8.09	-0.41	1.19e-14	Body mass index;
CRC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.4	6.78	0.35	5.58e-11	Crohn's disease;
CRC	cis	rs9323205	0.798	rs11157805	chr14:51658390	C/G	cg23942311	chr14:51606299	NA	0.6	9.33	0.46	1.59e-18	Cancer;
CRC	cis	rs2737618	0.651	rs2249172	chr1:200082955	A/G	cg21825944	chr1:200113062	NR5A2	0.45	6.64	0.34	1.28e-10	Uric acid levels;
CRC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.94	-15.5	-0.65	4.47e-41	Longevity;
CRC	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.05	0.36	1.08e-11	Menarche (age at onset);
CRC	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg10437265	chr15:77819839	NA	0.59	9.97	0.48	1.23e-20	Type 2 diabetes;
CRC	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.37	-0.38	1.43e-12	Inflammatory skin disease;
CRC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.68	8.96	0.44	2.5e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg00310523	chr12:86230176	RASSF9	0.44	7.49	0.38	6.47e-13	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26298387	chr1:160068041	IGSF8	0.45	6.32	0.33	8.75e-10	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.8	0.3	1.52e-8	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17142723	chr17:41324085	NBR1	0.36	6.8	0.35	4.97e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18357526	chr6:26021779	HIST1H4A	0.43	5.97	0.31	6.13e-9	Height;
CRC	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.5	-0.34	3.03e-10	Eye color traits;
CRC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.46	7.33	0.37	1.75e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.59	-0.43	3.63e-16	Breast cancer;
CRC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.45	6.1	0.32	2.99e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs6585424	1.000	rs6585424	chr10:81933748	A/G	cg11900509	chr10:81946545	ANXA11	-0.72	-8.83	-0.44	6.14e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.49	-6.28	-0.33	1.07e-9	Bronchopulmonary dysplasia;
CRC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.35	0.73	3.19e-56	Prudent dietary pattern;
CRC	cis	rs73200209	0.703	rs17498942	chr12:116686117	C/G	cg01776926	chr12:116560359	MED13L	-0.61	-7.27	-0.37	2.66e-12	Total body bone mineral density;
CRC	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.54	8.15	0.41	7.91e-15	Blood protein levels;
CRC	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.52	7.82	0.4	7.18e-14	Testicular germ cell tumor;
CRC	cis	rs4499344	0.633	rs259251	chr19:33149768	G/A	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.58	9.34	0.46	1.54e-18	Melanoma;
CRC	cis	rs2811415	0.531	rs13063727	chr3:127767618	C/G	cg13719885	chr3:127795394	NA	-0.37	-5.65	-0.3	3.49e-8	Lung function (FEV1/FVC);
CRC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.56	0.6	1.38e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg09264619	chr17:80180166	NA	0.41	6.76	0.35	6.46e-11	Life satisfaction;
CRC	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg20542592	chr8:11973495	FAM66D	-0.34	-5.69	-0.3	2.84e-8	Retinal vascular caliber;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25485084	chr12:118809325	TAOK3	0.47	7.24	0.37	3.17e-12	Response to antipsychotic treatment;
CRC	cis	rs4427176	0.765	rs17150478	chr8:9641034	C/T	cg21625330	chr8:9911636	MSRA	0.64	6.27	0.33	1.14e-9	Mosquito bite size;
CRC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg19635926	chr16:89946313	TCF25	0.56	5.95	0.31	6.86e-9	Skin colour saturation;
CRC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.51	0.5	1.74e-22	Menopause (age at onset);
CRC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.51	-5.87	-0.31	1.06e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg26762873	chr11:5879799	OR52E8	-0.47	-6.58	-0.34	1.88e-10	DNA methylation (variation);
CRC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.97	13.91	0.61	6.76e-35	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg07336999	chr16:89939803	TCF25	0.42	6.19	0.32	1.83e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.27	0.33	1.11e-9	Ovarian reserve;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14699228	chr3:49823994	IP6K1	-0.41	-6.56	-0.34	2.12e-10	Myopia (pathological);
CRC	cis	rs4700695	0.925	rs1845481	chr5:65397527	A/C	cg21114390	chr5:65439923	SFRS12	-0.49	-6.35	-0.33	7.17e-10	Facial morphology (factor 19);
CRC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16262614	chr3:133464971	TF	0.43	8.05	0.41	1.5e-14	Iron status biomarkers;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26928467	chr16:577442	SOLH;C16orf10	0.41	6.37	0.33	6.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg18402987	chr7:1209562	NA	0.43	6.23	0.33	1.39e-9	Longevity;Endometriosis;
CRC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg03152288	chr2:177042942	NA	0.79	12.56	0.57	8.27e-30	IgG glycosylation;
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg04824913	chr4:887549	GAK	0.48	6.63	0.34	1.39e-10	Sjögren's syndrome;
CRC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg19622623	chr12:86230825	RASSF9	0.41	6.35	0.33	7.04e-10	Major depressive disorder;
CRC	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.61	-0.3	4.38e-8	Coronary artery disease;
CRC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg13256891	chr4:100009986	ADH5	0.44	6.3	0.33	9.57e-10	Alcohol dependence;
CRC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	13.49	0.6	2.56e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.58	7.12	0.37	7e-12	Carotid intima media thickness;
CRC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	3.08e-24	Corneal astigmatism;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg27001607	chr7:76178636	LOC100133091	-0.51	-6.68	-0.35	1.02e-10	Parkinson's disease;
CRC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.81	-0.31	1.46e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.77	13.6	0.6	1.02e-33	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11212617	0.837	rs4754298	chr11:108023284	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.07	0.32	3.52e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg03013999	chr17:37608204	MED1	0.49	7.45	0.38	8.46e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.51	0.34	2.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.66	9.38	0.46	1.08e-18	Lung cancer;
CRC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-6.23	-0.32	1.42e-9	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03208016	chr1:180124071	QSOX1	0.44	6.01	0.31	4.82e-9	Anxiety disorder;
CRC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02018176	chr4:1364513	KIAA1530	-0.42	-7.2	-0.37	4.18e-12	Obesity-related traits;
CRC	cis	rs6589219	0.908	rs10789822	chr11:111162691	A/G	cg25129781	chr11:111156908	C11orf53	-0.31	-5.76	-0.3	1.96e-8	Colorectal cancer;
CRC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.39	-0.33	5.59e-10	Breast cancer;
CRC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg20203395	chr5:56204925	C5orf35	-0.41	-5.77	-0.3	1.88e-8	Coronary artery disease;
CRC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.4	7.6	0.39	3.11e-13	Mean corpuscular volume;
CRC	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.9	-0.44	3.84e-17	Coffee consumption (cups per day);
CRC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.92	-0.31	8.02e-9	Gout;Renal underexcretion gout;
CRC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg07718321	chr6:96025334	MANEA	0.49	5.82	0.31	1.38e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs3764400	0.506	rs2036521	chr17:46328976	T/G	cg10706073	chr17:46328419	SKAP1	-0.65	-6.69	-0.35	9.62e-11	Body mass index;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.73	9.77	0.47	5.72e-20	Alzheimer's disease;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg15763984	chr4:1342303	KIAA1530	0.47	8.08	0.41	1.23e-14	Longevity;
CRC	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.91	-0.4	3.91e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.55	8.04	0.41	1.62e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.37	5.85	0.31	1.21e-8	Crohn's disease;
CRC	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg09695851	chr17:3907499	NA	0.77	14.76	0.63	3.56e-38	Type 2 diabetes;
CRC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg10760299	chr15:45669010	GATM	0.49	7.79	0.39	8.71e-14	Homoarginine levels;
CRC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg01987224	chr1:201084466	NA	0.52	9.5	0.46	4.34e-19	Permanent tooth development;
CRC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-11.6	-0.54	2.54e-26	Vitiligo;
CRC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.55	8.67	0.43	2.02e-16	Type 2 diabetes;
CRC	cis	rs17767392	0.881	rs12880188	chr14:72009745	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.48	-6.66	-0.34	1.13e-10	Mitral valve prolapse;
CRC	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.47	7.31	0.37	2.07e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2811415	0.597	rs9819960	chr3:127784513	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.51	5.95	0.31	7.01e-9	Renal function-related traits (BUN);
CRC	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.22	28.25	0.84	5.77e-90	Schizophrenia;
CRC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg19824325	chr16:58548873	SETD6	1.0	6.84	0.35	3.87e-11	Schizophrenia;
CRC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.47	-7.19	-0.37	4.44e-12	Testicular germ cell tumor;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04830409	chr12:64615927	C12orf66	0.54	6.92	0.36	2.31e-11	Thyroid stimulating hormone;
CRC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.13	-0.32	2.53e-9	Bladder cancer;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.12	-0.32	2.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg05623727	chr3:50126028	RBM5	0.45	7.62	0.39	2.77e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.74	-10.15	-0.49	3e-21	Systemic lupus erythematosus;
CRC	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.33e-11	Prostate cancer;
CRC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.92	-0.31	8.16e-9	Colorectal cancer;
CRC	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg21155852	chr7:2048760	MAD1L1	-0.4	-6.04	-0.32	4.21e-9	Neuroticism;
CRC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.25	-0.71	6.72e-52	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13546538	chr9:111754815	CTNNAL1	-0.37	-6.0	-0.31	5.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9925964	0.933	rs4889530	chr16:31065918	T/A	cg03418659	chr16:31128414	MYST1	0.46	6.83	0.35	4.13e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.93	-0.31	7.7e-9	Type 2 diabetes;
CRC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.69	11.87	0.55	2.67e-27	Intelligence (multi-trait analysis);
CRC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg05192639	chr6:26864778	GUSBL1	0.33	6.35	0.33	7.19e-10	Schizophrenia;
CRC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.81	7.93	0.4	3.5e-14	Fat distribution (HIV);
CRC	trans	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg26043149	chr18:55253948	FECH	0.51	8.09	0.41	1.18e-14	Bone mineral density;
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.54	-10.06	-0.49	6.03e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.46	7.04	0.36	1.11e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	trans	rs2274459	0.673	rs35328423	chr6:33731592	C/T	cg06457534	chr11:91536479	NA	0.35	6.13	0.32	2.47e-9	Obesity (extreme);
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.83	13.04	0.58	1.32e-31	Menarche (age at onset);
CRC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.35	-6.08	-0.32	3.31e-9	Erythrocyte sedimentation rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01802975	chr1:67519155	SLC35D1	0.43	7.01	0.36	1.37e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg24046110	chr8:143859143	LYNX1	0.46	8.05	0.41	1.5e-14	Urinary tract infection frequency;
CRC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg10298567	chr3:47292165	KIF9	0.44	7.0	0.36	1.41e-11	Colorectal cancer;
CRC	cis	rs4481887	0.504	rs7529247	chr1:248359877	C/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg16898833	chr6:26189333	HIST1H4D	0.7	6.23	0.32	1.42e-9	Breast cancer;
CRC	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg06988349	chr10:69991859	ATOH7	0.32	5.95	0.31	6.76e-9	Optic disc area;
CRC	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg14191688	chr11:70257035	CTTN	0.4	5.67	0.3	3.1e-8	Coronary artery disease;
CRC	cis	rs6743376	0.556	rs2515396	chr2:113819175	G/A	cg24553058	chr2:113831203	IL1F10	0.42	6.94	0.36	2.13e-11	Inflammatory biomarkers;
CRC	cis	rs78663649	0.614	rs76626935	chr19:16581375	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.87	-5.94	-0.31	7.14e-9	White blood cell count;
CRC	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.47	-6.27	-0.33	1.15e-9	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.72	0.35	7.94e-11	Neuroticism;
CRC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg06781209	chr11:61594997	FADS2	-0.52	-7.47	-0.38	7.38e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs1891275	0.550	rs4933694	chr10:93499213	C/T	cg07889827	chr10:93443413	NA	-0.39	-6.58	-0.34	1.82e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.5	-6.79	-0.35	5.18e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	8.98	0.44	2.2e-17	Platelet distribution width;
CRC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg25767906	chr1:53392781	SCP2	0.42	6.67	0.34	1.11e-10	Monocyte count;
CRC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.37	6.01	0.31	5.06e-9	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02679291	chr19:48248902	GLTSCR2	0.41	6.12	0.32	2.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.57	-9.14	-0.45	6.56e-18	Height;
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg24046110	chr8:143859143	LYNX1	-0.78	-14.68	-0.63	7.29e-38	Urinary tract infection frequency;
CRC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg01472538	chr16:58549086	SETD6	1.03	6.64	0.34	1.3100000000000001e-10	Schizophrenia;
CRC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.91	-17.8	-0.7	4.19e-50	Blood protein levels;
CRC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg03948781	chr1:205179583	DSTYK	0.41	5.77	0.3	1.88e-8	Red blood cell count;
CRC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg19980929	chr12:42632907	YAF2	0.44	6.53	0.34	2.47e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs13064447	0.870	rs7631468	chr3:12754997	A/G	cg07775309	chr3:12595852	NA	-0.37	-5.9	-0.31	9.12e-9	Major depression and alcohol dependence;
CRC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.48	-0.38	6.87e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.19	-0.32	1.78e-9	Gout;Renal underexcretion gout;
CRC	cis	rs7945718	0.591	rs7937898	chr11:12703561	G/T	cg25843174	chr11:12811716	TEAD1	-0.41	-7.64	-0.39	2.47e-13	Educational attainment (years of education);
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.69	9.65	0.47	1.46e-19	Alzheimer's disease;
CRC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg25344623	chr2:136566232	LCT	-0.31	-5.68	-0.3	3e-8	Mosquito bite size;
CRC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.4	6.63	0.34	1.34e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg16102536	chr7:156981717	UBE3C	0.39	6.58	0.34	1.85e-10	Body mass index;
CRC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.55	-0.43	4.8e-16	Aortic root size;
CRC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.42	6.6	0.34	1.66e-10	Dupuytren's disease;
CRC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.6	-0.34	1.66e-10	Depression;
CRC	cis	rs6495367	1.000	rs28412916	chr15:79378167	A/C	cg17916960	chr15:79447300	NA	0.36	5.9	0.31	8.8e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.48	7.34	0.38	1.69e-12	Corneal astigmatism;
CRC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	cis	rs698833	0.926	rs786624	chr2:44604941	C/T	cg04920474	chr2:44395004	PPM1B	-0.42	-6.11	-0.32	2.8e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.59	-8.27	-0.41	3.42e-15	Menarche (age at onset);
CRC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.54	7.27	0.37	2.62e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2625529	0.775	rs4777466	chr15:72136872	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.65	-0.34	1.23e-10	Red blood cell count;
CRC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.68	-0.39	1.85e-13	Alzheimer's disease;
CRC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.53	6.13	0.32	2.49e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.19	0.32	1.8e-9	Hemoglobin concentration;
CRC	cis	rs2411233	1.000	rs10851374	chr15:39270049	C/A	cg23129342	chr15:39283510	NA	0.31	5.95	0.31	7.02e-9	Platelet count;
CRC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	8.34	0.42	2.02e-15	Lung cancer in ever smokers;
CRC	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.76	-10.25	-0.49	1.46e-21	White matter hyperintensity burden;
CRC	cis	rs1509123	0.609	rs7224971	chr17:6713999	A/T	cg12642237	chr17:6703447	TEKT1	0.57	5.88	0.31	1.03e-8	Blood metabolite levels;
CRC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.9	-11.26	-0.53	4.1e-25	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23113715	chr22:25800663	NA	0.51	8.0	0.4	2.14e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.65	-9.72	-0.47	8.74e-20	Cognitive function;
CRC	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg15704280	chr7:45808275	SEPT13	0.56	7.4	0.38	1.13e-12	Intraocular pressure;
CRC	cis	rs185694	1.000	rs595449	chr13:30896852	T/C	cg07600127	chr13:30881527	KATNAL1	-0.56	-5.97	-0.31	5.99e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16371860	chr21:42880448	TMPRSS2	0.42	6.92	0.36	2.4e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.47	7.83	0.4	6.85e-14	Coronary artery disease;
CRC	cis	rs2066819	1.000	rs35526714	chr12:56634639	G/C	cg26714650	chr12:56694279	CS	-1.46	-11.65	-0.54	1.76e-26	Psoriasis vulgaris;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20189904	chr20:35974307	SRC	-0.42	-6.06	-0.32	3.64e-9	Myopia (pathological);
CRC	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.55	-9.32	-0.46	1.74e-18	Airway imaging phenotypes;
CRC	cis	rs394563	0.625	rs394526	chr6:149796975	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.44	-6.91	-0.36	2.49e-11	Dupuytren's disease;
CRC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg04731861	chr2:219085781	ARPC2	0.27	5.69	0.3	2.83e-8	Ulcerative colitis;
CRC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg04719120	chr6:96025338	MANEA	-0.53	-5.81	-0.31	1.45e-8	Behavioural disinhibition (generation interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19436567	chr6:157099375	ARID1B	0.47	6.55	0.34	2.17e-10	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg19041857	chr6:27730383	NA	-0.43	-6.11	-0.32	2.74e-9	Parkinson's disease;
CRC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.49	6.69	0.35	9.71e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.44	-8.42	-0.42	1.16e-15	Alcohol dependence;
CRC	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg02683197	chr6:28174875	NA	0.84	11.1	0.52	1.64e-24	Depression;
CRC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.53	-7.92	-0.4	3.76e-14	Mean corpuscular hemoglobin;
CRC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.52	-5.73	-0.3	2.25e-8	Schizophrenia;
CRC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.43	-0.42	1.1e-15	Aortic root size;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	ch.14.35531994F	chr14:36462243	NA	-0.47	-7.03	-0.36	1.21e-11	Birth weight;Height;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.75	-0.43	1.12e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.91	-0.44	3.64e-17	Monocyte percentage of white cells;
CRC	cis	rs1950626	0.833	rs12891189	chr14:101415523	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	16.09	0.66	2.16e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg23283495	chr1:209979779	IRF6	0.46	6.53	0.34	2.43e-10	Cleft lip with or without cleft palate;
CRC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	1.0	18.41	0.71	1.64e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.19	0.45	4.67e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.56	0.47	2.93e-19	Blood protein levels;
CRC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.85	16.6	0.68	2.12e-45	White blood cell count;
CRC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg05585544	chr11:47624801	NA	0.47	8.52	0.43	5.86e-16	Subjective well-being;
CRC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg12927641	chr6:109611667	NA	-0.35	-6.22	-0.32	1.49e-9	Reticulocyte fraction of red cells;
CRC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.57	7.6	0.39	3.12e-13	IgG glycosylation;
CRC	cis	rs2386661	0.826	rs1317517	chr10:5672580	T/G	cg26603656	chr10:5671107	NA	0.54	8.91	0.44	3.52e-17	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04597389	chr17:79935740	ASPSCR1	0.43	6.02	0.31	4.68e-9	Anxiety disorder;
CRC	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg00086871	chr4:6988644	TBC1D14	1.01	7.58	0.39	3.49e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.64	-0.51	6.41e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg09659197	chr4:152720779	NA	-0.39	-8.0	-0.4	2.17e-14	Intelligence (multi-trait analysis);
CRC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.61	-0.3	4.29e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs6060717	0.610	rs1891151	chr20:34612726	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.33	-0.33	8.22e-10	Hip circumference adjusted for BMI;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.01	-10.5	-0.5	2e-22	Body mass index;
CRC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.51	-7.1	-0.36	7.8e-12	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.84	0.31	1.23e-8	Hemoglobin concentration;
CRC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg20573242	chr4:122745356	CCNA2	0.43	6.31	0.33	8.9e-10	Type 2 diabetes;
CRC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.85	0.51	1.16e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.43	-8.06	-0.41	1.4e-14	Colorectal cancer;
CRC	cis	rs4766646	0.619	rs10850883	chr12:110292513	G/A	cg01252219	chr12:110302105	GLTP	0.4	6.17	0.32	2.06e-9	Metabolite levels (MHPG);
CRC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg18683604	chr14:51561293	TRIM9	0.29	5.66	0.3	3.32e-8	Cancer;
CRC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.38	8.26	0.41	3.64e-15	Eye color traits;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.31e-10	Bipolar disorder;
CRC	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.97	-0.55	1.2100000000000001e-27	Coffee consumption (cups per day);
CRC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.12	0.32	2.59e-9	Cognitive ability;
CRC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.48	-7.74	-0.39	1.23e-13	Post bronchodilator FEV1;
CRC	cis	rs4731207	0.596	rs1011722	chr7:124605207	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.65	-7.05	-0.36	1.08e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs860295	0.812	rs2297775	chr1:155735012	C/T	cg02153340	chr1:155202674	NA	0.54	6.66	0.34	1.15e-10	Body mass index;
CRC	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.76	0.35	6.2e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg24289452	chr6:170231220	NA	-0.94	-7.59	-0.39	3.43e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.19	-0.52	7.81e-25	Eye color traits;
CRC	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11235871	chr3:49142143	QARS	0.46	6.55	0.34	2.2e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.74	0.3	2.1e-8	Depression;
CRC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg03044510	chr21:27107978	ATP5J;GABPA	0.42	6.33	0.33	8.1e-10	Body mass index;
CRC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.43	6.16	0.32	2.14e-9	Aortic root size;
CRC	cis	rs7173389	1.000	rs4489968	chr15:73665506	T/G	cg01796676	chr15:73680284	NA	0.51	6.76	0.35	6.43e-11	Resting heart rate;
CRC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.5	9.19	0.45	4.49e-18	Vitiligo;
CRC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.58	9.42	0.46	8.02e-19	Crohn's disease;
CRC	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.47	-5.92	-0.31	8.1e-9	Orofacial clefts;
CRC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16262614	chr3:133464971	TF	0.34	6.04	0.32	4.19e-9	Iron status biomarkers;
CRC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.52	-8.09	-0.41	1.16e-14	Breast cancer;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg02633924	chr17:75315563	SEPT9	-0.49	-6.3	-0.33	9.75e-10	Parkinson's disease;
CRC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-21.13	-0.76	3.29e-63	Hemostatic factors and hematological phenotypes;
CRC	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.52	-0.38	5.18e-13	Myopia (pathological);
CRC	cis	rs500492	0.542	rs449295	chr16:1074443	G/A	cg03495660	chr16:1074500	NA	0.43	5.68	0.3	2.95e-8	Polycystic ovary syndrome;
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg11843238	chr5:131593191	PDLIM4	0.36	6.97	0.36	1.77e-11	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18405786	chr19:18746985	KLHL26	0.43	6.16	0.32	2.06e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.92	0.31	8.26e-9	Bipolar disorder;
CRC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.48	6.67	0.35	1.06e-10	Tonsillectomy;
CRC	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.61	10.29	0.49	1.04e-21	Dupuytren's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14850771	chr21:34775459	IFNGR2	0.39	6.11	0.32	2.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07690219	chr3:49449608	TCTA;RHOA	0.51	5.75	0.3	2.09e-8	Menarche (age at onset);
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.26	-0.33	1.22e-9	Bipolar disorder;
CRC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.11	-0.32	2.86e-9	Schizophrenia;
CRC	cis	rs7209700	0.662	rs8074094	chr17:45348021	T/C	cg17185639	chr17:45330862	ITGB3	0.37	6.0	0.31	5.28e-9	IgG glycosylation;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg02683197	chr6:28174875	NA	0.65	7.09	0.36	8.01e-12	Parkinson's disease;
CRC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.12	-0.52	1.36e-24	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.27	-0.33	1.11e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08402873	chr20:10653164	JAG1	-0.48	-7.17	-0.37	4.94e-12	Daytime sleep phenotypes;
CRC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	10.38	0.5	4.9e-22	Systolic blood pressure;
CRC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg10790698	chr19:18539756	SSBP4	-0.47	-8.79	-0.44	8.33e-17	Breast cancer;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg26587870	chr6:27730563	NA	-0.43	-6.47	-0.34	3.49e-10	Parkinson's disease;
CRC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.43	-5.86	-0.31	1.1e-8	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.42	-0.33	4.89e-10	Aortic root size;
CRC	cis	rs9463078	0.753	rs1329716	chr6:44953758	C/T	cg25276700	chr6:44698697	NA	-0.28	-6.99	-0.36	1.55e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.76	-10.66	-0.51	5.5e-23	Plateletcrit;Platelet count;
CRC	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.59	-8.41	-0.42	1.3e-15	Squamous cell lung carcinoma;
CRC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.8	14.06	0.61	1.68e-35	Breast cancer;
CRC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg06713675	chr4:122721982	EXOSC9	0.38	6.12	0.32	2.69e-9	Type 2 diabetes;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.54	7.57	0.39	3.71e-13	Menarche (age at onset);
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg23807890	chr2:228736357	WDR69	-0.47	-6.56	-0.34	2.13e-10	Blood pressure;
CRC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.44	-0.38	8.69e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.49	-0.57	1.42e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg23100626	chr2:96804247	ASTL	0.26	6.91	0.36	2.58e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg20243544	chr17:37824526	PNMT	0.56	9.01	0.45	1.67e-17	Asthma;
CRC	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.11	9.6	0.47	2.06e-19	Mitochondrial DNA levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10800280	chr6:36646508	CDKN1A	0.42	6.55	0.34	2.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3750965	0.575	rs3018691	chr11:68884543	C/T	cg06818126	chr11:68850279	TPCN2	-0.43	-5.98	-0.31	5.82e-9	Hair color;
CRC	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg21155852	chr7:2048760	MAD1L1	-0.45	-6.3	-0.33	9.55e-10	Bipolar disorder;
CRC	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.8	-9.21	-0.45	3.84e-18	Dilated cardiomyopathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19557623	chr17:40540543	STAT3	0.46	6.42	0.33	4.81e-10	Response to antipsychotic treatment;
CRC	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg19875535	chr5:140030758	IK	-0.59	-9.64	-0.47	1.52e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.67	0.54	1.43e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs3764400	0.567	rs12939334	chr17:46302669	A/G	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.47	6.18	0.32	1.91e-9	Gut microbiome composition (summer);
CRC	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.5	7.34	0.38	1.71e-12	Caudate activity during reward;
CRC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.6	8.82	0.44	6.75e-17	Lung cancer;
CRC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.78	-0.3	1.76e-8	Ulcerative colitis;
CRC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	6.9	0.36	2.65e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.46	-6.87	-0.35	3.32e-11	Plateletcrit;
CRC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.83	-10.44	-0.5	3.13e-22	Breast cancer;
CRC	cis	rs10464059	0.700	rs6859159	chr5:179761769	C/T	cg26918954	chr5:179728553	GFPT2	-0.45	-5.66	-0.3	3.35e-8	Parkinson's disease;
CRC	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg03623178	chr6:28175578	NA	0.74	7.82	0.4	7.43e-14	Depression;
CRC	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-7.32	-0.37	1.96e-12	Metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00508499	chr22:38054505	PDXP	0.46	6.45	0.34	3.95e-10	Response to antipsychotic treatment;
CRC	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.85	-0.55	3.21e-27	Colorectal cancer;
CRC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.37	5.67	0.3	3.19e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg19223190	chr17:80058835	NA	-0.4	-6.27	-0.33	1.13e-9	Life satisfaction;
CRC	trans	rs875971	0.545	rs801212	chr7:66015630	C/G	cg02869306	chr7:64672164	INTS4L1	0.43	6.28	0.33	1.08e-9	Aortic root size;
CRC	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg27083787	chr2:113543245	IL1A	0.45	6.48	0.34	3.38e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	8.5	0.42	6.8e-16	Iron status biomarkers;
CRC	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-6.13	-0.32	2.45e-9	Caffeine consumption;
CRC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.31	5.88e-9	Heart rate;
CRC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg24562669	chr7:97807699	LMTK2	0.42	6.87	0.35	3.15e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-5.86	-0.31	1.13e-8	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15993709	chr1:153631130	SNAPIN	0.46	6.43	0.33	4.44e-10	Response to antipsychotic treatment;
CRC	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg03315344	chr16:75512273	CHST6	-0.51	-6.3	-0.33	9.52e-10	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg02683197	chr6:28174875	NA	0.69	9.8	0.48	4.69e-20	Cardiac Troponin-T levels;
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00166722	chr3:10149974	C3orf24	0.66	8.88	0.44	4.36e-17	Alzheimer's disease;
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg15786705	chr6:28176104	NA	0.62	6.67	0.34	1.11e-10	Depression;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.55	-0.38	4.45e-13	Total body bone mineral density;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01171360	chr6:293285	DUSP22	-0.44	-6.44	-0.33	4.35e-10	Menopause (age at onset);
CRC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg27205649	chr11:78285834	NARS2	0.53	6.83	0.35	4.04e-11	Alzheimer's disease (survival time);
CRC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.65	-11.65	-0.54	1.76e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg23193639	chr7:45961078	IGFBP3	0.4	6.62	0.34	1.5e-10	Sitting height ratio;
CRC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg03678062	chr6:149772716	ZC3H12D	-0.38	-6.84	-0.35	3.88e-11	Dupuytren's disease;
CRC	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg10298567	chr3:47292165	KIF9	0.41	6.38	0.33	5.89e-10	Colorectal cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11855759	chr17:9548802	USP43	0.45	6.02	0.31	4.7e-9	Hip circumference;
CRC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg14558114	chr2:88469736	THNSL2	0.59	5.84	0.31	1.25e-8	Plasma clusterin levels;
CRC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.65	0.39	2.29e-13	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01052666	chr22:22292729	PPM1F	0.46	6.81	0.35	4.77e-11	Response to antipsychotic treatment;
CRC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg01420254	chr6:26195488	NA	0.76	8.63	0.43	2.75e-16	Gout;Renal underexcretion gout;
CRC	cis	rs8032158	0.896	rs8028559	chr15:56130909	A/G	cg02198044	chr15:56286336	NEDD4	-0.37	-5.99	-0.31	5.49e-9	Keloid;
CRC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-10.04	-0.48	7e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.65	7.85	0.4	5.8e-14	Psoriasis;
CRC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg05623727	chr3:50126028	RBM5	-0.45	-7.5	-0.38	5.92e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2565722	0.583	rs2465875	chr6:161298404	A/T	cg03159191	chr6:161285451	NA	-0.39	-5.95	-0.31	6.89e-9	Blood protein levels;
CRC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.86	-0.48	2.94e-20	Total cholesterol levels;
CRC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg26603656	chr10:5671107	NA	0.42	7.15	0.37	5.76e-12	Breast cancer;
CRC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.14	25.93	0.82	1.68e-81	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26591144	chr17:1532201	SLC43A2	0.41	6.51	0.34	2.78e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-7.8	-0.4	8.2e-14	Vitamin D levels;
CRC	trans	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.49	-0.34	3.16e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.38	-5.67	-0.3	3.15e-8	IFN-related cytopenia;
CRC	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.59	-6.54	-0.34	2.32e-10	Blood protein levels;
CRC	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.74	-0.3	2.11e-8	Pulmonary function;
CRC	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.78	-0.3	1.71e-8	Subjective well-being;
CRC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.78	11.71	0.54	1.02e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20743544	chr7:32982957	RP9P	0.45	6.27	0.33	1.11e-9	Response to antipsychotic treatment;
CRC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.42	8.11	0.41	1.05e-14	Mean corpuscular volume;
CRC	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg01422370	chr2:73384389	NA	0.37	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.64	0.34	1.26e-10	Lymphocyte counts;
CRC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.33	6.07e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg04553112	chr3:125709451	NA	-0.51	-5.71	-0.3	2.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs4728302	0.838	rs13231095	chr7:133604436	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.52	-0.34	2.61e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.52	0.34	2.71e-10	Depression;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.77	-13.58	-0.6	1.19e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.64	-8.66	-0.43	2.16e-16	Extraversion;
CRC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.55	7.41	0.38	1.08e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.89e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.44	6.21	0.32	1.61e-9	Longevity;Endometriosis;
CRC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg04450456	chr4:17643702	FAM184B	0.39	6.22	0.32	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26653293	chr17:1619494	C17orf91;WDR81	0.39	6.12	0.32	2.73e-9	Schizophrenia;
CRC	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.53	7.4	0.38	1.14e-12	Response to antidepressants and depression;
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.74	-0.3	2.18e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.87	-15.26	-0.64	3.81e-40	Fuchs's corneal dystrophy;
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg26608667	chr7:1196370	ZFAND2A	0.35	5.67	0.3	3.16e-8	Longevity;Endometriosis;
CRC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.82	0.4	7.23e-14	Schizophrenia;
CRC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.59	10.38	0.5	5.06e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9928842	0.823	rs889514	chr16:75272512	A/G	cg08657710	chr16:75258780	CTRB1	-0.52	-6.58	-0.34	1.84e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs4728302	0.869	rs2059298	chr7:133603245	C/G	cg10665199	chr7:133106180	EXOC4	0.38	5.67	0.3	3.13e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1983170	0.736	rs11589162	chr1:91974743	C/G	cg21854759	chr1:92012499	NA	0.52	6.0	0.31	5.25e-9	Eosinophil percentage of white cells;
CRC	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.47	0.65	6.25e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.84	-0.31	1.22e-8	Gout;Renal underexcretion gout;
CRC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.39	7.58	0.39	3.64e-13	Mean corpuscular volume;
CRC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.57	-8.41	-0.42	1.24e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.67	-0.51	5.06e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg02683197	chr6:28174875	NA	0.62	8.8	0.44	7.86e-17	Parkinson's disease;
CRC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg13072238	chr3:49761600	GMPPB	-0.52	-6.1	-0.32	2.98e-9	Menarche (age at onset);
CRC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg03948781	chr1:205179583	DSTYK	0.41	5.63	0.3	3.92e-8	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06303635	chr10:45958759	MARCH8	0.34	6.57	0.34	2.01e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.09	-0.36	8.39e-12	Gut microbiome composition (summer);
CRC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.42	6.03	0.32	4.3e-9	Heart rate;
CRC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg15269541	chr15:43626905	ADAL	-0.5	-5.92	-0.31	8.17e-9	Lung cancer in ever smokers;
CRC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg23018236	chr17:30244563	NA	-0.64	-8.07	-0.41	1.34e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.48	5.99	0.31	5.51e-9	Bipolar disorder;
CRC	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.38	-5.63	-0.3	3.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.4	0.38	1.14e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.52	-9.79	-0.48	4.87e-20	Prostate cancer;
CRC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.51	6.83	0.35	4.01e-11	IgG glycosylation;
CRC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.04	12.55	0.57	8.83e-30	Eosinophil percentage of granulocytes;
CRC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.6	-8.19	-0.41	5.78e-15	DNA methylation (variation);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15345369	chr2:10262827	RRM2	-0.39	-6.1	-0.32	2.99e-9	Myopia (pathological);
CRC	cis	rs932541	1.000	rs6105610	chr20:16457333	A/C	cg17003395	chr20:16555519	KIF16B	0.41	5.66	0.3	3.38e-8	Intelligence;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.69	7.77	0.39	9.92e-14	Body mass index;
CRC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg23719950	chr11:63933701	MACROD1	-0.55	-5.89	-0.31	9.3e-9	Mean platelet volume;
CRC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.59	-6.18	-0.32	1.87e-9	White matter hyperintensity burden;
CRC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg01262667	chr19:19385393	TM6SF2	0.37	6.13	0.32	2.46e-9	Tonsillectomy;
CRC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.33	0.33	8.23e-10	Morning vs. evening chronotype;
CRC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg03948781	chr1:205179583	DSTYK	0.41	5.66	0.3	3.38e-8	Red blood cell count;
CRC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.51	7.73	0.39	1.3e-13	Emphysema distribution in smoking;
CRC	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.36	6.02	0.32	4.54e-9	Menopause (age at onset);
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16613143	chr17:2415359	METT10D	0.44	6.74	0.35	7.03e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg00947319	chr17:47005597	UBE2Z	-0.35	-5.99	-0.31	5.54e-9	Type 2 diabetes;
CRC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg02766259	chr12:125626809	AACS	-0.45	-7.72	-0.39	1.42e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.51	7.47	0.38	7.26e-13	Blood metabolite levels;
CRC	cis	rs7539542	0.556	rs10753926	chr1:202876085	C/T	cg19681188	chr1:202830198	LOC148709	0.46	6.67	0.35	1.09e-10	Mean platelet volume;
CRC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.58	8.54	0.43	5.08e-16	Lung cancer;
CRC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg18016565	chr1:150552671	MCL1	0.44	6.07	0.32	3.53e-9	Melanoma;
CRC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.83	9.85	0.48	3.07e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.42	6.47	0.34	3.62e-10	Recombination rate (males);
CRC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.21	5.95	0.31	6.88e-9	Asthma;
CRC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.12	-0.37	6.62e-12	Mean platelet volume;
CRC	cis	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg15845792	chr6:28175446	NA	-0.6	-5.98	-0.31	5.77e-9	Depression;
CRC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg16989719	chr2:238392110	NA	-0.39	-6.44	-0.33	4.12e-10	Prostate cancer;
CRC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.63	-0.39	2.53e-13	Blood metabolite levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04267590	chr5:14581942	FAM105A	0.44	6.02	0.31	4.65e-9	Anxiety disorder;
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg24046110	chr8:143859143	LYNX1	0.49	8.61	0.43	3.15e-16	Urinary tract infection frequency;
CRC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.9	16.39	0.67	1.5e-44	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.6	8.55	0.43	4.83e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00938859	chr5:1591904	SDHAP3	0.72	7.76	0.39	1.09e-13	Breast cancer;
CRC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06505273	chr16:24850292	NA	-0.38	-5.92	-0.31	7.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.98	0.31	5.76e-9	Prudent dietary pattern;
CRC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.42	-7.51	-0.38	5.56e-13	Prostate cancer;
CRC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.43	-5.84	-0.31	1.26e-8	Pulse pressure;
CRC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.02	-0.36	1.3e-11	HDL cholesterol;
CRC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.91	13.0	0.58	1.85e-31	Breast cancer;
CRC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.92	-0.4	3.73e-14	Gut microbiome composition (summer);
CRC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg20243544	chr17:37824526	PNMT	0.41	5.63	0.3	3.83e-8	Urinary metabolites;
CRC	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.47	-8.67	-0.43	1.97e-16	Hepatitis;
CRC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg14711859	chr11:8959438	ASCL3	-0.48	-8.17	-0.41	6.51e-15	Reticulocyte fraction of red cells;
CRC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.71	-10.64	-0.51	6.48e-23	Breast cancer;
CRC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	10.8	0.51	1.82e-23	Motion sickness;
CRC	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg25797454	chr6:150327115	RAET1K	0.32	5.64	0.3	3.71e-8	Alopecia areata;
CRC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg21466736	chr12:48725269	NA	-0.51	-8.02	-0.4	1.93e-14	Plateletcrit;
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.25	0.41	3.74e-15	Life satisfaction;
CRC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg04586622	chr2:25135609	ADCY3	-0.5	-9.04	-0.45	1.41e-17	Breast cancer;
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.69	0.75	1.75e-61	Prudent dietary pattern;
CRC	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.68	-11.61	-0.54	2.41e-26	Lewy body disease;
CRC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.28	-0.42	3.21e-15	Mean corpuscular volume;
CRC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg00769240	chr8:12517080	NA	-0.65	-7.34	-0.38	1.67e-12	Blood pressure (smoking interaction);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg20306533	chr22:18507404	MICAL3	0.43	6.39	0.33	5.66e-10	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg08743896	chr10:65200160	JMJD1C	-0.43	-6.13	-0.32	2.57e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.25	-0.45	2.94e-18	Platelet count;
CRC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.52	0.46	3.79e-19	Bladder cancer;
CRC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.7	-11.43	-0.53	1.09e-25	Lung cancer;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg10876282	chr6:28092338	ZSCAN16	0.46	6.28	0.33	1.07e-9	Parkinson's disease;
CRC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.38	7.67	0.39	1.93e-13	Schizophrenia;
CRC	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.5	-6.82	-0.35	4.3e-11	Tuberculosis;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.64	6.57	0.34	1.92e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg26587870	chr6:27730563	NA	-0.41	-5.64	-0.3	3.61e-8	Parkinson's disease;
CRC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.77	-9.17	-0.45	5.32e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.99	0.44	1.96e-17	Fuchs's corneal dystrophy;
CRC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.92	-15.84	-0.66	2.09e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg20487152	chr13:99095054	FARP1	0.42	6.36	0.33	6.9e-10	Neuroticism;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg20933634	chr6:27740509	NA	0.39	5.74	0.3	2.1e-8	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17561891	chr7:86849173	C7orf23	0.34	6.07	0.32	3.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9463078	0.625	rs3799986	chr6:44900253	C/T	cg25276700	chr6:44698697	NA	0.24	5.89	0.31	9.53e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs10411161	0.702	rs8113768	chr19:52383938	C/T	cg22319618	chr22:45562946	NUP50	-0.68	-7.53	-0.38	4.85e-13	Breast cancer;
CRC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.27e-17	Morning vs. evening chronotype;
CRC	cis	rs17023223	0.537	rs1057991	chr1:119575170	C/A	cg05756136	chr1:119680316	WARS2	-0.47	-6.38	-0.33	5.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.77	-13.88	-0.61	8.57e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg10756647	chr7:56101905	PSPH	0.73	7.98	0.4	2.44e-14	Diabetic kidney disease;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg05569086	chr8:143859399	LYNX1	0.42	6.92	0.36	2.35e-11	Urinary tract infection frequency;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01685246	chr16:30538016	ZNF768	0.38	5.96	0.31	6.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg13468214	chr4:1046988	NA	-0.33	-5.72	-0.3	2.45e-8	Recombination rate (males);
CRC	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.62	10.15	0.49	3.01e-21	Cancer;
CRC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.81	8.38	0.42	1.55e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs728616	0.614	rs61859198	chr10:82114628	C/A	cg05935833	chr10:81318306	SFTPA2	-0.6	-7.28	-0.37	2.44e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.41	-5.62	-0.3	4.03e-8	Longevity;Endometriosis;
CRC	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg24848437	chr7:2645542	IQCE	-0.58	-6.47	-0.34	3.45e-10	Urate levels in lean individuals;
CRC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.12	0.41	9.29e-15	Monocyte count;
CRC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.21	0.49	1.99e-21	Hemoglobin concentration;
CRC	cis	rs7258465	1.000	rs34010330	chr19:18559657	G/C	cg10790698	chr19:18539756	SSBP4	-0.44	-8.12	-0.41	9.46e-15	Breast cancer;
CRC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.74	-8.3	-0.42	2.67e-15	HIV-1 control;
CRC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.04	-0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.68	-0.43	1.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg09695851	chr17:3907499	NA	0.75	14.22	0.62	4.33e-36	Type 2 diabetes;
CRC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.17	0.32	1.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-0.63	-11.28	-0.53	3.71e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg19897017	chr7:2163380	MAD1L1	0.37	5.66	0.3	3.36e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg03351412	chr1:154909251	PMVK	0.51	7.22	0.37	3.73e-12	Prostate cancer;
CRC	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.56	-7.87	-0.4	5.31e-14	Waist circumference;Body mass index;
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg10729496	chr3:10149963	C3orf24	0.54	7.32	0.37	1.88e-12	Alzheimer's disease;
CRC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.66	-0.39	2.05e-13	Coronary artery disease;
CRC	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.17	9.49	0.46	4.8e-19	Mitochondrial DNA levels;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	5.6	0.3	4.47e-8	Bipolar disorder;
CRC	trans	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2734839	0.929	rs11608185	chr11:113294976	T/C	cg14159747	chr11:113255604	NA	0.46	7.95	0.4	2.95e-14	Information processing speed;
CRC	cis	rs35000415	0.938	rs17338998	chr7:128618559	C/T	cg19972273	chr7:128594194	NA	0.68	6.31	0.33	8.75e-10	Systemic lupus erythematosus;
CRC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.76	10.61	0.5	8.09e-23	Orofacial clefts;
CRC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.55	7.29	0.37	2.32e-12	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg19223190	chr17:80058835	NA	0.38	6.09	0.32	3.15e-9	Life satisfaction;
CRC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.45	5.87	0.31	1.05e-8	Large artery stroke;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.81	12.13	0.56	3.01e-28	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12763900	chr3:114866235	ZBTB20	0.44	6.31	0.33	8.76e-10	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg05585544	chr11:47624801	NA	-0.52	-9.43	-0.46	7.53e-19	Subjective well-being;
CRC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.42	6.21	0.32	1.6e-9	Hemoglobin concentration;
CRC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.13	-0.41	9.07e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00497091	chr1:145438415	TXNIP	0.45	6.45	0.34	3.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs9463078	0.739	rs6910749	chr6:44773892	A/G	cg25276700	chr6:44698697	NA	-0.27	-6.8	-0.35	4.92e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.37	6.08	0.32	3.37e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.8	8.72	0.43	1.43e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.36	-0.42	1.82e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg18764771	chr6:116381957	FRK	0.24	6.98	0.36	1.67e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs11628318	0.515	rs4906239	chr14:103078073	A/G	cg12046867	chr14:103022105	NA	-0.41	-5.66	-0.3	3.33e-8	Platelet count;
CRC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.18	0.37	4.69e-12	Colorectal cancer;
CRC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.12	0.32	2.73e-9	Bladder cancer;
CRC	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.66	-0.39	2.04e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.05	-0.32	4e-9	Joint mobility (Beighton score);
CRC	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.5	-7.67	-0.39	1.99e-13	Testicular germ cell tumor;
CRC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.41	7.84	0.4	6.48e-14	Ulcerative colitis;
CRC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg20243544	chr17:37824526	PNMT	0.55	8.52	0.43	5.73e-16	Asthma;
CRC	cis	rs7259376	0.905	rs12608842	chr19:22548013	C/G	cg02657401	chr19:22469223	NA	0.31	6.97	0.36	1.74e-11	Menopause (age at onset);
CRC	cis	rs6764363	0.545	rs331858	chr3:316550	A/T	cg02057681	chr3:285234	CHL1	-0.41	-6.95	-0.36	1.92e-11	Sudden cardiac arrest;
CRC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.66	0.39	2.07e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.9	-17.21	-0.69	8.44e-48	Intelligence (multi-trait analysis);
CRC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.72	12.71	0.57	2.24e-30	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg23254163	chr1:152506842	NA	0.5	10.0	0.48	9.8e-21	Hair morphology;
CRC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	4.98e-10	Tonsillectomy;
CRC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs6546324	0.625	rs4671813	chr2:67841835	A/T	cg15745817	chr2:67799979	NA	-0.56	-9.54	-0.47	3.44e-19	Endometriosis;
CRC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg18551225	chr6:44695536	NA	-0.41	-5.67	-0.3	3.18e-8	Total body bone mineral density;
CRC	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-6.95	-0.36	1.93e-11	Intelligence (multi-trait analysis);
CRC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.62	7.11	0.36	7.24e-12	Resting heart rate;
CRC	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg09184832	chr6:79620586	NA	-0.46	-7.86	-0.4	5.67e-14	Intelligence (multi-trait analysis);
CRC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg25972092	chr12:117363249	FBXW8	-0.51	-6.08	-0.32	3.24e-9	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg01721255	chr8:58191610	C8orf71	0.52	6.45	0.33	4.05e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg22535103	chr8:58192502	C8orf71	-0.44	-6.15	-0.32	2.28e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11502736	chr1:179923845	CEP350	0.46	6.6	0.34	1.69e-10	Response to antipsychotic treatment;
CRC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg14711859	chr11:8959438	ASCL3	-0.51	-8.2	-0.41	5.62e-15	Hemoglobin concentration;
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-6.0	-0.31	5.13e-9	Life satisfaction;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Depression;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13257812	chr3:27525884	NA	-0.38	-6.07	-0.32	3.43e-9	Myopia (pathological);
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-6.42	-0.33	4.9e-10	Height;
CRC	cis	rs1572438	1.000	rs1572438	chr6:858970	A/G	cg21062780	chr6:887772	NA	0.38	5.97	0.31	6.12e-9	Aging;
CRC	trans	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg02674126	chr19:40336878	FBL	0.42	6.74	0.35	6.98e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs11723261	0.582	rs6814287	chr4:122323	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	6.34	0.33	7.57e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs860295	0.702	rs10752611	chr1:155509107	C/T	cg02153340	chr1:155202674	NA	-0.58	-6.82	-0.35	4.35e-11	Body mass index;
CRC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg23127183	chr11:57508653	C11orf31	0.43	5.66	0.3	3.38e-8	Schizophrenia;
CRC	cis	rs4716602	0.596	rs10266659	chr7:156159278	A/G	cg16983916	chr7:156159713	NA	-0.41	-7.2	-0.37	4.05e-12	Anti-saccade response;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg23161317	chr6:28129485	ZNF389	0.46	5.93	0.31	7.69e-9	Depression;
CRC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.42	0.33	4.78e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.5	-9.08	-0.45	1.06e-17	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.06	-0.48	6.41e-21	Monocyte count;
CRC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	5.8	0.3	1.59e-8	Schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07325233	chr21:34638662	IL10RB	-0.41	-6.24	-0.33	1.37e-9	Myopia (pathological);
CRC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	8.43	0.42	1.09e-15	Response to antipsychotic treatment;
CRC	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg06935464	chr4:38784597	TLR10	0.58	6.05	0.32	3.84e-9	Breast cancer;
CRC	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.24	14.62	0.63	1.19e-37	Uric acid levels;
CRC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.13	-13.34	-0.59	9.36e-33	Diabetic kidney disease;
CRC	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.68	14.2	0.62	4.88e-36	Schizophrenia;
CRC	cis	rs7212590	0.881	rs7216675	chr17:57882674	T/C	cg10252138	chr17:58120427	NA	-0.53	-5.7	-0.3	2.63e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.63	5.72	0.3	2.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21028142	chr17:79581711	NPLOC4	-0.34	-6.98	-0.36	1.65e-11	Eye color traits;
CRC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.42	-0.42	1.17e-15	Height;
CRC	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg23815491	chr16:72088622	HP	0.64	7.99	0.4	2.35e-14	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02541231	chr11:2398776	CD81	0.46	6.41	0.33	5.13e-10	Response to antipsychotic treatment;
CRC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg02428538	chr16:24856791	SLC5A11	-0.59	-6.42	-0.33	4.78e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.28	0.33	1.06e-9	Bladder cancer;
CRC	cis	rs62432291	0.681	rs425906	chr6:159657575	C/T	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg14004847	chr7:1930337	MAD1L1	-0.39	-5.64	-0.3	3.74e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg10756647	chr7:56101905	PSPH	0.73	7.68	0.39	1.79e-13	Diabetic kidney disease;
CRC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg24675056	chr1:15929824	NA	0.53	7.22	0.37	3.68e-12	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05076971	chr7:117824189	NAA38	0.4	6.1	0.32	2.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg06092702	chr1:163392909	NA	-0.52	-8.24	-0.41	4.27e-15	Motion sickness;
CRC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.73	-11.76	-0.54	6.6e-27	Colorectal cancer;
CRC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg10862848	chr6:42927986	GNMT	-0.31	-6.17	-0.32	1.97e-9	Blood protein levels;
CRC	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.34	-6.68	-0.35	1.04e-10	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.77	-0.3	1.79e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg13390004	chr1:15929781	NA	0.5	6.9	0.36	2.6e-11	Systolic blood pressure;
CRC	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.48	6.38	0.33	6.04e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg06470822	chr6:28175283	NA	0.95	13.59	0.6	1.07e-33	Parkinson's disease;
CRC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.49	5.92	0.31	8.05e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.55	-6.69	-0.35	9.61e-11	Alzheimer's disease;
CRC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.62	9.27	0.46	2.52e-18	Bone mineral density;
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg16606324	chr3:10149918	C3orf24	0.67	7.74	0.39	1.2e-13	Alzheimer's disease;
CRC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.8	-14.02	-0.61	2.46e-35	Total body bone mineral density;
CRC	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.55	9.32	0.46	1.68e-18	Common traits (Other);
CRC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.76	10.88	0.51	9.29e-24	Heart rate;
CRC	cis	rs1958560	0.932	rs61987993	chr14:66070732	C/G	cg03016385	chr14:66212404	NA	-0.45	-6.19	-0.32	1.81e-9	Menarche (age at onset);
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.87	0.58	5.44e-31	Alzheimer's disease;
CRC	cis	rs11650494	0.710	rs76305536	chr17:47488913	G/A	cg08112188	chr17:47440006	ZNF652	0.88	7.15	0.37	5.58e-12	Prostate cancer;
CRC	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.98	-0.31	5.75e-9	Height;
CRC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.82	-0.31	1.39e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg08614441	chr13:113633676	MCF2L	-0.53	-9.31	-0.46	1.88e-18	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.56	8.74	0.43	1.17e-16	Diastolic blood pressure;
CRC	cis	rs62408225	0.862	rs60066732	chr6:90935383	A/G	cg06866423	chr6:90926672	BACH2	0.46	7.36	0.38	1.51e-12	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.69	10.97	0.52	4.55e-24	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9463078	0.764	rs1935551	chr6:44786035	T/G	cg25276700	chr6:44698697	NA	-0.27	-6.56	-0.34	2.14e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.33	-0.37	1.79e-12	Morning vs. evening chronotype;
CRC	cis	rs230203	0.506	rs230197	chr20:55776011	T/C	cg13236649	chr20:55835020	BMP7	0.42	6.27	0.33	1.14e-9	Monobrow;
CRC	cis	rs10486722	0.565	rs11766394	chr7:41758188	T/C	cg22138096	chr7:41772439	LOC285954	0.53	6.88	0.35	3e-11	Pit-and-Fissure caries;
CRC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.56	7.89	0.4	4.44e-14	Alcohol dependence;
CRC	cis	rs2072510	0.593	rs2540499	chr12:96399869	A/C	cg15438951	chr12:96389694	HAL	0.49	6.2	0.32	1.66e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs10833965	0.748	rs10833979	chr11:23232089	C/T	cg05245346	chr11:23248277	NA	0.36	5.82	0.31	1.41e-8	Cancer;
CRC	cis	rs747650	0.504	rs4752816	chr11:46979023	A/G	cg19486271	chr11:47235900	DDB2	-0.44	-5.84	-0.31	1.24e-8	Acne (severe);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12121587	chr11:66025327	KLC2	0.42	7.25	0.37	3.02e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.56	-0.63	2.08e-37	Body mass index;
CRC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.28	-0.49	1.15e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.6	-9.98	-0.48	1.14e-20	Prudent dietary pattern;
CRC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.78	11.07	0.52	2.07e-24	High light scatter reticulocyte count;
CRC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	1.03	13.47	0.6	2.98e-33	Cerebrospinal P-tau181p levels;
CRC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.14	-0.32	2.44e-9	Alzheimer's disease (late onset);
CRC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.49	-6.99	-0.36	1.53e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.33	-0.53	2.37e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg10645314	chr2:3704589	ALLC	-0.55	-6.43	-0.33	4.47e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs35847492	1.000	rs17730481	chr8:9276163	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.51	-0.34	2.73e-10	Neuroticism;
CRC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.64	0.47	1.58e-19	Cognitive test performance;
CRC	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg24249390	chr15:90295951	MESP1	0.57	9.24	0.45	3.11e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg24163568	chr5:669837	TPPP	0.43	6.84	0.35	3.94e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.47	-6.12	-0.32	2.64e-9	Tuberculosis;
CRC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.74	11.66	0.54	1.62e-26	Monocyte count;
CRC	cis	rs6681460	0.932	rs492109	chr1:67187133	C/A	cg02459107	chr1:67143332	SGIP1	-0.35	-6.02	-0.31	4.72e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.44	7.4	0.38	1.12e-12	Diastolic blood pressure;
CRC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.39	-6.24	-0.33	1.31e-9	Multiple sclerosis;
CRC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.09e-15	Platelet count;
CRC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg25985355	chr7:65971099	NA	-0.49	-5.73	-0.3	2.27e-8	Diabetic kidney disease;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-9.44	-0.46	6.9e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg22638593	chr5:131593259	PDLIM4	0.35	6.57	0.34	1.96e-10	Blood metabolite levels;
CRC	cis	rs12476592	0.571	rs262510	chr2:63886712	A/C	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.73e-56	Primary sclerosing cholangitis;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg16606324	chr3:10149918	C3orf24	0.61	7.88	0.4	4.89e-14	Alzheimer's disease;
CRC	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg24304309	chr1:154577895	ADAR	0.36	6.0	0.31	5.3e-9	Blood protein levels;
CRC	trans	rs11581859	0.950	rs17390223	chr1:99361788	A/G	cg12183875	chr3:169587454	LRRC31	-0.27	-6.1	-0.32	3.03e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.01	22.57	0.78	8.08e-69	Multiple system atrophy;
CRC	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.96	18.33	0.71	3.36e-52	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.68	9.65	0.47	1.42e-19	Longevity;
CRC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.49	7.89	0.4	4.5e-14	Crohn's disease;
CRC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg16447950	chr5:562315	NA	-0.79	-10.45	-0.5	2.87e-22	Lung disease severity in cystic fibrosis;
CRC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.51	8.4	0.42	1.38e-15	Cystic fibrosis severity;
CRC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg24209194	chr3:40518798	ZNF619	0.38	5.71	0.3	2.53e-8	Renal cell carcinoma;
CRC	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg16576597	chr16:28551801	NUPR1	0.48	7.3	0.37	2.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6807915	0.504	rs167467	chr3:12281183	A/G	cg04748988	chr3:12329223	PPARG	0.41	6.09	0.32	3.2e-9	Leprosy;
CRC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.37	-5.91	-0.31	8.73e-9	Blood metabolite levels;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.77	0.3	1.86e-8	Prudent dietary pattern;
CRC	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg21153622	chr11:89784906	NA	-0.45	-7.18	-0.37	4.68e-12	HDL cholesterol;
CRC	cis	rs8064454	0.870	rs11263763	chr17:36103565	C/T	cg04198914	chr17:36106025	HNF1B	-0.3	-6.73	-0.35	7.75e-11	Prostate cancer;
CRC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg00976097	chr5:421733	AHRR	-0.43	-5.66	-0.3	3.32e-8	Cystic fibrosis severity;
CRC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg02269571	chr22:50332266	NA	-0.92	-9.51	-0.46	4.22e-19	Schizophrenia;
CRC	cis	rs12541635	0.801	rs28709304	chr8:107106368	T/G	cg10147462	chr8:107024639	NA	-0.39	-6.05	-0.32	3.92e-9	Age of smoking initiation;
CRC	cis	rs11212617	1.000	rs7946955	chr11:108284833	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.58	0.34	1.81e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	9.49	0.46	4.98e-19	Nonalcoholic fatty liver disease;
CRC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.69	-11.58	-0.54	3.12e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.58	6.25	0.33	1.24e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03118206	chr6:138482933	KIAA1244	-0.4	-5.98	-0.31	5.67e-9	Myopia (pathological);
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16322302	chr3:49157769	USP19	0.45	6.59	0.34	1.73e-10	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.62	0.39	2.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.07	0.32	3.59e-9	Bipolar disorder;
CRC	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg08222913	chr3:52553049	STAB1	-0.37	-7.02	-0.36	1.28e-11	Electroencephalogram traits;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg02683197	chr6:28174875	NA	0.67	6.74	0.35	7.09e-11	Lung cancer in ever smokers;
CRC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.77	9.62	0.47	1.8e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.44	-6.26	-0.33	1.21e-9	Height;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.12	-0.37	6.88e-12	Bipolar disorder;
CRC	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg04239558	chr2:103089729	SLC9A4	0.37	6.37	0.33	6.43e-10	Blood protein levels;
CRC	cis	rs17767392	0.958	rs12894478	chr14:71825113	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.59	-6.77	-0.35	5.76e-11	Bipolar disorder;
CRC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.2	-0.32	1.67e-9	Height;
CRC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg06287003	chr12:125626642	AACS	-0.59	-8.16	-0.41	7.21e-15	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs12476592	0.543	rs262480	chr2:63873032	A/G	cg10828910	chr2:63850056	LOC388955	0.5	6.21	0.32	1.63e-9	Childhood ear infection;
CRC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.67	-0.35	1.05e-10	Total body bone mineral density;
CRC	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.74	11.44	0.53	9.61e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg01304814	chr3:48885189	PRKAR2A	0.75	5.76	0.3	1.88e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03779258	chr22:34316655	LARGE	0.38	6.25	0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.21e-10	Obesity-related traits;
CRC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.95	-0.4	2.93e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12922317	0.589	rs350216	chr16:12151140	C/T	cg02368508	chr16:12060182	TNFRSF17	0.41	6.11	0.32	2.8e-9	Schizophrenia;
CRC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-8.99	-0.44	2.04e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.53	7.49	0.38	6.52e-13	Testicular germ cell tumor;
CRC	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg09873164	chr1:152488093	CRCT1	0.4	6.75	0.35	6.85e-11	Hair morphology;
CRC	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02097616	chr17:62675921	NA	-0.52	-7.4	-0.38	1.14e-12	QT interval;
CRC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg00769240	chr8:12517080	NA	-0.54	-6.72	-0.35	8.02e-11	Blood pressure (smoking interaction);
CRC	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.62	9.07	0.45	1.07e-17	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.51	-11.71	-0.54	1.06e-26	Prostate cancer;
CRC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-1.02	-20.71	-0.75	1.42e-61	Headache;
CRC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-6.71	-0.35	8.44e-11	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00964710	chr16:14726998	BFAR	0.45	6.12	0.32	2.65e-9	Anxiety disorder;
CRC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.57e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg14530993	chr4:882597	GAK	0.8	7.59	0.39	3.35e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.41	6.26	0.33	1.17e-9	Endometrial cancer;
CRC	trans	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg21153622	chr11:89784906	NA	-0.49	-7.76	-0.39	1.08e-13	HDL cholesterol;
CRC	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg10517650	chr3:113235015	CCDC52	-0.37	-6.57	-0.34	1.97e-10	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.85	-0.74	3.48e-58	Primary sclerosing cholangitis;
CRC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg05683857	chr10:124030795	BTBD16	0.33	6.05	0.32	3.95e-9	Total body bone mineral density;
CRC	cis	rs6681460	1.000	rs6659968	chr1:67123459	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.33	0.42	2.27e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-11.26	-0.53	4.41e-25	Electroencephalogram traits;
CRC	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.66	0.51	5.41e-23	Ileal carcinoids;
CRC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Bladder cancer;
CRC	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.9e-16	Corneal astigmatism;
CRC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.61	6.86	0.35	3.38e-11	Vitiligo;
CRC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg04586622	chr2:25135609	ADCY3	-0.56	-10.5	-0.5	1.91e-22	Body mass index in non-asthmatics;
CRC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg14711859	chr11:8959438	ASCL3	-0.39	-6.48	-0.34	3.36e-10	Hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03630683	chr3:4534997	ITPR1	0.53	7.63	0.39	2.49e-13	Response to antipsychotic treatment;
CRC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.42	6.98	0.36	1.6e-11	Coronary artery disease;
CRC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	6.78	0.35	5.51e-11	Schizophrenia;
CRC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg19046167	chr17:80928561	B3GNTL1	0.49	6.7	0.35	9.06e-11	Glycated hemoglobin levels;
CRC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.47	-6.68	-0.35	1.03e-10	Diastolic blood pressure;
CRC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.35e-10	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17979952	chr6:117803953	DCBLD1	0.43	6.11	0.32	2.88e-9	Response to antipsychotic treatment;
CRC	cis	rs7781557	0.640	rs66712128	chr7:102616987	T/C	cg18108683	chr7:102477205	FBXL13	-0.49	-5.97	-0.31	6.01e-9	Colorectal adenoma (advanced);
CRC	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg14664628	chr15:75095509	CSK	0.42	5.79	0.3	1.66e-8	Systemic lupus erythematosus;
CRC	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.94	0.31	7.07e-9	Breast cancer;
CRC	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.46	6.94	0.36	2.1e-11	Coronary artery disease;
CRC	cis	rs17155006	0.655	rs424978	chr7:107724747	C/G	cg05962710	chr7:107745446	LAMB4	-0.35	-5.85	-0.31	1.21e-8	Pneumococcal bacteremia;
CRC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	3.03e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	1.12	10.87	0.51	1.01e-23	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	9.41	0.46	9.13e-19	Response to antipsychotic treatment;
CRC	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg17652424	chr22:38574118	PLA2G6	-0.18	-5.65	-0.3	3.49e-8	Cutaneous nevi;
CRC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.5	-0.46	4.57e-19	Heart rate;
CRC	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.59	8.52	0.43	5.96e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs61160187	0.582	rs62367872	chr5:60272770	A/G	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.73	-0.3	2.26e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs4700695	0.841	rs706680	chr5:65317338	T/C	cg21114390	chr5:65439923	SFRS12	0.58	7.04	0.36	1.16e-11	Facial morphology (factor 19);
CRC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.38	11.76	0.54	7.04e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7833986	1.000	rs7833986	chr8:57100149	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.64	0.39	2.43e-13	Height;
CRC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.9	12.86	0.58	6.12e-31	Breast cancer;
CRC	trans	rs474558	0.597	rs574293	chr10:99699426	G/A	cg05303249	chr11:66036138	RAB1B	-0.58	-8.6	-0.43	3.2e-16	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.72	-11.58	-0.54	3.13e-26	Mean platelet volume;
CRC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.51	7.76	0.39	1.09e-13	Aortic root size;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg23161317	chr6:28129485	ZNF389	0.46	6.51	0.34	2.82e-10	Cardiac Troponin-T levels;
CRC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	2.9e-24	Corneal astigmatism;
CRC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg03030879	chr14:75389066	RPS6KL1	0.55	8.98	0.44	2.1e-17	Caffeine consumption;
CRC	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.62	-0.39	2.79e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg21972741	chr5:435613	AHRR	0.55	7.45	0.38	8.34e-13	Cystic fibrosis severity;
CRC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.69	10.54	0.5	1.47e-22	Cognitive function;
CRC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.71	-11.81	-0.55	4.63e-27	Extrinsic epigenetic age acceleration;
CRC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.52	0.42	6e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg06494592	chr3:125709126	NA	-0.58	-6.85	-0.35	3.57e-11	Blood pressure (smoking interaction);
CRC	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.38	-11.56	-0.54	3.59e-26	Psoriasis vulgaris;
CRC	cis	rs3789045	0.520	rs2010432	chr1:204462619	G/T	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.86	-0.4	5.39e-14	Educational attainment (college completion);
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.34	2.9e-10	Bipolar disorder;
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.7	-11.59	-0.54	2.78e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg13447295	chr6:887704	NA	0.59	8.84	0.44	5.86e-17	Aging;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs7517126	1.000	rs7519501	chr1:196840173	T/C	cg13682187	chr1:196946512	CFHR5	-0.37	-6.02	-0.32	4.6e-9	Blood protein levels;
CRC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.97	-18.18	-0.71	1.32e-51	Cognitive ability;
CRC	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.7	-9.29	-0.46	2.22e-18	Blood pressure (smoking interaction);
CRC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.47	-0.34	3.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	trans	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg25482853	chr8:67687455	SGK3	0.45	6.04	0.32	4.27e-9	Obesity-related traits;
CRC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg18683604	chr14:51561293	TRIM9	0.29	5.66	0.3	3.25e-8	Cancer;
CRC	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.41	-7.97	-0.4	2.58e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg07404485	chr7:94953653	PON1	-0.47	-6.25	-0.33	1.27e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.36e-10	Alzheimer's disease;
CRC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.83	13.48	0.6	2.7e-33	Menarche (age at onset);
CRC	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg07617317	chr6:118971624	C6orf204	-0.51	-6.03	-0.32	4.34e-9	Diastolic blood pressure;
CRC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.39	7.12	0.37	6.97e-12	Height;
CRC	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.47	6.38	0.33	5.86e-10	Lymphocyte counts;Fibrinogen;
CRC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.83	-14.33	-0.62	1.65e-36	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06363041	chr3:131100598	NUDT16	0.47	6.4	0.33	5.48e-10	Anxiety disorder;
CRC	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.87	9.46	0.46	6.05e-19	Gut microbiota (bacterial taxa);
CRC	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.54	-0.47	3.39e-19	Prevalent atrial fibrillation;
CRC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.84	-14.77	-0.63	3.04e-38	Fuchs's corneal dystrophy;
CRC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24308560	chr3:49941425	MST1R	-0.45	-7.12	-0.37	6.61e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg06156847	chr2:113672199	IL1F7	-0.39	-5.96	-0.31	6.34e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.27	0.53	3.95e-25	Prudent dietary pattern;
CRC	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg22182287	chr2:3452347	TTC15	0.38	5.92	0.31	7.98e-9	Obesity-related traits;
CRC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.38	-6.77	-0.35	6.05e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.83	9.88	0.48	2.57e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	6.43	0.33	4.52e-10	Aortic root size;
CRC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg02869306	chr7:64672164	INTS4L1	0.44	6.18	0.32	1.9e-9	Aortic root size;
CRC	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.41	-6.66	-0.34	1.17e-10	Mean arterial pressure;
CRC	cis	rs989128	0.642	rs8077316	chr17:48626389	C/T	cg16068336	chr17:48637367	CACNA1G	-0.54	-7.73	-0.39	1.3e-13	Type 2 diabetes;
CRC	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-6.98	-0.36	1.63e-11	Multiple sclerosis;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.59	-8.25	-0.41	3.86e-15	Menopause (age at onset);
CRC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.81	-12.52	-0.57	1.09e-29	Multiple sclerosis;
CRC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg24977027	chr2:88469347	THNSL2	0.55	6.52	0.34	2.67e-10	Plasma clusterin levels;
CRC	trans	rs264943	0.714	rs264938	chr2:104296743	C/T	cg14722509	chr5:170815938	NPM1	-0.42	-5.96	-0.31	6.48e-9	HIV-1 viral setpoint;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04665351	chr12:3000000	TULP3	0.36	6.67	0.35	1.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg10279832	chr4:154682576	RNF175	0.39	5.91	0.31	8.67e-9	Response to statins (LDL cholesterol change);
CRC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.61	-0.47	1.97e-19	Subjective well-being;
CRC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.48	7.88	0.4	4.7e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.97	-0.4	2.55e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7259376	0.902	rs12978477	chr19:22577709	C/G	cg02657401	chr19:22469223	NA	0.3	6.63	0.34	1.37e-10	Menopause (age at onset);
CRC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.4	6.13	0.32	2.52e-9	Red blood cell count;
CRC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.54	9.57	0.47	2.67e-19	HDL cholesterol levels;
CRC	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.83	7.15	0.37	5.59e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg10876282	chr6:28092338	ZSCAN16	0.47	6.36	0.33	6.71e-10	Parkinson's disease;
CRC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	0.67	5.89	0.31	9.73e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.24	0.49	1.54e-21	Monocyte percentage of white cells;
CRC	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.55	-7.63	-0.39	2.51e-13	Triglycerides;
CRC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.98	0.31	5.83e-9	Prudent dietary pattern;
CRC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg10298567	chr3:47292165	KIF9	-0.37	-6.0	-0.31	5.28e-9	Colorectal cancer;
CRC	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.62	9.75	0.47	6.91e-20	Crohn's disease;
CRC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.62	0.3	4.08e-8	Tonsillectomy;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg18758796	chr5:131593413	PDLIM4	-0.39	-6.34	-0.33	7.79e-10	Breast cancer;
CRC	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs6717918	0.887	rs13020779	chr2:233149600	A/G	ch.2.233013039R	chr2:233304795	NA	0.47	6.57	0.34	2e-10	Height;
CRC	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg13385794	chr1:248469461	NA	0.4	7.0	0.36	1.47e-11	Common traits (Other);
CRC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.69	-11.73	-0.54	8.89e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.18	0.32	1.88e-9	Hair morphology;
CRC	cis	rs7086803	1.000	rs11196087	chr10:114506406	C/T	cg03281572	chr10:114502318	VTI1A	-0.73	-6.13	-0.32	2.53e-9	Lung cancer;
CRC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-5.62	-0.3	4.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.32	-5.65	-0.3	3.41e-8	Menarche (age at onset);
CRC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg16405210	chr4:1374714	KIAA1530	0.41	5.83	0.31	1.36e-8	Obesity-related traits;
CRC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.61	-0.54	2.39e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs6586163	1.000	rs7072828	chr10:90754953	T/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.31	-0.37	2.03e-12	Chronic lymphocytic leukemia;
CRC	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg13491945	chr12:107078410	RFX4	0.35	5.96	0.31	6.44e-9	Heart rate;
CRC	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.72	-9.79	-0.47	5e-20	Blood pressure (smoking interaction);
CRC	cis	rs4561483	0.743	rs28653099	chr16:12009150	C/A	cg08843971	chr16:11963173	GSPT1	0.5	7.41	0.38	1.05e-12	Testicular germ cell tumor;
CRC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg10305451	chr2:177043427	NA	-0.53	-6.85	-0.35	3.71e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.12	0.37	6.68e-12	Colorectal cancer;
CRC	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.64	9.03	0.45	1.46e-17	Primary sclerosing cholangitis;
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.34	-0.56	5.29e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg12927641	chr6:109611667	NA	-0.35	-6.23	-0.32	1.44e-9	Reticulocyte fraction of red cells;
CRC	cis	rs73206853	0.764	rs7312939	chr12:110564108	G/A	cg12870014	chr12:110450643	ANKRD13A	0.76	8.87	0.44	4.59e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg01134436	chr17:81009848	B3GNTL1	0.73	6.93	0.36	2.21e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg02269571	chr22:50332266	NA	-0.5	-6.92	-0.36	2.36e-11	Schizophrenia;
CRC	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg11901034	chr3:128598214	ACAD9	-0.6	-8.01	-0.4	2.04e-14	IgG glycosylation;
CRC	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.54	-7.24	-0.37	3.14e-12	Triglycerides;
CRC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	0.59	6.36	0.33	6.75e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs17767392	0.958	rs56407721	chr14:71963503	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.25	-0.37	2.94e-12	Mitral valve prolapse;
CRC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg25985355	chr7:65971099	NA	0.32	5.6	0.3	4.48e-8	Aortic root size;
CRC	cis	rs2077654	0.556	rs11024284	chr11:17444590	C/T	cg25308976	chr11:17434268	ABCC8	0.61	6.95	0.36	1.95e-11	Gout;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg15786705	chr6:28176104	NA	0.79	10.06	0.48	6.42e-21	Depression;
CRC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.69	-11.93	-0.55	1.61e-27	P wave terminal force;
CRC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.51	-6.96	-0.36	1.87e-11	Serum sulfate level;
CRC	trans	rs10242455	0.702	rs10251282	chr7:98990236	T/C	cg09045935	chr12:6379348	NA	0.99	7.45	0.38	8.27e-13	Blood metabolite levels;
CRC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg25204440	chr1:209979598	IRF6	-0.48	-6.32	-0.33	8.36e-10	Cleft lip with or without cleft palate;
CRC	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.28	-0.69	4.62e-48	Schizophrenia;
CRC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.79	13.49	0.6	2.56e-33	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CRC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-5.62	-0.3	4.08e-8	Bipolar disorder;
CRC	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg21153622	chr11:89784906	NA	-0.43	-7.01	-0.36	1.32e-11	Height;
CRC	cis	rs1124376	1.000	rs9819739	chr3:20140760	G/A	cg05072819	chr3:20081367	KAT2B	0.51	6.24	0.33	1.33e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg21625146	chr5:486483	SLC9A3	0.37	5.83	0.31	1.34e-8	Cystic fibrosis severity;
CRC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.67	10.33	0.49	7.48e-22	Height;
CRC	cis	rs2160860	0.729	rs56838465	chr8:39801480	G/T	cg11363097	chr8:39792086	IDO2	-0.45	-7.58	-0.39	3.66e-13	Blood metabolite levels;
CRC	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.11	-0.56	3.76e-28	Coffee consumption (cups per day);
CRC	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.47	-5.88	-0.31	9.92e-9	Coronary artery calcification;
CRC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.79	14.73	0.63	4.46e-38	Metabolic syndrome;
CRC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.5	7.17	0.37	5.1e-12	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22853526	chr1:113216965	MOV10	0.42	6.22	0.32	1.55e-9	Response to antipsychotic treatment;
CRC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.57	7.69	0.39	1.78e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	1.16	11.72	0.54	9.45e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg22359107	chr11:18655812	SPTY2D1	0.41	5.98	0.31	5.7e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20894110	chr13:23949701	SACS	0.36	6.1	0.32	2.97e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-8.3	-0.42	2.68e-15	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.17	0.45	5.23e-18	Coffee consumption (cups per day);
CRC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg06470822	chr6:28175283	NA	0.91	13.28	0.59	1.54e-32	Parkinson's disease;
CRC	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-12.24	-0.56	1.26e-28	Prostate cancer;
CRC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.39	-6.73	-0.35	7.77e-11	Schizophrenia;
CRC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.44	6.74	0.35	6.94e-11	Monocyte count;
CRC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12667521	chr19:29218732	NA	0.53	7.31	0.37	2.11e-12	Methadone dose in opioid dependence;
CRC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.6	8.93	0.44	3.13e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.51	8.3	0.42	2.8e-15	Aortic root size;
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg27588902	chr6:42928151	GNMT	-0.41	-7.41	-0.38	1.06e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.36e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs76533333	0.646	rs71446911	chr13:113377528	G/T	cg04656015	chr13:113407548	ATP11A	0.78	5.85	0.31	1.19e-8	Red cell distribution width;
CRC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.81	14.79	0.63	2.59e-38	Metabolic syndrome;
CRC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.65	-11.88	-0.55	2.53e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.84	13.13	0.59	6.07e-32	Height;
CRC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg08222913	chr3:52553049	STAB1	-0.33	-5.7	-0.3	2.66e-8	Bipolar disorder;
CRC	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg16512390	chr1:228756714	NA	0.68	6.36	0.33	6.65e-10	Chronic lymphocytic leukemia;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Parkinson's disease;
CRC	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.41	0.5	4.04e-22	Corneal astigmatism;
CRC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.6	-12.26	-0.56	1.06e-28	Schizophrenia;
CRC	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg07166546	chr14:35805898	NA	-0.31	-6.02	-0.31	4.66e-9	Psoriasis;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.97	-0.31	5.98e-9	Life satisfaction;
CRC	cis	rs391936	0.568	rs2931137	chr2:8466655	A/T	cg12167548	chr2:8464763	NA	0.34	6.41	0.33	5.13e-10	Selective IgA deficiency;
CRC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg00383909	chr3:49044727	WDR6	0.6	6.3	0.33	9.36e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.75	12.07	0.55	5.24e-28	Intelligence (multi-trait analysis);
CRC	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg11003573	chr3:44754125	ZNF502	-0.34	-5.9	-0.31	8.88e-9	Depressive symptoms;
CRC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.53	-7.96	-0.4	2.77e-14	HDL cholesterol;
CRC	cis	rs7174755	0.743	rs4777035	chr15:68605169	C/T	cg22576950	chr15:68522787	CLN6	-0.33	-5.6	-0.3	4.48e-8	Major depressive disorder;
CRC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.74	-8.41	-0.42	1.3e-15	Coronary artery disease;
CRC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg03909863	chr11:638404	DRD4	-0.52	-7.01	-0.36	1.36e-11	Systemic lupus erythematosus;
CRC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21028142	chr17:79581711	NPLOC4	0.35	7.0	0.36	1.48e-11	Eye color traits;
CRC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.57	-9.47	-0.46	5.63e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs17152411	1.000	rs12569940	chr10:126592684	T/C	cg07906193	chr10:126599966	NA	0.61	6.82	0.35	4.36e-11	Height;
CRC	trans	rs10911184	0.818	rs4652755	chr1:182953945	A/G	cg14803869	chr12:131237682	NA	0.53	6.21	0.32	1.56e-9	Diabetic kidney disease;
CRC	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.22	-0.32	1.52e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4774899	0.500	rs2170463	chr15:56931766	A/G	cg08128148	chr15:57256372	TCF12	-0.39	-5.63	-0.3	3.96e-8	Urinary tract infection frequency;
CRC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.88e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.29	-0.69	4.09e-48	Height;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg15147215	chr3:52552868	STAB1	-0.68	-12.04	-0.55	6.74e-28	Electroencephalogram traits;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.92	-11.89	-0.55	2.39e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg06970220	chr1:156163860	SLC25A44	0.49	6.92	0.36	2.31e-11	Testicular germ cell tumor;
CRC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	9.51	0.46	4.18e-19	Alzheimer's disease;
CRC	cis	rs10208940	0.777	rs6726966	chr2:68855856	A/G	cg12452813	chr2:68675892	NA	0.46	5.76	0.3	1.96e-8	Urate levels in lean individuals;
CRC	cis	rs9992667	0.911	rs28656945	chr4:38666746	G/A	cg19726192	chr4:38663646	FLJ13197	-0.72	-8.86	-0.44	5.09e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.35	-0.62	1.33e-36	Height;
CRC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	14.63	0.63	1.06e-37	Platelet count;
CRC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg02527881	chr3:46936655	PTH1R	0.37	6.74	0.35	6.98e-11	Colorectal cancer;
CRC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg03013999	chr17:37608204	MED1	0.49	7.44	0.38	8.92e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg01426195	chr3:39028469	NA	-0.37	-5.65	-0.3	3.48e-8	Handedness;
CRC	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.59	-0.34	1.75e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg25790453	chr13:113633590	MCF2L	-0.55	-9.64	-0.47	1.55e-19	Systolic blood pressure;
CRC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	12.91	0.58	4.08e-31	Multiple sclerosis;
CRC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.57	0.43	4.23e-16	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26011156	chr1:156183096	PMF1	0.44	6.37	0.33	6.46e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.49	0.38	6.54e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg01843034	chr6:37503916	NA	-0.43	-8.15	-0.41	7.61e-15	Cognitive performance;
CRC	trans	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg24644049	chr4:85504048	CDS1	0.83	6.97	0.36	1.69e-11	Skin colour saturation;
CRC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.56	-8.44	-0.42	1.05e-15	Aortic root size;
CRC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.86	12.87	0.58	5.43e-31	Platelet distribution width;
CRC	cis	rs3751196	1.000	rs2289258	chr12:104173880	G/A	cg02344784	chr12:104178138	NT5DC3	0.71	7.47	0.38	7.22e-13	Sense of smell;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.14	-0.37	5.9e-12	Total body bone mineral density;
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-6.08	-0.32	3.27e-9	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08494812	chr2:9983427	TAF1B	0.44	6.23	0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.61	-0.34	1.58e-10	Vitamin D levels;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg06470822	chr6:28175283	NA	0.82	12.23	0.56	1.37e-28	Cardiac Troponin-T levels;
CRC	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg08501292	chr6:25962987	TRIM38	1.15	10.02	0.48	8.32e-21	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.83	0.31	1.29e-8	Diabetic retinopathy;
CRC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.75	0.3	2.03e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg20935933	chr6:143382018	AIG1	0.5	6.47	0.34	3.65e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs12753569	0.748	rs6668566	chr1:76507675	C/G	cg00791851	chr1:76518896	NA	0.37	6.42	0.33	4.67e-10	Personality dimensions;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08235057	chr22:21057110	TMEM191A	0.43	6.36	0.33	6.71e-10	Intelligence (multi-trait analysis);
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg03877919	chr17:3572250	TMEM93;TAX1BP3	0.51	6.35	0.33	7.3e-10	Kashin-Beck disease;
CRC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg17724175	chr1:150552817	MCL1	0.48	7.1	0.36	7.85e-12	Melanoma;
CRC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.89	-16.04	-0.66	3.41e-43	Height;
CRC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.56	8.36	0.42	1.76e-15	Type 2 diabetes;
CRC	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg19683494	chr5:74908142	NA	0.42	5.6	0.3	4.42e-8	Age-related disease endophenotypes;
CRC	cis	rs7632954	0.935	rs2014865	chr3:8522890	G/C	cg03495237	chr3:8533978	NA	0.36	6.28	0.33	1.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10533536	chr8:145597427	ADCK5	0.44	6.39	0.33	5.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	18.57	0.72	3.78e-53	Prudent dietary pattern;
CRC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.46	-7.04	-0.36	1.1e-11	Multiple myeloma (IgH translocation);
CRC	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.86	-0.31	1.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02284587	chr1:64971218	CACHD1	-0.43	-6.44	-0.33	4.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.6	7.36	0.38	1.48e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.24	0.37	3.12e-12	Morning vs. evening chronotype;
CRC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.62	8.42	0.42	1.16e-15	High light scatter reticulocyte count;
CRC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.84	11.07	0.52	1.95e-24	Cerebrospinal P-tau181p levels;
CRC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.47	6.79	0.35	5.23e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.51	5.76	0.3	1.89e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12172441	chr6:28176163	NA	0.54	6.96	0.36	1.8e-11	Parkinson's disease;
CRC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.08	18.28	0.71	5.13e-52	Cognitive function;
CRC	cis	rs10512697	1.000	rs11741276	chr5:3577135	C/G	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg04455712	chr21:45112962	RRP1B	-0.34	-5.87	-0.31	1.07e-8	Mean corpuscular volume;
CRC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg02175503	chr12:58329896	NA	0.57	8.25	0.41	3.84e-15	Intelligence (multi-trait analysis);
CRC	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg24585782	chr17:78113791	EIF4A3	-0.37	-5.79	-0.3	1.68e-8	Yeast infection;
CRC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.43	6.82	0.35	4.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.38	7.41	0.38	1.06e-12	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25136310	chr19:5690528	RPL36	0.4	6.12	0.32	2.66e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-8.1	-0.41	1.06e-14	Total body bone mineral density;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg03623178	chr6:28175578	NA	0.92	13.02	0.58	1.52e-31	Parkinson's disease;
CRC	cis	rs6681460	0.932	rs618093	chr1:67178428	T/G	cg02459107	chr1:67143332	SGIP1	0.35	5.95	0.31	6.78e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.65	0.39	2.27e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg08314208	chr16:67682810	RLTPR	-0.58	-6.19	-0.32	1.76e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg19824325	chr16:58548873	SETD6	1.0	6.85	0.35	3.68e-11	Schizophrenia;
CRC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg18512352	chr11:47633146	NA	0.36	7.12	0.37	6.78e-12	Subjective well-being;
CRC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.12	0.37	6.77e-12	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg12458913	chr13:53173898	NA	0.56	8.69	0.43	1.78e-16	Lewy body disease;
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.92	-0.31	8.25e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10849893	0.557	rs61955091	chr12:121833975	A/G	cg01154721	chr12:121881891	KDM2B	-0.42	-6.29	-0.33	9.94e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg15145296	chr3:125709740	NA	-0.57	-6.75	-0.35	6.77e-11	Blood pressure (smoking interaction);
CRC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg00750074	chr16:89608354	SPG7	-0.51	-7.85	-0.4	5.82e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg21194808	chr1:2205498	SKI	-0.38	-5.75	-0.3	2.09e-8	Height;
CRC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.98	0.31	5.72e-9	Height;
CRC	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg10483660	chr13:112241077	NA	0.36	5.75	0.3	2e-8	Menarche (age at onset);
CRC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.37	6.1	0.32	2.94e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.01	-0.31	4.92e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03923535	chr7:1197113	ZFAND2A	0.72	10.76	0.51	2.5e-23	Longevity;Endometriosis;
CRC	cis	rs12692738	0.526	rs355855	chr2:165628875	C/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4731207	0.698	rs11980925	chr7:124483707	T/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2398893	0.883	rs11999153	chr9:96835847	G/A	cg14459158	chr9:96720562	NA	0.43	7.11	0.36	7.48e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.61	5.81	0.31	1.48e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg17674042	chr6:34482479	PACSIN1	-0.63	-7.45	-0.38	8.35e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg02023728	chr11:77925099	USP35	-0.36	-6.15	-0.32	2.29e-9	Alzheimer's disease (survival time);
CRC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.36	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.47	8.61	0.43	3.09e-16	Educational attainment (years of education);
CRC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.51	8.34	0.42	2.01e-15	Perceived unattractiveness to mosquitoes;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.64	-12.71	-0.57	2.21e-30	Electroencephalogram traits;
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg01721255	chr8:58191610	C8orf71	0.47	5.77	0.3	1.87e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg27534772	chr1:16042836	PLEKHM2	0.44	6.86	0.35	3.46e-11	Systolic blood pressure;
CRC	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.48	7.26	0.37	2.74e-12	HDL cholesterol;
CRC	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg13385794	chr1:248469461	NA	0.38	6.68	0.35	1.01e-10	Common traits (Other);
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.55	0.54	3.91e-26	Prudent dietary pattern;
CRC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg06243084	chr11:63990629	FERMT3	0.41	6.34	0.33	7.48e-10	Platelet count;
CRC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg02659138	chr7:134003124	SLC35B4	0.36	5.61	0.3	4.19e-8	Mean platelet volume;
CRC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.51	8.25	0.41	3.9e-15	Aortic root size;
CRC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.48	-0.42	7.49e-16	Hip circumference adjusted for BMI;
CRC	trans	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	14.88	0.63	1.19e-38	Chronic sinus infection;
CRC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.68	0.3	2.95e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.44	6.53	0.34	2.43e-10	Malaria;
CRC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg15465823	chr12:48382534	COL2A1	-0.35	-5.73	-0.3	2.24e-8	Glycated hemoglobin levels;
CRC	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg09873164	chr1:152488093	CRCT1	0.38	6.42	0.33	4.82e-10	Hair morphology;
CRC	trans	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg24644049	chr4:85504048	CDS1	0.87	7.11	0.36	7.24e-12	Skin colour saturation;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg13086574	chr8:135490821	ZFAT	-0.35	-6.2	-0.32	1.71e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs889398	0.741	rs6499268	chr16:69906529	G/A	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.31	-0.33	8.85e-10	Body mass index;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.16	-0.32	2.08e-9	Cognitive function;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg02560615	chr16:2274210	E4F1	-0.51	-6.53	-0.34	2.47e-10	Parkinson's disease;
CRC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg23758597	chr6:163146217	PARK2	-0.67	-6.71	-0.35	8.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg08222913	chr3:52553049	STAB1	-0.35	-6.27	-0.33	1.12e-9	Bipolar disorder;
CRC	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.7	7.01	0.36	1.35e-11	Plasma clusterin levels;
CRC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.61	-0.43	3.11e-16	Uric acid levels;
CRC	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-6.44	-0.33	4.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg26205652	chr12:48591994	NA	0.46	5.63	0.3	3.79e-8	Longevity (90 years and older);
CRC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg10589385	chr1:150898437	SETDB1	-0.33	-7.02	-0.36	1.27e-11	Melanoma;
CRC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.85	-0.74	3.48e-58	Primary sclerosing cholangitis;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg11843238	chr5:131593191	PDLIM4	0.35	6.49	0.34	3.23e-10	Blood metabolite levels;
CRC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.58	9.66	0.47	1.35e-19	Menopause (age at onset);
CRC	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	0.97	12.04	0.55	6.61e-28	Obesity-related traits;
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20092199	chr4:1342459	KIAA1530	0.37	6.66	0.34	1.16e-10	Obesity-related traits;
CRC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.65	8.62	0.43	2.88e-16	Multiple sclerosis;
CRC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.65	-0.75	2.33e-61	Myeloid white cell count;
CRC	trans	rs587242	1.000	rs722155	chr1:96906374	A/G	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg12856521	chr11:46389249	DGKZ	-0.43	-6.87	-0.35	3.24e-11	Leprosy;
CRC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-1.03	-11.14	-0.52	1.09e-24	Vitiligo;
CRC	cis	rs1322512	1.000	rs1290296	chr6:153010088	A/C	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.44	7.08	0.36	8.54e-12	Refractive error;
CRC	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.58	-0.34	1.86e-10	Blood protein levels;
CRC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Morning vs. evening chronotype;
CRC	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.68	-8.7	-0.43	1.65e-16	Birth weight;
CRC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg01788221	chr16:89496183	ANKRD11	-0.42	-6.45	-0.34	3.97e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg25985355	chr7:65971099	NA	-0.47	-5.65	-0.3	3.54e-8	Diabetic kidney disease;
CRC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg17467752	chr17:38218738	THRA	-0.38	-5.61	-0.3	4.32e-8	Self-reported allergy;
CRC	cis	rs863345	0.604	rs11265016	chr1:158503785	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg11833968	chr6:79620685	NA	-0.35	-6.15	-0.32	2.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6585424	1.000	rs12763392	chr10:81934995	C/T	cg11900509	chr10:81946545	ANXA11	0.75	9.11	0.45	8.38e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.77	-0.44	9.84e-17	Electroencephalogram traits;
CRC	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-6.79	-0.35	5.1e-11	Metabolite levels;
CRC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.41	-5.9	-0.31	8.8e-9	Bronchopulmonary dysplasia;
CRC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg00343986	chr7:65444356	GUSB	0.51	7.58	0.39	3.57e-13	Aortic root size;
CRC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.15e-13	Waist circumference;Weight;
CRC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.66	9.76	0.47	6.3e-20	Selective IgA deficiency;
CRC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.9	-15.52	-0.65	3.9e-41	Height;
CRC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.49	7.43	0.38	9.49e-13	Longevity;
CRC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6604026	0.656	rs2774949	chr1:93352553	T/C	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.48	-5.88	-0.31	1.02e-8	Coronary artery calcification;
CRC	cis	rs9469578	1.000	rs73743323	chr6:33705355	C/T	cg18708504	chr6:33715942	IP6K3	0.62	6.98	0.36	1.59e-11	Phosphorus levels;
CRC	cis	rs501120	0.564	rs11598314	chr10:44685795	A/G	cg09554077	chr10:44749378	NA	0.55	7.63	0.39	2.51e-13	Coronary artery disease;Coronary heart disease;
CRC	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.1	11.88	0.55	2.44e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.1	22.83	0.78	8.42e-70	Schizophrenia;
CRC	trans	rs12702919	0.714	rs11771608	chr7:9550414	T/C	cg15597424	chr4:24472487	NA	-0.39	-6.01	-0.31	4.8e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs832187	0.813	rs704368	chr3:63868337	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.4	5.72	0.3	2.41e-8	Schizophrenia;
CRC	cis	rs2730260	0.537	rs55662704	chr7:158864184	T/C	cg02254261	chr7:158964346	NA	-0.54	-6.25	-0.33	1.26e-9	Myopia (pathological);
CRC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.71	-10.08	-0.49	5.24e-21	Ileal carcinoids;
CRC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.65	-10.19	-0.49	2.28e-21	Huntington's disease progression;
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.53	9.01	0.44	1.73e-17	Aortic root size;
CRC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10804591	0.524	rs2811462	chr3:129303436	T/G	cg21885638	chr3:129306552	PLXND1	-0.5	-7.11	-0.37	7.21e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.72	10.6	0.5	9.11e-23	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27313501	chr16:2034198	GFER	0.47	6.59	0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.6	8.96	0.44	2.55e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11645453	chr3:52864694	ITIH4	0.36	6.39	0.33	5.61e-10	Bipolar disorder;
CRC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.19	-0.49	2.17e-21	Colorectal cancer;
CRC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.35	-0.46	1.35e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.53	6.58	0.34	1.83e-10	Body mass index;
CRC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg02569458	chr12:86230093	RASSF9	0.38	6.6	0.34	1.66e-10	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15309264	chr2:58274034	VRK2	0.42	6.02	0.31	4.69e-9	Response to antipsychotic treatment;
CRC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.37	8.49	0.42	7.43e-16	Multiple system atrophy;
CRC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.4	6.46	0.34	3.69e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.78	0.35	5.74e-11	Obesity-related traits;
CRC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg23996704	chr18:44553084	KATNAL2	-0.33	-6.27	-0.33	1.13e-9	Personality dimensions;
CRC	cis	rs7209700	0.662	rs11656865	chr17:45346489	A/G	cg17185639	chr17:45330862	ITGB3	0.38	6.09	0.32	3.09e-9	IgG glycosylation;
CRC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.51	-7.7	-0.39	1.59e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.39	0.42	1.43e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.77	9.39	0.46	1.03e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.95	-0.44	2.69e-17	Alzheimer's disease;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.97	-0.4	2.59e-14	Total body bone mineral density;
CRC	cis	rs2871473	1.000	rs1030024	chr2:103105769	A/T	cg09003973	chr2:102972529	NA	-0.48	-6.32	-0.33	8.28e-10	Blood protein levels;
CRC	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.49	8.61	0.43	3.05e-16	Testicular germ cell tumor;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg02033258	chr5:131593261	PDLIM4	0.46	8.64	0.43	2.54e-16	Acylcarnitine levels;
CRC	cis	rs60871478	0.735	rs10950455	chr7:831451	C/T	cg05535760	chr7:792225	HEATR2	-1.03	-12.21	-0.56	1.59e-28	Cerebrospinal P-tau181p levels;
CRC	cis	rs11229555	0.645	rs11601296	chr11:58423297	A/G	cg15696309	chr11:58395628	NA	-0.88	-9.19	-0.45	4.6e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg09659197	chr4:152720779	NA	0.4	8.44	0.42	1.05e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs650173	chr11:108174173	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.36	0.33	6.85e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg25797454	chr6:150327115	RAET1K	0.35	6.15	0.32	2.21e-9	Alopecia areata;
CRC	cis	rs6968419	0.747	rs3807968	chr7:115863446	G/A	cg02561103	chr7:115862891	TES	-0.43	-6.45	-0.33	4.1e-10	Intraocular pressure;
CRC	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg25547332	chr5:131281432	NA	0.39	5.69	0.3	2.79e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg00042356	chr1:8021962	PARK7	-0.5	-5.84	-0.31	1.25e-8	Inflammatory bowel disease;
CRC	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.77	8.67	0.43	1.99e-16	Neuroticism;
CRC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.63	-8.9	-0.44	3.79e-17	Cognitive function;
CRC	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03393821	chr1:145610981	POLR3C;RNF115	0.47	7.38	0.38	1.27e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs789852	0.867	rs1773177	chr3:194316181	A/C	cg21106136	chr3:194405973	FAM43A	-0.72	-6.0	-0.31	5.28e-9	QT interval;
CRC	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg00042356	chr1:8021962	PARK7	0.62	7.15	0.37	5.53e-12	Inflammatory bowel disease;
CRC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.54	-0.34	2.31e-10	Daytime sleep phenotypes;
CRC	cis	rs5745709	0.861	rs5745676	chr7:81372156	A/G	cg18944653	chr7:81381353	HGF	-0.29	-5.62	-0.3	3.99e-8	Gout;
CRC	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.76	-12.38	-0.56	3.84e-29	Ear protrusion;
CRC	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-5.83	-0.31	1.33e-8	Vitamin D levels;
CRC	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg03929089	chr4:120376271	NA	0.61	6.06	0.32	3.67e-9	Axial length;
CRC	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.45	6.4	0.33	5.2e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.52	9.16	0.45	5.86e-18	Common traits (Other);
CRC	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg11900509	chr10:81946545	ANXA11	-0.71	-7.16	-0.37	5.2e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7487075	0.820	rs7315493	chr12:46689427	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.82	0.31	1.38e-8	Itch intensity from mosquito bite;
CRC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.67	8.85	0.44	5.68e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04071446	chr10:115933849	C10orf118	0.48	6.21	0.32	1.61e-9	Thyroid stimulating hormone;
CRC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg03623178	chr6:28175578	NA	0.48	7.09	0.36	8.19e-12	Pubertal anthropometrics;
CRC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg04880052	chr2:219191631	PNKD	0.4	6.38	0.33	6.13e-10	Colorectal cancer;
CRC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg19812747	chr11:111475976	SIK2	-0.58	-10.08	-0.49	5.38e-21	Primary sclerosing cholangitis;
CRC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg16606324	chr3:10149918	C3orf24	0.69	9.48	0.46	5.29e-19	Alzheimer's disease;
CRC	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.49	7.23	0.37	3.4e-12	Primary sclerosing cholangitis;
CRC	trans	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.5	7.86	0.4	5.58e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg09659197	chr4:152720779	NA	0.5	10.56	0.5	1.21e-22	Intelligence (multi-trait analysis);
CRC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.68	10.86	0.51	1.14e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg23533926	chr12:111358616	MYL2	0.45	6.57	0.34	1.99e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-11.74	-0.54	8.32e-27	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.58	9.16	0.45	5.55e-18	N-glycan levels;
CRC	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.26	-6.28	-0.33	1.09e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.38	6.36	0.33	6.87e-10	Schizophrenia;
CRC	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs7953508	0.741	rs1498706	chr12:93996980	C/T	cg18151635	chr12:93972918	NA	-0.47	-7.02	-0.36	1.29e-11	Pubertal anthropometrics;
CRC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.97	0.58	2.29e-31	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	trans	rs2303319	0.504	rs62188990	chr2:162540635	G/A	cg15664909	chr17:685709	GLOD4;RNMTL1	-0.68	-5.99	-0.31	5.38e-9	Cognitive function;
CRC	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.8	-13.25	-0.59	2.05e-32	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20560186	chr6:109804103	ZBTB24	-0.39	-5.97	-0.31	6.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg24553058	chr2:113831203	IL1F10	0.39	6.31	0.33	9.19e-10	Protein quantitative trait loci;
CRC	trans	rs72956618	0.715	rs72933222	chr2:207319653	C/T	cg16073378	chr2:468413	NA	-0.65	-6.42	-0.33	4.86e-10	Tonsillectomy;
CRC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25517755	chr10:38738941	LOC399744	-0.42	-5.94	-0.31	7.22e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	cis	rs3760982	1.000	rs4802200	chr19:44289518	G/A	cg12072164	chr19:44306565	LYPD5	0.4	6.19	0.32	1.75e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12463550	chr7:65579703	CRCP	0.7	6.48	0.34	3.32e-10	Diabetic kidney disease;
CRC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.82	-15.82	-0.66	2.64e-42	Post bronchodilator FEV1;
CRC	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.63	-7.82	-0.4	7.23e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.48	9.21	0.45	3.8e-18	Renal cell carcinoma;
CRC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.09	-0.32	3.14e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.73	0.3	2.22e-8	Life satisfaction;
CRC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.66	11.06	0.52	2.19e-24	Resting heart rate;
CRC	trans	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg23976632	chr12:120875743	COX6A1	0.64	6.07	0.32	3.53e-9	Cholesterol, total;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.4	-7.26	-0.37	2.73e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7178572	0.633	rs907369	chr15:77843560	A/G	cg22256960	chr15:77711686	NA	-0.63	-8.99	-0.44	2.04e-17	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.65	-0.34	1.22e-10	Total body bone mineral density;
CRC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.76	13.58	0.6	1.2e-33	Oral cavity cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23659015	chr14:35099524	SNX6	0.43	6.17	0.32	2.02e-9	Response to antipsychotic treatment;
CRC	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg10820045	chr2:198174542	NA	0.41	6.94	0.36	2.09e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.22	-0.32	1.53e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg13490827	chr1:46269305	MAST2	-0.69	-6.05	-0.32	4.03e-9	Cognitive function;
CRC	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg03037974	chr15:76606532	NA	-0.53	-7.68	-0.39	1.89e-13	Blood metabolite levels;
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.36	-7.31	-0.37	1.99e-12	Electroencephalogram traits;
CRC	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg03258749	chr1:151040405	MLLT11	-0.47	-7.28	-0.37	2.55e-12	Childhood ear infection;
CRC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.31	0.42	2.54e-15	Height;
CRC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-1.05	-10.9	-0.52	7.87e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.65	5.74	0.3	2.15e-8	Yeast infection;
CRC	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg00105475	chr2:10696890	NA	0.47	7.54	0.38	4.64e-13	Prostate cancer;
CRC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.13	-0.52	1.25e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	13.22	0.59	2.64e-32	Alzheimer's disease;
CRC	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.41	6.4	0.33	5.43e-10	C-reactive protein levels;
CRC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg18709589	chr6:96969512	KIAA0776	-0.53	-6.03	-0.32	4.37e-9	Migraine;Coronary artery disease;
CRC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.57	-7.79	-0.39	8.71e-14	Colorectal cancer;
CRC	trans	rs55675132	0.548	rs75733320	chr1:115373820	T/C	cg25493687	chr8:27288214	PTK2B	0.5	6.17	0.32	1.96e-9	Schizophrenia;
CRC	cis	rs9311676	0.656	rs11712213	chr3:58384995	G/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.25	-0.33	1.25e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.65	0.39	2.21e-13	Schizophrenia;
CRC	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.82	11.77	0.54	6.14e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg02023728	chr11:77925099	USP35	0.35	5.93	0.31	7.75e-9	Testicular germ cell tumor;
CRC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.5	-7.48	-0.38	6.71e-13	Colorectal cancer;
CRC	cis	rs4700695	0.697	rs2561240	chr5:65235310	T/C	cg21114390	chr5:65439923	SFRS12	0.63	6.44	0.33	4.3e-10	Facial morphology (factor 19);
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg15763984	chr4:1342303	KIAA1530	0.44	6.79	0.35	5.24e-11	Obesity-related traits;
CRC	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.53	-9.46	-0.46	5.96e-19	Lung function (FVC);
CRC	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.66	-9.57	-0.47	2.72e-19	Body mass index;
CRC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.52	0.38	5.12e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg08754725	chr6:3293098	SLC22A23	0.8	7.55	0.38	4.19e-13	Obesity-related traits;
CRC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.54	8.02	0.4	1.84e-14	Lymphocyte counts;
CRC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.85	-15.15	-0.64	1.03e-39	Dementia with Lewy bodies;
CRC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.49	7.59	0.39	3.36e-13	Mean platelet volume;
CRC	trans	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.35	6.07	0.32	3.53e-9	Crohn's disease;
CRC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg08648136	chr8:956695	NA	-0.29	-6.14	-0.32	2.44e-9	Schizophrenia;
CRC	cis	rs6743376	0.556	rs1530550	chr2:113817513	A/T	cg09040174	chr2:113837401	NA	0.42	6.23	0.32	1.45e-9	Inflammatory biomarkers;
CRC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.46	-6.83	-0.35	4.03e-11	Height;
CRC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.52	-8.47	-0.42	8.18e-16	Breast cancer;
CRC	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg13736514	chr6:26305472	NA	-0.44	-7.37	-0.38	1.41e-12	Educational attainment;
CRC	cis	rs80207740	0.941	rs2076940	chr8:21836020	A/G	cg12468850	chr8:21767224	DOK2	-0.57	-6.28	-0.33	1.07e-9	Mean corpuscular hemoglobin;
CRC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.62	9.6	0.47	2.12e-19	Corneal astigmatism;
CRC	cis	rs7901135	0.962	rs4245601	chr10:60567581	C/G	cg23799393	chr10:60588674	BICC1	0.37	5.71	0.3	2.53e-8	Morning vs. evening chronotype;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg18833306	chr6:118973337	C6orf204	0.45	5.82	0.31	1.44e-8	Diastolic blood pressure;
CRC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.16	25.8	0.82	5.09e-81	IgG glycosylation;
CRC	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.38	-0.38	1.3e-12	Capecitabine sensitivity;
CRC	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.74	9.69	0.47	1.07e-19	Blood protein levels;
CRC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.39	5.63	0.3	3.78e-8	Tonsillectomy;
CRC	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.42	-6.43	-0.33	4.58e-10	Red blood cell count;
CRC	trans	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg18335740	chr13:41363409	SLC25A15	0.47	6.95	0.36	1.99e-11	Lewy body disease;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg15845792	chr6:28175446	NA	0.63	9.46	0.46	6.31e-19	Cardiac Troponin-T levels;
CRC	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg10876282	chr6:28092338	ZSCAN16	0.48	6.58	0.34	1.85e-10	Cardiac Troponin-T levels;
CRC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg17724175	chr1:150552817	MCL1	-0.46	-7.22	-0.37	3.54e-12	Tonsillectomy;
CRC	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	ch.8.33884649F	chr8:33765107	NA	0.45	6.58	0.34	1.83e-10	Body mass index;
CRC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg02869364	chr7:1081709	C7orf50	-0.39	-5.63	-0.3	3.87e-8	Bronchopulmonary dysplasia;
CRC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg02725872	chr8:58115012	NA	-0.53	-7.18	-0.37	4.55e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs6838801	0.892	rs56248930	chr4:77534438	A/T	cg17476223	chr4:77663285	SHROOM3	0.44	6.07	0.32	3.59e-9	Cleft lip with or without cleft palate;
CRC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.53	7.32	0.37	1.97e-12	Mammographic density (dense area);
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg12172441	chr6:28176163	NA	0.47	6.19	0.32	1.75e-9	Parkinson's disease;
CRC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.39	-6.67	-0.35	1.05e-10	Reticulocyte fraction of red cells;
CRC	cis	rs728616	0.681	rs17677908	chr10:82049603	A/G	cg05935833	chr10:81318306	SFTPA2	-0.61	-7.1	-0.36	7.84e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.5	7.18	0.37	4.71e-12	Height;
CRC	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg13385794	chr1:248469461	NA	0.39	6.68	0.35	9.97e-11	Common traits (Other);
CRC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg23533926	chr12:111358616	MYL2	0.52	7.74	0.39	1.21e-13	Extrinsic epigenetic age acceleration;
CRC	trans	rs4378999	0.748	rs6775666	chr3:51703064	A/G	cg18840832	chr19:44079285	XRCC1	-0.6	-6.0	-0.31	5.17e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.47	7.44	0.38	9e-13	Coronary artery disease;
CRC	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg01392867	chr16:30410429	ZNF48	0.38	6.1	0.32	3e-9	Tonsillectomy;
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg17346650	chr17:80929145	B3GNTL1	0.49	7.25	0.37	3.05e-12	Glycated hemoglobin levels;
CRC	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.8	13.15	0.59	4.87e-32	Height;
CRC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.47	2.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.1	0.52	1.52e-24	Monocyte percentage of white cells;
CRC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg25356066	chr3:128598488	ACAD9	0.39	5.66	0.3	3.22e-8	IgG glycosylation;
CRC	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg20628663	chr10:43360327	NA	-0.5	-6.12	-0.32	2.66e-9	Blood protein levels;
CRC	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.69	7.55	0.38	4.21e-13	Breast cancer;
CRC	trans	rs116966368	0.602	rs1785800	chr18:26281282	A/T	cg26893861	chr17:41843967	DUSP3	0.54	6.07	0.32	3.43e-9	Neuroticism;
CRC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.79	-12.05	-0.55	5.82e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.61	9.1	0.45	8.97e-18	Obesity-related traits;
CRC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg18099408	chr3:52552593	STAB1	0.35	5.88	0.31	9.97e-9	Body mass index;
CRC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs6772849	0.930	rs13434160	chr3:128374770	T/C	cg08795948	chr3:128337044	NA	0.36	6.28	0.33	1.06e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.43e-29	Menopause (age at onset);
CRC	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg09179987	chr1:167433047	CD247	0.48	7.1	0.36	7.65e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.21	-0.32	1.59e-9	Arsenic metabolism;
CRC	trans	rs1412337	1.000	rs909947	chr1:168615756	G/A	cg03540912	chr16:71792711	SNORD71;AP1G1	0.53	6.11	0.32	2.84e-9	Morbidity-free survival;
CRC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.81	13.55	0.6	1.54e-33	Menopause (age at onset);
CRC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg18876405	chr7:65276391	NA	0.44	6.12	0.32	2.67e-9	Aortic root size;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg21784768	chr11:537496	LRRC56	-0.59	-5.61	-0.3	4.27e-8	Body mass index;
CRC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg15282417	chr9:129245246	FAM125B	0.44	8.2	0.41	5.43e-15	Intraocular pressure;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.25	-0.49	1.37e-21	Bipolar disorder;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs12980942	0.591	rs2304231	chr19:41762670	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.47	0.34	3.49e-10	Coronary artery disease;
CRC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.56	-9.18	-0.45	4.9e-18	Pulse pressure;
CRC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.5	7.19	0.37	4.4e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.66	0.47	1.32e-19	Lung cancer;
CRC	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.98e-20	Exhaled nitric oxide output;
CRC	cis	rs7572644	0.679	rs12986980	chr2:28030437	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.18	0.32	1.87e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.94e-15	Life satisfaction;
CRC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.37	6.31	0.33	8.95e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs11068315	1.000	rs11068315	chr12:117510552	A/G	cg19846154	chr8:74332112	NA	-0.59	-6.14	-0.32	2.4e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	cis	rs12431939	1.000	rs58225416	chr14:51662196	C/T	cg23942311	chr14:51606299	NA	-0.54	-6.21	-0.32	1.58e-9	Cancer;
CRC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg01987224	chr1:201084466	NA	0.53	9.84	0.48	3.46e-20	Permanent tooth development;
CRC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.43	9.62	0.47	1.78e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.66	9.28	0.46	2.41e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.58	-0.34	1.82e-10	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.85	-0.35	3.57e-11	Response to antipsychotic treatment;
CRC	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.35	-0.42	1.93e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-11.54	-0.54	4.12e-26	Monocyte percentage of white cells;
CRC	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg02158880	chr13:53174818	NA	0.49	7.19	0.37	4.48e-12	Lewy body disease;
CRC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.82	9.94	0.48	1.55e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.5	-6.97	-0.36	1.7e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.44	0.62	5.96e-37	Chronic sinus infection;
CRC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-10.88	-0.51	9.35e-24	Platelet distribution width;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.19	-0.32	1.75e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.09	-12.75	-0.57	1.6e-30	Diabetic kidney disease;
CRC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-8.87	-0.44	4.81e-17	Morning vs. evening chronotype;
CRC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg21521518	chr4:53727714	RASL11B	0.41	6.0	0.31	5.26e-9	Optic nerve measurement (cup area);
CRC	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-0.77	-7.49	-0.38	6.53e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4363385	0.818	rs4452994	chr1:152986871	G/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.67	-7.21	-0.37	3.89e-12	Psoriasis;
CRC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	12.29	0.56	8.1e-29	Platelet count;
CRC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	11.27	0.53	3.94e-25	Monocyte percentage of white cells;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.67	-10.01	-0.48	9.31e-21	Menopause (age at onset);
CRC	cis	rs1552172	0.853	rs10752826	chr1:145602791	C/G	cg11743829	chr1:145714124	CD160	0.37	5.85	0.31	1.2e-8	Breast cancer;
CRC	cis	rs6564851	0.545	rs4889285	chr16:81252258	C/T	cg00908271	chr16:81254010	PKD1L2	-0.37	-6.07	-0.32	3.5e-9	Carotenoid and tocopherol levels;
CRC	cis	rs863345	0.604	rs12075228	chr1:158502256	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg17724175	chr1:150552817	MCL1	-0.51	-8.02	-0.4	1.9e-14	Tonsillectomy;
CRC	cis	rs7916697	0.626	rs3858145	chr10:70011838	A/G	cg06988349	chr10:69991859	ATOH7	0.39	7.45	0.38	8.43e-13	Optic disc area;
CRC	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.4	-6.55	-0.34	2.21e-10	Mean arterial pressure;
CRC	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.66	-8.82	-0.44	6.69e-17	Blood pressure (smoking interaction);
CRC	cis	rs672059	1.000	rs672119	chr1:183162506	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.1	0.36	7.63e-12	Hypertriglyceridemia;
CRC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.46	7.79	0.39	8.82e-14	Type 2 diabetes;
CRC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17848003	chr1:3704513	LRRC47	0.4	5.81	0.31	1.47e-8	Red cell distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02865149	chr11:58939797	DTX4	0.45	6.35	0.33	7.29e-10	Response to antipsychotic treatment;
CRC	cis	rs7317038	0.745	rs75590443	chr13:114015421	A/T	cg24344662	chr13:114018021	GRTP1	-0.41	-6.16	-0.32	2.09e-9	Mean platelet volume;
CRC	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.53	7.49	0.38	6.52e-13	Testicular germ cell tumor;
CRC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24308560	chr3:49941425	MST1R	-0.44	-7.04	-0.36	1.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg01305625	chr5:131593812	PDLIM4	0.34	5.61	0.3	4.38e-8	Acylcarnitine levels;
CRC	cis	rs12745968	0.653	rs1003116	chr1:93166401	C/T	cg17283838	chr1:93427260	FAM69A	-0.45	-6.1	-0.32	3.04e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-12.75	-0.58	1.59e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	19.31	0.73	4.64e-56	Primary sclerosing cholangitis;
CRC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.2	-0.32	1.68e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6681460	0.932	rs2044400	chr1:67054081	T/A	cg02459107	chr1:67143332	SGIP1	0.44	7.45	0.38	8.42e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.49	-9.28	-0.46	2.32e-18	Reticulocyte fraction of red cells;
CRC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	0.59	6.35	0.33	7.27e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.68	-9.66	-0.47	1.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg15845792	chr6:28175446	NA	0.97	13.08	0.58	8.89e-32	Depression;
CRC	cis	rs6604026	0.656	rs2811589	chr1:93367643	C/T	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.85	-0.4	5.83e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.65	-9.08	-0.45	1.04e-17	Refractive error;
CRC	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg20936604	chr3:58311152	NA	-0.72	-6.84	-0.35	3.78e-11	Cholesterol, total;
CRC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg10978503	chr1:24200527	CNR2	0.47	8.29	0.42	2.94e-15	Immature fraction of reticulocytes;
CRC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.53	8.27	0.41	3.38e-15	Intelligence (multi-trait analysis);
CRC	cis	rs17152411	1.000	rs1065301	chr10:126616038	A/G	cg07906193	chr10:126599966	NA	0.62	6.83	0.35	4.11e-11	Height;
CRC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.65e-10	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.74	7.89	0.4	4.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.18e-13	Motion sickness;
CRC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.83	-0.48	3.75e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg25164649	chr6:28176230	NA	0.6	8.51	0.42	6.46e-16	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08732623	chr10:127408269	C10orf137	0.43	6.6	0.34	1.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs228590	chr11:108096141	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.48	0.34	3.39e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg18939081	chr1:31884902	SERINC2	0.35	5.7	0.3	2.72e-8	Alcohol dependence;
CRC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.76	0.66	4.41e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.62	0.39	2.7e-13	Mean platelet volume;
CRC	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.54	5.64	0.3	3.61e-8	RR interval (heart rate);
CRC	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.87	8.1	0.41	1.12e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.39	-6.06	-0.32	3.8e-9	Blood metabolite levels;
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.02	-13.34	-0.59	9.74e-33	Alzheimer's disease;
CRC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.47	0.53	7.77e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.74	-0.3	2.16e-8	Coronary artery disease;
CRC	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg10517650	chr3:113235015	CCDC52	-0.4	-6.27	-0.33	1.13e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.6	9.68	0.47	1.17e-19	Vitiligo;
CRC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.7	-0.3	2.62e-8	Schizophrenia;
CRC	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.17	-0.64	8.62e-40	Exhaled nitric oxide output;
CRC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg26695010	chr11:65641043	EFEMP2	0.48	7.46	0.38	7.59e-13	Eosinophil percentage of white cells;
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs60311166	1.000	rs7643568	chr3:52578474	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.85	6.59	0.34	1.79e-10	CTACK levels;
CRC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-9.09	-0.45	9.84e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12760731	0.641	rs12036834	chr1:178236583	G/A	cg00404053	chr1:178313656	RASAL2	0.96	10.07	0.49	5.59e-21	Obesity-related traits;
CRC	cis	rs7538876	1.000	rs942457	chr1:17739586	G/A	cg07965774	chr1:17746286	RCC2	0.31	5.92	0.31	7.9e-9	Basal cell carcinoma;
CRC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.41	0.33	5.16e-10	Diabetic kidney disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03448396	chr3:38495949	LOC100128640;ACVR2B	0.44	6.83	0.35	4.18e-11	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08859206	chr1:53392774	SCP2	-0.4	-6.13	-0.32	2.45e-9	Monocyte count;
CRC	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.46	-7.27	-0.37	2.62e-12	Schizophrenia;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg00295835	chr11:113644563	ZW10	-0.41	-5.98	-0.31	5.66e-9	Daytime sleep phenotypes;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	trans	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06834434	chr14:75079333	LTBP2	0.57	6.88	0.35	3.1e-11	Obesity-related traits;
CRC	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.74	11.38	0.53	1.54e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.02	0.31	4.71e-9	Tonsillectomy;
CRC	cis	rs9818941	0.824	rs13065628	chr3:157789277	A/G	cg08654915	chr3:157813417	NA	-0.3	-5.64	-0.3	3.7e-8	Height;
CRC	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg25019722	chr6:37503610	NA	0.36	5.89	0.31	9.3e-9	Cognitive performance;
CRC	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	cis	rs4604732	0.588	rs4925552	chr1:247631749	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	7.7	0.39	1.64e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-8.62	-0.43	2.86e-16	Extraversion;
CRC	cis	rs17065868	0.764	rs9533849	chr13:45011384	T/C	cg10246903	chr13:45222710	NA	0.56	6.21	0.32	1.64e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.63	9.96	0.48	1.38e-20	Height;
CRC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.58	9.12	0.45	7.71e-18	IgG glycosylation;
CRC	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg17545662	chr6:170176663	C6orf70	0.49	5.86	0.31	1.15e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.33	6.62	0.34	1.45e-10	Ewing sarcoma;
CRC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.52	8.17	0.41	6.89e-15	Asthma (sex interaction);
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg26587870	chr6:27730563	NA	-0.37	-5.64	-0.3	3.62e-8	Cardiac Troponin-T levels;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.83	13.48	0.6	2.7e-33	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg06470822	chr6:28175283	NA	0.98	13.22	0.59	2.69e-32	Depression;
CRC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-0.59	-11.2	-0.53	7.13e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.37	6.9	0.36	2.65e-11	Height;
CRC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-13.14	-0.59	5.39e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg20387954	chr3:183756860	HTR3D	0.46	7.81	0.4	7.86e-14	Anterior chamber depth;
CRC	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg11900509	chr10:81946545	ANXA11	-0.71	-7.16	-0.37	5.2e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg24463073	chr6:118973353	C6orf204	0.44	6.14	0.32	2.44e-9	Diastolic blood pressure;
CRC	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.02	21.3	0.76	7.18e-64	Multiple myeloma;
CRC	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.64	10.82	0.51	1.47e-23	Type 2 diabetes;
CRC	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg00666640	chr1:248458726	OR2T12	0.35	6.56	0.34	2.15e-10	Common traits (Other);
CRC	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-1.03	-20.99	-0.76	1.12e-62	Multiple myeloma;
CRC	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.85	-0.35	3.62e-11	Schizophrenia;
CRC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.95	11.73	0.54	8.69e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	cis	rs501120	0.584	rs11595159	chr10:44680608	T/C	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.65	-6.87	-0.35	3.27e-11	Neuroticism;
CRC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.49	6.68	0.35	1.04e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.1	0.36	7.83e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg20092199	chr4:1342459	KIAA1530	0.45	7.23	0.37	3.5e-12	Obesity-related traits;
CRC	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.52	-0.38	5.35e-13	Cystic fibrosis severity;
CRC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg06287003	chr12:125626642	AACS	-0.51	-7.07	-0.36	9.34e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.83	0.35	4.12e-11	Waist circumference;Hip circumference;
CRC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg23262073	chr20:60523788	NA	-0.42	-6.65	-0.34	1.21e-10	Body mass index;
CRC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	5.81e-13	Motion sickness;
CRC	cis	rs7487075	0.820	rs2408505	chr12:46717824	C/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.58	0.34	1.83e-10	Itch intensity from mosquito bite;
CRC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.43	0.33	4.5e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.39	0.33	5.56e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3823572	0.564	rs2971955	chr7:133665939	C/T	cg03336402	chr7:133662267	EXOC4	0.59	9.47	0.46	5.5e-19	Intelligence (multi-trait analysis);
CRC	cis	rs12024301	0.557	rs12073256	chr1:183658377	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.63	6.04	0.32	4.23e-9	Axial length;
CRC	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg06632207	chr12:54070931	ATP5G2	0.41	7.09	0.36	8.23e-12	Height;
CRC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.43	-6.57	-0.34	1.95e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg04450456	chr4:17643702	FAM184B	0.39	6.35	0.33	7.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.68	11.12	0.52	1.32e-24	Age at first birth;
CRC	cis	rs7945718	0.621	rs10831894	chr11:12680733	G/A	cg25843174	chr11:12811716	TEAD1	0.4	7.43	0.38	9.67e-13	Educational attainment (years of education);
CRC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg02527881	chr3:46936655	PTH1R	0.42	7.54	0.38	4.75e-13	Colorectal cancer;
CRC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06505273	chr16:24850292	NA	0.51	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.68	-0.43	1.92e-16	HDL cholesterol;
CRC	cis	rs11212617	1.000	rs11212610	chr11:108274593	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.4	5.83	0.31	1.29e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18357526	chr6:26021779	HIST1H4A	0.41	6.0	0.31	5.31e-9	Height;
CRC	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.46	7.25	0.37	3.08e-12	Prostate cancer;
CRC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg06287003	chr12:125626642	AACS	-0.5	-7.5	-0.38	6.18e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.61e-14	Height;
CRC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.55	8.08	0.41	1.25e-14	Cognitive ability;
CRC	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.58	8.44	0.42	9.92e-16	Height;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12074093	chr17:16256568	CENPV	0.41	6.57	0.34	1.92e-10	Interleukin-6 levels;
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-11.36	-0.53	1.85e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08934607	chr11:20409647	PRMT3	0.47	6.08	0.32	3.35e-9	Thyroid stimulating hormone;
CRC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-7.31	-0.37	2.09e-12	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01794711	chr18:72163198	CNDP2	0.41	6.01	0.31	4.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg05192639	chr6:26864778	GUSBL1	0.31	6.05	0.32	4.01e-9	Schizophrenia;
CRC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.55	-0.71	4.64e-53	Schizophrenia;
CRC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.47	6.13	0.32	2.49e-9	White matter hyperintensity burden;
CRC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.31	-0.37	2.08e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs12900413	0.687	rs34284515	chr15:90308061	T/G	cg24249390	chr15:90295951	MESP1	-0.57	-9.13	-0.45	7.11e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg02524346	chr8:600233	NA	-0.93	-8.26	-0.41	3.66e-15	IgG glycosylation;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	ch.9.86947500F	chr9:87757680	NA	0.45	6.22	0.32	1.49e-9	Survival in pancreatic cancer;
CRC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg15790184	chr11:494944	RNH1	0.59	6.07	0.32	3.55e-9	Body mass index;
CRC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.55	8.67	0.43	2.04e-16	Colorectal cancer;
CRC	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.48e-17	Dupuytren's disease;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18301423	chr5:131593218	PDLIM4	0.45	7.62	0.39	2.8e-13	Acylcarnitine levels;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.66	-6.84	-0.35	3.89e-11	Depression;
CRC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.62	9.34	0.46	1.5e-18	Night sleep phenotypes;
CRC	trans	rs1864585	0.505	rs73208792	chr8:10680471	C/T	cg26278703	chr11:58910052	FAM111A	0.56	6.55	0.34	2.24e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19877921	chr17:61904685	PSMC5;FTSJ3	0.42	6.67	0.35	1.09e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-6.98	-0.36	1.6e-11	Schizophrenia;
CRC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.73	9.4	0.46	9.91e-19	Platelet count;
CRC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.24	-0.33	1.31e-9	Aortic root size;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.58	-10.74	-0.51	2.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg09163369	chr1:210001066	C1orf107	0.39	5.86	0.31	1.15e-8	Monobrow;
CRC	trans	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg17903999	chr18:56338584	MALT1	0.43	7.01	0.36	1.39e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.92	-0.36	2.32e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.38	-6.87	-0.35	3.28e-11	Reticulocyte fraction of red cells;
CRC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.16	0.32	2.15e-9	Aortic root size;
CRC	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.4	6.66	0.34	1.15e-10	Metabolite levels;
CRC	cis	rs773506	0.628	rs10733740	chr9:93933158	G/T	cg14446406	chr9:93919335	NA	0.43	7.27	0.37	2.58e-12	Type 2 diabetes nephropathy;
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	ch.2.3330114R	chr2:163935707	NA	0.43	6.05	0.32	4.02e-9	Monocyte count;
CRC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.79	-11.43	-0.53	1.05e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs73206853	0.764	rs970228	chr12:111070169	G/C	cg12870014	chr12:110450643	ANKRD13A	0.81	9.34	0.46	1.45e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04004882	chr2:215674386	BARD1	0.59	7.28	0.37	2.53e-12	Neuroblastoma;
CRC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	16.55	0.67	3.45e-45	Platelet count;
CRC	cis	rs17209837	1.000	rs45546132	chr7:87086140	C/T	cg00919237	chr7:87102261	ABCB4	-0.5	-6.1	-0.32	3.03e-9	Gallbladder cancer;
CRC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.51	8.15	0.41	7.53e-15	Migraine;
CRC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg24768116	chr2:27665128	KRTCAP3	0.33	7.32	0.37	1.95e-12	Total body bone mineral density;
CRC	cis	rs758324	0.812	rs667419	chr5:131282064	A/G	cg25547332	chr5:131281432	NA	0.36	5.74	0.3	2.17e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs3772130	0.564	rs4420917	chr3:121567863	T/C	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	cis	rs12760731	0.668	rs12073428	chr1:178427933	G/A	cg00404053	chr1:178313656	RASAL2	0.73	8.43	0.42	1.07e-15	Obesity-related traits;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.5	10.97	0.52	4.61e-24	Alcohol dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23128382	chr11:59382818	OSBP	0.45	6.28	0.33	1.09e-9	Response to antipsychotic treatment;
CRC	cis	rs174479	0.647	rs174457	chr11:61656975	T/C	cg01500311	chr11:61656094	FADS3	0.35	5.69	0.3	2.76e-8	Sphingolipid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19926395	chr7:150865207	GBX1	0.33	6.5	0.34	2.97e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.72	11.44	0.53	1e-25	Dental caries;
CRC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	12.19	0.56	1.8e-28	Menopause (age at onset);
CRC	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.05	-0.36	1.05e-11	Inflammatory skin disease;
CRC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg21466736	chr12:48725269	NA	0.46	7.04	0.36	1.12e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.58	-8.1	-0.41	1.09e-14	Pancreatic cancer;
CRC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg06494592	chr3:125709126	NA	-0.57	-6.78	-0.35	5.71e-11	Blood pressure (smoking interaction);
CRC	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7737355	0.773	rs184949	chr5:130815593	A/G	cg25547332	chr5:131281432	NA	-0.35	-5.69	-0.3	2.74e-8	Life satisfaction;
CRC	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.2e-12	Prostate cancer;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg08989290	chr16:615782	NHLRC4	0.48	9.3	0.46	1.96e-18	Height;
CRC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.64	10.5	0.5	1.95e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg03623178	chr6:28175578	NA	0.78	6.64	0.34	1.27e-10	Breast cancer;
CRC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.44	-7.89	-0.4	4.61e-14	Reticulocyte fraction of red cells;
CRC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs838147	0.537	rs602662	chr19:49206985	G/A	cg21064579	chr19:49206444	FUT2	0.49	8.48	0.42	7.99e-16	Dietary macronutrient intake;
CRC	cis	rs9826463	0.702	rs73228757	chr3:142320081	A/G	cg20824294	chr3:142316082	PLS1	0.42	6.69	0.35	9.5e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.11	19.05	0.72	4.69e-55	Cognitive function;
CRC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg16892393	chr17:41919603	NA	0.49	7.55	0.38	4.32e-13	Triglycerides;
CRC	trans	rs12702919	0.677	rs12702917	chr7:9550478	G/A	cg15597424	chr4:24472487	NA	-0.39	-5.99	-0.31	5.47e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.66	-11.27	-0.53	3.91e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg27615366	chr5:131592974	PDLIM4	0.29	5.64	0.3	3.68e-8	Breast cancer;
CRC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.76	10.12	0.49	3.87e-21	Coronary artery disease;
CRC	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg05340658	chr4:99064831	C4orf37	0.51	6.41	0.33	5.02e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg22079747	chr2:228736145	WDR69	-0.41	-5.65	-0.3	3.4e-8	Blood pressure;
CRC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.91	-0.31	8.4e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.49	-7.52	-0.38	5.23e-13	Type 2 diabetes;
CRC	cis	rs524281	0.861	rs9736673	chr11:65924024	T/A	cg16950941	chr11:66035639	RAB1B	-0.59	-7.65	-0.39	2.28e-13	Electroencephalogram traits;
CRC	cis	rs7605827	0.930	rs6728145	chr2:15573489	C/G	cg19274914	chr2:15703543	NA	0.39	5.99	0.31	5.53e-9	Educational attainment (years of education);
CRC	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.57	6.44	0.33	4.32e-10	Gastritis;
CRC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.19	-0.32	1.74e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.39e-12	Gut microbiome composition (summer);
CRC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg09165964	chr15:75287851	SCAMP5	0.55	8.78	0.44	9.3e-17	Breast cancer;
CRC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.6	0.34	1.62e-10	HIV-1 control;
CRC	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.12	0.32	2.71e-9	Endometrial cancer;
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08219700	chr8:58056026	NA	0.56	6.58	0.34	1.81e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg05304507	chr6:116381966	FRK	-0.29	-7.8	-0.4	8.18e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg07217954	chr7:1067459	C7orf50	0.51	6.03	0.32	4.33e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.36	6.17	0.32	2.06e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg26132723	chr8:70041827	NA	-0.35	-5.63	-0.3	3.87e-8	Dupuytren's disease;
CRC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.44	-6.02	-0.31	4.78e-9	Type 2 diabetes;
CRC	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.15	0.59	4.98e-32	Hip circumference;
CRC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.66	0.3	3.3e-8	Tonsillectomy;
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg17330251	chr7:94953956	PON1	-0.59	-7.5	-0.38	5.82e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.57	0.43	4.16e-16	Brugada syndrome;
CRC	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.46	0.65	6.33e-41	Fuchs's corneal dystrophy;
CRC	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	0.81	8.5	0.42	6.81e-16	Pediatric areal bone mineral density (radius);
CRC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.6	0.54	2.61e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4594175	0.926	rs7493621	chr14:51623665	C/T	cg23942311	chr14:51606299	NA	0.6	9.53	0.46	3.71e-19	Cancer;
CRC	trans	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.32	-0.37	1.91e-12	Endometrial cancer;
CRC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.13	-0.41	8.96e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.64	9.58	0.47	2.48e-19	Breast cancer;
CRC	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg18232548	chr7:50535776	DDC	-0.41	-6.18	-0.32	1.93e-9	Body mass index;
CRC	cis	rs7945718	0.621	rs10831888	chr11:12665604	T/C	cg25843174	chr11:12811716	TEAD1	0.37	6.87	0.35	3.28e-11	Educational attainment (years of education);
CRC	cis	rs11948739	0.539	rs10045319	chr5:130250710	G/A	cg08523029	chr5:130500466	HINT1	0.42	5.67	0.3	3.18e-8	Pediatric bone mineral content (hip);
CRC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.62	-9.73	-0.47	7.88e-20	Intelligence (multi-trait analysis);
CRC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.5	7.11	0.37	7.09e-12	Bone mineral density (spine);
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg01339444	chr6:118972232	C6orf204	0.53	6.02	0.31	4.77e-9	Renal cell carcinoma;
CRC	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.54	9.36	0.46	1.28e-18	Common traits (Other);
CRC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg22535103	chr8:58192502	C8orf71	-0.44	-5.81	-0.3	1.51e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg19773385	chr1:10388646	KIF1B	-0.48	-7.62	-0.39	2.76e-13	Hepatocellular carcinoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19917030	chr17:27507520	MYO18A	0.42	6.04	0.32	4.28e-9	Anxiety disorder;
CRC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.66	0.39	2.03e-13	Axial length;
CRC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.36	5.82	0.31	1.38e-8	Total body bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00655702	chr15:91478531	UNC45A	0.44	6.12	0.32	2.65e-9	Anxiety disorder;
CRC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg07701084	chr6:150067640	NUP43	0.54	7.42	0.38	1e-12	Lung cancer;
CRC	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.48	8.25	0.41	3.83e-15	Common traits (Other);
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg25164649	chr6:28176230	NA	0.78	10.96	0.52	4.9299999999999996e-24	Depression;
CRC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.87	-0.31	1.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	7.76	0.39	1.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.64	0.3	3.62e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.57	-5.89	-0.31	9.45e-9	White matter hyperintensity burden;
CRC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.07e-9	Crohn's disease;
CRC	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.56	8.02	0.4	1.93e-14	Breast cancer;
CRC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.46	6.14	0.32	2.38e-9	Protein C levels;
CRC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.45	-5.63	-0.3	3.94e-8	Gut microbiome composition (summer);
CRC	cis	rs1760803	0.754	rs6719	chr1:154179679	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-5.88	-0.31	9.99e-9	Nicotine dependence;
CRC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.64	10.92	0.52	7.04e-24	Resting heart rate;
CRC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-9.18	-0.45	5.05e-18	Mood instability;
CRC	cis	rs883565	0.740	rs6599003	chr3:39093326	A/G	cg01426195	chr3:39028469	NA	0.52	8.48	0.42	7.88e-16	Handedness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00502963	chr1:150488444	NA	0.38	6.36	0.33	6.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg15845792	chr6:28175446	NA	0.74	8.18	0.41	6.45e-15	Depression;
CRC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.96	-0.31	6.62e-9	Neuroticism;
CRC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg22676075	chr6:135203613	NA	0.45	6.79	0.35	5.25e-11	Red blood cell count;
CRC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs10229583	0.527	rs7783478	chr7:127328537	T/C	cg01233922	chr7:127693937	SND1	-0.49	-7.05	-0.36	1.03e-11	Type 2 diabetes;
CRC	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.67	11.22	0.53	5.79e-25	Cancer;
CRC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.7	0.3	2.61e-8	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10909163	chr13:41635251	WBP4	0.43	6.39	0.33	5.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg26587870	chr6:27730563	NA	-0.43	-6.37	-0.33	6.38e-10	Parkinson's disease;
CRC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs6764363	0.527	rs4684328	chr3:275101	T/C	cg02057681	chr3:285234	CHL1	0.4	6.71	0.35	8.69e-11	Sudden cardiac arrest;
CRC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.71	11.55	0.54	3.96e-26	Osteoporosis;
CRC	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg00469287	chr7:23338798	C7orf30	0.5	6.35	0.33	6.96e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.91	-11.54	-0.54	4.09e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs929596	0.603	rs2602363	chr2:234520525	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.7	-0.3	2.62e-8	Total bilirubin levels in HIV-1 infection;
CRC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.06	9.97	0.48	1.21e-20	Opioid sensitivity;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.79	-16.26	-0.67	5.02e-44	Electroencephalogram traits;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.7	-0.3	2.73e-8	Metabolite levels;
CRC	cis	rs9487051	0.646	rs11153166	chr6:109622494	C/T	cg01475377	chr6:109611718	NA	0.36	5.8	0.3	1.53e-8	Reticulocyte fraction of red cells;
CRC	cis	rs9326248	0.530	rs6589576	chr11:116735788	C/G	cg26566898	chr11:117069891	TAGLN	-0.4	-5.91	-0.31	8.66e-9	Blood protein levels;
CRC	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg22687807	chr8:143858763	LYNX1	-0.38	-6.63	-0.34	1.36e-10	Urinary tract infection frequency;
CRC	trans	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg04077850	chr5:125800366	GRAMD3	0.38	6.28	0.33	1.08e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.53	9.0	0.44	1.85e-17	Coronary artery disease;
CRC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.36	0.53	1.84e-25	Menarche (age at onset);
CRC	cis	rs2072510	0.643	rs2367755	chr12:96393082	T/C	cg15438951	chr12:96389694	HAL	-0.41	-5.62	-0.3	4.08e-8	Metabolite levels (small molecules and protein measures);
CRC	trans	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg24644049	chr4:85504048	CDS1	0.74	7.25	0.37	2.95e-12	Skin colour saturation;
CRC	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.61	8.72	0.43	1.36e-16	Uric acid levels;
CRC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	11.68	0.54	1.3e-26	Menarche (age at onset);
CRC	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-6.56	-0.34	2.11e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.86	11.15	0.52	1.05e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg18876405	chr7:65276391	NA	0.44	6.13	0.32	2.53e-9	Aortic root size;
CRC	cis	rs427941	0.668	rs201461	chr7:101741625	T/C	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs12144094	1.000	rs41276626	chr1:120262112	G/A	cg20995928	chr1:120229863	NA	0.48	5.8	0.3	1.58e-8	Height;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.01	24.19	0.8	5.53e-75	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.79	-10.62	-0.51	7.77e-23	Coronary artery disease;
CRC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.03	0.48	7.86e-21	Heart rate;
CRC	cis	rs1322512	1.000	rs2758812	chr6:152965908	C/T	cg03415253	chr6:152958462	SYNE1	-0.42	-6.53	-0.34	2.55e-10	Tonometry;
CRC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.66	11.71	0.54	1.02e-26	Height;
CRC	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-5.79	-0.3	1.68e-8	Daytime sleep phenotypes;
CRC	cis	rs7626444	0.605	rs7642801	chr3:196490306	G/C	cg12930392	chr3:196481615	PAK2	0.39	6.92	0.36	2.43e-11	Monocyte count;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.54	8.88	0.44	4.31e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg21620606	chr4:1342894	KIAA1530	-0.44	-7.12	-0.37	6.88e-12	Obesity-related traits;
CRC	cis	rs2227564	0.794	rs2688624	chr10:75695724	T/G	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.12	-0.37	6.94e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.68	-0.39	1.86e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.7	7.89	0.4	4.61e-14	Major depressive disorder;
CRC	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-7.79	-0.39	8.81e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg06223162	chr1:101003688	GPR88	0.39	6.95	0.36	1.92e-11	Breast cancer;
CRC	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg23387468	chr7:139079360	LUC7L2	0.4	6.97	0.36	1.72e-11	Diisocyanate-induced asthma;
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg10396713	chr8:602097	NA	0.58	5.84	0.31	1.27e-8	IgG glycosylation;
CRC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.52	-8.06	-0.41	1.47e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg09654669	chr8:57350985	NA	-0.4	-5.68	-0.3	2.99e-8	Obesity-related traits;
CRC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg06287003	chr12:125626642	AACS	-0.52	-7.03	-0.36	1.18e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-9.14	-0.45	6.56e-18	Rheumatoid arthritis;
CRC	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.44	-6.19	-0.32	1.79e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	0.64	6.98	0.36	1.63e-11	Prostate cancer;
CRC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.85	11.25	0.53	4.59e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.41	-6.25	-0.33	1.29e-9	High light scatter reticulocyte count;
CRC	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.73	12.97	0.58	2.38e-31	White blood cell count (basophil);
CRC	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.62	8.88	0.44	4.31e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg19683494	chr5:74908142	NA	0.5	6.28	0.33	1.06e-9	Age-related disease endophenotypes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25698102	chr12:57472712	TMEM194A	0.43	6.31	0.33	9.04e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.36	5.97	0.31	6.1e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.21	-0.32	1.56e-9	Bipolar disorder;
CRC	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6840360	0.582	rs2709827	chr4:152331252	G/C	cg09659197	chr4:152720779	NA	0.29	5.66	0.3	3.3e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.81	0.4	7.77e-14	Motion sickness;
CRC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg02569458	chr12:86230093	RASSF9	0.39	6.77	0.35	6.09e-11	Major depressive disorder;
CRC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.6	-7.06	-0.36	9.73e-12	Diabetic retinopathy;
CRC	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-8.22	-0.41	4.67e-15	Bone mineral density;
CRC	trans	rs9341835	0.772	rs9341841	chr6:64135010	G/A	cg13657004	chr13:50234944	EBPL	-0.37	-6.4	-0.33	5.31e-10	Schizophrenia;
CRC	cis	rs889398	0.677	rs68161338	chr16:69823778	T/G	cg00738113	chr16:70207722	CLEC18C	0.37	6.13	0.32	2.47e-9	Body mass index;
CRC	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.52	8.24	0.41	4.08e-15	Diastolic blood pressure;
CRC	cis	rs7635838	0.819	rs4684782	chr3:11518755	C/T	cg00170343	chr3:11313890	ATG7	-0.43	-6.52	-0.34	2.58e-10	HDL cholesterol;
CRC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.49	7.68	0.39	1.78e-13	Corneal astigmatism;
CRC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.84	-11.16	-0.52	9.37e-25	Initial pursuit acceleration;
CRC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.55	9.24	0.45	3.27e-18	Eye color traits;
CRC	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg14631576	chr9:95140430	CENPP	-0.33	-6.14	-0.32	2.41e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.54	8.71	0.43	1.49e-16	Aortic root size;
CRC	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.65	10.41	0.5	3.96e-22	Myopia (pathological);
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg09877947	chr5:131593287	PDLIM4	0.53	9.94	0.48	1.53e-20	Acylcarnitine levels;
CRC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.49	9.32	0.46	1.73e-18	Renal cell carcinoma;
CRC	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg24375607	chr4:120327624	NA	0.46	7.05	0.36	1.03e-11	Educational attainment;
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.67	10.45	0.5	2.86e-22	Breast cancer;
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg08200582	chr11:442649	ANO9	-0.71	-7.39	-0.38	1.2e-12	Body mass index;
CRC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	10.2	0.49	2.12e-21	Cognitive test performance;
CRC	cis	rs501120	0.657	rs11238908	chr10:44688080	T/G	cg09554077	chr10:44749378	NA	0.57	6.55	0.34	2.2e-10	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.53	8.54	0.43	4.99e-16	Prostate cancer;
CRC	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.12	-0.45	7.9e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.9	-0.31	8.82e-9	Lung cancer;
CRC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.61	6.26	0.33	1.19e-9	Axial length;
CRC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.71	-0.39	1.5e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs4869931	0.929	rs58824807	chr6:151006270	T/C	cg01367992	chr1:160766535	LY9	0.38	6.17	0.32	1.98e-9	Systolic blood pressure in sickle cell anemia;
CRC	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg15382696	chr6:118971807	C6orf204	0.62	7.43	0.38	9.18e-13	Renal cell carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06192289	chr12:102513805	NUP37;C12orf48	0.38	6.14	0.32	2.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs370915	0.524	rs28826385	chr4:187769452	C/T	cg12892747	chr4:187813459	NA	-0.56	-8.19	-0.41	5.73e-15	Gout;
CRC	cis	rs7259376	0.936	rs6511344	chr19:22535673	C/T	cg02657401	chr19:22469223	NA	-0.33	-7.46	-0.38	7.6e-13	Menopause (age at onset);
CRC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.46	9.05	0.45	1.32e-17	Prostate cancer;
CRC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg16476235	chr8:21771668	DOK2	0.39	6.54	0.34	2.37e-10	Mean corpuscular volume;
CRC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.08	14.88	0.63	1.19e-38	Orofacial clefts;
CRC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.78	-10.56	-0.5	1.19e-22	IgG glycosylation;
CRC	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg19875578	chr6:126661172	C6orf173	0.41	5.64	0.3	3.69e-8	Male-pattern baldness;
CRC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.53	-6.95	-0.36	1.95e-11	Body mass index;
CRC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.61	-8.45	-0.42	9.45e-16	DNA methylation (variation);
CRC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.6	-7.83	-0.4	6.64e-14	Schizophrenia;
CRC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.54	0.38	4.63e-13	Lung cancer in ever smokers;
CRC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.54	7.97	0.4	2.61e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg03623178	chr6:28175578	NA	0.87	9.3	0.46	1.95e-18	Lung cancer in ever smokers;
CRC	cis	rs4664293	0.802	rs7563417	chr2:160584273	A/C	cg08347373	chr2:160653686	CD302	-0.49	-7.7	-0.39	1.64e-13	Monocyte percentage of white cells;
CRC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.62	9.94	0.48	1.55e-20	Aortic root size;
CRC	cis	rs3020333	0.875	rs2941740	chr6:152009638	A/G	cg22157087	chr6:152012887	ESR1	0.53	7.86	0.4	5.43e-14	Total body bone mineral density;
CRC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.08	24.93	0.81	8.84e-78	Testicular germ cell tumor;
CRC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg04013166	chr16:89971882	TCF25	0.57	5.82	0.31	1.43e-8	Skin colour saturation;
CRC	cis	rs11622475	1.000	rs2273610	chr14:104387642	G/C	cg12183467	chr14:104352244	NA	-0.51	-7.0	-0.36	1.43e-11	Bipolar disorder;
CRC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg03037974	chr15:76606532	NA	-0.5	-7.43	-0.38	9.44e-13	Blood metabolite levels;
CRC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.43	6.96	0.36	1.81e-11	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20706768	chr7:55225183	EGFR	-0.37	-6.26	-0.33	1.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.29	-0.33	1.01e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.29	-0.33	1.02e-9	Longevity;Endometriosis;
CRC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg08888203	chr3:10149979	C3orf24	0.71	8.58	0.43	3.91e-16	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-11.71	-0.54	1.03e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2275731	0.506	rs7905643	chr10:16521007	T/G	cg04254609	chr10:16479192	PTER	-0.47	-6.45	-0.34	3.9e-10	Bone fracture in osteoporosis;
CRC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.65	-8.25	-0.41	3.91e-15	Vitamin D levels;
CRC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg15845792	chr6:28175446	NA	0.71	6.59	0.34	1.77e-10	Depression;
CRC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16024904	chr19:17905718	B3GNT3	0.36	5.68	0.3	2.92e-8	Tumor biomarkers;
CRC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.43	6.32	0.33	8.56e-10	Diastolic blood pressure;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg21784768	chr11:537496	LRRC56	-0.68	-6.45	-0.33	4.1e-10	Body mass index;
CRC	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.43	6.06	0.32	3.68e-9	Dialysis-related mortality;
CRC	cis	rs10760158	0.832	rs4836845	chr9:124049956	T/C	cg14417974	chr9:124058376	GSN	-0.34	-5.81	-0.31	1.48e-8	Pulse pressure;
CRC	cis	rs4731207	0.698	rs17147583	chr7:124470125	C/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.2	0.32	1.73e-9	Bipolar disorder;
CRC	trans	rs660498	0.785	rs2484203	chr10:27736292	C/T	cg13661793	chr10:32399026	NA	-0.33	-5.99	-0.31	5.65e-9	Asthma (childhood onset);
CRC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.71	10.78	0.51	2.03e-23	Tonsillectomy;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.6	10.89	0.51	8.63e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg15786705	chr6:28176104	NA	-0.6	-6.67	-0.34	1.11e-10	Parkinson's disease;
CRC	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg24463073	chr6:118973353	C6orf204	0.42	5.99	0.31	5.54e-9	Renal cell carcinoma;
CRC	cis	rs965469	0.779	rs6037571	chr20:3334322	C/T	cg25506879	chr20:3388711	C20orf194	-0.37	-5.77	-0.3	1.84e-8	IFN-related cytopenia;
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-0.64	-11.49	-0.53	6.67e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.5	7.82	0.4	7.14e-14	Red blood cell count;
CRC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg22777020	chr22:31556080	RNF185	0.56	6.47	0.34	3.64e-10	Colorectal cancer;
CRC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.74	-0.3	2.11e-8	High light scatter reticulocyte count;
CRC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.31	-0.56	6.78e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg24289452	chr6:170231220	NA	-0.57	-6.21	-0.32	1.6e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.58	9.04	0.45	1.4e-17	HDL cholesterol;
CRC	cis	rs9311676	0.618	rs12152336	chr3:58365146	T/A	cg06643156	chr3:58380774	PXK	0.42	6.55	0.34	2.17e-10	Systemic lupus erythematosus;
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.76	14.12	0.61	1.01e-35	Prudent dietary pattern;
CRC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.65	-9.65	-0.47	1.46e-19	Bladder cancer;
CRC	cis	rs12745968	0.589	rs6603989	chr1:93026928	G/T	cg17283838	chr1:93427260	FAM69A	-0.48	-6.32	-0.33	8.29e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg22117107	chr15:45993392	NA	-0.43	-8.65	-0.43	2.36e-16	Waist circumference;Weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26909954	chr8:127570872	FAM84B	0.42	6.11	0.32	2.81e-9	Response to antipsychotic treatment;
CRC	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.5	7.09	0.36	8.03e-12	Alzheimer's disease;
CRC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.7	11.82	0.55	4.31e-27	Extrinsic epigenetic age acceleration;
CRC	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg05502645	chr19:1971281	CSNK1G2	0.46	7.29	0.37	2.25e-12	Coronary artery disease;
CRC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09742643	chr7:157958748	PTPRN2	0.36	6.04	0.32	4.14e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	9.14	0.45	6.58e-18	Cognitive test performance;
CRC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.63	8.79	0.44	8.38e-17	Bronchopulmonary dysplasia;
CRC	trans	rs1612141	0.901	rs1112504	chr14:41709711	G/T	cg23649140	chr8:37661612	GPR124	0.46	6.08	0.32	3.37e-9	QT interval (drug interaction);
CRC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.98	-0.31	5.81e-9	Migraine;Coronary artery disease;
CRC	cis	rs6747952	0.899	rs2880132	chr2:239082976	G/A	cg07480446	chr2:239069576	NA	-0.37	-6.8	-0.35	4.82e-11	Mean corpuscular hemoglobin concentration;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16714605	chr19:10765132	ILF3;LOC147727	0.36	6.27	0.33	1.15e-9	Obesity-related traits;
CRC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg09473613	chr1:24152604	HMGCL	0.35	5.78	0.3	1.73e-8	Immature fraction of reticulocytes;
CRC	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.03	-0.36	1.17e-11	Putamen volume;
CRC	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12230513	0.732	rs59438785	chr12:55811665	A/G	cg19537932	chr12:55886519	OR6C68	-0.74	-9.46	-0.46	5.95e-19	Contrast sensitivity;
CRC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	17.74	0.7	7.17e-50	Smoking behavior;
CRC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.53	-0.38	4.85e-13	Alzheimer's disease;
CRC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg23996704	chr18:44553084	KATNAL2	-0.33	-6.83	-0.35	4.07e-11	Personality dimensions;
CRC	cis	rs2235544	0.579	rs1537322	chr1:54482306	G/T	cg25741118	chr1:54482237	LDLRAD1	-0.21	-6.0	-0.31	5.34e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg03037974	chr15:76606532	NA	-0.52	-7.35	-0.38	1.54e-12	Blood metabolite levels;
CRC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.46	6.49	0.34	3.08e-10	Blood pressure (smoking interaction);
CRC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.97	-18.47	-0.71	9.2e-53	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.24	6.66	0.34	1.16e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.41	6.51	0.34	2.73e-10	Self-reported allergy;
CRC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.37	-6.41	-0.33	4.98e-10	Height;
CRC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.45	-0.38	8.43e-13	Colorectal cancer;
CRC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.73	-7.53	-0.38	5.09e-13	Diabetic retinopathy;
CRC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg20542592	chr8:11973495	FAM66D	-0.33	-5.64	-0.3	3.69e-8	Retinal vascular caliber;
CRC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.55	-8.71	-0.43	1.5e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs294883	0.858	rs2879865	chr6:159718610	T/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg18016565	chr1:150552671	MCL1	0.43	5.95	0.31	6.7e-9	Melanoma;
CRC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.58	7.82	0.4	7.07e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.4	6.63	0.34	1.38e-10	Height;
CRC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.25e-9	Prudent dietary pattern;
CRC	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg01639898	chr1:32083012	HCRTR1	0.32	6.6	0.34	1.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg22110888	chr17:80059540	CCDC57	-0.44	-6.87	-0.35	3.2e-11	Life satisfaction;
CRC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.78	-0.3	1.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-8.33	-0.42	2.15e-15	Self-reported allergy;
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-9.07	-0.45	1.12e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg23032129	chr1:109941072	SORT1	-0.28	-5.93	-0.31	7.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.47	7.87	0.4	5.03e-14	Prevalent atrial fibrillation;
CRC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg01483505	chr11:975446	AP2A2	0.41	6.16	0.32	2.1e-9	Alzheimer's disease (late onset);
CRC	cis	rs12024301	0.557	rs7518362	chr1:183610578	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.66	0.39	2.13e-13	Neuroticism;
CRC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.59	8.91	0.44	3.52e-17	Subjective well-being;
CRC	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.95	0.31	6.94e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	1.11	13.59	0.6	1.11e-33	Iron status biomarkers;
CRC	cis	rs3015497	0.543	rs1565834	chr14:51011528	C/T	cg26011998	chr14:51135199	SAV1	0.45	5.65	0.3	3.5e-8	Mean platelet volume;
CRC	cis	rs6908034	0.607	rs77386860	chr6:19814755	A/C	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.33	-7.13	-0.37	6.34e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.82	-0.35	4.36e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg23565292	chr14:50234668	KLHDC2	-0.41	-5.96	-0.31	6.52e-9	Carotid intima media thickness;
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg22561889	chr6:118971681	C6orf204	0.52	6.69	0.35	9.59e-11	Renal cell carcinoma;
CRC	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.48	-8.74	-0.43	1.25e-16	Hip circumference;Waist circumference;
CRC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg11707556	chr5:10655725	ANKRD33B	0.36	6.82	0.35	4.49e-11	Coronary artery disease;
CRC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.77	0.6	2.27e-34	Chronic sinus infection;
CRC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.18	-0.32	1.88e-9	Reticulocyte count;
CRC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	9.25	0.45	2.91e-18	Parkinson's disease;
CRC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg24463073	chr6:118973353	C6orf204	0.51	6.69	0.35	9.44e-11	Diastolic blood pressure;
CRC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.68	-13.45	-0.6	3.72e-33	Coronary artery disease;
CRC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.89	-15.28	-0.64	3.35e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.78	-10.28	-0.49	1.11e-21	Initial pursuit acceleration;
CRC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.46	0.42	9.09e-16	Arsenic metabolism;
CRC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg04880052	chr2:219191631	PNKD	0.42	6.72	0.35	8.09e-11	Colorectal cancer;
CRC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg03315344	chr16:75512273	CHST6	0.49	5.93	0.31	7.78e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs2462686	0.965	rs1525831	chr7:45994409	C/T	cg15898840	chr7:45960834	IGFBP3	0.38	5.96	0.31	6.44e-9	Major depressive disorder;
CRC	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg08501292	chr6:25962987	TRIM38	-1.1	-9.11	-0.45	8.41e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.18	-0.37	4.75e-12	Life satisfaction;
CRC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.62	9.25	0.45	2.9e-18	Blood protein levels;
CRC	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg00691999	chr4:55094011	PDGFRA	0.44	6.34	0.33	7.43e-10	Corneal astigmatism;
CRC	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg25767906	chr1:53392781	SCP2	0.42	6.62	0.34	1.48e-10	Monocyte count;
CRC	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.52	8.98	0.44	2.11e-17	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg23650765	chr1:12612165	NA	0.34	6.52	0.34	2.7e-10	Optic cup area;
CRC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.22	14.71	0.63	5.29e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs8067545	1.000	rs9891739	chr17:19942177	C/T	cg13482628	chr17:19912719	NA	0.54	8.52	0.43	5.69e-16	Schizophrenia;
CRC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg18165381	chr3:44552316	NA	0.37	5.66	0.3	3.27e-8	Depressive symptoms;
CRC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg03037974	chr15:76606532	NA	0.66	11.11	0.52	1.44e-24	Blood metabolite levels;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg26872475	chr11:119039430	NLRX1	0.42	6.22	0.32	1.5e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.08	14.7	0.63	5.8e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-5.67	-0.3	3.07e-8	Monocyte percentage of white cells;
CRC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg13206674	chr6:150067644	NUP43	0.64	8.95	0.44	2.72e-17	Lung cancer;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg26587870	chr6:27730563	NA	-0.66	-6.84	-0.35	3.89e-11	Breast cancer;
CRC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg21466736	chr12:48725269	NA	0.52	7.88	0.4	4.92e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	trans	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg09872104	chr7:134855509	C7orf49	-0.82	-6.98	-0.36	1.68e-11	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg15845792	chr6:28175446	NA	0.94	12.56	0.57	7.64e-30	Parkinson's disease;
CRC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.79	17.53	0.7	4.58e-49	Breast cancer;
CRC	cis	rs9463078	0.605	rs13215618	chr6:44936568	A/G	cg25276700	chr6:44698697	NA	0.25	6.04	0.32	4.07e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.36	5.69	0.3	2.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.68	8.97	0.44	2.37e-17	Morning vs. evening chronotype;
CRC	trans	rs1367248	1.000	rs780038	chr2:125009945	A/T	cg07402188	chr19:40720005	MAP3K10	-0.45	-6.2	-0.32	1.7e-9	Tonometry;
CRC	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg23254163	chr1:152506842	NA	0.45	8.64	0.43	2.51e-16	Hair morphology;
CRC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg02741985	chr17:80059408	CCDC57	-0.45	-7.25	-0.37	2.94e-12	Life satisfaction;
CRC	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.63	6.45	0.33	4.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg24046110	chr8:143859143	LYNX1	0.49	8.61	0.43	3.15e-16	Urinary tract infection frequency;
CRC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.45	-5.95	-0.31	6.85e-9	Aortic root size;
CRC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.59	-9.72	-0.47	8.7e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg08795948	chr3:128337044	NA	0.34	5.77	0.3	1.83e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.64	9.63	0.47	1.73e-19	Lymphocyte counts;
CRC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.99	0.55	9.91e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.45	5.89	0.31	9.57e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.76	9.99	0.48	1.08e-20	Coronary artery disease;
CRC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.69	-0.35	9.62e-11	Type 2 diabetes;
CRC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg16540259	chr10:75572220	NDST2	0.38	6.29	0.33	1.02e-9	Inflammatory bowel disease;
CRC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.76	12.79	0.58	1.09e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg00334542	chr7:100209784	MOSPD3	-0.54	-6.84	-0.35	3.78e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8105895	0.935	rs2163835	chr19:22242679	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.85	0.31	1.2e-8	Diastolic blood pressure;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.13	0.32	2.54e-9	Bipolar disorder;
CRC	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.32	-5.67	-0.3	3.16e-8	Mean corpuscular volume;
CRC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-9.54	-0.47	3.32e-19	Personality dimensions;
CRC	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.49	7.59	0.39	3.23e-13	Type 2 diabetes;
CRC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg12639453	chr1:2035780	PRKCZ	0.34	6.7	0.35	8.83e-11	Height;
CRC	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg23024343	chr7:107201750	COG5	0.73	9.81	0.48	4.12e-20	Coronary artery disease;
CRC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg11070056	chr1:107600091	PRMT6	0.4	5.76	0.3	1.93e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1572438	0.811	rs6916731	chr6:880428	G/C	cg13447295	chr6:887704	NA	0.55	8.39	0.42	1.48e-15	Aging;
CRC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.52	-7.87	-0.4	5.16e-14	Menarche (age at onset);
CRC	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12315302	chr6:26189340	HIST1H4D	0.75	6.27	0.33	1.13e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg00603274	chr11:61596626	FADS2	-0.56	-7.54	-0.38	4.73e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-9.54	-0.47	3.41e-19	Coffee consumption (cups per day);
CRC	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg16558208	chr1:156270281	VHLL	0.58	9.08	0.45	1.03e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg21970626	chr13:21893289	NA	-0.44	-6.59	-0.34	1.8e-10	White matter hyperintensity burden;
CRC	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.62	8.89	0.44	3.98e-17	Schizophrenia;
CRC	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	13.1	0.59	7.5e-32	Hip circumference;
CRC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.33	1.01e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.44	6.25	0.33	1.24e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.42e-25	Intelligence (multi-trait analysis);
CRC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.4	7.92	0.4	3.72e-14	Hypertriglyceridemia;
CRC	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24796471	chr19:6737389	GPR108	0.42	6.5	0.34	3.06e-10	Schizophrenia;
CRC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.1	0.41	1.06e-14	Parkinson's disease;
CRC	cis	rs6662572	0.737	rs72677533	chr1:46536558	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.33	0.33	7.85e-10	Blood protein levels;
CRC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg27535305	chr1:53392650	SCP2	-0.38	-6.9	-0.36	2.72e-11	Monocyte count;
CRC	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.45	-6.3	-0.33	9.28e-10	Coronary artery disease;
CRC	trans	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.51	-0.34	2.78e-10	Neuroticism;
CRC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.35	5.9	0.31	9.2e-9	Emphysema distribution in smoking;
CRC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg21854759	chr1:92012499	NA	0.51	6.48	0.34	3.28e-10	Eosinophil percentage of white cells;
CRC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.72	-8.71	-0.43	1.54e-16	Hemostatic factors and hematological phenotypes;
CRC	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.81	-11.26	-0.53	4.44e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.13	0.64	1.32e-39	Bipolar disorder;
CRC	cis	rs10888329	0.707	rs6587437	chr1:248355867	T/G	cg00666640	chr1:248458726	OR2T12	0.44	6.97	0.36	1.75e-11	Autism spectrum disorder;
CRC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.59	8.01	0.4	2e-14	Orofacial clefts;
CRC	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg21138405	chr5:131827807	IRF1	0.36	5.99	0.31	5.55e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg24375607	chr4:120327624	NA	-0.47	-7.68	-0.39	1.84e-13	Corneal astigmatism;
CRC	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg08125733	chr17:73851984	WBP2	0.72	9.09	0.45	9.41e-18	Psoriasis;
CRC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.17	0.52	9.19e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg24644049	chr4:85504048	CDS1	0.77	6.8	0.35	5.05e-11	Skin colour saturation;
CRC	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.63	9.17	0.45	5.1e-18	Uric acid levels;
CRC	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg02927042	chr1:21476669	EIF4G3	0.4	6.45	0.34	3.98e-10	Superior frontal gyrus grey matter volume;
CRC	trans	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg18755114	chr2:209119030	IDH1	-0.4	-6.11	-0.32	2.87e-9	Blood protein levels;
CRC	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-5.8	-0.3	1.55e-8	Blood pressure;
CRC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10802521	chr3:52805072	NEK4	-0.52	-7.07	-0.36	9.17e-12	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	cis	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg14515779	chr1:101123966	NA	-0.41	-7.97	-0.4	2.69e-14	Monocyte count;
CRC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.5	7.17	0.37	4.86e-12	Height;
CRC	cis	rs6764363	0.527	rs62228321	chr3:279372	A/C	cg02057681	chr3:285234	CHL1	0.43	7.31	0.37	2.07e-12	Sudden cardiac arrest;
CRC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.77	13.85	0.61	1.14e-34	Oral cavity cancer;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01532600	chr16:285188	ITFG3	0.42	6.06	0.32	3.79e-9	Schizophrenia;
CRC	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs990171	1.000	rs1807782	chr2:103033147	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.4e-8	Lymphocyte counts;
CRC	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg15412446	chr2:106886593	NA	0.4	6.37	0.33	6.26e-10	Facial morphology (factor 23);
CRC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.67	-8.46	-0.42	8.85e-16	Bipolar disorder (body mass index interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10815165	chr10:105212270	CALHM2	0.34	6.06	0.32	3.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.43	-0.42	1.12e-15	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-7.96	-0.4	2.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25517755	chr10:38738941	LOC399744	0.41	5.86	0.31	1.13e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12760731	0.720	rs16852717	chr1:178309723	T/C	cg00404053	chr1:178313656	RASAL2	0.92	9.63	0.47	1.74e-19	Obesity-related traits;
CRC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg03233332	chr7:66118400	NA	-0.43	-5.87	-0.31	1.05e-8	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18565132	chr8:103613344	NA	0.36	6.04	0.32	4.22e-9	Obesity-related traits;
CRC	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12292205	chr6:26970375	C6orf41	-0.78	-8.36	-0.42	1.81e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.37	0.38	1.35e-12	Major depressive disorder;
CRC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.44	6.58	0.34	1.81e-10	Mean platelet volume;
CRC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.48	6.17	0.32	2.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg07713946	chr22:31675144	LIMK2	0.43	6.3	0.33	9.29e-10	Colorectal cancer;
CRC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.64	0.34	1.32e-10	Lung cancer;
CRC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.42	-7.04	-0.36	1.12e-11	Breast cancer;
CRC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.11e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg10272801	chr16:14013773	ERCC4	-0.67	-6.07	-0.32	3.6e-9	Cognitive function;
CRC	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg00919237	chr7:87102261	ABCB4	-0.51	-6.64	-0.34	1.3100000000000001e-10	Gallbladder cancer;
CRC	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.54	8.29	0.42	2.95e-15	Diastolic blood pressure;
CRC	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg16964102	chr10:135390573	NA	0.49	6.77	0.35	5.9e-11	Gout;
CRC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.46	7.37	0.38	1.4e-12	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg27565382	chr3:53032988	SFMBT1	0.7	6.19	0.32	1.76e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	0.68	10.8	0.51	1.73e-23	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.92	17.22	0.69	8.3e-48	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg06632207	chr12:54070931	ATP5G2	0.45	7.53	0.38	4.91e-13	Height;
CRC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.85	15.84	0.66	2.12e-42	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.83	11.94	0.55	1.5e-27	Cognitive function;
CRC	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.81	-14.1	-0.61	1.26e-35	Lewy body disease;
CRC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg18479299	chr3:125709523	NA	-0.55	-6.59	-0.34	1.75e-10	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7580658	0.550	rs62160290	chr2:128200695	C/T	cg09760422	chr2:128146352	NA	-0.31	-5.68	-0.3	2.98e-8	Protein C levels;
CRC	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.06	-0.32	3.82e-9	Height;
CRC	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.62	0.51	7.43e-23	Iron status biomarkers;
CRC	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs12760731	0.565	rs16828608	chr1:178129899	C/T	cg00404053	chr1:178313656	RASAL2	0.76	8.6	0.43	3.34e-16	Obesity-related traits;
CRC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.28e-20	Ileal carcinoids;
CRC	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-8.72	-0.43	1.37e-16	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg03030879	chr14:75389066	RPS6KL1	0.43	6.64	0.34	1.29e-10	Height;
CRC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.41	7.77	0.39	1.03e-13	Mean corpuscular volume;
CRC	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg19773385	chr1:10388646	KIF1B	-0.58	-8.04	-0.41	1.58e-14	Hepatocellular carcinoma;
CRC	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.69	-11.63	-0.54	1.98e-26	White blood cell count (basophil);
CRC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.62	8.37	0.42	1.64e-15	Smoking initiation;
CRC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.44	6.42	0.33	4.86e-10	Menopause (age at onset);
CRC	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.98	19.99	0.74	9.58e-59	Metabolite levels;
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.3	-6.43	-0.33	4.47e-10	IgG glycosylation;
CRC	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg03418659	chr16:31128414	MYST1	0.42	6.12	0.32	2.71e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-7.83	-0.4	6.55e-14	Initial pursuit acceleration;
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.76	11.4	0.53	1.33e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.56	7.32	0.37	1.88e-12	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.52	6.12	0.32	2.72e-9	Lymphocyte counts;
CRC	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg21095983	chr6:86352623	SYNCRIP	0.5	7.1	0.36	7.82e-12	Smooth-surface caries;
CRC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg13047869	chr3:10149882	C3orf24	0.39	5.92	0.31	8.16e-9	Alzheimer's disease;
CRC	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg12072164	chr19:44306565	LYPD5	0.38	6.08	0.32	3.25e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.58	-10.59	-0.5	9.83e-23	Total body bone mineral density;
CRC	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.03	-0.48	7.73e-21	Bipolar disorder;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18758796	chr5:131593413	PDLIM4	0.43	7.92	0.4	3.66e-14	Breast cancer;
CRC	cis	rs12760731	0.920	rs12750502	chr1:178487224	G/A	cg00404053	chr1:178313656	RASAL2	0.6	7.0	0.36	1.41e-11	Obesity-related traits;
CRC	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.46	-6.52	-0.34	2.61e-10	Body mass index;
CRC	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.59	-9.67	-0.47	1.25e-19	Schizophrenia;
CRC	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-8.2	-0.41	5.32e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7172809	0.643	rs16953967	chr15:77836521	C/T	cg10437265	chr15:77819839	NA	-0.37	-6.12	-0.32	2.66e-9	Glucose homeostasis traits;
CRC	cis	rs9648716	0.608	rs1267610	chr7:140525883	C/T	cg10747023	chr7:140774559	NA	0.45	6.2	0.32	1.71e-9	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12273811	chr6:28175739	NA	0.72	9.13	0.45	7.05e-18	Depression;
CRC	cis	rs7737355	0.812	rs31241	chr5:130808198	T/C	cg25547332	chr5:131281432	NA	0.35	5.6	0.3	4.52e-8	Life satisfaction;
CRC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.38	6.34	0.33	7.69e-10	Height;
CRC	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.29	-15.43	-0.65	8.74e-41	Diabetic kidney disease;
CRC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.47	8.53	0.43	5.41e-16	Immature fraction of reticulocytes;
CRC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.0	-0.31	5.12e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg13844804	chr7:814759	HEATR2	0.65	8.51	0.42	6.2e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04045327	chr4:905805	GAK	-0.41	-6.68	-0.35	1.02e-10	Systemic sclerosis;
CRC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.11	-0.41	1.01e-14	Height;
CRC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11645453	chr3:52864694	ITIH4	0.37	6.65	0.34	1.19e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.74	-11.74	-0.54	7.91e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18099408	chr3:52552593	STAB1	-0.52	-9.2	-0.45	4.13e-18	Electroencephalogram traits;
CRC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-9.13	-0.45	7.21e-18	Hip circumference adjusted for BMI;
CRC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-12.65	-0.57	3.74e-30	Cognitive function;
CRC	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	trans	rs1364477	0.529	rs7575327	chr2:186181992	A/G	cg12230250	chr22:40042864	CACNA1I	-0.29	-6.12	-0.32	2.69e-9	IgG glycosylation;
CRC	cis	rs72730918	0.590	rs1378895	chr15:51937295	G/A	cg14296394	chr15:51910925	DMXL2	-0.47	-6.32	-0.33	8.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.32	-8.72	-0.43	1.41e-16	Mean corpuscular volume;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg12273811	chr6:28175739	NA	0.66	10.07	0.49	5.57e-21	Cardiac Troponin-T levels;
CRC	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg27205649	chr11:78285834	NARS2	-0.46	-5.73	-0.3	2.24e-8	Alzheimer's disease (survival time);
CRC	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg20356878	chr3:121714668	ILDR1	-0.42	-6.01	-0.31	5.02e-9	Multiple sclerosis;
CRC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.4	-6.74	-0.35	7.29e-11	Blood metabolite levels;
CRC	cis	rs2929278	0.561	rs2927071	chr15:43919081	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.8	0.3	1.52e-8	Schizophrenia;
CRC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.82	14.48	0.62	4.37e-37	Breast cancer;
CRC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.72	-9.64	-0.47	1.55e-19	Coronary artery disease;
CRC	cis	rs17065868	0.764	rs9533854	chr13:45021880	A/T	cg10246903	chr13:45222710	NA	0.6	6.56	0.34	2.07e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.57	-8.09	-0.41	1.14e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg07404485	chr7:94953653	PON1	-0.45	-5.91	-0.31	8.36e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg04545296	chr12:48745243	ZNF641	0.36	6.15	0.32	2.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.83	-10.9	-0.51	8.14e-24	Vitiligo;
CRC	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.49	7.61	0.39	2.95e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-10.33	-0.49	7.38e-22	Personality dimensions;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.94	0.48	1.61e-20	Corneal astigmatism;
CRC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	2.94e-11	Glioblastoma;
CRC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg20628663	chr10:43360327	NA	0.72	7.32	0.37	1.93e-12	Pediatric bone mineral content (radius);
CRC	cis	rs72627123	0.867	rs8015927	chr14:74465756	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.71	-5.8	-0.3	1.52e-8	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06608945	chr2:219082296	ARPC2	0.44	6.33	0.33	8.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg24560729	chr4:1342394	KIAA1530	-0.34	-5.62	-0.3	4.12e-8	Obesity-related traits;
CRC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.63	-0.47	1.63e-19	Vitiligo;
CRC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg07299736	chr8:135490787	ZFAT	-0.37	-6.48	-0.34	3.41e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.78	10.87	0.51	1.03e-23	Neutrophil percentage of white cells;
CRC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.6	9.42	0.46	8.2e-19	Body mass index;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.75	-0.35	6.69e-11	Total body bone mineral density;
CRC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.84	-0.35	3.88e-11	IgG glycosylation;
CRC	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg01639898	chr1:32083012	HCRTR1	0.3	6.1	0.32	3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg00579200	chr11:133705235	NA	-0.41	-5.92	-0.31	7.91e-9	Childhood ear infection;
CRC	cis	rs6456156	0.904	rs2021033	chr6:167524239	C/T	cg07741184	chr6:167504864	NA	-0.34	-5.67	-0.3	3.07e-8	Primary biliary cholangitis;
CRC	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24249390	chr15:90295951	MESP1	-0.58	-9.28	-0.46	2.4e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.58	8.78	0.44	9.02e-17	Schizophrenia;
CRC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21028142	chr17:79581711	NPLOC4	0.32	6.8	0.35	5.02e-11	Eye color traits;
CRC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.82	9.22	0.45	3.69e-18	Breast cancer;
CRC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.37	-0.33	6.46e-10	Blood metabolite levels;
CRC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7572644	0.564	rs12995865	chr2:28025066	A/C	cg27432699	chr2:27873401	GPN1	0.45	5.73	0.3	2.24e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	8.23	0.41	4.56e-15	Iron status biomarkers;
CRC	cis	rs9311676	0.656	rs62258102	chr3:58378784	T/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg23422044	chr7:1970798	MAD1L1	-0.51	-5.99	-0.31	5.47e-9	Neuroticism;
CRC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.87	-9.89	-0.48	2.34e-20	Breast cancer;
CRC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.47	-6.7	-0.35	9.06e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.16	-0.37	5.44e-12	Height;
CRC	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg13057898	chr1:3703894	LRRC47	-0.4	-5.87	-0.31	1.06e-8	Red cell distribution width;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.78	-12.97	-0.58	2.34e-31	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg09659197	chr4:152720779	NA	0.42	8.5	0.42	6.93e-16	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.7	-7.75	-0.39	1.17e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.97e-12	Diisocyanate-induced asthma;
CRC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.53	-0.34	2.51e-10	Menopause (age at onset);
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10235961	chr3:48471218	PLXNB1	0.48	6.76	0.35	6.2e-11	Response to antipsychotic treatment;
CRC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.94	13.66	0.6	5.88e-34	Breast cancer;
CRC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-10.89	-0.51	8.91e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.41	-6.42	-0.33	4.67e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.6	9.33	0.46	1.62e-18	Corneal astigmatism;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg19041857	chr6:27730383	NA	-0.45	-6.39	-0.33	5.52e-10	Parkinson's disease;
CRC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.24	0.41	4.06e-15	Homoarginine levels;
CRC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.66	8.65	0.43	2.39e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.75	11.0	0.52	3.53e-24	Plateletcrit;Platelet count;
CRC	cis	rs12476592	0.516	rs11883730	chr2:63592230	A/C	cg10828910	chr2:63850056	LOC388955	-0.49	-6.0	-0.31	5.17e-9	Childhood ear infection;
CRC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg05585544	chr11:47624801	NA	0.53	9.31	0.46	1.84e-18	Subjective well-being;
CRC	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.63	-8.51	-0.42	6.45e-16	Cocaine dependence;
CRC	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.22	-0.32	1.49e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs2160860	0.729	rs7845003	chr8:39799765	C/T	cg11363097	chr8:39792086	IDO2	-0.45	-7.65	-0.39	2.28e-13	Blood metabolite levels;
CRC	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg03456212	chr7:26904342	SKAP2	0.55	6.44	0.33	4.21e-10	Type 1 diabetes;
CRC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg01629716	chr15:45996671	NA	0.4	8.25	0.41	3.97e-15	Waist circumference;Weight;
CRC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.52	7.74	0.39	1.24e-13	Resting heart rate;
CRC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.66	7.33	0.37	1.79e-12	Vitiligo;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Depression;
CRC	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.48	8.14	0.41	7.98e-15	Common traits (Other);
CRC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.13	-0.45	7.11e-18	Menarche (age at onset);
CRC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.54	8.31	0.42	2.46e-15	Aortic root size;
CRC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	10.8	0.51	1.77e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg09324608	chr17:30823087	MYO1D	0.35	5.91	0.31	8.67e-9	Schizophrenia;
CRC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.14	-12.02	-0.55	7.44e-28	Breast cancer;
CRC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.41	-6.31	-0.33	8.9e-10	Body mass index;
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.59e-14	Bipolar disorder;
CRC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18030545	chr6:107077498	QRSL1;RTN4IP1	0.46	6.61	0.34	1.58e-10	Response to antipsychotic treatment;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.38	5.74	0.3	2.12e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.61	-8.41	-0.42	1.29e-15	DNA methylation (variation);
CRC	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.84	-0.31	1.25e-8	Alzheimer's disease (survival time);
CRC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.72	11.38	0.53	1.64e-25	Colorectal cancer;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg08888203	chr3:10149979	C3orf24	0.7	7.42	0.38	1.03e-12	Alzheimer's disease;
CRC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-0.71	-9.09	-0.45	9.8e-18	Platelet distribution width;
CRC	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.81	12.39	0.56	3.3600000000000003e-29	Cognitive function;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.5	7.24	0.37	3.1e-12	Longevity;Endometriosis;
CRC	cis	rs6764363	0.527	rs7640724	chr3:283039	G/A	cg02057681	chr3:285234	CHL1	0.42	7.08	0.36	8.63e-12	Sudden cardiac arrest;
CRC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.6	8.6	0.43	3.34e-16	Arsenic metabolism;
CRC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.61	-0.43	2.98e-16	Hemoglobin concentration;
CRC	cis	rs2836754	1.000	rs11701004	chr21:40292102	C/G	cg02119577	chr21:40195074	ETS2	-0.35	-6.0	-0.31	5.17e-9	Crohn's disease;Body mass index;
CRC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.66	9.88	0.48	2.46e-20	Heart rate;
CRC	cis	rs10878977	0.542	rs12368608	chr12:69814447	C/G	cg20891283	chr12:69753455	YEATS4	-0.6	-5.91	-0.31	8.6e-9	Colorectal cancer;
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18099408	chr3:52552593	STAB1	0.46	7.87	0.4	5.16e-14	Bipolar disorder;
CRC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.79	8.65	0.43	2.34e-16	Skin colour saturation;
CRC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg20203395	chr5:56204925	C5orf35	-0.6	-6.98	-0.36	1.61e-11	Initial pursuit acceleration;
CRC	cis	rs6909279	0.678	rs6557143	chr6:151848611	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.38	-5.72	-0.3	2.34e-8	Bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04418576	chr14:103851554	MARK3	0.46	6.0	0.31	5.06e-9	Thyroid stimulating hormone;
CRC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.4	6.91	0.36	2.45e-11	Childhood ear infection;
CRC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.92	16.49	0.67	5.85e-45	IgG glycosylation;
CRC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.56	0.34	2.15e-10	Mood instability;
CRC	cis	rs9903692	0.754	rs12602948	chr17:46190929	G/A	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	9.93	0.48	1.69e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg09455208	chr3:40491958	NA	0.31	6.31	0.33	8.76e-10	Renal cell carcinoma;
CRC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	8.87	0.44	4.67e-17	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24511898	chr2:242576823	ATG4B;THAP4	0.46	6.53	0.34	2.46e-10	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.04	-0.36	1.15e-11	Major depressive disorder;
CRC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.55	7.23	0.37	3.35e-12	Monocyte percentage of white cells;
CRC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.92	17.0	0.68	6.03e-47	Intelligence (multi-trait analysis);
CRC	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.39	-6.57	-0.34	1.92e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg23104954	chr13:50701501	NA	-0.52	-6.02	-0.31	4.74e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CRC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.78	8.02	0.4	1.92e-14	Plasma clusterin levels;
CRC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.58	-0.34	1.89e-10	Total body bone mineral density;
CRC	cis	rs9682041	0.627	rs11917188	chr3:170088607	C/T	cg11886554	chr3:170076028	SKIL	0.67	8.22	0.41	4.9e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.43	-6.31	-0.33	8.79e-10	Ulcerative colitis;
CRC	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg23260525	chr10:116636907	FAM160B1	0.33	6.47	0.34	3.48e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg21620606	chr4:1342894	KIAA1530	-0.34	-5.76	-0.3	1.97e-8	Obesity-related traits;
CRC	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.43	-7.84	-0.4	6.27e-14	Reticulocyte fraction of red cells;
CRC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg14541582	chr5:601475	NA	-0.37	-7.38	-0.38	1.27e-12	Obesity-related traits;
CRC	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.91	-0.31	8.63e-9	Response to antipsychotic treatment;
CRC	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19882132	chr14:106167949	NA	-0.41	-6.21	-0.32	1.62e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.74	-14.06	-0.61	1.67e-35	Prudent dietary pattern;
CRC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg22676075	chr6:135203613	NA	0.38	5.81	0.31	1.46e-8	Red blood cell count;
CRC	cis	rs2971970	0.519	rs10232278	chr7:133628547	G/A	cg03336402	chr7:133662267	EXOC4	0.63	9.64	0.47	1.5700000000000001e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.85	13.55	0.6	1.57e-33	Glomerular filtration rate (creatinine);
CRC	trans	rs9903692	0.954	rs12936731	chr17:46128359	G/C	cg13910583	chr8:56987998	RPS20	-0.44	-5.99	-0.31	5.63e-9	Pulse pressure;
CRC	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.83	-0.4	6.67e-14	Intelligence (multi-trait analysis);
CRC	trans	rs7448080	0.702	rs62371207	chr5:123304036	T/G	cg23202058	chr4:185139648	ENPP6	0.62	6.46	0.34	3.77e-10	Alcohol dependence (age at onset);
CRC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-6.28	-0.33	1.1e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.69	10.04	0.48	7.33e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27265118	chr3:4344949	SETMAR	0.49	7.27	0.37	2.58e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10971721	0.731	rs12378261	chr9:33837172	C/T	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.53	7.62	0.39	2.65e-13	Type 2 diabetes;
CRC	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg27398640	chr15:77910606	LINGO1	-0.44	-7.53	-0.38	5e-13	Type 2 diabetes;
CRC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.62	6.49	0.34	3.15e-10	Fat distribution (HIV);
CRC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.22	-0.32	1.51e-9	Axial length;
CRC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.83	14.48	0.62	4.11e-37	Breast cancer;
CRC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg15083037	chr5:83017644	HAPLN1	-0.46	-6.28	-0.33	1.08e-9	Prostate cancer;
CRC	cis	rs12024301	0.557	rs76628322	chr1:183625835	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.51	0.34	2.76e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg21155852	chr7:2048760	MAD1L1	-0.49	-6.63	-0.34	1.35e-10	Bipolar disorder;
CRC	cis	rs7916697	0.520	rs4745957	chr10:70044702	A/G	cg06988349	chr10:69991859	ATOH7	-0.33	-5.85	-0.31	1.17e-8	Optic disc area;
CRC	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.6	-0.34	1.66e-10	Menarche (age at onset);
CRC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.48	0.34	3.27e-10	Lung cancer;
CRC	cis	rs2882667	0.894	rs10054478	chr5:138354075	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-5.86	-0.31	1.11e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.54	-7.03	-0.36	1.19e-11	Blood pressure (smoking interaction);
CRC	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg15571903	chr15:79123663	NA	0.34	6.92	0.36	2.4e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs5751901	0.688	rs2017869	chr22:24997309	C/G	cg15363607	chr22:24998974	GGT1	-0.42	-6.81	-0.35	4.55e-11	Protein quantitative trait loci;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27055842	chr21:33765028	C21orf119;URB1	0.37	5.99	0.31	5.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4692589	1.000	rs11732126	chr4:170937416	A/G	cg19918862	chr4:170955249	NA	0.39	6.39	0.33	5.54e-10	Anxiety disorder;
CRC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.34	6.51	0.34	2.85e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.15	0.41	7.87e-15	Platelet count;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.95	0.31	6.97e-9	Obesity-related traits;
CRC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg25985355	chr7:65971099	NA	0.32	5.71	0.3	2.55e-8	Aortic root size;
CRC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-6.47	-0.34	3.48e-10	Eosinophil percentage of white cells;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg02033258	chr5:131593261	PDLIM4	0.38	6.38	0.33	6.15e-10	Breast cancer;
CRC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.97	-14.43	-0.62	6.3e-37	Systemic lupus erythematosus;
CRC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	16.26	0.67	4.86e-44	Smoking behavior;
CRC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.52	7.42	0.38	1.03e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.83	-12.17	-0.56	2.27e-28	Response to antineoplastic agents;
CRC	trans	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.46	-0.38	7.63e-13	Endometrial cancer;
CRC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.65	-8.47	-0.42	8.16e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.93	-0.31	7.52e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7173389	1.000	rs11630367	chr15:73662855	A/G	cg01796676	chr15:73680284	NA	0.51	6.8	0.35	5.01e-11	Resting heart rate;
CRC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.57	-6.0	-0.31	5.12e-9	White matter hyperintensity burden;
CRC	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.63	-8.73	-0.43	1.28e-16	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.39	6.36	0.33	6.59e-10	Major depressive disorder;
CRC	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg17145862	chr1:211918768	LPGAT1	0.48	6.07	0.32	3.51e-9	Crohn's disease;
CRC	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.54	8.15	0.41	7.8e-15	Blood protein levels;
CRC	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-6.07	-0.32	3.58e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg10298567	chr3:47292165	KIF9	0.44	7.03	0.36	1.19e-11	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs4716602	0.542	rs35137250	chr7:156161066	T/C	cg16983916	chr7:156159713	NA	-0.39	-6.81	-0.35	4.57e-11	Anti-saccade response;
CRC	cis	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg15590007	chr10:45870220	ALOX5	-0.56	-6.01	-0.31	4.98e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.34	5.9	0.31	8.87e-9	Blood metabolite levels;
CRC	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.46	6.22	0.32	1.51e-9	Eye color traits;
CRC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.82	15.1	0.64	1.64e-39	Mean platelet volume;
CRC	cis	rs526821	0.595	rs565859	chr11:55297367	T/C	cg04317927	chr11:55418816	OR4S2	0.4	6.73	0.35	7.39e-11	Pediatric bone mineral density (spine);
CRC	trans	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg10756647	chr7:56101905	PSPH	0.69	8.32	0.42	2.29e-15	Diabetic kidney disease;
CRC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.86	-0.31	1.12e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg18761221	chr20:60518478	NA	-0.58	-9.14	-0.45	6.5e-18	Body mass index;
CRC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.52	6.83	0.35	3.99e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg17182837	chr8:41585554	ANK1	-0.4	-6.25	-0.33	1.3e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg08729031	chr10:102416179	NA	-0.42	-7.49	-0.38	6.37e-13	Body mass index;
CRC	cis	rs10865541	0.967	rs6751808	chr2:3397377	A/G	cg22182287	chr2:3452347	TTC15	0.38	5.92	0.31	8e-9	Obesity-related traits;
CRC	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	0.57	8.58	0.43	3.74e-16	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.59	-8.76	-0.44	1.01e-16	Platelet count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25009629	chr6:41748519	FRS3;PRICKLE4	-0.41	-6.16	-0.32	2.07e-9	Myopia (pathological);
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.63	-8.76	-0.43	1.03e-16	Blood pressure (smoking interaction);
CRC	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.52	8.34	0.42	2.08e-15	IgG glycosylation;
CRC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.04	16.68	0.68	1.03e-45	IgG glycosylation;
CRC	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.72	-15.63	-0.65	1.36e-41	Intelligence (multi-trait analysis);
CRC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	8.65	0.43	2.33e-16	Colorectal cancer;
CRC	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.03	0.68	4.35e-47	Electrocardiographic conduction measures;
CRC	cis	rs2386661	0.826	rs4427479	chr10:5682855	T/C	cg26603656	chr10:5671107	NA	-0.49	-8.06	-0.41	1.4e-14	Breast cancer;
CRC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.81	11.04	0.52	2.6e-24	Cerebrospinal P-tau181p levels;
CRC	cis	rs16852403	0.548	rs10913524	chr1:178221107	T/C	cg00404053	chr1:178313656	RASAL2	0.52	6.75	0.35	6.58e-11	Childhood ear infection;
CRC	cis	rs834811	0.563	rs10225343	chr7:135886320	C/A	cg01726295	chr7:135938950	NA	0.36	6.11	0.32	2.74e-9	Post-traumatic stress disorder;
CRC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.6	-8.96	-0.44	2.56e-17	Alcohol dependence;
CRC	cis	rs9468186	1	rs9468186	chr6:27626631	A/G	cg08798685	chr6:27730294	NA	-0.46	-6.2	-0.32	1.72e-9	Neuroticism;
CRC	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.68	-0.3	2.98e-8	Breast cancer;
CRC	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.66	-10.04	-0.48	7.24e-21	Dementia with Lewy bodies;
CRC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.54	5.83	0.31	1.32e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.79	0.66	3.5e-42	Platelet count;
CRC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.91	-0.58	4.01e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs3736485	0.844	rs11070853	chr15:51784203	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-6.33	-0.33	8.1e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs939584	0.935	rs7604752	chr2:643428	C/A	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg01874867	chr7:94954059	PON1	-0.52	-6.59	-0.34	1.74e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.65	11.6	0.54	2.5e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7527798	0.592	rs6684643	chr1:207846242	A/T	cg21110645	chr1:207815933	NA	-0.41	-6.24	-0.33	1.35e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9648716	1.000	rs6950312	chr7:140572183	T/A	cg10747023	chr7:140774559	NA	0.44	5.69	0.3	2.89e-8	Type 2 diabetes;
CRC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg19680485	chr15:31195859	MTMR15	0.48	6.68	0.35	1.04e-10	Huntington's disease progression;
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.66	-0.51	5.33e-23	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg03030879	chr14:75389066	RPS6KL1	0.43	6.55	0.34	2.23e-10	Height;
CRC	trans	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.93	0.36	2.23e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15120237	chr17:7747620	KDM6B	0.46	6.56	0.34	2.09e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08402873	chr20:10653164	JAG1	0.48	6.78	0.35	5.55e-11	Response to antipsychotic treatment;
CRC	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg09597638	chr17:3907349	NA	0.64	11.62	0.54	2.26e-26	Type 2 diabetes;
CRC	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.45	-0.34	4.05e-10	Depression;
CRC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	9.25	0.45	2.88e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg03690763	chr11:133734501	NA	-0.36	-6.05	-0.32	3.89e-9	Childhood ear infection;
CRC	cis	rs7945718	0.621	rs6485977	chr11:12678387	C/T	cg25843174	chr11:12811716	TEAD1	0.39	7.41	0.38	1.05e-12	Educational attainment (years of education);
CRC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.32	0.53	2.56e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.43	-7.55	-0.38	4.24e-13	Dilated cardiomyopathy;
CRC	cis	rs12476592	0.602	rs1356390	chr2:63669625	C/T	cg10828910	chr2:63850056	LOC388955	-0.46	-5.72	-0.3	2.39e-8	Childhood ear infection;
CRC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg09998033	chr7:158218633	PTPRN2	-0.64	-9.03	-0.45	1.46e-17	Obesity-related traits;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg03623178	chr6:28175578	NA	0.93	12.17	0.56	2.25e-28	Depression;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.6	8.0	0.4	2.09e-14	Alzheimer's disease;
CRC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg16235748	chr6:149772707	ZC3H12D	0.38	7.05	0.36	1.09e-11	Dupuytren's disease;
CRC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.46	-7.73	-0.39	1.32e-13	Major depressive disorder;
CRC	trans	rs2012709	0.901	rs56121682	chr5:32554712	T/G	cg03755955	chr8:6424269	MCPH1	0.44	6.43	0.33	4.39e-10	Breast cancer;
CRC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg25459000	chr22:39777742	SYNGR1	-0.32	-5.7	-0.3	2.63e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24306779	chr16:58060336	MMP15	0.45	6.41	0.33	5.1e-10	Response to antipsychotic treatment;
CRC	cis	rs11622475	0.953	rs6576012	chr14:104400159	T/C	cg12183467	chr14:104352244	NA	0.5	6.82	0.35	4.36e-11	Bipolar disorder;
CRC	cis	rs11212617	1.000	rs35244261	chr11:108283808	A/C	cg01991180	chr11:108092276	ATM;NPAT	-0.4	-5.79	-0.3	1.66e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg10517650	chr3:113235015	CCDC52	-0.4	-6.97	-0.36	1.73e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4731207	0.596	rs6952915	chr7:124685952	T/G	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	trans	rs9693857	0.520	rs6601320	chr8:9355888	G/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.36	0.33	6.9e-10	Systolic blood pressure;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00166722	chr3:10149974	C3orf24	0.65	8.86	0.44	5.13e-17	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.49	7.76	0.39	1.11e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg19131313	chr8:1704013	NA	-0.48	-6.66	-0.34	1.12e-10	Systolic blood pressure;
CRC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.45	-8.37	-0.42	1.65e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15094104	chr5:133406808	NA	0.49	6.63	0.34	1.36e-10	Thyroid stimulating hormone;
CRC	cis	rs9814567	0.858	rs4955548	chr3:134341060	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.73	-0.51	3.15e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs957448	1.000	rs12679345	chr8:95564533	A/G	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.62	-0.3	4.14e-8	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.52	-0.34	2.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	11.1	0.52	1.57e-24	Personality dimensions;
CRC	cis	rs4731207	0.662	rs6973134	chr7:124515373	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2077654	0.822	rs12279699	chr11:17443348	G/A	cg25308976	chr11:17434268	ABCC8	0.79	5.87	0.31	1.05e-8	Gout;
CRC	cis	rs1178968	1.000	rs917247	chr7:72761420	C/T	cg25889504	chr7:72793014	NA	-0.5	-6.15	-0.32	2.24e-9	Triglyceride levels;
CRC	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.04	-20.22	-0.74	1.18e-59	Schizophrenia;
CRC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.65	7.04	0.36	1.11e-11	Axial length;
CRC	cis	rs2298450	0.541	rs2835332	chr21:37656940	A/G	cg02919814	chr21:37666008	DOPEY2	-0.44	-6.43	-0.33	4.4e-10	Schizophrenia;
CRC	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.3	0.46	1.99e-18	Dupuytren's disease;
CRC	cis	rs77633900	0.772	rs2944377	chr15:76699652	C/A	cg21673338	chr15:77095150	SCAPER	-0.66	-5.61	-0.3	4.23e-8	Non-glioblastoma glioma;Glioma;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.76	0.3	1.95e-8	Parkinson's disease;
CRC	cis	rs807029	0.577	rs701834	chr10:102761801	C/T	cg04662943	chr10:102668895	NA	0.6	7.16	0.37	5.24e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20092199	chr4:1342459	KIAA1530	0.45	7.75	0.39	1.13e-13	Longevity;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg20933634	chr6:27740509	NA	-0.45	-6.55	-0.34	2.22e-10	Parkinson's disease;
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.59	7.37	0.38	1.38e-12	RR interval (heart rate);
CRC	cis	rs7172809	0.607	rs77744673	chr15:77842311	T/C	cg10437265	chr15:77819839	NA	-0.36	-5.99	-0.31	5.65e-9	Glucose homeostasis traits;
CRC	cis	rs720844	1.000	rs7571333	chr2:149335348	G/C	cg09247360	chr2:149335327	NA	-0.61	-7.57	-0.39	3.68e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.2	-0.32	1.66e-9	Educational attainment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02263479	chr16:2097837	NTHL1;TSC2	0.46	6.5	0.34	2.97e-10	Anxiety disorder;
CRC	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12273811	chr6:28175739	NA	0.62	8.22	0.41	4.78e-15	Parkinson's disease;
CRC	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.4	-7.29	-0.37	2.29e-12	Alcohol dependence;
CRC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.37	5.75	0.3	2.01e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-7.5	-0.38	6.13e-13	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26147372	chr3:49130904	QRICH1	0.44	6.2	0.32	1.65e-9	Anxiety disorder;
CRC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13844804	chr7:814759	HEATR2	0.58	6.44	0.33	4.12e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.44	0.33	4.34e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-6.84	-0.35	3.82e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.55	6.64	0.34	1.29e-10	Gut microbiome composition (summer);
CRC	cis	rs4664293	0.647	rs357028	chr2:160491842	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.62	-0.34	1.5e-10	Monocyte percentage of white cells;
CRC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	10.48	0.5	2.35e-22	Motion sickness;
CRC	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.13	9.17	0.45	5.3e-18	Economic and political preferences (immigration/crime);
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.4	7.04	0.36	1.12e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.58	-9.2	-0.45	4.09e-18	Huntington's disease progression;
CRC	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	7.77	0.39	9.92e-14	Schizophrenia;
CRC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.43	6.66	0.34	1.14e-10	Blood metabolite levels;
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.41	-0.33	5e-10	Glycated hemoglobin levels;
CRC	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.22	-0.49	1.81e-21	Body mass index;
CRC	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg26211634	chr5:139558579	C5orf32	-0.41	-7.13	-0.37	6.3e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.504	rs7541625	chr1:248362018	G/C	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs2013441	1.000	rs2526490	chr17:20097526	A/G	cg13482628	chr17:19912719	NA	-0.4	-6.07	-0.32	3.43e-9	Obesity-related traits;
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	3.96e-9	Total body bone mineral density;
CRC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg23996704	chr18:44553084	KATNAL2	0.29	5.66	0.3	3.36e-8	Personality dimensions;
CRC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.06	-0.32	3.69e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.36	-5.82	-0.31	1.4e-8	Ulcerative colitis;
CRC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg15440763	chr7:158190612	PTPRN2	0.38	6.28	0.33	1.06e-9	Obesity-related traits;
CRC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg04586622	chr2:25135609	ADCY3	-0.56	-10.22	-0.49	1.74e-21	Body mass index;
CRC	cis	rs4722166	0.532	rs1546763	chr7:22757843	G/A	cg05472934	chr7:22766657	IL6	0.66	10.41	0.5	3.91e-22	Lung cancer;
CRC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17467752	chr17:38218738	THRA	0.42	6.19	0.32	1.81e-9	Asthma;
CRC	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg01843034	chr6:37503916	NA	-0.36	-5.95	-0.31	6.95e-9	Cognitive performance;
CRC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg00129232	chr17:37814104	STARD3	-0.46	-7.29	-0.37	2.26e-12	Self-reported allergy;
CRC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.33	-6.08	-0.32	3.37e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.39	-5.84	-0.31	1.23e-8	Growth-regulated protein alpha levels;
CRC	cis	rs73206853	0.925	rs28670753	chr12:110826463	C/T	cg12870014	chr12:110450643	ANKRD13A	0.63	8.09	0.41	1.19e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27507545	chr10:103880405	LDB1	0.46	6.76	0.35	6.44e-11	Response to antipsychotic treatment;
CRC	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.84	-12.89	-0.58	4.61e-31	Response to temozolomide;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18436491	chr2:238657876	LRRFIP1	-0.38	-6.62	-0.34	1.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.52	8.22	0.41	4.72e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.46	0.42	8.98e-16	Schizophrenia;
CRC	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.43	0.42	1.11e-15	Platelet distribution width;
CRC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	14.23	0.62	3.89e-36	Hip circumference adjusted for BMI;
CRC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg05555928	chr11:63887634	MACROD1	-0.54	-6.42	-0.33	4.89e-10	Body mass index;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg06470822	chr6:28175283	NA	1.03	13.82	0.61	1.42e-34	Depression;
CRC	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.98	0.36	1.6e-11	Morning vs. evening chronotype;
CRC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.73	-7.31	-0.37	2.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9463078	0.809	rs6899845	chr6:45043352	A/C	cg25276700	chr6:44698697	NA	-0.27	-6.6	-0.34	1.65e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.41	6.41	0.33	5.18e-10	Obesity;
CRC	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.53	8.93	0.44	2.99e-17	Dupuytren's disease;
CRC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg11189052	chr15:85197271	WDR73	0.57	8.13	0.41	8.8e-15	Schizophrenia;
CRC	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg13385794	chr1:248469461	NA	0.41	7.32	0.37	1.94e-12	Common traits (Other);
CRC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.28	0.37	2.5e-12	Life satisfaction;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21629349	chr11:60691880	TMEM132A	-0.4	-6.15	-0.32	2.28e-9	Myopia (pathological);
CRC	cis	rs7259376	0.936	rs8111665	chr19:22588559	C/T	cg02657401	chr19:22469223	NA	0.31	6.72	0.35	8.02e-11	Menopause (age at onset);
CRC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.64	-0.47	1.6e-19	Height;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-7.39	-0.38	1.24e-12	Breast cancer;
CRC	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.46	-0.46	6.05e-19	Capecitabine sensitivity;
CRC	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg13119609	chr19:45449297	APOC2	0.31	5.9	0.31	9.2e-9	Blood protein levels;
CRC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.6	-8.31	-0.42	2.59e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.92e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.61	8.51	0.42	6.45e-16	Arsenic metabolism;
CRC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg05941027	chr17:61774174	LIMD2	0.35	6.25	0.33	1.27e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	16.54	0.67	3.79e-45	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-6.86	-0.35	3.33e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.31	-0.42	2.63e-15	Schizophrenia;
CRC	cis	rs55702914	0.746	rs7588530	chr2:198146698	A/C	cg20885578	chr2:198174922	NA	-0.35	-5.95	-0.31	6.76e-9	Major depression and alcohol dependence;
CRC	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2982552	0.805	rs3020345	chr6:152056368	T/G	cg22157087	chr6:152012887	ESR1	0.37	5.7	0.3	2.62e-8	Bone properties (heel);
CRC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-8.19	-0.41	5.65e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs12476592	0.636	rs196123	chr2:63841712	T/C	cg10828910	chr2:63850056	LOC388955	0.53	6.57	0.34	2.02e-10	Childhood ear infection;
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-0.6	-11.14	-0.52	1.14e-24	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21956150	chr19:1438388	RPS15	0.51	8.39	0.42	1.43e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.63	-9.0	-0.44	1.82e-17	Cognitive function;
CRC	trans	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg10756647	chr7:56101905	PSPH	0.77	8.22	0.41	4.72e-15	Diabetic kidney disease;
CRC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.2	0.32	1.73e-9	Monocyte percentage of white cells;
CRC	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-8.79	-0.44	8.5e-17	Urate levels in overweight individuals;
CRC	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-5.64	-0.3	3.76e-8	Schizophrenia;
CRC	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.05	-0.32	3.97e-9	Neuroticism;
CRC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.64	-8.91	-0.44	3.62e-17	Platelet count;
CRC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.59	-0.34	1.73e-10	Height;
CRC	cis	rs11212617	0.967	rs7127490	chr11:108286758	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.7	0.3	2.71e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.56	6.35	0.33	7.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.01	-0.31	5.03e-9	Life satisfaction;
CRC	cis	rs7523050	0.554	rs34086470	chr1:109485991	C/A	cg08274380	chr1:109419600	GPSM2	0.76	6.73	0.35	7.67e-11	Fat distribution (HIV);
CRC	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.82	-10.31	-0.49	8.69e-22	Blood pressure (smoking interaction);
CRC	cis	rs7614311	0.689	rs2276863	chr3:63849043	C/A	cg22134162	chr3:63841271	THOC7	-0.58	-5.91	-0.31	8.7e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.53	-7.0	-0.36	1.44e-11	DNA methylation (variation);
CRC	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg25019722	chr6:37503610	NA	-0.43	-6.17	-0.32	1.97e-9	Cognitive performance;
CRC	cis	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg11143507	chr3:125485238	NA	-0.58	-7.46	-0.38	7.69e-13	Blood pressure (smoking interaction);
CRC	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.42	-5.89	-0.31	9.73e-9	Blood protein levels;
CRC	cis	rs17234274	0.607	rs10833974	chr11:23221074	G/C	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.03e-8	Cancer;
CRC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-9.27	-0.45	2.59e-18	Initial pursuit acceleration;
CRC	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.47	-6.1	-0.32	2.91e-9	Migraine;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg21251018	chr6:28226885	NKAPL	0.49	7.72	0.39	1.44e-13	Cardiac Troponin-T levels;
CRC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.14e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.43	6.18	0.32	1.88e-9	Body mass index;
CRC	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg09873164	chr1:152488093	CRCT1	0.4	6.72	0.35	7.83e-11	Hair morphology;
CRC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg10298567	chr3:47292165	KIF9	0.37	5.62	0.3	4.11e-8	Colorectal cancer;
CRC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.47	-0.34	3.48e-10	QT interval;
CRC	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.23	-0.37	3.43e-12	Ulcerative colitis;
CRC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.63	7.72	0.39	1.45e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.82	0.55	4.16e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13385794	chr1:248469461	NA	0.39	6.97	0.36	1.79e-11	Common traits (Other);
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.68	-0.3	3.01e-8	Neuroticism;
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg24634471	chr8:143751801	JRK	-0.5	-6.77	-0.35	5.9e-11	Urinary tract infection frequency;
CRC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-8.13	-0.41	9.1e-15	Body mass index;
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.7	9.17	0.45	5.23e-18	Alzheimer's disease;
CRC	trans	rs1360141	1.000	rs1360141	chr9:74292016	C/G	cg07994661	chr4:153856847	NA	-0.33	-6.15	-0.32	2.21e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg14700821	chr5:64777802	ADAMTS6	-0.41	-5.99	-0.31	5.39e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21643547	chr1:205240462	TMCC2	0.47	7.91	0.4	3.9e-14	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.43	-0.53	1.06e-25	Coffee consumption (cups per day);
CRC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg13798780	chr7:105162888	PUS7	0.67	7.78	0.39	9.18e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7147624	0.683	rs8017258	chr14:66231017	C/G	cg03016385	chr14:66212404	NA	0.77	6.76	0.35	6.42e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.85	10.9	0.52	7.9e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg16892393	chr17:41919603	NA	0.51	7.09	0.36	8.33e-12	Triglycerides;
CRC	cis	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg00086871	chr4:6988644	TBC1D14	0.81	6.14	0.32	2.39e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	1.04	18.42	0.71	1.46e-52	Parkinson's disease;
CRC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.71	-9.2	-0.45	4.39e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26240231	chr7:1148101	C7orf50	-0.47	-6.85	-0.35	3.68e-11	Bronchopulmonary dysplasia;
CRC	trans	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg21302420	chr1:112162376	RAP1A	0.7	6.29	0.33	1.01e-9	Skin colour saturation;
CRC	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-6.03	-0.32	4.44e-9	Schizophrenia;
CRC	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.42	5.77	0.3	1.83e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.55	-0.43	4.67e-16	Initial pursuit acceleration;
CRC	trans	rs274508	0.926	rs905620	chr11:11102017	C/T	cg18158151	chr2:61372256	C2orf74	0.31	5.98	0.31	5.69e-9	Knee osteoarthritis;
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.03	-0.4	1.7e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg01426195	chr3:39028469	NA	-0.54	-8.61	-0.43	3.02e-16	Handedness;
CRC	cis	rs2398893	0.774	rs35888804	chr9:96887153	T/C	cg14459158	chr9:96720562	NA	0.45	6.42	0.33	4.79e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg02683197	chr6:28174875	NA	0.75	9.84	0.48	3.43e-20	Parkinson's disease;
CRC	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.8	10.5	0.5	1.9e-22	Obesity-related traits;
CRC	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg07807695	chr5:81608485	ATP6AP1L	-0.47	-7.4	-0.38	1.14e-12	Breast cancer;
CRC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.64	6.47	0.34	3.62e-10	Axial length;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg15786705	chr6:28176104	NA	0.48	7.16	0.37	5.19e-12	Cardiac Troponin-T levels;
CRC	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg19338460	chr6:170058176	WDR27	-0.75	-8.14	-0.41	8.03e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	13.66	0.6	6.03e-34	Schizophrenia;
CRC	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg08600765	chr20:34638493	LOC647979	-0.55	-6.12	-0.32	2.71e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg13390004	chr1:15929781	NA	0.49	7.0	0.36	1.45e-11	Systolic blood pressure;
CRC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg20885578	chr2:198174922	NA	-0.39	-7.21	-0.37	3.93e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23055938	chr1:160991191	F11R	0.39	6.0	0.31	5.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-0.72	-7.92	-0.4	3.79e-14	Post bronchodilator FEV1;
CRC	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.92	-0.36	2.4e-11	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-8.22	-0.41	4.69e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.83	-0.35	4.03e-11	Educational attainment;
CRC	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	trans	rs860818	1.000	rs858303	chr7:23243498	C/G	cg07869405	chr10:1444797	ADARB2	0.69	6.33	0.33	8.14e-10	Initial pursuit acceleration;
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.08	-0.45	1.05e-17	Bipolar disorder;
CRC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.22	0.67	6.67e-44	Chronic sinus infection;
CRC	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg00564723	chr10:75632066	CAMK2G	0.23	5.79	0.3	1.61e-8	Inflammatory bowel disease;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg20512303	chr5:131592959	PDLIM4	-0.4	-7.13	-0.37	6.55e-12	Acylcarnitine levels;
CRC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.12	10.98	0.52	4.12e-24	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.61	7.74	0.39	1.27e-13	Gut microbiome composition (summer);
CRC	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.5	6.33	0.33	7.9e-10	Recombination rate (females);
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-9.05	-0.45	1.29e-17	Bipolar disorder;
CRC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	0.84	8.75	0.43	1.11e-16	Gout;Renal underexcretion gout;
CRC	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.2e-12	Prostate cancer;
CRC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.03	0.32	4.49e-9	Diabetic retinopathy;
CRC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.67	8.91	0.44	3.47e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.66	7.29	0.37	2.28e-12	Vitiligo;
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-13.78	-0.6	2.1e-34	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg01993067	chr11:68851601	TPCN2	0.56	6.33	0.33	7.99e-10	Blond vs. brown hair color;
CRC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.82e-15	Mean platelet volume;
CRC	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.62	-9.57	-0.47	2.66e-19	Testicular germ cell tumor;
CRC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.39	-18.95	-0.72	1.2e-54	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10698222	chr7:99756139	C7orf43	0.42	6.79	0.35	5.39e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.82e-9	Bipolar disorder;
CRC	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg00601450	chr5:74908170	NA	0.41	5.77	0.3	1.84e-8	Age-related disease endophenotypes;
CRC	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg20744362	chr22:50050164	C22orf34	0.35	6.24	0.33	1.37e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.53	7.94	0.4	3.33e-14	Coronary artery disease;
CRC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.0	-0.36	1.42e-11	Mean corpuscular volume;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.42	-0.38	1e-12	Lymphocyte counts;
CRC	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.56	-7.43	-0.38	9.49e-13	Type 2 diabetes;
CRC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg16447950	chr5:562315	NA	-0.78	-10.46	-0.5	2.71e-22	Lung disease severity in cystic fibrosis;
CRC	cis	rs863345	0.526	rs2051067	chr1:158507398	G/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.53	7.26	0.37	2.75e-12	Menopause (age at onset);
CRC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.49	-8.72	-0.43	1.45e-16	Height;
CRC	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.53	7.86	0.4	5.46e-14	Testicular germ cell tumor;
CRC	cis	rs16924133	0.793	rs58772662	chr11:33141020	C/A	cg05567920	chr11:33183001	CSTF3	-0.77	-5.77	-0.3	1.81e-8	Anger;
CRC	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.66	6.74	0.35	7.01e-11	Pediatric areal bone mineral density (radius);
CRC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg23172400	chr8:95962367	TP53INP1	0.48	7.91	0.4	4.08e-14	Alzheimer's disease (late onset);
CRC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg22777020	chr22:31556080	RNF185	-0.53	-6.03	-0.32	4.47e-9	Colorectal cancer;
CRC	cis	rs7072216	0.652	rs11189600	chr10:100179274	A/G	cg26618903	chr10:100175079	PYROXD2	0.39	6.52	0.34	2.66e-10	Metabolite levels;
CRC	cis	rs16924133	1.000	rs12293487	chr11:33166176	A/C	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg24531977	chr5:56204891	C5orf35	-0.45	-6.91	-0.36	2.48e-11	Coronary artery disease;
CRC	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00338735	chr4:53728038	RASL11B	0.39	6.1	0.32	2.91e-9	Optic nerve measurement (cup area);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21389884	chr11:119599425	PVRL1	0.39	5.98	0.31	5.73e-9	Schizophrenia;
CRC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.78	13.12	0.59	6.58e-32	Bone mineral density;
CRC	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg26816564	chr1:7831052	VAMP3	0.54	6.07	0.32	3.48e-9	Inflammatory bowel disease;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.57	10.49	0.5	2.06e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg17524180	chr13:113633600	MCF2L	-0.68	-12.79	-0.58	1.13e-30	Systolic blood pressure;
CRC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg03013999	chr17:37608204	MED1	0.46	7.08	0.36	8.74e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.51	0.34	2.87e-10	Bipolar disorder;
CRC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	trans	rs7302981	0.746	rs836177	chr12:50491821	A/G	cg18430156	chr2:187558795	FAM171B	-0.37	-6.25	-0.33	1.27e-9	Systolic blood pressure;
CRC	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06156847	chr2:113672199	IL1F7	-0.45	-6.9	-0.36	2.66e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-9.02	-0.45	1.54e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs55871839	0.708	rs4738735	chr8:59816985	T/C	cg07426533	chr8:59803705	TOX	-0.34	-5.82	-0.31	1.37e-8	Pneumonia;
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg16606324	chr3:10149918	C3orf24	0.71	9.83	0.48	3.77e-20	Alzheimer's disease;
CRC	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.82	-0.44	6.74e-17	Coffee consumption (cups per day);
CRC	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg08896387	chr1:24191740	FUCA1	0.47	5.85	0.31	1.19e-8	Immature fraction of reticulocytes;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg06470822	chr6:28175283	NA	0.49	6.9	0.36	2.68e-11	Depression;
CRC	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg14593290	chr7:50529359	DDC	0.67	8.83	0.44	6.24e-17	Malaria;
CRC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.8	0.51	1.74e-23	Ileal carcinoids;
CRC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26850624	chr5:429559	AHRR	0.54	9.03	0.45	1.46e-17	Cystic fibrosis severity;
CRC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.44	6.38	0.33	6.05e-10	Prostate cancer;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg06470822	chr6:28175283	NA	-0.89	-13.18	-0.59	3.94e-32	Parkinson's disease;
CRC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.67	-0.3	3.12e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs3736485	0.934	rs11635216	chr15:51871947	A/G	cg08986416	chr15:51914746	DMXL2	0.46	6.56	0.34	2.07e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.31	-6.25	-0.33	1.3e-9	Lung cancer;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	0.37	6.65	0.34	1.26e-10	Hip circumference;
CRC	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.54	-7.34	-0.37	1.73e-12	Macular telangiectasia type 2;
CRC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.97	14.66	0.63	8.09e-38	Glomerular filtration rate (creatinine);
CRC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg19980929	chr12:42632907	YAF2	-0.39	-5.89	-0.31	9.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09239099	chr12:1100377	ERC1	0.43	6.11	0.32	2.75e-9	Survival in pancreatic cancer;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg11942470	chr9:86594803	HNRNPK;RMI1	0.48	6.13	0.32	2.57e-9	Resistin levels;
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.81	-0.51	1.69e-23	Bipolar disorder;
CRC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg19812747	chr11:111475976	SIK2	0.55	9.33	0.46	1.58e-18	Primary sclerosing cholangitis;
CRC	trans	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg11693508	chr17:37793320	STARD3	0.46	6.17	0.32	2e-9	Neuroticism;
CRC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-7.46	-0.38	7.9e-13	Dilated cardiomyopathy;
CRC	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg22256960	chr15:77711686	NA	-0.54	-8.17	-0.41	6.7e-15	Type 2 diabetes;
CRC	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg21827317	chr3:136751795	NA	0.35	5.81	0.31	1.44e-8	Neuroticism;
CRC	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-9.6	-0.47	2.19e-19	Colorectal cancer;
CRC	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.44	-6.35	-0.33	7.19e-10	Body mass index;
CRC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg23136738	chr11:925521	AP2A2	-0.42	-6.84	-0.35	3.78e-11	Alzheimer's disease (late onset);
CRC	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.45	-8.8	-0.44	8.05e-17	Alcohol dependence;
CRC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	9.36	0.46	1.29e-18	Psoriasis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05598539	chr7:128695331	TNPO3;LOC286016	0.48	6.78	0.35	5.75e-11	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.46e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg25411327	chr19:5210703	PTPRS	-0.59	-6.11	-0.32	2.76e-9	Schizophrenia;
CRC	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10047026	chr17:4613992	ARRB2	0.41	6.87	0.35	3.29e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4660214	0.666	rs11205739	chr1:39656401	G/A	cg11070191	chr1:39582205	MACF1	0.36	5.76	0.3	1.9e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs6897795	0.680	rs9329133	chr5:177609540	C/T	cg19598605	chr2:70056955	GMCL1	-0.67	-8.61	-0.43	3.09e-16	Plateletcrit;
CRC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg03934865	chr2:198174659	NA	-0.43	-6.92	-0.36	2.44e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.84	0.35	3.88e-11	Rheumatoid arthritis;
CRC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.57	8.66	0.43	2.14e-16	Blood protein levels;
CRC	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg09654669	chr8:57350985	NA	-0.41	-5.8	-0.3	1.59e-8	Obesity-related traits;
CRC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.46	8.53	0.43	5.38e-16	Age at first birth;
CRC	cis	rs7487075	0.786	rs4768110	chr12:46677461	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	6.11	0.32	2.84e-9	Itch intensity from mosquito bite;
CRC	cis	rs9969804	0.905	rs7864757	chr9:95399865	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.67	-0.3	3.1e-8	Height;
CRC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg00343986	chr7:65444356	GUSB	0.42	5.76	0.3	1.94e-8	Aortic root size;
CRC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-7.96	-0.4	2.76e-14	Chronic sinus infection;
CRC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.5	6.49	0.34	3.13e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.54	7.66	0.39	2.09e-13	Lung cancer;
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg17346650	chr17:80929145	B3GNTL1	0.46	6.7	0.35	8.9e-11	Glycated hemoglobin levels;
CRC	cis	rs501120	1.000	rs605445	chr10:44756779	C/T	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	9.13	0.45	7.01e-18	Hemoglobin concentration;
CRC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.54	6.85	0.35	3.58e-11	Neuroticism;
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg25193742	chr10:104614220	C10orf32	-0.72	-5.97	-0.31	6.32e-9	Cognitive function;
CRC	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.76	9.41	0.46	8.96e-19	Type 2 diabetes;
CRC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.86	-0.48	2.88e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.58	9.76	0.47	6.18e-20	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.02	0.45	1.57e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4325129	0.513	rs35393723	chr1:159505101	G/A	cg26466145	chr3:188665930	NA	-0.42	-6.52	-0.34	2.69e-10	Obesity-related traits;
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg20585869	chr8:24772333	NEFM	-0.38	-6.51	-0.34	2.86e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17608500	chr1:154955711	FLAD1	0.55	7.27	0.37	2.69e-12	Thyroid stimulating hormone;
CRC	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.38	7.41	0.38	1.07e-12	Self-rated health;
CRC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.78	0.3	1.71e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg21620606	chr4:1342894	KIAA1530	0.35	5.75	0.3	2.04e-8	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.75	-9.07	-0.45	1.12e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg15848620	chr12:58087721	OS9	0.58	8.09	0.41	1.12e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg06784218	chr1:46089804	CCDC17	-0.49	-7.78	-0.39	9.37e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.33	-0.33	8.03e-10	Gout;Renal underexcretion gout;
CRC	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg07862535	chr7:139043722	LUC7L2	0.54	7.05	0.36	1.09e-11	Diisocyanate-induced asthma;
CRC	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19182353	chr11:118479428	PHLDB1	-0.42	-6.39	-0.33	5.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11948739	0.610	rs2419754	chr5:130252688	T/C	cg08523029	chr5:130500466	HINT1	0.49	6.26	0.33	1.19e-9	Pediatric bone mineral content (hip);
CRC	cis	rs891088	0.677	rs11670960	chr19:7185504	C/T	cg09779027	chr19:7224513	INSR	-0.59	-6.08	-0.32	3.32e-9	Hip circumference adjusted for BMI;Height;
CRC	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg16576597	chr16:28551801	NUPR1	0.47	7.34	0.37	1.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.19	-0.32	1.8e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2982552	0.873	rs977532	chr6:152068883	C/T	cg22157087	chr6:152012887	ESR1	0.37	5.68	0.3	3.01e-8	Bone properties (heel);
CRC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg03623178	chr6:28175578	NA	0.48	7.06	0.36	9.9e-12	Pubertal anthropometrics;
CRC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg05139728	chr16:28306816	SBK1	-0.38	-6.23	-0.32	1.41e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12137294	0.761	rs1172150	chr1:205221861	A/G	cg24159697	chr1:205181237	DSTYK	-0.34	-6.08	-0.32	3.29e-9	Red cell distribution width;
CRC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.33	0.53	2.41e-25	Hip circumference adjusted for BMI;
CRC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.62	9.1	0.45	8.57e-18	Menarche (age at onset);
CRC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg20243544	chr17:37824526	PNMT	0.56	9.05	0.45	1.3e-17	Asthma;
CRC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.55	6.27	0.33	1.15e-9	Bipolar disorder;
CRC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.43	0.5	3.44e-22	Type 2 diabetes;
CRC	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg00105475	chr2:10696890	NA	0.46	7.18	0.37	4.56e-12	Prostate cancer;
CRC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.62	8.79	0.44	8.28e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7173389	1.000	rs7172796	chr15:73661687	T/G	cg01796676	chr15:73680284	NA	0.5	6.89	0.36	2.84e-11	Resting heart rate;
CRC	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.73	-12.82	-0.58	8.7e-31	White blood cell count (basophil);
CRC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.48	7.41	0.38	1.06e-12	Calcium levels;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	7.1	0.36	7.96e-12	Breast cancer;
CRC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.54	0.34	2.33e-10	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07991241	chr10:33269695	NA	0.48	6.23	0.32	1.42e-9	Thyroid stimulating hormone;
CRC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.46	7.98	0.4	2.43e-14	Sense of smell;
CRC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.56	9.75	0.47	6.63e-20	Bipolar disorder;
CRC	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.78	-0.3	1.74e-8	Male-pattern baldness;
CRC	cis	rs4731207	0.596	rs1011723	chr7:124605261	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.53	8.47	0.42	8.51e-16	Coronary artery disease;
CRC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.62	-10.02	-0.48	8.3e-21	Dental caries;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05384413	chr15:101142580	LINS1;ASB7	0.39	5.96	0.31	6.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	1.03	15.72	0.66	6.14e-42	Myopia (pathological);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19460713	chr2:201170819	SPATS2L	0.4	6.12	0.32	2.59e-9	Myopia (pathological);
CRC	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.82	-0.31	1.41e-8	Blood metabolite levels;
CRC	trans	rs10411161	0.702	rs17778790	chr19:52399559	C/T	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22249281	chr19:41082756	SHKBP1	0.45	6.35	0.33	7.23e-10	Response to antipsychotic treatment;
CRC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.13	-12.89	-0.58	4.63e-31	Diabetic kidney disease;
CRC	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg08071915	chr8:12219732	FAM66A	0.32	5.81	0.31	1.46e-8	Retinal vascular caliber;
CRC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-9.36	-0.46	1.25e-18	Monocyte percentage of white cells;
CRC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.75	12.9	0.58	4.49e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.68	7.7	0.39	1.58e-13	Breast cancer;
CRC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg09323728	chr8:95962352	TP53INP1	0.36	5.71	0.3	2.59e-8	Type 2 diabetes;
CRC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	cis	rs4290604	0.748	rs78343343	chr2:237965660	A/G	cg23555395	chr2:238036564	NA	0.56	5.76	0.3	1.94e-8	Asthma;
CRC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.16	-0.32	2.18e-9	Gout;Renal underexcretion gout;
CRC	cis	rs3741798	1.000	rs61922054	chr12:12499472	A/G	cg08615371	chr12:12503544	MANSC1	1.01	8.92	0.44	3.4e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6952809	1.000	rs6952809	chr7:2448493	T/C	cg23289794	chr7:2394357	EIF3B	-0.41	-5.68	-0.3	2.96e-8	Multiple sclerosis;
CRC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.49	-7.75	-0.39	1.16e-13	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08659621	chr20:48552817	RNF114	0.44	6.19	0.32	1.77e-9	Response to antipsychotic treatment;
CRC	cis	rs2882667	0.898	rs6882526	chr5:138382368	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.53e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.42	-6.95	-0.36	1.99e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg15234197	chr11:68924956	NA	0.44	6.1	0.32	2.9e-9	Blond vs. brown hair color;
CRC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.33	5.61	0.3	4.41e-8	Emphysema distribution in smoking;
CRC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg01483505	chr11:975446	AP2A2	0.44	7.34	0.37	1.74e-12	Alzheimer's disease (late onset);
CRC	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg23100626	chr2:96804247	ASTL	-0.28	-7.58	-0.39	3.46e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs4731207	0.672	rs2286174	chr7:124465876	C/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.54	6.02	0.31	4.72e-9	Initial pursuit acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26963976	chr16:57023483	NLRC5	0.4	6.18	0.32	1.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	11.39	0.53	1.42e-25	Cognitive ability;
CRC	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.63	-0.34	1.34e-10	Response to antipsychotic treatment;
CRC	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.25e-12	Body mass index;
CRC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.56	-7.56	-0.38	3.92e-13	Colorectal cancer;
CRC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.6	8.0	0.4	2.15e-14	Mean corpuscular hemoglobin;
CRC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.63	-0.57	4.24e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.56	10.12	0.49	3.99e-21	Multiple system atrophy;
CRC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.36	6.06	0.32	3.83e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6988985	0.530	rs3819497	chr8:143924052	C/T	cg10324643	chr8:143916377	GML	0.38	6.54	0.34	2.28e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.22	-32.16	-0.87	1.41e-103	Colorectal cancer;
CRC	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg13385794	chr1:248469461	NA	0.39	6.74	0.35	6.91e-11	Common traits (Other);
CRC	cis	rs3736485	0.808	rs28576876	chr15:51951252	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.46	-0.34	3.79e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg27661571	chr11:113659931	NA	-0.95	-11.13	-0.52	1.23e-24	Hip circumference adjusted for BMI;
CRC	cis	rs12144309	0.554	rs1970559	chr1:114377148	T/C	cg03325407	chr1:114423726	BCL2L15	0.35	6.48	0.34	3.35e-10	Coronary artery disease;
CRC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.91	-0.31	8.54e-9	Schizophrenia;
CRC	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.92	11.19	0.53	7.51e-25	Exhaled nitric oxide output;
CRC	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.46	-6.84	-0.35	3.92e-11	Body mass index;
CRC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.67	9.68	0.47	1.17e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03806916	chr4:25314368	ZCCHC4	0.41	6.38	0.33	6.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	0.98	8.0	0.4	2.12e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7932354	0.583	rs1007738	chr11:46849360	A/G	cg19486271	chr11:47235900	DDB2	0.43	6.48	0.34	3.29e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg17948913	chr5:572064	NA	0.5	5.79	0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg03161606	chr19:29218774	NA	0.54	6.21	0.32	1.56e-9	Methadone dose in opioid dependence;
CRC	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg12046867	chr14:103022105	NA	0.42	6.1	0.32	2.96e-9	Platelet count;
CRC	cis	rs11212617	0.902	rs61913892	chr11:108340216	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.27	0.33	1.12e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.6	-0.39	3.22e-13	Psoriasis;
CRC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.52	8.06	0.41	1.45e-14	Colorectal cancer;
CRC	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.62	10.14	0.49	3.32e-21	Itch intensity from mosquito bite;
CRC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.6	9.02	0.45	1.54e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs1325195	0.840	rs2816177	chr1:179248952	A/G	cg08060353	chr15:77889974	NA	0.38	5.98	0.31	5.82e-9	IgE grass sensitization;
CRC	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.98	8.06	0.41	1.41e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.64	0.3	3.59e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg08798685	chr6:27730294	NA	-0.73	-6.55	-0.34	2.16e-10	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	cis	rs9462027	0.527	rs6939600	chr6:34822176	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.9	-0.31	9.06e-9	Systemic lupus erythematosus;
CRC	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg15192750	chr16:69999425	NA	0.55	7.27	0.37	2.58e-12	IgE levels;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.81	-13.98	-0.61	3.46e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	7.28	0.37	2.5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg01904812	chr1:17746340	RCC2	0.36	5.9	0.31	9.12e-9	Basal cell carcinoma;
CRC	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.48e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	5.9	0.31	8.88e-9	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14824382	chr8:144680115	EEF1D;TIGD5	0.38	6.52	0.34	2.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.27	-0.33	1.11e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.55	-9.38	-0.46	1.1e-18	Iron status biomarkers;
CRC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg19337854	chr7:99768885	GPC2	0.48	6.42	0.33	4.73e-10	Lung function (FEV1/FVC);
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.41	-5.85	-0.31	1.17e-8	Longevity;Endometriosis;
CRC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.13	-20.62	-0.75	3.1e-61	Ulcerative colitis;
CRC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg25600027	chr14:23388339	RBM23	-0.53	-8.3	-0.42	2.72e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.52	8.33	0.42	2.25e-15	Menopause (age at onset);
CRC	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	9.21	0.45	3.8e-18	Bone mineral density;
CRC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.48	6.33	0.33	7.8e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2179367	0.920	rs638407	chr6:149738350	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.35	-5.65	-0.3	3.48e-8	Dupuytren's disease;
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.84	-0.31	1.24e-8	Total body bone mineral density;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.7e-9	Bipolar disorder;
CRC	cis	rs939584	1.000	rs6760274	chr2:652272	G/A	cg03610516	chr2:642275	NA	-0.43	-5.63	-0.3	3.94e-8	Body mass index;
CRC	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Parkinson's disease;
CRC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	8.67	0.43	2.05e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg19683494	chr5:74908142	NA	-0.49	-6.26	-0.33	1.23e-9	Age-related disease endophenotypes;
CRC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.46	-7.6	-0.39	3.21e-13	Migraine;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16645202	chr15:92397488	SLCO3A1	0.38	6.4	0.33	5.31e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09013092	chr16:90014962	DEF8	0.41	6.26	0.33	1.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	9.22	0.45	3.75e-18	Response to antipsychotic treatment;
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.67	-0.3	3.1e-8	Total body bone mineral density;
CRC	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.61	8.51	0.42	6.44e-16	Arsenic metabolism;
CRC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.83	11.54	0.54	4.12e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.38	0.69	1.84e-48	Blood protein levels;
CRC	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.63	11.78	0.54	5.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs243505	0.762	rs10241408	chr7:148481488	G/A	cg09806900	chr7:148480153	CUL1	0.55	7.94	0.4	3.33e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06156847	chr2:113672199	IL1F7	-0.45	-6.76	-0.35	6.47e-11	Pulmonary function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25947998	chr8:42948467	SGK196	0.46	6.47	0.34	3.55e-10	Response to antipsychotic treatment;
CRC	trans	rs6956675	1.000	rs1879843	chr7:62586129	A/G	cg01314568	chr7:57830625	NA	-0.68	-9.37	-0.46	1.21e-18	Obesity-related traits;
CRC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.8	14.42	0.62	7.42e-37	Breast cancer;
CRC	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.55	-7.7	-0.39	1.5700000000000001e-13	Carotid intima media thickness;
CRC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg15383120	chr6:291909	DUSP22	-0.52	-7.25	-0.37	2.98e-12	Menopause (age at onset);
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg03623178	chr6:28175578	NA	0.7	8.46	0.42	8.79e-16	Parkinson's disease;
CRC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.31	0.49	8.49e-22	Diabetic retinopathy;
CRC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.56	8.63	0.43	2.69e-16	Body mass index;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.48	7.3	0.37	2.13e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.88	14.75	0.63	3.94e-38	Alcohol dependence;
CRC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-0.98	-18.42	-0.71	1.46e-52	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27664600	chr15:44487605	FRMD5	0.45	6.95	0.36	1.91e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.48	6.49	0.34	3.23e-10	Schizophrenia;
CRC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg11833968	chr6:79620685	NA	-0.35	-6.04	-0.32	4.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	1.04	16.23	0.67	6.22e-44	Testicular germ cell tumor;
CRC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06238570	chr21:40685208	BRWD1	-0.74	-11.36	-0.53	1.87e-25	Cognitive function;
CRC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.9	16.38	0.67	1.65e-44	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg25456477	chr12:86230367	RASSF9	-0.39	-6.54	-0.34	2.36e-10	Major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23132254	chr6:18264719	DEK	0.38	5.96	0.31	6.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15171272	chr17:33905444	PEX12	0.41	6.03	0.32	4.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.43	0.33	4.43e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.45	5.73	0.3	2.21e-8	Aortic root size;
CRC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg05063087	chr10:102133314	C10orf75	-0.43	-6.08	-0.32	3.36e-9	Underweight status;
CRC	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg10279832	chr4:154682576	RNF175	0.38	5.77	0.3	1.82e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.42	6.81	0.35	4.76e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	trans	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg07393940	chr7:158741817	NA	0.51	7.38	0.38	1.34e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.59	9.97	0.48	1.2e-20	Prudent dietary pattern;
CRC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.58	8.89	0.44	3.96e-17	Mean platelet volume;
CRC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.7	-0.39	1.66e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.06	14.37	0.62	1.14e-36	Orofacial clefts;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg06470822	chr6:28175283	NA	0.68	9.05	0.45	1.29e-17	Parkinson's disease;
CRC	trans	rs4576506	0.536	rs10429469	chr9:31497248	G/T	cg26940518	chr16:1593766	IFT140;TMEM204	-0.66	-6.11	-0.32	2.86e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs79387448	0.808	rs77518775	chr2:103237642	T/C	cg09003973	chr2:102972529	NA	0.63	6.38	0.33	6.02e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs939584	1.000	rs7585056	chr2:631528	A/G	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00911488	chr4:106068604	TET2	0.43	6.72	0.35	7.82e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.6	10.02	0.48	8.79e-21	Mean corpuscular volume;
CRC	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg15234197	chr11:68924956	NA	0.42	5.8	0.3	1.57e-8	Blond vs. brown hair color;
CRC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.41	-8.02	-0.4	1.93e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07001447	chr2:187350515	ZC3H15	0.43	6.21	0.32	1.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.33	-0.37	1.8e-12	Aortic root size;
CRC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg20417195	chr1:21767127	NBPF3	0.44	6.59	0.34	1.72e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	11.2	0.53	6.89e-25	Bone mineral density;
CRC	cis	rs12476592	0.602	rs6724160	chr2:63786423	G/C	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02038323	chr12:121477093	OASL	0.45	6.44	0.33	4.25e-10	Response to antipsychotic treatment;
CRC	cis	rs1355223	0.867	rs11821793	chr11:34681462	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.91	-0.31	8.38e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.78	8.68	0.43	1.91e-16	Systolic blood pressure;
CRC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.25e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	10.17	0.49	2.64e-21	Myopia (pathological);
CRC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg26566898	chr11:117069891	TAGLN	0.27	5.78	0.3	1.7e-8	Blood protein levels;
CRC	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.93	-13.84	-0.61	1.25e-34	Ulcerative colitis;
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.63	-0.3	3.91e-8	Life satisfaction;
CRC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg25985355	chr7:65971099	NA	0.32	5.69	0.3	2.81e-8	Aortic root size;
CRC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg02683197	chr6:28174875	NA	0.47	6.51	0.34	2.77e-10	Cardiac Troponin-T levels;
CRC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.47	6.79	0.35	5.3e-11	Cognitive function;
CRC	cis	rs55883249	0.957	rs62119432	chr2:9753939	C/T	cg23886495	chr2:9695866	ADAM17	0.52	5.97	0.31	6.19e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.05	0.32	4.01e-9	Height;
CRC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.56	6.19	0.32	1.75e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.6	8.69	0.43	1.75e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06547771	chr11:43380393	TTC17	0.43	5.96	0.31	6.45e-9	Anxiety disorder;
CRC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg27661571	chr11:113659931	NA	0.61	7.18	0.37	4.54e-12	Hip circumference adjusted for BMI;
CRC	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.64	6.21	0.32	1.62e-9	Axial length;
CRC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs3800461	0.544	rs11754548	chr6:34504767	G/C	cg17674042	chr6:34482479	PACSIN1	-0.68	-7.93	-0.4	3.45e-14	Chronic lymphocytic leukemia;
CRC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg21665744	chr7:39171113	POU6F2	0.44	5.86	0.31	1.12e-8	IgG glycosylation;
CRC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.698	rs2079368	chr7:124485311	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.95	-0.36	2.02e-11	Response to antipsychotic treatment;
CRC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.56	-0.43	4.32e-16	Hemoglobin concentration;
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.48	7.07	0.36	9.12e-12	Parkinson's disease;
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg12273811	chr6:28175739	NA	0.61	8.65	0.43	2.3e-16	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg11843238	chr5:131593191	PDLIM4	-0.43	-7.33	-0.37	1.86e-12	Breast cancer;
CRC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.2	-13.5	-0.6	2.41e-33	Diabetic kidney disease;
CRC	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.52	7.82	0.4	7.17e-14	Prostate cancer;
CRC	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg22431228	chr1:16359049	CLCNKA	0.35	6.23	0.32	1.4e-9	Dilated cardiomyopathy;
CRC	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.51	-7.51	-0.38	5.62e-13	Coronary heart disease;
CRC	cis	rs4930561	0.714	rs1540209	chr11:67928520	A/C	cg04465784	chr11:67976953	SUV420H1	-0.3	-6.11	-0.32	2.82e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg27534772	chr1:16042836	PLEKHM2	0.53	10.38	0.5	4.9e-22	Systolic blood pressure;
CRC	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.61	8.61	0.43	3.13e-16	Arsenic metabolism;
CRC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg15902774	chr15:75289873	SCAMP5	-0.53	-6.16	-0.32	2.11e-9	Lung cancer;
CRC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg20885578	chr2:198174922	NA	-0.36	-6.41	-0.33	4.95e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs394563	0.601	rs367133	chr6:149797720	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.4	-6.63	-0.34	1.35e-10	Dupuytren's disease;
CRC	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.74	10.31	0.49	8.54e-22	Systemic lupus erythematosus;
CRC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	0.99	12.27	0.56	9.01e-29	Iron status biomarkers;
CRC	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	9.33	0.46	1.66e-18	Adiposity;
CRC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	27.12	0.83	6.77e-86	IgG glycosylation;
CRC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.78	7.43	0.38	9.65e-13	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg01312482	chr5:178451176	ZNF879	0.37	6.4	0.33	5.37e-10	Pubertal anthropometrics;
CRC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.92	0.31	8.32e-9	Melanoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25704110	chr12:4967040	NA	0.49	6.3	0.33	9.55e-10	Thyroid stimulating hormone;
CRC	cis	rs6804368	0.649	rs2219610	chr3:30762661	A/G	cg06106510	chr3:30762233	NA	-0.42	-7.49	-0.38	6.48e-13	Blood metabolite levels;
CRC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.33	0.46	1.62e-18	Tonsillectomy;
CRC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.4	5.92	0.31	7.95e-9	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs55821334	chr2:162452014	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.72	-5.97	-0.31	6.06e-9	Cognitive function;
CRC	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11446398	chr5:77624930	NA	0.46	6.38	0.33	6.06e-10	Triglycerides;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24015594	chr6:33539338	NA	0.43	6.17	0.32	1.97e-9	Response to antipsychotic treatment;
CRC	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg10756647	chr7:56101905	PSPH	0.77	8.04	0.41	1.6e-14	Diabetic kidney disease;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg20512303	chr5:131592959	PDLIM4	0.37	6.33	0.33	8.16e-10	Breast cancer;
CRC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.32	0.46	1.67e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs6804368	0.649	rs9858466	chr3:30758845	T/A	cg06106510	chr3:30762233	NA	0.42	7.55	0.38	4.2e-13	Blood metabolite levels;
CRC	cis	rs11212617	0.967	rs227086	chr11:108244251	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.58	0.34	1.85e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	14.43	0.62	6.66e-37	Lymphocyte percentage of white cells;
CRC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.03	-0.36	1.17e-11	Personality dimensions;
CRC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.01	-0.31	5e-9	Monocyte percentage of white cells;
CRC	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.72	-0.35	7.92e-11	Coronary artery disease;
CRC	cis	rs7173389	1.000	rs8040533	chr15:73664741	T/G	cg01796676	chr15:73680284	NA	0.5	6.61	0.34	1.56e-10	Resting heart rate;
CRC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.38	-6.09	-0.32	3.19e-9	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-6.19	-0.32	1.78e-9	Coronary artery disease;
CRC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.6	-8.5	-0.42	6.65e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.11	-12.77	-0.58	1.31e-30	Diabetic kidney disease;
CRC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.81	-12.91	-0.58	4.11e-31	Cognitive function;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg21620606	chr4:1342894	KIAA1530	0.4	7.11	0.36	7.25e-12	Obesity-related traits;
CRC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-6.17	-0.32	2.04e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg13856295	chr9:139396418	NOTCH1	-0.43	-5.69	-0.3	2.82e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.65	7.82	0.4	7.04e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.98	-0.36	1.6e-11	Aortic root size;
CRC	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg05194412	chr2:137003533	NA	0.43	6.61	0.34	1.55e-10	Colorectal cancer;
CRC	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11446398	chr5:77624930	NA	0.46	6.24	0.33	1.37e-9	Triglycerides;
CRC	cis	rs883565	0.569	rs1274968	chr3:39170090	A/G	cg01426195	chr3:39028469	NA	-0.41	-6.95	-0.36	1.96e-11	Handedness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05522046	chr3:52931664	TMEM110	0.5	7.0	0.36	1.43e-11	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19377384	chr3:140951430	ACPL2	0.49	6.54	0.34	2.33e-10	Thyroid stimulating hormone;
CRC	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.53	8.76	0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6585424	1.000	rs35025775	chr10:81924285	C/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.42	7.01	0.36	1.34e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9287719	0.649	rs10929684	chr2:10732224	C/T	cg00105475	chr2:10696890	NA	-0.45	-6.97	-0.36	1.69e-11	Prostate cancer;
CRC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg03013999	chr17:37608204	MED1	-0.47	-7.44	-0.38	8.58e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg02033258	chr5:131593261	PDLIM4	0.37	6.27	0.33	1.14e-9	Acylcarnitine levels;
CRC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.61e-14	Lung cancer;
CRC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	0.64	10.21	0.49	1.94e-21	Fibrinogen levels;
CRC	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg14092571	chr14:90743983	NA	0.39	6.04	0.32	4.23e-9	Mortality in heart failure;
CRC	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg18200150	chr17:30822561	MYO1D	0.47	9.09	0.45	9.82e-18	Schizophrenia;
CRC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg03037974	chr15:76606532	NA	0.53	7.95	0.4	3.06e-14	Blood metabolite levels;
CRC	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.45	6.48	0.34	3.32e-10	Malaria;
CRC	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Colorectal cancer;
CRC	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg20503657	chr10:835505	NA	-0.48	-6.56	-0.34	2.08e-10	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24867478	chr11:67029151	NA	0.37	6.24	0.33	1.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg01969543	chr11:61895209	INCENP	-0.49	-7.04	-0.36	1.1e-11	Breast cancer;
CRC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg14074117	chr16:1909714	C16orf73	0.41	5.63	0.3	3.77e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.33	-5.78	-0.3	1.72e-8	Menarche (age at onset);
CRC	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.53	-6.23	-0.32	1.46e-9	Inflammatory bowel disease;
CRC	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg01339444	chr6:118972232	C6orf204	0.52	5.74	0.3	2.11e-8	Diastolic blood pressure;
CRC	cis	rs6810498	0.932	rs10155365	chr4:26056021	G/A	cg12925881	chr4:26050407	NA	-0.42	-7.8	-0.39	8.38e-14	Alcohol dependence;
CRC	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.66	-9.57	-0.47	2.66e-19	Type 2 diabetes;
CRC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06201907	chr1:113249974	RHOC	0.4	6.53	0.34	2.55e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.65	-0.47	1.41e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg08075719	chr14:103021372	NA	0.65	7.44	0.38	9e-13	Platelet count;
CRC	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-1.24	-10.21	-0.49	1.89e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs62229266	0.659	rs2835245	chr21:37416708	C/T	cg08632701	chr21:37451849	NA	-0.42	-6.54	-0.34	2.32e-10	Mitral valve prolapse;
CRC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.58	6.34	0.33	7.43e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12541635	0.934	rs57715289	chr8:106967124	A/T	cg10147462	chr8:107024639	NA	0.44	7.05	0.36	1.04e-11	Age of smoking initiation;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg12273811	chr6:28175739	NA	0.55	5.82	0.31	1.42e-8	Lung cancer in ever smokers;
CRC	trans	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.37	0.38	1.39e-12	Skin colour saturation;
CRC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg00999904	chr2:3704751	ALLC	0.45	6.69	0.35	9.86e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.48	7.59	0.39	3.38e-13	Monocyte count;
CRC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg25456477	chr12:86230367	RASSF9	-0.33	-5.73	-0.3	2.22e-8	Major depressive disorder;
CRC	cis	rs4363385	0.679	rs6686285	chr1:152984561	T/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.25	-0.37	2.99e-12	Inflammatory skin disease;
CRC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.49	6.19	0.32	1.77e-9	Obesity-related traits;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13411897	chr3:12526166	TSEN2	0.37	5.98	0.31	5.88e-9	Obesity-related traits;
CRC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg09355771	chr2:177043147	NA	0.66	9.88	0.48	2.41e-20	IgG glycosylation;
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.65	0.54	1.64e-26	Prudent dietary pattern;
CRC	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6496667	0.821	rs8023767	chr15:90883494	C/A	cg04176472	chr15:90893244	GABARAPL3	0.56	6.49	0.34	3.13e-10	Rheumatoid arthritis;
CRC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	0.77	8.59	0.43	3.61e-16	Gout;Renal underexcretion gout;
CRC	cis	rs6961069	0.837	rs1761662	chr7:80238463	C/T	cg04458919	chr7:80252533	CD36	-0.34	-6.19	-0.32	1.8e-9	Platelet count;
CRC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.65e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9467711	0.720	rs3857546	chr6:26157762	C/T	cg16898833	chr6:26189333	HIST1H4D	0.64	5.87	0.31	1.04e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.39	-0.46	1.01e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg25985355	chr7:65971099	NA	0.53	6.05	0.32	3.9e-9	Diabetic kidney disease;
CRC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.49	-5.8	-0.3	1.53e-8	Menarche (age at onset);
CRC	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.32	0.65	2.39e-40	Fuchs's corneal dystrophy;
CRC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.66	-0.34	1.17e-10	Educational attainment;
CRC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg15396367	chr9:139972779	UAP1L1	0.44	6.74	0.35	7.25e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.53	8.41	0.42	1.25e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg08314208	chr16:67682810	RLTPR	-0.56	-6.04	-0.32	4.06e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6565681	0.943	rs6565683	chr17:78362300	A/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.57	-6.4	-0.33	5.48e-10	Moyamoya disease;
CRC	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.82	-14.26	-0.62	2.87e-36	Colorectal cancer;
CRC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-7.96	-0.4	2.89e-14	Type 2 diabetes;
CRC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg15465823	chr12:48382534	COL2A1	0.4	6.71	0.35	8.6e-11	Glycated hemoglobin levels;
CRC	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg21918786	chr6:109611834	NA	-0.33	-5.7	-0.3	2.65e-8	Reticulocyte fraction of red cells;
CRC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg15845792	chr6:28175446	NA	0.49	6.58	0.34	1.81e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	10.46	0.5	2.63e-22	Bone mineral density;
CRC	cis	rs737008	0.960	rs949429	chr16:11376029	C/T	cg00044050	chr16:11439710	C16orf75	-0.48	-6.62	-0.34	1.49e-10	Obesity-related traits;
CRC	cis	rs10503871	0.740	rs13249960	chr8:30417532	C/G	cg26383811	chr8:30366931	RBPMS	0.41	6.25	0.33	1.25e-9	Metabolite levels  (X-11787);
CRC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.47	6.24	0.33	1.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.77	9.08	0.45	1.05e-17	Migraine;Coronary artery disease;
CRC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.76	13.48	0.6	2.84e-33	Oral cavity cancer;
CRC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.56	8.49	0.42	6.99e-16	Aortic root size;
CRC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg06462663	chr19:18546047	ISYNA1	0.48	7.07	0.36	9.46e-12	Breast cancer;
CRC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg06219103	chr11:63990595	FERMT3	-0.38	-5.62	-0.3	4.18e-8	Platelet count;
CRC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.62	6.71	0.35	8.47e-11	Initial pursuit acceleration;
CRC	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.59	9.05	0.45	1.32e-17	HDL cholesterol;
CRC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.53	0.57	1.01e-29	Menopause (age at onset);
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-7.27	-0.37	2.63e-12	Breast cancer;
CRC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg16606324	chr3:10149918	C3orf24	0.46	6.58	0.34	1.8e-10	Alzheimer's disease;
CRC	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.45	6.84	0.35	3.94e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg12935359	chr14:103987150	CKB	-0.48	-7.24	-0.37	3.19e-12	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08247611	chr16:71928811	KIAA0174	-0.54	-6.4	-0.33	5.26e-10	Diisocyanate-induced asthma;
CRC	cis	rs12541635	0.801	rs12155859	chr8:107105384	C/T	cg10147462	chr8:107024639	NA	-0.39	-6.05	-0.32	3.92e-9	Age of smoking initiation;
CRC	cis	rs4073416	0.510	rs2268956	chr14:66090145	G/A	cg03016385	chr14:66212404	NA	-0.45	-6.2	-0.32	1.67e-9	N-glycan levels;
CRC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-21.02	-0.76	8.53e-63	Primary sclerosing cholangitis;
CRC	cis	rs7259376	0.936	rs4932760	chr19:22540455	T/G	cg02657401	chr19:22469223	NA	-0.33	-7.44	-0.38	8.94e-13	Menopause (age at onset);
CRC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.41	7.82	0.4	7.32e-14	Mean corpuscular volume;
CRC	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-10.61	-0.51	8e-23	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.42	0.46	8.34e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg09507567	chr10:124027408	NA	0.35	7.4	0.38	1.18e-12	Total body bone mineral density;
CRC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.51	-7.28	-0.37	2.55e-12	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12598048	chr15:22892705	CYFIP1	0.41	6.03	0.32	4.4e-9	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg07870213	chr5:140052090	DND1	0.6	8.06	0.41	1.45e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.55	0.47	3.06e-19	Bladder cancer;
CRC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.8	13.63	0.6	7.81e-34	Menopause (age at onset);
CRC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.623	rs1481342	chr7:124651479	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.48	4.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.85	0.31	1.17e-8	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23911465	chr14:75469330	EIF2B2	0.46	6.84	0.35	3.86e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg18721089	chr20:30220636	NA	-0.35	-5.84	-0.31	1.26e-8	Mean corpuscular hemoglobin;
CRC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.53	8.32	0.42	2.31e-15	Blood protein levels;
CRC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg03623178	chr6:28175578	NA	0.8	7.71	0.39	1.5e-13	Depression;
CRC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.36e-9	Red blood cell count;
CRC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-10.34	-0.5	7.1e-22	Tonsillectomy;
CRC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.93	-17.97	-0.7	8.73e-51	Myeloid white cell count;
CRC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	1.02e-12	Major depressive disorder;
CRC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.8	8.37	0.42	1.72e-15	Major depressive disorder;
CRC	trans	rs2303319	0.504	rs2175142	chr2:162450124	T/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.43e-9	Cognitive function;
CRC	trans	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.87	-0.35	3.17e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.58	8.02	0.4	1.94e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1e-22	Iron status biomarkers;
CRC	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.72	-11.52	-0.54	5.02e-26	Breast cancer;
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.56	0.34	2.1e-10	Alzheimer's disease;
CRC	cis	rs55882075	0.967	rs62404346	chr5:179141391	A/C	cg14593053	chr5:179126677	CANX	0.48	7.52	0.38	5.32e-13	Monocyte percentage of white cells;
CRC	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg23422044	chr7:1970798	MAD1L1	-0.4	-5.63	-0.3	3.89e-8	Bipolar disorder;
CRC	cis	rs6988985	0.765	rs6433	chr8:143993640	C/T	cg10324643	chr8:143916377	GML	0.36	5.87	0.31	1.08e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg27535305	chr1:53392650	SCP2	-0.36	-6.79	-0.35	5.25e-11	Monocyte count;
CRC	cis	rs16852403	0.517	rs12032786	chr1:178236176	A/G	cg00404053	chr1:178313656	RASAL2	0.48	6.12	0.32	2.6e-9	Childhood ear infection;
CRC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.34	-0.42	2.13e-15	Monocyte percentage of white cells;
CRC	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs2898681	0.614	rs4864680	chr4:53708421	T/G	cg00338735	chr4:53728038	RASL11B	0.43	6.41	0.33	5.12e-10	Optic nerve measurement (cup area);
CRC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.7	-0.47	9.65e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.57	-7.22	-0.37	3.71e-12	Ulcerative colitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09003876	chr18:33552519	C18orf21	0.4	5.99	0.31	5.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg23920097	chr1:209922102	NA	-0.54	-6.69	-0.35	9.58e-11	Red blood cell count;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg20933634	chr6:27740509	NA	0.43	6.32	0.33	8.73e-10	Parkinson's disease;
CRC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.55	7.71	0.39	1.48e-13	Height;
CRC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.27	-0.49	1.16e-21	Extrinsic epigenetic age acceleration;
CRC	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.53	-7.57	-0.39	3.67e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.63	7.69	0.39	1.76e-13	Type 2 diabetes nephropathy;
CRC	cis	rs4663866	1.000	rs34897410	chr2:239182123	T/C	cg16914508	chr2:239161102	PER2	0.78	8.01	0.4	2.01e-14	Irritable bowel syndrome;
CRC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.78	0.35	5.44e-11	Aortic root size;
CRC	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg25547332	chr5:131281432	NA	0.39	5.89	0.31	9.4e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.51	0.34	2.73e-10	Menopause (age at onset);
CRC	cis	rs17152411	1.000	rs7086447	chr10:126593553	C/A	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg06494592	chr3:125709126	NA	-0.55	-6.57	-0.34	2e-10	Blood pressure (smoking interaction);
CRC	cis	rs9462027	0.651	rs1543559	chr6:34784104	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.47	-0.42	8.2e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg19875578	chr6:126661172	C6orf173	0.44	6.12	0.32	2.62e-9	Male-pattern baldness;
CRC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.77	13.45	0.6	3.63e-33	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.61	-0.39	3.01e-13	Coronary artery disease;
CRC	cis	rs911119	0.913	rs6048926	chr20:23580987	C/A	cg16589663	chr20:23618590	CST3	0.42	5.81	0.3	1.51e-8	Chronic kidney disease;
CRC	cis	rs2070997	0.756	rs3808820	chr9:133726956	A/T	cg01000188	chr9:133769184	QRFP	0.5	5.92	0.31	8.21e-9	Response to amphetamines;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg03623178	chr6:28175578	NA	-0.79	-6.91	-0.36	2.6e-11	Depression;
CRC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.43	6.77	0.35	5.9e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7113874	0.589	rs6578969	chr11:8488991	G/A	cg20771178	chr11:8615675	STK33	-0.34	-5.68	-0.3	2.92e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13419809	chr10:102790978	SFXN3;PDZD7	0.4	6.59	0.34	1.79e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg08314208	chr16:67682810	RLTPR	-0.53	-6.0	-0.31	5.24e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14321424	chr11:46403087	MDK	0.41	6.49	0.34	3.1e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs1590305	0.786	rs6563550	chr13:38058413	C/T	cg03965764	chr11:45248109	NA	-0.59	-6.05	-0.32	3.96e-9	Hip geometry;
CRC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.44	6.33	0.33	8.22e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.42	-6.57	-0.34	2.02e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs11255291	0.668	rs6602265	chr10:7732939	A/G	cg00997801	chr10:7671259	ITIH5	0.4	5.95	0.31	6.72e-9	Ovarian reserve;
CRC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.18	-0.59	3.89e-32	Systemic lupus erythematosus;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.95	-0.4	3.07e-14	Total body bone mineral density;
CRC	cis	rs17641971	0.684	rs12545097	chr8:49951977	A/G	cg00325661	chr8:49890786	NA	0.34	5.78	0.3	1.76e-8	Blood metabolite levels;
CRC	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.67	-7.79	-0.39	9.03e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9311474	0.841	rs352139	chr3:52258372	T/C	cg18099408	chr3:52552593	STAB1	-0.34	-5.67	-0.3	3.11e-8	Electroencephalogram traits;
CRC	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg27395922	chr11:50257633	LOC441601	-0.41	-7.04	-0.36	1.13e-11	Height;
CRC	cis	rs9403521	0.673	rs3934959	chr6:143979710	A/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.22	-0.32	1.54e-9	Obesity-related traits;
CRC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.22	0.56	1.4e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg09476006	chr5:138032270	NA	0.46	7.4	0.38	1.18e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7945718	0.591	rs4489724	chr11:12684166	G/T	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.56	-0.34	2.03e-10	Systemic lupus erythematosus;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09797645	chr10:35415606	CREM	-0.38	-6.14	-0.32	2.33e-9	Obesity-related traits;
CRC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24308560	chr3:49941425	MST1R	0.5	8.23	0.41	4.39e-15	Intelligence (multi-trait analysis);
CRC	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.18	0.62	6.1e-36	Hypertriglyceridemia;
CRC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.92	15.8	0.66	2.99e-42	Parkinson's disease;
CRC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.97	-0.31	6.08e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg20935933	chr6:143382018	AIG1	0.51	6.48	0.34	3.38e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.0	0.36	1.44e-11	Morning vs. evening chronotype;
CRC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.42	-9.15	-0.45	5.94e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg12273811	chr6:28175739	NA	0.5	6.63	0.34	1.38e-10	Parkinson's disease;
CRC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg01304814	chr3:48885189	PRKAR2A	0.78	6.19	0.32	1.83e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
CRC	cis	rs4964805	0.913	rs36034617	chr12:104203615	G/C	cg02344784	chr12:104178138	NT5DC3	0.52	7.48	0.38	6.86e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.08	10.5	0.5	1.9e-22	Diabetic retinopathy;
CRC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.73	-0.43	1.26e-16	Chronic sinus infection;
CRC	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.8	12.86	0.58	6.01e-31	Height;
CRC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.98	0.7	7.57e-51	Platelet count;
CRC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	9.41	0.46	9.07e-19	Lymphocyte counts;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg04518342	chr5:131593106	PDLIM4	-0.56	-9.75	-0.47	6.97e-20	Acylcarnitine levels;
CRC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.62	0.6	8.2e-34	Chronic sinus infection;
CRC	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.46	-6.81	-0.35	4.6e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.78	10.22	0.49	1.78e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg19635926	chr16:89946313	TCF25	0.61	5.92	0.31	8.24e-9	Skin colour saturation;
CRC	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.9e-11	Electroencephalogram traits;
CRC	cis	rs6076065	0.723	rs743022	chr20:23401129	G/C	cg11657817	chr20:23433608	CST11	0.44	6.51	0.34	2.8e-10	Facial morphology (factor 15, philtrum width);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20462845	chr19:3572957	HMG20B	0.4	6.29	0.33	9.86e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.55	0.75	5.84e-61	Prudent dietary pattern;
CRC	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.94	-0.31	7.15e-9	Pulmonary function;
CRC	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.7	-10.93	-0.52	6.29e-24	Type 2 diabetes;
CRC	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.54	5.9	0.31	9.14e-9	RR interval (heart rate);
CRC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-8.26	-0.41	3.59e-15	Monocyte count;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg21251018	chr6:28226885	NKAPL	-0.45	-6.16	-0.32	2.07e-9	Depression;
CRC	cis	rs12745968	0.653	rs12123935	chr1:93175814	C/T	cg17283838	chr1:93427260	FAM69A	-0.42	-5.75	-0.3	1.99e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06937829	chr11:554920	C11orf35	0.45	6.38	0.33	5.98e-10	Response to antipsychotic treatment;
CRC	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.62	-9.7	-0.47	9.93e-20	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.58	7.89	0.4	4.61e-14	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25312481	chr1:10459146	PGD	0.41	7.1	0.36	7.75e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6968419	0.781	rs66652906	chr7:115881159	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.35	-0.33	7.09e-10	Intraocular pressure;
CRC	cis	rs1971762	0.527	rs4759211	chr12:53930945	T/C	cg06632207	chr12:54070931	ATP5G2	0.45	7.61	0.39	2.97e-13	Height;
CRC	cis	rs9931543	0.504	rs4784651	chr16:56311774	A/G	cg02433656	chr16:56322654	GNAO1	-0.49	-7.47	-0.38	7.51e-13	Subjective well-being;
CRC	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.58	-7.75	-0.39	1.19e-13	White matter hyperintensity burden;
CRC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.42	-6.07	-0.32	3.49e-9	Aortic root size;
CRC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.59	-8.7	-0.43	1.59e-16	Aortic root size;
CRC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.5	8.09	0.41	1.14e-14	Height;
CRC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.63	-0.34	1.34e-10	Obesity-related traits;
CRC	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.49	9.77	0.47	6.01e-20	Urate levels in overweight individuals;
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.87	-0.31	1.08e-8	Life satisfaction;
CRC	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.61	-9.57	-0.47	2.71e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.4	5.8	0.3	1.54e-8	Obesity-related traits;
CRC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	12.38	0.56	3.77e-29	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.45	-5.99	-0.31	5.44e-9	Parkinson's disease;
CRC	cis	rs820218	0.962	rs820129	chr17:73668107	A/G	cg01973089	chr17:73647209	RECQL5	0.33	6.19	0.32	1.84e-9	Rotator cuff tears;
CRC	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg21155852	chr7:2048760	MAD1L1	0.46	6.42	0.33	4.71e-10	Bipolar disorder;
CRC	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.54	7.2	0.37	4.02e-12	Prostate-specific antigen levels;
CRC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.1	0.52	1.58e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.79	11.45	0.53	8.71e-26	Menarche (age at onset);
CRC	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.47	-7.56	-0.38	4.1e-13	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CRC	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.51	5.78	0.3	1.72e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	15.82	0.66	2.6e-42	Lymphocyte percentage of white cells;
CRC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.86	15.28	0.64	3.36e-40	Blood protein levels;
CRC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.1	0.36	7.8e-12	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14298577	chr7:100272703	GNB2	0.4	6.24	0.33	1.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg12756093	chr1:115239321	AMPD1	-0.45	-5.67	-0.3	3.08e-8	Autism;
CRC	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg01605746	chr5:669925	TPPP	0.35	5.74	0.3	2.13e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs2257205	0.667	rs6503874	chr17:56780459	C/G	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.55	-8.03	-0.4	1.71e-14	Bone mineral density;
CRC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.65	-0.34	1.24e-10	Renal cell carcinoma;
CRC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.54	7.37	0.38	1.37e-12	Bronchopulmonary dysplasia;
CRC	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.51	-7.52	-0.38	5.32e-13	Cocaine dependence;
CRC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.48	-8.16	-0.41	7.14e-15	Childhood ear infection;
CRC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.44	5.9	0.31	8.94e-9	Schizophrenia;
CRC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg12639453	chr1:2035780	PRKCZ	-0.39	-7.52	-0.38	5.29e-13	Height;
CRC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg07274523	chr3:49395745	GPX1	0.48	6.55	0.34	2.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.54	6.4	0.33	5.38e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	cg04338863	chr8:33670619	NA	0.45	6.54	0.34	2.37e-10	Body mass index;
CRC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.48	6.81	0.35	4.61e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3018066	0.666	rs78488187	chr4:107037630	C/T	cg01869342	chr4:106983673	TBCK	0.46	6.03	0.32	4.52e-9	Cancer;
CRC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.78	13.02	0.58	1.48e-31	Blood protein levels;
CRC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.57	8.07	0.41	1.3e-14	Resting heart rate;
CRC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.48	-0.38	6.75e-13	Height;
CRC	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	cis	rs365302	1.000	rs483575	chr6:159651547	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.79	9.53	0.47	3.55e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs501120	1.000	rs518594	chr10:44757107	T/C	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.62	-8.02	-0.4	1.83e-14	Schizophrenia;
CRC	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg01843034	chr6:37503916	NA	-0.37	-6.64	-0.34	1.3100000000000001e-10	Cognitive performance;
CRC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.29	-0.33	1.03e-9	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs12469302	chr2:162433831	G/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.77	-6.19	-0.32	1.79e-9	Cognitive function;
CRC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.73	-0.43	1.27e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg23815491	chr16:72088622	HP	0.54	5.81	0.3	1.5e-8	Blood protein levels;
CRC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg05627522	chr15:75251581	NA	0.41	6.33	0.33	7.89e-10	Breast cancer;
CRC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.38	-5.95	-0.31	6.84e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.61	-9.59	-0.47	2.27e-19	Motion sickness;
CRC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.37	-6.81	-0.35	4.67e-11	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.54	-7.88	-0.4	4.93e-14	QRS duration;
CRC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.57	6.76	0.35	6.18e-11	Bipolar disorder;
CRC	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.84e-10	Breast cancer;
CRC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.71	11.12	0.52	1.39e-24	Corneal astigmatism;
CRC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.66	9.56	0.47	2.85e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg09676794	chr13:100310162	CLYBL	0.63	6.17	0.32	1.95e-9	Breast cancer;
CRC	cis	rs7731657	0.537	rs987024	chr5:130337029	T/G	cg08523029	chr5:130500466	HINT1	-0.44	-5.76	-0.3	1.98e-8	Fasting plasma glucose;
CRC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.26	0.53	4.33e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18504358	chr14:23340787	LRP10	0.47	6.1	0.32	2.99e-9	Thyroid stimulating hormone;
CRC	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.37	6.06	0.32	3.69e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09337511	chr12:112856520	PTPN11	0.46	6.47	0.34	3.48e-10	Anxiety disorder;
CRC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.62	9.58	0.47	2.46e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg14329157	chr2:228736135	WDR69	-0.47	-6.53	-0.34	2.48e-10	Blood pressure;
CRC	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.98	-17.92	-0.7	1.38e-50	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.33	-0.33	8.03e-10	Gout;Renal underexcretion gout;
CRC	cis	rs2274273	0.624	rs10129505	chr14:55776375	C/T	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.74	-0.3	2.18e-8	Protein biomarker;
CRC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.69	9.81	0.48	4.2e-20	Cleft lip with or without cleft palate;
CRC	trans	rs3747547	0.792	rs72726052	chr9:38056290	C/T	cg06834177	chr1:6333843	ACOT7	0.77	6.03	0.32	4.44e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CRC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.27	-0.37	2.6e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.51	7.34	0.38	1.67e-12	Pancreatic cancer;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.62	9.75	0.47	6.7e-20	Systemic lupus erythematosus;
CRC	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.36	0.33	6.57e-10	Subjective well-being;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14905632	chr17:38333933	RAPGEFL1	0.42	5.97	0.31	6.29e-9	Survival in pancreatic cancer;
CRC	trans	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg06636001	chr8:8085503	FLJ10661	0.44	5.97	0.31	6.04e-9	Neuroticism;
CRC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg12927641	chr6:109611667	NA	0.34	6.0	0.31	5.19e-9	Reticulocyte fraction of red cells;
CRC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg22777020	chr22:31556080	RNF185	-0.45	-6.0	-0.31	5.3e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg00376283	chr12:123451042	ABCB9	0.55	7.17	0.37	4.93e-12	Neutrophil percentage of white cells;
CRC	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.45	6.49	0.34	3.2e-10	Body mass index;
CRC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.31	-6.82	-0.35	4.38e-11	IgG glycosylation;
CRC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs2882667	0.690	rs288002	chr5:138232087	T/C	cg09476006	chr5:138032270	NA	0.54	8.95	0.44	2.66e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg07125278	chr16:67683757	RLTPR	-0.62	-6.73	-0.35	7.66e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	16.93	0.68	1.13e-46	Electrocardiographic conduction measures;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01839850	chr22:38240395	ANKRD54;MIR658	-0.51	-6.2	-0.32	1.72e-9	Diisocyanate-induced asthma;
CRC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.58	9.5	0.46	4.56e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.49	7.0	0.36	1.45e-11	Fibrinogen levels;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-0.85	-12.51	-0.57	1.18e-29	IgG glycosylation;
CRC	trans	rs7772172	1.000	rs2073516	chr6:16658617	C/T	cg22675453	chr15:52970418	KIAA1370	-0.41	-6.04	-0.32	4.2e-9	Educational attainment (years of education);
CRC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-14.66	-0.63	8.68e-38	Coronary artery disease;
CRC	cis	rs17065868	0.764	rs61949770	chr13:45024914	T/A	cg10246903	chr13:45222710	NA	0.54	5.65	0.3	3.56e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-7.65	-0.39	2.27e-13	Vitiligo;
CRC	cis	rs16852403	0.519	rs10913523	chr1:178220000	G/A	cg00404053	chr1:178313656	RASAL2	0.52	6.8	0.35	5.02e-11	Childhood ear infection;
CRC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-7.54	-0.38	4.73e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.69	11.16	0.52	9.92e-25	Breast cancer;
CRC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.8	0.35	4.83e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12024301	0.557	rs78012987	chr1:183598625	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.42	5.83	0.31	1.31e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.6	8.91	0.44	3.49e-17	Homoarginine levels;
CRC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.27	0.37	2.62e-12	Hip circumference adjusted for BMI;
CRC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.11	-0.69	2.25e-47	Body mass index;
CRC	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.5	7.36	0.38	1.5e-12	Glioblastoma;Glioma;
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.89	-0.44	4.18e-17	Alzheimer's disease;
CRC	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.74	-12.0	-0.55	9.01e-28	Pancreatic cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20357023	chr2:178417605	TTC30B	0.42	5.98	0.31	5.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9847710	0.524	rs11712910	chr3:53094194	C/A	cg15147215	chr3:52552868	STAB1	0.43	5.74	0.3	2.1e-8	Ulcerative colitis;
CRC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg00343986	chr7:65444356	GUSB	0.41	5.91	0.31	8.6e-9	Aortic root size;
CRC	trans	rs6928289	0.545	rs12207738	chr6:137674945	C/G	cg24169820	chr12:121711996	CAMKK2	-0.42	-6.17	-0.32	2.02e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6066835	1.000	rs3817991	chr20:47296365	G/C	cg18078177	chr20:47281410	PREX1	0.77	5.69	0.3	2.8e-8	Multiple myeloma;
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.44	0.46	7.01e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09329705	chr19:4909474	UHRF1	0.41	6.22	0.32	1.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.54	-7.12	-0.37	6.83e-12	Plateletcrit;
CRC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24375607	chr4:120327624	NA	-0.45	-7.21	-0.37	3.91e-12	Corneal astigmatism;
CRC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.26	-0.71	6.02e-52	Height;
CRC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.54	7.99	0.4	2.38e-14	Resting heart rate;
CRC	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs9584850	0.574	rs61969454	chr13:99170232	T/C	cg20487152	chr13:99095054	FARP1	0.42	5.6	0.3	4.44e-8	Neuroticism;
CRC	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.67	-0.35	1.09e-10	Breast cancer;
CRC	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.85	0.44	5.48e-17	Electrocardiographic conduction measures;
CRC	trans	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.18	-0.32	1.85e-9	Tuberculosis;
CRC	trans	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.26	-0.33	1.22e-9	Aortic root size;
CRC	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.57	6.36	0.33	6.65e-10	Coronary artery disease;
CRC	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.67	-5.92	-0.31	8.17e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
CRC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg06287003	chr12:125626642	AACS	-0.51	-7.05	-0.36	1.05e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.43	-0.33	4.44e-10	Bipolar disorder;
CRC	cis	rs2415984	0.622	rs10147795	chr14:46936528	C/T	cg14871534	chr14:47121158	RPL10L	-0.41	-5.96	-0.31	6.59e-9	Number of children ever born;
CRC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.5	6.87	0.35	3.23e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.510	rs17617406	chr10:82174556	C/T	cg05935833	chr10:81318306	SFTPA2	0.55	6.84	0.35	3.97e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9494145	0.680	rs4895440	chr6:135426558	A/T	cg22676075	chr6:135203613	NA	0.47	6.2	0.32	1.73e-9	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-8.25	-0.41	3.91e-15	Type 2 diabetes;
CRC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.63	0.39	2.56e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs2108622	0.727	rs62107763	chr19:15982598	T/C	cg13772218	chr19:15982569	NA	0.49	7.01	0.36	1.39e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16240137	chr5:171615938	STK10	0.42	6.32	0.33	8.37e-10	Response to antipsychotic treatment;
CRC	cis	rs7517126	1.000	rs57050675	chr1:196859544	G/A	cg13682187	chr1:196946512	CFHR5	-0.36	-5.63	-0.3	3.9e-8	Blood protein levels;
CRC	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg00852783	chr1:26633632	UBXN11	-0.49	-5.74	-0.3	2.12e-8	Obesity-related traits;
CRC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.57	8.81	0.44	7.42e-17	Asthma (sex interaction);
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.8	-0.4	8.04e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.65	10.29	0.49	1.04e-21	Colorectal cancer;
CRC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.3	-0.33	9.32e-10	Aortic root size;
CRC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.35	-5.75	-0.3	2.04e-8	Childhood ear infection;
CRC	cis	rs6969780	1.000	rs6973182	chr7:27172321	C/T	cg26364809	chr7:27145159	NA	-0.69	-6.45	-0.33	4.03e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.78	-12.43	-0.57	2.47e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.67e-14	Joint mobility (Beighton score);
CRC	cis	rs4494114	0.967	rs3814342	chr1:39325983	A/G	cg25970120	chr1:39325951	RRAGC	-0.43	-5.88	-0.31	1.02e-8	Blood protein levels;
CRC	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg02466173	chr16:30829666	NA	0.4	5.63	0.3	3.85e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.53	5.64	0.3	3.76e-8	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.14	-0.41	8.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.94	0.36	2.06e-11	Aortic root size;
CRC	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-6.6	-0.34	1.64e-10	Eosinophil percentage of white cells;
CRC	cis	rs4728142	0.604	rs10229001	chr7:128599397	C/T	cg06630958	chr7:128577819	IRF5	-0.34	-5.64	-0.3	3.74e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs17155006	0.664	rs410866	chr7:107744543	C/T	cg05962710	chr7:107745446	LAMB4	0.39	6.78	0.35	5.47e-11	Pneumococcal bacteremia;
CRC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg16060761	chr17:80687452	NA	0.45	6.53	0.34	2.45e-10	Breast cancer;
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.45	6.36	0.33	6.79e-10	Parkinson's disease;
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg20647610	chr2:228736258	WDR69	-0.5	-6.76	-0.35	6.37e-11	Blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27415969	chr3:186500848	EIF4A2	0.46	6.37	0.33	6.3e-10	Response to antipsychotic treatment;
CRC	trans	rs2797369	0.824	rs1775642	chr6:101616270	G/T	cg26346621	chr12:6873348	NA	-0.38	-6.1	-0.32	2.96e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	cis	rs12760731	0.668	rs73037529	chr1:178410203	A/T	cg00404053	chr1:178313656	RASAL2	0.95	9.79	0.47	5.03e-20	Obesity-related traits;
CRC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.92	14.82	0.63	2.04e-38	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	0.98	9.08	0.45	1.03e-17	Pulse pressure;
CRC	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg13736514	chr6:26305472	NA	-0.38	-6.25	-0.33	1.24e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.9	-0.4	4.29e-14	Resting heart rate;
CRC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-12.88	-0.58	5.11e-31	Asthma;
CRC	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg26353448	chr1:248524236	OR2T4	-0.34	-6.97	-0.36	1.72e-11	Common traits (Other);
CRC	cis	rs2415984	0.622	rs17672908	chr14:46934527	T/C	cg14871534	chr14:47121158	RPL10L	-0.44	-6.19	-0.32	1.76e-9	Number of children ever born;
CRC	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.41	-5.98	-0.31	5.84e-9	Red blood cell count;
CRC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.76e-10	Bladder cancer;
CRC	trans	rs4834770	0.746	rs2389747	chr4:120236102	C/T	cg25214090	chr10:38739885	LOC399744	0.39	6.13	0.32	2.45e-9	Blood protein levels;
CRC	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.39	6.13	0.32	2.57e-9	Recombination rate (males);
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-9.15	-0.45	6.02e-18	Neuroticism;
CRC	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.8	7.63	0.39	2.6e-13	Arsenic metabolism;
CRC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.72	-7.31	-0.37	1.99e-12	Systemic lupus erythematosus;
CRC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.91	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.5	6.32	0.33	8.58e-10	Alzheimer's disease (survival time);
CRC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.54	0.47	3.33e-19	Intelligence (multi-trait analysis);
CRC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.45	5.97	0.31	6.18e-9	Platelet distribution width;
CRC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16447950	chr5:562315	NA	-0.71	-9.55	-0.47	3.07e-19	Obesity-related traits;
CRC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.23	-0.45	3.41e-18	Triglycerides;
CRC	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg03929089	chr4:120376271	NA	-0.5	-6.03	-0.32	4.35e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11031096	0.542	rs1155146	chr11:3971020	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-6.77	-0.35	5.95e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg03037974	chr15:76606532	NA	-0.51	-7.67	-0.39	2.02e-13	Blood metabolite levels;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg05064044	chr6:292385	DUSP22	-0.58	-8.09	-0.41	1.17e-14	Menopause (age at onset);
CRC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-12.9	-0.58	4.14e-31	Blood metabolite levels;
CRC	cis	rs4664293	0.867	rs12998291	chr2:160595903	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg15147215	chr3:52552868	STAB1	0.45	7.41	0.38	1.06e-12	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26512406	chr16:28223152	XPO6	0.43	7.04	0.36	1.14e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6011002	0.590	rs1298721	chr20:62352319	T/C	cg01176363	chr20:62369445	LIME1	-0.72	-5.67	-0.3	3.18e-8	Dental caries;
CRC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.43	6.17	0.32	2.02e-9	Aortic root size;
CRC	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.41	0.53	1.27e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.4	6.49	0.34	3.11e-10	Obesity-related traits;
CRC	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.93	-0.31	7.66e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg18402987	chr7:1209562	NA	0.74	8.58	0.43	3.68e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1883415	0.750	rs2076316	chr6:24489741	A/C	cg20631270	chr6:24437470	GPLD1	0.39	5.7	0.3	2.74e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs73206853	0.563	rs9706438	chr12:111195158	A/G	cg12870014	chr12:110450643	ANKRD13A	0.73	8.42	0.42	1.19e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.72	9.78	0.47	5.4e-20	Coronary artery disease;
CRC	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg22182287	chr2:3452347	TTC15	0.38	6.06	0.32	3.71e-9	Obesity-related traits;
CRC	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.0	-18.5	-0.71	7.07e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg26162295	chr17:38119207	GSDMA	-0.34	-5.67	-0.3	3.09e-8	Myeloid white cell count;
CRC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg14829360	chr17:73884958	NA	-0.44	-7.05	-0.36	1.07e-11	Psoriasis;
CRC	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.74	11.32	0.53	2.51e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.21e-10	Obesity-related traits;
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg22110888	chr17:80059540	CCDC57	0.4	6.31	0.33	9.05e-10	Life satisfaction;
CRC	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.54	8.37	0.42	1.69e-15	Testicular germ cell tumor;
CRC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg02725872	chr8:58115012	NA	-0.37	-5.98	-0.31	5.7e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-10.67	-0.51	4.94e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.7	9.58	0.47	2.4e-19	Alzheimer's disease;
CRC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.74	11.25	0.53	4.8e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-9.73	-0.47	8e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.58	-8.44	-0.42	1.05e-15	Menarche (age at onset);
CRC	cis	rs4938330	0.608	rs2239011	chr11:117088994	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.04	-0.32	4.26e-9	Blood protein levels;
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg26304593	chr6:42947056	PEX6	-0.47	-6.83	-0.35	4.2e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg08772003	chr10:104629869	AS3MT	-0.35	-5.81	-0.31	1.47e-8	Arsenic metabolism;
CRC	trans	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.35	-0.33	6.99e-10	Aortic root size;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.35	5.84	0.31	1.27e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.07	0.32	3.58e-9	Diabetic retinopathy;
CRC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg15412446	chr2:106886593	NA	-0.5	-6.97	-0.36	1.7e-11	Facial morphology (factor 23);
CRC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.43	-6.61	-0.34	1.58e-10	Systemic lupus erythematosus;
CRC	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.62	7.97	0.4	2.59e-14	Chronic kidney disease;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg26608667	chr7:1196370	ZFAND2A	0.38	5.85	0.31	1.2e-8	Longevity;Endometriosis;
CRC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg17724175	chr1:150552817	MCL1	0.48	7.04	0.36	1.12e-11	Melanoma;
CRC	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg18683604	chr14:51561293	TRIM9	0.3	5.85	0.31	1.22e-8	Cancer;
CRC	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	0.96	16.25	0.67	5.03e-44	Dupuytren's disease;
CRC	cis	rs4731207	0.564	rs6977313	chr7:124681732	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg13844804	chr7:814759	HEATR2	0.64	8.31	0.42	2.52e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg03013999	chr17:37608204	MED1	0.45	7.03	0.36	1.2e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.31	5.97	0.31	6.06e-9	Blood metabolite levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24002213	chr7:91764177	CYP51A1	0.46	6.47	0.34	3.48e-10	Anxiety disorder;
CRC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	19.95	0.74	1.37e-58	Cognitive ability;
CRC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.59	0.6	1.12e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg03160526	chr17:80928410	B3GNTL1	0.46	6.99	0.36	1.56e-11	Breast cancer;
CRC	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg21506790	chr11:5277210	HBG2	0.35	5.87	0.31	1.07e-8	Hemoglobin levels;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg22263405	chr18:42259244	SETBP1	-0.45	-6.01	-0.31	4.96e-9	Type 1 diabetes;
CRC	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.83	-13.56	-0.6	1.37e-33	Hypospadias;
CRC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02228675	chr17:40259724	DHX58	0.48	6.82	0.35	4.27e-11	Fibrinogen levels;
CRC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.49	8.87	0.44	4.69e-17	Birth weight;
CRC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.05	-0.36	1.03e-11	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.13	0.41	8.85e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg04523069	chr9:97136363	HIATL1	0.37	5.67	0.3	3.05e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.28	0.33	1.09e-9	Diabetic kidney disease;
CRC	cis	rs7703744	0.681	rs73239280	chr5:118695579	G/A	cg23985447	chr5:118691066	TNFAIP8	0.43	6.17	0.32	1.97e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.38	7.44	0.38	8.78e-13	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg11993925	chr19:44307056	LYPD5	-0.48	-7.94	-0.4	3.2e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.74	0.3	2.17e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg05501817	chr11:14380813	RRAS2	-0.47	-6.51	-0.34	2.8e-10	Sense of smell;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-9.49	-0.46	4.98e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17095355	1.000	rs12263484	chr10:111697255	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.62	-9.12	-0.45	7.4e-18	Biliary atresia;
CRC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.51	-8.69	-0.43	1.69e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.79	6.22	0.32	1.51e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1891275	0.515	rs4244930	chr10:93466849	T/C	cg07889827	chr10:93443413	NA	-0.39	-6.45	-0.33	4.1e-10	Intelligence (multi-trait analysis);
CRC	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-7.01	-0.36	1.4e-11	Opioid sensitivity;
CRC	cis	rs17443541	0.507	rs6711524	chr2:200462940	T/C	cg03741458	chr2:200468445	NA	-0.37	-5.85	-0.31	1.18e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.52	-8.37	-0.42	1.72e-15	Type 2 diabetes;
CRC	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	5.77	0.3	1.86e-8	Longevity;
CRC	cis	rs972578	0.837	rs5758980	chr22:43243956	T/C	cg01576275	chr22:43409880	NA	-0.39	-6.1	-0.32	2.95e-9	Mean platelet volume;
CRC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-7.23	-0.37	3.41e-12	Alzheimer's disease (late onset);
CRC	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.2	18.64	0.72	2.04e-53	Atopic dermatitis;
CRC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.57	-6.94	-0.36	2.14e-11	Body mass index (adult);
CRC	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04146151	chr16:2155961	PKD1	-0.6	-8.07	-0.41	1.34e-14	Triglycerides;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg02683197	chr6:28174875	NA	0.61	8.77	0.44	9.69e-17	Parkinson's disease;
CRC	cis	rs10991814	1.000	rs79808025	chr9:93953419	C/A	cg14446406	chr9:93919335	NA	0.55	6.39	0.33	5.67e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-16.0	-0.66	5.1e-43	Primary sclerosing cholangitis;
CRC	cis	rs6968419	0.755	rs1141470	chr7:115898442	G/C	cg02561103	chr7:115862891	TES	-0.44	-6.61	-0.34	1.58e-10	Intraocular pressure;
CRC	trans	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg18288967	chr1:45987694	PRDX1	0.63	7.35	0.38	1.57e-12	Obesity-related traits;
CRC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.05	10.89	0.51	8.72e-24	Diabetic retinopathy;
CRC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.51	-7.28	-0.37	2.49e-12	Huntington's disease progression;
CRC	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.45	-6.55	-0.34	2.22e-10	Platelet distribution width;
CRC	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg00376283	chr12:123451042	ABCB9	0.54	7.08	0.36	8.54e-12	Neutrophil percentage of white cells;
CRC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg23815491	chr16:72088622	HP	0.49	7.37	0.38	1.37e-12	Fibrinogen levels;
CRC	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg04586622	chr2:25135609	ADCY3	-0.57	-9.76	-0.47	6.17e-20	Body mass index;
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg06494592	chr3:125709126	NA	-0.55	-6.72	-0.35	7.91e-11	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.42	9.14	0.45	6.65e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.56	6.47	0.34	3.49e-10	Menarche (age at onset);
CRC	cis	rs9903692	0.954	rs875066	chr17:46139732	T/G	cg10706073	chr17:46328419	SKAP1	-0.42	-5.68	-0.3	3.03e-8	Pulse pressure;
CRC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.51	7.22	0.37	3.6e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg18876405	chr7:65276391	NA	0.45	6.37	0.33	6.41e-10	Aortic root size;
CRC	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg02574844	chr11:5959923	NA	0.35	5.64	0.3	3.64e-8	DNA methylation (variation);
CRC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.75	8.68	0.43	1.88e-16	Eosinophilic esophagitis;
CRC	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg09659197	chr4:152720779	NA	0.52	10.89	0.51	8.52e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.76	11.92	0.55	1.74e-27	Multiple myeloma;
CRC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg16606324	chr3:10149918	C3orf24	0.7	9.74	0.47	7.03e-20	Alzheimer's disease;
CRC	cis	rs9992667	0.664	rs112691446	chr4:38665142	G/A	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.02	-0.45	1.62e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.7	0.54	1.1e-26	Prudent dietary pattern;
CRC	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.77	14.36	0.62	1.2e-36	Hip circumference;
CRC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.62	0.39	2.81e-13	Parkinson's disease;
CRC	cis	rs16975963	0.644	rs73035158	chr19:38141880	C/A	cg15135657	chr19:38346511	NA	-0.46	-6.4	-0.33	5.33e-10	Longevity;
CRC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.44	8.94	0.44	2.81e-17	Renal cell carcinoma;
CRC	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.45	6.74	0.35	7.24e-11	Insulin-like growth factors;
CRC	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.61	7.32	0.37	1.88e-12	Carotid intima media thickness;
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.97	-0.36	1.78e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12580194	1.000	rs7971451	chr12:55699950	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-8.42	-0.42	1.18e-15	Cancer;
CRC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08144172	chr1:41849203	NA	0.34	5.65	0.3	3.41e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.47	9.07	0.45	1.1e-17	Educational attainment (years of education);
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24034453	chr17:17597825	RAI1	0.44	6.19	0.32	1.82e-9	Response to antipsychotic treatment;
CRC	cis	rs6141769	0.518	rs6057631	chr20:31319149	A/G	cg13636640	chr20:31349939	DNMT3B	-0.4	-5.9	-0.31	8.93e-9	Subjective well-being;
CRC	cis	rs7178572	0.633	rs12900004	chr15:77844904	A/G	cg22256960	chr15:77711686	NA	-0.62	-9.22	-0.45	3.72e-18	Type 2 diabetes;
CRC	cis	rs4731207	0.672	rs66823127	chr7:124472329	G/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg18016565	chr1:150552671	MCL1	-0.48	-7.19	-0.37	4.3e-12	Tonsillectomy;
CRC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.44	-8.85	-0.44	5.53e-17	Renal cell carcinoma;
CRC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg02018176	chr4:1364513	KIAA1530	0.4	5.74	0.3	2.15e-8	Obesity-related traits;
CRC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.39	0.46	1.01e-18	Alcohol dependence;
CRC	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14019695	chr9:139328340	INPP5E	0.4	5.88	0.31	1.02e-8	Monocyte percentage of white cells;
CRC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.73	0.43	1.26e-16	Morning vs. evening chronotype;
CRC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg23229984	chr5:148520753	ABLIM3	0.54	7.02	0.36	1.3e-11	Breast cancer;
CRC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.45	0.62	5.37e-37	Platelet count;
CRC	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg23378565	chr7:2036160	MAD1L1	-0.4	-5.65	-0.3	3.48e-8	Neuroticism;
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg15790184	chr11:494944	RNH1	0.61	6.24	0.33	1.35e-9	Body mass index;
CRC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.51	8.45	0.42	9.35e-16	Major depressive disorder;
CRC	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.73	-0.35	7.64e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.58	7.39	0.38	1.24e-12	Diisocyanate-induced asthma;
CRC	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	25.47	0.81	8.58e-80	Schizophrenia;
CRC	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.73	-12.68	-0.57	2.75e-30	Bipolar disorder;
CRC	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.68	-9.19	-0.45	4.55e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg12306414	chr4:13549355	LOC285548	0.38	6.93	0.36	2.2e-11	Hip circumference;
CRC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	5.67	0.3	3.06e-8	Coronary artery disease;
CRC	trans	rs1035491	0.720	rs10940001	chr5:63960187	C/T	cg08645400	chr16:49307062	NA	0.35	6.18	0.32	1.88e-9	Body mass index;
CRC	cis	rs6496667	0.779	rs2283441	chr15:90970781	G/A	cg04176472	chr15:90893244	GABARAPL3	0.6	8.46	0.42	8.66e-16	Rheumatoid arthritis;
CRC	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.9e-16	Educational attainment;
CRC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.28	-0.46	2.28e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg00666640	chr1:248458726	OR2T12	0.39	7.18	0.37	4.69e-12	Common traits (Other);
CRC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.44	6.45	0.33	4.09e-10	Menopause (age at onset);
CRC	cis	rs10208940	0.614	rs7569174	chr2:68735336	G/T	cg12452813	chr2:68675892	NA	0.47	5.81	0.31	1.44e-8	Urate levels in lean individuals;
CRC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.51	7.72	0.39	1.44e-13	Aortic root size;
CRC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-9.51	-0.46	4.13e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs939584	1.000	rs7561317	chr2:644953	A/G	cg03610516	chr2:642275	NA	0.41	5.71	0.3	2.51e-8	Body mass index;
CRC	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.06	-0.71	3.7e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.12	-0.32	2.73e-9	Blood protein levels;
CRC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06634786	chr22:41940651	POLR3H	-0.44	-5.92	-0.31	8.23e-9	Vitiligo;
CRC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.56	0.43	4.47e-16	Homoarginine levels;
CRC	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg10382835	chr6:42185730	MRPS10	0.66	6.5	0.34	2.92e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
CRC	cis	rs863345	0.604	rs12041350	chr1:158482048	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	1.04e-9	Pneumococcal bacteremia;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg12172441	chr6:28176163	NA	0.6	6.56	0.34	2.1e-10	Parkinson's disease;
CRC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.08	0.36	8.64e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.16e-9	Pneumonia;
CRC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Melanoma;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg10973622	chr2:86423274	IMMT	0.27	5.61	0.3	4.27e-8	Night sleep phenotypes;
CRC	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.9	0.63	1.01e-38	Hypertriglyceridemia;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.84	-11.95	-0.55	1.34e-27	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg03233332	chr7:66118400	NA	-0.43	-5.87	-0.31	1.05e-8	Aortic root size;
CRC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.07	0.55	4.98e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	16.78	0.68	4.33e-46	Platelet count;
CRC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.82	14.59	0.63	1.64e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg04110750	chr16:69646130	NFAT5	-0.58	-7.98	-0.4	2.46e-14	IgE levels;
CRC	cis	rs4654899	0.897	rs7515308	chr1:21085653	G/C	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.7	-0.35	9.19e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.62	-0.3	4.18e-8	Schizophrenia;
CRC	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.39	0.46	1.05e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg23018236	chr17:30244563	NA	-0.45	-6.09	-0.32	3.17e-9	Hip circumference adjusted for BMI;
CRC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.84	0.31	1.23e-8	Lung cancer;
CRC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg14008862	chr17:28927542	LRRC37B2	0.56	5.82	0.31	1.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.26	-0.56	1.03e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg27205649	chr11:78285834	NARS2	0.51	6.59	0.34	1.77e-10	Alzheimer's disease (survival time);
CRC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.72	12.79	0.58	1.13e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6728642	0.519	rs4260285	chr2:97570081	A/G	cg26665480	chr2:98280029	ACTR1B	-0.55	-5.96	-0.31	6.47e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.83	0.35	4.22e-11	Mean platelet volume;
CRC	cis	rs59104589	0.550	rs62193172	chr2:242277715	G/C	cg19488206	chr2:242435732	STK25	0.47	6.66	0.34	1.18e-10	Fibrinogen levels;
CRC	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	7.44	0.38	8.7e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.94	0.36	2.07e-11	Resting heart rate;
CRC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.51	-7.96	-0.4	2.8e-14	Breast size;
CRC	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.39	-5.6	-0.3	4.51e-8	Ovarian reserve;
CRC	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg18646521	chr2:111875858	NA	0.38	6.04	0.32	4.23e-9	Chronic lymphocytic leukemia;
CRC	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	18.55	0.71	4.52e-53	Colorectal cancer;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg19193384	chr17:30244184	NA	-0.6	-6.01	-0.31	4.96e-9	Height;
CRC	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg22732515	chr19:44031385	ETHE1	0.7	10.69	0.51	4.19e-23	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.35	6.12	0.32	2.71e-9	Rheumatoid arthritis;
CRC	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	cg04338863	chr8:33670619	NA	-0.38	-6.43	-0.33	4.43e-10	Body mass index;
CRC	cis	rs1656402	0.906	rs1656401	chr2:233426601	A/G	cg03852847	chr2:233439513	NA	0.45	7.66	0.39	2.1e-13	Non-small cell lung cancer (survival);
CRC	cis	rs11229555	0.645	rs34350060	chr11:58184902	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.49	-9.22	-0.45	3.54e-18	Reticulocyte fraction of red cells;
CRC	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.93	-11.3	-0.53	2.98e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.97	-0.4	2.65e-14	Life satisfaction;
CRC	cis	rs6700896	0.897	rs28480230	chr1:66124075	C/T	cg04111102	chr1:66153794	NA	0.34	5.94	0.31	7.36e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.63e-9	Bipolar disorder;
CRC	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg05623727	chr3:50126028	RBM5	0.51	6.51	0.34	2.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.54	8.69	0.43	1.79e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4731207	0.623	rs719973	chr7:124631727	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.34	-0.33	7.73e-10	Cutaneous malignant melanoma;
CRC	trans	rs11654801	0.812	rs9914432	chr17:20857356	T/C	cg23759823	chr7:139672531	TBXAS1	-0.4	-6.41	-0.33	5.1e-10	Mosquito bite size;
CRC	trans	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.89	0.36	2.76e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg23461800	chr14:103021989	NA	0.69	7.76	0.39	1.08e-13	Platelet count;
CRC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.56	-8.73	-0.43	1.33e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.57	7.65	0.39	2.26e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12541635	0.966	rs12681183	chr8:107007156	T/A	cg10147462	chr8:107024639	NA	0.42	6.92	0.36	2.42e-11	Age of smoking initiation;
CRC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg18761221	chr20:60518478	NA	0.48	7.82	0.4	7.11e-14	Body mass index;
CRC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.52	-0.38	5.11e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg04025307	chr7:1156635	C7orf50	0.65	7.37	0.38	1.39e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	cis	rs7605827	0.930	rs3815597	chr2:15625404	T/C	cg19274914	chr2:15703543	NA	0.39	6.01	0.31	5e-9	Educational attainment (years of education);
CRC	cis	rs2108622	0.527	rs67617968	chr19:15977565	A/G	cg13772218	chr19:15982569	NA	0.39	5.66	0.3	3.22e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7703744	0.634	rs6884061	chr5:118683431	C/T	cg17471836	chr5:118691007	TNFAIP8	0.45	6.46	0.34	3.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.57e-10	Life satisfaction;
CRC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.68	10.13	0.49	3.68e-21	Corneal astigmatism;
CRC	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg11887960	chr12:57824829	NA	0.6	6.48	0.34	3.28e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg12756093	chr1:115239321	AMPD1	0.57	8.52	0.42	6.02e-16	Autism;
CRC	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-11.17	-0.52	8.64e-25	Exhaled nitric oxide levels;
CRC	cis	rs17065868	0.764	rs12146917	chr13:45035759	T/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.84	-0.35	3.76e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.08	0.52	1.79e-24	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg17724175	chr1:150552817	MCL1	-0.52	-8.42	-0.42	1.16e-15	Tonsillectomy;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg01801182	chr1:46998715	NA	0.34	5.97	0.31	6.16e-9	Depressive symptom measurement or major depressive disorder;
CRC	trans	rs701145	0.556	rs355762	chr3:154012614	G/A	cg22545385	chr10:131989303	NA	-0.42	-6.05	-0.32	3.99e-9	Coronary artery disease;
CRC	cis	rs4664293	0.625	rs62171641	chr2:160516505	G/A	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06544989	chr22:39130855	UNC84B	0.44	6.41	0.33	5.17e-10	Menopause (age at onset);
CRC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.81	0.4	7.88e-14	Resting heart rate;
CRC	cis	rs1971762	0.527	rs784568	chr12:53927554	C/A	cg06632207	chr12:54070931	ATP5G2	-0.49	-8.28	-0.42	3.18e-15	Height;
CRC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.52	7.21	0.37	3.82e-12	Schizophrenia;
CRC	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.68	-0.35	1.05e-10	Breast cancer;
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.36	-5.9	-0.31	9.13e-9	Total body bone mineral density;
CRC	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.53	9.08	0.45	1e-17	Dupuytren's disease;
CRC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg24881330	chr22:46731750	TRMU	0.69	6.63	0.34	1.36e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4664293	1.000	rs10184034	chr2:160505427	A/G	cg08347373	chr2:160653686	CD302	-0.38	-6.24	-0.33	1.38e-9	Monocyte percentage of white cells;
CRC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.36	-7.63	-0.39	2.48e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.66	11.79	0.54	5.41e-27	Height;
CRC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.59	10.69	0.51	4.17e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4700695	0.764	rs10066817	chr5:65319853	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.99	0.36	1.58e-11	Facial morphology (factor 19);
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	0.81	7.36	0.38	1.51e-12	IgG glycosylation;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg24046110	chr8:143859143	LYNX1	-0.43	-6.55	-0.34	2.2e-10	Urinary tract infection frequency;
CRC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-12.02	-0.55	7.44e-28	Asthma;
CRC	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.82	-0.4	7.31e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg17226575	chr8:90914282	OSGIN2	-0.43	-6.08	-0.32	3.24e-9	Energy expenditure (24h);
CRC	cis	rs9463078	0.774	rs7740083	chr6:45274742	G/A	cg25276700	chr6:44698697	NA	-0.28	-6.77	-0.35	5.75e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg21466736	chr12:48725269	NA	0.47	7.17	0.37	5.03e-12	Glycated hemoglobin levels;
CRC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.68	-9.65	-0.47	1.43e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.07	-0.49	5.66e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.51	8.63	0.43	2.68e-16	Dupuytren's disease;
CRC	cis	rs4660214	0.568	rs6692769	chr1:39683175	G/C	cg11070191	chr1:39582205	MACF1	0.36	5.77	0.3	1.86e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.66	8.64	0.43	2.54e-16	Gestational age at birth (maternal effect);
CRC	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.61	-0.3	4.36e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	0.97	19.76	0.74	7.37e-58	Myeloid white cell count;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.52	7.84	0.4	6.21e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.65	7.41	0.38	1.09e-12	Body mass index;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs4731207	0.596	rs12055904	chr7:124662864	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.77e-9	Cutaneous malignant melanoma;
CRC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.21	0.32	1.63e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.79	-16.14	-0.66	1.48e-43	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.72	-9.85	-0.48	3.12e-20	Gut microbiome composition (summer);
CRC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg19812747	chr11:111475976	SIK2	-0.56	-9.53	-0.46	3.7e-19	Primary sclerosing cholangitis;
CRC	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.38	5.72	0.3	2.39e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.59	9.23	0.45	3.46e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	9.08	0.45	1.01e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.86	15.89	0.66	1.36e-42	Hip circumference;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02738677	chr3:133265129	NA	-0.4	-6.19	-0.32	1.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg00074818	chr8:8560427	CLDN23	-0.39	-7.1	-0.36	7.73e-12	Obesity-related traits;
CRC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.71	0.35	8.75e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg06470822	chr6:28175283	NA	1.04	16.0	0.66	4.91e-43	Depression;
CRC	cis	rs6586163	0.872	rs7082720	chr10:90742049	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.08	-0.36	8.67e-12	Chronic lymphocytic leukemia;
CRC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18043075	chr10:115933939	MIR2110;C10orf118	0.45	6.24	0.33	1.36e-9	Anxiety disorder;
CRC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.65	0.54	1.78e-26	Bone mineral density;
CRC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.48	-7.07	-0.36	9.05e-12	Lymphocyte counts;
CRC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg06494592	chr3:125709126	NA	-0.58	-6.85	-0.35	3.57e-11	Blood pressure (smoking interaction);
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg26304593	chr6:42947056	PEX6	-0.44	-6.25	-0.33	1.26e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg21770322	chr7:97807741	LMTK2	-0.56	-8.3	-0.42	2.78e-15	Breast cancer;
CRC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.62	-7.69	-0.39	1.68e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.82	11.02	0.52	3.07e-24	Cerebrospinal P-tau181p levels;
CRC	cis	rs4594175	0.926	rs10138345	chr14:51624651	A/G	cg23942311	chr14:51606299	NA	0.64	9.71	0.47	9.35e-20	Cancer;
CRC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.19	-0.41	5.96e-15	Type 2 diabetes;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg18301423	chr5:131593218	PDLIM4	0.31	5.68	0.3	2.9e-8	Blood metabolite levels;
CRC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.42	-8.05	-0.41	1.56e-14	Ulcerative colitis;
CRC	cis	rs72730918	0.590	rs1378894	chr15:51937462	G/A	cg14296394	chr15:51910925	DMXL2	-0.47	-6.32	-0.33	8.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg02903104	chr8:1507517	DLGAP2	0.42	8.04	0.41	1.6e-14	Lung cancer;
CRC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.88	11.07	0.52	2.05e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.69	-0.39	1.68e-13	Hemoglobin concentration;
CRC	cis	rs356992	0.957	rs356993	chr2:60750560	C/T	cg08426369	chr2:60753602	BCL11A	-0.55	-7.55	-0.38	4.3e-13	Educational attainment (years of education);
CRC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg17724175	chr1:150552817	MCL1	0.4	6.19	0.32	1.75e-9	Melanoma;
CRC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.03	0.48	7.59e-21	Systolic blood pressure;
CRC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg13844804	chr7:814759	HEATR2	0.65	8.47	0.42	8.48e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.24	0.33	1.35e-9	IgG glycosylation;
CRC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg03732007	chr1:2071316	PRKCZ	-0.36	-5.75	-0.3	2e-8	Height;
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg24505167	chr7:1915268	MAD1L1	-0.4	-5.62	-0.3	4.18e-8	Bipolar disorder;
CRC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.44	6.16	0.32	2.06e-9	Eye color traits;
CRC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-0.88	-13.85	-0.61	1.13e-34	Urate levels;
CRC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.43	-6.0	-0.31	5.3300000000000004e-09	Lymphocyte counts;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg15786705	chr6:28176104	NA	0.48	6.42	0.33	4.89e-10	Parkinson's disease;
CRC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.69	-10.82	-0.51	1.53e-23	Height;
CRC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.04	-0.32	4.2e-9	Vitiligo;
CRC	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.76	-0.39	1.06e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs17767392	1.000	rs34746156	chr14:71752360	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.68	-0.35	1e-10	Mitral valve prolapse;
CRC	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-7.5	-0.38	6.15e-13	Vitamin D levels;
CRC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.38	-7.23	-0.37	3.34e-12	Ulcerative colitis;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.38	-8.93	-0.44	3.04e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.59	10.69	0.51	4.15e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg18335740	chr13:41363409	SLC25A15	0.5	7.84	0.4	6.23e-14	Lewy body disease;
CRC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-6.98	-0.36	1.65e-11	Total body bone mineral density;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.69	0.35	9.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.69	8.09	0.41	1.15e-14	Eotaxin levels;
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.08	-0.32	3.29e-9	Total body bone mineral density;
CRC	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-8.03	-0.4	1.73e-14	HDL cholesterol;
CRC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.9	0.58	4.48e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg19673125	chr6:150240577	RAET1G	0.3	5.85	0.31	1.17e-8	Testicular germ cell tumor;
CRC	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.43	6.12	0.32	2.61e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04004882	chr2:215674386	BARD1	0.61	7.49	0.38	6.45e-13	Neuroblastoma;
CRC	cis	rs4664293	0.625	rs6432543	chr2:160495331	C/A	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs6969780	1.000	rs6976129	chr7:27177746	C/T	cg26364809	chr7:27145159	NA	-0.73	-6.82	-0.35	4.39e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.44	7.65	0.39	2.27e-13	HDL cholesterol;
CRC	trans	rs7868992	0.515	rs902496	chr9:116989776	G/T	cg10545682	chr1:151512625	TUFT1	0.53	6.09	0.32	3.08e-9	Tourette syndrome;
CRC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.69	10.77	0.51	2.2e-23	Mean corpuscular hemoglobin;
CRC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.68	0.39	1.9e-13	Menopause (age at onset);
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg26587870	chr6:27730563	NA	-0.48	-7.15	-0.37	5.58e-12	Parkinson's disease;
CRC	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.31	-0.33	9.13e-10	Systemic lupus erythematosus;
CRC	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.46	-5.61	-0.3	4.34e-8	Hip geometry;
CRC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.22e-11	Morning vs. evening chronotype;
CRC	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg10756647	chr7:56101905	PSPH	0.75	7.81	0.4	7.97e-14	Gout;
CRC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.35	0.42	1.86e-15	Lymphocyte counts;
CRC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg03013636	chr16:1946785	NA	-0.38	-5.64	-0.3	3.74e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.66	9.68	0.47	1.16e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs17133277	0.702	rs56175518	chr7:3493365	A/G	cg25123566	chr12:47610734	FAM113B;LOC100233209	-0.51	-5.97	-0.31	6.21e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.44	6.72	0.35	8.18e-11	Hemoglobin concentration;
CRC	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg23425280	chr12:56401806	NA	-0.46	-5.71	-0.3	2.49e-8	Cancer;
CRC	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg00850481	chr1:228891306	NA	-0.42	-6.43	-0.33	4.4e-10	Chronic lymphocytic leukemia;
CRC	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.66	-10.17	-0.49	2.69e-21	Dilated cardiomyopathy;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg02570644	chr16:68123248	NFATC3	-0.51	-6.24	-0.33	1.36e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg15845792	chr6:28175446	NA	0.83	10.65	0.51	5.91e-23	Parkinson's disease;
CRC	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.41	5.61	0.3	4.35e-8	Breast cancer;
CRC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.46	-6.71	-0.35	8.75e-11	Uric acid clearance;
CRC	cis	rs7215564	0.908	rs2340770	chr17:78754770	T/C	cg09596252	chr17:78655493	RPTOR	-0.58	-6.1	-0.32	3.01e-9	Myopia (pathological);
CRC	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg15192750	chr16:69999425	NA	0.56	7.54	0.38	4.63e-13	IgE levels;
CRC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.79	14.04	0.61	2.04e-35	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs73206853	0.841	rs73191818	chr12:110918721	T/G	cg12870014	chr12:110450643	ANKRD13A	0.75	8.02	0.4	1.88e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06416885	chr4:100009900	ADH5	0.49	6.91	0.36	2.59e-11	Anxiety disorder;
CRC	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.53	0.46	3.72e-19	Ileal carcinoids;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.8e-9	Aortic root size;
CRC	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.58	7.93	0.4	3.35e-14	Coronary artery disease;
CRC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.45	-6.96	-0.36	1.88e-11	Psychosis in Alzheimer's disease;
CRC	cis	rs7605827	0.930	rs7577436	chr2:15528281	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.03e-9	Educational attainment (years of education);
CRC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.46	-6.76	-0.35	6.33e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.53	-9.59	-0.47	2.33e-19	Glycated hemoglobin levels;
CRC	cis	rs863345	0.967	rs10908681	chr1:158522712	C/T	cg12129480	chr1:158549410	OR10X1	-0.26	-5.68	-0.3	2.93e-8	Pneumococcal bacteremia;
CRC	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.96	-17.41	-0.69	1.42e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg01304814	chr3:48885189	PRKAR2A	0.86	6.24	0.33	1.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.41	5.61	0.3	4.22e-8	Protein C levels;
CRC	cis	rs9287719	0.649	rs12476554	chr2:10727747	A/G	cg00105475	chr2:10696890	NA	0.46	7.17	0.37	4.93e-12	Prostate cancer;
CRC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.07	12.57	0.57	7.19e-30	Sexual dysfunction (female);
CRC	cis	rs728616	0.702	rs78734698	chr10:81756449	G/A	cg05935833	chr10:81318306	SFTPA2	-0.77	-8.15	-0.41	7.96e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.5	6.72	0.35	7.91e-11	Caudate activity during reward;
CRC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.43	-6.55	-0.34	2.24e-10	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9322817	1.000	rs6942231	chr6:105191814	C/T	cg02098413	chr6:105308735	HACE1	-0.35	-6.5	-0.34	3.05e-10	Thyroid stimulating hormone;
CRC	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg11946769	chr3:48343235	NME6	-0.44	-5.88	-0.31	1.02e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02725872	chr8:58115012	NA	-0.59	-9.18	-0.45	4.97e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs1933755	0.614	rs6569692	chr6:130924488	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.79	6.0	0.31	5.35e-9	Colorectal cancer (calcium intake interaction);
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.83e-9	Life satisfaction;
CRC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-13.9	-0.61	6.86e-35	Gut microbiome composition (summer);
CRC	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-22.19	-0.77	2.39e-67	Exhaled nitric oxide levels;
CRC	cis	rs629535	0.734	rs542288	chr8:70057149	G/T	cg26132723	chr8:70041827	NA	-0.36	-5.92	-0.31	8.01e-9	Dupuytren's disease;
CRC	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg03418659	chr16:31128414	MYST1	0.44	6.5	0.34	3.05e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12826942	0.605	rs17801478	chr12:42481545	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	6.99	0.36	1.5e-11	Coronary artery disease;
CRC	cis	rs753955	0.592	rs1324972	chr13:24348159	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.4	5.61	0.3	4.3e-8	Lung cancer;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.71	12.11	0.56	3.71e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.46	6.71	0.35	8.61e-11	Emphysema distribution in smoking;
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg21155852	chr7:2048760	MAD1L1	0.47	6.42	0.33	4.78e-10	Bipolar disorder;
CRC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg15445000	chr17:37608096	MED1	-0.35	-6.12	-0.32	2.59e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.61	-7.69	-0.39	1.72e-13	Obesity (extreme);
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.41	6.45	0.34	4e-10	Electroencephalogram traits;
CRC	trans	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.94	0.36	2.07e-11	Mean corpuscular volume;
CRC	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg05784532	chr1:230284198	GALNT2	0.43	5.91	0.31	8.48e-9	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06588201	chr4:174430487	NA	0.22	6.19	0.32	1.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17270561	0.636	rs10946793	chr6:25699999	A/G	cg16482183	chr6:26056742	HIST1H1C	0.72	8.72	0.43	1.37e-16	Iron status biomarkers;
CRC	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.84	-0.4	6.46e-14	Multiple myeloma (hyperdiploidy);
CRC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	0.92	11.22	0.53	6.11e-25	Red blood cell traits;
CRC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg12365402	chr11:9010492	NRIP3	0.46	7.32	0.37	1.94e-12	Hemoglobin concentration;
CRC	trans	rs7314326	0.771	rs10771049	chr12:24121630	A/G	cg12543219	chr10:135016451	KNDC1	0.29	6.03	0.32	4.34e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14901232	chr18:74208357	NA	0.36	6.01	0.31	4.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1524976	1.000	rs4688570	chr3:65466168	G/C	cg16238336	chr3:65465873	MAGI1	0.49	7.2	0.37	4.23e-12	PR interval;
CRC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.48	-6.54	-0.34	2.31e-10	Renal function-related traits (BUN);
CRC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg23533926	chr12:111358616	MYL2	-0.5	-7.56	-0.38	4.1e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.08	-0.32	3.3e-9	Aortic root size;
CRC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.13	22.78	0.78	1.32e-69	Schizophrenia;
CRC	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg00277334	chr10:82204260	NA	0.37	5.83	0.31	1.31e-8	Sarcoidosis;
CRC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.44	6.88	0.35	3.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.83	-0.44	6.21e-17	Aortic root size;
CRC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.46	-6.91	-0.36	2.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs10200346	chr2:15635728	A/C	cg19274914	chr2:15703543	NA	0.39	6.0	0.31	5.1e-9	Educational attainment (years of education);
CRC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg11189052	chr15:85197271	WDR73	0.63	8.96	0.44	2.47e-17	Schizophrenia;
CRC	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg23750338	chr8:142222470	SLC45A4	-0.42	-5.79	-0.3	1.62e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	trans	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg20935933	chr6:143382018	AIG1	0.52	6.73	0.35	7.38e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20092199	chr4:1342459	KIAA1530	0.41	7.61	0.39	2.85e-13	Obesity-related traits;
CRC	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-9.12	-0.45	7.69e-18	Fuchs's corneal dystrophy;
CRC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	6.42	0.33	4.72e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6694672	1.000	rs1576877	chr1:197047639	A/G	cg13682187	chr1:196946512	CFHR5	0.55	8.15	0.41	7.57e-15	Asthma;
CRC	cis	rs7703744	0.681	rs73239278	chr5:118695051	G/A	cg02283238	chr5:118691126	TNFAIP8	0.47	6.41	0.33	4.98e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.58	7.35	0.38	1.56e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.01	0.64	3.66e-39	Colorectal cancer;
CRC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.31	-0.33	9.14e-10	Aortic root size;
CRC	cis	rs245880	0.740	rs245887	chr7:29190408	G/A	cg17163760	chr7:29186267	CPVL	-0.39	-6.73	-0.35	7.63e-11	Warfarin maintenance dose;
CRC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.45	6.26	0.33	1.21e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.5	-6.57	-0.34	1.94e-10	Menarche (age at onset);
CRC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg05623727	chr3:50126028	RBM5	-0.46	-7.62	-0.39	2.67e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.63e-9	Bipolar disorder;
CRC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg26061582	chr7:22766209	IL6	0.52	8.23	0.41	4.41e-15	Lung cancer;
CRC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg07561610	chr6:149771807	ZC3H12D	-0.31	-5.72	-0.3	2.34e-8	Dupuytren's disease;
CRC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.23e-9	Obesity-related traits;
CRC	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.62	9.17	0.45	5.2e-18	Morning vs. evening chronotype;
CRC	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.69	9.03	0.45	1.51e-17	Uric acid levels;
CRC	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.83	-10.55	-0.5	1.33e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg01941586	chr1:40203715	PPIE	-0.43	-5.9	-0.31	8.94e-9	Blood protein levels;
CRC	cis	rs7086803	1.000	rs7075671	chr10:114501685	A/G	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	trans	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg20935933	chr6:143382018	AIG1	0.5	6.46	0.34	3.66e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg15848620	chr12:58087721	OS9	-0.44	-6.17	-0.32	1.97e-9	Multiple sclerosis;
CRC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.46	-7.2	-0.37	4.21e-12	Breast cancer;
CRC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.93	14.16	0.62	7.07e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.54	7.75	0.39	1.18e-13	Obesity-related traits;
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.88	-0.44	4.3e-17	Bipolar disorder;
CRC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.6	8.95	0.44	2.68e-17	Lung cancer;
CRC	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	6.1	0.32	3.01e-9	Asthma;
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg10729496	chr3:10149963	C3orf24	0.5	6.64	0.34	1.28e-10	Alzheimer's disease;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg09877947	chr5:131593287	PDLIM4	0.35	6.41	0.33	5.14e-10	Blood metabolite levels;
CRC	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg19052272	chr2:3704530	ALLC	-0.47	-6.04	-0.32	4.11e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg15147215	chr3:52552868	STAB1	-0.54	-9.36	-0.46	1.28e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.98	-0.44	2.08e-17	Bipolar disorder;
CRC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	5.95	0.31	6.69e-9	Coronary artery disease;
CRC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.47	-7.61	-0.39	3.01e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg23625390	chr15:77176239	SCAPER	0.48	6.83	0.35	4.16e-11	Blood metabolite levels;
CRC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg02772935	chr3:125709198	NA	0.48	5.63	0.3	3.86e-8	Blood pressure (smoking interaction);
CRC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.37	0.5	5.43e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	5.99	0.31	5.39e-9	Diabetic retinopathy;
CRC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg23463467	chr20:60627584	TAF4	0.34	5.92	0.31	8.12e-9	Body mass index;
CRC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg26566898	chr11:117069891	TAGLN	-0.31	-6.55	-0.34	2.2e-10	Blood protein levels;
CRC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg08975724	chr8:8085496	FLJ10661	0.41	6.11	0.32	2.85e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.53	13.61	0.6	8.65e-34	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7725052	0.609	rs10941509	chr5:40462358	A/G	cg09067459	chr5:40385259	NA	-0.46	-7.58	-0.39	3.61e-13	Pediatric autoimmune diseases;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25490411	chr4:103681941	MANBA	0.5	7.13	0.37	6.53e-12	Response to antipsychotic treatment;
CRC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.69	0.3	2.8e-8	Neuroticism;
CRC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-14.74	-0.63	4.01e-38	Lymphocyte percentage of white cells;
CRC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.57	0.34	2.02e-10	Morning vs. evening chronotype;
CRC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.03	-0.4	1.76e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.46	6.78	0.35	5.42e-11	Melanoma;
CRC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg24253500	chr15:84953950	NA	0.38	6.49	0.34	3.23e-10	Schizophrenia;
CRC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.36	-6.78	-0.35	5.57e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08932106	chr10:23003259	PIP4K2A	0.47	6.52	0.34	2.6e-10	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19418924	chr11:2951659	PHLDA2	0.41	6.05	0.32	3.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.25	0.33	1.24e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.93	-0.31	7.83e-9	Red blood cell count;
CRC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.76	-11.26	-0.53	4.29e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.09e-22	Prudent dietary pattern;
CRC	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg01843034	chr6:37503916	NA	-0.39	-7.19	-0.37	4.31e-12	Cognitive performance;
CRC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.32	0.53	2.69e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.98	14.61	0.63	1.29e-37	Breast cancer;
CRC	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.49	-9.0	-0.44	1.87e-17	Common traits (Other);
CRC	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.54	7.25	0.37	2.97e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.37	5.68	0.3	2.96e-8	Joint mobility (Beighton score);
CRC	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg05935833	chr10:81318306	SFTPA2	-0.75	-8.24	-0.41	4.17e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg27427491	chr17:78079615	GAA	-0.36	-5.81	-0.3	1.51e-8	Yeast infection;
CRC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.58	8.92	0.44	3.42e-17	Vitiligo;
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.55	6.73	0.35	7.66e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.38	5.8	0.3	1.52e-8	Menarche (age at onset);
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg06494592	chr3:125709126	NA	-0.53	-6.78	-0.35	5.74e-11	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.28	5.64	0.3	3.66e-8	Lung cancer;
CRC	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg25182066	chr10:30743637	MAP3K8	-0.54	-7.27	-0.37	2.71e-12	Itch intensity from mosquito bite;
CRC	trans	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg21302420	chr1:112162376	RAP1A	0.65	6.41	0.33	5.02e-10	Skin colour saturation;
CRC	cis	rs77861329	1.000	rs55664415	chr3:52124885	G/A	cg08692210	chr3:52188851	WDR51A	0.83	6.97	0.36	1.69e-11	Macrophage inflammatory protein 1b levels;
CRC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg23533926	chr12:111358616	MYL2	-0.54	-8.21	-0.41	5e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg03160526	chr17:80928410	B3GNTL1	0.6	8.21	0.41	5.08e-15	Glycated hemoglobin levels;
CRC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.58	8.45	0.42	9.47e-16	Schizophrenia;
CRC	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg16558208	chr1:156270281	VHLL	0.58	9.04	0.45	1.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg18809830	chr7:99032528	PTCD1	-1.28	-8.7	-0.43	1.57e-16	Blood metabolite levels;
CRC	cis	rs1873147	1.000	rs12440411	chr15:63313581	T/G	cg12160578	chr15:63334699	TPM1	-0.4	-5.73	-0.3	2.28e-8	Orofacial clefts;
CRC	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.71	9.55	0.47	3.15e-19	Alzheimer's disease;
CRC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg16141378	chr3:129829833	LOC729375	0.42	6.15	0.32	2.28e-9	Triglycerides;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg18110333	chr6:292329	DUSP22	-0.58	-8.47	-0.42	8.16e-16	Menopause (age at onset);
CRC	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.23	-0.32	1.4e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2179367	0.959	rs4897125	chr6:149766208	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.37	-0.33	6.42e-10	Dupuytren's disease;
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.7	-0.3	2.67e-8	Life satisfaction;
CRC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	17.77	0.7	5.37e-50	Platelet count;
CRC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.2	-0.41	5.3e-15	Bladder cancer;
CRC	cis	rs1322512	0.677	rs2695255	chr6:152926004	G/A	cg03415253	chr6:152958462	SYNE1	-0.39	-6.14	-0.32	2.44e-9	Tonometry;
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg11843238	chr5:131593191	PDLIM4	0.36	6.53	0.34	2.43e-10	Blood metabolite levels;
CRC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg08075719	chr14:103021372	NA	-0.67	-7.73	-0.39	1.3e-13	Platelet count;
CRC	cis	rs501120	0.584	rs673778	chr10:44733739	G/T	cg09554077	chr10:44749378	NA	0.64	7.06	0.36	9.84e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.72	0.39	1.45e-13	Motion sickness;
CRC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg01529538	chr14:23388837	RBM23	0.39	5.99	0.31	5.49e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg12564285	chr5:131593104	PDLIM4	0.38	7.14	0.37	6.06e-12	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.22	-0.49	1.76e-21	Bipolar disorder;
CRC	cis	rs4908768	0.501	rs1473420	chr1:8616838	T/G	cg20416874	chr1:8611966	RERE	-0.46	-6.53	-0.34	2.49e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg22974920	chr21:40686053	BRWD1	-0.45	-6.21	-0.32	1.56e-9	Cognitive function;
CRC	cis	rs7264396	0.573	rs55969606	chr20:34075688	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.51	-0.34	2.73e-10	Total cholesterol levels;
CRC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg16434002	chr17:42200994	HDAC5	-0.46	-6.19	-0.32	1.79e-9	Total body bone mineral density;
CRC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.82	9.42	0.46	8.42e-19	Lung function (FEV1/FVC);
CRC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.42	6.09	0.32	3.17e-9	Schizophrenia;
CRC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg03037974	chr15:76606532	NA	0.69	12.13	0.56	3.19e-28	Blood metabolite levels;
CRC	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.22	-0.32	1.53e-9	Neuroticism;
CRC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.66	0.39	2.15e-13	Lymphocyte percentage of white cells;
CRC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.4	0.42	1.36e-15	Height;
CRC	cis	rs972578	0.837	rs6002966	chr22:43259855	T/C	cg01576275	chr22:43409880	NA	-0.41	-6.49	-0.34	3.13e-10	Mean platelet volume;
CRC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.51	-0.57	1.22e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	0.93	13.04	0.58	1.24e-31	Monocyte percentage of white cells;
CRC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.63	10.07	0.49	5.54e-21	Mean corpuscular hemoglobin;
CRC	cis	rs7849270	1.000	rs3124513	chr9:131904593	C/T	cg13538475	chr9:131942899	NA	0.33	6.23	0.33	1.4e-9	Blood metabolite ratios;
CRC	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.7	-8.9	-0.44	3.74e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.47	6.83	0.35	4.16e-11	Body mass index;
CRC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg25072359	chr17:41440525	NA	0.46	6.85	0.35	3.59e-11	Menopause (age at onset);
CRC	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg25856811	chr1:152973957	SPRR3	-0.23	-6.18	-0.32	1.94e-9	Inflammatory skin disease;
CRC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-8.17	-0.41	6.91e-15	Chronic sinus infection;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.72	9.18	0.45	5.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13959152	chr12:100535986	UHRF1BP1L	0.5	7.12	0.37	6.96e-12	Response to antipsychotic treatment;
CRC	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.66	-9.96	-0.48	1.37e-20	Ulcerative colitis;
CRC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.39	-6.17	-0.32	2.01e-9	Crohn's disease;
CRC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg19193384	chr17:30244184	NA	-0.48	-6.49	-0.34	3.2e-10	Hip circumference adjusted for BMI;
CRC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.43	0.33	4.59e-10	Tonsillectomy;
CRC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	ch.11.42038R	chr11:967971	AP2A2	0.61	10.16	0.49	2.82e-21	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-12.04	-0.55	6.33e-28	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.6	8.56	0.43	4.28e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Parkinson's disease;
CRC	cis	rs4731207	0.535	rs7806126	chr7:124601875	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.32	-5.99	-0.31	5.41e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.46	6.7	0.35	9.01e-11	Asthma;
CRC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.81	14.39	0.62	9.35e-37	Breast cancer;
CRC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.54	7.36	0.38	1.52e-12	IgG glycosylation;
CRC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg20811857	chr17:78079795	GAA	-0.34	-5.6	-0.3	4.5e-8	Yeast infection;
CRC	cis	rs6445967	1.000	rs11713627	chr3:58306946	T/G	cg23715586	chr3:58305044	RPP14	0.36	6.04	0.32	4.12e-9	Platelet count;
CRC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.74	-10.94	-0.52	5.91e-24	Immature fraction of reticulocytes;
CRC	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.93	-15.87	-0.66	1.66e-42	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.42	-21.1	-0.76	4.36e-63	Hemostatic factors and hematological phenotypes;
CRC	cis	rs1873147	1.000	rs12443285	chr15:63313596	C/T	cg12160578	chr15:63334699	TPM1	-0.4	-5.73	-0.3	2.28e-8	Orofacial clefts;
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00166722	chr3:10149974	C3orf24	0.65	8.67	0.43	1.95e-16	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11940663	chr21:46962454	SLC19A1	0.49	6.7	0.35	8.91e-11	Anxiety disorder;
CRC	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg27534772	chr1:16042836	PLEKHM2	0.42	7.01	0.36	1.32e-11	Systolic blood pressure;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10819733	chr22:24237672	NA	-0.35	-5.88	-0.31	1.03e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.51	7.87	0.4	5.23e-14	Corneal astigmatism;
CRC	cis	rs9462027	0.628	rs998278	chr6:34765584	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.01	-0.31	4.88e-9	Systemic lupus erythematosus;
CRC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.7	0.3	2.72e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg06713675	chr4:122721982	EXOSC9	0.37	6.01	0.31	4.94e-9	Type 2 diabetes;
CRC	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.61	9.78	0.47	5.5e-20	Tuberculosis;
CRC	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.49	8.03	0.4	1.73e-14	Coronary artery disease;
CRC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-7.14	-0.37	6.05e-12	Cystic fibrosis severity;
CRC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.73	-0.35	7.69e-11	Major depressive disorder;
CRC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.69	11.53	0.54	4.52e-26	Mean corpuscular hemoglobin;
CRC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-7.06	-0.36	9.86e-12	Lung cancer;
CRC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.88	0.35	3.1e-11	Morning vs. evening chronotype;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg14329157	chr2:228736135	WDR69	-0.45	-6.21	-0.32	1.56e-9	Blood pressure;
CRC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg19622623	chr12:86230825	RASSF9	-0.37	-5.64	-0.3	3.62e-8	Major depressive disorder;
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.45	0.57	1.98e-29	Alzheimer's disease;
CRC	cis	rs9876781	0.933	rs6442124	chr3:48505302	A/G	cg06066452	chr3:48470258	PLXNB1	0.21	5.61	0.3	4.28e-8	Longevity;
CRC	trans	rs11712655	0.961	rs9881700	chr3:135229503	A/C	cg14625040	chr2:6214447	NA	0.44	6.09	0.32	3.22e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.71	11.55	0.54	4.04e-26	Mean platelet volume;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg21251018	chr6:28226885	NKAPL	0.38	5.66	0.3	3.21e-8	Parkinson's disease;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.3	5.95	0.31	6.76e-9	Depression;
CRC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.1	-12.3	-0.56	7.15e-29	Diabetic kidney disease;
CRC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.83	-11.3	-0.53	3.14e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.72	-13.13	-0.59	5.77e-32	Leprosy;
CRC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.8	-11.46	-0.53	8.11e-26	Coronary artery disease;
CRC	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.51	9.87	0.48	2.76e-20	Educational attainment (years of education);
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg22777020	chr22:31556080	RNF185	-0.52	-6.14	-0.32	2.4e-9	Colorectal cancer;
CRC	cis	rs12024301	0.557	rs10911383	chr1:183603962	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.3	-0.67	3.3e-44	Hip circumference;
CRC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.57	7.63	0.39	2.58e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.5	-7.09	-0.36	8.34e-12	Coronary artery disease;
CRC	cis	rs2811415	0.597	rs67527747	chr3:127803083	G/A	cg13719885	chr3:127795394	NA	-0.4	-6.0	-0.31	5.26e-9	Lung function (FEV1/FVC);
CRC	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.61	-6.74	-0.35	7.21e-11	Blood protein levels;
CRC	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.06	-0.36	9.85e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.83	-13.39	-0.59	6.16e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.56	-0.38	4.07e-13	Cystic fibrosis severity;
CRC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.35	6.32	0.33	8.58e-10	Crohn's disease;
CRC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.46	-8.42	-0.42	1.17e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.68	10.76	0.51	2.44e-23	Hemoglobin concentration;
CRC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg06470822	chr6:28175283	NA	0.82	12.06	0.55	5.37e-28	Parkinson's disease;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.47	6.53	0.34	2.55e-10	Menarche (age at onset);
CRC	cis	rs427941	0.632	rs201527	chr7:101774451	T/C	cg06246474	chr7:101738831	CUX1	0.45	6.9	0.36	2.72e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs10503871	0.545	rs16877238	chr8:30503371	A/G	cg26383811	chr8:30366931	RBPMS	-0.38	-5.63	-0.3	3.88e-8	Metabolite levels  (X-11787);
CRC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.36	-0.38	1.53e-12	Testicular germ cell tumor;
CRC	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-1.1	-11.94	-0.55	1.52e-27	Mitochondrial DNA levels;
CRC	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.78	8.28	0.42	3.05e-15	Migraine;Coronary artery disease;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.9	21.1	0.76	4.03e-63	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.79	-8.56	-0.43	4.3e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg15511327	chr8:143859410	LYNX1	0.42	7.46	0.38	7.98e-13	Urinary tract infection frequency;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24739457	chr1:205821442	NA	0.44	6.44	0.33	4.18e-10	Menarche (age at onset);
CRC	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	trans	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.07	19.18	0.73	1.48e-55	Schizophrenia;
CRC	cis	rs4654899	0.802	rs2167811	chr1:21194510	A/G	cg02927042	chr1:21476669	EIF4G3	0.44	7.06	0.36	9.77e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.68	-8.48	-0.42	7.56e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg18830697	chr6:72922368	RIMS1	-0.39	-7.92	-0.4	3.81e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00704288	chr1:44172956	ST3GAL3	0.5	6.38	0.33	6.02e-10	Thyroid stimulating hormone;
CRC	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg00071950	chr4:10020882	SLC2A9	0.5	6.86	0.35	3.52e-11	Blood metabolite levels;
CRC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.49	7.7	0.39	1.5700000000000001e-13	Neuroticism;
CRC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.84	8.89	0.44	4.02e-17	Gastritis;
CRC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.24e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.14	23.8	0.8	1.56e-73	IgG glycosylation;
CRC	cis	rs995000	0.931	rs637723	chr1:62906728	C/T	cg19896129	chr1:63156450	NA	0.44	6.84	0.35	3.76e-11	Triglyceride levels;
CRC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17554472	chr22:41940697	POLR3H	-0.55	-5.93	-0.31	7.73e-9	Vitiligo;
CRC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg07718321	chr6:96025334	MANEA	0.52	6.13	0.32	2.57e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.98	-0.36	1.6e-11	Menopause (age at onset);
CRC	cis	rs1158570	0.564	rs2791343	chr8:131316030	C/T	cg21674704	chr8:131455249	NA	0.38	5.67	0.3	3.1e-8	Platelet count;
CRC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.43	-7.07	-0.36	9.27e-12	Obesity-related traits;
CRC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.61	9.27	0.46	2.51e-18	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.52	7.14	0.37	5.97e-12	Caudate activity during reward;
CRC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06671706	chr8:8559999	CLDN23	0.61	9.04	0.45	1.35e-17	Obesity-related traits;
CRC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.69	0.35	9.55e-11	Menarche (age at onset);
CRC	cis	rs73200209	0.744	rs73198040	chr12:116535736	G/C	cg01776926	chr12:116560359	MED13L	-0.58	-6.72	-0.35	8e-11	Total body bone mineral density;
CRC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.41	0.38	1.08e-12	Cognitive ability;
CRC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.81	0.4	7.69e-14	Colorectal cancer;
CRC	cis	rs2949837	0.581	rs2960436	chr7:45977282	G/A	cg23193639	chr7:45961078	IGFBP3	0.4	6.66	0.34	1.14e-10	Sitting height ratio;
CRC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.25	-0.33	1.27e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs12086130	0.892	rs57331401	chr1:51451372	G/A	cg07174182	chr1:51127561	FAF1	-0.72	-5.61	-0.3	4.26e-8	Hip circumference adjusted for BMI;Hip circumference;
CRC	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-8.3	-0.42	2.67e-15	Hypospadias;
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.6	8.36	0.42	1.81e-15	Obesity-related traits;
CRC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.67	-8.01	-0.4	1.98e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15985338	chr7:6048868	PMS2;AIMP2	0.46	6.08	0.32	3.26e-9	Hip circumference;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.47	-7.96	-0.4	2.79e-14	Type 2 diabetes;
CRC	cis	rs7605827	0.930	rs2058869	chr2:15679700	T/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	15.66	0.65	1.11e-41	Platelet count;
CRC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.54	7.42	0.38	1.01e-12	Height;
CRC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-6.13	-0.32	2.55e-9	Major depressive disorder;
CRC	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.74	-0.39	1.24e-13	Bipolar disorder;
CRC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg23172400	chr8:95962367	TP53INP1	0.4	6.11	0.32	2.88e-9	Type 2 diabetes;
CRC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.72	-11.6	-0.54	2.56e-26	Neurofibrillary tangles;
CRC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg15110403	chr19:17392923	ANKLE1	-0.36	-6.0	-0.31	5.23e-9	Systemic lupus erythematosus;
CRC	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12785122	chr17:10601181	C17orf48;SCO1	0.4	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg03037974	chr15:76606532	NA	0.69	12.09	0.55	4.35e-28	Blood metabolite levels;
CRC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg03929089	chr4:120376271	NA	-0.52	-6.41	-0.33	5.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.38e-30	Bone mineral density;
CRC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.65	-7.97	-0.4	2.56e-14	Gut microbiome composition (summer);
CRC	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.55	-6.71	-0.35	8.41e-11	Dental caries;
CRC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.87	0.31	1.06e-8	Renal function-related traits (BUN);
CRC	cis	rs9658691	0.920	rs72809360	chr10:90746990	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-6.3	-0.33	9.41e-10	Mosquito bite size;
CRC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg20243544	chr17:37824526	PNMT	0.47	5.61	0.3	4.22e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs1882538	0.901	rs35284403	chr7:132948884	T/C	cg10665199	chr7:133106180	EXOC4	0.51	7.22	0.37	3.69e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.66	10.12	0.49	4.04e-21	Hemoglobin concentration;
CRC	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg14458575	chr2:238380390	NA	0.45	7.75	0.39	1.13e-13	Prostate cancer;
CRC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.55	-0.47	3.01e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.73	-0.35	7.62e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	8.29	0.42	2.84e-15	Mean corpuscular hemoglobin;
CRC	cis	rs11212617	1.000	rs11212615	chr11:108281267	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.09	0.32	3.2e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.5	-9.28	-0.46	2.33e-18	Longevity;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg12273811	chr6:28175739	NA	0.6	8.82	0.44	7e-17	Parkinson's disease;
CRC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg17948913	chr5:572064	NA	0.54	6.07	0.32	3.57e-9	Lung disease severity in cystic fibrosis;
CRC	trans	rs4576506	0.536	rs71512719	chr9:31496127	T/A	cg26940518	chr16:1593766	IFT140;TMEM204	-0.65	-6.02	-0.31	4.71e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs889398	0.802	rs12925700	chr16:69793463	C/A	cg00738113	chr16:70207722	CLEC18C	0.37	6.22	0.32	1.5e-9	Body mass index;
CRC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.38	-0.33	6.15e-10	Daytime sleep phenotypes;
CRC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg00343986	chr7:65444356	GUSB	-0.5	-7.51	-0.38	5.69e-13	Aortic root size;
CRC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03744954	chr7:23637556	CCDC126	-0.36	-6.06	-0.32	3.73e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05067136	chr7:23338802	C7orf30	0.46	6.3	0.33	9.45e-10	Response to antipsychotic treatment;
CRC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19717773	chr7:2847554	GNA12	-0.47	-6.57	-0.34	1.98e-10	Height;
CRC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg11212589	chr17:38028394	ZPBP2	0.35	6.15	0.32	2.26e-9	Asthma;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg02683197	chr6:28174875	NA	0.75	9.78	0.47	5.25e-20	Parkinson's disease;
CRC	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg04110750	chr16:69646130	NFAT5	-0.5	-6.95	-0.36	1.94e-11	IgE levels;
CRC	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	10.11	0.49	4.32e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg24675056	chr1:15929824	NA	0.53	7.18	0.37	4.76e-12	Systolic blood pressure;
CRC	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg06484146	chr7:12443880	VWDE	-0.52	-6.96	-0.36	1.91e-11	Coronary artery disease;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13489040	chr1:152162507	NA	-0.5	-6.08	-0.32	3.31e-9	Monocyte percentage of white cells;
CRC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-7.31	-0.37	2e-12	Bipolar disorder;
CRC	cis	rs449789	0.524	rs4345420	chr6:159745037	G/A	cg14500486	chr6:159655392	FNDC1	-0.51	-7.76	-0.39	1.05e-13	Pulse pressure;
CRC	cis	rs9938149	0.736	rs6540223	chr16:88321436	A/G	cg05435882	chr16:88311214	NA	0.44	5.96	0.31	6.48e-9	Corneal structure;Central corneal thickness;
CRC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.09	-0.32	3.14e-9	Gout;Renal underexcretion gout;
CRC	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.76	12.55	0.57	8.45e-30	Mosquito bite size;
CRC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.5	7.27	0.37	2.57e-12	Total body bone mineral density;
CRC	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.45	-6.39	-0.33	5.67e-10	Large artery stroke;
CRC	cis	rs629535	0.862	rs654604	chr8:70048939	C/A	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.11	0.32	2.81e-9	Rheumatoid arthritis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21810621	chr11:1331345	LOC255512;TOLLIP	-0.41	-6.17	-0.32	2.01e-9	Myopia (pathological);
CRC	trans	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.58	0.39	3.52e-13	Endometrial cancer;
CRC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	6.47	0.34	3.6e-10	Monocyte percentage of white cells;
CRC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.77	10.41	0.5	3.94e-22	Vitiligo;
CRC	trans	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg16141378	chr3:129829833	LOC729375	0.42	6.31	0.33	9.1e-10	Joint mobility (Beighton score);
CRC	cis	rs4731207	0.570	rs2086505	chr7:124664157	A/T	cg23710748	chr7:124431027	NA	-0.43	-6.73	-0.35	7.69e-11	Cutaneous malignant melanoma;
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.9	0.48	2.17e-20	Cognitive test performance;
CRC	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg09659197	chr4:152720779	NA	0.32	5.77	0.3	1.84e-8	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19518383	chr11:64577818	MEN1	0.4	6.06	0.32	3.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9292777	0.518	rs6871834	chr5:40480187	C/T	cg09067459	chr5:40385259	NA	0.38	6.16	0.32	2.12e-9	Crohn's disease;Multiple sclerosis;
CRC	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.18	-0.52	8.09e-25	Coffee consumption (cups per day);
CRC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.46	-6.26	-0.33	1.21e-9	Type 2 diabetes;
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.67	10.04	0.48	7.41e-21	Corneal astigmatism;
CRC	cis	rs7619833	0.607	rs7634878	chr3:27241219	C/T	cg02860705	chr3:27208620	NA	0.36	5.89	0.31	9.74e-9	Breast cancer;
CRC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.67	-10.22	-0.49	1.79e-21	Metabolic syndrome;
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.01	-0.31	4.9e-9	Total body bone mineral density;
CRC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.51	-0.34	2.86e-10	Subjective well-being;
CRC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.6	5.76	0.3	1.94e-8	Yeast infection;
CRC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.57	-0.34	1.92e-10	Total cholesterol levels;
CRC	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg00042356	chr1:8021962	PARK7	0.71	7.46	0.38	7.93e-13	Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg07617317	chr6:118971624	C6orf204	0.5	6.21	0.32	1.56e-9	Diastolic blood pressure;
CRC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.83	12.82	0.58	8.29e-31	Platelet distribution width;
CRC	cis	rs9914988	0.887	rs7213285	chr17:27206029	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.51	6.35	0.33	7.22e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg12273811	chr6:28175739	NA	0.57	8.21	0.41	5.09e-15	Parkinson's disease;
CRC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.57	8.55	0.43	4.84e-16	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.66	8.25	0.41	3.76e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.23	6.27	0.33	1.16e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.59	8.08	0.41	1.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	0.79	9.58	0.47	2.55e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.43	6.21	0.32	1.62e-9	Aortic root size;
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.76	-0.3	1.91e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-0.98	-9.66	-0.47	1.3e-19	Breast cancer;
CRC	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.6	-8.74	-0.43	1.23e-16	Carotid intima media thickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04060830	chr9:132816023	GPR107	0.45	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg26918954	chr5:179728553	GFPT2	0.41	6.81	0.35	4.56e-11	Height;
CRC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.44	8.98	0.44	2.18e-17	Renal cell carcinoma;
CRC	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.53	-6.45	-0.33	4.05e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2882667	0.861	rs10043676	chr5:138389561	C/T	cg09476006	chr5:138032270	NA	0.43	7.26	0.37	2.89e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs3750082	0.889	rs12154586	chr7:32923371	T/C	cg05721444	chr7:32995514	FKBP9	0.5	7.76	0.39	1.12e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.77	11.26	0.53	4.39e-25	Menarche (age at onset);
CRC	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.41	6.44	0.33	4.29e-10	Red blood cell count;
CRC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.73	8.83	0.44	6.36e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg12273811	chr6:28175739	NA	0.53	7.19	0.37	4.49e-12	Parkinson's disease;
CRC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg16928487	chr17:17741425	SREBF1	0.61	11.36	0.53	1.86e-25	Total body bone mineral density;
CRC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.26	0.41	3.65e-15	Height;
CRC	cis	rs73206853	0.764	rs9737665	chr12:111031847	A/C	cg12870014	chr12:110450643	ANKRD13A	0.75	9.11	0.45	7.96e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.56	7.57	0.39	3.81e-13	Urinary tract infection frequency;
CRC	cis	rs6504950	0.800	rs9907961	chr17:53012927	C/G	cg26251398	chr17:52985966	TOM1L1	0.37	5.62	0.3	4.04e-8	Breast cancer;
CRC	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg11645453	chr3:52864694	ITIH4	0.36	6.79	0.35	5.15e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03923535	chr7:1197113	ZFAND2A	0.68	9.71	0.47	9.02e-20	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05350266	chr1:32687823	EIF3I;C1orf91	0.47	6.62	0.34	1.43e-10	Response to antipsychotic treatment;
CRC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.01	22.41	0.78	3.47e-68	Multiple system atrophy;
CRC	cis	rs4731207	0.565	rs10954053	chr7:124586815	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg08200582	chr11:442649	ANO9	-0.68	-6.87	-0.35	3.26e-11	Body mass index;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.48	5.75	0.3	2.05e-8	Depression;
CRC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.52	6.87	0.35	3.13e-11	Height;
CRC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg06470822	chr6:28175283	NA	-0.5	-6.95	-0.36	1.96e-11	Systemic lupus erythematosus;
CRC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.73	-0.3	2.25e-8	Diabetic kidney disease;
CRC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg21466736	chr12:48725269	NA	0.59	8.76	0.44	1.02e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1656402	1.000	rs1729253	chr2:233428740	G/C	cg03852847	chr2:233439513	NA	0.44	7.56	0.38	4.08e-13	Non-small cell lung cancer (survival);
CRC	cis	rs6735179	0.609	rs13405140	chr2:1759020	C/T	cg19300414	chr2:1746591	PXDN	0.35	6.17	0.32	2.04e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14385122	chr9:71320671	PIP5K1B	0.37	6.06	0.32	3.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.35	-5.88	-0.31	9.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12024301	0.557	rs12042642	chr1:183614246	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.78	-6.79	-0.35	5.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.96	-0.31	6.6e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg04990556	chr1:26633338	UBXN11	0.54	5.85	0.31	1.19e-8	Obesity-related traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01368872	chr15:91498139	RCCD1	0.43	6.58	0.34	1.85e-10	Schizophrenia;
CRC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.69	12.31	0.56	6.55e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10946940	0.896	rs12208078	chr6:27498581	G/A	cg21251018	chr6:28226885	NKAPL	-0.41	-6.33	-0.33	7.81e-10	Systemic lupus erythematosus;
CRC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg00734567	chr1:86172782	ZNHIT6	-0.48	-7.38	-0.38	1.35e-12	Urate levels in overweight individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05000123	chr14:20937394	PNP	0.43	6.16	0.32	2.09e-9	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.19	0.32	1.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.7	-0.39	1.64e-13	Gut microbiome composition (summer);
CRC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	6.16	0.32	2.11e-9	Diabetic retinopathy;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg16405210	chr4:1374714	KIAA1530	-0.39	-5.63	-0.3	3.83e-8	Obesity-related traits;
CRC	trans	rs7546	0.504	rs2075637	chr16:4938280	T/C	cg19252218	chr17:41477271	ARL4D	-0.44	-6.57	-0.34	1.98e-10	Cancer;
CRC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.88	-0.31	1.03e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-6.85	-0.35	3.64e-11	HDL cholesterol;
CRC	cis	rs12580194	0.593	rs7485991	chr12:55789129	T/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.22	-0.45	3.64e-18	Cancer;
CRC	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg24899294	chr7:1481343	MICALL2	-0.62	-6.64	-0.34	1.27e-10	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CRC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.83	-0.48	3.56e-20	Body mass index;
CRC	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.53	7.64	0.39	2.37e-13	Testicular germ cell tumor;
CRC	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.06e-10	Eye color traits;
CRC	cis	rs4731207	0.596	rs7779244	chr7:124652930	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.24	-0.33	1.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.76	12.33	0.56	5.58e-29	Selective IgA deficiency;
CRC	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	1.09	10.36	0.5	5.71e-22	Arsenic metabolism;
CRC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.59	9.8	0.48	4.69e-20	Birth weight;
CRC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	5.7	0.3	2.72e-8	Response to antipsychotic treatment;
CRC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.72	-0.39	1.38e-13	Heart rate;
CRC	cis	rs9925964	0.933	rs2303222	chr16:31085470	A/G	cg03418659	chr16:31128414	MYST1	0.46	6.79	0.35	5.14e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15585372	chr7:97910571	BRI3	0.45	6.76	0.35	6.11e-11	Intelligence (multi-trait analysis);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg21215323	chr15:41220556	DLL4	-0.41	-6.15	-0.32	2.2e-9	Daytime sleep phenotypes;
CRC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs7429990	1.000	rs7429990	chr3:47901803	C/A	cg11946769	chr3:48343235	NME6	0.5	6.24	0.33	1.32e-9	Educational attainment (years of education);
CRC	cis	rs59104589	0.535	rs73004374	chr2:242378000	T/C	cg19488206	chr2:242435732	STK25	0.46	6.89	0.36	2.8e-11	Fibrinogen levels;
CRC	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.47	8.68	0.43	1.85e-16	Intraocular pressure;
CRC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.32	-0.33	8.39e-10	Reticulocyte fraction of red cells;
CRC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.68	9.75	0.47	6.73e-20	Multiple sclerosis;
CRC	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.09	-15.06	-0.64	2.3e-39	Exhaled nitric oxide output;
CRC	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.62e-13	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23702657	chr12:49525491	TUBA1B	0.38	6.08	0.32	3.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.43	-6.6	-0.34	1.62e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg19257562	chr1:2043853	PRKCZ	0.42	6.83	0.35	4.03e-11	Height;
CRC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.74	-9.48	-0.46	5.22e-19	Coronary artery disease;
CRC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg17133734	chr15:86042851	AKAP13	0.42	6.66	0.34	1.15e-10	Coronary artery disease;
CRC	cis	rs17065868	0.764	rs61949763	chr13:45007475	T/C	cg10246903	chr13:45222710	NA	0.56	6.21	0.32	1.64e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.85	-0.31	1.19e-8	Life satisfaction;
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.36	-0.33	6.91e-10	Total body bone mineral density;
CRC	trans	rs13221576	0.569	rs13247984	chr7:93989677	A/T	cg25582398	chr5:1217743	SLC6A19	0.59	6.4	0.33	5.3e-10	Intelligence;
CRC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.63	11.06	0.52	2.13e-24	Schizophrenia;
CRC	cis	rs9398803	0.763	rs576049	chr6:126730543	T/G	cg19875578	chr6:126661172	C6orf173	0.42	6.02	0.31	4.78e-9	Male-pattern baldness;
CRC	cis	rs6960043	0.738	rs6461153	chr7:15059796	G/C	cg19272540	chr7:15055459	NA	-0.24	-6.43	-0.33	4.36e-10	Type 2 diabetes;
CRC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.4	6.18	0.32	1.86e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.45	6.01	0.31	4.87e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-14.52	-0.62	3.02e-37	Gut microbiome composition (summer);
CRC	cis	rs7781266	0.501	rs10274077	chr7:133624271	C/T	cg03336402	chr7:133662267	EXOC4	0.66	9.96	0.48	1.35e-20	Educational attainment (college completion);
CRC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	6.06	0.32	3.71e-9	Height;
CRC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.81	0.68	3.37e-46	Electrocardiographic conduction measures;
CRC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg15269541	chr15:43626905	ADAL	-0.57	-6.29	-0.33	9.92e-10	Lung cancer in ever smokers;
CRC	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg13482628	chr17:19912719	NA	-0.4	-6.17	-0.32	2e-9	Obesity-related traits;
CRC	trans	rs4658101	0.700	rs12048543	chr1:92050356	C/T	cg17068236	chr19:2051260	MKNK2	0.46	6.19	0.32	1.76e-9	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2.04e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.58	-8.24	-0.41	4.26e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-11.62	-0.54	2.25e-26	Asthma;
CRC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.69	12.1	0.55	4.1e-28	Gout;
CRC	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.43	-8.36	-0.42	1.84e-15	Alcohol dependence;
CRC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06636001	chr8:8085503	FLJ10661	0.47	5.8	0.3	1.53e-8	Obesity-related traits;
CRC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-6.36	-0.33	6.93e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.5	6.18	0.32	1.91e-9	Recombination rate (females);
CRC	cis	rs11212617	0.967	rs228589	chr11:108093208	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.37	0.33	6.28e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.29	0.75	6.44e-60	Prudent dietary pattern;
CRC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	7.06	0.36	9.72e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg16482183	chr6:26056742	HIST1H1C	-0.72	-9.17	-0.45	5.37e-18	Iron status biomarkers;
CRC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.54	-8.11	-0.41	1.02e-14	Monocyte count;
CRC	cis	rs4731207	0.698	rs12666427	chr7:124479352	A/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21972741	chr5:435613	AHRR	0.54	7.37	0.38	1.39e-12	Cystic fibrosis severity;
CRC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.23	-0.32	1.47e-9	Monocyte percentage of white cells;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.77	0.3	1.78e-8	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.25	0.49	1.38e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7487075	0.930	rs4076484	chr12:46833912	C/G	cg22049899	chr12:47219821	SLC38A4	0.32	6.44	0.33	4.31e-10	Itch intensity from mosquito bite;
CRC	trans	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg18335740	chr13:41363409	SLC25A15	0.61	9.8	0.48	4.77e-20	Lewy body disease;
CRC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg12193833	chr17:30244370	NA	0.71	8.11	0.41	9.97e-15	Hip circumference adjusted for BMI;
CRC	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.46	6.9	0.36	2.68e-11	Asthma;
CRC	cis	rs4728302	0.869	rs958405	chr7:133597151	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.81e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.43	6.35	0.33	7.21e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg11941060	chr3:133502564	NA	-0.47	-7.65	-0.39	2.28e-13	Iron status biomarkers;
CRC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.57	7.92	0.4	3.62e-14	Alcohol dependence;
CRC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19904058	chr10:135279010	LOC619207	-0.35	-6.78	-0.35	5.56e-11	Systemic lupus erythematosus;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21937244	chr14:103406412	CDC42BPB	-0.4	-6.04	-0.32	4.08e-9	Survival in pancreatic cancer;
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02290350	chr8:58132656	NA	-0.58	-6.83	-0.35	4.22e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg12963866	chr19:57752005	ZNF805	-0.41	-6.09	-0.32	3.15e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg14711859	chr11:8959438	ASCL3	0.41	6.87	0.35	3.13e-11	Hemoglobin concentration;
CRC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg17321639	chr7:2759063	NA	-0.54	-7.11	-0.36	7.26e-12	Height;
CRC	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg09659197	chr4:152720779	NA	0.32	5.71	0.3	2.48e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.46	-0.57	1.81e-29	Idiopathic membranous nephropathy;
CRC	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg17298326	chr8:142245477	NA	-0.37	-5.66	-0.3	3.36e-8	Immature fraction of reticulocytes;
CRC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.63	-0.34	1.35e-10	Headache;
CRC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.68	9.46	0.46	6.05e-19	Vitiligo;
CRC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-11.26	-0.53	4.24e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.43	-0.33	4.44e-10	Breast cancer;
CRC	cis	rs427941	0.703	rs201455	chr7:101740212	C/T	cg06246474	chr7:101738831	CUX1	0.45	7.18	0.37	4.77e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs3824347	0.804	rs2146047	chr9:77649155	T/C	cg01251476	chr9:77566080	C9orf40	0.37	5.74	0.3	2.13e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.51	6.44	0.33	4.27e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.84	-18.62	-0.72	2.33e-53	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11296937	chr11:64084966	PRDX5;TRMT112	0.39	6.03	0.32	4.39e-9	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.73	10.1	0.49	4.59e-21	Alzheimer's disease;
CRC	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.93	15.32	0.65	2.21e-40	Dupuytren's disease;
CRC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04221910	chr5:616842	CEP72	0.41	6.77	0.35	5.99e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.67	10.3	0.49	9.15e-22	Corneal astigmatism;
CRC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.34	-0.33	7.56e-10	Total cholesterol levels;
CRC	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.04	0.32	4.18e-9	Axial length;
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.44	-0.38	9.02e-13	Lymphocyte counts;
CRC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.57	-6.01	-0.31	5.02e-9	Schizophrenia;
CRC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.51	7.22	0.37	3.71e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.52	6.28	0.33	1.07e-9	Carotid intima media thickness;
CRC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.91	-11.49	-0.54	6.3e-26	Dilated cardiomyopathy;
CRC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.23	-14.41	-0.62	7.84e-37	Diabetic kidney disease;
CRC	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.63	-9.52	-0.46	3.87e-19	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.57	-7.97	-0.4	2.67e-14	Pancreatic cancer;
CRC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.37	6.35e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.03	0.32	4.34e-9	Renal cell carcinoma;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg20803232	chr8:42995089	HGSNAT	0.44	6.37	0.33	6.23e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg21251018	chr6:28226885	NKAPL	0.49	7.71	0.39	1.55e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	12.07	0.55	5.31e-28	Platelet count;
CRC	cis	rs6691722	0.503	rs12086212	chr1:24708740	C/T	cg02336364	chr1:24764700	NIPAL3	0.37	6.18	0.32	1.93e-9	Response to interferon beta in multiple sclerosis;
CRC	cis	rs7215564	0.908	rs36077104	chr17:78661757	T/A	cg09596252	chr17:78655493	RPTOR	0.57	6.12	0.32	2.59e-9	Myopia (pathological);
CRC	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg08314208	chr16:67682810	RLTPR	-0.69	-7.45	-0.38	8.48e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7215564	0.908	rs34199628	chr17:78661675	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.16	0.32	2.11e-9	Myopia (pathological);
CRC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.85	11.34	0.53	2.23e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7202877	0.656	rs4887812	chr16:75310052	G/A	cg03315344	chr16:75512273	CHST6	0.54	6.18	0.32	1.9e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.46	6.19	0.32	1.82e-9	Aortic root size;
CRC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.65	11.35	0.53	2.12e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13198984	chr17:80129470	CCDC57	0.48	8.27	0.41	3.28e-15	Life satisfaction;
CRC	cis	rs62432291	0.681	rs7757530	chr6:159647929	G/A	cg14500486	chr6:159655392	FNDC1	0.75	10.25	0.49	1.39e-21	Joint mobility (Beighton score);
CRC	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-8.44	-0.42	1.01e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.56	12.94	0.58	3.03e-31	Breast size;
CRC	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg12856521	chr11:46389249	DGKZ	0.76	10.47	0.5	2.5e-22	Crohn's disease;
CRC	cis	rs732072	0.826	rs11605773	chr11:65474090	T/C	cg21033440	chr11:65409861	SIPA1	-0.74	-6.03	-0.32	4.35e-9	Inflammatory bowel disease;
CRC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.57	7.61	0.39	2.94e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-8.71	-0.43	1.56e-16	Electroencephalogram traits;
CRC	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.77	-10.24	-0.49	1.47e-21	Blood pressure (smoking interaction);
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.18	-0.32	1.9e-9	Total body bone mineral density;
CRC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-6.37	-0.33	6.29e-10	Schizophrenia;
CRC	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.51	9.05	0.45	1.25e-17	Blood metabolite ratios;
CRC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.54	-8.68	-0.43	1.82e-16	Huntington's disease progression;
CRC	cis	rs16852403	0.583	rs10798596	chr1:178082642	T/C	cg00404053	chr1:178313656	RASAL2	0.63	8.03	0.4	1.79e-14	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23538765	chr19:34919100	UBA2	0.44	6.05	0.32	3.87e-9	Response to antipsychotic treatment;
CRC	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.78	-12.96	-0.58	2.67e-31	Survival in pancreatic cancer;
CRC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.78	13.0	0.58	1.76e-31	Blood protein levels;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg24011408	chr12:48396354	COL2A1	0.47	6.36	0.33	6.59e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2571521	0.887	rs9298879	chr9:26097224	A/C	cg11095027	chr11:1297066	TOLLIP	-0.46	-6.57	-0.34	1.95e-10	Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-7.91	-0.4	3.9e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.4	-0.38	1.12e-12	Colorectal cancer;
CRC	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg01493522	chr13:37497338	NA	-0.52	-7.16	-0.37	5.21e-12	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03516708	chr14:24024880	THTPA	0.45	6.4	0.33	5.4e-10	Intelligence (multi-trait analysis);
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg13610392	chr14:70078973	KIAA0247	-0.44	-6.01	-0.31	5.06e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-6.44	-0.33	4.12e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs362272	0.525	rs2471347	chr4:3044435	A/G	cg22930642	chr4:2936657	C4orf10;MFSD10	0.42	6.03	0.32	4.43e-9	Serum sulfate level;
CRC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg05805236	chr11:65401703	PCNXL3	0.37	6.05	0.32	3.99e-9	Acne (severe);
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.68	0.39	1.89e-13	Aortic root size;
CRC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.01	0.31	4.86e-9	Life satisfaction;
CRC	cis	rs6662572	0.703	rs4660890	chr1:46297452	G/C	cg08644498	chr1:46502608	NA	-0.44	-6.97	-0.36	1.74e-11	Blood protein levels;
CRC	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.67	10.6	0.5	8.62e-23	Intelligence (multi-trait analysis);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg09474336	chr3:195163530	ACAP2	-0.39	-6.22	-0.32	1.52e-9	Aortic root size;
CRC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.5	7.31	0.37	2.01e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.96	14.47	0.62	4.59e-37	IgG glycosylation;
CRC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg15848620	chr12:58087721	OS9	-0.61	-8.35	-0.42	1.97e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.47	0.46	5.78e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.73	12.02	0.55	8e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9826463	0.757	rs73240309	chr3:142240223	A/G	cg20824294	chr3:142316082	PLS1	0.4	6.69	0.35	9.6e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.71	-0.43	1.54e-16	Bipolar disorder;
CRC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.4	-6.42	-0.33	4.83e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.51	5.86	0.31	1.11e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.71	8.94	0.44	2.83e-17	Diisocyanate-induced asthma;
CRC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.5	7.82	0.4	7.14e-14	Red blood cell count;
CRC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg25281562	chr12:121454272	C12orf43	0.44	6.15	0.32	2.26e-9	N-glycan levels;
CRC	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	0.54	6.13	0.32	2.54e-9	Dental caries;
CRC	cis	rs6141769	0.542	rs28536730	chr20:31301954	A/C	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.98	-0.31	5.67e-9	Subjective well-being;
CRC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg10113582	chr4:905918	GAK	-0.39	-5.62	-0.3	4.18e-8	Systemic sclerosis;
CRC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.57	0.34	1.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.04	10.13	0.49	3.61e-21	Lymphocyte counts;
CRC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.64	-0.63	1.01e-37	Lymphocyte percentage of white cells;
CRC	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.5	-0.38	6e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.6	10.14	0.49	3.44e-21	Prudent dietary pattern;
CRC	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.34	-0.33	7.63e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs360798	0.532	rs189671	chr2:62959308	T/A	cg05376469	chr2:102649931	NA	0.38	6.01	0.31	4.85e-9	Coronary artery disease;
CRC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.55	7.59	0.39	3.23e-13	Lung cancer;
CRC	cis	rs2160860	0.929	rs10216901	chr8:39804593	C/T	cg11363097	chr8:39792086	IDO2	-0.4	-6.74	-0.35	7.31e-11	Blood metabolite levels;
CRC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg07930552	chr6:133119739	C6orf192	0.66	5.82	0.31	1.39e-8	Type 2 diabetes nephropathy;
CRC	cis	rs10071761	0.513	rs59830931	chr5:40363541	T/C	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.43	4.17e-16	Aortic root size;
CRC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.36	0.46	1.26e-18	Monocyte percentage of white cells;
CRC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06544989	chr22:39130855	UNC84B	-0.44	-6.6	-0.34	1.69e-10	Menopause (age at onset);
CRC	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg10279832	chr4:154682576	RNF175	0.38	5.69	0.3	2.83e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.33	0.42	2.19e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg20041105	chr8:143859282	LYNX1	-0.33	-5.77	-0.3	1.81e-8	Urinary tract infection frequency;
CRC	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg01843034	chr6:37503916	NA	-0.39	-7.02	-0.36	1.28e-11	Cognitive performance;
CRC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14685339	chr14:77787351	POMT2;GSTZ1	0.5	6.52	0.34	2.6e-10	Thyroid stimulating hormone;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03113121	chr19:46366686	FOXA3;SYMPK	0.48	6.74	0.35	6.96e-11	Response to antipsychotic treatment;
CRC	cis	rs9311676	0.656	rs11708895	chr3:58403042	T/C	cg06643156	chr3:58380774	PXK	0.4	5.91	0.31	8.55e-9	Systemic lupus erythematosus;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19937698	chr13:60970319	TDRD3	0.45	6.19	0.32	1.78e-9	Response to antipsychotic treatment;
CRC	cis	rs9648716	1.000	rs3789806	chr7:140449071	C/G	cg10747023	chr7:140774559	NA	0.45	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg21251018	chr6:28226885	NKAPL	0.39	5.95	0.31	6.81e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4908768	0.501	rs6577492	chr1:8575064	C/A	cg20416874	chr1:8611966	RERE	-0.42	-5.93	-0.31	7.72e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.55	6.83	0.35	4.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg06363034	chr20:62225388	GMEB2	-0.4	-6.17	-0.32	2.06e-9	Glioblastoma;
CRC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.53	9.02	0.45	1.65e-17	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.94	-0.31	7.19e-9	Obesity-related traits;
CRC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.47	6.76	0.35	6.21e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.94	-0.31	7.09e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	6.5	0.34	2.92e-10	Monocyte percentage of white cells;
CRC	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20887711	chr4:1340912	KIAA1530	0.41	5.9	0.31	9.05e-9	Obesity-related traits;
CRC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.53	8.99	0.44	2.05e-17	Aortic root size;
CRC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg10263370	chr3:44754102	ZNF502	-0.41	-6.78	-0.35	5.59e-11	Depressive symptoms;
CRC	cis	rs932287	0.858	rs7109896	chr11:9054522	A/G	cg12365402	chr11:9010492	NRIP3	0.39	6.3	0.33	9.69e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7804356	0.954	rs3801808	chr7:26896555	T/A	cg03456212	chr7:26904342	SKAP2	-0.5	-5.69	-0.3	2.77e-8	Type 1 diabetes;
CRC	cis	rs59104589	0.617	rs16843642	chr2:242351379	T/G	cg19488206	chr2:242435732	STK25	0.48	6.91	0.36	2.56e-11	Fibrinogen levels;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10819733	chr22:24237672	NA	-0.37	-6.39	-0.33	5.69e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.8	14.02	0.61	2.36e-35	Breast cancer;
CRC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.67	-8.49	-0.42	7.45e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.12	-0.32	2.65e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs17641971	0.684	rs7835336	chr8:49957895	A/G	cg00325661	chr8:49890786	NA	0.35	5.98	0.31	5.95e-9	Blood metabolite levels;
CRC	trans	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg17903999	chr18:56338584	MALT1	-0.43	-6.91	-0.36	2.48e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.44	0.33	4.15e-10	Life satisfaction;
CRC	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.84	11.02	0.52	3.13e-24	Iron status biomarkers;
CRC	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg11887960	chr12:57824829	NA	0.58	6.43	0.33	4.44e-10	Obesity-related traits;
CRC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.64	-9.39	-0.46	1.06e-18	Subjective well-being;
CRC	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.74	11.15	0.52	1.08e-24	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.9	0.31	8.84e-9	Life satisfaction;
CRC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-5.66	-0.3	3.28e-8	Major depressive disorder;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12172441	chr6:28176163	NA	0.52	7.22	0.37	3.63e-12	Cardiac Troponin-T levels;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.62	6.83	0.35	4.21e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13198984	chr17:80129470	CCDC57	0.45	8.01	0.4	1.99e-14	Life satisfaction;
CRC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-6.92	-0.36	2.41e-11	Response to bleomycin (chromatid breaks);
CRC	cis	rs16975963	0.644	rs11083427	chr19:38074152	G/T	cg15135657	chr19:38346511	NA	-0.46	-6.25	-0.33	1.31e-9	Longevity;
CRC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg25956985	chr22:39795188	MAP3K7IP1	-0.45	-6.63	-0.34	1.35e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs9292777	0.897	rs6890268	chr5:40406050	A/T	cg09067459	chr5:40385259	NA	0.52	9.13	0.45	7.13e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs17155006	0.530	rs408867	chr7:107743244	C/T	cg05962710	chr7:107745446	LAMB4	-0.39	-6.92	-0.36	2.31e-11	Pneumococcal bacteremia;
CRC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.92e-17	Hip circumference adjusted for BMI;
CRC	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg12856521	chr11:46389249	DGKZ	0.73	10.56	0.5	1.21e-22	Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14163827	chr9:134270147	NA	0.38	6.02	0.31	4.72e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.63	8.2	0.41	5.64e-15	Alzheimer's disease;
CRC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-6.38	-0.33	5.84e-10	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24437943	chr3:132136776	DNAJC13	0.47	6.51	0.34	2.79e-10	Response to antipsychotic treatment;
CRC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg10305451	chr2:177043427	NA	0.72	11.53	0.54	4.59e-26	IgG glycosylation;
CRC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.4	7.07	0.36	9.51e-12	Obesity-related traits;
CRC	cis	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.24	0.37	3.17e-12	Asthma;
CRC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	5.96	0.31	6.39e-9	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.75	-0.35	6.89e-11	Metabolite levels;
CRC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg11189052	chr15:85197271	WDR73	0.6	8.55	0.43	4.6e-16	Schizophrenia;
CRC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.68	-8.91	-0.44	3.43e-17	Multiple sclerosis;
CRC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.88	0.35	2.99e-11	Morning vs. evening chronotype;
CRC	cis	rs10242455	0.702	rs73711293	chr7:99081595	C/T	cg18809830	chr7:99032528	PTCD1	-1.3	-8.98	-0.44	2.15e-17	Blood metabolite levels;
CRC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg05709478	chr1:6581295	PLEKHG5	0.68	7.76	0.39	1.05e-13	Body mass index;
CRC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.48	-0.38	7e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg10217327	chr6:118973057	C6orf204	0.52	5.87	0.31	1.08e-8	Diastolic blood pressure;
CRC	cis	rs6088813	1.000	rs2425066	chr20:33927006	A/C	cg14752227	chr20:34000481	UQCC	0.37	5.69	0.3	2.76e-8	Height;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg08222913	chr3:52553049	STAB1	-0.33	-5.91	-0.31	8.53e-9	Bipolar disorder;
CRC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.39	-0.42	1.46e-15	Monocyte count;
CRC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs1223397	0.702	rs13191897	chr6:13288428	G/A	cg07912922	chr6:13274314	PHACTR1	0.54	6.48	0.34	3.33e-10	Blood pressure;
CRC	trans	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg19188899	chr13:112838565	NA	-0.42	-6.45	-0.34	3.88e-10	Systemic lupus erythematosus;
CRC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	8.36	0.42	1.79e-15	Cognitive test performance;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26125625	chr3:124860871	SLC12A8	0.2	6.04	0.32	4.23e-9	Myopia (pathological);
CRC	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg23815491	chr16:72088622	HP	0.41	5.99	0.31	5.53e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg17710535	chr19:10819994	QTRT1	0.48	7.57	0.39	3.78e-13	Inflammatory skin disease;
CRC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg03340356	chr1:67600835	NA	0.29	6.5	0.34	2.99e-10	Psoriasis;
CRC	trans	rs2055729	0.677	rs1962430	chr8:9759620	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.02	0.36	1.31e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg23205692	chr1:25664452	TMEM50A	-0.42	-5.77	-0.3	1.82e-8	Erythrocyte sedimentation rate;
CRC	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.8	11.17	0.52	8.64e-25	Orofacial clefts;
CRC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.81	13.38	0.59	6.69e-33	Menopause (age at onset);
CRC	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.19	11.24	0.53	5e-25	Prostate cancer;
CRC	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg12193833	chr17:30244370	NA	-0.71	-7.23	-0.37	3.45e-12	Height;
CRC	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.7	-0.3	2.64e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.81	14.23	0.62	3.87e-36	Chronic sinus infection;
CRC	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-0.61	-6.91	-0.36	2.5e-11	Blood protein levels;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.04	0.32	4.16e-9	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06019692	chr13:20207818	MPHOSPH8	0.39	6.0	0.31	5.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-7.05	-0.36	1.04e-11	Colorectal cancer;
CRC	cis	rs4728142	0.604	rs7783384	chr7:128681297	T/C	cg06630958	chr7:128577819	IRF5	-0.35	-5.68	-0.3	3.04e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg25856811	chr1:152973957	SPRR3	-0.28	-7.64	-0.39	2.38e-13	Inflammatory skin disease;
CRC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.92	-19.27	-0.73	6.24e-56	Urate levels in lean individuals;
CRC	cis	rs6504340	0.793	rs56128659	chr17:46621828	T/A	cg04904318	chr17:46607828	HOXB1	-0.52	-6.0	-0.31	5.08e-9	Primary tooth development (number of teeth);
CRC	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg04415270	chr2:102091202	RFX8	-0.57	-7.94	-0.4	3.2e-14	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg00531865	chr16:30841666	NA	-0.42	-5.98	-0.31	5.87e-9	Dementia with Lewy bodies;
CRC	cis	rs17767392	1.000	rs35122644	chr14:71780768	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.9	-0.36	2.71e-11	Mitral valve prolapse;
CRC	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.53	7.44	0.38	9.13e-13	Smooth-surface caries;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg19041857	chr6:27730383	NA	-0.6	-6.51	-0.34	2.88e-10	Lung cancer in ever smokers;
CRC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.66	-10.69	-0.51	4.15e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg13010199	chr12:38710504	ALG10B	0.52	6.46	0.34	3.77e-10	Bladder cancer;
CRC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.59	0.39	3.23e-13	Alzheimer's disease (late onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg19857114	chr3:176741225	TBL1XR1	-0.39	-6.18	-0.32	1.92e-9	Interleukin-6 levels;
CRC	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.84	-11.42	-0.53	1.1e-25	Asthma;
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	5.83	0.31	1.3e-8	Prudent dietary pattern;
CRC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	9.24	0.45	3.11e-18	Alzheimer's disease;
CRC	cis	rs2444240	1.000	rs573211	chr11:120044762	G/A	cg16005559	chr11:120040616	NA	-0.36	-5.64	-0.3	3.7e-8	Corneal curvature;
CRC	trans	rs6034559	0.521	rs6111223	chr20:16629479	A/C	cg04525892	chr12:65822627	MSRB3	0.39	6.13	0.32	2.57e-9	Obsessive-compulsive disorder or autism spectrum disorder;
CRC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.56	-0.5	1.22e-22	Breast cancer;
CRC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.21	0.32	1.58e-9	Prudent dietary pattern;
CRC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg01629716	chr15:45996671	NA	0.41	8.45	0.42	9.26e-16	Waist circumference;Weight;
CRC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.58	-0.39	3.52e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg13047869	chr3:10149882	C3orf24	0.36	5.73	0.3	2.27e-8	Alzheimer's disease;
CRC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.51	7.09	0.36	8.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.3	0.37	2.14e-12	Menopause (age at onset);
CRC	cis	rs16975963	0.793	rs1807157	chr19:38465523	G/T	cg15135657	chr19:38346511	NA	-0.44	-5.8	-0.3	1.52e-8	Longevity;
CRC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.73	10.28	0.49	1.13e-21	Blood metabolite levels;
CRC	trans	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.51	8.46	0.42	8.66e-16	Coronary artery disease;
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	trans	rs10411161	1.000	rs8108583	chr19:52364977	C/A	cg22319618	chr22:45562946	NUP50	-0.52	-6.03	-0.32	4.4e-9	Breast cancer;
CRC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.13	0.32	2.51e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.71	9.17	0.45	5.16e-18	Alzheimer's disease;
CRC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.69	-11.81	-0.55	4.65e-27	Dental caries;
CRC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg01304814	chr3:48885189	PRKAR2A	0.8	6.1	0.32	2.93e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.54e-9	Arsenic metabolism;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg06470822	chr6:28175283	NA	0.81	11.77	0.54	6.35e-27	Cardiac Troponin-T levels;
CRC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg27534772	chr1:16042836	PLEKHM2	0.55	10.69	0.51	4.19e-23	Systolic blood pressure;
CRC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.88	0.4	4.83e-14	Rheumatoid arthritis;
CRC	cis	rs7626444	0.625	rs1357287	chr3:196484967	A/G	cg12930392	chr3:196481615	PAK2	0.38	6.83	0.35	4.16e-11	Monocyte count;
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.15	-0.32	2.23e-9	Bipolar disorder;
CRC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.61	-9.64	-0.47	1.54e-19	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11343086	chr1:202113710	ARL8A	0.48	6.27	0.33	1.16e-9	Thyroid stimulating hormone;
CRC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg11833968	chr6:79620685	NA	-0.37	-6.47	-0.34	3.52e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg04165759	chr1:150448943	RPRD2	0.35	5.79	0.3	1.66e-8	Migraine;
CRC	cis	rs9462027	0.651	rs2395599	chr6:34641415	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.42e-10	Systemic lupus erythematosus;
CRC	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.65	7.91	0.4	3.86e-14	Eotaxin levels;
CRC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg25164649	chr6:28176230	NA	0.59	6.01	0.31	5.06e-9	Lung cancer in ever smokers;
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.51	0.34	2.74e-10	Bipolar disorder;
CRC	cis	rs6761276	0.635	rs4145013	chr2:113830688	C/T	cg24553058	chr2:113831203	IL1F10	0.38	5.71	0.3	2.56e-8	Protein quantitative trait loci;
CRC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg12573674	chr2:1569213	NA	-0.74	-7.76	-0.39	1.09e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.6	10.56	0.5	1.26e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.33	-6.63	-0.34	1.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.06e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs73200209	0.744	rs74349961	chr12:116467560	T/C	cg01776926	chr12:116560359	MED13L	-0.64	-7.6	-0.39	3.11e-13	Total body bone mineral density;
CRC	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg25856811	chr1:152973957	SPRR3	0.25	7.05	0.36	1.04e-11	Inflammatory skin disease;
CRC	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg09659197	chr4:152720779	NA	0.51	11.22	0.53	6.03e-25	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08679808	chr17:79886116	LOC92659;MAFG	0.42	6.8	0.35	5.05e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-5.77	-0.3	1.83e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.92	-11.74	-0.54	8.16e-27	Hair shape;
CRC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	6.09	0.32	3.08e-9	Lung function (FEV1/FVC);
CRC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.98	-0.31	5.73e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.64	-9.25	-0.45	3.01e-18	Subjective well-being;
CRC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	2.98e-9	Heart rate;
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.83	11.25	0.53	4.49e-25	Alzheimer's disease;
CRC	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.33	-0.37	1.83e-12	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.15	23.86	0.8	9.57e-74	IgG glycosylation;
CRC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-8.92	-0.44	3.23e-17	Hip circumference adjusted for BMI;
CRC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.61	-9.88	-0.48	2.58e-20	Personality dimensions;
CRC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.21	0.56	1.6e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.35	-6.83	-0.35	4.03e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs889398	0.594	rs8047194	chr16:69891510	G/T	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.89	-0.31	9.33e-9	Body mass index;
CRC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg11189052	chr15:85197271	WDR73	0.61	8.88	0.44	4.41e-17	Schizophrenia;
CRC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-5.71	-0.3	2.54e-8	Total body bone mineral density;
CRC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.48	-7.93	-0.4	3.48e-14	Neuroticism;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg12273811	chr6:28175739	NA	0.61	6.33	0.33	7.99e-10	Lung cancer in ever smokers;
CRC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.56	-7.4	-0.38	1.15e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20483112	chr1:11954174	NA	0.42	5.97	0.31	6.29e-9	Response to antipsychotic treatment;
CRC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.15	0.32	2.26e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.27	0.53	3.96e-25	Prudent dietary pattern;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.65	8.98	0.44	2.12e-17	Menarche (age at onset);
CRC	cis	rs13315871	1.000	rs71311869	chr3:58398922	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.14	-0.37	5.96e-12	Cholesterol, total;
CRC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.74	-0.3	2.17e-8	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.53	7.17	0.37	4.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg11887960	chr12:57824829	NA	0.63	6.79	0.35	5.32e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-7.0	-0.36	1.42e-11	Longevity;
CRC	cis	rs3790455	0.610	rs746527	chr1:156460511	C/T	cg14087168	chr1:156450669	MEF2D	-0.38	-6.62	-0.34	1.44e-10	Migraine;
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.37	0.38	1.37e-12	Electroencephalogram traits;
CRC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.58	9.28	0.46	2.31e-18	Vitiligo;
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.72	11.63	0.54	2.04e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13253111	0.766	rs56232071	chr8:28063230	A/T	cg26534493	chr8:28060551	NA	0.49	8.59	0.43	3.61e-16	Childhood body mass index;
CRC	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg23750338	chr8:142222470	SLC45A4	0.37	6.23	0.33	1.39e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg20041105	chr8:143859282	LYNX1	0.36	6.17	0.32	1.95e-9	Urinary tract infection frequency;
CRC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.81	13.61	0.6	9.13e-34	Menopause (age at onset);
CRC	trans	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.14	-0.32	2.33e-9	Axial length;
CRC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.86	-14.69	-0.63	6.45e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6681460	0.674	rs4134135	chr1:67012728	A/G	cg02459107	chr1:67143332	SGIP1	0.4	6.28	0.33	1.04e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	0.78	8.25	0.41	3.86e-15	Type 2 diabetes nephropathy;
CRC	cis	rs4363385	0.818	rs1890285	chr1:153015396	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.89	-0.35	2.92e-11	Inflammatory skin disease;
CRC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.91	-17.94	-0.7	1.16e-50	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.11	19.05	0.72	4.69e-55	Cognitive function;
CRC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg17796960	chr10:135278976	LOC619207	-0.37	-5.65	-0.3	3.53e-8	Systemic lupus erythematosus;
CRC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.58	9.07	0.45	1.07e-17	Body mass index;
CRC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12311346	chr5:56204834	C5orf35	-0.45	-6.78	-0.35	5.41e-11	Coronary artery disease;
CRC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.29	-0.71	4.7e-52	Height;
CRC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.91	-0.52	7.29e-24	Hepatocellular carcinoma;
CRC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.5	8.31	0.42	2.49e-15	Sum eosinophil basophil counts;
CRC	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.72	0.35	7.8e-11	Retinal vascular caliber;
CRC	cis	rs12922317	0.860	rs2541583	chr16:12131121	C/T	cg02368508	chr16:12060182	TNFRSF17	0.38	5.78	0.3	1.71e-8	Schizophrenia;
CRC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6662572	0.686	rs884443	chr1:46484421	G/C	cg08644498	chr1:46502608	NA	0.46	7.29	0.37	2.31e-12	Blood protein levels;
CRC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg06219103	chr11:63990595	FERMT3	-0.4	-6.13	-0.32	2.56e-9	Platelet count;
CRC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg22834771	chr12:69754056	YEATS4	-0.41	-5.88	-0.31	1.03e-8	Blood protein levels;
CRC	cis	rs9969804	0.905	rs7043114	chr9:95387983	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.72	-0.3	2.45e-8	Height;
CRC	cis	rs427941	0.632	rs201500	chr7:101757806	G/C	cg06246474	chr7:101738831	CUX1	0.44	6.77	0.35	6.08e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg02869306	chr7:64672164	INTS4L1	0.42	6.06	0.32	3.77e-9	Aortic root size;
CRC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.53	0.38	5.09e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14857596	chr12:72233493	TBC1D15	0.39	6.17	0.32	1.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.87	17.51	0.69	5.85e-49	White blood cell count;
CRC	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.87	-11.22	-0.53	6.08e-25	Hair shape;
CRC	cis	rs12760731	0.668	rs10913548	chr1:178372286	G/A	cg00404053	chr1:178313656	RASAL2	1.16	11.74	0.54	8.13e-27	Obesity-related traits;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg06470822	chr6:28175283	NA	0.75	10.79	0.51	2.01e-23	Parkinson's disease;
CRC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg20291162	chr17:40259547	DHX58	-0.55	-7.96	-0.4	2.8e-14	Fibrinogen levels;
CRC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.41	6.82	0.35	4.45e-11	Childhood ear infection;
CRC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.18	-0.74	1.7e-59	Primary sclerosing cholangitis;
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.43	6.44	0.33	4.34e-10	Obesity-related traits;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg22638593	chr5:131593259	PDLIM4	0.37	7.07	0.36	9.45e-12	Blood metabolite levels;
CRC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.41	7.45	0.38	8.35e-13	Schizophrenia;
CRC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.55	7.73	0.39	1.3e-13	Prostate-specific antigen levels;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs13272623	0.536	rs11985127	chr8:71743943	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.61	6.01	0.31	4.94e-9	IgG glycosylation;
CRC	cis	rs12024301	0.557	rs76070988	chr1:183633490	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.18	-0.32	1.86e-9	Menopause (age at onset);
CRC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg18764771	chr6:116381957	FRK	-0.27	-7.93	-0.4	3.5e-14	Cholesterol, total;LDL cholesterol;
CRC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.17	-0.32	2.04e-9	Height;
CRC	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.81	-0.3	1.51e-8	Blood protein levels;
CRC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.1	-0.45	8.6e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7463659	0.935	rs7844624	chr8:135433894	T/C	cg17885191	chr8:135476712	NA	-0.4	-5.89	-0.31	9.64e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03710140	chr20:5986599	CRLS1	0.41	6.6	0.34	1.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg27633287	chr12:130766243	NA	-0.38	-5.97	-0.31	6.31e-9	Menopause (age at onset);
CRC	cis	rs995000	0.931	rs10158897	chr1:62912919	C/T	cg19896129	chr1:63156450	NA	0.4	5.78	0.3	1.76e-8	Triglyceride levels;
CRC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.44	-5.87	-0.31	1.09e-8	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg25456477	chr12:86230367	RASSF9	0.36	6.21	0.32	1.56e-9	Major depressive disorder;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg15786705	chr6:28176104	NA	0.69	9.42	0.46	8.13e-19	Parkinson's disease;
CRC	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.65	-8.65	-0.43	2.36e-16	Multiple sclerosis;
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.5	7.31	0.37	2.04e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg15382696	chr6:118971807	C6orf204	0.57	7.09	0.36	8.07e-12	Diastolic blood pressure;
CRC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-7.75	-0.39	1.15e-13	P wave terminal force;
CRC	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.25	0.62	3.32e-36	Hypertriglyceridemia;
CRC	cis	rs972578	0.791	rs3091382	chr22:43291095	C/T	cg01576275	chr22:43409880	NA	-0.38	-6.03	-0.32	4.39e-9	Mean platelet volume;
CRC	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-6.4	-0.33	5.4e-10	Schizophrenia;
CRC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg03037974	chr15:76606532	NA	0.72	12.72	0.57	1.97e-30	Blood metabolite levels;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.49	-0.34	3.13e-10	Breast cancer;
CRC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg18230493	chr5:56204884	C5orf35	-0.41	-6.03	-0.32	4.36e-9	Breast cancer;Breast cancer (early onset);
CRC	trans	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.78	-14.31	-0.62	1.89e-36	Extrinsic epigenetic age acceleration;
CRC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	14.14	0.61	8.64e-36	Electrocardiographic conduction measures;
CRC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.79	13.42	0.59	4.56e-33	Menopause (age at onset);
CRC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	0.56	6.0	0.31	5.14e-9	Tonsillectomy;
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg12273811	chr6:28175739	NA	0.57	5.79	0.3	1.61e-8	Lung cancer in ever smokers;
CRC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.59	8.81	0.44	7.57e-17	Aortic root size;
CRC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg21335942	chr16:58549945	SETD6	0.86	5.72	0.3	2.39e-8	Schizophrenia;
CRC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg06287003	chr12:125626642	AACS	0.53	7.25	0.37	3e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.95	-0.31	6.79e-9	Life satisfaction;
CRC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.46	-7.58	-0.39	3.44e-13	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07927484	chr5:153826296	SAP30L	0.47	6.67	0.35	1.11e-10	Response to antipsychotic treatment;
CRC	cis	rs2857891	0.773	rs2638100	chr11:6969676	C/G	cg12728517	chr11:6947552	ZNF215	0.51	5.85	0.31	1.22e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.54	9.78	0.47	5.54e-20	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs7731657	0.537	rs10051429	chr5:130257549	C/T	cg08523029	chr5:130500466	HINT1	0.43	5.7	0.3	2.61e-8	Fasting plasma glucose;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.46	0.34	3.71e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7474896	0.832	rs35954589	chr10:37926383	G/A	cg16724811	chr16:15130678	PDXDC1	-0.62	-6.12	-0.32	2.72e-9	Obesity (extreme);
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg02683197	chr6:28174875	NA	0.47	6.68	0.35	1.04e-10	Pubertal anthropometrics;
CRC	cis	rs16973500	0.808	rs61523290	chr16:71943556	A/G	cg00732059	chr16:71740210	PHLPP2	-0.67	-6.87	-0.35	3.28e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.22	0.32	1.55e-9	Lung cancer;
CRC	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg21280719	chr6:42927975	GNMT	-0.34	-5.86	-0.31	1.1e-8	Blood protein levels;
CRC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.43	-6.63	-0.34	1.39e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-8.5	-0.42	6.81e-16	Gut microbiome composition (summer);
CRC	cis	rs2062225	0.935	rs1842981	chr2:111763490	T/A	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	9.75	0.47	6.99e-20	Menopause (age at onset);
CRC	cis	rs863345	0.604	rs12064489	chr1:158499449	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg19635926	chr16:89946313	TCF25	0.65	6.7	0.35	9.16e-11	Skin colour saturation;
CRC	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.76	0.39	1.09e-13	Breast cancer;
CRC	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg05623727	chr3:50126028	RBM5	-0.47	-8.05	-0.41	1.58e-14	Menarche (age at onset);
CRC	cis	rs9303542	0.625	rs8072250	chr17:46569216	C/T	cg04904318	chr17:46607828	HOXB1	-0.45	-5.73	-0.3	2.27e-8	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg08501292	chr6:25962987	TRIM38	1.12	9.46	0.46	6.01e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.51	7.12	0.37	6.86e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.77	7.18	0.37	4.74e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.5	-5.69	-0.3	2.83e-8	Body mass index;
CRC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.77	-10.3	-0.49	9.5e-22	Initial pursuit acceleration;
CRC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.65	10.51	0.5	1.87e-22	Breast cancer;
CRC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.58	-8.37	-0.42	1.72e-15	Longevity;
CRC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.81	8.87	0.44	4.86e-17	Body mass index;
CRC	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.27	-0.33	1.15e-9	HDL cholesterol;
CRC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.1	-19.05	-0.72	4.88e-55	Ulcerative colitis;
CRC	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg13206674	chr6:150067644	NUP43	0.47	5.66	0.3	3.23e-8	Lung cancer;
CRC	trans	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg26043149	chr18:55253948	FECH	0.51	7.82	0.4	7.29e-14	Bone mineral density;
CRC	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg21169611	chr9:106856078	SMC2	0.42	5.86	0.31	1.14e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.52	7.53	0.38	4.87e-13	Uric acid levels;
CRC	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.7	9.67	0.47	1.25e-19	White matter hyperintensity burden;
CRC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.39	-7.35	-0.38	1.61e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg11003573	chr3:44754125	ZNF502	-0.33	-5.68	-0.3	3e-8	Depressive symptoms;
CRC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg03623178	chr6:28175578	NA	-0.82	-7.95	-0.4	2.94e-14	Depression;
CRC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg25956985	chr22:39795188	MAP3K7IP1	-0.44	-6.53	-0.34	2.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-8.05	-0.41	1.58e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs802075	1.000	rs360564	chr6:49658090	T/C	cg20364632	chr6:49636226	NA	-0.36	-5.87	-0.31	1.05e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.64	-10.48	-0.5	2.36e-22	Motion sickness;
CRC	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg27205649	chr11:78285834	NARS2	0.49	6.2	0.32	1.65e-9	Alzheimer's disease (survival time);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19909895	chr3:128368930	RPN1	0.45	6.25	0.33	1.27e-9	Response to antipsychotic treatment;
CRC	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.63	-6.26	-0.33	1.2e-9	Response to haloperidol in psychosis;
CRC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	7.91	0.4	4.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg10729496	chr3:10149963	C3orf24	0.53	7.04	0.36	1.12e-11	Alzheimer's disease;
CRC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.8	9.74	0.47	7.54e-20	Initial pursuit acceleration;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.53	7.53	0.38	5e-13	Alzheimer's disease;
CRC	cis	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.51e-8	Dupuytren's disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09700085	chr3:45838028	SLC6A20	0.48	6.33	0.33	7.9e-10	Survival in pancreatic cancer;
CRC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.47	6.33	0.33	8.18e-10	Schizophrenia;
CRC	cis	rs9648716	1.000	rs1267645	chr7:140485335	T/C	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.14e-8	Type 2 diabetes;
CRC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.55	-7.77	-0.39	9.97e-14	Lymphocyte percentage of white cells;
CRC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.59	9.98	0.48	1.13e-20	Menopause (age at onset);
CRC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.59	7.27	0.37	2.7e-12	Bipolar disorder;
CRC	cis	rs7192380	0.965	rs7205551	chr16:69605968	G/A	cg00738113	chr16:70207722	CLEC18C	-0.32	-5.63	-0.3	3.82e-8	Sjögren's syndrome;
CRC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.45	6.47	0.34	3.51e-10	Alcohol dependence;
CRC	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg08501292	chr6:25962987	TRIM38	0.84	6.06	0.32	3.63e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg23136738	chr11:925521	AP2A2	0.41	6.77	0.35	6e-11	Alzheimer's disease (late onset);
CRC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.75	11.35	0.53	2.12e-25	High light scatter reticulocyte count;
CRC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.19	-0.37	4.3e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.65	-9.88	-0.48	2.49e-20	Body mass index;
CRC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	8.16e-11	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.6	9.29	0.46	2.22e-18	Aortic root size;
CRC	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg08717414	chr16:71523259	ZNF19	-0.51	-6.35	-0.33	7.13e-10	Post bronchodilator FEV1;
CRC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg24588162	chr13:113633484	MCF2L	-0.43	-7.63	-0.39	2.64e-13	Systolic blood pressure;
CRC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	8.24e-11	Colorectal cancer;
CRC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.52	-0.46	4e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.34	-0.33	7.76e-10	Aortic root size;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg08222913	chr3:52553049	STAB1	-0.41	-8.27	-0.41	3.28e-15	Electroencephalogram traits;
CRC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.92	17.45	0.69	1.02e-48	Height;
CRC	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg14515779	chr1:101123966	NA	-0.33	-5.87	-0.31	1.04e-8	Monocyte count;
CRC	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.46	-7.08	-0.36	8.96e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.75	-0.3	2e-8	Daytime sleep phenotypes;
CRC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.62	7.59	0.39	3.28e-13	Menarche (age at onset);
CRC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.5	9.78	0.47	5.49e-20	Renal cell carcinoma;
CRC	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.66	8.88	0.44	4.32e-17	Type 2 diabetes;
CRC	cis	rs9478638	0.592	rs162982	chr6:155634614	A/G	cg07943832	chr6:155568918	TIAM2	0.49	6.3	0.33	9.38e-10	Electroencephalogram traits;
CRC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.63	-7.15	-0.37	5.63e-12	Menarche (age at onset);
CRC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.97	-0.74	1.1e-58	Primary sclerosing cholangitis;
CRC	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg00631329	chr6:26305371	NA	-0.55	-9.35	-0.46	1.44e-18	Educational attainment;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02233558	chr5:127418922	SLC12A2;FLJ33630	-0.5	-5.96	-0.31	6.51e-9	Diisocyanate-induced asthma;
CRC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	cis	rs12760731	0.565	rs6701848	chr1:178156816	A/C	cg00404053	chr1:178313656	RASAL2	0.95	10.07	0.49	5.84e-21	Obesity-related traits;
CRC	cis	rs12318506	0.826	rs11180452	chr12:75693881	G/T	cg04728562	chr12:75699417	CAPS2	-0.84	-6.66	-0.34	1.15e-10	Coronary artery calcification;
CRC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.79	-9.66	-0.47	1.38e-19	Initial pursuit acceleration;
CRC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg12311346	chr5:56204834	C5orf35	-0.45	-6.73	-0.35	7.62e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg15845792	chr6:28175446	NA	0.9	13.66	0.6	5.69e-34	Parkinson's disease;
CRC	cis	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg05299278	chr17:33885742	SLFN14	-0.41	-6.24	-0.33	1.33e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.82	11.22	0.53	6.16e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg02683197	chr6:28174875	NA	0.56	7.16	0.37	5.29e-12	Parkinson's disease;
CRC	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.33	-0.56	5.61e-29	Leprosy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01353464	chr3:38180116	ACAA1;MYD88	0.34	6.53	0.34	2.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.48	6.57	0.34	1.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg22561889	chr6:118971681	C6orf204	0.5	6.25	0.33	1.24e-9	Diastolic blood pressure;
CRC	cis	rs9783347	0.961	rs4150588	chr11:18360131	G/A	cg15585147	chr11:18324498	HPS5	0.42	6.0	0.31	5.12e-9	Pancreatic cancer;
CRC	cis	rs7487075	0.820	rs7967669	chr12:46692991	C/T	cg22049899	chr12:47219821	SLC38A4	0.32	5.95	0.31	7.01e-9	Itch intensity from mosquito bite;
CRC	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-6.61	-0.34	1.56e-10	Coronary artery disease;
CRC	cis	rs12580194	0.593	rs74844018	chr12:55766871	G/A	cg23425280	chr12:56401806	NA	0.47	5.74	0.3	2.13e-8	Cancer;
CRC	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04400980	chr3:121553992	IQCB1;EAF2	0.43	5.98	0.31	5.86e-9	Response to antipsychotic treatment;
CRC	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg16141378	chr3:129829833	LOC729375	0.42	6.11	0.32	2.81e-9	Triglycerides;
CRC	cis	rs883565	0.569	rs784509	chr3:39166355	G/A	cg01426195	chr3:39028469	NA	0.42	6.99	0.36	1.56e-11	Handedness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13881405	chr9:92220388	GADD45G	0.41	5.98	0.31	5.74e-9	Response to antipsychotic treatment;
CRC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.78	-0.35	5.43e-11	Breast cancer;
CRC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.62	-9.24	-0.45	3.24e-18	Subjective well-being;
CRC	cis	rs12580194	0.593	rs7489047	chr12:55759851	A/G	cg19537932	chr12:55886519	OR6C68	-0.73	-9.19	-0.45	4.43e-18	Cancer;
CRC	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.85	-14.82	-0.63	1.99e-38	Longevity;
CRC	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.72	-0.39	1.38e-13	Bipolar disorder;
CRC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.5	7.71	0.39	1.46e-13	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05485520	chr3:45883628	LZTFL1	0.54	7.22	0.37	3.64e-12	Thyroid stimulating hormone;
CRC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg11143507	chr3:125485238	NA	-0.57	-7.37	-0.38	1.37e-12	Blood pressure (smoking interaction);
CRC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.13	0.32	2.51e-9	Rheumatoid arthritis;
CRC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18252515	chr7:66147081	NA	0.39	5.74	0.3	2.14e-8	Aortic root size;
CRC	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg00601450	chr5:74908170	NA	-0.41	-5.77	-0.3	1.84e-8	Age-related disease endophenotypes;
CRC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.25	0.45	2.97e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23161317	chr6:28129485	ZNF389	0.5	6.21	0.32	1.57e-9	Parkinson's disease;
CRC	cis	rs3823572	0.564	rs2953620	chr7:133666388	T/C	cg03336402	chr7:133662267	EXOC4	-0.66	-10.38	-0.5	5.04e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.84e-9	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23434193	chr8:74884752	TCEB1	0.6	8.06	0.41	1.47e-14	Thyroid stimulating hormone;
CRC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.79	13.1	0.59	7.56e-32	Diastolic blood pressure;
CRC	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.49	-9.02	-0.45	1.63e-17	Common traits (Other);
CRC	cis	rs9287719	0.649	rs10184776	chr2:10726446	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg19622623	chr12:86230825	RASSF9	0.4	6.36	0.33	6.66e-10	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15425530	chr17:2415361	METT10D	0.44	6.62	0.34	1.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.44	6.34	0.33	7.7e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg01420254	chr6:26195488	NA	0.75	8.48	0.42	7.58e-16	Gout;Renal underexcretion gout;
CRC	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	8.6	0.43	3.21e-16	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	7.47	0.38	7.21e-13	Height;
CRC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.41	8.02	0.4	1.82e-14	Mean corpuscular volume;
CRC	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.92	-12.19	-0.56	1.92e-28	Exhaled nitric oxide output;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00628130	chr8:95908808	CCNE2	0.5	6.82	0.35	4.51e-11	Survival in pancreatic cancer;
CRC	cis	rs3790645	1.000	rs282176	chr1:26898956	T/C	cg23229016	chr1:26872525	RPS6KA1	0.25	5.98	0.31	5.89e-9	Glucose homeostasis traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25088355	chr8:144691901	PYCRL	0.39	6.34	0.33	7.42e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.33	0.46	1.59e-18	Coffee consumption (cups per day);
CRC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-7.09	-0.36	8.02e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg01639898	chr1:32083012	HCRTR1	-0.3	-6.27	-0.33	1.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.45	5.88	0.31	1.03e-8	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	trans	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg07393940	chr7:158741817	NA	0.5	7.05	0.36	1.05e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.94	0.52	5.78e-24	Motion sickness;
CRC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg27565382	chr3:53032988	SFMBT1	0.7	6.16	0.32	2.07e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1868673	1.000	rs9784281	chr3:150159779	C/G	cg04908077	chr3:150187338	NA	-0.33	-5.64	-0.3	3.58e-8	Waist circumference;
CRC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.47	-9.2	-0.45	4.12e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7517126	1.000	rs7519492	chr1:196840125	T/C	cg13682187	chr1:196946512	CFHR5	-0.37	-5.97	-0.31	6.03e-9	Blood protein levels;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12172441	chr6:28176163	NA	0.53	7.17	0.37	5.02e-12	Cardiac Troponin-T levels;
CRC	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00938859	chr5:1591904	SDHAP3	-0.7	-7.37	-0.38	1.41e-12	Breast cancer;
CRC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.32	0.46	1.72e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1320333	0.685	rs6710875	chr2:699976	A/G	cg00500140	chr2:691012	NA	-0.55	-6.72	-0.35	7.83e-11	Obesity-related traits;
CRC	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg24553058	chr2:113831203	IL1F10	0.39	6.3	0.33	9.43e-10	Protein quantitative trait loci;
CRC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.93	-0.4	3.41e-14	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07796735	chr12:49932860	KCNH3	0.45	6.06	0.32	3.73e-9	Anxiety disorder;
CRC	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.39	-6.43	-0.33	4.44e-10	Mean arterial pressure;
CRC	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21659725	chr3:3221576	CRBN	-0.68	-9.33	-0.46	1.64e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.76	-0.39	1.08e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg05320533	chr16:89541815	ANKRD11	-0.43	-5.99	-0.31	5.57e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.46	-5.87	-0.31	1.04e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.41	-0.33	4.93e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9976767	0.932	rs28371062	chr21:43828267	C/T	cg23042151	chr21:43824109	UBASH3A	-0.37	-6.44	-0.33	4.17e-10	Type 1 diabetes;
CRC	cis	rs3889199	0.851	rs12561822	chr1:59673745	T/C	cg25881383	chr1:59680599	NA	-0.38	-6.05	-0.32	4.05e-9	Pulse pressure;
CRC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.34e-9	Major depressive disorder;
CRC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.5	-8.47	-0.42	8.02e-16	Calcium levels;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.4	6.98	0.36	1.59e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs965469	0.779	rs6037566	chr20:3331414	A/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.53	0.43	5.28e-16	Coffee consumption (cups per day);
CRC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	7.14	0.37	6.01e-12	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01956158	chr8:132916947	EFR3A	0.46	6.42	0.33	4.87e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg10729496	chr3:10149963	C3orf24	0.45	6.08	0.32	3.26e-9	Alzheimer's disease;
CRC	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg22546130	chr22:19950026	COMT	-0.25	-7.05	-0.36	1.03e-11	Blood metabolite levels;
CRC	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.62	-8.01	-0.4	2.04e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.86	-0.48	2.88e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.3	-0.33	9.38e-10	Aortic root size;
CRC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	10.68	0.51	4.84e-23	Hip circumference adjusted for BMI;
CRC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.65	9.68	0.47	1.14e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs8060686	0.858	rs8051587	chr16:67796315	A/C	cg07125278	chr16:67683757	RLTPR	-0.49	-6.5	-0.34	2.93e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.44	5.81	0.31	1.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg24375607	chr4:120327624	NA	0.47	7.32	0.37	1.95e-12	Corneal astigmatism;
CRC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.72	-8.71	-0.43	1.54e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-8.09	-0.41	1.16e-14	Coronary artery disease;
CRC	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.62	-9.77	-0.47	5.67e-20	Systemic lupus erythematosus;
CRC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg02993699	chr4:3415135	RGS12	-0.38	-6.49	-0.34	3.09e-10	Serum sulfate level;
CRC	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg22687807	chr8:143858763	LYNX1	-0.37	-6.47	-0.34	3.46e-10	Urinary tract infection frequency;
CRC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-0.84	-8.78	-0.44	9.23e-17	Gout;Renal underexcretion gout;
CRC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.52	-9.56	-0.47	2.93e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.54	8.66	0.43	2.11e-16	Type 2 diabetes;
CRC	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.96	11.01	0.52	3.29e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.58	-8.06	-0.41	1.43e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.63	-7.69	-0.39	1.69e-13	Menarche (age at onset);
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg15763984	chr4:1342303	KIAA1530	-0.33	-5.61	-0.3	4.35e-8	Obesity-related traits;
CRC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg02428538	chr16:24856791	SLC5A11	-0.54	-6.48	-0.34	3.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg15083037	chr5:83017644	HAPLN1	-0.51	-6.75	-0.35	6.56e-11	Prostate cancer;
CRC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.97	-0.4	2.57e-14	Morning vs. evening chronotype;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg06470822	chr6:28175283	NA	0.83	7.71	0.39	1.49e-13	Depression;
CRC	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg07424746	chr4:185654737	MLF1IP	0.51	5.69	0.3	2.8e-8	Blood protein levels;
CRC	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.79	-12.19	-0.56	1.84e-28	Testicular germ cell tumor;
CRC	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg14458575	chr2:238380390	NA	0.68	8.89	0.44	4.26e-17	Prostate cancer;
CRC	cis	rs9491140	0.539	rs11154224	chr6:124678535	G/A	cg05308643	chr6:124982296	NKAIN2	0.49	6.83	0.35	4.15e-11	Neuroticism;
CRC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.07	-0.36	9.13e-12	Alzheimer's disease (late onset);
CRC	cis	rs4908768	0.501	rs7527389	chr1:8556545	A/G	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	0.57	7.95	0.4	3.08e-14	Pulmonary function decline;
CRC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-8.42	-0.42	1.18e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-6.04	-0.32	4.1e-9	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06254406	chr13:103450982	BIVM;KDELC1	0.48	6.26	0.33	1.17e-9	Anxiety disorder;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.83	-0.31	1.31e-8	Depression;
CRC	cis	rs3790455	0.610	rs1171554	chr1:156474119	G/A	cg14087168	chr1:156450669	MEF2D	-0.35	-5.99	-0.31	5.39e-9	Migraine;
CRC	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.71	-9.44	-0.46	6.94e-19	Blood protein levels;
CRC	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg03605463	chr16:89740564	NA	-0.4	-5.69	-0.3	2.87e-8	Vitiligo;
CRC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.52	-7.37	-0.38	1.37e-12	Alzheimer's disease (late onset);
CRC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.45	6.0	0.31	5.11e-9	Cleft lip with or without cleft palate;
CRC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.39	-5.9	-0.31	8.97e-9	Mean corpuscular volume;
CRC	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.5	-0.34	2.93e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.67	-7.79	-0.39	8.84e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.65	-7.81	-0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs11229555	0.645	rs12291551	chr11:58176915	T/A	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7833986	1.000	rs34480844	chr8:57092973	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.84	0.35	3.95e-11	Height;
CRC	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.81	-0.35	4.64e-11	Longevity;Endometriosis;
CRC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	8.11	0.41	1.04e-14	Monocyte count;
CRC	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg21496419	chr19:44306685	LYPD5	0.35	6.52	0.34	2.6e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-7.91	-0.4	3.88e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.72	-0.3	2.4e-8	Total body bone mineral density;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.61	-0.39	2.92e-13	Breast cancer;
CRC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg03690763	chr11:133734501	NA	-0.37	-6.25	-0.33	1.27e-9	Childhood ear infection;
CRC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.84	14.27	0.62	2.74e-36	Blood metabolite levels;
CRC	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.7	-11.86	-0.55	2.99e-27	Itch intensity from mosquito bite;
CRC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.94	-17.2	-0.69	9.43e-48	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26149223	chr2:179345173	MIR548N;PLEKHA3	0.42	6.31	0.33	9.12e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.58	0.5	1.03e-22	Systolic blood pressure;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg24046110	chr8:143859143	LYNX1	-0.43	-6.91	-0.36	2.52e-11	Urinary tract infection frequency;
CRC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-1.02	-18.27	-0.71	5.62e-52	Parkinson's disease;
CRC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.28	14.8	0.63	2.39e-38	Diabetic kidney disease;
CRC	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg02319466	chr17:76381040	PGS1	0.36	5.61	0.3	4.3e-8	HDL cholesterol levels;
CRC	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.46	6.26	0.33	1.21e-9	Eye color traits;
CRC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.57	-0.38	3.88e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.57	-9.07	-0.45	1.09e-17	Schizophrenia;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.83	13.44	0.6	3.92e-33	Hemoglobin concentration;Hematocrit;
CRC	cis	rs523516	0.645	rs657723	chr17:37319103	T/C	cg20555674	chr17:37321631	ARL5C	0.38	7.82	0.4	7.19e-14	IgG glycosylation;
CRC	cis	rs9816226	0.591	rs74607912	chr3:185818559	G/A	cg00760338	chr3:185826511	ETV5	-0.64	-5.63	-0.3	3.93e-8	Obesity;Body mass index;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg10667969	chr3:149181941	NA	-0.53	-6.07	-0.32	3.53e-9	Optic disc area;
CRC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.38	-0.38	1.32e-12	Body mass index;
CRC	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	1.11	9.09	0.45	9.52e-18	Arsenic metabolism;
CRC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg20203395	chr5:56204925	C5orf35	-0.65	-7.76	-0.39	1.06e-13	Initial pursuit acceleration;
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.63	8.16	0.41	7.3e-15	Alzheimer's disease;
CRC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg21285383	chr16:89894308	SPIRE2	0.35	6.01	0.31	4.92e-9	Vitiligo;
CRC	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.39	-6.01	-0.31	5.06e-9	Bone mineral density;
CRC	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-5.99	-0.31	5.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	8.38	0.42	1.6e-15	Lymphocyte counts;
CRC	trans	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg26040332	chr1:27960788	FGR	0.32	6.13	0.32	2.5e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25608569	chr9:6008675	KIAA2026	-0.4	-6.22	-0.32	1.54e-9	Aortic root size;
CRC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg09473613	chr1:24152604	HMGCL	0.35	5.66	0.3	3.35e-8	Immature fraction of reticulocytes;
CRC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.67	-0.3	3.18e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.83	11.32	0.53	2.6e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.67	8.4	0.42	1.33e-15	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg00666640	chr1:248458726	OR2T12	0.51	8.97	0.44	2.31e-17	Common traits (Other);
CRC	cis	rs6694672	0.867	rs616675	chr1:197257556	C/T	cg13682187	chr1:196946512	CFHR5	0.5	7.05	0.36	1.05e-11	Asthma;
CRC	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg04110750	chr16:69646130	NFAT5	0.52	7.05	0.36	1.07e-11	IgE levels;
CRC	cis	rs9311676	0.632	rs62259772	chr3:58417416	C/T	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.39e-10	Systemic lupus erythematosus;
CRC	cis	rs7113874	0.544	rs9704807	chr11:8578771	G/C	cg20771178	chr11:8615675	STK33	-0.34	-5.61	-0.3	4.21e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.04	-14.44	-0.62	6.2e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg21294424	chr19:58662284	ZNF329	0.85	9.53	0.47	3.54e-19	Cholesterol, total;
CRC	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.51	-6.29	-0.33	1e-9	Coronary artery calcification;
CRC	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg01426195	chr3:39028469	NA	0.42	7.05	0.36	1.05e-11	Handedness;
CRC	cis	rs354033	0.918	rs67256453	chr7:149314756	T/C	cg24335155	chr7:149193227	ZNF746	0.38	6.02	0.32	4.59e-9	Multiple sclerosis;
CRC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg26102564	chr10:131424627	MGMT	0.38	5.67	0.3	3.05e-8	Response to temozolomide;
CRC	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.64	-8.32	-0.42	2.33e-15	Cocaine dependence;
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.38	5.82	0.31	1.36e-8	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg02353165	chr6:42928485	GNMT	0.54	6.91	0.36	2.57e-11	Blood protein levels;
CRC	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg27411982	chr8:10470053	RP1L1	-0.35	-5.74	-0.3	2.2e-8	Neuroticism;
CRC	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg14593290	chr7:50529359	DDC	-0.56	-7.68	-0.39	1.82e-13	Malaria;
CRC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.51	8.38	0.42	1.52e-15	Uric acid clearance;
CRC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.52	-8.37	-0.42	1.68e-15	Neurofibrillary tangles;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20786246	chr2:72377174	NA	0.42	5.98	0.31	5.84e-9	Response to antipsychotic treatment;
CRC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg18761221	chr20:60518478	NA	0.41	7.18	0.37	4.57e-12	Body mass index;
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.26e-9	Prudent dietary pattern;
CRC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.95	-0.36	1.91e-11	Lung cancer;
CRC	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.49	6.29	0.33	9.88e-10	Alzheimer's disease (survival time);
CRC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.77	0.44	9.87e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.63	-0.3	3.78e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-5.66	-0.3	3.29e-8	Skin colour saturation;
CRC	cis	rs4363385	0.693	rs608509	chr1:153034650	G/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.6	-0.34	1.62e-10	Inflammatory skin disease;
CRC	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.9	21.39	0.76	3.25e-64	Longevity;
CRC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.46	8.27	0.41	3.39e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-7.18	-0.37	4.68e-12	Itch intensity from mosquito bite;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12273811	chr6:28175739	NA	-0.77	-11.19	-0.53	7.31e-25	Depression;
CRC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.82	0.44	6.64e-17	Homoarginine levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10347199	chr17:7123561	DLG4;ACADVL	0.49	6.72	0.35	8.09e-11	Anxiety disorder;
CRC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.61	10.76	0.51	2.53e-23	Aortic root size;
CRC	cis	rs6662572	0.737	rs56316933	chr1:46266725	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.91	0.31	8.39e-9	Blood protein levels;
CRC	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg00105475	chr2:10696890	NA	0.45	7.09	0.36	8.01e-12	Prostate cancer;
CRC	cis	rs45544231	0.569	rs9923558	chr16:52548183	A/T	cg09051775	chr16:52580266	TOX3	-0.38	-6.16	-0.32	2.15e-9	Restless legs syndrome;
CRC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24308560	chr3:49941425	MST1R	-0.44	-6.81	-0.35	4.69e-11	Body mass index;
CRC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.41	-5.78	-0.3	1.72e-8	Daytime sleep phenotypes;
CRC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06544989	chr22:39130855	UNC84B	0.45	6.94	0.36	2.03e-11	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05007375	chr14:92588364	NDUFB1;CPSF2	0.45	7.36	0.38	1.49e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.55	8.2	0.41	5.46e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg15103426	chr22:29168792	CCDC117	-0.5	-6.86	-0.35	3.36e-11	Lymphocyte counts;
CRC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg00129232	chr17:37814104	STARD3	0.56	6.98	0.36	1.67e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg09904177	chr6:26538194	HMGN4	0.57	6.76	0.35	6.47e-11	Small cell lung carcinoma;
CRC	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.08	-0.32	3.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.5	7.22	0.37	3.59e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.46	6.88	0.35	3.02e-11	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg02527881	chr3:46936655	PTH1R	-0.34	-6.02	-0.32	4.55e-9	Colorectal cancer;
CRC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.55	6.78	0.35	5.61e-11	Response to diuretic therapy;
CRC	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg21153622	chr11:89784906	NA	0.46	7.44	0.38	8.9e-13	HDL cholesterol;
CRC	cis	rs2013441	0.896	rs1812934	chr17:20030960	A/T	cg13482628	chr17:19912719	NA	-0.4	-6.06	-0.32	3.69e-9	Obesity-related traits;
CRC	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	0.88	10.36	0.5	6.12e-22	Type 2 diabetes nephropathy;
CRC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.13	0.37	6.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.86	-11.76	-0.54	6.57e-27	Asthma;
CRC	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.12e-18	Blood protein levels;
CRC	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.94	-0.36	2.12e-11	Inflammatory skin disease;
CRC	cis	rs12024301	0.557	rs6677194	chr1:183635587	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.36	-5.97	-0.31	6.19e-9	Childhood ear infection;
CRC	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg01475377	chr6:109611718	NA	-0.35	-6.09	-0.32	3.18e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs330048	0.525	rs10112237	chr8:9072729	A/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-5.71	-0.3	2.52e-8	Systemic lupus erythematosus;
CRC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-6.22	-0.32	1.5e-9	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11353368	chr19:47363757	NA	0.43	6.43	0.33	4.61e-10	Response to antipsychotic treatment;
CRC	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.24	-0.37	3.29e-12	Inflammatory skin disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23376526	chr1:153748118	SLC27A3	0.42	6.3	0.33	9.31e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6479527	0.810	rs2153070	chr9:96751573	C/G	cg14459158	chr9:96720562	NA	0.41	7.43	0.38	9.19e-13	Esophageal adenocarcinoma;
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg10677697	chr7:45961126	IGFBP3	0.36	6.29	0.33	1.03e-9	Sitting height ratio;
CRC	cis	rs17767392	0.794	rs61991247	chr14:71860318	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.89	-0.35	2.93e-11	Mitral valve prolapse;
CRC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg03469805	chr14:105330648	KIAA0284	-0.33	-6.96	-0.36	1.89e-11	IgG glycosylation;
CRC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.42	-0.42	1.22e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.51	-6.88	-0.35	3.08e-11	Colorectal cancer;
CRC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	0.69	7.01	0.36	1.35e-11	Body mass index;
CRC	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.58e-11	Opioid sensitivity;
CRC	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.64	10.44	0.5	3.21e-22	Schizophrenia;
CRC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg07952391	chr2:88470173	THNSL2	-0.38	-5.87	-0.31	1.05e-8	Response to metformin (IC50);
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.82	-8.75	-0.43	1.15e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	8.02	0.4	1.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg13172432	chr1:205912842	SLC26A9	-0.34	-5.95	-0.31	6.92e-9	Cystic fibrosis-related diabetes;
CRC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg25767906	chr1:53392781	SCP2	-0.39	-6.1	-0.32	2.92e-9	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09103232	chr17:7185001	SLC2A4	0.44	6.09	0.32	3.23e-9	Response to antipsychotic treatment;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg14903685	chr15:70391316	TLE3	-0.57	-6.4	-0.33	5.44e-10	Lung adenocarcinoma;
CRC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.59	9.78	0.47	5.45e-20	Prostate cancer;
CRC	cis	rs447	1.000	rs12707619	chr7:83748427	T/C	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.79	-0.39	8.91e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11212617	0.935	rs183459	chr11:108089197	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.88	0.31	9.86e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11866815	0.602	rs60907769	chr16:380547	C/A	cg00101154	chr16:420108	MRPL28	0.53	5.71	0.3	2.5e-8	Body mass index;
CRC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-7.63	-0.39	2.57e-13	Neuroticism;
CRC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.7	-11.37	-0.53	1.75e-25	Cognitive function;
CRC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.2e-12	Corneal astigmatism;
CRC	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg25809561	chr17:30822961	MYO1D	0.51	9.23	0.45	3.28e-18	Schizophrenia;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg06470822	chr6:28175283	NA	1.01	13.28	0.59	1.55e-32	Depression;
CRC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.62	6.22	0.32	1.48e-9	Plasma clusterin levels;
CRC	cis	rs4731207	0.698	rs10269011	chr7:124478813	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.57	8.22	0.41	4.76e-15	Autism;
CRC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.44	5.95	0.31	6.73e-9	Schizophrenia;
CRC	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	cg04338863	chr8:33670619	NA	0.4	6.8	0.35	5.06e-11	Body mass index;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg01339444	chr6:118972232	C6orf204	0.56	6.09	0.32	3.14e-9	Diastolic blood pressure;
CRC	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg22778903	chr21:42741698	MX2	0.38	6.25	0.33	1.26e-9	Melanoma;
CRC	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg21452805	chr1:244014465	NA	0.53	7.14	0.37	5.9e-12	RR interval (heart rate);
CRC	cis	rs4237845	0.622	rs10783859	chr12:58332794	C/A	cg02175503	chr12:58329896	NA	0.76	11.83	0.55	3.9e-27	Intelligence (multi-trait analysis);
CRC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.42	5.76	0.3	1.94e-8	Response to amphetamines;
CRC	trans	rs6546324	0.539	rs4671192	chr2:67841855	A/G	cg00907274	chr3:27498161	SLC4A7	-0.48	-6.13	-0.32	2.55e-9	Endometriosis;
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg11843238	chr5:131593191	PDLIM4	0.34	6.38	0.33	5.98e-10	Blood metabolite levels;
CRC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.33	-0.42	2.24e-15	Intelligence (multi-trait analysis);
CRC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg04121214	chr22:50244548	NA	0.45	6.31	0.33	9.27e-10	Schizophrenia;
CRC	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg21798802	chr22:38057573	PDXP	0.35	5.68	0.3	2.93e-8	Fat distribution (HIV);
CRC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg10790698	chr19:18539756	SSBP4	-0.43	-8.4	-0.42	1.37e-15	Breast cancer;
CRC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg04166393	chr7:2884313	GNA12	0.51	6.75	0.35	6.85e-11	Height;
CRC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.9	-0.44	3.84e-17	Alcohol dependence;
CRC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.7	-9.07	-0.45	1.13e-17	Initial pursuit acceleration;
CRC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.41	6.53	0.34	2.55e-10	Dupuytren's disease;
CRC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg21251018	chr6:28226885	NKAPL	0.48	8.25	0.41	3.84e-15	Pubertal anthropometrics;
CRC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.61	9.29	0.46	2.17e-18	Pancreatic cancer;
CRC	cis	rs9303542	0.559	rs62066693	chr17:46617530	G/C	cg04904318	chr17:46607828	HOXB1	-0.53	-6.14	-0.32	2.36e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.95	0.48	1.51e-20	Cognitive test performance;
CRC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg25834613	chr7:1915315	MAD1L1	-0.48	-6.82	-0.35	4.38e-11	Bipolar disorder;
CRC	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.65	10.23	0.49	1.69e-21	Corneal astigmatism;
CRC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	15.17	0.64	8.49e-40	Smoking behavior;
CRC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.83	14.82	0.63	2.03e-38	Breast cancer;
CRC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg15147215	chr3:52552868	STAB1	0.43	7.05	0.36	1.09e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23888375	chr2:203776317	ALS2CR8;WDR12	-0.42	-6.06	-0.32	3.68e-9	Myopia (pathological);
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.41	-7.17	-0.37	4.97e-12	Lung cancer;
CRC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.23	-0.53	5.37e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	12.91	0.58	3.83e-31	Colorectal cancer;
CRC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.47	6.63	0.34	1.36e-10	Lung cancer;
CRC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.58	9.38	0.46	1.12e-18	Height;
CRC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.15	0.37	5.75e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg02725872	chr8:58115012	NA	-0.44	-6.23	-0.32	1.45e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg22244940	chr12:132335942	MMP17	0.44	6.49	0.34	3.07e-10	Migraine;
CRC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.49	-0.38	6.57e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.77	10.66	0.51	5.7e-23	Initial pursuit acceleration;
CRC	cis	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg06522879	chr11:64358276	SLC22A12	-0.51	-7.88	-0.4	4.91e-14	Urate levels in obese individuals;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12670061	chr16:67465042	HSD11B2	0.43	6.01	0.31	4.95e-9	Anxiety disorder;
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.63	6.54	0.34	2.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg13844804	chr7:814759	HEATR2	0.66	7.86	0.4	5.47e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02290350	chr8:58132656	NA	-0.61	-7.12	-0.37	6.7e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg26043149	chr18:55253948	FECH	-0.55	-8.25	-0.41	3.76e-15	Bone mineral density;
CRC	cis	rs6694672	1.000	rs1412640	chr1:197070815	T/C	cg13682187	chr1:196946512	CFHR5	0.51	8.24	0.41	4.16e-15	Asthma;
CRC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.42	-5.87	-0.31	1.06e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg23071808	chr14:103021642	NA	-0.64	-6.96	-0.36	1.84e-11	Platelet count;
CRC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.12	-0.37	6.61e-12	Mean corpuscular volume;
CRC	cis	rs501120	0.584	rs10900003	chr10:44698044	C/A	cg09554077	chr10:44749378	NA	0.69	7.91	0.4	4.04e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.6	-8.22	-0.41	4.87e-15	Carotid intima media thickness;
CRC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.2	0.45	4.37e-18	Heart rate;
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.22	0.32	1.51e-9	Prudent dietary pattern;
CRC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.57	10.34	0.5	6.81e-22	Coronary artery disease;
CRC	trans	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.42	6.26	0.33	1.18e-9	Cystic fibrosis severity;
CRC	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.82	-10.22	-0.49	1.74e-21	Red blood cell traits;
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.03	-10.72	-0.51	3.43e-23	Body mass index;
CRC	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg05925327	chr15:68127851	NA	-0.32	-6.15	-0.32	2.22e-9	Restless legs syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14431266	chr11:67057003	ANKRD13D	0.49	7.05	0.36	1.05e-11	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-6.03	-0.32	4.51e-9	Gut microbiome composition (summer);
CRC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	cis	rs972578	1.000	rs2256040	chr22:43398049	C/A	cg01576275	chr22:43409880	NA	-0.48	-7.92	-0.4	3.65e-14	Mean platelet volume;
CRC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.16	10.86	0.51	1.1e-23	Skin colour saturation;
CRC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.3	2.67e-8	Hemoglobin concentration;
CRC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26240231	chr7:1148101	C7orf50	-0.42	-5.7	-0.3	2.61e-8	Bronchopulmonary dysplasia;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg12172441	chr6:28176163	NA	0.47	6.19	0.32	1.75e-9	Parkinson's disease;
CRC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-7.92	-0.4	3.58e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg17724175	chr1:150552817	MCL1	-0.46	-7.22	-0.37	3.54e-12	Tonsillectomy;
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.37	-0.38	1.37e-12	Total body bone mineral density;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg11843238	chr5:131593191	PDLIM4	0.49	9.31	0.46	1.86e-18	Acylcarnitine levels;
CRC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.44	6.92	0.36	2.38e-11	Vitiligo;
CRC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.52	-9.04	-0.45	1.36e-17	Aortic root size;
CRC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg19223190	chr17:80058835	NA	0.39	6.17	0.32	2.02e-9	Life satisfaction;
CRC	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-6.93	-0.36	2.25e-11	Metabolite levels (Pyroglutamine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12235988	chr19:1605645	UQCR	0.38	5.96	0.31	6.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	6.02	0.32	4.62e-9	Breast cancer;
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg03804128	chr16:635623	NA	0.31	7.29	0.37	2.36e-12	Height;
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg07617317	chr6:118971624	C6orf204	0.5	6.21	0.32	1.56e-9	Diastolic blood pressure;
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.88	-0.35	3.04e-11	Bipolar disorder;
CRC	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg20203395	chr5:56204925	C5orf35	-0.42	-5.93	-0.31	7.8e-9	Coronary artery disease;
CRC	cis	rs728616	0.867	rs12781912	chr10:81918128	G/T	cg05935833	chr10:81318306	SFTPA2	-0.5	-5.98	-0.31	5.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.66	6.72	0.35	7.79e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg24634471	chr8:143751801	JRK	-0.46	-6.44	-0.33	4.22e-10	Urinary tract infection frequency;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg02683197	chr6:28174875	NA	0.73	8.97	0.44	2.34e-17	Parkinson's disease;
CRC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.55	-8.37	-0.42	1.67e-15	Uric acid levels;
CRC	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	5.93	0.31	7.66e-9	Ovarian reserve;
CRC	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg00631329	chr6:26305371	NA	-0.56	-9.46	-0.46	6.13e-19	Educational attainment;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.49	-7.32	-0.37	1.88e-12	Longevity;Endometriosis;
CRC	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg11130432	chr3:121712080	ILDR1	-0.48	-5.95	-0.31	6.91e-9	Multiple sclerosis;
CRC	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.51e-12	HDL cholesterol;
CRC	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.22	14.43	0.62	6.46e-37	Uric acid levels;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.95	17.6	0.7	2.44e-49	Primary sclerosing cholangitis;
CRC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.85	9.16	0.45	5.85e-18	Schizophrenia;
CRC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-7.77	-0.39	9.9e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.53	-6.12	-0.32	2.66e-9	Body mass index;
CRC	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.0	0.31	5.28e-9	Axial length;
CRC	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg07952391	chr2:88470173	THNSL2	0.64	6.34	0.33	7.37e-10	Plasma clusterin levels;
CRC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.34	-0.46	1.54e-18	Aortic root size;
CRC	cis	rs4774899	0.752	rs2464429	chr15:57348302	C/T	cg08128148	chr15:57256372	TCF12	-0.39	-5.66	-0.3	3.33e-8	Urinary tract infection frequency;
CRC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.8	-13.54	-0.6	1.64e-33	Cystic fibrosis severity;
CRC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.09	-0.36	8.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg16141378	chr3:129829833	LOC729375	-0.46	-6.82	-0.35	4.44e-11	Retinal vascular caliber;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg24560729	chr4:1342394	KIAA1530	0.33	5.74	0.3	2.11e-8	Obesity-related traits;
CRC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.55	-6.7	-0.35	8.84e-11	Diastolic blood pressure;
CRC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.62	8.91	0.44	3.58e-17	Schizophrenia;
CRC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.86	0.66	1.86e-42	Parkinson's disease;
CRC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.65	9.12	0.45	7.62e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.46	7.07	0.36	9.55e-12	HDL cholesterol;
CRC	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.23	6.22	0.32	1.55e-9	Type 2 diabetes;
CRC	cis	rs2249694	0.520	rs7096321	chr10:135324536	A/G	cg20169779	chr10:135381914	SYCE1	-0.54	-7.33	-0.37	1.76e-12	Obesity-related traits;
CRC	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.46	6.82	0.35	4.29e-11	Crohn's disease;
CRC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg16235748	chr6:149772707	ZC3H12D	0.37	6.56	0.34	2.13e-10	Dupuytren's disease;
CRC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-6.21	-0.32	1.62e-9	Schizophrenia;
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg08200770	chr17:80723486	TBCD	-0.5	-7.6	-0.39	3.09e-13	Glycated hemoglobin levels;
CRC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.86	-13.84	-0.61	1.15e-34	Multiple myeloma;
CRC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.54e-13	Mean platelet volume;
CRC	cis	rs972578	1.000	rs5759080	chr22:43393940	C/T	cg01576275	chr22:43409880	NA	-0.49	-7.88	-0.4	4.74e-14	Mean platelet volume;
CRC	cis	rs294883	0.701	rs4709293	chr6:159730481	A/G	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg14631576	chr9:95140430	CENPP	-0.32	-5.83	-0.31	1.34e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.46	7.73	0.39	1.3e-13	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26823989	chr1:87380673	SEP15;HS2ST1	0.4	7.04	0.36	1.14e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	9.04	0.45	1.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.62	-9.57	-0.47	2.72e-19	Dementia with Lewy bodies;
CRC	cis	rs737008	0.922	rs2070923	chr16:11369855	G/T	cg00044050	chr16:11439710	C16orf75	0.44	5.61	0.3	4.38e-8	Obesity-related traits;
CRC	cis	rs1223397	1.000	rs1223403	chr6:13271812	G/A	cg21538684	chr6:13274180	PHACTR1	0.49	6.02	0.31	4.69e-9	Blood pressure;
CRC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.55	8.13	0.41	8.91e-15	Response to temozolomide;
CRC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.12	-0.32	2.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00166722	chr3:10149974	C3orf24	0.65	8.86	0.44	5.13e-17	Alzheimer's disease;
CRC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	0.56	6.36	0.33	6.84e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs7635838	0.819	rs4684781	chr3:11516299	G/A	cg00170343	chr3:11313890	ATG7	0.43	6.53	0.34	2.53e-10	HDL cholesterol;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.53	-0.43	5.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.47	7.02	0.36	1.25e-11	Intelligence (multi-trait analysis);
CRC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.78	0.54	5.78e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg13047869	chr3:10149882	C3orf24	0.52	7.36	0.38	1.48e-12	Alzheimer's disease;
CRC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.49	8.05	0.41	1.48e-14	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.63	-0.3	3.8e-8	Life satisfaction;
CRC	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.55	8.16	0.41	7.36e-15	Melanoma;
CRC	cis	rs2398893	0.855	rs11791859	chr9:96788758	G/A	cg14459158	chr9:96720562	NA	0.39	6.4	0.33	5.5e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg06484146	chr7:12443880	VWDE	-0.54	-7.02	-0.36	1.28e-11	Coronary artery disease;
CRC	cis	rs672059	1.000	rs483783	chr1:183162152	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.49	6.93	0.36	2.2e-11	Hypertriglyceridemia;
CRC	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.62	7.32	0.37	1.88e-12	Bipolar disorder;
CRC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.27	-0.46	2.46e-18	Menarche (age at onset);
CRC	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg03929089	chr4:120376271	NA	0.67	6.42	0.33	4.68e-10	Axial length;
CRC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-6.03	-0.32	4.48e-9	Vitiligo;
CRC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.73	-12.16	-0.56	2.29e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.63	8.05	0.41	1.53e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg21770322	chr7:97807741	LMTK2	0.54	9.11	0.45	8.51e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.0	-0.79	1.81e-70	Myeloid white cell count;
CRC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.5	6.64	0.34	1.28e-10	Multiple sclerosis;
CRC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg03929089	chr4:120376271	NA	-0.49	-7.08	-0.36	8.76e-12	Coronary artery disease;
CRC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.01e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.81	0.35	4.52e-11	Bipolar disorder;
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg01874867	chr7:94954059	PON1	-0.51	-6.33	-0.33	7.86e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.63	10.37	0.5	5.44e-22	Schizophrenia;
CRC	cis	rs12612619	0.704	rs10185736	chr2:27321224	T/C	cg00617064	chr2:27272375	NA	0.41	6.61	0.34	1.59e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg12458913	chr13:53173898	NA	0.49	7.19	0.37	4.52e-12	Lewy body disease;
CRC	cis	rs699	0.698	rs2478528	chr1:230863396	T/C	cg07502417	chr1:230849801	AGT	0.29	5.94	0.31	7.11e-9	Coronary artery disease;
CRC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-6.08	-0.32	3.38e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.17	-0.32	1.95e-9	High light scatter reticulocyte count;
CRC	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.43	-6.26	-0.33	1.17e-9	QT interval;
CRC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.4	6.34	0.33	7.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.45	9.01	0.44	1.68e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.56	8.52	0.43	5.68e-16	Ulcerative colitis;
CRC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.62	9.54	0.47	3.25e-19	Corneal astigmatism;
CRC	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.8	-11.4	-0.53	1.35e-25	Gut microbiome composition (winter);
CRC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg25456477	chr12:86230367	RASSF9	0.34	6.01	0.31	4.96e-9	Major depressive disorder;
CRC	cis	rs7692995	1.000	rs7659195	chr4:18022692	T/C	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.51	-0.34	2.77e-10	Platelet distribution width;
CRC	cis	rs815815	0.608	rs6751198	chr2:47396274	C/T	cg27223769	chr2:47403360	CALM2	-0.6	-7.79	-0.39	8.81e-14	Dialysis-related mortality;
CRC	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.42	5.83	0.31	1.32e-8	Height;
CRC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.42	-6.15	-0.32	2.25e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs733592	0.599	rs12819124	chr12:48409054	G/T	cg21466736	chr12:48725269	NA	-0.43	-6.75	-0.35	6.5e-11	Plateletcrit;
CRC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg26893134	chr6:116381904	FRK	0.26	7.63	0.39	2.57e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1223397	0.651	rs2439543	chr6:13312153	A/C	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.37e-14	Colorectal cancer;
CRC	trans	rs75804782	0.810	rs55694368	chr2:239317692	G/T	cg01134436	chr17:81009848	B3GNTL1	0.72	6.43	0.33	4.4e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-1.0	-11.73	-0.54	9.05e-27	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17474435	chr12:50135167	TMBIM6	0.53	6.78	0.35	5.52e-11	Thyroid stimulating hormone;
CRC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.76	12.86	0.58	6.25e-31	Blood protein levels;
CRC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.32	0.42	2.36e-15	Height;
CRC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.59	-8.78	-0.44	9.43e-17	Other erythrocyte phenotypes;
CRC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.71	11.64	0.54	1.92e-26	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-6.04	-0.32	4.08e-9	Eosinophil percentage of white cells;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg21251018	chr6:28226885	NKAPL	0.47	7.36	0.38	1.49e-12	Parkinson's disease;
CRC	cis	rs3889199	0.924	rs12758643	chr1:59669918	C/T	cg25881383	chr1:59680599	NA	-0.38	-6.08	-0.32	3.36e-9	Pulse pressure;
CRC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.6	-0.39	3.02e-13	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23699148	chr19:53087184	ZNF701	-0.39	-6.51	-0.34	2.78e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg04969067	chr8:143858791	LYNX1	-0.42	-6.2	-0.32	1.7e-9	Urinary tract infection frequency;
CRC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.36	5.87	0.31	1.07e-8	Coronary artery disease;
CRC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg02993699	chr4:3415135	RGS12	-0.38	-6.32	-0.33	8.43e-10	Serum sulfate level;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.43	6.47	0.34	3.61e-10	Obesity-related traits;
CRC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.57	-8.73	-0.43	1.29e-16	Height;
CRC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.54	9.18	0.45	4.86e-18	Prudent dietary pattern;
CRC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.59	-9.14	-0.45	6.57e-18	Colorectal cancer;
CRC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.65	12.37	0.56	3.93e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3751196	0.901	rs77409472	chr12:104181616	C/T	cg02344784	chr12:104178138	NT5DC3	0.69	7.01	0.36	1.4e-11	Sense of smell;
CRC	trans	rs2303319	0.504	rs62188153	chr2:162313036	G/T	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.27	-0.33	1.13e-9	Cognitive function;
CRC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.62	-11.66	-0.54	1.56e-26	Educational attainment;
CRC	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg00105475	chr2:10696890	NA	0.45	7.12	0.37	6.81e-12	Prostate cancer;
CRC	cis	rs13315871	1.000	rs13320620	chr3:58408845	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg02007433	chr3:129722099	NA	-0.51	-6.13	-0.32	2.54e-9	Blood pressure (smoking interaction);
CRC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg13722127	chr7:150037890	RARRES2	0.47	7.82	0.4	7.37e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg09877947	chr5:131593287	PDLIM4	0.53	9.92	0.48	1.81e-20	Acylcarnitine levels;
CRC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg15848620	chr12:58087721	OS9	-0.6	-8.15	-0.41	7.76e-15	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23556923	chr17:62774590	LOC146880	0.26	6.52	0.34	2.72e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg11886554	chr3:170076028	SKIL	0.63	7.79	0.39	8.99e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg21854759	chr1:92012499	NA	0.46	6.17	0.32	1.98e-9	Eosinophil percentage of white cells;
CRC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.68	12.75	0.57	1.63e-30	Aortic root size;
CRC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.44	8.96	0.44	2.51e-17	Renal cell carcinoma;
CRC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23378565	chr7:2036160	MAD1L1	-0.41	-6.27	-0.33	1.13e-9	Bipolar disorder;
CRC	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.51	0.38	5.79e-13	Lung cancer in ever smokers;
CRC	cis	rs1561198	0.523	rs2040349	chr2:85889525	A/C	cg02493740	chr2:85810744	VAMP5	-0.39	-5.92	-0.31	8.25e-9	Coronary artery disease;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.3	-6.09	-0.32	3.08e-9	Cognitive function;
CRC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.92	14.82	0.63	2.04e-38	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.48	6.57	0.34	1.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12273811	chr6:28175739	NA	0.58	8.52	0.43	5.75e-16	Cardiac Troponin-T levels;
CRC	cis	rs6496667	0.642	rs58328011	chr15:91057629	C/A	cg04176472	chr15:90893244	GABARAPL3	0.55	7.94	0.4	3.16e-14	Rheumatoid arthritis;
CRC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.3	-5.63	-0.3	3.86e-8	Dilated cardiomyopathy;
CRC	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs2004318	1.000	rs73614626	chr19:55139399	T/C	cg03320607	chr19:54800032	LILRA3	-0.75	-6.0	-0.31	5.26e-9	Blood protein levels;
CRC	cis	rs762407	0.925	rs4594536	chr21:45164854	C/T	cg19815989	chr21:45161359	PDXK	-0.39	-5.63	-0.3	3.94e-8	Systolic blood pressure change trajectories;
CRC	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.54	9.16	0.45	5.87e-18	Dupuytren's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14023449	chr19:44342834	ZNF283	0.41	6.15	0.32	2.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg11519256	chr10:5708881	ASB13	0.49	6.09	0.32	3.07e-9	Childhood ear infection;
CRC	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.51	-7.59	-0.39	3.24e-13	Coronary heart disease;
CRC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.44	-6.56	-0.34	2.15e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg10517650	chr3:113235015	CCDC52	-0.4	-6.97	-0.36	1.73e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg03932441	chr10:102415297	NA	-0.33	-5.66	-0.3	3.31e-8	Body mass index;
CRC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.63	-7.22	-0.37	3.71e-12	Menarche (age at onset);
CRC	cis	rs11997175	0.713	rs4733455	chr8:33651290	C/T	ch.8.33884649F	chr8:33765107	NA	-0.43	-6.94	-0.36	2.13e-11	Body mass index;
CRC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.24	-0.49	1.56e-21	Breast cancer;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.93	-0.31	7.58e-9	Depression;
CRC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.81	0.55	4.61e-27	Hip circumference adjusted for BMI;
CRC	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg15571903	chr15:79123663	NA	0.31	6.14	0.32	2.42e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg04362960	chr10:104952993	NT5C2	-0.42	-5.92	-0.31	8.03e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.97	-0.36	1.75e-11	Bipolar disorder;
CRC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg24531977	chr5:56204891	C5orf35	-0.51	-7.55	-0.38	4.33e-13	Coronary artery disease;
CRC	trans	rs264943	0.783	rs7583069	chr2:104231852	C/T	cg19630665	chr10:5523276	NA	0.36	6.14	0.32	2.42e-9	HIV-1 viral setpoint;
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg18758796	chr5:131593413	PDLIM4	0.36	6.92	0.36	2.42e-11	Blood metabolite levels;
CRC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg27661571	chr11:113659931	NA	-0.93	-10.77	-0.51	2.28e-23	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25312966	chr22:24408316	CABIN1	0.44	6.21	0.32	1.57e-9	Response to antipsychotic treatment;
CRC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.45	-6.94	-0.36	2.16e-11	Platelet count;
CRC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.56	0.57	8.09e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg23100626	chr2:96804247	ASTL	0.27	7.02	0.36	1.29e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.45	6.9	0.36	2.67e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.43	-6.23	-0.32	1.43e-9	Aortic root size;
CRC	trans	rs4675374	0.505	rs61118437	chr2:204795383	C/T	cg03032253	chr19:4652450	TNFAIP8L1	0.52	6.01	0.31	4.84e-9	Celiac disease;
CRC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.54	-0.54	4.29e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg08888203	chr3:10149979	C3orf24	0.7	9.84	0.48	3.31e-20	Alzheimer's disease;
CRC	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	6.93	0.36	2.23e-11	Diisocyanate-induced asthma;
CRC	cis	rs1223397	0.651	rs202018	chr6:13301502	G/A	cg20827128	chr6:13274284	PHACTR1	0.37	5.69	0.3	2.8e-8	Blood pressure;
CRC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.63	0.39	2.51e-13	Height;
CRC	cis	rs4664293	0.867	rs4665110	chr2:160587525	C/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.63	9.32	0.46	1.7e-18	Lung cancer;
CRC	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.04	-0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.38	-5.87	-0.31	1.08e-8	Reticulocyte count;
CRC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-6.66	-0.34	1.12e-10	Coronary artery disease;
CRC	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.62	-0.39	2.68e-13	QT interval;
CRC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg00106254	chr7:1943704	MAD1L1	0.43	6.62	0.34	1.48e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	16.08	0.66	2.35e-43	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.86	10.33	0.49	7.36e-22	Menarche (age at onset);
CRC	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.77	9.89	0.48	2.23e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.37	-6.86	-0.35	3.52e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-6.78	-0.35	5.48e-11	Lymphocyte counts;
CRC	trans	rs7178691	0.705	rs1906445	chr15:53891205	T/C	cg05337636	chr17:78720537	RPTOR	-0.47	-6.34	-0.33	7.45e-10	Fear of severe pain;
CRC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.63e-18	Parkinson's disease;
CRC	cis	rs7737355	0.812	rs251012	chr5:131030295	A/G	cg25547332	chr5:131281432	NA	-0.37	-6.05	-0.32	3.96e-9	Life satisfaction;
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.52	-0.54	4.96e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.23	-0.53	5.3e-25	Chronic sinus infection;
CRC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	7.4	0.38	1.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06307176	chr5:131281290	NA	-0.39	-5.65	-0.3	3.39e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs600806	0.821	rs4970840	chr1:109873367	A/G	cg23032129	chr1:109941072	SORT1	-0.27	-5.8	-0.3	1.59e-8	Intelligence (multi-trait analysis);
CRC	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.53	9.57	0.47	2.58e-19	Schizophrenia;
CRC	cis	rs13272623	0.502	rs268627	chr8:71561041	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.47	-6.77	-0.35	5.98e-11	IgG glycosylation;
CRC	trans	rs2012709	0.870	rs4867114	chr5:32550128	C/T	cg03755955	chr8:6424269	MCPH1	-0.43	-6.47	-0.34	3.49e-10	Breast cancer;
CRC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	7.16	0.37	5.44e-12	Lung cancer in ever smokers;
CRC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.75	-10.15	-0.49	3.15e-21	Initial pursuit acceleration;
CRC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24308560	chr3:49941425	MST1R	0.4	6.01	0.31	5.01e-9	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13885325	chr10:89623122	PTEN;KILLIN	0.45	6.21	0.32	1.58e-9	Anxiety disorder;
CRC	cis	rs17152411	1.000	rs11245432	chr10:126616861	G/A	cg07906193	chr10:126599966	NA	0.58	5.68	0.3	2.98e-8	Height;
CRC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.26	0.33	1.23e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.18	-0.32	1.91e-9	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20624980	chr19:50432627	NUP62;ATF5;IL4I1	0.44	7.25	0.37	2.91e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13338022	chr15:43029438	CDAN1	0.42	6.15	0.32	2.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.53	8.16	0.41	7.24e-15	Colorectal cancer;
CRC	cis	rs2257205	0.667	rs7209498	chr17:56680642	G/A	cg25885038	chr17:56607967	SEPT4	-0.55	-5.99	-0.31	5.54e-9	Pancreatic cancer;
CRC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12315302	chr6:26189340	HIST1H4D	0.76	6.0	0.31	5.23e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg18876405	chr7:65276391	NA	0.46	6.37	0.33	6.52e-10	Aortic root size;
CRC	cis	rs3790844	0.876	rs3790847	chr1:200006217	G/T	cg07208853	chr1:200005219	NR5A2	0.36	8.98	0.44	2.09e-17	Pancreatic cancer;
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00166722	chr3:10149974	C3orf24	0.66	7.71	0.39	1.49e-13	Alzheimer's disease;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg11003573	chr3:44754125	ZNF502	-0.41	-5.81	-0.3	1.51e-8	IgG glycosylation;
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs7107770	0.583	rs1808861	chr11:125073943	G/C	cg27629782	chr11:125073726	PKNOX2	0.51	7.26	0.37	2.84e-12	Photic sneeze reflex;
CRC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg02135003	chr7:105160482	PUS7	-0.73	-10.52	-0.5	1.68e-22	Bipolar disorder (body mass index interaction);
CRC	cis	rs1572438	0.862	rs4959468	chr6:858056	C/A	cg13447295	chr6:887704	NA	-0.42	-6.13	-0.32	2.58e-9	Aging;
CRC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.58	8.56	0.43	4.48e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs17767392	1.000	rs35854505	chr14:71841477	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.73	-12.24	-0.56	1.25e-28	Metabolic syndrome;
CRC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.5	6.7	0.35	9e-11	Total body bone mineral density;
CRC	cis	rs10971721	0.822	rs11848	chr9:33921919	T/C	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	trans	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.11	-0.41	1.03e-14	Endometrial cancer;
CRC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-7.41	-0.38	1.04e-12	Schizophrenia;
CRC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.59	9.1	0.45	8.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.71	10.84	0.51	1.34e-23	Corneal astigmatism;
CRC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.5	7.0	0.36	1.43e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.49	-7.23	-0.37	3.31e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6728642	0.519	rs7589232	chr2:97566148	C/T	cg26665480	chr2:98280029	ACTR1B	-0.55	-6.13	-0.32	2.54e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	trans	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.64	0.34	1.26e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.52	7.88	0.4	4.75e-14	Lung cancer;
CRC	cis	rs11212617	0.967	rs228608	chr11:108088900	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.36	0.33	6.7e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg15105060	chr4:7024189	TBC1D14	-0.69	-5.86	-0.31	1.14e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.41	-6.49	-0.34	3.08e-10	Blood metabolite levels;
CRC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg11212589	chr17:38028394	ZPBP2	0.44	8.0	0.4	2.18e-14	Self-reported allergy;
CRC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	15.71	0.65	7.04e-42	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	7.67	0.39	2e-13	Response to antipsychotic treatment;
CRC	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.45	-5.81	-0.3	1.48e-8	Red blood cell traits;
CRC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.79	11.28	0.53	3.52e-25	Neutrophil percentage of white cells;
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.9	13.48	0.6	2.92e-33	Longevity;
CRC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg08213375	chr14:104286397	PPP1R13B	0.4	6.24	0.33	1.31e-9	Reticulocyte count;
CRC	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.79	-10.9	-0.52	7.88e-24	Blood pressure (smoking interaction);
CRC	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.73	10.13	0.49	3.49e-21	Systemic lupus erythematosus;
CRC	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.93	11.28	0.53	3.54e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-9.18	-0.45	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.26	11.54	0.54	4.31e-26	Prostate cancer;
CRC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	8.15	0.41	7.77e-15	Menarche (age at onset);
CRC	cis	rs10924970	0.934	rs6666023	chr1:235480068	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	6.08	0.32	3.36e-9	Asthma;
CRC	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg23100626	chr2:96804247	ASTL	0.28	7.18	0.37	4.71e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.88	0.51	9.5e-24	Exhaled nitric oxide output;
CRC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-5.8	-0.3	1.6e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.96	-0.31	6.61e-9	Morning vs. evening chronotype;
CRC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg27523141	chr10:43048294	ZNF37B	0.5	7.25	0.37	3.04e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17507749	chr15:85114479	UBE2QP1	0.62	8.75	0.43	1.15e-16	Schizophrenia;
CRC	cis	rs12024301	0.557	rs12031263	chr1:183591586	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg19537932	chr12:55886519	OR6C68	-0.69	-8.71	-0.43	1.49e-16	Cancer;
CRC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.53	8.04	0.41	1.66e-14	Morning vs. evening chronotype;
CRC	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.55	-7.29	-0.37	2.38e-12	Tonsillectomy;
CRC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	27.05	0.83	1.25e-85	IgG glycosylation;
CRC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg00310523	chr12:86230176	RASSF9	0.45	7.56	0.38	3.97e-13	Major depressive disorder;
CRC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	7.29	0.37	2.28e-12	Breast cancer;
CRC	trans	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg18335740	chr13:41363409	SLC25A15	0.61	9.69	0.47	1.07e-19	Lewy body disease;
CRC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.46	6.1	0.32	3.05e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg01788221	chr16:89496183	ANKRD11	0.44	6.78	0.35	5.54e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.52	8.97	0.44	2.22e-17	Aortic root size;
CRC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.58	7.08	0.36	8.66e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg20936604	chr3:58311152	NA	-0.76	-7.13	-0.37	6.48e-12	Cholesterol, total;
CRC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-17.36	-0.69	2.28e-48	Headache;
CRC	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg17133734	chr15:86042851	AKAP13	0.39	6.19	0.32	1.82e-9	Coronary artery disease;
CRC	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg21452805	chr1:244014465	NA	-0.42	-5.97	-0.31	6.11e-9	RR interval (heart rate);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23805785	chr1:32671112	IQCC	0.37	6.11	0.32	2.76e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927997	0.757	rs2212434	chr11:76281593	C/T	cg10400081	chr11:76299682	NA	-0.4	-7.29	-0.37	2.27e-12	Gut microbiota (functional units);Crohn's disease;
CRC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.28	-0.33	1.04e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.07	-0.69	3.23e-47	Coronary artery disease;
CRC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21972741	chr5:435613	AHRR	0.55	7.56	0.38	4.15e-13	Cystic fibrosis severity;
CRC	cis	rs7072216	0.922	rs942813	chr10:100153608	A/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.13	-0.32	2.58e-9	Metabolite levels;
CRC	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg23100626	chr2:96804247	ASTL	0.26	6.72	0.35	7.95e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.46	0.34	3.69e-10	Rheumatoid arthritis;
CRC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg18230493	chr5:56204884	C5orf35	-0.42	-5.99	-0.31	5.39e-9	Coronary artery disease;
CRC	cis	rs282587	0.597	rs450351	chr13:113394987	C/T	cg04656015	chr13:113407548	ATP11A	0.61	7.47	0.38	7.36e-13	Glycated hemoglobin levels;
CRC	cis	rs6460942	0.643	rs7780093	chr7:12233661	C/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.87	-0.4	5.18e-14	Height;
CRC	cis	rs4594175	0.926	rs12323654	chr14:51630894	G/T	cg23942311	chr14:51606299	NA	0.61	9.72	0.47	8.46e-20	Cancer;
CRC	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs4664293	0.647	rs10198053	chr2:160461680	G/A	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.84	15.41	0.65	1.01e-40	Lewy body disease;
CRC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg22110888	chr17:80059540	CCDC57	0.41	6.42	0.33	4.87e-10	Life satisfaction;
CRC	cis	rs10986311	0.775	rs7872979	chr9:127104412	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.4	6.1	0.32	2.94e-9	Vitiligo;
CRC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.5	-0.38	6.16e-13	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.77	0.3	1.85e-8	Lung cancer;
CRC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.91	11.34	0.53	2.16e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs1602565	1.000	rs1907605	chr11:29158507	A/G	cg20483690	chr1:225616668	LBR	-0.64	-6.7	-0.35	8.85e-11	Schizophrenia;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg26797661	chr1:151138516	LYSMD1;SCNM1	-0.42	-6.01	-0.31	4.88e-9	Protein C levels;
CRC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.2	-0.32	1.69e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs2969070	0.763	rs4721714	chr7:2498467	G/A	cg03277898	chr7:2518824	NA	-0.43	-6.2	-0.32	1.65e-9	Diastolic blood pressure;
CRC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg17031739	chr1:67600172	NA	0.37	5.87	0.31	1.07e-8	Psoriasis;
CRC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.66	-9.52	-0.46	4.02e-19	Response to antineoplastic agents;
CRC	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.97	-17.52	-0.69	5.33e-49	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.87e-11	Bipolar disorder;
CRC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.6	8.87	0.44	4.85e-17	Homoarginine levels;
CRC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.69	11.93	0.55	1.62e-27	Resting heart rate;
CRC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.53	9.39	0.46	1.07e-18	Multiple system atrophy;
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg05304507	chr6:116381966	FRK	0.29	7.4	0.38	1.16e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg07404485	chr7:94953653	PON1	-0.45	-6.04	-0.32	4.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg24289452	chr6:170231220	NA	-0.81	-7.02	-0.36	1.31e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg26260408	chr4:53727979	RASL11B	0.5	5.73	0.3	2.29e-8	Optic nerve measurement (cup area);
CRC	cis	rs9992667	0.955	rs28664852	chr4:38646100	A/C	cg19726192	chr4:38663646	FLJ13197	-0.66	-8.74	-0.43	1.23e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02725872	chr8:58115012	NA	-0.45	-6.82	-0.35	4.42e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg07952391	chr2:88470173	THNSL2	-0.45	-6.59	-0.34	1.78e-10	Response to metformin (IC50);
CRC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg03959625	chr15:84868606	LOC388152	0.41	6.07	0.32	3.55e-9	Schizophrenia;
CRC	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.5	-9.76	-0.47	6.4e-20	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03041860	chr2:208489911	FAM119A	0.47	6.53	0.34	2.45e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg15786705	chr6:28176104	NA	0.46	6.71	0.35	8.45e-11	Parkinson's disease;
CRC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.39	-5.8	-0.3	1.57e-8	IgE levels in asthmatics (D.p. specific);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05314271	chr8:28747585	INTS9;HMBOX1	0.46	6.68	0.35	1.04e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg27205649	chr11:78285834	NARS2	0.47	5.81	0.3	1.5e-8	Alzheimer's disease (survival time);
CRC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.98	-18.04	-0.71	4.72e-51	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.2	-0.32	1.66e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.52	8.36	0.42	1.85e-15	Prostate cancer;
CRC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.8	13.44	0.6	3.93e-33	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26794364	chr3:9691143	MTMR14	0.36	6.56	0.34	2.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-11.58	-0.54	3.03e-26	Asthma;
CRC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.76	-9.69	-0.47	1.07e-19	Initial pursuit acceleration;
CRC	trans	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg02659138	chr7:134003124	SLC35B4	0.45	7.94	0.4	3.16e-14	Mean platelet volume;
CRC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.53	10.73	0.51	3.07e-23	Bone mineral density;
CRC	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg20607287	chr7:12443886	VWDE	-0.55	-6.23	-0.32	1.41e-9	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18881247	chr2:157189314	NR4A2	-0.42	-6.65	-0.34	1.26e-10	Myopia (pathological);
CRC	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg03395651	chr16:88107091	BANP	0.56	7.19	0.37	4.43e-12	Menopause (age at onset);
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.83	-0.31	1.3e-8	Life satisfaction;
CRC	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.59	0.47	2.32e-19	Type 2 diabetes;
CRC	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg02094049	chr14:103021097	NA	-0.48	-6.07	-0.32	3.48e-9	Platelet count;
CRC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg02741985	chr17:80059408	CCDC57	-0.44	-7.2	-0.37	4.13e-12	Life satisfaction;
CRC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.72	11.21	0.53	6.63e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.73	9.71	0.47	9.45e-20	Coronary artery disease;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg15786705	chr6:28176104	NA	0.61	6.75	0.35	6.5e-11	Parkinson's disease;
CRC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.27	-0.33	1.12e-9	Joint mobility (Beighton score);
CRC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.48	6.77	0.35	5.83e-11	Granulocyte percentage of myeloid white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11718113	chr1:16011424	PLEKHM2	0.46	6.36	0.33	6.9e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.73	-0.51	3.19e-23	Alzheimer's disease;
CRC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg01483505	chr11:975446	AP2A2	0.41	6.63	0.34	1.41e-10	Alzheimer's disease (late onset);
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg04518342	chr5:131593106	PDLIM4	-0.33	-5.85	-0.31	1.2e-8	Blood metabolite levels;
CRC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.21	-6.03	-0.32	4.52e-9	Urinary metabolites;
CRC	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg13206674	chr6:150067644	NUP43	0.49	7.04	0.36	1.13e-11	Testicular germ cell tumor;
CRC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg20908204	chr19:46285434	DMPK	0.33	7.19	0.37	4.28e-12	Coronary artery disease;
CRC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg06522879	chr11:64358276	SLC22A12	0.55	8.22	0.41	4.83e-15	Urate levels in obese individuals;
CRC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg13072238	chr3:49761600	GMPPB	0.51	6.05	0.32	3.95e-9	Menarche (age at onset);
CRC	cis	rs995000	0.931	rs1168047	chr1:62983751	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.91	-0.36	2.57e-11	Triglyceride levels;
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.79	-0.39	8.99e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs4662945	0.762	rs2406822	chr2:130218178	C/T	cg05903289	chr2:130345205	NA	-0.3	-5.76	-0.3	1.89e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.78	-0.44	8.82e-17	Bipolar disorder;
CRC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg05639522	chr1:247681581	NA	0.46	6.95	0.36	1.91e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.68	0.39	1.84e-13	Platelet count;
CRC	cis	rs7924005	0.543	rs71479758	chr10:6177894	A/G	cg17191567	chr10:6178319	NA	-0.41	-5.95	-0.31	6.8e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs938554	0.784	rs13131257	chr4:9981889	T/C	cg00071950	chr4:10020882	SLC2A9	0.46	6.5	0.34	2.93e-10	Blood metabolite levels;
CRC	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg09455208	chr3:40491958	NA	0.31	6.06	0.32	3.74e-9	Renal cell carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21249729	chr9:138392748	C9orf116;MRPS2	0.43	7.11	0.36	7.12e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.66	-10.92	-0.52	6.61e-24	White blood cell count (basophil);
CRC	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.92	0.4	3.66e-14	Resting heart rate;
CRC	cis	rs9463078	0.739	rs1293467	chr6:44769204	C/G	cg25276700	chr6:44698697	NA	0.28	6.92	0.36	2.34e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.58	8.39	0.42	1.43e-15	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.38	-0.33	6.09e-10	Dupuytren's disease;
CRC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.14	0.45	6.78e-18	Intelligence (multi-trait analysis);
CRC	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.82	10.77	0.51	2.33e-23	Iron status biomarkers;
CRC	cis	rs12541635	1.000	rs1366969	chr8:107092851	A/T	cg10147462	chr8:107024639	NA	-0.38	-6.39	-0.33	5.73e-10	Age of smoking initiation;
CRC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.67	-8.79	-0.44	8.67e-17	Bronchopulmonary dysplasia;
CRC	cis	rs2380220	0.808	rs2716072	chr6:95909773	A/G	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs2072510	0.966	rs2660896	chr12:96423782	A/G	cg22491680	chr12:96389547	HAL	-0.39	-6.16	-0.32	2.08e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.71	0.39	1.47e-13	Total body bone mineral density;
CRC	cis	rs7538876	0.935	rs11577822	chr1:17754608	T/G	cg01904812	chr1:17746340	RCC2	0.37	5.94	0.31	7.44e-9	Basal cell carcinoma;
CRC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.86	11.42	0.53	1.14e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.45	8.01	0.4	2.04e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.5	7.28	0.37	2.43e-12	Intelligence (multi-trait analysis);
CRC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	0.91	10.87	0.51	9.82e-24	Red blood cell traits;
CRC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	7.67	0.39	1.97e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg16724585	chr3:197361211	NA	-0.48	-7.07	-0.36	9.12e-12	Pancreatic cancer;
CRC	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg12072164	chr19:44306565	LYPD5	-0.37	-5.86	-0.31	1.11e-8	Breast cancer;
CRC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.64	-8.35	-0.42	1.87e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.69	-8.75	-0.43	1.12e-16	Psoriasis;
CRC	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.64	10.07	0.49	5.92e-21	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05100916	chr7:112090586	IFRD1	0.52	6.92	0.36	2.39e-11	Thyroid stimulating hormone;
CRC	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.52	8.74	0.43	1.22e-16	Dupuytren's disease;
CRC	cis	rs5498	0.839	rs62130686	chr19:10408742	A/C	cg10604476	chr19:10403908	ICAM5	0.3	5.66	0.3	3.3e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CRC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.53	6.92	0.36	2.39e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.21	-0.32	1.59e-9	Height;
CRC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.73	12.32	0.56	6.18e-29	Cognitive function;
CRC	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.07	0.36	9.45e-12	Intelligence (multi-trait analysis);
CRC	trans	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs59104589	0.617	rs6672	chr2:242293021	A/G	cg19488206	chr2:242435732	STK25	0.47	6.81	0.35	4.76e-11	Fibrinogen levels;
CRC	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-8.52	-0.42	6e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs524281	0.731	rs2276036	chr11:66033430	C/T	cg16950941	chr11:66035639	RAB1B	-0.72	-8.16	-0.41	7.42e-15	Electroencephalogram traits;
CRC	cis	rs10986311	0.722	rs17315546	chr9:127148229	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.36	0.33	6.73e-10	Vitiligo;
CRC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.76	11.44	0.53	9.62e-26	Breast cancer;
CRC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.57	-0.34	1.96e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.74	-11.92	-0.55	1.81e-27	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17841782	chr1:59762205	FGGY	0.38	6.15	0.32	2.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.74	-0.43	1.21e-16	Bipolar disorder;
CRC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.72	0.39	1.37e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.88	10.19	0.49	2.18e-21	Psoriasis;
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19500275	chr17:80737654	TBCD	0.51	7.02	0.36	1.31e-11	Glycated hemoglobin levels;
CRC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg18876405	chr7:65276391	NA	0.45	6.34	0.33	7.56e-10	Aortic root size;
CRC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.84	0.31	1.26e-8	Ulcerative colitis;
CRC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.46	6.4	0.33	5.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.51	8.53	0.43	5.5e-16	Metabolite levels;
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg20119798	chr7:94954144	PON1	-0.49	-6.19	-0.32	1.77e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.11	-0.49	4.13e-21	Total cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17236293	chr7:6865970	C7orf28B	0.39	6.05	0.32	3.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.22	5.91	0.31	8.46e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.01	10.18	0.49	2.48e-21	Diabetic retinopathy;
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7113874	0.610	rs10840055	chr11:8494345	C/T	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.55	8.93	0.44	3.18e-17	Metabolite levels;
CRC	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.4	-6.69	-0.35	9.38e-11	Life satisfaction;
CRC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg27523141	chr10:43048294	ZNF37B	0.44	6.45	0.34	3.89e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	7.84	0.4	6.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11446398	chr5:77624930	NA	0.46	6.24	0.33	1.37e-9	Triglycerides;
CRC	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.42	6.84	0.35	3.92e-11	Sitting height ratio;
CRC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-10.74	-0.51	2.8e-23	Platelet distribution width;
CRC	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg15845792	chr6:28175446	NA	0.73	6.86	0.35	3.38e-11	Depression;
CRC	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg07537917	chr2:241836409	C2orf54	-0.21	-5.75	-0.3	2.05e-8	Urinary metabolites;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.29	0.33	9.93e-10	Depression;
CRC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.0	0.31	5.26e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.39	-5.93	-0.31	7.84e-9	Height;
CRC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.67	0.51	4.86e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	7.47	0.38	7.34e-13	Mean corpuscular volume;
CRC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.67	0.54	1.44e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-8.74	-0.43	1.2e-16	Menarche (age at onset);
CRC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.55	8.0	0.4	2.09e-14	Height;
CRC	cis	rs6968419	0.747	rs3807975	chr7:115880277	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.35	-0.33	7.09e-10	Intraocular pressure;
CRC	cis	rs2072510	1.000	rs2072510	chr12:96403199	A/G	cg22491680	chr12:96389547	HAL	0.37	5.88	0.31	1e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	0.93	11.09	0.52	1.66e-24	Red blood cell traits;
CRC	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.55	7.23	0.37	3.37e-12	Nonalcoholic fatty liver disease;
CRC	cis	rs7113874	0.504	rs10743081	chr11:8624100	T/G	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7737355	0.681	rs11242094	chr5:131072622	A/G	cg25547332	chr5:131281432	NA	0.35	5.61	0.3	4.37e-8	Life satisfaction;
CRC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.49	-7.94	-0.4	3.3e-14	Body mass index;
CRC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.64	-0.3	3.72e-8	Breast cancer;
CRC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18099408	chr3:52552593	STAB1	0.38	5.89	0.31	9.32e-9	Bipolar disorder;
CRC	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg13385794	chr1:248469461	NA	0.38	6.66	0.34	1.14e-10	Common traits (Other);
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg15786705	chr6:28176104	NA	0.58	7.1	0.36	7.58e-12	Parkinson's disease;
CRC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.34	-0.53	2.3e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.28	-0.49	1.13e-21	Total cholesterol levels;
CRC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	5.97e-10	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25428213	chr17:80929211	B3GNTL1	-0.39	-6.28	-0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.82	-10.96	-0.52	4.91e-24	Initial pursuit acceleration;
CRC	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg23234261	chr14:55582407	NA	-0.29	-5.81	-0.31	1.47e-8	Protein biomarker;
CRC	trans	rs867371	0.502	rs3759800	chr15:82532963	A/C	cg04831495	chr15:85060580	GOLGA6L5	0.39	6.09	0.32	3.14e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.53	7.54	0.38	4.55e-13	Schizophrenia;
CRC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.6	-8.98	-0.44	2.06e-17	Schizophrenia;
CRC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.16	0.41	6.94e-15	Monocyte count;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg06219103	chr11:63990595	FERMT3	0.48	7.69	0.39	1.73e-13	Platelet count;
CRC	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg06781209	chr11:61594997	FADS2	-0.43	-5.97	-0.31	6.27e-9	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg14345882	chr6:26364793	BTN3A2	0.77	6.28	0.33	1.04e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.24	-0.41	4.19e-15	Monocyte count;
CRC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07234876	chr8:600039	NA	-0.93	-8.14	-0.41	8.53e-15	IgG glycosylation;
CRC	trans	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.81	14.75	0.63	3.71e-38	Anterior chamber depth;
CRC	cis	rs28655083	0.529	rs662101	chr16:77105405	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.47	-6.7	-0.35	9.02e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg02390115	chr1:21767211	NBPF3	0.46	6.75	0.35	6.81e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.7	-11.4	-0.53	1.35e-25	Cognitive function;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg02181963	chr13:111358803	CARS2	0.4	6.03	0.32	4.45e-9	Menarche (age at onset);
CRC	trans	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.49	-0.34	3.23e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg15571903	chr15:79123663	NA	0.34	6.81	0.35	4.58e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.55	-10.22	-0.49	1.83e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23058613	chr11:62414236	GANAB	0.5	6.51	0.34	2.83e-10	Anxiety disorder;
CRC	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.68	9.06	0.45	1.2e-17	Uric acid levels;
CRC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15369054	chr17:80825471	TBCD	-0.36	-5.91	-0.31	8.45e-9	Breast cancer;
CRC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-7.06	-0.36	9.93e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg13953403	chr8:38034403	LSM1;BAG4	0.4	6.07	0.32	3.53e-9	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27054524	chr16:19097807	NA	0.49	7.06	0.36	1.02e-11	Response to antipsychotic treatment;
CRC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg14979609	chr8:8086686	FLJ10661	0.38	5.82	0.31	1.41e-8	Mood instability;
CRC	trans	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg25876840	chr17:41920477	NA	0.4	6.42	0.33	4.82e-10	Triglycerides;
CRC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.67	10.32	0.49	8.27e-22	Tonsillectomy;
CRC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.56	8.03	0.4	1.72e-14	Resting heart rate;
CRC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg12564285	chr5:131593104	PDLIM4	0.35	5.87	0.31	1.06e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	6.6	0.34	1.6e-10	Blood protein levels;
CRC	cis	rs7632954	0.669	rs9879912	chr3:8527801	C/T	cg03495237	chr3:8533978	NA	0.35	6.55	0.34	2.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.58	9.62	0.47	1.83e-19	Graves' disease;
CRC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18912574	chr7:65842487	NCRNA00174	0.38	6.49	0.34	3.22e-10	Aortic root size;
CRC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.85	-0.35	3.62e-11	Pulmonary function;
CRC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg00677455	chr12:58241039	CTDSP2	0.48	6.62	0.34	1.47e-10	Multiple sclerosis;
CRC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg07212818	chr11:638076	DRD4	-0.43	-5.77	-0.3	1.81e-8	Systemic lupus erythematosus;
CRC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.57	-9.5	-0.46	4.66e-19	Lung cancer in ever smokers;
CRC	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	0.5	5.77	0.3	1.88e-8	Dental caries;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg17949981	chr6:28129498	ZNF389	0.41	5.71	0.3	2.54e-8	Cardiac Troponin-T levels;
CRC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.51	0.38	5.67e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg14074117	chr16:1909714	C16orf73	0.34	5.95	0.31	6.71e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg07274523	chr3:49395745	GPX1	0.47	6.32	0.33	8.64e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.57	8.16	0.41	7.18e-15	Pancreatic cancer;
CRC	cis	rs1007738	0.579	rs61896136	chr11:47120299	C/A	cg19486271	chr11:47235900	DDB2	0.44	5.89	0.31	9.76e-9	Bone mineral density (hip);
CRC	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.6	8.46	0.42	9.15e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.98	0.44	2.15e-17	Fuchs's corneal dystrophy;
CRC	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg23234261	chr14:55582407	NA	-0.29	-5.73	-0.3	2.28e-8	Protein biomarker;
CRC	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg11645453	chr3:52864694	ITIH4	-0.4	-7.51	-0.38	5.64e-13	Body mass index;
CRC	cis	rs2569991	0.636	rs9211	chr3:12939546	A/G	cg22481960	chr3:13008800	IQSEC1	0.49	6.42	0.33	4.73e-10	Periodontitis (DPAL);
CRC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.6	9.79	0.48	4.86e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.37	-7.4	-0.38	1.18e-12	Cutaneous nevi;
CRC	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.61	-6.7	-0.35	9.26e-11	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.66	0.34	1.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-8.19	-0.41	5.78e-15	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21652107	chr4:48782392	FRYL	0.44	6.21	0.32	1.63e-9	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.24	0.33	1.34e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.76	-0.39	1.05e-13	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22087953	chr7:45847100	NA	-0.4	-6.44	-0.33	4.15e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.63	-8.46	-0.42	8.74e-16	Facial morphology (factor 19);
CRC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.42	-6.03	-0.32	4.3e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg10760299	chr15:45669010	GATM	0.51	8.12	0.41	9.73e-15	Homoarginine levels;
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg08200770	chr17:80723486	TBCD	-0.48	-7.42	-0.38	9.91e-13	Glycated hemoglobin levels;
CRC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.61	7.42	0.38	9.81e-13	Mean platelet volume;
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg24046110	chr8:143859143	LYNX1	0.49	8.57	0.43	4.11e-16	Urinary tract infection frequency;
CRC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.96	0.66	7.52e-43	Platelet count;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.34	-6.17	-0.32	2.05e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-13.84	-0.61	1.25e-34	Ulcerative colitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25411849	chr6:89855994	PM20D2	-0.41	-6.17	-0.32	2e-9	Myopia (pathological);
CRC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.71	-10.58	-0.5	1.06e-22	Inflammatory bowel disease;
CRC	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.6	9.71	0.47	9.02e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24274600	chr5:95066816	RHOBTB3	0.46	6.68	0.35	1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg13047869	chr3:10149882	C3orf24	0.55	6.66	0.34	1.17e-10	Alzheimer's disease;
CRC	cis	rs3889199	0.924	rs12752853	chr1:59668705	C/T	cg25881383	chr1:59680599	NA	-0.38	-6.11	-0.32	2.82e-9	Pulse pressure;
CRC	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg14593290	chr7:50529359	DDC	0.53	7.26	0.37	2.76e-12	Malaria;
CRC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.69	7.1	0.36	7.77e-12	Plasma clusterin levels;
CRC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.52	7.64	0.39	2.39e-13	Blood protein levels;
CRC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.7	-12.26	-0.56	1e-28	Hemoglobin concentration;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg15790184	chr11:494944	RNH1	0.61	6.25	0.33	1.27e-9	Body mass index;
CRC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.18	-17.29	-0.69	4.03e-48	Hip circumference adjusted for BMI;
CRC	cis	rs2625529	0.586	rs11639282	chr15:72435260	G/A	cg16672083	chr15:72433130	SENP8	0.4	6.09	0.32	3.13e-9	Red blood cell count;
CRC	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.76	-0.35	6.18e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.63	-7.69	-0.39	1.76e-13	Pursuit maintenance gain;
CRC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.52	7.67	0.39	2e-13	Aortic root size;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg19590674	chr17:25783100	NA	0.42	6.44	0.33	4.19e-10	Menarche (age at onset);
CRC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.62	7.12	0.37	6.85e-12	Vitiligo;
CRC	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg21918786	chr6:109611834	NA	0.35	5.87	0.31	1.06e-8	Reticulocyte fraction of red cells;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs77861329	1.000	rs55834589	chr3:52081724	C/T	cg08692210	chr3:52188851	WDR51A	0.82	6.9	0.36	2.73e-11	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.68	-9.72	-0.47	8.49e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.84	0.63	1.74e-38	Fuchs's corneal dystrophy;
CRC	trans	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg10756647	chr7:56101905	PSPH	0.72	7.51	0.38	5.66e-13	Diabetic kidney disease;
CRC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.46	8.27	0.41	3.43e-15	Height;
CRC	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.15e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg05585544	chr11:47624801	NA	-0.56	-10.06	-0.49	6.22e-21	Subjective well-being;
CRC	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-5.9	-0.31	9.01e-9	Coronary artery disease;
CRC	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-6.67	-0.35	1.09e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.81	14.41	0.62	8.01e-37	Total body bone mineral density;
CRC	cis	rs12024301	0.557	rs12041485	chr1:183591526	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.15	-0.52	1.08e-24	Bipolar disorder and schizophrenia;
CRC	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.46	6.7	0.35	8.95e-11	Primary sclerosing cholangitis;
CRC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.39	7.45	0.38	8.13e-13	Renal cell carcinoma;
CRC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg00579200	chr11:133705235	NA	-0.4	-5.92	-0.31	8.18e-9	Childhood ear infection;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg20933634	chr6:27740509	NA	0.5	7.0	0.36	1.47e-11	Parkinson's disease;
CRC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.52	-7.52	-0.38	5.24e-13	DNA methylation (variation);
CRC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.1e-16	Alcohol dependence;
CRC	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.72	8.61	0.43	3.04e-16	Uric acid levels;
CRC	cis	rs9969804	0.782	rs912262	chr9:95525557	C/T	cg14631576	chr9:95140430	CENPP	0.31	5.67	0.3	3.07e-8	Height;
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	14.7	0.63	5.81e-38	Alzheimer's disease;
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19500275	chr17:80737654	TBCD	0.53	7.28	0.37	2.56e-12	Glycated hemoglobin levels;
CRC	cis	rs600626	0.636	rs11236518	chr11:75453066	C/T	cg24262691	chr11:75473276	NA	0.49	6.77	0.35	5.94e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg06470822	chr6:28175283	NA	0.82	12.25	0.56	1.14e-28	Cardiac Troponin-T levels;
CRC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.59	7.31	0.37	2.02e-12	Mean platelet volume;
CRC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg11212589	chr17:38028394	ZPBP2	0.43	7.94	0.4	3.32e-14	Self-reported allergy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16150678	chr8:101170369	SPAG1	0.43	7.35	0.38	1.57e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.58	-7.1	-0.36	7.97e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2302190	0.882	rs9901693	chr17:56606915	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-7.76	-0.39	1.11e-13	Vitamin D levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27226861	chr4:71705278	GRSF1	0.4	6.64	0.34	1.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.39	5.85	0.31	1.21e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.49	-9.21	-0.45	3.85e-18	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21717879	chr19:572359	BSG	0.38	6.19	0.32	1.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-6.52	-0.34	2.65e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg10761708	chr20:43804764	PI3	0.5	5.69	0.3	2.77e-8	Blood protein levels;
CRC	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.75	-12.45	-0.57	1.99e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg21204522	chr6:27730016	NA	0.42	5.7	0.3	2.63e-8	Parkinson's disease;
CRC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg23018236	chr17:30244563	NA	0.53	6.72	0.35	7.79e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.08	0.49	5.16e-21	Platelet count;
CRC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.58	8.86	0.44	5.21e-17	Type 2 diabetes;
CRC	cis	rs55702914	0.809	rs2376407	chr2:198183465	A/G	cg10820045	chr2:198174542	NA	-0.48	-8.98	-0.44	2.14e-17	Major depression and alcohol dependence;
CRC	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.55	9.35	0.46	1.39e-18	Dupuytren's disease;
CRC	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-8.94	-0.44	2.92e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4400599	0.549	rs12044616	chr1:154189417	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.76	-0.3	1.91e-8	Platelet distribution width;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg24550644	chr17:30846204	MYO1D	0.42	7.15	0.37	5.57e-12	Schizophrenia;
CRC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23463467	chr20:60627584	TAF4	-0.37	-5.99	-0.31	5.39e-9	Body mass index;
CRC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.65	11.2	0.53	7.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4523957	0.690	rs4790884	chr17:2105299	G/C	cg16513277	chr17:2031491	SMG6	-0.52	-8.54	-0.43	5.01e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.58	-6.0	-0.31	5.23e-9	Schizophrenia;
CRC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.59	-11.61	-0.54	2.33e-26	Asthma (sex interaction);
CRC	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg12564285	chr5:131593104	PDLIM4	0.32	5.6	0.3	4.47e-8	Blood metabolite levels;
CRC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-7.07	-0.36	9.61e-12	Calcium levels;
CRC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.84	12.01	0.55	8.66e-28	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs56146971	0.703	rs76533089	chr14:91863973	G/T	cg16433844	chr14:91963127	SMEK1	-0.59	-6.12	-0.32	2.7e-9	Alzheimer disease and age of onset;
CRC	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.54	-8.69	-0.43	1.79e-16	Depressive symptoms (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01154849	chr17:16343053	NCRNA00188;SNORD65;SNORD49A	0.41	5.98	0.31	5.82e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.43	-20.51	-0.75	8.67e-61	Hip circumference adjusted for BMI;
CRC	cis	rs741668	0.931	rs61953335	chr13:46598816	G/A	cg06018095	chr13:46550134	ZC3H13	0.42	5.91	0.31	8.45e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-1.05	-10.95	-0.52	5.21e-24	Body mass index;
CRC	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg07423050	chr13:99094983	FARP1	0.41	6.54	0.34	2.37e-10	Longevity;
CRC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg20487152	chr13:99095054	FARP1	-0.46	-6.59	-0.34	1.71e-10	Longevity;
CRC	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg16386425	chr10:429943	DIP2C	0.44	5.73	0.3	2.25e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs1062746	0.545	rs3815947	chr16:87359648	C/T	cg02258303	chr16:87377426	FBXO31	-0.53	-7.4	-0.38	1.12e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.32	0.59	1.13e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.35	-0.75	3.57e-60	Height;
CRC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.48	7.38	0.38	1.32e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.44	6.62	0.34	1.49e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.92	11.13	0.52	1.19e-24	Eosinophil percentage of granulocytes;
CRC	trans	rs1973993	0.717	rs55650017	chr1:96952142	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.82	-0.35	4.39e-11	Weight;
CRC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.54	8.01	0.4	1.97e-14	Mean platelet volume;
CRC	cis	rs77633900	0.892	rs1810348	chr15:76632487	C/T	cg05412396	chr15:76631569	ISL2	-0.44	-5.79	-0.3	1.65e-8	Non-glioblastoma glioma;Glioma;
CRC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.56	6.13	0.32	2.57e-9	Gut microbiome composition (summer);
CRC	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg13491945	chr12:107078410	RFX4	0.37	6.29	0.33	9.86e-10	Heart rate;
CRC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.42	6.95	0.36	1.94e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02959429	chr17:27916858	GIT1	0.48	6.47	0.34	3.63e-10	Anxiety disorder;
CRC	cis	rs17601876	0.814	rs28637352	chr15:51559666	C/A	cg19946085	chr15:51559439	CYP19A1	-0.34	-6.97	-0.36	1.74e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.5	7.35	0.38	1.63e-12	Blood metabolite levels;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.47	7.02	0.36	1.27e-11	Longevity;Endometriosis;
CRC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.6	7.28	0.37	2.53e-12	Mean platelet volume;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg04969067	chr8:143858791	LYNX1	0.44	7.51	0.38	5.62e-13	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03583812	chr2:61244620	PEX13;PUS10	0.49	6.98	0.36	1.64e-11	Response to antipsychotic treatment;
CRC	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg06581033	chr10:766294	NA	-0.52	-5.87	-0.31	1.04e-8	Uric acid levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22682864	chr1:111326110	NA	0.48	6.41	0.33	4.99e-10	Thyroid stimulating hormone;
CRC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.53	-7.08	-0.36	8.56e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg04920474	chr2:44395004	PPM1B	0.42	5.82	0.31	1.37e-8	Height;
CRC	cis	rs3736485	0.966	rs28376817	chr15:51889280	A/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.46	-0.34	3.75e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg19812747	chr11:111475976	SIK2	-0.57	-9.89	-0.48	2.34e-20	Primary sclerosing cholangitis;
CRC	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.5	9.32	0.46	1.72e-18	Educational attainment (years of education);
CRC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.27	-0.33	1.1e-9	Monocyte percentage of white cells;
CRC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg12193833	chr17:30244370	NA	-0.57	-8.01	-0.4	1.94e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.95	-0.48	1.47e-20	Body mass index;
CRC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.25e-10	Alzheimer's disease (late onset);
CRC	trans	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg02869306	chr7:64672164	INTS4L1	0.42	6.04	0.32	4.26e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02018176	chr4:1364513	KIAA1530	0.4	6.62	0.34	1.46e-10	Obesity-related traits;
CRC	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-6.97	-0.36	1.77e-11	Self-reported allergy;
CRC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg05941027	chr17:61774174	LIMD2	0.36	6.22	0.32	1.53e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.09	-0.32	3.1e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg06636001	chr8:8085503	FLJ10661	0.47	7.08	0.36	8.95e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.99	-0.36	1.57e-11	IgG glycosylation;
CRC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg09829573	chr1:144692074	NBPF9	0.4	6.11	0.32	2.75e-9	Hip geometry;
CRC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.49	7.51	0.38	5.47e-13	Testicular germ cell tumor;
CRC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.65	9.81	0.48	4.38e-20	Platelet count;
CRC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.74	11.41	0.53	1.27e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs12928939	0.911	rs12917983	chr16:71835243	A/C	cg08717414	chr16:71523259	ZNF19	-0.51	-6.43	-0.33	4.45e-10	Post bronchodilator FEV1;
CRC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.59	0.34	1.78e-10	Obesity-related traits;
CRC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.45	0.53	8.7e-26	Bone mineral density;
CRC	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-6.06	-0.32	3.83e-9	Lung cancer;
CRC	cis	rs6011002	0.683	rs6089966	chr20:62361250	A/G	cg01176363	chr20:62369445	LIME1	-0.72	-5.67	-0.3	3.14e-8	Dental caries;
CRC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg18827107	chr12:86230957	RASSF9	-0.37	-6.04	-0.32	4.16e-9	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03398303	chr18:12702742	PSMG2;CEP76	0.45	6.22	0.32	1.48e-9	Response to antipsychotic treatment;
CRC	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.63	8.94	0.44	2.79e-17	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg21194808	chr1:2205498	SKI	0.44	6.66	0.34	1.14e-10	Coronary artery disease;
CRC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.69	-11.07	-0.52	2.02e-24	Motion sickness;
CRC	cis	rs2479724	0.598	rs4415146	chr6:41941980	G/T	cg17623882	chr6:41773611	USP49	0.45	7.31	0.37	2.04e-12	Menarche (age at onset);
CRC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.44	0.42	1.01e-15	Menarche (age at onset);
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.04	-0.55	6.41e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19778287	chr11:82905545	ANKRD42	0.46	6.56	0.34	2.11e-10	Response to antipsychotic treatment;
CRC	cis	rs6142102	0.961	rs2235596	chr20:32684309	A/G	cg08999081	chr20:33150536	PIGU	-0.37	-5.84	-0.31	1.26e-8	Skin pigmentation;
CRC	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg00666640	chr1:248458726	OR2T12	0.35	6.53	0.34	2.54e-10	Common traits (Other);
CRC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	19.05	0.72	4.76e-55	Prudent dietary pattern;
CRC	cis	rs7584330	0.554	rs6740834	chr2:238423442	T/C	cg08992911	chr2:238395768	MLPH	0.46	5.73	0.3	2.26e-8	Prostate cancer;
CRC	cis	rs12928939	0.911	rs12917983	chr16:71835243	A/C	cg03805757	chr16:71968109	PKD1L3	-0.46	-5.96	-0.31	6.62e-9	Post bronchodilator FEV1;
CRC	cis	rs12760731	0.920	rs12747346	chr1:178488809	T/C	cg00404053	chr1:178313656	RASAL2	0.59	6.91	0.36	2.47e-11	Obesity-related traits;
CRC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18402987	chr7:1209562	NA	0.43	6.62	0.34	1.45e-10	Longevity;Endometriosis;
CRC	cis	rs524281	0.731	rs1125078	chr11:65809875	C/A	cg16950941	chr11:66035639	RAB1B	0.51	6.05	0.32	3.98e-9	Electroencephalogram traits;
CRC	cis	rs2289681	0.525	rs12451394	chr17:42979592	G/A	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.53	-6.09	-0.32	3.23e-9	Cognitive function;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23161317	chr6:28129485	ZNF389	0.44	5.71	0.3	2.49e-8	Parkinson's disease;
CRC	cis	rs427941	0.703	rs10953358	chr7:101738226	T/C	cg06246474	chr7:101738831	CUX1	-0.46	-7.16	-0.37	5.46e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.71	11.48	0.53	7.27e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg02560186	chr11:3602584	NA	-0.47	-6.31	-0.33	9.08e-10	Blood pressure (smoking interaction);
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.57	8.84	0.44	5.93e-17	Bipolar disorder;
CRC	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg26703956	chr19:39260304	NA	-0.38	-6.24	-0.33	1.37e-9	Heart rate;
CRC	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg13385794	chr1:248469461	NA	0.34	6.2	0.32	1.71e-9	Common traits (Other);
CRC	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.66	-0.34	1.17e-10	Educational attainment;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	cis	rs16852403	0.548	rs10798600	chr1:178180719	C/T	cg00404053	chr1:178313656	RASAL2	0.49	6.38	0.33	5.97e-10	Childhood ear infection;
CRC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.48	7.23	0.37	3.38e-12	Breast cancer;
CRC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg19193384	chr17:30244184	NA	0.46	5.7	0.3	2.62e-8	Hip circumference adjusted for BMI;
CRC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.53	0.47	3.56e-19	Colorectal cancer;
CRC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.54	0.43	5.06e-16	Height;
CRC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.97e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs364477	1.000	rs364477	chr9:955794	A/G	cg13952963	chr9:998547	NA	-0.48	-6.27	-0.33	1.14e-9	Major depressive disorder;
CRC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg04719120	chr6:96025338	MANEA	0.52	6.39	0.33	5.56e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg03623178	chr6:28175578	NA	0.87	12.13	0.56	2.98e-28	Parkinson's disease;
CRC	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.73	11.76	0.54	6.58e-27	Mean platelet volume;
CRC	cis	rs73200209	0.744	rs17426239	chr12:116438287	A/G	cg01776926	chr12:116560359	MED13L	0.57	6.44	0.33	4.33e-10	Total body bone mineral density;
CRC	cis	rs965469	1.000	rs6133036	chr20:3349682	A/G	cg25506879	chr20:3388711	C20orf194	-0.4	-5.77	-0.3	1.81e-8	IFN-related cytopenia;
CRC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg24163568	chr5:669837	TPPP	0.43	6.83	0.35	4.09e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs1223397	0.651	rs2496146	chr6:13312474	A/G	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs7333181	1.000	rs36045739	chr13:112232686	G/A	cg27543320	chr13:112200689	NA	0.44	5.91	0.31	8.76e-9	Menopause (age at onset);
CRC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.88	-0.35	3.02e-11	Total body bone mineral density;
CRC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.76	0.51	2.55e-23	Coronary artery disease;
CRC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.72	0.3	2.41e-8	Homoarginine levels;
CRC	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07165851	chr6:158734300	TULP4	0.62	7.75	0.39	1.18e-13	Height;
CRC	cis	rs12997796	0.556	rs34933869	chr2:86922397	T/C	cg25203885	chr2:87302643	LOC285074	-0.58	-5.93	-0.31	7.58e-9	Schizophrenia;
CRC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	cis	rs860295	0.676	rs10908466	chr1:155429725	A/C	cg02153340	chr1:155202674	NA	-0.58	-6.82	-0.35	4.33e-11	Body mass index;
CRC	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.15	0.41	7.55e-15	Brugada syndrome;
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-8.04	-0.41	1.67e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	0.901	rs11212538	chr11:108045956	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.4	5.89	0.31	9.44e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.27	-5.81	-0.31	1.47e-8	Migraine;
CRC	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg10523679	chr1:76189770	ACADM	-0.39	-5.65	-0.3	3.43e-8	Daytime sleep phenotypes;
CRC	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.84	11.22	0.53	5.68e-25	IgG glycosylation;
CRC	cis	rs7605827	0.930	rs6723148	chr2:15592019	G/T	cg19274914	chr2:15703543	NA	0.38	5.77	0.3	1.84e-8	Educational attainment (years of education);
CRC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg19223190	chr17:80058835	NA	0.41	6.6	0.34	1.67e-10	Life satisfaction;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg23161317	chr6:28129485	ZNF389	0.44	6.41	0.33	5.12e-10	Parkinson's disease;
CRC	cis	rs7113874	0.589	rs10840058	chr11:8498399	G/T	cg20771178	chr11:8615675	STK33	0.34	5.67	0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.44	-6.15	-0.32	2.23e-9	Fibrinogen levels;
CRC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.52	0.71	5.84e-53	Parkinson's disease;
CRC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg15147215	chr3:52552868	STAB1	-0.57	-9.09	-0.45	9.6e-18	Bipolar disorder;
CRC	cis	rs932541	1.000	rs6034490	chr20:16457021	G/A	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	trans	rs2055729	0.710	rs6981023	chr8:9746585	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.3	-0.37	2.25e-12	Multiple myeloma (hyperdiploidy);
CRC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg21153622	chr11:89784906	NA	-0.38	-6.01	-0.31	4.86e-9	Height;
CRC	cis	rs11948739	0.539	rs1119863	chr5:130282399	T/G	cg08523029	chr5:130500466	HINT1	0.46	5.62	0.3	4.02e-8	Pediatric bone mineral content (hip);
CRC	cis	rs5751901	1.000	rs5751901	chr22:24992266	C/T	cg08808123	chr22:24999002	GGT1	0.4	5.85	0.31	1.19e-8	Protein quantitative trait loci;
CRC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.09	-0.49	4.87e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg23250157	chr14:64679961	SYNE2	0.48	7.39	0.38	1.24e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg04077850	chr5:125800366	GRAMD3	0.36	6.15	0.32	2.22e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.62	7.4	0.38	1.18e-12	Cleft lip with or without cleft palate;
CRC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05585630	chr7:157510462	PTPRN2	-0.43	-6.86	-0.35	3.47e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg15786705	chr6:28176104	NA	-0.58	-6.11	-0.32	2.89e-9	Depression;
CRC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.76	-0.39	1.05e-13	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05775451	chr1:228353712	C1orf69	0.39	6.26	0.33	1.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.38	0.42	1.6e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-7.93	-0.4	3.51e-14	Gut microbiome composition (summer);
CRC	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.96	-0.31	6.41e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.68	0.65	8.67e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.62	12.62	0.57	4.66e-30	Neuroticism;
CRC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Corneal astigmatism;
CRC	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00495681	chr13:53174319	NA	0.58	8.87	0.44	4.78e-17	Lewy body disease;
CRC	cis	rs10991814	0.920	rs76218486	chr9:94027677	T/A	cg14446406	chr9:93919335	NA	0.58	6.41	0.33	5.03e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.77	11.25	0.53	4.8e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.78	14.48	0.62	4.13e-37	Prudent dietary pattern;
CRC	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.81	-0.35	4.72e-11	Neuroticism;
CRC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs7212590	0.618	rs59767604	chr17:58041339	C/G	cg10252138	chr17:58120427	NA	-0.58	-6.28	-0.33	1.1e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg23942311	chr14:51606299	NA	-0.46	-6.98	-0.36	1.63e-11	Cancer;
CRC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.79	13.04	0.58	1.27e-31	Blood protein levels;
CRC	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.57	0.5	1.14e-22	Intelligence (multi-trait analysis);
CRC	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.61	11.02	0.52	3.06e-24	Blood metabolite ratios;
CRC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg25985355	chr7:65971099	NA	-0.32	-5.64	-0.3	3.73e-8	Aortic root size;
CRC	cis	rs6810498	0.774	rs4692328	chr4:26054619	C/T	cg12925881	chr4:26050407	NA	0.34	5.7	0.3	2.68e-8	Alcohol dependence;
CRC	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg23425280	chr12:56401806	NA	0.48	5.91	0.31	8.48e-9	Cancer;
CRC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.52e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12476592	0.602	rs1348805	chr2:63895673	A/G	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg15192750	chr16:69999425	NA	0.53	7.31	0.37	2e-12	IgE levels;
CRC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.57	9.49	0.46	4.75e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.69	9.18	0.45	4.79e-18	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.52	1.55e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg00343986	chr7:65444356	GUSB	0.42	6.05	0.32	3.98e-9	Aortic root size;
CRC	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg24304309	chr1:154577895	ADAR	-0.34	-5.65	-0.3	3.48e-8	Blood protein levels;
CRC	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs853679	1.000	rs853678	chr6:28297313	T/A	cg06470822	chr6:28175283	NA	0.59	6.14	0.32	2.39e-9	Depression;
CRC	cis	rs477692	0.507	rs7080570	chr10:131455328	C/T	cg05714579	chr10:131428358	MGMT	-0.41	-5.76	-0.3	1.96e-8	Response to temozolomide;
CRC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.45	6.07	0.32	3.56e-9	Pulse pressure;
CRC	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg19486271	chr11:47235900	DDB2	-0.49	-7.53	-0.38	4.81e-13	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg15282417	chr9:129245246	FAM125B	-0.45	-8.48	-0.42	7.7e-16	Intraocular pressure;
CRC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg08314208	chr16:67682810	RLTPR	-0.64	-7.34	-0.38	1.63e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.68	-10.65	-0.51	5.9e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3750082	0.889	rs970673	chr7:32927727	A/G	cg05721444	chr7:32995514	FKBP9	0.5	7.76	0.39	1.12e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg03623178	chr6:28175578	NA	0.51	7.16	0.37	5.35e-12	Parkinson's disease;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	9.16	0.45	5.88e-18	Lymphocyte counts;
CRC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.48	5.76	0.3	1.89e-8	Obesity-related traits;
CRC	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg08632701	chr21:37451849	NA	-0.43	-6.71	-0.35	8.49e-11	Mitral valve prolapse;
CRC	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11446398	chr5:77624930	NA	0.42	6.01	0.31	5.01e-9	Triglycerides;
CRC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.4	6.99	0.36	1.58e-11	Obesity-related traits;
CRC	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.52	8.38	0.42	1.55e-15	Monocyte percentage of white cells;
CRC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg01483505	chr11:975446	AP2A2	0.45	7.58	0.39	3.59e-13	Alzheimer's disease (late onset);
CRC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.71	0.39	1.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.8	10.45	0.5	2.9e-22	Diisocyanate-induced asthma;
CRC	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.57	-8.99	-0.44	1.93e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs12024301	0.557	rs7517163	chr1:183594872	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03923535	chr7:1197113	ZFAND2A	-0.6	-8.61	-0.43	3.15e-16	Longevity;Endometriosis;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg20512303	chr5:131592959	PDLIM4	0.38	6.51	0.34	2.77e-10	Breast cancer;
CRC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.81	9.24	0.45	3.05e-18	Migraine;Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00091162	chr1:167906284	BRP44;DCAF6	0.42	6.12	0.32	2.61e-9	Anxiety disorder;
CRC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.21	0.53	6.56e-25	Tonsillectomy;
CRC	cis	rs965469	1.000	rs2236087	chr20:3255905	C/T	cg25506879	chr20:3388711	C20orf194	-0.39	-5.63	-0.3	3.88e-8	IFN-related cytopenia;
CRC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.55	-7.94	-0.4	3.19e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10924970	0.687	rs10802286	chr1:235349239	A/G	cg09010748	chr1:235293032	TOMM20	0.4	5.63	0.3	3.83e-8	Asthma;
CRC	cis	rs1712517	0.836	rs7093039	chr10:105149547	A/G	cg05636881	chr10:105038444	INA	0.49	8.41	0.42	1.26e-15	Migraine;
CRC	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg22307029	chr19:49891270	CCDC155	0.64	6.08	0.32	3.32e-9	Multiple sclerosis;
CRC	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.81	-12.95	-0.58	2.76e-31	Hypospadias;
CRC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	1.04	12.45	0.57	1.95e-29	Eosinophil percentage of granulocytes;
CRC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.77	-0.35	5.97e-11	Monocyte count;
CRC	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg10437265	chr15:77819839	NA	0.67	12.38	0.56	3.61e-29	Type 2 diabetes;
CRC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg16989086	chr20:62203971	PRIC285	0.5	6.47	0.34	3.65e-10	Glioblastoma;
CRC	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.67	-6.41	-0.33	5.19e-10	Schizophrenia;
CRC	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	7.27	0.37	2.59e-12	Schizophrenia;
CRC	cis	rs9462027	0.628	rs9469909	chr6:34813077	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.02	-0.32	4.63e-9	Systemic lupus erythematosus;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.62	-0.34	1.42e-10	Bipolar disorder;
CRC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.73	-0.51	3.09e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.73	-11.75	-0.54	7.43e-27	Dilated cardiomyopathy;
CRC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.49	9.16	0.45	5.61e-18	Alcohol dependence;
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	8.75	0.43	1.14e-16	Blood protein levels;
CRC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg08314208	chr16:67682810	RLTPR	-0.64	-6.85	-0.35	3.57e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.16e-10	Obesity-related traits;
CRC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.71e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg05299278	chr17:33885742	SLFN14	0.39	5.86	0.31	1.14e-8	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs6810498	0.735	rs871384	chr4:26052506	A/T	cg12925881	chr4:26050407	NA	-0.42	-7.97	-0.4	2.59e-14	Alcohol dependence;
CRC	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	7.23	0.37	3.4e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7129556	0.954	rs11823651	chr11:77253879	G/A	cg12586386	chr11:77299805	AQP11	0.43	6.02	0.31	4.79e-9	Weight loss (gastric bypass surgery);
CRC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.93	0.36	2.27e-11	Morning vs. evening chronotype;
CRC	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.53	-6.48	-0.34	3.33e-10	Lymphocyte counts;
CRC	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.34	-0.33	7.69e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs73200209	0.912	rs59509739	chr12:116573496	A/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.79	-0.3	1.62e-8	Total body bone mineral density;
CRC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.41	0.5	4.01e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.48	8.16	0.41	6.97e-15	Common traits (Other);
CRC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg23136738	chr11:925521	AP2A2	-0.41	-7.01	-0.36	1.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg08831531	chr16:9218945	NA	-0.58	-8.08	-0.41	1.24e-14	Menopause (age at onset);
CRC	cis	rs6840360	0.582	rs59714108	chr4:152325939	G/A	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.33	-0.33	8.13e-10	Breast cancer;
CRC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg18279126	chr7:2041391	MAD1L1	0.4	5.93	0.31	7.82e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	8.2	0.41	5.52e-15	Cognitive test performance;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07513332	chr6:167530253	CCR6	-0.32	-5.79	-0.3	1.62e-8	Crohn's disease;
CRC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg27535305	chr1:53392650	SCP2	0.34	6.36	0.33	6.7e-10	Monocyte count;
CRC	cis	rs17065868	0.764	rs9533866	chr13:45037907	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.59	9.22	0.45	3.6e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs4523957	0.928	rs4790071	chr17:2173184	A/G	cg16513277	chr17:2031491	SMG6	-0.56	-9.56	-0.47	2.97e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6504950	0.800	rs8065361	chr17:53008853	A/T	cg26251398	chr17:52985966	TOM1L1	0.37	5.69	0.3	2.8e-8	Breast cancer;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.62	-9.83	-0.48	3.55e-20	Paraoxonase activity;
CRC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.97	12.01	0.55	8.78e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg04518342	chr5:131593106	PDLIM4	0.47	8.82	0.44	6.73e-17	Breast cancer;
CRC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.54	-0.34	2.41e-10	Reticulocyte fraction of red cells;
CRC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg15845792	chr6:28175446	NA	0.45	6.66	0.34	1.13e-10	Pubertal anthropometrics;
CRC	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg15192750	chr16:69999425	NA	0.56	7.55	0.38	4.24e-13	IgE levels;
CRC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg15448220	chr1:150897856	SETDB1	-0.4	-5.87	-0.31	1.04e-8	Tonsillectomy;
CRC	cis	rs6735179	0.837	rs6548058	chr2:1775108	T/A	cg19300414	chr2:1746591	PXDN	0.37	5.78	0.3	1.75e-8	Response to antipsychotic treatment;
CRC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	1.29	14.37	0.62	1.1e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.61	-5.91	-0.31	8.68e-9	Lung cancer;
CRC	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.38	4.61e-13	Height;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08219700	chr8:58056026	NA	0.56	6.65	0.34	1.2e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-11.16	-0.52	9.63e-25	Asthma;
CRC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	0.73	8.07	0.41	1.31e-14	Gout;Renal underexcretion gout;
CRC	cis	rs4654899	0.897	rs10799668	chr1:21169385	T/C	cg02927042	chr1:21476669	EIF4G3	0.41	6.64	0.34	1.3e-10	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04135372	chr2:99061383	INPP4A	0.41	6.37	0.33	6.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.99	-0.31	5.48e-9	Neuroticism;
CRC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.46	0.34	3.8e-10	Aortic root size;
CRC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg08075719	chr14:103021372	NA	-0.66	-7.86	-0.4	5.47e-14	Platelet count;
CRC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.77	7.8	0.4	8.13e-14	Diabetic retinopathy;
CRC	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.42	6.3	0.33	9.33e-10	Testicular germ cell tumor;
CRC	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.88	0.4	4.89e-14	Breast cancer;
CRC	cis	rs7215564	0.730	rs7214653	chr17:78581450	A/G	cg09596252	chr17:78655493	RPTOR	-0.63	-6.69	-0.35	9.83e-11	Myopia (pathological);
CRC	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg24998770	chr7:37888106	TXNDC3	0.38	6.07	0.32	3.48e-9	Alzheimer's disease (late onset);
CRC	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg04990556	chr1:26633338	UBXN11	0.55	5.86	0.31	1.15e-8	Obesity-related traits;
CRC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.71	9.89	0.48	2.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg10790698	chr19:18539756	SSBP4	-0.47	-8.71	-0.43	1.53e-16	Breast cancer;
CRC	trans	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg09045935	chr12:6379348	NA	1.15	8.8	0.44	7.62e-17	Blood metabolite levels;
CRC	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg23601416	chr22:19950040	COMT	0.29	7.89	0.4	4.6e-14	Blood metabolite levels;
CRC	trans	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg19894588	chr14:64061835	NA	-0.58	-7.69	-0.39	1.71e-13	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.18	-0.52	8.13e-25	Colorectal cancer;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.5	-7.33	-0.37	1.77e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.57	7.81	0.4	7.57e-14	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.81	13.41	0.59	5.24e-33	Intelligence (multi-trait analysis);
CRC	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.47	-0.38	7.07e-13	Caudate activity during reward;
CRC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg23018236	chr17:30244563	NA	-0.6	-8.03	-0.4	1.74e-14	Hip circumference adjusted for BMI;
CRC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.81	-0.35	4.6e-11	Response to antipsychotic treatment;
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.46	-6.1	-0.32	2.93e-9	Renal function-related traits (BUN);
CRC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.54	8.37	0.42	1.68e-15	Asthma (sex interaction);
CRC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.91	15.82	0.66	2.59e-42	Primary sclerosing cholangitis;
CRC	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	8.08	0.41	1.22e-14	Iron status biomarkers;
CRC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	trans	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg20935933	chr6:143382018	AIG1	-0.51	-6.71	-0.35	8.55e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs559356	0.519	rs523810	chr3:34848023	G/A	cg18960307	chr17:4699574	PSMB6	0.43	6.43	0.33	4.4e-10	Cognitive function;
CRC	trans	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg10756647	chr7:56101905	PSPH	0.71	7.95	0.4	2.97e-14	Diabetic kidney disease;
CRC	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	0.52	7.7	0.39	1.63e-13	Coronary artery disease;
CRC	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg09179987	chr1:167433047	CD247	0.56	8.84	0.44	5.72e-17	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.13	-0.32	2.54e-9	Gout;Renal underexcretion gout;
CRC	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21659725	chr3:3221576	CRBN	0.66	7.32	0.37	1.88e-12	Menarche (age at onset);
CRC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.54	7.66	0.39	2.11e-13	Alcohol dependence;
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.84	0.31	1.24e-8	Diastolic blood pressure;
CRC	cis	rs12760731	0.623	rs12691482	chr1:178421901	T/G	cg00404053	chr1:178313656	RASAL2	0.7	8.73	0.43	1.31e-16	Obesity-related traits;
CRC	cis	rs9584850	0.834	rs9584854	chr13:99118590	C/T	cg20487152	chr13:99095054	FARP1	0.43	6.28	0.33	1.1e-9	Neuroticism;
CRC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.82	12.47	0.57	1.74e-29	Cognitive function;
CRC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.48	7.39	0.38	1.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.47	6.96	0.36	1.8e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.45	6.19	0.32	1.83e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.39	5.7	0.3	2.64e-8	Asthma (bronchodilator response);
CRC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg02106180	chr16:845767	CHTF18	0.56	9.13	0.45	7.23e-18	Mean corpuscular volume;
CRC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	8.99	0.44	1.94e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg03923535	chr7:1197113	ZFAND2A	0.62	8.52	0.43	5.64e-16	Longevity;Endometriosis;
CRC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.39	-0.33	5.72e-10	Blood pressure (smoking interaction);
CRC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.69	10.13	0.49	3.56e-21	Longevity;
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg23590916	chr17:43697445	MGC57346	0.7	7.11	0.36	7.2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	5.9e-29	Cognitive function;
CRC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-8.15	-0.41	7.95e-15	Intelligence (multi-trait analysis);
CRC	cis	rs8014671	0.552	rs4899359	chr14:71027964	G/A	cg25576086	chr14:70833871	SYNJ2BP	0.37	6.13	0.32	2.51e-9	Prostate cancer;
CRC	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.3	-5.97	-0.31	6e-9	Breast cancer;
CRC	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg14458575	chr2:238380390	NA	0.46	6.51	0.34	2.8e-10	Prostate cancer;
CRC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	5.64	0.3	3.74e-8	Multiple sclerosis;
CRC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.42	9.4	0.46	9.75e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.72	-0.3	2.44e-8	Platelet distribution width;
CRC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.71	7.31	0.37	2.08e-12	Diabetic retinopathy;
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-8.87	-0.44	4.63e-17	Bipolar disorder;
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.65	-0.39	2.26e-13	Total body bone mineral density;
CRC	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg23173402	chr1:227635558	NA	0.59	6.02	0.32	4.56e-9	Major depressive disorder;
CRC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg03030879	chr14:75389066	RPS6KL1	0.48	7.61	0.39	2.83e-13	Height;
CRC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.81	-0.35	4.6e-11	Body mass index;
CRC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21643547	chr1:205240462	TMCC2	-0.38	-6.15	-0.32	2.19e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.8e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.1	-15.0	-0.64	4.06e-39	Exhaled nitric oxide output;
CRC	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg10756647	chr7:56101905	PSPH	0.76	7.97	0.4	2.69e-14	Gout;
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.71	9.58	0.47	2.48e-19	Alzheimer's disease;
CRC	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	0.9	8.73	0.43	1.28e-16	IgG glycosylation;
CRC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.27	0.46	2.53e-18	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.63	10.67	0.51	5.21e-23	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14489366	chr9:79521082	PRUNE2	-0.4	-6.19	-0.32	1.81e-9	Myopia (pathological);
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.1	-15.01	-0.64	3.68e-39	Exhaled nitric oxide output;
CRC	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.75	-12.32	-0.56	6.05e-29	Height;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12172441	chr6:28176163	NA	0.55	6.94	0.36	2.03e-11	Parkinson's disease;
CRC	cis	rs672059	1.000	rs659307	chr1:183163078	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	6.95	0.36	1.95e-11	Hypertriglyceridemia;
CRC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg13385521	chr17:29058706	SUZ12P	0.68	7.94	0.4	3.16e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26400169	chr5:131131892	FNIP1	0.42	6.1	0.32	2.98e-9	Response to antipsychotic treatment;
CRC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.44	0.46	6.87e-19	Cognitive test performance;
CRC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.59	8.41	0.42	1.23e-15	Pancreatic cancer;
CRC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.74	-10.68	-0.51	4.61e-23	Platelet distribution width;
CRC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.49	7.04	0.36	1.15e-11	Pancreatic cancer;
CRC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.49	-7.57	-0.39	3.82e-13	Monocyte count;
CRC	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg26727032	chr16:67993705	SLC12A4	-0.65	-9.9	-0.48	2.12e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg27121462	chr16:89883253	FANCA	0.42	6.32	0.33	8.71e-10	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25582403	chr17:37844421	ERBB2;PGAP3	0.43	6.22	0.32	1.54e-9	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26398333	chr1:153895721	GATAD2B	0.46	6.0	0.31	5.15e-9	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg22110888	chr17:80059540	CCDC57	0.4	6.36	0.33	6.76e-10	Life satisfaction;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.91	18.22	0.71	8.94e-52	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.46	-0.34	3.81e-10	Life satisfaction;
CRC	cis	rs17065868	0.649	rs1053948	chr13:45008333	G/C	cg10246903	chr13:45222710	NA	0.56	6.21	0.32	1.64e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.5	1.25e-22	Heart rate;
CRC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.68	6.85	0.35	3.71e-11	Initial pursuit acceleration;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg21620606	chr4:1342894	KIAA1530	0.48	8.41	0.42	1.31e-15	Longevity;
CRC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.57	9.81	0.48	4.4e-20	Iron status biomarkers;
CRC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-8.78	-0.44	9.14e-17	Ulcerative colitis;
CRC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.95e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.07	-0.36	9.13e-12	Alzheimer's disease (late onset);
CRC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.89	-0.48	2.36e-20	Schizophrenia;
CRC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.58	-8.31	-0.42	2.63e-15	Platelet distribution width;
CRC	cis	rs753955	0.592	rs4769288	chr13:24360434	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.44	-6.22	-0.32	1.53e-9	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24159451	chr19:9938429	UBL5	0.52	7.41	0.38	1.04e-12	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22150397	chr12:82752718	CCDC59;C12orf26	0.44	7.46	0.38	7.73e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg22561889	chr6:118971681	C6orf204	0.44	6.13	0.32	2.48e-9	Renal cell carcinoma;
CRC	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg17145862	chr1:211918768	LPGAT1	0.58	10.07	0.49	5.66e-21	Leprosy;
CRC	cis	rs7550918	1	rs7550918	chr1:247675559	C/T	cg21399703	chr1:247681439	NA	-0.53	-9.9	-0.48	2.12e-20	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18638793	chr12:108908854	FICD	0.43	6.1	0.32	2.9e-9	Response to antipsychotic treatment;
CRC	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.99	-14.97	-0.64	5.4e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03226245	chr19:36486125	SDHAF1	0.41	5.98	0.31	5.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.72	-7.55	-0.38	4.37e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.24	0.53	5.19e-25	Intelligence (multi-trait analysis);
CRC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg02549819	chr16:58548995	SETD6	1.2	7.97	0.4	2.72e-14	Schizophrenia;
CRC	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg02466173	chr16:30829666	NA	-0.66	-10.11	-0.49	4.1e-21	Dementia with Lewy bodies;
CRC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.42	-7.65	-0.39	2.27e-13	Prostate cancer;
CRC	cis	rs11229555	0.609	rs12291791	chr11:58186290	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	10.21	0.49	1.9e-21	Monocyte percentage of white cells;
CRC	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.79	11.66	0.54	1.52e-26	Blood metabolite levels;
CRC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.21	-0.53	6.53e-25	Bipolar disorder and schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04296778	chr1:94344488	DNTTIP2	0.41	6.02	0.31	4.53e-9	Intelligence (multi-trait analysis);
CRC	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	8.15	0.41	7.6e-15	Axial length;
CRC	cis	rs4731207	0.565	rs7780392	chr7:124575655	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-13.73	-0.6	3.08e-34	Cognitive function;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg08200770	chr17:80723486	TBCD	0.42	7.19	0.37	4.25e-12	Glycated hemoglobin levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07382149	chr1:150601807	ENSA	0.42	6.47	0.34	3.46e-10	Schizophrenia;
CRC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg23136738	chr11:925521	AP2A2	-0.53	-8.51	-0.42	6.18e-16	Alzheimer's disease (late onset);
CRC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.15	0.64	1.07e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	10.61	0.5	8.3e-23	Hip circumference adjusted for BMI;
CRC	cis	rs7517126	1.000	rs2133138	chr1:196843171	A/G	cg13682187	chr1:196946512	CFHR5	0.34	5.68	0.3	3e-8	Blood protein levels;
CRC	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg18850127	chr7:39170497	POU6F2	0.49	6.38	0.33	6.02e-10	IgG glycosylation;
CRC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.85	-0.31	1.21e-8	Alcohol dependence;
CRC	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.44	-7.1	-0.36	7.67e-12	Refractive error;
CRC	cis	rs12936587	0.748	rs12939297	chr17:17524247	G/A	cg09796270	chr17:17721594	SREBF1	-0.41	-5.91	-0.31	8.57e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.84	0.75	4.55e-62	Prudent dietary pattern;
CRC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.69	-11.03	-0.52	2.67e-24	Cognitive function;
CRC	trans	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg24644049	chr4:85504048	CDS1	0.9	7.37	0.38	1.39e-12	Skin colour saturation;
CRC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.6	-9.53	-0.47	3.61e-19	Calcium levels;
CRC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.77	0.39	9.87e-14	Platelet count;
CRC	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.41	-6.17	-0.32	2.04e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04674497	chr6:45346044	SUPT3H;RUNX2	0.43	6.28	0.33	1.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	8.17	0.41	6.59e-15	Bipolar disorder and schizophrenia;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24760647	chr2:220408209	TMEM198;CHPF	-0.4	-6.05	-0.32	3.92e-9	Obesity-related traits;
CRC	cis	rs59104589	0.617	rs59487360	chr2:242270433	A/G	cg19488206	chr2:242435732	STK25	0.46	6.4	0.33	5.31e-10	Fibrinogen levels;
CRC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.26	0.37	2.78e-12	Motion sickness;
CRC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg11843238	chr5:131593191	PDLIM4	0.55	9.76	0.47	6.4e-20	Acylcarnitine levels;
CRC	trans	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg21302420	chr1:112162376	RAP1A	0.65	6.41	0.33	5.02e-10	Skin colour saturation;
CRC	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg17182837	chr8:41585554	ANK1	-0.35	-5.76	-0.3	1.92e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.4	-6.7	-0.35	9.12e-11	Longevity;Endometriosis;
CRC	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs9462027	0.628	rs6457795	chr6:34819366	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.52e-9	Systemic lupus erythematosus;
CRC	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.57	-8.93	-0.44	3.13e-17	Motion sickness;
CRC	cis	rs9463078	0.605	rs10948188	chr6:44926212	G/A	cg25276700	chr6:44698697	NA	0.26	6.24	0.33	1.38e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9409565	0.559	rs9409774	chr9:97241983	G/A	cg04523069	chr9:97136363	HIATL1	0.43	5.88	0.31	9.92e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs76533333	0.646	rs71446628	chr13:113393611	C/T	cg04656015	chr13:113407548	ATP11A	0.75	5.73	0.3	2.22e-8	Red cell distribution width;
CRC	cis	rs375066	0.934	rs2191564	chr19:44367611	T/C	cg12072164	chr19:44306565	LYPD5	0.37	5.61	0.3	4.31e-8	Breast cancer;
CRC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.28	0.37	2.54e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg09655341	chr17:79618100	PDE6G	-0.39	-7.03	-0.36	1.21e-11	Eye color traits;
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.76	-0.58	1.48e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg04362960	chr10:104952993	NT5C2	0.46	6.11	0.32	2.84e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13144136	0.664	rs12501252	chr4:10661563	A/G	cg10242279	chr4:10666415	CLNK	-0.37	-6.41	-0.33	4.94e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.59	-8.23	-0.41	4.34e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7680126	0.633	rs17389602	chr4:10206926	T/A	cg00071950	chr4:10020882	SLC2A9	-0.53	-6.65	-0.34	1.19e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00139244	chr10:31608402	ZEB1;LOC220930	0.32	6.11	0.32	2.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-8.36	-0.42	1.84e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs77372450	0.636	rs10072471	chr5:157022207	G/C	cg25387487	chr5:157003181	ADAM19	-0.39	-5.68	-0.3	3.03e-8	Bipolar disorder (body mass index interaction);
CRC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.38	-6.11	-0.32	2.79e-9	Gout;Renal underexcretion gout;
CRC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.8	0.4	8.28e-14	Platelet count;
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.82	-0.58	8.43e-31	Alzheimer's disease;
CRC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg19812747	chr11:111475976	SIK2	0.52	8.13	0.41	8.69e-15	Primary sclerosing cholangitis;
CRC	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-7.11	-0.36	7.42e-12	Response to antipsychotic treatment;
CRC	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.48	5.92	0.31	8.01e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.7	-10.71	-0.51	3.58e-23	Menarche (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23429981	chr6:97345948	NDUFAF4	0.39	6.46	0.34	3.75e-10	Obesity-related traits;
CRC	cis	rs4964805	0.632	rs9706225	chr12:104188086	T/C	cg02344784	chr12:104178138	NT5DC3	0.79	15.0	0.64	4.21e-39	Attention deficit hyperactivity disorder;
CRC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg24463073	chr6:118973353	C6orf204	0.51	6.87	0.35	3.16e-11	Diastolic blood pressure;
CRC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	7.26	0.37	2.87e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.22	-0.45	3.73e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.54	8.0	0.4	2.09e-14	Itch intensity from mosquito bite;
CRC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg15744005	chr10:104629667	AS3MT	0.3	5.65	0.3	3.46e-8	Arsenic metabolism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19319088	chr7:6388563	C7orf70	0.38	6.19	0.32	1.84e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs12702919	0.869	rs10237257	chr7:9553854	G/A	cg15597424	chr4:24472487	NA	-0.39	-6.19	-0.32	1.83e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.45	18.09	0.71	2.95e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-12.23	-0.56	1.28e-28	Height;
CRC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.42	0.46	8.39e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.67	10.53	0.5	1.59e-22	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.91	17.27	0.69	4.93e-48	Intelligence (multi-trait analysis);
CRC	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.49	-8.67	-0.43	1.97e-16	Response to cytidine analogues (gemcitabine);
CRC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-8.74	-0.43	1.23e-16	Menarche (age at onset);
CRC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.6	-8.83	-0.44	6.42e-17	Aortic root size;
CRC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.27	-0.46	2.46e-18	Menarche (age at onset);
CRC	cis	rs3015497	0.789	rs10133849	chr14:51121700	A/G	cg09863266	chr14:51125203	SAV1	-0.32	-6.02	-0.31	4.68e-9	Mean platelet volume;
CRC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.67	0.39	2.02e-13	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13482236	chr15:59062977	FAM63B	0.45	6.25	0.33	1.28e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.43	6.14	0.32	2.35e-9	Aortic root size;
CRC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.49	7.57	0.39	3.78e-13	Corneal astigmatism;
CRC	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.78	7.8	0.4	8.09e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.53	0.43	5.44e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs7429990	0.932	rs34025851	chr3:47953733	C/A	cg11946769	chr3:48343235	NME6	0.46	5.9	0.31	8.99e-9	Educational attainment (years of education);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21963318	chr16:85832920	COX4I1;COX4NB	0.43	6.63	0.34	1.41e-10	Schizophrenia;
CRC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-8.63	-0.43	2.71e-16	Intelligence (multi-trait analysis);
CRC	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg25203885	chr2:87302643	LOC285074	-0.58	-5.87	-0.31	1.09e-8	Schizophrenia;
CRC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg03013636	chr16:1946785	NA	0.58	6.66	0.34	1.15e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.4	6.12	0.32	2.66e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg00469287	chr7:23338798	C7orf30	0.43	5.99	0.31	5.51e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.75	13.11	0.59	7.31e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.67	7.4	0.38	1.17e-12	Initial pursuit acceleration;
CRC	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.54	-0.34	2.31e-10	Response to antipsychotic treatment;
CRC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.78	-0.47	5.41e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg21770322	chr7:97807741	LMTK2	-0.67	-12.26	-0.56	1.01e-28	Breast cancer;
CRC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.32e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.85	-14.32	-0.62	1.68e-36	Ulcerative colitis;
CRC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.44	6.92	0.36	2.33e-11	Cleft lip with or without cleft palate;
CRC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.12	0.41	9.56e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.71	-11.94	-0.55	1.51e-27	Hip circumference adjusted for BMI;
CRC	cis	rs3736485	0.816	rs12443362	chr15:51874542	C/A	cg08986416	chr15:51914746	DMXL2	-0.48	-6.92	-0.36	2.39e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.38	-0.46	1.11e-18	Urate levels in obese individuals;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg02683197	chr6:28174875	NA	0.62	8.57	0.43	4.07e-16	Parkinson's disease;
CRC	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.53	8.18	0.41	6.37e-15	Coronary artery disease;
CRC	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg25457927	chr22:38595422	NA	-0.3	-5.76	-0.3	1.89e-8	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs6142102	0.961	rs1883524	chr20:32626107	G/A	cg08999081	chr20:33150536	PIGU	0.37	5.64	0.3	3.6e-8	Skin pigmentation;
CRC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.05e-29	Cognitive function;
CRC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.75	0.39	1.14e-13	Height;
CRC	cis	rs370915	0.607	rs28548850	chr4:187786716	G/A	cg12892747	chr4:187813459	NA	-0.56	-8.04	-0.41	1.67e-14	Gout;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg21770322	chr7:97807741	LMTK2	0.85	19.36	0.73	2.8e-56	Breast cancer;
CRC	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg02158880	chr13:53174818	NA	0.59	9.39	0.46	1.05e-18	Lewy body disease;
CRC	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.43	6.39	0.33	5.8e-10	Neutrophil percentage of white cells;
CRC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.28	-5.84	-0.31	1.26e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.68	10.3	0.49	9.17e-22	Corneal astigmatism;
CRC	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.11	11.97	0.55	1.19e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg22110888	chr17:80059540	CCDC57	0.41	6.39	0.33	5.61e-10	Life satisfaction;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg12564285	chr5:131593104	PDLIM4	0.39	7.27	0.37	2.7e-12	Blood metabolite levels;
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg20399509	chr21:47717575	C21orf57	-0.39	-6.31	-0.33	9.21e-10	Testicular germ cell tumor;
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.19	-0.32	1.76e-9	Neuroticism;
CRC	cis	rs12024301	0.557	rs12029935	chr1:183588983	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg10556349	chr10:835070	NA	-0.37	-7.0	-0.36	1.48e-11	Survival in rectal cancer;
CRC	trans	rs670292	0.564	rs607971	chr6:150677754	A/C	cg11381792	chr21:45432451	TRAPPC10	0.44	6.23	0.32	1.43e-9	Anger;
CRC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16447950	chr5:562315	NA	-0.73	-9.65	-0.47	1.41e-19	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22924680	chr5:43557135	PAIP1	-0.39	-6.09	-0.32	3.18e-9	Myopia (pathological);
CRC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.61	8.32	0.42	2.34e-15	Height;
CRC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.72	11.33	0.53	2.39e-25	Mean corpuscular hemoglobin;
CRC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9463078	0.774	rs4373351	chr6:45276324	T/C	cg25276700	chr6:44698697	NA	-0.28	-6.71	-0.35	8.73e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.24	-0.45	3.14e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7584330	0.740	rs13426236	chr2:238447940	A/G	cg14458575	chr2:238380390	NA	0.54	8.92	0.44	3.34e-17	Prostate cancer;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14213021	chr10:71930531	SAR1A	0.41	6.33	0.33	8.01e-10	Myopia (pathological);
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg11441379	chr12:63026424	NA	0.54	5.65	0.3	3.47e-8	IgG glycosylation;
CRC	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.6	-5.99	-0.31	5.54e-9	Night sleep phenotypes;
CRC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.75	-0.3	2.07e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9925964	0.933	rs881929	chr16:31079371	G/T	cg02466173	chr16:30829666	NA	0.43	5.82	0.31	1.41e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-16.54	-0.67	3.83e-45	Schizophrenia;
CRC	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.72	-7.91	-0.4	3.84e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.55	8.01	0.4	2.07e-14	Resting heart rate;
CRC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.83	-13.08	-0.58	9.21e-32	Cognitive ability;
CRC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.61	-9.73	-0.47	8.1e-20	Monocyte count;
CRC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg24675056	chr1:15929824	NA	-0.51	-7.21	-0.37	3.8e-12	Systolic blood pressure;
CRC	cis	rs17065868	0.764	rs11552414	chr13:45010867	C/T	cg10246903	chr13:45222710	NA	0.56	6.21	0.32	1.64e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-0.59	-7.96	-0.4	2.85e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.84	-0.31	1.25e-8	Neuroticism;
CRC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.77	-0.39	9.99e-14	Schizophrenia;
CRC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-5.94	-0.31	7.17e-9	Major depressive disorder;
CRC	cis	rs8105895	0.935	rs10422289	chr19:22256060	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.65	0.51	6.14e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	cis	rs3018066	0.748	rs12642900	chr4:107010329	T/C	cg01869342	chr4:106983673	TBCK	0.44	6.7	0.35	9.19e-11	Cancer;
CRC	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.52	8.84	0.44	5.97e-17	Aortic root size;
CRC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.08	-0.41	1.28e-14	Schizophrenia;
CRC	cis	rs1712517	0.873	rs1163086	chr10:105039579	A/G	cg05636881	chr10:105038444	INA	0.48	8.31	0.42	2.56e-15	Migraine;
CRC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.44	-5.79	-0.3	1.62e-8	Fibrinogen levels;
CRC	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.71	9.43	0.46	7.49e-19	Iron status biomarkers;
CRC	cis	rs6764363	0.733	rs186704	chr3:295418	T/C	cg02057681	chr3:285234	CHL1	-0.35	-5.71	-0.3	2.5e-8	Sudden cardiac arrest;
CRC	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06307176	chr5:131281290	NA	-0.4	-5.74	-0.3	2.12e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.48	7.47	0.38	7.46e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg25164649	chr6:28176230	NA	0.6	7.94	0.4	3.28e-14	Parkinson's disease;
CRC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.63	-9.29	-0.46	2.2e-18	Menarche (age at onset);
CRC	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.6	-0.34	1.66e-10	Breast cancer;
CRC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	trans	rs9409565	0.826	rs9409778	chr9:97242839	G/A	cg05679027	chr9:99775184	HIATL2	-0.41	-6.22	-0.32	1.52e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7264396	0.943	rs1810742	chr20:34109718	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.93	-0.36	2.17e-11	Total cholesterol levels;
CRC	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg16355469	chr20:37678765	NA	0.35	5.73	0.3	2.28e-8	Dialysis-related mortality;
CRC	cis	rs6838801	0.964	rs4859701	chr4:77564469	T/G	cg17476223	chr4:77663285	SHROOM3	-0.41	-5.63	-0.3	3.9e-8	Cleft lip with or without cleft palate;
CRC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	7.37	0.38	1.38e-12	Schizophrenia;
CRC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg24011408	chr12:48396354	COL2A1	0.44	6.13	0.32	2.5e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg21251018	chr6:28226885	NKAPL	0.39	6.08	0.32	3.31e-9	Parkinson's disease;
CRC	cis	rs9463078	0.727	rs2396371	chr6:44946550	C/T	cg25276700	chr6:44698697	NA	-0.28	-7.13	-0.37	6.58e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs28655083	0.529	rs589002	chr16:77104044	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.58	0.34	1.87e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.59	-7.48	-0.38	6.66e-13	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05506986	chr2:174220200	CDCA7	0.41	6.16	0.32	2.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg14631576	chr9:95140430	CENPP	-0.41	-7.33	-0.37	1.77e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.54	7.3	0.37	2.14e-12	Total body bone mineral density;
CRC	cis	rs6973256	0.605	rs7792396	chr7:133345526	T/C	cg10665199	chr7:133106180	EXOC4	0.48	7.58	0.39	3.67e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg00425431	chr15:90792223	TTLL13	0.32	5.68	0.3	2.91e-8	Rheumatoid arthritis;
CRC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.84	-0.35	3.86e-11	Height;
CRC	cis	rs2013441	0.670	rs35317166	chr17:19959820	T/A	cg13482628	chr17:19912719	NA	0.41	5.71	0.3	2.5e-8	Obesity-related traits;
CRC	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	15.83	0.66	2.27e-42	Platelet count;
CRC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg22676075	chr6:135203613	NA	0.42	6.33	0.33	8.1e-10	Red blood cell count;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg09877947	chr5:131593287	PDLIM4	0.43	7.01	0.36	1.39e-11	Breast cancer;
CRC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg04013166	chr16:89971882	TCF25	0.62	5.64	0.3	3.59e-8	Skin colour saturation;
CRC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.92	-16.26	-0.67	4.73e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg19337854	chr7:99768885	GPC2	0.47	5.93	0.31	7.64e-9	Lung function (FEV1/FVC);
CRC	cis	rs9549328	0.700	rs3011474	chr13:113617865	T/C	cg25790453	chr13:113633590	MCF2L	0.44	7.56	0.38	4e-13	Systolic blood pressure;
CRC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.66	9.19	0.45	4.44e-18	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg21153622	chr11:89784906	NA	-0.47	-7.41	-0.38	1.08e-12	HDL cholesterol;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.65	7.41	0.38	1.09e-12	Body mass index;
CRC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.56	-8.54	-0.43	4.93e-16	Coronary artery disease;
CRC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.84	-14.25	-0.62	3.27e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.6	-8.98	-0.44	2.09e-17	Blood metabolite levels;
CRC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.75e-13	Hip circumference adjusted for BMI;
CRC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg03959625	chr15:84868606	LOC388152	0.41	6.08	0.32	3.26e-9	Schizophrenia;
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05313302	chr10:75006908	DNAJC9	0.44	6.15	0.32	2.3e-9	Anxiety disorder;
CRC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg19223190	chr17:80058835	NA	-0.45	-7.24	-0.37	3.21e-12	Life satisfaction;
CRC	cis	rs9549328	0.614	rs35299896	chr13:113617229	G/T	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.24e-19	Systolic blood pressure;
CRC	cis	rs10971721	0.749	rs72725371	chr9:33825011	G/A	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.79e-9	Body mass index;
CRC	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg24759859	chr6:86352639	SYNCRIP	0.47	6.5	0.34	3.01e-10	Smooth-surface caries;
CRC	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg12856521	chr11:46389249	DGKZ	-0.41	-6.46	-0.34	3.69e-10	Leprosy;
CRC	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.47	-6.43	-0.33	4.6e-10	Squamous cell carcinoma;
CRC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.65	8.89	0.44	3.98e-17	Coronary artery disease;
CRC	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg06156847	chr2:113672199	IL1F7	-0.4	-6.03	-0.32	4.38e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.67	11.91	0.55	2.01e-27	Eye color traits;
CRC	cis	rs6662572	0.737	rs6665193	chr1:46347910	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.55	8.94	0.44	2.94e-17	Type 2 diabetes;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.82e-9	Bipolar disorder;
CRC	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.45	-8.03	-0.4	1.8e-14	Testicular germ cell tumor;
CRC	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs6445967	1.000	rs13059916	chr3:58316364	A/G	cg23715586	chr3:58305044	RPP14	0.36	5.99	0.31	5.44e-9	Platelet count;
CRC	cis	rs7374004	1.000	rs7374004	chr3:38625709	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.42	-5.74	-0.3	2.1e-8	PR interval;
CRC	cis	rs4700695	0.925	rs4700693	chr5:65399078	A/G	cg21114390	chr5:65439923	SFRS12	-0.63	-6.92	-0.36	2.31e-11	Facial morphology (factor 19);
CRC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg15147215	chr3:52552868	STAB1	-0.48	-7.8	-0.39	8.38e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg10820045	chr2:198174542	NA	-0.54	-9.16	-0.45	5.5e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg00343986	chr7:65444356	GUSB	-0.47	-6.83	-0.35	4.15e-11	Aortic root size;
CRC	cis	rs457287	0.772	rs465032	chr9:4833866	T/C	cg14182974	chr9:4791918	RCL1	0.42	5.9	0.31	8.81e-9	Platelet count;
CRC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-0.43	-5.85	-0.31	1.2e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.43	-0.42	1.1e-15	Schizophrenia;
CRC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.57	7.62	0.39	2.75e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.0	0.31	5.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.57	-8.69	-0.43	1.74e-16	Itch intensity from mosquito bite;
CRC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.45	9.25	0.45	2.89e-18	Renal cell carcinoma;
CRC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-12.96	-0.58	2.47e-31	Cognitive function;
CRC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.45	6.72	0.35	7.97e-11	N-glycan levels;
CRC	cis	rs7605827	0.866	rs9710962	chr2:15533884	C/A	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.43	-0.33	4.54e-10	Post bronchodilator FEV1;
CRC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.01	-0.36	1.32e-11	Joint mobility (Beighton score);
CRC	cis	rs28719689	0.655	rs17063833	chr8:1275384	A/G	cg22761795	chr8:1265118	NA	0.57	6.92	0.36	2.33e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.61	0.43	3.16e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg21625146	chr5:486483	SLC9A3	0.37	5.75	0.3	2.06e-8	Cystic fibrosis severity;
CRC	cis	rs9462027	0.628	rs10738078	chr6:34693917	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.07	0.32	3.49e-9	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27498211	chr16:4588826	C16orf5	0.31	6.24	0.33	1.35e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	7.08	0.36	8.57e-12	Obesity-related traits;
CRC	cis	rs7945718	0.621	rs7943920	chr11:12695614	A/G	cg25843174	chr11:12811716	TEAD1	0.4	7.11	0.37	7.06e-12	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18382590	chr9:131219195	ODF2	0.48	6.86	0.35	3.43e-11	Response to antipsychotic treatment;
CRC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	trans	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg17903999	chr18:56338584	MALT1	0.4	6.51	0.34	2.76e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg00083937	chr22:51039805	MAPK8IP2	-0.35	-5.72	-0.3	2.41e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.23	11.56	0.54	3.66e-26	Alzheimer's disease (late onset);
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.76	-11.44	-0.53	9.94e-26	Intelligence (multi-trait analysis);
CRC	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.62	-9.57	-0.47	2.66e-19	Testicular germ cell tumor;
CRC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.5	-6.02	-0.31	4.54e-9	Platelet distribution width;
CRC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.96e-9	Gut microbiome composition (summer);
CRC	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg14593290	chr7:50529359	DDC	0.62	8.15	0.41	7.72e-15	Malaria;
CRC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg06740227	chr12:86229804	RASSF9	0.39	5.86	0.31	1.09e-8	Major depressive disorder;
CRC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.28	0.56	8.75e-29	Menopause (age at onset);
CRC	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	9.22e-40	Hypertriglyceridemia;
CRC	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.53e-11	Coronary artery disease;
CRC	cis	rs3790844	0.678	rs3790854	chr1:200000125	C/T	cg13229857	chr1:200006247	NR5A2	-0.51	-7.45	-0.38	8.04e-13	Pancreatic cancer;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg12564285	chr5:131593104	PDLIM4	0.46	7.78	0.39	9.36e-14	Breast cancer;
CRC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg06204229	chr3:52865917	ITIH4	0.6	7.3	0.37	2.22e-12	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg05072774	chr3:49840536	C3orf54	-0.43	-5.74	-0.3	2.15e-8	Resting heart rate;
CRC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	8.16e-11	Blood pressure (smoking interaction);
CRC	trans	rs13315871	0.615	rs7625655	chr3:58337723	C/T	cg25250853	chr2:85822726	RNF181	-0.53	-6.35	-0.33	7.08e-10	Cholesterol, total;
CRC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg01761236	chr14:102990251	NA	-0.29	-5.77	-0.3	1.86e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs17092148	0.836	rs4322911	chr20:33182577	G/A	cg08999081	chr20:33150536	PIGU	0.49	6.35	0.33	7.34e-10	Neuroticism;
CRC	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.96	-0.31	6.43e-9	Height;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.19	-0.53	7.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6496667	0.738	rs5020807	chr15:91043188	C/A	cg04176472	chr15:90893244	GABARAPL3	0.54	7.76	0.39	1.08e-13	Rheumatoid arthritis;
CRC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.7	0.47	1.02e-19	Platelet count;
CRC	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.79	-9.97	-0.48	1.27e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.51	-8.36	-0.42	1.75e-15	Testicular germ cell tumor;
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg12326244	chr17:78078995	GAA	-0.38	-5.71	-0.3	2.46e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.46	6.38	0.33	5.86e-10	Corneal structure;
CRC	cis	rs3736485	0.932	rs2278988	chr15:51915234	A/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.39	-0.33	5.63e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg10845886	chr2:3471009	TTC15	-0.64	-9.53	-0.47	3.63e-19	Neurofibrillary tangles;
CRC	trans	rs10411161	0.690	rs7252336	chr19:52389514	C/T	cg22319618	chr22:45562946	NUP50	-0.65	-7.24	-0.37	3.26e-12	Breast cancer;
CRC	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.68	8.59	0.43	3.51e-16	Iron status biomarkers;
CRC	cis	rs4561483	0.603	rs17235629	chr16:11932421	C/T	cg08843971	chr16:11963173	GSPT1	-0.49	-7.39	-0.38	1.21e-12	Testicular germ cell tumor;
CRC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18912574	chr7:65842487	NCRNA00174	0.36	5.99	0.31	5.46e-9	Aortic root size;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.87	-19.9	-0.74	2.15e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.76	-11.31	-0.53	2.72e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.31	5.83	0.31	1.32e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs10924970	0.687	rs946027	chr1:235346286	T/C	cg09010748	chr1:235293032	TOMM20	-0.41	-5.74	-0.3	2.12e-8	Asthma;
CRC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.57	-8.08	-0.41	1.23e-14	Longevity;
CRC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	20.69	0.75	1.72e-61	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.32	-0.33	8.27e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.45	6.16	0.32	2.09e-9	Pulse pressure;
CRC	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	27.17	0.83	4.38e-86	Schizophrenia;
CRC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.96	-0.31	6.39e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.57	7.54	0.38	4.71e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg10729496	chr3:10149963	C3orf24	0.49	6.71	0.35	8.51e-11	Alzheimer's disease;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.45	-0.5	2.81e-22	Bipolar disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13692869	chr1:169336982	NME7;BLZF1	0.56	7.49	0.38	6.44e-13	Thyroid stimulating hormone;
CRC	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.53	8.49	0.42	7.06e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	trans	rs4853036	0.672	rs35293234	chr2:70025165	C/A	cg14633329	chr9:139640053	LCN6	-0.34	-5.98	-0.31	5.69e-9	Colorectal or endometrial cancer;
CRC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	1.03	17.99	0.7	7.33e-51	Parkinson's disease;
CRC	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07165851	chr6:158734300	TULP4	0.61	7.76	0.39	1.11e-13	Height;
CRC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg00334542	chr7:100209784	MOSPD3	0.54	6.72	0.35	7.8e-11	Other erythrocyte phenotypes;
CRC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.06	-17.63	-0.7	1.99e-49	Blood pressure (smoking interaction);
CRC	cis	rs11203032	0.831	rs4617498	chr10:90943713	G/A	cg16672925	chr10:90967113	CH25H	0.44	5.67	0.3	3.13e-8	Heart failure;
CRC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.29	0.53	3.24e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.09	-0.32	3.18e-9	Breast cancer;
CRC	cis	rs12540874	0.518	rs12718674	chr7:50627130	T/C	cg14593290	chr7:50529359	DDC	-0.45	-6.24	-0.33	1.31e-9	Systemic sclerosis;
CRC	cis	rs449789	0.817	rs1875814	chr6:159720266	G/A	cg14500486	chr6:159655392	FNDC1	-0.48	-7.39	-0.38	1.24e-12	Pulse pressure;
CRC	cis	rs11170631	0.504	rs10128880	chr12:53927783	T/C	cg06632207	chr12:54070931	ATP5G2	0.45	7.58	0.39	3.62e-13	Height;
CRC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.73	0.39	1.32e-13	Colorectal cancer;
CRC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.55	-9.14	-0.45	6.38e-18	Body mass index;
CRC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.83	7.35	0.38	1.62e-12	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.48	-5.89	-0.31	9.5e-9	Coronary artery calcification;
CRC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.64	-0.3	3.64e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg25834613	chr7:1915315	MAD1L1	-0.46	-6.59	-0.34	1.72e-10	Neuroticism;
CRC	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.51	-8.28	-0.42	3.14e-15	Testicular germ cell tumor;
CRC	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-5.86	-0.31	1.11e-8	Blood protein levels;
CRC	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.44	-7.26	-0.37	2.75e-12	Refractive error;
CRC	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs17127169	0.536	rs112625995	chr1:65496627	A/G	cg15583014	chr1:65468659	NA	0.89	6.12	0.32	2.71e-9	Sitting height ratio;
CRC	cis	rs6662572	0.737	rs4474301	chr1:46255272	A/G	cg08644498	chr1:46502608	NA	-0.43	-6.89	-0.36	2.8e-11	Blood protein levels;
CRC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.57	-8.29	-0.42	2.85e-15	Total body bone mineral density;
CRC	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.51	8.46	0.42	8.88e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg13611204	chr9:139324423	INPP5E	-0.42	-5.9	-0.31	8.84e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.81	13.33	0.59	1.05e-32	Menopause (age at onset);
CRC	cis	rs77972916	0.561	rs4372955	chr2:43566146	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.66	-0.3	3.26e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.42	0.38	9.88e-13	Hip circumference adjusted for BMI;
CRC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.57	-0.5	1.08e-22	Chronic sinus infection;
CRC	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.46	-7.17	-0.37	4.92e-12	Large artery stroke;
CRC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.59	6.72	0.35	7.95e-11	Bipolar disorder;
CRC	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.63	-9.82	-0.48	3.98e-20	Testicular germ cell tumor;
CRC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg08314208	chr16:67682810	RLTPR	0.63	7.21	0.37	3.95e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg11189052	chr15:85197271	WDR73	0.63	8.87	0.44	4.87e-17	Bipolar disorder lithium response (categorical) or schizophrenia;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg02683197	chr6:28174875	NA	0.62	8.5	0.42	6.91e-16	Parkinson's disease;
CRC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg12100956	chr17:78086420	GAA	-0.37	-5.73	-0.3	2.22e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.59	-0.34	1.76e-10	Fibrinogen levels;
CRC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg06238570	chr21:40685208	BRWD1	0.74	10.4	0.5	4.41e-22	Cognitive function;
CRC	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.54	-0.34	2.29e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12588638	chr12:83080208	TMTC2	0.44	6.41	0.33	5.15e-10	Response to antipsychotic treatment;
CRC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.62	9.82	0.48	4e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.3	-0.33	9.69e-10	Total body bone mineral density;
CRC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.36	-6.1	-0.32	2.92e-9	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg23018236	chr17:30244563	NA	-0.67	-8.01	-0.4	1.96e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg19041857	chr6:27730383	NA	-0.71	-6.67	-0.35	1.05e-10	Depression;
CRC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.69	-10.72	-0.51	3.49e-23	Dental caries;
CRC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.98	-0.44	2.14e-17	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg19223190	chr17:80058835	NA	0.4	6.52	0.34	2.63e-10	Life satisfaction;
CRC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.35	-0.56	4.69e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	8.71	0.43	1.49e-16	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.56	10.01	0.48	9.4e-21	HDL cholesterol levels;
CRC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg08314208	chr16:67682810	RLTPR	0.61	6.64	0.34	1.3e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9826463	0.702	rs28365824	chr3:142315114	C/A	cg20824294	chr3:142316082	PLS1	0.42	6.84	0.35	3.86e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg26751469	chr19:56116382	NA	-0.5	-6.23	-0.32	1.45e-9	Diisocyanate-induced asthma;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.8	12.03	0.55	6.84e-28	Intelligence (multi-trait analysis);
CRC	cis	rs516243	0.806	rs7545228	chr1:10740303	G/C	cg02903756	chr1:10750680	CASZ1	-0.42	-7.18	-0.37	4.57e-12	Migraine - clinic-based;
CRC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.43	6.23	0.32	1.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	14.54	0.63	2.38e-37	Platelet count;
CRC	cis	rs4925540	0.724	rs3104110	chr1:247173006	A/G	cg22502715	chr1:247171572	ZNF695	0.42	6.02	0.31	4.71e-9	Response to taxane treatment (docetaxel);
CRC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.6	-7.58	-0.39	3.58e-13	Obesity (extreme);
CRC	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.73	9.76	0.47	6.14e-20	Prostate cancer;
CRC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.65	-5.89	-0.31	9.39e-9	Yeast infection;
CRC	cis	rs2386661	0.522	rs11258044	chr10:5644392	C/T	cg26603656	chr10:5671107	NA	0.37	6.6	0.34	1.64e-10	Breast cancer;
CRC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.01	-0.31	5e-9	Monocyte percentage of white cells;
CRC	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.82	-14.37	-0.62	1.11e-36	Hip circumference;
CRC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4e-17	Electroencephalogram traits;
CRC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.18e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.48	-7.77	-0.39	1.03e-13	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26672739	chr14:77843588	C14orf174;TMED8	0.38	6.09	0.32	3.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.62	12.96	0.58	2.67e-31	Schizophrenia;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg15691649	chr6:25882328	NA	-0.56	-7.02	-0.36	1.3e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg04155289	chr7:94953770	PON1	-0.55	-7.01	-0.36	1.33e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.59	8.79	0.44	8.46e-17	Aortic root size;
CRC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.08	-12.91	-0.58	3.99e-31	Vitiligo;
CRC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.36	-6.83	-0.35	4.08e-11	Iron status biomarkers;
CRC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.6	-9.09	-0.45	9.19e-18	Menarche (age at onset);
CRC	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.1	-0.36	7.58e-12	QT interval;
CRC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	trans	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-6.0	-0.31	5.18e-9	Extraversion;
CRC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg08648136	chr8:956695	NA	0.32	5.75	0.3	2.06e-8	Schizophrenia;
CRC	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.37	5.82	0.31	1.36e-8	Monocyte percentage of white cells;
CRC	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg25809561	chr17:30822961	MYO1D	0.57	10.63	0.51	7.19e-23	Schizophrenia;
CRC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.39	-0.59	6.42e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11785858	chr4:153858123	NA	0.44	6.0	0.31	5.08e-9	Anxiety disorder;
CRC	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.57	0.54	3.42e-26	Bipolar disorder;
CRC	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.71	-11.73	-0.54	9.07e-27	Obesity-related traits;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg20933634	chr6:27740509	NA	0.42	5.85	0.31	1.21e-8	Parkinson's disease;
CRC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg18225595	chr11:63971243	STIP1	0.58	6.65	0.34	1.22e-10	Mean platelet volume;
CRC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.69	0.3	2.76e-8	Self-reported allergy;
CRC	cis	rs7932354	0.528	rs11039107	chr11:47157866	G/A	cg19486271	chr11:47235900	DDB2	0.46	6.7	0.35	9.27e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.17	-0.56	2.25e-28	Alzheimer's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11454606	chr11:67888949	CHKA	-0.39	-6.4	-0.33	5.41e-10	Myopia (pathological);
CRC	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.98	-16.79	-0.68	3.96e-46	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.28	-0.56	8.9e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg11003573	chr3:44754125	ZNF502	-0.34	-5.77	-0.3	1.8e-8	Depressive symptoms;
CRC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.3	6.21	0.32	1.59e-9	Lung cancer;
CRC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.59	9.19	0.45	4.49e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg27432699	chr2:27873401	GPN1	-0.57	-8.63	-0.43	2.72e-16	Total body bone mineral density;
CRC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.28	0.73	5.63e-56	Prudent dietary pattern;
CRC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.36	-5.65	-0.3	3.51e-8	Breast size;
CRC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.91	-0.31	8.67e-9	Gut microbiome composition (summer);
CRC	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08462924	chr1:41848221	NA	0.4	6.31	0.33	8.85e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.5	6.32	0.33	8.35e-10	Longevity;
CRC	cis	rs35000415	0.872	rs2070197	chr7:128589000	T/C	cg19972273	chr7:128594194	NA	0.67	5.98	0.31	5.74e-9	Systemic lupus erythematosus;
CRC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg06207120	chr15:45996521	NA	0.32	7.66	0.39	2.08e-13	Waist circumference;Weight;
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-9.66	-0.47	1.29e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.21	-0.45	3.8e-18	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg00105475	chr2:10696890	NA	0.46	7.04	0.36	1.13e-11	Prostate cancer;
CRC	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.48	-8.98	-0.44	2.09e-17	Hepatitis;
CRC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	6.86	0.35	3.42e-11	Obesity-related traits;
CRC	cis	rs17767392	0.794	rs61989255	chr14:71729657	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.36	-0.33	6.63e-10	Mitral valve prolapse;
CRC	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg26816564	chr1:7831052	VAMP3	0.55	6.08	0.32	3.26e-9	Inflammatory bowel disease;
CRC	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg23254163	chr1:152506842	NA	0.51	10.18	0.49	2.4e-21	Hair morphology;
CRC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.51	0.46	4.14e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.43	-7.96	-0.4	2.87e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22645636	chr2:55496232	MTIF2	0.48	6.78	0.35	5.75e-11	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.63	0.51	7.03e-23	Prudent dietary pattern;
CRC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.38	6.35	0.33	7.3e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.48	-8.97	-0.44	2.37e-17	Cognitive performance;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg21271961	chr1:95285780	SLC44A3	-0.4	-6.14	-0.32	2.39e-9	HDL cholesterol;
CRC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.1	-0.32	2.96e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.43	0.42	1.08e-15	Height;
CRC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs12024301	0.557	rs12047836	chr1:183615880	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2625529	0.730	rs1481860	chr15:72241857	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.43	0.33	4.51e-10	Red blood cell count;
CRC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg02135003	chr7:105160482	PUS7	-0.9	-11.7	-0.54	1.09e-26	Bipolar disorder (body mass index interaction);
CRC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.52	8.45	0.42	9.53e-16	Testicular germ cell tumor;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.7	0.35	9.26e-11	Tonsillectomy;
CRC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.25	-0.33	1.26e-9	Menopause (age at onset);
CRC	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.68	-7.68	-0.39	1.86e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.52	8.17	0.41	6.53e-15	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.76	-0.3	1.93e-8	Colorectal cancer;
CRC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg02766259	chr12:125626809	AACS	-0.4	-7.01	-0.36	1.36e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-7.28	-0.37	2.44e-12	Schizophrenia;
CRC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.44	6.13	0.32	2.53e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg04398451	chr17:18023971	MYO15A	0.36	6.01	0.31	4.84e-9	Coronary artery disease or ischemic stroke;
CRC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.61	6.64	0.34	1.28e-10	Body mass index;
CRC	cis	rs972578	0.791	rs5751380	chr22:43227867	G/C	cg01576275	chr22:43409880	NA	-0.36	-5.68	-0.3	2.96e-8	Mean platelet volume;
CRC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg23136738	chr11:925521	AP2A2	-0.39	-6.08	-0.32	3.37e-9	Alzheimer's disease (late onset);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05300939	chr11:44587523	CD82	0.4	6.1	0.32	2.92e-9	Myopia (pathological);
CRC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.85	11.77	0.54	6.13e-27	Initial pursuit acceleration;
CRC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-8.01	-0.4	2.06e-14	Fibrinogen levels;
CRC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.76	10.88	0.51	9.39e-24	Heart rate;
CRC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.09	0.36	8.14e-12	Aortic root size;
CRC	cis	rs9925964	1.000	rs9925964	chr16:31129895	A/G	cg03418659	chr16:31128414	MYST1	0.53	7.71	0.39	1.51e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.61	-0.3	4.31e-8	Lung cancer;
CRC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.51	-6.82	-0.35	4.41e-11	Multiple sclerosis;
CRC	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg09179987	chr1:167433047	CD247	0.47	7.04	0.36	1.11e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-13.05	-0.58	1.2e-31	Vitiligo;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11913072	chr19:11404605	NA	-0.5	-6.19	-0.32	1.8e-9	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14195377	chr11:60928647	VPS37C	0.38	6.07	0.32	3.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.54	-8.79	-0.44	8.63e-17	Coronary artery disease;
CRC	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.66	-8.99	-0.44	1.93e-17	Extraversion;
CRC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-12.13	-0.56	3.17e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.51	0.34	2.82e-10	Rheumatoid arthritis;
CRC	cis	rs6700896	0.931	rs4655584	chr1:66155515	T/G	cg04111102	chr1:66153794	NA	0.33	5.81	0.31	1.47e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs16852403	0.571	rs11800119	chr1:178144973	T/G	cg00404053	chr1:178313656	RASAL2	0.59	7.56	0.38	4.1e-13	Childhood ear infection;
CRC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.83	-0.4	6.73e-14	Body mass index;
CRC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.82	13.92	0.61	5.82e-35	Menopause (age at onset);
CRC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg12100956	chr17:78086420	GAA	-0.39	-6.1	-0.32	2.97e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.61	8.25	0.41	3.78e-15	Bipolar disorder;
CRC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-8.79	-0.44	8.39e-17	Menarche (age at onset);
CRC	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.3	-0.37	2.22e-12	Crohn's disease;
CRC	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.64	9.9	0.48	2.14e-20	Corneal astigmatism;
CRC	cis	rs17443541	0.507	rs4675716	chr2:200463370	A/C	cg03741458	chr2:200468445	NA	0.35	5.63	0.3	3.93e-8	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.28	-5.63	-0.3	3.96e-8	Total body bone mineral density;
CRC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.3	-0.37	2.2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.53e-19	Coronary artery disease;
CRC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.69	8.94	0.44	2.9e-17	Psoriasis;
CRC	trans	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs2270875	0.660	rs6982719	chr8:132930163	G/T	cg24184792	chr8:132919238	EFR3A	-0.54	-6.11	-0.32	2.77e-9	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.52	-9.69	-0.47	1.03e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.52	0.34	2.63e-10	Height;
CRC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.68	9.7	0.47	9.96e-20	Cleft lip with or without cleft palate;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09378111	chr2:211036309	C2orf67	0.53	7.06	0.36	9.82e-12	Thyroid stimulating hormone;
CRC	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.56	6.36	0.33	6.77e-10	Osteoarthritis;
CRC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.51	8.48	0.42	7.47e-16	Aortic root size;
CRC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg06484146	chr7:12443880	VWDE	-0.61	-6.64	-0.34	1.33e-10	Coronary artery disease;
CRC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	5.76	0.3	1.93e-8	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg12564285	chr5:131593104	PDLIM4	0.34	5.8	0.3	1.6e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg09127314	chr1:152161683	NA	-0.51	-5.89	-0.31	9.59e-9	Atopic dermatitis;
CRC	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg01388757	chr2:102091195	RFX8	0.59	8.06	0.41	1.43e-14	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06636001	chr8:8085503	FLJ10661	0.48	5.99	0.31	5.46e-9	Obesity-related traits;
CRC	cis	rs427941	0.595	rs201477	chr7:101746915	G/A	cg06246474	chr7:101738831	CUX1	0.43	6.62	0.34	1.45e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg23439141	chr13:113951774	LAMP1	0.54	6.22	0.32	1.51e-9	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18959360	chr18:43684205	ATP5A1;HAUS1	0.44	6.6	0.34	1.63e-10	Response to antipsychotic treatment;
CRC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg26913058	chr16:419975	MRPL28	-0.39	-5.68	-0.3	3.03e-8	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs243505	0.559	rs2072407	chr7:148508833	A/G	cg09806900	chr7:148480153	CUL1	0.55	7.71	0.39	1.5e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg03013999	chr17:37608204	MED1	0.46	7.0	0.36	1.41e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg13256891	chr4:100009986	ADH5	0.42	6.08	0.32	3.28e-9	Alcohol dependence;
CRC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.61	7.85	0.4	5.9e-14	Mean platelet volume;
CRC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.72	-8.21	-0.41	5.08e-15	Obesity-related traits;
CRC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.55	7.99	0.4	2.22e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs747334	0.791	rs2901176	chr10:92743250	G/A	cg15865243	chr12:34496342	NA	0.33	6.04	0.32	4.19e-9	Fibroblast growth factor basic levels;
CRC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.57	9.23	0.45	3.27e-18	Gout;
CRC	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.56	-0.43	4.48e-16	Neuroticism;
CRC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.05	-0.32	4.03e-9	Menopause (age at onset);
CRC	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-14.29	-0.62	2.27e-36	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.54	-6.13	-0.32	2.48e-9	Osteoarthritis;
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12000995	chr2:27665139	KRTCAP3	0.29	6.04	0.32	4.07e-9	Total body bone mineral density;
CRC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.91	-0.36	2.49e-11	IgG glycosylation;
CRC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.65	7.25	0.37	3e-12	Vitiligo;
CRC	cis	rs4664293	0.609	rs357033	chr2:160494473	T/C	cg08347373	chr2:160653686	CD302	-0.39	-6.68	-0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06307176	chr5:131281290	NA	0.43	6.39	0.33	5.8e-10	Life satisfaction;
CRC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.98	-0.36	1.64e-11	IgG glycosylation;
CRC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.85	0.55	3.15e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.48	5.99	0.31	5.51e-9	Bipolar disorder;
CRC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg23229984	chr5:148520753	ABLIM3	0.48	6.5	0.34	2.99e-10	Breast cancer;
CRC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-11.06	-0.52	2.22e-24	Vitiligo;
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg05084668	chr3:125655381	ALG1L	-0.44	-6.16	-0.32	2.09e-9	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06825448	chr2:240884925	NA	0.16	5.98	0.31	5.71e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.39	5.63	0.3	3.97e-8	Addiction;
CRC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.68	-0.3	2.93e-8	Red blood cell count;Reticulocyte count;
CRC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg21153622	chr11:89784906	NA	-0.38	-6.0	-0.31	5.28e-9	Height;
CRC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.48	5.77	0.3	1.79e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg17294928	chr15:75287854	SCAMP5	0.51	7.91	0.4	4.02e-14	Breast cancer;
CRC	cis	rs4290604	0.748	rs7594554	chr2:238065981	A/G	cg23555395	chr2:238036564	NA	-0.62	-6.29	-0.33	1.02e-9	Asthma;
CRC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.11	-0.36	7.3e-12	Personality dimensions;
CRC	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-8.12	-0.41	9.17e-15	Bone mineral density;
CRC	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.63	8.2	0.41	5.32e-15	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg03037974	chr15:76606532	NA	0.69	12.0	0.55	8.93e-28	Blood metabolite levels;
CRC	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.58	-6.72	-0.35	7.93e-11	Major depressive disorder;
CRC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.53	8.14	0.41	8.46e-15	Aortic root size;
CRC	cis	rs9903692	0.862	rs4794453	chr17:46184926	C/T	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg12100956	chr17:78086420	GAA	-0.37	-5.96	-0.31	6.46e-9	Yeast infection;
CRC	cis	rs12760731	0.511	rs10429849	chr1:178611933	G/A	cg00404053	chr1:178313656	RASAL2	0.6	6.94	0.36	2.05e-11	Obesity-related traits;
CRC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.25	-0.37	2.97e-12	Type 2 diabetes;
CRC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.14	-12.6	-0.57	5.69e-30	Diabetic kidney disease;
CRC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg00814883	chr7:100076585	TSC22D4	-0.52	-6.21	-0.32	1.57e-9	Lung function (FEV1/FVC);
CRC	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg04662943	chr10:102668895	NA	0.59	7.18	0.37	4.66e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.08	14.62	0.63	1.25e-37	Vitiligo;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25404069	chr7:150924520	ABCF2	0.43	6.2	0.32	1.65e-9	Anxiety disorder;
CRC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg27523141	chr10:43048294	ZNF37B	0.46	6.63	0.34	1.36e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg10756647	chr7:56101905	PSPH	0.75	7.61	0.39	2.98e-13	Diabetic kidney disease;
CRC	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg20488157	chr14:104394430	TDRD9	0.65	8.93	0.44	3e-17	Bipolar disorder;
CRC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg27535305	chr1:53392650	SCP2	0.39	7.07	0.36	9.36e-12	Monocyte count;
CRC	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.82	10.85	0.51	1.21e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg18490616	chr2:88469792	THNSL2	0.58	5.73	0.3	2.23e-8	Plasma clusterin levels;
CRC	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.38	5.95	0.31	6.82e-9	Height;
CRC	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.84	-0.35	3.91e-11	Multiple sclerosis;
CRC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.58	-8.22	-0.41	4.72e-15	Platelet distribution width;
CRC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.61	-0.34	1.58e-10	Coronary artery disease;
CRC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg06470822	chr6:28175283	NA	0.44	5.92	0.31	7.96e-9	Depression;
CRC	trans	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.54	-0.34	2.3e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.47	5.71	0.3	2.52e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09698166	chr20:21106763	PLK1S1	0.48	6.9	0.36	2.66e-11	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.29	-0.37	2.38e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs77861329	1.000	rs72964044	chr3:52092670	G/C	cg08692210	chr3:52188851	WDR51A	0.88	8.43	0.42	1.1e-15	Macrophage inflammatory protein 1b levels;
CRC	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg02106828	chr1:236959224	MTR	-0.42	-6.22	-0.32	1.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-11.05	-0.52	2.42e-24	Systemic lupus erythematosus;
CRC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.7	0.57	2.49e-30	Platelet count;
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.8	0.3	1.53e-8	Prudent dietary pattern;
CRC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.66	0.34	1.16e-10	Rheumatoid arthritis;
CRC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.41	5.82	0.31	1.37e-8	Erythrocyte sedimentation rate;
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.33	-0.33	8e-10	Total body bone mineral density;
CRC	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.65	-0.3	3.55e-8	Metabolite levels;
CRC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.68	10.39	0.5	4.69e-22	Lung cancer;
CRC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.64	-10.76	-0.51	2.49e-23	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.87	0.51	1.02e-23	Coronary artery disease;
CRC	trans	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.72	14.14	0.61	8.55e-36	Leprosy;
CRC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.37	6.35e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.43	-8.76	-0.44	1.02e-16	Migraine;
CRC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.57	8.23	0.41	4.4e-15	Inflammatory bowel disease;
CRC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg22834771	chr12:69754056	YEATS4	-0.4	-5.71	-0.3	2.52e-8	Blood protein levels;
CRC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	9.22	0.45	3.58e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg14673194	chr17:80132900	CCDC57	-0.5	-6.65	-0.34	1.21e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.61	9.39	0.46	1.03e-18	Aortic root size;
CRC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.81	12.33	0.56	5.44e-29	Cognitive function;
CRC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.64	11.5	0.54	5.95e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12059507	chr11:62606662	WDR74	-0.4	-5.98	-0.31	5.94e-9	Myopia (pathological);
CRC	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.4	-5.82	-0.31	1.36e-8	Height;
CRC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.68	-0.43	1.92e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-0.97	-9.34	-0.46	1.47e-18	Schizophrenia;
CRC	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.64	8.48	0.42	7.7e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.46	0.34	3.83e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg05941027	chr17:61774174	LIMD2	0.35	6.23	0.32	1.42e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs758324	0.812	rs12653237	chr5:131241778	C/T	cg25547332	chr5:131281432	NA	0.37	5.73	0.3	2.23e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg22532475	chr10:104410764	TRIM8	-0.35	-6.47	-0.34	3.57e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg15309053	chr8:964076	NA	0.33	5.87	0.31	1.06e-8	Schizophrenia;
CRC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.57	8.04	0.41	1.68e-14	Lymphocyte percentage of white cells;
CRC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.5	-8.0	-0.4	2.13e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2882667	0.728	rs10037071	chr5:138277847	A/G	cg09476006	chr5:138032270	NA	0.57	9.88	0.48	2.58e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18301423	chr5:131593218	PDLIM4	-0.47	-8.81	-0.44	7.24e-17	Acylcarnitine levels;
CRC	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg11292332	chr7:45801988	SEPT13	-0.34	-6.16	-0.32	2.12e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.54	6.99	0.36	1.58e-11	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06568038	chr16:30669663	NA	0.44	6.37	0.33	6.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.5	-6.08	-0.32	3.35e-9	Diabetic retinopathy;
CRC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg19761014	chr17:28927070	LRRC37B2	0.6	5.89	0.31	9.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs755249	0.567	rs2036463	chr1:39688075	G/A	cg18385671	chr1:39797026	MACF1	-0.43	-6.13	-0.32	2.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg13010199	chr12:38710504	ALG10B	0.44	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.99e-9	Aortic root size;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg15845792	chr6:28175446	NA	0.69	7.6	0.39	3.01e-13	Parkinson's disease;
CRC	cis	rs9462027	0.628	rs7752522	chr6:34760583	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.05	-0.32	4.04e-9	Systemic lupus erythematosus;
CRC	cis	rs45544231	0.544	rs7193453	chr16:52565150	C/T	cg09051775	chr16:52580266	TOX3	-0.4	-6.52	-0.34	2.6200000000000003e-10	Restless legs syndrome;
CRC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.43	-15.33	-0.65	2.03e-40	Plateletcrit;
CRC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.47	-0.34	3.5e-10	Schizophrenia;
CRC	cis	rs3812762	0.871	rs3862352	chr11:8818020	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.2	-0.32	1.68e-9	Hypospadias;
CRC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.59	9.6	0.47	2.13e-19	Prostate cancer;
CRC	cis	rs6908034	0.546	rs74514942	chr6:19810520	G/A	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.66	9.83	0.48	3.67e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.5	-8.16	-0.41	7.42e-15	Height;
CRC	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg25019722	chr6:37503610	NA	-0.46	-8.64	-0.43	2.42e-16	Cognitive performance;
CRC	cis	rs6496667	0.738	rs56337344	chr15:90988371	A/T	cg04176472	chr15:90893244	GABARAPL3	0.59	8.03	0.4	1.71e-14	Rheumatoid arthritis;
CRC	cis	rs2179367	0.881	rs2744432	chr6:149743871	A/C	cg16235748	chr6:149772707	ZC3H12D	0.37	5.97	0.31	6.1e-9	Dupuytren's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14235568	chr17:73774897	H3F3B	0.38	6.11	0.32	2.82e-9	Obesity-related traits;
CRC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.25	0.33	1.28e-9	Lung cancer;
CRC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg14844989	chr11:31128820	NA	-0.34	-6.0	-0.31	5.16e-9	Red blood cell count;
CRC	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.47	7.03	0.36	1.23e-11	Body mass index;
CRC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.47	7.38	0.38	1.26e-12	Corneal astigmatism;
CRC	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.58	10.28	0.49	1.08e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	6.41	0.33	5.05e-10	Lymphocyte counts;
CRC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.61	-9.94	-0.48	1.54e-20	P wave terminal force;
CRC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.82e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.52	7.58	0.39	3.66e-13	Type 2 diabetes;
CRC	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.55	-5.73	-0.3	2.27e-8	Coronary artery disease;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg11503833	chr11:492997	NA	0.56	5.89	0.31	9.64e-9	Body mass index;
CRC	trans	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.59	-0.34	1.73e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4743820	0.620	rs10991784	chr9:93917094	T/C	cg14446406	chr9:93919335	NA	0.77	13.47	0.6	2.94e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.6	10.6	0.5	8.89e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11212617	0.901	rs10789656	chr11:108024336	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.41	5.87	0.31	1.06e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.43	5.69	0.3	2.83e-8	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.15	0.49	3.02e-21	Corneal astigmatism;
CRC	cis	rs17155006	0.664	rs402113	chr7:107743664	A/G	cg05962710	chr7:107745446	LAMB4	-0.43	-7.6	-0.39	3.06e-13	Pneumococcal bacteremia;
CRC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.95	11.73	0.54	8.69e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.59	0.47	2.27e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg04165759	chr1:150448943	RPRD2	0.36	5.9	0.31	9.2e-9	Migraine;
CRC	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.51	-7.28	-0.37	2.48e-12	Triglycerides;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.57	-0.38	3.89e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	trans	rs58106596	0.800	rs11675826	chr2:232565507	T/C	cg01370599	chr3:116745421	NA	0.51	6.84	0.35	3.95e-11	White blood cell count;Lymphocyte counts;
CRC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.22	-0.56	1.44e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-10.61	-0.5	8.17e-23	Personality dimensions;
CRC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.96	0.48	1.33e-20	Platelet count;
CRC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.43	-6.48	-0.34	3.38e-10	Height;
CRC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg19847866	chr10:1019161	NA	0.4	5.82	0.31	1.43e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg03013999	chr17:37608204	MED1	0.47	7.22	0.37	3.74e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.8	11.45	0.53	8.99e-26	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.52	-7.09	-0.36	8.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.03	11.91	0.55	1.98e-27	Uric acid levels;
CRC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg03037974	chr15:76606532	NA	0.72	12.33	0.56	5.8e-29	Blood metabolite levels;
CRC	cis	rs294883	0.858	rs569882	chr6:159678599	C/G	cg14500486	chr6:159655392	FNDC1	0.37	6.14	0.32	2.31e-9	Coronary artery disease;
CRC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg23136738	chr11:925521	AP2A2	-0.54	-8.74	-0.43	1.22e-16	Alzheimer's disease (late onset);
CRC	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.46	-9.46	-0.46	6.09e-19	Hand grip strength;
CRC	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.54	-8.34	-0.42	2.12e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.79	-13.82	-0.61	1.39e-34	Lewy body disease;
CRC	trans	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg19188899	chr13:112838565	NA	-0.42	-6.45	-0.34	3.93e-10	Systemic lupus erythematosus;
CRC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.41	0.42	1.24e-15	Height;
CRC	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.49	8.61	0.43	3.05e-16	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs4731207	0.596	rs7795605	chr7:124578447	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs2072510	0.569	rs17677343	chr12:96397081	T/A	cg22491680	chr12:96389547	HAL	-0.5	-6.13	-0.32	2.46e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.85	0.31	1.2e-8	Renal function-related traits (BUN);
CRC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs457287	0.772	rs369064	chr9:4832130	G/T	cg14182974	chr9:4791918	RCL1	0.39	6.0	0.31	5.21e-9	Platelet count;
CRC	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg27534772	chr1:16042836	PLEKHM2	0.39	6.7	0.35	8.98e-11	Systolic blood pressure;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10819733	chr22:24237672	NA	-0.37	-6.43	-0.33	4.47e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg00343986	chr7:65444356	GUSB	-0.51	-7.57	-0.39	3.86e-13	Aortic root size;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.7e-9	Bipolar disorder;
CRC	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.22	0.37	3.69e-12	Testicular germ cell tumor;
CRC	cis	rs7916697	0.593	rs10762198	chr10:70023053	A/G	cg06988349	chr10:69991859	ATOH7	-0.38	-7.15	-0.37	5.64e-12	Optic disc area;
CRC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-5.95	-0.31	7.05e-9	Lung cancer;
CRC	trans	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg09045935	chr12:6379348	NA	0.87	7.24	0.37	3.24e-12	Blood metabolite levels;
CRC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.82	11.62	0.54	2.27e-26	Cognitive function;
CRC	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg06204229	chr3:52865917	ITIH4	0.43	5.95	0.31	6.94e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.37	-5.78	-0.3	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.59	-0.34	1.78e-10	Blood metabolite levels;
CRC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg25876840	chr17:41920477	NA	-0.46	-6.49	-0.34	3.21e-10	Triglycerides;
CRC	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.17	-0.32	2.01e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg18490616	chr2:88469792	THNSL2	-0.4	-5.8	-0.3	1.53e-8	Response to metformin (IC50);
CRC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.52	0.38	5.42e-13	Motion sickness;
CRC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	15.0	0.64	3.93e-39	Smoking behavior;
CRC	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg09232269	chr1:207846808	CR1L	-0.45	-7.33	-0.37	1.84e-12	Erythrocyte sedimentation rate;
CRC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.29	0.33	1e-9	Alzheimer's disease (late onset);
CRC	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg26741380	chr15:41871084	TYRO3	-0.46	-6.43	-0.33	4.57e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-6.03	-0.32	4.49e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs17126268	0.502	rs1340396	chr1:102890347	C/G	cg18468354	chr14:36993517	NA	-0.39	-6.3	-0.33	9.44e-10	Glomerular filtration rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02754225	chr10:76971001	VDAC2	0.4	6.43	0.33	4.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg10589385	chr1:150898437	SETDB1	0.29	6.13	0.32	2.47e-9	Melanoma;
CRC	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg06042504	chr8:55087323	NA	-0.37	-5.87	-0.31	1.06e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs972578	0.868	rs1076118	chr22:43299710	C/T	cg01576275	chr22:43409880	NA	0.38	5.91	0.31	8.74e-9	Mean platelet volume;
CRC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.52	7.74	0.39	1.25e-13	Obesity-related traits;
CRC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.23e-8	Protein C levels;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-8.17	-0.41	6.67e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.56	-9.03	-0.45	1.52e-17	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.56	-6.67	-0.35	1.11e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.47	-7.55	-0.38	4.31e-13	Eye color traits;
CRC	cis	rs8051149	0.793	rs12445334	chr16:87871213	G/A	cg01412419	chr16:87856264	NA	0.52	7.05	0.36	1.08e-11	Blood metabolite levels;
CRC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg22676075	chr6:135203613	NA	0.41	6.34	0.33	7.63e-10	Red blood cell count;
CRC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg12463550	chr7:65579703	CRCP	0.71	6.4	0.33	5.32e-10	Diabetic kidney disease;
CRC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg21466736	chr12:48725269	NA	-0.52	-7.84	-0.4	6.31e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg05044414	chr3:183734942	ABCC5	0.47	8.25	0.41	3.75e-15	Anterior chamber depth;
CRC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg02551604	chr5:131831745	NA	-0.56	-8.6	-0.43	3.28e-16	Asthma (sex interaction);
CRC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.51	-7.15	-0.37	5.64e-12	Lymphocyte counts;
CRC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg23107878	chr1:152161397	NA	0.43	6.21	0.32	1.58e-9	Inflammatory skin disease;
CRC	cis	rs12024301	0.557	rs6686494	chr1:183622598	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	0.9	11.42	0.53	1.17e-25	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.39	5.99	0.31	5.55e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-8.23	-0.41	4.39e-15	Hemoglobin concentration;
CRC	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.04	-0.36	1.11e-11	Major depressive disorder;
CRC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.56	8.49	0.42	7.22e-16	Blood protein levels;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg15845792	chr6:28175446	NA	0.73	6.43	0.33	4.37e-10	Depression;
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg17346650	chr17:80929145	B3GNTL1	0.46	6.81	0.35	4.66e-11	Glycated hemoglobin levels;
CRC	cis	rs1186222	0.505	rs2867803	chr7:75284941	C/A	cg05145297	chr7:75264568	HIP1	0.36	6.13	0.32	2.5e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24308560	chr3:49941425	MST1R	-0.44	-6.52	-0.34	2.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13088318	0.521	rs2553415	chr3:101095630	T/A	cg11279151	chr3:101281821	RG9MTD1	0.4	5.73	0.3	2.32e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	16.84	0.68	2.56e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.58	8.77	0.44	9.5e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg16540259	chr10:75572220	NDST2	0.38	6.15	0.32	2.26e-9	Inflammatory bowel disease;
CRC	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.06	22.74	0.78	1.84e-69	Multiple myeloma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00265317	chr16:70472993	ST3GAL2	0.36	5.97	0.31	6.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.44	-6.66	-0.34	1.14e-10	Systemic lupus erythematosus;
CRC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg15440763	chr7:158190612	PTPRN2	0.52	8.42	0.42	1.15e-15	Obesity-related traits;
CRC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.1	0.41	1.1e-14	Platelet count;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	0.98	23.34	0.79	9.1e-72	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.5	-0.5	1.96e-22	Bipolar disorder;
CRC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.76	6.15	0.32	2.28e-9	Major depressive disorder;
CRC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.15	0.32	2.28e-9	Diabetic kidney disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15164871	chr12:123380523	VPS37B	0.37	6.0	0.31	5.34e-9	Obesity-related traits;
CRC	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.4	12.18	0.56	1.99e-28	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7605827	0.930	rs4571032	chr2:15685038	A/G	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.18	0.45	5.05e-18	IgG glycosylation;
CRC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg20607287	chr7:12443886	VWDE	-0.64	-6.41	-0.33	5.11e-10	Coronary artery disease;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-7.52	-0.38	5.37e-13	Lymphocyte counts;
CRC	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	12.97	0.58	2.27e-31	Hip circumference;
CRC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.49	-8.88	-0.44	4.39e-17	Huntington's disease progression;
CRC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	14.58	0.63	1.69e-37	Menarche (age at onset);
CRC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg19622623	chr12:86230825	RASSF9	0.35	5.72	0.3	2.44e-8	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03940137	chr1:200708937	CAMSAP1L1	0.4	6.57	0.34	2.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.37	-0.38	1.38e-12	Caudate activity during reward;
CRC	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.44	-6.2	-0.32	1.71e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18099408	chr3:52552593	STAB1	-0.4	-6.62	-0.34	1.43e-10	Bipolar disorder;
CRC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.55	-7.71	-0.39	1.55e-13	Corneal structure;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg26912078	chr2:97523308	ANKRD39	-0.39	-6.13	-0.32	2.54e-9	HDL cholesterol;
CRC	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg19025524	chr12:109796872	NA	0.45	6.55	0.34	2.25e-10	Neuroticism;
CRC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18876405	chr7:65276391	NA	0.5	8.02	0.4	1.84e-14	Aortic root size;
CRC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-8.15	-0.41	7.84e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.29	0.33	1.01e-9	Lung cancer;
CRC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg18827107	chr12:86230957	RASSF9	-0.41	-6.73	-0.35	7.76e-11	Major depressive disorder;
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg20041105	chr8:143859282	LYNX1	0.44	7.93	0.4	3.35e-14	Urinary tract infection frequency;
CRC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg19223190	chr17:80058835	NA	0.42	6.58	0.34	1.81e-10	Life satisfaction;
CRC	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.38	-5.93	-0.31	7.46e-9	Endometrial cancer;
CRC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00933542	chr6:150070202	PCMT1	-0.29	-5.95	-0.31	7e-9	Lung cancer;
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.31	0.33	9.05e-10	Life satisfaction;
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	5.88	0.31	1.03e-8	Bipolar disorder;
CRC	cis	rs537930	0.560	rs877812	chr5:134346304	G/A	cg24576358	chr5:134350122	NA	0.32	5.66	0.3	3.35e-8	Height;
CRC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.8	9.97	0.48	1.21e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.92	15.89	0.66	1.38e-42	Colorectal cancer;
CRC	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	cis	rs1322512	1.000	rs2800634	chr6:153010414	G/A	cg03415253	chr6:152958462	SYNE1	0.39	5.82	0.31	1.37e-8	Tonometry;
CRC	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4731207	0.698	rs10227821	chr7:124449587	A/G	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs7215564	0.730	rs9901550	chr17:78584464	T/C	cg09596252	chr17:78655493	RPTOR	0.57	5.99	0.31	5.49e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01939414	chr2:103353548	MFSD9	0.47	6.72	0.35	8.03e-11	Response to antipsychotic treatment;
CRC	cis	rs939584	1.000	rs13412197	chr2:653250	A/G	cg03610516	chr2:642275	NA	-0.42	-5.74	-0.3	2.18e-8	Body mass index;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg00292662	chr22:38071168	LGALS1	0.41	6.08	0.32	3.38e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg24148841	chr6:4949437	CDYL	-0.41	-5.97	-0.31	6.08e-9	QT interval;
CRC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.65e-9	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20684399	chr9:96338308	PHF2	0.43	6.27	0.33	1.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg08027265	chr7:2291960	NA	-0.36	-5.81	-0.31	1.44e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.73	9.9	0.48	2.09e-20	Cognitive function;
CRC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg02773041	chr1:40204384	PPIE	0.62	9.12	0.45	7.45e-18	Blood protein levels;
CRC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.5	8.24	0.41	4.01e-15	Lipoprotein (a) levels;
CRC	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg00531865	chr16:30841666	NA	-0.42	-6.09	-0.32	3.15e-9	Dementia with Lewy bodies;
CRC	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.49	-7.45	-0.38	8.43e-13	Systemic sclerosis;
CRC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.44	5.94	0.31	7.26e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.54	7.93	0.4	3.56e-14	Lung cancer;
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg18833306	chr6:118973337	C6orf204	0.45	5.91	0.31	8.35e-9	Diastolic blood pressure;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.82	-12.95	-0.58	2.81e-31	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.43	0.42	1.12e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg24308560	chr3:49941425	MST1R	0.39	5.64	0.3	3.62e-8	Resting heart rate;
CRC	cis	rs905456	0.535	rs9813622	chr3:30748940	C/T	cg06106510	chr3:30762233	NA	0.37	6.46	0.34	3.72e-10	Positive affect;
CRC	cis	rs11997175	0.546	rs1561913	chr8:33587002	A/T	ch.8.33884649F	chr8:33765107	NA	0.43	6.69	0.35	9.6e-11	Body mass index;
CRC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg08807892	chr2:162101083	NA	0.45	6.65	0.34	1.21e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-15.79	-0.66	3.4e-42	Cognitive function;
CRC	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg21452805	chr1:244014465	NA	0.51	7.01	0.36	1.36e-11	RR interval (heart rate);
CRC	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg10556349	chr10:835070	NA	-0.36	-6.73	-0.35	7.49e-11	Survival in rectal cancer;
CRC	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.47	-7.28	-0.37	2.51e-12	Schizophrenia;
CRC	cis	rs12505749	0.542	rs12508008	chr4:57353767	G/A	cg06922635	chr4:57371607	ARL9	-0.54	-5.7	-0.3	2.66e-8	Airflow obstruction;
CRC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.16	-0.32	2.07e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg16724585	chr3:197361211	NA	-0.45	-6.74	-0.35	7.15e-11	Pancreatic cancer;
CRC	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-6.73	-0.35	7.6e-11	Axial length;
CRC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.73	8.83	0.44	6.4e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	0.94	18.28	0.71	5.15e-52	Height;
CRC	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg23627948	chr7:2760692	NA	0.47	5.62	0.3	3.98e-8	Childhood ear infection;
CRC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg18721089	chr20:30220636	NA	-0.31	-5.67	-0.3	3.16e-8	Mean corpuscular hemoglobin;
CRC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-5.8	-0.3	1.58e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	0.98	10.51	0.5	1.85e-22	Diabetic retinopathy;
CRC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg14671364	chr1:107599128	PRMT6	-0.56	-7.7	-0.39	1.6e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg22482690	chr17:47019901	SNF8	0.49	8.16	0.41	7.35e-15	Type 2 diabetes;
CRC	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs17152411	0.895	rs7084646	chr10:126585738	T/C	cg07906193	chr10:126599966	NA	0.56	6.34	0.33	7.77e-10	Height;
CRC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg13198984	chr17:80129470	CCDC57	0.44	7.83	0.4	6.88e-14	Life satisfaction;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg21577049	chr2:228736449	WDR69	-0.43	-5.77	-0.3	1.8e-8	Blood pressure;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.52	8.07	0.41	1.3e-14	Longevity;Endometriosis;
CRC	cis	rs7849270	0.921	rs6478864	chr9:131880630	C/G	cg13538475	chr9:131942899	NA	-0.29	-5.89	-0.31	9.75e-9	Blood metabolite ratios;
CRC	trans	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.59e-14	HDL cholesterol;
CRC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg01483505	chr11:975446	AP2A2	0.42	6.71	0.35	8.38e-11	Alzheimer's disease (late onset);
CRC	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg27649806	chr9:35101217	STOML2	0.38	6.08	0.32	3.37e-9	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.52	8.56	0.43	4.24e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.66	-0.34	1.15e-10	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg12273811	chr6:28175739	NA	-0.45	-6.34	-0.33	7.49e-10	Parkinson's disease;
CRC	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg04362960	chr10:104952993	NT5C2	0.52	6.21	0.32	1.56e-9	Waist circumference;Hip circumference;
CRC	cis	rs4964805	0.954	rs4964812	chr12:104189615	A/G	cg02344784	chr12:104178138	NT5DC3	0.56	8.45	0.42	9.23e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.49	-7.8	-0.4	8.32e-14	Corneal astigmatism;
CRC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.37	5.84	0.31	1.27e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg02772935	chr3:125709198	NA	-0.48	-5.73	-0.3	2.33e-8	Blood pressure (smoking interaction);
CRC	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.66	7.32	0.37	1.94e-12	Coronary artery disease;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg21856205	chr7:94953877	PON1	-0.49	-6.44	-0.33	4.12e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg27565382	chr3:53032988	SFMBT1	0.78	6.26	0.33	1.21e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg21251018	chr6:28226885	NKAPL	0.4	6.01	0.31	4.96e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.06e-9	Prudent dietary pattern;
CRC	cis	rs7781266	0.790	rs17597439	chr7:133160732	A/C	cg03336402	chr7:133662267	EXOC4	0.48	5.66	0.3	3.25e-8	Educational attainment (college completion);
CRC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg22676075	chr6:135203613	NA	0.4	6.1	0.32	2.95e-9	Red blood cell count;
CRC	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	12.01	0.55	8.69e-28	Height;
CRC	cis	rs6764363	0.527	rs13072907	chr3:279924	G/A	cg02057681	chr3:285234	CHL1	0.42	7.12	0.37	6.65e-12	Sudden cardiac arrest;
CRC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.7	-9.79	-0.47	5.08e-20	Breast cancer;
CRC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.42	6.4	0.33	5.49e-10	Red blood cell count;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg16558177	chr4:4109446	NA	-0.6	-8.45	-0.42	9.75e-16	Blood pressure (smoking interaction);
CRC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.58	0.39	3.6e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19909895	chr3:128368930	RPN1	0.52	6.76	0.35	6.36e-11	Thyroid stimulating hormone;
CRC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	7.74	0.39	1.22e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.91	-0.31	8.67e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.21	-5.63	-0.3	3.95e-8	Type 2 diabetes;
CRC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.62	-10.88	-0.51	9.41e-24	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.4	-5.78	-0.3	1.77e-8	Aortic root size;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.7	-0.39	1.59e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg10729496	chr3:10149963	C3orf24	0.48	5.63	0.3	3.81e-8	Alzheimer's disease;
CRC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.72	-11.47	-0.53	7.63e-26	Intelligence (multi-trait analysis);
CRC	cis	rs911119	0.913	rs2405392	chr20:23569186	C/T	cg16589663	chr20:23618590	CST3	0.44	6.06	0.32	3.75e-9	Chronic kidney disease;
CRC	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.63	9.94	0.48	1.62e-20	Testicular germ cell tumor;
CRC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	7.59	0.39	3.41e-13	Total body bone mineral density;
CRC	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg04132472	chr17:19861366	AKAP10	0.42	6.44	0.33	4.12e-10	Schizophrenia;
CRC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs7605827	0.836	rs13019322	chr2:15511270	G/A	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	0.48	6.23	0.32	1.42e-9	Childhood ear infection;
CRC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg02659138	chr7:134003124	SLC35B4	0.42	7.38	0.38	1.32e-12	Mean platelet volume;
CRC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.34	-6.27	-0.33	1.13e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1109861	0.535	rs7085721	chr10:11242780	G/A	cg24910943	chr10:11206320	CUGBP2	-0.29	-7.34	-0.38	1.67e-12	Urinary albumin-to-creatinine ratio;
CRC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg17401720	chr7:158221031	PTPRN2	-0.46	-7.68	-0.39	1.78e-13	Obesity-related traits;
CRC	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.96	11.6	0.54	2.56e-26	Diisocyanate-induced asthma;
CRC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	6.16	0.32	2.1e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	1.05	9.45	0.46	6.51e-19	Arsenic metabolism;
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.42	-5.74	-0.3	2.12e-8	Prudent dietary pattern;
CRC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.02	-0.36	1.25e-11	Height;
CRC	cis	rs1992660	0.510	rs6889125	chr5:40412590	A/T	cg09067459	chr5:40385259	NA	0.44	7.38	0.38	1.27e-12	Crohn's disease;
CRC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg23625390	chr15:77176239	SCAPER	0.48	7.03	0.36	1.21e-11	Blood metabolite levels;
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.63e-14	Bipolar disorder;
CRC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg18404041	chr3:52824283	ITIH1	-0.36	-7.02	-0.36	1.3e-11	Schizophrenia;
CRC	cis	rs12541635	0.639	rs6415444	chr8:107043797	G/A	cg10147462	chr8:107024639	NA	0.6	10.29	0.49	1.05e-21	Age of smoking initiation;
CRC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.58	-0.34	1.85e-10	Aortic root size;
CRC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg04731861	chr2:219085781	ARPC2	-0.32	-6.83	-0.35	4.23e-11	Colorectal cancer;
CRC	cis	rs12476592	0.602	rs959195	chr2:63804125	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.18	0.32	1.84e-9	Childhood ear infection;
CRC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.5	7.66	0.39	2.05e-13	Personality dimensions;
CRC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.97	0.4	2.55e-14	Height;
CRC	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg24463073	chr6:118973353	C6orf204	0.54	7.13	0.37	6.33e-12	Diastolic blood pressure;
CRC	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg16672083	chr15:72433130	SENP8	0.43	6.64	0.34	1.27e-10	Red blood cell count;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg10729496	chr3:10149963	C3orf24	0.5	6.81	0.35	4.67e-11	Alzheimer's disease;
CRC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.51	0.54	5.52e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6564851	0.506	rs61227863	chr16:81259814	T/C	cg05274606	chr16:81253692	PKD1L2	-0.39	-6.58	-0.34	1.85e-10	Carotenoid and tocopherol levels;
CRC	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.77	0.39	1.02e-13	Blood metabolite levels;
CRC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg20291162	chr17:40259547	DHX58	-0.55	-7.98	-0.4	2.46e-14	Fibrinogen levels;
CRC	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg04990556	chr1:26633338	UBXN11	-0.8	-12.89	-0.58	4.79e-31	Obesity-related traits;
CRC	cis	rs6076065	0.723	rs743024	chr20:23342476	C/T	cg11657817	chr20:23433608	CST11	-0.38	-6.04	-0.32	4.16e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.63	-11.8	-0.55	5.1e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg12311346	chr5:56204834	C5orf35	-0.44	-7.0	-0.36	1.44e-11	Coronary artery disease;
CRC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg14541582	chr5:601475	NA	-0.36	-7.37	-0.38	1.42e-12	Lung disease severity in cystic fibrosis;
CRC	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.51	7.64	0.39	2.35e-13	Corneal astigmatism;
CRC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.39	6.02	0.32	4.55e-9	Menarche (age at onset);
CRC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.45	-7.75	-0.39	1.17e-13	Primary biliary cholangitis;
CRC	cis	rs7932354	0.528	rs11039105	chr11:47157677	A/T	cg19486271	chr11:47235900	DDB2	0.47	6.85	0.35	3.65e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg25164649	chr6:28176230	NA	0.59	8.32	0.42	2.36e-15	Parkinson's disease;
CRC	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.55	-6.99	-0.36	1.51e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg21155852	chr7:2048760	MAD1L1	-0.51	-6.88	-0.35	3.09e-11	Bipolar disorder;
CRC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.56	6.35	0.33	7.35e-10	Bipolar disorder;
CRC	cis	rs1158570	0.521	rs10089819	chr8:131172968	C/T	cg21674704	chr8:131455249	NA	-0.46	-7.01	-0.36	1.39e-11	Platelet count;
CRC	cis	rs9976767	1.000	rs11702374	chr21:43829758	G/A	cg23042151	chr21:43824109	UBASH3A	-0.33	-5.84	-0.31	1.26e-8	Type 1 diabetes;
CRC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.48	-7.15	-0.37	5.69e-12	Menarche (age at onset);
CRC	cis	rs3785888	0.548	rs3885731	chr17:45033310	T/C	cg16759221	chr17:45003025	GOSR2	-0.72	-10.57	-0.5	1.12e-22	Cleft lip with or without cleft palate;
CRC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.83	-0.31	1.32e-8	Heart rate;
CRC	cis	rs3736485	0.966	rs28428679	chr15:51913040	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.38	-0.33	5.86e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	8.29	0.42	2.96e-15	Cognitive test performance;
CRC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	8.31	0.42	2.52e-15	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4561483	0.583	rs33636	chr16:11990323	C/G	cg08843971	chr16:11963173	GSPT1	-0.51	-7.72	-0.39	1.43e-13	Testicular germ cell tumor;
CRC	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg11189052	chr15:85197271	WDR73	0.56	7.07	0.36	9.41e-12	Schizophrenia;
CRC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.95	0.52	5.51e-24	Prudent dietary pattern;
CRC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg16342193	chr10:102329863	NA	-0.33	-5.69	-0.3	2.85e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg07828024	chr6:149772892	ZC3H12D	0.52	9.59	0.47	2.31e-19	Dupuytren's disease;
CRC	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18895155	chr7:99214691	ZNF498	-0.39	-6.34	-0.33	7.75e-10	Obesity-related traits;
CRC	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg21918786	chr6:109611834	NA	0.36	6.23	0.32	1.41e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.52	-8.3	-0.42	2.76e-15	Electroencephalogram traits;
CRC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.64	-0.39	2.43e-13	Colorectal cancer;
CRC	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg05998816	chr21:47859926	PCNT	0.5	5.68	0.3	2.94e-8	Lymphocyte counts;
CRC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.62	-0.47	1.8e-19	Morning vs. evening chronotype;
CRC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg02659138	chr7:134003124	SLC35B4	0.39	6.54	0.34	2.39e-10	Mean platelet volume;
CRC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.86e-9	Diabetic kidney disease;
CRC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	8.31	0.42	2.55e-15	Total body bone mineral density;
CRC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.63	-9.87	-0.48	2.64e-20	IgG glycosylation;
CRC	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.56	9.0	0.44	1.84e-17	Dupuytren's disease;
CRC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	5.74	0.3	2.1e-8	Mean corpuscular volume;
CRC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.43	0.53	1.09e-25	Bone mineral density;
CRC	cis	rs17162190	0.698	rs56241541	chr1:26840904	C/T	cg17456097	chr1:26900765	RPS6KA1	0.42	6.15	0.32	2.22e-9	Mean corpuscular volume;
CRC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.66	11.79	0.54	5.41e-27	Height;
CRC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.56	-9.68	-0.47	1.11e-19	Body mass index;
CRC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.5	-6.32	-0.33	8.69e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2072510	0.932	rs2070614	chr12:96390336	T/C	cg22491680	chr12:96389547	HAL	-0.39	-6.06	-0.32	3.82e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.76	-0.39	1.06e-13	Prevalent atrial fibrillation;
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.77	11.75	0.54	7.18e-27	Menarche (age at onset);
CRC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-9.17	-0.45	5.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.19e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7781557	0.640	rs73192025	chr7:102591489	T/C	cg18108683	chr7:102477205	FBXL13	-0.49	-5.76	-0.3	1.9e-8	Colorectal adenoma (advanced);
CRC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg14673194	chr17:80132900	CCDC57	-0.51	-6.79	-0.35	5.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.64	-9.0	-0.44	1.81e-17	DNA methylation (variation);
CRC	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.43	6.25	0.33	1.27e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg23463467	chr20:60627584	TAF4	0.33	5.72	0.3	2.4e-8	Body mass index;
CRC	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.86	9.43	0.46	7.59e-19	Inflammatory bowel disease;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.55	-10.4	-0.5	4.33e-22	Acylcarnitine levels;
CRC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-13.0	-0.58	1.9e-31	Cognitive function;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.53	-0.34	2.55e-10	Bipolar disorder;
CRC	trans	rs800082	1.000	rs12637885	chr3:144291254	G/T	cg24215973	chr2:240111563	HDAC4	-0.51	-6.91	-0.36	2.56e-11	Smoking behavior;
CRC	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.83	11.93	0.55	1.67e-27	Cognitive function;
CRC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6679356	0.789	rs6695348	chr1:67827016	T/C	cg24364144	chr1:67875067	SERBP1	0.43	6.61	0.34	1.55e-10	Primary biliary cholangitis;
CRC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg21466736	chr12:48725269	NA	0.5	7.75	0.39	1.12e-13	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-9.41	-0.46	8.77e-19	Pancreatic cancer;
CRC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.71	-0.3	2.49e-8	Lung cancer;
CRC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.49e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.99	18.35	0.71	2.67e-52	Gut microbiome composition (winter);
CRC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.59	8.89	0.44	4.13e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg09877947	chr5:131593287	PDLIM4	-0.45	-7.27	-0.37	2.72e-12	Breast cancer;
CRC	cis	rs2579500	0.807	rs6753926	chr2:97298949	T/C	cg23100626	chr2:96804247	ASTL	-0.23	-5.65	-0.3	3.54e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.6	0.5	9.01e-23	Corneal astigmatism;
CRC	cis	rs4356975	0.522	rs7679184	chr4:69965930	C/G	cg25583503	chr4:69962676	UGT2B7	-0.32	-5.8	-0.3	1.55e-8	Obesity-related traits;
CRC	cis	rs7731657	0.537	rs3962196	chr5:130372512	A/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.95	-0.31	6.73e-9	Fasting plasma glucose;
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg10729496	chr3:10149963	C3orf24	0.58	7.52	0.38	5.23e-13	Alzheimer's disease;
CRC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.54	7.32	0.37	1.95e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg14711859	chr11:8959438	ASCL3	0.35	5.65	0.3	3.43e-8	Hemoglobin concentration;
CRC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.83	-13.53	-0.6	1.8e-33	Cognitive function;
CRC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg26958806	chr6:27640298	NA	0.63	5.69	0.3	2.78e-8	Breast cancer;
CRC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.59	8.79	0.44	8.47e-17	Corneal astigmatism;
CRC	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg13736514	chr6:26305472	NA	-0.47	-7.68	-0.39	1.89e-13	Mosquito bite size;
CRC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg22777020	chr22:31556080	RNF185	-0.53	-6.04	-0.32	4.08e-9	Colorectal cancer;
CRC	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg23260525	chr10:116636907	FAM160B1	0.31	6.73	0.35	7.51e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.75	13.69	0.6	4.57e-34	Lewy body disease;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-0.85	-8.97	-0.44	2.22e-17	Post bronchodilator FEV1;
CRC	cis	rs6840360	0.606	rs2709813	chr4:152357444	T/C	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.72	0.39	1.43e-13	Breast cancer;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.36	-0.33	6.93e-10	Cognitive function;
CRC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.82	-12.4	-0.56	3.04e-29	Cognitive ability;
CRC	trans	rs800082	1.000	rs800082	chr3:144340205	A/G	cg24215973	chr2:240111563	HDAC4	0.51	6.94	0.36	2.07e-11	Smoking behavior;
CRC	cis	rs9322817	0.583	rs9391226	chr6:105158405	T/C	cg02098413	chr6:105308735	HACE1	-0.42	-8.21	-0.41	5.1e-15	Thyroid stimulating hormone;
CRC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.69	-10.44	-0.5	3.23e-22	Initial pursuit acceleration;
CRC	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.4	6.56	0.34	2.08e-10	Resting heart rate;
CRC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.36	-7.46	-0.38	7.58e-13	Cutaneous nevi;
CRC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.51	7.67	0.39	1.9e-13	Aortic root size;
CRC	cis	rs4731207	0.596	rs6466973	chr7:124605426	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.4	-7.14	-0.37	5.96e-12	Venous thromboembolism;
CRC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.16	-0.69	1.36e-47	Body mass index;
CRC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.79	12.04	0.55	6.34e-28	Cognitive function;
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.05	0.32	3.94e-9	Longevity;
CRC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.59	0.43	3.44e-16	Lymphocyte percentage of white cells;
CRC	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.78	-0.39	9.4e-14	Bipolar disorder;
CRC	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg23100626	chr2:96804247	ASTL	0.28	7.23	0.37	3.38e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg16606324	chr3:10149918	C3orf24	0.7	9.74	0.47	7.03e-20	Alzheimer's disease;
CRC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.58	-10.52	-0.5	1.69e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	1.01	10.19	0.49	2.29e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4290604	0.831	rs7608514	chr2:238023578	C/A	cg23555395	chr2:238036564	NA	-0.66	-6.67	-0.35	1.09e-10	Asthma;
CRC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg06470822	chr6:28175283	NA	0.81	6.57	0.34	2.03e-10	Depression;
CRC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg03233332	chr7:66118400	NA	0.45	6.3	0.33	9.62e-10	Aortic root size;
CRC	cis	rs4380275	1.000	rs4359695	chr2:774214	G/C	cg27237671	chr2:676223	TMEM18	-0.43	-6.18	-0.32	1.95e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.61	9.8	0.48	4.47e-20	Breast cancer;
CRC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.8	8.69	0.43	1.7e-16	Body mass index;
CRC	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.2	-0.32	1.68e-9	Daytime sleep phenotypes;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg04915425	chr11:47236385	DDB2	0.44	6.05	0.32	3.86e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs310501	0.843	rs515334	chr5:82901788	C/T	cg26920327	chr19:41035836	SPTBN4	-0.39	-5.97	-0.31	6.28e-9	Major depressive disorder;
CRC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.73	-0.35	7.33e-11	Menopause (age at onset);
CRC	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	1.12	10.35	0.5	6.61e-22	Arsenic metabolism;
CRC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.65	-7.89	-0.4	4.56e-14	Menarche (age at onset);
CRC	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.97	-0.36	1.7e-11	Coronary artery disease;
CRC	trans	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg03564338	chr16:50585384	NKD1	0.54	6.07	0.32	3.56e-9	Body mass index;
CRC	trans	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg21659725	chr3:3221576	CRBN	0.6	6.12	0.32	2.63e-9	Menarche (age at onset);
CRC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.38	-5.69	-0.3	2.77e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs3018066	0.831	rs6533237	chr4:106954292	T/C	cg01869342	chr4:106983673	TBCK	0.38	5.86	0.31	1.15e-8	Cancer;
CRC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg25985355	chr7:65971099	NA	-0.32	-5.61	-0.3	4.26e-8	Aortic root size;
CRC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.52	-8.23	-0.41	4.52e-15	Neurofibrillary tangles;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.72	10.21	0.49	1.87e-21	Alzheimer's disease;
CRC	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.37	-5.64	-0.3	3.64e-8	Inflammatory bowel disease;
CRC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.75	9.4	0.46	9.37e-19	Gestational age at birth (maternal effect);
CRC	trans	rs4276421	0.869	rs1351720	chr5:45561903	G/A	cg04793272	chr11:119020941	ABCG4	-0.38	-6.1	-0.32	3.03e-9	P wave duration;
CRC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg20387954	chr3:183756860	HTR3D	-0.44	-7.02	-0.36	1.28e-11	Anterior chamber depth;
CRC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.83	-12.41	-0.56	2.76e-29	Blood metabolite levels;
CRC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-0.43	-5.83	-0.31	1.34e-8	LDL cholesterol;Cholesterol, total;
CRC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-7.58	-0.39	3.65e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6499129	0.867	rs8056770	chr16:67416730	A/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-7.29	-0.37	2.37e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.53	8.26	0.41	3.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.57	-9.14	-0.45	6.54e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.88	0.31	9.83e-9	Diabetic kidney disease;
CRC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.73	-0.35	7.71e-11	Platelet distribution width;
CRC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.73	10.11	0.49	4.1e-21	Coronary artery disease;
CRC	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07165851	chr6:158734300	TULP4	0.63	7.98	0.4	2.48e-14	Height;
CRC	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.5	-7.7	-0.39	1.64e-13	Testicular germ cell tumor;
CRC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.29	6.54	0.34	2.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.698	rs6961292	chr7:124503189	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.48	7.2	0.37	4.06e-12	Testicular germ cell tumor;
CRC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-14.97	-0.64	5.39e-39	Gut microbiome composition (summer);
CRC	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.64	-10.73	-0.51	3.05e-23	Depressive symptoms (multi-trait analysis);
CRC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.61	-11.31	-0.53	2.89e-25	Aortic root size;
CRC	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.48	0.42	7.93e-16	Arsenic metabolism;
CRC	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.63	8.63	0.43	2.64e-16	Coronary artery disease;
CRC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.7	-11.4	-0.53	1.35e-25	Cognitive function;
CRC	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	1.0	12.64	0.57	4.01e-30	IgG glycosylation;
CRC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg11212589	chr17:38028394	ZPBP2	0.43	8.03	0.4	1.71e-14	Self-reported allergy;
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.53	0.34	2.57e-10	Bipolar disorder;
CRC	cis	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg15845792	chr6:28175446	NA	-0.61	-6.27	-0.33	1.14e-9	Depression;
CRC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.52	8.14	0.41	8.26e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.79	-10.82	-0.51	1.56e-23	Initial pursuit acceleration;
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.68	-7.36	-0.38	1.49e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	0.591	rs6945587	chr7:12356992	G/A	cg06484146	chr7:12443880	VWDE	-0.55	-5.68	-0.3	3.02e-8	Coronary artery disease;
CRC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg13722127	chr7:150037890	RARRES2	0.5	7.96	0.4	2.84e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.41	5.71	0.3	2.47e-8	Renal cell carcinoma;
CRC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.5	-0.57	1.38e-29	Type 2 diabetes;
CRC	cis	rs2811415	0.597	rs11721156	chr3:127796627	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.86	-0.31	1.12e-8	Lung function (FEV1/FVC);
CRC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg27205649	chr11:78285834	NARS2	0.47	5.79	0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs6076065	0.723	rs2249943	chr20:23378098	A/G	cg11657817	chr20:23433608	CST11	0.45	6.61	0.34	1.55e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.18	0.49	2.53e-21	Asthma;
CRC	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.69	-12.29	-0.56	8.25e-29	Lewy body disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13478031	chr18:47808184	MBD1	0.45	6.2	0.32	1.64e-9	Anxiety disorder;
CRC	trans	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.96	-0.36	1.81e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg03030879	chr14:75389066	RPS6KL1	0.49	7.53	0.38	4.88e-13	Height;
CRC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg20203395	chr5:56204925	C5orf35	-0.4	-5.63	-0.3	3.83e-8	Coronary artery disease;
CRC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg20908204	chr19:46285434	DMPK	0.34	7.61	0.39	2.82e-13	Coronary artery disease;
CRC	trans	rs28643277	0.671	rs10906921	chr10:15555056	T/C	cg18315834	chr14:64909119	MTHFD1	0.41	6.02	0.31	4.67e-9	Periodontitis (CDC/AAP);
CRC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg21505886	chr4:1724428	TMEM129;TACC3	0.4	5.75	0.3	1.99e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.22	-6.17	-0.32	1.95e-9	Urinary metabolites;
CRC	cis	rs230203	0.506	rs6070027	chr20:55780898	C/T	cg13236649	chr20:55835020	BMP7	-0.38	-5.75	-0.3	1.99e-8	Monobrow;
CRC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg18478394	chr8:109455254	TTC35	0.38	5.8	0.3	1.55e-8	Dupuytren's disease;
CRC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.72	-12.57	-0.57	7.46e-30	Hemoglobin concentration;
CRC	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.12	-0.32	2.59e-9	Myopia (pathological);
CRC	trans	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg26043149	chr18:55253948	FECH	-0.53	-8.28	-0.42	3.04e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.55	-8.13	-0.41	8.67e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg14329157	chr2:228736135	WDR69	-0.42	-6.17	-0.32	2.05e-9	Blood pressure;
CRC	cis	rs4789294	0.806	rs9896887	chr17:74444059	G/A	cg06840243	chr17:74442338	UBE2O	0.43	6.13	0.32	2.51e-9	Lymphocyte percentage of white cells;
CRC	cis	rs66569888	0.538	rs56291108	chr2:106757143	G/A	cg16099169	chr2:106886729	NA	-0.37	-5.66	-0.3	3.29e-8	Facial morphology (factor 23);
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg15845792	chr6:28175446	NA	0.73	10.85	0.51	1.19e-23	Parkinson's disease;
CRC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.55	7.49	0.38	6.45e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.87	-15.97	-0.66	6.42e-43	Body mass index;
CRC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	14.52	0.62	2.96e-37	Lymphocyte percentage of white cells;
CRC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.84	-9.73	-0.47	7.72e-20	Breast cancer;
CRC	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	8.98	0.44	2.2e-17	Platelet distribution width;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.49	8.28	0.42	3.19e-15	Crohn's disease;
CRC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.62	7.31	0.37	2.02e-12	Diabetic retinopathy;
CRC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.37	-0.46	1.24e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.47	8.84	0.44	6.01e-17	Alcohol dependence;
CRC	cis	rs673253	0.520	rs3791034	chr1:44145130	A/G	cg10881128	chr1:44031826	PTPRF	0.24	5.82	0.31	1.42e-8	Intelligence (multi-trait analysis);
CRC	cis	rs35771425	0.619	rs7538812	chr1:211442186	A/G	cg25617285	chr1:211431773	RCOR3	-0.4	-5.74	-0.3	2.2e-8	Educational attainment (years of education);
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg15786705	chr6:28176104	NA	0.51	7.44	0.38	8.81e-13	Cardiac Troponin-T levels;
CRC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.72	9.29	0.46	2.15e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.55	9.76	0.47	6.14e-20	Optic cup area;
CRC	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.64	9.84	0.48	3.37e-20	Itch intensity from mosquito bite;
CRC	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg06470822	chr6:28175283	NA	0.98	13.22	0.59	2.69e-32	Depression;
CRC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg16928487	chr17:17741425	SREBF1	0.55	10.37	0.5	5.42e-22	Total body bone mineral density;
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg06096015	chr1:231504339	EGLN1	0.42	6.45	0.34	3.97e-10	Hemoglobin concentration;
CRC	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.51	7.71	0.39	1.52e-13	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.64	0.75	2.54e-61	Prudent dietary pattern;
CRC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.56	-7.63	-0.39	2.55e-13	Multiple sclerosis;
CRC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	7.5	0.38	6.01e-13	Coronary artery disease;
CRC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.49	7.3	0.37	2.12e-12	Corneal astigmatism;
CRC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	8.0	0.4	2.08e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.87	-0.44	4.81e-17	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.51	8.15	0.41	7.48e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1524976	1.000	rs1524976	chr3:65486388	A/G	cg16238336	chr3:65465873	MAGI1	0.5	6.43	0.33	4.59e-10	PR interval;
CRC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	11.04	0.52	2.63e-24	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03856714	chr2:96658020	NA	0.46	6.49	0.34	3.15e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.68	10.83	0.51	1.36e-23	Type 2 diabetes;
CRC	cis	rs17767392	0.918	rs17767499	chr14:71867275	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.84	-0.35	3.96e-11	Mitral valve prolapse;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.37	1.72e-12	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12551166	chr16:85645228	KIAA0182	0.46	6.7	0.35	9.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.81	0.48	4.41e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg27534772	chr1:16042836	PLEKHM2	-0.42	-6.65	-0.34	1.19e-10	Systolic blood pressure;
CRC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.39	0.38	1.24e-12	Endometrial cancer;
CRC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg00769240	chr8:12517080	NA	0.51	6.4	0.33	5.42e-10	Blood pressure (smoking interaction);
CRC	trans	rs7302981	0.667	rs7308692	chr12:50627654	C/T	cg21483700	chr19:12943593	RTBDN	0.37	5.99	0.31	5.61e-9	Systolic blood pressure;
CRC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg00129232	chr17:37814104	STARD3	-0.41	-6.54	-0.34	2.4e-10	Self-reported allergy;
CRC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-9.93	-0.48	1.74e-20	Dental caries;
CRC	cis	rs7638909	0.512	rs7645178	chr3:38597558	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.51	-7.29	-0.37	2.27e-12	Electrocardiographic conduction measures;
CRC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.86	-10.03	-0.48	7.61e-21	Breast cancer;
CRC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00791764	chr4:53727839	RASL11B	0.51	6.9	0.36	2.73e-11	Optic nerve measurement (cup area);
CRC	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.11	0.45	8.3e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.88	-0.31	9.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.27	-0.41	3.39e-15	Gut microbiome composition (summer);
CRC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg10263370	chr3:44754102	ZNF502	-0.36	-6.14	-0.32	2.39e-9	Depressive symptoms;
CRC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.48	-6.99	-0.36	1.57e-11	Melanoma;
CRC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.61	9.02	0.45	1.59e-17	Morning vs. evening chronotype;
CRC	cis	rs9549328	0.614	rs35299896	chr13:113617229	G/T	cg08614441	chr13:113633676	MCF2L	0.4	7.08	0.36	8.76e-12	Systolic blood pressure;
CRC	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.87	10.47	0.5	2.44e-22	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.24	6.61	0.34	1.58e-10	Type 2 diabetes;
CRC	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.78	0.35	5.46e-11	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.11	-0.32	2.89e-9	Depression;
CRC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.78	-10.11	-0.49	4.1e-21	Initial pursuit acceleration;
CRC	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg22852734	chr6:133119734	C6orf192	0.81	6.72	0.35	7.89e-11	Type 2 diabetes nephropathy;
CRC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.87	-15.87	-0.66	1.69e-42	Coronary artery disease;
CRC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.54	-6.01	-0.31	5.06e-9	Red blood cell count;
CRC	cis	rs12024301	0.557	rs12027675	chr1:183657048	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg10729496	chr3:10149963	C3orf24	0.54	7.19	0.37	4.3e-12	Alzheimer's disease;
CRC	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.43	-0.38	9.5e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3824347	0.804	rs4527947	chr9:77587202	T/A	cg01251476	chr9:77566080	C9orf40	0.37	5.7	0.3	2.66e-8	Urinary magnesium-to-creatinine ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17687970	chr8:22462467	KIAA1967	0.38	7.21	0.37	3.76e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.8	-11.52	-0.54	4.88e-26	Blood trace element (Zn levels);
CRC	trans	rs783540	0.934	rs783530	chr15:83266549	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.26	-0.33	1.18e-9	Schizophrenia;
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.71	0.75	1.47e-61	Prudent dietary pattern;
CRC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	6.78	0.35	5.53e-11	Cognitive test performance;
CRC	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.36	-6.03	-0.32	4.34e-9	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09448058	chr2:70521051	SNRPG	0.43	5.98	0.31	5.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg02683197	chr6:28174875	NA	0.62	8.4	0.42	1.32e-15	Parkinson's disease;
CRC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg25164649	chr6:28176230	NA	0.47	6.9	0.36	2.75e-11	Cardiac Troponin-T levels;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg14329157	chr2:228736135	WDR69	-0.44	-6.15	-0.32	2.27e-9	Blood pressure;
CRC	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg21466736	chr12:48725269	NA	0.47	7.37	0.38	1.39e-12	Plateletcrit;
CRC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.2	0.41	5.53e-15	Height;
CRC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.55	0.47	3.04e-19	Cognitive test performance;
CRC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.79	10.97	0.52	4.45e-24	Cognitive function;
CRC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-7.75	-0.39	1.14e-13	Type 2 diabetes;
CRC	cis	rs7086803	1.000	rs7075510	chr10:114501509	C/T	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg02033258	chr5:131593261	PDLIM4	0.38	6.4	0.33	5.28e-10	Breast cancer;
CRC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	6.89	0.36	2.78e-11	Coronary artery disease;
CRC	cis	rs7605827	0.930	rs11898971	chr2:15613678	C/T	cg19274914	chr2:15703543	NA	-0.4	-5.97	-0.31	6.28e-9	Educational attainment (years of education);
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.04	0.32	4.16e-9	Prudent dietary pattern;
CRC	cis	rs10924970	0.934	rs4288584	chr1:235436631	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.94	0.31	7.23e-9	Asthma;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.88	-0.35	3.08e-11	Response to antipsychotic treatment;
CRC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.49	7.64	0.39	2.39e-13	Red blood cell count;
CRC	cis	rs2252790	0.899	rs1204854	chr6:116580896	T/A	cg18764771	chr6:116381957	FRK	-0.21	-5.67	-0.3	3.15e-8	Fast beta electroencephalogram;
CRC	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.5	7.56	0.38	3.92e-13	Testicular germ cell tumor;
CRC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19623624	chr10:135278901	LOC619207	-0.37	-6.09	-0.32	3.15e-9	Systemic lupus erythematosus;
CRC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.55	8.8	0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.48	0.34	3.36e-10	Mean platelet volume;
CRC	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg15282417	chr9:129245246	FAM125B	0.44	8.11	0.41	1.01e-14	Intraocular pressure;
CRC	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-7.01	-0.36	1.39e-11	Menarche (age at onset);
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	1.05	20.17	0.74	1.78e-59	Menarche (age at onset);
CRC	cis	rs17152411	0.895	rs7906592	chr10:126627861	C/G	cg07906193	chr10:126599966	NA	0.62	6.89	0.36	2.79e-11	Height;
CRC	trans	rs1376359	0.636	rs12753266	chr1:103120262	G/A	cg16220183	chr17:56609687	SEPT4	-0.48	-6.64	-0.34	1.28e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.59	7.69	0.39	1.72e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.84e-9	Schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21403771	chr7:131241396	PODXL	0.38	6.24	0.33	1.35e-9	Schizophrenia;
CRC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg13047869	chr3:10149882	C3orf24	-0.38	-6.02	-0.32	4.55e-9	Alzheimer's disease;
CRC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.71	0.51	3.63e-23	Motion sickness;
CRC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.0	0.44	1.81e-17	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12068969	chr15:77362720	TSPAN3	0.43	5.96	0.31	6.42e-9	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg06238570	chr21:40685208	BRWD1	0.75	10.48	0.5	2.33e-22	Cognitive function;
CRC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.9	15.94	0.66	8.83e-43	Prostate cancer;
CRC	cis	rs7605827	0.930	rs2241236	chr2:15655480	A/G	cg19274914	chr2:15703543	NA	0.4	6.0	0.31	5.16e-9	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24120822	chr15:69113128	ANP32A	0.4	6.04	0.32	4.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.9	-0.36	2.75e-11	Mean corpuscular volume;
CRC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.48	6.39	0.33	5.6e-10	Total body bone mineral density;
CRC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.09	-13.34	-0.59	9.89e-33	Vitiligo;
CRC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06544989	chr22:39130855	UNC84B	0.42	6.16	0.32	2.09e-9	Menopause (age at onset);
CRC	cis	rs6717918	0.887	rs6746834	chr2:233158817	C/T	ch.2.233013039R	chr2:233304795	NA	-0.5	-7.03	-0.36	1.2e-11	Height;
CRC	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.6	-8.59	-0.43	3.52e-16	Coronary artery disease;
CRC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.65	-9.32	-0.46	1.69e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg04362960	chr10:104952993	NT5C2	-0.58	-6.73	-0.35	7.7e-11	Arsenic metabolism;
CRC	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg18833306	chr6:118973337	C6orf204	0.47	6.03	0.32	4.32e-9	Diastolic blood pressure;
CRC	cis	rs9937943	0.616	rs12923487	chr16:74644112	G/T	cg01733217	chr16:74700730	RFWD3	0.7	7.38	0.38	1.35e-12	Neutrophil percentage of white cells;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg21204522	chr6:27730016	NA	-0.41	-5.63	-0.3	3.86e-8	Parkinson's disease;
CRC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.81	14.38	0.62	1.05e-36	Vitiligo;
CRC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.62	11.52	0.54	5.06e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.48	6.48	0.34	3.43e-10	Primary sclerosing cholangitis;
CRC	cis	rs10046574	0.731	rs10267977	chr7:135159392	G/A	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.89	-0.44	4.24e-17	Bipolar disorder;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg02475695	chr16:616220	NHLRC4	0.45	7.28	0.37	2.42e-12	Height;
CRC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.29	-15.37	-0.65	1.43e-40	Diabetic kidney disease;
CRC	cis	rs9296095	0.607	rs9469485	chr6:33514093	C/T	cg14003231	chr6:33640908	ITPR3	0.46	7.01	0.36	1.36e-11	Platelet count;
CRC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg14530993	chr4:882597	GAK	0.78	7.72	0.39	1.38e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg03013999	chr17:37608204	MED1	0.45	6.91	0.36	2.54e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.57	8.88	0.44	4.4e-17	Colorectal cancer;
CRC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg00406319	chr10:126851303	NA	-0.41	-6.16	-0.32	2.07e-9	Menarche (age at onset);
CRC	trans	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg17712092	chr4:129076599	LARP1B	-0.43	-6.23	-0.32	1.42e-9	Acne (severe);
CRC	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg24803719	chr17:45855879	NA	-0.29	-5.9	-0.31	8.95e-9	IgG glycosylation;
CRC	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.85	-16.19	-0.67	8.91e-44	Hip circumference;
CRC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.96	0.31	6.34e-9	Menopause (age at onset);
CRC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-21.13	-0.76	3.29e-63	Hemostatic factors and hematological phenotypes;
CRC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg11292332	chr7:45801988	SEPT13	-0.34	-6.16	-0.32	2.12e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.67	0.3	3.16e-8	Major depressive disorder;
CRC	cis	rs2692947	0.695	rs12464148	chr2:96596710	G/C	cg23100626	chr2:96804247	ASTL	0.25	6.92	0.36	2.31e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15985338	chr7:6048868	PMS2;AIMP2	0.4	6.19	0.32	1.82e-9	Interleukin-6 levels;
CRC	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg23254163	chr1:152506842	NA	0.44	8.41	0.42	1.27e-15	Hair morphology;
CRC	cis	rs7605827	0.780	rs2287279	chr2:15667778	G/A	cg19274914	chr2:15703543	NA	0.39	5.83	0.31	1.32e-8	Educational attainment (years of education);
CRC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.47	-5.9	-0.31	8.87e-9	White blood cell count;
CRC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.82	-10.34	-0.5	6.68e-22	Eosinophil percentage of granulocytes;
CRC	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.68	0.3	2.99e-8	Corneal astigmatism;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.21	-0.37	3.78e-12	Longevity;Endometriosis;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.39	-9.22	-0.45	3.57e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.6	0.43	3.24e-16	Homoarginine levels;
CRC	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	8.03	0.4	1.71e-14	Blood protein levels;
CRC	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.7	-10.64	-0.51	6.45e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.05	-0.52	2.38e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg04586622	chr2:25135609	ADCY3	-0.58	-9.66	-0.47	1.35e-19	Body mass index;
CRC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.62	8.97	0.44	2.25e-17	Intelligence (multi-trait analysis);
CRC	cis	rs12143943	0.966	rs2369246	chr1:204567762	C/T	cg17419461	chr1:204415978	PIK3C2B	0.4	6.04	0.32	4.28e-9	Cognitive performance;
CRC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.95	-0.4	2.97e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.65	-8.49	-0.42	7.35e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.14	-24.62	-0.81	1.25e-76	IgG glycosylation;
CRC	cis	rs1179624	0.639	rs13233152	chr7:75272055	C/T	cg05145297	chr7:75264568	HIP1	0.61	8.39	0.42	1.42e-15	Age-related nuclear cataracts;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.42	0.42	1.16e-15	Lymphocyte counts;
CRC	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.85	0.51	1.22e-23	Ileal carcinoids;
CRC	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.5	-7.61	-0.39	2.97e-13	Schizophrenia;
CRC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg17346650	chr17:80929145	B3GNTL1	0.33	5.7	0.3	2.62e-8	Breast cancer;
CRC	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.77	-14.22	-0.62	4.06e-36	Hip circumference;
CRC	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.17	-0.32	2.04e-9	Alzheimer's disease (late onset);
CRC	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.44	6.44	0.33	4.33e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg21770322	chr7:97807741	LMTK2	0.53	8.62	0.43	2.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	8.85	0.44	5.5e-17	Menarche (age at onset);
CRC	cis	rs3996993	0.809	rs1984728	chr6:52677591	C/T	cg20803780	chr6:52668592	GSTA1	0.35	6.24	0.33	1.37e-9	Hemoglobin concentration;
CRC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.56	-8.25	-0.41	3.76e-15	Dental caries;
CRC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg11070056	chr1:107600091	PRMT6	-0.4	-5.74	-0.3	2.12e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.73	-9.48	-0.46	5.09e-19	Initial pursuit acceleration;
CRC	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg20916646	chr4:852691	GAK	0.54	7.4	0.38	1.18e-12	Sjögren's syndrome;
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-0.9	-9.83	-0.48	3.65e-20	Body mass index;
CRC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg21770322	chr7:97807741	LMTK2	0.51	8.39	0.42	1.44e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg26043149	chr18:55253948	FECH	0.51	7.85	0.4	5.82e-14	Bone mineral density;
CRC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.56	-0.34	2.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg04110750	chr16:69646130	NFAT5	-0.57	-7.74	-0.39	1.24e-13	IgE levels;
CRC	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.51	-8.4	-0.42	1.4e-15	Metabolite levels;
CRC	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg25856811	chr1:152973957	SPRR3	-0.27	-7.55	-0.38	4.33e-13	Inflammatory skin disease;
CRC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.51	-0.46	4.17e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg07153921	chr17:41440717	NA	-0.37	-5.69	-0.3	2.8e-8	Menopause (age at onset);
CRC	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.76	10.43	0.5	3.33e-22	IgG glycosylation;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.47	5.77	0.3	1.84e-8	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg27615366	chr5:131592974	PDLIM4	0.32	5.75	0.3	2e-8	Acylcarnitine levels;
CRC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.89	-0.36	2.9e-11	Height;
CRC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.58	-8.97	-0.44	2.27e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs11098699	0.821	rs11935129	chr4:124207106	T/A	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-5.83	-0.31	1.3e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.46	7.45	0.38	8.16e-13	Fat distribution (HIV);
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.31e-17	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.74	-12.72	-0.57	2.07e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.47	-7.58	-0.39	3.48e-13	Post bronchodilator FEV1;
CRC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	1.01	13.49	0.6	2.68e-33	Psoriasis;
CRC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-9.57	-0.47	2.73e-19	Height;
CRC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.74	-0.3	2.19e-8	Reticulocyte count;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg24003225	chr3:184870891	C3orf70	-0.43	-6.31	-0.33	8.83e-10	Birth weight;Height;
CRC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	13.53	0.6	1.88e-33	Cognitive ability;
CRC	cis	rs1007738	0.542	rs4752970	chr11:47208982	A/G	cg19486271	chr11:47235900	DDB2	-0.44	-6.07	-0.32	3.43e-9	Bone mineral density (hip);
CRC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	8.94	0.44	2.9e-17	Schizophrenia;
CRC	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.67	9.0	0.44	1.79e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs1322512	1.000	rs7744715	chr6:152949026	G/A	cg03415253	chr6:152958462	SYNE1	-0.42	-6.43	-0.33	4.53e-10	Tonometry;
CRC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.18	-0.32	1.87e-9	Menopause (age at onset);
CRC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg01605746	chr5:669925	TPPP	0.34	5.6	0.3	4.45e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs2303319	0.504	rs57419108	chr2:162311357	G/C	cg19471553	chr17:41393123	NA	-0.7	-6.07	-0.32	3.48e-9	Cognitive function;
CRC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.89	-14.83	-0.63	1.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg16447950	chr5:562315	NA	-0.83	-11.29	-0.53	3.31e-25	Lung disease severity in cystic fibrosis;
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg01339444	chr6:118972232	C6orf204	0.54	6.02	0.32	4.65e-9	Diastolic blood pressure;
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02290350	chr8:58132656	NA	-0.42	-6.07	-0.32	3.57e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg19338460	chr6:170058176	WDR27	-0.71	-7.74	-0.39	1.27e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs939584	0.867	rs34119520	chr2:632760	T/C	cg03610516	chr2:642275	NA	0.42	5.65	0.3	3.49e-8	Body mass index;
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-8.15	-0.41	7.47e-15	IgG glycosylation;
CRC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg26918954	chr5:179728553	GFPT2	-0.42	-6.87	-0.35	3.29e-11	Height;
CRC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.67	-0.3	3.13e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-8.24	-0.41	4.2e-15	Schizophrenia;
CRC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.91	-15.93	-0.66	9.48e-43	Height;
CRC	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.53	0.38	5.05e-13	Schizophrenia;
CRC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.54	-0.34	2.3e-10	Mean corpuscular volume;
CRC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.24	0.53	5.01e-25	Prudent dietary pattern;
CRC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.34	0.33	7.7e-10	Height;
CRC	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	0.91	8.58	0.43	3.82e-16	Pulse pressure;
CRC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg21138405	chr5:131827807	IRF1	-0.36	-6.21	-0.32	1.59e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.9	0.4	4.33e-14	Platelet count;
CRC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.74	-10.96	-0.52	5.07e-24	Response to antineoplastic agents;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22856972	chr6:134275178	TBPL1	0.43	6.56	0.34	2.06e-10	Response to antipsychotic treatment;
CRC	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg16898833	chr6:26189333	HIST1H4D	0.74	6.39	0.33	5.72e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1656402	1.000	rs1190440	chr2:233422274	G/A	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg00976097	chr5:421733	AHRR	-0.42	-5.78	-0.3	1.72e-8	Cystic fibrosis severity;
CRC	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-11.82	-0.55	4.12e-27	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	9.58	0.47	2.52e-19	Ileal carcinoids;
CRC	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg02811702	chr13:24901961	NA	0.46	6.32	0.33	8.48e-10	Obesity-related traits;
CRC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg06363034	chr20:62225388	GMEB2	-0.44	-6.8	-0.35	4.95e-11	Glioblastoma;
CRC	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.65	-0.3	3.46e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs73200209	0.912	rs57465027	chr12:116627026	G/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.82	-0.31	1.43e-8	Total body bone mineral density;
CRC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.35	-0.33	7.25e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7246760	1.000	rs7246772	chr19:9886283	C/T	cg16876255	chr19:9731953	ZNF561	0.69	5.71	0.3	2.49e-8	Pursuit maintenance gain;
CRC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.54	8.67	0.43	2.05e-16	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05604720	chr8:90769698	RIPK2	0.47	6.94	0.36	2.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg02683197	chr6:28174875	NA	0.67	7.19	0.37	4.4e-12	Parkinson's disease;
CRC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.65	9.9	0.48	2.18e-20	Corneal astigmatism;
CRC	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.42	-0.42	1.2e-15	Alcohol dependence;
CRC	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	cis	rs4561483	0.551	rs1126889	chr16:12061910	C/G	cg08843971	chr16:11963173	GSPT1	-0.45	-6.31	-0.33	8.96e-10	Testicular germ cell tumor;
CRC	cis	rs2227564	0.830	rs2633322	chr10:75693932	T/C	cg00564723	chr10:75632066	CAMK2G	-0.3	-7.08	-0.36	8.83e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.61	-10.0	-0.48	1e-20	Colorectal cancer;
CRC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.67	8.43	0.42	1.09e-15	Menarche (age at onset);
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-8.75	-0.43	1.16e-16	Mean platelet volume;Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15957017	chr4:71571214	RUFY3	0.38	6.18	0.32	1.92e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	7.27	0.37	2.63e-12	Motion sickness;
CRC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.53	-8.58	-0.43	3.92e-16	Neurofibrillary tangles;
CRC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.05	-0.41	1.53e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg24851651	chr11:66362959	CCS	-0.38	-6.54	-0.34	2.3e-10	Educational attainment (years of education);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07791671	chr2:242255336	SEPT2;HDLBP	0.46	6.36	0.33	6.84e-10	Anxiety disorder;
CRC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.71	11.0	0.52	3.55e-24	Tonsillectomy;
CRC	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.61	-9.28	-0.46	2.26e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs972578	0.840	rs8138151	chr22:43386003	T/A	cg01576275	chr22:43409880	NA	-0.48	-7.66	-0.39	2.14e-13	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08207256	chr19:10828848	DNM2;MIR638	0.4	7.51	0.38	5.65e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.7	9.31	0.46	1.88e-18	Bladder cancer;
CRC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Bladder cancer;
CRC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.4	-6.33	-0.33	8.15e-10	Dupuytren's disease;
CRC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-10.04	-0.48	7.38e-21	Menarche (age at onset);
CRC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.92	11.13	0.52	1.19e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.5	-5.73	-0.3	2.31e-8	Coronary artery disease;
CRC	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.07	14.64	0.63	1.04e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00762468	chr16:103568	POLR3K;SNRNP25	0.38	5.96	0.31	6.33e-9	Obesity-related traits;
CRC	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.27	-0.33	1.13e-9	Height;
CRC	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.38	-5.68	-0.3	3.01e-8	Plateletcrit;
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.64	8.31	0.42	2.59e-15	Alzheimer's disease;
CRC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.56	-8.42	-0.42	1.22e-15	Uric acid levels;
CRC	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg14631576	chr9:95140430	CENPP	-0.3	-5.63	-0.3	3.78e-8	Height;
CRC	cis	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg18809830	chr7:99032528	PTCD1	-1.14	-8.35	-0.42	1.92e-15	Blood metabolite levels;
CRC	cis	rs6432018	1.000	rs3951115	chr2:9740561	T/C	cg12832956	chr2:9616023	IAH1	-0.38	-5.75	-0.3	2.08e-8	Heart rate variability traits;
CRC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06462663	chr19:18546047	ISYNA1	0.48	7.36	0.38	1.47e-12	Breast cancer;
CRC	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg16964102	chr10:135390573	NA	-0.47	-6.45	-0.33	4.08e-10	Gout;
CRC	cis	rs4731207	0.596	rs2402756	chr7:124579782	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.71e-9	Cutaneous malignant melanoma;
CRC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.05	-0.41	1.48e-14	Height;
CRC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.25	-0.41	3.81e-15	Type 2 diabetes;
CRC	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg27398640	chr15:77910606	LINGO1	-0.44	-7.52	-0.38	5.19e-13	Type 2 diabetes;
CRC	cis	rs1983170	0.736	rs13447495	chr1:91974965	A/G	cg21854759	chr1:92012499	NA	0.52	6.0	0.31	5.25e-9	Eosinophil percentage of white cells;
CRC	cis	rs365302	1.000	rs485368	chr6:159651361	C/G	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.7	9.17	0.45	5.13e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg21024916	chr3:4535815	ITPR1	-0.35	-6.04	-0.32	4.28e-9	Aortic root size;
CRC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12292205	chr6:26970375	C6orf41	-0.6	-6.75	-0.35	6.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg12218747	chr21:37451666	NA	-0.37	-6.16	-0.32	2.11e-9	Mitral valve prolapse;
CRC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.22	0.69	8.3e-48	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-6.17	-0.32	2.03e-9	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17008164	chr15:31507824	NA	0.4	6.92	0.36	2.43e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs938554	0.784	rs7682751	chr4:9976294	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	5.64	0.3	3.62e-8	Blood metabolite levels;
CRC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg22676075	chr6:135203613	NA	0.4	6.25	0.33	1.27e-9	Red blood cell count;
CRC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21643547	chr1:205240462	TMCC2	-0.43	-6.78	-0.35	5.71e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg07217954	chr7:1067459	C7orf50	0.55	5.61	0.3	4.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4400599	1.000	rs4400599	chr1:154127100	A/G	cg05139571	chr1:154127138	NUP210L	0.46	7.32	0.37	1.97e-12	Platelet distribution width;
CRC	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.7	-12.27	-0.56	9.65e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs2072510	0.966	rs1990611	chr12:96413984	G/A	cg22491680	chr12:96389547	HAL	-0.38	-5.95	-0.31	7.03e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs2062225	1.000	rs1157084	chr2:111755123	G/A	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.7	11.31	0.53	2.78e-25	Response to diuretic therapy;
CRC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg24300038	chr13:113819356	PROZ	0.5	6.61	0.34	1.51e-10	Platelet distribution width;
CRC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.7	-9.06	-0.45	1.17e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg20933634	chr6:27740509	NA	0.59	8.66	0.43	2.1e-16	Parkinson's disease;
CRC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.59	-7.55	-0.38	4.36e-13	Gut microbiome composition (summer);
CRC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.12	-0.45	7.52e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg01987224	chr1:201084466	NA	-0.5	-9.56	-0.47	2.84e-19	Permanent tooth development;
CRC	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg03929089	chr4:120376271	NA	-0.47	-6.74	-0.35	7.08e-11	Height;
CRC	cis	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-6.21	-0.32	1.56e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.76	-12.15	-0.56	2.66e-28	Multiple myeloma;
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg21856205	chr7:94953877	PON1	-0.5	-6.45	-0.34	3.88e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg15448220	chr1:150897856	SETDB1	-0.4	-6.2	-0.32	1.64e-9	Tonsillectomy;
CRC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.62	11.22	0.53	5.75e-25	Schizophrenia;
CRC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.73	-12.65	-0.57	3.59e-30	Ulcerative colitis;
CRC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.53	6.98	0.36	1.59e-11	IgG glycosylation;
CRC	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg23920097	chr1:209922102	NA	-0.45	-5.67	-0.3	3.2e-8	Red blood cell count;
CRC	trans	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17467752	chr17:38218738	THRA	-0.42	-6.12	-0.32	2.72e-9	Asthma and hay fever;
CRC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.98	14.41	0.62	7.9e-37	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	3.08e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs6129564	0.731	rs6029074	chr20:38999927	C/G	cg12409982	chr3:137489312	NA	-0.5	-6.04	-0.32	4.09e-9	Cranial base width;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg23123621	chr4:1343375	KIAA1530	-0.37	-6.9	-0.36	2.68e-11	Obesity-related traits;
CRC	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.48	9.06	0.45	1.19e-17	Pediatric bone mineral content (femoral neck);
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.64	8.48	0.42	8e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.39	-6.75	-0.35	6.61e-11	Reticulocyte fraction of red cells;
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.46	-6.4	-0.33	5.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.71	0.47	8.96e-20	Fuchs's corneal dystrophy;
CRC	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg10820045	chr2:198174542	NA	-0.56	-9.43	-0.46	7.69e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg19539972	chr4:7069911	GRPEL1	0.44	6.0	0.31	5.3300000000000004e-09	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	0.88	16.18	0.67	1.01e-43	Height;
CRC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-6.27	-0.33	1.14e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg17903999	chr18:56338584	MALT1	0.41	7.06	0.36	9.88e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13844804	chr7:814759	HEATR2	-0.57	-6.43	-0.33	4.62e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg05185784	chr16:90016020	DEF8	-0.54	-7.82	-0.4	7.31e-14	Squamous cell carcinoma;
CRC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.08	-0.32	3.29e-9	Diabetic kidney disease;
CRC	cis	rs2797685	0.617	rs172933	chr1:7844680	T/C	cg06712362	chr1:7811235	CAMTA1	-0.44	-5.8	-0.3	1.53e-8	Crohn's disease;
CRC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg12193833	chr17:30244370	NA	0.45	6.01	0.31	4.79e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10887265	1	rs10887265	chr10:86015573	G/C	cg02698580	chr10:86016643	RGR	0.45	6.91	0.36	2.59e-11	Myopia;
CRC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg13844804	chr7:814759	HEATR2	0.65	8.47	0.42	8.46e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	0.77	8.9	0.44	3.75e-17	Gout;Renal underexcretion gout;
CRC	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.12	-0.37	6.99e-12	Morning vs. evening chronotype;
CRC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg23533926	chr12:111358616	MYL2	-0.45	-6.65	-0.34	1.23e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.63	-7.72	-0.39	1.41e-13	Diabetic retinopathy;
CRC	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.42	-0.38	1.01e-12	Caudate activity during reward;
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00166722	chr3:10149974	C3orf24	0.65	8.81	0.44	7.45e-17	Alzheimer's disease;
CRC	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg02702477	chr5:179499311	RNF130	0.54	6.35	0.33	7.35e-10	LDL cholesterol;
CRC	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-7.34	-0.38	1.65e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.49	-0.38	6.4e-13	Hemoglobin concentration;
CRC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg12564285	chr5:131593104	PDLIM4	-0.32	-5.82	-0.31	1.38e-8	Blood metabolite levels;
CRC	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg04415270	chr2:102091202	RFX8	-0.54	-7.98	-0.4	2.45e-14	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.85	-13.67	-0.6	5.3e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg04053776	chr11:6947353	ZNF215	0.51	6.84	0.35	3.86e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	0.81	7.38	0.38	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25942691	chr19:36705733	ZNF565;ZNF146	0.44	6.49	0.34	3.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.53	-8.0	-0.4	2.18e-14	Coronary artery disease;
CRC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.51	-8.3	-0.42	2.77e-15	Height;
CRC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-5.97	-0.31	6.2e-9	Asthma;
CRC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.2	-0.37	4.21e-12	Retinal vascular caliber;
CRC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-18.87	-0.72	2.42e-54	Ulcerative colitis;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg12172441	chr6:28176163	NA	0.5	6.65	0.34	1.22e-10	Parkinson's disease;
CRC	cis	rs2764208	0.860	rs205286	chr6:34551334	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.89	-0.31	9.39e-9	Systemic lupus erythematosus;
CRC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.4	-6.03	-0.32	4.29e-9	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11865413	chr10:72969054	NA	0.5	7.37	0.38	1.38e-12	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg15845792	chr6:28175446	NA	0.61	8.31	0.42	2.61e-15	Parkinson's disease;
CRC	cis	rs6973256	0.828	rs2041996	chr7:133390510	G/A	cg10665199	chr7:133106180	EXOC4	-0.38	-5.64	-0.3	3.72e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.48	7.29	0.37	2.35e-12	Corneal astigmatism;
CRC	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.72	0.63	4.93e-38	Exhaled nitric oxide output;
CRC	cis	rs4478858	0.746	rs10798832	chr1:31688630	C/G	cg00250761	chr1:31883323	NA	0.31	5.82	0.31	1.4e-8	Alcohol dependence;
CRC	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.53	8.96	0.44	2.44e-17	Metabolite levels;
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20563921	chr11:62420975	INTS5	0.42	6.09	0.32	3.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg10862848	chr6:42927986	GNMT	-0.3	-5.64	-0.3	3.75e-8	Blood protein levels;
CRC	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg13385794	chr1:248469461	NA	0.38	6.68	0.35	1.01e-10	Common traits (Other);
CRC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg11632617	chr15:75315747	PPCDC	-0.56	-8.05	-0.41	1.52e-14	Blood trace element (Zn levels);
CRC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.89	0.36	2.81e-11	Renal cell carcinoma;
CRC	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg21972741	chr5:435613	AHRR	-0.39	-5.65	-0.3	3.41e-8	Cystic fibrosis severity;
CRC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg02869306	chr7:64672164	INTS4L1	0.43	6.28	0.33	1.07e-9	Aortic root size;
CRC	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	8.91	0.44	3.53e-17	Ulcerative colitis;
CRC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.43	5.76	0.3	1.98e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.49	8.38	0.42	1.59e-15	Coronary artery disease;
CRC	cis	rs4700695	0.841	rs448454	chr5:65293462	G/A	cg21114390	chr5:65439923	SFRS12	0.5	6.3	0.33	9.48e-10	Facial morphology (factor 19);
CRC	cis	rs62432291	0.681	rs439126	chr6:159656632	T/C	cg14500486	chr6:159655392	FNDC1	-0.76	-10.39	-0.5	4.8e-22	Joint mobility (Beighton score);
CRC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.91	0.31	8.57e-9	Melanoma;
CRC	cis	rs77633900	0.772	rs284903	chr15:76744813	G/A	cg21673338	chr15:77095150	SCAPER	-0.69	-6.18	-0.32	1.89e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.42	6.06	0.32	3.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs231513	0.954	rs231504	chr17:41970906	C/G	cg26893861	chr17:41843967	DUSP3	-0.63	-6.41	-0.33	4.92e-10	Cognitive function;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.97	-0.4	2.56e-14	Electroencephalogram traits;
CRC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.49	7.77	0.39	1.01e-13	Height;
CRC	cis	rs7632954	1.000	rs9863622	chr3:8524604	C/T	cg03495237	chr3:8533978	NA	0.33	5.88	0.31	9.99e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	1.01	11.6	0.54	2.65e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.1	-0.32	2.96e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg00631329	chr6:26305371	NA	-0.4	-6.89	-0.36	2.86e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg17724175	chr1:150552817	MCL1	0.39	6.0	0.31	5.11e-9	Melanoma;
CRC	cis	rs4658101	0.700	rs10874796	chr1:92050825	T/C	cg24006770	chr1:92056542	NA	0.46	6.84	0.35	3.97e-11	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg02254774	chr11:50257496	LOC441601	-0.47	-6.62	-0.34	1.47e-10	Height;
CRC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.1	-0.36	7.67e-12	Mean corpuscular volume;
CRC	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg06632207	chr12:54070931	ATP5G2	-0.48	-8.72	-0.43	1.41e-16	Height;
CRC	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg14593290	chr7:50529359	DDC	-0.53	-7.32	-0.37	1.9e-12	Malaria;
CRC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg05623727	chr3:50126028	RBM5	-0.43	-7.24	-0.37	3.18e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6961069	0.935	rs819437	chr7:80223996	C/T	cg04458919	chr7:80252533	CD36	-0.33	-5.79	-0.3	1.65e-8	Platelet count;
CRC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.81	-0.3	1.51e-8	Skin colour saturation;
CRC	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.65	-11.09	-0.52	1.72e-24	White blood cell count (basophil);
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg02560186	chr11:3602584	NA	-0.63	-9.51	-0.46	4.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.74	9.89	0.48	2.29e-20	Coronary artery disease;
CRC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21643547	chr1:205240462	TMCC2	-0.45	-7.26	-0.37	2.84e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.17	0.32	2.05e-9	Renal function-related traits (BUN);
CRC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.68	-9.28	-0.46	2.26e-18	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.54	9.59	0.47	2.29e-19	Hypertriglyceridemia;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	trans	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg20935933	chr6:143382018	AIG1	0.53	6.11	0.32	2.85e-9	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7215564	0.908	rs34333328	chr17:78683420	G/A	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.26e-9	Myopia (pathological);
CRC	cis	rs7224737	0.750	rs12325861	chr17:40289412	T/C	cg20291162	chr17:40259547	DHX58	-0.45	-5.82	-0.31	1.39e-8	Fibrinogen levels;
CRC	cis	rs720844	0.684	rs930652	chr2:149317494	C/T	cg09247360	chr2:149335327	NA	-0.56	-6.03	-0.32	4.49e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs12699921	0.572	rs2030725	chr7:17868331	T/C	cg02066331	chr6:17282778	RBM24	-0.35	-6.02	-0.31	4.63e-9	Fibrinogen levels;
CRC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.86	-0.4	5.55e-14	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03108330	chr19:2900762	ZNF57	0.34	6.0	0.31	5.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-12.19	-0.56	1.9e-28	Extrinsic epigenetic age acceleration;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg03790207	chr6:42947109	PEX6	-0.44	-6.18	-0.32	1.92e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	1.26	14.07	0.61	1.59e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9292777	0.720	rs4957130	chr5:40399541	C/A	cg09067459	chr5:40385259	NA	-0.55	-8.97	-0.44	2.31e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.51	7.56	0.38	4.17e-13	Breast cancer;
CRC	cis	rs2223471	0.870	rs2744494	chr6:50757690	G/A	cg03432817	chr6:50765336	NA	0.38	6.02	0.32	4.54e-9	Subcutaneous adipose tissue;
CRC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg17545662	chr6:170176663	C6orf70	0.57	6.54	0.34	2.31e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.01	16.04	0.66	3.52e-43	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01110552	chr10:103578627	MGEA5	0.47	6.75	0.35	6.7e-11	Response to antipsychotic treatment;
CRC	cis	rs4716602	0.609	rs12386633	chr7:156158232	G/C	cg16983916	chr7:156159713	NA	-0.39	-6.92	-0.36	2.42e-11	Anti-saccade response;
CRC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.62	7.51	0.38	5.45e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10484885	0.553	rs6901718	chr6:90243843	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.14	-0.32	2.37e-9	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-0.8	-8.16	-0.41	7.05e-15	Magnesium levels;
CRC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.93	0.52	6.5e-24	Motion sickness;
CRC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.58	9.64	0.47	1.6e-19	Intelligence (multi-trait analysis);
CRC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.62	9.04	0.45	1.43e-17	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.67	0.3	3.18e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6681460	1.000	rs1325263	chr1:67129791	C/A	cg02459107	chr1:67143332	SGIP1	0.46	7.95	0.4	3.03e-14	Presence of antiphospholipid antibodies;
CRC	trans	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.64	0.39	2.47e-13	Educational attainment;
CRC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06656553	chr16:89960601	TCF25	-0.68	-5.67	-0.3	3.16e-8	Skin colour saturation;
CRC	cis	rs4838594	0.563	rs4838598	chr10:49679413	A/G	cg17291251	chr10:49678358	ARHGAP22	0.44	7.01	0.36	1.33e-11	Daytime sleep phenotypes;
CRC	cis	rs12760731	0.920	rs16852934	chr1:178479290	C/T	cg00404053	chr1:178313656	RASAL2	0.61	7.17	0.37	5.02e-12	Obesity-related traits;
CRC	cis	rs6662572	0.703	rs55641506	chr1:46580708	G/A	cg08644498	chr1:46502608	NA	0.43	7.01	0.36	1.32e-11	Blood protein levels;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg00329300	chr1:161008462	TSTD1	-0.47	-7.11	-0.36	7.05e-12	Lung cancer;
CRC	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.58	8.98	0.44	2.17e-17	Autism;
CRC	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.8	-11.58	-0.54	2.97e-26	Pubertal anthropometrics;
CRC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg10298567	chr3:47292165	KIF9	0.43	7.06	0.36	1.02e-11	Colorectal cancer;
CRC	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg14593290	chr7:50529359	DDC	0.5	7.17	0.37	5.13e-12	Malaria;
CRC	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg10305451	chr2:177043427	NA	0.62	8.88	0.44	4.28e-17	IgG glycosylation;
CRC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16402443	chr7:2598526	IQCE	0.43	6.82	0.35	4.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20092199	chr4:1342459	KIAA1530	0.33	5.77	0.3	1.87e-8	Longevity;
CRC	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.77	-13.97	-0.61	3.77e-35	Hip circumference;
CRC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.58	10.23	0.49	1.63e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7849270	1.000	rs10760589	chr9:131906293	T/C	cg13538475	chr9:131942899	NA	-0.29	-5.74	-0.3	2.11e-8	Blood metabolite ratios;
CRC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg21153622	chr11:89784906	NA	-0.42	-6.96	-0.36	1.85e-11	Height;
CRC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.15	-0.32	2.2e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4973397	0.765	rs13030174	chr2:232271284	A/C	cg13347044	chr2:232276743	NA	0.47	6.74	0.35	7.12e-11	Anti-saccade response;
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.43	6.0	0.31	5.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg08222913	chr3:52553049	STAB1	-0.38	-7.52	-0.38	5.33e-13	Bipolar disorder;
CRC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	7.9e-11	Colorectal cancer;
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-7.38	-0.38	1.31e-12	Renal function-related traits (BUN);
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg04204079	chr8:58130323	NA	-0.47	-5.94	-0.31	7.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26839812	chr6:16129282	MYLIP	0.43	6.03	0.32	4.45e-9	Response to antipsychotic treatment;
CRC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.95	12.4	0.56	3.19e-29	Triglycerides;
CRC	cis	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg12964065	chr18:77638022	KCNG2	0.57	6.04	0.32	4.19e-9	Opioid sensitivity;
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.35	-5.6	-0.3	4.44e-8	Life satisfaction;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-1.07	-17.81	-0.7	3.74e-50	Blood pressure (smoking interaction);
CRC	trans	rs6129564	0.731	rs1969696	chr20:38989872	T/C	cg12409982	chr3:137489312	NA	-0.44	-5.97	-0.31	6e-9	Cranial base width;
CRC	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.72	-6.94	-0.36	2.05e-11	Putamen volume;
CRC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.49	9.65	0.47	1.48e-19	Renal cell carcinoma;
CRC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.4	7.84	0.4	6.44e-14	Mean corpuscular volume;
CRC	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.65	10.95	0.52	5.25e-24	Neutrophil percentage of white cells;
CRC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.56	7.42	0.38	1.01e-12	Homoarginine levels;
CRC	trans	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg13565492	chr6:43139072	SRF	-0.72	-7.27	-0.37	2.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg02569219	chr17:2266849	SGSM2	-0.38	-6.32	-0.33	8.55e-10	Proinsulin levels;
CRC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.48	-7.53	-0.38	4.8e-13	Monocyte count;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg02683197	chr6:28174875	NA	0.72	8.85	0.44	5.44e-17	Parkinson's disease;
CRC	cis	rs231513	0.954	rs231494	chr17:41976928	G/C	cg26893861	chr17:41843967	DUSP3	-0.62	-6.27	-0.33	1.11e-9	Cognitive function;
CRC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	5.95	0.31	6.71e-9	Height;
CRC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg06713675	chr4:122721982	EXOSC9	-0.39	-6.34	-0.33	7.65e-10	Type 2 diabetes;
CRC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.89	-0.31	9.64e-9	Aortic root size;
CRC	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.51	-5.67	-0.3	3.19e-8	Neuroticism;
CRC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	-0.55	-9.14	-0.45	6.65e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg24977027	chr2:88469347	THNSL2	0.52	5.94	0.31	7.21e-9	Plasma clusterin levels;
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg12172441	chr6:28176163	NA	0.56	5.8	0.3	1.54e-8	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22297305	chr22:18923471	PRODH	0.39	6.16	0.32	2.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10413329	0.810	rs10401950	chr19:13101197	C/G	cg13338734	chr19:13113668	NFIX	0.33	5.66	0.3	3.23e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.59	-0.34	1.73e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26027482	chr12:1100598	ERC1	0.45	6.37	0.33	6.33e-10	Response to antipsychotic treatment;
CRC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.45	-6.27	-0.33	1.13e-9	Aortic root size;
CRC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.46e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs524281	0.861	rs535395	chr11:65906534	A/G	cg16950941	chr11:66035639	RAB1B	0.57	7.25	0.37	2.94e-12	Electroencephalogram traits;
CRC	trans	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-13.88	-0.61	8.38e-35	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06102153	chr16:4674926	MGRN1	0.42	6.89	0.36	2.78e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs720844	1.000	rs1020468	chr2:149334413	A/G	cg09247360	chr2:149335327	NA	-0.61	-7.68	-0.39	1.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.23e-37	Hypertriglyceridemia;
CRC	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-7.45	-0.38	8.43e-13	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.92e-9	Aortic root size;
CRC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.64	9.29	0.46	2.2e-18	Intelligence (multi-trait analysis);
CRC	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg01794103	chr15:78342494	TBC1D2B	0.43	5.9	0.31	9.1e-9	Breast cancer;
CRC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg13798780	chr7:105162888	PUS7	0.67	7.93	0.4	3.42e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg16898833	chr6:26189333	HIST1H4D	0.77	6.45	0.33	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.68	-11.08	-0.52	1.78e-24	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.85	-15.69	-0.65	8.57e-42	Breast cancer;
CRC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.62	9.87	0.48	2.72e-20	Height;
CRC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.36	-5.77	-0.3	1.86e-8	Height;
CRC	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg11887960	chr12:57824829	NA	0.59	6.57	0.34	2e-10	Obesity-related traits;
CRC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	1.1	11.18	0.52	8.1e-25	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23739036	chr1:2343736	PEX10	0.44	6.23	0.32	1.43e-9	Response to antipsychotic treatment;
CRC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.53	-9.02	-0.45	1.65e-17	Iron status biomarkers;
CRC	cis	rs4964805	0.559	rs1469999	chr12:104208111	A/G	cg02344784	chr12:104178138	NT5DC3	-0.48	-6.66	-0.34	1.12e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg11693508	chr17:37793320	STARD3	-0.63	-7.62	-0.39	2.69e-13	Bipolar disorder;
CRC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.6	10.94	0.52	5.87e-24	Aortic root size;
CRC	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg24531977	chr5:56204891	C5orf35	-0.48	-7.36	-0.38	1.45e-12	Coronary artery disease;
CRC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.46	7.26	0.37	2.86e-12	Testicular germ cell tumor;
CRC	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg20312557	chr2:97357134	FER1L5	-0.61	-5.68	-0.3	2.93e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.86	11.87	0.55	2.82e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.67	0.39	1.98e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs834811	0.602	rs7779031	chr7:135889681	A/G	cg01726295	chr7:135938950	NA	-0.35	-6.08	-0.32	3.24e-9	Post-traumatic stress disorder;
CRC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg08772003	chr10:104629869	AS3MT	-0.38	-6.47	-0.34	3.57e-10	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.77	0.3	1.86e-8	Prudent dietary pattern;
CRC	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg23141183	chr17:80185318	SLC16A3	0.42	5.88	0.31	1.01e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs10863936	0.558	rs7522330	chr1:212234104	A/T	cg03890664	chr19:10613492	KEAP1	-0.43	-6.0	-0.31	5.1e-9	Height;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27383975	chr19:17356182	NR2F6	0.56	6.32	0.33	8.4e-10	Interleukin-4 levels;
CRC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.54	-8.24	-0.41	4.04e-15	Coronary artery disease;
CRC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs4942783	0.647	rs9590972	chr13:31583488	A/G	cg22761482	chr13:31579400	NA	-0.33	-5.77	-0.3	1.83e-8	Subjective well-being;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg20041105	chr8:143859282	LYNX1	-0.41	-6.78	-0.35	5.61e-11	Urinary tract infection frequency;
CRC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.1e-9	Obesity-related traits;
CRC	cis	rs77861329	0.748	rs735768	chr3:52174970	A/C	cg08692210	chr3:52188851	WDR51A	0.5	5.98	0.31	5.82e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg26666090	chr16:58549219	SETD6	0.94	6.49	0.34	3.19e-10	Schizophrenia;
CRC	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.7	-0.39	1.59e-13	HDL cholesterol;
CRC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg21523564	chr15:75251491	NA	0.42	6.12	0.32	2.65e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.63	11.63	0.54	1.96e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	7.52	0.38	5.19e-13	Hemoglobin concentration;
CRC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24308560	chr3:49941425	MST1R	-0.45	-7.12	-0.37	6.61e-12	Intelligence (multi-trait analysis);
CRC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.93	-0.36	2.23e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs997295	0.570	rs17241808	chr15:67892792	A/G	cg24247231	chr15:67904302	MAP2K5	-0.33	-5.8	-0.3	1.52e-8	Motion sickness;
CRC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.76	13.5	0.6	2.46e-33	Metabolite levels;
CRC	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.45	-6.16	-0.32	2.09e-9	HDL cholesterol;
CRC	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg22134325	chr11:66188745	NPAS4	0.37	6.28	0.33	1.1e-9	Airway imaging phenotypes;
CRC	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg04586622	chr2:25135609	ADCY3	-0.35	-6.04	-0.32	4.15e-9	Body mass index in non-asthmatics;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22583711	chr7:154795321	PAXIP1;LOC202781	0.43	7.0	0.36	1.42e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg02683197	chr6:28174875	NA	0.88	10.83	0.51	1.42e-23	Depression;
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg10729496	chr3:10149963	C3orf24	0.5	6.6	0.34	1.61e-10	Alzheimer's disease;
CRC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg09655341	chr17:79618100	PDE6G	-0.35	-5.94	-0.31	7.05e-9	Eye color traits;
CRC	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.41	7.48	0.38	7.01e-13	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg24562669	chr7:97807699	LMTK2	0.45	7.43	0.38	9.75e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.63	-10.31	-0.49	8.81e-22	Monocyte count;
CRC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.73	-12.76	-0.58	1.48e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg11611856	chr9:139973337	UAP1L1	-0.51	-8.05	-0.41	1.53e-14	Cerebrospinal fluid biomarker levels;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg04919811	chr17:78870302	RPTOR	-0.45	-6.3	-0.33	9.66e-10	Lung cancer;
CRC	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	1.01	12.84	0.58	7.03e-31	IgG glycosylation;
CRC	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.43	6.26	0.33	1.22e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1790761	0.967	rs7131041	chr11:67230184	A/T	cg17375396	chr11:67202808	RPS6KB2	0.33	5.78	0.3	1.78e-8	Mean corpuscular volume;
CRC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.33e-9	Heart rate;
CRC	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg00105475	chr2:10696890	NA	0.45	7.29	0.37	2.26e-12	Prostate cancer;
CRC	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg08462924	chr1:41848221	NA	0.4	6.19	0.32	1.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.66	9.42	0.46	8.3e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.24	0.45	3.13e-18	Iron status biomarkers;
CRC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.59	8.09	0.41	1.16e-14	Lung cancer;
CRC	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.67	9.14	0.45	6.7e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.45	-8.23	-0.41	4.4e-15	Bipolar disorder and schizophrenia;
CRC	trans	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg10756647	chr7:56101905	PSPH	-0.78	-8.02	-0.4	1.83e-14	Diabetic kidney disease;
CRC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg07195577	chr17:27052828	TLCD1	0.41	5.91	0.31	8.45e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.44	-7.89	-0.4	4.6e-14	Reticulocyte fraction of red cells;
CRC	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.75	10.59	0.5	9.64e-23	Heart rate;
CRC	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg15145296	chr3:125709740	NA	-0.56	-6.49	-0.34	3.08e-10	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.69	0.35	9.6e-11	Lung cancer;
CRC	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-8.9	-0.44	3.82e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.57	-9.66	-0.47	1.38e-19	Body mass index;
CRC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg13057898	chr1:3703894	LRRC47	0.53	6.96	0.36	1.82e-11	Red cell distribution width;
CRC	cis	rs12476592	0.602	rs10168545	chr2:63734284	C/A	cg10828910	chr2:63850056	LOC388955	0.48	5.97	0.31	6.27e-9	Childhood ear infection;
CRC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.51	-9.73	-0.47	7.89e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.5	-6.25	-0.33	1.31e-9	Recombination rate (females);
CRC	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.92	0.31	7.99e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.67	-9.08	-0.45	1.03e-17	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs55788414	0.932	rs12103303	chr16:81181497	A/G	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.7	-0.35	9.27e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs1867631	0.585	rs4655639	chr1:67089090	T/C	cg02459107	chr1:67143332	SGIP1	0.34	6.17	0.32	1.96e-9	Menopause (age at onset);
CRC	cis	rs12745968	0.653	rs6660136	chr1:93165207	T/A	cg17283838	chr1:93427260	FAM69A	-0.43	-5.85	-0.31	1.17e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.39	5.95	0.31	6.8e-9	Endometrial cancer;
CRC	cis	rs10751667	0.557	rs12281858	chr11:1022187	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	8.77	0.44	9.87e-17	Alzheimer's disease (late onset);
CRC	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	1.01	12.62	0.57	4.62e-30	IgG glycosylation;
CRC	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.44	-6.52	-0.34	2.6e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.76	-0.35	6.25e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.38	-5.74	-0.3	2.11e-8	Platelet count;
CRC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.66	9.36	0.46	1.27e-18	Lung cancer;
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.74e-12	Urinary tract infection frequency;
CRC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.11	-12.34	-0.56	5.34e-29	Diabetic kidney disease;
CRC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg16141378	chr3:129829833	LOC729375	0.42	6.32	0.33	8.75e-10	Neuroticism;
CRC	cis	rs6761276	0.635	rs4849150	chr2:113830582	A/C	cg24553058	chr2:113831203	IL1F10	0.42	6.6	0.34	1.6e-10	Protein quantitative trait loci;
CRC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.68	-10.19	-0.49	2.29e-21	Corneal astigmatism;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg27532560	chr4:187881888	NA	-0.54	-9.58	-0.47	2.44e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.57	-9.37	-0.46	1.17e-18	Body mass index;
CRC	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.53	-0.38	4.9e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.67	-6.76	-0.35	6.2e-11	Verbal memory performance (residualized delayed recall change);
CRC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.62	10.03	0.48	7.58e-21	Aortic root size;
CRC	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg09307838	chr4:120376055	NA	0.64	9.48	0.46	5.15e-19	Educational attainment;
CRC	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg10494257	chr1:16342123	HSPB7	0.45	6.33	0.33	7.97e-10	Dilated cardiomyopathy;
CRC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-6.27	-0.33	1.16e-9	Daytime sleep phenotypes;
CRC	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00801512	chr17:28996047	NA	0.47	5.99	0.31	5.41e-9	Hip circumference adjusted for BMI;
CRC	cis	rs11212617	0.902	rs599406	chr11:108118234	T/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.34	0.33	7.78e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.55	6.69	0.35	9.76e-11	Cannabis dependence symptom count;
CRC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.01	0.31	4.79e-9	Morning vs. evening chronotype;
CRC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.6	-0.34	1.68e-10	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13421935	chr4:153700886	ARFIP1;TIGD4	0.44	5.99	0.31	5.35e-9	Anxiety disorder;
CRC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg05562828	chr17:3906858	NA	0.69	12.44	0.57	2.25e-29	Type 2 diabetes;
CRC	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.74	7.5	0.38	5.81e-13	Blood protein levels;
CRC	cis	rs145308728	1	rs145308728	chr15:91000156	GTA/G	cg04176472	chr15:90893244	GABARAPL3	0.56	7.84	0.4	6.34e-14	Lymphocyte percentage of white cells;
CRC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.05	-0.41	1.5e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7517126	1.000	rs56300393	chr1:196841394	G/A	cg13682187	chr1:196946512	CFHR5	-0.37	-5.97	-0.31	6.03e-9	Blood protein levels;
CRC	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.67	8.55	0.43	4.82e-16	Iron status biomarkers;
CRC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.87	0.48	2.78e-20	Ileal carcinoids;
CRC	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-6.96	-0.36	1.82e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.61	-9.55	-0.47	3.17e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.92	-19.06	-0.72	4.49e-55	Urate levels in lean individuals;
CRC	trans	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg02869306	chr7:64672164	INTS4L1	0.43	6.09	0.32	3.19e-9	Aortic root size;
CRC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00339695	chr16:24857497	SLC5A11	0.26	6.01	0.31	5.01e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22686022	chr17:61851232	DDX42;CCDC47	0.44	6.27	0.33	1.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3789045	0.774	rs11801299	chr1:204529084	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.55	-7.75	-0.39	1.16e-13	Educational attainment (college completion);
CRC	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg05585544	chr11:47624801	NA	0.48	8.42	0.42	1.19e-15	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20032723	chr11:126174041	DCPS	0.48	6.82	0.35	4.42e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15929228	chr2:240323491	HDAC4	0.41	6.72	0.35	8.04e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.65	7.13	0.37	6.53e-12	Axial length;
CRC	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg09659197	chr4:152720779	NA	0.39	7.68	0.39	1.82e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.64	9.54	0.47	3.23e-19	Blood protein levels;
CRC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.51	-0.34	2.77e-10	Lung cancer;
CRC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	9.88	0.48	2.57e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.65	9.54	0.47	3.3e-19	Menopause (age at onset);
CRC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17507749	chr15:85114479	UBE2QP1	0.62	8.83	0.44	6.36e-17	Schizophrenia;
CRC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg13390004	chr1:15929781	NA	0.53	7.26	0.37	2.78e-12	Systolic blood pressure;
CRC	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.74	-8.24	-0.41	4.27e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.51	8.62	0.43	2.86e-16	Dupuytren's disease;
CRC	trans	rs11825064	1.000	rs11825064	chr11:134477854	G/C	cg00033773	chr19:12779366	MORG1;C19orf56	0.53	6.01	0.31	5.02e-9	Seasonality;
CRC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.48	6.49	0.34	3.23e-10	Schizophrenia;
CRC	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs642858	1.000	rs6933684	chr6:140300384	C/T	cg27524944	chr6:140295369	NA	0.36	6.01	0.31	5.06e-9	Type 2 diabetes;
CRC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.91	8.64	0.43	2.46e-16	Type 2 diabetes;
CRC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.5	7.48	0.38	6.67e-13	Corneal astigmatism;
CRC	cis	rs6764363	0.616	rs9814099	chr3:286206	A/G	cg02057681	chr3:285234	CHL1	-0.41	-6.04	-0.32	4.2e-9	Sudden cardiac arrest;
CRC	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg27223183	chr8:87520930	FAM82B	-0.44	-5.67	-0.3	3.17e-8	Caudate activity during reward;
CRC	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.63	-8.35	-0.42	1.88e-15	Facial morphology (factor 19);
CRC	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.65	8.51	0.42	6.25e-16	Uric acid levels;
CRC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	15.64	0.65	1.34e-41	Bipolar disorder;
CRC	cis	rs4664293	0.836	rs13397597	chr2:160603595	A/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.76	12.57	0.57	7.19e-30	Height;
CRC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg05304507	chr6:116381966	FRK	0.32	8.87	0.44	4.84e-17	Cholesterol, total;LDL cholesterol;
CRC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.46	0.5	2.69e-22	Heart rate;
CRC	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.43	6.38	0.33	6.07e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg11781535	chr10:38893821	NA	-0.53	-6.26	-0.33	1.2e-9	Optic disc area;
CRC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.46	6.71	0.35	8.35e-11	Aortic root size;
CRC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	8.88	0.44	4.54e-17	Height;
CRC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.4	-5.71	-0.3	2.59e-8	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.82e-9	Height;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg03623178	chr6:28175578	NA	0.79	11.83	0.55	3.95e-27	Cardiac Troponin-T levels;
CRC	cis	rs7680126	0.596	rs11731652	chr4:10292984	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.48	-0.34	3.28e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17309711	chr11:45826527	SLC35C1	0.53	7.61	0.39	3.01e-13	Response to antipsychotic treatment;
CRC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg16358738	chr2:241808595	AGXT	-0.39	-5.93	-0.31	7.46e-9	Urinary metabolites;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg02683197	chr6:28174875	NA	0.82	11.17	0.52	8.77e-25	Depression;
CRC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.61	9.54	0.47	3.42e-19	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.92	14.69	0.63	6.51e-38	Menarche (age at onset);
CRC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.72	-11.8	-0.55	4.72e-27	Breast cancer;
CRC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.59	0.63	1.51e-37	Chronic sinus infection;
CRC	cis	rs10760158	0.832	rs10760164	chr9:124011162	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	trans	rs12432203	1.000	rs72622439	chr14:51736948	C/A	cg14592830	chr9:122318704	NA	0.58	6.0	0.31	5.07e-9	Cancer;
CRC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg13043300	chr11:71146211	DHCR7	-0.46	-6.2	-0.32	1.73e-9	Vitamin D levels;
CRC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.5	7.1	0.36	7.85e-12	Schizophrenia;
CRC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25466368	chr3:193853978	HES1	0.46	6.98	0.36	1.59e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Parkinson's disease;
CRC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg19635926	chr16:89946313	TCF25	0.57	5.96	0.31	6.58e-9	Skin colour saturation;
CRC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.62	7.12	0.37	6.85e-12	Vitiligo;
CRC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg02766259	chr12:125626809	AACS	0.41	7.83	0.4	6.74e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.64	8.13	0.41	8.69e-15	Arsenic metabolism;
CRC	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.4	5.86	0.31	1.12e-8	Platelet distribution width;
CRC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.48	-8.24	-0.41	4.08e-15	Hypertriglyceridemia;
CRC	trans	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg18335740	chr13:41363409	SLC25A15	0.63	10.04	0.48	7.43e-21	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22557350	chr10:126432983	FAM53B	0.43	6.18	0.32	1.93e-9	Response to antipsychotic treatment;
CRC	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.66	-10.63	-0.51	6.8e-23	Total cholesterol levels;
CRC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg23587288	chr2:27483067	SLC30A3	-0.44	-6.54	-0.34	2.36e-10	Blood metabolite levels;
CRC	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg07699608	chr10:75541558	CHCHD1	0.58	5.82	0.31	1.41e-8	Incident atrial fibrillation;
CRC	cis	rs7692995	1.000	rs7696532	chr4:18029299	C/T	cg08925142	chr4:18023851	LCORL	-0.53	-5.98	-0.31	5.94e-9	Height;
CRC	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg09455208	chr3:40491958	NA	0.29	5.62	0.3	4.14e-8	Renal cell carcinoma;
CRC	cis	rs995000	0.895	rs783291	chr1:62914978	G/A	cg19896129	chr1:63156450	NA	0.43	6.59	0.34	1.75e-10	Triglyceride levels;
CRC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg12935359	chr14:103987150	CKB	-0.39	-6.44	-0.33	4.13e-10	Body mass index;
CRC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg11062466	chr8:58055876	NA	0.49	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.37	5.66	0.3	3.34e-8	Height;
CRC	cis	rs72627123	0.656	rs6574169	chr14:74637178	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.72	-5.67	-0.3	3.06e-8	Morning vs. evening chronotype;
CRC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.25	0.53	4.54e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17114402	chr2:97778470	ANKRD36	0.47	7.34	0.38	1.66e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.69	-9.34	-0.46	1.55e-18	Platelet count;
CRC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.58	-9.24	-0.45	3.18e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.95	-0.52	5.26e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.53	8.36	0.42	1.76e-15	Height;
CRC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.81	-0.44	7.5e-17	Personality dimensions;
CRC	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-6.82	-0.35	4.44e-11	Dental caries;
CRC	cis	rs995000	0.839	rs1168028	chr1:62969431	G/A	cg19896129	chr1:63156450	NA	-0.39	-6.08	-0.32	3.29e-9	Triglyceride levels;
CRC	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg27205649	chr11:78285834	NARS2	0.48	6.06	0.32	3.81e-9	Alzheimer's disease (survival time);
CRC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg24308560	chr3:49941425	MST1R	-0.42	-5.93	-0.31	7.5e-9	Resting heart rate;
CRC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-6.34	-0.33	7.58e-10	Menarche (age at onset);
CRC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.42	0.38	9.93e-13	Menopause (age at onset);
CRC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.81	-0.35	4.76e-11	IgG glycosylation;
CRC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.37	5.8	0.3	1.58e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4547160	1.000	rs4547160	chr12:63503650	A/C	cg26727693	chr12:63544175	AVPR1A	0.41	8.22	0.41	4.7e-15	Morning vs. evening chronotype;
CRC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.52	-9.42	-0.46	8.25e-19	Longevity;
CRC	cis	rs17152411	0.895	rs11245418	chr10:126586319	T/C	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.44	-9.1	-0.45	8.59e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
CRC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.44	5.88	0.31	9.91e-9	Schizophrenia;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg12172441	chr6:28176163	NA	0.54	7.31	0.37	2.06e-12	Cardiac Troponin-T levels;
CRC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	8.03	0.4	1.78e-14	Aortic root size;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.7	-11.27	-0.53	3.81e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.58	7.15	0.37	5.76e-12	Carotid intima media thickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15959262	chr8:102381107	NACAP1	-0.38	-6.06	-0.32	3.76e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01392097	chr7:101331643	NA	0.49	6.97	0.36	1.72e-11	Response to antipsychotic treatment;
CRC	cis	rs10982256	0.567	rs1000709	chr9:117237754	C/T	cg13636371	chr9:117264095	DFNB31	0.32	6.16	0.32	2.13e-9	Bipolar disorder;
CRC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.64	-17.36	-0.69	2.23e-48	Urate levels in overweight individuals;
CRC	cis	rs4688759	0.764	rs11716961	chr3:49908338	G/A	cg00383909	chr3:49044727	WDR6	1.38	10.23	0.49	1.67e-21	Blood protein levels;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11215015	chr1:197116161	ASPM	-0.6	-7.68	-0.39	1.89e-13	Monocyte percentage of white cells;
CRC	trans	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg19894588	chr14:64061835	NA	-0.58	-7.8	-0.4	8.15e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg19223190	chr17:80058835	NA	0.43	6.82	0.35	4.37e-11	Life satisfaction;
CRC	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.82	-0.55	3.98e-27	Exhaled nitric oxide output;
CRC	cis	rs4237845	0.611	rs7978588	chr12:58304783	G/C	cg02175503	chr12:58329896	NA	0.79	12.45	0.57	2.12e-29	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.47	7.42	0.38	1.02e-12	Eye color traits;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg04981696	chr16:16044519	ABCC1	-0.46	-6.63	-0.34	1.34e-10	Birth weight;Height;
CRC	cis	rs7781266	0.947	rs2542264	chr7:133480664	C/T	cg03336402	chr7:133662267	EXOC4	-0.55	-7.15	-0.37	5.66e-12	Educational attainment (college completion);
CRC	trans	rs1584120	0.830	rs7315662	chr12:23514531	T/C	cg15904523	chr19:44763979	ZNF233	-0.42	-5.98	-0.31	5.84e-9	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg21153622	chr11:89784906	NA	0.46	7.39	0.38	1.26e-12	HDL cholesterol;
CRC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg10494257	chr1:16342123	HSPB7	0.45	6.0	0.31	5.3e-9	Dilated cardiomyopathy;
CRC	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg26165608	chr6:5261829	LYRM4;FARS2	-0.45	-5.66	-0.3	3.23e-8	Height;
CRC	cis	rs2398893	0.889	rs7870790	chr9:96779553	G/A	cg14459158	chr9:96720562	NA	0.42	6.82	0.35	4.47e-11	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg26043149	chr18:55253948	FECH	0.53	8.03	0.4	1.78e-14	Bone mineral density;
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg02033258	chr5:131593261	PDLIM4	0.34	6.32	0.33	8.36e-10	Blood metabolite levels;
CRC	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg17470449	chr10:769945	NA	-0.44	-6.33	-0.33	7.84e-10	Uric acid levels;
CRC	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.75	-10.04	-0.48	7.2e-21	White matter hyperintensity burden;
CRC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.85	-12.44	-0.57	2.23e-29	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg14847009	chr1:175162515	KIAA0040	-0.26	-5.68	-0.3	2.89e-8	Alcohol dependence;
CRC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg27083787	chr2:113543245	IL1A	0.45	6.47	0.34	3.5e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.53	0.65	3.62e-41	Fuchs's corneal dystrophy;
CRC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.61	-9.83	-0.48	3.71e-20	Aortic root size;
CRC	cis	rs1950626	0.699	rs12880424	chr14:101459660	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	15.9	0.66	1.28e-42	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4970966	0.951	rs6665912	chr1:150544093	T/C	cg17724175	chr1:150552817	MCL1	-0.48	-5.87	-0.31	1.08e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg22532475	chr10:104410764	TRIM8	0.32	5.66	0.3	3.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.37	0.38	1.43e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.93	17.78	0.7	4.82e-50	Height;
CRC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.67	-0.39	1.98e-13	Alzheimer's disease;
CRC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.7	9.8	0.48	4.69e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg05935833	chr10:81318306	SFTPA2	-0.49	-5.85	-0.31	1.21e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.34	0.46	1.46e-18	Height;
CRC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.55	8.19	0.41	5.68e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg21153622	chr11:89784906	NA	-0.5	-8.42	-0.42	1.19e-15	HDL cholesterol;
CRC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.4e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg01483505	chr11:975446	AP2A2	0.45	7.28	0.37	2.52e-12	Alzheimer's disease (late onset);
CRC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg08075719	chr14:103021372	NA	-0.68	-7.93	-0.4	3.47e-14	Platelet count;
CRC	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg00738113	chr16:70207722	CLEC18C	0.47	8.1	0.41	1.11e-14	Sjögren's syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27662123	chr14:100842884	WARS;WDR25	0.45	6.43	0.33	4.44e-10	Anxiety disorder;
CRC	cis	rs2274273	0.648	rs58553156	chr14:55582694	T/A	cg10130446	chr14:55658398	DLGAP5	-0.44	-6.16	-0.32	2.09e-9	Protein biomarker;
CRC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.61	8.62	0.43	2.96e-16	Obesity-related traits;
CRC	cis	rs10924970	0.967	rs4659678	chr1:235396697	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg00603274	chr11:61596626	FADS2	-0.47	-6.59	-0.34	1.72e-10	Bipolar disorder;
CRC	cis	rs9463078	0.845	rs9369514	chr6:44797271	C/A	cg25276700	chr6:44698697	NA	-0.25	-6.08	-0.32	3.4e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs526821	0.595	rs517627	chr11:55356489	C/T	cg04317927	chr11:55418816	OR4S2	0.4	6.85	0.35	3.57e-11	Pediatric bone mineral density (spine);
CRC	cis	rs902774	0.818	rs17120257	chr12:53303331	T/C	cg16329197	chr12:53359506	NA	-0.54	-5.77	-0.3	1.8e-8	Prostate cancer;
CRC	trans	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	cis	rs10486722	0.603	rs10279802	chr7:41774169	G/A	cg22138096	chr7:41772439	LOC285954	0.38	5.8	0.3	1.54e-8	Pit-and-Fissure caries;
CRC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	0.91	17.41	0.69	1.38e-48	Bone mineral density;
CRC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg25456477	chr12:86230367	RASSF9	0.34	5.81	0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg16416165	chr4:3325029	RGS12	0.39	5.77	0.3	1.85e-8	Serum sulfate level;
CRC	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.49	-5.94	-0.31	7.24e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.4	6.65	0.34	1.21e-10	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00287636	chr16:49892218	NA	-0.38	-6.7	-0.35	9.32e-11	Myopia (pathological);
CRC	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18779060	chr21:38740667	DYRK1A	-0.48	-6.02	-0.31	4.7e-9	Intelligence (multi-trait analysis);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00267196	chr8:135710113	ZFAT	0.44	6.49	0.34	3.07e-10	Interleukin-6 levels;
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg18301423	chr5:131593218	PDLIM4	0.37	6.14	0.32	2.36e-9	Breast cancer;
CRC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.22	0.32	1.52e-9	Hemoglobin concentration;
CRC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.51	-7.16	-0.37	5.23e-12	Eosinophil percentage of white cells;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11611950	chr6:24667276	ACOT13;TTRAP	0.37	6.16	0.32	2.16e-9	Obesity-related traits;
CRC	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.12	-8.94	-0.44	2.92e-17	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
CRC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.7	9.89	0.48	2.25e-20	Multiple sclerosis;
CRC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.83	-9.99	-0.48	1.05e-20	Bronchopulmonary dysplasia;
CRC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.61	8.08	0.41	1.22e-14	Orofacial clefts;
CRC	cis	rs7173389	0.551	rs11638230	chr15:73656261	G/A	cg01796676	chr15:73680284	NA	0.62	5.9	0.31	8.94e-9	Resting heart rate;
CRC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.76	0.35	6.34e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	1.0	18.55	0.71	4.56e-53	Gut microbiome composition (winter);
CRC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.56	-0.34	2.06e-10	Total body bone mineral density;
CRC	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg15282417	chr9:129245246	FAM125B	0.44	8.09	0.41	1.18e-14	Intraocular pressure;
CRC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-6.34	-0.33	7.51e-10	Schizophrenia;
CRC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.58	8.46	0.42	8.96e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.63	-0.34	1.39e-10	Eye color traits;
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg02033258	chr5:131593261	PDLIM4	0.4	7.69	0.39	1.69e-13	Breast cancer;
CRC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-8.05	-0.41	1.48e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.43	6.77	0.35	5.89e-11	High light scatter reticulocyte count;
CRC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg05192639	chr6:26864778	GUSBL1	0.33	5.9	0.31	8.99e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6968419	0.585	rs10953816	chr7:115918527	A/G	cg19719915	chr7:115928094	NA	0.4	6.58	0.34	1.84e-10	Intraocular pressure;
CRC	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.17	0.41	6.49e-15	Type 2 diabetes;
CRC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.7	0.47	1.02e-19	Cognitive test performance;
CRC	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.34	-7.83	-0.4	6.66e-14	Corneal astigmatism;
CRC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.88	-0.35	2.95e-11	Response to antipsychotic treatment;
CRC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.69	-10.73	-0.51	3.19e-23	Blood protein levels;
CRC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg17687789	chr3:40543613	NA	0.3	5.62	0.3	4.15e-8	Renal cell carcinoma;
CRC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg16892393	chr17:41919603	NA	0.4	6.04	0.32	4.08e-9	Triglycerides;
CRC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg13057898	chr1:3703894	LRRC47	0.53	6.99	0.36	1.53e-11	Red cell distribution width;
CRC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-7.29	-0.37	2.25e-12	Monocyte percentage of white cells;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24543526	chr10:75911479	ADK;AP3M1	0.42	6.32	0.33	8.67e-10	Schizophrenia;
CRC	cis	rs9826463	0.757	rs73240316	chr3:142266061	A/G	cg20824294	chr3:142316082	PLS1	0.42	7.06	0.36	1.01e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27209983	chr11:124824125	CCDC15	0.43	6.03	0.32	4.43e-9	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg27068330	chr11:65405492	SIPA1	0.44	6.55	0.34	2.26e-10	Acne (severe);
CRC	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.75	-7.82	-0.4	7.28e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.07	0.41	1.34e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26850624	chr5:429559	AHRR	0.52	8.8	0.44	8.1e-17	Cystic fibrosis severity;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg15790184	chr11:494944	RNH1	0.67	6.63	0.34	1.34e-10	Body mass index;
CRC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.65	-11.18	-0.52	8.29e-25	Dental caries;
CRC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.45	7.27	0.37	2.67e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg07424746	chr4:185654737	MLF1IP	0.54	5.7	0.3	2.74e-8	Blood protein levels;
CRC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.56	-0.43	4.45e-16	Aortic root size;
CRC	cis	rs55788414	0.932	rs28583467	chr16:81186428	G/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.04	-0.36	1.11e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs6585424	1.000	rs11201966	chr10:81931780	T/C	cg11900509	chr10:81946545	ANXA11	-0.72	-8.84	-0.44	5.72e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.44	6.18	0.32	1.89e-9	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22112460	chr1:32688107	C1orf91;EIF3I	0.46	6.54	0.34	2.32e-10	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-6.0	-0.31	5.34e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02220365	chr11:67211717	CORO1B	0.37	6.31	0.33	8.82e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs6600671	1.000	rs12047116	chr1:121185770	G/A	cg00646200	chr1:148855367	NA	0.34	6.2	0.32	1.72e-9	Hip geometry;
CRC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.67	10.48	0.5	2.21e-22	Facial morphology (factor 23);
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.96	-0.31	6.33e-9	Obesity-related traits;
CRC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12463550	chr7:65579703	CRCP	0.68	6.17	0.32	2.02e-9	Diabetic kidney disease;
CRC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.45	-8.37	-0.42	1.65e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.51e-17	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23740310	chr12:12878752	APOLD1	0.45	6.12	0.32	2.6e-9	Response to antipsychotic treatment;
CRC	cis	rs35740288	0.862	rs11637444	chr15:86311188	G/A	cg20737812	chr15:86336631	KLHL25	-0.36	-5.61	-0.3	4.28e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00371891	chr19:4723959	DPP9	0.45	6.29	0.33	1.03e-9	Response to antipsychotic treatment;
CRC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.28	0.46	2.35e-18	Height;
CRC	cis	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg00086871	chr4:6988644	TBC1D14	1.0	6.66	0.34	1.14e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.73	0.39	1.29e-13	Aortic root size;
CRC	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg14593290	chr7:50529359	DDC	0.64	8.47	0.42	8.37e-16	Malaria;
CRC	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	1.04	18.34	0.71	3.05e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.75	-0.39	1.17e-13	Total body bone mineral density;
CRC	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.42	-5.95	-0.31	6.96e-9	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07325233	chr21:34638662	IL10RB	0.37	6.0	0.31	5.24e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs294883	0.739	rs962337	chr6:159729404	T/A	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.6	-0.47	2.19e-19	Neuroticism;
CRC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-7.86	-0.4	5.48e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-8.2	-0.41	5.52e-15	Blood pressure (smoking interaction);
CRC	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.52	8.18	0.41	6.17e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21643547	chr1:205240462	TMCC2	0.45	7.63	0.39	2.54e-13	Platelet count;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg03790207	chr6:42947109	PEX6	-0.52	-7.68	-0.39	1.82e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20140052	chr17:79367844	NA	0.39	5.98	0.31	5.7e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04349673	chr14:36278568	RALGAPA1	0.45	6.03	0.32	4.38e-9	Response to antipsychotic treatment;
CRC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.82	0.55	4.16e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.79	0.35	5.23e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg06581033	chr10:766294	NA	-0.5	-5.76	-0.3	1.93e-8	Uric acid levels;
CRC	cis	rs1656402	0.953	rs1190446	chr2:233420683	G/C	cg03852847	chr2:233439513	NA	0.43	7.06	0.36	9.92e-12	Non-small cell lung cancer (survival);
CRC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.66e-17	Prostate cancer;
CRC	trans	rs2303319	0.504	rs72873603	chr2:162469665	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.25	-0.37	3.06e-12	Aortic root size;
CRC	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	5.63	0.3	3.93e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.45	-6.99	-0.36	1.57e-11	Height;
CRC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.75	12.16	0.56	2.32e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.3	-0.33	9.47e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9925964	0.804	rs9926533	chr16:31014179	C/T	cg03418659	chr16:31128414	MYST1	0.42	6.22	0.32	1.54e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs365302	0.672	rs396364	chr6:159611151	C/T	cg14500486	chr6:159655392	FNDC1	0.6	8.59	0.43	3.42e-16	Coronary heart disease;
CRC	cis	rs863345	0.604	rs2317969	chr1:158491753	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.97	-17.97	-0.7	8.88e-51	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg05139728	chr16:28306816	SBK1	-0.37	-5.98	-0.31	5.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg05527609	chr1:210001259	C1orf107	-0.5	-5.63	-0.3	3.78e-8	Red blood cell count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20181420	chr10:60028918	CISD1;IPMK	0.41	6.75	0.35	6.81e-11	Obesity-related traits;
CRC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs3736485	0.934	rs28695624	chr15:51874928	A/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg13092806	chr2:177043255	NA	0.66	9.37	0.46	1.18e-18	IgG glycosylation;
CRC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.52	-9.42	-0.46	8.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	1.05	21.87	0.77	4.22e-66	Multiple myeloma;
CRC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.79	-0.35	5.09e-11	Response to antipsychotic treatment;
CRC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	5.69	0.3	2.81e-8	Schizophrenia;
CRC	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.58	-8.84	-0.44	5.99e-17	Lewy body disease;
CRC	cis	rs9549328	0.670	rs35992827	chr13:113616752	G/A	cg08614441	chr13:113633676	MCF2L	0.37	6.59	0.34	1.76e-10	Systolic blood pressure;
CRC	cis	rs11997175	0.653	rs7817167	chr8:33633088	A/C	ch.8.33884649F	chr8:33765107	NA	0.42	6.48	0.34	3.37e-10	Body mass index;
CRC	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg25382214	chr1:3105252	PRDM16	0.42	7.32	0.37	1.9e-12	Migraine;
CRC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	1.04	13.15	0.59	5.14e-32	Orofacial clefts;
CRC	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	11.64	0.54	1.89e-26	Height;
CRC	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.57	-0.34	1.97e-10	Monocyte count;
CRC	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg16482183	chr6:26056742	HIST1H1C	0.73	9.21	0.45	3.97e-18	Iron status biomarkers;
CRC	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.58	-0.34	1.83e-10	Eye color traits;
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.46	6.38	0.33	6.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.55	9.16	0.45	5.74e-18	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.44	6.41	0.33	5.12e-10	Waist circumference;Hip circumference;
CRC	cis	rs7091068	0.566	rs1326220	chr10:95486155	G/A	cg20715218	chr10:95462985	C10orf4	0.54	5.71	0.3	2.57e-8	Urinary tract infection frequency;
CRC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.46	-6.56	-0.34	2.06e-10	Schizophrenia;
CRC	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg15704280	chr7:45808275	SEPT13	0.61	6.18	0.32	1.93e-9	Intraocular pressure;
CRC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.34	0.38	1.7e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23629415	chr14:54955474	GMFB	0.54	7.22	0.37	3.55e-12	Thyroid stimulating hormone;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg19041857	chr6:27730383	NA	-0.48	-6.05	-0.32	3.9e-9	Breast cancer;
CRC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	0.99	14.56	0.63	2.05e-37	Breast cancer;
CRC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.9	-0.4	4.09e-14	Cystic fibrosis severity;
CRC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg21854759	chr1:92012499	NA	-0.49	-7.56	-0.38	3.92e-13	Breast cancer;
CRC	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.57	-0.34	1.93e-10	Acne (severe);
CRC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.51	8.8	0.44	8.15e-17	Aortic root size;
CRC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.61	10.77	0.51	2.3e-23	Bone mineral density;
CRC	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.46	-0.38	7.65e-13	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.24	0.53	5.2e-25	Prudent dietary pattern;
CRC	cis	rs7932354	0.583	rs7480140	chr11:46856335	A/G	cg19486271	chr11:47235900	DDB2	-0.43	-6.55	-0.34	2.25e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7725052	0.561	rs6890667	chr5:40457232	T/A	cg09067459	chr5:40385259	NA	-0.4	-6.15	-0.32	2.19e-9	Pediatric autoimmune diseases;
CRC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg16797656	chr11:68205561	LRP5	0.36	5.75	0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg23461800	chr14:103021989	NA	0.56	6.7	0.35	9.17e-11	Platelet count;
CRC	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg05044414	chr3:183734942	ABCC5	0.43	7.52	0.38	5.38e-13	Anterior chamber depth;
CRC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg27427491	chr17:78079615	GAA	0.45	5.86	0.31	1.12e-8	Yeast infection;
CRC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.11	-12.26	-0.56	1.04e-28	Diabetic kidney disease;
CRC	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg14191688	chr11:70257035	CTTN	0.4	5.66	0.3	3.29e-8	Coronary artery disease;
CRC	cis	rs7725052	0.609	rs10941508	chr5:40459067	A/G	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.45	-6.77	-0.35	6e-11	Cerebrospinal P-tau181p levels;
CRC	trans	rs7142881	0.508	rs4981871	chr14:32118636	T/C	cg10453823	chr2:190539512	ANKAR	-0.4	-5.99	-0.31	5.65e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs9463078	0.546	rs6458418	chr6:45014997	G/A	cg25276700	chr6:44698697	NA	0.24	5.65	0.3	3.54e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.8	-10.65	-0.51	6.01e-23	Initial pursuit acceleration;
CRC	cis	rs8105895	0.935	rs62111030	chr19:22279375	C/A	cg02912127	chr19:22235281	ZNF257	-0.41	-5.71	-0.3	2.54e-8	Body mass index (change over time);
CRC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs447	0.806	rs929334	chr7:83744373	T/C	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.76	-0.3	1.95e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs35520189	0.591	rs6722962	chr2:113701383	T/G	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs2635047	0.542	rs2684853	chr18:44793532	G/A	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.84	-0.31	1.28e-8	Educational attainment;
CRC	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg00531865	chr16:30841666	NA	0.49	7.0	0.36	1.48e-11	Dementia with Lewy bodies;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01593421	chr7:65303149	NA	-0.41	-6.71	-0.35	8.6e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10242455	0.702	rs28668326	chr7:98998153	G/A	cg18809830	chr7:99032528	PTCD1	-1.12	-8.16	-0.41	7.01e-15	Blood metabolite levels;
CRC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg00677455	chr12:58241039	CTDSP2	-0.47	-6.79	-0.35	5.12e-11	Multiple sclerosis;
CRC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs6546324	0.625	rs6717863	chr2:67844799	C/A	cg15745817	chr2:67799979	NA	-0.57	-9.7	-0.47	1.01e-19	Endometriosis;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12172441	chr6:28176163	NA	0.56	7.57	0.39	3.8e-13	Parkinson's disease;
CRC	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.89e-8	Prostate cancer;
CRC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	0.94	9.69	0.47	1.09e-19	Interleukin-17 levels;
CRC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.53	7.04	0.36	1.1e-11	Obesity-related traits;
CRC	cis	rs601339	0.938	rs1696345	chr12:123183060	T/G	cg25190513	chr12:123201362	GPR109B	-0.5	-6.25	-0.33	1.31e-9	Adiponectin levels;
CRC	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.62	9.62	0.47	1.82e-19	Educational attainment;
CRC	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.6	9.69	0.47	1.06e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg08888203	chr3:10149979	C3orf24	0.67	9.19	0.45	4.67e-18	Alzheimer's disease;
CRC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.54e-30	Bone mineral density;
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18357526	chr6:26021779	HIST1H4A	0.41	5.99	0.31	5.36e-9	Height;
CRC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg03152288	chr2:177042942	NA	0.81	13.08	0.59	8.83e-32	IgG glycosylation;
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.59	-8.23	-0.41	4.36e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.62	10.58	0.5	1.05e-22	Mean corpuscular volume;
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02825527	chr7:2087843	MAD1L1	0.45	5.61	0.3	4.31e-8	Bipolar disorder;
CRC	cis	rs7605827	0.930	rs4668909	chr2:15607842	T/C	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg19812747	chr11:111475976	SIK2	0.55	8.98	0.44	2.08e-17	Primary sclerosing cholangitis;
CRC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg16558177	chr4:4109446	NA	0.52	6.33	0.33	7.86e-10	Blood pressure (smoking interaction);
CRC	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.39	5.74	0.3	2.14e-8	Mean corpuscular hemoglobin;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg27134732	chr2:85108175	C2orf89	-0.46	-6.63	-0.34	1.39e-10	Schizophrenia;
CRC	cis	rs6076065	0.723	rs6137908	chr20:23344590	G/A	cg11657817	chr20:23433608	CST11	0.43	6.25	0.33	1.31e-9	Facial morphology (factor 15, philtrum width);
CRC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-17.93	-0.7	1.29e-50	Coronary artery disease;
CRC	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.58	6.54	0.34	2.29e-10	Childhood ear infection;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02668984	chr17:48172022	PDK2	-0.54	-6.64	-0.34	1.29e-10	Diisocyanate-induced asthma;
CRC	cis	rs10991814	1.000	rs78826784	chr9:93944200	G/A	cg14446406	chr9:93919335	NA	0.61	6.97	0.36	1.74e-11	Neutrophil percentage of granulocytes;
CRC	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg17294928	chr15:75287854	SCAMP5	-0.42	-6.07	-0.32	3.48e-9	Caffeine consumption;
CRC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26371787	chr6:7910221	TXNDC5	0.4	6.26	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-12.36	-0.56	4.52e-29	Neuroticism;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.93	-22.01	-0.77	1.17e-66	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.85	9.35	0.46	1.44e-18	Gastritis;
CRC	cis	rs2160860	0.965	rs7013824	chr8:39808425	A/G	cg11363097	chr8:39792086	IDO2	-0.4	-6.66	-0.34	1.14e-10	Blood metabolite levels;
CRC	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg02569458	chr12:86230093	RASSF9	0.4	6.77	0.35	6.08e-11	Major depressive disorder;
CRC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.92	-0.48	1.84e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.5	-10.86	-0.51	1.13e-23	Rheumatoid arthritis;
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13047869	chr3:10149882	C3orf24	0.51	7.07	0.36	9.31e-12	Alzheimer's disease;
CRC	cis	rs7172809	0.643	rs75159723	chr15:77841841	A/G	cg10437265	chr15:77819839	NA	-0.35	-5.86	-0.31	1.13e-8	Glucose homeostasis traits;
CRC	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.75	-8.06	-0.41	1.41e-14	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21792150	chr3:101567884	NFKBIZ	0.39	6.05	0.32	3.91e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.46	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg25164649	chr6:28176230	NA	0.75	9.35	0.46	1.35e-18	Depression;
CRC	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.4	-5.69	-0.3	2.84e-8	Neuroticism;
CRC	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.48	5.93	0.31	7.8e-9	Recombination rate (females);
CRC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg18764771	chr6:116381957	FRK	0.25	7.02	0.36	1.28e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs698833	0.926	rs1067370	chr2:44652343	T/G	cg04920474	chr2:44395004	PPM1B	0.42	6.11	0.32	2.79e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg12870014	chr12:110450643	ANKRD13A	0.86	9.64	0.47	1.53e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.54	-5.87	-0.31	1.04e-8	Schizophrenia;
CRC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg22800045	chr5:56110881	MAP3K1	0.47	5.85	0.31	1.21e-8	Initial pursuit acceleration;
CRC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg27101125	chr19:17392770	ANKLE1	0.32	5.74	0.3	2.13e-8	Systemic lupus erythematosus;
CRC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg02186141	chr17:80864562	TBCD	-0.38	-5.65	-0.3	3.45e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.73	-11.63	-0.54	1.94e-26	Total body bone mineral density;
CRC	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.5	9.42	0.46	8.46e-19	Educational attainment (years of education);
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg27532560	chr4:187881888	NA	-0.56	-10.28	-0.49	1.1e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.55	5.96	0.31	6.48e-9	Initial pursuit acceleration;
CRC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	8.18	0.41	6.21e-15	Monocyte count;
CRC	cis	rs9287719	0.649	rs10175884	chr2:10718534	C/T	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg15147215	chr3:52552868	STAB1	0.42	7.03	0.36	1.17e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.68	11.08	0.52	1.79e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.94	0.36	2.11e-11	Mean corpuscular volume;
CRC	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg22482690	chr17:47019901	SNF8	-0.5	-8.23	-0.41	4.56e-15	Type 2 diabetes;
CRC	cis	rs9467603	0.800	rs4236040	chr6:25761209	T/C	cg08501292	chr6:25962987	TRIM38	-0.93	-8.38	-0.42	1.56e-15	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg11875773	chr22:50468633	TTLL8	-0.69	-6.05	-0.32	3.84e-9	Cognitive function;
CRC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.36	-5.64	-0.3	3.62e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.97	14.66	0.63	8.09e-38	Glomerular filtration rate (creatinine);
CRC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.75	0.39	1.13e-13	Mean platelet volume;
CRC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg19338460	chr6:170058176	WDR27	-0.62	-7.11	-0.36	7.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.62	-7.92	-0.4	3.68e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22807378	chr6:170151601	TCTE3;C6orf70	0.38	6.28	0.33	1.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.74	-0.51	2.89e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.56	6.78	0.35	5.54e-11	Heart rate;
CRC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.27	-0.46	2.49e-18	Type 2 diabetes;
CRC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.47	-6.73	-0.35	7.56e-11	Tuberculosis;
CRC	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.73	8.97	0.44	2.23e-17	Educational attainment;
CRC	cis	rs394563	0.625	rs384306	chr6:149796140	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.43	-6.74	-0.35	7.2e-11	Dupuytren's disease;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg25667490	chr4:72052924	SLC4A4	0.38	6.04	0.32	4.22e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.06	0.32	3.83e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.3	5.69	0.3	2.83e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.06	-0.79	1.07e-70	Myeloid white cell count;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg25164649	chr6:28176230	NA	0.62	8.92	0.44	3.31e-17	Cardiac Troponin-T levels;
CRC	cis	rs2292096	0.929	rs6667419	chr1:200756197	G/C	cg07580975	chr1:200843333	NA	0.43	5.92	0.31	8.27e-9	Epilepsy;
CRC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.8	12.26	0.56	1e-28	Type 2 diabetes;
CRC	cis	rs4654899	0.897	rs10916859	chr1:21087956	A/G	cg02927042	chr1:21476669	EIF4G3	-0.44	-6.87	-0.35	3.29e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg09127314	chr1:152161683	NA	0.52	6.57	0.34	1.95e-10	Atopic dermatitis;
CRC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.57	8.57	0.43	4.01e-16	Type 2 diabetes;
CRC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.59	0.47	2.2e-19	Cognitive test performance;
CRC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.59	9.61	0.47	2.03e-19	Tonsillectomy;
CRC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.91	-16.08	-0.66	2.35e-43	Height;
CRC	cis	rs11212617	1.000	rs608086	chr11:108185023	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.5	0.34	2.91e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.45	6.06	0.32	3.63e-9	Pulse pressure;
CRC	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.42	6.88	0.35	3.03e-11	Menopause (age at onset);
CRC	cis	rs889398	0.742	rs12446197	chr16:69854869	A/G	cg00738113	chr16:70207722	CLEC18C	0.36	6.2	0.32	1.69e-9	Body mass index;
CRC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg11189052	chr15:85197271	WDR73	0.59	8.58	0.43	3.73e-16	Schizophrenia;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg12172441	chr6:28176163	NA	0.51	6.24	0.33	1.34e-9	Parkinson's disease;
CRC	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.79	12.06	0.55	5.49e-28	Testicular germ cell tumor;
CRC	trans	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.36	-6.19	-0.32	1.76e-9	Schizophrenia;
CRC	cis	rs8008758	1.000	rs915379	chr14:101689392	T/C	cg26224664	chr14:101693935	NA	-0.4	-6.09	-0.32	3.21e-9	Body mass index (alcohol intake interaction);
CRC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg27565382	chr3:53032988	SFMBT1	0.7	6.16	0.32	2.07e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs62408225	0.962	rs58521088	chr6:90985198	A/T	cg06866423	chr6:90926672	BACH2	0.48	7.9	0.4	4.14e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2415984	0.622	rs12435397	chr14:46940867	G/A	cg14871534	chr14:47121158	RPL10L	-0.44	-6.23	-0.32	1.43e-9	Number of children ever born;
CRC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg09876464	chr15:85330779	ZNF592	0.39	6.5	0.34	2.99e-10	Schizophrenia;
CRC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.77e-8	Major depressive disorder;
CRC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.52	8.17	0.41	6.53e-15	Intelligence (multi-trait analysis);
CRC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg26762873	chr11:5879799	OR52E8	-0.49	-8.32	-0.42	2.36e-15	DNA methylation (variation);
CRC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.28e-20	Ileal carcinoids;
CRC	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04631757	chr12:58176492	TSFM	0.42	6.02	0.31	4.63e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9468186	1	rs9468186	chr6:27626631	A/G	cg03623178	chr6:28175578	NA	0.5	6.06	0.32	3.78e-9	Neuroticism;
CRC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.88	9.01	0.44	1.68e-17	Major depressive disorder;
CRC	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.42	5.9	0.31	9.22e-9	Response to statin therapy;
CRC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.54	-8.31	-0.42	2.52e-15	Corneal astigmatism;
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18301423	chr5:131593218	PDLIM4	0.37	6.94	0.36	2.12e-11	Breast cancer;
CRC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.31	-0.37	2.04e-12	Mean corpuscular volume;
CRC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg20243544	chr17:37824526	PNMT	0.41	5.71	0.3	2.54e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs10924970	0.935	rs4659674	chr1:235392354	T/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs7107770	1.000	rs61911056	chr11:125088380	A/T	cg27629782	chr11:125073726	PKNOX2	0.49	5.88	0.31	1.03e-8	Photic sneeze reflex;
CRC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg03623178	chr6:28175578	NA	0.68	7.08	0.36	8.59e-12	Depression;
CRC	cis	rs11212617	1.000	rs650173	chr11:108174173	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.41	6.14	0.32	2.33e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9463078	0.774	rs6458441	chr6:45327401	G/T	cg25276700	chr6:44698697	NA	0.29	6.83	0.35	4.06e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs959260	1.000	rs2053158	chr17:73393459	A/T	cg20590849	chr17:73267439	MIF4GD	0.44	5.83	0.31	1.3e-8	Systemic lupus erythematosus;
CRC	cis	rs3772130	0.540	rs11717089	chr3:121563271	C/T	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.45	-0.34	4.01e-10	Longevity;Endometriosis;
CRC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7538876	0.903	rs730153	chr1:17749504	A/G	cg01904812	chr1:17746340	RCC2	-0.35	-5.8	-0.3	1.54e-8	Basal cell carcinoma;
CRC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.53	-7.37	-0.38	1.42e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.16	-24.69	-0.81	7.19e-77	Exhaled nitric oxide output;
CRC	cis	rs9341808	0.667	rs583426	chr6:80946687	G/A	cg08355045	chr6:80787529	NA	-0.36	-6.07	-0.32	3.59e-9	Sitting height ratio;
CRC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.85	-0.35	3.69e-11	Breast cancer;
CRC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg26395211	chr5:140044315	WDR55	0.38	5.68	0.3	3.04e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg13319975	chr6:146136371	FBXO30	0.39	5.93	0.31	7.81e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.48e-9	Homoarginine levels;
CRC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg21294424	chr19:58662284	ZNF329	0.83	9.33	0.46	1.62e-18	Cholesterol, total;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.4	-0.5	4.44e-22	Bipolar disorder;
CRC	cis	rs1158570	0.521	rs10089819	chr8:131172968	C/T	cg26053073	chr8:131455383	NA	-0.42	-6.45	-0.33	4.04e-10	Platelet count;
CRC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg01262667	chr19:19385393	TM6SF2	0.38	6.3	0.33	9.76e-10	Tonsillectomy;
CRC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11003009	chr5:74632112	HMGCR	0.44	6.54	0.34	2.33e-10	Thyroid stimulating hormone;
CRC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.73	7.8	0.4	8.27e-14	Major depressive disorder;
CRC	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg01339444	chr6:118972232	C6orf204	0.57	6.07	0.32	3.53e-9	Renal cell carcinoma;
CRC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.56	8.17	0.41	6.92e-15	Multiple sclerosis;
CRC	cis	rs12024301	0.557	rs7542304	chr1:183595180	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.58	8.19	0.41	5.73e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs10411161	0.702	rs17835311	chr19:52386781	A/C	cg22319618	chr22:45562946	NUP50	-0.64	-6.64	-0.34	1.28e-10	Breast cancer;
CRC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg11766577	chr21:47581405	C21orf56	-0.38	-5.81	-0.31	1.44e-8	Testicular germ cell tumor;
CRC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.24	-16.22	-0.67	6.66e-44	Breast cancer;
CRC	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	8.19	0.41	5.86e-15	Aortic root size;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg25164649	chr6:28176230	NA	0.56	5.71	0.3	2.54e-8	Lung cancer in ever smokers;
CRC	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.07	-16.8	-0.68	3.48e-46	Colorectal cancer;
CRC	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.61	-0.34	1.59e-10	Acne (severe);
CRC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg14671364	chr1:107599128	PRMT6	-0.61	-8.29	-0.42	3e-15	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.5	-7.44	-0.38	8.66e-13	Schizophrenia;
CRC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs2386661	0.543	rs61832673	chr10:5643818	C/T	cg26603656	chr10:5671107	NA	0.37	6.61	0.34	1.55e-10	Breast cancer;
CRC	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg14458575	chr2:238380390	NA	0.41	6.02	0.32	4.64e-9	Prostate cancer;
CRC	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg26741380	chr15:41871084	TYRO3	-0.47	-6.93	-0.36	2.27e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg04562611	chr16:615315	C16orf11	0.35	5.93	0.31	7.66e-9	Height;
CRC	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg26248373	chr2:1572462	NA	-0.63	-6.54	-0.34	2.3e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg25767906	chr1:53392781	SCP2	0.52	8.04	0.41	1.61e-14	Monocyte count;
CRC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.38	-5.89	-0.31	9.53e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg15145174	chr5:6755386	POLS	-0.44	-6.49	-0.34	3.22e-10	Menopause (age at onset);
CRC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.56	-7.5	-0.38	6.16e-13	Colorectal cancer;
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.57	-0.5	1.14e-22	Electroencephalogram traits;
CRC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.03e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1891275	0.515	rs7475294	chr10:93508199	T/C	cg07889827	chr10:93443413	NA	-0.38	-6.43	-0.33	4.55e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg02033258	chr5:131593261	PDLIM4	0.34	6.39	0.33	5.77e-10	Perceived unattractiveness to mosquitoes;
CRC	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg00042356	chr1:8021962	PARK7	0.61	6.95	0.36	2.02e-11	Inflammatory bowel disease;
CRC	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.49	8.04	0.41	1.62e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg23996704	chr18:44553084	KATNAL2	-0.29	-5.66	-0.3	3.29e-8	Educational attainment;
CRC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.3	2.69e-8	Hemoglobin concentration;
CRC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.82	15.07	0.64	2.24e-39	Anterior chamber depth;
CRC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg10790698	chr19:18539756	SSBP4	-0.45	-8.61	-0.43	3.07e-16	Breast cancer;
CRC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.44	-6.7	-0.35	8.93e-11	Cardiovascular disease risk factors;
CRC	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg02811702	chr13:24901961	NA	0.48	6.63	0.34	1.4e-10	Obesity-related traits;
CRC	trans	rs6678914	1.000	rs4950774	chr1:202190546	G/A	cg19977628	chr5:1262072	TERT	0.43	6.24	0.33	1.33e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-11.22	-0.53	5.78e-25	Colorectal cancer;
CRC	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg10820045	chr2:198174542	NA	0.4	6.71	0.35	8.56e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9467603	0.547	rs2039069	chr6:25424327	G/A	cg16898833	chr6:26189333	HIST1H4D	-0.76	-5.81	-0.3	1.5e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.99	14.28	0.62	2.57e-36	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24308560	chr3:49941425	MST1R	-0.45	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.47	-9.07	-0.45	1.09e-17	Educational attainment (years of education);
CRC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg07153921	chr17:41440717	NA	-0.37	-5.62	-0.3	4.14e-8	Menopause (age at onset);
CRC	cis	rs860295	0.702	rs12025532	chr1:155369302	C/T	cg02153340	chr1:155202674	NA	-0.58	-6.86	-0.35	3.43e-11	Body mass index;
CRC	cis	rs11229555	0.645	rs61903159	chr11:58184475	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg02569458	chr12:86230093	RASSF9	0.39	6.66	0.34	1.16e-10	Major depressive disorder;
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.58e-8	Prudent dietary pattern;
CRC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-6.83	-0.35	4.07e-11	Arsenic metabolism;
CRC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.43	8.62	0.43	2.84e-16	Vitiligo;
CRC	cis	rs294883	0.858	rs12203970	chr6:159723788	A/T	cg14500486	chr6:159655392	FNDC1	-0.34	-5.65	-0.3	3.55e-8	Coronary artery disease;
CRC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.38	6.58	0.34	1.85e-10	Crohn's disease;
CRC	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg22256960	chr15:77711686	NA	-0.42	-5.65	-0.3	3.51e-8	Type 2 diabetes;
CRC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-6.67	-0.35	1.06e-10	Subjective well-being;
CRC	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.47	6.92	0.36	2.35e-11	Carotid intima media thickness;
CRC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.43	-6.31	-0.33	9.07e-10	Ulcerative colitis;
CRC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.62	9.05	0.45	1.28e-17	Breast cancer;
CRC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.26	0.37	2.9e-12	Parkinson's disease;
CRC	cis	rs2692947	0.759	rs2949885	chr2:96662415	A/G	cg23100626	chr2:96804247	ASTL	0.25	6.88	0.35	3.09e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg06343869	chr13:115079967	ZNF828	0.43	6.17	0.32	2.02e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg17903999	chr18:56338584	MALT1	-0.43	-7.3	-0.37	2.22e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7640424	0.929	rs326358	chr3:107822310	C/T	cg09227934	chr3:107805635	CD47	0.43	6.5	0.34	2.98e-10	Body mass index;
CRC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.29	0.46	2.22e-18	Bladder cancer;
CRC	cis	rs9928842	0.941	rs8057145	chr16:75256251	A/G	cg08657710	chr16:75258780	CTRB1	-0.57	-6.73	-0.35	7.33e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.31	5.74	0.3	2.13e-8	Huntington's disease progression;
CRC	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.07e-8	Type 2 diabetes;
CRC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.05	11.85	0.55	3.18e-27	Hip circumference adjusted for BMI;
CRC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11212617	1.000	rs186595	chr11:108251211	C/A	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.65	0.34	1.25e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.15	0.32	2.22e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.05	-0.32	3.94e-9	Bipolar disorder;
CRC	trans	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg10756647	chr7:56101905	PSPH	0.77	8.14	0.41	8.52e-15	Diabetic kidney disease;
CRC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.76	11.49	0.54	6.38e-26	Multiple sclerosis;
CRC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-7.94	-0.4	3.17e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.51	7.15	0.37	5.65e-12	Obesity-related traits;
CRC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg15445000	chr17:37608096	MED1	-0.41	-7.73	-0.39	1.29e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02290350	chr8:58132656	NA	-0.44	-6.5	-0.34	3e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg23100626	chr2:96804247	ASTL	-0.29	-7.81	-0.4	7.66e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-8.16	-0.41	7.41e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs7617773	0.823	rs9839446	chr3:48194666	T/A	cg11946769	chr3:48343235	NME6	-0.51	-6.83	-0.35	4.12e-11	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.07	-12.34	-0.56	5.05e-29	Diabetic kidney disease;
CRC	cis	rs7113874	0.569	rs10840077	chr11:8601210	A/T	cg02811074	chr11:8615871	STK33	0.35	6.06	0.32	3.75e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.56	-7.37	-0.38	1.38e-12	Gut microbiome composition (summer);
CRC	cis	rs4728302	0.838	rs10224828	chr7:133591071	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.85	0.31	1.22e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.48	7.27	0.37	2.71e-12	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg25164649	chr6:28176230	NA	-0.76	-9.3	-0.46	1.94e-18	Depression;
CRC	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.3	-0.33	9.48e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-7.31	-0.37	2e-12	Glycated hemoglobin levels;
CRC	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg08501292	chr6:25962987	TRIM38	1.11	9.7	0.47	9.84e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-6.04	-0.32	4.28e-9	Vitamin D levels;
CRC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg12365402	chr11:9010492	NRIP3	0.53	8.78	0.44	9.43e-17	Hemoglobin concentration;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg26918957	chr8:22926800	TNFRSF10B	-0.5	-6.08	-0.32	3.35e-9	Type 1 diabetes;
CRC	cis	rs3087591	0.521	rs1013948	chr17:29530709	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	9.41	0.46	8.68e-19	Hip circumference;
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg21268650	chr7:45961089	IGFBP3	-0.41	-6.87	-0.35	3.21e-11	Sitting height ratio;
CRC	cis	rs3736485	0.816	rs4143722	chr15:51867191	C/G	cg08986416	chr15:51914746	DMXL2	-0.48	-6.97	-0.36	1.78e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.68e-9	Recombination rate (females);
CRC	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg16989719	chr2:238392110	NA	-0.35	-5.73	-0.3	2.3e-8	Prostate cancer;
CRC	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	6.78	0.35	5.43e-11	Neutrophil percentage of white cells;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.69	5.85	0.31	1.21e-8	Breast cancer;
CRC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg23141183	chr17:80185318	SLC16A3	0.4	5.62	0.3	4.11e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg05639522	chr1:247681581	NA	0.46	6.95	0.36	1.91e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg02537909	chr2:165697595	COBLL1	-0.51	-6.07	-0.32	3.54e-9	Hirschsprung disease;
CRC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22624212	chr21:44298959	WDR4	0.41	6.07	0.32	3.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg13043300	chr11:71146211	DHCR7	0.48	6.53	0.34	2.45e-10	Vitamin D levels;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg08798685	chr6:27730294	NA	-0.43	-6.2	-0.32	1.64e-9	Parkinson's disease;
CRC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.54	8.6	0.43	3.23e-16	IgG glycosylation;
CRC	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg10820045	chr2:198174542	NA	-0.53	-9.12	-0.45	7.78e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs6678914	1.000	rs12129536	chr1:202189338	T/C	cg19977628	chr5:1262072	TERT	0.4	5.97	0.31	6.14e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.73	0.43	1.27e-16	Prostate cancer;
CRC	cis	rs9648716	1.000	rs1267603	chr7:140544447	T/C	cg10747023	chr7:140774559	NA	0.43	5.61	0.3	4.2e-8	Type 2 diabetes;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23708337	chr7:1209742	NA	0.39	5.82	0.31	1.36e-8	Longevity;Endometriosis;
CRC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.62	-0.39	2.77e-13	Eye color traits;
CRC	cis	rs10450586	0.932	rs10082611	chr11:27320108	C/G	cg10370305	chr11:27303972	NA	0.35	5.76	0.3	1.98e-8	Total body bone mineral density;
CRC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg13206674	chr6:150067644	NUP43	0.49	7.04	0.36	1.13e-11	Testicular germ cell tumor;
CRC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.16	25.31	0.81	3.42e-79	IgG glycosylation;
CRC	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg01420254	chr6:26195488	NA	0.73	6.04	0.32	4.13e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	8.04	0.41	1.65e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs12431939	0.948	rs12435444	chr14:51656071	C/T	cg23942311	chr14:51606299	NA	-0.53	-6.4	-0.33	5.41e-10	Cancer;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs6815814	0.904	rs2101521	chr4:38811551	C/T	cg06935464	chr4:38784597	TLR10	0.62	7.76	0.39	1.08e-13	Breast cancer;
CRC	cis	rs28655083	1.000	rs8045658	chr16:77056343	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.59	-8.25	-0.41	3.77e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs4363385	0.747	rs1129655	chr1:152958267	T/C	cg25856811	chr1:152973957	SPRR3	-0.28	-7.64	-0.39	2.38e-13	Inflammatory skin disease;
CRC	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-9.11	-0.45	8.1e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.47	-7.91	-0.4	4.05e-14	Height;
CRC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.44	-7.08	-0.36	8.58e-12	Testicular germ cell tumor;
CRC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg24562669	chr7:97807699	LMTK2	0.47	7.9	0.4	4.14e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs972578	0.837	rs1983647	chr22:43255182	T/G	cg01576275	chr22:43409880	NA	-0.4	-6.34	-0.33	7.65e-10	Mean platelet volume;
CRC	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg23461800	chr14:103021989	NA	-0.71	-9.19	-0.45	4.62e-18	Platelet count;
CRC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg03037974	chr15:76606532	NA	0.59	9.98	0.48	1.18e-20	Blood metabolite levels;
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg24562669	chr7:97807699	LMTK2	0.45	7.52	0.38	5.11e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.54	-8.1	-0.41	1.06e-14	Psychosis in Alzheimer's disease;
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.54	-0.38	4.52e-13	Bipolar disorder;
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.74	-0.35	7.13e-11	Bipolar disorder;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07167872	chr1:205819463	PM20D1	-0.44	-6.47	-0.34	3.59e-10	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.61	10.2	0.49	2.05e-21	Prudent dietary pattern;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg02902800	chr4:6784175	KIAA0232	0.48	6.16	0.32	2.09e-9	Plasma plasminogen activator levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25096193	chr3:16306690	OXNAD1;DPH3	0.44	6.23	0.32	1.41e-9	Anxiety disorder;
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.63	0.57	4.38e-30	Alzheimer's disease;
CRC	cis	rs12024301	0.557	rs12045554	chr1:183625753	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7487075	0.718	rs4768735	chr12:46944134	G/T	cg22049899	chr12:47219821	SLC38A4	-0.3	-5.98	-0.31	5.94e-9	Itch intensity from mosquito bite;
CRC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.41	-6.96	-0.36	1.9e-11	Height;
CRC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.867	rs56235549	chr10:81834948	G/A	cg05935833	chr10:81318306	SFTPA2	-0.59	-6.9	-0.36	2.69e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.64	8.72	0.43	1.44e-16	Multiple sclerosis;
CRC	cis	rs365302	1.000	rs684052	chr6:159651247	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.78	0.35	5.7e-11	Coronary heart disease;
CRC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg10820045	chr2:198174542	NA	-0.53	-9.51	-0.46	4.1e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg01388757	chr2:102091195	RFX8	-0.35	-5.65	-0.3	3.48e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	10.21	0.49	1.89e-21	HIV-1 control;
CRC	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.4	6.78	0.35	5.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.53	-0.38	4.84e-13	Alzheimer's disease;
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.43	7.31	0.37	2.08e-12	Lung cancer;
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.75	11.61	0.54	2.39e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs10043228	1.000	rs6876972	chr5:115642519	C/T	cg03160740	chr3:42544400	VIPR1	-0.65	-6.04	-0.32	4.18e-9	Asthma or chronic obstructive pulmonary disease;
CRC	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.26	-0.33	1.23e-9	Height;
CRC	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.14	-0.56	2.82e-28	Coffee consumption (cups per day);
CRC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.36	6.33	0.33	8.21e-10	Alopecia areata;
CRC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg11901034	chr3:128598214	ACAD9	-0.5	-6.23	-0.32	1.44e-9	IgG glycosylation;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg25164649	chr6:28176230	NA	0.78	9.69	0.47	1.04e-19	Depression;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg12172441	chr6:28176163	NA	0.44	6.48	0.34	3.34e-10	Cardiac Troponin-T levels;
CRC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.51	6.38	0.33	6.02e-10	Recombination rate (females);
CRC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08059820	chr3:184080810	CLCN2;POLR2H	0.49	6.76	0.35	6.35e-11	Anxiety disorder;
CRC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.22	0.32	1.49e-9	Menopause (age at onset);
CRC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.56	-0.47	2.8e-19	Migraine;Coronary artery disease;
CRC	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg17470449	chr10:769945	NA	0.58	7.98	0.4	2.53e-14	Uric acid levels;
CRC	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.92	-0.31	8.19e-9	Arsenic metabolism;
CRC	cis	rs864537	0.691	rs9662048	chr1:167412947	A/T	cg09179987	chr1:167433047	CD247	-0.4	-6.14	-0.32	2.33e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.45	6.97	0.36	1.7e-11	Refractive error;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg15511327	chr8:143859410	LYNX1	-0.39	-6.13	-0.32	2.52e-9	Urinary tract infection frequency;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg04255276	chr11:65314021	LTBP3	0.36	6.41	0.33	5.01e-10	Menarche (age at onset);
CRC	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg00490450	chr3:139108681	COPB2	-0.43	-6.49	-0.34	3.11e-10	Obesity-related traits;
CRC	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg11130432	chr3:121712080	ILDR1	-0.51	-6.67	-0.35	1.06e-10	Multiple sclerosis;
CRC	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg26603656	chr10:5671107	NA	0.42	7.11	0.36	7.29e-12	Breast cancer;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg01191114	chr3:48936118	SLC25A20	-0.68	-5.96	-0.31	6.49e-9	Cognitive function;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04873026	chr21:30365177	RNF160	0.43	6.66	0.34	1.13e-10	Myopia (pathological);
CRC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.57	-9.21	-0.45	3.98e-18	Intelligence (multi-trait analysis);
CRC	trans	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.58	0.39	3.59e-13	Educational attainment;
CRC	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.09	-0.41	1.15e-14	Total cholesterol levels;
CRC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg26061582	chr7:22766209	IL6	0.5	7.95	0.4	3.04e-14	Lung cancer;
CRC	cis	rs4731207	0.564	rs1471569	chr7:124650721	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.27e-9	Cutaneous malignant melanoma;
CRC	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg19683494	chr5:74908142	NA	0.5	6.28	0.33	1.06e-9	Age-related disease endophenotypes;
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg01874867	chr7:94954059	PON1	-0.52	-6.59	-0.34	1.74e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg15790184	chr11:494944	RNH1	0.61	6.24	0.33	1.35e-9	Body mass index;
CRC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.25	0.33	1.26e-9	Aortic root size;
CRC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.61	13.71	0.6	3.82e-34	Airflow obstruction;
CRC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.93	0.52	6.09e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.92	0.31	8.26e-9	Monocyte percentage of white cells;
CRC	cis	rs9403521	0.898	rs3924969	chr6:143979399	C/G	cg18240653	chr6:144019428	PHACTR2	-0.57	-6.47	-0.34	3.48e-10	Obesity-related traits;
CRC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg15848620	chr12:58087721	OS9	-0.63	-8.58	-0.43	3.87e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.69	-8.7	-0.43	1.59e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	10.63	0.51	7.19e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg18187862	chr3:45730750	SACM1L	0.46	6.7	0.35	9.15e-11	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg15786705	chr6:28176104	NA	0.57	7.88	0.4	4.81e-14	Parkinson's disease;
CRC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.14	0.32	2.32e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg21620606	chr4:1342894	KIAA1530	-0.37	-6.49	-0.34	3.18e-10	Obesity-related traits;
CRC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-9.85	-0.48	3.02e-20	Coronary artery disease;
CRC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.49	-9.04	-0.45	1.41e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs17065868	0.764	rs55633498	chr13:45020560	G/A	cg10246903	chr13:45222710	NA	0.59	5.83	0.31	1.33e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg16950941	chr11:66035639	RAB1B	0.57	7.9	0.4	4.34e-14	Electroencephalogram traits;
CRC	cis	rs990171	0.913	rs2272128	chr2:103039929	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	5.68	0.3	2.97e-8	Lymphocyte counts;
CRC	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	12.97	0.58	2.27e-31	Hip circumference;
CRC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.51	7.09	0.36	8.01e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08206623	chr11:2907334	CDKN1C	0.43	6.17	0.32	1.97e-9	Survival in pancreatic cancer;
CRC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-7.01	-0.36	1.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.54	-8.11	-0.41	1e-14	Blood protein levels;
CRC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.67	11.03	0.52	2.73e-24	Lung cancer;
CRC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg02094049	chr14:103021097	NA	-0.56	-7.51	-0.38	5.44e-13	Platelet count;
CRC	cis	rs56399783	0.901	rs17241904	chr7:2875574	C/T	cg19731401	chr7:2775893	GNA12	0.61	6.46	0.34	3.72e-10	Childhood ear infection;
CRC	cis	rs57561814	1.000	rs57561814	chr7:22753675	G/C	cg26061582	chr7:22766209	IL6	0.78	6.37	0.33	6.26e-10	Tonsillectomy;
CRC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.39	6.89	0.35	2.93e-11	Primary biliary cholangitis;
CRC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.71	-0.3	2.57e-8	Life satisfaction;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg15786705	chr6:28176104	NA	0.47	6.82	0.35	4.5e-11	Parkinson's disease;
CRC	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	12.0	0.55	8.93e-28	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	ch.12.1569034F	chr12:77413631	NA	0.44	6.4	0.33	5.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.52	0.38	5.37e-13	Aortic root size;
CRC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs17106184	1.000	rs59786222	chr1:51295793	C/T	cg02869289	chr19:46177325	MIR642;GIPR	0.62	6.07	0.32	3.51e-9	Type 2 diabetes;
CRC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.5	8.04	0.41	1.66e-14	Height;
CRC	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.82	10.82	0.51	1.5e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.73e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	7.68e-17	Dupuytren's disease;
CRC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.88	-0.4	4.77e-14	Gut microbiome composition (summer);
CRC	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.69	7.31	0.37	2.04e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.78	-15.16	-0.64	9.45e-40	Obesity-related traits;
CRC	trans	rs924135	0.634	rs246221	chr16:16138322	T/C	cg06794141	chr16:77535527	NA	0.39	5.98	0.31	5.77e-9	White blood cell count (basophil);Blood metabolite levels;
CRC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.96	-19.27	-0.73	6.37e-56	Height;
CRC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.4	5.95	0.31	7.01e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs891088	0.695	rs28695870	chr19:7197988	C/T	cg09779027	chr19:7224513	INSR	-0.59	-7.31	-0.37	2.1e-12	Hip circumference adjusted for BMI;Height;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg18827107	chr12:86230957	RASSF9	-0.46	-7.54	-0.38	4.63e-13	Major depressive disorder;
CRC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.43	6.56	0.34	2.03e-10	Colorectal cancer;
CRC	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg17724175	chr1:150552817	MCL1	-0.53	-8.51	-0.42	6.16e-16	Tonsillectomy;
CRC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg11822372	chr1:151115635	SEMA6C	0.46	5.75	0.3	2.02e-8	Blood trace element (Cu levels);
CRC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	17.33	0.69	2.96e-48	Platelet count;
CRC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.2	-0.32	1.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg18722847	chr3:44754129	ZNF502	-0.34	-5.74	-0.3	2.17e-8	Depressive symptoms;
CRC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.83	0.55	3.97e-27	Platelet count;
CRC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.96	15.32	0.65	2.31e-40	Primary sclerosing cholangitis;
CRC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg00769240	chr8:12517080	NA	-0.68	-7.78	-0.39	9.14e-14	Blood pressure (smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19082920	chr1:202830751	LOC148709	0.45	6.01	0.31	4.82e-9	Thyroid stimulating hormone;
CRC	cis	rs55702914	0.712	rs10931778	chr2:198148922	C/T	cg03934865	chr2:198174659	NA	-0.4	-6.93	-0.36	2.28e-11	Major depression and alcohol dependence;
CRC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.6	7.37	0.38	1.35e-12	Mean platelet volume;
CRC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.43	7.0	0.36	1.48e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.73	12.71	0.57	2.18e-30	Prostate cancer;
CRC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06544989	chr22:39130855	UNC84B	-0.47	-7.92	-0.4	3.63e-14	Menopause (age at onset);
CRC	cis	rs62408225	0.963	rs1321859	chr6:91011673	C/T	cg06866423	chr6:90926672	BACH2	0.5	8.33	0.42	2.28e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg10724054	chr17:3904396	NA	-0.46	-7.57	-0.39	3.71e-13	Type 2 diabetes;
CRC	trans	rs2908835	0.503	rs73056812	chr12:11609577	C/A	cg03979024	chr10:419189	DIP2C	-0.39	-6.07	-0.32	3.45e-9	Information processing speed;
CRC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.29	0.46	2.12e-18	Colorectal cancer;
CRC	cis	rs7707921	1.000	rs4703879	chr5:81553815	C/T	cg17942617	chr5:81327376	ATG10	0.4	5.87	0.31	1.06e-8	Breast cancer;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg23161317	chr6:28129485	ZNF389	0.43	5.98	0.31	5.95e-9	Parkinson's disease;
CRC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg07274523	chr3:49395745	GPX1	0.46	6.02	0.31	4.74e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8141797	0.748	rs3788368	chr22:24577986	T/C	cg20894457	chr22:24584366	SUSD2	0.6	7.66	0.39	2.09e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg16892393	chr17:41919603	NA	0.61	8.97	0.44	2.31e-17	Triglycerides;
CRC	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg06172871	chr16:72088244	HP	0.44	6.45	0.33	4.08e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.98	-0.4	2.44e-14	Intelligence (multi-trait analysis);
CRC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.6e-10	Morning vs. evening chronotype;
CRC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.52	-0.34	2.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.95	-13.66	-0.6	5.9e-34	Hip circumference adjusted for BMI;
CRC	cis	rs11212617	0.967	rs227053	chr11:108226855	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.01	0.31	4.96e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.27	-6.24	-0.33	1.32e-9	Total body bone mineral density;
CRC	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg23996704	chr18:44553084	KATNAL2	-0.29	-5.66	-0.3	3.29e-8	Educational attainment;
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.48	8.41	0.42	1.25e-15	Hypertriglyceridemia;
CRC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.35	5.79	0.3	1.65e-8	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
CRC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.55e-8	Total body bone mineral density;
CRC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.45	6.54	0.34	2.4e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg13319975	chr6:146136371	FBXO30	0.38	5.78	0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06748153	chr16:50279807	NA	0.39	6.58	0.34	1.87e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.49	-8.81	-0.44	7.1e-17	Migraine;
CRC	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-6.25	-0.33	1.29e-9	Schizophrenia;
CRC	cis	rs2462686	0.965	rs1534151	chr7:45984645	A/G	cg23193639	chr7:45961078	IGFBP3	-0.37	-5.74	-0.3	2.2e-8	Major depressive disorder;
CRC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	16.52	0.67	4.73e-45	Platelet count;
CRC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18803079	chr1:64014643	EFCAB7;DLEU2L	-0.4	-6.35	-0.33	6.96e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.2	0.37	4.09e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg11843238	chr5:131593191	PDLIM4	-0.35	-6.42	-0.33	4.78e-10	Blood metabolite levels;
CRC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.54	-7.43	-0.38	9.26e-13	Blood metabolite levels;
CRC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.88	11.77	0.54	6.28e-27	Initial pursuit acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11784697	chr19:1104586	GPX4	0.44	6.03	0.32	4.4e-9	Anxiety disorder;
CRC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.71	11.09	0.52	1.73e-24	Corneal astigmatism;
CRC	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg06484146	chr7:12443880	VWDE	-0.54	-7.09	-0.36	8.29e-12	Coronary artery disease;
CRC	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	trans	rs6956675	0.957	rs28541324	chr7:62608767	G/A	cg01314568	chr7:57830625	NA	-0.69	-9.26	-0.45	2.68e-18	Obesity-related traits;
CRC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.7	7.77	0.39	1.03e-13	Vitiligo;
CRC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.2	-12.13	-0.56	3.02e-28	Breast cancer;
CRC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg02683197	chr6:28174875	NA	0.69	9.03	0.45	1.53e-17	Parkinson's disease;
CRC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.77	-0.3	1.82e-8	Blood protein levels;
CRC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.99	0.31	5.41e-9	Height;
CRC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg10298567	chr3:47292165	KIF9	0.38	6.17	0.32	2.03e-9	Colorectal cancer;
CRC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.27	-0.33	1.1e-9	Monocyte percentage of white cells;
CRC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.5	6.56	0.34	2.03e-10	IgG glycosylation;
CRC	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.52	8.73	0.43	1.29e-16	Dupuytren's disease;
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.18	0.59	3.68e-32	Alzheimer's disease;
CRC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.07	-0.41	1.31e-14	Height;
CRC	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg12317470	chr15:67143691	NA	0.79	6.87	0.35	3.26e-11	Lung cancer (smoking interaction);
CRC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	17.29	0.69	4.24e-48	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg07617317	chr6:118971624	C6orf204	0.51	6.32	0.33	8.53e-10	Renal cell carcinoma;
CRC	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.43	-0.53	1.03e-25	Coffee consumption (cups per day);
CRC	cis	rs1552172	0.853	rs913513	chr1:145595423	G/A	cg11743829	chr1:145714124	CD160	0.36	5.75	0.3	2.06e-8	Breast cancer;
CRC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.67	-9.51	-0.46	4.3e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.49	7.5	0.38	6.06e-13	Corneal astigmatism;
CRC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.87	-0.58	5.48e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	10.95	0.52	5.42e-24	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.44	6.96e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7215564	0.818	rs1032130	chr17:78610636	A/G	cg09596252	chr17:78655493	RPTOR	-0.64	-6.33	-0.33	8.02e-10	Myopia (pathological);
CRC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-8.06	-0.41	1.39e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7503807	0.515	rs12601001	chr17:78681084	T/C	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.86e-8	Obesity;
CRC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.3	-6.5	-0.34	3.03e-10	IgG glycosylation;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg12273811	chr6:28175739	NA	0.5	6.63	0.34	1.38e-10	Parkinson's disease;
CRC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.67	-8.14	-0.41	8.07e-15	Rheumatoid arthritis;
CRC	cis	rs7215564	0.908	rs4969411	chr17:78747982	T/C	cg09596252	chr17:78655493	RPTOR	-0.55	-5.79	-0.3	1.65e-8	Myopia (pathological);
CRC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg15147215	chr3:52552868	STAB1	-0.58	-8.98	-0.44	2.18e-17	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.0	-0.31	5.15e-9	Menopause (age at onset);
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg20160996	chr11:63990575	FERMT3	0.38	6.21	0.32	1.57e-9	Platelet count;
CRC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg10589385	chr1:150898437	SETDB1	0.3	6.24	0.33	1.34e-9	Tonsillectomy;
CRC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg11861562	chr11:117069780	TAGLN	0.34	6.34	0.33	7.39e-10	Blood protein levels;
CRC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.49	7.89	0.4	4.48e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7605827	0.897	rs11885852	chr2:15515371	A/C	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	3.97e-9	Educational attainment (years of education);
CRC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.69	6.51	0.34	2.84e-10	Major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26816438	chr1:45139524	TMEM53;C1orf228	0.41	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg21972741	chr5:435613	AHRR	0.5	6.67	0.35	1.08e-10	Cystic fibrosis severity;
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.63	-10.4	-0.5	4.34e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg13385794	chr1:248469461	NA	0.41	7.28	0.37	2.46e-12	Common traits (Other);
CRC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.37	0.38	1.42e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg05313129	chr8:58192883	C8orf71	-0.44	-6.05	-0.32	3.92e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg07817883	chr1:32538562	TMEM39B	1.7	13.65	0.6	6.13e-34	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.6	8.0	0.4	2.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10242455	0.702	rs6976017	chr7:99249999	G/A	cg18809830	chr7:99032528	PTCD1	-1.04	-7.34	-0.38	1.68e-12	Blood metabolite levels;
CRC	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg03162506	chr22:38580953	NA	0.28	5.98	0.31	5.7e-9	Cutaneous nevi;
CRC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06931245	chr8:28351501	FZD3	0.4	6.11	0.32	2.74e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs427941	0.655	rs201468	chr7:101742673	C/T	cg06246474	chr7:101738831	CUX1	0.45	7.03	0.36	1.22e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.46	7.29	0.37	2.36e-12	Testicular germ cell tumor;
CRC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.52	8.38	0.42	1.6e-15	Aortic root size;
CRC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	8.9	0.44	3.69e-17	Menopause (age at onset);
CRC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	8.94	0.44	2.88e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg27087555	chr16:88793112	FAM38A	-1.49	-13.43	-0.6	4.33e-33	Plateletcrit;
CRC	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg11901034	chr3:128598214	ACAD9	-0.61	-8.06	-0.41	1.4e-14	IgG glycosylation;
CRC	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.37	6.0	0.31	5.21e-9	Height;
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg09877947	chr5:131593287	PDLIM4	0.34	6.06	0.32	3.71e-9	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.63	6.51	0.34	2.76e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.39e-12	HDL cholesterol;
CRC	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.05	19.88	0.74	2.52e-58	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13331940	chr15:59663987	MYO1E	0.4	6.35	0.33	7.06e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg22561889	chr6:118971681	C6orf204	0.5	6.43	0.33	4.51e-10	Diastolic blood pressure;
CRC	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg26875233	chr11:93583750	C11orf90	0.3	5.64	0.3	3.76e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21732842	chr11:47198564	ARFGAP2	-0.43	-6.68	-0.35	1.04e-10	Myopia (pathological);
CRC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.67	0.6	5.24e-34	Schizophrenia;
CRC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-10.69	-0.51	4.17e-23	Systemic lupus erythematosus;
CRC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07167872	chr1:205819463	PM20D1	-0.44	-6.22	-0.32	1.48e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.43	9.31	0.46	1.8e-18	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.94	-18.03	-0.7	5.18e-51	Height;
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.56	9.2	0.45	4.3e-18	Testicular germ cell tumor;
CRC	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg13491945	chr12:107078410	RFX4	0.35	5.94	0.31	7.11e-9	Heart rate;
CRC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg00484396	chr16:3507460	NAT15	-0.57	-5.88	-0.31	9.9e-9	Tuberculosis;
CRC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.42	-7.23	-0.37	3.36e-12	Eye color traits;
CRC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.72	11.51	0.54	5.51e-26	Colorectal cancer;
CRC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.88	-16.3	-0.67	3.23e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.66	-11.39	-0.53	1.46e-25	Body mass index;
CRC	cis	rs9322817	0.691	rs2486143	chr6:105308593	A/G	cg02098413	chr6:105308735	HACE1	0.43	8.4	0.42	1.35e-15	Thyroid stimulating hormone;
CRC	trans	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg27094323	chr7:1216898	NA	-0.4	-6.61	-0.34	1.52e-10	Longevity;Endometriosis;
CRC	cis	rs10971721	0.822	rs72727318	chr9:33901800	A/T	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03647317	chr4:187891568	NA	0.47	7.76	0.39	1.06e-13	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26591879	chr1:161736013	ATF6	-0.41	-6.36	-0.33	6.64e-10	Aortic root size;
CRC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.09	0.32	3.1e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs205391	0.947	rs412951	chr16:28053011	A/C	cg05061471	chr11:14994561	CALCA	0.52	6.02	0.31	4.65e-9	Obesity-related traits;
CRC	cis	rs728616	0.614	rs35193855	chr10:81788495	C/A	cg05935833	chr10:81318306	SFTPA2	-0.53	-7.12	-0.37	7.03e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg01426195	chr3:39028469	NA	-0.42	-6.0	-0.31	5.19e-9	Handedness;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.46	-10.42	-0.5	3.71e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17218026	chr1:154582156	ADAR	-0.65	-11.03	-0.52	2.86e-24	Blood protein levels;
CRC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg18876405	chr7:65276391	NA	0.47	6.51	0.34	2.85e-10	Aortic root size;
CRC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	6.78	0.35	5.45e-11	Lung function (FEV1/FVC);
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg20041105	chr8:143859282	LYNX1	0.45	8.09	0.41	1.13e-14	Urinary tract infection frequency;
CRC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.63	10.72	0.51	3.38e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.56	6.96	0.36	1.84e-11	Blood protein levels;
CRC	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	1.07	10.25	0.49	1.39e-21	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.65	-11.01	-0.52	3.32e-24	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg18512352	chr11:47633146	NA	0.33	6.53	0.34	2.48e-10	Subjective well-being;
CRC	cis	rs10208940	0.841	rs7598760	chr2:68837054	A/G	cg12452813	chr2:68675892	NA	0.48	6.02	0.31	4.69e-9	Urate levels in lean individuals;
CRC	trans	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04565464	chr8:145669602	NFKBIL2	0.42	6.58	0.34	1.87e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.66	-9.52	-0.46	3.81e-19	Menopause (age at onset);
CRC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	cis	rs12044355	0.929	rs12045248	chr1:231850748	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.07	0.32	3.43e-9	Alzheimer's disease;
CRC	cis	rs77633900	0.685	rs2469556	chr15:76650148	G/A	cg21673338	chr15:77095150	SCAPER	-0.74	-6.93	-0.36	2.29e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.75	0.35	6.86e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.1	0.56	3.79e-28	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-0.58	-7.95	-0.4	3.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg06484146	chr7:12443880	VWDE	-0.64	-6.83	-0.35	4.2e-11	Coronary artery disease;
CRC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.63	-11.64	-0.54	1.85e-26	Educational attainment;
CRC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.64	-0.47	1.59e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.79	11.03	0.52	2.79e-24	Cognitive function;
CRC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-7.19	-0.37	4.49e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.47	-7.06	-0.36	1.02e-11	Body mass index;
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.51	-0.57	1.18e-29	Idiopathic membranous nephropathy;
CRC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.11	0.41	9.95e-15	Rheumatoid arthritis;
CRC	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.3	0.37	2.21e-12	Diisocyanate-induced asthma;
CRC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg06484146	chr7:12443880	VWDE	-0.55	-7.49	-0.38	6.31e-13	Coronary artery disease;
CRC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-5.67	-0.3	3.17e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg21251018	chr6:28226885	NKAPL	0.44	5.95	0.31	6.99e-9	Parkinson's disease;
CRC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17554472	chr22:41940697	POLR3H	0.56	5.71	0.3	2.55e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.43	6.62	0.34	1.46e-10	Vitiligo;
CRC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.36	0.53	1.81e-25	Bone mineral density;
CRC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.74	10.83	0.51	1.37e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg03013999	chr17:37608204	MED1	-0.42	-6.12	-0.32	2.72e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs720844	1.000	rs7590549	chr2:149333736	C/T	cg09247360	chr2:149335327	NA	0.62	7.76	0.39	1.1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-6.02	-0.31	4.69e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.56	7.16	0.37	5.25e-12	Body mass index (adult);
CRC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-9.51	-0.46	4.29e-19	Monocyte percentage of white cells;
CRC	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	6.15	0.32	2.24e-9	Neuroticism;
CRC	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.82	-0.4	7.01e-14	QT interval;
CRC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.59	-9.17	-0.45	5.42e-18	Corneal astigmatism;
CRC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-14.04	-0.61	2.07e-35	Blood metabolite levels;
CRC	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.39	5.64	0.3	3.61e-8	Platelet distribution width;
CRC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.38	6.1	0.32	3.01e-9	Major depressive disorder;
CRC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.66	9.76	0.47	6.28e-20	Heart rate;
CRC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.63	0.39	2.57e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.55	8.75	0.43	1.1e-16	Colorectal cancer;
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg05569086	chr8:143859399	LYNX1	0.38	6.58	0.34	1.88e-10	Urinary tract infection frequency;
CRC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg11189052	chr15:85197271	WDR73	0.57	7.98	0.4	2.41e-14	Schizophrenia;
CRC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg09264619	chr17:80180166	NA	-0.37	-6.33	-0.33	8.13e-10	Life satisfaction;
CRC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.67	8.35	0.42	1.92e-15	Menarche (age at onset);
CRC	trans	rs16846053	0.792	rs72875528	chr2:162533523	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Blood osmolality (transformed sodium);
CRC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.72	11.67	0.54	1.45e-26	Dental caries;
CRC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.5	6.92	0.36	2.34e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.64	-7.52	-0.38	5.43e-13	Menarche (age at onset);
CRC	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.39	5.88	0.31	1.01e-8	Colorectal cancer;
CRC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.42	0.46	8.51e-19	Lymphocyte counts;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.95	-0.4	3.07e-14	Total body bone mineral density;
CRC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	16.15	0.67	1.26e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg21251018	chr6:28226885	NKAPL	-0.62	-10.96	-0.52	4.88e-24	Cardiac Troponin-T levels;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg15786705	chr6:28176104	NA	0.48	6.42	0.33	4.89e-10	Parkinson's disease;
CRC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.5	-6.55	-0.34	2.27e-10	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.93e-15	Life satisfaction;
CRC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg14541582	chr5:601475	NA	-0.33	-6.42	-0.33	4.64e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg09873164	chr1:152488093	CRCT1	0.35	6.0	0.31	5.27e-9	Hair morphology;
CRC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02290350	chr8:58132656	NA	-0.49	-5.93	-0.31	7.66e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	7.84	0.4	6.34e-14	Body mass index;
CRC	trans	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg17903999	chr18:56338584	MALT1	0.43	7.01	0.36	1.36e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg03874509	chr1:107600012	PRMT6	0.43	5.79	0.3	1.64e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg05527609	chr1:210001259	C1orf107	-0.56	-5.88	-0.31	1.01e-8	Red blood cell count;
CRC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.48	4.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg13729891	chr17:7108468	DLG4	-0.47	-7.45	-0.38	8.41e-13	Adiponectin levels;
CRC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg04586622	chr2:25135609	ADCY3	-0.55	-10.17	-0.49	2.62e-21	Body mass index;
CRC	cis	rs9786986	0.764	rs382584	chr1:235696155	A/C	cg08848088	chr1:235714526	GNG4	0.49	5.76	0.3	1.89e-8	Body mass index;
CRC	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.59	8.39	0.42	1.41e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.58	6.15	0.32	2.3e-9	Axial length;
CRC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.57	8.3	0.42	2.81e-15	Height;
CRC	cis	rs6735179	0.549	rs56066419	chr2:1755649	G/A	cg19300414	chr2:1746591	PXDN	0.33	5.8	0.3	1.55e-8	Response to antipsychotic treatment;
CRC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.49	8.02	0.4	1.88e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.63	-0.39	2.5e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs17023223	0.537	rs17023185	chr1:119610787	C/T	cg05756136	chr1:119680316	WARS2	-0.5	-6.51	-0.34	2.87e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg09876464	chr15:85330779	ZNF592	0.47	8.09	0.41	1.14e-14	P wave terminal force;
CRC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.62	8.83	0.44	6.45e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3748682	1.000	rs3748682	chr1:38279987	C/T	cg12658694	chr1:38397304	INPP5B	-0.46	-6.09	-0.32	3.22e-9	Hypothyroidism;
CRC	cis	rs2062225	1.000	rs1384793	chr2:111766127	C/A	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg05313129	chr8:58192883	C8orf71	0.44	6.05	0.32	3.97e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.21	-0.32	1.6e-9	Tonsillectomy;
CRC	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.6	-8.12	-0.41	9.43e-15	Iron status biomarkers;
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.53	7.82	0.4	7.28e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.13	-0.32	2.49e-9	Coronary artery disease;
CRC	trans	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg26043149	chr18:55253948	FECH	-0.45	-6.75	-0.35	6.76e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.77	0.3	1.87e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.52	6.78	0.35	5.48e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04742047	chr19:14544036	PKN1	0.36	6.07	0.32	3.51e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.94	-14.88	-0.63	1.2e-38	Gout;
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.53	-0.54	4.46e-26	Alzheimer's disease;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg02683197	chr6:28174875	NA	0.57	7.53	0.38	5.05e-13	Parkinson's disease;
CRC	cis	rs6700896	0.931	rs1938498	chr1:66098653	T/C	cg04111102	chr1:66153794	NA	0.32	5.67	0.3	3.06e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.26	-0.53	4.38e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg01843034	chr6:37503916	NA	-0.48	-8.8	-0.44	7.73e-17	Cognitive performance;
CRC	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg05756136	chr1:119680316	WARS2	-0.53	-7.24	-0.37	3.29e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg02158880	chr13:53174818	NA	0.41	5.84	0.31	1.27e-8	Lewy body disease;
CRC	cis	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg15786705	chr6:28176104	NA	0.7	5.78	0.3	1.74e-8	Depression;
CRC	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-6.15	-0.32	2.28e-9	Schizophrenia;
CRC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.64	8.37	0.42	1.65e-15	Bipolar disorder;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.81	-13.1	-0.59	7.58e-32	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24833071	chr7:75115655	POM121C	0.41	6.77	0.35	5.76e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg19318889	chr4:1322082	MAEA	0.4	5.74	0.3	2.13e-8	Obesity-related traits;
CRC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	trans	rs4276421	0.806	rs2337412	chr5:45483512	G/T	cg04793272	chr11:119020941	ABCG4	-0.39	-6.46	-0.34	3.86e-10	P wave duration;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07219710	chr6:74230925	EEF1A1	-0.44	-6.37	-0.33	6.34e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs887797	0.576	rs9914573	chr17:64591389	A/G	cg27019712	chr17:64599478	PRKCA	-0.37	-5.65	-0.3	3.51e-8	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
CRC	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-6.05	-0.32	3.85e-9	Axial length;
CRC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.82	14.03	0.61	2.33e-35	Menopause (age at onset);
CRC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.54	7.66	0.39	2.09e-13	Lung cancer;
CRC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.37	7.09	0.36	8.03e-12	Iron status biomarkers;
CRC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg00745463	chr17:30367425	LRRC37B	-0.55	-6.76	-0.35	6.19e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg24331049	chr13:111365604	ING1	0.6	8.13	0.41	8.89e-15	Coronary artery disease;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg07808590	chr11:64137524	RPS6KA4	0.41	6.07	0.32	3.51e-9	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08089702	chr22:21822289	NA	0.49	6.34	0.33	7.36e-10	Thyroid stimulating hormone;
CRC	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg00919237	chr7:87102261	ABCB4	-0.54	-7.09	-0.36	8.37e-12	Gallbladder cancer;
CRC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.23	15.05	0.64	2.68e-39	Eosinophil percentage of granulocytes;
CRC	trans	rs9903692	0.954	rs2051821	chr17:46143515	T/C	cg13910583	chr8:56987998	RPS20	-0.45	-6.04	-0.32	4.2e-9	Pulse pressure;
CRC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06544989	chr22:39130855	UNC84B	0.46	7.15	0.37	5.81e-12	Menopause (age at onset);
CRC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg26028573	chr6:26043587	HIST1H2BB	0.39	5.61	0.3	4.29e-8	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.6	9.48	0.46	5.13e-19	Monocyte count;
CRC	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.23	0.64	4.96e-40	Colorectal cancer;
CRC	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg05784532	chr1:230284198	GALNT2	0.44	6.19	0.32	1.75e-9	Coronary artery disease;
CRC	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.63	10.13	0.49	3.73e-21	Hepatocellular carcinoma;
CRC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.38	-8.81	-0.44	7.14e-17	Mean corpuscular volume;
CRC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg17321639	chr7:2759063	NA	-0.53	-7.09	-0.36	8.11e-12	Height;
CRC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.24	0.37	3.17e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.54	-7.18	-0.37	4.7e-12	Height;
CRC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.58	10.5	0.5	1.94e-22	Multiple system atrophy;
CRC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21248554	chr2:27665150	KRTCAP3	0.31	6.97	0.36	1.7e-11	Total body bone mineral density;
CRC	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.54	-7.53	-0.38	4.94e-13	Triglyceride levels;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg22687807	chr8:143858763	LYNX1	-0.46	-7.14	-0.37	6.2e-12	Urinary tract infection frequency;
CRC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.98	0.55	1.12e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.49	7.63	0.39	2.54e-13	Red blood cell count;
CRC	cis	rs7246760	1.000	rs113915533	chr19:9881379	A/C	cg16876255	chr19:9731953	ZNF561	0.69	5.71	0.3	2.49e-8	Pursuit maintenance gain;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg03790207	chr6:42947109	PEX6	-0.52	-7.68	-0.39	1.82e-13	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs889398	0.617	rs55887947	chr16:69893343	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.21	-0.32	1.58e-9	Body mass index;
CRC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-7.53	-0.38	4.86e-13	Bipolar disorder;
CRC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.98	0.31	5.84e-9	Lung cancer;
CRC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.77	11.71	0.54	1.07e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg00769240	chr8:12517080	NA	-0.66	-7.45	-0.38	8.21e-13	Blood pressure (smoking interaction);
CRC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.93	16.06	0.66	3.02e-43	Parkinson's disease;
CRC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg19223190	chr17:80058835	NA	0.41	6.67	0.35	1.09e-10	Life satisfaction;
CRC	cis	rs6681460	1.000	rs1329978	chr1:67116231	C/T	cg02459107	chr1:67143332	SGIP1	0.46	7.94	0.4	3.15e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs10986311	0.722	rs6478660	chr9:127133920	A/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.49	0.34	3.22e-10	Vitiligo;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg14840727	chr4:7783969	AFAP1	-0.52	-6.1	-0.32	3.05e-9	Optic disc area;
CRC	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg01312482	chr5:178451176	ZNF879	-0.36	-5.99	-0.31	5.53e-9	Pubertal anthropometrics;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27180563	chr19:13056485	RAD23A	0.43	6.17	0.32	1.99e-9	Anxiety disorder;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg08798685	chr6:27730294	NA	-0.39	-5.92	-0.31	8.2e-9	Parkinson's disease;
CRC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.81	11.34	0.53	2.26e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1891275	0.515	rs7092745	chr10:93483820	C/T	cg07889827	chr10:93443413	NA	-0.39	-6.5	-0.34	3.01e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg14664628	chr15:75095509	CSK	0.45	6.27	0.33	1.11e-9	Systemic lupus erythematosus;
CRC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.58	-8.0	-0.4	2.08e-14	DNA methylation (variation);
CRC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	8.23	0.41	4.38e-15	Iron status biomarkers;
CRC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11764359	chr7:65958608	NA	-0.6	-9.48	-0.46	5.13e-19	Aortic root size;
CRC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.8	13.69	0.6	4.46e-34	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18252515	chr7:66147081	NA	0.42	5.9	0.31	9.22e-9	Aortic root size;
CRC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.83	-0.44	6.38e-17	Aortic root size;
CRC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-6.93	-0.36	2.19e-11	Alzheimer's disease (late onset);
CRC	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.66	6.03	0.32	4.3e-9	Left atrial antero-posterior diameter;
CRC	cis	rs7487075	0.578	rs4768713	chr12:46814047	A/G	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.45	7.78	0.39	9.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg21153622	chr11:89784906	NA	-0.48	-7.6	-0.39	3.06e-13	HDL cholesterol;
CRC	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.29	-0.33	1.01e-9	Fractional excretion of uric acid;
CRC	cis	rs17092148	0.652	rs7269526	chr20:33053293	G/C	cg08999081	chr20:33150536	PIGU	-0.45	-5.68	-0.3	3.02e-8	Neuroticism;
CRC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.83	-13.54	-0.6	1.68e-33	Cognitive function;
CRC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg19792802	chr11:65647270	CTSW	0.5	7.55	0.38	4.23e-13	Crohn's disease;
CRC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	0.95	7.98	0.4	2.46e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.25	-0.33	1.3e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg25193494	chr16:90016004	DEF8	-0.43	-6.16	-0.32	2.14e-9	Squamous cell carcinoma;
CRC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	5.89	0.31	9.33e-9	Height;
CRC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg13072238	chr3:49761600	GMPPB	-0.51	-5.78	-0.3	1.74e-8	Menarche (age at onset);
CRC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.78	-0.58	1.21e-30	Vitiligo;
CRC	trans	rs507506	0.771	rs929229	chr17:7105399	C/T	cg15655154	chr3:113604241	GRAMD1C	0.59	9.74	0.47	7.57e-20	Adiponectin levels;
CRC	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.85	-0.31	1.16e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.38	6.29	0.33	9.9e-10	Major depressive disorder;
CRC	cis	rs10924970	0.967	rs6680443	chr1:235480067	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	6.08	0.32	3.36e-9	Asthma;
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.77	8.84	0.44	5.74e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.65	-9.61	-0.47	1.91e-19	Cognitive function;
CRC	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.57	8.29	0.42	2.9e-15	Testicular germ cell tumor;
CRC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.66	-9.97	-0.48	1.23e-20	Huntington's disease progression;
CRC	cis	rs11229555	0.645	rs7929028	chr11:58188258	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg14825688	chr5:132208181	LEAP2	-0.49	-5.72	-0.3	2.37e-8	Apolipoprotein A-IV levels;
CRC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.96	15.0	0.64	3.97e-39	Testicular germ cell tumor;
CRC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.81	-10.94	-0.52	5.99e-24	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03277652	chr8:142011117	PTK2	0.47	7.68	0.39	1.87e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.66	9.69	0.47	1.07e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg26666090	chr16:58549219	SETD6	0.94	6.49	0.34	3.19e-10	Schizophrenia;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.76	0.39	1.07e-13	Cognitive ability;
CRC	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.5	-0.42	6.5e-16	Total cholesterol levels;
CRC	cis	rs4664293	0.967	rs13020365	chr2:160476404	G/A	cg08347373	chr2:160653686	CD302	-0.45	-7.25	-0.37	2.95e-12	Monocyte percentage of white cells;
CRC	cis	rs4363385	0.818	rs10888525	chr1:153000215	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.8	-0.35	5.09e-11	Inflammatory skin disease;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg07617317	chr6:118971624	C6orf204	0.52	6.48	0.34	3.43e-10	Diastolic blood pressure;
CRC	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.19	0.37	4.48e-12	Eye color traits;
CRC	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.58	7.8	0.4	8.03e-14	Adiposity;
CRC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.49	6.32	0.33	8.72e-10	Bipolar disorder;
CRC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.6	-7.57	-0.39	3.83e-13	Hip circumference adjusted for BMI;
CRC	cis	rs990171	1.000	rs6737668	chr2:103093081	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	5.71	0.3	2.5e-8	Lymphocyte counts;
CRC	cis	rs2062225	1.000	rs3789093	chr2:111750549	C/T	cg11729679	chr2:111877065	BCL2L11	-0.58	-5.63	-0.3	3.81e-8	Monocyte count;
CRC	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.32	1.41e-9	Systemic lupus erythematosus;
CRC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.2	-0.37	4.11e-12	Height;
CRC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.61	-9.75	-0.47	6.61e-20	Dental caries;
CRC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.49	-6.32	-0.33	8.28e-10	Body mass index;
CRC	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.51	7.34	0.38	1.67e-12	Testicular germ cell tumor;
CRC	cis	rs17092148	0.616	rs1122174	chr20:33110846	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.65	0.3	3.45e-8	Neuroticism;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg27615366	chr5:131592974	PDLIM4	0.33	5.86	0.31	1.1e-8	Acylcarnitine levels;
CRC	cis	rs7692995	1.000	rs13144742	chr4:17974181	A/G	cg08925142	chr4:18023851	LCORL	-0.5	-5.65	-0.3	3.39e-8	Height;
CRC	trans	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg18335740	chr13:41363409	SLC25A15	0.54	8.15	0.41	7.54e-15	Lewy body disease;
CRC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.69	-13.47	-0.6	2.94e-33	Breast cancer;
CRC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg03689076	chr20:33865952	NA	0.47	6.64	0.34	1.27e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg02007433	chr3:129722099	NA	-0.51	-6.26	-0.33	1.19e-9	Blood pressure (smoking interaction);
CRC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.41	6.19	0.32	1.76e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.85	12.58	0.57	7e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg06172871	chr16:72088244	HP	0.41	6.06	0.32	3.76e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.43	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.33	0.37	1.74e-12	Blood metabolite levels;
CRC	trans	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18288967	chr1:45987694	PRDX1	0.68	7.72	0.39	1.37e-13	Obesity-related traits;
CRC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg08213375	chr14:104286397	PPP1R13B	0.37	6.06	0.32	3.81e-9	Reticulocyte count;
CRC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-8.14	-0.41	8.44e-15	Morning vs. evening chronotype;
CRC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.43	6.19	0.32	1.8e-9	HIV-1 control;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.63	-8.7	-0.43	1.63e-16	Obesity-related traits;
CRC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg00603274	chr11:61596626	FADS2	-0.5	-6.87	-0.35	3.17e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg10677697	chr7:45961126	IGFBP3	0.41	6.88	0.35	2.98e-11	Sitting height ratio;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13980533	chr15:32322829	CHRNA7	0.4	6.26	0.33	1.18e-9	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18274279	chr7:73153629	ABHD11	0.42	5.99	0.31	5.39e-9	Anxiety disorder;
CRC	cis	rs3736485	0.816	rs6493503	chr15:51821041	C/G	cg08986416	chr15:51914746	DMXL2	-0.49	-7.06	-0.36	9.93e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.4	-0.42	1.36e-15	Bipolar disorder;
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.33	-0.53	2.36e-25	Alzheimer's disease;
CRC	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.46	7.76	0.39	1.05e-13	Red cell distribution width;
CRC	cis	rs539514	0.664	rs1323712	chr13:76300085	C/G	cg04757411	chr13:76259545	LMO7	-0.36	-6.06	-0.32	3.81e-9	Type 1 diabetes;
CRC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.59	8.79	0.44	8.6e-17	Lung cancer;
CRC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	trans	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs629535	0.783	rs538832	chr8:70033817	A/G	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg09324608	chr17:30823087	MYO1D	0.33	5.63	0.3	3.89e-8	Schizophrenia;
CRC	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.92	6.29	0.33	1.02e-9	LDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22608147	chr4:77069698	NUP54	0.51	7.66	0.39	2.09e-13	Intelligence (multi-trait analysis);
CRC	trans	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg26043149	chr18:55253948	FECH	-0.47	-7.14	-0.37	6.03e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.63	9.23	0.45	3.3e-18	Breast cancer;
CRC	cis	rs77972916	0.519	rs13411327	chr2:43515483	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.97	-0.31	6.02e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs17443541	0.507	rs4675698	chr2:200451350	T/C	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.48	-0.34	3.4e-10	Total body bone mineral density;
CRC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.56	-9.38	-0.46	1.12e-18	Body mass index;
CRC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.79	-16.33	-0.67	2.65e-44	Prostate cancer;
CRC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.45	9.12	0.45	7.46e-18	Vitiligo;
CRC	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	1.08	9.82	0.48	3.92e-20	Arsenic metabolism;
CRC	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg19407955	chr1:165599744	MGST3	-0.52	-6.62	-0.34	1.49e-10	Total ventricular volume;
CRC	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg12855166	chr17:30846586	MYO1D	-0.37	-6.02	-0.32	4.57e-9	Schizophrenia;
CRC	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs9467160	0.871	rs13191455	chr6:24448459	T/C	cg20631270	chr6:24437470	GPLD1	0.47	6.61	0.34	1.53e-10	Liver enzyme levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02157667	chr16:85722621	GINS2	0.45	6.16	0.32	2.09e-9	Response to antipsychotic treatment;
CRC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.68	-10.18	-0.49	2.43e-21	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.7	-0.39	1.61e-13	HDL cholesterol;
CRC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.52	0.43	5.78e-16	Menopause (age at onset);
CRC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.42	9.41	0.46	9.02e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.8	0.35	4.87e-11	Aortic root size;
CRC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.04	-0.32	4.09e-9	Total body bone mineral density;
CRC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.55	6.36	0.33	6.6e-10	Bipolar disorder;
CRC	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg27432699	chr2:27873401	GPN1	-0.86	-16.77	-0.68	4.89e-46	Oral cavity cancer;
CRC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.14	-0.32	2.42e-9	Alzheimer's disease (late onset);
CRC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg19824325	chr16:58548873	SETD6	1.0	6.84	0.35	3.87e-11	Schizophrenia;
CRC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.1	-0.32	2.99e-9	Blood metabolite levels;
CRC	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.7	-11.11	-0.52	1.47e-24	Coronary artery disease;
CRC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.31	0.33	9.12e-10	Melanoma;
CRC	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.72	-10.22	-0.49	1.78e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7725052	0.609	rs7728925	chr5:40456652	T/C	cg09067459	chr5:40385259	NA	0.39	6.43	0.33	4.42e-10	Pediatric autoimmune diseases;
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.61	-11.06	-0.52	2.12e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.57	7.94	0.4	3.15e-14	Lung cancer;
CRC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-7.72	-0.39	1.37e-13	Aortic root size;
CRC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	cis	rs7546094	1.000	rs1994604	chr1:113156426	C/T	cg22162597	chr1:113214053	CAPZA1	0.45	6.22	0.32	1.54e-9	Platelet distribution width;
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.38	5.87	0.31	1.04e-8	Life satisfaction;
CRC	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	0.77	7.83	0.4	6.98e-14	Pediatric areal bone mineral density (radius);
CRC	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.47	6.75	0.35	6.58e-11	Social autistic-like traits;
CRC	cis	rs77861329	1.000	rs183029	chr3:52209884	A/G	cg08692210	chr3:52188851	WDR51A	0.84	7.83	0.4	6.75e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26685501	chr1:38019921	SNIP1	0.41	6.12	0.32	2.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.54	7.76	0.39	1.11e-13	Lung cancer;
CRC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.62	-7.26	-0.37	2.83e-12	Blood trace element (Zn levels);
CRC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg08999081	chr20:33150536	PIGU	0.45	5.87	0.31	1.05e-8	Protein C levels;
CRC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg12639453	chr1:2035780	PRKCZ	0.3	5.6	0.3	4.46e-8	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05454237	chr11:14913849	CYP2R1	0.47	6.57	0.34	1.92e-10	Response to antipsychotic treatment;
CRC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.54	8.25	0.41	3.77e-15	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10309340	chr10:102747329	C10orf2;MRPL43	-0.44	-6.86	-0.35	3.39e-11	Myopia (pathological);
CRC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.52	8.89	0.44	4.24e-17	Aortic root size;
CRC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.39	-0.56	3.33e-29	Type 2 diabetes;
CRC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.59	8.46	0.42	9.13e-16	Pancreatic cancer;
CRC	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.92	-0.31	8.16e-9	Type 2 diabetes;
CRC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06585566	chr19:57276794	NA	0.35	6.33	0.33	8.14e-10	Interleukin-6 levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26667821	chr1:155099774	EFNA1	0.45	6.49	0.34	3.17e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg08888203	chr3:10149979	C3orf24	0.6	8.42	0.42	1.22e-15	Alzheimer's disease;
CRC	cis	rs1958560	0.932	rs61987994	chr14:66070733	A/G	cg03016385	chr14:66212404	NA	-0.45	-6.19	-0.32	1.81e-9	Menarche (age at onset);
CRC	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg07930552	chr6:133119739	C6orf192	0.64	5.64	0.3	3.58e-8	Type 2 diabetes nephropathy;
CRC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg00343986	chr7:65444356	GUSB	-0.5	-7.51	-0.38	5.55e-13	Aortic root size;
CRC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs2257205	0.667	rs8068677	chr17:56869386	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-6.26	-0.33	1.2e-9	Schizophrenia;
CRC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg21681030	chr2:46777652	RHOQ	0.45	6.05	0.32	3.89e-9	Height;
CRC	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-7.28	-0.37	2.49e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.38	-0.33	6.15e-10	Bipolar disorder;
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg23590916	chr17:43697445	MGC57346	0.7	7.4	0.38	1.17e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-0.72	-7.01	-0.36	1.39e-11	Magnesium levels;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg15786705	chr6:28176104	NA	0.55	7.73	0.39	1.34e-13	Parkinson's disease;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg12516270	chr8:143859308	LYNX1	0.44	7.77	0.39	9.92e-14	Urinary tract infection frequency;
CRC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg12046867	chr14:103022105	NA	-0.76	-9.2	-0.45	4.16e-18	Platelet count;
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00166722	chr3:10149974	C3orf24	0.66	8.84	0.44	5.84e-17	Alzheimer's disease;
CRC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	7.44	0.38	8.72e-13	Height;
CRC	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.9	-0.44	3.86e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg13837822	chr10:26931731	LOC731789	0.56	8.54	0.43	5.12e-16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg19223190	chr17:80058835	NA	-0.38	-6.05	-0.32	3.96e-9	Life satisfaction;
CRC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.7	-12.8	-0.58	1.02e-30	Educational attainment;
CRC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.35	0.38	1.61e-12	Hip circumference adjusted for BMI;
CRC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.64	10.52	0.5	1.6400000000000001e-22	Calcium levels;
CRC	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.93	15.32	0.65	2.37e-40	Dupuytren's disease;
CRC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.61	7.59	0.39	3.37e-13	Post bronchodilator FEV1;
CRC	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.58	-8.22	-0.41	4.6e-15	Mean platelet volume;
CRC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg12193833	chr17:30244370	NA	-0.75	-8.75	-0.43	1.13e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg09658497	chr7:2847517	GNA12	-0.4	-6.66	-0.34	1.14e-10	Height;
CRC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.93	-0.31	7.87e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18402987	chr7:1209562	NA	0.43	6.47	0.34	3.54e-10	Longevity;Endometriosis;
CRC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02725872	chr8:58115012	NA	-0.52	-7.24	-0.37	3.13e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.54	7.89	0.4	4.38e-14	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	1.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.36	6.11	0.32	2.86e-9	Sitting height ratio;
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg01639898	chr1:32083012	HCRTR1	0.31	6.42	0.33	4.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.25e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.72	-0.43	1.39e-16	Bipolar disorder;
CRC	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg07828340	chr4:882639	GAK	0.92	8.92	0.44	3.35e-17	Parkinson's disease;
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg15147215	chr3:52552868	STAB1	-0.6	-10.0	-0.48	9.92e-21	Bipolar disorder;
CRC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-9.31	-0.46	1.88e-18	Chronic sinus infection;
CRC	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.48	7.08	0.36	8.63e-12	Autism;
CRC	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg07606381	chr6:8435919	SLC35B3	-0.41	-6.08	-0.32	3.27e-9	Motion sickness;
CRC	trans	rs6000782	0.590	rs1079981	chr22:37929464	A/G	cg01410359	chr2:38302230	CYP1B1	0.45	6.01	0.31	4.9e-9	Autoimmune hepatitis type-1;
CRC	cis	rs73206853	0.686	rs7974047	chr12:111119631	C/T	cg12870014	chr12:110450643	ANKRD13A	0.76	8.03	0.4	1.8e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg21153622	chr11:89784906	NA	-0.37	-5.98	-0.31	5.8e-9	Height;
CRC	cis	rs17767392	0.957	rs35692397	chr14:71756683	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.82	-0.35	4.34e-11	Mitral valve prolapse;
CRC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	6.18	0.32	1.95e-9	Lung cancer;
CRC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.19	-0.32	1.79e-9	Axial length;
CRC	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.74	0.35	7.19e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs965469	0.857	rs6037523	chr20:3249463	A/T	cg25506879	chr20:3388711	C20orf194	-0.38	-5.75	-0.3	2e-8	IFN-related cytopenia;
CRC	cis	rs12024301	0.557	rs10911385	chr1:183606183	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	10.5	0.5	1.98e-22	Hip circumference adjusted for BMI;
CRC	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.55	8.67	0.43	2.01e-16	Mean corpuscular volume;
CRC	cis	rs4727963	0.511	rs846655	chr7:122645560	A/G	cg03640110	chr7:122635026	TAS2R16	-0.52	-10.08	-0.49	5.33e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16925090	chr11:101785516	KIAA1377;ANGPTL5	0.46	6.71	0.35	8.64e-11	Response to antipsychotic treatment;
CRC	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.38	5.96	0.31	6.37e-9	Endometrial cancer;
CRC	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.45	-6.28	-0.33	1.07e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.75e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.46e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg27661571	chr11:113659931	NA	-0.95	-11.08	-0.52	1.91e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18867708	chr6:26865862	GUSBL1	-0.42	-5.89	-0.31	9.8e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg18758796	chr5:131593413	PDLIM4	0.4	6.46	0.34	3.83e-10	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03323938	chr19:39663667	PAK4	-0.36	-5.98	-0.31	5.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg09998033	chr7:158218633	PTPRN2	-0.44	-5.89	-0.31	9.38e-9	Obesity-related traits;
CRC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg03340356	chr1:67600835	NA	0.25	5.71	0.3	2.52e-8	Psoriasis;
CRC	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg25885038	chr17:56607967	SEPT4	-0.51	-7.72	-0.39	1.44e-13	Vitamin D levels;
CRC	trans	rs10021731	0.718	rs1585447	chr4:115412068	G/C	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	8.95	0.44	2.71e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2975734	0.680	rs1052453	chr8:10108325	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.59	-0.39	3.24e-13	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs939584	1.000	rs10190313	chr2:647577	A/G	cg03610516	chr2:642275	NA	0.41	5.93	0.31	7.83e-9	Body mass index;
CRC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.57	-0.34	1.94e-10	Major depressive disorder;
CRC	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.89	21.05	0.76	6.83e-63	Longevity;
CRC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.3	0.37	2.21e-12	Motion sickness;
CRC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.47	-0.38	7.52e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg13567813	chr19:50879636	NR1H2	-0.61	-6.13	-0.32	2.49e-9	Plasma thyroid-stimulating hormone levels;
CRC	trans	rs963731	0.649	rs297129	chr2:39299271	C/T	cg13401531	chr11:70333281	SHANK2	-0.69	-6.1	-0.32	3.02e-9	Corticobasal degeneration;
CRC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg23815491	chr16:72088622	HP	0.49	7.51	0.38	5.77e-13	Fibrinogen levels;
CRC	cis	rs9925964	0.869	rs749670	chr16:31088625	A/G	cg02466173	chr16:30829666	NA	0.43	5.87	0.31	1.09e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.68	-11.51	-0.54	5.59e-26	P wave terminal force;
CRC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.58	0.5	1.02e-22	Platelet count;
CRC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07690219	chr3:49449608	TCTA;RHOA	0.53	5.81	0.31	1.46e-8	Menarche (age at onset);
CRC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg18099408	chr3:52552593	STAB1	0.34	5.83	0.31	1.35e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg07514618	chr14:103979422	NA	-0.44	-6.9	-0.36	2.66e-11	Body mass index;
CRC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.39	-7.54	-0.38	4.74e-13	Mean corpuscular volume;
CRC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	8.45	0.42	9.27e-16	Hemoglobin concentration;
CRC	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.61	-8.59	-0.43	3.43e-16	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.89	14.08	0.61	1.49e-35	Schizophrenia;
CRC	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.49	-5.77	-0.3	1.86e-8	Hip geometry;
CRC	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg07125278	chr16:67683757	RLTPR	-0.48	-6.6	-0.34	1.68e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.55	-8.99	-0.44	2.04e-17	Congenital heart disease (maternal effect);
CRC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.02	0.32	4.59e-9	Cognitive ability;
CRC	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg08477640	chr19:41863820	B9D2	0.48	7.46	0.38	7.65e-13	Migraine;Coronary artery disease;
CRC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.33	-6.08	-0.32	3.37e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg15763984	chr4:1342303	KIAA1530	0.34	5.69	0.3	2.76e-8	Obesity-related traits;
CRC	cis	rs2811415	0.597	rs2878507	chr3:127793923	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.86	-0.31	1.12e-8	Lung function (FEV1/FVC);
CRC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-10.77	-0.51	2.25e-23	Migraine;Coronary artery disease;
CRC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg03160526	chr17:80928410	B3GNTL1	0.64	8.89	0.44	4.14e-17	Glycated hemoglobin levels;
CRC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg19223190	chr17:80058835	NA	-0.39	-6.06	-0.32	3.63e-9	Life satisfaction;
CRC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-9.0	-0.44	1.83e-17	Sudden cardiac arrest;
CRC	cis	rs3996993	0.809	rs4144185	chr6:52702948	A/G	cg20803780	chr6:52668592	GSTA1	-0.36	-6.74	-0.35	7.18e-11	Hemoglobin concentration;
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.48	8.09	0.41	1.14e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.74	-0.35	7.23e-11	Major depressive disorder;
CRC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.1	-0.32	2.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.77	11.67	0.54	1.46e-26	Menarche (age at onset);
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg06207120	chr15:45996521	NA	0.32	7.82	0.4	7.26e-14	Waist circumference;Weight;
CRC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.54	7.97	0.4	2.68e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.48	7.53	0.38	4.84e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.79	14.23	0.62	3.84e-36	Metabolite levels;
CRC	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg17674042	chr6:34482479	PACSIN1	-0.67	-7.79	-0.39	8.91e-14	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13012494	chr21:47604986	C21orf56	0.42	6.39	0.33	5.8e-10	Testicular germ cell tumor;
CRC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-8.04	-0.41	1.66e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.42	-0.38	1.03e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	6.99	0.36	1.54e-11	Obesity-related traits;
CRC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.05	0.32	3.89e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.17	-0.32	1.96e-9	Bladder cancer;
CRC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.44	5.83	0.31	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.53	-7.32	-0.37	1.94e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10208940	0.920	rs6724540	chr2:68779356	A/G	cg12452813	chr2:68675892	NA	0.47	5.9	0.31	9.19e-9	Urate levels in lean individuals;
CRC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-6.79	-0.35	5.35e-11	Height;
CRC	cis	rs1158570	0.500	rs7846376	chr8:131155443	G/A	cg26053073	chr8:131455383	NA	-0.41	-6.22	-0.32	1.51e-9	Platelet count;
CRC	cis	rs10924970	0.781	rs10802589	chr1:235444049	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.84e-9	Asthma;
CRC	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.67	10.41	0.5	4.15e-22	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg21153622	chr11:89784906	NA	0.49	7.98	0.4	2.4e-14	HDL cholesterol;
CRC	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.49	-7.15	-0.37	5.65e-12	Breast cancer;
CRC	cis	rs10071761	0.513	rs56952742	chr5:40368332	A/G	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.04	-0.32	4.16e-9	Bipolar disorder;
CRC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.94	0.4	3.18e-14	Parkinson's disease;
CRC	cis	rs11212617	0.934	rs2056267	chr11:108061808	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.85	0.31	1.2e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs12478296	1.000	rs6717667	chr2:242997530	C/T	cg06834434	chr14:75079333	LTBP2	0.51	6.14	0.32	2.31e-9	Obesity-related traits;
CRC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.57	-8.94	-0.44	2.79e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.9	-0.31	8.92e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.53	8.99	0.44	1.95e-17	Testicular germ cell tumor;
CRC	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.41	-0.46	8.95e-19	Neuroticism;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21638108	chr19:19431283	KIAA0892;SF4	0.38	6.31	0.33	9.07e-10	Obesity-related traits;
CRC	cis	rs6662572	0.737	rs4518839	chr1:46376690	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.85	-0.31	1.21e-8	Blood protein levels;
CRC	cis	rs863345	0.604	rs11265008	chr1:158498671	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.4	6.02	0.31	4.76e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg15654264	chr1:150340011	RPRD2	0.42	6.19	0.32	1.76e-9	Migraine;
CRC	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg11901034	chr3:128598214	ACAD9	-0.5	-6.23	-0.32	1.44e-9	IgG glycosylation;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Depression;
CRC	cis	rs12431939	0.948	rs67116854	chr14:51670464	G/A	cg23942311	chr14:51606299	NA	-0.53	-6.35	-0.33	7.21e-10	Cancer;
CRC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.75	-0.35	6.83e-11	Body mass index;
CRC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.42	6.7	0.35	9.31e-11	High light scatter reticulocyte count;
CRC	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg06307176	chr5:131281290	NA	-0.42	-6.31	-0.33	8.8e-10	Life satisfaction;
CRC	cis	rs7725052	0.609	rs10052842	chr5:40450848	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.61	-0.34	1.53e-10	Pediatric autoimmune diseases;
CRC	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.46	-7.48	-0.38	6.93e-13	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25832598	chr1:247094143	AHCTF1	0.41	6.01	0.31	4.88e-9	Response to antipsychotic treatment;
CRC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg20684491	chr1:25596433	NA	0.43	7.68	0.39	1.88e-13	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs9463078	0.774	rs12199720	chr6:45307443	C/T	cg25276700	chr6:44698697	NA	0.29	6.98	0.36	1.6e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.43	9.59	0.47	2.25e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-7.25	-0.37	3.01e-12	Putamen volume;
CRC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	1.28	14.22	0.62	4.24e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.52	0.43	5.9e-16	Colonoscopy-negative controls vs population controls;
CRC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg27661571	chr11:113659931	NA	-0.98	-10.93	-0.52	6.31e-24	Hip circumference adjusted for BMI;
CRC	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg12908607	chr1:44402522	ARTN	-0.34	-6.06	-0.32	3.7e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.8	13.54	0.6	1.66e-33	Menopause (age at onset);
CRC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg24578937	chr1:2090814	PRKCZ	-0.42	-7.75	-0.39	1.16e-13	Height;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11645453	chr3:52864694	ITIH4	0.35	6.02	0.32	4.62e-9	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.78	-0.3	1.75e-8	Bipolar disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05278650	chr3:13009132	IQSEC1	-0.42	-6.31	-0.33	9.01e-10	Myopia (pathological);
CRC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	-0.61	-6.89	-0.36	2.87e-11	Tonsillectomy;
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11645453	chr3:52864694	ITIH4	0.36	6.22	0.32	1.48e-9	Bipolar disorder;
CRC	cis	rs9783347	1.000	rs4150610	chr11:18364140	A/G	cg15585147	chr11:18324498	HPS5	0.45	6.32	0.33	8.5e-10	Pancreatic cancer;
CRC	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg15051795	chr19:1816298	MIR1909;REXO1	-0.46	-6.05	-0.32	3.89e-9	Mean platelet volume;
CRC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.46	6.82	0.35	4.49e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg15845792	chr6:28175446	NA	-1.0	-13.56	-0.6	1.39e-33	Depression;
CRC	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.8	13.15	0.59	4.87e-32	Height;
CRC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.1	-15.94	-0.66	8.66e-43	Hip circumference adjusted for BMI;
CRC	cis	rs3823572	0.542	rs10224226	chr7:133626662	G/A	cg03336402	chr7:133662267	EXOC4	0.68	10.39	0.5	4.76e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.7	-11.61	-0.54	2.42e-26	Breast cancer;
CRC	cis	rs3823572	0.564	rs4728305	chr7:133666949	C/T	cg03336402	chr7:133662267	EXOC4	-0.67	-10.6	-0.5	8.85e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.27	0.33	1.16e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.52	-7.4	-0.38	1.13e-12	Caudate activity during reward;
CRC	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.73	9.69	0.47	1.05e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.49	-6.83	-0.35	4.12e-11	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.26	-0.33	1.19e-9	Bipolar disorder;
CRC	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	9.65	0.47	1.41e-19	Systolic blood pressure;
CRC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.67	-0.43	1.98e-16	Aortic root size;
CRC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg03037974	chr15:76606532	NA	0.83	17.0	0.68	5.85e-47	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.59	8.97	0.44	2.22e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2735413	0.837	rs4888735	chr16:78083742	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.42	-0.38	1.03e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.27	0.59	1.79e-32	Platelet count;
CRC	trans	rs4272382	1	rs4272382	chr8:8433488	C/T	cg13072446	chr1:151019727	C1orf56;BNIPL	-0.53	-5.96	-0.31	6.32e-9	Response to cytidine analogues (gemcitabine);
CRC	trans	rs1864729	1.000	rs1835743	chr8:98282643	T/C	cg08679828	chr8:102218111	ZNF706	-0.63	-7.54	-0.38	4.76e-13	Estradiol plasma levels (breast cancer);
CRC	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.53	-7.31	-0.37	2.09e-12	Schizophrenia;
CRC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.33e-16	Response to antipsychotic treatment;
CRC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.91	-0.44	3.55e-17	Electroencephalogram traits;
CRC	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.44	5.97	0.31	6.06e-9	Morning vs. evening chronotype;
CRC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg15848620	chr12:58087721	OS9	-0.63	-8.65	-0.43	2.26e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg23100626	chr2:96804247	ASTL	0.32	8.93	0.44	2.97e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.35	-0.69	2.52e-48	Height;
CRC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-6.11	-0.32	2.8e-9	IgG glycosylation;
CRC	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.42	-7.28	-0.37	2.52e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.55	-0.5	1.31e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs78077440	1.000	rs78951062	chr5:40323887	C/A	cg09067459	chr5:40385259	NA	-0.54	-5.88	-0.31	9.99e-9	Multiple sclerosis;
CRC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.44	6.43	0.33	4.5e-10	Menarche (age at onset);
CRC	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.25	0.41	3.84e-15	Platelet distribution width;
CRC	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.05	-0.36	1.06e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg21302420	chr1:112162376	RAP1A	0.62	6.29	0.33	9.82e-10	Skin colour saturation;
CRC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.59	6.58	0.34	1.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.72	-0.35	8.09e-11	Mean corpuscular volume;
CRC	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.74	0.3	2.12e-8	Coronary artery disease;
CRC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.55	7.74	0.39	1.23e-13	Height;
CRC	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.48	6.46	0.34	3.73e-10	Lymphocyte counts;Fibrinogen;
CRC	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.49	7.69	0.39	1.67e-13	Red blood cell count;
CRC	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg20503657	chr10:835505	NA	0.73	8.54	0.43	4.99e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.35	0.33	7.02e-10	Tonsillectomy;
CRC	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.42	-6.84	-0.35	3.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CRC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.51	-7.04	-0.36	1.16e-11	Corneal structure;
CRC	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.58	-7.19	-0.37	4.46e-12	Platelet distribution width;
CRC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg04121214	chr22:50244548	NA	0.46	7.18	0.37	4.73e-12	Schizophrenia;
CRC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.55	-7.58	-0.39	3.52e-13	Colorectal cancer;
CRC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg26116260	chr4:7069785	GRPEL1	-0.66	-5.74	-0.3	2.13e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.62	-7.45	-0.38	8.46e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7113874	0.589	rs7939731	chr11:8510299	T/G	cg20771178	chr11:8615675	STK33	-0.35	-5.75	-0.3	2.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg00646200	chr1:148855367	NA	-0.35	-6.53	-0.34	2.53e-10	Hip geometry;
CRC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-6.7	-0.35	9.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg22110888	chr17:80059540	CCDC57	0.41	6.39	0.33	5.57e-10	Life satisfaction;
CRC	cis	rs3018066	0.867	rs7693333	chr4:107047594	A/C	cg01869342	chr4:106983673	TBCK	-0.37	-5.8	-0.3	1.58e-8	Cancer;
CRC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.43	-6.11	-0.32	2.77e-9	DNA methylation (variation);
CRC	cis	rs6534441	1.000	rs12651542	chr4:125419479	T/G	cg21609808	chr4:125404261	NA	-0.38	-5.76	-0.3	1.98e-8	Major depressive disorder;
CRC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.42	9.27	0.46	2.5e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.4	-0.33	5.38e-10	Aortic root size;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg15845792	chr6:28175446	NA	0.92	13.04	0.58	1.34e-31	Parkinson's disease;
CRC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg07636037	chr3:49044803	WDR6	-0.82	-6.2	-0.32	1.68e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	0.6	6.69	0.35	9.36e-11	Prostate cancer;
CRC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.35e-16	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.09	0.32	3.1e-9	Depression;
CRC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg08888203	chr3:10149979	C3orf24	0.49	7.57	0.39	3.85e-13	Alzheimer's disease;
CRC	cis	rs6743226	0.748	rs12620606	chr2:242154015	A/G	cg10021735	chr2:242295487	FARP2	0.43	6.21	0.32	1.58e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	trans	rs2303319	0.504	rs56405014	chr2:162497603	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.58e-9	Cognitive function;
CRC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.46	6.76	0.35	6.27e-11	Obesity-related traits;
CRC	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg24562669	chr7:97807699	LMTK2	-0.51	-7.77	-0.39	1.03e-13	Breast cancer;
CRC	trans	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg10756647	chr7:56101905	PSPH	-0.79	-8.16	-0.41	7.21e-15	Diabetic kidney disease;
CRC	cis	rs12476592	0.602	rs4671065	chr2:63791131	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs4663866	0.901	rs3739067	chr2:239184203	G/A	cg16914508	chr2:239161102	PER2	0.74	7.35	0.38	1.56e-12	Irritable bowel syndrome;
CRC	trans	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg24628676	chr5:59189846	PDE4D	-0.3	-5.96	-0.31	6.32e-9	Urinary tract infection frequency;
CRC	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6973256	0.605	rs10227672	chr7:133326196	G/C	cg10665199	chr7:133106180	EXOC4	-0.45	-7.09	-0.36	8.48e-12	Intelligence (multi-trait analysis);
CRC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.5	-7.68	-0.39	1.86e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.47	-6.65	-0.34	1.26e-10	Height;
CRC	trans	rs10230207	0.647	rs985882	chr7:19575505	A/G	cg03214765	chr19:55678215	C19orf51	0.46	6.3	0.33	9.3e-10	Intracranial aneurysm;
CRC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs1044826	0.553	rs295469	chr3:139212900	G/A	cg00490450	chr3:139108681	COPB2	0.44	6.46	0.34	3.84e-10	Obesity-related traits;
CRC	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg13491945	chr12:107078410	RFX4	0.35	6.07	0.32	3.52e-9	Heart rate;
CRC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.44	-7.38	-0.38	1.3e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.19	0.32	1.82e-9	Parkinson's disease;
CRC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06634786	chr22:41940651	POLR3H	-0.44	-6.02	-0.32	4.61e-9	Vitiligo;
CRC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.32	0.37	1.97e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06396496	chr3:53289970	TKT	0.52	7.32	0.37	1.91e-12	Response to antipsychotic treatment;
CRC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.44	-6.53	-0.34	2.43e-10	Body mass index;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg01758942	chr3:52551074	STAB1	0.32	6.31	0.33	9.19e-10	Hemoglobin concentration;
CRC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.47	6.43	0.33	4.41e-10	Aortic root size;
CRC	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg15997130	chr1:24165203	NA	-0.66	-8.31	-0.42	2.49e-15	Immature fraction of reticulocytes;
CRC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.83	-14.13	-0.61	9.4e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11212617	1.000	rs608086	chr11:108185023	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.22	0.32	1.52e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07362569	chr17:61921086	SMARCD2	0.38	5.7	0.3	2.66e-8	Prudent dietary pattern;
CRC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.6	9.14	0.45	6.54e-18	Corneal astigmatism;
CRC	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg08717414	chr16:71523259	ZNF19	-0.48	-5.93	-0.31	7.85e-9	Post bronchodilator FEV1;
CRC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg03160526	chr17:80928410	B3GNTL1	0.55	7.79	0.39	8.78e-14	Glycated hemoglobin levels;
CRC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg18512352	chr11:47633146	NA	0.36	7.1	0.36	7.8e-12	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09435190	chr22:50968297	TYMP	0.39	6.0	0.31	5.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.44	-6.0	-0.31	5.17e-9	Longevity;Endometriosis;
CRC	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	21.9	0.77	3.14e-66	Colorectal cancer;
CRC	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.67	6.91	0.36	2.51e-11	Type 2 diabetes;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg03623178	chr6:28175578	NA	0.75	10.59	0.5	9.61e-23	Parkinson's disease;
CRC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.64	8.66	0.43	2.14e-16	Multiple sclerosis;
CRC	trans	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg26043149	chr18:55253948	FECH	-0.57	-8.28	-0.42	3.22e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg18806716	chr10:30721971	MAP3K8	0.47	7.22	0.37	3.6e-12	Inflammatory bowel disease;
CRC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg05562828	chr17:3906858	NA	0.46	5.96	0.31	6.33e-9	Type 2 diabetes;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.96	16.38	0.67	1.56e-44	Height;
CRC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.72	13.1	0.59	7.36e-32	Myeloid white cell count;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11717700	chr4:154387421	KIAA0922	0.38	6.02	0.31	4.7e-9	Schizophrenia;
CRC	cis	rs6662572	0.737	rs1355641	chr1:46599143	T/A	cg08644498	chr1:46502608	NA	0.44	6.99	0.36	1.57e-11	Blood protein levels;
CRC	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.72	-10.35	-0.5	6.43e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg06988349	chr10:69991859	ATOH7	0.34	6.18	0.32	1.87e-9	Optic disc area;
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.48	-6.33	-0.33	8.23e-10	Caudate activity during reward;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12648201	chr2:27665141	KRTCAP3	0.29	5.78	0.3	1.69e-8	Total body bone mineral density;
CRC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.52	0.34	2.71e-10	Mean platelet volume;
CRC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-7.94	-0.4	3.31e-14	Neuroticism;
CRC	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg23417306	chr2:180868811	CWC22	-0.45	-6.09	-0.32	3.1e-9	Schizophrenia;
CRC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg02725872	chr8:58115012	NA	-0.37	-6.64	-0.34	1.29e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.47	6.14	0.32	2.37e-9	Body mass index;
CRC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg26061582	chr7:22766209	IL6	0.51	8.04	0.41	1.66e-14	Lung cancer;
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg25164649	chr6:28176230	NA	0.62	5.91	0.31	8.41e-9	Depression;
CRC	cis	rs4664293	0.867	rs13432	chr2:160625727	C/G	cg08347373	chr2:160653686	CD302	-0.49	-7.7	-0.39	1.64e-13	Monocyte percentage of white cells;
CRC	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	trans	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg06840491	chr10:48416966	GDF2	-0.35	-6.18	-0.32	1.88e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.34	-6.14	-0.32	2.38e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs10242455	0.702	rs73397481	chr7:99030108	C/T	cg09045935	chr12:6379348	NA	1.18	9.09	0.45	9.34e-18	Blood metabolite levels;
CRC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg04450456	chr4:17643702	FAM184B	0.37	5.87	0.31	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.91	-16.71	-0.68	7.93e-46	Body mass index;
CRC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg20607287	chr7:12443886	VWDE	-0.64	-6.38	-0.33	6.05e-10	Coronary artery disease;
CRC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.69	-8.55	-0.43	4.81e-16	Coronary artery disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02281226	chr17:9479218	STX8;WDR16	-0.41	-6.75	-0.35	6.8e-11	Aortic root size;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg25164649	chr6:28176230	NA	0.47	6.95	0.36	2e-11	Cardiac Troponin-T levels;
CRC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.39	0.42	1.47e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg22495460	chr2:25135724	ADCY3	0.66	11.01	0.52	3.24e-24	Body mass index in non-asthmatics;
CRC	cis	rs7078219	0.543	rs10786557	chr10:101283328	C/G	cg09788492	chr10:101292477	NKX2-3	0.28	5.64	0.3	3.67e-8	Dental caries;
CRC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg20607287	chr7:12443886	VWDE	-0.68	-7.33	-0.37	1.84e-12	Coronary artery disease;
CRC	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg14515779	chr1:101123966	NA	-0.35	-6.18	-0.32	1.95e-9	Monocyte count;
CRC	trans	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.35	-0.33	7.24e-10	Lung cancer in ever smokers;
CRC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.39	0.38	1.19e-12	Lung cancer in ever smokers;
CRC	cis	rs6840360	0.642	rs7658169	chr4:152353414	G/A	cg09659197	chr4:152720779	NA	0.33	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.41	6.39	0.33	5.7e-10	Recombination rate (males);
CRC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Depression;
CRC	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08517826	chr3:33759932	CLASP2	-0.42	-6.27	-0.33	1.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs972578	0.967	rs4822236	chr22:43358088	A/G	cg01576275	chr22:43409880	NA	-0.45	-7.25	-0.37	3.08e-12	Mean platelet volume;
CRC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.65	-11.58	-0.54	2.98e-26	Breast cancer;
CRC	cis	rs10888329	0.741	rs6587438	chr1:248355881	G/C	cg00666640	chr1:248458726	OR2T12	0.44	6.97	0.36	1.75e-11	Autism spectrum disorder;
CRC	cis	rs2072510	1.000	rs1978331	chr12:96409201	A/G	cg22491680	chr12:96389547	HAL	-0.37	-5.88	-0.31	9.99e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.25	-0.45	3.02e-18	Alcohol dependence;
CRC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.82	0.7	3.44e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.77	-0.35	5.99e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	0.74	8.28	0.42	3.11e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.73	9.9	0.48	2.16e-20	Coronary artery disease;
CRC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg04121214	chr22:50244548	NA	0.42	5.95	0.31	6.94e-9	Schizophrenia;
CRC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.49	7.33	0.37	1.78e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg02683197	chr6:28174875	NA	-0.44	-6.1	-0.32	2.92e-9	Cardiac Troponin-T levels;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.4	6.59	0.34	1.79e-10	Longevity;
CRC	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.49	7.24	0.37	3.28e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg14003231	chr6:33640908	ITPR3	0.51	8.26	0.41	3.71e-15	Plateletcrit;
CRC	cis	rs10760158	0.832	rs3827678	chr9:124046722	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.8	-0.3	1.57e-8	Pulse pressure;
CRC	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.77	-12.04	-0.55	6.75e-28	Body mass index;
CRC	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.09	-0.41	1.14e-14	Neuroticism;
CRC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.43	7.1	0.36	7.77e-12	Obesity-related traits;
CRC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.98	-0.4	2.38e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.49	0.34	3.14e-10	Menarche (age at onset);
CRC	cis	rs995000	0.899	rs11577840	chr1:62991369	T/C	cg19896129	chr1:63156450	NA	-0.45	-6.94	-0.36	2.07e-11	Triglyceride levels;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24513433	chr18:47088234	LIPG	0.39	6.26	0.33	1.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg17764715	chr19:33622953	WDR88	0.45	6.52	0.34	2.63e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7739232	0.920	rs74447887	chr6:53529219	A/G	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	8.0	0.4	2.17e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.89	-0.36	2.82e-11	Response to antipsychotic treatment;
CRC	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.69	-10.89	-0.51	8.35e-24	Neurofibrillary tangles;
CRC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.33	1.26e-9	Heart rate;
CRC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg18479299	chr3:125709523	NA	-0.55	-6.58	-0.34	1.86e-10	Blood pressure (smoking interaction);
CRC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.76	0.39	1.09e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.69	9.03	0.45	1.51e-17	Uric acid levels;
CRC	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.54	-0.47	3.46e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6743376	0.533	rs10206428	chr2:113826475	A/G	cg24553058	chr2:113831203	IL1F10	0.35	5.83	0.31	1.32e-8	Inflammatory biomarkers;
CRC	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.58	-6.72	-0.35	7.93e-11	Major depressive disorder;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.76	12.66	0.57	3.25e-30	Longevity;Endometriosis;
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.97	0.44	2.23e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs73206853	0.841	rs73206847	chr12:110672353	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	7.8	0.39	8.42e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg24375607	chr4:120327624	NA	-0.4	-6.33	-0.33	8.23e-10	Corneal astigmatism;
CRC	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg01181863	chr3:195395398	SDHAP2	0.55	6.46	0.34	3.66e-10	Red cell distribution width;
CRC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.54	7.74	0.39	1.19e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2415984	0.622	rs11846013	chr14:46932291	A/C	cg14871534	chr14:47121158	RPL10L	0.43	6.29	0.33	1.04e-9	Number of children ever born;
CRC	cis	rs2882667	0.931	rs12719518	chr5:138340976	T/C	cg09476006	chr5:138032270	NA	0.44	7.32	0.37	1.97e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg10298567	chr3:47292165	KIF9	0.38	6.09	0.32	3.06e-9	Colorectal cancer;
CRC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg26838691	chr2:24397539	C2orf84	0.4	5.66	0.3	3.22e-8	Asthma;
CRC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg05585544	chr11:47624801	NA	-0.47	-8.25	-0.41	3.78e-15	Subjective well-being;
CRC	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.55	-8.94	-0.44	2.78e-17	Coronary artery disease;
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	6.31	0.33	9.06e-10	Breast cancer;
CRC	trans	rs1376359	0.636	rs7536383	chr1:103123803	C/A	cg16220183	chr17:56609687	SEPT4	-0.47	-6.48	-0.34	3.34e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3812762	0.701	rs4929915	chr11:8824418	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.77	-0.3	1.86e-8	Hypospadias;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.71	-12.4	-0.56	3.17e-29	Dental caries;
CRC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.39	5.72	0.3	2.45e-8	Aortic root size;
CRC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.42	-0.46	8.21e-19	Platelet count;
CRC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.19	0.32	1.8e-9	Lung cancer;
CRC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	13.59	0.6	1.06e-33	Colorectal cancer;
CRC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.8e-8	Colorectal cancer;
CRC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.63	6.99	0.36	1.58e-11	Lymphocyte counts;
CRC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.59	7.86	0.4	5.38e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg03948781	chr1:205179583	DSTYK	0.43	5.94	0.31	7.43e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg09659197	chr4:152720779	NA	0.4	8.26	0.41	3.7e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	7.39	0.38	1.21e-12	Schizophrenia;
CRC	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.35	5.71	0.3	2.59e-8	Menarche (age at onset);
CRC	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.54	0.38	4.64e-13	Height;
CRC	cis	rs6604026	0.922	rs71652510	chr1:93366357	T/C	cg22128645	chr1:93425802	FAM69A	-0.4	-5.86	-0.31	1.15e-8	Multiple sclerosis;
CRC	cis	rs755249	0.567	rs61779309	chr1:39940499	T/C	cg18385671	chr1:39797026	MACF1	-0.41	-5.67	-0.3	3.1e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg12183467	chr14:104352244	NA	-0.47	-6.76	-0.35	6.16e-11	Bipolar disorder;
CRC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.4	6.18	0.32	1.84e-9	Methadone dose in opioid dependence;
CRC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.15	-0.37	5.5e-12	Blood metabolite levels;
CRC	cis	rs4731207	0.596	rs1481332	chr7:124577262	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-10.28	-0.49	1.12e-21	Heart rate;
CRC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.44	5.99	0.31	5.36e-9	Cognitive ability;
CRC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg05304507	chr6:116381966	FRK	0.29	7.96	0.4	2.91e-14	Cholesterol, total;LDL cholesterol;
CRC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.97	-0.36	1.74e-11	Blood pressure (smoking interaction);
CRC	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg27398640	chr15:77910606	LINGO1	-0.46	-8.05	-0.41	1.5e-14	Type 2 diabetes;
CRC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.64	11.83	0.55	3.91e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23629415	chr14:54955474	GMFB	0.44	6.26	0.33	1.2e-9	Response to antipsychotic treatment;
CRC	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.82	-0.55	3.98e-27	Exhaled nitric oxide output;
CRC	cis	rs720844	1.000	rs10454124	chr2:149345749	A/G	cg09247360	chr2:149335327	NA	-0.63	-7.73	-0.39	1.3e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg26597838	chr10:835615	NA	0.6	7.94	0.4	3.15e-14	Eosinophil percentage of granulocytes;
CRC	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.81	13.37	0.59	7.47e-33	Height;
CRC	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg26741380	chr15:41871084	TYRO3	-0.41	-6.22	-0.32	1.49e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.3	0.37	2.17e-12	Triglycerides;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.64	-9.77	-0.47	5.83e-20	Monocyte percentage of white cells;
CRC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-8.31	-0.42	2.61e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	7.92	0.4	3.63e-14	Obesity-related traits;
CRC	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.55	-6.42	-0.33	4.69e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.88	-14.09	-0.61	1.3e-35	Cognitive function;
CRC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.08	0.32	3.27e-9	Rheumatoid arthritis;
CRC	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.82	-0.4	7.31e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg12365402	chr11:9010492	NRIP3	0.49	7.94	0.4	3.15e-14	Hemoglobin concentration;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg18301423	chr5:131593218	PDLIM4	-0.38	-6.34	-0.33	7.76e-10	Breast cancer;
CRC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.48	7.55	0.38	4.24e-13	Eye color traits;
CRC	cis	rs12760731	0.565	rs12040475	chr1:178185651	G/A	cg00404053	chr1:178313656	RASAL2	1.11	11.47	0.53	7.73e-26	Obesity-related traits;
CRC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg19041857	chr6:27730383	NA	-0.49	-6.28	-0.33	1.09e-9	Breast cancer;
CRC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.09	-0.52	1.73e-24	Blood trace element (Zn levels);
CRC	trans	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs76993477	0.666	rs75007377	chr1:169714267	G/A	cg03211132	chr1:169703751	SELE	0.58	5.7	0.3	2.72e-8	Tonsillectomy;
CRC	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.63	9.2	0.45	4.34e-18	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.59	-0.34	1.72e-10	Depression;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.11	-0.36	7.36e-12	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg04204079	chr8:58130323	NA	-0.46	-5.8	-0.3	1.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg09003973	chr2:102972529	NA	0.68	7.54	0.38	4.74e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg00319359	chr11:70116639	PPFIA1	0.56	6.34	0.33	7.73e-10	Coronary artery disease;
CRC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg05110241	chr16:68378359	PRMT7	0.76	7.69	0.39	1.66e-13	Schizophrenia;
CRC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg13844804	chr7:814759	HEATR2	0.67	8.51	0.42	6.32e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.59	9.5	0.46	4.4e-19	Obesity-related traits;
CRC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.04	0.32	4.25e-9	Alzheimer's disease (late onset);
CRC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.53	-0.47	3.6e-19	Body mass index;
CRC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.59	9.25	0.45	2.92e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.51	6.03	0.32	4.35e-9	Tourette syndrome;
CRC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.69	-13.71	-0.6	3.87e-34	Educational attainment;
CRC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.51	6.66	0.34	1.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.07	0.45	1.14e-17	IgG glycosylation;
CRC	trans	rs948562	1.000	rs76435840	chr11:58285981	G/T	cg26660744	chr1:1573181	CDK11B	0.52	6.1	0.32	2.93e-9	Lymphoma;
CRC	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.07e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg03037974	chr15:76606532	NA	0.71	12.66	0.57	3.3e-30	Blood metabolite levels;
CRC	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg18232548	chr7:50535776	DDC	0.46	6.01	0.31	4.99e-9	Malaria;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg18758796	chr5:131593413	PDLIM4	0.39	6.35	0.33	7.24e-10	Breast cancer;
CRC	cis	rs1322512	1.000	rs2758785	chr6:153010878	C/T	cg03415253	chr6:152958462	SYNE1	0.42	6.51	0.34	2.85e-10	Tonometry;
CRC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg24879335	chr3:133465180	TF	0.31	5.62	0.3	4.03e-8	Iron status biomarkers;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.67	10.27	0.49	1.23e-21	Longevity;Endometriosis;
CRC	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.57	-8.08	-0.41	1.21e-14	Triglycerides;
CRC	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.57	5.61	0.3	4.24e-8	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07552157	chr3:142720316	SR140	0.39	6.26	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.47	6.71	0.35	8.65e-11	Response to temozolomide;
CRC	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.59	-7.96	-0.4	2.89e-14	White matter hyperintensity burden;
CRC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg12658694	chr1:38397304	INPP5B	0.43	6.02	0.31	4.75e-9	Coronary artery disease;
CRC	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg15571903	chr15:79123663	NA	0.31	6.13	0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg14515779	chr1:101123966	NA	-0.43	-8.31	-0.42	2.55e-15	Monocyte count;
CRC	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.98	18.15	0.71	1.65e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.05e-29	Cognitive function;
CRC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.5	7.95	0.4	3.01e-14	Red blood cell count;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.09e-22	Prudent dietary pattern;
CRC	cis	rs713587	0.571	rs563590	chr2:25331172	A/G	cg22495460	chr2:25135724	ADCY3	0.4	6.0	0.31	5.35e-9	Body mass index in non-asthmatics;
CRC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg15445000	chr17:37608096	MED1	0.35	6.18	0.32	1.91e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6681460	0.901	rs1373911	chr1:67041065	T/C	cg02459107	chr1:67143332	SGIP1	0.45	7.21	0.37	3.85e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg01879757	chr17:41196368	BRCA1	-0.4	-6.0	-0.31	5.24e-9	Menopause (age at onset);
CRC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.35	-5.95	-0.31	7e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs12612619	0.732	rs10432697	chr2:27272052	T/C	cg00617064	chr2:27272375	NA	-0.4	-6.69	-0.35	9.89e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs4073416	0.542	rs10142283	chr14:66044129	G/A	cg03016385	chr14:66212404	NA	-0.46	-6.32	-0.33	8.4e-10	N-glycan levels;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.45	-9.55	-0.47	3.13e-19	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02671540	chr2:61244799	PEX13;PUS10	0.45	6.71	0.35	8.49e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02290350	chr8:58132656	NA	-0.53	-7.91	-0.4	3.99e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4654899	0.833	rs10916858	chr1:21086602	C/G	cg02927042	chr1:21476669	EIF4G3	-0.42	-6.55	-0.34	2.22e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.16	-0.37	5.39e-12	Gut microbiome composition (summer);
CRC	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg11038491	chr20:34638489	LOC647979	-0.6	-7.21	-0.37	3.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Depression;
CRC	cis	rs8020095	0.571	rs8009087	chr14:67564210	C/T	cg00791868	chr14:66963628	C14orf53	-0.51	-6.87	-0.35	3.14e-11	Depression (quantitative trait);
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.63	7.07	0.36	9.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg08314208	chr16:67682810	RLTPR	-0.66	-7.0	-0.36	1.44e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.52	0.34	2.58e-10	Axial length;
CRC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs8060686	0.858	rs7206671	chr16:67807146	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-10.74	-0.51	2.82e-23	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg03037974	chr15:76606532	NA	0.69	12.16	0.56	2.4e-28	Blood metabolite levels;
CRC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.91	16.64	0.68	1.56e-45	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg19678392	chr7:94953810	PON1	-0.59	-7.3	-0.37	2.19e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.4	0.42	1.31e-15	Schizophrenia;
CRC	trans	rs10242455	0.702	rs78218664	chr7:99154381	C/A	cg09045935	chr12:6379348	NA	1.12	8.09	0.41	1.14e-14	Blood metabolite levels;
CRC	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg18135206	chr14:102964638	TECPR2	0.54	6.42	0.33	4.82e-10	Blood protein levels;
CRC	cis	rs10512697	0.803	rs13172911	chr5:3578242	T/C	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.62	9.42	0.46	8.19e-19	Inflammatory bowel disease;
CRC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.71	0.35	8.34e-11	Schizophrenia;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10708793	chr17:40264626	DHX58	0.46	6.35	0.33	7.26e-10	Survival in pancreatic cancer;
CRC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.11	-0.36	7.23e-12	Hemoglobin concentration;
CRC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.12	0.32	2.62e-9	Height;
CRC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.3	0.33	9.56e-10	Rheumatoid arthritis;
CRC	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.72	7.58	0.39	3.48e-13	Breast cancer;
CRC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.41	-0.42	1.27e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.95	0.31	6.75e-9	Ovarian reserve;
CRC	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg23254163	chr1:152506842	NA	0.5	10.11	0.49	4.05e-21	Hair morphology;
CRC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.49	-6.48	-0.34	3.28e-10	Type 2 diabetes;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.48	-7.04	-0.36	1.11e-11	Longevity;Endometriosis;
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg22079747	chr2:228736145	WDR69	-0.44	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs2530545	0.660	rs2530546	chr7:34697224	C/T	cg14401837	chr7:34697493	NPSR1	0.51	6.85	0.35	3.64e-11	IgG glycosylation;
CRC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg20607287	chr7:12443886	VWDE	-0.66	-6.84	-0.35	3.78e-11	Coronary artery disease;
CRC	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.84	-11.93	-0.55	1.66e-27	Platelet distribution width;
CRC	cis	rs9992667	0.955	rs28418927	chr4:38626130	A/C	cg19726192	chr4:38663646	FLJ13197	-0.65	-8.16	-0.41	7.27e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.57	8.45	0.42	9.72e-16	Morning vs. evening chronotype;
CRC	cis	rs3736485	0.808	rs55982453	chr15:51951245	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-5.84	-0.31	1.27e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.74	8.67	0.43	1.95e-16	Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00718791	chr11:76432872	GUCY2E	0.46	6.49	0.34	3.08e-10	Response to antipsychotic treatment;
CRC	cis	rs1179624	0.767	rs12539806	chr7:75257290	C/A	cg05145297	chr7:75264568	HIP1	0.53	7.16	0.37	5.15e-12	Age-related nuclear cataracts;
CRC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.79	-12.62	-0.57	4.68e-30	Cognitive function;
CRC	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.62	-8.73	-0.43	1.34e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.44	0.38	8.69e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.65	-9.93	-0.48	1.73e-20	Dementia with Lewy bodies;
CRC	cis	rs9549328	0.614	rs35872678	chr13:113617231	A/T	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.32e-19	Systolic blood pressure;
CRC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.49	7.58	0.39	3.47e-13	Response to antineoplastic agents;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13622267	chr4:68411338	CENPC1	0.49	6.2	0.32	1.72e-9	Thyroid stimulating hormone;
CRC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.42	0.33	4.78e-10	Bladder cancer;
CRC	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-7.23	-0.37	3.49e-12	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.98	17.91	0.7	1.45e-50	Gut microbiome composition (winter);
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-8.63	-0.43	2.69e-16	Bipolar disorder;
CRC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg00129232	chr17:37814104	STARD3	0.58	7.09	0.36	8.09e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg25809561	chr17:30822961	MYO1D	0.53	9.52	0.46	3.82e-19	Schizophrenia;
CRC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.28	0.73	5.63e-56	Prudent dietary pattern;
CRC	cis	rs731174	0.797	rs501252	chr1:38154170	A/G	cg06917450	chr1:38156652	C1orf109	-0.52	-7.21	-0.37	3.82e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-6.96	-0.36	1.81e-11	Tuberculosis;
CRC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.05	-0.55	5.86e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg09796270	chr17:17721594	SREBF1	0.53	8.65	0.43	2.24e-16	Total body bone mineral density;
CRC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg08314208	chr16:67682810	RLTPR	-0.56	-6.06	-0.32	3.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg05585544	chr11:47624801	NA	-0.61	-10.86	-0.51	1.1e-23	Subjective well-being;
CRC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.24e-10	Dupuytren's disease;
CRC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.47	0.42	8.18e-16	Height;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg03790207	chr6:42947109	PEX6	-0.5	-7.23	-0.37	3.47e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg19682013	chr15:45996608	NA	-0.35	-7.24	-0.37	3.16e-12	Waist circumference;Weight;
CRC	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	trans	rs11264213	0.643	rs10908407	chr1:36162328	C/T	cg07175433	chr4:21947400	KCNIP4	0.37	6.36	0.33	6.71e-10	Schizophrenia;
CRC	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.75	-10.2	-0.49	2.05e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.99	0.44	2.04e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg07404485	chr7:94953653	PON1	-0.43	-5.64	-0.3	3.62e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.67	0.54	1.46e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg26850624	chr5:429559	AHRR	0.56	9.37	0.46	1.16e-18	Cystic fibrosis severity;
CRC	cis	rs1347297	0.789	rs11688081	chr2:179280799	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.41	-5.65	-0.3	3.43e-8	Alzheimer disease and age of onset;
CRC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24308560	chr3:49941425	MST1R	-0.46	-7.28	-0.37	2.53e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.56	0.43	4.53e-16	Coffee consumption (cups per day);
CRC	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.15	0.32	2.27e-9	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16411895	chr7:123174614	IQUB	0.41	6.88	0.35	3.07e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg02033258	chr5:131593261	PDLIM4	0.48	8.4	0.42	1.31e-15	Acylcarnitine levels;
CRC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.44	-8.69	-0.43	1.69e-16	Prostate cancer;
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.83	-18.38	-0.71	2.12e-52	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.64	-0.3	3.68e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.6	-11.29	-0.53	3.23e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg27534772	chr1:16042836	PLEKHM2	0.55	10.93	0.52	6.22e-24	Systolic blood pressure;
CRC	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.67	10.83	0.51	1.37e-23	Cognitive test performance;
CRC	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg07617317	chr6:118971624	C6orf204	0.49	6.0	0.31	5.29e-9	Diastolic blood pressure;
CRC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg07828024	chr6:149772892	ZC3H12D	0.47	8.73	0.43	1.3e-16	Dupuytren's disease;
CRC	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.94	14.18	0.62	5.77e-36	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24361620	chr11:45868787	CRY2	0.45	6.4	0.33	5.34e-10	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.39	5.99	0.31	5.54e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.62	9.03	0.45	1.52e-17	Morning vs. evening chronotype;
CRC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.52	0.38	5.27e-13	Lung cancer;
CRC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.49	9.63	0.47	1.66e-19	Renal cell carcinoma;
CRC	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.49	-9.88	-0.48	2.58e-20	Schizophrenia;
CRC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.85	-0.31	1.19e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18776286	chr10:52383679	SGMS1	0.46	6.46	0.34	3.78e-10	Anxiety disorder;
CRC	cis	rs236352	0.576	rs2303993	chr6:36842427	C/G	cg10099585	chr6:36853529	C6orf89	-0.46	-6.47	-0.34	3.59e-10	Heart rate;
CRC	cis	rs10046574	0.519	rs34274894	chr7:135214725	G/C	cg27474649	chr7:135195673	CNOT4	0.6	5.64	0.3	3.6e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.01	-0.36	1.39e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2233152	0.572	rs10411008	chr19:41297241	T/C	cg21869046	chr19:41225005	ITPKC	0.37	5.86	0.31	1.14e-8	Kawasaki disease;
CRC	cis	rs12476592	0.602	rs6546009	chr2:63745742	G/C	cg10828910	chr2:63850056	LOC388955	0.49	6.07	0.32	3.6e-9	Childhood ear infection;
CRC	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg09873164	chr1:152488093	CRCT1	0.38	6.34	0.33	7.53e-10	Hair morphology;
CRC	cis	rs9487051	0.698	rs35849756	chr6:109644610	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.96	-0.31	6.59e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg03037974	chr15:76606532	NA	-0.51	-7.24	-0.37	3.14e-12	Blood metabolite levels;
CRC	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-7.8	-0.4	8.13e-14	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4700695	0.841	rs251610	chr5:65278481	G/T	cg21114390	chr5:65439923	SFRS12	-0.52	-6.34	-0.33	7.61e-10	Facial morphology (factor 19);
CRC	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg25834613	chr7:1915315	MAD1L1	-0.39	-6.13	-0.32	2.5e-9	Bipolar disorder;
CRC	cis	rs3026101	0.671	rs11868032	chr17:5283617	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	7.84	0.4	6.48e-14	Body mass index;
CRC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg17724175	chr1:150552817	MCL1	0.5	7.33	0.37	1.83e-12	Melanoma;
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6504622	0.905	rs3851785	chr17:45040147	T/G	cg16759221	chr17:45003025	GOSR2	-0.55	-8.68	-0.43	1.85e-16	Orofacial clefts;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg06470822	chr6:28175283	NA	1.01	13.28	0.59	1.55e-32	Depression;
CRC	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.76	-8.0	-0.4	2.14e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-6.0	-0.31	5.32e-9	Schizophrenia;
CRC	cis	rs55788414	1.000	rs9921827	chr16:81181869	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.82	-0.4	7.31e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs1642645	0.831	rs1327711	chr1:42495949	A/G	cg16926213	chr1:1841314	NA	-0.45	-6.44	-0.33	4.25e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs6743376	0.556	rs2515398	chr2:113819334	A/C	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.53	8.76	0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1009181	0.585	rs2183947	chr6:26159356	G/A	cg13736514	chr6:26305472	NA	-0.42	-6.26	-0.33	1.21e-9	Childhood ear infection;
CRC	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.46	6.99	0.36	1.54e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg24675056	chr1:15929824	NA	0.51	7.31	0.37	2.11e-12	Systolic blood pressure;
CRC	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg16989719	chr2:238392110	NA	-0.42	-7.61	-0.39	2.87e-13	Prostate cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07464025	chr10:13482639	BEND7	0.38	6.19	0.32	1.75e-9	Interleukin-6 levels;
CRC	cis	rs55702914	0.712	rs10931778	chr2:198148922	C/T	cg20885578	chr2:198174922	NA	-0.35	-6.14	-0.32	2.32e-9	Major depression and alcohol dependence;
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.62	-0.34	1.44e-10	Bipolar disorder;
CRC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.72	12.01	0.55	8.26e-28	Alzheimer's disease (late onset);
CRC	cis	rs3804749	0.966	rs3792369	chr3:122840731	C/T	cg26084141	chr3:122786895	PDIA5	-0.22	-5.95	-0.31	6.95e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.67	10.04	0.48	7.41e-21	Corneal astigmatism;
CRC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.65	0.3	3.47e-8	Personality dimensions;
CRC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.61	0.43	3.07e-16	Schizophrenia;
CRC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.15	0.49	3.07e-21	Heart rate;
CRC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg10298567	chr3:47292165	KIF9	0.39	6.6	0.34	1.62e-10	Colorectal cancer;
CRC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-8.94	-0.44	2.93e-17	Longevity;Endometriosis;
CRC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg00647820	chr17:40259828	DHX58	-0.47	-6.67	-0.35	1.06e-10	Fibrinogen levels;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg10596483	chr8:143751796	JRK	-0.45	-6.39	-0.33	5.8e-10	Urinary tract infection frequency;
CRC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21028142	chr17:79581711	NPLOC4	0.36	7.31	0.37	2.1e-12	Eye color traits;
CRC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17152411	0.895	rs61872120	chr10:126583588	T/G	cg07906193	chr10:126599966	NA	0.52	5.81	0.3	1.5e-8	Height;
CRC	cis	rs11574514	1.000	rs59343240	chr16:67850529	C/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.02	-0.31	4.73e-9	Crohn's disease;
CRC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.6	9.79	0.48	4.86e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg26248373	chr2:1572462	NA	-0.81	-11.22	-0.53	5.8e-25	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.9	-11.23	-0.53	5.56e-25	Hair shape;
CRC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg20885578	chr2:198174922	NA	-0.39	-6.47	-0.34	3.61e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.5	6.98	0.36	1.67e-11	Pancreatic cancer;
CRC	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg17133734	chr15:86042851	AKAP13	-0.43	-6.83	-0.35	4.1e-11	Coronary artery disease;
CRC	cis	rs2013441	1.000	rs2703804	chr17:20107195	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.57	-0.34	1.95e-10	Obesity-related traits;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11645453	chr3:52864694	ITIH4	0.35	6.19	0.32	1.8e-9	Bipolar disorder;
CRC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.12	-0.32	2.68e-9	Joint mobility (Beighton score);
CRC	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg02659138	chr7:134003124	SLC35B4	0.4	6.96	0.36	1.84e-11	Mean platelet volume;
CRC	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.69	-9.28	-0.46	2.42e-18	Prostate cancer;
CRC	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.4	6.17	0.32	1.99e-9	Endometrial cancer;
CRC	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg15571903	chr15:79123663	NA	0.34	6.92	0.36	2.4e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.37	6.85	0.35	3.69e-11	Iron status biomarkers;
CRC	trans	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg07393940	chr7:158741817	NA	0.52	7.49	0.38	6.46e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.88	10.19	0.49	2.18e-21	Psoriasis;
CRC	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.39	-6.51	-0.34	2.75e-10	Mean arterial pressure;
CRC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.71	0.39	1.54e-13	Motion sickness;
CRC	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.62	9.1	0.45	8.64e-18	Dementia with Lewy bodies;
CRC	cis	rs12476592	0.602	rs2121351	chr2:63828361	G/A	cg10828910	chr2:63850056	LOC388955	0.5	6.13	0.32	2.54e-9	Childhood ear infection;
CRC	trans	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.9e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg06713098	chr7:45960367	IGFBP3	0.43	6.92	0.36	2.34e-11	Sitting height ratio;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.81	-0.55	4.64e-27	Type 2 diabetes;
CRC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.44	0.33	4.28e-10	Tonsillectomy;
CRC	cis	rs2811415	0.597	rs10934837	chr3:127726173	A/G	cg13719885	chr3:127795394	NA	-0.38	-5.83	-0.31	1.32e-8	Lung function (FEV1/FVC);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14976978	chr11:67159397	RAD9A	-0.4	-6.22	-0.32	1.54e-9	Myopia (pathological);
CRC	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.48	6.18	0.32	1.86e-9	Exhaled nitric oxide output;
CRC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.59	-8.21	-0.41	5.06e-15	Menopause (age at onset);
CRC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.7	12.62	0.57	4.66e-30	Prostate cancer;
CRC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.55	6.36	0.33	6.6e-10	Bipolar disorder;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.9	-0.44	3.76e-17	Bipolar disorder;
CRC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-6.04	-0.32	4.12e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	10.64	0.51	6.41e-23	Intelligence (multi-trait analysis);
CRC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.74	11.21	0.53	6.57e-25	Gestational age at birth (maternal effect);
CRC	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.49	8.51	0.42	6.42e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.61	9.06	0.45	1.23e-17	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.49	6.49	0.34	3.18e-10	Adiposity;
CRC	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-7.11	-0.36	7.42e-12	Response to antipsychotic treatment;
CRC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.38	-6.56	-0.34	2.09e-10	Reticulocyte fraction of red cells;
CRC	trans	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg02674126	chr19:40336878	FBL	0.42	6.74	0.35	6.98e-11	Hyperactive-impulsive symptoms;
CRC	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.61	0.39	2.85e-13	Neuroticism;
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.33	0.33	8.16e-10	Life satisfaction;
CRC	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.5	7.26	0.37	2.73e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	0.71	8.88	0.44	4.41e-17	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.4	0.46	9.55e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.53	-0.43	5.31e-16	Chronic sinus infection;
CRC	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg14003231	chr6:33640908	ITPR3	0.46	7.36	0.38	1.52e-12	Height;
CRC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.46	6.54	0.34	2.39e-10	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02573121	chr1:46806359	NSUN4	0.4	6.07	0.32	3.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg26893134	chr6:116381904	FRK	0.26	6.34	0.33	7.49e-10	Total cholesterol levels;
CRC	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.19	-0.53	7.43e-25	Colorectal cancer;
CRC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.54	-8.1	-0.41	1.07e-14	Blood protein levels;
CRC	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg21827317	chr3:136751795	NA	0.35	5.81	0.31	1.44e-8	Neuroticism;
CRC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg14530993	chr4:882597	GAK	0.82	7.82	0.4	7.15e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.56	6.24	0.33	1.38e-9	Vitiligo;
CRC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg17775713	chr3:133465469	TF	-0.38	-6.96	-0.36	1.85e-11	Iron status biomarkers (transferrin levels);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12373195	chr12:64798416	XPOT	0.39	5.97	0.31	6.06e-9	Anxiety disorder;
CRC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.6	10.61	0.51	7.98e-23	Aortic root size;
CRC	cis	rs3814231	0.531	rs11196446	chr10:115471016	A/C	cg24846397	chr10:115438155	CASP7	-0.35	-5.7	-0.3	2.6e-8	Vitiligo;
CRC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.01	-0.61	2.7900000000000003e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.47	8.31	0.42	2.63e-15	Systemic lupus erythematosus;
CRC	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.44	-6.36	-0.33	6.91e-10	Macular telangiectasia type 2;
CRC	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.76	-12.39	-0.56	3.32e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs711830	0.931	rs717852	chr2:177031623	C/T	cg13092806	chr2:177043255	NA	0.73	8.75	0.43	1.15e-16	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.65	8.79	0.44	8.24e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.46	-7.02	-0.36	1.27e-11	Testicular germ cell tumor;
CRC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.68	-9.65	-0.47	1.43e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg19508488	chr2:152266495	RIF1	0.49	6.91	0.36	2.5e-11	Squamous cell lung carcinoma;
CRC	cis	rs2530545	0.762	rs10245221	chr7:34667197	A/C	cg14401837	chr7:34697493	NPSR1	-0.43	-6.35	-0.33	7.1e-10	IgG glycosylation;
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.57	-6.56	-0.34	2.06e-10	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03689054	chr17:81037743	METRNL	0.4	6.05	0.32	3.83e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01334186	chr1:151372572	PSMB4	0.44	6.31	0.33	9.14e-10	Response to antipsychotic treatment;
CRC	cis	rs939584	0.866	rs13405307	chr2:650973	T/C	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.46e-9	Body mass index;
CRC	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	1.06	11.64	0.54	1.85e-26	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg09659197	chr4:152720779	NA	0.31	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg01721255	chr8:58191610	C8orf71	0.53	6.6	0.34	1.69e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.56	-6.91	-0.36	2.5e-11	Body mass index;
CRC	cis	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg04733911	chr16:78082701	NA	-0.43	-7.11	-0.36	7.29e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	6.55	0.34	2.26e-10	Mean corpuscular volume;
CRC	trans	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg19622623	chr12:86230825	RASSF9	-0.38	-6.28	-0.33	1.09e-9	Major depressive disorder;
CRC	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.4	5.89	0.31	9.46e-9	Life satisfaction;
CRC	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.2	-0.41	5.51e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg06470822	chr6:28175283	NA	0.81	12.0	0.55	9.1e-28	Cardiac Troponin-T levels;
CRC	cis	rs375066	0.551	rs10500286	chr19:44331613	T/C	cg19542119	chr19:44331823	ZNF283	0.41	5.74	0.3	2.1e-8	Breast cancer;
CRC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.94	0.4	3.21e-14	Colorectal cancer;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg06470822	chr6:28175283	NA	0.59	8.56	0.43	4.49e-16	Parkinson's disease;
CRC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.47	-6.58	-0.34	1.88e-10	Response to temozolomide;
CRC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg18764771	chr6:116381957	FRK	0.25	7.1	0.36	7.64e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.62	7.94	0.4	3.25e-14	Cocaine dependence;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16790682	chr12:57984821	PIP4K2C	0.41	6.18	0.32	1.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	7.99	0.4	2.25e-14	Height;
CRC	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.66	0.3	3.3e-8	Putamen volume;
CRC	cis	rs12143943	0.866	rs12030639	chr1:204530924	C/T	cg17419461	chr1:204415978	PIK3C2B	0.39	6.21	0.32	1.61e-9	Cognitive performance;
CRC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24308560	chr3:49941425	MST1R	0.43	6.6	0.34	1.69e-10	Body mass index;
CRC	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.55	-6.96	-0.36	1.83e-11	Diisocyanate-induced asthma;
CRC	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.57	-8.93	-0.44	3.07e-17	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.28	-0.33	1.08e-9	Coronary artery disease;
CRC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg20333904	chr2:240724165	NA	-0.34	-6.66	-0.34	1.15e-10	Obesity-related traits;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg19913688	chr11:428466	ANO9	-0.7	-7.19	-0.37	4.26e-12	Body mass index;
CRC	cis	rs7074356	0.688	rs7898558	chr10:82183505	G/T	cg27171509	chr10:82033454	MAT1A	-0.36	-6.62	-0.34	1.5e-10	Borderline personality disorder;
CRC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02290350	chr8:58132656	NA	-0.42	-5.9	-0.31	8.92e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg09455208	chr3:40491958	NA	0.43	8.21	0.41	5.2e-15	Renal cell carcinoma;
CRC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.23	0.49	1.61e-21	Heart rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02401220	chr17:39845253	EIF1	0.49	7.77	0.39	9.92e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.66	0.47	1.3e-19	Monocyte percentage of white cells;
CRC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.61	10.18	0.49	2.43e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.43e-10	Bipolar disorder;
CRC	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.83	-0.31	1.3e-8	Migraine;Coronary artery disease;
CRC	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.24	-0.41	4.15e-15	Idiopathic membranous nephropathy;
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.69	10.0	0.48	9.65e-21	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.57	8.5	0.42	6.7e-16	Type 2 diabetes;
CRC	cis	rs7725052	0.609	rs12520532	chr5:40455445	T/C	cg09067459	chr5:40385259	NA	-0.4	-6.58	-0.34	1.86e-10	Pediatric autoimmune diseases;
CRC	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg16486109	chr11:613632	IRF7	0.7	11.59	0.54	2.75e-26	Systemic lupus erythematosus;
CRC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.45	6.54	0.34	2.33e-10	Menopause (age at onset);
CRC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.41	6.74	0.35	7.2e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.35	7.54	0.38	4.76e-13	Total body bone mineral density;
CRC	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg06204229	chr3:52865917	ITIH4	0.63	7.37	0.38	1.41e-12	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4865169	0.595	rs4865165	chr4:57765546	A/G	cg24291500	chr4:57773398	REST	-0.29	-5.83	-0.31	1.3e-8	Breast cancer;
CRC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.54	8.3	0.42	2.67e-15	Aortic root size;
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg27532560	chr4:187881888	NA	-0.55	-10.06	-0.48	6.26e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.54	7.97	0.4	2.68e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22708233	chr11:47198576	ARFGAP2	0.36	6.24	0.33	1.35e-9	Obesity-related traits;
CRC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.62	0.57	4.78e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg04756594	chr16:24857601	SLC5A11	0.23	5.76	0.3	1.88e-8	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.46	-0.34	3.77e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.97	-0.31	6.02e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.55	8.37	0.42	1.64e-15	Idiopathic membranous nephropathy;
CRC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg20243544	chr17:37824526	PNMT	0.4	5.63	0.3	3.87e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg16141378	chr3:129829833	LOC729375	-0.46	-7.08	-0.36	8.9e-12	Systolic blood pressure;
CRC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24308560	chr3:49941425	MST1R	0.39	5.94	0.31	7.41e-9	Body mass index;
CRC	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg16342193	chr10:102329863	NA	-0.35	-5.82	-0.31	1.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.54	-0.38	4.76e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.81	-0.35	4.6e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.99	-0.4	2.27e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs3736485	0.844	rs67524810	chr15:51805291	A/C	cg08986416	chr15:51914746	DMXL2	-0.48	-6.93	-0.36	2.29e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.58	-6.21	-0.32	1.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4711336	1.000	rs2296736	chr6:33656250	T/C	cg14003231	chr6:33640908	ITPR3	0.52	8.25	0.41	3.94e-15	Height;
CRC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	18.55	0.71	4.31e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.54	7.53	0.38	4.79e-13	Graves' disease;
CRC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg22110888	chr17:80059540	CCDC57	0.43	6.77	0.35	5.97e-11	Life satisfaction;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12172441	chr6:28176163	NA	0.63	7.43	0.38	9.41e-13	Depression;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	trans	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg24644049	chr4:85504048	CDS1	0.87	7.08	0.36	8.68e-12	Skin colour saturation;
CRC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.52	-8.48	-0.42	7.57e-16	Huntington's disease progression;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.47	-6.84	-0.35	3.84e-11	Blood pressure (smoking interaction);
CRC	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg08999081	chr20:33150536	PIGU	0.45	5.69	0.3	2.78e-8	Neuroticism;
CRC	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.23	-0.37	3.46e-12	Cholesterol, total;
CRC	cis	rs459193	1.000	rs465002	chr5:55808475	C/T	cg26646659	chr5:55776364	NA	0.42	5.65	0.3	3.48e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs6700896	0.931	rs7546242	chr1:66093030	C/T	cg04111102	chr1:66153794	NA	0.33	5.81	0.31	1.48e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.52	-8.18	-0.41	6.09e-15	Corneal astigmatism;
CRC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg05861140	chr6:150128134	PCMT1	-0.35	-5.64	-0.3	3.6e-8	Lung cancer;
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.73	0.3	2.33e-8	Prudent dietary pattern;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg16606324	chr3:10149918	C3orf24	0.6	8.14	0.41	8.28e-15	Alzheimer's disease;
CRC	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22674798	chr1:3096360	PRDM16	0.38	7.79	0.39	9.06e-14	Migraine;
CRC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.49	-0.34	3.07e-10	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23436918	chr7:16685595	BZW2;ANKMY2	0.44	6.37	0.33	6.5e-10	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62187597	chr2:162398263	A/T	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.64	0.3	3.7e-8	Lung cancer;
CRC	cis	rs938554	0.784	rs13102218	chr4:9976113	G/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.65	0.34	1.21e-10	Blood metabolite levels;
CRC	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.61	-0.39	2.84e-13	Type 2 diabetes;
CRC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.47	6.4	0.33	5.29e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.33	6.61	0.34	1.55e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	8.69	0.43	1.73e-16	Breast cancer;
CRC	cis	rs6563739	0.628	rs9603588	chr13:40224412	T/C	cg00026919	chr13:40226031	NA	0.5	6.41	0.33	4.98e-10	Menarche (age at onset);
CRC	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.7	12.18	0.56	1.99e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg17724175	chr1:150552817	MCL1	0.44	6.71	0.35	8.35e-11	Melanoma;
CRC	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg15192750	chr16:69999425	NA	0.55	7.27	0.37	2.58e-12	IgE levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21838329	chr15:81173075	KIAA1199	0.35	6.15	0.32	2.23e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17152411	1.000	rs11245440	chr10:126634572	C/T	cg07906193	chr10:126599966	NA	0.57	5.74	0.3	2.15e-8	Height;
CRC	cis	rs9296095	1.000	rs9296095	chr6:33542523	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.03	0.36	1.23e-11	Platelet count;
CRC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg04166393	chr7:2884313	GNA12	0.39	5.72	0.3	2.43e-8	Height;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.41	-7.59	-0.39	3.36e-13	Bipolar disorder;
CRC	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.52	-7.1	-0.36	7.96e-12	Urinary tract infection frequency;
CRC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.36	11.14	0.52	1.1e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2708977	0.667	rs772156	chr2:97029830	G/A	cg23100626	chr2:96804247	ASTL	0.23	6.08	0.32	3.29e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg09264619	chr17:80180166	NA	0.39	6.5	0.34	3.04e-10	Life satisfaction;
CRC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.79	-0.35	5.4e-11	Lung cancer;
CRC	cis	rs354225	0.615	rs12713274	chr2:54848728	C/T	cg26097391	chr2:54893211	SPTBN1	-0.4	-6.16	-0.32	2.1e-9	Schizophrenia;
CRC	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.41	6.95	0.36	1.95e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.48	-7.78	-0.39	9.72e-14	Testicular germ cell tumor;
CRC	cis	rs12403795	0.527	rs114286538	chr1:150269177	A/T	cg17724175	chr1:150552817	MCL1	0.64	5.89	0.31	9.62e-9	Illicit drug use;
CRC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	1.14	10.62	0.51	7.57e-23	Thyroid stimulating hormone;
CRC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.12	-0.32	2.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.72	8.0	0.4	2.21e-14	Vitiligo;
CRC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.54	-8.48	-0.42	7.53e-16	Aortic root size;
CRC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.51	7.3	0.37	2.18e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.13	-0.32	2.45e-9	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25759457	chr1:172502420	C1orf9	0.5	7.13	0.37	6.45e-12	Response to antipsychotic treatment;
CRC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg11189052	chr15:85197271	WDR73	0.58	8.43	0.42	1.1e-15	Schizophrenia;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	trans	rs8124695	0.649	rs16985175	chr20:39011254	A/G	cg15699267	chr20:61809557	MIR124-3	-0.53	-6.04	-0.32	4.19e-9	Dupuytren's disease;
CRC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg04657146	chr19:12876947	HOOK2	0.39	5.61	0.3	4.32e-8	Bipolar disorder;
CRC	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-6.13	-0.32	2.49e-9	Coronary artery disease;
CRC	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-9.24	-0.45	3.06e-18	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.63	9.03	0.45	1.47e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.76	-0.3	1.98e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.08e-33	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.48	8.0	0.4	2.09e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.22	0.32	1.49e-9	Hair morphology;
CRC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.49	-7.09	-0.36	7.99e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg05721444	chr7:32995514	FKBP9	0.45	6.62	0.34	1.44e-10	Red cell distribution width;
CRC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.15e-8	Bladder cancer;
CRC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg18375707	chr11:64034959	PLCB3	0.48	6.03	0.32	4.34e-9	Mean platelet volume;
CRC	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.64	-8.73	-0.43	1.28e-16	White matter hyperintensity burden;
CRC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-7.26	-0.37	2.73e-12	Schizophrenia;
CRC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.61	-0.3	4.36e-8	Reticulocyte count;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.56	8.36	0.42	1.78e-15	Lymphocyte counts;
CRC	trans	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg01134436	chr17:81009848	B3GNTL1	0.74	6.74	0.35	7.25e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.72	-0.3	2.42e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg09835421	chr16:68378352	PRMT7	-0.73	-7.54	-0.38	4.5e-13	Magnesium levels;
CRC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg04719120	chr6:96025338	MANEA	0.52	6.43	0.33	4.56e-10	Behavioural disinhibition (generation interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26260149	chr4:20701950	PACRGL	0.44	6.04	0.32	4.09e-9	Anxiety disorder;
CRC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg25344623	chr2:136566232	LCT	0.32	5.89	0.31	9.62e-9	Mosquito bite size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08553284	chr12:4381997	CCND2	0.4	6.77	0.35	6.07e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs77633900	0.881	rs80003765	chr15:76657075	T/A	cg21673338	chr15:77095150	SCAPER	-0.7	-6.06	-0.32	3.77e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.4	-0.46	9.47e-19	Body mass index;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg06470822	chr6:28175283	NA	0.8	12.29	0.56	8.04e-29	Parkinson's disease;
CRC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.77	13.33	0.59	1.05e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg10780112	chr6:138725213	HEBP2	-0.43	-6.63	-0.34	1.39e-10	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01390591	chr3:143690991	C3orf58	0.46	6.27	0.33	1.13e-9	Anxiety disorder;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.66	6.97	0.36	1.77e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg24046110	chr8:143859143	LYNX1	-0.48	-8.35	-0.42	1.87e-15	Urinary tract infection frequency;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02099313	chr1:231114956	TTC13;ARV1	0.51	6.71	0.35	8.27e-11	Thyroid stimulating hormone;
CRC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.6	8.86	0.44	5.07e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg21153622	chr11:89784906	NA	-0.44	-7.1	-0.36	7.82e-12	HDL cholesterol;
CRC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.65	0.39	2.24e-13	Height;
CRC	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.22	-0.32	1.49e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg10498984	chr16:28874827	SH2B1	-0.73	-5.97	-0.31	6.13e-9	Cognitive function;
CRC	cis	rs17767392	0.813	rs61989386	chr14:71986545	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.4	-0.33	5.28e-10	Mitral valve prolapse;
CRC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.49	9.25	0.45	3.02e-18	Smoking initiation;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg04269497	chr6:167369491	RNASET2	-0.71	-6.01	-0.31	4.99e-9	Blood osmolality (transformed sodium);
CRC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg01262667	chr19:19385393	TM6SF2	0.37	6.23	0.33	1.39e-9	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02317742	chr2:85981021	ATOH8	0.47	6.59	0.34	1.7e-10	Response to antipsychotic treatment;
CRC	cis	rs16975963	0.644	rs59426132	chr19:38092770	T/G	cg15135657	chr19:38346511	NA	-0.43	-6.02	-0.31	4.66e-9	Longevity;
CRC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.51	7.09	0.36	8.01e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.63	7.95	0.4	3.01e-14	Cocaine dependence;
CRC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.88	-12.74	-0.57	1.69e-30	Platelet distribution width;
CRC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.34	-6.35	-0.33	7.07e-10	Abdominal aortic aneurysm;
CRC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.32	0.37	1.92e-12	Aortic root size;
CRC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.66	8.82	0.44	6.68e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.66	10.26	0.49	1.29e-21	Initial pursuit acceleration;
CRC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.7	7.96	0.4	2.83e-14	Major depressive disorder;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.29	-0.33	9.83e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	6.01	0.31	5.05e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21436751	chr20:18118344	PET117	0.44	6.08	0.32	3.35e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06648271	chr10:126432949	FAM53B	0.43	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.76	-11.65	-0.54	1.7e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs4873772	0.800	rs4873478	chr8:48523296	C/G	cg05343739	chr1:154731938	KCNN3	0.35	6.13	0.32	2.55e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9462027	0.606	rs2814979	chr6:34578425	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.1	-0.32	2.91e-9	Systemic lupus erythematosus;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.82	-10.97	-0.52	4.39e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.69	10.69	0.51	4.27e-23	Tonsillectomy;
CRC	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Dilated cardiomyopathy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16854524	chr4:83931902	LIN54	0.46	6.03	0.32	4.36e-9	Thyroid stimulating hormone;
CRC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.58	0.43	3.88e-16	Lymphocyte counts;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02124459	chr5:141256135	PCDH1	0.5	6.73	0.35	7.44e-11	Thyroid stimulating hormone;
CRC	cis	rs7120118	0.517	rs3758671	chr11:47273089	G/C	cg25783544	chr11:47291846	MADD	0.64	5.77	0.3	1.85e-8	HDL cholesterol;
CRC	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg22134325	chr11:66188745	NPAS4	-0.33	-5.72	-0.3	2.41e-8	Airway imaging phenotypes;
CRC	cis	rs6662572	0.737	rs7533750	chr1:46558434	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.26	0.33	1.22e-9	Blood protein levels;
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg04025307	chr7:1156635	C7orf50	0.61	6.78	0.35	5.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg12046867	chr14:103022105	NA	-0.63	-8.66	-0.43	2.18e-16	Platelet count;
CRC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg23758597	chr6:163146217	PARK2	-0.62	-6.2	-0.32	1.65e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.61	8.32	0.42	2.43e-15	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04510639	chr17:74722764	JMJD6;C17orf95	0.4	6.31	0.33	8.81e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg20203395	chr5:56204925	C5orf35	-0.47	-6.46	-0.34	3.73e-10	Coronary artery disease;
CRC	cis	rs1223397	0.938	rs3817741	chr6:13279507	A/G	cg00460589	chr6:13274354	PHACTR1	-0.46	-5.94	-0.31	7.43e-9	Blood pressure;
CRC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg11901034	chr3:128598214	ACAD9	0.52	7.6	0.39	3.03e-13	IgG glycosylation;
CRC	cis	rs758324	0.812	rs11242095	chr5:131152575	A/G	cg25547332	chr5:131281432	NA	0.36	5.78	0.3	1.7e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.31	-0.37	2.05e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.76	12.74	0.57	1.77e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2415984	0.579	rs2642091	chr14:46972754	A/G	cg14871534	chr14:47121158	RPL10L	0.38	5.65	0.3	3.43e-8	Number of children ever born;
CRC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.37	-5.63	-0.3	3.96e-8	Hemoglobin concentration;
CRC	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.23	6.01	0.31	4.81e-9	Type 2 diabetes;
CRC	cis	rs4731207	0.564	rs6967420	chr7:124609360	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.23	-0.32	1.46e-9	Cutaneous malignant melanoma;
CRC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg02033258	chr5:131593261	PDLIM4	-0.34	-5.96	-0.31	6.66e-9	Breast cancer;Mosquito bite size;
CRC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.53	-11.41	-0.53	1.25e-25	Intelligence (multi-trait analysis);
CRC	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg19731401	chr7:2775893	GNA12	0.53	5.84	0.31	1.26e-8	White matter integrity;
CRC	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.75	9.35	0.46	1.4e-18	Type 2 diabetes;
CRC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.63	-0.54	2e-26	Type 2 diabetes;
CRC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.95	0.44	2.66e-17	Schizophrenia;
CRC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.56	7.89	0.4	4.44e-14	Alcohol dependence;
CRC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg03690763	chr11:133734501	NA	-0.35	-5.72	-0.3	2.4e-8	Childhood ear infection;
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg15848620	chr12:58087721	OS9	-0.65	-8.98	-0.44	2.14e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6922632	0.867	rs1343625	chr6:24112737	C/G	cg26194775	chr6:24126114	NRSN1	-0.63	-7.61	-0.39	2.98e-13	Information processing speed;
CRC	cis	rs7584330	0.554	rs3751106	chr2:238428418	G/A	cg14458575	chr2:238380390	NA	0.43	6.01	0.31	4.86e-9	Prostate cancer;
CRC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.49	7.2	0.37	4.01e-12	Inflammatory bowel disease;
CRC	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.73	8.64	0.43	2.55e-16	Eotaxin levels;
CRC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.71	10.49	0.5	2.17e-22	Longevity;
CRC	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.33	-0.37	1.81e-12	Schizophrenia;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg25164649	chr6:28176230	NA	0.65	8.64	0.43	2.53e-16	Parkinson's disease;
CRC	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.9	12.35	0.56	4.91e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.15e-10	Obesity-related traits;
CRC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.12	-0.32	2.6e-9	Post bronchodilator FEV1;
CRC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.81	11.76	0.54	6.78e-27	Cognitive function;
CRC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.53	-8.61	-0.43	3.04e-16	Caffeine consumption;
CRC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.67	-0.39	1.94e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg10589385	chr1:150898437	SETDB1	0.34	7.28	0.37	2.49e-12	Melanoma;
CRC	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.59	-8.58	-0.43	3.9e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs73206853	0.841	rs56017468	chr12:110653857	T/C	cg12870014	chr12:110450643	ANKRD13A	0.79	7.63	0.39	2.58e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg25834613	chr7:1915315	MAD1L1	-0.48	-6.87	-0.35	3.21e-11	Bipolar disorder;
CRC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	17.68	0.7	1.19e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.41	-8.79	-0.44	8.21e-17	Urinary metabolites;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg22561889	chr6:118971681	C6orf204	0.49	6.31	0.33	9.17e-10	Diastolic blood pressure;
CRC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg24675056	chr1:15929824	NA	0.49	6.66	0.34	1.12e-10	Systolic blood pressure;
CRC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.35	5.82	0.31	1.44e-8	Blood metabolite levels;
CRC	cis	rs4728302	0.869	rs10808273	chr7:133597691	G/C	cg03336402	chr7:133662267	EXOC4	-0.45	-6.5	-0.34	2.97e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.45	0.38	8.34e-13	Motion sickness;
CRC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.5	-9.91	-0.48	2.03e-20	Ulcerative colitis;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg15845792	chr6:28175446	NA	0.6	7.95	0.4	3.01e-14	Parkinson's disease;
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg13627451	chr15:52043674	TMOD2;LYSMD2	0.37	6.05	0.32	3.88e-9	Age-related macular degeneration;
CRC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.73	-0.39	1.35e-13	Height;
CRC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg09695851	chr17:3907499	NA	-0.5	-6.2	-0.32	1.67e-9	Type 2 diabetes;
CRC	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.4	-5.68	-0.3	2.91e-8	Type 2 diabetes;
CRC	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.49	-6.42	-0.33	4.65e-10	Pulse pressure;
CRC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.41	0.53	1.29e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.89	9.38	0.46	1.13e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.67	10.71	0.51	3.67e-23	Breast cancer;
CRC	cis	rs9311676	0.656	rs34579268	chr3:58410554	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg07125278	chr16:67683757	RLTPR	-0.57	-6.08	-0.32	3.36e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.74	-0.35	7.09e-11	Response to antipsychotic treatment;
CRC	cis	rs4662945	0.724	rs4427966	chr2:130221148	G/A	cg05962382	chr2:130345044	NA	-0.34	-5.87	-0.31	1.06e-8	Response to cytidine analogues (gemcitabine);
CRC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.34	-0.42	2.03e-15	Height;
CRC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.22e-22	Chronic sinus infection;
CRC	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.52	8.79	0.44	8.43e-17	Breast cancer;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.51	7.41	0.38	1.08e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg26587870	chr6:27730563	NA	-0.63	-6.09	-0.32	3.1e-9	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01061575	chr22:45098367	PRR5-ARHGAP8;PRR5	0.48	6.79	0.35	5.19e-11	Response to antipsychotic treatment;
CRC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg16141378	chr3:129829833	LOC729375	0.41	6.05	0.32	3.98e-9	Triglycerides;
CRC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg21951975	chr1:209979733	IRF6	0.48	6.54	0.34	2.34e-10	Cleft lip with or without cleft palate;
CRC	cis	rs7538876	0.935	rs11577822	chr1:17754608	T/G	cg07965774	chr1:17746286	RCC2	0.33	6.17	0.32	1.95e-9	Basal cell carcinoma;
CRC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg25767906	chr1:53392781	SCP2	-0.38	-5.84	-0.31	1.26e-8	Monocyte count;
CRC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.47e-10	Tonsillectomy;
CRC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06544989	chr22:39130855	UNC84B	0.46	7.17	0.37	5.11e-12	Menopause (age at onset);
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.58	-0.34	1.88e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg02184673	chr11:123066560	ASAM	0.3	6.06	0.32	3.66e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs5751901	0.688	rs2017869	chr22:24997309	C/G	cg08808123	chr22:24999002	GGT1	-0.39	-5.9	-0.31	9.19e-9	Protein quantitative trait loci;
CRC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.56	6.45	0.34	3.97e-10	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.53	7.22	0.37	3.63e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.66	12.14	0.56	2.88e-28	Calcium levels;
CRC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg22495460	chr2:25135724	ADCY3	-0.87	-16.95	-0.68	9.6e-47	Body mass index;
CRC	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg19131313	chr8:1704013	NA	0.49	5.8	0.3	1.52e-8	Systolic blood pressure;
CRC	cis	rs73206853	0.686	rs73194018	chr12:111127697	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.79	0.3	1.6e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.76	-0.39	1.05e-13	Asthma;
CRC	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-6.55	-0.34	2.19e-10	Height;
CRC	cis	rs10769945	0.679	rs7105710	chr11:1918083	T/C	cg23202291	chr11:1979235	NA	0.42	6.11	0.32	2.88e-9	DNA methylation (variation);
CRC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.67	9.58	0.47	2.42e-19	Menopause (age at onset);
CRC	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.06	-0.41	1.38e-14	Depression;
CRC	cis	rs35883536	1.000	rs1577504	chr1:101123913	A/T	cg14515779	chr1:101123966	NA	-0.44	-8.65	-0.43	2.35e-16	Monocyte count;
CRC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.11	-0.37	7.07e-12	QT interval;
CRC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.06	-12.27	-0.56	9.34e-29	Diabetic kidney disease;
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.58	9.83	0.48	3.67e-20	Prudent dietary pattern;
CRC	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	1.0	18.47	0.71	9.02e-53	Gut microbiome composition (winter);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg21574204	chr6:28048958	ZNF165	0.4	5.97	0.31	6.03e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.11	19.3	0.73	4.74e-56	Cognitive function;
CRC	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-7.88	-0.4	4.8e-14	Hepatocellular carcinoma;
CRC	cis	rs728616	0.614	rs17678338	chr10:82098146	C/T	cg11900509	chr10:81946545	ANXA11	-0.56	-6.33	-0.33	8.22e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg08501292	chr6:25962987	TRIM38	-0.95	-8.23	-0.41	4.57e-15	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27574256	chr1:52607756	ZFYVE9	0.48	6.79	0.35	5.3e-11	Anxiety disorder;
CRC	cis	rs7517126	1.000	rs6428366	chr1:196844167	C/T	cg13682187	chr1:196946512	CFHR5	0.35	5.68	0.3	2.95e-8	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17231661	chr11:119039801	NLRX1	0.39	6.01	0.31	4.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.26e-11	Alzheimer's disease (late onset);
CRC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.98	0.58	2.23e-31	Bone mineral density;
CRC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24308560	chr3:49941425	MST1R	0.43	6.79	0.35	5.22e-11	Body mass index;
CRC	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.39	5.94	0.31	7.11e-9	Testicular germ cell tumor;
CRC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg20203395	chr5:56204925	C5orf35	-0.48	-6.54	-0.34	2.38e-10	Coronary artery disease;
CRC	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg12935359	chr14:103987150	CKB	-0.44	-5.6	-0.3	4.45e-8	Monocyte count;
CRC	cis	rs9903692	0.954	rs7217496	chr17:46154202	A/G	cg21215337	chr17:46176117	CBX1	0.42	7.79	0.39	8.93e-14	Pulse pressure;
CRC	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.51	7.38	0.38	1.32e-12	Primary sclerosing cholangitis;
CRC	cis	rs9584850	0.834	rs9584855	chr13:99119000	G/T	cg20487152	chr13:99095054	FARP1	-0.39	-5.92	-0.31	8.23e-9	Neuroticism;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg15845792	chr6:28175446	NA	0.95	13.61	0.6	8.98e-34	Parkinson's disease;
CRC	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg15867307	chr2:238110829	NA	0.44	7.23	0.37	3.34e-12	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs6496667	1.000	rs7178663	chr15:90897058	C/T	cg04176472	chr15:90893244	GABARAPL3	0.62	8.5	0.42	6.52e-16	Rheumatoid arthritis;
CRC	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-18.65	-0.72	1.83e-53	Schizophrenia;
CRC	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.45	9.95	0.48	1.49e-20	Cutaneous nevi;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Parkinson's disease;
CRC	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.24	-0.49	1.49e-21	Bipolar disorder;
CRC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg18833306	chr6:118973337	C6orf204	0.44	5.71	0.3	2.53e-8	Renal cell carcinoma;
CRC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg18876405	chr7:65276391	NA	0.45	6.29	0.33	9.96e-10	Aortic root size;
CRC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.64	0.39	2.36e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.73	-12.82	-0.58	8.7e-31	White blood cell count (basophil);
CRC	cis	rs11191205	0.644	rs10883667	chr10:103384849	A/T	cg15320455	chr10:103880129	LDB1	0.54	6.01	0.31	5.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.18	-0.56	2.02e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg24861191	chr19:2740086	SLC39A3	0.43	5.97	0.31	6.17e-9	Depressive symptom measurement or major depressive disorder;
CRC	trans	rs4586057	0.671	rs12261011	chr10:92580807	A/G	cg26894278	chr13:21016241	CRYL1	0.4	5.99	0.31	5.63e-9	Economic and political preferences (time);
CRC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.76	-0.47	6.09e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6681460	0.649	rs6691033	chr1:67007429	C/T	cg02459107	chr1:67143332	SGIP1	0.37	5.78	0.3	1.77e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.6	10.78	0.51	2.09e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.7	8.57	0.43	4.08e-16	Iron status biomarkers;
CRC	trans	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg16141378	chr3:129829833	LOC729375	0.43	6.48	0.34	3.37e-10	Joint mobility (Beighton score);
CRC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.48	-7.76	-0.39	1.05e-13	Body mass index;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.39	-9.43	-0.46	7.53e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg16606324	chr3:10149918	C3orf24	0.68	7.93	0.4	3.39e-14	Alzheimer's disease;
CRC	cis	rs1712517	0.771	rs61869827	chr10:105079439	T/C	cg05636881	chr10:105038444	INA	0.45	8.01	0.4	2.02e-14	Migraine;
CRC	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.73	-12.82	-0.58	8.7e-31	White blood cell count (basophil);
CRC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.72	-0.3	2.38e-8	Coronary artery disease;
CRC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.9e-12	Aortic root size;
CRC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.82	-14.48	-0.62	4.27e-37	Breast cancer;
CRC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.35	-0.42	1.91e-15	Aortic root size;
CRC	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.95	14.6	0.63	1.42e-37	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	8.69	0.43	1.79e-16	Eosinophil percentage of white cells;
CRC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg15145296	chr3:125709740	NA	-0.52	-6.36	-0.33	6.63e-10	Blood pressure (smoking interaction);
CRC	cis	rs11229555	0.645	rs11229450	chr11:58201629	G/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.45	0.42	9.3e-16	Height;
CRC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.62	8.42	0.42	1.16e-15	Smoking initiation;
CRC	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-12.41	-0.56	2.86e-29	Brugada syndrome;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.05	0.52	2.32e-24	Prudent dietary pattern;
CRC	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg23100626	chr2:96804247	ASTL	-0.29	-7.62	-0.39	2.7e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.72	0.35	8.22e-11	Mean platelet volume;
CRC	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.47	6.9	0.36	2.71e-11	Testicular germ cell tumor;
CRC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.68	-7.37	-0.38	1.41e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs2342371	0.641	rs4916427	chr3:196094213	C/T	cg15048948	chr3:196158458	UBXN7	0.53	6.38	0.33	6.18e-10	Fat distribution (HIV);
CRC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg27534772	chr1:16042836	PLEKHM2	0.42	7.03	0.36	1.19e-11	Systolic blood pressure;
CRC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.8	-12.92	-0.58	3.64e-31	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.21	-0.56	1.58e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg15192750	chr16:69999425	NA	0.58	7.64	0.39	2.43e-13	IgE levels;
CRC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.65	-10.18	-0.49	2.4e-21	Glaucoma (primary open-angle);
CRC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.41	-7.73	-0.39	1.34e-13	Alzheimer's disease (late onset);
CRC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.59	6.19	0.32	1.79e-9	Mean platelet volume;
CRC	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg04656015	chr13:113407548	ATP11A	-0.53	-6.04	-0.32	4.17e-9	Glycated hemoglobin levels;
CRC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg22244940	chr12:132335942	MMP17	0.4	5.86	0.31	1.12e-8	Migraine;
CRC	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.45	-5.94	-0.31	7.4e-9	Neuroticism;
CRC	cis	rs7849270	0.959	rs1410017	chr9:131913430	C/T	cg13538475	chr9:131942899	NA	-0.29	-5.75	-0.3	2.04e-8	Blood metabolite ratios;
CRC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg00769240	chr8:12517080	NA	-0.54	-6.7	-0.35	9.27e-11	Blood pressure (smoking interaction);
CRC	cis	rs8141797	1.000	rs5760229	chr22:24560254	C/G	cg20894457	chr22:24584366	SUSD2	0.66	6.51	0.34	2.77e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg24375607	chr4:120327624	NA	0.47	7.33	0.37	1.79e-12	Corneal astigmatism;
CRC	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.38	-5.74	-0.3	2.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs7215564	0.818	rs4889776	chr17:78592385	C/T	cg09596252	chr17:78655493	RPTOR	0.61	5.71	0.3	2.52e-8	Myopia (pathological);
CRC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg13072238	chr3:49761600	GMPPB	0.5	5.74	0.3	2.11e-8	Menarche (age at onset);
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.8	12.26	0.56	1.03e-28	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg19622623	chr12:86230825	RASSF9	-0.37	-5.63	-0.3	3.81e-8	Major depressive disorder;
CRC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.93	-11.68	-0.54	1.39e-26	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg22777020	chr22:31556080	RNF185	-0.51	-5.88	-0.31	1.03e-8	Colorectal cancer;
CRC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.43e-59	Hip circumference adjusted for BMI;
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg07414643	chr4:187882934	NA	0.37	6.47	0.34	3.47e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.5	6.76	0.35	6.24e-11	Height;
CRC	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.75	-7.94	-0.4	3.29e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.43	6.07	0.32	3.6e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs4743820	0.503	rs10991791	chr9:93921505	T/C	cg14446406	chr9:93919335	NA	-0.48	-8.43	-0.42	1.12e-15	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.56	-0.34	2.09e-10	Body mass index;
CRC	cis	rs860295	0.702	rs12746592	chr1:155505967	G/A	cg02153340	chr1:155202674	NA	-0.58	-6.82	-0.35	4.35e-11	Body mass index;
CRC	cis	rs10046574	0.519	rs7810403	chr7:135216172	G/A	cg27474649	chr7:135195673	CNOT4	0.61	5.81	0.31	1.44e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.89	-0.36	2.82e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.77	9.92	0.48	1.82e-20	Monocyte percentage of white cells;
CRC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.86e-15	Mean platelet volume;
CRC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.45	-6.53	-0.34	2.49e-10	Myeloid white cell count;
CRC	cis	rs7916697	0.628	rs10998036	chr10:70016678	C/G	cg06988349	chr10:69991859	ATOH7	-0.37	-6.72	-0.35	8.21e-11	Optic disc area;
CRC	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg08600765	chr20:34638493	LOC647979	-0.59	-7.27	-0.37	2.69e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-18.73	-0.72	8.93e-54	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg22110888	chr17:80059540	CCDC57	-0.45	-7.33	-0.37	1.8e-12	Life satisfaction;
CRC	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.55	8.16	0.41	7.08e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-13.04	-0.58	1.24e-31	Vitiligo;
CRC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.64	-9.9	-0.48	2.21e-20	Breast cancer;
CRC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.9	12.54	0.57	9.42e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-0.99	-11.76	-0.54	6.91e-27	Hip circumference adjusted for BMI;
CRC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.84	-12.75	-0.58	1.56e-30	Response to antineoplastic agents;
CRC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.47	-7.54	-0.38	4.65e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs10208940	0.764	rs6737302	chr2:68782837	A/G	cg12452813	chr2:68675892	NA	0.47	5.9	0.31	9.19e-9	Urate levels in lean individuals;
CRC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.58	-0.39	3.44e-13	Bipolar disorder;
CRC	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg25797454	chr6:150327115	RAET1K	-0.4	-6.68	-0.35	1.04e-10	Alopecia areata;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15299721	chr4:103997510	NHEDC2	0.41	6.02	0.31	4.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.62	-9.49	-0.46	4.71e-19	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01488865	chr20:61569319	C20orf11;DIDO1	0.39	6.05	0.32	3.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.57	10.25	0.49	1.36e-21	Blood metabolite ratios;
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	9.95	0.48	1.48e-20	Cognitive test performance;
CRC	cis	rs789852	0.867	rs1773176	chr3:194316238	C/G	cg21106136	chr3:194405973	FAM43A	0.68	5.91	0.31	8.71e-9	QT interval;
CRC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.18	0.32	1.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.38	-5.79	-0.3	1.61e-8	Ulcerative colitis;
CRC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.72	-11.45	-0.53	8.61e-26	Total body bone mineral density;
CRC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg16506815	chr2:162101123	NA	-0.39	-5.84	-0.31	1.22e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05665937	chr4:1216051	CTBP1	-0.39	-5.99	-0.31	5.58e-9	Obesity-related traits;
CRC	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg05194412	chr2:137003533	NA	0.44	6.89	0.35	2.9e-11	Colorectal cancer;
CRC	cis	rs10905065	0.930	rs7909988	chr10:5736388	A/T	cg11519256	chr10:5708881	ASB13	0.46	6.63	0.34	1.38e-10	Menopause (age at onset);
CRC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-7.25	-0.37	3.03e-12	Blood pressure (smoking interaction);
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.11	-0.32	2.81e-9	Total body bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17176195	chr11:71639533	LOC100133315;RNF121	0.5	6.42	0.33	4.84e-10	Thyroid stimulating hormone;
CRC	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.66	-9.67	-0.47	1.23e-19	Blood protein levels;
CRC	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg03315344	chr16:75512273	CHST6	0.49	5.65	0.3	3.51e-8	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25706373	chr1:206858537	MAPKAPK2	0.45	6.27	0.33	1.13e-9	Anxiety disorder;
CRC	cis	rs41005	1.000	rs41005	chr2:8111231	A/G	cg03155496	chr2:8117019	LOC339788	-0.39	-7.04	-0.36	1.15e-11	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg05527609	chr1:210001259	C1orf107	-0.57	-6.29	-0.33	1.01e-9	Red blood cell count;
CRC	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg24851651	chr11:66362959	CCS	0.38	6.41	0.33	5.04e-10	Educational attainment (years of education);
CRC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.7e-8	Bladder cancer;
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg01874867	chr7:94954059	PON1	-0.52	-6.46	-0.34	3.79e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.51	6.11	0.32	2.81e-9	Gut microbiome composition (summer);
CRC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg16482183	chr6:26056742	HIST1H1C	-0.6	-8.12	-0.41	9.28e-15	Iron status biomarkers;
CRC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.41	-0.33	4.93e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg09417038	chr21:47716443	C21orf57	-0.41	-6.8	-0.35	4.94e-11	Testicular germ cell tumor;
CRC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.32	-0.49	8.03e-22	Total cholesterol levels;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	9.24	0.45	3.11e-18	Alzheimer's disease;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg21577049	chr2:228736449	WDR69	-0.47	-6.2	-0.32	1.71e-9	Blood pressure;
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.54	-0.38	4.52e-13	Bipolar disorder;
CRC	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg27205649	chr11:78285834	NARS2	0.5	6.41	0.33	5.19e-10	Alzheimer's disease (survival time);
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.76	14.24	0.62	3.62e-36	Prudent dietary pattern;
CRC	cis	rs12618769	0.652	rs17506535	chr2:99222834	G/C	cg18455616	chr2:99124870	INPP4A	0.35	5.82	0.31	1.41e-8	Bipolar disorder;
CRC	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg06935464	chr4:38784597	TLR10	0.58	5.84	0.31	1.22e-8	Breast cancer;
CRC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-7.21	-0.37	3.93e-12	Aortic root size;
CRC	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.45	-6.68	-0.35	1.01e-10	Body mass index;
CRC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.82	11.35	0.53	2.04e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	8.18	0.41	6.07e-15	Adiposity;
CRC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.89	-0.48	2.27e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	8.39	0.42	1.49e-15	Response to antipsychotic treatment;
CRC	cis	rs9903692	0.954	rs34750858	chr17:46132937	T/A	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26924209	chr1:193074740	GLRX2	0.45	6.66	0.34	1.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7849530	0.538	rs11788610	chr9:94969508	A/G	cg21205276	chr9:95056231	IARS;SNORA84	0.58	6.02	0.32	4.56e-9	Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction);
CRC	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.42	-5.94	-0.31	7.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg09526685	chr4:187126073	CYP4V2	0.38	5.61	0.3	4.28e-8	Activated partial thromboplastin time;
CRC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg05139728	chr16:28306816	SBK1	0.37	6.01	0.31	4.85e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.82	-14.24	-0.62	3.66e-36	Height;
CRC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12463550	chr7:65579703	CRCP	-0.63	-6.04	-0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	0.97	10.07	0.49	5.84e-21	Diabetic retinopathy;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg12273811	chr6:28175739	NA	0.57	8.37	0.42	1.73e-15	Parkinson's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15693898	chr3:183602556	PARL	0.41	6.47	0.34	3.53e-10	Obesity-related traits;
CRC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.58	8.8	0.44	7.9e-17	Intelligence (multi-trait analysis);
CRC	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg10820045	chr2:198174542	NA	0.38	6.38	0.33	6.09e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg21577049	chr2:228736449	WDR69	-0.47	-6.28	-0.33	1.09e-9	Blood pressure;
CRC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.21	0.69	8.33e-48	Platelet count;
CRC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.65	9.51	0.46	4.26e-19	Menopause (age at onset);
CRC	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.52	7.88	0.4	4.94e-14	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24858591	chr3:44803638	KIAA1143;KIF15	0.46	6.77	0.35	5.89e-11	Response to antipsychotic treatment;
CRC	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.37	-6.25	-0.33	1.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg03013999	chr17:37608204	MED1	0.47	7.31	0.37	2.05e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-5.84	-0.31	1.23e-8	Schizophrenia;
CRC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.16	0.37	5.33e-12	Hemoglobin concentration;
CRC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg21153622	chr11:89784906	NA	-0.37	-6.05	-0.32	3.95e-9	Coronary artery disease;
CRC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg23018236	chr17:30244563	NA	-0.66	-7.59	-0.39	3.33e-13	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.78	-0.3	1.71e-8	Aortic root size;
CRC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg13334819	chr7:99746414	C7orf59	-0.44	-6.0	-0.31	5.32e-9	Coronary artery disease;
CRC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-8.93	-0.44	2.98e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-6.48	-0.34	3.43e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	6.94	0.36	2.12e-11	Schizophrenia;
CRC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg00383909	chr3:49044727	WDR6	0.64	6.76	0.35	6.37e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	0.48	6.34	0.33	7.73e-10	Blood protein levels;
CRC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.43	7.34	0.38	1.68e-12	Major depressive disorder;
CRC	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.73	-8.2	-0.41	5.5e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg00601486	chr12:48723148	H1FNT	-0.35	-6.71	-0.35	8.48e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.51	6.47	0.34	3.65e-10	Age-related disease endophenotypes;
CRC	cis	rs2172802	0.629	rs62304005	chr4:62494219	C/T	cg04118610	chr4:62707027	LPHN3	0.38	5.64	0.3	3.6e-8	Partial epilepsies;
CRC	trans	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg10756647	chr7:56101905	PSPH	0.77	7.94	0.4	3.29e-14	Diabetic kidney disease;
CRC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg02569458	chr12:86230093	RASSF9	0.38	6.57	0.34	1.99e-10	Major depressive disorder;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.76	11.48	0.53	6.93e-26	Menarche (age at onset);
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.03	-25.55	-0.82	4.1e-80	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.3	0.33	9.55e-10	IgG glycosylation;
CRC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.59	-0.34	1.75e-10	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14049615	chr4:87928107	AFF1	-0.42	-6.23	-0.32	1.4e-9	Myopia (pathological);
CRC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg05639522	chr1:247681581	NA	0.46	6.98	0.36	1.68e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.53	-8.36	-0.42	1.77e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg18827107	chr12:86230957	RASSF9	0.36	5.71	0.3	2.49e-8	Major depressive disorder;
CRC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg10570241	chr7:158785291	NA	0.48	8.25	0.41	3.73e-15	Facial morphology (factor 20);
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg10876282	chr6:28092338	ZSCAN16	0.4	5.83	0.31	1.32e-8	Pubertal anthropometrics;
CRC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg17885191	chr8:135476712	NA	0.52	7.03	0.36	1.18e-11	Hypertension (SNP x SNP interaction);
CRC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.37	5.88	0.31	9.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.52	-7.71	-0.39	1.49e-13	Systemic sclerosis;
CRC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.03	-0.36	1.23e-11	IgG glycosylation;
CRC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.61	-9.65	-0.47	1.46e-19	Dental caries;
CRC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.65e-10	Diabetic kidney disease;
CRC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.56	6.16	0.32	2.09e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.57	8.9	0.44	3.95e-17	Vitiligo;
CRC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.45	-0.38	8.28e-13	Cutaneous nevi;
CRC	cis	rs13202913	0.581	rs12662412	chr6:151824309	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	6.66	0.34	1.18e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.51	-6.66	-0.34	1.14e-10	Colorectal cancer;
CRC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg13047869	chr3:10149882	C3orf24	0.36	5.7	0.3	2.73e-8	Alzheimer's disease;
CRC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.66	9.19	0.45	4.5e-18	Vitiligo;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27657473	chr17:4901092	INCA1;KIF1C	-0.41	-6.26	-0.33	1.19e-9	Myopia (pathological);
CRC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg10589385	chr1:150898437	SETDB1	0.29	6.0	0.31	5.3e-9	Melanoma;
CRC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.42	8.28	0.42	3.08e-15	Vitiligo;
CRC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.71	11.12	0.52	1.32e-24	Body mass index;
CRC	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg01422370	chr2:73384389	NA	0.35	5.73	0.3	2.3e-8	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.51	-7.07	-0.36	9.23e-12	Alzheimer's disease;
CRC	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.31	1.47e-8	Metabolite levels;
CRC	cis	rs4700695	0.841	rs417152	chr5:65316205	G/A	cg21114390	chr5:65439923	SFRS12	0.57	6.99	0.36	1.58e-11	Facial morphology (factor 19);
CRC	cis	rs11212617	0.967	rs228588	chr11:108113331	C/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.13	0.32	2.52e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg09876464	chr15:85330779	ZNF592	0.44	7.31	0.37	2.09e-12	P wave terminal force;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05056390	chr11:124824120	CCDC15	0.45	6.27	0.33	1.15e-9	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.38	-6.03	-0.32	4.49e-9	Blood metabolite levels;
CRC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.2	-0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg11176159	chr1:28213800	NA	-0.29	-5.75	-0.3	2.08e-8	Corneal astigmatism;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg04025307	chr7:1156635	C7orf50	0.64	6.76	0.35	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01200585	chr1:228362443	C1orf69	0.39	5.73	0.3	2.22e-8	Diastolic blood pressure;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.66	10.22	0.49	1.76e-21	Height;
CRC	cis	rs365302	1.000	rs432598	chr6:159645755	C/G	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.76e-10	Coronary heart disease;
CRC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg20885578	chr2:198174922	NA	-0.38	-6.33	-0.33	8.07e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg21784768	chr11:537496	LRRC56	-0.66	-6.13	-0.32	2.48e-9	Body mass index;
CRC	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.61	-9.23	-0.45	3.38e-18	Schizophrenia;
CRC	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.57	-8.59	-0.43	3.55e-16	Blood protein levels;
CRC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg04731861	chr2:219085781	ARPC2	0.32	6.5	0.34	2.93e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs7932354	0.528	rs4319472	chr11:47109514	G/C	cg03339077	chr11:47165057	C11orf49	-0.45	-6.19	-0.32	1.77e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg08755490	chr11:65554678	OVOL1	0.49	7.19	0.37	4.33e-12	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
CRC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.56	0.6	1.38e-33	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03044510	chr21:27107978	ATP5J;GABPA	0.41	6.54	0.34	2.31e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg22495460	chr2:25135724	ADCY3	0.65	10.99	0.52	3.73e-24	Body mass index in non-asthmatics;
CRC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg20387954	chr3:183756860	HTR3D	0.47	8.04	0.41	1.6e-14	Anterior chamber depth;
CRC	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.61	-9.79	-0.47	5.03e-20	Smoking behavior;
CRC	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	0.87	9.52	0.46	3.87e-19	Gut microbiota (bacterial taxa);
CRC	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.45	-7.3	-0.37	2.2e-12	Refractive error;
CRC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06505273	chr16:24850292	NA	0.53	6.93	0.36	2.2e-11	Intelligence (multi-trait analysis);
CRC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.58	9.14	0.45	6.66e-18	Lymphocyte percentage of white cells;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.95	0.36	1.97e-11	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg24300038	chr13:113819356	PROZ	0.44	6.01	0.31	4.96e-9	Platelet distribution width;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg06781209	chr11:61594997	FADS2	-0.71	-8.37	-0.42	1.64e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.7e-8	Prudent dietary pattern;
CRC	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.56	10.91	0.52	7.62e-24	Cognitive performance;
CRC	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.53	9.26	0.45	2.66e-18	Endometriosis;
CRC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12315302	chr6:26189340	HIST1H4D	0.71	5.76	0.3	1.93e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.61	-10.01	-0.48	9.04e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	0.83	6.35	0.33	7.02e-10	Fat distribution (HIV);
CRC	cis	rs1552172	0.887	rs718942	chr1:145662853	T/A	cg11743829	chr1:145714124	CD160	-0.41	-6.16	-0.32	2.16e-9	Breast cancer;
CRC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.23	-0.32	1.41e-9	Arsenic metabolism;
CRC	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.81	-14.48	-0.62	4.19e-37	Lewy body disease;
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.33e-9	Prudent dietary pattern;
CRC	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.64	-8.51	-0.42	6.05e-16	Iron status biomarkers;
CRC	cis	rs17767392	0.834	rs56362777	chr14:71735418	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.42	-0.33	4.67e-10	Mitral valve prolapse;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.6	-8.23	-0.41	4.37e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.81	10.04	0.48	7.17e-21	Glomerular filtration rate (creatinine);
CRC	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.62	-9.3	-0.46	1.96e-18	Schizophrenia;
CRC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.4	6.7	0.35	9e-11	Alcohol dependence;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.67	7.71	0.39	1.48e-13	Body mass index;
CRC	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	13.99	0.61	3.3e-35	Colorectal cancer;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg02683197	chr6:28174875	NA	0.64	7.5	0.38	6.09e-13	Parkinson's disease;
CRC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg14345882	chr6:26364793	BTN3A2	0.66	5.75	0.3	2.03e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg21970626	chr13:21893289	NA	0.45	5.91	0.31	8.39e-9	White matter hyperintensity burden;
CRC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.63	-10.99	-0.52	3.98e-24	Coronary artery disease;
CRC	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.63	0.72	2.21e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6840360	0.642	rs7682770	chr4:152390413	A/C	cg09659197	chr4:152720779	NA	0.34	6.64	0.34	1.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	16.24	0.67	5.94e-44	Testicular germ cell tumor;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg03646922	chr17:4167316	ANKFY1	-0.4	-6.14	-0.32	2.41e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg12516270	chr8:143859308	LYNX1	0.42	7.54	0.38	4.55e-13	Urinary tract infection frequency;
CRC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.44	-0.42	1.03e-15	Height;
CRC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.61	-0.39	2.87e-13	Body mass index;
CRC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.36	-6.26	-0.33	1.22e-9	Dupuytren's disease;
CRC	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg21153622	chr11:89784906	NA	0.46	7.39	0.38	1.26e-12	HDL cholesterol;
CRC	trans	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.07	-0.32	3.57e-9	Tuberculosis;
CRC	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.95	12.01	0.55	8.27e-28	Exhaled nitric oxide levels;
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.73	11.02	0.52	3e-24	Menarche (age at onset);
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.6	-0.3	4.5e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.53	0.38	4.91e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-12.42	-0.56	2.62e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.52	-8.06	-0.41	1.43e-14	Body mass index;
CRC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.51	8.6	0.43	3.29e-16	Aortic root size;
CRC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	9.14e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.9	-0.36	2.73e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7259376	0.875	rs9304996	chr19:22486535	A/G	cg02657401	chr19:22469223	NA	-0.36	-8.0	-0.4	2.14e-14	Menopause (age at onset);
CRC	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-6.46	-0.34	3.71e-10	Neuroticism;
CRC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg11189052	chr15:85197271	WDR73	0.57	7.55	0.38	4.25e-13	Schizophrenia;
CRC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.96	-19.27	-0.73	6.37e-56	Height;
CRC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg25985355	chr7:65971099	NA	-0.35	-5.64	-0.3	3.7e-8	Corneal structure;
CRC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg10298567	chr3:47292165	KIF9	-0.35	-5.83	-0.31	1.33e-8	Colorectal cancer;
CRC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.74	-0.35	6.97e-11	Monocyte count;
CRC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.56	-8.43	-0.42	1.07e-15	Prostate cancer;
CRC	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg20203395	chr5:56204925	C5orf35	-0.41	-5.76	-0.3	1.94e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-0.75	-6.74	-0.35	7.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22779477	chr10:127408223	C10orf137	0.37	6.18	0.32	1.89e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.44	7.95	0.4	2.93e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.47	-8.77	-0.44	9.9900000000000006e-17	Educational attainment (years of education);
CRC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg12218747	chr21:37451666	NA	-0.43	-7.39	-0.38	1.25e-12	Mitral valve prolapse;
CRC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg12560992	chr17:57184187	TRIM37	0.44	5.84	0.31	1.24e-8	Cognitive test performance;
CRC	trans	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg26043149	chr18:55253948	FECH	-0.48	-7.43	-0.38	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg15212455	chr7:39170539	POU6F2	0.45	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.52	-5.73	-0.3	2.25e-8	Schizophrenia;
CRC	cis	rs9906695	1.000	rs17652000	chr17:32550104	C/A	cg12698626	chr17:32581466	CCL2	0.41	5.63	0.3	3.81e-8	Monocyte percentage of white cells;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg15382696	chr6:118971807	C6orf204	0.62	8.0	0.4	2.17e-14	Diastolic blood pressure;
CRC	cis	rs17713451	0.593	rs75885547	chr7:151279118	T/C	cg18404559	chr7:151322523	PRKAG2	-0.54	-6.2	-0.32	1.66e-9	Interleukin-4 levels;
CRC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg10911889	chr6:126070802	HEY2	0.38	5.79	0.3	1.65e-8	Brugada syndrome;
CRC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.52	8.85	0.44	5.6e-17	Migraine;
CRC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.44	0.69	1.04e-48	Platelet count;
CRC	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg18232548	chr7:50535776	DDC	0.47	6.62	0.34	1.43e-10	Malaria;
CRC	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.35	-6.68	-0.35	9.97e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.59	-7.8	-0.4	8.2e-14	Colorectal cancer;
CRC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg03030879	chr14:75389066	RPS6KL1	0.38	5.67	0.3	3.12e-8	Height;
CRC	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg09003973	chr2:102972529	NA	0.41	5.86	0.31	1.11e-8	Blood protein levels;
CRC	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.43	6.73	0.35	7.76e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CRC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.88	0.31	9.98e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.59	8.85	0.44	5.43e-17	Aortic root size;
CRC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.26	-0.33	1.17e-9	Tonsillectomy;
CRC	cis	rs12760731	0.720	rs2175254	chr1:178319105	G/A	cg00404053	chr1:178313656	RASAL2	1.12	11.43	0.53	1.04e-25	Obesity-related traits;
CRC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.44	6.79	0.35	5.28e-11	Cleft lip with or without cleft palate;
CRC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.45	9.11	0.45	8.09e-18	Vitiligo;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg22105103	chr4:187893119	NA	0.61	10.54	0.5	1.38e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05165064	chr20:18037039	OVOL2	0.47	6.58	0.34	1.88e-10	Thyroid stimulating hormone;
CRC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.96	0.4	2.84e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.66	-0.6	5.87e-34	Extrinsic epigenetic age acceleration;
CRC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.95	17.24	0.69	6.44e-48	IgG glycosylation;
CRC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.89	-0.31	9.35e-9	Heart rate;
CRC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	6.96e-16	Aortic root size;
CRC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.36	-0.33	6.75e-10	Breast cancer;
CRC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg26322434	chr3:61237156	FHIT	0.42	6.1	0.32	3.04e-9	Interleukin-6 levels;
CRC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.02	-21.95	-0.77	2.14e-66	Myeloid white cell count;
CRC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.86	-12.08	-0.55	4.59e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.76	-0.35	6.38e-11	Cognitive function;
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.6	10.33	0.49	7.77e-22	Prudent dietary pattern;
CRC	cis	rs7113874	0.569	rs10769924	chr11:8623193	C/A	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.22e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.86	-0.31	1.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17282769	chr12:11802362	ETV6	0.39	6.34	0.33	7.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.33	0.65	2.18e-40	Colorectal cancer;
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.22	-0.32	1.54e-9	Bipolar disorder;
CRC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.69	8.97	0.44	2.24e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.62	6.57	0.34	1.95e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.61	11.06	0.52	2.14e-24	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	10.22	0.49	1.79e-21	Bone mineral density;
CRC	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.53	7.52	0.38	5.24e-13	Pulmonary function decline;
CRC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg09655341	chr17:79618100	PDE6G	0.35	6.05	0.32	3.95e-9	Eye color traits;
CRC	cis	rs6662572	0.737	rs75490316	chr1:46553785	G/A	cg08644498	chr1:46502608	NA	0.43	6.6	0.34	1.64e-10	Blood protein levels;
CRC	cis	rs1891275	0.515	rs1080496	chr10:93444262	C/T	cg07889827	chr10:93443413	NA	0.4	6.9	0.36	2.67e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.69	-11.69	-0.54	1.27e-26	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.62	-0.3	4.06e-8	Daytime sleep phenotypes;
CRC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg11262906	chr1:85462892	MCOLN2	-0.5	-6.96	-0.36	1.83e-11	Serum sulfate level;
CRC	cis	rs10242455	0.702	rs115279860	chr7:98994492	C/T	cg18809830	chr7:99032528	PTCD1	-1.28	-8.67	-0.43	1.94e-16	Blood metabolite levels;
CRC	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg14191688	chr11:70257035	CTTN	0.39	6.11	0.32	2.89e-9	Coronary artery disease;
CRC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.62	-7.08	-0.36	8.59e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.47	-8.67	-0.43	1.97e-16	Hepatitis;
CRC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.59	-0.34	1.79e-10	Bipolar disorder;
CRC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs3804749	0.966	rs9823527	chr3:122842611	G/A	cg26084141	chr3:122786895	PDIA5	0.22	6.15	0.32	2.23e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25973374	chr1:24194516	FUCA1	0.46	5.99	0.31	5.37e-9	Anxiety disorder;
CRC	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.21	-0.32	1.59e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.82	11.69	0.54	1.24e-26	Cognitive function;
CRC	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg08717414	chr16:71523259	ZNF19	-0.46	-5.87	-0.31	1.04e-8	Post bronchodilator FEV1;
CRC	trans	rs12744310	0.887	rs34539673	chr1:41796817	G/A	cg19175123	chr10:103411746	FBXW4	0.44	6.0	0.31	5.21e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	7.49	0.38	6.2800000000000005e-13	Corneal astigmatism;
CRC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.79	14.33	0.62	1.65e-36	Anterior chamber depth;
CRC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.1	-0.32	2.99e-9	Heart rate;
CRC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg18016565	chr1:150552671	MCL1	0.46	6.3	0.33	9.72e-10	Melanoma;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg05457514	chr20:44034744	DBNDD2;SYS1-DBNDD2	-0.42	-6.15	-0.32	2.19e-9	Aortic root size;
CRC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg06028605	chr16:24865363	SLC5A11	0.44	8.07	0.41	1.33e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7692995	1.000	rs73098848	chr4:17941027	G/C	cg08925142	chr4:18023851	LCORL	-0.52	-5.74	-0.3	2.14e-8	Height;
CRC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.72	8.07	0.41	1.3e-14	Systolic blood pressure;
CRC	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.69	8.73	0.43	1.34e-16	Hip circumference adjusted for BMI;
CRC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	8.92	0.44	3.29e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg02772935	chr3:125709198	NA	-0.49	-5.74	-0.3	2.11e-8	Blood pressure (smoking interaction);
CRC	cis	rs16852403	0.517	rs12034044	chr1:178234409	G/T	cg00404053	chr1:178313656	RASAL2	0.47	5.8	0.3	1.54e-8	Childhood ear infection;
CRC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg12193833	chr17:30244370	NA	-0.76	-8.88	-0.44	4.43e-17	Hip circumference adjusted for BMI;
CRC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg24130564	chr14:104152367	KLC1	0.42	5.86	0.31	1.14e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11679072	1.000	rs13410551	chr2:240447431	A/T	cg03276489	chr2:240449683	NA	-0.91	-9.19	-0.45	4.49e-18	Blood pressure (smoking interaction);
CRC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg16576597	chr16:28551801	NUPR1	0.49	7.13	0.37	6.53e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.69	9.42	0.46	8.11e-19	Breast cancer;
CRC	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.66	0.3	3.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs231513	0.954	rs231516	chr17:41963205	G/A	cg26893861	chr17:41843967	DUSP3	-0.65	-6.58	-0.34	1.85e-10	Cognitive function;
CRC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg07713946	chr22:31675144	LIMK2	-0.39	-5.63	-0.3	3.94e-8	Colorectal cancer;
CRC	cis	rs4073416	0.542	rs1889731	chr14:65942711	C/G	cg03016385	chr14:66212404	NA	-0.43	-5.94	-0.31	7.44e-9	N-glycan levels;
CRC	cis	rs7527798	0.592	rs11118278	chr1:207831357	C/G	cg09232269	chr1:207846808	CR1L	-0.5	-8.39	-0.42	1.43e-15	Erythrocyte sedimentation rate;
CRC	cis	rs17155006	0.746	rs985152	chr7:107750357	G/A	cg05962710	chr7:107745446	LAMB4	-0.41	-7.33	-0.37	1.77e-12	Pneumococcal bacteremia;
CRC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.85	15.96	0.66	7.24e-43	Dental caries;
CRC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-12.98	-0.58	2.22e-31	Obesity-related traits;
CRC	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.52	-7.53	-0.38	5.06e-13	Iron status biomarkers;
CRC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.75	-0.51	2.71e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	10.41	0.5	4.04e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9467160	1.000	rs6922631	chr6:24438734	G/A	cg20631270	chr6:24437470	GPLD1	0.51	6.53	0.34	2.48e-10	Liver enzyme levels;
CRC	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.78	-0.3	1.71e-8	Subjective well-being;
CRC	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg26727032	chr16:67993705	SLC12A4	-0.64	-8.68	-0.43	1.82e-16	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.32	3.02e-9	Arsenic metabolism;
CRC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	10.74	0.51	2.78e-23	Motion sickness;
CRC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.15	0.52	1.01e-24	Prudent dietary pattern;
CRC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.63	-8.48	-0.42	7.47e-16	Mean corpuscular hemoglobin;
CRC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.73	11.35	0.53	1.98e-25	Tonsillectomy;
CRC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.86	-0.51	1.1e-23	Blood trace element (Zn levels);
CRC	cis	rs2252521	0.553	rs317705	chr7:29097148	T/C	cg11728747	chr7:29037910	CPVL	-0.52	-7.25	-0.37	2.96e-12	Cognitive performance;
CRC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.63	8.55	0.43	4.55e-16	Coronary artery disease;
CRC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	0.65	7.65	0.39	2.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7605827	0.930	rs2052435	chr2:15687306	A/T	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg02683197	chr6:28174875	NA	0.61	8.44	0.42	9.89e-16	Parkinson's disease;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg26304593	chr6:42947056	PEX6	-0.42	-5.99	-0.31	5.39e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08422181	chr19:4909468	UHRF1	0.44	6.26	0.33	1.17e-9	Anxiety disorder;
CRC	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-8.89	-0.44	4.05e-17	Brugada syndrome;
CRC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.69	11.3	0.53	3.08e-25	Type 2 diabetes;
CRC	cis	rs12024301	0.557	rs12038369	chr1:183608146	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg09760422	chr2:128146352	NA	-0.3	-5.79	-0.3	1.67e-8	Protein C levels;
CRC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.85	-14.56	-0.63	1.97e-37	Height;
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.67	9.85	0.48	3.24e-20	Menarche (age at onset);
CRC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-7.93	-0.4	3.49e-14	Aortic root size;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg27018124	chr22:26879714	HPS4;SRRD	0.41	6.04	0.32	4.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.82	-14.36	-0.62	1.21e-36	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg23161317	chr6:28129485	ZNF389	0.43	6.12	0.32	2.66e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.62	0.54	2.28e-26	Alzheimer's disease;
CRC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.53	-8.07	-0.41	1.29e-14	Aortic root size;
CRC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.66	8.81	0.44	7.3e-17	Morning vs. evening chronotype;
CRC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	9.37	0.46	1.23e-18	Lymphocyte counts;
CRC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg05585544	chr11:47624801	NA	-0.55	-9.76	-0.47	6.31e-20	Subjective well-being;
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.43	7.31	0.37	2.03e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg18612461	chr15:75251733	NA	0.38	5.75	0.3	1.99e-8	Breast cancer;
CRC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	1.02	14.59	0.63	1.52e-37	Breast cancer;
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.63	8.25	0.41	3.98e-15	Alzheimer's disease;
CRC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.85	11.43	0.53	1.05e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	10.79	0.51	1.94e-23	Mean corpuscular hemoglobin;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21400344	chr1:25870172	LDLRAP1	0.48	6.54	0.34	2.31e-10	Hip circumference;
CRC	cis	rs73195822	0.614	rs7975139	chr12:111221131	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.68	0.39	1.87e-13	Itch intensity from mosquito bite;
CRC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.64	-0.34	1.3e-10	Height;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22373392	chr17:45973408	SP2	0.47	6.16	0.32	2.11e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9463078	0.753	rs1980265	chr6:44928868	C/A	cg25276700	chr6:44698697	NA	-0.28	-6.74	-0.35	6.95e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.5	-0.34	2.97e-10	Subjective well-being;
CRC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.59	9.4	0.46	9.22e-19	Body mass index;
CRC	cis	rs9311676	0.609	rs55797456	chr3:58378206	C/T	cg06643156	chr3:58380774	PXK	0.41	6.2	0.32	1.67e-9	Systemic lupus erythematosus;
CRC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg15786705	chr6:28176104	NA	0.63	6.06	0.32	3.78e-9	Depression;
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg01874867	chr7:94954059	PON1	-0.53	-6.58	-0.34	1.82e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.73	11.33	0.53	2.48e-25	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs860295	0.812	rs12024257	chr1:155780536	G/A	cg02153340	chr1:155202674	NA	-0.52	-6.21	-0.32	1.57e-9	Body mass index;
CRC	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	0.54	8.15	0.41	7.7e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.52	-9.79	-0.48	4.94e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs6761276	0.932	rs10186133	chr2:113836944	G/T	cg24553058	chr2:113831203	IL1F10	0.38	5.82	0.31	1.4e-8	Protein quantitative trait loci;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.44	6.58	0.34	1.9e-10	Menarche (age at onset);
CRC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.68	-9.67	-0.47	1.28e-19	DNA methylation (variation);
CRC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.97	-0.55	1.16e-27	Type 2 diabetes;
CRC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.71	6.79	0.35	5.34e-11	Diabetic retinopathy;
CRC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.51	6.48	0.34	3.41e-10	Recombination rate (females);
CRC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.1	10.9	0.52	7.71e-24	Diabetic retinopathy;
CRC	trans	rs4576506	0.536	rs13286245	chr9:31496532	T/A	cg26940518	chr16:1593766	IFT140;TMEM204	-0.66	-6.11	-0.32	2.86e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.4	0.38	1.11e-12	Eye color traits;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg25164649	chr6:28176230	NA	0.62	8.85	0.44	5.46e-17	Cardiac Troponin-T levels;
CRC	trans	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.48	0.38	6.79e-13	Endometrial cancer;
CRC	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.18	-0.49	2.39e-21	Inflammatory bowel disease;
CRC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.75	12.89	0.58	4.83e-31	Body mass index;
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.22	-0.32	1.49e-9	Bipolar disorder;
CRC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg10589385	chr1:150898437	SETDB1	0.3	6.13	0.32	2.45e-9	Urate levels;
CRC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.43	8.6	0.43	3.4e-16	Renal cell carcinoma;
CRC	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.03	-0.36	1.22e-11	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs72730918	0.564	rs2414112	chr15:51903024	C/T	cg14296394	chr15:51910925	DMXL2	-0.45	-5.91	-0.31	8.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.61	-9.03	-0.45	1.45e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12581662	chr19:36706085	ZNF565;ZNF146	0.43	6.18	0.32	1.92e-9	Survival in pancreatic cancer;
CRC	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg17145862	chr1:211918768	LPGAT1	0.5	6.59	0.34	1.71e-10	Crohn's disease;
CRC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs860295	0.627	rs11264410	chr1:155745349	G/A	cg02153340	chr1:155202674	NA	-0.53	-6.55	-0.34	2.21e-10	Body mass index;
CRC	cis	rs12024301	0.557	rs12043560	chr1:183594102	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.7	6.75	0.35	6.53e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs62229266	0.682	rs11700546	chr21:37371139	A/C	cg12218747	chr21:37451666	NA	-0.39	-6.64	-0.34	1.27e-10	Mitral valve prolapse;
CRC	cis	rs1223397	0.938	rs3734878	chr6:13288850	C/T	cg21538684	chr6:13274180	PHACTR1	0.48	5.63	0.3	3.93e-8	Blood pressure;
CRC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs972578	1.000	rs1569508	chr22:43359130	T/C	cg01576275	chr22:43409880	NA	-0.46	-7.47	-0.38	7.44e-13	Mean platelet volume;
CRC	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.81	-0.3	1.5e-8	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.71e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	6.42	0.33	4.66e-10	Menarche (age at onset);
CRC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-12.55	-0.57	8.52e-30	Asthma;
CRC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.5	8.13	0.41	8.85e-15	Height;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg15368822	chr1:226070397	TMEM63A	0.43	5.98	0.31	5.68e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs1062746	0.527	rs35143469	chr16:87335483	T/C	cg02258303	chr16:87377426	FBXO31	-0.49	-7.14	-0.37	6.2e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.52	-6.34	-0.33	7.45e-10	Fat distribution (HIV);
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg21251018	chr6:28226885	NKAPL	0.38	5.97	0.31	6.16e-9	Parkinson's disease;
CRC	cis	rs4728142	0.604	rs10239340	chr7:128668510	T/G	cg06630958	chr7:128577819	IRF5	-0.35	-5.74	-0.3	2.14e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs7254114	0.578	rs3745682	chr19:11313256	C/T	cg02815516	chr19:11306319	KANK2	-0.35	-6.33	-0.33	8.07e-10	Immature fraction of reticulocytes;
CRC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.67	13.96	0.61	4.12e-35	Schizophrenia;
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg17346650	chr17:80929145	B3GNTL1	0.49	7.38	0.38	1.29e-12	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18879991	chr6:27861393	HIST1H2AM;HIST1H2BO	0.54	8.44	0.42	9.95e-16	Liver disease severity in Alagille syndrome;
CRC	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.23	-6.22	-0.32	1.49e-9	Type 2 diabetes;
CRC	trans	rs6044834	0.671	rs4239724	chr20:17445078	A/G	cg24693218	chr3:170023372	PRKCI	0.48	6.01	0.31	4.92e-9	Obesity-related traits;
CRC	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg00769240	chr8:12517080	NA	-0.74	-6.64	-0.34	1.27e-10	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.52	8.82	0.44	7e-17	Aortic root size;
CRC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs3751196	0.708	rs77265338	chr12:104149689	G/A	cg02344784	chr12:104178138	NT5DC3	0.68	6.33	0.33	8.16e-10	Sense of smell;
CRC	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.38	-9.26	-0.45	2.72e-18	Diastolic blood pressure;
CRC	cis	rs73058052	0.531	rs3745475	chr19:50100295	A/G	cg15963326	chr19:50037085	RCN3	-0.37	-5.84	-0.31	1.25e-8	Fibrinogen levels;
CRC	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.41	5.85	0.31	1.16e-8	Blood metabolite levels;
CRC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg00343986	chr7:65444356	GUSB	0.42	6.14	0.32	2.39e-9	Aortic root size;
CRC	cis	rs17592366	0.517	rs10145350	chr14:35279109	A/C	cg09327582	chr14:35236912	BAZ1A	0.45	6.03	0.32	4.34e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.38	-8.93	-0.44	3.04e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3751196	0.710	rs3812802	chr12:104215874	C/T	cg02344784	chr12:104178138	NT5DC3	0.7	8.24	0.41	4.16e-15	Sense of smell;
CRC	cis	rs2811415	0.627	rs9289325	chr3:127779693	A/C	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs539514	0.690	rs504273	chr13:76310850	C/T	cg04757411	chr13:76259545	LMO7	-0.36	-6.05	-0.32	4.04e-9	Type 1 diabetes;
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.27	0.75	7.25e-60	Prudent dietary pattern;
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg19041857	chr6:27730383	NA	-0.76	-7.43	-0.38	9.26e-13	Depression;
CRC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg02772935	chr3:125709198	NA	-0.5	-5.81	-0.3	1.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.84	0.51	1.31e-23	Prudent dietary pattern;
CRC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27067234	chr6:107077272	RTN4IP1;QRSL1	0.5	6.91	0.36	2.57e-11	Anxiety disorder;
CRC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.86	11.82	0.55	3.99e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	1.0	18.87	0.72	2.33e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.42	0.38	1.03e-12	Eye color traits;
CRC	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.66	-8.99	-0.44	1.93e-17	Extraversion;
CRC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	8.36	0.42	1.79e-15	LDL cholesterol;Cholesterol, total;
CRC	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	7.49	0.38	6.2800000000000005e-13	Mean corpuscular volume;
CRC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.5	6.71	0.35	8.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg11189052	chr15:85197271	WDR73	-0.63	-8.95	-0.44	2.65e-17	Schizophrenia;
CRC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.27	-0.33	1.13e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.57	-8.5	-0.42	6.57e-16	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg02033258	chr5:131593261	PDLIM4	-0.4	-7.71	-0.39	1.56e-13	Breast cancer;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01509451	chr4:1873985	WHSC1	-0.42	-6.08	-0.32	3.37e-9	Daytime sleep phenotypes;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04305677	chr7:2281541	NUDT1;FTSJ2	0.39	6.13	0.32	2.48e-9	Schizophrenia;
CRC	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg17674042	chr6:34482479	PACSIN1	-0.68	-8.75	-0.43	1.11e-16	Pubertal anthropometrics;Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24861191	chr19:2740086	SLC39A3	0.43	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.83	15.46	0.65	6.76e-41	Vitiligo;
CRC	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.38	-5.75	-0.3	2.02e-8	Height;
CRC	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.47	5.9	0.31	9.09e-9	Metabolite levels;
CRC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.9	-0.44	3.84e-17	Alcohol dependence;
CRC	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.16e-9	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg06896663	chr8:82754093	SNX16	-0.69	-6.06	-0.32	3.82e-9	Cognitive function;
CRC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02807482	chr3:125708958	NA	-0.41	-5.73	-0.3	2.24e-8	Blood pressure (smoking interaction);
CRC	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.57	9.95	0.48	1.5e-20	Leprosy;
CRC	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.38	-0.33	6.18e-10	Educational attainment;
CRC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.44	6.23	0.32	1.42e-9	Resistin levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25431026	chr19:7701841	STXBP2	0.52	7.2	0.37	4.1e-12	Anxiety disorder;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.58	-0.39	3.44e-13	Bipolar disorder;
CRC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.51	-7.28	-0.37	2.44e-12	Alzheimer's disease;
CRC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.79	8.02	0.4	1.93e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7849270	0.851	rs1819381	chr9:131908007	G/A	cg13538475	chr9:131942899	NA	-0.29	-5.73	-0.3	2.24e-8	Blood metabolite ratios;
CRC	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.79	-13.83	-0.61	1.33e-34	Lewy body disease;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg04562611	chr16:615315	C16orf11	0.36	6.07	0.32	3.6e-9	Height;
CRC	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.46	8.25	0.41	3.83e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23763197	chr11:118965649	H2AFX	0.43	6.53	0.34	2.47e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.84	0.35	3.84e-11	Diastolic blood pressure;
CRC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg21132104	chr15:45694354	SPATA5L1	0.42	6.0	0.31	5.3e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.49	-0.62	3.69e-37	Body mass index;
CRC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.51	7.64	0.39	2.43e-13	Lymphocyte counts;
CRC	cis	rs9462027	0.628	rs6924898	chr6:34811199	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.4e-9	Systemic lupus erythematosus;
CRC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	1.0	16.33	0.67	2.51e-44	Parkinson's disease;
CRC	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg02023728	chr11:77925099	USP35	-0.37	-6.33	-0.33	7.83e-10	Alzheimer's disease (survival time);
CRC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg06238570	chr21:40685208	BRWD1	0.74	10.4	0.5	4.41e-22	Cognitive function;
CRC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg26769984	chr7:1090371	C7orf50	0.51	6.3	0.33	9.3e-10	Bronchopulmonary dysplasia;
CRC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	trans	rs12702919	0.714	rs11760291	chr7:9550415	G/A	cg15597424	chr4:24472487	NA	-0.39	-6.04	-0.32	4.19e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07165851	chr6:158734300	TULP4	0.58	7.22	0.37	3.52e-12	Height;
CRC	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg00601450	chr5:74908170	NA	-0.41	-5.77	-0.3	1.84e-8	Age-related disease endophenotypes;
CRC	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.68	-10.81	-0.51	1.6e-23	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00605358	chr12:89747739	DUSP6	0.55	7.2	0.37	4.14e-12	Thyroid stimulating hormone;
CRC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg00734567	chr1:86172782	ZNHIT6	-0.46	-7.11	-0.37	7.17e-12	Urate levels in overweight individuals;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24483655	chr1:53686142	C1orf123	-0.51	-6.23	-0.32	1.42e-9	Monocyte percentage of white cells;
CRC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg01483505	chr11:975446	AP2A2	0.45	7.44	0.38	9.1e-13	Alzheimer's disease (late onset);
CRC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.61	-0.43	3.11e-16	Uric acid levels;
CRC	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.68	-11.46	-0.53	8.41e-26	Type 2 diabetes;
CRC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.88	0.44	4.28e-17	Morning vs. evening chronotype;
CRC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	7.02	0.36	1.25e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09093137	chr7:105028539	SRPK2	0.48	6.26	0.33	1.18e-9	Thyroid stimulating hormone;
CRC	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.89	11.01	0.52	3.38e-24	HDL cholesterol;HDL cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27611857	chr2:99347979	MGAT4A	0.4	6.3	0.33	9.66e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02771843	chr3:69062953	C3orf64	0.41	6.62	0.34	1.46e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04315863	chr15:34330588	AVEN;CHRM5	0.47	6.92	0.36	2.36e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	trans	rs10875746	0.859	rs12305511	chr12:48582716	C/T	cg16281234	chr15:35388805	NA	0.49	6.32	0.33	8.53e-10	Longevity (90 years and older);
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.97	-0.31	6e-9	Total body bone mineral density;
CRC	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.49	-9.04	-0.45	1.35e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.54	7.29	0.37	2.31e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.49	-8.32	-0.42	2.37e-15	Lung function (FVC);
CRC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Corneal astigmatism;
CRC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.44	6.94	0.36	2.11e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg10790698	chr19:18539756	SSBP4	-0.45	-8.46	-0.42	8.74e-16	Breast cancer;
CRC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg04545296	chr12:48745243	ZNF641	0.34	5.77	0.3	1.83e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6479527	0.810	rs2153070	chr9:96751573	C/G	cg13460858	chr9:96720652	NA	0.3	5.67	0.3	3.19e-8	Esophageal adenocarcinoma;
CRC	trans	rs7671189	0.502	rs10939367	chr4:11740193	C/A	cg18054620	chr5:111191530	C5orf13	-0.3	-6.03	-0.32	4.39e-9	Obesity-related traits;
CRC	cis	rs329648	0.889	rs329647	chr11:133764666	G/C	cg15485101	chr11:133734466	NA	0.37	6.09	0.32	3.17e-9	Parkinson's disease;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.28	-0.33	1.07e-9	Blood metabolite levels;
CRC	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.67	-7.39	-0.38	1.19e-12	Axial length;
CRC	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.68	-0.51	4.62e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02359409	chr6:42947317	PEX6	-0.59	-9.23	-0.45	3.5e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg12172441	chr6:28176163	NA	0.54	7.41	0.38	1.11e-12	Parkinson's disease;
CRC	cis	rs7546094	1.000	rs10857963	chr1:113091487	C/T	cg22162597	chr1:113214053	CAPZA1	0.43	5.93	0.31	7.67e-9	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03809994	chr4:75023664	MTHFD2L	0.41	6.58	0.34	1.88e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.33	-6.07	-0.32	3.53e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg02741985	chr17:80059408	CCDC57	0.43	7.2	0.37	4.16e-12	Life satisfaction;
CRC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.59	0.34	1.7e-10	Rheumatoid arthritis;
CRC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg16342193	chr10:102329863	NA	-0.38	-5.83	-0.31	1.33e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg00310523	chr12:86230176	RASSF9	0.4	6.62	0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg00601450	chr5:74908170	NA	0.41	5.76	0.3	1.95e-8	Age-related disease endophenotypes;
CRC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.4	6.53	0.34	2.54e-10	Major depressive disorder;
CRC	trans	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg18288967	chr1:45987694	PRDX1	0.69	7.62	0.39	2.75e-13	Obesity-related traits;
CRC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.91	17.8	0.7	4.22e-50	Intelligence (multi-trait analysis);
CRC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.54	-7.02	-0.36	1.3e-11	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00177013	chr20:62339100	ARFRP1;ZGPAT	0.5	7.2	0.37	4.02e-12	Response to antipsychotic treatment;
CRC	cis	rs6700896	0.931	rs1938490	chr1:66132800	T/A	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs62458065	0.850	rs7808992	chr7:32470677	C/T	cg20159608	chr7:32802032	NA	-0.55	-6.56	-0.34	2.11e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg01392867	chr16:30410429	ZNF48	0.38	6.03	0.32	4.51e-9	Tonsillectomy;
CRC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.45	-6.85	-0.35	3.68e-11	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00106211	chr6:36514552	STK38	0.43	6.4	0.33	5.37e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg02869306	chr7:64672164	INTS4L1	0.34	5.63	0.3	3.96e-8	Calcium levels;
CRC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg15848620	chr12:58087721	OS9	0.5	6.96	0.36	1.83e-11	Multiple sclerosis;
CRC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.76	0.43	1.04e-16	Hip circumference adjusted for BMI;
CRC	cis	rs10986311	0.775	rs13300918	chr9:127145290	A/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.25	0.33	1.29e-9	Vitiligo;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22263405	chr18:42259244	SETBP1	-0.36	-6.0	-0.31	5.3e-9	Brain structure;
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	8.24	0.41	4.07e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	0.77	7.83	0.4	6.98e-14	Pediatric areal bone mineral density (radius);
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg06470822	chr6:28175283	NA	0.82	8.34	0.42	2.13e-15	Lung cancer in ever smokers;
CRC	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.84	0.44	5.7e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.56	9.62	0.47	1.79e-19	Aortic root size;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg11843238	chr5:131593191	PDLIM4	0.44	7.4	0.38	1.17e-12	Breast cancer;
CRC	cis	rs4664293	0.967	rs7590607	chr2:160545635	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.19	-0.32	1.83e-9	Monocyte percentage of white cells;
CRC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg19622623	chr12:86230825	RASSF9	0.41	6.47	0.34	3.54e-10	Major depressive disorder;
CRC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.95	11.2	0.53	6.98e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.54	-7.3	-0.37	2.21e-12	Height;
CRC	cis	rs73206853	0.764	rs16940909	chr12:111054591	G/C	cg12870014	chr12:110450643	ANKRD13A	0.76	9.26	0.45	2.73e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg14061069	chr19:46274453	DMPK	-0.59	-8.96	-0.44	2.46e-17	Coronary artery disease;
CRC	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg00666640	chr1:248458726	OR2T12	-0.54	-9.77	-0.47	5.59e-20	Common traits (Other);
CRC	cis	rs8105895	0.935	rs7247041	chr19:22249790	G/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg15465823	chr12:48382534	COL2A1	-0.34	-5.62	-0.3	4.13e-8	Plateletcrit;
CRC	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg14825688	chr5:132208181	LEAP2	-0.38	-5.92	-0.31	8.21e-9	Apolipoprotein A-IV levels;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg15786705	chr6:28176104	NA	0.78	9.71	0.47	9.33e-20	Depression;
CRC	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.84	-0.31	1.24e-8	Brugada syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27554509	chr20:61847579	YTHDF1	0.45	6.5	0.34	2.98e-10	Anxiety disorder;
CRC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.81	-0.48	4.36e-20	Personality dimensions;
CRC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg27411982	chr8:10470053	RP1L1	0.36	5.62	0.3	4.01e-8	Retinal vascular caliber;
CRC	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.6	5.79	0.3	1.64e-8	IgG glycosylation;
CRC	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.39	-0.33	5.59e-10	Coronary artery disease;
CRC	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.15e-10	Obesity-related traits;
CRC	cis	rs6922632	0.867	rs6934526	chr6:24114746	G/C	cg26194775	chr6:24126114	NRSN1	-0.62	-7.23	-0.37	3.37e-12	Information processing speed;
CRC	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.88	-0.31	1.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg01339444	chr6:118972232	C6orf204	0.54	6.01	0.31	4.89e-9	Diastolic blood pressure;
CRC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg03934865	chr2:198174659	NA	-0.45	-7.73	-0.39	1.34e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00319567	chr13:60971258	TDRD3	0.52	7.01	0.36	1.33e-11	Survival in pancreatic cancer;
CRC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg00129232	chr17:37814104	STARD3	0.58	7.09	0.36	8.09e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.83	-13.33	-0.59	1.06e-32	Cognitive function;
CRC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg22496339	chr2:162101262	NA	0.59	8.1	0.41	1.09e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.56	8.01	0.4	1.94e-14	Melanoma;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.65	-12.19	-0.56	1.87e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg06156847	chr2:113672199	IL1F7	-0.38	-5.67	-0.3	3.13e-8	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.85	-0.44	5.64e-17	Menarche (age at onset);
CRC	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04733989	chr22:42467013	NAGA	0.4	5.62	0.3	4.12e-8	Cognitive function;
CRC	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.47	6.11	0.32	2.79e-9	Alzheimer's disease (survival time);
CRC	cis	rs4760636	0.648	rs12818241	chr12:48157019	A/G	cg13326926	chr12:48153388	RAPGEF3	-0.61	-6.11	-0.32	2.75e-9	Urate levels;
CRC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg26805224	chr10:79626177	DLG5	-0.49	-7.31	-0.37	2.02e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10486722	0.651	rs2190336	chr7:41801254	A/G	cg22138096	chr7:41772439	LOC285954	0.62	7.46	0.38	8.01e-13	Pit-and-Fissure caries;
CRC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg05090351	chr10:126851162	NA	0.55	7.68	0.39	1.86e-13	Menarche (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22691505	chr7:6312217	CYTH3	0.42	6.92	0.36	2.33e-11	Obesity-related traits;
CRC	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.45	6.08	0.32	3.42e-9	Pulse pressure;
CRC	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg25838818	chr2:108905173	SULT1C2	-0.37	-6.07	-0.32	3.57e-9	Blood pressure;
CRC	cis	rs12050794	0.671	rs62022788	chr15:72559326	T/G	cg16672083	chr15:72433130	SENP8	0.47	7.12	0.37	6.96e-12	Metabolite levels (HVA/MHPG ratio);
CRC	trans	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	7.96	0.4	2.83e-14	Ulcerative colitis;
CRC	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.46	-7.65	-0.39	2.22e-13	Endometriosis;
CRC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.67	7.17	0.37	5.14e-12	Axial length;
CRC	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.49	-8.2	-0.41	5.39e-15	Endometriosis;
CRC	cis	rs2565722	0.825	rs2489928	chr6:161256391	A/G	cg03159191	chr6:161285451	NA	-0.49	-5.97	-0.31	6.27e-9	Blood protein levels;
CRC	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg15131784	chr3:139108705	COPB2	-0.41	-5.94	-0.31	7.11e-9	Obesity-related traits;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-6.78	-0.35	5.43e-11	Height;
CRC	cis	rs3789045	0.774	rs12041243	chr1:204490470	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.95	-0.4	3.06e-14	Educational attainment (college completion);
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg21251018	chr6:28226885	NKAPL	0.38	5.73	0.3	2.24e-8	Parkinson's disease;
CRC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.52	-0.34	2.64e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.22	-0.32	1.55e-9	Aortic root size;
CRC	cis	rs62408225	1.000	rs11757155	chr6:90941240	C/T	cg06866423	chr6:90926672	BACH2	0.51	8.25	0.41	3.92e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.99e-9	Aortic root size;
CRC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	-0.41	-5.65	-0.3	3.46e-8	Schizophrenia;
CRC	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg26182253	chr13:112236782	NA	0.31	6.25	0.33	1.26e-9	Hepatitis;
CRC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.54	-7.29	-0.37	2.37e-12	Educational attainment;
CRC	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.77	8.62	0.43	2.95e-16	Neuroticism;
CRC	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.62	-0.34	1.45e-10	Depression;
CRC	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.51e-10	Prostate cancer;
CRC	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.97	11.38	0.53	1.58e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg12516270	chr8:143859308	LYNX1	0.44	7.77	0.39	9.84e-14	Urinary tract infection frequency;
CRC	cis	rs2380220	0.808	rs2716074	chr6:95907662	T/C	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.54	7.8	0.4	8.22e-14	Lymphocyte counts;
CRC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.38	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs34779708	0.801	rs12255409	chr10:35535425	G/A	cg03585969	chr10:35415529	CREM	0.55	7.02	0.36	1.25e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.65	0.47	1.45e-19	Common traits (Other);
CRC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.25	-0.33	1.29e-9	Tonsillectomy;
CRC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.31	-0.33	9.1e-10	Schizophrenia;
CRC	cis	rs501120	1.000	rs554568	chr10:44755446	C/T	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.96	15.86	0.66	1.74e-42	Parkinson's disease;
CRC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.72	10.57	0.5	1.09e-22	Immature fraction of reticulocytes;
CRC	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.84	0.35	3.85e-11	Mean corpuscular volume;
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.92	-13.67	-0.6	5.38e-34	Dupuytren's disease;
CRC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.66	10.56	0.5	1.22e-22	Vitiligo;
CRC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.16	-0.52	9.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg22653602	chr6:90529138	MDN1	-0.46	-7.03	-0.36	1.2e-11	Daytime sleep phenotypes;
CRC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg10760299	chr15:45669010	GATM	0.5	7.74	0.39	1.26e-13	Homoarginine levels;
CRC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.56	0.43	4.47e-16	Homoarginine levels;
CRC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-15.29	-0.64	3.08e-40	Cognitive function;
CRC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.52	8.17	0.41	6.93e-15	Colorectal cancer;
CRC	cis	rs4654899	0.931	rs935917	chr1:21167102	A/T	cg02927042	chr1:21476669	EIF4G3	-0.42	-6.7	-0.35	8.88e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	0.72	6.4	0.33	5.31e-10	Fat distribution (HIV);
CRC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.5	7.38	0.38	1.29e-12	Blood metabolite levels;
CRC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.19	0.45	4.67e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg24154853	chr7:158122151	PTPRN2	-0.53	-7.97	-0.4	2.69e-14	Response to amphetamines;
CRC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.54	8.43	0.42	1.12e-15	Aortic root size;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.34	0.37	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.08	-12.36	-0.56	4.53e-29	Diabetic kidney disease;
CRC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.78	-13.48	-0.6	2.8e-33	Breast cancer;
CRC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00934597	chr7:893267	UNC84A	-0.54	-7.47	-0.38	7.21e-13	Perceived unattractiveness to mosquitoes;
CRC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.25	-0.33	1.28e-9	Monocyte count;
CRC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg03160526	chr17:80928410	B3GNTL1	-0.44	-6.64	-0.34	1.3e-10	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04421424	chr19:57791681	ZNF460	0.47	6.01	0.31	5.04e-9	Thyroid stimulating hormone;
CRC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg02659138	chr7:134003124	SLC35B4	0.39	6.49	0.34	3.14e-10	Mean platelet volume;
CRC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.99	0.48	1.05e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.4	6.59	0.34	1.79e-10	Longevity;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg15845792	chr6:28175446	NA	0.86	12.78	0.58	1.16e-30	Parkinson's disease;
CRC	cis	rs4664293	0.867	rs1427328	chr2:160618575	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg14487702	chr8:22132665	PIWIL2	0.38	5.77	0.3	1.86e-8	Hypertriglyceridemia;
CRC	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.48	-0.38	6.85e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.42	7.41	0.38	1.11e-12	Age at first birth;
CRC	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.47	-5.89	-0.31	9.29e-9	Tourette syndrome;
CRC	cis	rs12745968	0.653	rs6604013	chr1:93192134	A/G	cg17283838	chr1:93427260	FAM69A	-0.44	-5.99	-0.31	5.4e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.67e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.01	0.31	4.99e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg22638593	chr5:131593259	PDLIM4	0.49	9.08	0.45	1.05e-17	Acylcarnitine levels;
CRC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.66e-23	Aortic root size;
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg19223190	chr17:80058835	NA	0.39	6.3	0.33	9.57e-10	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62187571	chr2:162374319	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.54e-9	Cognitive function;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg13714271	chr9:33076774	SMU1	0.44	6.11	0.32	2.75e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg17330251	chr7:94953956	PON1	-0.59	-7.5	-0.38	5.82e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg18809830	chr7:99032528	PTCD1	-1.08	-7.99	-0.4	2.29e-14	Blood metabolite levels;
CRC	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg11003573	chr3:44754125	ZNF502	-0.35	-5.96	-0.31	6.56e-9	Depressive symptoms;
CRC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-6.17	-0.32	2.05e-9	Menopause (age at onset);
CRC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.52	6.68	0.35	1.04e-10	Obesity-related traits;
CRC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.51	-8.45	-0.42	9.25e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.76	-8.03	-0.4	1.79e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.79	-13.15	-0.59	4.94e-32	Obesity-related traits;
CRC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg00246817	chr9:123691163	NA	-0.46	-5.85	-0.31	1.16e-8	Rheumatoid arthritis;
CRC	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg13962466	chr20:25176127	ENTPD6	0.41	6.32	0.33	8.62e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg25797454	chr6:150327115	RAET1K	0.38	6.35	0.33	7.14e-10	Alopecia areata;
CRC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.46	-6.84	-0.35	3.94e-11	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.94	-17.84	-0.7	2.9e-50	Height;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.77	-15.99	-0.66	5.33e-43	Electroencephalogram traits;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.61	9.59	0.47	2.33e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.49	6.92	0.36	2.33e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.5	-5.69	-0.3	2.83e-8	Body mass index;
CRC	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg15192750	chr16:69999425	NA	0.57	7.69	0.39	1.75e-13	IgE levels;
CRC	cis	rs3018066	0.867	rs3109960	chr4:107214171	T/C	cg01869342	chr4:106983673	TBCK	0.37	5.69	0.3	2.83e-8	Cancer;
CRC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.56	8.71	0.43	1.53e-16	Blood metabolite levels;
CRC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.21	-0.32	1.61e-9	Lung cancer;
CRC	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.45	6.41	0.33	5.04e-10	Height;
CRC	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-17.46	-0.69	9.32e-49	Schizophrenia;
CRC	cis	rs12476592	0.571	rs7577952	chr2:63787212	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02807482	chr3:125708958	NA	-0.45	-5.65	-0.3	3.39e-8	Blood pressure (smoking interaction);
CRC	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.75	-0.3	2.06e-8	Monocyte percentage of white cells;
CRC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg22532475	chr10:104410764	TRIM8	-0.37	-6.8	-0.35	4.94e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2227564	0.729	rs2688611	chr10:75653372	G/T	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.63	-0.39	2.58e-13	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg21153622	chr11:89784906	NA	0.43	7.04	0.36	1.13e-11	Coronary artery disease;
CRC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.8	-12.28	-0.56	8.52e-29	Response to temozolomide;
CRC	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.39	-0.33	5.83e-10	Retinal vascular caliber;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-9.05	-0.45	1.32e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.5	-6.95	-0.36	1.97e-11	Triglycerides;
CRC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.41	-6.48	-0.34	3.3e-10	Height;
CRC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg02896835	chr1:92012615	NA	-0.48	-6.25	-0.33	1.27e-9	Eosinophil percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13086606	chr15:69452796	MIR548H4;GLCE	0.42	6.03	0.32	4.34e-9	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.61	-9.57	-0.47	2.58e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg05562828	chr17:3906858	NA	-0.65	-11.81	-0.55	4.68e-27	Type 2 diabetes;
CRC	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	11.98	0.55	1.1e-27	Height;
CRC	cis	rs9549328	0.589	rs34144481	chr13:113617322	T/G	cg17524180	chr13:113633600	MCF2L	0.52	9.34	0.46	1.46e-18	Systolic blood pressure;
CRC	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.43	5.93	0.31	7.78e-9	Body mass index;
CRC	cis	rs7737355	0.812	rs11746227	chr5:130961236	C/T	cg25547332	chr5:131281432	NA	0.37	5.74	0.3	2.21e-8	Life satisfaction;
CRC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.11	0.49	4.19e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.92	-8.25	-0.41	3.95e-15	Putamen volume;
CRC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.92	-14.26	-0.62	2.89e-36	Longevity;
CRC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg04450456	chr4:17643702	FAM184B	0.37	5.88	0.31	9.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg15145296	chr3:125709740	NA	-0.59	-6.97	-0.36	1.72e-11	Blood pressure (smoking interaction);
CRC	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.55	-7.49	-0.38	6.37e-13	Inflammatory bowel disease;
CRC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.93	0.64	7.31e-39	Lymphocyte percentage of white cells;
CRC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.43	-0.38	9.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs77861329	0.748	rs12629791	chr3:52175783	C/T	cg08692210	chr3:52188851	WDR51A	0.5	5.89	0.31	9.43e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6586163	1.000	rs6586164	chr10:90752031	T/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.51	-7.45	-0.38	8.36e-13	Chronic lymphocytic leukemia;
CRC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg07138768	chr7:917805	C7orf20	0.3	5.72	0.3	2.45e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.6	9.07	0.45	1.14e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	7.1	0.36	7.89e-12	Obesity-related traits;
CRC	trans	rs12554020	0.581	rs4255201	chr9:96163337	G/A	cg23291280	chr19:31847970	NA	-0.7	-6.31	-0.33	9.14e-10	Schizophrenia;
CRC	cis	rs73206853	0.702	rs7960516	chr12:110529238	T/A	cg12870014	chr12:110450643	ANKRD13A	0.64	8.17	0.41	6.67e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.26	0.37	2.74e-12	Eye color traits;
CRC	cis	rs6764363	0.527	rs13091420	chr3:277889	A/G	cg02057681	chr3:285234	CHL1	0.4	6.69	0.35	9.83e-11	Sudden cardiac arrest;
CRC	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.65	-10.49	-0.5	2.08e-22	Mean platelet volume;
CRC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.9	17.57	0.7	3.18e-49	Bone mineral density;
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.18	-0.32	1.9e-9	Total body bone mineral density;
CRC	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg22495460	chr2:25135724	ADCY3	-0.86	-16.44	-0.67	9.68e-45	Body mass index in non-asthmatics;
CRC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg18876405	chr7:65276391	NA	0.44	6.21	0.32	1.58e-9	Aortic root size;
CRC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.45	6.43	0.33	4.51e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs73200209	0.704	rs17498131	chr12:116436185	C/G	cg01776926	chr12:116560359	MED13L	-0.63	-7.54	-0.38	4.5e-13	Total body bone mineral density;
CRC	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg05507819	chr15:63340323	TPM1	0.47	6.24	0.33	1.32e-9	HDL cholesterol;
CRC	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg05935833	chr10:81318306	SFTPA2	-0.75	-8.25	-0.41	3.97e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.42	-7.2	-0.37	4.12e-12	Lung cancer;
CRC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.54	0.47	3.46e-19	Platelet count;
CRC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg11271282	chr2:238384023	NA	0.48	5.6	0.3	4.45e-8	Prostate cancer;
CRC	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.78	-10.53	-0.5	1.54e-22	IgG glycosylation;
CRC	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.62	9.84	0.48	3.32e-20	Lewy body disease;
CRC	cis	rs11212617	0.935	rs652541	chr11:108226025	C/T	cg01991180	chr11:108092276	ATM;NPAT	-0.42	-6.12	-0.32	2.61e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.05	0.36	1.08e-11	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.28	0.33	1.05e-9	Depression;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09529537	chr5:78531947	JMY	-0.55	-6.7	-0.35	8.8e-11	Diisocyanate-induced asthma;
CRC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.63	9.25	0.45	2.93e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.7	-10.1	-0.49	4.41e-21	Body mass index;
CRC	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.86e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.39	5.67	0.3	3.05e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs12431939	1.000	rs12431939	chr14:51692699	A/G	cg23942311	chr14:51606299	NA	0.54	6.44	0.33	4.32e-10	Cancer;
CRC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.77	0.35	6.05e-11	Tonsillectomy;
CRC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.36	6.14	0.32	2.34e-9	Erythrocyte sedimentation rate;
CRC	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.48	7.35	0.38	1.57e-12	Carotid intima media thickness;
CRC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	0.96	14.14	0.61	8.27e-36	Initial pursuit acceleration;
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.53	-7.51	-0.38	5.66e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg05585544	chr11:47624801	NA	-0.52	-9.45	-0.46	6.66e-19	Subjective well-being;
CRC	cis	rs9928842	0.823	rs4888365	chr16:75282247	A/G	cg08657710	chr16:75258780	CTRB1	-0.57	-6.58	-0.34	1.91e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.64	11.77	0.54	6.11e-27	Type 2 diabetes;
CRC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg10589385	chr1:150898437	SETDB1	-0.27	-5.71	-0.3	2.57e-8	Melanoma;
CRC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.98	-0.36	1.62e-11	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
CRC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.37	6.17	0.32	1.96e-9	Anterior chamber depth;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13010990	chr3:122103261	FAM162A;CCDC58	0.43	6.02	0.31	4.61e-9	Response to antipsychotic treatment;
CRC	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.76	-12.77	-0.58	1.35e-30	Idiopathic membranous nephropathy;
CRC	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.47	-5.77	-0.3	1.86e-8	Coronary artery calcification;
CRC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg05192639	chr6:26864778	GUSBL1	0.32	6.08	0.32	3.41e-9	Schizophrenia;
CRC	cis	rs995000	0.868	rs6666816	chr1:63171199	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.79	-0.35	5.09e-11	Triglyceride levels;
CRC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.67	-0.3	3.16e-8	Tuberculosis;
CRC	cis	rs11614062	0.761	rs11107115	chr12:93972987	A/G	cg18151635	chr12:93972918	NA	-0.8	-11.54	-0.54	4.1e-26	Height;
CRC	cis	rs4728142	0.584	rs6965542	chr7:128655918	C/T	cg06630958	chr7:128577819	IRF5	-0.35	-5.78	-0.3	1.74e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs3736485	0.932	rs4775946	chr15:51775930	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.43	-0.33	4.41e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.42	-6.94	-0.36	2.09e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.73	-11.74	-0.54	7.86e-27	Total body bone mineral density;
CRC	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.99	-11.71	-0.54	1.01e-26	Blood protein levels;
CRC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.53	8.82	0.44	6.94e-17	Schizophrenia;
CRC	cis	rs9326248	0.590	rs2542063	chr11:116684767	C/T	cg26566898	chr11:117069891	TAGLN	0.27	5.85	0.31	1.19e-8	Blood protein levels;
CRC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg02321871	chr13:50159138	RCBTB1	-0.45	-6.32	-0.33	8.5e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	cis	rs2637266	0.549	rs4633402	chr10:78414244	C/A	cg18941641	chr10:78392320	NA	-0.36	-6.05	-0.32	4.04e-9	Pulmonary function;
CRC	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.54	9.11	0.45	8.36e-18	Dupuytren's disease;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	1.03	20.06	0.74	5.16e-59	Menarche (age at onset);
CRC	cis	rs2298450	0.717	rs9974041	chr21:37634873	G/A	cg02919814	chr21:37666008	DOPEY2	-0.5	-6.65	-0.34	1.23e-10	Schizophrenia;
CRC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.33	0.42	2.21e-15	Rheumatoid arthritis;
CRC	cis	rs910187	0.597	rs1883885	chr20:45795456	T/C	cg27589058	chr20:45804311	EYA2	-0.34	-6.39	-0.33	5.75e-10	Migraine;
CRC	cis	rs2160860	0.773	rs11787388	chr8:39799193	G/T	cg11363097	chr8:39792086	IDO2	-0.42	-7.39	-0.38	1.22e-12	Blood metabolite levels;
CRC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.46	7.11	0.36	7.21e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.51	8.69	0.43	1.75e-16	Dupuytren's disease;
CRC	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.56	-7.24	-0.37	3.29e-12	Platelet distribution width;
CRC	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17691542	chr6:26056736	HIST1H1C	0.69	7.69	0.39	1.67e-13	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07817097	chr1:179851575	TOR1AIP1	0.44	6.93	0.36	2.25e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg13565492	chr6:43139072	SRF	-0.85	-6.18	-0.32	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06651054	chr15:83680015	C15orf40	0.5	6.57	0.34	1.91e-10	Thyroid stimulating hormone;
CRC	cis	rs1572438	0.839	rs6597297	chr6:864484	C/T	cg13447295	chr6:887704	NA	0.44	6.69	0.35	9.7e-11	Aging;
CRC	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg24505167	chr7:1915268	MAD1L1	-0.49	-7.44	-0.38	8.84e-13	Bipolar disorder;
CRC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg12193833	chr17:30244370	NA	-0.68	-8.38	-0.42	1.57e-15	Hip circumference adjusted for BMI;
CRC	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.66	10.41	0.5	3.84e-22	Lewy body disease;
CRC	cis	rs7692995	0.920	rs73802707	chr4:17932319	C/T	cg08925142	chr4:18023851	LCORL	-0.55	-5.95	-0.31	7.03e-9	Height;
CRC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.46	0.5	2.77e-22	Menopause (age at onset);
CRC	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.57	-0.47	2.69e-19	Type 2 diabetes;
CRC	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26638003	chr17:685505	GLOD4;RNMTL1	0.41	6.0	0.31	5.2e-9	Response to antipsychotic treatment;
CRC	cis	rs1223397	0.938	rs35511719	chr6:13282442	T/C	cg00460589	chr6:13274354	PHACTR1	0.49	5.98	0.31	5.74e-9	Blood pressure;
CRC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.76	-0.72	6.72e-54	Height;
CRC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.53	5.96	0.31	6.46e-9	Initial pursuit acceleration;
CRC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg08755490	chr11:65554678	OVOL1	0.42	6.15	0.32	2.24e-9	Acne (severe);
CRC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	trans	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg10756647	chr7:56101905	PSPH	0.72	7.98	0.4	2.39e-14	Diabetic kidney disease;
CRC	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.76	0.54	6.77e-27	Coffee consumption (cups per day);
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.45	0.42	9.34e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6968419	0.547	rs72603593	chr7:115894376	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.45	-0.34	3.94e-10	Intraocular pressure;
CRC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-6.45	-0.34	4e-10	Total body bone mineral density;
CRC	cis	rs7705042	0.865	rs6580223	chr5:141489027	G/T	cg07392085	chr5:141489673	NDFIP1	0.46	7.25	0.37	3e-12	Asthma;
CRC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg13206674	chr6:150067644	NUP43	0.52	7.15	0.37	5.81e-12	Testicular germ cell tumor;
CRC	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg08501292	chr6:25962987	TRIM38	0.64	6.15	0.32	2.27e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7781266	0.619	rs4731992	chr7:133702097	A/G	cg03336402	chr7:133662267	EXOC4	-0.58	-6.73	-0.35	7.75e-11	Educational attainment (college completion);
CRC	cis	rs9549328	0.564	rs34556022	chr13:113617437	G/A	cg24588162	chr13:113633484	MCF2L	0.36	6.52	0.34	2.68e-10	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12830829	chr14:51707081	TMX1	0.44	6.91	0.36	2.54e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.86	11.4	0.53	1.3e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.74	9.54	0.47	3.32e-19	Platelet count;
CRC	trans	rs4621152	1.000	rs11894340	chr2:217917167	A/G	cg14039228	chr17:38374778	WIPF2	-0.39	-6.05	-0.32	3.89e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs17023223	0.537	rs7532510	chr1:119594236	A/G	cg05756136	chr1:119680316	WARS2	-0.51	-6.79	-0.35	5.35e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.48	6.7	0.35	9.05e-11	Lung cancer;
CRC	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.43	6.77	0.35	5.78e-11	Schizophrenia;
CRC	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	1.02	12.62	0.57	4.6e-30	IgG glycosylation;
CRC	cis	rs7113874	0.589	rs7939731	chr11:8510299	T/G	cg17679104	chr11:8615758	STK33	-0.36	-5.92	-0.31	8.19e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg13753209	chr17:57696993	CLTC	0.45	5.88	0.31	9.94e-9	Hemoglobin concentration;
CRC	cis	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg03623178	chr6:28175578	NA	0.9	7.35	0.38	1.55e-12	Depression;
CRC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.56	9.17	0.45	5.41e-18	Aortic root size;
CRC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.52	-6.95	-0.36	1.99e-11	Body mass index;
CRC	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	8.94	0.44	2.86e-17	Ulcerative colitis;
CRC	cis	rs7932354	0.528	rs7125807	chr11:47041163	G/T	cg19486271	chr11:47235900	DDB2	0.42	6.19	0.32	1.79e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	cis	rs72627123	1.000	rs72627117	chr14:74355233	T/C	cg19860245	chr14:74300557	NA	-0.51	-5.63	-0.3	3.81e-8	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg12273811	chr6:28175739	NA	0.51	6.99	0.36	1.49e-11	Parkinson's disease;
CRC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.64	-8.12	-0.41	9.37e-15	Mean platelet volume;
CRC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.87	0.44	4.74e-17	Homoarginine levels;
CRC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg12573674	chr2:1569213	NA	-0.74	-7.7	-0.39	1.59e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg08501292	chr6:25962987	TRIM38	0.94	9.22	0.45	3.55e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.48	7.33	0.37	1.84e-12	Corneal astigmatism;
CRC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg25251562	chr2:3704773	ALLC	-0.47	-5.94	-0.31	7.09e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg16281234	chr15:35388805	NA	-0.5	-6.3	-0.33	9.68e-10	Longevity (90 years and older);
CRC	trans	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.18	0.32	1.91e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22857025	chr5:266934	NA	-0.91	-7.92	-0.4	3.57e-14	Asthma (childhood onset);
CRC	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg26893861	chr17:41843967	DUSP3	-0.82	-7.36	-0.38	1.52e-12	Cognitive function;
CRC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.62	8.39	0.42	1.5e-15	Smoking initiation;
CRC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.82	14.39	0.62	8.96e-37	Chronic sinus infection;
CRC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24088775	chr19:12595630	ZNF709	0.38	6.2	0.32	1.7e-9	Obesity-related traits;
CRC	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.6	8.4	0.42	1.36e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.41	7.01	0.36	1.39e-11	Total body bone mineral density;
CRC	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.04	18.13	0.71	2.1e-51	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.89	-0.31	9.61e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs236352	0.576	rs2116447	chr6:36837364	T/C	cg10099585	chr6:36853529	C6orf89	-0.45	-6.3	-0.33	9.3e-10	Heart rate;
CRC	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.49	6.31	0.33	9.24e-10	Cholesterol, total;
CRC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.37	5.68	0.3	2.89e-8	Schizophrenia;
CRC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.84	0.31	1.28e-8	Bladder cancer;
CRC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg11707556	chr5:10655725	ANKRD33B	0.36	6.58	0.34	1.81e-10	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17115147	chr6:45345601	RUNX2;SUPT3H	-0.42	-6.48	-0.34	3.37e-10	Myopia (pathological);
CRC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.79	0.3	1.69e-8	Ulcerative colitis;
CRC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.24	-14.68	-0.63	7.09e-38	Diabetic kidney disease;
CRC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.81	-0.4	7.68e-14	Mood instability;
CRC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.64	0.51	6.61e-23	Bone mineral density;
CRC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg05304507	chr6:116381966	FRK	-0.32	-8.95	-0.44	2.63e-17	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7725052	0.609	rs13358164	chr5:40455962	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.57	-0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.49	9.21	0.45	4.05e-18	Smoking initiation;
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.5	8.93	0.44	3.17e-17	Hypertriglyceridemia;
CRC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg07636037	chr3:49044803	WDR6	-0.64	-6.13	-0.32	2.5e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.47	0.38	7.15e-13	Lung cancer;
CRC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	7.12	0.37	6.79e-12	Motion sickness;
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.16	26.67	0.83	3.01e-84	IgG glycosylation;
CRC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg10760299	chr15:45669010	GATM	0.49	7.84	0.4	6.41e-14	Homoarginine levels;
CRC	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00938859	chr5:1591904	SDHAP3	0.66	6.07	0.32	3.52e-9	Breast cancer;
CRC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26240231	chr7:1148101	C7orf50	-0.47	-6.48	-0.34	3.44e-10	Bronchopulmonary dysplasia;
CRC	cis	rs3812762	0.833	rs10500705	chr11:8805261	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.18	-0.32	1.87e-9	Hypospadias;
CRC	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.41	-7.95	-0.4	2.95e-14	Migraine;
CRC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-6.83	-0.35	4.09e-11	Total body bone mineral density;
CRC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.73	0.3	2.33e-8	Bladder cancer;
CRC	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.13	-9.44	-0.46	7.14e-19	Mitochondrial DNA levels;
CRC	cis	rs7849270	0.760	rs419636	chr9:131931277	T/C	cg13538475	chr9:131942899	NA	0.31	5.85	0.31	1.19e-8	Blood metabolite ratios;
CRC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg11861562	chr11:117069780	TAGLN	0.4	7.92	0.4	3.63e-14	Blood protein levels;
CRC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.67	-11.06	-0.52	2.19e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.59	-10.11	-0.49	4.04e-21	Calcium levels;
CRC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg03286735	chr4:906491	GAK	-0.28	-6.01	-0.31	4.83e-9	Systemic sclerosis;
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.43	6.16	0.32	2.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.49	7.16	0.37	5.31e-12	Menarche (age at onset);
CRC	cis	rs9394438	0.628	rs10947680	chr6:37543668	T/C	cg00985040	chr6:37553208	NA	-0.38	-6.22	-0.32	1.52e-9	IgG glycosylation;
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11900509	chr10:81946545	ANXA11	-0.46	-6.81	-0.35	4.79e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.79	-9.92	-0.48	1.86e-20	Platelet count;
CRC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.28	-0.46	2.39e-18	Migraine;Coronary artery disease;
CRC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.58	6.39	0.33	5.66e-10	Bipolar disorder;
CRC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.57	0.47	2.67e-19	Cognitive test performance;
CRC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.57	6.71	0.35	8.37e-11	Menarche (age at onset);
CRC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.16	0.69	1.43e-47	Platelet count;
CRC	trans	rs9409565	0.821	rs9299419	chr9:97066584	C/T	cg05679027	chr9:99775184	HIATL2	0.4	6.11	0.32	2.77e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.8	13.22	0.59	2.66e-32	Height;
CRC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	7.47	0.38	7.24e-13	Parkinson's disease;
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.75	9.47	0.46	5.59e-19	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07352234	chr8:121457652	MTBP;MRPL13	0.44	6.89	0.36	2.92e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.5	7.47	0.38	7.3e-13	Headache;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.76	-0.3	1.88e-8	Total body bone mineral density;
CRC	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.66	9.75	0.47	6.62e-20	Platelet count;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.36	-0.38	1.5e-12	Lymphocyte counts;
CRC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.0	0.44	1.84e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.44	6.76	0.35	6.34e-11	Monocyte count;
CRC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.8	-13.38	-0.59	6.77e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.24	-0.37	3.28e-12	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.52	7.5	0.38	5.8e-13	Response to antipsychotic treatment;
CRC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.76	0.3	1.91e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg24562669	chr7:97807699	LMTK2	0.44	7.3	0.37	2.12e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14119001	chr9:139324193	INPP5E	-0.47	-6.72	-0.35	7.96e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs2252521	0.583	rs1846490	chr7:29080827	G/A	cg11728747	chr7:29037910	CPVL	-0.48	-6.75	-0.35	6.51e-11	Cognitive performance;
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.14	-0.37	6.07e-12	Glycated hemoglobin levels;
CRC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24308560	chr3:49941425	MST1R	0.43	6.82	0.35	4.29e-11	Body mass index;
CRC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.14	-0.32	2.36e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.44	6.54	0.34	2.42e-10	Neutrophil percentage of white cells;
CRC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.49	-7.16	-0.37	5.2e-12	White blood cell count;
CRC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.57	-9.43	-0.46	7.51e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.64	8.25	0.41	3.82e-15	Iron status biomarkers;
CRC	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg16964102	chr10:135390573	NA	0.52	7.3	0.37	2.14e-12	Gout;
CRC	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg08614441	chr13:113633676	MCF2L	-0.47	-8.05	-0.41	1.51e-14	Systolic blood pressure;
CRC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.48	-0.38	7.02e-13	Myopia (pathological);
CRC	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.68	5.87	0.31	1.07e-8	Schizophrenia;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-7.31	-0.37	2e-12	Glycated hemoglobin levels;
CRC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.36	0.62	1.21e-36	Chronic sinus infection;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19071035	chr6:20404090	E2F3	0.47	6.8	0.35	4.91e-11	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13674316	chr14:55518174	MAPK1IP1L	0.41	6.27	0.33	1.14e-9	Intelligence (multi-trait analysis);
CRC	trans	rs587242	0.911	rs61786490	chr1:96897274	T/G	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg02569219	chr17:2266849	SGSM2	0.38	5.75	0.3	2.03e-8	Autism spectrum disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17111669	chr20:44718800	NCOA5	0.41	6.15	0.32	2.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.43	-0.33	4.46e-10	Total cholesterol levels;
CRC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.46	-0.34	3.7e-10	Electroencephalogram traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25481680	chr10:105110878	PCGF6	0.42	6.8	0.35	4.88e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.25	0.33	1.29e-9	Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.32	-0.46	1.78e-18	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.74	-0.51	2.89e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg21132104	chr15:45694354	SPATA5L1	0.4	5.62	0.3	4.01e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs57506017	0.517	rs12666279	chr7:12260552	G/A	cg26461140	chr11:72811902	FCHSD2	0.59	6.69	0.35	9.44e-11	Neuroticism;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.61	8.5	0.42	6.56e-16	Longevity;Endometriosis;
CRC	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.54	9.32	0.46	1.76e-18	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2380220	0.808	rs2613554	chr6:95916782	C/A	cg04719120	chr6:96025338	MANEA	-0.53	-5.86	-0.31	1.14e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.8	14.03	0.61	2.33e-35	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.49	6.85	0.35	3.71e-11	Schizophrenia;
CRC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg21770322	chr7:97807741	LMTK2	0.87	19.62	0.73	2.74e-57	Breast cancer;
CRC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.44	0.33	4.21e-10	Aortic root size;
CRC	cis	rs7538876	0.935	rs6586542	chr1:17763566	C/G	cg01904812	chr1:17746340	RCC2	-0.4	-6.75	-0.35	6.7e-11	Basal cell carcinoma;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.61	9.24	0.45	3.24e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg03013636	chr16:1946785	NA	0.52	6.49	0.34	3.24e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.54	7.69	0.39	1.78e-13	Lung cancer;
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.52	7.49	0.38	6.58e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.27	-0.46	2.46e-18	Bone mineral density;
CRC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22029157	chr1:209979665	IRF6	0.61	6.76	0.35	6.47e-11	Coronary artery disease;
CRC	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.46	6.04	0.32	4.19e-9	HDL cholesterol;
CRC	cis	rs2267708	0.504	rs3903523	chr7:124668032	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.73e-9	Chronic lymphocytic leukemia;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19346786	chr7:2764209	NA	-0.39	-6.57	-0.34	1.93e-10	Height;
CRC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.89	-0.31	9.48e-9	Alcohol dependence;
CRC	cis	rs1179624	0.767	rs34160770	chr7:75259242	C/T	cg05145297	chr7:75264568	HIP1	0.54	7.32	0.37	1.93e-12	Age-related nuclear cataracts;
CRC	cis	rs16973500	0.808	rs72801786	chr16:71955085	C/T	cg00732059	chr16:71740210	PHLPP2	-0.67	-6.9	-0.36	2.7e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.44	-5.94	-0.31	7.24e-9	Multiple myeloma;
CRC	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.48	0.34	3.28e-10	Morning vs. evening chronotype;
CRC	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg18764771	chr6:116381957	FRK	0.26	6.24	0.33	1.34e-9	Total cholesterol levels;
CRC	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg03623178	chr6:28175578	NA	-0.68	-7.24	-0.37	3.23e-12	Depression;
CRC	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg10437265	chr15:77819839	NA	-0.62	-10.38	-0.5	5.12e-22	Type 2 diabetes;
CRC	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg25171089	chr10:5708825	ASB13	0.41	5.75	0.3	2.04e-8	Menopause (age at onset);
CRC	cis	rs4132509	1.000	rs9782883	chr1:243892532	A/G	cg21452805	chr1:244014465	NA	0.47	6.33	0.33	8.23e-10	RR interval (heart rate);
CRC	cis	rs12431939	0.947	rs59298295	chr14:51659047	T/G	cg23942311	chr14:51606299	NA	-0.57	-6.39	-0.33	5.84e-10	Cancer;
CRC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.71	10.94	0.52	5.68e-24	Diastolic blood pressure;
CRC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg12463550	chr7:65579703	CRCP	0.76	6.72	0.35	7.81e-11	Diabetic kidney disease;
CRC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	11.95	0.55	1.35e-27	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.29	-5.99	-0.31	5.47e-9	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00945735	chr7:41982767	NA	0.35	6.34	0.33	7.42e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs17152411	0.793	rs7085829	chr10:126587142	A/G	cg07906193	chr10:126599966	NA	0.57	6.45	0.33	4.08e-10	Height;
CRC	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg00631329	chr6:26305371	NA	-0.55	-9.31	-0.46	1.84e-18	Educational attainment;
CRC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.58	9.76	0.47	6.18e-20	Menopause (age at onset);
CRC	trans	rs9341835	0.772	rs9294196	chr6:64135193	A/G	cg13657004	chr13:50234944	EBPL	0.37	6.24	0.33	1.35e-9	Schizophrenia;
CRC	cis	rs6479527	0.806	rs2211362	chr9:96750361	A/T	cg14459158	chr9:96720562	NA	0.41	7.52	0.38	5.11e-13	Esophageal adenocarcinoma;
CRC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.93	0.36	2.19e-11	Mean platelet volume;
CRC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.12	-0.32	2.7e-9	Morning vs. evening chronotype;
CRC	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg21496419	chr19:44306685	LYPD5	-0.34	-6.34	-0.33	7.49e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.7	12.52	0.57	1.16e-29	Obesity-related traits;
CRC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg12927641	chr6:109611667	NA	-0.36	-6.51	-0.34	2.77e-10	Reticulocyte fraction of red cells;
CRC	cis	rs3101457	0.515	rs4658632	chr1:244516949	G/T	cg09033006	chr1:244517177	C1orf100	-0.45	-6.32	-0.33	8.48e-10	Smoking behavior;
CRC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-7.66	-0.39	2.08e-13	Schizophrenia;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.44	6.97	0.36	1.7e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg05623727	chr3:50126028	RBM5	0.42	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2836754	1.000	rs2836751	chr21:40290959	C/T	cg02119577	chr21:40195074	ETS2	-0.35	-6.04	-0.32	4.13e-9	Crohn's disease;Body mass index;
CRC	cis	rs7605827	0.930	rs1019360	chr2:15524741	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-6.07	-0.32	3.43e-9	Electroencephalogram traits;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.62	9.44	0.46	7.26e-19	Testicular germ cell tumor;
CRC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.42	5.6	0.3	4.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.48	-7.19	-0.37	4.48e-12	Breast size;
CRC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24308560	chr3:49941425	MST1R	-0.44	-7.04	-0.36	1.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00495681	chr13:53174319	NA	0.62	9.4	0.46	9.76e-19	Lewy body disease;
CRC	cis	rs4908768	0.501	rs6577488	chr1:8534529	T/C	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-5.76	-0.3	1.91e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg10298567	chr3:47292165	KIF9	0.38	6.11	0.32	2.74e-9	Colorectal cancer;
CRC	trans	rs6546324	0.625	rs11900280	chr2:67840401	T/C	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.21	-0.32	1.6e-9	Endometriosis;
CRC	cis	rs9925964	0.967	rs12716981	chr16:31118024	C/A	cg03418659	chr16:31128414	MYST1	0.52	7.62	0.39	2.67e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16139199	chr18:19180362	ESCO1	0.43	6.23	0.32	1.43e-9	Response to antipsychotic treatment;
CRC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.54	8.74	0.43	1.19e-16	Asthma;
CRC	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg10761708	chr20:43804764	PI3	0.5	5.63	0.3	3.85e-8	Blood protein levels;
CRC	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.55	5.84	0.31	1.27e-8	RR interval (heart rate);
CRC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.43	5.81	0.31	1.46e-8	Intelligence (multi-trait analysis);
CRC	trans	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg07817883	chr1:32538562	TMEM39B	0.7	7.88	0.4	4.84e-14	Monocyte percentage of white cells;
CRC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg25876840	chr17:41920477	NA	0.53	7.11	0.36	7.48e-12	Triglycerides;
CRC	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-6.87	-0.35	3.25e-11	HDL cholesterol;
CRC	trans	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg14791747	chr16:20752902	THUMPD1	0.53	6.64	0.34	1.32e-10	Cognitive test performance;
CRC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.8	-13.36	-0.59	8.34e-33	Obesity-related traits;
CRC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-9.39	-0.46	1.05e-18	Total body bone mineral density;
CRC	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.34	-0.33	7.72e-10	Diastolic blood pressure;
CRC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.07	-0.45	1.06e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	0.79	7.35	0.38	1.56e-12	Thyroid stimulating hormone;
CRC	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.65	-8.88	-0.44	4.57e-17	Extraversion;
CRC	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	0.52	5.96	0.31	6.35e-9	Dental caries;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg21251018	chr6:28226885	NKAPL	-0.58	-10.1	-0.49	4.6e-21	Cardiac Troponin-T levels;
CRC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.93	-0.52	6.03e-24	Monocyte count;
CRC	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg22529645	chr1:3704559	LRRC47	0.44	5.89	0.31	9.44e-9	Red cell distribution width;
CRC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.43	-0.38	9.38e-13	Colorectal cancer;
CRC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.19	-0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04450332	chr5:110408780	TSLP	0.42	5.91	0.31	8.42e-9	Eosinophilic esophagitis;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg15845792	chr6:28175446	NA	0.7	7.65	0.39	2.28e-13	Parkinson's disease;
CRC	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.9	20.85	0.75	4.04e-62	Longevity;
CRC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg03037974	chr15:76606532	NA	-0.5	-7.06	-0.36	9.85e-12	Blood metabolite levels;
CRC	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.36	-6.91	-0.36	2.46e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.67	7.4	0.38	1.17e-12	Breast cancer;
CRC	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg03934865	chr2:198174659	NA	-0.4	-6.24	-0.33	1.37e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.66	8.87	0.44	4.8e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.29	0.33	1.02e-9	Height;
CRC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg25834613	chr7:1915315	MAD1L1	-0.46	-6.5	-0.34	2.95e-10	Bipolar disorder;
CRC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.42	6.06	0.32	3.69e-9	Renal cell carcinoma;
CRC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg16576597	chr16:28551801	NUPR1	0.48	6.9	0.36	2.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13373360	chr4:149364881	NR3C2	0.37	6.07	0.32	3.45e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.72	10.94	0.52	5.95e-24	Corneal astigmatism;
CRC	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.57	-9.38	-0.46	1.09e-18	Neuroticism;
CRC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.48	-9.08	-0.45	9.94e-18	Alcohol dependence;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg26870460	chr11:6947759	ZNF215	0.58	6.05	0.32	3.85e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.49	7.69	0.39	1.78e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.43	-0.38	9.25e-13	Morning vs. evening chronotype;
CRC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg13319975	chr6:146136371	FBXO30	0.43	6.51	0.34	2.88e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.59	7.12	0.37	6.85e-12	Chronic sinus infection;
CRC	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg12700464	chr11:78128424	GAB2	-0.47	-5.76	-0.3	1.96e-8	Testicular germ cell tumor;
CRC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.51	7.07	0.36	9.15e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.65	-11.05	-0.52	2.41e-24	Subjective well-being (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.69	-7.77	-0.39	1.04e-13	Vitiligo;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg15786705	chr6:28176104	NA	0.53	6.93	0.36	2.17e-11	Parkinson's disease;
CRC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg23262073	chr20:60523788	NA	-0.35	-5.7	-0.3	2.72e-8	Body mass index;
CRC	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.48	-8.99	-0.44	2.04e-17	Hepatitis;
CRC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg19193384	chr17:30244184	NA	-0.54	-6.44	-0.33	4.33e-10	Hip circumference adjusted for BMI;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg21251018	chr6:28226885	NKAPL	0.46	6.93	0.36	2.28e-11	Cardiac Troponin-T levels;
CRC	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg18323236	chr1:24743029	NIPAL3	0.38	5.64	0.3	3.66e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.56	8.26	0.41	3.67e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04533189	chr17:64298763	PRKCA	0.33	6.12	0.32	2.74e-9	Obesity-related traits;
CRC	cis	rs9900062	0.586	rs6504249	chr17:62676149	A/G	cg02097616	chr17:62675921	NA	0.47	6.27	0.33	1.13e-9	QT interval;
CRC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.51	-6.74	-0.35	6.97e-11	Glioblastoma;
CRC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.34	-5.94	-0.31	7.2e-9	Menarche (age at onset);
CRC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg03948781	chr1:205179583	DSTYK	0.41	5.61	0.3	4.22e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.17	-0.37	5e-12	Inflammatory skin disease;
CRC	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.68	10.56	0.5	1.17e-22	Diastolic blood pressure;
CRC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg00976097	chr5:421733	AHRR	-0.44	-6.02	-0.31	4.69e-9	Cystic fibrosis severity;
CRC	cis	rs56307353	0.513	rs2041120	chr19:1961474	C/T	cg26776924	chr19:1969666	CSNK1G2	0.49	7.8	0.4	8.08e-14	Coronary artery disease;
CRC	cis	rs8141797	1.000	rs8138799	chr22:24556902	G/A	cg20894457	chr22:24584366	SUSD2	0.63	7.2	0.37	4.05e-12	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.65	-0.34	1.25e-10	Mood instability;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-8.07	-0.41	1.3e-14	Longevity;Endometriosis;
CRC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.42	-5.65	-0.3	3.5e-8	Cognitive function;
CRC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg16235748	chr6:149772707	ZC3H12D	0.36	6.34	0.33	7.53e-10	Dupuytren's disease;
CRC	cis	rs972578	0.806	rs5751386	chr22:43245345	T/C	cg01576275	chr22:43409880	NA	-0.39	-6.05	-0.32	3.99e-9	Mean platelet volume;
CRC	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg04811098	chr7:155088454	INSIG1	0.42	6.49	0.34	3.17e-10	Stem cell growth factor beta levels;
CRC	cis	rs9463078	0.585	rs1748235	chr6:45141361	T/C	cg25276700	chr6:44698697	NA	-0.23	-5.6	-0.3	4.44e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.96	14.22	0.62	4.36e-36	IgG glycosylation;
CRC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.19	-0.53	7.42e-25	Eye color traits;
CRC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.57	-0.34	1.94e-10	Major depressive disorder;
CRC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.77	0.3	1.84e-8	Multiple sclerosis;
CRC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg15465823	chr12:48382534	COL2A1	-0.38	-6.36	-0.33	6.57e-10	Glycated hemoglobin levels;
CRC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg05185784	chr16:90016020	DEF8	0.56	8.69	0.43	1.78e-16	Squamous cell carcinoma;
CRC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.22	-0.56	1.44e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg20673091	chr1:2541236	MMEL1	0.37	5.98	0.31	5.88e-9	Ulcerative colitis;
CRC	cis	rs12922317	0.556	rs11648938	chr16:12094149	C/T	cg09319797	chr16:12061715	TNFRSF17	0.32	5.69	0.3	2.78e-8	Schizophrenia;
CRC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg19622623	chr12:86230825	RASSF9	-0.38	-5.85	-0.31	1.18e-8	Major depressive disorder;
CRC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.46	-5.81	-0.31	1.47e-8	Aortic root size;
CRC	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.88	-0.31	1.02e-8	Metabolite levels;
CRC	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	9.03e-40	Colorectal cancer;
CRC	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg24289452	chr6:170231220	NA	-0.93	-7.57	-0.39	3.88e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.04	14.75	0.63	3.78e-38	Vitiligo;
CRC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg22117107	chr15:45993392	NA	-0.44	-8.88	-0.44	4.52e-17	Waist circumference;Weight;
CRC	cis	rs939584	1.000	rs12714415	chr2:651430	T/C	cg03610516	chr2:642275	NA	-0.43	-5.93	-0.31	7.78e-9	Body mass index;
CRC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg03609598	chr5:56110824	MAP3K1	-0.6	-7.02	-0.36	1.31e-11	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10683054	chr6:132129037	ENPP1	0.36	5.97	0.31	6.01e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.09	0.32	3.12e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10865849	chr10:48355149	ZNF488	0.45	6.45	0.34	3.95e-10	Response to antipsychotic treatment;
CRC	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.7	-9.29	-0.46	2.22e-18	Blood pressure (smoking interaction);
CRC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.91	-16.78	-0.68	4.25e-46	Intelligence (multi-trait analysis);
CRC	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.04	7.53	0.38	5.02e-13	Economic and political preferences (immigration/crime);
CRC	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg23202291	chr11:1979235	NA	0.45	6.15	0.32	2.18e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg09779027	chr19:7224513	INSR	1.01	22.37	0.78	5.08e-68	Hypothyroidism;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.65	10.22	0.49	1.74e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs1179624	0.679	rs62475464	chr7:75263197	G/A	cg05145297	chr7:75264568	HIP1	0.57	7.63	0.39	2.61e-13	Age-related nuclear cataracts;
CRC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.74	8.59	0.43	3.67e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	0.99	10.94	0.52	5.59e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs4785204	1.000	rs7187350	chr16:50099036	C/A	cg07960154	chr17:37760198	NEUROD2	-0.65	-6.05	-0.32	3.98e-9	Esophageal cancer (squamous cell);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg25957114	chr5:147582460	SPINK6	-0.43	-6.6	-0.34	1.62e-10	HDL cholesterol;
CRC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-8.34	-0.42	2.04e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.63	0.39	2.5e-13	Height;
CRC	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.63	-5.76	-0.3	1.92e-8	White matter integrity;
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg02033258	chr5:131593261	PDLIM4	0.33	6.32	0.33	8.7e-10	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg22988483	chr14:93581567	ITPK1	-0.67	-6.03	-0.32	4.48e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Depression;
CRC	cis	rs10924970	0.649	rs6697580	chr1:235484609	T/A	cg09010748	chr1:235293032	TOMM20	-0.4	-5.65	-0.3	3.57e-8	Asthma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11802732	chr17:2206917	SRR;SMG6	0.47	6.11	0.32	2.79e-9	Thyroid stimulating hormone;
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg27432699	chr2:27873401	GPN1	-0.51	-7.82	-0.4	7.11e-14	Total body bone mineral density;
CRC	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg23920097	chr1:209922102	NA	-0.5	-5.62	-0.3	4.07e-8	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20611850	chr19:41284006	RAB4B	0.49	7.49	0.38	6.2800000000000005e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13844804	chr7:814759	HEATR2	-0.56	-5.88	-0.31	9.96e-9	Cerebrospinal P-tau181p levels;
CRC	trans	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.27	0.41	3.39e-15	Endometrial cancer;
CRC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.58	-7.94	-0.4	3.27e-14	DNA methylation (variation);
CRC	trans	rs9545047	0.669	rs9545113	chr13:79996152	G/A	cg07061582	chr15:90234082	PEX11A;WDR93	0.41	5.97	0.31	6.15e-9	Schizophrenia;
CRC	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.6	8.69	0.43	1.75e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg05501817	chr11:14380813	RRAS2	-0.45	-5.96	-0.31	6.43e-9	Sense of smell;
CRC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.09	0.64	1.79e-39	Smoking behavior;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.93	0.74	1.63e-58	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24438655	chr17:45727598	KPNB1	0.46	6.57	0.34	1.95e-10	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13655586	chr7:111202389	IMMP2L	0.41	6.04	0.32	4.27e-9	Schizophrenia;
CRC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.46	-7.09	-0.36	8.44e-12	Response to antineoplastic agents;
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-5.85	-0.31	1.16e-8	Menopause (age at onset);
CRC	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.75	0.3	2.04e-8	Prostate cancer;
CRC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg13047869	chr3:10149882	C3orf24	0.39	5.95	0.31	6.9e-9	Alzheimer's disease;
CRC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.49	6.38	0.33	5.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.46	-6.76	-0.35	6.2e-11	Platelet distribution width;
CRC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg13206674	chr6:150067644	NUP43	0.48	5.84	0.31	1.28e-8	Lung cancer;
CRC	cis	rs282587	0.569	rs373653	chr13:113406699	A/G	cg04656015	chr13:113407548	ATP11A	0.58	7.45	0.38	8.25e-13	Glycated hemoglobin levels;
CRC	cis	rs7799006	0.929	rs745566	chr7:2256406	T/C	cg08027265	chr7:2291960	NA	-0.4	-5.98	-0.31	5.8e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-6.14	-0.32	2.35e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05393045	chr10:119256233	EMX2OS	0.44	6.15	0.32	2.21e-9	Response to antipsychotic treatment;
CRC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.44	6.28	0.33	1.07e-9	Cognitive ability;
CRC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.5	8.01	0.4	1.99e-14	Calcium levels;
CRC	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg00105475	chr2:10696890	NA	0.45	7.1	0.36	7.95e-12	Prostate cancer;
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.69	-0.35	9.47e-11	Total body bone mineral density;
CRC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.73	11.46	0.53	7.95e-26	Tonsillectomy;
CRC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg04880052	chr2:219191631	PNKD	-0.39	-5.88	-0.31	1.03e-8	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg14664628	chr15:75095509	CSK	0.52	6.31	0.33	9.22e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg09659197	chr4:152720779	NA	0.52	11.41	0.53	1.21e-25	Intelligence (multi-trait analysis);
CRC	cis	rs16924133	0.793	rs67622484	chr11:33209057	A/G	cg05567920	chr11:33183001	CSTF3	-0.78	-6.08	-0.32	3.39e-9	Anger;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg02683197	chr6:28174875	NA	0.73	7.17	0.37	4.91e-12	Lung cancer in ever smokers;
CRC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.91	0.55	1.95e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg27121462	chr16:89883253	FANCA	0.44	6.54	0.34	2.33e-10	Vitiligo;
CRC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.46	-0.34	3.72e-10	Blood pressure (smoking interaction);
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.92	-0.44	3.24e-17	Bipolar disorder;
CRC	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.67	10.73	0.51	3.2e-23	Pulmonary function decline;
CRC	cis	rs7072216	1.000	rs7072216	chr10:100156853	A/G	cg26618903	chr10:100175079	PYROXD2	-0.41	-7.14	-0.37	5.83e-12	Metabolite levels;
CRC	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.93	0.31	7.81e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg14329157	chr2:228736135	WDR69	0.43	5.82	0.31	1.41e-8	Blood pressure;
CRC	cis	rs2000999	0.514	rs35930480	chr16:72217681	G/A	cg04254540	chr16:71951199	KIAA0174	-0.71	-5.79	-0.3	1.62e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.49	-6.36	-0.33	6.69e-10	Body mass index;
CRC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.27	-0.33	1.16e-9	Aortic root size;
CRC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg06740227	chr12:86229804	RASSF9	0.39	5.94	0.31	7.29e-9	Major depressive disorder;
CRC	cis	rs1223397	0.702	rs1223400	chr6:13271242	T/C	cg06879394	chr6:13274151	PHACTR1	0.55	6.61	0.34	1.55e-10	Blood pressure;
CRC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.56	9.0	0.44	1.79e-17	Type 2 diabetes;
CRC	cis	rs4653767	0.573	rs708770	chr1:226912135	C/T	cg05049329	chr1:226924846	ITPKB	0.29	6.57	0.34	1.95e-10	Parkinson's disease;
CRC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-11.32	-0.53	2.58e-25	Migraine;Coronary artery disease;
CRC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.36	-0.46	1.31e-18	Platelet count;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11645453	chr3:52864694	ITIH4	0.34	5.92	0.31	8.26e-9	Bipolar disorder;
CRC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-5.99	-0.31	5.38e-9	Alzheimer's disease (late onset);
CRC	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.56	10.08	0.49	5.18e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00995911	chr19:45004602	ZNF180	0.42	6.82	0.35	4.45e-11	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs711830	1.000	rs1562315	chr2:177045482	T/A	cg13092806	chr2:177043255	NA	0.74	9.46	0.46	5.9e-19	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.64	8.61	0.43	3.15e-16	Multiple sclerosis;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg00063174	chr2:228736253	WDR69	-0.48	-6.48	-0.34	3.35e-10	Blood pressure;
CRC	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.52	9.22	0.45	3.57e-18	Common traits (Other);
CRC	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.71	-0.3	2.51e-8	Breast cancer;
CRC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.74	0.35	7.09e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.64	-12.7	-0.57	2.33e-30	Electroencephalogram traits;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.51	6.51	0.34	2.8e-10	Longevity;
CRC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-7.21	-0.37	3.79e-12	Aortic root size;
CRC	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.62	9.33	0.46	1.65e-18	Corneal astigmatism;
CRC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.39	-0.42	1.48e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.43	-6.73	-0.35	7.69e-11	Asthma;
CRC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.52	8.46	0.42	8.66e-16	Tonsillectomy;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg12273811	chr6:28175739	NA	0.57	8.36	0.42	1.76e-15	Parkinson's disease;
CRC	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07165851	chr6:158734300	TULP4	0.61	7.75	0.39	1.15e-13	Height;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Parkinson's disease;
CRC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.97	-0.36	1.7e-11	Aortic root size;
CRC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg23815491	chr16:72088622	HP	0.46	6.78	0.35	5.69e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs1223397	0.938	rs9381884	chr6:13278788	A/G	cg00460589	chr6:13274354	PHACTR1	0.46	5.82	0.31	1.4e-8	Blood pressure;
CRC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.89	-0.31	9.7e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.32	6.02	0.32	4.62e-9	Blood protein levels;
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.49	5.83	0.31	1.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg20243544	chr17:37824526	PNMT	0.56	9.01	0.44	1.72e-17	Asthma;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg12172441	chr6:28176163	NA	0.56	5.8	0.3	1.54e-8	Depression;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.47	7.46	0.38	7.83e-13	Schizophrenia;
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.49	0.42	7.08e-16	Menarche (age at onset);
CRC	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg14593290	chr7:50529359	DDC	-0.54	-7.53	-0.38	4.84e-13	Malaria;
CRC	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.7	-9.08	-0.45	1.01e-17	Blood pressure (smoking interaction);
CRC	cis	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg05627522	chr15:75251581	NA	0.38	5.83	0.31	1.33e-8	Breast cancer;
CRC	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg11130432	chr3:121712080	ILDR1	-0.49	-6.1	-0.32	2.97e-9	Multiple sclerosis;
CRC	cis	rs8141797	0.901	rs5751811	chr22:24570772	G/A	cg20894457	chr22:24584366	SUSD2	0.66	6.51	0.34	2.77e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg03037974	chr15:76606532	NA	0.72	12.67	0.57	3.16e-30	Blood metabolite levels;
CRC	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.69	9.75	0.47	6.98e-20	Body mass index;
CRC	cis	rs526821	0.595	rs532278	chr11:55344983	A/G	cg04317927	chr11:55418816	OR4S2	0.39	6.63	0.34	1.37e-10	Pediatric bone mineral density (spine);
CRC	cis	rs7665939	0.860	rs72709247	chr4:190126086	A/G	cg09826759	chr4:190284978	NA	-0.65	-5.64	-0.3	3.58e-8	Amyotrophic lateral sclerosis;
CRC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.66	-10.78	-0.51	2.12e-23	Personality dimensions;
CRC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.54	8.12	0.41	9.26e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs12318506	0.793	rs71460129	chr12:75699427	C/T	cg04728562	chr12:75699417	CAPS2	-0.96	-7.25	-0.37	2.91e-12	Coronary artery calcification;
CRC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.76	-10.06	-0.48	6.3e-21	Initial pursuit acceleration;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg15845792	chr6:28175446	NA	0.73	6.48	0.34	3.27e-10	Breast cancer;
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.73	9.96	0.48	1.34e-20	Alzheimer's disease;
CRC	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg26597838	chr10:835615	NA	0.67	7.69	0.39	1.75e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg13047869	chr3:10149882	C3orf24	0.56	6.66	0.34	1.15e-10	Alzheimer's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05815920	chr10:103880348	LDB1	-0.42	-6.64	-0.34	1.32e-10	Myopia (pathological);
CRC	cis	rs4728302	0.869	rs12707129	chr7:133593177	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.56	-0.34	2.04e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.05	-0.36	1.03e-11	Alzheimer's disease (late onset);
CRC	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.5	-7.47	-0.38	7.38e-13	Schizophrenia;
CRC	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.45	7.05	0.36	1.05e-11	HDL cholesterol;
CRC	cis	rs4700695	0.841	rs784276	chr5:65317332	A/T	cg21114390	chr5:65439923	SFRS12	0.51	6.37	0.33	6.55e-10	Facial morphology (factor 19);
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.71	-0.3	2.54e-8	Depression;
CRC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.5	8.07	0.41	1.3e-14	Menopause (age at onset);
CRC	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.75	-7.87	-0.4	5.12e-14	Recalcitrant atopic dermatitis;
CRC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.66	11.69	0.54	1.19e-26	Diastolic blood pressure;
CRC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.74	0.43	1.19e-16	Parkinson's disease;
CRC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.88	-11.59	-0.54	2.9e-26	Gut microbiome composition (summer);
CRC	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.53	-7.91	-0.4	3.89e-14	Multiple sclerosis;
CRC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg02741985	chr17:80059408	CCDC57	0.43	7.23	0.37	3.4e-12	Life satisfaction;
CRC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.52	9.12	0.45	7.76e-18	Multiple system atrophy;
CRC	cis	rs4654899	0.802	rs6426648	chr1:21179527	A/G	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.93	-0.4	3.35e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	7.55	0.38	4.39e-13	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg10354764	chr16:3285464	ZNF200	-0.54	-6.63	-0.34	1.34e-10	Diisocyanate-induced asthma;
CRC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.86	-14.11	-0.61	1.06e-35	Blood metabolite levels;
CRC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.53	-8.16	-0.41	6.95e-15	Age at first birth;
CRC	cis	rs2625529	0.730	rs7403191	chr15:72160964	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.48	-0.34	3.29e-10	Red blood cell count;
CRC	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg17393016	chr17:79283390	C17orf55	-0.28	-5.77	-0.3	1.84e-8	Frontotemporal dementia;
CRC	cis	rs6840360	0.573	rs4696249	chr4:152264647	A/G	cg09659197	chr4:152720779	NA	0.33	6.37	0.33	6.19e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.67	10.69	0.51	4.24e-23	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg27422857	chr2:105853526	NA	-0.36	-6.71	-0.35	8.32e-11	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24823993	chr22:42085003	NHP2L1	0.47	7.12	0.37	6.77e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg19683494	chr5:74908142	NA	0.49	6.05	0.32	3.97e-9	Age-related disease endophenotypes;
CRC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg24881330	chr22:46731750	TRMU	0.56	6.63	0.34	1.35e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.51	7.69	0.39	1.77e-13	Platelet distribution width;
CRC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.59	9.27	0.46	2.49e-18	Height;
CRC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-9.29	-0.46	2.14e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6840360	0.642	rs2709822	chr4:152351500	A/G	cg09659197	chr4:152720779	NA	0.34	6.69	0.35	9.53e-11	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09580147	chr16:22431764	RRN3P3	0.46	6.86	0.35	3.35e-11	Myopia (pathological);
CRC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg16989719	chr2:238392110	NA	-0.41	-6.69	-0.35	9.51e-11	Prostate cancer;
CRC	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.5	0.34	3.06e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12024301	0.557	rs6658064	chr1:183621175	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg00791764	chr4:53727839	RASL11B	0.59	6.29	0.33	1.02e-9	Optic nerve measurement (cup area);
CRC	cis	rs9311676	0.656	rs7647184	chr3:58370046	C/T	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs6679356	0.789	rs1908632	chr1:67805806	G/T	cg24364144	chr1:67875067	SERBP1	0.41	6.24	0.33	1.38e-9	Primary biliary cholangitis;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg15786705	chr6:28176104	NA	0.47	6.84	0.35	3.92e-11	Parkinson's disease;
CRC	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.51	-0.54	5.39e-26	Psoriasis vulgaris;
CRC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-9.87	-0.48	2.66e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.41	6.2	0.32	1.68e-9	Endometrial cancer;
CRC	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.34	-5.97	-0.31	6.23e-9	Airway imaging phenotypes;
CRC	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg01993067	chr11:68851601	TPCN2	0.56	6.33	0.33	7.99e-10	Blond vs. brown hair color;
CRC	cis	rs7264396	0.887	rs4911510	chr20:34093153	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.55	-0.34	2.26e-10	Total cholesterol levels;
CRC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-8.8	-0.44	8.16e-17	Urinary metabolites;
CRC	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.7	-0.3	2.69e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	11.26	0.53	4.22e-25	Mean platelet volume;
CRC	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.84	15.45	0.65	7.12e-41	Hip circumference;
CRC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg27535305	chr1:53392650	SCP2	0.34	6.32	0.33	8.34e-10	Monocyte count;
CRC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.52	6.97	0.36	1.76e-11	Obesity-related traits;
CRC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.09	-0.36	8.44e-12	Blood metabolite levels;
CRC	cis	rs3026101	0.671	rs3026115	chr17:5285222	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	7.55	0.38	4.31e-13	Body mass index;
CRC	cis	rs7527798	0.592	rs960088	chr1:207827067	A/C	cg09232269	chr1:207846808	CR1L	-0.45	-7.31	-0.37	2.02e-12	Erythrocyte sedimentation rate;
CRC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-1.1	-18.2	-0.71	1.07e-51	Blood pressure (smoking interaction);
CRC	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg16141378	chr3:129829833	LOC729375	-0.45	-6.8	-0.35	4.97e-11	Mood instability;
CRC	cis	rs59104589	1.000	rs59104589	chr2:242237902	C/T	cg10021735	chr2:242295487	FARP2	0.44	5.98	0.31	5.69e-9	Fibrinogen levels;
CRC	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14952089	chr5:126366488	MARCH3	0.41	6.14	0.32	2.4e-9	Schizophrenia;
CRC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.79	-0.39	8.68e-14	Coronary artery disease;
CRC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.42	6.67	0.35	1.09e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs4746091	1.000	rs61650587	chr10:73398722	G/A	cg22763136	chr10:73395000	CDH23	0.42	6.18	0.32	1.91e-9	Selective IgA deficiency;
CRC	cis	rs1519814	1.000	rs4871041	chr8:121136584	C/T	cg22335954	chr8:121166405	COL14A1	-0.56	-6.44	-0.33	4.13e-10	Breast cancer;
CRC	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg05234568	chr11:5960015	NA	0.4	6.06	0.32	3.74e-9	DNA methylation (variation);
CRC	trans	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg26043149	chr18:55253948	FECH	0.5	7.46	0.38	7.7e-13	Bone mineral density;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg19318889	chr4:1322082	MAEA	-0.41	-6.38	-0.33	5.88e-10	Obesity-related traits;
CRC	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.83	7.01	0.36	1.34e-11	LDL cholesterol;
CRC	cis	rs9846480	0.598	rs6439804	chr3:138056550	T/C	cg25476813	chr3:138050155	TXNDC6	-0.38	-5.73	-0.3	2.24e-8	Whole-brain volume (Alzheimer's disease interaction);
CRC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.18	-0.32	1.91e-9	Axial length;
CRC	cis	rs9992667	0.955	rs73232876	chr4:38647509	C/T	cg19726192	chr4:38663646	FLJ13197	-0.69	-8.6	-0.43	3.27e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg20811857	chr17:78079795	GAA	-0.4	-6.33	-0.33	8.05e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg25459000	chr22:39777742	SYNGR1	-0.34	-6.05	-0.32	3.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.75	10.43	0.5	3.54e-22	Bronchopulmonary dysplasia;
CRC	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.63	-8.68	-0.43	1.82e-16	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00814883	chr7:100076585	TSC22D4	0.44	6.98	0.36	1.65e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg15192750	chr16:69999425	NA	0.52	6.97	0.36	1.71e-11	IgE levels;
CRC	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.26	-0.33	1.2e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.58	-9.28	-0.46	2.26e-18	Intelligence (multi-trait analysis);
CRC	trans	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg09045935	chr12:6379348	NA	1.03	8.84	0.44	5.85e-17	Blood metabolite levels;
CRC	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.72	-0.35	8.22e-11	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04465201	chr20:32699025	EIF2S2	0.45	6.47	0.34	3.57e-10	Response to antipsychotic treatment;
CRC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg17524180	chr13:113633600	MCF2L	-0.68	-12.82	-0.58	8.76e-31	Systolic blood pressure;
CRC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.39	6.41	0.33	4.92e-10	Height;
CRC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg19337854	chr7:99768885	GPC2	0.47	6.29	0.33	9.99e-10	Lung function (FEV1/FVC);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg25947998	chr8:42948467	SGK196	-0.41	-6.06	-0.32	3.68e-9	Daytime sleep phenotypes;
CRC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg25356066	chr3:128598488	ACAD9	0.39	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.85	-12.75	-0.57	1.62e-30	Ulcerative colitis;
CRC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	9.42	0.46	8.36e-19	Monocyte count;
CRC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.11	-0.49	4.33e-21	Total cholesterol levels;
CRC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.22	0.56	1.46e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-6.03	-0.32	4.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2188554	0.740	rs213948	chr7:117194470	G/A	cg09181792	chr7:117119393	CFTR	0.33	5.95	0.31	6.94e-9	Esophageal adenocarcinoma;
CRC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.54	-7.16	-0.37	5.45e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.42	-5.99	-0.31	5.36e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.9	-0.31	8.88e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.51	7.09	0.36	8.18e-12	Methadone dose in opioid dependence;
CRC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.82	-0.4	7.17e-14	Caffeine consumption;
CRC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg27588902	chr6:42928151	GNMT	-0.36	-5.72	-0.3	2.34e-8	Blood protein levels;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg21251018	chr6:28226885	NKAPL	-0.46	-6.5	-0.34	2.9e-10	Parkinson's disease;
CRC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	7.55	0.38	4.43e-13	Personality dimensions;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02190572	chr10:74057806	NA	0.4	6.17	0.32	2.02e-9	Interleukin-6 levels;
CRC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.82	0.51	1.53e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs832540	0.866	rs252894	chr5:56224339	A/C	cg24531977	chr5:56204891	C5orf35	0.43	6.37	0.33	6.54e-10	Coronary artery disease;
CRC	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.68	9.63	0.47	1.72e-19	Body mass index;
CRC	cis	rs6960043	0.738	rs10266209	chr7:15058691	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.4	-0.33	5.26e-10	Type 2 diabetes;
CRC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.81	-0.35	4.64e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	0.8	10.02	0.48	8.79e-21	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-6.62	-0.34	1.44e-10	Bone mineral density (hip);Bone mineral density (spine);
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.77	-0.3	1.79e-8	Breast cancer;
CRC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg23920097	chr1:209922102	NA	-0.5	-5.66	-0.3	3.25e-8	Red blood cell count;
CRC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.52	7.65	0.39	2.2e-13	Lung cancer;
CRC	trans	rs473651	0.904	rs501333	chr2:239336045	G/A	cg13521940	chr21:36262239	RUNX1	-0.41	-6.07	-0.32	3.54e-9	Multiple system atrophy;
CRC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.46e-9	Ulcerative colitis;
CRC	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.27	-0.41	3.31e-15	Biliary atresia;
CRC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg04545296	chr12:48745243	ZNF641	-0.37	-6.49	-0.34	3.08e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.44	9.45	0.46	6.74e-19	Blood protein levels;
CRC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-5.64	-0.3	3.71e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.8	10.99	0.52	3.77e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10512697	0.803	rs77728185	chr5:3577798	T/A	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05030574	chr11:65189075	NEAT1	0.49	6.98	0.36	1.61e-11	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.47	0.53	7.78e-26	Prudent dietary pattern;
CRC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	9.23	0.45	3.47e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.49	5.77	0.3	1.87e-8	QRS duration;
CRC	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-7.03	-0.36	1.22e-11	Colorectal cancer;
CRC	cis	rs17234274	0.644	rs1947939	chr11:23221739	T/C	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.02e-8	Cancer;
CRC	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.53	-7.92	-0.4	3.82e-14	Body mass index;
CRC	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	1.15	9.97	0.48	1.26e-20	Mitochondrial DNA levels;
CRC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.32e-11	Height;
CRC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.43	-6.79	-0.35	5.36e-11	Monocyte count;
CRC	cis	rs1223397	0.651	rs957175	chr6:13311243	C/T	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg10596483	chr8:143751796	JRK	-0.49	-6.67	-0.35	1.09e-10	Urinary tract infection frequency;
CRC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg12193833	chr17:30244370	NA	-0.75	-8.72	-0.43	1.4e-16	Hip circumference adjusted for BMI;
CRC	trans	rs12481514	0.702	rs73586667	chr20:4303278	T/C	cg11071926	chr1:116380316	NHLH2	-0.52	-6.1	-0.32	2.91e-9	Paneth cell defects in Crohn's disease;
CRC	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg14593290	chr7:50529359	DDC	0.59	7.9	0.4	4.2e-14	Malaria;
CRC	trans	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg17903999	chr18:56338584	MALT1	0.4	6.69	0.35	9.83e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.28e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs812925	0.533	rs60997156	chr2:61396539	T/A	cg10580144	chr2:61372316	C2orf74	0.35	7.81	0.4	7.58e-14	Immature fraction of reticulocytes;
CRC	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg14581129	chr12:53358946	NA	-0.91	-8.83	-0.44	6.57e-17	Prostate cancer;
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.77	14.09	0.61	1.3e-35	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.62	9.14	0.45	6.71e-18	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26829925	chr15:80216159	C15orf37;ST20	0.47	6.43	0.33	4.43e-10	Anxiety disorder;
CRC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.11	20.66	0.75	2.27e-61	Cognitive function;
CRC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs6662572	0.737	rs6429592	chr1:46472153	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-6.0	-0.31	5.17e-9	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19427701	chr9:140196790	NRARP	0.43	6.1	0.32	3.02e-9	Response to antipsychotic treatment;
CRC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-11.71	-0.54	1.02e-26	Asthma;
CRC	cis	rs2346160	0.899	rs206977	chr6:167690746	G/C	cg27333441	chr6:167680455	NA	-0.38	-6.21	-0.32	1.58e-9	Parental extreme longevity (95 years and older);
CRC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg04117972	chr1:227635322	NA	-0.64	-6.85	-0.35	3.7e-11	Major depressive disorder;
CRC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg09264619	chr17:80180166	NA	0.38	6.28	0.33	1.06e-9	Life satisfaction;
CRC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg00343986	chr7:65444356	GUSB	-0.4	-5.7	-0.3	2.61e-8	Aortic root size;
CRC	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg02927042	chr1:21476669	EIF4G3	-0.52	-8.07	-0.41	1.31e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.51	0.46	4.25e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.42	6.02	0.31	4.71e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22371845	chr8:140718096	NA	0.44	6.19	0.32	1.75e-9	Response to antipsychotic treatment;
CRC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.3	3.58e-8	Body mass index;
CRC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.28	-0.33	1.08e-9	Diabetic kidney disease;
CRC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-0.96	-13.3	-0.59	1.36e-32	Hip circumference adjusted for BMI;
CRC	trans	rs2172802	0.570	rs2133009	chr4:62516026	T/C	cg25787300	chr7:101599518	CUX1	-0.42	-5.97	-0.31	6.22e-9	Partial epilepsies;
CRC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg04586622	chr2:25135609	ADCY3	-0.54	-10.05	-0.48	6.83e-21	Body mass index;
CRC	cis	rs7804356	1.000	rs3801814	chr7:26881302	T/G	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.1e-8	Type 1 diabetes;
CRC	cis	rs2108622	0.727	rs2158511	chr19:15986647	C/T	cg13772218	chr19:15982569	NA	0.48	6.75	0.35	6.72e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.1	-0.32	2.92e-9	Menopause (age at onset);
CRC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	10.05	0.48	6.9299999999999992e-21	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14886145	chr10:74451829	CCDC109A	0.46	6.44	0.33	4.25e-10	Response to antipsychotic treatment;
CRC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.58	0.39	3.6e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg12273811	chr6:28175739	NA	0.51	5.71	0.3	2.55e-8	Parkinson's disease;
CRC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-8.18	-0.41	6.14e-15	Lung cancer in ever smokers;
CRC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-6.75	-0.35	6.61e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.46	7.92	0.4	3.66e-14	Testicular germ cell tumor;
CRC	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg14139581	chr11:64358342	SLC22A12	0.38	6.03	0.32	4.38e-9	Urate levels in obese individuals;
CRC	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg21930842	chr2:241631663	AQP12A	0.42	6.49	0.34	3.16e-10	Response to metformin (IC50);
CRC	trans	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg18187862	chr3:45730750	SACM1L	0.45	6.54	0.34	2.35e-10	Primary sclerosing cholangitis;
CRC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg13390004	chr1:15929781	NA	0.5	7.06	0.36	9.67e-12	Systolic blood pressure;
CRC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	8.73	0.43	1.3e-16	Colorectal cancer;
CRC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.61	0.3	4.23e-8	Rheumatoid arthritis;
CRC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.6	0.34	1.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.49	-7.1	-0.36	7.89e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.97	0.31	6.04e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg22988483	chr14:93581567	ITPK1	-0.68	-6.29	-0.33	1.03e-9	Cognitive function;
CRC	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.56	-8.97	-0.44	2.23e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.23e-8	Protein C levels;
CRC	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.64	-9.74	-0.47	7.04e-20	Blood protein levels;
CRC	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg00666640	chr1:248458726	OR2T12	-0.47	-8.96	-0.44	2.53e-17	Common traits (Other);
CRC	cis	rs863345	0.604	rs6663277	chr1:158495001	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.1	-0.32	2.94e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs10046574	0.831	rs7780028	chr7:135092556	A/G	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	5.74	0.3	2.2e-8	Renal function-related traits (BUN);
CRC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.77	0.47	5.59e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.54	-0.43	5.05e-16	Bone mineral density;
CRC	cis	rs7209700	0.889	rs16941801	chr17:45354543	G/C	cg08085267	chr17:45401833	C17orf57	0.46	6.53	0.34	2.53e-10	IgG glycosylation;
CRC	trans	rs2012709	0.935	rs11742628	chr5:32563122	T/G	cg03755955	chr8:6424269	MCPH1	0.44	6.53	0.34	2.56e-10	Breast cancer;
CRC	trans	rs58106596	0.517	rs17271845	chr2:232653173	G/T	cg01370599	chr3:116745421	NA	0.48	6.23	0.32	1.43e-9	White blood cell count;Lymphocyte counts;
CRC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg05585544	chr11:47624801	NA	-0.5	-8.88	-0.44	4.49e-17	Subjective well-being;
CRC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.13	-0.37	6.51e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-6.76	-0.35	6.3e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.7e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.35	-5.78	-0.3	1.72e-8	Personality dimensions;
CRC	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.77	-10.24	-0.49	1.47e-21	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21076935	chr2:10861602	ATP6V1C2	0.37	6.46	0.34	3.72e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg07507251	chr3:52567010	NT5DC2	-0.39	-5.81	-0.3	1.51e-8	Body mass index;
CRC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.92	0.52	6.6e-24	Prostate cancer;
CRC	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg22495460	chr2:25135724	ADCY3	-0.9	-18.46	-0.71	1.04e-52	Body mass index in non-asthmatics;
CRC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.75	0.39	1.15e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7259376	0.623	rs7252078	chr19:22503015	G/A	cg02657401	chr19:22469223	NA	-0.3	-6.44	-0.33	4.24e-10	Menopause (age at onset);
CRC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.33	-5.84	-0.31	1.23e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.32	-0.33	8.44e-10	Aortic root size;
CRC	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-8.14	-0.41	8e-15	Squamous cell lung carcinoma;
CRC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.49	-7.36	-0.38	1.49e-12	Menarche (age at onset);
CRC	cis	rs4973397	0.668	rs4973393	chr2:232289526	G/T	cg13347044	chr2:232276743	NA	0.41	5.92	0.31	8.16e-9	Anti-saccade response;
CRC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26850624	chr5:429559	AHRR	-0.68	-10.78	-0.51	2.14e-23	Cystic fibrosis severity;
CRC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg13880726	chr7:1868755	MAD1L1	0.43	5.77	0.3	1.84e-8	Bipolar disorder;
CRC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg02869306	chr7:64672164	INTS4L1	-0.4	-6.04	-0.32	4.19e-9	Aortic root size;
CRC	cis	rs4964805	0.594	rs3812805	chr12:104170872	C/T	cg02344784	chr12:104178138	NT5DC3	0.42	6.15	0.32	2.28e-9	Attention deficit hyperactivity disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02571725	chr16:1832656	SPSB3;NUBP2	0.48	6.67	0.35	1.06e-10	Response to antipsychotic treatment;
CRC	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.61	-8.04	-0.41	1.59e-14	White matter hyperintensity burden;
CRC	cis	rs939584	0.825	rs7579971	chr2:631603	C/T	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg23533926	chr12:111358616	MYL2	-0.55	-8.31	-0.42	2.49e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	7.63	0.39	2.59e-13	Hip circumference adjusted for BMI;
CRC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.5	6.46	0.34	3.84e-10	Menopause (age at onset);
CRC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.62	-10.89	-0.51	8.89e-24	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Macular telangiectasia type 2;
CRC	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14119001	chr9:139324193	INPP5E	-0.51	-7.33	-0.37	1.82e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.44	-0.33	4.31e-10	Total body bone mineral density;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg12273811	chr6:28175739	NA	0.62	9.12	0.45	7.46e-18	Parkinson's disease;
CRC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.81	14.21	0.62	4.72e-36	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03940137	chr1:200708937	CAMSAP1L1	-0.4	-5.97	-0.31	6.27e-9	Myopia (pathological);
CRC	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.41	-6.07	-0.32	3.45e-9	Motion sickness;
CRC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.66	7.02	0.36	1.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24686357	chr4:48272266	TEC	0.45	6.37	0.33	6.41e-10	Anxiety disorder;
CRC	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.98	-0.31	5.92e-9	Breast cancer;
CRC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.67	0.3	3.13e-8	Self-reported allergy;
CRC	cis	rs12431939	0.857	rs2999383	chr14:51648755	C/T	cg23942311	chr14:51606299	NA	-0.49	-6.36	-0.33	6.56e-10	Cancer;
CRC	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.56	8.28	0.42	3.15e-15	Blood protein levels;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg20608306	chr11:116969690	SIK3	0.31	6.3	0.33	9.55e-10	Blood protein levels;
CRC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.23	0.45	3.27e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.92	-17.58	-0.7	3.08e-49	Longevity;
CRC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.43	-6.99	-0.36	1.52e-11	Resting heart rate;
CRC	cis	rs1545257	0.560	rs7561752	chr2:24643834	A/G	cg06627628	chr2:24431161	ITSN2	0.47	6.88	0.35	2.99e-11	Sjögren's syndrome;
CRC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg02527881	chr3:46936655	PTH1R	0.4	7.18	0.37	4.75e-12	Colorectal cancer;
CRC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.68	11.12	0.52	1.36e-24	Colorectal cancer;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg03233332	chr7:66118400	NA	0.44	6.11	0.32	2.87e-9	Aortic root size;
CRC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.73	9.9	0.48	2.09e-20	Cognitive function;
CRC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	10.22	0.49	1.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs587242	0.955	rs12739556	chr1:96977901	C/T	cg10631902	chr5:14652156	NA	0.4	6.15	0.32	2.26e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg02569458	chr12:86230093	RASSF9	-0.39	-6.56	-0.34	2.11e-10	Major depressive disorder;
CRC	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.47	5.98	0.31	5.87e-9	Exhaled nitric oxide output;
CRC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.43	-8.45	-0.42	9.54e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-6.3	-0.33	9.4e-10	Schizophrenia;
CRC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg21251018	chr6:28226885	NKAPL	0.48	7.85	0.4	5.87e-14	Depression;
CRC	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg11189052	chr15:85197271	WDR73	0.53	7.11	0.37	7.08e-12	Alzheimer's disease (age of onset);
CRC	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg14092571	chr14:90743983	NA	0.39	6.0	0.31	5.22e-9	Mortality in heart failure;
CRC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.45	-6.11	-0.32	2.76e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7572644	0.699	rs2016616	chr2:28134037	A/G	cg27432699	chr2:27873401	GPN1	-0.41	-5.66	-0.3	3.38e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs9648716	1.000	rs1267624	chr7:140535764	A/C	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-14.69	-0.63	6.5e-38	Height;
CRC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.95	-17.71	-0.7	9.35e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.75	-0.47	6.55e-20	Schizophrenia;
CRC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.65	-10.82	-0.51	1.55e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.62	9.76	0.47	6.41e-20	Intelligence (multi-trait analysis);
CRC	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.06	-0.36	9.98e-12	Body mass index;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg04623168	chr12:112546260	NAA25	-0.44	-6.29	-0.33	9.91e-10	Daytime sleep phenotypes;
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg09264619	chr17:80180166	NA	0.36	5.98	0.31	5.94e-9	Life satisfaction;
CRC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.83	-14.02	-0.61	2.46e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.41	6.17	0.32	1.97e-9	Hemoglobin concentration;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg02683197	chr6:28174875	NA	0.85	10.69	0.51	4.25e-23	Depression;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs7703744	0.597	rs73237297	chr5:118691121	G/T	cg23917399	chr5:118691751	TNFAIP8	0.42	5.95	0.31	6.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg04880052	chr2:219191631	PNKD	0.42	6.84	0.35	3.96e-11	Colorectal cancer;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.67	5.72	0.3	2.33e-8	Breast cancer;
CRC	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.61	-6.28	-0.33	1.07e-9	Coronary artery disease;
CRC	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-7.1	-0.36	7.84e-12	Inflammatory skin disease;
CRC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.67	10.09	0.49	5.05e-21	Menopause (age at onset);
CRC	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.39	5.88	0.31	1.02e-8	Sudden cardiac arrest;
CRC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.41	6.69	0.35	9.89e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549328	0.542	rs36172983	chr13:113616582	T/C	cg20742385	chr13:113633654	MCF2L	0.55	9.39	0.46	1.01e-18	Systolic blood pressure;
CRC	cis	rs12541635	0.934	rs62527361	chr8:107021574	T/A	cg10147462	chr8:107024639	NA	0.41	6.78	0.35	5.72e-11	Age of smoking initiation;
CRC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.74	-0.43	1.23e-16	Hemoglobin concentration;
CRC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.57	-7.9	-0.4	4.14e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg05562828	chr17:3906858	NA	0.57	10.01	0.48	8.84e-21	Type 2 diabetes;
CRC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12501888	chr15:85177176	SCAND2	-0.36	-5.97	-0.31	6.29e-9	P wave terminal force;
CRC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.39	-5.81	-0.3	1.5e-8	Primary biliary cholangitis;
CRC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg21699342	chr2:239360505	ASB1	-0.47	-6.32	-0.33	8.68e-10	Multiple system atrophy;
CRC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.61e-14	Lung cancer;
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.47	6.4	0.33	5.37e-10	Menarche (age at onset);
CRC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.64	-0.47	1.6e-19	Height;
CRC	cis	rs2421770	0.530	rs3858470	chr11:35365444	T/C	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.67	-0.35	1.08e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg24562669	chr7:97807699	LMTK2	0.44	7.27	0.37	2.71e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg13385794	chr1:248469461	NA	0.39	6.74	0.35	7.22e-11	Common traits (Other);
CRC	cis	rs11229555	0.645	rs11560908	chr11:58434545	A/C	cg15696309	chr11:58395628	NA	0.84	8.83	0.44	6.28e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.64	-0.6	7.19e-34	Blood metabolite levels;
CRC	cis	rs13253111	0.624	rs35990565	chr8:28107815	C/T	cg26534493	chr8:28060551	NA	0.45	7.74	0.39	1.21e-13	Childhood body mass index;
CRC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.62	10.55	0.5	1.35e-22	Mean corpuscular volume;
CRC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.28	-0.33	1.08e-9	Alzheimer's disease (late onset);
CRC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-8.53	-0.43	5.24e-16	Sense of smell;
CRC	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2637266	0.538	rs4379767	chr10:78472596	G/A	cg18941641	chr10:78392320	NA	-0.35	-5.85	-0.31	1.16e-8	Pulmonary function;
CRC	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg27534772	chr1:16042836	PLEKHM2	0.42	7.09	0.36	8.14e-12	Systolic blood pressure;
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.9	-0.44	3.79e-17	Bipolar disorder;
CRC	trans	rs7623430	0.598	rs6550406	chr3:36218075	A/T	cg16587794	chr15:69706675	KIF23	-0.43	-6.34	-0.33	7.65e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg03623178	chr6:28175578	NA	0.9	13.0	0.58	1.81e-31	Parkinson's disease;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg23123621	chr4:1343375	KIAA1530	-0.33	-5.91	-0.31	8.56e-9	Obesity-related traits;
CRC	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.99	20.81	0.75	5.84e-62	Metabolite levels;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg16606324	chr3:10149918	C3orf24	0.7	9.74	0.47	7.03e-20	Alzheimer's disease;
CRC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.52	-9.36	-0.46	1.28e-18	Schizophrenia;
CRC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	8.19	0.41	5.86e-15	Aortic root size;
CRC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg14673194	chr17:80132900	CCDC57	-0.51	-6.74	-0.35	7.09e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2252521	0.643	rs4141275	chr7:29079870	C/T	cg11728747	chr7:29037910	CPVL	-0.33	-5.95	-0.31	6.85e-9	Cognitive performance;
CRC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.08	-0.32	3.27e-9	Morning vs. evening chronotype;
CRC	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.02	-0.31	4.7e-9	Breast cancer;
CRC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.64	0.39	2.33e-13	Motion sickness;
CRC	trans	rs11673344	0.528	rs578655	chr19:37410757	A/G	cg18947437	chr10:1231002	ADARB2	-0.34	-6.06	-0.32	3.74e-9	Obesity-related traits;
CRC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg15358701	chr1:161410459	NA	-0.65	-6.88	-0.35	2.96e-11	Rheumatoid arthritis;
CRC	cis	rs9898058	0.769	rs12150425	chr17:47913932	C/T	cg06375292	chr17:47786311	SLC35B1	-0.74	-5.65	-0.3	3.45e-8	Milk allergy;
CRC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.76	0.44	1.02e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.12	0.41	9.59e-15	Red blood cell count;
CRC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.47	-0.34	3.53e-10	Total cholesterol levels;
CRC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg08999081	chr20:33150536	PIGU	0.45	5.71	0.3	2.56e-8	Protein C levels;
CRC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.47	6.87	0.35	3.18e-11	Obesity-related traits;
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg05279229	chr7:1896384	MAD1L1	-0.36	-5.7	-0.3	2.68e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.97	-0.36	1.7e-11	QT interval;
CRC	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17691542	chr6:26056736	HIST1H1C	0.95	10.61	0.5	8.2000000000000006e-23	Iron status biomarkers;
CRC	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg07195577	chr17:27052828	TLCD1	0.44	5.73	0.3	2.23e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9837602	0.938	rs793457	chr3:99518987	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.23	0.32	1.44e-9	Breast cancer;
CRC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.63	-9.24	-0.45	3.09e-18	Menarche (age at onset);
CRC	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.56	8.76	0.43	1.09e-16	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg01639898	chr1:32083012	HCRTR1	0.32	6.71	0.35	8.62e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2004318	1.000	rs4097296	chr19:55141019	G/A	cg03320607	chr19:54800032	LILRA3	-0.75	-6.0	-0.31	5.26e-9	Blood protein levels;
CRC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.57	0.43	3.95e-16	Height;
CRC	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg27395922	chr11:50257633	LOC441601	0.48	6.28	0.33	1.07e-9	Intraocular pressure;
CRC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg15205204	chr1:6545172	PLEKHG5	0.4	5.73	0.3	2.26e-8	Body mass index;
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg13736514	chr6:26305472	NA	-0.36	-6.17	-0.32	1.99e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07165851	chr6:158734300	TULP4	0.61	7.64	0.39	2.43e-13	Height;
CRC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.89	-0.44	4.11e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg15845792	chr6:28175446	NA	0.83	8.58	0.43	3.7e-16	Lung cancer in ever smokers;
CRC	cis	rs9463078	0.691	rs6928753	chr6:45340070	T/C	cg25276700	chr6:44698697	NA	0.25	5.95	0.31	6.81e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.58	-7.98	-0.4	2.41e-14	Body mass index;
CRC	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg27205649	chr11:78285834	NARS2	-0.44	-5.72	-0.3	2.38e-8	Alzheimer's disease (survival time);
CRC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.55	-0.38	4.32e-13	Aortic root size;
CRC	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.06	-0.32	3.74e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs9513593	1.000	rs1964898	chr13:99997181	A/G	cg21788972	chr13:99853209	UBAC2	0.46	6.01	0.31	4.91e-9	Psoriasis;
CRC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.67	9.14	0.45	6.56e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-17.13	-0.69	1.81e-47	Intelligence (multi-trait analysis);
CRC	cis	rs9925964	0.933	rs12448321	chr16:31048280	C/T	cg02466173	chr16:30829666	NA	0.44	5.94	0.31	7.14e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.24	0.41	4e-15	Menopause (age at onset);
CRC	cis	rs185694	1.000	rs185694	chr13:30885223	C/T	cg07600127	chr13:30881527	KATNAL1	0.58	6.56	0.34	2.12e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.53	7.41	0.38	1.08e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	0.65	9.78	0.47	5.47e-20	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.56	6.24	0.33	1.38e-9	Vitiligo;
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.6	10.2	0.49	2.03e-21	Prudent dietary pattern;
CRC	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.56	-8.07	-0.41	1.37e-14	Malaria;
CRC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.51	8.33	0.42	2.18e-15	Coronary artery disease;
CRC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.37e-10	Breast cancer;
CRC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg09658497	chr7:2847517	GNA12	0.34	5.71	0.3	2.57e-8	Height;
CRC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	0.99	9.72	0.47	8.19e-20	Diabetic retinopathy;
CRC	cis	rs8141797	0.901	rs2001106	chr22:24535229	A/G	cg20894457	chr22:24584366	SUSD2	0.62	8.17	0.41	6.92e-15	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg23463467	chr20:60627584	TAF4	0.44	8.31	0.42	2.47e-15	Body mass index;
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.58	-7.38	-0.38	1.28e-12	Alzheimer's disease;
CRC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.61	10.75	0.51	2.62e-23	Aortic root size;
CRC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg14847009	chr1:175162515	KIAA0040	0.3	6.61	0.34	1.55e-10	Alcohol dependence;
CRC	trans	rs10411161	1.000	rs10402988	chr19:52363104	G/A	cg22319618	chr22:45562946	NUP50	-0.52	-6.03	-0.32	4.4e-9	Breast cancer;
CRC	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg19773385	chr1:10388646	KIF1B	-0.65	-10.38	-0.5	5.1e-22	Hepatocellular carcinoma;
CRC	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.56	-0.34	2.09e-10	IgG glycosylation;
CRC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.8	0.3	1.57e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.31	-0.33	8.77e-10	Coronary artery disease;
CRC	cis	rs6545883	0.524	rs2694619	chr2:61536901	C/T	cg10580144	chr2:61372316	C2orf74	-0.34	-7.47	-0.38	7.34e-13	Tuberculosis;
CRC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg17346650	chr17:80929145	B3GNTL1	0.37	5.82	0.31	1.38e-8	Breast cancer;
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.64	-9.92	-0.48	1.79e-20	Platelet count;
CRC	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.66	9.19	0.45	4.59e-18	White matter hyperintensity burden;
CRC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.5	6.18	0.32	1.85e-9	Gut microbiome composition (summer);
CRC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg16447950	chr5:562315	NA	-0.84	-10.57	-0.5	1.15e-22	Lung disease severity in cystic fibrosis;
CRC	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.45	6.91	0.36	2.46e-11	Capecitabine sensitivity;
CRC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.22	0.37	3.53e-12	Aortic root size;
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg10729496	chr3:10149963	C3orf24	0.5	6.11	0.32	2.82e-9	Alzheimer's disease;
CRC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg13385521	chr17:29058706	SUZ12P	0.68	7.95	0.4	3.09e-14	Body mass index;
CRC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg14036092	chr11:66035641	RAB1B	0.47	6.49	0.34	3.12e-10	Electroencephalogram traits;
CRC	cis	rs62408225	0.963	rs45553631	chr6:90981657	C/T	cg06866423	chr6:90926672	BACH2	0.48	7.97	0.4	2.55e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg11212589	chr17:38028394	ZPBP2	0.43	8.03	0.4	1.71e-14	Self-reported allergy;
CRC	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg10756647	chr7:56101905	PSPH	0.75	8.09	0.41	1.15e-14	Gout;
CRC	cis	rs71403859	0.504	rs12926413	chr16:71972325	T/C	cg03805757	chr16:71968109	PKD1L3	-0.66	-5.72	-0.3	2.42e-8	Post bronchodilator FEV1;
CRC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	7.1	0.36	7.54e-12	Lung cancer in ever smokers;
CRC	cis	rs4499344	0.531	rs259247	chr19:33147657	T/C	cg22980127	chr19:33182716	NUDT19	-0.4	-5.61	-0.3	4.27e-8	Mean platelet volume;
CRC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg23461800	chr14:103021989	NA	-0.69	-7.9	-0.4	4.23e-14	Platelet count;
CRC	trans	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg13565492	chr6:43139072	SRF	-0.58	-6.05	-0.32	3.96e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.55	-7.71	-0.39	1.51e-13	Longevity;
CRC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.43	0.53	1.09e-25	Monocyte percentage of white cells;
CRC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.51	-6.74	-0.35	6.93e-11	Blood metabolite levels;
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.38	5.76	0.3	1.91e-8	Longevity;Endometriosis;
CRC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.55	-7.52	-0.38	5.24e-13	Coronary artery disease;
CRC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-5.79	-0.3	1.66e-8	Joint mobility (Beighton score);
CRC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.52	-7.92	-0.4	3.67e-14	Calcium levels;
CRC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.38	-8.71	-0.43	1.5e-16	Multiple system atrophy;
CRC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.56	8.45	0.42	9.71e-16	Cognitive function;
CRC	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg15654264	chr1:150340011	RPRD2	0.42	6.19	0.32	1.76e-9	Migraine;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19046167	chr17:80928561	B3GNTL1	0.52	7.55	0.38	4.29e-13	Glycated hemoglobin levels;
CRC	cis	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg12106634	chr11:108092400	ATM;NPAT	-0.41	-6.03	-0.32	4.4e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2814982	0.605	rs75152896	chr6:34477793	G/A	cg17674042	chr6:34482479	PACSIN1	-1.01	-11.07	-0.52	2.01e-24	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.74	-11.67	-0.54	1.41e-26	Platelet distribution width;
CRC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg20573242	chr4:122745356	CCNA2	0.41	6.14	0.32	2.4e-9	Type 2 diabetes;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02018176	chr4:1364513	KIAA1530	-0.42	-7.28	-0.37	2.52e-12	Obesity-related traits;
CRC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.63	0.3	3.9e-8	Cystic fibrosis severity;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.58	8.92	0.44	3.35e-17	Longevity;Endometriosis;
CRC	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg08533674	chr1:46993347	NA	0.71	9.73	0.47	7.94e-20	Monobrow;
CRC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-6.1	-0.32	2.94e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg24578937	chr1:2090814	PRKCZ	-0.39	-7.03	-0.36	1.2e-11	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18149653	chr12:53267995	NA	0.45	6.43	0.33	4.61e-10	Response to antipsychotic treatment;
CRC	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	7.41	0.38	1.05e-12	Schizophrenia;
CRC	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg14458575	chr2:238380390	NA	0.54	6.99	0.36	1.57e-11	Prostate cancer;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg20512303	chr5:131592959	PDLIM4	-0.43	-8.28	-0.42	3.05e-15	Acylcarnitine levels;
CRC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.39	5.65	0.3	3.5e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-6.92	-0.36	2.43e-11	Eye color traits;
CRC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.13	0.41	8.78e-15	Height;
CRC	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.61	-0.43	2.98e-16	Hemoglobin concentration;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg00614641	chr11:61596405	FADS2	-0.56	-6.93	-0.36	2.28e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-11.1	-0.52	1.63e-24	Ulcerative colitis;
CRC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.95	-0.48	1.49e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg13010199	chr12:38710504	ALG10B	0.45	6.38	0.33	6.15e-10	Morning vs. evening chronotype;
CRC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.53	7.56	0.38	4.09e-13	Longevity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12713848	chr20:35401901	DSN1	0.43	7.12	0.37	6.98e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg12564285	chr5:131593104	PDLIM4	0.38	7.18	0.37	4.62e-12	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.7	9.92	0.48	1.9e-20	Alzheimer's disease;
CRC	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.61	-5.68	-0.3	2.93e-8	White matter integrity;
CRC	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.76	-9.71	-0.47	9.16e-20	IgG glycosylation;
CRC	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg10437265	chr15:77819839	NA	0.59	9.93	0.48	1.75e-20	Type 2 diabetes;
CRC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.7	10.87	0.51	1.05e-23	Corneal astigmatism;
CRC	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.34	-0.33	7.49e-10	Metabolite levels;
CRC	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.5	-5.87	-0.31	1.08e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg20203395	chr5:56204925	C5orf35	0.52	7.3	0.37	2.19e-12	Coronary artery disease;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg15763984	chr4:1342303	KIAA1530	0.45	6.95	0.36	1.94e-11	Obesity-related traits;
CRC	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.74	-12.38	-0.56	3.63e-29	Itch intensity from mosquito bite;
CRC	cis	rs12760731	0.565	rs11583503	chr1:178169663	G/C	cg00404053	chr1:178313656	RASAL2	1.05	10.93	0.52	6.36e-24	Obesity-related traits;
CRC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.59	6.79	0.35	5.27e-11	Lymphocyte counts;
CRC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.72	-0.35	7.81e-11	Total body bone mineral density;
CRC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.81	-0.3	1.52e-8	Daytime sleep phenotypes;
CRC	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.92	-15.95	-0.66	8.15e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg10790698	chr19:18539756	SSBP4	-0.42	-8.03	-0.4	1.79e-14	Breast cancer;
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.49	7.74	0.39	1.21e-13	Red blood cell count;
CRC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	8.05	0.41	1.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.34	0.46	1.55e-18	Vitamin D levels;
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg11843238	chr5:131593191	PDLIM4	0.36	6.69	0.35	9.43e-11	Blood metabolite levels;
CRC	cis	rs6088813	1.000	rs6141546	chr20:33949282	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.82	-0.31	1.39e-8	Height;
CRC	cis	rs1572438	0.759	rs9379144	chr6:846919	C/G	cg13447295	chr6:887704	NA	0.48	6.74	0.35	7.31e-11	Aging;
CRC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.1	-0.36	7.51e-12	Mean platelet volume;
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.47	-6.41	-0.33	5.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	5.96	0.31	6.34e-9	Prudent dietary pattern;
CRC	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.4	-6.87	-0.35	3.29e-11	Hip circumference;Waist circumference;
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.5	0.54	6.02e-26	Prudent dietary pattern;
CRC	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.21	0.45	3.97e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-6.19	-0.32	1.77e-9	Major depressive disorder;
CRC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.48	0.34	3.45e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.47	6.2	0.32	1.68e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.45	0.34	4.02e-10	Myopia (pathological);
CRC	cis	rs79387448	0.745	rs57942521	chr2:103139849	A/G	cg00507830	chr2:103233733	NA	0.54	5.84	0.31	1.27e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs11212617	1.000	rs608086	chr11:108185023	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.2	0.32	1.68e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg21747405	chr11:67723411	NA	-0.58	-9.13	-0.45	6.88e-18	Blood pressure (smoking interaction);
CRC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.68	11.28	0.53	3.59e-25	Alzheimer's disease (late onset);
CRC	cis	rs6445967	1.000	rs3796215	chr3:58316657	A/G	cg23715586	chr3:58305044	RPP14	0.37	6.01	0.31	4.82e-9	Platelet count;
CRC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.45	6.82	0.35	4.26e-11	Menopause (age at onset);
CRC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.5	9.58	0.47	2.47e-19	Iron status biomarkers (transferrin levels);
CRC	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg03929089	chr4:120376271	NA	-0.64	-7.05	-0.36	1.05e-11	Axial length;
CRC	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.98	-0.31	5.7e-9	Height;
CRC	trans	rs6066835	0.572	rs12329434	chr20:47260191	T/C	cg21109867	chr19:55897418	RPL28	-0.83	-6.25	-0.33	1.24e-9	Multiple myeloma;
CRC	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-7.11	-0.36	7.42e-12	Response to antipsychotic treatment;
CRC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.55	5.98	0.31	5.66e-9	Schizophrenia;
CRC	cis	rs6700896	0.931	rs10889569	chr1:66086194	A/T	cg04111102	chr1:66153794	NA	0.33	5.95	0.31	6.81e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.65	10.49	0.5	2.1e-22	Colorectal cancer;
CRC	trans	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg14576681	chr2:42588304	COX7A2L	0.46	5.99	0.31	5.42e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.61	9.22	0.45	3.61e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1322512	1.000	rs2758777	chr6:153007467	G/T	cg03415253	chr6:152958462	SYNE1	0.4	6.13	0.32	2.49e-9	Tonometry;
CRC	cis	rs12973672	1.000	rs10421599	chr19:35767933	G/A	cg12095397	chr19:35769544	USF2	0.43	5.67	0.3	3.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	13.45	0.6	3.74e-33	Menopause (age at onset);
CRC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg19635926	chr16:89946313	TCF25	0.69	7.3	0.37	2.21e-12	Skin colour saturation;
CRC	cis	rs720844	0.748	rs34671855	chr2:149366385	C/T	cg09247360	chr2:149335327	NA	-0.56	-5.79	-0.3	1.69e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.44	6.34	0.33	7.47e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs7605827	0.897	rs6729018	chr2:15540676	A/G	cg19274914	chr2:15703543	NA	0.39	5.93	0.31	7.81e-9	Educational attainment (years of education);
CRC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.66	-10.82	-0.51	1.56e-23	Gestational age at birth (maternal effect);
CRC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.8	10.86	0.51	1.11e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg00620190	chr6:26240307	HIST1H4F	-0.49	-5.75	-0.3	2.06e-8	Gout;Renal underexcretion gout;
CRC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.73	-0.3	2.33e-8	Tonsillectomy;
CRC	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg05585544	chr11:47624801	NA	-0.4	-6.3	-0.33	9.28e-10	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.27	14.75	0.63	3.81e-38	Diabetic kidney disease;
CRC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.2	-0.37	4.14e-12	Morning vs. evening chronotype;
CRC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.6	9.1	0.45	9.01e-18	Selective IgA deficiency;
CRC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-8.39	-0.42	1.45e-15	Chronic sinus infection;
CRC	cis	rs1223397	0.651	rs2458309	chr6:13312086	G/A	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs4964805	0.913	rs12229276	chr12:104204771	G/T	cg02344784	chr12:104178138	NT5DC3	-0.51	-7.91	-0.4	3.88e-14	Attention deficit hyperactivity disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07150314	chr2:27579984	GTF3C2	0.43	6.03	0.32	4.37e-9	Anxiety disorder;
CRC	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.43	5.73	0.3	2.27e-8	Diastolic blood pressure;
CRC	cis	rs910873	0.505	rs7261964	chr20:33205011	C/T	cg08999081	chr20:33150536	PIGU	0.49	5.96	0.31	6.38e-9	Melanoma;
CRC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.43	6.34	0.33	7.37e-10	Menopause (age at onset);
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg15845792	chr6:28175446	NA	0.84	8.59	0.43	3.66e-16	Lung cancer in ever smokers;
CRC	cis	rs932541	0.955	rs6043994	chr20:16457896	G/A	cg17003395	chr20:16555519	KIF16B	0.41	5.7	0.3	2.7e-8	Intelligence;
CRC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.27	0.64	3.58e-40	Platelet count;
CRC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.67	-0.3	3.13e-8	Erythrocyte sedimentation rate;
CRC	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg17143192	chr8:8559678	CLDN23	0.44	5.76	0.3	1.96e-8	Obesity-related traits;
CRC	cis	rs12541635	0.966	rs62525734	chr8:106984056	T/C	cg10147462	chr8:107024639	NA	0.44	7.23	0.37	3.31e-12	Age of smoking initiation;
CRC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.39	-5.84	-0.31	1.25e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.67	0.39	1.95e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg25930673	chr12:123319894	HIP1R	0.95	7.26	0.37	2.78e-12	Adiponectin levels;
CRC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.95	13.63	0.6	7.53e-34	Breast cancer;
CRC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.64	0.34	1.33e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg11038491	chr20:34638489	LOC647979	-0.6	-6.73	-0.35	7.62e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.6	10.2	0.49	2.03e-21	Prudent dietary pattern;
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg22687807	chr8:143858763	LYNX1	0.5	8.8	0.44	8.06e-17	Urinary tract infection frequency;
CRC	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.73	10.58	0.5	1.03e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.9	10.3	0.49	9.55e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg03623178	chr6:28175578	NA	0.77	11.37	0.53	1.66e-25	Parkinson's disease;
CRC	cis	rs2637266	0.600	rs11001823	chr10:78326767	G/A	cg18941641	chr10:78392320	NA	-0.35	-5.85	-0.31	1.21e-8	Pulmonary function;
CRC	cis	rs10208940	0.920	rs7604110	chr2:68790161	A/G	cg12452813	chr2:68675892	NA	-0.45	-5.75	-0.3	2.03e-8	Urate levels in lean individuals;
CRC	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.95	-13.52	-0.6	1.94e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.63	7.98	0.4	2.4e-14	Cocaine dependence;
CRC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg20607287	chr7:12443886	VWDE	-0.59	-7.3	-0.37	2.12e-12	Coronary artery disease;
CRC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg23216685	chr1:86174607	ZNHIT6	-0.27	-6.61	-0.34	1.58e-10	Urate levels in overweight individuals;
CRC	cis	rs7760949	0.888	rs9296853	chr6:13893945	T/A	cg27413430	chr6:13925136	RNF182	0.31	5.66	0.3	3.31e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.56	-6.74	-0.35	7.28e-11	Body mass index;
CRC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg03929089	chr4:120376271	NA	-0.46	-6.42	-0.33	4.85e-10	HDL cholesterol;
CRC	cis	rs4728142	1.000	rs4728142	chr7:128573967	C/T	cg14349538	chr7:128577651	IRF5	-0.42	-6.8	-0.35	4.87e-11	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.51	-6.33	-0.33	8.15e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.02	-0.32	4.65e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.82	-13.19	-0.59	3.59e-32	Cognitive function;
CRC	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.5	7.3	0.37	2.13e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.4	7.42	0.38	1.03e-12	Lung cancer;
CRC	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg12218747	chr21:37451666	NA	-0.41	-7.0	-0.36	1.46e-11	Mitral valve prolapse;
CRC	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	0.9	8.96	0.44	2.39e-17	Mitochondrial DNA levels;
CRC	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg09163369	chr1:210001066	C1orf107	0.54	6.77	0.35	5.77e-11	Orofacial clefts;
CRC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg05110241	chr16:68378359	PRMT7	0.71	7.28	0.37	2.48e-12	Schizophrenia;
CRC	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	11.21	0.53	6.21e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg23417306	chr2:180868811	CWC22	-0.42	-5.67	-0.3	3.14e-8	Schizophrenia;
CRC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.68	-7.81	-0.4	7.69e-14	Vitiligo;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.6	-0.54	2.66e-26	Alzheimer's disease;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg26608667	chr7:1196370	ZFAND2A	0.45	7.34	0.38	1.67e-12	Longevity;Endometriosis;
CRC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.99	18.11	0.71	2.45e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7849270	1.000	rs9697030	chr9:131920181	T/C	cg13538475	chr9:131942899	NA	-0.34	-6.34	-0.33	7.58e-10	Blood metabolite ratios;
CRC	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.09	-0.36	8.22e-12	Schizophrenia;
CRC	trans	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg10756647	chr7:56101905	PSPH	-0.78	-8.05	-0.41	1.55e-14	Diabetic kidney disease;
CRC	trans	rs2407314	0.639	rs1630897	chr8:4085206	T/G	cg02458499	chr8:110280928	NUDCD1	-0.33	-6.11	-0.32	2.88e-9	Insulin resistance/response;
CRC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg00343986	chr7:65444356	GUSB	0.53	8.11	0.41	1.03e-14	Aortic root size;
CRC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.68	-7.78	-0.39	9.39e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.41	7.44	0.38	8.97e-13	Prostate cancer;
CRC	cis	rs7680126	0.596	rs714436	chr4:10314667	A/C	cg00071950	chr4:10020882	SLC2A9	-0.49	-6.33	-0.33	7.81e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.55	-7.67	-0.39	1.9e-13	Facial morphology (factor 19);
CRC	cis	rs6545883	0.507	rs10169662	chr2:61507936	T/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.82	-0.4	7.06e-14	Tuberculosis;
CRC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.21	-0.37	3.81e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.39	6.87	0.35	3.16e-11	Cardiovascular disease risk factors;
CRC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg13010199	chr12:38710504	ALG10B	0.42	6.09	0.32	3.07e-9	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11998173	chr5:107007752	EFNA5	0.41	6.07	0.32	3.6e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.51	7.66	0.39	2.13e-13	Cognitive test performance;
CRC	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.49	-7.97	-0.4	2.68e-14	Metabolite levels;
CRC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10991454	chr2:30834674	LCLAT1	0.29	6.3	0.33	9.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg25600027	chr14:23388339	RBM23	-0.53	-8.37	-0.42	1.65e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	7.15	0.37	5.68e-12	Breast cancer;
CRC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.52	-8.54	-0.43	5.22e-16	Sense of smell;
CRC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.63	-0.39	2.56e-13	Mean corpuscular volume;
CRC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg20203395	chr5:56204925	C5orf35	-0.66	-7.97	-0.4	2.65e-14	Initial pursuit acceleration;
CRC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg17182837	chr8:41585554	ANK1	0.53	7.58	0.39	3.54e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.66	9.48	0.46	5.32e-19	Multiple sclerosis;
CRC	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg04221910	chr5:616842	CEP72	-0.39	-5.8	-0.3	1.59e-8	Obesity-related traits;
CRC	cis	rs1545257	0.550	rs66943245	chr2:24631075	G/A	cg06627628	chr2:24431161	ITSN2	-0.46	-6.73	-0.35	7.57e-11	Sjögren's syndrome;
CRC	cis	rs9938149	0.706	rs12711488	chr16:88319421	C/G	cg05435882	chr16:88311214	NA	-0.46	-6.12	-0.32	2.6e-9	Corneal structure;Central corneal thickness;
CRC	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.68	12.47	0.57	1.65e-29	Hip circumference;
CRC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.32	-0.33	8.35e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg25856811	chr1:152973957	SPRR3	-0.21	-5.86	-0.31	1.1e-8	Inflammatory skin disease;
CRC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.68	9.64	0.47	1.51e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.71	0.57	2.19e-30	Menopause (age at onset);
CRC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.87	0.35	3.14e-11	Body mass index;
CRC	cis	rs12476592	0.571	rs262475	chr2:63869045	A/T	cg10828910	chr2:63850056	LOC388955	0.5	6.25	0.33	1.3e-9	Childhood ear infection;
CRC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-7.07	-0.36	9.56e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.46	6.99	0.36	1.56e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg18758796	chr5:131593413	PDLIM4	0.43	6.8	0.35	4.98e-11	Breast cancer;
CRC	cis	rs7605827	0.897	rs2890488	chr2:15635439	T/A	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	12.66	0.57	3.33e-30	Alzheimer's disease;
CRC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg21851534	chr17:3907994	ZZEF1	-0.37	-6.05	-0.32	3.87e-9	Type 2 diabetes;
CRC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	8.87	0.44	4.74e-17	Schizophrenia;
CRC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg21466736	chr12:48725269	NA	-0.52	-7.69	-0.39	1.78e-13	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.59	7.69	0.39	1.72e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	3.99e-16	Life satisfaction;
CRC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.48	-7.44	-0.38	8.69e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.44	6.38	0.33	5.94e-10	Tonsillectomy;
CRC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg00343986	chr7:65444356	GUSB	0.46	6.73	0.35	7.44e-11	Aortic root size;
CRC	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	9.62	0.47	1.76e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	14.21	0.62	4.58e-36	Platelet count;
CRC	cis	rs7635838	0.892	rs9310384	chr3:11491980	A/G	cg00170343	chr3:11313890	ATG7	0.44	6.73	0.35	7.62e-11	HDL cholesterol;
CRC	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.54	-0.34	2.29e-10	Acne (severe);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26649394	chr18:32870462	ZNF271;ZNF397OS	0.41	5.99	0.31	5.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg08071915	chr8:12219732	FAM66A	0.34	6.16	0.32	2.12e-9	Retinal vascular caliber;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.46	6.84	0.35	3.83e-11	Menarche (age at onset);
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Parkinson's disease;
CRC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg01420254	chr6:26195488	NA	0.79	8.84	0.44	6.05e-17	Gout;Renal underexcretion gout;
CRC	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.69	0.35	9.36e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg15511327	chr8:143859410	LYNX1	-0.43	-7.14	-0.37	5.92e-12	Urinary tract infection frequency;
CRC	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.5	-0.34	3.05e-10	Coronary artery disease;
CRC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.43	6.25	0.33	1.3e-9	Childhood ear infection;
CRC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-5.99	-0.31	5.49e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.02	-0.32	4.6e-9	Tonsillectomy;
CRC	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg08501292	chr6:25962987	TRIM38	0.9	8.44	0.42	1.05e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.7	-9.15	-0.45	6.32e-18	High light scatter reticulocyte count;
CRC	cis	rs6758955	0.929	rs73161277	chr2:10480883	A/G	cg15773312	chr2:10472214	HPCAL1	-0.74	-9.56	-0.47	2.91e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	cis	rs1223397	1.000	rs1223402	chr6:13271640	G/A	cg20827128	chr6:13274284	PHACTR1	0.54	6.54	0.34	2.38e-10	Blood pressure;
CRC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.67	-10.76	-0.51	2.43e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.96	-0.52	4.88e-24	Electroencephalogram traits;
CRC	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg25011176	chr20:3776985	CDC25B	0.4	5.69	0.3	2.88e-8	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs55840249	chr2:162426849	C/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.16	-0.32	2.06e-9	Cognitive function;
CRC	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.83	15.89	0.66	1.4e-42	Hip circumference;
CRC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg21770322	chr7:97807741	LMTK2	0.59	9.85	0.48	3.04e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg10724054	chr17:3904396	NA	-0.46	-7.56	-0.38	4.16e-13	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.46	0.34	3.81e-10	Lung cancer;
CRC	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-7.08	-0.36	8.79e-12	Coronary artery disease;
CRC	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg16070123	chr10:51489643	NA	-0.33	-5.61	-0.3	4.26e-8	Prostate-specific antigen levels;
CRC	cis	rs9491140	0.539	rs10872283	chr6:124685919	G/A	cg22366943	chr6:124882293	NKAIN2	0.56	8.38	0.42	1.57e-15	Neuroticism;
CRC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.55	8.9	0.44	3.74e-17	Breast cancer;
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.87	-19.92	-0.74	1.77e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg07713946	chr22:31675144	LIMK2	0.42	6.29	0.33	1.02e-9	Colorectal cancer;
CRC	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg04586622	chr2:25135609	ADCY3	-0.58	-9.98	-0.48	1.12e-20	Body mass index;
CRC	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.64	11.08	0.52	1.91e-24	Metabolite levels;
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.47	0.53	7.33e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg05941027	chr17:61774174	LIMD2	0.33	5.74	0.3	2.17e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg12160578	chr15:63334699	TPM1	0.63	7.53	0.38	5.02e-13	Orofacial clefts;
CRC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.82	-13.36	-0.59	7.68e-33	Plateletcrit;Platelet count;
CRC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.81	13.6	0.6	9.97e-34	Menopause (age at onset);
CRC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.67	-8.14	-0.41	8.07e-15	Rheumatoid arthritis;
CRC	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.89	11.18	0.52	8.18e-25	Prostate cancer;
CRC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.83	14.5	0.62	3.6e-37	Breast cancer;
CRC	cis	rs12922317	0.556	rs8062691	chr16:12091829	A/G	cg02368508	chr16:12060182	TNFRSF17	-0.5	-8.41	-0.42	1.23e-15	Schizophrenia;
CRC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg23996704	chr18:44553084	KATNAL2	-0.34	-6.93	-0.36	2.22e-11	Personality dimensions;
CRC	cis	rs4711350	0.862	rs652049	chr6:33711420	C/T	cg07979401	chr6:33739406	LEMD2	0.48	5.95	0.31	6.77e-9	Schizophrenia;
CRC	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.55	-6.15	-0.32	2.3e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg26576206	chr19:1064938	ABCA7	0.43	6.33	0.33	8e-10	Alzheimer's disease (late onset);
CRC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.27	-0.46	2.49e-18	Type 2 diabetes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24057176	chr19:1275466	C19orf24	0.38	6.04	0.32	4.28e-9	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.85	-11.58	-0.54	3.01e-26	Asthma;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg19041857	chr6:27730383	NA	-0.47	-6.51	-0.34	2.77e-10	Parkinson's disease;
CRC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-13.38	-0.59	6.93e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.43	5.95	0.31	6.84e-9	Diastolic blood pressure;
CRC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-8.05	-0.41	1.51e-14	Crohn's disease;
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg03623178	chr6:28175578	NA	0.66	10.08	0.49	5.38e-21	Cardiac Troponin-T levels;
CRC	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.37	-6.49	-0.34	3.12e-10	Breast cancer;
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.55	7.52	0.38	5.16e-13	Alzheimer's disease;
CRC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg02527881	chr3:46936655	PTH1R	-0.37	-6.8	-0.35	5.02e-11	Colorectal cancer;
CRC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	8.1	0.41	1.08e-14	Neuroticism;
CRC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.52	6.94	0.36	2.03e-11	Methadone dose in opioid dependence;
CRC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg15123519	chr2:136567270	LCT	0.31	5.83	0.31	1.36e-8	Mosquito bite size;
CRC	cis	rs245880	0.740	rs245888	chr7:29190414	C/T	cg17163760	chr7:29186267	CPVL	-0.39	-6.73	-0.35	7.63e-11	Warfarin maintenance dose;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-7.09	-0.36	8.29e-12	Type 2 diabetes;
CRC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.63	-11.02	-0.52	2.9e-24	Coronary artery disease;
CRC	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.58	-8.09	-0.41	1.18e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7532866	0.885	rs7517224	chr1:26731029	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.4	-6.01	-0.31	5.04e-9	Height;
CRC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Body mass index;
CRC	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.44	6.33	0.33	7.98e-10	Height;
CRC	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.65	0.34	1.2e-10	Blood protein levels;
CRC	cis	rs4731207	0.967	rs3807544	chr7:124400705	G/A	cg23710748	chr7:124431027	NA	0.39	6.27	0.33	1.16e-9	Cutaneous malignant melanoma;
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.36	-0.38	1.52e-12	Bipolar disorder;
CRC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.47	-6.55	-0.34	2.21e-10	IgG glycosylation;
CRC	cis	rs16852403	0.507	rs451341	chr1:178097515	G/A	cg00404053	chr1:178313656	RASAL2	-0.41	-5.66	-0.3	3.32e-8	Childhood ear infection;
CRC	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg09659197	chr4:152720779	NA	0.52	11.24	0.53	4.87e-25	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.57e-27	Cognitive function;
CRC	trans	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.96	-0.4	2.77e-14	Diabetic kidney disease;
CRC	cis	rs11161851	0.609	rs1327093	chr1:75369429	C/T	cg11196437	chr1:75593865	LHX8	-0.27	-5.61	-0.3	4.29e-8	Visceral fat;
CRC	cis	rs7923609	0.846	rs10740116	chr10:65094992	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.77	-0.3	1.81e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.45	5.82	0.31	1.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7572644	0.640	rs9678430	chr2:28057129	G/C	cg27432699	chr2:27873401	GPN1	0.45	6.11	0.32	2.79e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg14631576	chr9:95140430	CENPP	-0.41	-7.24	-0.37	3.14e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20447654	chr14:45366388	C14orf28	0.43	6.1	0.32	2.95e-9	Response to antipsychotic treatment;
CRC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg24209194	chr3:40518798	ZNF619	0.42	6.51	0.34	2.74e-10	Renal cell carcinoma;
CRC	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.5	8.14	0.41	8.31e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg05925327	chr15:68127851	NA	-0.3	-5.88	-0.31	9.87e-9	Restless legs syndrome;
CRC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg07700843	chr1:2391317	NA	-0.39	-6.33	-0.33	7.88e-10	Schizophrenia;
CRC	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.54	6.33	0.33	8.14e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	6.69	0.35	9.83e-11	Rheumatoid arthritis;
CRC	cis	rs7605827	0.930	rs6431707	chr2:15638165	A/T	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.59e-9	Educational attainment (years of education);
CRC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg18876405	chr7:65276391	NA	0.46	6.46	0.34	3.85e-10	Aortic root size;
CRC	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.73	9.9	0.48	2.21e-20	Coronary artery disease;
CRC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.72	12.65	0.57	3.74e-30	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.47	7.5	0.38	6.01e-13	Calcium levels;
CRC	cis	rs728616	0.681	rs34816332	chr10:81907967	G/A	cg05935833	chr10:81318306	SFTPA2	-0.54	-6.26	-0.33	1.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.48	-6.45	-0.34	4.02e-10	Pancreatic cancer;
CRC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg12463550	chr7:65579703	CRCP	-0.73	-6.53	-0.34	2.56e-10	Diabetic kidney disease;
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.7	0.39	1.63e-13	Alzheimer's disease;
CRC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.52	8.24	0.41	4.03e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.08	-0.45	1e-17	Bipolar disorder;
CRC	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-10.94	-0.52	5.68e-24	Coronary artery disease;
CRC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.72	-8.15	-0.41	7.69e-15	Obesity-related traits;
CRC	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.39	-0.46	1.02e-18	Prevalent atrial fibrillation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18276145	chr4:72052432	SLC4A4	0.39	6.45	0.34	3.9e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.2	-0.32	1.68e-9	Alzheimer's disease (late onset);
CRC	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.64	-0.47	1.51e-19	Hip circumference adjusted for BMI;
CRC	trans	rs7011507	1.000	rs76948763	chr8:49192004	A/G	cg04544946	chr8:978226	NA	0.44	6.19	0.32	1.82e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs317865	0.748	rs73234656	chr4:16212702	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.64	5.77	0.3	1.87e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01711073	chr1:37980396	MEAF6	0.46	6.35	0.33	7.03e-10	Anxiety disorder;
CRC	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.43	-0.33	4.51e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.71	0.35	8.7e-11	Lung cancer;
CRC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg19223190	chr17:80058835	NA	-0.41	-6.39	-0.33	5.53e-10	Life satisfaction;
CRC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23378565	chr7:2036160	MAD1L1	0.42	6.39	0.33	5.82e-10	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.43	6.36	0.33	6.83e-10	Menopause (age at onset);
CRC	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	0.8	12.52	0.57	1.1e-29	Breast cancer;
CRC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg19678392	chr7:94953810	PON1	-0.52	-6.52	-0.34	2.58e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1950626	0.623	rs3742401	chr14:101453344	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.76	12.3	0.56	7.39e-29	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.23	15.05	0.64	2.68e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-8.59	-0.43	3.52e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.67	7.46	0.38	7.85e-13	Vitiligo;
CRC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.4	-5.94	-0.31	7.37e-9	Pulse pressure;
CRC	cis	rs6011002	0.745	rs1151625	chr20:62369997	C/T	cg01176363	chr20:62369445	LIME1	0.73	5.68	0.3	3.02e-8	Dental caries;
CRC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg13753209	chr17:57696993	CLTC	0.44	5.81	0.3	1.49e-8	Hemoglobin concentration;
CRC	trans	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg07817883	chr1:32538562	TMEM39B	1.51	13.3	0.59	1.33e-32	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg23093090	chr10:104574429	C10orf26	-0.43	-5.92	-0.31	8.19e-9	Arsenic metabolism;
CRC	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.55	0.34	2.26e-10	Body mass index;
CRC	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.85	0.35	3.64e-11	Prostate cancer;
CRC	trans	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg10756647	chr7:56101905	PSPH	0.73	8.05	0.41	1.58e-14	Diabetic kidney disease;
CRC	cis	rs9303280	0.901	rs7216558	chr17:38070071	C/T	cg11212589	chr17:38028394	ZPBP2	-0.42	-7.67	-0.39	1.92e-13	Self-reported allergy;
CRC	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.5	-10.94	-0.52	5.95e-24	Rheumatoid arthritis;
CRC	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.65	-10.13	-0.49	3.68e-21	Intelligence (multi-trait analysis);
CRC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.75	7.59	0.39	3.24e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.44	6.05	0.32	3.99e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg20041105	chr8:143859282	LYNX1	-0.32	-5.65	-0.3	3.45e-8	Urinary tract infection frequency;
CRC	cis	rs2229774	1.000	rs11170481	chr12:53611791	C/T	cg21746001	chr12:53610772	RARG	-0.57	-5.98	-0.31	5.67e-9	Anthracycline-induced cardiotoxicity in childhood cancer;
CRC	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.57	6.33	0.33	8.02e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.77	-0.44	1.01e-16	Bipolar disorder;
CRC	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.35	5.81	0.31	1.45e-8	Mean arterial pressure;
CRC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.72	11.47	0.53	7.68e-26	Mean corpuscular hemoglobin;
CRC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.52	-8.67	-0.43	2.04e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-12.89	-0.58	4.55e-31	Systemic lupus erythematosus;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.7	9.17	0.45	5.21e-18	Alzheimer's disease;
CRC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-1.04	-21.24	-0.76	1.22e-63	Headache;
CRC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.78	0.54	5.75e-27	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg13047869	chr3:10149882	C3orf24	0.51	7.18	0.37	4.76e-12	Alzheimer's disease;
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg01788221	chr16:89496183	ANKRD11	-0.43	-6.56	-0.34	2.14e-10	Multiple myeloma (IgH translocation);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25304775	chr11:64885222	ZNHIT2	0.36	5.98	0.31	5.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.35	-7.5	-0.38	6.1e-13	Schizophrenia;
CRC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.42	-5.8	-0.3	1.57e-8	Daytime sleep phenotypes;
CRC	cis	rs6988985	0.560	rs4418320	chr8:143944138	G/A	cg10324643	chr8:143916377	GML	0.36	6.04	0.32	4.21e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs17767392	0.846	rs12127	chr14:71956270	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.46	-6.08	-0.32	3.38e-9	Mitral valve prolapse;
CRC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg04362960	chr10:104952993	NT5C2	0.44	5.99	0.31	5.58e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3764400	0.567	rs67345313	chr17:46302201	T/C	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.22e-10	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02530464	chr5:176449541	ZNF346	0.48	6.13	0.32	2.56e-9	Thyroid stimulating hormone;
CRC	trans	rs11654801	0.812	rs11656525	chr17:20881745	T/C	cg23759823	chr7:139672531	TBXAS1	-0.41	-6.12	-0.32	2.64e-9	Mosquito bite size;
CRC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.57	8.0	0.4	2.2e-14	Lung cancer;
CRC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.68	9.23	0.45	3.48e-18	Breast cancer;
CRC	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg23293999	chr7:106826042	HBP1	-0.49	-5.61	-0.3	4.26e-8	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17573594	chr12:110338513	TCHP	0.45	6.09	0.32	3.09e-9	Thyroid stimulating hormone;
CRC	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.28e-36	Colorectal cancer;
CRC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.47	7.85	0.4	5.98e-14	Platelet count;
CRC	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.06	-0.32	3.68e-9	Subjective well-being;
CRC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.72	8.9	0.44	3.71e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.55	8.69	0.43	1.72e-16	Breast cancer;
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg22687807	chr8:143858763	LYNX1	-0.4	-7.01	-0.36	1.35e-11	Urinary tract infection frequency;
CRC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.16	26.05	0.82	5.8e-82	IgG glycosylation;
CRC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.54	-6.25	-0.33	1.3e-9	Coronary artery calcification;
CRC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-11.21	-0.53	6.38e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg25834613	chr7:1915315	MAD1L1	-0.43	-6.31	-0.33	9.27e-10	Neuroticism;
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.92	0.58	3.51e-31	Alzheimer's disease;
CRC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08859206	chr1:53392774	SCP2	0.63	9.81	0.48	4.26e-20	Monocyte count;
CRC	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs11212617	0.967	rs227067	chr11:108209360	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.6	0.3	4.44e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.55	-7.46	-0.38	7.7e-13	Obesity-related traits;
CRC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.83	-14.35	-0.62	1.38e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.55	-7.72	-0.39	1.36e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.44	8.74	0.43	1.26e-16	Vitiligo;
CRC	cis	rs6988636	0.710	rs17316158	chr8:124157607	A/C	cg27053337	chr8:124217698	FAM83A	0.41	5.69	0.3	2.77e-8	Urinary uromodulin levels;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg12172441	chr6:28176163	NA	0.47	6.16	0.32	2.09e-9	Parkinson's disease;
CRC	cis	rs2282802	0.685	rs11745502	chr5:139558808	G/A	cg26211634	chr5:139558579	C5orf32	-0.44	-7.73	-0.39	1.32e-13	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.29	0.37	2.28e-12	Aortic root size;
CRC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.42	6.79	0.35	5.35e-11	Resting heart rate;
CRC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.19	-0.32	1.77e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.62	-0.34	1.44e-10	Bipolar disorder;
CRC	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.51	-0.5	1.84e-22	Hepatocellular carcinoma;
CRC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.95	-0.31	6.77e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02290350	chr8:58132656	NA	-0.59	-7.14	-0.37	6.05e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00745463	chr17:30367425	LRRC37B	0.72	7.51	0.38	5.5e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.18	0.52	8.01e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	14.67	0.63	7.72e-38	Smoking behavior;
CRC	cis	rs501916	0.634	rs1561483	chr15:48069488	A/C	cg16110827	chr15:48056943	SEMA6D	-0.42	-6.14	-0.32	2.35e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg01448562	chr3:133502909	NA	0.37	5.84	0.31	1.23e-8	Iron status biomarkers (transferrin levels);
CRC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-9.57	-0.47	2.65e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg22777020	chr22:31556080	RNF185	-0.51	-5.86	-0.31	1.15e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg03037974	chr15:76606532	NA	0.77	14.52	0.63	2.86e-37	Blood metabolite levels;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.75	11.29	0.53	3.33e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg14352298	chr13:112236639	NA	-0.27	-6.11	-0.32	2.87e-9	Hepatitis;
CRC	cis	rs59104589	0.617	rs60178325	chr2:242300651	A/T	cg19488206	chr2:242435732	STK25	0.47	6.68	0.35	1.02e-10	Fibrinogen levels;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg12172441	chr6:28176163	NA	0.52	7.29	0.37	2.4e-12	Parkinson's disease;
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.36	-0.38	1.5e-12	Lymphocyte counts;
CRC	cis	rs7113874	0.589	rs10840060	chr11:8500045	A/C	cg17679104	chr11:8615758	STK33	0.36	5.89	0.31	9.64e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.9	-0.52	7.9e-24	Pancreatic cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16221841	chr14:77279127	ANGEL1	0.44	6.29	0.33	9.93e-10	Anxiety disorder;
CRC	cis	rs6764363	0.565	rs625589	chr3:288775	A/T	cg02057681	chr3:285234	CHL1	-0.41	-6.71	-0.35	8.73e-11	Sudden cardiac arrest;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg12585429	chr16:49889252	NA	-0.41	-6.04	-0.32	4.12e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg13385794	chr1:248469461	NA	0.38	6.66	0.34	1.14e-10	Common traits (Other);
CRC	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.49	6.83	0.35	4.09e-11	Neuroticism;
CRC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.95	-19.14	-0.73	2.04e-55	Height;
CRC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.5	6.84	0.35	3.83e-11	Obesity-related traits;
CRC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-5.72	-0.3	2.44e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.76e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.59	-10.43	-0.5	3.35e-22	Total body bone mineral density;
CRC	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.55	6.96	0.36	1.88e-11	Coronary artery disease;
CRC	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg22495460	chr2:25135724	ADCY3	-0.87	-14.99	-0.64	4.51e-39	Body mass index;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg00887444	chr13:31248228	NA	0.44	6.04	0.32	4.12e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg23972785	chr8:11611189	GATA4	-0.4	-5.68	-0.3	2.89e-8	Myopia (pathological);
CRC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	-0.66	-7.27	-0.37	2.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg23161317	chr6:28129485	ZNF389	0.44	6.27	0.33	1.16e-9	Parkinson's disease;
CRC	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.07	21.65	0.77	3.11e-65	Schizophrenia;
CRC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg10298567	chr3:47292165	KIF9	0.38	5.96	0.31	6.55e-9	Colorectal cancer;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.43	-5.94	-0.31	7.26e-9	Prudent dietary pattern;
CRC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.12	-0.41	9.35e-15	Body mass index;
CRC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.74	0.39	1.27e-13	Platelet count;
CRC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.44	5.89	0.31	9.35e-9	Schizophrenia;
CRC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.77	-10.63	-0.51	6.97e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.47	7.04	0.36	1.11e-11	Menopause (age at onset);
CRC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg02254261	chr7:158964346	NA	-0.51	-5.86	-0.31	1.15e-8	Myopia (pathological);
CRC	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.95	-0.31	6.74e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg07701084	chr6:150067640	NUP43	0.42	5.95	0.31	6.87e-9	Lung cancer;
CRC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	2e-33	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.05	10.23	0.49	1.68e-21	Diabetic retinopathy;
CRC	cis	rs883565	0.528	rs9818979	chr3:38963835	C/G	cg01426195	chr3:39028469	NA	0.38	6.38	0.33	5.95e-10	Handedness;
CRC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	16.88	0.68	1.68e-46	Prudent dietary pattern;
CRC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.61	-0.39	2.95e-13	Schizophrenia;
CRC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg11707556	chr5:10655725	ANKRD33B	0.47	7.66	0.39	2.06e-13	Coronary artery disease;
CRC	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg20737812	chr15:86336631	KLHL25	-0.43	-6.62	-0.34	1.44e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.16	-0.32	2.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.72	9.72	0.47	8.68e-20	Alzheimer's disease;
CRC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.95	-19.14	-0.73	2.04e-55	Height;
CRC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.43	8.58	0.43	3.84e-16	Renal cell carcinoma;
CRC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.73	-0.51	3.23e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-7.98	-0.4	2.44e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs10450586	0.932	rs10742172	chr11:27314297	C/T	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.16	0.37	5.33e-12	Colorectal cancer;
CRC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg09264619	chr17:80180166	NA	0.51	7.32	0.37	1.9e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg09877947	chr5:131593287	PDLIM4	0.36	6.73	0.35	7.53e-11	Blood metabolite levels;
CRC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.47	6.47	0.34	3.58e-10	Height;
CRC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.61	11.25	0.53	4.79e-25	Immature fraction of reticulocytes;
CRC	cis	rs1506636	0.539	rs17701547	chr7:123383461	A/G	cg03229431	chr7:123269106	ASB15	-0.71	-8.63	-0.43	2.66e-16	Plateletcrit;Platelet count;
CRC	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.22	0.45	3.71e-18	Ileal carcinoids;
CRC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.6	10.1	0.49	4.48e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.46	5.69	0.3	2.85e-8	Aortic root size;
CRC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg18099408	chr3:52552593	STAB1	0.34	5.95	0.31	6.78e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	7.03	0.36	1.2e-11	Motion sickness;
CRC	trans	rs4308415	0.781	rs12498631	chr4:67811543	T/C	cg19648955	chr2:177134095	MTX2	-0.43	-6.34	-0.33	7.43e-10	Educational attainment (years of education);
CRC	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg22134325	chr11:66188745	NPAS4	0.37	6.11	0.32	2.86e-9	Airway imaging phenotypes;
CRC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.48	0.42	7.92e-16	Rheumatoid arthritis;
CRC	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg08501292	chr6:25962987	TRIM38	-0.64	-6.94	-0.36	2.09e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg19761014	chr17:28927070	LRRC37B2	0.6	5.89	0.31	9.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.57	-8.01	-0.4	1.95e-14	Response to bleomycin (chromatid breaks);
CRC	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	0.65	6.98	0.36	1.68e-11	Prostate cancer;
CRC	cis	rs2565722	0.825	rs1247540	chr6:161253016	G/A	cg03159191	chr6:161285451	NA	-0.48	-5.81	-0.31	1.46e-8	Blood protein levels;
CRC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.61	-0.3	4.32e-8	Migraine;Coronary artery disease;
CRC	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.6	-8.82	-0.44	6.96e-17	Blood pressure (smoking interaction);
CRC	cis	rs11212617	0.905	rs172927	chr11:108124299	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.82	0.31	1.43e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs972578	0.936	rs2267486	chr22:43384017	C/A	cg01576275	chr22:43409880	NA	-0.48	-7.71	-0.39	1.47e-13	Mean platelet volume;
CRC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.37	-0.38	1.36e-12	HDL cholesterol;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.99	-0.4	2.25e-14	Total body bone mineral density;
CRC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.66	10.25	0.49	1.36e-21	Breast cancer;
CRC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg02659138	chr7:134003124	SLC35B4	0.4	6.96	0.36	1.84e-11	Mean platelet volume;
CRC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.12	0.66	1.72e-43	Platelet count;
CRC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.76	14.55	0.63	2.33e-37	Body mass index;
CRC	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg05507819	chr15:63340323	TPM1	0.47	6.22	0.32	1.52e-9	HDL cholesterol;
CRC	cis	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg15845792	chr6:28175446	NA	0.84	5.82	0.31	1.37e-8	Depression;
CRC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.38	0.38	1.33e-12	Breast cancer;
CRC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.4	6.55	0.34	2.26e-10	Huntington's disease progression;
CRC	cis	rs7932354	0.583	rs10769212	chr11:46893498	C/A	cg19486271	chr11:47235900	DDB2	-0.42	-6.36	-0.33	6.58e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg15445000	chr17:37608096	MED1	0.35	6.2	0.32	1.69e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg03623178	chr6:28175578	NA	0.92	12.19	0.56	1.91e-28	Depression;
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.51	7.2	0.37	4.24e-12	Alzheimer's disease;
CRC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.35	7.11	0.36	7.27e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.56	-0.5	1.22e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg04969067	chr8:143858791	LYNX1	0.41	6.43	0.33	4.42e-10	Urinary tract infection frequency;
CRC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.81	7.68	0.39	1.89e-13	Diabetic retinopathy;
CRC	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.72	9.61	0.47	1.95e-19	Menopause (age at onset);
CRC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	8.57	0.43	4.05e-16	IgG glycosylation;
CRC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.62	-7.71	-0.39	1.5e-13	Schizophrenia;
CRC	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg21770322	chr7:97807741	LMTK2	0.54	7.89	0.4	4.44e-14	Breast cancer;
CRC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg17294928	chr15:75287854	SCAMP5	0.45	6.82	0.35	4.48e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.42	-0.38	9.97e-13	Aortic root size;
CRC	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.32	-0.33	8.45e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	12.03	0.55	7.15e-28	Hip circumference adjusted for BMI;
CRC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.66	8.2	0.41	5.5e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23526204	chr20:43992176	SYS1;SYS1-DBNDD2	0.39	6.0	0.31	5.28e-9	Obesity-related traits;
CRC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.55	-6.99	-0.36	1.57e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.99	0.31	5.47e-9	Metabolite levels;
CRC	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.66	11.46	0.53	8.55e-26	Blood protein levels;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18110333	chr6:292329	DUSP22	-0.59	-8.58	-0.43	3.93e-16	Menopause (age at onset);
CRC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.56	-8.01	-0.4	2.05e-14	Menarche (age at onset);
CRC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	7.91	0.4	3.89e-14	Motion sickness;
CRC	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg25190513	chr12:123201362	GPR109B	-0.49	-6.27	-0.33	1.11e-9	Adiponectin levels;
CRC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.46	-6.16	-0.32	2.15e-9	Diastolic blood pressure;
CRC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.54	7.46	0.38	7.55e-13	Gut microbiome composition (summer);
CRC	cis	rs4629710	0.562	rs3798252	chr6:131583758	A/T	cg12606694	chr6:131520996	AKAP7	0.53	8.0	0.4	2.19e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.96	18.42	0.71	1.43e-52	Height;
CRC	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.82	0.48	3.92e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg16576597	chr16:28551801	NUPR1	-0.48	-7.03	-0.36	1.19e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.3	0.46	2.04e-18	Bladder cancer;
CRC	trans	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg10659575	chr11:102188233	BIRC3	0.51	6.03	0.32	4.34e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.33	7.72	0.39	1.39e-13	Corneal astigmatism;
CRC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg15654264	chr1:150340011	RPRD2	-0.39	-5.84	-0.31	1.22e-8	Cerebrospinal fluid biomarker levels;
CRC	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg11038491	chr20:34638489	LOC647979	-0.59	-7.18	-0.37	4.59e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-8.51	-0.42	6.43e-16	Gut microbiome composition (summer);
CRC	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg09324608	chr17:30823087	MYO1D	0.33	5.72	0.3	2.43e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21684385	chr6:143772210	ADAT2;PEX3	0.44	6.08	0.32	3.27e-9	Response to antipsychotic treatment;
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg06494592	chr3:125709126	NA	-0.53	-6.73	-0.35	7.61e-11	Blood pressure (smoking interaction);
CRC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg21335942	chr16:58549945	SETD6	0.91	5.86	0.31	1.13e-8	Schizophrenia;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg03388025	chr16:89894329	SPIRE2	0.36	6.7	0.35	9.18e-11	Vitiligo;
CRC	cis	rs728616	0.717	rs116884206	chr10:81990546	A/G	cg11900509	chr10:81946545	ANXA11	-0.74	-6.9	-0.36	2.65e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg01339444	chr6:118972232	C6orf204	0.56	6.09	0.32	3.14e-9	Diastolic blood pressure;
CRC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg02527881	chr3:46936655	PTH1R	0.38	7.08	0.36	8.93e-12	Colorectal cancer;
CRC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg07423050	chr13:99094983	FARP1	0.4	6.29	0.33	9.91e-10	Longevity;
CRC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.71	10.48	0.5	2.36e-22	Corneal astigmatism;
CRC	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.48	0.38	6.64e-13	Eye color traits;
CRC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.75	0.47	6.72e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2462686	1.000	rs809298	chr7:45998344	C/A	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.86	-0.31	1.11e-8	Major depressive disorder;
CRC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.7	8.59	0.43	3.49e-16	Mean platelet volume;
CRC	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg10517650	chr3:113235015	CCDC52	-0.38	-6.66	-0.34	1.14e-10	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.4	-0.5	4.29e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg03037974	chr15:76606532	NA	-0.53	-7.55	-0.38	4.22e-13	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.51	7.39	0.38	1.22e-12	Response to antipsychotic treatment;
CRC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.42	-7.49	-0.38	6.5e-13	Reticulocyte fraction of red cells;
CRC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-6.34	-0.33	7.41e-10	Plateletcrit;
CRC	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg09417038	chr21:47716443	C21orf57	0.38	6.64	0.34	1.3100000000000001e-10	Testicular germ cell tumor;
CRC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.12	0.41	9.78e-15	Menopause (age at onset);
CRC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.75	12.76	0.58	1.4e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.87	10.66	0.51	5.49e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg10130564	chr11:117069849	TAGLN	-0.39	-7.38	-0.38	1.34e-12	Blood protein levels;
CRC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.5	7.33	0.37	1.8e-12	Blood metabolite levels;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.71	-11.44	-0.53	9.46e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg17674042	chr6:34482479	PACSIN1	-0.92	-9.2	-0.45	4.09e-18	Chronic lymphocytic leukemia;
CRC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.8	-13.33	-0.59	1.03e-32	Paraoxonase activity;
CRC	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.37	-5.92	-0.31	7.91e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.07	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg04165759	chr1:150448943	RPRD2	0.35	5.72	0.3	2.44e-8	Migraine;
CRC	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.5	-5.74	-0.3	2.18e-8	Lymphocyte percentage of white cells;
CRC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg13390004	chr1:15929781	NA	0.53	7.25	0.37	2.99e-12	Systolic blood pressure;
CRC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14895029	chr7:2775587	GNA12	-0.45	-6.49	-0.34	3.18e-10	Height;
CRC	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.54	7.75	0.39	1.14e-13	White matter hyperintensity burden;
CRC	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.57	7.59	0.39	3.33e-13	Schizophrenia;
CRC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	1.02	18.11	0.71	2.41e-51	Parkinson's disease;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23161317	chr6:28129485	ZNF389	0.44	5.73	0.3	2.27e-8	Parkinson's disease;
CRC	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01015199	chr6:53409878	GCLC	0.51	7.37	0.38	1.4e-12	Anxiety disorder;
CRC	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg02033258	chr5:131593261	PDLIM4	0.31	5.6	0.3	4.5e-8	Blood metabolite levels;
CRC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.48	7.36	0.38	1.49e-12	Red blood cell count;
CRC	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs9359856	0.564	rs1179902	chr6:90321545	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.71	-7.88	-0.4	4.72e-14	Bipolar disorder;
CRC	cis	rs9400239	0.622	rs1268169	chr6:109007977	A/C	cg11073813	chr6:109029018	NA	-0.39	-6.2	-0.32	1.72e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs2213920	0.679	rs4979536	chr9:118213738	C/T	cg13918206	chr9:118159781	DEC1	0.61	5.82	0.31	1.4e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	trans	rs6066835	0.702	rs6095228	chr20:47279876	A/G	cg21109867	chr19:55897418	RPL28	0.74	5.98	0.31	5.73e-9	Multiple myeloma;
CRC	trans	rs660498	0.785	rs2484204	chr10:27738002	G/A	cg13661793	chr10:32399026	NA	-0.34	-6.11	-0.32	2.76e-9	Asthma (childhood onset);
CRC	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.67	-0.3	3.2e-8	Axial length;
CRC	cis	rs7605827	0.930	rs13017972	chr2:15699739	A/G	cg19274914	chr2:15703543	NA	0.37	5.65	0.3	3.57e-8	Educational attainment (years of education);
CRC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg04166393	chr7:2884313	GNA12	0.38	5.7	0.3	2.64e-8	Height;
CRC	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	trans	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg14791747	chr16:20752902	THUMPD1	0.54	6.78	0.35	5.64e-11	Cognitive test performance;
CRC	cis	rs4660214	0.666	rs7553009	chr1:39713113	C/T	cg11070191	chr1:39582205	MACF1	0.36	5.73	0.3	2.23e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06156847	chr2:113672199	IL1F7	0.49	7.48	0.38	6.69e-13	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01655355	chr19:17982748	SLC5A5	0.39	6.09	0.32	3.18e-9	Response to antipsychotic treatment;
CRC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.81	-11.36	-0.53	1.85e-25	Intelligence (multi-trait analysis);
CRC	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.79	14.21	0.62	4.4e-36	Hip circumference;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg24634471	chr8:143751801	JRK	-0.49	-6.7	-0.35	9.05e-11	Urinary tract infection frequency;
CRC	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.34	-5.83	-0.31	1.29e-8	Airway imaging phenotypes;
CRC	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg00277334	chr10:82204260	NA	-0.5	-5.62	-0.3	4.01e-8	Post bronchodilator FEV1;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26957173	chr10:75173848	ANXA7	0.39	6.28	0.33	1.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7215564	0.908	rs4243241	chr17:78660502	A/C	cg09596252	chr17:78655493	RPTOR	0.54	5.73	0.3	2.25e-8	Myopia (pathological);
CRC	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg07979401	chr6:33739406	LEMD2	-0.49	-6.1	-0.32	2.94e-9	Schizophrenia;
CRC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.77	-0.35	5.98e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.76	-0.35	6.15e-11	Mean corpuscular volume;
CRC	cis	rs9925964	0.933	rs749671	chr16:31088347	G/A	cg02466173	chr16:30829666	NA	0.44	5.73	0.3	2.25e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.72	-10.87	-0.51	1.04e-23	Menarche (age at onset);
CRC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.37	-5.74	-0.3	2.15e-8	Coronary artery disease;
CRC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-7.42	-0.38	1.02e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.14	0.45	6.75e-18	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05501829	chr17:3749777	C17orf85	0.42	6.21	0.32	1.6e-9	Response to antipsychotic treatment;
CRC	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.56	7.57	0.39	3.89e-13	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2882667	0.931	rs10070021	chr5:138324706	A/G	cg09476006	chr5:138032270	NA	0.42	7.09	0.36	8.17e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.59	-7.93	-0.4	3.44e-14	White matter hyperintensity burden;
CRC	cis	rs17155006	0.664	rs411396	chr7:107744759	A/G	cg05962710	chr7:107745446	LAMB4	-0.4	-7.12	-0.37	6.77e-12	Pneumococcal bacteremia;
CRC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.53	7.75	0.39	1.16e-13	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00665395	chr2:219575490	TTLL4	0.48	6.09	0.32	3.11e-9	Thyroid stimulating hormone;
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.22	-0.56	1.48e-28	Alzheimer's disease;
CRC	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.66	-8.07	-0.41	1.35e-14	Response to hepatitis C treatment;
CRC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.82	11.17	0.52	8.68e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.64	0.54	1.81e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.53	6.93	0.36	2.24e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35883536	1.000	rs35883536	chr1:101106534	G/A	cg14515779	chr1:101123966	NA	-0.43	-8.3	-0.42	2.75e-15	Monocyte count;
CRC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.49	6.57	0.34	1.98e-10	Schizophrenia;
CRC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.4	0.38	1.12e-12	Blood metabolite levels;
CRC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.14	-0.45	6.63e-18	Birth weight;
CRC	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg01493522	chr13:37497338	NA	-0.49	-6.87	-0.35	3.16e-11	Coronary artery disease;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03923535	chr7:1197113	ZFAND2A	0.61	8.46	0.42	9.01e-16	Longevity;Endometriosis;
CRC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.5	6.79	0.35	5.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg27432699	chr2:27873401	GPN1	-0.52	-8.01	-0.4	1.99e-14	Total body bone mineral density;
CRC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg08314208	chr16:67682810	RLTPR	-0.57	-6.09	-0.32	3.17e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.41	6.52	0.34	2.68e-10	Glycated hemoglobin levels;
CRC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21643547	chr1:205240462	TMCC2	-0.37	-6.06	-0.32	3.83e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.75	-0.35	6.83e-11	Body mass index;
CRC	cis	rs1223397	0.651	rs202019	chr6:13301790	A/C	cg20827128	chr6:13274284	PHACTR1	0.38	5.75	0.3	2.07e-8	Blood pressure;
CRC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-5.81	-0.31	1.47e-8	Heart rate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13452400	chr2:7006280	CMPK2	0.46	6.25	0.33	1.3e-9	Anxiety disorder;
CRC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg26248373	chr2:1572462	NA	-0.66	-7.1	-0.36	7.65e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.79e-9	Life satisfaction;
CRC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-11.21	-0.53	6.17e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg04121214	chr22:50244548	NA	0.42	5.63	0.3	3.84e-8	Schizophrenia;
CRC	cis	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg11143507	chr3:125485238	NA	-0.58	-7.46	-0.38	7.69e-13	Blood pressure (smoking interaction);
CRC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.52	-7.0	-0.36	1.42e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg17333051	chr19:2783644	SGTA	0.43	6.68	0.35	1.02e-10	Total cholesterol levels;
CRC	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.67	-9.45	-0.46	6.33e-19	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.51	-9.69	-0.47	1.03e-19	HIV-1 susceptibility;
CRC	cis	rs7705042	0.865	rs12655465	chr5:141522213	C/T	cg07392085	chr5:141489673	NDFIP1	0.45	7.19	0.37	4.4e-12	Asthma;
CRC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	6.06	0.32	3.76e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.49	7.1	0.36	7.87e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.49	-0.34	3.2e-10	Type 2 diabetes;
CRC	cis	rs36715	0.904	rs36701	chr5:127552529	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	6.74	0.35	7.03e-11	Breast cancer;
CRC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-8.32	-0.42	2.4e-15	Monocyte count;
CRC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.6	-8.64	-0.43	2.48e-16	Menarche (age at onset);
CRC	trans	rs7968440	0.651	rs7309519	chr12:50652280	G/A	cg00474734	chr12:53645975	MFSD5	0.37	5.96	0.31	6.47e-9	Fibrinogen;
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.31e-36	Prudent dietary pattern;
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.51	0.34	2.74e-10	Bipolar disorder;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23817779	chr6:5261046	LYRM4;FARS2	0.41	6.46	0.34	3.75e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.42	-0.33	4.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg08743896	chr10:65200160	JMJD1C	-0.43	-6.2	-0.32	1.7e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.83	-0.4	6.76e-14	Prevalent atrial fibrillation;
CRC	cis	rs4363385	0.571	rs387930	chr1:153050058	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.41	-0.33	5.08e-10	Inflammatory skin disease;
CRC	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.57	7.85	0.4	6.09e-14	Pulmonary function decline;
CRC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.7	-0.6	4.06e-34	Blood metabolite levels;
CRC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg06462663	chr19:18546047	ISYNA1	0.49	7.39	0.38	1.2e-12	Breast cancer;
CRC	cis	rs73206853	0.764	rs67715513	chr12:110562910	G/A	cg12870014	chr12:110450643	ANKRD13A	0.83	10.65	0.51	5.74e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	trans	rs6011368	0.740	rs6062357	chr20:62892739	C/T	cg13869341	chr1:15865	WASH5P	0.42	6.22	0.32	1.48e-9	Clozapine-induced cytotoxicity;
CRC	cis	rs9925964	0.933	rs2359612	chr16:31103796	A/G	cg10396673	chr16:31104726	VKORC1	-0.33	-5.6	-0.3	4.48e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg27490568	chr2:178487706	NA	0.55	5.64	0.3	3.67e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.56	-8.27	-0.41	3.43e-15	Type 1 diabetes;
CRC	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.44	0.38	8.95e-13	Eye color traits;
CRC	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg25344623	chr2:136566232	LCT	0.33	5.98	0.31	5.97e-9	Mosquito bite size;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg16606324	chr3:10149918	C3orf24	0.63	6.43	0.33	4.61e-10	Alzheimer's disease;
CRC	cis	rs6460942	0.908	rs79175014	chr7:12245378	T/G	cg06484146	chr7:12443880	VWDE	-0.66	-6.56	-0.34	2.1e-10	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg18833306	chr6:118973337	C6orf204	0.45	5.95	0.31	6.95e-9	Diastolic blood pressure;
CRC	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.59	7.25	0.37	3.06e-12	Obesity (extreme);
CRC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs8099014	0.906	rs4940696	chr18:56106596	C/T	cg19312305	chr18:56117016	MIR122	0.45	6.88	0.35	3.11e-11	Platelet count;
CRC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-10.2	-0.49	2.05e-21	Body mass index;
CRC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.81	11.64	0.54	1.9e-26	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05573837	chr3:42696434	ZBTB47	-0.42	-6.77	-0.35	5.85e-11	Myopia (pathological);
CRC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.44	7.39	0.38	1.24e-12	Schizophrenia;
CRC	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg09127314	chr1:152161683	NA	0.47	5.99	0.31	5.61e-9	Atopic dermatitis;
CRC	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg16898833	chr6:26189333	HIST1H4D	0.67	5.91	0.31	8.41e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.63	8.48	0.42	7.51e-16	Facial morphology (factor 19);
CRC	cis	rs7762018	0.505	rs79938197	chr6:170059932	A/T	cg24289452	chr6:170231220	NA	-0.98	-7.04	-0.36	1.12e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs939584	0.932	rs2903490	chr2:651290	A/G	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.21	0.32	1.58e-9	Diabetic retinopathy;
CRC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.79	13.4	0.59	5.5e-33	Menopause (age at onset);
CRC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07513332	chr6:167530253	CCR6	0.45	7.99	0.4	2.32e-14	Primary biliary cholangitis;
CRC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg26528668	chr16:1614120	IFT140	0.38	5.97	0.31	6.12e-9	Coronary artery disease;
CRC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg23018236	chr17:30244563	NA	-0.61	-7.72	-0.39	1.44e-13	Hip circumference adjusted for BMI;
CRC	cis	rs3789045	0.774	rs4252697	chr1:204501383	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.55	-7.83	-0.4	6.98e-14	Educational attainment (college completion);
CRC	trans	rs12699921	0.572	rs2030725	chr7:17868331	T/C	cg15753394	chr6:17282781	RBM24	-0.36	-5.96	-0.31	6.37e-9	Fibrinogen levels;
CRC	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.57	-7.83	-0.4	6.56e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-6.94	-0.36	2.13e-11	Menarche (age at onset);
CRC	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg18646521	chr2:111875858	NA	0.37	5.73	0.3	2.25e-8	Chronic lymphocytic leukemia;
CRC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.51	-8.45	-0.42	9.27e-16	Prudent dietary pattern;
CRC	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	1.05	12.7	0.57	2.45e-30	Diisocyanate-induced asthma;
CRC	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg01858014	chr14:56050164	KTN1	-0.81	-6.11	-0.32	2.87e-9	Putamen volume;
CRC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.61	8.12	0.41	9.49e-15	Mean platelet volume;
CRC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.23	-0.37	3.38e-12	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00030291	chr7:8302094	ICA1	0.38	6.04	0.32	4.23e-9	Obesity-related traits;
CRC	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.42	6.14	0.32	2.32e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4731207	0.698	rs727506	chr7:124462027	A/G	cg23710748	chr7:124431027	NA	0.36	5.83	0.31	1.31e-8	Cutaneous malignant melanoma;
CRC	cis	rs863345	0.604	rs2023632	chr1:158459034	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.07	-0.32	3.49e-9	Pneumococcal bacteremia;
CRC	trans	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg01448155	chr10:3564782	NA	0.52	6.22	0.32	1.5e-9	Lymphocyte percentage of white cells;
CRC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.09	-0.36	7.99e-12	Personality dimensions;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.61	9.6	0.47	2.14e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	11.16	0.52	9.7e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.4	-6.18	-0.32	1.85e-9	Breast cancer;
CRC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.66	7.93	0.4	3.37e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12745968	0.589	rs6695638	chr1:93023486	G/A	cg17283838	chr1:93427260	FAM69A	-0.44	-6.02	-0.32	4.61e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.96	12.25	0.56	1.13e-28	Exhaled nitric oxide levels;
CRC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.55	8.08	0.41	1.25e-14	Cognitive ability;
CRC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.84	-0.44	5.9e-17	Aortic root size;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18301423	chr5:131593218	PDLIM4	0.44	8.17	0.41	6.63e-15	Acylcarnitine levels;
CRC	cis	rs3760982	1.000	rs11669175	chr19:44289824	A/G	cg11993925	chr19:44307056	LYPD5	0.47	7.85	0.4	5.8e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg07052231	chr12:7363540	PEX5	0.51	8.06	0.41	1.42e-14	IgG glycosylation;
CRC	cis	rs4700695	0.925	rs6449799	chr5:65394476	A/G	cg21114390	chr5:65439923	SFRS12	-0.54	-6.87	-0.35	3.31e-11	Facial morphology (factor 19);
CRC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg15131784	chr3:139108705	COPB2	0.39	5.65	0.3	3.5e-8	Obesity-related traits;
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.45	0.34	3.95e-10	Life satisfaction;
CRC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2.1e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.68	9.05	0.45	1.32e-17	Multiple sclerosis;
CRC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.64	-7.53	-0.38	4.81e-13	Skin colour saturation;
CRC	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg23920097	chr1:209922102	NA	0.52	6.59	0.34	1.77e-10	Red blood cell count;
CRC	trans	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-7.0	-0.36	1.41e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg13628971	chr7:2884303	GNA12	0.42	6.41	0.33	5.05e-10	Height;
CRC	cis	rs77861329	1.000	rs9811707	chr3:52190657	G/A	cg08692210	chr3:52188851	WDR51A	0.86	8.11	0.41	1.03e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.35	-5.68	-0.3	2.97e-8	Diastolic blood pressure;
CRC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs6662572	0.737	rs6429593	chr1:46505235	T/G	cg08644498	chr1:46502608	NA	0.46	7.41	0.38	1.11e-12	Blood protein levels;
CRC	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.63	-6.7	-0.35	9.13e-11	Verbal memory performance (residualized delayed recall change);
CRC	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg27205649	chr11:78285834	NARS2	0.5	6.07	0.32	3.5e-9	Alzheimer's disease (survival time);
CRC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13198984	chr17:80129470	CCDC57	-0.46	-7.98	-0.4	2.39e-14	Life satisfaction;
CRC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg12193833	chr17:30244370	NA	-0.63	-8.24	-0.41	4.13e-15	Hip circumference adjusted for BMI;
CRC	cis	rs62432291	0.681	rs418859	chr6:159649695	A/T	cg14500486	chr6:159655392	FNDC1	0.75	10.25	0.49	1.39e-21	Joint mobility (Beighton score);
CRC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.12	-20.75	-0.75	9.51e-62	Dilated cardiomyopathy;
CRC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24170415	chr4:185747632	ACSL1	0.43	6.16	0.32	2.1e-9	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs3771570	0.748	rs62186361	chr2:242168518	G/A	cg21155796	chr2:242212141	HDLBP	0.57	6.21	0.32	1.6e-9	Prostate cancer;
CRC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.52	7.93	0.4	3.48e-14	Red blood cell count;
CRC	cis	rs4728142	0.738	rs3807306	chr7:128580680	A/C	cg06630958	chr7:128577819	IRF5	0.4	6.96	0.36	1.82e-11	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.44	6.47	0.34	3.62e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	7.12	0.37	6.79e-12	Motion sickness;
CRC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.71	-0.3	2.47e-8	Primary biliary cholangitis;
CRC	cis	rs12024301	0.557	rs6693049	chr1:183624260	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs6472235	0.807	rs60667481	chr8:66928360	G/A	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.52	6.68	0.35	9.94e-11	Obesity-related traits;
CRC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.67	11.37	0.53	1.78e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg17710535	chr19:10819994	QTRT1	0.45	6.54	0.34	2.33e-10	Inflammatory skin disease;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.46	5.8	0.3	1.57e-8	Bladder cancer;
CRC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.57	-7.46	-0.38	7.85e-13	Gut microbiome composition (summer);
CRC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.5	-7.23	-0.37	3.34e-12	DNA methylation (variation);
CRC	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.22	-5.78	-0.3	1.76e-8	Type 2 diabetes;
CRC	cis	rs10242455	0.702	rs73713507	chr7:99138603	G/A	cg18809830	chr7:99032528	PTCD1	-1.32	-9.15	-0.45	6.31e-18	Blood metabolite levels;
CRC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg16141378	chr3:129829833	LOC729375	0.4	6.05	0.32	3.86e-9	Retinal vascular caliber;
CRC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.89	-8.98	-0.44	2.19e-17	Breast cancer;
CRC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	7.6	0.39	3.19e-13	Multiple sclerosis;
CRC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.97e-22	Menopause (age at onset);
CRC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.79	-0.35	5.15e-11	Retinal vascular caliber;
CRC	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg23167259	chr10:102495509	NA	-0.45	-6.45	-0.34	3.9e-10	Alzheimer's disease;
CRC	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.92	0.44	3.23e-17	Coffee consumption (cups per day);
CRC	trans	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg19894588	chr14:64061835	NA	-0.58	-7.8	-0.4	8.15e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.5	-7.07	-0.36	9.19e-12	Breast cancer;
CRC	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg00086871	chr4:6988644	TBC1D14	0.8	6.25	0.33	1.28e-9	Granulocyte percentage of myeloid white cells;
CRC	trans	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg05376469	chr2:102649931	NA	-0.38	-6.21	-0.32	1.57e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.53	6.31	0.33	8.99e-10	Lymphocyte counts;
CRC	cis	rs2072510	0.966	rs11108372	chr12:96394517	A/G	cg22491680	chr12:96389547	HAL	-0.39	-6.08	-0.32	3.36e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg16476235	chr8:21771668	DOK2	0.41	6.89	0.36	2.84e-11	Mean corpuscular volume;
CRC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	16.89	0.68	1.63e-46	Platelet count;
CRC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.12	0.49	3.81e-21	Menopause (age at onset);
CRC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg05941027	chr17:61774174	LIMD2	0.33	5.64	0.3	3.65e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1983891	0.865	rs10947980	chr6:41525739	A/G	cg20194872	chr6:41519635	FOXP4	0.43	5.85	0.31	1.17e-8	Prostate cancer;
CRC	cis	rs6840360	0.642	rs7666571	chr4:152443273	C/T	cg09659197	chr4:152720779	NA	0.32	6.43	0.33	4.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg10437265	chr15:77819839	NA	0.69	12.73	0.57	1.9e-30	Type 2 diabetes;
CRC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.54	-8.13	-0.41	9.05e-15	Asthma (sex interaction);
CRC	cis	rs16975963	0.843	rs241954	chr19:38277530	C/T	cg15135657	chr19:38346511	NA	-0.43	-5.77	-0.3	1.87e-8	Longevity;
CRC	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.48	7.71	0.39	1.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg17911788	chr17:44343683	NA	0.57	6.87	0.35	3.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.75	0.39	1.19e-13	Mean platelet volume;
CRC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.2	0.32	1.67e-9	Obesity-related traits;
CRC	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.41	6.44	0.33	4.29e-10	Red blood cell count;
CRC	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.56	9.96	0.48	1.32e-20	Common traits (Other);
CRC	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.9	-0.31	9.06e-9	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	19.0	0.72	7.38e-55	Prudent dietary pattern;
CRC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18357526	chr6:26021779	HIST1H4A	0.43	6.05	0.32	4.01e-9	Height;
CRC	trans	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg09045935	chr12:6379348	NA	1.13	9.23	0.45	3.42e-18	Blood metabolite levels;
CRC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.82	14.65	0.63	8.85e-38	Vitiligo;
CRC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg13491945	chr12:107078410	RFX4	0.35	6.0	0.31	5.34e-9	Heart rate;
CRC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.38	-6.63	-0.34	1.38e-10	Schizophrenia;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg12172441	chr6:28176163	NA	0.43	6.13	0.32	2.55e-9	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg20024234	chr21:43431083	ZNF295	-0.68	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg25456477	chr12:86230367	RASSF9	0.37	6.16	0.32	2.13e-9	Major depressive disorder;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg24463073	chr6:118973353	C6orf204	0.52	6.91	0.36	2.52e-11	Diastolic blood pressure;
CRC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15353389	chr12:120525027	CCDC64	0.47	6.02	0.31	4.77e-9	Thyroid stimulating hormone;
CRC	trans	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg00953403	chr17:74099816	EXOC7	-0.47	-6.95	-0.36	1.98e-11	Psychosis in Alzheimer's disease;
CRC	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg19897017	chr7:2163380	MAD1L1	-0.6	-8.92	-0.44	3.34e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs55702914	0.837	rs2195507	chr2:198172336	T/C	cg03934865	chr2:198174659	NA	-0.39	-6.81	-0.35	4.56e-11	Major depression and alcohol dependence;
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.59	10.19	0.49	2.27e-21	Prudent dietary pattern;
CRC	trans	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.04	-0.32	4.1e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.48	0.53	6.99e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.88	0.31	9.92e-9	IgG glycosylation;
CRC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.44	6.6	0.34	1.65e-10	Mean platelet volume;
CRC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.95	-17.56	-0.7	3.48e-49	Coronary artery disease;
CRC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.62	-9.19	-0.45	4.48e-18	Subjective well-being;
CRC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.57	7.56	0.38	4e-13	IgG glycosylation;
CRC	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.64	8.35	0.42	1.98e-15	Uric acid levels;
CRC	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg11038491	chr20:34638489	LOC647979	-0.58	-7.4	-0.38	1.12e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg25885038	chr17:56607967	SEPT4	-0.37	-5.74	-0.3	2.15e-8	Vitamin D levels;
CRC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.51	5.63	0.3	3.96e-8	Vitiligo;
CRC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.18e-35	Mean platelet volume;
CRC	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.49	8.52	0.43	5.98e-16	Common traits (Other);
CRC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.47	6.62	0.34	1.47e-10	Diastolic blood pressure;
CRC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg07700843	chr1:2391317	NA	-0.48	-7.49	-0.38	6.51e-13	Non-obstructive azoospermia;
CRC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.23	0.37	3.33e-12	Lung cancer;
CRC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg20129853	chr10:51489980	NA	-0.36	-5.92	-0.31	8.09e-9	Prostate-specific antigen levels;
CRC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.53	-8.01	-0.4	1.96e-14	Corneal astigmatism;
CRC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.12	0.32	2.71e-9	Prudent dietary pattern;
CRC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.6	10.74	0.51	2.91e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.4	-5.78	-0.3	1.71e-8	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14544983	chr19:47248940	FKRP;STRN4	0.51	7.15	0.37	5.82e-12	Anxiety disorder;
CRC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.93	-0.31	7.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg27615366	chr5:131592974	PDLIM4	-0.36	-7.02	-0.36	1.25e-11	Acylcarnitine levels;
CRC	cis	rs990171	0.607	rs2192752	chr2:102769373	A/C	cg22835712	chr2:102737379	NA	-0.45	-5.72	-0.3	2.35e-8	Lymphocyte counts;
CRC	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.67	0.3	3.2e-8	Heart rate;
CRC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg26893134	chr6:116381904	FRK	-0.29	-8.5	-0.42	6.79e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.77	9.39	0.46	1.06e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.44	-7.96	-0.4	2.75e-14	Huntington's disease progression;
CRC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg07274523	chr3:49395745	GPX1	0.48	6.18	0.32	1.91e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg05044414	chr3:183734942	ABCC5	0.48	8.31	0.42	2.55e-15	Anterior chamber depth;
CRC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-0.55	-5.83	-0.31	1.35e-8	Lung cancer;
CRC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.67	0.57	3.21e-30	Menopause (age at onset);
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.73	7.7	0.39	1.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.96	-0.31	6.32e-9	Daytime sleep phenotypes;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg10876282	chr6:28092338	ZSCAN16	0.49	6.78	0.35	5.55e-11	Cardiac Troponin-T levels;
CRC	cis	rs4908768	0.539	rs7526171	chr1:8650185	T/C	cg20416874	chr1:8611966	RERE	-0.42	-5.9	-0.31	8.86e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs460214	0.528	rs4817954	chr21:40023857	C/T	cg05519781	chr21:40033154	ERG	-0.42	-5.98	-0.31	5.67e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.48	6.57	0.34	1.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.79	-9.51	-0.46	4.25e-19	Multiple sclerosis;
CRC	cis	rs9326248	0.689	rs4516002	chr11:116999059	A/G	cg26566898	chr11:117069891	TAGLN	0.41	6.46	0.34	3.82e-10	Blood protein levels;
CRC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg21251018	chr6:28226885	NKAPL	0.39	5.98	0.31	5.98e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg10298567	chr3:47292165	KIF9	-0.35	-5.83	-0.31	1.33e-8	Colorectal cancer;
CRC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.72	10.23	0.49	1.61e-21	Heart rate;
CRC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg18761221	chr20:60518478	NA	0.54	8.31	0.42	2.62e-15	Body mass index;
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	6.01	0.31	4.86e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7215564	0.908	rs35725122	chr17:78663275	A/T	cg09596252	chr17:78655493	RPTOR	0.54	6.08	0.32	3.26e-9	Myopia (pathological);
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.38	5.71	0.3	2.48e-8	Longevity;Endometriosis;
CRC	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.34	16.61	0.68	2.03e-45	Uric acid levels;
CRC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.64	10.56	0.5	1.23e-22	Temperament;
CRC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.26	-0.33	1.24e-9	Menopause (age at onset);
CRC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.85	-0.44	5.31e-17	IgG glycosylation;
CRC	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.5	-8.23	-0.41	4.34e-15	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.58	0.43	3.81e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.0	9.41	0.46	9.08e-19	Diabetic retinopathy;
CRC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	6.42	0.33	4.63e-10	Obesity-related traits;
CRC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.41	5.63	0.3	3.79e-8	IgG glycosylation;
CRC	cis	rs6662572	0.737	rs10789476	chr1:46305362	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.82	-0.31	1.43e-8	Blood protein levels;
CRC	cis	rs1552172	0.922	rs12724816	chr1:145639324	G/T	cg11743829	chr1:145714124	CD160	-0.42	-6.38	-0.33	6.15e-10	Breast cancer;
CRC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.52	-6.81	-0.35	4.57e-11	Monocyte percentage of white cells;
CRC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-6.36	-0.33	6.66e-10	Platelet distribution width;
CRC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.62	10.16	0.49	2.9e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.37	0.38	1.43e-12	Motion sickness;
CRC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.11	0.32	2.75e-9	Tonsillectomy;
CRC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg16558177	chr4:4109446	NA	-0.56	-6.7	-0.35	8.94e-11	Blood pressure (smoking interaction);
CRC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.41	6.24	0.33	1.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7487075	1.000	rs7976280	chr12:46800825	G/A	cg22049899	chr12:47219821	SLC38A4	0.33	6.53	0.34	2.53e-10	Itch intensity from mosquito bite;
CRC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.0	-0.31	5.31e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	trans	rs16957091	0.528	rs72713795	chr15:43141628	T/A	cg07673103	chr8:74277181	NA	0.55	6.0	0.31	5.09e-9	MGMT methylation in smokers;
CRC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-5.93	-0.31	7.5e-9	Menarche (age at onset);
CRC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.6	9.09	0.45	9.84e-18	Schizophrenia;
CRC	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg16950941	chr11:66035639	RAB1B	-0.55	-7.35	-0.38	1.56e-12	Electroencephalogram traits;
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.7	7.81	0.4	7.99e-14	Body mass index;
CRC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.93	0.36	2.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.64	-10.53	-0.5	1.56e-22	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs926938	0.783	rs10858053	chr1:115297374	A/G	cg12756093	chr1:115239321	AMPD1	-0.7	-10.81	-0.51	1.61e-23	Autism;
CRC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.04	15.42	0.65	9.52e-41	Lymphocyte percentage of white cells;
CRC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02619805	chr19:5623015	SAFB2;SAFB	0.51	7.14	0.37	6e-12	Anxiety disorder;
CRC	cis	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-6.2	-0.32	1.67e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.71	11.01	0.52	3.26e-24	Corneal astigmatism;
CRC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.35	-0.53	2.04e-25	Hemoglobin concentration;
CRC	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.49	8.88	0.44	4.51e-17	Migraine;
CRC	trans	rs12495832	0.778	rs79133147	chr3:147934169	A/T	cg10221266	chr7:153579447	NA	0.53	6.0	0.31	5.26e-9	Chin dimples;
CRC	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg23254163	chr1:152506842	NA	0.45	8.87	0.44	4.86e-17	Hair morphology;
CRC	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.55	8.03	0.41	1.69e-14	Sudden cardiac arrest;
CRC	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.44	-5.83	-0.31	1.33e-8	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-8.14	-0.41	8.48e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Parkinson's disease;
CRC	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.53	-7.4	-0.38	1.15e-12	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.66	12.41	0.56	2.91e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2072510	0.643	rs2367755	chr12:96393082	T/C	cg22491680	chr12:96389547	HAL	-0.49	-7.08	-0.36	8.97e-12	Metabolite levels (small molecules and protein measures);
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-7.92	-0.4	3.68e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg10729496	chr3:10149963	C3orf24	0.45	6.13	0.32	2.57e-9	Alzheimer's disease;
CRC	cis	rs653465	0.709	rs1609978	chr3:27203626	G/A	cg02860705	chr3:27208620	NA	-0.39	-6.04	-0.32	4.15e-9	Breast cancer (early onset);
CRC	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg10802521	chr3:52805072	NEK4	0.44	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.86	-0.31	1.11e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg05132306	chr1:1846340	CALML6	-0.46	-7.18	-0.37	4.58e-12	Body mass index;
CRC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.95	-0.36	2.01e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.41	-0.33	5.15e-10	Bipolar disorder;
CRC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg00769240	chr8:12517080	NA	-0.57	-6.69	-0.35	9.86e-11	Blood pressure (smoking interaction);
CRC	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	8.64	0.43	2.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.5	8.1	0.41	1.11e-14	Testicular germ cell tumor;
CRC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.93	17.28	0.69	4.48e-48	Intelligence (multi-trait analysis);
CRC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.48	-6.65	-0.34	1.22e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7216064	1.000	rs62084210	chr17:65828710	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-7.76	-0.39	1.06e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06700265	chr12:12715028	DUSP16	0.42	5.98	0.31	5.88e-9	Response to antipsychotic treatment;
CRC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.73	0.43	1.3e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg15786705	chr6:28176104	NA	0.58	8.21	0.41	5.23e-15	Cardiac Troponin-T levels;
CRC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	9.57	0.47	2.57e-19	Hip circumference adjusted for BMI;
CRC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg17633681	chr16:88106987	BANP	0.8	13.72	0.6	3.32e-34	Menopause (age at onset);
CRC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg10978503	chr1:24200527	CNR2	0.51	9.04	0.45	1.39e-17	Immature fraction of reticulocytes;
CRC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.12	-0.32	2.69e-9	Arsenic metabolism;
CRC	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg26182253	chr13:112236782	NA	0.31	6.3	0.33	9.74e-10	Hepatitis;
CRC	cis	rs7259376	0.905	rs11879791	chr19:22536939	A/G	cg02657401	chr19:22469223	NA	-0.33	-7.44	-0.38	8.57e-13	Menopause (age at onset);
CRC	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg12855166	chr17:30846586	MYO1D	-0.35	-5.67	-0.3	3.14e-8	Schizophrenia;
CRC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-8.72	-0.43	1.41e-16	Depression;
CRC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	15.11	0.64	1.57e-39	Mean platelet volume;
CRC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-9.5	-0.46	4.43e-19	Chronic sinus infection;
CRC	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.69	-9.63	-0.47	1.72e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs995000	0.931	rs636497	chr1:62920029	A/G	cg19896129	chr1:63156450	NA	0.44	6.78	0.35	5.59e-11	Triglyceride levels;
CRC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-5.91	-0.31	8.62e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.81	0.61	1.49e-34	Alzheimer's disease;
CRC	cis	rs9292777	0.720	rs1545334	chr5:40430118	C/T	cg09067459	chr5:40385259	NA	-0.49	-8.06	-0.41	1.47e-14	Crohn's disease;Multiple sclerosis;
CRC	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg07424746	chr4:185654737	MLF1IP	-0.57	-5.7	-0.3	2.66e-8	Blood protein levels;
CRC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.62	9.61	0.47	1.92e-19	Blood metabolite levels;
CRC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.29	-0.46	2.16e-18	Type 2 diabetes;
CRC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.76	-0.3	1.94e-8	Total body bone mineral density;
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg09877947	chr5:131593287	PDLIM4	0.43	7.14	0.37	5.93e-12	Breast cancer;
CRC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.53	9.07	0.45	1.14e-17	Common traits (Other);
CRC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	7.23	0.37	3.49e-12	Mood instability;
CRC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.26e-13	Schizophrenia;
CRC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg22110888	chr17:80059540	CCDC57	0.41	6.47	0.34	3.51e-10	Life satisfaction;
CRC	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.62	-0.3	4.15e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg17903999	chr18:56338584	MALT1	0.42	7.06	0.36	9.77e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.21	-0.32	1.61e-9	Daytime sleep phenotypes;
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	trans	rs28411352	0.922	rs12118489	chr1:38247673	T/G	cg19525872	chr12:130934808	RIMBP2	-0.4	-6.01	-0.31	5.04e-9	Rheumatoid arthritis;
CRC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-6.66	-0.34	1.15e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg23683012	chr15:78369302	TBC1D2B	0.49	6.28	0.33	1.07e-9	Breast cancer;
CRC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	7.39	0.38	1.23e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg18240653	chr6:144019428	PHACTR2	-0.56	-6.15	-0.32	2.23e-9	Obesity-related traits;
CRC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg05044414	chr3:183734942	ABCC5	0.47	8.2	0.41	5.57e-15	Anterior chamber depth;
CRC	cis	rs12745968	0.589	rs6682801	chr1:93074541	C/T	cg17283838	chr1:93427260	FAM69A	-0.49	-6.6	-0.34	1.62e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9925964	0.933	rs8050894	chr16:31104509	C/G	cg02466173	chr16:30829666	NA	0.4	5.61	0.3	4.4e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg07274523	chr3:49395745	GPX1	0.48	6.45	0.33	4.06e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	8.06	0.41	1.45e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3751196	0.708	rs7485127	chr12:104207864	C/T	cg02344784	chr12:104178138	NT5DC3	0.7	7.12	0.37	6.87e-12	Sense of smell;
CRC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.43	-6.77	-0.35	5.94e-11	Migraine;Coronary artery disease;
CRC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.63	7.25	0.37	2.94e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg27535305	chr1:53392650	SCP2	0.33	6.15	0.32	2.25e-9	Monocyte count;
CRC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-1.03	-20.89	-0.76	2.86e-62	Headache;
CRC	cis	rs12983728	0.572	rs59114323	chr19:58649994	C/T	cg08687515	chr19:58661962	ZNF329	0.51	6.32	0.33	8.56e-10	Cholesterol, total;
CRC	trans	rs12495832	0.778	rs6793965	chr3:147938200	A/C	cg10221266	chr7:153579447	NA	0.54	6.14	0.32	2.41e-9	Chin dimples;
CRC	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-1.05	-11.97	-0.55	1.18e-27	Blood protein levels;
CRC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.56	-6.68	-0.35	1.05e-10	Body mass index;
CRC	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.54	8.62	0.43	2.84e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg21251018	chr6:28226885	NKAPL	0.47	6.23	0.33	1.39e-9	Depression;
CRC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg03013999	chr17:37608204	MED1	-0.48	-7.42	-0.38	9.94e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs501916	1.000	rs3743276	chr15:48055119	C/T	cg16110827	chr15:48056943	SEMA6D	0.35	6.0	0.31	5.06e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg07699608	chr10:75541558	CHCHD1	0.61	6.37	0.33	6.53e-10	Incident atrial fibrillation;
CRC	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.98	0.44	2.17e-17	Coffee consumption (cups per day);
CRC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.91	-15.96	-0.66	7.54e-43	Cognitive function;
CRC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.61	10.33	0.49	7.72e-22	Resting heart rate;
CRC	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.55	8.47	0.42	8.11e-16	Lewy body disease;
CRC	cis	rs2030114	0.583	rs7195329	chr16:51590733	G/A	cg03758633	chr16:51611768	NA	0.35	5.84	0.31	1.28e-8	Blood pressure measurement (high sodium and potassium intervention);
CRC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.35	0.53	2.02e-25	Bone mineral density;
CRC	trans	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.79	-0.35	5.11e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.34	-5.74	-0.3	2.12e-8	Personality dimensions;
CRC	trans	rs13079221	0.614	rs172429	chr3:14905513	T/G	cg18308285	chr17:7942551	ALOX15B	0.42	6.12	0.32	2.66e-9	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.26	0.41	3.56e-15	Menopause (age at onset);
CRC	cis	rs12431939	0.857	rs4547259	chr14:51669224	T/G	cg23942311	chr14:51606299	NA	0.49	6.73	0.35	7.53e-11	Cancer;
CRC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.48	9.32	0.46	1.75e-18	Renal cell carcinoma;
CRC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.51	-7.51	-0.38	5.8e-13	Longevity;
CRC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.58	9.82	0.48	3.93e-20	Menopause (age at onset);
CRC	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.67	-0.35	1.1e-10	Multiple sclerosis;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.46	-7.88	-0.4	4.7e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	1.03	18.15	0.71	1.69e-51	Parkinson's disease;
CRC	cis	rs9292777	0.933	rs6879489	chr5:40425190	T/G	cg09067459	chr5:40385259	NA	0.53	9.25	0.45	3.02e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.56	8.16	0.41	7.26e-15	Lung cancer;
CRC	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.38	-11.53	-0.54	4.7e-26	Psoriasis vulgaris;
CRC	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.96	-0.4	2.9e-14	Homocysteine levels;
CRC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.8	14.02	0.61	2.36e-35	Breast cancer;
CRC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg15147215	chr3:52552868	STAB1	-0.44	-6.48	-0.34	3.28e-10	Schizophrenia;
CRC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.3	-0.71	4.41e-52	Height;
CRC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg09473613	chr1:24152604	HMGCL	-0.36	-6.16	-0.32	2.1e-9	Immature fraction of reticulocytes;
CRC	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.92	-0.36	2.36e-11	Inflammatory skin disease;
CRC	cis	rs11212617	1.000	rs11212617	chr11:108283161	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.3	0.33	9.79e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-5.99	-0.31	5.54e-9	Metabolite levels;
CRC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.39	-6.57	-0.34	1.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg12963866	chr19:57752005	ZNF805	-0.43	-6.32	-0.33	8.31e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg03623178	chr6:28175578	NA	0.72	7.24	0.37	3.29e-12	Parkinson's disease;
CRC	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.73	0.35	7.64e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg08075719	chr14:103021372	NA	0.6	6.65	0.34	1.19e-10	Platelet count;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg21251018	chr6:28226885	NKAPL	0.51	5.95	0.31	6.9e-9	Depression;
CRC	cis	rs243505	0.528	rs1558419	chr7:148480233	C/T	cg09806900	chr7:148480153	CUL1	0.56	8.45	0.42	9.87e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.09	-12.53	-0.57	1.06e-29	Diabetic kidney disease;
CRC	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg09904177	chr6:26538194	HMGN4	-0.44	-6.18	-0.32	1.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg23920097	chr1:209922102	NA	-0.5	-6.39	-0.33	5.6e-10	Red blood cell count;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.31	-0.37	2e-12	Bipolar disorder;
CRC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.55	0.54	3.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.4	6.46	0.34	3.72e-10	Breast cancer;
CRC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.8	14.21	0.62	4.48e-36	Breast cancer;
CRC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.43	1.09e-16	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21156815	chr8:22526736	BIN3	0.4	6.79	0.35	5.33e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg18375707	chr11:64034959	PLCB3	0.48	5.96	0.31	6.38e-9	Mean platelet volume;
CRC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	17.32	0.69	3.19e-48	Electrocardiographic conduction measures;
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.53	-9.46	-0.46	5.88e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg20243544	chr17:37824526	PNMT	0.42	6.6	0.34	1.69e-10	Self-reported allergy;
CRC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.76	-11.42	-0.53	1.15e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7626444	0.625	rs9877495	chr3:196483280	G/A	cg12930392	chr3:196481615	PAK2	0.39	7.11	0.36	7.25e-12	Monocyte count;
CRC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg01483505	chr11:975446	AP2A2	0.42	6.83	0.35	4.14e-11	Alzheimer's disease (late onset);
CRC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.44	-8.12	-0.41	9.71e-15	Reticulocyte fraction of red cells;
CRC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11645453	chr3:52864694	ITIH4	0.39	6.64	0.34	1.26e-10	Bipolar disorder;
CRC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg05623727	chr3:50126028	RBM5	0.46	7.58	0.39	3.49e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.53	-8.71	-0.43	1.51e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg05623727	chr3:50126028	RBM5	-0.43	-7.31	-0.37	2.04e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.36	-0.33	6.75e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00429477	chr12:6798907	ZNF384	0.45	7.0	0.36	1.4e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg11070056	chr1:107600091	PRMT6	-0.37	-5.61	-0.3	4.31e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.04	-0.36	1.11e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.48	-9.57	-0.47	2.72e-19	Prostate cancer;
CRC	cis	rs4658101	0.906	rs1192404	chr1:92068967	A/G	cg24006770	chr1:92056542	NA	0.5	5.77	0.3	1.87e-8	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	8.87	0.44	4.87e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg08222913	chr3:52553049	STAB1	-0.36	-7.11	-0.37	7.12e-12	Bipolar disorder;
CRC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-5.71	-0.3	2.52e-8	Total cholesterol levels;
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.49	6.79	0.35	5.28e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6743376	0.556	rs2515396	chr2:113819175	G/A	cg09040174	chr2:113837401	NA	0.44	6.5	0.34	3.01e-10	Inflammatory biomarkers;
CRC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.76	7.13	0.37	6.24e-12	Type 2 diabetes;
CRC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg02007433	chr3:129722099	NA	-0.46	-6.3	-0.33	9.67e-10	Blood pressure (smoking interaction);
CRC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.5	-6.85	-0.35	3.68e-11	Dental caries;
CRC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.1	-12.86	-0.58	6.13e-31	Diabetic kidney disease;
CRC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.97	-0.31	6.07e-9	Aortic root size;
CRC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.54	0.47	3.36e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-7.88	-0.4	4.97e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg03395651	chr16:88107091	BANP	0.58	7.63	0.39	2.6e-13	Menopause (age at onset);
CRC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.8	13.89	0.61	7.52e-35	Breast cancer;
CRC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.71	0.35	8.75e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.72	0.39	1.37e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9463078	0.677	rs1886345	chr6:45078266	A/G	cg25276700	chr6:44698697	NA	-0.24	-5.64	-0.3	3.72e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22979080	chr17:4693765	NA	0.41	6.25	0.33	1.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-12.13	-0.56	3.17e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg12516270	chr8:143859308	LYNX1	0.44	7.8	0.4	8.3e-14	Urinary tract infection frequency;
CRC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.56	7.76	0.39	1.11e-13	Gut microbiome composition (summer);
CRC	cis	rs6445967	1.000	rs6777105	chr3:58307644	A/G	cg23715586	chr3:58305044	RPP14	0.35	5.99	0.31	5.37e-9	Platelet count;
CRC	cis	rs2072510	0.569	rs61937880	chr12:96390867	C/A	cg22491680	chr12:96389547	HAL	-0.49	-6.08	-0.32	3.33e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg02683197	chr6:28174875	NA	0.57	7.53	0.38	5.05e-13	Parkinson's disease;
CRC	cis	rs9469913	0.542	rs114863007	chr6:34729158	G/A	cg17674042	chr6:34482479	PACSIN1	-0.89	-7.9	-0.4	4.21e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg03013636	chr16:1946785	NA	0.57	6.56	0.34	2.07e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.41	-0.46	9.07e-19	Body mass index;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg05569086	chr8:143859399	LYNX1	-0.4	-6.33	-0.33	8.02e-10	Urinary tract infection frequency;
CRC	cis	rs863345	0.604	rs12034004	chr1:158463885	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.32	-0.33	8.42e-10	Pneumococcal bacteremia;
CRC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg03233332	chr7:66118400	NA	-0.41	-5.97	-0.31	6.29e-9	Aortic root size;
CRC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg12458913	chr13:53173898	NA	0.77	14.02	0.61	2.45e-35	Lewy body disease;
CRC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg01788221	chr16:89496183	ANKRD11	-0.48	-7.45	-0.38	8.5e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.49	7.44	0.38	8.81e-13	Red blood cell count;
CRC	cis	rs17092148	0.887	rs4911430	chr20:33145404	C/G	cg08999081	chr20:33150536	PIGU	0.51	6.6	0.34	1.66e-10	Neuroticism;
CRC	cis	rs2857891	0.695	rs2346002	chr11:6987741	T/C	cg04053776	chr11:6947353	ZNF215	0.42	6.38	0.33	6.16e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg25193494	chr16:90016004	DEF8	0.52	7.45	0.38	8.56e-13	Squamous cell carcinoma;
CRC	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.13	-0.45	7.34e-18	Rheumatoid arthritis;
CRC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg02683197	chr6:28174875	NA	0.74	7.45	0.38	8.36e-13	Parkinson's disease;
CRC	cis	rs6011002	0.808	rs1291211	chr20:62337622	A/G	cg01176363	chr20:62369445	LIME1	-0.6	-5.71	-0.3	2.49e-8	Dental caries;
CRC	cis	rs4938330	0.608	rs4938358	chr11:117084091	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.0	-0.31	5.31e-9	Blood protein levels;
CRC	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg12183467	chr14:104352244	NA	-0.48	-6.71	-0.35	8.32e-11	Bipolar disorder;
CRC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.61	9.47	0.46	5.44e-19	Corneal astigmatism;
CRC	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.92	0.31	8.01e-9	Height;
CRC	cis	rs12580194	0.593	rs79104523	chr12:55749220	T/C	cg19537932	chr12:55886519	OR6C68	-0.69	-8.95	-0.44	2.63e-17	Cancer;
CRC	cis	rs12612619	0.704	rs6742004	chr2:27309659	A/C	cg00617064	chr2:27272375	NA	-0.37	-6.03	-0.32	4.51e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00338735	chr4:53728038	RASL11B	0.48	6.51	0.34	2.8e-10	Optic nerve measurement (cup area);
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-8.52	-0.43	5.72e-16	Longevity;Endometriosis;
CRC	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.08	0.36	8.66e-12	Mean corpuscular volume;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-5.7	-0.3	2.63e-8	Alzheimer's disease (survival time);
CRC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.59	-9.91	-0.48	2.02e-20	Menopause (age at onset);
CRC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.4	-0.59	5.88e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg07393940	chr7:158741817	NA	-0.51	-7.38	-0.38	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg07393940	chr7:158741817	NA	-0.52	-7.44	-0.38	8.79e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg17903999	chr18:56338584	MALT1	0.41	6.92	0.36	2.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.44	-6.68	-0.35	9.99e-11	Red blood cell count;
CRC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.98	0.52	4.03e-24	Motion sickness;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.65	10.45	0.5	2.82e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.34	-6.25	-0.33	1.27e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.65	-0.43	2.29e-16	Platelet count;
CRC	cis	rs55788414	0.932	rs11649028	chr16:81185326	G/A	cg06400318	chr16:81190750	PKD1L2	0.55	6.75	0.35	6.88e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.55	8.31	0.42	2.49e-15	Schizophrenia;
CRC	cis	rs858239	0.867	rs10250602	chr7:23303701	T/C	cg00469287	chr7:23338798	C7orf30	0.46	5.83	0.31	1.3e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6662572	0.737	rs56301932	chr1:46422086	G/A	cg08644498	chr1:46502608	NA	0.44	6.87	0.35	3.31e-11	Blood protein levels;
CRC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.36	-5.75	-0.3	2.08e-8	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13521891	chr12:95466445	NR2C1	0.45	6.02	0.31	4.67e-9	Thyroid stimulating hormone;
CRC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.58	8.69	0.43	1.72e-16	Cognitive test performance;
CRC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24308560	chr3:49941425	MST1R	-0.47	-7.44	-0.38	9e-13	Intelligence (multi-trait analysis);
CRC	cis	rs73195822	0.667	rs60579973	chr12:111245629	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.65	0.3	3.54e-8	Itch intensity from mosquito bite;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg22638593	chr5:131593259	PDLIM4	0.42	7.87	0.4	5.24e-14	Breast cancer;
CRC	cis	rs6585424	0.925	rs11201964	chr10:81931367	A/G	cg11900509	chr10:81946545	ANXA11	-0.72	-8.84	-0.44	5.72e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs12432203	1.000	rs61987265	chr14:51728808	T/C	cg14592830	chr9:122318704	NA	0.6	6.18	0.32	1.92e-9	Cancer;
CRC	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.51	7.42	0.38	1e-12	Testicular germ cell tumor;
CRC	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.39	-6.08	-0.32	3.38e-9	Type 2 diabetes;
CRC	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.51	-8.59	-0.43	3.5e-16	Crohn's disease;
CRC	cis	rs11650494	0.516	rs117384420	chr17:47505383	G/C	cg08112188	chr17:47440006	ZNF652	0.84	6.89	0.36	2.82e-11	Prostate cancer;
CRC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.8	13.69	0.6	4.46e-34	Menopause (age at onset);
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01171360	chr6:293285	DUSP22	-0.47	-6.67	-0.35	1.09e-10	Menopause (age at onset);
CRC	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.58	8.1	0.41	1.08e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-7.86	-0.4	5.7e-14	Gut microbiome composition (summer);
CRC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	13.1	0.59	7.85e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.99	0.31	5.41e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.94	-0.48	1.53e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs9463078	0.804	rs9395086	chr6:45225331	T/A	cg25276700	chr6:44698697	NA	-0.27	-6.52	-0.34	2.68e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg18827107	chr12:86230957	RASSF9	-0.39	-6.31	-0.33	8.89e-10	Major depressive disorder;
CRC	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.52	-0.34	2.58e-10	Coronary artery calcification;
CRC	cis	rs3736485	0.966	rs4774596	chr15:51910975	C/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.38	-0.33	5.97e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg20512303	chr5:131592959	PDLIM4	0.39	6.71	0.35	8.63e-11	Breast cancer;
CRC	cis	rs4362	0.902	rs4325	chr17:61563200	G/T	cg21881537	chr17:61574411	ACE	0.34	5.87	0.31	1.09e-8	Blood metabolite levels;
CRC	cis	rs6076065	0.723	rs6132604	chr20:23342226	G/A	cg11657817	chr20:23433608	CST11	0.44	6.55	0.34	2.26e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.46	-7.33	-0.37	1.74e-12	Schizophrenia;
CRC	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-7.24	-0.37	3.22e-12	Response to antipsychotic treatment;
CRC	cis	rs185694	1.000	rs202101	chr13:30897337	A/G	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.22	-0.32	1.48e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.97	-0.31	6.15e-9	Metabolite levels;
CRC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.07	0.45	1.07e-17	Alzheimer's disease;
CRC	cis	rs3018066	0.698	rs10027207	chr4:107083779	T/C	cg01869342	chr4:106983673	TBCK	0.37	5.74	0.3	2.15e-8	Cancer;
CRC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.48	8.02	0.4	1.9e-14	Major depressive disorder;
CRC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-9.38	-0.46	1.1e-18	Coronary artery disease;
CRC	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.61	9.83	0.48	3.62e-20	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.62	-10.1	-0.49	4.71e-21	Corneal structure;
CRC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.9	11.59	0.54	2.74e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24308560	chr3:49941425	MST1R	0.43	6.82	0.35	4.25e-11	Body mass index;
CRC	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	0.62	9.83	0.48	3.57e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.36	-5.96	-0.31	6.38e-9	Lymphocyte counts;
CRC	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.46	-7.14	-0.37	6.1e-12	Testicular germ cell tumor;
CRC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.76	0.39	1.07e-13	Cognitive ability;
CRC	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.31	-6.3	-0.33	9.47e-10	Cutaneous nevi;
CRC	trans	rs2303319	0.504	rs57464189	chr2:162419312	G/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs12922317	0.538	rs446289	chr16:12070486	T/G	cg02368508	chr16:12060182	TNFRSF17	-0.44	-6.96	-0.36	1.81e-11	Schizophrenia;
CRC	trans	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg17903999	chr18:56338584	MALT1	-0.43	-7.11	-0.36	7.25e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.73	-12.65	-0.57	3.59e-30	Ulcerative colitis;
CRC	trans	rs17730929	0.659	rs1033095	chr4:67232011	A/G	cg05901279	chr12:42979568	PRICKLE1	-0.52	-5.99	-0.31	5.55e-9	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.2	-0.37	4.17e-12	Glycated hemoglobin levels;
CRC	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg26741380	chr15:41871084	TYRO3	-0.46	-6.54	-0.34	2.4e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19626725	chr5:178986131	RUFY1	0.36	6.4	0.33	5.45e-10	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08117032	chr8:38325144	FGFR1	0.33	6.53	0.34	2.52e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.2	-0.37	4.03e-12	Tuberculosis;
CRC	cis	rs10743315	0.778	rs965861	chr12:19360719	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.63	-7.93	-0.4	3.37e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg04110750	chr16:69646130	NFAT5	-0.52	-6.83	-0.35	4.06e-11	IgE levels;
CRC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-0.58	-8.43	-0.42	1.11e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.66	9.44	0.46	7.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6585424	1.000	rs3851055	chr10:81938096	T/C	cg11900509	chr10:81946545	ANXA11	-0.72	-8.86	-0.44	5.08e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg22153745	chr1:153894579	GATAD2B	-0.62	-9.5	-0.46	4.44e-19	Total cholesterol levels;
CRC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.81e-10	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.65	7.74	0.39	1.22e-13	Bipolar disorder;
CRC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	6.85	0.35	3.64e-11	Obesity-related traits;
CRC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg13722127	chr7:150037890	RARRES2	0.47	7.63	0.39	2.48e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.55	6.86	0.35	3.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.44	6.46	0.34	3.82e-10	Asthma;
CRC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.66	-0.34	1.14e-10	Reticulocyte fraction of red cells;
CRC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.05	-0.66	3.08e-43	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg00246817	chr9:123691163	NA	-0.45	-5.75	-0.3	2.04e-8	Rheumatoid arthritis;
CRC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.37	-0.33	6.23e-10	Height;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.72	-7.88	-0.4	4.8e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21959181	chr7:150755243	CDK5;SLC4A2	0.43	7.66	0.39	2.12e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.67	-0.3	3.07e-8	Inflammatory bowel disease;
CRC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.44e-14	Menopause (age at onset);
CRC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs2302729	0.578	rs10848682	chr12:2771756	C/G	cg19945202	chr12:2788847	CACNA1C	-0.43	-6.93	-0.36	2.28e-11	Sleep quality;
CRC	trans	rs17033702	0.560	rs1607904	chr2:67757780	G/T	cg11936311	chr5:178957434	NA	-0.31	-6.0	-0.31	5.14e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg11887960	chr12:57824829	NA	0.59	6.52	0.34	2.61e-10	Obesity-related traits;
CRC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.74	-11.92	-0.55	1.85e-27	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2108622	0.727	rs3093216	chr19:15987737	A/G	cg13772218	chr19:15982569	NA	0.48	6.75	0.35	6.72e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.69	11.69	0.54	1.24e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.81	13.63	0.6	7.36e-34	Menopause (age at onset);
CRC	trans	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg24644049	chr4:85504048	CDS1	0.87	7.12	0.37	7.01e-12	Skin colour saturation;
CRC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.63	9.54	0.47	3.34e-19	Blood protein levels;
CRC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	7.9e-11	Colorectal cancer;
CRC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.06	0.52	2.12e-24	Bone mineral density;
CRC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.31	-0.79	1.24e-71	Myeloid white cell count;
CRC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.01e-12	Headache;
CRC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.45	6.58	0.34	1.83e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.53	8.64	0.43	2.55e-16	Breast cancer;
CRC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-6.44	-0.33	4.27e-10	Arsenic metabolism;
CRC	cis	rs231513	0.911	rs231515	chr17:41964083	A/G	cg26893861	chr17:41843967	DUSP3	-0.65	-6.57	-0.34	1.94e-10	Cognitive function;
CRC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.36	6.93	0.36	2.23e-11	Renal cell carcinoma;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg22561889	chr6:118971681	C6orf204	0.5	6.43	0.33	4.49e-10	Diastolic blood pressure;
CRC	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.37	6.37	0.33	6.37e-10	Airway imaging phenotypes;
CRC	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg17182837	chr8:41585554	ANK1	-0.36	-5.68	-0.3	2.89e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg05623727	chr3:50126028	RBM5	-0.46	-7.83	-0.4	6.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.01	-0.31	4.96e-9	Blood protein levels;
CRC	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	0.77	7.72	0.39	1.42e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs4731207	0.591	rs1481336	chr7:124696739	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg07478791	chr1:31886160	SERINC2	-0.4	-5.64	-0.3	3.76e-8	Alcohol dependence;
CRC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.46	7.06	0.36	9.99e-12	Red blood cell count;
CRC	cis	rs1712517	0.740	rs4917387	chr10:105108455	T/C	cg05636881	chr10:105038444	INA	0.47	8.05	0.41	1.53e-14	Migraine;
CRC	cis	rs243505	0.660	rs243488	chr7:148446649	G/A	cg09806900	chr7:148480153	CUL1	-0.6	-7.47	-0.38	7.52e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07701084	chr6:150067640	NUP43	0.49	7.17	0.37	4.95e-12	Testicular germ cell tumor;
CRC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.7	-0.39	1.58e-13	Colorectal cancer;
CRC	cis	rs10242455	0.702	rs74416635	chr7:99180569	G/A	cg18809830	chr7:99032528	PTCD1	-1.2	-8.67	-0.43	1.94e-16	Blood metabolite levels;
CRC	cis	rs294883	0.858	rs6932095	chr6:159720458	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.76	-0.3	1.95e-8	Coronary artery disease;
CRC	cis	rs3764400	0.567	rs12600980	chr17:46187141	C/T	cg10706073	chr17:46328419	SKAP1	0.61	6.62	0.34	1.44e-10	Body mass index;
CRC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.5	-8.12	-0.41	9.41e-15	Huntington's disease progression;
CRC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.68	-0.3	2.98e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.52	5.8	0.3	1.58e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs243505	0.732	rs10255478	chr7:148501985	C/G	cg09806900	chr7:148480153	CUL1	0.52	7.45	0.38	8.26e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.49e-8	Total body bone mineral density;
CRC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg21625146	chr5:486483	SLC9A3	-0.37	-5.69	-0.3	2.77e-8	Cystic fibrosis severity;
CRC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg25767906	chr1:53392781	SCP2	0.42	6.66	0.34	1.15e-10	Monocyte count;
CRC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg26162295	chr17:38119207	GSDMA	-0.36	-6.54	-0.34	2.4e-10	Asthma and hay fever;
CRC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04731861	chr2:219085781	ARPC2	0.33	6.95	0.36	2.01e-11	Colorectal cancer;
CRC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.72	-0.35	8.06e-11	Schizophrenia;
CRC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.53	0.43	5.37e-16	Menopause (age at onset);
CRC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg07424746	chr4:185654737	MLF1IP	0.61	6.07	0.32	3.48e-9	Blood protein levels;
CRC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.51	6.78	0.35	5.45e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.58	8.42	0.42	1.19e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	1.12	10.64	0.51	6.59e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.49	-0.34	3.08e-10	Bipolar disorder;
CRC	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	cg04338863	chr8:33670619	NA	0.41	6.18	0.32	1.86e-9	Body mass index;
CRC	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.16	-0.32	2.15e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.97	13.91	0.61	6.76e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6662572	1.000	rs72688452	chr1:46092365	G/A	cg08644498	chr1:46502608	NA	0.45	6.6	0.34	1.68e-10	Blood protein levels;
CRC	cis	rs3849570	0.533	rs6548782	chr3:81993287	T/G	cg07356753	chr3:81810745	GBE1	-0.48	-6.4	-0.33	5.35e-10	Waist circumference;Body mass index;
CRC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.54	-6.58	-0.34	1.81e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.67	6.81	0.35	4.59e-11	Axial length;
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg04727332	chr7:45960243	IGFBP3	0.36	5.65	0.3	3.46e-8	Sitting height ratio;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.79	-12.07	-0.55	5.09e-28	Intelligence (multi-trait analysis);
CRC	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg00042356	chr1:8021962	PARK7	0.56	6.89	0.35	2.92e-11	Inflammatory bowel disease;
CRC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.81	12.39	0.56	3.3600000000000003e-29	Cognitive function;
CRC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.72	-9.7	-0.47	9.79e-20	Blood pressure (smoking interaction);
CRC	cis	rs4654899	0.802	rs12137203	chr1:21109088	T/A	cg02927042	chr1:21476669	EIF4G3	-0.44	-6.89	-0.36	2.87e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.61	8.38	0.42	1.54e-15	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19752117	chr17:4850710	PFN1	0.53	7.51	0.38	5.54e-13	Response to antipsychotic treatment;
CRC	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.62	-8.74	-0.43	1.21e-16	Coronary artery disease;
CRC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06544989	chr22:39130855	UNC84B	0.45	6.83	0.35	4.13e-11	Menopause (age at onset);
CRC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.37	5.61	0.3	4.29e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.59	9.97	0.48	1.27e-20	Schizophrenia;
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.36	-7.65	-0.39	2.17e-13	Menopause (age at onset);
CRC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg19812747	chr11:111475976	SIK2	-0.56	-9.35	-0.46	1.41e-18	Primary sclerosing cholangitis;
CRC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg24505167	chr7:1915268	MAD1L1	-0.4	-5.81	-0.3	1.51e-8	Neuroticism;
CRC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.58	-0.47	2.55e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.61	0.6	9.15e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6921919	0.848	rs9468350	chr6:28319107	A/G	cg21251018	chr6:28226885	NKAPL	0.42	6.22	0.32	1.55e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg12658694	chr1:38397304	INPP5B	-0.59	-7.95	-0.4	2.92e-14	Coronary artery disease;
CRC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	6.53	0.34	2.55e-10	Platelet count;
CRC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.44	-8.05	-0.41	1.56e-14	Reticulocyte fraction of red cells;
CRC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.51	-7.12	-0.37	6.72e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.85	9.81	0.48	4.4e-20	Psoriasis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06076054	chr21:19191045	C21orf91	0.48	6.82	0.35	4.42e-11	Response to antipsychotic treatment;
CRC	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.59	7.8	0.4	8.21e-14	Mammographic density (dense area);
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg26587870	chr6:27730563	NA	-0.42	-6.27	-0.33	1.16e-9	Parkinson's disease;
CRC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.56	7.25	0.37	2.98e-12	Menopause (age at onset);
CRC	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.79	0.3	1.63e-8	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg13556452	chr1:2391241	NA	-0.36	-5.75	-0.3	2.08e-8	Non-obstructive azoospermia;
CRC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.47	6.81	0.35	4.78e-11	HIV-1 control;
CRC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.93	-0.36	2.24e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg13072238	chr3:49761600	GMPPB	0.56	6.07	0.32	3.43e-9	Menarche (age at onset);
CRC	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.41	6.82	0.35	4.3e-11	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.39	0.46	1e-18	Alzheimer's disease;
CRC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg23565292	chr14:50234668	KLHDC2	-0.44	-6.21	-0.32	1.57e-9	Carotid intima media thickness;
CRC	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg03690763	chr11:133734501	NA	-0.36	-5.97	-0.31	6.21e-9	Childhood ear infection;
CRC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg25804541	chr17:80189381	SLC16A3	0.3	5.68	0.3	3.02e-8	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13338022	chr15:43029438	CDAN1	0.46	6.56	0.34	2.05e-10	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.47	-0.34	3.53e-10	Total body bone mineral density;
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg13880726	chr7:1868755	MAD1L1	-0.46	-5.63	-0.3	3.89e-8	Bipolar disorder;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg25224543	chr5:52405696	MOCS2	0.4	6.04	0.32	4.14e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20848390	chr8:59465780	SDCBP	0.47	6.73	0.35	7.48e-11	Anxiety disorder;
CRC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.88	-0.44	4.55e-17	Monocyte count;
CRC	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-5.94	-0.31	7.37e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4731207	0.698	rs4731222	chr7:124481635	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7113874	0.589	rs11041944	chr11:8500996	G/A	cg17679104	chr11:8615758	STK33	0.35	5.83	0.31	1.33e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11252337	chr19:2273843	NA	0.45	6.21	0.32	1.63e-9	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg02683197	chr6:28174875	NA	-0.66	-7.2	-0.37	4.16e-12	Parkinson's disease;
CRC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	0.37	6.2	0.32	1.72e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14895029	chr7:2775587	GNA12	-0.43	-6.2	-0.32	1.72e-9	Height;
CRC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.44	-6.68	-0.35	1.02e-10	Bone mineral density;
CRC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.73	9.32	0.46	1.71e-18	Behavioural disinhibition (generation interaction);
CRC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.4	-7.63	-0.39	2.53e-13	Mean corpuscular volume;
CRC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.59	9.88	0.48	2.43e-20	Calcium levels;
CRC	cis	rs1572438	1.000	rs873559	chr6:875336	G/A	cg13447295	chr6:887704	NA	0.44	6.25	0.33	1.25e-9	Aging;
CRC	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	5.6	0.3	4.47e-8	Breast cancer;
CRC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	10.97	0.52	4.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg19325359	chr11:85955589	EED	0.43	6.12	0.32	2.64e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.64	8.24	0.41	4.16e-15	Bipolar disorder;
CRC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.94	-16.8	-0.68	3.46e-46	Cognitive function;
CRC	cis	rs6460942	0.730	rs7780477	chr7:12233750	G/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.78	-0.35	5.44e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.78	13.98	0.61	3.45e-35	Mean platelet volume;
CRC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg23298862	chr7:158159286	PTPRN2	0.39	6.16	0.32	2.1e-9	Calcium levels;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs995000	0.931	rs998403	chr1:62928549	G/A	cg19896129	chr1:63156450	NA	0.4	5.91	0.31	8.41e-9	Triglyceride levels;
CRC	cis	rs12024301	0.557	rs114086623	chr1:183648626	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.49	6.76	0.35	6.12e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.08e-38	Intelligence (multi-trait analysis);
CRC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg00246817	chr9:123691163	NA	-0.47	-5.9	-0.31	9.04e-9	Rheumatoid arthritis;
CRC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.62	7.15	0.37	5.6e-12	Vitiligo;
CRC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg20608306	chr11:116969690	SIK3	0.33	6.88	0.35	3.07e-11	Blood protein levels;
CRC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.46	6.52	0.34	2.6e-10	Cognitive ability;
CRC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.97	11.62	0.54	2.17e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.37	-6.15	-0.32	2.19e-9	Mean arterial pressure;
CRC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.13	0.41	8.85e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.53	7.46	0.38	7.87e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.52	-8.43	-0.42	1.13e-15	Blood pressure (smoking interaction);
CRC	cis	rs17162190	0.698	rs12086684	chr1:26837067	C/A	cg17456097	chr1:26900765	RPS6KA1	0.42	6.18	0.32	1.94e-9	Mean corpuscular volume;
CRC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.22	-0.32	1.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.83	-0.35	4.16e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg24884572	chr19:58661833	ZNF329	0.75	8.23	0.41	4.52e-15	Cholesterol, total;
CRC	cis	rs990171	1.000	rs1420106	chr2:103035044	C/T	cg03938978	chr2:103052716	IL18RAP	-0.43	-5.61	-0.3	4.3e-8	Lymphocyte counts;
CRC	cis	rs847649	0.692	rs6949391	chr7:102446863	C/T	cg18108683	chr7:102477205	FBXL13	-0.67	-11.29	-0.53	3.37e-25	Morning vs. evening chronotype;
CRC	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.06	0.32	3.64e-9	Morning vs. evening chronotype;
CRC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.97	-0.31	6.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.63	-0.34	1.39e-10	Inflammatory skin disease;
CRC	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg00105475	chr2:10696890	NA	0.45	7.12	0.37	6.81e-12	Prostate cancer;
CRC	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg15654264	chr1:150340011	RPRD2	0.37	5.67	0.3	3.11e-8	Migraine;
CRC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg02741985	chr17:80059408	CCDC57	0.44	7.33	0.37	1.76e-12	Life satisfaction;
CRC	cis	rs67385638	0.862	rs11036641	chr11:5310578	A/G	cg21506790	chr11:5277210	HBG2	0.36	5.77	0.3	1.85e-8	Hemoglobin levels;
CRC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg19582491	chr16:67682965	RLTPR	-0.58	-6.92	-0.36	2.32e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.38	6.37	0.33	6.36e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg23018236	chr17:30244563	NA	-0.67	-8.11	-0.41	9.97e-15	Hip circumference adjusted for BMI;
CRC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.68	-8.9	-0.44	3.69e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10089324	chr1:51984752	EPS15	0.51	6.66	0.34	1.13e-10	Thyroid stimulating hormone;
CRC	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.58	-8.72	-0.43	1.38e-16	Bone mineral density;
CRC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.59	10.24	0.49	1.58e-21	Schizophrenia;
CRC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg03948781	chr1:205179583	DSTYK	0.42	5.85	0.31	1.2e-8	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.59	-9.16	-0.45	5.83e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.42	-0.33	4.72e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.61	9.55	0.47	3.06e-19	Corneal astigmatism;
CRC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.89	-14.16	-0.62	7.2e-36	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.09	0.45	9.59e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs6738825	0.606	rs10931784	chr2:198405636	T/A	cg10820045	chr2:198174542	NA	0.34	6.08	0.32	3.36e-9	Crohn's disease;
CRC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.43	6.48	0.34	3.33e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.43	6.11	0.32	2.74e-9	Cystic fibrosis severity;
CRC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.65	7.86	0.4	5.53e-14	Cleft lip with or without cleft palate;
CRC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.74	10.16	0.49	2.75e-21	Cognitive function;
CRC	cis	rs939584	1.000	rs13396935	chr2:653195	G/A	cg03610516	chr2:642275	NA	-0.42	-5.78	-0.3	1.75e-8	Body mass index;
CRC	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-5.92	-0.31	8.16e-9	Vitamin D levels;
CRC	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.7	8.33	0.42	2.21e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23721301	chr10:112064230	SMNDC1	0.4	6.5	0.34	2.95e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.36	-5.83	-0.31	1.3e-8	Schizophrenia;
CRC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-13.43	-0.59	4.45e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.17e-8	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03274021	chr8:130952480	FAM49B	0.47	6.04	0.32	4.24e-9	Thyroid stimulating hormone;
CRC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.91	17.31	0.69	3.38e-48	Blood protein levels;
CRC	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-8.55	-0.43	4.56e-16	Plateletcrit;Platelet count;
CRC	cis	rs12101261	0.580	rs3783949	chr14:81448382	A/C	cg06600135	chr14:81408086	NA	0.4	5.93	0.31	7.69e-9	Graves' disease;
CRC	cis	rs12760731	0.582	rs6700741	chr1:178566386	C/T	cg00404053	chr1:178313656	RASAL2	0.56	6.81	0.35	4.69e-11	Obesity-related traits;
CRC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg21475434	chr5:93447410	FAM172A	-0.49	-6.16	-0.32	2.1e-9	Diabetic retinopathy;
CRC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04476341	chr5:669733	TPPP	-0.42	-6.87	-0.35	3.14e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs3540	0.960	rs6496675	chr15:90982756	C/T	cg04176472	chr15:90893244	GABARAPL3	0.37	6.48	0.34	3.42e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg22638593	chr5:131593259	PDLIM4	0.35	6.39	0.33	5.71e-10	Blood metabolite levels;
CRC	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg17133734	chr15:86042851	AKAP13	0.39	6.31	0.33	9.23e-10	Interstitial lung disease;
CRC	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	1.04	12.45	0.57	2.04e-29	Diisocyanate-induced asthma;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.19	-0.53	7.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10489849	0.730	rs72713603	chr1:159231430	T/C	cg11166453	chr1:247681781	NA	-0.39	-6.04	-0.32	4.22e-9	Select biomarker traits;
CRC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs4700695	0.764	rs27701	chr5:65377526	G/C	cg21114390	chr5:65439923	SFRS12	-0.48	-6.15	-0.32	2.19e-9	Facial morphology (factor 19);
CRC	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-1.0	-10.54	-0.5	1.39e-22	Post bronchodilator FEV1;
CRC	cis	rs17443541	0.507	rs4675697	chr2:200450808	C/T	cg03741458	chr2:200468445	NA	-0.38	-6.11	-0.32	2.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.53e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.45	7.35	0.38	1.62e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg00166722	chr3:10149974	C3orf24	0.68	7.84	0.4	6.29e-14	Alzheimer's disease;
CRC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg12193833	chr17:30244370	NA	-0.62	-7.94	-0.4	3.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg19773385	chr1:10388646	KIF1B	-0.47	-7.45	-0.38	8.53e-13	Hepatocellular carcinoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12199425	chr5:90676154	LOC100129716;ARRDC3	0.42	6.07	0.32	3.46e-9	Anxiety disorder;
CRC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-7.95	-0.4	2.95e-14	Chronic sinus infection;
CRC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.67	-11.37	-0.53	1.7e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.95	-0.36	1.95e-11	Menopause (age at onset);
CRC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-0.92	-17.94	-0.7	1.17e-50	Myeloid white cell count;
CRC	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg08800497	chr19:1970008	CSNK1G2	0.58	9.13	0.45	7.36e-18	Coronary artery disease;
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.21e-15	Bipolar disorder;
CRC	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.48	-0.38	7.04e-13	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.46	-5.97	-0.31	6.22e-9	Heschl's gyrus morphology;
CRC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.48	-6.22	-0.32	1.49e-9	Obesity-related traits;
CRC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-6.3	-0.33	9.35e-10	Daytime sleep phenotypes;
CRC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.53	8.9	0.44	3.75e-17	Schizophrenia;
CRC	cis	rs9525927	0.570	rs9533797	chr13:44799368	A/C	cg19190762	chr13:44806055	NA	0.52	6.63	0.34	1.34e-10	Dupuytren's disease;
CRC	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.12	9.41	0.46	8.98e-19	Mitochondrial DNA levels;
CRC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg13777783	chr17:79615861	NA	-0.3	-5.64	-0.3	3.71e-8	Eye color traits;
CRC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg26893134	chr6:116381904	FRK	0.27	7.73	0.39	1.33e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.47	7.13	0.37	6.6e-12	Testicular germ cell tumor;
CRC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg10589385	chr1:150898437	SETDB1	0.34	7.05	0.36	1.03e-11	Melanoma;
CRC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.88	0.4	4.83e-14	Diabetic retinopathy;
CRC	cis	rs883565	0.569	rs784508	chr3:39166484	C/T	cg01426195	chr3:39028469	NA	0.42	6.99	0.36	1.56e-11	Handedness;
CRC	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.11	-0.56	3.76e-28	Coffee consumption (cups per day);
CRC	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.61	-9.31	-0.46	1.92e-18	Height;
CRC	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.51	13.4	0.59	5.67e-33	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.59	-9.95	-0.48	1.46e-20	Birth weight;
CRC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.67	-0.39	1.98e-13	Alzheimer's disease;
CRC	cis	rs55702914	0.628	rs67657812	chr2:198387401	A/G	cg10820045	chr2:198174542	NA	0.34	5.96	0.31	6.6e-9	Major depression and alcohol dependence;
CRC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs6694672	1.000	rs1412633	chr1:197027220	C/G	cg13682187	chr1:196946512	CFHR5	0.49	7.59	0.39	3.24e-13	Asthma;
CRC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.51	8.29	0.42	2.97e-15	Coronary artery disease;
CRC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg00343986	chr7:65444356	GUSB	0.42	5.74	0.3	2.19e-8	Calcium levels;
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg20041105	chr8:143859282	LYNX1	0.44	7.93	0.4	3.35e-14	Urinary tract infection frequency;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.65	-12.98	-0.58	2.15e-31	Electroencephalogram traits;
CRC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg19812747	chr11:111475976	SIK2	-0.53	-8.81	-0.44	7.59e-17	Primary sclerosing cholangitis;
CRC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.93	0.36	2.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.6	8.52	0.43	5.95e-16	Arsenic metabolism;
CRC	cis	rs6540556	0.608	rs2064148	chr1:209909385	C/T	cg23920097	chr1:209922102	NA	0.48	5.99	0.31	5.59e-9	Red blood cell count;
CRC	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.97	0.4	2.65e-14	Breast cancer;
CRC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.33	-0.33	7.95e-10	Gout;Renal underexcretion gout;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg27615366	chr5:131592974	PDLIM4	0.29	5.63	0.3	3.84e-8	Breast cancer;
CRC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg08314208	chr16:67682810	RLTPR	-0.64	-6.74	-0.35	6.97e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4478858	0.684	rs3753374	chr1:31740668	C/T	cg00250761	chr1:31883323	NA	-0.4	-7.65	-0.39	2.23e-13	Alcohol dependence;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10471644	chr12:6976491	TPI1	0.4	6.15	0.32	2.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.56	7.9	0.4	4.29e-14	Arsenic metabolism;
CRC	cis	rs4728302	0.869	rs6467510	chr7:133607968	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.76	0.3	1.97e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.07	-14.34	-0.62	1.5e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6694672	0.764	rs6669113	chr1:197143279	A/C	cg13682187	chr1:196946512	CFHR5	0.46	7.25	0.37	3.09e-12	Asthma;
CRC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.16	-16.92	-0.68	1.22e-46	Hip circumference adjusted for BMI;
CRC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	11.0	0.52	3.53e-24	Personality dimensions;
CRC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.94	0.31	7.23e-9	Homoarginine levels;
CRC	cis	rs728616	0.867	rs17606361	chr10:81845411	G/C	cg11900509	chr10:81946545	ANXA11	-0.56	-5.83	-0.31	1.3e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9469890	0.591	rs11754773	chr6:34577257	A/G	cg14254433	chr6:34482411	PACSIN1	-0.73	-6.49	-0.34	3.14e-10	Pubertal anthropometrics;Coronary artery disease;
CRC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.88	-0.4	4.83e-14	Neuroticism;
CRC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.17	0.37	5.1e-12	Motion sickness;
CRC	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	1.1	11.79	0.54	5.31e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.04	-0.41	1.65e-14	Height;
CRC	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg15485101	chr11:133734466	NA	0.42	7.16	0.37	5.36e-12	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00859112	chr14:99736559	BCL11B	0.43	6.29	0.33	1.01e-9	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.18e-13	Motion sickness;
CRC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.8	-13.28	-0.59	1.64e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11212617	0.967	rs396552	chr11:108221483	G/C	cg01991180	chr11:108092276	ATM;NPAT	0.42	5.97	0.31	6.15e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7215564	0.908	rs35103651	chr17:78666732	T/C	cg09596252	chr17:78655493	RPTOR	0.57	6.16	0.32	2.08e-9	Myopia (pathological);
CRC	cis	rs6681460	1.000	rs6670378	chr1:67126585	C/T	cg02459107	chr1:67143332	SGIP1	0.47	8.26	0.41	3.48e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs9649465	0.967	rs2402666	chr7:123285478	A/T	cg03229431	chr7:123269106	ASB15	-0.4	-6.1	-0.32	2.97e-9	Migraine;
CRC	cis	rs9533799	0.559	rs9533796	chr13:44790446	C/G	cg19190762	chr13:44806055	NA	0.43	5.74	0.3	2.1e-8	Amyotrophic lateral sclerosis;
CRC	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.5	7.28	0.37	2.48e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.29e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.96	-0.4	2.9e-14	Homocysteine levels;
CRC	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg22495460	chr2:25135724	ADCY3	-0.88	-15.15	-0.64	1.04e-39	Body mass index;
CRC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.94	17.01	0.68	5.56e-47	Cognitive ability;
CRC	cis	rs6952808	0.724	rs7792631	chr7:1982779	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-10.7	-0.51	3.88e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.53	-7.37	-0.38	1.42e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg02527881	chr3:46936655	PTH1R	0.41	7.28	0.37	2.45e-12	Colorectal cancer;
CRC	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.73	9.28	0.46	2.3e-18	Iron status biomarkers;
CRC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.66	9.28	0.46	2.32e-18	Vitamin D levels;
CRC	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.66	-9.01	-0.44	1.73e-17	Body mass index;
CRC	trans	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg01314568	chr7:57830625	NA	-0.68	-9.2	-0.45	4.16e-18	Obesity-related traits;
CRC	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.98	-0.36	1.63e-11	Multiple sclerosis;
CRC	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg08501292	chr6:25962987	TRIM38	1.12	10.69	0.51	4.27e-23	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6496667	0.738	rs62020723	chr15:90971738	G/C	cg04176472	chr15:90893244	GABARAPL3	0.6	8.33	0.42	2.21e-15	Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20166106	chr17:78120787	EIF4A3	0.46	6.47	0.34	3.51e-10	Anxiety disorder;
CRC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.79	14.28	0.62	2.55e-36	Anterior chamber depth;
CRC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg08075719	chr14:103021372	NA	-0.7	-9.58	-0.47	2.53e-19	Platelet count;
CRC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26240231	chr7:1148101	C7orf50	-0.41	-5.92	-0.31	8.1e-9	Bronchopulmonary dysplasia;
CRC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.7	-9.11	-0.45	8.53e-18	Initial pursuit acceleration;
CRC	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg23920097	chr1:209922102	NA	-0.53	-6.53	-0.34	2.51e-10	Red blood cell count;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.56	-0.38	3.99e-13	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23068124	chr14:58711505	PSMA3	0.5	6.48	0.34	3.34e-10	Thyroid stimulating hormone;
CRC	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg23260525	chr10:116636907	FAM160B1	0.32	6.29	0.33	1.01e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01174859	chr7:128379317	CALU	0.41	6.61	0.34	1.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23708337	chr7:1209742	NA	0.51	7.78	0.39	9.18e-14	Longevity;Endometriosis;
CRC	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg18232548	chr7:50535776	DDC	-0.46	-6.62	-0.34	1.43e-10	Malaria;
CRC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.49	-9.26	-0.45	2.75e-18	Reticulocyte fraction of red cells;
CRC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.0	-0.31	5.06e-9	Morning vs. evening chronotype;
CRC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg25600027	chr14:23388339	RBM23	-0.52	-8.06	-0.41	1.47e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Melanoma;
CRC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg17775713	chr3:133465469	TF	-0.37	-6.92	-0.36	2.42e-11	Iron status biomarkers;
CRC	cis	rs6694672	0.850	rs3891964	chr1:197066074	C/T	cg13682187	chr1:196946512	CFHR5	-0.43	-6.87	-0.35	3.31e-11	Asthma;
CRC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg21132104	chr15:45694354	SPATA5L1	0.42	6.1	0.32	2.96e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs3812762	0.871	rs11042068	chr11:8815599	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.07	-0.32	3.57e-9	Hypospadias;
CRC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.1	0.56	3.85e-28	Hip circumference adjusted for BMI;
CRC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-19.44	-0.73	1.39e-56	Hemostatic factors and hematological phenotypes;
CRC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.53	6.77	0.35	5.85e-11	Morning vs. evening chronotype;
CRC	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg13385794	chr1:248469461	NA	0.4	7.1	0.36	7.96e-12	Common traits (Other);
CRC	cis	rs3018066	0.867	rs7673101	chr4:107095505	T/C	cg01869342	chr4:106983673	TBCK	0.37	5.7	0.3	2.6e-8	Cancer;
CRC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.63	-8.2	-0.41	5.31e-15	Body mass index;
CRC	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.63	11.4	0.53	1.33e-25	Blood metabolite ratios;
CRC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.53	-8.41	-0.42	1.23e-15	Corneal astigmatism;
CRC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.57	8.41	0.42	1.29e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.46	0.6	3.24e-33	Vitiligo;
CRC	cis	rs62458065	0.850	rs7785659	chr7:32461015	C/T	cg20159608	chr7:32802032	NA	-0.54	-6.64	-0.34	1.26e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.45	5.72	0.3	2.39e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.46	5.89	0.31	9.7e-9	HDL cholesterol;
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	0.78	8.78	0.44	9.3e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	7.96	0.4	2.84e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.41	-0.33	4.96e-10	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.53	-7.51	-0.38	5.47e-13	Coronary artery disease;
CRC	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg02820901	chr13:113351484	ATP11A	0.6	6.6	0.34	1.62e-10	Glycated hemoglobin levels;
CRC	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.62	7.83	0.4	6.88e-14	Red blood cell traits;
CRC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.64	-0.34	1.32e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg26587870	chr6:27730563	NA	-0.37	-5.64	-0.3	3.62e-8	Cardiac Troponin-T levels;
CRC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.27	-0.37	2.62e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs10991814	0.920	rs78181783	chr9:94032205	C/T	cg14446406	chr9:93919335	NA	0.55	5.95	0.31	7.05e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.66	9.0	0.44	1.83e-17	Multiple sclerosis;
CRC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	5.91	0.31	8.63e-9	Renal function-related traits (BUN);
CRC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-10.71	-0.51	3.69e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg23234261	chr14:55582407	NA	-0.29	-5.78	-0.3	1.75e-8	Protein biomarker;
CRC	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg17120908	chr11:65337727	SSSCA1	-0.69	-7.61	-0.39	2.89e-13	Bone mineral density;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.67	-7.55	-0.38	4.36e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.95	10.47	0.5	2.45e-22	Eosinophil percentage of granulocytes;
CRC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.68	-10.9	-0.52	7.79e-24	Motion sickness;
CRC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.53	5.85	0.31	1.17e-8	Initial pursuit acceleration;
CRC	cis	rs11233250	0.502	rs12422030	chr11:82405529	A/G	cg17391194	chr11:82401662	NA	0.42	6.34	0.33	7.61e-10	Glioblastoma;Glioma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19898230	chr1:37980216	MEAF6	0.45	6.35	0.33	7.03e-10	Anxiety disorder;
CRC	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg13856295	chr9:139396418	NOTCH1	-0.43	-5.7	-0.3	2.6e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.64	8.46	0.42	8.61e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-7.91	-0.4	4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.5	6.59	0.34	1.73e-10	Height;
CRC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.51	0.34	2.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4594175	0.926	rs10149006	chr14:51615265	A/C	cg23942311	chr14:51606299	NA	0.65	10.48	0.5	2.33e-22	Cancer;
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg05084668	chr3:125655381	ALG1L	-0.47	-6.92	-0.36	2.41e-11	Blood pressure (smoking interaction);
CRC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg16558177	chr4:4109446	NA	-0.49	-5.97	-0.31	6.09e-9	Blood pressure (smoking interaction);
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg14329157	chr2:228736135	WDR69	0.46	6.31	0.33	9.17e-10	Blood pressure;
CRC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.58	-0.47	2.56e-19	Heart rate;
CRC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.41	5.75	0.3	2e-8	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-10.28	-0.49	1.12e-21	Brugada syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09920427	chr19:12777674	MORG1;MAN2B1	0.54	7.85	0.4	5.84e-14	Response to antipsychotic treatment;
CRC	cis	rs10178094	0.669	rs7595982	chr2:161332385	T/G	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.07	-0.32	3.61e-9	White blood cell count;
CRC	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.58	-9.4	-0.46	9.51e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg00086871	chr4:6988644	TBC1D14	1.03	7.79	0.39	8.6e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg03316587	chr8:142245164	NA	-0.4	-6.04	-0.32	4.16e-9	Immature fraction of reticulocytes;
CRC	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.44	-6.19	-0.32	1.75e-9	Blood metabolite levels;
CRC	cis	rs61160187	0.582	rs12652830	chr5:60252482	A/G	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.74	-0.3	2.13e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.06	0.32	3.81e-9	Aortic root size;
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18099408	chr3:52552593	STAB1	-0.49	-8.35	-0.42	1.96e-15	Bipolar disorder;
CRC	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.11	0.32	2.83e-9	Neuroticism;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg18402987	chr7:1209562	NA	-0.43	-6.4	-0.33	5.46e-10	Longevity;Endometriosis;
CRC	cis	rs4731207	0.596	rs6957525	chr7:124656377	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg04497992	chr16:616212	NHLRC4	0.39	6.06	0.32	3.68e-9	Height;
CRC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.71	-9.11	-0.45	8.07e-18	Initial pursuit acceleration;
CRC	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg12458913	chr13:53173898	NA	-0.4	-6.0	-0.31	5.18e-9	Lewy body disease;
CRC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.4	-6.59	-0.34	1.75e-10	Blood metabolite levels;
CRC	trans	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.84	0.35	3.98e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3736485	0.934	rs2414106	chr15:51868741	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.63	-0.34	1.41e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7626444	0.625	rs2686599	chr3:196483794	G/A	cg12930392	chr3:196481615	PAK2	0.39	7.11	0.36	7.25e-12	Monocyte count;
CRC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.43	8.72	0.43	1.36e-16	Renal cell carcinoma;
CRC	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.44	6.62	0.34	1.5e-10	HDL cholesterol;
CRC	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.53	-0.71	5.39e-53	Schizophrenia;
CRC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.09	0.55	4.21e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs8108034	0.920	rs30480	chr19:39807213	A/G	cg09325174	chr14:50154983	POLE2	-0.5	-6.0	-0.31	5.31e-9	Lung adenocarcinoma;
CRC	cis	rs73200209	0.789	rs74420242	chr12:116551289	A/T	cg01776926	chr12:116560359	MED13L	-0.62	-7.27	-0.37	2.7e-12	Total body bone mineral density;
CRC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.67	8.28	0.42	3.04e-15	Cognitive test performance;
CRC	cis	rs3789045	0.560	rs1107339	chr1:204411942	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.82	-10.9	-0.52	7.79e-24	Educational attainment (college completion);
CRC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg07274523	chr3:49395745	GPX1	0.47	5.98	0.31	5.79e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14868726	chr18:2571660	METTL4;NDC80	0.49	6.61	0.34	1.53e-10	Thyroid stimulating hormone;
CRC	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-7.22	-0.37	3.7e-12	Electroencephalogram traits;
CRC	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.86	-0.31	1.14e-8	Height;
CRC	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.64	-8.05	-0.41	1.53e-14	Coronary artery disease;
CRC	trans	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg21153622	chr11:89784906	NA	-0.47	-7.6	-0.39	3.01e-13	HDL cholesterol;
CRC	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.52	8.25	0.41	3.78e-15	Metabolite levels (MHPG);
CRC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.65	-0.51	5.95e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg06092702	chr1:163392909	NA	-0.54	-8.5	-0.42	6.64e-16	Motion sickness;
CRC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Melanoma;
CRC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg10978503	chr1:24200527	CNR2	-0.51	-8.85	-0.44	5.3e-17	Immature fraction of reticulocytes;
CRC	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.53	-8.52	-0.43	5.96e-16	Schizophrenia;
CRC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.51	7.41	0.38	1.07e-12	Type 2 diabetes;
CRC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	7.29	0.37	2.33e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.48	-6.91	-0.36	2.47e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs17095355	1.000	rs921351	chr10:111704715	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.97	-0.4	2.62e-14	Biliary atresia;
CRC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.54	7.96	0.4	2.81e-14	Lung cancer;
CRC	trans	rs4714291	0.832	rs1524087	chr6:40057504	A/G	cg02267698	chr19:7991119	CTXN1	-0.51	-7.04	-0.36	1.14e-11	Strep throat;
CRC	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.6	9.98	0.48	1.12e-20	Mean corpuscular volume;
CRC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg05552183	chr6:42928497	GNMT	0.47	6.57	0.34	1.92e-10	Blood protein levels;
CRC	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.89	15.38	0.65	1.4e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.54	7.7	0.39	1.63e-13	Mean platelet volume;
CRC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.36	5.7	0.3	2.73e-8	Ulcerative colitis;
CRC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.81	-0.44	7.46e-17	Aortic root size;
CRC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-7.47	-0.38	7.27e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.31	-0.42	2.57e-15	Gut microbiome composition (summer);
CRC	cis	rs1322512	1.000	rs2758782	chr6:153010341	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg24274428	chr6:13328569	TBC1D7	-0.44	-6.48	-0.34	3.28e-10	Daytime sleep phenotypes;
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.48	5.87	0.31	1.08e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-10.2	-0.49	2.14e-21	Mean platelet volume;
CRC	cis	rs995000	0.931	rs10889349	chr1:63081919	A/G	cg19896129	chr1:63156450	NA	0.42	6.57	0.34	1.98e-10	Triglyceride levels;
CRC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.5	0.65	4.65e-41	Platelet count;
CRC	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.66	9.29	0.46	2.13e-18	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07671174	chr3:58224051	ABHD6	0.52	6.78	0.35	5.62e-11	Anxiety disorder;
CRC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg15440763	chr7:158190612	PTPRN2	0.47	7.43	0.38	9.45e-13	Obesity-related traits;
CRC	cis	rs1178968	1.000	rs757938	chr7:72778573	A/G	cg25889504	chr7:72793014	NA	0.49	5.83	0.31	1.32e-8	Triglyceride levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11543725	chr11:10329292	NA	0.36	6.08	0.32	3.25e-9	Obesity-related traits;
CRC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg13057898	chr1:3703894	LRRC47	0.52	6.85	0.35	3.61e-11	Red cell distribution width;
CRC	cis	rs12024301	0.557	rs61040652	chr1:183642153	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg06156847	chr2:113672199	IL1F7	-0.4	-5.98	-0.31	5.91e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20307385	chr11:47447363	PSMC3	-0.5	-6.64	-0.34	1.29e-10	Subjective well-being;
CRC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.65	-8.69	-0.43	1.71e-16	Urate levels in lean individuals;
CRC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg17133734	chr15:86042851	AKAP13	0.43	6.88	0.35	2.94e-11	Coronary artery disease;
CRC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.4	-6.02	-0.31	4.72e-9	Vitiligo;
CRC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.06	-0.32	3.77e-9	Mean corpuscular volume;
CRC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.52	5.82	0.31	1.4e-8	Vitiligo;
CRC	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.18	0.49	2.53e-21	Asthma;
CRC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.25	-0.33	1.3e-9	Colorectal cancer;
CRC	cis	rs755249	0.567	rs61783376	chr1:39769000	T/C	cg18385671	chr1:39797026	MACF1	-0.42	-5.98	-0.31	5.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08393086	chr7:100081535	C7orf51	0.39	6.23	0.32	1.45e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg26367366	chr8:4980734	NA	0.49	6.22	0.32	1.49e-9	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.42	6.71	0.35	8.32e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg12855166	chr17:30846586	MYO1D	-0.37	-6.01	-0.31	4.87e-9	Schizophrenia;
CRC	trans	rs6693295	0.729	rs10802325	chr1:246213454	C/A	cg03680032	chr11:94965610	SESN3	0.53	6.57	0.34	2e-10	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.77	11.24	0.53	4.96e-25	High light scatter reticulocyte count;
CRC	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.27	0.37	2.6e-12	Eye color traits;
CRC	cis	rs863345	0.604	rs10797012	chr1:158465485	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.11	-0.32	2.86e-9	Pneumococcal bacteremia;
CRC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.76	-0.3	1.93e-8	Lung cancer;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.4	-5.72	-0.3	2.45e-8	Longevity;Endometriosis;
CRC	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg25804541	chr17:80189381	SLC16A3	-0.32	-5.98	-0.31	5.67e-9	Life satisfaction;
CRC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-8.1	-0.41	1.12e-14	Hemoglobin concentration;
CRC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	15.45	0.65	7.14e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-5.67	-0.3	3.11e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.54	-6.65	-0.34	1.21e-10	Obesity (extreme);
CRC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.64	-10.66	-0.51	5.7e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.39	-5.61	-0.3	4.2e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CRC	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.59	0.34	1.78e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16266895	chr12:101674004	UTP20	0.44	6.23	0.32	1.44e-9	Response to antipsychotic treatment;
CRC	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.43	6.37	0.33	6.44e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg00531865	chr16:30841666	NA	-0.44	-6.36	-0.33	6.82e-10	Dementia with Lewy bodies;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02725872	chr8:58115012	NA	-0.54	-7.8	-0.4	8.17e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs16975963	0.843	rs73041047	chr19:38299289	T/C	cg15135657	chr19:38346511	NA	-0.45	-5.91	-0.31	8.61e-9	Longevity;
CRC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.79	-10.66	-0.51	5.31e-23	Initial pursuit acceleration;
CRC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg16141378	chr3:129829833	LOC729375	0.43	6.7	0.35	8.97e-11	Neuroticism;
CRC	cis	rs16867335	0.652	rs1528439	chr2:181462035	C/T	cg23363182	chr2:181467187	NA	-0.52	-8.37	-0.42	1.64e-15	Survival in rectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16118817	chr19:4792497	FEM1A	0.33	5.99	0.31	5.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg07865391	chr16:88106882	BANP	0.45	5.95	0.31	6.92e-9	Menopause (age at onset);
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.82	-0.35	4.49e-11	Blood metabolite levels;
CRC	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.21	31.22	0.86	2.14e-100	Colorectal cancer;
CRC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.73	-12.7	-0.57	2.45e-30	Body mass index;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.65	-9.34	-0.46	1.55e-18	Obesity-related traits;
CRC	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Tonsillectomy;
CRC	cis	rs11030122	0.632	rs7925954	chr11:3982746	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-6.89	-0.35	2.92e-11	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.55	-7.14	-0.37	5.91e-12	Alzheimer's disease (survival time);
CRC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg21466736	chr12:48725269	NA	0.47	7.15	0.37	5.57e-12	Glycated hemoglobin levels;
CRC	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.51	7.72	0.39	1.4e-13	Testicular germ cell tumor;
CRC	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.94	-0.36	2.07e-11	Multiple myeloma (hyperdiploidy);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26534993	chr2:3291401	TSSC1	-0.47	-6.19	-0.32	1.83e-9	Hip circumference;
CRC	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg23100626	chr2:96804247	ASTL	0.27	7.07	0.36	9.2e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-8.39	-0.42	1.5e-15	Monocyte count;
CRC	trans	rs8089364	0.917	rs35476226	chr18:57885593	C/G	cg05871254	chr17:14213225	HS3ST3B1	-0.45	-6.45	-0.34	4.07e-10	Type 2 diabetes;Body mass index;
CRC	cis	rs16852403	0.517	rs7531227	chr1:178232469	C/T	cg00404053	chr1:178313656	RASAL2	0.49	6.18	0.32	1.88e-9	Childhood ear infection;
CRC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.83	-0.35	4.18e-11	Bladder cancer;
CRC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg23815491	chr16:72088622	HP	0.5	7.6	0.39	3.09e-13	Fibrinogen levels;
CRC	cis	rs9400239	0.584	rs1268179	chr6:109017237	G/C	cg11073813	chr6:109029018	NA	-0.38	-5.84	-0.31	1.23e-8	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.75	-0.35	6.61e-11	Inflammatory skin disease;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg04518342	chr5:131593106	PDLIM4	-0.36	-6.53	-0.34	2.54e-10	Breast cancer;
CRC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	7.43	0.38	9.24e-13	Hemoglobin concentration;
CRC	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21215323	chr15:41220556	DLL4	0.52	7.63	0.39	2.57e-13	Response to antipsychotic treatment;
CRC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg05729581	chr11:3078854	CARS	-0.4	-5.72	-0.3	2.44e-8	Longevity;
CRC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.48	7.41	0.38	1.05e-12	Monobrow;
CRC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg06935464	chr4:38784597	TLR10	0.55	5.66	0.3	3.27e-8	Breast cancer;
CRC	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.63	9.8	0.48	4.51e-20	Corneal astigmatism;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg05698098	chr11:61595494	FADS2	-0.42	-5.73	-0.3	2.3e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.62	14.01	0.61	2.8e-35	Airflow obstruction;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg06470822	chr6:28175283	NA	0.8	12.0	0.55	9.26e-28	Parkinson's disease;
CRC	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg02023728	chr11:77925099	USP35	-0.36	-6.07	-0.32	3.53e-9	Alzheimer's disease (survival time);
CRC	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg20194872	chr6:41519635	FOXP4	0.4	5.89	0.31	9.33e-9	Prostate cancer;
CRC	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.64	-0.39	2.46e-13	Caudate activity during reward;
CRC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.7	8.37	0.42	1.65e-15	Diabetic retinopathy;
CRC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg23461800	chr14:103021989	NA	0.64	6.94	0.36	2.11e-11	Platelet count;
CRC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.6	-7.72	-0.39	1.43e-13	Dilated cardiomyopathy;
CRC	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06307176	chr5:131281290	NA	0.43	6.28	0.33	1.05e-9	Life satisfaction;
CRC	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.59	6.83	0.35	4.23e-11	Neutrophil percentage of white cells;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02018176	chr4:1364513	KIAA1530	0.39	6.56	0.34	2.07e-10	Obesity-related traits;
CRC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg02428538	chr16:24856791	SLC5A11	-0.54	-6.3	-0.33	9.54e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-7.37	-0.38	1.43e-12	Menarche (age at onset);
CRC	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.76	-0.3	1.98e-8	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.6	6.38	0.33	5.99e-10	Initial pursuit acceleration;
CRC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.72	6.11	0.32	2.88e-9	Putamen volume;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg26608667	chr7:1196370	ZFAND2A	0.44	7.16	0.37	5.41e-12	Longevity;Endometriosis;
CRC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.36	-5.78	-0.3	1.76e-8	Ulcerative colitis;
CRC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg17467752	chr17:38218738	THRA	-0.37	-5.65	-0.3	3.39e-8	Self-reported allergy;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.47	-6.5	-0.34	2.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.22e-22	Chronic sinus infection;
CRC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg13390004	chr1:15929781	NA	0.5	6.88	0.35	3.01e-11	Systolic blood pressure;
CRC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg14541582	chr5:601475	NA	-0.35	-7.25	-0.37	3.02e-12	Obesity-related traits;
CRC	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-8.25	-0.41	3.81e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg21153622	chr11:89784906	NA	-0.37	-6.0	-0.31	5.06e-9	Coronary artery disease;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07506689	chr16:72459978	NA	0.48	6.0	0.31	5.07e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.46	-7.21	-0.37	3.86e-12	Asthma;
CRC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	8.02	0.4	1.87e-14	Total body bone mineral density;
CRC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg03623178	chr6:28175578	NA	0.53	7.8	0.4	8.33e-14	Pubertal anthropometrics;
CRC	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg06581033	chr10:766294	NA	-0.48	-5.76	-0.3	1.94e-8	Uric acid levels;
CRC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg15358701	chr1:161410459	NA	-0.62	-6.63	-0.34	1.39e-10	Rheumatoid arthritis;
CRC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-17.13	-0.69	1.81e-47	Intelligence (multi-trait analysis);
CRC	trans	rs596169	0.541	rs73111535	chr1:219222850	C/A	cg09853702	chr12:47665230	NA	0.82	6.36	0.33	6.59e-10	Intraocular pressure;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23708337	chr7:1209742	NA	0.44	6.52	0.34	2.6e-10	Longevity;Endometriosis;
CRC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg21115004	chr1:67520352	SLC35D1	-0.4	-5.8	-0.3	1.54e-8	Lymphocyte percentage of white cells;
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.31	-0.46	1.84e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-0.65	-11.45	-0.53	8.72e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.33	-5.68	-0.3	2.96e-8	Menarche (age at onset);
CRC	cis	rs4728302	0.869	rs7805864	chr7:133610390	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.73	0.3	2.22e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg05698098	chr11:61595494	FADS2	-0.42	-5.71	-0.3	2.52e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.54	12.03	0.55	7.34e-28	Alcohol dependence;
CRC	cis	rs9311676	0.609	rs62258133	chr3:58398318	C/G	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.51	6.96	0.36	1.82e-11	Morning vs. evening chronotype;
CRC	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg21155852	chr7:2048760	MAD1L1	-0.43	-5.74	-0.3	2.13e-8	Neuroticism;
CRC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.42	6.26	0.33	1.2e-9	Platelet distribution width;
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.21	-0.41	5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.94	-0.31	7.39e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.6	0.43	3.35e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.5	-9.42	-0.46	8.42e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg26721908	chr21:47610096	LSS	0.45	7.39	0.38	1.21e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00309650	chr4:88312547	HSD17B11	0.43	6.34	0.33	7.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg13092806	chr2:177043255	NA	0.8	12.86	0.58	5.95e-31	IgG glycosylation;
CRC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20887711	chr4:1340912	KIAA1530	-0.45	-6.48	-0.34	3.37e-10	Obesity-related traits;
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.78	11.68	0.54	1.36e-26	Menarche (age at onset);
CRC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	7.57	0.39	3.86e-13	Height;
CRC	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	6.71	0.35	8.75e-11	Menarche (age at onset);
CRC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-14.88	-0.63	1.21e-38	Prostate cancer;
CRC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.45	-5.74	-0.3	2.2e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg03934865	chr2:198174659	NA	-0.47	-7.33	-0.37	1.76e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00612595	chr21:47717864	NA	0.41	6.62	0.34	1.44e-10	Testicular germ cell tumor;
CRC	cis	rs3804749	0.966	rs3792378	chr3:122845077	G/A	cg26084141	chr3:122786895	PDIA5	0.23	6.16	0.32	2.16e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.49	-9.22	-0.45	3.54e-18	Reticulocyte fraction of red cells;
CRC	cis	rs7725052	0.609	rs7709690	chr5:40456871	G/A	cg09067459	chr5:40385259	NA	0.39	6.43	0.33	4.42e-10	Pediatric autoimmune diseases;
CRC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19564637	chr14:56584874	PELI2	0.43	6.05	0.32	3.92e-9	Response to antipsychotic treatment;
CRC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.39	-5.84	-0.31	1.27e-8	Breast cancer;
CRC	cis	rs16924133	0.793	rs12292299	chr11:33132499	G/A	cg05567920	chr11:33183001	CSTF3	-0.77	-5.8	-0.3	1.58e-8	Anger;
CRC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.95	-11.96	-0.55	1.32e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg09003973	chr2:102972529	NA	0.4	5.77	0.3	1.81e-8	Blood protein levels;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.27	0.56	9.74e-29	Platelet count;
CRC	cis	rs11212617	0.967	rs4754305	chr11:108075912	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.48	0.34	3.31e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg26918954	chr5:179728553	GFPT2	-0.42	-6.87	-0.35	3.29e-11	Height;
CRC	trans	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.42	7.19	0.37	4.38e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.93	-22.01	-0.77	1.17e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg21251018	chr6:28226885	NKAPL	-0.4	-6.26	-0.33	1.2e-9	Systemic lupus erythematosus;
CRC	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg21169611	chr9:106856078	SMC2	0.42	5.87	0.31	1.06e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.69	7.23	0.37	3.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.8	10.4	0.5	4.33e-22	Initial pursuit acceleration;
CRC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.52	8.1	0.41	1.05e-14	Monocyte count;
CRC	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg04904318	chr17:46607828	HOXB1	-0.53	-6.12	-0.32	2.64e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.74e-11	Common traits (Other);
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.16	-0.49	2.75e-21	Bipolar disorder;
CRC	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.9	0.48	2.11e-20	Ileal carcinoids;
CRC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	0.76	6.12	0.32	2.68e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02725872	chr8:58115012	NA	-0.59	-9.19	-0.45	4.66e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	1.000	rs853679	chr6:28296863	C/A	cg15786705	chr6:28176104	NA	0.55	5.97	0.31	6.08e-9	Depression;
CRC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs3889199	0.924	rs60199046	chr1:59663341	A/G	cg25881383	chr1:59680599	NA	-0.39	-6.23	-0.32	1.41e-9	Pulse pressure;
CRC	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg11693508	chr17:37793320	STARD3	0.64	8.23	0.41	4.39e-15	Bipolar disorder;
CRC	cis	rs728616	0.681	rs35420115	chr10:81908188	A/G	cg11900509	chr10:81946545	ANXA11	-0.74	-8.44	-0.42	1.06e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg11861562	chr11:117069780	TAGLN	0.38	8.08	0.41	1.28e-14	Blood protein levels;
CRC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.5	7.0	0.36	1.44e-11	Inflammatory bowel disease;
CRC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.37	6.52	0.34	2.71e-10	Dilated cardiomyopathy;
CRC	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.12	0.64	1.37e-39	Fuchs's corneal dystrophy;
CRC	cis	rs7705042	0.793	rs7705547	chr5:141514027	A/G	cg07392085	chr5:141489673	NDFIP1	0.45	7.26	0.37	2.75e-12	Asthma;
CRC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg09876464	chr15:85330779	ZNF592	0.45	7.74	0.39	1.2e-13	P wave terminal force;
CRC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-13.14	-0.59	5.28e-32	Bipolar disorder and schizophrenia;
CRC	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.66	-11.54	-0.54	4.24e-26	Brugada syndrome;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg26587870	chr6:27730563	NA	-0.41	-5.64	-0.3	3.61e-8	Parkinson's disease;
CRC	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.66	-10.92	-0.52	6.61e-24	White blood cell count (basophil);
CRC	cis	rs6662572	0.737	rs7552810	chr1:46452823	A/C	cg08644498	chr1:46502608	NA	0.46	7.23	0.37	3.4e-12	Blood protein levels;
CRC	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg20041105	chr8:143859282	LYNX1	-0.32	-5.66	-0.3	3.28e-8	Urinary tract infection frequency;
CRC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.56	-8.45	-0.42	9.87e-16	Cotinine glucuronidation;
CRC	cis	rs863345	0.625	rs950487	chr1:158460130	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24198128	chr19:18682398	UBA52	0.5	6.53	0.34	2.49e-10	Thyroid stimulating hormone;
CRC	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.9	-11.78	-0.54	5.77e-27	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.16	-13.27	-0.59	1.71e-32	Diabetic kidney disease;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg27432699	chr2:27873401	GPN1	-0.49	-7.55	-0.38	4.26e-13	Total body bone mineral density;
CRC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.63	13.69	0.6	4.55e-34	Schizophrenia;
CRC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.07	0.32	3.57e-9	Bladder cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07231102	chr3:19988460	RAB5A	0.4	6.04	0.32	4.23e-9	Intelligence (multi-trait analysis);
CRC	trans	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg20993868	chr7:22813445	NA	0.4	7.79	0.39	8.81e-14	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.39	6.77	0.35	6.06e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg01758942	chr3:52551074	STAB1	0.3	5.94	0.31	7.07e-9	Electroencephalogram traits;
CRC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.73	-0.66	5.59e-42	Intelligence (multi-trait analysis);
CRC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.78	9.05	0.45	1.27e-17	Breast cancer;
CRC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.5	-8.09	-0.41	1.13e-14	Huntington's disease progression;
CRC	cis	rs4731207	0.565	rs7811203	chr7:124653374	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	cis	rs17152411	0.895	rs7086128	chr10:126587373	A/G	cg07906193	chr10:126599966	NA	0.58	6.83	0.35	4.2e-11	Height;
CRC	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg19773385	chr1:10388646	KIF1B	-0.57	-7.88	-0.4	4.99e-14	Hepatocellular carcinoma;
CRC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.58	-7.93	-0.4	3.36e-14	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg17133734	chr15:86042851	AKAP13	0.42	6.6	0.34	1.69e-10	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs28595511	chr1:183661833	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-7.84	-0.4	6.29e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.42	0.33	4.7e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.45	-6.42	-0.33	4.74e-10	Type 2 diabetes;
CRC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg10431340	chr1:161279108	MPZ	-0.52	-6.96	-0.36	1.84e-11	Rheumatoid arthritis;
CRC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.39	5.67	0.3	3.09e-8	Eosinophil percentage of white cells;
CRC	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.48	-5.66	-0.3	3.24e-8	Hip geometry;
CRC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.53e-46	Breast cancer;
CRC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.46	6.62	0.34	1.42e-10	Lymphocyte counts;
CRC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.62	-6.92	-0.36	2.31e-11	Menarche (age at onset);
CRC	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-5.62	-0.3	4e-8	Pulmonary function;
CRC	cis	rs72634258	0.945	rs7517357	chr1:8025275	C/T	cg00042356	chr1:8021962	PARK7	0.69	7.27	0.37	2.7e-12	Inflammatory bowel disease;
CRC	cis	rs6662572	0.737	rs2067635	chr1:46537946	T/G	cg08644498	chr1:46502608	NA	0.45	7.07	0.36	9.62e-12	Blood protein levels;
CRC	cis	rs7215564	0.908	rs35361366	chr17:78684751	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.22e-9	Myopia (pathological);
CRC	cis	rs10512697	0.772	rs34012000	chr5:3536248	T/C	cg19473799	chr5:3511975	NA	-0.78	-6.0	-0.31	5.14e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg22654517	chr2:96458247	NA	0.32	5.72	0.3	2.43e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	9.15	0.45	6.11e-18	Mean corpuscular volume;
CRC	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg08477640	chr19:41863820	B9D2	0.54	7.6	0.39	3.09e-13	Colorectal cancer;
CRC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.73	-9.34	-0.46	1.55e-18	Coronary artery disease;
CRC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg09796270	chr17:17721594	SREBF1	0.39	6.16	0.32	2.09e-9	Total body bone mineral density;
CRC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.44	6.33	0.33	8.09e-10	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.52	7.04	0.36	1.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08293760	chr1:220445750	RAB3GAP2	0.46	6.28	0.33	1.05e-9	Response to antipsychotic treatment;
CRC	cis	rs2486012	1.000	rs1548634	chr1:44399608	T/C	cg12908607	chr1:44402522	ARTN	0.43	5.72	0.3	2.37e-8	Intelligence (multi-trait analysis);
CRC	cis	rs16867335	1.000	rs11887445	chr2:181490442	C/T	cg23363182	chr2:181467187	NA	-0.49	-6.7	-0.35	9.01e-11	Survival in rectal cancer;
CRC	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.67	-0.3	3.21e-8	Migraine;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-9.36	-0.46	1.25e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.32	8.79	0.44	8.42e-17	Blood metabolite levels;
CRC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.62	-10.21	-0.49	1.86e-21	Colorectal cancer;
CRC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-17.32	-0.69	3.07e-48	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.97	0.36	1.69e-11	Diastolic blood pressure;
CRC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg14137381	chr5:502291	SLC9A3	-0.32	-5.63	-0.3	3.91e-8	Cystic fibrosis severity;
CRC	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg04850286	chr10:81895943	PLAC9	0.38	6.72	0.35	7.9e-11	Sarcoidosis;
CRC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg18490616	chr2:88469792	THNSL2	0.58	5.85	0.31	1.22e-8	Plasma clusterin levels;
CRC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	12.02	0.55	7.68e-28	Chronic sinus infection;
CRC	cis	rs7760949	0.963	rs9396248	chr6:13906360	A/G	cg27413430	chr6:13925136	RNF182	0.31	5.65	0.3	3.53e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.74	10.58	0.5	1.03e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs12760731	0.565	rs34593395	chr1:178129488	C/T	cg00404053	chr1:178313656	RASAL2	1.09	11.33	0.53	2.46e-25	Obesity-related traits;
CRC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg04586622	chr2:25135609	ADCY3	-0.56	-10.45	-0.5	2.87e-22	Body mass index;
CRC	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.42	-8.19	-0.41	5.85e-15	Migraine;
CRC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.82	11.68	0.54	1.28e-26	Response to antineoplastic agents;
CRC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.38	-0.33	6.02e-10	Aortic root size;
CRC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-15.22	-0.64	5.49e-40	Lymphocyte percentage of white cells;
CRC	cis	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg05299278	chr17:33885742	SLFN14	-0.4	-6.08	-0.32	3.39e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg27565382	chr3:53032988	SFMBT1	0.7	6.21	0.32	1.63e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	8.07	0.41	1.32e-14	Electrocardiographic conduction measures;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg25164649	chr6:28176230	NA	0.41	5.7	0.3	2.73e-8	Parkinson's disease;
CRC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg05132306	chr1:1846340	CALML6	-0.45	-6.93	-0.36	2.26e-11	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10972625	chr1:143745140	LOC100286793;FLJ39739	-0.45	-6.85	-0.35	3.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6700896	0.897	rs11208696	chr1:66121781	T/G	cg04111102	chr1:66153794	NA	0.34	5.92	0.31	8.22e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg12273811	chr6:28175739	NA	0.6	6.11	0.32	2.84e-9	Lung cancer in ever smokers;
CRC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.72	12.5	0.57	1.35e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.39	-5.93	-0.31	7.7e-9	HDL cholesterol levels;
CRC	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg20885578	chr2:198174922	NA	-0.37	-5.69	-0.3	2.83e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg16141378	chr3:129829833	LOC729375	-0.43	-5.96	-0.31	6.37e-9	Neuroticism;
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg10820045	chr2:198174542	NA	0.39	6.55	0.34	2.2e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05976695	chr10:7860543	TAF3	0.46	6.27	0.33	1.16e-9	Anxiety disorder;
CRC	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.68	-11.18	-0.52	8.34e-25	Hepatocellular carcinoma;
CRC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.76	12.89	0.58	4.89e-31	Total body bone mineral density;
CRC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.79	13.94	0.61	4.99e-35	Metabolic syndrome;
CRC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg25251562	chr2:3704773	ALLC	-0.43	-6.2	-0.32	1.65e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.47	6.44	0.33	4.25e-10	Morning vs. evening chronotype;
CRC	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.77	10.2	0.49	2.03e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.78	11.36	0.53	1.94e-25	Gout;
CRC	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	14.4	0.62	8.33e-37	Lewy body disease;
CRC	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06544989	chr22:39130855	UNC84B	0.47	7.44	0.38	8.98e-13	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	trans	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg17903999	chr18:56338584	MALT1	0.4	6.55	0.34	2.25e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-8.47	-0.42	8.01e-16	Colorectal cancer;
CRC	cis	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg26958806	chr6:27640298	NA	0.85	5.66	0.3	3.23e-8	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.5	5.89	0.31	9.46e-9	Diabetic retinopathy;
CRC	cis	rs9826463	0.757	rs73240310	chr3:142240459	T/C	cg20824294	chr3:142316082	PLS1	0.41	6.89	0.36	2.77e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.48	-6.94	-0.36	2.14e-11	Dementia with Lewy bodies;
CRC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.25	-0.59	2.04e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21028142	chr17:79581711	NPLOC4	0.38	8.32	0.42	2.38e-15	Eye color traits;
CRC	cis	rs2457480	0.516	rs10899992	chr10:44648515	C/T	cg09554077	chr10:44749378	NA	0.46	5.9	0.31	8.85e-9	Coronary artery disease;
CRC	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.49	6.28	0.33	1.06e-9	Exhaled nitric oxide output;
CRC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.88	0.48	2.55e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.28	-0.37	2.52e-12	Inflammatory skin disease;
CRC	cis	rs995000	0.931	rs10889343	chr1:63026429	T/G	cg19896129	chr1:63156450	NA	-0.43	-6.67	-0.35	1.06e-10	Triglyceride levels;
CRC	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.51	6.31	0.33	9.25e-10	Recombination rate (females);
CRC	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-5.87	-0.31	1.09e-8	Daytime sleep phenotypes;
CRC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.68	-11.49	-0.54	6.33e-26	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	17.68	0.7	1.27e-49	Body mass index (adult);
CRC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.7	-10.82	-0.51	1.56e-23	Menopause (age at onset);
CRC	cis	rs55702914	0.712	rs12619296	chr2:198148767	A/G	cg03934865	chr2:198174659	NA	-0.36	-6.29	-0.33	9.91e-10	Major depression and alcohol dependence;
CRC	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.87	16.77	0.68	4.79e-46	Bone mineral density;
CRC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg03623178	chr6:28175578	NA	0.83	6.66	0.34	1.12e-10	Depression;
CRC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.49	-6.15	-0.32	2.26e-9	Vitiligo;
CRC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.56	7.31	0.37	2.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.58	6.68	0.35	1.02e-10	Coronary artery disease;
CRC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.12	0.32	2.71e-9	Personality dimensions;
CRC	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.9	-0.4	4.36e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7487075	0.786	rs59919892	chr12:46712230	A/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.54	0.34	2.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.07	0.32	3.6e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg08075719	chr14:103021372	NA	0.54	6.67	0.35	1.08e-10	Platelet count;
CRC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.47	7.26	0.37	2.85e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs12449964	0.524	rs4925092	chr17:17568931	A/G	cg09796270	chr17:17721594	SREBF1	0.47	8.06	0.41	1.39e-14	Coronary artery disease or ischemic stroke;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.95	12.11	0.56	3.67e-28	IgG glycosylation;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg06243084	chr11:63990629	FERMT3	0.45	7.24	0.37	3.16e-12	Platelet count;
CRC	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.77	0.39	1.02e-13	Coronary heart disease;
CRC	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.81	8.53	0.43	5.43e-16	Gastritis;
CRC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.65	-9.76	-0.47	6.46e-20	Total body bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14671666	chr5:41904456	C5orf51	0.44	6.16	0.32	2.1e-9	Anxiety disorder;
CRC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.41	6.15	0.32	2.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.66	11.81	0.55	4.44e-27	Height;
CRC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.62	-9.01	-0.45	1.67e-17	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.34	-6.05	-0.32	3.84e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	7.1	0.36	7.53e-12	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07555797	chr14:61788314	PRKCH	0.37	6.1	0.32	3.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.45	-7.44	-0.38	9.02e-13	Refractive error;
CRC	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.43	-7.05	-0.36	1.06e-11	Weight;
CRC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.48	6.42	0.33	4.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07976860	chr16:67281332	FHOD1	0.37	6.37	0.33	6.49e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg13490827	chr1:46269305	MAST2	-0.7	-6.28	-0.33	1.09e-9	Cognitive function;
CRC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.41	5.8	0.3	1.57e-8	Red blood cell count;
CRC	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg24130564	chr14:104152367	KLC1	-0.42	-5.66	-0.3	3.36e-8	Reticulocyte count;
CRC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg08200582	chr11:442649	ANO9	-0.7	-7.12	-0.37	6.8e-12	Body mass index;
CRC	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.5	-8.71	-0.43	1.46e-16	Migraine - clinic-based;
CRC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg07809909	chr20:30433512	FOXS1	0.35	5.64	0.3	3.58e-8	Mean corpuscular hemoglobin;
CRC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg24463073	chr6:118973353	C6orf204	0.52	6.85	0.35	3.69e-11	Diastolic blood pressure;
CRC	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg12858261	chr2:113808755	IL1F8	0.46	6.68	0.35	1.02e-10	Protein quantitative trait loci;
CRC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg20790798	chr5:1857306	NA	-0.46	-6.96	-0.36	1.88e-11	Cardiovascular disease risk factors;
CRC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.72	-7.9	-0.4	4.17e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.83	10.67	0.51	5.14e-23	Diisocyanate-induced asthma;
CRC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-11.38	-0.53	1.54e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7626444	0.584	rs11711813	chr3:196467338	C/T	cg12930392	chr3:196481615	PAK2	0.38	6.66	0.34	1.14e-10	Monocyte count;
CRC	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.61	-0.3	4.38e-8	Coronary artery disease;
CRC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-0.84	-7.78	-0.39	9.76e-14	Putamen volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12625874	chr1:1284440	DVL1	0.41	6.0	0.31	5.19e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg12244665	chr8:104325860	FZD6	-0.33	-5.98	-0.31	5.79e-9	Calcium levels;
CRC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.22	-0.32	1.54e-9	Arsenic metabolism;
CRC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg25833597	chr17:30823145	MYO1D	0.34	5.64	0.3	3.7e-8	Schizophrenia;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.22e-12	Bipolar disorder;
CRC	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg05714579	chr10:131428358	MGMT	0.54	7.65	0.39	2.2e-13	Response to temozolomide;
CRC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.75	8.68	0.43	1.88e-16	Eosinophilic esophagitis;
CRC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg16482183	chr6:26056742	HIST1H1C	0.45	6.75	0.35	6.81e-11	Height;
CRC	trans	rs9545047	0.716	rs2265378	chr13:79999716	T/C	cg07061582	chr15:90234082	PEX11A;WDR93	-0.41	-5.97	-0.31	6.15e-9	Schizophrenia;
CRC	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg13491945	chr12:107078410	RFX4	0.34	5.87	0.31	1.09e-8	Heart rate;
CRC	cis	rs7680126	0.596	rs28441463	chr4:10289577	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.04	-0.32	4.26e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg14003231	chr6:33640908	ITPR3	-0.46	-7.49	-0.38	6.59e-13	Plateletcrit;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07376846	chr1:203765385	ZC3H11A	0.46	6.59	0.34	1.74e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	1.04	8.39	0.42	1.44e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.43	0.33	4.49e-10	Morning vs. evening chronotype;
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.56	-10.0	-0.48	9.93e-21	Lung cancer;
CRC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.07	-0.32	3.62e-9	Menopause (age at onset);
CRC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.54	-9.67	-0.47	1.21e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12463550	chr7:65579703	CRCP	0.67	6.41	0.33	5.16e-10	Diabetic kidney disease;
CRC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3889199	0.924	rs12755444	chr1:59681252	A/G	cg25881383	chr1:59680599	NA	-0.38	-6.28	-0.33	1.08e-9	Pulse pressure;
CRC	cis	rs6968419	0.755	rs2402057	chr7:115897096	C/T	cg02561103	chr7:115862891	TES	0.42	6.38	0.33	6.12e-10	Intraocular pressure;
CRC	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg03013636	chr16:1946785	NA	-0.47	-5.85	-0.31	1.18e-8	Insulin-like growth factors;
CRC	trans	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg23954465	chr10:8078038	NA	-0.28	-6.19	-0.32	1.79e-9	Gut microbiome composition (summer);
CRC	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg13736514	chr6:26305472	NA	-0.4	-6.51	-0.34	2.88e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.49	6.24	0.33	1.38e-9	Alzheimer's disease;
CRC	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg20936604	chr3:58311152	NA	-0.73	-7.25	-0.37	3.06e-12	Cholesterol, total;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs7605827	0.930	rs2287274	chr2:15658577	T/C	cg19274914	chr2:15703543	NA	0.38	5.72	0.3	2.4e-8	Educational attainment (years of education);
CRC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.85	-15.96	-0.66	7.37e-43	Body mass index;
CRC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.47	7.23	0.37	3.47e-12	Motion sickness;
CRC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.46	-5.74	-0.3	2.21e-8	White blood cell count;
CRC	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.66	-8.67	-0.43	2.05e-16	Dementia with Lewy bodies;
CRC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.61	8.71	0.43	1.48e-16	Alcohol dependence;
CRC	cis	rs720844	0.628	rs16828791	chr2:149296887	C/T	cg09247360	chr2:149335327	NA	-0.56	-5.83	-0.31	1.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9469578	0.901	rs57303110	chr6:33706159	G/A	cg18708504	chr6:33715942	IP6K3	0.6	6.7	0.35	9.31e-11	Phosphorus levels;
CRC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs10021731	0.718	rs1460771	chr4:115407911	C/T	cg25927708	chr2:119603813	EN1	0.33	6.29	0.33	1.03e-9	Optic disc area;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg02033258	chr5:131593261	PDLIM4	-0.37	-6.41	-0.33	5.17e-10	Breast cancer;
CRC	cis	rs375066	0.586	rs2883946	chr19:44352688	G/A	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.41	6.36	0.33	6.92e-10	Corneal astigmatism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18452149	chr3:108308268	KIAA1524;DZIP3	-0.4	-6.29	-0.33	1.01e-9	Myopia (pathological);
CRC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg22777020	chr22:31556080	RNF185	0.53	6.26	0.33	1.17e-9	Colorectal cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09253211	chr11:63438586	ATL3	-0.45	-6.85	-0.35	3.64e-11	Myopia (pathological);
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.2	0.32	1.66e-9	Prudent dietary pattern;
CRC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.94	0.31	7.15e-9	Protein C levels;
CRC	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma;
CRC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.7	-8.67	-0.43	2.04e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg25019722	chr6:37503610	NA	-0.41	-7.39	-0.38	1.2e-12	Cognitive performance;
CRC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.81	-9.94	-0.48	1.62e-20	Lung function (FEV1/FVC);
CRC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	-0.6	-7.03	-0.36	1.19e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.66	-0.39	2.04e-13	Vitiligo;
CRC	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.5	9.02	0.45	1.63e-17	Waist-hip ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12450255	chr15:34659304	LPCAT4	0.47	6.06	0.32	3.74e-9	Thyroid stimulating hormone;
CRC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.04e-9	Bladder cancer;
CRC	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.47	-7.0	-0.36	1.47e-11	Birth weight;
CRC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.32	-0.33	8.29e-10	Aortic root size;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg20615401	chr6:28092323	ZSCAN16	0.45	5.9	0.31	9.1e-9	Cardiac Troponin-T levels;
CRC	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg16898833	chr6:26189333	HIST1H4D	0.66	5.77	0.3	1.8e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	trans	rs12439619	0.739	rs4778988	chr15:82540337	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.5	-7.1	-0.36	7.69e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1950626	0.743	rs1956734	chr14:101399830	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.89	-13.53	-0.6	1.86e-33	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.8	12.15	0.56	2.51e-28	Multiple sclerosis;
CRC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.64	6.73	0.35	7.75e-11	Tonsillectomy;
CRC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07294406	chr7:64700536	NA	0.38	6.06	0.32	3.77e-9	Calcium levels;
CRC	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg22495460	chr2:25135724	ADCY3	-0.85	-15.85	-0.66	1.9e-42	Body mass index;
CRC	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.54	-7.47	-0.38	7.19e-13	Tuberculosis;
CRC	cis	rs6479527	0.840	rs2225458	chr9:96756805	A/G	cg14459158	chr9:96720562	NA	0.41	7.48	0.38	6.61e-13	Esophageal adenocarcinoma;
CRC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-11.89	-0.55	2.22e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.78	11.45	0.53	9.28e-26	Neutrophil percentage of white cells;
CRC	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.52	-8.01	-0.4	1.94e-14	Mean corpuscular volume;
CRC	cis	rs4237845	0.611	rs4335583	chr12:58305111	T/C	cg02175503	chr12:58329896	NA	0.79	12.42	0.57	2.55e-29	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.64	-0.34	1.32e-10	Aortic root size;
CRC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg03037974	chr15:76606532	NA	0.71	12.42	0.56	2.71e-29	Blood metabolite levels;
CRC	cis	rs17227506	0.630	rs67670052	chr8:13443474	G/C	cg03566418	chr8:13424080	C8orf48	0.35	6.01	0.31	4.97e-9	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.74	11.98	0.55	1.04e-27	Longevity;Endometriosis;
CRC	cis	rs7605827	0.930	rs9287664	chr2:15597116	A/G	cg19274914	chr2:15703543	NA	-0.39	-5.99	-0.31	5.51e-9	Educational attainment (years of education);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19428682	chr12:42538191	GXYLT1	0.42	6.11	0.32	2.74e-9	Anxiety disorder;
CRC	cis	rs4662945	0.688	rs62174139	chr2:130202775	G/C	cg05962382	chr2:130345044	NA	-0.33	-5.76	-0.3	1.91e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.85	-9.83	-0.48	3.67e-20	Breast cancer;
CRC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.37	-0.46	1.17e-18	Platelet count;
CRC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg03013999	chr17:37608204	MED1	0.45	6.91	0.36	2.6e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.6	-0.39	3.18e-13	Eye color traits;
CRC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.33	-7.26	-0.37	2.73e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26635366	chr16:30710347	SRCAP	0.45	6.28	0.33	1.1e-9	Anxiety disorder;
CRC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg21285383	chr16:89894308	SPIRE2	0.34	5.73	0.3	2.25e-8	Vitiligo;
CRC	cis	rs2637266	0.500	rs11001799	chr10:78252554	T/C	cg18941641	chr10:78392320	NA	-0.35	-5.69	-0.3	2.79e-8	Pulmonary function;
CRC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs10201564	chr2:15623608	C/G	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.66	9.81	0.48	4.12e-20	Corneal astigmatism;
CRC	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.33	0.65	2.18e-40	Colorectal cancer;
CRC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg22777020	chr22:31556080	RNF185	-0.51	-5.82	-0.31	1.42e-8	Colorectal cancer;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg03623178	chr6:28175578	NA	0.69	9.22	0.45	3.71e-18	Parkinson's disease;
CRC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.35e-16	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg03037974	chr15:76606532	NA	0.73	12.65	0.57	3.69e-30	Blood metabolite levels;
CRC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.66	7.52	0.38	5.25e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs883565	0.569	rs7637036	chr3:38997778	C/T	cg01426195	chr3:39028469	NA	-0.42	-7.01	-0.36	1.35e-11	Handedness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26222042	chr5:31532200	RNASEN;C5orf22	0.47	6.04	0.32	4.24e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.61	-11.09	-0.52	1.71e-24	Aortic root size;
CRC	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.83	-0.55	3.66e-27	Idiopathic membranous nephropathy;
CRC	cis	rs17362650	0.653	rs12474647	chr2:9554280	A/T	cg12832956	chr2:9616023	IAH1	-0.48	-6.49	-0.34	3.09e-10	Alcohol dependence (age at onset);
CRC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.8	-0.35	4.86e-11	Mean corpuscular volume;
CRC	cis	rs6681460	0.966	rs10749765	chr1:67150280	C/T	cg02459107	chr1:67143332	SGIP1	0.39	6.93	0.36	2.2e-11	Presence of antiphospholipid antibodies;
CRC	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.63	0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg23996704	chr18:44553084	KATNAL2	-0.33	-6.73	-0.35	7.53e-11	Personality dimensions;
CRC	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg01657329	chr11:68192670	LRP5	-0.54	-6.55	-0.34	2.16e-10	Bone mineral density (spine);
CRC	trans	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg26043149	chr18:55253948	FECH	-0.51	-7.08	-0.36	8.98e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg24375607	chr4:120327624	NA	0.47	7.49	0.38	6.26e-13	Corneal astigmatism;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18758796	chr5:131593413	PDLIM4	0.44	8.4	0.42	1.35e-15	Breast cancer;
CRC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.96	12.13	0.56	3.18e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-8.02	-0.4	1.89e-14	Hemoglobin concentration;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg21784768	chr11:537496	LRRC56	-0.59	-5.64	-0.3	3.67e-8	Body mass index;
CRC	trans	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.48	-0.34	3.29e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.82	9.16	0.45	5.68e-18	Breast cancer;
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg07862535	chr7:139043722	LUC7L2	0.54	7.05	0.36	1.09e-11	Diisocyanate-induced asthma;
CRC	cis	rs910187	0.571	rs3827049	chr20:45801319	T/A	cg27589058	chr20:45804311	EYA2	-0.44	-8.64	-0.43	2.45e-16	Migraine;
CRC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.61	8.35	0.42	1.93e-15	Obesity-related traits;
CRC	cis	rs2108622	0.727	rs8101038	chr19:15982864	C/T	cg13772218	chr19:15982569	NA	0.49	7.01	0.36	1.39e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.76	-10.69	-0.51	4.33e-23	High light scatter reticulocyte count;
CRC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg15790184	chr11:494944	RNH1	0.57	5.8	0.3	1.52e-8	Body mass index;
CRC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.75	-0.35	6.74e-11	Dupuytren's disease;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg12172441	chr6:28176163	NA	-0.57	-6.3	-0.33	9.5e-10	Parkinson's disease;
CRC	cis	rs11233250	0.502	rs17144103	chr11:82403522	C/A	cg17391194	chr11:82401662	NA	0.43	6.64	0.34	1.29e-10	Glioblastoma;Glioma;
CRC	cis	rs11229555	0.609	rs11229434	chr11:58185501	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg03934865	chr2:198174659	NA	0.43	6.58	0.34	1.87e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.51	7.8	0.39	8.4e-14	Corneal astigmatism;
CRC	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.71	-10.88	-0.51	9.56e-24	Response to temozolomide;
CRC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.16	25.92	0.82	1.73e-81	IgG glycosylation;
CRC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.67	10.1	0.49	4.45e-21	Lung cancer;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.37	5.63	0.3	3.93e-8	Mean corpuscular volume;
CRC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.44	6.02	0.32	4.61e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-9.56	-0.47	2.76e-19	Migraine;
CRC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.56	-0.47	2.8e-19	Heart rate;
CRC	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg00601450	chr5:74908170	NA	0.45	5.64	0.3	3.73e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.1	0.64	1.63e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.89	0.4	4.42e-14	Mean platelet volume;
CRC	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.54	-6.08	-0.32	3.26e-9	Neutrophil percentage of white cells;
CRC	cis	rs739496	0.542	rs10849937	chr12:111792427	A/G	cg10833066	chr12:111807467	FAM109A	0.54	7.0	0.36	1.46e-11	Platelet count;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg03623178	chr6:28175578	NA	0.76	10.69	0.51	4.45e-23	Parkinson's disease;
CRC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg03030879	chr14:75389066	RPS6KL1	0.47	6.91	0.36	2.53e-11	Height;
CRC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg12311346	chr5:56204834	C5orf35	-0.48	-7.3	-0.37	2.15e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.05	0.32	3.9e-9	Blood metabolite levels;
CRC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.8	14.59	0.63	1.54e-37	Anterior chamber depth;
CRC	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg00086871	chr4:6988644	TBC1D14	1.03	7.79	0.39	8.6e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg03037974	chr15:76606532	NA	-0.5	-7.28	-0.37	2.47e-12	Blood metabolite levels;
CRC	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg22687807	chr8:143858763	LYNX1	-0.37	-6.47	-0.34	3.46e-10	Urinary tract infection frequency;
CRC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	11.67	0.54	1.4e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg27068330	chr11:65405492	SIPA1	0.43	6.05	0.32	3.97e-9	Urate levels;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.17	-0.37	4.91e-12	Chronic sinus infection;
CRC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.56	-0.34	2.14e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.76	11.1	0.52	1.61e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.52	8.65	0.43	2.23e-16	Calcium levels;
CRC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18713687	chr3:195489789	MUC4	0.65	7.19	0.37	4.27e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.46	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	13.13	0.59	5.98e-32	Electrocardiographic conduction measures;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05141026	chr8:145064874	GRINA	0.41	6.19	0.32	1.75e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg04969067	chr8:143858791	LYNX1	0.44	7.53	0.38	4.79e-13	Urinary tract infection frequency;
CRC	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.46	7.28	0.37	2.55e-12	Anterior chamber depth;
CRC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg21770322	chr7:97807741	LMTK2	0.53	8.66	0.43	2.22e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9469890	0.591	rs11754773	chr6:34577257	A/G	cg17674042	chr6:34482479	PACSIN1	-0.9	-8.07	-0.41	1.34e-14	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12667521	chr19:29218732	NA	0.53	7.28	0.37	2.45e-12	Methadone dose in opioid dependence;
CRC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.78	0.66	3.81e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07830110	chr22:38794284	LOC400927	0.52	7.44	0.38	8.59e-13	Response to antipsychotic treatment;
CRC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.81	13.61	0.6	9.13e-34	Menopause (age at onset);
CRC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.76	-11.23	-0.53	5.41e-25	Refractive error;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26183330	chr7:35577229	NA	0.43	5.96	0.31	6.36e-9	Anxiety disorder;
CRC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs17023223	0.537	rs2765531	chr1:119585497	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-6.33	-0.33	7.91e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7712401	0.686	rs185007	chr5:122199318	C/T	cg18764291	chr5:122110994	SNX2	0.36	5.74	0.3	2.21e-8	Mean platelet volume;
CRC	cis	rs7945718	0.591	rs7926971	chr11:12698040	A/G	cg25843174	chr11:12811716	TEAD1	0.42	7.75	0.39	1.13e-13	Educational attainment (years of education);
CRC	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.78	-0.39	9.74e-14	Menarche (age at onset);
CRC	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.45	9.21	0.45	4e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	0.89	7.8	0.4	8.09e-14	Left atrial antero-posterior diameter;
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.09	-0.36	8.22e-12	Bipolar disorder;
CRC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.38	-6.68	-0.35	1.03e-10	Age at first birth;
CRC	cis	rs990171	1.000	rs917996	chr2:103082273	C/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Lymphocyte counts;
CRC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.76	11.49	0.54	6.44e-26	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.83e-9	Depression;
CRC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg21285383	chr16:89894308	SPIRE2	0.36	6.05	0.32	3.97e-9	Vitiligo;
CRC	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.59	-0.39	3.27e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg26373071	chr5:1325741	CLPTM1L	0.49	8.74	0.43	1.17e-16	Lung cancer;
CRC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.56e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.48	-0.71	8.39e-53	Height;
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.72	10.51	0.5	1.79e-22	Menarche (age at onset);
CRC	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg25838818	chr2:108905173	SULT1C2	0.34	5.66	0.3	3.24e-8	Blood pressure;
CRC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg11679014	chr22:38092719	TRIOBP	-0.27	-5.69	-0.3	2.76e-8	Fat distribution (HIV);
CRC	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg00666640	chr1:248458726	OR2T12	0.4	7.22	0.37	3.67e-12	Common traits (Other);
CRC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg20885578	chr2:198174922	NA	-0.45	-7.09	-0.36	8.18e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.4	-6.05	-0.32	3.87e-9	Monocyte count;
CRC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.55	7.49	0.38	6.44e-13	Bronchopulmonary dysplasia;
CRC	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg14768367	chr16:72042858	DHODH	-0.6	-6.74	-0.35	7.24e-11	Blood protein levels;
CRC	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06307176	chr5:131281290	NA	0.41	5.78	0.3	1.74e-8	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11259409	chr11:1331124	LOC255512;TOLLIP	0.39	6.42	0.33	4.63e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg18187862	chr3:45730750	SACM1L	-0.44	-6.19	-0.32	1.78e-9	Primary sclerosing cholangitis;
CRC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	14.22	0.62	4.03e-36	Platelet count;
CRC	cis	rs59104589	0.569	rs4254498	chr2:242363611	G/C	cg19488206	chr2:242435732	STK25	0.49	7.1	0.36	7.78e-12	Fibrinogen levels;
CRC	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.59	8.4	0.42	1.39e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg04545296	chr12:48745243	ZNF641	0.36	6.22	0.32	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.54	8.32	0.42	2.39e-15	Diastolic blood pressure;
CRC	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.58	7.53	0.38	4.97e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.43	-0.38	9.53e-13	Life satisfaction;
CRC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg11212589	chr17:38028394	ZPBP2	0.34	6.1	0.32	2.93e-9	Asthma;
CRC	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.52	6.82	0.35	4.46e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22162010	chr1:113249994	RHOC	0.38	6.93	0.36	2.2e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.66	8.11	0.41	1.03e-14	Obesity (extreme);
CRC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg11941060	chr3:133502564	NA	-0.41	-6.79	-0.35	5.25e-11	Iron status biomarkers;
CRC	cis	rs7487075	0.930	rs11183468	chr12:46806261	A/T	cg22049899	chr12:47219821	SLC38A4	0.32	6.44	0.33	4.15e-10	Itch intensity from mosquito bite;
CRC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.69	-0.35	9.5e-11	Alcohol dependence;
CRC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.49	-9.63	-0.47	1.71e-19	Prostate cancer;
CRC	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg09003973	chr2:102972529	NA	0.68	7.56	0.38	3.99e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs2108622	0.727	rs62106156	chr19:15980424	C/T	cg13772218	chr19:15982569	NA	0.48	6.75	0.35	6.63e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg18833306	chr6:118973337	C6orf204	0.48	6.81	0.35	4.78e-11	Diastolic blood pressure;
CRC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-8.65	-0.43	2.27e-16	Coronary artery disease;
CRC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.52	7.49	0.38	6.32e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.41	-7.0	-0.36	1.41e-11	Childhood ear infection;
CRC	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.68	-11.53	-0.54	4.57e-26	White blood cell count (basophil);
CRC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.0	-12.68	-0.57	2.82e-30	Diabetic kidney disease;
CRC	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg05756136	chr1:119680316	WARS2	-0.53	-7.3	-0.37	2.17e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7605827	0.930	rs4668912	chr2:15610882	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.67	0.39	1.99e-13	Response to temozolomide;
CRC	trans	rs11782652	1.000	rs76837345	chr8:82668818	A/G	cg26586384	chr17:12526632	NA	0.76	5.98	0.31	5.81e-9	Epithelial ovarian cancer;Ovarian cancer;
CRC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.95	16.11	0.66	1.8e-43	Total cholesterol levels;
CRC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	8.75	0.43	1.12e-16	Eosinophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06978021	chr20:61493312	TCFL5	0.45	6.47	0.34	3.59e-10	Anxiety disorder;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.33	0.33	8.26e-10	Bipolar disorder;
CRC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.47	0.42	8.18e-16	Height;
CRC	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.3	-0.56	7.56e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.67	10.51	0.5	1.88e-22	Breast cancer;
CRC	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.42	-0.38	9.91e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.64	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.78	-12.69	-0.57	2.61e-30	Ear protrusion;
CRC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg23018236	chr17:30244563	NA	-0.63	-7.69	-0.39	1.73e-13	Hip circumference adjusted for BMI;
CRC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.7	0.35	8.8e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs9462846	0.959	rs2235831	chr6:42883911	G/C	cg21280719	chr6:42927975	GNMT	-0.33	-6.34	-0.33	7.59e-10	Blood protein levels;
CRC	cis	rs1011108	0.518	rs935172	chr2:26804247	A/G	cg18742855	chr2:26800399	C2orf70	-0.35	-5.83	-0.31	1.31e-8	Periodontal microbiota;
CRC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.6	-8.09	-0.41	1.18e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg03934865	chr2:198174659	NA	-0.43	-6.81	-0.35	4.66e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs41005	1.000	rs13402078	chr2:8113107	C/T	cg03155496	chr2:8117019	LOC339788	-0.38	-6.64	-0.34	1.3e-10	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-12.61	-0.57	5.05e-30	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.44e-13	Motion sickness;
CRC	cis	rs3018066	0.867	rs7692652	chr4:107047493	C/T	cg01869342	chr4:106983673	TBCK	-0.37	-5.88	-0.31	9.89e-9	Cancer;
CRC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.63	-10.38	-0.5	5.15e-22	Age at first birth;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22834172	chr17:37774349	NA	0.49	6.33	0.33	8.24e-10	Thyroid stimulating hormone;
CRC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-9.41	-0.46	8.77e-19	Pancreatic cancer;
CRC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg21132104	chr15:45694354	SPATA5L1	0.41	5.96	0.31	6.57e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.48	-7.44	-0.38	8.71e-13	Response to interferon beta in multiple sclerosis;
CRC	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.64	-8.96	-0.44	2.48e-17	Type 2 diabetes;
CRC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg14828511	chr1:107599125	PRMT6	-0.45	-6.5	-0.34	2.99e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.43	-9.84	-0.48	3.31e-20	Coronary artery disease;
CRC	cis	rs988712	0.622	rs2030323	chr11:27728539	A/C	cg10635145	chr11:27742435	BDNF	0.41	6.23	0.32	1.42e-9	Obesity;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg17023971	chr6:2415850	NA	-0.4	-6.07	-0.32	3.51e-9	Body mass index;
CRC	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.54	8.65	0.43	2.28e-16	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23713156	chr17:80606235	WDR45L	-0.44	-6.46	-0.34	3.73e-10	Myopia (pathological);
CRC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.38	-0.33	5.92e-10	Schizophrenia;
CRC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.85	-15.04	-0.64	2.95e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07256006	chr1:156182774	PMF1	0.53	7.55	0.38	4.18e-13	Response to antipsychotic treatment;
CRC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.64	8.11	0.41	1.05e-14	Cleft lip with or without cleft palate;
CRC	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg27417294	chr10:81904244	PLAC9	-0.37	-5.82	-0.31	1.42e-8	Sarcoidosis;
CRC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.82	13.6	0.6	9.9e-34	Menopause (age at onset);
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg05569086	chr8:143859399	LYNX1	-0.33	-5.8	-0.3	1.55e-8	Urinary tract infection frequency;
CRC	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.66	-7.85	-0.4	6.01e-14	Ulcerative colitis;
CRC	cis	rs17713451	0.635	rs113032029	chr7:151270211	G/A	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.42	-0.33	4.66e-10	Interleukin-4 levels;
CRC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg14008862	chr17:28927542	LRRC37B2	0.54	6.31	0.33	9.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3857067	0.934	rs899132	chr4:95040022	A/C	cg11021082	chr4:95130006	SMARCAD1	0.38	5.7	0.3	2.68e-8	QT interval;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12801072	chr3:5229809	EDEM1	0.38	6.07	0.32	3.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg03037974	chr15:76606532	NA	0.69	12.16	0.56	2.47e-28	Blood metabolite levels;
CRC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg14324370	chr2:177042789	NA	0.8	13.4	0.59	5.87e-33	IgG glycosylation;
CRC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg03923535	chr7:1197113	ZFAND2A	0.43	5.85	0.31	1.18e-8	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03105770	chr11:82997414	CCDC90B	0.44	5.98	0.31	5.92e-9	Anxiety disorder;
CRC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	5.72	0.3	2.43e-8	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18491775	chr10:76586186	MYST4	0.56	7.63	0.39	2.49e-13	Thyroid stimulating hormone;
CRC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.55	-0.6	1.52e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04219625	chr11:66247798	DPP3	0.41	6.14	0.32	2.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg18478394	chr8:109455254	TTC35	0.38	5.89	0.31	9.79e-9	Dupuytren's disease;
CRC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.92	11.77	0.54	6.17e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg20615401	chr6:28092323	ZSCAN16	0.46	6.26	0.33	1.18e-9	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.74	-13.96	-0.61	4.29e-35	Prudent dietary pattern;
CRC	cis	rs2708240	0.666	rs2710121	chr7:147608448	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.4	-5.88	-0.31	1.01e-8	QT interval (drug interaction);
CRC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	0.69	6.25	0.33	1.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg04289385	chr6:36355825	ETV7	0.39	5.71	0.3	2.48e-8	Platelet distribution width;
CRC	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg13175173	chr14:55914753	NA	-0.52	-9.9	-0.48	2.06e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs12692738	0.526	rs650330	chr2:165624861	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg27615366	chr5:131592974	PDLIM4	0.32	5.69	0.3	2.79e-8	Breast cancer;
CRC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.25	0.41	3.98e-15	Menopause (age at onset);
CRC	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg07424746	chr4:185654737	MLF1IP	-0.63	-5.98	-0.31	5.66e-9	Blood protein levels;
CRC	cis	rs11212617	0.935	rs4623864	chr11:108051300	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.1	0.32	2.97e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs17767392	0.918	rs72728427	chr14:71769989	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	1.01	8.57	0.43	4.18e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.9	0.31	9.22e-9	Ovarian reserve;
CRC	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg15654264	chr1:150340011	RPRD2	0.42	6.22	0.32	1.55e-9	Migraine;
CRC	cis	rs6838801	0.892	rs28568554	chr4:77576016	T/G	cg17476223	chr4:77663285	SHROOM3	0.42	5.9	0.31	9.22e-9	Cleft lip with or without cleft palate;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2979489	0.945	rs2979472	chr8:30291704	G/C	cg26383811	chr8:30366931	RBPMS	0.69	9.45	0.46	6.43e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg04545296	chr12:48745243	ZNF641	0.36	6.18	0.32	1.88e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06058923	chr6:80488001	NA	0.44	6.97	0.36	1.78e-11	Obesity-related traits;
CRC	cis	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg27411982	chr8:10470053	RP1L1	0.36	5.65	0.3	3.46e-8	Neuroticism;
CRC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg25452165	chr22:42524984	CYP2D6	0.42	5.92	0.31	8.25e-9	Cognitive function;
CRC	trans	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.76	0.35	6.22e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.87	-0.31	1.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	1.0	12.85	0.58	6.4e-31	Vitiligo;
CRC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.73	-0.47	8.05e-20	Body mass index;
CRC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.46	-7.22	-0.37	3.68e-12	Breast cancer;
CRC	cis	rs10760158	0.739	rs10760163	chr9:124008452	C/A	cg14417974	chr9:124058376	GSN	-0.33	-5.6	-0.3	4.46e-8	Pulse pressure;
CRC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.15	0.37	5.83e-12	Rheumatoid arthritis;
CRC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.21	0.32	1.57e-9	Lung cancer;
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.35	-5.9	-0.31	8.84e-9	Lung cancer;
CRC	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg03938978	chr2:103052716	IL18RAP	0.47	7.25	0.37	3.04e-12	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03306564	chr11:64902099	SYVN1	0.48	6.68	0.35	1.02e-10	Response to antipsychotic treatment;
CRC	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.47	8.38	0.42	1.61e-15	Weight;
CRC	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.42	5.98	0.31	5.71e-9	Macular telangiectasia type 2;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19769827	chr1:203259772	NA	0.4	6.12	0.32	2.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.47	6.08	0.32	3.37e-9	Obesity-related traits;
CRC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	6.05	0.32	3.87e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg23920097	chr1:209922102	NA	-0.54	-6.65	-0.34	1.22e-10	Red blood cell count;
CRC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-6.99	-0.36	1.51e-11	Response to antipsychotic treatment;
CRC	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg05507819	chr15:63340323	TPM1	0.46	6.05	0.32	3.88e-9	HDL cholesterol;
CRC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.98	-0.48	1.2e-20	Aortic root size;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	trans	rs17607347	0.738	rs1297137	chr16:72412385	T/C	cg27230510	chr3:50404023	CACNA2D2	-0.54	-6.05	-0.32	4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2814982	0.514	rs73405691	chr6:34468767	A/G	cg14254433	chr6:34482411	PACSIN1	-0.57	-6.53	-0.34	2.44e-10	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.48	7.66	0.39	2.13e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.49	6.38	0.33	6.15e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs11098699	0.784	rs11947137	chr4:124205966	C/G	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.34	-0.33	7.52e-10	Morning vs. evening chronotype;
CRC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.81	9.18	0.45	4.9e-18	Breast cancer;
CRC	cis	rs2493151	1.000	rs2478542	chr1:230879511	T/C	cg07502417	chr1:230849801	AGT	0.28	5.65	0.3	3.4e-8	Blood protein levels;
CRC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.66	12.09	0.55	4.32e-28	Prudent dietary pattern;
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.69	-0.54	1.22e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs243505	0.737	rs243513	chr7:148429806	G/A	cg09806900	chr7:148480153	CUL1	-0.53	-6.68	-0.35	1.03e-10	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06620762	chr15:76136437	UBE2Q2	0.47	6.74	0.35	7.06e-11	Response to antipsychotic treatment;
CRC	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.44	-5.71	-0.3	2.51e-8	Height;
CRC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	13.48	0.6	2.83e-33	Cognitive ability;
CRC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.02	-0.36	1.29e-11	Reticulocyte fraction of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23260255	chr3:187871479	LPP	0.46	6.52	0.34	2.7e-10	Response to antipsychotic treatment;
CRC	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.65	-10.46	-0.5	2.63e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.17	-9.73	-0.47	7.81e-20	Mitochondrial DNA levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23365832	chr22:26986032	TPST2	0.44	6.11	0.32	2.84e-9	Anxiety disorder;
CRC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.72	-9.16	-0.45	5.73e-18	Initial pursuit acceleration;
CRC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg21798802	chr22:38057573	PDXP	0.37	6.24	0.33	1.35e-9	Fat distribution (HIV);
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg09877947	chr5:131593287	PDLIM4	0.36	6.46	0.34	3.74e-10	Blood metabolite levels;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg08460590	chr17:7495881	FXR2	-0.45	-6.04	-0.32	4.23e-9	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11208039	chr11:19138753	ZDHHC13	0.43	6.01	0.31	4.8e-9	Response to antipsychotic treatment;
CRC	cis	rs10046574	0.831	rs7797208	chr7:135137729	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg18850127	chr7:39170497	POU6F2	0.5	6.43	0.33	4.42e-10	IgG glycosylation;
CRC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.72	10.69	0.51	4.31e-23	Immature fraction of reticulocytes;
CRC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg11212589	chr17:38028394	ZPBP2	0.37	6.28	0.33	1.06e-9	Asthma;
CRC	trans	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg26043149	chr18:55253948	FECH	0.51	7.92	0.4	3.78e-14	Bone mineral density;
CRC	cis	rs13098911	0.540	rs9845382	chr3:46111759	C/T	cg12691230	chr3:46064611	XCR1	-0.52	-6.11	-0.32	2.89e-9	Celiac disease;
CRC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.18	-0.37	4.56e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg26762873	chr11:5879799	OR52E8	0.4	6.51	0.34	2.77e-10	DNA methylation (variation);
CRC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.36e-10	Alzheimer's disease;
CRC	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg24851651	chr11:66362959	CCS	0.37	6.37	0.33	6.38e-10	Educational attainment (years of education);
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg21784768	chr11:537496	LRRC56	-0.69	-6.56	-0.34	2.11e-10	Body mass index;
CRC	cis	rs6504950	0.830	rs17745231	chr17:53036529	C/G	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	cis	rs2070997	0.938	rs3808817	chr9:133746060	C/T	cg01000188	chr9:133769184	QRFP	0.58	6.73	0.35	7.74e-11	Response to amphetamines;
CRC	cis	rs17713451	0.593	rs80311488	chr7:151279117	G/A	cg18404559	chr7:151322523	PRKAG2	-0.54	-6.27	-0.33	1.11e-9	Interleukin-4 levels;
CRC	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.67	11.24	0.53	4.9e-25	Cancer;
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg09877947	chr5:131593287	PDLIM4	-0.32	-5.68	-0.3	3.04e-8	Blood metabolite levels;
CRC	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.43	-6.35	-0.33	7.16e-10	Neutrophil percentage of white cells;
CRC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.53	-8.48	-0.42	7.79e-16	Menopause (age at onset);
CRC	trans	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.78	-0.39	9.21e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.57	-0.72	3.67e-53	Primary sclerosing cholangitis;
CRC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.81	13.61	0.6	9.13e-34	Menopause (age at onset);
CRC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.97	16.17	0.67	1.12e-43	Ewing sarcoma;
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.71	0.54	1.01e-26	Prudent dietary pattern;
CRC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.17	24.03	0.8	2.24e-74	IgG glycosylation;
CRC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.66	-10.77	-0.51	2.23e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06536750	chr1:6846042	CAMTA1	0.41	6.27	0.33	1.12e-9	Schizophrenia;
CRC	cis	rs7725052	0.609	rs6451507	chr5:40458688	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.57	-0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.71	9.59	0.47	2.25e-19	Coronary artery disease;
CRC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.75	10.45	0.5	2.84e-22	Schizophrenia;
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.55	6.15	0.32	2.26e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs3750082	0.621	rs7778110	chr7:32949001	C/T	cg05721444	chr7:32995514	FKBP9	0.48	6.21	0.32	1.62e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg18335740	chr13:41363409	SLC25A15	0.54	8.26	0.41	3.51e-15	Lewy body disease;
CRC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.54	7.19	0.37	4.4e-12	Neutrophil percentage of white cells;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg16132339	chr22:24313637	DDTL;DDT	-0.58	-9.03	-0.45	1.51e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.68	0.6	4.96e-34	Platelet count;
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg12273811	chr6:28175739	NA	0.45	6.4	0.33	5.4e-10	Parkinson's disease;
CRC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.52	8.8	0.44	8.05e-17	Systemic lupus erythematosus;
CRC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.32	3.02e-9	Arsenic metabolism;
CRC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.56	10.29	0.49	1.01e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.47	5.98	0.31	5.94e-9	Thyroid stimulating hormone;
CRC	cis	rs7113874	0.589	rs7949017	chr11:8492127	C/T	cg17679104	chr11:8615758	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg20542592	chr8:11973495	FAM66D	0.36	6.21	0.32	1.63e-9	Retinal vascular caliber;
CRC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.67	9.88	0.48	2.44e-20	Cognitive function;
CRC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	8.71	0.43	1.47e-16	Eosinophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05013483	chr15:72978625	HIGD2B;BBS4	0.45	6.0	0.31	5.29e-9	Anxiety disorder;
CRC	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-6.03	-0.32	4.47e-9	Migraine - clinic-based;
CRC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.2	-15.29	-0.64	2.89e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg12302830	chr20:33297742	TP53INP2	-0.41	-6.12	-0.32	2.69e-9	HDL cholesterol;
CRC	cis	rs9891119	0.550	rs7219059	chr17:40521670	T/C	cg06270615	chr17:40516068	STAT3	-0.31	-6.1	-0.32	3.04e-9	Multiple sclerosis;Crohn's disease;
CRC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	0.98	14.44	0.62	6.21e-37	Breast cancer;
CRC	trans	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg11693508	chr17:37793320	STARD3	0.48	6.44	0.33	4.14e-10	Neuroticism;
CRC	trans	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.57	-0.39	3.73e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.64	10.86	0.51	1.07e-23	Prostate cancer;
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg25482853	chr8:67687455	SGK3	1.16	13.2	0.59	3.15e-32	Obesity-related traits;
CRC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.57	-0.39	3.84e-13	Gut microbiome composition (summer);
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.17	-0.32	1.99e-9	Height;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg15786705	chr6:28176104	NA	0.79	10.76	0.51	2.44e-23	Depression;
CRC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.58	7.84	0.4	6.26e-14	Menopause (age at onset);
CRC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg21854759	chr1:92012499	NA	0.48	7.36	0.38	1.46e-12	Breast cancer;
CRC	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg17218026	chr1:154582156	ADAR	0.63	10.22	0.49	1.74e-21	Blood protein levels;
CRC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.39	6.93	0.36	2.17e-11	Cardiovascular disease risk factors;
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.67	9.77	0.47	6.02e-20	Alzheimer's disease;
CRC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12315302	chr6:26189340	HIST1H4D	0.81	6.23	0.32	1.45e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg20636351	chr8:55087400	NA	-0.33	-5.86	-0.31	1.11e-8	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20314438	chr6:126661369	C6orf173	0.51	6.55	0.34	2.21e-10	Thyroid stimulating hormone;
CRC	cis	rs8032158	1.000	rs8026172	chr15:56125182	T/A	cg02198044	chr15:56286336	NEDD4	-0.38	-5.97	-0.31	6.31e-9	Keloid;
CRC	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.62	-11.41	-0.53	1.23e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.19	-0.52	7.81e-25	Eye color traits;
CRC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	9.09	0.45	9.49e-18	Schizophrenia;
CRC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.63	10.43	0.5	3.47e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	1.01	20.09	0.74	3.94e-59	Headache;
CRC	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg02158880	chr13:53174818	NA	0.42	6.0	0.31	5.07e-9	Lewy body disease;
CRC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.37	6.2	0.32	1.67e-9	Height;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.55	-8.34	-0.42	1.99e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg20933634	chr6:27740509	NA	0.45	6.56	0.34	2.05e-10	Hepatitis A;
CRC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.9	17.3	0.69	3.92e-48	Intelligence (multi-trait analysis);
CRC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.55	6.37	0.33	6.43e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg09066997	chr16:75300724	BCAR1	-0.6	-6.1	-0.32	2.93e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.58	0.34	1.83e-10	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg09264619	chr17:80180166	NA	0.37	6.15	0.32	2.26e-9	Life satisfaction;
CRC	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg00603274	chr11:61596626	FADS2	-0.45	-6.57	-0.34	1.96e-10	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
CRC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.71	0.43	1.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.09	-0.32	3.09e-9	Menopause (age at onset);
CRC	trans	rs9341835	0.772	rs9344090	chr6:64135830	G/A	cg13657004	chr13:50234944	EBPL	-0.37	-6.22	-0.32	1.48e-9	Schizophrenia;
CRC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.61	-8.91	-0.44	3.68e-17	Menarche (age at onset);
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg25164649	chr6:28176230	NA	0.46	6.76	0.35	6.23e-11	Cardiac Troponin-T levels;
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg15382696	chr6:118971807	C6orf204	0.61	7.95	0.4	2.97e-14	Diastolic blood pressure;
CRC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.74	-0.3	2.16e-8	Breast cancer;
CRC	trans	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg06791473	chr12:49259579	RND1	-0.62	-6.17	-0.32	2e-9	Blood protein levels;
CRC	cis	rs282587	0.530	rs282602	chr13:113392644	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.79	0.39	8.78e-14	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12991161	chr17:26684865	TMEM199;POLDIP2	0.52	7.29	0.37	2.27e-12	Response to antipsychotic treatment;
CRC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.97	-0.36	1.77e-11	IgG glycosylation;
CRC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.56	9.29	0.46	2.22e-18	Breast cancer;
CRC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.77	10.68	0.51	4.51e-23	Orofacial clefts;
CRC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.97	-0.31	6.02e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg18465962	chr7:100767262	NA	0.58	7.22	0.37	3.61e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs10743315	0.547	rs7310796	chr12:19362390	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.67	-8.35	-0.42	1.94e-15	Gut microbiota (bacterial taxa);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15959319	chr5:32174494	GOLPH3	0.38	6.52	0.34	2.6e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg18230493	chr5:56204884	C5orf35	-0.39	-5.76	-0.3	1.91e-8	Coronary artery disease;
CRC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.35	-0.33	7.08e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.58	-10.01	-0.48	9.21e-21	Aortic root size;
CRC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.36e-10	Schizophrenia;
CRC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg18764771	chr6:116381957	FRK	0.24	7.04	0.36	1.15e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-13.48	-0.6	2.8e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.59	8.06	0.41	1.43e-14	Menopause (age at onset);
CRC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.46	-0.46	6.17e-19	Aortic root size;
CRC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs6066835	1.000	rs6066828	chr20:47344233	C/T	cg18078177	chr20:47281410	PREX1	0.62	5.93	0.31	7.5e-9	Multiple myeloma;
CRC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.49	7.86	0.4	5.56e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg23018236	chr17:30244563	NA	-0.67	-7.99	-0.4	2.29e-14	Hip circumference adjusted for BMI;
CRC	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.22	14.83	0.63	1.88e-38	Lung disease severity in cystic fibrosis;
CRC	cis	rs2279817	0.908	rs12137775	chr1:18018927	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.54	6.4	0.33	5.26e-10	Neuroticism;
CRC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.58	-7.97	-0.4	2.68e-14	Menopause (age at onset);
CRC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.41	-0.5	4.04e-22	Initial pursuit acceleration;
CRC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg12927641	chr6:109611667	NA	0.34	6.04	0.32	4.13e-9	Reticulocyte fraction of red cells;
CRC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg24375607	chr4:120327624	NA	0.47	7.59	0.39	3.42e-13	Corneal astigmatism;
CRC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.16	-0.41	7.39e-15	Neuroticism;
CRC	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.28	0.46	2.36e-18	Fuchs's corneal dystrophy;
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg15485101	chr11:133734466	NA	0.4	7.16	0.37	5.26e-12	Childhood ear infection;
CRC	cis	rs728616	0.867	rs726289	chr10:81706951	C/T	cg05935833	chr10:81318306	SFTPA2	-0.74	-8.13	-0.41	9.14e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23378565	chr7:2036160	MAD1L1	-0.46	-6.53	-0.34	2.51e-10	Bipolar disorder;
CRC	trans	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg24644049	chr4:85504048	CDS1	0.91	7.97	0.4	2.59e-14	Skin colour saturation;
CRC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05472934	chr7:22766657	IL6	0.78	12.66	0.57	3.39e-30	Lung cancer;
CRC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.98	0.31	5.66e-9	Height;
CRC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-7.34	-0.38	1.71e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.65	9.14	0.45	6.38e-18	Vitamin D levels;
CRC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.66	6.76	0.35	6.44e-11	Plasma clusterin levels;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg19041857	chr6:27730383	NA	-0.46	-6.42	-0.33	4.87e-10	Parkinson's disease;
CRC	trans	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg24644049	chr4:85504048	CDS1	0.69	6.01	0.31	4.99e-9	Skin colour saturation;
CRC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg21620606	chr4:1342894	KIAA1530	0.4	7.15	0.37	5.57e-12	Longevity;
CRC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.64	9.59	0.47	2.37e-19	Breast cancer;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg06470822	chr6:28175283	NA	1.01	13.28	0.59	1.55e-32	Depression;
CRC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.12	0.45	7.92e-18	High light scatter reticulocyte count;
CRC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg21951975	chr1:209979733	IRF6	0.46	5.6	0.3	4.48e-8	Cleft lip with or without cleft palate;
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.22e-9	Diastolic blood pressure;
CRC	cis	rs73200209	0.744	rs7959347	chr12:116479781	A/G	cg01776926	chr12:116560359	MED13L	-0.64	-7.69	-0.39	1.74e-13	Total body bone mineral density;
CRC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.72	10.91	0.52	7.23e-24	Systemic sclerosis;
CRC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg15147215	chr3:52552868	STAB1	-0.43	-6.05	-0.32	3.92e-9	Schizophrenia;
CRC	trans	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg00938859	chr5:1591904	SDHAP3	0.65	6.02	0.31	4.63e-9	Breast cancer;
CRC	trans	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.43	-0.38	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg23123621	chr4:1343375	KIAA1530	0.36	6.51	0.34	2.8e-10	Obesity-related traits;
CRC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.28e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.58	-8.75	-0.43	1.16e-16	Asthma;
CRC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.55	8.44	0.42	1e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6496667	0.779	rs2107436	chr15:91042921	A/T	cg04176472	chr15:90893244	GABARAPL3	0.54	7.79	0.39	9.1e-14	Rheumatoid arthritis;
CRC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.4	6.59	0.34	1.71e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg06223162	chr1:101003688	GPR88	-0.34	-6.14	-0.32	2.42e-9	Monocyte count;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg21251018	chr6:28226885	NKAPL	0.38	5.74	0.3	2.13e-8	Parkinson's disease;
CRC	trans	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg21153622	chr11:89784906	NA	0.43	6.8	0.35	4.85e-11	HDL cholesterol;
CRC	cis	rs972578	0.967	rs1883314	chr22:43374807	G/C	cg01576275	chr22:43409880	NA	-0.49	-7.84	-0.4	6.52e-14	Mean platelet volume;
CRC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.05	13.07	0.58	1.02e-31	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.79	-16.35	-0.67	2.2e-44	Longevity;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.5	-7.3	-0.37	2.25e-12	Systemic sclerosis;
CRC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.42	-6.76	-0.35	6.19e-11	Monocyte count;
CRC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.48	-7.33	-0.37	1.76e-12	Total body bone mineral density;
CRC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.66	-8.94	-0.44	2.95e-17	Metabolic syndrome;
CRC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	9.09	0.45	9.3e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-6.76	-0.35	6.18e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs2279817	0.735	rs12075624	chr1:17991573	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-5.78	-0.3	1.71e-8	Neuroticism;
CRC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.8	8.61	0.43	2.98e-16	Gout;Renal underexcretion gout;
CRC	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.75	10.06	0.49	6.23e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	9.62	0.47	1.8e-19	Height;
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg10398005	chr11:117014888	PAFAH1B2	-0.41	-6.14	-0.32	2.34e-9	Blood protein levels;
CRC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-6.04	-0.32	4.17e-9	IgG glycosylation;
CRC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg13206674	chr6:150067644	NUP43	0.49	7.04	0.36	1.13e-11	Testicular germ cell tumor;
CRC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg13722127	chr7:150037890	RARRES2	-0.37	-5.95	-0.31	6.69e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.65	-0.34	1.26e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.69	-0.43	1.78e-16	Body mass index;
CRC	cis	rs2811415	0.627	rs4602340	chr3:127732942	A/C	cg13719885	chr3:127795394	NA	-0.37	-5.66	-0.3	3.24e-8	Lung function (FEV1/FVC);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00715988	chr14:96968640	PAPOLA	0.42	6.4	0.33	5.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03923535	chr7:1197113	ZFAND2A	0.58	8.19	0.41	5.69e-15	Longevity;Endometriosis;
CRC	cis	rs3015497	0.586	rs12587821	chr14:51092554	A/G	cg09863266	chr14:51125203	SAV1	-0.3	-5.76	-0.3	1.92e-8	Mean platelet volume;
CRC	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg21153622	chr11:89784906	NA	0.43	6.7	0.35	9.1e-11	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15620385	chr12:26986279	ITPR2	0.37	6.32	0.33	8.62e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.65	0.43	2.36e-16	Fuchs's corneal dystrophy;
CRC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.32	-5.75	-0.3	1.99e-8	Menarche (age at onset);
CRC	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.08	-15.9	-0.66	1.28e-42	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05360402	chr5:110848191	STARD4	0.44	6.13	0.32	2.47e-9	Response to antipsychotic treatment;
CRC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.56	10.03	0.48	8.05e-21	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13047869	chr3:10149882	C3orf24	0.52	7.06	0.36	9.86e-12	Alzheimer's disease;
CRC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.43	5.85	0.31	1.21e-8	Diastolic blood pressure;
CRC	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg09695851	chr17:3907499	NA	0.76	14.45	0.62	5.69e-37	Type 2 diabetes;
CRC	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.59	-8.95	-0.44	2.75e-17	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24707616	chr17:16342815	NCRNA00188;SNORD49B;SNORD49A	0.52	7.53	0.38	5.04e-13	Response to antipsychotic treatment;
CRC	cis	rs2070997	0.667	rs7851946	chr9:133719256	A/T	cg01000188	chr9:133769184	QRFP	-0.44	-5.64	-0.3	3.62e-8	Response to amphetamines;
CRC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.43	8.3	0.42	2.7e-15	Mean corpuscular volume;
CRC	cis	rs16852403	0.548	rs1412784	chr1:178206664	A/G	cg00404053	chr1:178313656	RASAL2	0.5	6.53	0.34	2.55e-10	Childhood ear infection;
CRC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.58	7.89	0.4	4.61e-14	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03209496	chr7:99725123	MBLAC1	0.43	6.24	0.33	1.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg01843034	chr6:37503916	NA	-0.44	-8.2	-0.41	5.61e-15	Cognitive performance;
CRC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.59	-0.47	2.26e-19	Heart rate;
CRC	cis	rs6662572	1.000	rs72688460	chr1:46111094	C/T	cg08644498	chr1:46502608	NA	0.44	6.05	0.32	3.95e-9	Blood protein levels;
CRC	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-17.82	-0.7	3.5e-50	Schizophrenia;
CRC	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.34	6.16	0.32	2.18e-9	Neuroticism;
CRC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.38	6.58	0.34	1.85e-10	Systemic lupus erythematosus;
CRC	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg21918786	chr6:109611834	NA	-0.33	-5.72	-0.3	2.33e-8	Reticulocyte fraction of red cells;
CRC	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg09597638	chr17:3907349	NA	-0.67	-11.85	-0.55	3.17e-27	Type 2 diabetes;
CRC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-1.03	-14.23	-0.62	3.94e-36	Lymphocyte counts;
CRC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg18612461	chr15:75251733	NA	0.4	6.18	0.32	1.94e-9	Breast cancer;
CRC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg09165964	chr15:75287851	SCAMP5	-0.52	-8.25	-0.41	3.97e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.57	9.38	0.46	1.14e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-7.16	-0.37	5.3e-12	Bone mineral density;
CRC	cis	rs3736485	0.966	rs10519312	chr15:51912971	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.38	-0.33	5.86e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.3	5.67	0.3	3.09e-8	QRS complex (12-leadsum);
CRC	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.47	-0.34	3.5e-10	Educational attainment;
CRC	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.62	-7.72	-0.39	1.44e-13	Body mass index;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-8.07	-0.41	1.29e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.89	0.31	9.44e-9	Renal cell carcinoma;
CRC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.89	9.04	0.45	1.4e-17	Lymphocyte counts;
CRC	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	15.57	0.65	2.39e-41	Smoking behavior;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08456130	chr6:151773385	RMND1;C6orf211	0.49	7.52	0.38	5.21e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg10756647	chr7:56101905	PSPH	-0.77	-7.85	-0.4	5.93e-14	Diabetic kidney disease;
CRC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.89	0.51	8.92e-24	Prudent dietary pattern;
CRC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg05941027	chr17:61774174	LIMD2	0.35	6.38	0.33	5.92e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs10035650	0.546	rs11949638	chr5:93907889	C/T	cg21051031	chr5:93905482	C5orf36;MIR1974	-0.38	-6.16	-0.32	2.08e-9	Cancer;
CRC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg23750338	chr8:142222470	SLC45A4	-0.39	-6.69	-0.35	9.42e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.64	8.58	0.43	3.84e-16	Multiple sclerosis;
CRC	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.41	5.83	0.31	1.31e-8	Subjective well-being;
CRC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-0.93	-11.65	-0.54	1.67e-26	Red blood cell traits;
CRC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.82	-0.48	4.01e-20	Total cholesterol levels;
CRC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg24879335	chr3:133465180	TF	0.37	6.86	0.35	3.44e-11	Iron status biomarkers;
CRC	cis	rs3736594	0.513	rs6751087	chr2:27778016	T/C	cg27432699	chr2:27873401	GPN1	0.66	8.49	0.42	7.24e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs4481887	0.538	rs10888328	chr1:248378777	G/A	cg00666640	chr1:248458726	OR2T12	0.43	7.58	0.39	3.62e-13	Common traits (Other);
CRC	cis	rs10924970	0.687	rs10802441	chr1:235357698	A/T	cg09010748	chr1:235293032	TOMM20	-0.4	-5.65	-0.3	3.5e-8	Asthma;
CRC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.69	7.1	0.36	7.77e-12	Plasma clusterin levels;
CRC	cis	rs12230513	0.732	rs4318592	chr12:55837124	C/A	cg19537932	chr12:55886519	OR6C68	-0.73	-9.49	-0.46	5.01e-19	Contrast sensitivity;
CRC	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg27398640	chr15:77910606	LINGO1	-0.46	-7.98	-0.4	2.48e-14	Type 2 diabetes;
CRC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.62	0.3	4.02e-8	Hemoglobin concentration;
CRC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.51	8.35	0.42	1.94e-15	Monobrow;
CRC	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06634786	chr22:41940651	POLR3H	0.44	5.85	0.31	1.18e-8	Vitiligo;
CRC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg18099408	chr3:52552593	STAB1	0.35	6.02	0.32	4.63e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg17885191	chr8:135476712	NA	0.53	7.39	0.38	1.23e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs2530545	0.543	rs61121916	chr7:34671351	G/T	cg14401837	chr7:34697493	NPSR1	0.54	5.67	0.3	3.17e-8	IgG glycosylation;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7923609	0.869	rs9971352	chr10:65265108	A/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.94	-0.31	7.27e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3857067	1.000	rs7694631	chr4:95016931	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.17e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.33	-0.42	2.17e-15	Gut microbiome composition (summer);
CRC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg05299278	chr17:33885742	SLFN14	0.4	5.99	0.31	5.59e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg06470822	chr6:28175283	NA	0.68	9.25	0.45	3e-18	Parkinson's disease;
CRC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.68	8.9	0.44	3.69e-17	Morning vs. evening chronotype;
CRC	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.53	-8.1	-0.41	1.11e-14	Blood protein levels;
CRC	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg14003231	chr6:33640908	ITPR3	0.55	8.71	0.43	1.46e-16	Plateletcrit;
CRC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.54e-9	Arsenic metabolism;
CRC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.89	-0.31	9.55e-9	Blood pressure (smoking interaction);
CRC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.37	-0.33	6.31e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.01	9.35	0.46	1.42e-18	Lymphocyte counts;
CRC	cis	rs2411233	1.000	rs11070163	chr15:39277151	A/G	cg23129342	chr15:39283510	NA	-0.32	-6.05	-0.32	3.87e-9	Platelet count;
CRC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs12408261	0.685	rs4085125	chr1:189277546	A/T	cg18397308	chr19:18672850	C19orf50	0.43	6.42	0.33	4.8e-10	Number of pregnancies;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.36	-0.33	6.91e-10	Total body bone mineral density;
CRC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg20684491	chr1:25596433	NA	0.42	7.48	0.38	6.74e-13	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.95	-12.73	-0.57	1.82e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03952484	chr1:149899818	SF3B4	0.52	7.33	0.37	1.78e-12	Response to antipsychotic treatment;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg20119798	chr7:94954144	PON1	-0.53	-6.54	-0.34	2.35e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.63	8.77	0.44	9.53e-17	Blood protein levels;
CRC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg17321639	chr7:2759063	NA	-0.54	-7.32	-0.37	1.93e-12	Height;
CRC	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg20936604	chr3:58311152	NA	-0.77	-7.34	-0.38	1.65e-12	Cholesterol, total;
CRC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.81	10.97	0.52	4.6e-24	Initial pursuit acceleration;
CRC	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.77	-8.16	-0.41	7.07e-15	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.66	10.34	0.5	6.8e-22	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18531175	chr5:43483681	C5orf28	0.38	6.14	0.32	2.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg01426195	chr3:39028469	NA	-0.53	-8.58	-0.43	3.86e-16	Handedness;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg06538757	chr5:177631493	HNRNPAB	-0.41	-6.05	-0.32	3.86e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7429990	0.864	rs319693	chr3:47886580	G/T	cg11946769	chr3:48343235	NME6	0.45	5.78	0.3	1.72e-8	Educational attainment (years of education);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06805064	chr13:52263093	WDFY2	-0.44	-6.09	-0.32	3.1e-9	Myopia (pathological);
CRC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-7.88	-0.4	4.99e-14	Aortic root size;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02725872	chr8:58115012	NA	0.59	9.18	0.45	5.05e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.51	-8.46	-0.42	8.79e-16	Height;
CRC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	11.42	0.53	1.12e-25	Electrocardiographic conduction measures;
CRC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.87	-0.35	3.27e-11	HDL cholesterol;
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.98	-0.52	4.02e-24	Electroencephalogram traits;
CRC	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg00691999	chr4:55094011	PDGFRA	0.42	6.25	0.33	1.31e-9	Corneal astigmatism;
CRC	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg03469862	chr11:68924853	NA	0.47	6.03	0.32	4.33e-9	Blond vs. brown hair color;
CRC	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.16e-10	Obesity-related traits;
CRC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.42	8.58	0.43	3.72e-16	IgG glycosylation;
CRC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.34	-0.42	2.06e-15	Aortic root size;
CRC	cis	rs10486722	0.607	rs2108173	chr7:41771295	G/C	cg22138096	chr7:41772439	LOC285954	0.71	8.34	0.42	2.07e-15	Pit-and-Fissure caries;
CRC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.07	-0.32	3.57e-9	Bipolar disorder;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.45	5.82	0.31	1.39e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.72	-8.04	-0.41	1.6e-14	Obesity-related traits;
CRC	trans	rs1373453	0.908	rs17106874	chr12:70044923	G/A	cg06033789	chr8:105899330	NA	0.42	6.03	0.32	4.51e-9	Orofacial clefts;
CRC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.36	-0.46	1.31e-18	Platelet count;
CRC	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.73	-12.59	-0.57	6.05e-30	Idiopathic membranous nephropathy;
CRC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.83	12.17	0.56	2.24e-28	Intelligence (multi-trait analysis);
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-7.51	-0.38	5.51e-13	Renal function-related traits (BUN);
CRC	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.3	-0.53	3.04e-25	Coffee consumption (cups per day);
CRC	cis	rs9341808	0.591	rs7741013	chr6:80916330	G/A	cg08355045	chr6:80787529	NA	0.33	5.73	0.3	2.22e-8	Sitting height ratio;
CRC	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.34	6.16	0.32	2.18e-9	Neuroticism;
CRC	cis	rs12449964	0.524	rs4925092	chr17:17568931	A/G	cg16928487	chr17:17741425	SREBF1	-0.34	-5.74	-0.3	2.12e-8	Coronary artery disease or ischemic stroke;
CRC	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.64	8.98	0.44	2.19e-17	Platelet count;
CRC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg23136738	chr11:925521	AP2A2	-0.5	-8.18	-0.41	6.27e-15	Alzheimer's disease (late onset);
CRC	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.5	8.2	0.41	5.41e-15	HDL cholesterol;
CRC	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.75	-11.2	-0.53	6.91e-25	Waist circumference;Body mass index;
CRC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.46	-6.79	-0.35	5.37e-11	Platelet distribution width;
CRC	cis	rs6546324	0.625	rs2861689	chr2:67838604	C/G	cg15745817	chr2:67799979	NA	-0.53	-9.29	-0.46	2.25e-18	Endometriosis;
CRC	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg04239558	chr2:103089729	SLC9A4	0.35	6.07	0.32	3.58e-9	Blood protein levels;
CRC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-6.17	-0.32	2.01e-9	Schizophrenia;
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg15192750	chr16:69999425	NA	0.56	7.54	0.38	4.67e-13	IgE levels;
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.18	10.8	0.51	1.72e-23	Prostate cancer;
CRC	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	15.85	0.66	1.91e-42	Mean corpuscular hemoglobin;
CRC	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.85	0.35	3.64e-11	Hemoglobin concentration;
CRC	trans	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg03623178	chr6:28175578	NA	0.84	7.64	0.39	2.39e-13	Depression;
CRC	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.51	-8.02	-0.4	1.89e-14	Caffeine consumption;
CRC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg02659138	chr7:134003124	SLC35B4	0.38	6.31	0.33	9.12e-10	Mean platelet volume;
CRC	cis	rs4073416	0.542	rs8017880	chr14:65942924	G/C	cg03016385	chr14:66212404	NA	-0.44	-6.1	-0.32	3.05e-9	N-glycan levels;
CRC	cis	rs62229266	0.659	rs2835245	chr21:37416708	C/T	cg12218747	chr21:37451666	NA	-0.36	-6.16	-0.32	2.18e-9	Mitral valve prolapse;
CRC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.11	-0.32	2.87e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.54	-0.5	1.44e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.45	6.01	0.31	5.04e-9	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00026974	chr17:42298151	UBTF	0.44	7.0	0.36	1.44e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg03885332	chr11:832357	CD151	-0.4	-5.93	-0.31	7.57e-9	Mean platelet volume;
CRC	cis	rs883565	0.569	rs1274971	chr3:39161464	G/A	cg01426195	chr3:39028469	NA	-0.42	-7.0	-0.36	1.4e-11	Handedness;
CRC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg03013999	chr17:37608204	MED1	0.45	6.74	0.35	7.08e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.77	10.66	0.51	5.37e-23	Orofacial clefts;
CRC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg24505167	chr7:1915268	MAD1L1	-0.37	-5.68	-0.3	2.9e-8	Neuroticism;
CRC	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11161846	chr1:160990452	F11R	-0.49	-7.36	-0.38	1.48e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.28	-0.33	1.07e-9	Alzheimer's disease (late onset);
CRC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.68	11.03	0.52	2.76e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1656402	1.000	rs2077929	chr2:233425738	G/A	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.5	7.85	0.4	5.97e-14	Neurofibrillary tangles;
CRC	cis	rs7605827	0.930	rs4668445	chr2:15515838	C/T	cg19274914	chr2:15703543	NA	0.38	5.74	0.3	2.13e-8	Educational attainment (years of education);
CRC	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg25834613	chr7:1915315	MAD1L1	-0.5	-7.78	-0.39	9.28e-14	Bipolar disorder;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg20615401	chr6:28092323	ZSCAN16	0.45	5.9	0.31	9.1e-9	Cardiac Troponin-T levels;
CRC	cis	rs11955398	0.625	rs6874072	chr5:59987682	C/G	cg02684056	chr5:59996105	DEPDC1B	0.4	5.84	0.31	1.23e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6123683	0.964	rs6127983	chr20:55824475	T/C	cg13236649	chr20:55835020	BMP7	0.43	6.14	0.32	2.4e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg07606381	chr6:8435919	SLC35B3	-0.64	-9.92	-0.48	1.82e-20	Motion sickness;
CRC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.67	-9.44	-0.46	7.06e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.38	6.39	0.33	5.72e-10	Blood metabolite levels;
CRC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.61	-7.44	-0.38	9.12e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06544989	chr22:39130855	UNC84B	0.44	6.51	0.34	2.8e-10	Menopause (age at onset);
CRC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	11.11	0.52	1.46e-24	Motion sickness;
CRC	cis	rs9826463	0.582	rs73238176	chr3:142114256	G/A	cg20824294	chr3:142316082	PLS1	0.37	5.88	0.31	1.03e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.52	9.37	0.46	1.17e-18	Common traits (Other);
CRC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg09165964	chr15:75287851	SCAMP5	0.43	6.6	0.34	1.65e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.61	-6.93	-0.36	2.22e-11	Ulcerative colitis;
CRC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.55	-9.17	-0.45	5.26e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.32	-0.33	8.3e-10	Height;
CRC	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.47	8.36	0.42	1.79e-15	Quantitative traits;
CRC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg23093090	chr10:104574429	C10orf26	-0.4	-5.7	-0.3	2.7e-8	Arsenic metabolism;
CRC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21972741	chr5:435613	AHRR	0.55	7.56	0.38	4.15e-13	Cystic fibrosis severity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06247172	chr6:34216481	C6orf1	0.44	6.36	0.33	6.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.54	7.5	0.38	6.18e-13	Triglycerides;
CRC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.19	-0.41	5.96e-15	Type 2 diabetes;
CRC	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.49	-7.8	-0.39	8.46e-14	Schizophrenia;
CRC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.76	-0.35	6.34e-11	Type 2 diabetes;
CRC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.91	0.31	8.34e-9	Gout;
CRC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.87	14.34	0.62	1.4e-36	Cognitive function;
CRC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg15848620	chr12:58087721	OS9	-0.65	-9.21	-0.45	3.84e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2294693	0.679	rs12200923	chr6:40970092	T/G	cg14769373	chr6:40998127	UNC5CL	-0.46	-5.62	-0.3	4.06e-8	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.52	7.96	0.4	2.85e-14	Height;
CRC	cis	rs3736485	0.966	rs8040080	chr15:51904459	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.65	-0.34	1.22e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.88	-16.45	-0.67	8.44e-45	Coronary artery disease;
CRC	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.59	7.69	0.39	1.73e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.57	7.84	0.4	6.45e-14	Adiposity;
CRC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.22	0.49	1.81e-21	Menopause (age at onset);
CRC	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.66	0.34	1.18e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.75	-0.3	2.05e-8	Blood protein levels;
CRC	cis	rs6743226	0.811	rs12471975	chr2:242154849	C/T	cg10021735	chr2:242295487	FARP2	0.44	6.43	0.33	4.47e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.66	-0.39	2.06e-13	Total body bone mineral density;
CRC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.79	0.54	5.33e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.4	7.66	0.39	2.05e-13	Mean corpuscular volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18728606	chr19:2050773	MKNK2	0.45	6.12	0.32	2.64e-9	Anxiety disorder;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12273811	chr6:28175739	NA	0.74	9.25	0.45	2.82e-18	Depression;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6546324	0.625	rs2861700	chr2:67855441	A/G	cg15745817	chr2:67799979	NA	0.57	9.72	0.47	8.44e-20	Endometriosis;
CRC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.56	-8.73	-0.43	1.32e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23857200	chr19:39882127	MED29;PAF1	0.47	6.02	0.31	4.72e-9	Anxiety disorder;
CRC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.24e-19	Intelligence (multi-trait analysis);
CRC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07294406	chr7:64700536	NA	-0.38	-6.33	-0.33	7.88e-10	Calcium levels;
CRC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.89	-0.31	9.32e-9	Arsenic metabolism;
CRC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg11965913	chr1:205819406	PM20D1	-0.47	-6.78	-0.35	5.55e-11	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.88	0.63	1.17e-38	Intelligence (multi-trait analysis);
CRC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.49	0.53	6.66e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12580194	0.593	rs66902680	chr12:55724080	A/C	cg19537932	chr12:55886519	OR6C68	-0.7	-8.81	-0.44	7.51e-17	Cancer;
CRC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.03	0.55	7.09e-28	Menopause (age at onset);
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg12728517	chr11:6947552	ZNF215	0.56	5.95	0.31	6.96e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02290350	chr8:58132656	NA	-0.44	-6.41	-0.33	4.95e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg10756647	chr7:56101905	PSPH	0.68	7.0	0.36	1.46e-11	Diabetic kidney disease;
CRC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.83	0.31	1.32e-8	Height;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg15845792	chr6:28175446	NA	0.64	9.61	0.47	1.9e-19	Cardiac Troponin-T levels;
CRC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.82	-0.35	4.51e-11	Mood instability;
CRC	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.64	-7.52	-0.38	5.13e-13	Ulcerative colitis;
CRC	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.37	-0.46	1.19e-18	Neuroticism;
CRC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.72	-9.72	-0.47	8.27e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05402854	chr6:111408840	SLC16A10	0.33	6.25	0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07859876	chr3:50654386	MAPKAPK3	0.46	6.82	0.35	4.48e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg08999081	chr20:33150536	PIGU	0.43	5.69	0.3	2.76e-8	Protein C levels;
CRC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.7	10.76	0.51	2.47e-23	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25057861	chr10:72142518	LRRC20	0.43	6.76	0.35	6.29e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.8	-12.79	-0.58	1.12e-30	Cognitive function;
CRC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.62	8.95	0.44	2.63e-17	Menarche (age at onset);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09477292	chr4:6577027	MAN2B2	0.41	6.12	0.32	2.73e-9	Myopia (pathological);
CRC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.72	0.39	1.38e-13	Axial length;
CRC	cis	rs12519773	0.534	rs2453763	chr5:92376460	T/A	cg18783429	chr5:92414398	NA	-0.34	-7.23	-0.37	3.51e-12	Migraine;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg25164649	chr6:28176230	NA	0.59	6.01	0.31	5.06e-9	Lung cancer in ever smokers;
CRC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.75	10.94	0.52	5.76e-24	Schizophrenia;
CRC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-8.23	-0.41	4.3e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.54	8.74	0.43	1.24e-16	Gout;
CRC	cis	rs10450586	0.863	rs1478690	chr11:27295878	A/G	cg10370305	chr11:27303972	NA	-0.38	-6.25	-0.33	1.29e-9	Total body bone mineral density;
CRC	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.73	0.39	1.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg15145174	chr5:6755386	POLS	-0.46	-6.78	-0.35	5.53e-11	Menopause (age at onset);
CRC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.85	11.1	0.52	1.52e-24	Iron status biomarkers;
CRC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.71	10.46	0.5	2.62e-22	Corneal astigmatism;
CRC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.74	12.96	0.58	2.47e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.65	11.16	0.52	9.75e-25	Prostate cancer;
CRC	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.51	-6.41	-0.33	5.01e-10	Body mass index;
CRC	cis	rs12541635	0.932	rs1835267	chr8:107044435	C/T	cg10147462	chr8:107024639	NA	0.46	7.75	0.39	1.19e-13	Age of smoking initiation;
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg15704280	chr7:45808275	SEPT13	-0.62	-7.31	-0.37	2.09e-12	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg02073511	chr16:3550924	CLUAP1	0.51	6.03	0.32	4.47e-9	Body mass index;
CRC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg07090678	chr1:91966139	CDC7	-0.36	-5.63	-0.3	3.9e-8	Breast cancer;
CRC	trans	rs2084898	0.891	rs501021	chr11:120000872	T/C	cg10387956	chr15:72646210	HEXA	0.68	6.27	0.33	1.12e-9	Stroke (pediatric);
CRC	cis	rs34929064	0.536	rs2961279	chr7:22638154	T/C	cg26061582	chr7:22766209	IL6	-0.38	-5.61	-0.3	4.26e-8	Major depression and alcohol dependence;
CRC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg15396367	chr9:139972779	UAP1L1	-0.4	-6.14	-0.32	2.44e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg27194152	chr7:157982427	PTPRN2	0.38	5.94	0.31	7.26e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs12580194	0.593	rs7313465	chr12:55736863	C/T	cg23425280	chr12:56401806	NA	0.47	6.02	0.31	4.68e-9	Cancer;
CRC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.66	0.57	3.42e-30	Platelet count;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.57	-0.34	1.96e-10	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	5.96	0.31	6.6e-9	Prudent dietary pattern;
CRC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.01	0.55	8.28e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14514618	chr14:68171536	RDH12	0.42	6.04	0.32	4.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg02569458	chr12:86230093	RASSF9	0.46	7.85	0.4	6.05e-14	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00366814	chr2:75061219	HK2	-0.41	-6.25	-0.33	1.29e-9	Myopia (pathological);
CRC	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.51	0.42	6.3e-16	Hip circumference adjusted for BMI;
CRC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg20203395	chr5:56204925	C5orf35	-0.46	-6.35	-0.33	7.36e-10	Coronary artery disease;
CRC	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.37	-7.02	-0.36	1.31e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg05623727	chr3:50126028	RBM5	0.52	6.75	0.35	6.83e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.71	-0.39	1.48e-13	Bipolar disorder;
CRC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.79	0.35	5.21e-11	Axial length;
CRC	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.62	10.19	0.49	2.32e-21	Motion sickness;
CRC	cis	rs59901009	0.569	rs12280005	chr11:10228452	G/A	cg23875677	chr11:10229755	SBF2	-0.53	-5.97	-0.31	6.29e-9	Hematocrit;Hemoglobin concentration;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.58	8.48	0.42	7.69e-16	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06975499	chr17:40896881	EZH1	0.44	6.34	0.33	7.56e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.574	rs6671520	chr1:152944156	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.6	-0.34	1.64e-10	Inflammatory skin disease;
CRC	cis	rs3736485	0.789	rs11070857	chr15:51857220	C/T	cg08986416	chr15:51914746	DMXL2	-0.44	-6.1	-0.32	3e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-8.1	-0.41	1.11e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.9	-11.45	-0.53	8.8e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4660214	0.666	rs950805	chr1:39705458	A/C	cg11070191	chr1:39582205	MACF1	0.36	5.61	0.3	4.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.63	-9.6	-0.47	2.1e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg21918786	chr6:109611834	NA	0.38	6.56	0.34	2.1e-10	Reticulocyte fraction of red cells;
CRC	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg25856811	chr1:152973957	SPRR3	-0.21	-5.77	-0.3	1.81e-8	Inflammatory skin disease;
CRC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg11189052	chr15:85197271	WDR73	0.55	7.38	0.38	1.28e-12	Schizophrenia;
CRC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1891275	0.515	rs2153653	chr10:93495926	T/A	cg07889827	chr10:93443413	NA	-0.4	-6.61	-0.34	1.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg10305451	chr2:177043427	NA	0.72	11.29	0.53	3.29e-25	IgG glycosylation;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.68	0.3	2.95e-8	Depression;
CRC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-12.54	-0.57	9.61e-30	Prostate cancer;
CRC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-5.74	-0.3	2.12e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16004800	chr12:4758496	NDUFA9	0.44	6.28	0.33	1.06e-9	Response to antipsychotic treatment;
CRC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17507749	chr15:85114479	UBE2QP1	0.62	8.93	0.44	3.03e-17	Schizophrenia;
CRC	cis	rs2737618	0.698	rs2737678	chr1:200088041	C/T	cg21825944	chr1:200113062	NR5A2	-0.5	-6.94	-0.36	2.09e-11	Uric acid levels;
CRC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-6.99	-0.36	1.54e-11	Hemoglobin concentration;
CRC	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg12856521	chr11:46389249	DGKZ	-0.43	-6.73	-0.35	7.69e-11	Leprosy;
CRC	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.79	10.33	0.49	7.52e-22	Diisocyanate-induced asthma;
CRC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.15	0.71	1.69e-51	Parkinson's disease;
CRC	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.56	-0.34	2.04e-10	Electroencephalogram traits;
CRC	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.51	8.01	0.4	2.05e-14	Coronary artery disease;
CRC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.13	-0.32	2.53e-9	Fractional excretion of uric acid;
CRC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.83	13.05	0.58	1.21e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.22e-8	Protein C levels;
CRC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.96	16.87	0.68	1.95e-46	IgG glycosylation;
CRC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg13047869	chr3:10149882	C3orf24	0.55	6.66	0.34	1.17e-10	Alzheimer's disease;
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg03623178	chr6:28175578	NA	0.61	8.65	0.43	2.37e-16	Parkinson's disease;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.48	7.16	0.37	5.18e-12	Longevity;
CRC	cis	rs3026101	0.697	rs2107152	chr17:5297350	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs992157	0.730	rs2891078	chr2:219184432	C/T	cg04880052	chr2:219191631	PNKD	0.4	6.08	0.32	3.32e-9	Colorectal cancer;
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.55	7.42	0.38	1.03e-12	Height;
CRC	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg26353448	chr1:248524236	OR2T4	-0.35	-7.19	-0.37	4.3e-12	Common traits (Other);
CRC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.32	-0.37	1.88e-12	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14927277	chr11:28129967	METT5D1;KIF18A	0.5	7.2	0.37	4.09e-12	Response to antipsychotic treatment;
CRC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.72	0.6	3.35e-34	Breast cancer;
CRC	cis	rs59104589	0.521	rs60988810	chr2:242430084	C/A	cg19488206	chr2:242435732	STK25	0.43	6.92	0.36	2.31e-11	Fibrinogen levels;
CRC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-10.4	-0.5	4.29e-22	Tonsillectomy;
CRC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.23	-0.37	3.44e-12	Aortic root size;
CRC	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.34	-0.53	2.17e-25	Colorectal cancer;
CRC	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg13385794	chr1:248469461	NA	0.38	6.67	0.35	1.09e-10	Common traits (Other);
CRC	cis	rs12476592	0.602	rs262533	chr2:63906048	C/G	cg10828910	chr2:63850056	LOC388955	0.52	6.39	0.33	5.59e-10	Childhood ear infection;
CRC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.54	0.38	4.58e-13	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06452647	chr12:49961750	MCRS1	0.45	6.4	0.33	5.5e-10	Response to antipsychotic treatment;
CRC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	11.63	0.54	2.04e-26	Hip circumference adjusted for BMI;
CRC	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.88	-16.49	-0.67	5.77e-45	Hip circumference;
CRC	cis	rs7707921	0.958	rs6452447	chr5:81482522	A/G	cg17942617	chr5:81327376	ATG10	-0.4	-5.94	-0.31	7.22e-9	Breast cancer;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg20041105	chr8:143859282	LYNX1	-0.42	-6.98	-0.36	1.66e-11	Urinary tract infection frequency;
CRC	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.52	7.7	0.39	1.58e-13	Coronary artery disease;
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05398773	chr8:71581521	XKR9;LACTB2	-0.45	-7.2	-0.37	4.11e-12	Myopia (pathological);
CRC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.85	16.14	0.66	1.48e-43	Dental caries;
CRC	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.68	11.09	0.52	1.77e-24	Cancer;
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.67	9.75	0.47	6.71e-20	Alzheimer's disease;
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg04204079	chr8:58130323	NA	-0.46	-5.8	-0.3	1.57e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.57	-6.22	-0.32	1.52e-9	Coronary artery disease;
CRC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg19812747	chr11:111475976	SIK2	0.54	8.39	0.42	1.49e-15	Primary sclerosing cholangitis;
CRC	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.77	11.8	0.55	4.75e-27	Immature fraction of reticulocytes;
CRC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg01081584	chr15:40268610	EIF2AK4	-0.73	-6.59	-0.34	1.72e-10	Response to haloperidol in psychosis;
CRC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg26898958	chr10:38383359	ZNF37A	-0.42	-6.05	-0.32	3.87e-9	HDL cholesterol;
CRC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01065977	chr19:18549689	ISYNA1	0.37	5.72	0.3	2.36e-8	Breast cancer;
CRC	cis	rs9992667	0.955	rs1000571	chr4:38662895	G/A	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.02	-0.45	1.62e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.75	6.96	0.36	1.91e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.36	-10.38	-0.5	4.96e-22	Mean corpuscular volume;
CRC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.56	-8.32	-0.42	2.43e-15	Bronchopulmonary dysplasia;
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.39	-0.33	5.65e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.41	-0.38	1.1e-12	Hemoglobin concentration;
CRC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	6.26	0.33	1.22e-9	Diabetic retinopathy;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg23161317	chr6:28129485	ZNF389	0.43	5.71	0.3	2.46e-8	Parkinson's disease;
CRC	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg13086574	chr8:135490821	ZFAT	-0.36	-5.94	-0.31	7.21e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.97	-14.27	-0.62	2.6e-36	Systemic lupus erythematosus;
CRC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.66	-10.97	-0.52	4.6e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11191205	0.686	rs10883668	chr10:103398834	G/A	cg15320455	chr10:103880129	LDB1	0.56	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.59	10.67	0.51	4.86e-23	Blood metabolite ratios;
CRC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg21475434	chr5:93447410	FAM172A	-0.45	-6.36	-0.33	6.59e-10	Diabetic retinopathy;
CRC	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.58	6.68	0.35	1.02e-10	Osteoarthritis;
CRC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg24110177	chr3:50126178	RBM5	0.44	6.59	0.34	1.71e-10	Menarche (age at onset);
CRC	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-7.3	-0.37	2.21e-12	Schizophrenia;
CRC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.02	-0.4	1.83e-14	Schizophrenia;
CRC	cis	rs2033908	0.620	rs1440272	chr11:12852309	G/A	cg25843174	chr11:12811716	TEAD1	-0.4	-7.01	-0.36	1.35e-11	Sitting height ratio;
CRC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.53	7.24	0.37	3.24e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.58	-0.39	3.5e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.87	16.66	0.68	1.32e-45	Hip circumference;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg25164649	chr6:28176230	NA	0.5	5.77	0.3	1.88e-8	Depression;
CRC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.79	0.44	8.51e-17	Rheumatoid arthritis;
CRC	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.37	-8.95	-0.44	2.65e-17	Diastolic blood pressure;
CRC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2882667	1.000	rs2060222	chr5:138308466	C/T	cg09476006	chr5:138032270	NA	0.44	7.15	0.37	5.63e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg09877947	chr5:131593287	PDLIM4	0.43	7.07	0.36	9.52e-12	Breast cancer;
CRC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.45	-0.42	9.32e-16	Aortic root size;
CRC	trans	rs7395662	0.853	rs4882062	chr11:48453271	A/G	cg21153622	chr11:89784906	NA	0.45	7.0	0.36	1.42e-11	HDL cholesterol;
CRC	cis	rs12449964	0.524	rs4925093	chr17:17568946	G/T	cg09796270	chr17:17721594	SREBF1	0.46	8.01	0.4	2.05e-14	Coronary artery disease or ischemic stroke;
CRC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	6.04	0.32	4.06e-9	Schizophrenia;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.42	1.07e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12760731	0.623	rs1342849	chr1:178296692	A/G	cg00404053	chr1:178313656	RASAL2	0.71	9.05	0.45	1.31e-17	Obesity-related traits;
CRC	cis	rs4664293	0.867	rs2098976	chr2:160593775	T/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.42	6.6	0.34	1.69e-10	Monocyte count;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07308232	chr7:1071921	C7orf50	-0.45	-6.17	-0.32	1.97e-9	Longevity;Endometriosis;
CRC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.9	16.52	0.67	4.61e-45	Intelligence (multi-trait analysis);
CRC	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg13476313	chr9:127244764	NR5A1	0.28	5.71	0.3	2.55e-8	Menarche (age at onset);
CRC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16447950	chr5:562315	NA	-0.74	-9.72	-0.47	8.22e-20	Obesity-related traits;
CRC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.17	0.37	4.89e-12	Lung cancer in ever smokers;
CRC	cis	rs2882667	0.690	rs288032	chr5:138215328	G/A	cg09476006	chr5:138032270	NA	0.54	8.92	0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg18230493	chr5:56204884	C5orf35	-0.39	-5.81	-0.31	1.46e-8	Coronary artery disease;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.52	7.52	0.38	5.35e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.62	-7.79	-0.39	8.96e-14	Immature fraction of reticulocytes;
CRC	cis	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg05636881	chr10:105038444	INA	0.5	8.75	0.43	1.1e-16	Migraine;
CRC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.82	12.67	0.57	3.15e-30	Cognitive function;
CRC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.54	-6.98	-0.36	1.64e-11	Mean platelet volume;
CRC	cis	rs9463078	0.746	rs9395095	chr6:45273877	C/A	cg25276700	chr6:44698697	NA	-0.28	-6.73	-0.35	7.53e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg15786705	chr6:28176104	NA	0.6	6.74	0.35	7.32e-11	Parkinson's disease;
CRC	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.51	6.18	0.32	1.84e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs12940923	1.000	rs12940923	chr17:56369849	A/T	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg15358701	chr1:161410459	NA	-0.66	-7.03	-0.36	1.21e-11	Rheumatoid arthritis;
CRC	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg20636351	chr8:55087400	NA	-0.35	-5.98	-0.31	5.76e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11446398	chr5:77624930	NA	-0.48	-6.61	-0.34	1.51e-10	Triglycerides;
CRC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.54	6.9	0.36	2.76e-11	Morning vs. evening chronotype;
CRC	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg25686905	chr3:183603175	PARL	-0.44	-6.23	-0.32	1.44e-9	Menopause (age at onset);
CRC	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.34	-0.42	2.08e-15	Waist circumference adjusted for body mass index;
CRC	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.67	-0.34	1.12e-10	Coronary artery disease;
CRC	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg13491945	chr12:107078410	RFX4	0.35	6.06	0.32	3.67e-9	Heart rate;
CRC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-10.84	-0.51	1.29e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs3020333	0.755	rs1293935	chr6:152017958	C/G	cg22157087	chr6:152012887	ESR1	0.46	6.96	0.36	1.85e-11	Total body bone mineral density;
CRC	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.62	-0.34	1.48e-10	Educational attainment;
CRC	cis	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg16876255	chr19:9731953	ZNF561	0.68	5.71	0.3	2.5e-8	Pursuit maintenance gain;
CRC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.68	0.51	4.61e-23	Motion sickness;
CRC	cis	rs10512697	0.803	rs11745378	chr5:3579723	G/A	cg19473799	chr5:3511975	NA	-0.72	-5.69	-0.3	2.81e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6546324	0.625	rs6752799	chr2:67858503	G/A	cg15745817	chr2:67799979	NA	-0.57	-9.68	-0.47	1.16e-19	Endometriosis;
CRC	cis	rs2016266	0.614	rs7303922	chr12:53654219	A/G	cg06632207	chr12:54070931	ATP5G2	0.47	5.98	0.31	5.77e-9	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs8085804	1.000	rs658728	chr18:40222856	C/T	cg15579888	chr18:48722878	MEX3C	-0.4	-6.01	-0.31	4.8e-9	Cognitive performance;
CRC	cis	rs3889199	1.000	rs12753566	chr1:59654019	T/C	cg25881383	chr1:59680599	NA	-0.37	-6.02	-0.31	4.68e-9	Pulse pressure;
CRC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.67	12.2	0.56	1.72e-28	Prostate cancer;
CRC	cis	rs7553864	0.518	rs10747341	chr1:87627331	G/A	cg17711365	chr1:87617296	LOC339524	0.43	6.69	0.35	9.76e-11	Smoking behavior;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.76	-11.06	-0.52	2.11e-24	Intelligence (multi-trait analysis);
CRC	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg06606381	chr12:133084897	FBRSL1	-0.97	-6.84	-0.35	3.96e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.24	-0.33	1.32e-9	Aortic root size;
CRC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.42	6.44	0.33	4.34e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg17724175	chr1:150552817	MCL1	0.47	7.08	0.36	8.64e-12	Melanoma;
CRC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg24879335	chr3:133465180	TF	0.31	5.68	0.3	3.03e-8	Iron status biomarkers;
CRC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg09998033	chr7:158218633	PTPRN2	-0.48	-6.74	-0.35	7.21e-11	Obesity-related traits;
CRC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.57e-27	Cognitive function;
CRC	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.48	6.31	0.33	9.17e-10	Breast cancer;
CRC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-10.57	-0.5	1.17e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.06	-0.36	1.02e-11	IgG glycosylation;
CRC	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.72	11.23	0.53	5.64e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg09184832	chr6:79620586	NA	-0.46	-8.01	-0.4	2e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11645453	chr3:52864694	ITIH4	0.37	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02807482	chr3:125708958	NA	-0.43	-5.72	-0.3	2.37e-8	Blood pressure (smoking interaction);
CRC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.67	8.95	0.44	2.61e-17	Bladder cancer;
CRC	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	7.83	0.4	6.7e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-8.28	-0.42	3.24e-15	Bipolar disorder;
CRC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs728616	0.558	rs12414691	chr10:82156982	A/T	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.97	-0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs889398	0.741	rs6499270	chr16:69917740	A/G	cg00738113	chr16:70207722	CLEC18C	0.34	5.79	0.3	1.63e-8	Body mass index;
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18099408	chr3:52552593	STAB1	0.38	6.18	0.32	1.9e-9	Bipolar disorder;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg20512303	chr5:131592959	PDLIM4	0.38	6.97	0.36	1.75e-11	Blood metabolite levels;
CRC	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.58e-11	Opioid sensitivity;
CRC	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.74	13.51	0.6	2.16e-33	Prostate cancer;
CRC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg16606324	chr3:10149918	C3orf24	0.48	7.09	0.36	8.29e-12	Alzheimer's disease;
CRC	cis	rs720844	0.688	rs13010027	chr2:149326704	G/A	cg09247360	chr2:149335327	NA	-0.55	-5.98	-0.31	5.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	13.83	0.61	1.26e-34	Lymphocyte percentage of white cells;
CRC	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.54	8.09	0.41	1.13e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.63	0.34	1.41e-10	Rheumatoid arthritis;
CRC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.48	0.65	5.58e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.54	-0.34	2.37e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg03929089	chr4:120376271	NA	-0.55	-6.97	-0.36	1.76e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-6.85	-0.35	3.72e-11	Bone mineral density;
CRC	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg17524265	chr8:144659883	NAPRT1	0.65	5.63	0.3	3.85e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.19	-0.32	1.77e-9	Height;
CRC	trans	rs1578862	0.872	rs1771918	chr1:247433035	A/G	cg06850283	chr5:44389769	FGF10	-0.26	-6.36	-0.33	6.76e-10	Monocyte percentage of white cells;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10082270	chr16:87425748	FBXO31;MAP1LC3B	0.39	6.02	0.31	4.56e-9	Schizophrenia;
CRC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.54	-0.5	1.45e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg19678392	chr7:94953810	PON1	-0.6	-7.35	-0.38	1.54e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.43	-6.17	-0.32	2.04e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.76	-13.33	-0.59	1.07e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	18.24	0.71	7.34e-52	Colorectal cancer;
CRC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg05709478	chr1:6581295	PLEKHG5	0.65	7.63	0.39	2.57e-13	Body mass index;
CRC	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg18833306	chr6:118973337	C6orf204	0.45	5.81	0.3	1.49e-8	Diastolic blood pressure;
CRC	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.82	12.58	0.57	6.93e-30	Testicular germ cell tumor;
CRC	cis	rs8105895	0.877	rs8100768	chr19:22270468	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.63	-0.3	3.89e-8	Body mass index (change over time);
CRC	cis	rs12826942	0.605	rs17801484	chr12:42483931	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.2	0.32	1.72e-9	Coronary artery disease;
CRC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg02741985	chr17:80059408	CCDC57	-0.46	-7.37	-0.38	1.38e-12	Life satisfaction;
CRC	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg09654669	chr8:57350985	NA	-0.38	-5.65	-0.3	3.57e-8	Obesity-related traits;
CRC	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg12700464	chr11:78128424	GAB2	-0.49	-5.91	-0.31	8.33e-9	Testicular germ cell tumor;
CRC	cis	rs3736485	0.578	rs11638106	chr15:51969295	C/T	cg08986416	chr15:51914746	DMXL2	-0.39	-5.66	-0.3	3.31e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-8.83	-0.44	6.42e-17	Cognitive function;
CRC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.71	10.05	0.48	6.63e-21	Response to diuretic therapy;
CRC	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.35	-6.56	-0.34	2.09e-10	Monocyte count;
CRC	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.52	5.89	0.31	9.33e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.51	7.88	0.4	4.76e-14	Corneal astigmatism;
CRC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.72	11.6	0.54	2.62e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.02	0.4	1.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.64	-7.46	-0.38	8.01e-13	Body mass index;
CRC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.84	-16.2	-0.67	8.18e-44	Bone mineral density;
CRC	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.58	-0.34	1.9e-10	Height;
CRC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.54	8.67	0.43	1.96e-16	Aortic root size;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg06386533	chr2:46925753	SOCS5	0.45	5.67	0.3	3.15e-8	Height;
CRC	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg10523679	chr1:76189770	ACADM	-0.39	-5.61	-0.3	4.39e-8	Daytime sleep phenotypes;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.77	0.35	5.85e-11	Morning vs. evening chronotype;
CRC	cis	rs4692589	0.965	rs6847470	chr4:170954468	T/C	cg19918862	chr4:170955249	NA	0.36	5.71	0.3	2.5e-8	Anxiety disorder;
CRC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.63	-9.01	-0.44	1.73e-17	Lung cancer;
CRC	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.7	9.05	0.45	1.29e-17	Blood protein levels;
CRC	cis	rs12580194	0.593	rs7487895	chr12:55796720	T/C	cg19537932	chr12:55886519	OR6C68	-0.73	-9.28	-0.46	2.34e-18	Cancer;
CRC	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.71	-0.43	1.52e-16	Bipolar disorder;
CRC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-7.37	-0.38	1.41e-12	Coronary artery disease;
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-8.34	-0.42	2.1e-15	Intelligence (multi-trait analysis);
CRC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.52	-8.06	-0.41	1.43e-14	Body mass index;
CRC	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.65	-7.03	-0.36	1.23e-11	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.69	-10.48	-0.5	2.33e-22	Menarche (age at onset);
CRC	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.45	-6.57	-0.34	1.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.54	7.29	0.37	2.27e-12	Height;
CRC	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs4731207	0.662	rs7782031	chr7:124505784	C/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs17767392	0.595	rs60536344	chr14:71654400	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.46	-5.86	-0.31	1.15e-8	Mitral valve prolapse;
CRC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg26893134	chr6:116381904	FRK	0.28	7.97	0.4	2.67e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	7.93	0.4	3.43e-14	Obesity-related traits;
CRC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06544989	chr22:39130855	UNC84B	0.46	7.01	0.36	1.37e-11	Menopause (age at onset);
CRC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg02951883	chr7:2050386	MAD1L1	-0.75	-11.66	-0.54	1.51e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.19	0.45	4.59e-18	Height;
CRC	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs6834538	1.000	rs6823117	chr4:113447354	T/C	cg10021238	chr4:113569128	MIR367;LARP7	-0.43	-6.12	-0.32	2.62e-9	Free thyroxine concentration;
CRC	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-8.52	-0.42	6e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.34	-0.71	3.01e-52	Height;
CRC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg07211511	chr3:129823064	LOC729375	0.52	6.23	0.32	1.43e-9	Blood pressure (smoking interaction);
CRC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg15147215	chr3:52552868	STAB1	-0.54	-9.36	-0.46	1.28e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03642513	chr4:71859104	DCK	0.48	6.99	0.36	1.5e-11	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg20022578	chr7:73081950	VPS37D	0.39	5.97	0.31	6.29e-9	Schizophrenia;
CRC	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.43	-6.17	-0.32	2.02e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.58	-7.18	-0.37	4.7e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg02323633	chr5:73937762	ENC1	0.59	6.33	0.33	8.23e-10	Airway imaging phenotypes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25504222	chr19:4639508	TNFAIP8L1	0.42	6.43	0.33	4.62e-10	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg14074117	chr16:1909714	C16orf73	0.45	6.16	0.32	2.12e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23378565	chr7:2036160	MAD1L1	-0.48	-6.88	-0.35	3.08e-11	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11759937	chr19:47729458	BBC3	0.39	6.33	0.33	8.08e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.27	-0.46	2.46e-18	Body mass index;
CRC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs9463078	0.547	rs9472362	chr6:44751285	C/A	cg25276700	chr6:44698697	NA	0.3	7.62	0.39	2.74e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.43	-0.33	4.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.43	-0.33	4.62e-10	Electroencephalogram traits;
CRC	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg15845792	chr6:28175446	NA	1.01	13.44	0.6	4.09e-33	Depression;
CRC	cis	rs1950626	0.833	rs35436326	chr14:101396148	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.88	0.66	1.43e-42	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	20.81	0.75	5.86e-62	Exhaled nitric oxide output;
CRC	cis	rs6662572	0.737	rs72692603	chr1:46378838	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.74	0.3	2.17e-8	Blood protein levels;
CRC	trans	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg09045935	chr12:6379348	NA	1.03	8.86	0.44	5.29e-17	Blood metabolite levels;
CRC	trans	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg10756647	chr7:56101905	PSPH	0.74	7.74	0.39	1.23e-13	Diabetic kidney disease;
CRC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.76	11.6	0.54	2.66e-26	Intelligence (multi-trait analysis);
CRC	trans	rs17086954	0.548	rs62436482	chr6:156321151	C/T	cg07027430	chr16:7354685	A2BP1	-0.2	-5.98	-0.31	5.87e-9	Early childhood aggressive behavior;
CRC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.44	6.07	0.32	3.48e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg20503657	chr10:835505	NA	0.73	8.36	0.42	1.85e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg13856295	chr9:139396418	NOTCH1	-0.42	-5.86	-0.31	1.12e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs6761276	0.866	rs12469822	chr2:113830563	C/T	cg24553058	chr2:113831203	IL1F10	0.41	6.52	0.34	2.6200000000000003e-10	Protein quantitative trait loci;
CRC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.09	12.92	0.58	3.64e-31	Sexual dysfunction (female);
CRC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg01483505	chr11:975446	AP2A2	0.44	7.33	0.37	1.81e-12	Alzheimer's disease (late onset);
CRC	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	0.96	10.0	0.48	9.65e-21	Gut microbiota (bacterial taxa);
CRC	trans	rs10411161	0.810	rs57171871	chr19:52385332	T/C	cg22319618	chr22:45562946	NUP50	-0.69	-6.0	-0.31	5.21e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22674793	chr4:71570323	RUFY3	0.39	6.33	0.33	7.92e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6988985	0.667	rs7818953	chr8:143959289	T/C	cg10324643	chr8:143916377	GML	0.39	6.39	0.33	5.63e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07513332	chr6:167530253	CCR6	0.36	6.34	0.33	7.37e-10	Crohn's disease;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.84	18.93	0.72	1.37e-54	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg06606381	chr12:133084897	FBRSL1	-0.98	-6.94	-0.36	2.1e-11	Lung cancer in ever smokers;
CRC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg12639453	chr1:2035780	PRKCZ	0.35	6.82	0.35	4.37e-11	Height;
CRC	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg21798802	chr22:38057573	PDXP	0.37	6.11	0.32	2.75e-9	Fat distribution (HIV);
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.76	14.24	0.62	3.62e-36	Prudent dietary pattern;
CRC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg02574844	chr11:5959923	NA	-0.42	-5.73	-0.3	2.28e-8	DNA methylation (variation);
CRC	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	0.93	7.09	0.36	8.34e-12	Fat distribution (HIV);
CRC	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg02158880	chr13:53174818	NA	0.48	7.24	0.37	3.16e-12	Lewy body disease;
CRC	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.71	0.35	8.52e-11	Lymphocyte counts;
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.76e-9	Life satisfaction;
CRC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg00343986	chr7:65444356	GUSB	0.49	7.25	0.37	3.04e-12	Aortic root size;
CRC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg01721255	chr8:58191610	C8orf71	0.48	6.06	0.32	3.81e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.35	5.7	0.3	2.63e-8	Sitting height ratio;
CRC	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.51	7.82	0.4	7.42e-14	HDL cholesterol;
CRC	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.75	9.38	0.46	1.07e-18	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10457504	chr17:19281708	MAPK7	0.49	6.59	0.34	1.72e-10	Thyroid stimulating hormone;
CRC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.68	10.68	0.51	4.64e-23	Sudden cardiac arrest;
CRC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.75	-13.32	-0.59	1.14e-32	Oral cavity cancer;
CRC	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.2	12.89	0.58	4.87e-31	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg00011284	chr16:53469344	RBL2	0.51	6.09	0.32	3.1e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs9837602	0.688	rs793488	chr3:99495567	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	5.86	0.31	1.15e-8	Breast cancer;
CRC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg25811766	chr13:21894605	NA	0.57	6.77	0.35	5.88e-11	White matter hyperintensity burden;
CRC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.79	-0.44	8.62e-17	Platelet count;
CRC	cis	rs12476592	0.571	rs262520	chr2:63892432	T/C	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.41	5.69	0.3	2.8e-8	Breast cancer;
CRC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.63e-8	Morning vs. evening chronotype;
CRC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs9648716	1.000	rs56797136	chr7:140573485	C/T	cg10747023	chr7:140774559	NA	0.45	5.82	0.31	1.36e-8	Type 2 diabetes;
CRC	cis	rs7619833	0.620	rs11129270	chr3:27257943	A/G	cg02860705	chr3:27208620	NA	0.37	5.86	0.31	1.15e-8	Breast cancer;
CRC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-15.47	-0.65	5.8e-41	Prostate cancer;
CRC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg08314208	chr16:67682810	RLTPR	-0.54	-5.94	-0.31	7.18e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-8.74	-0.43	1.22e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.56	9.19	0.45	4.6e-18	Blood protein levels;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.46	5.83	0.31	1.32e-8	Lung function (FEV1/FVC);
CRC	cis	rs755249	0.567	rs61779308	chr1:39938257	C/T	cg18385671	chr1:39797026	MACF1	-0.41	-5.68	-0.3	2.93e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg25456477	chr12:86230367	RASSF9	0.33	5.78	0.3	1.69e-8	Major depressive disorder;
CRC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg21138405	chr5:131827807	IRF1	0.32	5.69	0.3	2.75e-8	Blood metabolite levels;
CRC	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg15145174	chr5:6755386	POLS	-0.46	-6.8	-0.35	5e-11	Menopause (age at onset);
CRC	cis	rs6662572	0.737	rs6673894	chr1:46301182	G/A	cg08644498	chr1:46502608	NA	-0.44	-6.97	-0.36	1.74e-11	Blood protein levels;
CRC	cis	rs60871478	0.838	rs12530859	chr7:835034	G/A	cg13798912	chr7:905769	UNC84A	-0.53	-5.88	-0.31	1.03e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.11e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.05e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.4	7.95	0.4	3.07e-14	Hypertriglyceridemia;
CRC	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-0.79	-7.72	-0.39	1.41e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg03030879	chr14:75389066	RPS6KL1	0.47	7.46	0.38	7.56e-13	Height;
CRC	cis	rs883565	0.771	rs3736573	chr3:39129742	A/C	cg01426195	chr3:39028469	NA	-0.54	-8.3	-0.42	2.82e-15	Handedness;
CRC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.76	7.42	0.38	1.04e-12	Type 2 diabetes;
CRC	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	9.72	0.47	8.54e-20	Myopia (pathological);
CRC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.98	12.79	0.58	1.12e-30	Triglycerides;
CRC	cis	rs73206853	0.764	rs6606685	chr12:110881986	C/G	cg12870014	chr12:110450643	ANKRD13A	0.7	8.9	0.44	3.95e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.77	-7.55	-0.38	4.39e-13	Coronary artery disease;
CRC	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.55	7.47	0.38	7.21e-13	Height;
CRC	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg26816564	chr1:7831052	VAMP3	-0.57	-6.59	-0.34	1.79e-10	Inflammatory bowel disease;
CRC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg20811857	chr17:78079795	GAA	0.53	7.21	0.37	3.81e-12	Yeast infection;
CRC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg14711859	chr11:8959438	ASCL3	0.42	7.03	0.36	1.23e-11	Hemoglobin concentration;
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg10217327	chr6:118973057	C6orf204	0.5	5.69	0.3	2.82e-8	Diastolic blood pressure;
CRC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg22974920	chr21:40686053	BRWD1	-0.45	-6.0	-0.31	5.12e-9	Cognitive function;
CRC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	0.69	7.77	0.39	9.92e-14	Body mass index;
CRC	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg00791851	chr1:76518896	NA	-0.4	-7.13	-0.37	6.38e-12	Personality dimensions;
CRC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.74	10.05	0.48	6.51e-21	Platelet count;
CRC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.42	-6.34	-0.33	7.48e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.24	0.37	3.2e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.57	9.7	0.47	9.56e-20	Menarche (age at onset);
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.48	-6.18	-0.32	1.85e-9	Alopecia areata;
CRC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	11.01	0.52	3.4e-24	Coronary artery disease;
CRC	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.61	-9.7	-0.47	1.02e-19	Eosinophil percentage of white cells;
CRC	trans	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg00953403	chr17:74099816	EXOC7	-0.46	-6.22	-0.32	1.54e-9	Psychosis in Alzheimer's disease;
CRC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg13809815	chr14:24912071	SDR39U1	0.43	6.53	0.34	2.43e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21613324	chr5:175875188	FAF2	0.49	6.96	0.36	1.89e-11	Response to antipsychotic treatment;
CRC	cis	rs6793245	0.801	rs41315485	chr3:38590275	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.66	-0.3	3.28e-8	QT interval;
CRC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg12564285	chr5:131593104	PDLIM4	0.38	5.65	0.3	3.55e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg00601450	chr5:74908170	NA	0.45	5.64	0.3	3.73e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-7.56	-0.38	4.12e-13	Coronary artery disease;
CRC	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.19	-9.37	-0.46	1.17e-18	Economic and political preferences (immigration/crime);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11064558	chr21:43430383	ZNF295	0.43	6.01	0.31	4.91e-9	Response to antipsychotic treatment;
CRC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.55	9.98	0.48	1.12e-20	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.59	-7.64	-0.39	2.4e-13	Diisocyanate-induced asthma;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg22561889	chr6:118971681	C6orf204	0.51	6.6	0.34	1.68e-10	Diastolic blood pressure;
CRC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.57	8.69	0.43	1.71e-16	Coronary artery disease;
CRC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.46	0.42	8.88e-16	Lymphocyte counts;
CRC	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.5	6.39	0.33	5.61e-10	Recombination rate (females);
CRC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.55	-9.04	-0.45	1.38e-17	Platelet count;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg10272801	chr16:14013773	ERCC4	-0.69	-6.16	-0.32	2.15e-9	Cognitive function;
CRC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.94	11.17	0.52	8.94e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19078334	chr9:113019254	TXN	0.42	6.08	0.32	3.42e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg17145862	chr1:211918768	LPGAT1	0.53	6.19	0.32	1.77e-9	Crohn's disease;
CRC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg20243544	chr17:37824526	PNMT	0.38	5.73	0.3	2.28e-8	Self-reported allergy;
CRC	cis	rs17155006	0.746	rs430628	chr7:107746214	T/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.67	-11.84	-0.55	3.39e-27	Prudent dietary pattern;
CRC	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.77	-8.19	-0.41	5.79e-15	Non-glioblastoma glioma;Glioma;
CRC	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.52	8.05	0.41	1.5e-14	Corneal astigmatism;
CRC	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.94	0.4	3.15e-14	Breast cancer;
CRC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.14	-0.37	6.1e-12	Height;
CRC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg25174290	chr11:3078921	CARS	-0.42	-5.82	-0.31	1.39e-8	Calcium levels;
CRC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.52	-7.98	-0.4	2.51e-14	Aortic root size;
CRC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.01	10.15	0.49	3.01e-21	Diabetic retinopathy;
CRC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.49	6.98	0.36	1.68e-11	Response to temozolomide;
CRC	cis	rs911119	0.955	rs2067488	chr20:23594331	T/G	cg16589663	chr20:23618590	CST3	0.44	6.17	0.32	1.96e-9	Chronic kidney disease;
CRC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.6	7.92	0.4	3.63e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.77	-15.11	-0.64	1.49e-39	Prostate cancer;
CRC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17848003	chr1:3704513	LRRC47	0.4	5.81	0.31	1.47e-8	Red cell distribution width;
CRC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.51	6.95	0.36	1.92e-11	Red blood cell count;
CRC	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.47	0.46	5.62e-19	Blood protein levels;
CRC	cis	rs78472555	1.000	rs11247124	chr15:100265725	C/T	cg18869061	chr15:100272053	LYSMD4	-0.54	-6.84	-0.35	3.83e-11	Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	7.97	0.4	2.71e-14	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10878768	chr1:33430605	RNF19B	0.43	6.16	0.32	2.1e-9	Response to antipsychotic treatment;
CRC	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg13919466	chr1:32135498	COL16A1	-0.31	-5.81	-0.31	1.46e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.78	-0.35	5.44e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs243505	0.559	rs7802887	chr7:148494758	C/T	cg09806900	chr7:148480153	CUL1	0.56	7.91	0.4	3.88e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.89	-15.17	-0.64	9.25e-40	Body mass index;
CRC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg21466736	chr12:48725269	NA	0.51	7.97	0.4	2.6e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg14191688	chr11:70257035	CTTN	0.4	5.65	0.3	3.55e-8	Coronary artery disease;
CRC	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.33	16.09	0.66	2.34e-43	Uric acid levels;
CRC	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.64	-0.34	1.28e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg10596483	chr8:143751796	JRK	-0.45	-6.27	-0.33	1.14e-9	Urinary tract infection frequency;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20887711	chr4:1340912	KIAA1530	-0.42	-5.98	-0.31	5.78e-9	Obesity-related traits;
CRC	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.65	8.41	0.42	1.25e-15	Prostate cancer;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg27304813	chr3:120068385	LRRC58	-0.4	-6.04	-0.32	4.13e-9	Daytime sleep phenotypes;
CRC	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg06042504	chr8:55087323	NA	-0.36	-5.72	-0.3	2.35e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.1	0.55	4.01e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2271001	0.518	rs905551	chr11:19096299	C/G	cg23684973	chr10:1780003	ADARB2	0.35	6.1	0.32	3.02e-9	Gut microbiome composition (winter);
CRC	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.07	9.25	0.45	2.99e-18	Mitochondrial DNA levels;
CRC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.36	5.69	0.3	2.8e-8	Height;
CRC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.62	-9.57	-0.47	2.68e-19	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02128655	chr19:17186722	MYO9B;HAUS8	0.39	5.97	0.31	6.07e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04568155	chr16:14724289	PARN	0.48	6.66	0.34	1.14e-10	Response to antipsychotic treatment;
CRC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.53	0.47	3.56e-19	Intelligence (multi-trait analysis);
CRC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.57	10.32	0.49	8.21e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.87	11.04	0.52	2.54e-24	Iron status biomarkers;
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07167872	chr1:205819463	PM20D1	0.45	6.18	0.32	1.93e-9	Parkinson's disease;
CRC	cis	rs12928939	0.723	rs34053338	chr16:71849974	C/T	cg03805757	chr16:71968109	PKD1L3	-0.48	-6.05	-0.32	3.83e-9	Post bronchodilator FEV1;
CRC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.54	-10.03	-0.48	7.77e-21	Dupuytren's disease;
CRC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg19223190	chr17:80058835	NA	0.41	6.59	0.34	1.78e-10	Life satisfaction;
CRC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg08075719	chr14:103021372	NA	-0.48	-6.39	-0.33	5.65e-10	Platelet count;
CRC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.69	-8.25	-0.41	3.81e-15	HIV-1 control;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg02683197	chr6:28174875	NA	0.68	9.47	0.46	5.81e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.56	9.92	0.48	1.78e-20	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg24463073	chr6:118973353	C6orf204	0.5	6.69	0.35	9.8e-11	Diastolic blood pressure;
CRC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-6.05	-0.32	4.04e-9	Fibrinogen levels;
CRC	cis	rs990171	1.000	rs3755274	chr2:103002395	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.37e-8	Lymphocyte counts;
CRC	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg00086871	chr4:6988644	TBC1D14	0.92	6.89	0.35	2.9e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.52	6.9	0.36	2.67e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-15.9	-0.66	1.28e-42	Body mass index;
CRC	cis	rs9292777	0.805	rs12659057	chr5:40414875	A/G	cg09067459	chr5:40385259	NA	0.51	8.86	0.44	4.94e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16262614	chr3:133464971	TF	0.37	6.34	0.33	7.45e-10	Iron status biomarkers;
CRC	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.91	-0.31	8.68e-9	Tuberculosis;
CRC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.48	7.31	0.37	1.99e-12	Testicular germ cell tumor;
CRC	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.0	0.44	1.91e-17	Fuchs's corneal dystrophy;
CRC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.54	12.34	0.56	5.15e-29	Breast cancer;
CRC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.57	8.61	0.43	3.11e-16	Aortic root size;
CRC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	7.98	0.4	2.47e-14	Total body bone mineral density;
CRC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.56	-0.43	4.45e-16	Aortic root size;
CRC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.6	10.24	0.49	1.56e-21	Resting heart rate;
CRC	cis	rs9311676	0.656	rs62258134	chr3:58398447	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg07513332	chr6:167530253	CCR6	-0.4	-7.25	-0.37	2.93e-12	Primary biliary cholangitis;
CRC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	9.39	0.46	1.05e-18	Schizophrenia;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.53	-0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.12	0.32	2.71e-9	Prudent dietary pattern;
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.46e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7113874	0.569	rs7131358	chr11:8558333	G/C	cg02811074	chr11:8615871	STK33	-0.36	-6.1	-0.32	2.92e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.39	-11.42	-0.53	1.14e-25	Psoriasis vulgaris;
CRC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-8.71	-0.43	1.54e-16	Neuroticism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21011043	chr12:96252937	SNRPF	0.45	6.3	0.33	9.34e-10	Anxiety disorder;
CRC	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.64	-11.26	-0.53	4.37e-25	Lewy body disease;
CRC	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg08481491	chr3:125900108	ALDH1L1	-0.34	-5.97	-0.31	6.17e-9	Metabolite levels;
CRC	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs10450586	0.863	rs6484284	chr11:27298890	C/T	cg10370305	chr11:27303972	NA	0.38	6.23	0.32	1.42e-9	Total body bone mineral density;
CRC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.73	-8.21	-0.41	5.01e-15	Psoriasis;
CRC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg03013999	chr17:37608204	MED1	0.47	7.31	0.37	2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.13	-0.45	7.11e-18	Menarche (age at onset);
CRC	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	12.11	0.56	3.5e-28	Coffee consumption (cups per day);
CRC	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.37	-0.33	6.39e-10	Breast cancer;
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.71	-0.39	1.47e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.68	-0.35	1e-10	Capecitabine sensitivity;
CRC	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.53	-9.03	-0.45	1.52e-17	Coronary artery disease;Body mass index;
CRC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.42	-8.5	-0.42	6.75e-16	Schizophrenia;
CRC	cis	rs7725052	0.609	rs4957298	chr5:40455245	G/T	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs3106136	0.843	rs7438414	chr4:95265822	T/C	cg11021082	chr4:95130006	SMARCAD1	0.41	6.17	0.32	2.04e-9	Capecitabine sensitivity;
CRC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs17767392	0.829	rs35796129	chr14:71758598	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.87	-0.35	3.2e-11	Mitral valve prolapse;
CRC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.48	-0.42	7.78e-16	Monocyte count;
CRC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.51	8.55	0.43	4.84e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs7555117	0.763	rs1461356	chr1:61037015	C/T	cg16795821	chr3:142720237	SR140	-0.36	-6.02	-0.31	4.72e-9	Facial morphology (factor 19);
CRC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-9.94	-0.48	1.51e-20	Bladder cancer;
CRC	trans	rs9813712	0.597	rs11711883	chr3:129960210	C/T	cg23942268	chr17:6347992	FAM64A	-0.41	-6.01	-0.31	5.03e-9	Response to amphetamines;
CRC	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.69	-0.3	2.83e-8	Type 2 diabetes;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg24331354	chr3:14444067	SLC6A6	-0.41	-6.0	-0.31	5.11e-9	HDL cholesterol;
CRC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.08	10.79	0.51	1.99e-23	Diabetic retinopathy;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00166722	chr3:10149974	C3orf24	0.58	7.04	0.36	1.15e-11	Alzheimer's disease;
CRC	cis	rs7849270	1.000	rs3124514	chr9:131904608	C/T	cg13538475	chr9:131942899	NA	0.33	6.23	0.33	1.4e-9	Blood metabolite ratios;
CRC	cis	rs891088	0.695	rs35296670	chr19:7198004	G/A	cg09779027	chr19:7224513	INSR	-0.61	-7.47	-0.38	7.43e-13	Hip circumference adjusted for BMI;Height;
CRC	cis	rs7680126	0.672	rs10939819	chr4:10290661	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.97	-0.31	6.23e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg17524180	chr13:113633600	MCF2L	0.52	9.24	0.45	3.04e-18	Systolic blood pressure;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	trans	rs6693295	0.605	rs4396095	chr1:246213270	A/G	cg17980625	chr11:94965587	SESN3	0.48	6.05	0.32	3.9e-9	Migraine - clinic-based;Migraine with aura;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21860679	chr12:89745673	DUSP6	0.45	6.14	0.32	2.42e-9	Anxiety disorder;
CRC	trans	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg21335942	chr16:58549945	SETD6	0.85	5.69	0.3	2.79e-8	Schizophrenia;
CRC	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.51	-0.34	2.79e-10	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.75	-0.3	2.07e-8	Life satisfaction;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg10876282	chr6:28092338	ZSCAN16	0.46	6.1	0.32	2.94e-9	Parkinson's disease;
CRC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.9	0.31	9.27e-9	Height;
CRC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.63	10.26	0.49	1.3e-21	Aortic root size;
CRC	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	6.0	0.31	5.2e-9	Neuroticism;
CRC	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.36	6.38	0.33	6.05e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg17545662	chr6:170176663	C6orf70	0.53	5.82	0.31	1.37e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.46	-7.96	-0.4	2.85e-14	Birth weight;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02010524	chr4:57333365	SRP72	0.42	6.0	0.31	5.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.42	0.42	1.16e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.91	0.44	3.67e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.33	5.65	0.3	3.5e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg17133734	chr15:86042851	AKAP13	0.4	6.53	0.34	2.5e-10	Coronary artery disease;
CRC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.34	5.63	0.3	3.95e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21306212	chr13:79979929	RBM26	0.45	6.5	0.34	2.96e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Depression;
CRC	cis	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg14515779	chr1:101123966	NA	-0.43	-8.31	-0.42	2.46e-15	Monocyte count;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg21251018	chr6:28226885	NKAPL	0.47	6.16	0.32	2.1e-9	Depression;
CRC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.65	0.39	2.21e-13	Schizophrenia;
CRC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.32e-20	Corneal astigmatism;
CRC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg07952391	chr2:88470173	THNSL2	0.6	6.24	0.33	1.32e-9	Plasma clusterin levels;
CRC	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg20356878	chr3:121714668	ILDR1	0.51	7.99	0.4	2.3e-14	Cognitive performance;
CRC	trans	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg10756647	chr7:56101905	PSPH	-0.66	-7.61	-0.39	2.95e-13	Diabetic kidney disease;
CRC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.37	-0.33	6.24e-10	Alzheimer's disease (late onset);
CRC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.6	-8.4	-0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.51	-9.28	-0.46	2.4e-18	Vitiligo;
CRC	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21659725	chr3:3221576	CRBN	0.46	6.63	0.34	1.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg12193833	chr17:30244370	NA	-0.74	-8.72	-0.43	1.45e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg05562828	chr17:3906858	NA	0.72	13.48	0.6	2.89e-33	Type 2 diabetes;
CRC	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.48	-7.22	-0.37	3.58e-12	Systemic sclerosis;
CRC	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.82	11.77	0.54	6.14e-27	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs11587400	0.656	rs6689415	chr1:115107469	G/T	cg12756093	chr1:115239321	AMPD1	0.44	6.06	0.32	3.77e-9	Autism;
CRC	cis	rs3204270	0.759	rs77740144	chr17:79608968	G/A	cg09655341	chr17:79618100	PDE6G	0.64	7.65	0.39	2.29e-13	Dental caries;
CRC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.61	7.21	0.37	3.94e-12	Hip circumference adjusted for BMI;
CRC	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.09e-10	Eye color traits;
CRC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.7e-8	Lung cancer;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.48	-6.87	-0.35	3.19e-11	Longevity;Endometriosis;
CRC	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.68	9.21	0.45	4.07e-18	Breast cancer;
CRC	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.77	-6.11	-0.32	2.81e-9	Hippocampal volume;
CRC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg05192639	chr6:26864778	GUSBL1	0.34	6.07	0.32	3.62e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.52	-9.11	-0.45	8.43e-18	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11179286	chr13:115047994	UPF3A	0.39	6.03	0.32	4.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg27094323	chr7:1216898	NA	-0.4	-6.47	-0.34	3.65e-10	Longevity;Endometriosis;
CRC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg03395651	chr16:88107091	BANP	0.55	7.29	0.37	2.31e-12	Menopause (age at onset);
CRC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.48	7.41	0.38	1.08e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs853679	0.567	rs16894106	chr6:28400339	G/A	cg21251018	chr6:28226885	NKAPL	0.42	6.11	0.32	2.78e-9	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02641675	chr6:74363634	SLC17A5	0.44	7.01	0.36	1.38e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.43e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.65	-0.3	3.47e-8	Vitiligo;
CRC	cis	rs11098699	0.821	rs13114886	chr4:124217302	T/A	cg09941581	chr4:124220074	SPATA5	0.39	5.76	0.3	1.96e-8	Mosquito bite size;
CRC	cis	rs4073416	0.508	rs7146993	chr14:66048872	A/G	cg03016385	chr14:66212404	NA	0.45	6.09	0.32	3.18e-9	N-glycan levels;
CRC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg23996704	chr18:44553084	KATNAL2	-0.34	-7.07	-0.36	9.52e-12	Personality dimensions;
CRC	cis	rs7264396	0.887	rs4281980	chr20:34096581	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.28	-0.33	1.07e-9	Total cholesterol levels;
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg04155289	chr7:94953770	PON1	-0.62	-7.71	-0.39	1.55e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg20811857	chr17:78079795	GAA	-0.41	-6.61	-0.34	1.52e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00692933	chr16:68877417	TMCO7	0.45	6.15	0.32	2.24e-9	Response to antipsychotic treatment;
CRC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.79	8.2	0.41	5.45e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg19773385	chr1:10388646	KIF1B	-0.48	-7.58	-0.39	3.44e-13	Hepatocellular carcinoma;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.27	-0.33	1.16e-9	Bipolar disorder;
CRC	cis	rs2270875	0.736	rs7832443	chr8:132886443	C/T	cg24184792	chr8:132919238	EFR3A	0.54	5.64	0.3	3.68e-8	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg06042504	chr8:55087323	NA	-0.43	-6.78	-0.35	5.55e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg25456477	chr12:86230367	RASSF9	0.38	6.65	0.34	1.23e-10	Major depressive disorder;
CRC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.37	7.26	0.37	2.85e-12	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.95e-8	Coronary artery calcification;
CRC	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.54	8.2	0.41	5.55e-15	Testicular germ cell tumor;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	ch.8.34907260F	chr8:34787718	NA	0.53	6.28	0.33	1.09e-9	Kashin-Beck disease;
CRC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.4	-5.96	-0.31	6.36e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4073416	0.518	rs8013442	chr14:65871861	A/G	cg03016385	chr14:66212404	NA	-0.43	-5.95	-0.31	6.94e-9	N-glycan levels;
CRC	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg21153622	chr11:89784906	NA	0.44	7.01	0.36	1.34e-11	HDL cholesterol;
CRC	cis	rs4321325	0.733	rs78516281	chr2:127944564	G/C	cg11380483	chr2:127933992	NA	0.57	7.11	0.36	7.23e-12	Protein C levels;
CRC	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.84	-10.4	-0.5	4.44e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11645453	chr3:52864694	ITIH4	0.34	5.92	0.31	7.98e-9	Bipolar disorder;
CRC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.83	14.63	0.63	1.06e-37	Intelligence (multi-trait analysis);
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.38	-6.69	-0.35	9.48e-11	Age at first birth;
CRC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.98	0.4	2.54e-14	Height;
CRC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.93e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.26e-9	Prudent dietary pattern;
CRC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.27e-20	Hip circumference adjusted for BMI;
CRC	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg09760422	chr2:128146352	NA	-0.36	-6.92	-0.36	2.34e-11	Protein C levels;
CRC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg24308560	chr3:49941425	MST1R	-0.43	-6.18	-0.32	1.85e-9	Resting heart rate;
CRC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.08	0.41	1.27e-14	Lung cancer;
CRC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-10.59	-0.5	9.32e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6496667	0.779	rs2074582	chr15:91009177	A/G	cg04176472	chr15:90893244	GABARAPL3	0.53	7.5	0.38	6.06e-13	Rheumatoid arthritis;
CRC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg26721908	chr21:47610096	LSS	-0.41	-6.36	-0.33	6.85e-10	Testicular germ cell tumor;
CRC	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg10761708	chr20:43804764	PI3	0.52	5.99	0.31	5.6e-9	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04680037	chr1:33430483	RNF19B	0.41	5.96	0.31	6.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg12590608	chr7:158785262	NA	0.37	6.51	0.34	2.75e-10	Facial morphology (factor 20);
CRC	cis	rs12024301	0.557	rs16861241	chr1:183589167	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.72	6.86	0.35	3.52e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.13	-0.45	7.13e-18	Bipolar disorder;
CRC	cis	rs9469890	0.604	rs78871484	chr6:34503677	T/C	cg17674042	chr6:34482479	PACSIN1	-0.66	-7.76	-0.39	1.1e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg09659197	chr4:152720779	NA	0.52	11.42	0.53	1.18e-25	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.22	-0.32	1.5e-9	Bipolar disorder;
CRC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg27432699	chr2:27873401	GPN1	0.6	9.21	0.45	3.88e-18	Total body bone mineral density;
CRC	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg15147215	chr3:52552868	STAB1	-0.45	-7.23	-0.37	3.49e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg00129232	chr17:37814104	STARD3	0.55	7.1	0.36	7.89e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.11	-0.36	7.39e-12	Gut microbiome composition (summer);
CRC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg08213375	chr14:104286397	PPP1R13B	0.58	11.92	0.55	1.83e-27	Schizophrenia;
CRC	cis	rs4234798	0.527	rs4689668	chr4:7249378	T/A	cg18431297	chr4:7219810	SORCS2	0.5	8.23	0.41	4.43e-15	Insulin-like growth factors;
CRC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26769984	chr7:1090371	C7orf50	0.55	8.11	0.41	1.01e-14	Bronchopulmonary dysplasia;
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.8	15.3	0.64	2.82e-40	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20118422	chr15:64455210	PPIB	0.41	6.76	0.35	6.42e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.5	-6.93	-0.36	2.22e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.39	-5.76	-0.3	1.94e-8	Hip circumference adjusted for BMI;
CRC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.69	-8.64	-0.43	2.52e-16	Coronary artery disease;
CRC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.6	9.42	0.46	8.3e-19	Height;
CRC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.48	-9.23	-0.45	3.35e-18	Alcohol dependence;
CRC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.78	-0.54	5.63e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg25164649	chr6:28176230	NA	0.61	8.56	0.43	4.36e-16	Parkinson's disease;
CRC	cis	rs9308731	0.965	rs6758181	chr2:111886914	C/T	cg04202892	chr2:111875749	ACOXL	0.35	5.66	0.3	3.25e-8	Chronic lymphocytic leukemia;
CRC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.7	0.3	2.61e-8	Vitiligo;
CRC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg06470822	chr6:28175283	NA	0.76	7.09	0.36	8.3e-12	Depression;
CRC	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.58	-8.81	-0.44	7.58e-17	Ulcerative colitis;
CRC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg00343986	chr7:65444356	GUSB	0.45	6.64	0.34	1.28e-10	Aortic root size;
CRC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.57	7.96	0.4	2.87e-14	Multiple sclerosis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25765569	chr12:117175636	C12orf49;RNFT2	-0.43	-6.25	-0.33	1.25e-9	Myopia (pathological);
CRC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg02569458	chr12:86230093	RASSF9	0.47	7.97	0.4	2.55e-14	Major depressive disorder;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg05031797	chr17:60557085	TLK2	-0.43	-6.2	-0.32	1.66e-9	Daytime sleep phenotypes;
CRC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.06	-0.32	3.64e-9	Major depressive disorder;
CRC	cis	rs1322512	1.000	rs9371620	chr6:152949230	T/G	cg03415253	chr6:152958462	SYNE1	-0.42	-6.43	-0.33	4.53e-10	Tonometry;
CRC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.82	0.31	1.37e-8	Diabetic retinopathy;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.45	6.01	0.31	4.87e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.63	-8.72	-0.43	1.39e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs911119	0.866	rs4815223	chr20:23577112	C/A	cg16589663	chr20:23618590	CST3	0.41	5.77	0.3	1.85e-8	Chronic kidney disease;
CRC	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg12172441	chr6:28176163	NA	0.54	7.43	0.38	9.55e-13	Parkinson's disease;
CRC	cis	rs9378357	0.850	rs7770256	chr6:3294153	G/A	cg08754725	chr6:3293098	SLC22A23	-0.81	-7.52	-0.38	5.41e-13	Obesity-related traits;
CRC	cis	rs8141797	0.901	rs5760236	chr22:24572034	G/A	cg20894457	chr22:24584366	SUSD2	0.66	6.51	0.34	2.77e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg18479299	chr3:125709523	NA	-0.49	-5.96	-0.31	6.46e-9	Blood pressure (smoking interaction);
CRC	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.1	-15.87	-0.66	1.67e-42	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.16	-0.41	6.96e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg21452805	chr1:244014465	NA	0.51	6.81	0.35	4.58e-11	RR interval (heart rate);
CRC	cis	rs73206853	0.686	rs60439011	chr12:110909179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.84	9.77	0.47	5.83e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.43	6.21	0.32	1.62e-9	HIV-1 control;
CRC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01065977	chr19:18549689	ISYNA1	-0.43	-6.76	-0.35	6.36e-11	Breast cancer;
CRC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.6	9.78	0.47	5.17e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.42	-6.33	-0.33	8.17e-10	Hemoglobin concentration;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.7	0.35	9.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9648716	1.000	rs6961127	chr7:140613952	G/T	cg10747023	chr7:140774559	NA	0.47	6.1	0.32	2.98e-9	Type 2 diabetes;
CRC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.65	-0.51	6.01e-23	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg08461752	chr10:43522343	NA	0.77	6.16	0.32	2.12e-9	Pediatric bone mineral content (radius);
CRC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.79	-0.55	5.25e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.62	-11.15	-0.52	1.06e-24	Aortic root size;
CRC	trans	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.53	-7.89	-0.4	4.38e-14	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	11.93	0.55	1.68e-27	Platelet count;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg25312474	chr6:142468512	VTA1	-0.42	-6.27	-0.33	1.17e-9	Brain structure;
CRC	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-6.45	-0.33	4.11e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.04	19.82	0.74	4.3e-58	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg19622623	chr12:86230825	RASSF9	0.4	6.36	0.33	6.66e-10	Major depressive disorder;
CRC	cis	rs17095355	1.000	rs12571674	chr10:111717608	C/T	cg00817464	chr10:111662876	XPNPEP1	0.56	6.66	0.34	1.12e-10	Biliary atresia;
CRC	cis	rs10924970	0.625	rs12044028	chr1:235492972	T/G	cg09010748	chr1:235293032	TOMM20	-0.42	-5.86	-0.31	1.13e-8	Asthma;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg00919237	chr7:87102261	ABCB4	-0.54	-7.09	-0.36	8.37e-12	Gallbladder cancer;
CRC	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.43	-5.98	-0.31	5.72e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.67	-10.28	-0.49	1.15e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.11e-12	HDL cholesterol;
CRC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.85	-14.82	-0.63	1.97e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg23254163	chr1:152506842	NA	0.5	10.11	0.49	4.05e-21	Hair morphology;
CRC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.16	0.32	2.13e-9	Aortic root size;
CRC	trans	rs9968300	0.727	rs11728154	chr4:149660723	G/A	cg17504397	chr17:38574575	TOP2A	0.55	6.02	0.31	4.54e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg21856205	chr7:94953877	PON1	0.49	6.4	0.33	5.39e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.37	5.84	0.31	1.25e-8	Total body bone mineral density;
CRC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.43	7.04	0.36	1.15e-11	Obesity-related traits;
CRC	cis	rs2072510	0.569	rs7970524	chr12:96390152	A/G	cg22491680	chr12:96389547	HAL	-0.46	-6.05	-0.32	3.93e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	15.14	0.64	1.15e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4964805	0.526	rs934845	chr12:104185257	T/G	cg02344784	chr12:104178138	NT5DC3	0.81	15.89	0.66	1.37e-42	Attention deficit hyperactivity disorder;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg18758796	chr5:131593413	PDLIM4	0.39	6.4	0.33	5.39e-10	Blood metabolite levels;
CRC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.86	14.6	0.63	1.44e-37	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.45	7.02	0.36	1.27e-11	C-reactive protein levels;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.09	0.32	3.15e-9	Bipolar disorder;
CRC	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.58	-9.45	-0.46	6.48e-19	Body mass index;
CRC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.79	11.78	0.54	5.66e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.44	-6.36	-0.33	6.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.49	-7.89	-0.4	4.5e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.52	7.31	0.37	2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.65	-0.34	1.23e-10	Eye color traits;
CRC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.7	0.3	2.7e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-18.36	-0.71	2.61e-52	Schizophrenia;
CRC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.45	-0.38	8.51e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6479527	0.806	rs10761308	chr9:96753643	A/G	cg14459158	chr9:96720562	NA	0.41	7.64	0.39	2.36e-13	Esophageal adenocarcinoma;
CRC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.59	6.45	0.33	4.05e-10	Initial pursuit acceleration;
CRC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.66	-8.1	-0.41	1.06e-14	Gut microbiome composition (summer);
CRC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.29	6.11	0.32	2.89e-9	Homoarginine levels;
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg15382696	chr6:118971807	C6orf204	0.61	7.91	0.4	4.08e-14	Diastolic blood pressure;
CRC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.9	-18.56	-0.72	3.91e-53	Urate levels in lean individuals;
CRC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg15147215	chr3:52552868	STAB1	0.43	7.23	0.37	3.5e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.56	8.69	0.43	1.7e-16	Diastolic blood pressure;
CRC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.53	8.11	0.41	1.04e-14	Fibrinogen levels;
CRC	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	7.98	0.4	2.51e-14	Iron status biomarkers;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg12273811	chr6:28175739	NA	0.53	7.6	0.39	3.1400000000000003e-13	Parkinson's disease;
CRC	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.35	0.42	1.91e-15	Schizophrenia;
CRC	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.11	0.45	8.52e-18	Systemic lupus erythematosus;
CRC	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg09344028	chr17:70110421	NA	0.49	7.33	0.37	1.77e-12	Thyroid hormone levels;
CRC	trans	rs10090774	0.760	rs10111852	chr8:141937541	A/G	cg14360659	chr9:137029702	RNU6ATAC	-0.45	-6.16	-0.32	2.11e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.27	0.59	1.76e-32	Alzheimer's disease;
CRC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07234876	chr8:600039	NA	1.0	9.43	0.46	7.42e-19	IgG glycosylation;
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg07507251	chr3:52567010	NT5DC2	0.45	6.39	0.33	5.82e-10	Bipolar disorder;
CRC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg04518342	chr5:131593106	PDLIM4	0.41	6.73	0.35	7.36e-11	Acylcarnitine levels;
CRC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.5	-6.46	-0.34	3.84e-10	Glioblastoma;
CRC	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg13722127	chr7:150037890	RARRES2	0.48	7.56	0.38	4.04e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.68	-10.66	-0.51	5.48e-23	Monocyte percentage of white cells;
CRC	trans	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg10756647	chr7:56101905	PSPH	-0.6	-7.11	-0.36	7.4e-12	Diabetic kidney disease;
CRC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.23	-14.38	-0.62	9.77e-37	Diabetic kidney disease;
CRC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.78	9.46	0.46	5.95e-19	Lung function (FEV1/FVC);
CRC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.0	-0.31	5.34e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.74	8.67	0.43	1.99e-16	Eotaxin levels;
CRC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg15226275	chr6:116381976	FRK	0.3	8.45	0.42	9.45e-16	Cholesterol, total;LDL cholesterol;
CRC	trans	rs12495832	0.778	rs77639470	chr3:147903892	G/A	cg10221266	chr7:153579447	NA	0.55	6.06	0.32	3.81e-9	Chin dimples;
CRC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.64	-9.49	-0.46	4.81e-19	Menarche (age at onset);
CRC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.93	16.45	0.67	8.26e-45	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs6460942	0.908	rs78780802	chr7:12233216	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.05	-0.32	4.03e-9	Coronary artery disease;
CRC	trans	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg10756647	chr7:56101905	PSPH	0.75	7.45	0.38	8.5e-13	Diabetic kidney disease;
CRC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg10356904	chr22:49881777	NA	-0.32	-6.02	-0.32	4.59e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.51	8.17	0.41	6.81e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.54	-8.23	-0.41	4.52e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-7.22	-0.37	3.64e-12	Ulcerative colitis;
CRC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.79	9.64	0.47	1.55e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg24848437	chr7:2645542	IQCE	-0.54	-5.82	-0.31	1.39e-8	Urate levels in lean individuals;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.2	0.49	2.13e-21	Diabetic retinopathy;
CRC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.39	6.16	0.32	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg02772935	chr3:125709198	NA	-0.48	-5.69	-0.3	2.82e-8	Blood pressure (smoking interaction);
CRC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg02659138	chr7:134003124	SLC35B4	-0.36	-5.95	-0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.45	-6.31	-0.33	9.03e-10	Blood metabolite levels;
CRC	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg23920097	chr1:209922102	NA	-0.54	-6.65	-0.34	1.22e-10	Red blood cell count;
CRC	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-14.79	-0.63	2.74e-38	Exhaled nitric oxide output;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.32	-7.02	-0.36	1.24e-11	IgG glycosylation;
CRC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-12.19	-0.56	1.82e-28	Refractive error;
CRC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.5	6.77	0.35	5.79e-11	Schizophrenia;
CRC	trans	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg04077850	chr5:125800366	GRAMD3	0.38	6.24	0.33	1.33e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.41	7.46	0.38	7.72e-13	Common traits (Other);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26034150	chr2:201936608	FAM126B;NDUFB3	0.41	6.01	0.31	4.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.05	-0.41	1.5e-14	Menarche (age at onset);
CRC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg07636037	chr3:49044803	WDR6	-0.85	-6.46	-0.34	3.81e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-5.83	-0.31	1.3e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.45	0.46	6.57e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.57	-8.76	-0.43	1.07e-16	Vitiligo;
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02825527	chr7:2087843	MAD1L1	-0.5	-5.91	-0.31	8.66e-9	Bipolar disorder;
CRC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg05585544	chr11:47624801	NA	-0.62	-10.84	-0.51	1.34e-23	Subjective well-being;
CRC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.66	11.84	0.55	3.51e-27	Eye color traits;
CRC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.55	8.84	0.44	5.93e-17	Breast cancer;
CRC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.29	0.37	2.34e-12	Systolic blood pressure;
CRC	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg08314208	chr16:67682810	RLTPR	-0.66	-7.43	-0.38	9.64e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.51	-6.55	-0.34	2.18e-10	Alzheimer's disease (survival time);
CRC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.48	6.48	0.34	3.4e-10	Schizophrenia;
CRC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.63	-8.98	-0.44	2.15e-17	Systolic blood pressure;
CRC	cis	rs10946940	0.965	rs10946935	chr6:27501345	T/C	cg21251018	chr6:28226885	NKAPL	-0.41	-6.33	-0.33	7.81e-10	Systemic lupus erythematosus;
CRC	trans	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg10756647	chr7:56101905	PSPH	0.76	7.74	0.39	1.2e-13	Diabetic kidney disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13099106	chr12:120525172	CCDC64	0.51	6.91	0.36	2.49e-11	Thyroid stimulating hormone;
CRC	cis	rs57561814	0.655	rs8180726	chr7:22749306	A/C	cg26061582	chr7:22766209	IL6	0.73	6.27	0.33	1.17e-9	Tonsillectomy;
CRC	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22985785	chr1:22352096	HSPC157	0.42	6.27	0.33	1.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16253168	chr6:13614902	NOL7	0.46	6.56	0.34	2.09e-10	Response to antipsychotic treatment;
CRC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16447950	chr5:562315	NA	-0.74	-9.76	-0.47	6.14e-20	Obesity-related traits;
CRC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg03339717	chr7:157503488	PTPRN2	0.34	5.91	0.31	8.33e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7705042	0.826	rs11749731	chr5:141500436	A/C	cg07392085	chr5:141489673	NDFIP1	0.47	7.44	0.38	8.94e-13	Asthma;
CRC	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06307176	chr5:131281290	NA	-0.43	-6.43	-0.33	4.55e-10	Life satisfaction;
CRC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.58	-0.47	2.39e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg05585544	chr11:47624801	NA	-0.62	-11.26	-0.53	4.14e-25	Subjective well-being;
CRC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg16606324	chr3:10149918	C3orf24	0.48	7.33	0.37	1.78e-12	Alzheimer's disease;
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.43	0.53	1.07e-25	Alzheimer's disease;
CRC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	7.24	0.37	3.22e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.82	14.27	0.62	2.67e-36	Blood protein levels;
CRC	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg00319359	chr11:70116639	PPFIA1	0.65	6.89	0.36	2.78e-11	Coronary artery disease;
CRC	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.71	-9.78	-0.47	5.31e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.67	0.39	1.98e-13	Lung cancer;
CRC	cis	rs4664293	0.867	rs2081722	chr2:160594208	A/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.6	-0.3	4.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.65	9.59	0.47	2.27e-19	Menopause (age at onset);
CRC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.02	0.7	5.41e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00116463	chr17:19266443	B9D1	0.38	6.21	0.32	1.64e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.6	0.47	2.18e-19	Corneal astigmatism;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07442639	chr11:3014225	NAP1L4	0.46	6.3	0.33	9.29e-10	Survival in pancreatic cancer;
CRC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.57	7.55	0.38	4.21e-13	Multiple sclerosis;
CRC	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.58	-7.39	-0.38	1.21e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg20933634	chr6:27740509	NA	0.57	8.08	0.41	1.24e-14	Parkinson's disease;
CRC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-9.74	-0.47	7.1e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg13844804	chr7:814759	HEATR2	-0.65	-8.35	-0.42	1.87e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs9462027	0.651	rs4259246	chr6:34803947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.72	-0.3	2.34e-8	Systemic lupus erythematosus;
CRC	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.59	-0.72	3.14e-53	Schizophrenia;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.68	10.43	0.5	3.34e-22	Longevity;Endometriosis;
CRC	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.44	6.97	0.36	1.75e-11	Red blood cell count;
CRC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg17948913	chr5:572064	NA	0.52	5.95	0.31	6.79e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	trans	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg10756647	chr7:56101905	PSPH	-0.76	-7.89	-0.4	4.47e-14	Diabetic kidney disease;
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg10729496	chr3:10149963	C3orf24	0.5	6.53	0.34	2.55e-10	Alzheimer's disease;
CRC	cis	rs28489187	0.706	rs233074	chr1:85809065	T/C	cg17737388	chr1:85724454	C1orf52	0.37	5.6	0.3	4.46e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg03923535	chr7:1197113	ZFAND2A	0.48	6.65	0.34	1.22e-10	Longevity;Endometriosis;
CRC	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg20469991	chr17:27169893	C17orf63	0.47	5.91	0.31	8.55e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	6.87	0.35	3.18e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.84	14.85	0.63	1.52e-38	Breast cancer;
CRC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.21	-0.53	6.35e-25	Chronic sinus infection;
CRC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg10700019	chr8:145984882	NA	-0.29	-5.79	-0.3	1.67e-8	Age at first birth;
CRC	cis	rs9891119	0.965	rs7217655	chr17:40496024	C/T	cg06270615	chr17:40516068	STAT3	-0.27	-5.97	-0.31	6.21e-9	Multiple sclerosis;Crohn's disease;
CRC	trans	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg07817883	chr1:32538562	TMEM39B	0.62	6.77	0.35	6e-11	Monocyte percentage of white cells;
CRC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg26248373	chr2:1572462	NA	-0.83	-12.38	-0.56	3.62e-29	IgG glycosylation;
CRC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.4	6.25	0.33	1.27e-9	Red blood cell count;
CRC	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg19688584	chr6:167529678	CCR6	-0.33	-6.15	-0.32	2.28e-9	Rheumatoid arthritis;
CRC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg08755490	chr11:65554678	OVOL1	0.53	6.79	0.35	5.13e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.66	-0.34	1.15e-10	Total body bone mineral density;
CRC	cis	rs9462027	0.539	rs2814963	chr6:34708908	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.12	-0.32	2.72e-9	Systemic lupus erythematosus;
CRC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg13628971	chr7:2884303	GNA12	0.42	6.58	0.34	1.85e-10	Height;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg24494008	chr3:160116838	IFT80;SMC4	-0.42	-6.32	-0.33	8.3e-10	Aortic root size;
CRC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.8	-0.3	1.52e-8	Lung cancer;
CRC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.75	12.22	0.56	1.46e-28	DNA methylation (variation);
CRC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.76	0.35	6.39e-11	Body mass index;
CRC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg00383909	chr3:49044727	WDR6	0.44	5.64	0.3	3.76e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.47	-5.91	-0.31	8.62e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs73206853	0.925	rs12310834	chr12:110762756	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	8.28	0.42	3.22e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.29	6.07	0.32	3.54e-9	Lung cancer;
CRC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.56	-0.34	2.06e-10	Total body bone mineral density;
CRC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.61	9.0	0.44	1.84e-17	Schizophrenia;
CRC	cis	rs4731207	0.671	rs4397336	chr7:124503196	C/T	cg23710748	chr7:124431027	NA	0.38	5.75	0.3	2.08e-8	Cutaneous malignant melanoma;
CRC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg18404041	chr3:52824283	ITIH1	-0.34	-6.03	-0.32	4.29e-9	Schizophrenia;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18002905	chr4:8442565	ACOX3	-0.51	-6.0	-0.31	5.23e-9	Monocyte percentage of white cells;
CRC	cis	rs4731207	0.596	rs12537473	chr7:124586711	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.87	-0.44	4.63e-17	Bipolar disorder;
CRC	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg13607699	chr17:42295918	UBTF	-0.49	-6.26	-0.33	1.17e-9	Total body bone mineral density;
CRC	cis	rs12692738	0.526	rs355862	chr2:165630100	A/G	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg05072774	chr3:49840536	C3orf54	0.43	5.87	0.31	1.08e-8	Resting heart rate;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg07005513	chr11:61595956	FADS2	-0.47	-5.8	-0.3	1.57e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs7224610	0.966	rs3794748	chr17:53365172	A/G	cg02383154	chr17:53343283	HLF	-0.33	-5.85	-0.31	1.16e-8	Urate levels;
CRC	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.57	7.92	0.4	3.6e-14	Coronary artery disease;
CRC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg16576620	chr11:61596068	FADS2	-0.47	-5.78	-0.3	1.72e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs6968419	0.714	rs17138472	chr7:115892738	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.43	-0.33	4.55e-10	Intraocular pressure;
CRC	cis	rs883565	0.740	rs6599006	chr3:39114276	T/G	cg01426195	chr3:39028469	NA	-0.54	-8.68	-0.43	1.86e-16	Handedness;
CRC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.52	0.43	5.84e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	-0.51	-8.26	-0.41	3.52e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.48	-8.35	-0.42	1.93e-15	Birth weight;
CRC	cis	rs3751196	0.708	rs12425537	chr12:104151931	T/C	cg02344784	chr12:104178138	NT5DC3	0.65	5.82	0.31	1.41e-8	Sense of smell;
CRC	cis	rs11161851	0.839	rs12120668	chr1:75321017	G/C	cg11196437	chr1:75593865	LHX8	-0.28	-5.71	-0.3	2.5e-8	Visceral fat;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg22638593	chr5:131593259	PDLIM4	0.38	6.32	0.33	8.31e-10	Breast cancer;
CRC	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg21496419	chr19:44306685	LYPD5	0.34	6.42	0.33	4.66e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.72	0.35	8.25e-11	HIV-1 control;
CRC	cis	rs7082209	0.941	rs67379075	chr10:44811968	A/C	cg09554077	chr10:44749378	NA	0.44	5.87	0.31	1.04e-8	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
CRC	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.66	10.82	0.51	1.49e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-7.34	-0.38	1.68e-12	Congenital heart disease (maternal effect);
CRC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.4	-6.58	-0.34	1.83e-10	Obesity-related traits;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg21251018	chr6:28226885	NKAPL	0.47	7.26	0.37	2.83e-12	Cardiac Troponin-T levels;
CRC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.42	-0.42	1.14e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-7.78	-0.39	9.33e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg21424120	chr2:232395308	NMUR1	0.28	5.68	0.3	3.03e-8	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18089145	chr14:39572493	SEC23A	0.41	6.07	0.32	3.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7781557	0.938	rs73192015	chr7:102511732	C/T	cg18108683	chr7:102477205	FBXL13	-0.49	-6.44	-0.33	4.12e-10	Colorectal adenoma (advanced);
CRC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg08075719	chr14:103021372	NA	0.63	7.03	0.36	1.23e-11	Platelet count;
CRC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.81	-10.88	-0.51	9.16e-24	Initial pursuit acceleration;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.56	6.71	0.35	8.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg07713946	chr22:31675144	LIMK2	0.39	5.67	0.3	3.14e-8	Colorectal cancer;
CRC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg19682013	chr15:45996608	NA	-0.3	-6.26	-0.33	1.2e-9	Waist circumference;Weight;
CRC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-5.99	-0.31	5.52e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06231882	chr16:81040594	CENPN;C16orf61	0.56	7.41	0.38	1.06e-12	Thyroid stimulating hormone;
CRC	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg20542592	chr8:11973495	FAM66D	0.32	5.63	0.3	3.82e-8	Retinal vascular caliber;
CRC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg16342193	chr10:102329863	NA	-0.36	-5.86	-0.31	1.14e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.47	-7.46	-0.38	7.67e-13	Schizophrenia;
CRC	cis	rs9659323	1.000	rs9658899	chr1:119504543	G/A	cg26570165	chr1:119541833	NA	-0.38	-6.46	-0.34	3.67e-10	Body mass index;
CRC	cis	rs2882667	0.861	rs10075541	chr5:138390318	C/T	cg09476006	chr5:138032270	NA	0.43	7.26	0.37	2.89e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.43	6.2	0.32	1.67e-9	HIV-1 control;
CRC	cis	rs2179367	0.920	rs638407	chr6:149738350	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.16	-0.32	2.08e-9	Dupuytren's disease;
CRC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.89e-9	Hemoglobin concentration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17272331	chr6:101328506	ASCC3	0.47	6.29	0.33	1.03e-9	Thyroid stimulating hormone;
CRC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg17031739	chr1:67600172	NA	0.45	7.04	0.36	1.12e-11	Psoriasis;
CRC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.76	10.85	0.51	1.21e-23	Heart rate;
CRC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.66	8.75	0.43	1.14e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	trans	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg06840491	chr10:48416966	GDF2	-0.34	-5.99	-0.31	5.54e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.69	11.59	0.54	2.89e-26	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02386183	chr20:13619553	TASP1	0.41	6.72	0.35	8.1e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.49	7.06	0.36	1.02e-11	Breast cancer;
CRC	cis	rs12936587	0.748	rs12939297	chr17:17524247	G/A	cg16928487	chr17:17741425	SREBF1	0.39	5.82	0.31	1.42e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.47	5.94	0.31	7.08e-9	Bladder cancer;
CRC	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg16141378	chr3:129829833	LOC729375	0.4	6.31	0.33	9.01e-10	Joint mobility (Beighton score);
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	cis	rs7429990	0.930	rs7374516	chr3:48002640	T/C	cg11946769	chr3:48343235	NME6	0.44	5.8	0.3	1.53e-8	Educational attainment (years of education);
CRC	cis	rs11955398	0.501	rs10067618	chr5:60010995	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.4	-5.82	-0.31	1.41e-8	Intelligence (multi-trait analysis);
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08989290	chr16:615782	NHLRC4	0.47	9.39	0.46	1.06e-18	Height;
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.8	15.29	0.64	2.98e-40	Prudent dietary pattern;
CRC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg03609598	chr5:56110824	MAP3K1	0.59	7.99	0.4	2.34e-14	Initial pursuit acceleration;
CRC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.3e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16677162	chr22:22465502	NA	0.34	6.07	0.32	3.53e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg06243866	chr13:111019493	COL4A2	-0.43	-6.72	-0.35	7.97e-11	White matter hyperintensity burden;
CRC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs3026445	0.851	rs34840178	chr12:110832027	A/G	cg12870014	chr12:110450643	ANKRD13A	0.37	5.79	0.3	1.66e-8	QT interval;
CRC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.47	7.91	0.4	3.95e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.5	9.88	0.48	2.55e-20	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00941241	chr1:9885960	CLSTN1	0.38	6.2	0.32	1.73e-9	Response to antipsychotic treatment;
CRC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11645453	chr3:52864694	ITIH4	0.47	8.38	0.42	1.55e-15	Bipolar disorder;
CRC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.79	11.57	0.54	3.43e-26	Neutrophil percentage of white cells;
CRC	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.71	-13.0	-0.58	1.87e-31	Leprosy;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg12273811	chr6:28175739	NA	0.57	8.47	0.42	8.16e-16	Parkinson's disease;
CRC	cis	rs7605827	0.897	rs4668908	chr2:15589290	G/T	cg19274914	chr2:15703543	NA	0.37	5.72	0.3	2.4e-8	Educational attainment (years of education);
CRC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.67	-0.39	1.95e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg18479299	chr3:125709523	NA	0.5	5.95	0.31	6.85e-9	Blood pressure (smoking interaction);
CRC	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.88	11.47	0.53	7.46e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.52	7.09	0.36	8.49e-12	Graves' disease;
CRC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.69	-8.98	-0.44	2.18e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.57	8.24	0.41	4.03e-15	Testicular germ cell tumor;
CRC	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	trans	rs6472235	0.837	rs4380924	chr8:66920744	C/A	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.07	-0.32	3.54e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs6840360	0.557	rs4696261	chr4:152322659	C/G	cg09659197	chr4:152720779	NA	0.33	6.32	0.33	8.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17155006	0.638	rs2074747	chr7:107744735	G/A	cg05962710	chr7:107745446	LAMB4	-0.43	-7.58	-0.39	3.63e-13	Pneumococcal bacteremia;
CRC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.55	-6.43	-0.33	4.48e-10	Initial pursuit acceleration;
CRC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.41	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg13736514	chr6:26305472	NA	-0.42	-6.96	-0.36	1.89e-11	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CRC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.52	-8.5	-0.42	6.81e-16	Body mass index;
CRC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.53	-6.58	-0.34	1.8e-10	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24840228	chr9:131037543	C9orf119;GOLGA2	0.36	5.98	0.31	5.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14561672	chr9:139014975	NA	-0.39	-6.23	-0.32	1.44e-9	Myopia (pathological);
CRC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	5.65	0.3	3.54e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg15786705	chr6:28176104	NA	0.42	6.31	0.33	8.97e-10	Pubertal anthropometrics;
CRC	cis	rs863345	0.535	rs12068285	chr1:158499632	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.18	-0.32	1.88e-9	Pneumococcal bacteremia;
CRC	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg05507819	chr15:63340323	TPM1	0.46	6.05	0.32	3.88e-9	HDL cholesterol;
CRC	cis	rs10924970	0.625	rs10925127	chr1:235378659	C/T	cg09010748	chr1:235293032	TOMM20	-0.4	-5.68	-0.3	2.98e-8	Asthma;
CRC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.71	-8.19	-0.41	6.02e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.47	7.46	0.38	7.57e-13	Red blood cell count;
CRC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.61	-8.59	-0.43	3.65e-16	Subjective well-being;
CRC	cis	rs59104589	0.617	rs62193220	chr2:242353493	G/A	cg19488206	chr2:242435732	STK25	0.43	6.4	0.33	5.37e-10	Fibrinogen levels;
CRC	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.61	-8.69	-0.43	1.69e-16	Coronary artery disease;
CRC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.58	9.76	0.47	6.18e-20	Menopause (age at onset);
CRC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg15147215	chr3:52552868	STAB1	-0.43	-7.02	-0.36	1.28e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.68	-0.35	1.04e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11355319	chr5:89825117	LYSMD3	0.41	6.0	0.31	5.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs11255291	1.000	rs11255291	chr10:7736904	C/T	cg00997801	chr10:7671259	ITIH5	0.4	5.81	0.31	1.44e-8	Ovarian reserve;
CRC	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.35	6.0	0.31	5.11e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg09264619	chr17:80180166	NA	0.35	5.84	0.31	1.25e-8	Life satisfaction;
CRC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.85	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4780401	0.901	rs34774904	chr16:11817107	G/A	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.61	-0.3	4.32e-8	Rheumatoid arthritis;
CRC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.01	-0.31	5e-9	Monocyte percentage of white cells;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg12564285	chr5:131593104	PDLIM4	0.4	7.74	0.39	1.24e-13	Blood metabolite levels;
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.57	-0.43	4.05e-16	Bipolar disorder;
CRC	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.62	-0.34	1.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7725052	0.544	rs6451500	chr5:40448195	C/G	cg09067459	chr5:40385259	NA	0.38	6.37	0.33	6.42e-10	Pediatric autoimmune diseases;
CRC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg23283495	chr1:209979779	IRF6	0.46	6.56	0.34	2.06e-10	Cleft lip with or without cleft palate;
CRC	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.75	0.35	6.71e-11	Morning vs. evening chronotype;
CRC	cis	rs12760731	0.511	rs10429850	chr1:178612000	A/G	cg00404053	chr1:178313656	RASAL2	0.58	6.88	0.35	2.96e-11	Obesity-related traits;
CRC	cis	rs12541635	0.966	rs1496182	chr8:107024505	C/T	cg10147462	chr8:107024639	NA	0.46	7.78	0.39	9.16e-14	Age of smoking initiation;
CRC	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg16416165	chr4:3325029	RGS12	0.38	5.71	0.3	2.54e-8	Mean platelet volume;
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.74	-0.51	2.81e-23	Alzheimer's disease;
CRC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.7	11.7	0.54	1.08e-26	Alzheimer's disease (late onset);
CRC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.55	-0.43	4.63e-16	Urinary metabolites;
CRC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.57	-8.76	-0.43	1.04e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7680126	0.596	rs12511337	chr4:10311972	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	6.46	0.34	3.86e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.54	-8.52	-0.43	5.82e-16	Metabolite levels (Pyroglutamine);
CRC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-8.9	-0.44	3.75e-17	Intelligence (multi-trait analysis);
CRC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.19	0.32	1.8e-9	IgG glycosylation;
CRC	trans	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.08	-15.3	-0.64	2.83e-40	Exhaled nitric oxide output;
CRC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg16342193	chr10:102329863	NA	-0.35	-5.73	-0.3	2.32e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.18	-0.45	4.97e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.79	10.54	0.5	1.45e-22	Obesity-related traits;
CRC	cis	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg16898833	chr6:26189333	HIST1H4D	-0.69	-5.9	-0.31	9.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.46	7.46	0.38	7.87e-13	Major depressive disorder;
CRC	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.58	-9.13	-0.45	6.92e-18	Hyperactive-impulsive symptoms;
CRC	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg10217327	chr6:118973057	C6orf204	0.54	5.62	0.3	4.04e-8	Diastolic blood pressure;
CRC	cis	rs2072510	0.593	rs2660838	chr12:96416383	T/C	cg09636302	chr12:96389483	HAL	-0.51	-6.28	-0.33	1.05e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.87	-0.35	3.28e-11	Bipolar disorder;
CRC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg03959625	chr15:84868606	LOC388152	0.42	6.36	0.33	6.88e-10	Schizophrenia;
CRC	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg11693508	chr17:37793320	STARD3	0.59	6.71	0.35	8.43e-11	Neuroticism;
CRC	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.57	6.66	0.34	1.19e-10	Blood trace element (Cu levels);
CRC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.7	-10.27	-0.49	1.17e-21	Multiple sclerosis;
CRC	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Hypertriglyceridemia;
CRC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.4	6.07	0.32	3.48e-9	Longevity;
CRC	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.39	6.02	0.31	4.71e-9	Endometrial cancer;
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg25164649	chr6:28176230	NA	0.78	9.69	0.47	1.04e-19	Depression;
CRC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-8.74	-0.43	1.23e-16	Personality dimensions;
CRC	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.84	-0.35	3.77e-11	Coronary artery disease;
CRC	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg07541023	chr7:19748670	TWISTNB	0.57	5.63	0.3	3.85e-8	Thyroid stimulating hormone;
CRC	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.67	0.51	5.12e-23	Bipolar disorder;
CRC	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg12870014	chr12:110450643	ANKRD13A	0.81	9.47	0.46	5.52e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.93	0.31	7.51e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-15.74	-0.66	5.06e-42	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs2223471	0.840	rs2744495	chr6:50756663	T/C	cg03432817	chr6:50765336	NA	0.4	6.5	0.34	3.01e-10	Subcutaneous adipose tissue;
CRC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.56	-8.57	-0.43	4.1e-16	Uric acid levels;
CRC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.65	-0.68	1.36e-45	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13617204	chr6:27832869	HIST1H2AL	0.38	5.98	0.31	5.87e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.69	-0.3	2.75e-8	Life satisfaction;
CRC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg22110888	chr17:80059540	CCDC57	0.38	6.07	0.32	3.61e-9	Life satisfaction;
CRC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.35	-0.38	1.63e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.25	6.66	0.34	1.17e-10	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00166722	chr3:10149974	C3orf24	-0.68	-9.35	-0.46	1.43e-18	Alzheimer's disease;
CRC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.67	-0.39	1.98e-13	Alzheimer's disease;
CRC	cis	rs2882667	0.898	rs4380651	chr5:138391072	A/G	cg09476006	chr5:138032270	NA	0.44	7.34	0.38	1.7e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.91	11.03	0.52	2.69e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.89	-16.93	-0.68	1.12e-46	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.39	-5.72	-0.3	2.42e-8	Platelet distribution width;
CRC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.3	0.67	3.49e-44	Electrocardiographic conduction measures;
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg08347473	chr17:78092826	GAA	-0.35	-5.76	-0.3	1.92e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.73	7.88	0.4	4.81e-14	Breast cancer;
CRC	cis	rs4356975	0.563	rs11932131	chr4:69949547	G/T	cg25583503	chr4:69962676	UGT2B7	-0.31	-5.68	-0.3	2.92e-8	Obesity-related traits;
CRC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.06	10.61	0.5	8.48e-23	Diabetic retinopathy;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg25164649	chr6:28176230	NA	0.54	7.3	0.37	2.13e-12	Parkinson's disease;
CRC	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06307176	chr5:131281290	NA	-0.41	-6.02	-0.32	4.58e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.61	-0.43	2.98e-16	Hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08785274	chr1:161068252	KLHDC9	0.42	6.27	0.33	1.14e-9	Response to antipsychotic treatment;
CRC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.7	-11.96	-0.55	1.24e-27	Body mass index;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg09423085	chr2:68478351	PPP3R1	0.44	6.17	0.32	2.01e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.3	0.33	9.49e-10	Lung cancer;
CRC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.46	-9.31	-0.46	1.92e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	11.32	0.53	2.65e-25	Menopause (age at onset);
CRC	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-11.77	-0.54	6.15e-27	Exhaled nitric oxide output;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg10130564	chr11:117069849	TAGLN	0.34	5.91	0.31	8.76e-9	Blood protein levels;
CRC	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-6.76	-0.35	6.2e-11	Schizophrenia;
CRC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.5	7.66	0.39	2.05e-13	Corneal astigmatism;
CRC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.98	12.83	0.58	8.19e-31	Vitiligo;
CRC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.3	0.49	9.6e-22	Menopause (age at onset);
CRC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	0.39	6.06	0.32	3.62e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.54	8.47	0.42	8.21e-16	Height;
CRC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg20487152	chr13:99095054	FARP1	-0.46	-6.65	-0.34	1.19e-10	Longevity;
CRC	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.42	6.35	0.33	7.12e-10	Neutrophil percentage of white cells;
CRC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg16898833	chr6:26189333	HIST1H4D	0.82	7.16	0.37	5.26e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.68	0.39	1.84e-13	Axial length;
CRC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.63	-8.83	-0.44	6.39e-17	DNA methylation (variation);
CRC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg20607287	chr7:12443886	VWDE	-0.64	-6.66	-0.34	1.15e-10	Coronary artery disease;
CRC	cis	rs2811415	0.597	rs11719889	chr3:127805780	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.91	-0.31	8.77e-9	Lung function (FEV1/FVC);
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg21251018	chr6:28226885	NKAPL	0.54	8.51	0.42	6.19e-16	Parkinson's disease;
CRC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.95	-17.81	-0.7	3.86e-50	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-5.97	-0.31	6.31e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.38	0.33	6.16e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.43	9.5	0.46	4.37e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.65	8.67	0.43	2.06e-16	Multiple sclerosis;
CRC	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg25856811	chr1:152973957	SPRR3	-0.23	-6.26	-0.33	1.2e-9	Inflammatory skin disease;
CRC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg18512352	chr11:47633146	NA	-0.37	-7.33	-0.37	1.75e-12	Subjective well-being;
CRC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-10.0	-0.48	9.9e-21	HDL cholesterol;
CRC	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.55	0.47	3.03e-19	Type 2 diabetes;
CRC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21028142	chr17:79581711	NPLOC4	0.34	7.01	0.36	1.35e-11	Eye color traits;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-11.4	-0.53	1.39e-25	Longevity;Endometriosis;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12172441	chr6:28176163	NA	-0.69	-9.21	-0.45	3.79e-18	Depression;
CRC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg09876464	chr15:85330779	ZNF592	0.48	8.4	0.42	1.36e-15	P wave terminal force;
CRC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.3	6.73	0.35	7.52e-11	IgG glycosylation;
CRC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg01262667	chr19:19385393	TM6SF2	0.35	5.75	0.3	2e-8	Tonsillectomy;
CRC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg17724175	chr1:150552817	MCL1	0.47	7.01	0.36	1.35e-11	Melanoma;
CRC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	12.18	0.56	2.01e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.56	7.98	0.4	2.41e-14	Melanoma;
CRC	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.35	-5.7	-0.3	2.71e-8	Left ventricle wall thickness;
CRC	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg18850127	chr7:39170497	POU6F2	0.5	6.43	0.33	4.42e-10	IgG glycosylation;
CRC	cis	rs7147624	1.000	rs61987807	chr14:66207050	G/T	cg03016385	chr14:66212404	NA	-1.04	-10.44	-0.5	3.06e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2734839	0.964	rs2734831	chr11:113293596	G/T	cg14159747	chr11:113255604	NA	-0.41	-7.16	-0.37	5.25e-12	Information processing speed;
CRC	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg26182253	chr13:112236782	NA	0.31	6.25	0.33	1.3e-9	Hepatitis;
CRC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs972578	1.000	rs4820502	chr22:43387915	C/A	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.96e-14	Mean platelet volume;
CRC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.46	7.78	0.39	9.16e-14	Alcohol dependence;
CRC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07685180	chr8:600429	NA	0.86	8.6	0.43	3.32e-16	IgG glycosylation;
CRC	cis	rs10924970	0.649	rs12729988	chr1:235372580	G/A	cg09010748	chr1:235293032	TOMM20	-0.4	-5.64	-0.3	3.72e-8	Asthma;
CRC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.88	-14.65	-0.63	9.61e-38	Blood metabolite levels;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Parkinson's disease;
CRC	cis	rs6662572	0.703	rs17855317	chr1:46500613	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.95	0.31	6.91e-9	Blood protein levels;
CRC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.63	-0.51	6.96e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.58e-8	Aortic root size;
CRC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.22e-15	Morning vs. evening chronotype;
CRC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg19193384	chr17:30244184	NA	-0.49	-6.33	-0.33	7.9e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.66	9.67	0.47	1.29e-19	Selective IgA deficiency;
CRC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.47	-9.29	-0.46	2.22e-18	Intelligence (multi-trait analysis);
CRC	cis	rs3750082	0.603	rs2278818	chr7:32961180	C/T	cg05721444	chr7:32995514	FKBP9	0.5	6.37	0.33	6.34e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.11	-0.45	8.21e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.62	10.38	0.5	5.16e-22	Colorectal cancer;
CRC	cis	rs62408225	1.000	rs62408224	chr6:90955995	A/G	cg06866423	chr6:90926672	BACH2	0.49	8.06	0.41	1.42e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.4	5.95	0.31	6.68e-9	Colorectal cancer;
CRC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-13.91	-0.61	6.53e-35	Vitiligo;
CRC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.25	-0.37	2.93e-12	Personality dimensions;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg08888203	chr3:10149979	C3orf24	0.65	7.55	0.38	4.33e-13	Alzheimer's disease;
CRC	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.42	-6.28	-0.33	1.05e-9	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14056668	chr15:52122448	TMOD3	0.51	7.19	0.37	4.32e-12	Response to antipsychotic treatment;
CRC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.59	-7.99	-0.4	2.33e-14	Response to antineoplastic agents;
CRC	cis	rs10751667	0.557	rs12281858	chr11:1022187	C/T	cg23136738	chr11:925521	AP2A2	-0.38	-5.85	-0.31	1.2e-8	Alzheimer's disease (late onset);
CRC	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.62	-0.34	1.44e-10	Menopause (age at onset);
CRC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.5	8.08	0.41	1.25e-14	Calcium levels;
CRC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.51	-5.87	-0.31	1.06e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-5.95	-0.31	6.96e-9	Renal function-related traits (BUN);
CRC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.81	-9.8	-0.48	4.51e-20	Initial pursuit acceleration;
CRC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.97	-0.31	6e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs10243593	0.698	rs10275761	chr7:40073282	A/G	cg13911576	chr9:84174038	NA	0.34	6.0	0.31	5.32e-9	Lymphocyte counts;
CRC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.28	-0.49	1.15e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg27534772	chr1:16042836	PLEKHM2	0.42	6.97	0.36	1.78e-11	Systolic blood pressure;
CRC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.12	0.45	7.86e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.68	-12.21	-0.56	1.6e-28	Lewy body disease;
CRC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.47	7.44	0.38	8.66e-13	Menopause (age at onset);
CRC	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.58	10.26	0.49	1.31e-21	Common traits (Other);
CRC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg26043149	chr18:55253948	FECH	0.53	8.1	0.41	1.12e-14	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22161983	chr8:103818636	NA	0.51	7.61	0.39	2.82e-13	Intelligence (multi-trait analysis);
CRC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.37	6.1	0.32	2.93e-9	Red cell distribution width;
CRC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4074493	0.928	rs4310430	chr1:231172881	T/G	cg22172038	chr1:231176991	FAM89A	0.34	5.86	0.31	1.14e-8	Carotid plaque burden (smoking interaction);
CRC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg24375607	chr4:120327624	NA	0.47	7.37	0.38	1.41e-12	Corneal astigmatism;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg20512303	chr5:131592959	PDLIM4	0.4	7.58	0.39	3.67e-13	Acylcarnitine levels;
CRC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.81	0.4	7.89e-14	Platelet count;
CRC	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.51	6.96	0.36	1.87e-11	Caudate activity during reward;
CRC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.47	-7.03	-0.36	1.22e-11	Response to antineoplastic agents;
CRC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.76	-0.3	1.94e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg02766259	chr12:125626809	AACS	-0.48	-7.73	-0.39	1.29e-13	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04786791	chr1:218458496	RRP15	0.42	5.99	0.31	5.62e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12651014	chr10:32735292	CCDC7	0.42	6.68	0.35	1.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1223397	0.651	rs2439535	chr6:13305822	C/T	cg07912922	chr6:13274314	PHACTR1	0.39	5.95	0.31	6.78e-9	Blood pressure;
CRC	cis	rs1873147	1.000	rs2130165	chr15:63314519	C/T	cg12160578	chr15:63334699	TPM1	-0.41	-5.94	-0.31	7.42e-9	Orofacial clefts;
CRC	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	8.68	0.43	1.88e-16	Ulcerative colitis;
CRC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.46	-7.47	-0.38	7.34e-13	Aortic root size;
CRC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.56	8.64	0.43	2.47e-16	Methadone dose in opioid dependence;
CRC	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg13385794	chr1:248469461	NA	0.38	6.67	0.35	1.06e-10	Common traits (Other);
CRC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg16102536	chr7:156981717	UBE3C	-0.39	-6.68	-0.35	9.94e-11	Body mass index;
CRC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.49	9.52	0.46	3.77e-19	Renal cell carcinoma;
CRC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.52	-7.74	-0.39	1.27e-13	Asthma;
CRC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.63	9.71	0.47	9.04e-20	Corneal astigmatism;
CRC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.44	7.69	0.39	1.67e-13	HDL cholesterol;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs6662572	0.703	rs4660909	chr1:46477326	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-6.0	-0.31	5.17e-9	Blood protein levels;
CRC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.52	-7.85	-0.4	5.78e-14	Dementia with Lewy bodies;
CRC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.47	6.89	0.35	2.9100000000000002e-11	Headache;
CRC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg06494592	chr3:125709126	NA	-0.56	-6.72	-0.35	8.11e-11	Blood pressure (smoking interaction);
CRC	cis	rs12999616	0.817	rs62157581	chr2:98327502	G/T	cg26665480	chr2:98280029	ACTR1B	0.52	6.43	0.33	4.6e-10	Colorectal cancer;
CRC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg25876840	chr17:41920477	NA	0.54	7.81	0.4	7.61e-14	Triglycerides;
CRC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.17	-0.32	2.02e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21166047	chr9:7478187	NA	-0.37	-5.97	-0.31	6.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.78	-13.06	-0.58	1.08e-31	Blood protein levels;
CRC	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	10.54	0.5	1.47e-22	Exhaled nitric oxide output;
CRC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg23758597	chr6:163146217	PARK2	-0.64	-6.28	-0.33	1.05e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg07211511	chr3:129823064	LOC729375	-0.61	-6.92	-0.36	2.42e-11	Blood pressure (smoking interaction);
CRC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-12.49	-0.57	1.4e-29	Electrocardiographic conduction measures;
CRC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg03013999	chr17:37608204	MED1	-0.45	-5.91	-0.31	8.39e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg18678763	chr11:4115507	RRM1	-0.37	-5.85	-0.31	1.19e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1179624	0.679	rs62475465	chr7:75265541	C/T	cg05145297	chr7:75264568	HIP1	0.6	8.2	0.41	5.44e-15	Age-related nuclear cataracts;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg26587870	chr6:27730563	NA	-0.42	-6.37	-0.33	6.51e-10	Parkinson's disease;
CRC	cis	rs2013441	1.000	rs9897328	chr17:20174852	G/A	cg13482628	chr17:19912719	NA	-0.4	-6.15	-0.32	2.2e-9	Obesity-related traits;
CRC	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.61	-9.28	-0.46	2.26e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.66	9.38	0.46	1.13e-18	Vitamin D levels;
CRC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.35	5.86	0.31	1.1e-8	Major depressive disorder;
CRC	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.53	9.05	0.45	1.24e-17	Educational attainment;
CRC	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.52	-6.71	-0.35	8.6e-11	Corneal structure;
CRC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.64	-10.22	-0.49	1.85e-21	Facial morphology (factor 23);
CRC	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	6.16	0.32	2.16e-9	Blood metabolite levels;
CRC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.09	0.32	3.13e-9	Aortic root size;
CRC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.68	11.44	0.53	9.34e-26	Gestational age at birth (maternal effect);
CRC	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.48	8.62	0.43	2.79e-16	Sitting height ratio;
CRC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg13798780	chr7:105162888	PUS7	0.54	6.91	0.36	2.46e-11	Bipolar disorder (body mass index interaction);
CRC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-6.85	-0.35	3.64e-11	Major depressive disorder;
CRC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.92	0.36	2.32e-11	Blood metabolite levels;
CRC	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs231513	0.954	rs231505	chr17:41970268	A/T	cg26893861	chr17:41843967	DUSP3	0.57	5.79	0.3	1.64e-8	Cognitive function;
CRC	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.61	-5.95	-0.31	6.97e-9	Yeast infection;
CRC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.03	-0.32	4.49e-9	Diabetic kidney disease;
CRC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg10298567	chr3:47292165	KIF9	0.4	6.43	0.33	4.47e-10	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21441505	chr4:1714055	SLBP	0.38	6.08	0.32	3.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg19041857	chr6:27730383	NA	-0.71	-6.65	-0.34	1.2e-10	Depression;
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.81	10.52	0.5	1.6400000000000001e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27089754	chr16:75590036	TMEM231	0.44	6.13	0.32	2.56e-9	Anxiety disorder;
CRC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.45	-7.43	-0.38	9.15e-13	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03301945	chr19:10764555	ILF3;LOC147727	0.45	6.33	0.33	7.96e-10	Anxiety disorder;
CRC	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg09659197	chr4:152720779	NA	0.51	10.79	0.51	1.88e-23	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg26875233	chr11:93583750	C11orf90	-0.31	-6.02	-0.32	4.6e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.61	8.8	0.44	7.61e-17	Schizophrenia;
CRC	cis	rs12541635	0.739	rs1896915	chr8:107083520	G/T	cg10147462	chr8:107024639	NA	0.51	9.27	0.46	2.49e-18	Age of smoking initiation;
CRC	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg02811702	chr13:24901961	NA	0.43	5.97	0.31	5.99e-9	Obesity-related traits;
CRC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs3789045	0.729	rs61817460	chr1:204543579	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.53	-7.54	-0.38	4.61e-13	Educational attainment (college completion);
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.8	13.29	0.59	1.5e-32	Menopause (age at onset);
CRC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-7.21	-0.37	3.78e-12	Coronary artery disease;
CRC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.65	-8.92	-0.44	3.39e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.51	6.87	0.35	3.15e-11	Alzheimer's disease;
CRC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.15	0.45	6.17e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12024301	0.557	rs6688641	chr1:183635678	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs11654801	0.836	rs11654932	chr17:20872947	G/A	cg23759823	chr7:139672531	TBXAS1	-0.38	-6.0	-0.31	5.26e-9	Mosquito bite size;
CRC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.26	0.33	1.17e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg07972458	chr1:204535000	NA	0.37	5.72	0.3	2.34e-8	Schizophrenia;
CRC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	0.967	rs227062	chr11:108205383	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.43	0.33	4.48e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21944135	chr22:30163316	UCRC;ZMAT5	0.41	6.11	0.32	2.83e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs17767392	0.958	rs61989374	chr14:71940581	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.18	-0.37	4.66e-12	Mitral valve prolapse;
CRC	cis	rs5747327	0.557	rs2895951	chr22:18232368	C/T	cg13346441	chr22:18231586	BID	0.34	5.61	0.3	4.2e-8	Myeloid white cell count;Granulocyte count;
CRC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.52	9.15	0.45	5.94e-18	Schizophrenia;
CRC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg27068330	chr11:65405492	SIPA1	0.48	7.0	0.36	1.45e-11	Acne (severe);
CRC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.3	0.42	2.66e-15	Intraocular pressure;
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg11900509	chr10:81946545	ANXA11	-0.71	-7.34	-0.38	1.71e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.5	-6.51	-0.34	2.76e-10	Renal function-related traits (BUN);
CRC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.75	-0.43	1.1e-16	Hemoglobin concentration;
CRC	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg22561889	chr6:118971681	C6orf204	0.53	6.68	0.35	1.01e-10	Diastolic blood pressure;
CRC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.47	-0.34	3.62e-10	Morning vs. evening chronotype;
CRC	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg01475377	chr6:109611718	NA	-0.35	-6.09	-0.32	3.18e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs7113874	0.589	rs6578969	chr11:8488991	G/A	cg17679104	chr11:8615758	STK33	-0.35	-5.78	-0.3	1.71e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.57	0.43	4.07e-16	Corneal astigmatism;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg12172441	chr6:28176163	NA	0.45	6.47	0.34	3.51e-10	Cardiac Troponin-T levels;
CRC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.44	5.97	0.31	6.18e-9	Red blood cell count;
CRC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg13390004	chr1:15929781	NA	-0.5	-7.02	-0.36	1.29e-11	Systolic blood pressure;
CRC	trans	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg10756647	chr7:56101905	PSPH	-0.79	-8.16	-0.41	7.21e-15	Diabetic kidney disease;
CRC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg05861140	chr6:150128134	PCMT1	0.36	5.77	0.3	1.84e-8	Lung cancer;
CRC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg21153622	chr11:89784906	NA	-0.5	-8.34	-0.42	2.13e-15	HDL cholesterol;
CRC	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg05110241	chr16:68378359	PRMT7	-0.44	-5.61	-0.3	4.23e-8	Schizophrenia;
CRC	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.51	-7.51	-0.38	5.74e-13	Menopause (age at onset);
CRC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-6.03	-0.32	4.32e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.51	7.81	0.4	7.63e-14	Corneal astigmatism;
CRC	trans	rs7027930	0.560	rs62531538	chr9:600893	T/C	cg27061366	chr19:13044373	FARSA	0.5	6.4	0.33	5.32e-10	Pulmonary function decline;
CRC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.84	14.74	0.63	4.19e-38	Breast cancer;
CRC	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	cg04338863	chr8:33670619	NA	0.4	6.8	0.35	5.06e-11	Body mass index;
CRC	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg11245181	chr6:149772854	ZC3H12D	0.48	7.4	0.38	1.15e-12	Dupuytren's disease;
CRC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg07195577	chr17:27052828	TLCD1	0.41	5.81	0.31	1.45e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs672059	1.000	rs544352	chr1:183157546	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.29	0.37	2.38e-12	Hypertriglyceridemia;
CRC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.65	-0.51	5.95e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.11e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.55	7.1	0.36	7.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03771878	chr16:30760186	PHKG2	0.43	6.51	0.34	2.87e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg20933634	chr6:27740509	NA	0.65	9.13	0.45	7.01e-18	Parkinson's disease;
CRC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00989217	chr21:33651492	C21orf45	0.52	7.23	0.37	3.51e-12	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.86	-0.35	3.44e-11	Major depressive disorder;
CRC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.93	-0.31	7.46e-9	Schizophrenia;
CRC	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.77	8.66	0.43	2.14e-16	Neuroticism;
CRC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg14458575	chr2:238380390	NA	0.69	8.3	0.42	2.77e-15	Prostate cancer;
CRC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.46	6.53	0.34	2.43e-10	Bipolar disorder;
CRC	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.49	8.34	0.42	2.08e-15	Common traits (Other);
CRC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.64	10.29	0.49	1.01e-21	Aortic root size;
CRC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.83	12.49	0.57	1.42e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs954108	0.809	rs715704	chr13:29369317	C/T	cg11788234	chr13:29393811	NA	-0.42	-6.62	-0.34	1.43e-10	Obesity-related traits;
CRC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.52	-9.84	-0.48	3.33e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg18151635	chr12:93972918	NA	-0.58	-8.45	-0.42	9.69e-16	Pubertal anthropometrics;
CRC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg03013999	chr17:37608204	MED1	0.47	7.3	0.37	2.19e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg24531977	chr5:56204891	C5orf35	-0.44	-6.87	-0.35	3.18e-11	Breast cancer;Breast cancer (early onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19602773	chr3:52007747	ABHD14B;ABHD14A	0.39	6.53	0.34	2.53e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.43	6.43	0.33	4.61e-10	Neutrophil percentage of white cells;
CRC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg25456477	chr12:86230367	RASSF9	0.36	6.23	0.32	1.46e-9	Major depressive disorder;
CRC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.79	11.59	0.54	2.72e-26	Neutrophil percentage of white cells;
CRC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	6.11	0.32	2.78e-9	Obesity-related traits;
CRC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17848003	chr1:3704513	LRRC47	0.39	5.65	0.3	3.42e-8	Red cell distribution width;
CRC	cis	rs2066819	1.000	rs117779516	chr12:56750872	G/C	cg26714650	chr12:56694279	CS	-1.45	-10.81	-0.51	1.6e-23	Psoriasis vulgaris;
CRC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.46	-6.71	-0.35	8.75e-11	Uric acid clearance;
CRC	cis	rs995000	0.965	rs10789113	chr1:63015199	A/T	cg19896129	chr1:63156450	NA	0.4	5.83	0.31	1.29e-8	Triglyceride levels;
CRC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.76	13.2	0.59	3.22e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.1	0.32	2.95e-9	Bladder cancer;
CRC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.41	-0.42	1.27e-15	Aortic root size;
CRC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.07	-0.32	3.57e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs12580194	0.593	rs4590978	chr12:55725086	G/T	cg19537932	chr12:55886519	OR6C68	-0.7	-8.73	-0.43	1.31e-16	Cancer;
CRC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.55	8.87	0.44	4.72e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.49	-6.91	-0.36	2.53e-11	Large artery stroke;
CRC	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg10517650	chr3:113235015	CCDC52	-0.41	-7.29	-0.37	2.4e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.72	0.3	2.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12580194	1.000	rs12580194	chr12:55696558	A/G	cg19537932	chr12:55886519	OR6C68	0.61	8.44	0.42	1.01e-15	Cancer;
CRC	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg09003973	chr2:102972529	NA	0.41	5.6	0.3	4.43e-8	Blood protein levels;
CRC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.45	6.64	0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.41	11.64	0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg05623727	chr3:50126028	RBM5	-0.45	-7.38	-0.38	1.33e-12	Intelligence (multi-trait analysis);
CRC	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.86	16.6	0.68	2.24e-45	Hip circumference;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg03623178	chr6:28175578	NA	0.94	12.21	0.56	1.62e-28	Depression;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg00614641	chr11:61596405	FADS2	-0.54	-6.49	-0.34	3.09e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.79	9.61	0.47	1.91e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-9.63	-0.47	1.69e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	11.02	0.52	3.07e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.61	-0.3	4.38e-8	Breast cancer;
CRC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg13047869	chr3:10149882	C3orf24	0.36	5.7	0.3	2.73e-8	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09755102	chr1:33283495	S100PBP;YARS	0.56	7.34	0.38	1.65e-12	Thyroid stimulating hormone;
CRC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	11.35	0.53	1.98e-25	Neutrophil percentage of white cells;
CRC	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.37	-5.93	-0.31	7.86e-9	Alcohol dependence;
CRC	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg14673194	chr17:80132900	CCDC57	0.48	6.24	0.33	1.36e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.75	-7.87	-0.4	5.12e-14	Recalcitrant atopic dermatitis;
CRC	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg00677455	chr12:58241039	CTDSP2	-0.41	-5.97	-0.31	6.21e-9	Multiple sclerosis;
CRC	cis	rs9462027	0.651	rs7752390	chr6:34790624	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.4e-9	Systemic lupus erythematosus;
CRC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.59	-6.23	-0.32	1.42e-9	Schizophrenia;
CRC	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.56	-8.95	-0.44	2.66e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs17155006	0.746	rs435522	chr7:107748701	A/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00339695	chr16:24857497	SLC5A11	0.26	6.01	0.31	5.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.53	7.83	0.4	6.78e-14	Response to temozolomide;
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.47	-6.59	-0.34	1.7e-10	Longevity;Endometriosis;
CRC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.52	-6.9	-0.36	2.75e-11	Obesity-related traits;
CRC	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.53	-7.87	-0.4	5.26e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06875740	chr19:51307921	C19orf48	0.41	6.2	0.32	1.72e-9	Obesity-related traits;
CRC	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg12560992	chr17:57184187	TRIM37	0.53	7.29	0.37	2.33e-12	Testicular germ cell tumor;
CRC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.31	-0.33	9.13e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	6.62	0.34	1.47e-10	Platelet count;
CRC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18099408	chr3:52552593	STAB1	0.34	5.81	0.31	1.46e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg15786705	chr6:28176104	NA	0.81	11.69	0.54	1.25e-26	Depression;
CRC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.19	-0.32	1.78e-9	Axial length;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg18301423	chr5:131593218	PDLIM4	0.38	6.28	0.33	1.05e-9	Breast cancer;
CRC	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg09324608	chr17:30823087	MYO1D	0.36	6.15	0.32	2.31e-9	Schizophrenia;
CRC	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.73	9.71	0.47	9.45e-20	Coronary artery disease;
CRC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.08	0.32	3.27e-9	Morning vs. evening chronotype;
CRC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.71	-11.35	-0.53	2.12e-25	Dental caries;
CRC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg17724175	chr1:150552817	MCL1	0.49	7.28	0.37	2.54e-12	Melanoma;
CRC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.82	12.17	0.56	2.14e-28	Breast cancer;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	6.96	0.36	1.9e-11	Breast cancer;
CRC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.73	11.52	0.54	5.08e-26	Intelligence (multi-trait analysis);
CRC	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg15145174	chr5:6755386	POLS	-0.4	-5.95	-0.31	7.03e-9	Menopause (age at onset);
CRC	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.45	-6.49	-0.34	3.12e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12463550	chr7:65579703	CRCP	0.59	5.78	0.3	1.7e-8	Diabetic kidney disease;
CRC	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg00105475	chr2:10696890	NA	0.46	7.47	0.38	7.36e-13	Prostate cancer;
CRC	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.66	0.47	1.31e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.82	10.63	0.51	6.79e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs2055729	0.885	rs13268133	chr8:9731470	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.58	0.34	1.84e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs17095355	1.000	rs55781439	chr10:111670220	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.81	-0.4	7.98e-14	Biliary atresia;
CRC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg15845792	chr6:28175446	NA	0.49	6.55	0.34	2.19e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.62	6.51	0.34	2.84e-10	Vitiligo;
CRC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.27	0.41	3.29e-15	Menopause (age at onset);
CRC	cis	rs7705042	0.793	rs7705547	chr5:141514027	A/G	cg08523384	chr5:141488047	NDFIP1	-0.31	-5.68	-0.3	3.02e-8	Asthma;
CRC	cis	rs939584	0.935	rs13391851	chr2:642467	A/G	cg03610516	chr2:642275	NA	0.43	5.64	0.3	3.58e-8	Body mass index;
CRC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.9	15.31	0.65	2.45e-40	Primary sclerosing cholangitis;
CRC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-6.24	-0.33	1.31e-9	Menopause (age at onset);
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg03929089	chr4:120376271	NA	0.58	6.2	0.32	1.68e-9	Intraocular pressure;
CRC	trans	rs4130344	0.595	rs7697179	chr4:159863583	A/C	cg04008429	chr3:160167646	TRIM59	-0.4	-5.97	-0.31	6.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.44	0.33	4.21e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.35	-0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.53	-7.13	-0.37	6.28e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.66	-6.15	-0.32	2.21e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.48	7.06	0.36	9.9e-12	Breast cancer;
CRC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.12	0.56	3.4e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.48	-6.5	-0.34	3.06e-10	Colorectal cancer;
CRC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	0.9	10.7	0.51	3.87e-23	Iron status biomarkers;
CRC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.09	12.59	0.57	6.33e-30	Diabetic kidney disease;
CRC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.38	-7.33	-0.37	1.75e-12	Subjective well-being;
CRC	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg04989706	chr14:50066350	PPIL5	-0.51	-7.17	-0.37	4.91e-12	Carotid intima media thickness;
CRC	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.04e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	7.41	0.38	1.09e-12	Response to antipsychotic treatment;
CRC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.53	0.5	1.51e-22	Diabetic retinopathy;
CRC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.65	10.15	0.49	3.18e-21	Initial pursuit acceleration;
CRC	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg10437265	chr15:77819839	NA	0.65	11.1	0.52	1.64e-24	Type 2 diabetes;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.58	0.34	1.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	11.09	0.52	1.74e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.84	12.6	0.57	5.55e-30	Response to antineoplastic agents;
CRC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.74	9.85	0.48	3.19e-20	Platelet count;
CRC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.69	-9.8	-0.48	4.75e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19089394	chr11:66610747	RCE1;C11orf80	0.48	6.57	0.34	1.93e-10	Anxiety disorder;
CRC	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.32	0.62	1.72e-36	Colorectal cancer;
CRC	cis	rs7630877	0.719	rs1524514	chr3:179673066	T/C	cg18765712	chr3:179670323	PEX5L	0.5	7.18	0.37	4.82e-12	Type 2 diabetes;
CRC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.52	7.29	0.37	2.29e-12	Cognitive function;
CRC	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.17	0.45	5.44e-18	Coffee consumption (cups per day);
CRC	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.82	10.15	0.49	3.13e-21	Hip circumference adjusted for BMI;
CRC	cis	rs2227564	0.645	rs2633309	chr10:75654086	G/A	cg00564723	chr10:75632066	CAMK2G	-0.24	-5.71	-0.3	2.55e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg15786705	chr6:28176104	NA	0.6	6.74	0.35	7.32e-11	Parkinson's disease;
CRC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.49	-0.46	4.71e-19	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.72	-0.3	2.41e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.08	-0.32	3.29e-9	Mood instability;
CRC	cis	rs6504622	0.905	rs2317997	chr17:45027648	T/C	cg16759221	chr17:45003025	GOSR2	-0.53	-8.42	-0.42	1.17e-15	Orofacial clefts;
CRC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-7.05	-0.36	1.09e-11	Colorectal cancer;
CRC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.33	-5.92	-0.31	7.88e-9	Menarche (age at onset);
CRC	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	cg04338863	chr8:33670619	NA	0.36	5.74	0.3	2.19e-8	Body mass index;
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.71	10.99	0.52	3.7e-24	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.861	rs10896086	chr11:65914764	T/A	cg16950941	chr11:66035639	RAB1B	-0.61	-7.47	-0.38	7.43e-13	Electroencephalogram traits;
CRC	cis	rs3750082	0.852	rs7786669	chr7:32898338	A/G	cg05721444	chr7:32995514	FKBP9	0.49	7.63	0.39	2.57e-13	Glomerular filtration rate (creatinine);
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg21115516	chr19:9251333	ZNF317	0.53	6.28	0.33	1.08e-9	Kashin-Beck disease;
CRC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.34	5.71	0.3	2.48e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	7.47	0.38	7.42e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.14	-0.32	2.42e-9	Alzheimer's disease (late onset);
CRC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg20387954	chr3:183756860	HTR3D	0.44	7.36	0.38	1.47e-12	Anterior chamber depth;
CRC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg18827107	chr12:86230957	RASSF9	-0.4	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.31	5.92	0.31	8.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.46	-9.14	-0.45	6.39e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg20631270	chr6:24437470	GPLD1	0.5	7.08	0.36	8.98e-12	Liver enzyme levels;
CRC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.63	13.35	0.59	8.5e-33	Schizophrenia;
CRC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.48	-0.34	3.37e-10	Monocyte percentage of white cells;
CRC	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-0.96	-9.0	-0.44	1.82e-17	Pulse pressure;
CRC	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.64	8.69	0.43	1.78e-16	Uric acid levels;
CRC	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.44	-8.45	-0.42	9.35e-16	Alcohol dependence;
CRC	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg05139728	chr16:28306816	SBK1	-0.33	-5.63	-0.3	3.77e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.63	-9.93	-0.48	1.71e-20	Systemic lupus erythematosus;
CRC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.03	0.68	4.35e-47	Electrocardiographic conduction measures;
CRC	cis	rs728616	0.614	rs17678338	chr10:82098146	C/T	cg05935833	chr10:81318306	SFTPA2	-0.59	-7.26	-0.37	2.73e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	7.7	0.39	1.63e-13	Height;
CRC	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg16753122	chr16:57506917	DOK4	0.54	6.28	0.33	1.05e-9	Blood protein levels;
CRC	cis	rs17767392	0.718	rs35609708	chr14:71843844	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs12760731	0.565	rs11580064	chr1:178226520	A/G	cg00404053	chr1:178313656	RASAL2	0.96	10.07	0.49	5.59e-21	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs55821334	chr2:162452014	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.17	-0.32	2.06e-9	Cognitive function;
CRC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.69	-11.2	-0.53	7.13e-25	Lung cancer;
CRC	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg12458913	chr13:53173898	NA	0.39	5.7	0.3	2.73e-8	Lewy body disease;
CRC	cis	rs11212617	0.967	rs227076	chr11:108218905	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.34	0.33	7.54e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.57	8.33	0.42	2.24e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs559356	0.519	rs554650	chr3:34840139	G/A	cg18960307	chr17:4699574	PSMB6	0.4	6.04	0.32	4.2e-9	Cognitive function;
CRC	cis	rs10450586	0.863	rs7484147	chr11:27298126	T/C	cg10370305	chr11:27303972	NA	0.38	6.11	0.32	2.86e-9	Total body bone mineral density;
CRC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	12.05	0.55	6.02e-28	Mean platelet volume;
CRC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg03037974	chr15:76606532	NA	0.69	12.06	0.55	5.61e-28	Blood metabolite levels;
CRC	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.44	-7.45	-0.38	8.16e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	4.04e-9	Total body bone mineral density;
CRC	cis	rs7680126	0.596	rs35782983	chr4:10117728	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-6.28	-0.33	1.08e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07570687	chr10:102243282	WNT8B	0.44	5.66	0.3	3.36e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.61	9.28	0.46	2.42e-18	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23152667	chr5:77072348	TBCA	0.42	6.49	0.34	3.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg12560992	chr17:57184187	TRIM37	-0.57	-7.87	-0.4	5.06e-14	Testicular germ cell tumor;
CRC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.84	0.4	6.37e-14	Colorectal cancer;
CRC	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg27398640	chr15:77910606	LINGO1	0.42	7.09	0.36	8.26e-12	Type 2 diabetes;
CRC	cis	rs3825932	0.961	rs28655102	chr15:79232700	C/T	cg25744700	chr15:79237217	CTSH	0.39	5.97	0.31	6.3e-9	Type 1 diabetes;
CRC	cis	rs62577244	0.645	rs12001733	chr9:138431675	G/T	cg14582108	chr9:138439003	OBP2A	0.52	8.06	0.41	1.39e-14	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
CRC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-7.74	-0.39	1.27e-13	Mean corpuscular volume;
CRC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg00409905	chr10:38381863	ZNF37A	0.47	6.3	0.33	9.75e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.57e-9	Bladder cancer;
CRC	cis	rs7725052	0.609	rs7721742	chr5:40474477	A/G	cg09067459	chr5:40385259	NA	0.4	6.57	0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6594713	0.819	rs13180522	chr5:112726022	A/G	cg12552261	chr5:112820674	MCC	0.42	5.76	0.3	1.96e-8	Brain cytoarchitecture;
CRC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.62	-11.15	-0.52	1.06e-24	Aortic root size;
CRC	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg07699608	chr10:75541558	CHCHD1	0.7	6.76	0.35	6.2e-11	Incident atrial fibrillation;
CRC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.36	5.93	0.31	7.49e-9	Survival in rectal cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23486179	chr3:49466665	NICN1	0.45	6.03	0.32	4.43e-9	Hip circumference;
CRC	cis	rs6758955	0.850	rs55638790	chr2:10480389	C/T	cg15773312	chr2:10472214	HPCAL1	-0.83	-9.76	-0.47	6.34e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg23254163	chr1:152506842	NA	0.47	9.51	0.46	4.23e-19	Hair morphology;
CRC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.5	6.71	0.35	8.27e-11	Optic nerve measurement (cup area);
CRC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-10.44	-0.5	3.04e-22	Initial pursuit acceleration;
CRC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.77e-10	Bladder cancer;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.41	0.33	5.03e-10	Electroencephalogram traits;
CRC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.24	0.45	3.04e-18	Bladder cancer;
CRC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.33	-5.76	-0.3	1.88e-8	Menarche (age at onset);
CRC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.5	-7.59	-0.39	3.31e-13	Obesity-related traits;
CRC	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.04	18.28	0.71	5.3e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.63	-9.67	-0.47	1.22e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.41	0.42	1.28e-15	Schizophrenia;
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.4	-5.82	-0.31	1.38e-8	Bipolar disorder;
CRC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.48	7.19	0.37	4.29e-12	Corneal astigmatism;
CRC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12311346	chr5:56204834	C5orf35	-0.44	-6.7	-0.35	9.07e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg14593290	chr7:50529359	DDC	-0.65	-8.61	-0.43	3.06e-16	Malaria;
CRC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	6.16	0.32	2.16e-9	Retinal vascular caliber;
CRC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-10.08	-0.49	5.44e-21	Bipolar disorder;
CRC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Bladder cancer;
CRC	cis	rs10733682	0.524	rs10987422	chr9:129462687	C/A	cg00232160	chr9:129468157	NA	0.34	5.78	0.3	1.76e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.68	-8.82	-0.44	7.03e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.49	9.8	0.48	4.76e-20	Ulcerative colitis;
CRC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg19847866	chr10:1019161	NA	-0.39	-5.69	-0.3	2.85e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.42	5.71	0.3	2.47e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs11209185	0.509	rs9436789	chr1:68441456	G/A	cg22082780	chr1:68452167	NA	0.39	5.82	0.31	1.44e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	9.76	0.47	6.16e-20	Calcium levels;
CRC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg24849736	chr1:201084428	NA	0.59	10.5	0.5	1.97e-22	Permanent tooth development;
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.7	8.56	0.43	4.4e-16	Body mass index;
CRC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.43	-5.88	-0.31	1e-8	Height;
CRC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.54	8.62	0.43	2.78e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-11.0	-0.52	3.53e-24	Prudent dietary pattern;
CRC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	1.02	18.52	0.71	5.84e-53	Parkinson's disease;
CRC	cis	rs7705042	0.865	rs249643	chr5:141524746	C/G	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.5e-8	Asthma;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg08533674	chr1:46993347	NA	-0.82	-10.33	-0.49	7.5e-22	Monobrow;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02359409	chr6:42947317	PEX6	-0.58	-9.16	-0.45	5.57e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg04904318	chr17:46607828	HOXB1	-0.53	-6.12	-0.32	2.64e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07921184	chr16:71880281	ATXN1L	0.45	7.0	0.36	1.44e-11	Schizophrenia;
CRC	trans	rs75246769	0.636	rs76951614	chr7:145700773	C/G	cg14916917	chr5:81574294	RPS23	0.94	6.38	0.33	6.08e-10	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.49	6.85	0.35	3.71e-11	Schizophrenia;
CRC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2e-8	Bladder cancer;
CRC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.33	10.98	0.52	4.15e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4917833	0.752	rs4598598	chr10:100216817	C/T	cg25691326	chr10:100228212	HPSE2	0.35	5.64	0.3	3.67e-8	Pediatric bone mineral density (femoral neck);
CRC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.49	6.52	0.34	2.61e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg04545296	chr12:48745243	ZNF641	0.36	6.0	0.31	5.27e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.65	-9.15	-0.45	5.97e-18	Autism;
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00166722	chr3:10149974	C3orf24	-0.66	-7.96	-0.4	2.79e-14	Alzheimer's disease;
CRC	cis	rs4654899	0.895	rs7515590	chr1:21216664	T/C	cg02927042	chr1:21476669	EIF4G3	0.42	6.74	0.35	7.06e-11	Superior frontal gyrus grey matter volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06300141	chr3:32612708	DYNC1LI1	0.51	7.62	0.39	2.81e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.56	7.97	0.4	2.71e-14	Lung cancer;
CRC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.46	-6.07	-0.32	3.59e-9	Gut microbiome composition (summer);
CRC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.56	7.76	0.39	1.05e-13	Gestational age at birth (maternal effect);
CRC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.54	8.62	0.43	2.95e-16	Prostate cancer;
CRC	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	8.44	0.42	1.05e-15	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-8.51	-0.42	6.25e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.41	-6.26	-0.33	1.23e-9	Mean platelet volume;
CRC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.09	18.35	0.71	2.76e-52	Total cholesterol levels;
CRC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.61	9.85	0.48	3.15e-20	Height;
CRC	cis	rs6952809	1.000	rs7350030	chr7:2449157	G/A	cg23289794	chr7:2394357	EIF3B	-0.42	-5.71	-0.3	2.58e-8	Multiple sclerosis;
CRC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.46	6.6	0.34	1.66e-10	Melanoma;
CRC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg00074818	chr8:8560427	CLDN23	0.36	6.73	0.35	7.71e-11	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.12	-0.32	2.69e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg27535305	chr1:53392650	SCP2	-0.35	-6.46	-0.34	3.79e-10	Monocyte count;
CRC	trans	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.03	-0.32	4.31e-9	Aortic root size;
CRC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	5.98	0.31	5.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.86	-0.35	3.52e-11	Mean corpuscular volume;
CRC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.56	9.28	0.46	2.29e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.43	-6.36	-0.33	6.82e-10	Body mass index;
CRC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg08772003	chr10:104629869	AS3MT	0.35	6.34	0.33	7.55e-10	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg11861562	chr11:117069780	TAGLN	0.28	6.16	0.32	2.12e-9	Blood protein levels;
CRC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg00647820	chr17:40259828	DHX58	-0.46	-6.59	-0.34	1.78e-10	Fibrinogen levels;
CRC	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.64	10.47	0.5	2.56e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg12870014	chr12:110450643	ANKRD13A	0.85	10.3	0.49	9.63e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.04	0.36	1.13e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.63	7.62	0.39	2.76e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2414095	0.520	rs3784307	chr15:51506634	G/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.11	-0.32	2.79e-9	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
CRC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.71	10.88	0.51	9.34e-24	Corneal astigmatism;
CRC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg03037974	chr15:76606532	NA	-0.52	-7.69	-0.39	1.72e-13	Blood metabolite levels;
CRC	trans	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.72e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	7.44	0.38	8.6e-13	Obesity-related traits;
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg16606324	chr3:10149918	C3orf24	0.65	6.77	0.35	5.81e-11	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08726342	chr22:50689161	HDAC10	0.41	6.28	0.33	1.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs294883	0.858	rs294885	chr6:159681052	T/C	cg14500486	chr6:159655392	FNDC1	-0.35	-5.79	-0.3	1.66e-8	Coronary artery disease;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg14646075	chr2:228736089	WDR69	-0.43	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.87	8.62	0.43	2.91e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-12.67	-0.57	3.17e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00166722	chr3:10149974	C3orf24	0.62	8.46	0.42	9.05e-16	Alzheimer's disease;
CRC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.67e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg03013999	chr17:37608204	MED1	-0.48	-7.51	-0.38	5.62e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs1656402	0.863	rs6437069	chr2:233456647	C/T	cg03852847	chr2:233439513	NA	-0.41	-6.97	-0.36	1.71e-11	Non-small cell lung cancer (survival);
CRC	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.5	6.67	0.35	1.1e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.53	-0.38	4.88e-13	Major depressive disorder;
CRC	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg04289385	chr6:36355825	ETV7	0.39	5.71	0.3	2.48e-8	Platelet distribution width;
CRC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg10729496	chr3:10149963	C3orf24	0.49	6.6	0.34	1.7e-10	Alzheimer's disease;
CRC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.88	11.77	0.54	6.18e-27	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs4276421	0.806	rs7732970	chr5:45452146	C/T	cg04793272	chr11:119020941	ABCG4	-0.38	-6.31	-0.33	9.19e-10	P wave duration;
CRC	trans	rs34156428	0.591	rs12574491	chr11:16806473	T/A	cg05563613	chr7:99070410	ZNF789	0.72	6.0	0.31	5.15e-9	Coronary artery disease;
CRC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.85	0.44	5.36e-17	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03873659	chr3:123304056	PTPLB	0.44	6.01	0.31	4.9e-9	Response to antipsychotic treatment;
CRC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.37	6.19	0.32	1.8e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg06470822	chr6:28175283	NA	0.83	12.2	0.56	1.72e-28	Parkinson's disease;
CRC	cis	rs67981189	0.501	rs3829954	chr14:71455540	A/G	cg15910301	chr14:71632612	NA	0.29	5.7	0.3	2.61e-8	Schizophrenia;
CRC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg18279126	chr7:2041391	MAD1L1	0.41	6.0	0.31	5.1e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.29	0.37	2.32e-12	Eye color traits;
CRC	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.49	7.24	0.37	3.29e-12	Testicular germ cell tumor;
CRC	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.61	-8.37	-0.42	1.66e-15	Extraversion;
CRC	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.32	5.62	0.3	4.12e-8	Heart rate;
CRC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.56	8.42	0.42	1.18e-15	Sudden cardiac arrest;
CRC	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg27205649	chr11:78285834	NARS2	0.5	6.07	0.32	3.5e-9	Alzheimer's disease (survival time);
CRC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.62e-20	Intelligence (multi-trait analysis);
CRC	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.69	-10.8	-0.51	1.8e-23	Type 2 diabetes;
CRC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.29e-9	Aortic root size;
CRC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg00310523	chr12:86230176	RASSF9	-0.43	-7.37	-0.38	1.39e-12	Major depressive disorder;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg11843238	chr5:131593191	PDLIM4	0.54	9.66	0.47	1.36e-19	Acylcarnitine levels;
CRC	cis	rs7605827	0.866	rs2160696	chr2:15518983	A/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.05e-8	Educational attainment (years of education);
CRC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.46	6.64	0.34	1.29e-10	Lymphocyte counts;
CRC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.41	-5.9	-0.31	9.22e-9	Alzheimer's disease (late onset);
CRC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.52	7.76	0.39	1.09e-13	Response to temozolomide;
CRC	cis	rs6546324	0.540	rs4671811	chr2:67827416	G/A	cg15745817	chr2:67799979	NA	-0.52	-8.68	-0.43	1.82e-16	Endometriosis;
CRC	cis	rs7635838	0.827	rs9826044	chr3:11458075	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.24	0.33	1.35e-9	HDL cholesterol;
CRC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.4	-5.73	-0.3	2.25e-8	Daytime sleep phenotypes;
CRC	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.92	-12.37	-0.56	4e-29	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg23334365	chr11:67806337	TCIRG1	0.48	6.26	0.33	1.23e-9	Plasma plasminogen activator levels;
CRC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.43	-9.66	-0.47	1.36e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.68	-0.57	2.79e-30	Ulcerative colitis;
CRC	cis	rs12476592	0.602	rs4671068	chr2:63798333	C/T	cg10828910	chr2:63850056	LOC388955	0.47	6.0	0.31	5.2e-9	Childhood ear infection;
CRC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	8.91	0.44	3.52e-17	Eosinophil percentage of white cells;
CRC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.59	10.69	0.51	4.47e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg03774468	chr3:140950104	ACPL2	-0.66	-6.1	-0.32	3.01e-9	Cognitive function;
CRC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg02421172	chr7:1938701	MAD1L1	-0.42	-5.82	-0.31	1.4e-8	Bipolar disorder;
CRC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.44	-8.5	-0.42	6.61e-16	Subjective well-being;
CRC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.57	8.18	0.41	6.38e-15	Multiple sclerosis;
CRC	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.1e-10	Hepatitis;
CRC	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg14036092	chr11:66035641	RAB1B	-0.46	-5.62	-0.3	4.09e-8	Electroencephalogram traits;
CRC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg20203395	chr5:56204925	C5orf35	-0.59	-6.9	-0.36	2.63e-11	Initial pursuit acceleration;
CRC	cis	rs3823572	0.542	rs2860599	chr7:133648625	C/T	cg03336402	chr7:133662267	EXOC4	0.68	10.51	0.5	1.79e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-8.81	-0.44	7.55e-17	Menarche (age at onset);
CRC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18357526	chr6:26021779	HIST1H4A	0.44	6.38	0.33	6.13e-10	Height;
CRC	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.56	10.23	0.49	1.62e-21	Cognitive performance;
CRC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	cis	rs2882667	0.690	rs288024	chr5:138223792	A/G	cg09476006	chr5:138032270	NA	0.55	9.14	0.45	6.76e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.3	0.53	3.11e-25	Prudent dietary pattern;
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.22e-14	Alzheimer's disease;
CRC	trans	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg18288967	chr1:45987694	PRDX1	0.65	7.13	0.37	6.35e-12	Obesity-related traits;
CRC	cis	rs860295	0.702	rs3738590	chr1:155630752	A/G	cg02153340	chr1:155202674	NA	-0.57	-7.03	-0.36	1.2e-11	Body mass index;
CRC	cis	rs10208940	0.777	rs35682733	chr2:68717001	G/C	cg12452813	chr2:68675892	NA	0.5	6.17	0.32	2e-9	Urate levels in lean individuals;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg12172441	chr6:28176163	NA	0.55	7.14	0.37	5.96e-12	Parkinson's disease;
CRC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.25	0.41	3.85e-15	Schizophrenia;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.26	-0.33	1.23e-9	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.07	-0.32	3.5e-9	Diabetic kidney disease;
CRC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.2	0.53	7.2e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08964912	chr20:60982779	CABLES2	0.44	6.23	0.32	1.39e-9	Response to antipsychotic treatment;
CRC	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-9.62	-0.47	1.79e-19	Myopia (pathological);
CRC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.35	-0.33	7.09e-10	Aortic root size;
CRC	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.49	9.11	0.45	8.26e-18	Educational attainment (years of education);
CRC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.73	-8.37	-0.42	1.66e-15	Obesity-related traits;
CRC	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg00601450	chr5:74908170	NA	0.49	6.12	0.32	2.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3736485	0.873	rs12441759	chr15:51755033	C/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.65	-0.34	1.23e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg25459000	chr22:39777742	SYNGR1	0.36	6.55	0.34	2.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg15654264	chr1:150340011	RPRD2	0.42	6.29	0.33	1.04e-9	Migraine;
CRC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg23244877	chr17:73518230	TSEN54	0.46	7.41	0.38	1.11e-12	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg09455208	chr3:40491958	NA	0.32	6.37	0.33	6.22e-10	Renal cell carcinoma;
CRC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.63	7.15	0.37	5.78e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21407906	chr20:61427925	C20orf20	0.4	6.84	0.35	3.79e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-6.97	-0.36	1.73e-11	Alzheimer's disease (late onset);
CRC	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg15704280	chr7:45808275	SEPT13	-0.64	-6.27	-0.33	1.12e-9	Intraocular pressure;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23486345	chr6:99797485	C6orf168	0.4	6.04	0.32	4.07e-9	Survival in pancreatic cancer;
CRC	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.54	-0.38	4.56e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.03	0.45	1.45e-17	Fuchs's corneal dystrophy;
CRC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs6747952	0.899	rs1374387	chr2:239085687	A/C	cg07480446	chr2:239069576	NA	-0.37	-6.91	-0.36	2.55e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg01475377	chr6:109611718	NA	-0.34	-5.98	-0.31	5.7e-9	Reticulocyte fraction of red cells;
CRC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.61	11.47	0.53	7.56e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	6.82	0.35	4.44e-11	Obesity-related traits;
CRC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.58	-8.16	-0.41	7.39e-15	Pancreatic cancer;
CRC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.82	-12.35	-0.56	4.71e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.65	8.7	0.43	1.58e-16	Alcohol dependence;
CRC	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	6.02	0.31	4.71e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.58	0.5	1.03e-22	Coffee consumption (cups per day);
CRC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.47	-8.86	-0.44	5.06e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg19904058	chr10:135279010	LOC619207	-0.28	-5.65	-0.3	3.48e-8	Systemic lupus erythematosus;
CRC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.68	-0.51	4.78e-23	Chronic sinus infection;
CRC	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-6.32	-0.33	8.54e-10	Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg24730871	chr19:19516902	GATAD2A	0.39	6.39	0.33	5.82e-10	Interleukin-6 levels;
CRC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.76	0.54	6.56e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg19678392	chr7:94953810	PON1	-0.56	-7.24	-0.37	3.3e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13557688	chr9:119449590	ASTN2;TRIM32	0.38	6.27	0.33	1.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.98	14.41	0.62	7.9e-37	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	1.99e-11	Morning vs. evening chronotype;
CRC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.06e-32	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg01529538	chr14:23388837	RBM23	0.39	6.02	0.32	4.56e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.46	-6.6	-0.34	1.64e-10	Blood pressure (smoking interaction);
CRC	cis	rs1532331	0.865	rs6862639	chr5:43166254	A/G	cg09164108	chr5:43007320	NA	0.38	5.89	0.31	9.72e-9	Menarche (age at onset);
CRC	cis	rs17227506	0.679	rs67768235	chr8:13443286	T/C	cg03566418	chr8:13424080	C8orf48	0.35	5.92	0.31	7.94e-9	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.84	13.44	0.6	3.95e-33	Platelet distribution width;
CRC	cis	rs1572438	0.760	rs7740748	chr6:869509	T/C	cg21062780	chr6:887772	NA	-0.38	-5.98	-0.31	5.78e-9	Aging;
CRC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.95	0.52	5.46e-24	Prudent dietary pattern;
CRC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.74	0.57	1.77e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-10.1	-0.49	4.63e-21	Body mass index;
CRC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.89e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg05585544	chr11:47624801	NA	-0.62	-11.39	-0.53	1.48e-25	Subjective well-being;
CRC	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.55	0.5	1.31e-22	Coffee consumption (cups per day);
CRC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg10298567	chr3:47292165	KIF9	-0.4	-6.25	-0.33	1.3e-9	Colorectal cancer;
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-0.56	-7.62	-0.39	2.74e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg21620606	chr4:1342894	KIAA1530	0.37	6.4	0.33	5.37e-10	Obesity-related traits;
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.42	-7.38	-0.38	1.29e-12	Lung cancer;
CRC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.6	-9.47	-0.46	5.53e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.22	0.32	1.48e-9	Height;
CRC	cis	rs9039	1.000	rs56193985	chr16:9207199	C/A	cg08831531	chr16:9218945	NA	-0.46	-5.93	-0.31	7.59e-9	Menopause (age at onset);
CRC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.52	0.6	2.03e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg11547950	chr5:77652471	NA	-0.49	-7.08	-0.36	9e-12	Triglycerides;
CRC	cis	rs7626444	0.625	rs843531	chr3:196481771	T/C	cg12930392	chr3:196481615	PAK2	0.39	7.11	0.36	7.25e-12	Monocyte count;
CRC	cis	rs2462686	1.000	rs2965071	chr7:46001382	T/A	cg23193639	chr7:45961078	IGFBP3	0.37	5.72	0.3	2.37e-8	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg02683197	chr6:28174875	NA	0.88	10.7	0.51	3.93e-23	Depression;
CRC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.37	-6.75	-0.35	6.5e-11	Reticulocyte fraction of red cells;
CRC	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.44	6.92	0.36	2.34e-11	Schizophrenia;
CRC	cis	rs364477	0.904	rs279905	chr9:959821	T/C	cg13952963	chr9:998547	NA	0.55	5.88	0.31	9.89e-9	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19260500	chr3:133969278	RYK	0.43	6.05	0.32	3.92e-9	Anxiety disorder;
CRC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.41	6.15	0.32	2.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.15	-0.45	6.36e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7725052	0.609	rs61422440	chr5:40447157	G/A	cg09067459	chr5:40385259	NA	-0.44	-7.23	-0.37	3.46e-12	Pediatric autoimmune diseases;
CRC	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.22	-5.94	-0.31	7.15e-9	Type 2 diabetes;
CRC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.82	-11.97	-0.55	1.2e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.51	-0.34	2.82e-10	Coronary artery calcification;
CRC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Melanoma;
CRC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08219700	chr8:58056026	NA	0.56	6.45	0.34	3.97e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.58	-0.43	3.94e-16	Uric acid levels;
CRC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-7.19	-0.37	4.36e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs294883	0.739	rs962339	chr6:159729165	G/T	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs3751196	0.901	rs55987022	chr12:104205100	G/C	cg02344784	chr12:104178138	NT5DC3	0.69	6.98	0.36	1.62e-11	Sense of smell;
CRC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.83	11.93	0.55	1.67e-27	Cognitive function;
CRC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.79	0.39	9.12e-14	Height;
CRC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.79e-9	Hemoglobin concentration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05243909	chr16:2097910	NTHL1;TSC2	0.49	6.23	0.32	1.46e-9	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.86	-13.34	-0.59	9.63e-33	Blood metabolite levels;
CRC	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.0	-0.48	1.01e-20	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.62	-8.24	-0.41	4.14e-15	DNA methylation (variation);
CRC	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.91	-17.15	-0.69	1.5e-47	Longevity;
CRC	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg23234261	chr14:55582407	NA	-0.29	-5.72	-0.3	2.39e-8	Protein biomarker;
CRC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.64	-12.13	-0.56	3.04e-28	Refractive error;
CRC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.53	11.82	0.55	4.25e-27	Alcohol dependence;
CRC	cis	rs7605827	0.897	rs11901455	chr2:15623888	C/T	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg27489772	chr12:121021490	NA	-0.49	-6.6	-0.34	1.62e-10	Type 1 diabetes nephropathy;
CRC	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg08992911	chr2:238395768	MLPH	0.65	6.52	0.34	2.69e-10	Prostate cancer;
CRC	cis	rs3751196	0.808	rs61512578	chr12:104218838	C/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.55	0.38	4.35e-13	Sense of smell;
CRC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.4	6.4	0.33	5.35e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02228675	chr17:40259724	DHX58	-0.5	-7.01	-0.36	1.38e-11	Fibrinogen levels;
CRC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.83	0.31	1.31e-8	Bladder cancer;
CRC	cis	rs9462027	0.540	rs2814951	chr6:34695081	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.18	-0.37	4.77e-12	Breast cancer;
CRC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg10431340	chr1:161279108	MPZ	-0.5	-6.82	-0.35	4.4e-11	Rheumatoid arthritis;
CRC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08030210	chr19:10362462	MRPL4	0.48	6.08	0.32	3.33e-9	Thyroid stimulating hormone;
CRC	cis	rs4654899	0.897	rs10916856	chr1:21082074	A/C	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.69	-0.35	9.37e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.83	13.29	0.59	1.53e-32	Cognitive function;
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg02772935	chr3:125709198	NA	-0.46	-5.98	-0.31	5.91e-9	Blood pressure (smoking interaction);
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg04969067	chr8:143858791	LYNX1	0.45	7.59	0.39	3.26e-13	Urinary tract infection frequency;
CRC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.58	8.17	0.41	6.8e-15	Arsenic metabolism;
CRC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.61	-0.75	3.6e-61	Height;
CRC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg17775713	chr3:133465469	TF	0.33	5.85	0.31	1.19e-8	Iron status biomarkers;
CRC	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg17133734	chr15:86042851	AKAP13	-0.4	-6.34	-0.33	7.43e-10	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02767759	chr16:30366751	CD2BP2	0.46	5.99	0.31	5.53e-9	Thyroid stimulating hormone;
CRC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg04315214	chr1:2043799	PRKCZ	0.34	6.09	0.32	3.1e-9	Height;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.43	6.44	0.33	4.34e-10	Obesity-related traits;
CRC	cis	rs9976767	0.896	rs9975920	chr21:43818656	A/G	cg23042151	chr21:43824109	UBASH3A	-0.37	-6.57	-0.34	1.99e-10	Type 1 diabetes;
CRC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.54	-9.72	-0.47	8.63e-20	Educational attainment;
CRC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg08200582	chr11:442649	ANO9	0.64	6.54	0.34	2.32e-10	Body mass index;
CRC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg05501817	chr11:14380813	RRAS2	-0.43	-5.85	-0.31	1.16e-8	Vitamin D levels;
CRC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.39	6.33	0.33	8.21e-10	Height;
CRC	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.03	0.55	6.96e-28	Coffee consumption (cups per day);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00805381	chr6:24720818	C6orf62	0.43	6.3	0.33	9.48e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg14631576	chr9:95140430	CENPP	0.31	5.76	0.3	1.96e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs2730260	0.736	rs7784586	chr7:158836379	T/C	cg02254261	chr7:158964346	NA	-0.52	-6.21	-0.32	1.57e-9	Myopia (pathological);
CRC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02018176	chr4:1364513	KIAA1530	0.48	7.93	0.4	3.43e-14	Obesity-related traits;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg22535103	chr8:58192502	C8orf71	-0.48	-6.95	-0.36	1.93e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19243130	chr11:124543550	SIAE;SPA17	0.37	6.09	0.32	3.17e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17840164	chr10:104262570	SUFU;ACTR1A	0.44	6.13	0.32	2.45e-9	Response to antipsychotic treatment;
CRC	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg15147215	chr3:52552868	STAB1	-0.42	-6.88	-0.35	2.96e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.83	-0.31	1.3e-8	Migraine;Coronary artery disease;
CRC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06544989	chr22:39130855	UNC84B	0.47	6.98	0.36	1.69e-11	Menopause (age at onset);
CRC	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14843902	chr17:47492407	PHB	0.37	6.24	0.33	1.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.62	10.62	0.51	7.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.88	-0.44	4.39e-17	Neuroticism;
CRC	cis	rs365302	1.000	rs378194	chr6:159646323	C/T	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.76e-10	Coronary heart disease;
CRC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.28	0.42	3.14e-15	Height;
CRC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.44	5.79	0.3	1.63e-8	Daytime sleep phenotypes;
CRC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.68	10.35	0.5	6.36e-22	Calcium levels;
CRC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg26554054	chr8:600488	NA	0.7	6.91	0.36	2.51e-11	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13244110	chr17:40688572	NAGLU	0.46	6.45	0.34	3.93e-10	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.78	12.62	0.57	4.87e-30	Blood metabolite levels;
CRC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.38	-5.75	-0.3	2.06e-8	Red blood cell count;
CRC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg10820045	chr2:198174542	NA	-0.54	-10.2	-0.49	2.08e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg23262073	chr20:60523788	NA	-0.46	-7.17	-0.37	5.07e-12	Body mass index;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg10729496	chr3:10149963	C3orf24	0.55	7.12	0.37	6.94e-12	Alzheimer's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg13099106	chr12:120525172	CCDC64	-0.49	-6.17	-0.32	2.03e-9	Diisocyanate-induced asthma;
CRC	cis	rs7259376	0.623	rs12610063	chr19:22493057	C/T	cg02657401	chr19:22469223	NA	-0.31	-6.8	-0.35	4.97e-11	Menopause (age at onset);
CRC	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-9.24	-0.45	3.2e-18	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02228675	chr17:40259724	DHX58	-0.48	-6.8	-0.35	5.05e-11	Fibrinogen levels;
CRC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.62	6.69	0.35	9.7e-11	Gut microbiome composition (summer);
CRC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-6.02	-0.32	4.65e-9	Monocyte count;
CRC	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.92	0.44	3.23e-17	Coffee consumption (cups per day);
CRC	cis	rs7107770	1.000	rs34457642	chr11:125086200	A/T	cg27629782	chr11:125073726	PKNOX2	0.51	6.21	0.32	1.57e-9	Photic sneeze reflex;
CRC	cis	rs12472274	0.646	rs34989058	chr2:239074698	C/T	cg17459225	chr2:239074497	NA	0.68	8.13	0.41	9.13e-15	Phospholipid levels (plasma);
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg12172441	chr6:28176163	NA	0.58	6.78	0.35	5.72e-11	Parkinson's disease;
CRC	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg11738485	chr19:12877000	HOOK2	0.39	5.69	0.3	2.75e-8	Bipolar disorder;
CRC	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg26875233	chr11:93583750	C11orf90	-0.31	-6.02	-0.32	4.6e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.47	7.2	0.37	4e-12	Red blood cell count;
CRC	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.73	9.72	0.47	8.56e-20	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs7517010	chr1:183594728	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.9	0.36	2.76e-11	Morning vs. evening chronotype;
CRC	trans	rs1642645	0.831	rs2042064	chr1:42491429	C/T	cg16926213	chr1:1841314	NA	-0.43	-6.11	-0.32	2.74e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs7821565	0.904	rs1370444	chr8:52164298	G/A	cg09187163	chr7:72721838	NSUN5	-0.41	-5.98	-0.31	5.79e-9	Tuberculosis;
CRC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg24879335	chr3:133465180	TF	0.31	5.76	0.3	1.95e-8	Iron status biomarkers;
CRC	cis	rs2551802	0.615	rs17395735	chr2:177067780	C/T	cg13092806	chr2:177043255	NA	0.53	7.14	0.37	6.1e-12	Motion sickness;
CRC	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg04586622	chr2:25135609	ADCY3	-0.54	-9.2	-0.45	4.19e-18	Body mass index;
CRC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-7.88	-0.4	4.75e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.26	-0.45	2.75e-18	Reticulocyte fraction of red cells;
CRC	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.52	9.17	0.45	5.35e-18	Weight;
CRC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.4	5.8	0.3	1.54e-8	Migraine;
CRC	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.1	0.52	1.55e-24	Coffee consumption (cups per day);
CRC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.85	15.09	0.64	1.79e-39	Intelligence (multi-trait analysis);
CRC	cis	rs3741151	0.686	rs1938777	chr11:73122340	A/G	cg17517138	chr11:73019481	ARHGEF17	0.53	5.75	0.3	2.09e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs703970	0.522	rs2802363	chr10:80988837	A/G	cg20744163	chr10:80999841	ZMIZ1	-0.37	-6.34	-0.33	7.41e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.75	9.08	0.45	1e-17	Diisocyanate-induced asthma;
CRC	cis	rs727505	0.754	rs55859595	chr7:124783083	G/T	cg23710748	chr7:124431027	NA	-0.67	-11.43	-0.53	1.04e-25	Lewy body disease;
CRC	cis	rs2070997	0.617	rs3808816	chr9:133746117	C/T	cg01000188	chr9:133769184	QRFP	-0.56	-7.58	-0.39	3.57e-13	Response to amphetamines;
CRC	cis	rs12780046	0.536	rs2862599	chr10:101085582	G/A	cg26459859	chr10:101118273	CNNM1	-0.44	-5.96	-0.31	6.66e-9	Non-glioblastoma glioma;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.59	8.0	0.4	2.12e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-5.7	-0.3	2.69e-8	Putamen volume;
CRC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg10431340	chr1:161279108	MPZ	-0.57	-7.49	-0.38	6.53e-13	Rheumatoid arthritis;
CRC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.52	-8.28	-0.42	3.21e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12315302	chr6:26189340	HIST1H4D	0.82	6.33	0.33	8.12e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.72	7.36	0.38	1.52e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg15445000	chr17:37608096	MED1	-0.35	-6.17	-0.32	2.03e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg15786705	chr6:28176104	NA	0.54	7.4	0.38	1.16e-12	Parkinson's disease;
CRC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.87	0.31	1.07e-8	Homoarginine levels;
CRC	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.41	1.5e-14	Cognitive performance;
CRC	trans	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.97	0.31	6.27e-9	Metabolite levels;
CRC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg27534772	chr1:16042836	PLEKHM2	0.53	10.39	0.5	4.58e-22	Systolic blood pressure;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.94	-0.31	7.43e-9	Depression;
CRC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg16898833	chr6:26189333	HIST1H4D	0.94	7.65	0.39	2.25e-13	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25055477	chr6:34360916	NUDT3	0.41	6.13	0.32	2.5e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15605011	chr1:110162477	AMPD2	0.43	7.53	0.38	5.02e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7680126	0.596	rs4698030	chr4:10315850	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.99	-0.31	5.53e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.72	0.3	2.43e-8	Major depressive disorder;
CRC	cis	rs9311676	0.656	rs6773193	chr3:58385960	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg23229016	chr1:26872525	RPS6KA1	0.24	5.7	0.3	2.65e-8	Glucose homeostasis traits;
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.01	-23.12	-0.79	6.45e-71	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.68	0.65	8.67e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12560992	chr17:57184187	TRIM37	-0.59	-8.61	-0.43	2.97e-16	Testicular germ cell tumor;
CRC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.14	-11.82	-0.55	4.15e-27	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14906251	chr6:40555731	LRFN2	0.45	6.25	0.33	1.25e-9	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10033612	chr16:1664176	CRAMP1L	0.4	7.09	0.36	8.29e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.37	5.69	0.3	2.88e-8	Height;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-8.76	-0.43	1.03e-16	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.78	-0.44	9.27e-17	Aortic root size;
CRC	trans	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg02811702	chr13:24901961	NA	0.48	6.66	0.34	1.16e-10	Obesity-related traits;
CRC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg25834613	chr7:1915315	MAD1L1	-0.34	-5.73	-0.3	2.28e-8	Neuroticism;
CRC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg18761221	chr20:60518478	NA	0.48	7.87	0.4	5.33e-14	Body mass index;
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg15654264	chr1:150340011	RPRD2	0.44	6.63	0.34	1.42e-10	Migraine;
CRC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.03	-0.4	1.81e-14	Height;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.77	-0.35	6.02e-11	Bipolar disorder;
CRC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.52	-8.35	-0.42	1.95e-15	Type 2 diabetes;
CRC	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.62	0.43	2.95e-16	Menopause (age at onset);
CRC	cis	rs9462027	0.606	rs4624858	chr6:34802301	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.04	-0.32	4.16e-9	Systemic lupus erythematosus;
CRC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.05	9.72	0.47	8.7e-20	Diabetic retinopathy;
CRC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.6	7.8	0.4	8e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.09e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.54	8.16	0.41	7.42e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	9.2	0.45	4.17e-18	Cognitive test performance;
CRC	cis	rs7731657	0.537	rs7725020	chr5:130285115	C/G	cg08523029	chr5:130500466	HINT1	0.49	6.19	0.32	1.83e-9	Fasting plasma glucose;
CRC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.57	-7.4	-0.38	1.15e-12	Body mass index;
CRC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.56	-0.34	2.04e-10	Subjective well-being;
CRC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg18404041	chr3:52824283	ITIH1	0.34	6.37	0.33	6.29e-10	Schizophrenia;
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.64	-10.11	-0.49	4.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4731207	0.596	rs12111658	chr7:124584768	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg04906043	chr13:21280425	IL17D	0.46	7.08	0.36	8.97e-12	Dental caries;
CRC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.6	7.02	0.36	1.24e-11	Vitiligo;
CRC	cis	rs2457480	0.543	rs1482473	chr10:44707598	G/C	cg09554077	chr10:44749378	NA	0.48	6.31	0.33	9.16e-10	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs3889889	chr1:183621446	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.44	0.33	4.11e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8022206	0.841	rs1958113	chr14:68637906	A/T	cg19578161	chr14:68482919	RAD51L1	0.42	5.66	0.3	3.38e-8	Platelet count;Mean platelet volume;
CRC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg24829409	chr8:58192753	C8orf71	-0.44	-5.85	-0.31	1.17e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.52	8.37	0.42	1.64e-15	Aortic root size;
CRC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg16476235	chr8:21771668	DOK2	0.39	6.85	0.35	3.62e-11	Mean corpuscular volume;
CRC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.78	14.69	0.63	6.4e-38	Prudent dietary pattern;
CRC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.6	8.27	0.41	3.47e-15	Lung cancer;
CRC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.45	6.0	0.31	5.12e-9	Heart rate;
CRC	cis	rs17331151	0.505	rs13066644	chr3:52565247	G/A	cg07884673	chr3:53033167	SFMBT1	0.76	6.08	0.32	3.31e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	1.07	11.38	0.53	1.58e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1465370	0.720	rs7811462	chr7:130017487	G/A	cg03229158	chr7:130009420	NA	0.44	6.26	0.33	1.23e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg20295408	chr7:1910781	MAD1L1	0.4	5.72	0.3	2.38e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.79	0.3	1.62e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg07617317	chr6:118971624	C6orf204	0.49	6.22	0.32	1.51e-9	Diastolic blood pressure;
CRC	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.5	7.96	0.4	2.79e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.18	-0.56	1.96e-28	Alzheimer's disease;
CRC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.57	7.63	0.39	2.58e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.33	-0.53	2.36e-25	Alzheimer's disease;
CRC	cis	rs2811415	0.597	rs6802633	chr3:127774722	A/G	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.17e-8	Lung function (FEV1/FVC);
CRC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg10298567	chr3:47292165	KIF9	-0.38	-5.96	-0.31	6.55e-9	Colorectal cancer;
CRC	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg09597638	chr17:3907349	NA	0.65	11.76	0.54	6.61e-27	Type 2 diabetes;
CRC	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg27535305	chr1:53392650	SCP2	0.34	6.36	0.33	6.57e-10	Monocyte count;
CRC	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg27286572	chr17:3796072	CAMKK1	-0.46	-7.01	-0.36	1.32e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.65	-8.21	-0.41	5.18e-15	Multiple sclerosis;
CRC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg27523141	chr10:43048294	ZNF37B	0.5	7.32	0.37	1.98e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.77	-9.94	-0.48	1.53e-20	Pancreatic cancer;
CRC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.17	-0.32	1.99e-9	Aortic root size;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg22638593	chr5:131593259	PDLIM4	0.42	7.75	0.39	1.13e-13	Breast cancer;
CRC	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg15147215	chr3:52552868	STAB1	-0.54	-8.45	-0.42	9.39e-16	Bipolar disorder;
CRC	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.45	-0.38	8.03e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2882667	0.858	rs4643949	chr5:138372345	C/T	cg09476006	chr5:138032270	NA	0.44	7.44	0.38	8.77e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13614946	chr1:100315421	AGL	0.52	6.77	0.35	5.97e-11	Thyroid stimulating hormone;
CRC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.42	0.5	3.63e-22	Systolic blood pressure;
CRC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.41	6.73	0.35	7.37e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.39	5.99	0.31	5.45e-9	Endometrial cancer;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg23459997	chr3:9932426	JAGN1	-0.4	-6.01	-0.31	5.05e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2257205	0.667	rs7220884	chr17:56743948	G/A	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.87e-8	Pancreatic cancer;
CRC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.71	-0.47	9.06e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.87	0.31	1.08e-8	Diabetic retinopathy;
CRC	cis	rs17152411	0.895	rs66531168	chr10:126586908	T/A	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.44	-7.06	-0.36	9.66e-12	Coronary artery disease;
CRC	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.73	-10.2	-0.49	2.15e-21	Vitiligo;
CRC	cis	rs17767392	0.958	rs722633	chr14:71898788	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.47	5.72	0.3	2.34e-8	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02290350	chr8:58132656	NA	0.58	7.92	0.4	3.72e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.88	-0.4	4.7e-14	Total cholesterol levels;
CRC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	1.01	10.96	0.52	5.03e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.66	-0.3	3.31e-8	Height;
CRC	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.61	8.19	0.41	5.86e-15	Coronary artery disease;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02290350	chr8:58132656	NA	-0.5	-6.19	-0.32	1.75e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.81	-13.31	-0.59	1.24e-32	Hypospadias;
CRC	cis	rs4853036	0.951	rs10165061	chr2:70146363	C/T	cg02498382	chr2:70120550	SNRNP27	-0.45	-6.92	-0.36	2.36e-11	Colorectal or endometrial cancer;
CRC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg10790698	chr19:18539756	SSBP4	0.46	8.68	0.43	1.84e-16	Breast cancer;
CRC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	11.96	0.55	1.33e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.55	-8.27	-0.41	3.43e-15	Longevity;
CRC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg24375607	chr4:120327624	NA	-0.41	-6.44	-0.33	4.12e-10	Corneal astigmatism;
CRC	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg09127314	chr1:152161683	NA	0.46	5.93	0.31	7.56e-9	Atopic dermatitis;
CRC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-10.19	-0.49	2.2e-21	Breast cancer;
CRC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg03690763	chr11:133734501	NA	-0.35	-5.86	-0.31	1.13e-8	Childhood ear infection;
CRC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg24562669	chr7:97807699	LMTK2	0.42	7.04	0.36	1.1e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.46	7.16	0.37	5.27e-12	Height;
CRC	cis	rs7827545	0.545	rs4909477	chr8:135562976	A/G	cg17885191	chr8:135476712	NA	0.64	7.62	0.39	2.81e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg14345882	chr6:26364793	BTN3A2	0.48	6.19	0.32	1.83e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.67	10.23	0.49	1.61e-21	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11310125	chr2:113239311	TTL	0.4	6.42	0.33	4.72e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg07972458	chr1:204535000	NA	0.37	5.72	0.3	2.34e-8	Schizophrenia;
CRC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.95	-19.14	-0.73	2.04e-55	Height;
CRC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.35	0.38	1.62e-12	Motion sickness;
CRC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.47	7.36	0.38	1.48e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.81	-0.3	1.5e-8	Type 2 diabetes;
CRC	trans	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-7.7	-0.39	1.62e-13	Endometrial cancer;
CRC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.73	-0.35	7.69e-11	Dupuytren's disease;
CRC	trans	rs7011507	0.945	rs13268843	chr8:49201957	C/T	cg04544946	chr8:978226	NA	0.45	5.99	0.31	5.52e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.63	-0.39	2.51e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg19337854	chr7:99768885	GPC2	0.44	5.89	0.31	9.65e-9	Lung function (FEV1/FVC);
CRC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.6	8.48	0.42	7.85e-16	Breast cancer;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.98	-0.36	1.61e-11	Obesity-related traits;
CRC	cis	rs427943	0.750	rs2838807	chr21:46619001	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.44	5.93	0.31	7.53e-9	Body mass index;
CRC	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg04586622	chr2:25135609	ADCY3	-0.42	-6.95	-0.36	1.92e-11	Body mass index;
CRC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04505727	chr17:79885823	LOC92659;MAFG	0.46	6.43	0.33	4.59e-10	Anxiety disorder;
CRC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg23463467	chr20:60627584	TAF4	0.4	8.15	0.41	7.93e-15	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03705947	chr1:68152081	GADD45A	0.54	7.15	0.37	5.76e-12	Thyroid stimulating hormone;
CRC	cis	rs10450586	0.829	rs6484286	chr11:27301922	G/A	cg10370305	chr11:27303972	NA	0.37	6.08	0.32	3.41e-9	Total body bone mineral density;
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.34e-11	Prostate cancer;
CRC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.19e-12	Testicular germ cell tumor;
CRC	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg00603274	chr11:61596626	FADS2	0.4	6.06	0.32	3.69e-9	Trans fatty acid levels;
CRC	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg04586622	chr2:25135609	ADCY3	-0.57	-9.66	-0.47	1.3e-19	Body mass index;
CRC	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg00738113	chr16:70207722	CLEC18C	-0.4	-5.74	-0.3	2.15e-8	IgE levels;
CRC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.62	0.39	2.68e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg23262073	chr20:60523788	NA	-0.41	-6.97	-0.36	1.79e-11	Body mass index;
CRC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.59	9.62	0.47	1.85e-19	Colorectal cancer;
CRC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.78	-0.35	5.63e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg06840491	chr10:48416966	GDF2	-0.35	-6.08	-0.32	3.25e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07513332	chr6:167530253	CCR6	0.37	5.9	0.31	9.15e-9	Crohn's disease;
CRC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.73e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3736485	0.966	rs10775144	chr15:51891134	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.44	-0.33	4.27e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs4363385	0.747	rs6665575	chr1:152960506	G/A	cg25856811	chr1:152973957	SPRR3	-0.27	-7.44	-0.38	8.88e-13	Inflammatory skin disease;
CRC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.55	-8.02	-0.4	1.81e-14	Cognitive ability;
CRC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg13073564	chr4:8508604	NA	-0.45	-7.04	-0.36	1.15e-11	Response to antineoplastic agents;
CRC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.85	-12.62	-0.57	4.71e-30	Gut microbiome composition (summer);
CRC	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.71	-9.83	-0.48	3.53e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.58	-6.44	-0.33	4.17e-10	Vitiligo;
CRC	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.81	-0.3	1.5e-8	Type 2 diabetes;
CRC	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.35	-0.42	1.93e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs11627756	0.915	rs11850368	chr14:103131770	G/C	cg12046867	chr14:103022105	NA	0.44	6.05	0.32	3.97e-9	Mean platelet volume;
CRC	cis	rs12024301	0.557	rs12022469	chr1:183601157	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.65e-9	Bipolar disorder;
CRC	cis	rs7394190	0.748	rs4746151	chr10:75578720	G/T	cg07699608	chr10:75541558	CHCHD1	0.59	6.01	0.31	5.03e-9	Incident atrial fibrillation;
CRC	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg20742385	chr13:113633654	MCF2L	-0.58	-9.9	-0.48	2.17e-20	Systolic blood pressure;
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg07617317	chr6:118971624	C6orf204	0.5	6.12	0.32	2.65e-9	Diastolic blood pressure;
CRC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	9.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.45e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs4294134	0.935	rs3110823	chr7:135357476	A/C	cg20392616	chr7:135392013	SLC13A4	0.49	6.09	0.32	3.09e-9	Paget's disease;
CRC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.59	0.43	3.55e-16	Prostate cancer;
CRC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.52	-7.1	-0.36	7.97e-12	Serum sulfate level;
CRC	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg12458913	chr13:53173898	NA	0.48	6.85	0.35	3.58e-11	Lewy body disease;
CRC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.75	-0.3	2.04e-8	Migraine;Coronary artery disease;
CRC	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.85	-10.64	-0.51	6.4e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg20737812	chr15:86336631	KLHL25	-0.43	-7.07	-0.36	9.54e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.23	-0.32	1.41e-9	Arsenic metabolism;
CRC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.57e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.41	-6.42	-0.33	4.64e-10	C-reactive protein levels;
CRC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.71	-9.32	-0.46	1.75e-18	Bronchopulmonary dysplasia;
CRC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.55	8.91	0.44	3.63e-17	Type 2 diabetes;
CRC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.31	5.88e-9	Heart rate;
CRC	cis	rs12826942	1.000	rs12826942	chr12:42796300	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.0	0.36	1.48e-11	Coronary artery disease;
CRC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg20291162	chr17:40259547	DHX58	-0.55	-7.91	-0.4	4e-14	Fibrinogen levels;
CRC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.63	-8.24	-0.41	4.15e-15	Immature fraction of reticulocytes;
CRC	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg11003573	chr3:44754125	ZNF502	-0.33	-5.68	-0.3	2.98e-8	Depressive symptoms;
CRC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.33	-0.33	7.89e-10	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.71	0.3	2.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.5	8.12	0.41	9.14e-15	Testicular germ cell tumor;
CRC	cis	rs7605827	0.930	rs7586201	chr2:15575735	G/A	cg19274914	chr2:15703543	NA	0.39	5.86	0.31	1.11e-8	Educational attainment (years of education);
CRC	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.6	9.17	0.45	5.12e-18	Obesity;
CRC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.64	-7.44	-0.38	8.68e-13	Menarche (age at onset);
CRC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.9	16.65	0.68	1.44e-45	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00166722	chr3:10149974	C3orf24	0.64	8.57	0.43	4.11e-16	Alzheimer's disease;
CRC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg25193742	chr10:104614220	C10orf32	-0.72	-5.97	-0.31	6.32e-9	Cognitive function;
CRC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.5	7.85	0.4	5.87e-14	Carotid intima media thickness;
CRC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.5	6.73	0.35	7.61e-11	Height;
CRC	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.52	7.07	0.36	9.37e-12	Caudate activity during reward;
CRC	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.45	-9.15	-0.45	6.05e-18	Renal cell carcinoma;
CRC	cis	rs9549328	0.700	rs4907568	chr13:113617574	A/T	cg17524180	chr13:113633600	MCF2L	-0.53	-9.67	-0.47	1.21e-19	Systolic blood pressure;
CRC	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.51	-7.31	-0.37	1.98e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.39	6.03	0.32	4.46e-9	Endometrial cancer;
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.51	7.69	0.39	1.69e-13	Prostate cancer;
CRC	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.93	16.52	0.67	4.52e-45	Obesity (extreme);
CRC	cis	rs7707921	0.957	rs2059891	chr5:81508792	G/C	cg17942617	chr5:81327376	ATG10	-0.39	-5.82	-0.31	1.39e-8	Breast cancer;
CRC	trans	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg24644049	chr4:85504048	CDS1	0.77	7.05	0.36	1.06e-11	Skin colour saturation;
CRC	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg27205649	chr11:78285834	NARS2	-0.45	-5.67	-0.3	3.08e-8	Alzheimer's disease (survival time);
CRC	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.69	6.67	0.35	1.11e-10	Intraocular pressure;
CRC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg18230493	chr5:56204884	C5orf35	-0.5	-7.23	-0.37	3.36e-12	Coronary artery disease;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg15511327	chr8:143859410	LYNX1	-0.39	-6.13	-0.32	2.52e-9	Urinary tract infection frequency;
CRC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.66	-0.34	1.14e-10	Renal cell carcinoma;
CRC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.47	8.51	0.42	6.21e-16	Schizophrenia;
CRC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.39	-0.56	3.43e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.5	-6.33	-0.33	8.08e-10	Mitral valve prolapse;
CRC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.39	6.87	0.35	3.16e-11	Cardiovascular disease risk factors;
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.52	6.92	0.36	2.37e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.49	-7.21	-0.37	3.85e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg13385794	chr1:248469461	NA	0.37	6.56	0.34	2.1e-10	Common traits (Other);
CRC	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.59	7.83	0.4	6.61e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs6681460	1.000	rs2147777	chr1:67129254	A/T	cg02459107	chr1:67143332	SGIP1	0.47	8.26	0.41	3.48e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs8067545	0.532	rs17759609	chr17:19992514	C/G	cg13482628	chr17:19912719	NA	0.4	5.92	0.31	7.89e-9	Schizophrenia;
CRC	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.81	0.44	7.42e-17	Dupuytren's disease;
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg27411982	chr8:10470053	RP1L1	0.36	5.6	0.3	4.44e-8	Neuroticism;
CRC	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12314729	chr11:45361763	NA	-0.42	-6.18	-0.32	1.85e-9	Myopia (pathological);
CRC	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.68	-10.05	-0.48	6.87e-21	Schizophrenia;
CRC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.52	6.88	0.35	3.03e-11	Height;
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	3.99e-16	Life satisfaction;
CRC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.44	-6.7	-0.35	8.92e-11	Birth weight;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01043910	chr6:132834340	STX7	0.48	7.04	0.36	1.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs661713	0.734	rs9111	chr6:90981653	C/T	cg06866423	chr6:90926672	BACH2	0.38	5.62	0.3	4.18e-8	Hypothyroidism;
CRC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.57	8.97	0.44	2.37e-17	Gestational age at birth (maternal effect);
CRC	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.19	0.67	8.85e-44	Electrocardiographic conduction measures;
CRC	cis	rs11229555	0.645	rs12803648	chr11:58177561	G/T	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01594514	chr11:67374213	NDUFV1	0.41	6.59	0.34	1.78e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.57	-7.98	-0.4	2.4e-14	Systemic lupus erythematosus;
CRC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8105895	0.935	rs8103518	chr19:22246952	G/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-6.98	-0.36	1.65e-11	Height;
CRC	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.97	17.96	0.7	9.48e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.04	-0.32	4.18e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23903597	chr17:61704154	MAP3K3	-0.44	-6.05	-0.32	3.99e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.19	-0.32	1.8e-9	Aortic root size;
CRC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg16141378	chr3:129829833	LOC729375	0.47	7.21	0.37	3.92e-12	Neuroticism;
CRC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.29	0.46	2.16e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg09904177	chr6:26538194	HMGN4	-0.41	-5.64	-0.3	3.73e-8	Intelligence (multi-trait analysis);
CRC	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.64	-10.19	-0.49	2.22e-21	Smoking behavior;
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19500275	chr17:80737654	TBCD	0.5	6.83	0.35	4.02e-11	Glycated hemoglobin levels;
CRC	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg24289452	chr6:170231220	NA	-0.93	-7.55	-0.38	4.3e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg16892393	chr17:41919603	NA	0.5	6.92	0.36	2.32e-11	Triglycerides;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg12172441	chr6:28176163	NA	0.53	7.3	0.37	2.19e-12	Cardiac Troponin-T levels;
CRC	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg11038491	chr20:34638489	LOC647979	-0.66	-8.26	-0.41	3.71e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6700896	0.897	rs2375805	chr1:66156567	C/T	cg04111102	chr1:66153794	NA	0.34	5.89	0.31	9.43e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.76e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4731207	0.698	rs7778544	chr7:124527481	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs12476592	0.602	rs10865338	chr2:63732509	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.7	11.82	0.55	3.99e-27	Alzheimer's disease (late onset);
CRC	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	0.68	10.19	0.49	2.24e-21	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg22638593	chr5:131593259	PDLIM4	0.39	7.22	0.37	3.56e-12	Breast cancer;
CRC	cis	rs3741151	0.686	rs7927344	chr11:73207517	T/C	cg17517138	chr11:73019481	ARHGEF17	0.55	5.86	0.31	1.11e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4664293	0.867	rs4664301	chr2:160623366	C/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.82	15.89	0.66	1.38e-42	Hip circumference;
CRC	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	11.21	0.53	6.56e-25	Nonalcoholic fatty liver disease;
CRC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	0.82	6.55	0.34	2.25e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.47	-7.55	-0.38	4.37e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18912574	chr7:65842487	NCRNA00174	0.33	5.62	0.3	4.06e-8	Aortic root size;
CRC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-5.67	-0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.25	-0.41	3.74e-15	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.14e-9	Prudent dietary pattern;
CRC	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.91	-0.36	2.51e-11	Multiple sclerosis;
CRC	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg23684204	chr15:91497937	RCCD1	0.46	7.03	0.36	1.22e-11	Attention deficit hyperactivity disorder;
CRC	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg03929089	chr4:120376271	NA	0.54	7.23	0.37	3.33e-12	Intraocular pressure;
CRC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.98	0.44	2.1e-17	Menarche (age at onset);
CRC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.44	6.8	0.35	4.81e-11	Testicular germ cell tumor;
CRC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.48	-0.53	7.11e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs6735179	0.761	rs6723862	chr2:1779260	T/C	cg19300414	chr2:1746591	PXDN	0.39	6.5	0.34	2.99e-10	Response to antipsychotic treatment;
CRC	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.46	6.65	0.34	1.21e-10	Lung cancer;
CRC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.78	-0.47	5.18e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.46	7.68e-19	Bladder cancer;
CRC	trans	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.25	0.33	1.3e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg25767906	chr1:53392781	SCP2	0.42	6.66	0.34	1.15e-10	Monocyte count;
CRC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg03885332	chr11:832357	CD151	-0.43	-6.4	-0.33	5.5e-10	Mean platelet volume;
CRC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.51	7.08	0.36	8.51e-12	Lymphocyte counts;
CRC	cis	rs4930561	0.739	rs7118045	chr11:67978734	C/G	cg04465784	chr11:67976953	SUV420H1	-0.29	-5.89	-0.31	9.72e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.62	-7.83	-0.4	6.87e-14	Gut microbiome composition (summer);
CRC	trans	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg08231274	chr14:57735852	MUDENG;EXOC5	-0.59	-6.2	-0.32	1.72e-9	Longevity (90 years and older);
CRC	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg05527609	chr1:210001259	C1orf107	-0.56	-6.27	-0.33	1.17e-9	Red blood cell count;
CRC	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.64	-9.38	-0.46	1.11e-18	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07035147	chr4:74904607	CXCL3	0.45	6.37	0.33	6.47e-10	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20098514	chr17:39845086	EIF1	0.45	6.12	0.32	2.69e-9	Anxiety disorder;
CRC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.57	-11.11	-0.52	1.39e-24	Asthma (sex interaction);
CRC	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.82	11.61	0.54	2.33e-26	Itch intensity from mosquito bite;
CRC	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.54	-8.98	-0.44	2.16e-17	Congenital heart disease (maternal effect);
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18110333	chr6:292329	DUSP22	-0.58	-8.56	-0.43	4.52e-16	Menopause (age at onset);
CRC	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	cg04338863	chr8:33670619	NA	0.47	7.45	0.38	8.26e-13	Body mass index;
CRC	cis	rs1891275	0.515	rs7093728	chr10:93443617	C/T	cg07889827	chr10:93443413	NA	-0.39	-6.66	-0.34	1.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs798766	1.000	rs798744	chr4:1714684	C/A	cg05874882	chr4:1763078	NA	-0.37	-6.73	-0.35	7.62e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.72e-12	Inflammatory skin disease;
CRC	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg02927042	chr1:21476669	EIF4G3	0.36	5.66	0.3	3.33e-8	Superior frontal gyrus grey matter volume;
CRC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.68	10.48	0.5	2.26e-22	Coronary artery disease;
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.7	9.48	0.46	5.31e-19	Alzheimer's disease;
CRC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg11292332	chr7:45801988	SEPT13	-0.38	-6.83	-0.35	4.14e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-7.59	-0.39	3.33e-13	Menarche (age at onset);
CRC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	8.29	0.42	3.02e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg15786705	chr6:28176104	NA	0.66	8.45	0.42	9.36e-16	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23330034	chr19:41770021	HNRNPUL1	0.46	6.74	0.35	7.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.4	7.53	0.38	4.77e-13	Ulcerative colitis;
CRC	cis	rs7572644	0.640	rs13027427	chr2:28021043	G/T	cg27432699	chr2:27873401	GPN1	0.45	5.72	0.3	2.4e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.4	6.89	0.36	2.77e-11	Height;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg20647610	chr2:228736258	WDR69	-0.47	-6.44	-0.33	4.14e-10	Blood pressure;
CRC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.59	8.12	0.41	9.58e-15	Arsenic metabolism;
CRC	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.74	-10.25	-0.49	1.45e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg21839984	chr17:30846986	MYO1D	-0.33	-5.74	-0.3	2.15e-8	Schizophrenia;
CRC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-9.1	-0.45	9.04e-18	Lymphocyte percentage of white cells;
CRC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.68	10.01	0.48	9.13e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.71	-9.85	-0.48	3.25e-20	Pubertal anthropometrics;
CRC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.58	-10.01	-0.48	9.22e-21	Iron status biomarkers;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.99	0.4	2.33e-14	Breast cancer;
CRC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.43	5.98	0.31	5.88e-9	Breast cancer;
CRC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg00603274	chr11:61596626	FADS2	0.46	7.02	0.36	1.25e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs9287719	0.649	rs9973456	chr2:10718130	C/T	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	2.96e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg14673194	chr17:80132900	CCDC57	0.49	6.42	0.33	4.73e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11645453	chr3:52864694	ITIH4	-0.41	-6.84	-0.35	3.88e-11	Bipolar disorder;
CRC	cis	rs17155006	0.691	rs409815	chr7:107745443	A/G	cg05962710	chr7:107745446	LAMB4	0.4	7.18	0.37	4.65e-12	Pneumococcal bacteremia;
CRC	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.22	-0.32	1.48e-9	Mood instability;
CRC	cis	rs12137294	0.866	rs1172140	chr1:205213024	G/A	cg24159697	chr1:205181237	DSTYK	-0.34	-6.14	-0.32	2.42e-9	Red cell distribution width;
CRC	cis	rs713477	0.692	rs8019270	chr14:55907172	C/G	cg13175173	chr14:55914753	NA	-0.43	-7.43	-0.38	9.2e-13	Pediatric bone mineral content (femoral neck);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26260540	chr19:589513	HCN2	0.33	6.38	0.33	5.96e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18107078	chr1:162760321	HSD17B7	-0.43	-5.96	-0.31	6.38e-9	Breast cancer;
CRC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg07125278	chr16:67683757	RLTPR	-0.61	-6.74	-0.35	7.23e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-11.87	-0.55	2.79e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7731657	0.537	rs2188957	chr5:130253459	C/T	cg08523029	chr5:130500466	HINT1	0.42	5.7	0.3	2.61e-8	Fasting plasma glucose;
CRC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.95	-0.44	2.64e-17	Aortic root size;
CRC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.71e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-10.84	-0.51	1.33e-23	Bone mineral density;
CRC	trans	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	8.72	0.43	1.45e-16	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.66	-0.3	3.3e-8	Aortic root size;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.6e-22	Bipolar disorder;
CRC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg25985355	chr7:65971099	NA	-0.34	-5.73	-0.3	2.22e-8	Corneal structure;
CRC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.97	-0.31	6.3e-9	Aortic root size;
CRC	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.67	10.46	0.5	2.59e-22	Corneal astigmatism;
CRC	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg23815491	chr16:72088622	HP	0.5	7.33	0.37	1.77e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg21155852	chr7:2048760	MAD1L1	-0.49	-6.71	-0.35	8.7e-11	Bipolar disorder;
CRC	cis	rs758324	0.755	rs2221674	chr5:131242218	T/A	cg25547332	chr5:131281432	NA	-0.36	-5.68	-0.3	3.01e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12292205	chr6:26970375	C6orf41	-0.53	-5.71	-0.3	2.55e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.65	10.42	0.5	3.8e-22	Type 2 diabetes;
CRC	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg04239558	chr2:103089729	SLC9A4	0.36	6.18	0.32	1.95e-9	Blood protein levels;
CRC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.63	6.39	0.33	5.78e-10	Axial length;
CRC	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.87	-0.31	1.06e-8	Daytime sleep phenotypes;
CRC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.77	11.7	0.54	1.16e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.83	-11.12	-0.52	1.31e-24	Asthma;
CRC	trans	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg13565492	chr6:43139072	SRF	-0.72	-7.5	-0.38	6.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7517126	1.000	rs13374399	chr1:196842006	G/A	cg13682187	chr1:196946512	CFHR5	-0.37	-6.13	-0.32	2.58e-9	Blood protein levels;
CRC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.85	0.68	2.34e-46	Platelet count;
CRC	trans	rs783540	0.900	rs783525	chr15:83284629	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.9	-0.36	2.65e-11	Schizophrenia;
CRC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.44	-0.42	1.02e-15	Metabolite levels;
CRC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.48	-0.46	5.22e-19	Platelet count;
CRC	trans	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg24644049	chr4:85504048	CDS1	0.66	6.0	0.31	5.3300000000000004e-09	Interleukin-17 levels;
CRC	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg08501292	chr6:25962987	TRIM38	1.06	9.38	0.46	1.08e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.65	-9.48	-0.46	5.41e-19	Type 2 diabetes;
CRC	trans	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg21302420	chr1:112162376	RAP1A	0.67	6.6	0.34	1.61e-10	Skin colour saturation;
CRC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.29	-0.46	2.22e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	1.13	10.19	0.49	2.22e-21	Arsenic metabolism;
CRC	cis	rs10450586	0.932	rs899303	chr11:27309681	A/G	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.98	0.31	5.92e-9	IgG glycosylation;
CRC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.45	-6.77	-0.35	5.98e-11	Platelet distribution width;
CRC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.57	-0.72	3.59e-53	Primary sclerosing cholangitis;
CRC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.98	19.99	0.74	9.7e-59	Primary sclerosing cholangitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18796520	chr12:4758272	NDUFA9	0.45	6.36	0.33	6.88e-10	Response to antipsychotic treatment;
CRC	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg16724585	chr3:197361211	NA	-0.46	-6.91	-0.36	2.58e-11	Pancreatic cancer;
CRC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg25985355	chr7:65971099	NA	-0.47	-5.65	-0.3	3.54e-8	Diabetic kidney disease;
CRC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	0.74	5.97	0.31	5.98e-9	Height;
CRC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg07195577	chr17:27052828	TLCD1	0.4	5.68	0.3	3e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17767392	0.846	rs2332576	chr14:71765507	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.06	-0.32	3.68e-9	Mitral valve prolapse;
CRC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
CRC	cis	rs7712401	0.755	rs1545696	chr5:122102442	A/G	cg18764291	chr5:122110994	SNX2	0.37	5.91	0.31	8.64e-9	Mean platelet volume;
CRC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.65	-9.98	-0.48	1.16e-20	Prudent dietary pattern;
CRC	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.61	9.14	0.45	6.66e-18	Monocyte count;
CRC	cis	rs501120	0.584	rs11238937	chr10:44719816	T/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.71	0.35	8.37e-11	Lung cancer;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.5	-0.34	2.98e-10	Total body bone mineral density;
CRC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.57	7.72	0.39	1.39e-13	Uric acid levels;
CRC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.43	-20.42	-0.75	2e-60	Hip circumference adjusted for BMI;
CRC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.51	6.23	0.33	1.39e-9	Recombination rate (females);
CRC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.92	17.75	0.7	6.17e-50	Menopause (age at onset);
CRC	trans	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg06840491	chr10:48416966	GDF2	-0.35	-5.99	-0.31	5.61e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.62	9.51	0.46	4.33e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-9.36	-0.46	1.32e-18	Colorectal cancer;
CRC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg25356066	chr3:128598488	ACAD9	-0.38	-5.64	-0.3	3.72e-8	IgG glycosylation;
CRC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.07	0.66	2.66e-43	Platelet count;
CRC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.28	0.49	1.11e-21	Platelet count;
CRC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.3	-0.37	2.22e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.77	-0.3	1.86e-8	Total body bone mineral density;
CRC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.49	7.37	0.38	1.4e-12	Corneal astigmatism;
CRC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.13	10.96	0.52	4.84e-24	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-6.36	-0.33	6.7e-10	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19701416	chr10:28592092	NA	-0.52	-6.27	-0.33	1.16e-9	Diisocyanate-induced asthma;
CRC	cis	rs9434723	0.920	rs11801562	chr1:9293156	G/A	cg04199779	chr1:9294473	H6PD	0.52	6.06	0.32	3.62e-9	Height;
CRC	trans	rs12439619	0.921	rs56042848	chr15:82527585	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.44	-6.09	-0.32	3.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.76	-15.27	-0.64	3.51e-40	Prostate cancer;
CRC	trans	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg07817883	chr1:32538562	TMEM39B	-0.63	-7.9	-0.4	4.1e-14	Monocyte percentage of white cells;
CRC	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.77	0.63	3.05e-38	Exhaled nitric oxide output;
CRC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.65	-10.21	-0.49	1.98e-21	Blood protein levels;
CRC	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.4e-8	Blood pressure;
CRC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg15848620	chr12:58087721	OS9	-0.65	-8.91	-0.44	3.64e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.28	-0.37	2.55e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.62	8.96	0.44	2.49e-17	Response to temozolomide;
CRC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.13	-0.32	2.5e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.88	10.68	0.51	4.85e-23	Obesity-related traits;
CRC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.69	9.26	0.45	2.7e-18	Platelet count;
CRC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.57	-9.14	-0.45	6.47e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02807482	chr3:125708958	NA	-0.45	-5.65	-0.3	3.39e-8	Blood pressure (smoking interaction);
CRC	cis	rs10450586	0.965	rs10450589	chr11:27308819	A/C	cg10370305	chr11:27303972	NA	0.36	5.8	0.3	1.59e-8	Total body bone mineral density;
CRC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.08	-0.49	5.41e-21	Monocyte count;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.03	-0.45	1.53e-17	Bipolar disorder;
CRC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.98	18.05	0.71	4.09e-51	Headache;
CRC	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.32	0.49	8.14e-22	Corneal astigmatism;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.37	6.05	0.32	3.84e-9	Major depressive disorder;
CRC	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.5	-8.49	-0.42	7.34e-16	Crohn's disease;
CRC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg10589385	chr1:150898437	SETDB1	0.31	6.63	0.34	1.4e-10	Melanoma;
CRC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.67	7.61	0.39	2.99e-13	Vitiligo;
CRC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.9	9.03	0.45	1.47e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4690686	0.538	rs7436387	chr4:177257723	T/G	cg17059388	chr4:177262070	NA	0.38	5.68	0.3	2.93e-8	Essential tremor;
CRC	cis	rs12024301	0.557	rs75291028	chr1:183609985	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	5.76	0.3	1.94e-8	Parkinson's disease;
CRC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.84	0.48	3.47e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.55	6.93	0.36	2.2e-11	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg07125278	chr16:67683757	RLTPR	-0.62	-7.17	-0.37	5.04e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	22.73	0.78	1.94e-69	Schizophrenia;
CRC	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.42	-8.0	-0.4	2.13e-14	Alcohol dependence;
CRC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.04	-0.36	1.12e-11	IgG glycosylation;
CRC	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.65	6.68	0.35	9.97e-11	Pediatric areal bone mineral density (radius);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21062897	chr14:50999680	MAP4K5;ATL1	0.39	6.29	0.33	1.01e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27408887	chr6:16129570	MYLIP	-0.39	-6.01	-0.31	4.88e-9	Myopia (pathological);
CRC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.37	5.69	0.3	2.77e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.53	8.64	0.43	2.47e-16	Gout;
CRC	trans	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg17712092	chr4:129076599	LARP1B	0.52	6.88	0.35	3.09e-11	DNA methylation (variation);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04208787	chr11:118966294	H2AFX	0.4	6.01	0.31	4.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.59	-8.75	-0.43	1.11e-16	Colorectal cancer;
CRC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.7	9.67	0.47	1.23e-19	Platelet count;
CRC	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.46	-7.44	-0.38	8.99e-13	Refractive error;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs990171	1.000	rs6543134	chr2:103050458	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs4400599	0.618	rs1194602	chr1:154231943	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.69	-0.3	2.75e-8	Platelet distribution width;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.83	-0.44	6.25e-17	Bipolar disorder;
CRC	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg20356878	chr3:121714668	ILDR1	-0.49	-7.29	-0.37	2.39e-12	Multiple sclerosis;
CRC	cis	rs995000	0.931	rs1168132	chr1:63133468	T/A	cg19896129	chr1:63156450	NA	-0.42	-6.45	-0.34	3.99e-10	Triglyceride levels;
CRC	cis	rs9292777	0.720	rs12515722	chr5:40412018	C/A	cg09067459	chr5:40385259	NA	-0.53	-8.69	-0.43	1.72e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.52	8.83	0.44	6.58e-17	Testicular germ cell tumor;
CRC	cis	rs9549328	0.614	rs34306822	chr13:113616499	G/A	cg08614441	chr13:113633676	MCF2L	0.4	6.97	0.36	1.69e-11	Systolic blood pressure;
CRC	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.76	0.39	1.11e-13	Height;
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg18833306	chr6:118973337	C6orf204	0.45	6.01	0.31	4.81e-9	Diastolic blood pressure;
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18301423	chr5:131593218	PDLIM4	0.37	6.88	0.35	3.04e-11	Breast cancer;
CRC	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg09127314	chr1:152161683	NA	-0.45	-5.86	-0.31	1.14e-8	Atopic dermatitis;
CRC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg15145296	chr3:125709740	NA	-0.58	-6.91	-0.36	2.52e-11	Blood pressure (smoking interaction);
CRC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.66	-0.51	5.7e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.53	9.36	0.46	1.25e-18	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	6.07	0.32	3.5e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.5	7.71	0.39	1.46e-13	Corneal astigmatism;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg01305625	chr5:131593812	PDLIM4	-0.36	-5.97	-0.31	6.15e-9	Acylcarnitine levels;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg15786705	chr6:28176104	NA	0.69	9.98	0.48	1.13e-20	Parkinson's disease;
CRC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs972578	1.000	rs1569509	chr22:43359261	A/G	cg01576275	chr22:43409880	NA	-0.44	-7.21	-0.37	3.75e-12	Mean platelet volume;
CRC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg22535103	chr8:58192502	C8orf71	-0.44	-5.85	-0.31	1.21e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7259376	0.869	rs10402396	chr19:22601809	G/C	cg02657401	chr19:22469223	NA	0.31	6.82	0.35	4.25e-11	Menopause (age at onset);
CRC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.59	-7.95	-0.4	2.94e-14	Colorectal cancer;
CRC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg15744005	chr10:104629667	AS3MT	-0.32	-6.66	-0.34	1.15e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25517755	chr10:38738941	LOC399744	-0.42	-6.09	-0.32	3.14e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05952643	chr9:132597404	C9orf78;USP20	0.45	6.63	0.34	1.38e-10	Schizophrenia;
CRC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.91	-15.92	-0.66	1.01e-42	Cognitive function;
CRC	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg09455208	chr3:40491958	NA	0.32	6.41	0.33	4.94e-10	Renal cell carcinoma;
CRC	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.44	-0.33	4.18e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.56	-9.39	-0.46	1.05e-18	Total body bone mineral density;
CRC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg26248373	chr2:1572462	NA	-0.71	-7.95	-0.4	2.92e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9891119	0.576	rs6503697	chr17:40501579	A/T	cg06270615	chr17:40516068	STAT3	-0.35	-7.56	-0.38	3.99e-13	Multiple sclerosis;Crohn's disease;
CRC	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-13.34	-0.59	9.52e-33	Colorectal cancer;
CRC	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	cis	rs713477	0.505	rs8019209	chr14:55891329	C/T	cg13175173	chr14:55914753	NA	-0.48	-7.8	-0.4	8.2e-14	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.67	9.14	0.45	6.46e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.5	7.42	0.38	1.01e-12	Longevity;
CRC	cis	rs1524976	1.000	rs62255278	chr3:65475846	A/T	cg16238336	chr3:65465873	MAGI1	-0.54	-7.72	-0.39	1.43e-13	PR interval;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15806109	chr3:125802485	SLC41A3	0.46	6.4	0.33	5.33e-10	Response to antipsychotic treatment;
CRC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.76	0.68	5.05e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24249390	chr15:90295951	MESP1	-0.59	-9.5	-0.46	4.43e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg17330251	chr7:94953956	PON1	-0.61	-7.65	-0.39	2.21e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg08533674	chr1:46993347	NA	0.74	9.24	0.45	3.25e-18	Monobrow;
CRC	cis	rs6957923	0.934	rs9969137	chr7:23478288	C/T	cg20265043	chr7:23510089	IGF2BP3	0.37	5.61	0.3	4.3e-8	Height;
CRC	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.47	6.35	0.33	7.09e-10	Crohn's disease;
CRC	cis	rs245880	0.666	rs245894	chr7:29192686	G/C	cg17163760	chr7:29186267	CPVL	-0.4	-6.9	-0.36	2.6e-11	Warfarin maintenance dose;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12901283	chr17:53045974	COX11;STXBP4	0.45	6.73	0.35	7.69e-11	Schizophrenia;
CRC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.16	23.7	0.79	3.99e-73	IgG glycosylation;
CRC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg23533926	chr12:111358616	MYL2	-0.53	-8.04	-0.41	1.59e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05043048	chr1:45266447	PLK3	0.43	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.53	-9.09	-0.45	9.72e-18	Iron status biomarkers;
CRC	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-7.95	-0.4	3.07e-14	Prevalent atrial fibrillation;
CRC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.5e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.81	0.44	7.18e-17	Coffee consumption (cups per day);
CRC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.66	12.26	0.56	9.89e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg23463467	chr20:60627584	TAF4	0.35	6.13	0.32	2.51e-9	Body mass index;
CRC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg19193384	chr17:30244184	NA	-0.65	-7.51	-0.38	5.54e-13	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09455096	chr2:61765470	XPO1	0.46	6.46	0.34	3.72e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10211518	chr19:633735	POLRMT	0.44	6.07	0.32	3.47e-9	Response to antipsychotic treatment;
CRC	cis	rs883565	0.740	rs10510698	chr3:39107993	A/C	cg01426195	chr3:39028469	NA	-0.55	-9.07	-0.45	1.11e-17	Handedness;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg07217954	chr7:1067459	C7orf50	0.51	5.94	0.31	7.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.88	-0.31	1.01e-8	Obesity-related traits;
CRC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18912574	chr7:65842487	NCRNA00174	0.37	6.32	0.33	8.6e-10	Aortic root size;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs7264396	0.887	rs4911502	chr20:34063034	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.22	-0.32	1.51e-9	Total cholesterol levels;
CRC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.19	0.37	4.48e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02421172	chr7:1938701	MAD1L1	0.42	5.62	0.3	4.11e-8	Bipolar disorder;
CRC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg03160526	chr17:80928410	B3GNTL1	0.49	8.01	0.4	1.99e-14	Breast cancer;
CRC	cis	rs600626	0.636	rs11236515	chr11:75451411	A/G	cg24262691	chr11:75473276	NA	0.52	7.09	0.36	8.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.39	6.73	0.35	7.52e-11	Crohn's disease;
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg13722127	chr7:150037890	RARRES2	0.47	7.38	0.38	1.26e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	7.58	0.39	3.58e-13	Diisocyanate-induced asthma;
CRC	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.59	-6.53	-0.34	2.57e-10	Coronary artery disease;
CRC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.91	17.31	0.69	3.38e-48	Blood protein levels;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.68	-0.3	2.93e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg02398342	chr17:80708632	TBCD;FN3K	0.54	6.47	0.34	3.6e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	trans	rs4073221	0.520	rs13065273	chr3:18194852	T/C	cg19396872	chr19:8495671	MARCH2	0.63	6.23	0.32	1.46e-9	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00873521	chr9:95056130	IARS;SNORA84	0.49	6.91	0.36	2.51e-11	Response to antipsychotic treatment;
CRC	cis	rs9847710	0.524	rs11712910	chr3:53094194	C/A	cg18099408	chr3:52552593	STAB1	0.4	5.61	0.3	4.27e-8	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17424859	chr6:71319002	NA	-0.4	-6.33	-0.33	8.16e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	0.95	10.12	0.49	3.91e-21	Gut microbiota (bacterial taxa);
CRC	cis	rs9908102	0.710	rs56988654	chr17:12912635	T/G	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03463641	chr2:25565497	DNMT3A	-0.49	-5.98	-0.31	5.87e-9	Monocyte percentage of white cells;
CRC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16262614	chr3:133464971	TF	0.32	5.66	0.3	3.27e-8	Iron status biomarkers;
CRC	cis	rs10760158	0.832	rs10818522	chr9:124019010	A/C	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg18230493	chr5:56204884	C5orf35	-0.39	-5.98	-0.31	5.98e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-17.39	-0.69	1.77e-48	Height;
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.78	-0.51	2.09e-23	Body mass index;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg23123621	chr4:1343375	KIAA1530	0.34	6.19	0.32	1.81e-9	Obesity-related traits;
CRC	cis	rs375066	0.623	rs1549957	chr19:44354238	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg19980929	chr12:42632907	YAF2	0.44	6.56	0.34	2.14e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.57	10.25	0.49	1.36e-21	Blood metabolite ratios;
CRC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.47	6.26	0.33	1.22e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.25	0.41	3.98e-15	Menopause (age at onset);
CRC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.46	7.02	0.36	1.27e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.47	7.1	0.36	7.51e-12	Menopause (age at onset);
CRC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	11.41	0.53	1.3e-25	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg26695010	chr11:65641043	EFEMP2	0.45	6.88	0.35	3.07e-11	Eosinophil percentage of white cells;
CRC	trans	rs17111230	0.675	rs1349568	chr14:41315945	A/C	cg19983597	chr14:21852154	SUPT16H	0.43	5.98	0.31	5.97e-9	Congenital heart disease (inherited effect);
CRC	cis	rs73206853	0.841	rs73191829	chr12:110948906	A/G	cg12870014	chr12:110450643	ANKRD13A	0.74	6.38	0.33	6.1e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg12564285	chr5:131593104	PDLIM4	0.47	9.05	0.45	1.27e-17	Breast cancer;
CRC	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.62e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg06522879	chr11:64358276	SLC22A12	0.59	9.27	0.46	2.44e-18	Urate levels in obese individuals;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08329777	chr17:79885590	LOC92659;MAFG	0.41	5.97	0.31	6.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg13615338	chr4:55094005	PDGFRA	0.4	5.81	0.3	1.51e-8	Corneal astigmatism;
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg20041105	chr8:143859282	LYNX1	0.44	7.85	0.4	5.91e-14	Urinary tract infection frequency;
CRC	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg25547332	chr5:131281432	NA	0.4	5.63	0.3	3.89e-8	Life satisfaction;
CRC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.37	-0.33	6.34e-10	Joint mobility (Beighton score);
CRC	cis	rs1656402	0.954	rs3111399	chr2:233429810	G/A	cg03852847	chr2:233439513	NA	0.44	7.51	0.38	5.71e-13	Non-small cell lung cancer (survival);
CRC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.45	6.96	0.36	1.89e-11	Monocyte count;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg27094323	chr7:1216898	NA	-0.37	-6.02	-0.31	4.68e-9	Longevity;Endometriosis;
CRC	cis	rs282587	0.569	rs282593	chr13:113378882	T/C	cg04656015	chr13:113407548	ATP11A	0.62	7.84	0.4	6.28e-14	Glycated hemoglobin levels;
CRC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg03351412	chr1:154909251	PMVK	0.5	7.6	0.39	3.06e-13	Prostate cancer;
CRC	cis	rs713587	0.520	rs522806	chr2:25316584	C/A	cg22495460	chr2:25135724	ADCY3	0.43	6.47	0.34	3.64e-10	Body mass index in non-asthmatics;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.71	11.63	0.54	1.97e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	14.17	0.62	6.75e-36	Platelet count;
CRC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.52	-8.83	-0.44	6.37e-17	Aortic root size;
CRC	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.93	-0.36	2.16e-11	Systemic lupus erythematosus;
CRC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.62	9.17	0.45	5.2e-18	Morning vs. evening chronotype;
CRC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg20417195	chr1:21767127	NBPF3	0.41	5.9	0.31	8.86e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.57	-10.41	-0.5	4.07e-22	Educational attainment;
CRC	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg04132472	chr17:19861366	AKAP10	0.44	6.94	0.36	2.08e-11	Schizophrenia;
CRC	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	6.45	0.34	4.08e-10	Depression;
CRC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg23533926	chr12:111358616	MYL2	-0.45	-6.57	-0.34	1.99e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg14003231	chr6:33640908	ITPR3	0.51	8.26	0.41	3.71e-15	Plateletcrit;
CRC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg10298567	chr3:47292165	KIF9	-0.35	-5.7	-0.3	2.71e-8	Colorectal cancer;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02807482	chr3:125708958	NA	-0.45	-5.65	-0.3	3.39e-8	Blood pressure (smoking interaction);
CRC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.38	5.88	0.31	1.01e-8	Hemoglobin concentration;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07002965	chr16:88923228	GALNS;TRAPPC2L	0.45	6.13	0.32	2.58e-9	Survival in pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06713521	chr6:7313605	SSR1	0.39	6.2	0.32	1.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7215564	0.818	rs35459747	chr17:78661475	T/C	cg09596252	chr17:78655493	RPTOR	0.53	5.66	0.3	3.38e-8	Myopia (pathological);
CRC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg19193384	chr17:30244184	NA	-0.5	-6.62	-0.34	1.47e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.52	0.43	5.93e-16	Menopause (age at onset);
CRC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.26	-0.37	2.76e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.64	10.57	0.5	1.08e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	cis	rs9549328	0.699	rs2993345	chr13:113617086	C/T	cg24588162	chr13:113633484	MCF2L	0.36	6.5	0.34	2.9e-10	Systolic blood pressure;
CRC	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.12	17.14	0.69	1.7e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg05627522	chr15:75251581	NA	0.37	5.72	0.3	2.46e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04407579	chr13:99228509	STK24	0.41	6.97	0.36	1.76e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.58	8.28	0.42	3.16e-15	Pancreatic cancer;
CRC	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.23	-0.37	3.4e-12	Ulcerative colitis;
CRC	cis	rs669446	0.562	rs3791036	chr1:44155383	A/G	cg12908607	chr1:44402522	ARTN	-0.34	-5.71	-0.3	2.47e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.44	6.55	0.34	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs55675132	0.548	rs76034359	chr1:115375048	C/G	cg25493687	chr8:27288214	PTK2B	0.5	6.06	0.32	3.77e-9	Schizophrenia;
CRC	cis	rs4654899	0.802	rs935918	chr1:21145660	C/T	cg02927042	chr1:21476669	EIF4G3	-0.53	-8.02	-0.4	1.82e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs6893807	1.000	rs3814424	chr5:87968953	C/T	cg09002922	chr5:87956389	LOC645323	-0.41	-5.69	-0.3	2.82e-8	Body mass index;
CRC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.7	-9.7	-0.47	9.61e-20	Platelet count;
CRC	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02228675	chr17:40259724	DHX58	-0.5	-7.01	-0.36	1.38e-11	Fibrinogen levels;
CRC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	1.38	12.37	0.56	3.96e-29	Blood protein levels;
CRC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	6.24	0.33	1.35e-9	Height;
CRC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg12046867	chr14:103022105	NA	-0.84	-11.52	-0.54	5.2e-26	Platelet count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09408520	chr2:157188965	NR4A2	0.46	6.03	0.32	4.5e-9	Thyroid stimulating hormone;
CRC	cis	rs758324	0.812	rs601441	chr5:131284433	C/T	cg25547332	chr5:131281432	NA	-0.36	-5.85	-0.31	1.16e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.48	7.33	0.37	1.79e-12	Testicular germ cell tumor;
CRC	cis	rs7113874	0.610	rs10840055	chr11:8494345	C/T	cg17679104	chr11:8615758	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.46	6.29	0.33	9.97e-10	Aortic root size;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg04969067	chr8:143858791	LYNX1	0.44	7.44	0.38	8.59e-13	Urinary tract infection frequency;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.64	10.39	0.5	4.75e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg17775713	chr3:133465469	TF	0.36	6.44	0.33	4.32e-10	Iron status biomarkers (transferrin levels);
CRC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.73	-0.3	2.31e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs713477	0.654	rs7143800	chr14:55917734	A/G	cg13175173	chr14:55914753	NA	-0.45	-7.99	-0.4	2.34e-14	Pediatric bone mineral content (femoral neck);
CRC	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.62	10.11	0.49	4.25e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.08e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.44	-8.05	-0.41	1.48e-14	Intelligence (multi-trait analysis);
CRC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.81	0.35	4.72e-11	Axial length;
CRC	cis	rs11948739	0.573	rs736046	chr5:130278613	A/G	cg08523029	chr5:130500466	HINT1	0.49	6.19	0.32	1.83e-9	Pediatric bone mineral content (hip);
CRC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg18478394	chr8:109455254	TTC35	-0.39	-5.75	-0.3	2.09e-8	Dupuytren's disease;
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg10729496	chr3:10149963	C3orf24	0.5	6.45	0.33	4.04e-10	Alzheimer's disease;
CRC	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-5.79	-0.3	1.63e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.63	9.16	0.45	5.77e-18	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25599242	chr11:63304337	RARRES3	0.47	6.15	0.32	2.21e-9	Thyroid stimulating hormone;
CRC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.93	-0.31	7.56e-9	Gout;
CRC	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.53	8.99	0.44	1.94e-17	Dupuytren's disease;
CRC	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.8	-0.35	4.98e-11	Inflammatory skin disease;
CRC	cis	rs600626	0.529	rs11236527	chr11:75469310	A/G	cg24262691	chr11:75473276	NA	-0.54	-8.39	-0.42	1.43e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7605827	0.836	rs2052436	chr2:15697518	T/C	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.76	13.29	0.59	1.54e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	5.97e-10	Red blood cell count;
CRC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.43	7.2	0.37	4.2e-12	Crohn's disease;
CRC	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg13615338	chr4:55094005	PDGFRA	0.4	5.8	0.3	1.57e-8	Corneal astigmatism;
CRC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg10820045	chr2:198174542	NA	-0.55	-11.04	-0.52	2.61e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.66	8.52	0.43	5.97e-16	Psoriasis;
CRC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg11212589	chr17:38028394	ZPBP2	-0.43	-8.02	-0.4	1.92e-14	Self-reported allergy;
CRC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.66	10.86	0.51	1.09e-23	Obesity-related traits;
CRC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.4	6.13	0.32	2.5e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.8	-12.97	-0.58	2.36e-31	Menarche (age at onset);
CRC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-6.13	-0.32	2.5e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7932354	0.528	rs4752967	chr11:47169376	T/C	cg03339077	chr11:47165057	C11orf49	-0.47	-6.66	-0.34	1.12e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.43	-6.86	-0.35	3.39e-11	Monocyte count;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg03623178	chr6:28175578	NA	0.93	12.26	0.56	9.88e-29	Depression;
CRC	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg24438145	chr17:48624694	SPATA20	0.44	6.46	0.34	3.76e-10	Type 2 diabetes;
CRC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.53	-7.89	-0.4	4.38e-14	Coronary artery disease;
CRC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.53	6.72	0.35	8.12e-11	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.44	6.3	0.33	9.51e-10	Longevity;Endometriosis;
CRC	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.76	8.5	0.42	6.78e-16	Neuroticism;
CRC	cis	rs12024301	0.557	rs12061628	chr1:183653559	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.79	-0.68	4.09e-46	Hip circumference;
CRC	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.5	6.45	0.33	4.04e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs747650	0.892	rs1976143	chr11:47225534	G/A	cg03339077	chr11:47165057	C11orf49	0.46	6.51	0.34	2.85e-10	Acne (severe);
CRC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.23	-0.32	1.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.8	12.62	0.57	4.88e-30	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26114571	chr19:3225002	BRUNOL5	0.43	6.65	0.34	1.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.74	-10.47	-0.5	2.57e-22	Alzheimer's disease;
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg24560729	chr4:1342394	KIAA1530	0.38	6.14	0.32	2.36e-9	Obesity-related traits;
CRC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg05507819	chr15:63340323	TPM1	0.47	6.21	0.32	1.56e-9	HDL cholesterol;
CRC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.62	-7.61	-0.39	2.98e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	7.04	0.36	1.15e-11	Breast cancer;
CRC	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.79	0.44	8.21e-17	Coffee consumption (cups per day);
CRC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.66	6.47	0.34	3.48e-10	Plasma clusterin levels;
CRC	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg10820045	chr2:198174542	NA	-0.51	-8.89	-0.44	4.05e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.6	-9.11	-0.45	8.23e-18	Body mass index;
CRC	cis	rs12476592	0.602	rs174485	chr2:63857402	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.09	0.32	3.15e-9	Childhood ear infection;
CRC	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.55	-9.53	-0.47	3.53e-19	Lung function (FVC);
CRC	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-7.85	-0.4	5.81e-14	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg12927641	chr6:109611667	NA	-0.36	-6.38	-0.33	6.1e-10	Reticulocyte fraction of red cells;
CRC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg17911788	chr17:44343683	NA	0.57	6.98	0.36	1.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2223471	0.719	rs9357673	chr6:50779653	C/T	cg03432817	chr6:50765336	NA	0.37	5.8	0.3	1.58e-8	Subcutaneous adipose tissue;
CRC	cis	rs3018066	0.748	rs80076579	chr4:106991115	A/T	cg01869342	chr4:106983673	TBCK	0.44	6.71	0.35	8.61e-11	Cancer;
CRC	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg03315344	chr16:75512273	CHST6	-0.51	-5.9	-0.31	8.84e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.55	-8.14	-0.41	8.07e-15	Bone mineral density;
CRC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07157834	chr1:205819609	PM20D1	0.42	5.82	0.31	1.37e-8	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/G	cg14094164	chr13:61491000	NA	0.42	9.41	0.46	8.67e-19	Polychlorinated biphenyl levels;
CRC	cis	rs11212617	0.967	rs662578	chr11:108194557	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.25	0.33	1.27e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4716602	0.542	rs10249935	chr7:156159781	G/A	cg16983916	chr7:156159713	NA	-0.4	-6.92	-0.36	2.41e-11	Anti-saccade response;
CRC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.6	-8.81	-0.44	7.3e-17	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.56	-0.34	2.05e-10	Type 2 diabetes;
CRC	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.48	6.56	0.34	2.06e-10	Height;
CRC	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.46	5.79	0.3	1.6e-8	Aortic root size;
CRC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg15440763	chr7:158190612	PTPRN2	0.34	5.61	0.3	4.2e-8	Obesity-related traits;
CRC	cis	rs6968419	0.747	rs1004109	chr7:115862296	A/T	cg02561103	chr7:115862891	TES	0.43	6.61	0.34	1.54e-10	Intraocular pressure;
CRC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-6.69	-0.35	9.63e-11	Chronic sinus infection;
CRC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg02428538	chr16:24856791	SLC5A11	-0.53	-6.2	-0.32	1.66e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.78	-0.35	5.61e-11	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg27661571	chr11:113659931	NA	0.88	9.84	0.48	3.5e-20	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.79	-0.39	9.04e-14	Height;
CRC	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.5	0.65	4.47e-41	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.33	0.59	1.03e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg05673287	chr15:77411982	SGK269	-0.53	-8.14	-0.41	8.13e-15	Type 2 diabetes;
CRC	cis	rs6662572	0.737	rs11211247	chr1:46476587	G/T	cg08644498	chr1:46502608	NA	0.44	7.05	0.36	1.07e-11	Blood protein levels;
CRC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg08501292	chr6:25962987	TRIM38	0.79	6.17	0.32	2e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.01e-12	Headache;
CRC	cis	rs9409565	0.855	rs7042481	chr9:97064273	C/A	cg04523069	chr9:97136363	HIATL1	-0.4	-6.01	-0.31	5.04e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02869364	chr7:1081709	C7orf50	0.44	5.73	0.3	2.31e-8	Bronchopulmonary dysplasia;
CRC	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg25834613	chr7:1915315	MAD1L1	-0.43	-6.3	-0.33	9.36e-10	Bipolar disorder;
CRC	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.82	-15.72	-0.65	6.47e-42	Oral cavity cancer;
CRC	cis	rs6840360	0.642	rs6855845	chr4:152417380	A/G	cg09659197	chr4:152720779	NA	0.33	6.54	0.34	2.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg09597638	chr17:3907349	NA	-0.62	-11.72	-0.54	9.55e-27	Type 2 diabetes;
CRC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.59	-10.73	-0.51	3.06e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.39	-0.33	5.59e-10	Breast cancer;
CRC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.2	-0.32	1.67e-9	Alzheimer's disease (late onset);
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg15845792	chr6:28175446	NA	0.89	9.2	0.45	4.22e-18	Lung cancer in ever smokers;
CRC	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg23920097	chr1:209922102	NA	0.53	6.48	0.34	3.43e-10	Red blood cell count;
CRC	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.51	-0.42	6.45e-16	Response to antipsychotic treatment;
CRC	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.64	-11.39	-0.53	1.5e-25	Lewy body disease;
CRC	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.83	-0.31	1.33e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.98	0.52	4.29e-24	Bipolar disorder;
CRC	cis	rs755249	0.567	rs4660636	chr1:39770227	T/C	cg18385671	chr1:39797026	MACF1	-0.42	-5.98	-0.31	5.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs7580658	0.864	rs4150441	chr2:128040915	T/C	cg09760422	chr2:128146352	NA	-0.3	-5.99	-0.31	5.43e-9	Protein C levels;
CRC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-11.99	-0.55	1.04e-27	Prostate cancer;
CRC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.97	-0.36	1.69e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	5.8	0.3	1.56e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg20119798	chr7:94954144	PON1	-0.48	-6.19	-0.32	1.83e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg00666640	chr1:248458726	OR2T12	0.48	8.18	0.41	6.14e-15	Common traits (Other);
CRC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.35	-0.33	7.26e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.38	0.46	1.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs59901009	0.911	rs61192802	chr11:10200742	A/G	cg23875677	chr11:10229755	SBF2	-0.47	-5.84	-0.31	1.25e-8	Hematocrit;Hemoglobin concentration;
CRC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg14530993	chr4:882597	GAK	0.79	7.79	0.39	8.83e-14	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg13628971	chr7:2884303	GNA12	0.38	5.75	0.3	2.07e-8	Height;
CRC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg00531865	chr16:30841666	NA	0.5	7.1	0.36	7.91e-12	Dementia with Lewy bodies;
CRC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.33	-0.79	9.69e-72	Myeloid white cell count;
CRC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.82	0.31	1.42e-8	Self-reported allergy;
CRC	cis	rs6681460	0.866	rs1856318	chr1:67024215	T/C	cg02459107	chr1:67143332	SGIP1	0.46	7.36	0.38	1.45e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs73198271	0.530	rs11778326	chr8:8651566	T/G	cg01851573	chr8:8652454	MFHAS1	0.56	7.08	0.36	8.86e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.88	-0.31	1.03e-8	Life satisfaction;
CRC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Bone mineral density;
CRC	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	5.64	0.3	3.76e-8	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg26043149	chr18:55253948	FECH	0.53	8.09	0.41	1.13e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25330514	chr12:110152300	C12orf34	0.41	6.41	0.33	5.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-8.11	-0.41	1.02e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03584783	chr1:173836803	GAS5;SNORD76;SNORD75;SNORD77;ZBTB37	0.42	6.76	0.35	6.2e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.46	5.89	0.31	9.39e-9	Huntington's disease progression;
CRC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg18099408	chr3:52552593	STAB1	0.35	6.03	0.32	4.48e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21365899	chr1:231558446	EGLN1	0.41	6.02	0.31	4.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg04969067	chr8:143858791	LYNX1	0.45	7.66	0.39	2.15e-13	Urinary tract infection frequency;
CRC	cis	rs6479527	0.806	rs1592153	chr9:96745836	A/C	cg14459158	chr9:96720562	NA	0.41	7.36	0.38	1.5e-12	Esophageal adenocarcinoma;
CRC	cis	rs62432291	0.681	rs294913	chr6:159667227	G/A	cg14500486	chr6:159655392	FNDC1	-0.74	-9.0	-0.44	1.91e-17	Joint mobility (Beighton score);
CRC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg14711859	chr11:8959438	ASCL3	0.45	7.61	0.39	2.88e-13	Hemoglobin concentration;
CRC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.5	-8.29	-0.42	2.87e-15	Aortic root size;
CRC	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-6.43	-0.33	4.56e-10	Immature fraction of reticulocytes;
CRC	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Visceral adipose tissue adjusted for BMI;
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg12516270	chr8:143859308	LYNX1	-0.7	-13.14	-0.59	5.43e-32	Urinary tract infection frequency;
CRC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.85	11.74	0.54	8.26e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.42	9.25	0.45	2.97e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg10544611	chr16:67998164	SLC12A4	-0.53	-5.64	-0.3	3.66e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.31	-0.37	2.04e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.37	5.89	0.31	9.67e-9	Total body bone mineral density;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01774158	chr5:133562094	PPP2CA	0.44	6.0	0.31	5.27e-9	Survival in pancreatic cancer;
CRC	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.42	-0.38	1.03e-12	Type 2 diabetes;
CRC	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.21	-0.37	3.77e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6066835	1.000	rs6066820	chr20:47318444	T/C	cg18078177	chr20:47281410	PREX1	0.68	5.67	0.3	3.09e-8	Multiple myeloma;
CRC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.43	5.81	0.3	1.51e-8	Schizophrenia;
CRC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg03233332	chr7:66118400	NA	-0.43	-5.87	-0.31	1.05e-8	Aortic root size;
CRC	trans	rs72956618	1.000	rs68160031	chr2:207489365	T/G	cg20754261	chr2:468330	NA	-0.63	-6.09	-0.32	3.22e-9	Tonsillectomy;
CRC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.65	8.64	0.43	2.45e-16	Morning vs. evening chronotype;
CRC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg01529538	chr14:23388837	RBM23	0.39	5.92	0.31	7.93e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs3790844	1.000	rs3790844	chr1:200007432	A/G	cg13229857	chr1:200006247	NR5A2	0.6	8.59	0.43	3.62e-16	Pancreatic cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05935374	chr11:82782929	RAB30	0.47	6.15	0.32	2.3e-9	Thyroid stimulating hormone;
CRC	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.52	7.29	0.37	2.4e-12	Glioblastoma;Glioma;
CRC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg12682573	chr17:27188876	MIR451;MIR144	0.59	8.33	0.42	2.24e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg06784218	chr1:46089804	CCDC17	-0.51	-8.24	-0.41	4.07e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.45	6.99	0.36	1.53e-11	Red blood cell count;
CRC	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-6.95	-0.36	1.99e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.21	-0.49	1.89e-21	Bipolar disorder;
CRC	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg00732059	chr16:71740210	PHLPP2	-0.65	-6.72	-0.35	7.98e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg20684491	chr1:25596433	NA	0.41	7.08	0.36	8.54e-12	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.78	10.91	0.52	7.6e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.46	6.58	0.34	1.89e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs17607347	0.738	rs8056067	chr16:72347401	G/C	cg27230510	chr3:50404023	CACNA2D2	-0.53	-6.01	-0.31	4.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.63	12.91	0.58	4.04e-31	Schizophrenia;
CRC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.34	-6.37	-0.33	6.26e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.6	8.4	0.42	1.35e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.37	-0.38	1.36e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.43	6.66	0.34	1.18e-10	Longevity;Endometriosis;
CRC	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg12573674	chr2:1569213	NA	-0.62	-7.23	-0.37	3.41e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.52	6.6	0.34	1.66e-10	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16098923	chr2:88927231	EIF2AK3	0.39	6.44	0.33	4.13e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19419581	chr17:79482410	NA	-0.55	-6.81	-0.35	4.7e-11	Diisocyanate-induced asthma;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.53	7.75	0.39	1.15e-13	Longevity;
CRC	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg21138405	chr5:131827807	IRF1	-0.38	-6.58	-0.34	1.84e-10	Breast cancer;Mosquito bite size;
CRC	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.65	-7.61	-0.39	2.98e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-1.08	-13.72	-0.6	3.4e-34	Blood pressure (smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16176301	chr11:8933372	ST5;C11orf17	0.54	7.07	0.36	9.46e-12	Thyroid stimulating hormone;
CRC	cis	rs3018066	0.666	rs28866820	chr4:107031077	T/C	cg01869342	chr4:106983673	TBCK	0.45	5.9	0.31	8.95e-9	Cancer;
CRC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.27	6.11	0.32	2.75e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.64	8.64	0.43	2.5e-16	Alzheimer's disease;
CRC	cis	rs2617583	0.530	rs10060889	chr5:1456803	A/G	cg07148919	chr5:1466943	LPCAT1	-0.43	-5.81	-0.31	1.44e-8	Breast cancer;
CRC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.47	6.55	0.34	2.27e-10	Lymphocyte counts;
CRC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.4	0.38	1.13e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3740540	0.530	rs2362507	chr10:126290820	A/G	cg04949429	chr10:126290192	LHPP	0.43	6.35	0.33	7.13e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9463078	0.804	rs9463081	chr6:45233108	G/A	cg25276700	chr6:44698697	NA	-0.27	-6.49	-0.34	3.07e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs775227	1.000	rs66518523	chr3:113004759	G/T	cg18753928	chr3:113234510	CCDC52	-0.49	-6.16	-0.32	2.09e-9	Dental caries;
CRC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	1.09	11.1	0.52	1.52e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg14631576	chr9:95140430	CENPP	-0.37	-6.42	-0.33	4.74e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	0.54	6.15	0.32	2.25e-9	Dental caries;
CRC	cis	rs7546094	1.000	rs3013440	chr1:113195789	G/A	cg22162597	chr1:113214053	CAPZA1	-0.42	-5.75	-0.3	2.04e-8	Platelet distribution width;
CRC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg02869306	chr7:64672164	INTS4L1	0.43	6.36	0.33	6.93e-10	Aortic root size;
CRC	cis	rs17209837	1.000	rs17149640	chr7:87086039	A/C	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg13047869	chr3:10149882	C3orf24	0.52	7.13	0.37	6.56e-12	Alzheimer's disease;
CRC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg07636037	chr3:49044803	WDR6	-0.66	-5.85	-0.31	1.18e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.6	-0.5	8.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1519814	0.956	rs7827008	chr8:121130281	A/T	cg22335954	chr8:121166405	COL14A1	-0.49	-6.03	-0.32	4.52e-9	Breast cancer;
CRC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.75	-0.35	6.5500000000000006e-11	Monocyte count;
CRC	cis	rs6496667	0.558	rs61653706	chr15:91076654	G/A	cg04176472	chr15:90893244	GABARAPL3	0.48	7.26	0.37	2.75e-12	Rheumatoid arthritis;
CRC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.63	9.62	0.47	1.84e-19	Response to diuretic therapy;
CRC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.9	0.31	9.05e-9	Personality dimensions;
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.65	8.77	0.44	9.52e-17	Alzheimer's disease;
CRC	trans	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.8e-15	Bone mineral density;
CRC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg02741985	chr17:80059408	CCDC57	0.45	7.31	0.37	2.08e-12	Life satisfaction;
CRC	cis	rs1223397	0.938	rs3817742	chr6:13279552	T/C	cg07912922	chr6:13274314	PHACTR1	0.5	6.18	0.32	1.87e-9	Blood pressure;
CRC	cis	rs1448094	0.558	rs7485285	chr12:86483641	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-7.11	-0.36	7.39e-12	Major depressive disorder;
CRC	cis	rs7680126	0.596	rs12503603	chr4:10313757	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-7.25	-0.37	2.95e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01517273	chr1:154599968	ADAR	0.43	5.99	0.31	5.63e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15539395	chr19:59086703	MGC2752	0.46	6.75	0.35	6.78e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.53	8.38	0.42	1.59e-15	Prostate cancer;
CRC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg10578991	chr7:12443926	VWDE	-0.5	-5.98	-0.31	5.94e-9	Coronary artery disease;
CRC	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.38	0.56	3.79e-29	Height;
CRC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	9.53	0.47	3.55e-19	Cognitive test performance;
CRC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.39	-5.9	-0.31	9.06e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.62	7.91	0.4	3.84e-14	Neutrophil percentage of white cells;
CRC	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.4	-5.73	-0.3	2.26e-8	Neuroticism;
CRC	cis	rs7705042	0.828	rs7737631	chr5:141506615	T/G	cg07392085	chr5:141489673	NDFIP1	0.45	6.97	0.36	1.69e-11	Asthma;
CRC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.38	6.93	0.36	2.2e-11	Obesity-related traits;
CRC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.15	-0.32	2.22e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-6.91	-0.36	2.47e-11	Breast cancer;
CRC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.56	7.41	0.38	1.07e-12	Height;
CRC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.82	-11.09	-0.52	1.7e-24	Initial pursuit acceleration;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg22062239	chr16:31106011	VKORC1	0.44	6.11	0.32	2.74e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg06204229	chr3:52865917	ITIH4	0.5	5.86	0.31	1.11e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	1.03	18.28	0.71	4.94e-52	Parkinson's disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24620338	chr11:71498715	FAM86C	0.42	6.56	0.34	2.06e-10	Schizophrenia;
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg08798685	chr6:27730294	NA	0.4	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
CRC	cis	rs77633900	0.772	rs2078437	chr15:76669580	A/G	cg21673338	chr15:77095150	SCAPER	0.68	6.31	0.33	9.13e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg10876282	chr6:28092338	ZSCAN16	0.43	5.74	0.3	2.16e-8	Parkinson's disease;
CRC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.99	0.4	2.35e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.6	8.38	0.42	1.51e-15	Hypertension (SNP x SNP interaction);
CRC	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg09873164	chr1:152488093	CRCT1	0.36	6.05	0.32	3.84e-9	Hair morphology;
CRC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.63	-0.34	1.39e-10	Headache;
CRC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.53	8.43	0.42	1.07e-15	Prostate cancer;
CRC	trans	rs16953946	0.542	rs8048249	chr16:80743431	C/G	cg11504718	chr13:113537807	ATP11A	-0.57	-6.01	-0.31	4.94e-9	Inflammatory bowel disease;
CRC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.36	-5.62	-0.3	4.08e-8	Blood metabolite levels;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg14646075	chr2:228736089	WDR69	-0.46	-6.2	-0.32	1.72e-9	Blood pressure;
CRC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.61	-0.39	2.91e-13	Educational attainment;
CRC	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	cg04338863	chr8:33670619	NA	0.44	6.99	0.36	1.52e-11	Body mass index;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg23807890	chr2:228736357	WDR69	-0.5	-6.91	-0.36	2.53e-11	Blood pressure;
CRC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.55e-13	Mean platelet volume;
CRC	cis	rs3736485	0.903	rs9944241	chr15:51898058	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.46	-0.34	3.73e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11212617	1.000	rs645485	chr11:108168863	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.12	0.32	2.73e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs6758955	0.850	rs6755410	chr2:10480083	A/C	cg15773312	chr2:10472214	HPCAL1	-0.83	-9.55	-0.47	3.01e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-6.98	-0.36	1.66e-11	Dental caries;
CRC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.79	-14.31	-0.62	1.89e-36	Breast cancer;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.63	9.72	0.47	8.33e-20	Corneal astigmatism;
CRC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	5.6	0.3	4.43e-8	Breast cancer;
CRC	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.53	7.62	0.39	2.8e-13	Corneal astigmatism;
CRC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.58	9.76	0.47	6.18e-20	Menopause (age at onset);
CRC	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.39	7.1	0.36	7.71e-12	Breast cancer;
CRC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.7	-11.69	-0.54	1.25e-26	Caffeine consumption;
CRC	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.56	-7.75	-0.39	1.18e-13	Alzheimer's disease;
CRC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.58	-10.39	-0.5	4.61e-22	Aortic root size;
CRC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-13.24	-0.59	2.19e-32	Blood metabolite levels;
CRC	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.56	10.13	0.49	3.62e-21	Cognitive performance;
CRC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.66	8.76	0.43	1.09e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg02569458	chr12:86230093	RASSF9	0.38	6.51	0.34	2.85e-10	Major depressive disorder;
CRC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.5	7.37	0.38	1.36e-12	Height;
CRC	trans	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg24434056	chr13:112550360	NA	0.36	6.01	0.31	4.89e-9	Cleft lip with or without cleft palate;
CRC	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg15147215	chr3:52552868	STAB1	0.42	6.74	0.35	7.13e-11	Body mass index;
CRC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.25	-0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.46	0.34	3.79e-10	Renal cell carcinoma;
CRC	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.69	-10.65	-0.51	5.92e-23	Type 2 diabetes;
CRC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.44	-0.38	8.71e-13	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg22153745	chr1:153894579	GATAD2B	-0.53	-7.44	-0.38	8.6e-13	Total cholesterol levels;
CRC	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.54	-7.97	-0.4	2.7e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.62	6.22	0.32	1.48e-9	Plasma clusterin levels;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.13	-0.32	2.58e-9	Bipolar disorder;
CRC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.59	11.88	0.55	2.57e-27	Asthma (sex interaction);
CRC	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-7.07	-0.36	9.19e-12	Schizophrenia;
CRC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg09264619	chr17:80180166	NA	0.38	6.44	0.33	4.28e-10	Life satisfaction;
CRC	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg24463073	chr6:118973353	C6orf204	0.5	6.21	0.32	1.63e-9	Renal cell carcinoma;
CRC	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg17788362	chr6:86352627	SYNCRIP	0.5	6.88	0.35	3e-11	Smooth-surface caries;
CRC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-7.1	-0.36	7.87e-12	Calcium levels;
CRC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.49	0.34	3.15e-10	Life satisfaction;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8070740	0.786	rs34856659	chr17:5327572	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	6.86	0.35	3.46e-11	Menopause (age at onset);
CRC	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.73	-12.62	-0.57	4.77e-30	White blood cell count (basophil);
CRC	cis	rs7605827	0.930	rs6733647	chr2:15542159	A/G	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs7264396	0.832	rs224349	chr20:34045392	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.85	-0.35	3.64e-11	Total cholesterol levels;
CRC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.16	0.37	5.16e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.55	9.15	0.45	5.95e-18	Sjögren's syndrome;
CRC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-7.2	-0.37	4.11e-12	Morning vs. evening chronotype;
CRC	cis	rs6679356	0.789	rs6672670	chr1:67818577	C/T	cg24364144	chr1:67875067	SERBP1	0.43	6.66	0.34	1.14e-10	Primary biliary cholangitis;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.89	-0.35	2.9e-11	Obesity-related traits;
CRC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.4	7.85	0.4	5.83e-14	Tonsillectomy;
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.27e-9	Cognitive function;
CRC	cis	rs17095355	1.000	rs734163	chr10:111698192	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.53	-7.27	-0.37	2.68e-12	Biliary atresia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20376447	chr17:60143446	MED13	0.46	6.82	0.35	4.29e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.26	-0.33	1.22e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg20885578	chr2:198174922	NA	-0.42	-6.82	-0.35	4.34e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs965469	0.779	rs6133034	chr20:3337661	A/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.69	-0.3	2.86e-8	IFN-related cytopenia;
CRC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg11915388	chr22:42470451	FAM109B	-0.42	-6.47	-0.34	3.63e-10	Schizophrenia;
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11547950	chr5:77652471	NA	-0.48	-7.03	-0.36	1.19e-11	Triglycerides;
CRC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg24881330	chr22:46731750	TRMU	0.57	5.65	0.3	3.46e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg01843034	chr6:37503916	NA	-0.48	-8.8	-0.44	7.73e-17	Cognitive performance;
CRC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.23e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.61	-9.64	-0.47	1.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg21251018	chr6:28226885	NKAPL	0.4	6.09	0.32	3.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg12172441	chr6:28176163	NA	0.53	5.77	0.3	1.85e-8	Depression;
CRC	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg15660573	chr17:549704	VPS53	-0.86	-15.77	-0.66	3.96e-42	Prostate cancer;
CRC	cis	rs9648428	0.515	rs4723485	chr7:36205242	G/T	cg14708893	chr7:36124863	NA	-0.44	-6.34	-0.33	7.43e-10	Obesity-related traits;
CRC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg27535305	chr1:53392650	SCP2	0.36	6.42	0.33	4.77e-10	Monocyte count;
CRC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.19e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg23260525	chr10:116636907	FAM160B1	0.32	6.4	0.33	5.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18912574	chr7:65842487	NCRNA00174	-0.36	-5.97	-0.31	6.21e-9	Aortic root size;
CRC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg00343986	chr7:65444356	GUSB	-0.51	-7.62	-0.39	2.71e-13	Aortic root size;
CRC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.4	-0.33	5.38e-10	Aortic root size;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Parkinson's disease;
CRC	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg13798912	chr7:905769	UNC84A	0.59	6.43	0.33	4.59e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	5.71	0.3	2.52e-8	Schizophrenia;
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg05279229	chr7:1896384	MAD1L1	-0.36	-5.7	-0.3	2.64e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.79	9.82	0.48	4.06e-20	Lung function (FEV1/FVC);
CRC	cis	rs5753037	0.676	rs6006267	chr22:30216982	C/A	cg01021169	chr22:30184971	ASCC2	-0.43	-6.67	-0.35	1.07e-10	Type 1 diabetes;
CRC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	11.6	0.54	2.58e-26	High light scatter reticulocyte count;
CRC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.03	0.4	1.8e-14	Red blood cell count;
CRC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.21	0.32	1.62e-9	Self-reported allergy;
CRC	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.62	-8.49	-0.42	7.19e-16	Blood protein levels;
CRC	cis	rs1223397	0.651	rs2439542	chr6:13311823	G/A	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg21452805	chr1:244014465	NA	0.5	6.68	0.35	1.01e-10	RR interval (heart rate);
CRC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.11	12.18	0.56	1.97e-28	Sexual dysfunction (female);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg26422674	chr12:10766150	MAGOHB	0.38	5.99	0.31	5.37e-9	Body mass index;
CRC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg17294928	chr15:75287854	SCAMP5	0.5	7.74	0.39	1.27e-13	Breast cancer;
CRC	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg23920097	chr1:209922102	NA	-0.55	-6.73	-0.35	7.61e-11	Red blood cell count;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg25164649	chr6:28176230	NA	-0.74	-9.4	-0.46	9.82e-19	Depression;
CRC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.47	6.0	0.31	5.3300000000000004e-09	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.95	0.44	2.75e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs73186030	0.920	rs2001548	chr3:122032789	C/T	cg16331599	chr3:121796627	CD86	0.51	5.8	0.3	1.52e-8	Serum parathyroid hormone levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26942392	chr20:5591638	RP5-1022P6.2	0.48	7.73	0.39	1.32e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.89	-0.4	4.39e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.24	-0.41	4.05e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.89	0.36	2.84e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.61	-0.43	3.08e-16	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.62	10.03	0.48	7.74e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg16476235	chr8:21771668	DOK2	0.35	6.02	0.31	4.66e-9	Mean corpuscular volume;
CRC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.52	-8.26	-0.41	3.7e-15	Immature fraction of reticulocytes;
CRC	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.66	11.17	0.52	8.96e-25	Cancer;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.06	-0.32	3.73e-9	Cognitive function;
CRC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.64	-0.39	2.44e-13	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg16576597	chr16:28551801	NUPR1	0.43	5.85	0.31	1.18e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.92	-0.36	2.36e-11	Inflammatory skin disease;
CRC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.18	-0.41	6.23e-15	Hemoglobin concentration;
CRC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.64	-8.52	-0.42	6e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg00495681	chr13:53174319	NA	-0.54	-7.9	-0.4	4.3e-14	Lewy body disease;
CRC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.19	0.32	1.78e-9	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05529848	chr2:25600059	NA	0.45	6.37	0.33	6.39e-10	Response to antipsychotic treatment;
CRC	cis	rs9649465	0.967	rs6966470	chr7:123299855	C/T	cg03229431	chr7:123269106	ASB15	0.38	5.86	0.31	1.14e-8	Migraine;
CRC	cis	rs6743376	0.556	rs2441376	chr2:113817755	T/C	cg24553058	chr2:113831203	IL1F10	0.42	6.9	0.36	2.69e-11	Inflammatory biomarkers;
CRC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.25	-0.37	3.08e-12	Schizophrenia;
CRC	cis	rs4728302	0.869	rs10231102	chr7:133573310	G/A	cg10665199	chr7:133106180	EXOC4	0.43	6.52	0.34	2.68e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	8.42	0.42	1.21e-15	Height;
CRC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg18764771	chr6:116381957	FRK	0.26	7.42	0.38	1.03e-12	Cholesterol, total;LDL cholesterol;
CRC	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.55	-0.71	4.42e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs9545047	0.680	rs9574405	chr13:79903078	A/G	cg07061582	chr15:90234082	PEX11A;WDR93	0.41	5.97	0.31	6.22e-9	Schizophrenia;
CRC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.58	0.54	3.06e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg22834771	chr12:69754056	YEATS4	-0.42	-5.94	-0.31	7.35e-9	Blood protein levels;
CRC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg13206674	chr6:150067644	NUP43	0.67	9.39	0.46	1.02e-18	Lung cancer;
CRC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.74	0.3	2.17e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.18	0.32	1.84e-9	Menopause (age at onset);
CRC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04880052	chr2:219191631	PNKD	-0.43	-6.8	-0.35	4.8e-11	Colorectal cancer;
CRC	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24538372	chr2:105953882	C2orf49	0.47	6.54	0.34	2.33e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18591801	chr3:52553433	STAB1	-0.35	-6.97	-0.36	1.78e-11	Electroencephalogram traits;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Depression;
CRC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.67	10.51	0.5	1.88e-22	Breast cancer;
CRC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg07952391	chr2:88470173	THNSL2	-0.42	-6.2	-0.32	1.71e-9	Response to metformin (IC50);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08578305	chr12:25403937	KRAS	0.39	6.02	0.31	4.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.57	-7.28	-0.37	2.5e-12	DNA methylation (variation);
CRC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.45	6.41	0.33	5.03e-10	Alcohol dependence;
CRC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.54	7.93	0.4	3.47e-14	Lung cancer;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg26304593	chr6:42947056	PEX6	-0.41	-5.75	-0.3	2.05e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.75	-14.16	-0.62	7.07e-36	Prudent dietary pattern;
CRC	cis	rs6968419	0.674	rs12669768	chr7:115907140	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.2	-0.32	1.66e-9	Intraocular pressure;
CRC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg02018176	chr4:1364513	KIAA1530	0.48	7.9	0.4	4.1e-14	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.38	6.42	0.33	4.82e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.8	-0.4	8.16e-14	Lobe size;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg05865860	chr7:158649142	WDR60	-0.7	-5.97	-0.31	6.26e-9	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22455090	chr5:89825803	LYSMD3	0.43	6.14	0.32	2.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.53	-7.14	-0.37	6.07e-12	Height;
CRC	cis	rs12024301	0.557	rs10911399	chr1:183646903	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.69	5.88	0.31	9.99e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.86	-0.55	2.97e-27	Exhaled nitric oxide output;
CRC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.33	-6.14	-0.32	2.35e-9	Menarche (age at onset);
CRC	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.55	6.92	0.36	2.4e-11	Platelet count;
CRC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg15440763	chr7:158190612	PTPRN2	-0.38	-6.17	-0.32	1.96e-9	Obesity-related traits;
CRC	trans	rs4824093	0.610	rs9627799	chr22:50317989	C/T	cg09872104	chr7:134855509	C7orf49	-0.79	-7.27	-0.37	2.67e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.8	12.55	0.57	8.94e-30	Cognitive function;
CRC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs17152411	0.895	rs11245420	chr10:126586469	T/C	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	cis	rs7527798	0.592	rs10863437	chr1:207817612	T/C	cg09232269	chr1:207846808	CR1L	-0.5	-7.96	-0.4	2.73e-14	Erythrocyte sedimentation rate;
CRC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.87	0.4	5.16e-14	Menopause (age at onset);
CRC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg22532475	chr10:104410764	TRIM8	-0.38	-6.95	-0.36	1.95e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg02018176	chr4:1364513	KIAA1530	0.48	7.96	0.4	2.74e-14	Obesity-related traits;
CRC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.93	0.4	3.4e-14	Red blood cell count;
CRC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.45	9.23	0.45	3.29e-18	Vitiligo;
CRC	trans	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg19894588	chr14:64061835	NA	0.43	6.31	0.33	8.9e-10	Glioblastoma;Glioma;
CRC	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.61	-0.39	2.88e-13	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.79	-11.87	-0.55	2.73e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.55	8.26	0.41	3.59e-15	Blood protein levels;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.58	-0.47	2.56e-19	Heart rate;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg02033258	chr5:131593261	PDLIM4	0.37	6.27	0.33	1.14e-9	Breast cancer;
CRC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-12.36	-0.56	4.36e-29	Vitiligo;
CRC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.92	-0.52	6.54e-24	Extrinsic epigenetic age acceleration;
CRC	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.56	8.35	0.42	1.95e-15	Corneal astigmatism;
CRC	cis	rs727479	0.502	rs12148604	chr15:51501404	A/G	cg19946085	chr15:51559439	CYP19A1	0.28	5.89	0.31	9.3e-9	Estradiol levels;
CRC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-10.99	-0.52	4e-24	Motion sickness;
CRC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg03037974	chr15:76606532	NA	-0.52	-7.66	-0.39	2.14e-13	Blood metabolite levels;
CRC	cis	rs7113874	0.569	rs10769916	chr11:8598214	G/A	cg17679104	chr11:8615758	STK33	-0.36	-6.02	-0.31	4.73e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.51	-9.63	-0.47	1.72e-19	Longevity;
CRC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg21399703	chr1:247681439	NA	0.47	7.65	0.39	2.24e-13	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22123729	chr4:54232041	SCFD2	0.41	5.98	0.31	5.85e-9	Response to antipsychotic treatment;
CRC	cis	rs4908768	0.501	rs6577502	chr1:8615577	T/C	cg20416874	chr1:8611966	RERE	-0.46	-6.53	-0.34	2.49e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs17767392	1.000	rs61991204	chr14:71768073	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs2386661	0.826	rs10795723	chr10:5675983	C/T	cg26603656	chr10:5671107	NA	0.55	9.16	0.45	5.86e-18	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25219047	chr19:3500813	DOHH	0.47	6.5	0.34	2.9e-10	Response to antipsychotic treatment;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg07617317	chr6:118971624	C6orf204	0.49	6.06	0.32	3.7e-9	Diastolic blood pressure;
CRC	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	1.06	8.99	0.44	1.96e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg16476235	chr8:21771668	DOK2	0.4	6.84	0.35	3.89e-11	Mean corpuscular volume;
CRC	cis	rs375066	0.623	rs1549956	chr19:44354138	T/G	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs9322817	0.669	rs4079063	chr6:105266118	A/G	cg02098413	chr6:105308735	HACE1	-0.44	-8.6	-0.43	3.29e-16	Thyroid stimulating hormone;
CRC	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.53	7.41	0.38	1.1e-12	Glioblastoma;Glioma;
CRC	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.56	9.12	0.45	7.58e-18	Neuroticism;
CRC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.4	6.8	0.35	5.08e-11	Diastolic blood pressure;
CRC	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.7	-9.48	-0.46	5.16e-19	Coronary artery disease;
CRC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.83	18.33	0.71	3.32e-52	Breast cancer;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg27615366	chr5:131592974	PDLIM4	-0.33	-5.8	-0.3	1.57e-8	Breast cancer;
CRC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.35	-5.75	-0.3	2.07e-8	Esophageal squamous cell carcinoma;
CRC	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.68	10.67	0.51	5e-23	Colorectal cancer;
CRC	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.69	-0.35	9.69e-11	Osteoarthritis;
CRC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.75	0.66	4.84e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.92e-18	Dupuytren's disease;
CRC	cis	rs4731207	0.698	rs1468378	chr7:124458359	C/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs12286929	0.589	rs4938190	chr11:115087750	C/T	cg04055981	chr11:115044050	NA	0.37	5.65	0.3	3.55e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.52	-6.46	-0.34	3.79e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.73	-8.21	-0.41	5.01e-15	Psoriasis;
CRC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.47	0.42	8.2e-16	Menopause (age at onset);
CRC	cis	rs4929949	0.901	rs4475924	chr11:8620009	T/C	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index;
CRC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.44	8.95	0.44	2.61e-17	Renal cell carcinoma;
CRC	cis	rs1552172	0.811	rs12402787	chr1:145609971	T/C	cg11743829	chr1:145714124	CD160	-0.42	-6.31	-0.33	9.18e-10	Breast cancer;
CRC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.4	6.05	0.32	3.83e-9	Endometrial cancer;
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.03	-0.36	1.23e-11	Bipolar disorder;
CRC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.59	8.93	0.44	3.16e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs4604732	0.642	rs4400652	chr1:247636479	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.62	0.34	1.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs55675132	0.548	rs79783412	chr1:115373478	G/A	cg25493687	chr8:27288214	PTK2B	0.5	6.17	0.32	1.96e-9	Schizophrenia;
CRC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.07	12.59	0.57	6.34e-30	Cannabis dependence symptom count;
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg08222913	chr3:52553049	STAB1	-0.37	-7.04	-0.36	1.1e-11	Electroencephalogram traits;
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.48	-7.09	-0.36	8.19e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.59	-7.36	-0.38	1.45e-12	Platelet distribution width;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.58	-8.68	-0.43	1.82e-16	Menopause (age at onset);
CRC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.0	0.68	6.03e-47	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13198984	chr17:80129470	CCDC57	0.44	7.63	0.39	2.49e-13	Life satisfaction;
CRC	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.28	-0.42	3.06e-15	Brugada syndrome;
CRC	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.03	-0.36	1.17e-11	Menarche (age at onset);
CRC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg02033258	chr5:131593261	PDLIM4	-0.34	-5.96	-0.31	6.66e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.53e-15	Bladder cancer;
CRC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.27	6.09	0.32	3.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25517755	chr10:38738941	LOC399744	-0.43	-6.3	-0.33	9.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.54	6.66	0.34	1.12e-10	Bipolar disorder (body mass index interaction);
CRC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.51	0.6	2.08e-33	Platelet count;
CRC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg11833968	chr6:79620685	NA	-0.35	-5.95	-0.31	7.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg23625390	chr15:77176239	SCAPER	0.48	6.83	0.35	4.16e-11	Blood metabolite levels;
CRC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.57	-7.43	-0.38	9.51e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg15455643	chr13:111040242	COL4A2	0.34	5.64	0.3	3.65e-8	White matter hyperintensity burden;
CRC	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.41	-6.03	-0.32	4.28e-9	Body mass index;
CRC	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-0.55	-6.45	-0.33	4.04e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.65	6.68	0.35	1.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg06470822	chr6:28175283	NA	0.68	9.05	0.45	1.29e-17	Parkinson's disease;
CRC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.59	-0.34	1.7e-10	Lung cancer;
CRC	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.73	0.3	2.23e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.47	6.96	0.36	1.9e-11	Red blood cell count;
CRC	cis	rs7605827	0.866	rs2032692	chr2:15616847	A/G	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.64e-8	Educational attainment (years of education);
CRC	cis	rs73198271	0.562	rs113730597	chr8:8651573	G/A	cg01851573	chr8:8652454	MFHAS1	0.56	7.08	0.36	8.86e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.56	8.08	0.41	1.21e-14	Night sleep phenotypes;
CRC	cis	rs6693567	0.826	rs1260387	chr1:150371448	T/C	cg17724175	chr1:150552817	MCL1	-0.5	-7.29	-0.37	2.29e-12	Migraine;
CRC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.7	-12.3	-0.56	7.41e-29	Prostate cancer;
CRC	cis	rs4380275	0.931	rs4538239	chr2:774238	C/T	cg27237671	chr2:676223	TMEM18	-0.43	-6.18	-0.32	1.95e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg16102536	chr7:156981717	UBE3C	0.4	6.79	0.35	5.41e-11	Body mass index;
CRC	trans	rs6011368	0.749	rs4809418	chr20:62915231	G/A	cg13869341	chr1:15865	WASH5P	-0.53	-8.1	-0.41	1.06e-14	Clozapine-induced cytotoxicity;
CRC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.92	-0.52	6.61e-24	Blood trace element (Zn levels);
CRC	cis	rs7215564	0.908	rs901066	chr17:78659617	C/G	cg09596252	chr17:78655493	RPTOR	0.54	5.81	0.3	1.48e-8	Myopia (pathological);
CRC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg09218773	chr11:619014	MUPCDH	-0.43	-6.34	-0.33	7.78e-10	Systemic lupus erythematosus;
CRC	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.75	9.68	0.47	1.12e-19	Systolic blood pressure;
CRC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg05585544	chr11:47624801	NA	-0.62	-11.44	-0.53	9.35e-26	Subjective well-being;
CRC	cis	rs10208940	0.920	rs6708618	chr2:68722597	C/A	cg12452813	chr2:68675892	NA	0.5	6.17	0.32	2e-9	Urate levels in lean individuals;
CRC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.48	-0.5	2.37e-22	Bipolar disorder and schizophrenia;
CRC	trans	rs6546324	0.580	rs4362541	chr2:67842866	A/T	cg00907274	chr3:27498161	SLC4A7	-0.48	-6.1	-0.32	3.03e-9	Endometriosis;
CRC	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg25600027	chr14:23388339	RBM23	-0.45	-6.84	-0.35	3.96e-11	Cognitive ability (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.41	-6.06	-0.32	3.78e-9	Renal cell carcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11750756	chr12:50135418	TMBIM6	0.54	7.13	0.37	6.31e-12	Thyroid stimulating hormone;
CRC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs9976767	0.792	rs883868	chr21:43845092	C/T	cg23042151	chr21:43824109	UBASH3A	0.37	6.44	0.33	4.29e-10	Type 1 diabetes;
CRC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.47	-0.34	3.57e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05340844	chr15:90808742	NGRN	0.5	6.33	0.33	7.95e-10	Thyroid stimulating hormone;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg26028573	chr6:26043587	HIST1H2BB	0.52	7.59	0.39	3.41e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs3732004	chr2:15713783	C/T	cg19274914	chr2:15703543	NA	0.41	6.15	0.32	2.25e-9	Educational attainment (years of education);
CRC	trans	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24308560	chr3:49941425	MST1R	-0.51	-7.95	-0.4	2.93e-14	Intelligence (multi-trait analysis);
CRC	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.93	11.66	0.54	1.56e-26	Exhaled nitric oxide levels;
CRC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.46	-7.88	-0.4	4.9e-14	Primary biliary cholangitis;
CRC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.67	0.51	4.87e-23	Prudent dietary pattern;
CRC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg18512352	chr11:47633146	NA	-0.41	-7.91	-0.4	3.94e-14	Subjective well-being;
CRC	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg14036092	chr11:66035641	RAB1B	-0.48	-5.8	-0.3	1.58e-8	Electroencephalogram traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25201980	chr8:146127417	ZNF250	0.48	6.72	0.35	8.25e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02522952	chr6:119671260	MAN1A1	0.4	6.55	0.34	2.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.85	8.03	0.4	1.7e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs59901009	0.911	rs61889955	chr11:10183445	G/T	cg23875677	chr11:10229755	SBF2	-0.46	-5.68	-0.3	3e-8	Hematocrit;Hemoglobin concentration;
CRC	trans	rs800082	1.000	rs9882503	chr3:144321296	A/T	cg24215973	chr2:240111563	HDAC4	-0.53	-7.52	-0.38	5.16e-13	Smoking behavior;
CRC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	0.89	9.07	0.45	1.11e-17	Gout;Renal underexcretion gout;
CRC	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg13491945	chr12:107078410	RFX4	0.34	5.84	0.31	1.25e-8	Heart rate;
CRC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.25	0.37	2.95e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.4	-0.33	5.26e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.58	-9.17	-0.45	5.11e-18	Intelligence (multi-trait analysis);
CRC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.51	6.43	0.33	4.45e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.72e-8	Prudent dietary pattern;
CRC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.51	-7.52	-0.38	5.32e-13	White blood cell count;
CRC	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.91	-15.88	-0.66	1.45e-42	Survival in pancreatic cancer;
CRC	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.74	-11.2	-0.53	7.03e-25	Waist circumference;Body mass index;
CRC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.46	7.03	0.36	1.22e-11	Cleft lip with or without cleft palate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27263386	chr21:33984714	C21orf59	0.5	7.2	0.37	4.11e-12	Response to antipsychotic treatment;
CRC	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg07856975	chr6:36356162	ETV7	0.47	5.87	0.31	1.06e-8	Platelet distribution width;
CRC	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-6.75	-0.35	6.61e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg20608306	chr11:116969690	SIK3	0.35	7.33	0.37	1.76e-12	Blood protein levels;
CRC	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg10756647	chr7:56101905	PSPH	0.76	8.08	0.41	1.26e-14	Gout;
CRC	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.93	0.36	2.2e-11	Mean corpuscular volume;
CRC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.72	-11.74	-0.54	8.32e-27	Height;
CRC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.76	16.52	0.67	4.67e-45	Breast cancer;
CRC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.87	0.4	5.08e-14	Colorectal cancer;
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.59	6.21	0.32	1.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.68	-0.3	2.93e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg19635926	chr16:89946313	TCF25	0.66	6.17	0.32	1.99e-9	Skin colour saturation;
CRC	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg23034840	chr1:205782522	SLC41A1	-0.52	-5.83	-0.31	1.31e-8	Prostate-specific antigen levels;
CRC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.29	0.42	2.99e-15	Lung cancer;
CRC	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-0.84	-10.54	-0.5	1.46e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-7.11	-0.37	7.08e-12	Blood metabolite levels;
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.01	-0.4	2.01e-14	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.51	0.54	5.33e-26	Prudent dietary pattern;
CRC	cis	rs7833986	1.000	rs56699713	chr8:57096670	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.81	0.35	4.56e-11	Height;
CRC	cis	rs1881396	0.947	rs8731	chr2:27873326	C/G	cg27432699	chr2:27873401	GPN1	0.63	8.07	0.41	1.3e-14	Nonalcoholic fatty liver disease;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.05	-0.32	3.87e-9	Depression;
CRC	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg13385794	chr1:248469461	NA	0.38	6.67	0.35	1.09e-10	Common traits (Other);
CRC	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.63	8.28	0.42	3.12e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.54	-9.1	-0.45	8.54e-18	Systemic lupus erythematosus;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg02869364	chr7:1081709	C7orf50	-0.38	-6.06	-0.32	3.72e-9	Longevity;Endometriosis;
CRC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg02741985	chr17:80059408	CCDC57	-0.42	-6.7	-0.35	9.15e-11	Life satisfaction;
CRC	trans	rs529967	0.797	rs555540	chr3:124166965	A/C	cg01377916	chr16:46654868	SHCBP1	-0.46	-6.34	-0.33	7.68e-10	Acute graft versus host disease in bone marrow transplantation (donor effect);
CRC	cis	rs2530545	0.619	rs6955936	chr7:34662450	C/T	cg14401837	chr7:34697493	NPSR1	0.42	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.59	0.63	1.54e-37	Chronic sinus infection;
CRC	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.57	-7.92	-0.4	3.63e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg20542592	chr8:11973495	FAM66D	0.32	5.69	0.3	2.81e-8	Retinal vascular caliber;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07718463	chr19:30303131	CCNE1	0.49	7.45	0.38	8.05e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12273811	chr6:28175739	NA	0.71	9.2	0.45	4.28e-18	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.43	-7.92	-0.4	3.58e-14	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.61	8.03	0.4	1.76e-14	Alzheimer's disease;
CRC	cis	rs9908102	0.740	rs8078710	chr17:12910662	G/A	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22162010	chr1:113249994	RHOC	-0.37	-6.13	-0.32	2.49e-9	Myopia (pathological);
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18402987	chr7:1209562	NA	0.46	6.69	0.35	9.76e-11	Longevity;Endometriosis;
CRC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.46	0.34	3.7e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg16606324	chr3:10149918	C3orf24	0.69	9.43	0.46	7.91e-19	Alzheimer's disease;
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.7	10.06	0.49	6.03e-21	Alzheimer's disease;
CRC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.73	-0.39	1.33e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg10437265	chr15:77819839	NA	0.58	10.42	0.5	3.62e-22	Type 2 diabetes;
CRC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	7.26	0.37	2.75e-12	Headache;
CRC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg20684491	chr1:25596433	NA	0.4	6.85	0.35	3.61e-11	Erythrocyte sedimentation rate;
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg16606324	chr3:10149918	C3orf24	0.61	7.94	0.4	3.33e-14	Alzheimer's disease;
CRC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.27	0.64	3.58e-40	Platelet count;
CRC	cis	rs9937943	0.667	rs11862508	chr16:74598688	T/C	cg01733217	chr16:74700730	RFWD3	0.72	8.18	0.41	6.38e-15	Neutrophil percentage of white cells;
CRC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	8.94	0.44	2.77e-17	Cognitive test performance;
CRC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.64	-10.4	-0.5	4.36e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.68	-10.06	-0.49	6.09e-21	Corneal astigmatism;
CRC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.8	7.94	0.4	3.32e-14	Diabetic retinopathy;
CRC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	13.36	0.59	7.84e-33	Electrocardiographic conduction measures;
CRC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.79	-10.41	-0.5	4.06e-22	Initial pursuit acceleration;
CRC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.44	7.6	0.39	3.08e-13	Major depressive disorder;
CRC	trans	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg26043149	chr18:55253948	FECH	-0.5	-6.8	-0.35	4.9e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12172441	chr6:28176163	NA	0.53	7.32	0.37	1.96e-12	Cardiac Troponin-T levels;
CRC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg11189052	chr15:85197271	WDR73	0.64	9.22	0.45	3.73e-18	Schizophrenia;
CRC	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.16	-0.32	2.13e-9	Retinal vascular caliber;
CRC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg12792011	chr19:58661915	ZNF329	0.75	8.19	0.41	5.94e-15	Cholesterol, total;
CRC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05210131	chr2:182757482	SSFA2	0.39	6.14	0.32	2.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg01262667	chr19:19385393	TM6SF2	0.37	6.03	0.32	4.41e-9	Tonsillectomy;
CRC	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg20936604	chr3:58311152	NA	-0.76	-7.27	-0.37	2.69e-12	Cholesterol, total;
CRC	trans	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg17903999	chr18:56338584	MALT1	0.41	6.71	0.35	8.45e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	6.07	0.32	3.44e-9	Educational attainment (years of education);
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.53	7.69	0.39	1.69e-13	Subjective well-being;
CRC	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.71	14.1	0.61	1.26e-35	Leprosy;
CRC	cis	rs524281	0.773	rs7925123	chr11:65993213	G/C	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.72	-0.47	8.49e-20	Chronic sinus infection;
CRC	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.47	-7.91	-0.4	3.87e-14	Migraine - clinic-based;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.5	-8.04	-0.41	1.69e-14	Caffeine consumption;
CRC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-9.73	-0.47	7.66e-20	Total cholesterol levels;
CRC	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.48	-8.99	-0.44	2.04e-17	Hepatitis;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.62	-0.39	2.67e-13	Breast cancer;
CRC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.61	7.78	0.39	9.31e-14	Bronchopulmonary dysplasia;
CRC	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.05	-0.36	1.04e-11	Caudate activity during reward;
CRC	cis	rs7932354	0.583	rs6485695	chr11:46836165	C/T	cg19486271	chr11:47235900	DDB2	-0.42	-6.08	-0.32	3.31e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.0	-0.48	1.02e-20	Lung cancer;
CRC	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.75	-12.27	-0.56	9.35e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.38	6.69	0.35	9.62e-11	Reticulocyte fraction of red cells;
CRC	cis	rs755249	0.567	rs1126313	chr1:39639744	A/C	cg18385671	chr1:39797026	MACF1	0.41	5.77	0.3	1.86e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.48	-6.73	-0.35	7.46e-11	Eotaxin levels;
CRC	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.36	0.33	6.86e-10	Breast cancer;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg10217327	chr6:118973057	C6orf204	0.51	5.73	0.3	2.29e-8	Diastolic blood pressure;
CRC	trans	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.94	-0.36	2.05e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg08755490	chr11:65554678	OVOL1	0.44	6.34	0.33	7.57e-10	Acne (severe);
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.07	-0.55	5.3e-28	Alzheimer's disease;
CRC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg04731861	chr2:219085781	ARPC2	-0.32	-6.78	-0.35	5.56e-11	Colorectal cancer;
CRC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.24	-0.56	1.18e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.9	-15.13	-0.64	1.32e-39	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.63	9.6	0.47	2.18e-19	Crohn's disease;
CRC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg22532475	chr10:104410764	TRIM8	0.33	5.71	0.3	2.53e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg17710535	chr19:10819994	QTRT1	0.45	6.29	0.33	1.01e-9	Inflammatory skin disease;
CRC	cis	rs7112925	0.738	rs12803688	chr11:66833265	G/A	cg24851651	chr11:66362959	CCS	-0.33	-5.74	-0.3	2.15e-8	Height;
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.8	15.25	0.64	4.21e-40	Prudent dietary pattern;
CRC	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-6.31	-0.33	9.06e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg22561889	chr6:118971681	C6orf204	0.52	6.7	0.35	9.08e-11	Diastolic blood pressure;
CRC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg17133734	chr15:86042851	AKAP13	0.4	6.48	0.34	3.44e-10	Interstitial lung disease;
CRC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23262073	chr20:60523788	NA	0.38	6.45	0.33	4.06e-10	Body mass index;
CRC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg02007433	chr3:129722099	NA	-0.47	-6.46	-0.34	3.74e-10	Blood pressure (smoking interaction);
CRC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-17.62	-0.7	2.16e-49	Height;
CRC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg15147215	chr3:52552868	STAB1	0.54	8.16	0.41	7.07e-15	Bipolar disorder;
CRC	cis	rs10924970	0.934	rs3856241	chr1:235429692	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.8	0.3	1.53e-8	Asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00162206	chr2:113239913	TTL	0.43	6.27	0.33	1.13e-9	Response to antipsychotic treatment;
CRC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.52	6.92	0.36	2.39e-11	Lymphocyte counts;
CRC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.96	12.19	0.56	1.85e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg16476235	chr8:21771668	DOK2	0.4	6.98	0.36	1.59e-11	Mean corpuscular volume;
CRC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.72	8.67	0.43	1.96e-16	Type 2 diabetes nephropathy;
CRC	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg14844989	chr11:31128820	NA	0.35	6.18	0.32	1.87e-9	Red blood cell count;
CRC	cis	rs10512697	0.649	rs34098513	chr5:3486403	G/C	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg13736514	chr6:26305472	NA	0.37	6.26	0.33	1.19e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Parkinson's disease;
CRC	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.66	-10.51	-0.5	1.81e-22	Hepatocellular carcinoma;
CRC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.0	-0.31	5.28e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg14541582	chr5:601475	NA	-0.37	-7.19	-0.37	4.49e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg24531977	chr5:56204891	C5orf35	-0.46	-6.94	-0.36	2.08e-11	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.67	9.45	0.46	6.71e-19	Lung cancer;
CRC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.55	8.78	0.44	9.17e-17	Tonsillectomy;
CRC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.46	6.54	0.34	2.36e-10	Type 2 diabetes;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.66	7.02	0.36	1.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.61	-8.93	-0.44	3.04e-17	Menarche (age at onset);
CRC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-9.88	-0.48	2.57e-20	Tonsillectomy;
CRC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.46	-7.17	-0.37	5.12e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.8	14.25	0.62	3.19e-36	Breast cancer;
CRC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.1	-0.32	2.9e-9	Menarche (age at onset);
CRC	trans	rs9771228	0.870	rs215605	chr7:32336965	G/T	cg02979224	chr7:93204462	CALCR	0.36	6.33	0.33	7.9e-10	Cognitive ability;Verbal-numerical reasoning;
CRC	cis	rs2882667	0.690	rs288033	chr5:138214094	A/G	cg09476006	chr5:138032270	NA	0.57	9.99	0.48	1.03e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs854555	0.651	rs854546	chr7:94923764	A/C	cg04155289	chr7:94953770	PON1	0.45	6.19	0.32	1.81e-9	Response to TNF antagonist treatment;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.41	-7.6	-0.39	3.13e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.78	-0.35	5.41e-11	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-10.19	-0.49	2.22e-21	Height;
CRC	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg01858014	chr14:56050164	KTN1	-0.92	-7.31	-0.37	2e-12	Putamen volume;
CRC	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg02811702	chr13:24901961	NA	0.47	6.5	0.34	2.96e-10	Obesity-related traits;
CRC	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-5.82	-0.31	1.39e-8	Daytime sleep phenotypes;
CRC	cis	rs364477	1.000	rs370435	chr9:954997	T/C	cg13952963	chr9:998547	NA	0.51	6.57	0.34	1.95e-10	Major depressive disorder;
CRC	cis	rs17601876	1.000	rs17601876	chr15:51553909	C/T	cg19946085	chr15:51559439	CYP19A1	0.3	5.94	0.31	7.34e-9	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.45	7.11	0.37	7.09e-12	Platelet count;
CRC	trans	rs7757969	0.500	rs9387042	chr6:112155670	T/G	cg08211895	chr2:48828358	STON1-GTF2A1L	0.31	6.1	0.32	3.05e-9	Schizophrenia;
CRC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.45	6.23	0.32	1.42e-9	IgG glycosylation;
CRC	cis	rs7209700	0.777	rs8073827	chr17:45344662	G/T	cg08085267	chr17:45401833	C17orf57	0.44	6.13	0.32	2.52e-9	IgG glycosylation;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.92	11.13	0.52	1.2e-24	Exhaled nitric oxide output;
CRC	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.33	-0.37	1.8e-12	QT interval;
CRC	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.45	-6.41	-0.33	5.12e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	trans	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.72e-15	Bone mineral density;
CRC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.26	-0.45	2.63e-18	Type 2 diabetes;
CRC	cis	rs356992	0.767	rs1896297	chr2:60738227	A/G	cg08426369	chr2:60753602	BCL11A	-0.47	-6.59	-0.34	1.7e-10	Educational attainment (years of education);
CRC	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.24	0.64	4.81e-40	Colorectal cancer;
CRC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg05304507	chr6:116381966	FRK	0.31	8.24	0.41	4.01e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg07701084	chr6:150067640	NUP43	0.56	6.66	0.34	1.18e-10	Lung cancer;
CRC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.7	10.47	0.5	2.41e-22	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.82	0.51	1.57e-23	Systolic blood pressure;
CRC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.49	-0.5	2.16e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg10298567	chr3:47292165	KIF9	0.41	6.38	0.33	5.89e-10	Colorectal cancer;
CRC	cis	rs7539542	0.600	rs9943282	chr1:202895140	C/T	cg19681188	chr1:202830198	LOC148709	0.45	6.44	0.33	4.18e-10	Mean platelet volume;
CRC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	5.92	0.31	8.11e-9	Asthma;
CRC	trans	rs7615952	0.605	rs34865555	chr3:125304134	C/T	cg02560186	chr11:3602584	NA	-0.64	-6.03	-0.32	4.4e-9	Blood pressure (smoking interaction);
CRC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.82	11.35	0.53	1.98e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg05283184	chr6:79620031	NA	-0.44	-6.38	-0.33	5.85e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	9.05	0.45	1.23e-17	Ulcerative colitis;
CRC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg19193384	chr17:30244184	NA	0.62	7.01	0.36	1.38e-11	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.62	9.52	0.46	3.9e-19	Menopause (age at onset);
CRC	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg12218747	chr21:37451666	NA	0.44	7.59	0.39	3.35e-13	Mitral valve prolapse;
CRC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg00074818	chr8:8560427	CLDN23	0.35	6.41	0.33	5.04e-10	Obesity-related traits;
CRC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg25281562	chr12:121454272	C12orf43	0.39	5.69	0.3	2.83e-8	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg02659138	chr7:134003124	SLC35B4	0.37	6.45	0.34	3.99e-10	Mean platelet volume;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg27422857	chr2:105853526	NA	-0.33	-6.14	-0.32	2.38e-9	Type 2 diabetes;
CRC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg25767906	chr1:53392781	SCP2	-0.4	-6.22	-0.32	1.5e-9	Monocyte count;
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.26	-6.07	-0.32	3.59e-9	Total body bone mineral density;
CRC	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-6.93	-0.36	2.28e-11	Osteoarthritis;
CRC	cis	rs3772130	1.000	rs3772128	chr3:121345094	G/T	cg20356878	chr3:121714668	ILDR1	0.49	7.64	0.39	2.33e-13	Cognitive performance;
CRC	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.59	9.95	0.48	1.45e-20	Dupuytren's disease;
CRC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.44	0.33	4.13e-10	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22560197	chr1:70687124	SFRS11	0.37	6.11	0.32	2.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg15845792	chr6:28175446	NA	0.77	11.37	0.53	1.74e-25	Parkinson's disease;
CRC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.6	-0.39	3.1e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg12516270	chr8:143859308	LYNX1	0.42	7.35	0.38	1.61e-12	Urinary tract infection frequency;
CRC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.87	-14.42	-0.62	7.04e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg15282417	chr9:129245246	FAM125B	0.46	8.38	0.42	1.55e-15	Intraocular pressure;
CRC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.32	5.93	0.31	7.52e-9	Blood protein levels;
CRC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.23	-0.37	3.49e-12	Mean platelet volume;
CRC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg15848620	chr12:58087721	OS9	-0.63	-8.74	-0.43	1.26e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.48	-8.39	-0.42	1.5e-15	Facial morphology (factor 20);
CRC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.47	8.18	0.41	6.34e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.37	-6.29	-0.33	1.03e-9	Blood metabolite levels;
CRC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.27e-46	Breast cancer;
CRC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg10760299	chr15:45669010	GATM	0.49	7.81	0.4	7.61e-14	Homoarginine levels;
CRC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.86	-0.31	1.1e-8	Gout;Renal underexcretion gout;
CRC	cis	rs727505	0.866	rs67132333	chr7:124719801	A/G	cg23710748	chr7:124431027	NA	-0.72	-12.33	-0.56	5.81e-29	Lewy body disease;
CRC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.45	-8.42	-0.42	1.2e-15	Intelligence (multi-trait analysis);
CRC	trans	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.98e-14	Bone mineral density;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg21251018	chr6:28226885	NKAPL	0.48	7.36	0.38	1.47e-12	Parkinson's disease;
CRC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	27.09	0.83	8.96e-86	Testicular germ cell tumor;
CRC	cis	rs911119	0.908	rs6048950	chr20:23603252	A/G	cg16589663	chr20:23618590	CST3	0.45	6.32	0.33	8.44e-10	Chronic kidney disease;
CRC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-6.01	-0.31	4.85e-9	Lung cancer;
CRC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.48	-7.54	-0.38	4.72e-13	Monocyte count;
CRC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	11.03	0.52	2.71e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg17724175	chr1:150552817	MCL1	-0.46	-7.28	-0.37	2.49e-12	Lymphocyte counts;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03523550	chr11:64001996	VEGFB	0.39	6.23	0.32	1.43e-9	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.52	7.62	0.39	2.76e-13	Lung cancer;
CRC	cis	rs3018066	0.748	rs7340989	chr4:107148720	G/A	cg01869342	chr4:106983673	TBCK	0.43	6.48	0.34	3.31e-10	Cancer;
CRC	trans	rs2303319	0.504	rs62187611	chr2:162431946	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.77	-6.19	-0.32	1.79e-9	Cognitive function;
CRC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.09	0.52	1.76e-24	Bone mineral density;
CRC	trans	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg01505111	chr6:125621795	HDDC2	0.38	6.07	0.32	3.59e-9	DNA methylation (variation);
CRC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.75	-13.04	-0.58	1.25e-31	Body mass index;
CRC	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg20045696	chr14:77926864	AHSA1	-0.64	-6.08	-0.32	3.36e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	trans	rs67073037	0.955	rs3924272	chr2:29167678	C/T	cg13899017	chr1:159158444	CADM3	-0.37	-6.23	-0.32	1.39e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs2415984	0.579	rs17740937	chr14:46959273	A/G	cg14871534	chr14:47121158	RPL10L	-0.44	-6.23	-0.32	1.43e-9	Number of children ever born;
CRC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.73	0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg00647820	chr17:40259828	DHX58	0.41	5.74	0.3	2.14e-8	Fibrinogen levels;
CRC	cis	rs4363385	0.693	rs662506	chr1:153048386	A/C	cg25856811	chr1:152973957	SPRR3	0.24	6.57	0.34	1.96e-10	Inflammatory skin disease;
CRC	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg10298567	chr3:47292165	KIF9	0.42	6.56	0.34	2.07e-10	Colorectal cancer;
CRC	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.56	-9.02	-0.45	1.6e-17	Type 2 diabetes;
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.64	0.34	1.3e-10	Bipolar disorder;
CRC	trans	rs800082	0.690	rs2717392	chr3:144280080	T/C	cg24215973	chr2:240111563	HDAC4	0.57	8.89	0.44	4.06e-17	Smoking behavior;
CRC	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg03013636	chr16:1946785	NA	-0.47	-5.85	-0.31	1.18e-8	Insulin-like growth factors;
CRC	cis	rs6429082	0.509	rs35446932	chr1:235523480	C/T	cg26050004	chr1:235667680	B3GALNT2	0.42	6.0	0.31	5.15e-9	Adiposity;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.96	0.44	2.48e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg03013999	chr17:37608204	MED1	-0.46	-6.95	-0.36	1.97e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg18809830	chr7:99032528	PTCD1	-0.93	-7.32	-0.37	1.89e-12	Blood metabolite levels;
CRC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg21972741	chr5:435613	AHRR	0.48	5.61	0.3	4.25e-8	Cystic fibrosis severity;
CRC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.6	9.96	0.48	1.34e-20	Calcium levels;
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg15382696	chr6:118971807	C6orf204	0.59	7.5	0.38	6.18e-13	Diastolic blood pressure;
CRC	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg13482628	chr17:19912719	NA	0.54	8.68	0.43	1.81e-16	Schizophrenia;
CRC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg24977027	chr2:88469347	THNSL2	0.63	7.73	0.39	1.29e-13	Plasma clusterin levels;
CRC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.49	0.34	3.13e-10	Bladder cancer;
CRC	trans	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.55	-7.49	-0.38	6.6e-13	Intelligence (multi-trait analysis);
CRC	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.44	-7.1	-0.36	7.67e-12	Refractive error;
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.91	-22.06	-0.77	7.6e-67	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26714650	chr12:56694279	CS	-1.4	-10.71	-0.51	3.55e-23	Psoriasis vulgaris;
CRC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.68	10.27	0.49	1.24e-21	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs9549328	0.700	rs4907570	chr13:113617651	T/C	cg08614441	chr13:113633676	MCF2L	0.4	7.08	0.36	8.76e-12	Systolic blood pressure;
CRC	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.71	11.08	0.52	1.79e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.45	7.45	0.38	8.36e-13	Testicular germ cell tumor;
CRC	trans	rs7011507	1.000	rs13261342	chr8:49195847	C/A	cg04544946	chr8:978226	NA	0.44	5.98	0.31	5.96e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.75	0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.53	-0.5	1.59e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2398893	0.889	rs2039313	chr9:96781684	C/G	cg14459158	chr9:96720562	NA	-0.4	-6.59	-0.34	1.78e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.37	-0.38	1.39e-12	Gut microbiome composition (summer);
CRC	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	trans	rs12517041	1.000	rs7734125	chr5:23300072	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.56	-6.2	-0.32	1.74e-9	Calcium levels;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.32	-6.49	-0.34	3.07e-10	Electroencephalogram traits;
CRC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.24	0.33	1.37e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.48	6.17	0.32	1.99e-9	Blood metabolite levels;
CRC	cis	rs6961069	0.774	rs1054516	chr7:80284942	T/C	cg04458919	chr7:80252533	CD36	0.35	6.06	0.32	3.65e-9	Platelet count;
CRC	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg16141378	chr3:129829833	LOC729375	0.4	6.13	0.32	2.58e-9	Triglycerides;
CRC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg07507251	chr3:52567010	NT5DC2	-0.38	-5.76	-0.3	1.97e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.49	8.05	0.41	1.54e-14	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg02725872	chr8:58115012	NA	-0.47	-7.44	-0.38	8.91e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs8005677	0.828	rs35085068	chr14:23409909	C/A	cg25600027	chr14:23388339	RBM23	-0.42	-6.3	-0.33	9.66e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg00071950	chr4:10020882	SLC2A9	-0.41	-6.32	-0.33	8.44e-10	Blood metabolite levels;
CRC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.4	0.42	1.38e-15	Platelet count;
CRC	cis	rs501120	0.810	rs510785	chr10:44749990	C/A	cg09554077	chr10:44749378	NA	0.9	13.3	0.59	1.4e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg03934865	chr2:198174659	NA	-0.46	-7.81	-0.4	7.76e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.71	-10.83	-0.51	1.35e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg07322936	chr10:88137208	NA	-0.62	-8.67	-0.43	2.08e-16	Schizophrenia;
CRC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg23071808	chr14:103021642	NA	-0.64	-7.19	-0.37	4.38e-12	Platelet count;
CRC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.49	-9.34	-0.46	1.52e-18	Reticulocyte fraction of red cells;
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.99	-0.44	1.98e-17	Bipolar disorder;
CRC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg07713946	chr22:31675144	LIMK2	-0.4	-5.68	-0.3	2.98e-8	Colorectal cancer;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg06470822	chr6:28175283	NA	0.75	10.22	0.49	1.85e-21	Parkinson's disease;
CRC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	6.13	0.32	2.48e-9	IgG glycosylation;
CRC	cis	rs4453791	0.696	rs35330920	chr3:38956328	T/G	cg02254461	chr3:39195904	CSRNP1	0.46	5.79	0.3	1.66e-8	Social communication problems;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg27661571	chr11:113659931	NA	-0.95	-11.08	-0.52	1.91e-24	Hip circumference adjusted for BMI;
CRC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg26762873	chr11:5879799	OR52E8	-0.4	-5.88	-0.31	1.01e-8	DNA methylation (variation);
CRC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg04450456	chr4:17643702	FAM184B	0.35	5.71	0.3	2.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.56	-8.73	-0.43	1.32e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs11581903	0.568	rs11205978	chr1:53076057	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.71	5.65	0.3	3.42e-8	Joint mobility (Beighton score);
CRC	cis	rs4594175	0.926	rs10498421	chr14:51586412	A/G	cg23942311	chr14:51606299	NA	-0.65	-10.79	-0.51	1.96e-23	Cancer;
CRC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.14	0.45	6.68e-18	Cognitive test performance;
CRC	cis	rs9547692	0.938	rs4520715	chr13:37459113	C/T	cg01493522	chr13:37497338	NA	-0.59	-7.96	-0.4	2.77e-14	Coronary artery disease;
CRC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.97	0.48	1.25e-20	Alzheimer's disease (late onset);
CRC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.03e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.96	-12.4	-0.56	3.1e-29	Exhaled nitric oxide output;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg16721101	chr20:25176146	ENTPD6	-0.7	-6.09	-0.32	3.23e-9	Cognitive function;
CRC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.37	6.18	0.32	1.94e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	10.53	0.5	1.53e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg02428538	chr16:24856791	SLC5A11	-0.58	-6.67	-0.35	1.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg10589385	chr1:150898437	SETDB1	0.28	6.01	0.31	4.89e-9	Tonsillectomy;
CRC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.04	-0.32	4.1e-9	Alzheimer's disease (late onset);
CRC	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-7.18	-0.37	4.82e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.65	-9.65	-0.47	1.5e-19	Refractive error;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12274314	chr17:62223237	SNORA76;SNORD104	0.47	6.52	0.34	2.7e-10	Response to antipsychotic treatment;
CRC	cis	rs2227564	0.672	rs2459449	chr10:75669013	T/C	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.22	-0.37	3.57e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.76	-0.3	1.96e-8	Daytime sleep phenotypes;
CRC	cis	rs453193	0.597	rs3111416	chr2:8452313	G/A	cg12167548	chr2:8464763	NA	0.37	6.52	0.34	2.72e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.7	8.97	0.44	2.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-7.36	-0.38	1.52e-12	Airway imaging phenotypes;
CRC	cis	rs995000	0.965	rs11207977	chr1:62977307	C/T	cg19896129	chr1:63156450	NA	0.4	5.84	0.31	1.23e-8	Triglyceride levels;
CRC	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg23100626	chr2:96804247	ASTL	0.27	7.07	0.36	9.2e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg11130432	chr3:121712080	ILDR1	-0.46	-5.81	-0.3	1.49e-8	Multiple sclerosis;
CRC	cis	rs6504950	0.830	rs12938118	chr17:53037359	T/C	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	cis	rs7072216	0.922	rs6584191	chr10:100152055	C/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.67	-0.35	1.09e-10	Metabolite levels;
CRC	cis	rs972578	1.000	rs5759062	chr22:43363195	C/G	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	7.01e-11	Tonsillectomy;
CRC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.88	11.97	0.55	1.19e-27	Gut microbiome composition (summer);
CRC	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg14352298	chr13:112236639	NA	0.3	6.77	0.35	5.79e-11	Hepatitis;
CRC	cis	rs7553864	1.000	rs4626859	chr1:87614020	G/A	cg02083836	chr1:87617350	LOC339524	0.35	6.24	0.33	1.36e-9	Smoking behavior;
CRC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-6.47	-0.34	3.46e-10	Systemic lupus erythematosus;
CRC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.67	9.63	0.47	1.66e-19	QT interval;
CRC	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.59	7.25	0.37	3.04e-12	Obesity (extreme);
CRC	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.53	-8.05	-0.41	1.49e-14	Breast size;
CRC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.43	7.07	0.36	9.08e-12	Alcohol dependence;
CRC	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg03934865	chr2:198174659	NA	-0.45	-7.12	-0.37	6.84e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg02683197	chr6:28174875	NA	0.64	6.59	0.34	1.77e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7605827	0.930	rs2049719	chr2:15515058	A/G	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.78e-8	Educational attainment (years of education);
CRC	cis	rs1712517	0.904	rs7905968	chr10:105135319	C/T	cg05636881	chr10:105038444	INA	0.48	8.28	0.42	3.13e-15	Migraine;
CRC	cis	rs7259376	0.623	rs58636168	chr19:22530129	C/A	cg02657401	chr19:22469223	NA	-0.3	-6.27	-0.33	1.14e-9	Menopause (age at onset);
CRC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.57	-8.0	-0.4	2.17e-14	Pancreatic cancer;
CRC	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg12856521	chr11:46389249	DGKZ	-0.43	-6.78	-0.35	5.74e-11	Leprosy;
CRC	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	22.07	0.77	6.84e-67	Colorectal cancer;
CRC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg03037974	chr15:76606532	NA	-0.46	-6.54	-0.34	2.33e-10	Blood metabolite levels;
CRC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg19041857	chr6:27730383	NA	-0.75	-6.59	-0.34	1.79e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.47	6.21	0.32	1.56e-9	Schizophrenia;
CRC	cis	rs7932354	0.583	rs10769210	chr11:46872227	G/A	cg19486271	chr11:47235900	DDB2	-0.42	-6.55	-0.34	2.26e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.92	0.4	3.58e-14	Lung cancer;
CRC	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs802075	0.967	rs635895	chr6:49658348	C/T	cg20364632	chr6:49636226	NA	-0.37	-5.97	-0.31	6.3e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.55	-6.7	-0.35	9.14e-11	Body mass index;
CRC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.23	-16.46	-0.67	7.71e-45	Breast cancer;
CRC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-8.68	-0.43	1.88e-16	Asthma;
CRC	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.82	14.96	0.64	5.91e-39	Metabolic syndrome;
CRC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.71	0.65	6.72e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-8.87	-0.44	4.8e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15099410	chr1:28585832	SESN2	0.43	6.33	0.33	7.96e-10	Response to antipsychotic treatment;
CRC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	5.05e-15	Red blood cell count;
CRC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.49	-9.82	-0.48	4.02e-20	Intelligence (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg07884673	chr3:53033167	SFMBT1	0.65	5.71	0.3	2.51e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.51	-7.79	-0.39	8.61e-14	HDL cholesterol;
CRC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg06470822	chr6:28175283	NA	0.83	6.79	0.35	5.23e-11	Depression;
CRC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.38	6.43	0.33	4.55e-10	Schizophrenia;
CRC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.94	-17.95	-0.7	1.03e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg13047869	chr3:10149882	C3orf24	0.5	7.15	0.37	5.6e-12	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs259282	0.851	rs174083	chr19:33141180	A/G	cg08127369	chr19:33164662	ANKRD27	0.37	5.86	0.31	1.1e-8	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08838784	chr17:16557147	ZNF624	0.37	5.96	0.31	6.49e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs16846073	chr2:162586548	C/G	cg25193742	chr10:104614220	C10orf32	-0.72	-6.15	-0.32	2.29e-9	Cognitive function;
CRC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.97	13.51	0.6	2.11e-33	Breast cancer;
CRC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	10.46	0.5	2.74e-22	Multiple sclerosis;
CRC	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.74	-9.4	-0.46	9.65e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs873917	0.577	rs784612	chr1:40122939	T/C	cg06209491	chr1:40138402	NT5C1A	-0.49	-7.34	-0.38	1.63e-12	Amyotrophic lateral sclerosis;
CRC	cis	rs10242455	0.702	rs10251282	chr7:98990236	T/C	cg18809830	chr7:99032528	PTCD1	-1.11	-7.93	-0.4	3.46e-14	Blood metabolite levels;
CRC	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg20744362	chr22:50050164	C22orf34	0.34	6.03	0.32	4.37e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.8	-0.35	4.85e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.36	5.95	0.31	6.88e-9	Total body bone mineral density;
CRC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.59	9.97	0.48	1.25e-20	Prudent dietary pattern;
CRC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.6	9.1	0.45	8.65e-18	Lung cancer;
CRC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg09582351	chr12:29534625	ERGIC2	0.34	7.32	0.37	1.93e-12	QT interval;
CRC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.6	-8.85	-0.44	5.48e-17	Acne (severe);
CRC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	8.25e-11	Blood pressure (smoking interaction);
CRC	cis	rs4234798	1.000	rs4689653	chr4:7223319	T/G	cg18431297	chr4:7219810	SORCS2	0.63	11.33	0.53	2.41e-25	Insulin-like growth factors;
CRC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.51	7.81	0.4	7.91e-14	Corneal astigmatism;
CRC	cis	rs73206853	0.764	rs56127909	chr12:110833763	G/A	cg12870014	chr12:110450643	ANKRD13A	0.78	8.56	0.43	4.41e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg05044414	chr3:183734942	ABCC5	0.43	7.37	0.38	1.35e-12	Anterior chamber depth;
CRC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.54	-9.24	-0.45	3.04e-18	Iron status biomarkers;
CRC	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.6	-5.66	-0.3	3.22e-8	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.66	8.64	0.43	2.54e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg04611788	chr3:186434169	KNG1	-0.6	-8.83	-0.44	6.23e-17	Blood protein levels;
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs7731657	0.537	rs10478953	chr5:130185380	A/C	cg08523029	chr5:130500466	HINT1	0.46	6.17	0.32	1.95e-9	Fasting plasma glucose;
CRC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs2275731	0.625	rs7904333	chr10:16476271	C/T	cg04254609	chr10:16479192	PTER	-0.47	-6.83	-0.35	4.06e-11	Bone fracture in osteoporosis;
CRC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-7.64	-0.39	2.47e-13	Personality dimensions;
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg27532560	chr4:187881888	NA	-0.56	-10.2	-0.49	2.05e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.54	8.61	0.43	3.16e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg22495460	chr2:25135724	ADCY3	-0.88	-16.58	-0.67	2.68e-45	Body mass index;
CRC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.5	-7.92	-0.4	3.77e-14	Prostate cancer;
CRC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg16989719	chr2:238392110	NA	-0.4	-6.45	-0.34	3.92e-10	Prostate cancer;
CRC	cis	rs4731207	0.596	rs1481339	chr7:124708237	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.28	-0.33	1.07e-9	Cutaneous malignant melanoma;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg24046110	chr8:143859143	LYNX1	-0.44	-7.09	-0.36	8.09e-12	Urinary tract infection frequency;
CRC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.77	-0.39	1.03e-13	Hemoglobin concentration;
CRC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.36e-24	Prudent dietary pattern;
CRC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.4	7.58	0.39	3.45e-13	Mean corpuscular volume;
CRC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg15269541	chr15:43626905	ADAL	-0.49	-5.9	-0.31	9.27e-9	Lung cancer in ever smokers;
CRC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.72	-0.39	1.38e-13	Gut microbiome composition (summer);
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.41	-7.58	-0.39	3.59e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.78	-0.35	5.43e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	5.73	0.3	2.27e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg04202892	chr2:111875749	ACOXL	0.47	7.7	0.39	1.61e-13	Chronic lymphocytic leukemia;
CRC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.67	-11.57	-0.54	3.37e-26	Depressive symptoms (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19958009	chr14:50087420	RPL36AL;MGAT2	0.4	6.56	0.34	2.05e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	1.06	12.66	0.57	3.45e-30	Hip circumference adjusted for BMI;
CRC	cis	rs863345	0.604	rs949398	chr1:158461983	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-11.42	-0.53	1.17e-25	Colorectal cancer;
CRC	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.76	12.81	0.58	9.45e-31	Eosinophil percentage of white cells;
CRC	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.54	6.21	0.32	1.63e-9	Lung function (FEV1/FVC);
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.26e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.9	-17.71	-0.7	9.21e-50	Metabolic syndrome;
CRC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.55	7.38	0.38	1.28e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg23234261	chr14:55582407	NA	-0.29	-5.84	-0.31	1.25e-8	Protein biomarker;
CRC	cis	rs883565	0.569	rs784489	chr3:39173426	T/C	cg01426195	chr3:39028469	NA	0.42	6.97	0.36	1.71e-11	Handedness;
CRC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.68	0.35	9.99e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.51	-8.55	-0.43	4.73e-16	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09766769	chr16:4852830	ROGDI	0.44	6.13	0.32	2.48e-9	Anxiety disorder;
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.66	-0.34	1.17e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg03623178	chr6:28175578	NA	0.45	6.0	0.31	5.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.14	-0.32	2.43e-9	Crohn's disease;
CRC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.85	-0.44	5.49e-17	Platelet count;
CRC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.1	-0.52	1.56e-24	Bipolar disorder and schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09930748	chr19:36359327	APLP1	-0.41	-6.3	-0.33	9.74e-10	Myopia (pathological);
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.55	6.98	0.36	1.67e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs4834770	0.717	rs1022146	chr4:120236103	A/G	cg25214090	chr10:38739885	LOC399744	0.39	6.13	0.32	2.45e-9	Blood protein levels;
CRC	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03605463	chr16:89740564	NA	0.62	9.55	0.47	3.18e-19	Vitiligo;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.61	-8.58	-0.43	3.7e-16	Blood pressure (smoking interaction);
CRC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.2	-0.32	1.73e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.5	-6.78	-0.35	5.72e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11748023	0.605	rs185123	chr5:139517197	T/C	cg26211634	chr5:139558579	C5orf32	0.36	6.29	0.33	1.01e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2055729	0.645	rs62489486	chr8:9741925	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.0	0.36	1.45e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg22842854	chr12:123319900	HIP1R	-0.73	-5.74	-0.3	2.1e-8	Adiponectin levels;
CRC	cis	rs12286929	0.669	rs11606837	chr11:115042837	C/T	cg04055981	chr11:115044050	NA	0.44	7.06	0.36	1.02e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	14.93	0.64	7.65e-39	Colorectal cancer;
CRC	cis	rs6694672	0.867	rs4244141	chr1:197143618	G/A	cg13682187	chr1:196946512	CFHR5	0.52	7.85	0.4	5.91e-14	Asthma;
CRC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg12501888	chr15:85177176	SCAND2	-0.36	-5.85	-0.31	1.18e-8	P wave terminal force;
CRC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.53	8.92	0.44	3.31e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.91	17.35	0.69	2.44e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	7.03	0.36	1.19e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg27499820	chr13:21296301	IL17D	-0.37	-5.82	-0.31	1.37e-8	Dental caries;
CRC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.87	0.31	1.05e-8	Rheumatoid arthritis;
CRC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-11.13	-0.52	1.22e-24	Systemic lupus erythematosus;
CRC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.34	0.5	6.91e-22	Hip circumference adjusted for BMI;
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.59	-9.02	-0.45	1.55e-17	Bipolar disorder;
CRC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.45	-0.38	8.37e-13	Height;
CRC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.93	-0.36	2.29e-11	Colorectal cancer;
CRC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.46	7.02	0.36	1.29e-11	Menopause (age at onset);
CRC	cis	rs2992756	0.663	rs1360915	chr1:18801804	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.4	-5.69	-0.3	2.74e-8	Breast cancer;
CRC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.29	0.53	3.23e-25	Motion sickness;
CRC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg19318889	chr4:1322082	MAEA	0.41	5.93	0.31	7.58e-9	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02625641	chr15:59041175	ADAM10	0.48	6.03	0.32	4.37e-9	Thyroid stimulating hormone;
CRC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.42	-6.57	-0.34	1.95e-10	Blood metabolite levels;
CRC	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg06204229	chr3:52865917	ITIH4	0.58	7.94	0.4	3.2e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg15845792	chr6:28175446	NA	-1.01	-15.68	-0.65	9.08e-42	Depression;
CRC	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg15704280	chr7:45808275	SEPT13	0.56	6.2	0.32	1.73e-9	Intraocular pressure;
CRC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.3	3.18e-8	Diabetic retinopathy;
CRC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg10494257	chr1:16342123	HSPB7	0.44	5.8	0.3	1.56e-8	Dilated cardiomyopathy;
CRC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.61	10.18	0.49	2.39e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.89	-11.32	-0.53	2.66e-25	Hair shape;
CRC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.53	-8.59	-0.43	3.58e-16	Aortic root size;
CRC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.88	-10.69	-0.51	4.19e-23	Diabetic kidney disease;
CRC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.48	9.65	0.47	1.46e-19	Subjective well-being;
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13047869	chr3:10149882	C3orf24	0.54	7.53	0.38	4.82e-13	Alzheimer's disease;
CRC	cis	rs7072216	0.615	rs6584195	chr10:100160747	G/A	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.69	-0.3	2.86e-8	Metabolite levels;
CRC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg06238570	chr21:40685208	BRWD1	0.74	10.35	0.5	6.5600000000000005e-22	Cognitive function;
CRC	cis	rs317865	0.737	rs73234648	chr4:16193602	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	5.71	0.3	2.58e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.45	6.73	0.35	7.51e-11	Type 2 diabetes;
CRC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.5	-8.59	-0.43	3.44e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg20615401	chr6:28092323	ZSCAN16	0.44	5.76	0.3	1.88e-8	Parkinson's disease;
CRC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.27	-0.67	4.47e-44	Height;
CRC	cis	rs35883536	1.000	rs6681906	chr1:101086414	C/T	cg14515779	chr1:101123966	NA	-0.45	-8.65	-0.43	2.25e-16	Monocyte count;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg15845792	chr6:28175446	NA	0.73	10.85	0.51	1.19e-23	Parkinson's disease;
CRC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	6.94	0.36	2.08e-11	Aortic root size;
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs600626	0.588	rs10899116	chr11:75476195	C/T	cg24262691	chr11:75473276	NA	0.51	6.97	0.36	1.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.48	7.2	0.37	4.15e-12	Pancreatic cancer;
CRC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	16.09	0.66	2.15e-43	Smoking behavior;
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.72	10.63	0.51	6.78e-23	Menarche (age at onset);
CRC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.46	-0.34	3.71e-10	Dupuytren's disease;
CRC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg16141378	chr3:129829833	LOC729375	0.46	6.84	0.35	3.85e-11	Neuroticism;
CRC	cis	rs113835537	0.877	rs3867132	chr11:66309269	C/T	cg22134325	chr11:66188745	NPAS4	0.38	6.12	0.32	2.63e-9	Airway imaging phenotypes;
CRC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.94	-0.52	5.78e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.39	-0.38	1.25e-12	Morning vs. evening chronotype;
CRC	cis	rs7781266	0.842	rs1862871	chr7:133215165	A/C	cg03336402	chr7:133662267	EXOC4	-0.55	-6.3	-0.33	9.81e-10	Educational attainment (college completion);
CRC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	6.01	0.31	4.8e-9	Aortic root size;
CRC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg16486109	chr11:613632	IRF7	0.65	11.83	0.55	3.72e-27	Systemic lupus erythematosus;
CRC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.55	8.39	0.42	1.48e-15	Fibrinogen levels;
CRC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.43	7.06	0.36	9.66e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7605827	0.930	rs13384921	chr2:15602840	C/T	cg19274914	chr2:15703543	NA	0.38	5.79	0.3	1.67e-8	Educational attainment (years of education);
CRC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.44	8.14	0.41	8.12e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg13615338	chr4:55094005	PDGFRA	0.42	6.01	0.31	4.81e-9	Corneal astigmatism;
CRC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg22677401	chr17:46026860	NA	-0.7	-6.05	-0.32	3.89e-9	Cognitive function;
CRC	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.46	7.42	0.38	9.84e-13	Carotid intima media thickness;
CRC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.61	-0.75	3.6e-61	Height;
CRC	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg00531865	chr16:30841666	NA	0.48	6.74	0.35	6.96e-11	Dementia with Lewy bodies;
CRC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.91	-0.36	2.55e-11	Alzheimer's disease (late onset);
CRC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.92	9.0	0.44	1.79e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.61	-9.64	-0.47	1.6e-19	Corneal astigmatism;
CRC	cis	rs9462027	0.628	rs11759151	chr6:34747603	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.54	-0.34	2.41e-10	Reticulocyte fraction of red cells;
CRC	cis	rs73206853	0.841	rs73206882	chr12:110840515	G/A	cg12870014	chr12:110450643	ANKRD13A	0.77	8.37	0.42	1.64e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg03037974	chr15:76606532	NA	-0.55	-8.24	-0.41	4.17e-15	Blood metabolite levels;
CRC	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.84	-9.04	-0.45	1.4e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.89	-15.16	-0.64	9.77e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs354033	1.000	rs354045	chr7:149300608	G/T	cg24335155	chr7:149193227	ZNF746	-0.38	-6.42	-0.33	4.82e-10	Multiple sclerosis;
CRC	cis	rs55788414	0.860	rs1806875	chr16:81184069	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	7.74	0.39	1.26e-13	Lung cancer in ever smokers;
CRC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.69	10.56	0.5	1.18e-22	Tonsillectomy;
CRC	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.61	-9.38	-0.46	1.15e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.58	-6.13	-0.32	2.54e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	5.96	0.31	6.34e-9	Prudent dietary pattern;
CRC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	13.13	0.59	5.72e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.85	-0.31	1.17e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.55	7.01	0.36	1.34e-11	Neutrophil percentage of white cells;
CRC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.66	-11.99	-0.55	9.75e-28	Type 2 diabetes;
CRC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-7.74	-0.39	1.22e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	0.98	14.9	0.63	9.91e-39	Cognitive function;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg23123621	chr4:1343375	KIAA1530	0.34	6.1	0.32	3.01e-9	Obesity-related traits;
CRC	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.71	-0.35	8.61e-11	Breast cancer;
CRC	cis	rs7781266	0.739	rs17576069	chr7:133066514	A/G	cg03336402	chr7:133662267	EXOC4	0.51	6.04	0.32	4.11e-9	Educational attainment (college completion);
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg08798685	chr6:27730294	NA	-0.57	-6.16	-0.32	2.13e-9	Lung cancer in ever smokers;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.75	9.58	0.47	2.38e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs7632954	0.531	rs11720160	chr3:8517932	A/T	cg03495237	chr3:8533978	NA	-0.35	-6.44	-0.33	4.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.51	0.42	6.25e-16	Height;
CRC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	trans	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg02674126	chr19:40336878	FBL	0.42	6.7	0.35	8.83e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs7259376	0.871	rs34187872	chr19:22607883	G/A	cg02657401	chr19:22469223	NA	0.31	6.76	0.35	6.46e-11	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.43	-7.07	-0.36	9.63e-12	Metabolite levels;
CRC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.5	-7.75	-0.39	1.14e-13	Aortic root size;
CRC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.49	-5.74	-0.3	2.13e-8	Multiple sclerosis;
CRC	trans	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg01874867	chr7:94954059	PON1	-0.52	-6.6	-0.34	1.64e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.14	0.41	8.41e-15	Menopause (age at onset);
CRC	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg06581033	chr10:766294	NA	-0.47	-5.71	-0.3	2.58e-8	Uric acid levels;
CRC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.69	9.28	0.46	2.32e-18	Initial pursuit acceleration;
CRC	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg10483660	chr13:112241077	NA	0.36	5.81	0.31	1.46e-8	Menarche (age at onset);
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg16576620	chr11:61596068	FADS2	-0.51	-6.68	-0.35	1.01e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg14829360	chr17:73884958	NA	-0.44	-7.05	-0.36	1.07e-11	Psoriasis;
CRC	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-0.65	-5.89	-0.31	9.49e-9	Pediatric areal bone mineral density (radius);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04328701	chr17:40761179	FAM134C;TUBG1	0.45	6.33	0.33	8.03e-10	Response to antipsychotic treatment;
CRC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.38	-0.33	6.05e-10	Breast cancer;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08132132	chr8:82644559	CHMP4C	-0.38	-6.31	-0.33	9.01e-10	Daytime sleep phenotypes;
CRC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.68	0.54	1.28e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1973993	0.745	rs9437743	chr1:96961723	C/T	cg10631902	chr5:14652156	NA	0.41	6.86	0.35	3.33e-11	Weight;
CRC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16262614	chr3:133464971	TF	0.34	6.01	0.31	4.93e-9	Iron status biomarkers;
CRC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-11.42	-0.53	1.15e-25	Vitiligo;
CRC	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.15	-0.32	2.19e-9	Coronary artery disease;
CRC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.13	0.32	2.58e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg24628676	chr5:59189846	PDE4D	-0.3	-6.08	-0.32	3.3e-9	Urinary tract infection frequency;
CRC	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.59	-8.28	-0.42	3.11e-15	Personality dimensions;
CRC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	5.95	0.31	6.97e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.44	-6.04	-0.32	4.06e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg08501292	chr6:25962987	TRIM38	0.96	9.14	0.45	6.69e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.47	6.87	0.35	3.31e-11	Pulmonary function decline;
CRC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg00383909	chr3:49044727	WDR6	0.48	5.92	0.31	7.98e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.91	-13.22	-0.59	2.63e-32	Dupuytren's disease;
CRC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.81	0.48	4.41e-20	Bladder cancer;
CRC	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.46	7.58	0.39	3.55e-13	Alcohol dependence (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14071762	chr20:61904060	ARFGAP1	0.38	6.17	0.32	1.99e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg02007433	chr3:129722099	NA	-0.51	-6.2	-0.32	1.67e-9	Blood pressure (smoking interaction);
CRC	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs4561483	0.583	rs11075030	chr16:11976414	C/A	cg08843971	chr16:11963173	GSPT1	0.51	7.63	0.39	2.49e-13	Testicular germ cell tumor;
CRC	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg14673194	chr17:80132900	CCDC57	0.5	6.59	0.34	1.75e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.74	7.49	0.38	6.43e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.81	-0.4	7.69e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.671	rs12530981	chr7:124521722	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-6.21	-0.32	1.57e-9	Educational attainment;
CRC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.67	-10.81	-0.51	1.66e-23	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05903289	chr2:130345205	NA	-0.36	-6.84	-0.35	3.96e-11	Response to cytidine analogues (gemcitabine);
CRC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.57	7.54	0.38	4.59e-13	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26847753	chr15:44119241	WDR76	0.39	6.22	0.32	1.51e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs783540	0.967	rs783529	chr15:83267981	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.49	-0.34	3.1e-10	Schizophrenia;
CRC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.55	-9.09	-0.45	9.55e-18	Type 2 diabetes;
CRC	cis	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg03623178	chr6:28175578	NA	0.73	7.35	0.38	1.57e-12	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10546176	chr5:34929404	DNAJC21	0.41	7.19	0.37	4.49e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26546685	chr4:100870642	LOC256880;H2AFZ	0.5	6.82	0.35	4.39e-11	Anxiety disorder;
CRC	cis	rs75920871	0.557	rs11216275	chr11:116975704	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-7.07	-0.36	9.14e-12	Subjective well-being;
CRC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.61	-11.34	-0.53	2.13e-25	Educational attainment;
CRC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.49	0.34	3.19e-10	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26271690	chr1:202830559	LOC148709	0.45	6.4	0.33	5.33e-10	Response to antipsychotic treatment;
CRC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg10398005	chr11:117014888	PAFAH1B2	-0.4	-5.69	-0.3	2.75e-8	Blood protein levels;
CRC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	7.02	0.36	1.25e-11	Headache;
CRC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	15.52	0.65	3.72e-41	Electrocardiographic conduction measures;
CRC	cis	rs728616	0.558	rs55803802	chr10:81752664	A/G	cg05935833	chr10:81318306	SFTPA2	-0.54	-7.02	-0.36	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.62	6.42	0.33	4.73e-10	Axial length;
CRC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg19913688	chr11:428466	ANO9	-0.73	-6.95	-0.36	1.93e-11	Body mass index;
CRC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.27	5.84	0.31	1.22e-8	Educational attainment (years of education);
CRC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.41	-5.75	-0.3	2.08e-8	DNA methylation (variation);
CRC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.2	0.32	1.69e-9	Primary sclerosing cholangitis;
CRC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.67	7.69	0.39	1.77e-13	Cleft lip with or without cleft palate;
CRC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.82e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.43	-8.49	-0.42	7.13e-16	Alcohol dependence;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.54	6.95	0.36	1.98e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.89	-0.36	2.78e-11	Mean corpuscular volume;
CRC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.48	-6.96	-0.36	1.86e-11	Colorectal cancer;
CRC	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.08	0.36	8.65e-12	Menarche (age at onset);
CRC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	12.31	0.56	6.54e-29	Lymphocyte percentage of white cells;
CRC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.18	0.69	1.12e-47	Intelligence (multi-trait analysis);
CRC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.75	11.17	0.52	8.96e-25	Neutrophil percentage of white cells;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.61	-0.3	4.21e-8	Parkinson's disease;
CRC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.4	5.77	0.3	1.82e-8	Aortic root size;
CRC	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg20019720	chr6:154832845	CNKSR3	0.52	8.71	0.43	1.5e-16	Lipoprotein (a) levels;
CRC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.16	-12.06	-0.55	5.57e-28	Breast cancer;
CRC	cis	rs720844	0.832	rs4972369	chr2:149287440	C/T	cg09247360	chr2:149335327	NA	-0.5	-6.02	-0.31	4.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1539053	0.932	rs11207086	chr1:58117341	A/C	cg20292791	chr1:58089357	DAB1	-0.38	-6.73	-0.35	7.64e-11	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.72	0.51	3.27e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09974205	chr1:222638972	NA	0.49	6.27	0.33	1.11e-9	Thyroid stimulating hormone;
CRC	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.76	10.56	0.5	1.23e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.76	11.17	0.52	9.07e-25	Neutrophil percentage of white cells;
CRC	cis	rs10760158	0.800	rs4836847	chr9:124058943	C/T	cg14417974	chr9:124058376	GSN	-0.33	-5.67	-0.3	3.1e-8	Pulse pressure;
CRC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.96	-0.48	1.39e-20	Monocyte percentage of white cells;
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.53	-7.35	-0.38	1.6e-12	Alzheimer's disease;
CRC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.64e-17	Prostate cancer;
CRC	cis	rs4757319	0.515	rs10832437	chr11:15433225	C/T	cg03245590	chr11:15329459	NA	0.52	9.24	0.45	3.06e-18	Breast cancer;
CRC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg16141378	chr3:129829833	LOC729375	0.42	6.17	0.32	2.05e-9	Triglycerides;
CRC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.38	0.42	1.6e-15	Height;
CRC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.1	0.32	3.05e-9	Height;
CRC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.52	-8.22	-0.41	4.91e-15	Aortic root size;
CRC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.51	7.8	0.39	8.42e-14	Corneal astigmatism;
CRC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.38	-0.33	5.84e-10	Longevity;Endometriosis;
CRC	cis	rs17162190	0.698	rs55840663	chr1:26840826	G/A	cg17456097	chr1:26900765	RPS6KA1	0.42	6.15	0.32	2.22e-9	Mean corpuscular volume;
CRC	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg11861562	chr11:117069780	TAGLN	0.34	6.34	0.33	7.39e-10	Blood protein levels;
CRC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.4	8.68	0.43	1.88e-16	Eye color traits;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg24350909	chr7:6677433	NA	-0.44	-6.57	-0.34	1.95e-10	Daytime sleep phenotypes;
CRC	cis	rs12936587	0.601	rs7212538	chr17:17554587	T/G	cg09796270	chr17:17721594	SREBF1	-0.47	-8.0	-0.4	2.18e-14	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg25876840	chr17:41920477	NA	-0.41	-6.59	-0.34	1.75e-10	Triglycerides;
CRC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg00343986	chr7:65444356	GUSB	-0.5	-7.51	-0.38	5.69e-13	Aortic root size;
CRC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.85	0.35	3.62e-11	Morning vs. evening chronotype;
CRC	cis	rs7605827	0.930	rs4668927	chr2:15706683	C/T	cg19274914	chr2:15703543	NA	0.4	6.12	0.32	2.62e-9	Educational attainment (years of education);
CRC	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.69	-0.3	2.84e-8	Pulmonary function;
CRC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.57	9.82	0.48	3.93e-20	Age at first birth;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00462763	chr11:64949223	CAPN1	0.44	6.17	0.32	2e-9	Response to antipsychotic treatment;
CRC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.46	-7.39	-0.38	1.25e-12	Monocyte count;
CRC	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg13043300	chr11:71146211	DHCR7	-0.44	-6.01	-0.31	4.82e-9	Vitamin D levels;
CRC	cis	rs524281	0.861	rs10896090	chr11:65945186	A/G	cg16950941	chr11:66035639	RAB1B	-0.61	-7.24	-0.37	3.15e-12	Electroencephalogram traits;
CRC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.33e-11	Menopause (age at onset);
CRC	cis	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg06092702	chr1:163392909	NA	0.53	8.3	0.42	2.67e-15	Motion sickness;
CRC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg27490568	chr2:178487706	NA	0.38	5.64	0.3	3.66e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.59	-5.8	-0.3	1.57e-8	Vitiligo;
CRC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg03909863	chr11:638404	DRD4	-0.53	-7.29	-0.37	2.38e-12	Systemic lupus erythematosus;
CRC	cis	rs2072510	0.569	rs2540488	chr12:96426745	G/A	cg22491680	chr12:96389547	HAL	-0.5	-6.16	-0.32	2.13e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.47	7.83	0.4	6.98e-14	Alcohol dependence (age at onset);
CRC	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.55	8.55	0.43	4.63e-16	HDL cholesterol;
CRC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2797369	0.713	rs2813655	chr6:101586319	T/G	cg26346621	chr12:6873348	NA	0.38	6.03	0.32	4.45e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg04025307	chr7:1156635	C7orf50	0.65	7.38	0.38	1.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	trans	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.02	-0.31	4.74e-9	Educational attainment (years of education);
CRC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.48	7.12	0.37	6.62e-12	Melanoma;
CRC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg18478394	chr8:109455254	TTC35	0.43	6.44	0.33	4.34e-10	Dupuytren's disease;
CRC	cis	rs6496667	0.642	rs12148876	chr15:91065208	G/A	cg04176472	chr15:90893244	GABARAPL3	0.51	7.64	0.39	2.41e-13	Rheumatoid arthritis;
CRC	trans	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.47	0.34	3.61e-10	Primary sclerosing cholangitis;
CRC	cis	rs1223397	0.702	rs13191897	chr6:13288428	G/A	cg00460589	chr6:13274354	PHACTR1	0.5	6.04	0.32	4.08e-9	Blood pressure;
CRC	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg02072170	chr3:194406190	FAM43A	0.42	7.13	0.37	6.42e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.74	7.89	0.4	4.64e-14	Mean corpuscular volume;
CRC	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg24851651	chr11:66362959	CCS	-0.39	-6.69	-0.35	9.43e-11	Educational attainment (years of education);
CRC	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.49	7.66	0.39	2.1e-13	Body mass index;
CRC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.13	-0.52	1.25e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.47	-7.42	-0.38	1.04e-12	Adiponectin levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13662262	chr21:30364895	RNF160	0.49	6.26	0.33	1.18e-9	Thyroid stimulating hormone;
CRC	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	0.55	7.51	0.38	5.58e-13	Pulmonary function decline;
CRC	cis	rs2252790	1.000	rs12214926	chr6:116643292	C/T	cg18764771	chr6:116381957	FRK	0.22	5.75	0.3	2e-8	Fast beta electroencephalogram;
CRC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21643547	chr1:205240462	TMCC2	-0.46	-7.83	-0.4	6.96e-14	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.87	-0.48	2.65e-20	Hip circumference adjusted for BMI;
CRC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.77	-13.48	-0.6	2.84e-33	Prostate cancer;
CRC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.77	-0.39	1.03e-13	Hemoglobin concentration;
CRC	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg17023122	chr1:144479586	NA	-0.42	-5.98	-0.31	5.89e-9	Hip geometry;
CRC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg26721908	chr21:47610096	LSS	-0.37	-5.62	-0.3	4.15e-8	Testicular germ cell tumor;
CRC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.46	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs10210302	0.504	rs1000141	chr2:234242347	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.91	0.36	2.58e-11	Crohn's disease;
CRC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg16892393	chr17:41919603	NA	0.47	7.33	0.37	1.78e-12	Triglycerides;
CRC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.54	6.97	0.36	1.77e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6743376	0.509	rs1530552	chr2:113818120	G/T	cg24553058	chr2:113831203	IL1F10	0.42	6.93	0.36	2.24e-11	Inflammatory biomarkers;
CRC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg04731861	chr2:219085781	ARPC2	-0.3	-6.14	-0.32	2.37e-9	Colorectal cancer;
CRC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg20607287	chr7:12443886	VWDE	-0.64	-6.41	-0.33	5.11e-10	Coronary artery disease;
CRC	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg01639898	chr1:32083012	HCRTR1	0.31	6.43	0.33	4.39e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08687137	chr11:62389499	B3GAT3	0.36	6.06	0.32	3.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.55	0.63	2.31e-37	Mean platelet volume;
CRC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.48	7.53	0.38	4.83e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	cis	rs2735413	0.914	rs12448754	chr16:78066747	T/C	cg04733911	chr16:78082701	NA	-0.37	-6.03	-0.32	4.33e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	12.86	0.58	6.11e-31	Lymphocyte percentage of white cells;
CRC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16262614	chr3:133464971	TF	0.4	7.17	0.37	5.11e-12	Iron status biomarkers;
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.59	8.84	0.44	6.11e-17	Obesity-related traits;
CRC	cis	rs4664293	0.867	rs7603274	chr2:160592690	G/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.82	-0.4	7.45e-14	Hemoglobin concentration;
CRC	cis	rs2270875	1.000	rs10464830	chr8:132932383	C/T	cg24184792	chr8:132919238	EFR3A	-0.67	-6.7	-0.35	9.08e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg07617317	chr6:118971624	C6orf204	0.5	6.25	0.33	1.25e-9	Renal cell carcinoma;
CRC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	7.34	0.38	1.63e-12	Platelet count;
CRC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.81	-0.35	4.6e-11	Cutaneous nevi;
CRC	cis	rs908922	0.535	rs11205006	chr1:152440176	A/T	cg09873164	chr1:152488093	CRCT1	0.38	5.79	0.3	1.62e-8	Hair morphology;
CRC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	0.59	6.29	0.33	1.01e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.44	7.29	0.37	2.33e-12	Refractive error;
CRC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg24375607	chr4:120327624	NA	0.48	7.39	0.38	1.23e-12	Corneal astigmatism;
CRC	cis	rs59104589	0.617	rs3771567	chr2:242358619	G/A	cg19488206	chr2:242435732	STK25	0.45	6.63	0.34	1.34e-10	Fibrinogen levels;
CRC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.0	0.4	2.19e-14	Platelet count;
CRC	cis	rs600626	0.541	rs11236528	chr11:75469476	T/C	cg24262691	chr11:75473276	NA	0.53	7.9	0.4	4.18e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg03934865	chr2:198174659	NA	-0.46	-8.35	-0.42	1.95e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.61	8.42	0.42	1.18e-15	Neutrophil percentage of white cells;
CRC	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg18551225	chr6:44695536	NA	-0.41	-5.97	-0.31	6.18e-9	Total body bone mineral density;
CRC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg27523141	chr10:43048294	ZNF37B	0.47	7.01	0.36	1.38e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9906695	0.898	rs3760396	chr17:32581441	G/C	cg12698626	chr17:32581466	CCL2	0.47	6.12	0.32	2.61e-9	Monocyte percentage of white cells;
CRC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.53	0.57	1.04e-29	Menopause (age at onset);
CRC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.61	10.94	0.52	5.94e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.81	0.48	4.41e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg15845792	chr6:28175446	NA	-0.61	-6.14	-0.32	2.41e-9	Depression;
CRC	cis	rs9903692	0.954	rs875065	chr17:46139569	C/T	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11645453	chr3:52864694	ITIH4	0.35	6.3	0.33	9.46e-10	Electroencephalogram traits;
CRC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21972741	chr5:435613	AHRR	0.55	7.56	0.38	4.15e-13	Cystic fibrosis severity;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02717630	chr16:46865118	C16orf87	-0.43	-6.7	-0.35	8.88e-11	Myopia (pathological);
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.38	-9.09	-0.45	9.22e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21962918	chr5:134094454	DDX46	-0.4	-6.12	-0.32	2.64e-9	Myopia (pathological);
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg26587870	chr6:27730563	NA	-0.42	-6.29	-0.33	9.83e-10	Parkinson's disease;
CRC	cis	rs9659323	1.000	rs10923715	chr1:119535334	A/T	cg26570165	chr1:119541833	NA	0.39	6.55	0.34	2.28e-10	Body mass index;
CRC	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.55	-6.18	-0.32	1.85e-9	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.68	-0.51	4.69e-23	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07071157	chr11:72525331	ATG16L2	0.4	6.79	0.35	5.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10450586	0.764	rs6484287	chr11:27302272	T/A	cg10370305	chr11:27303972	NA	0.38	6.14	0.32	2.37e-9	Total body bone mineral density;
CRC	trans	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	8.96	0.44	2.51e-17	Ulcerative colitis;
CRC	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.62	-0.39	2.68e-13	QT interval;
CRC	cis	rs4728302	0.869	rs889826	chr7:133595871	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.51	-0.34	2.78e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.48	7.4	0.38	1.14e-12	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.5	-6.75	-0.35	6.76e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg02560186	chr11:3602584	NA	-0.56	-7.1	-0.36	7.58e-12	Blood pressure (smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25290303	chr17:6916095	RNASEK	0.42	6.07	0.32	3.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-8.18	-0.41	6.14e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg15848620	chr12:58087721	OS9	-0.62	-8.48	-0.42	7.49e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.84	-0.35	3.95e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.83	-11.79	-0.55	5.27e-27	Gut microbiome composition (summer);
CRC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17554472	chr22:41940697	POLR3H	-0.56	-5.89	-0.31	9.38e-9	Vitiligo;
CRC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.76	0.43	1.04e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.55	10.23	0.49	1.7e-21	Common traits (Other);
CRC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00166722	chr3:10149974	C3orf24	-0.4	-6.16	-0.32	2.08e-9	Alzheimer's disease;
CRC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg16342193	chr10:102329863	NA	-0.36	-5.9	-0.31	9.08e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.61	8.89	0.44	4.18e-17	Cognitive function;
CRC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	0.99	10.61	0.5	8.17e-23	Diabetic retinopathy;
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg04155289	chr7:94953770	PON1	-0.63	-7.73	-0.39	1.32e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-7.5	-0.38	6.06e-13	Major depressive disorder;
CRC	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg09003973	chr2:102972529	NA	0.42	5.93	0.31	7.87e-9	Blood protein levels;
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.57	9.05	0.45	1.29e-17	Aortic root size;
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs12999616	0.817	rs7425883	chr2:98331521	C/G	cg26665480	chr2:98280029	ACTR1B	-0.53	-6.55	-0.34	2.25e-10	Colorectal cancer;
CRC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	8.02	0.4	1.91e-14	Lung cancer in ever smokers;
CRC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.54	8.98	0.44	2.2e-17	Crohn's disease;
CRC	trans	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg18335740	chr13:41363409	SLC25A15	-0.52	-7.63	-0.39	2.59e-13	Lewy body disease;
CRC	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.53	7.49	0.38	6.36e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.9	-11.51	-0.54	5.66e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.59	-7.96	-0.4	2.83e-14	White matter hyperintensity burden;
CRC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.56	-0.34	2.06e-10	Total body bone mineral density;
CRC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.75	-14.06	-0.61	1.78e-35	Body mass index;
CRC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.19	0.71	1.2e-51	Cognitive ability;
CRC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.45	-6.6	-0.34	1.64e-10	Uric acid clearance;
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	7.09	0.36	8.22e-12	Lymphocyte counts;
CRC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.4	9.38	0.46	1.11e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.1	0.64	1.7e-39	Primary sclerosing cholangitis;
CRC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.6	-12.04	-0.55	6.81e-28	Asthma (sex interaction);
CRC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23378565	chr7:2036160	MAD1L1	-0.47	-6.54	-0.34	2.3e-10	Bipolar disorder;
CRC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg11212589	chr17:38028394	ZPBP2	-0.44	-8.02	-0.4	1.89e-14	Self-reported allergy;
CRC	cis	rs12476592	0.571	rs190519	chr2:63858425	T/A	cg10828910	chr2:63850056	LOC388955	0.47	5.94	0.31	7.38e-9	Childhood ear infection;
CRC	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.55	-8.31	-0.42	2.53e-15	Ulcerative colitis;
CRC	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.58	6.1	0.32	3.04e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg08798685	chr6:27730294	NA	-0.49	-6.88	-0.35	3.11e-11	Parkinson's disease;
CRC	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.49	6.38	0.33	6.16e-10	Breast cancer;
CRC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-5.94	-0.31	7.39e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.37	6.09	0.32	3.1e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg24562669	chr7:97807699	LMTK2	0.44	7.37	0.38	1.4e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg22096450	chr11:6947773	ZNF215	0.61	6.38	0.33	6.15e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs596169	0.655	rs6697647	chr1:219159834	A/G	cg09853702	chr12:47665230	NA	0.8	6.23	0.32	1.41e-9	Intraocular pressure;
CRC	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg15147215	chr3:52552868	STAB1	-0.46	-7.5	-0.38	5.86e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.5	7.51	0.38	5.52e-13	Response to antineoplastic agents;
CRC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg03563238	chr19:33554763	RHPN2	-0.31	-5.63	-0.3	3.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.87	16.84	0.68	2.55e-46	Bone mineral density;
CRC	cis	rs7487075	0.820	rs4238102	chr12:46726496	T/A	cg22049899	chr12:47219821	SLC38A4	0.35	6.87	0.35	3.18e-11	Itch intensity from mosquito bite;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg27094323	chr7:1216898	NA	-0.35	-5.74	-0.3	2.19e-8	Longevity;Endometriosis;
CRC	cis	rs4700695	0.841	rs44267	chr5:65274311	G/A	cg21114390	chr5:65439923	SFRS12	0.59	6.63	0.34	1.35e-10	Facial morphology (factor 19);
CRC	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.99	20.38	0.75	2.8e-60	Metabolite levels;
CRC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16524936	chr4:1340807	KIAA1530	-0.42	-5.79	-0.3	1.64e-8	Longevity;
CRC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.46	-6.82	-0.35	4.29e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs6732252	chr2:15595473	T/C	cg19274914	chr2:15703543	NA	0.38	5.79	0.3	1.62e-8	Educational attainment (years of education);
CRC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg06470822	chr6:28175283	NA	0.48	6.43	0.33	4.59e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg10756647	chr7:56101905	PSPH	0.72	7.69	0.39	1.71e-13	Diabetic kidney disease;
CRC	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg15654264	chr1:150340011	RPRD2	0.39	6.01	0.31	5.05e-9	Migraine;
CRC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.54e-15	Morning vs. evening chronotype;
CRC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.59	8.0	0.4	2.1e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.66	8.71	0.43	1.48e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12273811	chr6:28175739	NA	0.56	8.11	0.41	1.02e-14	Parkinson's disease;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.69	-10.18	-0.49	2.41e-21	Menopause (age at onset);
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.06	0.69	3.53e-47	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00834958	chr7:100077147	TSC22D4	0.44	6.26	0.33	1.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-8.53	-0.43	5.24e-16	Sense of smell;
CRC	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	9.05	0.45	1.23e-17	Ulcerative colitis;
CRC	cis	rs10512697	0.772	rs13154653	chr5:3518916	C/A	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.55	8.47	0.42	8.58e-16	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07335843	chr2:133030691	NA	-0.37	-6.73	-0.35	7.75e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg05044414	chr3:183734942	ABCC5	0.46	8.03	0.4	1.79e-14	Anterior chamber depth;
CRC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs1465370	0.568	rs10253113	chr7:130009311	A/G	cg03229158	chr7:130009420	NA	0.5	7.16	0.37	5.23e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	17.19	0.69	9.99e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.54	-7.4	-0.38	1.12e-12	Coronary artery disease;
CRC	cis	rs6076065	1.000	rs2405231	chr20:23342239	A/C	cg11657817	chr20:23433608	CST11	0.38	6.1	0.32	2.98e-9	Facial morphology (factor 15, philtrum width);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00303776	chr10:103454253	FBXW4	0.49	6.94	0.36	2.13e-11	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg01919652	chr6:150259930	NA	-0.69	-5.99	-0.31	5.48e-9	Cognitive function;
CRC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.96	-18.36	-0.71	2.48e-52	Primary sclerosing cholangitis;
CRC	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg16558208	chr1:156270281	VHLL	0.58	9.04	0.45	1.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21685432	chr20:57556415	TH1L	0.35	6.06	0.32	3.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg27083787	chr2:113543245	IL1A	0.48	6.39	0.33	5.74e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.44	-8.36	-0.42	1.73e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.93	16.02	0.66	4.17e-43	Menarche (age at onset);
CRC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-8.33	-0.42	2.2e-15	Vitiligo;
CRC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.79	13.41	0.59	5.14e-33	Menopause (age at onset);
CRC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.7	-0.43	1.62e-16	Aortic root size;
CRC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.6	9.23	0.45	3.34e-18	Night sleep phenotypes;
CRC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.9	-18.14	-0.71	1.87e-51	Urate levels in lean individuals;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19720077	chr14:51135033	SAV1	0.39	6.05	0.32	4.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9903692	0.909	rs9899275	chr17:46129315	C/T	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24415082	chr16:74700811	RFWD3	0.45	6.48	0.34	3.35e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16442050	chr2:27294098	LOC100128731	0.47	6.75	0.35	6.69e-11	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.9e-16	Corneal astigmatism;
CRC	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg06223162	chr1:101003688	GPR88	-0.35	-6.38	-0.33	6.07e-10	Monocyte count;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.4	5.66	0.3	3.34e-8	Obesity-related traits;
CRC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.49	7.75	0.39	1.18e-13	Red blood cell count;
CRC	cis	rs731174	0.797	rs678511	chr1:38156427	T/C	cg06917450	chr1:38156652	C1orf109	-0.52	-7.15	-0.37	5.79e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg04969067	chr8:143858791	LYNX1	0.45	7.58	0.39	3.66e-13	Urinary tract infection frequency;
CRC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-7.24	-0.37	3.28e-12	Major depressive disorder;
CRC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.55	10.17	0.49	2.62e-21	HDL cholesterol levels;
CRC	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.67	9.81	0.48	4.23e-20	Body mass index;
CRC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	10.09	0.49	5.05e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.47	7.22	0.37	3.65e-12	Corneal astigmatism;
CRC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.86	17.04	0.68	4.11e-47	Myeloid white cell count;
CRC	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.74	0.3	2.17e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	trans	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	7.02	0.36	1.24e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg19041857	chr6:27730383	NA	-0.72	-6.75	-0.35	6.7e-11	Breast cancer;
CRC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.65	11.9	0.55	2.05e-27	Calcium levels;
CRC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg00338735	chr4:53728038	RASL11B	0.36	5.77	0.3	1.84e-8	Optic nerve measurement (cup area);
CRC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.69	-0.43	1.69e-16	Hemoglobin concentration;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.37	5.83	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.53	-8.03	-0.4	1.78e-14	Mean corpuscular hemoglobin;
CRC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.46	-8.93	-0.44	3.13e-17	Prostate cancer;
CRC	cis	rs3026101	0.671	rs1065482	chr17:5284719	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	7.47	0.38	7.09e-13	Body mass index;
CRC	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg09659197	chr4:152720779	NA	0.44	8.93	0.44	3.05e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.62	-10.3	-0.49	9.84e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg12888358	chr2:86668281	KDM3A	-0.48	-6.61	-0.34	1.54e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg18335740	chr13:41363409	SLC25A15	0.53	7.94	0.4	3.21e-14	Lewy body disease;
CRC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg10724054	chr17:3904396	NA	0.48	7.64	0.39	2.34e-13	Type 2 diabetes;
CRC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.66	-8.21	-0.41	5.12e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.4	7.47	0.38	7.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.08	-15.25	-0.64	4.51e-40	Exhaled nitric oxide output;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg21251018	chr6:28226885	NKAPL	0.46	6.52	0.34	2.59e-10	Parkinson's disease;
CRC	cis	rs990171	0.913	rs10190555	chr2:102994056	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.77	0.3	1.82e-8	Lymphocyte counts;
CRC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg15786705	chr6:28176104	NA	0.74	9.47	0.46	5.74e-19	Depression;
CRC	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg10802521	chr3:52805072	NEK4	0.41	5.69	0.3	2.86e-8	Schizophrenia;
CRC	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg18806716	chr10:30721971	MAP3K8	0.5	7.51	0.38	5.6e-13	Inflammatory bowel disease;
CRC	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	cg04338863	chr8:33670619	NA	0.38	6.09	0.32	3.13e-9	Body mass index;
CRC	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg20356878	chr3:121714668	ILDR1	-0.44	-5.97	-0.31	6.14e-9	Multiple sclerosis;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg00063174	chr2:228736253	WDR69	-0.51	-6.86	-0.35	3.49e-11	Blood pressure;
CRC	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs62229266	0.659	rs7275820	chr21:37409414	G/A	cg08632701	chr21:37451849	NA	-0.4	-6.27	-0.33	1.16e-9	Mitral valve prolapse;
CRC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg07195577	chr17:27052828	TLCD1	0.42	6.03	0.32	4.32e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs61160187	0.582	rs34619	chr5:60465365	G/A	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.69	-0.3	2.85e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.9	-0.48	2.08e-20	Bone mineral density;
CRC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.57	6.0	0.31	5.13e-9	Initial pursuit acceleration;
CRC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg09796270	chr17:17721594	SREBF1	-0.55	-9.92	-0.48	1.87e-20	Total body bone mineral density;
CRC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.42	9.09	0.45	9.39e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.44	-6.84	-0.35	3.81e-11	Asthma;
CRC	cis	rs11958404	0.860	rs72818116	chr5:157440616	G/T	cg05962755	chr5:157440814	NA	0.96	12.14	0.56	2.72e-28	IgG glycosylation;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg02466173	chr16:30829666	NA	-0.61	-9.25	-0.45	2.95e-18	Dementia with Lewy bodies;
CRC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.66	-0.57	3.32e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg15763984	chr4:1342303	KIAA1530	0.45	6.78	0.35	5.42e-11	Obesity-related traits;
CRC	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.67	-10.44	-0.5	3.12e-22	Total cholesterol levels;
CRC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg20243544	chr17:37824526	PNMT	0.37	5.62	0.3	4.05e-8	Self-reported allergy;
CRC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.74	-12.68	-0.57	2.92e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-0.7	-6.85	-0.35	3.61e-11	IgG glycosylation;
CRC	trans	rs62209635	0.500	rs6088295	chr20:32344656	G/A	cg22889316	chr6:5181057	LYRM4	0.54	5.97	0.31	6.31e-9	Loneliness;
CRC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg21425842	chr6:26240939	HIST1H4F	-0.35	-5.76	-0.3	1.95e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.43	6.57	0.34	1.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg22815214	chr1:201083145	CACNA1S	-0.63	-10.89	-0.51	8.38e-24	Permanent tooth development;
CRC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.38	6.09	0.32	3.22e-9	Testicular germ cell tumor;
CRC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.67	-9.23	-0.45	3.41e-18	Platelet count;
CRC	cis	rs8105895	0.935	rs8104630	chr19:22247277	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.53	6.76	0.35	6.42e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.59	8.98	0.44	2.15e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg00691999	chr4:55094011	PDGFRA	0.41	5.76	0.3	1.89e-8	Corneal astigmatism;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.36	6.04	0.32	4.28e-9	Electroencephalogram traits;
CRC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.86	13.42	0.59	4.67e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs7739232	0.920	rs75168938	chr6:53530047	C/A	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg09491104	chr22:46646882	C22orf40	-0.48	-7.51	-0.38	5.72e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg18761221	chr20:60518478	NA	0.44	7.01	0.36	1.34e-11	Body mass index;
CRC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.52	7.43	0.38	9.67e-13	Schizophrenia;
CRC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg25482853	chr8:67687455	SGK3	0.71	8.91	0.44	3.53e-17	Obesity-related traits;
CRC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.85	0.44	5.49e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg11130432	chr3:121712080	ILDR1	0.5	6.66	0.34	1.15e-10	Multiple sclerosis;
CRC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.03	12.61	0.57	5.2e-30	Nonalcoholic fatty liver disease;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.42	6.33	0.33	8.15e-10	Obesity-related traits;
CRC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg08648136	chr8:956695	NA	0.35	6.8	0.35	4.84e-11	Schizophrenia;
CRC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	7.17	0.37	5.01e-12	Cognitive test performance;
CRC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.7	-0.35	8.99e-11	Total body bone mineral density;
CRC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.85	-12.97	-0.58	2.35e-31	Blood metabolite levels;
CRC	cis	rs9463078	0.764	rs494982	chr6:44937255	C/T	cg25276700	chr6:44698697	NA	-0.28	-7.08	-0.36	8.79e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19625216	chr1:249132108	ZNF672	0.44	6.32	0.33	8.65e-10	Response to antipsychotic treatment;
CRC	cis	rs2274273	0.662	rs66476033	chr14:55660863	C/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.75	-0.3	2.08e-8	Protein biomarker;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg03490839	chr16:73082051	ZFHX3	-0.44	-6.27	-0.33	1.14e-9	Protein C levels;
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.62	-0.34	1.5e-10	Monocyte count;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg14487702	chr8:22132665	PIWIL2	0.4	5.96	0.31	6.39e-9	Hypertriglyceridemia;
CRC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.69	8.87	0.44	4.68e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1511802	0.666	rs2292424	chr4:187120625	G/A	cg24794857	chr4:187113578	CYP4V2	0.39	5.62	0.3	4.11e-8	Blood protein levels;
CRC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.39	6.25	0.33	1.26e-9	Alzheimer's disease (late onset);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg05446464	chr6:86387543	SNORD50B;SNHG5;SNORD50A	-0.39	-6.1	-0.32	3.02e-9	Aortic root size;
CRC	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.77	-8.45	-0.42	9.35e-16	Intelligence (multi-trait analysis);
CRC	trans	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.62	8.83	0.44	6.45e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs11212617	0.967	rs227041	chr11:108222801	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.66	0.34	1.15e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.74	-10.26	-0.49	1.32e-21	Blood protein levels;
CRC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	8.13	0.41	8.59e-15	Monocyte count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26509146	chr13:80055601	NDFIP2	0.4	6.18	0.32	1.84e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg21770322	chr7:97807741	LMTK2	0.53	8.62	0.43	2.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.5	6.81	0.35	4.54e-11	Type 1 diabetes nephropathy;
CRC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.55	-9.45	-0.46	6.81e-19	Schizophrenia;
CRC	cis	rs6479527	0.875	rs7858069	chr9:96769258	A/G	cg14459158	chr9:96720562	NA	0.37	6.68	0.35	1.02e-10	Esophageal adenocarcinoma;
CRC	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.58	9.15	0.45	5.97e-18	Corneal astigmatism;
CRC	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.69	8.35	0.42	1.98e-15	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.47	7.16	0.37	5.21e-12	Corneal astigmatism;
CRC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	1.1	10.48	0.5	2.33e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg11483887	chr15:78441560	IDH3A	-0.46	-6.34	-0.33	7.65e-10	Protein C levels;
CRC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25517755	chr10:38738941	LOC399744	-0.42	-6.01	-0.31	5.01e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9322817	0.902	rs9404576	chr6:105184640	T/G	cg02098413	chr6:105308735	HACE1	-0.36	-6.65	-0.34	1.2e-10	Thyroid stimulating hormone;
CRC	trans	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg26043149	chr18:55253948	FECH	-0.49	-7.56	-0.38	4.02e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.55	6.98	0.36	1.67e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg01483505	chr11:975446	AP2A2	0.39	5.92	0.31	7.91e-9	Alzheimer's disease (late onset);
CRC	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.79	9.74	0.47	7.33e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg13722127	chr7:150037890	RARRES2	0.36	5.84	0.31	1.28e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg10437265	chr15:77819839	NA	0.67	11.85	0.55	3.34e-27	Type 2 diabetes;
CRC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg15105011	chr4:940614	TMEM175	-0.39	-5.82	-0.31	1.41e-8	Parkinson's disease;
CRC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.81	0.4	7.77e-14	Motion sickness;
CRC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.52	8.37	0.42	1.64e-15	Aortic root size;
CRC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg24759859	chr6:86352639	SYNCRIP	0.48	6.67	0.35	1.1e-10	Smooth-surface caries;
CRC	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.41	-6.08	-0.32	3.24e-9	IFN-related cytopenia;
CRC	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg13385794	chr1:248469461	NA	0.4	7.05	0.36	1.03e-11	Common traits (Other);
CRC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.47	0.34	3.57e-10	Axial length;
CRC	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg13385794	chr1:248469461	NA	0.39	6.68	0.35	9.97e-11	Common traits (Other);
CRC	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.54	-0.34	2.3e-10	Caffeine consumption;
CRC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.22	0.53	6.03e-25	Prudent dietary pattern;
CRC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.37	-5.73	-0.3	2.24e-8	DNA methylation (variation);
CRC	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.61	9.47	0.46	5.8e-19	Corneal astigmatism;
CRC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.28	0.53	3.77e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.55	7.99	0.4	2.36e-14	Lung cancer;
CRC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.37	6.13	0.32	2.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6496667	0.821	rs13329289	chr15:90897454	C/T	cg04176472	chr15:90893244	GABARAPL3	0.52	7.95	0.4	3.04e-14	Rheumatoid arthritis;
CRC	cis	rs800160	0.777	rs2651779	chr11:2344270	G/A	cg09785033	chr11:2336066	TSPAN32	-0.47	-5.61	-0.3	4.31e-8	Bacteremia;
CRC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.53	-0.5	1.59e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.36	-0.33	6.68e-10	Dupuytren's disease;
CRC	trans	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg19188899	chr13:112838565	NA	-0.43	-6.69	-0.35	9.72e-11	Systemic lupus erythematosus;
CRC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg13057898	chr1:3703894	LRRC47	-0.41	-5.82	-0.31	1.37e-8	Mean corpuscular volume;
CRC	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.13	-9.43	-0.46	7.38e-19	Mitochondrial DNA levels;
CRC	cis	rs7632954	0.935	rs7619333	chr3:8530583	G/A	cg03495237	chr3:8533978	NA	0.34	5.64	0.3	3.57e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.51	8.06	0.41	1.41e-14	Red blood cell count;
CRC	cis	rs6564219	1	rs6564219	chr16:75222006	G/C	cg09066997	chr16:75300724	BCAR1	0.64	6.0	0.31	5.09e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.69	12.15	0.56	2.61e-28	Gout;
CRC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.55	-0.6	1.57e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.58	7.96	0.4	2.87e-14	Adiposity;
CRC	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.62	-9.92	-0.48	1.77e-20	Breast cancer;
CRC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.26	-0.33	1.2e-9	Lung cancer;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.73	12.12	0.56	3.29e-28	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15138986	chr10:131935156	GLRX3	-0.41	-6.02	-0.31	4.75e-9	Myopia (pathological);
CRC	cis	rs863345	0.604	rs10908670	chr1:158502113	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.43	6.36	0.33	6.77e-10	Menopause (age at onset);
CRC	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.49	7.14	0.37	6.15e-12	Response to antidepressants in depression;
CRC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.59e-18	Platelet count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01237565	chr14:105715025	BRF1;BTBD6	0.51	7.19	0.37	4.43e-12	Anxiety disorder;
CRC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg03037974	chr15:76606532	NA	0.64	11.16	0.52	9.32e-25	Blood metabolite levels;
CRC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	6.36	0.33	6.83e-10	Schizophrenia;
CRC	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.98	-0.7	7.79e-51	Schizophrenia;
CRC	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg03469862	chr11:68924853	NA	0.47	6.03	0.32	4.33e-9	Blond vs. brown hair color;
CRC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.63	11.46	0.53	8.46e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.49	-9.21	-0.45	3.82e-18	Reticulocyte fraction of red cells;
CRC	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.22	0.45	3.55e-18	Ileal carcinoids;
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-6.02	-0.31	4.78e-9	Life satisfaction;
CRC	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.42	6.0	0.31	5.34e-9	Schizophrenia;
CRC	cis	rs9463078	0.753	rs636845	chr6:44935341	C/T	cg25276700	chr6:44698697	NA	-0.28	-7.05	-0.36	1.06e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs972578	1.000	rs2267482	chr22:43380548	G/C	cg01576275	chr22:43409880	NA	-0.46	-7.28	-0.37	2.52e-12	Mean platelet volume;
CRC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2227564	0.729	rs2633306	chr10:75652447	G/T	cg00564723	chr10:75632066	CAMK2G	0.33	7.77	0.39	1.01e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.48	-8.98	-0.44	2.09e-17	Hepatitis;
CRC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	0.84	7.64	0.39	2.34e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2569991	0.636	rs361221	chr3:12922767	A/C	cg22481960	chr3:13008800	IQSEC1	0.49	6.33	0.33	8.16e-10	Periodontitis (DPAL);
CRC	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.43	-6.17	-0.32	2.04e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg09040174	chr2:113837401	NA	0.43	5.79	0.3	1.64e-8	Protein quantitative trait loci;
CRC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.47	7.46	0.38	7.64e-13	Platelet count;
CRC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.82	0.31	1.38e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.96	-0.31	6.62e-9	Red blood cell count;
CRC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.25	-0.33	1.24e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg24130564	chr14:104152367	KLC1	0.42	5.67	0.3	3.08e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4664293	0.934	rs4380179	chr2:160541575	G/T	cg08347373	chr2:160653686	CD302	-0.38	-6.19	-0.32	1.83e-9	Monocyte percentage of white cells;
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.45	-0.38	8.09e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg19257562	chr1:2043853	PRKCZ	0.4	6.62	0.34	1.46e-10	Height;
CRC	cis	rs7809950	0.861	rs2701682	chr7:107295835	G/A	cg23024343	chr7:107201750	COG5	0.7	9.37	0.46	1.2e-18	Coronary artery disease;
CRC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.85	-0.31	1.17e-8	Obesity-related traits;
CRC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.79	13.58	0.6	1.21e-33	Dementia with Lewy bodies;
CRC	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.34	-5.86	-0.31	1.15e-8	Pneumonia;
CRC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.59	8.8	0.44	7.87e-17	Aortic root size;
CRC	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.41	6.46	0.34	3.85e-10	Monocyte count;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.61	-5.93	-0.31	7.61e-9	IgG glycosylation;
CRC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.52	8.22	0.41	4.72e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.71	11.15	0.52	1.09e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.86	14.87	0.63	1.27e-38	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs231513	0.954	rs231500	chr17:41973374	T/C	cg26893861	chr17:41843967	DUSP3	-0.62	-6.37	-0.33	6.48e-10	Cognitive function;
CRC	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.25	14.99	0.64	4.45e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.86	13.89	0.61	8.04e-35	Menarche (age at onset);
CRC	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg22089800	chr15:90895588	ZNF774	0.5	7.97	0.4	2.67e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg20129853	chr10:51489980	NA	-0.41	-6.93	-0.36	2.2e-11	Prostate-specific antigen levels;
CRC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.64	8.53	0.43	5.53e-16	Schizophrenia;
CRC	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.76	-15.27	-0.64	3.58e-40	Prostate cancer;
CRC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.42	-0.42	1.21e-15	Bladder cancer;
CRC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg10723962	chr6:26240782	HIST1H4F	-0.36	-5.75	-0.3	2.06e-8	Gout;Renal underexcretion gout;
CRC	trans	rs12517041	1.000	rs2081953	chr5:23295682	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	8.9e-20	Hair morphology;
CRC	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.57	8.43	0.42	1.13e-15	Adiposity;
CRC	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.44	8.79	0.44	8.75e-17	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4664293	0.836	rs11687502	chr2:160616975	T/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.52	-8.69	-0.43	1.76e-16	Common traits (Other);
CRC	cis	rs6066835	0.764	rs28741053	chr20:47378114	T/C	cg18078177	chr20:47281410	PREX1	0.67	5.7	0.3	2.62e-8	Multiple myeloma;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg20933634	chr6:27740509	NA	0.59	8.6	0.43	3.36e-16	Parkinson's disease;
CRC	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.19	-18.29	-0.71	4.51e-52	Blood pressure (smoking interaction);
CRC	cis	rs73206853	0.563	rs80044246	chr12:111133535	C/A	cg12870014	chr12:110450643	ANKRD13A	0.8	9.08	0.45	1.04e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg02927042	chr1:21476669	EIF4G3	0.45	7.22	0.37	3.56e-12	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13645902	chr11:118661758	DDX6	0.4	6.18	0.32	1.88e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs77972916	0.536	rs11694173	chr2:43590899	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.51	5.89	0.31	9.74e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.5	7.92	0.4	3.68e-14	Prostate cancer;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.3	-0.33	9.64e-10	Bipolar disorder;
CRC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-11.29	-0.53	3.22e-25	Asthma;
CRC	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg15687855	chr3:44754131	ZNF502	-0.34	-5.66	-0.3	3.3e-8	Depressive symptoms;
CRC	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.57	-6.92	-0.36	2.41e-11	Ulcerative colitis;
CRC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.95	-0.31	6.88e-9	Gout;
CRC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg02725872	chr8:58115012	NA	-0.32	-5.63	-0.3	3.94e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.75	0.3	2.03e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11212617	1.000	rs186593	chr11:108262439	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.41e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg24562669	chr7:97807699	LMTK2	0.79	17.64	0.7	1.72e-49	Breast cancer;
CRC	trans	rs4586057	0.812	rs11186341	chr10:92623448	G/C	cg26894278	chr13:21016241	CRYL1	0.36	6.04	0.32	4.13e-9	Economic and political preferences (time);
CRC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.43	5.65	0.3	3.53e-8	Coronary artery disease;
CRC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.74	10.05	0.48	6.51e-21	Platelet count;
CRC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.66	-10.02	-0.48	8.71e-21	Other erythrocyte phenotypes;
CRC	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-8.02	-0.4	1.83e-14	Hepatocellular carcinoma;
CRC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.57	8.47	0.42	8.23e-16	Menopause (age at onset);
CRC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.56	8.39	0.42	1.41e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.62	0.43	2.84e-16	Lymphocyte counts;
CRC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02772935	chr3:125709198	NA	-0.49	-5.71	-0.3	2.46e-8	Blood pressure (smoking interaction);
CRC	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg04110750	chr16:69646130	NFAT5	-0.58	-7.93	-0.4	3.35e-14	IgE levels;
CRC	cis	rs3751196	0.901	rs17794246	chr12:104177338	A/G	cg02344784	chr12:104178138	NT5DC3	-0.67	-7.31	-0.37	2.09e-12	Sense of smell;
CRC	cis	rs13315871	0.929	rs9811074	chr3:58421846	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	cis	rs4731207	0.564	rs12531311	chr7:124625546	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg20041105	chr8:143859282	LYNX1	-0.41	-6.87	-0.35	3.15e-11	Urinary tract infection frequency;
CRC	cis	rs731174	0.759	rs591567	chr1:38149847	A/G	cg06917450	chr1:38156652	C1orf109	-0.51	-7.18	-0.37	4.74e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.87	16.08	0.66	2.45e-43	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.65	-0.34	1.19e-10	Blood metabolite levels;
CRC	cis	rs9992667	0.577	rs10021686	chr4:38705257	C/T	cg19726192	chr4:38663646	FLJ13197	-0.59	-6.72	-0.35	8.08e-11	Eosinophil percentage of granulocytes;
CRC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-9.04	-0.45	1.42e-17	Monocyte count;
CRC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.83	-13.38	-0.59	6.55e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6496667	0.779	rs8024110	chr15:90947453	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.53	-7.49	-0.38	6.36e-13	Rheumatoid arthritis;
CRC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg24562669	chr7:97807699	LMTK2	0.42	7.04	0.36	1.1e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg02254774	chr11:50257496	LOC441601	0.47	6.52	0.34	2.69e-10	Height;
CRC	cis	rs4664293	0.867	rs12692564	chr2:160617837	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg20041105	chr8:143859282	LYNX1	-0.41	-6.48	-0.34	3.38e-10	Urinary tract infection frequency;
CRC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.7	10.36	0.5	5.81e-22	Immature fraction of reticulocytes;
CRC	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg06581033	chr10:766294	NA	-0.5	-5.76	-0.3	1.93e-8	Uric acid levels;
CRC	cis	rs17209837	0.646	rs11532733	chr7:87117982	A/G	cg00919237	chr7:87102261	ABCB4	-0.51	-6.43	-0.33	4.5e-10	Gallbladder cancer;
CRC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21171335	chr12:122356390	WDR66	0.39	5.91	0.31	8.61e-9	Mean corpuscular volume;
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg19678392	chr7:94953810	PON1	-0.59	-7.36	-0.38	1.49e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.58	0.47	2.55e-19	Alzheimer's disease;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg10876282	chr6:28092338	ZSCAN16	0.4	5.7	0.3	2.67e-8	Cardiac Troponin-T levels;
CRC	cis	rs77861329	0.748	rs749995	chr3:52176701	C/T	cg08692210	chr3:52188851	WDR51A	0.5	5.89	0.31	9.43e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.44	-7.3	-0.37	2.23e-12	Breast cancer;
CRC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.86	15.19	0.64	7.39e-40	Height;
CRC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.21	-0.41	5.24e-15	Calcium levels;
CRC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.65	9.16	0.45	5.67e-18	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25517755	chr10:38738941	LOC399744	0.45	6.56	0.34	2.07e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.99	0.36	1.58e-11	Melanoma;
CRC	cis	rs2072510	0.569	rs61937881	chr12:96393587	C/T	cg09636302	chr12:96389483	HAL	-0.53	-6.49	-0.34	3.1e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.41	-6.69	-0.35	9.71e-11	Type 2 diabetes;
CRC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.17e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.03	-0.32	4.41e-9	Educational attainment;
CRC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.49	-7.05	-0.36	1.03e-11	HDL cholesterol;
CRC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	trans	rs2045966	0.881	rs508052	chr8:98524688	C/T	cg07320695	chr4:107423690	NA	0.52	6.22	0.32	1.54e-9	nicotine metabolite ratio in current smokers;
CRC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg03013636	chr16:1946785	NA	0.59	7.16	0.37	5.31e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-7.1	-0.36	7.87e-12	Calcium levels;
CRC	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.83	12.71	0.57	2.22e-30	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18076766	chr12:102455961	CCDC53	0.43	5.96	0.31	6.39e-9	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-5.86	-0.31	1.12e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.33	-0.42	2.21e-15	Mean platelet volume;
CRC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.88	0.31	1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg22676075	chr6:135203613	NA	-0.65	-10.08	-0.49	5.16e-21	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg09163369	chr1:210001066	C1orf107	0.41	5.78	0.3	1.77e-8	Orofacial clefts;
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs4722166	0.532	rs6963866	chr7:22757341	C/T	cg05472934	chr7:22766657	IL6	0.64	9.93	0.48	1.76e-20	Lung cancer;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg15845792	chr6:28175446	NA	0.6	7.95	0.4	3.01e-14	Parkinson's disease;
CRC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.88	10.85	0.51	1.2e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.64	8.64	0.43	2.56e-16	Schizophrenia;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg13264159	chr8:625131	ERICH1	0.77	7.39	0.38	1.24e-12	IgG glycosylation;
CRC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.18	11.57	0.54	3.24e-26	Skin colour saturation;
CRC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	6.74	0.35	7.28e-11	Initial pursuit acceleration;
CRC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-11.47	-0.53	7.69e-26	Extrinsic epigenetic age acceleration;
CRC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.8	-0.39	8.34e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg23100626	chr2:96804247	ASTL	-0.31	-8.57	-0.43	4.06e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.4	6.08	0.32	3.32e-9	Mean corpuscular volume;
CRC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg02527881	chr3:46936655	PTH1R	0.37	6.78	0.35	5.52e-11	Colorectal cancer;
CRC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.08	0.45	1.03e-17	Menarche (age at onset);
CRC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.83	0.35	4.16e-11	Melanoma;
CRC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.86	-13.99	-0.61	3.2e-35	Multiple myeloma;
CRC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.64	9.7	0.47	9.7e-20	Birth weight;
CRC	cis	rs6700896	0.931	rs10789193	chr1:66129646	A/T	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.77	-12.79	-0.58	1.15e-30	Obesity-related traits;
CRC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.71	0.6	3.81e-34	Breast cancer;
CRC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.6	8.55	0.43	4.86e-16	Intelligence (multi-trait analysis);
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg25580254	chr12:8088937	SLC2A3	-0.39	-6.01	-0.31	5e-9	Age-related macular degeneration;
CRC	cis	rs3026445	0.851	rs1502337	chr12:111062852	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.42	-6.68	-0.35	1.03e-10	QT interval;
CRC	cis	rs7904985	0.924	rs2217223	chr10:88111630	A/G	cg07322936	chr10:88137208	NA	0.51	7.35	0.38	1.57e-12	Barrett's esophagus;
CRC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.4	-5.8	-0.3	1.57e-8	Aortic root size;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.43	6.44	0.33	4.21e-10	Menopause (age at onset);
CRC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg00074818	chr8:8560427	CLDN23	0.31	5.68	0.3	2.94e-8	Obesity-related traits;
CRC	cis	rs7071206	0.704	rs11002234	chr10:79434458	A/G	cg07817648	chr10:79422355	NA	-0.48	-6.42	-0.33	4.75e-10	Bone mineral density;
CRC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg18876405	chr7:65276391	NA	0.47	6.41	0.33	5.04e-10	Aortic root size;
CRC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.37	-0.33	6.42e-10	Menopause (age at onset);
CRC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg13777783	chr17:79615861	NA	-0.3	-5.7	-0.3	2.6e-8	Eye color traits;
CRC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg00246817	chr9:123691163	NA	-0.48	-6.12	-0.32	2.67e-9	Rheumatoid arthritis;
CRC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-6.09	-0.32	3.06e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg23123621	chr4:1343375	KIAA1530	-0.37	-7.01	-0.36	1.39e-11	Obesity-related traits;
CRC	cis	rs4979906	1.000	rs11002248	chr10:79446961	A/G	cg07817648	chr10:79422355	NA	-0.43	-5.64	-0.3	3.57e-8	Mortality in heart failure;
CRC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg04450456	chr4:17643702	FAM184B	0.42	6.6	0.34	1.61e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.8e-30	Body mass index;
CRC	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg09127314	chr1:152161683	NA	-0.45	-5.73	-0.3	2.33e-8	Atopic dermatitis;
CRC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.6	-0.34	1.66e-10	Monocyte count;
CRC	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg01475377	chr6:109611718	NA	-0.33	-5.79	-0.3	1.62e-8	Reticulocyte fraction of red cells;
CRC	cis	rs10946940	0.864	rs13201411	chr6:27498217	G/C	cg21251018	chr6:28226885	NKAPL	-0.42	-6.55	-0.34	2.28e-10	Systemic lupus erythematosus;
CRC	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.6	8.95	0.44	2.64e-17	Schizophrenia;
CRC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.26	0.33	1.19e-9	Height;
CRC	cis	rs629535	0.814	rs652483	chr8:70055083	G/A	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.59e-8	Dupuytren's disease;
CRC	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg23435118	chr5:141488016	NDFIP1	-0.47	-7.44	-0.38	8.88e-13	Crohn's disease;
CRC	trans	rs6472235	0.778	rs58967538	chr8:66927783	G/C	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg20119798	chr7:94954144	PON1	-0.44	-5.61	-0.3	4.36e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs11088226	0.709	rs55860967	chr21:33880018	G/A	cg09050820	chr6:167586206	TCP10L2	0.65	7.13	0.37	6.27e-12	Gastritis;
CRC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.42	6.1	0.32	2.92e-9	Bone properties (heel);
CRC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg19635926	chr16:89946313	TCF25	0.63	5.61	0.3	4.35e-8	Skin colour saturation;
CRC	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg20636351	chr8:55087400	NA	-0.34	-6.07	-0.32	3.51e-9	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs2099149	0.748	rs354128	chr12:30505536	C/G	cg21144006	chr12:74931510	LOC552889	0.5	6.39	0.33	5.6e-10	Cannabis use;
CRC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.46	-7.03	-0.36	1.22e-11	Cleft lip with or without cleft palate;
CRC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg20387954	chr3:183756860	HTR3D	0.46	7.95	0.4	3.09e-14	Anterior chamber depth;
CRC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.45e-11	Cholesterol, total;LDL cholesterol;
CRC	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg17145862	chr1:211918768	LPGAT1	0.55	9.39	0.46	1.01e-18	Leprosy;
CRC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.76	-0.3	1.95e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg19980929	chr12:42632907	YAF2	-0.39	-5.91	-0.31	8.67e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.3	-6.5	-0.34	3.04e-10	IgG glycosylation;
CRC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg21153622	chr11:89784906	NA	0.43	6.9	0.36	2.64e-11	Coronary artery disease;
CRC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.53	7.81	0.4	7.94e-14	Resting heart rate;
CRC	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.62	8.1	0.41	1.08e-14	Uric acid levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27449864	chr7:73133982	STX1A	0.39	6.14	0.32	2.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.26	-0.33	1.22e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.55	-0.34	2.17e-10	Total body bone mineral density;
CRC	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.79	-14.12	-0.61	1.05e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.73	-11.4	-0.53	1.37e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs9409565	0.516	rs114766729	chr9:97069901	C/T	cg05679027	chr9:99775184	HIATL2	0.39	5.97	0.31	6.03e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg24058013	chr18:77568902	NA	-0.47	-7.89	-0.4	4.54e-14	Schizophrenia;
CRC	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.46	-0.38	7.85e-13	Caudate activity during reward;
CRC	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.25	12.24	0.56	1.25e-28	Granulocyte percentage of myeloid white cells;
CRC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg16892393	chr17:41919603	NA	0.56	7.83	0.4	6.58e-14	Triglycerides;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-10.34	-0.5	6.9e-22	Longevity;Endometriosis;
CRC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg03030879	chr14:75389066	RPS6KL1	0.4	6.15	0.32	2.31e-9	Height;
CRC	cis	rs12431939	0.779	rs2999381	chr14:51645368	T/C	cg23942311	chr14:51606299	NA	0.49	6.81	0.35	4.68e-11	Cancer;
CRC	cis	rs55788414	0.932	rs7185658	chr16:81189336	A/G	cg06400318	chr16:81190750	PKD1L2	-0.62	-7.18	-0.37	4.55e-12	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.89	-0.44	4.24e-17	Hemoglobin concentration;
CRC	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.45	6.87	0.35	3.22e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	13.98	0.61	3.57e-35	Alzheimer's disease;
CRC	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.55	7.72	0.39	1.44e-13	Testicular germ cell tumor;
CRC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.1	-0.41	1.12e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs12143943	0.834	rs34812029	chr1:204546987	A/G	cg17419461	chr1:204415978	PIK3C2B	0.42	6.47	0.34	3.5e-10	Cognitive performance;
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.14	-0.45	6.43e-18	Intelligence (multi-trait analysis);
CRC	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.66	6.29	0.33	9.9e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.56	0.5	1.26e-22	Coronary artery disease;
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.53	-0.38	4.99e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.01	-0.31	5.01e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.45	6.17	0.32	1.99e-9	Height;
CRC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.17	-0.37	5.07e-12	Mean corpuscular volume;
CRC	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.36	5.62	0.3	4.08e-8	Educational attainment;
CRC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.05e-32	Cannabis dependence symptom count;
CRC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg21665744	chr7:39171113	POU6F2	0.42	5.66	0.3	3.25e-8	IgG glycosylation;
CRC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.78	-8.66	-0.43	2.16e-16	Hip circumference adjusted for BMI;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.48	-6.81	-0.35	4.77e-11	Longevity;Endometriosis;
CRC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.64	10.21	0.49	1.95e-21	Height;
CRC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg16892393	chr17:41919603	NA	0.5	6.99	0.36	1.5e-11	Triglycerides;
CRC	cis	rs6662572	0.737	rs7555458	chr1:46554142	A/G	cg08644498	chr1:46502608	NA	0.45	7.19	0.37	4.27e-12	Blood protein levels;
CRC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.85	-13.39	-0.59	6.09e-33	Hemoglobin concentration;Hematocrit;
CRC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.54	6.9	0.36	2.76e-11	Morning vs. evening chronotype;
CRC	trans	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg03006477	chr6:74432658	CD109	0.36	6.41	0.33	5.01e-10	Blood protein levels;Calcium levels;
CRC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs75920871	0.660	rs4938330	chr11:116928514	C/G	cg20608306	chr11:116969690	SIK3	-0.32	-5.92	-0.31	8.16e-9	Subjective well-being;
CRC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-15.74	-0.66	5.48e-42	Body mass index;
CRC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg22482690	chr17:47019901	SNF8	0.48	8.08	0.41	1.28e-14	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.17	-0.37	4.83e-12	Tuberculosis;
CRC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.74	7.74	0.39	1.27e-13	Cognitive ability (multi-trait analysis);
CRC	cis	rs2298450	0.550	rs36037816	chr21:37656115	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-6.43	-0.33	4.4e-10	Schizophrenia;
CRC	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg03339077	chr11:47165057	C11orf49	0.5	7.3	0.37	2.22e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg15448220	chr1:150897856	SETDB1	0.48	6.83	0.35	4.16e-11	Tonsillectomy;
CRC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.71	9.68	0.47	1.15e-19	Initial pursuit acceleration;
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.99	11.34	0.53	2.17e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg21620606	chr4:1342894	KIAA1530	0.36	5.91	0.31	8.33e-9	Obesity-related traits;
CRC	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.97	7.95	0.4	2.97e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18867708	chr6:26865862	GUSBL1	-0.41	-5.72	-0.3	2.34e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4908768	0.539	rs922366	chr1:8653733	C/A	cg20416874	chr1:8611966	RERE	-0.42	-5.95	-0.31	6.76e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs728616	0.571	rs113030473	chr10:81649031	G/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.59	-0.39	3.41e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2415984	0.622	rs10131871	chr14:46931700	A/G	cg14871534	chr14:47121158	RPL10L	0.43	6.14	0.32	2.38e-9	Number of children ever born;
CRC	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00938859	chr5:1591904	SDHAP3	0.73	7.77	0.39	9.95e-14	Breast cancer;
CRC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	10.48	0.5	2.35e-22	Motion sickness;
CRC	cis	rs2072510	0.593	rs2540497	chr12:96404275	A/T	cg15438951	chr12:96389694	HAL	-0.46	-5.65	-0.3	3.53e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.46	7.2	0.37	4.04e-12	Red blood cell count;
CRC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.56	-0.67	3.26e-45	Height;
CRC	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg10298567	chr3:47292165	KIF9	0.36	5.63	0.3	3.9e-8	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12568633	chr10:73533407	CDH23;C10orf54	0.39	6.48	0.34	3.36e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	10.63	0.51	6.74e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.63	9.57	0.47	2.74e-19	Menopause (age at onset);
CRC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg17294928	chr15:75287854	SCAMP5	-0.44	-6.49	-0.34	3.11e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs7546094	1.000	rs7544663	chr1:113089006	A/G	cg22162597	chr1:113214053	CAPZA1	-0.44	-6.18	-0.32	1.94e-9	Platelet distribution width;
CRC	cis	rs11203032	0.831	rs11203014	chr10:90940333	C/G	cg16672925	chr10:90967113	CH25H	0.45	5.66	0.3	3.24e-8	Heart failure;
CRC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.64e-39	Lymphocyte percentage of white cells;
CRC	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.45	6.8	0.35	5.05e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs3736594	0.643	rs2384655	chr2:27952235	A/T	cg27432699	chr2:27873401	GPN1	-0.62	-8.8	-0.44	8.04e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7705042	0.828	rs6580224	chr5:141489306	A/G	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.86	-0.31	1.14e-8	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05842370	chr22:41682224	RANGAP1	0.42	6.72	0.35	8.11e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.81	-0.4	7.74e-14	Monocyte percentage of white cells;
CRC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.65	6.76	0.35	6.42e-11	Inflammatory bowel disease;
CRC	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg14664628	chr15:75095509	CSK	0.44	6.19	0.32	1.83e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg02527881	chr3:46936655	PTH1R	-0.34	-6.05	-0.32	3.85e-9	Colorectal cancer;
CRC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.09	-0.32	3.23e-9	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	8.96	0.44	2.53e-17	Pulse pressure;
CRC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.05	-0.41	1.55e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.56	9.25	0.45	2.96e-18	Mean corpuscular volume;
CRC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.42	0.33	4.73e-10	Morning vs. evening chronotype;
CRC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.66	11.72	0.54	9.36e-27	Height;
CRC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.91	-0.31	8.45e-9	Vitiligo;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.87	-0.4	5.05e-14	Bipolar disorder;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.78	-12.83	-0.58	7.99e-31	Height;
CRC	trans	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-6.77	-0.35	5.95e-11	Menarche (age at onset);
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.6	8.81	0.44	7.37e-17	Intelligence (multi-trait analysis);
CRC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.56	-8.21	-0.41	5.07e-15	Response to temozolomide;
CRC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.53	-0.38	4.88e-13	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	12.02	0.55	7.64e-28	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9914544	0.628	rs4924924	chr17:18677774	C/G	cg26306683	chr17:18585705	ZNF286B	0.39	5.73	0.3	2.3e-8	Educational attainment (years of education);
CRC	cis	rs2274273	0.624	rs11848575	chr14:55755788	A/G	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.73	-0.3	2.24e-8	Protein biomarker;
CRC	cis	rs6662572	0.737	rs4423055	chr1:46259980	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.22	-0.32	1.52e-9	Blood protein levels;
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg04155289	chr7:94953770	PON1	-0.59	-7.48	-0.38	6.83e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-0.9	-15.63	-0.65	1.37e-41	Body mass index;
CRC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg09127314	chr1:152161683	NA	0.51	6.52	0.34	2.66e-10	Atopic dermatitis;
CRC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.61	-6.9	-0.36	2.75e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-5.85	-0.31	1.18e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	11.19	0.52	7.68e-25	Mean platelet volume;
CRC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.76	-0.35	6.22e-11	Colorectal cancer;
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.6	10.29	0.49	1.01e-21	Prudent dietary pattern;
CRC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg04166393	chr7:2884313	GNA12	0.39	6.01	0.31	4.94e-9	Height;
CRC	cis	rs2195987	0.874	rs4932934	chr19:24107333	T/A	cg00460763	chr19:23944615	RPSAP58	0.54	5.8	0.3	1.55e-8	Testicular germ cell tumor;
CRC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.69	-9.35	-0.46	1.39e-18	Platelet count;
CRC	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.6	-8.36	-0.42	1.74e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg12639453	chr1:2035780	PRKCZ	0.31	5.88	0.31	1.01e-8	Height;
CRC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.63	-12.59	-0.57	6.21e-30	Intelligence (multi-trait analysis);
CRC	cis	rs61160187	0.582	rs62372103	chr5:60145448	A/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-6.0	-0.31	5.11e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg03623178	chr6:28175578	NA	0.92	13.05	0.58	1.2e-31	Parkinson's disease;
CRC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.39	-5.8	-0.3	1.58e-8	Breast cancer;
CRC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.68	0.3	2.95e-8	Diabetic retinopathy;
CRC	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.82	-10.57	-0.5	1.14e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04221910	chr5:616842	CEP72	-0.41	-6.87	-0.35	3.22e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs2637266	0.558	rs1907331	chr10:78244948	T/C	cg18941641	chr10:78392320	NA	-0.34	-5.61	-0.3	4.32e-8	Pulmonary function;
CRC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.75	8.2	0.41	5.54e-15	Major depressive disorder;
CRC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg09655341	chr17:79618100	PDE6G	-0.35	-6.07	-0.32	3.5e-9	Eye color traits;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg02527881	chr3:46936655	PTH1R	0.39	7.1	0.36	7.7e-12	Colorectal cancer;
CRC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.66	-11.15	-0.52	1.08e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13047869	chr3:10149882	C3orf24	0.51	6.45	0.34	3.96e-10	Alzheimer's disease;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.46	-0.34	3.86e-10	Parkinson's disease;
CRC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.48	7.99	0.4	2.25e-14	Crohn's disease;
CRC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.91	11.42	0.53	1.15e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.36	-0.33	6.62e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2249296	0.586	rs4656108	chr1:86925400	A/G	cg17424433	chr1:86913263	CLCA2	-0.42	-5.94	-0.31	7.13e-9	Crohn's disease-related phenotypes;
CRC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg17971929	chr21:40555470	PSMG1	-0.47	-6.16	-0.32	2.12e-9	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22190833	chr7:150929518	CHPF2	0.33	6.58	0.34	1.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.57	0.39	3.69e-13	Schizophrenia;
CRC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.67	0.54	1.44e-26	Prudent dietary pattern;
CRC	trans	rs7011507	1.000	rs76272647	chr8:49194001	G/A	cg04544946	chr8:978226	NA	0.48	6.76	0.35	6.43e-11	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg10298567	chr3:47292165	KIF9	0.42	6.56	0.34	2.07e-10	Colorectal cancer;
CRC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.93	-0.36	2.27e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.46	-6.37	-0.33	6.29e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg04969067	chr8:143858791	LYNX1	-0.4	-6.12	-0.32	2.61e-9	Urinary tract infection frequency;
CRC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.37	1.72e-12	Alzheimer's disease;
CRC	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.06	-0.41	1.47e-14	Waist circumference adjusted for body mass index;
CRC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.51	0.38	5.58e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.57	8.88	0.44	4.4e-17	Colorectal cancer;
CRC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg17401720	chr7:158221031	PTPRN2	0.48	7.83	0.4	6.86e-14	Obesity-related traits;
CRC	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg21251018	chr6:28226885	NKAPL	0.38	5.64	0.3	3.58e-8	Parkinson's disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg05108160	chr13:110790284	NA	-0.42	-6.27	-0.33	1.14e-9	Daytime sleep phenotypes;
CRC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg10298567	chr3:47292165	KIF9	0.39	6.03	0.32	4.51e-9	Colorectal cancer;
CRC	cis	rs863345	0.604	rs11264985	chr1:158465166	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.35	-0.33	7.19e-10	Pneumococcal bacteremia;
CRC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.04	0.36	1.15e-11	Breast cancer;
CRC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.83	14.98	0.64	4.88e-39	Breast cancer;
CRC	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg26665480	chr2:98280029	ACTR1B	-0.53	-5.63	-0.3	3.89e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02290350	chr8:58132656	NA	-0.62	-7.02	-0.36	1.27e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00676969	chr14:74485475	ENTPD5;C14orf45	-0.42	-6.32	-0.33	8.28e-10	Myopia (pathological);
CRC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg00343986	chr7:65444356	GUSB	0.43	5.81	0.3	1.48e-8	Corneal structure;
CRC	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.17	-0.37	4.92e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.93	-0.36	2.24e-11	Colorectal cancer;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg10396713	chr8:602097	NA	0.56	5.66	0.3	3.35e-8	IgG glycosylation;
CRC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg15848620	chr12:58087721	OS9	-0.6	-8.33	-0.42	2.17e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.37	0.38	1.37e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg11271282	chr2:238384023	NA	0.46	5.81	0.3	1.5e-8	Prostate cancer;
CRC	cis	rs2811415	0.597	rs9869012	chr3:127728663	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.9	-0.31	8.84e-9	Lung function (FEV1/FVC);
CRC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.66	0.6	6.03e-34	Schizophrenia;
CRC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.34	5.79	0.3	1.67e-8	Major depressive disorder;
CRC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg23758597	chr6:163146217	PARK2	-0.56	-5.74	-0.3	2.2e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.46	8.55	0.43	4.58e-16	Educational attainment (years of education);
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	8.67	0.43	2.07e-16	Lymphocyte counts;
CRC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.9	10.29	0.49	1e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg20811857	chr17:78079795	GAA	-0.46	-6.69	-0.35	9.75e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.45	-6.45	-0.33	4.11e-10	Platelet distribution width;
CRC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.72	11.38	0.53	1.64e-25	Colorectal cancer;
CRC	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg23229984	chr5:148520753	ABLIM3	-0.47	-6.31	-0.33	8.8e-10	Breast cancer;
CRC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.73	11.82	0.55	4.15e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17261708	chr5:176794207	RGS14	0.48	7.82	0.4	7.35e-14	Hemoglobin concentration;Hematocrit;
CRC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg04267008	chr7:1944627	MAD1L1	-0.78	-10.95	-0.52	5.3e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs9595066	1.000	rs4942282	chr13:44708416	G/A	cg04068111	chr13:44716778	NA	-0.51	-6.46	-0.34	3.86e-10	Schizophrenia;
CRC	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.46	-6.01	-0.31	4.85e-9	Tuberculosis;
CRC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.67	-0.35	1.08e-10	Lung cancer;
CRC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.59	-6.88	-0.35	2.99e-11	Bronchopulmonary dysplasia;
CRC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.5	6.22	0.32	1.51e-9	Recombination rate (females);
CRC	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg14036092	chr11:66035641	RAB1B	-0.44	-5.79	-0.3	1.67e-8	Electroencephalogram traits;
CRC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.0	9.41	0.46	9.08e-19	Diabetic retinopathy;
CRC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.65e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7849270	1.000	rs10819464	chr9:131876277	G/A	cg13538475	chr9:131942899	NA	-0.3	-6.15	-0.32	2.22e-9	Blood metabolite ratios;
CRC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg12193833	chr17:30244370	NA	-0.74	-8.62	-0.43	2.87e-16	Hip circumference adjusted for BMI;
CRC	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.69	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.66	-0.57	3.36e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg16672083	chr15:72433130	SENP8	0.47	6.82	0.35	4.37e-11	Red blood cell count;
CRC	trans	rs11712655	1.000	rs9860731	chr3:135225679	G/T	cg14625040	chr2:6214447	NA	-0.44	-6.2	-0.32	1.7e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg05527609	chr1:210001259	C1orf107	-0.62	-6.72	-0.35	8.2e-11	Red blood cell count;
CRC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.51	7.25	0.37	2.92e-12	Cognitive function;
CRC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.63	10.91	0.52	7.39e-24	Schizophrenia;
CRC	trans	rs7027930	0.524	rs7029777	chr9:612433	A/G	cg27061366	chr19:13044373	FARSA	0.47	6.0	0.31	5.3e-9	Pulmonary function decline;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09192942	chr16:75682004	KARS;TERF2IP	0.43	6.79	0.35	5.17e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13198984	chr17:80129470	CCDC57	0.45	7.96	0.4	2.75e-14	Life satisfaction;
CRC	cis	rs2657888	0.628	rs2638335	chr12:56880672	C/T	cg23002907	chr12:56915593	RBMS2	-0.4	-6.28	-0.33	1.08e-9	Adiponectin levels;
CRC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.85	-14.73	-0.63	4.41e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7487075	0.893	rs4768116	chr12:46733030	G/T	cg22049899	chr12:47219821	SLC38A4	0.35	6.82	0.35	4.45e-11	Itch intensity from mosquito bite;
CRC	cis	rs3823572	0.564	rs10272509	chr7:133636302	A/G	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.75	-11.82	-0.55	4.23e-27	Prostate cancer;
CRC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.51	0.5	1.75e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7487075	0.859	rs7961994	chr12:46755112	A/T	cg22049899	chr12:47219821	SLC38A4	0.32	5.89	0.31	9.34e-9	Itch intensity from mosquito bite;
CRC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs4731207	0.967	rs2267708	chr7:124392512	C/T	cg23710748	chr7:124431027	NA	0.4	6.49	0.34	3.2e-10	Cutaneous malignant melanoma;
CRC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.41	8.67	0.43	2e-16	Urinary metabolites;
CRC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg00129232	chr17:37814104	STARD3	0.55	6.96	0.36	1.83e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	10.66	0.51	5.3e-23	Mean platelet volume;
CRC	trans	rs7165102	1.000	rs6494521	chr15:65739928	A/T	cg22383888	chr3:27764816	EOMES	-0.28	-5.99	-0.31	5.61e-9	Mean corpuscular hemoglobin;
CRC	cis	rs9549328	0.614	rs34306822	chr13:113616499	G/A	cg24588162	chr13:113633484	MCF2L	0.36	6.43	0.33	4.47e-10	Systolic blood pressure;
CRC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.97	-18.93	-0.72	1.36e-54	Height;
CRC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg10494973	chr17:80897199	TBCD	-0.36	-5.63	-0.3	3.9e-8	Breast cancer;
CRC	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.53	-8.2	-0.41	5.32e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05358749	chr7:23145602	KLHL7	0.47	7.18	0.37	4.82e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.54	5.96	0.31	6.36e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.45	-8.19	-0.41	5.98e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7739232	0.920	rs17216194	chr6:53528467	C/T	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.46	18.42	0.71	1.48e-52	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1124376	0.832	rs6793985	chr3:20136485	T/C	cg05072819	chr3:20081367	KAT2B	0.46	5.78	0.3	1.7e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03923535	chr7:1197113	ZFAND2A	0.51	7.61	0.39	2.89e-13	Longevity;Endometriosis;
CRC	cis	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg11900509	chr10:81946545	ANXA11	-0.72	-8.54	-0.43	4.91e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.46	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.8e-13	Colorectal cancer;
CRC	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.72	-11.89	-0.55	2.29e-27	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs891088	0.695	rs35296670	chr19:7198004	G/A	cg00428638	chr19:7224713	INSR	-0.62	-7.6	-0.39	3.04e-13	Hip circumference adjusted for BMI;Height;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10800280	chr6:36646508	CDKN1A	0.38	5.96	0.31	6.55e-9	Interleukin-6 levels;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg05569086	chr8:143859399	LYNX1	-0.4	-6.12	-0.32	2.59e-9	Urinary tract infection frequency;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.2	-0.32	1.68e-9	Cognitive function;
CRC	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.52	-7.37	-0.38	1.38e-12	Caudate activity during reward;
CRC	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-9.78	-0.47	5.52e-20	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	11.58	0.54	3.08e-26	Prudent dietary pattern;
CRC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.64	-9.74	-0.47	7.51e-20	Menopause (age at onset);
CRC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.52	7.2	0.37	4.23e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.69	-0.47	1.08e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs910187	0.624	rs6063077	chr20:45787261	C/T	cg27589058	chr20:45804311	EYA2	-0.34	-6.15	-0.32	2.24e-9	Migraine;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17156767	chr19:30364462	NA	0.41	6.55	0.34	2.27e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04433306	chr7:129592730	UBE2H	0.42	6.29	0.33	9.88e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg21620606	chr4:1342894	KIAA1530	0.51	8.19	0.41	5.9e-15	Obesity-related traits;
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg20340149	chr2:122407145	CLASP1	0.38	5.99	0.31	5.6e-9	Age-related macular degeneration;
CRC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.45	-6.41	-0.33	5.1e-10	Response to temozolomide;
CRC	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg13615338	chr4:55094005	PDGFRA	0.4	5.62	0.3	3.97e-8	Corneal astigmatism;
CRC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.44	6.71	0.35	8.71e-11	Coronary artery disease;
CRC	cis	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg26958806	chr6:27640298	NA	0.93	6.56	0.34	2.11e-10	Depression;
CRC	cis	rs847649	0.692	rs10279449	chr7:102462636	T/C	cg18108683	chr7:102477205	FBXL13	-0.67	-11.27	-0.53	3.85e-25	Morning vs. evening chronotype;
CRC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.72	0.35	7.98e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.44	6.28	0.33	1.07e-9	Cognitive ability;
CRC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.52	-8.8	-0.44	7.65e-17	Aortic root size;
CRC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.81	12.33	0.56	5.44e-29	Cognitive function;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-8.95	-0.44	2.65e-17	Schizophrenia;
CRC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.39e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs8099014	0.770	rs1135519	chr18:56117145	C/T	cg12907477	chr18:56117327	MIR122	0.47	5.97	0.31	6.1e-9	Platelet count;
CRC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.55	7.71	0.39	1.5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg24562669	chr7:97807699	LMTK2	0.43	7.06	0.36	9.7e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.33	-5.88	-0.31	1.01e-8	Menarche (age at onset);
CRC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.62	-0.3	3.99e-8	Total body bone mineral density;
CRC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.48	-7.56	-0.38	4.02e-13	Coronary artery disease;
CRC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.64	-11.93	-0.55	1.69e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.6	-7.92	-0.4	3.75e-14	Post bronchodilator FEV1;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Depression;
CRC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.75	0.39	1.17e-13	Axial length;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg06470822	chr6:28175283	NA	0.85	9.7	0.47	1.01e-19	Parkinson's disease;
CRC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg19041857	chr6:27730383	NA	-0.72	-6.75	-0.35	6.7e-11	Breast cancer;
CRC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.9	-0.36	2.65e-11	Mean corpuscular volume;
CRC	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.85	-15.05	-0.64	2.7e-39	Lewy body disease;
CRC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	1.01	20.26	0.75	7.99e-60	Headache;
CRC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.3	0.33	9.5e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	10.48	0.5	2.35e-22	Motion sickness;
CRC	cis	rs17641971	0.619	rs7013425	chr8:49953085	G/A	cg00325661	chr8:49890786	NA	0.36	6.27	0.33	1.11e-9	Blood metabolite levels;
CRC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg25456477	chr12:86230367	RASSF9	0.38	6.43	0.33	4.41e-10	Major depressive disorder;
CRC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.51	7.95	0.4	3.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg14847009	chr1:175162515	KIAA0040	0.29	6.55	0.34	2.26e-10	Alcohol dependence;
CRC	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg02336364	chr1:24764700	NIPAL3	-0.38	-6.64	-0.34	1.3e-10	Response to interferon beta in multiple sclerosis;
CRC	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg23112188	chr14:24563095	PCK2	-0.39	-7.57	-0.39	3.74e-13	IgG glycosylation;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.14	-0.45	6.6e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.39	-9.33	-0.46	1.6e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg15147215	chr3:52552868	STAB1	0.38	5.86	0.31	1.11e-8	Schizophrenia;
CRC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.58	0.39	3.46e-13	Motion sickness;
CRC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg20387954	chr3:183756860	HTR3D	0.46	7.81	0.4	7.86e-14	Anterior chamber depth;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.56	10.07	0.49	5.93e-21	Acylcarnitine levels;
CRC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-10.93	-0.52	6.27e-24	Hemoglobin concentration;
CRC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.73	-10.64	-0.51	6.46e-23	Schizophrenia;
CRC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.51	-10.67	-0.51	4.98e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs55702914	0.628	rs55813500	chr2:198389172	G/A	cg10820045	chr2:198174542	NA	0.33	5.88	0.31	1.02e-8	Major depression and alcohol dependence;
CRC	cis	rs1847505	0.559	rs1475496	chr13:61566031	G/C	cg14094164	chr13:61491000	NA	0.33	6.22	0.32	1.47e-9	Polychlorinated biphenyl levels;
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.72	9.56	0.47	2.94e-19	Alzheimer's disease;
CRC	trans	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg02869306	chr7:64672164	INTS4L1	-0.45	-6.45	-0.34	3.89e-10	Aortic root size;
CRC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg03037974	chr15:76606532	NA	-0.51	-7.61	-0.39	2.83e-13	Blood metabolite levels;
CRC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg14711859	chr11:8959438	ASCL3	0.44	7.4	0.38	1.13e-12	Immature fraction of reticulocytes;
CRC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.75	-12.38	-0.56	3.83e-29	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs58106596	0.800	rs67402940	chr2:232566499	T/C	cg01370599	chr3:116745421	NA	0.52	7.1	0.36	7.73e-12	White blood cell count;Lymphocyte counts;
CRC	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.54	10.43	0.5	3.5e-22	Age-related hearing impairment;
CRC	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg12856521	chr11:46389249	DGKZ	-0.48	-7.92	-0.4	3.77e-14	Leprosy;
CRC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.93	0.52	6.15e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.85	0.4	5.98e-14	Breast cancer;
CRC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.57	-7.15	-0.37	5.64e-12	Platelet distribution width;
CRC	trans	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg17903999	chr18:56338584	MALT1	0.42	7.01	0.36	1.37e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06938063	chr1:207925405	CD46	0.51	6.7	0.35	9.02e-11	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg03037974	chr15:76606532	NA	0.69	11.63	0.54	2.04e-26	Blood metabolite levels;
CRC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.58	7.11	0.36	7.3e-12	Response to diuretic therapy;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.39	-0.33	5.78e-10	Electroencephalogram traits;
CRC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.53	-8.49	-0.42	7.03e-16	Body mass index;
CRC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.64	-8.49	-0.42	7.39e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg14196790	chr5:131705035	SLC22A5	0.36	6.34	0.33	7.57e-10	Blood metabolite levels;
CRC	cis	rs3736485	0.844	rs62014659	chr15:51818591	G/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.73	-0.35	7.7e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.31	-0.46	1.82e-18	Migraine;Coronary artery disease;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22696252	chr3:97540975	NA	0.44	5.97	0.31	6.18e-9	Hip circumference;
CRC	cis	rs17092148	0.887	rs6058077	chr20:33140999	G/A	cg08999081	chr20:33150536	PIGU	0.5	6.34	0.33	7.36e-10	Neuroticism;
CRC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg23018236	chr17:30244563	NA	-0.65	-7.78	-0.39	9.41e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.63	-0.34	1.41e-10	Metabolite levels;
CRC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.51	-0.38	5.64e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.62	-0.39	2.67e-13	Breast cancer;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg24375607	chr4:120327624	NA	0.45	6.88	0.35	3.06e-11	Corneal astigmatism;
CRC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg13072238	chr3:49761600	GMPPB	0.52	5.68	0.3	2.91e-8	Menarche (age at onset);
CRC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.17	-0.32	1.97e-9	Daytime sleep phenotypes;
CRC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.61	-9.43	-0.46	7.53e-19	Dental caries;
CRC	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.75	0.54	7.16e-27	Coffee consumption (cups per day);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11276198	chr12:25404189	KRAS	0.44	6.2	0.32	1.72e-9	Anxiety disorder;
CRC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.94	14.88	0.63	1.17e-38	Parkinson's disease;
CRC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.88	-0.31	1.01e-8	Coronary artery disease;
CRC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.53	7.13	0.37	6.34e-12	Obesity-related traits;
CRC	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg23387468	chr7:139079360	LUC7L2	0.4	6.86	0.35	3.34e-11	Diisocyanate-induced asthma;
CRC	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.57	7.93	0.4	3.54e-14	Coronary artery disease;
CRC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.66	-11.26	-0.53	4.3e-25	Gout;
CRC	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg10167463	chr7:75959203	YWHAG	-0.38	-5.61	-0.3	4.35e-8	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.65	10.39	0.5	4.63e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20386705	chr6:38607295	BTBD9	0.44	6.25	0.33	1.3e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09380636	chr19:4791861	FEM1A	0.44	6.49	0.34	3.07e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg00166722	chr3:10149974	C3orf24	0.66	7.51	0.38	5.52e-13	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03984733	chr9:116139085	HDHD3	0.43	5.96	0.31	6.39e-9	Response to antipsychotic treatment;
CRC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.58	-8.56	-0.43	4.47e-16	Sudden cardiac arrest;
CRC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.63	-0.47	1.7e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.52	-7.33	-0.37	1.82e-12	Serum sulfate level;
CRC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.68	-12.57	-0.57	7.32e-30	Breast cancer;
CRC	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	1.05	9.84	0.48	3.29e-20	Arsenic metabolism;
CRC	cis	rs12760731	0.623	rs10798604	chr1:178254568	A/G	cg00404053	chr1:178313656	RASAL2	-0.63	-7.97	-0.4	2.6e-14	Obesity-related traits;
CRC	cis	rs11166927	0.901	rs7827091	chr8:140812044	G/C	cg16909799	chr8:140841666	TRAPPC9	0.37	5.72	0.3	2.37e-8	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.68	-11.14	-0.52	1.12e-24	Sudden cardiac arrest;
CRC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.55	8.26	0.41	3.49e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	6.36	0.33	6.65e-10	Urinary tract infection frequency;
CRC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg27535305	chr1:53392650	SCP2	0.39	6.97	0.36	1.72e-11	Monocyte count;
CRC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.66	-0.68	1.23e-45	Height;
CRC	cis	rs12541635	0.966	rs11782609	chr8:106967919	G/A	cg10147462	chr8:107024639	NA	0.43	6.9	0.36	2.7e-11	Age of smoking initiation;
CRC	cis	rs1124376	0.882	rs6791385	chr3:20136439	A/C	cg05072819	chr3:20081367	KAT2B	0.46	5.78	0.3	1.7e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.73	0.3	2.3e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg11212589	chr17:38028394	ZPBP2	0.34	6.02	0.32	4.64e-9	Asthma;
CRC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.75	-0.3	2.05e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-8.09	-0.41	1.13e-14	Testicular germ cell tumor;
CRC	trans	rs1200821	0.641	rs11011162	chr10:37674483	G/C	cg25427524	chr10:38739819	LOC399744	0.43	6.34	0.33	7.62e-10	Hemostatic factors and hematological phenotypes;
CRC	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.62e-12	Inflammatory skin disease;
CRC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.54	-7.96	-0.4	2.76e-14	Myeloid white cell count;
CRC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg22110888	chr17:80059540	CCDC57	-0.41	-6.46	-0.34	3.81e-10	Life satisfaction;
CRC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.81	7.92	0.4	3.59e-14	Fat distribution (HIV);
CRC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.53	-9.01	-0.44	1.73e-17	Aortic root size;
CRC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.66	9.28	0.46	2.32e-18	Vitamin D levels;
CRC	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	cg04338863	chr8:33670619	NA	-0.4	-6.2	-0.32	1.67e-9	Body mass index;
CRC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.74	8.89	0.44	4.18e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.7	-12.3	-0.56	7.44e-29	Prostate cancer;
CRC	cis	rs972578	1.000	rs11913527	chr22:43364634	G/C	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.42	6.96	0.36	1.86e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.46	-6.37	-0.33	6.3e-10	Lung cancer;
CRC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.82	15.42	0.65	9.44e-41	Metabolic syndrome;
CRC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg06970220	chr1:156163860	SLC25A44	0.5	7.05	0.36	1.05e-11	Testicular germ cell tumor;
CRC	cis	rs17152411	0.901	rs7098050	chr10:126657015	G/T	cg07906193	chr10:126599966	NA	0.59	6.02	0.31	4.78e-9	Height;
CRC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.66	-8.85	-0.44	5.42e-17	Systemic lupus erythematosus;
CRC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.24	0.33	1.33e-9	Mean platelet volume;
CRC	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	8.12	0.41	9.35e-15	Iron status biomarkers;
CRC	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00338735	chr4:53728038	RASL11B	0.43	5.65	0.3	3.51e-8	Optic nerve measurement (cup area);
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg21251018	chr6:28226885	NKAPL	0.47	7.22	0.37	3.59e-12	Cardiac Troponin-T levels;
CRC	cis	rs868943	0.582	rs34224224	chr6:116464219	A/T	cg15226275	chr6:116381976	FRK	0.26	6.08	0.32	3.31e-9	Total cholesterol levels;
CRC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.36	-6.53	-0.34	2.45e-10	Blood protein levels;
CRC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg27523141	chr10:43048294	ZNF37B	-0.44	-6.42	-0.33	4.79e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.73	0.35	7.6e-11	Ulcerative colitis;
CRC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.26	0.53	4.34e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.59	10.56	0.5	1.19e-22	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.8e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.68	11.58	0.54	3.17e-26	Height;
CRC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	16.99	0.68	6.29e-47	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-7.43	-0.38	9.24e-13	Aortic root size;
CRC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.42	7.9	0.4	4.19e-14	Childhood ear infection;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg03623178	chr6:28175578	NA	0.77	11.36	0.53	1.86e-25	Cardiac Troponin-T levels;
CRC	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-7.34	-0.37	1.73e-12	Response to antipsychotic treatment;
CRC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.0	0.36	1.44e-11	Rheumatoid arthritis;
CRC	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.25	15.0	0.64	4.06e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs728616	0.867	rs55835350	chr10:81801728	A/T	cg11900509	chr10:81946545	ANXA11	-0.57	-6.19	-0.32	1.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.45	-6.8	-0.35	4.92e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19721215	chr19:13001564	GCDH	0.42	6.1	0.32	2.98e-9	Intelligence (multi-trait analysis);
CRC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	-0.51	-8.22	-0.41	4.87e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.48	7.17	0.37	4.97e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.95	-0.36	1.92e-11	IgG glycosylation;
CRC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.32	0.33	8.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg25797454	chr6:150327115	RAET1K	0.38	6.47	0.34	3.51e-10	Alopecia areata;
CRC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-12.39	-0.56	3.29e-29	Dental caries;
CRC	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.39	6.63	0.34	1.39e-10	Sitting height ratio;
CRC	cis	rs629535	0.725	rs639127	chr8:70073251	A/G	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.51e-8	Dupuytren's disease;
CRC	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg12458913	chr13:53173898	NA	-0.53	-8.22	-0.41	4.8e-15	Lewy body disease;
CRC	trans	rs2055729	0.710	rs112406488	chr8:9736362	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.94	0.36	2.03e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.96	-19.7	-0.74	1.34e-57	Myeloid white cell count;
CRC	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.49	7.6	0.39	3.07e-13	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg15845792	chr6:28175446	NA	0.64	9.61	0.47	1.97e-19	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18387017	chr1:1167389	SDF4;B3GALT6	0.37	6.02	0.31	4.59e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs4308415	0.726	rs1390069	chr4:67802098	G/T	cg19648955	chr2:177134095	MTX2	-0.41	-5.99	-0.31	5.44e-9	Educational attainment (years of education);
CRC	cis	rs77972916	0.517	rs17406126	chr2:43546632	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.85	-0.31	1.21e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.25	-0.37	2.99e-12	Height;
CRC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.29	-0.42	2.88e-15	Chronic sinus infection;
CRC	trans	rs7299538	0.966	rs7963439	chr12:46084699	G/A	cg20672981	chr7:27242161	NA	-0.44	-6.07	-0.32	3.52e-9	Gut microbiome composition (winter);
CRC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.51	-9.21	-0.45	4.07e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg26875233	chr11:93583750	C11orf90	-0.33	-6.36	-0.33	6.89e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.51	8.01	0.4	1.96e-14	Height;
CRC	cis	rs17443541	0.507	rs10196380	chr2:200456655	G/C	cg03741458	chr2:200468445	NA	-0.36	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.78	14.56	0.63	2.02e-37	Prudent dietary pattern;
CRC	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.06e-17	Dupuytren's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15555727	chr8:144692268	PYCRL	0.43	6.37	0.33	6.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg10760299	chr15:45669010	GATM	0.5	7.82	0.4	7.18e-14	Homoarginine levels;
CRC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.56	7.15	0.37	5.72e-12	Mean platelet volume;
CRC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg24503407	chr1:205819492	PM20D1	0.46	6.23	0.32	1.46e-9	Parkinson's disease;
CRC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg07274523	chr3:49395745	GPX1	0.47	6.34	0.33	7.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00166722	chr3:10149974	C3orf24	0.64	8.73	0.43	1.3e-16	Alzheimer's disease;
CRC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.67	11.1	0.52	1.53e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg18876405	chr7:65276391	NA	0.44	6.15	0.32	2.3e-9	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23893906	chr12:6798535	ZNF384	-0.39	-5.97	-0.31	6e-9	Myopia (pathological);
CRC	cis	rs6743376	0.556	rs957201	chr2:113821200	T/C	cg24553058	chr2:113831203	IL1F10	0.43	7.15	0.37	5.56e-12	Inflammatory biomarkers;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg25164649	chr6:28176230	NA	0.64	8.97	0.44	2.29e-17	Cardiac Troponin-T levels;
CRC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	11.2	0.53	7.07e-25	Hip circumference adjusted for BMI;
CRC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg15448220	chr1:150897856	SETDB1	0.48	6.86	0.35	3.44e-11	Melanoma;
CRC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg03690763	chr11:133734501	NA	-0.34	-5.72	-0.3	2.37e-8	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00515161	chr17:59940900	BRIP1	-0.48	-7.52	-0.38	5.21e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg18833306	chr6:118973337	C6orf204	0.44	5.71	0.3	2.54e-8	Diastolic blood pressure;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg23978390	chr7:1156363	C7orf50	0.52	5.87	0.31	1.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-7.87	-0.4	5.21e-14	Longevity;
CRC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.47	7.04	0.36	1.11e-11	Menopause (age at onset);
CRC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg05132306	chr1:1846340	CALML6	-0.44	-6.8	-0.35	4.84e-11	Body mass index;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg26182253	chr13:112236782	NA	-0.31	-6.25	-0.33	1.24e-9	Hepatitis;
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.16	-0.32	2.14e-9	Bipolar disorder;
CRC	cis	rs911119	0.913	rs6106685	chr20:23581612	A/C	cg16589663	chr20:23618590	CST3	0.42	5.81	0.3	1.51e-8	Chronic kidney disease;
CRC	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.83	-0.31	1.33e-8	Endometrial cancer;
CRC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.6	8.5	0.42	6.56e-16	Homoarginine levels;
CRC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.45	-6.46	-0.34	3.87e-10	High light scatter reticulocyte count;
CRC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	8.96	0.44	2.38e-17	Monocyte percentage of white cells;
CRC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg00579200	chr11:133705235	NA	-0.39	-5.65	-0.3	3.48e-8	Childhood ear infection;
CRC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.49	-5.69	-0.3	2.76e-8	Menarche (age at onset);
CRC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.7	-0.51	3.9e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	6.44	0.33	4.13e-10	Initial pursuit acceleration;
CRC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10624583	chr12:53440492	TENC1	0.49	7.35	0.38	1.57e-12	Response to antipsychotic treatment;
CRC	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg20608306	chr11:116969690	SIK3	0.34	6.43	0.33	4.49e-10	Subjective well-being;
CRC	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg25547332	chr5:131281432	NA	0.39	5.95	0.31	6.82e-9	Life satisfaction;
CRC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.62	9.52	0.46	3.84e-19	Birth weight;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16402443	chr7:2598526	IQCE	0.45	7.18	0.37	4.58e-12	Obesity-related traits;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg15786705	chr6:28176104	NA	-0.82	-12.03	-0.55	7.19e-28	Depression;
CRC	cis	rs7572644	0.582	rs7570730	chr2:28022675	G/A	cg27432699	chr2:27873401	GPN1	0.45	5.66	0.3	3.27e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg13385794	chr1:248469461	NA	0.39	6.93	0.36	2.28e-11	Common traits (Other);
CRC	cis	rs8044868	0.530	rs9932951	chr16:72075341	A/G	cg23815491	chr16:72088622	HP	0.48	6.81	0.35	4.56e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg04202892	chr2:111875749	ACOXL	0.43	7.04	0.36	1.11e-11	Chronic lymphocytic leukemia;
CRC	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.74	0.47	7.5599999999999994e-20	Bipolar disorder;
CRC	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg25182066	chr10:30743637	MAP3K8	-0.4	-5.77	-0.3	1.83e-8	Inflammatory bowel disease;
CRC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	6.14	0.32	2.37e-9	Diabetic retinopathy;
CRC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.25	-0.33	1.25e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-0.83	-9.03	-0.45	1.48e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	6.89	0.36	2.77e-11	Menarche (age at onset);
CRC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.36	-6.55	-0.34	2.25e-10	Monobrow;
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg09658497	chr7:2847517	GNA12	-0.4	-5.61	-0.3	4.29e-8	Height;
CRC	cis	rs501120	0.925	rs1746052	chr10:44778546	G/T	cg09554077	chr10:44749378	NA	-0.81	-10.9	-0.51	8.26e-24	Coronary artery disease;Coronary heart disease;
CRC	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg06172871	chr16:72088244	HP	0.43	6.36	0.33	6.92e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.09	18.38	0.71	2.07e-52	Cognitive function;
CRC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16931877	chr3:32726605	CNOT10	0.38	6.63	0.34	1.34e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.32	-0.33	8.73e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11688874	chr10:28822482	WAC	0.48	6.91	0.36	2.54e-11	Response to antipsychotic treatment;
CRC	cis	rs2969070	0.965	rs9691234	chr7:2508415	A/G	cg03277898	chr7:2518824	NA	-0.43	-6.15	-0.32	2.2e-9	Diastolic blood pressure;
CRC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg24562669	chr7:97807699	LMTK2	0.79	17.64	0.7	1.72e-49	Breast cancer;
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.34	-5.69	-0.3	2.79e-8	Lung cancer;
CRC	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-1.1	-12.97	-0.58	2.41e-31	Blood pressure (smoking interaction);
CRC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.1	0.32	2.95e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.59	10.05	0.48	6.89e-21	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18890864	chr5:131826458	IRF1	0.4	6.21	0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.8	-0.3	1.55e-8	Breast cancer;
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02290350	chr8:58132656	NA	-0.57	-7.92	-0.4	3.81e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18301423	chr5:131593218	PDLIM4	0.37	6.78	0.35	5.42e-11	Breast cancer;
CRC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg02089348	chr4:1724449	TMEM129;TACC3	0.4	5.73	0.3	2.21e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg08034379	chr2:228736324	WDR69	-0.54	-7.27	-0.37	2.62e-12	Blood pressure;
CRC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg27490568	chr2:178487706	NA	0.38	5.64	0.3	3.69e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02018176	chr4:1364513	KIAA1530	0.48	7.93	0.4	3.43e-14	Obesity-related traits;
CRC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.71	-9.21	-0.45	4.03e-18	Initial pursuit acceleration;
CRC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02376097	chr19:46275166	DMPK	0.38	6.02	0.32	4.63e-9	Coronary artery disease;
CRC	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.38	-6.32	-0.33	8.54e-10	Mean arterial pressure;
CRC	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.62	9.17	0.45	5.2e-18	Morning vs. evening chronotype;
CRC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg07125278	chr16:67683757	RLTPR	-0.49	-6.77	-0.35	5.9e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2860975	1.000	rs7920659	chr10:96767924	T/C	cg09036531	chr10:96991505	NA	-0.43	-5.95	-0.31	6.79e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.45	-7.21	-0.37	3.93e-12	Neurofibrillary tangles;
CRC	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg00105475	chr2:10696890	NA	0.46	7.17	0.37	5.09e-12	Prostate cancer;
CRC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.76	-0.35	6.38e-11	Monocyte percentage of white cells;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.43	7.27	0.37	2.58e-12	Lung cancer;
CRC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	6.11	0.32	2.86e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	trans	rs820077	0.557	rs6457807	chr6:35142899	T/C	cg23173586	chr14:20945319	PNP	-0.29	-6.04	-0.32	4.09e-9	Systemic lupus erythematosus;
CRC	cis	rs9928842	0.771	rs2870471	chr16:75274282	A/G	cg08657710	chr16:75258780	CTRB1	0.47	6.1	0.32	2.93e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.56	0.43	4.49e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg23996704	chr18:44553084	KATNAL2	-0.3	-5.9	-0.31	8.93e-9	Personality dimensions;
CRC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.97	-0.68	7.73e-47	Electrocardiographic conduction measures;
CRC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg14324370	chr2:177042789	NA	0.81	13.12	0.59	6.36e-32	IgG glycosylation;
CRC	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs4728302	0.869	rs11770927	chr7:133593126	G/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.56	-0.34	2.04e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.55	0.38	4.28e-13	Motion sickness;
CRC	cis	rs7725052	0.609	rs9292778	chr5:40443296	A/G	cg09067459	chr5:40385259	NA	-0.4	-6.6	-0.34	1.68e-10	Pediatric autoimmune diseases;
CRC	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg08823186	chr16:347294	AXIN1	0.42	6.42	0.33	4.82e-10	Morning vs. evening chronotype;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06446895	chr17:79829189	ARHGDIA	0.48	6.69	0.35	9.49e-11	Survival in pancreatic cancer;
CRC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.43	-0.33	4.36e-10	Monocyte count;
CRC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.53	7.81	0.4	7.65e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.49	7.45	0.38	8.47e-13	Corneal astigmatism;
CRC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05507819	chr15:63340323	TPM1	0.39	5.79	0.3	1.66e-8	Platelet count;
CRC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.65	-17.68	-0.7	1.16e-49	Urate levels in overweight individuals;
CRC	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.7	8.85	0.44	5.59e-17	Hip circumference adjusted for BMI;
CRC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg19193384	chr17:30244184	NA	-0.67	-7.78	-0.39	9.36e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16447950	chr5:562315	NA	-0.77	-10.13	-0.49	3.62e-21	Obesity-related traits;
CRC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.19	-17.01	-0.68	5.15e-47	Hip circumference adjusted for BMI;
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.52	9.73	0.47	8.03e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.53	7.42	0.38	9.99e-13	Graves' disease;
CRC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.96	-18.51	-0.71	6.51e-53	Height;
CRC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg00198680	chr16:28758506	NA	0.35	5.73	0.3	2.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg26868354	chr6:35699952	LOC285847	-0.45	-6.21	-0.32	1.56e-9	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26566046	chr12:80083628	PAWR	0.42	6.71	0.35	8.63e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.75	11.36	0.53	1.95e-25	Breast cancer;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg25164649	chr6:28176230	NA	0.65	8.57	0.43	4.18e-16	Parkinson's disease;
CRC	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg06092702	chr1:163392909	NA	-0.39	-6.05	-0.32	3.87e-9	Motion sickness;
CRC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.69	8.99	0.44	1.97e-17	Bladder cancer;
CRC	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.44	-6.44	-0.33	4.32e-10	Body mass index;
CRC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg02931644	chr1:25747376	RHCE	-0.34	-5.8	-0.3	1.52e-8	Erythrocyte sedimentation rate;
CRC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg12658694	chr1:38397304	INPP5B	0.51	7.16	0.37	5.17e-12	Coronary artery disease;
CRC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-12.54	-0.57	9.61e-30	Prostate cancer;
CRC	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg13206674	chr6:150067644	NUP43	0.43	5.64	0.3	3.57e-8	Lung cancer;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.78	12.0	0.55	9.33e-28	Menarche (age at onset);
CRC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg24699146	chr1:24152579	HMGCL	-0.32	-5.67	-0.3	3.1e-8	Immature fraction of reticulocytes;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.63	6.54	0.34	2.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.65	8.96	0.44	2.52e-17	Morning vs. evening chronotype;
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg18758796	chr5:131593413	PDLIM4	0.34	6.32	0.33	8.46e-10	Blood metabolite levels;
CRC	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.51	-0.38	5.56e-13	Type 2 diabetes;
CRC	cis	rs860772	0.500	rs857683	chr1:158574585	G/A	cg12129480	chr1:158549410	OR10X1	-0.26	-5.63	-0.3	3.82e-8	Lymphocyte percentage of white cells;
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg22110888	chr17:80059540	CCDC57	0.4	6.35	0.33	7.28e-10	Life satisfaction;
CRC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg00587665	chr15:100533223	ADAMTS17	-0.45	-7.46	-0.38	7.69e-13	Height;
CRC	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.45	-0.53	8.9e-26	Colorectal cancer;
CRC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg13206674	chr6:150067644	NUP43	0.52	7.15	0.37	5.81e-12	Testicular germ cell tumor;
CRC	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.49	-6.06	-0.32	3.7e-9	Coronary artery calcification;
CRC	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Dilated cardiomyopathy;
CRC	cis	rs554111	0.509	rs495522	chr1:21105994	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.61	-0.3	4.25e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs939584	1.000	rs4429506	chr2:652576	C/A	cg03610516	chr2:642275	NA	0.41	5.92	0.31	8.24e-9	Body mass index;
CRC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg14196790	chr5:131705035	SLC22A5	-0.35	-5.77	-0.3	1.79e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08715135	chr8:126442747	TRIB1	-0.53	-6.47	-0.34	3.6e-10	Diisocyanate-induced asthma;
CRC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.35	8.03	0.4	1.73e-14	Corneal astigmatism;
CRC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg09264619	chr17:80180166	NA	0.36	5.86	0.31	1.11e-8	Life satisfaction;
CRC	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.6	-6.83	-0.35	4.07e-11	Gastritis;
CRC	cis	rs3789045	0.913	rs55678522	chr1:204573481	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.53	-7.54	-0.38	4.48e-13	Educational attainment (college completion);
CRC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.48	-6.07	-0.32	3.62e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs2018683	0.600	rs717891	chr7:29000374	C/T	cg19402173	chr7:128379420	CALU	-0.48	-6.57	-0.34	2.02e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs55675132	0.510	rs6696332	chr1:115300370	T/C	cg12756093	chr1:115239321	AMPD1	0.54	6.23	0.32	1.42e-9	Schizophrenia;
CRC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.48	6.76	0.35	6.28e-11	Lung cancer;
CRC	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.13	17.08	0.69	2.71e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-6.31	-0.33	8.95e-10	Body mass index;
CRC	trans	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg13565492	chr6:43139072	SRF	-0.72	-7.43	-0.38	9.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.52	6.57	0.34	1.98e-10	Alzheimer's disease (survival time);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04516253	chr19:40596853	ZNF780A	-0.38	-6.04	-0.32	4.08e-9	Aortic root size;
CRC	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	8.71	0.43	1.49e-16	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.43	6.9	0.36	2.64e-11	Sitting height ratio;
CRC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.55	8.8	0.44	7.72e-17	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.13e-12	Corneal astigmatism;
CRC	trans	rs7027930	0.520	rs4384034	chr9:607005	C/G	cg27061366	chr19:13044373	FARSA	0.51	6.29	0.33	1e-9	Pulmonary function decline;
CRC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.45	-6.09	-0.32	3.2e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.33	6.77	0.35	6.02e-11	Alzheimer's disease (late onset);
CRC	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18252515	chr7:66147081	NA	0.41	6.04	0.32	4.12e-9	Aortic root size;
CRC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.43	6.75	0.35	6.49e-11	Osteoporosis;
CRC	cis	rs9513593	1.000	rs747848	chr13:100036182	C/T	cg21788972	chr13:99853209	UBAC2	0.43	5.6	0.3	4.5e-8	Psoriasis;
CRC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.46	6.27	0.33	1.12e-9	Aortic root size;
CRC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.46	7.25	0.37	2.97e-12	Type 2 diabetes;
CRC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Bladder cancer;
CRC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg27087555	chr16:88793112	FAM38A	0.5	5.69	0.3	2.77e-8	Autism spectrum disorder-related traits;
CRC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.68	10.35	0.5	6.24e-22	Menopause (age at onset);
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg25164649	chr6:28176230	NA	0.54	7.8	0.4	8.06e-14	Parkinson's disease;
CRC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg15465823	chr12:48382534	COL2A1	-0.39	-6.41	-0.33	4.9e-10	Glycated hemoglobin levels;
CRC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg00990874	chr7:1149470	C7orf50	-0.62	-7.7	-0.39	1.59e-13	Bronchopulmonary dysplasia;
CRC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.69	-11.85	-0.55	3.36e-27	Dental caries;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg20512303	chr5:131592959	PDLIM4	-0.4	-6.83	-0.35	4.06e-11	Breast cancer;
CRC	trans	rs7395662	0.674	rs7124275	chr11:48162305	C/T	cg21153622	chr11:89784906	NA	-0.41	-6.27	-0.33	1.12e-9	HDL cholesterol;
CRC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12292205	chr6:26970375	C6orf41	-0.47	-6.48	-0.34	3.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg15786705	chr6:28176104	NA	0.49	6.49	0.34	3.18e-10	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11992237	chr8:74791052	UBE2W	0.42	6.97	0.36	1.69e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	5.94	0.31	7.37e-9	Asthma;
CRC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.75	10.95	0.52	5.53e-24	Schizophrenia;
CRC	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.57	8.18	0.41	6.1e-15	Testicular germ cell tumor;
CRC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.07e-9	Crohn's disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06463759	chr7:128502823	ATP6V1F	0.47	6.65	0.34	1.19e-10	Survival in pancreatic cancer;
CRC	cis	rs7429990	0.965	rs7642590	chr3:48099750	G/A	cg11946769	chr3:48343235	NME6	-0.47	-6.01	-0.31	5.01e-9	Educational attainment (years of education);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10310846	chr10:28821381	WAC	0.45	6.02	0.31	4.75e-9	Anxiety disorder;
CRC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	8.2	0.41	5.37e-15	Body mass index;
CRC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.72	10.69	0.51	4.31e-23	Immature fraction of reticulocytes;
CRC	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.32	16.01	0.66	4.44e-43	Uric acid levels;
CRC	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.59	-7.77	-0.39	1.01e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg12365402	chr11:9010492	NRIP3	0.54	8.85	0.44	5.45e-17	Hemoglobin concentration;
CRC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.53	5.78	0.3	1.72e-8	Vitiligo;
CRC	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.62	10.45	0.5	2.87e-22	Tuberculosis;
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.75	-0.3	1.99e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.73	12.35	0.56	4.89e-29	Body mass index;
CRC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg01472538	chr16:58549086	SETD6	1.06	6.94	0.36	2.05e-11	Schizophrenia;
CRC	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.57	8.54	0.43	4.9e-16	Lewy body disease;
CRC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.67	10.66	0.51	5.57e-23	Sudden cardiac arrest;
CRC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.61	9.67	0.47	1.25e-19	Breast cancer;
CRC	cis	rs3736485	0.966	rs9920124	chr15:51908942	T/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.53	-0.34	2.57e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.52	-7.97	-0.4	2.55e-14	Schizophrenia;
CRC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.61	-9.2	-0.45	4.25e-18	Blood pressure (smoking interaction);
CRC	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg09655341	chr17:79618100	PDE6G	0.59	6.96	0.36	1.85e-11	Dental caries;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03662217	chr21:35747882	FAM165B	0.48	6.18	0.32	1.87e-9	Thyroid stimulating hormone;
CRC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.08	0.36	8.85e-12	Rheumatoid arthritis;
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.14e-9	Prudent dietary pattern;
CRC	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.74	0.43	1.2e-16	Mean corpuscular volume;
CRC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4936891	0.577	rs12224791	chr11:123919128	A/G	cg22125253	chr11:123886957	OR10G4	-0.3	-5.68	-0.3	2.92e-8	Male fertility;
CRC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	7.87	0.4	5.3e-14	Response to antipsychotic treatment;
CRC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.46	-5.62	-0.3	4.06e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg17321639	chr7:2759063	NA	-0.37	-5.66	-0.3	3.34e-8	Height;
CRC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg27661571	chr11:113659931	NA	-0.77	-9.59	-0.47	2.24e-19	Hip circumference adjusted for BMI;
CRC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.6	9.36	0.46	1.31e-18	Coronary artery disease;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg06470822	chr6:28175283	NA	0.84	9.56	0.47	2.85e-19	Parkinson's disease;
CRC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.57	9.35	0.46	1.38e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg02007433	chr3:129722099	NA	-0.46	-6.25	-0.33	1.27e-9	Blood pressure (smoking interaction);
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.42	5.99	0.31	5.39e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11989122	0.543	rs4876390	chr8:118808566	A/G	cg02216535	chr4:85308929	NA	-0.38	-6.39	-0.33	5.74e-10	Height;
CRC	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.39e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19856771	chr13:42780042	DGKH	0.46	7.55	0.38	4.46e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-7.01	-0.36	1.39e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9938149	0.706	rs7198116	chr16:88318648	T/C	cg05435882	chr16:88311214	NA	-0.46	-6.12	-0.32	2.59e-9	Corneal structure;Central corneal thickness;
CRC	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.99	-0.31	5.57e-9	Endometrial cancer;
CRC	cis	rs834811	0.583	rs4732179	chr7:135873681	C/T	cg01726295	chr7:135938950	NA	0.35	6.06	0.32	3.81e-9	Post-traumatic stress disorder;
CRC	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.72	8.71	0.43	1.5e-16	Exhaled nitric oxide output;
CRC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.53	-5.81	-0.31	1.47e-8	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
CRC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.84	-0.44	5.75e-17	Bipolar disorder;
CRC	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg15571903	chr15:79123663	NA	0.34	6.92	0.36	2.4e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.54	0.47	3.4e-19	Birth weight;
CRC	cis	rs10971721	0.822	rs10971773	chr9:33898779	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13692869	chr1:169336982	NME7;BLZF1	0.42	6.27	0.33	1.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2257205	0.667	rs74961279	chr17:56904991	C/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.85	-0.31	1.2e-8	Pancreatic cancer;
CRC	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.39	5.97	0.31	6.03e-9	Red blood cell count;
CRC	cis	rs2062225	1.000	rs10180604	chr2:111760987	A/G	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg26762873	chr11:5879799	OR52E8	-0.48	-7.16	-0.37	5.39e-12	DNA methylation (variation);
CRC	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg07424746	chr4:185654737	MLF1IP	-0.6	-5.84	-0.31	1.25e-8	Blood protein levels;
CRC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.93	17.78	0.7	4.82e-50	Height;
CRC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg00786952	chr1:21763130	NA	0.49	8.42	0.42	1.15e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.85	-0.31	1.21e-8	Total body bone mineral density;
CRC	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.56	-6.25	-0.33	1.26e-9	Type 2 diabetes;
CRC	cis	rs4604732	0.588	rs4356092	chr1:247632668	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.49	7.61	0.39	2.93e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg23034840	chr1:205782522	SLC41A1	0.49	6.53	0.34	2.48e-10	Menarche (age at onset);
CRC	cis	rs1847505	0.609	rs9538998	chr13:61571160	A/G	cg14094164	chr13:61491000	NA	0.32	6.25	0.33	1.28e-9	Polychlorinated biphenyl levels;
CRC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.69	9.3	0.46	2.03e-18	High light scatter reticulocyte count;
CRC	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg09695851	chr17:3907499	NA	0.47	6.01	0.31	4.79e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.46	-0.38	7.6e-13	Mean platelet volume;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.72	-11.28	-0.53	3.75e-25	Menarche (age at onset);
CRC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.52	7.55	0.38	4.24e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.8	-14.27	-0.62	2.69e-36	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.61	-9.62	-0.47	1.8e-19	Testicular germ cell tumor;
CRC	cis	rs77861329	1.000	rs352149	chr3:52209530	C/A	cg08692210	chr3:52188851	WDR51A	0.83	7.81	0.4	7.57e-14	Macrophage inflammatory protein 1b levels;
CRC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.6	-8.23	-0.41	4.37e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg26162295	chr17:38119207	GSDMA	-0.34	-5.67	-0.3	3.09e-8	Myeloid white cell count;
CRC	cis	rs2415984	0.579	rs12147928	chr14:46972569	C/T	cg14871534	chr14:47121158	RPL10L	0.4	6.18	0.32	1.91e-9	Number of children ever born;
CRC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.87e-24	Motion sickness;
CRC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.51	0.42	6.25e-16	Height;
CRC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01429635	chr16:4357936	NA	-0.53	-6.29	-0.33	1.01e-9	Diisocyanate-induced asthma;
CRC	trans	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg21302420	chr1:112162376	RAP1A	0.66	6.31	0.33	8.91e-10	Skin colour saturation;
CRC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.13	-0.32	2.53e-9	Daytime sleep phenotypes;
CRC	cis	rs10924970	0.967	rs1933251	chr1:235451172	G/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.77	0.3	1.87e-8	Asthma;
CRC	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg00105475	chr2:10696890	NA	0.45	7.31	0.37	2.1e-12	Prostate cancer;
CRC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg17724175	chr1:150552817	MCL1	0.47	7.07	0.36	9.3e-12	Melanoma;
CRC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.74	-11.37	-0.53	1.69e-25	Platelet distribution width;
CRC	cis	rs11587400	0.634	rs4839385	chr1:115121461	A/G	cg12756093	chr1:115239321	AMPD1	0.43	5.85	0.31	1.18e-8	Autism;
CRC	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.59	-8.82	-0.44	6.91e-17	Multiple sclerosis;
CRC	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.7	-0.43	1.59e-16	Coffee consumption (cups per day);
CRC	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	6.5	0.34	2.95e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.46	-7.03	-0.36	1.17e-11	Monocyte count;
CRC	cis	rs2108622	0.727	rs62107770	chr19:15985425	A/G	cg13772218	chr19:15982569	NA	0.48	6.84	0.35	3.96e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	5.99	0.31	5.39e-9	Diabetic retinopathy;
CRC	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.74	7.69	0.39	1.73e-13	Pulse pressure;
CRC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg15468180	chr1:107600409	PRMT6	0.43	6.42	0.33	4.68e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg20811857	chr17:78079795	GAA	-0.44	-6.3	-0.33	9.63e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg17691542	chr6:26056736	HIST1H1C	0.48	7.28	0.37	2.45e-12	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06671706	chr8:8559999	CLDN23	-0.56	-8.25	-0.41	3.76e-15	Obesity-related traits;
CRC	cis	rs6968419	0.747	rs3757730	chr7:115882323	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.35	-0.33	7.09e-10	Intraocular pressure;
CRC	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.61	-7.6	-0.39	3.07e-13	Hair shape;
CRC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.49	7.24	0.37	3.1e-12	Corneal astigmatism;
CRC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.64	10.38	0.5	5.13e-22	Height;
CRC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.3	0.53	3.18e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.56	9.45	0.46	6.32e-19	Schizophrenia;
CRC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.72	-11.15	-0.52	1.05e-24	Cognitive function;
CRC	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.58	-10.01	-0.48	9.02e-21	Liver enzyme levels;
CRC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.57	-7.75	-0.39	1.18e-13	Coronary artery disease;
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.57	-0.5	1.14e-22	Bipolar disorder;
CRC	cis	rs6681460	1.000	rs9662962	chr1:67121364	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.38	0.42	1.54e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.81	11.17	0.52	9.08e-25	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg03030879	chr14:75389066	RPS6KL1	0.4	6.18	0.32	1.9e-9	Height;
CRC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.5	7.33	0.37	1.77e-12	Platelet distribution width;
CRC	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.43	6.92	0.36	2.4e-11	Coronary artery disease;
CRC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg08213375	chr14:104286397	PPP1R13B	0.57	11.68	0.54	1.31e-26	Schizophrenia;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg08461752	chr10:43522343	NA	-0.82	-7.57	-0.38	3.91e-13	Pediatric bone mineral content (radius);
CRC	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg06204229	chr3:52865917	ITIH4	0.58	7.91	0.4	3.9e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.59	7.88	0.4	4.94e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17261708	chr5:176794207	RGS14	-0.6	-8.9	-0.44	3.71e-17	Hemoglobin concentration;Hematocrit;
CRC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.48	-7.77	-0.39	1.04e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.5	0.38	6.17e-13	Height;
CRC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg19223190	chr17:80058835	NA	-0.44	-6.96	-0.36	1.9e-11	Life satisfaction;
CRC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.51	-7.39	-0.38	1.22e-12	Multiple sclerosis;
CRC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg24562669	chr7:97807699	LMTK2	0.44	7.32	0.37	1.97e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.38	-0.38	1.32e-12	Endometrial cancer;
CRC	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.43	5.81	0.31	1.46e-8	Colorectal cancer;
CRC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.4	-6.7	-0.35	8.89e-11	Height;
CRC	cis	rs672059	1.000	rs522372	chr1:183157449	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.5	-7.28	-0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.11	-13.96	-0.61	4.06e-35	Vitiligo;
CRC	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.1	9.36	0.46	1.31e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.58	-0.39	3.67e-13	Superior frontal gyrus grey matter volume;
CRC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.89	-0.48	2.27e-20	Height;
CRC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	7.58	0.39	3.5e-13	Mean platelet volume;
CRC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg10398005	chr11:117014888	PAFAH1B2	0.42	6.17	0.32	1.97e-9	Blood protein levels;
CRC	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg25182066	chr10:30743637	MAP3K8	0.47	6.34	0.33	7.4e-10	Inflammatory bowel disease;
CRC	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.45	9.75	0.47	6.87e-20	Prostate cancer;
CRC	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.67	10.5	0.5	1.99e-22	Corneal astigmatism;
CRC	cis	rs11681884	0.710	rs928940	chr2:113877495	G/T	cg09040174	chr2:113837401	NA	0.52	5.64	0.3	3.63e-8	Stroke;
CRC	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.79	-12.48	-0.57	1.54e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02970861	chr11:62359288	TUT1	0.42	6.0	0.31	5.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.55	8.4	0.42	1.32e-15	Calcium levels;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01638175	chr3:49171179	LAMB2	0.4	6.53	0.34	2.54e-10	Myopia (pathological);
CRC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	8.38	0.42	1.54e-15	Mood instability;
CRC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.41	-5.87	-0.31	1.06e-8	Alzheimer's disease (late onset);
CRC	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.42	6.71	0.35	8.63e-11	Sitting height ratio;
CRC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg22110888	chr17:80059540	CCDC57	-0.43	-6.69	-0.35	9.49e-11	Life satisfaction;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg20160996	chr11:63990575	FERMT3	0.41	6.57	0.34	2.02e-10	Platelet count;
CRC	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.56	0.43	4.53e-16	Coffee consumption (cups per day);
CRC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.41	-0.59	5.15e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.55	-8.71	-0.43	1.54e-16	Height;
CRC	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg00531865	chr16:30841666	NA	0.47	6.78	0.35	5.6e-11	Dementia with Lewy bodies;
CRC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.38	5.97	0.31	6.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3764400	0.508	rs978263	chr17:46180664	A/G	cg10706073	chr17:46328419	SKAP1	0.61	6.62	0.34	1.44e-10	Body mass index;
CRC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.44	8.07	0.41	1.3e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg17885191	chr8:135476712	NA	0.52	7.17	0.37	5.13e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.26	0.33	1.19e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.7	11.58	0.54	2.96e-26	Colorectal cancer;
CRC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.7	-11.6	-0.54	2.55e-26	Ulcerative colitis;
CRC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg04880052	chr2:219191631	PNKD	-0.4	-6.6	-0.34	1.64e-10	Colorectal cancer;
CRC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.45	6.5	0.34	3.01e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-6.56	-0.34	2.05e-10	Coronary artery disease;
CRC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-7.34	-0.38	1.71e-12	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.01	16.12	0.66	1.76e-43	Cognitive function;
CRC	cis	rs10894147	0.756	rs1783916	chr11:129757099	G/A	cg27255275	chr11:129766154	NFRKB	0.41	5.72	0.3	2.44e-8	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg08888203	chr3:10149979	C3orf24	0.6	8.47	0.42	8.55e-16	Alzheimer's disease;
CRC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg18904891	chr8:8559673	CLDN23	0.48	6.63	0.34	1.4e-10	Obesity-related traits;
CRC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	9.85	0.48	3.09e-20	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg15763984	chr4:1342303	KIAA1530	0.34	5.76	0.3	1.89e-8	Obesity-related traits;
CRC	cis	rs12612619	0.704	rs6714547	chr2:27321206	T/G	cg00617064	chr2:27272375	NA	-0.36	-5.84	-0.31	1.27e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.7	-0.43	1.64e-16	Smoking initiation;
CRC	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.89	-13.87	-0.61	8.84e-35	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16740543	chr6:170123723	PHF10	0.44	6.44	0.33	4.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.84	-0.31	1.27e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.43	5.83e-16	Colorectal cancer;
CRC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.49	0.42	7.08e-16	Menarche (age at onset);
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.43	-0.38	9.15e-13	Bipolar disorder;
CRC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.43	-7.1	-0.36	7.66e-12	Migraine;
CRC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.48	6.7	0.35	8.9e-11	Lung cancer;
CRC	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.48	-9.05	-0.45	1.27e-17	Hepatitis;
CRC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.6	9.72	0.47	8.33e-20	Height;
CRC	cis	rs174479	0.677	rs174456	chr11:61656182	G/T	cg01500311	chr11:61656094	FADS3	0.35	5.65	0.3	3.55e-8	Sphingolipid levels;
CRC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.87	-16.19	-0.67	8.67e-44	Dementia with Lewy bodies;
CRC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.68	-11.3	-0.53	3.19e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.47	7.64	0.39	2.35e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10493356	chr22:31608270	LIMK2	0.49	6.96	0.36	1.85e-11	Anxiety disorder;
CRC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.45	-0.38	8.53e-13	Psoriasis;
CRC	cis	rs7212590	0.748	rs59685433	chr17:57891207	T/C	cg10252138	chr17:58120427	NA	-0.54	-5.64	-0.3	3.73e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.54	8.26	0.41	3.49e-15	Aortic root size;
CRC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.52	6.81	0.35	4.54e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.75	9.66	0.47	1.37e-19	Monocyte percentage of white cells;
CRC	trans	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.47	-0.34	3.54e-10	Aortic root size;
CRC	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.68	-7.96	-0.4	2.87e-14	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.41	6.57	0.34	1.92e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07560534	chr9:100745354	ANP32B	0.49	6.71	0.35	8.52e-11	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.75	13.11	0.59	7.31e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.65	-10.22	-0.49	1.74e-21	Cognitive function;
CRC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.51	-8.01	-0.4	2.01e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.21	-0.32	1.63e-9	Menopause (age at onset);
CRC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.44	-7.68	-0.39	1.83e-13	Monocyte count;
CRC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.92	0.55	1.82e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.18	-0.32	1.84e-9	Bipolar disorder;
CRC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.52	7.74	0.39	1.23e-13	Lymphocyte counts;
CRC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.48	-7.41	-0.38	1.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg20041105	chr8:143859282	LYNX1	-0.7	-13.22	-0.59	2.61e-32	Urinary tract infection frequency;
CRC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-11.23	-0.53	5.62e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.43	-8.35	-0.42	1.97e-15	Alcohol dependence;
CRC	cis	rs3026445	0.778	rs7976889	chr12:110857694	A/G	cg12870014	chr12:110450643	ANKRD13A	0.37	5.7	0.3	2.73e-8	QT interval;
CRC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg24140574	chr1:16342155	HSPB7	0.42	5.61	0.3	4.31e-8	Dilated cardiomyopathy;
CRC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.64	10.28	0.49	1.11e-21	Dental caries;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg15845792	chr6:28175446	NA	0.76	7.99	0.4	2.34e-14	Depression;
CRC	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg21918786	chr6:109611834	NA	-0.35	-6.05	-0.32	3.9e-9	Reticulocyte fraction of red cells;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.45	6.7	0.35	8.96e-11	Menopause (age at onset);
CRC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.53	-6.71	-0.35	8.66e-11	DNA methylation (variation);
CRC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-8.39	-0.42	1.42e-15	Vitiligo;
CRC	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.6	-9.24	-0.45	3.14e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg02734326	chr4:10020555	SLC2A9	0.36	5.73	0.3	2.32e-8	Bone mineral density;
CRC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	0.98	14.93	0.64	7.78e-39	Monocyte percentage of white cells;
CRC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-6.77	-0.35	5.84e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.6	-6.99	-0.36	1.5e-11	Blood trace element (Zn levels);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27367093	chr11:72145746	CLPB	0.47	7.69	0.39	1.77e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.63	10.09	0.49	4.8e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6681460	1.000	rs2031478	chr1:67123742	C/A	cg02459107	chr1:67143332	SGIP1	0.48	8.33	0.42	2.27e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs16867321	0.950	rs1919148	chr2:181501758	G/A	cg23363182	chr2:181467187	NA	-0.51	-6.65	-0.34	1.21e-10	Obesity;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22331074	chr8:42751762	RNF170;HOOK3	0.41	6.45	0.34	3.88e-10	Schizophrenia;
CRC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.4	-0.33	5.2400000000000005e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.36	5.61	0.3	4.22e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-8.57	-0.43	3.96e-16	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11339840	chr1:203596058	ATP2B4	0.47	6.14	0.32	2.32e-9	Thyroid stimulating hormone;
CRC	trans	rs17641971	0.965	rs341815	chr8:49978424	A/C	cg18784943	chr17:79371681	NA	-0.41	-6.22	-0.32	1.54e-9	Blood metabolite levels;
CRC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.89	15.68	0.65	8.9e-42	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.9	-0.31	8.9e-9	High light scatter reticulocyte count;
CRC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-5.97	-0.31	6.27e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13198984	chr17:80129470	CCDC57	0.45	8.01	0.4	1.99e-14	Life satisfaction;
CRC	cis	rs7572733	0.565	rs11891750	chr2:198434319	G/A	cg10820045	chr2:198174542	NA	0.34	5.99	0.31	5.42e-9	Dermatomyositis;
CRC	cis	rs73058052	0.867	rs57940349	chr19:50097607	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.79	0.3	1.6e-8	Fibrinogen levels;
CRC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.85	-14.74	-0.63	4.03e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.38e-30	Bone mineral density;
CRC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.43e-16	Life satisfaction;
CRC	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg02770688	chr6:168491649	NA	0.59	8.68	0.43	1.86e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs6694672	1.000	rs10922169	chr1:197101105	T/C	cg13682187	chr1:196946512	CFHR5	0.47	7.53	0.38	4.89e-13	Asthma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22708233	chr11:47198576	ARFGAP2	-0.37	-6.01	-0.31	5.01e-9	Myopia (pathological);
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg10729496	chr3:10149963	C3orf24	0.5	6.74	0.35	7.23e-11	Alzheimer's disease;
CRC	cis	rs4665630	0.522	rs114880940	chr2:23930352	G/A	cg07265300	chr2:24346000	PFN4;LOC375190	0.79	5.78	0.3	1.69e-8	Hypertension;
CRC	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.53	8.97	0.44	2.24e-17	Dupuytren's disease;
CRC	cis	rs4920343	0.737	rs4920530	chr1:19095101	A/C	cg19637330	chr1:19110922	NA	-0.4	-6.02	-0.31	4.67e-9	Knee osteoarthritis;
CRC	cis	rs9549260	0.753	rs9532578	chr13:41236407	G/A	cg21288729	chr13:41239152	FOXO1	0.48	5.96	0.31	6.37e-9	Red blood cell count;
CRC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-13.46	-0.6	3.38e-33	Vitiligo;
CRC	cis	rs4290604	1.000	rs4290604	chr2:238070885	A/G	cg23555395	chr2:238036564	NA	-0.5	-5.96	-0.31	6.6e-9	Asthma;
CRC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg11915388	chr22:42470451	FAM109B	-0.42	-6.47	-0.34	3.63e-10	Schizophrenia;
CRC	trans	rs2303319	0.504	rs72870226	chr2:162420429	T/C	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.65	8.85	0.44	5.36e-17	Alcohol dependence;
CRC	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.63	9.79	0.47	4.8e-20	Corneal astigmatism;
CRC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.68	-0.3	2.97e-8	Mean platelet volume;
CRC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.84	-13.57	-0.6	1.31e-33	Height;
CRC	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg25856811	chr1:152973957	SPRR3	-0.23	-6.04	-0.32	4.23e-9	Inflammatory skin disease;
CRC	cis	rs9648716	0.935	rs1267615	chr7:140513650	T/C	cg10747023	chr7:140774559	NA	0.44	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	trans	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg07817883	chr1:32538562	TMEM39B	0.67	7.37	0.38	1.36e-12	Monocyte percentage of white cells;
CRC	cis	rs8045833	0.714	rs749681	chr16:88570675	A/G	cg05152867	chr16:88568237	ZFPM1	0.36	5.98	0.31	5.71e-9	Vascular endothelial growth factor levels;
CRC	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.64	8.09	0.41	1.13e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.77	-14.47	-0.62	4.73e-37	Body mass index;
CRC	trans	rs600806	0.850	rs2303875	chr1:109955010	A/C	cg22273042	chr8:81083829	TPD52	-0.45	-6.0	-0.31	5.16e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13064914	chr1:26799365	HMGN2	0.44	6.07	0.32	3.62e-9	Anxiety disorder;
CRC	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg26353448	chr1:248524236	OR2T4	-0.31	-5.95	-0.31	6.97e-9	Common traits (Other);
CRC	cis	rs7619833	0.620	rs9842044	chr3:27263248	G/C	cg02860705	chr3:27208620	NA	0.37	5.85	0.31	1.16e-8	Breast cancer;
CRC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.42	8.55	0.43	4.81e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.42	6.75	0.35	6.51e-11	Coronary artery disease;
CRC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.62	-8.92	-0.44	3.35e-17	Obesity-related traits;
CRC	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.53	-7.71	-0.39	1.49e-13	Triglycerides;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg19320564	chr1:40157253	HPCAL4	0.37	5.98	0.31	5.93e-9	Body mass index;
CRC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg21251018	chr6:28226885	NKAPL	0.41	6.24	0.33	1.35e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs196889	0.831	rs196890	chr8:24733546	G/C	cg08034077	chr17:50236087	CA10	0.44	6.16	0.32	2.11e-9	Seasonality;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03446863	chr6:41702426	TFEB	0.43	5.97	0.31	6.21e-9	Response to antipsychotic treatment;
CRC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.44	-7.84	-0.4	6.46e-14	Dilated cardiomyopathy;
CRC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.59	-8.12	-0.41	9.65e-15	Arsenic metabolism;
CRC	cis	rs9807989	0.839	rs4988955	chr2:102967928	A/G	cg03938978	chr2:103052716	IL18RAP	0.36	5.71	0.3	2.53e-8	Asthma;
CRC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg14191688	chr11:70257035	CTTN	0.44	5.88	0.31	9.92e-9	Coronary artery disease;
CRC	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.72	-10.3	-0.49	9.63e-22	Blood protein levels;
CRC	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.36	-0.42	1.77e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg08222913	chr3:52553049	STAB1	-0.37	-6.91	-0.36	2.49e-11	Electroencephalogram traits;
CRC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg10790698	chr19:18539756	SSBP4	-0.45	-8.72	-0.43	1.37e-16	Breast cancer;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.56	8.26	0.41	3.64e-15	Lymphocyte counts;
CRC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.6	10.62	0.51	7.44e-23	Aortic root size;
CRC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-6.28	-0.33	1.06e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16447950	chr5:562315	NA	-0.72	-9.24	-0.45	3.15e-18	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26210003	chr14:65290110	SPTB	0.41	6.03	0.32	4.34e-9	Response to antipsychotic treatment;
CRC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg19193384	chr17:30244184	NA	-0.53	-6.88	-0.35	3.1e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.26	0.53	4.12e-25	Bone mineral density;
CRC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-7.46	-0.38	7.82e-13	Colorectal cancer;
CRC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.64	10.41	0.5	3.98e-22	Height;
CRC	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg27398640	chr15:77910606	LINGO1	-0.41	-6.94	-0.36	2.07e-11	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06005396	chr19:590541	HCN2	0.35	6.12	0.32	2.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.49e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg17470449	chr10:769945	NA	0.64	8.39	0.42	1.42e-15	Uric acid levels;
CRC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.01	16.04	0.66	3.63e-43	Cognitive function;
CRC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg16898833	chr6:26189333	HIST1H4D	0.94	7.7	0.39	1.64e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg17321639	chr7:2759063	NA	-0.54	-7.24	-0.37	3.16e-12	Height;
CRC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	12.29	0.56	8.1e-29	Platelet count;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg24560729	chr4:1342394	KIAA1530	0.4	7.03	0.36	1.19e-11	Longevity;
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg06470822	chr6:28175283	NA	0.67	5.84	0.31	1.25e-8	Breast cancer;
CRC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.48	8.88	0.44	4.43e-17	Total body bone mineral density;
CRC	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg21424120	chr2:232395308	NMUR1	0.28	5.68	0.3	3.03e-8	Noise-induced hearing loss;
CRC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.48	-7.1	-0.36	7.67e-12	Tonsillectomy;
CRC	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.67	8.41	0.42	1.26e-15	Phospholipid levels (plasma);
CRC	cis	rs10046574	0.831	rs7780345	chr7:135137731	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg23009290	chr3:125982568	NA	-0.34	-5.98	-0.31	5.73e-9	Migraine;
CRC	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg19582491	chr16:67682965	RLTPR	-0.4	-5.67	-0.3	3.2e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.77	0.44	9.66e-17	Rheumatoid arthritis;
CRC	cis	rs7705042	0.865	rs2338822	chr5:141503059	T/C	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.76	-0.3	1.97e-8	Asthma;
CRC	cis	rs12760731	0.511	rs12758980	chr1:178611633	G/A	cg00404053	chr1:178313656	RASAL2	0.6	6.94	0.36	2.05e-11	Obesity-related traits;
CRC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-7.57	-0.39	3.78e-13	Bone mineral density;
CRC	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-13.05	-0.58	1.22e-31	Colorectal cancer;
CRC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.52	0.43	5.83e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg24585782	chr17:78113791	EIF4A3	-0.37	-5.71	-0.3	2.56e-8	Yeast infection;
CRC	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.6	-0.34	1.66e-10	Depression;
CRC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07165851	chr6:158734300	TULP4	0.61	7.72	0.39	1.41e-13	Height;
CRC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs995000	0.931	rs583609	chr1:62916796	T/C	cg19896129	chr1:63156450	NA	0.43	6.62	0.34	1.5e-10	Triglyceride levels;
CRC	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg23229984	chr5:148520753	ABLIM3	0.47	6.44	0.33	4.25e-10	Breast cancer;
CRC	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.39	6.1	0.32	3.01e-9	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg24289452	chr6:170231220	NA	-0.81	-6.87	-0.35	3.18e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg19635926	chr16:89946313	TCF25	0.65	6.21	0.32	1.55e-9	Skin colour saturation;
CRC	cis	rs9292777	0.777	rs16869930	chr5:40394954	G/A	cg09067459	chr5:40385259	NA	-0.57	-9.39	-0.46	1.01e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs9659323	0.804	rs10923722	chr1:119543486	C/T	cg26570165	chr1:119541833	NA	-0.43	-7.15	-0.37	5.81e-12	Body mass index;
CRC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.45	-7.36	-0.38	1.46e-12	Testicular germ cell tumor;
CRC	trans	rs75804782	1.000	rs75804782	chr2:239316043	T/C	cg01134436	chr17:81009848	B3GNTL1	0.73	6.56	0.34	2.03e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.59	10.47	0.5	2.44e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.09	-12.71	-0.57	2.3e-30	Diabetic kidney disease;
CRC	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.17	-9.75	-0.47	6.94e-20	Mitochondrial DNA levels;
CRC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.43	8.65	0.43	2.3e-16	Vitiligo;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg11875773	chr22:50468633	TTLL8	-0.7	-6.07	-0.32	3.62e-9	Cognitive function;
CRC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg23018236	chr17:30244563	NA	0.61	7.09	0.36	8.34e-12	Hip circumference adjusted for BMI;
CRC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.51	9.41	0.46	8.93e-19	IgG glycosylation;
CRC	cis	rs6743376	0.556	rs2515399	chr2:113819451	G/T	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.99	-0.36	1.54e-11	Schizophrenia;
CRC	trans	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg01505111	chr6:125621795	HDDC2	0.38	6.04	0.32	4.06e-9	DNA methylation (variation);
CRC	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.61	-8.33	-0.42	2.14e-15	Facial morphology (factor 19);
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg14191688	chr11:70257035	CTTN	0.42	5.85	0.31	1.18e-8	Coronary artery disease;
CRC	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.83	10.46	0.5	2.67e-22	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg18876405	chr7:65276391	NA	0.45	6.28	0.33	1.08e-9	Aortic root size;
CRC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.36	-7.62	-0.39	2.76e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-21.4	-0.76	2.91e-64	Hemostatic factors and hematological phenotypes;
CRC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14895029	chr7:2775587	GNA12	-0.46	-6.45	-0.34	3.88e-10	Height;
CRC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg21665744	chr7:39171113	POU6F2	0.44	5.9	0.31	9.26e-9	IgG glycosylation;
CRC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.55	8.8	0.44	7.77e-17	Prostate cancer;
CRC	trans	rs1941687	0.702	rs9956636	chr18:31304974	C/T	cg27147174	chr7:100797783	AP1S1	-0.37	-6.05	-0.32	4.01e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-9.88	-0.48	2.42e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.59	-9.05	-0.45	1.25e-17	Colorectal cancer;
CRC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.43	9.48	0.46	5.38e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9900972	0.842	rs2009196	chr17:76870581	C/G	cg20937029	chr17:76870563	TIMP2	-0.43	-6.27	-0.33	1.1e-9	Obesity-related traits;
CRC	cis	rs7113874	0.569	rs10160805	chr11:8600393	C/T	cg20771178	chr11:8615675	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg04518342	chr5:131593106	PDLIM4	0.38	6.65	0.34	1.24e-10	Blood metabolite levels;
CRC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.55	8.05	0.41	1.49e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg09596252	chr17:78655493	RPTOR	0.54	5.7	0.3	2.7e-8	Myopia (pathological);
CRC	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.49e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00338735	chr4:53728038	RASL11B	0.45	6.02	0.31	4.75e-9	Optic nerve measurement (cup area);
CRC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.28	-0.53	3.67e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg15226275	chr6:116381976	FRK	0.3	8.56	0.43	4.52e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg16989719	chr2:238392110	NA	-0.44	-8.0	-0.4	2.11e-14	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22566565	chr10:131909018	NA	0.49	7.0	0.36	1.47e-11	Response to antipsychotic treatment;
CRC	trans	rs11031096	0.702	rs183484	chr11:4141132	C/A	cg22978087	chr8:24814126	NEFL	0.33	6.08	0.32	3.36e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg26816564	chr1:7831052	VAMP3	0.55	6.16	0.32	2.15e-9	Inflammatory bowel disease;
CRC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs12210905	1.000	rs6938397	chr6:27231224	C/G	cg05005425	chr1:167687389	NA	0.62	6.29	0.33	1.03e-9	Hip circumference adjusted for BMI;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11427898	chr15:38544983	SPRED1	0.34	6.07	0.32	3.48e-9	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05227434	chr19:47249937	FKRP;STRN4	0.39	5.96	0.31	6.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs645485	chr11:108168863	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.19	0.32	1.74e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.82	0.31	1.4e-8	Heart rate;
CRC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.58	10.5	0.5	1.99e-22	Multiple system atrophy;
CRC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.52	7.13	0.37	6.35e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.96	-0.31	6.32e-9	Monocyte percentage of white cells;
CRC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.77	-0.3	1.85e-8	Breast cancer;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg15786705	chr6:28176104	NA	0.53	6.98	0.36	1.64e-11	Parkinson's disease;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.5	0.6	2.34e-33	Alzheimer's disease;
CRC	cis	rs3018066	0.831	rs10008773	chr4:106947203	T/C	cg01869342	chr4:106983673	TBCK	0.4	6.12	0.32	2.68e-9	Cancer;
CRC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	15.43	0.65	8.56e-41	Smoking behavior;
CRC	cis	rs7517126	0.614	rs7530627	chr1:197044480	T/C	cg13682187	chr1:196946512	CFHR5	0.47	7.35	0.38	1.56e-12	Blood protein levels;
CRC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.5	-8.43	-0.42	1.1e-15	Calcium levels;
CRC	cis	rs10971721	0.822	rs10971803	chr9:33933287	C/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.55	-8.3	-0.42	2.69e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg00155535	chr12:132671473	NA	0.45	7.66	0.39	2.11e-13	Anti-saccade response;
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.38	5.66	0.3	3.27e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg05376469	chr2:102649931	NA	-0.37	-5.97	-0.31	6.3e-9	Coronary artery disease;
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-7.44	-0.38	8.68e-13	Menarche (age at onset);
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00496025	chr7:73038982	MLXIPL	0.37	6.05	0.32	3.96e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg04518342	chr5:131593106	PDLIM4	0.42	6.94	0.36	2.03e-11	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24942285	chr3:47866555	DHX30	0.49	6.77	0.35	5.95e-11	Anxiety disorder;
CRC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.54	6.93	0.36	2.25e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.99	11.2	0.53	7.23e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25517755	chr10:38738941	LOC399744	0.41	5.91	0.31	8.44e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23161317	chr6:28129485	ZNF389	-0.43	-5.69	-0.3	2.8e-8	Depression;
CRC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg14349672	chr11:133703707	NA	0.35	5.78	0.3	1.71e-8	Childhood ear infection;
CRC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.7	11.72	0.54	9.41e-27	Alzheimer's disease (late onset);
CRC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-12.49	-0.57	1.5e-29	Cognitive function;
CRC	cis	rs11229555	0.645	rs12295551	chr11:58188983	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6743226	0.840	rs6747036	chr2:242227054	T/C	cg10021735	chr2:242295487	FARP2	0.45	6.37	0.33	6.31e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg08222913	chr3:52553049	STAB1	0.34	6.22	0.32	1.54e-9	Electroencephalogram traits;
CRC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.45	0.65	7.2e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.39	-6.52	-0.34	2.68e-10	Height;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.58	9.21	0.45	3.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.04	0.32	4.19e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg05562828	chr17:3906858	NA	0.57	9.75	0.47	6.53e-20	Type 2 diabetes;
CRC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.39	-0.33	5.8e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg19328814	chr18:14132536	ZNF519	-0.48	-6.69	-0.35	9.4e-11	Lung cancer;
CRC	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg20169779	chr10:135381914	SYCE1	0.78	11.28	0.53	3.59e-25	Gout;
CRC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg26587870	chr6:27730563	NA	-0.6	-5.91	-0.31	8.73e-9	Depression;
CRC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.48	-0.34	3.39e-10	Aortic root size;
CRC	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7781266	0.842	rs62470027	chr7:133290717	G/A	cg03336402	chr7:133662267	EXOC4	0.45	5.71	0.3	2.56e-8	Educational attainment (college completion);
CRC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.04	0.32	4.05e-9	Hemoglobin concentration;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg21709803	chr11:61594965	FADS2	-0.6	-7.22	-0.37	3.73e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg27398640	chr15:77910606	LINGO1	-0.43	-7.28	-0.37	2.42e-12	Type 2 diabetes;
CRC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg03037974	chr15:76606532	NA	0.68	11.55	0.54	4.06e-26	Blood metabolite levels;
CRC	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-7.94	-0.4	3.19e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4073416	0.542	rs7140695	chr14:65929132	T/C	cg03016385	chr14:66212404	NA	-0.43	-5.94	-0.31	7.31e-9	N-glycan levels;
CRC	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.8	-13.23	-0.59	2.41e-32	Hypospadias;
CRC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.9	-12.21	-0.56	1.54e-28	Vitiligo;
CRC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg08648136	chr8:956695	NA	0.37	6.45	0.33	4.06e-10	Schizophrenia;
CRC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.39	-0.42	1.45e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg23533926	chr12:111358616	MYL2	-0.6	-9.32	-0.46	1.73e-18	Breast cancer;
CRC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.78	13.71	0.6	3.6e-34	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12692738	0.526	rs355842	chr2:165622669	C/T	cg03182029	chr2:165697222	COBLL1	0.51	5.98	0.31	5.74e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.4	5.77	0.3	1.82e-8	Aortic root size;
CRC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.35	-0.33	7.11e-10	Alzheimer's disease (late onset);
CRC	cis	rs2223471	0.719	rs2744485	chr6:50772616	C/G	cg03432817	chr6:50765336	NA	0.43	6.93	0.36	2.24e-11	Subcutaneous adipose tissue;
CRC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	0.87	6.92	0.36	2.31e-11	Type 2 diabetes nephropathy;
CRC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.42	7.59	0.39	3.42e-13	Height;
CRC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.15	0.49	3.05e-21	Systolic blood pressure;
CRC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg21399703	chr1:247681439	NA	0.47	7.65	0.39	2.24e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg15786705	chr6:28176104	NA	0.63	8.99	0.44	2.02e-17	Cardiac Troponin-T levels;
CRC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.39	-6.87	-0.35	3.13e-11	Reticulocyte fraction of red cells;
CRC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.6	8.33	0.42	2.23e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg15654264	chr1:150340011	RPRD2	-0.39	-5.8	-0.3	1.58e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.66	10.25	0.49	1.46e-21	Monocyte percentage of white cells;
CRC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.56	8.37	0.42	1.67e-15	Obesity-related traits;
CRC	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.68	-0.3	3.01e-8	Height;
CRC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03236992	chr16:78133292	WWOX	0.42	6.33	0.33	7.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.17	-0.41	6.79e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.91	0.72	1.7e-54	Cognitive ability;
CRC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.42	-6.74	-0.35	7.16e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12476592	0.516	rs6734648	chr2:63801525	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.49	-0.5	2.16e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs7113874	0.589	rs10769908	chr11:8484089	A/G	cg02811074	chr11:8615871	STK33	0.37	6.22	0.32	1.51e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs501120	1.000	rs607363	chr10:44761623	A/G	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg21251018	chr6:28226885	NKAPL	0.46	6.46	0.34	3.67e-10	Parkinson's disease;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26824705	chr1:20834772	MUL1	0.4	6.16	0.32	2.14e-9	Myopia (pathological);
CRC	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg24759859	chr6:86352639	SYNCRIP	0.47	6.61	0.34	1.54e-10	Smooth-surface caries;
CRC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.28	-0.33	1.04e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.62	-8.79	-0.44	8.66e-17	Neuroticism;
CRC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.55	8.24	0.41	4.27e-15	Lymphocyte counts;
CRC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.59	8.53	0.43	5.29e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.29	-0.46	2.21e-18	Aortic root size;
CRC	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.44	-0.38	9.02e-13	Type 2 diabetes;
CRC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg25985355	chr7:65971099	NA	-0.34	-5.68	-0.3	2.94e-8	Corneal structure;
CRC	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg23202291	chr11:1979235	NA	0.53	7.63	0.39	2.62e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg15848620	chr12:58087721	OS9	-0.57	-7.78	-0.39	9.56e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg25856811	chr1:152973957	SPRR3	0.24	6.65	0.34	1.25e-10	Inflammatory skin disease;
CRC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.5	-9.42	-0.46	8.27e-19	Longevity;
CRC	cis	rs10046574	0.831	rs78220593	chr7:135166787	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg23996704	chr18:44553084	KATNAL2	0.3	5.84	0.31	1.27e-8	Personality dimensions;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11200644	chr18:72265018	LOC400657	0.41	6.15	0.32	2.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Parkinson's disease;
CRC	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg14003231	chr6:33640908	ITPR3	0.47	7.41	0.38	1.09e-12	Plateletcrit;
CRC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.09	19.98	0.74	1e-58	Cognitive function;
CRC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.65	-8.0	-0.4	2.2e-14	Bronchopulmonary dysplasia;
CRC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg12365402	chr11:9010492	NRIP3	-0.37	-6.42	-0.33	4.76e-10	Hematocrit;
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg04969067	chr8:143858791	LYNX1	0.44	7.45	0.38	8.37e-13	Urinary tract infection frequency;
CRC	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg16591659	chr17:78472290	NA	0.4	5.71	0.3	2.47e-8	Fractional excretion of uric acid;
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02807482	chr3:125708958	NA	-0.46	-5.95	-0.31	6.78e-9	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06544989	chr22:39130855	UNC84B	0.45	6.84	0.35	3.88e-11	Menopause (age at onset);
CRC	trans	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.94	-0.36	2.05e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs3996993	0.597	rs62412891	chr6:52713902	C/T	cg20803780	chr6:52668592	GSTA1	0.4	7.0	0.36	1.42e-11	Hemoglobin concentration;
CRC	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.71	-10.03	-0.48	7.59e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00598858	chr19:11545966	PRKCSH;CCDC151	0.44	6.2	0.32	1.66e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6835098	0.539	rs1383628	chr4:174194453	C/T	cg08422745	chr4:174089978	GALNT7	-0.6	-9.21	-0.45	3.92e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11255230	chr18:60987808	BCL2	0.42	6.72	0.35	8.21e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg03959625	chr15:84868606	LOC388152	0.41	6.08	0.32	3.27e-9	Schizophrenia;
CRC	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.78	11.19	0.53	7.54e-25	Gut microbiome composition (winter);
CRC	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.06	14.74	0.63	4.07e-38	Exhaled nitric oxide output;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.47	7.96	0.4	2.77e-14	Primary biliary cholangitis;
CRC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.89	-14.02	-0.61	2.47e-35	Headache;
CRC	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-0.87	-7.83	-0.4	6.84e-14	Left atrial antero-posterior diameter;
CRC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-1.1	-12.68	-0.57	2.87e-30	Blood pressure (smoking interaction);
CRC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg06970220	chr1:156163860	SLC25A44	0.44	6.19	0.32	1.75e-9	Testicular germ cell tumor;
CRC	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.44	-6.34	-0.33	7.41e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.88	0.31	9.92e-9	IgG glycosylation;
CRC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.98	-0.4	2.49e-14	Chronic sinus infection;
CRC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.98	0.31	5.87e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.71	14.01	0.61	2.65e-35	Leprosy;
CRC	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.0	-0.31	5.3e-9	Metabolite levels;
CRC	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.44	-6.72	-0.35	8.14e-11	Carotid intima media thickness;
CRC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.66	-0.34	1.14e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.98	-0.31	5.97e-9	Life satisfaction;
CRC	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg06223162	chr1:101003688	GPR88	-0.35	-6.49	-0.34	3.12e-10	Monocyte count;
CRC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg08210727	chr20:33865349	NA	-0.49	-6.27	-0.33	1.16e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs16975963	0.644	rs12462505	chr19:38138125	C/G	cg15135657	chr19:38346511	NA	-0.46	-6.37	-0.33	6.28e-10	Longevity;
CRC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.63	-0.43	2.74e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.25	-0.45	2.94e-18	Platelet count;
CRC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.76	-12.41	-0.56	2.89e-29	Height;
CRC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	7.02	0.36	1.25e-11	Iron status biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18607418	chr19:15667338	NA	0.45	6.37	0.33	6.39e-10	Response to antipsychotic treatment;
CRC	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-6.47	-0.34	3.65e-10	Coronary artery disease;
CRC	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg05272587	chr13:111038400	COL4A2	0.38	5.76	0.3	1.94e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.0	0.36	1.46e-11	Ulcerative colitis;
CRC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.58	7.9	0.4	4.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg18230493	chr5:56204884	C5orf35	0.39	6.0	0.31	5.21e-9	Coronary artery disease;
CRC	cis	rs12143943	0.934	rs868097	chr1:204580139	C/T	cg17419461	chr1:204415978	PIK3C2B	0.36	5.66	0.3	3.3e-8	Cognitive performance;
CRC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs10242455	1.000	rs17161692	chr7:98953863	A/G	cg18809830	chr7:99032528	PTCD1	0.66	6.14	0.32	2.4e-9	Blood metabolite levels;
CRC	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg10263370	chr3:44754102	ZNF502	-0.36	-5.92	-0.31	7.94e-9	Depressive symptoms;
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.47e-8	Prudent dietary pattern;
CRC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg03037974	chr15:76606532	NA	0.71	12.27	0.56	9.37e-29	Blood metabolite levels;
CRC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	cis	rs7301826	0.651	rs4759525	chr12:131316281	T/C	cg11011512	chr12:131303247	STX2	0.39	5.85	0.31	1.18e-8	Plasma plasminogen activator levels;
CRC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg26727032	chr16:67993705	SLC12A4	0.59	6.35	0.33	7.31e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.0	-0.4	2.16e-14	Menopause (age at onset);
CRC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	7.05	0.36	1.04e-11	Mean platelet volume;
CRC	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg24726965	chr2:63606136	C2orf86	-0.37	-5.75	-0.3	2.01e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.07	-0.36	9.38e-12	Morning vs. evening chronotype;
CRC	cis	rs7626444	0.585	rs860050	chr3:196474447	T/G	cg12930392	chr3:196481615	PAK2	0.4	7.1	0.36	7.93e-12	Monocyte count;
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg08888203	chr3:10149979	C3orf24	0.74	9.0	0.44	1.82e-17	Alzheimer's disease;
CRC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	trans	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.26	-0.45	2.73e-18	Endometrial cancer;
CRC	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.28	-0.37	2.44e-12	Triglycerides;
CRC	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg05370193	chr1:21551575	ECE1	0.36	5.76	0.3	1.91e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13198984	chr17:80129470	CCDC57	0.46	8.04	0.41	1.6e-14	Life satisfaction;
CRC	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.66	0.34	1.18e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7705042	0.865	rs166079	chr5:141528959	C/T	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.48e-8	Asthma;
CRC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.21	-0.32	1.62e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.04	-0.32	4.12e-9	Morning vs. evening chronotype;
CRC	cis	rs3771570	1.000	rs62193209	chr2:242323523	A/G	cg21155796	chr2:242212141	HDLBP	0.62	6.31	0.33	8.85e-10	Prostate cancer;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.61	9.08	0.45	1.01e-17	Methadone dose in opioid dependence;
CRC	cis	rs12745968	0.624	rs6675753	chr1:93215596	T/C	cg17283838	chr1:93427260	FAM69A	-0.46	-6.29	-0.33	1e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.65	-7.44	-0.38	8.68e-13	Vitiligo;
CRC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg22110888	chr17:80059540	CCDC57	0.38	6.07	0.32	3.61e-9	Life satisfaction;
CRC	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.14	0.32	2.32e-9	Hair morphology;
CRC	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg21918786	chr6:109611834	NA	-0.33	-5.7	-0.3	2.65e-8	Reticulocyte fraction of red cells;
CRC	cis	rs11229555	0.609	rs12289198	chr11:58175057	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs1364705	1.000	rs12677951	chr8:120226900	C/G	cg27215916	chr8:120218354	NA	-0.39	-5.66	-0.3	3.32e-8	Hippocampal atrophy;
CRC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07648498	chr16:89883185	FANCA	0.41	5.79	0.3	1.66e-8	Vitiligo;
CRC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.63	-11.44	-0.53	9.57e-26	Coronary artery disease;
CRC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg23758597	chr6:163146217	PARK2	-0.66	-6.82	-0.35	4.46e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs501120	0.584	rs1704228	chr10:44673050	C/T	cg09554077	chr10:44749378	NA	0.69	7.83	0.4	6.91e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs10760279	0.685	rs10985975	chr9:126113272	G/C	cg23210278	chr2:220439623	INHA	0.33	6.01	0.31	4.84e-9	Body mass index;
CRC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-6.57	-0.34	1.94e-10	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9491140	0.539	rs10872287	chr6:124694573	T/G	cg22366943	chr6:124882293	NKAIN2	0.56	7.44	0.38	9.1e-13	Neuroticism;
CRC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.37	-8.52	-0.43	5.83e-16	Mean corpuscular volume;
CRC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.34	-0.38	1.63e-12	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.56	-8.14	-0.41	8.43e-15	Resting heart rate;
CRC	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.85	-0.35	3.65e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04731861	chr2:219085781	ARPC2	0.37	7.99	0.4	2.37e-14	Colorectal cancer;
CRC	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.73	-8.15	-0.41	7.58e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.71	-9.17	-0.45	5.41e-18	Dementia with Lewy bodies;
CRC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.66	-0.47	1.33e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg27094323	chr7:1216898	NA	-0.36	-5.71	-0.3	2.57e-8	Longevity;Endometriosis;
CRC	cis	rs2302190	0.882	rs7216856	chr17:56472295	C/T	cg25885038	chr17:56607967	SEPT4	-0.38	-6.04	-0.32	4.14e-9	Vitamin D levels;
CRC	trans	rs16846053	0.584	rs57840078	chr2:162402459	T/G	cg18122310	chr12:50236657	BCDIN3D	-0.72	-5.99	-0.31	5.65e-9	Blood osmolality (transformed sodium);
CRC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.53	-0.43	5.59e-16	Schizophrenia;
CRC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	19.1	0.73	3.07e-55	Prudent dietary pattern;
CRC	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.4	-7.44	-0.38	8.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	1.03	20.97	0.76	1.31e-62	Headache;
CRC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.65	10.11	0.49	4.07e-21	Tuberculosis;
CRC	cis	rs2415984	0.622	rs2415997	chr14:46930446	A/C	cg14871534	chr14:47121158	RPL10L	-0.43	-6.16	-0.32	2.17e-9	Number of children ever born;
CRC	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg24553058	chr2:113831203	IL1F10	-0.55	-8.7	-0.43	1.66e-16	Protein quantitative trait loci;
CRC	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg11901034	chr3:128598214	ACAD9	-0.54	-6.43	-0.33	4.47e-10	IgG glycosylation;
CRC	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg18646521	chr2:111875858	NA	0.39	6.12	0.32	2.62e-9	Chronic lymphocytic leukemia;
CRC	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg06935464	chr4:38784597	TLR10	0.59	5.95	0.31	6.72e-9	Breast cancer;
CRC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.55	-8.57	-0.43	4.18e-16	Hyperactive-impulsive symptoms;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg02683197	chr6:28174875	NA	0.75	9.93	0.48	1.67e-20	Parkinson's disease;
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7224610	0.898	rs4299205	chr17:53366146	T/G	cg05452524	chr17:53343029	HLF	-0.35	-5.64	-0.3	3.59e-8	Urate levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25887236	chr18:74844781	MBP	0.4	6.48	0.34	3.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.35e-9	Life satisfaction;
CRC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.86	0.31	1.11e-8	Height;
CRC	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg11143507	chr3:125485238	NA	-0.7	-6.11	-0.32	2.85e-9	Blood pressure (smoking interaction);
CRC	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg14515779	chr1:101123966	NA	0.38	7.03	0.36	1.21e-11	Monocyte count;
CRC	cis	rs2346160	0.899	rs206974	chr6:167690300	G/A	cg27333441	chr6:167680455	NA	-0.4	-6.71	-0.35	8.78e-11	Parental extreme longevity (95 years and older);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19354023	chr10:89577882	ATAD1;CFLP1	0.43	6.05	0.32	3.98e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.44	-6.2	-0.32	1.65e-9	DNA methylation (variation);
CRC	cis	rs3791406	0.654	rs3752804	chr2:240029490	C/T	cg08444004	chr2:240086178	HDAC4	-0.32	-5.77	-0.3	1.83e-8	Skin aging (microtopography measurement);
CRC	cis	rs12431939	0.598	rs10873047	chr14:51727239	G/T	cg23942311	chr14:51606299	NA	0.51	6.77	0.35	5.91e-11	Cancer;
CRC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.65	-9.81	-0.48	4.19e-20	Other erythrocyte phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12665724	chr11:43364829	API5	-0.39	-6.1	-0.32	2.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg21192091	chr7:2758800	NA	0.35	5.8	0.3	1.53e-8	Height;
CRC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.31	0.67	2.93e-44	Electrocardiographic conduction measures;
CRC	cis	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg22963979	chr7:1858916	MAD1L1	0.46	7.11	0.37	7.13e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs1322512	0.917	rs2250013	chr6:153006539	A/T	cg03415253	chr6:152958462	SYNE1	0.4	6.03	0.32	4.39e-9	Tonometry;
CRC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg20358437	chr6:27870759	NA	0.59	5.82	0.31	1.36e-8	Parkinson's disease;
CRC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.15	14.73	0.63	4.62e-38	Uric acid levels;
CRC	trans	rs4352210	0.963	rs4670727	chr2:37760784	G/A	cg13134662	chr9:136858680	VAV2	-0.41	-5.99	-0.31	5.46e-9	RR interval (heart rate);
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg14520829	chr3:18390388	SATB1	0.42	6.45	0.34	3.9e-10	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg08270630	chr22:50330655	NA	-0.45	-5.91	-0.31	8.61e-9	Schizophrenia;
CRC	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg12193833	chr17:30244370	NA	-0.67	-8.42	-0.42	1.22e-15	Hip circumference adjusted for BMI;
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-7.23	-0.37	3.48e-12	Lymphocyte counts;
CRC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.61	8.47	0.42	8.49e-16	Obesity-related traits;
CRC	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.8	-0.44	7.99e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.8	10.29	0.49	1.05e-21	Height;
CRC	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.16	24.42	0.8	7.15e-76	Exhaled nitric oxide output;
CRC	cis	rs12760731	0.623	rs10913541	chr1:178347714	G/A	cg00404053	chr1:178313656	RASAL2	0.74	9.33	0.46	1.56e-18	Obesity-related traits;
CRC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.7	7.77	0.39	1.03e-13	Vitiligo;
CRC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.51	-7.96	-0.4	2.75e-14	Testicular germ cell tumor;
CRC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.82	11.35	0.53	1.98e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.5	7.47	0.38	7.16e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10046574	0.561	rs17481974	chr7:135195701	A/G	cg27474649	chr7:135195673	CNOT4	0.67	6.16	0.32	2.14e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.37	-0.33	6.27e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	11.41	0.53	1.2e-25	High light scatter reticulocyte count;
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs12744310	0.887	rs72667608	chr1:41794773	A/G	cg19175123	chr10:103411746	FBXW4	0.46	6.13	0.32	2.55e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg09876464	chr15:85330779	ZNF592	0.39	6.51	0.34	2.89e-10	P wave terminal force;
CRC	cis	rs3747547	0.892	rs72724200	chr9:37952144	G/A	cg13774184	chr9:37916125	SHB	-0.86	-5.71	-0.3	2.47e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CRC	trans	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg18288967	chr1:45987694	PRDX1	0.7	7.92	0.4	3.67e-14	Obesity-related traits;
CRC	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg05527609	chr1:210001259	C1orf107	0.48	5.72	0.3	2.41e-8	Red blood cell count;
CRC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg24588162	chr13:113633484	MCF2L	-0.43	-7.58	-0.39	3.57e-13	Systolic blood pressure;
CRC	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.59	-6.93	-0.36	2.26e-11	Post bronchodilator FEV1;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13577407	chr3:57994372	FLNB	0.41	6.73	0.35	7.59e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.75	-0.35	6.83e-11	Body mass index;
CRC	cis	rs755249	0.567	rs1537817	chr1:39639653	A/G	cg18385671	chr1:39797026	MACF1	0.4	5.73	0.3	2.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.41	-6.17	-0.32	2.03e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-7.34	-0.37	1.73e-12	Response to antipsychotic treatment;
CRC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.64	7.44	0.38	8.68e-13	Menarche (age at onset);
CRC	cis	rs9648716	1.000	rs62485365	chr7:140588215	T/G	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.25	-18.08	-0.71	3.05e-51	Hip circumference adjusted for BMI;
CRC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.59	8.05	0.41	1.57e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg06494592	chr3:125709126	NA	-0.56	-6.73	-0.35	7.33e-11	Blood pressure (smoking interaction);
CRC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg02353165	chr6:42928485	GNMT	0.63	9.21	0.45	4.06e-18	Blood protein levels;
CRC	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.12	-0.37	6.67e-12	Schizophrenia;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.51	-7.83	-0.4	6.96e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.48	7.02	0.36	1.3e-11	Obesity-related traits;
CRC	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.71	-12.74	-0.57	1.77e-30	Lewy body disease;
CRC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-12.22	-0.56	1.41e-28	Developmental language disorder (linguistic errors);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06443542	chr10:100206752	HPS1	0.4	6.37	0.33	6.51e-10	Obesity-related traits;
CRC	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs11581903	0.568	rs34087138	chr1:53083567	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.79	6.17	0.32	1.96e-9	Joint mobility (Beighton score);
CRC	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg09659197	chr4:152720779	NA	0.36	6.97	0.36	1.71e-11	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg17903999	chr18:56338584	MALT1	0.43	7.1	0.36	7.75e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg21251018	chr6:28226885	NKAPL	0.42	6.7	0.35	9.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6681460	0.932	rs524114	chr1:67188335	C/T	cg02459107	chr1:67143332	SGIP1	-0.36	-6.24	-0.33	1.31e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.04	-0.41	1.62e-14	Gut microbiome composition (summer);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06593406	chr17:46696139	NA	0.42	6.04	0.32	4.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg14191688	chr11:70257035	CTTN	0.5	6.52	0.34	2.63e-10	Coronary artery disease;
CRC	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg16558208	chr1:156270281	VHLL	-0.5	-7.85	-0.4	6.03e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02709261	chr1:179051893	TOR3A	-0.55	-6.58	-0.34	1.9e-10	Diisocyanate-induced asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13696566	chr3:119013055	CDGAP	0.41	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.4	-0.42	1.34e-15	Body mass index;
CRC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.62	7.86	0.4	5.51e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.63	9.9	0.48	2.14e-20	Breast cancer;
CRC	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg23250157	chr14:64679961	SYNE2	0.5	7.61	0.39	2.85e-13	Atrial fibrillation;
CRC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg15848620	chr12:58087721	OS9	0.6	8.12	0.41	9.56e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.47	6.36	0.33	6.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.81	0.4	7.95e-14	Parkinson's disease;
CRC	trans	rs6472235	0.837	rs6983945	chr8:66930466	G/C	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.62	10.0	0.48	9.83e-21	Monocyte count;
CRC	cis	rs6840360	0.642	rs2709815	chr4:152363772	T/C	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.67	8.46	0.42	8.74e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	9.67	0.47	1.28e-19	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04849788	chr3:160283695	KPNA4	0.54	7.01	0.36	1.37e-11	Thyroid stimulating hormone;
CRC	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg19560979	chr8:11627473	NEIL2	0.45	6.33	0.33	7.9e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.41	-7.65	-0.39	2.23e-13	Ulcerative colitis;
CRC	cis	rs7113874	0.589	rs10840056	chr11:8498064	A/C	cg17679104	chr11:8615758	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg00734567	chr1:86172782	ZNHIT6	-0.49	-7.49	-0.38	6.49e-13	Urate levels in overweight individuals;
CRC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.85	0.35	3.63e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.38	0.38	1.32e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04749771	chr14:59950705	C14orf149;JKAMP	0.46	6.12	0.32	2.59e-9	Anxiety disorder;
CRC	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.3	1.5e-8	Metabolite levels;
CRC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg12458913	chr13:53173898	NA	0.8	14.9	0.63	1.01e-38	Lewy body disease;
CRC	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.6	0.34	1.67e-10	Alzheimer's disease (survival time);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21400344	chr1:25870172	LDLRAP1	0.45	7.39	0.38	1.24e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs728616	0.867	rs2152548	chr10:81802667	G/A	cg11900509	chr10:81946545	ANXA11	-0.61	-6.46	-0.34	3.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.17	-0.45	5.33e-18	Metabolite levels;
CRC	cis	rs3924048	0.519	rs11121927	chr1:12614403	G/C	cg00291366	chr1:12616550	NA	0.48	6.74	0.35	7.24e-11	Optic cup area;
CRC	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	7.44	0.38	8.99e-13	Neuroticism;
CRC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.92	-17.12	-0.69	1.97e-47	Height;
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.51	5.98	0.31	5.82e-9	Lung function (FEV1/FVC);
CRC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.64	-10.17	-0.49	2.6e-21	Motion sickness;
CRC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.51	7.32	0.37	1.88e-12	Pancreatic cancer;
CRC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs365302	1.000	rs486468	chr6:159651205	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.48	7.78	0.39	9.25e-14	Testicular germ cell tumor;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.77	9.81	0.48	4.41e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.99	0.31	5.46e-9	Educational attainment (years of education);
CRC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.63	0.43	2.61e-16	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg13385794	chr1:248469461	NA	0.39	6.98	0.36	1.62e-11	Common traits (Other);
CRC	trans	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.95	-0.36	1.94e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg07125278	chr16:67683757	RLTPR	-0.63	-7.24	-0.37	3.12e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-0.91	-15.67	-0.65	9.55e-42	Body mass index;
CRC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.12	-0.32	2.59e-9	Eosinophil percentage of white cells;
CRC	cis	rs9783347	1.000	rs4150566	chr11:18355599	C/G	cg15585147	chr11:18324498	HPS5	0.43	6.08	0.32	3.29e-9	Pancreatic cancer;
CRC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-7.53	-0.38	4.86e-13	Coronary artery disease;
CRC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg13047869	chr3:10149882	C3orf24	0.39	5.93	0.31	7.54e-9	Alzheimer's disease;
CRC	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg16898833	chr6:26189333	HIST1H4D	0.74	6.09	0.32	3.16e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6735179	0.647	rs749089	chr2:1763213	T/C	cg19300414	chr2:1746591	PXDN	0.35	6.21	0.32	1.63e-9	Response to antipsychotic treatment;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	6.03	0.32	4.38e-9	Electroencephalogram traits;
CRC	cis	rs11308613	1	rs11308613	chr13:38558010	GT/G	cg26068090	chr13:38518217	NA	-0.4	-5.86	-0.31	1.1e-8	Mild influenza (H1N1) infection;
CRC	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24249390	chr15:90295951	MESP1	-0.56	-8.69	-0.43	1.71e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs12580194	0.593	rs61957899	chr12:55731971	C/T	cg23425280	chr12:56401806	NA	0.47	6.03	0.32	4.47e-9	Cancer;
CRC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.64	-0.51	6.34e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg22110888	chr17:80059540	CCDC57	0.43	6.7	0.35	9.27e-11	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10440483	chr1:23810433	ASAP3	0.45	6.09	0.32	3.11e-9	Anxiety disorder;
CRC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.18	-17.22	-0.69	7.98e-48	Hip circumference adjusted for BMI;
CRC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.63	7.58	0.39	3.48e-13	Mean platelet volume;
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.57	-0.34	1.97e-10	Lymphocyte counts;
CRC	cis	rs501916	0.634	rs3743286	chr15:48065792	A/G	cg16110827	chr15:48056943	SEMA6D	-0.5	-7.46	-0.38	7.85e-13	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.97	0.44	2.37e-17	Morning vs. evening chronotype;
CRC	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.43	7.08	0.36	8.71e-12	Sitting height ratio;
CRC	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-7.89	-0.4	4.53e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.53e-10	Response to antipsychotic treatment;
CRC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg06671706	chr8:8559999	CLDN23	0.62	9.09	0.45	9.32e-18	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg24562669	chr7:97807699	LMTK2	0.44	7.24	0.37	3.11e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13198984	chr17:80129470	CCDC57	0.47	8.31	0.42	2.54e-15	Life satisfaction;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26547359	chr10:16859530	RSU1	-0.44	-6.91	-0.36	2.46e-11	Myopia (pathological);
CRC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.53	7.52	0.38	5.34e-13	Pancreatic cancer;
CRC	cis	rs17443541	0.507	rs4675705	chr2:200456952	T/C	cg03741458	chr2:200468445	NA	-0.36	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg12560992	chr17:57184187	TRIM37	0.53	6.22	0.32	1.55e-9	Vitamin D levels;
CRC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.37	0.42	1.68e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs72634501	0.716	rs4660165	chr1:39578532	C/T	cg18385671	chr1:39797026	MACF1	0.43	6.01	0.31	5e-9	HDL cholesterol;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-10.45	-0.5	3.02e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.71	-11.52	-0.54	5.22e-26	Coronary artery disease;
CRC	cis	rs4664293	0.647	rs6724151	chr2:160499299	C/A	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.65	-0.39	2.24e-13	Triglycerides;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.94	-23.56	-0.79	1.37e-72	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.23	6.18	0.32	1.84e-9	Type 2 diabetes;
CRC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	9.11	0.45	8.5e-18	Lymphocyte counts;
CRC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.64	-0.39	2.32e-13	Alzheimer's disease;
CRC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg25251562	chr2:3704773	ALLC	0.43	6.48	0.34	3.41e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg22561889	chr6:118971681	C6orf204	0.5	6.52	0.34	2.71e-10	Diastolic blood pressure;
CRC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.46	0.34	3.8e-10	Aortic root size;
CRC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.61	10.22	0.49	1.79e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg17470449	chr10:769945	NA	0.64	8.39	0.42	1.42e-15	Uric acid levels;
CRC	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg23127183	chr11:57508653	C11orf31	-0.52	-7.04	-0.36	1.12e-11	Schizophrenia;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12172441	chr6:28176163	NA	-0.64	-7.52	-0.38	5.12e-13	Depression;
CRC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.28	-0.56	8.71e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4853036	0.904	rs7578366	chr2:70135695	C/T	cg02498382	chr2:70120550	SNRNP27	-0.45	-6.92	-0.36	2.36e-11	Colorectal or endometrial cancer;
CRC	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg12590608	chr7:158785262	NA	-0.42	-6.58	-0.34	1.81e-10	Facial morphology (factor 20);
CRC	trans	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.73	-0.35	7.51e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg21827317	chr3:136751795	NA	0.35	5.63	0.3	3.91e-8	Neuroticism;
CRC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.44	5.7	0.3	2.73e-8	Response to diuretic therapy;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.53	8.4	0.42	1.35e-15	Electroencephalogram traits;
CRC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg05044414	chr3:183734942	ABCC5	0.48	8.33	0.42	2.17e-15	Anterior chamber depth;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04628197	chr6:143771878	ADAT2;PEX3	0.38	6.01	0.31	4.94e-9	Obesity-related traits;
CRC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg00250761	chr1:31883323	NA	-0.4	-7.41	-0.38	1.08e-12	Alcohol dependence;
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.92	0.36	2.37e-11	Mean corpuscular volume;
CRC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.82	12.79	0.58	1.09e-30	Diastolic blood pressure;
CRC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg27535305	chr1:53392650	SCP2	0.36	6.42	0.33	4.77e-10	Monocyte count;
CRC	cis	rs4750440	0.702	rs7911259	chr10:14031051	T/C	cg00551146	chr10:14014579	FRMD4A	0.36	5.74	0.3	2.11e-8	Adiponectin levels;
CRC	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.3	-0.37	2.14e-12	Response to radiotherapy in cancer (late toxicity);
CRC	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg15704280	chr7:45808275	SEPT13	0.56	6.34	0.33	7.66e-10	Intraocular pressure;
CRC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.57	8.47	0.42	8.25e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.79	13.51	0.6	2.13e-33	Menopause (age at onset);
CRC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7113874	0.524	rs10769926	chr11:8623674	C/A	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.7	-0.35	9.27e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg02569458	chr12:86230093	RASSF9	0.41	6.84	0.35	3.79e-11	Major depressive disorder;
CRC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04671367	chr2:220159849	PTPRN;MIR153-1	0.44	6.27	0.33	1.13e-9	Response to antipsychotic treatment;
CRC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.52	7.54	0.38	4.61e-13	Uric acid levels;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg03804128	chr16:635623	NA	0.3	6.9	0.36	2.63e-11	Height;
CRC	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.01	-0.31	4.94e-9	Retinal vascular caliber;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27294431	chr1:186344717	TPR;C1orf27;MIR548F1	0.48	6.19	0.32	1.81e-9	Thyroid stimulating hormone;
CRC	cis	rs12900413	0.687	rs6496602	chr15:90317797	A/G	cg24249390	chr15:90295951	MESP1	-0.57	-9.35	-0.46	1.36e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.57	-9.31	-0.46	1.82e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg00105475	chr2:10696890	NA	0.45	7.27	0.37	2.63e-12	Prostate cancer;
CRC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.95	12.57	0.57	7.49e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg10665199	chr7:133106180	EXOC4	0.46	7.21	0.37	3.96e-12	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.49	-0.38	6.52e-13	Colorectal cancer;
CRC	trans	rs12438945	0.638	rs1915215	chr15:55199477	A/C	cg18374948	chr20:62194192	PRIC285	0.45	6.31	0.33	8.86e-10	Glucose homeostasis traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24482724	chr7:43878609	NA	0.36	6.07	0.32	3.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.71	8.99	0.44	2.02e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.87	15.53	0.65	3.5e-41	Multiple system atrophy;
CRC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg03030879	chr14:75389066	RPS6KL1	0.45	6.83	0.35	4.12e-11	Height;
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg26116260	chr4:7069785	GRPEL1	-0.48	-7.14	-0.37	6.14e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg23815491	chr16:72088622	HP	0.51	7.92	0.4	3.65e-14	Fibrinogen levels;
CRC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.92	0.36	2.32e-11	Blood metabolite levels;
CRC	cis	rs6585424	0.929	rs12256429	chr10:81938632	A/G	cg11900509	chr10:81946545	ANXA11	-0.7	-8.68	-0.43	1.83e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.54	-9.88	-0.48	2.5e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg08314208	chr16:67682810	RLTPR	-0.47	-5.66	-0.3	3.25e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.46	0.42	8.98e-16	Height;
CRC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.54	6.85	0.35	3.62e-11	Morning vs. evening chronotype;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg20095338	chr12:76478402	NAP1L1	0.5	6.48	0.34	3.26e-10	Hip circumference;
CRC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.44	-6.5	-0.34	2.92e-10	Cognitive test performance;
CRC	cis	rs10450586	0.863	rs6484285	chr11:27299127	G/A	cg10370305	chr11:27303972	NA	0.38	6.23	0.32	1.42e-9	Total body bone mineral density;
CRC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.69	11.18	0.52	7.93e-25	Colorectal cancer;
CRC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	16.35	0.67	2.22e-44	Platelet count;
CRC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.69	10.61	0.5	8.23e-23	Diastolic blood pressure;
CRC	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg23112188	chr14:24563095	PCK2	-0.36	-7.02	-0.36	1.29e-11	IgG glycosylation;
CRC	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg06462663	chr19:18546047	ISYNA1	0.49	7.08	0.36	9.04e-12	Breast cancer;
CRC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.61	9.12	0.45	7.81e-18	Lung cancer;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.61	-8.55	-0.43	4.86e-16	Blood pressure (smoking interaction);
CRC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.02	10.46	0.5	2.75e-22	Diabetic retinopathy;
CRC	cis	rs7945705	0.902	rs11042088	chr11:8843515	T/A	cg12365402	chr11:9010492	NRIP3	0.43	6.7	0.35	9.32e-11	Hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06906980	chr8:86157935	CA13	0.37	6.19	0.32	1.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.62	-0.3	4e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13604008	chr9:135906154	GTF3C5	0.39	6.05	0.32	3.99e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.66	-9.43	-0.46	7.56e-19	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.72	11.3	0.53	3.17e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.51	6.86	0.35	3.52e-11	Schizophrenia;
CRC	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.09	-15.21	-0.64	6e-40	Exhaled nitric oxide output;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg27532560	chr4:187881888	NA	0.55	10.16	0.49	2.85e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.75	-11.78	-0.54	5.8e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.66	6.33	0.33	8.06e-10	Initial pursuit acceleration;
CRC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.76	14.55	0.63	2.18e-37	Body mass index;
CRC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.67e-18	Parkinson's disease;
CRC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.52	8.06	0.41	1.39e-14	Methadone dose in opioid dependence;
CRC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.01	-0.31	4.82e-9	Diabetic kidney disease;
CRC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.69	11.0	0.52	3.53e-24	Type 2 diabetes;
CRC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.77	-0.54	6.28e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg15412446	chr2:106886593	NA	0.58	8.42	0.42	1.19e-15	Facial morphology (factor 23);
CRC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.79	7.9	0.4	4.24e-14	Diabetic retinopathy;
CRC	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg27284194	chr4:1044797	NA	0.52	5.96	0.31	6.48e-9	Recombination rate (females);
CRC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.33	-0.37	1.8e-12	Chronic sinus infection;
CRC	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.89e-8	Prostate cancer;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg15845792	chr6:28175446	NA	0.78	10.29	0.49	1.02e-21	Parkinson's disease;
CRC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.69	-0.39	1.7e-13	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21501234	chr15:64683155	TRIP4	0.49	7.58	0.39	3.58e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.39	6.26	0.33	1.18e-9	Total body bone mineral density;
CRC	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.16	0.45	5.87e-18	Dupuytren's disease;
CRC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg02569458	chr12:86230093	RASSF9	-0.45	-7.67	-0.39	1.98e-13	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.46	6.73	0.35	7.56e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3018066	0.831	rs6842919	chr4:106958170	A/G	cg01869342	chr4:106983673	TBCK	0.42	6.43	0.33	4.55e-10	Cancer;
CRC	cis	rs2108622	0.785	rs3093199	chr19:15989871	T/A	cg13772218	chr19:15982569	NA	0.48	6.8	0.35	4.99e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg12205742	chr18:68097929	NA	-0.51	-6.58	-0.34	1.9e-10	Hip circumference;
CRC	trans	rs4591358	0.638	rs6732435	chr2:196406225	C/A	cg12742475	chr15:75233485	NA	0.31	6.1	0.32	2.99e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
CRC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.79	0.51	1.94e-23	Motion sickness;
CRC	cis	rs853679	0.567	rs7740429	chr6:28399246	G/A	cg21251018	chr6:28226885	NKAPL	0.42	6.06	0.32	3.79e-9	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08210568	chr3:15141216	ZFYVE20	0.46	6.36	0.33	6.66e-10	Thyroid stimulating hormone;
CRC	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg09659197	chr4:152720779	NA	0.47	9.97	0.48	1.24e-20	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18912574	chr7:65842487	NCRNA00174	0.39	6.7	0.35	9.19e-11	Aortic root size;
CRC	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	6.46	0.34	3.83e-10	Neuroticism;
CRC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg00769240	chr8:12517080	NA	-0.66	-7.22	-0.37	3.65e-12	Blood pressure (smoking interaction);
CRC	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.42	-5.69	-0.3	2.81e-8	Schizophrenia;
CRC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.37	5.73	0.3	2.3e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.14	-0.32	2.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	trans	rs7144011	0.654	rs4903847	chr14:79854832	A/G	cg13986881	chr7:73669141	RFC2	-0.49	-7.18	-0.37	4.65e-12	Waist circumference;Hip circumference;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11263705	chr1:181059175	IER5	0.43	5.98	0.31	5.92e-9	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04616222	chr10:99078965	FRAT1	0.39	6.06	0.32	3.79e-9	Schizophrenia;
CRC	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.66	-10.24	-0.49	1.52e-21	Ulcerative colitis;
CRC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.77	-10.67	-0.51	4.9e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.51	9.37	0.46	1.15e-18	Educational attainment (years of education);
CRC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs12612619	0.704	rs7602823	chr2:27309406	G/A	cg00617064	chr2:27272375	NA	0.41	6.72	0.35	7.84e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.51	8.04	0.41	1.66e-14	Neurofibrillary tangles;
CRC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.45	-0.34	4e-10	Electroencephalogram traits;
CRC	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.54	7.51	0.38	5.75e-13	Triglycerides;
CRC	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.51	-7.21	-0.37	3.87e-12	Schizophrenia;
CRC	cis	rs7072216	0.922	rs7097824	chr10:100151799	A/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.25	-0.33	1.29e-9	Metabolite levels;
CRC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.73	12.84	0.58	7.06e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.64	9.64	0.47	1.56e-19	Breast cancer;
CRC	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	6.82	0.35	4.39e-11	Lymphocyte counts;
CRC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.22	15.02	0.64	3.51e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.8	12.23	0.56	1.37e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.35	-0.46	1.38e-18	Prevalent atrial fibrillation;
CRC	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg15192750	chr16:69999425	NA	0.57	7.37	0.38	1.39e-12	IgE levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09614276	chr2:28975489	PPP1CB	0.42	6.07	0.32	3.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.4	-7.21	-0.37	3.87e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-12.4	-0.56	3.09e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.68	-0.3	3.02e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23378565	chr7:2036160	MAD1L1	-0.43	-5.88	-0.31	1.02e-8	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13720744	chr22:21271392	CRKL	0.43	6.15	0.32	2.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg26958806	chr6:27640298	NA	-0.83	-5.69	-0.3	2.75e-8	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg26727032	chr16:67993705	SLC12A4	-0.65	-8.23	-0.41	4.45e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.75	-0.3	2.05e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.12	-0.41	9.62e-15	Intelligence (multi-trait analysis);
CRC	cis	rs75422866	0.867	rs73104103	chr12:48063387	A/G	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.03	-0.32	4.46e-9	Pneumonia;
CRC	trans	rs10504390	0.656	rs74776773	chr8:66544150	G/A	cg26403416	chr21:43771339	TFF2	0.6	6.14	0.32	2.38e-9	IgG glycosylation;
CRC	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-0.66	-9.8	-0.48	4.69e-20	Acne (severe);
CRC	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg18830697	chr6:72922368	RIMS1	-0.39	-7.92	-0.4	3.81e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	9.44	0.46	6.94e-19	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23142935	chr16:22385308	CDR2	0.46	6.64	0.34	1.3100000000000001e-10	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.68	7.6	0.39	3.04e-13	Vitiligo;
CRC	cis	rs4654899	0.680	rs6692553	chr1:21221497	C/T	cg02927042	chr1:21476669	EIF4G3	0.37	5.73	0.3	2.27e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs1062746	0.502	rs11649601	chr16:87339220	G/C	cg02258303	chr16:87377426	FBXO31	-0.56	-8.22	-0.41	4.78e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.47	7.15	0.37	5.74e-12	Testicular germ cell tumor;
CRC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.27	-0.41	3.44e-15	Mean platelet volume;
CRC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg12463550	chr7:65579703	CRCP	0.63	5.98	0.31	5.8e-9	Diabetic kidney disease;
CRC	cis	rs73200209	0.912	rs61935854	chr12:116655496	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.78	-0.3	1.72e-8	Total body bone mineral density;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-5.63	-0.3	3.92e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg15147215	chr3:52552868	STAB1	-0.46	-7.53	-0.38	4.9e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.63	11.64	0.54	1.89e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.37	6.05	0.32	3.88e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.75	-12.27	-0.56	9.78e-29	Plateletcrit;Platelet count;
CRC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg13844804	chr7:814759	HEATR2	-0.68	-7.88	-0.4	4.93e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg09659197	chr4:152720779	NA	0.52	11.47	0.53	7.73e-26	Intelligence (multi-trait analysis);
CRC	trans	rs10504390	0.585	rs118053995	chr8:66554766	G/A	cg26403416	chr21:43771339	TFF2	0.59	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.4	6.14	0.32	2.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.83	-9.93	-0.48	1.68e-20	Initial pursuit acceleration;
CRC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.81	13.63	0.6	7.36e-34	Menopause (age at onset);
CRC	cis	rs3751196	0.908	rs78660952	chr12:104214990	A/T	cg02344784	chr12:104178138	NT5DC3	0.7	8.24	0.41	4.16e-15	Sense of smell;
CRC	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg01422370	chr2:73384389	NA	0.38	6.03	0.32	4.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.05	-0.36	1.08e-11	Aortic root size;
CRC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.59	8.47	0.42	8.46e-16	Crohn's disease;
CRC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg21922841	chr17:72744131	SLC9A3R1	-0.28	-6.03	-0.32	4.5e-9	Monocyte count;
CRC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg21138405	chr5:131827807	IRF1	-0.36	-6.24	-0.33	1.33e-9	Breast cancer;Mosquito bite size;
CRC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg08975724	chr8:8085496	FLJ10661	0.39	6.07	0.32	3.55e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg04553112	chr3:125709451	NA	-0.52	-5.84	-0.31	1.24e-8	Blood pressure (smoking interaction);
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg00769240	chr8:12517080	NA	-0.74	-10.23	-0.49	1.64e-21	Blood pressure (smoking interaction);
CRC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.97e-22	Menopause (age at onset);
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10819733	chr22:24237672	NA	-0.35	-6.0	-0.31	5.14e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.94	-13.45	-0.6	3.66e-33	Breast cancer;
CRC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg14352298	chr13:112236639	NA	0.29	6.59	0.34	1.74e-10	Hepatitis;
CRC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.97	-0.36	1.7e-11	Aortic root size;
CRC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	10.48	0.5	2.37e-22	Prudent dietary pattern;
CRC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.66	8.48	0.42	7.48e-16	Bronchopulmonary dysplasia;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg26460816	chr5:65892187	MAST4	0.34	6.0	0.31	5.21e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.57	7.83	0.4	6.71e-14	Hemoglobin concentration;
CRC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.49	-6.06	-0.32	3.78e-9	Bipolar disorder;
CRC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.88	10.19	0.49	2.18e-21	Psoriasis;
CRC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg24289452	chr6:170231220	NA	-0.54	-6.01	-0.31	5.05e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg12855166	chr17:30846586	MYO1D	0.36	5.82	0.31	1.42e-8	Schizophrenia;
CRC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-7.08	-0.36	8.98e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg21548813	chr6:291882	DUSP22	-0.53	-7.33	-0.37	1.83e-12	Menopause (age at onset);
CRC	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.55	10.4	0.5	4.28e-22	Urate levels in lean individuals;
CRC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.44	7.31	0.37	2.08e-12	Major depressive disorder;
CRC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.99	12.83	0.58	8.12e-31	Cerebrospinal P-tau181p levels;
CRC	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.54	-9.69	-0.47	1.06e-19	Common traits (Other);
CRC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.44	-7.13	-0.37	6.29e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.07	0.36	9.43e-12	Cardiac Troponin-T levels;
CRC	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.52	7.41	0.38	1.07e-12	Corneal astigmatism;
CRC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.51	-7.52	-0.38	5.23e-13	Dementia with Lewy bodies;
CRC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.53	0.5	1.51e-22	Skin colour saturation;
CRC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02807482	chr3:125708958	NA	-0.45	-5.65	-0.3	3.39e-8	Blood pressure (smoking interaction);
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg25164649	chr6:28176230	NA	0.54	7.3	0.37	2.13e-12	Parkinson's disease;
CRC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg18512352	chr11:47633146	NA	-0.36	-7.0	-0.36	1.42e-11	Subjective well-being;
CRC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg12437481	chr16:420112	MRPL28	-0.64	-8.23	-0.41	4.31e-15	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.64	6.49	0.34	3.15e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4757319	0.515	rs10832402	chr11:15334036	C/T	cg03245590	chr11:15329459	NA	-0.55	-9.85	-0.48	3.03e-20	Breast cancer;
CRC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.47	8.74	0.43	1.25e-16	Renal cell carcinoma;
CRC	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.68	5.6	0.3	4.45e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg21770322	chr7:97807741	LMTK2	0.54	8.87	0.44	4.84e-17	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	0.92	11.23	0.53	5.4e-25	Hip circumference adjusted for BMI;
CRC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg27074582	chr2:240114406	HDAC4	0.4	5.75	0.3	2.05e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg13385794	chr1:248469461	NA	0.4	6.8	0.35	4.87e-11	Common traits (Other);
CRC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.43	-5.64	-0.3	3.68e-8	Parkinson's disease;
CRC	cis	rs17152411	0.843	rs7904691	chr10:126582927	G/T	cg07906193	chr10:126599966	NA	0.55	6.17	0.32	1.95e-9	Height;
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.38	6.82	0.35	4.39e-11	Cardiovascular disease risk factors;
CRC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-10.67	-0.51	4.9e-23	Personality dimensions;
CRC	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.39	7.01	0.36	1.34e-11	Hepatitis;
CRC	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg27532560	chr4:187881888	NA	0.54	10.05	0.48	6.48e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg18240062	chr17:79603768	NPLOC4	0.55	8.36	0.42	1.77e-15	Myopia;
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs9311676	0.656	rs11130636	chr3:58380098	C/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs7215564	0.908	rs59252837	chr17:78717155	A/G	cg09596252	chr17:78655493	RPTOR	0.58	6.25	0.33	1.28e-9	Myopia (pathological);
CRC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg05139728	chr16:28306816	SBK1	-0.33	-5.63	-0.3	3.77e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.1	-0.45	9.06e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.66	-11.09	-0.52	1.77e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg18335740	chr13:41363409	SLC25A15	0.55	8.48	0.42	8e-16	Lewy body disease;
CRC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.84	-11.65	-0.54	1.72e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg09264619	chr17:80180166	NA	0.38	6.28	0.33	1.08e-9	Life satisfaction;
CRC	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.48	-6.2	-0.32	1.71e-9	Systemic lupus erythematosus;
CRC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.69	10.74	0.51	2.99e-23	Diastolic blood pressure;
CRC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.82	9.16	0.45	5.68e-18	Breast cancer;
CRC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg16141378	chr3:129829833	LOC729375	0.42	6.4	0.33	5.2e-10	Triglycerides;
CRC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.72	12.02	0.55	7.59e-28	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.66	8.8	0.44	7.85e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.62	9.4	0.46	9.26e-19	Menopause (age at onset);
CRC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.44	-0.46	7.25e-19	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9914544	0.564	rs8072860	chr17:18807884	T/C	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.27	-0.33	1.14e-9	Educational attainment (years of education);
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.42	6.09	0.32	3.24e-9	Longevity;Endometriosis;
CRC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.47	7.17	0.37	5.06e-12	Corneal astigmatism;
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.31	0.37	2.06e-12	Alzheimer's disease;
CRC	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.85	-14.62	-0.63	1.17e-37	Longevity;
CRC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.76	10.12	0.49	4e-21	Coronary artery disease;
CRC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.79	0.39	8.74e-14	Height;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg15786705	chr6:28176104	NA	0.54	7.06	0.36	1.01e-11	Parkinson's disease;
CRC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.73	11.54	0.54	4.38e-26	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg27615366	chr5:131592974	PDLIM4	0.34	6.48	0.34	3.38e-10	Acylcarnitine levels;
CRC	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.64	9.15	0.45	6.22e-18	Coronary artery disease;
CRC	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.27	0.46	2.56e-18	Iron status biomarkers;
CRC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg22834771	chr12:69754056	YEATS4	0.41	5.81	0.31	1.46e-8	Blood protein levels;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg26587870	chr6:27730563	NA	0.43	6.77	0.35	5.86e-11	Parkinson's disease;
CRC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.89	14.0	0.61	3e-35	Cognitive ability;
CRC	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.66	8.79	0.44	8.55e-17	Uric acid levels;
CRC	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg21851534	chr17:3907994	ZZEF1	0.36	6.26	0.33	1.2e-9	Type 2 diabetes;
CRC	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.8	-0.44	8.15e-17	Neuroticism;
CRC	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg09655341	chr17:79618100	PDE6G	0.61	6.41	0.33	4.93e-10	Dental caries;
CRC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs6445967	1.000	rs62258069	chr3:58315263	A/T	cg23715586	chr3:58305044	RPP14	0.37	6.01	0.31	4.82e-9	Platelet count;
CRC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	8.26	0.41	3.58e-15	Resting heart rate;
CRC	cis	rs11203032	0.831	rs11203017	chr10:90948709	C/T	cg16672925	chr10:90967113	CH25H	0.46	5.79	0.3	1.66e-8	Heart failure;
CRC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.62	10.03	0.48	7.58e-21	Aortic root size;
CRC	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg16576597	chr16:28551801	NUPR1	0.49	7.46	0.38	7.89e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4731207	0.698	rs12538083	chr7:124554057	T/C	cg23710748	chr7:124431027	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Cutaneous malignant melanoma;
CRC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.65	-6.95	-0.36	1.91e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg00383909	chr3:49044727	WDR6	0.45	5.66	0.3	3.24e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg19913688	chr11:428466	ANO9	-0.72	-7.54	-0.38	4.53e-13	Body mass index;
CRC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.85	-14.05	-0.61	1.81e-35	Prudent dietary pattern;
CRC	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.4	-6.94	-0.36	2.11e-11	Hip circumference;Waist circumference;
CRC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.61	-0.39	2.98e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.51	7.9	0.4	4.1e-14	HDL cholesterol;
CRC	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.43	6.68	0.35	9.93e-11	C-reactive protein levels;
CRC	cis	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg20159608	chr7:32802032	NA	-0.59	-7.37	-0.38	1.36e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.51	7.27	0.37	2.72e-12	Corneal astigmatism;
CRC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg12317470	chr15:67143691	NA	0.71	7.26	0.37	2.78e-12	Lung cancer (smoking interaction);
CRC	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.68	-8.51	-0.42	6.4e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.63	8.25	0.41	3.83e-15	Alzheimer's disease;
CRC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg24011408	chr12:48396354	COL2A1	-0.44	-6.47	-0.34	3.47e-10	Glycated hemoglobin levels;
CRC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-10.44	-0.5	3.21e-22	Sudden cardiac arrest;
CRC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.81	14.33	0.62	1.58e-36	Vitiligo;
CRC	cis	rs9287719	0.593	rs13009015	chr2:10763118	T/A	cg00105475	chr2:10696890	NA	0.47	7.12	0.37	6.73e-12	Prostate cancer;
CRC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.86	11.68	0.54	1.38e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.86e-9	Arsenic metabolism;
CRC	trans	rs1413885	1.000	rs1536174	chr1:65813709	G/C	cg26534493	chr8:28060551	NA	-0.37	-6.01	-0.31	5e-9	Anticoagulant levels;
CRC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.84	-14.46	-0.62	4.99e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg18404041	chr3:52824283	ITIH1	0.42	7.65	0.39	2.27e-13	Schizophrenia;
CRC	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg13491945	chr12:107078410	RFX4	0.36	6.16	0.32	2.13e-9	Heart rate;
CRC	cis	rs76793172	0.660	rs3760843	chr19:46288706	A/T	cg11657440	chr19:46296263	DMWD	-0.56	-5.96	-0.31	6.65e-9	Eosinophil counts;
CRC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.65	-12.07	-0.55	5.12e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.76	12.66	0.57	3.53e-30	Mosquito bite size;
CRC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.64	-0.51	6.5e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26240231	chr7:1148101	C7orf50	-0.42	-6.04	-0.32	4.14e-9	Bronchopulmonary dysplasia;
CRC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17554472	chr22:41940697	POLR3H	-0.57	-5.96	-0.31	6.34e-9	Vitiligo;
CRC	cis	rs7274811	0.688	rs56234419	chr20:32086447	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.45	-5.98	-0.31	5.84e-9	Height;
CRC	trans	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg26043149	chr18:55253948	FECH	-0.49	-7.42	-0.38	9.82e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.38	-0.33	5.98e-10	Dupuytren's disease;
CRC	cis	rs6840360	0.642	rs1443089	chr4:152450300	A/G	cg09659197	chr4:152720779	NA	0.33	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.49	8.65	0.43	2.28e-16	Information processing speed;
CRC	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.59	8.65	0.43	2.3e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg27535305	chr1:53392650	SCP2	0.39	6.97	0.36	1.72e-11	Monocyte count;
CRC	cis	rs11212617	0.967	rs60683001	chr11:108257787	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.63	0.34	1.39e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.86e-12	Prostate cancer;
CRC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.41	6.33	0.33	8.21e-10	Type 2 diabetes;
CRC	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.45	7.21	0.37	3.75e-12	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CRC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.61	8.9	0.44	3.71e-17	Multiple sclerosis;
CRC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.87	-0.48	2.66e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.58	9.87	0.48	2.72e-20	Breast cancer;
CRC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.36	-7.42	-0.38	1.04e-12	Cutaneous nevi;
CRC	cis	rs1712517	0.771	rs7921655	chr10:105113701	C/T	cg05636881	chr10:105038444	INA	0.48	8.22	0.41	4.68e-15	Migraine;
CRC	cis	rs1178968	1.000	rs1178959	chr7:72777093	T/C	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs7301826	0.651	rs12228957	chr12:131296066	T/C	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.51	-7.64	-0.39	2.45e-13	Calcium levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.43	6.08	0.32	3.32e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg19223190	chr17:80058835	NA	-0.42	-6.42	-0.33	4.88e-10	Life satisfaction;
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg06713098	chr7:45960367	IGFBP3	0.42	6.65	0.34	1.25e-10	Sitting height ratio;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09501006	chr9:78505549	PCSK5	0.46	6.76	0.35	6.18e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.86	-12.08	-0.55	4.55e-28	Type 2 diabetes;
CRC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.47	7.12	0.37	6.98e-12	Red blood cell count;
CRC	cis	rs524281	0.682	rs4483592	chr11:65990439	C/T	cg14036092	chr11:66035641	RAB1B	-0.56	-6.36	-0.33	6.73e-10	Electroencephalogram traits;
CRC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.47	7.4	0.38	1.16e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg24361086	chr7:123388661	WASL	0.49	6.16	0.32	2.07e-9	Resistin levels;
CRC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.62	0.34	1.44e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.56	6.49	0.34	3.15e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg23533926	chr12:111358616	MYL2	-0.52	-7.82	-0.4	7.43e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.52	-0.75	7.88e-61	Primary sclerosing cholangitis;
CRC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg02569458	chr12:86230093	RASSF9	0.4	6.66	0.34	1.12e-10	Major depressive disorder;
CRC	trans	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg26043149	chr18:55253948	FECH	0.54	8.28	0.42	3.09e-15	Bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05314606	chr18:46478925	NA	0.45	6.3	0.33	9.58e-10	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.97	-0.48	1.29e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.65	0.34	1.25e-10	Response to temozolomide;
CRC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.42	-7.09	-0.36	8.2e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.82	14.75	0.63	3.69e-38	Vitiligo;
CRC	trans	rs909848	0.583	rs479934	chr1:71442206	C/T	cg23933503	chr22:44255884	SULT4A1	-0.39	-6.07	-0.32	3.47e-9	IgG glycosylation;
CRC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg20790798	chr5:1857306	NA	-0.45	-6.82	-0.35	4.3e-11	Cardiovascular disease risk factors;
CRC	cis	rs4499344	0.633	rs259262	chr19:33153951	G/A	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg25985355	chr7:65971099	NA	-0.32	-5.67	-0.3	3.12e-8	Aortic root size;
CRC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.73	11.48	0.53	7.02e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.39	-0.38	1.2e-12	Height;
CRC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg20608306	chr11:116969690	SIK3	-0.3	-5.62	-0.3	4.04e-8	Blood protein levels;
CRC	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.53	-6.05	-0.32	3.93e-9	Coronary artery disease;
CRC	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg01639898	chr1:32083012	HCRTR1	0.3	6.28	0.33	1.1e-9	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26708280	chr2:190649305	PMS1;ORMDL1	0.54	7.08	0.36	8.85e-12	Thyroid stimulating hormone;
CRC	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	1.05	8.48	0.42	7.47e-16	Economic and political preferences (immigration/crime);
CRC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg26816564	chr1:7831052	VAMP3	0.58	6.32	0.33	8.47e-10	Inflammatory bowel disease;
CRC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg05623727	chr3:50126028	RBM5	-0.45	-7.38	-0.38	1.33e-12	Intelligence (multi-trait analysis);
CRC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.51	-7.18	-0.37	4.65e-12	Pancreatic cancer;
CRC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.68	10.09	0.49	4.79e-21	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03661160	chr7:97881541	TECPR1	0.45	7.36	0.38	1.45e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	16.07	0.66	2.57e-43	Lymphocyte percentage of white cells;
CRC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.46	-7.43	-0.38	9.15e-13	Obesity-related traits;
CRC	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg17691542	chr6:26056736	HIST1H1C	-0.63	-8.02	-0.4	1.91e-14	Iron status biomarkers;
CRC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.38	-6.72	-0.35	7.93e-11	Abdominal aortic aneurysm;
CRC	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.51	6.71	0.35	8.67e-11	Coronary artery disease;
CRC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg15440763	chr7:158190612	PTPRN2	-0.41	-6.64	-0.34	1.28e-10	Obesity-related traits;
CRC	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.34e-11	Response to antipsychotic treatment;
CRC	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg18612461	chr15:75251733	NA	-0.37	-5.64	-0.3	3.57e-8	Caffeine consumption;
CRC	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg09659197	chr4:152720779	NA	0.53	11.71	0.54	1.06e-26	Intelligence (multi-trait analysis);
CRC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.7	-11.76	-0.54	6.76e-27	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02308097	chr17:79868996	PCYT2	0.45	6.33	0.33	8.1e-10	Anxiety disorder;
CRC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.54	-7.9	-0.4	4.27e-14	Height;
CRC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.37	-5.89	-0.31	9.8e-9	Multiple sclerosis;
CRC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg23254163	chr1:152506842	NA	0.45	8.66	0.43	2.2e-16	Hair morphology;
CRC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg00343986	chr7:65444356	GUSB	-0.5	-7.46	-0.38	7.61e-13	Aortic root size;
CRC	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg23127183	chr11:57508653	C11orf31	-0.53	-7.1	-0.36	7.73e-12	Schizophrenia;
CRC	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.61	-0.34	1.56e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Body mass index;
CRC	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.85	-15.05	-0.64	2.48e-39	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05332869	chr20:39658073	TOP1	0.44	6.04	0.32	4.27e-9	Response to antipsychotic treatment;
CRC	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.57	0.34	1.92e-10	Morning vs. evening chronotype;
CRC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.45	-5.6	-0.3	4.48e-8	Obesity-related traits;
CRC	cis	rs4290604	0.748	rs12692198	chr2:238057391	C/A	cg23555395	chr2:238036564	NA	-0.67	-6.81	-0.35	4.62e-11	Asthma;
CRC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.48	0.42	7.81e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.47	7.3	0.37	2.17e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.53	6.2	0.32	1.71e-9	Pulse pressure;
CRC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.49	6.25	0.33	1.26e-9	Schizophrenia;
CRC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg11189052	chr15:85197271	WDR73	0.57	8.19	0.41	5.99e-15	Schizophrenia;
CRC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.76	-0.43	1.08e-16	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs9826463	0.757	rs79576118	chr3:142244645	A/C	cg13928417	chr9:124498782	DAB2IP	-0.53	-5.97	-0.31	6.09e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.66	0.34	1.12e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg00129232	chr17:37814104	STARD3	0.37	5.61	0.3	4.19e-8	Asthma;
CRC	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.79	9.75	0.47	6.64e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.49	-6.05	-0.32	3.93e-9	Coronary artery calcification;
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.57	9.92	0.48	1.87e-20	Leprosy;
CRC	cis	rs9462027	0.628	rs9469894	chr6:34774725	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.32	4.37e-9	Systemic lupus erythematosus;
CRC	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg19875535	chr5:140030758	IK	0.41	6.26	0.33	1.23e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03188948	chr7:1209495	NA	0.43	6.29	0.33	9.85e-10	Longevity;Endometriosis;
CRC	cis	rs2274273	0.624	rs7159824	chr14:55772536	C/T	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.74	-0.3	2.18e-8	Protein biomarker;
CRC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.5	-8.69	-0.43	1.78e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.56	8.13	0.41	8.9e-15	Obesity-related traits;
CRC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.44	-6.14	-0.32	2.38e-9	Prudent dietary pattern;
CRC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.98	0.31	5.83e-9	Melanoma;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs965469	0.779	rs6051746	chr20:3307290	C/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.66	-0.3	3.37e-8	IFN-related cytopenia;
CRC	cis	rs728616	0.558	rs116434658	chr10:81754626	G/A	cg05935833	chr10:81318306	SFTPA2	-0.55	-7.13	-0.37	6.42e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.11	0.61	1.13e-35	Mean platelet volume;
CRC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.72	-12.34	-0.56	5.1e-29	Age at first birth;
CRC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.35	5.71	0.3	2.54e-8	Menarche (age at onset);
CRC	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.18	12.4	0.56	3.09e-29	Opioid sensitivity;
CRC	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.97	0.52	4.54e-24	Exhaled nitric oxide output;
CRC	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.35	-5.63	-0.3	3.89e-8	Height;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.41	-7.27	-0.37	2.67e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg26043149	chr18:55253948	FECH	0.53	8.21	0.41	5.13e-15	Bone mineral density;
CRC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.84	10.35	0.5	6.46e-22	Menarche (age at onset);
CRC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg10298567	chr3:47292165	KIF9	-0.36	-5.96	-0.31	6.33e-9	Colorectal cancer;
CRC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.74	9.85	0.48	3.12e-20	Platelet count;
CRC	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.66	7.14	0.37	5.98e-12	Childhood ear infection;
CRC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg24562669	chr7:97807699	LMTK2	0.8	17.62	0.7	2.1e-49	Breast cancer;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23708337	chr7:1209742	NA	0.43	6.37	0.33	6.55e-10	Longevity;Endometriosis;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg04369251	chr14:32671021	NA	0.43	6.09	0.32	3.09e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs80207740	1.000	rs17296501	chr8:21849566	C/T	cg12468850	chr8:21767224	DOK2	-0.52	-6.08	-0.32	3.24e-9	Mean corpuscular hemoglobin;
CRC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg23758597	chr6:163146217	PARK2	-0.65	-6.58	-0.34	1.91e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg06484146	chr7:12443880	VWDE	-0.54	-7.46	-0.38	8e-13	Coronary artery disease;
CRC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.17	0.41	6.8e-15	Parkinson's disease;
CRC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg01879757	chr17:41196368	BRCA1	-0.4	-5.96	-0.31	6.61e-9	Menopause (age at onset);
CRC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	10.11	0.49	4.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.72	-12.64	-0.57	3.92e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg08270630	chr22:50330655	NA	0.41	6.12	0.32	2.7e-9	Schizophrenia;
CRC	trans	rs9826463	0.757	rs75100831	chr3:142244647	T/C	cg13928417	chr9:124498782	DAB2IP	-0.53	-5.97	-0.31	6.09e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg00318322	chr16:67708822	GFOD2	-0.32	-6.02	-0.32	4.53e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.77	6.77	0.35	6.01e-11	Body mass index;
CRC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.51	8.98	0.44	2.07e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg16589663	chr20:23618590	CST3	0.56	7.27	0.37	2.64e-12	Chronic kidney disease;
CRC	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg03315344	chr16:75512273	CHST6	0.5	5.96	0.31	6.52e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg26587870	chr6:27730563	NA	-0.38	-5.95	-0.31	6.72e-9	Hepatitis A;
CRC	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg18404041	chr3:52824283	ITIH1	0.34	6.21	0.32	1.6e-9	Schizophrenia;
CRC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg17724175	chr1:150552817	MCL1	0.4	6.15	0.32	2.27e-9	Melanoma;
CRC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.72	-11.23	-0.53	5.62e-25	Blood metabolite levels;
CRC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.34	-0.37	1.72e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.73	0.39	1.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2303319	0.504	rs62188987	chr2:162525686	T/A	cg12500891	chr11:57225987	NA	-0.67	-6.12	-0.32	2.62e-9	Cognitive function;
CRC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg00601450	chr5:74908170	NA	0.4	5.6	0.3	4.48e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CRC	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.09	0.41	1.2e-14	Type 2 diabetes;
CRC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07951810	chr12:65153561	GNS	-0.44	-6.27	-0.33	1.11e-9	Asthma;
CRC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.17	-0.32	1.96e-9	Alzheimer's disease (late onset);
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.62	8.76	0.43	1.04e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.52	-8.36	-0.42	1.75e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg00691999	chr4:55094011	PDGFRA	0.44	6.46	0.34	3.74e-10	Corneal astigmatism;
CRC	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.54	8.1	0.41	1.08e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg02119577	chr21:40195074	ETS2	-0.37	-6.28	-0.33	1.08e-9	Non-small cell lung cancer (survival);
CRC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg04166393	chr7:2884313	GNA12	0.41	6.27	0.33	1.1e-9	Height;
CRC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.11	0.49	4.15e-21	Platelet count;
CRC	trans	rs6956675	0.874	rs6968344	chr7:62574533	A/G	cg01314568	chr7:57830625	NA	-0.68	-9.31	-0.46	1.91e-18	Obesity-related traits;
CRC	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg16898833	chr6:26189333	HIST1H4D	0.7	5.76	0.3	1.93e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7572644	0.640	rs4666022	chr2:28057823	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.23	0.32	1.44e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.57	-9.72	-0.47	8.23e-20	Prevalent atrial fibrillation;
CRC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.99	-19.49	-0.73	8.32e-57	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.66	-8.73	-0.43	1.34e-16	Facial morphology (factor 19);
CRC	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.57	9.93	0.48	1.73e-20	Leprosy;
CRC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg16141378	chr3:129829833	LOC729375	0.42	6.14	0.32	2.38e-9	Triglycerides;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg08852759	chr2:33701319	RASGRP3	-0.39	-6.14	-0.32	2.35e-9	HDL cholesterol;
CRC	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.54	8.2	0.41	5.59e-15	Testicular germ cell tumor;
CRC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg10589385	chr1:150898437	SETDB1	0.3	6.08	0.32	3.34e-9	Melanoma;
CRC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.27	-15.22	-0.64	5.52e-40	Diabetic kidney disease;
CRC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-8.17	-0.41	6.83e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.81	-13.78	-0.6	2.11e-34	Bone mineral density;
CRC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.53	7.57	0.39	3.7e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.46	5.82	0.31	1.39e-8	Aortic root size;
CRC	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	0.79	10.84	0.51	1.32e-23	Gout;
CRC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.32	0.37	1.86e-12	Hip circumference adjusted for BMI;
CRC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.5	-8.72	-0.43	1.38e-16	Hypertriglyceridemia;
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.68	8.84	0.44	5.82e-17	Alzheimer's disease;
CRC	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg20608306	chr11:116969690	SIK3	-0.31	-5.81	-0.31	1.47e-8	Blood protein levels;
CRC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.78	-9.7	-0.47	9.76e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg21399703	chr1:247681439	NA	0.48	7.88	0.4	4.91e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7539542	0.556	rs6427979	chr1:202869503	T/C	cg19681188	chr1:202830198	LOC148709	0.47	6.8	0.35	4.94e-11	Mean platelet volume;
CRC	cis	rs7264396	0.887	rs224351	chr20:34052273	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.61	-0.34	1.55e-10	Total cholesterol levels;
CRC	cis	rs9533799	1.000	rs2282064	chr13:44805870	G/A	cg19190762	chr13:44806055	NA	0.62	9.49	0.46	4.7e-19	Amyotrophic lateral sclerosis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06404838	chr11:117015391	PAFAH1B2	0.48	6.43	0.33	4.43e-10	Survival in pancreatic cancer;
CRC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04880052	chr2:219191631	PNKD	-0.44	-6.96	-0.36	1.83e-11	Colorectal cancer;
CRC	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.85e-13	Vitamin D levels;
CRC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.64	10.59	0.5	9.21e-23	Calcium levels;
CRC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg18016565	chr1:150552671	MCL1	0.42	5.83	0.31	1.36e-8	Melanoma;
CRC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.45	-6.69	-0.35	9.48e-11	Breast size;
CRC	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg09344028	chr17:70110421	NA	0.44	6.73	0.35	7.58e-11	Thyroid hormone levels;
CRC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.19	0.37	4.45e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.29	6.15	0.32	2.27e-9	Homoarginine levels;
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.55	-8.63	-0.43	2.66e-16	Aortic root size;
CRC	cis	rs728616	0.681	rs17677908	chr10:82049603	A/G	cg11900509	chr10:81946545	ANXA11	-0.56	-6.1	-0.32	2.94e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg26816564	chr1:7831052	VAMP3	-0.52	-6.21	-0.32	1.58e-9	Inflammatory bowel disease;
CRC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.49	7.6	0.39	3.06e-13	Bone mineral density;
CRC	cis	rs12024301	0.557	rs74981998	chr1:183593829	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.74	6.74	0.35	6.91e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11947960	chr2:112655492	MERTK	0.42	6.02	0.31	4.68e-9	Response to antipsychotic treatment;
CRC	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.43	7.07	0.36	9.62e-12	Menopause (age at onset);
CRC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-8.0	-0.4	2.15e-14	Hemoglobin concentration;
CRC	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg21095983	chr6:86352623	SYNCRIP	0.5	7.21	0.37	3.77e-12	Smooth-surface caries;
CRC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs9462027	0.628	rs9469891	chr6:34767396	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.47e-9	Systemic lupus erythematosus;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12273811	chr6:28175739	NA	0.62	9.07	0.45	1.1e-17	Cardiac Troponin-T levels;
CRC	trans	rs4276421	0.776	rs56908114	chr5:45416794	T/C	cg04793272	chr11:119020941	ABCG4	-0.38	-6.35	-0.33	7.18e-10	P wave duration;
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg04727332	chr7:45960243	IGFBP3	0.37	5.91	0.31	8.5e-9	Sitting height ratio;
CRC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg26603656	chr10:5671107	NA	0.44	7.53	0.38	4.95e-13	Breast cancer;
CRC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.24	-0.33	1.37e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27277367	chr15:100106179	MEF2A	-0.43	-6.33	-0.33	8.03e-10	Myopia (pathological);
CRC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg21770322	chr7:97807741	LMTK2	0.54	8.96	0.44	2.43e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.33	-0.37	1.81e-12	Coronary artery disease;
CRC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-6.06	-0.32	3.77e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.06	-0.36	9.75e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.72	10.84	0.51	1.31e-23	Testicular germ cell tumor;
CRC	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.91	-0.31	8.49e-9	Educational attainment (years of education);
CRC	cis	rs11948739	0.501	rs3981332	chr5:130372203	A/T	cg08523029	chr5:130500466	HINT1	-0.46	-5.98	-0.31	5.75e-9	Pediatric bone mineral content (hip);
CRC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.43	6.72	0.35	7.87e-11	Red blood cell count;
CRC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.81	0.3	1.5e-8	IgG glycosylation;
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.77	-0.3	1.8e-8	Neuroticism;
CRC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.52	-8.82	-0.44	6.68e-17	Aortic root size;
CRC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.78	11.94	0.55	1.54e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.75	-7.81	-0.4	7.94e-14	Coronary artery disease;
CRC	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24249390	chr15:90295951	MESP1	-0.6	-9.49	-0.46	4.94e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7301826	0.627	rs73162873	chr12:131296013	A/G	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	trans	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg18288967	chr1:45987694	PRDX1	0.66	6.54	0.34	2.38e-10	Obesity-related traits;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18099408	chr3:52552593	STAB1	-0.51	-8.8	-0.44	8.1e-17	Electroencephalogram traits;
CRC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	9.04	0.45	1.39e-17	Eosinophil percentage of white cells;
CRC	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.52	6.8	0.35	4.98e-11	Coronary artery disease;
CRC	trans	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg26043149	chr18:55253948	FECH	-0.52	-8.07	-0.41	1.33e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg00745463	chr17:30367425	LRRC37B	0.53	6.62	0.34	1.49e-10	Hip circumference adjusted for BMI;
CRC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg13628971	chr7:2884303	GNA12	0.47	6.47	0.34	3.58e-10	Height;
CRC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg18612461	chr15:75251733	NA	0.37	5.85	0.31	1.21e-8	Breast cancer;
CRC	trans	rs1864585	0.552	rs73208794	chr8:10681248	C/G	cg26278703	chr11:58910052	FAM111A	0.56	6.55	0.34	2.24e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs1178968	0.901	rs7779909	chr7:72751966	G/T	cg25889504	chr7:72793014	NA	0.51	5.87	0.31	1.08e-8	Triglyceride levels;
CRC	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg26220594	chr1:19110978	NA	-0.41	-6.41	-0.33	5.04e-10	Knee osteoarthritis;
CRC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.58	7.84	0.4	6.13e-14	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.39	6.48	0.34	3.34e-10	Survival in rectal cancer;
CRC	cis	rs16852403	0.548	rs615226	chr1:178194524	A/G	cg00404053	chr1:178313656	RASAL2	0.48	6.25	0.33	1.27e-9	Childhood ear infection;
CRC	cis	rs4908768	0.501	rs1463050	chr1:8597042	G/A	cg20416874	chr1:8611966	RERE	-0.46	-6.64	-0.34	1.32e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.64	-10.21	-0.49	1.97e-21	Motion sickness;
CRC	cis	rs9359856	0.872	rs9344948	chr6:90308226	T/G	cg13799429	chr6:90582589	CASP8AP2	0.43	6.06	0.32	3.63e-9	Bipolar disorder;
CRC	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-6.0	-0.31	5.08e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg16606324	chr3:10149918	C3orf24	0.62	8.02	0.4	1.87e-14	Alzheimer's disease;
CRC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg12193833	chr17:30244370	NA	-0.62	-7.94	-0.4	3.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.45	5.65	0.3	3.53e-8	Aortic root size;
CRC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-13.75	-0.6	2.73e-34	Glomerular filtration rate (creatinine);
CRC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg11003573	chr3:44754125	ZNF502	-0.33	-5.64	-0.3	3.67e-8	Depressive symptoms;
CRC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg03037974	chr15:76606532	NA	0.56	9.24	0.45	3.11e-18	Blood metabolite levels;
CRC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.45	-0.42	9.43e-16	Height;
CRC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.48	9.6	0.47	2.17e-19	Alcohol dependence;
CRC	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	6.77	0.35	5.93e-11	Hip circumference adjusted for BMI;
CRC	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.58	-8.01	-0.4	1.95e-14	Myopia;
CRC	cis	rs7605827	0.930	rs10189180	chr2:15685949	T/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.63	0.3	3.95e-8	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02018176	chr4:1364513	KIAA1530	0.48	7.84	0.4	6.25e-14	Obesity-related traits;
CRC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07570687	chr10:102243282	WNT8B	0.44	5.66	0.3	3.36e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11191205	0.644	rs12354716	chr10:103386775	C/A	cg15320455	chr10:103880129	LDB1	0.54	6.01	0.31	5.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.5	7.04	0.36	1.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03647317	chr4:187891568	NA	-0.55	-10.13	-0.49	3.48e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.41	-6.08	-0.32	3.36e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.37	6.26	0.33	1.18e-9	Schizophrenia;
CRC	cis	rs755249	0.567	rs905381	chr1:39688552	T/G	cg18385671	chr1:39797026	MACF1	-0.43	-6.13	-0.32	2.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.9	-10.67	-0.51	4.95e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.4e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg15845792	chr6:28175446	NA	0.66	6.3	0.33	9.77e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.98	0.4	2.38e-14	Menopause (age at onset);
CRC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.71	-11.56	-0.54	3.75e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs972578	1.000	rs4822247	chr22:43403290	C/T	cg01576275	chr22:43409880	NA	-0.51	-8.38	-0.42	1.53e-15	Mean platelet volume;
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.98	0.4	2.46e-14	Height;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.94	0.44	2.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.49	7.69	0.39	1.68e-13	Red blood cell count;
CRC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26240231	chr7:1148101	C7orf50	-0.44	-6.06	-0.32	3.83e-9	Bronchopulmonary dysplasia;
CRC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.48	7.56	0.38	3.98e-13	Mean platelet volume;
CRC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg26741380	chr15:41871084	TYRO3	-0.46	-6.83	-0.35	4.23e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.73	11.69	0.54	1.23e-26	Plateletcrit;Platelet count;
CRC	cis	rs8105895	0.877	rs2163837	chr19:22242236	G/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17507749	chr15:85114479	UBE2QP1	0.6	8.56	0.43	4.26e-16	Schizophrenia;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-6.07	-0.32	3.49e-9	Total body bone mineral density;
CRC	cis	rs1223397	0.651	rs2496147	chr6:13313233	C/T	cg20827128	chr6:13274284	PHACTR1	0.37	5.74	0.3	2.18e-8	Blood pressure;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg12516270	chr8:143859308	LYNX1	-0.42	-6.95	-0.36	1.96e-11	Urinary tract infection frequency;
CRC	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.35	12.74	0.57	1.69e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.76e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs3889199	0.707	rs10493256	chr1:59688948	A/G	cg25881383	chr1:59680599	NA	0.37	6.1	0.32	2.99e-9	Pulse pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01717948	chr16:30709586	SRCAP	0.48	6.54	0.34	2.32e-10	Anxiety disorder;
CRC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.34	5.82	0.31	1.39e-8	Emphysema distribution in smoking;
CRC	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.37	-6.35	-0.33	7.32e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	trans	rs12517041	1.000	rs2081954	chr5:23295705	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-6.08	-0.32	3.3e-9	Calcium levels;
CRC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.45	5.88	0.31	1.03e-8	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg26373071	chr5:1325741	CLPTM1L	0.55	9.84	0.48	3.38e-20	Lung cancer;
CRC	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg10437265	chr15:77819839	NA	0.66	11.62	0.54	2.13e-26	Type 2 diabetes;
CRC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.98	0.44	2.1e-17	Hip circumference adjusted for BMI;
CRC	trans	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg18335740	chr13:41363409	SLC25A15	0.54	8.26	0.41	3.51e-15	Lewy body disease;
CRC	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg27398640	chr15:77910606	LINGO1	0.45	7.72	0.39	1.45e-13	Type 2 diabetes;
CRC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.79	10.76	0.51	2.39e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg05874882	chr4:1763078	NA	0.33	5.9	0.31	8.99e-9	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-0.9	-7.57	-0.38	3.91e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.68	10.85	0.51	1.18e-23	Lung cancer;
CRC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.58	10.52	0.5	1.69e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.74	-0.35	7.07e-11	Putamen volume;
CRC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.09	0.55	4.21e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.44	6.13	0.32	2.53e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	6.07	0.32	3.62e-9	Height;
CRC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg27535305	chr1:53392650	SCP2	0.39	7.0	0.36	1.42e-11	Monocyte count;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.82	12.51	0.57	1.22e-29	Menarche (age at onset);
CRC	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.06	-0.32	3.67e-9	Mood instability;
CRC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.45	-6.92	-0.36	2.43e-11	Corneal astigmatism;
CRC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.97	12.04	0.55	6.75e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs7259376	0.936	rs12459636	chr19:22542439	C/T	cg02657401	chr19:22469223	NA	0.33	7.42	0.38	9.91e-13	Menopause (age at onset);
CRC	cis	rs79387448	0.935	rs7567133	chr2:103253128	C/A	cg09003973	chr2:102972529	NA	0.59	6.67	0.34	1.11e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.43	6.58	0.34	1.91e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs73206853	0.640	rs2098140	chr12:110726081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.78	8.2	0.41	5.55e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg00738113	chr16:70207722	CLEC18C	-0.4	-5.7	-0.3	2.63e-8	IgE levels;
CRC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-0.68	-6.49	-0.34	3.07e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.73	0.3	2.33e-8	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01883208	chr1:233316809	PCNXL2	-0.39	-6.05	-0.32	3.89e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.64	-9.26	-0.45	2.78e-18	Menopause (age at onset);
CRC	cis	rs2160860	0.773	rs11779700	chr8:39797778	C/T	cg11363097	chr8:39792086	IDO2	-0.43	-7.26	-0.37	2.77e-12	Blood metabolite levels;
CRC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg22535103	chr8:58192502	C8orf71	-0.49	-5.6	-0.3	4.49e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs12980942	0.810	rs35812313	chr19:41789178	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.52	5.96	0.31	6.4e-9	Coronary artery disease;
CRC	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.53	7.67	0.39	1.97e-13	Monocyte count;
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9311676	0.656	rs6445977	chr3:58379560	T/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.92e-10	Systemic lupus erythematosus;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.58	8.91	0.44	3.66e-17	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01213445	chr15:91537450	PRC1	0.37	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.4	-0.38	1.12e-12	Colorectal cancer;
CRC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-11.77	-0.54	6.06e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.6	-0.39	3.12e-13	Hemoglobin concentration;
CRC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg01392867	chr16:30410429	ZNF48	-0.36	-5.71	-0.3	2.53e-8	Tonsillectomy;
CRC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg00531865	chr16:30841666	NA	-0.4	-5.68	-0.3	2.93e-8	Dementia with Lewy bodies;
CRC	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg10437265	chr15:77819839	NA	0.59	9.99	0.48	1.03e-20	Type 2 diabetes;
CRC	trans	rs10411161	0.935	rs8107422	chr19:52368775	C/A	cg22319618	chr22:45562946	NUP50	-0.52	-6.15	-0.32	2.23e-9	Breast cancer;
CRC	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.8	0.35	4.95e-11	Menarche (age at onset);
CRC	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.71	9.47	0.46	5.73e-19	Iron status biomarkers;
CRC	cis	rs11574514	1.000	rs16957524	chr16:67798005	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-6.43	-0.33	4.56e-10	Crohn's disease;
CRC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg06470822	chr6:28175283	NA	0.82	8.39	0.42	1.49e-15	Parkinson's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11871820	chr6:131949485	MED23	-0.41	-5.99	-0.31	5.51e-9	Myopia (pathological);
CRC	cis	rs9311676	0.656	rs9881869	chr3:58333255	G/A	cg06643156	chr3:58380774	PXK	-0.44	-6.8	-0.35	4.99e-11	Systemic lupus erythematosus;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg10766172	chr7:27498479	NA	-0.51	-6.01	-0.31	4.82e-9	Optic disc area;
CRC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.13	0.32	2.46e-9	Aortic root size;
CRC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.4	-5.82	-0.31	1.36e-8	Menarche (age at onset);
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.09	0.36	8.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg25173405	chr17:45401733	C17orf57	-0.45	-6.95	-0.36	2.01e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg24588162	chr13:113633484	MCF2L	-0.43	-7.64	-0.39	2.4e-13	Systolic blood pressure;
CRC	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.43	-6.57	-0.34	1.98e-10	Endometrial cancer;
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg07617317	chr6:118971624	C6orf204	0.52	6.4	0.33	5.29e-10	Diastolic blood pressure;
CRC	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.82	-13.0	-0.58	1.88e-31	Hypospadias;
CRC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-21.47	-0.76	1.48e-64	Hemostatic factors and hematological phenotypes;
CRC	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	7.39	0.38	1.2e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.73	11.54	0.54	4.38e-26	Intelligence (multi-trait analysis);
CRC	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg23920097	chr1:209922102	NA	0.51	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg27534772	chr1:16042836	PLEKHM2	0.44	7.44	0.38	8.59e-13	Systolic blood pressure;
CRC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.97	-18.83	-0.72	3.58e-54	Height;
CRC	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.62	-9.94	-0.48	1.59e-20	Systemic lupus erythematosus;
CRC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.68	9.21	0.45	4.07e-18	Breast cancer;
CRC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.47	-6.74	-0.35	7.27e-11	Lymphocyte counts;
CRC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.2	-0.37	4.11e-12	Bipolar disorder;
CRC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.46	6.88	0.35	2.94e-11	Subjective well-being;
CRC	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg05507819	chr15:63340323	TPM1	0.45	5.72	0.3	2.35e-8	HDL cholesterol;
CRC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.88	15.52	0.65	3.72e-41	Prostate cancer;
CRC	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.46	-6.66	-0.34	1.17e-10	Large artery stroke;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.75	12.6	0.57	5.52e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.61	-9.95	-0.48	1.47e-20	Dental caries;
CRC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.55	8.14	0.41	8.33e-15	Cognitive ability;
CRC	cis	rs61160187	0.517	rs6884966	chr5:60193339	T/C	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg05608388	chr19:18794257	CRTC1	-0.57	-6.02	-0.31	4.78e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23222573	chr20:13765663	ESF1;C20orf7	0.46	6.85	0.35	3.6e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2462686	1.000	rs809298	chr7:45998344	C/A	cg23193639	chr7:45961078	IGFBP3	-0.38	-5.86	-0.31	1.14e-8	Major depressive disorder;
CRC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-16.29	-0.67	3.52e-44	Coronary artery disease;
CRC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.79	-13.8	-0.61	1.73e-34	Breast cancer;
CRC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg11292332	chr7:45801988	SEPT13	-0.38	-7.02	-0.36	1.26e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs17443541	0.507	rs2122535	chr2:200456289	G/A	cg03741458	chr2:200468445	NA	-0.36	-5.71	-0.3	2.49e-8	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13746315	chr15:94774850	NA	0.47	6.51	0.34	2.87e-10	Anxiety disorder;
CRC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.95	0.4	3.05e-14	Height;
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20092199	chr4:1342459	KIAA1530	0.34	5.9	0.31	8.88e-9	Obesity-related traits;
CRC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.52	-0.34	2.6200000000000003e-10	Breast cancer;
CRC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.38	0.33	6.1e-10	Cognitive ability;
CRC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	16.39	0.67	1.53e-44	Platelet count;
CRC	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg10820045	chr2:198174542	NA	0.42	7.13	0.37	6.4e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.57	-9.16	-0.45	5.49e-18	Mean corpuscular volume;
CRC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.54	8.72	0.43	1.44e-16	Coronary artery disease;
CRC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.52	7.39	0.38	1.26e-12	Cognitive function;
CRC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg24503407	chr1:205819492	PM20D1	-0.43	-5.92	-0.31	8e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg20515095	chr8:8998461	PPP1R3B	0.42	5.68	0.3	2.99e-8	Myopia (pathological);
CRC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.48	-7.88	-0.4	4.89e-14	Body mass index;
CRC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.74	8.43	0.42	1.07e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg02869364	chr7:1081709	C7orf50	0.38	5.93	0.31	7.55e-9	Longevity;Endometriosis;
CRC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.8	12.62	0.57	4.88e-30	Cognitive function;
CRC	trans	rs800082	0.516	rs6765790	chr3:144225908	A/G	cg24215973	chr2:240111563	HDAC4	0.48	6.65	0.34	1.26e-10	Smoking behavior;
CRC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.13	-13.64	-0.6	6.76e-34	Diabetic kidney disease;
CRC	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg00852783	chr1:26633632	UBXN11	-0.47	-5.67	-0.3	3.09e-8	Obesity-related traits;
CRC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg10911889	chr6:126070802	HEY2	0.39	5.92	0.31	7.99e-9	Brugada syndrome;
CRC	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04432606	chr2:179315409	PRKRA;MIR548N;DFNB59	0.44	6.2	0.32	1.69e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.04	-0.32	4.11e-9	Life satisfaction;
CRC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.41	6.17	0.32	1.97e-9	Hemoglobin concentration;
CRC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.84	-0.4	6.18e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg09873164	chr1:152488093	CRCT1	0.39	6.49	0.34	3.08e-10	Hair morphology;
CRC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-12.26	-0.56	1.03e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.44	6.29	0.33	1e-9	Lymphocyte counts;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg20989729	chr11:101981056	YAP1	-0.41	-6.24	-0.33	1.32e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg13491945	chr12:107078410	RFX4	0.36	6.24	0.33	1.31e-9	Heart rate;
CRC	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg23100626	chr2:96804247	ASTL	0.27	7.18	0.37	4.62e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs8040855	0.657	rs6496733	chr15:85673176	G/T	cg10818794	chr15:86012489	AKAP13	0.42	5.61	0.3	4.38e-8	Bulimia nervosa;
CRC	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.67e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg20243544	chr17:37824526	PNMT	0.53	7.92	0.4	3.66e-14	Asthma;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.53	9.87	0.48	2.64e-20	Blood metabolite levels;
CRC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098699	0.821	rs4833887	chr4:124208033	T/C	cg09941581	chr4:124220074	SPATA5	0.4	5.84	0.31	1.25e-8	Mosquito bite size;
CRC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.54	-9.78	-0.47	5.42e-20	Bipolar disorder;
CRC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-12.19	-0.56	1.9e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	8.1	0.41	1.11e-14	Adiposity;
CRC	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	1.0	18.58	0.72	3.27e-53	Gut microbiome composition (winter);
CRC	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.62	-5.94	-0.31	7.38e-9	Alzheimer's disease (late onset);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg02668729	chr1:41445680	CTPS	0.45	6.22	0.32	1.47e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.56	8.24	0.41	4.09e-15	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.47	7.0	0.36	1.44e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.52	-6.07	-0.32	3.46e-9	Vitiligo;
CRC	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg01312482	chr5:178451176	ZNF879	-0.35	-6.09	-0.32	3.13e-9	Pubertal anthropometrics;
CRC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.89	-15.86	-0.66	1.84e-42	Height;
CRC	trans	rs4478147	0.636	rs72665746	chr4:87466471	G/C	cg01215037	chr19:50083917	PRRG2;NOSIP	0.45	5.97	0.31	6.1e-9	Migraine - clinic-based;
CRC	trans	rs7180079	0.920	rs11071790	chr15:64601979	G/A	cg22857141	chr5:123707481	NA	0.48	6.03	0.32	4.52e-9	Monocyte count;
CRC	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.48	7.0	0.36	1.48e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.67	6.8	0.35	4.95e-11	Axial length;
CRC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.27	0.33	1.16e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.44	-9.76	-0.47	6.22e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25517755	chr10:38738941	LOC399744	0.44	6.28	0.33	1.09e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.58	8.92	0.44	3.41e-17	Vitiligo;
CRC	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	5.73	0.3	2.27e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg23127183	chr11:57508653	C11orf31	0.53	7.43	0.38	9.34e-13	Schizophrenia;
CRC	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.54	8.62	0.43	2.88e-16	Coronary artery disease;
CRC	cis	rs4700695	0.920	rs251303	chr5:65248753	A/C	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.58	8.14	0.41	8.41e-15	Longevity;Endometriosis;
CRC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.77	-0.44	9.58e-17	Platelet count;
CRC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.75	-9.93	-0.48	1.64e-20	Coronary artery disease;
CRC	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.89	-10.65	-0.51	6.17e-23	Diisocyanate-induced asthma;
CRC	trans	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg19894588	chr14:64061835	NA	-0.57	-7.87	-0.4	5.07e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg07217954	chr7:1067459	C7orf50	0.55	5.66	0.3	3.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg20203395	chr5:56204925	C5orf35	-0.45	-6.01	-0.31	4.91e-9	Coronary artery disease;
CRC	cis	rs59104589	0.583	rs12624195	chr2:242254734	G/C	cg19488206	chr2:242435732	STK25	0.45	6.25	0.33	1.28e-9	Fibrinogen levels;
CRC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg05623727	chr3:50126028	RBM5	0.46	7.76	0.39	1.1e-13	Intelligence (multi-trait analysis);
CRC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	9.17	0.45	5.34e-18	Triglycerides;
CRC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.52	8.13	0.41	8.82e-15	Monocyte count;
CRC	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg13385794	chr1:248469461	NA	0.35	6.06	0.32	3.81e-9	Common traits (Other);
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg12560992	chr17:57184187	TRIM37	0.46	6.51	0.34	2.87e-10	Primary tooth development (time to first tooth eruption);
CRC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.15	-0.37	5.68e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-0.43	-5.85	-0.31	1.2e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	0.56	8.73	0.43	1.29e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.62	9.07	0.45	1.07e-17	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg12458913	chr13:53173898	NA	-0.48	-7.07	-0.36	9.36e-12	Lewy body disease;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg20615401	chr6:28092323	ZSCAN16	0.46	6.08	0.32	3.28e-9	Cardiac Troponin-T levels;
CRC	cis	rs9925964	0.804	rs4889606	chr16:31011183	C/T	cg03418659	chr16:31128414	MYST1	-0.43	-6.41	-0.33	4.97e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.6	8.15	0.41	7.58e-15	Neutrophil percentage of white cells;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg24046110	chr8:143859143	LYNX1	-0.43	-6.61	-0.34	1.56e-10	Urinary tract infection frequency;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg00684032	chr4:1343700	KIAA1530	0.39	5.93	0.31	7.87e-9	Obesity-related traits;
CRC	cis	rs4757319	0.515	rs4312044	chr11:15341931	G/A	cg03245590	chr11:15329459	NA	0.52	8.94	0.44	2.92e-17	Breast cancer;
CRC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	1.16	11.72	0.54	9.45e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs59104589	0.959	rs60624480	chr2:242297118	G/A	cg10021735	chr2:242295487	FARP2	0.42	5.96	0.31	6.57e-9	Fibrinogen levels;
CRC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.36	0.33	6.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6717918	0.651	rs2633264	chr2:233124685	C/T	ch.2.233013039R	chr2:233304795	NA	-0.48	-5.86	-0.31	1.15e-8	Height;
CRC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.92	-17.32	-0.69	3.2e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.8	-0.55	4.81e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg12870014	chr12:110450643	ANKRD13A	0.82	10.61	0.5	8.15e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.76	-7.53	-0.38	4.86e-13	Coronary artery disease;
CRC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.43	-0.33	4.36e-10	Monocyte count;
CRC	cis	rs12476592	0.602	rs262478	chr2:63872386	T/C	cg10828910	chr2:63850056	LOC388955	0.48	5.83	0.31	1.36e-8	Childhood ear infection;
CRC	cis	rs12618769	0.597	rs72821956	chr2:99159966	G/T	cg18455616	chr2:99124870	INPP4A	0.35	5.85	0.31	1.16e-8	Bipolar disorder;
CRC	cis	rs6496667	0.779	rs8039288	chr15:91000445	A/T	cg04176472	chr15:90893244	GABARAPL3	0.57	8.16	0.41	7.07e-15	Rheumatoid arthritis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21023284	chr11:6624872	ILK;RRP8	0.39	6.05	0.32	3.89e-9	Schizophrenia;
CRC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.21	0.37	3.77e-12	Morning vs. evening chronotype;
CRC	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.77	-10.17	-0.49	2.71e-21	Blood metabolite levels;
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.69	9.65	0.47	1.46e-19	Alzheimer's disease;
CRC	cis	rs2857891	0.817	rs2638102	chr11:6968610	T/C	cg04053776	chr11:6947353	ZNF215	0.41	5.93	0.31	7.5e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg11212589	chr17:38028394	ZPBP2	0.43	7.96	0.4	2.89e-14	Self-reported allergy;
CRC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg02741985	chr17:80059408	CCDC57	0.43	6.99	0.36	1.5e-11	Life satisfaction;
CRC	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.8	-14.58	-0.63	1.66e-37	Lewy body disease;
CRC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.78	-0.47	5.21e-20	Hip circumference adjusted for BMI;
CRC	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg00603274	chr11:61596626	FADS2	-0.39	-5.75	-0.3	2.07e-8	Trans fatty acid levels;
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	7.91e-9	Prudent dietary pattern;
CRC	cis	rs427941	0.550	rs201514	chr7:101768910	T/C	cg06246474	chr7:101738831	CUX1	0.37	5.66	0.3	3.27e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.16	-0.32	2.13e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16988976	chr2:99953032	EIF5B;TXNDC9	0.49	6.79	0.35	5.25e-11	Response to antipsychotic treatment;
CRC	trans	rs2403907	0.758	rs2823133	chr21:16568941	A/C	cg00407105	chr4:90231041	NA	-0.4	-6.11	-0.32	2.8e-9	Breast cancer;
CRC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.61	9.27	0.46	2.48e-18	Mean corpuscular hemoglobin;
CRC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.45	0.46	6.4e-19	Cognitive test performance;
CRC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.71	-10.57	-0.5	1.12e-22	Acne (severe);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26241694	chr19:12512136	ZNF799	0.43	6.1	0.32	2.95e-9	Response to antipsychotic treatment;
CRC	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg01475377	chr6:109611718	NA	-0.35	-6.07	-0.32	3.56e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-9.9	-0.48	2.12e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-6.34	-0.33	7.71e-10	Electroencephalogram traits;
CRC	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.52	-6.45	-0.33	4.07e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.58	-9.23	-0.45	3.41e-18	Breast cancer;
CRC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.82	14.45	0.62	5.33e-37	Breast cancer;
CRC	cis	rs4728302	0.838	rs10264922	chr7:133598975	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.5	-0.34	2.97e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs397969	0.646	rs1638526	chr17:19848450	T/C	cg04132472	chr17:19861366	AKAP10	0.39	5.62	0.3	3.98e-8	Platelet count;
CRC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.47	-6.98	-0.36	1.62e-11	Tonsillectomy;
CRC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg15192750	chr16:69999425	NA	0.61	8.06	0.41	1.42e-14	IgE levels;
CRC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg04166393	chr7:2884313	GNA12	0.4	6.1	0.32	3.04e-9	Height;
CRC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg08314208	chr16:67682810	RLTPR	-0.6	-6.42	-0.33	4.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.5	6.95	0.36	2.01e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.73	0.43	1.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg25985355	chr7:65971099	NA	-0.55	-6.22	-0.32	1.49e-9	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09602753	chr10:134574192	INPP5A	0.38	6.16	0.32	2.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs539514	0.627	rs9530463	chr13:76293772	C/T	cg04757411	chr13:76259545	LMO7	-0.36	-6.13	-0.32	2.55e-9	Type 1 diabetes;
CRC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	7.19	0.37	4.34e-12	Response to antipsychotic treatment;
CRC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg18721089	chr20:30220636	NA	0.34	6.01	0.31	4.95e-9	Mean corpuscular hemoglobin;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11496792	chr9:123477254	MEGF9	0.48	6.13	0.32	2.46e-9	Thyroid stimulating hormone;
CRC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.65	9.63	0.47	1.73e-19	Vitamin D levels;
CRC	trans	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.65	10.31	0.49	8.71e-22	Colorectal cancer;
CRC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.34	0.38	1.66e-12	Platelet count;
CRC	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.47	6.82	0.35	4.38e-11	Primary sclerosing cholangitis;
CRC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.89	-0.44	4.15e-17	Alcohol dependence;
CRC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	trans	rs10242455	0.702	rs115279860	chr7:98994492	C/T	cg09045935	chr12:6379348	NA	0.94	6.54	0.34	2.39e-10	Blood metabolite levels;
CRC	cis	rs995000	0.931	rs1168036	chr1:62962734	A/G	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.5e-11	Triglyceride levels;
CRC	cis	rs9903692	0.779	rs6504025	chr17:46166073	G/A	cg21215337	chr17:46176117	CBX1	0.42	7.78	0.39	9.74e-14	Pulse pressure;
CRC	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	6.42	0.33	4.65e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2179367	0.887	rs6570965	chr6:149717476	C/A	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.29	-0.33	9.9e-10	Dupuytren's disease;
CRC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02290350	chr8:58132656	NA	-0.53	-7.83	-0.4	6.55e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg08645402	chr16:4508243	NA	0.59	9.81	0.48	4.12e-20	Schizophrenia;
CRC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-7.98	-0.4	2.38e-14	Intelligence (multi-trait analysis);
CRC	trans	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg21659725	chr3:3221576	CRBN	0.61	6.38	0.33	6.03e-10	Menarche (age at onset);
CRC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12172441	chr6:28176163	NA	0.61	7.16	0.37	5.36e-12	Depression;
CRC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg04362960	chr10:104952993	NT5C2	0.44	6.22	0.32	1.5e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg12856521	chr11:46389249	DGKZ	-0.44	-6.98	-0.36	1.61e-11	Leprosy;
CRC	cis	rs34375054	1.000	rs3751178	chr12:125664357	C/T	cg02766259	chr12:125626809	AACS	0.33	5.75	0.3	2.08e-8	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02119927	chr10:71078141	HK1	0.44	6.0	0.31	5.15e-9	Anxiety disorder;
CRC	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.64	-10.67	-0.51	5.13e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.44	0.38	8.76e-13	Mean platelet volume;
CRC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.49	-7.42	-0.38	1.01e-12	Testicular germ cell tumor;
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg16060761	chr17:80687452	NA	-0.45	-5.86	-0.31	1.15e-8	Glycated hemoglobin levels;
CRC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.82	16.21	0.67	7.66e-44	Oral cavity cancer;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	9.98	0.48	1.14e-20	Lymphocyte counts;
CRC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	14.63	0.63	1.09e-37	Primary sclerosing cholangitis;
CRC	cis	rs10894147	0.756	rs1016364	chr11:129744872	A/G	cg27255275	chr11:129766154	NFRKB	0.39	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg11941060	chr3:133502564	NA	-0.37	-5.74	-0.3	2.18e-8	Ankle injury;
CRC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.81	13.96	0.61	4.24e-35	Total body bone mineral density;
CRC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.71	-0.51	3.69e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-6.08	-0.32	3.4e-9	Height;
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg20137461	chr3:169782135	GPR160	0.65	6.05	0.32	3.97e-9	Temperament (bipolar disorder);
CRC	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-8.03	-0.4	1.8e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg05941027	chr17:61774174	LIMD2	0.35	5.99	0.31	5.62e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.54	8.59	0.43	3.54e-16	Sum eosinophil basophil counts;Eosinophil counts;
CRC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.44	-0.38	8.67e-13	Retinal vascular caliber;
CRC	cis	rs6867913	1.000	rs12519447	chr5:141457161	G/A	cg08523384	chr5:141488047	NDFIP1	0.43	6.31	0.33	8.81e-10	Asthma;
CRC	cis	rs3018066	0.867	rs3109958	chr4:107233188	A/G	cg01869342	chr4:106983673	TBCK	0.36	5.61	0.3	4.23e-8	Cancer;
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg15763984	chr4:1342303	KIAA1530	0.35	6.17	0.32	2.06e-9	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.78	-0.35	5.48e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg06470822	chr6:28175283	NA	0.9	12.72	0.57	2.11e-30	Parkinson's disease;
CRC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.72	-7.19	-0.37	4.3e-12	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs12432203	1.000	rs72622434	chr14:51734570	C/T	cg14592830	chr9:122318704	NA	0.56	5.99	0.31	5.46e-9	Cancer;
CRC	trans	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg10756647	chr7:56101905	PSPH	0.77	7.85	0.4	5.94e-14	Diabetic kidney disease;
CRC	cis	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg15786705	chr6:28176104	NA	0.73	6.04	0.32	4.18e-9	Depression;
CRC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.96	-0.36	1.82e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.72	11.36	0.53	1.95e-25	Platelet count;
CRC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg01629716	chr15:45996671	NA	0.38	7.63	0.39	2.55e-13	Waist circumference;Weight;
CRC	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg07979401	chr6:33739406	LEMD2	-0.48	-5.92	-0.31	7.98e-9	Schizophrenia;
CRC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.6	9.56	0.47	2.91e-19	Vitiligo;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs12760731	0.720	rs2862379	chr1:178442906	T/A	cg00404053	chr1:178313656	RASAL2	0.96	9.99	0.48	1.1e-20	Obesity-related traits;
CRC	cis	rs1223397	0.938	rs9395602	chr6:13278753	C/T	cg06879394	chr6:13274151	PHACTR1	0.51	6.07	0.32	3.47e-9	Blood pressure;
CRC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.64	10.37	0.5	5.35e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.72	0.54	9.41e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6810498	0.735	rs16878007	chr4:26051504	A/G	cg12925881	chr4:26050407	NA	0.41	7.93	0.4	3.45e-14	Alcohol dependence;
CRC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg23750338	chr8:142222470	SLC45A4	0.45	7.65	0.39	2.23e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.42	-7.59	-0.39	3.43e-13	Height;
CRC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.59	10.38	0.5	4.93e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg13385794	chr1:248469461	NA	0.4	7.23	0.37	3.39e-12	Common traits (Other);
CRC	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg00697916	chr3:65342644	MAGI1	-0.27	-6.12	-0.32	2.72e-9	Energy expenditure (24h);
CRC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.68	0.51	4.61e-23	Hip circumference adjusted for BMI;
CRC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06505273	chr16:24850292	NA	-0.41	-6.15	-0.32	2.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg04239562	chr7:158767014	NA	0.36	5.65	0.3	3.42e-8	Facial morphology (factor 20);
CRC	cis	rs7680126	0.633	rs55766779	chr4:10287039	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.27	-0.33	1.14e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4731207	0.672	rs7792883	chr7:124448021	A/G	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg01788221	chr16:89496183	ANKRD11	0.45	7.02	0.36	1.3e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg17524180	chr13:113633600	MCF2L	-0.65	-12.11	-0.56	3.5e-28	Systolic blood pressure;
CRC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.14e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg07153921	chr17:41440717	NA	-0.39	-5.85	-0.31	1.19e-8	Menopause (age at onset);
CRC	cis	rs7626444	0.625	rs1486358	chr3:196485590	T/C	cg12930392	chr3:196481615	PAK2	0.39	7.11	0.36	7.25e-12	Monocyte count;
CRC	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.73	-0.3	2.29e-8	Electroencephalogram traits;
CRC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs2692947	0.759	rs11687113	chr2:96658588	A/G	cg23100626	chr2:96804247	ASTL	0.27	7.58	0.39	3.53e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.57	6.39	0.33	5.7e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.45	6.34	0.33	7.42e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4780355	0.918	rs1646019	chr16:11359680	C/T	cg00044050	chr16:11439710	C16orf75	0.42	5.83	0.31	1.31e-8	Crohn's disease and psoriasis;
CRC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.55	8.09	0.41	1.13e-14	Lung cancer;
CRC	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.66	-0.34	1.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.6	-12.12	-0.56	3.45e-28	Asthma (sex interaction);
CRC	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13385794	chr1:248469461	NA	0.39	6.97	0.36	1.79e-11	Common traits (Other);
CRC	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.74	0.35	7e-11	Response to antipsychotic treatment;
CRC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	-0.53	-8.81	-0.44	7.46e-17	Intelligence (multi-trait analysis);
CRC	trans	rs7555668	0.628	rs3128372	chr1:112857586	C/G	cg21406518	chr20:62794798	MYT1	-0.4	-6.38	-0.33	5.97e-10	Cognitive performance;
CRC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.1	-0.36	7.69e-12	Height;
CRC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg19635926	chr16:89946313	TCF25	0.67	6.28	0.33	1.08e-9	Skin colour saturation;
CRC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.1	-0.32	2.99e-9	Reticulocyte count;
CRC	cis	rs17213078	0.505	rs6735859	chr2:106744603	T/C	cg15412446	chr2:106886593	NA	0.36	5.79	0.3	1.64e-8	Facial morphology (factor 23);
CRC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg11887960	chr12:57824829	NA	0.6	6.7	0.35	9.16e-11	Obesity-related traits;
CRC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg04539111	chr16:67997858	SLC12A4	-0.51	-5.91	-0.31	8.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.21	-16.45	-0.67	8.87e-45	Breast cancer;
CRC	cis	rs17767392	0.681	rs17767266	chr14:71681331	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.59	-7.04	-0.36	1.13e-11	Mitral valve prolapse;
CRC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg07701084	chr6:150067640	NUP43	0.55	7.99	0.4	2.26e-14	Testicular germ cell tumor;
CRC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg05627522	chr15:75251581	NA	0.38	5.88	0.31	1.02e-8	Breast cancer;
CRC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.28	0.46	2.26e-18	Monocyte percentage of white cells;
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg13047869	chr3:10149882	C3orf24	0.51	7.2	0.37	4.24e-12	Alzheimer's disease;
CRC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.48	6.1	0.32	2.98e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg19683494	chr5:74908142	NA	-0.58	-6.31	-0.33	9.16e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12187049	chr5:70882888	MCCC2	0.56	7.56	0.38	4.04e-13	Thyroid stimulating hormone;
CRC	cis	rs2249694	0.520	rs7095379	chr10:135328532	C/T	cg20169779	chr10:135381914	SYCE1	-0.55	-7.7	-0.39	1.58e-13	Obesity-related traits;
CRC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg11189052	chr15:85197271	WDR73	-0.55	-7.59	-0.39	3.29e-13	Schizophrenia;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg07332563	chr6:291687	DUSP22	-0.48	-6.84	-0.35	3.79e-11	Menopause (age at onset);
CRC	cis	rs17152411	1.000	rs7097282	chr10:126593492	T/C	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	trans	rs11654801	0.812	rs16962469	chr17:20858432	A/G	cg23759823	chr7:139672531	TBXAS1	-0.42	-6.47	-0.34	3.62e-10	Mosquito bite size;
CRC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.53	-8.91	-0.44	3.62e-17	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06911519	chr2:28615662	FOSL2	0.44	6.08	0.32	3.4e-9	Response to antipsychotic treatment;
CRC	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg25790453	chr13:113633590	MCF2L	-0.5	-8.63	-0.43	2.6e-16	Systolic blood pressure;
CRC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.82	-11.17	-0.52	9.26e-25	Height;
CRC	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.46	-7.84	-0.4	6.24e-14	Schizophrenia;
CRC	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg19223190	chr17:80058835	NA	0.4	6.29	0.33	1.04e-9	Life satisfaction;
CRC	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg00490450	chr3:139108681	COPB2	0.52	7.5	0.38	5.96e-13	Obesity-related traits;
CRC	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg06092702	chr1:163392909	NA	-0.53	-8.28	-0.42	3.11e-15	Motion sickness;
CRC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.9	-15.66	-0.65	1.1e-41	Cognitive function;
CRC	cis	rs7703744	0.681	rs73239280	chr5:118695579	G/A	cg02283238	chr5:118691126	TNFAIP8	0.46	6.34	0.33	7.53e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg20573242	chr4:122745356	CCNA2	-0.4	-6.0	-0.31	5.16e-9	Type 2 diabetes;
CRC	trans	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg18335740	chr13:41363409	SLC25A15	0.55	8.95	0.44	2.72e-17	Lewy body disease;
CRC	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-7.45	-0.38	8.46e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.63	7.87	0.4	5.2e-14	Arsenic metabolism;
CRC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg06935464	chr4:38784597	TLR10	0.58	5.79	0.3	1.66e-8	Breast cancer;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg06235973	chr19:14183619	LOC113230	0.39	5.96	0.31	6.47e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.48	8.55	0.43	4.74e-16	Prostate-specific antigen levels;
CRC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.9	16.01	0.66	4.56e-43	Intelligence (multi-trait analysis);
CRC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.53	10.92	0.52	6.76e-24	Alcohol dependence;
CRC	cis	rs34333482	1	rs34333482	chr6:116855952	A/AG	cg03003256	chr6:116849557	FAM26D;BET3L	0.45	6.92	0.36	2.44e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg03623178	chr6:28175578	NA	0.68	9.49	0.46	4.72e-19	Parkinson's disease;
CRC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg16447950	chr5:562315	NA	-0.81	-10.62	-0.51	7.76e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs447	1.000	rs7785708	chr7:83752668	C/T	cg22846510	chr7:83753280	SEMA3A	-0.55	-7.06	-0.36	1.01e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.66	8.29	0.42	3e-15	Menarche (age at onset);
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg04155289	chr7:94953770	PON1	-0.59	-7.53	-0.38	5.06e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.33e-10	Childhood ear infection;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12273811	chr6:28175739	NA	0.77	11.05	0.52	2.42e-24	Depression;
CRC	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	6.19e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.79	12.02	0.55	7.77e-28	Testicular germ cell tumor;
CRC	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-5.71	-0.3	2.59e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg18758796	chr5:131593413	PDLIM4	0.4	6.29	0.33	9.83e-10	Blood metabolite levels;
CRC	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.63	7.97	0.4	2.58e-14	Uric acid levels;
CRC	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg05049329	chr1:226924846	ITPKB	0.41	9.04	0.45	1.36e-17	Parkinson's disease;
CRC	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg23229984	chr5:148520753	ABLIM3	-0.47	-6.57	-0.34	1.92e-10	Breast cancer;
CRC	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	1.02	12.31	0.56	6.77e-29	Obesity-related traits;
CRC	trans	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg25214090	chr10:38739885	LOC399744	0.39	6.12	0.32	2.67e-9	Diastolic blood pressure;
CRC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.84	14.64	0.63	9.67e-38	Height;
CRC	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.54	7.93	0.4	3.54e-14	Testicular germ cell tumor;
CRC	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg26805224	chr10:79626177	DLG5	-0.49	-7.2	-0.37	4.04e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.68	-0.43	1.9e-16	Coronary artery disease;
CRC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg06470822	chr6:28175283	NA	1.0	15.13	0.64	1.23e-39	Depression;
CRC	cis	rs4917833	0.738	rs7067713	chr10:100221120	T/C	cg19043522	chr10:100227446	HPSE2	0.38	5.81	0.31	1.47e-8	Pediatric bone mineral density (femoral neck);
CRC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.92	-0.31	8.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg25809561	chr17:30822961	MYO1D	0.5	9.0	0.44	1.9e-17	Schizophrenia;
CRC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg06470822	chr6:28175283	NA	0.85	6.98	0.36	1.63e-11	Depression;
CRC	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	6.26	0.33	1.23e-9	Body mass index;
CRC	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg20356878	chr3:121714668	ILDR1	0.51	8.09	0.41	1.14e-14	Cognitive performance;
CRC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.52	0.34	2.71e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-8.57	-0.43	4.09e-16	Personality dimensions;
CRC	cis	rs7680126	0.632	rs11731464	chr4:10148376	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-5.86	-0.31	1.12e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg03623178	chr6:28175578	NA	0.93	12.26	0.56	9.88e-29	Depression;
CRC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.79	-12.62	-0.57	4.83e-30	Menopause (age at onset);
CRC	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg13385794	chr1:248469461	NA	-0.34	-5.67	-0.3	3.05e-8	Common traits (Other);
CRC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg19193384	chr17:30244184	NA	-0.53	-6.66	-0.34	1.15e-10	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06869415	chr14:35183946	CFL2	0.44	6.1	0.32	3.05e-9	Anxiety disorder;
CRC	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg01993067	chr11:68851601	TPCN2	-0.42	-5.75	-0.3	2.03e-8	Blond vs. brown hair color;
CRC	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.82	11.61	0.54	2.33e-26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-10.06	-0.49	6.21e-21	Mean platelet volume;
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg21620606	chr4:1342894	KIAA1530	0.56	10.21	0.49	1.87e-21	Longevity;
CRC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.45	-6.25	-0.33	1.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.72	-7.25	-0.37	3.09e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.41	6.71	0.35	8.56e-11	Resting heart rate;
CRC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.53	-6.66	-0.34	1.16e-10	Psoriasis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13060520	chr10:35379343	CUL2	0.49	6.98	0.36	1.61e-11	Anxiety disorder;
CRC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.28	-0.46	2.31e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg25164649	chr6:28176230	NA	0.65	9.05	0.45	1.29e-17	Parkinson's disease;
CRC	trans	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg18335740	chr13:41363409	SLC25A15	-0.54	-8.59	-0.43	3.6e-16	Lewy body disease;
CRC	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg27205649	chr11:78285834	NARS2	0.51	6.41	0.33	5.07e-10	Alzheimer's disease (survival time);
CRC	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.55	9.3	0.46	2.01e-18	Age of smoking initiation;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg09868299	chr11:69259957	NA	-0.43	-6.19	-0.32	1.82e-9	Lymphocyte counts;
CRC	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.93	12.07	0.55	5.08e-28	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg01987224	chr1:201084466	NA	0.54	10.01	0.48	9.4e-21	Permanent tooth development;
CRC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.79	-9.61	-0.47	1.95e-19	Metabolite levels (HVA/5-HIAA ratio);
CRC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.39	6.13	0.32	2.52e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.77	-0.35	5.97e-11	Monocyte count;
CRC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg23590916	chr17:43697445	MGC57346	0.61	6.14	0.32	2.35e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg00105475	chr2:10696890	NA	-0.45	-7.42	-0.38	1e-12	Prostate cancer;
CRC	trans	rs2303319	0.504	rs60824222	chr2:162368719	A/C	cg27113153	chr11:123612418	ZNF202	-0.72	-6.17	-0.32	1.96e-9	Cognitive function;
CRC	cis	rs41005	1.000	rs193932	chr2:8107383	C/T	cg03155496	chr2:8117019	LOC339788	-0.39	-6.92	-0.36	2.43e-11	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	trans	rs2898857	0.524	rs2072153	chr17:47390014	C/G	cg11430096	chr6:110968061	CDK19	-0.51	-7.63	-0.39	2.64e-13	Cancer;
CRC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.55	8.32	0.42	2.45e-15	Body mass index;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.05	10.48	0.5	2.35e-22	Skin colour saturation;
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.59	-9.42	-0.46	8.25e-19	Glycated hemoglobin levels;
CRC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.52	-9.92	-0.48	1.8899999999999998e-20	Prostate cancer;
CRC	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	19.57	0.73	4.28e-57	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.67	8.37	0.42	1.62e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg06172871	chr16:72088244	HP	0.44	6.45	0.33	4.08e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg15147215	chr3:52552868	STAB1	-0.61	-10.13	-0.49	3.53e-21	Bipolar disorder;
CRC	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.51	8.28	0.42	3.19e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.76	0.3	1.91e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.66	12.26	0.56	9.89e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs10411161	0.752	rs10402107	chr19:52384600	A/G	cg22319618	chr22:45562946	NUP50	-0.69	-7.57	-0.39	3.9e-13	Breast cancer;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.81	8.93	0.44	2.98e-17	Breast cancer;
CRC	cis	rs6076065	0.723	rs6132607	chr20:23390373	C/G	cg11657817	chr20:23433608	CST11	-0.42	-6.29	-0.33	1e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.61	-8.04	-0.41	1.6e-14	Schizophrenia;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg21172814	chr1:180199001	LHX4	-0.4	-6.02	-0.31	4.76e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg24851651	chr11:66362959	CCS	0.39	6.61	0.34	1.57e-10	HIV-1 susceptibility;
CRC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg25456477	chr12:86230367	RASSF9	-0.36	-6.15	-0.32	2.31e-9	Major depressive disorder;
CRC	cis	rs6694672	1.000	rs9427661	chr1:196946546	T/C	cg13682187	chr1:196946512	CFHR5	-0.51	-8.08	-0.41	1.21e-14	Asthma;
CRC	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	5.74	0.3	2.13e-8	Breast cancer;
CRC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg10298567	chr3:47292165	KIF9	0.38	5.93	0.31	7.63e-9	Colorectal cancer;
CRC	cis	rs2108622	0.727	rs12610189	chr19:15978641	T/G	cg13772218	chr19:15982569	NA	0.48	6.72	0.35	8.16e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	trans	rs55675132	0.548	rs17274725	chr1:115377469	C/T	cg25493687	chr8:27288214	PTK2B	0.49	6.0	0.31	5.23e-9	Schizophrenia;
CRC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.61	-8.82	-0.44	6.66e-17	Menarche (age at onset);
CRC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.65	10.04	0.48	7.38e-21	Bipolar disorder and schizophrenia;
CRC	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg11251499	chr4:57774202	REST	-0.44	-6.46	-0.34	3.79e-10	Platelet-derived growth factor BB levels;
CRC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.54	7.85	0.4	5.97e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.82	-0.31	1.41e-8	Gut microbiome composition (summer);
CRC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.37	-5.76	-0.3	1.98e-8	Crohn's disease;
CRC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg18612461	chr15:75251733	NA	-0.37	-5.71	-0.3	2.48e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs1322512	0.876	rs1744372	chr6:152944926	C/G	cg03415253	chr6:152958462	SYNE1	-0.41	-6.38	-0.33	6.06e-10	Tonometry;
CRC	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12292205	chr6:26970375	C6orf41	-0.79	-8.34	-0.42	1.99e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.73	0.3	2.33e-8	Bladder cancer;
CRC	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg00857998	chr1:205179979	DSTYK	0.41	5.68	0.3	3.04e-8	Schizophrenia;
CRC	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-6.44	-0.33	4.28e-10	Lymphocyte counts;
CRC	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg13491945	chr12:107078410	RFX4	0.35	5.95	0.31	7.03e-9	Heart rate;
CRC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.56	9.17	0.45	5.44e-18	Brugada syndrome;
CRC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.66	10.33	0.49	7.42e-22	Gestational age at birth (maternal effect);
CRC	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.17	17.1	0.69	2.26e-47	Atopic dermatitis;
CRC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.77	-13.13	-0.59	5.96e-32	Breast cancer;
CRC	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.79	-0.3	1.67e-8	Pulmonary function;
CRC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.73	11.94	0.55	1.54e-27	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs365302	1.000	rs365302	chr6:159646333	C/T	cg14500486	chr6:159655392	FNDC1	-0.43	-6.75	-0.35	6.87e-11	Coronary heart disease;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg09877947	chr5:131593287	PDLIM4	0.43	7.01	0.36	1.33e-11	Breast cancer;
CRC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-18.41	-0.71	1.63e-52	Height;
CRC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.33	0.59	1.07e-32	Menarche (age at onset);
CRC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg08270630	chr22:50330655	NA	-0.4	-5.75	-0.3	2e-8	Schizophrenia;
CRC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.43	6.35	0.33	7.09e-10	Menarche (age at onset);
CRC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.62	-0.75	3.22e-61	Height;
CRC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.63	-10.96	-0.52	4.86e-24	Body mass index;
CRC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.78	-9.59	-0.47	2.29e-19	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00063649	chr15:67813698	C15orf61	0.44	5.98	0.31	5.77e-9	Anxiety disorder;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.5	5.96	0.31	6.54e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.44	-5.66	-0.3	3.27e-8	DNA methylation (variation);
CRC	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.55	-5.72	-0.3	2.42e-8	Iris characteristics;
CRC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.33	0.33	8.25e-10	Bladder cancer;
CRC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.51	8.19	0.41	5.69e-15	Aortic root size;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg26587870	chr6:27730563	NA	-0.45	-6.57	-0.34	2.01e-10	Parkinson's disease;
CRC	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg16928487	chr17:17741425	SREBF1	-0.37	-6.21	-0.32	1.56e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg25985355	chr7:65971099	NA	0.32	5.7	0.3	2.62e-8	Aortic root size;
CRC	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.49	-0.38	6.56e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.82	9.18	0.45	5.07e-18	Breast cancer;
CRC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	trans	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg19025524	chr12:109796872	NA	-0.46	-6.13	-0.32	2.58e-9	Neuroticism;
CRC	trans	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg00953403	chr17:74099816	EXOC7	-0.5	-6.79	-0.35	5.34e-11	Psychosis in Alzheimer's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02252918	chr12:124458442	ZNF664;CCDC92	-0.6	-7.31	-0.37	2.1e-12	Diisocyanate-induced asthma;
CRC	trans	rs67073037	0.955	rs12620770	chr2:29144892	C/T	cg13899017	chr1:159158444	CADM3	-0.36	-6.09	-0.32	3.16e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.5	6.38	0.33	5.92e-10	Cholesterol, total;
CRC	cis	rs2795502	0.630	rs873300	chr10:43537155	C/T	cg08461752	chr10:43522343	NA	-0.78	-7.0	-0.36	1.42e-11	Blood protein levels;
CRC	cis	rs11212617	1.000	rs660429	chr11:108181511	A/C	cg12106634	chr11:108092400	ATM;NPAT	0.41	6.11	0.32	2.85e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.49	7.68	0.39	1.78e-13	Corneal astigmatism;
CRC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.34	6.14	0.32	2.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs16858210	0.837	rs1879254	chr3:183609471	C/T	cg25686905	chr3:183603175	PARL	-0.41	-5.74	-0.3	2.18e-8	Menopause (age at onset);
CRC	trans	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.42	-0.38	1.03e-12	Endometrial cancer;
CRC	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.46	-5.75	-0.3	1.99e-8	Putamen volume;
CRC	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.63	8.96	0.44	2.48e-17	Coronary artery disease;
CRC	cis	rs7731657	0.537	rs2189504	chr5:130298900	C/A	cg08523029	chr5:130500466	HINT1	-0.49	-6.19	-0.32	1.75e-9	Fasting plasma glucose;
CRC	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg10761708	chr20:43804764	PI3	0.5	5.65	0.3	3.49e-8	Blood protein levels;
CRC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.71	-0.43	1.53e-16	Breast cancer;
CRC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.25	0.59	2.17e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg15123519	chr2:136567270	LCT	-0.33	-6.57	-0.34	1.93e-10	Mosquito bite size;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg10387458	chr1:93645817	TMED5;CCDC18	0.46	6.14	0.32	2.43e-9	Hip circumference;
CRC	cis	rs7429990	0.965	rs1013431	chr3:48029118	A/C	cg11946769	chr3:48343235	NME6	-0.43	-5.71	-0.3	2.58e-8	Educational attainment (years of education);
CRC	cis	rs17095355	1.000	rs61614979	chr10:111743994	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.39	-0.42	1.43e-15	Biliary atresia;
CRC	cis	rs17270561	0.636	rs9379779	chr6:25695441	G/T	cg17691542	chr6:26056736	HIST1H1C	0.6	7.32	0.37	1.87e-12	Iron status biomarkers;
CRC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.56	-8.43	-0.42	1.07e-15	Uric acid levels;
CRC	cis	rs4700695	0.764	rs251278	chr5:65381826	G/A	cg21114390	chr5:65439923	SFRS12	-0.47	-6.11	-0.32	2.83e-9	Facial morphology (factor 19);
CRC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.74	10.9	0.51	8.27e-24	Breast cancer;
CRC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.96	0.31	6.49e-9	Height;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-10.32	-0.49	8.05e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.74	10.4	0.5	4.32e-22	Platelet count;
CRC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.72	0.3	2.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.52	6.94	0.36	2.13e-11	Extraversion;
CRC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg03037974	chr15:76606532	NA	0.55	8.44	0.42	1.03e-15	Blood metabolite levels;
CRC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.58	-8.31	-0.42	2.52e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.42	0.33	4.83e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.54	9.66	0.47	1.38e-19	Common traits (Other);
CRC	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.56	9.66	0.47	1.36e-19	Congenital heart disease (maternal effect);
CRC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.62	9.66	0.47	1.37e-19	Corneal astigmatism;
CRC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg27068330	chr11:65405492	SIPA1	-0.48	-6.58	-0.34	1.86e-10	Breast cancer;
CRC	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.54	9.63	0.47	1.74e-19	Common traits (Other);
CRC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.62	-0.34	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg00691999	chr4:55094011	PDGFRA	0.44	6.27	0.33	1.13e-9	Corneal astigmatism;
CRC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg22495460	chr2:25135724	ADCY3	-0.89	-17.5	-0.69	5.99e-49	Body mass index;
CRC	cis	rs6717918	0.561	rs2633260	chr2:233132810	T/C	ch.2.233013039R	chr2:233304795	NA	0.54	6.37	0.33	6.28e-10	Height;
CRC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.54	7.96	0.4	2.81e-14	Lung cancer;
CRC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg23283495	chr1:209979779	IRF6	0.35	6.05	0.32	3.88e-9	Monobrow;
CRC	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	13.78	0.61	1.95e-34	Fuchs's corneal dystrophy;
CRC	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg23417306	chr2:180868811	CWC22	0.42	5.97	0.31	5.99e-9	Schizophrenia;
CRC	cis	rs9928842	0.823	rs6564243	chr16:75296001	A/C	cg08657710	chr16:75258780	CTRB1	-0.56	-6.5	-0.34	2.97e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.83	13.11	0.59	7.1e-32	Menarche (age at onset);
CRC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.27	-0.37	2.64e-12	Height;
CRC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	6.43	0.33	4.61e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.65	-0.34	1.19e-10	Mean corpuscular volume;
CRC	cis	rs449789	0.857	rs625687	chr6:159703294	G/A	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-7.12	-0.37	6.73e-12	Eye color traits;
CRC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.62	9.93	0.48	1.76e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08664810	chr1:92949973	GFI1	0.4	6.16	0.32	2.15e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7027930	0.524	rs16921135	chr9:614252	C/T	cg27061366	chr19:13044373	FARSA	0.48	6.15	0.32	2.28e-9	Pulmonary function decline;
CRC	cis	rs1124376	0.882	rs7639282	chr3:20133873	G/A	cg05072819	chr3:20081367	KAT2B	0.51	6.08	0.32	3.37e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg23161317	chr6:28129485	ZNF389	0.45	6.32	0.33	8.37e-10	Parkinson's disease;
CRC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg25251562	chr2:3704773	ALLC	-0.49	-6.16	-0.32	2.09e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.73	11.68	0.54	1.34e-26	Plateletcrit;Platelet count;
CRC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.95	11.98	0.55	1.09e-27	Eosinophil percentage of granulocytes;
CRC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.16	0.37	5.18e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.47	7.97	0.4	2.56e-14	Common traits (Other);
CRC	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.59	-6.4	-0.33	5.35e-10	Coronary artery disease;
CRC	cis	rs758324	0.812	rs519240	chr5:131269453	G/A	cg25547332	chr5:131281432	NA	-0.37	-5.98	-0.31	5.72e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-9.37	-0.46	1.2e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.94	11.76	0.54	6.7399999999999993e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs2274273	0.624	rs67386901	chr14:55757364	C/T	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.66	-0.3	3.28e-8	Protein biomarker;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08056012	chr3:130612679	ATP2C1	0.39	6.2	0.32	1.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs672059	1.000	rs638781	chr1:183157358	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.13	0.37	6.54e-12	Hypertriglyceridemia;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg02560186	chr11:3602584	NA	-0.63	-9.54	-0.47	3.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg09659197	chr4:152720779	NA	-0.51	-10.78	-0.51	2.09e-23	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.28	-0.42	3.08e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	0.84	8.8	0.44	7.89e-17	Skin colour saturation;
CRC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.54	-0.47	3.31e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3823572	0.564	rs2953632	chr7:133644261	T/A	cg03336402	chr7:133662267	EXOC4	-0.66	-10.32	-0.49	8.34e-22	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg17775713	chr3:133465469	TF	0.36	6.66	0.34	1.12e-10	Iron status biomarkers;
CRC	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg09873164	chr1:152488093	CRCT1	0.39	6.58	0.34	1.84e-10	Hair morphology;
CRC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.68	0.51	4.61e-23	Motion sickness;
CRC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12315302	chr6:26189340	HIST1H4D	0.75	6.28	0.33	1.05e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg23136738	chr11:925521	AP2A2	-0.4	-6.1	-0.32	3.01e-9	Alzheimer's disease (late onset);
CRC	cis	rs12983728	0.572	rs59114323	chr19:58649994	C/T	cg21294424	chr19:58662284	ZNF329	0.52	6.57	0.34	1.98e-10	Cholesterol, total;
CRC	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg22561889	chr6:118971681	C6orf204	0.48	5.92	0.31	8.26e-9	Diastolic blood pressure;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.53	9.84	0.48	3.31e-20	Acylcarnitine levels;
CRC	cis	rs6804368	0.649	rs9819728	chr3:30761827	T/C	cg06106510	chr3:30762233	NA	0.35	6.42	0.33	4.67e-10	Blood metabolite levels;
CRC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.11	-12.36	-0.56	4.21e-29	Diabetic kidney disease;
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.83	-0.35	3.99e-11	Bipolar disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08467595	chr3:13009117	IQSEC1	-0.39	-6.02	-0.31	4.73e-9	Myopia (pathological);
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.95	0.44	2.65e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.49	7.75	0.39	1.18e-13	Red blood cell count;
CRC	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.44	6.4	0.33	5.42e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg24977027	chr2:88469347	THNSL2	0.53	6.15	0.32	2.29e-9	Plasma clusterin levels;
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.52	10.97	0.52	4.43e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs8097070	0.661	rs9966711	chr18:23171413	C/G	cg09098825	chr3:47866946	DHX30	0.56	6.05	0.32	3.87e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.84	0.35	3.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.71	10.88	0.51	9.53e-24	Corneal astigmatism;
CRC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.34	5.77	0.3	1.86e-8	Major depressive disorder;
CRC	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.3	-0.37	2.2e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	0.84	6.39	0.33	5.65e-10	Blood metabolite levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg26293423	chr5:71613149	MRPS27	-0.38	-5.97	-0.31	6.06e-9	HDL cholesterol;
CRC	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg09655341	chr17:79618100	PDE6G	0.58	6.74	0.35	7.07e-11	Dental caries;
CRC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-10.05	-0.48	6.71e-21	Height;
CRC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg18479299	chr3:125709523	NA	-0.55	-6.64	-0.34	1.33e-10	Blood pressure (smoking interaction);
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.72	-11.37	-0.53	1.71e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.49	7.63	0.39	2.62e-13	Type 2 diabetes;
CRC	cis	rs2000999	0.524	rs12933482	chr16:72189604	A/G	cg04254540	chr16:71951199	KIAA0174	-0.77	-6.38	-0.33	6.11e-10	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	trans	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	6.12	0.32	2.65e-9	Metabolite levels;
CRC	cis	rs9925964	0.933	rs10871454	chr16:31048079	C/T	cg03418659	chr16:31128414	MYST1	0.47	6.79	0.35	5.39e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-7.0	-0.36	1.41e-11	Morning vs. evening chronotype;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02835734	chr2:28974942	PPP1CB	-0.44	-6.43	-0.33	4.49e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg21856205	chr7:94953877	PON1	-0.49	-6.32	-0.33	8.6e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.73	-16.0	-0.66	4.99e-43	Intelligence (multi-trait analysis);
CRC	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.44	6.88	0.35	2.95e-11	Social autistic-like traits;
CRC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.71	11.4	0.53	1.38e-25	Dental caries;
CRC	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.75	8.71	0.43	1.51e-16	Eotaxin levels;
CRC	cis	rs7539542	0.556	rs4950888	chr1:202872625	C/T	cg19681188	chr1:202830198	LOC148709	0.46	6.67	0.35	1.09e-10	Mean platelet volume;
CRC	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg24011408	chr12:48396354	COL2A1	-0.39	-5.64	-0.3	3.61e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.44	6.53	0.34	2.51e-10	Menopause (age at onset);
CRC	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.31	-6.62	-0.34	1.46e-10	Educational attainment (years of education);
CRC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.89	0.58	4.57e-31	Bone mineral density;
CRC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg24675056	chr1:15929824	NA	0.48	6.52	0.34	2.66e-10	Systolic blood pressure;
CRC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25621393	chr5:149737060	TCOF1	0.4	6.16	0.32	2.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.57	8.83	0.44	6.39e-17	Breast cancer;
CRC	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.6	8.83	0.44	6.58e-17	Red blood cell count;
CRC	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05903289	chr2:130345205	NA	-0.41	-8.12	-0.41	9.69e-15	Response to cytidine analogues (gemcitabine);
CRC	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg25930673	chr12:123319894	HIP1R	0.72	6.09	0.32	3.16e-9	Adiponectin levels;
CRC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.82	-9.92	-0.48	1.85e-20	Initial pursuit acceleration;
CRC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	0.7	6.24	0.33	1.34e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-9.09	-0.45	9.53e-18	Hemoglobin concentration;
CRC	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg20742385	chr13:113633654	MCF2L	-0.63	-10.69	-0.51	4.36e-23	Systolic blood pressure;
CRC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.41	7.92	0.4	3.7e-14	Mean corpuscular volume;
CRC	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.51	-7.13	-0.37	6.21e-12	Primary sclerosing cholangitis;
CRC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.4	-0.46	9.66e-19	Body mass index;
CRC	cis	rs6694672	0.867	rs1764800	chr1:197250615	G/A	cg13682187	chr1:196946512	CFHR5	0.5	7.05	0.36	1.05e-11	Asthma;
CRC	trans	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.85	0.4	5.73e-14	Diabetic kidney disease;
CRC	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	8.88	0.44	4.52e-17	Iron status biomarkers;
CRC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.22	0.41	4.85e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.46	-7.42	-0.38	9.77e-13	Mean corpuscular volume;
CRC	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.64	-8.99	-0.44	1.99e-17	Psoriasis;
CRC	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg22153745	chr1:153894579	GATAD2B	-0.6	-9.25	-0.45	2.99e-18	Total cholesterol levels;
CRC	cis	rs6662572	0.578	rs6662306	chr1:46287286	G/A	cg08644498	chr1:46502608	NA	0.44	6.91	0.36	2.59e-11	Blood protein levels;
CRC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.37	6.19	0.32	1.8e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg05714579	chr10:131428358	MGMT	0.5	6.96	0.36	1.81e-11	Response to temozolomide;
CRC	cis	rs4930561	0.714	rs7122250	chr11:67946472	T/C	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.98	-0.31	5.78e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.63	-0.34	1.35e-10	Headache;
CRC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.67	10.68	0.51	4.57e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.55	-9.1	-0.45	8.77e-18	Caffeine consumption;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg01758942	chr3:52551074	STAB1	0.31	6.24	0.33	1.33e-9	Electroencephalogram traits;
CRC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-7.48	-0.38	7.02e-13	Obesity (extreme);
CRC	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg04111102	chr1:66153794	NA	0.33	5.77	0.3	1.83e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg12100956	chr17:78086420	GAA	-0.38	-6.8	-0.35	4.96e-11	Yeast infection;
CRC	trans	rs33794	0.564	rs6799689	chr3:45226973	C/T	cg00688460	chr12:48922396	NA	0.27	6.0	0.31	5.07e-9	Lung function (forced expiratory volume in 1 second);
CRC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.72	-10.77	-0.51	2.33e-23	Inflammatory bowel disease;
CRC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.22	0.37	3.62e-12	Major depressive disorder;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg22081084	chr1:89990230	LRRC8B	-0.39	-6.0	-0.31	5.12e-9	Daytime sleep phenotypes;
CRC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04880052	chr2:219191631	PNKD	-0.42	-6.64	-0.34	1.3100000000000001e-10	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.59	-9.21	-0.45	4.07e-18	Body mass index;
CRC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg02549819	chr16:58548995	SETD6	1.2	7.97	0.4	2.72e-14	Schizophrenia;
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-8.29	-0.42	2.99e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10946940	0.632	rs9366698	chr6:27672035	C/G	cg06470822	chr6:28175283	NA	0.55	6.83	0.35	4.12e-11	Systemic lupus erythematosus;
CRC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.67	0.34	1.11e-10	Mean platelet volume;
CRC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.89	0.63	1.07e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11212617	0.967	rs7942014	chr11:108326174	G/C	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.67	0.3	3.13e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg07636037	chr3:49044803	WDR6	-0.72	-6.08	-0.32	3.38e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.73	11.21	0.53	6.53e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23711144	chr16:3108784	MMP25	0.45	6.21	0.32	1.62e-9	Response to antipsychotic treatment;
CRC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.75	12.6	0.57	5.52e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg08798685	chr6:27730294	NA	-0.42	-6.09	-0.32	3.08e-9	Parkinson's disease;
CRC	cis	rs13272623	0.502	rs268601	chr8:71518548	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.45	-6.55	-0.34	2.28e-10	IgG glycosylation;
CRC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.08	-12.36	-0.56	4.53e-29	Diabetic kidney disease;
CRC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.5	8.77	0.44	9.45e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.8	-12.85	-0.58	6.45e-31	Hypospadias;
CRC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.76	0.39	1.09e-13	Lung cancer;
CRC	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.71	-0.35	8.71e-11	Eye color traits;
CRC	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.87	16.72	0.68	7.54e-46	Hip circumference;
CRC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg19223190	chr17:80058835	NA	-0.5	-7.97	-0.4	2.55e-14	Life satisfaction;
CRC	cis	rs7707921	1.000	rs749402	chr5:81561325	C/T	cg17942617	chr5:81327376	ATG10	0.39	5.8	0.3	1.53e-8	Breast cancer;
CRC	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.92	-11.65	-0.54	1.75e-26	Hair shape;
CRC	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.58	8.1	0.41	1.08e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04363768	chr8:56793160	LYN	0.44	6.47	0.34	3.46e-10	Response to antipsychotic treatment;
CRC	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg13385794	chr1:248469461	NA	0.39	6.68	0.35	9.97e-11	Common traits (Other);
CRC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.47	8.05	0.41	1.51e-14	Childhood ear infection;
CRC	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	6.63	0.34	1.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2857891	0.695	rs2857887	chr11:6984001	A/G	cg04053776	chr11:6947353	ZNF215	0.41	6.21	0.32	1.61e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23388714	chr18:51750950	MBD2	0.4	6.27	0.33	1.15e-9	Schizophrenia;
CRC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14895029	chr7:2775587	GNA12	-0.49	-7.05	-0.36	1.07e-11	Height;
CRC	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.37	6.29	0.33	1.02e-9	Blood metabolite levels;
CRC	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg19773385	chr1:10388646	KIF1B	-0.56	-7.47	-0.38	7.19e-13	Hepatocellular carcinoma;
CRC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.8	14.56	0.63	2.12e-37	Metabolic syndrome;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg21192091	chr7:2758800	NA	-0.35	-5.79	-0.3	1.61e-8	Height;
CRC	cis	rs3106136	0.843	rs4282187	chr4:95273145	T/C	cg11021082	chr4:95130006	SMARCAD1	0.43	6.44	0.33	4.34e-10	Capecitabine sensitivity;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg21577049	chr2:228736449	WDR69	-0.43	-5.79	-0.3	1.64e-8	Blood pressure;
CRC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg05623727	chr3:50126028	RBM5	0.46	7.69	0.39	1.76e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg25193494	chr16:90016004	DEF8	-0.46	-6.93	-0.36	2.19e-11	Melanoma;
CRC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.1	12.91	0.58	3.79e-31	Sexual dysfunction (female);
CRC	trans	rs12495832	0.778	rs78156073	chr3:147898520	C/T	cg10221266	chr7:153579447	NA	0.56	6.13	0.32	2.54e-9	Chin dimples;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05950833	chr1:32688296	C1orf91;EIF3I	0.44	6.16	0.32	2.1e-9	Response to antipsychotic treatment;
CRC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg17401720	chr7:158221031	PTPRN2	0.38	5.94	0.31	7.34e-9	Obesity-related traits;
CRC	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg15711740	chr2:61764176	XPO1	-0.51	-6.97	-0.36	1.72e-11	Tuberculosis;
CRC	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.46	-6.84	-0.35	3.89e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.93	0.44	3.16e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg20933634	chr6:27740509	NA	0.63	7.31	0.37	2e-12	Parkinson's disease;
CRC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg04990556	chr1:26633338	UBXN11	-0.48	-6.15	-0.32	2.31e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-7.4	-0.38	1.11e-12	Hepatocellular carcinoma;
CRC	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg19338460	chr6:170058176	WDR27	-0.76	-8.29	-0.42	2.95e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.6	-0.3	4.44e-8	Gout;Renal underexcretion gout;
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.54	8.67	0.43	2.07e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	7.55	0.38	4.44e-13	Corneal astigmatism;
CRC	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg04824913	chr4:887549	GAK	0.43	6.16	0.32	2.18e-9	Systemic sclerosis;
CRC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.16	0.41	7.04e-15	Lung cancer;
CRC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg08314208	chr16:67682810	RLTPR	-0.62	-7.06	-0.36	9.97e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.65	-11.89	-0.55	2.39e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.74	-14.41	-0.62	7.9e-37	Prostate cancer;
CRC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.38	-6.01	-0.31	5.04e-9	Ulcerative colitis;
CRC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.62	-9.0	-0.44	1.79e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.34e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.84	16.62	0.68	1.87e-45	White blood cell count;
CRC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.53	-6.05	-0.32	4.02e-9	Vitiligo;
CRC	trans	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.09	-0.32	3.09e-9	Educational attainment (years of education);
CRC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.38	6.1	0.32	3.01e-9	Major depressive disorder;
CRC	cis	rs2786111	0.965	rs1764623	chr1:197288308	G/T	cg13682187	chr1:196946512	CFHR5	0.29	5.67	0.3	3.19e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.83	-0.44	6.25e-17	Bipolar disorder;
CRC	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.38	8.34	0.42	2.04e-15	Urate levels in overweight individuals;
CRC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.64	0.39	2.42e-13	Axial length;
CRC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-7.25	-0.37	3.03e-12	Blood pressure (smoking interaction);
CRC	cis	rs10991814	1.000	rs60953089	chr9:93948053	A/G	cg14446406	chr9:93919335	NA	0.51	6.21	0.32	1.64e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs6679356	0.789	rs3977726	chr1:67815915	C/A	cg24364144	chr1:67875067	SERBP1	0.43	6.66	0.34	1.14e-10	Primary biliary cholangitis;
CRC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.45	9.04	0.45	1.38e-17	Alcohol dependence;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.42	5.9	0.31	8.85e-9	Longevity;
CRC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.83	12.75	0.58	1.59e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.92	14.12	0.61	1.01e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.4	6.43	0.33	4.46e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg15147215	chr3:52552868	STAB1	-0.59	-9.6	-0.47	2.06e-19	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25625872	chr20:62258572	GMEB2	0.45	6.58	0.34	1.83e-10	Anxiety disorder;
CRC	trans	rs2303319	0.504	rs55841284	chr2:162560011	A/G	cg03757145	chr4:76555832	CDKL2	-0.65	-6.02	-0.31	4.58e-9	Cognitive function;
CRC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.55	8.11	0.41	1.05e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.4	7.88	0.4	4.85e-14	Vitiligo;
CRC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.49	-7.09	-0.36	8.15e-12	Testicular germ cell tumor;
CRC	trans	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.62	0.34	1.46e-10	Mean corpuscular volume;
CRC	trans	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg11843238	chr5:131593191	PDLIM4	0.49	9.02	0.45	1.63e-17	Blood metabolite levels;
CRC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg03948781	chr1:205179583	DSTYK	0.41	5.61	0.3	4.22e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.73	11.0	0.52	3.69e-24	Menarche (age at onset);
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.85	13.32	0.59	1.15e-32	Menarche (age at onset);
CRC	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.6	-6.59	-0.34	1.77e-10	Coronary artery disease;
CRC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg17031739	chr1:67600172	NA	0.43	6.87	0.35	3.17e-11	Psoriasis;
CRC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg07274523	chr3:49395745	GPX1	0.48	6.37	0.33	6.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11209185	0.509	rs9436790	chr1:68447044	G/A	cg22082780	chr1:68452167	NA	0.4	6.14	0.32	2.36e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.43	-0.69	1.16e-48	Body mass index;
CRC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	7.6	0.39	3.12e-13	Total body bone mineral density;
CRC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.17e-13	Educational attainment;
CRC	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.52	-6.76	-0.35	6.24e-11	Coronary artery disease;
CRC	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.46	6.61	0.34	1.52e-10	Subjective well-being;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg08200770	chr17:80723486	TBCD	0.42	7.19	0.37	4.25e-12	Glycated hemoglobin levels;
CRC	cis	rs8014671	0.531	rs12880777	chr14:70874695	A/G	cg20409590	chr14:70655382	SLC8A3	-0.3	-5.75	-0.3	1.99e-8	Prostate cancer;
CRC	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg04110750	chr16:69646130	NFAT5	-0.51	-6.75	-0.35	6.86e-11	IgE levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24070195	chr17:46969581	ATP5G1	0.44	6.2	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17261708	chr5:176794207	RGS14	-0.53	-8.59	-0.43	3.6e-16	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.79	8.19	0.41	5.81e-15	Diabetic retinopathy;
CRC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.42	8.25	0.41	3.73e-15	Mean corpuscular volume;
CRC	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.61	-8.61	-0.43	3e-16	Hair shape;
CRC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.83	0.44	6.2e-17	Rheumatoid arthritis;
CRC	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg03929089	chr4:120376271	NA	-0.73	-11.88	-0.55	2.6e-27	Height;
CRC	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-10.33	-0.49	7.45e-22	Hepatocellular carcinoma;
CRC	cis	rs1838105	0.674	rs10514915	chr17:45166126	C/T	cg16759221	chr17:45003025	GOSR2	-0.61	-9.33	-0.46	1.58e-18	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs9807989	0.839	rs1362348	chr2:102984624	C/G	cg03938978	chr2:103052716	IL18RAP	0.37	6.05	0.32	3.99e-9	Asthma;
CRC	cis	rs2617583	0.509	rs4738	chr5:1461568	C/T	cg07148919	chr5:1466943	LPCAT1	-0.45	-5.79	-0.3	1.68e-8	Breast cancer;
CRC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.85	16.8	0.68	3.47e-46	White blood cell count (basophil);White blood cell count;
CRC	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg16964102	chr10:135390573	NA	-0.38	-6.15	-0.32	2.29e-9	Obesity-related traits;
CRC	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs73206853	0.841	rs73191826	chr12:110943001	G/T	cg12870014	chr12:110450643	ANKRD13A	0.76	8.15	0.41	7.69e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.8	-0.35	4.89e-11	Height;
CRC	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.59	-9.39	-0.46	9.96e-19	Neuroticism;
CRC	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg18833306	chr6:118973337	C6orf204	0.46	5.88	0.31	1.01e-8	Diastolic blood pressure;
CRC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.98	-18.22	-0.71	9.12e-52	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.35	-5.76	-0.3	1.9e-8	Childhood ear infection;
CRC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.58	8.72	0.43	1.44e-16	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11179286	chr13:115047994	UPF3A	0.42	6.6	0.34	1.63e-10	Obesity-related traits;
CRC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg02428538	chr16:24856791	SLC5A11	0.6	7.04	0.36	1.1e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.63	8.21	0.41	5.11e-15	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.59	7.23	0.37	3.38e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.7	-9.05	-0.45	1.26e-17	Initial pursuit acceleration;
CRC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg25600027	chr14:23388339	RBM23	-0.53	-8.37	-0.42	1.65e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs9549328	0.699	rs2993345	chr13:113617086	C/T	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.33e-19	Systolic blood pressure;
CRC	cis	rs9462846	0.960	rs12194860	chr6:42862934	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-5.79	-0.3	1.68e-8	Blood protein levels;
CRC	cis	rs6564851	0.506	rs62054662	chr16:81258173	G/C	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.65	-0.3	3.53e-8	Carotenoid and tocopherol levels;
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.69	-0.35	9.78e-11	Bipolar disorder;
CRC	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	0.92	10.13	0.49	3.58e-21	Atopic dermatitis;
CRC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg15193198	chr20:60906057	LAMA5	0.42	6.82	0.35	4.27e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs333947	0.800	rs6537885	chr1:110478803	A/G	cg22379905	chr12:6601357	MRPL51	-0.47	-6.43	-0.33	4.61e-10	White blood cell count;Monocyte count;
CRC	cis	rs73206853	0.697	rs16934006	chr12:110527907	T/A	cg12870014	chr12:110450643	ANKRD13A	0.75	8.93	0.44	3.16e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg10761708	chr20:43804764	PI3	0.5	5.65	0.3	3.47e-8	Blood protein levels;
CRC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.8	10.06	0.48	6.39e-21	Initial pursuit acceleration;
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg00777555	chr3:57583074	ARF4	0.41	6.04	0.32	4.16e-9	Crohn's disease;
CRC	cis	rs12692738	0.526	rs366225	chr2:165610236	G/C	cg03182029	chr2:165697222	COBLL1	0.5	5.85	0.31	1.16e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-13.21	-0.59	2.88e-32	Ulcerative colitis;
CRC	cis	rs2444240	0.583	rs75389345	chr11:120039924	T/G	cg04390734	chr11:120039366	NA	0.29	5.82	0.31	1.43e-8	Corneal curvature;
CRC	cis	rs4664293	0.932	rs4665104	chr2:160532358	C/T	cg08347373	chr2:160653686	CD302	-0.37	-6.08	-0.32	3.32e-9	Monocyte percentage of white cells;
CRC	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg06781209	chr11:61594997	FADS2	-0.43	-6.25	-0.33	1.25e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.65	7.3	0.37	2.16e-12	Body mass index;
CRC	cis	rs6694672	0.717	rs1537319	chr1:197052804	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.65	0.39	2.3e-13	Asthma;
CRC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.66	-0.47	1.35e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs28829049	0.536	rs2073106	chr1:19549343	G/C	cg22333259	chr1:19394757	NA	0.37	5.7	0.3	2.64e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.43	-0.38	9.18e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6586163	0.872	rs7082101	chr10:90741615	C/A	cg13456138	chr10:90753195	FAS	-0.44	-6.58	-0.34	1.84e-10	Chronic lymphocytic leukemia;
CRC	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.55	9.0	0.44	1.84e-17	Educational attainment;
CRC	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg01065977	chr19:18549689	ISYNA1	-0.44	-6.94	-0.36	2.09e-11	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07143296	chr11:65383706	PCNXL3	0.41	6.26	0.33	1.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7781557	0.582	rs2411061	chr7:102613490	T/A	cg18108683	chr7:102477205	FBXL13	-0.49	-5.71	-0.3	2.51e-8	Colorectal adenoma (advanced);
CRC	cis	rs56399783	0.614	rs73047355	chr7:2758145	G/A	cg19731401	chr7:2775893	GNA12	0.66	6.95	0.36	2.02e-11	Childhood ear infection;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg23161317	chr6:28129485	ZNF389	0.37	5.71	0.3	2.58e-8	Pubertal anthropometrics;
CRC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.92	18.5	0.71	7.09e-53	Height;
CRC	cis	rs4664293	0.967	rs6432548	chr2:160545537	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.19	-0.32	1.83e-9	Monocyte percentage of white cells;
CRC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.66	-10.13	-0.49	3.56e-21	Height;
CRC	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg01843034	chr6:37503916	NA	-0.38	-6.87	-0.35	3.2e-11	Cognitive performance;
CRC	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg06988349	chr10:69991859	ATOH7	0.32	5.93	0.31	7.6e-9	Optic disc area;
CRC	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg06484146	chr7:12443880	VWDE	-0.61	-6.56	-0.34	2.05e-10	Coronary artery disease;
CRC	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.36	0.38	1.45e-12	Eye color traits;
CRC	cis	rs6717918	0.620	rs7570112	chr2:233150452	A/G	ch.2.233013039R	chr2:233304795	NA	0.58	7.39	0.38	1.19e-12	Height;
CRC	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg24289452	chr6:170231220	NA	-0.92	-7.57	-0.39	3.83e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21467203	chr3:49911342	NA	-0.26	-6.28	-0.33	1.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.74	-0.3	2.16e-8	Gout;Renal underexcretion gout;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14771734	chr5:79703670	ZFYVE16	0.42	5.98	0.31	5.93e-9	Response to antipsychotic treatment;
CRC	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-5.83	-0.31	1.3e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg09163369	chr1:210001066	C1orf107	0.41	5.77	0.3	1.85e-8	Orofacial clefts;
CRC	cis	rs1656402	1.000	rs1656397	chr2:233428927	G/C	cg03852847	chr2:233439513	NA	0.44	7.56	0.38	4.08e-13	Non-small cell lung cancer (survival);
CRC	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.71	-0.57	2.24e-30	Leprosy;
CRC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.71	0.51	3.64e-23	Cognitive function;
CRC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.27	-0.41	3.44e-15	Mean platelet volume;
CRC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07701084	chr6:150067640	NUP43	0.49	7.17	0.37	4.95e-12	Testicular germ cell tumor;
CRC	cis	rs12760731	0.720	rs1397185	chr1:178381698	G/A	cg00404053	chr1:178313656	RASAL2	0.98	10.15	0.49	3.04e-21	Obesity-related traits;
CRC	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.48	7.6	0.39	3.06e-13	Testicular germ cell tumor;
CRC	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.42	-7.14	-0.37	5.97e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.9	0.31	9.27e-9	Height;
CRC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.61e-9	Height;
CRC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg13482628	chr17:19912719	NA	-0.4	-6.18	-0.32	1.92e-9	Obesity-related traits;
CRC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.4	6.16	0.32	2.14e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg03623178	chr6:28175578	NA	0.79	11.69	0.54	1.22e-26	Cardiac Troponin-T levels;
CRC	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.55	6.87	0.35	3.22e-11	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.66	0.43	2.13e-16	Menopause (age at onset);
CRC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	7.02	0.36	1.27e-11	Height;
CRC	cis	rs9292777	0.776	rs10473190	chr5:40412607	C/A	cg09067459	chr5:40385259	NA	0.51	8.91	0.44	3.65e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.89	-0.36	2.81e-11	Monocyte count;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24153199	chr14:50698328	SOS2	0.4	6.0	0.31	5.3e-9	Schizophrenia;
CRC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.81	13.61	0.6	9.13e-34	Menopause (age at onset);
CRC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.52	7.65	0.39	2.24e-13	High light scatter reticulocyte count;
CRC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.24	-16.52	-0.67	4.4e-45	Breast cancer;
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg06713098	chr7:45960367	IGFBP3	0.41	6.51	0.34	2.73e-10	Sitting height ratio;
CRC	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.73	-0.3	2.29e-8	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06757925	chr1:70671216	LRRC40;SFRS11	0.48	6.32	0.33	8.7e-10	Thyroid stimulating hormone;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22813821	chr12:72148853	RAB21	0.46	6.26	0.33	1.18e-9	Anxiety disorder;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg15845792	chr6:28175446	NA	1.04	13.81	0.61	1.6e-34	Depression;
CRC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.58	10.65	0.51	5.97e-23	Aortic root size;
CRC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.48	-7.22	-0.37	3.53e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.83e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.44	7.06	0.36	9.77e-12	Schizophrenia;
CRC	cis	rs10971721	0.822	rs7856487	chr9:33870940	C/T	cg13495928	chr9:33750294	PRSS3	0.54	5.72	0.3	2.41e-8	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00852613	chr13:50159829	RCBTB1	0.45	7.23	0.37	3.42e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.74	-10.07	-0.49	5.92e-21	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.49e-10	Depression;
CRC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.5	6.97	0.36	1.7e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-8.31	-0.42	2.53e-15	Systolic blood pressure;
CRC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.5	-6.7	-0.35	8.87e-11	Urate levels;
CRC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.44	7.11	0.36	7.49e-12	Resting heart rate;
CRC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.64	11.21	0.53	6.42e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06544989	chr22:39130855	UNC84B	-0.45	-6.83	-0.35	4.07e-11	Menopause (age at onset);
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg02891801	chr12:6472782	SCNN1A	0.61	6.41	0.33	5.12e-10	Airway imaging phenotypes;
CRC	cis	rs7605827	0.930	rs6733519	chr2:15525567	T/C	cg19274914	chr2:15703543	NA	0.38	5.63	0.3	3.81e-8	Educational attainment (years of education);
CRC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg14828511	chr1:107599125	PRMT6	0.55	7.49	0.38	6.37e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.55	7.45	0.38	8.53e-13	Resting heart rate;
CRC	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.82	-0.55	3.98e-27	Exhaled nitric oxide output;
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg08200582	chr11:442649	ANO9	-0.69	-7.04	-0.36	1.16e-11	Body mass index;
CRC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.55	6.45	0.34	3.95e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7394190	0.688	rs3812629	chr10:75407290	G/A	cg07699608	chr10:75541558	CHCHD1	0.62	6.35	0.33	6.95e-10	Incident atrial fibrillation;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18172804	chr1:146714232	CHD1L	0.44	6.25	0.33	1.3e-9	Anxiety disorder;
CRC	cis	rs7849270	1.000	rs7023900	chr9:131891152	C/G	cg13538475	chr9:131942899	NA	-0.31	-6.03	-0.32	4.33e-9	Blood metabolite ratios;
CRC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.62	-7.85	-0.4	6.07e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg16060761	chr17:80687452	NA	0.42	6.0	0.31	5.21e-9	Breast cancer;
CRC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg00734567	chr1:86172782	ZNHIT6	-0.48	-7.26	-0.37	2.79e-12	Urate levels in overweight individuals;
CRC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.47	-9.26	-0.45	2.65e-18	Prostate cancer;
CRC	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg27205649	chr11:78285834	NARS2	-0.47	-5.79	-0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.62	8.94	0.44	2.94e-17	Height;
CRC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.17	-0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg15845792	chr6:28175446	NA	0.45	6.24	0.33	1.35e-9	Depression;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg23161317	chr6:28129485	ZNF389	0.43	5.9	0.31	9.23e-9	Parkinson's disease;
CRC	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.7	-10.84	-0.51	1.34e-23	Type 2 diabetes;
CRC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23850377	chr2:20251576	LAPTM4A	-0.53	-6.45	-0.34	3.92e-10	Diisocyanate-induced asthma;
CRC	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg10820045	chr2:198174542	NA	-0.56	-9.64	-0.47	1.62e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	9.2e-17	Coffee consumption (cups per day);
CRC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg11157611	chr1:21499906	EIF4G3	0.32	5.6	0.3	4.47e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10819733	chr22:24237672	NA	-0.35	-6.06	-0.32	3.7e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs427941	0.632	rs382228	chr7:101786064	A/C	cg06246474	chr7:101738831	CUX1	0.43	6.59	0.34	1.79e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.88	-11.25	-0.53	4.66e-25	Hair shape;
CRC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.49	7.16	0.37	5.28e-12	N-glycan levels;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg12516270	chr8:143859308	LYNX1	-0.42	-6.84	-0.35	3.78e-11	Urinary tract infection frequency;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg03623178	chr6:28175578	NA	0.77	11.68	0.54	1.3e-26	Parkinson's disease;
CRC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.59	8.01	0.4	1.95e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.18	-0.32	1.91e-9	Axial length;
CRC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-14.65	-0.63	8.89e-38	Gut microbiome composition (summer);
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.35	5.85	0.31	1.21e-8	Lung cancer;
CRC	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.43	-6.76	-0.35	6.21e-11	C-reactive protein levels;
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.29	-0.56	8.15e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.6	-8.13	-0.41	8.7e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg13385794	chr1:248469461	NA	0.33	5.84	0.31	1.27e-8	Common traits (Other);
CRC	cis	rs7635838	0.892	rs7644968	chr3:11489493	C/T	cg00170343	chr3:11313890	ATG7	0.41	6.32	0.33	8.7e-10	HDL cholesterol;
CRC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.52	-0.38	5.24e-13	Mood instability;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07886860	chr3:40566285	ZNF621	0.42	6.39	0.33	5.65e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.27	0.33	1.11e-9	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11609344	chr7:44240862	YKT6	0.46	6.8	0.35	4.94e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.65	-0.3	3.44e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.86	-15.02	-0.64	3.52e-39	Longevity;
CRC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg04989706	chr14:50066350	PPIL5	-0.54	-7.45	-0.38	8.18e-13	Carotid intima media thickness;
CRC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.72	10.65	0.51	5.78e-23	Breast cancer;
CRC	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.51	7.88	0.4	4.77e-14	Corneal astigmatism;
CRC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	6.14	0.32	2.37e-9	Diabetic retinopathy;
CRC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg21238619	chr17:78079768	GAA	0.45	7.04	0.36	1.1e-11	Yeast infection;
CRC	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-6.76	-0.35	6.2e-11	Schizophrenia;
CRC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	9.49	0.46	4.78e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.84	-10.45	-0.5	3.01e-22	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.93	-0.31	7.69e-9	Coronary artery disease;
CRC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.66	7.83	0.4	6.69e-14	Lymphocyte counts;
CRC	cis	rs4683142	0.518	rs6802312	chr3:46025941	T/C	cg08033130	chr3:45983597	CXCR6;FYCO1	0.41	5.65	0.3	3.4e-8	Methadone dose in opioid dependence;
CRC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.56	8.37	0.42	1.66e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.71	11.13	0.52	1.24e-24	Monocyte count;
CRC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.38	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	13.69	0.6	4.36e-34	Chronic sinus infection;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-8.14	-0.41	8.5e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.38	-0.33	5.87e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.63	-0.3	3.81e-8	Testicular germ cell tumor;
CRC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.48	9.13	0.45	7.17e-18	Renal cell carcinoma;
CRC	cis	rs886126	0.684	rs3858704	chr12:111705893	A/G	cg10833066	chr12:111807467	FAM109A	0.42	6.12	0.32	2.68e-9	Coronary heart disease;
CRC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.43	0.42	1.12e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.59	9.25	0.45	2.93e-18	Tuberculosis;
CRC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.53e-12	Menopause (age at onset);
CRC	cis	rs2657888	0.628	rs3809122	chr12:56882710	A/T	cg23002907	chr12:56915593	RBMS2	-0.39	-6.23	-0.32	1.46e-9	Adiponectin levels;
CRC	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg10820045	chr2:198174542	NA	0.42	7.34	0.38	1.71e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.5	-8.31	-0.42	2.49e-15	Aortic root size;
CRC	cis	rs3764400	0.567	rs2240120	chr17:46142144	C/T	cg10706073	chr17:46328419	SKAP1	-0.64	-6.85	-0.35	3.69e-11	Body mass index;
CRC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.4	0.33	5.43e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.59	8.79	0.44	8.19e-17	Corneal astigmatism;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg21204522	chr6:27730016	NA	-0.41	-5.79	-0.3	1.6e-8	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.66	0.34	1.18e-10	Lung cancer;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg22638593	chr5:131593259	PDLIM4	0.35	6.47	0.34	3.59e-10	Blood metabolite levels;
CRC	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.65	-0.39	2.24e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.840	rs10890849	chr11:108363755	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.75	0.3	2.01e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs11581859	0.950	rs72730315	chr1:99380147	C/T	cg12183875	chr3:169587454	LRRC31	0.28	6.27	0.33	1.14e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.64	-12.06	-0.55	5.47e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg08755490	chr11:65554678	OVOL1	0.44	6.34	0.33	7.57e-10	Acne (severe);
CRC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg04518342	chr5:131593106	PDLIM4	-0.33	-5.86	-0.31	1.11e-8	Blood metabolite levels;
CRC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	8.89	0.44	4.13e-17	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23808061	chr1:179923593	CEP350	0.45	6.31	0.33	9.16e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.6	-9.66	-0.47	1.36e-19	Obesity-related traits;
CRC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg22495460	chr2:25135724	ADCY3	-0.88	-17.7	-0.7	9.95e-50	Body mass index in non-asthmatics;
CRC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg16358738	chr2:241808595	AGXT	-0.4	-6.25	-0.33	1.24e-9	Urinary metabolites;
CRC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg00666640	chr1:248458726	OR2T12	0.4	7.33	0.37	1.83e-12	Common traits (Other);
CRC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-7.05	-0.36	1.09e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.32	4.61e-9	Morning vs. evening chronotype;
CRC	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.5	-6.35	-0.33	7.1e-10	Insulin-like growth factors;
CRC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg24110177	chr3:50126178	RBM5	0.42	5.73	0.3	2.22e-8	Intelligence (multi-trait analysis);
CRC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.42e-12	Colorectal cancer;
CRC	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-6.03	-0.32	4.38e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.44	-6.37	-0.33	6.21e-10	Breast cancer;
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.43	6.44	0.33	4.34e-10	Obesity-related traits;
CRC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg03233332	chr7:66118400	NA	-0.41	-5.6	-0.3	4.51e-8	Aortic root size;
CRC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.78	13.26	0.59	1.95e-32	Lung cancer;
CRC	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg00319359	chr11:70116639	PPFIA1	0.55	5.88	0.31	1.03e-8	Coronary artery disease;
CRC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs3790844	0.746	rs3790850	chr1:200005193	C/G	cg07208853	chr1:200005219	NR5A2	0.36	8.86	0.44	5.09e-17	Pancreatic cancer;
CRC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.56	0.47	2.97e-19	Platelet count;
CRC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg16540259	chr10:75572220	NDST2	0.38	5.91	0.31	8.5e-9	Inflammatory bowel disease;
CRC	cis	rs315934	0.621	rs2121326	chr2:113846975	C/G	cg24553058	chr2:113831203	IL1F10	0.48	5.69	0.3	2.85e-8	Dysmenorrheic pain;
CRC	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.32	-0.33	8.37e-10	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10137990	chr8:145137203	GPAA1	0.35	6.0	0.31	5.29e-9	Obesity-related traits;
CRC	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.4	6.01	0.31	4.79e-9	Coronary artery disease;
CRC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.44	-6.86	-0.35	3.46e-11	Asthma;
CRC	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.96	-12.38	-0.56	3.67e-29	Exhaled nitric oxide output;
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg04553112	chr3:125709451	NA	-0.49	-5.81	-0.3	1.49e-8	Blood pressure (smoking interaction);
CRC	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg00507830	chr2:103233733	NA	0.52	5.77	0.3	1.81e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.72	10.79	0.51	1.87e-23	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg08888203	chr3:10149979	C3orf24	0.68	9.09	0.45	9.46e-18	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20766702	chr5:102594493	C5orf30	0.45	6.36	0.33	6.86e-10	Anxiety disorder;
CRC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg24562669	chr7:97807699	LMTK2	0.5	8.5	0.42	6.53e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.59	-8.33	-0.42	2.21e-15	Inflammatory bowel disease;
CRC	cis	rs6662572	0.737	rs7555458	chr1:46554142	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.21	0.32	1.57e-9	Blood protein levels;
CRC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.64	0.39	2.35e-13	Mean platelet volume;
CRC	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg26695010	chr11:65641043	EFEMP2	0.49	7.46	0.38	7.68e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs3851050	0.704	rs7901131	chr10:81873327	T/A	cg16857335	chr19:47633940	SAE1	0.48	6.26	0.33	1.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.05	-14.72	-0.63	5.16e-38	Exhaled nitric oxide output;
CRC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.67	7.13	0.37	6.42e-12	Inflammatory bowel disease;
CRC	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.55	7.54	0.38	4.62e-13	Coronary artery disease;
CRC	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.73	-10.53	-0.5	1.55e-22	Vitiligo;
CRC	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg01339444	chr6:118972232	C6orf204	0.56	6.09	0.32	3.14e-9	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26851410	chr19:2785307	THOP1	0.43	5.97	0.31	6.07e-9	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.81	0.51	1.64e-23	Bone mineral density;
CRC	cis	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg09363841	chr1:37513479	NA	-0.51	-8.8	-0.44	7.78e-17	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg12064134	chr16:90016061	DEF8	-0.6	-5.63	-0.3	3.83e-8	Skin colour saturation;
CRC	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.16	-9.52	-0.46	3.9e-19	Mitochondrial DNA levels;
CRC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.98	12.38	0.56	3.74e-29	Eosinophil percentage of granulocytes;
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg16606324	chr3:10149918	C3orf24	0.69	9.6	0.47	2.1e-19	Alzheimer's disease;
CRC	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.99	-18.5	-0.71	7.22e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg00343986	chr7:65444356	GUSB	-0.47	-7.07	-0.36	9.5e-12	Aortic root size;
CRC	cis	rs11212617	0.902	rs11212546	chr11:108064935	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.38	5.67	0.3	3.1e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.66	0.34	1.18e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs6472235	0.837	rs60020249	chr8:66928647	C/T	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	trans	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg26043149	chr18:55253948	FECH	-0.49	-7.51	-0.38	5.78e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3741151	0.686	rs7938391	chr11:73221957	A/G	cg17517138	chr11:73019481	ARHGEF17	0.54	5.85	0.31	1.2e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg21251018	chr6:28226885	NKAPL	0.48	7.48	0.38	6.95e-13	Cardiac Troponin-T levels;
CRC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.75	9.79	0.48	4.94e-20	Platelet count;
CRC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.77	-10.6	-0.5	9.16e-23	White matter hyperintensity burden;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17079137	chr17:27070735	TRAF4	0.45	6.11	0.32	2.77e-9	Survival in pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01272601	chr2:69871685	AAK1	0.47	6.65	0.34	1.24e-10	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.06e-15	Menopause (age at onset);
CRC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.31	-0.37	2.09e-12	Self-reported allergy;
CRC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.41	7.96	0.4	2.86e-14	Mean corpuscular volume;
CRC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.95	14.3	0.62	2.16e-36	Diastolic blood pressure;
CRC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.57	-8.4	-0.42	1.37e-15	Dental caries;
CRC	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.67e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs2745967	0.740	rs2796253	chr1:208067409	G/A	cg09788693	chr1:208063733	CD34	0.47	7.04	0.36	1.13e-11	Resting heart rate;
CRC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg13390004	chr1:15929781	NA	0.5	7.09	0.36	8.03e-12	Systolic blood pressure;
CRC	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.04	20.11	0.74	3.29e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.51	7.93	0.4	3.41e-14	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.91	-17.8	-0.7	4.19e-50	Intelligence (multi-trait analysis);
CRC	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.47	6.75	0.35	6.7e-11	Pulmonary function decline;
CRC	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.51	7.47	0.38	7.13e-13	Glioblastoma;Glioma;
CRC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.46	7.11	0.36	7.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.49	9.9	0.48	2.09e-20	Ulcerative colitis;
CRC	trans	rs587242	1.000	rs10489740	chr1:96919182	G/A	cg10631902	chr5:14652156	NA	0.45	7.05	0.36	1.08e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	8.43	0.42	1.06e-15	Personality dimensions;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg10876282	chr6:28092338	ZSCAN16	0.4	5.71	0.3	2.52e-8	Cardiac Troponin-T levels;
CRC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.4	-7.11	-0.36	7.47e-12	Reticulocyte fraction of red cells;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg18301423	chr5:131593218	PDLIM4	-0.38	-6.27	-0.33	1.11e-9	Acylcarnitine levels;
CRC	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.5	7.23	0.37	3.39e-12	Testicular germ cell tumor;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg08200582	chr11:442649	ANO9	-0.71	-7.44	-0.38	8.72e-13	Body mass index;
CRC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.45	6.86	0.35	3.47e-11	Asthma;
CRC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.64	10.63	0.51	6.77e-23	Brugada syndrome;
CRC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.66	-10.97	-0.52	4.56e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg04518342	chr5:131593106	PDLIM4	0.37	6.65	0.34	1.25e-10	Blood metabolite levels;
CRC	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.62e-13	Testicular germ cell tumor;
CRC	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.77	12.32	0.56	6.39e-29	Alcohol dependence;
CRC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.06	-12.44	-0.57	2.13e-29	Diabetic kidney disease;
CRC	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.73	-16.09	-0.66	2.27e-43	Intelligence (multi-trait analysis);
CRC	trans	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs12760731	0.582	rs6658398	chr1:178558881	T/C	cg00404053	chr1:178313656	RASAL2	0.67	7.37	0.38	1.43e-12	Obesity-related traits;
CRC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.52	-0.38	5.13e-13	Schizophrenia;
CRC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.81	-11.14	-0.52	1.12e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.71	0.51	3.6e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-7.54	-0.38	4.63e-13	Major depressive disorder;
CRC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.17	-0.32	1.97e-9	QT interval;
CRC	cis	rs6681460	0.625	rs12138066	chr1:67103816	C/T	cg02459107	chr1:67143332	SGIP1	0.32	5.81	0.31	1.48e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg05341575	chr12:125625032	AACS	-0.4	-5.62	-0.3	4.03e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.71	10.19	0.49	2.19e-21	Cognitive function;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg17942371	chr19:796826	PTBP1	0.43	6.3	0.33	9.57e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg19635926	chr16:89946313	TCF25	0.65	6.21	0.32	1.55e-9	Skin colour saturation;
CRC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.41	-5.89	-0.31	9.51e-9	Daytime sleep phenotypes;
CRC	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg01475377	chr6:109611718	NA	0.35	6.11	0.32	2.79e-9	Reticulocyte fraction of red cells;
CRC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.52	0.71	5.84e-53	Parkinson's disease;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.52	6.27	0.33	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.61	7.93	0.4	3.5e-14	Nonalcoholic fatty liver disease;
CRC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.42	-9.34	-0.46	1.47e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg09659197	chr4:152720779	NA	0.52	11.26	0.53	4.18e-25	Intelligence (multi-trait analysis);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16708785	chr19:38085709	ZNF540;ZNF571	0.4	6.01	0.31	5.02e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.42	-8.04	-0.41	1.6e-14	Migraine;
CRC	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.39	-6.64	-0.34	1.3100000000000001e-10	Life satisfaction;
CRC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg10570241	chr7:158785291	NA	0.46	7.59	0.39	3.3e-13	Facial morphology (factor 20);
CRC	cis	rs711830	0.587	rs10188827	chr2:177007664	C/T	cg13092806	chr2:177043255	NA	0.54	6.18	0.32	1.88e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.73	-11.53	-0.54	4.47e-26	Colorectal cancer;
CRC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.91	-17.2	-0.69	9.93e-48	Intelligence (multi-trait analysis);
CRC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg04362960	chr10:104952993	NT5C2	-0.42	-5.94	-0.31	7.28e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.67	-8.93	-0.44	3.1e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3790844	0.667	rs3790843	chr1:200010824	A/G	cg13229857	chr1:200006247	NR5A2	-0.51	-7.46	-0.38	7.65e-13	Pancreatic cancer;
CRC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.75	0.68	5.43e-46	Chronic sinus infection;
CRC	cis	rs2249625	0.523	rs2463707	chr6:72861732	G/A	cg18830697	chr6:72922368	RIMS1	-0.31	-6.19	-0.32	1.8e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg25019722	chr6:37503610	NA	-0.5	-9.29	-0.46	2.17e-18	Cognitive performance;
CRC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.43	0.33	4.45e-10	Morning vs. evening chronotype;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg14225146	chr17:72744664	SLC9A3R1	-0.68	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21687924	chr11:3400496	ZNF195	0.47	6.21	0.32	1.57e-9	Anxiety disorder;
CRC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.6	9.85	0.48	3.25e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.46	9.36	0.46	1.25e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.75	-10.4	-0.5	4.37e-22	Coronary artery disease;
CRC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.58	-6.93	-0.36	2.25e-11	Body mass index;
CRC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg23463467	chr20:60627584	TAF4	0.32	5.66	0.3	3.25e-8	Body mass index;
CRC	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.27e-19	Blood protein levels;
CRC	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.76	0.39	1.09e-13	Breast cancer;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg06470822	chr6:28175283	NA	0.9	13.27	0.59	1.68e-32	Parkinson's disease;
CRC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.49	-10.75	-0.51	2.71e-23	Rheumatoid arthritis;
CRC	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	1.04	16.34	0.67	2.3e-44	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg07636037	chr3:49044803	WDR6	-0.63	-6.74	-0.35	7.05e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.1	-0.32	2.96e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.81	0.44	7.32e-17	Rheumatoid arthritis;
CRC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg21918786	chr6:109611834	NA	-0.42	-7.36	-0.38	1.47e-12	Reticulocyte fraction of red cells;
CRC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.8	13.3	0.59	1.38e-32	Blood protein levels;
CRC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.73	-11.4	-0.53	1.33e-25	Monocyte count;
CRC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.53	7.93	0.4	3.45e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6908034	0.556	rs77486465	chr6:19803862	T/G	cg02682789	chr6:19804855	NA	0.81	6.89	0.35	2.9100000000000002e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	0.31	5.92	0.31	8.06e-9	Colorectal cancer;
CRC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.63	-7.6	-0.39	3.19e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.51	0.42	6.4e-16	Homoarginine levels;
CRC	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg26703956	chr19:39260304	NA	-0.38	-5.93	-0.31	7.85e-9	Heart rate;
CRC	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg22134325	chr11:66188745	NPAS4	0.36	5.85	0.31	1.18e-8	Airway imaging phenotypes;
CRC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg23461800	chr14:103021989	NA	-0.76	-9.99	-0.48	1.08e-20	Platelet count;
CRC	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg13491945	chr12:107078410	RFX4	-0.36	-6.14	-0.32	2.36e-9	Heart rate;
CRC	cis	rs6445525	0.870	rs2060023	chr3:65999532	C/T	cg06109867	chr3:66002991	MAGI1	0.37	6.09	0.32	3.07e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-6.08	-0.32	3.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.47	7.58	0.39	3.55e-13	Corneal astigmatism;
CRC	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.87	9.03	0.45	1.5e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-10.95	-0.52	5.22e-24	Exhaled nitric oxide output;
CRC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.07	-0.32	3.56e-9	Bipolar disorder;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.59	-8.54	-0.43	5.04e-16	Menopause (age at onset);
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg15147215	chr3:52552868	STAB1	-0.61	-9.94	-0.48	1.54e-20	Bipolar disorder;
CRC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.18	-0.52	8.34e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.61	-0.3	4.37e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.32	-18.32	-0.71	3.62e-52	Hip circumference adjusted for BMI;
CRC	cis	rs6662572	0.737	rs7533750	chr1:46558434	G/C	cg08644498	chr1:46502608	NA	0.45	7.18	0.37	4.64e-12	Blood protein levels;
CRC	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg14664628	chr15:75095509	CSK	0.54	6.47	0.34	3.53e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.73	-0.3	2.25e-8	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13388111	chr11:61062665	VWCE	0.34	6.34	0.33	7.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg12458913	chr13:53173898	NA	-0.58	-9.27	-0.46	2.55e-18	Lewy body disease;
CRC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.48	8.65e-21	Lung cancer;
CRC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.44	-7.94	-0.4	3.21e-14	Monocyte count;
CRC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	1.1	22.48	0.78	1.83e-68	Lewy body disease;
CRC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg03030879	chr14:75389066	RPS6KL1	0.47	7.21	0.37	3.91e-12	Height;
CRC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.78	-0.3	1.75e-8	Bipolar disorder;
CRC	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.13	-0.37	6.6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs863345	0.604	rs11264981	chr1:158455890	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.05	-0.32	3.87e-9	Pneumococcal bacteremia;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00166722	chr3:10149974	C3orf24	0.66	7.71	0.39	1.49e-13	Alzheimer's disease;
CRC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg08501292	chr6:25962987	TRIM38	1.1	10.5	0.5	1.9e-22	Autism spectrum disorder or schizophrenia;
CRC	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg04662943	chr10:102668895	NA	0.61	7.13	0.37	6.44e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.57	7.84	0.4	6.49e-14	Pulmonary function decline;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg25164649	chr6:28176230	NA	0.77	9.54	0.47	3.29e-19	Depression;
CRC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.8	-12.6	-0.57	5.5e-30	Multiple myeloma;
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	0.93	11.01	0.52	3.31e-24	Type 2 diabetes nephropathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02467765	chr4:78978708	FRAS1	0.41	6.18	0.32	1.91e-9	Response to antipsychotic treatment;
CRC	cis	rs2274273	0.686	rs66531545	chr14:55587460	T/C	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.72	-0.3	2.33e-8	Protein biomarker;
CRC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.64	9.66	0.47	1.3e-19	Initial pursuit acceleration;
CRC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.83	11.96	0.55	1.32e-27	Cognitive function;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.64	8.48	0.42	8e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	8.86e-20	Hair morphology;
CRC	cis	rs1639906	0.560	rs1624785	chr7:2258139	T/C	cg19897017	chr7:2163380	MAD1L1	0.41	5.93	0.31	7.57e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.44	6.77	0.35	6.07e-11	Ulcerative colitis;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02359409	chr6:42947317	PEX6	-0.68	-11.36	-0.53	1.83e-25	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg22495460	chr2:25135724	ADCY3	-0.87	-14.86	-0.63	1.37e-38	Body mass index;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg22638593	chr5:131593259	PDLIM4	-0.41	-6.92	-0.36	2.44e-11	Breast cancer;
CRC	cis	rs2898857	0.504	rs7214496	chr17:47384611	C/G	cg08112188	chr17:47440006	ZNF652	0.42	5.61	0.3	4.21e-8	Cancer;
CRC	cis	rs10392	0.543	rs3752292	chr20:37570475	G/A	cg27552599	chr20:37590471	DHX35	0.37	5.72	0.3	2.45e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.92	0.44	3.24e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg25767906	chr1:53392781	SCP2	0.45	7.23	0.37	3.5e-12	Monocyte count;
CRC	cis	rs12024301	0.557	rs10911410	chr1:183661361	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.62	0.39	2.74e-13	Height;
CRC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.8	0.44	8.09e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6694672	1.000	rs857020	chr1:197017473	C/T	cg13682187	chr1:196946512	CFHR5	0.43	6.92	0.36	2.35e-11	Asthma;
CRC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.8	14.22	0.62	4.36e-36	Breast cancer;
CRC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.56	8.21	0.41	5.14e-15	Response to temozolomide;
CRC	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.14	-0.32	2.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg12573674	chr2:1569213	NA	-0.73	-7.39	-0.38	1.23e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.47	-6.44	-0.33	4.14e-10	Carotid intima media thickness;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.68	11.92	0.55	1.83e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	11.65	0.54	1.77e-26	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23079732	chr1:26232465	STMN1	0.39	6.05	0.32	3.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.56	8.9	0.44	3.88e-17	Mean corpuscular volume;
CRC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.39	6.45	0.34	3.91e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg11843238	chr5:131593191	PDLIM4	-0.32	-5.93	-0.31	7.63e-9	Blood metabolite levels;
CRC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.91	-0.31	8.75e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg15786705	chr6:28176104	NA	0.68	10.33	0.49	7.66e-22	Cardiac Troponin-T levels;
CRC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg14593290	chr7:50529359	DDC	-0.54	-7.36	-0.38	1.44e-12	Malaria;
CRC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg21285383	chr16:89894308	SPIRE2	0.38	6.56	0.34	2.09e-10	Vitiligo;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs863345	0.604	rs1342948	chr1:158463294	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.16	-0.32	2.16e-9	Pneumococcal bacteremia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03952484	chr1:149899818	SF3B4	0.48	6.17	0.32	2.03e-9	Thyroid stimulating hormone;
CRC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.97	-0.31	6e-9	Total body bone mineral density;
CRC	cis	rs2013441	1.000	rs17686839	chr17:20039171	A/G	cg13482628	chr17:19912719	NA	0.41	6.33	0.33	7.87e-10	Obesity-related traits;
CRC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-6.31	-0.33	9.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25522149	chr19:11372842	DOCK6	0.38	6.02	0.31	4.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg06470822	chr6:28175283	NA	0.76	8.05	0.41	1.49e-14	Depression;
CRC	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.67	0.35	1.05e-10	Body mass index;
CRC	cis	rs17253792	0.545	rs12894368	chr14:56025178	C/A	cg01858014	chr14:56050164	KTN1	-0.84	-6.52	-0.34	2.6200000000000003e-10	Putamen volume;
CRC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.79	10.88	0.51	9.36e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.52	5.94	0.31	7.24e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg02569458	chr12:86230093	RASSF9	0.4	6.75	0.35	6.7e-11	Major depressive disorder;
CRC	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.71	-10.38	-0.5	5.02e-22	Pubertal anthropometrics;
CRC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg00850481	chr1:228891306	NA	0.45	7.04	0.36	1.12e-11	Chronic lymphocytic leukemia;
CRC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg19318889	chr4:1322082	MAEA	0.4	5.68	0.3	2.94e-8	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.56	8.13	0.41	8.97e-15	Lung cancer;
CRC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.68	5.79	0.3	1.68e-8	Putamen volume;
CRC	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.62	9.07	0.45	1.07e-17	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.67	9.79	0.47	5.15e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg04969067	chr8:143858791	LYNX1	-0.42	-6.33	-0.33	8.17e-10	Urinary tract infection frequency;
CRC	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.46	6.48	0.34	3.36e-10	Height;
CRC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg10356904	chr22:49881777	NA	-0.34	-6.53	-0.34	2.56e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs12476592	0.602	rs262482	chr2:63877042	C/T	cg10828910	chr2:63850056	LOC388955	0.5	6.16	0.32	2.1e-9	Childhood ear infection;
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg23193639	chr7:45961078	IGFBP3	0.38	6.38	0.33	6.18e-10	Sitting height ratio;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.42	0.33	4.83e-10	Depression;
CRC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.47	6.9	0.36	2.64e-11	Colorectal cancer;
CRC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.51	-6.11	-0.32	2.86e-9	Coronary artery calcification;
CRC	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.88	0.35	3.11e-11	Coronary artery disease;
CRC	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.68	-10.24	-0.49	1.5e-21	Blood pressure (smoking interaction);
CRC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg21251018	chr6:28226885	NKAPL	0.37	5.6	0.3	4.48e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6743376	0.556	rs12475161	chr2:113823626	T/C	cg24553058	chr2:113831203	IL1F10	0.43	7.09	0.36	8.4e-12	Inflammatory biomarkers;
CRC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg11833968	chr6:79620685	NA	-0.37	-6.48	-0.34	3.34e-10	Intelligence (multi-trait analysis);
CRC	trans	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg06834434	chr14:75079333	LTBP2	0.55	6.5	0.34	2.92e-10	Obesity-related traits;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.57	7.0	0.36	1.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.23	0.45	3.46e-18	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06104511	chr16:46655473	SHCBP1	0.43	6.18	0.32	1.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg00531865	chr16:30841666	NA	-0.43	-5.82	-0.31	1.41e-8	Multiple myeloma;
CRC	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.52	8.0	0.4	2.19e-14	Corneal astigmatism;
CRC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.86	-12.8	-0.58	9.96e-31	Blood metabolite levels;
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.28	-0.37	2.46e-12	Lymphocyte counts;
CRC	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.58	6.68	0.35	1.02e-10	Osteoarthritis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10542027	chr5:78532229	JMY	0.47	6.35	0.33	7.22e-10	Thyroid stimulating hormone;
CRC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.97	0.31	6.07e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26500144	chr6:36646390	CDKN1A	0.39	6.6	0.34	1.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg11212589	chr17:38028394	ZPBP2	0.46	8.71	0.43	1.5e-16	Asthma;
CRC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.84	14.73	0.63	4.46e-38	Birth weight;
CRC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.58	-0.34	1.89e-10	Total body bone mineral density;
CRC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.44	0.5	3.07e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.62	-9.95	-0.48	1.43e-20	Aortic root size;
CRC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.43	-0.5	3.32e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12630931	1.000	rs35280753	chr3:31978094	A/G	cg21375017	chr3:31988082	OSBPL10	0.43	5.87	0.31	1.05e-8	Periodontal disease-related phenotypes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05935374	chr11:82782929	RAB30	0.45	6.7	0.35	9.25e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs3814231	0.531	rs12771689	chr10:115467068	A/G	cg24846397	chr10:115438155	CASP7	-0.35	-5.75	-0.3	2.09e-8	Vitiligo;
CRC	cis	rs55788414	0.932	rs35852981	chr16:81180897	G/A	cg06400318	chr16:81190750	PKD1L2	-0.66	-6.45	-0.33	4.06e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.58	-9.49	-0.46	5.01e-19	Body mass index;
CRC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.63	0.39	2.53e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00230368	chr6:160389833	IGF2R	0.46	6.66	0.34	1.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.51	9.02	0.45	1.57e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3812762	0.783	rs11042070	chr11:8819367	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.54	-8.08	-0.41	1.21e-14	Hypospadias;
CRC	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.75	12.48	0.57	1.54e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.53	6.19	0.32	1.82e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23161317	chr6:28129485	ZNF389	0.45	5.92	0.31	8.06e-9	Depression;
CRC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.89	-14.12	-0.61	9.75e-36	Blood metabolite levels;
CRC	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg12218747	chr21:37451666	NA	-0.41	-6.85	-0.35	3.6e-11	Mitral valve prolapse;
CRC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.63	-11.33	-0.53	2.46e-25	Breast cancer;
CRC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg19847866	chr10:1019161	NA	0.4	5.82	0.31	1.43e-8	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02437376	chr10:76969880	VDAC2	0.46	6.33	0.33	7.85e-10	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.07	17.99	0.7	6.94e-51	Cognitive function;
CRC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg26162295	chr17:38119207	GSDMA	-0.36	-6.54	-0.34	2.4e-10	Asthma;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg20615401	chr6:28092323	ZSCAN16	0.45	5.9	0.31	9.1e-9	Cardiac Troponin-T levels;
CRC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.75	0.3	2e-8	HDL cholesterol;
CRC	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-6.22	-0.32	1.51e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg14784868	chr12:69753453	YEATS4	0.47	5.93	0.31	7.51e-9	Response to diuretic therapy;
CRC	cis	rs7635838	0.892	rs9310379	chr3:11434143	C/T	cg00170343	chr3:11313890	ATG7	-0.37	-5.65	-0.3	3.44e-8	HDL cholesterol;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14022721	chr22:25507536	KIAA1671	0.48	6.57	0.34	1.93e-10	Thyroid stimulating hormone;
CRC	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg17182837	chr8:41585554	ANK1	-0.53	-7.21	-0.37	3.89e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.43	-6.21	-0.32	1.61e-9	Aortic root size;
CRC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.25	0.37	2.97e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.4	6.06	0.32	3.65e-9	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.69	0.43	1.69e-16	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.56	9.19	0.45	4.51e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg01097406	chr16:89675127	NA	0.44	8.42	0.42	1.21e-15	Hemoglobin concentration;
CRC	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.41	5.85	0.31	1.16e-8	Blood metabolite levels;
CRC	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.86	-0.31	1.12e-8	Reticulocyte fraction of red cells;
CRC	cis	rs10045504	0.502	rs72746051	chr5:38759817	G/A	cg15396434	chr5:38725168	NA	-0.63	-6.14	-0.32	2.32e-9	Night sleep phenotypes;
CRC	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.53	7.15	0.37	5.76e-12	Educational attainment (years of education);
CRC	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.93	16.92	0.68	1.26e-46	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	7.13	0.37	6.51e-12	Bipolar disorder;
CRC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg21970626	chr13:21893289	NA	-0.46	-6.95	-0.36	1.96e-11	White matter hyperintensity burden;
CRC	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg23533926	chr12:111358616	MYL2	-0.46	-6.76	-0.35	6.19e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6546324	0.580	rs4362541	chr2:67842866	A/T	cg15745817	chr2:67799979	NA	-0.56	-9.57	-0.47	2.59e-19	Endometriosis;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg12273811	chr6:28175739	NA	0.4	5.87	0.31	1.08e-8	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23489587	chr5:177303156	LOC728554	0.46	6.64	0.34	1.3e-10	Thyroid stimulating hormone;
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-8.89	-0.44	4.25e-17	Bipolar disorder;
CRC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	10.52	0.5	1.6400000000000001e-22	Prudent dietary pattern;
CRC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.25	0.33	1.29e-9	Lung cancer;
CRC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.83e-9	Depression;
CRC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-7.33	-0.37	1.85e-12	Type 2 diabetes;
CRC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	8.96	0.44	2.42e-17	Monocyte percentage of white cells;
CRC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.35	-5.81	-0.3	1.49e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-5.94	-0.31	7.32e-9	Alzheimer's disease (late onset);
CRC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg17948913	chr5:572064	NA	0.55	6.33	0.33	7.93e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs720844	0.554	rs4972378	chr2:149335158	A/G	cg09247360	chr2:149335327	NA	0.48	6.28	0.33	1.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.48	0.34	3.45e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg27615366	chr5:131592974	PDLIM4	0.34	6.46	0.34	3.73e-10	Acylcarnitine levels;
CRC	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg24553058	chr2:113831203	IL1F10	0.39	6.3	0.33	9.43e-10	Protein quantitative trait loci;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25724310	chr10:127512489	BCCIP;UROS	0.43	6.14	0.32	2.44e-9	Response to antipsychotic treatment;
CRC	trans	rs587242	1.000	rs1853738	chr1:96895992	A/G	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg08999081	chr20:33150536	PIGU	0.46	5.88	0.31	9.91e-9	Protein C levels;
CRC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	9.04	0.45	1.34e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.46	-7.9	-0.4	4.26e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.68	-0.3	2.97e-8	Acylcarnitine levels;
CRC	trans	rs9545047	0.645	rs9635027	chr13:79869673	G/A	cg07061582	chr15:90234082	PEX11A;WDR93	0.42	5.99	0.31	5.57e-9	Schizophrenia;
CRC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.44	5.79	0.3	1.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.85	0.4	5.82e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.54	-8.72	-0.43	1.45e-16	Huntington's disease progression;
CRC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-8.28	-0.42	3.03e-15	Chronic sinus infection;
CRC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.53	7.7	0.39	1.6e-13	Uric acid levels;
CRC	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.77	-14.67	-0.63	7.87e-38	Body mass index;
CRC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.6	11.22	0.53	5.7e-25	Total body bone mineral density;
CRC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.53	-6.72	-0.35	8.03e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.22	-0.32	1.53e-9	Aortic root size;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Parkinson's disease;
CRC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.63	8.75	0.43	1.14e-16	Gestational age at birth (maternal effect);
CRC	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg13206674	chr6:150067644	NUP43	-0.48	-5.8	-0.3	1.55e-8	Lung cancer;
CRC	cis	rs2298450	0.550	rs9974155	chr21:37654390	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-6.43	-0.33	4.4e-10	Schizophrenia;
CRC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg08075719	chr14:103021372	NA	0.65	7.52	0.38	5.42e-13	Platelet count;
CRC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.55	0.6	1.55e-33	Prudent dietary pattern;
CRC	cis	rs4664293	0.867	rs6761145	chr2:160582184	A/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg05187965	chr10:45406764	TMEM72	-0.34	-6.76	-0.35	6.22e-11	Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27576415	chr15:41709087	RTF1	0.56	7.42	0.38	1e-12	Thyroid stimulating hormone;
CRC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.73	-13.14	-0.59	5.32e-32	Prostate cancer;
CRC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.87	0.55	2.68e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs364477	0.547	rs438294	chr9:979611	A/T	cg13952963	chr9:998547	NA	0.5	6.2	0.32	1.7e-9	Major depressive disorder;
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.56	8.82	0.44	6.65e-17	Bipolar disorder;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.79e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.52	-8.81	-0.44	7.2e-17	Systemic lupus erythematosus;
CRC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.56	6.39	0.33	5.59e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg10820045	chr2:198174542	NA	0.45	8.01	0.4	1.99e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.31	0.37	2.04e-12	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg04733911	chr16:78082701	NA	-0.43	-7.08	-0.36	8.69e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.59	9.55	0.47	2.98e-19	Migraine;
CRC	trans	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9322817	0.902	rs7764251	chr6:105197091	G/T	cg02098413	chr6:105308735	HACE1	-0.36	-6.58	-0.34	1.9e-10	Thyroid stimulating hormone;
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg10217327	chr6:118973057	C6orf204	0.51	5.85	0.31	1.21e-8	Renal cell carcinoma;
CRC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.53	7.8	0.4	8.22e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs4481887	0.508	rs4390207	chr1:248400174	C/T	cg00666640	chr1:248458726	OR2T12	0.45	7.14	0.37	6.09e-12	Common traits (Other);
CRC	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.51	-7.09	-0.36	8.03e-12	Triglycerides;
CRC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.8	14.67	0.63	8.01e-38	Metabolic syndrome;
CRC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.48	-6.43	-0.33	4.53e-10	Prostate cancer;
CRC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.41	-19.88	-0.74	2.49e-58	Hip circumference adjusted for BMI;
CRC	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg00071950	chr4:10020882	SLC2A9	0.44	6.64	0.34	1.33e-10	Blood metabolite levels;
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg27532560	chr4:187881888	NA	0.47	7.64	0.39	2.41e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	11.93	0.55	1.64e-27	Schizophrenia;
CRC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg11861562	chr11:117069780	TAGLN	0.41	9.38	0.46	1.08e-18	Blood protein levels;
CRC	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.7	-0.3	2.6e-8	Type 2 diabetes;
CRC	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.07e-11	Common traits (Other);
CRC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19784903	chr17:45786737	TBKBP1	-0.35	-5.75	-0.3	2.08e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.81	-13.2	-0.59	3.24e-32	Hypospadias;
CRC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.63	-9.18	-0.45	5.04e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.82	-10.76	-0.51	2.52e-23	Initial pursuit acceleration;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22719782	chr11:114310057	REXO2	-0.41	-6.34	-0.33	7.39e-10	Obesity-related traits;
CRC	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.62	8.95	0.44	2.67e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-12.37	-0.56	4.18e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.95	0.31	6.81e-9	Rheumatoid arthritis;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.54	8.11	0.41	9.81e-15	Blood metabolite levels;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	10.43	0.5	3.35e-22	Lymphocyte counts;
CRC	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg20387954	chr3:183756860	HTR3D	0.38	6.47	0.34	3.52e-10	Anterior chamber depth;
CRC	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.29	6.05	0.32	4.03e-9	Height;
CRC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.38	-6.05	-0.32	3.95e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.18	0.45	4.82e-18	Personality dimensions;
CRC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg24011408	chr12:48396354	COL2A1	0.47	6.39	0.33	5.64e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg19622623	chr12:86230825	RASSF9	-0.42	-6.78	-0.35	5.42e-11	Major depressive disorder;
CRC	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.48	7.56	0.38	4.03e-13	Red blood cell count;
CRC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.08e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.62	9.59	0.47	2.21e-19	Longevity;Endometriosis;
CRC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06636001	chr8:8085503	FLJ10661	0.45	5.79	0.3	1.66e-8	Obesity-related traits;
CRC	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.71	11.19	0.52	7.85e-25	Mean platelet volume;
CRC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	8.97	0.44	2.23e-17	Personality dimensions;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg03790207	chr6:42947109	PEX6	0.4	5.79	0.3	1.63e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.45	6.3	0.33	9.5e-10	Systolic blood pressure;
CRC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.41	-0.33	4.97e-10	Response to antipsychotic treatment;
CRC	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06307176	chr5:131281290	NA	0.45	6.6	0.34	1.65e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9403521	1.000	rs9390126	chr6:143980432	A/G	cg18240653	chr6:144019428	PHACTR2	-0.58	-6.67	-0.35	1.06e-10	Obesity-related traits;
CRC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15369054	chr17:80825471	TBCD	-0.36	-5.97	-0.31	6.27e-9	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21757043	chr3:128444882	RAB7A	0.51	7.58	0.39	3.5e-13	Response to antipsychotic treatment;
CRC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.4	5.64	0.3	3.76e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.99	-0.44	1.96e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.68	10.19	0.49	2.26e-21	Lung cancer;
CRC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.61	8.69	0.43	1.75e-16	Platelet distribution width;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.23	5.61	0.3	4.38e-8	Parkinson's disease;
CRC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg08773314	chr2:239334832	ASB1	0.37	7.75	0.39	1.15e-13	Multiple system atrophy;
CRC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	10.21	0.49	1.91e-21	Schizophrenia;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg22638593	chr5:131593259	PDLIM4	0.36	6.12	0.32	2.7e-9	Blood metabolite levels;
CRC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.47	6.64	0.34	1.27e-10	Methadone dose in opioid dependence;
CRC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.47	-7.14	-0.37	6.19e-12	Cognitive test performance;
CRC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.46	6.96	0.36	1.86e-11	Menopause (age at onset);
CRC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg25956985	chr22:39795188	MAP3K7IP1	0.43	6.35	0.33	7.17e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.47	-0.34	3.58e-10	Bipolar disorder;
CRC	cis	rs6842789	0.545	rs12642448	chr4:124921046	T/C	cg01723706	chr4:124814442	LOC285419	0.42	5.69	0.3	2.86e-8	Neuroticism;
CRC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.28	0.49	1.11e-21	Platelet count;
CRC	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.48	7.8	0.4	8.3e-14	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-12.3	-0.56	7.49e-29	Colorectal cancer;
CRC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg10263370	chr3:44754102	ZNF502	-0.37	-6.09	-0.32	3.12e-9	Depressive symptoms;
CRC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.67	-11.64	-0.54	1.91e-26	Educational attainment;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.55	-10.22	-0.49	1.83e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs16867321	0.950	rs1919155	chr2:181457053	T/C	cg23363182	chr2:181467187	NA	-0.56	-7.17	-0.37	5.02e-12	Obesity;
CRC	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg06917450	chr1:38156652	C1orf109	-0.5	-6.97	-0.36	1.71e-11	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs3001167	1.000	rs3009387	chr1:194552725	A/G	cg19011063	chr5:170171465	NA	0.56	6.11	0.32	2.87e-9	Obesity-related traits;
CRC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg03233332	chr7:66118400	NA	-0.42	-5.83	-0.31	1.34e-8	Aortic root size;
CRC	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.47	6.95	0.36	1.95e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.04	0.32	4.19e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.42	0.56	2.68e-29	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11922371	chr17:48226442	PPP1R9B	0.47	6.58	0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs9648716	1.000	rs964942	chr7:140622355	T/C	cg10747023	chr7:140774559	NA	0.46	6.02	0.31	4.76e-9	Type 2 diabetes;
CRC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg11212589	chr17:38028394	ZPBP2	0.42	7.65	0.39	2.19e-13	Self-reported allergy;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08723769	chr16:89627049	RPL13;SNORD68	-0.4	-6.4	-0.33	5.41e-10	Myopia (pathological);
CRC	cis	rs11229555	0.645	rs7930547	chr11:58197616	A/C	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.53	-0.34	2.51e-10	Menopause (age at onset);
CRC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg02869306	chr7:64672164	INTS4L1	-0.34	-5.77	-0.3	1.83e-8	Calcium levels;
CRC	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg16141378	chr3:129829833	LOC729375	0.43	6.55	0.34	2.27e-10	Triglycerides;
CRC	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3767633	0.858	rs10753645	chr1:161815364	T/C	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs10512697	0.892	rs71594958	chr5:3540342	G/A	cg19473799	chr5:3511975	NA	-0.79	-6.17	-0.32	1.99e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.79	0.47	4.99e-20	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.6	-5.8	-0.3	1.57e-8	Alzheimer's disease (late onset);
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg03923535	chr7:1197113	ZFAND2A	0.55	8.01	0.4	1.96e-14	Longevity;Endometriosis;
CRC	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg12756093	chr1:115239321	AMPD1	0.47	6.58	0.34	1.81e-10	Autism;
CRC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg11245181	chr6:149772854	ZC3H12D	0.58	10.21	0.49	1.95e-21	Dupuytren's disease;
CRC	trans	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg03800765	chr3:11313984	ATG7	-0.41	-6.1	-0.32	2.9e-9	Inflammatory skin disease;
CRC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.37	0.69	2.02e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.86	15.79	0.66	3.32e-42	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.32	-0.37	1.89e-12	Bipolar disorder;
CRC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Morning vs. evening chronotype;
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg22687807	chr8:143858763	LYNX1	0.5	8.91	0.44	3.48e-17	Urinary tract infection frequency;
CRC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg10589385	chr1:150898437	SETDB1	0.32	6.56	0.34	2.08e-10	Melanoma;
CRC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.66	0.63	8.22e-38	Chronic sinus infection;
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	trans	rs2055729	0.677	rs13270146	chr8:9740595	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.58	-0.34	1.89e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg05585544	chr11:47624801	NA	-0.61	-10.84	-0.51	1.25e-23	Subjective well-being;
CRC	trans	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg15845792	chr6:28175446	NA	0.67	6.48	0.34	3.34e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg19812747	chr11:111475976	SIK2	0.43	6.35	0.33	6.97e-10	Primary sclerosing cholangitis;
CRC	cis	rs1867631	0.585	rs12094526	chr1:67126114	A/G	cg02459107	chr1:67143332	SGIP1	0.36	6.3	0.33	9.31e-10	Menopause (age at onset);
CRC	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg19197139	chr17:4613644	ARRB2	-0.59	-8.59	-0.43	3.59e-16	Lymphocyte counts;
CRC	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.05	-0.41	1.53e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg13034943	chr12:132379564	ULK1	-0.69	-5.96	-0.31	6.33e-9	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04119843	chr1:1284268	DVL1	0.49	6.99	0.36	1.51e-11	Response to antipsychotic treatment;
CRC	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg07299736	chr8:135490787	ZFAT	-0.38	-6.44	-0.33	4.31e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs12760731	0.623	rs10913539	chr1:178336682	T/C	cg00404053	chr1:178313656	RASAL2	0.75	9.45	0.46	6.51e-19	Obesity-related traits;
CRC	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.86	15.76	0.66	4.38e-42	Tonsillectomy;
CRC	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.44	6.79	0.35	5.15e-11	Schizophrenia;
CRC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7932354	0.583	rs4294527	chr11:46828799	A/T	cg19486271	chr11:47235900	DDB2	-0.43	-6.48	-0.34	3.3e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.5	-7.33	-0.37	1.81e-12	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.16	0.32	2.07e-9	Bladder cancer;
CRC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg17948913	chr5:572064	NA	0.51	5.88	0.31	1.01e-8	Obesity-related traits;
CRC	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.82	-0.4	7.47e-14	Bipolar disorder;
CRC	cis	rs11191205	0.644	rs75972556	chr10:103377022	G/A	cg15320455	chr10:103880129	LDB1	0.57	6.18	0.32	1.87e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21819024	chr1:52344978	NRD1	-0.52	-6.42	-0.33	4.77e-10	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16015499	chr1:159888603	TAGLN2	-0.41	-6.53	-0.34	2.43e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg21678189	chr6:10838625	NA	0.4	6.17	0.32	2.02e-9	Interleukin-6 levels;
CRC	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg12560992	chr17:57184187	TRIM37	0.53	6.17	0.32	1.98e-9	Vitamin D levels;
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.53	7.25	0.37	3.02e-12	Height;
CRC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg27523141	chr10:43048294	ZNF37B	0.47	6.91	0.36	2.55e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-8.46	-0.42	9.03e-16	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs939584	1.000	rs7560246	chr2:643469	T/C	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-6.7	-0.35	9.06e-11	Coronary artery disease;
CRC	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.6	0.43	3.26e-16	Coffee consumption (cups per day);
CRC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs12044355	1.000	rs12044355	chr1:231844347	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.99	0.31	5.54e-9	Alzheimer's disease;
CRC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.37	5.79	0.3	1.64e-8	Height;
CRC	cis	rs11212617	0.967	rs227072	chr11:108212093	A/C	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.43	0.33	4.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.51	-7.71	-0.39	1.5e-13	Response to antineoplastic agents;
CRC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.32	-0.46	1.74e-18	Smoking initiation;
CRC	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.64	-7.13	-0.37	6.46e-12	Lymphocyte percentage of white cells;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg25164649	chr6:28176230	NA	-0.67	-8.54	-0.43	4.92e-16	Parkinson's disease;
CRC	trans	rs17033702	0.585	rs12615683	chr2:67737466	A/C	cg11936311	chr5:178957434	NA	0.34	6.51	0.34	2.82e-10	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg23254163	chr1:152506842	NA	0.45	9.15	0.45	6.31e-18	Hair morphology;
CRC	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.33	5.67	0.3	3.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6565681	0.760	rs9901680	chr17:78378088	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.55	-5.93	-0.31	7.56e-9	Moyamoya disease;
CRC	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg24438145	chr17:48624694	SPATA20	0.43	6.28	0.33	1.09e-9	Type 2 diabetes;
CRC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.23	-0.33	1.39e-9	Aortic root size;
CRC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.5	7.09	0.36	8.16e-12	Morning vs. evening chronotype;
CRC	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg08847533	chr14:75593920	NEK9	0.4	5.79	0.3	1.6e-8	Caffeine consumption;
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg18279126	chr7:2041391	MAD1L1	0.44	6.76	0.35	6.12e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-6.89	-0.36	2.87e-11	Eye color traits;
CRC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.43e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.55	6.73	0.35	7.73e-11	Lymphocyte counts;
CRC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.23	0.37	3.49e-12	Lung cancer in ever smokers;
CRC	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.83	9.5	0.46	4.66e-19	Lung function (FEV1/FVC);
CRC	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.89	-0.31	9.8e-9	Neuroticism;
CRC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg17691542	chr6:26056736	HIST1H1C	0.42	6.54	0.34	2.42e-10	Height;
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.17	-0.45	5.3e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26587870	chr6:27730563	NA	0.67	6.81	0.35	4.76e-11	Depression;
CRC	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.4	-6.22	-0.32	1.49e-9	Renal cell carcinoma;
CRC	cis	rs7680126	0.596	rs714436	chr4:10314667	A/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.4	-0.33	5.26e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs883565	0.582	rs7623343	chr3:39146792	A/C	cg01426195	chr3:39028469	NA	-0.47	-7.79	-0.39	8.7e-14	Handedness;
CRC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg19223190	chr17:80058835	NA	0.41	6.67	0.35	1.09e-10	Life satisfaction;
CRC	cis	rs1610096	0.538	rs2279796	chr19:1059004	A/G	cg26576206	chr19:1064938	ABCA7	0.38	5.75	0.3	2.05e-8	Neutrophil percentage of granulocytes;
CRC	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs6663390	0.831	rs11118880	chr1:208085583	T/A	cg03990033	chr1:208084030	CD34	0.49	6.5	0.34	2.97e-10	Facial morphology (factor 18);
CRC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.74e-12	Obesity-related traits;
CRC	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.81	-14.19	-0.62	5.26e-36	Lewy body disease;
CRC	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg14844989	chr11:31128820	NA	0.35	6.07	0.32	3.58e-9	Red blood cell count;
CRC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg04132472	chr17:19861366	AKAP10	0.45	7.11	0.37	7.11e-12	Schizophrenia;
CRC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.1	13.46	0.6	3.4e-33	Night sleep phenotypes;
CRC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-5.98	-0.31	5.88e-9	Eosinophil percentage of white cells;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.39	-0.38	1.26e-12	Breast cancer;
CRC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg17321639	chr7:2759063	NA	0.53	7.05	0.36	1.06e-11	Height;
CRC	cis	rs6694672	0.764	rs4342879	chr1:197131655	T/C	cg13682187	chr1:196946512	CFHR5	0.46	7.26	0.37	2.85e-12	Asthma;
CRC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg27523141	chr10:43048294	ZNF37B	0.44	6.32	0.33	8.44e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg21918786	chr6:109611834	NA	-0.35	-6.05	-0.32	3.9e-9	Reticulocyte fraction of red cells;
CRC	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg10517650	chr3:113235015	CCDC52	-0.37	-5.78	-0.3	1.76e-8	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg14828511	chr1:107599125	PRMT6	-0.5	-7.35	-0.38	1.54e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.57	-5.86	-0.31	1.11e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg18479299	chr3:125709523	NA	-0.55	-6.53	-0.34	2.45e-10	Blood pressure (smoking interaction);
CRC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.76	12.34	0.56	5.39e-29	Breast cancer;
CRC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	7.81	0.4	7.5e-14	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.26	-0.37	2.75e-12	Chronic sinus infection;
CRC	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.57	-8.37	-0.42	1.63e-15	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-17.53	-0.7	4.55e-49	Ulcerative colitis;
CRC	cis	rs1519814	0.696	rs6985424	chr8:121062976	C/T	cg22335954	chr8:121166405	COL14A1	-0.61	-6.53	-0.34	2.51e-10	Breast cancer;
CRC	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg22495460	chr2:25135724	ADCY3	-0.72	-11.83	-0.55	3.81e-27	Body mass index;
CRC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg15845792	chr6:28175446	NA	0.49	6.55	0.34	2.19e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21659725	chr3:3221576	CRBN	0.44	6.55	0.34	2.23e-10	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15229027	chr14:64805542	ESR2	0.41	6.25	0.33	1.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3823572	0.542	rs62470446	chr7:133631002	C/T	cg03336402	chr7:133662267	EXOC4	0.68	10.42	0.5	3.79e-22	Intelligence (multi-trait analysis);
CRC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg26762873	chr11:5879799	OR52E8	-0.4	-5.89	-0.31	9.6e-9	DNA methylation (variation);
CRC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.15	-0.32	2.29e-9	Arsenic metabolism;
CRC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.57	8.76	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-5.69	-0.3	2.81e-8	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14751398	chr6:20402153	E2F3	0.46	6.56	0.34	2.05e-10	Response to antipsychotic treatment;
CRC	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.72	12.89	0.58	4.56e-31	Hip circumference;
CRC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.44	-6.97	-0.36	1.77e-11	Asthma;
CRC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.94	0.74	1.46e-58	Prudent dietary pattern;
CRC	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg21153622	chr11:89784906	NA	-0.45	-7.27	-0.37	2.58e-12	HDL cholesterol;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg25164649	chr6:28176230	NA	0.77	9.45	0.46	6.39e-19	Depression;
CRC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg19635926	chr16:89946313	TCF25	0.62	6.0	0.31	5.19e-9	Skin colour saturation;
CRC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.54	7.32	0.37	1.97e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	0.89	10.96	0.52	5.04e-24	Blood protein levels;
CRC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs231513	0.769	rs537169	chr17:41976740	G/A	cg26893861	chr17:41843967	DUSP3	-0.63	-6.36	-0.33	6.63e-10	Cognitive function;
CRC	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg09264619	chr17:80180166	NA	-0.49	-6.86	-0.35	3.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	12.86	0.58	6.3e-31	Body mass index (adult);
CRC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg07274523	chr3:49395745	GPX1	-0.46	-6.04	-0.32	4.16e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.58e-8	Prudent dietary pattern;
CRC	cis	rs11585357	0.501	rs58620951	chr1:17573965	G/A	cg08277548	chr1:17600880	PADI3	-0.67	-7.81	-0.4	7.6e-14	Hair shape;
CRC	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.59	-11.05	-0.52	2.35e-24	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	1.17	10.78	0.51	2.08e-23	Arsenic metabolism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01869960	chr2:136289456	R3HDM1;ZRANB3	0.47	6.76	0.35	6.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	7.73	0.39	1.3e-13	Personality dimensions;
CRC	trans	rs11825064	0.666	rs2156704	chr11:134485021	T/C	cg00033773	chr19:12779366	MORG1;C19orf56	0.44	6.15	0.32	2.29e-9	Seasonality;
CRC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg11766577	chr21:47581405	C21orf56	0.38	5.82	0.31	1.4e-8	Testicular germ cell tumor;
CRC	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg02466173	chr16:30829666	NA	0.63	9.43	0.46	7.37e-19	Dementia with Lewy bodies;
CRC	cis	rs427943	0.712	rs983749	chr21:46601851	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	5.99	0.31	5.5e-9	Body mass index;
CRC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg10570241	chr7:158785291	NA	0.52	9.41	0.46	8.87e-19	Facial morphology (factor 20);
CRC	trans	rs13315871	0.615	rs6793358	chr3:58356454	C/G	cg25250853	chr2:85822726	RNF181	0.52	6.21	0.32	1.6e-9	Cholesterol, total;
CRC	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.68	14.1	0.61	1.25e-35	Intelligence (multi-trait analysis);
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg20356147	chr3:127914850	EEFSEC	-0.53	-6.54	-0.34	2.4e-10	Lymphocyte counts;
CRC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.97	-0.36	1.77e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12172441	chr6:28176163	NA	0.54	7.51	0.38	5.63e-13	Parkinson's disease;
CRC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg15962314	chr1:44399869	ARTN	0.3	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg25173405	chr17:45401733	C17orf57	0.43	6.6	0.34	1.61e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7623430	1.000	rs1450004	chr3:36192176	G/A	cg16587794	chr15:69706675	KIF23	0.41	6.01	0.31	4.88e-9	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);
CRC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg22495460	chr2:25135724	ADCY3	0.87	17.27	0.69	5.11e-48	Body mass index;
CRC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-9.18	-0.45	4.86e-18	Mean corpuscular hemoglobin concentration;
CRC	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg03929089	chr4:120376271	NA	-0.52	-6.41	-0.33	5.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.63	10.1	0.49	4.39e-21	Chronic sinus infection;
CRC	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.59	-6.68	-0.35	1.03e-10	Blood protein levels;
CRC	cis	rs10486722	0.651	rs6975680	chr7:41803450	A/G	cg22138096	chr7:41772439	LOC285954	0.63	7.72	0.39	1.38e-13	Pit-and-Fissure caries;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg11809157	chr19:47734715	BBC3	-0.44	-6.06	-0.32	3.68e-9	Birth weight;Height;
CRC	cis	rs12760731	0.623	rs3791025	chr1:178357907	C/G	cg00404053	chr1:178313656	RASAL2	0.72	8.99	0.44	1.94e-17	Obesity-related traits;
CRC	cis	rs12541635	0.677	rs7003520	chr8:107061724	G/A	cg10147462	chr8:107024639	NA	0.61	10.58	0.5	1.02e-22	Age of smoking initiation;
CRC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs9303542	0.559	rs35621842	chr17:46606222	C/T	cg04904318	chr17:46607828	HOXB1	-0.56	-6.54	-0.34	2.28e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg04871131	chr7:94954202	PON1	-0.46	-5.64	-0.3	3.63e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg06470822	chr6:28175283	NA	0.63	6.95	0.36	2e-11	Parkinson's disease;
CRC	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.57	8.54	0.43	4.9e-16	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11200644	chr18:72265018	LOC400657	0.45	6.47	0.34	3.52e-10	Response to antipsychotic treatment;
CRC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.82	11.35	0.53	1.98e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.61	-9.44	-0.46	7.18e-19	Menarche (age at onset);
CRC	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.11	0.45	8.36e-18	Dupuytren's disease;
CRC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.47	7.1	0.36	7.81e-12	Mean platelet volume;
CRC	cis	rs78545713	0.502	rs3823157	chr6:26272039	A/G	cg08578491	chr6:26276143	NA	0.48	6.6	0.34	1.65e-10	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.65	8.91	0.44	3.5e-17	Platelet count;
CRC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg25347419	chr2:177043501	NA	0.59	9.18	0.45	5.04e-18	IgG glycosylation;
CRC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg12046867	chr14:103022105	NA	0.76	9.03	0.45	1.44e-17	Platelet count;
CRC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.58e-12	Height;
CRC	trans	rs2403907	0.758	rs2823134	chr21:16569063	A/G	cg00407105	chr4:90231041	NA	-0.4	-6.13	-0.32	2.52e-9	Breast cancer;
CRC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg00310523	chr12:86230176	RASSF9	0.43	7.28	0.37	2.42e-12	Major depressive disorder;
CRC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.37	-0.56	4.1e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.44	7.12	0.37	6.79e-12	Obesity-related traits;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.68	10.37	0.5	5.5e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg13072238	chr3:49761600	GMPPB	-0.52	-6.04	-0.32	4.14e-9	Menarche (age at onset);
CRC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-7.82	-0.4	7.16e-14	Colorectal cancer;
CRC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg16141378	chr3:129829833	LOC729375	-0.46	-6.85	-0.35	3.67e-11	Retinal vascular caliber;
CRC	cis	rs3857067	1.000	rs2865330	chr4:95004716	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.04	-0.32	4.06e-9	QT interval;
CRC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg00383909	chr3:49044727	WDR6	0.46	5.77	0.3	1.84e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.62	-7.92	-0.4	3.73e-14	Body mass index;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.35	5.66	0.3	3.23e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.53	8.54	0.43	5.16e-16	Motion sickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25998860	chr5:126853954	PRRC1	0.47	6.12	0.32	2.66e-9	Thyroid stimulating hormone;
CRC	cis	rs1867631	0.585	rs5008753	chr1:67092248	A/G	cg02459107	chr1:67143332	SGIP1	0.33	5.9	0.31	9.17e-9	Menopause (age at onset);
CRC	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.77	-10.26	-0.49	1.33e-21	Blood pressure (smoking interaction);
CRC	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	5.79	0.3	1.62e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.64	11.21	0.53	6.37e-25	Superior crus of antihelix expression;
CRC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	1.29	12.5	0.57	1.36e-29	Schizophrenia;
CRC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.59	-9.45	-0.46	6.6e-19	Monocyte count;
CRC	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.06	-0.55	5.62e-28	Exhaled nitric oxide levels;
CRC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg23262073	chr20:60523788	NA	-0.38	-6.28	-0.33	1.07e-9	Body mass index;
CRC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.21	-0.41	5.18e-15	Chronic sinus infection;
CRC	cis	rs863345	0.604	rs2157687	chr1:158493000	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	7e-9	Pneumococcal bacteremia;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.27	-0.33	1.12e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10878977	0.542	rs60878854	chr12:69815236	G/A	cg20891283	chr12:69753455	YEATS4	-0.6	-5.92	-0.31	8.13e-9	Colorectal cancer;
CRC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.58	-0.6	1.19e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.23	14.72	0.63	4.77e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.12	-15.0	-0.64	3.94e-39	Vitiligo;
CRC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.6	8.71	0.43	1.51e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.29e-19	Corneal astigmatism;
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.6e-12	Life satisfaction;
CRC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17767392	0.834	rs11626886	chr14:71727155	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.2	-0.32	1.74e-9	Mitral valve prolapse;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16204370	chr22:41682343	RANGAP1	0.44	6.83	0.35	4.17e-11	Schizophrenia;
CRC	cis	rs28655083	0.957	rs7185514	chr16:77070129	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.59	-8.4	-0.42	1.33e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9648716	1.000	rs10281508	chr7:140565218	T/C	cg10747023	chr7:140774559	NA	0.43	5.64	0.3	3.61e-8	Type 2 diabetes;
CRC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.59	0.54	2.81e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.5	-7.57	-0.39	3.84e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4731207	0.724	rs10257255	chr7:124479678	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.28e-9	Cutaneous malignant melanoma;
CRC	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg09127314	chr1:152161683	NA	0.46	5.69	0.3	2.77e-8	Atopic dermatitis;
CRC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg03948781	chr1:205179583	DSTYK	0.42	5.85	0.31	1.2e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.13	10.46	0.5	2.64e-22	Skin colour saturation;
CRC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg12273811	chr6:28175739	NA	0.55	7.7	0.39	1.56e-13	Parkinson's disease;
CRC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.78	12.5	0.57	1.32e-29	Breast cancer;
CRC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg14847009	chr1:175162515	KIAA0040	0.31	6.97	0.36	1.72e-11	Alcohol dependence;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg25164649	chr6:28176230	NA	0.65	8.57	0.43	4.18e-16	Parkinson's disease;
CRC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.69	8.34	0.42	2.01e-15	Chronic sinus infection;
CRC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.57	-0.6	1.3e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.47	-6.16	-0.32	2.16e-9	Tuberculosis;
CRC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.52	0.34	2.6e-10	Morning vs. evening chronotype;
CRC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.23	0.32	1.46e-9	HIV-1 control;
CRC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.92	11.13	0.52	1.19e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.29	-0.53	3.23e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4561483	0.583	rs11075027	chr16:11948895	T/C	cg08843971	chr16:11963173	GSPT1	0.52	7.72	0.39	1.38e-13	Testicular germ cell tumor;
CRC	cis	rs17095355	1.000	rs17126902	chr10:111710381	A/G	cg00817464	chr10:111662876	XPNPEP1	0.64	7.81	0.4	7.98e-14	Biliary atresia;
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.8	-0.51	1.77e-23	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03571604	chr17:17875744	TOM1L2;LRRC48	0.41	6.68	0.35	1e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg14711859	chr11:8959438	ASCL3	-0.37	-5.89	-0.31	9.53e-9	Hemoglobin concentration;
CRC	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg06737308	chr4:185021514	ENPP6	0.37	5.68	0.3	2.89e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	trans	rs724568	0.681	rs1978656	chr2:67920009	A/G	cg15815156	chr15:52472201	GNB5	-0.41	-6.29	-0.33	1.01e-9	Major depressive disorder (broad);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14843216	chr17:56064736	VEZF1	0.44	6.14	0.32	2.41e-9	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.66	11.0	0.52	3.6e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09732282	chr15:58474918	AQP9	0.45	7.01	0.36	1.39e-11	Response to antipsychotic treatment;
CRC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.57	9.0	0.44	1.8e-17	Eosinophil percentage of white cells;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg12873262	chr11:134094364	NCAPD3;VPS26B	-0.42	-6.05	-0.32	3.92e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.42	6.3	0.33	9.44e-10	Resting heart rate;
CRC	cis	rs7209700	0.632	rs11657963	chr17:45347533	G/A	cg08085267	chr17:45401833	C17orf57	0.44	5.98	0.31	5.88e-9	IgG glycosylation;
CRC	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg11130432	chr3:121712080	ILDR1	-0.51	-6.08	-0.32	3.28e-9	Multiple sclerosis;
CRC	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg17085576	chr10:5658249	NA	-0.41	-5.86	-0.31	1.11e-8	Breast cancer;
CRC	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg01843034	chr6:37503916	NA	-0.35	-5.81	-0.31	1.46e-8	Cognitive performance;
CRC	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.84	-15.17	-0.64	9.22e-40	Itch intensity from mosquito bite;
CRC	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.81	12.44	0.57	2.14e-29	Ulcerative colitis;
CRC	cis	rs12580194	0.593	rs12579408	chr12:55764348	G/A	cg23425280	chr12:56401806	NA	0.47	5.7	0.3	2.71e-8	Cancer;
CRC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.79	0.39	9.09e-14	Height;
CRC	cis	rs6088813	1.000	rs6087698	chr20:33948919	A/G	cg14752227	chr20:34000481	UQCC	-0.37	-5.82	-0.31	1.37e-8	Height;
CRC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.28	0.49	1.13e-21	Hemoglobin concentration;
CRC	cis	rs12760731	0.565	rs10913520	chr1:178200760	A/T	cg00404053	chr1:178313656	RASAL2	1.05	10.89	0.51	8.62e-24	Obesity-related traits;
CRC	cis	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-7.79	-0.39	9.01e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg07423050	chr13:99094983	FARP1	-0.42	-6.36	-0.33	6.67e-10	Educational attainment (years of education);
CRC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.37	0.33	6.44e-10	Red blood cell count;
CRC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02891801	chr12:6472782	SCNN1A	0.45	6.26	0.33	1.18e-9	Response to antipsychotic treatment;
CRC	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.91	17.03	0.68	4.29e-47	Longevity;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg22638593	chr5:131593259	PDLIM4	-0.52	-9.27	-0.46	2.47e-18	Acylcarnitine levels;
CRC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg15571903	chr15:79123663	NA	0.34	6.91	0.36	2.55e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg19812747	chr11:111475976	SIK2	-0.52	-8.35	-0.42	1.87e-15	Primary sclerosing cholangitis;
CRC	cis	rs3812762	0.912	rs10769953	chr11:8778352	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.37	6.02	0.32	4.62e-9	Hypospadias;
CRC	cis	rs7605827	0.866	rs9287665	chr2:15667263	A/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg06818126	chr11:68850279	TPCN2	-0.47	-6.64	-0.34	1.26e-10	Hair color;
CRC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.62	-0.34	1.51e-10	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg15845792	chr6:28175446	NA	1.03	14.0	0.61	3e-35	Depression;
CRC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg03315344	chr16:75512273	CHST6	0.48	5.82	0.31	1.4e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.73	11.55	0.54	3.94e-26	Intelligence (multi-trait analysis);
CRC	cis	rs282587	0.597	rs390177	chr13:113413033	A/G	cg04656015	chr13:113407548	ATP11A	0.57	7.49	0.38	6.24e-13	Glycated hemoglobin levels;
CRC	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg06581033	chr10:766294	NA	-0.5	-5.74	-0.3	2.17e-8	Uric acid levels;
CRC	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.05	-0.32	3.93e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg06766960	chr11:133703094	NA	-0.32	-5.73	-0.3	2.24e-8	Childhood ear infection;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23944232	chr2:86948118	RMND5A	0.37	5.99	0.31	5.5e-9	Interleukin-6 levels;
CRC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.82e-9	Height;
CRC	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.9	-0.31	8.94e-9	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.56	0.38	4.03e-13	Obesity-related traits;
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.93	-15.12	-0.64	1.44e-39	Dupuytren's disease;
CRC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg01831904	chr17:28903510	LRRC37B2	0.46	5.64	0.3	3.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-7.53	-0.38	4.94e-13	Metabolite levels;
CRC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg14541582	chr5:601475	NA	-0.34	-6.46	-0.34	3.71e-10	Obesity-related traits;
CRC	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.48	-6.85	-0.35	3.53e-11	Male sexual orientation;
CRC	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.56	-7.3	-0.37	2.21e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.74	-0.47	7.42e-20	Body mass index;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.51	6.07	0.32	3.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg05014952	chr14:35873130	NFKBIA	-0.43	-6.06	-0.32	3.68e-9	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2.03e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1322512	1.000	rs2996635	chr6:153011163	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.05	0.32	4.05e-9	Tonometry;
CRC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.56	-8.56	-0.43	4.28e-16	Schizophrenia;
CRC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.21	0.49	1.87e-21	Heart rate;
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.65	-0.34	1.19e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.61	-0.43	3.11e-16	Bipolar disorder;
CRC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.68	8.93	0.44	3.1e-17	Bladder cancer;
CRC	cis	rs4547160	0.781	rs12228037	chr12:63484560	C/T	cg26727693	chr12:63544175	AVPR1A	0.41	7.63	0.39	2.54e-13	Morning vs. evening chronotype;
CRC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.85	-9.81	-0.48	4.2e-20	Breast cancer;
CRC	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.65	8.22	0.41	4.87e-15	Breast cancer;
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.05	-0.32	3.92e-9	Bipolar disorder;
CRC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg13072238	chr3:49761600	GMPPB	-0.52	-5.96	-0.31	6.51e-9	Menarche (age at onset);
CRC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.76	-0.3	1.94e-8	Eosinophil percentage of white cells;
CRC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.33	-5.99	-0.31	5.48e-9	Multiple sclerosis;
CRC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.74	9.85	0.48	3.12e-20	Platelet count;
CRC	trans	rs35094601	1.000	rs11679023	chr2:139225571	G/A	cg25299176	chr17:1303341	YWHAE	-0.47	-6.67	-0.35	1.1e-10	Schizophrenia;
CRC	cis	rs4363385	0.747	rs1999886	chr1:152955522	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.09e-13	Inflammatory skin disease;
CRC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg03233332	chr7:66118400	NA	0.43	5.98	0.31	5.79e-9	Aortic root size;
CRC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.25	-0.62	3.15e-36	Body mass index;
CRC	cis	rs62229266	0.625	rs62230813	chr21:37403432	C/T	cg12218747	chr21:37451666	NA	-0.36	-6.06	-0.32	3.74e-9	Mitral valve prolapse;
CRC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg21138405	chr5:131827807	IRF1	-0.34	-5.75	-0.3	2.03e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg15269541	chr15:43626905	ADAL	-0.62	-6.48	-0.34	3.31e-10	Lung cancer in ever smokers;
CRC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.66	9.96	0.48	1.36e-20	Bladder cancer;
CRC	cis	rs17023223	0.581	rs12064109	chr1:119642296	T/C	cg05756136	chr1:119680316	WARS2	-0.52	-6.56	-0.34	2.15e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg20512303	chr5:131592959	PDLIM4	0.29	5.74	0.3	2.1e-8	Blood metabolite levels;
CRC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	10.02	0.48	8.63e-21	Systemic lupus erythematosus;
CRC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.45	6.6	0.34	1.63e-10	Cisplatin-induced ototoxicity;
CRC	cis	rs7680126	0.633	rs11728093	chr4:10296407	A/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.27	-0.37	2.61e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs12432203	1.000	rs72622442	chr14:51744868	A/G	cg14592830	chr9:122318704	NA	0.59	5.98	0.31	5.91e-9	Cancer;
CRC	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg23461800	chr14:103021989	NA	-0.69	-8.89	-0.44	4.25e-17	Platelet count;
CRC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg25811766	chr13:21894605	NA	-0.57	-5.89	-0.31	9.71e-9	White matter hyperintensity burden;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26057283	chr7:73082469	VPS37D	0.37	6.93	0.36	2.22e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs524281	0.817	rs10791859	chr11:65978453	C/T	cg14036092	chr11:66035641	RAB1B	-0.52	-6.11	-0.32	2.89e-9	Electroencephalogram traits;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg24634471	chr8:143751801	JRK	-0.45	-6.38	-0.33	5.86e-10	Urinary tract infection frequency;
CRC	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12315302	chr6:26189340	HIST1H4D	0.77	5.99	0.31	5.51e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.56	-8.37	-0.42	1.63e-15	Body mass index;
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg08546805	chr12:8549446	NA	-0.43	-6.55	-0.34	2.26e-10	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Depression;
CRC	cis	rs4731207	0.698	rs10255209	chr7:124554927	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.02	-0.32	4.57e-9	Cutaneous malignant melanoma;
CRC	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg18806716	chr10:30721971	MAP3K8	-0.55	-7.52	-0.38	5.39e-13	Inflammatory bowel disease;
CRC	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg18404041	chr3:52824283	ITIH1	-0.36	-6.63	-0.34	1.38e-10	Bipolar disorder;
CRC	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.37	-6.15	-0.32	2.2e-9	Sudden cardiac arrest;
CRC	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg16482183	chr6:26056742	HIST1H1C	0.78	9.68	0.47	1.15e-19	Iron status biomarkers;
CRC	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.51	8.91	0.44	3.44e-17	Blood metabolite ratios;
CRC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.56	-5.73	-0.3	2.25e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.74	-11.98	-0.55	1.12e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs12580194	0.556	rs12099811	chr12:55731200	T/A	cg23425280	chr12:56401806	NA	0.47	5.86	0.31	1.1e-8	Cancer;
CRC	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	7.07	0.36	9.56e-12	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg17294928	chr15:75287854	SCAMP5	-0.43	-6.44	-0.33	4.12e-10	Caffeine consumption;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs3026101	0.671	rs8077472	chr17:5299359	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.41	6.15	0.32	2.25e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.26	-0.33	1.22e-9	Bipolar disorder;
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.46	-6.35	-0.33	7.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9648716	0.554	rs4726020	chr7:140603652	A/G	cg10747023	chr7:140774559	NA	0.46	6.3	0.33	9.52e-10	Type 2 diabetes;
CRC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.96	-0.31	6.46e-9	Life satisfaction;
CRC	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.64	-9.45	-0.46	6.64e-19	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02281514	chr2:216946545	PECR;TMEM169	0.45	6.04	0.32	4.14e-9	Anxiety disorder;
CRC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.48	6.79	0.35	5.38e-11	Diastolic blood pressure;
CRC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.9	-10.09	-0.49	5.02e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-15.63	-0.65	1.36e-41	Primary sclerosing cholangitis;
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.15	-0.32	2.28e-9	QT interval;
CRC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg20354231	chr13:53171401	NA	-0.46	-7.38	-0.38	1.31e-12	Lewy body disease;
CRC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.31	12.57	0.57	7.47e-30	Cognitive function;
CRC	cis	rs400736	0.562	rs12711516	chr1:8181227	G/C	cg25007680	chr1:8021821	PARK7	-0.44	-5.82	-0.31	1.39e-8	Response to antidepressants and depression;
CRC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs4728302	0.869	rs889825	chr7:133596227	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.51	-0.34	2.78e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7932354	0.528	rs4752957	chr11:47125632	T/G	cg19486271	chr11:47235900	DDB2	-0.45	-6.73	-0.35	7.77e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg21452805	chr1:244014465	NA	0.46	6.11	0.32	2.78e-9	RR interval (heart rate);
CRC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.74	10.49	0.5	2.08e-22	High light scatter reticulocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09860653	chr1:19970708	NBL1	0.43	7.11	0.36	7.43e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14905632	chr17:38333933	RAPGEFL1	0.4	6.12	0.32	2.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.58	-8.12	-0.41	9.73e-15	Longevity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10620100	chr15:40714174	NA	0.53	7.03	0.36	1.22e-11	Thyroid stimulating hormone;
CRC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.39	-6.78	-0.35	5.51e-11	Reticulocyte fraction of red cells;
CRC	trans	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg02509730	chr13:100310205	CLYBL	0.6	6.17	0.32	2.04e-9	Breast cancer;
CRC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-6.02	-0.31	4.73e-9	Schizophrenia;
CRC	cis	rs7264396	0.887	rs8116304	chr20:34054409	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.15	-0.32	2.24e-9	Total cholesterol levels;
CRC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.11	-0.73	2.63e-55	Primary sclerosing cholangitis;
CRC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg17724175	chr1:150552817	MCL1	0.39	6.0	0.31	5.11e-9	Melanoma;
CRC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-11.04	-0.52	2.52e-24	Hepatocellular carcinoma;
CRC	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg19812747	chr11:111475976	SIK2	0.42	6.16	0.32	2.17e-9	Primary sclerosing cholangitis;
CRC	cis	rs7926971	0.704	rs4463830	chr11:12659331	C/T	cg25843174	chr11:12811716	TEAD1	0.35	6.08	0.32	3.28e-9	Height;
CRC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.98	12.55	0.57	8.38e-30	Cerebrospinal P-tau181p levels;
CRC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.52	7.52	0.38	5.41e-13	Uric acid levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05886006	chr1:161359784	NA	0.44	6.27	0.33	1.11e-9	Response to antipsychotic treatment;
CRC	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-1.14	-12.49	-0.57	1.4e-29	Mitochondrial DNA levels;
CRC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.4	7.6	0.39	3.18e-13	Ulcerative colitis;
CRC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	8.02	0.4	1.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.6	-9.12	-0.45	7.5e-18	Body mass index;
CRC	trans	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.67	-0.39	1.95e-13	HDL cholesterol;
CRC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.45	9.31	0.46	1.9e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs4243830	0.826	rs3908553	chr1:6621921	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.85	7.49	0.38	6.52e-13	Body mass index;
CRC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.49	6.76	0.35	6.47e-11	Height;
CRC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg03623178	chr6:28175578	NA	0.84	8.04	0.41	1.62e-14	Depression;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	10.8	0.51	1.8e-23	Prudent dietary pattern;
CRC	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg01388757	chr2:102091195	RFX8	0.38	5.93	0.31	7.86e-9	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg00999904	chr2:3704751	ALLC	-0.53	-6.66	-0.34	1.16e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.49	-7.33	-0.37	1.76e-12	Height;
CRC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.66	-11.36	-0.53	1.81e-25	Refractive error;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10836036	chr1:155278714	FDPS	0.41	6.53	0.34	2.55e-10	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12672932	chr2:153575114	ARL6IP6;PRPF40A	0.44	5.97	0.31	6.22e-9	Anxiety disorder;
CRC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.52	9.37	0.46	1.22e-18	Hypertriglyceridemia;
CRC	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.52	7.07	0.36	9.37e-12	Caudate activity during reward;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	trans	rs1973993	0.672	rs17367240	chr1:96960057	G/A	cg10631902	chr5:14652156	NA	-0.42	-7.14	-0.37	6.16e-12	Weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15459342	chr1:228296991	MRPL55	0.46	6.48	0.34	3.3e-10	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg02683197	chr6:28174875	NA	0.62	8.5	0.42	6.91e-16	Parkinson's disease;
CRC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-20.09	-0.74	3.73e-59	Headache;
CRC	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.67	6.95	0.36	1.98e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	cis	rs728616	0.867	rs17886286	chr10:81703852	C/G	cg11900509	chr10:81946545	ANXA11	-0.65	-6.56	-0.34	2.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg14829360	chr17:73884958	NA	-0.43	-6.67	-0.34	1.11e-10	Psoriasis;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs6540556	0.608	rs4844891	chr1:209914409	A/C	cg23920097	chr1:209922102	NA	-0.48	-5.85	-0.31	1.22e-8	Red blood cell count;
CRC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg25985355	chr7:65971099	NA	-0.53	-5.99	-0.31	5.45e-9	Diabetic kidney disease;
CRC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.6	7.59	0.39	3.27e-13	Cleft lip with or without cleft palate;
CRC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.44	-9.71	-0.47	9.36e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.4	-0.38	1.12e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg02811702	chr13:24901961	NA	0.45	6.22	0.32	1.53e-9	Obesity-related traits;
CRC	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.37	0.82	3.89e-83	Schizophrenia;
CRC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-9.05	-0.45	1.32e-17	Cognitive function;
CRC	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.61	8.83	0.44	6.5e-17	Plateletcrit;Platelet count;
CRC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg19980929	chr12:42632907	YAF2	0.43	6.42	0.33	4.87e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.16	25.92	0.82	1.73e-81	IgG glycosylation;
CRC	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.48	-7.72	-0.39	1.45e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19350839	chr7:65338055	VKORC1L1	0.39	6.75	0.35	6.63e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.46	7.36	0.38	1.5e-12	Obesity-related traits;
CRC	cis	rs71403859	0.730	rs71386933	chr16:71821800	A/T	cg08717414	chr16:71523259	ZNF19	-1.07	-9.6	-0.47	2.1e-19	Post bronchodilator FEV1;
CRC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-6.76	-0.35	6.21e-11	Educational attainment;
CRC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg15123519	chr2:136567270	LCT	-0.35	-6.74	-0.35	6.96e-11	Mosquito bite size;
CRC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01073178	chr12:117537710	TESC	0.43	6.01	0.31	4.96e-9	Survival in pancreatic cancer;
CRC	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg16347377	chr7:143956670	OR2A7	-0.55	-6.39	-0.33	5.67e-10	Obesity-related traits;
CRC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.25	-0.33	1.29e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg10760299	chr15:45669010	GATM	0.52	8.31	0.42	2.58e-15	Homoarginine levels;
CRC	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg09455208	chr3:40491958	NA	0.43	8.21	0.41	5.2e-15	Renal cell carcinoma;
CRC	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.44	-6.25	-0.33	1.31e-9	Eye color traits;
CRC	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg02023728	chr11:77925099	USP35	-0.36	-6.16	-0.32	2.12e-9	Alzheimer's disease (survival time);
CRC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.46	-0.38	7.57e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-13.1	-0.59	7.99e-32	Vitiligo;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg12273811	chr6:28175739	NA	0.51	6.99	0.36	1.49e-11	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05193430	chr14:68086242	ARG2	0.41	6.09	0.32	3.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.81	-11.1	-0.52	1.55e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.33	-0.46	1.65e-18	Capecitabine sensitivity;
CRC	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.45	-8.3	-0.42	2.78e-15	Huntington's disease progression;
CRC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg17948913	chr5:572064	NA	-0.5	-5.74	-0.3	2.11e-8	Obesity-related traits;
CRC	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg12218747	chr21:37451666	NA	-0.45	-7.8	-0.39	8.38e-14	Mitral valve prolapse;
CRC	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.59	-0.43	3.49e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2274273	0.638	rs3825614	chr14:55729387	G/A	cg10130446	chr14:55658398	DLGAP5	-0.45	-6.07	-0.32	3.58e-9	Protein biomarker;
CRC	trans	rs204595	0.965	rs204585	chr7:20902288	A/G	cg02372745	chr13:50365574	KPNA3	0.47	6.26	0.33	1.22e-9	Depressive symptoms (stressful life events interaction);
CRC	cis	rs3026101	0.671	rs3026134	chr17:5309690	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs10760158	0.768	rs2149805	chr9:124021499	T/G	cg14417974	chr9:124058376	GSN	-0.34	-5.68	-0.3	2.96e-8	Pulse pressure;
CRC	trans	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.21e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.54	7.59	0.39	3.27e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.45	-7.84	-0.4	6.13e-14	Response to cytidine analogues (gemcitabine);
CRC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.51	-6.69	-0.35	9.48e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.39	0.53	1.47e-25	Prudent dietary pattern;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg12963246	chr6:28129442	ZNF389	0.45	5.67	0.3	3.2e-8	Depression;
CRC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.47	7.19	0.37	4.44e-12	Longevity;
CRC	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18462168	chr15:22892545	CYFIP1	-0.55	-6.64	-0.34	1.26e-10	Diisocyanate-induced asthma;
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.51	9.07	0.45	1.13e-17	Hypertriglyceridemia;
CRC	trans	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg02257048	chr17:78880031	RPTOR	-0.39	-6.09	-0.32	3.21e-9	Hip circumference;
CRC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg20673091	chr1:2541236	MMEL1	0.36	5.82	0.31	1.43e-8	Ulcerative colitis;
CRC	cis	rs10128264	0.934	rs1250590	chr10:80983786	A/C	cg20744163	chr10:80999841	ZMIZ1	0.44	7.67	0.39	2e-13	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.64	9.65	0.47	1.45e-19	Lung cancer;
CRC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg05139728	chr16:28306816	SBK1	-0.38	-6.25	-0.33	1.28e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg13385794	chr1:248469461	NA	0.39	6.65	0.34	1.23e-10	Common traits (Other);
CRC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.44	8.19	0.41	5.85e-15	Iron status biomarkers (transferrin levels);
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.35	1.01e-10	Bipolar disorder;
CRC	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-5.81	-0.31	1.45e-8	Type 2 diabetes;
CRC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25517755	chr10:38738941	LOC399744	0.45	6.56	0.34	2.07e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2384207	0.818	rs7299870	chr12:113708590	A/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.51	6.38	0.33	5.96e-10	Response to fenofibrate (adiponectin levels);
CRC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.76	12.23	0.56	1.37e-28	Breast cancer;
CRC	cis	rs1992660	0.523	rs6897022	chr5:40336546	A/G	cg09067459	chr5:40385259	NA	-0.44	-7.46	-0.38	7.7e-13	Crohn's disease;
CRC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.54	-8.38	-0.42	1.59e-15	Aortic root size;
CRC	cis	rs6496667	0.600	rs9806361	chr15:91073867	G/A	cg04176472	chr15:90893244	GABARAPL3	0.49	7.23	0.37	3.45e-12	Rheumatoid arthritis;
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.01	-19.38	-0.73	2.36e-56	Prudent dietary pattern;
CRC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.63	9.54	0.47	3.43e-19	Testicular germ cell tumor;
CRC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.75	0.39	1.19e-13	Mean platelet volume;
CRC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg10431340	chr1:161279108	MPZ	-0.56	-7.38	-0.38	1.32e-12	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20843052	chr2:61293725	KIAA1841	0.49	7.76	0.39	1.06e-13	Response to antipsychotic treatment;
CRC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	6.74	0.35	7.22e-11	Response to antipsychotic treatment;
CRC	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg09659197	chr4:152720779	NA	-0.44	-8.63	-0.43	2.64e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg11861562	chr11:117069780	TAGLN	0.35	6.42	0.33	4.82e-10	Blood protein levels;
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.77	13.1	0.59	7.48e-32	Bipolar disorder and schizophrenia;
CRC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12541635	0.966	rs12680670	chr8:107006811	T/G	cg10147462	chr8:107024639	NA	0.42	6.92	0.36	2.42e-11	Age of smoking initiation;
CRC	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.32	5.63	0.3	3.78e-8	Heart rate;
CRC	cis	rs10849893	0.595	rs6489811	chr12:121893626	C/T	cg01154721	chr12:121881891	KDM2B	0.45	6.57	0.34	1.97e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg20356878	chr3:121714668	ILDR1	0.5	7.7	0.39	1.63e-13	Cognitive performance;
CRC	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.74	10.46	0.5	2.64e-22	Systemic lupus erythematosus;
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg16606324	chr3:10149918	C3orf24	0.69	9.43	0.46	7.91e-19	Alzheimer's disease;
CRC	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg09659197	chr4:152720779	NA	0.52	11.3	0.53	3.04e-25	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg24505167	chr7:1915268	MAD1L1	-0.49	-7.47	-0.38	7.32e-13	Bipolar disorder;
CRC	cis	rs3751196	0.808	rs17034648	chr12:104219000	C/T	cg02344784	chr12:104178138	NT5DC3	0.65	7.07	0.36	9.27e-12	Sense of smell;
CRC	cis	rs4780401	0.728	rs8191290	chr16:11765954	C/A	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.62	-0.3	4.17e-8	Rheumatoid arthritis;
CRC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg00745463	chr17:30367425	LRRC37B	0.58	7.67	0.39	1.93e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.32	0.33	8.41e-10	Aortic root size;
CRC	cis	rs3018066	0.867	rs10008428	chr4:107081028	G/T	cg01869342	chr4:106983673	TBCK	0.37	5.74	0.3	2.15e-8	Cancer;
CRC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.27	-0.53	3.85e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg15845792	chr6:28175446	NA	0.75	11.17	0.52	8.62e-25	Parkinson's disease;
CRC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.58	9.28	0.46	2.39e-18	Obesity-related traits;
CRC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.61	10.52	0.5	1.62e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.45	-0.38	8.18e-13	Hematocrit;
CRC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.08	-0.36	8.94e-12	IgG glycosylation;
CRC	cis	rs3018066	0.867	rs10004611	chr4:107092820	A/G	cg01869342	chr4:106983673	TBCK	0.37	5.7	0.3	2.73e-8	Cancer;
CRC	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.71	13.73	0.6	3.21e-34	Mean corpuscular hemoglobin;
CRC	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.67	10.33	0.49	7.69e-22	Corneal astigmatism;
CRC	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg00601450	chr5:74908170	NA	0.41	5.76	0.3	1.95e-8	Age-related disease endophenotypes;
CRC	cis	rs7605827	0.930	rs1024869	chr2:15549043	G/C	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.98e-9	Educational attainment (years of education);
CRC	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg11003573	chr3:44754125	ZNF502	-0.36	-6.16	-0.32	2.11e-9	Depressive symptoms;
CRC	cis	rs59104589	0.617	rs61615527	chr2:242342768	T/A	cg19488206	chr2:242435732	STK25	0.43	6.33	0.33	7.84e-10	Fibrinogen levels;
CRC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13126279	chr21:47581558	C21orf56	-0.38	-5.63	-0.3	3.9e-8	Testicular germ cell tumor;
CRC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg08501292	chr6:25962987	TRIM38	0.86	8.01	0.4	2.02e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.71	10.13	0.49	3.74e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.43	-6.51	-0.34	2.83e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs990171	1.000	rs6755786	chr2:103048103	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.9	0.31	9.09e-9	Lymphocyte counts;
CRC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.04	0.45	1.42e-17	Cognitive test performance;
CRC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.65	-10.47	-0.5	2.45e-22	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg14008862	chr17:28927542	LRRC37B2	0.5	5.76	0.3	1.95e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.79	14.37	0.62	1.14e-36	Metabolic syndrome;
CRC	cis	rs7394190	1.000	rs10824026	chr10:75421208	A/G	cg26549892	chr10:75416844	SYNPO2L	-0.45	-5.83	-0.31	1.34e-8	Incident atrial fibrillation;
CRC	cis	rs11212617	0.935	rs227055	chr11:108261261	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.41	5.98	0.31	5.87e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6840360	0.582	rs57585665	chr4:152327017	G/C	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17955752	chr17:79935872	ASPSCR1	0.4	6.06	0.32	3.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg11189052	chr15:85197271	WDR73	0.61	8.49	0.42	7.45e-16	Schizophrenia;
CRC	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.42	6.2	0.32	1.66e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.54	7.88	0.4	4.91e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.13	0.49	3.54e-21	Ileal carcinoids;
CRC	cis	rs2415984	0.622	rs61993301	chr14:46949667	C/T	cg14871534	chr14:47121158	RPL10L	-0.44	-6.26	-0.33	1.22e-9	Number of children ever born;
CRC	cis	rs35520189	0.556	rs12470439	chr2:113701164	G/A	cg12858261	chr2:113808755	IL1F8	0.49	6.86	0.35	3.42e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.55	-0.57	8.82e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.85	0.4	5.97e-14	Plateletcrit;
CRC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg20811857	chr17:78079795	GAA	-0.41	-6.6	-0.34	1.69e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg14003231	chr6:33640908	ITPR3	0.49	7.69	0.39	1.71e-13	Plateletcrit;
CRC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg19223190	chr17:80058835	NA	0.42	6.74	0.35	7.27e-11	Life satisfaction;
CRC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.53	-9.09	-0.45	9.72e-18	Iron status biomarkers;
CRC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.74	-12.11	-0.56	3.73e-28	Lung cancer;
CRC	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.52	-8.55	-0.43	4.56e-16	Facial morphology (factor 15, philtrum width);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05038121	chr15:80444758	FAH	0.49	6.8	0.35	4.92e-11	Response to antipsychotic treatment;
CRC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.49	7.64	0.39	2.37e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.62	-10.89	-0.51	8.94e-24	Body mass index;
CRC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.77	13.51	0.6	2.14e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2411233	1.000	rs11070166	chr15:39280797	G/T	cg23129342	chr15:39283510	NA	0.31	5.82	0.31	1.43e-8	Platelet count;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00967121	chr5:153418461	MFAP3;FAM114A2	0.46	6.91	0.36	2.5e-11	Interleukin-6 levels;
CRC	cis	rs887797	0.557	rs9909348	chr17:64576325	T/C	cg27019712	chr17:64599478	PRKCA	-0.37	-5.65	-0.3	3.56e-8	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
CRC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.15	0.45	6.1e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.59	9.99	0.48	1.05e-20	Breast cancer;
CRC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.53	6.77	0.35	5.85e-11	Morning vs. evening chronotype;
CRC	cis	rs3736485	0.966	rs6493513	chr15:51910174	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.49	-0.34	3.2e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-11.59	-0.54	2.88e-26	Refractive error;
CRC	cis	rs7703744	0.681	rs73239278	chr5:118695051	G/A	cg19893178	chr5:118692011	TNFAIP8	0.44	5.92	0.31	8.01e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7619427	0.544	rs58289556	chr3:44034726	C/T	cg09408571	chr1:101003634	GPR88	0.46	6.26	0.33	1.17e-9	Schizophrenia;
CRC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg18230493	chr5:56204884	C5orf35	-0.42	-6.07	-0.32	3.45e-9	Coronary artery disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16311334	chr11:926082	AP2A2	0.39	6.0	0.31	5.12e-9	Schizophrenia;
CRC	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-10.31	-0.49	8.78e-22	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.58	8.29	0.42	2.82e-15	Arsenic metabolism;
CRC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg01480708	chr17:30846118	MYO1D	-0.37	-5.93	-0.31	7.73e-9	Schizophrenia;
CRC	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.73e-11	Inflammatory skin disease;
CRC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg10298567	chr3:47292165	KIF9	0.37	6.05	0.32	3.93e-9	Colorectal cancer;
CRC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.46	6.5	0.34	3e-10	Aortic root size;
CRC	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.21	-0.37	3.85e-12	Inflammatory bowel disease;
CRC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.9	-0.8	7.05e-74	Myeloid white cell count;
CRC	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg09085632	chr11:111637200	PPP2R1B	0.64	8.99	0.44	2.04e-17	Primary sclerosing cholangitis;
CRC	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.55	9.43	0.46	7.85e-19	Dupuytren's disease;
CRC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-17.16	-0.69	1.39e-47	Primary sclerosing cholangitis;
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.56	-9.02	-0.45	1.62e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9491140	0.539	rs12204076	chr6:124693493	A/G	cg05308643	chr6:124982296	NKAIN2	0.51	6.83	0.35	4.05e-11	Neuroticism;
CRC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.52	5.89	0.31	9.36e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs888194	0.677	rs2075431	chr12:109874621	C/T	cg19025524	chr12:109796872	NA	-0.39	-5.71	-0.3	2.52e-8	Neuroticism;
CRC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02438591	chr16:2205559	TRAF7;SNORD60	0.4	6.0	0.31	5.32e-9	Response to antipsychotic treatment;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03923535	chr7:1197113	ZFAND2A	0.77	11.7	0.54	1.12e-26	Longevity;Endometriosis;
CRC	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.43	-0.33	4.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg12927641	chr6:109611667	NA	-0.38	-6.77	-0.35	5.88e-11	Reticulocyte fraction of red cells;
CRC	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg04176472	chr15:90893244	GABARAPL3	-0.35	-6.02	-0.32	4.56e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.47	6.62	0.34	1.47e-10	Diastolic blood pressure;
CRC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg01193554	chr1:41846683	NA	-0.36	-5.89	-0.31	9.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.588	rs17675223	chr14:55862236	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.92	-0.31	8.12e-9	Protein biomarker;
CRC	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg08614441	chr13:113633676	MCF2L	-0.53	-9.4	-0.46	9.66e-19	Systolic blood pressure;
CRC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.44	-6.39	-0.33	5.75e-10	Height;
CRC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.44	0.38	9.07e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.71	10.97	0.52	4.39e-24	Tonsillectomy;
CRC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	10.03	0.48	7.81e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs17126268	0.502	rs6687748	chr1:102885219	T/C	cg18468354	chr14:36993517	NA	0.38	6.12	0.32	2.65e-9	Glomerular filtration rate;
CRC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.06	10.59	0.5	9.22e-23	Diabetic retinopathy;
CRC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.61	-9.06	-0.45	1.16e-17	Systolic blood pressure;
CRC	cis	rs4731207	0.698	rs7789859	chr7:124519472	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg23100626	chr2:96804247	ASTL	0.28	7.14	0.37	6.15e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.48	-6.66	-0.34	1.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-7.11	-0.36	7.24e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6504622	0.967	rs11869840	chr17:44996100	A/G	cg16759221	chr17:45003025	GOSR2	0.45	7.02	0.36	1.31e-11	Orofacial clefts;
CRC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg18335740	chr13:41363409	SLC25A15	0.52	7.71	0.39	1.53e-13	Lewy body disease;
CRC	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.97	-0.31	6.15e-9	Metabolite levels;
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg22110888	chr17:80059540	CCDC57	-0.4	-6.17	-0.32	2.06e-9	Life satisfaction;
CRC	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.64	7.84	0.4	6.18e-14	Obesity (extreme);
CRC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.42	-0.42	1.15e-15	Morning vs. evening chronotype;
CRC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18402987	chr7:1209562	NA	0.42	6.35	0.33	7e-10	Longevity;Endometriosis;
CRC	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.82	-0.4	7.47e-14	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00350652	chr1:109584526	WDR47	0.44	7.04	0.36	1.1e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.7	7.76	0.39	1.05e-13	Inflammatory bowel disease;
CRC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg02659138	chr7:134003124	SLC35B4	0.35	6.05	0.32	4.05e-9	Mean platelet volume;
CRC	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg22687807	chr8:143858763	LYNX1	-0.37	-6.56	-0.34	2.06e-10	Urinary tract infection frequency;
CRC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	11.34	0.53	2.29e-25	Monocyte percentage of white cells;
CRC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.67	-10.16	-0.49	2.83e-21	IgG glycosylation;
CRC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg25834613	chr7:1915315	MAD1L1	-0.46	-6.67	-0.35	1.07e-10	Bipolar disorder;
CRC	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01668174	chr2:106810661	UXS1	0.46	6.44	0.33	4.25e-10	Response to antipsychotic treatment;
CRC	cis	rs720844	0.684	rs36067597	chr2:149313404	C/G	cg09247360	chr2:149335327	NA	-0.58	-6.04	-0.32	4.12e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg12856521	chr11:46389249	DGKZ	0.43	6.78	0.35	5.59e-11	Leprosy;
CRC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.89	-0.4	4.43e-14	Total body bone mineral density;
CRC	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.67	11.4	0.53	1.39e-25	Blood protein levels;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg25116269	chr2:55509523	PRDXDD1P	-0.43	-6.49	-0.34	3.24e-10	Birth weight;Height;
CRC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.6	9.61	0.47	1.98e-19	Obesity-related traits;
CRC	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg06935464	chr4:38784597	TLR10	0.57	5.72	0.3	2.44e-8	Breast cancer;
CRC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.7	10.81	0.51	1.69e-23	Corneal astigmatism;
CRC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs939584	0.935	rs10865551	chr2:641863	T/A	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs3736485	0.966	rs10220909	chr15:51762412	C/A	cg08986416	chr15:51914746	DMXL2	-0.41	-5.84	-0.31	1.27e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-10.55	-0.5	1.31e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg13073564	chr4:8508604	NA	-0.47	-6.95	-0.36	2.01e-11	Response to antineoplastic agents;
CRC	cis	rs7172809	0.897	rs907387	chr15:77828751	T/C	cg10437265	chr15:77819839	NA	-0.4	-6.75	-0.35	6.52e-11	Glucose homeostasis traits;
CRC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.72	-11.2	-0.53	6.82e-25	Menopause (age at onset);
CRC	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.58	-9.02	-0.45	1.63e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg11833968	chr6:79620685	NA	0.37	6.56	0.34	2.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.62	8.84	0.44	5.92e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.36	-5.67	-0.3	3.2e-8	Platelet distribution width;
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.76	14.32	0.62	1.69e-36	Prudent dietary pattern;
CRC	cis	rs12024301	0.557	rs12047865	chr1:183615929	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.65	-10.17	-0.49	2.68e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.49	8.88	0.44	4.54e-17	Total body bone mineral density;
CRC	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.47	5.63	0.3	3.88e-8	Lung function (FEV1/FVC);
CRC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.59e-10	Blood metabolite levels;
CRC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.01	-0.36	1.36e-11	Bipolar disorder;
CRC	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06677660	chr19:49140777	SEC1;DBP	-0.46	-5.86	-0.31	1.1e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs12936587	0.601	rs11655881	chr17:17553133	G/A	cg09796270	chr17:17721594	SREBF1	-0.45	-7.63	-0.39	2.47e-13	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.41	-6.23	-0.32	1.43e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1699337	0.538	rs66615477	chr3:12298314	G/T	cg04748988	chr3:12329223	PPARG	-0.4	-5.95	-0.31	6.91e-9	Cholesterol, total;
CRC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.69	-0.39	1.7e-13	Vitiligo;
CRC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.59	-10.26	-0.49	1.26e-21	Iron status biomarkers;
CRC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06544989	chr22:39130855	UNC84B	-0.44	-6.61	-0.34	1.56e-10	Menopause (age at onset);
CRC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.69	-11.53	-0.54	4.72e-26	Asthma;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg02683197	chr6:28174875	NA	0.63	8.49	0.42	7.22e-16	Parkinson's disease;
CRC	cis	rs990171	0.802	rs1558650	chr2:103060024	T/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.38e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.14	0.37	6.15e-12	Major depressive disorder;
CRC	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.34	12.82	0.58	8.63e-31	Granulocyte percentage of myeloid white cells;
CRC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg04166393	chr7:2884313	GNA12	0.39	6.05	0.32	3.97e-9	Height;
CRC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg04121214	chr22:50244548	NA	0.41	5.87	0.31	1.04e-8	Schizophrenia;
CRC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.65	-11.14	-0.52	1.1e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.53	-0.38	4.88e-13	QT interval;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.67	7.26	0.37	2.83e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg24308560	chr3:49941425	MST1R	-0.42	-5.93	-0.31	7.5e-9	Resting heart rate;
CRC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.35	5.83	0.31	1.3e-8	Blood metabolite levels;
CRC	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.52	-0.67	4.36e-45	Hip circumference;
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg08888203	chr3:10149979	C3orf24	0.67	9.49	0.46	4.83e-19	Alzheimer's disease;
CRC	cis	rs11030122	0.547	rs10767721	chr11:3953411	G/C	cg18678763	chr11:4115507	RRM1	-0.39	-6.61	-0.34	1.59e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.98	-0.31	5.81e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.18	0.37	4.6e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2811415	0.627	rs13316354	chr3:127751772	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.82	-11.64	-0.54	1.88e-26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.91	8.62	0.43	2.79e-16	Type 2 diabetes;
CRC	cis	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg14541582	chr5:601475	NA	-0.35	-6.98	-0.36	1.63e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg05623727	chr3:50126028	RBM5	-0.41	-6.29	-0.33	9.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg18225595	chr11:63971243	STIP1	-0.42	-6.5	-0.34	3.07e-10	Platelet count;
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.48	-0.53	6.79e-26	Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg27661571	chr11:113659931	NA	-0.95	-11.08	-0.52	1.91e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.45	-7.38	-0.38	1.27e-12	Refractive error;
CRC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.18e-35	Mean platelet volume;
CRC	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg02158880	chr13:53174818	NA	0.55	8.83	0.44	6.47e-17	Lewy body disease;
CRC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg21132104	chr15:45694354	SPATA5L1	0.42	6.06	0.32	3.76e-9	Response to fenofibrate (adiponectin levels);
CRC	trans	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.05	0.36	1.08e-11	Ulcerative colitis;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg00224911	chr4:74486142	RASSF6	-0.55	-6.51	-0.34	2.8e-10	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-7.96	-0.4	2.88e-14	Type 2 diabetes;
CRC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.44	-6.0	-0.31	5.09e-9	Gut microbiome composition (summer);
CRC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.39	7.42	0.38	1.03e-12	Ulcerative colitis;
CRC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.51	7.45	0.38	8.05e-13	Chronic sinus infection;
CRC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg14541582	chr5:601475	NA	-0.33	-6.6	-0.34	1.61e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.35	-6.09	-0.32	3.24e-9	Erythrocyte sedimentation rate;
CRC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19904058	chr10:135279010	LOC619207	-0.35	-6.78	-0.35	5.56e-11	Systemic lupus erythematosus;
CRC	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	cg04338863	chr8:33670619	NA	0.44	6.96	0.36	1.8e-11	Body mass index;
CRC	cis	rs7605827	0.897	rs11684844	chr2:15640552	T/A	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg05639522	chr1:247681581	NA	0.5	7.3	0.37	2.18e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11212617	1.000	rs2356801	chr11:108281999	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.4	0.33	5.31e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg12590608	chr7:158785262	NA	0.37	6.4	0.33	5.45e-10	Facial morphology (factor 20);
CRC	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.46	-0.42	8.64e-16	Alcohol dependence;
CRC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.86	10.19	0.49	2.18e-21	Glomerular filtration rate (creatinine);
CRC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.89e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.27	-0.79	1.67e-71	Myeloid white cell count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09916155	chr16:1728187	HN1L	0.47	6.26	0.33	1.2e-9	Anxiety disorder;
CRC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.06	10.36	0.5	5.88e-22	Diabetic retinopathy;
CRC	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.5	-0.38	5.93e-13	QT interval;
CRC	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	7.43	0.38	9.17e-13	Schizophrenia;
CRC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.52	-8.74	-0.43	1.24e-16	Dupuytren's disease;
CRC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.9	-0.31	8.87e-9	Cognitive function;
CRC	cis	rs9322817	0.691	rs9391241	chr6:105223663	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.41e-16	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	22.95	0.78	2.88e-70	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02439053	chr19:18390991	JUND	0.39	6.13	0.32	2.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.74	7.58	0.39	3.47e-13	Diabetic retinopathy;
CRC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.63	-10.27	-0.49	1.2e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.42	0.33	4.82e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.56	-7.62	-0.39	2.75e-13	Diabetic retinopathy;
CRC	cis	rs13315871	1.000	rs9849482	chr3:58422087	G/T	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	cis	rs11098699	0.769	rs11726870	chr4:124229175	A/G	cg09941581	chr4:124220074	SPATA5	0.39	5.81	0.3	1.49e-8	Mosquito bite size;
CRC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg03013999	chr17:37608204	MED1	0.48	7.35	0.38	1.59e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7546094	0.967	rs1032312	chr1:113112746	G/A	cg22162597	chr1:113214053	CAPZA1	0.43	5.94	0.31	7.2e-9	Platelet distribution width;
CRC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.47	-6.57	-0.34	1.99e-10	Multiple myeloma;
CRC	cis	rs3736485	0.966	rs8041514	chr15:51866054	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.7	-0.43	1.64e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg13491945	chr12:107078410	RFX4	0.34	5.86	0.31	1.1e-8	Heart rate;
CRC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.62e-14	Colorectal cancer;
CRC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg19635926	chr16:89946313	TCF25	0.66	6.84	0.35	3.9e-11	Interleukin-17 levels;
CRC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.58	-9.21	-0.45	3.9e-18	Intelligence (multi-trait analysis);
CRC	cis	rs17767392	0.813	rs34991781	chr14:71921576	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.42	-0.33	4.81e-10	Mitral valve prolapse;
CRC	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg13962466	chr20:25176127	ENTPD6	-0.42	-6.66	-0.34	1.16e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.16	-0.37	5.33e-12	Life satisfaction;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.6	-8.37	-0.42	1.64e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg04871131	chr7:94954202	PON1	-0.46	-5.61	-0.3	4.23e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1322512	0.959	rs2623985	chr6:152948748	T/C	cg03415253	chr6:152958462	SYNE1	-0.42	-6.43	-0.33	4.53e-10	Tonometry;
CRC	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.94	0.36	2.1e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg23229984	chr5:148520753	ABLIM3	0.48	6.64	0.34	1.33e-10	Breast cancer;
CRC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg06470822	chr6:28175283	NA	0.68	6.8	0.35	4.98e-11	Depression;
CRC	cis	rs11212617	0.967	rs227053	chr11:108226855	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.16	0.32	2.08e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2188554	0.711	rs213947	chr7:117192608	A/G	cg09181792	chr7:117119393	CFTR	0.33	6.07	0.32	3.49e-9	Esophageal adenocarcinoma;
CRC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg11833968	chr6:79620685	NA	-0.36	-6.12	-0.32	2.65e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4964805	0.913	rs7134701	chr12:104202691	C/T	cg02344784	chr12:104178138	NT5DC3	0.53	7.79	0.39	8.84e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg11843238	chr5:131593191	PDLIM4	0.41	7.79	0.39	9.14e-14	Breast cancer;
CRC	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg18551225	chr6:44695536	NA	-0.41	-5.92	-0.31	8.07e-9	Total body bone mineral density;
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg20647610	chr2:228736258	WDR69	-0.47	-6.45	-0.33	4.09e-10	Blood pressure;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg12172441	chr6:28176163	NA	0.46	6.44	0.33	4.21e-10	Parkinson's disease;
CRC	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg14003231	chr6:33640908	ITPR3	-0.49	-7.93	-0.4	3.52e-14	Height;
CRC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.61	8.51	0.42	6.45e-16	Arsenic metabolism;
CRC	cis	rs3736485	0.652	rs2054166	chr15:51974910	A/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.32	-0.33	8.73e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg03013999	chr17:37608204	MED1	-0.46	-6.95	-0.36	1.97e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	1.04	18.54	0.71	4.71e-53	Parkinson's disease;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.39	6.87	0.35	3.27e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg25019722	chr6:37503610	NA	-0.51	-9.55	-0.47	3.13e-19	Cognitive performance;
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.02	24.01	0.8	2.59e-74	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.72	0.43	1.42e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.97	-0.31	6.21e-9	Diabetic retinopathy;
CRC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg21625146	chr5:486483	SLC9A3	-0.48	-5.71	-0.3	2.55e-8	Cystic fibrosis severity;
CRC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	0.98	14.44	0.62	6.21e-37	Breast cancer;
CRC	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.36	5.73	0.3	2.29e-8	Sudden cardiac arrest;
CRC	cis	rs4711350	0.906	rs3957165	chr6:33784864	A/G	cg07979401	chr6:33739406	LEMD2	0.49	6.18	0.32	1.85e-9	Schizophrenia;
CRC	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.42	6.03	0.32	4.33e-9	Obesity-related traits;
CRC	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Depression;
CRC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.87	-0.4	5.11e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10992471	0.580	rs7852698	chr9:95396409	C/T	cg14631576	chr9:95140430	CENPP	-0.33	-5.64	-0.3	3.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.44	-7.45	-0.38	8.47e-13	Coronary artery disease;
CRC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.51	-6.86	-0.35	3.36e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.69	0.39	1.68e-13	Lung cancer in ever smokers;
CRC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07513332	chr6:167530253	CCR6	0.36	5.68	0.3	2.94e-8	Crohn's disease;
CRC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.61	-0.75	3.6e-61	Height;
CRC	cis	rs7725052	0.720	rs10073277	chr5:40488686	A/G	cg09067459	chr5:40385259	NA	0.37	5.97	0.31	6.31e-9	Pediatric autoimmune diseases;
CRC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.77	-12.7	-0.57	2.37e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg17133734	chr15:86042851	AKAP13	0.41	6.73	0.35	7.47e-11	Interstitial lung disease;
CRC	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.3	6.39	0.33	5.52e-10	Diastolic blood pressure;
CRC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	8.6	0.43	3.39e-16	Height;
CRC	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.52	6.96	0.36	1.89e-11	Total body bone mineral density;
CRC	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg05639522	chr1:247681581	NA	0.56	6.07	0.32	3.48e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	0.92	11.22	0.53	6.11e-25	Red blood cell traits;
CRC	cis	rs4664293	0.647	rs7580539	chr2:160445749	C/T	cg08347373	chr2:160653686	CD302	-0.38	-6.44	-0.33	4.12e-10	Monocyte percentage of white cells;
CRC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.67	10.42	0.5	3.7e-22	Testicular germ cell tumor;
CRC	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.96	-0.36	1.87e-11	Coronary artery disease;
CRC	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg20194872	chr6:41519635	FOXP4	0.4	5.86	0.31	1.12e-8	Prostate cancer;
CRC	cis	rs972578	0.837	rs5996246	chr22:43297421	A/T	cg01576275	chr22:43409880	NA	-0.44	-6.91	-0.36	2.48e-11	Mean platelet volume;
CRC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.76	-0.3	1.92e-8	Arsenic metabolism;
CRC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.01	0.4	1.95e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg24675056	chr1:15929824	NA	0.54	7.0	0.36	1.44e-11	Systolic blood pressure;
CRC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg21251018	chr6:28226885	NKAPL	0.63	11.77	0.54	6.06e-27	Pubertal anthropometrics;
CRC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.38	-5.76	-0.3	1.89e-8	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg16358738	chr2:241808595	AGXT	-0.41	-6.09	-0.32	3.22e-9	Urinary metabolites;
CRC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.99	14.15	0.62	7.96e-36	Gut microbiome composition (summer);
CRC	cis	rs731174	0.797	rs670692	chr1:38148124	G/A	cg06917450	chr1:38156652	C1orf109	-0.52	-7.23	-0.37	3.42e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.8	-11.5	-0.54	6e-26	Blood trace element (Zn levels);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00042657	chr1:171753628	METTL13	0.37	6.44	0.33	4.12e-10	Aortic root size;
CRC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	7.49	0.38	6.23e-13	Menarche (age at onset);
CRC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	cis	rs3087591	0.659	rs757377	chr17:29720426	G/A	cg24425628	chr17:29625626	OMG;NF1	0.74	13.38	0.59	6.49e-33	Hip circumference;
CRC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.77	-7.99	-0.4	2.25e-14	Coronary artery disease;
CRC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23378565	chr7:2036160	MAD1L1	-0.46	-6.65	-0.34	1.19e-10	Bipolar disorder;
CRC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg10589385	chr1:150898437	SETDB1	0.3	6.42	0.33	4.78e-10	Melanoma;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg22638593	chr5:131593259	PDLIM4	-0.37	-6.29	-0.33	1.03e-9	Breast cancer;
CRC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-6.35	-0.33	7.32e-10	Blood pressure (smoking interaction);
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg08798685	chr6:27730294	NA	-0.57	-6.29	-0.33	9.95e-10	Lung cancer in ever smokers;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg06074448	chr4:187884817	NA	-0.59	-10.66	-0.51	5.47e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.64	9.36	0.46	1.28e-18	Corneal astigmatism;
CRC	cis	rs4664293	0.836	rs4665118	chr2:160659449	G/T	cg08347373	chr2:160653686	CD302	-0.41	-6.31	-0.33	9.13e-10	Monocyte percentage of white cells;
CRC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-6.8	-0.35	5.02e-11	Blood metabolite levels;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg15786705	chr6:28176104	NA	0.74	9.57	0.47	2.68e-19	Parkinson's disease;
CRC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.66	7.79	0.39	8.85e-14	Gut microbiome composition (summer);
CRC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.43	-6.34	-0.33	7.38e-10	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26918957	chr8:22926800	TNFRSF10B	0.4	6.05	0.32	3.89e-9	Intelligence (multi-trait analysis);
CRC	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.42	-0.65	9.24e-41	Exhaled nitric oxide output;
CRC	trans	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg13385794	chr1:248469461	NA	0.36	6.27	0.33	1.14e-9	Common traits (Other);
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.68	-0.43	1.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.6	-8.58	-0.43	3.77e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg08501292	chr6:25962987	TRIM38	1.15	9.94	0.48	1.63e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.4	6.7	0.35	9.18e-11	Total body bone mineral density;
CRC	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-8.61	-0.43	3.04e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.64	13.18	0.59	3.67e-32	Schizophrenia;
CRC	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.03	0.45	1.46e-17	Coffee consumption (cups per day);
CRC	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.63	8.1	0.41	1.1e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.64	0.3	3.59e-8	Diabetic retinopathy;
CRC	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg14119001	chr9:139324193	INPP5E	-0.53	-7.52	-0.38	5.18e-13	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.2	0.32	1.67e-9	Diabetic kidney disease;
CRC	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg16576597	chr16:28551801	NUPR1	0.44	6.75	0.35	6.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1035144	0.546	rs2215981	chr14:81444967	G/A	cg06600135	chr14:81408086	NA	-0.53	-7.86	-0.4	5.6e-14	Male sexual orientation;
CRC	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg16540259	chr10:75572220	NDST2	0.49	7.4	0.38	1.13e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg17724175	chr1:150552817	MCL1	0.48	7.08	0.36	8.66e-12	Melanoma;
CRC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.46	6.62	0.34	1.48e-10	Emphysema distribution in smoking;
CRC	cis	rs6662572	0.686	rs59091734	chr1:46285809	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.08	0.32	3.33e-9	Blood protein levels;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg02683197	chr6:28174875	NA	0.76	9.96	0.48	1.33e-20	Parkinson's disease;
CRC	trans	rs56283067	0.887	rs7349931	chr6:44783674	C/T	cg12017007	chr17:27277572	PHF12	0.54	6.15	0.32	2.22e-9	Total body bone mineral density;
CRC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.73	-0.3	2.24e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.66	-0.39	2.16e-13	Axial length;
CRC	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-7.64	-0.39	2.41e-13	Electrocardiographic conduction measures;
CRC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg15534755	chr11:117069859	TAGLN	0.35	5.95	0.31	6.96e-9	Blood protein levels;
CRC	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.88	10.88	0.51	9.53e-24	Exhaled nitric oxide output;
CRC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.64	9.8	0.48	4.65e-20	Corneal astigmatism;
CRC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.45	7.93	0.4	3.52e-14	Childhood ear infection;
CRC	cis	rs9463078	0.683	rs911524	chr6:44747204	G/A	cg25276700	chr6:44698697	NA	0.25	5.95	0.31	6.9e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg17724175	chr1:150552817	MCL1	0.44	6.69	0.35	9.45e-11	Melanoma;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12273811	chr6:28175739	NA	0.63	8.16	0.41	7.43e-15	Parkinson's disease;
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg19046167	chr17:80928561	B3GNTL1	0.42	5.87	0.31	1.04e-8	Glycated hemoglobin levels;
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03452623	chr4:187889614	NA	-0.88	-19.12	-0.73	2.47e-55	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.42	6.09	0.32	3.23e-9	Emphysema distribution in smoking;
CRC	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	7.7	0.39	1.63e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg26727032	chr16:67993705	SLC12A4	0.55	6.41	0.33	5.01e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.51	0.54	5.33e-26	Prudent dietary pattern;
CRC	cis	rs17601876	0.814	rs3889391	chr15:51558422	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-6.16	-0.32	2.17e-9	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	trans	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg22495460	chr2:25135724	ADCY3	-0.86	-16.45	-0.67	8.68e-45	Body mass index;
CRC	cis	rs12692738	0.526	rs392050	chr2:165630793	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.52	-8.77	-0.44	9.97e-17	Huntington's disease progression;
CRC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.05	-0.68	3.89e-47	Height;
CRC	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg06606381	chr12:133084897	FBRSL1	-0.75	-5.96	-0.31	6.36e-9	Urinary tract infection frequency;
CRC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.06	-17.76	-0.7	5.67e-50	Dilated cardiomyopathy;
CRC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	5.78	0.3	1.76e-8	Diabetic retinopathy;
CRC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg00277769	chr7:97922759	BAIAP2L1	0.6	10.27	0.49	1.17e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.41	8.08	0.41	1.28e-14	Vitiligo;
CRC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-6.86	-0.35	3.45e-11	Type 2 diabetes;
CRC	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	0.9	11.08	0.52	1.8e-24	Height;
CRC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.5	9.55	0.47	3.18e-19	Alcohol dependence;
CRC	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.69	-11.3	-0.53	3.19e-25	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg25304816	chr1:36627734	MAP7D1	0.41	5.61	0.3	4.21e-8	Corneal structure;
CRC	cis	rs10450586	0.932	rs10835154	chr11:27315356	G/A	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15985400	chr11:76091674	PRKRIR	0.43	6.71	0.35	8.56e-11	Interleukin-6 levels;
CRC	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg13736514	chr6:26305472	NA	-0.44	-7.13	-0.37	6.25e-12	Educational attainment;
CRC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-13.87	-0.61	8.96e-35	Blood metabolite levels;
CRC	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-5.86	-0.31	1.12e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.83	11.32	0.53	2.68e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.91	-17.91	-0.7	1.53e-50	Intelligence (multi-trait analysis);
CRC	trans	rs12706411	0.717	rs17144531	chr7:122174453	A/C	cg04149356	chr5:158139306	EBF1	0.63	6.02	0.31	4.62e-9	Alzheimer disease and age of onset;
CRC	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.53	-7.24	-0.37	3.13e-12	Post bronchodilator FEV1;
CRC	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.72	-0.3	2.41e-8	Daytime sleep phenotypes;
CRC	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	0.93	11.28	0.53	3.74e-25	Height;
CRC	cis	rs4964805	0.594	rs11111759	chr12:104163183	T/C	cg02344784	chr12:104178138	NT5DC3	0.46	7.15	0.37	5.78e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	0.75	8.11	0.41	1.01e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.6	-9.4	-0.46	9.39e-19	Breast cancer;
CRC	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.24	-0.33	1.33e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.57	-8.6	-0.43	3.23e-16	Height;
CRC	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.35	5.95	0.31	6.89e-9	Blood metabolite ratios;
CRC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg09165964	chr15:75287851	SCAMP5	0.57	9.14	0.45	6.48e-18	Breast cancer;
CRC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.56	-7.44	-0.38	8.87e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg15848620	chr12:58087721	OS9	-0.66	-9.22	-0.45	3.74e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.18	0.37	4.6e-12	Life satisfaction;
CRC	trans	rs2303319	0.504	rs12473088	chr2:162485073	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.09	-0.32	3.1e-9	Cognitive function;
CRC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	trans	rs3001167	0.881	rs12566391	chr1:194554844	C/A	cg22004422	chr13:113740730	MCF2L	-0.58	-6.43	-0.33	4.51e-10	Obesity-related traits;
CRC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.56	8.17	0.41	6.86e-15	Uric acid levels;
CRC	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg06581033	chr10:766294	NA	-0.51	-5.79	-0.3	1.62e-8	Uric acid levels;
CRC	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg09659197	chr4:152720779	NA	0.44	8.78	0.44	9.11e-17	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14774160	chr17:4901081	INCA1;KIF1C	0.39	6.08	0.32	3.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6088813	0.925	rs4353719	chr20:33977349	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.72	-0.3	2.33e-8	Height;
CRC	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.48	6.18	0.32	1.86e-9	Exhaled nitric oxide output;
CRC	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.77	8.64	0.43	2.48e-16	Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07926482	chr16:84651521	COTL1	-0.43	-6.56	-0.34	2.04e-10	Myopia (pathological);
CRC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.4	-0.33	5.45e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9925964	0.967	rs4889620	chr16:31131174	G/A	cg03418659	chr16:31128414	MYST1	0.53	7.74	0.39	1.22e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg19041857	chr6:27730383	NA	-0.77	-6.87	-0.35	3.3e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-12.86	-0.58	6e-31	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.06e-16	Schizophrenia;
CRC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.59	-9.93	-0.48	1.65e-20	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18252515	chr7:66147081	NA	0.39	5.6	0.3	4.46e-8	Aortic root size;
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg10677697	chr7:45961126	IGFBP3	0.35	6.26	0.33	1.18e-9	Sitting height ratio;
CRC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.3	0.46	2.04e-18	Vitamin D levels;
CRC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg12639453	chr1:2035780	PRKCZ	0.31	5.74	0.3	2.2e-8	Height;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.51	-6.25	-0.33	1.26e-9	Bronchopulmonary dysplasia;
CRC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.77	-12.73	-0.57	1.84e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg18721089	chr20:30220636	NA	-0.33	-6.08	-0.32	3.37e-9	Mean corpuscular hemoglobin;
CRC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.83	15.3	0.64	2.85e-40	Metabolic syndrome;
CRC	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.42	-6.74	-0.35	7.27e-11	Corneal astigmatism;
CRC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.5	6.86	0.35	3.48e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.39	8.45	0.42	9.54e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs12230513	0.732	rs67290413	chr12:55869876	T/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.15	-0.45	6.05e-18	Contrast sensitivity;
CRC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.51	8.24	0.41	4.19e-15	Aortic root size;
CRC	cis	rs6499255	0.951	rs57565297	chr16:69723122	G/T	cg15192750	chr16:69999425	NA	0.58	7.66	0.39	2.13e-13	IgE levels;
CRC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-16.64	-0.68	1.6e-45	Height;
CRC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.51	0.67	5.05e-45	Platelet count;
CRC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.38	8.57	0.43	4.12e-16	Multiple system atrophy;
CRC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg19875535	chr5:140030758	IK	0.4	6.21	0.32	1.57e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.9e-16	Corneal astigmatism;
CRC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.79	-9.03	-0.45	1.43e-17	Skin colour saturation;
CRC	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.54	7.49	0.38	6.25e-13	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.4	-6.45	-0.34	3.9e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs847649	1.000	rs1100046	chr7:102549295	T/A	cg18108683	chr7:102477205	FBXL13	-0.57	-9.27	-0.45	2.6e-18	Morning vs. evening chronotype;
CRC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.99	12.4	0.56	2.99e-29	Vitiligo;
CRC	cis	rs4664293	0.801	rs7589771	chr2:160584132	C/T	cg08347373	chr2:160653686	CD302	-0.35	-5.61	-0.3	4.36e-8	Monocyte percentage of white cells;
CRC	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	7.16	0.37	5.4e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs17155006	0.664	rs448833	chr7:107739181	A/G	cg05962710	chr7:107745446	LAMB4	-0.43	-7.53	-0.38	4.79e-13	Pneumococcal bacteremia;
CRC	cis	rs2274471	0.540	rs10815162	chr9:5122291	G/C	cg03390472	chr9:5043263	JAK2	-0.51	-5.88	-0.31	9.97e-9	Crohn's disease;
CRC	cis	rs3789045	0.560	rs2271424	chr1:204403311	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.81	-10.92	-0.52	6.99e-24	Educational attainment (college completion);
CRC	cis	rs427941	0.667	rs201436	chr7:101733576	T/C	cg06246474	chr7:101738831	CUX1	0.45	7.1	0.36	7.51e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.96	0.4	2.76e-14	Breast cancer;
CRC	cis	rs6764363	0.527	rs13062390	chr3:280054	C/T	cg02057681	chr3:285234	CHL1	0.42	7.13	0.37	6.58e-12	Sudden cardiac arrest;
CRC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.49	-8.52	-0.43	5.93e-16	Facial morphology (factor 20);
CRC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.94	-0.36	2.08e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.34	-5.65	-0.3	3.39e-8	Childhood ear infection;
CRC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg11608241	chr8:8085544	FLJ10661	-0.39	-5.68	-0.3	2.93e-8	Mood instability;
CRC	cis	rs2882667	0.861	rs10037106	chr5:138365490	G/T	cg09476006	chr5:138032270	NA	0.44	7.31	0.37	2.05e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs17095355	1.000	rs12244557	chr10:111746142	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.52	-0.42	6.01e-16	Biliary atresia;
CRC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-6.19	-0.32	1.82e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg11875773	chr22:50468633	TTLL8	-0.7	-6.07	-0.32	3.62e-9	Cognitive function;
CRC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.62	-9.82	-0.48	3.99e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg16670446	chr17:27188758	MIR451;MIR144	-0.57	-9.54	-0.47	3.26e-19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.64	7.74	0.39	1.2e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.51	-7.97	-0.4	2.58e-14	Body mass index;
CRC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.91	13.8	0.61	1.76e-34	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs988712	0.550	rs988748	chr11:27724745	C/G	cg10635145	chr11:27742435	BDNF	0.4	6.02	0.32	4.64e-9	Obesity;
CRC	cis	rs9469913	0.675	rs6907508	chr6:34592090	A/G	cg17674042	chr6:34482479	PACSIN1	-0.74	-7.12	-0.37	6.88e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.23	0.45	3.43e-18	Coffee consumption (cups per day);
CRC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg27535305	chr1:53392650	SCP2	-0.35	-6.32	-0.33	8.43e-10	Monocyte count;
CRC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.73	-0.39	1.28e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.19	-0.37	4.47e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	cg04338863	chr8:33670619	NA	0.42	6.72	0.35	7.87e-11	Body mass index;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.74	10.51	0.5	1.85e-22	Obesity-related traits;
CRC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-5.72	-0.3	2.34e-8	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	8.32	0.42	2.35e-15	Rheumatoid arthritis;
CRC	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02972257	chr16:68554789	NA	0.63	7.34	0.37	1.74e-12	Plateletcrit;
CRC	cis	rs1223397	0.938	rs3817738	chr6:13279388	G/T	cg21538684	chr6:13274180	PHACTR1	0.5	5.75	0.3	2.04e-8	Blood pressure;
CRC	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	0.56	6.52	0.34	2.64e-10	Prostate cancer;
CRC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg15123519	chr2:136567270	LCT	0.32	6.32	0.33	8.6e-10	Mosquito bite size;
CRC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg18473234	chr19:5097819	KDM4B	-0.53	-6.61	-0.34	1.54e-10	Monocyte percentage of white cells;
CRC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg03013999	chr17:37608204	MED1	-0.47	-7.25	-0.37	2.91e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.27	-0.46	2.53e-18	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05434655	chr2:178078121	HNRNPA3	0.44	6.2	0.32	1.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.561	rs7727592	chr5:77804547	G/A	cg11547950	chr5:77652471	NA	-0.44	-6.36	-0.33	6.82e-10	Triglycerides;
CRC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.5	0.38	6.01e-13	Lung function (FEV1/FVC);
CRC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-8.22	-0.41	4.61e-15	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.77	-10.73	-0.51	3.08e-23	Blood pressure (smoking interaction);
CRC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.49	-9.47	-0.46	5.79e-19	Intelligence (multi-trait analysis);
CRC	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.43	7.69	0.39	1.67e-13	Blood metabolite ratios;
CRC	trans	rs1903068	0.927	rs12331507	chr4:56011889	A/G	cg27327334	chr3:48484191	CCDC72	-0.39	-6.73	-0.35	7.77e-11	Endometriosis;
CRC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.78	-13.06	-0.58	1.06e-31	Obesity-related traits;
CRC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg15465823	chr12:48382534	COL2A1	0.37	6.11	0.32	2.75e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg25767906	chr1:53392781	SCP2	0.45	7.22	0.37	3.55e-12	Monocyte count;
CRC	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.59	-7.35	-0.38	1.54e-12	Hair shape;
CRC	cis	rs12745968	0.589	rs7417452	chr1:93032053	A/G	cg17283838	chr1:93427260	FAM69A	-0.47	-6.3	-0.33	9.54e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.52	9.16	0.45	5.86e-18	Common traits (Other);
CRC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-6.45	-0.33	4.02e-10	Neuroticism;
CRC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.56	9.03	0.45	1.49e-17	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20795550	chr18:12702739	PSMG2;CEP76	0.45	6.24	0.33	1.37e-9	Anxiety disorder;
CRC	cis	rs9520326	1.000	rs9520326	chr13:107865442	T/C	cg07094987	chr13:107865374	FAM155A	-0.37	-5.85	-0.31	1.21e-8	Obsessive-compulsive symptoms;
CRC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.7	-12.29	-0.56	8.25e-29	Prostate cancer;
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.5	0.38	6.01e-13	Lung function (FEV1/FVC);
CRC	trans	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.63	0.34	1.36e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.86	-20.17	-0.74	1.85e-59	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.48	-0.38	6.97e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.41	-7.01	-0.36	1.36e-11	Lung cancer;
CRC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.44	6.74	0.35	7.19e-11	Monocyte count;
CRC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.63	0.65	1.46e-41	Primary sclerosing cholangitis;
CRC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.94	9.63	0.47	1.71e-19	Breast cancer;
CRC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.45	-0.34	3.94e-10	Breast cancer;
CRC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.03	16.35	0.67	2.07e-44	Cognitive function;
CRC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.52	7.09	0.36	8.43e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.39	-0.33	5.57e-10	Acylcarnitine levels;
CRC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.56	9.11	0.45	8.31e-18	Coronary artery disease;
CRC	cis	rs939584	0.735	rs13035713	chr2:633659	T/C	cg03610516	chr2:642275	NA	0.42	5.65	0.3	3.49e-8	Body mass index;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg21251018	chr6:28226885	NKAPL	0.44	6.58	0.34	1.81e-10	Parkinson's disease;
CRC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg02880119	chr16:3481970	NA	0.42	5.7	0.3	2.62e-8	Body mass index (adult);
CRC	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.51	0.65	4.16e-41	Fuchs's corneal dystrophy;
CRC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg07617317	chr6:118971624	C6orf204	0.46	5.71	0.3	2.52e-8	Diastolic blood pressure;
CRC	cis	rs10512697	0.655	rs35928407	chr5:3503392	G/C	cg19473799	chr5:3511975	NA	-0.82	-6.32	-0.33	8.41e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg11833968	chr6:79620685	NA	-0.35	-6.1	-0.32	2.98e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg26721908	chr21:47610096	LSS	0.41	6.28	0.33	1.04e-9	Testicular germ cell tumor;
CRC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg24011408	chr12:48396354	COL2A1	-0.43	-6.34	-0.33	7.49e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.38	6.19	0.32	1.74e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.05	0.32	4.05e-9	Prudent dietary pattern;
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.12	-0.37	6.88e-12	Bipolar disorder;
CRC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg12273811	chr6:28175739	NA	0.37	5.67	0.3	3.17e-8	Pubertal anthropometrics;
CRC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.65	9.99	0.48	1.08e-20	Corneal astigmatism;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.57	-10.08	-0.49	5.26e-21	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.48	-0.42	7.71e-16	Bone mineral density;
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg02569458	chr12:86230093	RASSF9	0.4	6.83	0.35	4.18e-11	Major depressive disorder;
CRC	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.03	-0.32	4.36e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs35883536	0.967	rs1984134	chr1:101109307	A/G	cg14515779	chr1:101123966	NA	-0.43	-8.3	-0.42	2.82e-15	Monocyte count;
CRC	cis	rs4664293	0.867	rs7562060	chr2:160587129	T/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.65	9.48	0.46	5.19e-19	Menopause (age at onset);
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg24046110	chr8:143859143	LYNX1	0.61	10.8	0.51	1.84e-23	Urinary tract infection frequency;
CRC	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg04611788	chr3:186434169	KNG1	0.58	8.34	0.42	2.08e-15	Blood protein levels;
CRC	cis	rs3018066	0.589	rs56053435	chr4:107028186	T/A	cg01869342	chr4:106983673	TBCK	0.43	5.74	0.3	2.14e-8	Cancer;
CRC	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.44	-6.75	-0.35	6.84e-11	Asthma;
CRC	cis	rs231513	0.954	rs231501	chr17:41972303	C/T	cg26893861	chr17:41843967	DUSP3	-0.62	-6.36	-0.33	6.9e-10	Cognitive function;
CRC	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.62	-0.39	2.64e-13	Caudate activity during reward;
CRC	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.47	6.61	0.34	1.59e-10	Diastolic blood pressure;
CRC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.61	-0.47	1.92e-19	Heart rate;
CRC	trans	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg07393940	chr7:158741817	NA	0.5	7.24	0.37	3.1e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-6.08	-0.32	3.34e-9	Alzheimer's disease (survival time);
CRC	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg19637330	chr1:19110922	NA	-0.49	-6.8	-0.35	4.86e-11	Drug-induced liver injury (nitrofurantoin);
CRC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.62	-0.3	4.04e-8	Lung cancer;
CRC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.89	0.35	2.93e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.63	6.92	0.36	2.34e-11	Height;
CRC	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-6.19	-0.32	1.75e-9	Breast cancer;
CRC	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg10437265	chr15:77819839	NA	0.63	11.19	0.52	7.68e-25	Type 2 diabetes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01246254	chr10:124134882	PLEKHA1	-0.42	-5.98	-0.31	5.7e-9	Myopia (pathological);
CRC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.59	7.71	0.39	1.48e-13	Coronary artery disease;
CRC	trans	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-6.03	-0.32	4.37e-9	Schizophrenia;
CRC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.9	-0.36	2.64e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.95	-0.4	3.07e-14	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03911494	chr16:71660463	MARVELD3	0.38	6.07	0.32	3.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg03013999	chr17:37608204	MED1	-0.47	-7.33	-0.37	1.78e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.41	8.02	0.4	1.92e-14	Renal cell carcinoma;
CRC	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg09796270	chr17:17721594	SREBF1	0.4	6.52	0.34	2.6200000000000003e-10	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs4727027	0.769	rs2140957	chr7:148758885	A/G	cg23583168	chr7:148888333	NA	-0.89	-14.78	-0.63	2.93e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.39	-5.83	-0.31	1.35e-8	Mean corpuscular volume;
CRC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.64	0.34	1.33e-10	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07025478	chr12:66563505	TMBIM4	0.46	6.56	0.34	2.11e-10	Response to antipsychotic treatment;
CRC	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg15654264	chr1:150340011	RPRD2	0.4	5.73	0.3	2.27e-8	Migraine;
CRC	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.54	5.62	0.3	3.97e-8	Coronary artery disease;
CRC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.26	0.67	4.63e-44	Chronic sinus infection;
CRC	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.5	-8.09	-0.41	1.13e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.35	5.6	0.3	4.41e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg22638593	chr5:131593259	PDLIM4	0.39	6.32	0.33	8.28e-10	Breast cancer;
CRC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.46	-6.78	-0.35	5.56e-11	Plateletcrit;
CRC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg11579758	chr4:1086637	RNF212	0.4	6.42	0.33	4.7e-10	Recombination rate (males);
CRC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.68	9.96	0.48	1.33e-20	Total body bone mineral density;
CRC	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.48	6.18	0.32	1.86e-9	Exhaled nitric oxide output;
CRC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.26	-0.37	2.76e-12	Morning vs. evening chronotype;
CRC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	11.93	0.55	1.7e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg00261534	chr10:3826854	KLF6	-0.43	-6.33	-0.33	7.95e-10	Daytime sleep phenotypes;
CRC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg01472538	chr16:58549086	SETD6	1.12	7.38	0.38	1.28e-12	Schizophrenia;
CRC	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg06307176	chr5:131281290	NA	0.42	6.36	0.33	6.61e-10	Life satisfaction;
CRC	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg09127314	chr1:152161683	NA	-0.49	-5.65	-0.3	3.45e-8	Atopic dermatitis;
CRC	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.54	7.69	0.39	1.75e-13	Testicular germ cell tumor;
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-8.75	-0.43	1.12e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg20936604	chr3:58311152	NA	-0.79	-7.42	-0.38	1e-12	Cholesterol, total;
CRC	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.43	6.5	0.34	3.01e-10	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22947007	chr19:12886204	HOOK2	0.48	6.79	0.35	5.09e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03039399	chr16:3930658	CREBBP	0.39	5.99	0.31	5.45e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.93	0.36	2.16e-11	Retinal vascular caliber;
CRC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.86	14.77	0.63	3.09e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg08807892	chr2:162101083	NA	0.46	6.7	0.35	9e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.56	-0.34	2.13e-10	Lung cancer;
CRC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.27	-0.46	2.46e-18	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07869135	chr8:123794843	ZHX2	0.46	6.08	0.32	3.25e-9	Thyroid stimulating hormone;
CRC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.69	11.81	0.55	4.62e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.68	-8.95	-0.44	2.72e-17	Platelet count;
CRC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.53	7.3	0.37	2.12e-12	Height;
CRC	cis	rs7827545	0.545	rs16905172	chr8:135556373	A/G	cg17885191	chr8:135476712	NA	0.64	7.85	0.4	6.08e-14	Hypertension (SNP x SNP interaction);
CRC	cis	rs1572438	1.000	rs9328455	chr6:864095	C/T	cg21062780	chr6:887772	NA	-0.39	-5.96	-0.31	6.47e-9	Aging;
CRC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg23996704	chr18:44553084	KATNAL2	0.32	6.4	0.33	5.31e-10	Educational attainment;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.64	7.32	0.37	1.94e-12	Vitiligo;
CRC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07636037	chr3:49044803	WDR6	-0.63	-7.47	-0.38	7.16e-13	Menarche (age at onset);
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.97	-0.4	2.56e-14	Electroencephalogram traits;
CRC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.62	7.4	0.38	1.18e-12	Cleft lip with or without cleft palate;
CRC	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg07972458	chr1:204535000	NA	-0.36	-5.74	-0.3	2.11e-8	Schizophrenia;
CRC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.41	-0.42	1.23e-15	Monocyte percentage of white cells;
CRC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg09998033	chr7:158218633	PTPRN2	0.52	7.29	0.37	2.29e-12	Obesity-related traits;
CRC	cis	rs16924133	0.793	rs16923830	chr11:33136437	T/C	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg04362960	chr10:104952993	NT5C2	-0.43	-6.02	-0.32	4.55e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg04969067	chr8:143858791	LYNX1	-0.36	-6.07	-0.32	3.58e-9	Urinary tract infection frequency;
CRC	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg26816564	chr1:7831052	VAMP3	0.53	6.38	0.33	5.93e-10	Inflammatory bowel disease;
CRC	trans	rs12699921	0.632	rs2691615	chr7:17887180	C/G	cg15753394	chr6:17282781	RBM24	-0.36	-6.12	-0.32	2.69e-9	Fibrinogen levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12713142	chr12:57081325	PTGES3	0.48	6.83	0.35	4.02e-11	Response to antipsychotic treatment;
CRC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.79	-13.81	-0.61	1.52e-34	Breast cancer;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg16606324	chr3:10149918	C3orf24	0.69	9.75	0.47	6.97e-20	Alzheimer's disease;
CRC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.49	-8.97	-0.44	2.25e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-0.6	-5.9	-0.31	9.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	5.75	0.3	1.99e-8	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.42	7.04	0.36	1.15e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.83	-9.86	-0.48	2.95e-20	Initial pursuit acceleration;
CRC	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-6.49	-0.34	3.21e-10	Neutrophil percentage of white cells;
CRC	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg16558177	chr4:4109446	NA	-0.47	-6.04	-0.32	4.22e-9	Blood pressure (smoking interaction);
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg21251018	chr6:28226885	NKAPL	0.51	7.86	0.4	5.51e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.72	-11.17	-0.52	9.27e-25	Tonsillectomy;
CRC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-16.5	-0.67	5.24e-45	Height;
CRC	cis	rs9292777	0.901	rs6878213	chr5:40433576	C/T	cg09067459	chr5:40385259	NA	0.51	8.87	0.44	4.77e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.53	7.16	0.37	5.38e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg20092199	chr4:1342459	KIAA1530	0.34	5.78	0.3	1.74e-8	Obesity-related traits;
CRC	trans	rs941898	0.574	rs8006662	chr14:100577890	C/T	cg10265472	chr16:20753215	THUMPD1	0.68	6.13	0.32	2.49e-9	White matter hyperintensity burden;
CRC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.44	5.79	0.3	1.65e-8	Cognitive ability;
CRC	cis	rs55702914	0.935	rs17405525	chr2:198214183	C/G	cg10820045	chr2:198174542	NA	-0.35	-6.23	-0.32	1.43e-9	Major depression and alcohol dependence;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.84	15.08	0.64	1.91e-39	Lewy body disease;
CRC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.86	0.31	1.15e-8	Hemoglobin concentration;
CRC	cis	rs7605827	0.897	rs7567750	chr2:15690412	C/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.63	10.5	0.5	1.89e-22	Vitiligo;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20092199	chr4:1342459	KIAA1530	0.34	5.9	0.31	8.88e-9	Obesity-related traits;
CRC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg03678062	chr6:149772716	ZC3H12D	0.34	6.05	0.32	4e-9	Dupuytren's disease;
CRC	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg04662943	chr10:102668895	NA	0.59	7.21	0.37	3.94e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12813709	chr11:576467	PHRF1;LOC143666	-0.39	-6.02	-0.31	4.78e-9	Myopia (pathological);
CRC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg19046167	chr17:80928561	B3GNTL1	0.45	6.99	0.36	1.58e-11	Breast cancer;
CRC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.3	-0.56	7.15e-29	Ulcerative colitis;
CRC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.36	-0.38	1.46e-12	Mean corpuscular volume;
CRC	trans	rs10090774	0.965	rs4246123	chr8:141775168	C/A	cg15523980	chr1:234136308	SLC35F3	0.4	5.97	0.31	6.02e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg03623178	chr6:28175578	NA	0.88	8.56	0.43	4.34e-16	Depression;
CRC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-8.61	-0.43	3.07e-16	Homoarginine levels;
CRC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs73206853	0.619	rs112148402	chr12:111171493	T/C	cg12870014	chr12:110450643	ANKRD13A	0.76	7.9	0.4	4.34e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.61	10.1	0.49	4.57e-21	Obesity-related traits;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg03623178	chr6:28175578	NA	-0.78	-10.39	-0.5	4.59e-22	Parkinson's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06530742	chr19:41223047	ITPKC;ADCK4	0.42	6.56	0.34	2.15e-10	Obesity-related traits;
CRC	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.28	-0.46	2.4e-18	Prevalent atrial fibrillation;
CRC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.83	0.44	6.42e-17	Schizophrenia;
CRC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.46	-6.84	-0.35	3.94e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg12927641	chr6:109611667	NA	0.33	5.69	0.3	2.77e-8	Reticulocyte fraction of red cells;
CRC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.74	10.48	0.5	2.32e-22	Cognitive function;
CRC	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.28e-36	Hypertriglyceridemia;
CRC	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07417863	chr1:120396167	NA	-0.4	-6.47	-0.34	3.53e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs35883536	0.967	rs4991930	chr1:101122755	T/C	cg14515779	chr1:101123966	NA	-0.43	-8.29	-0.42	2.84e-15	Monocyte count;
CRC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.57	-8.95	-0.44	2.69e-17	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17465063	chr10:111985564	MXI1	0.44	6.93	0.36	2.22e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.53	8.91	0.44	3.47e-17	Systemic lupus erythematosus;
CRC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.69	10.97	0.52	4.66e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11212617	1.000	rs11212619	chr11:108289167	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.41	6.08	0.32	3.34e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg11907262	chr19:34310911	NA	0.43	6.25	0.33	1.26e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.83	-0.35	4.04e-11	HDL cholesterol;
CRC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.8	-10.03	-0.48	7.97e-21	Body mass index;
CRC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.48	6.49	0.34	3.23e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.65	-9.23	-0.45	3.31e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4728142	0.604	rs10954215	chr7:128645513	T/C	cg06630958	chr7:128577819	IRF5	-0.35	-5.73	-0.3	2.26e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.58	-9.92	-0.48	1.88e-20	Calcium levels;
CRC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg12365402	chr11:9010492	NRIP3	0.47	7.75	0.39	1.18e-13	Hemoglobin concentration;
CRC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.48	7.05	0.36	1.06e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.34	0.33	7.67e-10	Rheumatoid arthritis;
CRC	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.7	-0.47	9.73e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.74	-12.84	-0.58	7.27e-31	Body mass index;
CRC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.51	-0.38	5.71e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg24375607	chr4:120327624	NA	0.44	6.83	0.35	4.17e-11	Corneal astigmatism;
CRC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg27532560	chr4:187881888	NA	-0.55	-9.97	-0.48	1.28e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.77	12.05	0.55	6.12e-28	Body mass index;
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.42	-9.22	-0.45	3.61e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs910187	0.641	rs3818011	chr20:45816566	A/G	cg27589058	chr20:45804311	EYA2	-0.39	-7.51	-0.38	5.63e-13	Migraine;
CRC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg11212589	chr17:38028394	ZPBP2	0.47	8.83	0.44	6.39e-17	Self-reported allergy;
CRC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.46	-0.34	3.81e-10	Coronary artery disease;
CRC	trans	rs33794	0.577	rs245214	chr3:45241622	C/G	cg00688460	chr12:48922396	NA	0.27	5.97	0.31	6.06e-9	Lung function (forced expiratory volume in 1 second);
CRC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg08885800	chr1:201084119	NA	0.49	9.02	0.45	1.55e-17	Permanent tooth development;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.54	9.71	0.47	9.39e-20	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14022721	chr22:25507536	KIAA1671	0.45	6.61	0.34	1.52e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg00343986	chr7:65444356	GUSB	0.53	7.66	0.39	2.12e-13	Aortic root size;
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.71	8.6	0.43	3.27e-16	Body mass index;
CRC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.46	-8.16	-0.41	7.06e-15	Systemic lupus erythematosus;
CRC	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.74	13.25	0.59	2.05e-32	Inhibitory control;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02895995	chr19:7554069	PEX11G	0.47	6.71	0.35	8.29e-11	Response to antipsychotic treatment;
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	trans	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg18335740	chr13:41363409	SLC25A15	0.46	7.18	0.37	4.61e-12	Lewy body disease;
CRC	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.57	8.05	0.41	1.53e-14	Plateletcrit;
CRC	cis	rs61160187	0.582	rs12655209	chr5:60306052	C/T	cg16298547	chr5:60138761	ELOVL7	0.27	5.83	0.31	1.31e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.86	0.31	1.11e-8	Tonsillectomy;
CRC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg08314208	chr16:67682810	RLTPR	-0.63	-6.75	-0.35	6.58e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.42	6.9	0.36	2.61e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg01629716	chr15:45996671	NA	0.41	8.51	0.42	6.27e-16	Waist circumference;Weight;
CRC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10512697	0.655	rs13157404	chr5:3473854	C/T	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-0.61	-6.08	-0.32	3.32e-9	Lung cancer;
CRC	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.49	6.88	0.35	3.07e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9635542	0.833	rs73522915	chr16:5007440	T/C	cg06510647	chr16:5006106	NA	-0.61	-6.67	-0.34	1.1e-10	Lung cancer (asbestos exposure interaction);Cancer;
CRC	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15021585	chr13:21099875	CRYL1	0.44	6.35	0.33	7.01e-10	Anxiety disorder;
CRC	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg00938859	chr5:1591904	SDHAP3	0.69	7.58	0.39	3.49e-13	Breast cancer;
CRC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.13	-0.32	2.55e-9	Life satisfaction;
CRC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	5.82	0.31	1.38e-8	Obesity-related traits;
CRC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	ch.11.42038R	chr11:967971	AP2A2	0.59	10.18	0.49	2.44e-21	Alzheimer's disease (late onset);
CRC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.48	6.06	0.32	3.66e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.83	0.35	4.08e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg15226275	chr6:116381976	FRK	0.3	7.85	0.4	5.89e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs3736485	0.934	rs7170330	chr15:51859313	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-5.92	-0.31	7.91e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.92	-0.44	3.39e-17	Bipolar disorder;
CRC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.27	-0.37	2.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg10517650	chr3:113235015	CCDC52	-0.38	-6.08	-0.32	3.42e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg12573674	chr2:1569213	NA	0.74	7.66	0.39	2.17e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.7	0.39	1.56e-13	Obesity-related traits;
CRC	cis	rs9379832	1	rs9379832	chr6:26186200	A/G	cg00631329	chr6:26305371	NA	-0.48	-7.48	-0.38	6.82e-13	Birth weight;
CRC	cis	rs860295	0.702	rs12081067	chr1:155358982	A/G	cg02153340	chr1:155202674	NA	-0.57	-6.77	-0.35	5.96e-11	Body mass index;
CRC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17554472	chr22:41940697	POLR3H	0.54	5.72	0.3	2.44e-8	Vitiligo;
CRC	cis	rs7394190	0.748	rs4746147	chr10:75527708	A/G	cg07699608	chr10:75541558	CHCHD1	0.6	6.34	0.33	7.42e-10	Incident atrial fibrillation;
CRC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg01843034	chr6:37503916	NA	-0.43	-8.16	-0.41	7.32e-15	Cognitive performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11164639	chr15:91192950	NA	0.39	6.34	0.33	7.63e-10	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25375453	chr3:14219857	LSM3;XPC	0.44	6.3	0.33	9.52e-10	Anxiety disorder;
CRC	trans	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg02033258	chr5:131593261	PDLIM4	0.49	8.67	0.43	1.97e-16	Acylcarnitine levels;
CRC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	12.04	0.55	6.54e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg08992911	chr2:238395768	MLPH	0.59	6.11	0.32	2.82e-9	Prostate cancer;
CRC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.66	6.47	0.34	3.48e-10	Plasma clusterin levels;
CRC	cis	rs73206853	0.764	rs16940935	chr12:111107470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.86	9.77	0.47	5.65e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.29	0.37	2.33e-12	Testicular germ cell tumor;
CRC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.27	0.33	1.12e-9	Aortic root size;
CRC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg05861140	chr6:150128134	PCMT1	-0.35	-5.74	-0.3	2.1e-8	Lung cancer;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Parkinson's disease;
CRC	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg25649188	chr17:73499917	CASKIN2	0.63	6.35	0.33	7.18e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06470822	chr6:28175283	NA	-0.66	-5.61	-0.3	4.35e-8	Depression;
CRC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.25	-0.33	1.27e-9	Aortic root size;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg06470822	chr6:28175283	NA	0.76	10.12	0.49	3.9e-21	Parkinson's disease;
CRC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg17401720	chr7:158221031	PTPRN2	-0.39	-6.43	-0.33	4.57e-10	Obesity-related traits;
CRC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.45	-5.95	-0.31	6.89e-9	Menarche (age at onset);
CRC	cis	rs7212590	0.655	rs56198517	chr17:57976582	G/T	cg10252138	chr17:58120427	NA	-0.6	-6.09	-0.32	3.21e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg19500275	chr17:80737654	TBCD	-0.4	-6.03	-0.32	4.46e-9	Glycated hemoglobin levels;
CRC	cis	rs6546324	0.559	rs11126134	chr2:67781064	G/T	cg15745817	chr2:67799979	NA	0.48	7.84	0.4	6.53e-14	Endometriosis;
CRC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.65	0.47	1.44e-19	Cognitive test performance;
CRC	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg22256960	chr15:77711686	NA	0.6	7.17	0.37	5.13e-12	Type 2 diabetes;
CRC	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.52	-0.38	5.11e-13	Menarche (age at onset);
CRC	cis	rs10046574	0.831	rs10278289	chr7:135089662	A/G	cg27474649	chr7:135195673	CNOT4	0.63	5.67	0.3	3.07e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.61	-9.39	-0.46	1.06e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg22153745	chr1:153894579	GATAD2B	0.52	7.31	0.37	2.04e-12	Total cholesterol levels;
CRC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-12.62	-0.57	4.92e-30	Cognitive function;
CRC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.8	-0.35	4.86e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.36	-5.71	-0.3	2.53e-8	Endometrial cancer;
CRC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.06	13.39	0.59	6.38e-33	Vitiligo;
CRC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg21466736	chr12:48725269	NA	-0.48	-7.35	-0.38	1.54e-12	Glycated hemoglobin levels;
CRC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.48	-7.68	-0.39	1.87e-13	Coronary artery disease;
CRC	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.72	7.36	0.38	1.52e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.44	-6.66	-0.34	1.17e-10	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04056875	chr12:50101363	FMNL3	0.43	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.67	0.43	2.01e-16	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05134831	chr1:36621785	MAP7D1	0.36	6.34	0.33	7.66e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.6	10.07	0.49	5.87e-21	Prudent dietary pattern;
CRC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg10760299	chr15:45669010	GATM	0.44	6.76	0.35	6.16e-11	Homoarginine levels;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg12172441	chr6:28176163	NA	0.45	6.55	0.34	2.25e-10	Pubertal anthropometrics;
CRC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.67	-9.43	-0.46	7.54e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.45	-6.28	-0.33	1.07e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs12024301	0.557	rs78503512	chr1:183643289	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.04	-11.6	-0.54	2.54e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs929596	0.564	rs2741030	chr2:234536152	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.7	-0.3	2.62e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg00166722	chr3:10149974	C3orf24	0.43	6.26	0.33	1.22e-9	Alzheimer's disease;
CRC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg13010199	chr12:38710504	ALG10B	0.46	6.57	0.34	2.02e-10	Morning vs. evening chronotype;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg03160526	chr17:80928410	B3GNTL1	0.57	7.43	0.38	9.46e-13	Glycated hemoglobin levels;
CRC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg23996704	chr18:44553084	KATNAL2	-0.39	-7.69	-0.39	1.7e-13	Personality dimensions;
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg19223190	chr17:80058835	NA	0.39	6.32	0.33	8.75e-10	Life satisfaction;
CRC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.72	10.03	0.48	8.03e-21	Breast cancer;
CRC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.99	0.44	1.94e-17	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-6.92	-0.36	2.36e-11	Blood metabolite levels;
CRC	cis	rs2742417	1.000	rs1877934	chr3:45753295	G/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg13844804	chr7:814759	HEATR2	0.65	8.49	0.42	7.41e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg14828511	chr1:107599125	PRMT6	-0.57	-7.85	-0.4	5.73e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2811415	0.597	rs11715883	chr3:127726465	C/T	cg13719885	chr3:127795394	NA	-0.38	-5.75	-0.3	2.01e-8	Lung function (FEV1/FVC);
CRC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.22	-6.14	-0.32	2.37e-9	Urinary metabolites;
CRC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg26587870	chr6:27730563	NA	-0.6	-5.98	-0.31	5.78e-9	Breast cancer;
CRC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.83	15.13	0.64	1.31e-39	Metabolic syndrome;
CRC	cis	rs7605827	0.930	rs12692272	chr2:15680801	C/T	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg10298567	chr3:47292165	KIF9	-0.41	-6.77	-0.35	5.84e-11	Colorectal cancer;
CRC	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg06484146	chr7:12443880	VWDE	-0.64	-6.53	-0.34	2.42e-10	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.5e-9	Prudent dietary pattern;
CRC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.64	-0.47	1.51e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs2257205	0.667	rs7217890	chr17:56731265	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.78	-0.3	1.76e-8	Pancreatic cancer;
CRC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg17031739	chr1:67600172	NA	0.45	7.18	0.37	4.63e-12	Psoriasis;
CRC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg24562669	chr7:97807699	LMTK2	0.78	17.37	0.69	2.11e-48	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15785704	chr17:30669010	C17orf75	0.43	6.4	0.33	5.38e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9928842	0.882	rs4737	chr16:75238103	A/G	cg08657710	chr16:75258780	CTRB1	0.45	6.2	0.32	1.73e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg12927641	chr6:109611667	NA	-0.38	-6.62	-0.34	1.42e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-7.2	-0.37	4.14e-12	Hepatocellular carcinoma;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04053862	chr2:179345017	MIR548N;PLEKHA3	0.49	6.61	0.34	1.58e-10	Survival in pancreatic cancer;
CRC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.61	9.75	0.47	6.69e-20	Aortic root size;
CRC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.61	-11.28	-0.53	3.74e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.71	8.93	0.44	3.12e-17	Behavioural disinhibition (generation interaction);
CRC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.6	-9.36	-0.46	1.25e-18	Aortic root size;
CRC	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.0	-0.31	5.3300000000000004e-09	Subjective well-being;
CRC	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg12560992	chr17:57184187	TRIM37	0.53	6.05	0.32	3.89e-9	Vitamin D levels;
CRC	cis	rs427943	0.778	rs8134789	chr21:46619558	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.44	-6.04	-0.32	4.06e-9	Body mass index;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg25164649	chr6:28176230	NA	0.65	8.57	0.43	4.18e-16	Parkinson's disease;
CRC	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.66	-8.83	-0.44	6.22e-17	Facial morphology (factor 19);
CRC	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg23425280	chr12:56401806	NA	0.47	5.72	0.3	2.44e-8	Cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23090870	chr19:38755753	SPINT2	0.4	6.41	0.33	4.96e-10	Anxiety disorder;
CRC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.48	5.99	0.31	5.5e-9	Recombination rate (females);
CRC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.43	5.61	0.3	4.39e-8	Coronary artery disease;
CRC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg02869364	chr7:1081709	C7orf50	-0.37	-5.86	-0.31	1.13e-8	Longevity;Endometriosis;
CRC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-8.12	-0.41	9.51e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.51	-0.57	1.18e-29	Idiopathic membranous nephropathy;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg11843238	chr5:131593191	PDLIM4	0.34	6.43	0.33	4.54e-10	Blood metabolite levels;
CRC	trans	rs9820070	1.000	rs11721263	chr3:187688435	T/C	cg09907068	chr2:197159060	HECW2	0.38	6.37	0.33	6.23e-10	Hematological and biochemical traits;
CRC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	10.34	0.5	6.86e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.51	7.13	0.37	6.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.5	7.42	0.38	1e-12	Body mass index;
CRC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg24375607	chr4:120327624	NA	0.48	7.56	0.38	4e-13	Corneal astigmatism;
CRC	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg23018236	chr17:30244563	NA	-0.58	-5.94	-0.31	7.07e-9	Height;
CRC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.61	11.56	0.54	3.48e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.61	10.09	0.49	4.83e-21	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25377726	chr2:45838438	SRBD1	0.43	6.21	0.32	1.58e-9	Response to antipsychotic treatment;
CRC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.75e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.89	-0.31	9.55e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg20291162	chr17:40259547	DHX58	-0.54	-7.85	-0.4	6.06e-14	Fibrinogen levels;
CRC	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-13.08	-0.58	9.14e-32	Ulcerative colitis;
CRC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.42	7.75	0.39	1.15e-13	Intelligence (multi-trait analysis);
CRC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.56	-8.68	-0.43	1.93e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.5	10.11	0.49	4.27e-21	Ulcerative colitis;
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg15147215	chr3:52552868	STAB1	-0.61	-9.96	-0.48	1.38e-20	Bipolar disorder;
CRC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.72	11.05	0.52	2.45e-24	Corneal astigmatism;
CRC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.11	-0.49	4.18e-21	Monocyte count;
CRC	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg23425280	chr12:56401806	NA	0.44	5.61	0.3	4.19e-8	Cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12876261	chr7:56119223	PSPH;CCT6A	-0.4	-6.01	-0.31	4.97e-9	Myopia (pathological);
CRC	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.63	10.43	0.5	3.47e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.43	6.85	0.35	3.55e-11	High light scatter reticulocyte count;
CRC	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg25876840	chr17:41920477	NA	0.37	5.79	0.3	1.63e-8	Triglycerides;
CRC	cis	rs4728302	0.869	rs958404	chr7:133597186	G/T	cg10665199	chr7:133106180	EXOC4	-0.38	-5.76	-0.3	1.9e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7264396	0.887	rs6060438	chr20:34077403	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.56	-0.34	2.11e-10	Total cholesterol levels;
CRC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg05043794	chr9:111880884	C9orf5	-0.32	-5.97	-0.31	6.04e-9	Menarche (age at onset);
CRC	cis	rs6504622	0.537	rs189899	chr17:45000529	G/C	cg16759221	chr17:45003025	GOSR2	-0.68	-11.04	-0.52	2.62e-24	Orofacial clefts;
CRC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.49	6.23	0.32	1.42e-9	Recombination rate (females);
CRC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.4	5.62	0.3	4.1e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg26958806	chr6:27640298	NA	0.93	6.56	0.34	2.11e-10	Depression;
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg27432699	chr2:27873401	GPN1	-0.62	-9.48	-0.46	5.21e-19	Menopause (age at onset);
CRC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg10130564	chr11:117069849	TAGLN	0.37	7.03	0.36	1.21e-11	Blood protein levels;
CRC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg20203395	chr5:56204925	C5orf35	0.54	7.36	0.38	1.52e-12	Initial pursuit acceleration;
CRC	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg24505167	chr7:1915268	MAD1L1	-0.47	-7.2	-0.37	4.23e-12	Bipolar disorder;
CRC	cis	rs243505	0.767	rs243518	chr7:148425028	A/G	cg09806900	chr7:148480153	CUL1	-0.46	-5.89	-0.31	9.61e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.55	-6.3	-0.33	9.4e-10	Post bronchodilator FEV1;
CRC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11226328	chr1:29213367	EPB41	-0.47	-6.13	-0.32	2.48e-9	Diisocyanate-induced asthma;
CRC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.59	6.96	0.36	1.81e-11	Type 2 diabetes nephropathy;
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.04	-0.32	4.15e-9	Total body bone mineral density;
CRC	cis	rs9491140	0.539	rs980657	chr6:124690330	C/T	cg22366943	chr6:124882293	NKAIN2	0.53	8.05	0.41	1.56e-14	Neuroticism;
CRC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg10130564	chr11:117069849	TAGLN	0.38	7.03	0.36	1.22e-11	Blood protein levels;
CRC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.67	9.77	0.47	5.72e-20	Menopause (age at onset);
CRC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.68	11.08	0.52	1.92e-24	Body mass index;
CRC	cis	rs672059	0.967	rs657901	chr1:183163411	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.48	6.95	0.36	1.95e-11	Hypertriglyceridemia;
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg27432699	chr2:27873401	GPN1	-0.57	-8.78	-0.44	8.88e-17	Total body bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12500284	chr19:16683309	SLC35E1	0.47	6.69	0.35	9.68e-11	Anxiety disorder;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.6	-10.96	-0.52	4.77e-24	Tonsillectomy;
CRC	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg27534772	chr1:16042836	PLEKHM2	0.45	7.5	0.38	6.07e-13	Systolic blood pressure;
CRC	cis	rs56146971	0.714	rs79810056	chr14:91852929	A/G	cg16433844	chr14:91963127	SMEK1	-0.52	-6.11	-0.32	2.75e-9	Alzheimer disease and age of onset;
CRC	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.94e-40	Hypertriglyceridemia;
CRC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.45	-6.41	-0.33	4.96e-10	Platelet distribution width;
CRC	trans	rs3851050	1.000	rs3851050	chr10:81882370	A/G	cg16857335	chr19:47633940	SAE1	0.42	6.03	0.32	4.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg14631576	chr9:95140430	CENPP	-0.41	-7.34	-0.37	1.73e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20255042	chr10:75757586	VCL	0.38	6.0	0.31	5.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.45	-0.34	3.91e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg12458913	chr13:53173898	NA	0.42	6.15	0.32	2.26e-9	Lewy body disease;
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.88	11.52	0.54	4.97e-26	IgG glycosylation;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg25164649	chr6:28176230	NA	0.57	5.9	0.31	9.27e-9	Lung cancer in ever smokers;
CRC	cis	rs28655083	0.509	rs664408	chr16:77104820	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.59	0.34	1.76e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03195600	chr16:11350371	SOCS1	0.45	7.23	0.37	3.32e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.82	0.31	1.4e-8	Corneal astigmatism;
CRC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.68	0.43	1.85e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	6.24	0.33	1.34e-9	Menopause (age at onset);
CRC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.38	-0.56	3.61e-29	Type 2 diabetes;
CRC	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg23254163	chr1:152506842	NA	0.45	9.15	0.45	6.31e-18	Hair morphology;
CRC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	5.05e-15	Red blood cell count;
CRC	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.49	6.41	0.33	5.1e-10	Neuroticism;
CRC	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.46	9.63	0.47	1.74e-19	Height;
CRC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13198984	chr17:80129470	CCDC57	-0.46	-7.97	-0.4	2.65e-14	Life satisfaction;
CRC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.57	-8.65	-0.43	2.39e-16	Huntington's disease progression;
CRC	cis	rs6460942	0.749	rs79221452	chr7:12202897	T/C	cg06484146	chr7:12443880	VWDE	-0.62	-5.86	-0.31	1.12e-8	Coronary artery disease;
CRC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.5	7.6	0.39	3.11e-13	Blood metabolite levels;
CRC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.87	-0.35	3.15e-11	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14361641	chr2:70056642	GMCL1	0.48	6.26	0.33	1.2e-9	Thyroid stimulating hormone;
CRC	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg01475377	chr6:109611718	NA	-0.36	-5.94	-0.31	7.07e-9	Reticulocyte fraction of red cells;
CRC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.7	11.72	0.54	9.56e-27	Alzheimer's disease (late onset);
CRC	cis	rs8014671	0.553	rs34273029	chr14:70892225	C/T	cg25576086	chr14:70833871	SYNJ2BP	-0.36	-6.06	-0.32	3.63e-9	Prostate cancer;
CRC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-7.64	-0.39	2.37e-13	Testicular germ cell tumor;
CRC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg19622623	chr12:86230825	RASSF9	0.38	5.81	0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-6.91	-0.36	2.55e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.33	-6.87	-0.35	3.29e-11	Intelligence (multi-trait analysis);
CRC	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	8.9e-20	Hair morphology;
CRC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-8.79	-0.44	8.55e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02624704	chr1:173446429	PRDX6	0.37	6.65	0.34	1.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.48	-6.58	-0.34	1.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.61	-7.77	-0.39	1.03e-13	Schizophrenia;
CRC	cis	rs7605827	0.930	rs4668910	chr2:15608013	C/A	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	9.33	0.46	1.56e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg18758796	chr5:131593413	PDLIM4	0.4	6.48	0.34	3.43e-10	Breast cancer;
CRC	cis	rs62408225	1.000	rs2089126	chr6:90970212	A/G	cg06866423	chr6:90926672	BACH2	0.48	7.94	0.4	3.23e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.0	12.25	0.56	1.08e-28	Uric acid levels;
CRC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Bladder cancer;
CRC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg01766193	chr7:157202248	DNAJB6	-0.35	-5.81	-0.31	1.48e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.51	-0.62	3.28e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg02033258	chr5:131593261	PDLIM4	-0.5	-9.05	-0.45	1.24e-17	Acylcarnitine levels;
CRC	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.73	-11.98	-0.55	1.13e-27	Bipolar disorder;
CRC	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-10.07	-0.49	5.93e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.81	-13.13	-0.59	5.7e-32	Bipolar disorder;
CRC	cis	rs8105895	0.935	rs10406551	chr19:22244520	T/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs4731207	0.562	rs6466991	chr7:124691966	T/G	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.59	8.41	0.42	1.28e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg20515095	chr8:8998461	PPP1R3B	-0.46	-5.79	-0.3	1.64e-8	Myopia (pathological);
CRC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.52	-7.2	-0.37	4.23e-12	Tuberculosis;
CRC	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	trans	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.45	-6.98	-0.36	1.59e-11	Height;
CRC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs12936587	0.595	rs9911672	chr17:17528670	C/T	cg09796270	chr17:17721594	SREBF1	0.39	5.95	0.31	6.86e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.39	-0.42	1.42e-15	Height;
CRC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.7	9.94	0.48	1.62e-20	Corneal astigmatism;
CRC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg04731861	chr2:219085781	ARPC2	0.34	6.94	0.36	2.13e-11	Colorectal cancer;
CRC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	10.56	0.5	1.21e-22	Prudent dietary pattern;
CRC	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.55	-8.31	-0.42	2.52e-15	Monobrow;
CRC	cis	rs1007738	0.597	rs10838635	chr11:46945227	G/A	cg19486271	chr11:47235900	DDB2	-0.45	-6.79	-0.35	5.24e-11	Bone mineral density (hip);
CRC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg19678392	chr7:94953810	PON1	-0.51	-6.97	-0.36	1.74e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.59	9.62	0.47	1.77e-19	Systemic lupus erythematosus;
CRC	cis	rs728616	0.681	rs55838345	chr10:82085120	G/C	cg05935833	chr10:81318306	SFTPA2	-0.57	-7.0	-0.36	1.48e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	1.02	20.32	0.75	4.57e-60	Headache;
CRC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg10570241	chr7:158785291	NA	0.52	9.25	0.45	2.82e-18	Facial morphology (factor 20);
CRC	cis	rs12318506	0.826	rs11180453	chr12:75694006	T/C	cg04728562	chr12:75699417	CAPS2	-0.85	-6.67	-0.35	1.1e-10	Coronary artery calcification;
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.04	-0.32	4.24e-9	Total body bone mineral density;
CRC	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.63	-9.66	-0.47	1.37e-19	Hepatocellular carcinoma;
CRC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	8.08	0.41	1.24e-14	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.5	-8.25	-0.41	3.86e-15	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09192333	chr22:38142150	TRIOBP	0.38	6.62	0.34	1.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg25019722	chr6:37503610	NA	-0.5	-9.29	-0.46	2.17e-18	Cognitive performance;
CRC	trans	rs587242	1.000	rs509588	chr1:96891552	G/C	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	6.55	0.34	2.21e-10	Mood instability;
CRC	cis	rs6840360	0.667	rs2709832	chr4:152379394	C/G	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg06470822	chr6:28175283	NA	0.89	13.5	0.6	2.35e-33	Parkinson's disease;
CRC	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg19077165	chr18:44547161	KATNAL2	0.38	5.73	0.3	2.27e-8	Educational attainment (years of education);
CRC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.45	-0.38	8.54e-13	Headache;
CRC	cis	rs6545883	0.524	rs12992614	chr2:61593076	C/T	cg10580144	chr2:61372316	C2orf74	-0.35	-7.9	-0.4	4.33e-14	Tuberculosis;
CRC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.52	7.64	0.39	2.47e-13	Blood protein levels;
CRC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg12963866	chr19:57752005	ZNF805	-0.39	-5.75	-0.3	2.02e-8	Hyperactive-impulsive symptoms;
CRC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.5	7.2	0.37	4.15e-12	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17113216	chr4:83821792	THAP9	0.37	5.99	0.31	5.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg03623178	chr6:28175578	NA	0.74	8.1	0.41	1.08e-14	Parkinson's disease;
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg02018176	chr4:1364513	KIAA1530	0.39	5.72	0.3	2.38e-8	Obesity-related traits;
CRC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.54	0.43	5.2e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.72	-11.15	-0.52	1.05e-24	Cognitive function;
CRC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.58	-8.71	-0.43	1.55e-16	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27546264	chr17:76183398	AFMID;TK1	0.48	6.61	0.34	1.52e-10	Anxiety disorder;
CRC	cis	rs883565	0.740	rs2037655	chr3:39072754	T/C	cg01426195	chr3:39028469	NA	-0.53	-8.53	-0.43	5.4e-16	Handedness;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17151058	chr1:172502035	C1orf9	0.39	6.0	0.31	5.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.0	9.9	0.48	2.12e-20	Diabetic retinopathy;
CRC	cis	rs2227564	0.729	rs2633304	chr10:75650650	T/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.63	-0.39	2.58e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg10820045	chr2:198174542	NA	-0.53	-9.64	-0.47	1.51e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg05679027	chr9:99775184	HIATL2	-0.41	-6.15	-0.32	2.24e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg06470822	chr6:28175283	NA	1.01	15.38	0.65	1.29e-40	Depression;
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-6.22	-0.32	1.51e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg07809909	chr20:30433512	FOXS1	0.35	5.64	0.3	3.75e-8	Mean corpuscular hemoglobin;
CRC	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.38	-5.93	-0.31	7.85e-9	Refractive error;
CRC	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg14541582	chr5:601475	NA	-0.32	-6.64	-0.34	1.29e-10	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.68	-0.3	3.03e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.6	0.39	3.1e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.44	0.38	9.04e-13	Height;
CRC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-6.54	-0.34	2.36e-10	Asthma;
CRC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12463550	chr7:65579703	CRCP	0.7	6.5	0.34	3.03e-10	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00840257	chr16:8963031	CARHSP1	0.38	6.2	0.32	1.67e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.43e-59	Hip circumference adjusted for BMI;
CRC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	10.9	0.52	8.04e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs16867321	0.950	rs2887180	chr2:181449305	C/A	cg23363182	chr2:181467187	NA	-0.56	-7.17	-0.37	5.02e-12	Obesity;
CRC	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.63	6.62	0.34	1.48e-10	Body mass index;
CRC	cis	rs727505	0.564	rs67745021	chr7:124868018	T/C	cg23710748	chr7:124431027	NA	-0.62	-10.29	-0.49	1.04e-21	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08265551	chr1:151032119	CDC42SE1;MLLT11	0.37	6.45	0.34	4.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3736485	0.609	rs1456299	chr15:51982065	T/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.63	-0.3	3.89e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06307176	chr5:131281290	NA	-0.43	-6.43	-0.33	4.55e-10	Life satisfaction;
CRC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.44	-6.68	-0.35	1.05e-10	Blood metabolite levels;
CRC	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg12682573	chr17:27188876	MIR451;MIR144	-0.58	-8.49	-0.42	7.41e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	0.71	7.89	0.4	4.58e-14	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15034861	chr7:77428679	PHTF2;TMEM60	0.42	6.22	0.32	1.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12760731	0.565	rs12030488	chr1:178094751	A/C	cg00404053	chr1:178313656	RASAL2	-1.0	-10.69	-0.51	4.48e-23	Obesity-related traits;
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg07404485	chr7:94953653	PON1	-0.47	-6.15	-0.32	2.29e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06505273	chr16:24850292	NA	0.52	6.46	0.34	3.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.72	-0.3	2.43e-8	Life satisfaction;
CRC	cis	rs2462686	1.000	rs2462327	chr7:45993039	C/A	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.81	-0.3	1.49e-8	Major depressive disorder;
CRC	cis	rs6968419	0.755	rs2896180	chr7:115897871	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.46	-0.34	3.83e-10	Intraocular pressure;
CRC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.29	-0.46	2.16e-18	Type 2 diabetes;
CRC	cis	rs7259376	0.936	rs4932759	chr19:22540105	C/T	cg02657401	chr19:22469223	NA	-0.34	-7.61	-0.39	2.85e-13	Menopause (age at onset);
CRC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.92	14.8	0.63	2.39e-38	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.61	-10.04	-0.48	7.08e-21	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.52	5.94	0.31	7.24e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10950113	chr16:69166907	CHTF8;CIRH1A	0.4	6.0	0.31	5.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg10802521	chr3:52805072	NEK4	0.44	6.14	0.32	2.34e-9	Schizophrenia;
CRC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg09163369	chr1:210001066	C1orf107	0.46	6.35	0.33	7.09e-10	Orofacial clefts;
CRC	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.96	-0.31	6.5e-9	Metabolite levels;
CRC	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	7.1	0.36	7.84e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.59	9.5	0.46	4.45e-19	Anterior chamber depth;
CRC	cis	rs2692947	0.759	rs1917890	chr2:96672001	C/T	cg23100626	chr2:96804247	ASTL	0.24	6.64	0.34	1.3100000000000001e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-7.18	-0.37	4.77e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9928842	0.722	rs1035540	chr16:75278795	A/G	cg08657710	chr16:75258780	CTRB1	-0.57	-6.79	-0.35	5.26e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.65	0.39	2.21e-13	Schizophrenia;
CRC	trans	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.0	0.36	1.46e-11	Ulcerative colitis;
CRC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-9.04	-0.45	1.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.3	-0.56	7.23e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg24675056	chr1:15929824	NA	0.51	7.04	0.36	1.14e-11	Systolic blood pressure;
CRC	cis	rs11166629	1.000	rs4909331	chr8:135644540	T/C	cg27224718	chr8:135614730	ZFAT	0.52	7.68	0.39	1.82e-13	Smoking quantity;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01027365	chr2:191184571	HIBCH	0.4	6.19	0.32	1.82e-9	Obesity-related traits;
CRC	cis	rs11212617	0.967	rs228608	chr11:108088900	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.27	0.33	1.14e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.22e-37	Hypertriglyceridemia;
CRC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.43	-20.51	-0.75	8.67e-61	Hip circumference adjusted for BMI;
CRC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.72	10.03	0.48	7.82e-21	Breast cancer;
CRC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.75	10.21	0.49	1.99e-21	Cognitive function;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs11212617	1.000	rs228594	chr11:108104525	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.17	0.32	2.01e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.43e-9	Bipolar disorder;
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg08200770	chr17:80723486	TBCD	0.48	7.53	0.38	5.07e-13	Glycated hemoglobin levels;
CRC	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	0.89	9.03	0.45	1.45e-17	Gout;Renal underexcretion gout;
CRC	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.59	-7.99	-0.4	2.38e-14	White matter hyperintensity burden;
CRC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7113874	0.504	rs10743081	chr11:8624100	T/G	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18788524	chr1:145096602	SEC22B	-0.42	-6.37	-0.33	6.19e-10	Myopia (pathological);
CRC	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg03929089	chr4:120376271	NA	0.64	5.98	0.31	5.74e-9	Axial length;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25604994	chr2:201983264	CFLAR	0.5	6.58	0.34	1.89e-10	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg06470822	chr6:28175283	NA	0.87	12.36	0.56	4.32e-29	Parkinson's disease;
CRC	trans	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.43	0.33	4.46e-10	Ulcerative colitis;
CRC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.74	-9.96	-0.48	1.37e-20	Initial pursuit acceleration;
CRC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.58	0.54	3.15e-26	Monocyte percentage of white cells;
CRC	cis	rs9463078	0.764	rs10948187	chr6:44921320	A/G	cg25276700	chr6:44698697	NA	0.27	6.69	0.35	9.45e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.88	0.35	2.99e-11	Morning vs. evening chronotype;
CRC	cis	rs4664293	0.625	rs6738523	chr2:160537714	G/A	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.67e-10	Monocyte percentage of white cells;
CRC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg07090678	chr1:91966139	CDC7	0.42	6.9	0.36	2.68e-11	Breast cancer;
CRC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.04e-9	Prudent dietary pattern;
CRC	cis	rs7932354	0.536	rs10838620	chr11:46818098	G/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.51	-0.34	2.77e-10	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07574458	chr4:17513646	QDPR	0.36	6.05	0.32	3.95e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg18335740	chr13:41363409	SLC25A15	-0.57	-8.99	-0.44	1.92e-17	Lewy body disease;
CRC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg20673091	chr1:2541236	MMEL1	0.38	5.92	0.31	8.16e-9	Ulcerative colitis;
CRC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	1.0	12.51	0.57	1.19e-29	Vitiligo;
CRC	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.68	-12.87	-0.58	5.36e-31	Educational attainment;
CRC	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs7998202	0.667	rs282575	chr13:113359524	G/C	cg01692110	chr13:113365389	ATP11A	-0.49	-5.95	-0.31	6.9e-9	Glycated hemoglobin levels;
CRC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.93	-0.4	3.47e-14	Gut microbiome composition (summer);
CRC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.45	-6.5	-0.34	3.01e-10	Tonsillectomy;
CRC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.85	-9.81	-0.48	4.13e-20	Breast cancer;
CRC	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.58	6.45	0.33	4.06e-10	Coronary artery disease;
CRC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg08314208	chr16:67682810	RLTPR	-0.63	-6.59	-0.34	1.78e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.51	8.95	0.44	2.75e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836754	1.000	rs2836751	chr21:40290959	C/T	cg20434300	chr21:40194735	ETS2	-0.34	-5.83	-0.31	1.36e-8	Crohn's disease;Body mass index;
CRC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg08314208	chr16:67682810	RLTPR	-0.62	-6.51	-0.34	2.78e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs789852	0.867	rs9288751	chr3:194316294	C/G	cg21106136	chr3:194405973	FAM43A	0.72	6.02	0.31	4.66e-9	QT interval;
CRC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-7.47	-0.38	7.35e-13	Headache;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg24560729	chr4:1342394	KIAA1530	0.43	7.81	0.4	7.65e-14	Longevity;
CRC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.48	0.42	7.5e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs75246769	1.000	rs111654554	chr7:145646556	G/C	cg21982490	chr5:124845866	NA	-0.67	-6.28	-0.33	1.07e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs17209837	1.000	rs60123540	chr7:87085182	T/C	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.64	8.26	0.41	3.49e-15	Dilated cardiomyopathy;
CRC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.66	8.67	0.43	2.01e-16	Cognitive function;
CRC	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	0.91	11.94	0.55	1.55e-27	Blood protein levels;
CRC	cis	rs7487075	0.619	rs7134289	chr12:46838336	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.75	0.3	2.01e-8	Itch intensity from mosquito bite;
CRC	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.41	6.36	0.33	6.72e-10	Obesity;
CRC	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg09654669	chr8:57350985	NA	-0.37	-6.28	-0.33	1.07e-9	Obesity-related traits;
CRC	cis	rs1950626	0.833	rs12892225	chr14:101415413	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	16.01	0.66	4.75e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.22	0.53	5.89e-25	Prudent dietary pattern;
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.09e-10	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06720001	chr18:51795815	POLI	0.45	6.05	0.32	4.01e-9	Anxiety disorder;
CRC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg09264619	chr17:80180166	NA	0.5	7.26	0.37	2.77e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.16	27.43	0.83	5.25e-87	Testicular germ cell tumor;
CRC	cis	rs4692589	0.556	rs13133562	chr4:170965709	C/T	cg19918862	chr4:170955249	NA	0.53	6.97	0.36	1.69e-11	Anxiety disorder;
CRC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.61	9.65	0.47	1.44e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.48	-8.17	-0.41	6.81e-15	Endometriosis;
CRC	cis	rs7246865	0.603	rs10423719	chr19:17211568	T/C	cg19418318	chr19:17219073	MYO9B	0.42	7.53	0.38	4.94e-13	Reticulocyte fraction of red cells;
CRC	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.32	-0.33	8.67e-10	Mean corpuscular hemoglobin concentration;
CRC	trans	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg21153622	chr11:89784906	NA	0.5	8.08	0.41	1.22e-14	HDL cholesterol;
CRC	trans	rs6956675	1.000	rs1967430	chr7:62599308	C/T	cg01314568	chr7:57830625	NA	-0.68	-9.27	-0.46	2.56e-18	Obesity-related traits;
CRC	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg16141378	chr3:129829833	LOC729375	0.41	6.29	0.33	1.02e-9	Joint mobility (Beighton score);
CRC	trans	rs10411161	0.702	rs7251571	chr19:52389057	A/G	cg22319618	chr22:45562946	NUP50	-0.6	-6.85	-0.35	3.54e-11	Breast cancer;
CRC	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg20387954	chr3:183756860	HTR3D	0.43	7.4	0.38	1.14e-12	Anterior chamber depth;
CRC	cis	rs4929949	0.932	rs10840087	chr11:8616255	G/A	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.22e-9	Body mass index;
CRC	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg09476006	chr5:138032270	NA	0.41	6.56	0.34	2.06e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4132509	1.000	rs9782958	chr1:243892972	C/G	cg21452805	chr1:244014465	NA	0.46	6.48	0.34	3.31e-10	RR interval (heart rate);
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg24560729	chr4:1342394	KIAA1530	-0.35	-5.69	-0.3	2.81e-8	Obesity-related traits;
CRC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-6.04	-0.32	4.28e-9	IgG glycosylation;
CRC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.38	0.53	1.54e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.45	6.67	0.35	1.08e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.7	-8.27	-0.41	3.31e-15	Prostate cancer;
CRC	cis	rs17162190	0.605	rs9438626	chr1:26775367	G/C	cg17456097	chr1:26900765	RPS6KA1	0.44	6.28	0.33	1.04e-9	Mean corpuscular volume;
CRC	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.85	-0.4	6.1e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.18	14.45	0.62	5.3e-37	Eosinophil percentage of granulocytes;
CRC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	8.75	0.43	1.14e-16	Schizophrenia;
CRC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.6	-8.64	-0.43	2.48e-16	Menarche (age at onset);
CRC	trans	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-6.45	-0.34	3.95e-10	Menarche (age at onset);
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.48	-7.28	-0.37	2.52e-12	Glycated hemoglobin levels;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg02683197	chr6:28174875	NA	0.78	9.5	0.46	4.55e-19	Depression;
CRC	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.97	16.5	0.67	5.22e-45	Dupuytren's disease;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg11843238	chr5:131593191	PDLIM4	0.43	8.21	0.41	5.21e-15	Breast cancer;
CRC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.17	-0.49	2.61e-21	Body mass index;
CRC	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg00507830	chr2:103233733	NA	0.54	6.08	0.32	3.36e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs11212617	0.967	rs1003624	chr11:108152645	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.14	0.32	2.42e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.69	-9.36	-0.46	1.33e-18	Pubertal anthropometrics;
CRC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg12463550	chr7:65579703	CRCP	0.63	5.86	0.31	1.11e-8	Diabetic kidney disease;
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.47	0.53	7.35e-26	Prudent dietary pattern;
CRC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.8	0.7	4.11e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.45	-8.19	-0.41	5.66e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs75422866	0.510	rs73105818	chr12:48120321	C/T	cg14736327	chr12:48174669	SLC48A1	-0.73	-5.8	-0.3	1.6e-8	Pneumonia;
CRC	trans	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg00953403	chr17:74099816	EXOC7	-0.45	-6.13	-0.32	2.45e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs9303542	0.625	rs4239209	chr17:46574317	T/A	cg04904318	chr17:46607828	HOXB1	0.47	6.11	0.32	2.81e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg23996704	chr18:44553084	KATNAL2	-0.38	-7.59	-0.39	3.26e-13	Personality dimensions;
CRC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.0	-0.52	3.65e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs11212617	1.000	rs1003623	chr11:108152582	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.14	0.32	2.42e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg13072238	chr3:49761600	GMPPB	0.5	5.74	0.3	2.21e-8	Menarche (age at onset);
CRC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.47	-6.95	-0.36	1.97e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9303542	0.559	rs55859232	chr17:46612645	A/G	cg04904318	chr17:46607828	HOXB1	-0.53	-6.21	-0.32	1.63e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.66	10.68	0.51	4.83e-23	Schizophrenia;
CRC	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.46	-6.83	-0.35	4.05e-11	Neutrophil percentage of white cells;
CRC	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27467005	chr19:17622279	PGLS	0.47	5.99	0.31	5.58e-9	Thyroid stimulating hormone;
CRC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg19318889	chr4:1322082	MAEA	0.41	5.83	0.31	1.29e-8	Obesity-related traits;
CRC	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-7.29	-0.37	2.39e-12	Obesity (extreme);
CRC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	1.01	10.95	0.52	5.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.59e-9	Cognitive function;
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.39	-6.77	-0.35	5.83e-11	Lung cancer;
CRC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg14008862	chr17:28927542	LRRC37B2	0.56	5.8	0.3	1.6e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.41e-12	Colorectal cancer;
CRC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.65	-0.34	1.24e-10	Mean corpuscular volume;
CRC	trans	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.61	-9.28	-0.46	2.26e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26771998	chr10:75490334	BMS1P4	0.43	6.71	0.35	8.47e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.46	-8.93	-0.44	3.15e-17	Prostate cancer;
CRC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.61	7.25	0.37	3.05e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.48	-0.38	6.61e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27037990	chr4:184427250	ING2	0.41	7.36	0.38	1.48e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg00383909	chr3:49044727	WDR6	0.49	6.16	0.32	2.08e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.36	8.08e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	8.43	0.42	1.09e-15	Mean platelet volume;
CRC	cis	rs4716602	0.596	rs28451598	chr7:156158974	G/A	cg16983916	chr7:156159713	NA	-0.39	-6.97	-0.36	1.74e-11	Anti-saccade response;
CRC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.64	11.04	0.52	2.61e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.74	0.43	1.21e-16	Parkinson's disease;
CRC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg18230493	chr5:56204884	C5orf35	-0.51	-7.43	-0.38	9.74e-13	Coronary artery disease;
CRC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.68	10.95	0.52	5.15e-24	Mean corpuscular hemoglobin;
CRC	cis	rs7580658	0.613	rs12463538	chr2:128196854	G/T	cg09760422	chr2:128146352	NA	-0.31	-5.68	-0.3	2.89e-8	Protein C levels;
CRC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-9.44	-0.46	7.09e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.52	-7.6	-0.39	3.06e-13	Vitiligo;
CRC	cis	rs4561483	0.514	rs33639	chr16:11989499	A/C	cg08843971	chr16:11963173	GSPT1	-0.46	-6.76	-0.35	6.3e-11	Testicular germ cell tumor;
CRC	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg14593290	chr7:50529359	DDC	-0.43	-6.29	-0.33	1.03e-9	Body mass index;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.49	8.4	0.42	1.4e-15	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27114086	chr1:155658701	YY1AP1;DAP3	0.45	6.29	0.33	1.02e-9	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg07972541	chr16:28961971	NFATC2IP	-0.71	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.5	5.63	0.3	3.89e-8	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17546822	chr22:41865178	ACO2;PHF5A	0.47	6.93	0.36	2.28e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02590856	chr6:117923645	GOPC	0.44	6.0	0.31	5.17e-9	Anxiety disorder;
CRC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg00290994	chr1:41848739	NA	0.56	8.54	0.43	5.11e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3864277	0.510	rs31478	chr5:131423475	T/C	cg02033258	chr5:131593261	PDLIM4	0.33	6.01	0.31	4.79e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.13	-0.37	6.28e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg26805224	chr10:79626177	DLG5	-0.52	-7.43	-0.38	9.54e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.6	-8.87	-0.44	4.86e-17	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05742354	chr1:10856609	CASZ1	0.43	6.23	0.32	1.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.83	10.84	0.51	1.31e-23	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg18827107	chr12:86230957	RASSF9	0.45	7.58	0.39	3.54e-13	Major depressive disorder;
CRC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.59	-8.81	-0.44	7.57e-17	Aortic root size;
CRC	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.6	6.84	0.35	3.86e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	-0.51	-8.26	-0.41	3.49e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg10217327	chr6:118973057	C6orf204	0.52	5.92	0.31	8.31e-9	Diastolic blood pressure;
CRC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.31	-0.53	2.72e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.86	-11.11	-0.52	1.51e-24	Initial pursuit acceleration;
CRC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.79	0.51	1.94e-23	Motion sickness;
CRC	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	1.01	12.84	0.58	7.03e-31	IgG glycosylation;
CRC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.83	-9.45	-0.46	6.42e-19	Breast cancer;
CRC	trans	rs6048205	1.000	rs2277763	chr20:22548294	C/T	cg09295799	chr6:5994235	NA	-0.62	-6.12	-0.32	2.59e-9	Fasting blood glucose (BMI interaction);Fasting blood glucose;
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg00587665	chr15:100533223	ADAMTS17	0.39	6.92	0.36	2.31e-11	Height;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg03790207	chr6:42947109	PEX6	-0.52	-7.6	-0.39	3.16e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21972741	chr5:435613	AHRR	0.53	7.37	0.38	1.41e-12	Cystic fibrosis severity;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg23247704	chr1:116518985	SLC22A15	-0.7	-6.04	-0.32	4.14e-9	Blood osmolality (transformed sodium);
CRC	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg23254163	chr1:152506842	NA	0.49	9.69	0.47	1.07e-19	Hair morphology;
CRC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg19257562	chr1:2043853	PRKCZ	0.38	6.42	0.33	4.66e-10	Height;
CRC	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg21251018	chr6:28226885	NKAPL	0.4	6.01	0.31	4.96e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.7	-12.65	-0.57	3.57e-30	Obesity-related traits;
CRC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.89	-16.76	-0.68	5.06e-46	Obesity-related traits;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06222517	chr3:49577284	NA	0.4	5.89	0.31	9.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.02	10.47	0.5	2.42e-22	Diabetic retinopathy;
CRC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.55	0.38	4.4e-13	Motion sickness;
CRC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.51	-7.48	-0.38	6.84e-13	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.3	-6.54	-0.34	2.3e-10	IgG glycosylation;
CRC	cis	rs524281	0.731	rs3829937	chr11:65787666	G/A	cg16950941	chr11:66035639	RAB1B	-0.55	-6.01	-0.31	4.81e-9	Electroencephalogram traits;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20092199	chr4:1342459	KIAA1530	0.36	6.45	0.34	3.88e-10	Obesity-related traits;
CRC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.46	6.8	0.35	4.87e-11	Testicular germ cell tumor;
CRC	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.44	-0.33	4.13e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.37	-0.33	6.31e-10	Alzheimer's disease (late onset);
CRC	cis	rs727479	0.502	rs8029120	chr15:51504934	A/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.02	-0.31	4.66e-9	Estradiol levels;
CRC	cis	rs4731207	0.698	rs6968187	chr7:124563340	T/G	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs863345	0.604	rs7548349	chr1:158493726	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	7e-9	Pneumococcal bacteremia;
CRC	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.6	8.16	0.41	6.96e-15	Coronary artery disease;
CRC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.64	6.94	0.36	2.09e-11	Vitiligo;
CRC	cis	rs995000	0.929	rs636523	chr1:62920008	A/G	cg19896129	chr1:63156450	NA	0.43	6.38	0.33	5.93e-10	Triglyceride levels;
CRC	trans	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.72	-9.58	-0.47	2.55e-19	Coronary artery disease;
CRC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.44	6.47	0.34	3.55e-10	Emphysema distribution in smoking;
CRC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.5	-0.38	6.11e-13	Depression;
CRC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	12.18	0.56	1.97e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06044117	chr11:95523445	FAM76B;CEP57	0.43	6.36	0.33	6.59e-10	Schizophrenia;
CRC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs8177876	0.642	rs56032321	chr16:81117906	A/C	cg09779152	chr17:73205364	NUP85	0.61	5.98	0.31	5.79e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.49	6.94	0.36	2.03e-11	Bone mineral density (spine);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14309501	chr19:17445715	ANO8	-0.39	-6.1	-0.32	2.92e-9	Myopia (pathological);
CRC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.6	-0.3	4.47e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.56	-7.74	-0.39	1.22e-13	Caudate activity during reward;
CRC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.54	0.34	2.39e-10	Lung cancer;
CRC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg23018236	chr17:30244563	NA	-0.67	-8.02	-0.4	1.83e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9400239	0.584	rs1268178	chr6:109017284	T/G	cg11073813	chr6:109029018	NA	-0.38	-5.96	-0.31	6.61e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.92	-15.34	-0.65	1.92e-40	Dupuytren's disease;
CRC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.45	-6.64	-0.34	1.32e-10	Height;
CRC	cis	rs12580194	1.000	rs7308316	chr12:55709162	T/A	cg19537932	chr12:55886519	OR6C68	-0.6	-8.39	-0.42	1.45e-15	Cancer;
CRC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.5	8.09	0.41	1.16e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.61	9.1	0.45	9.08e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.26	-0.45	2.78e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.63	8.43	0.42	1.11e-15	Uric acid levels;
CRC	cis	rs703970	0.560	rs1250576	chr10:80964796	A/C	cg20744163	chr10:80999841	ZMIZ1	-0.37	-6.08	-0.32	3.37e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.77	-12.31	-0.56	6.46e-29	Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01524091	chr6:44281032	AARS2	0.39	6.1	0.32	2.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3015497	0.616	rs4901044	chr14:51090295	A/G	cg09863266	chr14:51125203	SAV1	-0.3	-5.76	-0.3	1.93e-8	Mean platelet volume;
CRC	cis	rs12980942	0.810	rs8105901	chr19:41792092	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.26	0.33	1.21e-9	Coronary artery disease;
CRC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17507749	chr15:85114479	UBE2QP1	0.65	9.55	0.47	2.98e-19	Schizophrenia;
CRC	cis	rs7932354	0.710	rs6485702	chr11:46898771	T/C	cg19486271	chr11:47235900	DDB2	-0.46	-7.38	-0.38	1.29e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.24	0.41	4.27e-15	Platelet count;
CRC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Melanoma;
CRC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.43	6.91	0.36	2.5e-11	Resting heart rate;
CRC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.83	9.88	0.48	2.57e-20	Eosinophil percentage of granulocytes;
CRC	trans	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg10756647	chr7:56101905	PSPH	0.73	8.05	0.41	1.58e-14	Diabetic kidney disease;
CRC	cis	rs2992756	0.663	rs2992757	chr1:18807137	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.39	-5.86	-0.31	1.14e-8	Breast cancer;
CRC	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.55	10.04	0.48	6.97e-21	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs2857891	0.695	rs2857887	chr11:6984001	A/G	cg22096450	chr11:6947773	ZNF215	0.5	5.93	0.31	7.53e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.62	10.04	0.48	7.47e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.17	0.32	1.99e-9	Menopause (age at onset);
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg24634471	chr8:143751801	JRK	-0.5	-6.91	-0.36	2.49e-11	Urinary tract infection frequency;
CRC	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.47	6.97	0.36	1.77e-11	Birth weight;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.47	-6.67	-0.35	1.07e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.71	0.47	9.26e-20	Ileal carcinoids;
CRC	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.43	6.13	0.32	2.5e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2569991	0.588	rs62240725	chr3:12929360	A/G	cg22481960	chr3:13008800	IQSEC1	0.45	5.82	0.31	1.37e-8	Periodontitis (DPAL);
CRC	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.7	-9.47	-0.46	5.6e-19	Pubertal anthropometrics;
CRC	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.39	5.98	0.31	5.73e-9	Monocyte count;
CRC	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg17691542	chr6:26056736	HIST1H1C	0.74	9.27	0.45	2.6e-18	Iron status biomarkers;
CRC	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg15571903	chr15:79123663	NA	0.31	6.18	0.32	1.95e-9	Coronary artery disease;
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.36	0.53	1.81e-25	Bone mineral density;
CRC	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg18827107	chr12:86230957	RASSF9	-0.36	-5.67	-0.3	3.05e-8	Major depressive disorder;
CRC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	7.95	0.4	3.04e-14	Body mass index;
CRC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg24675056	chr1:15929824	NA	0.5	7.19	0.37	4.29e-12	Systolic blood pressure;
CRC	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.84	-0.4	6.24e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg05569086	chr8:143859399	LYNX1	0.37	6.35	0.33	7.33e-10	Urinary tract infection frequency;
CRC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	6.61	0.34	1.54e-10	Hip circumference adjusted for BMI;
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.73	-0.51	3.15e-23	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08171195	chr1:155214570	GBA	0.42	5.97	0.31	6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9462027	0.628	rs6937314	chr6:34799308	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.61	0.54	2.38e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467773	0.550	rs4712987	chr6:26399615	A/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.23	-0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-8.88	-0.44	4.49e-17	Body mass index;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18484507	chr14:67982176	TMEM229B	0.38	5.99	0.31	5.42e-9	Interleukin-6 levels;
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.3	1.5e-8	Metabolite levels;
CRC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-5.8	-0.3	1.58e-8	Bronchopulmonary dysplasia;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg01758942	chr3:52551074	STAB1	0.3	5.93	0.31	7.76e-9	Electroencephalogram traits;
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21659725	chr3:3221576	CRBN	-0.69	-7.14	-0.37	6.11e-12	Menarche (age at onset);
CRC	trans	rs11800820	0.567	rs3124116	chr1:246707051	G/C	cg26885821	chr6:124125002	NKAIN2	0.37	5.99	0.31	5.65e-9	Obesity-related traits;
CRC	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg10437265	chr15:77819839	NA	0.69	12.66	0.57	3.27e-30	Type 2 diabetes;
CRC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.54	8.45	0.42	9.28e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg14949292	chr17:78079608	GAA	-0.41	-5.6	-0.3	4.44e-8	Yeast infection;
CRC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg25164649	chr6:28176230	NA	0.64	6.58	0.34	1.84e-10	Parkinson's disease;
CRC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg19193384	chr17:30244184	NA	-0.49	-6.73	-0.35	7.54e-11	Hip circumference adjusted for BMI;
CRC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.77	-13.0	-0.58	1.76e-31	Breast cancer;
CRC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.84	-0.48	3.29e-20	Schizophrenia;
CRC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.6	0.34	1.63e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg18827107	chr12:86230957	RASSF9	-0.37	-5.91	-0.31	8.45e-9	Major depressive disorder;
CRC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.55	0.34	2.15e-10	Lung cancer;
CRC	cis	rs17023223	0.537	rs2765530	chr1:119584396	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-6.33	-0.33	7.91e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6997458	0.713	rs703	chr8:86389403	T/C	cg21346043	chr8:86351067	CA3	-0.26	-5.76	-0.3	1.95e-8	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg18972013	chr17:78078605	GAA	-0.39	-5.62	-0.3	4e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs1973993	0.717	rs56209707	chr1:96972973	C/A	cg10631902	chr5:14652156	NA	-0.42	-7.0	-0.36	1.44e-11	Weight;
CRC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.16	-0.41	6.96e-15	Chronic sinus infection;
CRC	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs9303542	0.625	rs4793889	chr17:46592352	A/G	cg04904318	chr17:46607828	HOXB1	0.48	6.21	0.32	1.64e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs6681460	0.966	rs10889644	chr1:67145322	C/A	cg02459107	chr1:67143332	SGIP1	0.45	8.25	0.41	3.95e-15	Presence of antiphospholipid antibodies;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03392900	chr1:1167310	SDF4;B3GALT6	0.47	6.27	0.33	1.13e-9	Anxiety disorder;
CRC	cis	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg15845792	chr6:28175446	NA	0.8	6.52	0.34	2.67e-10	Depression;
CRC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.43	8.9	0.44	3.69e-17	Renal cell carcinoma;
CRC	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.35	0.53	2e-25	Height;
CRC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg18016565	chr1:150552671	MCL1	0.41	5.75	0.3	2.01e-8	Melanoma;
CRC	cis	rs317865	0.737	rs16893153	chr4:16181798	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.55	5.99	0.31	5.4e-9	Kidney disease (early stage) in type 1 diabetes;
CRC	trans	rs11264213	0.711	rs489534	chr1:36155418	C/T	cg07175433	chr4:21947400	KCNIP4	-0.37	-6.36	-0.33	6.71e-10	Schizophrenia;
CRC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.36	5.82	0.31	1.39e-8	Ulcerative colitis;
CRC	trans	rs6693295	0.729	rs2185073	chr1:246213341	G/A	cg17980625	chr11:94965587	SESN3	0.48	6.05	0.32	3.9e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.11	10.67	0.51	5.15e-23	Diabetic retinopathy;
CRC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.44	-6.43	-0.33	4.61e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.57	-9.02	-0.45	1.54e-17	Capecitabine sensitivity;
CRC	cis	rs9648716	0.935	rs6957490	chr7:140560307	C/T	cg10747023	chr7:140774559	NA	0.45	5.82	0.31	1.42e-8	Type 2 diabetes;
CRC	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.6	-8.26	-0.41	3.6e-15	Extraversion;
CRC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg21153622	chr11:89784906	NA	-0.44	-7.15	-0.37	5.71e-12	Coronary artery disease;
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.74	-0.39	1.26e-13	Menopause (age at onset);
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.71	10.12	0.49	3.84e-21	Menarche (age at onset);
CRC	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.49	-6.26	-0.33	1.22e-9	Body mass index;
CRC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.59	-8.78	-0.44	8.99e-17	Aortic root size;
CRC	cis	rs883565	0.740	rs9311203	chr3:39072079	T/C	cg01426195	chr3:39028469	NA	-0.52	-8.3	-0.42	2.64e-15	Handedness;
CRC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.4	-6.9	-0.36	2.65e-11	Vitiligo;
CRC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.01	0.4	2.07e-14	Resting heart rate;
CRC	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg18827107	chr12:86230957	RASSF9	-0.36	-5.7	-0.3	2.68e-8	Major depressive disorder;
CRC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg04880052	chr2:219191631	PNKD	0.44	6.76	0.35	6.14e-11	Colorectal cancer;
CRC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.44	5.78	0.3	1.74e-8	Platelet distribution width;
CRC	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.48	-8.16	-0.41	7.37e-15	Dental caries;
CRC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.96	-0.36	1.84e-11	Colorectal cancer;
CRC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.35	6.27	0.33	1.13e-9	Crohn's disease;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.56	-8.44	-0.42	9.89e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.49	7.16	0.37	5.24e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.73	10.92	0.52	6.54e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.87	11.68	0.54	1.33e-26	Menarche (age at onset);
CRC	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg13385794	chr1:248469461	NA	0.36	6.26	0.33	1.17e-9	Common traits (Other);
CRC	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	0.9	10.82	0.51	1.58e-23	Height;
CRC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.63	9.79	0.47	5.05e-20	Corneal astigmatism;
CRC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-6.44	-0.33	4.22e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09392819	chr2:26568944	SELI;GPR113	0.39	6.47	0.34	3.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg23920097	chr1:209922102	NA	-0.5	-5.68	-0.3	2.9e-8	Red blood cell count;
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.82	0.31	1.44e-8	Diastolic blood pressure;
CRC	cis	rs1656402	1.000	rs1729252	chr2:233428582	A/G	cg03852847	chr2:233439513	NA	-0.43	-7.57	-0.39	3.83e-13	Non-small cell lung cancer (survival);
CRC	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.64	-0.47	1.56e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20824237	chr3:99979579	TBC1D23	0.42	6.03	0.32	4.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg12046867	chr14:103022105	NA	0.72	8.12	0.41	9.31e-15	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17445839	chr17:79859999	NPB	0.41	7.55	0.38	4.37e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.36	0.5	5.83e-22	Menopause (age at onset);
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.45	6.68	0.35	1.03e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.71	8.4	0.42	1.4e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-6.47	-0.34	3.54e-10	Squamous cell lung carcinoma;
CRC	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg11693508	chr17:37793320	STARD3	0.62	7.06	0.36	1.02e-11	Neuroticism;
CRC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg24562669	chr7:97807699	LMTK2	-0.4	-6.56	-0.34	2.06e-10	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	12.27	0.56	9.47e-29	Platelet count;
CRC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.86	-15.93	-0.66	9.21e-43	Dementia with Lewy bodies;
CRC	cis	rs2730260	0.537	rs73169239	chr7:158884305	C/A	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.57	10.42	0.5	3.78e-22	Coronary artery disease;
CRC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg15147215	chr3:52552868	STAB1	0.43	7.09	0.36	8.02e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-7.94	-0.4	3.12e-14	Glycated hemoglobin levels;
CRC	cis	rs10512697	0.655	rs62338651	chr5:3472166	C/A	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg19894588	chr14:64061835	NA	-0.57	-7.87	-0.4	5.07e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg01639898	chr1:32083012	HCRTR1	0.28	5.7	0.3	2.69e-8	Intelligence (multi-trait analysis);
CRC	cis	rs919433	0.714	rs2333855	chr2:198200213	T/G	cg03934865	chr2:198174659	NA	-0.4	-6.4	-0.33	5.33e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7527798	0.592	rs1323722	chr1:207823405	C/T	cg21110645	chr1:207815933	NA	-0.41	-6.36	-0.33	6.69e-10	Erythrocyte sedimentation rate;
CRC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.57	-9.17	-0.45	5.26e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	1.14	11.02	0.52	3.12e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs11212617	0.967	rs664982	chr11:108225483	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.56	0.34	2.03e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	0.94	10.62	0.51	7.26e-23	Type 2 diabetes nephropathy;
CRC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.85	12.61	0.57	5.31e-30	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-6.18	-0.32	1.88e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21955686	chr17:6555093	C17orf100;MED31	0.38	6.01	0.31	4.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg23260525	chr10:116636907	FAM160B1	0.32	6.41	0.33	4.98e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.57e-27	Cognitive function;
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.41	-5.71	-0.3	2.59e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.84	15.4	0.65	1.17e-40	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.52	7.83	0.4	6.76e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.58	0.34	1.9e-10	Lung cancer;
CRC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.31	-0.33	9.17e-10	Crohn's disease;
CRC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg21466736	chr12:48725269	NA	0.46	7.12	0.37	6.99e-12	Glycated hemoglobin levels;
CRC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.77	0.47	5.98e-20	Cognitive test performance;
CRC	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-0.98	-10.15	-0.49	3.16e-21	Post bronchodilator FEV1;
CRC	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.69	9.57	0.47	2.67e-19	Coronary artery disease;
CRC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.93	-17.93	-0.7	1.28e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.57	10.82	0.51	1.54e-23	Cognitive performance;
CRC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.32e-10	Bladder cancer;
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13198984	chr17:80129470	CCDC57	0.47	8.37	0.42	1.73e-15	Life satisfaction;
CRC	cis	rs9341808	0.667	rs7746917	chr6:80931503	T/C	cg08355045	chr6:80787529	NA	0.33	5.75	0.3	2.02e-8	Sitting height ratio;
CRC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.11	0.36	7.24e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.81	12.86	0.58	6.31e-31	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.04e-12	Testicular germ cell tumor;
CRC	cis	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg20159608	chr7:32802032	NA	-0.59	-6.9	-0.36	2.61e-11	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-6.58	-0.34	1.91e-10	Coronary artery disease;
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.8	7.97	0.4	2.66e-14	IgG glycosylation;
CRC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.62	-9.57	-0.47	2.57e-19	Colorectal cancer;
CRC	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg16989719	chr2:238392110	NA	-0.45	-7.01	-0.36	1.37e-11	Prostate cancer;
CRC	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.35	-6.01	-0.31	4.85e-9	Airway imaging phenotypes;
CRC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.44	7.5	0.38	5.93e-13	Facial morphology (factor 20);
CRC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.13	0.45	7.08e-18	Bladder cancer;
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg03909863	chr11:638404	DRD4	-0.44	-6.26	-0.33	1.17e-9	Systemic lupus erythematosus;
CRC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.18	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.35	-0.5	6.61e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.11	-0.41	9.98e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.52	7.75	0.39	1.17e-13	Lymphocyte counts;
CRC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.05	13.07	0.58	1.02e-31	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.54	8.16	0.41	7.43e-15	Prostate cancer;
CRC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.58	-0.72	3.48e-53	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02758870	chr4:100871523	LOC256880;H2AFZ	0.39	6.36	0.33	6.72e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24991452	chr6:35996059	MAPK14	-0.49	-5.97	-0.31	6.16e-9	Diisocyanate-induced asthma;
CRC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	16.3	0.67	3.35e-44	Testicular germ cell tumor;
CRC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.51	6.64	0.34	1.3e-10	Menopause (age at onset);
CRC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.24	-0.37	3.19e-12	Major depressive disorder;
CRC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg18016565	chr1:150552671	MCL1	0.43	5.95	0.31	6.7e-9	Melanoma;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg15845792	chr6:28175446	NA	0.97	13.03	0.58	1.43e-31	Depression;
CRC	cis	rs6496667	0.600	rs28674812	chr15:91077809	G/T	cg04176472	chr15:90893244	GABARAPL3	0.49	7.49	0.38	6.43e-13	Rheumatoid arthritis;
CRC	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs995000	0.931	rs597078	chr1:62917857	G/A	cg19896129	chr1:63156450	NA	0.44	6.73	0.35	7.45e-11	Triglyceride levels;
CRC	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg15845792	chr6:28175446	NA	0.73	10.86	0.51	1.09e-23	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.54	-5.67	-0.3	3.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-7.0	-0.36	1.41e-11	Blood pressure (smoking interaction);
CRC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.5	-7.09	-0.36	8.46e-12	Coronary artery disease;
CRC	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Systolic blood pressure;
CRC	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg16989719	chr2:238392110	NA	-0.39	-7.94	-0.4	3.23e-14	Prostate cancer;
CRC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.93	0.48	1.74e-20	Bladder cancer;
CRC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-6.41	-0.33	4.95e-10	Total body bone mineral density;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg27615366	chr5:131592974	PDLIM4	0.34	5.86	0.31	1.1e-8	Breast cancer;
CRC	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.54	-7.88	-0.4	4.93e-14	QRS duration;
CRC	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs4750440	0.702	rs4750444	chr10:14029068	C/T	cg00551146	chr10:14014579	FRMD4A	0.38	6.1	0.32	3e-9	Adiponectin levels;
CRC	cis	rs8060686	0.925	rs13336189	chr16:67814152	C/A	cg07125278	chr16:67683757	RLTPR	-0.46	-5.98	-0.31	5.85e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.39	6.44	0.33	4.32e-10	Major depressive disorder;
CRC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.98	0.4	2.51e-14	Arsenic metabolism;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg08034379	chr2:228736324	WDR69	-0.53	-7.16	-0.37	5.22e-12	Blood pressure;
CRC	cis	rs7086803	0.557	rs7088796	chr10:114486621	G/A	cg03281572	chr10:114502318	VTI1A	0.63	5.6	0.3	4.46e-8	Lung cancer;
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.67	7.76	0.39	1.07e-13	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27172057	chr12:64616385	C12orf66	0.48	6.7	0.35	9.2e-11	Response to antipsychotic treatment;
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.44	6.58	0.34	1.88e-10	Menarche (age at onset);
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg12516270	chr8:143859308	LYNX1	-0.39	-6.15	-0.32	2.24e-9	Urinary tract infection frequency;
CRC	cis	rs4731207	1.000	rs4731207	chr7:124396645	G/A	cg23710748	chr7:124431027	NA	0.4	6.44	0.33	4.19e-10	Cutaneous malignant melanoma;
CRC	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-9.59	-0.47	2.21e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15752043	chr10:120789955	NANOS1	0.46	6.61	0.34	1.53e-10	Response to antipsychotic treatment;
CRC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.46	7.28	0.37	2.55e-12	Height;
CRC	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg00105475	chr2:10696890	NA	0.45	7.27	0.37	2.63e-12	Prostate cancer;
CRC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.84	0.55	3.47e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.5	-9.85	-0.48	3.03e-20	Ulcerative colitis;
CRC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.72	10.24	0.49	1.47e-21	Height;
CRC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.48	0.46	5.37e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17092148	0.887	rs6059916	chr20:33148861	T/G	cg08999081	chr20:33150536	PIGU	0.51	6.6	0.34	1.66e-10	Neuroticism;
CRC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.8	7.79	0.39	8.84e-14	Diabetic retinopathy;
CRC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.63	-6.26	-0.33	1.22e-9	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.05	0.32	3.99e-9	Total body bone mineral density;
CRC	cis	rs2179367	0.959	rs544947	chr6:149723548	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-5.89	-0.31	9.7e-9	Dupuytren's disease;
CRC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.52	7.57	0.38	3.91e-13	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg00495681	chr13:53174319	NA	0.56	7.99	0.4	2.35e-14	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26002955	chr11:6255951	FAM160A2	0.38	6.29	0.33	1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.49	7.5	0.38	6.06e-13	Corneal astigmatism;
CRC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.46	5.93	0.31	7.48e-9	Daytime sleep phenotypes;
CRC	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg03037974	chr15:76606532	NA	0.46	6.42	0.33	4.78e-10	Blood metabolite levels;
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03934478	chr11:495069	RNH1	0.67	7.36	0.38	1.45e-12	Body mass index;
CRC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02018176	chr4:1364513	KIAA1530	0.48	7.93	0.4	3.43e-14	Obesity-related traits;
CRC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.95	-0.36	1.91e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-8.95	-0.44	2.61e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	12.89	0.58	4.79e-31	Bone mineral density;
CRC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12667521	chr19:29218732	NA	0.46	6.44	0.33	4.26e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	11.2	0.53	7.17e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.57	11.04	0.52	2.55e-24	Sjögren's syndrome;
CRC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.87	0.4	5.09e-14	Lung cancer;
CRC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.72	12.47	0.57	1.66e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01814139	chr3:49840136	C3orf54	-0.4	-6.09	-0.32	3.12e-9	Myopia (pathological);
CRC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.49	6.77	0.35	5.99e-11	Total body bone mineral density;
CRC	cis	rs12745968	0.589	rs722356	chr1:92982405	G/A	cg17283838	chr1:93427260	FAM69A	-0.44	-6.02	-0.32	4.63e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs1681630	0.848	rs1631174	chr11:47974373	A/C	cg15704280	chr7:45808275	SEPT13	-0.45	-6.02	-0.31	4.73e-9	Height;
CRC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg05341575	chr12:125625032	AACS	-0.39	-5.99	-0.31	5.61e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs12936587	0.601	rs7212538	chr17:17554587	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.38	-5.73	-0.3	2.24e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg23071808	chr14:103021642	NA	0.54	6.16	0.32	2.1e-9	Platelet count;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg11407514	chr10:99094219	FRAT2	0.44	6.19	0.32	1.78e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.79	13.57	0.6	1.3e-33	Menopause (age at onset);
CRC	cis	rs965469	0.842	rs6051776	chr20:3332062	T/C	cg25506879	chr20:3388711	C20orf194	-0.38	-5.88	-0.31	1.03e-8	IFN-related cytopenia;
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.36	-8.48	-0.42	7.5e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.44	6.04	0.32	4.09e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.65	8.9	0.44	3.81e-17	Asthma;
CRC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.34	6.44	0.33	4.13e-10	Mean corpuscular volume;
CRC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-0.98	-14.41	-0.62	7.74e-37	Hip circumference adjusted for BMI;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16221875	chr6:21588597	NA	-0.51	-6.39	-0.33	5.62e-10	Diisocyanate-induced asthma;
CRC	cis	rs7487075	1.000	rs12813763	chr12:46822904	G/T	cg22049899	chr12:47219821	SLC38A4	-0.31	-6.04	-0.32	4.14e-9	Itch intensity from mosquito bite;
CRC	cis	rs427943	0.695	rs8128889	chr21:46615331	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.44	5.97	0.31	6.09e-9	Body mass index;
CRC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg00343986	chr7:65444356	GUSB	-0.49	-7.3	-0.37	2.16e-12	Aortic root size;
CRC	cis	rs4665630	0.522	rs2712054	chr2:23956123	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	0.52	5.63	0.3	3.96e-8	Hypertension;
CRC	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.62	9.37	0.46	1.16e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-6.09	-0.32	3.21e-9	Bipolar disorder;
CRC	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.93	-0.55	1.64e-27	Colorectal cancer;
CRC	cis	rs524281	0.731	rs476551	chr11:66006323	G/C	cg14036092	chr11:66035641	RAB1B	-0.58	-6.71	-0.35	8.61e-11	Electroencephalogram traits;
CRC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.92	-0.31	8.04e-9	Arsenic metabolism;
CRC	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.53	-9.02	-0.45	1.54e-17	Congenital heart disease (maternal effect);
CRC	cis	rs7429990	1.000	rs319680	chr3:47898307	A/G	cg11946769	chr3:48343235	NME6	0.46	5.8	0.3	1.55e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg08885800	chr1:201084119	NA	0.49	8.93	0.44	2.97e-17	Permanent tooth development;
CRC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	6.96e-16	Aortic root size;
CRC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.62	12.41	0.56	2.91e-29	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25635316	chr7:23637023	CCDC126	0.49	6.5	0.34	2.95e-10	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.53	9.43	0.46	7.58e-19	Common traits (Other);
CRC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg12064134	chr16:90016061	DEF8	-0.69	-6.14	-0.32	2.38e-9	Skin colour saturation;
CRC	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.69	-0.3	2.78e-8	Superior crus of antihelix expression;
CRC	cis	rs17095355	1.000	rs75079039	chr10:111745121	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.59	-6.98	-0.36	1.59e-11	Biliary atresia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20261243	chr20:44718728	NCOA5	0.52	7.52	0.38	5.15e-13	Response to antipsychotic treatment;
CRC	cis	rs1983891	1.000	rs4714483	chr6:41528214	G/A	cg20194872	chr6:41519635	FOXP4	0.4	5.75	0.3	2.04e-8	Prostate cancer;
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.62	-10.93	-0.52	6.38e-24	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.88	10.85	0.51	1.2e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg24308560	chr3:49941425	MST1R	-0.46	-7.16	-0.37	5.19e-12	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg00074818	chr8:8560427	CLDN23	0.4	7.28	0.37	2.44e-12	Obesity-related traits;
CRC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.13	0.52	1.23e-24	Prudent dietary pattern;
CRC	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg15571903	chr15:79123663	NA	-0.31	-6.05	-0.32	3.86e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12463550	chr7:65579703	CRCP	0.66	6.19	0.32	1.79e-9	Diabetic kidney disease;
CRC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-9.96	-0.48	1.37e-20	Total cholesterol levels;
CRC	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.98	18.25	0.71	7e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg07393940	chr7:158741817	NA	-0.52	-7.43	-0.38	9.26e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.56	-5.78	-0.3	1.75e-8	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs17301013	0.606	rs11487399	chr1:174496267	C/T	cg15203214	chr6:379489	NA	0.38	5.97	0.31	6.01e-9	Systemic lupus erythematosus;
CRC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg11766577	chr21:47581405	C21orf56	-0.39	-5.83	-0.31	1.32e-8	Testicular germ cell tumor;
CRC	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg12564285	chr5:131593104	PDLIM4	0.36	5.95	0.31	6.84e-9	Blood metabolite levels;
CRC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.52	8.71	0.43	1.47e-16	Mosquito bite size;
CRC	cis	rs9469578	0.792	rs73743329	chr6:33713943	T/A	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.15	-0.32	2.29e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-9.51	-0.46	4.03e-19	Vitiligo;
CRC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.38	-0.42	1.58e-15	Biliary atresia;
CRC	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.46	5.7	0.3	2.64e-8	Metabolite levels;
CRC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.86	0.55	2.95e-27	Platelet count;
CRC	cis	rs3736485	0.934	rs4143724	chr15:51870413	T/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.63	-0.34	1.41e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg23533926	chr12:111358616	MYL2	-0.55	-8.38	-0.42	1.6e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs7605827	0.897	rs10166429	chr2:15514472	A/C	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.78e-8	Educational attainment (years of education);
CRC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.48	-0.46	5.08e-19	Heart rate;
CRC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.25	0.41	3.86e-15	Menopause (age at onset);
CRC	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.76	-8.02	-0.4	1.86e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg20203395	chr5:56204925	C5orf35	-0.41	-5.82	-0.31	1.38e-8	Coronary artery disease;
CRC	cis	rs7739232	0.920	rs79431838	chr6:53526721	G/A	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-8.17	-0.41	6.79e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg15534755	chr11:117069859	TAGLN	-0.35	-6.56	-0.34	2.05e-10	Blood protein levels;
CRC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.56e-11	Opioid sensitivity;
CRC	cis	rs7517126	1.000	rs7514704	chr1:196839991	A/G	cg13682187	chr1:196946512	CFHR5	-0.37	-6.04	-0.32	4.2e-9	Blood protein levels;
CRC	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.47	6.99	0.36	1.57e-11	Birth weight;
CRC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.69	10.35	0.5	6.24e-22	Cognitive function;
CRC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.81	-0.31	1.47e-8	Cognitive function;
CRC	cis	rs10875943	0.751	rs11168962	chr12:49672739	A/T	cg17570948	chr12:49726661	C1QL4	-0.37	-6.25	-0.33	1.28e-9	Prostate cancer;
CRC	cis	rs11650494	0.710	rs8065814	chr17:47470720	T/C	cg08112188	chr17:47440006	ZNF652	0.67	5.99	0.31	5.63e-9	Prostate cancer;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg07395648	chr5:131743802	NA	-0.44	-6.04	-0.32	4.12e-9	Breast cancer;
CRC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.46	7.38	0.38	1.34e-12	Obesity-related traits;
CRC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg08648136	chr8:956695	NA	0.29	5.61	0.3	4.3e-8	Schizophrenia;
CRC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg11632617	chr15:75315747	PPCDC	-0.56	-7.96	-0.4	2.86e-14	Blood trace element (Zn levels);
CRC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.58	5.61	0.3	4.21e-8	Major depressive disorder;
CRC	cis	rs10991814	0.920	rs10512210	chr9:94048529	A/G	cg14446406	chr9:93919335	NA	-0.55	-6.31	-0.33	9.14e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.45	7.36	0.38	1.49e-12	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.61	-8.97	-0.44	2.37e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.49	-8.05	-0.41	1.56e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.3	0.33	9.78e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21643547	chr1:205240462	TMCC2	-0.37	-6.11	-0.32	2.85e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg27398640	chr15:77910606	LINGO1	-0.41	-6.83	-0.35	4.04e-11	Type 2 diabetes;
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12588279	chr6:26043732	HIST1H2BB	-0.43	-6.43	-0.33	4.51e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg22676075	chr6:135203613	NA	0.4	6.12	0.32	2.65e-9	Red blood cell count;
CRC	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg06172871	chr16:72088244	HP	0.43	6.25	0.33	1.27e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg18288967	chr1:45987694	PRDX1	0.68	7.23	0.37	3.33e-12	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.55	6.46	0.34	3.69e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.63	9.98	0.48	1.12e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg21970626	chr13:21893289	NA	0.46	6.0	0.31	5.12e-9	White matter hyperintensity burden;
CRC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.59	-7.73	-0.39	1.29e-13	Multiple sclerosis;
CRC	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.65	-10.93	-0.52	6.03e-24	Neuroticism;
CRC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.94	-0.68	1.01e-46	Height;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.7e-9	Bipolar disorder;
CRC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.05	-0.32	4.03e-9	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03840924	chr17:47645509	NA	0.4	5.98	0.31	5.94e-9	Intelligence (multi-trait analysis);
CRC	trans	rs16984718	1.000	rs16984718	chr2:18509254	C/T	cg03909902	chr12:108154529	PRDM4	0.55	6.1	0.32	3.05e-9	Urate levels in obese individuals;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.68	10.38	0.5	5.16e-22	Corneal astigmatism;
CRC	trans	rs4308415	0.753	rs1390071	chr4:67802231	G/A	cg19648955	chr2:177134095	MTX2	-0.41	-5.99	-0.31	5.44e-9	Educational attainment (years of education);
CRC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.51	7.91	0.4	3.87e-14	Corneal astigmatism;
CRC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.4	-5.76	-0.3	1.97e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.74	13.6	0.6	1.01e-33	Cancer;
CRC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.62	-11.69	-0.54	1.22e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00339695	chr16:24857497	SLC5A11	0.28	6.86	0.35	3.39e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.69	0.35	9.39e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg11843238	chr5:131593191	PDLIM4	0.35	6.45	0.33	4.08e-10	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-9.28	-0.46	2.38e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	ch.1.1254747R	chr1:39934760	MACF1	0.42	6.07	0.32	3.43e-9	Schizophrenia;
CRC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06505273	chr16:24850292	NA	-0.37	-5.67	-0.3	3.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.47	-7.18	-0.37	4.77e-12	Height;
CRC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-7.01	-0.36	1.37e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.31	0.33	8.89e-10	Morning vs. evening chronotype;
CRC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.49	6.67	0.35	1.1e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg06470822	chr6:28175283	NA	0.88	12.01	0.55	8.51e-28	Depression;
CRC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.59	-9.3	-0.46	2.02e-18	Aortic root size;
CRC	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg07513332	chr6:167530253	CCR6	0.38	6.9	0.36	2.6e-11	Primary biliary cholangitis;
CRC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg21194808	chr1:2205498	SKI	0.39	6.08	0.32	3.31e-9	Height;
CRC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.75	-12.32	-0.56	6.13e-29	Breast cancer;
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.97	-0.55	1.15e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.98	-16.67	-0.68	1.12e-45	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.4	0.62	8.78e-37	Fuchs's corneal dystrophy;
CRC	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg00935504	chr16:1863053	HAGH	0.31	5.62	0.3	4.07e-8	Blood metabolite levels;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg12273811	chr6:28175739	NA	0.48	6.73	0.35	7.39e-11	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.54	8.12	0.41	9.4e-15	Breast cancer;
CRC	cis	rs2274273	0.600	rs10131730	chr14:55840092	C/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.13	-0.32	2.46e-9	Protein biomarker;
CRC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.77	-0.7	5.11e-50	Height;
CRC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.4	5.82	0.31	1.4e-8	Renal cell carcinoma;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg03623178	chr6:28175578	NA	0.75	10.6	0.5	9.08e-23	Parkinson's disease;
CRC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17848003	chr1:3704513	LRRC47	0.4	5.92	0.31	8.3e-9	Red cell distribution width;
CRC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.69	-9.08	-0.45	1.02e-17	Blood pressure (smoking interaction);
CRC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.92	-16.06	-0.66	3.01e-43	Height;
CRC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg16342193	chr10:102329863	NA	-0.34	-5.81	-0.3	1.51e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg13844804	chr7:814759	HEATR2	0.68	8.66	0.43	2.2e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs6534441	0.727	rs58293561	chr4:125440801	C/T	cg21609808	chr4:125404261	NA	0.39	5.63	0.3	3.77e-8	Major depressive disorder;
CRC	cis	rs3020333	0.875	rs3020336	chr6:152013760	G/T	cg22157087	chr6:152012887	ESR1	0.53	7.87	0.4	5.16e-14	Total body bone mineral density;
CRC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.87	-0.61	8.95e-35	Blood metabolite levels;
CRC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.12	-19.7	-0.74	1.29e-57	Ulcerative colitis;
CRC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.77	13.6	0.6	1e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.81	15.43	0.65	8.96e-41	Prudent dietary pattern;
CRC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg09218773	chr11:619014	MUPCDH	-0.42	-6.04	-0.32	4.13e-9	Systemic lupus erythematosus;
CRC	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.77	-0.35	5.97e-11	Blood metabolite levels;
CRC	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.9	-14.16	-0.62	7.02e-36	Response to temozolomide;
CRC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg00343986	chr7:65444356	GUSB	-0.47	-6.52	-0.34	2.69e-10	Aortic root size;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg05865860	chr7:158649142	WDR60	-0.71	-5.97	-0.31	6.26e-9	Cognitive function;
CRC	cis	rs802075	1.000	rs360560	chr6:49659634	C/A	cg20364632	chr6:49636226	NA	-0.36	-5.87	-0.31	1.05e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.34	5.64	0.3	3.76e-8	Self-reported allergy;
CRC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg18282456	chr14:51561492	TRIM9	0.28	5.61	0.3	4.35e-8	Cancer;
CRC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg10589385	chr1:150898437	SETDB1	0.29	6.13	0.32	2.47e-9	Tonsillectomy;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7147624	0.572	rs72714498	chr14:66037734	C/T	cg03016385	chr14:66212404	NA	1.05	8.32	0.42	2.38e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.97	-19.07	-0.72	3.93e-55	Height;
CRC	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.79	7.64	0.39	2.36e-13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg13206674	chr6:150067644	NUP43	0.44	6.2	0.32	1.71e-9	Lung cancer;
CRC	cis	rs1552172	0.887	rs34695381	chr1:145683334	G/C	cg11743829	chr1:145714124	CD160	-0.43	-6.36	-0.33	6.74e-10	Breast cancer;
CRC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.57	-7.8	-0.4	8.03e-14	Response to antineoplastic agents;
CRC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-12.72	-0.57	1.97e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.45	6.61	0.34	1.54e-10	Lymphocyte counts;
CRC	cis	rs1320333	0.772	rs2867116	chr2:682363	C/A	cg20966539	chr2:681320	NA	0.65	6.11	0.32	2.76e-9	Obesity-related traits;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.05	-0.32	4.03e-9	Total body bone mineral density;
CRC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16447950	chr5:562315	NA	-0.78	-10.26	-0.49	1.35e-21	Obesity-related traits;
CRC	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.42	6.52	0.34	2.67e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.43	-0.33	4.41e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg13385794	chr1:248469461	NA	0.36	6.34	0.33	7.63e-10	Common traits (Other);
CRC	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.37	-5.7	-0.3	2.72e-8	Breast cancer;
CRC	cis	rs12044355	0.896	rs11122324	chr1:231859181	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.86	0.31	1.14e-8	Alzheimer's disease;
CRC	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.81	-14.19	-0.62	5.26e-36	Lewy body disease;
CRC	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg16898833	chr6:26189333	HIST1H4D	0.65	5.76	0.3	1.88e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.31	-5.7	-0.3	2.69e-8	Cutaneous nevi;
CRC	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.61	9.27	0.46	2.59e-18	Obesity-related traits;
CRC	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	0.93	11.25	0.53	4.78e-25	Height;
CRC	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.03	0.32	4.35e-9	Ovarian reserve;
CRC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.36	-5.7	-0.3	2.7e-8	Red cell distribution width;
CRC	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.57	9.91	0.48	1.97e-20	Age of smoking initiation;
CRC	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.68	-0.39	1.88e-13	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21426974	chr4:140005758	ELF2	0.37	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14725858	chr5:36241190	C5orf33	0.42	6.24	0.33	1.37e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-0.58	-8.39	-0.42	1.5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.75	13.09	0.59	8.08e-32	Prudent dietary pattern;
CRC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg03037974	chr15:76606532	NA	-0.41	-5.99	-0.31	5.44e-9	Blood metabolite levels;
CRC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-6.81	-0.35	4.6e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg13777783	chr17:79615861	NA	0.3	5.73	0.3	2.28e-8	Eye color traits;
CRC	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.4	-6.07	-0.32	3.43e-9	IFN-related cytopenia;
CRC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.25	-0.59	2.04e-32	Glomerular filtration rate (creatinine);
CRC	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.88	9.65	0.47	1.49e-19	Uric acid levels;
CRC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg21770322	chr7:97807741	LMTK2	0.53	8.66	0.43	2.11e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.58	-6.08	-0.32	3.28e-9	Opioid sensitivity;
CRC	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg00277334	chr10:82204260	NA	0.37	5.93	0.31	7.57e-9	Sarcoidosis;
CRC	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg10761708	chr20:43804764	PI3	0.5	5.8	0.3	1.54e-8	Blood protein levels;
CRC	cis	rs77861329	1.000	rs9847092	chr3:52199453	T/C	cg08692210	chr3:52188851	WDR51A	0.89	8.51	0.42	6.37e-16	Macrophage inflammatory protein 1b levels;
CRC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.54	7.93	0.4	3.47e-14	Resting heart rate;
CRC	cis	rs11166629	1.000	rs7818331	chr8:135639653	C/T	cg27224718	chr8:135614730	ZFAT	0.49	7.28	0.37	2.52e-12	Smoking quantity;
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.29	-0.46	2.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.83	-14.9	-0.63	9.63e-39	Colorectal cancer;
CRC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-15.35	-0.65	1.7e-40	Vitiligo;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg05378032	chr9:131798819	FAM73B	-0.42	-6.06	-0.32	3.64e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.14	-9.48	-0.46	5.05e-19	Mitochondrial DNA levels;
CRC	trans	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg26043149	chr18:55253948	FECH	-0.47	-7.13	-0.37	6.39e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-8.34	-0.42	2.08e-15	Chronic sinus infection;
CRC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg07393940	chr7:158741817	NA	0.52	7.31	0.37	2e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.83	7.88	0.4	4.83e-14	Diabetic retinopathy;
CRC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.68	11.73	0.54	9.01e-27	Age at first birth;
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.27	-0.33	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg27534772	chr1:16042836	PLEKHM2	0.43	7.26	0.37	2.74e-12	Systolic blood pressure;
CRC	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.42	0.38	1.03e-12	Eye color traits;
CRC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.87	-0.31	1.05e-8	Lung cancer;
CRC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg19812747	chr11:111475976	SIK2	0.43	6.2	0.32	1.65e-9	Primary sclerosing cholangitis;
CRC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.96	-0.31	6.46e-9	Lung cancer;
CRC	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.54	-0.34	2.3e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.56	6.67	0.35	1.1e-10	Ulcerative colitis;
CRC	cis	rs59104589	0.521	rs56697150	chr2:242430085	C/A	cg19488206	chr2:242435732	STK25	0.43	6.92	0.36	2.31e-11	Fibrinogen levels;
CRC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.38	-6.17	-0.32	2.05e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7849270	0.959	rs2094704	chr9:131918294	A/G	cg13538475	chr9:131942899	NA	-0.34	-6.34	-0.33	7.58e-10	Blood metabolite ratios;
CRC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.56	-0.34	2.09e-10	Mean corpuscular volume;
CRC	cis	rs1158570	0.500	rs7846376	chr8:131155443	G/A	cg21674704	chr8:131455249	NA	-0.41	-6.21	-0.32	1.58e-9	Platelet count;
CRC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg09655341	chr17:79618100	PDE6G	0.57	6.88	0.35	3.08e-11	Dental caries;
CRC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.45	0.34	3.96e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.67	9.48	0.46	5.14e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.52	-0.43	5.82e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.4	0.42	1.36e-15	Height;
CRC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg17724175	chr1:150552817	MCL1	0.44	6.72	0.35	8.22e-11	Melanoma;
CRC	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.7	9.85	0.48	3.22e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs7527798	0.571	rs11118237	chr1:207818719	G/A	cg09232269	chr1:207846808	CR1L	-0.49	-7.69	-0.39	1.74e-13	Erythrocyte sedimentation rate;
CRC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.7	-0.35	8.9e-11	Total body bone mineral density;
CRC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg15845792	chr6:28175446	NA	0.49	7.3	0.37	2.22e-12	Pubertal anthropometrics;
CRC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg07636037	chr3:49044803	WDR6	-0.8	-5.89	-0.31	9.69e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg08071915	chr8:12219732	FAM66A	0.33	6.03	0.32	4.37e-9	Retinal vascular caliber;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00473834	chr3:23987430	NR1D2	0.47	6.13	0.32	2.48e-9	Anxiety disorder;
CRC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.63	-9.8	-0.48	4.66e-20	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.7	-9.23	-0.45	3.38e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	9.51	0.46	4.18e-19	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.08	-0.32	3.24e-9	Life satisfaction;
CRC	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg21851534	chr17:3907994	ZZEF1	0.36	6.13	0.32	2.55e-9	Type 2 diabetes;
CRC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.49	-9.26	-0.45	2.75e-18	Reticulocyte fraction of red cells;
CRC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	7.86	0.4	5.61e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma (childhood onset);
CRC	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.4	-5.67	-0.3	3.15e-8	Intelligence;
CRC	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.58	8.2	0.41	5.55e-15	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00455178	chr11:14913981	CYP2R1	0.42	6.37	0.33	6.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.38	-7.17	-0.37	4.85e-12	Breast cancer;
CRC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg21132104	chr15:45694354	SPATA5L1	0.42	6.21	0.32	1.61e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.38	7.13	0.37	6.49e-12	Mean corpuscular volume;
CRC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.77	0.47	5.76e-20	Alzheimer's disease (late onset);
CRC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.61	-8.88	-0.44	4.4e-17	Menarche (age at onset);
CRC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.93	-17.27	-0.69	5.06e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.89	-20.48	-0.75	1.13e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.31e-12	Putamen volume;
CRC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg08222913	chr3:52553049	STAB1	-0.32	-5.62	-0.3	4.04e-8	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04496233	chr11:64863659	C11orf2	0.5	7.05	0.36	1.05e-11	Response to antipsychotic treatment;
CRC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.52	-0.46	4e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg03060546	chr3:49711283	APEH	0.4	5.66	0.3	3.33e-8	Menarche (age at onset);
CRC	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg05182265	chr7:156933206	UBE3C	0.62	8.98	0.44	2.09e-17	Type 2 diabetes;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.39	-0.38	1.26e-12	Breast cancer;
CRC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.29	-0.46	2.17e-18	Dupuytren's disease;
CRC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.44e-20	Aortic root size;
CRC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.75	-0.3	2e-8	Major depressive disorder;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg21546874	chr1:9294571	H6PD	-0.7	-6.03	-0.32	4.44e-9	Cognitive function;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.71	11.53	0.54	4.5e-26	Longevity;Endometriosis;
CRC	cis	rs7835763	0.642	rs2468152	chr8:119106765	A/T	cg11592677	chr8:119110466	EXT1	-0.39	-6.39	-0.33	5.66e-10	Autism spectrum disorder;
CRC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.38	-5.69	-0.3	2.79e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg21970626	chr13:21893289	NA	0.44	5.8	0.3	1.59e-8	White matter hyperintensity burden;
CRC	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg06470822	chr6:28175283	NA	0.62	6.81	0.35	4.6e-11	Depression;
CRC	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.64	-9.26	-0.45	2.71e-18	Type 2 diabetes;
CRC	cis	rs3018066	0.831	rs10003024	chr4:107074097	G/A	cg01869342	chr4:106983673	TBCK	0.37	5.74	0.3	2.15e-8	Cancer;
CRC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg07865391	chr16:88106882	BANP	0.46	6.05	0.32	3.86e-9	Menopause (age at onset);
CRC	trans	rs2018683	0.649	rs221171	chr7:29006139	C/G	cg19402173	chr7:128379420	CALU	0.47	6.55	0.34	2.24e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg23463467	chr20:60627584	TAF4	0.41	7.51	0.38	5.56e-13	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06221470	chr7:2353869	SNX8	0.37	6.12	0.32	2.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.12	-0.37	6.98e-12	Major depressive disorder;
CRC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.6	8.14	0.41	8.41e-15	Menopause (age at onset);
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.46	7.92	0.4	3.76e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.68	11.03	0.52	2.76e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9361491	0.657	rs9448537	chr6:79437747	G/A	cg05283184	chr6:79620031	NA	-0.37	-5.69	-0.3	2.84e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.09e-10	Bipolar disorder;
CRC	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg04586622	chr2:25135609	ADCY3	-0.48	-8.59	-0.43	3.64e-16	Body mass index;
CRC	cis	rs9491140	0.539	rs11154228	chr6:124686042	A/G	cg22366943	chr6:124882293	NKAIN2	0.56	8.4	0.42	1.39e-15	Neuroticism;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg18232548	chr7:50535776	DDC	-0.41	-6.28	-0.33	1.1e-9	Body mass index;
CRC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.07	-0.55	5.16e-28	Primary sclerosing cholangitis;
CRC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.06	-12.27	-0.56	9.34e-29	Diabetic kidney disease;
CRC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg24562669	chr7:97807699	LMTK2	0.79	17.64	0.7	1.69e-49	Breast cancer;
CRC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.46	5.94	0.31	7.35e-9	Obesity-related traits;
CRC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.68	10.43	0.5	3.46e-22	Calcium levels;
CRC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg25876840	chr17:41920477	NA	0.5	7.61	0.39	2.87e-13	Triglycerides;
CRC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.99	0.31	5.57e-9	Lung cancer;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	5.64	0.3	3.59e-8	Longevity;
CRC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg15744005	chr10:104629667	AS3MT	-0.36	-6.65	-0.34	1.25e-10	Arsenic metabolism;
CRC	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.52	9.29	0.46	2.22e-18	Vitiligo;
CRC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.8	12.24	0.56	1.19e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.69	7.77	0.39	9.92e-14	Body mass index;
CRC	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.47	5.98	0.31	5.87e-9	Neuroticism;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg09755102	chr1:33283495	S100PBP;YARS	-0.44	-6.76	-0.35	6.23e-11	Aortic root size;
CRC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.0	-0.52	3.67e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg11189052	chr15:85197271	WDR73	0.61	8.81	0.44	7.07e-17	Schizophrenia;
CRC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.67	9.89	0.48	2.35e-20	Longevity;
CRC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.55	8.07	0.41	1.31e-14	Tuberculosis;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg09264619	chr17:80180166	NA	-0.36	-6.04	-0.32	4.23e-9	Life satisfaction;
CRC	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg27053337	chr8:124217698	FAM83A	0.45	6.08	0.32	3.35e-9	Urinary uromodulin levels;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg06470822	chr6:28175283	NA	0.86	13.52	0.6	1.92e-33	Cardiac Troponin-T levels;
CRC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	9.01	0.45	1.67e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2795502	0.630	rs3004257	chr10:43480529	C/T	cg08461752	chr10:43522343	NA	-0.85	-7.64	-0.39	2.38e-13	Blood protein levels;
CRC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.66	-10.86	-0.51	1.08e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.71	0.54	1e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.33	0.37	1.76e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg00490450	chr3:139108681	COPB2	0.44	6.58	0.34	1.89e-10	Obesity-related traits;
CRC	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.81	-10.35	-0.5	6.47e-22	Diisocyanate-induced asthma;
CRC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.43	6.49	0.34	3.23e-10	Alzheimer's disease (late onset);
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11645453	chr3:52864694	ITIH4	0.35	5.99	0.31	5.43e-9	Bipolar disorder;
CRC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	18.46	0.71	9.86e-53	Prudent dietary pattern;
CRC	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg13385794	chr1:248469461	NA	0.38	6.71	0.35	8.44e-11	Common traits (Other);
CRC	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.74	11.73	0.54	8.65e-27	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.05	-0.32	3.89e-9	Pubertal anthropometrics;
CRC	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg00105475	chr2:10696890	NA	0.45	7.12	0.37	6.81e-12	Prostate cancer;
CRC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-8.02	-0.4	1.94e-14	Aortic root size;
CRC	trans	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg10756647	chr7:56101905	PSPH	0.77	7.84	0.4	6.51e-14	Diabetic kidney disease;
CRC	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg12855166	chr17:30846586	MYO1D	-0.35	-5.62	-0.3	4.06e-8	Schizophrenia;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08695707	chr1:197871847	C1orf53	-0.42	-6.18	-0.32	1.88e-9	Daytime sleep phenotypes;
CRC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.7	11.21	0.53	6.32e-25	Corneal astigmatism;
CRC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg15147215	chr3:52552868	STAB1	0.49	8.39	0.42	1.45e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10189230	0.546	rs6727259	chr2:222358292	C/G	cg14652038	chr2:222343519	EPHA4	-0.37	-6.0	-0.31	5.27e-9	Urate levels in lean individuals;
CRC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.62	0.51	7.72e-23	Diabetic retinopathy;
CRC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.37	5.75	0.3	2.04e-8	Crohn's disease;
CRC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.59	9.28	0.46	2.27e-18	Lewy body disease;
CRC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg23018236	chr17:30244563	NA	-0.66	-7.82	-0.4	7.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1448094	0.617	rs1354258	chr12:86485647	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.14	-0.37	5.87e-12	Major depressive disorder;
CRC	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.32	0.37	1.92e-12	Neuroticism;
CRC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	7.13	0.37	6.28e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.57	0.63	1.8e-37	Hypertriglyceridemia;
CRC	trans	rs1933755	0.541	rs59942439	chr6:130920937	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.92	-6.72	-0.35	7.93e-11	Colorectal cancer (calcium intake interaction);
CRC	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg24375607	chr4:120327624	NA	0.46	7.05	0.36	1.03e-11	Educational attainment;
CRC	trans	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg26043149	chr18:55253948	FECH	-0.47	-7.11	-0.36	7.18e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg08885800	chr1:201084119	NA	0.39	7.07	0.36	9.44e-12	Permanent tooth development;
CRC	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs3018066	0.748	rs10030019	chr4:106998448	G/A	cg01869342	chr4:106983673	TBCK	0.44	6.68	0.35	1.04e-10	Cancer;
CRC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.53	-7.4	-0.38	1.12e-12	Serum sulfate level;
CRC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.72	-10.91	-0.52	7.63e-24	Immature fraction of reticulocytes;
CRC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.26	0.37	2.89e-12	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14715455	chr9:73035436	NA	0.41	5.99	0.31	5.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.31	-5.71	-0.3	2.52e-8	Longevity;Endometriosis;
CRC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.85	-0.48	3.08e-20	Hip circumference adjusted for BMI;
CRC	cis	rs28493229	0.881	rs73931345	chr19:41180347	G/A	cg21869046	chr19:41225005	ITPKC	0.44	6.45	0.33	4.07e-10	Kawasaki disease;
CRC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.69	-9.05	-0.45	1.32e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg05874882	chr4:1763078	NA	-0.38	-7.06	-0.36	1.02e-11	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg16141378	chr3:129829833	LOC729375	0.41	6.04	0.32	4.28e-9	Joint mobility (Beighton score);
CRC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg25382214	chr1:3105252	PRDM16	-0.47	-7.46	-0.38	7.54e-13	Migraine;
CRC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-6.78	-0.35	5.66e-11	Height;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12588279	chr6:26043732	HIST1H2BB	-0.48	-7.01	-0.36	1.36e-11	Intelligence (multi-trait analysis);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg18602325	chr19:44100565	ZNF576;IRGQ	-0.38	-6.36	-0.33	6.85e-10	Aortic root size;
CRC	cis	rs73206853	0.841	rs78843188	chr12:110827923	G/C	cg12870014	chr12:110450643	ANKRD13A	0.78	8.56	0.43	4.41e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9359856	1.000	rs2026650	chr6:90311633	C/G	cg13799429	chr6:90582589	CASP8AP2	0.45	6.39	0.33	5.52e-10	Bipolar disorder;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-6.85	-0.35	3.54e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg11522145	chr4:3412961	RGS12	-0.42	-6.49	-0.34	3.18e-10	Serum sulfate level;
CRC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.62	9.59	0.47	2.31e-19	Corneal astigmatism;
CRC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.29	0.53	3.34e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.57	-11.53	-0.54	4.7e-26	Neuroticism;
CRC	cis	rs9868809	0.649	rs17256786	chr3:48604016	C/G	cg00383909	chr3:49044727	WDR6	1.13	7.77	0.39	1.04e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.52	-7.2	-0.37	4.03e-12	Tuberculosis;
CRC	cis	rs1044826	0.642	rs295482	chr3:139229264	A/T	cg00490450	chr3:139108681	COPB2	-0.43	-6.45	-0.33	4.1e-10	Obesity-related traits;
CRC	trans	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg10756647	chr7:56101905	PSPH	-0.78	-8.02	-0.4	1.83e-14	Diabetic kidney disease;
CRC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.44	-9.76	-0.47	6.22e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.45	6.41	0.33	5.19e-10	Diastolic blood pressure;
CRC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.61	9.86	0.48	2.88e-20	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs12541635	0.801	rs12155862	chr8:107105243	G/A	cg10147462	chr8:107024639	NA	-0.39	-6.05	-0.32	3.92e-9	Age of smoking initiation;
CRC	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg04990556	chr1:26633338	UBXN11	0.54	5.73	0.3	2.22e-8	Obesity-related traits;
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.57	-0.34	1.91e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg18709589	chr6:96969512	KIAA0776	0.53	5.87	0.31	1.04e-8	Migraine;Coronary artery disease;
CRC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.09	-0.32	3.11e-9	Menopause (age at onset);
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg23517124	chr12:50419441	RACGAP1	0.42	5.98	0.31	5.95e-9	Underweight status;
CRC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.6	6.59	0.34	1.8e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.5	6.88	0.35	3.06e-11	Longevity;Endometriosis;
CRC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.64	0.34	1.28e-10	Tonsillectomy;
CRC	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.69	-0.35	9.45e-11	Educational attainment (years of education);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13294780	chr4:140005756	ELF2	-0.41	-6.23	-0.32	1.39e-9	Myopia (pathological);
CRC	trans	rs33794	0.577	rs245213	chr3:45241629	A/G	cg00688460	chr12:48922396	NA	0.27	5.97	0.31	6.06e-9	Lung function (forced expiratory volume in 1 second);
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg14196790	chr5:131705035	SLC22A5	0.34	6.06	0.32	3.69e-9	Blood metabolite levels;
CRC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.32	-0.42	2.35e-15	Gut microbiome composition (summer);
CRC	trans	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg18187862	chr3:45730750	SACM1L	0.46	6.58	0.34	1.83e-10	Primary sclerosing cholangitis;
CRC	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-7.28	-0.37	2.41e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.51	6.79	0.35	5.1e-11	Breast cancer;
CRC	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02065795	chr15:64673455	KIAA0101	0.47	6.09	0.32	3.14e-9	Thyroid stimulating hormone;
CRC	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.1	-0.36	7.85e-12	Triglycerides;
CRC	cis	rs7172809	0.607	rs78510848	chr15:77842308	G/C	cg10437265	chr15:77819839	NA	-0.36	-5.99	-0.31	5.65e-9	Glucose homeostasis traits;
CRC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg05185784	chr16:90016020	DEF8	0.62	9.13	0.45	7.14e-18	Squamous cell carcinoma;
CRC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.48	6.09	0.32	3.23e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17443541	0.507	rs971325	chr2:200450294	A/G	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.57	8.3	0.42	2.79e-15	Squamous cell lung carcinoma;
CRC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg13390004	chr1:15929781	NA	0.5	7.09	0.36	8.36e-12	Systolic blood pressure;
CRC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	0.95	18.79	0.72	5e-54	Height;
CRC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.57	10.46	0.5	2.76e-22	Coronary artery disease;
CRC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.49	-6.15	-0.32	2.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.63	-6.0	-0.31	5.32e-9	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01099580	chr10:89264946	MINPP1	0.4	6.27	0.33	1.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg03609598	chr5:56110824	MAP3K1	-0.44	-6.23	-0.32	1.47e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg23100626	chr2:96804247	ASTL	0.26	7.11	0.37	7.19e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.45	-0.33	4.04e-10	Lymphocyte counts;
CRC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg15440763	chr7:158190612	PTPRN2	0.41	6.52	0.34	2.63e-10	Obesity-related traits;
CRC	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06634786	chr22:41940651	POLR3H	-0.44	-5.85	-0.31	1.18e-8	Vitiligo;
CRC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.4	-6.47	-0.34	3.45e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg17691542	chr6:26056736	HIST1H1C	0.43	5.75	0.3	2e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.724	rs10229152	chr7:124538285	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.13	-0.32	2.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg21194808	chr1:2205498	SKI	-0.4	-6.13	-0.32	2.47e-9	Height;
CRC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.51	-8.42	-0.42	1.17e-15	Aortic root size;
CRC	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg18827107	chr12:86230957	RASSF9	-0.39	-5.99	-0.31	5.37e-9	Major depressive disorder;
CRC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.84	-0.35	3.87e-11	Body mass index;
CRC	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.07	-14.82	-0.63	2.09e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.7	-11.66	-0.54	1.6e-26	Longevity;
CRC	trans	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg18288967	chr1:45987694	PRDX1	0.64	7.23	0.37	3.37e-12	Obesity-related traits;
CRC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-8.67	-0.43	1.99e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs713477	0.654	rs6573030	chr14:55913720	T/G	cg13175173	chr14:55914753	NA	-0.43	-7.74	-0.39	1.23e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.43	8.82	0.44	6.79e-17	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.7	-0.51	3.89e-23	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00166722	chr3:10149974	C3orf24	0.61	7.91	0.4	3.89e-14	Alzheimer's disease;
CRC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.62	8.46	0.42	8.8e-16	Smoking initiation;
CRC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.59	-0.5	9.95e-23	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg24644049	chr4:85504048	CDS1	0.86	6.92	0.36	2.32e-11	Skin colour saturation;
CRC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.06	-0.36	9.88e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.47	5.82	0.31	1.4e-8	Bladder cancer;
CRC	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.72	11.24	0.53	5.04e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.64	-8.57	-0.43	4.22e-16	Multiple sclerosis;
CRC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.37	0.46	1.23e-18	Lymphocyte counts;
CRC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.39	6.72	0.35	8.06e-11	Crohn's disease;
CRC	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.91	0.36	2.52e-11	Mean corpuscular volume;
CRC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-0.82	-8.26	-0.41	3.54e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.46	6.41	0.33	5.06e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.14	23.72	0.79	3.34e-73	IgG glycosylation;
CRC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	0.71	6.48	0.34	3.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.83	-0.55	3.9e-27	Type 2 diabetes;
CRC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.6	10.62	0.51	7.84e-23	Aortic root size;
CRC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.59	0.43	3.61e-16	Arsenic metabolism;
CRC	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.8	9.26	0.45	2.77e-18	Uric acid levels;
CRC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg07884673	chr3:53033167	SFMBT1	0.67	5.89	0.31	9.73e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.02	18.9	0.72	1.81e-54	Primary sclerosing cholangitis;
CRC	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.94	-15.18	-0.64	8.33e-40	Dupuytren's disease;
CRC	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg04289385	chr6:36355825	ETV7	0.39	5.71	0.3	2.48e-8	Platelet distribution width;
CRC	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.44	6.44	0.33	4.14e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs863345	0.604	rs6666805	chr1:158498305	G/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.59	7.91	0.4	3.96e-14	Schizophrenia;
CRC	trans	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg24644049	chr4:85504048	CDS1	0.77	7.03	0.36	1.23e-11	Skin colour saturation;
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg04155289	chr7:94953770	PON1	-0.62	-7.74	-0.39	1.21e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.19	-0.32	1.8e-9	Aortic root size;
CRC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	6.15	0.32	2.25e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6662572	0.737	rs11211206	chr1:46323192	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg06737308	chr4:185021514	ENPP6	-0.45	-6.77	-0.35	5.92e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.44	-8.13	-0.41	8.67e-15	Reticulocyte fraction of red cells;
CRC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.56	7.25	0.37	3.06e-12	Neutrophil percentage of white cells;
CRC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg22532475	chr10:104410764	TRIM8	-0.35	-6.48	-0.34	3.41e-10	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19988671	chr7:155589783	NA	0.41	6.21	0.32	1.64e-9	Response to antipsychotic treatment;
CRC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.43	-7.21	-0.37	3.76e-12	Prostate-specific antigen levels;
CRC	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg21452805	chr1:244014465	NA	0.49	6.41	0.33	4.95e-10	RR interval (heart rate);
CRC	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.51	0.34	2.87e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg19223190	chr17:80058835	NA	0.41	6.45	0.33	4.04e-10	Life satisfaction;
CRC	cis	rs3736485	0.934	rs17609693	chr15:51868000	T/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.64	-0.34	1.33e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.46	-6.95	-0.36	1.96e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.78	-13.74	-0.6	2.92e-34	Breast cancer;
CRC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.39	6.08	0.32	3.35e-9	Crohn's disease;
CRC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.62	9.32	0.46	1.72e-18	Menopause (age at onset);
CRC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.39	-6.64	-0.34	1.27e-10	Height;
CRC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.63	0.43	2.68e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg11189052	chr15:85197271	WDR73	0.59	8.36	0.42	1.75e-15	Schizophrenia;
CRC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.34	5.93	0.31	7.66e-9	Mean corpuscular hemoglobin;
CRC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg03929089	chr4:120376271	NA	0.58	6.31	0.33	8.87e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.32	-5.85	-0.31	1.17e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.55	8.53	0.43	5.46e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.5	-0.34	2.93e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.33e-15	Type 2 diabetes;
CRC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg06204229	chr3:52865917	ITIH4	0.52	5.86	0.31	1.13e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.86	-13.95	-0.61	4.71e-35	Blood metabolite levels;
CRC	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.62	-8.3	-0.42	2.78e-15	White matter hyperintensity burden;
CRC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	8.42	0.42	1.21e-15	Menarche (age at onset);
CRC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.7	-8.37	-0.42	1.72e-15	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23526204	chr20:43992176	SYS1;SYS1-DBNDD2	0.42	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.86	-0.51	1.1e-23	Blood trace element (Zn levels);
CRC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg15534755	chr11:117069859	TAGLN	-0.35	-6.52	-0.34	2.6200000000000003e-10	Blood protein levels;
CRC	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.62	0.3	4.06e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.5	6.71	0.35	8.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.57	8.26	0.41	3.49e-15	Homoarginine levels;
CRC	cis	rs9925964	0.933	rs2359612	chr16:31103796	A/G	cg03418659	chr16:31128414	MYST1	-0.44	-6.33	-0.33	8.02e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25637824	chr1:54304148	TMEM48	0.5	6.91	0.36	2.55e-11	Anxiety disorder;
CRC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.32	19.68	0.74	1.61e-57	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg23425280	chr12:56401806	NA	0.45	5.62	0.3	4.06e-8	Cancer;
CRC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.47	6.8	0.35	4.93e-11	Blood metabolite levels;
CRC	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.73	9.69	0.47	1.06e-19	Prostate cancer;
CRC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg20487152	chr13:99095054	FARP1	-0.44	-6.36	-0.33	6.89e-10	Longevity;
CRC	cis	rs4662945	0.762	rs28510974	chr2:130215288	G/A	cg05962382	chr2:130345044	NA	-0.36	-6.07	-0.32	3.62e-9	Response to cytidine analogues (gemcitabine);
CRC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg03037974	chr15:76606532	NA	-0.59	-9.67	-0.47	1.26e-19	Blood metabolite levels;
CRC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg03060546	chr3:49711283	APEH	0.41	5.91	0.31	8.73e-9	Menarche (age at onset);
CRC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg10911889	chr6:126070802	HEY2	0.38	5.84	0.31	1.29e-8	Brugada syndrome;
CRC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.07	0.36	9.56e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1223397	0.689	rs2439539	chr6:13308833	G/A	cg20827128	chr6:13274284	PHACTR1	0.39	5.96	0.31	6.67e-9	Blood pressure;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg14196790	chr5:131705035	SLC22A5	0.34	6.05	0.32	3.84e-9	Blood metabolite levels;
CRC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.53	7.69	0.39	1.72e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.95	-0.4	3.02e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.46	7.6	0.39	3.1400000000000003e-13	Major depressive disorder;
CRC	cis	rs7901135	0.962	rs9415584	chr10:60567917	A/C	cg23799393	chr10:60588674	BICC1	0.37	5.67	0.3	3.09e-8	Morning vs. evening chronotype;
CRC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.51	6.71	0.35	8.47e-11	Obesity-related traits;
CRC	cis	rs7429990	0.932	rs6803741	chr3:48123540	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.74	-0.3	2.11e-8	Educational attainment (years of education);
CRC	cis	rs60871478	0.838	rs12530859	chr7:835034	G/A	cg05535760	chr7:792225	HEATR2	-1.01	-12.55	-0.57	8.38e-30	Cerebrospinal P-tau181p levels;
CRC	cis	rs6840360	0.582	rs2724555	chr4:152341878	A/G	cg09659197	chr4:152720779	NA	0.33	6.5	0.34	2.98e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.64	9.59	0.47	2.27e-19	Initial pursuit acceleration;
CRC	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg14325436	chr19:17404977	ABHD8	-0.35	-5.62	-0.3	4.04e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	6.05	0.32	4.05e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.61	-7.56	-0.38	4.02e-13	Body mass index;
CRC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.62	-6.22	-0.32	1.51e-9	Plasma clusterin levels;
CRC	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg14844989	chr11:31128820	NA	0.34	6.26	0.33	1.21e-9	Red blood cell count;
CRC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.74e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg06046430	chr4:77819534	ANKRD56	0.41	5.68	0.3	2.94e-8	Emphysema distribution in smoking;
CRC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	0.88	10.32	0.49	8.03e-22	Type 2 diabetes nephropathy;
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-12.88	-0.58	4.97e-31	Alzheimer's disease;
CRC	cis	rs2625529	0.730	rs2929528	chr15:72269337	C/A	cg16672083	chr15:72433130	SENP8	0.44	6.39	0.33	5.75e-10	Red blood cell count;
CRC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	9.86	0.48	2.92e-20	Hip circumference adjusted for BMI;
CRC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.4	6.22	0.32	1.51e-9	Blood protein levels;
CRC	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.6	9.17	0.45	5.15e-18	Ulcerative colitis;
CRC	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.58	8.45	0.42	9.44e-16	Uric acid levels;
CRC	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg25019722	chr6:37503610	NA	-0.39	-7.11	-0.36	7.23e-12	Cognitive performance;
CRC	cis	rs12024301	0.557	rs57834388	chr1:183642443	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.82	6.81	0.35	4.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.96	-0.31	6.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg17903999	chr18:56338584	MALT1	0.44	7.39	0.38	1.24e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.39	-0.33	5.61e-10	Obesity-related traits;
CRC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg00579200	chr11:133705235	NA	-0.4	-5.64	-0.3	3.71e-8	Childhood ear infection;
CRC	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.51	8.0	0.4	2.21e-14	Schizophrenia;
CRC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg08999081	chr20:33150536	PIGU	0.45	5.81	0.31	1.44e-8	Protein C levels;
CRC	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg12218747	chr21:37451666	NA	-0.43	-6.75	-0.35	6.5e-11	Mitral valve prolapse;
CRC	cis	rs939584	1.000	rs10865548	chr2:631606	A/G	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	cis	rs7512552	0.803	rs9436127	chr1:150490565	G/A	cg15654264	chr1:150340011	RPRD2	0.59	7.92	0.4	3.63e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg05754148	chr16:3507555	NAT15	-0.68	-6.86	-0.35	3.48e-11	Tuberculosis;
CRC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.53	0.5	1.6e-22	Ileal carcinoids;
CRC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-6.96	-0.36	1.8e-11	Neuroticism;
CRC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-8.96	-0.44	2.4e-17	Cognitive function;
CRC	trans	rs11581859	0.950	rs17392389	chr1:99357704	T/C	cg12183875	chr3:169587454	LRRC31	0.27	6.27	0.33	1.12e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg02683197	chr6:28174875	NA	0.62	8.6	0.43	3.34e-16	Parkinson's disease;
CRC	cis	rs6834538	0.744	rs11936846	chr4:113409270	G/A	cg10021238	chr4:113569128	MIR367;LARP7	-0.4	-6.0	-0.31	5.06e-9	Free thyroxine concentration;
CRC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	13.72	0.6	3.42e-34	Exhaled nitric oxide output;
CRC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.45	5.77	0.3	1.79e-8	Response to diuretic therapy;
CRC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.66	-10.48	-0.5	2.25e-22	Height;
CRC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06481639	chr22:41940642	POLR3H	0.53	5.65	0.3	3.43e-8	Vitiligo;
CRC	cis	rs10911390	0.744	rs7552563	chr1:183649620	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.6	5.62	0.3	4.06e-8	Systemic lupus erythematosus;
CRC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.67	8.92	0.44	3.38e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.6	-9.05	-0.45	1.31e-17	Schizophrenia;
CRC	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.64	-8.66	-0.43	2.16e-16	Malaria;
CRC	cis	rs10450586	0.863	rs7123749	chr11:27303855	A/G	cg10370305	chr11:27303972	NA	0.4	6.47	0.34	3.45e-10	Total body bone mineral density;
CRC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	13.69	0.6	4.34e-34	Smoking behavior;
CRC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-6.28	-0.33	1.09e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs524281	0.773	rs2282568	chr11:66052832	C/G	cg16950941	chr11:66035639	RAB1B	-0.72	-8.12	-0.41	9.39e-15	Electroencephalogram traits;
CRC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-1.04	-20.96	-0.76	1.52e-62	Headache;
CRC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.27	14.47	0.62	4.65e-37	Uric acid levels;
CRC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.51	8.25	0.41	3.87e-15	Aortic root size;
CRC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.47	0.57	1.66e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.62	-9.07	-0.45	1.11e-17	Menarche (age at onset);
CRC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg02741985	chr17:80059408	CCDC57	0.45	7.41	0.38	1.06e-12	Life satisfaction;
CRC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg16141378	chr3:129829833	LOC729375	0.42	6.23	0.32	1.42e-9	Retinal vascular caliber;
CRC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.11	-0.32	2.88e-9	Arsenic metabolism;
CRC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.42	6.75	0.35	6.51e-11	Red blood cell count;
CRC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg13390004	chr1:15929781	NA	0.52	7.28	0.37	2.49e-12	Systolic blood pressure;
CRC	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.42	6.06	0.32	3.73e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs965469	0.545	rs6051845	chr20:3402792	A/G	cg25506879	chr20:3388711	C20orf194	-0.34	-5.86	-0.31	1.12e-8	IFN-related cytopenia;
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.04	0.36	1.09e-11	Life satisfaction;
CRC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.35	-0.5	6.51e-22	Chronic sinus infection;
CRC	cis	rs990171	0.955	rs2058658	chr2:103054803	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg15845792	chr6:28175446	NA	0.92	12.48	0.57	1.64e-29	Parkinson's disease;
CRC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.81	14.24	0.62	3.43e-36	Breast cancer;
CRC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.84	0.35	3.77e-11	Hemoglobin concentration;
CRC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.58	7.8	0.39	8.49e-14	Height;
CRC	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-11.01	-0.52	3.36e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18402987	chr7:1209562	NA	0.46	6.67	0.35	1.09e-10	Longevity;Endometriosis;
CRC	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-8.17	-0.41	6.87e-15	Hepatocellular carcinoma;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.82	10.63	0.51	7.03e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg27205649	chr11:78285834	NARS2	0.48	6.03	0.32	4.36e-9	Alzheimer's disease (survival time);
CRC	cis	rs3018066	0.666	rs74571473	chr4:107046595	T/C	cg01869342	chr4:106983673	TBCK	0.48	6.19	0.32	1.75e-9	Cancer;
CRC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.24	-0.56	1.24e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.34	-0.42	2.08e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-10.08	-0.49	5.14e-21	Platelet distribution width;
CRC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.3	10.59	0.5	9.7e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.99	-18.6	-0.72	2.74e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04399615	chr6:142468354	VTA1	0.44	6.08	0.32	3.42e-9	Anxiety disorder;
CRC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.38	5.62	0.3	3.97e-8	Colorectal cancer;
CRC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.56	-0.38	4.18e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.58	7.94	0.4	3.29e-14	Lung cancer;
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg25834613	chr7:1915315	MAD1L1	-0.42	-5.89	-0.31	9.29e-9	Neuroticism;
CRC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.3	0.53	3.09e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.54	-0.34	2.42e-10	Life satisfaction;
CRC	cis	rs863345	0.564	rs12145401	chr1:158494693	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.88e-9	Pneumococcal bacteremia;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.47	-0.34	3.47e-10	Reticulocyte fraction of red cells;
CRC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs4664293	0.867	rs7566584	chr2:160584795	A/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.85	0.66	1.99e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.53	7.45	0.38	8.27e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.7e-21	Depression;
CRC	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.74	7.9	0.4	4.17e-14	Breast cancer;
CRC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.57	7.71	0.39	1.5e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.95	15.39	0.65	1.21e-40	Primary sclerosing cholangitis;
CRC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg11212589	chr17:38028394	ZPBP2	0.43	7.77	0.39	1.04e-13	Self-reported allergy;
CRC	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.48	7.44	0.38	8.87e-13	Schizophrenia;
CRC	cis	rs7705042	0.793	rs1036207	chr5:141499041	A/G	cg07392085	chr5:141489673	NDFIP1	0.47	7.41	0.38	1.07e-12	Asthma;
CRC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg17333051	chr19:2783644	SGTA	0.44	6.67	0.35	1.06e-10	Total cholesterol levels;
CRC	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg13385794	chr1:248469461	NA	0.38	6.63	0.34	1.39e-10	Common traits (Other);
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-9.1	-0.45	8.89e-18	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.53	-7.85	-0.4	5.96e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	7.01	0.36	1.37e-11	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.79	13.42	0.59	4.91e-33	Menopause (age at onset);
CRC	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg24519413	chr1:26490540	NA	0.38	6.35	0.33	7.05e-10	Height;
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.8	-11.58	-0.54	2.97e-26	Height;
CRC	cis	rs2882667	0.690	rs1976562	chr5:138110594	G/A	cg09476006	chr5:138032270	NA	-0.56	-9.6	-0.47	2.19e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg10820045	chr2:198174542	NA	0.33	5.67	0.3	3.06e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.96	0.31	6.42e-9	Homoarginine levels;
CRC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.6	-0.39	3.17e-13	Bipolar disorder;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg08798685	chr6:27730294	NA	-0.39	-5.89	-0.31	9.65e-9	Parkinson's disease;
CRC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.98	-0.52	4.16e-24	Hepatocellular carcinoma;
CRC	trans	rs10242455	0.702	rs58348977	chr7:99188014	G/A	cg09045935	chr12:6379348	NA	1.15	8.44	0.42	9.95e-16	Blood metabolite levels;
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.06	0.52	2.21e-24	Prudent dietary pattern;
CRC	cis	rs9463078	0.691	rs9381361	chr6:45011417	A/C	cg25276700	chr6:44698697	NA	-0.25	-6.18	-0.32	1.89e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	trans	rs2303319	0.582	rs56315911	chr2:162560186	G/T	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.45	-0.34	4.07e-10	Cognitive function;
CRC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.59	9.19	0.45	4.67e-18	Aortic root size;
CRC	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.33e-10	Vitamin D levels;
CRC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07701084	chr6:150067640	NUP43	0.49	7.05	0.36	1.07e-11	Testicular germ cell tumor;
CRC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.91	-15.93	-0.66	9.48e-43	Height;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.5	5.96	0.31	6.54e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg15412446	chr2:106886593	NA	-0.38	-6.14	-0.32	2.35e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.07	9.9	0.48	2.17e-20	Alzheimer's disease (late onset);
CRC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.91	-10.42	-0.5	3.78e-22	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26329020	chr12:32909488	YARS2	0.47	6.12	0.32	2.69e-9	Thyroid stimulating hormone;
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg06470822	chr6:28175283	NA	0.67	5.84	0.31	1.25e-8	Depression;
CRC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg13057898	chr1:3703894	LRRC47	0.54	7.1	0.36	7.53e-12	Red cell distribution width;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.39	-0.33	5.55e-10	Breast cancer;
CRC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.6	10.22	0.49	1.81e-21	Birth weight;
CRC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg07713946	chr22:31675144	LIMK2	-0.39	-5.64	-0.3	3.6e-8	Colorectal cancer;
CRC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.69	9.7	0.47	9.65e-20	Cognitive function;
CRC	cis	rs243505	0.660	rs3779038	chr7:148542822	C/T	cg09806900	chr7:148480153	CUL1	0.52	6.67	0.35	1.07e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.55	8.23	0.41	4.44e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.27	0.56	9.74e-29	Platelet count;
CRC	cis	rs12692738	0.526	rs355859	chr2:165629520	T/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.57	-0.47	2.62e-19	Subjective well-being;
CRC	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.39	-6.46	-0.34	3.7e-10	Mean arterial pressure;
CRC	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.45	-6.53	-0.34	2.56e-10	Body mass index;
CRC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg16141378	chr3:129829833	LOC729375	-0.39	-5.98	-0.31	5.91e-9	Triglycerides;
CRC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg02527881	chr3:46936655	PTH1R	-0.37	-6.86	-0.35	3.47e-11	Colorectal cancer;
CRC	cis	rs7259376	0.840	rs1985135	chr19:22523578	A/G	cg02657401	chr19:22469223	NA	-0.38	-8.15	-0.41	7.44e-15	Menopause (age at onset);
CRC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	10.68	0.51	4.6e-23	Motion sickness;
CRC	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.16e-9	Life satisfaction;
CRC	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg21839984	chr17:30846986	MYO1D	-0.34	-5.83	-0.31	1.31e-8	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27656398	chr12:123451108	ABCB9	0.39	6.43	0.33	4.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.42	-6.39	-0.33	5.66e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.65	10.12	0.49	3.78e-21	Birth weight;
CRC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg14196790	chr5:131705035	SLC22A5	0.36	5.8	0.3	1.56e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg05562828	chr17:3906858	NA	-0.66	-11.4	-0.53	1.3e-25	Type 2 diabetes;
CRC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.63	0.63	1.07e-37	Mean platelet volume;
CRC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.49	6.84	0.35	3.89e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.63	-0.3	3.82e-8	Reticulocyte count;
CRC	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg15571903	chr15:79123663	NA	0.34	6.92	0.36	2.4e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg08071915	chr8:12219732	FAM66A	0.32	5.77	0.3	1.82e-8	Retinal vascular caliber;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg01339444	chr6:118972232	C6orf204	0.53	6.03	0.32	4.29e-9	Diastolic blood pressure;
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg22110888	chr17:80059540	CCDC57	0.41	6.5	0.34	2.95e-10	Life satisfaction;
CRC	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg03258749	chr1:151040405	MLLT11	-0.47	-7.28	-0.37	2.55e-12	Childhood ear infection;
CRC	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg14593290	chr7:50529359	DDC	0.55	7.7	0.39	1.65e-13	Malaria;
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg18479299	chr3:125709523	NA	-0.54	-6.28	-0.33	1.04e-9	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs988712	0.622	rs4922793	chr11:27729505	A/G	cg10635145	chr11:27742435	BDNF	-0.41	-6.09	-0.32	3.12e-9	Obesity;
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.25e-10	Alzheimer's disease;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg23807890	chr2:228736357	WDR69	-0.49	-6.61	-0.34	1.58e-10	Blood pressure;
CRC	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.49	8.35	0.42	1.88e-15	Testicular germ cell tumor;
CRC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.68	0.35	1.02e-10	Tonsillectomy;
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.04	0.32	4.2e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg24011408	chr12:48396354	COL2A1	-0.44	-6.49	-0.34	3.25e-10	Glycated hemoglobin levels;
CRC	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg19640130	chr10:64028056	RTKN2	-0.35	-5.67	-0.3	3.12e-8	Rheumatoid arthritis;
CRC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg14711859	chr11:8959438	ASCL3	0.46	7.47	0.38	7.27e-13	Hemoglobin concentration;
CRC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.61	9.05	0.45	1.29e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg15193198	chr20:60906057	LAMA5	0.42	6.4	0.33	5.48e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg11900509	chr10:81946545	ANXA11	-0.66	-6.66	-0.34	1.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.65	-6.33	-0.33	8.11e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	7.3	0.37	2.16e-12	Lung cancer in ever smokers;
CRC	cis	rs3731896	0.571	rs77251296	chr2:220193172	A/G	cg00436969	chr2:220197716	RESP18	-0.46	-6.09	-0.32	3.14e-9	Educational attainment;
CRC	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.32	-0.37	1.94e-12	Colorectal cancer;
CRC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.79	11.3	0.53	3.2e-25	Neutrophil percentage of white cells;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18402987	chr7:1209562	NA	0.39	5.89	0.31	9.65e-9	Longevity;Endometriosis;
CRC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg21132104	chr15:45694354	SPATA5L1	0.42	6.07	0.32	3.57e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.43	6.35	0.33	7.01e-10	Pulmonary function decline;
CRC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.67	0.34	1.11e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg02972257	chr16:68554789	NA	0.45	5.65	0.3	3.4e-8	Colorectal cancer;
CRC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.11	0.49	4.19e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg24881330	chr22:46731750	TRMU	0.57	6.75	0.35	6.69e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11212617	1.000	rs609261	chr11:108158134	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.07	0.32	3.56e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg02549819	chr16:58548995	SETD6	1.2	7.97	0.4	2.72e-14	Schizophrenia;
CRC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-5.85	-0.31	1.2e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-12.07	-0.55	5.1e-28	Lung cancer;
CRC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.64	8.54	0.43	5.15e-16	Smoking initiation;
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-6.92	-0.36	2.4e-11	Putamen volume;
CRC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg14711859	chr11:8959438	ASCL3	0.46	7.64	0.39	2.32e-13	Hemoglobin concentration;
CRC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg05627522	chr15:75251581	NA	0.41	6.32	0.33	8.65e-10	Breast cancer;
CRC	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.73	9.71	0.47	9.45e-20	Coronary artery disease;
CRC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	11.89	0.55	2.29e-27	Bone mineral density;
CRC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.98	12.81	0.58	9.59e-31	Triglycerides;
CRC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.65	-11.88	-0.55	2.48e-27	Aortic root size;
CRC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg13607699	chr17:42295918	UBTF	-0.53	-7.18	-0.37	4.7e-12	Bone mineral density (hip);Bone mineral density (spine);
CRC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg26248373	chr2:1572462	NA	-0.63	-6.54	-0.34	2.3e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.79	15.64	0.65	1.35e-41	Mean corpuscular hemoglobin;
CRC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.08	0.45	9.99e-18	Hip circumference adjusted for BMI;
CRC	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.38	0.5	5.14e-22	Fuchs's corneal dystrophy;
CRC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.44	7.15	0.37	5.53e-12	Lung cancer;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Depression;
CRC	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.96	-0.31	6.36e-9	Alzheimer's disease (survival time);
CRC	cis	rs11233250	0.502	rs11233262	chr11:82402077	T/C	cg17391194	chr11:82401662	NA	0.44	6.73	0.35	7.69e-11	Glioblastoma;Glioma;
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	0.72	7.64	0.39	2.45e-13	Body mass index;
CRC	cis	rs459193	0.917	rs40270	chr5:55804552	A/C	cg26646659	chr5:55776364	NA	0.47	6.29	0.33	1.01e-9	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.44	-5.86	-0.31	1.15e-8	Gut microbiome composition (summer);
CRC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.31	-0.33	9.12e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.66	10.3	0.49	9.43e-22	Mood instability;
CRC	cis	rs12745968	0.629	rs2145824	chr1:93200401	T/A	cg17283838	chr1:93427260	FAM69A	-0.45	-6.03	-0.32	4.36e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11522767	chr6:157342961	ARID1B	-0.48	-5.98	-0.31	5.8e-9	Diisocyanate-induced asthma;
CRC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg24675056	chr1:15929824	NA	0.52	7.31	0.37	2.06e-12	Systolic blood pressure;
CRC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.84	-10.79	-0.51	1.93e-23	Initial pursuit acceleration;
CRC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg19622623	chr12:86230825	RASSF9	-0.36	-5.85	-0.31	1.22e-8	Major depressive disorder;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg19913688	chr11:428466	ANO9	-0.7	-7.25	-0.37	2.95e-12	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13275814	chr11:6640775	TPP1	0.42	6.24	0.33	1.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.48	4.84e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.67	0.35	1.09e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.35	5.93	0.31	7.86e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.33e-15	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04185729	chr11:65382031	MAP3K11	0.42	6.12	0.32	2.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.91	11.42	0.53	1.15e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.6	9.08	0.45	1.05e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.81	11.76	0.54	6.78e-27	Cognitive function;
CRC	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.46	7.89	0.4	4.64e-14	Common traits (Other);
CRC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg05585544	chr11:47624801	NA	-0.62	-11.44	-0.53	9.35e-26	Subjective well-being;
CRC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.76e-16	Menopause (age at onset);
CRC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-9.8	-0.48	4.7e-20	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg21153622	chr11:89784906	NA	-0.39	-6.16	-0.32	2.17e-9	Height;
CRC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg00074818	chr8:8560427	CLDN23	0.4	6.81	0.35	4.65e-11	Obesity-related traits;
CRC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	11.39	0.53	1.42e-25	Cognitive ability;
CRC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg12193833	chr17:30244370	NA	-0.76	-8.88	-0.44	4.33e-17	Hip circumference adjusted for BMI;
CRC	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.72	-10.93	-0.52	6.33e-24	Waist circumference;Body mass index;
CRC	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.9e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg20041105	chr8:143859282	LYNX1	-0.33	-5.76	-0.3	1.97e-8	Urinary tract infection frequency;
CRC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.44	6.77	0.35	5.94e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg20356878	chr3:121714668	ILDR1	-0.47	-6.11	-0.32	2.79e-9	Multiple sclerosis;
CRC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.58	-0.39	3.52e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02290350	chr8:58132656	NA	-0.5	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg15786705	chr6:28176104	NA	0.61	8.79	0.44	8.77e-17	Cardiac Troponin-T levels;
CRC	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.55	0.34	2.2e-10	Homocysteine levels;
CRC	cis	rs12936587	0.748	rs11871738	chr17:17525243	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.81	-0.3	1.5e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.72	0.3	2.37e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.36	5.65	0.3	3.5e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg18301423	chr5:131593218	PDLIM4	0.37	6.2	0.32	1.72e-9	Breast cancer;
CRC	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.74	11.08	0.52	1.84e-24	Testicular germ cell tumor;
CRC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg05941027	chr17:61774174	LIMD2	0.36	6.4	0.33	5.23e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.28	0.33	1.05e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.56	-9.92	-0.48	1.88e-20	Iron status biomarkers;
CRC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.66	8.7	0.43	1.63e-16	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09789050	chr5:61699876	DIMT1L	0.45	6.13	0.32	2.47e-9	Response to antipsychotic treatment;
CRC	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg04110750	chr16:69646130	NFAT5	0.49	6.89	0.35	2.9e-11	IgE levels;
CRC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg16447950	chr5:562315	NA	-0.84	-11.31	-0.53	2.82e-25	Lung disease severity in cystic fibrosis;
CRC	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.36	0.71	2.61e-52	Cognitive ability;
CRC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	7.85	0.4	5.96e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.56	-8.85	-0.44	5.48e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.3e-9	Prudent dietary pattern;
CRC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-6.02	-0.31	4.73e-9	Schizophrenia;
CRC	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg27398640	chr15:77910606	LINGO1	-0.46	-8.03	-0.4	1.79e-14	Type 2 diabetes;
CRC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.64	-8.91	-0.44	3.47e-17	Neuroticism;
CRC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg15107132	chr11:63991130	FERMT3	-0.38	-6.22	-0.32	1.48e-9	Platelet count;
CRC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-11.37	-0.53	1.7e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.78	8.36	0.42	1.76e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.55	-8.18	-0.41	6.37e-15	Vitiligo;
CRC	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.55	9.08	0.45	1.04e-17	Common traits (Other);
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg15790184	chr11:494944	RNH1	0.61	6.26	0.33	1.18e-9	Body mass index;
CRC	cis	rs7804356	1.000	rs73069533	chr7:26892325	G/A	cg03456212	chr7:26904342	SKAP2	-0.5	-5.69	-0.3	2.85e-8	Type 1 diabetes;
CRC	cis	rs16867321	1.000	rs16867321	chr2:181362379	C/T	cg23363182	chr2:181467187	NA	-0.51	-6.17	-0.32	2.02e-9	Obesity;
CRC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg08600765	chr20:34638493	LOC647979	-0.63	-7.6	-0.39	3.21e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.47	6.17	0.32	2.05e-9	Thyroid stimulating hormone;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12605341	chr20:18547891	LOC388789	0.42	6.11	0.32	2.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg13319975	chr6:146136371	FBXO30	0.39	5.77	0.3	1.83e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.9	16.62	0.68	1.87e-45	Intelligence (multi-trait analysis);
CRC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.44	7.87	0.4	5.26e-14	Schizophrenia;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg12205047	chr1:117209954	IGSF3	-0.4	-6.15	-0.32	2.23e-9	Aortic root size;
CRC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.11e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.57	8.56	0.43	4.35e-16	Tuberculosis;
CRC	cis	rs1223397	0.651	rs2439537	chr6:13307824	C/T	cg07912922	chr6:13274314	PHACTR1	0.39	5.96	0.31	6.38e-9	Blood pressure;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.71	-11.02	-0.52	3.07e-24	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.35	-6.1	-0.32	2.93e-9	Orofacial clefts;
CRC	trans	rs1578862	1.000	rs6426236	chr1:247434445	A/G	cg06850283	chr5:44389769	FGF10	0.25	5.99	0.31	5.49e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg07512295	chr2:234599026	UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.38	5.69	0.3	2.75e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9326248	0.590	rs2542063	chr11:116684767	C/T	cg11861562	chr11:117069780	TAGLN	0.28	6.42	0.33	4.85e-10	Blood protein levels;
CRC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.47	6.97	0.36	1.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg16576597	chr16:28551801	NUPR1	0.47	6.55	0.34	2.23e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs889398	0.741	rs6499269	chr16:69908918	T/C	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.21	-0.32	1.63e-9	Body mass index;
CRC	trans	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg05175333	chr18:18692284	ROCK1	-0.48	-6.02	-0.31	4.71e-9	Obesity (extreme);
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg18301423	chr5:131593218	PDLIM4	0.38	6.3	0.33	9.36e-10	Breast cancer;
CRC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.38	0.38	1.27e-12	Total body bone mineral density;
CRC	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.48	6.15	0.32	2.21e-9	Exhaled nitric oxide output;
CRC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.67	-7.95	-0.4	3.05e-14	Vitiligo;
CRC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.7	-11.03	-0.52	2.83e-24	Lung cancer;
CRC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg16447950	chr5:562315	NA	-0.79	-10.45	-0.5	2.87e-22	Lung disease severity in cystic fibrosis;
CRC	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.61	8.31	0.42	2.62e-15	Menopause (age at onset);
CRC	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg13385794	chr1:248469461	NA	0.36	6.26	0.33	1.21e-9	Common traits (Other);
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.54	-11.32	-0.53	2.68e-25	Longevity;Endometriosis;
CRC	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg25838818	chr2:108905173	SULT1C2	0.38	6.15	0.32	2.25e-9	Blood pressure;
CRC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.89	15.98	0.66	6.28e-43	Subjective well-being;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.77	-0.72	5.95e-54	Height;
CRC	cis	rs7605827	0.930	rs1125533	chr2:15617751	C/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.77	12.1	0.55	4.07e-28	Height;
CRC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.19	16.66	0.68	1.29e-45	Breast cancer;
CRC	cis	rs1062746	0.527	rs12934628	chr16:87335161	A/G	cg02258303	chr16:87377426	FBXO31	-0.51	-7.44	-0.38	8.99e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.58	-8.65	-0.43	2.29e-16	Pancreatic cancer;
CRC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.51	-8.43	-0.42	1.12e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-6.62	-0.34	1.49e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-12.16	-0.56	2.34e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg04586622	chr2:25135609	ADCY3	-0.56	-10.47	-0.5	2.58e-22	Body mass index;
CRC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.8	14.02	0.61	2.36e-35	Breast cancer;
CRC	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.72	-0.39	1.45e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.3	-0.33	9.74e-10	Aortic root size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11865413	chr10:72969054	NA	-0.48	-6.05	-0.32	3.88e-9	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.42	7.21	0.37	3.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04503171	chr8:110346293	NUDCD1;ENY2	0.42	6.22	0.32	1.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.58	-5.94	-0.31	7.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.96	0.36	1.83e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.569	rs7799535	chr7:124592060	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.03	-0.32	4.4e-9	Cutaneous malignant melanoma;
CRC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-8.69	-0.43	1.75e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.48	7.63	0.39	2.47e-13	Red blood cell count;
CRC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg15848620	chr12:58087721	OS9	-0.65	-9.03	-0.45	1.54e-17	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs8085804	1.000	rs658728	chr18:40222856	C/T	cg00372669	chr10:75571033	NDST2	-0.42	-6.16	-0.32	2.18e-9	Cognitive performance;
CRC	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-8.82	-0.44	6.63e-17	Hypospadias;
CRC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg14541582	chr5:601475	NA	-0.32	-6.61	-0.34	1.57e-10	Obesity-related traits;
CRC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.76	0.44	1.03e-16	Coronary artery disease;
CRC	cis	rs995000	0.931	rs1168050	chr1:62986955	C/T	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.56e-11	Triglyceride levels;
CRC	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.33	0.46	1.56e-18	Iron status biomarkers;
CRC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.82	-0.35	4.32e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	8.07	0.41	1.31e-14	Motion sickness;
CRC	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.54	-8.14	-0.41	8.3e-15	Body mass index;
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.7	-0.35	9.17e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg15468180	chr1:107600409	PRMT6	0.38	5.74	0.3	2.12e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02328223	chr3:127541927	MGLL	0.38	6.35	0.33	7.25e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.06	0.41	1.41e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.7	-10.85	-0.51	1.21e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.37	6.26	0.33	1.18e-9	Schizophrenia;
CRC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.52	7.39	0.38	1.2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7274811	0.901	rs17404047	chr20:32305781	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.53	-6.9	-0.36	2.67e-11	Height;
CRC	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.72	-9.73	-0.47	7.91e-20	Blood pressure (smoking interaction);
CRC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.43	-6.65	-0.34	1.24e-10	Renal cell carcinoma;
CRC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.58	-0.47	2.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.7	10.76	0.51	2.4e-23	QRS duration;
CRC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.53	-7.61	-0.39	2.87e-13	Urate levels;
CRC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-6.26	-0.33	1.2e-9	Schizophrenia;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20887711	chr4:1340912	KIAA1530	0.43	6.17	0.32	2.03e-9	Obesity-related traits;
CRC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.38	5.68	0.3	2.94e-8	Hemoglobin concentration;
CRC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-11.5	-0.54	5.82e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.83	-10.26	-0.49	1.33e-21	Blood pressure (smoking interaction);
CRC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.52	8.08	0.41	1.24e-14	Aortic root size;
CRC	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.16	-0.52	9.81e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.86	-13.56	-0.6	1.36e-33	Response to temozolomide;
CRC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.83	15.06	0.64	2.36e-39	Breast cancer;
CRC	cis	rs4750440	0.702	rs4748068	chr10:14030692	T/A	cg00551146	chr10:14014579	FRMD4A	0.37	5.91	0.31	8.59e-9	Adiponectin levels;
CRC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.9	0.31	8.98e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg23760165	chr11:61595485	FADS2	-0.45	-5.74	-0.3	2.2e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19947233	chr4:90032727	TIGD2	-0.38	-6.14	-0.32	2.42e-9	Myopia (pathological);
CRC	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.52	-8.31	-0.42	2.55e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.33	-0.53	2.39e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.52	-7.65	-0.39	2.2e-13	Lung cancer;
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg21784768	chr11:537496	LRRC56	-0.59	-5.92	-0.31	8.31e-9	Body mass index;
CRC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.86	-13.32	-0.59	1.09e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.78	-0.3	1.73e-8	Protein biomarker;
CRC	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	1.13	10.19	0.49	2.34e-21	Arsenic metabolism;
CRC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13198984	chr17:80129470	CCDC57	0.5	8.76	0.43	1.06e-16	Life satisfaction;
CRC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.9	10.55	0.5	1.36e-22	Psoriasis;
CRC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.84	-0.51	1.32e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.02e-22	Corneal astigmatism;
CRC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.65	-0.54	1.72e-26	Blood trace element (Zn levels);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25750404	chr12:6579648	VAMP1	0.48	6.82	0.35	4.29e-11	Response to antipsychotic treatment;
CRC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.51	-7.12	-0.37	6.9e-12	Tuberculosis;
CRC	trans	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg17903999	chr18:56338584	MALT1	0.42	6.97	0.36	1.73e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2303319	0.504	rs62188990	chr2:162540635	G/A	cg22988483	chr14:93581567	ITPK1	-0.67	-6.08	-0.32	3.35e-9	Cognitive function;
CRC	cis	rs7932354	0.528	rs11039112	chr11:47174296	C/T	cg03339077	chr11:47165057	C11orf49	-0.46	-6.51	-0.34	2.81e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg03929089	chr4:120376271	NA	0.66	5.96	0.31	6.44e-9	Myopia (pathological);
CRC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.38	-5.85	-0.31	1.16e-8	Mean corpuscular volume;
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.85	-0.31	1.19e-8	Life satisfaction;
CRC	cis	rs1009181	0.585	rs2183947	chr6:26159356	G/A	cg00631329	chr6:26305371	NA	-0.44	-6.52	-0.34	2.68e-10	Childhood ear infection;
CRC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg21747405	chr11:67723411	NA	-0.44	-6.28	-0.33	1.06e-9	Blood pressure (smoking interaction);
CRC	trans	rs12431410	0.550	rs10138254	chr14:60209188	A/G	cg00680277	chr2:3465103	TTC15	-0.37	-5.97	-0.31	6.19e-9	Schizophrenia;
CRC	cis	rs4728302	0.869	rs6955707	chr7:133612188	G/A	cg10665199	chr7:133106180	EXOC4	0.37	5.6	0.3	4.49e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.58	0.54	2.99e-26	Prudent dietary pattern;
CRC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.86	-0.31	1.15e-8	Reticulocyte count;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.64	0.34	1.32e-10	Bipolar disorder;
CRC	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg09003973	chr2:102972529	NA	0.73	8.05	0.41	1.48e-14	Gut microbiota (bacterial taxa);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23506944	chr17:28257236	EFCAB5;SSH2	0.43	6.82	0.35	4.39e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg16482183	chr6:26056742	HIST1H1C	0.76	9.46	0.46	5.88e-19	Iron status biomarkers;
CRC	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.6	8.77	0.44	9.84e-17	Coronary artery disease;
CRC	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-11.55	-0.54	3.9e-26	Colorectal cancer;
CRC	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.11	0.56	3.56e-28	Exhaled nitric oxide levels;
CRC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.76	12.91	0.58	3.84e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07308943	chr2:29093510	TRMT61B	0.47	6.6	0.34	1.63e-10	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.54	-0.34	2.4e-10	Menopause (age at onset);
CRC	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.02	-0.4	1.84e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.44	6.02	0.31	4.77e-9	Tuberculosis;
CRC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.45	-8.31	-0.42	2.55e-15	Reticulocyte fraction of red cells;
CRC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.34	5.79	0.3	1.67e-8	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18523979	chr3:13009124	IQSEC1	-0.4	-6.28	-0.33	1.06e-9	Myopia (pathological);
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg10876282	chr6:28092338	ZSCAN16	0.44	5.83	0.31	1.31e-8	Parkinson's disease;
CRC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.66	10.24	0.49	1.56e-21	Testicular germ cell tumor;
CRC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg18230493	chr5:56204884	C5orf35	-0.39	-5.85	-0.31	1.21e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.95	-9.69	-0.47	1.09e-19	Cerebrospinal P-tau181p levels;
CRC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.66	8.7	0.43	1.63e-16	Morning vs. evening chronotype;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14479329	chr6:167370587	RNASET2	-0.41	-6.2	-0.32	1.7e-9	Brain structure;
CRC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.42e-10	Breast cancer;
CRC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.79	13.91	0.61	6.53e-35	Oral cavity cancer;
CRC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg15083037	chr5:83017644	HAPLN1	-0.46	-5.73	-0.3	2.25e-8	Prostate cancer;
CRC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-7.81	-0.4	7.71e-14	Monocyte count;
CRC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-0.86	-12.69	-0.57	2.63e-30	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14780845	chr17:41323115	NBR1	0.5	8.41	0.42	1.25e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs9648716	1.000	rs7798031	chr7:140602599	C/A	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.38	-6.43	-0.33	4.43e-10	Schizophrenia;
CRC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.38	6.33	0.33	8.02e-10	Breast cancer;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.67	-0.3	3.19e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg24289452	chr6:170231220	NA	-0.81	-7.16	-0.37	5.4e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg14828511	chr1:107599125	PRMT6	-0.49	-6.86	-0.35	3.49e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.75	-0.35	6.53e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
CRC	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg23920097	chr1:209922102	NA	-0.53	-6.67	-0.35	1.06e-10	Red blood cell count;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.39	-7.22	-0.37	3.71e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg14711859	chr11:8959438	ASCL3	-0.5	-8.22	-0.41	4.9e-15	Hemoglobin concentration;
CRC	cis	rs41005	1.000	rs34505904	chr2:8115159	T/C	cg03155496	chr2:8117019	LOC339788	-0.39	-6.72	-0.35	8.04e-11	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs17095355	0.892	rs7085888	chr10:111713930	A/G	cg00817464	chr10:111662876	XPNPEP1	0.57	7.88	0.4	4.8e-14	Biliary atresia;
CRC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-7.89	-0.4	4.62e-14	Aortic root size;
CRC	trans	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.21	-0.32	1.59e-9	Height;
CRC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.71	12.63	0.57	4.28e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.12	-0.49	3.94e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg14664628	chr15:75095509	CSK	0.4	5.88	0.31	9.88e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs889398	0.774	rs6499263	chr16:69890149	T/C	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.28	-0.33	1.08e-9	Body mass index;
CRC	cis	rs4964805	0.594	rs10861095	chr12:104165387	A/G	cg02344784	chr12:104178138	NT5DC3	0.47	7.23	0.37	3.35e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-17.46	-0.69	9.32e-49	Schizophrenia;
CRC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.82	-13.88	-0.61	8.15e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg03037974	chr15:76606532	NA	-0.53	-7.98	-0.4	2.51e-14	Blood metabolite levels;
CRC	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.19	-0.37	4.35e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs3026101	0.671	rs2871210	chr17:5305027	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.89	0.35	2.9100000000000002e-11	Body mass index;
CRC	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.47	-5.97	-0.31	6.15e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.49	-6.43	-0.33	4.39e-10	Ulcerative colitis;
CRC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-9.08	-0.45	9.89e-18	Prostate cancer;
CRC	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.49	-0.34	3.18e-10	Depression;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19500275	chr17:80737654	TBCD	0.51	7.09	0.36	8.31e-12	Glycated hemoglobin levels;
CRC	cis	rs1545257	0.537	rs11125582	chr2:24646213	C/T	cg06627628	chr2:24431161	ITSN2	-0.48	-7.16	-0.37	5.17e-12	Sjögren's syndrome;
CRC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.56	8.16	0.41	6.94e-15	Monocyte count;
CRC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.45	-0.33	4.1e-10	Body mass index;
CRC	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.53	7.44	0.38	8.65e-13	Response to antidepressants and depression;
CRC	cis	rs7849270	1.000	rs4713	chr9:131910805	A/T	cg13538475	chr9:131942899	NA	0.33	6.49	0.34	3.13e-10	Blood metabolite ratios;
CRC	cis	rs17067123	0.614	rs6850226	chr4:180052577	T/G	cg26610307	chr4:180072759	NA	-0.57	-6.9	-0.36	2.66e-11	Response to hepatitis C treatment;
CRC	cis	rs9311676	0.656	rs12497250	chr3:58399399	T/C	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.49	-6.45	-0.34	4.01e-10	Caudate activity during reward;
CRC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.78	0.39	9.69e-14	Resting heart rate;
CRC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg02390115	chr1:21767211	NBPF3	0.53	7.91	0.4	3.88e-14	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.51	-0.34	2.75e-10	Life satisfaction;
CRC	cis	rs6445967	1.000	rs9847151	chr3:58285808	G/A	cg23715586	chr3:58305044	RPP14	0.36	6.18	0.32	1.89e-9	Platelet count;
CRC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.63	9.25	0.45	2.95e-18	Total body bone mineral density;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg20047235	chr7:150755417	CDK5;SLC4A2	-0.42	-5.97	-0.31	6.23e-9	Birth weight;Height;
CRC	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.43	6.84	0.35	3.92e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.64	0.54	1.9e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.52	7.45	0.38	8.08e-13	Corneal structure;
CRC	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg13385794	chr1:248469461	NA	0.34	5.82	0.31	1.37e-8	Common traits (Other);
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.33	-0.33	8.1e-10	Lymphocyte counts;
CRC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.56	-7.44	-0.38	8.72e-13	Gut microbiome composition (summer);
CRC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.39	-0.33	5.77e-10	Breast cancer;
CRC	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg12963866	chr19:57752005	ZNF805	-0.41	-6.06	-0.32	3.72e-9	Hyperactive-impulsive symptoms;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24303698	chr19:46367351	SYMPK;FOXA3	0.44	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs73206853	0.764	rs58535454	chr12:111003457	C/T	cg12870014	chr12:110450643	ANKRD13A	0.81	9.34	0.46	1.45e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9463078	0.547	rs1338908	chr6:44728812	C/T	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.85e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.38	6.28	0.33	1.08e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.8	10.49	0.5	2.19e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg11843238	chr5:131593191	PDLIM4	0.34	6.56	0.34	2.1e-10	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg10820045	chr2:198174542	NA	0.4	6.69	0.35	9.65e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12826942	0.876	rs17548889	chr12:42722219	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.61	0.39	2.89e-13	Coronary artery disease;
CRC	trans	rs59551326	0.512	rs2829659	chr21:26621921	C/T	cg01704976	chr3:52273381	TWF2	0.52	6.01	0.31	4.85e-9	Alcohol dependence;
CRC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.72	-9.33	-0.46	1.62e-18	Body mass index;
CRC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.26	14.46	0.62	5.09e-37	Diabetic kidney disease;
CRC	cis	rs12024301	0.557	rs16861256	chr1:183592594	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.74	-6.57	-0.34	1.94e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.55	7.8	0.4	8.21e-14	Melanoma;
CRC	cis	rs6545883	0.560	rs11677776	chr2:61503113	T/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.81	-0.4	7.63e-14	Tuberculosis;
CRC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.62	-9.56	-0.47	2.78e-19	Colorectal cancer;
CRC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg00999904	chr2:3704751	ALLC	-0.53	-6.7	-0.35	9.16e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg07090678	chr1:91966139	CDC7	0.42	6.9	0.36	2.68e-11	Breast cancer;
CRC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-9.93	-0.48	1.73e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs6662572	0.737	rs72692613	chr1:46399557	A/C	cg08644498	chr1:46502608	NA	0.44	6.68	0.35	1.04e-10	Blood protein levels;
CRC	cis	rs16858210	0.647	rs67397446	chr3:183618143	C/T	cg25686905	chr3:183603175	PARL	-0.48	-5.94	-0.31	7.1e-9	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.77	-0.44	1e-16	Aortic root size;
CRC	cis	rs9283706	0.594	rs1366338	chr5:66344307	A/G	cg11590213	chr5:66331682	MAST4	-0.43	-5.98	-0.31	5.85e-9	Coronary artery disease;
CRC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.53	-7.3	-0.37	2.19e-12	Urate levels in lean individuals;
CRC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	9.1	0.45	9.14e-18	Alzheimer's disease;
CRC	cis	rs4731207	0.596	rs1026836	chr7:124683632	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg23972785	chr8:11611189	GATA4	-0.43	-5.97	-0.31	6.19e-9	Myopia (pathological);
CRC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13398993	chr8:66546079	ARMC1	0.45	6.46	0.34	3.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg04607235	chr12:12878440	APOLD1	-1.01	-13.78	-0.6	2.03e-34	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05898629	chr16:3812688	CREBBP	-0.39	-6.15	-0.32	2.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.52	11.82	0.55	4.09e-27	Prostate cancer;
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg06207120	chr15:45996521	NA	0.31	7.54	0.38	4.74e-13	Waist circumference;Weight;
CRC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	13.0	0.58	1.84e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.33	-0.33	8.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.62	7.16	0.37	5.23e-12	Vitiligo;
CRC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-6.37	-0.33	6.51e-10	Menarche (age at onset);
CRC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.5	7.25	0.37	3.03e-12	Height;
CRC	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.57	0.38	3.91e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs9308731	0.583	rs7596789	chr2:111932616	G/A	cg04202892	chr2:111875749	ACOXL	0.42	6.78	0.35	5.58e-11	Chronic lymphocytic leukemia;
CRC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.57	8.3	0.42	2.69e-15	Testicular germ cell tumor;
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg12516270	chr8:143859308	LYNX1	-0.43	-7.52	-0.38	5.35e-13	Urinary tract infection frequency;
CRC	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	6.81	0.35	4.75e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.65	-9.74	-0.47	7.33e-20	Non-response to antidepressants and depression;
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.49	-0.42	7.42e-16	Electroencephalogram traits;
CRC	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.52	0.34	2.58e-10	Intraocular pressure;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00024722	chr15:32163260	NA	-0.39	-6.14	-0.32	2.39e-9	Aortic root size;
CRC	cis	rs9463078	0.715	rs9395049	chr6:44792718	C/T	cg25276700	chr6:44698697	NA	0.25	6.12	0.32	2.61e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.51	8.38	0.42	1.6e-15	Metabolite levels (small molecules and protein measures);
CRC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03769523	chr10:104613934	C10orf32	0.43	6.02	0.31	4.59e-9	Response to antipsychotic treatment;
CRC	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg11204139	chr17:3907470	NA	0.76	14.24	0.62	3.65e-36	Type 2 diabetes;
CRC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg02569458	chr12:86230093	RASSF9	0.47	7.98	0.4	2.53e-14	Major depressive disorder;
CRC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg16591659	chr17:78472290	NA	-0.41	-6.09	-0.32	3.18e-9	Fractional excretion of uric acid;
CRC	cis	rs10512697	0.803	rs13189635	chr5:3575571	T/A	cg19473799	chr5:3511975	NA	-0.72	-5.67	-0.3	3.12e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg08798685	chr6:27730294	NA	-0.63	-6.13	-0.32	2.57e-9	Depression;
CRC	cis	rs11679072	1.000	rs7573739	chr2:240448123	G/A	cg03276489	chr2:240449683	NA	-0.93	-9.41	-0.46	8.71e-19	Blood pressure (smoking interaction);
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.74	10.05	0.48	6.72e-21	Alzheimer's disease;
CRC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.63e-10	Schizophrenia;
CRC	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg05585544	chr11:47624801	NA	-0.39	-6.06	-0.32	3.66e-9	Mean corpuscular hemoglobin;
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.94	-0.31	7.17e-9	Total body bone mineral density;
CRC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.84	0.35	3.89e-11	Aortic root size;
CRC	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.21	-0.37	3.82e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg20607287	chr7:12443886	VWDE	-0.53	-5.86	-0.31	1.1e-8	Coronary artery disease;
CRC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.57	-9.13	-0.45	6.89e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-6.11	-0.32	2.86e-9	Lung cancer;
CRC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.67	-0.39	1.95e-13	QT interval;
CRC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.2	11.3	0.53	3.17e-25	Alzheimer's disease (late onset);
CRC	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.81	8.88	0.44	4.36e-17	Anti-saccade response;
CRC	trans	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg10756647	chr7:56101905	PSPH	0.71	7.67	0.39	1.92e-13	Diabetic kidney disease;
CRC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg02269571	chr22:50332266	NA	0.62	8.58	0.43	3.78e-16	Schizophrenia;
CRC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24308560	chr3:49941425	MST1R	-0.43	-6.67	-0.35	1.09e-10	Body mass index;
CRC	trans	rs12495832	0.778	rs4681395	chr3:147889283	T/C	cg10221266	chr7:153579447	NA	0.57	6.14	0.32	2.44e-9	Chin dimples;
CRC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.34	-5.67	-0.3	3.19e-8	Vitiligo;
CRC	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-9.37	-0.46	1.22e-18	Coronary artery disease;
CRC	trans	rs6011368	0.792	rs6512309	chr20:62892584	A/G	cg13869341	chr1:15865	WASH5P	0.41	6.04	0.32	4.19e-9	Clozapine-induced cytotoxicity;
CRC	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.64	9.84	0.48	3.37e-20	Itch intensity from mosquito bite;
CRC	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg09085632	chr11:111637200	PPP2R1B	0.5	6.46	0.34	3.83e-10	Breast cancer;
CRC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.97	-10.57	-0.5	1.1e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.78	0.47	5.38e-20	Bipolar disorder;
CRC	trans	rs596169	0.655	rs12087006	chr1:219203397	T/C	cg09853702	chr12:47665230	NA	0.82	6.39	0.33	5.63e-10	Intraocular pressure;
CRC	cis	rs6681460	1.000	rs2872078	chr1:67127367	C/A	cg02459107	chr1:67143332	SGIP1	0.45	7.51	0.38	5.73e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.5	-8.17	-0.41	6.89e-15	Post bronchodilator FEV1;
CRC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg03929089	chr4:120376271	NA	-0.46	-6.6	-0.34	1.62e-10	HDL cholesterol;
CRC	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.63	-8.98	-0.44	2.1e-17	Coronary artery disease;
CRC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.77	-11.6	-0.54	2.52e-26	Acne (severe);
CRC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16447950	chr5:562315	NA	-0.73	-9.65	-0.47	1.41e-19	Obesity-related traits;
CRC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.49	7.19	0.37	4.52e-12	Bladder cancer;
CRC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.56	8.13	0.41	8.9e-15	Obesity-related traits;
CRC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.24	-0.33	1.32e-9	Aortic root size;
CRC	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.81	7.7	0.39	1.65e-13	Diabetic retinopathy;
CRC	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.65	12.59	0.57	6.41e-30	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg06636001	chr8:8085503	FLJ10661	0.44	6.42	0.33	4.69e-10	Neuroticism;
CRC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.51	8.14	0.41	8.43e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg08533674	chr1:46993347	NA	-0.72	-9.39	-0.46	1.02e-18	Monobrow;
CRC	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.84	-0.31	1.25e-8	Subjective well-being;
CRC	trans	rs4276421	0.869	rs62369107	chr5:45552765	G/T	cg04793272	chr11:119020941	ABCG4	-0.37	-6.09	-0.32	3.14e-9	P wave duration;
CRC	cis	rs2730260	0.800	rs73169216	chr7:158834662	G/A	cg02254261	chr7:158964346	NA	-0.57	-6.32	-0.33	8.37e-10	Myopia (pathological);
CRC	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	0.54	6.45	0.34	4e-10	Prostate cancer;
CRC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02290350	chr8:58132656	NA	-0.41	-5.66	-0.3	3.21e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg02007433	chr3:129722099	NA	-0.51	-6.13	-0.32	2.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg12751644	chr20:60527061	NA	-0.38	-5.89	-0.31	9.56e-9	Body mass index;
CRC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.37	2.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg10733145	chr11:60673895	PRPF19	0.37	6.12	0.32	2.59e-9	Parkinson's disease;
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.48	-0.34	3.28e-10	Lymphocyte counts;
CRC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.61	-9.3	-0.46	2e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.5	6.28	0.33	1.06e-9	Neuroticism;
CRC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	15.34	0.65	1.89e-40	Intelligence (multi-trait analysis);
CRC	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.54	7.46	0.38	7.68e-13	Glioblastoma;Glioma;
CRC	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg06417478	chr19:12876846	HOOK2	-0.42	-5.65	-0.3	3.43e-8	Bipolar disorder;
CRC	trans	rs6601327	0.898	rs1458942	chr8:9406602	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.48	-0.34	3.45e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	0.86	6.9	0.36	2.74e-11	Fat distribution (HIV);
CRC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg00769240	chr8:12517080	NA	-0.68	-7.78	-0.39	9.14e-14	Blood pressure (smoking interaction);
CRC	cis	rs990171	0.837	rs1568681	chr2:103014696	C/T	cg03938978	chr2:103052716	IL18RAP	0.47	5.94	0.31	7.25e-9	Lymphocyte counts;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.74	-9.19	-0.45	4.55e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.64	8.77	0.44	9.78e-17	Methadone dose in opioid dependence;
CRC	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.93	-0.31	7.52e-9	Educational attainment;
CRC	cis	rs6594713	0.819	rs10061462	chr5:112726205	A/T	cg12552261	chr5:112820674	MCC	0.41	5.65	0.3	3.42e-8	Brain cytoarchitecture;
CRC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.28	-0.46	2.29e-18	Bladder cancer;
CRC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg00750074	chr16:89608354	SPG7	-0.48	-7.14	-0.37	6.07e-12	Multiple myeloma (IgH translocation);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24311251	chr13:44453387	CCDC122;C13orf31	0.37	5.97	0.31	6.31e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	1.19	14.38	0.62	1e-36	Lung disease severity in cystic fibrosis;
CRC	cis	rs12143943	0.738	rs11240750	chr1:204459786	T/C	cg17419461	chr1:204415978	PIK3C2B	0.38	6.02	0.31	4.75e-9	Cognitive performance;
CRC	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.77	9.64	0.47	1.6e-19	Obesity-related traits;
CRC	cis	rs3772130	1.000	rs2070180	chr3:121351338	A/G	cg20356878	chr3:121714668	ILDR1	-0.48	-7.5	-0.38	6.05e-13	Cognitive performance;
CRC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	trans	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-6.96	-0.36	1.83e-11	Menarche (age at onset);
CRC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.48	9.69	0.47	1.06e-19	Ulcerative colitis;
CRC	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.54	9.42	0.46	8.4e-19	Common traits (Other);
CRC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg03013999	chr17:37608204	MED1	-0.48	-7.43	-0.38	9.53e-13	Glomerular filtration rate (creatinine);
CRC	trans	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg10756647	chr7:56101905	PSPH	-0.79	-8.26	-0.41	3.68e-15	Diabetic kidney disease;
CRC	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg26727032	chr16:67993705	SLC12A4	-0.75	-11.92	-0.55	1.73e-27	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.72	9.92	0.48	1.85e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg00999904	chr2:3704751	ALLC	-0.79	-9.75	-0.47	6.72e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg05941027	chr17:61774174	LIMD2	0.37	6.71	0.35	8.59e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.72	-10.78	-0.51	2.1e-23	Platelet distribution width;
CRC	cis	rs8050755	0.649	rs1800720	chr16:2105400	C/T	cg04515572	chr16:2107413	TSC2	-0.69	-7.15	-0.37	5.65e-12	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18238491	chr18:47901440	SKA1	0.46	7.01	0.36	1.39e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7259376	0.936	rs6511350	chr19:22594697	A/G	cg02657401	chr19:22469223	NA	0.32	7.0	0.36	1.41e-11	Menopause (age at onset);
CRC	cis	rs1124376	1.000	rs4417886	chr3:20108511	C/T	cg05072819	chr3:20081367	KAT2B	0.56	6.65	0.34	1.2e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.28e-11	Body mass index;
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.55	-0.34	2.28e-10	Longevity;
CRC	cis	rs364477	0.721	rs279876	chr9:996439	G/T	cg13952963	chr9:998547	NA	-0.59	-6.87	-0.35	3.26e-11	Major depressive disorder;
CRC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.71	-11.15	-0.52	1.06e-24	Cognitive ability;
CRC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-9.16	-0.45	5.76e-18	Total cholesterol levels;
CRC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.67	8.69	0.43	1.78e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.45	6.32	0.33	8.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6743376	0.556	rs2441375	chr2:113817268	T/C	cg09040174	chr2:113837401	NA	0.44	6.42	0.33	4.87e-10	Inflammatory biomarkers;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05556477	chr5:131705319	SLC22A5	0.42	5.97	0.31	6.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.45e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-6.95	-0.36	1.97e-11	Colorectal cancer;
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02807482	chr3:125708958	NA	-0.43	-5.99	-0.31	5.35e-9	Blood pressure (smoking interaction);
CRC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.19	-0.37	4.36e-12	QT interval;
CRC	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg20512303	chr5:131592959	PDLIM4	-0.36	-5.66	-0.3	3.22e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg01081584	chr15:40268610	EIF2AK4	-0.65	-6.08	-0.32	3.28e-9	Response to haloperidol in psychosis;
CRC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16262614	chr3:133464971	TF	0.4	7.1	0.36	7.79e-12	Iron status biomarkers;
CRC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg20387954	chr3:183756860	HTR3D	0.45	7.61	0.39	2.97e-13	Anterior chamber depth;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg19041857	chr6:27730383	NA	-0.45	-6.47	-0.34	3.65e-10	Parkinson's disease;
CRC	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.64	6.72	0.35	8.18e-11	Chronic lymphocytic leukemia;
CRC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg07952391	chr2:88470173	THNSL2	0.66	6.69	0.35	9.43e-11	Plasma clusterin levels;
CRC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.92	-0.36	2.41e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg20607287	chr7:12443886	VWDE	-0.6	-6.22	-0.32	1.53e-9	Coronary artery disease;
CRC	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	17.19	0.69	9.99e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26240231	chr7:1148101	C7orf50	-0.43	-5.73	-0.3	2.26e-8	Bronchopulmonary dysplasia;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg23161317	chr6:28129485	ZNF389	0.4	6.06	0.32	3.64e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.62	-0.43	2.91e-16	Aortic root size;
CRC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.84	-10.98	-0.52	4.25e-24	Gut microbiome composition (summer);
CRC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.47	6.16	0.32	2.15e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	7.42	0.38	1.01e-12	Aortic root size;
CRC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.54	8.14	0.41	8.44e-15	Schizophrenia;
CRC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.58	9.16	0.45	5.8e-18	Breast cancer;
CRC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.45	-8.32	-0.42	2.32e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.77	-11.27	-0.53	3.99e-25	Multiple sclerosis;
CRC	cis	rs365302	0.953	rs389041	chr6:159646853	G/A	cg14500486	chr6:159655392	FNDC1	0.43	6.63	0.34	1.41e-10	Coronary heart disease;
CRC	cis	rs6694672	0.867	rs4915307	chr1:197048608	T/C	cg13682187	chr1:196946512	CFHR5	0.47	7.35	0.38	1.56e-12	Asthma;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.7	0.54	1.09e-26	Alzheimer's disease;
CRC	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg09659197	chr4:152720779	NA	0.47	9.97	0.48	1.24e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg04969067	chr8:143858791	LYNX1	-0.4	-6.07	-0.32	3.45e-9	Urinary tract infection frequency;
CRC	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.45	-5.79	-0.3	1.61e-8	Alopecia areata;
CRC	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-7.94	-0.4	3.24e-14	Response to antipsychotic treatment;
CRC	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg27205649	chr11:78285834	NARS2	0.47	5.73	0.3	2.31e-8	Alzheimer's disease (survival time);
CRC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.7e-8	Lung cancer;
CRC	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.39	-0.33	5.6e-10	Body mass index;
CRC	cis	rs2257205	0.667	rs9893027	chr17:56653448	G/C	cg25885038	chr17:56607967	SEPT4	-0.56	-6.17	-0.32	2.04e-9	Pancreatic cancer;
CRC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.39	5.99	0.31	5.54e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.51	8.41	0.42	1.27e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg19622623	chr12:86230825	RASSF9	0.4	6.32	0.33	8.38e-10	Major depressive disorder;
CRC	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg24851651	chr11:66362959	CCS	-0.38	-6.41	-0.33	5.06e-10	Educational attainment (years of education);
CRC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.71	-10.73	-0.51	3.2e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.81	-13.72	-0.6	3.49e-34	Height;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg04518342	chr5:131593106	PDLIM4	0.47	8.82	0.44	6.79e-17	Breast cancer;
CRC	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.79	16.07	0.66	2.57e-43	Leprosy;
CRC	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg20169779	chr10:135381914	SYCE1	-0.63	-10.64	-0.51	6.49e-23	Obesity-related traits;
CRC	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg10820045	chr2:198174542	NA	-0.38	-6.29	-0.33	1.03e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7932354	0.583	rs7943866	chr11:46881954	C/T	cg19486271	chr11:47235900	DDB2	-0.42	-6.34	-0.33	7.49e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg17775713	chr3:133465469	TF	0.33	5.87	0.31	1.07e-8	Iron status biomarkers;
CRC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-5.93	-0.31	7.49e-9	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22962396	chr19:3762602	MRPL54;APBA3	0.46	6.35	0.33	7.13e-10	Response to antipsychotic treatment;
CRC	cis	rs10924970	0.649	rs12748629	chr1:235425959	T/C	cg09010748	chr1:235293032	TOMM20	-0.41	-5.66	-0.3	3.37e-8	Asthma;
CRC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-7.42	-0.38	1.02e-12	Headache;
CRC	cis	rs62408225	0.962	rs1604830	chr6:90969221	T/C	cg06866423	chr6:90926672	BACH2	0.5	8.15	0.41	7.56e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg25214090	chr10:38739885	LOC399744	0.39	6.0	0.31	5.15e-9	Diastolic blood pressure;
CRC	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg19418458	chr7:158789849	NA	-0.49	-8.23	-0.41	4.54e-15	Facial morphology (factor 20);
CRC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg23355997	chr17:7154831	DULLARD;C17orf81	-0.54	-6.53	-0.34	2.49e-10	Type 1 diabetes;
CRC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.42	-0.38	9.86e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.72	9.25	0.45	2.88e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02290575	chr7:100964799	RABL5	0.38	6.3	0.33	9.74e-10	Interleukin-6 levels;
CRC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg09264619	chr17:80180166	NA	-0.36	-6.1	-0.32	3e-9	Life satisfaction;
CRC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.57	8.29	0.42	3.02e-15	Lung cancer;
CRC	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.49	-7.11	-0.36	7.28e-12	Large artery stroke;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14885145	chr10:104262292	SUFU;ACTR1A	0.42	5.96	0.31	6.41e-9	Response to antipsychotic treatment;
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.58	8.68	0.43	1.91e-16	Monocyte percentage of white cells;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22708290	chr12:56368226	RAB5B	-0.42	-6.27	-0.33	1.17e-9	Brain structure;
CRC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg26587870	chr6:27730563	NA	-0.45	-6.06	-0.32	3.65e-9	Breast cancer;
CRC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg02725872	chr8:58115012	NA	-0.37	-5.98	-0.31	5.7e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15687855	chr3:44754131	ZNF502	-0.33	-5.61	-0.3	4.39e-8	Depressive symptoms;
CRC	trans	rs1459104	0.778	rs11827099	chr11:55794945	C/T	cg03313212	chr12:104850718	CHST11	-0.5	-5.99	-0.31	5.37e-9	Body mass index;
CRC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	19.47	0.73	1.03e-56	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg15786705	chr6:28176104	NA	0.76	9.34	0.46	1.53e-18	Depression;
CRC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg25876840	chr17:41920477	NA	0.58	8.23	0.41	4.34e-15	Triglycerides;
CRC	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg11503833	chr11:492997	NA	0.47	5.63	0.3	3.85e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.33	-6.04	-0.32	4.21e-9	Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05639258	chr11:64879330	TM7SF2	0.48	6.29	0.33	1.03e-9	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05519310	chr11:66627619	PC;LRFN4	-0.38	-6.84	-0.35	3.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg22676075	chr6:135203613	NA	0.41	6.32	0.33	8.47e-10	Red blood cell count;
CRC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9837602	1.000	rs34626154	chr3:99756312	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.16	-0.32	2.16e-9	Breast cancer;
CRC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg03609598	chr5:56110824	MAP3K1	0.59	7.94	0.4	3.29e-14	Initial pursuit acceleration;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.5	8.55	0.43	4.56e-16	Hypertriglyceridemia;
CRC	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.46	8.35	0.42	1.92e-15	Blood metabolite ratios;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg10876282	chr6:28092338	ZSCAN16	0.5	6.75	0.35	6.5500000000000006e-11	Cardiac Troponin-T levels;
CRC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.75	-0.3	2.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.53	-7.31	-0.37	2.04e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7781266	0.790	rs4728284	chr7:133102295	A/T	cg03336402	chr7:133662267	EXOC4	0.5	5.94	0.31	7.19e-9	Educational attainment (college completion);
CRC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.49	7.19	0.37	4.36e-12	Blood metabolite levels;
CRC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.52	0.46	3.88e-19	Hip circumference adjusted for BMI;
CRC	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.69	9.54	0.47	3.3e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	1.02	15.64	0.65	1.26e-41	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22855052	chr12:6982535	SPSB2	0.37	6.64	0.34	1.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.28	-0.37	2.54e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-15.8	-0.66	3.09e-42	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Parkinson's disease;
CRC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.81	-14.27	-0.62	2.58e-36	Metabolic syndrome;
CRC	cis	rs282587	0.569	rs399569	chr13:113398464	A/T	cg04656015	chr13:113407548	ATP11A	0.64	7.85	0.4	6.08e-14	Glycated hemoglobin levels;
CRC	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg23127183	chr11:57508653	C11orf31	-0.53	-7.17	-0.37	4.83e-12	Schizophrenia;
CRC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-19.18	-0.73	1.47e-55	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.93	-0.36	2.2e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.81	10.22	0.49	1.73e-21	Iron status biomarkers;
CRC	cis	rs7605827	0.930	rs7578126	chr2:15522772	C/T	cg19274914	chr2:15703543	NA	0.37	5.67	0.3	3.08e-8	Educational attainment (years of education);
CRC	cis	rs12928939	0.859	rs11670	chr16:71679027	G/T	cg08717414	chr16:71523259	ZNF19	-0.47	-5.83	-0.31	1.35e-8	Post bronchodilator FEV1;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg03623178	chr6:28175578	NA	0.86	13.55	0.6	1.59e-33	Cardiac Troponin-T levels;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg23459997	chr3:9932426	JAGN1	0.54	6.46	0.34	3.76e-10	Kashin-Beck disease;
CRC	cis	rs10924970	0.967	rs4659784	chr1:235482463	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	6.13	0.32	2.51e-9	Asthma;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.05	-0.41	1.51e-14	Total body bone mineral density;
CRC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.84	-0.31	1.22e-8	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.26	-0.37	2.74e-12	Bipolar disorder;
CRC	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg06092702	chr1:163392909	NA	-0.5	-7.92	-0.4	3.78e-14	Motion sickness;
CRC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.37	-5.76	-0.3	1.92e-8	Crohn's disease;
CRC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.01e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1712517	0.525	rs11191667	chr10:105128898	G/A	cg04362960	chr10:104952993	NT5C2	-0.44	-5.71	-0.3	2.51e-8	Migraine;
CRC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.41	6.71	0.35	8.45e-11	Resting heart rate;
CRC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4073416	0.568	rs7158153	chr14:66034586	C/A	cg03016385	chr14:66212404	NA	-0.45	-6.27	-0.33	1.14e-9	N-glycan levels;
CRC	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.5	0.42	6.81e-16	Coffee consumption (cups per day);
CRC	cis	rs6496667	0.955	rs8039263	chr15:90900597	G/A	cg04176472	chr15:90893244	GABARAPL3	0.49	7.42	0.38	1e-12	Rheumatoid arthritis;
CRC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg04731861	chr2:219085781	ARPC2	0.27	5.69	0.3	2.83e-8	Ulcerative colitis;
CRC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg02527881	chr3:46936655	PTH1R	-0.37	-7.02	-0.36	1.3e-11	Colorectal cancer;
CRC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.59	-0.47	2.27e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs77861329	1.000	rs9843299	chr3:52137469	G/T	cg08692210	chr3:52188851	WDR51A	0.82	6.95	0.36	1.98e-11	Macrophage inflammatory protein 1b levels;
CRC	cis	rs7215564	0.818	rs35059200	chr17:78661619	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.16	0.32	2.11e-9	Myopia (pathological);
CRC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.69	8.08e-49	Height;
CRC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs13315871	1.000	rs13315871	chr3:58381287	G/A	cg20936604	chr3:58311152	NA	-0.71	-6.5	-0.34	2.93e-10	Cholesterol, total;
CRC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.77	0.39	9.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.41	-5.78	-0.3	1.72e-8	Daytime sleep phenotypes;
CRC	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.43	-5.98	-0.31	5.72e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-8.99	-0.44	2.04e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.51	6.95	0.36	1.95e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4974559	0.585	rs1680025	chr4:1265477	T/C	cg02980000	chr4:1222292	CTBP1	-0.43	-5.62	-0.3	4.02e-8	Systolic blood pressure;
CRC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.98	-0.36	1.66e-11	Colorectal cancer;
CRC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.95	13.72	0.6	3.35e-34	Breast cancer;
CRC	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.52	-0.43	5.89e-16	Biliary atresia;
CRC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.68	9.69	0.47	1.03e-19	Longevity;
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.92	13.04	0.58	1.32e-31	Alzheimer's disease;
CRC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.84	-0.35	3.78e-11	Total body bone mineral density;
CRC	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.65	-8.89	-0.44	4.25e-17	Extraversion;
CRC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.5e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.73	-11.77	-0.54	6.36e-27	Blood protein levels;
CRC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.61	10.47	0.5	2.56e-22	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.21	0.37	3.79e-12	Eye color traits;
CRC	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg14345882	chr6:26364793	BTN3A2	0.7	5.75	0.3	2.03e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09085639	chr17:79670810	MRPL12	0.44	6.52	0.34	2.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg05683857	chr10:124030795	BTBD16	-0.32	-5.74	-0.3	2.19e-8	Total body bone mineral density;
CRC	cis	rs6741819	0.911	rs2292931	chr2:7137488	A/G	cg27144453	chr2:7172511	RNF144A	-0.41	-5.99	-0.31	5.49e-9	Response to antipsychotic treatment;
CRC	cis	rs17162190	0.698	rs4659375	chr1:26804090	G/A	cg17456097	chr1:26900765	RPS6KA1	0.44	6.37	0.33	6.31e-10	Mean corpuscular volume;
CRC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg09179987	chr1:167433047	CD247	0.5	7.38	0.38	1.32e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs9549328	0.565	rs35988856	chr13:113617427	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.52	0.34	2.68e-10	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.62	12.96	0.58	2.67e-31	Schizophrenia;
CRC	cis	rs10450586	0.932	rs899302	chr11:27309577	T/C	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg26061582	chr7:22766209	IL6	0.55	8.34	0.42	2.03e-15	Lung cancer;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg21620606	chr4:1342894	KIAA1530	-0.42	-7.68	-0.39	1.8e-13	Obesity-related traits;
CRC	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	0.89	7.75	0.39	1.18e-13	Fat distribution (HIV);
CRC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg21970626	chr13:21893289	NA	-0.43	-6.21	-0.32	1.64e-9	White matter hyperintensity burden;
CRC	trans	rs117598310	0.915	rs41318744	chr8:75922760	A/C	cg22249754	chr7:5353456	TNRC18	-0.45	-6.03	-0.32	4.47e-9	Optic cup area;
CRC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20307385	chr11:47447363	PSMC3	-0.56	-7.81	-0.4	7.68e-14	Subjective well-being;
CRC	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.48	-7.72	-0.39	1.45e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.83	8.23	0.41	4.37e-15	Diabetic retinopathy;
CRC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.51	-8.33	-0.42	2.24e-15	Testicular germ cell tumor;
CRC	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg26353448	chr1:248524236	OR2T4	-0.32	-6.17	-0.32	1.97e-9	Common traits (Other);
CRC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.99	-0.36	1.53e-11	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11450715	chr2:171627404	NA	0.37	6.34	0.33	7.53e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.67	-0.35	1.09e-10	Total body bone mineral density;
CRC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.83	13.18	0.59	3.79e-32	Platelet distribution width;
CRC	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.46	5.86	0.31	1.12e-8	Cancer;
CRC	cis	rs4731207	0.596	rs11980178	chr7:124604660	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	8.78	0.44	9.24e-17	Eosinophil percentage of white cells;
CRC	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.54	7.3	0.37	2.16e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15557168	chr22:42548783	NA	-0.34	-5.62	-0.3	4.08e-8	Cognitive function;
CRC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg00343986	chr7:65444356	GUSB	0.42	5.85	0.31	1.22e-8	Aortic root size;
CRC	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.56	-8.17	-0.41	6.7e-15	Lewy body disease;
CRC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.28	0.42	3.08e-15	Gut microbiome composition (summer);
CRC	cis	rs4290604	0.748	rs78545853	chr2:238005148	C/T	cg23555395	chr2:238036564	NA	0.6	6.14	0.32	2.41e-9	Asthma;
CRC	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.62	-0.34	1.46e-10	Depression;
CRC	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.48	7.48	0.38	6.7e-13	Red blood cell count;
CRC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.75	-11.58	-0.54	3.11e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.58	-9.3	-0.46	2.03e-18	Total body bone mineral density;
CRC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg05941027	chr17:61774174	LIMD2	0.36	6.4	0.33	5.23e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg20397358	chr22:38597902	MAFF	-0.71	-6.17	-0.32	2.03e-9	Cognitive function;
CRC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.46	6.95	0.36	1.97e-11	Red blood cell count;
CRC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.52	5.88	0.31	9.9e-9	Bipolar disorder;
CRC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.94	-13.97	-0.61	3.66e-35	Systemic lupus erythematosus;
CRC	trans	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	9.01	0.44	1.71e-17	Schizophrenia;
CRC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.7	9.14	0.45	6.76e-18	Dilated cardiomyopathy;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05658717	chr12:118407033	KSR2	-0.4	-6.04	-0.32	4.16e-9	Myopia (pathological);
CRC	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	8.01	0.4	1.99e-14	Neuroticism;
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	8.45	0.42	9.74e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.31	-0.46	1.86e-18	Urate levels in obese individuals;
CRC	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg09455208	chr3:40491958	NA	-0.42	-8.52	-0.43	5.87e-16	Renal cell carcinoma;
CRC	trans	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg01134436	chr17:81009848	B3GNTL1	0.58	6.49	0.34	3.15e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6479527	0.904	rs10122334	chr9:96864227	A/G	cg13460858	chr9:96720652	NA	0.31	5.6	0.3	4.49e-8	Esophageal adenocarcinoma;
CRC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg19622623	chr12:86230825	RASSF9	-0.37	-5.6	-0.3	4.45e-8	Major depressive disorder;
CRC	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.36	-6.05	-0.32	4.01e-9	Sitting height ratio;
CRC	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg07299736	chr8:135490787	ZFAT	-0.39	-6.48	-0.34	3.27e-10	Hypertension (SNP x SNP interaction);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg20899266	chr3:9471176	SETD5	-0.41	-6.4	-0.33	5.49e-10	HDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03487115	chr7:91569843	AKAP9	0.41	6.09	0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg00086871	chr4:6988644	TBC1D14	0.88	6.48	0.34	3.32e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4731207	0.698	rs11975788	chr7:124497811	T/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg24531977	chr5:56204891	C5orf35	0.48	7.38	0.38	1.27e-12	Coronary artery disease;
CRC	cis	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg04523069	chr9:97136363	HIATL1	0.37	5.62	0.3	4.05e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg07212818	chr11:638076	DRD4	-0.45	-5.81	-0.31	1.48e-8	Systemic lupus erythematosus;
CRC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg18016565	chr1:150552671	MCL1	0.42	5.8	0.3	1.57e-8	Melanoma;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.41	5.86	0.31	1.12e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.67	9.59	0.47	2.36e-19	Alzheimer's disease;
CRC	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg25019722	chr6:37503610	NA	-0.51	-9.49	-0.46	4.84e-19	Cognitive performance;
CRC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07701084	chr6:150067640	NUP43	0.52	7.03	0.36	1.2e-11	Testicular germ cell tumor;
CRC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-11.16	-0.52	9.91e-25	Personality dimensions;
CRC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00531246	chr13:114174973	TMCO3	-0.35	-6.03	-0.32	4.31e-9	Cancer;
CRC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13126279	chr21:47581558	C21orf56	0.35	5.6	0.3	4.49e-8	Testicular germ cell tumor;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25412384	chr14:23341283	LRP10	0.47	6.23	0.32	1.43e-9	Thyroid stimulating hormone;
CRC	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.49	8.01	0.4	1.97e-14	Bone mineral density;
CRC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15369054	chr17:80825471	TBCD	-0.48	-5.86	-0.31	1.15e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13679077	chr7:22862647	TOMM7	0.41	6.36	0.33	6.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg02993699	chr4:3415135	RGS12	-0.38	-6.26	-0.33	1.18e-9	Serum sulfate level;
CRC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.54	7.18	0.37	4.54e-12	Height;
CRC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.62	-8.18	-0.41	6.12e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12760731	0.843	rs12033565	chr1:178491966	A/G	cg00404053	chr1:178313656	RASAL2	-0.63	-6.79	-0.35	5.37e-11	Obesity-related traits;
CRC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.76	12.9	0.58	4.36e-31	Body mass index;
CRC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.73	-8.35	-0.42	1.94e-15	Obesity-related traits;
CRC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.81	-12.49	-0.57	1.48e-29	Cognitive function;
CRC	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.42	5.93	0.31	7.69e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15094104	chr5:133406808	NA	-0.5	-6.32	-0.33	8.39e-10	Diisocyanate-induced asthma;
CRC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg11833968	chr6:79620685	NA	0.37	6.28	0.33	1.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10982256	0.774	rs10817626	chr9:117254541	G/A	cg13636371	chr9:117264095	DFNB31	0.37	7.01	0.36	1.33e-11	Bipolar disorder;
CRC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.34	-0.37	1.73e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.77	-0.47	6.01e-20	Hip circumference adjusted for BMI;
CRC	cis	rs883565	0.543	rs35628459	chr3:39174437	T/A	cg01426195	chr3:39028469	NA	0.4	6.5	0.34	2.92e-10	Handedness;
CRC	cis	rs6835098	0.520	rs2127896	chr4:174211285	G/A	cg08422745	chr4:174089978	GALNT7	-0.64	-9.0	-0.44	1.91e-17	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.73	-11.35	-0.53	1.97e-25	Tonsillectomy;
CRC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.17	-13.25	-0.59	2.03e-32	Diabetic kidney disease;
CRC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.56	8.06	0.41	1.4e-14	Platelet distribution width;
CRC	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	1.02	12.7	0.57	2.45e-30	IgG glycosylation;
CRC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.37	5.8	0.3	1.6e-8	Height;
CRC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.76	10.92	0.52	6.69e-24	Heart rate;
CRC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg26805224	chr10:79626177	DLG5	0.48	7.02	0.36	1.31e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.49	-8.2	-0.41	5.52e-15	Endometriosis;
CRC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg04121214	chr22:50244548	NA	-0.4	-6.31	-0.33	8.91e-10	Schizophrenia;
CRC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.63	11.67	0.54	1.42e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2289681	0.583	rs2289674	chr17:42953409	A/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.53	-6.22	-0.32	1.53e-9	Cognitive function;
CRC	cis	rs4731207	0.596	rs6964090	chr7:124667116	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.03	-0.32	4.36e-9	Cutaneous malignant melanoma;
CRC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg03929089	chr4:120376271	NA	-0.49	-7.18	-0.37	4.75e-12	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13928520	chr1:146522365	NA	-0.37	-5.97	-0.31	6.01e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7538876	0.935	rs2526827	chr1:17730825	G/A	cg07965774	chr1:17746286	RCC2	0.3	5.73	0.3	2.29e-8	Basal cell carcinoma;
CRC	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg19025524	chr12:109796872	NA	-0.47	-6.72	-0.35	8.22e-11	Neuroticism;
CRC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.26	0.45	2.71e-18	Height;
CRC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg08755490	chr11:65554678	OVOL1	0.43	6.39	0.33	5.53e-10	Acne (severe);
CRC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.37	0.53	1.73e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.41	-5.97	-0.31	6.19e-9	QT interval;
CRC	trans	rs711355	0.872	rs785423	chr15:30174376	A/G	cg19414016	chr13:113697165	MCF2L	-0.42	-6.3	-0.33	9.44e-10	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.49	-7.18	-0.37	4.66e-12	Total body bone mineral density;
CRC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-7.26	-0.37	2.73e-12	Schizophrenia;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg12172441	chr6:28176163	NA	0.6	6.56	0.34	2.1e-10	Parkinson's disease;
CRC	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.56	9.11	0.45	7.96e-18	Corneal astigmatism;
CRC	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.77	13.21	0.59	3.08e-32	Ear protrusion;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg25303599	chr11:61595807	FADS2	-0.49	-6.53	-0.34	2.53e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg06204229	chr3:52865917	ITIH4	0.5	5.76	0.3	1.98e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg00250761	chr1:31883323	NA	-0.4	-7.53	-0.38	4.98e-13	Alcohol dependence;
CRC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.58	-9.43	-0.46	7.56e-19	Prostate cancer;
CRC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.59	-9.84	-0.48	3.37e-20	Schizophrenia;
CRC	cis	rs9341808	0.600	rs590641	chr6:80966483	A/G	cg08355045	chr6:80787529	NA	0.35	5.83	0.31	1.32e-8	Sitting height ratio;
CRC	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.82	-0.63	2.09e-38	Exhaled nitric oxide output;
CRC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg27535305	chr1:53392650	SCP2	-0.39	-7.04	-0.36	1.13e-11	Monocyte count;
CRC	cis	rs11212617	1.000	rs228591	chr11:108097333	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.46	6.91	0.36	2.5e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Parkinson's disease;
CRC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.38	0.33	5.86e-10	Total body bone mineral density;
CRC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.84	-14.59	-0.63	1.56e-37	Prudent dietary pattern;
CRC	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg02702477	chr5:179499311	RNF130	0.51	5.87	0.31	1.04e-8	LDL cholesterol;
CRC	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.36	7.75	0.39	1.16e-13	Total body bone mineral density;
CRC	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.32	6.63	0.34	1.36e-10	Migraine;
CRC	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg10761708	chr20:43804764	PI3	0.5	5.68	0.3	2.93e-8	Blood protein levels;
CRC	cis	rs9462027	0.628	rs9462026	chr6:34797033	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.15	-0.32	2.28e-9	Systemic lupus erythematosus;
CRC	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.54	9.06	0.45	1.16e-17	Facial morphology (factor 15, philtrum width);
CRC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg08200770	chr17:80723486	TBCD	-0.51	-7.76	-0.39	1.1e-13	Glycated hemoglobin levels;
CRC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.77	-0.3	1.8e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg15786705	chr6:28176104	NA	0.8	9.96	0.48	1.31e-20	Depression;
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.47	6.75	0.35	6.74e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	1.99e-8	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.68	0.65	8.67e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4731207	0.596	rs7799518	chr7:124575684	A/C	cg23710748	chr7:124431027	NA	-0.4	-6.37	-0.33	6.31e-10	Cutaneous malignant melanoma;
CRC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.83	-0.31	1.34e-8	Aortic root size;
CRC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.87	0.48	2.71e-20	Platelet count;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.2	-0.56	1.65e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.74	13.81	0.61	1.57e-34	Leprosy;
CRC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg13628971	chr7:2884303	GNA12	0.4	6.19	0.32	1.81e-9	Height;
CRC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.62	9.1	0.45	8.79e-18	Breast cancer;
CRC	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.86	16.37	0.67	1.7e-44	Hip circumference;
CRC	cis	rs17767392	0.958	rs7145755	chr14:71848110	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.84	-0.35	3.87e-11	Mitral valve prolapse;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15613982	chr20:18488017	SEC23B	0.42	6.03	0.32	4.41e-9	Response to antipsychotic treatment;
CRC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.79	12.35	0.56	4.92e-29	Breast cancer;
CRC	cis	rs11030122	0.547	rs10767720	chr11:3953297	T/C	cg18678763	chr11:4115507	RRM1	-0.39	-6.61	-0.34	1.59e-10	Mean platelet volume;Platelet distribution width;
CRC	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.54	0.5	1.46e-22	Corneal astigmatism;
CRC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	0.28	6.66	0.34	1.13e-10	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10116431	chr3:143690928	C3orf58	0.38	6.24	0.33	1.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.49	-6.74	-0.35	7.31e-11	Multiple myeloma;
CRC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	16.9	0.68	1.41e-46	Testicular germ cell tumor;
CRC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg00769240	chr8:12517080	NA	0.54	6.88	0.35	3.08e-11	Blood pressure (smoking interaction);
CRC	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.5	7.38	0.38	1.28e-12	Glioblastoma;Glioma;
CRC	cis	rs8170	1.000	rs66753001	chr19:17394839	A/G	cg04749549	chr19:17459798	NA	-0.46	-6.18	-0.32	1.9e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.31	-6.34	-0.33	7.49e-10	Cystic fibrosis severity;
CRC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.41	0.42	1.28e-15	Height;
CRC	cis	rs4908760	0.965	rs10864353	chr1:8549716	A/G	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Vitiligo;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.71e-9	Depression;
CRC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.61	7.87	0.4	5.15e-14	Gut microbiome composition (summer);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19169234	chr9:128469688	MAPKAP1	0.48	6.36	0.33	6.76e-10	Thyroid stimulating hormone;
CRC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-1.01	-13.77	-0.6	2.28e-34	Lymphocyte counts;
CRC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-5.65	-0.3	3.53e-8	Monocyte percentage of white cells;
CRC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg02766259	chr12:125626809	AACS	-0.45	-8.36	-0.42	1.79e-15	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg02972257	chr16:68554789	NA	0.44	5.63	0.3	3.83e-8	Colorectal cancer;
CRC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg17321639	chr7:2759063	NA	-0.52	-6.95	-0.36	2.03e-11	Height;
CRC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.61	-0.34	1.53e-10	Breast cancer;
CRC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.31	-0.33	8.85e-10	Gout;Renal underexcretion gout;
CRC	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg03929089	chr4:120376271	NA	0.64	6.02	0.31	4.77e-9	Axial length;
CRC	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.44	6.67	0.34	1.12e-10	HDL cholesterol;
CRC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.43	-9.65	-0.47	1.47e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.38	6.06	0.32	3.77e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg03929089	chr4:120376271	NA	-0.64	-7.03	-0.36	1.16e-11	Axial length;
CRC	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg17788362	chr6:86352627	SYNCRIP	0.56	7.85	0.4	5.85e-14	Smooth-surface caries;
CRC	trans	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg26043149	chr18:55253948	FECH	0.51	7.76	0.39	1.05e-13	Bone mineral density;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg05064044	chr6:292385	DUSP22	-0.56	-7.97	-0.4	2.68e-14	Menopause (age at onset);
CRC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.66	-0.47	1.33e-19	Heart rate;
CRC	cis	rs904251	0.605	rs4257849	chr6:37410969	T/G	cg25019722	chr6:37503610	NA	-0.4	-5.85	-0.31	1.21e-8	Cognitive performance;
CRC	trans	rs12517041	1.000	rs35753092	chr5:23277623	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.14	-0.32	2.38e-9	Calcium levels;
CRC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.43	6.0	0.31	5.18e-9	Aortic root size;
CRC	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.51	7.3	0.37	2.24e-12	Ovarian reserve;
CRC	cis	rs335206	1.000	rs335204	chr5:122506260	C/A	cg16368670	chr5:122501738	PRDM6	-0.29	-5.71	-0.3	2.5e-8	QRS duration;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg23161317	chr6:28129485	ZNF389	0.47	6.73	0.35	7.5e-11	Cardiac Troponin-T levels;
CRC	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg19773385	chr1:10388646	KIF1B	-0.49	-7.76	-0.39	1.06e-13	Hepatocellular carcinoma;
CRC	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg00666640	chr1:248458726	OR2T12	0.49	8.73	0.43	1.34e-16	Common traits (Other);
CRC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.58	-9.37	-0.46	1.21e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.5	0.65	4.47e-41	Bipolar disorder;
CRC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.77	11.07	0.52	2e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.86e-9	Arsenic metabolism;
CRC	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.51	8.46	0.42	8.96e-16	Metabolite levels (small molecules and protein measures);
CRC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.42	-0.38	1.02e-12	Colorectal cancer;
CRC	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.12	0.45	7.5e-18	Dupuytren's disease;
CRC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.41	0.42	1.25e-15	Height;
CRC	cis	rs728616	0.867	rs79904324	chr10:81804688	A/G	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.82	-0.35	4.41e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.74	-0.3	2.11e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.87	-0.4	5.13e-14	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.54	7.32	0.37	1.88e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg19673125	chr6:150240577	RAET1G	0.3	5.8	0.3	1.58e-8	Testicular germ cell tumor;
CRC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg00316803	chr15:76480434	C15orf27	-0.4	-6.9	-0.36	2.63e-11	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.63	9.84	0.48	3.47e-20	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg04110750	chr16:69646130	NFAT5	-0.56	-7.74	-0.39	1.22e-13	IgE levels;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	cis	rs6066835	0.867	rs6095278	chr20:47363413	C/T	cg18078177	chr20:47281410	PREX1	0.63	5.89	0.31	9.41e-9	Multiple myeloma;
CRC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.79	0.66	3.5e-42	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.68	-11.83	-0.55	3.77e-27	Educational attainment;
CRC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.52	-0.38	5.38e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.26	-0.37	2.78e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.57	-7.68	-0.39	1.78e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.37	5.63	0.3	3.78e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	15.34	0.65	1.96e-40	Ulcerative colitis;
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2274273	0.624	rs66551709	chr14:55791022	A/T	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.77	-0.3	1.79e-8	Protein biomarker;
CRC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg25834613	chr7:1915315	MAD1L1	-0.47	-6.79	-0.35	5.26e-11	Bipolar disorder;
CRC	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg15704280	chr7:45808275	SEPT13	0.62	5.98	0.31	5.71e-9	Axial length;
CRC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.47	6.54	0.34	2.29e-10	Tuberculosis;
CRC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg07274523	chr3:49395745	GPX1	0.46	5.93	0.31	7.77e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.71	7.04	0.36	1.1e-11	Fat distribution (HIV);
CRC	trans	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg26043149	chr18:55253948	FECH	-0.48	-7.32	-0.37	1.95e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.44	9.03	0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg09873164	chr1:152488093	CRCT1	0.37	6.22	0.32	1.49e-9	Hair morphology;
CRC	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.53	7.19	0.37	4.51e-12	Caudate activity during reward;
CRC	cis	rs6496667	0.779	rs2283442	chr15:90971478	C/G	cg04176472	chr15:90893244	GABARAPL3	0.6	8.29	0.42	2.86e-15	Rheumatoid arthritis;
CRC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.56	0.63	2.05e-37	Chronic sinus infection;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg26114003	chr2:25016152	CENPO;C2orf79	0.44	6.17	0.32	1.98e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.85	-0.4	5.85e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.97	0.31	6.28e-9	Tonsillectomy;
CRC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg20387954	chr3:183756860	HTR3D	0.45	7.67	0.39	1.91e-13	Anterior chamber depth;
CRC	cis	rs4664293	1.000	rs2357382	chr2:160493125	G/C	cg08347373	chr2:160653686	CD302	-0.38	-6.24	-0.33	1.38e-9	Monocyte percentage of white cells;
CRC	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.74	11.39	0.53	1.5e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.73	-0.54	8.43e-27	Exhaled nitric oxide output;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg04025307	chr7:1156635	C7orf50	0.65	6.94	0.36	2.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg07274523	chr3:49395745	GPX1	0.46	6.26	0.33	1.19e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.51	5.88	0.31	9.94e-9	Dental caries;
CRC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.57	0.34	1.95e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.11	0.32	2.75e-9	Lung cancer;
CRC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg07125278	chr16:67683757	RLTPR	-0.63	-7.25	-0.37	3.09e-12	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17602823	chr1:28586543	SESN2	0.43	6.92	0.36	2.38e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.97	11.95	0.55	1.37e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg23601416	chr22:19950040	COMT	-0.26	-7.15	-0.37	5.79e-12	Blood metabolite levels;
CRC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-8.44	-0.42	1.01e-15	Total body bone mineral density;
CRC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.66	-0.34	1.18e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg03623178	chr6:28175578	NA	0.67	9.51	0.46	4.25e-19	Parkinson's disease;
CRC	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.55	-8.4	-0.42	1.37e-15	Eosinophil percentage of white cells;
CRC	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.74	-8.09	-0.41	1.19e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13405485	chr10:13628859	PRPF18	0.39	6.46	0.34	3.81e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg26776924	chr19:1969666	CSNK1G2	0.46	7.36	0.38	1.51e-12	Coronary artery disease;
CRC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.29e-20	Ileal carcinoids;
CRC	trans	rs10504390	0.585	rs79812520	chr8:66507615	T/C	cg26403416	chr21:43771339	TFF2	0.64	6.54	0.34	2.37e-10	IgG glycosylation;
CRC	cis	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg04523069	chr9:97136363	HIATL1	0.37	5.77	0.3	1.8e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg05283184	chr6:79620031	NA	-0.44	-7.32	-0.37	1.89e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-1.04	-10.72	-0.51	3.38e-23	Body mass index;
CRC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.79	8.04	0.41	1.68e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.63	-12.18	-0.56	2.04e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg10756647	chr7:56101905	PSPH	0.74	7.72	0.39	1.43e-13	Diabetic kidney disease;
CRC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	15.72	0.65	6.17e-42	Smoking behavior;
CRC	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.54	0.47	3.31e-19	Type 2 diabetes;
CRC	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02176678	chr2:219576539	TTLL4	0.5	7.86	0.4	5.48e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.29	0.42	2.9e-15	Vitiligo;
CRC	cis	rs939584	1.000	rs13021737	chr2:632348	A/G	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.58e-8	Body mass index;
CRC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.97	0.4	2.6e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs12024301	0.557	rs80013399	chr1:183598837	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.68	10.39	0.5	4.84e-22	Hemoglobin concentration;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17727855	chr9:108007124	SLC44A1	-0.4	-6.15	-0.32	2.21e-9	Myopia (pathological);
CRC	cis	rs10512697	0.803	rs13177899	chr5:3578923	T/C	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.29	6.12	0.32	2.69e-9	Lung cancer;
CRC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	8.68	0.43	1.83e-16	Cognitive test performance;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg18100827	chr3:119013497	CDGAP	-0.47	-5.99	-0.31	5.62e-9	Parkinson's disease;
CRC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	trans	rs246600	0.543	rs246607	chr5:142513686	C/T	cg16052198	chr19:52264411	FPR2	-0.32	-6.34	-0.33	7.44e-10	Coronary artery disease;
CRC	cis	rs2252521	0.666	rs1117873	chr7:29086980	T/C	cg11728747	chr7:29037910	CPVL	-0.33	-6.04	-0.32	4.27e-9	Cognitive performance;
CRC	cis	rs501120	1.000	rs634963	chr10:44760033	T/C	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.56	8.23	0.41	4.44e-15	Melanoma;
CRC	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg07856975	chr6:36356162	ETV7	0.48	5.98	0.31	5.7e-9	Platelet distribution width;
CRC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.52	0.34	2.63e-10	Height;
CRC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-0.99	-12.74	-0.57	1.64e-30	Vitiligo;
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	8.18	0.41	6.4e-15	Obesity-related traits;
CRC	cis	rs939584	0.877	rs7594220	chr2:643320	G/A	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.58	7.0	0.36	1.45e-11	Carotid intima media thickness;
CRC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	11.9	0.55	2.08e-27	Bone mineral density;
CRC	cis	rs3018066	0.831	rs11732791	chr4:107157238	T/C	cg01869342	chr4:106983673	TBCK	-0.36	-5.64	-0.3	3.66e-8	Cancer;
CRC	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.22	-5.7	-0.3	2.67e-8	Type 2 diabetes;
CRC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-6.52	-0.34	2.72e-10	Eosinophil percentage of white cells;
CRC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.47	-8.84	-0.44	6.04e-17	Reticulocyte fraction of red cells;
CRC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.5	8.85	0.44	5.45e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20252735	chr7:56019475	MRPS17	0.41	6.03	0.32	4.48e-9	Response to antipsychotic treatment;
CRC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg27489772	chr12:121021490	NA	-0.47	-6.59	-0.34	1.72e-10	Type 1 diabetes nephropathy;
CRC	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg03030879	chr14:75389066	RPS6KL1	0.44	7.03	0.36	1.19e-11	Caffeine consumption;
CRC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg12573674	chr2:1569213	NA	-0.68	-7.56	-0.38	3.95e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg10820045	chr2:198174542	NA	-0.5	-8.67	-0.43	1.97e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.66	8.29	0.42	2.99e-15	Body mass index;
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.38	-0.38	1.34e-12	Life satisfaction;
CRC	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.45	-6.31	-0.33	8.86e-10	Lung cancer;
CRC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.75	11.18	0.52	8.28e-25	Breast cancer;
CRC	trans	rs4869931	0.929	rs73010188	chr6:151006620	T/C	cg01367992	chr1:160766535	LY9	0.37	6.06	0.32	3.76e-9	Systolic blood pressure in sickle cell anemia;
CRC	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.31	-0.33	9.11e-10	Rheumatoid arthritis;
CRC	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.48	-7.6	-0.39	3.03e-13	Schizophrenia;
CRC	cis	rs3018066	0.831	rs28394440	chr4:106944126	C/A	cg01869342	chr4:106983673	TBCK	0.39	6.02	0.31	4.75e-9	Cancer;
CRC	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg08462924	chr1:41848221	NA	0.4	6.19	0.32	1.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg12193833	chr17:30244370	NA	-0.75	-8.76	-0.43	1.09e-16	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07499643	chr1:43424067	SLC2A1	0.43	6.36	0.33	6.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg19682013	chr15:45996608	NA	0.32	6.68	0.35	1.01e-10	Waist circumference;Weight;
CRC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.67	0.54	1.44e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs832187	0.813	rs704370	chr3:63868250	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.4	5.72	0.3	2.41e-8	Schizophrenia;
CRC	cis	rs2051211	0.895	rs17037798	chr3:38555474	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.77	-0.3	1.83e-8	QRS duration;
CRC	cis	rs9616064	0.670	rs9616045	chr22:46949292	C/T	cg05621596	chr22:47072043	GRAMD4	-0.56	-8.43	-0.42	1.11e-15	Urate levels in obese individuals;
CRC	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.04	-0.55	6.79e-28	Coffee consumption (cups per day);
CRC	cis	rs534126	1.000	rs534126	chr7:142921234	C/T	cg04039957	chr7:143013207	CLCN1	0.37	6.48	0.34	3.37e-10	Cancer;
CRC	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg00319359	chr11:70116639	PPFIA1	0.56	6.11	0.32	2.76e-9	Coronary artery disease;
CRC	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.41	6.28	0.33	1.05e-9	Red blood cell count;
CRC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg20119798	chr7:94954144	PON1	-0.46	-5.69	-0.3	2.78e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25976393	chr20:34680652	NA	0.42	6.39	0.33	5.72e-10	Anxiety disorder;
CRC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	9.0	0.44	1.85e-17	Height;
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.29e-11	Alzheimer's disease;
CRC	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg21839984	chr17:30846986	MYO1D	-0.35	-6.07	-0.32	3.46e-9	Schizophrenia;
CRC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-8.33	-0.42	2.25e-15	Total cholesterol levels;
CRC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-12.8	-0.58	1.04e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.25	0.45	2.83e-18	Platelet count;
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.54	8.3	0.42	2.8e-15	Corneal astigmatism;
CRC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.62	-9.67	-0.47	1.22e-19	Menopause (age at onset);
CRC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.78	-0.44	8.82e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2303319	0.504	rs16846073	chr2:162586548	C/G	cg04551154	chr10:95462393	C10orf4	-0.69	-5.96	-0.31	6.38e-9	Cognitive function;
CRC	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.47	-5.82	-0.31	1.41e-8	Obesity-related traits;
CRC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.87	-16.07	-0.66	2.79e-43	Coronary artery disease;
CRC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.7	-8.17	-0.41	6.68e-15	Obesity-related traits;
CRC	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.45	0.46	6.58e-19	Fuchs's corneal dystrophy;
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg19624444	chr7:2048497	MAD1L1	0.33	5.9	0.31	8.96e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs501916	0.634	rs10851459	chr15:48061510	C/A	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.62	-0.34	1.43e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-1.07	-10.58	-0.5	1.03e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg02158880	chr13:53174818	NA	0.49	7.4	0.38	1.13e-12	Lewy body disease;
CRC	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.61	12.42	0.57	2.58e-29	Neuroticism;
CRC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg18827107	chr12:86230957	RASSF9	-0.37	-6.12	-0.32	2.61e-9	Major depressive disorder;
CRC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.45	-6.34	-0.33	7.54e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.51	-9.7	-0.47	9.88e-20	Educational attainment (years of education);
CRC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.17	-9.75	-0.47	6.94e-20	Mitochondrial DNA levels;
CRC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.69	12.96	0.58	2.64e-31	Coronary artery disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03430067	chr19:14016927	C19orf57;CC2D1A	0.48	6.43	0.33	4.61e-10	Survival in pancreatic cancer;
CRC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg05540913	chr6:167530185	CCR6	-0.39	-7.14	-0.37	6.07e-12	Primary biliary cholangitis;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11645453	chr3:52864694	ITIH4	0.36	6.31	0.33	8.84e-10	Bipolar disorder;
CRC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.87	0.4	5.21e-14	Lung cancer;
CRC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	0.6	6.87	0.35	3.31e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.69	-0.35	9.68e-11	Breast cancer;
CRC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg10298567	chr3:47292165	KIF9	0.37	5.98	0.31	5.68e-9	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11961288	chr19:45681945	BLOC1S3;TRAPPC6A	0.45	6.44	0.33	4.12e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6662572	0.737	rs72677545	chr1:46571221	C/T	cg08644498	chr1:46502608	NA	0.46	7.36	0.38	1.45e-12	Blood protein levels;
CRC	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.37	-5.92	-0.31	7.91e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.81	-9.7	-0.47	1.01e-19	Initial pursuit acceleration;
CRC	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.6	-9.5	-0.46	4.44e-19	Breast cancer;
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg02683197	chr6:28174875	NA	-0.89	-12.67	-0.57	3.01e-30	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10349436	chr2:106015079	FHL2	0.41	6.42	0.33	4.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg12273811	chr6:28175739	NA	0.59	8.61	0.43	3.11e-16	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs4731207	0.596	rs6466966	chr7:124580327	A/G	cg23710748	chr7:124431027	NA	0.38	6.12	0.32	2.7e-9	Cutaneous malignant melanoma;
CRC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg16342193	chr10:102329863	NA	-0.37	-6.04	-0.32	4.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.13	-9.43	-0.46	7.38e-19	Mitochondrial DNA levels;
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.57	-7.73	-0.39	1.33e-13	Renal function-related traits (BUN);
CRC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg04315214	chr1:2043799	PRKCZ	-0.35	-6.06	-0.32	3.76e-9	Height;
CRC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg23590916	chr17:43697445	MGC57346	0.73	7.26	0.37	2.84e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.28	0.33	1.06e-9	Diabetic kidney disease;
CRC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-9.98	-0.48	1.12e-20	Cognitive function;
CRC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.54	6.1	0.32	2.99e-9	Bipolar disorder;
CRC	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.74	-11.08	-0.52	1.87e-24	Waist circumference;Body mass index;
CRC	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg04132472	chr17:19861366	AKAP10	0.43	6.83	0.35	4.01e-11	Schizophrenia;
CRC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.71	-0.47	9.27e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.55	8.58	0.43	3.74e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.57	6.42	0.33	4.69e-10	Gastritis;
CRC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.81	-11.43	-0.53	1.06e-25	Asthma;
CRC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg20387954	chr3:183756860	HTR3D	0.45	7.69	0.39	1.69e-13	Anterior chamber depth;
CRC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg10760299	chr15:45669010	GATM	0.5	7.73	0.39	1.29e-13	Homoarginine levels;
CRC	cis	rs4728302	0.869	rs7792905	chr7:133595602	G/T	cg03336402	chr7:133662267	EXOC4	-0.45	-6.51	-0.34	2.78e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.25	-0.33	1.26e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-11.05	-0.52	2.43e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.73	8.75	0.43	1.11e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs34467563	1.000	rs35096529	chr8:97385140	T/A	cg20465794	chr11:111169943	C11orf92;C11orf93	-0.43	-6.02	-0.31	4.67e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.38	6.41	0.33	5.02e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2857891	0.817	rs2638094	chr11:6981488	A/G	cg12728517	chr11:6947552	ZNF215	0.56	5.9	0.31	9.21e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg14191688	chr11:70257035	CTTN	0.44	5.94	0.31	7.39e-9	Coronary artery disease;
CRC	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.36	7.82	0.4	7.32e-14	Total body bone mineral density;
CRC	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg07424746	chr4:185654737	MLF1IP	-0.6	-5.84	-0.31	1.25e-8	Blood protein levels;
CRC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg16797656	chr11:68205561	LRP5	0.37	5.84	0.31	1.27e-8	Total body bone mineral density;
CRC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.65	0.43	2.38e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.44	-0.38	8.88e-13	HDL cholesterol;
CRC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.58	-11.35	-0.53	2.06e-25	Asthma (sex interaction);
CRC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-8.16	-0.41	7.33e-15	Gut microbiome composition (summer);
CRC	cis	rs863345	0.604	rs879637	chr1:158462697	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.31	-0.33	8.84e-10	Pneumococcal bacteremia;
CRC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.83	0.35	4.07e-11	Dupuytren's disease;
CRC	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg05935833	chr10:81318306	SFTPA2	-0.75	-8.19	-0.41	5.8e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.59	7.7	0.39	1.6e-13	Multiple sclerosis;
CRC	trans	rs6546324	0.625	rs2902025	chr2:67842424	A/G	cg00907274	chr3:27498161	SLC4A7	-0.48	-6.13	-0.32	2.55e-9	Endometriosis;
CRC	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg20936604	chr3:58311152	NA	-0.72	-6.79	-0.35	5.21e-11	Cholesterol, total;
CRC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.42	9.27	0.45	2.61e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs524281	0.773	rs2155198	chr11:66014300	C/T	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg22917237	chr19:18633401	ELL	-0.42	-6.11	-0.32	2.75e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.94	11.26	0.53	4.34e-25	Orofacial clefts;
CRC	cis	rs10089	0.552	rs58595196	chr5:127558338	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	7.59	0.39	3.25e-13	Ileal carcinoids;
CRC	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg14003231	chr6:33640908	ITPR3	0.49	7.87	0.4	5.32e-14	Plateletcrit;
CRC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.88	8.73	0.43	1.32e-16	Lymphocyte counts;
CRC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.83	11.86	0.55	2.96e-27	Cognitive function;
CRC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg19318889	chr4:1322082	MAEA	0.4	5.65	0.3	3.41e-8	Obesity-related traits;
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg15845792	chr6:28175446	NA	0.71	6.06	0.32	3.71e-9	Breast cancer;
CRC	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg18758796	chr5:131593413	PDLIM4	0.32	5.64	0.3	3.59e-8	Blood metabolite levels;
CRC	cis	rs17767392	0.918	rs3784062	chr14:72090505	T/G	cg13720639	chr14:72061746	SIPA1L1	0.55	6.66	0.34	1.13e-10	Mitral valve prolapse;
CRC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.92	0.4	3.71e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12476592	0.602	rs171902	chr2:63903236	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.33	0.33	7.99e-10	Childhood ear infection;
CRC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.47	-8.82	-0.44	6.68e-17	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg16606324	chr3:10149918	C3orf24	0.45	6.8	0.35	4.87e-11	Alzheimer's disease;
CRC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-10.31	-0.49	9.11e-22	Developmental language disorder (linguistic errors);
CRC	cis	rs7781266	0.739	rs11765450	chr7:133069682	A/G	cg03336402	chr7:133662267	EXOC4	-0.52	-6.17	-0.32	1.99e-9	Educational attainment (college completion);
CRC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.57	-9.01	-0.45	1.67e-17	Vitiligo;
CRC	cis	rs7705042	0.865	rs12653866	chr5:141489921	C/T	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.79	-0.3	1.62e-8	Asthma;
CRC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg01483505	chr11:975446	AP2A2	0.45	7.39	0.38	1.24e-12	Alzheimer's disease (late onset);
CRC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.92	0.48	1.8899999999999998e-20	Migraine;Coronary artery disease;
CRC	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.5	-7.78	-0.39	9.28e-14	Type 2 diabetes;
CRC	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg09184832	chr6:79620586	NA	-0.46	-7.89	-0.4	4.48e-14	Intelligence (multi-trait analysis);
CRC	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg03469862	chr11:68924853	NA	0.46	6.03	0.32	4.33e-9	Blond vs. brown hair color;
CRC	cis	rs8014671	0.553	rs8019852	chr14:70883943	G/A	cg25576086	chr14:70833871	SYNJ2BP	-0.36	-6.05	-0.32	3.87e-9	Prostate cancer;
CRC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.19	-0.32	1.77e-9	Major depressive disorder;
CRC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.52	10.03	0.48	7.88e-21	Urate levels in lean individuals;
CRC	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.38	6.16	0.32	2.09e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.57	-5.93	-0.31	7.57e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs354033	1.000	rs354033	chr7:149289464	A/G	cg24335155	chr7:149193227	ZNF746	-0.36	-6.07	-0.32	3.62e-9	Multiple sclerosis;
CRC	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg06238570	chr21:40685208	BRWD1	0.69	9.1	0.45	9.08e-18	Cognitive function;
CRC	cis	rs7129220	0.512	rs12279871	chr11:10228196	G/A	cg23875677	chr11:10229755	SBF2	-0.53	-5.97	-0.31	6.29e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg17182837	chr8:41585554	ANK1	-0.36	-5.64	-0.3	3.73e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26837270	chr19:42746884	GSK3A	0.38	6.02	0.31	4.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg03623178	chr6:28175578	NA	0.74	7.82	0.4	7.43e-14	Depression;
CRC	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.68	-7.94	-0.4	3.19e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.7	-8.17	-0.41	6.68e-15	Obesity-related traits;
CRC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.4	0.53	1.39e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg11833968	chr6:79620685	NA	-0.35	-6.23	-0.32	1.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.931	rs1168085	chr1:63112320	C/G	cg19896129	chr1:63156450	NA	-0.4	-6.23	-0.32	1.4e-9	Triglyceride levels;
CRC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24308560	chr3:49941425	MST1R	0.48	7.6	0.39	3.19e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg10756647	chr7:56101905	PSPH	0.7	7.47	0.38	7.51e-13	Diabetic kidney disease;
CRC	cis	rs12760731	0.623	rs1342848	chr1:178296461	A/G	cg00404053	chr1:178313656	RASAL2	0.71	9.05	0.45	1.31e-17	Obesity-related traits;
CRC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg14979609	chr8:8086686	FLJ10661	-0.34	-5.67	-0.3	3.06e-8	Mood instability;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21479305	chr19:14640168	TECR;MIR639	0.39	5.97	0.31	6.12e-9	Schizophrenia;
CRC	cis	rs7082209	1.000	rs12265306	chr10:44811617	C/G	cg09554077	chr10:44749378	NA	0.43	5.73	0.3	2.32e-8	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
CRC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg00300879	chr1:26503847	CNKSR1	0.29	5.63	0.3	3.87e-8	QRS complex (12-leadsum);
CRC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg02993699	chr4:3415135	RGS12	0.4	6.67	0.35	1.09e-10	Serum sulfate level;
CRC	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.09	-0.32	3.18e-9	Breast cancer;
CRC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.68e-9	Diabetic kidney disease;
CRC	cis	rs13144136	0.687	rs11737643	chr4:10658199	T/A	cg10242279	chr4:10666415	CLNK	-0.39	-6.63	-0.34	1.39e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3857067	1.000	rs1397026	chr4:95013729	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg24046110	chr8:143859143	LYNX1	0.61	10.78	0.51	2.12e-23	Urinary tract infection frequency;
CRC	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg04989706	chr14:50066350	PPIL5	-0.48	-6.8	-0.35	5.04e-11	Carotid intima media thickness;
CRC	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg14593290	chr7:50529359	DDC	0.63	8.51	0.42	6.21e-16	Malaria;
CRC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.76	-0.39	1.06e-13	Neuroticism;
CRC	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.54	8.34	0.42	2.04e-15	Diastolic blood pressure;
CRC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.68	10.3	0.49	9.6e-22	Menopause (age at onset);
CRC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	7.08	0.36	8.86e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.52	8.1	0.41	1.06e-14	Red blood cell count;
CRC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg20959480	chr12:125599568	AACS	0.39	5.8	0.3	1.59e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.5	7.48	0.38	7e-13	Longevity;
CRC	cis	rs1552172	0.922	rs1778523	chr1:145698023	C/G	cg11743829	chr1:145714124	CD160	-0.4	-5.95	-0.31	6.93e-9	Breast cancer;
CRC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.42	-6.63	-0.34	1.38e-10	Coronary artery disease;
CRC	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg12046867	chr14:103022105	NA	0.43	6.28	0.33	1.07e-9	Platelet count;
CRC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.59	-8.71	-0.43	1.53e-16	Lung cancer;
CRC	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg16724585	chr3:197361211	NA	-0.49	-7.19	-0.37	4.47e-12	Pancreatic cancer;
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.11	0.52	1.42e-24	Prudent dietary pattern;
CRC	trans	rs12797204	0.793	rs4456272	chr11:83469530	C/T	cg07421806	chr5:128301136	SLC27A6	-0.6	-6.01	-0.31	4.99e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CRC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.6	8.14	0.41	8.12e-15	Neutrophil percentage of white cells;
CRC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.5	-6.69	-0.35	9.53e-11	White matter hyperintensity burden;
CRC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.87	0.31	1.05e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg27342122	chr8:133787442	PHF20L1	-0.71	-6.02	-0.31	4.6e-9	Cognitive function;
CRC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12292205	chr6:26970375	C6orf41	-0.6	-6.73	-0.35	7.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2811415	0.597	rs6801215	chr3:127762336	C/T	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.39	-0.38	1.25e-12	Morning vs. evening chronotype;
CRC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.69	9.78	0.47	5.26e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs10991814	0.841	rs7029087	chr9:94061633	A/G	cg14446406	chr9:93919335	NA	0.58	6.46	0.34	3.77e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.41	-6.35	-0.33	7.14e-10	Electroencephalogram traits;
CRC	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.85	9.07	0.45	1.07e-17	Gastritis;
CRC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg03709012	chr19:19516395	GATAD2A	0.46	5.79	0.3	1.68e-8	Perceived unattractiveness to mosquitoes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23117447	chr6:34394069	RPS10	0.47	6.64	0.34	1.3e-10	Response to antipsychotic treatment;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.62	8.85	0.44	5.68e-17	Schizophrenia;
CRC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.52	0.34	2.61e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6681460	1.000	rs6689864	chr1:67068112	T/C	cg02459107	chr1:67143332	SGIP1	0.45	7.63	0.39	2.51e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg08999081	chr20:33150536	PIGU	0.45	5.84	0.31	1.24e-8	Protein C levels;
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20456258	chr4:962124	DGKQ	0.29	5.91	0.31	8.51e-9	Sjögren's syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25533943	chr17:43325323	LOC100133991	0.35	5.98	0.31	5.84e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg23533926	chr12:111358616	MYL2	-0.54	-8.21	-0.41	5e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg14631576	chr9:95140430	CENPP	-0.39	-6.76	-0.35	6.18e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg24375607	chr4:120327624	NA	0.47	7.5	0.38	6.07e-13	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21584983	chr19:11640070	ECSIT	0.51	7.29	0.37	2.33e-12	Response to antipsychotic treatment;
CRC	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.42	0.38	1.03e-12	Eye color traits;
CRC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.68	-8.4	-0.42	1.35e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg09695851	chr17:3907499	NA	0.5	6.36	0.33	6.84e-10	Type 2 diabetes;
CRC	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-0.71	-7.64	-0.39	2.4e-13	Pediatric areal bone mineral density (radius);
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.77	-0.39	1.01e-13	Total body bone mineral density;
CRC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2.1e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg15845792	chr6:28175446	NA	-0.69	-7.67	-0.39	1.94e-13	Parkinson's disease;
CRC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-9.04	-0.45	1.38e-17	Hemoglobin concentration;
CRC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-5.74	-0.3	2.14e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs970548	0.954	rs12249012	chr10:45992470	G/A	cg15590007	chr10:45870220	ALOX5	0.48	6.1	0.32	2.9e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	14.87	0.63	1.28e-38	Primary sclerosing cholangitis;
CRC	cis	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg19078520	chr2:135676222	CCNT2	0.37	5.82	0.31	1.4e-8	Parkinson's disease;
CRC	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.54	-7.86	-0.4	5.72e-14	High light scatter reticulocyte percentage of red cells;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg18553292	chr19:3762619	MRPL54;APBA3	0.47	6.58	0.34	1.91e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.87	16.42	0.67	1.12e-44	Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14126493	chr5:176831297	F12	0.39	6.27	0.33	1.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12249377	0.519	rs11597471	chr10:92598767	C/G	cg14313238	chr10:92632228	RPP30	0.45	6.35	0.33	7e-10	White matter microstructure (global fractional anisotropy);
CRC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.63	-0.6	7.43e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-7.98	-0.4	2.46e-14	Fibrinogen levels;
CRC	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.36	0.42	1.81e-15	Arsenic metabolism;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg27094323	chr7:1216898	NA	-0.45	-7.58	-0.39	3.62e-13	Longevity;Endometriosis;
CRC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	0.56	5.97	0.31	6.31e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.39e-26	Prudent dietary pattern;
CRC	cis	rs6662572	0.686	rs72677541	chr1:46561560	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.26	0.33	1.22e-9	Blood protein levels;
CRC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.41	5.67	0.3	3.2e-8	Parkinson's disease;
CRC	cis	rs73206853	0.841	rs28772589	chr12:110845040	C/T	cg12870014	chr12:110450643	ANKRD13A	0.78	8.56	0.43	4.41e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.59	9.67	0.47	1.2e-19	Pursuit maintenance gain;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07762054	chr11:75273187	SERPINH1	0.47	6.05	0.32	3.99e-9	Anxiety disorder;
CRC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06953865	chr19:18549723	ISYNA1	-0.37	-5.65	-0.3	3.56e-8	Breast cancer;
CRC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.52	7.15	0.37	5.69e-12	Schizophrenia;
CRC	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg14191688	chr11:70257035	CTTN	0.43	5.92	0.31	8.02e-9	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.28	-15.03	-0.64	3.08e-39	Diabetic kidney disease;
CRC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.58	-9.34	-0.46	1.48e-18	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.51	6.73	0.35	7.55e-11	Height;
CRC	cis	rs1044826	0.692	rs184155	chr3:139229772	G/A	cg00490450	chr3:139108681	COPB2	-0.43	-6.45	-0.33	4.1e-10	Obesity-related traits;
CRC	cis	rs2346160	0.899	rs206972	chr6:167689552	C/T	cg04673565	chr6:167680447	NA	-0.34	-5.96	-0.31	6.42e-9	Parental extreme longevity (95 years and older);
CRC	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.45	6.68	0.35	1.02e-10	Body mass index;
CRC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg04166393	chr7:2884313	GNA12	0.37	5.65	0.3	3.43e-8	Height;
CRC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.54	8.44	0.42	1.05e-15	IgG glycosylation;
CRC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg19622623	chr12:86230825	RASSF9	-0.38	-5.78	-0.3	1.71e-8	Major depressive disorder;
CRC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg06484146	chr7:12443880	VWDE	-0.71	-8.04	-0.41	1.64e-14	Coronary artery disease;
CRC	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.08	0.36	8.65e-12	Menarche (age at onset);
CRC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg13777783	chr17:79615861	NA	0.3	5.72	0.3	2.44e-8	Eye color traits;
CRC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.16	-0.52	9.81e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.45	-6.57	-0.34	2.01e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.23	-0.33	1.39e-9	Breast cancer;
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.67	-0.3	3.13e-8	Subjective well-being;
CRC	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	5.75	0.3	2.01e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg11446398	chr5:77624930	NA	0.42	5.92	0.31	8.18e-9	Triglycerides;
CRC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs728616	0.764	rs11201025	chr10:81742158	T/G	cg05935833	chr10:81318306	SFTPA2	-0.48	-5.74	-0.3	2.18e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4728302	1.000	rs4728302	chr7:133630463	C/T	cg03336402	chr7:133662267	EXOC4	0.46	6.91	0.36	2.44e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg02811702	chr13:24901961	NA	0.48	6.63	0.34	1.4e-10	Obesity-related traits;
CRC	cis	rs3736485	0.868	rs2124592	chr15:51922979	G/A	cg08986416	chr15:51914746	DMXL2	-0.48	-6.82	-0.35	4.42e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	6.57	0.34	1.95e-10	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06946942	chr8:94929024	PDP1	0.42	6.09	0.32	3.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7595037	0.663	rs7422301	chr2:68655623	A/G	cg12452813	chr2:68675892	NA	-0.41	-6.01	-0.31	5.01e-9	Multiple sclerosis;
CRC	cis	rs7259376	0.869	rs11673228	chr19:22596084	G/A	cg02657401	chr19:22469223	NA	0.3	6.65	0.34	1.2e-10	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04603834	chr13:50571387	TRIM13;DLEU2	0.44	6.33	0.33	7.82e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.4	0.62	8.82e-37	Fuchs's corneal dystrophy;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.61	-8.62	-0.43	2.88e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.81	11.12	0.52	1.29e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.51	9.06	0.45	1.19e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg18827107	chr12:86230957	RASSF9	0.37	5.73	0.3	2.21e-8	Major depressive disorder;
CRC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02290350	chr8:58132656	NA	-0.41	-5.85	-0.31	1.21e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg19812747	chr11:111475976	SIK2	-0.57	-9.79	-0.47	5.04e-20	Primary sclerosing cholangitis;
CRC	cis	rs6076065	0.723	rs6083095	chr20:23354090	C/T	cg11657817	chr20:23433608	CST11	0.43	6.31	0.33	8.78e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.76	-0.3	1.89e-8	Metabolite levels;
CRC	cis	rs7274811	0.625	rs293723	chr20:31927706	A/G	cg21523528	chr20:32077966	CBFA2T2	0.42	6.01	0.31	4.91e-9	Height;
CRC	trans	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.95	-0.36	1.99e-11	Neuroticism;
CRC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.83	15.15	0.64	1.06e-39	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06224551	chr11:124670268	C11orf61	0.4	6.34	0.33	7.63e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg27068330	chr11:65405492	SIPA1	0.41	5.72	0.3	2.38e-8	Urate levels;
CRC	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs185694	1.000	rs653251	chr13:30894542	C/T	cg07600127	chr13:30881527	KATNAL1	-0.54	-5.84	-0.31	1.28e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.97	-13.65	-0.6	6.09e-34	Lymphocyte counts;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg21548813	chr6:291882	DUSP22	-0.53	-7.34	-0.38	1.68e-12	Menopause (age at onset);
CRC	cis	rs9463078	0.506	rs4714820	chr6:44736737	T/A	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.81e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.42	6.86	0.35	3.41e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg20933634	chr6:27740509	NA	0.58	8.19	0.41	5.65e-15	Parkinson's disease;
CRC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-0.92	-16.07	-0.66	2.77e-43	Body mass index;
CRC	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.6	10.78	0.51	2.04e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.74	0.43	1.19e-16	Parkinson's disease;
CRC	cis	rs6681460	0.932	rs665319	chr1:67175488	A/G	cg02459107	chr1:67143332	SGIP1	0.35	5.95	0.31	6.91e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07513332	chr6:167530253	CCR6	0.35	6.33	0.33	7.98e-10	Crohn's disease;
CRC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.28	-6.69	-0.35	9.64e-11	Urate levels in overweight individuals;
CRC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.6	-0.34	1.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.6	7.54	0.38	4.49e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.06	0.69	3.53e-47	Platelet count;
CRC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.35	-0.59	8.82e-33	Systemic lupus erythematosus;
CRC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.98	0.66	5.9e-43	Platelet count;
CRC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg12573674	chr2:1569213	NA	-0.77	-8.18	-0.41	6.35e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.86	-12.67	-0.57	3.22e-30	Response to antineoplastic agents;
CRC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.46	7.14	0.37	5.84e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg12458913	chr13:53173898	NA	0.52	8.02	0.4	1.88e-14	Lewy body disease;
CRC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg00769240	chr8:12517080	NA	-0.57	-7.0	-0.36	1.47e-11	Blood pressure (smoking interaction);
CRC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs10986311	0.832	rs867610	chr9:127086129	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.41	-5.99	-0.31	5.54e-9	Vitiligo;
CRC	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.43	6.3	0.33	9.35e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Parkinson's disease;
CRC	cis	rs17152411	0.895	rs7079416	chr10:126587312	C/G	cg07906193	chr10:126599966	NA	0.57	6.45	0.33	4.11e-10	Height;
CRC	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.81	-12.53	-0.57	1e-29	Blood pressure (smoking interaction);
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.51	7.23	0.37	3.43e-12	Pancreatic cancer;
CRC	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg10724054	chr17:3904396	NA	0.45	7.1	0.36	7.76e-12	Type 2 diabetes;
CRC	cis	rs10512697	0.655	rs34428582	chr5:3503596	A/G	cg19473799	chr5:3511975	NA	-0.82	-6.32	-0.33	8.41e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg12386194	chr3:101231763	SENP7	0.49	6.98	0.36	1.6e-11	Colorectal cancer;
CRC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.49	7.46	0.38	7.97e-13	Fibrinogen levels;
CRC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg27661571	chr11:113659931	NA	-0.61	-8.01	-0.4	2.05e-14	Hip circumference adjusted for BMI;
CRC	trans	rs11581859	0.950	rs7521703	chr1:99359039	A/G	cg12183875	chr3:169587454	LRRC31	0.25	5.99	0.31	5.39e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.73	-11.33	-0.53	2.41e-25	Cognitive function;
CRC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.36	6.1	0.32	2.97e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs10242455	0.717	rs58649180	chr7:99336045	C/T	cg18809830	chr7:99032528	PTCD1	-0.8	-5.98	-0.31	5.96e-9	Blood metabolite levels;
CRC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.28	0.42	3.2e-15	Height;
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.5	-6.34	-0.33	7.58e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.19	0.32	1.74e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.95	0.31	6.97e-9	Prudent dietary pattern;
CRC	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.87	11.26	0.53	4.14e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg15845792	chr6:28175446	NA	0.66	9.22	0.45	3.55e-18	Parkinson's disease;
CRC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.65	-11.87	-0.55	2.63e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19410789	chr1:226249811	LOC440926;H3F3A	0.43	6.0	0.31	5.14e-9	Response to antipsychotic treatment;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg00597713	chr6:42947103	PEX6	-0.4	-5.69	-0.3	2.88e-8	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs1223397	0.524	rs2496151	chr6:13314541	A/G	cg07912922	chr6:13274314	PHACTR1	0.36	5.69	0.3	2.83e-8	Blood pressure;
CRC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.68	0.35	1.03e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg20811857	chr17:78079795	GAA	-0.46	-7.66	-0.39	2.1e-13	Yeast infection;
CRC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	8.1	0.41	1.05e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4547160	0.606	rs10784329	chr12:63477676	C/T	cg26727693	chr12:63544175	AVPR1A	-0.43	-7.83	-0.4	6.9e-14	Morning vs. evening chronotype;
CRC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	8.98	0.44	2.08e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.43	0.69	1.17e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05143954	chr8:103424275	UBR5	0.44	6.92	0.36	2.4e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1465370	0.720	rs2402995	chr7:130016595	C/T	cg03229158	chr7:130009420	NA	0.46	6.43	0.33	4.51e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.67	-8.94	-0.44	2.93e-17	Hypospadias;
CRC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.5	7.38	0.38	1.33e-12	Corneal astigmatism;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.39	-0.38	1.22e-12	Total body bone mineral density;
CRC	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg09344028	chr17:70110421	NA	0.44	6.73	0.35	7.77e-11	Thyroid hormone levels;
CRC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.48	5.67	0.3	3.17e-8	Dental caries;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-11.86	-0.55	2.94e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg23650765	chr1:12612165	NA	0.38	7.32	0.37	1.96e-12	Optic cup area;
CRC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-8.24	-0.41	4.01e-15	Mean corpuscular volume;
CRC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	6.03	0.32	4.39e-9	Height;
CRC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.12	13.67	0.6	5.31e-34	Vitiligo;
CRC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	10.04	0.48	7.38e-21	HIV-1 control;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs12137294	0.866	rs896318	chr1:205205784	A/G	cg24159697	chr1:205181237	DSTYK	-0.34	-6.25	-0.33	1.31e-9	Red cell distribution width;
CRC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg20933634	chr6:27740509	NA	0.64	9.08	0.45	1.03e-17	Parkinson's disease;
CRC	cis	rs4692589	0.581	rs6821231	chr4:170959988	C/T	cg19918862	chr4:170955249	NA	0.52	7.11	0.36	7.44e-12	Anxiety disorder;
CRC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg05623727	chr3:50126028	RBM5	-0.44	-7.37	-0.38	1.39e-12	Intelligence (multi-trait analysis);
CRC	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.97	12.24	0.56	1.17e-28	Exhaled nitric oxide levels;
CRC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-11.02	-0.52	3.06e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.76	14.31	0.62	1.87e-36	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg00666640	chr1:248458726	OR2T12	0.49	8.68	0.43	1.83e-16	Common traits (Other);
CRC	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.73	9.77	0.47	5.91e-20	Coronary artery disease;
CRC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Body mass index;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.62	11.63	0.54	1.95e-26	Tonsillectomy;
CRC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg20811857	chr17:78079795	GAA	0.39	6.47	0.34	3.48e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.47	6.23	0.33	1.4e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.3	0.33	9.55e-10	IgG glycosylation;
CRC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.66	9.67	0.47	1.29e-19	Selective IgA deficiency;
CRC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.11	13.62	0.6	8.15e-34	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20409358	chr4:174255887	HMGB2	0.47	6.75	0.35	6.85e-11	Response to antipsychotic treatment;
CRC	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg18232548	chr7:50535776	DDC	-0.4	-6.18	-0.32	1.92e-9	Body mass index;
CRC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-5.91	-0.31	8.59e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07498280	chr19:1250537	MIDN	-0.39	-6.0	-0.31	5.34e-9	Aortic root size;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.6	6.23	0.32	1.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13717333	chr12:122459966	BCL7A	0.52	7.19	0.37	4.31e-12	Anxiety disorder;
CRC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-9.51	-0.46	4.07e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.02	10.5	0.5	1.98e-22	Diabetic retinopathy;
CRC	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.65	7.17	0.37	5.14e-12	Bipolar disorder;
CRC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.63	-0.34	1.35e-10	Total cholesterol levels;
CRC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.52	7.59	0.39	3.27e-13	Systemic lupus erythematosus;
CRC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs2346160	0.899	rs172283	chr6:167691225	T/C	cg27333441	chr6:167680455	NA	-0.38	-6.16	-0.32	2.08e-9	Parental extreme longevity (95 years and older);
CRC	cis	rs13144136	0.687	rs12511309	chr4:10657137	A/G	cg10242279	chr4:10666415	CLNK	-0.38	-6.5	-0.34	2.93e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg12273811	chr6:28175739	NA	0.51	5.71	0.3	2.55e-8	Parkinson's disease;
CRC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.8	-0.44	7.71e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.34e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.89	0.31	9.77e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-6.15	-0.32	2.31e-9	Lung cancer;
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.48	6.7	0.35	9.11e-11	Menarche (age at onset);
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg20512303	chr5:131592959	PDLIM4	0.4	6.88	0.35	3.07e-11	Acylcarnitine levels;
CRC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.69	0.47	1.09e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg02527881	chr3:46936655	PTH1R	0.38	7.08	0.36	8.93e-12	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17022635	chr16:31190875	FUS	0.43	6.19	0.32	1.74e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.63	9.96	0.48	1.37e-20	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.24	-0.59	2.25e-32	Alzheimer's disease;
CRC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-6.07	-0.32	3.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg21784768	chr11:537496	LRRC56	-0.69	-6.56	-0.34	2.11e-10	Body mass index;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg25164649	chr6:28176230	NA	0.68	10.13	0.49	3.57e-21	Cardiac Troponin-T levels;
CRC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg19337854	chr7:99768885	GPC2	0.47	5.91	0.31	8.46e-9	Lung function (FEV1/FVC);
CRC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.7	-0.3	2.68e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.51	8.25	0.41	3.8e-15	Coronary artery disease;
CRC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.21	-16.57	-0.67	2.78e-45	Breast cancer;
CRC	trans	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg21659725	chr3:3221576	CRBN	0.63	6.49	0.34	3.16e-10	Menarche (age at onset);
CRC	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.57	10.07	0.49	5.63e-21	Age of smoking initiation;
CRC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.12e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3026101	0.671	rs1071705	chr17:5290033	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.82	0.35	4.25e-11	Body mass index;
CRC	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.67	11.52	0.54	5.03e-26	Blood protein levels;
CRC	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.43	5.77	0.3	1.85e-8	Coronary artery disease;
CRC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02018176	chr4:1364513	KIAA1530	0.38	6.14	0.32	2.41e-9	Longevity;
CRC	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.54	8.15	0.41	7.8e-15	Blood protein levels;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.48	6.49	0.34	3.23e-10	Schizophrenia;
CRC	trans	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.46	-7.76	-0.39	1.1e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06634786	chr22:41940651	POLR3H	-0.44	-5.74	-0.3	2.13e-8	Neuroticism;
CRC	cis	rs7712401	0.720	rs10075963	chr5:122185421	T/A	cg18764291	chr5:122110994	SNX2	0.36	5.75	0.3	2.05e-8	Mean platelet volume;
CRC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg25124228	chr12:125621409	AACS	-0.53	-6.71	-0.35	8.69e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-10.41	-0.5	3.88e-22	Personality dimensions;
CRC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.63	-11.87	-0.55	2.69e-27	Corneal structure;
CRC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.64	9.83	0.48	3.73e-20	Birth weight;
CRC	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.65	0.34	1.25e-10	Lymphocyte counts;
CRC	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.26	0.33	1.23e-9	Body mass index;
CRC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg11189052	chr15:85197271	WDR73	0.67	9.98	0.48	1.16e-20	Schizophrenia;
CRC	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg23587288	chr2:27483067	SLC30A3	0.34	6.01	0.31	4.91e-9	Blood metabolite levels;
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00166722	chr3:10149974	C3orf24	0.61	7.96	0.4	2.85e-14	Alzheimer's disease;
CRC	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.74	8.75	0.43	1.11e-16	Eotaxin levels;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	8.34	0.42	2.07e-15	Breast cancer;
CRC	cis	rs938554	0.784	rs11722229	chr4:9980697	C/A	cg00071950	chr4:10020882	SLC2A9	0.46	6.51	0.34	2.83e-10	Blood metabolite levels;
CRC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.98	18.54	0.71	4.88e-53	Cognitive ability;
CRC	cis	rs7113874	0.569	rs11041978	chr11:8578150	T/C	cg20771178	chr11:8615675	STK33	-0.34	-5.61	-0.3	4.21e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.55	-0.38	4.4e-13	Endometrial cancer;
CRC	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.43	5.92	0.31	7.96e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.09	0.41	1.16e-14	Menopause (age at onset);
CRC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.94	0.31	7.43e-9	Renal function-related traits (BUN);
CRC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.77	0.54	6.11e-27	Monocyte percentage of white cells;
CRC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.28	-0.33	1.09e-9	Alzheimer's disease (late onset);
CRC	cis	rs10207060	0.500	rs56346503	chr2:240719409	T/C	cg07506560	chr2:240697449	NA	0.43	5.85	0.31	1.18e-8	Obesity-related traits;
CRC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.3e-13	Corneal astigmatism;
CRC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg13390004	chr1:15929781	NA	0.5	6.84	0.35	3.94e-11	Systolic blood pressure;
CRC	cis	rs12612619	0.732	rs1053609	chr2:27293150	G/T	cg00617064	chr2:27272375	NA	-0.38	-6.44	-0.33	4.17e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs9292777	0.777	rs60343748	chr5:40394661	T/A	cg09067459	chr5:40385259	NA	-0.54	-8.99	-0.44	1.92e-17	Crohn's disease;Multiple sclerosis;
CRC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg23590916	chr17:43697445	MGC57346	-0.55	-6.05	-0.32	3.84e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg08071915	chr8:12219732	FAM66A	0.32	5.75	0.3	2.05e-8	Systolic blood pressure;
CRC	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.66	6.52	0.34	2.7e-10	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13894748	chr10:102107266	SCD	0.49	6.94	0.36	2.04e-11	Response to antipsychotic treatment;
CRC	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.59	10.01	0.48	9.17e-21	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg24578937	chr1:2090814	PRKCZ	-0.48	-8.61	-0.43	3.14e-16	Height;
CRC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.57	10.26	0.49	1.33e-21	Multiple system atrophy;
CRC	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.57	7.92	0.4	3.6e-14	Coronary artery disease;
CRC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.42	-9.22	-0.45	3.61e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg20203395	chr5:56204925	C5orf35	0.54	7.36	0.38	1.45e-12	Initial pursuit acceleration;
CRC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.39	6.89	0.35	2.92e-11	Crohn's disease;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00763094	chr1:171455187	BAT2L2	-0.53	-6.24	-0.33	1.31e-9	Monocyte percentage of white cells;
CRC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-7.71	-0.39	1.51e-13	Total body bone mineral density;
CRC	cis	rs6988985	0.728	rs7388251	chr8:143969208	T/C	cg10324643	chr8:143916377	GML	0.38	6.17	0.32	1.96e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14478610	chr2:127864964	BIN1	0.48	6.87	0.35	3.27e-11	Response to antipsychotic treatment;
CRC	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg00277334	chr10:82204260	NA	-0.54	-5.87	-0.31	1.08e-8	Post bronchodilator FEV1;
CRC	cis	rs1800795	0.530	rs62449494	chr7:22758035	A/G	cg05472934	chr7:22766657	IL6	0.45	6.33	0.33	8.09e-10	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23084309	chr19:6280164	MLLT1	0.46	6.27	0.33	1.14e-9	Hip circumference;
CRC	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.57	-8.48	-0.42	7.82e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.38	-0.42	1.56e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg22495460	chr2:25135724	ADCY3	-0.83	-15.43	-0.65	8.23e-41	Body mass index in non-asthmatics;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08613594	chr2:201374742	KCTD18	0.45	6.33	0.33	8.02e-10	Anxiety disorder;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg20175449	chr11:118123099	MPZL3	-0.52	-6.43	-0.33	4.45e-10	Diisocyanate-induced asthma;
CRC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-20.41	-0.75	2.08e-60	Primary sclerosing cholangitis;
CRC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.02e-22	Corneal astigmatism;
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg10729496	chr3:10149963	C3orf24	0.51	6.6	0.34	1.68e-10	Alzheimer's disease;
CRC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.46	6.68	0.35	1.02e-10	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00529697	chr5:75013131	C5orf37	0.35	6.44	0.33	4.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg24253500	chr15:84953950	NA	0.37	6.3	0.33	9.58e-10	Schizophrenia;
CRC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-5.85	-0.31	1.2e-8	Height;
CRC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.25	14.71	0.63	5.27e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17024643	chr1:214725274	PTPN14	0.38	6.06	0.32	3.72e-9	Myopia (pathological);
CRC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.68	-11.53	-0.54	4.47e-26	Breast cancer;
CRC	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.37	0.42	1.7e-15	Coffee consumption (cups per day);
CRC	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.59	9.05	0.45	1.29e-17	Obesity;
CRC	cis	rs7705042	0.796	rs1835965	chr5:141501771	G/A	cg07392085	chr5:141489673	NDFIP1	0.47	7.42	0.38	1.03e-12	Asthma;
CRC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.92	-0.36	2.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.2	-0.41	5.45e-15	Aortic root size;
CRC	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.62	-0.68	1.91e-45	Electrocardiographic conduction measures;
CRC	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg24553058	chr2:113831203	IL1F10	0.55	8.64	0.43	2.47e-16	Protein quantitative trait loci;
CRC	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20333904	chr2:240724165	NA	0.3	5.73	0.3	2.21e-8	Obesity-related traits;
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg02772935	chr3:125709198	NA	-0.48	-5.69	-0.3	2.78e-8	Blood pressure (smoking interaction);
CRC	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg09344028	chr17:70110421	NA	0.45	7.09	0.36	8.31e-12	Thyroid hormone levels;
CRC	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg09127314	chr1:152161683	NA	0.49	6.28	0.33	1.05e-9	Atopic dermatitis;
CRC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.69	10.06	0.48	6.36e-21	DNA methylation (variation);
CRC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.84	0.4	6.44e-14	Mean corpuscular volume;
CRC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.43	6.36	0.33	6.89e-10	Resting heart rate;
CRC	cis	rs6896969	0.504	rs10472332	chr5:40368373	T/G	cg09067459	chr5:40385259	NA	0.46	8.03	0.4	1.71e-14	Multiple sclerosis;
CRC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.38	5.82	0.31	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.63	9.13	0.45	7.26e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	9.51	0.46	4.18e-19	Alzheimer's disease;
CRC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.45	-5.96	-0.31	6.44e-9	Gut microbiome composition (summer);
CRC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg24250549	chr1:154909240	PMVK	0.44	6.47	0.34	3.58e-10	Prostate cancer;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg15786705	chr6:28176104	NA	0.54	7.44	0.38	8.74e-13	Parkinson's disease;
CRC	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg05714579	chr10:131428358	MGMT	0.46	6.37	0.33	6.3e-10	Response to temozolomide;
CRC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.06	9.98	0.48	1.12e-20	Opioid sensitivity;
CRC	cis	rs17401966	0.597	rs56221672	chr1:10247313	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-7.6	-0.39	3.1400000000000003e-13	Hepatocellular carcinoma;
CRC	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg11204139	chr17:3907470	NA	0.43	5.99	0.31	5.45e-9	Type 2 diabetes;
CRC	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.53	6.31	0.33	9.27e-10	Blood protein levels;
CRC	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg10437265	chr15:77819839	NA	0.49	8.44	0.42	1.02e-15	Type 2 diabetes;
CRC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.81	0.44	7.32e-17	Rheumatoid arthritis;
CRC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg15763984	chr4:1342303	KIAA1530	0.45	6.83	0.35	4.02e-11	Obesity-related traits;
CRC	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg06818126	chr11:68850279	TPCN2	-0.48	-6.81	-0.35	4.64e-11	Hair color;
CRC	cis	rs17065868	0.764	rs17065818	chr13:45022180	T/C	cg10246903	chr13:45222710	NA	0.6	6.53	0.34	2.45e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.2	-0.41	5.62e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-11.98	-0.55	1.05e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg22777020	chr22:31556080	RNF185	0.55	6.29	0.33	1.02e-9	Colorectal cancer;
CRC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg19812747	chr11:111475976	SIK2	-0.56	-9.73	-0.47	7.8500000000000006e-20	Primary sclerosing cholangitis;
CRC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg18827107	chr12:86230957	RASSF9	0.39	5.98	0.31	5.76e-9	Major depressive disorder;
CRC	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.7	-5.84	-0.31	1.24e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg26248373	chr2:1572462	NA	-0.64	-8.07	-0.41	1.35e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15450734	chr14:103541957	NA	0.53	7.69	0.39	1.76e-13	Response to antipsychotic treatment;
CRC	cis	rs9549328	0.614	rs35299896	chr13:113617229	G/T	cg20742385	chr13:113633654	MCF2L	0.56	9.53	0.46	3.7e-19	Systolic blood pressure;
CRC	cis	rs6694672	0.867	rs7534353	chr1:197096480	T/G	cg13682187	chr1:196946512	CFHR5	0.48	7.58	0.39	3.5e-13	Asthma;
CRC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs6496667	0.779	rs2301829	chr15:90992687	A/G	cg04176472	chr15:90893244	GABARAPL3	0.58	8.16	0.41	7.06e-15	Rheumatoid arthritis;
CRC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.45	6.56	0.34	2.07e-10	Emphysema distribution in smoking;
CRC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.64	10.04	0.48	7.38e-21	Gestational age at birth (maternal effect);
CRC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.41	-6.45	-0.33	4.1e-10	Monocyte count;
CRC	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.59	-8.33	-0.42	2.18e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.03	0.64	3.06e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg04415270	chr2:102091202	RFX8	-0.58	-8.21	-0.41	5.23e-15	Chronic rhinosinusitis with nasal polyps;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01074628	chr11:74204917	LIPT2	0.5	6.43	0.33	4.48e-10	Thyroid stimulating hormone;
CRC	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.43	6.33	0.33	7.93e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.92	-0.4	3.72e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.24	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.55	0.43	4.65e-16	Electrocardiographic conduction measures;
CRC	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg05623727	chr3:50126028	RBM5	0.54	6.88	0.35	2.94e-11	Intelligence (multi-trait analysis);
CRC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg09163369	chr1:210001066	C1orf107	0.59	7.28	0.37	2.49e-12	Orofacial clefts;
CRC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.06e-15	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.55	7.99	0.4	2.22e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12936587	0.569	rs8073683	chr17:17555596	C/T	cg16928487	chr17:17741425	SREBF1	0.34	5.63	0.3	3.95e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26378065	chr17:18585709	ZNF286B	0.42	5.82	0.31	1.39e-8	Educational attainment (years of education);
CRC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg00255919	chr5:131827918	IRF1	0.36	6.11	0.32	2.81e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg02683197	chr6:28174875	NA	-0.89	-12.85	-0.58	6.48e-31	Depression;
CRC	cis	rs12931792	0.782	rs6565176	chr16:30174926	T/C	cg17640201	chr16:30407289	ZNF48	0.44	6.38	0.33	6.16e-10	Tonsillectomy;
CRC	cis	rs12745968	0.589	rs4970707	chr1:92986446	G/A	cg17283838	chr1:93427260	FAM69A	-0.47	-6.36	-0.33	6.83e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg16989086	chr20:62203971	PRIC285	0.48	6.17	0.32	2.05e-9	Glioblastoma;
CRC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs2070997	0.702	rs2841177	chr9:133764207	C/T	cg01000188	chr9:133769184	QRFP	0.56	5.69	0.3	2.81e-8	Response to amphetamines;
CRC	cis	rs4731207	0.698	rs6960504	chr7:124530314	A/G	cg23710748	chr7:124431027	NA	-0.37	-5.9	-0.31	9.08e-9	Cutaneous malignant melanoma;
CRC	cis	rs10905065	0.895	rs1858447	chr10:5852230	A/G	cg11519256	chr10:5708881	ASB13	-0.42	-6.12	-0.32	2.69e-9	Menopause (age at onset);
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.93	0.74	1.63e-58	Prudent dietary pattern;
CRC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.34	0.33	7.42e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.6e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg06470822	chr6:28175283	NA	0.98	13.34	0.59	9.69e-33	Depression;
CRC	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg09655341	chr17:79618100	PDE6G	0.56	6.58	0.34	1.81e-10	Dental caries;
CRC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg11212589	chr17:38028394	ZPBP2	-0.34	-5.95	-0.31	6.86e-9	Asthma;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg06007323	chr4:6784769	KIAA0232	-0.46	-6.31	-0.33	8.8e-10	Protein C levels;
CRC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.52	-6.08	-0.32	3.26e-9	Vitiligo;
CRC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.66	7.69	0.39	1.73e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.64	6.63	0.34	1.37e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12999616	0.948	rs35958372	chr2:98330858	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	7.29	0.37	2.31e-12	Colorectal cancer;
CRC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.47	-9.51	-0.46	4.15e-19	Renal cell carcinoma;
CRC	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg11843238	chr5:131593191	PDLIM4	-0.43	-7.39	-0.38	1.26e-12	Breast cancer;
CRC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.48	9.43	0.46	7.65e-19	Ulcerative colitis;
CRC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.92	-8.25	-0.41	3.95e-15	Putamen volume;
CRC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.51	-7.6	-0.39	3.13e-13	Corneal astigmatism;
CRC	cis	rs76993477	0.666	rs76991533	chr1:169711577	T/C	cg03211132	chr1:169703751	SELE	0.58	5.7	0.3	2.72e-8	Tonsillectomy;
CRC	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg25182066	chr10:30743637	MAP3K8	-0.38	-5.78	-0.3	1.78e-8	Inflammatory bowel disease;
CRC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg03037974	chr15:76606532	NA	-0.54	-7.78	-0.39	9.15e-14	Blood metabolite levels;
CRC	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg21452805	chr1:244014465	NA	0.6	6.21	0.32	1.63e-9	RR interval (heart rate);
CRC	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg26182253	chr13:112236782	NA	0.31	6.28	0.33	1.09e-9	Hepatitis;
CRC	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg27398640	chr15:77910606	LINGO1	0.45	7.72	0.39	1.45e-13	Type 2 diabetes;
CRC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg04362960	chr10:104952993	NT5C2	-0.45	-6.3	-0.33	9.48e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.7	-9.34	-0.46	1.46e-18	Blood protein levels;
CRC	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg11579758	chr4:1086637	RNF212	0.41	6.67	0.35	1.06e-10	Recombination rate (males);
CRC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.32e-11	Lung cancer;
CRC	cis	rs449789	0.857	rs2451988	chr6:159714390	G/A	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.44	7.7	0.39	1.62e-13	HDL cholesterol;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.46	6.9	0.36	2.62e-11	Obesity-related traits;
CRC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.44	6.63	0.34	1.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.967	rs1583598	chr11:108305989	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.68	0.3	3.01e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.35	5.7	0.3	2.74e-8	Sitting height ratio;
CRC	cis	rs2179367	0.887	rs2143076	chr6:149746451	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.35	-5.8	-0.3	1.59e-8	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.93e-9	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08351143	chr9:33817857	UBE2R2	0.46	6.27	0.33	1.12e-9	Response to antipsychotic treatment;
CRC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.57	-9.65	-0.47	1.5e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.33	-6.14	-0.32	2.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg20615401	chr6:28092323	ZSCAN16	0.44	5.76	0.3	1.95e-8	Parkinson's disease;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.45	5.63	0.3	3.88e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.67	10.77	0.51	2.23e-23	Height;
CRC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	7.08	0.36	8.77e-12	Lung cancer in ever smokers;
CRC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-5.87	-0.31	1.04e-8	Alzheimer's disease (late onset);
CRC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.44	0.53	9.92e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg21194808	chr1:2205498	SKI	0.4	5.91	0.31	8.73e-9	Height;
CRC	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.59	0.34	1.72e-10	Blood protein levels;
CRC	trans	rs9341835	0.772	rs6919709	chr6:64139856	C/T	cg13657004	chr13:50234944	EBPL	-0.37	-6.25	-0.33	1.3e-9	Schizophrenia;
CRC	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.55	8.84	0.44	5.94e-17	Mean corpuscular volume;
CRC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.81e-16	Prostate cancer;
CRC	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.68	5.81	0.31	1.47e-8	Mortality in heart failure;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg18301423	chr5:131593218	PDLIM4	0.39	6.46	0.34	3.77e-10	Acylcarnitine levels;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12273811	chr6:28175739	NA	0.63	8.44	0.42	9.98e-16	Parkinson's disease;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg18122411	chr2:122513043	TSN	-0.43	-6.03	-0.32	4.51e-9	Protein C levels;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.47	7.26	0.37	2.84e-12	Longevity;Endometriosis;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02787772	chr8:26435434	DPYSL2	0.41	6.0	0.31	5.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs892085	0.681	rs3826803	chr19:10883126	C/G	cg17710535	chr19:10819994	QTRT1	-0.39	-5.99	-0.31	5.57e-9	Psoriasis vulgaris;Psoriasis;
CRC	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg25885038	chr17:56607967	SEPT4	-0.51	-7.7	-0.39	1.63e-13	Vitamin D levels;
CRC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.78	-14.91	-0.64	8.94e-39	Prudent dietary pattern;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.22	-0.56	1.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.61	-8.59	-0.43	3.43e-16	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2252521	0.524	rs2074782	chr7:29070653	C/T	cg11728747	chr7:29037910	CPVL	-0.5	-7.21	-0.37	3.86e-12	Cognitive performance;
CRC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg07713946	chr22:31675144	LIMK2	-0.4	-5.68	-0.3	2.98e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.44	-7.05	-0.36	1.06e-11	Obesity-related traits;
CRC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.47	-0.34	3.56e-10	Platelet distribution width;
CRC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.35	-7.53	-0.38	5.06e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.45	6.7	0.35	8.97e-11	Cognitive test performance;
CRC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg11212589	chr17:38028394	ZPBP2	0.43	7.93	0.4	3.34e-14	Self-reported allergy;
CRC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg07153921	chr17:41440717	NA	-0.37	-5.73	-0.3	2.3e-8	Menopause (age at onset);
CRC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.43	-8.35	-0.42	1.88e-15	Systolic blood pressure;
CRC	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.59	9.43	0.46	7.85e-19	Corneal astigmatism;
CRC	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.55	-8.27	-0.41	3.36e-15	Body mass index;
CRC	cis	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg15845792	chr6:28175446	NA	0.8	6.39	0.33	5.67e-10	Depression;
CRC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.6	-0.47	2.14e-19	Schizophrenia;
CRC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.51	7.15	0.37	5.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.4	6.91	0.36	2.45e-11	Childhood ear infection;
CRC	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	7.45	0.38	8.11e-13	Body mass index;
CRC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-7.86	-0.4	5.47e-14	Monocyte count;
CRC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg17401720	chr7:158221031	PTPRN2	0.42	7.07	0.36	9.4e-12	Obesity-related traits;
CRC	cis	rs7209700	0.547	rs7217214	chr17:45355227	T/C	cg08085267	chr17:45401833	C17orf57	0.54	6.43	0.33	4.52e-10	IgG glycosylation;
CRC	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.86	-0.63	1.39e-38	Exhaled nitric oxide output;
CRC	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg14458575	chr2:238380390	NA	0.52	6.86	0.35	3.51e-11	Prostate cancer;
CRC	trans	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg06206626	chr22:26825900	ASPHD2	0.42	6.23	0.32	1.39e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg09597638	chr17:3907349	NA	-0.64	-11.54	-0.54	4.26e-26	Type 2 diabetes;
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg22105103	chr4:187893119	NA	0.59	10.4	0.5	4.36e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2072510	0.593	rs2660900	chr12:96405077	T/C	cg15438951	chr12:96389694	HAL	-0.48	-5.83	-0.31	1.32e-8	Metabolite levels (small molecules and protein measures);
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg02077165	chr1:28241257	RPA2	-0.6	-6.02	-0.31	4.54e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.77	12.86	0.58	6.33e-31	Colorectal cancer;
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.64	-0.51	6.69e-23	Alzheimer's disease;
CRC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg08916839	chr5:415575	AHRR	0.85	8.42	0.42	1.21e-15	Fat distribution (HIV);
CRC	cis	rs4930561	0.714	rs7130844	chr11:67927517	C/T	cg04465784	chr11:67976953	SUV420H1	-0.3	-6.13	-0.32	2.54e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	7.1	0.36	7.88e-12	Eye color traits;
CRC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.21	-16.66	-0.68	1.3e-45	Breast cancer;
CRC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg07828024	chr6:149772892	ZC3H12D	0.48	8.82	0.44	7.05e-17	Dupuytren's disease;
CRC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.72	7.73	0.39	1.31e-13	Diabetic retinopathy;
CRC	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.46	-9.06	-0.45	1.19e-17	Schizophrenia;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08219700	chr8:58056026	NA	0.55	6.5	0.34	2.99e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17162190	0.590	rs6669111	chr1:26828182	A/G	cg17456097	chr1:26900765	RPS6KA1	0.41	5.99	0.31	5.4e-9	Mean corpuscular volume;
CRC	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg25809561	chr17:30822961	MYO1D	0.52	9.43	0.46	7.81e-19	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00172330	chr1:28052294	FAM76A	0.45	6.02	0.31	4.54e-9	Anxiety disorder;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg09877947	chr5:131593287	PDLIM4	0.44	8.15	0.41	7.61e-15	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25104457	chr1:26201866	NA	0.38	6.0	0.31	5.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.78	-11.29	-0.53	3.41e-25	Multiple sclerosis;
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg03160526	chr17:80928410	B3GNTL1	0.51	6.92	0.36	2.37e-11	Glycated hemoglobin levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05047319	chr11:86748661	TMEM135	0.51	7.32	0.37	1.89e-12	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg19508488	chr2:152266495	RIF1	0.48	6.95	0.36	1.99e-11	Lung cancer;
CRC	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	7.7	0.39	1.63e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18644834	chr5:72861711	UTP15;ANKRA2	0.43	6.2	0.32	1.69e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.24	-0.33	1.33e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.98	-0.36	1.61e-11	Bipolar disorder;
CRC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-8.03	-0.4	1.73e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.78	11.39	0.53	1.5e-25	Breast cancer;
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg21268650	chr7:45961089	IGFBP3	0.35	6.07	0.32	3.56e-9	Sitting height ratio;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Parkinson's disease;
CRC	cis	rs4731207	0.536	rs2127967	chr7:124605672	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg10876282	chr6:28092338	ZSCAN16	0.44	5.83	0.31	1.3e-8	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17158059	chr2:55746762	CCDC104	0.48	6.21	0.32	1.6e-9	Thyroid stimulating hormone;
CRC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.88	0.35	3.1e-11	Morning vs. evening chronotype;
CRC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.06	11.25	0.53	4.8e-25	Diabetic retinopathy;
CRC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.85	0.31	1.19e-8	Bladder cancer;
CRC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10820045	chr2:198174542	NA	-0.57	-11.46	-0.53	8.38e-26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs911119	0.955	rs55897275	chr20:23595953	A/T	cg16589663	chr20:23618590	CST3	0.44	6.16	0.32	2.12e-9	Chronic kidney disease;
CRC	cis	rs1256061	0.624	rs1152582	chr14:64692630	G/C	cg23250157	chr14:64679961	SYNE2	0.46	7.14	0.37	6.03e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.9	0.36	2.69e-11	Height;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.64	-9.25	-0.45	2.88e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.24	-0.59	2.32e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs4664293	0.967	rs13397722	chr2:160515651	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.46	-0.38	7.7e-13	Monocyte percentage of white cells;
CRC	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.14	-0.32	2.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15739944	chr9:99212660	HABP4	0.44	6.49	0.34	3.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.76	-11.89	-0.55	2.35e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.38	-0.38	1.26e-12	Triglycerides;
CRC	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.45	6.64	0.34	1.32e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg06470822	chr6:28175283	NA	0.8	11.89	0.55	2.23e-27	Cardiac Troponin-T levels;
CRC	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg13482628	chr17:19912719	NA	0.54	8.59	0.43	3.65e-16	Schizophrenia;
CRC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg00383909	chr3:49044727	WDR6	0.48	5.92	0.31	7.98e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.29	-0.71	4.7e-52	Height;
CRC	cis	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg05636881	chr10:105038444	INA	-0.45	-7.84	-0.4	6.27e-14	Migraine;
CRC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.78	11.39	0.53	1.5e-25	Breast cancer;
CRC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.52	7.45	0.38	8.13e-13	Lymphocyte counts;
CRC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg22777020	chr22:31556080	RNF185	-0.51	-5.94	-0.31	7.35e-9	Colorectal cancer;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.08	0.45	1.05e-17	Bladder cancer;
CRC	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg27121462	chr16:89883253	FANCA	0.4	6.05	0.32	3.87e-9	Vitiligo;
CRC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.63	0.43	2.75e-16	Rheumatoid arthritis;
CRC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-10.34	-0.5	6.8e-22	Calcium levels;
CRC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.07	-0.32	3.45e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg23758597	chr6:163146217	PARK2	-0.66	-6.79	-0.35	5.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.72	11.29	0.53	3.4e-25	Intelligence (multi-trait analysis);
CRC	cis	rs4478858	0.684	rs3737755	chr1:31744168	G/A	cg00250761	chr1:31883323	NA	-0.4	-7.65	-0.39	2.23e-13	Alcohol dependence;
CRC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.59	7.39	0.38	1.21e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg16070018	chr6:26224392	HIST1H3E	-0.58	-5.8	-0.3	1.54e-8	Gout;Renal underexcretion gout;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg04969067	chr8:143858791	LYNX1	-0.42	-6.65	-0.34	1.22e-10	Urinary tract infection frequency;
CRC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.86	-14.31	-0.62	1.88e-36	Ulcerative colitis;
CRC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.56	-0.34	2.04e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.46	-0.34	3.8e-10	Aortic root size;
CRC	cis	rs7212590	0.655	rs8070039	chr17:57973585	G/C	cg10252138	chr17:58120427	NA	-0.6	-6.09	-0.32	3.21e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-6.31	-0.33	9.23e-10	Coronary artery disease;
CRC	cis	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg20159608	chr7:32802032	NA	-0.61	-7.64	-0.39	2.41e-13	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.46	-0.38	7.94e-13	Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.71	0.43	1.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.6	7.79	0.39	8.76e-14	Multiple sclerosis;
CRC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.66	9.07	0.45	1.07e-17	Coronary artery disease;
CRC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg02683114	chr2:24398427	C2orf84	0.35	5.68	0.3	3.01e-8	Asthma;
CRC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.93	0.31	7.47e-9	Renal function-related traits (BUN);
CRC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.54	-8.35	-0.42	1.93e-15	Aortic root size;
CRC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	7.02	0.36	1.28e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.7	9.18	0.45	5.08e-18	High light scatter reticulocyte count;
CRC	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.48	-5.65	-0.3	3.49e-8	Hip geometry;
CRC	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.66	-10.71	-0.51	3.7e-23	Hepatocellular carcinoma;
CRC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.42	5.85	0.31	1.19e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.54	-5.65	-0.3	3.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.71	8.01	0.4	2.03e-14	Major depressive disorder;
CRC	trans	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg07393940	chr7:158741817	NA	-0.51	-7.38	-0.38	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7945705	0.902	rs11042088	chr11:8843515	T/A	cg00186954	chr11:8933980	ST5;C11orf17	0.41	6.21	0.32	1.57e-9	Hemoglobin concentration;
CRC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	5.61	0.3	4.28e-8	Protein C levels;
CRC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12172441	chr6:28176163	NA	0.6	7.2	0.37	4.23e-12	Depression;
CRC	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg17182837	chr8:41585554	ANK1	0.59	8.16	0.41	7.33e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg11941060	chr3:133502564	NA	-0.52	-8.34	-0.42	2.07e-15	Iron status biomarkers;
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg10729496	chr3:10149963	C3orf24	0.53	6.62	0.34	1.42e-10	Alzheimer's disease;
CRC	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.65	-11.01	-0.52	3.32e-24	Colorectal cancer;
CRC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg24375607	chr4:120327624	NA	-0.46	-7.66	-0.39	2.08e-13	Corneal astigmatism;
CRC	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.19e-10	Common traits (Other);
CRC	cis	rs7605827	0.897	rs6734288	chr2:15526222	T/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.73	0.63	4.56e-38	Mean platelet volume;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.52	5.94	0.31	7.24e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.41	6.14	0.32	2.37e-9	Red cell distribution width;
CRC	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00308216	chr16:66440692	NA	0.44	5.99	0.31	5.62e-9	Response to antipsychotic treatment;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.68	10.25	0.49	1.44e-21	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.71	-0.3	2.56e-8	Diabetic kidney disease;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.62	-8.33	-0.42	2.25e-15	Alzheimer's disease;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg03623178	chr6:28175578	NA	0.66	10.06	0.49	6.13e-21	Cardiac Troponin-T levels;
CRC	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.35	7.52	0.38	5.11e-13	Total body bone mineral density;
CRC	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.34	-0.33	7.37e-10	Eye color traits;
CRC	cis	rs2735413	0.918	rs12918409	chr16:78082681	G/A	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.2	-15.54	-0.65	3.09e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-9.8	-0.48	4.6e-20	Body mass index;
CRC	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.0	13.88	0.61	8.21e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg22349387	chr12:9600060	DDX12	-0.36	-5.65	-0.3	3.41e-8	Breast size;
CRC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.88	-0.78	5.34e-70	Myeloid white cell count;
CRC	trans	rs12699921	0.632	rs1524776	chr7:17872093	C/A	cg15753394	chr6:17282781	RBM24	-0.36	-6.13	-0.32	2.5e-9	Fibrinogen levels;
CRC	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.66	10.95	0.52	5.54e-24	Mean corpuscular volume;
CRC	cis	rs6460942	0.818	rs116613169	chr7:12234669	T/C	cg06484146	chr7:12443880	VWDE	-0.67	-6.55	-0.34	2.22e-10	Coronary artery disease;
CRC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.68	-12.44	-0.57	2.26e-29	Breast cancer;
CRC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg01557791	chr16:72042693	DHODH	-0.51	-5.7	-0.3	2.68e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.19	0.32	1.8e-9	Hemoglobin concentration;
CRC	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg12218747	chr21:37451666	NA	-0.45	-7.75	-0.39	1.18e-13	Mitral valve prolapse;
CRC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg03609598	chr5:56110824	MAP3K1	0.59	8.32	0.42	2.35e-15	Initial pursuit acceleration;
CRC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg23815491	chr16:72088622	HP	0.5	7.6	0.39	3.09e-13	Fibrinogen levels;
CRC	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.54	8.59	0.43	3.49e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.36	0.56	4.4e-29	Chronic sinus infection;
CRC	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.7	0.72	1.09e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.34	-5.92	-0.31	8.17e-9	Height;
CRC	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg04110750	chr16:69646130	NFAT5	-0.53	-7.24	-0.37	3.13e-12	IgE levels;
CRC	trans	rs2665103	0.632	rs3902959	chr15:82544927	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.11	-0.32	2.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg26870460	chr11:6947759	ZNF215	0.58	6.06	0.32	3.73e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16975973	chr12:77459865	E2F7	0.49	7.03	0.36	1.18e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08866780	chr21:27543523	APP	0.42	6.48	0.34	3.34e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.59	-8.23	-0.41	4.29e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs73195822	0.614	rs17190144	chr12:111214767	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	7.46	0.38	8e-13	Itch intensity from mosquito bite;
CRC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.34	-6.91	-0.36	2.58e-11	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04048411	chr12:94541943	PLXNC1	0.39	6.76	0.35	6.38e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg27561072	chr1:19812431	CAPZB	0.42	6.6	0.34	1.64e-10	Schizophrenia;
CRC	cis	rs13315871	1.000	rs11719957	chr3:58415031	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	cis	rs6691722	0.503	rs6667695	chr1:24707669	G/A	cg18323236	chr1:24743029	NIPAL3	0.39	5.68	0.3	2.96e-8	Response to interferon beta in multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16755220	chr16:12070685	RUNDC2A	0.36	6.21	0.32	1.6e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg06636001	chr8:8085503	FLJ10661	0.51	7.01	0.36	1.35e-11	Schizophrenia;
CRC	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg04586622	chr2:25135609	ADCY3	0.57	9.81	0.48	4.26e-20	Body mass index;
CRC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg07274523	chr3:49395745	GPX1	0.46	6.02	0.31	4.74e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg08992911	chr2:238395768	MLPH	0.6	6.07	0.32	3.56e-9	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01555791	chr17:1012288	ABR	0.52	6.68	0.35	1e-10	Thyroid stimulating hormone;
CRC	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg12845895	chr18:77676008	PQLC1	0.41	5.85	0.31	1.21e-8	Schizophrenia;
CRC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.49	0.65	5.06e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.03	0.48	7.78e-21	Monocyte percentage of white cells;
CRC	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.23	-0.56	1.28e-28	Coffee consumption (cups per day);
CRC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.66	-9.96	-0.48	1.39e-20	Initial pursuit acceleration;
CRC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg19980929	chr12:42632907	YAF2	0.41	6.16	0.32	2.17e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.44	0.69	1.04e-48	Platelet count;
CRC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg00310523	chr12:86230176	RASSF9	0.43	7.21	0.37	3.87e-12	Major depressive disorder;
CRC	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg02896835	chr1:92012615	NA	0.54	6.65	0.34	1.25e-10	Eosinophil percentage of white cells;
CRC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.63	7.9	0.4	4.32e-14	Cocaine dependence;
CRC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg07212818	chr11:638076	DRD4	-0.45	-5.81	-0.31	1.48e-8	Systemic lupus erythematosus;
CRC	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.3	-0.33	9.42e-10	Triglycerides;
CRC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.79	0.3	1.67e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.29	0.33	9.83e-10	Lung cancer;
CRC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg00089314	chr5:135169284	LOC153328	-0.34	-5.96	-0.31	6.36e-9	Electroencephalographic traits in alcoholism;
CRC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-12.72	-0.57	1.94e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.98	0.4	2.47e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.52	7.53	0.38	4.82e-13	Height;
CRC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.35	6.33	0.33	8.24e-10	Childhood ear infection;
CRC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.71	-10.23	-0.49	1.62e-21	Inflammatory bowel disease;
CRC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.9	0.4	4.28e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.55	-7.57	-0.39	3.85e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.64	-0.34	1.32e-10	Major depressive disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22792432	chr18:18691067	ROCK1	0.4	6.18	0.32	1.93e-9	Schizophrenia;
CRC	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.75	15.96	0.66	7.4e-43	Intelligence (multi-trait analysis);
CRC	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.12	-0.37	6.84e-12	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.53	8.69	0.43	1.74e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	16.51	0.67	4.95e-45	Platelet count;
CRC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	0.99	17.22	0.69	7.74e-48	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10435706	chr6:150039699	LATS1	0.47	6.22	0.32	1.47e-9	Thyroid stimulating hormone;
CRC	cis	rs6681460	0.932	rs2044399	chr1:67054080	T/C	cg02459107	chr1:67143332	SGIP1	0.44	7.45	0.38	8.42e-13	Presence of antiphospholipid antibodies;
CRC	trans	rs11654801	0.812	rs62056764	chr17:20875145	A/G	cg23759823	chr7:139672531	TBXAS1	-0.38	-6.0	-0.31	5.17e-9	Mosquito bite size;
CRC	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.57	-6.4	-0.33	5.47e-10	Blood protein levels;
CRC	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.49	-6.3	-0.33	9.34e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4731207	0.596	rs7810299	chr7:124645104	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.17	-0.49	2.65e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs79387448	0.745	rs75644281	chr2:103151316	A/T	cg09003973	chr2:102972529	NA	0.73	8.14	0.41	8.53e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.34	2.16e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.51	7.09	0.36	8.43e-12	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2303319	0.504	rs62187658	chr2:162488095	A/C	cg25193742	chr10:104614220	C10orf32	-0.78	-6.16	-0.32	2.17e-9	Cognitive function;
CRC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg22529645	chr1:3704559	LRRC47	0.42	5.76	0.3	1.88e-8	Red cell distribution width;
CRC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-11.33	-0.53	2.46e-25	Body mass index;
CRC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	9.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.45	6.02	0.31	4.73e-9	Bladder cancer;
CRC	trans	rs55675132	0.548	rs12120464	chr1:115377691	C/T	cg25493687	chr8:27288214	PTK2B	0.49	6.0	0.31	5.23e-9	Schizophrenia;
CRC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.8	0.7	4.05e-50	Platelet count;
CRC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.53	-0.38	4.84e-13	Alzheimer's disease;
CRC	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg09237302	chr4:906077	GAK	-0.33	-5.89	-0.31	9.39e-9	Systemic sclerosis;
CRC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.8	14.68	0.63	7.06e-38	Metabolic syndrome;
CRC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.29	0.42	2.87e-15	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22227586	chr10:88854610	FAM35A;GLUD1	0.4	6.25	0.33	1.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06307176	chr5:131281290	NA	0.43	6.36	0.33	6.6e-10	Life satisfaction;
CRC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg24300038	chr13:113819356	PROZ	0.51	6.79	0.35	5.17e-11	Platelet distribution width;
CRC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg26762873	chr11:5879799	OR52E8	-0.48	-7.2	-0.37	4.19e-12	DNA methylation (variation);
CRC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.64	0.3	3.58e-8	Major depressive disorder;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.8	-0.4	8.03e-14	Acylcarnitine levels;
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.24	-0.59	2.25e-32	Alzheimer's disease;
CRC	cis	rs17601876	0.814	rs7181429	chr15:51559496	G/A	cg19946085	chr15:51559439	CYP19A1	-0.35	-7.06	-0.36	9.77e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.78	12.17	0.56	2.2e-28	Menarche (age at onset);
CRC	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.68	7.52	0.38	5.16e-13	Breast cancer;
CRC	cis	rs10242455	0.702	rs73713580	chr7:99241610	C/T	cg18809830	chr7:99032528	PTCD1	-1.04	-7.34	-0.38	1.68e-12	Blood metabolite levels;
CRC	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.75	-11.69	-0.54	1.2e-26	Immature fraction of reticulocytes;
CRC	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg10820045	chr2:198174542	NA	0.39	6.58	0.34	1.86e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.28	-0.33	1.04e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg22687807	chr8:143858763	LYNX1	-0.38	-6.57	-0.34	1.98e-10	Urinary tract infection frequency;
CRC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.93	-0.55	1.69e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.54	7.49	0.38	6.23e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.66	10.86	0.51	1.11e-23	Lung cancer;
CRC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.42	6.38	0.33	6.18e-10	Red blood cell count;
CRC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-9.75	-0.47	6.87e-20	Depression;
CRC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.54	8.73	0.43	1.33e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg11553311	chr5:66541588	NA	0.47	8.1	0.41	1.06e-14	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01398432	chr7:102389392	FAM185A	0.44	6.32	0.33	8.52e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.94	-0.36	2.04e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-19.04	-0.72	5.24e-55	Ulcerative colitis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15309264	chr2:58274034	VRK2	-0.49	-6.12	-0.32	2.64e-9	Diisocyanate-induced asthma;
CRC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.61	10.2	0.49	2.05e-21	Prudent dietary pattern;
CRC	cis	rs9403521	0.673	rs7772565	chr6:143993070	A/T	cg18240653	chr6:144019428	PHACTR2	0.44	5.83	0.31	1.35e-8	Obesity-related traits;
CRC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.66	-8.13	-0.41	8.89e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.41	7.92	0.4	3.73e-14	Hypertriglyceridemia;
CRC	trans	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg15226275	chr6:116381976	FRK	0.3	7.05	0.36	1.04e-11	Total cholesterol levels;
CRC	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg01312482	chr5:178451176	ZNF879	-0.34	-5.68	-0.3	2.89e-8	Pubertal anthropometrics;
CRC	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.4	-6.03	-0.32	4.32e-9	Neutrophil percentage of white cells;
CRC	cis	rs12541635	0.934	rs2115703	chr8:107045935	C/G	cg10147462	chr8:107024639	NA	0.45	7.56	0.38	3.98e-13	Age of smoking initiation;
CRC	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.93e-14	Height;
CRC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.31	0.46	1.88e-18	Dupuytren's disease;
CRC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.86	0.35	3.32e-11	Lung disease severity in cystic fibrosis;
CRC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19717773	chr7:2847554	GNA12	-0.48	-6.84	-0.35	3.85e-11	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00603428	chr6:122721289	HSF2	0.47	6.18	0.32	1.84e-9	Anxiety disorder;
CRC	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	1.14	17.8	0.7	3.94e-50	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.5	6.33	0.33	7.9e-10	Recombination rate (females);
CRC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.2	-0.41	5.35e-15	Hemoglobin concentration;
CRC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg02094049	chr14:103021097	NA	-0.54	-6.94	-0.36	2.16e-11	Platelet count;
CRC	cis	rs652260	1.000	rs652260	chr19:7900562	C/T	cg26014689	chr19:7917955	EVI5L	-0.54	-8.83	-0.44	6.37e-17	Menarche (age at onset);
CRC	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg10437265	chr15:77819839	NA	0.66	12.4	0.56	3.06e-29	Type 2 diabetes;
CRC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg05585544	chr11:47624801	NA	-0.61	-10.91	-0.52	7.39e-24	Subjective well-being;
CRC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.79	-0.44	8.78e-17	Response to antipsychotic treatment;
CRC	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg25182066	chr10:30743637	MAP3K8	-0.37	-5.62	-0.3	4.07e-8	Inflammatory bowel disease;
CRC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.34	5.84	0.31	1.28e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07908229	chr1:182353640	GLUL	-0.39	-6.16	-0.32	2.17e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.67	10.24	0.49	1.58e-21	Corneal astigmatism;
CRC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.14	-0.32	2.32e-9	Monocyte percentage of white cells;
CRC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.14	-0.32	2.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs17065868	0.764	rs9595130	chr13:45043439	G/A	cg10246903	chr13:45222710	NA	0.55	5.85	0.31	1.18e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	cg04338863	chr8:33670619	NA	0.4	6.39	0.33	5.7e-10	Body mass index;
CRC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.5	7.02	0.36	1.3e-11	Morning vs. evening chronotype;
CRC	cis	rs7113874	0.524	rs10769922	chr11:8621752	G/A	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg04586622	chr2:25135609	ADCY3	0.36	6.09	0.32	3.16e-9	Body mass index in non-asthmatics;
CRC	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.43	-7.03	-0.36	1.18e-11	Refractive error;
CRC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.26	0.33	1.22e-9	Morning vs. evening chronotype;
CRC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg23758597	chr6:163146217	PARK2	-0.6	-6.71	-0.35	8.55e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-20.41	-0.75	2.08e-60	Primary sclerosing cholangitis;
CRC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	18.2	0.71	1.06e-51	Smoking behavior;
CRC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.75	-10.28	-0.49	1.08e-21	Asthma;
CRC	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	15.28	0.64	3.35e-40	Smoking behavior;
CRC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.65	10.71	0.51	3.64e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg05585544	chr11:47624801	NA	-0.5	-8.86	-0.44	5e-17	Subjective well-being;
CRC	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg07514618	chr14:103979422	NA	0.31	5.84	0.31	1.22e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg16964102	chr10:135390573	NA	-0.42	-6.99	-0.36	1.58e-11	Obesity-related traits;
CRC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg01639898	chr1:32083012	HCRTR1	0.3	6.1	0.32	3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.65	-9.08	-0.45	1.01e-17	Psoriasis;
CRC	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg17375396	chr11:67202808	RPS6KB2	0.33	5.65	0.3	3.43e-8	Mean corpuscular volume;
CRC	trans	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg18187862	chr3:45730750	SACM1L	0.46	6.56	0.34	2.15e-10	Primary sclerosing cholangitis;
CRC	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg06632207	chr12:54070931	ATP5G2	0.42	7.15	0.37	5.74e-12	Height;
CRC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.29	0.46	2.18e-18	Parkinson's disease;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg09877947	chr5:131593287	PDLIM4	0.36	6.79	0.35	5.31e-11	Blood metabolite levels;
CRC	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg23425280	chr12:56401806	NA	0.44	5.61	0.3	4.19e-8	Cancer;
CRC	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	0.79	12.41	0.56	2.81e-29	Breast cancer;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.42	6.33	0.33	8.17e-10	Lymphocyte counts;
CRC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.46	-6.35	-0.33	7.19e-10	Renal function-related traits (BUN);
CRC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.35	0.56	4.64e-29	Menopause (age at onset);
CRC	cis	rs4757319	0.515	rs4313573	chr11:15330598	A/G	cg03245590	chr11:15329459	NA	0.53	9.49	0.46	5.04e-19	Breast cancer;
CRC	cis	rs16975963	0.644	rs11083430	chr19:38139488	A/G	cg15135657	chr19:38346511	NA	-0.47	-6.4	-0.33	5.2400000000000005e-10	Longevity;
CRC	cis	rs12612619	0.724	rs7355650	chr2:27245475	T/C	cg00617064	chr2:27272375	NA	0.38	6.16	0.32	2.13e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.56	8.81	0.44	7.35e-17	Type 2 diabetes;
CRC	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg23229984	chr5:148520753	ABLIM3	0.48	6.59	0.34	1.79e-10	Breast cancer;
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg07617317	chr6:118971624	C6orf204	0.52	6.48	0.34	3.43e-10	Diastolic blood pressure;
CRC	trans	rs4918814	0.869	rs7093880	chr10:115107503	A/G	cg25339052	chr2:196399403	NA	-0.39	-5.99	-0.31	5.37e-9	Neuroticism (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05214047	chr5:56112645	MAP3K1	-0.52	-6.13	-0.32	2.48e-9	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16106770	chr11:120206550	ARHGEF12	0.41	6.6	0.34	1.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12476592	0.543	rs2592387	chr2:63894834	C/T	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08977639	chr16:1047820	NA	-0.48	-6.21	-0.32	1.6e-9	Diisocyanate-induced asthma;
CRC	trans	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg26043149	chr18:55253948	FECH	0.51	7.85	0.4	5.94e-14	Bone mineral density;
CRC	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.61e-14	Height;
CRC	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	6.12	0.32	2.61e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04908186	chr3:170588253	RPL22L1	0.48	6.07	0.32	3.54e-9	Thyroid stimulating hormone;
CRC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg27565382	chr3:53032988	SFMBT1	0.7	6.27	0.33	1.11e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.25	-0.33	1.27e-9	Dupuytren's disease;
CRC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg10790698	chr19:18539756	SSBP4	-0.45	-8.6	-0.43	3.27e-16	Breast cancer;
CRC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg00310523	chr12:86230176	RASSF9	0.44	7.36	0.38	1.5e-12	Major depressive disorder;
CRC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.85	-0.44	5.49e-17	Platelet count;
CRC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.19	0.32	1.79e-9	Tonsillectomy;
CRC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.61	9.82	0.48	3.97e-20	Type 2 diabetes;
CRC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.84e-24	Corneal astigmatism;
CRC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.44	6.71	0.35	8.71e-11	Coronary artery disease;
CRC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.34	6.76	0.35	6.3e-11	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16447950	chr5:562315	NA	-0.74	-9.75	-0.47	6.69e-20	Obesity-related traits;
CRC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.71	0.47	9.43e-20	Bladder cancer;
CRC	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.58	-8.09	-0.41	1.13e-14	Arsenic metabolism;
CRC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.39	-6.28	-0.33	1.06e-9	Type 2 diabetes;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25057861	chr10:72142518	LRRC20	0.4	6.12	0.32	2.64e-9	Schizophrenia;
CRC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.43	9.02	0.45	1.59e-17	Renal cell carcinoma;
CRC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.56	-8.95	-0.44	2.63e-17	Mean corpuscular hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06985934	chr11:61584717	FADS1	0.32	6.22	0.32	1.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg09796270	chr17:17721594	SREBF1	-0.46	-7.55	-0.38	4.33e-13	Total body bone mineral density;
CRC	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.71	10.94	0.52	5.68e-24	Diastolic blood pressure;
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg21918786	chr6:109611834	NA	-0.36	-6.11	-0.32	2.87e-9	Reticulocyte fraction of red cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18091465	chr15:82551086	EFTUD1	-0.39	-6.38	-0.33	6.12e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7429990	0.901	rs6442091	chr3:48043058	T/C	cg11946769	chr3:48343235	NME6	-0.5	-6.34	-0.33	7.42e-10	Educational attainment (years of education);
CRC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg10790698	chr19:18539756	SSBP4	-0.45	-8.56	-0.43	4.31e-16	Breast cancer;
CRC	cis	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg15105060	chr4:7024189	TBC1D14	-0.64	-5.63	-0.3	3.97e-8	Granulocyte percentage of myeloid white cells;
CRC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg00717180	chr2:96193071	NA	-0.37	-5.97	-0.31	6.27e-9	HDL cholesterol;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg23161317	chr6:28129485	ZNF389	0.39	5.81	0.31	1.45e-8	Cardiac Troponin-T levels;
CRC	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.74	9.47	0.46	5.46e-19	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26115449	chr3:180707572	DNAJC19	0.41	6.51	0.34	2.77e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.14	-15.19	-0.64	7.72e-40	Vitiligo;
CRC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.05	0.61	1.95e-35	Mean platelet volume;
CRC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.49e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg13565492	chr6:43139072	SRF	-0.54	-6.13	-0.32	2.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10982256	1.000	rs4979413	chr9:117259548	A/G	cg13636371	chr9:117264095	DFNB31	0.37	7.18	0.37	4.72e-12	Bipolar disorder;
CRC	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg00540400	chr15:79124168	NA	-0.3	-5.61	-0.3	4.28e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg09650180	chr20:62225654	GMEB2	-0.5	-6.65	-0.34	1.23e-10	Glioblastoma;
CRC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg12365402	chr11:9010492	NRIP3	-0.58	-10.64	-0.51	6.65e-23	Hemoglobin concentration;
CRC	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.58	-6.84	-0.35	3.97e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg23743428	chr13:21893420	NA	-0.39	-5.91	-0.31	8.78e-9	White matter hyperintensity burden;
CRC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg24011408	chr12:48396354	COL2A1	0.47	6.39	0.33	5.64e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg16989086	chr20:62203971	PRIC285	0.47	6.03	0.32	4.52e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg23254163	chr1:152506842	NA	0.45	8.81	0.44	7.19e-17	Hair morphology;
CRC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.81	-13.82	-0.61	1.41e-34	Cystic fibrosis severity;
CRC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.67	-9.58	-0.47	2.54e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg21523564	chr15:75251491	NA	0.41	6.08	0.32	3.42e-9	Breast cancer;
CRC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.57	-10.08	-0.49	5.21e-21	Intelligence (multi-trait analysis);
CRC	cis	rs739496	0.542	rs7312913	chr12:111793552	A/G	cg10833066	chr12:111807467	FAM109A	0.55	7.19	0.37	4.47e-12	Platelet count;
CRC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg05562828	chr17:3906858	NA	0.57	9.75	0.47	6.53e-20	Type 2 diabetes;
CRC	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	1.07	11.38	0.53	1.58e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg24851651	chr11:66362959	CCS	-0.39	-6.86	-0.35	3.45e-11	Educational attainment (years of education);
CRC	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.44	6.54	0.34	2.29e-10	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08118649	chr12:99038419	APAF1;IKBIP	0.43	6.99	0.36	1.54e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08136276	chr4:83351514	HNRPDL;ENOPH1	0.43	5.98	0.31	5.86e-9	Anxiety disorder;
CRC	cis	rs12612619	0.761	rs34732613	chr2:27254796	T/C	cg00617064	chr2:27272375	NA	-0.38	-6.37	-0.33	6.23e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs889398	0.617	rs4985447	chr16:69885166	G/A	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.44	-0.33	4.24e-10	Body mass index;
CRC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg21620606	chr4:1342894	KIAA1530	0.38	6.54	0.34	2.3e-10	Obesity-related traits;
CRC	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.61	-0.39	2.87e-13	Neuroticism;
CRC	cis	rs11255291	0.668	rs719748	chr10:7731885	A/G	cg13340899	chr10:7670827	ITIH5	0.38	5.64	0.3	3.61e-8	Ovarian reserve;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg27524519	chr4:84377120	HELQ;MRPS18C	0.42	6.05	0.32	3.92e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.08	-0.32	3.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02290350	chr8:58132656	NA	-0.45	-5.75	-0.3	2.01e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-10.35	-0.5	6.25e-22	Platelet distribution width;
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg16606324	chr3:10149918	C3orf24	0.58	7.03	0.36	1.19e-11	Alzheimer's disease;
CRC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg19318889	chr4:1322082	MAEA	0.39	5.61	0.3	4.3e-8	Obesity-related traits;
CRC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.44	-6.42	-0.33	4.84e-10	Uric acid clearance;
CRC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.76	12.49	0.57	1.44e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.61	7.09	0.36	8.08e-12	Vitiligo;
CRC	cis	rs2084637	0.965	rs118028534	chr11:122420646	G/A	cg21585512	chr11:122030076	LOC399959	-0.38	-6.72	-0.35	7.98e-11	Stroke;
CRC	cis	rs10878977	0.542	rs17225223	chr12:69810208	C/T	cg20891283	chr12:69753455	YEATS4	-0.61	-5.97	-0.31	6.31e-9	Colorectal cancer;
CRC	trans	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg17903999	chr18:56338584	MALT1	-0.4	-6.54	-0.34	2.33e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.5	7.72	0.39	1.41e-13	Testicular germ cell tumor;
CRC	cis	rs8099014	0.906	rs4940692	chr18:56099715	A/G	cg19312305	chr18:56117016	MIR122	-0.33	-5.61	-0.3	4.3e-8	Platelet count;
CRC	cis	rs12980942	0.872	rs3816052	chr19:41773797	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.44	5.69	0.3	2.78e-8	Coronary artery disease;
CRC	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Colorectal cancer;
CRC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-10.44	-0.5	3.11e-22	Dental caries;
CRC	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.7	11.25	0.53	4.58e-25	Neurofibrillary tangles;
CRC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.55	8.16	0.41	7.26e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2424590	1.000	rs2424591	chr20:23637093	G/T	cg16589663	chr20:23618590	CST3	-0.51	-6.85	-0.35	3.56e-11	Blood protein levels;
CRC	cis	rs282587	0.597	rs1278659	chr13:113386497	G/T	cg04656015	chr13:113407548	ATP11A	0.62	7.65	0.39	2.17e-13	Glycated hemoglobin levels;
CRC	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg06204229	chr3:52865917	ITIH4	0.56	8.07	0.41	1.31e-14	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs10021731	0.692	rs11722125	chr4:115411530	C/G	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.76	-10.06	-0.48	6.39e-21	Initial pursuit acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26806071	chr4:154074259	TRIM2	0.44	6.09	0.32	3.14e-9	Response to antipsychotic treatment;
CRC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg21770322	chr7:97807741	LMTK2	0.53	8.66	0.43	2.14e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.33e-13	Motion sickness;
CRC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.76	14.26	0.62	2.98e-36	Prudent dietary pattern;
CRC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.79	-9.28	-0.46	2.36e-18	Hemostatic factors and hematological phenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07140808	chr4:78978772	FRAS1	0.54	7.73	0.39	1.3e-13	Response to antipsychotic treatment;
CRC	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg04850286	chr10:81895943	PLAC9	-0.37	-6.69	-0.35	9.53e-11	Sarcoidosis;
CRC	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.48	6.48	0.34	3.33e-10	Tuberculosis;
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg08798685	chr6:27730294	NA	-0.43	-6.17	-0.32	1.95e-9	Parkinson's disease;
CRC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg25834613	chr7:1915315	MAD1L1	-0.47	-6.76	-0.35	6.28e-11	Bipolar disorder;
CRC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg06987292	chr12:125626746	AACS	-0.34	-5.87	-0.31	1.09e-8	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.9	0.4	4.13e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7605827	0.930	rs7601661	chr2:15597409	A/G	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.58e-9	Educational attainment (years of education);
CRC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg07713946	chr22:31675144	LIMK2	0.39	5.98	0.31	5.9e-9	Colorectal cancer;
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg22687807	chr8:143858763	LYNX1	0.51	9.17	0.45	5.35e-18	Urinary tract infection frequency;
CRC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.64	10.04	0.48	7.52e-21	Height;
CRC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.65	-7.81	-0.4	7.91e-14	Menarche (age at onset);
CRC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02228675	chr17:40259724	DHX58	-0.49	-6.9	-0.36	2.7e-11	Fibrinogen levels;
CRC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.59	9.46	0.46	6.03e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.52	6.73	0.35	7.7e-11	Alzheimer's disease (survival time);
CRC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.95	12.3	0.56	7.2e-29	Triglycerides;
CRC	cis	rs6788895	1.000	rs2014279	chr3:150487945	G/T	cg09723797	chr3:150481914	SIAH2	0.75	6.29	0.33	9.85e-10	Breast cancer;
CRC	trans	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19862616	chr7:65841803	NCRNA00174	0.47	6.41	0.33	4.96e-10	Eotaxin levels;
CRC	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.53	8.47	0.42	8.46e-16	Coronary artery disease;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-7.81	-0.4	7.58e-14	Breast cancer;
CRC	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-7.2	-0.37	4.18e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.91	-17.72	-0.7	8.56e-50	Height;
CRC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg15448220	chr1:150897856	SETDB1	-0.45	-6.43	-0.33	4.58e-10	Urate levels;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg20397358	chr22:38597902	MAFF	-0.71	-6.17	-0.32	2.03e-9	Cognitive function;
CRC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.8	0.3	1.55e-8	Prudent dietary pattern;
CRC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.15e-9	Lung cancer;
CRC	cis	rs17767392	0.958	rs12879243	chr14:71905815	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-7.04	-0.36	1.13e-11	Mitral valve prolapse;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-19.57	-0.73	4.38e-57	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.7	7.84	0.4	6.22e-14	Major depressive disorder;
CRC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.09	-0.49	4.87e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-7.43	-0.38	9.34e-13	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.57	7.05	0.36	1.04e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24308560	chr3:49941425	MST1R	-0.41	-6.15	-0.32	2.24e-9	Body mass index;
CRC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.72	0.39	1.45e-13	Breast cancer;
CRC	trans	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.97	0.36	1.75e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg23387468	chr7:139079360	LUC7L2	-0.41	-7.18	-0.37	4.57e-12	Diisocyanate-induced asthma;
CRC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.58	-7.59	-0.39	3.25e-13	Gut microbiome composition (summer);
CRC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.6	8.73	0.43	1.35e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	6.94	0.36	2.14e-11	Adiposity;
CRC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.95	11.72	0.54	9.34e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.4	6.98	0.36	1.59e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.85	-0.44	5.45e-17	Type 2 diabetes;
CRC	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	0.91	7.9	0.4	4.23e-14	Left atrial antero-posterior diameter;
CRC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00166722	chr3:10149974	C3orf24	-0.45	-6.71	-0.35	8.54e-11	Alzheimer's disease;
CRC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.66	8.75	0.43	1.14e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg02033258	chr5:131593261	PDLIM4	0.38	6.48	0.34	3.39e-10	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09464487	chr12:100593423	ACTR6	0.44	6.06	0.32	3.79e-9	Response to antipsychotic treatment;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg09731288	chr10:112632370	PDCD4	-0.6	-6.82	-0.35	4.32e-11	Lung adenocarcinoma;
CRC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.09	0.49	4.78e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg15269541	chr15:43626905	ADAL	-0.5	-5.92	-0.31	8.13e-9	Lung cancer in ever smokers;
CRC	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.7	-12.3	-0.56	7.09e-29	Coronary artery disease;
CRC	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg21280719	chr6:42927975	GNMT	-0.33	-5.86	-0.31	1.11e-8	Blood protein levels;
CRC	trans	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg17903999	chr18:56338584	MALT1	-0.44	-7.32	-0.37	1.93e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg20119798	chr7:94954144	PON1	0.39	5.62	0.3	4.01e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9533799	1.000	rs11620543	chr13:44798371	G/A	cg19190762	chr13:44806055	NA	0.66	10.14	0.49	3.22e-21	Amyotrophic lateral sclerosis;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Depression;
CRC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg11861562	chr11:117069780	TAGLN	-0.32	-7.06	-0.36	9.83e-12	Blood protein levels;
CRC	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg14191688	chr11:70257035	CTTN	0.46	5.93	0.31	7.67e-9	Coronary artery disease;
CRC	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.61	-9.33	-0.46	1.63e-18	Body mass index;
CRC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.83	-0.31	1.32e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26816564	chr1:7831052	VAMP3	0.79	8.95	0.44	2.56e-17	Inflammatory bowel disease;
CRC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg23815491	chr16:72088622	HP	0.51	7.9	0.4	4.32e-14	Fibrinogen levels;
CRC	cis	rs812925	0.784	rs1177304	chr2:61388164	C/G	cg10580144	chr2:61372316	C2orf74	0.32	6.24	0.33	1.32e-9	Immature fraction of reticulocytes;
CRC	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.35	-6.03	-0.32	4.49e-9	Airway imaging phenotypes;
CRC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.62	12.57	0.57	7.28e-30	Schizophrenia;
CRC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-6.77	-0.35	5.79e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.43	8.83	0.44	6.18e-17	Renal cell carcinoma;
CRC	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.45	5.61	0.3	4.39e-8	Alzheimer's disease (survival time);
CRC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.15	-0.32	2.3e-9	Daytime sleep phenotypes;
CRC	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.88	-0.31	1.02e-8	Pulmonary function;
CRC	trans	rs783540	0.874	rs10468217	chr15:83248079	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.35	-6.22	-0.32	1.54e-9	Schizophrenia;
CRC	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.64	8.5	0.42	6.85e-16	Uric acid levels;
CRC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg16141378	chr3:129829833	LOC729375	0.42	6.1	0.32	2.95e-9	Myopia (pathological);
CRC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.02	10.31	0.49	8.6e-22	Diabetic retinopathy;
CRC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.69	7.99	0.4	2.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.64	-12.79	-0.58	1.08e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21659725	chr3:3221576	CRBN	0.66	7.3	0.37	2.24e-12	Menarche (age at onset);
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08219700	chr8:58056026	NA	0.58	6.69	0.35	9.52e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.68	0.6	4.96e-34	Platelet count;
CRC	cis	rs9891119	0.576	rs35314169	chr17:40515826	C/T	cg06270615	chr17:40516068	STAT3	-0.34	-7.17	-0.37	4.87e-12	Multiple sclerosis;Crohn's disease;
CRC	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg14459158	chr9:96720562	NA	-0.46	-7.56	-0.38	4.06e-13	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg21724239	chr8:58056113	NA	0.52	7.04	0.36	1.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.5	-0.5	1.92e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.43	-6.61	-0.34	1.53e-10	Cerebrospinal P-tau181p levels;
CRC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.93	-0.48	1.75e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11060661	chr22:24314208	DDT;DDTL	-0.49	-8.37	-0.42	1.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg11522145	chr4:3412961	RGS12	-0.38	-6.03	-0.32	4.41e-9	Serum sulfate level;
CRC	cis	rs972578	0.967	rs7291153	chr22:43356499	C/T	cg01576275	chr22:43409880	NA	-0.46	-7.42	-0.38	9.77e-13	Mean platelet volume;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18301423	chr5:131593218	PDLIM4	0.46	7.88	0.4	4.72e-14	Acylcarnitine levels;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg12273811	chr6:28175739	NA	0.58	6.36	0.33	6.76e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg12365402	chr11:9010492	NRIP3	-0.49	-8.35	-0.42	1.99e-15	Hemoglobin concentration;
CRC	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.58e-9	Systemic lupus erythematosus;
CRC	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-0.82	-8.53	-0.43	5.26e-16	Pediatric areal bone mineral density (radius);
CRC	trans	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.7e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	trans	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	6.06	0.32	3.69e-9	Metabolite levels;
CRC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.48	-9.62	-0.47	1.88e-19	Subjective well-being;
CRC	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg12856521	chr11:46389249	DGKZ	-0.5	-8.29	-0.42	2.85e-15	Leprosy;
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.71	-0.43	1.54e-16	Bipolar disorder;
CRC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.63	12.64	0.57	3.97e-30	HDL cholesterol levels;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg05569086	chr8:143859399	LYNX1	-0.39	-6.43	-0.33	4.45e-10	Urinary tract infection frequency;
CRC	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.8	0.55	4.81e-27	Bone mineral density;
CRC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.88	0.4	4.81e-14	Platelet count;
CRC	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg01422370	chr2:73384389	NA	0.37	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	trans	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.87	-0.31	1.09e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22958951	chr11:119252637	USP2	0.47	6.55	0.34	2.27e-10	Response to antipsychotic treatment;
CRC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.95	11.06	0.52	2.17e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.88	14.55	0.63	2.28e-37	Menarche (age at onset);
CRC	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.92	16.04	0.66	3.39e-43	Colorectal cancer;
CRC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.72	11.62	0.54	2.14e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg23250157	chr14:64679961	SYNE2	-0.52	-7.95	-0.4	2.96e-14	Atrial fibrillation;
CRC	cis	rs449789	0.857	rs9355713	chr6:159722548	C/T	cg14500486	chr6:159655392	FNDC1	-0.5	-7.56	-0.38	4.1e-13	Pulse pressure;
CRC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.49	-0.38	6.57e-13	Height;
CRC	cis	rs9359856	0.879	rs4707552	chr6:90300841	A/G	cg13799429	chr6:90582589	CASP8AP2	0.47	6.55	0.34	2.17e-10	Bipolar disorder;
CRC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.43	0.33	4.41e-10	Aortic root size;
CRC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg01097406	chr16:89675127	NA	0.38	7.34	0.38	1.69e-12	Hemoglobin concentration;
CRC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.42	0.42	1.15e-15	Cognitive test performance;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24639504	chr13:25875833	NUPL1	0.36	6.09	0.32	3.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	0.98	14.86	0.63	1.36e-38	Monocyte percentage of white cells;
CRC	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg21851534	chr17:3907994	ZZEF1	-0.36	-6.03	-0.32	4.41e-9	Type 2 diabetes;
CRC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.59	-8.56	-0.43	4.24e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.32	0.42	2.34e-15	Schizophrenia;
CRC	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.38	-6.57	-0.34	2.02e-10	Pneumonia;
CRC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02228675	chr17:40259724	DHX58	-0.5	-7.01	-0.36	1.38e-11	Fibrinogen levels;
CRC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg14530993	chr4:882597	GAK	0.66	6.3	0.33	9.5e-10	Parkinson's disease;
CRC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.57	8.32	0.42	2.37e-15	Type 2 diabetes;
CRC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.72	-9.36	-0.46	1.25e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs539514	0.501	rs8000656	chr13:76400640	A/G	cg04757411	chr13:76259545	LMO7	0.37	6.09	0.32	3.16e-9	Type 1 diabetes;
CRC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.62	10.58	0.5	1.01e-22	Mean corpuscular volume;
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg04969067	chr8:143858791	LYNX1	0.43	7.41	0.38	1.04e-12	Urinary tract infection frequency;
CRC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg11070056	chr1:107600091	PRMT6	0.4	5.65	0.3	3.55e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.76	-0.3	1.98e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg12315302	chr6:26189340	HIST1H4D	0.76	6.19	0.32	1.76e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10849893	0.538	rs7961855	chr12:121829943	C/T	cg01154721	chr12:121881891	KDM2B	-0.42	-6.29	-0.33	9.94e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.66	10.27	0.49	1.2e-21	Itch intensity from mosquito bite;
CRC	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg05874882	chr4:1763078	NA	-0.38	-7.09	-0.36	8.04e-12	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs12024301	0.557	rs6674368	chr1:183603375	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.8	0.35	5.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg14530993	chr4:882597	GAK	0.82	7.82	0.4	7.42e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs73206853	0.841	rs73191819	chr12:110920182	C/T	cg12870014	chr12:110450643	ANKRD13A	0.75	8.02	0.4	1.88e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg24644049	chr4:85504048	CDS1	0.91	7.97	0.4	2.59e-14	Skin colour saturation;
CRC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-7.69	-0.39	1.69e-13	Bipolar disorder;
CRC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.82	12.55	0.57	8.88e-30	Menarche (age at onset);
CRC	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.44	0.42	1.03e-15	Coffee consumption (cups per day);
CRC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg24585782	chr17:78113791	EIF4A3	-0.47	-6.54	-0.34	2.37e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.58	-8.22	-0.41	4.72e-15	Platelet distribution width;
CRC	cis	rs812925	0.784	rs6735081	chr2:61460717	C/T	cg10580144	chr2:61372316	C2orf74	-0.32	-6.64	-0.34	1.27e-10	Immature fraction of reticulocytes;
CRC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs3736485	0.844	rs8024506	chr15:51792934	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.41	-0.33	5.03e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.68	9.45	0.46	6.58e-19	Vitiligo;
CRC	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.47	-6.03	-0.32	4.44e-9	Alopecia areata;
CRC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.62	0.3	4.13e-8	Eosinophil percentage of white cells;
CRC	cis	rs1519814	1.000	rs7818027	chr8:121158662	G/C	cg22335954	chr8:121166405	COL14A1	-0.59	-6.83	-0.35	4.11e-11	Breast cancer;
CRC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.89	9.24	0.45	3.25e-18	Arsenic metabolism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26976181	chr19:18434160	LSM4	0.43	6.24	0.33	1.37e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Parkinson's disease;
CRC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg13047869	chr3:10149882	C3orf24	0.38	5.93	0.31	7.73e-9	Alzheimer's disease;
CRC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg10589385	chr1:150898437	SETDB1	0.32	6.79	0.35	5.21e-11	Melanoma;
CRC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.5	8.81	0.44	7.43e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg04849180	chr8:52921640	NA	-0.37	-5.98	-0.31	5.83e-9	HDL cholesterol;
CRC	cis	rs3751196	0.710	rs59651914	chr12:104222211	T/A	cg02344784	chr12:104178138	NT5DC3	0.69	7.04	0.36	1.1e-11	Sense of smell;
CRC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21845817	chr2:96068451	FAHD2A	0.45	6.44	0.33	4.12e-10	Anxiety disorder;
CRC	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.62	0.43	2.93e-16	Coffee consumption (cups per day);
CRC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg01483505	chr11:975446	AP2A2	0.43	6.96	0.36	1.87e-11	Alzheimer's disease (late onset);
CRC	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg09455208	chr3:40491958	NA	0.31	6.34	0.33	7.75e-10	Renal cell carcinoma;
CRC	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.68	-0.3	2.93e-8	Daytime sleep phenotypes;
CRC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-6.79	-0.35	5.29e-11	Major depressive disorder;
CRC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.56	-0.65	2.61e-41	Gut microbiome composition (summer);
CRC	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg05044414	chr3:183734942	ABCC5	0.46	7.6	0.39	3.1e-13	Anterior chamber depth;
CRC	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.79e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg05299278	chr17:33885742	SLFN14	-0.41	-6.24	-0.33	1.33e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.76	-0.35	6.19e-11	Total body bone mineral density;
CRC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg24562669	chr7:97807699	LMTK2	0.45	7.59	0.39	3.4e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs2179367	0.959	rs480034	chr6:149735430	C/T	cg16235748	chr6:149772707	ZC3H12D	0.35	5.72	0.3	2.39e-8	Dupuytren's disease;
CRC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.55	10.79	0.51	1.92e-23	Schizophrenia;
CRC	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	10.63	0.51	6.74e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11255291	1.000	rs7901428	chr10:7732419	C/T	cg00997801	chr10:7671259	ITIH5	0.44	6.5	0.34	2.96e-10	Ovarian reserve;
CRC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.4	6.41	0.33	5.03e-10	Testicular germ cell tumor;
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26587870	chr6:27730563	NA	-0.65	-6.76	-0.35	6.13e-11	Depression;
CRC	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg18404041	chr3:52824283	ITIH1	-0.34	-5.96	-0.31	6.42e-9	Schizophrenia;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Parkinson's disease;
CRC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg18404041	chr3:52824283	ITIH1	-0.37	-6.87	-0.35	3.19e-11	Schizophrenia;
CRC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.96	0.66	7.52e-43	Platelet count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05775742	chr12:121022424	NA	0.44	6.25	0.33	1.29e-9	Anxiety disorder;
CRC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04880052	chr2:219191631	PNKD	-0.42	-6.64	-0.34	1.3100000000000001e-10	Colorectal cancer;
CRC	cis	rs17767392	0.813	rs12878989	chr14:71856184	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.85	-0.31	1.17e-8	Mitral valve prolapse;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00251738	chr7:77428046	PHTF2;TMEM60	0.49	7.26	0.37	2.73e-12	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.32	-0.33	8.44e-10	Aortic root size;
CRC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.7	-10.27	-0.49	1.2e-21	Other erythrocyte phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18992706	chr13:44453352	CCDC122;C13orf31	0.33	6.36	0.33	6.78e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.67e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12024301	0.557	rs3889890	chr1:183621385	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.46	7.72	0.39	1.4e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2055729	0.601	rs12546952	chr8:9744002	G/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.11	-0.32	2.78e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.69	-8.71	-0.43	1.54e-16	Dilated cardiomyopathy;
CRC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.4	7.58	0.39	3.45e-13	Mean corpuscular volume;
CRC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.64	10.08	0.49	5.26e-21	Prostate cancer;
CRC	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.55	6.16	0.32	2.1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.59	8.33	0.42	2.14e-15	Menopause (age at onset);
CRC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-9.63	-0.47	1.75e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.2	-0.41	5.35e-15	Hemoglobin concentration;
CRC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.48	-6.85	-0.35	3.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4743820	0.620	rs10991787	chr9:93917218	A/G	cg14446406	chr9:93919335	NA	0.77	13.47	0.6	2.94e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12578567	chr10:69835225	HERC4	0.48	6.82	0.35	4.38e-11	Response to antipsychotic treatment;
CRC	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.36	-0.38	1.51e-12	Type 2 diabetes;
CRC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.84	0.66	2.15e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-5.92	-0.31	8.13e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.68	-10.99	-0.52	3.75e-24	Cognitive function;
CRC	cis	rs9467603	0.925	rs4712969	chr6:25764192	A/G	cg08501292	chr6:25962987	TRIM38	-0.88	-8.33	-0.42	2.16e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.38	-5.85	-0.31	1.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.47	7.44	0.38	8.79e-13	Sitting height ratio;
CRC	cis	rs9491140	0.539	rs10872285	chr6:124689145	C/T	cg19267163	chr6:125004984	NKAIN2	0.53	6.85	0.35	3.61e-11	Neuroticism;
CRC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.62	-9.71	-0.47	9.33e-20	Intelligence (multi-trait analysis);
CRC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.63	-9.93	-0.48	1.74e-20	Dental caries;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg09417038	chr21:47716443	C21orf57	-0.42	-6.9	-0.36	2.66e-11	Testicular germ cell tumor;
CRC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.5	-0.34	3.04e-10	Body mass index;
CRC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg16005559	chr11:120040616	NA	-0.45	-6.36	-0.33	6.61e-10	Stroke (pediatric);
CRC	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.57	-10.83	-0.51	1.38e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg08501292	chr6:25962987	TRIM38	0.89	6.15	0.32	2.3e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg25164649	chr6:28176230	NA	0.6	7.91	0.4	4.06e-14	Parkinson's disease;
CRC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-9.96	-0.48	1.3e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.7	8.29	0.42	2.98e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.75	0.47	6.98e-20	Alzheimer's disease (late onset);
CRC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14671364	chr1:107599128	PRMT6	0.62	8.45	0.42	9.23e-16	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.35	-0.33	7.33e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg19731401	chr7:2775893	GNA12	0.64	7.2	0.37	4.02e-12	Childhood ear infection;
CRC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.7	10.97	0.52	4.62e-24	Blood protein levels;
CRC	cis	rs13418455	0.619	rs1518709	chr2:181230398	A/G	cg23363182	chr2:181467187	NA	-0.39	-5.72	-0.3	2.4e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.73	-13.35	-0.59	9.02e-33	Leprosy;
CRC	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	cis	rs6968419	0.755	rs6966770	chr7:115895718	A/G	cg02561103	chr7:115862891	TES	-0.37	-5.75	-0.3	1.99e-8	Intraocular pressure;
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.72	-0.43	1.44e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7739232	0.850	rs76135039	chr6:53529138	C/T	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.4	5.73	0.3	2.32e-8	Obesity-related traits;
CRC	cis	rs67981189	0.529	rs17108862	chr14:71464666	G/A	cg15910301	chr14:71632612	NA	0.29	5.79	0.3	1.63e-8	Schizophrenia;
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.29e-9	Bipolar disorder;
CRC	cis	rs3996993	0.573	rs10948726	chr6:52695461	G/T	cg20803780	chr6:52668592	GSTA1	0.4	6.71	0.35	8.57e-11	Hemoglobin concentration;
CRC	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.58	-8.09	-0.41	1.15e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg09075268	chr16:1270372	CACNA1H	0.4	6.1	0.32	2.9e-9	Blood protein levels;
CRC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.43	-7.9	-0.4	4.19e-14	Huntington's disease progression;
CRC	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.46	-6.7	-0.35	8.88e-11	Breast cancer;
CRC	cis	rs524281	0.954	rs549187	chr11:65898631	C/T	cg14036092	chr11:66035641	RAB1B	-0.49	-6.78	-0.35	5.59e-11	Electroencephalogram traits;
CRC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.79e-13	Motion sickness;
CRC	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg15234197	chr11:68924956	NA	0.44	6.12	0.32	2.72e-9	Blond vs. brown hair color;
CRC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.54	7.9	0.4	4.31e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.57	0.47	2.57e-19	Coffee consumption (cups per day);
CRC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.47	-0.34	3.53e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12580194	0.593	rs67015069	chr12:55759968	T/A	cg19537932	chr12:55886519	OR6C68	-0.73	-9.19	-0.45	4.43e-18	Cancer;
CRC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.95	-19.09	-0.72	3.22e-55	Height;
CRC	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg19875535	chr5:140030758	IK	0.46	6.98	0.36	1.59e-11	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.51	-7.11	-0.36	7.24e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg04166393	chr7:2884313	GNA12	0.45	6.03	0.32	4.46e-9	Height;
CRC	cis	rs8105895	0.799	rs6511327	chr19:22286899	T/A	cg02657401	chr19:22469223	NA	-0.36	-5.85	-0.31	1.18e-8	Body mass index (change over time);
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg01874867	chr7:94954059	PON1	-0.49	-6.36	-0.33	6.6e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09011732	chr2:74730507	LOC151534;LBX2	0.45	7.03	0.36	1.16e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.46	0.42	9.13e-16	Arsenic metabolism;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.01	0.31	4.88e-9	Ovarian reserve;
CRC	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-10.36	-0.5	5.94e-22	Blood protein levels;
CRC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.8	0.48	4.69e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg12172441	chr6:28176163	NA	0.51	6.26	0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.97	0.36	1.78e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.39e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg23254163	chr1:152506842	NA	0.47	9.15	0.45	6.23e-18	Hair morphology;
CRC	cis	rs11748023	0.605	rs152409	chr5:139521808	T/C	cg26211634	chr5:139558579	C5orf32	0.36	6.1	0.32	2.98e-9	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16904090	chr1:40997253	ZNF684	0.49	6.37	0.33	6.25e-10	Thyroid stimulating hormone;
CRC	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg16068336	chr17:48637367	CACNA1G	-0.51	-7.49	-0.38	6.44e-13	Type 2 diabetes;
CRC	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.46	-6.52	-0.34	2.71e-10	Lung cancer;
CRC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-8.06	-0.41	1.42e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.5	-8.16	-0.41	7.25e-15	Caffeine consumption;
CRC	trans	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg20935933	chr6:143382018	AIG1	0.5	6.46	0.34	3.8e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg06781209	chr11:61594997	FADS2	-0.42	-5.99	-0.31	5.58e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.72	11.37	0.53	1.76e-25	Tonsillectomy;
CRC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.24	0.33	1.37e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.98	-19.25	-0.73	7.43e-56	Height;
CRC	trans	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.79e-15	Bone mineral density;
CRC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg17720231	chr1:159915374	IGSF9	-0.4	-5.97	-0.31	6.19e-9	Birth weight;Height;
CRC	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.78	-11.32	-0.53	2.53e-25	Multiple sclerosis;
CRC	cis	rs10924970	0.967	rs8179454	chr1:235460719	C/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.02	0.32	4.63e-9	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02432107	chr7:102105641	ALKBH4;LRWD1	0.38	6.23	0.32	1.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.88	-15.07	-0.64	2.15e-39	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg08741688	chr4:3415352	RGS12	-0.45	-6.65	-0.34	1.19e-10	Serum sulfate level;
CRC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs13144136	0.687	rs7677121	chr4:10654107	G/T	cg10242279	chr4:10666415	CLNK	-0.36	-6.19	-0.32	1.83e-9	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.42	-6.49	-0.34	3.21e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg07809909	chr20:30433512	FOXS1	0.35	5.7	0.3	2.65e-8	Mean corpuscular hemoglobin;
CRC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg15147215	chr3:52552868	STAB1	-0.59	-9.2	-0.45	4.14e-18	Bipolar disorder;
CRC	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg05194412	chr2:137003533	NA	0.44	6.89	0.35	2.9e-11	Colorectal cancer;
CRC	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.77	14.0	0.61	3.03e-35	Lewy body disease;
CRC	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	1.1	12.9	0.58	4.37e-31	Obesity-related traits;
CRC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg17724175	chr1:150552817	MCL1	0.44	6.66	0.34	1.14e-10	Melanoma;
CRC	cis	rs7072216	0.881	rs2274247	chr10:100150148	G/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.17	-0.32	2.05e-9	Metabolite levels;
CRC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.51	-6.11	-0.32	2.86e-9	Coronary artery calcification;
CRC	cis	rs7703744	0.681	rs11957102	chr5:118701899	G/T	cg19893178	chr5:118692011	TNFAIP8	0.44	5.81	0.3	1.5e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.4	7.91	0.4	4.03e-14	Mean corpuscular volume;
CRC	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg24289452	chr6:170231220	NA	-0.6	-6.58	-0.34	1.89e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.37	-5.64	-0.3	3.7e-8	Height;
CRC	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg23100626	chr2:96804247	ASTL	0.26	6.86	0.35	3.42e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9826463	0.702	rs55994893	chr3:142304694	G/C	cg20824294	chr3:142316082	PLS1	0.42	6.84	0.35	3.86e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	15.68	0.65	9.39e-42	Leprosy;
CRC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.51	7.87	0.4	5.19e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.85	0.35	3.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-8.2	-0.41	5.4e-15	HDL cholesterol;
CRC	cis	rs868943	0.582	rs12196141	chr6:116489550	C/T	cg15226275	chr6:116381976	FRK	-0.26	-5.87	-0.31	1.05e-8	Total cholesterol levels;
CRC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.83	-0.48	3.72e-20	Height;
CRC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-12.76	-0.58	1.48e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.69	9.2	0.45	4.18e-18	Alzheimer's disease;
CRC	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.7	7.04	0.36	1.13e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.6	8.3	0.42	2.66e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg11522145	chr4:3412961	RGS12	0.36	5.74	0.3	2.12e-8	Serum sulfate level;
CRC	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.63	-0.63	1.07e-37	Exhaled nitric oxide output;
CRC	cis	rs6662572	0.737	rs10890356	chr1:46317924	A/G	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.48	7.01	0.36	1.34e-11	Autism;
CRC	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg20512303	chr5:131592959	PDLIM4	-0.35	-5.66	-0.3	3.3e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.37	5.88	0.31	9.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.51	8.77	0.44	9.53e-17	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15057440	chr2:74685383	WBP1	0.43	6.02	0.31	4.64e-9	Response to antipsychotic treatment;
CRC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.27	6.99	0.36	1.58e-11	Iron status biomarkers;
CRC	cis	rs4290604	0.679	rs73083545	chr2:237983894	C/G	cg23555395	chr2:238036564	NA	0.54	7.03	0.36	1.2e-11	Asthma;
CRC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg15123519	chr2:136567270	LCT	0.3	5.65	0.3	3.46e-8	Mosquito bite size;
CRC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.72	-0.3	2.43e-8	Migraine;Coronary artery disease;
CRC	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	0.95	9.37	0.46	1.19e-18	Mitochondrial DNA levels;
CRC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.03	-0.4	1.74e-14	Aortic root size;
CRC	cis	rs7209700	0.963	rs1000232	chr17:45356561	T/C	cg08085267	chr17:45401833	C17orf57	0.48	7.05	0.36	1.05e-11	IgG glycosylation;
CRC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.98	13.11	0.59	6.89e-32	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.42	5.84	0.31	1.25e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.36	6.38	0.33	6.18e-10	Crohn's disease;
CRC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.47	6.57	0.34	1.99e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs7113874	0.569	rs4929942	chr11:8625096	A/G	cg02811074	chr11:8615871	STK33	0.35	5.98	0.31	5.83e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg19812747	chr11:111475976	SIK2	-0.44	-6.99	-0.36	1.49e-11	Primary sclerosing cholangitis;
CRC	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.58	-0.47	2.53e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.52	-8.35	-0.42	1.86e-15	Coronary artery disease;
CRC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.86	0.31	1.14e-8	Systemic lupus erythematosus;
CRC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg04719120	chr6:96025338	MANEA	0.6	7.9	0.4	4.36e-14	Behavioural disinhibition (generation interaction);
CRC	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg09003973	chr2:102972529	NA	0.68	7.54	0.38	4.74e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.54	0.54	4.32e-26	Prudent dietary pattern;
CRC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.52	-0.43	5.97e-16	Morning vs. evening chronotype;
CRC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.19	-0.45	4.68e-18	Bipolar disorder and schizophrenia;
CRC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg21153622	chr11:89784906	NA	-0.4	-6.24	-0.33	1.34e-9	Height;
CRC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.49	-6.94	-0.36	2.1e-11	Height;
CRC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg09473613	chr1:24152604	HMGCL	0.35	5.67	0.3	3.16e-8	Immature fraction of reticulocytes;
CRC	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.87	-0.48	2.77e-20	Blood protein levels;
CRC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg25600027	chr14:23388339	RBM23	-0.53	-8.3	-0.42	2.69e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs9341808	0.667	rs6938280	chr6:80897782	G/A	cg08355045	chr6:80787529	NA	0.34	5.86	0.31	1.1e-8	Sitting height ratio;
CRC	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.74	11.15	0.52	1.08e-24	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg09264619	chr17:80180166	NA	-0.36	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	trans	rs11825064	0.636	rs67824656	chr11:134485625	T/G	cg00033773	chr19:12779366	MORG1;C19orf56	0.45	6.17	0.32	1.97e-9	Seasonality;
CRC	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg20356878	chr3:121714668	ILDR1	0.51	7.75	0.39	1.19e-13	Cognitive performance;
CRC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.37	5.65	0.3	3.39e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.4	6.19	0.32	1.79e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	-0.51	-8.26	-0.41	3.53e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.47	-6.18	-0.32	1.93e-9	Renal function-related traits (BUN);
CRC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10924970	0.534	rs10925362	chr1:235464380	G/A	cg09010748	chr1:235293032	TOMM20	-0.43	-5.92	-0.31	8.25e-9	Asthma;
CRC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.61	-9.7	-0.47	9.86e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.4	6.52	0.34	2.6200000000000003e-10	Major depressive disorder;
CRC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.37	-0.42	1.72e-15	Electroencephalogram traits;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.86	-0.4	5.35e-14	Total body bone mineral density;
CRC	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg00105475	chr2:10696890	NA	0.44	7.14	0.37	6.13e-12	Prostate cancer;
CRC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	25.81	0.82	4.42e-81	IgG glycosylation;
CRC	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.57	8.32	0.42	2.38e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg08999081	chr20:33150536	PIGU	0.46	5.68	0.3	2.89e-8	Neuroticism;
CRC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.75	-0.35	6.62e-11	Alzheimer's disease (late onset);
CRC	trans	rs684232	0.666	rs461521	chr17:622497	G/T	cg22807402	chr17:73269154	SLC25A19	-0.34	-6.02	-0.31	4.57e-9	Prostate cancer;
CRC	trans	rs4378999	0.660	rs9824522	chr3:50771992	C/T	cg12383621	chr7:7735611	RPA3	-0.48	-6.02	-0.31	4.74e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.1e-16	Alcohol dependence;
CRC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.59	8.0	0.4	2.12e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.4e-9	Crohn's disease;
CRC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg01472538	chr16:58549086	SETD6	1.1	7.06	0.36	1.01e-11	Schizophrenia;
CRC	cis	rs9322817	0.583	rs7746856	chr6:105146360	A/C	cg02098413	chr6:105308735	HACE1	0.43	8.19	0.41	5.71e-15	Thyroid stimulating hormone;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02873525	chr19:48675305	NA	-0.4	-6.02	-0.31	4.74e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs365302	1.000	rs2245986	chr6:159648661	G/A	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs17155006	0.621	rs436573	chr7:107739906	A/T	cg05962710	chr7:107745446	LAMB4	-0.37	-6.73	-0.35	7.54e-11	Pneumococcal bacteremia;
CRC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.51	-7.98	-0.4	2.53e-14	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg23032129	chr1:109941072	SORT1	-0.29	-6.08	-0.32	3.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg18827107	chr12:86230957	RASSF9	-0.42	-6.68	-0.35	9.97e-11	Major depressive disorder;
CRC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	7.33	0.37	1.8e-12	Schizophrenia;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.44	6.5	0.34	3.01e-10	Obesity-related traits;
CRC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-6.49	-0.34	3.17e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.68	-8.29	-0.42	2.91e-15	Schizophrenia;
CRC	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.56	8.33	0.42	2.28e-15	HDL cholesterol;
CRC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg15440763	chr7:158190612	PTPRN2	0.36	5.73	0.3	2.26e-8	Obesity-related traits;
CRC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs1868673	1.000	rs9813752	chr3:150151120	G/A	cg04908077	chr3:150187338	NA	-0.33	-5.65	-0.3	3.49e-8	Waist circumference;
CRC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.59	7.32	0.37	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg22687807	chr8:143858763	LYNX1	-0.37	-6.47	-0.34	3.46e-10	Urinary tract infection frequency;
CRC	cis	rs338389	0.516	rs7359201	chr15:68313749	T/C	cg22576950	chr15:68522787	CLN6	-0.37	-6.17	-0.32	2.01e-9	Survival in rectal cancer;
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14487482	chr3:135969043	PCCB	0.43	6.12	0.32	2.66e-9	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.78	-0.51	2.18e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg02993699	chr4:3415135	RGS12	0.34	5.67	0.3	3.1e-8	Serum sulfate level;
CRC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.33	-0.53	2.45e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg13722127	chr7:150037890	RARRES2	0.49	7.58	0.39	3.52e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg14844989	chr11:31128820	NA	0.35	6.18	0.32	1.87e-9	Red blood cell count;
CRC	cis	rs13272623	0.502	rs268599	chr8:71517401	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.45	-6.47	-0.34	3.45e-10	IgG glycosylation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22852276	chr20:35724169	RBL1	0.41	6.06	0.32	3.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.596	rs10231818	chr7:124574184	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg27427491	chr17:78079615	GAA	-0.37	-5.91	-0.31	8.59e-9	Yeast infection;
CRC	cis	rs4663866	0.901	rs35390666	chr2:239193578	C/T	cg16914508	chr2:239161102	PER2	0.73	7.62	0.39	2.78e-13	Irritable bowel syndrome;
CRC	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.43	6.6	0.34	1.62e-10	Coronary artery disease;
CRC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.61	10.18	0.49	2.35e-21	Hemoglobin concentration;Hematocrit;
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02290350	chr8:58132656	NA	-0.51	-6.39	-0.33	5.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.54	-7.86	-0.4	5.42e-14	Monocyte count;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg12564285	chr5:131593104	PDLIM4	0.45	7.55	0.38	4.27e-13	Breast cancer;
CRC	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg05579598	chr16:88989069	CBFA2T3	0.35	6.85	0.35	3.59e-11	Social autistic-like traits;
CRC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg08755490	chr11:65554678	OVOL1	0.4	5.81	0.31	1.48e-8	Acne (severe);
CRC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.49	6.57	0.34	1.92e-10	Height;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.36	6.0	0.31	5.28e-9	Electroencephalogram traits;
CRC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.73	-11.84	-0.55	3.58e-27	Menarche (age at onset);
CRC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.36	0.42	1.82e-15	Lung cancer;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg10620530	chr9:139922595	C9orf139;ABCA2	-0.4	-5.97	-0.31	6.25e-9	Daytime sleep phenotypes;
CRC	trans	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg26043149	chr18:55253948	FECH	0.54	8.28	0.42	3.11e-15	Bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03756088	chr1:230203084	GALNT2	0.43	6.08	0.32	3.42e-9	Anxiety disorder;
CRC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-6.24	-0.33	1.34e-9	Acne (severe);
CRC	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg08890418	chr1:21044141	KIF17	0.31	5.73	0.3	2.33e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.66	-9.25	-0.45	2.82e-18	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg12273811	chr6:28175739	NA	0.51	6.82	0.35	4.5e-11	Parkinson's disease;
CRC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.84	14.96	0.64	5.65e-39	Breast cancer;
CRC	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.88	0.44	4.49e-17	Coffee consumption (cups per day);
CRC	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg09873164	chr1:152488093	CRCT1	0.36	5.99	0.31	5.48e-9	Hair morphology;
CRC	cis	rs629535	0.911	rs688612	chr8:70011887	C/T	cg26132723	chr8:70041827	NA	-0.36	-5.88	-0.31	9.89e-9	Dupuytren's disease;
CRC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.89	-0.4	4.37e-14	Gut microbiome composition (summer);
CRC	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.36	5.7	0.3	2.71e-8	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.38	-6.45	-0.34	3.94e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.35	6.74	0.35	6.94e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.86	-14.39	-0.62	9.73e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg13491945	chr12:107078410	RFX4	-0.35	-6.11	-0.32	2.88e-9	Heart rate;
CRC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.75	-7.83	-0.4	6.98e-14	Coronary artery disease;
CRC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6141769	0.542	rs6057625	chr20:31304994	G/A	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.87	-0.31	1.04e-8	Subjective well-being;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.93	-22.01	-0.77	1.17e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg19784903	chr17:45786737	TBKBP1	-0.34	-5.61	-0.3	4.35e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs12476592	0.571	rs2592386	chr2:63894064	A/G	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.49	7.63	0.39	2.54e-13	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02099313	chr1:231114956	TTC13;ARV1	0.45	6.43	0.33	4.52e-10	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03605463	chr16:89740564	NA	0.41	6.07	0.32	3.43e-9	Vitiligo;
CRC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.36	-6.56	-0.34	2.03e-10	Menarche (age at onset);
CRC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.53	8.43	0.42	1.07e-15	Prostate cancer;
CRC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg20041105	chr8:143859282	LYNX1	-0.33	-5.89	-0.31	9.77e-9	Urinary tract infection frequency;
CRC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.84	0.31	1.23e-8	Heart rate;
CRC	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.65	-10.07	-0.49	5.67e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11229555	0.645	rs11229436	chr11:58186009	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.28	-0.33	1.07e-9	Morning vs. evening chronotype;
CRC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-6.04	-0.32	4.27e-9	Heart rate;
CRC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.78	-0.47	5.35e-20	Body mass index;
CRC	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.7	-0.39	1.65e-13	Height;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16189954	chr22:29138267	HSCB;CHEK2	-0.38	-6.06	-0.32	3.65e-9	Aortic root size;
CRC	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.69	11.86	0.55	2.9e-27	White blood cell count (basophil);
CRC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.53	-9.31	-0.46	1.91e-18	Educational attainment;
CRC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.43	0.33	4.44e-10	Morning vs. evening chronotype;
CRC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg22777020	chr22:31556080	RNF185	0.46	5.61	0.3	4.21e-8	Colorectal cancer;
CRC	cis	rs1524976	0.941	rs1404550	chr3:65487427	G/C	cg16238336	chr3:65465873	MAGI1	0.5	6.43	0.33	4.59e-10	PR interval;
CRC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.93	-0.4	3.52e-14	Intelligence (multi-trait analysis);
CRC	cis	rs12913538	0.747	rs7167910	chr15:62888516	C/T	cg09983546	chr15:62884068	NA	-0.5	-7.73	-0.39	1.36e-13	Sleep depth;
CRC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.5	-8.79	-0.44	8.23e-17	Birth weight;
CRC	cis	rs6088813	1.000	rs6088825	chr20:33995972	C/T	cg14752227	chr20:34000481	UQCC	-0.37	-5.75	-0.3	2.01e-8	Height;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg20933634	chr6:27740509	NA	0.58	6.43	0.33	4.56e-10	Parkinson's disease;
CRC	cis	rs3789045	1.000	rs3747631	chr1:204587569	G/C	cg17419461	chr1:204415978	PIK3C2B	-0.49	-6.94	-0.36	2.05e-11	Educational attainment (college completion);
CRC	cis	rs4889855	0.556	rs9911795	chr17:78626115	T/C	cg16591659	chr17:78472290	NA	-0.41	-6.09	-0.32	3.1e-9	Fractional excretion of uric acid;
CRC	cis	rs12745968	0.623	rs4294424	chr1:93139374	T/C	cg17283838	chr1:93427260	FAM69A	-0.47	-6.37	-0.33	6.34e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	9.01	0.44	1.71e-17	Menarche (age at onset);
CRC	cis	rs2882667	0.898	rs6882330	chr5:138382182	A/G	cg09476006	chr5:138032270	NA	0.44	7.4	0.38	1.12e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.66	0.51	5.39e-23	Motion sickness;
CRC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-5.62	-0.3	4.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-5.92	-0.31	8.21e-9	Schizophrenia;
CRC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg11833968	chr6:79620685	NA	-0.37	-6.47	-0.34	3.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.33	-5.81	-0.31	1.45e-8	Menarche (age at onset);
CRC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.39	6.12	0.32	2.68e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg23650765	chr1:12612165	NA	0.35	6.62	0.34	1.48e-10	Optic cup area;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg21251018	chr6:28226885	NKAPL	0.49	6.27	0.33	1.14e-9	Depression;
CRC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.54	-8.74	-0.43	1.21e-16	Aortic root size;
CRC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.08	-0.32	3.4e-9	Alzheimer's disease (late onset);
CRC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.43	-6.3	-0.33	9.61e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.05	-25.27	-0.81	4.48e-79	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.43	6.66	0.34	1.14e-10	Cleft lip with or without cleft palate;
CRC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.6	-8.2	-0.41	5.54e-15	Carotid intima media thickness;
CRC	cis	rs2637266	0.561	rs11492375	chr10:78513974	T/C	cg18941641	chr10:78392320	NA	-0.36	-6.18	-0.32	1.91e-9	Pulmonary function;
CRC	trans	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.72	0.35	8.23e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.67	10.72	0.51	3.53e-23	Urate levels;
CRC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.56	8.37	0.42	1.64e-15	Body mass index;
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.71	0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.58	10.22	0.49	1.79e-21	Common traits (Other);
CRC	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg12458913	chr13:53173898	NA	0.39	5.68	0.3	2.97e-8	Lewy body disease;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.28	-0.49	1.13e-21	Bipolar disorder;
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	10.96	0.52	5.02e-24	Prudent dietary pattern;
CRC	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.24	11.59	0.54	2.8e-26	Granulocyte percentage of myeloid white cells;
CRC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.19	0.52	7.76e-25	Prudent dietary pattern;
CRC	cis	rs4731207	0.505	rs7791488	chr7:124578268	A/G	cg23710748	chr7:124431027	NA	-0.42	-6.57	-0.34	1.98e-10	Cutaneous malignant melanoma;
CRC	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.63	10.45	0.5	3.01e-22	Phospholipid levels (plasma);
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.77	9.81	0.48	4.41e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs17767392	0.958	rs7156313	chr14:72052310	G/C	cg13720639	chr14:72061746	SIPA1L1	0.57	7.1	0.36	7.61e-12	Mitral valve prolapse;
CRC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.92	-17.04	-0.68	4.2e-47	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg00601486	chr12:48723148	H1FNT	-0.35	-6.75	-0.35	6.49e-11	Glycated hemoglobin levels;
CRC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00745463	chr17:30367425	LRRC37B	0.72	7.51	0.38	5.5e-13	Hip circumference adjusted for BMI;
CRC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.68	-9.24	-0.45	3.2e-18	Heart rate;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg08697092	chr19:56879933	ZNF542	0.36	6.29	0.33	9.99e-10	Kashin-Beck disease;
CRC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.67	0.39	1.91e-13	Axial length;
CRC	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.84	-13.84	-0.61	1.18e-34	Lewy body disease;
CRC	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-0.65	-7.71	-0.39	1.49e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.45	7.41	0.38	1.07e-12	Total cholesterol levels;
CRC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.94	-0.31	7.28e-9	Breast cancer;Breast cancer (early onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21775445	chr20:1373916	FKBP1A	0.42	5.96	0.31	6.48e-9	Response to antipsychotic treatment;
CRC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg01483505	chr11:975446	AP2A2	0.46	7.67	0.39	2.02e-13	Alzheimer's disease (late onset);
CRC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.67	10.1	0.49	4.69e-21	Menopause (age at onset);
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg04969067	chr8:143858791	LYNX1	0.45	7.61	0.39	2.99e-13	Urinary tract infection frequency;
CRC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.46	1.19e-18	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg11693508	chr17:37793320	STARD3	0.48	6.44	0.33	4.14e-10	Neuroticism;
CRC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.43	6.92	0.36	2.43e-11	Monocyte count;
CRC	cis	rs12476592	0.602	rs1446563	chr2:63898124	T/G	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs2421770	0.504	rs7943314	chr11:35363823	A/G	cg13971030	chr11:35366721	SLC1A2	-0.39	-6.74	-0.35	7.04e-11	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.46	-0.34	3.8e-10	Aortic root size;
CRC	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg05569086	chr8:143859399	LYNX1	0.4	6.91	0.36	2.51e-11	Urinary tract infection frequency;
CRC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.8	13.54	0.6	1.66e-33	Menopause (age at onset);
CRC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg27661571	chr11:113659931	NA	-0.94	-10.87	-0.51	9.91e-24	Hip circumference adjusted for BMI;
CRC	trans	rs2055729	0.614	rs10108550	chr8:9741633	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.75	-0.35	6.83e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.77	-10.26	-0.49	1.32e-21	White matter hyperintensity burden;
CRC	cis	rs4664293	0.867	rs11681245	chr2:160629393	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.77	-11.89	-0.55	2.31e-27	Response to temozolomide;
CRC	cis	rs672059	1.000	rs575474	chr1:183158599	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.28	0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs7605827	0.930	rs13004154	chr2:15664325	A/G	cg19274914	chr2:15703543	NA	0.37	5.65	0.3	3.43e-8	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17627654	chr11:70508410	SHANK2	0.21	6.28	0.33	1.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.46	-8.78	-0.44	8.92e-17	Prostate cancer;
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.12	-0.37	6.88e-12	Bipolar disorder;
CRC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.06	9.97	0.48	1.21e-20	Opioid sensitivity;
CRC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.53	-8.75	-0.43	1.17e-16	Iron status biomarkers;
CRC	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.77	14.42	0.62	6.98e-37	Lewy body disease;
CRC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.46	-6.75	-0.35	6.67e-11	Platelet distribution width;
CRC	trans	rs6011368	0.585	rs13043326	chr20:62914092	C/A	cg13869341	chr1:15865	WASH5P	0.42	6.1	0.32	2.99e-9	Clozapine-induced cytotoxicity;
CRC	cis	rs73198271	0.531	rs56100346	chr8:8652844	C/T	cg01851573	chr8:8652454	MFHAS1	0.55	6.84	0.35	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00224911	chr4:74486142	RASSF6	0.41	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg17724175	chr1:150552817	MCL1	0.56	9.06	0.45	1.23e-17	Tonsillectomy;
CRC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12483801	chr4:183727862	NA	0.66	7.92	0.4	3.78e-14	Pediatric autoimmune diseases;
CRC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.7	-0.43	1.64e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs9903692	0.909	rs8078125	chr17:46145709	T/G	cg21215337	chr17:46176117	CBX1	0.42	7.78	0.39	9.36e-14	Pulse pressure;
CRC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.63	9.15	0.45	6.05e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13433994	chr3:23958502	NKIRAS1;RPL15	0.37	5.99	0.31	5.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg11843238	chr5:131593191	PDLIM4	0.33	5.77	0.3	1.85e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.41	5.78	0.3	1.73e-8	Vitamin D levels;
CRC	cis	rs863345	0.604	rs12120526	chr1:158498404	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.37	-0.73	2.48e-56	Primary sclerosing cholangitis;
CRC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03932406	chr2:65657881	SPRED2	0.4	6.16	0.32	2.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07741184	chr6:167504864	NA	-0.32	-5.68	-0.3	2.95e-8	Rheumatoid arthritis;
CRC	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.48	0.42	7.87e-16	Corneal astigmatism;
CRC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.34	2.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.83	10.53	0.5	1.57e-22	Monocyte percentage of white cells;
CRC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg01448562	chr3:133502909	NA	-0.47	-7.0	-0.36	1.45e-11	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.49	8.16	0.41	7.38e-15	Airway imaging phenotypes;
CRC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	11.11	0.52	1.46e-24	Tonsillectomy;
CRC	cis	rs11212617	0.935	rs11212543	chr11:108054922	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.31	0.33	8.94e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs501916	0.634	rs603569	chr15:48058929	G/A	cg16110827	chr15:48056943	SEMA6D	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.98	-0.31	5.71e-9	Gut microbiome composition (summer);
CRC	cis	rs7333181	0.858	rs34554065	chr13:112241190	T/C	cg27543320	chr13:112200689	NA	0.49	6.1	0.32	2.93e-9	Menopause (age at onset);
CRC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.71	7.26	0.37	2.82e-12	Diabetic retinopathy;
CRC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.42	-0.75	2e-60	Hip circumference adjusted for BMI;
CRC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.81	14.72	0.63	4.88e-38	Metabolic syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27409012	chr1:162531173	UAP1	0.44	6.31	0.33	8.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs12230513	0.732	rs7957446	chr12:55839631	G/C	cg19537932	chr12:55886519	OR6C68	-0.73	-9.52	-0.46	3.95e-19	Contrast sensitivity;
CRC	cis	rs17155006	0.746	rs446800	chr7:107747928	A/C	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs727505	0.721	rs11534064	chr7:124767997	G/T	cg23710748	chr7:124431027	NA	0.64	11.28	0.53	3.48e-25	Lewy body disease;
CRC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.58	6.44	0.33	4.15e-10	Initial pursuit acceleration;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg20512303	chr5:131592959	PDLIM4	-0.4	-6.91	-0.36	2.5e-11	Breast cancer;
CRC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-1.12	-18.23	-0.71	7.93e-52	Blood pressure (smoking interaction);
CRC	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg00531865	chr16:30841666	NA	-0.44	-6.28	-0.33	1.05e-9	Dementia with Lewy bodies;
CRC	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.9	-0.44	3.88e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.83	-9.54	-0.47	3.28e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12024301	0.557	rs75281768	chr1:183645768	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.73	6.43	0.33	4.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.07	-0.32	3.62e-9	Menopause (age at onset);
CRC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.56	-8.92	-0.44	3.37e-17	IgG glycosylation;
CRC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.42	5.95	0.31	7.03e-9	Aortic root size;
CRC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.05	-0.32	3.9e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs564309	1.000	rs491670	chr1:228599952	G/C	cg24066601	chr6:26271455	HIST1H3G	0.57	6.17	0.32	1.99e-9	Hip circumference (psychosocial stress interaction);
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.63	10.63	0.51	6.97e-23	Prudent dietary pattern;
CRC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.68	0.3	3.01e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg17958423	chr11:6947583	ZNF215	0.58	6.04	0.32	4.27e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.56	-9.34	-0.46	1.54e-18	Eye color traits;
CRC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.94	0.52	5.73e-24	Motion sickness;
CRC	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.13	-0.37	6.28e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-0.95	-8.8	-0.44	8.1e-17	Blood protein levels;
CRC	cis	rs8141797	0.901	rs17004848	chr22:24538918	C/T	cg20894457	chr22:24584366	SUSD2	0.65	6.98	0.36	1.62e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg21601837	chr3:125900065	ALDH1L1	-0.35	-5.66	-0.3	3.23e-8	Metabolite levels;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18301423	chr5:131593218	PDLIM4	0.44	8.18	0.41	6.25e-15	Acylcarnitine levels;
CRC	cis	rs926392	0.896	rs4812357	chr20:37683071	C/T	cg16355469	chr20:37678765	NA	-0.35	-5.67	-0.3	3.05e-8	Dialysis-related mortality;
CRC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.07	-0.32	3.56e-9	Bipolar disorder;
CRC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg14008862	chr17:28927542	LRRC37B2	0.54	5.68	0.3	2.91e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	7.14	0.37	5.93e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.54	8.43	0.42	1.08e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg00919237	chr7:87102261	ABCB4	-0.54	-7.09	-0.36	8.37e-12	Gallbladder cancer;
CRC	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.56	0.47	2.91e-19	Corneal astigmatism;
CRC	cis	rs7605827	0.893	rs7590540	chr2:15719652	A/T	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.38e-9	Educational attainment (years of education);
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.53	7.99	0.4	2.28e-14	Breast cancer;
CRC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.72	8.35	0.42	1.86e-15	Hip circumference adjusted for BMI;
CRC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.33	0.46	1.61e-18	Heart rate;
CRC	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-6.18	-0.32	1.93e-9	Endometrial cancer;
CRC	cis	rs1572438	0.899	rs3799325	chr6:859115	C/T	cg13447295	chr6:887704	NA	0.42	6.1	0.32	2.95e-9	Aging;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg03623178	chr6:28175578	NA	-1.0	-15.2	-0.64	6.65e-40	Depression;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg01239735	chr12:214224	IQSEC3	-0.25	-6.28	-0.33	1.1e-9	Lung cancer;
CRC	cis	rs629535	0.814	rs549643	chr8:70062884	C/T	cg26132723	chr8:70041827	NA	0.34	5.69	0.3	2.82e-8	Dupuytren's disease;
CRC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.66	-0.34	1.13e-10	Lung cancer;
CRC	cis	rs2274273	0.662	rs4040064	chr14:55678088	G/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.81	-0.31	1.46e-8	Protein biomarker;
CRC	cis	rs4728302	0.869	rs6943986	chr7:133616965	G/A	cg10665199	chr7:133106180	EXOC4	0.41	6.18	0.32	1.86e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.4	-7.67	-0.39	2e-13	Intelligence (multi-trait analysis);
CRC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg12311346	chr5:56204834	C5orf35	-0.48	-7.18	-0.37	4.56e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.41	-6.5	-0.34	3.01e-10	Height;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg15845792	chr6:28175446	NA	0.75	10.52	0.5	1.61e-22	Parkinson's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12112058	chr1:224622605	WDR26	-0.49	-6.2	-0.32	1.65e-9	Diisocyanate-induced asthma;
CRC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.78	-9.35	-0.46	1.41e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12476592	0.602	rs4671516	chr2:63790555	G/T	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg16342193	chr10:102329863	NA	-0.33	-5.62	-0.3	3.98e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	8.66	0.43	2.13e-16	IgG glycosylation;
CRC	cis	rs802075	0.967	rs360563	chr6:49658270	C/T	cg20364632	chr6:49636226	NA	-0.37	-6.07	-0.32	3.46e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg24463073	chr6:118973353	C6orf204	0.48	6.22	0.32	1.49e-9	Diastolic blood pressure;
CRC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.51	8.58	0.43	3.74e-16	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg09659197	chr4:152720779	NA	0.38	7.96	0.4	2.84e-14	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16388829	chr2:97202323	ARID5A	-0.6	-7.33	-0.37	1.77e-12	Diisocyanate-induced asthma;
CRC	cis	rs7429990	0.965	rs7426976	chr3:48022573	A/C	cg11946769	chr3:48343235	NME6	-0.43	-5.71	-0.3	2.58e-8	Educational attainment (years of education);
CRC	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-13.73	-0.6	3.19e-34	Ulcerative colitis;
CRC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.62	0.43	2.87e-16	Neuroticism;
CRC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg22903471	chr2:27725779	GCKR	0.33	5.66	0.3	3.37e-8	Oral cavity cancer;
CRC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.67	-0.39	1.95e-13	Response to antipsychotic treatment;
CRC	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.11	-0.32	2.86e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.62	-7.26	-0.37	2.77e-12	Ulcerative colitis;
CRC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.3	3.66e-8	Hemoglobin concentration;
CRC	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg19773385	chr1:10388646	KIF1B	-0.49	-7.86	-0.4	5.57e-14	Hepatocellular carcinoma;
CRC	cis	rs7274811	0.711	rs291691	chr20:32002878	G/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.8	0.3	1.59e-8	Height;
CRC	cis	rs7626444	0.584	rs844542	chr3:196479303	C/T	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.66	13.02	0.58	1.5e-31	Menarche (age at onset);
CRC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-13.42	-0.59	4.59e-33	Vitiligo;
CRC	cis	rs2252790	1.000	rs13214667	chr6:116637440	G/A	cg18764771	chr6:116381957	FRK	0.22	5.75	0.3	2e-8	Fast beta electroencephalogram;
CRC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	0.7	6.3	0.33	9.27e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18402987	chr7:1209562	NA	0.46	6.78	0.35	5.72e-11	Longevity;Endometriosis;
CRC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.06	-12.17	-0.56	2.23e-28	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.47	-0.46	5.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.62	-0.43	2.8e-16	Uric acid levels;
CRC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg11204139	chr17:3907470	NA	0.74	13.07	0.58	1.01e-31	Type 2 diabetes;
CRC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.41	7.99	0.4	2.23e-14	Mean corpuscular volume;
CRC	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.46	7.0	0.36	1.46e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.73	11.53	0.54	4.47e-26	Colorectal cancer;
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg09597638	chr17:3907349	NA	0.64	11.62	0.54	2.26e-26	Type 2 diabetes;
CRC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.93	-0.31	7.82e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg00666640	chr1:248458726	OR2T12	0.43	7.64	0.39	2.34e-13	Common traits (Other);
CRC	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.58	-8.0	-0.4	2.18e-14	Waist circumference;Body mass index;
CRC	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.41	-7.37	-0.38	1.37e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04407579	chr13:99228509	STK24	-0.41	-6.34	-0.33	7.39e-10	Myopia (pathological);
CRC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.77	13.31	0.59	1.28e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4523957	0.820	rs9908972	chr17:2103810	A/C	cg16513277	chr17:2031491	SMG6	-0.52	-8.63	-0.43	2.58e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27301249	chr20:44718793	NCOA5	-0.51	-6.25	-0.33	1.28e-9	Diisocyanate-induced asthma;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04871131	chr7:94954202	PON1	-0.6	-9.53	-0.47	3.66e-19	Paraoxonase activity;
CRC	cis	rs1519814	1.000	rs7000103	chr8:121166200	A/C	cg22335954	chr8:121166405	COL14A1	-0.59	-6.84	-0.35	3.81e-11	Breast cancer;
CRC	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg16070018	chr6:26224392	HIST1H3E	0.67	5.69	0.3	2.76e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-15.15	-0.64	1.04e-39	Body mass index;
CRC	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.47	-6.29	-0.33	1.01e-9	Serum thyroid-stimulating hormone levels;
CRC	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.66	-0.34	1.12e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	7.73	0.39	1.35e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg07699608	chr10:75541558	CHCHD1	0.61	6.38	0.33	5.97e-10	Incident atrial fibrillation;
CRC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.82e-9	Height;
CRC	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg06223162	chr1:101003688	GPR88	-0.35	-6.31	-0.33	8.77e-10	Monocyte count;
CRC	trans	rs2303319	0.504	rs55782047	chr2:162440255	A/C	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.21	-0.32	1.64e-9	Cognitive function;
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.69	-9.82	-0.48	3.99e-20	Longevity;
CRC	cis	rs990171	0.955	rs3817465	chr2:103039584	A/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.78	0.3	1.69e-8	Lymphocyte counts;
CRC	cis	rs4711336	0.967	rs4713658	chr6:33667117	C/G	cg14003231	chr6:33640908	ITPR3	0.44	7.0	0.36	1.44e-11	Height;
CRC	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg05562828	chr17:3906858	NA	0.73	13.99	0.61	3.12e-35	Type 2 diabetes;
CRC	trans	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg20935933	chr6:143382018	AIG1	0.49	6.46	0.34	3.8e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.13	0.32	2.58e-9	Bipolar disorder;
CRC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.74	10.47	0.5	2.54e-22	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25346583	chr19:16296095	FAM32A	0.52	7.66	0.39	2.07e-13	Intelligence (multi-trait analysis);
CRC	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	7.89	0.4	4.54e-14	Breast cancer;
CRC	cis	rs6764363	0.527	rs13060510	chr3:279638	T/A	cg02057681	chr3:285234	CHL1	0.42	7.12	0.37	6.65e-12	Sudden cardiac arrest;
CRC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25517755	chr10:38738941	LOC399744	-0.45	-6.49	-0.34	3.25e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07208322	chr5:177027175	B4GALT7	0.45	6.37	0.33	6.31e-10	Anxiety disorder;
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.58	-11.02	-0.52	3e-24	Educational attainment;
CRC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg19773385	chr1:10388646	KIF1B	-0.57	-7.89	-0.4	4.53e-14	Hepatocellular carcinoma;
CRC	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	1.05	21.76	0.77	1.12e-65	Multiple myeloma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02184338	chr7:101331866	NA	0.43	6.97	0.36	1.72e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.2e-9	Bipolar disorder;
CRC	cis	rs7107770	1.000	rs35183670	chr11:125090912	G/A	cg27629782	chr11:125073726	PKNOX2	0.48	5.82	0.31	1.39e-8	Photic sneeze reflex;
CRC	cis	rs12580194	0.593	rs67934812	chr12:55785591	T/G	cg19537932	chr12:55886519	OR6C68	-0.72	-9.08	-0.45	9.94e-18	Cancer;
CRC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.23	-0.41	4.36e-15	Gut microbiome composition (summer);
CRC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.41	6.7	0.35	9.29e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg26608667	chr7:1196370	ZFAND2A	0.42	6.85	0.35	3.54e-11	Longevity;Endometriosis;
CRC	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.39	7.36	0.38	1.45e-12	Panic disorder;
CRC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.6	9.85	0.48	3.25e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13736514	chr6:26305472	NA	-0.47	-7.63	-0.39	2.5e-13	Educational attainment;
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg20041105	chr8:143859282	LYNX1	0.46	8.24	0.41	4.25e-15	Urinary tract infection frequency;
CRC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-11.28	-0.53	3.58e-25	Gut microbiome composition (summer);
CRC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg11189052	chr15:85197271	WDR73	-0.63	-8.99	-0.44	2.05e-17	Schizophrenia;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.14	0.32	2.33e-9	Parkinson's disease;
CRC	cis	rs12476592	0.543	rs10170988	chr2:63650582	T/C	cg10828910	chr2:63850056	LOC388955	0.52	6.26	0.33	1.19e-9	Childhood ear infection;
CRC	cis	rs17092148	0.790	rs6058079	chr20:33142873	G/A	cg08999081	chr20:33150536	PIGU	0.5	6.44	0.33	4.27e-10	Neuroticism;
CRC	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.33	5.84	0.31	1.26e-8	Monocyte count;
CRC	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg16358738	chr2:241808595	AGXT	0.38	6.64	0.34	1.27e-10	Urinary metabolites;
CRC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.67	0.43	2.06e-16	Rheumatoid arthritis;
CRC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.42	-9.48	-0.46	5.05e-19	Blood protein levels;
CRC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	10.96	0.52	4.9299999999999996e-24	Neutrophil percentage of white cells;
CRC	cis	rs7703744	0.634	rs3797340	chr5:118691737	C/G	cg17471836	chr5:118691007	TNFAIP8	0.43	6.07	0.32	3.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.5	-7.79	-0.39	9.07e-14	Type 2 diabetes;
CRC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.83	-0.55	3.9e-27	Type 2 diabetes;
CRC	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.6	-9.23	-0.45	3.42e-18	Myopia (pathological);
CRC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg07713946	chr22:31675144	LIMK2	0.4	5.74	0.3	2.16e-8	Colorectal cancer;
CRC	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.48	8.57	0.43	4.01e-16	Information processing speed;
CRC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.01	-0.31	5.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.47	-7.0	-0.36	1.46e-11	Tonsillectomy;
CRC	cis	rs1223397	0.524	rs2496152	chr6:13314547	A/G	cg07912922	chr6:13274314	PHACTR1	0.36	5.69	0.3	2.83e-8	Blood pressure;
CRC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.37	-6.92	-0.36	2.34e-11	Iron status biomarkers;
CRC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg12386194	chr3:101231763	SENP7	0.48	6.86	0.35	3.45e-11	Colorectal cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18756060	chr2:27294719	LOC100128731	0.45	6.33	0.33	8.25e-10	Anxiety disorder;
CRC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.5e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.59	-9.85	-0.48	3.17e-20	Dupuytren's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20312087	chr8:145754193	MGC70857	0.38	6.09	0.32	3.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.54e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.72	7.09	0.36	8.19e-12	Type 2 diabetes;
CRC	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.04	0.36	1.15e-11	Bipolar disorder;
CRC	cis	rs2811415	0.597	rs9827421	chr3:127775499	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.59	8.59	0.43	3.42e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.58	7.08	0.36	8.82e-12	Vitiligo;
CRC	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.43	-0.42	1.12e-15	Monocyte percentage of white cells;
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.56	0.75	5.48e-61	Prudent dietary pattern;
CRC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg03161606	chr19:29218774	NA	0.54	6.38	0.33	5.85e-10	Methadone dose in opioid dependence;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16956456	chr5:172483378	C5orf41	-0.51	-6.27	-0.33	1.12e-9	Diisocyanate-induced asthma;
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.59e-14	Bipolar disorder;
CRC	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.71	7.18	0.37	4.79e-12	Severe influenza A (H1N1) infection;
CRC	cis	rs17767392	0.881	rs10138557	chr14:72061718	C/T	cg13720639	chr14:72061746	SIPA1L1	0.56	7.1	0.36	7.55e-12	Mitral valve prolapse;
CRC	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.46	8.23	0.41	4.37e-15	Blood metabolite ratios;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13047869	chr3:10149882	C3orf24	0.5	6.68	0.35	1.02e-10	Alzheimer's disease;
CRC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs3741151	0.892	rs7105705	chr11:73012319	T/G	cg17517138	chr11:73019481	ARHGEF17	0.69	7.26	0.37	2.85e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.91	-17.02	-0.68	4.88e-47	Body mass index;
CRC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.48	-0.46	5.24e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.43	9.5	0.46	4.37e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs2274273	0.624	rs7150234	chr14:55802181	A/G	cg10130446	chr14:55658398	DLGAP5	-0.44	-6.16	-0.32	2.12e-9	Protein biomarker;
CRC	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.4	-0.33	5.48e-10	QT interval;
CRC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.43	6.66	0.34	1.14e-10	Cleft lip with or without cleft palate;
CRC	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.55	9.56	0.47	2.9e-19	Common traits (Other);
CRC	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg08632701	chr21:37451849	NA	0.46	7.24	0.37	3.11e-12	Mitral valve prolapse;
CRC	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.57	8.81	0.44	7.4e-17	Pancreatic cancer;
CRC	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.38	-5.66	-0.3	3.31e-8	Mean corpuscular volume;
CRC	trans	rs3118914	1.000	rs3116603	chr13:51112122	G/C	cg09222023	chr3:138669322	C3orf72	0.35	6.0	0.31	5.18e-9	Height;
CRC	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.76	-0.3	1.98e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12760731	0.720	rs11805590	chr1:178308911	A/G	cg00404053	chr1:178313656	RASAL2	0.87	9.55	0.47	3.1e-19	Obesity-related traits;
CRC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg16070018	chr6:26224392	HIST1H3E	0.6	5.82	0.31	1.38e-8	Gout;Renal underexcretion gout;
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.84	14.68	0.63	7.14e-38	Blood protein levels;
CRC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4272382	1	rs4272382	chr8:8433488	C/T	cg19996406	chr8:8318774	NA	0.43	5.77	0.3	1.88e-8	Response to cytidine analogues (gemcitabine);
CRC	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.83	-10.39	-0.5	4.76e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.43	-6.2	-0.32	1.65e-9	Calcium levels;
CRC	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.97	11.41	0.53	1.27e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12745968	0.589	rs10874727	chr1:93103152	T/C	cg17283838	chr1:93427260	FAM69A	-0.45	-6.18	-0.32	1.94e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21194808	chr1:2205498	SKI	-0.42	-6.76	-0.35	6.42e-11	Coronary artery disease;
CRC	cis	rs4731207	0.564	rs12531996	chr7:124619460	T/C	cg23710748	chr7:124431027	NA	-0.4	-6.23	-0.32	1.46e-9	Cutaneous malignant melanoma;
CRC	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg04586622	chr2:25135609	ADCY3	-0.55	-9.37	-0.46	1.22e-18	Body mass index;
CRC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.61	8.62	0.43	2.94e-16	Height;
CRC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.38	-6.85	-0.35	3.62e-11	Monocyte count;
CRC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-7.06	-0.36	9.89e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.66	6.9	0.36	2.62e-11	Coronary artery disease;
CRC	cis	rs12760731	0.641	rs10047148	chr1:178250266	T/C	cg00404053	chr1:178313656	RASAL2	0.96	10.07	0.49	5.59e-21	Obesity-related traits;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.43	7.03	0.36	1.2e-11	Longevity;
CRC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.69	11.99	0.55	1.02e-27	Resting heart rate;
CRC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.54e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.14	0.41	8.41e-15	Menopause (age at onset);
CRC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg08614441	chr13:113633676	MCF2L	-0.52	-9.27	-0.46	2.54e-18	Systolic blood pressure;
CRC	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.71	-6.92	-0.36	2.4e-11	Putamen volume;
CRC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.79	-9.76	-0.47	6.29e-20	Multiple sclerosis;
CRC	cis	rs1223397	1.000	rs1232392	chr6:13272671	C/G	cg06879394	chr6:13274151	PHACTR1	0.55	6.63	0.34	1.39e-10	Blood pressure;
CRC	cis	rs10878977	0.542	rs9645827	chr12:69814495	G/A	cg20891283	chr12:69753455	YEATS4	-0.6	-5.92	-0.31	8.13e-9	Colorectal cancer;
CRC	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12560992	chr17:57184187	TRIM37	0.53	7.22	0.37	3.69e-12	Testicular germ cell tumor;
CRC	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.52	7.72	0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.45	-7.32	-0.37	1.97e-12	Lung function (FVC);
CRC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg12193833	chr17:30244370	NA	-0.63	-7.95	-0.4	3.01e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02359409	chr6:42947317	PEX6	-0.65	-10.29	-0.49	1.06e-21	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs720844	0.882	rs7599758	chr2:149293880	C/T	cg09247360	chr2:149335327	NA	-0.55	-6.74	-0.35	7.22e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.29	6.1	0.32	2.99e-9	Migraine;
CRC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg17294928	chr15:75287854	SCAMP5	0.51	7.95	0.4	3.04e-14	Breast cancer;
CRC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.48	9.64	0.47	1.54e-19	Schizophrenia;
CRC	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.46	6.53	0.34	2.42e-10	Plateletcrit;Platelet count;
CRC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-0.92	-15.9	-0.66	1.24e-42	Body mass index;
CRC	trans	rs587242	1.000	rs552032	chr1:96895482	G/C	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.02	-0.4	1.81e-14	Axial length;
CRC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg21153622	chr11:89784906	NA	-0.52	-8.71	-0.43	1.46e-16	HDL cholesterol;
CRC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.53	7.66	0.39	2.08e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	5.91	0.31	8.74e-9	Menopause (age at onset);
CRC	cis	rs2336384	1.000	rs7551874	chr1:12048130	A/G	cg13216073	chr1:12042593	MFN2	0.48	7.02	0.36	1.26e-11	Platelet count;
CRC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.67	9.85	0.48	3.15e-20	Bipolar disorder;
CRC	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.51	7.28	0.37	2.4e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2836754	1.000	rs2836754	chr21:40291740	C/T	cg20434300	chr21:40194735	ETS2	0.35	6.12	0.32	2.73e-9	Crohn's disease;Body mass index;
CRC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg25204440	chr1:209979598	IRF6	0.5	7.08	0.36	8.78e-12	Cleft lip with or without cleft palate;
CRC	cis	rs8037137	0.915	rs79548680	chr15:91505779	G/C	cg23684204	chr15:91497937	RCCD1	0.51	5.6	0.3	4.43e-8	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CRC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.72	11.02	0.52	2.94e-24	Gestational age at birth (maternal effect);
CRC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg23957660	chr17:17878224	LRRC48	0.42	7.66	0.39	2.03e-13	Total body bone mineral density;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-6.04	-0.32	4.17e-9	Lymphocyte counts;
CRC	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.64	9.28	0.46	2.37e-18	Schizophrenia;
CRC	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.82	0.44	6.97e-17	Dupuytren's disease;
CRC	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg00105475	chr2:10696890	NA	0.45	7.28	0.37	2.43e-12	Prostate cancer;
CRC	trans	rs4325129	1.000	rs7555008	chr1:159457808	T/C	cg01965939	chr5:148442694	SH3TC2	-0.28	-6.04	-0.32	4.18e-9	Obesity-related traits;
CRC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06544989	chr22:39130855	UNC84B	0.49	7.78	0.39	9.32e-14	Menopause (age at onset);
CRC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.81	14.4	0.62	8.66e-37	Vitiligo;
CRC	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.38	-11.56	-0.54	3.59e-26	Psoriasis vulgaris;
CRC	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.2	0.32	1.66e-9	Systemic lupus erythematosus;
CRC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.26	-0.45	2.65e-18	Schizophrenia;
CRC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg10911889	chr6:126070802	HEY2	0.39	5.92	0.31	7.99e-9	Brugada syndrome;
CRC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg14541582	chr5:601475	NA	-0.33	-6.51	-0.34	2.76e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7605827	0.930	rs6431696	chr2:15540009	C/A	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-0.68	-6.99	-0.36	1.58e-11	Schizophrenia;
CRC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.55	8.16	0.41	7.31e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg23298862	chr7:158159286	PTPRN2	0.37	5.71	0.3	2.49e-8	Calcium levels;
CRC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.44	7.13	0.37	6.38e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg07884673	chr3:53033167	SFMBT1	-0.75	-6.24	-0.33	1.33e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs4731207	0.967	rs2299902	chr7:124397814	G/T	cg23710748	chr7:124431027	NA	0.39	6.26	0.33	1.18e-9	Cutaneous malignant melanoma;
CRC	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg13611204	chr9:139324423	INPP5E	-0.41	-5.78	-0.3	1.71e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.87	-0.31	1.07e-8	Neuroticism;
CRC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.42	-6.28	-0.33	1.08e-9	Obesity-related traits;
CRC	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.4	5.92	0.31	8.3e-9	Breast cancer;
CRC	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg03948781	chr1:205179583	DSTYK	0.42	5.86	0.31	1.1e-8	Red blood cell count;
CRC	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg00071950	chr4:10020882	SLC2A9	0.42	6.36	0.33	6.85e-10	Blood metabolite levels;
CRC	cis	rs965469	0.619	rs6037565	chr20:3330308	T/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.86	-0.35	3.5e-11	Dupuytren's disease;
CRC	cis	rs61677309	1.000	rs61706007	chr11:118167278	T/G	cg06090739	chr11:118230722	UBE4A	0.41	5.67	0.3	3.21e-8	Lung cancer in ever smokers;
CRC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg25204440	chr1:209979598	IRF6	0.48	5.65	0.3	3.57e-8	Cleft lip with or without cleft palate;
CRC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.53	8.1	0.41	1.05e-14	Sudden cardiac arrest;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.55	9.59	0.47	2.26e-19	Acylcarnitine levels;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.54	-5.65	-0.3	3.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg14003231	chr6:33640908	ITPR3	0.49	8.02	0.4	1.85e-14	Plateletcrit;
CRC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.15	14.73	0.63	4.62e-38	Uric acid levels;
CRC	trans	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg09045935	chr12:6379348	NA	-0.77	-6.19	-0.32	1.8e-9	Blood metabolite levels;
CRC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.16	23.69	0.79	4.09e-73	IgG glycosylation;
CRC	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.47	6.38	0.33	6.16e-10	Cholesterol, total;
CRC	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.8	-0.39	8.43e-14	Bipolar disorder;
CRC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.41	-0.38	1.09e-12	Schizophrenia;
CRC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.51	7.88	0.4	4.68e-14	Height;
CRC	cis	rs8130944	0.859	rs11700836	chr21:44112463	A/G	cg23590273	chr21:44105265	PDE9A	-0.35	-5.62	-0.3	3.99e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	11.21	0.53	6.56e-25	Nonalcoholic fatty liver disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06557630	chr16:49889701	NA	0.38	6.95	0.36	1.99e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.93	17.54	0.7	4.25e-49	Height;
CRC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg20608306	chr11:116969690	SIK3	0.29	5.72	0.3	2.43e-8	Blood protein levels;
CRC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.88	0.31	1.03e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg12564285	chr5:131593104	PDLIM4	0.33	5.74	0.3	2.15e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.49	7.13	0.37	6.42e-12	Height;
CRC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg09655341	chr17:79618100	PDE6G	-0.37	-6.19	-0.32	1.77e-9	Eye color traits;
CRC	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.45	-5.82	-0.31	1.38e-8	Red blood cell traits;
CRC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg14541582	chr5:601475	NA	-0.32	-7.05	-0.36	1.05e-11	Obesity-related traits;
CRC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg12046867	chr14:103022105	NA	0.76	9.03	0.45	1.44e-17	Platelet count;
CRC	cis	rs9311474	0.652	rs352158	chr3:52217704	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-5.94	-0.31	7.31e-9	Electroencephalogram traits;
CRC	cis	rs9469578	0.636	rs16869463	chr6:33714983	A/G	cg18708504	chr6:33715942	IP6K3	-0.49	-6.03	-0.32	4.28e-9	Phosphorus levels;
CRC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	9.3	0.46	1.98e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12190007	0.508	rs6605539	chr6:169731997	A/T	cg16388071	chr6:169726476	NA	0.46	7.08	0.36	8.72e-12	Obesity-related traits;
CRC	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.9	-16.29	-0.67	3.61e-44	Longevity;
CRC	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.77	11.46	0.53	8.33e-26	Intelligence (multi-trait analysis);
CRC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.87	0.44	4.85e-17	Homoarginine levels;
CRC	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.07	-14.92	-0.64	8.66e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg10790698	chr19:18539756	SSBP4	-0.43	-8.19	-0.41	5.83e-15	Breast cancer;
CRC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.83e-13	Corneal astigmatism;
CRC	cis	rs12541635	0.677	rs6469026	chr8:107006356	T/C	cg10147462	chr8:107024639	NA	0.57	9.51	0.46	4.12e-19	Age of smoking initiation;
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg07404485	chr7:94953653	PON1	-0.47	-6.05	-0.32	3.87e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24308560	chr3:49941425	MST1R	-0.49	-7.65	-0.39	2.21e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	0.84	9.03	0.45	1.5e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.3	0.42	2.69e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6504622	1.000	rs4968285	chr17:45015632	T/C	cg16759221	chr17:45003025	GOSR2	0.45	7.09	0.36	8.29e-12	Orofacial clefts;
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg21856205	chr7:94953877	PON1	-0.52	-6.67	-0.35	1.06e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.54	-8.34	-0.42	1.99e-15	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11035813	chr11:71159731	DHCR7	0.42	5.96	0.31	6.34e-9	Response to antipsychotic treatment;
CRC	cis	rs4664293	0.967	rs9646765	chr2:160565648	T/C	cg08347373	chr2:160653686	CD302	-0.44	-7.19	-0.37	4.33e-12	Monocyte percentage of white cells;
CRC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.48	7.43	0.38	9.59e-13	Mood instability;
CRC	cis	rs4664293	0.867	rs6740910	chr2:160649220	G/A	cg08347373	chr2:160653686	CD302	-0.51	-7.97	-0.4	2.62e-14	Monocyte percentage of white cells;
CRC	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg11038491	chr20:34638489	LOC647979	-0.67	-8.44	-0.42	1.03e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.34	7.73	0.39	1.3e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.62	10.12	0.49	3.83e-21	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.25e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg15571903	chr15:79123663	NA	0.31	6.21	0.32	1.61e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.37	6.48	0.34	3.38e-10	Primary biliary cholangitis;
CRC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg20119798	chr7:94954144	PON1	-0.44	-5.69	-0.3	2.8e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg10876282	chr6:28092338	ZSCAN16	0.48	6.51	0.34	2.81e-10	Parkinson's disease;
CRC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg06462663	chr19:18546047	ISYNA1	0.5	7.39	0.38	1.26e-12	Breast cancer;
CRC	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg09695851	chr17:3907499	NA	0.84	16.63	0.68	1.62e-45	Type 2 diabetes;
CRC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.82	-14.63	-0.63	1.1e-37	Colorectal cancer;
CRC	cis	rs7945718	0.621	rs11022465	chr11:12686139	C/T	cg25843174	chr11:12811716	TEAD1	-0.39	-7.26	-0.37	2.87e-12	Educational attainment (years of education);
CRC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg15468180	chr1:107600409	PRMT6	0.43	6.41	0.33	5.13e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg01843034	chr6:37503916	NA	-0.44	-8.28	-0.42	3.2e-15	Cognitive performance;
CRC	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.56	8.65	0.43	2.28e-16	Monobrow;
CRC	cis	rs9938149	0.736	rs7501109	chr16:88320862	C/G	cg05435882	chr16:88311214	NA	0.45	6.02	0.32	4.61e-9	Corneal structure;Central corneal thickness;
CRC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.56	9.45	0.46	6.32e-19	Schizophrenia;
CRC	cis	rs9311676	0.632	rs12487420	chr3:58399511	A/G	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg18551225	chr6:44695536	NA	-0.41	-5.97	-0.31	6.18e-9	Total body bone mineral density;
CRC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.51	8.66	0.43	2.15e-16	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06473843	chr1:32757546	HDAC1	0.42	6.62	0.34	1.49e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg19875578	chr6:126661172	C6orf173	0.44	6.21	0.32	1.64e-9	Male-pattern baldness;
CRC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg00343986	chr7:65444356	GUSB	0.43	6.2	0.32	1.7e-9	Aortic root size;
CRC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.67	-0.39	1.95e-13	Coronary artery disease;
CRC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.88	-0.44	4.49e-17	Joint mobility (Beighton score);
CRC	trans	rs10242455	0.571	rs13438288	chr7:98916414	T/G	cg09045935	chr12:6379348	NA	0.94	7.24	0.37	3.29e-12	Blood metabolite levels;
CRC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.75	-0.43	1.12e-16	Aortic root size;
CRC	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg19688584	chr6:167529678	CCR6	-0.35	-6.37	-0.33	6.26e-10	Primary biliary cholangitis;
CRC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.43	7.35	0.38	1.61e-12	Rheumatoid arthritis;
CRC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.45	-0.42	9.43e-16	Height;
CRC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.61	9.04	0.45	1.41e-17	Lung cancer;
CRC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.4	-5.95	-0.31	7.01e-9	Lymphocyte counts;
CRC	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg02353165	chr6:42928485	GNMT	0.54	6.91	0.36	2.57e-11	Blood protein levels;
CRC	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg26816564	chr1:7831052	VAMP3	0.85	9.29	0.46	2.2e-18	Inflammatory bowel disease;
CRC	trans	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.21	-0.32	1.63e-9	Aortic root size;
CRC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.38	-0.42	1.56e-15	Personality dimensions;
CRC	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.51	-7.45	-0.38	8.22e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.26	-0.37	2.84e-12	Capecitabine sensitivity;
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.76	14.12	0.61	1.01e-35	Prudent dietary pattern;
CRC	cis	rs6496667	0.600	rs62019401	chr15:91071855	C/T	cg04176472	chr15:90893244	GABARAPL3	0.49	7.4	0.38	1.18e-12	Rheumatoid arthritis;
CRC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.47	-8.28	-0.42	3.11e-15	Dupuytren's disease;
CRC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg02018176	chr4:1364513	KIAA1530	0.39	6.58	0.34	1.82e-10	Obesity-related traits;
CRC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.02	-0.36	1.29e-11	IgG glycosylation;
CRC	trans	rs7027930	0.524	rs11791403	chr9:604686	C/T	cg27061366	chr19:13044373	FARSA	0.51	6.36	0.33	6.93e-10	Pulmonary function decline;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24642196	chr1:161136063	PPOX	0.4	6.13	0.32	2.58e-9	Schizophrenia;
CRC	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.91	17.51	0.69	5.67e-49	Lewy body disease;
CRC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.5	-0.54	5.99e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg14458575	chr2:238380390	NA	0.51	7.09	0.36	8.12e-12	Prostate cancer;
CRC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.77	-0.35	5.76e-11	Response to antipsychotic treatment;
CRC	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg22495460	chr2:25135724	ADCY3	-0.84	-16.2	-0.67	8.51e-44	Body mass index;
CRC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg11168104	chr5:1857477	NA	-0.38	-6.59	-0.34	1.79e-10	Cardiovascular disease risk factors;
CRC	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.78	-8.5	-0.42	6.72e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg09491104	chr22:46646882	C22orf40	-0.39	-5.88	-0.31	1.03e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.59	-9.59	-0.47	2.25e-19	Idiopathic membranous nephropathy;
CRC	cis	rs758324	0.812	rs13165154	chr5:131155020	C/T	cg25547332	chr5:131281432	NA	0.36	5.69	0.3	2.81e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.68	-0.35	1.01e-10	Breast cancer;
CRC	cis	rs1712517	0.503	rs72846198	chr10:105098024	G/A	cg04362960	chr10:104952993	NT5C2	-0.46	-6.06	-0.32	3.73e-9	Migraine;
CRC	trans	rs587242	1.000	rs7543590	chr1:96892216	T/C	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs10982256	0.905	rs10982255	chr9:117255744	C/T	cg13636371	chr9:117264095	DFNB31	0.39	7.46	0.38	7.99e-13	Bipolar disorder;
CRC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-7.4	-0.38	1.17e-12	Colorectal cancer;
CRC	cis	rs7605827	0.930	rs7588148	chr2:15706392	G/A	cg19274914	chr2:15703543	NA	0.41	6.14	0.32	2.43e-9	Educational attainment (years of education);
CRC	cis	rs13144136	0.687	rs11723949	chr4:10658093	G/T	cg10242279	chr4:10666415	CLNK	-0.39	-6.63	-0.34	1.39e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12172441	chr6:28176163	NA	0.6	7.38	0.38	1.33e-12	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.71	0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.37	-0.33	6.46e-10	Blood metabolite levels;
CRC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.61	-8.03	-0.4	1.73e-14	Body mass index;
CRC	cis	rs860295	0.665	rs11264393	chr1:155574471	C/A	cg02153340	chr1:155202674	NA	-0.51	-6.43	-0.33	4.4e-10	Body mass index;
CRC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.64	9.58	0.47	2.38e-19	Selective IgA deficiency;
CRC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	12.26	0.56	1.03e-28	Menopause (age at onset);
CRC	cis	rs4731207	0.698	rs6466955	chr7:124518766	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.14	-0.32	2.36e-9	Cutaneous malignant melanoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13980007	chr1:61547494	NFIA	0.44	6.59	0.34	1.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.76	-10.7	-0.51	4.01e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.63	9.01	0.44	1.71e-17	Schizophrenia;
CRC	cis	rs9303542	0.559	rs12947405	chr17:46614755	C/T	cg04904318	chr17:46607828	HOXB1	-0.53	-6.2	-0.32	1.68e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.83	-14.64	-0.63	1.03e-37	Coronary artery disease;
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.48	-6.62	-0.34	1.49e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg15848620	chr12:58087721	OS9	-0.65	-8.91	-0.44	3.64e-17	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00699235	chr12:49962218	MCRS1	-0.39	-5.96	-0.31	6.44e-9	Aortic root size;
CRC	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg14092571	chr14:90743983	NA	0.39	5.98	0.31	5.81e-9	Mortality in heart failure;
CRC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.23	-0.41	4.34e-15	Bipolar disorder;
CRC	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.41	6.7	0.35	9.3e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.63	-0.34	1.36e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg02683197	chr6:28174875	NA	0.75	9.78	0.47	5.25e-20	Parkinson's disease;
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg24829409	chr8:58192753	C8orf71	-0.55	-7.79	-0.39	8.58e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.34	6.26	0.33	1.22e-9	Panic disorder;
CRC	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.53	9.62	0.47	1.75e-19	Common traits (Other);
CRC	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.56	10.05	0.48	6.72e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23312964	chr11:47430184	SLC39A13	0.46	6.34	0.33	7.68e-10	Anxiety disorder;
CRC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.88	-0.31	1e-8	Intelligence (multi-trait analysis);
CRC	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg11993925	chr19:44307056	LYPD5	-0.38	-6.2	-0.32	1.64e-9	Breast cancer;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg04518342	chr5:131593106	PDLIM4	0.36	6.73	0.35	7.48e-11	Blood metabolite levels;
CRC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.84	15.62	0.65	1.53e-41	Metabolic syndrome;
CRC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg14541582	chr5:601475	NA	-0.33	-6.59	-0.34	1.73e-10	Obesity-related traits;
CRC	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.21	-0.32	1.58e-9	Blood pressure;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg11951909	chr7:158497997	NCAPG2	-0.48	-7.31	-0.37	2.04e-12	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs3824347	0.839	rs4745372	chr9:77584225	G/A	cg01251476	chr9:77566080	C9orf40	0.37	5.7	0.3	2.63e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.57	8.71	0.43	1.46e-16	Blood metabolite levels;
CRC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg26695010	chr11:65641043	EFEMP2	0.48	7.47	0.38	7.46e-13	Eosinophil percentage of white cells;
CRC	cis	rs972578	0.806	rs8137128	chr22:43385996	A/T	cg01576275	chr22:43409880	NA	-0.48	-7.68	-0.39	1.87e-13	Mean platelet volume;
CRC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.44	-6.13	-0.32	2.45e-9	Coronary artery disease;
CRC	cis	rs713477	0.678	rs4901566	chr14:55912663	C/A	cg21836586	chr14:55907198	TBPL2	0.31	5.73	0.3	2.26e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.53	8.88	0.44	4.27e-17	Breast cancer;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg03790207	chr6:42947109	PEX6	-0.44	-6.17	-0.32	2.02e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.26	12.94	0.58	3.06e-31	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.42	-0.33	4.62e-10	Type 2 diabetes;
CRC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg03037974	chr15:76606532	NA	-0.54	-7.97	-0.4	2.68e-14	Blood metabolite levels;
CRC	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.55	7.57	0.38	3.91e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.54	8.82	0.44	6.85e-17	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15045943	chr5:171614719	STK10	0.59	7.96	0.4	2.77e-14	Thyroid stimulating hormone;
CRC	cis	rs4731207	0.671	rs10085867	chr7:124486168	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.39	-0.38	1.19e-12	Monocyte percentage of white cells;
CRC	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg08632701	chr21:37451849	NA	-0.43	-6.74	-0.35	7e-11	Mitral valve prolapse;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24076778	chr1:151512662	TUFT1	0.44	6.44	0.33	4.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.56	-0.34	2.06e-10	Coronary artery disease;
CRC	cis	rs6968419	0.755	rs10500059	chr7:115900394	C/T	cg02561103	chr7:115862891	TES	-0.44	-6.55	-0.34	2.21e-10	Intraocular pressure;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg12172441	chr6:28176163	NA	0.49	6.29	0.33	9.97e-10	Parkinson's disease;
CRC	cis	rs3026101	0.624	rs1058398	chr17:5288760	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.4	-6.69	-0.35	9.63e-11	Body mass index;
CRC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg23018236	chr17:30244563	NA	-0.49	-6.51	-0.34	2.73e-10	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16921014	chr4:146403948	SMAD1	0.39	5.99	0.31	5.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg12516270	chr8:143859308	LYNX1	0.44	7.79	0.39	8.89e-14	Urinary tract infection frequency;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10598356	chr15:63797185	USP3	0.47	7.33	0.37	1.81e-12	Schizophrenia;
CRC	cis	rs6496667	0.779	rs7181256	chr15:90966518	T/C	cg04176472	chr15:90893244	GABARAPL3	0.58	8.17	0.41	6.49e-15	Rheumatoid arthritis;
CRC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.62	9.58	0.47	2.44e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg07402062	chr16:89894098	SPIRE2	-0.44	-5.79	-0.3	1.63e-8	Vitiligo;
CRC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15369054	chr17:80825471	TBCD	-0.35	-5.86	-0.31	1.13e-8	Breast cancer;
CRC	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.96	0.4	2.76e-14	Breast cancer;
CRC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24308560	chr3:49941425	MST1R	0.46	7.23	0.37	3.51e-12	Blood protein levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26529371	chr19:12911983	PRDX2	0.34	6.29	0.33	9.9e-10	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17708571	chr19:2151588	AP3D1	0.37	6.38	0.33	6.07e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.2	-0.56	1.7e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.86	13.81	0.61	1.51e-34	Menarche (age at onset);
CRC	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg02820901	chr13:113351484	ATP11A	0.65	7.49	0.38	6.49e-13	Glycated hemoglobin levels;
CRC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.12	0.52	1.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.07	12.89	0.58	4.71e-31	Vitiligo;
CRC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg10589385	chr1:150898437	SETDB1	0.3	6.31	0.33	9.09e-10	Melanoma;
CRC	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.48	6.54	0.34	2.39e-10	Obesity-related traits;
CRC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.4	-0.46	9.54e-19	Platelet count;
CRC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-5.97	-0.31	6.04e-9	Aortic root size;
CRC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg10790698	chr19:18539756	SSBP4	-0.45	-8.6	-0.43	3.27e-16	Breast cancer;
CRC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.95	-19.14	-0.73	2.04e-55	Height;
CRC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-8.99	-0.44	2.05e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg20487152	chr13:99095054	FARP1	-0.41	-6.11	-0.32	2.8e-9	Neuroticism;
CRC	cis	rs10450586	0.863	rs10437622	chr11:27307178	C/T	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	8.22	0.41	4.63e-15	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.43	5.61	0.3	4.28e-8	Protein C levels;
CRC	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	7.2	0.37	4.07e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.38	5.87	0.31	1.08e-8	Myeloid white cell count;
CRC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg03013999	chr17:37608204	MED1	0.47	7.28	0.37	2.48e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21643547	chr1:205240462	TMCC2	-0.42	-7.06	-0.36	9.72e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg16476235	chr8:21771668	DOK2	0.37	5.99	0.31	5.55e-9	Mean corpuscular volume;
CRC	cis	rs2274471	0.645	rs3780375	chr9:5109431	G/A	cg03390472	chr9:5043263	JAK2	-0.55	-6.29	-0.33	9.87e-10	Crohn's disease;
CRC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.69	-8.52	-0.42	5.98e-16	Coronary artery disease;
CRC	trans	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg24644049	chr4:85504048	CDS1	0.92	7.64	0.39	2.42e-13	Skin colour saturation;
CRC	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg25885038	chr17:56607967	SEPT4	-0.5	-7.59	-0.39	3.27e-13	Vitamin D levels;
CRC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.49	-7.57	-0.39	3.74e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.99	0.4	2.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12024301	0.557	rs12037290	chr1:183637038	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2036402	1.000	rs7719994	chr5:156430076	T/C	cg21915449	chr5:156456672	HAVCR1	-0.46	-5.62	-0.3	3.99e-8	Hypertriglyceridemia;
CRC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.56	-7.06	-0.36	1.02e-11	Platelet distribution width;
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg04553112	chr3:125709451	NA	-0.48	-6.14	-0.32	2.33e-9	Blood pressure (smoking interaction);
CRC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg04545296	chr12:48745243	ZNF641	0.36	6.19	0.32	1.81e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.7	8.21	0.41	5.13e-15	Prostate cancer;
CRC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.39	0.38	1.23e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg24375607	chr4:120327624	NA	-0.5	-7.96	-0.4	2.85e-14	Corneal astigmatism;
CRC	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg19537932	chr12:55886519	OR6C68	-0.66	-8.56	-0.43	4.26e-16	Cancer;
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13047869	chr3:10149882	C3orf24	0.53	6.46	0.34	3.76e-10	Alzheimer's disease;
CRC	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11645453	chr3:52864694	ITIH4	0.35	6.36	0.33	6.75e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19105961	chr17:4046223	CYB5D2;ZZEF1	0.48	6.52	0.34	2.68e-10	Hip circumference;
CRC	trans	rs6678914	1.000	rs6678914	chr1:202187176	G/A	cg19977628	chr5:1262072	TERT	0.4	6.0	0.31	5.23e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg04287289	chr16:89883240	FANCA	0.54	8.28	0.42	3.04e-15	Vitiligo;
CRC	cis	rs995000	0.868	rs1168017	chr1:63002551	A/G	cg19896129	chr1:63156450	NA	-0.45	-7.04	-0.36	1.15e-11	Triglyceride levels;
CRC	cis	rs13082711	0.539	rs383135	chr3:27555866	A/G	cg02860705	chr3:27208620	NA	-0.41	-6.08	-0.32	3.34e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.19	12.5	0.57	1.37e-29	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.58	-9.16	-0.45	5.68e-18	Prostate cancer;
CRC	trans	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg10006042	chr16:23042421	NA	0.4	6.21	0.32	1.55e-9	Lung cancer (smoking interaction);
CRC	cis	rs760762	0.506	rs6129731	chr20:39660687	A/C	cg11668512	chr20:39929580	ZHX3	0.37	5.65	0.3	3.47e-8	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
CRC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.67	-11.13	-0.52	1.21e-24	Asthma;
CRC	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-7.79	-0.39	9.06e-14	Obesity (extreme);
CRC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.06	0.32	3.76e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg27121462	chr16:89883253	FANCA	0.56	8.66	0.43	2.17e-16	Vitiligo;
CRC	cis	rs7932354	0.583	rs10838629	chr11:46906845	G/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.42	-0.33	4.75e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.39	-5.97	-0.31	6.1e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg01339444	chr6:118972232	C6orf204	0.51	6.09	0.32	3.24e-9	Diastolic blood pressure;
CRC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg02527881	chr3:46936655	PTH1R	0.39	7.18	0.37	4.82e-12	Colorectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26027482	chr12:1100598	ERC1	0.5	6.46	0.34	3.71e-10	Thyroid stimulating hormone;
CRC	cis	rs4700695	0.841	rs152996	chr5:65256506	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg00129232	chr17:37814104	STARD3	0.54	7.28	0.37	2.54e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-17.46	-0.69	9.32e-49	Schizophrenia;
CRC	cis	rs6896969	0.510	rs6880419	chr5:40428913	C/T	cg09067459	chr5:40385259	NA	0.45	7.75	0.39	1.19e-13	Multiple sclerosis;
CRC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg00129232	chr17:37814104	STARD3	-0.59	-7.21	-0.37	3.76e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-7.48	-0.38	6.89e-13	Colorectal cancer;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02290350	chr8:58132656	NA	0.51	6.42	0.33	4.74e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	0.95	12.76	0.58	1.43e-30	Cannabis dependence symptom count;
CRC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7527798	0.592	rs7539772	chr1:207833301	G/A	cg09232269	chr1:207846808	CR1L	-0.51	-8.12	-0.41	9.14e-15	Erythrocyte sedimentation rate;
CRC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.32	0.37	1.88e-12	Breast cancer;
CRC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	7.28	0.37	2.48e-12	Rheumatoid arthritis;
CRC	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.47	-6.87	-0.35	3.31e-11	Breast cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05643349	chr16:30935108	FBXL19;NCRNA00095	0.56	7.48	0.38	6.78e-13	Hip circumference;
CRC	cis	rs143111788	1	rs143111788	chr6:41919175	CCAGCTACT/C	cg17623882	chr6:41773611	USP49	-0.52	-8.35	-0.42	1.92e-15	Red cell distribution width;
CRC	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg14139581	chr11:64358342	SLC22A12	-0.39	-6.2	-0.32	1.73e-9	Urate levels in obese individuals;
CRC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg18761221	chr20:60518478	NA	0.41	7.38	0.38	1.34e-12	Body mass index;
CRC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.19	-0.41	5.7e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.47	-6.61	-0.34	1.59e-10	Diastolic blood pressure;
CRC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	cis	rs6681460	0.899	rs502690	chr1:67182403	A/T	cg02459107	chr1:67143332	SGIP1	0.38	6.77	0.35	6.1e-11	Presence of antiphospholipid antibodies;
CRC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.19	-13.16	-0.59	4.5e-32	Diabetic kidney disease;
CRC	cis	rs7508679	0.692	rs10413734	chr19:7227871	T/G	cg09779027	chr19:7224513	INSR	-0.94	-15.49	-0.65	5.16e-41	Hypothyroidism;
CRC	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.99	-12.28	-0.56	8.94e-29	Orofacial clefts;
CRC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.0	0.44	1.87e-17	Bladder cancer;
CRC	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg22495460	chr2:25135724	ADCY3	-0.87	-14.86	-0.63	1.4e-38	Body mass index;
CRC	cis	rs2811415	0.597	rs9813824	chr3:127761959	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16010707	chr12:83081048	TMTC2	0.41	6.19	0.32	1.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.43	-8.62	-0.43	2.84e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.65	10.06	0.49	6.07e-21	Methadone dose in opioid dependence;
CRC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.12	-0.32	2.6e-9	Aortic root size;
CRC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg14003231	chr6:33640908	ITPR3	0.44	7.24	0.37	3.12e-12	Plateletcrit;
CRC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-9.08	-0.45	1.02e-17	Blood protein levels;
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg04025307	chr7:1156635	C7orf50	0.64	6.66	0.34	1.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs4730268	0.768	rs79139176	chr7:107438298	C/G	cg18560240	chr7:107437656	SLC26A3	-0.55	-5.7	-0.3	2.69e-8	IgG glycosylation;
CRC	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.23e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs9925964	0.869	rs2288004	chr16:31054040	G/C	cg03418659	chr16:31128414	MYST1	0.47	6.84	0.35	3.8e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg17294928	chr15:75287854	SCAMP5	0.57	8.72	0.43	1.42e-16	Breast cancer;
CRC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.83	-11.71	-0.54	1.07e-26	Cerebrospinal P-tau181p levels;
CRC	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg05283184	chr6:79620031	NA	-0.44	-6.39	-0.33	5.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.47	7.42	0.38	1.02e-12	Eye color traits;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg22677401	chr17:46026860	NA	-0.68	-6.15	-0.32	2.24e-9	Cognitive function;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.75	11.77	0.54	6.44e-27	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16197653	chr6:170101828	WDR27;C6orf120	0.42	6.44	0.33	4.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.5	8.28	0.42	3.07e-15	Lipoprotein (a) levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15674719	chr19:1407747	DAZAP1	0.4	6.42	0.33	4.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg12935359	chr14:103987150	CKB	-0.37	-6.19	-0.32	1.83e-9	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05776488	chr1:231113872	TTC13;ARV1	0.47	6.5	0.34	2.94e-10	Response to antipsychotic treatment;
CRC	cis	rs2908197	0.806	rs6465098	chr7:75972947	T/C	cg10167463	chr7:75959203	YWHAG	-0.41	-6.07	-0.32	3.45e-9	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	6.22	0.32	1.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.68	0.35	1e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.8	-16.02	-0.66	4.21e-43	Prostate cancer;
CRC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs243505	0.737	rs243538	chr7:148404379	G/A	cg09806900	chr7:148480153	CUL1	-0.5	-6.25	-0.33	1.24e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.18	0.41	6.25e-15	Arsenic metabolism;
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.47	7.02	0.36	1.28e-11	Parkinson's disease;
CRC	trans	rs12699921	0.598	rs2691607	chr7:17879103	G/A	cg02066331	chr6:17282778	RBM24	-0.35	-6.08	-0.32	3.38e-9	Fibrinogen levels;
CRC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg20417195	chr1:21767127	NBPF3	0.46	6.93	0.36	2.25e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7737355	0.812	rs548635	chr5:131055546	G/T	cg25547332	chr5:131281432	NA	-0.38	-6.05	-0.32	3.88e-9	Life satisfaction;
CRC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg23996704	chr18:44553084	KATNAL2	-0.34	-7.02	-0.36	1.25e-11	Personality dimensions;
CRC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.83	0.55	3.67e-27	Monocyte percentage of white cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00699235	chr12:49962218	MCRS1	0.51	6.62	0.34	1.48e-10	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.68	10.31	0.49	8.96e-22	Corneal astigmatism;
CRC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg05941027	chr17:61774174	LIMD2	0.35	6.3	0.33	9.71e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.53	-8.3	-0.42	2.63e-15	Intelligence (multi-trait analysis);
CRC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.46	-7.45	-0.38	8.24e-13	Hemoglobin concentration;
CRC	cis	rs2179367	0.919	rs577001	chr6:149646308	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.15	-0.32	2.19e-9	Dupuytren's disease;
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg15534755	chr11:117069859	TAGLN	0.29	5.76	0.3	1.96e-8	Blood protein levels;
CRC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg00086871	chr4:6988644	TBC1D14	0.91	7.75	0.39	1.14e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg14583973	chr4:3374767	RGS12	0.29	5.61	0.3	4.35e-8	Serum sulfate level;
CRC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg12886066	chr13:90015518	NA	0.48	6.46	0.34	3.67e-10	Myocardial infarction;
CRC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	13.48	0.6	2.83e-33	Cognitive ability;
CRC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg26805224	chr10:79626177	DLG5	-0.45	-6.69	-0.35	9.47e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg09582351	chr12:29534625	ERGIC2	-0.28	-6.12	-0.32	2.62e-9	QT interval;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg25952886	chr17:31320651	SPACA3	-0.58	-6.81	-0.35	4.7e-11	Lymphocyte counts;
CRC	trans	rs16846053	0.786	rs62187567	chr2:162363066	G/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.17	-0.32	1.96e-9	Blood osmolality (transformed sodium);
CRC	cis	rs11255291	0.668	rs4749169	chr10:7737661	G/C	cg00997801	chr10:7671259	ITIH5	0.41	6.09	0.32	3.14e-9	Ovarian reserve;
CRC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg19812747	chr11:111475976	SIK2	0.55	9.11	0.45	8e-18	Primary sclerosing cholangitis;
CRC	trans	rs2078087	1.000	rs11577151	chr1:183381795	A/G	cg14266927	chr14:75987682	BATF	-0.61	-6.35	-0.33	7.1e-10	Obesity-related traits;
CRC	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.76	6.62	0.34	1.48e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7725052	0.609	rs10044710	chr5:40444472	A/G	cg09067459	chr5:40385259	NA	-0.39	-6.44	-0.33	4.31e-10	Pediatric autoimmune diseases;
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.45	-0.34	4e-10	Lymphocyte counts;
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg11843238	chr5:131593191	PDLIM4	0.42	7.25	0.37	3.07e-12	Breast cancer;
CRC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg19812747	chr11:111475976	SIK2	-0.47	-7.79	-0.39	8.56e-14	Primary sclerosing cholangitis;
CRC	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-0.94	-8.05	-0.41	1.53e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.59	6.2	0.32	1.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.68	-10.51	-0.5	1.85e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg14979609	chr8:8086686	FLJ10661	-0.36	-5.81	-0.3	1.5e-8	Joint mobility (Beighton score);
CRC	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.73	11.64	0.54	1.85e-26	Plateletcrit;Platelet count;
CRC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.62	-10.01	-0.48	9.02e-21	Aortic root size;
CRC	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg24644049	chr4:85504048	CDS1	0.91	7.97	0.4	2.59e-14	Skin colour saturation;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg21251018	chr6:28226885	NKAPL	0.47	7.29	0.37	2.36e-12	Parkinson's disease;
CRC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.76	-0.35	6.2e-11	Mean corpuscular volume;
CRC	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg20194872	chr6:41519635	FOXP4	0.39	5.65	0.3	3.56e-8	Prostate cancer;
CRC	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.73	0.35	7.42e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg19223190	chr17:80058835	NA	-0.49	-7.81	-0.4	7.58e-14	Life satisfaction;
CRC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg09491104	chr22:46646882	C22orf40	-0.43	-7.15	-0.37	5.66e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	10.43	0.5	3.44e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	18.31	0.71	3.83e-52	Prudent dietary pattern;
CRC	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.7	-8.68	-0.43	1.86e-16	Bone mineral density;
CRC	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg26384229	chr12:38710491	ALG10B	0.43	5.99	0.31	5.4e-9	Morning vs. evening chronotype;
CRC	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	cis	rs10971721	0.822	rs72725398	chr9:33875918	A/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.15	0.32	2.22e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg08027265	chr7:2291960	NA	-0.37	-6.31	-0.33	9.07e-10	Schizophrenia;
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00166722	chr3:10149974	C3orf24	0.67	9.32	0.46	1.71e-18	Alzheimer's disease;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.35	-6.6	-0.34	1.62e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg23262073	chr20:60523788	NA	-0.47	-7.33	-0.37	1.76e-12	Body mass index;
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-8.07	-0.41	1.35e-14	Bipolar disorder;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg10876282	chr6:28092338	ZSCAN16	0.49	6.57	0.34	1.99e-10	Parkinson's disease;
CRC	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.51	-7.01	-0.36	1.36e-11	Tuberculosis;
CRC	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.39	5.8	0.3	1.52e-8	Kawasaki disease;
CRC	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-13.31	-0.59	1.28e-32	Colorectal cancer;
CRC	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.67	11.01	0.52	3.18e-24	Myopia (pathological);
CRC	cis	rs62229266	0.659	rs2835243	chr21:37413946	C/T	cg08632701	chr21:37451849	NA	-0.41	-6.41	-0.33	5.02e-10	Mitral valve prolapse;
CRC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.91	11.05	0.52	2.45e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.53	-0.5	1.57e-22	Alzheimer's disease;
CRC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.33	0.33	8.22e-10	Aortic root size;
CRC	cis	rs6834538	0.520	rs11943167	chr4:113414179	G/A	cg10021238	chr4:113569128	MIR367;LARP7	-0.36	-5.65	-0.3	3.55e-8	Free thyroxine concentration;
CRC	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg13919466	chr1:32135498	COL16A1	-0.31	-5.79	-0.3	1.67e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.23	0.37	3.47e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.46	-0.42	8.74e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25621096	chr1:151032116	CDC42SE1;MLLT11	-0.39	-6.34	-0.33	7.71e-10	Myopia (pathological);
CRC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.67	5.7	0.3	2.61e-8	Putamen volume;
CRC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.78	-12.41	-0.56	2.79e-29	Plateletcrit;Platelet count;
CRC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.58	6.23	0.32	1.44e-9	Urinary 1,3-butadiene metabolite levels in smokers;
CRC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	8.06	0.41	1.44e-14	Height;
CRC	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg14515779	chr1:101123966	NA	0.35	5.88	0.31	1.03e-8	Monocyte count;
CRC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-7.47	-0.38	7.28e-13	HDL cholesterol;
CRC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.03	11.7	0.54	1.15e-26	Vitiligo;
CRC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.28	0.49	1.09e-21	Hemoglobin concentration;
CRC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.47	8.14	0.41	8.25e-15	Primary biliary cholangitis;
CRC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.69	-7.03	-0.36	1.23e-11	Systemic lupus erythematosus;
CRC	cis	rs61996546	0.622	rs35521364	chr15:26867145	G/A	cg15066197	chr15:26874202	GABRB3	-0.39	-5.99	-0.31	5.37e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg06238570	chr21:40685208	BRWD1	0.78	10.76	0.51	2.51e-23	Cognitive function;
CRC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.49	-8.72	-0.43	1.41e-16	Blood metabolite levels;
CRC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.56e-11	Aortic root size;
CRC	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg17470449	chr10:769945	NA	0.51	7.05	0.36	1.03e-11	Uric acid levels;
CRC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-17.3	-0.69	3.95e-48	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg14329157	chr2:228736135	WDR69	-0.48	-6.72	-0.35	8.19e-11	Blood pressure;
CRC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.27	-0.33	1.12e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7731657	0.510	rs10045858	chr5:130251039	C/T	cg08523029	chr5:130500466	HINT1	0.42	5.65	0.3	3.47e-8	Fasting plasma glucose;
CRC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.59	7.38	0.38	1.3e-12	Gut microbiome composition (summer);
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg24634471	chr8:143751801	JRK	-0.46	-6.14	-0.32	2.35e-9	Urinary tract infection frequency;
CRC	cis	rs4888630	0.596	rs7185964	chr16:77484585	A/C	cg10121788	chr16:77469583	ADAMTS18	-0.33	-5.94	-0.31	7.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.45	-6.77	-0.35	6e-11	Cerebrospinal P-tau181p levels;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.51	-7.24	-0.37	3.16e-12	Menopause (age at onset);
CRC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg09835421	chr16:68378352	PRMT7	-0.75	-7.99	-0.4	2.25e-14	Schizophrenia;
CRC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.74	12.49	0.57	1.41e-29	Systemic lupus erythematosus;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.57	8.45	0.42	9.72e-16	Lymphocyte counts;
CRC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.54	-7.7	-0.39	1.6e-13	Mean platelet volume;
CRC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.7	6.36	0.33	6.68e-10	Major depressive disorder;
CRC	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg04920474	chr2:44395004	PPM1B	0.42	6.2	0.32	1.73e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg25164649	chr6:28176230	NA	0.57	7.55	0.38	4.3e-13	Parkinson's disease;
CRC	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg08501292	chr6:25962987	TRIM38	0.65	6.33	0.33	8.03e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.62	-9.98	-0.48	1.2e-20	Aortic root size;
CRC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.56	8.43	0.42	1.12e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg23920097	chr1:209922102	NA	-0.5	-6.49	-0.34	3.25e-10	Red blood cell count;
CRC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg07074390	chr21:40555500	PSMG1	-0.45	-6.03	-0.32	4.5e-9	Cognitive function;
CRC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-10.38	-0.5	5.17e-22	Vitiligo;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17174230	chr11:65337779	SSSCA1	0.46	6.38	0.33	6.04e-10	Anxiety disorder;
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg15382696	chr6:118971807	C6orf204	0.59	7.64	0.39	2.45e-13	Diastolic blood pressure;
CRC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	7.63	0.39	2.55e-13	Gut microbiome composition (summer);
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.58	-10.81	-0.51	1.71e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg22013790	chr1:91990662	CDC7	0.43	5.84	0.31	1.23e-8	Eosinophil percentage of white cells;
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-7.17	-0.37	5.01e-12	Total body bone mineral density;
CRC	cis	rs4731207	0.596	rs7810654	chr7:124645089	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.4	5.68	0.3	3e-8	Erythrocyte sedimentation rate;
CRC	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.27	-0.37	2.69e-12	Cholesterol, total;
CRC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.47	7.5	0.38	5.99e-13	Hemoglobin concentration;
CRC	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.72	-11.94	-0.55	1.5e-27	Ear protrusion;
CRC	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg18385501	chr17:73401976	GRB2	0.5	6.38	0.33	5.96e-10	Beard thickness;
CRC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.49	6.86	0.35	3.35e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.15	-0.45	5.92e-18	Bipolar disorder;
CRC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.71	12.73	0.57	1.9e-30	Asthma;
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg01339444	chr6:118972232	C6orf204	0.53	6.03	0.32	4.29e-9	Renal cell carcinoma;
CRC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.48	-7.53	-0.38	4.98e-13	Menopause (age at onset);
CRC	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.3	-0.37	2.19e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.73	0.51	3.04e-23	Motion sickness;
CRC	cis	rs7586879	0.663	rs6760328	chr2:25077991	T/C	cg04586622	chr2:25135609	ADCY3	-0.51	-8.32	-0.42	2.39e-15	Body mass index;
CRC	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.54	-6.13	-0.32	2.53e-9	Menarche (age at onset);
CRC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-6.94	-0.36	2.07e-11	Body mass index (adult);
CRC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-5.76	-0.3	1.89e-8	Bipolar disorder;
CRC	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg19338460	chr6:170058176	WDR27	-0.73	-7.89	-0.4	4.53e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6088813	1.000	rs6142369	chr20:33973315	T/G	cg14752227	chr20:34000481	UQCC	-0.37	-5.6	-0.3	4.46e-8	Height;
CRC	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg18827107	chr12:86230957	RASSF9	0.37	5.95	0.31	6.93e-9	Major depressive disorder;
CRC	cis	rs3812762	0.871	rs3844100	chr11:8817808	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.27	0.33	1.11e-9	Hypospadias;
CRC	cis	rs12505749	0.542	rs4618376	chr4:57345659	G/A	cg06922635	chr4:57371607	ARL9	-0.54	-5.7	-0.3	2.66e-8	Airflow obstruction;
CRC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.95	-0.4	3.11e-14	Height;
CRC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.05	0.32	4.05e-9	Heart rate;
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.7	-0.35	9.26e-11	Lymphocyte counts;
CRC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.4	-6.14	-0.32	2.38e-9	Total body bone mineral density;
CRC	cis	rs11229555	0.609	rs12273517	chr11:58201094	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-7.46	-0.38	7.93e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg26132723	chr8:70041827	NA	-0.35	-5.63	-0.3	3.87e-8	Dupuytren's disease;
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg17378563	chr5:133861150	PHF15	-0.68	-6.11	-0.32	2.87e-9	Temperament (bipolar disorder);
CRC	cis	rs2530545	0.502	rs2125404	chr7:34697388	C/T	cg14401837	chr7:34697493	NPSR1	-0.6	-7.3	-0.37	2.15e-12	IgG glycosylation;
CRC	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg21918786	chr6:109611834	NA	-0.35	-5.94	-0.31	7.08e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12315302	chr6:26189340	HIST1H4D	0.82	6.33	0.33	8.12e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.86	-11.25	-0.53	4.48e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.67	-0.7	1.39e-49	Height;
CRC	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.42	-0.38	1.01e-12	Caudate activity during reward;
CRC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.63	8.97	0.44	2.28e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.48	-6.43	-0.33	4.5e-10	Blood metabolite levels;
CRC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.38	5.64	0.3	3.58e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.58	6.78	0.35	5.41e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	7.68	0.39	1.88e-13	Coronary artery disease;
CRC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.6	8.59	0.43	3.61e-16	Arsenic metabolism;
CRC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg16892393	chr17:41919603	NA	-0.5	-6.88	-0.35	3.06e-11	Triglycerides;
CRC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.41	5.76	0.3	1.96e-8	Red blood cell count;
CRC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.7	0.47	9.87e-20	Lung cancer;
CRC	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg09127314	chr1:152161683	NA	0.51	6.4	0.33	5.3e-10	Atopic dermatitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08763126	chr6:109416997	C6orf182	0.46	6.57	0.34	2.02e-10	Response to antipsychotic treatment;
CRC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.57	7.43	0.38	9.25e-13	IgG glycosylation;
CRC	cis	rs282587	0.569	rs4907750	chr13:113391348	C/A	cg04656015	chr13:113407548	ATP11A	0.57	7.41	0.38	1.07e-12	Glycated hemoglobin levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10053149	chr1:28908509	SNHG12;SNORA44;SNORA16A	0.48	6.61	0.34	1.54e-10	Survival in pancreatic cancer;
CRC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg15147215	chr3:52552868	STAB1	-0.5	-8.09	-0.41	1.17e-14	Electroencephalogram traits;
CRC	cis	rs2992756	0.553	rs2992745	chr1:18809896	A/T	cg14356550	chr1:18808102	KLHDC7A	-0.38	-5.76	-0.3	1.92e-8	Breast cancer;
CRC	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg10756647	chr7:56101905	PSPH	0.76	7.86	0.4	5.47e-14	Diabetic kidney disease;
CRC	cis	rs6011002	0.636	rs1758199	chr20:62352827	T/C	cg01176363	chr20:62369445	LIME1	-0.72	-5.67	-0.3	3.18e-8	Dental caries;
CRC	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.46	7.78	0.39	9.53e-14	Testicular germ cell tumor;
CRC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.68	10.02	0.48	8.55e-21	Immature fraction of reticulocytes;
CRC	cis	rs6066835	0.867	rs6095277	chr20:47363257	A/G	cg18078177	chr20:47281410	PREX1	-0.61	-5.8	-0.3	1.56e-8	Multiple myeloma;
CRC	cis	rs2795502	0.702	rs3123750	chr10:43227824	C/A	cg20628663	chr10:43360327	NA	-0.56	-6.99	-0.36	1.53e-11	Blood protein levels;
CRC	cis	rs4716602	0.596	rs13221649	chr7:156160793	G/A	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.65e-11	Anti-saccade response;
CRC	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.59	10.04	0.48	7.33e-21	Prudent dietary pattern;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg12172441	chr6:28176163	NA	0.43	6.3	0.33	9.3e-10	Pubertal anthropometrics;
CRC	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg00290994	chr1:41848739	NA	0.53	7.99	0.4	2.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.56	-7.22	-0.37	3.62e-12	Bipolar disorder;
CRC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.51	-6.24	-0.33	1.32e-9	Body mass index;
CRC	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg08314208	chr16:67682810	RLTPR	-0.48	-5.79	-0.3	1.64e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg02428538	chr16:24856791	SLC5A11	-0.54	-6.32	-0.33	8.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg12365402	chr11:9010492	NRIP3	-0.38	-6.55	-0.34	2.17e-10	Hemoglobin concentration;
CRC	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.57	8.54	0.43	4.9e-16	Lewy body disease;
CRC	trans	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg18288967	chr1:45987694	PRDX1	0.63	7.54	0.38	4.53e-13	Obesity-related traits;
CRC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.61	0.43	3.09e-16	Homoarginine levels;
CRC	cis	rs4601821	0.635	rs11214579	chr11:113208186	A/C	cg14159747	chr11:113255604	NA	-0.43	-7.82	-0.4	7.11e-14	Alcoholic chronic pancreatitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15747848	chr15:40074985	FSIP1	0.48	7.0	0.36	1.44e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.63	6.7	0.35	8.96e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14481911	chr2:242438436	STK25	-0.37	-6.19	-0.32	1.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg21620606	chr4:1342894	KIAA1530	0.41	7.23	0.37	3.38e-12	Obesity-related traits;
CRC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.38	-6.66	-0.34	1.17e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg09654669	chr8:57350985	NA	-0.4	-5.68	-0.3	2.99e-8	Obesity-related traits;
CRC	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.66	7.16	0.37	5.18e-12	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg17321639	chr7:2759063	NA	-0.54	-7.14	-0.37	6.2e-12	Height;
CRC	trans	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg21153622	chr11:89784906	NA	-0.49	-7.81	-0.4	7.62e-14	HDL cholesterol;
CRC	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.5	6.39	0.33	5.83e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg06550200	chr5:1325588	CLPTM1L	0.63	9.56	0.47	2.77e-19	Lung cancer;
CRC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.53	7.01	0.36	1.39e-11	Height;
CRC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg25985355	chr7:65971099	NA	-0.44	-5.77	-0.3	1.83e-8	Diabetic kidney disease;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.65	8.55	0.43	4.57e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.65	11.55	0.54	3.88e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.61	0.3	4.4e-8	Protein C levels;
CRC	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.8	-0.35	5.07e-11	Response to antipsychotic treatment;
CRC	trans	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg24644049	chr4:85504048	CDS1	0.87	7.08	0.36	8.68e-12	Skin colour saturation;
CRC	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-5.83	-0.31	1.3e-8	Brugada syndrome;
CRC	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg12458913	chr13:53173898	NA	0.39	5.7	0.3	2.62e-8	Lewy body disease;
CRC	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg27205649	chr11:78285834	NARS2	0.49	6.23	0.32	1.41e-9	Alzheimer's disease (survival time);
CRC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.66	8.06	0.41	1.38e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.74	-0.51	2.95e-23	Bipolar disorder;
CRC	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg00383909	chr3:49044727	WDR6	0.44	5.68	0.3	2.91e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.52	6.91	0.36	2.51e-11	Obesity-related traits;
CRC	cis	rs10486722	0.624	rs11761217	chr7:41772275	C/T	cg22138096	chr7:41772439	LOC285954	-0.39	-5.88	-0.31	1.02e-8	Pit-and-Fissure caries;
CRC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.09	-0.32	3.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04498580	chr4:140478204	SETD7	0.42	5.98	0.31	5.78e-9	Response to antipsychotic treatment;
CRC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg25767906	chr1:53392781	SCP2	-0.39	-5.98	-0.31	5.75e-9	Monocyte count;
CRC	trans	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg13565492	chr6:43139072	SRF	-0.71	-7.12	-0.37	7.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.4	-7.04	-0.36	1.13e-11	Obesity-related traits;
CRC	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg15485101	chr11:133734466	NA	0.46	7.89	0.4	4.41e-14	Childhood ear infection;
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-11.14	-0.52	1.15e-24	Prudent dietary pattern;
CRC	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.86	-0.31	1.15e-8	Triglycerides;
CRC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg14530993	chr4:882597	GAK	0.75	6.93	0.36	2.17e-11	Parkinson's disease;
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.92e-9	Prudent dietary pattern;
CRC	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03605463	chr16:89740564	NA	0.62	9.56	0.47	2.77e-19	Vitiligo;
CRC	cis	rs4824093	0.544	rs7410765	chr22:50315924	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.85	-0.4	5.86e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.88	9.11	0.45	8.21e-18	Arsenic metabolism;
CRC	cis	rs1712517	0.744	rs11191641	chr10:105052940	C/T	cg05636881	chr10:105038444	INA	0.47	8.08	0.41	1.23e-14	Migraine;
CRC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.61	9.75	0.47	6.57e-20	Melanoma;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04983606	chr1:178996021	FAM20B	-0.4	-6.08	-0.32	3.3e-9	Aortic root size;
CRC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-7.65	-0.39	2.31e-13	Headache;
CRC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg23587288	chr2:27483067	SLC30A3	-0.42	-5.94	-0.31	7.27e-9	Blood metabolite levels;
CRC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.91	0.31	8.48e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	cis	rs11203032	0.831	rs4417181	chr10:90967093	T/C	cg16672925	chr10:90967113	CH25H	0.46	6.13	0.32	2.45e-9	Heart failure;
CRC	cis	rs9584850	0.540	rs61969457	chr13:99176742	C/T	cg20487152	chr13:99095054	FARP1	0.45	5.65	0.3	3.46e-8	Neuroticism;
CRC	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.57	-8.0	-0.4	2.15e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg23254163	chr1:152506842	NA	0.45	9.14	0.45	6.46e-18	Hair morphology;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg26304593	chr6:42947056	PEX6	-0.43	-6.16	-0.32	2.09e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg06238570	chr21:40685208	BRWD1	0.78	10.89	0.51	8.51e-24	Cognitive function;
CRC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.53	5.96	0.31	6.67e-9	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13198984	chr17:80129470	CCDC57	0.45	8.01	0.4	1.99e-14	Life satisfaction;
CRC	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.99	-0.36	1.53e-11	Hemoglobin concentration;
CRC	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-12.26	-0.56	1.02e-28	Colorectal cancer;
CRC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg14530993	chr4:882597	GAK	0.79	7.79	0.39	8.83e-14	Intelligence (multi-trait analysis);
CRC	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg13092806	chr2:177043255	NA	0.73	8.76	0.43	1.07e-16	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg05627522	chr15:75251581	NA	0.5	7.58	0.39	3.59e-13	Breast cancer;
CRC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-5.96	-0.31	6.37e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16275967	chr1:161172255	NDUFS2	0.47	6.16	0.32	2.17e-9	Thyroid stimulating hormone;
CRC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.81	-0.4	7.64e-14	Cystic fibrosis severity;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21703068	chr21:35015322	ITSN1;CRYZL1	0.4	6.44	0.33	4.19e-10	Schizophrenia;
CRC	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg21153622	chr11:89784906	NA	-0.44	-7.11	-0.36	7.07e-12	HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23132254	chr6:18264719	DEK	0.45	6.31	0.33	8.99e-10	Anxiety disorder;
CRC	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.62	-0.34	1.45e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);
CRC	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg16589663	chr20:23618590	CST3	0.43	6.28	0.33	1.05e-9	Chronic kidney disease;
CRC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.15	0.37	5.49e-12	Rheumatoid arthritis;
CRC	cis	rs531930	0.563	rs332607	chr6:124723354	C/T	cg22366943	chr6:124882293	NKAIN2	0.41	6.27	0.33	1.11e-9	Celiac disease;
CRC	cis	rs2306032	0.669	rs10838622	chr11:46856536	T/C	cg19486271	chr11:47235900	DDB2	-0.47	-7.76	-0.39	1.08e-13	Total body bone mineral density;
CRC	cis	rs2235544	0.664	rs12036530	chr1:54476323	T/C	cg25741118	chr1:54482237	LDLRAD1	-0.21	-5.83	-0.31	1.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.51	6.48	0.34	3.41e-10	Recombination rate (females);
CRC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.13	-0.52	1.21e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg19894588	chr14:64061835	NA	-0.59	-8.02	-0.4	1.91e-14	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg26043149	chr18:55253948	FECH	0.5	7.46	0.38	7.59e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.73	11.43	0.53	1.02e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.77	-0.3	1.85e-8	Alzheimer's disease (survival time);
CRC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.82	11.18	0.52	8.48e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-6.93	-0.36	2.2e-11	Blood metabolite levels;
CRC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.64	10.59	0.5	9.21e-23	Calcium levels;
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.46	6.39	0.33	5.68e-10	Parkinson's disease;
CRC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg03340356	chr1:67600835	NA	0.3	6.86	0.35	3.5e-11	Psoriasis;
CRC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-9.36	-0.46	1.28e-18	Heart rate;
CRC	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.49	-5.89	-0.31	9.32e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7258465	0.965	rs748609	chr19:18560282	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.36	-0.33	6.82e-10	Breast cancer;
CRC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.48	-0.38	6.74e-13	Psoriasis;
CRC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.85	0.68	2.34e-46	Platelet count;
CRC	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg23127183	chr11:57508653	C11orf31	-0.53	-7.43	-0.38	9.4e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg02290350	chr8:58132656	NA	0.4	5.69	0.3	2.85e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.5	-6.39	-0.33	5.63e-10	Resting heart rate;
CRC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg21194808	chr1:2205498	SKI	0.4	5.98	0.31	5.73e-9	Height;
CRC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.63	10.64	0.51	6.52e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09597638	chr17:3907349	NA	0.56	9.53	0.47	3.59e-19	Type 2 diabetes;
CRC	cis	rs3736485	0.903	rs750162	chr15:51907153	A/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.44	-0.33	4.34e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7550918	1	rs7550918	chr1:247675559	C/T	cg18198730	chr1:247681584	NA	-0.59	-10.43	-0.5	3.47e-22	Platelet count;
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg23590916	chr17:43697445	MGC57346	0.7	7.25	0.37	2.9e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4728142	0.604	rs4731536	chr7:128640293	C/T	cg06630958	chr7:128577819	IRF5	-0.34	-5.62	-0.3	4.04e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg17775713	chr3:133465469	TF	0.35	6.23	0.32	1.41e-9	Iron status biomarkers (transferrin levels);
CRC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.69	9.3	0.46	2.03e-18	High light scatter reticulocyte count;
CRC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg03609598	chr5:56110824	MAP3K1	0.68	8.12	0.41	9.19e-15	Initial pursuit acceleration;
CRC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.62	10.62	0.51	7.28e-23	Body mass index;
CRC	trans	rs2055729	0.677	rs592420	chr8:9760420	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.14	0.32	2.43e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.63	-0.3	3.78e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg01483505	chr11:975446	AP2A2	0.42	6.71	0.35	8.38e-11	Alzheimer's disease (late onset);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23891596	chr19:50169132	IRF3;BCL2L12	0.41	6.1	0.32	2.95e-9	Myopia (pathological);
CRC	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs6504622	0.545	rs10853087	chr17:45006112	C/G	cg16759221	chr17:45003025	GOSR2	0.55	8.77	0.44	9.77e-17	Orofacial clefts;
CRC	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg17710535	chr19:10819994	QTRT1	0.42	5.86	0.31	1.13e-8	Inflammatory skin disease;
CRC	trans	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg26043149	chr18:55253948	FECH	-0.49	-7.51	-0.38	5.74e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.89	-16.62	-0.68	1.92e-45	Height;
CRC	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.35	-6.01	-0.31	5.03e-9	Reticulocyte fraction of red cells;
CRC	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-8.82	-0.44	6.76e-17	Hypospadias;
CRC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.66	-9.3	-0.46	2.04e-18	DNA methylation (variation);
CRC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.62	-9.61	-0.47	1.99e-19	Aortic root size;
CRC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg23262073	chr20:60523788	NA	-0.42	-6.63	-0.34	1.38e-10	Body mass index;
CRC	cis	rs45544231	0.544	rs9926163	chr16:52565641	G/T	cg09051775	chr16:52580266	TOX3	-0.4	-6.52	-0.34	2.6200000000000003e-10	Restless legs syndrome;
CRC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.56	-9.27	-0.46	2.49e-18	Prostate cancer;
CRC	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-8.48	-0.42	7.63e-16	Ulcerative colitis;
CRC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg21573476	chr21:45109991	RRP1B	-0.39	-5.76	-0.3	1.94e-8	Mean corpuscular volume;
CRC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.39	-0.38	1.25e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10512697	0.655	rs34299253	chr5:3510569	T/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-7.97	-0.4	2.69e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.94	-0.31	7.16e-9	Longevity;Endometriosis;
CRC	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.48	-7.23	-0.37	3.45e-12	Pulmonary function decline;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg15786705	chr6:28176104	NA	0.64	9.23	0.45	3.27e-18	Parkinson's disease;
CRC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.74	-12.05	-0.55	6.13e-28	Lung cancer;
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg10217327	chr6:118973057	C6orf204	0.51	5.78	0.3	1.73e-8	Diastolic blood pressure;
CRC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.6	9.78	0.47	5.3e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg11900509	chr10:81946545	ANXA11	-0.63	-6.57	-0.34	2.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.55	-7.6	-0.39	3.12e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.62	9.19	0.45	4.62e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.46	-0.38	7.67e-13	HDL cholesterol;
CRC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.59	8.51	0.42	6.4e-16	Homoarginine levels;
CRC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg23018236	chr17:30244563	NA	-0.64	-7.88	-0.4	4.72e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.16	-0.49	2.86e-21	Primary sclerosing cholangitis;
CRC	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs728616	0.681	rs35420115	chr10:81908188	A/G	cg05935833	chr10:81318306	SFTPA2	-0.54	-6.22	-0.32	1.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.44	6.79	0.35	5.14e-11	Longevity;Endometriosis;
CRC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.78	-0.3	1.74e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-20.98	-0.76	1.25e-62	Primary sclerosing cholangitis;
CRC	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg08314208	chr16:67682810	RLTPR	-0.55	-6.04	-0.32	4.2e-9	HDL cholesterol;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14947789	chr14:55738283	FBXO34	0.41	6.44	0.33	4.24e-10	Schizophrenia;
CRC	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.57	-10.02	-0.48	8.77e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.13	-0.32	2.52e-9	Height;
CRC	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg16892393	chr17:41919603	NA	0.55	7.7	0.39	1.6e-13	Triglycerides;
CRC	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg00250761	chr1:31883323	NA	-0.45	-8.81	-0.44	7.3e-17	Alcohol dependence;
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs3018066	0.867	rs3113249	chr4:107239130	G/T	cg01869342	chr4:106983673	TBCK	0.36	5.62	0.3	4.1e-8	Cancer;
CRC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg25985355	chr7:65971099	NA	0.51	5.77	0.3	1.81e-8	Diabetic kidney disease;
CRC	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg26182253	chr13:112236782	NA	0.31	6.3	0.33	9.74e-10	Hepatitis;
CRC	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	0.98	8.0	0.4	2.12e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg20607287	chr7:12443886	VWDE	-0.63	-6.27	-0.33	1.14e-9	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs11804300	chr1:183654557	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.67	8.7	0.43	1.61e-16	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg20607287	chr7:12443886	VWDE	-0.69	-7.29	-0.37	2.4e-12	Coronary artery disease;
CRC	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.43	-5.95	-0.31	6.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs4586057	0.767	rs11186352	chr10:92651794	G/C	cg26894278	chr13:21016241	CRYL1	0.39	6.44	0.33	4.13e-10	Economic and political preferences (time);
CRC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.68	10.03	0.48	7.75e-21	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01524091	chr6:44281032	AARS2	0.4	6.25	0.33	1.28e-9	Obesity-related traits;
CRC	cis	rs728616	0.571	rs113030473	chr10:81649031	G/T	cg11900509	chr10:81946545	ANXA11	-0.68	-6.61	-0.34	1.53e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs6011368	0.607	rs6062363	chr20:62912463	C/T	cg13869341	chr1:15865	WASH5P	0.43	6.83	0.35	4.15e-11	Clozapine-induced cytotoxicity;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12771053	chr1:155145617	TRIM46;KRTCAP2	0.42	6.27	0.33	1.12e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27173322	chr11:61584112	MIR1908;FADS1	0.35	6.46	0.34	3.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.67	10.94	0.52	5.68e-24	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.76	-13.19	-0.59	3.51e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg03690763	chr11:133734501	NA	0.34	5.69	0.3	2.86e-8	Childhood ear infection;
CRC	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg23815491	chr16:72088622	HP	0.47	6.58	0.34	1.85e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.1	-0.41	1.06e-14	Bipolar disorder;
CRC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg05585544	chr11:47624801	NA	-0.59	-10.89	-0.51	8.44e-24	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09491787	chr5:139781927	ANKHD1;ANKHD1-EIF4EBP3	0.5	7.0	0.36	1.43e-11	Response to antipsychotic treatment;
CRC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg21285383	chr16:89894308	SPIRE2	0.36	6.05	0.32	4.04e-9	Vitiligo;
CRC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.53	-0.5	1.54e-22	Breast cancer;
CRC	cis	rs860295	0.702	rs2175391	chr1:155625602	G/T	cg02153340	chr1:155202674	NA	0.53	7.13	0.37	6.36e-12	Body mass index;
CRC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg24130564	chr14:104152367	KLC1	-0.45	-5.93	-0.31	7.66e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.55	0.43	4.74e-16	Schizophrenia;
CRC	cis	rs4917833	0.764	rs1925645	chr10:100220472	T/C	cg19043522	chr10:100227446	HPSE2	0.37	5.61	0.3	4.21e-8	Pediatric bone mineral density (femoral neck);
CRC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg23071808	chr14:103021642	NA	-0.64	-7.19	-0.37	4.38e-12	Platelet count;
CRC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.93	17.58	0.7	3.07e-49	Intelligence (multi-trait analysis);
CRC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg05527609	chr1:210001259	C1orf107	-0.45	-5.81	-0.31	1.47e-8	Monobrow;
CRC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.62	12.29	0.56	7.75e-29	HDL cholesterol levels;
CRC	cis	rs4750440	0.706	rs11258767	chr10:14016565	C/T	cg00551146	chr10:14014579	FRMD4A	0.37	6.04	0.32	4.25e-9	Adiponectin levels;
CRC	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.61	9.84	0.48	3.46e-20	Cancer;
CRC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.68	-8.22	-0.41	4.66e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2310173	0.651	rs11689480	chr2:102674501	G/A	cg20856504	chr2:102616538	IL1R2	0.35	5.75	0.3	2.01e-8	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	cis	rs9931543	0.504	rs9922112	chr16:56314687	A/C	cg02433656	chr16:56322654	GNAO1	0.48	7.2	0.37	3.99e-12	Subjective well-being;
CRC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.61	-9.06	-0.45	1.18e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07513332	chr6:167530253	CCR6	0.35	6.33	0.33	7.98e-10	Crohn's disease;
CRC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg11843238	chr5:131593191	PDLIM4	-0.31	-5.69	-0.3	2.86e-8	Blood metabolite levels;
CRC	cis	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg05299278	chr17:33885742	SLFN14	0.4	5.97	0.31	6.23e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg06470822	chr6:28175283	NA	-1.02	-13.36	-0.59	8e-33	Depression;
CRC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.24	0.37	3.11e-12	Platelet count;
CRC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.87	-10.06	-0.49	6.01e-21	Breast cancer;
CRC	cis	rs9491140	0.539	rs2208814	chr6:124692555	G/A	cg22366943	chr6:124882293	NKAIN2	0.57	8.09	0.41	1.19e-14	Neuroticism;
CRC	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg08461752	chr10:43522343	NA	-0.63	-5.9	-0.31	9.27e-9	Blood protein levels;
CRC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs2882667	0.898	rs6862393	chr5:138364698	T/C	cg09476006	chr5:138032270	NA	0.44	7.47	0.38	7.39e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.69	9.03	0.45	1.49e-17	Breast cancer;
CRC	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.58	7.0	0.36	1.45e-11	Carotid intima media thickness;
CRC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.52	-6.07	-0.32	3.46e-9	Vitiligo;
CRC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.41	5.86	0.31	1.11e-8	Red blood cell count;
CRC	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg23815491	chr16:72088622	HP	0.64	8.12	0.41	9.28e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.96	15.81	0.66	2.7e-42	Parkinson's disease;
CRC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs294883	0.826	rs9355264	chr6:159700955	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg13722127	chr7:150037890	RARRES2	0.48	7.83	0.4	6.64e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.98	-0.36	1.68e-11	Type 2 diabetes;
CRC	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.66	-10.8	-0.51	1.81e-23	Hepatocellular carcinoma;
CRC	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.55	7.4	0.38	1.17e-12	Birth weight;
CRC	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg18612461	chr15:75251733	NA	-0.38	-5.82	-0.31	1.41e-8	Caffeine consumption;
CRC	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-6.03	-0.32	4.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9914544	0.545	rs7222748	chr17:18787976	T/C	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.1	-0.32	2.93e-9	Educational attainment (years of education);
CRC	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg15145174	chr5:6755386	POLS	-0.46	-6.8	-0.35	5e-11	Menopause (age at onset);
CRC	cis	rs7804356	1.000	rs7802715	chr7:26852720	C/A	cg03456212	chr7:26904342	SKAP2	-0.52	-5.68	-0.3	2.98e-8	Type 1 diabetes;
CRC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.57	8.68	0.43	1.81e-16	Blood protein levels;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	15.62	0.65	1.56e-41	Electrocardiographic conduction measures;
CRC	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.72	-8.11	-0.41	9.89e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg24375607	chr4:120327624	NA	0.49	7.56	0.38	3.93e-13	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg07507251	chr3:52567010	NT5DC2	0.45	6.51	0.34	2.8e-10	Bipolar disorder;
CRC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg20887711	chr4:1340912	KIAA1530	-0.45	-6.38	-0.33	6.1e-10	Obesity-related traits;
CRC	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg15654264	chr1:150340011	RPRD2	0.43	6.52	0.34	2.68e-10	Migraine;
CRC	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.05e-14	Type 2 diabetes;
CRC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.55	6.63	0.34	1.34e-10	Red cell distribution width;
CRC	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-6.05	-0.32	3.99e-9	Carotid intima media thickness;
CRC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg14530993	chr4:882597	GAK	0.8	7.59	0.39	3.35e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.63	-9.06	-0.45	1.21e-17	Obesity-related traits;
CRC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.5	-7.22	-0.37	3.73e-12	Height;
CRC	cis	rs972578	0.837	rs7364152	chr22:43316667	A/G	cg01576275	chr22:43409880	NA	-0.37	-5.73	-0.3	2.3e-8	Mean platelet volume;
CRC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.53	7.86	0.4	5.7e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.27	0.33	1.13e-9	Aortic root size;
CRC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.4	7.57	0.39	3.73e-13	Ulcerative colitis;
CRC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg16928487	chr17:17741425	SREBF1	0.49	8.3	0.42	2.65e-15	Total body bone mineral density;
CRC	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.58	-0.34	1.86e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg11645453	chr3:52864694	ITIH4	-0.42	-7.73	-0.39	1.34e-13	Body mass index;
CRC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	7.44	0.38	8.93e-13	Menopause (age at onset);
CRC	trans	rs10050311	0.685	rs7678571	chr4:87754713	C/T	cg02563553	chr3:135913687	MSL2	0.51	6.37	0.33	6.46e-10	Insulin-related traits;
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg00814883	chr7:100076585	TSC22D4	-0.51	-5.82	-0.31	1.38e-8	Lung function (FEV1/FVC);
CRC	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg11130432	chr3:121712080	ILDR1	0.53	6.94	0.36	2.1e-11	Multiple sclerosis;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.59	7.95	0.4	3.01e-14	Alzheimer's disease;
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.14	-0.32	2.43e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.61	-8.71	-0.43	1.54e-16	Coronary artery disease;
CRC	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg16898833	chr6:26189333	HIST1H4D	0.99	7.54	0.38	4.65e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	0.72	7.97	0.4	2.58e-14	Gout;Renal underexcretion gout;
CRC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg00647820	chr17:40259828	DHX58	-0.46	-6.56	-0.34	2.12e-10	Fibrinogen levels;
CRC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg18512352	chr11:47633146	NA	-0.41	-7.91	-0.4	3.94e-14	Subjective well-being;
CRC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.8	9.29	0.46	2.2e-18	Eosinophilic esophagitis;
CRC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg04719120	chr6:96025338	MANEA	0.52	6.43	0.33	4.56e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.62	8.74	0.43	1.23e-16	Multiple sclerosis;
CRC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs4073416	0.510	rs10873190	chr14:65981439	G/T	cg03016385	chr14:66212404	NA	-0.42	-5.93	-0.31	7.71e-9	N-glycan levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04832844	chr4:26321136	RBPJ	0.4	6.34	0.33	7.6e-10	Intelligence (multi-trait analysis);
CRC	trans	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg06834434	chr14:75079333	LTBP2	0.55	6.48	0.34	3.33e-10	Obesity-related traits;
CRC	cis	rs10484885	0.775	rs62416027	chr6:90608054	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.71	-7.8	-0.39	8.44e-14	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.31	-0.37	1.99e-12	Coronary artery disease;
CRC	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg22495460	chr2:25135724	ADCY3	-0.66	-11.3	-0.53	3.04e-25	Body mass index in non-asthmatics;
CRC	trans	rs453301	0.686	rs6748	chr8:8890802	C/T	cg16141378	chr3:129829833	LOC729375	0.4	6.13	0.32	2.57e-9	Joint mobility (Beighton score);
CRC	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.37	-0.38	1.35e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12172441	chr6:28176163	NA	0.61	7.27	0.37	2.7e-12	Depression;
CRC	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	5.92	0.31	7.92e-9	Cardiovascular disease risk factors;
CRC	cis	rs9292777	0.666	rs5026793	chr5:40436612	C/T	cg09067459	chr5:40385259	NA	-0.53	-8.63	-0.43	2.76e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.62	-9.03	-0.45	1.43e-17	Systolic blood pressure;
CRC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs305851	0.846	rs2651317	chr6:39767137	A/G	cg02386599	chr6:39769542	DAAM2	0.37	5.81	0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.54	0.38	4.64e-13	Height;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg23760165	chr11:61595485	FADS2	-0.47	-6.32	-0.33	8.47e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9494145	0.652	rs9399137	chr6:135419018	T/C	cg22676075	chr6:135203613	NA	0.57	7.19	0.37	4.42e-12	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg11843238	chr5:131593191	PDLIM4	0.35	6.39	0.33	5.83e-10	Blood metabolite levels;
CRC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg13319975	chr6:146136371	FBXO30	0.41	6.13	0.32	2.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00166722	chr3:10149974	C3orf24	0.66	9.02	0.45	1.59e-17	Alzheimer's disease;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.62	0.6	8.27e-34	Prudent dietary pattern;
CRC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.79	10.7	0.51	4.12e-23	Initial pursuit acceleration;
CRC	cis	rs6662572	0.578	rs6662306	chr1:46287286	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.87	0.31	1.04e-8	Blood protein levels;
CRC	trans	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-6.87	-0.35	3.16e-11	Blood metabolite levels;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02772935	chr3:125709198	NA	-0.52	-6.11	-0.32	2.89e-9	Blood pressure (smoking interaction);
CRC	cis	rs9303280	0.617	rs6503525	chr17:38095174	C/G	cg26162295	chr17:38119207	GSDMA	0.31	5.63	0.3	3.76e-8	Self-reported allergy;
CRC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.23	-0.41	4.57e-15	Hemoglobin concentration;
CRC	cis	rs9463078	0.764	rs9395051	chr6:44825715	C/A	cg25276700	chr6:44698697	NA	-0.26	-6.33	-0.33	7.82e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg13010199	chr12:38710504	ALG10B	0.46	6.52	0.34	2.6200000000000003e-10	Morning vs. evening chronotype;
CRC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg27661571	chr11:113659931	NA	-0.69	-8.79	-0.44	8.72e-17	Hip circumference adjusted for BMI;
CRC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.61	-9.62	-0.47	1.84e-19	Motion sickness;
CRC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.59	7.21	0.37	3.98e-12	Body mass index;
CRC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.42	-9.5	-0.46	4.45e-19	Temperament;
CRC	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg01993067	chr11:68851601	TPCN2	0.53	5.93	0.31	7.58e-9	Blond vs. brown hair color;
CRC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.92	0.31	7.96e-9	Tonsillectomy;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.55	-0.38	4.2e-13	Bipolar disorder;
CRC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.35	6.44	0.33	4.16e-10	Mean corpuscular volume;
CRC	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg04586622	chr2:25135609	ADCY3	-0.48	-8.59	-0.43	3.62e-16	Body mass index;
CRC	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg14186256	chr22:23484241	RTDR1	0.46	5.9	0.31	8.93e-9	Serum parathyroid hormone levels;
CRC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg19582491	chr16:67682965	RLTPR	-0.57	-6.53	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg03678062	chr6:149772716	ZC3H12D	0.34	6.18	0.32	1.9e-9	Dupuytren's disease;
CRC	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.63	-8.68	-0.43	1.8e-16	White matter hyperintensity burden;
CRC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg20786939	chr1:226374532	ACBD3	-0.41	-5.98	-0.31	5.7e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.58	-8.71	-0.43	1.52e-16	Aortic root size;
CRC	trans	rs11654801	0.755	rs11658791	chr17:20881698	G/A	cg23759823	chr7:139672531	TBXAS1	-0.41	-6.12	-0.32	2.64e-9	Mosquito bite size;
CRC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.82	0.31	1.39e-8	Renal function-related traits (BUN);
CRC	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.9	0.36	2.61e-11	Response to antipsychotic treatment;
CRC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.64	-10.91	-0.52	7.13e-24	Dental caries;
CRC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.43	6.58	0.34	1.87e-10	Obesity-related traits;
CRC	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.46	6.71	0.35	8.28e-11	Testicular germ cell tumor;
CRC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.71	12.96	0.58	2.68e-31	Prostate cancer;
CRC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.49	-7.33	-0.37	1.85e-12	Response to antineoplastic agents;
CRC	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.5	-8.06	-0.41	1.38e-14	Dental caries;
CRC	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.22	0.37	3.69e-12	Testicular germ cell tumor;
CRC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.58	9.38	0.46	1.12e-18	Height;
CRC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg21854759	chr1:92012499	NA	-0.51	-6.51	-0.34	2.82e-10	Eosinophil percentage of white cells;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08219700	chr8:58056026	NA	0.55	6.5	0.34	2.99e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg26875233	chr11:93583750	C11orf90	-0.33	-6.52	-0.34	2.65e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.4	-6.58	-0.34	1.9e-10	Iron status biomarkers;
CRC	cis	rs4728302	0.869	rs6962865	chr7:133599433	T/A	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.8e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg10589385	chr1:150898437	SETDB1	0.32	6.54	0.34	2.4e-10	Melanoma;
CRC	cis	rs136211	0.929	rs1883273	chr22:36769685	A/G	cg16924664	chr22:36878180	TXN2	-0.4	-5.9	-0.31	9.17e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.73	12.02	0.55	8e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2579519	0.547	rs2463560	chr2:96595589	T/C	cg23100626	chr2:96804247	ASTL	0.25	6.92	0.36	2.31e-11	Diastolic blood pressure;
CRC	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.35	-6.01	-0.31	4.85e-9	Airway imaging phenotypes;
CRC	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.54	7.0	0.36	1.48e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-9.3	-0.46	2.01e-18	Schizophrenia;
CRC	cis	rs11585357	0.501	rs72646770	chr1:17580767	T/C	cg08277548	chr1:17600880	PADI3	-0.66	-7.69	-0.39	1.69e-13	Hair shape;
CRC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.69	10.75	0.51	2.66e-23	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.67	8.53	0.43	5.3e-16	Gut microbiome composition (summer);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01972394	chr1:19229528	ALDH4A1	0.42	6.27	0.33	1.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.07	10.71	0.51	3.56e-23	Diabetic retinopathy;
CRC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.43	-0.38	9.66e-13	Joint mobility (Beighton score);
CRC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.05	-0.32	3.85e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.08	18.2	0.71	1.07e-51	Cognitive function;
CRC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.45	-0.34	4.01e-10	Alzheimer's disease (late onset);
CRC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13198984	chr17:80129470	CCDC57	0.42	7.24	0.37	3.1e-12	Life satisfaction;
CRC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.51	6.7	0.35	8.79e-11	Obesity-related traits;
CRC	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg21452805	chr1:244014465	NA	0.5	6.76	0.35	6.12e-11	RR interval (heart rate);
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg15511327	chr8:143859410	LYNX1	0.39	6.82	0.35	4.39e-11	Urinary tract infection frequency;
CRC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.65	-0.34	1.21e-10	Mean corpuscular hemoglobin;
CRC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.49	7.5	0.38	6.06e-13	Corneal astigmatism;
CRC	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.49	7.08	0.36	8.64e-12	Coronary heart disease;
CRC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.74	9.47	0.46	5.46e-19	Iron status biomarkers;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02725872	chr8:58115012	NA	-0.54	-7.07	-0.36	9.5e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.57	9.62	0.47	1.88e-19	Breast cancer;
CRC	cis	rs6120849	0.901	rs6058193	chr20:33734464	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	5.72	0.3	2.34e-8	Protein C levels;
CRC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.6	-7.08	-0.36	8.62e-12	Blood protein levels;
CRC	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.65	11.1	0.52	1.51e-24	Eosinophil percentage of white cells;
CRC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.18	0.49	2.52e-21	Heart rate;
CRC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg01483505	chr11:975446	AP2A2	0.43	6.82	0.35	4.37e-11	Alzheimer's disease (late onset);
CRC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.41	-0.33	4.94e-10	IgG glycosylation;
CRC	cis	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg02972257	chr16:68554789	NA	0.51	6.38	0.33	5.95e-10	Colorectal cancer;
CRC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.47	-7.33	-0.37	1.76e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg23815491	chr16:72088622	HP	0.59	9.27	0.46	2.47e-18	Fibrinogen levels;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg27094323	chr7:1216898	NA	-0.37	-6.09	-0.32	3.08e-9	Longevity;Endometriosis;
CRC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.2	-14.32	-0.62	1.67e-36	Diabetic kidney disease;
CRC	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.64	5.76	0.3	1.96e-8	Parkinson's disease;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12273811	chr6:28175739	NA	0.69	8.81	0.44	7.29e-17	Depression;
CRC	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.62	-10.6	-0.5	8.53e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.53	6.78	0.35	5.71e-11	Morning vs. evening chronotype;
CRC	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	1.03	11.07	0.52	2.03e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg24675056	chr1:15929824	NA	0.49	6.66	0.34	1.12e-10	Systolic blood pressure;
CRC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg17724175	chr1:150552817	MCL1	0.49	7.31	0.37	2.03e-12	Melanoma;
CRC	cis	rs4973397	0.601	rs2034412	chr2:232288061	C/G	cg13347044	chr2:232276743	NA	-0.4	-5.91	-0.31	8.41e-9	Anti-saccade response;
CRC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.36	-6.81	-0.35	4.74e-11	Iron status biomarkers;
CRC	cis	rs28493229	0.708	rs73546845	chr19:41158717	C/T	cg21869046	chr19:41225005	ITPKC	0.42	6.39	0.33	5.78e-10	Kawasaki disease;
CRC	cis	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg12185399	chr6:27640341	NA	0.8	5.86	0.31	1.11e-8	Depression;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg03623178	chr6:28175578	NA	0.95	12.39	0.56	3.47e-29	Depression;
CRC	cis	rs910187	0.678	rs6018330	chr20:45813216	C/T	cg27589058	chr20:45804311	EYA2	-0.39	-7.38	-0.38	1.29e-12	Migraine;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.86	-18.4	-0.71	1.68e-52	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12560992	chr17:57184187	TRIM37	0.5	6.83	0.35	4.04e-11	Testicular germ cell tumor;
CRC	cis	rs6694672	1.000	rs1412631	chr1:197037237	C/T	cg13682187	chr1:196946512	CFHR5	-0.41	-6.87	-0.35	3.25e-11	Asthma;
CRC	cis	rs9513593	1.000	rs1927724	chr13:99992312	A/C	cg21788972	chr13:99853209	UBAC2	0.46	5.97	0.31	6.29e-9	Psoriasis;
CRC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.81	-0.35	4.63e-11	Breast cancer;
CRC	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.5	7.98	0.4	2.41e-14	Schizophrenia;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08135327	chr2:134877962	NA	0.39	6.28	0.33	1.06e-9	Interleukin-6 levels;
CRC	cis	rs7487075	1.000	rs12827740	chr12:46848115	T/A	cg22049899	chr12:47219821	SLC38A4	0.31	6.16	0.32	2.12e-9	Itch intensity from mosquito bite;
CRC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05347473	chr6:146136440	FBXO30	0.4	6.06	0.32	3.71e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.44	-6.52	-0.34	2.63e-10	Neutrophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26004255	chr14:24584161	DCAF11	0.47	6.39	0.33	5.82e-10	Anxiety disorder;
CRC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.31	0.49	8.54e-22	Type 2 diabetes;
CRC	trans	rs360798	0.532	rs11125942	chr2:62966758	T/C	cg05376469	chr2:102649931	NA	0.38	6.04	0.32	4.2e-9	Coronary artery disease;
CRC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.4	-7.24	-0.37	3.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6681460	0.898	rs2483704	chr1:67195353	C/T	cg02459107	chr1:67143332	SGIP1	-0.37	-6.3	-0.33	9.3e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	0.53	5.89	0.31	9.72e-9	Left atrial antero-posterior diameter;
CRC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg01472538	chr16:58549086	SETD6	1.1	7.19	0.37	4.4e-12	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18604133	chr13:27746144	USP12	0.46	6.47	0.34	3.62e-10	Anxiety disorder;
CRC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.53	7.67	0.39	1.99e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs375066	0.935	rs10414702	chr19:44380536	A/G	cg12072164	chr19:44306565	LYPD5	0.37	5.61	0.3	4.36e-8	Breast cancer;
CRC	trans	rs12699921	0.566	rs2723515	chr7:17855466	A/G	cg15753394	chr6:17282781	RBM24	-0.36	-6.16	-0.32	2.18e-9	Fibrinogen levels;
CRC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.14	-0.41	8.5e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg15845792	chr6:28175446	NA	-0.46	-6.25	-0.33	1.24e-9	Systemic lupus erythematosus;
CRC	cis	rs17209837	0.915	rs17149660	chr7:87089524	T/C	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg02023728	chr11:77925099	USP35	-0.37	-6.24	-0.33	1.33e-9	Alzheimer's disease (survival time);
CRC	cis	rs4459895	0.762	rs10804914	chr3:187970450	A/G	cg17585528	chr3:187988060	LPP	-0.56	-6.07	-0.32	3.62e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg08200582	chr11:442649	ANO9	-0.71	-6.89	-0.36	2.83e-11	Body mass index;
CRC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.43	6.52	0.34	2.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.5	0.42	6.7e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.69	-0.39	1.7e-13	Response to antipsychotic treatment;
CRC	trans	rs6546043	0.559	rs11125986	chr2:64132637	T/C	cg20306022	chr2:7947960	NA	-0.51	-5.97	-0.31	6.22e-9	Clozapine-induced agranulocytosis;
CRC	cis	rs501120	0.584	rs7100370	chr10:44698508	A/C	cg09554077	chr10:44749378	NA	0.67	7.5	0.38	5.94e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.47	-0.38	7.07e-13	Caudate activity during reward;
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.72	-11.51	-0.54	5.26e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	12.29	0.56	8.1e-29	Platelet count;
CRC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg13556452	chr1:2391241	NA	-0.42	-7.46	-0.38	7.99e-13	Schizophrenia;
CRC	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.71	-8.11	-0.41	1.01e-14	Bipolar disorder;
CRC	cis	rs12541635	0.934	rs4734893	chr8:106990275	T/G	cg10147462	chr8:107024639	NA	0.43	6.98	0.36	1.61e-11	Age of smoking initiation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09379601	chr19:12992224	DNASE2	0.5	6.55	0.34	2.19e-10	Thyroid stimulating hormone;
CRC	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.88	9.65	0.47	1.49e-19	Uric acid levels;
CRC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-6.41	-0.33	5.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg20933634	chr6:27740509	NA	0.63	7.28	0.37	2.52e-12	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	6.91	0.36	2.54e-11	Breast cancer;
CRC	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.45	7.11	0.37	7.05e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9659323	1.000	rs9659323	chr1:119504361	A/G	cg26570165	chr1:119541833	NA	-0.38	-6.46	-0.34	3.67e-10	Body mass index;
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg23193639	chr7:45961078	IGFBP3	0.4	6.64	0.34	1.29e-10	Sitting height ratio;
CRC	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg09127314	chr1:152161683	NA	-0.46	-5.81	-0.31	1.46e-8	Atopic dermatitis;
CRC	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg25714306	chr4:1656736	FAM53A	-0.31	-5.62	-0.3	4.03e-8	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.69	-7.38	-0.38	1.27e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg24644049	chr4:85504048	CDS1	0.91	7.51	0.38	5.67e-13	Skin colour saturation;
CRC	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg27499820	chr13:21296301	IL17D	-0.37	-5.97	-0.31	6.25e-9	Dental caries;
CRC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.52	-8.11	-0.41	1.02e-14	Testicular germ cell tumor;
CRC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg03013999	chr17:37608204	MED1	0.45	6.92	0.36	2.36e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.7	0.39	1.62e-13	Lymphocyte percentage of white cells;
CRC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.46	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.37	6.52	0.34	2.6e-10	Crohn's disease;
CRC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg11003573	chr3:44754125	ZNF502	-0.34	-5.81	-0.3	1.49e-8	Depressive symptoms;
CRC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.61	0.43	3.02e-16	Cognitive test performance;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00497091	chr1:145438415	TXNIP	0.49	6.28	0.33	1.05e-9	Thyroid stimulating hormone;
CRC	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.4	-6.21	-0.32	1.61e-9	Type 1 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00654709	chr1:93646505	TMED5;CCDC18	0.43	6.22	0.32	1.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2569991	0.541	rs2596905	chr3:12937672	A/C	cg22481960	chr3:13008800	IQSEC1	-0.52	-6.47	-0.34	3.45e-10	Periodontitis (DPAL);
CRC	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.85	0.35	3.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.74	-11.1	-0.52	1.53e-24	Waist circumference;Body mass index;
CRC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.62	7.56	0.38	4.07e-13	Mean platelet volume;
CRC	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.4	-5.93	-0.31	7.51e-9	Adiposity;
CRC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.5	-7.57	-0.39	3.84e-13	Corneal astigmatism;
CRC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.34	-0.42	2.01e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.53	7.0	0.36	1.45e-11	Multiple sclerosis;
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg20160996	chr11:63990575	FERMT3	0.4	6.48	0.34	3.36e-10	Platelet count;
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg24046110	chr8:143859143	LYNX1	0.49	8.52	0.42	6.03e-16	Urinary tract infection frequency;
CRC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.7	-11.31	-0.53	2.72e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.08	13.14	0.59	5.59e-32	Sexual dysfunction (female);
CRC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.08	10.68	0.51	4.63e-23	Skin colour saturation;
CRC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg03623178	chr6:28175578	NA	0.45	6.0	0.31	5.12e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg06606381	chr12:133084897	FBRSL1	1.45	11.78	0.54	5.72e-27	Depression;
CRC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg04990556	chr1:26633338	UBXN11	-0.47	-6.17	-0.32	1.98e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg18301423	chr5:131593218	PDLIM4	0.39	6.59	0.34	1.77e-10	Breast cancer;
CRC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.64	-9.05	-0.45	1.32e-17	DNA methylation (variation);
CRC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.37	-5.91	-0.31	8.33e-9	Ulcerative colitis;
CRC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.52	-8.74	-0.43	1.22e-16	Aortic root size;
CRC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02018176	chr4:1364513	KIAA1530	0.48	7.84	0.4	6.25e-14	Obesity-related traits;
CRC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.55	0.43	4.71e-16	Morning vs. evening chronotype;
CRC	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.84	-9.87	-0.48	2.65e-20	Dilated cardiomyopathy;
CRC	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg11693508	chr17:37793320	STARD3	0.61	7.0	0.36	1.47e-11	Neuroticism;
CRC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg07507251	chr3:52567010	NT5DC2	-0.39	-5.98	-0.31	5.83e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.79	11.94	0.55	1.53e-27	Testicular germ cell tumor;
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23708337	chr7:1209742	NA	0.38	5.81	0.31	1.45e-8	Longevity;Endometriosis;
CRC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg16670446	chr17:27188758	MIR451;MIR144	-0.55	-8.73	-0.43	1.33e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16026627	chr12:49393027	DDN	0.46	6.3	0.33	9.71e-10	Thyroid stimulating hormone;
CRC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.63	10.91	0.52	7.16e-24	Schizophrenia;
CRC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18099408	chr3:52552593	STAB1	-0.48	-8.3	-0.42	2.81e-15	Bipolar disorder;
CRC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.8	-0.55	5.04e-27	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-5.95	-0.31	7.03e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg02869306	chr7:64672164	INTS4L1	0.44	6.36	0.33	6.89e-10	Aortic root size;
CRC	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.42	-5.77	-0.3	1.79e-8	Height;
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg22638593	chr5:131593259	PDLIM4	0.41	7.63	0.39	2.52e-13	Breast cancer;
CRC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.66	9.2	0.45	4.27e-18	Birth weight;
CRC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.5	6.33	0.33	8.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg02702477	chr5:179499311	RNF130	0.55	6.33	0.33	7.99e-10	LDL cholesterol;
CRC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.61	0.43	3.05e-16	Schizophrenia;
CRC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.54	7.68	0.39	1.81e-13	Schizophrenia;
CRC	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg13491945	chr12:107078410	RFX4	0.35	6.17	0.32	2e-9	Heart rate;
CRC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.83	0.31	1.29e-8	Diabetic retinopathy;
CRC	cis	rs1800795	0.599	rs1546762	chr7:22757503	C/T	cg05472934	chr7:22766657	IL6	0.66	10.41	0.5	3.91e-22	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CRC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-7.77	-0.39	1.04e-13	Gut microbiome composition (summer);
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.31	-0.53	2.74e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg19980929	chr12:42632907	YAF2	-0.43	-6.34	-0.33	7.4e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.54	8.62	0.43	2.88e-16	Breast cancer;
CRC	cis	rs13315871	1.000	rs13071688	chr3:58398730	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.14	-0.37	5.96e-12	Cholesterol, total;
CRC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg07718321	chr6:96025334	MANEA	0.51	5.98	0.31	5.83e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.1	13.12	0.59	6.44e-32	Eosinophil percentage of granulocytes;
CRC	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.47	8.01	0.4	2.01e-14	Testicular germ cell tumor;
CRC	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.11	-18.97	-0.72	9.74e-55	Schizophrenia;
CRC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13198984	chr17:80129470	CCDC57	0.43	7.61	0.39	2.95e-13	Life satisfaction;
CRC	cis	rs4664293	0.867	rs16844269	chr2:160599080	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.9	-0.36	2.65e-11	Mean corpuscular volume;
CRC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-11.05	-0.52	2.3e-24	Glomerular filtration rate (creatinine);
CRC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.65	-11.78	-0.54	6.03e-27	Breast cancer;
CRC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg24209194	chr3:40518798	ZNF619	-0.44	-6.88	-0.35	3.06e-11	Renal cell carcinoma;
CRC	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.75	-9.23	-0.45	3.38e-18	Multiple sclerosis;
CRC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg26893134	chr6:116381904	FRK	0.26	7.12	0.37	6.89e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.91	-11.54	-0.54	4.09e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.75	12.69	0.57	2.65e-30	Body mass index;
CRC	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-6.59	-0.34	1.76e-10	Schizophrenia;
CRC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.67	10.07	0.49	5.69e-21	Menarche (age at onset);
CRC	cis	rs9462027	0.628	rs10947521	chr6:34689377	G/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.07	0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.8	0.48	4.54e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg22676075	chr6:135203613	NA	0.41	6.39	0.33	5.63e-10	Red blood cell count;
CRC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg12311346	chr5:56204834	C5orf35	-0.52	-7.97	-0.4	2.68e-14	Coronary artery disease;
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg21204522	chr6:27730016	NA	-0.41	-5.61	-0.3	4.28e-8	Parkinson's disease;
CRC	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.92	11.38	0.53	1.56e-25	Exhaled nitric oxide output;
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg15845792	chr6:28175446	NA	0.73	6.45	0.34	3.9e-10	Depression;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12172441	chr6:28176163	NA	0.55	6.96	0.36	1.83e-11	Parkinson's disease;
CRC	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.66	-8.61	-0.43	3.17e-16	Hip circumference adjusted for BMI;
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	0.84	7.67	0.39	1.91e-13	IgG glycosylation;
CRC	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.46	0.46	6.22e-19	Schizophrenia;
CRC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg25876840	chr17:41920477	NA	0.53	7.42	0.38	1e-12	Triglycerides;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.48	5.7	0.3	2.72e-8	Depression;
CRC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.53	7.57	0.38	3.91e-13	Schizophrenia;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg05569086	chr8:143859399	LYNX1	-0.39	-6.43	-0.33	4.45e-10	Urinary tract infection frequency;
CRC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg10838469	chr11:2211741	NA	-0.47	-6.62	-0.34	1.45e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CRC	cis	rs9584850	0.708	rs4411372	chr13:99130423	T/C	cg20487152	chr13:99095054	FARP1	0.39	5.6	0.3	4.44e-8	Neuroticism;
CRC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.57	8.57	0.43	4.13e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg10589385	chr1:150898437	SETDB1	0.28	5.94	0.31	7.44e-9	Melanoma;
CRC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg18016565	chr1:150552671	MCL1	0.43	6.11	0.32	2.87e-9	Melanoma;
CRC	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.52	8.74	0.43	1.22e-16	Dupuytren's disease;
CRC	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	0.73	7.06	0.36	1e-11	Mean corpuscular volume;
CRC	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.85	0.44	5.66e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg05623727	chr3:50126028	RBM5	-0.44	-7.47	-0.38	7.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-7.57	-0.38	3.89e-13	Primary sclerosing cholangitis;
CRC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.82	12.72	0.57	2.08e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs6838801	0.964	rs7686697	chr4:77570354	T/A	cg17476223	chr4:77663285	SHROOM3	0.41	5.61	0.3	4.2e-8	Cleft lip with or without cleft palate;
CRC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg14530993	chr4:882597	GAK	0.82	7.87	0.4	5.02e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	8.47	0.42	8.24e-16	Response to antipsychotic treatment;
CRC	cis	rs6479527	0.840	rs1331217	chr9:96766510	A/C	cg14459158	chr9:96720562	NA	0.41	7.4	0.38	1.16e-12	Esophageal adenocarcinoma;
CRC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs11212617	0.967	rs227066	chr11:108209199	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.75	0.3	2.06e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs2882667	0.898	rs2882792	chr5:138380480	G/T	cg09476006	chr5:138032270	NA	0.44	7.44	0.38	8.91e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg19338460	chr6:170058176	WDR27	-0.72	-7.88	-0.4	4.8e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9545047	0.680	rs9545114	chr13:79997879	G/A	cg07061582	chr15:90234082	PEX11A;WDR93	0.41	5.97	0.31	6.15e-9	Schizophrenia;
CRC	cis	rs11955398	0.647	rs6449483	chr5:59995393	C/T	cg02684056	chr5:59996105	DEPDC1B	0.43	6.12	0.32	2.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg17948913	chr5:572064	NA	0.51	5.91	0.31	8.58e-9	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6076065	0.723	rs6076073	chr20:23414489	G/A	cg11657817	chr20:23433608	CST11	0.42	6.19	0.32	1.76e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7605827	0.897	rs10166702	chr2:15528454	T/C	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	7.9e-9	Educational attainment (years of education);
CRC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.91	17.35	0.69	2.44e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg09307838	chr4:120376055	NA	0.64	9.48	0.46	5.15e-19	Educational attainment;
CRC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.72	10.6	0.5	9.06e-23	Immature fraction of reticulocytes;
CRC	cis	rs6743376	0.533	rs10206428	chr2:113826475	A/G	cg09040174	chr2:113837401	NA	0.41	6.2	0.32	1.71e-9	Inflammatory biomarkers;
CRC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg00430287	chr6:116382876	FRK	-0.2	-5.96	-0.31	6.65e-9	Cholesterol, total;LDL cholesterol;
CRC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.55	-8.9	-0.44	3.78e-17	Pulse pressure;
CRC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.5	6.97	0.36	1.7e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19857114	chr3:176741225	TBL1XR1	-0.49	-8.18	-0.41	6.12e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.44	6.33	0.33	8.19e-10	Asthma;
CRC	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg20356878	chr3:121714668	ILDR1	0.52	7.66	0.39	2.09e-13	Multiple sclerosis;
CRC	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.44	6.47	0.34	3.48e-10	Red blood cell count;
CRC	cis	rs9462846	0.692	rs1819325	chr6:42859748	C/A	cg21280719	chr6:42927975	GNMT	-0.34	-6.53	-0.34	2.49e-10	Blood protein levels;
CRC	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.43	-6.06	-0.32	3.73e-9	Daytime sleep phenotypes;
CRC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.53	6.94	0.36	2.13e-11	Multiple sclerosis;
CRC	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg12935359	chr14:103987150	CKB	-0.54	-8.06	-0.41	1.46e-14	Body mass index;
CRC	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.56	7.62	0.39	2.74e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	trans	rs994014	0.846	rs1115919	chr4:82173397	A/G	cg25444236	chr13:96329629	DNAJC3	-0.44	-5.97	-0.31	6.06e-9	Height;
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg15147215	chr3:52552868	STAB1	-0.67	-11.76	-0.54	6.88e-27	Electroencephalogram traits;
CRC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	0.91	10.97	0.52	4.52e-24	Iron status biomarkers;
CRC	cis	rs4731207	0.671	rs5022495	chr7:124444024	A/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17267835	chr6:161413433	MAP3K4	0.45	6.7	0.35	9.16e-11	Response to antipsychotic treatment;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23708337	chr7:1209742	NA	0.53	8.14	0.41	8.34e-15	Longevity;Endometriosis;
CRC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.5	7.26	0.37	2.89e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-6.54	-0.34	2.34e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs11581859	0.950	rs17119203	chr1:99373662	C/T	cg12183875	chr3:169587454	LRRC31	0.27	6.37	0.33	6.5e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg11707556	chr5:10655725	ANKRD33B	0.37	6.72	0.35	7.93e-11	Coronary artery disease;
CRC	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-8.24	-0.41	4.03e-15	HDL cholesterol;
CRC	trans	rs6426142	0.790	rs2050627	chr1:224824195	A/G	cg11504805	chr13:114815119	RASA3	-0.51	-5.96	-0.31	6.36e-9	Cancer;
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg12516270	chr8:143859308	LYNX1	0.44	7.93	0.4	3.55e-14	Urinary tract infection frequency;
CRC	cis	rs4478858	0.746	rs60073066	chr1:31689589	G/A	cg00250761	chr1:31883323	NA	0.31	5.92	0.31	8.29e-9	Alcohol dependence;
CRC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.41	6.62	0.34	1.48e-10	Dupuytren's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16365086	chr5:150603689	CCDC69	0.43	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.02	0.36	1.29e-11	Prostate cancer;
CRC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.38	-0.33	5.9e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.78	-0.3	1.75e-8	Bipolar disorder;
CRC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg03037974	chr15:76606532	NA	0.67	11.27	0.53	4.03e-25	Blood metabolite levels;
CRC	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.66	10.67	0.51	5.05e-23	Cancer;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg23161317	chr6:28129485	ZNF389	0.45	6.56	0.34	2.05e-10	Parkinson's disease;
CRC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.75e-9	Ulcerative colitis;
CRC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg12573674	chr2:1569213	NA	-0.74	-7.54	-0.38	4.61e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.49	7.86	0.4	5.72e-14	Coronary artery disease;
CRC	cis	rs1179624	0.679	rs12536918	chr7:75266699	C/T	cg05145297	chr7:75264568	HIP1	0.63	8.68	0.43	1.8e-16	Age-related nuclear cataracts;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg02033258	chr5:131593261	PDLIM4	0.36	6.92	0.36	2.4e-11	Blood metabolite levels;
CRC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.61	-0.39	2.98e-13	Blood trace element (Zn levels);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg01492649	chr11:86749237	TMEM135	0.43	6.03	0.32	4.48e-9	Depressive symptom measurement or major depressive disorder;
CRC	trans	rs9771228	0.965	rs7806397	chr7:32303339	T/C	cg02979224	chr7:93204462	CALCR	0.35	6.02	0.31	4.7e-9	Cognitive ability;Verbal-numerical reasoning;
CRC	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.23	-9.97	-0.48	1.26e-20	Mitochondrial DNA levels;
CRC	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.39	-5.79	-0.3	1.65e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.69e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.63	12.91	0.58	4.04e-31	Schizophrenia;
CRC	trans	rs6546324	0.625	rs6717863	chr2:67844799	C/A	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.14	-0.32	2.38e-9	Endometriosis;
CRC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.65	9.79	0.47	5.07e-20	Birth weight;
CRC	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.64	0.3	3.63e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.39	7.62	0.39	2.75e-13	Mean corpuscular volume;
CRC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.12	0.52	1.36e-24	Colorectal cancer;
CRC	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg03929089	chr4:120376271	NA	0.66	5.96	0.31	6.44e-9	Myopia (pathological);
CRC	cis	rs501120	0.584	rs11238929	chr10:44708596	T/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg19223190	chr17:80058835	NA	0.41	6.56	0.34	2.12e-10	Life satisfaction;
CRC	cis	rs6694672	1.000	rs12677	chr1:197053373	G/A	cg13682187	chr1:196946512	CFHR5	0.48	7.65	0.39	2.3e-13	Asthma;
CRC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.6	-8.93	-0.44	3.13e-17	Aortic root size;
CRC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.44	-8.03	-0.4	1.72e-14	Prostate cancer;
CRC	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg11130432	chr3:121712080	ILDR1	-0.51	-6.65	-0.34	1.23e-10	Multiple sclerosis;
CRC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.46	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg20488157	chr14:104394430	TDRD9	-0.67	-9.25	-0.45	2.86e-18	Bipolar disorder;
CRC	cis	rs9296736	0.922	rs614956	chr6:53950865	G/A	cg04374786	chr6:53939321	C6orf142	0.45	7.39	0.38	1.25e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg12273811	chr6:28175739	NA	0.46	6.96	0.36	1.86e-11	Cardiac Troponin-T levels;
CRC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.96	0.36	1.91e-11	Mood instability;
CRC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.42	-5.99	-0.31	5.4e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.49	-6.69	-0.35	9.48e-11	Intelligence (multi-trait analysis);
CRC	cis	rs67981189	0.579	rs2240533	chr14:71541026	T/C	cg15910301	chr14:71632612	NA	0.31	6.18	0.32	1.95e-9	Schizophrenia;
CRC	cis	rs12519773	0.526	rs4285204	chr5:92528272	C/T	cg18783429	chr5:92414398	NA	0.28	5.94	0.31	7.45e-9	Migraine;
CRC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg23018236	chr17:30244563	NA	-0.65	-7.74	-0.39	1.21e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg13798780	chr7:105162888	PUS7	0.67	7.93	0.4	3.42e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.73	0.3	2.3e-8	Rheumatoid arthritis;
CRC	cis	rs3823572	0.525	rs2346445	chr7:133717904	T/C	cg03336402	chr7:133662267	EXOC4	-0.66	-9.31	-0.46	1.9e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2811415	0.597	rs9827668	chr3:127775480	G/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg00947319	chr17:47005597	UBE2Z	-0.35	-6.08	-0.32	3.41e-9	Type 2 diabetes;
CRC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg03037974	chr15:76606532	NA	0.66	11.61	0.54	2.33e-26	Blood metabolite levels;
CRC	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.65	-9.46	-0.46	6.05e-19	Type 2 diabetes;
CRC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.55	10.17	0.49	2.62e-21	HDL cholesterol levels;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg06470822	chr6:28175283	NA	0.61	8.88	0.44	4.53e-17	Parkinson's disease;
CRC	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.49	8.63	0.43	2.75e-16	Testicular germ cell tumor;
CRC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.41	6.07	0.32	3.51e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	trans	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.99	0.36	1.54e-11	Mean corpuscular volume;
CRC	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg04586622	chr2:25135609	ADCY3	-0.38	-6.78	-0.35	5.65e-11	Body mass index in non-asthmatics;
CRC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	27.12	0.83	6.77e-86	IgG glycosylation;
CRC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg20607287	chr7:12443886	VWDE	-0.6	-6.22	-0.32	1.55e-9	Coronary artery disease;
CRC	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg20356878	chr3:121714668	ILDR1	0.49	7.65	0.39	2.22e-13	Cognitive performance;
CRC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.15	0.45	5.95e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg13777783	chr17:79615861	NA	-0.3	-5.71	-0.3	2.53e-8	Eye color traits;
CRC	cis	rs12745968	0.561	rs4847306	chr1:93216972	C/G	cg17283838	chr1:93427260	FAM69A	-0.44	-5.97	-0.31	5.99e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.94e-9	Schizophrenia;
CRC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.57	8.3	0.42	2.74e-15	Type 2 diabetes;
CRC	cis	rs56307353	0.513	rs2041120	chr19:1961474	C/T	cg24355006	chr19:1969744	CSNK1G2	0.53	8.53	0.43	5.27e-16	Coronary artery disease;
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.49	6.76	0.35	6.24e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.72	10.32	0.49	8.13e-22	Cognitive function;
CRC	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	1.04	12.93	0.58	3.41e-31	IgG glycosylation;
CRC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.71	-8.53	-0.43	5.35e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg03623178	chr6:28175578	NA	0.7	8.4	0.42	1.32e-15	Parkinson's disease;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg21251018	chr6:28226885	NKAPL	0.57	10.06	0.49	6.22e-21	Cardiac Troponin-T levels;
CRC	cis	rs2415984	0.570	rs28674745	chr14:46924415	G/C	cg14871534	chr14:47121158	RPL10L	-0.44	-6.28	-0.33	1.06e-9	Number of children ever born;
CRC	cis	rs7517126	1.000	rs2336505	chr1:196843655	A/G	cg13682187	chr1:196946512	CFHR5	-0.35	-5.7	-0.3	2.69e-8	Blood protein levels;
CRC	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.52	10.02	0.48	8.14e-21	Urate levels in lean individuals;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.52	7.66	0.39	2.15e-13	Longevity;Endometriosis;
CRC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.44	-6.06	-0.32	3.76e-9	Diastolic blood pressure;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.79	-13.46	-0.6	3.22e-33	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg23425280	chr12:56401806	NA	0.47	5.95	0.31	6.88e-9	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08498830	chr11:832797	CD151	0.43	6.16	0.32	2.14e-9	Response to antipsychotic treatment;
CRC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg03361068	chr14:51561562	TRIM9	0.28	5.74	0.3	2.21e-8	Cancer;
CRC	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg03037974	chr15:76606532	NA	-0.55	-8.08	-0.41	1.25e-14	Blood metabolite levels;
CRC	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg00601450	chr5:74908170	NA	0.38	5.73	0.3	2.28e-8	Age-related disease endophenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24928043	chr6:44191279	SLC29A1	0.37	6.14	0.32	2.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg24463073	chr6:118973353	C6orf204	0.52	6.84	0.35	3.84e-11	Diastolic blood pressure;
CRC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.54	-9.0	-0.44	1.86e-17	Age at first birth;
CRC	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.56	-6.58	-0.34	1.83e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs2857891	0.773	rs2638100	chr11:6969676	C/G	cg04053776	chr11:6947353	ZNF215	0.42	5.98	0.31	5.92e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg26587870	chr6:27730563	NA	-0.44	-6.74	-0.35	6.91e-11	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.45	6.72	0.35	8.06e-11	Breast cancer;
CRC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.71	-14.15	-0.62	7.92e-36	Breast cancer;
CRC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.43	-0.33	4.6e-10	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13961709	chr14:74486189	C14orf45;ENTPD5	0.55	7.24	0.37	3.25e-12	Thyroid stimulating hormone;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg22171725	chr15:72523569	PKM2	0.49	6.22	0.32	1.53e-9	Resistin levels;
CRC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.41	5.6	0.3	4.47e-8	Emphysema distribution in smoking;
CRC	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.93	9.18	0.45	5.08e-18	Blood protein levels;
CRC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	6.01	0.31	5.04e-9	Renal function-related traits (BUN);
CRC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.9	-0.4	4.09e-14	Cystic fibrosis severity;
CRC	cis	rs11233250	0.502	rs963575	chr11:82412298	A/G	cg17391194	chr11:82401662	NA	0.39	6.03	0.32	4.3e-9	Glioblastoma;Glioma;
CRC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	9.79	0.48	4.91e-20	Hemoglobin concentration;
CRC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg08027265	chr7:2291960	NA	-0.37	-6.37	-0.33	6.51e-10	Schizophrenia;
CRC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg14631576	chr9:95140430	CENPP	-0.41	-7.24	-0.37	3.14e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.97	-0.31	6.21e-9	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09264088	chr15:63569686	APH1B	0.38	6.01	0.31	4.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	5.82	0.31	1.36e-8	Bipolar disorder;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.52	6.14	0.32	2.44e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.45	-6.45	-0.33	4.09e-10	Platelet distribution width;
CRC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.66	11.37	0.53	1.69e-25	Mean corpuscular volume;
CRC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.96	0.52	4.76e-24	Coronary artery disease;
CRC	cis	rs6586163	0.967	rs10887877	chr10:90753038	A/G	cg13456138	chr10:90753195	FAS	-0.44	-6.8	-0.35	5.07e-11	Chronic lymphocytic leukemia;
CRC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	12.95	0.58	2.73e-31	Menarche (age at onset);
CRC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.69	9.47	0.46	5.63e-19	Vitiligo;
CRC	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	21.21	0.76	1.53e-63	Metabolite levels;
CRC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.85	0.44	5.32e-17	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.86	-10.15	-0.49	3.12e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs75059851	0.778	rs73034263	chr11:133808038	C/G	cg17703048	chr11:133852993	NA	-0.45	-6.03	-0.32	4.44e-9	Schizophrenia;
CRC	cis	rs7781557	1.000	rs727175	chr7:102471780	T/C	cg18108683	chr7:102477205	FBXL13	-0.56	-7.07	-0.36	9.05e-12	Colorectal adenoma (advanced);
CRC	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.7	-7.18	-0.37	4.61e-12	Type 2 diabetes;
CRC	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.54	-6.24	-0.33	1.35e-9	Blood protein levels;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg26587870	chr6:27730563	NA	-0.45	-6.55	-0.34	2.18e-10	Parkinson's disease;
CRC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg16482183	chr6:26056742	HIST1H1C	0.42	6.16	0.32	2.17e-9	Height;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.6	-0.39	3.22e-13	Psoriasis;
CRC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg03013999	chr17:37608204	MED1	-0.46	-6.85	-0.35	3.7e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.82	-14.2	-0.62	5.17e-36	Height;
CRC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	3.04e-10	Fibrinogen levels;
CRC	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg24759859	chr6:86352639	SYNCRIP	0.45	6.26	0.33	1.19e-9	Smooth-surface caries;
CRC	cis	rs2252521	1.000	rs2252521	chr7:29041190	C/T	cg11728747	chr7:29037910	CPVL	0.34	6.13	0.32	2.56e-9	Cognitive performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16403912	chr8:23104730	CHMP7	0.45	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg14191688	chr11:70257035	CTTN	0.48	6.2	0.32	1.71e-9	Coronary artery disease;
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg05313129	chr8:58192883	C8orf71	-0.42	-5.84	-0.31	1.23e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06307176	chr5:131281290	NA	-0.41	-5.96	-0.31	6.63e-9	Life satisfaction;
CRC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.57	7.99	0.4	2.23e-14	Resting heart rate;
CRC	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg15131784	chr3:139108705	COPB2	-0.4	-5.82	-0.31	1.42e-8	Obesity-related traits;
CRC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg03948781	chr1:205179583	DSTYK	0.43	5.98	0.31	5.9e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9443189	1.000	rs9443189	chr6:76495882	A/G	cg01950844	chr6:76311363	SENP6	0.56	6.65	0.34	1.2e-10	Prostate cancer;
CRC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg14593290	chr7:50529359	DDC	-0.44	-6.38	-0.33	6.02e-10	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19672329	chr7:98923317	ARPC1A	0.46	6.3	0.33	9.35e-10	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs673253	0.556	rs489319	chr1:44131794	C/T	cg10881128	chr1:44031826	PTPRF	0.23	6.11	0.32	2.88e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23039201	chr2:27851887	GPN1;CCDC121	0.4	6.51	0.34	2.89e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-16.9	-0.68	1.5e-46	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17819983	chr9:140189914	NA	-0.41	-6.11	-0.32	2.81e-9	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18331098	chr11:120081749	OAF	0.42	6.29	0.33	9.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.41	9.08	0.45	1.06e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.77	-0.3	1.8e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06656553	chr16:89960601	TCF25	-0.66	-5.93	-0.31	7.58e-9	Skin colour saturation;
CRC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.1	0.32	2.99e-9	Diabetic kidney disease;
CRC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.74	-0.35	6.95e-11	Total body bone mineral density;
CRC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.49	6.59	0.34	1.76e-10	IgG glycosylation;
CRC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg24910161	chr17:38119198	GSDMA	-0.36	-5.94	-0.31	7.28e-9	Myeloid white cell count;
CRC	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.75	7.63	0.39	2.49e-13	Neuroticism;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg24375607	chr4:120327624	NA	0.48	7.31	0.37	2.08e-12	Corneal astigmatism;
CRC	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg03651054	chr13:50194643	NA	0.29	5.61	0.3	4.27e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.53e-10	Response to antipsychotic treatment;
CRC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg02007433	chr3:129722099	NA	-0.44	-5.98	-0.31	5.81e-9	Blood pressure (smoking interaction);
CRC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.81	-13.02	-0.58	1.5e-31	Cognitive function;
CRC	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.4	6.8	0.35	5e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12980942	0.872	rs12974420	chr19:41798660	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.52	6.02	0.31	4.73e-9	Coronary artery disease;
CRC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.31	12.49	0.57	1.48e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.34	-0.46	1.54e-18	Urate levels in obese individuals;
CRC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.69	-10.92	-0.52	6.83e-24	Coronary artery disease;
CRC	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.59	-8.17	-0.41	6.53e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	8.61	0.43	3.02e-16	Cognitive test performance;
CRC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.44	6.83	0.35	4.14e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-10.44	-0.5	3.26e-22	Heart rate;
CRC	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg03030879	chr14:75389066	RPS6KL1	0.41	6.16	0.32	2.1e-9	Height;
CRC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.35	6.81	0.35	4.74e-11	Renal cell carcinoma;
CRC	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-7.89	-0.4	4.44e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg05569086	chr8:143859399	LYNX1	0.38	6.74	0.35	7.09e-11	Urinary tract infection frequency;
CRC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.41	6.7	0.35	9.2e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01766534	chr2:224822249	MRPL44	0.43	5.97	0.31	6.31e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.63	-0.43	2.73e-16	Aortic root size;
CRC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.53	-7.74	-0.39	1.26e-13	Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21126573	chr17:7755257	KDM6B	0.46	6.02	0.31	4.53e-9	Anxiety disorder;
CRC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg11632617	chr15:75315747	PPCDC	-0.54	-7.25	-0.37	3.02e-12	Blood trace element (Zn levels);
CRC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.05	-0.36	1.04e-11	Total body bone mineral density;
CRC	trans	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.56	-6.61	-0.34	1.59e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-9.32	-0.46	1.77e-18	Hip circumference adjusted for BMI;
CRC	cis	rs12286929	0.617	rs11607928	chr11:115102224	A/G	cg04055981	chr11:115044050	NA	0.37	5.74	0.3	2.18e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.38	-6.85	-0.35	3.7e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7731657	0.537	rs2097797	chr5:130355151	C/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.8	-0.3	1.57e-8	Fasting plasma glucose;
CRC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg15848620	chr12:58087721	OS9	0.54	6.34	0.33	7.73e-10	Multiple sclerosis;
CRC	cis	rs12476592	0.602	rs6546019	chr2:63817440	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.06	0.32	3.75e-9	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06124975	chr6:107810578	SOBP	0.44	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
CRC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21028142	chr17:79581711	NPLOC4	0.33	6.97	0.36	1.77e-11	Eye color traits;
CRC	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.98	0.31	5.92e-9	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06998765	chr14:75389618	RPS6KL1	0.23	5.63	0.3	3.9e-8	Caffeine consumption;
CRC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg16898833	chr6:26189333	HIST1H4D	0.94	7.65	0.39	2.25e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg15181151	chr6:150070149	PCMT1	0.3	5.74	0.3	2.2e-8	Lung cancer;
CRC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.22	-0.41	4.69e-15	Alzheimer's disease (late onset);
CRC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.09	18.57	0.72	3.71e-53	Cognitive function;
CRC	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg02398342	chr17:80708632	TBCD;FN3K	0.53	6.24	0.33	1.37e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.75	15.13	0.64	1.23e-39	Leprosy;
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.9	12.6	0.57	5.78e-30	Alzheimer's disease;
CRC	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg06632207	chr12:54070931	ATP5G2	0.45	7.54	0.38	4.73e-13	Height;
CRC	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.28e-10	Obesity-related traits;
CRC	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg10437265	chr15:77819839	NA	0.67	11.95	0.55	1.41e-27	Type 2 diabetes;
CRC	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.02	0.45	1.6e-17	Coffee consumption (cups per day);
CRC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg04362960	chr10:104952993	NT5C2	0.46	6.18	0.32	1.85e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg14711859	chr11:8959438	ASCL3	0.4	6.77	0.35	5.98e-11	Hemoglobin concentration;
CRC	cis	rs501120	1.000	rs687175	chr10:44751910	C/T	cg09554077	chr10:44749378	NA	-0.89	-13.4	-0.59	5.55e-33	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6681460	0.625	rs6680364	chr1:67104834	G/A	cg02459107	chr1:67143332	SGIP1	0.32	5.77	0.3	1.85e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.72	-0.47	8.69e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.52	7.05	0.36	1.08e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.13	19.08	0.72	3.72e-55	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs4731207	0.596	rs1871770	chr7:124630839	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.34	-0.33	7.73e-10	Cutaneous malignant melanoma;
CRC	cis	rs62229266	0.659	rs2835258	chr21:37424365	G/A	cg12218747	chr21:37451666	NA	-0.38	-6.42	-0.33	4.65e-10	Mitral valve prolapse;
CRC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.05	0.36	1.05e-11	Life satisfaction;
CRC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.88	-0.4	4.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.9	-0.51	8.19e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg11130432	chr3:121712080	ILDR1	-0.54	-6.31	-0.33	9.1e-10	Multiple sclerosis;
CRC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg12193833	chr17:30244370	NA	-0.61	-7.36	-0.38	1.5e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.72	-0.3	2.43e-8	Life satisfaction;
CRC	cis	rs7705042	0.865	rs166079	chr5:141528959	C/T	cg07392085	chr5:141489673	NDFIP1	0.46	7.35	0.38	1.6e-12	Asthma;
CRC	cis	rs12692738	0.526	rs355843	chr2:165622946	A/G	cg03182029	chr2:165697222	COBLL1	0.51	5.98	0.31	5.74e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.45	-0.5	2.85e-22	Alzheimer's disease;
CRC	cis	rs17767392	0.871	rs35468256	chr14:71839524	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg14515779	chr1:101123966	NA	-0.44	-8.4	-0.42	1.33e-15	Monocyte count;
CRC	cis	rs17092148	0.887	rs4302281	chr20:33171645	C/T	cg08999081	chr20:33150536	PIGU	-0.45	-5.89	-0.31	9.34e-9	Neuroticism;
CRC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.11	-0.32	2.83e-9	Menopause (age at onset);
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg12516270	chr8:143859308	LYNX1	0.4	7.1	0.36	7.66e-12	Urinary tract infection frequency;
CRC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.73	-0.3	2.24e-8	Life satisfaction;
CRC	cis	rs2530545	0.512	rs2893482	chr7:34629104	C/T	cg14401837	chr7:34697493	NPSR1	-0.36	-5.63	-0.3	3.82e-8	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.37	-6.04	-0.32	4.18e-9	Diastolic blood pressure;
CRC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	7.94	0.4	3.22e-14	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.67	9.91	0.48	1.92e-20	Cognitive function;
CRC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.91	10.35	0.5	6.29e-22	Psoriasis;
CRC	trans	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.23	6.16	0.32	2.12e-9	Type 2 diabetes;
CRC	cis	rs13144136	0.687	rs11734917	chr4:10660359	C/T	cg10242279	chr4:10666415	CLNK	-0.38	-6.46	-0.34	3.73e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.49	6.9	0.36	2.73e-11	HDL cholesterol;
CRC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.41	6.7	0.35	8.91e-11	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14275779	chr17:40830236	PLEKHH3	0.48	6.74	0.35	7.14e-11	Response to antipsychotic treatment;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21215811	chr17:40925428	VPS25	0.45	7.17	0.37	5.11e-12	Myopia (pathological);
CRC	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg25809561	chr17:30822961	MYO1D	0.52	9.16	0.45	5.75e-18	Schizophrenia;
CRC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.54	7.37	0.38	1.37e-12	Total body bone mineral density;
CRC	cis	rs1403694	1.000	rs1624230	chr3:186438935	A/C	cg04611788	chr3:186434169	KNG1	0.45	6.86	0.35	3.33e-11	Blood protein levels;
CRC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.48	-0.38	6.72e-13	Mean corpuscular volume;
CRC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-5.64	-0.3	3.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg15534755	chr11:117069859	TAGLN	0.34	6.67	0.35	1.09e-10	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02971627	chr15:59042282	ADAM10	0.49	6.15	0.32	2.26e-9	Thyroid stimulating hormone;
CRC	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.91	-0.4	4.04e-14	Cholesterol, total;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.71	0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg10935138	chr17:73851978	WBP2	0.56	6.98	0.36	1.59e-11	Psoriasis;
CRC	cis	rs9992667	0.704	rs3900761	chr4:38611582	C/G	cg19726192	chr4:38663646	FLJ13197	0.6	6.5	0.34	2.91e-10	Eosinophil percentage of granulocytes;
CRC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.56	8.47	0.42	8.43e-16	Calcium levels;
CRC	cis	rs7572733	0.537	rs2340688	chr2:198438425	A/G	cg10820045	chr2:198174542	NA	0.36	6.18	0.32	1.91e-9	Dermatomyositis;
CRC	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.13	-0.37	6.27e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg18232548	chr7:50535776	DDC	0.49	6.79	0.35	5.29e-11	Malaria;
CRC	cis	rs10071761	0.513	rs12518585	chr5:40361676	G/A	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.66	-0.39	2.14e-13	Total body bone mineral density;
CRC	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.7	8.36	0.42	1.8e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs834811	0.563	rs1121038	chr7:135879132	T/C	cg01726295	chr7:135938950	NA	0.34	5.69	0.3	2.85e-8	Post-traumatic stress disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07376846	chr1:203765385	ZC3H11A	0.45	6.2	0.32	1.65e-9	Response to antipsychotic treatment;
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg24046110	chr8:143859143	LYNX1	0.49	8.65	0.43	2.37e-16	Urinary tract infection frequency;
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.82	-0.31	1.42e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.84	13.86	0.61	1e-34	Menarche (age at onset);
CRC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.77	-0.51	2.3e-23	Body mass index;
CRC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.66	10.8	0.51	1.82e-23	Colorectal cancer;
CRC	cis	rs12922317	0.589	rs350215	chr16:12151283	A/G	cg02368508	chr16:12060182	TNFRSF17	-0.39	-5.87	-0.31	1.05e-8	Schizophrenia;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.62	-0.54	2.25e-26	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11601666	chr17:8286754	RPL26	0.41	6.42	0.33	4.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.97	14.02	0.61	2.38e-35	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2303319	0.582	rs62187608	chr2:162431138	T/G	cg00039960	chr17:7142925	PHF23	-0.73	-5.99	-0.31	5.63e-9	Cognitive function;
CRC	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12172441	chr6:28176163	NA	0.55	6.94	0.36	2.03e-11	Parkinson's disease;
CRC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg03030879	chr14:75389066	RPS6KL1	0.47	7.21	0.37	3.87e-12	Height;
CRC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.8	-12.02	-0.55	7.62e-28	Acne (severe);
CRC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg21948803	chr22:24024719	LOC91316	-0.58	-6.75	-0.35	6.88e-11	Lymphocyte counts;
CRC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.59	-8.9	-0.44	3.75e-17	Height;
CRC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.31	0.37	2.09e-12	Motion sickness;
CRC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg20243544	chr17:37824526	PNMT	0.55	8.87	0.44	4.67e-17	Asthma;
CRC	cis	rs4716602	0.622	rs36071136	chr7:156166303	G/C	cg16983916	chr7:156159713	NA	-0.33	-5.62	-0.3	4.02e-8	Anti-saccade response;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg02683197	chr6:28174875	NA	0.63	8.77	0.44	1e-16	Parkinson's disease;
CRC	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.34e-11	Prostate cancer;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.09e-22	Prudent dietary pattern;
CRC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.74	-0.54	8.41e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs356992	0.830	rs356991	chr2:60744872	T/G	cg08426369	chr2:60753602	BCL11A	0.54	7.46	0.38	8e-13	Educational attainment (years of education);
CRC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26373071	chr5:1325741	CLPTM1L	0.5	8.98	0.44	2.09e-17	Lung cancer;
CRC	cis	rs2882667	1.000	rs10064130	chr5:138309307	C/T	cg09476006	chr5:138032270	NA	0.46	7.37	0.38	1.41e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11098699	0.769	rs6812009	chr4:124215392	A/G	cg09941581	chr4:124220074	SPATA5	0.42	6.28	0.33	1.05e-9	Mosquito bite size;
CRC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg12365402	chr11:9010492	NRIP3	-0.35	-5.84	-0.31	1.24e-8	Hematocrit;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg23034840	chr1:205782522	SLC41A1	0.5	6.65	0.34	1.21e-10	Menarche (age at onset);
CRC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg19223190	chr17:80058835	NA	-0.5	-8.11	-0.41	1e-14	Life satisfaction;
CRC	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	11.82	0.55	4.25e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	cis	rs11212617	1.000	rs609261	chr11:108158134	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.16	0.32	2.08e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.41	-6.38	-0.33	6.1e-10	Blood metabolite levels;
CRC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.59	10.32	0.49	8.43e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg06581033	chr10:766294	NA	-0.5	-5.76	-0.3	1.93e-8	Uric acid levels;
CRC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.43	6.41	0.33	5.09e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6840360	0.642	rs2034061	chr4:152420756	C/T	cg09659197	chr4:152720779	NA	0.33	6.54	0.34	2.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.4	5.73	0.3	2.27e-8	HDL cholesterol;
CRC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.61	7.71	0.39	1.54e-13	Dilated cardiomyopathy;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.66	-10.73	-0.51	3.06e-23	Monocyte percentage of white cells;
CRC	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	cis	rs55871839	0.708	rs1562612	chr8:59817068	A/G	cg07426533	chr8:59803705	TOX	-0.34	-5.87	-0.31	1.06e-8	Pneumonia;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg06872519	chr11:6947619	ZNF215	0.58	5.79	0.3	1.68e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.39	-5.87	-0.31	1.06e-8	Longevity;
CRC	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.32	8.07	0.41	1.31e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23653712	chr4:52904379	SGCB	0.46	6.49	0.34	3.14e-10	Anxiety disorder;
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg12516270	chr8:143859308	LYNX1	0.56	9.85	0.48	3.12e-20	Urinary tract infection frequency;
CRC	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12560992	chr17:57184187	TRIM37	0.56	7.65	0.39	2.25e-13	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg05250797	chr16:70222502	NA	-0.44	-6.14	-0.32	2.42e-9	IgE levels;
CRC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.52	-7.07	-0.36	9.57e-12	Glycated hemoglobin levels;
CRC	trans	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg16141378	chr3:129829833	LOC729375	0.43	6.44	0.33	4.3e-10	Mood instability;
CRC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.78	-13.17	-0.59	4.24e-32	Obesity-related traits;
CRC	trans	rs11654801	0.947	rs716959	chr17:20916590	A/G	cg23759823	chr7:139672531	TBXAS1	-0.48	-6.91	-0.36	2.47e-11	Mosquito bite size;
CRC	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg02158880	chr13:53174818	NA	0.49	7.37	0.38	1.37e-12	Lewy body disease;
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.33	-0.42	2.18e-15	Electroencephalogram traits;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg03609269	chr1:53393023	SCP2	-0.39	-6.15	-0.32	2.29e-9	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15798279	chr7:6523691	KDELR2	0.45	6.37	0.33	6.33e-10	Response to antipsychotic treatment;
CRC	cis	rs3751196	0.808	rs56314567	chr12:104209772	C/T	cg02344784	chr12:104178138	NT5DC3	0.69	7.11	0.36	7.23e-12	Sense of smell;
CRC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02450064	chr17:40260053	DHX58	-0.43	-6.24	-0.33	1.38e-9	Fibrinogen levels;
CRC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.07	0.71	3.39e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.48	6.34	0.33	7.5e-10	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	15.84	0.66	2.1e-42	Colorectal cancer;
CRC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.67	8.87	0.44	4.75e-17	Morning vs. evening chronotype;
CRC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.9	-0.4	4.35e-14	Gut microbiome composition (summer);
CRC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-8.8	-0.44	7.66e-17	Morning vs. evening chronotype;
CRC	cis	rs755249	0.567	rs72637906	chr1:39708302	G/A	cg18385671	chr1:39797026	MACF1	-0.44	-6.09	-0.32	3.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg04110750	chr16:69646130	NFAT5	-0.54	-7.49	-0.38	6.47e-13	IgE levels;
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg15147215	chr3:52552868	STAB1	-0.66	-11.7	-0.54	1.08e-26	Electroencephalogram traits;
CRC	cis	rs2811415	0.561	rs9857061	chr3:127763226	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.54	0.5	1.46e-22	Corneal astigmatism;
CRC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	7.47	0.38	7.05e-13	Breast cancer;
CRC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.71	11.38	0.53	1.57e-25	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg04880052	chr2:219191631	PNKD	0.42	6.76	0.35	6.16e-11	Colorectal cancer;
CRC	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.34	5.61	0.3	4.19e-8	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
CRC	cis	rs939584	1.000	rs4854343	chr2:638107	G/A	cg03610516	chr2:642275	NA	0.42	5.68	0.3	2.91e-8	Body mass index;
CRC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	15.42	0.65	9.26e-41	Lymphocyte percentage of white cells;
CRC	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg18833306	chr6:118973337	C6orf204	0.45	5.81	0.3	1.49e-8	Diastolic blood pressure;
CRC	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.52	7.99	0.4	2.34e-14	Calcium levels;
CRC	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg11788234	chr13:29393811	NA	0.53	9.23	0.45	3.35e-18	Obesity-related traits;
CRC	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg26353448	chr1:248524236	OR2T4	-0.34	-6.49	-0.34	3.09e-10	Common traits (Other);
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.19	-0.45	4.45e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.7	8.29	0.42	2.85e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.47	6.65	0.34	1.22e-10	Lung cancer;
CRC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.62	-9.55	-0.47	3.16e-19	Colorectal cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19689029	chr1:150898761	SETDB1	-0.38	-6.12	-0.32	2.64e-9	Aortic root size;
CRC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06544989	chr22:39130855	UNC84B	0.44	6.93	0.36	2.22e-11	Menopause (age at onset);
CRC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.79	-13.2	-0.59	3.3e-32	Coronary artery disease;
CRC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.78	13.58	0.6	1.16e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.67	12.33	0.56	5.6e-29	Body mass index;
CRC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg01097406	chr16:89675127	NA	0.44	8.52	0.43	5.83e-16	Hemoglobin concentration;
CRC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg20573242	chr4:122745356	CCNA2	0.43	6.3	0.33	9.36e-10	Type 2 diabetes;
CRC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.19	0.69	1.08e-47	Platelet count;
CRC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg03030879	chr14:75389066	RPS6KL1	0.43	6.47	0.34	3.59e-10	Height;
CRC	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg12315302	chr6:26189340	HIST1H4D	0.78	6.15	0.32	2.21e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24437429	chr17:1012418	ABR	0.48	6.74	0.35	7.15e-11	Anxiety disorder;
CRC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg03013999	chr17:37608204	MED1	-0.43	-6.43	-0.33	4.39e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg27534772	chr1:16042836	PLEKHM2	0.45	7.64	0.39	2.33e-13	Systolic blood pressure;
CRC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.29	-0.42	2.95e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg21856205	chr7:94953877	PON1	-0.52	-6.57	-0.34	2.01e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.93	0.52	6.05e-24	Motion sickness;
CRC	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.51	5.71	0.3	2.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.5	-6.3	-0.33	9.43e-10	Parkinson's disease;
CRC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.39	8.95	0.44	2.58e-17	Multiple system atrophy;
CRC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-0.89	-10.0	-0.48	9.92e-21	Breast cancer;
CRC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.61	-0.43	3.07e-16	Breast cancer;
CRC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg27661571	chr11:113659931	NA	-0.77	-9.59	-0.47	2.24e-19	Hip circumference adjusted for BMI;
CRC	cis	rs10484885	0.759	rs56230212	chr6:90234654	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.52	-0.34	2.67e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.4	5.69	0.3	2.83e-8	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs741668	0.897	rs56223000	chr13:46602635	G/A	cg06018095	chr13:46550134	ZC3H13	0.43	5.93	0.31	7.54e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs12711979	0.513	rs1454241	chr2:3851675	A/G	cg17052675	chr2:3827356	NA	0.36	6.38	0.33	6.14e-10	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg26851410	chr19:2785307	THOP1	-0.43	-6.18	-0.32	1.91e-9	Schizophrenia;
CRC	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.68	-6.98	-0.36	1.63e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7607369	0.559	rs6741592	chr2:219658609	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.23	-0.33	1.39e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg26353448	chr1:248524236	OR2T4	-0.33	-6.36	-0.33	6.59e-10	Common traits (Other);
CRC	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg07796016	chr1:152779584	LCE1C	-0.39	-5.73	-0.3	2.26e-8	Inflammatory skin disease;
CRC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3736485	0.966	rs12102203	chr15:51791559	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-6.17	-0.32	2.06e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg22495460	chr2:25135724	ADCY3	-0.82	-13.57	-0.6	1.31e-33	Body mass index;
CRC	cis	rs9549328	0.616	rs35086993	chr13:113617305	G/A	cg24588162	chr13:113633484	MCF2L	0.36	6.51	0.34	2.89e-10	Systolic blood pressure;
CRC	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg27205649	chr11:78285834	NARS2	0.52	6.68	0.35	1.01e-10	Alzheimer's disease (survival time);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18115495	chr7:65579946	CRCP	0.44	7.59	0.39	3.39e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.49	6.7	0.35	9.31e-11	Type 1 diabetes nephropathy;
CRC	cis	rs55788414	0.932	rs34444956	chr16:81185412	C/T	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.45	6.16	0.32	2.09e-9	Pulse pressure;
CRC	cis	rs4363385	0.693	rs440598	chr1:153044733	T/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.86e-10	Inflammatory skin disease;
CRC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	5.62	0.3	4.14e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.62	10.3	0.49	9.78e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs4728302	0.869	rs958404	chr7:133597186	G/T	cg03336402	chr7:133662267	EXOC4	0.44	6.43	0.33	4.5e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.42	5.79	0.3	1.67e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	7.68	0.39	1.78e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18099408	chr3:52552593	STAB1	-0.51	-8.9	-0.44	3.81e-17	Electroencephalogram traits;
CRC	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.67	-0.39	1.99e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1223397	0.651	rs2458314	chr6:13309224	C/T	cg20827128	chr6:13274284	PHACTR1	0.44	6.93	0.36	2.21e-11	Blood pressure;
CRC	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.56	10.14	0.49	3.25e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.53	9.53	0.47	3.54e-19	Vitiligo;
CRC	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg02811702	chr13:24901961	NA	0.47	6.6	0.34	1.64e-10	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg01191114	chr3:48936118	SLC25A20	-0.69	-6.0	-0.31	5.27e-9	Cognitive function;
CRC	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg25809561	chr17:30822961	MYO1D	-0.59	-11.15	-0.52	1.02e-24	Schizophrenia;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg03844506	chr4:4109441	NA	-0.51	-7.65	-0.39	2.2e-13	Blood pressure (smoking interaction);
CRC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-9.12	-0.45	7.41e-18	Mean corpuscular hemoglobin concentration;
CRC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.35	-0.42	1.88e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.5	7.25	0.37	3.09e-12	Height;
CRC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.37	-0.33	6.39e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.71	-7.66	-0.39	2.08e-13	Bipolar disorder;
CRC	cis	rs11212617	0.967	rs12272183	chr11:108077181	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.27	0.33	1.16e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.36	6.06	0.32	3.79e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg05681148	chr13:28195812	POLR1D;LNX2	-0.43	-6.09	-0.32	3.18e-9	Underweight status;
CRC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.57	8.54	0.43	5.08e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg20203395	chr5:56204925	C5orf35	-0.6	-8.17	-0.41	6.93e-15	Initial pursuit acceleration;
CRC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.98	0.31	5.68e-9	Schizophrenia;
CRC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.3	-0.46	2.01e-18	Intelligence (multi-trait analysis);
CRC	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg25019722	chr6:37503610	NA	-0.42	-7.61	-0.39	2.98e-13	Cognitive performance;
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg06470822	chr6:28175283	NA	0.95	9.78	0.47	5.18e-20	Depression;
CRC	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg12700464	chr11:78128424	GAB2	-0.48	-5.88	-0.31	1.03e-8	Testicular germ cell tumor;
CRC	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.01	9.32	0.46	1.67e-18	Lymphocyte counts;
CRC	cis	rs55702914	0.742	rs6744206	chr2:198148522	A/G	cg03934865	chr2:198174659	NA	-0.4	-6.92	-0.36	2.38e-11	Major depression and alcohol dependence;
CRC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.66	9.31	0.46	1.9e-18	Vitiligo;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg20041105	chr8:143859282	LYNX1	-0.41	-6.55	-0.34	2.18e-10	Urinary tract infection frequency;
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.42	5.71	0.3	2.59e-8	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.85	0.44	5.52e-17	Rheumatoid arthritis;
CRC	cis	rs17443541	0.507	rs7562008	chr2:200454560	A/G	cg03741458	chr2:200468445	NA	-0.38	-5.96	-0.31	6.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg14515779	chr1:101123966	NA	-0.43	-8.4	-0.42	1.36e-15	Monocyte count;
CRC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.66	8.81	0.44	7.3e-17	Morning vs. evening chronotype;
CRC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.68	10.54	0.5	1.39e-22	Gestational age at birth (maternal effect);
CRC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg12365402	chr11:9010492	NRIP3	0.57	10.72	0.51	3.31e-23	Hemoglobin concentration;
CRC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg24531977	chr5:56204891	C5orf35	-0.49	-7.54	-0.38	4.73e-13	Coronary artery disease;
CRC	cis	rs4731207	0.596	rs4406330	chr7:124641491	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.27e-9	Cutaneous malignant melanoma;
CRC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.98	-18.68	-0.72	1.4e-53	Height;
CRC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg08075719	chr14:103021372	NA	-0.68	-7.94	-0.4	3.23e-14	Platelet count;
CRC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg20578329	chr17:80767326	TBCD	-0.7	-9.22	-0.45	3.53e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19385725	chr18:21166173	NPC1	0.38	6.16	0.32	2.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.44	6.01	0.31	4.84e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18591801	chr3:52553433	STAB1	-0.29	-5.61	-0.3	4.2e-8	Electroencephalogram traits;
CRC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg27427491	chr17:78079615	GAA	-0.49	-7.17	-0.37	4.9e-12	Yeast infection;
CRC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.4	5.63	0.3	3.84e-8	Aortic root size;
CRC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.53	0.54	4.49e-26	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18113596	chr7:57247912	LOC642006	-0.32	-6.16	-0.32	2.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4132509	1.000	rs6429433	chr1:243857994	C/T	cg21452805	chr1:244014465	NA	0.51	6.75	0.35	6.84e-11	RR interval (heart rate);
CRC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.21	0.32	1.55e-9	Blood metabolite levels;
CRC	cis	rs4654899	0.802	rs61781104	chr1:21257235	T/A	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.35	-0.38	1.59e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.82	0.35	4.46e-11	Obesity-related traits;
CRC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.18e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17767392	0.918	rs12894016	chr14:71883088	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.88	-16.17	-0.67	1.06e-43	Coronary artery disease;
CRC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.85	-0.4	5.9e-14	Gut microbiome composition (summer);
CRC	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06307176	chr5:131281290	NA	0.42	6.08	0.32	3.42e-9	Life satisfaction;
CRC	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.97	-0.36	1.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05952120	chr17:61554416	ACE	0.41	6.5	0.34	2.9e-10	Interleukin-6 levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg09528111	chr14:31495531	AP4S1;STRN3	0.47	6.53	0.34	2.43e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg15193198	chr20:60906057	LAMA5	-0.43	-6.35	-0.33	7.12e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.48	7.34	0.38	1.69e-12	Corneal astigmatism;
CRC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.52	8.56	0.43	4.26e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.74	-11.29	-0.53	3.47e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2882667	0.931	rs10069528	chr5:138354027	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-5.89	-0.31	9.36e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7932354	0.502	rs11600668	chr11:47193566	G/A	cg03339077	chr11:47165057	C11orf49	-0.46	-6.16	-0.32	2.06e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg08213375	chr14:104286397	PPP1R13B	0.44	6.95	0.36	1.95e-11	Reticulocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23111772	chr20:62338704	ARFRP1;ZGPAT	0.4	6.29	0.33	1.03e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.51	7.98	0.4	2.42e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg03160526	chr17:80928410	B3GNTL1	-0.41	-5.85	-0.31	1.21e-8	Breast cancer;
CRC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.54e-9	Arsenic metabolism;
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg17346650	chr17:80929145	B3GNTL1	0.48	7.11	0.37	7.13e-12	Glycated hemoglobin levels;
CRC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.71	10.13	0.49	3.5e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.57	8.69	0.43	1.71e-16	Schizophrenia;
CRC	cis	rs12143943	0.966	rs12038102	chr1:204551407	G/A	cg17419461	chr1:204415978	PIK3C2B	0.43	6.43	0.33	4.52e-10	Cognitive performance;
CRC	cis	rs972578	0.967	rs2413736	chr22:43338839	G/A	cg01576275	chr22:43409880	NA	-0.45	-7.25	-0.37	3.09e-12	Mean platelet volume;
CRC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.13	0.37	6.4e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.27	-0.37	2.6e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.59	8.56	0.43	4.47e-16	Homoarginine levels;
CRC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg22777020	chr22:31556080	RNF185	0.44	5.82	0.31	1.43e-8	Colorectal cancer;
CRC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.5	-6.67	-0.35	1.07e-10	Glioblastoma;
CRC	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.71	9.1	0.45	9.12e-18	Prostate cancer;
CRC	cis	rs7192380	0.825	rs3811348	chr16:69782855	C/T	cg00738113	chr16:70207722	CLEC18C	0.37	6.24	0.33	1.37e-9	Sjögren's syndrome;
CRC	trans	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.25	-0.37	2.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.33	-0.33	7.99e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.93	13.35	0.59	8.71e-33	Breast cancer;
CRC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg04450456	chr4:17643702	FAM184B	-0.37	-5.94	-0.31	7.24e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.39	-0.38	1.25e-12	Morning vs. evening chronotype;
CRC	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.45	7.4	0.38	1.14e-12	Refractive error;
CRC	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.6	-9.38	-0.46	1.12e-18	Monocyte count;
CRC	trans	rs274508	0.926	rs274491	chr11:11099798	A/G	cg18158151	chr2:61372256	C2orf74	0.33	6.43	0.33	4.45e-10	Knee osteoarthritis;
CRC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.66	-8.37	-0.42	1.63e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9303542	0.559	rs56038617	chr17:46612578	C/T	cg04904318	chr17:46607828	HOXB1	-0.54	-6.24	-0.33	1.36e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7605827	0.930	rs7577130	chr2:15527859	G/A	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	7.9e-9	Educational attainment (years of education);
CRC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg18230493	chr5:56204884	C5orf35	0.38	5.85	0.31	1.18e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.73	13.65	0.6	6.56e-34	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	trans	rs17192198	0.661	rs73198557	chr12:90076293	G/T	cg17836913	chr1:54723679	SSBP3	-0.46	-6.02	-0.31	4.59e-9	Diastolic blood pressure;
CRC	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.41	6.83	0.35	4.06e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg17515076	chr17:73810948	UNK	0.39	6.19	0.32	1.74e-9	White matter hyperintensity burden;
CRC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.35	0.42	1.93e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg24562669	chr7:97807699	LMTK2	0.44	7.32	0.37	1.97e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg22777020	chr22:31556080	RNF185	0.49	5.93	0.31	7.6e-9	Colorectal cancer;
CRC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.72	-0.3	2.36e-8	Asthma;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder;
CRC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.77	-11.49	-0.54	6.25e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.41	-6.83	-0.35	4.06e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.48	0.34	3.33e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.62	5.98	0.31	5.74e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00166722	chr3:10149974	C3orf24	0.39	6.03	0.32	4.29e-9	Alzheimer's disease;
CRC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.84	-0.7	2.9e-50	Height;
CRC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.75	11.11	0.52	1.44e-24	Menopause (age at onset);
CRC	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.62e-12	Inflammatory skin disease;
CRC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.62	12.96	0.58	2.67e-31	Schizophrenia;
CRC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.43	0.53	1.04e-25	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00347280	chr1:45477834	HECTD3;UROD	0.44	6.13	0.32	2.52e-9	Response to antipsychotic treatment;
CRC	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg23740940	chr11:68924746	NA	0.44	5.75	0.3	2.04e-8	Blond vs. brown hair color;
CRC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.56	-9.0	-0.44	1.9e-17	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27339505	chr5:140998609	DIAPH1	0.51	6.95	0.36	1.91e-11	Anxiety disorder;
CRC	cis	rs12692738	0.526	rs355867	chr2:165631057	C/T	cg03182029	chr2:165697222	COBLL1	0.51	6.07	0.32	3.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.67	8.84	0.44	6.12e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.79	-0.39	9.04e-14	Prevalent atrial fibrillation;
CRC	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.39	6.04	0.32	4.16e-9	Diastolic blood pressure;
CRC	cis	rs1320333	0.772	rs17786111	chr2:700562	C/T	cg00500140	chr2:691012	NA	0.58	6.69	0.35	9.39e-11	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.73	0.43	1.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.44	7.63	0.39	2.59e-13	Common traits (Other);
CRC	cis	rs720844	0.684	rs13008203	chr2:149301897	C/A	cg09247360	chr2:149335327	NA	-0.58	-6.02	-0.32	4.55e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09423610	chr7:902986	UNC84A	-0.38	-6.35	-0.33	6.98e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg25152348	chr22:50946712	NCAPH2;LMF2	-0.42	-6.19	-0.32	1.79e-9	Birth weight;Height;
CRC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.73	10.9	0.52	8.07e-24	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg11887960	chr12:57824829	NA	0.62	6.76	0.35	6.26e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.66	7.79	0.39	8.63e-14	Vitiligo;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Parkinson's disease;
CRC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.5	6.45	0.33	4.04e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	6.13	0.32	2.49e-9	Height;
CRC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.41	6.41	0.33	5.01e-10	Methadone dose in opioid dependence;
CRC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.74	-10.54	-0.5	1.38e-22	Platelet distribution width;
CRC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-6.99	-0.36	1.51e-11	Lymphocyte counts;Fibrinogen;
CRC	cis	rs3824867	0.738	rs1228024	chr11:47951353	C/A	cg05585544	chr11:47624801	NA	-0.42	-7.11	-0.37	7.21e-12	Mean corpuscular hemoglobin;
CRC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.77	0.47	5.59e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.76	13.28	0.59	1.65e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg21153622	chr11:89784906	NA	0.44	7.09	0.36	8.39e-12	HDL cholesterol;
CRC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.56	7.55	0.38	4.32e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00475322	chr7:917719	C7orf20	0.42	7.43	0.38	9.54e-13	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-6.42	-0.33	4.63e-10	Total body bone mineral density;
CRC	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg11204139	chr17:3907470	NA	0.47	6.53	0.34	2.48e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg02702477	chr5:179499311	RNF130	-0.55	-6.34	-0.33	7.5e-10	LDL cholesterol;
CRC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.75	0.51	2.69e-23	Motion sickness;
CRC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.19	-0.41	5.78e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.53	0.38	4.88e-13	Eye color traits;
CRC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.36	-7.12	-0.37	6.85e-12	Subjective well-being;
CRC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.41	-6.0	-0.31	5.2e-9	Gout;Renal underexcretion gout;
CRC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.65	11.91	0.55	1.97e-27	Aortic root size;
CRC	cis	rs11212617	0.967	rs7118967	chr11:108057856	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.96	0.31	6.59e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs754466	0.706	rs7099526	chr10:79657705	C/G	cg17075019	chr10:79541650	NA	-0.78	-12.01	-0.55	8.7300000000000009e-28	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.54	-9.47	-0.46	5.74e-19	Aortic root size;
CRC	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	9.17	0.45	5.42e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg02569458	chr12:86230093	RASSF9	0.38	6.57	0.34	1.99e-10	Major depressive disorder;
CRC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg12682573	chr17:27188876	MIR451;MIR144	-0.57	-8.17	-0.41	6.6e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6738825	0.565	rs17787829	chr2:198419798	T/C	cg10820045	chr2:198174542	NA	0.32	5.69	0.3	2.88e-8	Crohn's disease;
CRC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.58	9.1	0.45	9.03e-18	Monocyte count;
CRC	cis	rs9584850	0.794	rs72655609	chr13:99128622	C/G	cg07423050	chr13:99094983	FARP1	0.44	6.01	0.31	4.97e-9	Neuroticism;
CRC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.9	11.05	0.52	2.39e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-10.07	-0.49	5.62e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.61	-8.56	-0.43	4.46e-16	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.68	11.78	0.54	5.72e-27	Gout;
CRC	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg22192744	chr12:123187474	GPR109A	-0.4	-5.67	-0.3	3.16e-8	Adiponectin levels;
CRC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19970200	chr7:47621223	NA	0.44	6.58	0.34	1.86e-10	Response to antipsychotic treatment;
CRC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12463550	chr7:65579703	CRCP	0.62	5.95	0.31	6.68e-9	Diabetic kidney disease;
CRC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.41	-0.38	1.1e-12	Major depressive disorder;
CRC	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.51	9.65	0.47	1.48e-19	Alcoholic chronic pancreatitis;
CRC	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.85	14.85	0.63	1.58e-38	Multiple myeloma;
CRC	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg23920097	chr1:209922102	NA	-0.52	-6.53	-0.34	2.55e-10	Red blood cell count;
CRC	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.59	-0.39	3.32e-13	Thrombosis;
CRC	cis	rs858239	0.863	rs274054	chr7:23390467	G/C	cg00469287	chr7:23338798	C7orf30	0.48	6.38	0.33	5.84e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.5	8.13	0.41	8.83e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.67	7.75	0.39	1.15e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.73	13.55	0.6	1.54e-33	Prudent dietary pattern;
CRC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.55	-8.53	-0.43	5.61e-16	Obesity-related traits;
CRC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.46	6.99	0.36	1.53e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7940866	0.874	rs10894290	chr11:130811049	T/G	cg12179176	chr11:130786555	SNX19	0.57	8.47	0.42	8.34e-16	Schizophrenia;
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00166722	chr3:10149974	C3orf24	0.66	9.01	0.45	1.66e-17	Alzheimer's disease;
CRC	cis	rs2386661	0.826	rs1317516	chr10:5672720	A/G	cg26603656	chr10:5671107	NA	-0.54	-8.38	-0.42	1.57e-15	Breast cancer;
CRC	trans	rs10242455	1.000	rs1859690	chr7:99227172	A/G	cg09045935	chr12:6379348	NA	0.61	6.72	0.35	7.84e-11	Blood metabolite levels;
CRC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg23018236	chr17:30244563	NA	-0.67	-8.01	-0.4	1.96e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.91	-0.31	8.35e-9	Reticulocyte fraction of red cells;
CRC	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.4	5.91	0.31	8.7e-9	Platelet distribution width;
CRC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.67	9.93	0.48	1.65e-20	Menopause (age at onset);
CRC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.58	9.63	0.47	1.69e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg13491945	chr12:107078410	RFX4	0.37	6.3	0.33	9.59e-10	Heart rate;
CRC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg00484396	chr16:3507460	NAT15	-0.62	-6.48	-0.34	3.37e-10	Tuberculosis;
CRC	cis	rs6695223	0.571	rs4907133	chr1:85538947	A/G	cg11262906	chr1:85462892	MCOLN2	-0.48	-6.11	-0.32	2.85e-9	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg10483660	chr13:112241077	NA	0.35	5.65	0.3	3.57e-8	Menarche (age at onset);
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg20092199	chr4:1342459	KIAA1530	0.47	7.71	0.39	1.5e-13	Obesity-related traits;
CRC	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg15123519	chr2:136567270	LCT	-0.3	-5.76	-0.3	1.96e-8	Mosquito bite size;
CRC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.82	7.76	0.39	1.07e-13	Diabetic retinopathy;
CRC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.96	-0.4	2.88e-14	Schizophrenia;
CRC	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10971721	0.822	rs10971723	chr9:33829602	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.58	-0.34	1.82e-10	Lung cancer;
CRC	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	18.63	0.72	2.21e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg06766960	chr11:133703094	NA	-0.34	-6.14	-0.32	2.43e-9	Childhood ear infection;
CRC	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.56	-9.37	-0.46	1.18e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.48	7.0	0.36	1.42e-11	Coronary heart disease;
CRC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg04518342	chr5:131593106	PDLIM4	0.46	7.31	0.37	2.06e-12	Breast cancer;
CRC	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg27171509	chr10:82033454	MAT1A	-0.47	-8.53	-0.43	5.25e-16	Borderline personality disorder;
CRC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg21251018	chr6:28226885	NKAPL	0.52	8.68	0.43	1.92e-16	Depression;
CRC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.75	0.39	1.19e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg20684491	chr1:25596433	NA	0.42	7.35	0.38	1.57e-12	Erythrocyte sedimentation rate;
CRC	cis	rs9467603	0.547	rs7752195	chr6:25419094	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.79	-6.31	-0.33	8.79e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg20203395	chr5:56204925	C5orf35	-0.72	-8.56	-0.43	4.42e-16	Initial pursuit acceleration;
CRC	cis	rs7259376	0.936	rs16999064	chr19:22552602	A/G	cg02657401	chr19:22469223	NA	-0.32	-6.96	-0.36	1.87e-11	Menopause (age at onset);
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg24634471	chr8:143751801	JRK	-0.45	-6.41	-0.33	5.18e-10	Urinary tract infection frequency;
CRC	cis	rs2160860	0.773	rs55698142	chr8:39796429	T/C	cg11363097	chr8:39792086	IDO2	-0.43	-7.29	-0.37	2.33e-12	Blood metabolite levels;
CRC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.49	9.67	0.47	1.26e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	6.22	0.32	1.53e-9	Ovarian reserve;
CRC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22520562	chr4:82392859	RASGEF1B	0.36	6.14	0.32	2.4e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.56	0.75	5.27e-61	Prudent dietary pattern;
CRC	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg01312482	chr5:178451176	ZNF879	-0.37	-6.15	-0.32	2.26e-9	Pubertal anthropometrics;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.75	9.31	0.46	1.82e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-17.83	-0.7	3.11e-50	Height;
CRC	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg27398640	chr15:77910606	LINGO1	0.44	7.5	0.38	5.82e-13	Type 2 diabetes;
CRC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.29	-15.43	-0.65	8.93e-41	Diabetic kidney disease;
CRC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.66	8.94	0.44	2.88e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.45	-6.43	-0.33	4.52e-10	Breast cancer;
CRC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.53	7.58	0.39	3.48e-13	Schizophrenia;
CRC	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.64	10.31	0.49	9.09e-22	Myopia (pathological);
CRC	trans	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-7.61	-0.39	2.88e-13	Endometrial cancer;
CRC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg15465823	chr12:48382534	COL2A1	0.38	6.31	0.33	8.92e-10	Glycated hemoglobin levels;
CRC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.41	-0.59	4.96e-33	Educational attainment;
CRC	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.81	10.35	0.5	6.29e-22	Iron status biomarkers;
CRC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.53	-0.5	1.59e-22	Total cholesterol levels;
CRC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg22535103	chr8:58192502	C8orf71	-0.49	-5.81	-0.31	1.46e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11916758	chr5:133512809	SKP1	0.4	6.65	0.34	1.25e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.59	-0.72	3.14e-53	Schizophrenia;
CRC	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.72e-12	Inflammatory skin disease;
CRC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg02321871	chr13:50159138	RCBTB1	-0.43	-6.15	-0.32	2.21e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16975985	chr12:49524048	TUBA1B	0.4	6.07	0.32	3.55e-9	Myopia (pathological);
CRC	cis	rs6545883	0.525	rs1729658	chr2:61373520	C/T	cg10580144	chr2:61372316	C2orf74	0.29	6.02	0.32	4.58e-9	Tuberculosis;
CRC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.58	9.24	0.45	3.06e-18	Lewy body disease;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.42	5.79	0.3	1.63e-8	Breast cancer;
CRC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg03030879	chr14:75389066	RPS6KL1	0.45	6.91	0.36	2.45e-11	Height;
CRC	cis	rs9393813	0.516	rs4711152	chr6:27380202	C/T	cg02683197	chr6:28174875	NA	0.39	5.62	0.3	3.99e-8	Bipolar disorder;
CRC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg00343986	chr7:65444356	GUSB	0.49	7.42	0.38	1e-12	Aortic root size;
CRC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.79	-0.3	1.68e-8	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14321424	chr11:46403087	MDK	0.39	6.0	0.31	5.26e-9	Interleukin-6 levels;
CRC	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg05527609	chr1:210001259	C1orf107	-0.57	-6.29	-0.33	1.03e-9	Red blood cell count;
CRC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.17	-0.41	6.79e-15	Type 2 diabetes;
CRC	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-5.62	-0.3	4.15e-8	Red cell distribution width;
CRC	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.89	-17.07	-0.69	3.2e-47	Longevity;
CRC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg17775713	chr3:133465469	TF	0.37	6.71	0.35	8.7e-11	Iron status biomarkers (transferrin levels);
CRC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.04	10.13	0.49	3.61e-21	Lymphocyte counts;
CRC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.59	8.79	0.44	8.46e-17	Aortic root size;
CRC	cis	rs4073416	0.542	rs6573616	chr14:66046816	A/G	cg03016385	chr14:66212404	NA	-0.46	-6.23	-0.32	1.47e-9	N-glycan levels;
CRC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg15832292	chr6:96025679	MANEA	-0.6	-6.35	-0.33	7.11e-10	Behavioural disinhibition (generation interaction);
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.66	-9.41	-0.46	8.63e-19	Menopause (age at onset);
CRC	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg23920097	chr1:209922102	NA	-0.52	-6.59	-0.34	1.72e-10	Red blood cell count;
CRC	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.6	8.65	0.43	2.37e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-1.06	-10.93	-0.52	6.34e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg11843238	chr5:131593191	PDLIM4	0.33	5.71	0.3	2.49e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.59	-0.39	3.4e-13	Morning vs. evening chronotype;
CRC	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg24209194	chr3:40518798	ZNF619	0.42	6.21	0.32	1.64e-9	Renal cell carcinoma;
CRC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.62	9.6	0.47	2.1e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.67	12.17	0.56	2.21e-28	Schizophrenia;
CRC	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.39	-0.38	1.21e-12	Schizophrenia;
CRC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12463550	chr7:65579703	CRCP	0.7	6.29	0.33	9.95e-10	Diabetic kidney disease;
CRC	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.4	5.81	0.31	1.48e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.99e-23	Gut microbiome composition (summer);
CRC	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg00631329	chr6:26305371	NA	-0.53	-8.71	-0.43	1.55e-16	Educational attainment;
CRC	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.58	8.54	0.43	5.13e-16	Lewy body disease;
CRC	cis	rs6743376	0.509	rs3180234	chr2:113820655	A/T	cg24553058	chr2:113831203	IL1F10	0.44	7.18	0.37	4.61e-12	Inflammatory biomarkers;
CRC	trans	rs333332	0.961	rs333334	chr3:124328346	C/G	cg08451243	chr11:1273788	MUC5B	0.41	6.5	0.34	2.9e-10	Heschl's gyrus morphology;
CRC	cis	rs6504622	1.000	rs11079745	chr17:45044147	C/A	cg16759221	chr17:45003025	GOSR2	0.47	7.46	0.38	7.87e-13	Orofacial clefts;
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.84	-0.4	6.39e-14	Total body bone mineral density;
CRC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg05501817	chr11:14380813	RRAS2	0.44	5.88	0.31	1.03e-8	Sense of smell;
CRC	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.63	9.88	0.48	2.41e-20	Corneal astigmatism;
CRC	cis	rs6534441	0.857	rs1509525	chr4:125455457	G/A	cg21609808	chr4:125404261	NA	0.4	5.89	0.31	9.36e-9	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	cis	rs995000	0.931	rs1168086	chr1:63112389	A/G	cg19896129	chr1:63156450	NA	-0.41	-6.24	-0.33	1.38e-9	Triglyceride levels;
CRC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-6.2	-0.32	1.71e-9	Body mass index (adult);
CRC	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.38	-6.42	-0.33	4.69e-10	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	trans	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg05679027	chr9:99775184	HIATL2	-0.41	-6.18	-0.32	1.85e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.24	-0.37	3.1e-12	Venous thromboembolism;
CRC	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	5.75	0.3	2.08e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.45	-8.57	-0.43	4.2e-16	Subjective well-being;
CRC	cis	rs10760158	0.800	rs10739595	chr9:124056021	T/C	cg14417974	chr9:124058376	GSN	-0.34	-5.75	-0.3	2.04e-8	Pulse pressure;
CRC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.78	-0.3	1.73e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07590406	chr3:58292066	RPP14	0.52	6.83	0.35	4.05e-11	Thyroid stimulating hormone;
CRC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.83	-14.39	-0.62	9.32e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg20933634	chr6:27740509	NA	0.39	5.81	0.31	1.46e-8	Parkinson's disease;
CRC	cis	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.83	-0.35	4.07e-11	Hemostatic factors and hematological phenotypes;
CRC	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.61	8.54	0.43	4.9e-16	Chronic kidney disease;
CRC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.94	0.31	7.38e-9	Lung cancer;
CRC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.67	9.0	0.44	1.84e-17	Bladder cancer;
CRC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-9.5	-0.46	4.44e-19	Monocyte percentage of white cells;
CRC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.1	21.19	0.76	1.86e-63	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21900616	chr22:20286845	NA	0.44	6.28	0.33	1.09e-9	Response to antipsychotic treatment;
CRC	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg16892393	chr17:41919603	NA	-0.53	-5.78	-0.3	1.71e-8	Cognitive function;
CRC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg22676075	chr6:135203613	NA	0.39	6.07	0.32	3.51e-9	Red blood cell count;
CRC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.02	-0.55	8.05e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.95	11.98	0.55	1.09e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg20203395	chr5:56204925	C5orf35	0.65	8.18	0.41	6.33e-15	Initial pursuit acceleration;
CRC	cis	rs10833965	0.748	rs10833979	chr11:23232089	C/T	cg16745844	chr11:23258850	NA	0.36	5.68	0.3	2.93e-8	Cancer;
CRC	cis	rs3764400	0.567	rs36071506	chr17:46279772	C/T	cg10706073	chr17:46328419	SKAP1	-0.61	-6.75	-0.35	6.66e-11	Body mass index;
CRC	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg15107132	chr11:63991130	FERMT3	-0.39	-6.36	-0.33	6.95e-10	Platelet count;
CRC	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	7.11	0.36	7.23e-12	Breast cancer;
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs3018066	0.666	rs13534	chr4:107270027	G/A	cg01869342	chr4:106983673	TBCK	0.47	6.05	0.32	3.85e-9	Cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10800003	chr3:169940158	PRKCI	0.45	6.65	0.34	1.2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg19193384	chr17:30244184	NA	-0.53	-6.66	-0.34	1.15e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg08071915	chr8:12219732	FAM66A	0.34	6.16	0.32	2.12e-9	Retinal vascular caliber;
CRC	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg03162506	chr22:38580953	NA	0.26	5.62	0.3	4.15e-8	Cutaneous nevi;
CRC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.7	0.3	2.73e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg20744362	chr22:50050164	C22orf34	0.34	6.32	0.33	8.57e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.72	-9.25	-0.45	3.03e-18	Bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11643463	chr12:93323276	EEA1	0.44	6.2	0.32	1.71e-9	Anxiety disorder;
CRC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.08	0.36	8.64e-12	Neuroticism;
CRC	cis	rs2270875	1.000	rs76695849	chr8:132926989	A/G	cg24184792	chr8:132919238	EFR3A	-0.69	-6.99	-0.36	1.55e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs4780401	0.933	rs4439779	chr16:11826841	A/G	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.69	-0.3	2.75e-8	Rheumatoid arthritis;
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg21268650	chr7:45961089	IGFBP3	0.36	6.27	0.33	1.16e-9	Sitting height ratio;
CRC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.23	-0.37	3.4e-12	Personality dimensions;
CRC	cis	rs868943	0.582	rs12210252	chr6:116477493	G/T	cg15226275	chr6:116381976	FRK	-0.24	-5.63	-0.3	3.8e-8	Total cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18743068	chr10:94831650	NA	0.46	7.38	0.38	1.29e-12	Intelligence (multi-trait analysis);
CRC	trans	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg02936872	chr9:99801550	CTSL2	0.48	6.18	0.32	1.85e-9	Iron status biomarkers;
CRC	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg20356878	chr3:121714668	ILDR1	0.52	7.65	0.39	2.25e-13	Multiple sclerosis;
CRC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.13	0.32	2.57e-9	Hip circumference adjusted for BMI;
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg01866215	chr16:3150293	NA	-0.71	-6.27	-0.33	1.11e-9	Temperament (bipolar disorder);
CRC	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg10556349	chr10:835070	NA	-0.35	-6.76	-0.35	6.32e-11	Survival in rectal cancer;
CRC	cis	rs6604026	0.922	rs12746956	chr1:93312142	A/G	cg22128645	chr1:93425802	FAM69A	-0.39	-5.72	-0.3	2.36e-8	Multiple sclerosis;
CRC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.22	0.64	5.89e-40	Lymphocyte percentage of white cells;
CRC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.82	-11.79	-0.55	5.22e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.52	-7.31	-0.37	2.09e-12	Educational attainment (college completion);
CRC	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg27147174	chr7:100797783	AP1S1	0.35	6.12	0.32	2.72e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.02	-0.45	1.64e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9914988	0.560	rs8066347	chr17:27244473	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.5	6.36	0.33	6.69e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.46	6.46	0.34	3.81e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26291818	chr8:61429582	RAB2A	0.39	6.43	0.33	4.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-6.9	-0.36	2.63e-11	Putamen volume;
CRC	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.86	-0.31	1.14e-8	Height;
CRC	cis	rs9786986	0.764	rs10925929	chr1:235696885	C/T	cg08848088	chr1:235714526	GNG4	0.52	6.2	0.32	1.67e-9	Body mass index;
CRC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg04719120	chr6:96025338	MANEA	0.57	6.55	0.34	2.24e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.56	-0.38	4.18e-13	Bladder cancer;
CRC	cis	rs7209700	0.662	rs8066295	chr17:45348203	A/G	cg08085267	chr17:45401833	C17orf57	-0.42	-5.81	-0.31	1.48e-8	IgG glycosylation;
CRC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	6.03e-10	Red blood cell count;
CRC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg15763984	chr4:1342303	KIAA1530	0.34	5.64	0.3	3.65e-8	Longevity;
CRC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.99	21.34	0.76	4.82e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.32	-5.95	-0.31	6.87e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2811415	0.597	rs11721281	chr3:127790935	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.92	-0.31	8.18e-9	Lung function (FEV1/FVC);
CRC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.63	0.34	1.36e-10	Lung cancer;
CRC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg18479299	chr3:125709523	NA	-0.5	-6.19	-0.32	1.8e-9	Blood pressure (smoking interaction);
CRC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.7	-12.06	-0.55	5.62e-28	Cancer;
CRC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.64	10.88	0.51	9.11e-24	Prostate cancer;
CRC	cis	rs1555322	0.530	rs6058224	chr20:33881774	C/T	cg13662093	chr20:33865505	NA	0.43	5.8	0.3	1.54e-8	Attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05955566	chr12:99038273	IKBIP;APAF1	0.51	8.02	0.4	1.82e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.2	0.41	5.41e-15	Rheumatoid arthritis;
CRC	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.59	7.97	0.4	2.71e-14	Adiposity;
CRC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg17545662	chr6:170176663	C6orf70	0.56	6.38	0.33	5.95e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-11.88	-0.55	2.47e-27	Asthma;
CRC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg27661571	chr11:113659931	NA	-0.62	-8.09	-0.41	1.15e-14	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00306249	chr3:184017680	PSMD2	0.5	7.47	0.38	7.33e-13	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.32	5.67	0.3	3.15e-8	Heart rate;
CRC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	6.07	0.32	3.49e-9	Menopause (age at onset);
CRC	cis	rs1572438	0.899	rs9379160	chr6:859966	A/G	cg13447295	chr6:887704	NA	-0.43	-6.51	-0.34	2.86e-10	Aging;
CRC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.47	8.53	0.43	5.33e-16	Monocyte count;
CRC	cis	rs7487075	0.859	rs4768698	chr12:46749088	C/T	cg22049899	chr12:47219821	SLC38A4	-0.34	-6.77	-0.35	5.8e-11	Itch intensity from mosquito bite;
CRC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.31	0.46	1.85e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.98	-0.36	1.63e-11	Bipolar disorder;
CRC	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg05935833	chr10:81318306	SFTPA2	-0.6	-7.18	-0.37	4.63e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.22	-0.37	3.66e-12	Bipolar disorder;
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.74e-12	Urinary tract infection frequency;
CRC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.69	0.3	2.8e-8	Hemoglobin concentration;
CRC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26240231	chr7:1148101	C7orf50	-0.43	-5.77	-0.3	1.88e-8	Bronchopulmonary dysplasia;
CRC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.58	8.87	0.44	4.85e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.73	-0.3	2.33e-8	Tonsillectomy;
CRC	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg04989706	chr14:50066350	PPIL5	-0.59	-8.24	-0.41	4.15e-15	Carotid intima media thickness;
CRC	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07165851	chr6:158734300	TULP4	0.62	7.76	0.39	1.11e-13	Height;
CRC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-6.21	-0.32	1.63e-9	Schizophrenia;
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.09	-0.32	3.23e-9	Total body bone mineral density;
CRC	cis	rs12530845	0.887	rs6948382	chr7:135323576	G/A	cg23117316	chr7:135346802	PL-5283	-0.41	-5.67	-0.3	3.06e-8	Red blood cell traits;
CRC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.55	5.95	0.31	6.71e-9	Schizophrenia;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.6	9.77	0.47	5.65e-20	Vitiligo;
CRC	trans	rs10021731	0.718	rs13104081	chr4:115453797	A/G	cg25927708	chr2:119603813	EN1	-0.34	-6.41	-0.33	5.11e-10	Optic disc area;
CRC	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.95	-0.36	1.92e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	6.83	0.35	4.05e-11	Breast cancer;
CRC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.62	7.61	0.39	2.93e-13	Blood trace element (Zn levels);
CRC	cis	rs910187	0.605	rs2235907	chr20:45809652	A/G	cg27589058	chr20:45804311	EYA2	-0.4	-7.73	-0.39	1.33e-13	Migraine;
CRC	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.5	0.34	3.01e-10	Homocysteine levels;
CRC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.38	0.46	1.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.71	-9.19	-0.45	4.46e-18	Bronchopulmonary dysplasia;
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg01874867	chr7:94954059	PON1	-0.49	-6.32	-0.33	8.45e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Body mass index;
CRC	cis	rs72799341	0.706	rs1060506	chr16:31133449	C/T	cg02466173	chr16:30829666	NA	-0.44	-5.98	-0.31	5.89e-9	Diastolic blood pressure;
CRC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.44	-0.53	9.57e-26	Ulcerative colitis;
CRC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg06096015	chr1:231504339	EGLN1	0.42	6.39	0.33	5.73e-10	Hemoglobin concentration;
CRC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.92	-16.26	-0.67	4.88e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.8	12.57	0.57	7.26e-30	Breast cancer;
CRC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.54	0.43	5.06e-16	Height;
CRC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.88	0.31	1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.42	6.2	0.32	1.69e-9	Hemoglobin concentration;
CRC	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg05304507	chr6:116381966	FRK	0.29	6.52	0.34	2.61e-10	Total cholesterol levels;
CRC	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-7.89	-0.4	4.53e-14	Prevalent atrial fibrillation;
CRC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg26893134	chr6:116381904	FRK	0.27	7.77	0.39	9.88e-14	Cholesterol, total;LDL cholesterol;
CRC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg21153622	chr11:89784906	NA	-0.51	-8.48	-0.42	7.88e-16	HDL cholesterol;
CRC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.18	-0.45	4.97e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.48	7.5	0.38	6.18e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.8	10.22	0.49	1.81e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg25838818	chr2:108905173	SULT1C2	-0.49	-7.87	-0.4	5.07e-14	Lobe size;
CRC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.74	-12.56	-0.57	8e-30	Hemoglobin concentration;
CRC	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.48	7.33	0.37	1.79e-12	HDL cholesterol;
CRC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg20959480	chr12:125599568	AACS	0.39	5.62	0.3	4.04e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.62	10.85	0.51	1.16e-23	Coronary artery disease;
CRC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.22	-16.66	-0.68	1.26e-45	Breast cancer;
CRC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	16.07	0.66	2.57e-43	Lymphocyte percentage of white cells;
CRC	cis	rs4731207	0.698	rs7796150	chr7:124521217	C/T	cg23710748	chr7:124431027	NA	-0.37	-6.09	-0.32	3.2e-9	Cutaneous malignant melanoma;
CRC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.73	0.3	2.23e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs365302	0.909	rs12191109	chr6:159652103	C/A	cg14500486	chr6:159655392	FNDC1	-0.44	-6.82	-0.35	4.31e-11	Coronary heart disease;
CRC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.15	24.64	0.81	1.07e-76	IgG glycosylation;
CRC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.82	0.31	1.39e-8	Ulcerative colitis;
CRC	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.7	7.57	0.39	3.71e-13	Platelet distribution width;
CRC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.74	-13.15	-0.59	5.08e-32	Prostate cancer;
CRC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-9.3	-0.46	2.08e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7605827	0.866	rs2276664	chr2:15701002	A/T	cg19274914	chr2:15703543	NA	0.37	5.63	0.3	3.95e-8	Educational attainment (years of education);
CRC	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-6.27	-0.33	1.11e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.52	6.99	0.36	1.56e-11	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.37	7.41	0.38	1.07e-12	Lung cancer;
CRC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg23018236	chr17:30244563	NA	-0.57	-7.15	-0.37	5.62e-12	Hip circumference adjusted for BMI;
CRC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.62	-9.36	-0.46	1.29e-18	Blood pressure (smoking interaction);
CRC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg00310523	chr12:86230176	RASSF9	0.43	7.28	0.37	2.42e-12	Major depressive disorder;
CRC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	7.61	0.39	2.87e-13	Neuroticism;
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg00106254	chr7:1943704	MAD1L1	-0.37	-5.88	-0.31	1.03e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg19539972	chr4:7069911	GRPEL1	0.41	6.01	0.31	4.87e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.65	-11.2	-0.53	6.89e-25	Dental caries;
CRC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.02	10.5	0.5	1.92e-22	Diabetic retinopathy;
CRC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.64	-0.39	2.35e-13	Axial length;
CRC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	7.55	0.38	4.39e-13	Response to antipsychotic treatment;
CRC	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg25019722	chr6:37503610	NA	-0.48	-8.87	-0.44	4.78e-17	Cognitive performance;
CRC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.29	0.42	2.85e-15	Homoarginine levels;
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00166722	chr3:10149974	C3orf24	0.66	8.88	0.44	4.36e-17	Alzheimer's disease;
CRC	trans	rs7976838	0.808	rs12824305	chr12:60145729	C/T	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.35	0.62	1.31e-36	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25079743	chr16:30441674	DCTPP1	0.44	6.25	0.33	1.25e-9	Response to antipsychotic treatment;
CRC	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg21153622	chr11:89784906	NA	-0.45	-7.27	-0.37	2.58e-12	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15057251	chr18:32621312	MAPRE2	0.47	6.99	0.36	1.54e-11	Response to antipsychotic treatment;
CRC	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.88	-19.72	-0.74	1.11e-57	Longevity;
CRC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg16141378	chr3:129829833	LOC729375	0.45	6.44	0.33	4.33e-10	Triglycerides;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.58	-8.06	-0.41	1.42e-14	Intelligence (multi-trait analysis);
CRC	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.6	8.37	0.42	1.7e-15	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.45	-0.42	9.25e-16	Monocyte percentage of white cells;
CRC	cis	rs457287	1.000	rs692725	chr9:4835173	G/A	cg14182974	chr9:4791918	RCL1	0.43	6.29	0.33	1.01e-9	Platelet count;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06077046	chr15:49913394	C15orf33;DTWD1	0.41	6.08	0.32	3.24e-9	Schizophrenia;
CRC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.2	-0.37	4.05e-12	Monocyte percentage of white cells;
CRC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.08	0.32	3.33e-9	Tonsillectomy;
CRC	cis	rs9783347	1.000	rs4150564	chr11:18355308	G/A	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg08546805	chr12:8549446	NA	-0.43	-6.47	-0.34	3.45e-10	Blood pressure (smoking interaction);
CRC	cis	rs2857891	1.000	rs2857891	chr11:6962957	C/T	cg26870460	chr11:6947759	ZNF215	0.56	5.85	0.31	1.18e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.44	5.89	0.31	9.58e-9	Aortic root size;
CRC	cis	rs9322817	0.691	rs7753202	chr6:105215289	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.37e-16	Thyroid stimulating hormone;
CRC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-11.82	-0.55	4.01e-27	Personality dimensions;
CRC	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06307176	chr5:131281290	NA	0.45	6.45	0.34	3.91e-10	Life satisfaction;
CRC	cis	rs7703744	0.634	rs3797340	chr5:118691737	C/G	cg19893178	chr5:118692011	TNFAIP8	0.44	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13198984	chr17:80129470	CCDC57	0.45	8.01	0.4	1.99e-14	Life satisfaction;
CRC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.41	-6.03	-0.32	4.42e-9	Neurofibrillary tangles;
CRC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	1.11	12.97	0.58	2.27e-31	Obesity-related traits;
CRC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.48	6.25	0.33	1.28e-9	Obesity-related traits;
CRC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.62	-10.65	-0.51	5.83e-23	Breast cancer;
CRC	cis	rs2798269	0.528	rs9509810	chr13:22169006	C/T	cg18095732	chr13:22033692	ZDHHC20	0.41	6.44	0.33	4.32e-10	PR segment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20386705	chr6:38607295	BTBD9	0.46	6.0	0.31	5.26e-9	Thyroid stimulating hormone;
CRC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg21770322	chr7:97807741	LMTK2	0.5	8.14	0.41	8.24e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg13175173	chr14:55914753	NA	-0.52	-9.9	-0.48	2.06e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg23625390	chr15:77176239	SCAPER	0.39	5.79	0.3	1.61e-8	Blood metabolite levels;
CRC	cis	rs73195822	0.667	rs7967278	chr12:111239011	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.68	0.3	2.9e-8	Itch intensity from mosquito bite;
CRC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.25	15.12	0.64	1.35e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.29	-15.4	-0.65	1.09e-40	Diabetic kidney disease;
CRC	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg15903213	chr10:43522190	NA	-0.74	-5.75	-0.3	2.01e-8	Pediatric bone mineral content (radius);
CRC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.4	6.14	0.32	2.37e-9	Longevity;Endometriosis;
CRC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg05192639	chr6:26864778	GUSBL1	0.33	6.0	0.31	5.26e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-9.75	-0.47	6.81e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-6.04	-0.32	4.1e-9	Gut microbiome composition (summer);
CRC	cis	rs501916	0.796	rs628501	chr15:48027328	C/G	cg16110827	chr15:48056943	SEMA6D	-0.5	-7.7	-0.39	1.61e-13	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.83	17.41	0.69	1.4e-48	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21403089	chr7:108166784	PNPLA8	0.41	6.96	0.36	1.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	9.26	0.45	2.75e-18	Response to antipsychotic treatment;
CRC	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-7.26	-0.37	2.89e-12	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19310740	chr8:103424477	UBR5	0.49	6.38	0.33	6.14e-10	Thyroid stimulating hormone;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10261958	chr15:38544292	SPRED1	0.43	6.14	0.32	2.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.63	0.47	1.74e-19	Common traits (Other);
CRC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg16342193	chr10:102329863	NA	-0.34	-5.61	-0.3	4.35e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2013441	1.000	rs2526458	chr17:20092200	C/T	cg13482628	chr17:19912719	NA	-0.4	-6.07	-0.32	3.43e-9	Obesity-related traits;
CRC	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.46	7.16	0.37	5.43e-12	Testicular germ cell tumor;
CRC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.56	-8.71	-0.43	1.46e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9323205	0.723	rs12587352	chr14:51739441	T/C	cg23942311	chr14:51606299	NA	-0.5	-5.75	-0.3	2.09e-8	Cancer;
CRC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg17775713	chr3:133465469	TF	0.37	6.81	0.35	4.55e-11	Iron status biomarkers (transferrin levels);
CRC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	6.93	0.36	2.17e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.05e-13	Diabetic kidney disease;
CRC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.49	-7.88	-0.4	4.77e-14	Huntington's disease progression;
CRC	cis	rs10760158	0.800	rs4837823	chr9:124012011	T/A	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.15	24.77	0.81	3.54e-77	IgG glycosylation;
CRC	cis	rs2346160	0.899	rs1736585	chr6:167688325	G/A	cg04673565	chr6:167680447	NA	-0.39	-6.58	-0.34	1.8e-10	Parental extreme longevity (95 years and older);
CRC	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.5	7.28	0.37	2.52e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.58	-7.35	-0.38	1.59e-12	Aortic root size;
CRC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.55	7.76	0.39	1.07e-13	Melanoma;
CRC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.79	7.44	0.38	8.86e-13	Thyroid stimulating hormone;
CRC	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.66	-7.76	-0.39	1.11e-13	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs282587	0.569	rs426765	chr13:113414798	A/T	cg04656015	chr13:113407548	ATP11A	0.59	7.56	0.38	3.96e-13	Glycated hemoglobin levels;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Depression;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.75	11.82	0.55	4.32e-27	Longevity;Endometriosis;
CRC	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg25547332	chr5:131281432	NA	-0.38	-6.13	-0.32	2.57e-9	Life satisfaction;
CRC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2321882	0.834	rs746717	chr13:59476752	A/G	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.46	0.5	2.74e-22	Hip circumference adjusted for BMI;
CRC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg17420585	chr12:42539391	GXYLT1	-0.44	-6.32	-0.33	8.41e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs1597595	0.857	rs6719702	chr2:147907637	C/T	cg11888359	chr19:4936127	UHRF1	0.45	6.05	0.32	3.92e-9	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
CRC	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg02158880	chr13:53174818	NA	-0.47	-7.37	-0.38	1.36e-12	Lewy body disease;
CRC	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.9	-0.31	8.88e-9	Height;
CRC	trans	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.7	-9.12	-0.45	7.38e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg01335087	chr22:19950166	COMT	-0.23	-6.58	-0.34	1.84e-10	Blood metabolite levels;
CRC	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.96	-0.31	6.5e-9	Metabolite levels;
CRC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg11707556	chr5:10655725	ANKRD33B	0.37	6.49	0.34	3.21e-10	Height;
CRC	cis	rs911119	0.913	rs6048924	chr20:23578996	G/A	cg16589663	chr20:23618590	CST3	0.42	5.85	0.31	1.2e-8	Chronic kidney disease;
CRC	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg16964102	chr10:135390573	NA	0.53	7.44	0.38	8.92e-13	Gout;
CRC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.41	5.89	0.31	9.48e-9	Schizophrenia;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.71	12.08	0.55	4.59e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.65	-10.06	-0.49	6.32e-21	Corneal astigmatism;
CRC	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-7.51	-0.38	5.5e-13	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26320760	chr14:89021243	PTPN21	0.41	6.55	0.34	2.2e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg08798685	chr6:27730294	NA	-0.48	-6.66	-0.34	1.12e-10	Parkinson's disease;
CRC	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.65	-8.42	-0.42	1.15e-15	Hip circumference adjusted for BMI;
CRC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.87	10.25	0.49	1.43e-21	Psoriasis;
CRC	cis	rs1256061	0.624	rs1152577	chr14:64697485	T/G	cg23250157	chr14:64679961	SYNE2	0.46	7.12	0.37	6.85e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-18.93	-0.72	1.46e-54	Headache;
CRC	cis	rs17234274	0.600	rs10767019	chr11:23234911	C/T	cg05245346	chr11:23248277	NA	0.35	5.66	0.3	3.21e-8	Cancer;
CRC	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg06606381	chr12:133084897	FBRSL1	0.61	6.46	0.34	3.72e-10	Depression;
CRC	cis	rs7215564	0.908	rs34785514	chr17:78661166	A/G	cg09596252	chr17:78655493	RPTOR	0.54	5.73	0.3	2.25e-8	Myopia (pathological);
CRC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg03623178	chr6:28175578	NA	0.72	7.21	0.37	3.76e-12	Parkinson's disease;
CRC	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.36	0.53	1.83e-25	Bipolar disorder;
CRC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg23378565	chr7:2036160	MAD1L1	-0.44	-6.1	-0.32	3.05e-9	Bipolar disorder;
CRC	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.53	0.34	2.51e-10	Blood protein levels;
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg10217327	chr6:118973057	C6orf204	0.51	5.76	0.3	1.93e-8	Diastolic blood pressure;
CRC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.36	-6.85	-0.35	3.56e-11	Colorectal cancer;
CRC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg17757837	chr7:157058334	UBE3C	-0.63	-9.73	-0.47	7.67e-20	Body mass index;
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.53	0.34	2.57e-10	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs17767392	1.000	rs7142180	chr14:71759895	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.82	-0.35	4.34e-11	Mitral valve prolapse;
CRC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.44	-5.95	-0.31	6.79e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg10113582	chr4:905918	GAK	0.39	5.6	0.3	4.42e-8	Systemic sclerosis;
CRC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg21970626	chr13:21893289	NA	-0.45	-6.77	-0.35	5.93e-11	White matter hyperintensity burden;
CRC	cis	rs812925	0.659	rs2167565	chr2:61476458	C/T	cg10580144	chr2:61372316	C2orf74	-0.33	-6.78	-0.35	5.57e-11	Immature fraction of reticulocytes;
CRC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.98	11.97	0.55	1.17e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.58	9.68	0.47	1.19e-19	Breast cancer;
CRC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.08	0.32	3.26e-9	Rheumatoid arthritis;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.32	0.37	1.94e-12	Lymphocyte counts;
CRC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-8.45	-0.42	9.33e-16	Chronic sinus infection;
CRC	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02825527	chr7:2087843	MAD1L1	-0.52	-6.28	-0.33	1.08e-9	Neuroticism;
CRC	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.73	-7.61	-0.39	2.83e-13	Inflammatory biomarkers;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01166180	chr19:36606541	POLR2I;TBCB	0.51	6.48	0.34	3.26e-10	Thyroid stimulating hormone;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg10684905	chr12:2999782	TULP3	-0.4	-6.0	-0.31	5.18e-9	Birth weight;Height;
CRC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	9.93	0.48	1.71e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02450064	chr17:40260053	DHX58	-0.43	-6.24	-0.33	1.38e-9	Fibrinogen levels;
CRC	cis	rs4908768	0.539	rs7547411	chr1:8638145	A/G	cg20416874	chr1:8611966	RERE	-0.42	-5.91	-0.31	8.69e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.65	0.54	1.76e-26	Prudent dietary pattern;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg03790207	chr6:42947109	PEX6	-0.49	-6.91	-0.36	2.47e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.92	0.4	3.66e-14	Resting heart rate;
CRC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.49	-7.56	-0.38	4.17e-13	Prostate cancer;
CRC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.45	-6.69	-0.35	9.39e-11	Ulcerative colitis;
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.42	8.14	0.41	8.27e-15	Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13754859	chr14:24584296	DCAF11	0.5	6.54	0.34	2.3e-10	Thyroid stimulating hormone;
CRC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg21251018	chr6:28226885	NKAPL	0.4	6.09	0.32	3.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1883415	0.552	rs2143083	chr6:24507054	C/T	cg20631270	chr6:24437470	GPLD1	0.39	5.9	0.31	8.81e-9	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.74	-12.21	-0.56	1.5e-28	Height;
CRC	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg09455208	chr3:40491958	NA	0.31	6.06	0.32	3.74e-9	Renal cell carcinoma;
CRC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.52	-7.12	-0.37	6.71e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13446153	chr8:41435704	AGPAT6	0.38	6.03	0.32	4.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg04731861	chr2:219085781	ARPC2	0.34	6.94	0.36	2.13e-11	Colorectal cancer;
CRC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.39	-6.62	-0.34	1.46e-10	Height;
CRC	cis	rs2274273	0.624	rs11848456	chr14:55755392	A/G	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.78	-0.3	1.74e-8	Protein biomarker;
CRC	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.74	9.8	0.48	4.62e-20	Prostate cancer;
CRC	cis	rs755249	0.567	rs61782157	chr1:39762889	C/T	cg18385671	chr1:39797026	MACF1	-0.42	-5.98	-0.31	5.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg14530993	chr4:882597	GAK	0.75	6.93	0.36	2.17e-11	Parkinson's disease;
CRC	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.47	-6.58	-0.34	1.81e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs863345	0.625	rs10489833	chr1:158490451	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg17724175	chr1:150552817	MCL1	-0.46	-7.28	-0.37	2.55e-12	Tonsillectomy;
CRC	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.62	-9.84	-0.48	3.39e-20	Corneal astigmatism;
CRC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.81	0.4	7.71e-14	Height;
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg16558177	chr4:4109446	NA	-0.62	-8.74	-0.43	1.23e-16	Blood pressure (smoking interaction);
CRC	cis	rs6662572	0.906	rs11590549	chr1:46086329	C/T	cg08644498	chr1:46502608	NA	0.36	5.87	0.31	1.09e-8	Blood protein levels;
CRC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.77	-11.4	-0.53	1.35e-25	Neutrophil percentage of white cells;
CRC	cis	rs713477	0.967	rs10150596	chr14:55916167	A/G	cg13175173	chr14:55914753	NA	0.53	9.98	0.48	1.11e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg02269571	chr22:50332266	NA	0.62	8.44	0.42	9.96e-16	Schizophrenia;
CRC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.53	-6.56	-0.34	2.12e-10	Diastolic blood pressure;
CRC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg07195577	chr17:27052828	TLCD1	0.42	6.03	0.32	4.32e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2012709	0.935	rs6879109	chr5:32564547	A/C	cg03755955	chr8:6424269	MCPH1	0.43	6.33	0.33	7.9e-10	Breast cancer;
CRC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.24	-0.33	1.37e-9	Aortic root size;
CRC	cis	rs12580194	0.593	rs61957924	chr12:55744100	T/C	cg23425280	chr12:56401806	NA	0.45	5.72	0.3	2.41e-8	Cancer;
CRC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.23	-0.37	3.43e-12	Morning vs. evening chronotype;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07739959	chr3:48754206	IP6K2	-0.42	-6.51	-0.34	2.84e-10	Aortic root size;
CRC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.51	7.09	0.36	8.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12826942	0.765	rs17592014	chr12:42550147	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.38	0.33	6.11e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05747105	chr6:53224391	NA	0.36	6.0	0.31	5.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.79	0.61	1.92e-34	Schizophrenia;
CRC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.95	0.44	2.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg13919466	chr1:32135498	COL16A1	-0.31	-6.0	-0.31	5.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg13043300	chr11:71146211	DHCR7	-0.47	-6.39	-0.33	5.76e-10	Vitamin D levels;
CRC	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg06307176	chr5:131281290	NA	-0.4	-5.91	-0.31	8.73e-9	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20754634	chr17:7218651	GPS2	0.4	6.86	0.35	3.47e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	1.03	8.34	0.42	2.05e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg27398640	chr15:77910606	LINGO1	-0.44	-7.53	-0.38	4.81e-13	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24179850	chr19:56154938	ZNF581	0.39	5.97	0.31	6.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg22495460	chr2:25135724	ADCY3	-0.72	-11.83	-0.55	3.81e-27	Body mass index;
CRC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg27427491	chr17:78079615	GAA	-0.37	-5.93	-0.31	7.47e-9	Yeast infection;
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.07	-0.41	1.31e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg16964102	chr10:135390573	NA	-0.49	-6.88	-0.35	3.02e-11	Gout;
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.07	0.32	3.46e-9	Bipolar disorder;
CRC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.6	11.19	0.53	7.46e-25	Educational attainment;
CRC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.55	-6.61	-0.34	1.55e-10	Blood trace element (Zn levels);
CRC	cis	rs41271951	0.512	rs12090246	chr1:151107496	G/A	cg11822372	chr1:151115635	SEMA6C	-0.72	-5.81	-0.31	1.46e-8	Blood protein levels;
CRC	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.37	-6.14	-0.32	2.43e-9	Mean arterial pressure;
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14828511	chr1:107599125	PRMT6	0.48	7.01	0.36	1.32e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7107770	1.000	rs4936997	chr11:125090227	C/T	cg27629782	chr11:125073726	PKNOX2	0.47	5.67	0.3	3.14e-8	Photic sneeze reflex;
CRC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-9.92	-0.48	1.83e-20	Menarche (age at onset);
CRC	cis	rs72634258	0.945	rs3766606	chr1:8022197	G/T	cg00042356	chr1:8021962	PARK7	0.68	8.37	0.42	1.67e-15	Inflammatory bowel disease;
CRC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg17724175	chr1:150552817	MCL1	0.48	6.93	0.36	2.18e-11	Melanoma;
CRC	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.87	16.65	0.68	1.46e-45	Hip circumference;
CRC	cis	rs3736485	0.808	rs28485410	chr15:51949885	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.36	-0.33	6.88e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg09659197	chr4:152720779	NA	-0.43	-8.83	-0.44	6.53e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg10677697	chr7:45961126	IGFBP3	0.35	6.14	0.32	2.44e-9	Sitting height ratio;
CRC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.11	-0.32	2.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-9.35	-0.46	1.34e-18	Menarche (age at onset);
CRC	trans	rs9914544	0.544	rs4244595	chr17:18677329	C/T	cg04702396	chr17:15466718	FAM18B2	0.47	7.46	0.38	7.67e-13	Educational attainment (years of education);
CRC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.76	13.1	0.59	7.99e-32	Colorectal cancer;
CRC	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg16482183	chr6:26056742	HIST1H1C	1.04	11.72	0.54	9.62e-27	Iron status biomarkers;
CRC	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg09659197	chr4:152720779	NA	0.52	11.2	0.53	7.17e-25	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.59	0.65	2.1e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg23018236	chr17:30244563	NA	-0.65	-7.83	-0.4	6.85e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg09473613	chr1:24152604	HMGCL	0.35	6.03	0.32	4.37e-9	Immature fraction of reticulocytes;
CRC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg03233332	chr7:66118400	NA	-0.43	-5.96	-0.31	6.51e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs16845945	chr2:162480684	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.18	-0.32	1.94e-9	Cognitive function;
CRC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-11.53	-0.54	4.77e-26	Asthma;
CRC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.72	-8.03	-0.4	1.74e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.53	8.34	0.42	2.02e-15	Menopause (age at onset);
CRC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.48	6.66	0.34	1.13e-10	Lymphocyte counts;
CRC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.07	17.76	0.7	5.96e-50	Schizophrenia;
CRC	cis	rs231513	0.954	rs231524	chr17:41953212	G/A	cg26893861	chr17:41843967	DUSP3	-0.73	-7.37	-0.38	1.37e-12	Cognitive function;
CRC	cis	rs10046574	0.519	rs17403948	chr7:135215169	C/T	cg27474649	chr7:135195673	CNOT4	-0.61	-5.8	-0.3	1.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.58	10.56	0.5	1.24e-22	Age of smoking initiation;
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg04871131	chr7:94954202	PON1	-0.47	-5.77	-0.3	1.81e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg16898833	chr6:26189333	HIST1H4D	0.94	7.7	0.39	1.64e-13	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2797369	0.713	rs9390724	chr6:101521557	G/C	cg26346621	chr12:6873348	NA	-0.41	-6.12	-0.32	2.68e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg04545296	chr12:48745243	ZNF641	0.35	6.1	0.32	2.96e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg15845792	chr6:28175446	NA	0.9	11.93	0.55	1.61e-27	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg05865860	chr7:158649142	WDR60	-0.71	-5.97	-0.31	6.26e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.92	-0.36	2.41e-11	IgG glycosylation;
CRC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.89	0.4	4.39e-14	Resting heart rate;
CRC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.66	-10.54	-0.5	1.38e-22	Sudden cardiac arrest;
CRC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.03	-12.4	-0.56	3.16e-29	Hip circumference adjusted for BMI;
CRC	trans	rs7180079	0.925	rs11071789	chr15:64596057	C/T	cg22857141	chr5:123707481	NA	0.48	6.09	0.32	3.14e-9	Monocyte count;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs8141797	0.901	rs176157	chr22:24503987	C/T	cg20894457	chr22:24584366	SUSD2	0.62	7.52	0.38	5.37e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.85	10.72	0.51	3.37e-23	Iron status biomarkers;
CRC	cis	rs73206853	0.563	rs73194046	chr12:111191665	A/G	cg12870014	chr12:110450643	ANKRD13A	0.73	8.56	0.43	4.32e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04317338	chr11:64019027	PLCB3	0.42	5.8	0.3	1.58e-8	Platelet count;
CRC	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.76	10.43	0.5	3.33e-22	IgG glycosylation;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg25164649	chr6:28176230	NA	0.7	7.93	0.4	3.42e-14	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11991806	chr6:112408804	TUBE1;C6orf225	0.53	7.93	0.4	3.51e-14	Intelligence (multi-trait analysis);
CRC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.61	-11.93	-0.55	1.58e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.63	7.47	0.38	7.06e-13	Bipolar disorder;
CRC	cis	rs4776997	0.559	rs12902904	chr15:68076533	G/A	cg08154944	chr15:67813145	C15orf61	-0.44	-5.66	-0.3	3.23e-8	Verbal declarative memory;
CRC	cis	rs7605827	0.856	rs35549453	chr2:15527220	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.05e-8	Educational attainment (years of education);
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg26587870	chr6:27730563	NA	-0.36	-5.76	-0.3	1.97e-8	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	cis	rs365302	0.716	rs452651	chr6:159610946	C/T	cg14500486	chr6:159655392	FNDC1	0.52	7.91	0.4	3.92e-14	Coronary heart disease;
CRC	cis	rs10242455	1.000	rs6948775	chr7:98945480	A/G	cg18809830	chr7:99032528	PTCD1	-0.75	-6.5	-0.34	2.96e-10	Blood metabolite levels;
CRC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.34	-6.18	-0.32	1.84e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03402775	chr3:108308147	DZIP3;KIAA1524	0.44	6.31	0.33	8.87e-10	Intelligence (multi-trait analysis);
CRC	trans	rs17507216	0.718	rs4779033	chr15:83245384	C/T	cg02798295	chr19:804596	PTBP1	0.43	6.04	0.32	4.22e-9	Excessive daytime sleepiness;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23609821	chr14:20937494	PNP	0.48	6.97	0.36	1.79e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.9	-11.45	-0.53	8.8e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.46	5.83	0.31	1.32e-8	Lung function (FEV1/FVC);
CRC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.57	0.57	7.49e-30	Height;
CRC	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11446398	chr5:77624930	NA	0.44	5.83	0.31	1.29e-8	Triglycerides;
CRC	cis	rs7916697	0.626	rs61854803	chr10:70014638	T/C	cg06988349	chr10:69991859	ATOH7	0.39	7.29	0.37	2.26e-12	Optic disc area;
CRC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg12064134	chr16:90016061	DEF8	-0.62	-5.62	-0.3	4.11e-8	Skin colour saturation;
CRC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.44	6.54	0.34	2.31e-10	Platelet distribution width;
CRC	cis	rs117623576	0.680	rs11008756	chr10:32363137	A/G	cg03047570	chr10:32398778	NA	-0.63	-7.0	-0.36	1.46e-11	Anti-saccade response;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg02033258	chr5:131593261	PDLIM4	0.46	8.66	0.43	2.08e-16	Acylcarnitine levels;
CRC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.7	12.47	0.57	1.65e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.29	-5.94	-0.31	7.3e-9	Depression;
CRC	cis	rs2637266	0.561	rs11001867	chr10:78491455	A/T	cg18941641	chr10:78392320	NA	0.35	5.91	0.31	8.47e-9	Pulmonary function;
CRC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.88	0.4	4.67e-14	Lung cancer;
CRC	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-19.25	-0.73	7.48e-56	Ulcerative colitis;
CRC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg16476235	chr8:21771668	DOK2	0.38	6.24	0.33	1.33e-9	Mean corpuscular volume;
CRC	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.77	-10.15	-0.49	3.03e-21	IgG glycosylation;
CRC	cis	rs6988985	0.693	rs10093796	chr8:143978424	T/C	cg10324643	chr8:143916377	GML	0.38	6.27	0.33	1.15e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.58	8.49	0.42	7.02e-16	Response to amphetamines;
CRC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	6.81	0.35	4.57e-11	Reticulocyte count;
CRC	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.86e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-8.74	-0.43	1.17e-16	Blood pressure (smoking interaction);
CRC	cis	rs2486012	0.678	rs2906460	chr1:44335323	A/G	cg12908607	chr1:44402522	ARTN	-0.42	-5.77	-0.3	1.81e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg21784768	chr11:537496	LRRC56	-0.72	-6.87	-0.35	3.26e-11	Body mass index;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.57	-8.16	-0.41	7.15e-15	IgG glycosylation;
CRC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.45	-0.34	3.93e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1656402	1.000	rs1729254	chr2:233428809	A/G	cg03852847	chr2:233439513	NA	0.44	7.56	0.38	4.08e-13	Non-small cell lung cancer (survival);
CRC	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.55	7.16	0.37	5.31e-12	Mammographic density (dense area);
CRC	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.53	7.5	0.38	6.19e-13	Testicular germ cell tumor;
CRC	cis	rs995000	0.929	rs2029763	chr1:63013134	A/G	cg19896129	chr1:63156450	NA	0.4	5.78	0.3	1.76e-8	Triglyceride levels;
CRC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg23533926	chr12:111358616	MYL2	-0.53	-7.97	-0.4	2.56e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg09003973	chr2:102972529	NA	0.72	7.67	0.39	1.94e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.82	-9.19	-0.45	4.62e-18	Breast cancer;
CRC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg11833968	chr6:79620685	NA	-0.37	-6.33	-0.33	7.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg02158880	chr13:53174818	NA	-0.44	-6.34	-0.33	7.44e-10	Lewy body disease;
CRC	cis	rs6694672	0.618	rs10429911	chr1:197146144	A/C	cg13682187	chr1:196946512	CFHR5	0.44	7.04	0.36	1.11e-11	Asthma;
CRC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.69	0.65	8.34e-42	Chronic sinus infection;
CRC	cis	rs6893807	1.000	rs1422191	chr5:87949158	G/A	cg09002922	chr5:87956389	LOC645323	-0.45	-6.53	-0.34	2.5e-10	Body mass index;
CRC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.77	-14.06	-0.61	1.67e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.58	9.27	0.45	2.57e-18	Vitiligo;
CRC	cis	rs4692589	0.581	rs34149802	chr4:170960284	A/G	cg19918862	chr4:170955249	NA	0.52	7.0	0.36	1.48e-11	Anxiety disorder;
CRC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg05585544	chr11:47624801	NA	-0.4	-6.5	-0.34	3.01e-10	Schizophrenia;
CRC	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	7.52	0.38	5.14e-13	Ileal carcinoids;
CRC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.64	-0.3	3.6e-8	Colorectal cancer;
CRC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.91	0.4	3.85e-14	Joint mobility (Beighton score);
CRC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.61	7.25	0.37	3.03e-12	Lymphocyte counts;
CRC	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	cg04338863	chr8:33670619	NA	0.42	6.65	0.34	1.21e-10	Body mass index;
CRC	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.06e-12	HDL cholesterol;
CRC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.54	0.34	2.37e-10	Aortic root size;
CRC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg11632617	chr15:75315747	PPCDC	-0.56	-7.96	-0.4	2.86e-14	Blood trace element (Zn levels);
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg19052272	chr2:3704530	ALLC	-0.41	-5.61	-0.3	4.2e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg24416660	chr17:73865998	NA	-0.4	-6.08	-0.32	3.34e-9	Psoriasis;
CRC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.86	-0.4	5.6e-14	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18752785	chr20:3996394	RNF24	0.46	7.26	0.37	2.72e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs7142881	0.604	rs6571468	chr14:32288862	G/A	cg26207357	chr2:190539199	NA	0.39	5.96	0.31	6.33e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.37	6.85	0.35	3.71e-11	Height;
CRC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.71	11.05	0.52	2.34e-24	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.51	6.53	0.34	2.53e-10	Longevity;
CRC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.48	7.39	0.38	1.2e-12	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.65	9.55	0.47	3.16e-19	Menopause (age at onset);
CRC	trans	rs800082	0.839	rs62275528	chr3:144293687	T/C	cg24215973	chr2:240111563	HDAC4	-0.53	-6.82	-0.35	4.32e-11	Smoking behavior;
CRC	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.01	-0.31	5.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28829049	0.508	rs4578242	chr1:19391565	G/C	cg13387374	chr1:19411106	UBR4	0.42	6.06	0.32	3.66e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.62	10.09	0.49	5.02e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.52	-7.42	-0.38	1.01e-12	Triglycerides;
CRC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.56	-8.93	-0.44	3.09e-17	Aortic root size;
CRC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.45	5.64	0.3	3.58e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs9341835	0.584	rs2096346	chr6:64153014	T/C	cg13657004	chr13:50234944	EBPL	-0.37	-6.38	-0.33	6.03e-10	Schizophrenia;
CRC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg08027265	chr7:2291960	NA	-0.37	-6.36	-0.33	6.64e-10	Schizophrenia;
CRC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg20203395	chr5:56204925	C5orf35	-0.67	-8.03	-0.41	1.69e-14	Initial pursuit acceleration;
CRC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.53	-0.34	2.56e-10	Menopause (age at onset);
CRC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.4	6.04	0.32	4.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.68	12.22	0.56	1.5e-28	Age at first birth;
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg05569086	chr8:143859399	LYNX1	0.4	6.98	0.36	1.68e-11	Urinary tract infection frequency;
CRC	trans	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg02869306	chr7:64672164	INTS4L1	-0.45	-6.64	-0.34	1.26e-10	Aortic root size;
CRC	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.51	7.42	0.38	1.03e-12	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10200477	chr1:87801011	LMO4	0.39	6.7	0.35	9.03e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg13206674	chr6:150067644	NUP43	0.54	6.68	0.35	1.02e-10	Lung cancer;
CRC	trans	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg01448155	chr10:3564782	NA	-0.5	-6.09	-0.32	3.23e-9	Lymphocyte percentage of white cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06391107	chr19:40502439	ZNF546	0.48	6.12	0.32	2.63e-9	Thyroid stimulating hormone;
CRC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21052403	chr11:320889	IFITM3	0.42	6.75	0.35	6.56e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg03030879	chr14:75389066	RPS6KL1	0.56	9.01	0.45	1.66e-17	Caffeine consumption;
CRC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg22110888	chr17:80059540	CCDC57	-0.45	-7.15	-0.37	5.78e-12	Life satisfaction;
CRC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.46	6.63	0.34	1.39e-10	Urate levels;
CRC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.22	0.49	1.81e-21	Menopause (age at onset);
CRC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg24675056	chr1:15929824	NA	0.5	6.85	0.35	3.58e-11	Systolic blood pressure;
CRC	cis	rs9326248	0.773	rs1060211	chr11:117039797	G/A	cg26566898	chr11:117069891	TAGLN	0.39	6.96	0.36	1.85e-11	Blood protein levels;
CRC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.36	6.65	0.34	1.26e-10	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18724032	chr3:171758176	FNDC3B	0.37	6.73	0.35	7.44e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg00343986	chr7:65444356	GUSB	0.42	6.0	0.31	5.24e-9	Aortic root size;
CRC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg03013999	chr17:37608204	MED1	0.46	7.04	0.36	1.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.72	-9.26	-0.45	2.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.72	-0.35	8.01e-11	Reticulocyte fraction of red cells;
CRC	cis	rs6076065	0.723	rs2424530	chr20:23369354	A/G	cg11657817	chr20:23433608	CST11	0.45	6.68	0.35	1.02e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.66	-8.69	-0.43	1.76e-16	Hypospadias;
CRC	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg23202291	chr11:1979235	NA	0.46	6.34	0.33	7.74e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-8.31	-0.42	2.55e-15	Parkinson's disease;
CRC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.81	16.95	0.68	9.06e-47	Prostate cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16333535	chr22:24093440	ZNF70	-0.54	-6.64	-0.34	1.27e-10	Diisocyanate-induced asthma;
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-11.87	-0.55	2.79e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.86	-14.56	-0.63	2.12e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg06581033	chr10:766294	NA	-0.5	-5.73	-0.3	2.28e-8	Uric acid levels;
CRC	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.04	-0.32	4.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.08	14.83	0.63	1.78e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6969780	1.000	rs1548497	chr7:27174316	A/G	cg26364809	chr7:27145159	NA	0.69	6.63	0.34	1.36e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.18	-0.45	4.85e-18	Type 2 diabetes;
CRC	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.61	-8.55	-0.43	4.74e-16	Type 2 diabetes;
CRC	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg04165759	chr1:150448943	RPRD2	0.36	5.92	0.31	7.88e-9	Migraine;
CRC	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.01	0.31	4.92e-9	Lung cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23932593	chr6:133135524	RPS12;SNORD101	-0.41	-6.07	-0.32	3.46e-9	Myopia (pathological);
CRC	trans	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.48	0.38	6.77e-13	Endometrial cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18382341	chr1:230778080	COG2	0.43	6.07	0.32	3.51e-9	Anxiety disorder;
CRC	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg01312482	chr5:178451176	ZNF879	-0.36	-5.98	-0.31	5.94e-9	Pubertal anthropometrics;
CRC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.73	-0.39	1.32e-13	Hemoglobin concentration;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.61	0.3	4.39e-8	Electroencephalogram traits;
CRC	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.5	7.35	0.38	1.63e-12	Blood metabolite levels;
CRC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg23112188	chr14:24563095	PCK2	-0.36	-6.92	-0.36	2.33e-11	IgG glycosylation;
CRC	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-9.0	-0.44	1.85e-17	Bone mineral density;
CRC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.21	16.75	0.68	5.5e-46	Breast cancer;
CRC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.67	10.02	0.48	8.25e-21	Corneal astigmatism;
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg18833306	chr6:118973337	C6orf204	0.45	5.95	0.31	6.95e-9	Diastolic blood pressure;
CRC	cis	rs9292777	0.777	rs56284872	chr5:40392384	A/G	cg09067459	chr5:40385259	NA	-0.57	-9.39	-0.46	1.05e-18	Crohn's disease;Multiple sclerosis;
CRC	trans	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg21302420	chr1:112162376	RAP1A	0.67	6.0	0.31	5.08e-9	Skin colour saturation;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.94	-0.31	7.43e-9	Depression;
CRC	trans	rs10021731	0.692	rs10516602	chr4:115407330	C/T	cg25927708	chr2:119603813	EN1	-0.32	-5.96	-0.31	6.5e-9	Optic disc area;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg15845792	chr6:28175446	NA	-0.66	-9.21	-0.45	3.96e-18	Parkinson's disease;
CRC	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.45	-5.86	-0.31	1.14e-8	Gut microbiome composition (summer);
CRC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.58	8.75	0.43	1.1e-16	Blood metabolite levels;
CRC	cis	rs2708977	0.637	rs618454	chr2:97080093	C/G	cg23100626	chr2:96804247	ASTL	0.23	6.0	0.31	5.34e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.74e-12	Obesity-related traits;
CRC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.42	-8.39	-0.42	1.41e-15	Subjective well-being;
CRC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	ch.11.42038R	chr11:967971	AP2A2	0.55	9.42	0.46	8.52e-19	Alzheimer's disease (late onset);
CRC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.47	-7.13	-0.37	6.38e-12	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.71	0.54	1.07e-26	Alzheimer's disease;
CRC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.48	6.94	0.36	2.03e-11	Lymphocyte counts;
CRC	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	0.8	7.12	0.37	6.76e-12	Economic and political preferences (immigration/crime);
CRC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.58	-0.47	2.4e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12692738	0.526	rs355826	chr2:165612355	A/C	cg03182029	chr2:165697222	COBLL1	0.5	5.9	0.31	8.88e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.06	-25.45	-0.81	9.94e-80	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7605827	0.897	rs12692274	chr2:15707711	A/G	cg19274914	chr2:15703543	NA	0.4	6.12	0.32	2.62e-9	Educational attainment (years of education);
CRC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg07274523	chr3:49395745	GPX1	0.45	6.05	0.32	4.03e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg22495460	chr2:25135724	ADCY3	-0.78	-14.34	-0.62	1.43e-36	Body mass index;
CRC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.26	5.73	0.3	2.28e-8	Educational attainment (years of education);
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-10.69	-0.51	4.28e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg00631329	chr6:26305371	NA	-0.43	-7.26	-0.37	2.83e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.41	-6.22	-0.32	1.53e-9	Platelet distribution width;
CRC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.25	0.37	2.95e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.12	-0.37	7.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs6546324	0.625	rs4671813	chr2:67841835	A/T	cg00907274	chr3:27498161	SLC4A7	-0.48	-6.13	-0.32	2.55e-9	Endometriosis;
CRC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.67	-11.46	-0.53	8e-26	Iron status biomarkers;
CRC	trans	rs1979967	0.524	rs28687858	chr15:79661109	T/C	cg14802097	chr12:42970349	PRICKLE1	0.49	6.04	0.32	4.2e-9	Interleukin-18 levels;
CRC	cis	rs3823572	0.504	rs2971968	chr7:133642599	C/A	cg03336402	chr7:133662267	EXOC4	-0.68	-10.48	-0.5	2.23e-22	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.4	-0.33	5.35e-10	Cognitive function;
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.71	0.54	1.02e-26	Prudent dietary pattern;
CRC	cis	rs17152411	0.843	rs7896051	chr10:126583119	T/C	cg07906193	chr10:126599966	NA	0.54	6.0	0.31	5.1e-9	Height;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25291941	chr8:99129319	POP1;HRSP12	0.43	6.69	0.35	9.65e-11	Interleukin-6 levels;
CRC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.5	8.71	0.43	1.55e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg14515779	chr1:101123966	NA	0.38	7.16	0.37	5.23e-12	Monocyte count;
CRC	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg23254163	chr1:152506842	NA	0.44	8.71	0.43	1.53e-16	Hair morphology;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg08222913	chr3:52553049	STAB1	-0.36	-6.78	-0.35	5.51e-11	Electroencephalogram traits;
CRC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.43	5.64	0.3	3.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg22117107	chr15:45993392	NA	-0.45	-8.97	-0.44	2.28e-17	Waist circumference;Weight;
CRC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.57	0.6	1.25e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.08	0.45	9.93e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.64	-8.48	-0.42	7.63e-16	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7212938	0.570	rs8071050	chr17:38106599	A/G	cg00129232	chr17:37814104	STARD3	0.37	5.7	0.3	2.73e-8	Asthma and hay fever;
CRC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.93	16.8	0.68	3.52e-46	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27001607	chr7:76178636	LOC100133091	0.46	6.19	0.32	1.8e-9	Anxiety disorder;
CRC	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.56	-8.69	-0.43	1.72e-16	Diastolic blood pressure;
CRC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03264133	chr6:25882463	NA	0.4	5.95	0.31	7.02e-9	Height;
CRC	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.46	-5.61	-0.3	4.3e-8	Coronary artery calcification;
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg12564285	chr5:131593104	PDLIM4	0.49	9.51	0.46	4.16e-19	Breast cancer;
CRC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.53	-0.34	2.55e-10	Height;
CRC	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.11e-9	Hair morphology;
CRC	cis	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg07356753	chr3:81810745	GBE1	-0.53	-7.06	-0.36	1.02e-11	Extraversion;
CRC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.65	-8.42	-0.42	1.19e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg17788362	chr6:86352627	SYNCRIP	-0.46	-6.49	-0.34	3.08e-10	Smooth-surface caries;
CRC	cis	rs7086803	1.000	rs7096588	chr10:114500851	A/C	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.96	-0.31	6.39e-9	Pulmonary function;
CRC	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg00318322	chr16:67708822	GFOD2	-0.31	-5.99	-0.31	5.54e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.45	-5.91	-0.31	8.71e-9	Height;
CRC	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg10756647	chr7:56101905	PSPH	0.75	7.82	0.4	7.35e-14	Diabetic kidney disease;
CRC	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	5.69	0.3	2.75e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg15845792	chr6:28175446	NA	0.75	11.11	0.52	1.51e-24	Parkinson's disease;
CRC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.45	8.11	0.41	1.03e-14	Height;
CRC	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg00042356	chr1:8021962	PARK7	0.73	7.64	0.39	2.36e-13	Inflammatory bowel disease;
CRC	cis	rs2992756	0.663	rs2992762	chr1:18804609	A/G	cg14356550	chr1:18808102	KLHDC7A	-0.4	-5.87	-0.31	1.05e-8	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23435730	chr3:127770634	SEC61A1	0.45	6.15	0.32	2.28e-9	Thyroid stimulating hormone;
CRC	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.48	-5.82	-0.31	1.41e-8	Coronary artery calcification;
CRC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.39	0.38	1.24e-12	Blood metabolite levels;
CRC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.53	8.72	0.43	1.38e-16	Gout;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18084450	chr1:235530719	TBCE	0.45	6.66	0.34	1.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg15147215	chr3:52552868	STAB1	-0.43	-6.88	-0.35	3.1e-11	Body mass index;
CRC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.7	-8.39	-0.42	1.46e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7172809	0.897	rs78412727	chr15:77827185	A/G	cg10437265	chr15:77819839	NA	-0.4	-6.75	-0.35	6.52e-11	Glucose homeostasis traits;
CRC	trans	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19904058	chr10:135279010	LOC619207	-0.35	-6.71	-0.35	8.35e-11	Systemic lupus erythematosus;
CRC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.81	12.56	0.57	8.3e-30	Platelet distribution width;
CRC	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg18135206	chr14:102964638	TECPR2	0.52	6.19	0.32	1.81e-9	Plateletcrit;
CRC	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.51	7.47	0.38	7.46e-13	Pulmonary function decline;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.45	5.66	0.3	3.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.43	0.46	7.7e-19	Coffee consumption (cups per day);
CRC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.91	0.4	3.96e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	9.35	0.46	1.37e-18	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg06606381	chr12:133084897	FBRSL1	-0.94	-7.11	-0.36	7.46e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg15786705	chr6:28176104	NA	0.57	7.98	0.4	2.53e-14	Parkinson's disease;
CRC	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg02820901	chr13:113351484	ATP11A	0.61	6.65	0.34	1.2e-10	Glycated hemoglobin levels;
CRC	cis	rs6880778	0.505	rs12658567	chr5:40391932	G/T	cg09067459	chr5:40385259	NA	-0.47	-8.04	-0.41	1.68e-14	Inflammatory bowel disease;
CRC	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.54	-7.98	-0.4	2.39e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg02683197	chr6:28174875	NA	0.67	6.03	0.32	4.47e-9	Depression;
CRC	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	7.93	0.4	3.47e-14	Bipolar disorder;
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00166722	chr3:10149974	C3orf24	0.69	8.15	0.41	7.57e-15	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04533189	chr17:64298763	PRKCA	0.37	6.91	0.36	2.46e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.12	-0.45	7.54e-18	Alzheimer's disease;
CRC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg09876464	chr15:85330779	ZNF592	0.46	8.19	0.41	5.93e-15	P wave terminal force;
CRC	cis	rs12137294	0.866	rs1077883	chr1:205210415	G/T	cg24159697	chr1:205181237	DSTYK	-0.34	-6.25	-0.33	1.31e-9	Red cell distribution width;
CRC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.82	0.31	1.4e-8	IgG glycosylation;
CRC	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.8	-0.3	1.59e-8	Daytime sleep phenotypes;
CRC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.66	-0.39	2.09e-13	Gut microbiome composition (summer);
CRC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00166722	chr3:10149974	C3orf24	0.39	6.03	0.32	4.29e-9	Alzheimer's disease;
CRC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg24375607	chr4:120327624	NA	0.47	7.33	0.37	1.79e-12	Corneal astigmatism;
CRC	trans	rs11654801	0.812	rs11655512	chr17:20851735	A/G	cg23759823	chr7:139672531	TBXAS1	-0.43	-6.49	-0.34	3.13e-10	Mosquito bite size;
CRC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	5.74	0.3	2.17e-8	Schizophrenia;
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.6	-9.77	-0.47	5.63e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg10790698	chr19:18539756	SSBP4	-0.43	-8.19	-0.41	5.83e-15	Breast cancer;
CRC	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.05	0.32	3.89e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.71	11.64	0.54	1.82e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02018176	chr4:1364513	KIAA1530	0.4	6.74	0.35	6.93e-11	Longevity;
CRC	cis	rs524281	0.773	rs11227447	chr11:66048280	G/C	cg16950941	chr11:66035639	RAB1B	-0.72	-8.12	-0.41	9.39e-15	Electroencephalogram traits;
CRC	cis	rs9826463	0.702	rs73228762	chr3:142325220	A/C	cg20824294	chr3:142316082	PLS1	0.44	6.1	0.32	2.99e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg00383909	chr3:49044727	WDR6	0.44	5.73	0.3	2.24e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.58	-8.08	-0.41	1.27e-14	Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg15786705	chr6:28176104	NA	0.74	9.41	0.46	8.75e-19	Depression;
CRC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.93	0.31	7.74e-9	Rheumatoid arthritis;
CRC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.62	9.49	0.46	4.71e-19	Night sleep phenotypes;
CRC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg11632617	chr15:75315747	PPCDC	-0.56	-7.95	-0.4	3.01e-14	Blood trace element (Zn levels);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21123913	chr4:89513664	HERC3	-0.41	-6.29	-0.33	1.02e-9	Myopia (pathological);
CRC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.69	-0.3	2.75e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg26762873	chr11:5879799	OR52E8	-0.41	-6.01	-0.31	4.87e-9	DNA methylation (variation);
CRC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-8.82	-0.44	6.72e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg06238570	chr21:40685208	BRWD1	0.76	10.52	0.5	1.66e-22	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25093320	chr17:80023187	DUS1L	0.49	6.38	0.33	5.96e-10	Anxiety disorder;
CRC	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.67	8.18	0.41	6.34e-15	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg23127183	chr11:57508653	C11orf31	-0.53	-7.08	-0.36	8.9e-12	Schizophrenia;
CRC	cis	rs4073416	0.542	rs10144979	chr14:65997638	G/A	cg03016385	chr14:66212404	NA	-0.42	-5.93	-0.31	7.71e-9	N-glycan levels;
CRC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg00343986	chr7:65444356	GUSB	-0.46	-6.39	-0.33	5.69e-10	Aortic root size;
CRC	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg02466173	chr16:30829666	NA	0.61	9.0	0.44	1.87e-17	Dementia with Lewy bodies;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04661747	chr11:46264818	NA	0.44	6.29	0.33	1.01e-9	Response to antipsychotic treatment;
CRC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg02659138	chr7:134003124	SLC35B4	0.42	7.35	0.38	1.57e-12	Mean platelet volume;
CRC	cis	rs10503871	0.657	rs6997017	chr8:30341945	A/G	cg26383811	chr8:30366931	RBPMS	0.5	7.95	0.4	3.11e-14	Metabolite levels  (X-11787);
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg27094323	chr7:1216898	NA	-0.41	-6.78	-0.35	5.68e-11	Longevity;Endometriosis;
CRC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.69	-0.35	9.65e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.56	7.68	0.39	1.85e-13	Waist circumference;Body mass index;
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg15147215	chr3:52552868	STAB1	-0.64	-11.08	-0.52	1.91e-24	Bipolar disorder;
CRC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.92	11.73	0.54	9.09e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.69	0.39	1.74e-13	Height;
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg10217327	chr6:118973057	C6orf204	0.52	5.91	0.31	8.63e-9	Diastolic blood pressure;
CRC	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg02702477	chr5:179499311	RNF130	0.69	7.6	0.39	3.1400000000000003e-13	LDL cholesterol;
CRC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.16	-0.32	2.07e-9	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg13198984	chr17:80129470	CCDC57	0.42	7.33	0.37	1.77e-12	Life satisfaction;
CRC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.92e-17	Hip circumference adjusted for BMI;
CRC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.44	0.46	7.29e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg04990556	chr1:26633338	UBXN11	-0.47	-5.92	-0.31	7.95e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00495681	chr13:53174319	NA	-0.54	-7.82	-0.4	7.3e-14	Lewy body disease;
CRC	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.5	7.62	0.39	2.66e-13	Atrial fibrillation;
CRC	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg13385794	chr1:248469461	NA	0.4	7.11	0.36	7.23e-12	Common traits (Other);
CRC	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.53	7.24	0.37	3.25e-12	Caudate activity during reward;
CRC	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.89	-0.31	9.71e-9	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs67073037	0.955	rs67612857	chr2:29161707	G/C	cg13899017	chr1:159158444	CADM3	-0.37	-6.14	-0.32	2.4e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.76	13.1	0.59	7.48e-32	Colorectal cancer;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg02683197	chr6:28174875	NA	0.72	7.18	0.37	4.65e-12	Lung cancer in ever smokers;
CRC	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.48	8.3	0.42	2.74e-15	Testicular germ cell tumor;
CRC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.59	9.36	0.46	1.33e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.54	-8.44	-0.42	9.91e-16	Schizophrenia;
CRC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.42	-6.4	-0.33	5.2400000000000005e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2303319	0.504	rs2175142	chr2:162450124	T/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.59	9.07	0.45	1.09e-17	Schizophrenia;
CRC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-12.15	-0.56	2.51e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg15192750	chr16:69999425	NA	0.61	8.17	0.41	6.81e-15	IgE levels;
CRC	cis	rs7705042	0.897	rs249681	chr5:141538017	G/C	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.55e-8	Asthma;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13479780	chr6:41909532	CCND3	0.44	6.13	0.32	2.57e-9	Survival in pancreatic cancer;
CRC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg23298862	chr7:158159286	PTPRN2	0.49	7.03	0.36	1.17e-11	Response to amphetamines;
CRC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.54	-7.49	-0.38	6.26e-13	Corneal structure;
CRC	cis	rs501120	0.584	rs7086639	chr10:44698695	C/T	cg09554077	chr10:44749378	NA	0.69	7.91	0.4	4.04e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.91	17.67	0.7	1.31e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.59	8.61	0.43	3.16e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.15e-9	Lung cancer;
CRC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07513332	chr6:167530253	CCR6	0.37	6.18	0.32	1.89e-9	Primary biliary cholangitis;
CRC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.4	0.42	1.38e-15	Mood instability;
CRC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17507749	chr15:85114479	UBE2QP1	0.62	8.8	0.44	7.9e-17	Schizophrenia;
CRC	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg16486109	chr11:613632	IRF7	0.64	11.34	0.53	2.3e-25	Systemic lupus erythematosus;
CRC	cis	rs6921919	0.789	rs13210258	chr6:28308671	G/T	cg21251018	chr6:28226885	NKAPL	0.43	6.47	0.34	3.53e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg20936604	chr3:58311152	NA	-0.72	-7.15	-0.37	5.58e-12	Cholesterol, total;
CRC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-0.95	-10.01	-0.48	8.8e-21	Diabetic retinopathy;
CRC	cis	rs16975963	0.793	rs12460735	chr19:38313550	C/T	cg15135657	chr19:38346511	NA	-0.44	-5.92	-0.31	8.15e-9	Longevity;
CRC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	1.06	21.5	0.76	1.2e-64	Lewy body disease;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.53	-0.43	5.31e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.54	9.71	0.47	8.88e-20	Lung cancer;
CRC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12311346	chr5:56204834	C5orf35	-0.45	-6.83	-0.35	4.12e-11	Breast cancer;Breast cancer (early onset);
CRC	trans	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.82e-13	HDL cholesterol;
CRC	cis	rs2223471	0.719	rs9381901	chr6:50765751	A/G	cg03432817	chr6:50765336	NA	0.35	5.64	0.3	3.61e-8	Subcutaneous adipose tissue;
CRC	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg23100626	chr2:96804247	ASTL	-0.26	-6.61	-0.34	1.51e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.57	9.08	0.45	1.05e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg20243544	chr17:37824526	PNMT	0.54	8.26	0.41	3.71e-15	Asthma;
CRC	cis	rs453193	0.714	rs2562008	chr2:8447640	A/G	cg12167548	chr2:8464763	NA	0.29	5.75	0.3	2.02e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1320333	0.772	rs2867136	chr2:701455	T/C	cg00500140	chr2:691012	NA	-0.55	-6.7	-0.35	9.06e-11	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7527798	0.592	rs6671969	chr1:207839667	C/T	cg09232269	chr1:207846808	CR1L	-0.52	-8.51	-0.42	6.22e-16	Erythrocyte sedimentation rate;
CRC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg18198730	chr1:247681584	NA	-0.59	-10.03	-0.48	7.66e-21	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg06494592	chr3:125709126	NA	-0.52	-6.86	-0.35	3.36e-11	Blood pressure (smoking interaction);
CRC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.52	7.88	0.4	4.86e-14	Colorectal cancer;
CRC	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.65	-9.56	-0.47	2.86e-19	Type 2 diabetes;
CRC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.35	-5.74	-0.3	2.19e-8	Ulcerative colitis;
CRC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.47	-8.94	-0.44	2.86e-17	Reticulocyte fraction of red cells;
CRC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.79	0.3	1.63e-8	Prudent dietary pattern;
CRC	cis	rs6691722	0.503	rs6692646	chr1:24707629	C/T	cg02336364	chr1:24764700	NIPAL3	0.37	6.13	0.32	2.53e-9	Response to interferon beta in multiple sclerosis;
CRC	trans	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg03701575	chr16:83960119	NA	0.34	5.97	0.31	6.14e-9	Asthma;
CRC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.58	0.54	3.15e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg22349387	chr12:9600060	DDX12	-0.36	-5.71	-0.3	2.53e-8	Breast size;
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11645453	chr3:52864694	ITIH4	0.34	5.92	0.31	8.26e-9	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27098574	chr16:75285489	BCAR1	0.44	7.09	0.36	8.04e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4757319	0.515	rs7125389	chr11:15438571	A/G	cg03245590	chr11:15329459	NA	0.52	9.0	0.44	1.88e-17	Breast cancer;
CRC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.46	5.98	0.31	5.68e-9	Response to diuretic therapy;
CRC	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.5	8.49	0.42	7.39e-16	Testicular germ cell tumor;
CRC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg06363034	chr20:62225388	GMEB2	-0.41	-6.34	-0.33	7.76e-10	Glioblastoma;
CRC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.36	5.65	0.3	3.5e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.13	0.37	6.51e-12	Mean corpuscular volume;
CRC	trans	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.04	-0.36	1.1e-11	QT interval;
CRC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.43	6.46	0.34	3.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16841327	chr22:46466183	NA	0.38	6.53	0.34	2.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg16060761	chr17:80687452	NA	-0.48	-6.13	-0.32	2.55e-9	Glycated hemoglobin levels;
CRC	cis	rs4728302	0.838	rs10225605	chr7:133591676	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.25e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.43	5.87	0.31	1.04e-8	Educational attainment (years of education);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg20087303	chr14:70233840	SFRS5;LOC100289511	0.38	6.15	0.32	2.22e-9	Schizophrenia;
CRC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.89	10.5	0.5	1.9e-22	Gut microbiome composition (summer);
CRC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.18	0.52	7.95e-25	Prudent dietary pattern;
CRC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.1e-9	Obesity-related traits;
CRC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.68	-11.08	-0.52	1.92e-24	Asthma;
CRC	cis	rs9463078	0.764	rs10948194	chr6:44951990	A/C	cg25276700	chr6:44698697	NA	-0.28	-6.9	-0.36	2.61e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	1.01	20.09	0.74	3.94e-59	Headache;
CRC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.43	-6.65	-0.34	1.24e-10	Breast cancer;
CRC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.52	7.66	0.39	2.05e-13	Blood protein levels;
CRC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.64e-39	Lymphocyte percentage of white cells;
CRC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg05941027	chr17:61774174	LIMD2	0.36	6.4	0.33	5.23e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	7.07	0.36	9.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.77	10.96	0.52	4.9299999999999996e-24	Neutrophil percentage of white cells;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg01947301	chr1:205718900	NUCKS1	-0.41	-6.06	-0.32	3.79e-9	Birth weight;Height;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.87	18.17	0.71	1.34e-51	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg20203395	chr5:56204925	C5orf35	0.57	7.85	0.4	5.99e-14	Initial pursuit acceleration;
CRC	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.67	6.57	0.34	2.01e-10	Eosinophilic esophagitis;
CRC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.41	-7.38	-0.38	1.31e-12	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg10298567	chr3:47292165	KIF9	0.35	5.68	0.3	2.94e-8	Colorectal cancer;
CRC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg15786705	chr6:28176104	NA	0.57	5.78	0.3	1.73e-8	Parkinson's disease;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg03790207	chr6:42947109	PEX6	-0.53	-7.75	-0.39	1.17e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.53	-9.14	-0.45	6.65e-18	Aortic root size;
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.36	-0.38	1.48e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg15845792	chr6:28175446	NA	0.68	8.8	0.44	8.02e-17	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.53e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4938330	0.608	rs12418744	chr11:117084537	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-5.98	-0.31	5.71e-9	Blood protein levels;
CRC	cis	rs7705042	0.828	rs6877864	chr5:141503839	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.24	0.37	3.13e-12	Asthma;
CRC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.79	-0.44	8.47e-17	IgG glycosylation;
CRC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.43	5.78	0.3	1.75e-8	Schizophrenia;
CRC	cis	rs3849570	0.533	rs6548784	chr3:81995889	G/A	cg07356753	chr3:81810745	GBE1	-0.46	-6.26	-0.33	1.19e-9	Waist circumference;Body mass index;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.62	9.74	0.47	7.5e-20	Longevity;Endometriosis;
CRC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.53	0.57	1.01e-29	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05147328	chr17:79849438	ANAPC11;THOC4	0.49	6.99	0.36	1.57e-11	Response to antipsychotic treatment;
CRC	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.32	5.74	0.3	2.16e-8	Pneumonia;
CRC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.77	14.08	0.61	1.42e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg15845792	chr6:28175446	NA	0.85	11.63	0.54	2.09e-26	Depression;
CRC	cis	rs7918232	0.596	rs7902540	chr10:27304693	C/T	cg14442939	chr10:27389572	ANKRD26	0.55	7.09	0.36	8.29e-12	Breast cancer;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12172441	chr6:28176163	NA	0.62	7.28	0.37	2.53e-12	Depression;
CRC	cis	rs7113874	0.589	rs2028882	chr11:8504854	A/C	cg17679104	chr11:8615758	STK33	-0.36	-5.89	-0.31	9.31e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg10217327	chr6:118973057	C6orf204	0.5	5.69	0.3	2.82e-8	Diastolic blood pressure;
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.5	-0.34	3.02e-10	Glycated hemoglobin levels;
CRC	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.64	6.6	0.34	1.6e-10	Blood protein levels;
CRC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.86	-0.31	1.13e-8	Colorectal cancer;
CRC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg20742385	chr13:113633654	MCF2L	-0.6	-8.97	-0.44	2.28e-17	Systolic blood pressure;
CRC	cis	rs995000	0.868	rs6682423	chr1:63171063	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.79	-0.35	5.09e-11	Triglyceride levels;
CRC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-16.16	-0.67	1.19e-43	Electrocardiographic conduction measures;
CRC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.47	7.45	0.38	8.45e-13	Eye color traits;
CRC	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs4660214	0.614	rs11205802	chr1:39699114	C/T	cg11070191	chr1:39582205	MACF1	0.36	5.81	0.3	1.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg19812747	chr11:111475976	SIK2	0.43	6.17	0.32	1.97e-9	Primary sclerosing cholangitis;
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.44	6.46	0.34	3.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.43	6.15	0.32	2.3e-9	Vitiligo;
CRC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.45	-7.38	-0.38	1.29e-12	Monocyte count;
CRC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.26	0.62	2.94e-36	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg23996704	chr18:44553084	KATNAL2	0.38	7.52	0.38	5.38e-13	Personality dimensions;
CRC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.62	-0.3	4.05e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs10507419	1.000	rs10507419	chr13:35186452	A/T	cg00944431	chr1:10896004	NA	-0.41	-6.0	-0.31	5.08e-9	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);
CRC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7487075	0.619	rs10748450	chr12:46857102	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.72	0.3	2.38e-8	Itch intensity from mosquito bite;
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg15382696	chr6:118971807	C6orf204	0.6	7.65	0.39	2.19e-13	Diastolic blood pressure;
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.72	0.39	1.4e-13	Alzheimer's disease;
CRC	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.44	-6.45	-0.34	3.95e-10	Body mass index;
CRC	trans	rs2055729	0.710	rs114038384	chr8:9737519	T/A	cg06636001	chr8:8085503	FLJ10661	0.57	6.94	0.36	2.04e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.32	-6.77	-0.35	5.89e-11	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	5.98e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.19	-0.32	1.77e-9	Bipolar disorder;
CRC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.66	-9.35	-0.46	1.44e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg03013999	chr17:37608204	MED1	0.47	7.21	0.37	3.86e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.58	-9.08	-0.45	1.05e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.33	4.06e-10	Electroencephalogram traits;
CRC	cis	rs2249694	0.520	rs10857730	chr10:135326822	T/G	cg20169779	chr10:135381914	SYCE1	-0.55	-7.51	-0.38	5.53e-13	Obesity-related traits;
CRC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.55	7.29	0.37	2.26e-12	Height;
CRC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-9.84	-0.48	3.39e-20	Bipolar disorder;
CRC	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.26	0.37	2.74e-12	Eye color traits;
CRC	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.77	8.66	0.43	2.14e-16	Neuroticism;
CRC	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg09659197	chr4:152720779	NA	0.43	8.85	0.44	5.36e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.81	0.4	7.61e-14	Blood metabolite levels;
CRC	cis	rs7849270	0.760	rs1075650	chr9:131938913	T/C	cg13538475	chr9:131942899	NA	0.31	5.68	0.3	2.97e-8	Blood metabolite ratios;
CRC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.11	13.59	0.6	1.05e-33	Vitiligo;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg15786705	chr6:28176104	NA	0.56	7.01	0.36	1.32e-11	Parkinson's disease;
CRC	cis	rs1033849	0.507	rs1998478	chr13:24721774	C/T	cg14860438	chr13:24731302	NA	0.34	5.65	0.3	3.52e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.48	7.43	0.38	9.63e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.53	9.38	0.46	1.07e-18	Common traits (Other);
CRC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.55	8.8	0.44	7.65e-17	Gestational age at birth (maternal effect);
CRC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg25459000	chr22:39777742	SYNGR1	-0.35	-6.13	-0.32	2.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.9	-13.62	-0.6	8.26e-34	Breast cancer;
CRC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-7.55	-0.38	4.4e-13	Coronary artery disease;
CRC	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.5	8.06	0.41	1.43e-14	Birth weight;
CRC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg03160526	chr17:80928410	B3GNTL1	-0.47	-7.73	-0.39	1.31e-13	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01428115	chr11:46402506	MDK	0.48	6.92	0.36	2.43e-11	Response to antipsychotic treatment;
CRC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.4	0.42	1.35e-15	Schizophrenia;
CRC	cis	rs10924970	0.967	rs2152954	chr1:235417780	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.78e-8	Asthma;
CRC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.73	-0.3	2.22e-8	Migraine;Coronary artery disease;
CRC	trans	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.55	-0.38	4.4e-13	Endometrial cancer;
CRC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg09582351	chr12:29534625	ERGIC2	0.32	6.85	0.35	3.58e-11	QT interval;
CRC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.56	-5.98	-0.31	5.7e-9	Schizophrenia;
CRC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.33	-0.33	7.9e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.98	13.39	0.59	6.33e-33	Educational attainment;
CRC	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.64	-8.77	-0.44	9.63e-17	Cocaine dependence;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14430982	chr8:145691629	CYHR1;KIFC2	0.5	6.64	0.34	1.29e-10	Anxiety disorder;
CRC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.56	-8.64	-0.43	2.47e-16	Schizophrenia;
CRC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.26	0.33	1.23e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg01788221	chr16:89496183	ANKRD11	-0.46	-7.07	-0.36	9.52e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg18761221	chr20:60518478	NA	0.4	6.95	0.36	1.96e-11	Body mass index;
CRC	cis	rs4731207	0.596	rs2402762	chr7:124599846	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.21	-0.32	1.58e-9	Cutaneous malignant melanoma;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18297960	chr7:1142765	C7orf50	-0.43	-5.97	-0.31	5.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.81	14.71	0.63	5.61e-38	Anterior chamber depth;
CRC	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg14458575	chr2:238380390	NA	0.52	6.86	0.35	3.51e-11	Prostate cancer;
CRC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.59	0.47	2.24e-19	Cognitive test performance;
CRC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-7.83	-0.4	6.74e-14	Body mass index;
CRC	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg21869046	chr19:41225005	ITPKC	-0.38	-5.87	-0.31	1.08e-8	Kawasaki disease;
CRC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.43	-7.18	-0.37	4.62e-12	Sitting height ratio;
CRC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.57	-9.44	-0.46	7.31e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg26043149	chr18:55253948	FECH	-0.53	-8.09	-0.41	1.19e-14	Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17001531	chr1:16825540	NA	0.41	6.57	0.34	1.97e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7487075	0.964	rs2408497	chr12:46796751	A/G	cg17501823	chr12:47219793	SLC38A4	0.32	5.64	0.3	3.58e-8	Itch intensity from mosquito bite;
CRC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.68	10.67	0.51	5.26e-23	Breast cancer;
CRC	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg06917450	chr1:38156652	C1orf109	-0.52	-7.17	-0.37	5.07e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg02018176	chr4:1364513	KIAA1530	0.47	7.7	0.39	1.56e-13	Obesity-related traits;
CRC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.67	-0.43	1.96e-16	Aortic root size;
CRC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.73	9.39	0.46	1.04e-18	Psoriasis;
CRC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.48	-9.31	-0.46	1.84e-18	Subjective well-being;
CRC	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg19875535	chr5:140030758	IK	0.45	6.85	0.35	3.65e-11	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.45	9.29	0.46	2.21e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg05507819	chr15:63340323	TPM1	0.46	6.05	0.32	3.88e-9	HDL cholesterol;
CRC	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.71	12.46	0.57	1.8e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.6	-9.84	-0.48	3.42e-20	Waist circumference adjusted for body mass index;
CRC	cis	rs3736485	0.868	rs9744054	chr15:51933163	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.55	-0.34	2.18e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24937269	chr2:101179488	PDCL3	0.49	6.87	0.35	3.16e-11	Response to antipsychotic treatment;
CRC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.03	14.59	0.63	1.64e-37	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.28	0.33	1.07e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-7.07	-0.36	9.09e-12	Aortic root size;
CRC	cis	rs6681460	0.934	rs10889635	chr1:67075575	G/A	cg02459107	chr1:67143332	SGIP1	0.44	7.45	0.38	8.42e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.36	6.12	0.32	2.61e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Parkinson's disease;
CRC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg08888203	chr3:10149979	C3orf24	0.48	7.18	0.37	4.64e-12	Alzheimer's disease;
CRC	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	6.03	0.32	4.48e-9	Ovarian reserve;
CRC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg27535305	chr1:53392650	SCP2	-0.32	-5.7	-0.3	2.64e-8	Monocyte count;
CRC	cis	rs12580194	1.000	rs7968881	chr12:55694434	A/C	cg19537932	chr12:55886519	OR6C68	-0.57	-7.9	-0.4	4.11e-14	Cancer;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg22638593	chr5:131593259	PDLIM4	0.49	9.26	0.45	2.74e-18	Acylcarnitine levels;
CRC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.73	-0.3	2.22e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.54	8.06	0.41	1.38e-14	Blood protein levels;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.51	7.67	0.39	2.02e-13	Breast cancer;
CRC	cis	rs113835537	0.877	rs57127845	chr11:66318325	C/T	cg22134325	chr11:66188745	NPAS4	0.35	5.75	0.3	2.05e-8	Airway imaging phenotypes;
CRC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.5	6.81	0.35	4.64e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.82	-11.97	-0.55	1.2e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	6.8	0.35	4.95e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26240231	chr7:1148101	C7orf50	-0.43	-5.81	-0.3	1.49e-8	Bronchopulmonary dysplasia;
CRC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	1.05	10.13	0.49	3.69e-21	Cognitive function;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20092199	chr4:1342459	KIAA1530	0.4	7.3	0.37	2.12e-12	Obesity-related traits;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.45	-0.42	9.79e-16	Electroencephalogram traits;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.62	9.55	0.47	3.04e-19	Longevity;Endometriosis;
CRC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.34	-6.45	-0.34	3.94e-10	Colorectal cancer;
CRC	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.56	-7.75	-0.39	1.18e-13	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.55	0.6	1.54e-33	Prudent dietary pattern;
CRC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg10589385	chr1:150898437	SETDB1	0.33	7.08	0.36	8.55e-12	Melanoma;
CRC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.54	-7.9	-0.4	4.19e-14	Height;
CRC	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.65	-8.28	-0.42	3.04e-15	Blood protein levels;
CRC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg10570241	chr7:158785291	NA	0.44	7.38	0.38	1.3e-12	Facial morphology (factor 20);
CRC	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg00086871	chr4:6988644	TBC1D14	0.91	6.86	0.35	3.36e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg07828024	chr6:149772892	ZC3H12D	0.48	9.07	0.45	1.08e-17	Dupuytren's disease;
CRC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg18099408	chr3:52552593	STAB1	-0.37	-6.12	-0.32	2.61e-9	Electroencephalogram traits;
CRC	cis	rs4731207	0.623	rs28807101	chr7:124598826	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.34e-9	Cutaneous malignant melanoma;
CRC	cis	rs4072705	0.614	rs35929043	chr9:127234356	T/C	cg13476313	chr9:127244764	NR5A1	0.28	5.64	0.3	3.65e-8	Menarche (age at onset);
CRC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg02683197	chr6:28174875	NA	0.74	7.48	0.38	6.93e-13	Parkinson's disease;
CRC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.48	6.46	0.34	3.84e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-7.9	-0.4	4.37e-14	Response to antipsychotic treatment;
CRC	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	0.66	7.1	0.36	7.64e-12	Prostate cancer;
CRC	cis	rs11229555	0.645	rs34054511	chr11:58204943	A/C	cg15696309	chr11:58395628	NA	-0.82	-10.44	-0.5	3.27e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg13206674	chr6:150067644	NUP43	0.48	6.95	0.36	1.93e-11	Testicular germ cell tumor;
CRC	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.42	-6.72	-0.35	7.89e-11	Corneal astigmatism;
CRC	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.59	7.59	0.39	3.37e-13	Plateletcrit;
CRC	cis	rs17767392	0.881	rs35589413	chr14:71991676	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.47	-6.24	-0.33	1.37e-9	Mitral valve prolapse;
CRC	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.51	-7.4	-0.38	1.14e-12	Testicular germ cell tumor;
CRC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg17724175	chr1:150552817	MCL1	-0.46	-7.28	-0.37	2.55e-12	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00300090	chr3:4345167	SETMAR	0.42	6.63	0.34	1.36e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg10756647	chr7:56101905	PSPH	0.71	7.81	0.4	7.72e-14	Diabetic kidney disease;
CRC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.36	-0.62	1.17e-36	Body mass index;
CRC	cis	rs7120118	0.517	rs11530168	chr11:47322986	A/G	cg25783544	chr11:47291846	MADD	0.62	5.77	0.3	1.81e-8	HDL cholesterol;
CRC	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg16540259	chr10:75572220	NDST2	0.38	5.93	0.31	7.67e-9	Inflammatory bowel disease;
CRC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.24e-11	Life satisfaction;
CRC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg03233332	chr7:66118400	NA	-0.42	-5.68	-0.3	2.97e-8	Aortic root size;
CRC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12463550	chr7:65579703	CRCP	0.7	6.45	0.34	3.97e-10	Diabetic kidney disease;
CRC	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.44	6.92	0.36	2.32e-11	Testicular germ cell tumor;
CRC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.72	9.75	0.47	6.62e-20	Platelet count;
CRC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.72	8.18	0.41	6.46e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.6	-0.34	1.62e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg24588162	chr13:113633484	MCF2L	-0.39	-6.83	-0.35	4.01e-11	Systolic blood pressure;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg12172441	chr6:28176163	NA	0.51	6.98	0.36	1.63e-11	Parkinson's disease;
CRC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.61	8.44	0.42	1.02e-15	Mean platelet volume;
CRC	cis	rs758324	0.738	rs399714	chr5:131318788	C/T	cg25547332	chr5:131281432	NA	-0.36	-5.72	-0.3	2.41e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg19537932	chr12:55886519	OR6C68	-0.72	-8.99	-0.44	1.99e-17	Cancer;
CRC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-13.29	-0.59	1.52e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.29	-0.42	2.89e-15	Monocyte count;
CRC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.41	7.22	0.37	3.53e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.64	0.34	1.32e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg16670446	chr17:27188758	MIR451;MIR144	0.59	10.06	0.49	6.19e-21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.82	0.4	7.2e-14	Coronary heart disease;
CRC	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg02466173	chr16:30829666	NA	-0.58	-8.57	-0.43	4.15e-16	Dementia with Lewy bodies;
CRC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg24881330	chr22:46731750	TRMU	0.63	5.63	0.3	3.82e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	6.09	0.32	3.19e-9	Resistin levels;
CRC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg15465823	chr12:48382534	COL2A1	0.38	6.26	0.33	1.17e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.64	0.47	1.53e-19	Intelligence (multi-trait analysis);
CRC	trans	rs9840812	0.656	rs4678437	chr3:136317665	C/T	cg00086297	chr16:3662233	BTBD12	0.48	6.17	0.32	2.01e-9	Fibrinogen levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02619805	chr19:5623015	SAFB2;SAFB	0.41	6.06	0.32	3.77e-9	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.23	5.63	0.3	3.89e-8	Parkinson's disease;
CRC	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.47	-7.29	-0.37	2.33e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg16068336	chr17:48637367	CACNA1G	-0.51	-7.45	-0.38	8.31e-13	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.91	14.15	0.62	7.73e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg08798685	chr6:27730294	NA	-0.5	-6.51	-0.34	2.87e-10	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-8.83	-0.44	6.34e-17	Height;
CRC	cis	rs2179367	0.959	rs521845	chr6:149671698	A/C	cg07828024	chr6:149772892	ZC3H12D	0.36	5.99	0.31	5.47e-9	Dupuytren's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27305525	chr1:154955752	FLAD1	0.51	6.55	0.34	2.21e-10	Thyroid stimulating hormone;
CRC	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.83	0.44	6.16e-17	Mean corpuscular volume;
CRC	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.71	11.09	0.52	1.69e-24	Lewy body disease;
CRC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.48	-0.6	2.9e-33	Blood metabolite levels;
CRC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.37	-7.11	-0.37	7.16e-12	Iron status biomarkers;
CRC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.5	-6.4	-0.33	5.41e-10	Vitiligo;
CRC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.55	6.15	0.32	2.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.33	6.63	0.34	1.35e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.94	11.56	0.54	3.59e-26	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16711694	chr5:34656625	RAI14	0.37	6.11	0.32	2.88e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.67	-11.76	-0.54	6.83e-27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.8	14.47	0.62	4.46e-37	Anterior chamber depth;
CRC	cis	rs11031096	0.542	rs10742200	chr11:3989521	A/T	cg18678763	chr11:4115507	RRM1	-0.4	-6.7	-0.35	9.07e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.64	-0.34	1.29e-10	Response to antipsychotic treatment;
CRC	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.62	9.79	0.48	4.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg23758597	chr6:163146217	PARK2	-0.51	-5.9	-0.31	8.81e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.32	-0.33	8.39e-10	Reticulocyte fraction of red cells;
CRC	cis	rs62432291	0.614	rs370434	chr6:159654551	C/G	cg14500486	chr6:159655392	FNDC1	-0.77	-10.45	-0.5	3.02e-22	Joint mobility (Beighton score);
CRC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.56	-9.19	-0.45	4.4e-18	Schizophrenia;
CRC	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-7.1	-0.36	7.67e-12	Schizophrenia;
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.61	8.76	0.43	1.05e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg23807890	chr2:228736357	WDR69	-0.51	-7.04	-0.36	1.15e-11	Blood pressure;
CRC	cis	rs17065868	0.764	rs60806722	chr13:45021236	A/G	cg10246903	chr13:45222710	NA	0.58	6.47	0.34	3.46e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs8040855	0.627	rs12909130	chr15:85590501	T/C	cg10818794	chr15:86012489	AKAP13	-0.43	-5.69	-0.3	2.77e-8	Bulimia nervosa;
CRC	cis	rs10450586	0.932	rs10835153	chr11:27313863	A/T	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23161317	chr6:28129485	ZNF389	0.51	6.36	0.33	6.66e-10	Depression;
CRC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg14847009	chr1:175162515	KIAA0040	0.3	6.66	0.34	1.18e-10	Alcohol dependence;
CRC	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.69	-8.0	-0.4	2.2e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.61	-0.47	2e-19	Monocyte percentage of white cells;
CRC	cis	rs7692995	1.000	rs35081654	chr4:18017938	A/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26392691	chr15:51915035	DMXL2	0.46	6.79	0.35	5.28e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.71	-0.3	2.57e-8	Life satisfaction;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg09525994	chr12:48512905	PFKM	0.47	6.71	0.35	8.62e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.41	8.26	0.41	3.51e-15	Mean corpuscular volume;
CRC	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg17145862	chr1:211918768	LPGAT1	0.49	6.4	0.33	5.47e-10	Crohn's disease;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg20512303	chr5:131592959	PDLIM4	0.39	6.75	0.35	6.72e-11	Breast cancer;
CRC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.66	-10.02	-0.48	8.47e-21	Acne (severe);
CRC	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.54	-8.78	-0.44	9.33e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.62	9.72	0.47	8.54e-20	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9409565	0.658	rs2809768	chr9:97128369	G/A	cg05679027	chr9:99775184	HIATL2	0.44	6.72	0.35	8.19e-11	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.56	-9.66	-0.47	1.33e-19	Body mass index;
CRC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.33	-12.55	-0.57	8.93e-30	Plateletcrit;
CRC	trans	rs6693295	0.729	rs10802325	chr1:246213454	C/A	cg17980625	chr11:94965587	SESN3	0.48	6.05	0.32	3.9e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.83	9.7	0.47	1.02e-19	Obesity-related traits;
CRC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26850624	chr5:429559	AHRR	0.52	8.82	0.44	7.02e-17	Cystic fibrosis severity;
CRC	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.4	-6.26	-0.33	1.23e-9	Red blood cell count;
CRC	cis	rs9478638	0.507	rs9371882	chr6:155638741	G/A	cg07943832	chr6:155568918	TIAM2	-0.58	-7.38	-0.38	1.27e-12	Electroencephalogram traits;
CRC	cis	rs9469578	1.000	rs6923565	chr6:33707112	G/A	cg18708504	chr6:33715942	IP6K3	0.64	7.42	0.38	1.02e-12	Phosphorus levels;
CRC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.55	-7.42	-0.38	1.03e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs3001167	0.867	rs12124558	chr1:194565350	T/G	cg19011063	chr5:170171465	NA	0.59	6.09	0.32	3.11e-9	Obesity-related traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg20483215	chr17:72919318	OTOP2;USH1G	0.42	6.24	0.33	1.35e-9	Schizophrenia;
CRC	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.56	8.01	0.4	2.06e-14	Pulmonary function decline;
CRC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.44	-8.09	-0.41	1.14e-14	Iron status biomarkers;
CRC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.29e-24	Motion sickness;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.44	-9.62	-0.47	1.84e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	5.68	0.3	2.93e-8	Neutrophil percentage of white cells;
CRC	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.6	-7.46	-0.38	7.96e-13	Fractional excretion of uric acid;
CRC	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.46	-7.67	-0.39	2.02e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.28	0.37	2.46e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg01483505	chr11:975446	AP2A2	0.45	7.49	0.38	6.22e-13	Alzheimer's disease (late onset);
CRC	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.96	-0.4	2.77e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs847649	0.699	rs10242028	chr7:102527785	C/G	cg18108683	chr7:102477205	FBXL13	-0.63	-10.98	-0.52	4.3e-24	Morning vs. evening chronotype;
CRC	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.83	13.73	0.6	3.08e-34	Height;
CRC	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.79	12.14	0.56	2.89e-28	Testicular germ cell tumor;
CRC	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.64	8.48	0.42	7.75e-16	Birth weight;
CRC	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.47	5.96	0.31	6.36e-9	Urinary tract infection frequency;
CRC	trans	rs10050311	0.698	rs4693780	chr4:87641219	A/G	cg00004207	chr2:38977301	SFRS7	-0.5	-6.19	-0.32	1.75e-9	Insulin-related traits;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg25164649	chr6:28176230	NA	-0.54	-7.72	-0.39	1.39e-13	Parkinson's disease;
CRC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.38	0.33	5.87e-10	Mood instability;
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.38	-5.79	-0.3	1.65e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	9.18	0.45	4.75e-18	Fuchs's corneal dystrophy;
CRC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.81	-0.4	7.8500000000000006e-14	Hemoglobin concentration;
CRC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	6.72	0.35	7.95e-11	Response to antipsychotic treatment;
CRC	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg25019722	chr6:37503610	NA	-0.47	-8.73	-0.43	1.28e-16	Cognitive performance;
CRC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg24011408	chr12:48396354	COL2A1	0.45	6.1	0.32	3.01e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.43	-6.79	-0.35	5.19e-11	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg14844989	chr11:31128820	NA	0.35	6.18	0.32	1.86e-9	Red blood cell count;
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg20512303	chr5:131592959	PDLIM4	0.37	7.12	0.37	6.75e-12	Breast cancer;
CRC	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.47	0.34	3.52e-10	Melanoma;
CRC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.59	9.96	0.48	1.3e-20	Lung cancer in ever smokers;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.22e-12	Bipolar disorder;
CRC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg24209194	chr3:40518798	ZNF619	0.42	6.33	0.33	8.25e-10	Renal cell carcinoma;
CRC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.16	0.41	6.99e-15	Lung cancer;
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.43	-8.64	-0.43	2.47e-16	Renal cell carcinoma;
CRC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.53	-6.32	-0.33	8.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.56	-0.75	5.59e-61	Height;
CRC	trans	rs12310399	0.611	rs7961230	chr12:95565867	C/A	cg16511708	chr18:23671264	SS18	0.41	5.97	0.31	6.1e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CRC	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.71	-10.31	-0.49	8.6e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg13385794	chr1:248469461	NA	0.38	6.58	0.34	1.87e-10	Common traits (Other);
CRC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.93	-11.84	-0.55	3.62e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.61e-14	Height;
CRC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.6	7.3	0.37	2.25e-12	Mean platelet volume;
CRC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.64	8.63	0.43	2.58e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs7705042	0.865	rs6874308	chr5:141506911	C/T	cg07392085	chr5:141489673	NDFIP1	0.46	7.27	0.37	2.59e-12	Asthma;
CRC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg24562669	chr7:97807699	LMTK2	0.43	7.09	0.36	8.16e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4728302	0.643	rs6978605	chr7:133720125	T/C	cg03336402	chr7:133662267	EXOC4	-0.44	-6.83	-0.35	4.19e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.38	0.46	1.12e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.82	-0.35	4.39e-11	Body mass index;
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg26587870	chr6:27730563	NA	-0.56	-6.42	-0.33	4.87e-10	Lung cancer in ever smokers;
CRC	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-1.21	-11.51	-0.54	5.31e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.83	0.31	1.31e-8	Bladder cancer;
CRC	cis	rs1009181	0.585	rs72834696	chr6:26161399	G/A	cg00631329	chr6:26305371	NA	-0.42	-6.16	-0.32	2.16e-9	Childhood ear infection;
CRC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	trans	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg18288967	chr1:45987694	PRDX1	0.67	6.73	0.35	7.56e-11	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.74e-12	Urinary tract infection frequency;
CRC	cis	rs6076065	0.723	rs6083119	chr20:23390923	T/G	cg11657817	chr20:23433608	CST11	0.44	6.31	0.33	9.24e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.44e-9	Homoarginine levels;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg01612440	chr4:3296283	NA	0.4	5.71	0.3	2.54e-8	Serum sulfate level;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.6	10.15	0.49	3.03e-21	Prudent dietary pattern;
CRC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.93	-11.32	-0.53	2.55e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.76	-14.41	-0.62	7.91e-37	Lewy body disease;
CRC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.49	0.54	6.58e-26	Prudent dietary pattern;
CRC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.14	14.61	0.63	1.32e-37	Uric acid levels;
CRC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg03934865	chr2:198174659	NA	-0.45	-8.05	-0.41	1.53e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10905065	0.965	rs7078711	chr10:5744985	C/G	cg11519256	chr10:5708881	ASB13	0.46	6.63	0.34	1.38e-10	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04348427	chr16:3450780	ZNF174;ZNF434	0.44	6.09	0.32	3.1e-9	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02466933	chr2:9770529	YWHAQ	0.38	6.82	0.35	4.46e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.54	-7.26	-0.37	2.86e-12	Tonsillectomy;
CRC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.45	6.43	0.33	4.6e-10	Lung cancer;
CRC	cis	rs1532331	0.865	rs4866971	chr5:43151537	C/T	cg09164108	chr5:43007320	NA	0.38	5.82	0.31	1.42e-8	Menarche (age at onset);
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg10596483	chr8:143751796	JRK	-0.45	-6.4	-0.33	5.49e-10	Urinary tract infection frequency;
CRC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.39	-0.5	4.76e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.84	0.63	1.63e-38	Mean platelet volume;
CRC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg24011408	chr12:48396354	COL2A1	0.43	6.26	0.33	1.18e-9	Glycated hemoglobin levels;
CRC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.6	-0.47	2.14e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6496667	0.865	rs1971899	chr15:90890664	C/A	cg04176472	chr15:90893244	GABARAPL3	0.56	8.57	0.43	4.14e-16	Rheumatoid arthritis;
CRC	trans	rs17112901	1.000	rs2862985	chr10:102062809	G/A	cg12052765	chr10:50816963	SLC18A3;CHAT	-0.47	-6.04	-0.32	4.27e-9	Obesity-related traits;
CRC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12292205	chr6:26970375	C6orf41	-0.47	-6.54	-0.34	2.33e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.85	-0.4	5.9e-14	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.55	9.62	0.47	1.88e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	8.84	0.44	5.83e-17	Lymphocyte counts;Red cell distribution width;
CRC	trans	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg18187862	chr3:45730750	SACM1L	0.49	7.0	0.36	1.4e-11	Primary sclerosing cholangitis;
CRC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	6.09	0.32	3.18e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs501120	0.584	rs1746042	chr10:44731897	C/T	cg09554077	chr10:44749378	NA	0.62	6.84	0.35	3.9e-11	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.59	-0.34	1.78e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9311676	0.632	rs62258094	chr3:58371770	T/G	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.6	7.93	0.4	3.53e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs12900413	0.687	rs35562959	chr15:90310537	C/T	cg24249390	chr15:90295951	MESP1	-0.58	-9.31	-0.46	1.9e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.73	7.5	0.38	5.81e-13	Plasma clusterin levels;
CRC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.44	-0.46	7.1e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg13206674	chr6:150067644	NUP43	0.48	6.95	0.36	1.93e-11	Testicular germ cell tumor;
CRC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-10.21	-0.49	1.93e-21	Menarche (age at onset);
CRC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09018467	chr17:55055306	SCPEP1	0.43	5.99	0.31	5.65e-9	Response to antipsychotic treatment;
CRC	cis	rs56399783	0.901	rs17132744	chr7:2874982	T/C	cg19731401	chr7:2775893	GNA12	0.56	6.09	0.32	3.16e-9	Childhood ear infection;
CRC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.59	-8.8	-0.44	8.12e-17	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04267590	chr5:14581942	FAM105A	0.38	6.05	0.32	4e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.85	0.35	3.58e-11	Menopause (age at onset);
CRC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.56	6.67	0.34	1.11e-10	Bipolar disorder;
CRC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.89	0.4	4.46e-14	Rheumatoid arthritis;
CRC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.52	8.65	0.43	2.33e-16	Menarche (age at onset);
CRC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.75	11.25	0.53	4.57e-25	Corneal astigmatism;
CRC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg00074818	chr8:8560427	CLDN23	0.39	7.0	0.36	1.48e-11	Obesity-related traits;
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg25164649	chr6:28176230	NA	0.69	7.78	0.39	9.77e-14	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg15511327	chr8:143859410	LYNX1	0.35	6.16	0.32	2.09e-9	Urinary tract infection frequency;
CRC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.55	-0.38	4.37e-13	High light scatter reticulocyte count;
CRC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.66	12.19	0.56	1.78e-28	Aortic root size;
CRC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.66	-8.08	-0.41	1.27e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg08614441	chr13:113633676	MCF2L	-0.53	-9.35	-0.46	1.43e-18	Systolic blood pressure;
CRC	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.47	6.79	0.35	5.13e-11	Coronary heart disease;
CRC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.46	-8.58	-0.43	3.72e-16	Iron status biomarkers;
CRC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg03013999	chr17:37608204	MED1	0.45	6.77	0.35	5.76e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.55	7.37	0.38	1.41e-12	Height;
CRC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg13385521	chr17:29058706	SUZ12P	-0.59	-7.48	-0.38	7.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7926971	0.631	rs7938009	chr11:12660882	C/T	cg25843174	chr11:12811716	TEAD1	0.33	5.93	0.31	7.58e-9	Height;
CRC	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.54	-8.49	-0.42	7.16e-16	Testicular germ cell tumor;
CRC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-6.81	-0.35	4.61e-11	Bipolar disorder;
CRC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.99	21.34	0.76	4.82e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg16606324	chr3:10149918	C3orf24	0.69	9.75	0.47	6.97e-20	Alzheimer's disease;
CRC	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg25124228	chr12:125621409	AACS	-0.53	-6.44	-0.33	4.16e-10	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.91	9.49	0.46	4.86e-19	Intelligence (multi-trait analysis);
CRC	trans	rs9650657	0.644	rs7012206	chr8:10697015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.04	-0.32	4.22e-9	Neuroticism;
CRC	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.45	5.69	0.3	2.87e-8	Metabolite levels;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.43	6.3	0.33	9.28e-10	Bipolar disorder;
CRC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.43	-7.78	-0.39	9.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg00603274	chr11:61596626	FADS2	0.53	6.47	0.34	3.53e-10	Neutrophil count;Sum basophil neutrophil counts;
CRC	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs10242455	0.571	rs45593341	chr7:99304911	C/A	cg18809830	chr7:99032528	PTCD1	-0.95	-7.28	-0.37	2.47e-12	Blood metabolite levels;
CRC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.8	14.23	0.62	3.79e-36	Breast cancer;
CRC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.53	8.18	0.41	6.34e-15	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08320164	chr19:18228740	MAST3	0.41	6.89	0.36	2.92e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg08222913	chr3:52553049	STAB1	-0.36	-6.87	-0.35	3.15e-11	Electroencephalogram traits;
CRC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.41	-5.95	-0.31	6.96e-9	Asthma;
CRC	cis	rs11212617	0.905	rs1893813	chr11:108054604	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.39	5.71	0.3	2.48e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg18646521	chr2:111875858	NA	0.4	6.33	0.33	8.21e-10	Chronic lymphocytic leukemia;
CRC	cis	rs3751196	0.808	rs78288940	chr12:104211454	T/C	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs11212617	0.967	rs3781868	chr11:108059569	T/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.3	0.33	9.48e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	8.56	0.43	4.42e-16	Rheumatoid arthritis;
CRC	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.8	-14.1	-0.61	1.19e-35	Lewy body disease;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg20647610	chr2:228736258	WDR69	-0.5	-6.76	-0.35	6.37e-11	Blood pressure;
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.68	-0.39	1.78e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9905704	0.627	rs1267543	chr17:56656624	A/G	cg12560992	chr17:57184187	TRIM37	-0.51	-6.03	-0.32	4.46e-9	Testicular germ cell tumor;
CRC	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.05	0.45	1.24e-17	Dupuytren's disease;
CRC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.54	7.06	0.36	1.03e-11	Obesity-related traits;
CRC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.84	-10.81	-0.51	1.64e-23	Gut microbiome composition (summer);
CRC	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg22495460	chr2:25135724	ADCY3	-0.72	-11.83	-0.55	3.81e-27	Body mass index;
CRC	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg11887960	chr12:57824829	NA	0.59	6.56	0.34	2.05e-10	Obesity-related traits;
CRC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.6	9.84	0.48	3.28e-20	Mean corpuscular hemoglobin;
CRC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg05623727	chr3:50126028	RBM5	-0.37	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg10437265	chr15:77819839	NA	0.67	11.95	0.55	1.41e-27	Type 2 diabetes;
CRC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.42	0.5	3.6e-22	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2811415	0.597	rs13059751	chr3:127782662	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg26893134	chr6:116381904	FRK	0.26	7.58	0.39	3.52e-13	Cholesterol, total;LDL cholesterol;
CRC	trans	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg14791747	chr16:20752902	THUMPD1	0.54	6.75	0.35	6.85e-11	Cognitive test performance;
CRC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.63	8.4	0.42	1.39e-15	Smoking initiation;
CRC	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg16906346	chr6:24646782	KIAA0319	-0.57	-8.83	-0.44	6.32e-17	Colorectal or endometrial cancer;
CRC	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg07856975	chr6:36356162	ETV7	0.49	5.96	0.31	6.63e-9	Platelet distribution width;
CRC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	5.75	0.3	2.07e-8	Diabetic retinopathy;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg21251018	chr6:28226885	NKAPL	0.51	5.95	0.31	6.9e-9	Depression;
CRC	cis	rs6694672	1.000	rs1759007	chr1:197027606	C/T	cg13682187	chr1:196946512	CFHR5	-0.5	-8.04	-0.41	1.65e-14	Asthma;
CRC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg18099408	chr3:52552593	STAB1	0.35	5.97	0.31	6.26e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg27068330	chr11:65405492	SIPA1	0.43	6.35	0.33	7.22e-10	Acne (severe);
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-8.41	-0.42	1.3e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.53	5.88	0.31	9.95e-9	Lung cancer;
CRC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.37	-6.27	-0.33	1.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.51	7.14	0.37	5.89e-12	Obesity-related traits;
CRC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.14	0.32	2.34e-9	Aortic root size;
CRC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg00255919	chr5:131827918	IRF1	0.59	11.64	0.54	1.89e-26	Asthma (sex interaction);
CRC	trans	rs34043159	0.965	rs2068397	chr2:102378744	C/A	cg23013864	chr6:17393396	CAP2	0.41	5.99	0.31	5.58e-9	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00462311	chr14:24837184	NFATC4	-0.43	-6.63	-0.34	1.41e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.47	7.16	0.37	5.26e-12	Corneal astigmatism;
CRC	cis	rs10208940	0.920	rs35118992	chr2:68699460	G/A	cg12452813	chr2:68675892	NA	0.52	6.43	0.33	4.44e-10	Urate levels in lean individuals;
CRC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.59	9.98	0.48	1.15e-20	Prudent dietary pattern;
CRC	cis	rs7487075	0.859	rs7968283	chr12:46759136	A/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.41	0.33	5.1e-10	Itch intensity from mosquito bite;
CRC	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg26097391	chr2:54893211	SPTBN1	0.4	5.99	0.31	5.36e-9	Schizophrenia;
CRC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.68	9.17	0.45	5.48e-18	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14760355	chr2:176046503	ATP5G3	0.42	5.96	0.31	6.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg24644049	chr4:85504048	CDS1	0.86	7.2	0.37	4.07e-12	Skin colour saturation;
CRC	cis	rs294883	0.821	rs211494	chr6:159671092	C/T	cg14500486	chr6:159655392	FNDC1	-0.38	-6.33	-0.33	7.81e-10	Coronary artery disease;
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.56	-0.38	4.14e-13	Total body bone mineral density;
CRC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg17321639	chr7:2759063	NA	-0.51	-6.76	-0.35	6.16e-11	Height;
CRC	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.64	-10.1	-0.49	4.66e-21	Cognitive test performance;
CRC	cis	rs938554	0.868	rs734553	chr4:9923004	G/T	cg11266682	chr4:10021025	SLC2A9	0.36	5.79	0.3	1.65e-8	Blood metabolite levels;
CRC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg22676075	chr6:135203613	NA	0.46	7.15	0.37	5.55e-12	Red blood cell count;
CRC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg13722127	chr7:150037890	RARRES2	0.53	7.96	0.4	2.83e-14	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22251877	chr8:125551349	TATDN1;NDUFB9	0.37	6.0	0.31	5.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.66	8.62	0.43	2.81e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.66	-0.39	2.13e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.65	0.63	8.94e-38	Breast cancer;
CRC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg16141378	chr3:129829833	LOC729375	0.41	6.04	0.32	4.19e-9	Neuroticism;
CRC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	0.81	8.2	0.41	5.4e-15	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02735133	chr16:23652915	PALB2;DCTN5	0.47	6.57	0.34	2.01e-10	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.58	0.43	3.88e-16	Lymphocyte counts;
CRC	cis	rs972578	0.868	rs2273143	chr22:43280650	T/C	cg01576275	chr22:43409880	NA	-0.41	-6.44	-0.33	4.16e-10	Mean platelet volume;
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg04727332	chr7:45960243	IGFBP3	0.35	5.67	0.3	3.09e-8	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00454517	chr12:122607850	MLXIP	0.43	6.51	0.34	2.75e-10	Response to antipsychotic treatment;
CRC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.56	-0.34	2.14e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.59	6.1	0.32	2.92e-9	Fat distribution (HIV);
CRC	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg04990556	chr1:26633338	UBXN11	0.55	5.86	0.31	1.15e-8	Obesity-related traits;
CRC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.78	8.68	0.43	1.91e-16	Systolic blood pressure;
CRC	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.9	-11.45	-0.53	8.8e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg23298862	chr7:158159286	PTPRN2	0.39	6.16	0.32	2.1e-9	Calcium levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02976543	chr2:239197607	PER2	0.52	6.55	0.34	2.2e-10	Thyroid stimulating hormone;
CRC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg14711859	chr11:8959438	ASCL3	0.38	6.43	0.33	4.38e-10	Hemoglobin concentration;
CRC	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.58	8.56	0.43	4.48e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg16141378	chr3:129829833	LOC729375	0.56	8.17	0.41	6.69e-15	Mood instability;
CRC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.65	7.42	0.38	1.03e-12	Body mass index;
CRC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.02	-0.45	1.64e-17	Chronic sinus infection;
CRC	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.46	8.83	0.44	6.25e-17	Educational attainment (years of education);
CRC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.78	12.81	0.58	9.18e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.64	-7.9	-0.4	4.22e-14	Vitamin D levels;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.67	-8.63	-0.43	2.76e-16	Mean platelet volume;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.73	11.87	0.55	2.62e-27	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4728302	0.869	rs13231079	chr7:133604373	C/G	cg10665199	chr7:133106180	EXOC4	0.38	5.66	0.3	3.32e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26240231	chr7:1148101	C7orf50	-0.41	-5.96	-0.31	6.66e-9	Bronchopulmonary dysplasia;
CRC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	trans	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.51	-6.03	-0.32	4.29e-9	Obesity-related traits;
CRC	cis	rs4908768	0.501	rs11121194	chr1:8569906	C/T	cg20416874	chr1:8611966	RERE	-0.45	-6.45	-0.33	4.03e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg09473613	chr1:24152604	HMGCL	0.35	5.75	0.3	1.99e-8	Immature fraction of reticulocytes;
CRC	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.67	-7.81	-0.4	7.86e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg08461752	chr10:43522343	NA	0.69	6.75	0.35	6.89e-11	Blood protein levels;
CRC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.62	0.47	1.77e-19	Ileal carcinoids;
CRC	cis	rs9584850	0.574	rs17471079	chr13:99168721	C/T	cg07423050	chr13:99094983	FARP1	0.48	5.78	0.3	1.73e-8	Neuroticism;
CRC	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.53	-9.5	-0.46	4.4e-19	Common traits (Other);
CRC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg14541582	chr5:601475	NA	-0.33	-6.6	-0.34	1.61e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg20203395	chr5:56204925	C5orf35	-0.71	-8.49	-0.42	6.99e-16	Initial pursuit acceleration;
CRC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg19622623	chr12:86230825	RASSF9	0.41	6.76	0.35	6.18e-11	Major depressive disorder;
CRC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.83	0.31	1.32e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.83	-9.96	-0.48	1.34e-20	Bronchopulmonary dysplasia;
CRC	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg09127314	chr1:152161683	NA	0.52	6.8	0.35	5.05e-11	Atopic dermatitis;
CRC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg24562669	chr7:97807699	LMTK2	0.43	7.2	0.37	4.11e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg21466736	chr12:48725269	NA	0.46	7.35	0.38	1.62e-12	Plateletcrit;
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.28	-0.56	8.67e-29	Alzheimer's disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg15798279	chr7:6523691	KDELR2	-0.42	-6.3	-0.33	9.78e-10	Daytime sleep phenotypes;
CRC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	7.44	0.38	8.68e-13	Height;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.04	-0.41	1.62e-14	Blood metabolite levels;
CRC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg19318889	chr4:1322082	MAEA	0.45	6.73	0.35	7.63e-11	Longevity;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.85	-0.31	1.2e-8	Obesity-related traits;
CRC	cis	rs10486722	0.603	rs10486721	chr7:41784860	G/A	cg22138096	chr7:41772439	LOC285954	0.37	5.63	0.3	3.87e-8	Pit-and-Fissure caries;
CRC	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg13385794	chr1:248469461	NA	0.39	6.98	0.36	1.62e-11	Common traits (Other);
CRC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg19812747	chr11:111475976	SIK2	0.52	8.16	0.41	7.39e-15	Primary sclerosing cholangitis;
CRC	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.87	-18.15	-0.71	1.72e-51	Ulcerative colitis;
CRC	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.4	-5.96	-0.31	6.52e-9	Red blood cell count;
CRC	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.9	-0.36	2.74e-11	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21046078	chr11:28129852	METT5D1;KIF18A	0.42	6.02	0.31	4.64e-9	Response to antipsychotic treatment;
CRC	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.57	8.75	0.43	1.14e-16	Dementia with Lewy bodies;
CRC	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.53	-7.13	-0.37	6.21e-12	Triglycerides;
CRC	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.83	-13.57	-0.6	1.3e-33	Plateletcrit;Platelet count;
CRC	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	1.05	21.6	0.77	4.95e-65	Multiple myeloma;
CRC	cis	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg02972257	chr16:68554789	NA	0.44	5.65	0.3	3.54e-8	Colorectal cancer;
CRC	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg11915388	chr22:42470451	FAM109B	0.43	6.53	0.34	2.44e-10	Schizophrenia;
CRC	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-6.82	-0.35	4.33e-11	Coronary artery disease;
CRC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg01761236	chr14:102990251	NA	-0.28	-5.69	-0.3	2.8e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.33	0.46	1.59e-18	Tonsillectomy;
CRC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.45	-0.34	4.01e-10	Coronary artery disease;
CRC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	0.66	5.86	0.31	1.1e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg03233332	chr7:66118400	NA	0.46	6.22	0.32	1.51e-9	Aortic root size;
CRC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.42	-6.05	-0.32	3.95e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.81	-0.4	7.64e-14	Cystic fibrosis severity;
CRC	cis	rs16975963	0.644	rs73031321	chr19:38040858	C/T	cg15135657	chr19:38346511	NA	-0.43	-6.04	-0.32	4.15e-9	Longevity;
CRC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs2303319	0.504	rs13417851	chr2:162559919	T/G	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.4	-0.33	5.33e-10	Cognitive function;
CRC	cis	rs6662572	0.774	rs6696284	chr1:46571684	C/A	cg08644498	chr1:46502608	NA	0.43	7.07	0.36	9.5e-12	Blood protein levels;
CRC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22659014	chr13:30169727	SLC7A1	0.42	6.09	0.32	3.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg27635394	chr6:26043820	HIST1H2BB	0.4	5.88	0.31	1.03e-8	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14744768	chr7:116312291	MET	0.46	6.48	0.34	3.31e-10	Anxiety disorder;
CRC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.89e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg25164649	chr6:28176230	NA	0.62	8.85	0.44	5.46e-17	Cardiac Troponin-T levels;
CRC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.85	0.66	1.99e-42	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04116494	chr14:76618702	C14orf118	0.47	6.66	0.34	1.17e-10	Response to antipsychotic treatment;
CRC	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg26353448	chr1:248524236	OR2T4	-0.32	-6.17	-0.32	2.02e-9	Common traits (Other);
CRC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	trans	rs2055729	0.645	rs12543996	chr8:9742666	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.01	-0.31	4.83e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.16	-16.06	-0.66	3.02e-43	Vitiligo;
CRC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.79	12.29	0.56	7.87e-29	Breast cancer;
CRC	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg15309053	chr8:964076	NA	-0.34	-5.79	-0.3	1.64e-8	Schizophrenia;
CRC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg03623178	chr6:28175578	NA	0.78	6.65	0.34	1.22e-10	Depression;
CRC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-17.49	-0.69	6.64e-49	Coronary artery disease;
CRC	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.0	0.36	1.45e-11	Prostate cancer;
CRC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg02766259	chr12:125626809	AACS	0.46	7.81	0.4	7.66e-14	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg11326919	chr17:43324904	LOC100133991	-0.67	-5.98	-0.31	5.88e-9	Cognitive function;
CRC	cis	rs4664293	0.625	rs7564585	chr2:160632093	G/A	cg08347373	chr2:160653686	CD302	0.43	7.42	0.38	1.03e-12	Monocyte percentage of white cells;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg00769240	chr8:12517080	NA	-0.74	-10.23	-0.49	1.64e-21	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs56274002	chr2:162536715	A/T	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.06	-0.36	9.83e-12	Total cholesterol levels;
CRC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.79	15.19	0.64	7.37e-40	Prudent dietary pattern;
CRC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg05925327	chr15:68127851	NA	-0.3	-5.87	-0.31	1.04e-8	Restless legs syndrome;
CRC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg11189052	chr15:85197271	WDR73	0.61	9.04	0.45	1.35e-17	Schizophrenia;
CRC	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.59	0.34	1.73e-10	Subjective well-being;
CRC	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg01420254	chr6:26195488	NA	-0.67	-5.82	-0.31	1.41e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.83	-11.17	-0.52	9e-25	IgG glycosylation;
CRC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.66	8.06	0.41	1.4e-14	Arsenic metabolism;
CRC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.19	-15.94	-0.66	8.54e-43	Breast cancer;
CRC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.96	-0.31	6.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.48	-9.02	-0.45	1.6e-17	Hepatitis;
CRC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.43	5.91	0.31	8.43e-9	Schizophrenia;
CRC	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg20936604	chr3:58311152	NA	-0.76	-7.98	-0.4	2.4e-14	Cholesterol, total;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.79e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.54	-8.08	-0.41	1.22e-14	Bone mineral density;
CRC	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg11887960	chr12:57824829	NA	0.64	7.18	0.37	4.66e-12	Obesity-related traits;
CRC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.68	-10.94	-0.52	5.85e-24	Sudden cardiac arrest;
CRC	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg13385794	chr1:248469461	NA	0.41	7.46	0.38	7.75e-13	Common traits (Other);
CRC	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.59	8.01	0.4	2e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-11.46	-0.53	8.45e-26	Blood trace element (Zn levels);
CRC	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg19773385	chr1:10388646	KIF1B	-0.56	-7.55	-0.38	4.46e-13	Hepatocellular carcinoma;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	1.05	20.17	0.74	1.78e-59	Menarche (age at onset);
CRC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.54	8.41	0.42	1.25e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.25	0.33	1.24e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11792075	chr6:53412972	NA	0.45	6.4	0.33	5.26e-10	Anxiety disorder;
CRC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.46	-7.07	-0.36	9.56e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.93	14.1	0.61	1.23e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg13615338	chr4:55094005	PDGFRA	0.42	6.19	0.32	1.79e-9	Corneal astigmatism;
CRC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg13073564	chr4:8508604	NA	0.44	6.76	0.35	6.29e-11	Response to antineoplastic agents;
CRC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.17	0.52	8.58e-25	Tonsillectomy;
CRC	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.49	-0.38	6.5e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs62458065	0.850	rs62458100	chr7:32473142	C/G	cg20159608	chr7:32802032	NA	-0.55	-6.56	-0.34	2.09e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.37	-5.94	-0.31	7.35e-9	Sitting height ratio;
CRC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	7.43	0.38	9.46e-13	Obesity-related traits;
CRC	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg21174375	chr14:64681225	SYNE2	-0.39	-6.5	-0.34	2.96e-10	Atrial fibrillation;
CRC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg18827107	chr12:86230957	RASSF9	-0.4	-5.92	-0.31	8.1e-9	Major depressive disorder;
CRC	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg09184832	chr6:79620586	NA	-0.45	-7.71	-0.39	1.52e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.44	7.01	0.36	1.39e-11	Sitting height ratio;
CRC	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.48	6.28	0.33	1.05e-9	Exhaled nitric oxide output;
CRC	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg15511327	chr8:143859410	LYNX1	-0.38	-6.08	-0.32	3.34e-9	Urinary tract infection frequency;
CRC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.23	0.45	3.31e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg13390004	chr1:15929781	NA	0.48	6.93	0.36	2.29e-11	Systolic blood pressure;
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg01475377	chr6:109611718	NA	-0.35	-6.07	-0.32	3.56e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20024234	chr21:43431083	ZNF295	0.38	6.2	0.32	1.66e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02290350	chr8:58132656	NA	-0.43	-6.11	-0.32	2.78e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.94	11.82	0.55	4.02e-27	Exhaled nitric oxide levels;
CRC	cis	rs12476592	0.602	rs187801	chr2:63867446	A/C	cg10828910	chr2:63850056	LOC388955	-0.49	-6.1	-0.32	2.9e-9	Childhood ear infection;
CRC	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.74	-10.29	-0.49	1.05e-21	Coronary artery disease;
CRC	cis	rs9463078	0.526	rs1159131	chr6:44972209	T/C	cg25276700	chr6:44698697	NA	0.25	6.23	0.33	1.39e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.66	9.92	0.48	1.79e-20	Selective IgA deficiency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04232466	chr8:21988724	HR	0.53	7.79	0.39	8.68e-14	Response to antipsychotic treatment;
CRC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.43	5.78	0.3	1.76e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.13	0.32	2.57e-9	Tonsillectomy;
CRC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.38	6.09	0.32	3.11e-9	Major depressive disorder;
CRC	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	0.96	18.28	0.71	5.22e-52	Eosinophil percentage of white cells;
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg17346650	chr17:80929145	B3GNTL1	0.49	7.16	0.37	5.18e-12	Glycated hemoglobin levels;
CRC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.63	12.91	0.58	4.04e-31	Schizophrenia;
CRC	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.79	-14.6	-0.63	1.43e-37	Hip circumference;
CRC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.75	10.92	0.52	6.81e-24	Schizophrenia;
CRC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.48	7.36	0.38	1.51e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg03938978	chr2:103052716	IL18RAP	0.46	7.22	0.37	3.7e-12	Blood protein levels;
CRC	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.52	6.42	0.33	4.67e-10	Neuroticism;
CRC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.1	-12.34	-0.56	5.31e-29	Diabetic kidney disease;
CRC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-7.85	-0.4	6.12e-14	Vitiligo;
CRC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-9.04	-0.45	1.41e-17	Morning vs. evening chronotype;
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg17676237	chr17:17400340	RASD1	0.38	6.03	0.32	4.43e-9	Interleukin-6 levels;
CRC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.6	-7.08	-0.36	8.94e-12	Blood protein levels;
CRC	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg24253500	chr15:84953950	NA	0.39	5.74	0.3	2.15e-8	Schizophrenia;
CRC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.81	0.35	4.7e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg19773385	chr1:10388646	KIF1B	-0.56	-7.86	-0.4	5.59e-14	Hepatocellular carcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.46	5.96	0.31	6.41e-9	Thyroid stimulating hormone;
CRC	cis	rs10128264	0.841	rs2790766	chr10:80960616	A/G	cg18737081	chr10:80999807	ZMIZ1	0.34	6.41	0.33	5.03e-10	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs55788414	0.932	rs2317123	chr16:81182636	A/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.85	-0.35	3.54e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.09	10.57	0.5	1.14e-22	Diabetic retinopathy;
CRC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.31	-0.33	9.16e-10	Aortic root size;
CRC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.93	-0.36	2.27e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.68	9.06	0.45	1.23e-17	Uric acid levels;
CRC	cis	rs243505	0.965	rs243503	chr7:148436106	G/C	cg09806900	chr7:148480153	CUL1	-0.46	-6.57	-0.34	2.02e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.1	10.34	0.5	6.73e-22	Prostate cancer;
CRC	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.58	-5.85	-0.31	1.18e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.74	7.11	0.36	7.28e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg25164649	chr6:28176230	NA	0.59	8.32	0.42	2.36e-15	Parkinson's disease;
CRC	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.53	8.77	0.44	9.65e-17	Menarche (age at onset);
CRC	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.44	-8.74	-0.43	1.23e-16	Migraine;
CRC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.93	-0.66	9.48e-43	Height;
CRC	cis	rs860295	0.702	rs12039893	chr1:155614815	A/C	cg02153340	chr1:155202674	NA	-0.56	-6.7	-0.35	9.09e-11	Body mass index;
CRC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.4	-5.98	-0.31	5.7e-9	Crohn's disease;
CRC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.23	-0.32	1.43e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.54	-0.34	2.4e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs185694	0.948	rs200512	chr13:30906446	C/T	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.32	-0.33	8.4e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.67	9.32	0.46	1.77e-18	Alzheimer's disease;
CRC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg23461800	chr14:103021989	NA	-0.76	-10.32	-0.49	8.41e-22	Platelet count;
CRC	cis	rs8105895	0.935	rs9653157	chr19:22249490	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	10.13	0.49	3.46e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.64	10.34	0.5	7.01e-22	Corneal astigmatism;
CRC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.63	10.43	0.5	3.49e-22	Calcium levels;
CRC	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs2882667	0.690	rs10071381	chr5:138272848	C/T	cg09476006	chr5:138032270	NA	0.58	9.96	0.48	1.3e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.32	-0.33	8.55e-10	Breast cancer;
CRC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.34	-0.5	7.19e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.52	10.77	0.51	2.35e-23	Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06805064	chr13:52263093	WDFY2	0.46	7.03	0.36	1.17e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.19	-13.16	-0.59	4.5e-32	Diabetic kidney disease;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg08132940	chr7:1081526	C7orf50	-0.53	-5.61	-0.3	4.27e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg15147215	chr3:52552868	STAB1	0.46	7.78	0.39	9.36e-14	Body mass index;
CRC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.92e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.73	12.22	0.56	1.38e-28	Blood protein levels;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.59	-8.3	-0.42	2.71e-15	Menopause (age at onset);
CRC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.36	0.33	6.91e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs807029	0.577	rs750866	chr10:102761458	A/G	cg04662943	chr10:102668895	NA	0.61	7.09	0.36	8.22e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg16576597	chr16:28551801	NUPR1	0.48	6.79	0.35	5.22e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.18	-0.37	4.67e-12	Type 2 diabetes;
CRC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.42	6.69	0.35	9.6e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.71	-7.04	-0.36	1.11e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.76	-12.36	-0.56	4.3e-29	Myeloid white cell count;
CRC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.42	6.15	0.32	2.27e-9	Bone properties (heel);
CRC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.37	0.53	1.67e-25	Asthma (sex interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09662431	chr10:73975914	ASCC1;C10orf104	0.45	6.5	0.34	2.92e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg23202291	chr11:1979235	NA	-0.57	-8.0	-0.4	2.13e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg13390004	chr1:15929781	NA	0.5	6.88	0.35	3.01e-11	Systolic blood pressure;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg07404485	chr7:94953653	PON1	-0.45	-6.02	-0.32	4.58e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.16	0.45	5.58e-18	Parkinson's disease;
CRC	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.03	-0.36	1.17e-11	Putamen volume;
CRC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.73	-8.26	-0.41	3.5e-15	Obesity-related traits;
CRC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.6	0.47	2.14e-19	Cognitive test performance;
CRC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg19041857	chr6:27730383	NA	-0.42	-5.94	-0.31	7.29e-9	Parkinson's disease;
CRC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.9	0.36	2.71e-11	Morning vs. evening chronotype;
CRC	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06368369	chr3:148709353	GYG1	0.41	6.25	0.33	1.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.27	-0.33	1.16e-9	Aortic root size;
CRC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.62	-0.39	2.67e-13	Blood metabolite levels;
CRC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg17467752	chr17:38218738	THRA	-0.42	-6.44	-0.33	4.31e-10	Self-reported allergy;
CRC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.29	0.37	2.32e-12	Parkinson's disease;
CRC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-9.34	-0.46	1.5e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.43	-5.8	-0.3	1.52e-8	Tonsillectomy;
CRC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg25985355	chr7:65971099	NA	-0.49	-5.73	-0.3	2.27e-8	Diabetic kidney disease;
CRC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.67	-7.07	-0.36	9.11e-12	Initial pursuit acceleration;
CRC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.63	9.58	0.47	2.44e-19	Crohn's disease;
CRC	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.46	7.76	0.39	1.08e-13	Testicular germ cell tumor;
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.47	7.07	0.36	9.44e-12	Menarche (age at onset);
CRC	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.57	-6.87	-0.35	3.16e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.56	6.61	0.34	1.55e-10	Carotid intima media thickness;
CRC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg21770322	chr7:97807741	LMTK2	-0.69	-12.68	-0.57	2.97e-30	Breast cancer;
CRC	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.68	-11.03	-0.52	2.85e-24	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.71	-10.89	-0.51	8.38e-24	Pancreatic cancer;
CRC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.51	8.35	0.42	1.98e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.95e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.16	-0.56	2.37e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.64	10.73	0.51	3.18e-23	P wave terminal force;
CRC	cis	rs9906695	0.846	rs3091317	chr17:32594257	T/C	cg12698626	chr17:32581466	CCL2	0.44	6.0	0.31	5.19e-9	Monocyte percentage of white cells;
CRC	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg10517650	chr3:113235015	CCDC52	-0.41	-7.07	-0.36	9.15e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03670158	chr17:41323431	NBR1	0.46	6.47	0.34	3.47e-10	Response to antipsychotic treatment;
CRC	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22590775	chr19:49891494	CCDC155	0.64	6.38	0.33	5.87e-10	Multiple sclerosis;
CRC	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.55	-0.34	2.24e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15369054	chr17:80825471	TBCD	-0.39	-6.22	-0.32	1.53e-9	Breast cancer;
CRC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.81	12.74	0.57	1.68e-30	Height;
CRC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.53	-0.38	4.9e-13	Psoriasis;
CRC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg13777783	chr17:79615861	NA	-0.3	-5.67	-0.3	3.13e-8	Eye color traits;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23161317	chr6:28129485	ZNF389	0.46	6.02	0.31	4.79e-9	Depression;
CRC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	11.98	0.55	1.06e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg05132306	chr1:1846340	CALML6	-0.48	-7.32	-0.37	1.9e-12	Body mass index;
CRC	cis	rs16975963	0.843	rs73029180	chr19:38420406	C/T	cg15135657	chr19:38346511	NA	-0.44	-5.92	-0.31	7.99e-9	Longevity;
CRC	cis	rs2742417	0.935	rs2248991	chr3:45754749	G/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.64e-17	Prostate cancer;
CRC	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.05	22.28	0.78	1.13e-67	Multiple myeloma;
CRC	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.53	6.22	0.32	1.52e-9	QRS duration;
CRC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg25459000	chr22:39777742	SYNGR1	-0.32	-5.63	-0.3	3.83e-8	Intelligence (multi-trait analysis);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23486179	chr3:49466665	NICN1	0.41	6.44	0.33	4.23e-10	Interleukin-6 levels;
CRC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.57	9.96	0.48	1.3e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg25767906	chr1:53392781	SCP2	0.4	6.53	0.34	2.53e-10	Monocyte count;
CRC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.13	-20.52	-0.75	7.65e-61	Ulcerative colitis;
CRC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.97	-18.65	-0.72	1.84e-53	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs728616	0.867	rs61859008	chr10:81831711	C/G	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.42	-0.33	4.66e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg07507251	chr3:52567010	NT5DC2	0.43	6.02	0.31	4.74e-9	Bipolar disorder;
CRC	cis	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg18131467	chr2:239335373	ASB1	-0.72	-6.24	-0.33	1.32e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	1.03	18.15	0.71	1.69e-51	Parkinson's disease;
CRC	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	0.57	8.89	0.44	4.08e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.11	-0.37	7.11e-12	HDL cholesterol;
CRC	cis	rs7091068	0.566	rs7082701	chr10:95501042	G/T	cg20715218	chr10:95462985	C10orf4	0.54	5.71	0.3	2.46e-8	Urinary tract infection frequency;
CRC	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg13385794	chr1:248469461	NA	0.39	6.88	0.35	3.03e-11	Common traits (Other);
CRC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.53	5.89	0.31	9.41e-9	Vitiligo;
CRC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg15848620	chr12:58087721	OS9	-0.64	-8.98	-0.44	2.1e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg06238570	chr21:40685208	BRWD1	0.74	10.4	0.5	4.41e-22	Cognitive function;
CRC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.01	0.31	4.79e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02725872	chr8:58115012	NA	-0.39	-6.63	-0.34	1.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.07	-0.32	3.52e-9	Triglycerides;
CRC	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.12	9.47	0.46	5.76e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.83	-0.35	4.22e-11	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg25456477	chr12:86230367	RASSF9	0.42	7.03	0.36	1.22e-11	Major depressive disorder;
CRC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.93	16.72	0.68	7.27e-46	Cognitive function;
CRC	cis	rs425535	0.757	rs164616	chr4:74798566	A/G	cg01447579	chr4:74847100	PF4	0.62	5.69	0.3	2.82e-8	Blood protein levels;
CRC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.99	-0.31	5.61e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-7.81	-0.4	7.72e-14	IgG glycosylation;
CRC	cis	rs7259376	0.936	rs2195965	chr19:22538111	C/T	cg02657401	chr19:22469223	NA	-0.34	-7.62	-0.39	2.73e-13	Menopause (age at onset);
CRC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.48	-8.66	-0.43	2.22e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.72	8.96	0.44	2.41e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs7209700	0.662	rs8080254	chr17:45347892	C/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.88	-0.31	1.01e-8	IgG glycosylation;
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg02033258	chr5:131593261	PDLIM4	0.38	7.65	0.39	2.23e-13	Blood metabolite levels;
CRC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg04545296	chr12:48745243	ZNF641	0.36	6.22	0.32	1.52e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7916697	0.593	rs7912895	chr10:70021498	A/G	cg06988349	chr10:69991859	ATOH7	0.39	7.27	0.37	2.69e-12	Optic disc area;
CRC	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	9.14	0.45	6.36e-18	Ileal carcinoids;
CRC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	9.84	0.48	3.41e-20	Cognitive test performance;
CRC	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-6.0	-0.31	5.34e-9	Axial length;
CRC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13198984	chr17:80129470	CCDC57	0.48	8.36	0.42	1.84e-15	Life satisfaction;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg04553112	chr3:125709451	NA	-0.5	-5.7	-0.3	2.61e-8	Blood pressure (smoking interaction);
CRC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg06766960	chr11:133703094	NA	-0.36	-6.5	-0.34	3.03e-10	Childhood ear infection;
CRC	cis	rs4478137	0.931	rs7665672	chr4:164236875	G/A	cg06758707	chr4:164254230	NPY1R	0.39	6.01	0.31	4.9e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg15845792	chr6:28175446	NA	0.66	7.8	0.4	8.13e-14	Parkinson's disease;
CRC	cis	rs7605827	0.930	rs7568459	chr2:15691026	C/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.15	-0.32	2.29e-9	Mean platelet volume;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.15	-0.32	2.23e-9	Bipolar disorder;
CRC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.42	6.65	0.34	1.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.48	-7.03	-0.36	1.23e-11	Monocyte count;
CRC	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.06	9.16	0.45	5.53e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-10.82	-0.51	1.47e-23	Platelet distribution width;
CRC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04731861	chr2:219085781	ARPC2	-0.36	-7.9	-0.4	4.22e-14	Colorectal cancer;
CRC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	9.04	0.45	1.4e-17	Lymphocyte counts;
CRC	trans	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg13565492	chr6:43139072	SRF	-0.62	-6.47	-0.34	3.46e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg23815491	chr16:72088622	HP	0.51	6.3	0.33	9.58e-10	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24836583	chr19:19051747	HOMER3	0.43	6.89	0.36	2.84e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.61	9.09	0.45	9.44e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg18551225	chr6:44695536	NA	-0.41	-5.9	-0.31	8.9e-9	Total body bone mineral density;
CRC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.39	6.42	0.33	4.88e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.71	0.65	6.73e-42	Chronic sinus infection;
CRC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.64	-0.34	1.27e-10	Renal cell carcinoma;
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg08798685	chr6:27730294	NA	0.38	5.66	0.3	3.24e-8	Systemic lupus erythematosus;
CRC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg17321639	chr7:2759063	NA	-0.53	-7.15	-0.37	5.82e-12	Height;
CRC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.51	7.15	0.37	5.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg22777020	chr22:31556080	RNF185	-0.53	-6.04	-0.32	4.08e-9	Colorectal cancer;
CRC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.73	0.43	1.34e-16	Rheumatoid arthritis;
CRC	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.41	6.0	0.31	5.35e-9	Osteoporosis;
CRC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.41	5.72	0.3	2.39e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg20302342	chr1:156215951	PAQR6	0.35	6.92	0.36	2.37e-11	Tonsillectomy;
CRC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.54	8.7	0.43	1.57e-16	Height;
CRC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	0.84	8.8	0.44	7.89e-17	Skin colour saturation;
CRC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg02993699	chr4:3415135	RGS12	-0.4	-6.53	-0.34	2.55e-10	Serum sulfate level;
CRC	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.46	0.42	9.02e-16	Arsenic metabolism;
CRC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.53e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg00225070	chr15:80189496	MTHFS	-0.42	-6.48	-0.34	3.43e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg08460590	chr17:7495881	FXR2	-0.43	-6.02	-0.31	4.55e-9	Lung cancer;
CRC	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.78	0.66	3.75e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.15	-0.74	2.29e-59	Primary sclerosing cholangitis;
CRC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.65e-9	Aortic root size;
CRC	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.74	10.31	0.49	8.54e-22	Systemic lupus erythematosus;
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.63	-0.57	4.42e-30	Bipolar disorder and schizophrenia;
CRC	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg27395922	chr11:50257633	LOC441601	0.49	6.21	0.32	1.6e-9	Intraocular pressure;
CRC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.73	10.28	0.49	1.13e-21	Blood metabolite levels;
CRC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-7.54	-0.38	4.47e-13	Aortic root size;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg17321639	chr7:2759063	NA	-0.56	-7.76	-0.39	1.06e-13	Height;
CRC	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.76	8.5	0.42	6.78e-16	Neuroticism;
CRC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.54	-0.43	5.23e-16	Uric acid levels;
CRC	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.44	6.95	0.36	2e-11	Schizophrenia;
CRC	cis	rs780094	0.500	rs7570476	chr2:27784658	C/T	cg27432699	chr2:27873401	GPN1	0.45	5.87	0.31	1.07e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.96	16.52	0.67	4.66e-45	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg24505167	chr7:1915268	MAD1L1	-0.45	-6.35	-0.33	6.97e-10	Bipolar disorder;
CRC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.46	7.83e-19	Bladder cancer;
CRC	cis	rs6961069	0.722	rs4626520	chr7:80260023	G/A	cg04458919	chr7:80252533	CD36	0.34	5.89	0.31	9.42e-9	Platelet count;
CRC	cis	rs17767392	0.681	rs61989208	chr14:71691037	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.5	-0.34	2.98e-10	Mitral valve prolapse;
CRC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.55	8.54	0.43	5.2e-16	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CRC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.1e-16	Alcohol dependence;
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg01339444	chr6:118972232	C6orf204	0.53	6.0	0.31	5.22e-9	Diastolic blood pressure;
CRC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	11.39	0.53	1.45e-25	Total body bone mineral density;
CRC	cis	rs2415984	0.622	rs28487986	chr14:46924435	T/G	cg14871534	chr14:47121158	RPL10L	-0.43	-6.19	-0.32	1.77e-9	Number of children ever born;
CRC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.4	5.93	0.31	7.78e-9	Monocyte count;
CRC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	8.08	0.41	1.25e-14	Iron status biomarkers;
CRC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.85	13.38	0.59	6.93e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.5	8.04	0.41	1.68e-14	Height;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.51	-7.89	-0.4	4.59e-14	Electroencephalogram traits;
CRC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-8.65	-0.43	2.37e-16	Chronic sinus infection;
CRC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.46	7.56	0.38	4.03e-13	Pulse pressure;
CRC	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg18721089	chr20:30220636	NA	-0.36	-5.82	-0.31	1.39e-8	Mean corpuscular hemoglobin;
CRC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg08071915	chr8:12219732	FAM66A	-0.36	-6.32	-0.33	8.73e-10	Triglycerides;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg08798685	chr6:27730294	NA	-0.48	-6.78	-0.35	5.61e-11	Parkinson's disease;
CRC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg21972741	chr5:435613	AHRR	0.47	6.46	0.34	3.73e-10	Cystic fibrosis severity;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.46	-0.34	3.86e-10	Parkinson's disease;
CRC	trans	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg06875740	chr19:51307921	C19orf48	-0.66	-6.0	-0.31	5.19e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg27532560	chr4:187881888	NA	-0.56	-10.23	-0.49	1.63e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6604026	0.922	rs58270016	chr1:93295723	T/C	cg17283838	chr1:93427260	FAM69A	0.45	5.68	0.3	2.92e-8	Multiple sclerosis;
CRC	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.66	10.6	0.5	8.61e-23	Corneal astigmatism;
CRC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-12.8	-0.58	1.04e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg22482690	chr17:47019901	SNF8	-0.52	-8.2	-0.41	5.41e-15	Type 2 diabetes;
CRC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.52	-8.3	-0.42	2.79e-15	Huntington's disease progression;
CRC	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg14191688	chr11:70257035	CTTN	0.52	7.15	0.37	5.49e-12	Coronary artery disease;
CRC	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-5.99	-0.31	5.6e-9	Metabolite levels;
CRC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg10820045	chr2:198174542	NA	-0.55	-10.34	-0.5	6.7e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg17724175	chr1:150552817	MCL1	-0.51	-8.18	-0.41	6.1e-15	Tonsillectomy;
CRC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.65	-11.38	-0.53	1.6e-25	Prostate cancer;
CRC	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg21155852	chr7:2048760	MAD1L1	-0.4	-5.62	-0.3	4.03e-8	Bipolar disorder;
CRC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.58	-9.92	-0.48	1.78e-20	Menarche (age at onset);
CRC	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.45	7.99	0.4	2.34e-14	Testicular germ cell tumor;
CRC	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.57	8.54	0.43	5.09e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg01629716	chr15:45996671	NA	-0.42	-8.5	-0.42	6.55e-16	Waist circumference;Weight;
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg07074390	chr21:40555500	PSMG1	-0.44	-5.95	-0.31	7.03e-9	Cognitive function;
CRC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.79	0.39	9.12e-14	Motion sickness;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26243254	chr12:132434651	EP400	0.47	6.7	0.35	8.94e-11	Anxiety disorder;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.4	-5.7	-0.3	2.68e-8	Obesity-related traits;
CRC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.71	-10.53	-0.5	1.58e-22	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08635118	chr7:6144369	USP42	0.4	6.12	0.32	2.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.95	-0.31	6.79e-9	Longevity;Endometriosis;
CRC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.62	7.6	0.39	3.2e-13	Menarche (age at onset);
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg04796162	chr7:45961102	IGFBP3	0.4	6.82	0.35	4.5e-11	Sitting height ratio;
CRC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg09876464	chr15:85330779	ZNF592	0.37	6.08	0.32	3.33e-9	P wave terminal force;
CRC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg06238570	chr21:40685208	BRWD1	0.78	10.73	0.51	3.05e-23	Cognitive function;
CRC	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.53	7.32	0.37	1.97e-12	Mammographic density (dense area);
CRC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.97	12.55	0.57	8.7e-30	Triglycerides;
CRC	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg14345882	chr6:26364793	BTN3A2	0.43	6.65	0.34	1.19e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01685739	chr7:150756773	SLC4A2	0.38	6.25	0.33	1.24e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.65	-0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.09	0.36	8.44e-12	Hemoglobin concentration;
CRC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.6	-9.24	-0.45	3.1e-18	Aortic root size;
CRC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.39	-0.42	1.48e-15	Schizophrenia;
CRC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.63	8.93	0.44	3.11e-17	Arsenic metabolism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00748821	chr4:83932227	LIN54	-0.51	-6.22	-0.32	1.54e-9	Diisocyanate-induced asthma;
CRC	cis	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg15845792	chr6:28175446	NA	-0.79	-5.63	-0.3	3.81e-8	Depression;
CRC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.48	7.32	0.37	1.89e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg19041857	chr6:27730383	NA	-0.72	-6.75	-0.35	6.7e-11	Breast cancer;
CRC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg26248373	chr2:1572462	NA	-0.66	-7.2	-0.37	4.09e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	8.75	0.43	1.11e-16	Total cholesterol levels;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg15786705	chr6:28176104	NA	0.73	9.31	0.46	1.85e-18	Depression;
CRC	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.46	6.86	0.35	3.49e-11	Crohn's disease;
CRC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.91	-0.36	2.53e-11	Bipolar disorder;
CRC	cis	rs972578	0.967	rs4822238	chr22:43364795	G/C	cg01576275	chr22:43409880	NA	-0.45	-7.21	-0.37	3.88e-12	Mean platelet volume;
CRC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18252515	chr7:66147081	NA	0.39	5.6	0.3	4.46e-8	Aortic root size;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.88	-0.51	9.7e-24	Bipolar disorder;
CRC	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.72	-13.07	-0.58	1.01e-31	Leprosy;
CRC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.8	-9.77	-0.47	5.96e-20	Initial pursuit acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17979863	chr2:231852034	NA	0.51	7.33	0.37	1.76e-12	Response to antipsychotic treatment;
CRC	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg13736514	chr6:26305472	NA	-0.45	-7.34	-0.38	1.67e-12	Educational attainment;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg06470822	chr6:28175283	NA	1.03	13.51	0.6	2.11e-33	Depression;
CRC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.34	-6.32	-0.33	8.52e-10	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.35	1.11e-10	Axial length;
CRC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.86	-14.51	-0.62	3.15e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg22777020	chr22:31556080	RNF185	0.53	6.28	0.33	1.09e-9	Colorectal cancer;
CRC	trans	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.68	8.55	0.43	4.63e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-10.86	-0.51	1.1e-23	Hepatocellular carcinoma;
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.49	-7.42	-0.38	9.8e-13	Tonsillectomy;
CRC	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.98	-6.94	-0.36	2.1e-11	Intelligence (multi-trait analysis);
CRC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg27661571	chr11:113659931	NA	-0.55	-6.77	-0.35	5.81e-11	Hip circumference adjusted for BMI;
CRC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.6	10.2	0.49	2.03e-21	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	5.85	0.31	1.2e-8	Prudent dietary pattern;
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.62	-9.59	-0.47	2.36e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10971721	0.822	rs56370320	chr9:33865628	T/C	cg13495928	chr9:33750294	PRSS3	0.55	5.94	0.31	7.19e-9	Body mass index;
CRC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.5	0.67	5.24e-45	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2051211	0.895	rs2300670	chr3:38555815	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.68	-0.3	3e-8	QRS duration;
CRC	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.17	15.01	0.64	3.69e-39	Uric acid levels;
CRC	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg01339444	chr6:118972232	C6orf204	0.53	5.94	0.31	7.25e-9	Diastolic blood pressure;
CRC	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.4	6.65	0.34	1.25e-10	Testicular germ cell tumor;
CRC	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.48	-6.94	-0.36	2.03e-11	Pulmonary function decline;
CRC	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	13.05	0.58	1.15e-31	Hip circumference;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg07395648	chr5:131743802	NA	0.41	5.69	0.3	2.87e-8	Breast cancer;
CRC	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-14.85	-0.63	1.57e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs55675132	0.548	rs75587174	chr1:115373507	G/A	cg25493687	chr8:27288214	PTK2B	0.5	6.17	0.32	1.96e-9	Schizophrenia;
CRC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.57	7.17	0.37	5.13e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg00814883	chr7:100076585	TSC22D4	-0.5	-6.04	-0.32	4.14e-9	Lung function (FEV1/FVC);
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg26354017	chr1:205819088	PM20D1	0.43	5.97	0.31	6.11e-9	Parkinson's disease;
CRC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.74	0.39	1.2e-13	Motion sickness;
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.15	0.41	7.88e-15	Menarche (age at onset);
CRC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.47	7.45	0.38	8.45e-13	Eye color traits;
CRC	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.58	8.58	0.43	3.74e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg20119798	chr7:94954144	PON1	-0.49	-6.17	-0.32	2.01e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.67	-9.62	-0.47	1.82e-19	Multiple sclerosis;
CRC	cis	rs7705042	0.570	rs12655443	chr5:141467856	G/T	cg07392085	chr5:141489673	NDFIP1	0.35	5.76	0.3	1.93e-8	Asthma;
CRC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.47	6.68	0.35	1.02e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7635838	0.892	rs7372723	chr3:11466511	G/A	cg00170343	chr3:11313890	ATG7	0.41	6.29	0.33	1.03e-9	HDL cholesterol;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.01	-10.5	-0.5	2e-22	Body mass index;
CRC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.91	0.31	8.4e-9	Personality dimensions;
CRC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.72	11.05	0.52	2.45e-24	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03574882	chr7:151574332	PRKAG2	0.41	6.5	0.34	2.99e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg13256891	chr4:100009986	ADH5	0.48	6.83	0.35	4.12e-11	Alcohol dependence;
CRC	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.59	-7.96	-0.4	2.83e-14	White matter hyperintensity burden;
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17848003	chr1:3704513	LRRC47	0.4	5.84	0.31	1.25e-8	Red cell distribution width;
CRC	cis	rs9583531	0.891	rs9521906	chr13:111358000	T/G	cg24331049	chr13:111365604	ING1	-0.63	-6.69	-0.35	9.49e-11	Coronary artery disease;
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.35	0.5	6.4e-22	Corneal astigmatism;
CRC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.69	13.77	0.6	2.19e-34	Coronary artery disease;
CRC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.23	-0.32	1.42e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-7.95	-0.4	3.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg21798802	chr22:38057573	PDXP	0.36	5.92	0.31	8.06e-9	Fat distribution (HIV);
CRC	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.65	8.4	0.42	1.31e-15	Uric acid levels;
CRC	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg06238570	chr21:40685208	BRWD1	0.75	10.2	0.49	2.1e-21	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14776943	chr17:42201167	HDAC5	0.47	6.6	0.34	1.61e-10	Response to antipsychotic treatment;
CRC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.91	13.97	0.61	3.89e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.46	6.02	0.32	4.54e-9	Exhaled nitric oxide output;
CRC	trans	rs1265507	0.666	rs2076966	chr12:114869775	T/C	cg11700868	chr17:38521232	GJD3	0.42	5.99	0.31	5.5e-9	Percent mammographic density;
CRC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.55	8.0	0.4	2.18e-14	Longevity;
CRC	cis	rs7429990	0.965	rs2166770	chr3:48005673	A/C	cg11946769	chr3:48343235	NME6	0.44	5.73	0.3	2.26e-8	Educational attainment (years of education);
CRC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14895029	chr7:2775587	GNA12	-0.44	-6.45	-0.34	3.92e-10	Height;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg20615401	chr6:28092323	ZSCAN16	0.44	5.77	0.3	1.82e-8	Parkinson's disease;
CRC	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg25809561	chr17:30822961	MYO1D	0.57	10.2	0.49	2.01e-21	Schizophrenia;
CRC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.08	0.32	3.31e-9	Schizophrenia;
CRC	cis	rs9549328	0.611	rs72661939	chr13:113617498	C/T	cg20742385	chr13:113633654	MCF2L	0.56	9.5	0.46	4.54e-19	Systolic blood pressure;
CRC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.49	0.42	7.09e-16	Coffee consumption (cups per day);
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.76	12.88	0.58	5.31e-31	Obesity-related traits;
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.77	-0.39	1.03e-13	Total body bone mineral density;
CRC	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg19338460	chr6:170058176	WDR27	-0.76	-8.3	-0.42	2.78e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-12.7	-0.57	2.45e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9462846	0.881	rs9296402	chr6:42875650	G/A	cg21280719	chr6:42927975	GNMT	-0.35	-6.66	-0.34	1.13e-10	Blood protein levels;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.4	-6.27	-0.33	1.12e-9	Glycated hemoglobin levels;
CRC	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg04990556	chr1:26633338	UBXN11	0.53	5.66	0.3	3.23e-8	Obesity-related traits;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02018176	chr4:1364513	KIAA1530	-0.62	-9.78	-0.47	5.43e-20	Obesity-related traits;
CRC	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.63	10.67	0.51	5.21e-23	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.78	0.44	9.24e-17	Schizophrenia;
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.65	0.54	1.76e-26	Prudent dietary pattern;
CRC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.6	-0.34	1.65e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.66	7.25	0.37	2.95e-12	Axial length;
CRC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.85	-10.9	-0.52	7.81e-24	Gut microbiome composition (summer);
CRC	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.47	6.85	0.35	3.6e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-13.16	-0.59	4.41e-32	Gut microbiome composition (summer);
CRC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs3731896	0.700	rs11903211	chr2:220193434	A/G	cg00436969	chr2:220197716	RESP18	-0.46	-6.09	-0.32	3.14e-9	Educational attainment;
CRC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.9	-0.31	9.11e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.63	-10.04	-0.48	7.52e-21	Aortic root size;
CRC	cis	rs7215564	0.908	rs79961397	chr17:78687146	T/A	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.22e-9	Myopia (pathological);
CRC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.6	11.05	0.52	2.29e-24	Immature fraction of reticulocytes;
CRC	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.56	-0.34	2.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg02811702	chr13:24901961	NA	0.47	6.61	0.34	1.57e-10	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg24046110	chr8:143859143	LYNX1	0.5	8.63	0.43	2.74e-16	Urinary tract infection frequency;
CRC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.45	-7.04	-0.36	1.13e-11	Monocyte count;
CRC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.85	12.55	0.57	8.88e-30	Response to antineoplastic agents;
CRC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.48	6.12	0.32	2.6e-9	Aortic root size;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg19041857	chr6:27730383	NA	-0.44	-5.94	-0.31	7.12e-9	Parkinson's disease;
CRC	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11547950	chr5:77652471	NA	-0.51	-7.61	-0.39	2.87e-13	Triglycerides;
CRC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.82	14.96	0.64	5.57e-39	Anterior chamber depth;
CRC	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.49	7.05	0.36	1.07e-11	Primary sclerosing cholangitis;
CRC	cis	rs1355223	0.902	rs11605785	chr11:34751387	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.75	-0.3	2.01e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg23298862	chr7:158159286	PTPRN2	0.38	5.98	0.31	5.8e-9	Calcium levels;
CRC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg23920097	chr1:209922102	NA	-0.5	-6.26	-0.33	1.17e-9	Red blood cell count;
CRC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.84	-9.6	-0.47	2.18e-19	Iron status biomarkers;
CRC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.81	12.99	0.58	1.95e-31	Cognitive function;
CRC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.66	-8.04	-0.41	1.62e-14	Bronchopulmonary dysplasia;
CRC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-6.0	-0.31	5.14e-9	Gut microbiome composition (summer);
CRC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg15832292	chr6:96025679	MANEA	0.58	6.02	0.32	4.57e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs4692589	0.772	rs34642369	chr4:170973469	G/A	cg19918862	chr4:170955249	NA	0.46	6.99	0.36	1.56e-11	Anxiety disorder;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.95e-9	Depression;
CRC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs867529	0.620	rs335121	chr2:89084327	G/C	cg26627705	chr2:89060884	NA	0.56	7.41	0.38	1.1e-12	Height;
CRC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.78	-13.81	-0.61	1.57e-34	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.39	-5.65	-0.3	3.39e-8	Menarche (age at onset);
CRC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg00343986	chr7:65444356	GUSB	0.44	6.19	0.32	1.77e-9	Aortic root size;
CRC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.54	6.65	0.34	1.2e-10	Blood protein levels;
CRC	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg10820045	chr2:198174542	NA	0.41	7.05	0.36	1.03e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.69	11.61	0.54	2.37e-26	Mean corpuscular volume;
CRC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg09582351	chr12:29534625	ERGIC2	0.34	7.48	0.38	6.8e-13	QT interval;
CRC	cis	rs4664293	0.605	rs12991516	chr2:160442065	A/G	cg08347373	chr2:160653686	CD302	-0.35	-5.85	-0.31	1.17e-8	Monocyte percentage of white cells;
CRC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.39	5.76	0.3	1.93e-8	Schizophrenia;
CRC	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.53	9.53	0.47	3.48e-19	Common traits (Other);
CRC	trans	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg20935933	chr6:143382018	AIG1	0.5	6.54	0.34	2.38e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.59	-0.34	1.79e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs6095360	0.546	rs6012562	chr20:47535261	A/C	cg02963556	chr12:132588637	EP400NL	0.4	6.08	0.32	3.33e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9287719	0.649	rs10208103	chr2:10720867	G/A	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg21548813	chr6:291882	DUSP22	-0.52	-7.34	-0.38	1.68e-12	Menopause (age at onset);
CRC	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-0.85	-12.51	-0.57	1.18e-29	IgG glycosylation;
CRC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.68	-13.3	-0.59	1.32e-32	Educational attainment;
CRC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg13206674	chr6:150067644	NUP43	0.53	7.62	0.39	2.77e-13	Lung cancer;
CRC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.41	5.91	0.31	8.46e-9	Obesity-related traits;
CRC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.45	5.93	0.31	7.47e-9	Gut microbiome composition (summer);
CRC	cis	rs61677309	1.000	rs1599809	chr11:118179200	G/A	cg06090739	chr11:118230722	UBE4A	0.42	5.72	0.3	2.34e-8	Lung cancer in ever smokers;
CRC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.47	7.16	0.37	5.26e-12	Corneal astigmatism;
CRC	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.63	-0.34	1.41e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.78	16.64	0.68	1.61e-45	Breast cancer;
CRC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.5	-6.85	-0.35	3.69e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg21724239	chr8:58056113	NA	0.58	7.75	0.39	1.16e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.25	-0.33	1.3e-9	Coronary artery calcification;
CRC	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.53	-8.79	-0.44	8.32e-17	Congenital heart disease (maternal effect);
CRC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.84	0.44	5.92e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg22495460	chr2:25135724	ADCY3	-0.82	-15.44	-0.65	7.85e-41	Body mass index;
CRC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.6	-6.72	-0.35	8.19e-11	Menarche (age at onset);
CRC	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.54	9.32	0.46	1.76e-18	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.95	-0.44	2.61e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.22e-22	Bipolar disorder;
CRC	cis	rs3825932	0.736	rs1036939	chr15:79237324	C/A	cg25744700	chr15:79237217	CTSH	0.38	5.82	0.31	1.41e-8	Type 1 diabetes;
CRC	trans	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-15.22	-0.64	5.64e-40	Chronic sinus infection;
CRC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg27535305	chr1:53392650	SCP2	0.34	6.3	0.33	9.79e-10	Monocyte count;
CRC	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-7.29	-0.37	2.38e-12	Coronary artery disease;
CRC	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg15123519	chr2:136567270	LCT	0.35	6.87	0.35	3.17e-11	Mosquito bite size;
CRC	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.74	9.2	0.45	4.38e-18	Iron status biomarkers;
CRC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.46	6.68	0.35	1.01e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg10437265	chr15:77819839	NA	0.68	12.05	0.55	5.92e-28	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08720519	chr16:70558200	SF3B3;COG4	0.44	6.01	0.31	4.86e-9	Response to antipsychotic treatment;
CRC	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg10517650	chr3:113235015	CCDC52	-0.37	-6.58	-0.34	1.83e-10	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg09659197	chr4:152720779	NA	0.54	11.65	0.54	1.66e-26	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.98	-19.37	-0.73	2.6e-56	Height;
CRC	cis	rs4936891	0.577	rs4565912	chr11:123904395	A/G	cg22125253	chr11:123886957	OR10G4	-0.33	-5.79	-0.3	1.63e-8	Male fertility;
CRC	cis	rs6088813	1.000	rs6087702	chr20:33995945	T/A	cg14752227	chr20:34000481	UQCC	-0.36	-5.6	-0.3	4.45e-8	Height;
CRC	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.44	-6.38	-0.33	5.98e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.85	-14.78	-0.63	2.8900000000000003e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.35	-0.33	6.97e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	12.06	0.55	5.61e-28	Cognitive ability;
CRC	cis	rs6586163	1.000	rs3824729	chr10:90752616	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.51	-7.47	-0.38	7.23e-13	Chronic lymphocytic leukemia;
CRC	trans	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg10756647	chr7:56101905	PSPH	0.74	8.12	0.41	9.34e-15	Diabetic kidney disease;
CRC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.56	-9.01	-0.44	1.76e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.59	-10.02	-0.48	8.4e-21	Alzheimer's disease (late onset);
CRC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.54	-0.43	5.22e-16	Monocyte count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03884976	chr16:577621	SOLH;C16orf10	0.47	6.3	0.33	9.53e-10	Anxiety disorder;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg00063174	chr2:228736253	WDR69	-0.51	-6.88	-0.35	3.07e-11	Blood pressure;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg12172441	chr6:28176163	NA	0.47	6.53	0.34	2.49e-10	Hepatitis A;
CRC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg15440763	chr7:158190612	PTPRN2	0.4	6.31	0.33	8.9e-10	Obesity-related traits;
CRC	trans	rs10504390	0.656	rs79932695	chr8:66547075	T/C	cg26403416	chr21:43771339	TFF2	0.6	6.14	0.32	2.38e-9	IgG glycosylation;
CRC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.48	6.14	0.32	2.41e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21446345	chr15:70390985	TLE3	0.45	6.54	0.34	2.37e-10	Response to antipsychotic treatment;
CRC	cis	rs17092148	0.616	rs6059908	chr20:33132159	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.67	0.3	3.09e-8	Neuroticism;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg11861562	chr11:117069780	TAGLN	0.31	6.91	0.36	2.5e-11	Blood protein levels;
CRC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.59	8.56	0.43	4.41e-16	Lymphocyte counts;
CRC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.65	-11.21	-0.53	6.38e-25	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.74	-12.25	-0.56	1.1e-28	Cystic fibrosis severity;
CRC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg16102536	chr7:156981717	UBE3C	0.4	6.71	0.35	8.48e-11	Body mass index;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.25	-6.28	-0.33	1.06e-9	Lymphocyte counts;
CRC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.5	8.15	0.41	7.48e-15	Lipoprotein (a) levels;
CRC	cis	rs10046574	0.561	rs10214966	chr7:135196642	A/G	cg27474649	chr7:135195673	CNOT4	0.67	6.16	0.32	2.14e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs863345	0.504	rs2482966	chr1:158563321	T/A	cg12129480	chr1:158549410	OR10X1	-0.34	-7.17	-0.37	4.96e-12	Pneumococcal bacteremia;
CRC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg05627522	chr15:75251581	NA	0.4	5.99	0.31	5.36e-9	Breast cancer;
CRC	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.53	6.51	0.34	2.8e-10	Cognitive test performance;
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs9914266	1	rs9914266	chr17:2133250	T/C	cg16513277	chr17:2031491	SMG6	-0.52	-8.79	-0.44	8.39e-17	Myocardial infarction;
CRC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.65	-13.7	-0.6	4.08e-34	Schizophrenia;
CRC	trans	rs6788895	1.000	rs6795396	chr3:150510227	C/T	cg12790874	chr13:100310405	CLYBL	-0.69	-6.04	-0.32	4.06e-9	Breast cancer;
CRC	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg00277334	chr10:82204260	NA	0.38	6.08	0.32	3.37e-9	Sarcoidosis;
CRC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg09355771	chr2:177043147	NA	0.69	10.74	0.51	2.94e-23	IgG glycosylation;
CRC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.9	-0.44	3.92e-17	Aortic root size;
CRC	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg21155852	chr7:2048760	MAD1L1	-0.4	-5.66	-0.3	3.25e-8	Bipolar disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg19590290	chr4:104119639	CENPE	0.4	6.34	0.33	7.7e-10	Schizophrenia;
CRC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.03	0.32	4.52e-9	Glioblastoma;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	cis	rs6694672	1.000	rs857017	chr1:197019055	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.43	0.38	9.48e-13	Asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08252325	chr2:71098940	NA	0.4	6.28	0.33	1.08e-9	Response to antipsychotic treatment;
CRC	cis	rs6534441	0.818	rs11946186	chr4:125457073	C/T	cg21609808	chr4:125404261	NA	0.39	5.88	0.31	9.92e-9	Major depressive disorder;
CRC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs6561151	0.957	rs9316058	chr13:44485076	G/C	cg17145862	chr1:211918768	LPGAT1	0.5	7.13	0.37	6.38e-12	Crohn's disease;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs9311676	0.632	rs4130877	chr3:58374893	T/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs16975963	0.545	rs12461753	chr19:38202515	G/A	cg15135657	chr19:38346511	NA	-0.49	-6.53	-0.34	2.48e-10	Longevity;
CRC	cis	rs7705042	0.865	rs249642	chr5:141524980	G/C	cg07392085	chr5:141489673	NDFIP1	0.45	7.25	0.37	2.94e-12	Asthma;
CRC	cis	rs629535	0.748	rs689410	chr8:70037558	G/A	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.9	-0.8	7.05e-74	Myeloid white cell count;
CRC	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg10483660	chr13:112241077	NA	0.36	5.78	0.3	1.76e-8	Menarche (age at onset);
CRC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg14593290	chr7:50529359	DDC	-0.46	-6.54	-0.34	2.35e-10	Systemic sclerosis;
CRC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16447950	chr5:562315	NA	-0.73	-9.79	-0.47	5.05e-20	Obesity-related traits;
CRC	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg00666640	chr1:248458726	OR2T12	0.43	7.64	0.39	2.34e-13	Common traits (Other);
CRC	cis	rs6973256	0.897	rs9656424	chr7:133325031	A/T	cg10665199	chr7:133106180	EXOC4	-0.38	-5.84	-0.31	1.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.27	0.45	2.57e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.88	-0.51	9.7e-24	Bipolar disorder;
CRC	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg25173405	chr17:45401733	C17orf57	-0.4	-6.08	-0.32	3.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.47	6.25	0.33	1.27e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.36	6.71	0.35	8.71e-11	Obesity-related traits;
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.45	-8.32	-0.42	2.32e-15	Reticulocyte fraction of red cells;
CRC	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg08222913	chr3:52553049	STAB1	-0.35	-6.24	-0.33	1.34e-9	Bipolar disorder;
CRC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.63	-10.01	-0.48	9.17e-21	Height;
CRC	cis	rs863345	0.604	rs10908665	chr1:158499889	T/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27641522	chr18:53447560	NA	0.33	6.1	0.32	2.98e-9	Survival in pancreatic cancer;
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg15898840	chr7:45960834	IGFBP3	0.53	8.36	0.42	1.82e-15	Sitting height ratio;
CRC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.46	7.29	0.37	2.33e-12	Dupuytren's disease;
CRC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.49	0.65	5.06e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg03701575	chr16:83960119	NA	0.35	5.98	0.31	5.73e-9	Asthma;
CRC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg01941586	chr1:40203715	PPIE	0.44	6.22	0.32	1.53e-9	Blood protein levels;
CRC	cis	rs73206853	0.688	rs57530940	chr12:110597842	C/T	cg12870014	chr12:110450643	ANKRD13A	0.79	8.0	0.4	2.21e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.37	5.67	0.3	3.2e-8	Cleft lip with or without cleft palate;
CRC	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.54	-8.27	-0.41	3.34e-15	Eosinophil percentage of white cells;
CRC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.49	7.69	0.39	1.76e-13	Resting heart rate;
CRC	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.82	0.44	6.76e-17	Coffee consumption (cups per day);
CRC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.24e-30	Bone mineral density;
CRC	cis	rs9311474	0.652	rs352158	chr3:52217704	C/T	cg15147215	chr3:52552868	STAB1	-0.45	-7.24	-0.37	3.17e-12	Electroencephalogram traits;
CRC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.58	11.35	0.53	1.99e-25	Asthma (sex interaction);
CRC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.44	-0.33	4.14e-10	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15508020	chr16:58232206	CSNK2A2	0.48	6.83	0.35	4.04e-11	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg13047869	chr3:10149882	C3orf24	0.56	7.51	0.38	5.62e-13	Alzheimer's disease;
CRC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.53	-10.19	-0.49	2.21e-21	Height;
CRC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	0.37	5.7	0.3	2.66e-8	Axial length;
CRC	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.58	-8.81	-0.44	7.58e-17	Ulcerative colitis;
CRC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10524888	chr4:39529563	UGDH	0.4	6.53	0.34	2.55e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg08071915	chr8:12219732	FAM66A	0.32	5.77	0.3	1.82e-8	Retinal vascular caliber;
CRC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.76	14.55	0.63	2.33e-37	Body mass index;
CRC	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.56	9.57	0.47	2.62e-19	Chronic obstructive pulmonary disease;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg03844506	chr4:4109441	NA	-0.5	-7.42	-0.38	1.01e-12	Blood pressure (smoking interaction);
CRC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.06	-0.32	3.75e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.45	-7.12	-0.37	6.86e-12	Coronary artery disease;
CRC	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.7	0.47	1.03e-19	Coffee consumption (cups per day);
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.78	0.44	9.09e-17	Alzheimer's disease;
CRC	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg21839984	chr17:30846986	MYO1D	-0.34	-5.62	-0.3	4.07e-8	Schizophrenia;
CRC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.5	7.46	0.38	7.8e-13	Birth weight;
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.53	7.19	0.37	4.51e-12	Caudate activity during reward;
CRC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.19	0.37	4.36e-12	Rheumatoid arthritis;
CRC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.42	-0.46	8.21e-19	Platelet count;
CRC	cis	rs6758955	0.850	rs6743846	chr2:10480415	A/G	cg15773312	chr2:10472214	HPCAL1	0.83	9.69	0.47	1.04e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg15786705	chr6:28176104	NA	0.63	9.0	0.44	1.89e-17	Cardiac Troponin-T levels;
CRC	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	7.11	0.37	7.08e-12	Blood metabolite levels;
CRC	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.77	-0.35	6.09e-11	Multiple sclerosis;
CRC	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg21851534	chr17:3907994	ZZEF1	0.37	6.46	0.34	3.69e-10	Type 2 diabetes;
CRC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.66	-9.39	-0.46	1.04e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.85	0.66	1.88e-42	Fuchs's corneal dystrophy;
CRC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	0.95	7.98	0.4	2.46e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6804368	0.649	rs1461069	chr3:30759900	T/C	cg06106510	chr3:30762233	NA	0.42	7.6	0.39	3.13e-13	Blood metabolite levels;
CRC	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg07274523	chr3:49395745	GPX1	0.46	6.3	0.33	9.47e-10	Educational attainment;
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10150615	chr22:24372951	LOC391322	-0.54	-7.83	-0.4	6.92e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg20243544	chr17:37824526	PNMT	0.37	5.68	0.3	2.89e-8	Self-reported allergy;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.61	10.44	0.5	3.05e-22	Mean corpuscular volume;
CRC	trans	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg13777783	chr17:79615861	NA	-0.3	-5.73	-0.3	2.27e-8	Eye color traits;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-6.03	-0.32	4.36e-9	Longevity;Endometriosis;
CRC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.71	11.06	0.52	2.17e-24	Intelligence (multi-trait analysis);
CRC	cis	rs9491140	0.539	rs12529386	chr6:124678200	A/G	cg22366943	chr6:124882293	NKAIN2	0.55	8.27	0.42	3.27e-15	Neuroticism;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg04130057	chr1:159895524	TAGLN2	0.57	6.13	0.32	2.5e-9	Airway imaging phenotypes;
CRC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.38	0.38	1.32e-12	Calcium levels;
CRC	cis	rs9903692	1.000	rs9903692	chr17:46273929	G/A	cg21215337	chr17:46176117	CBX1	0.43	7.86	0.4	5.45e-14	Pulse pressure;
CRC	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg24024056	chr10:102415556	NA	-0.35	-7.0	-0.36	1.44e-11	Body mass index;
CRC	trans	rs12517041	1.000	rs6452110	chr5:23299802	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.13	-0.37	6.27e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg01420254	chr6:26195488	NA	0.82	8.79	0.44	8.38e-17	Gout;Renal underexcretion gout;
CRC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.38	6.8	0.35	4.95e-11	Primary biliary cholangitis;
CRC	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg10556349	chr10:835070	NA	-0.36	-7.12	-0.37	6.87e-12	Survival in rectal cancer;
CRC	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg09184832	chr6:79620586	NA	-0.45	-7.72	-0.39	1.43e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg20354231	chr13:53171401	NA	-0.44	-7.13	-0.37	6.43e-12	Lewy body disease;
CRC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs2160860	0.736	rs7839885	chr8:39799238	G/A	cg11363097	chr8:39792086	IDO2	-0.42	-7.27	-0.37	2.68e-12	Blood metabolite levels;
CRC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg23625390	chr15:77176239	SCAPER	0.39	5.62	0.3	4.02e-8	Blood metabolite levels;
CRC	cis	rs2067615	0.965	rs4964484	chr12:107113024	A/C	cg13491945	chr12:107078410	RFX4	-0.35	-5.9	-0.31	8.85e-9	Heart rate;
CRC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	3.08e-24	Corneal astigmatism;
CRC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.67	-0.3	3.19e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.76	11.12	0.52	1.31e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6504622	0.818	rs758391	chr17:45017241	G/A	cg16759221	chr17:45003025	GOSR2	-0.52	-7.83	-0.4	6.72e-14	Orofacial clefts;
CRC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	9.92e-18	Bladder cancer;
CRC	trans	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.74	-0.39	1.26e-13	HDL cholesterol;
CRC	cis	rs2481665	0.510	rs2481676	chr1:62627675	C/T	cg18591186	chr1:62594603	INADL	-0.62	-9.49	-0.46	4.91e-19	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.25	-0.33	1.26e-9	Menopause (age at onset);
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.38	0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.59	-9.61	-0.47	2.04e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	cis	rs10512697	1.000	rs34469550	chr5:3571040	T/G	cg19473799	chr5:3511975	NA	-0.76	-5.86	-0.31	1.1e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg11518657	chr1:67396239	MIER1	-0.57	-6.07	-0.32	3.47e-9	Lymphocyte percentage of white cells;
CRC	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.7	-0.35	9.26e-11	Coronary artery disease;
CRC	cis	rs938554	0.694	rs4697700	chr4:9945792	C/G	cg00071950	chr4:10020882	SLC2A9	0.43	6.08	0.32	3.38e-9	Blood metabolite levels;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12273811	chr6:28175739	NA	0.56	7.94	0.4	3.3e-14	Parkinson's disease;
CRC	trans	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-7.03	-0.36	1.17e-11	Ulcerative colitis;
CRC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.7e-9	Rheumatoid arthritis;
CRC	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg10437265	chr15:77819839	NA	-0.47	-8.47	-0.42	8.41e-16	Type 2 diabetes;
CRC	cis	rs539514	0.664	rs560069	chr13:76309344	A/G	cg04757411	chr13:76259545	LMO7	0.36	6.01	0.31	5e-9	Type 1 diabetes;
CRC	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.49	-7.19	-0.37	4.27e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.77	-0.3	1.85e-8	Life satisfaction;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19046167	chr17:80928561	B3GNTL1	0.5	7.02	0.36	1.28e-11	Glycated hemoglobin levels;
CRC	cis	rs7731657	0.537	rs9327578	chr5:130181064	C/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.84	-0.31	1.25e-8	Fasting plasma glucose;
CRC	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.44	6.52	0.34	2.63e-10	Platelet distribution width;
CRC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg13777783	chr17:79615861	NA	0.3	5.68	0.3	2.91e-8	Eye color traits;
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.45	-0.42	9.79e-16	Electroencephalogram traits;
CRC	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-11.75	-0.54	7.2e-27	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.49	7.41	0.38	1.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg21115391	chr11:93143810	CCDC67	-0.38	-5.63	-0.3	3.8e-8	Pulmonary function decline;
CRC	trans	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.82	-0.35	4.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2302729	0.578	rs7315556	chr12:2773855	G/A	cg19945202	chr12:2788847	CACNA1C	-0.49	-7.79	-0.39	9.09e-14	Sleep quality;
CRC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg04450456	chr4:17643702	FAM184B	0.41	6.58	0.34	1.88e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.53	8.53	0.43	5.55e-16	Breast cancer;
CRC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.82	-11.95	-0.55	1.35e-27	Multiple sclerosis;
CRC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.68	8.89	0.44	4e-17	Morning vs. evening chronotype;
CRC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.62	6.19	0.32	1.8e-9	Plasma clusterin levels;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07513332	chr6:167530253	CCR6	0.37	6.07	0.32	3.52e-9	Primary biliary cholangitis;
CRC	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.84	0.68	2.62e-46	Electrocardiographic conduction measures;
CRC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.0	-0.31	5.15e-9	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17371249	chr1:241682474	FH	0.43	5.97	0.31	6.26e-9	Response to antipsychotic treatment;
CRC	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.62	-8.71	-0.43	1.53e-16	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2882667	0.658	rs288003	chr5:138231955	T/G	cg09476006	chr5:138032270	NA	0.54	8.95	0.44	2.66e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01272601	chr2:69871685	AAK1	0.41	6.0	0.31	5.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.44	6.01	0.31	4.91e-9	Aortic root size;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg14646075	chr2:228736089	WDR69	-0.45	-6.14	-0.32	2.43e-9	Blood pressure;
CRC	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.44	-6.14	-0.32	2.36e-9	Fibrinogen levels;
CRC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-9.85	-0.48	3.09e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	0.59	6.12	0.32	2.72e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	16.13	0.66	1.55e-43	Platelet count;
CRC	cis	rs7572644	0.664	rs12473340	chr2:28023797	G/A	cg27432699	chr2:27873401	GPN1	0.45	5.63	0.3	3.85e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.86	10.94	0.52	5.88e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3857067	1.000	rs1397025	chr4:95018987	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg27094323	chr7:1216898	NA	-0.37	-6.04	-0.32	4.18e-9	Longevity;Endometriosis;
CRC	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.55	8.12	0.41	9.39e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg07636037	chr3:49044803	WDR6	-0.7	-6.14	-0.32	2.36e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs10128264	0.902	rs1250584	chr10:80976442	G/T	cg20744163	chr10:80999841	ZMIZ1	-0.42	-7.2	-0.37	3.99e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	trans	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg01134436	chr17:81009848	B3GNTL1	-0.74	-7.15	-0.37	5.77e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs55788414	0.932	rs59201365	chr16:81185681	C/G	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.63	-0.34	1.38e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs11212617	0.935	rs227064	chr11:108207393	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.41	5.91	0.31	8.77e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.92	-0.31	8.18e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.65	-9.31	-0.46	1.87e-18	DNA methylation (variation);
CRC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	8.28	0.42	3.11e-15	Cognitive test performance;
CRC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.5	8.02	0.4	1.9e-14	Testicular germ cell tumor;
CRC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.48	6.36	0.33	6.66e-10	Obesity-related traits;
CRC	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.61	8.56	0.43	4.33e-16	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs8135828	1.000	rs11704899	chr22:29918482	C/T	cg05402634	chr11:70644141	SHANK2	0.56	6.2	0.32	1.71e-9	Lipid traits;
CRC	cis	rs6496667	0.779	rs10083670	chr15:91022135	C/T	cg04176472	chr15:90893244	GABARAPL3	0.51	7.32	0.37	1.9e-12	Rheumatoid arthritis;
CRC	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-7.61	-0.39	2.97e-13	Prevalent atrial fibrillation;
CRC	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg26353448	chr1:248524236	OR2T4	-0.33	-6.86	-0.35	3.51e-11	Common traits (Other);
CRC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.75	11.24	0.53	5.11e-25	High light scatter reticulocyte count;
CRC	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.46	-0.38	7.85e-13	Caudate activity during reward;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg20933634	chr6:27740509	NA	0.56	7.74	0.39	1.26e-13	Parkinson's disease;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.61	8.31	0.42	2.62e-15	Menopause (age at onset);
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg06074448	chr4:187884817	NA	-0.6	-10.89	-0.51	8.5e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.15	0.32	2.27e-9	Endometrial cancer;
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.6	-0.39	3.06e-13	Total body bone mineral density;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23325670	chr19:17337031	OCEL1	0.37	6.01	0.31	4.9e-9	Obesity-related traits;
CRC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.87	10.25	0.49	1.43e-21	Psoriasis;
CRC	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg27083787	chr2:113543245	IL1A	0.45	6.47	0.34	3.5e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.51	5.62	0.3	3.99e-8	Coronary artery disease;
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg10398005	chr11:117014888	PAFAH1B2	-0.4	-5.66	-0.3	3.33e-8	Blood protein levels;
CRC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.24	-0.53	5.06e-25	Blood trace element (Zn levels);
CRC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.62	0.34	1.45e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03986968	chr15:34330894	AVEN;CHRM5	0.4	6.23	0.32	1.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg20684491	chr1:25596433	NA	0.4	6.84	0.35	3.82e-11	Erythrocyte sedimentation rate;
CRC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.65e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05065690	chr12:49246007	DDX23	0.51	6.64	0.34	1.28e-10	Thyroid stimulating hormone;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07721005	chr5:87564621	TMEM161B	0.39	5.98	0.31	5.86e-9	Myopia (pathological);
CRC	cis	rs4664293	0.647	rs6756502	chr2:160554583	T/G	cg08347373	chr2:160653686	CD302	0.39	6.61	0.34	1.58e-10	Monocyte percentage of white cells;
CRC	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.5	-7.92	-0.4	3.63e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.62	9.53	0.47	3.63e-19	Corneal astigmatism;
CRC	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.44	6.58	0.34	1.81e-10	Obesity-related traits;
CRC	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.64	0.47	1.56e-19	Coffee consumption (cups per day);
CRC	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	6.01	0.31	4.94e-9	Response to antipsychotic treatment;
CRC	cis	rs8105895	0.935	rs62111027	chr19:22269019	T/C	cg02657401	chr19:22469223	NA	-0.37	-5.73	-0.3	2.32e-8	Body mass index (change over time);
CRC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg25347419	chr2:177043501	NA	0.58	9.04	0.45	1.41e-17	IgG glycosylation;
CRC	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	7.56	0.38	4.03e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.65	-9.89	-0.48	2.36e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs4664293	0.647	rs7562850	chr2:160441534	G/A	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.66	12.13	0.56	3.09e-28	Calcium levels;
CRC	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.87	-0.31	1.08e-8	Metabolite levels;
CRC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.44	6.12	0.32	2.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.46	8.69	0.43	1.75e-16	Intraocular pressure;
CRC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg15534755	chr11:117069859	TAGLN	0.35	6.74	0.35	6.96e-11	Blood protein levels;
CRC	cis	rs1712517	0.787	rs1163089	chr10:105043964	G/A	cg05636881	chr10:105038444	INA	0.48	8.12	0.41	9.61e-15	Migraine;
CRC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-8.18	-0.41	6.31e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.47	-0.34	3.66e-10	Total body bone mineral density;
CRC	cis	rs9462846	0.853	rs7740252	chr6:42871045	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-6.47	-0.34	3.65e-10	Blood protein levels;
CRC	cis	rs2982552	0.967	rs2982556	chr6:152056842	G/A	cg22157087	chr6:152012887	ESR1	0.4	6.24	0.33	1.36e-9	Bone properties (heel);
CRC	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.53	-0.38	5.08e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	11.63	0.54	2.05e-26	Tonsillectomy;
CRC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.53	6.62	0.34	1.49e-10	Methadone dose in opioid dependence;
CRC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs990171	0.913	rs4851009	chr2:103055644	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs12143943	0.966	rs6669246	chr1:204557561	A/G	cg17419461	chr1:204415978	PIK3C2B	0.41	6.35	0.33	7.3e-10	Cognitive performance;
CRC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg22815214	chr1:201083145	CACNA1S	0.51	6.39	0.33	5.64e-10	Permanent tooth development;
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.57	7.73	0.39	1.34e-13	Alzheimer's disease;
CRC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg23136738	chr11:925521	AP2A2	-0.5	-7.97	-0.4	2.56e-14	Alzheimer's disease (late onset);
CRC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg25767906	chr1:53392781	SCP2	-0.38	-5.93	-0.31	7.8e-9	Monocyte count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04677470	chr13:22247804	FGF9	0.52	6.63	0.34	1.4e-10	Thyroid stimulating hormone;
CRC	cis	rs939584	1.000	rs10173167	chr2:646767	G/A	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.67	-8.58	-0.43	3.92e-16	Mean platelet volume;
CRC	trans	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg07393940	chr7:158741817	NA	-0.51	-7.38	-0.38	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.18	-0.49	2.42e-21	Bipolar disorder;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.44	6.18	0.32	1.85e-9	Longevity;Endometriosis;
CRC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.41	7.04	0.36	1.12e-11	Total body bone mineral density;
CRC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.4	-0.33	5.23e-10	Aortic root size;
CRC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.64e-17	Prostate cancer;
CRC	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.06	0.41	1.38e-14	Menarche (age at onset);
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg11843238	chr5:131593191	PDLIM4	0.33	6.37	0.33	6.51e-10	Blood metabolite levels;
CRC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg08270630	chr22:50330655	NA	0.67	6.36	0.33	6.78e-10	Schizophrenia;
CRC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.06	0.32	3.73e-9	Tonsillectomy;
CRC	cis	rs9649465	0.967	rs7809453	chr7:123301940	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-5.69	-0.3	2.82e-8	Migraine;
CRC	trans	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg11693508	chr17:37793320	STARD3	0.48	6.44	0.33	4.14e-10	Neuroticism;
CRC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.46	-6.83	-0.35	4.16e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.92	-0.55	1.82e-27	Alzheimer's disease;
CRC	cis	rs3996993	0.702	rs6458871	chr6:52665977	C/T	cg20803780	chr6:52668592	GSTA1	-0.37	-6.86	-0.35	3.44e-11	Hemoglobin concentration;
CRC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg09655341	chr17:79618100	PDE6G	0.57	6.83	0.35	4.23e-11	Dental caries;
CRC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	10.8	0.51	1.83e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.22e-13	QT interval;
CRC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg21153622	chr11:89784906	NA	-0.37	-5.97	-0.31	6.05e-9	Height;
CRC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg01483505	chr11:975446	AP2A2	0.39	5.98	0.31	5.75e-9	Alzheimer's disease (late onset);
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg01339444	chr6:118972232	C6orf204	0.53	6.0	0.31	5.22e-9	Diastolic blood pressure;
CRC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.4	8.62	0.43	2.78e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.68e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.84	-0.31	1.26e-8	Metabolite levels;
CRC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.51	0.5	1.75e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24308560	chr3:49941425	MST1R	0.5	8.23	0.41	4.39e-15	Intelligence (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.36	6.67	0.35	1.09e-10	Panic disorder;
CRC	cis	rs9648716	1.000	rs17161762	chr7:140589208	C/T	cg10747023	chr7:140774559	NA	0.44	5.81	0.31	1.46e-8	Type 2 diabetes;
CRC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg22110888	chr17:80059540	CCDC57	0.38	5.93	0.31	7.53e-9	Life satisfaction;
CRC	cis	rs6429082	0.509	rs2246554	chr1:235520176	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	6.72	0.35	8.12e-11	Adiposity;
CRC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.44	0.38	8.86e-13	Motion sickness;
CRC	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.62	7.98	0.4	2.45e-14	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs910187	0.678	rs6122564	chr20:45814745	A/C	cg27589058	chr20:45804311	EYA2	-0.38	-7.27	-0.37	2.7e-12	Migraine;
CRC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.28	0.33	1.05e-9	Melanoma;
CRC	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg00291366	chr1:12616550	NA	0.6	10.78	0.51	2.11e-23	Optic cup area;
CRC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.56	-6.88	-0.35	2.96e-11	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01784859	chr1:160001849	PIGM	0.51	7.15	0.37	5.65e-12	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00495681	chr13:53174319	NA	0.61	9.03	0.45	1.45e-17	Lewy body disease;
CRC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg06363034	chr20:62225388	GMEB2	-0.44	-6.8	-0.35	5.06e-11	Glioblastoma;
CRC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.68	9.61	0.47	2.02e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7173389	0.551	rs77883904	chr15:73678498	C/A	cg01796676	chr15:73680284	NA	0.59	5.84	0.31	1.28e-8	Resting heart rate;
CRC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg05139728	chr16:28306816	SBK1	-0.38	-6.23	-0.32	1.41e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.72	-0.35	8.04e-11	Breast cancer;
CRC	trans	rs2012709	0.935	rs34666745	chr5:32552432	G/A	cg03755955	chr8:6424269	MCPH1	0.45	6.63	0.34	1.39e-10	Breast cancer;
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg15382696	chr6:118971807	C6orf204	0.62	8.05	0.41	1.5e-14	Renal cell carcinoma;
CRC	cis	rs7901135	0.924	rs7099432	chr10:60559615	G/A	cg23799393	chr10:60588674	BICC1	0.39	6.0	0.31	5.27e-9	Morning vs. evening chronotype;
CRC	cis	rs7605827	0.930	rs12692264	chr2:15539229	T/A	cg19274914	chr2:15703543	NA	0.4	5.92	0.31	8.18e-9	Educational attainment (years of education);
CRC	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg19537932	chr12:55886519	OR6C68	-0.71	-9.12	-0.45	7.79e-18	Cancer;
CRC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.54	-7.72	-0.39	1.42e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.38	0.56	3.75e-29	Height;
CRC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.04	-0.45	1.42e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.22	-0.32	1.54e-9	Arsenic metabolism;
CRC	trans	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg21153622	chr11:89784906	NA	0.45	7.1	0.36	7.58e-12	HDL cholesterol;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg06470822	chr6:28175283	NA	1.01	13.37	0.59	7.38e-33	Depression;
CRC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg09582351	chr12:29534625	ERGIC2	-0.28	-6.03	-0.32	4.41e-9	QT interval;
CRC	cis	rs2882667	0.898	rs2882792	chr5:138380480	G/T	cg04439458	chr5:138467593	SIL1	-0.33	-5.98	-0.31	5.93e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-6.54	-0.34	2.31e-10	Longevity;Endometriosis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17876050	chr2:170655740	SSB	0.38	6.07	0.32	3.5e-9	Schizophrenia;
CRC	trans	rs12660387	1.000	rs62415794	chr6:65267623	T/C	cg13393512	chr9:135749454	C9orf98	0.51	5.96	0.31	6.5e-9	Schizophrenia;
CRC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.56	0.54	3.54e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs34311866	0.577	rs11736181	chr4:877412	C/T	cg07828340	chr4:882639	GAK	0.59	5.95	0.31	6.98e-9	Parkinson's disease;
CRC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.38	-6.82	-0.35	4.5e-11	Longevity;
CRC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.33	5.76	0.3	1.98e-8	Height;
CRC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg24140574	chr1:16342155	HSPB7	0.43	5.74	0.3	2.11e-8	Dilated cardiomyopathy;
CRC	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.42	6.7	0.35	8.95e-11	Monocyte count;
CRC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg21770322	chr7:97807741	LMTK2	-0.74	-13.87	-0.61	9.53e-35	Breast cancer;
CRC	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.47	9.41	0.46	8.87e-19	Hand grip strength;
CRC	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg14768256	chr3:44754587	ZNF502	-0.49	-6.22	-0.32	1.52e-9	IgG glycosylation;
CRC	cis	rs1320333	0.772	rs17786111	chr2:700562	C/T	cg20966539	chr2:681320	NA	0.62	6.09	0.32	3.2e-9	Obesity-related traits;
CRC	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.92	-0.4	3.67e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg13596910	chr17:42254336	C17orf65;ASB16	0.36	6.07	0.32	3.47e-9	Aortic root size;
CRC	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.44	7.06	0.36	1.01e-11	Schizophrenia;
CRC	trans	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.81	11.89	0.55	2.36e-27	Cognitive function;
CRC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03383713	chr16:771506	FAM173A	0.43	6.04	0.32	4.08e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	6.55	0.34	2.26e-10	Body mass index;
CRC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.42	-6.14	-0.32	2.32e-9	Tonsillectomy;
CRC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.53	5.73	0.3	2.31e-8	Schizophrenia;
CRC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.36	5.63	0.3	3.83e-8	Mean platelet volume;
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.6	10.28	0.49	1.13e-21	Prudent dietary pattern;
CRC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19346786	chr7:2764209	NA	-0.41	-6.85	-0.35	3.73e-11	Height;
CRC	trans	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg13565492	chr6:43139072	SRF	-0.72	-7.46	-0.38	7.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.72	0.3	2.39e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	11.11	0.52	1.5e-24	Motion sickness;
CRC	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg15192750	chr16:69999425	NA	0.51	6.85	0.35	3.66e-11	IgE levels;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.66	0.43	2.16e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4657015	1.000	rs4657015	chr1:161272441	A/G	cg18430411	chr8:144873183	SCRIB	-0.49	-9.01	-0.44	1.69e-17	Visceral adipose tissue adjusted for BMI;
CRC	cis	rs73195822	0.614	rs55946973	chr12:111214936	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	7.46	0.38	8e-13	Itch intensity from mosquito bite;
CRC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-10.61	-0.51	8e-23	Immature fraction of reticulocytes;
CRC	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	5.99	0.31	5.56e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.41	-7.7	-0.39	1.5700000000000001e-13	Migraine;
CRC	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6496667	0.779	rs8041401	chr15:90958545	A/G	cg04176472	chr15:90893244	GABARAPL3	0.6	7.83	0.4	6.92e-14	Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14460003	chr20:31173015	NA	0.36	6.53	0.34	2.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-7.91	-0.4	4e-14	Fibrinogen levels;
CRC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.5	7.97	0.4	2.62e-14	Menopause (age at onset);
CRC	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg20356878	chr3:121714668	ILDR1	-0.45	-6.5	-0.34	2.95e-10	Multiple sclerosis;
CRC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg21747405	chr11:67723411	NA	-0.43	-6.13	-0.32	2.45e-9	Blood pressure (smoking interaction);
CRC	cis	rs2154427	1.000	rs2833962	chr21:34174289	A/G	cg16417831	chr21:33958411	TCP10L	0.47	5.92	0.31	8.31e-9	Bilirubin levels;
CRC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-6.59	-0.34	1.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.71	-10.85	-0.51	1.24e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.47	7.7	0.39	1.61e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.6	9.38	0.46	1.09e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.52	7.15	0.37	5.69e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg10756647	chr7:56101905	PSPH	0.69	7.36	0.38	1.47e-12	Diabetic kidney disease;
CRC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-17.69	-0.7	1.15e-49	Body mass index;
CRC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.49	-6.02	-0.32	4.59e-9	Diastolic blood pressure;
CRC	cis	rs4731207	0.561	rs6975148	chr7:124686508	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00802000	chr16:706648	WDR90	-0.41	-5.92	-0.31	8.25e-9	Height;
CRC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.45	-6.51	-0.34	2.79e-10	Type 2 diabetes;
CRC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.49	9.32	0.46	1.73e-18	Renal cell carcinoma;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.62	-8.25	-0.41	3.78e-15	Alzheimer's disease;
CRC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.61	-9.7	-0.47	1.01e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9584850	0.834	rs9584854	chr13:99118590	C/T	cg07423050	chr13:99094983	FARP1	0.43	6.0	0.31	5.22e-9	Neuroticism;
CRC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg14196790	chr5:131705035	SLC22A5	0.36	5.88	0.31	1.02e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	6.94	0.36	2.04e-11	Diastolic blood pressure;
CRC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.98	0.31	5.7e-9	Cognitive ability;
CRC	trans	rs4942242	1.000	rs9594987	chr13:44230994	C/T	cg26741380	chr15:41871084	TYRO3	0.41	6.11	0.32	2.82e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.69	0.3	2.82e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.44	-0.38	8.72e-13	Body mass index;
CRC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.57	7.75	0.39	1.17e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs12530845	0.887	rs59400686	chr7:135360029	A/G	cg23117316	chr7:135346802	PL-5283	-0.43	-6.0	-0.31	5.32e-9	Red blood cell traits;
CRC	cis	rs7546094	1.000	rs6691932	chr1:113144263	T/C	cg22162597	chr1:113214053	CAPZA1	0.43	6.02	0.31	4.69e-9	Platelet distribution width;
CRC	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg15571903	chr15:79123663	NA	0.31	6.13	0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.19	-0.32	1.77e-9	Diabetic kidney disease;
CRC	trans	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg08222913	chr3:52553049	STAB1	-0.36	-6.78	-0.35	5.62e-11	Electroencephalogram traits;
CRC	cis	rs6563739	0.616	rs7985594	chr13:40218606	C/G	cg00026919	chr13:40226031	NA	0.45	5.68	0.3	2.96e-8	Menarche (age at onset);
CRC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg25344623	chr2:136566232	LCT	0.32	5.81	0.31	1.47e-8	Mosquito bite size;
CRC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.36	7.24	0.37	3.1e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg17903999	chr18:56338584	MALT1	0.42	7.23	0.37	3.51e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1572438	0.899	rs9379160	chr6:859966	A/G	cg21062780	chr6:887772	NA	-0.34	-5.63	-0.3	3.88e-8	Aging;
CRC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.74	-10.5	-0.5	1.94e-22	Platelet distribution width;
CRC	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-6.53	-0.34	2.45e-10	Caffeine consumption;
CRC	cis	rs713477	0.692	rs56280202	chr14:55911201	C/T	cg13175173	chr14:55914753	NA	-0.43	-7.52	-0.38	5.3e-13	Pediatric bone mineral content (femoral neck);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13884470	chr9:86595151	HNRNPK;RMI1	0.48	8.42	0.42	1.19e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs9491140	0.539	rs2208814	chr6:124692555	G/A	cg19267163	chr6:125004984	NKAIN2	0.47	6.1	0.32	3.04e-9	Neuroticism;
CRC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.99	-0.48	1.07e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.46	7.8	0.4	8.25e-14	Testicular germ cell tumor;
CRC	cis	rs6662572	0.686	rs11805376	chr1:46559664	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.38	0.33	6.09e-10	Blood protein levels;
CRC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.98	-0.44	2.2e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9549328	0.565	rs36145949	chr13:113616608	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.43	0.33	4.47e-10	Systolic blood pressure;
CRC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg17333051	chr19:2783644	SGTA	0.47	6.9	0.36	2.64e-11	Total cholesterol levels;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg10729496	chr3:10149963	C3orf24	0.49	6.35	0.33	7.07e-10	Alzheimer's disease;
CRC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.92e-30	Blood trace element (Zn levels);
CRC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.63	7.15	0.37	5.78e-12	Vitiligo;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg15786705	chr6:28176104	NA	0.64	9.23	0.45	3.27e-18	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23983136	chr10:88768846	AGAP11	-0.35	-5.98	-0.31	5.82e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2975734	1.000	rs2975734	chr8:10090097	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.07	-0.32	3.54e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6141769	0.542	rs28548407	chr20:31301495	T/C	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.84	-0.31	1.27e-8	Subjective well-being;
CRC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.54	-0.34	2.38e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.42	-6.07	-0.32	3.62e-9	Renal cell carcinoma;
CRC	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	6.25	0.33	1.28e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.76	13.43	0.59	4.46e-33	Oral cavity cancer;
CRC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.62	-9.07	-0.45	1.09e-17	Corneal astigmatism;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-6.17	-0.32	1.99e-9	Lymphocyte counts;
CRC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg15445000	chr17:37608096	MED1	0.34	6.11	0.32	2.81e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs4481887	0.516	rs11204613	chr1:248379155	A/G	cg00666640	chr1:248458726	OR2T12	-0.35	-6.33	-0.33	7.89e-10	Common traits (Other);
CRC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg01126855	chr4:183727586	NA	0.58	5.78	0.3	1.76e-8	Pediatric autoimmune diseases;
CRC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.82	-0.4	7.19e-14	Vitiligo;
CRC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg26554054	chr8:600488	NA	0.69	6.94	0.36	2.15e-11	IgG glycosylation;
CRC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.19	-0.32	1.83e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.77	11.62	0.54	2.23e-26	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.76	-0.35	6.14e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.6	5.88	0.31	9.92e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.29	-0.53	3.38e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs2223471	0.967	rs2281158	chr6:50730735	C/G	cg03432817	chr6:50765336	NA	0.39	6.32	0.33	8.72e-10	Subcutaneous adipose tissue;
CRC	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg13385794	chr1:248469461	NA	0.4	6.74	0.35	6.91e-11	Common traits (Other);
CRC	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.8	12.31	0.56	6.7200000000000006e-29	Testicular germ cell tumor;
CRC	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	1.05	20.58	0.75	4.42e-61	Platelet distribution width;
CRC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.55	7.9	0.4	4.1e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs6743376	0.509	rs1530552	chr2:113818120	G/T	cg09040174	chr2:113837401	NA	0.44	6.4	0.33	5.36e-10	Inflammatory biomarkers;
CRC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.7	10.82	0.51	1.46e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg10589385	chr1:150898437	SETDB1	0.32	6.53	0.34	2.43e-10	Melanoma;
CRC	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.6	8.47	0.42	8.42e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.49	6.7	0.35	9.14e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.86	10.95	0.52	5.42e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4731207	0.509	rs6977699	chr7:124617109	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.26	-0.33	1.22e-9	Cutaneous malignant melanoma;
CRC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.76	-12.89	-0.58	4.87e-31	Breast cancer;
CRC	trans	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg23954465	chr10:8078038	NA	-0.28	-6.19	-0.32	1.8e-9	Gut microbiome composition (summer);
CRC	cis	rs501120	0.866	rs607609	chr10:44750209	T/C	cg09554077	chr10:44749378	NA	0.89	13.17	0.59	4.18e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.6	9.71	0.47	9.23e-20	Itch intensity from mosquito bite;
CRC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.67	10.43	0.5	3.45e-22	Monocyte count;
CRC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.38e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.01	-0.31	4.92e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06470822	chr6:28175283	NA	0.65	5.61	0.3	4.22e-8	Depression;
CRC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07570687	chr10:102243282	WNT8B	0.44	5.66	0.3	3.36e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7209700	0.547	rs884696	chr17:45341244	C/A	cg08085267	chr17:45401833	C17orf57	0.58	7.28	0.37	2.44e-12	IgG glycosylation;
CRC	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg10761708	chr20:43804764	PI3	0.51	5.82	0.31	1.37e-8	Blood protein levels;
CRC	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	cis	rs7259376	0.905	rs2082479	chr19:22539847	T/C	cg02657401	chr19:22469223	NA	-0.34	-7.62	-0.39	2.73e-13	Menopause (age at onset);
CRC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.51	7.69	0.39	1.69e-13	Corneal astigmatism;
CRC	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06307176	chr5:131281290	NA	0.45	6.44	0.33	4.33e-10	Life satisfaction;
CRC	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.64	-9.02	-0.45	1.6e-17	Neuroticism;
CRC	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.57	8.3	0.42	2.69e-15	Testicular germ cell tumor;
CRC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.65	-10.52	-0.5	1.71e-22	Glaucoma (primary open-angle);
CRC	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.6e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.54	5.91	0.31	8.53e-9	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24119481	chr19:16683605	SLC35E1	0.47	6.1	0.32	3.02e-9	Thyroid stimulating hormone;
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg08200582	chr11:442649	ANO9	-0.69	-7.04	-0.36	1.16e-11	Body mass index;
CRC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.29	-0.42	2.97e-15	Type 2 diabetes;
CRC	cis	rs7172809	0.897	rs16968893	chr15:77825082	A/G	cg10437265	chr15:77819839	NA	-0.4	-6.84	-0.35	3.8e-11	Glucose homeostasis traits;
CRC	cis	rs7274811	0.711	rs291697	chr20:31985248	T/C	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.8	0.3	1.55e-8	Height;
CRC	cis	rs7635838	0.964	rs7624086	chr3:11412620	C/G	cg00170343	chr3:11313890	ATG7	0.42	6.31	0.33	9.06e-10	HDL cholesterol;
CRC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.57	-9.47	-0.46	5.75e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.43	5.61	0.3	4.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg03188948	chr7:1209495	NA	-0.43	-6.29	-0.33	1.02e-9	Longevity;Endometriosis;
CRC	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	6.44	0.33	4.31e-10	Breast cancer;
CRC	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg05049329	chr1:226924846	ITPKB	0.32	7.11	0.37	7.16e-12	Parkinson's disease;
CRC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.57	-0.38	3.88e-13	Hemoglobin concentration;
CRC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.79	-0.51	1.89e-23	Monocyte count;
CRC	cis	rs2227564	0.729	rs2675676	chr10:75648287	A/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.52	-0.38	5.23e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg06470822	chr6:28175283	NA	0.71	10.51	0.5	1.76e-22	Cardiac Troponin-T levels;
CRC	cis	rs11212617	1.000	rs641605	chr11:108101919	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.15	0.32	2.25e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.77	-0.3	1.8e-8	Cognitive function;
CRC	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.54	7.23	0.37	3.37e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.45	-6.92	-0.36	2.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.37	6.04	0.32	4.2e-9	Total body bone mineral density;
CRC	cis	rs17767392	0.881	rs2190240	chr14:72024889	T/C	cg13720639	chr14:72061746	SIPA1L1	0.56	6.93	0.36	2.25e-11	Mitral valve prolapse;
CRC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.34	-0.42	2.03e-15	Height;
CRC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg05839533	chr17:39642907	KRT36	-0.33	-5.96	-0.31	6.54e-9	Malaria;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg03525424	chr17:48238931	NA	0.4	5.97	0.31	6.15e-9	Schizophrenia;
CRC	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.7	8.17	0.41	6.89e-15	Neutrophil percentage of white cells;
CRC	trans	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg10756647	chr7:56101905	PSPH	0.73	7.98	0.4	2.44e-14	Diabetic kidney disease;
CRC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.55	-8.26	-0.41	3.67e-15	Response to temozolomide;
CRC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.47	-0.46	5.71e-19	Heart rate;
CRC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.94	0.36	2.07e-11	Mood instability;
CRC	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg23254163	chr1:152506842	NA	0.41	6.83	0.35	4.06e-11	Hair morphology;
CRC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6988985	0.560	rs4736343	chr8:143933200	G/A	cg10324643	chr8:143916377	GML	0.39	6.32	0.33	8.73e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12571687	chr6:44215362	HSP90AB1	0.44	6.54	0.34	2.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.95	18.05	0.71	4.22e-51	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07690219	chr3:49449608	TCTA;RHOA	0.5	5.76	0.3	1.95e-8	Menarche (age at onset);
CRC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.4	5.88	0.31	1.01e-8	Platelet distribution width;
CRC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.48	-6.84	-0.35	3.75e-11	Diastolic blood pressure;
CRC	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-10.39	-0.5	4.54e-22	Colorectal cancer;
CRC	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.58	-9.43	-0.46	7.82e-19	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.13	-0.32	2.5e-9	Aortic root size;
CRC	cis	rs11212617	1.000	rs609429	chr11:108196509	G/C	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.27	0.33	1.14e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	11.51	0.54	5.41e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4731207	0.698	rs2107936	chr7:124449041	A/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.85	15.0	0.64	4.01e-39	Breast cancer;
CRC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.63	-9.33	-0.46	1.66e-18	Acne (severe);
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg09877947	chr5:131593287	PDLIM4	0.42	5.93	0.31	7.83e-9	Breast cancer;
CRC	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	0.61	9.63	0.47	1.73e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs11031096	0.676	rs7120125	chr11:3941264	C/T	cg18678763	chr11:4115507	RRM1	0.35	5.77	0.3	1.88e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg14003231	chr6:33640908	ITPR3	0.46	7.36	0.38	1.5e-12	Height;
CRC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.33e-29	Prostate cancer;
CRC	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.05e-12	HDL cholesterol;
CRC	cis	rs77633900	0.772	rs157769	chr15:76834397	G/A	cg21673338	chr15:77095150	SCAPER	-0.73	-6.28	-0.33	1.04e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg14768367	chr16:72042858	DHODH	-0.48	-5.84	-0.31	1.23e-8	Blood protein levels;
CRC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg14458575	chr2:238380390	NA	0.46	6.57	0.34	2.02e-10	Prostate cancer;
CRC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06221963	chr1:154839813	KCNN3	0.39	6.08	0.32	3.26e-9	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15323084	chr1:1556707	MIB2	-0.44	-6.06	-0.32	3.73e-9	Anxiety disorder;
CRC	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.64	-7.57	-0.39	3.83e-13	Ulcerative colitis;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg16326998	chr7:5553266	FBXL18	0.56	6.48	0.34	3.4e-10	Body mass index;
CRC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.53	6.69	0.35	9.55e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02280908	chr2:28615925	FOSL2	0.46	6.82	0.35	4.37e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg25164649	chr6:28176230	NA	0.58	8.29	0.42	2.9e-15	Parkinson's disease;
CRC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.74	-12.39	-0.56	3.53e-29	Breast cancer;
CRC	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	6.46	0.34	3.76e-10	Response to antipsychotic treatment;
CRC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.43	7.13	0.37	6.3e-12	Type 2 diabetes;
CRC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.52	6.77	0.35	5.93e-11	Cleft lip with or without cleft palate;
CRC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.55	9.74	0.47	7.5e-20	Body mass index;
CRC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.1	-0.32	2.93e-9	Menopause (age at onset);
CRC	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.75	10.57	0.5	1.16e-22	Vitiligo;
CRC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.64	-10.32	-0.49	8.16e-22	Dental caries;
CRC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.86	-0.31	1.11e-8	Heart rate;
CRC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21963583	chr11:68658836	MRPL21	0.6	10.28	0.49	1.15e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11212617	0.934	rs2056267	chr11:108061808	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.85	0.31	1.18e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg02683197	chr6:28174875	NA	0.66	8.59	0.43	3.46e-16	Parkinson's disease;
CRC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.55	-0.5	1.29e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg09237302	chr4:906077	GAK	0.44	7.52	0.38	5.16e-13	Systemic sclerosis;
CRC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.74	-12.73	-0.57	1.85e-30	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27658640	chr17:4843839	RNF167;SLC25A11	0.48	6.93	0.36	2.19e-11	Response to antipsychotic treatment;
CRC	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-5.83	-0.31	1.31e-8	Schizophrenia;
CRC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.52	0.43	5.78e-16	Menopause (age at onset);
CRC	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-5.87	-0.31	1.08e-8	Alzheimer's disease (survival time);
CRC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.05	0.45	1.28e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.5	-9.77	-0.47	5.93e-20	Hepatitis;
CRC	cis	rs847649	1.000	rs847648	chr7:102553850	C/T	cg18108683	chr7:102477205	FBXL13	-0.57	-9.36	-0.46	1.31e-18	Morning vs. evening chronotype;
CRC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.69	11.07	0.52	2.08e-24	Hepatocellular carcinoma;
CRC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg20542592	chr8:11973495	FAM66D	-0.32	-5.72	-0.3	2.39e-8	Retinal vascular caliber;
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.17	-0.32	2e-9	Intelligence (multi-trait analysis);
CRC	trans	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg25482853	chr8:67687455	SGK3	1.15	13.73	0.6	3.24e-34	Lung disease severity in cystic fibrosis;
CRC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.57	8.65	0.43	2.24e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.8	-0.35	5.07e-11	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.33	-0.46	1.6e-18	Bone mineral density;
CRC	cis	rs9322817	0.583	rs9377667	chr6:105154880	G/A	cg02098413	chr6:105308735	HACE1	-0.42	-8.22	-0.41	4.63e-15	Thyroid stimulating hormone;
CRC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16447950	chr5:562315	NA	-0.83	-10.78	-0.51	2.14e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg01262667	chr19:19385393	TM6SF2	0.37	6.17	0.32	2.05e-9	Tonsillectomy;
CRC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg02527881	chr3:46936655	PTH1R	0.37	6.74	0.35	6.98e-11	Colorectal cancer;
CRC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.52	9.39	0.46	1.01e-18	Vitiligo;
CRC	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-5.87	-0.31	1.04e-8	Coronary artery disease;
CRC	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg07513332	chr6:167530253	CCR6	-0.4	-7.02	-0.36	1.27e-11	Primary biliary cholangitis;
CRC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19717773	chr7:2847554	GNA12	-0.5	-6.98	-0.36	1.64e-11	Height;
CRC	cis	rs883565	0.655	rs7633233	chr3:39146724	G/T	cg01426195	chr3:39028469	NA	-0.54	-8.53	-0.43	5.32e-16	Handedness;
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	trans	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg13565492	chr6:43139072	SRF	-0.76	-5.97	-0.31	5.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6700896	0.931	rs10749755	chr1:66129530	C/T	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.45	6.01	0.31	4.87e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.42	6.23	0.32	1.43e-9	Crohn's disease;
CRC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.15	0.32	2.28e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.91	13.96	0.61	4.08e-35	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs7814319	0.700	rs35290014	chr8:97263930	T/C	cg20787634	chr8:97240163	UQCRB	-0.46	-7.45	-0.38	8.34e-13	Lung function (FVC);
CRC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg08493051	chr2:3487164	NA	-0.42	-6.12	-0.32	2.62e-9	Neurofibrillary tangles;
CRC	cis	rs4481887	0.597	rs2185358	chr1:248585259	T/A	cg00666640	chr1:248458726	OR2T12	0.36	6.16	0.32	2.13e-9	Common traits (Other);
CRC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.47	8.25e-20	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24308560	chr3:49941425	MST1R	-0.5	-7.9	-0.4	4.12e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs6759785	chr2:15529269	A/C	cg19274914	chr2:15703543	NA	0.39	5.77	0.3	1.82e-8	Educational attainment (years of education);
CRC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg01721255	chr8:58191610	C8orf71	0.5	6.19	0.32	1.81e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs12760731	0.720	rs12161419	chr1:178379040	A/C	cg00404053	chr1:178313656	RASAL2	0.98	10.15	0.49	3.04e-21	Obesity-related traits;
CRC	cis	rs4731207	0.596	rs1531717	chr7:124644690	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	0.61	6.48	0.34	3.28e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-8.04	-0.41	1.64e-14	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13030908	chr1:11741533	MAD2L2	0.44	6.23	0.32	1.47e-9	Response to antipsychotic treatment;
CRC	trans	rs800082	1.000	rs11718059	chr3:144305997	G/A	cg24215973	chr2:240111563	HDAC4	-0.51	-6.89	-0.36	2.89e-11	Smoking behavior;
CRC	cis	rs16975963	0.644	rs12162238	chr19:38082385	A/T	cg15135657	chr19:38346511	NA	-0.46	-6.32	-0.33	8.7e-10	Longevity;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg11251499	chr4:57774202	REST	-0.42	-6.4	-0.33	5.49e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.51	-7.38	-0.38	1.3e-12	Large artery stroke;
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.6	0.54	2.6e-26	Prudent dietary pattern;
CRC	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.73	0.35	7.76e-11	Menarche (age at onset);
CRC	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg24726965	chr2:63606136	C2orf86	-0.38	-5.8	-0.3	1.58e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.4	6.96	0.36	1.8e-11	Skin aging (microtopography measurement);
CRC	cis	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg15590007	chr10:45870220	ALOX5	0.58	5.99	0.31	5.6e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg11271282	chr2:238384023	NA	0.48	5.63	0.3	3.83e-8	Prostate cancer;
CRC	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg14119001	chr9:139324193	INPP5E	-0.44	-5.89	-0.31	9.75e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs10971721	0.822	rs10971802	chr9:33933282	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.63	-0.47	1.67e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.57	-8.52	-0.43	5.82e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg08888203	chr3:10149979	C3orf24	0.48	7.32	0.37	1.9e-12	Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.14	0.52	1.11e-24	Prudent dietary pattern;
CRC	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09426994	chr11:118478258	PHLDB1	-0.4	-6.11	-0.32	2.81e-9	Myopia (pathological);
CRC	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.7	-12.41	-0.56	2.76e-29	Mean platelet volume;
CRC	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.54	-8.27	-0.41	3.34e-15	Eosinophil percentage of white cells;
CRC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.94	15.71	0.65	6.81e-42	Primary sclerosing cholangitis;
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg01339444	chr6:118972232	C6orf204	0.54	6.02	0.32	4.65e-9	Diastolic blood pressure;
CRC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg18761221	chr20:60518478	NA	0.45	7.21	0.37	3.8e-12	Body mass index;
CRC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.71	-0.51	3.69e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.69	-10.77	-0.51	2.22e-23	Diastolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14655249	chr9:86595816	HNRNPK;RMI1	0.48	6.25	0.33	1.29e-9	Thyroid stimulating hormone;
CRC	cis	rs6142102	0.961	rs1055857	chr20:32613873	A/G	cg08999081	chr20:33150536	PIGU	0.37	5.64	0.3	3.71e-8	Skin pigmentation;
CRC	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.71	0.3	2.57e-8	Educational attainment;
CRC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.39	-6.23	-0.32	1.41e-9	Iron status biomarkers;
CRC	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.75	0.35	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.65	-9.43	-0.46	7.64e-19	Bipolar disorder;
CRC	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg09127314	chr1:152161683	NA	-0.46	-5.68	-0.3	2.95e-8	Atopic dermatitis;
CRC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00255919	chr5:131827918	IRF1	0.58	11.45	0.53	8.9e-26	Asthma (sex interaction);
CRC	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.52	9.16	0.45	5.86e-18	Common traits (Other);
CRC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.74	-0.47	7.45e-20	Primary sclerosing cholangitis;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23708337	chr7:1209742	NA	0.4	5.82	0.31	1.4e-8	Longevity;Endometriosis;
CRC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.36	5.72	0.3	2.38e-8	Height;
CRC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.82	-14.68	-0.63	6.92e-38	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04910470	chr15:41709534	RTF1	0.39	6.4	0.33	5.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311676	0.656	rs11917567	chr3:58382254	C/T	cg06643156	chr3:58380774	PXK	0.41	6.34	0.33	7.65e-10	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.93e-9	Depression;
CRC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	5.96	0.31	6.36e-9	Axial length;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.52	8.0	0.4	2.14e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.51	-0.34	2.81e-10	Breast cancer;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	9.23	0.45	3.31e-18	Lymphocyte counts;
CRC	cis	rs863345	0.604	rs11264991	chr1:158472861	T/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.24	-0.33	1.33e-9	Pneumococcal bacteremia;
CRC	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg14458575	chr2:238380390	NA	0.54	7.09	0.36	8.5e-12	Prostate cancer;
CRC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.79	-11.8	-0.55	4.92e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7538876	0.935	rs4920607	chr1:17760098	A/G	cg01904812	chr1:17746340	RCC2	0.39	6.33	0.33	8.12e-10	Basal cell carcinoma;
CRC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.55	9.53	0.47	3.53e-19	Common traits (Other);
CRC	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg16964102	chr10:135390573	NA	-0.49	-6.88	-0.35	3.09e-11	Gout;
CRC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.91e-9	Arsenic metabolism;
CRC	cis	rs6586163	1.000	rs1926195	chr10:90753758	G/A	cg13456138	chr10:90753195	FAS	-0.43	-6.61	-0.34	1.56e-10	Chronic lymphocytic leukemia;
CRC	cis	rs4664293	0.625	rs11693108	chr2:160428587	C/T	cg08347373	chr2:160653686	CD302	-0.38	-6.41	-0.33	4.95e-10	Monocyte percentage of white cells;
CRC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg03732007	chr1:2071316	PRKCZ	-0.41	-6.92	-0.36	2.34e-11	Height;
CRC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-0.83	-12.74	-0.57	1.67e-30	Blood trace element (Zn levels);
CRC	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg01843034	chr6:37503916	NA	-0.38	-6.94	-0.36	2.05e-11	Cognitive performance;
CRC	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.65	9.71	0.47	8.97e-20	Schizophrenia;
CRC	cis	rs728616	0.614	rs61859210	chr10:82131468	G/C	cg11900509	chr10:81946545	ANXA11	-0.56	-6.3	-0.33	9.41e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.69	7.93	0.4	3.55e-14	Hemostatic factors and hematological phenotypes;
CRC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	5.84	0.31	1.26e-8	Renal function-related traits (BUN);
CRC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.89	0.44	3.97e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.57	10.26	0.49	1.33e-21	Multiple system atrophy;
CRC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.65	-0.3	3.39e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Parkinson's disease;
CRC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg17724175	chr1:150552817	MCL1	0.44	6.55	0.34	2.27e-10	Melanoma;
CRC	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg16898833	chr6:26189333	HIST1H4D	0.84	7.08	0.36	8.95e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.93	-0.31	7.7e-9	Type 2 diabetes;
CRC	cis	rs73200209	0.744	rs59619030	chr12:116475001	T/C	cg01776926	chr12:116560359	MED13L	-0.63	-7.5	-0.38	6.13e-13	Total body bone mineral density;
CRC	cis	rs989128	0.614	rs1132414	chr17:48628092	A/G	cg24438145	chr17:48624694	SPATA20	0.51	7.37	0.38	1.35e-12	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03771185	chr4:775700	NA	0.46	6.46	0.34	3.83e-10	Response to antipsychotic treatment;
CRC	cis	rs7246967	0.608	rs2569725	chr19:23016010	C/A	cg23217946	chr19:22817039	ZNF492	0.4	5.62	0.3	3.98e-8	Bronchopulmonary dysplasia;
CRC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg08798685	chr6:27730294	NA	0.38	5.69	0.3	2.76e-8	Systemic lupus erythematosus;
CRC	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs1007738	0.580	rs2279439	chr11:47196982	C/T	cg19486271	chr11:47235900	DDB2	0.45	5.89	0.31	9.63e-9	Bone mineral density (hip);
CRC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.99	0.4	2.29e-14	Aortic root size;
CRC	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.53	-8.76	-0.44	1.02e-16	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs4481887	0.604	rs10888330	chr1:248410506	A/T	cg00666640	chr1:248458726	OR2T12	0.41	6.55	0.34	2.26e-10	Common traits (Other);
CRC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.62	0.51	7.72e-23	Diabetic retinopathy;
CRC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs12024301	0.557	rs10911391	chr1:183617094	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.27	-0.37	2.7e-12	Bipolar disorder;
CRC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-5.63	-0.3	3.79e-8	Major depressive disorder;
CRC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.98	0.55	1.12e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02688348	chr11:57103429	SSRP1	0.41	6.1	0.32	2.96e-9	Schizophrenia;
CRC	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.73	7.29	0.37	2.25e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg21466736	chr12:48725269	NA	0.47	7.45	0.38	8.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12172441	chr6:28176163	NA	0.69	9.19	0.45	4.69e-18	Depression;
CRC	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg02702477	chr5:179499311	RNF130	0.56	6.47	0.34	3.5e-10	LDL cholesterol;
CRC	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.59	9.22	0.45	3.77e-18	HDL cholesterol;
CRC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg14558114	chr2:88469736	THNSL2	0.58	5.84	0.31	1.27e-8	Plasma clusterin levels;
CRC	cis	rs354033	0.837	rs6971236	chr7:149184850	A/C	cg24335155	chr7:149193227	ZNF746	-0.44	-6.83	-0.35	4.11e-11	Multiple sclerosis;
CRC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	11.88	0.55	2.51e-27	Platelet count;
CRC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.41	8.0	0.4	2.13e-14	Mean corpuscular volume;
CRC	trans	rs4668356	0.543	rs1989613	chr2:172034292	A/G	cg12499123	chr5:10250085	CCT5;FAM173B	0.66	6.0	0.31	5.3300000000000004e-09	Cognitive performance;
CRC	trans	rs2055729	0.677	rs6990268	chr8:9741171	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.02	-0.31	4.54e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.5	-0.38	6e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.68	8.63	0.43	2.66e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg20608306	chr11:116969690	SIK3	-0.31	-5.64	-0.3	3.58e-8	Subjective well-being;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.36	7.36	0.38	1.51e-12	Lung cancer;
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.67	6.99	0.36	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17209837	1.000	rs45554032	chr7:87078547	G/T	cg00919237	chr7:87102261	ABCB4	-0.47	-5.61	-0.3	4.28e-8	Gallbladder cancer;
CRC	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.54	-7.47	-0.38	7.4e-13	Blood pressure (smoking interaction);
CRC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
CRC	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.69	-9.59	-0.47	2.37e-19	Ileal carcinoids;
CRC	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.89	-0.44	4.04e-17	Schizophrenia;
CRC	cis	rs9648716	1.000	rs765373	chr7:140626976	C/T	cg10747023	chr7:140774559	NA	0.46	6.02	0.31	4.76e-9	Type 2 diabetes;
CRC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.21	-0.32	1.6e-9	Height;
CRC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs12143943	0.866	rs3789051	chr1:204494436	C/T	cg17419461	chr1:204415978	PIK3C2B	0.39	6.02	0.32	4.6e-9	Cognitive performance;
CRC	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg09915433	chr19:53449742	NA	-0.6	-9.1	-0.45	8.63e-18	Psoriasis;
CRC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg04586622	chr2:25135609	ADCY3	0.54	10.11	0.49	4.14e-21	Body mass index;
CRC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs7707921	1.000	rs2407064	chr5:81457358	C/A	cg17942617	chr5:81327376	ATG10	-0.38	-5.66	-0.3	3.34e-8	Breast cancer;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.58	7.61	0.39	2.86e-13	Urate levels in lean individuals;
CRC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.75	11.61	0.54	2.42e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-8.22	-0.41	4.66e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg14345882	chr6:26364793	BTN3A2	0.43	6.65	0.34	1.19e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.51	8.34	0.42	2.07e-15	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg18833306	chr6:118973337	C6orf204	0.46	5.97	0.31	6.28e-9	Diastolic blood pressure;
CRC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg27101125	chr19:17392770	ANKLE1	-0.33	-5.75	-0.3	1.99e-8	Systemic lupus erythematosus;
CRC	cis	rs710987	0.787	rs828544	chr5:3520064	G/T	cg09148417	chr5:3513521	NA	-0.28	-5.64	-0.3	3.72e-8	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.59	8.26	0.41	3.54e-15	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.07	-12.45	-0.57	1.96e-29	Diabetic kidney disease;
CRC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	7.43	0.38	9.15e-13	Parkinson's disease;
CRC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.81	14.16	0.62	7.15e-36	Chronic sinus infection;
CRC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.4	5.92	0.31	8.23e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-1.02	-17.18	-0.69	1.11e-47	Eosinophil percentage of white cells;
CRC	cis	rs7626444	0.543	rs843528	chr3:196480335	G/A	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	cis	rs7091068	0.706	rs4919398	chr10:95429162	C/T	cg20715218	chr10:95462985	C10orf4	0.53	5.83	0.31	1.35e-8	Urinary tract infection frequency;
CRC	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.48	6.08	0.32	3.34e-9	Alzheimer's disease (survival time);
CRC	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.51	-7.68	-0.39	1.82e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.44	5.71	0.3	2.48e-8	Vitiligo;
CRC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.62	-0.39	2.65e-13	Gut microbiome composition (summer);
CRC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs2274471	0.645	rs3780376	chr9:5109485	G/T	cg03390472	chr9:5043263	JAK2	-0.54	-6.3	-0.33	9.67e-10	Crohn's disease;
CRC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.61	7.47	0.38	7.45e-13	Body mass index;
CRC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-6.18	-0.32	1.84e-9	Response to metformin (IC50);
CRC	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.59	-8.01	-0.4	1.96e-14	Body mass index;
CRC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.95	-0.31	6.76e-9	Calcium levels;
CRC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.95	12.36	0.56	4.29e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.7	-0.51	4.06e-23	Monocyte count;
CRC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.41	0.65	1.03e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.33	0.33	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.55	6.11	0.32	2.87e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.89	0.55	2.36e-27	Alzheimer's disease;
CRC	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.63	7.87	0.4	5.27e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg14791747	chr16:20752902	THUMPD1	0.54	6.72	0.35	8.13e-11	Cognitive test performance;
CRC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg14673194	chr17:80132900	CCDC57	0.49	6.37	0.33	6.36e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05863116	chr5:133562407	PPP2CA	0.39	6.19	0.32	1.75e-9	Schizophrenia;
CRC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.16	-0.32	2.17e-9	Bipolar disorder;
CRC	cis	rs863345	0.604	rs11265007	chr1:158498522	C/T	cg12129480	chr1:158549410	OR10X1	0.3	6.31	0.33	8.92e-10	Pneumococcal bacteremia;
CRC	cis	rs17592366	0.517	rs4982219	chr14:35286483	A/T	cg09327582	chr14:35236912	BAZ1A	0.48	6.71	0.35	8.66e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.46	6.07	0.32	3.55e-9	Coronary artery disease;
CRC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-8.75	-0.43	1.16e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg13385794	chr1:248469461	NA	0.37	6.44	0.33	4.21e-10	Common traits (Other);
CRC	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg20019720	chr6:154832845	CNKSR3	0.49	7.92	0.4	3.61e-14	Lipoprotein (a) levels;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.93	-0.31	7.58e-9	Depression;
CRC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.08	10.71	0.51	3.77e-23	Skin colour saturation;
CRC	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.57	8.29	0.42	2.88e-15	Height;
CRC	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	cg04338863	chr8:33670619	NA	0.36	5.69	0.3	2.74e-8	Body mass index;
CRC	cis	rs17767392	0.958	rs10873246	chr14:72153693	A/G	cg13720639	chr14:72061746	SIPA1L1	0.56	7.03	0.36	1.2e-11	Mitral valve prolapse;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.36	0.38	1.44e-12	Cardiac Troponin-T levels;
CRC	trans	rs7604735	0.963	rs957293	chr2:145833187	A/G	cg26010734	chr19:15344046	EPHX3	-0.36	-6.01	-0.31	5.01e-9	Coronary artery disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12044210	chr15:29213858	APBA2	0.37	6.09	0.32	3.1e-9	Interleukin-6 levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21652505	chr19:40023540	EID2B	0.39	6.09	0.32	3.2e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2241685	0.680	rs11695699	chr2:1954444	G/A	cg24940230	chr11:8046101	NA	0.49	6.0	0.31	5.3300000000000004e-09	Attention deficit hyperactivity disorder;
CRC	cis	rs73195822	0.667	rs7967408	chr12:111164408	A/C	cg12870014	chr12:110450643	ANKRD13A	0.75	8.89	0.44	4.07e-17	Itch intensity from mosquito bite;
CRC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-6.07	-0.32	3.59e-9	Carotid intima media thickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17330983	chr14:23770641	PPP1R3E	0.44	6.03	0.32	4.47e-9	Response to antipsychotic treatment;
CRC	cis	rs6604026	0.922	rs12728322	chr1:93294792	C/T	cg17283838	chr1:93427260	FAM69A	0.44	5.6	0.3	4.47e-8	Multiple sclerosis;
CRC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.44	6.61	0.34	1.51e-10	Monobrow;
CRC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.93	-14.93	-0.64	7.46e-39	Gut microbiota (bacterial taxa);
CRC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg13256891	chr4:100009986	ADH5	0.4	5.9	0.31	8.95e-9	Alcohol dependence;
CRC	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-5.86	-0.31	1.11e-8	Schizophrenia;
CRC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	1.04	12.52	0.57	1.13e-29	Eosinophil percentage of granulocytes;
CRC	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg13491945	chr12:107078410	RFX4	0.36	6.18	0.32	1.89e-9	Heart rate;
CRC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg21724239	chr8:58056113	NA	0.58	7.75	0.39	1.17e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg24977027	chr2:88469347	THNSL2	-0.33	-5.64	-0.3	3.71e-8	Response to metformin (IC50);
CRC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.62	0.39	2.66e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg03690763	chr11:133734501	NA	-0.35	-5.86	-0.31	1.14e-8	Childhood ear infection;
CRC	cis	rs117623576	0.680	rs211415	chr10:32397358	C/T	cg03047570	chr10:32398778	NA	0.66	7.04	0.36	1.1e-11	Anti-saccade response;
CRC	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg21153622	chr11:89784906	NA	-0.5	-7.95	-0.4	2.95e-14	HDL cholesterol;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.84	-0.4	6.39e-14	Total body bone mineral density;
CRC	cis	rs16975963	0.790	rs11083434	chr19:38283953	A/G	cg15135657	chr19:38346511	NA	-0.44	-5.89	-0.31	9.55e-9	Longevity;
CRC	cis	rs7605827	0.930	rs13030859	chr2:15701038	G/A	cg19274914	chr2:15703543	NA	0.37	5.63	0.3	3.95e-8	Educational attainment (years of education);
CRC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.4	-0.38	1.16e-12	Retinal vascular caliber;
CRC	trans	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg05555928	chr11:63887634	MACROD1	-0.52	-6.32	-0.33	8.31e-10	Body mass index;
CRC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg24562669	chr7:97807699	LMTK2	-0.61	-11.48	-0.53	6.83e-26	Breast cancer;
CRC	cis	rs185694	1.000	rs846495	chr13:30894250	T/C	cg07600127	chr13:30881527	KATNAL1	-0.56	-5.87	-0.31	1.09e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.08	-0.32	3.37e-9	Height;
CRC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.53	8.43	0.42	1.13e-15	Hemoglobin concentration;Hematocrit;
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04314247	chr1:95286125	SLC44A3	0.47	8.29	0.42	2.84e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.86	0.55	3e-27	Prudent dietary pattern;
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.37	0.5	5.38e-22	Prudent dietary pattern;
CRC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-6.93	-0.36	2.25e-11	Colorectal cancer;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg15845792	chr6:28175446	NA	0.61	8.01	0.4	2.04e-14	Parkinson's disease;
CRC	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg18806716	chr10:30721971	MAP3K8	-0.54	-7.37	-0.38	1.35e-12	Inflammatory bowel disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27051335	chr15:75018733	CYP1A1	0.45	6.14	0.32	2.39e-9	Anxiety disorder;
CRC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	8.83	0.44	6.27e-17	Eosinophil percentage of white cells;
CRC	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.61	-5.68	-0.3	2.93e-8	White matter integrity;
CRC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg15962314	chr1:44399869	ARTN	0.31	5.92	0.31	8.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6585424	1.000	rs12268619	chr10:81920660	A/C	cg11900509	chr10:81946545	ANXA11	-0.72	-8.84	-0.44	5.82e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.49	7.24	0.37	3.1e-12	Blood metabolite levels;
CRC	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	0.91	11.3	0.53	3.14e-25	Red blood cell traits;
CRC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.58	7.99	0.4	2.23e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-11.7	-0.54	1.09e-26	Bipolar disorder (body mass index interaction);
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.47	0.38	7.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.76	-0.39	1.07e-13	Gut microbiome composition (summer);
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg25164649	chr6:28176230	NA	-0.47	-6.87	-0.35	3.25e-11	Cardiac Troponin-T levels;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.09e-10	Bipolar disorder;
CRC	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.44	-6.2	-0.32	1.71e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-9.76	-0.47	6.43e-20	Pancreatic cancer;
CRC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-20.28	-0.75	6.78e-60	Primary sclerosing cholangitis;
CRC	cis	rs7973719	1.000	rs12828040	chr12:7326541	T/C	cg07052231	chr12:7363540	PEX5	0.49	7.99	0.4	2.26e-14	IgG glycosylation;
CRC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.63	9.52	0.46	3.81e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg09567732	chr5:177631413	HNRNPAB	0.47	6.35	0.33	7.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg16892393	chr17:41919603	NA	0.44	6.77	0.35	5.89e-11	Triglycerides;
CRC	cis	rs731174	0.797	rs679742	chr1:38156190	C/G	cg06917450	chr1:38156652	C1orf109	-0.51	-7.09	-0.36	8.17e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	22.33	0.78	6.82e-68	Schizophrenia;
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.07	-0.36	9.21e-12	IgG glycosylation;
CRC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.66	7.99	0.4	2.24e-14	Menarche (age at onset);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg08045063	chr3:43147672	C3orf39	-0.41	-6.05	-0.32	3.98e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.33	0.65	2.06e-40	Platelet count;
CRC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.49	7.07	0.36	9.08e-12	Menopause (age at onset);
CRC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.79	-0.47	5.05e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg19196414	chr17:27188595	MIR451;MIR144	-0.39	-5.69	-0.3	2.82e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.74	-0.68	6.37e-46	Hip circumference;
CRC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.67	10.0	0.48	9.66e-21	Menopause (age at onset);
CRC	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.8	14.64	0.63	1.05e-37	Lewy body disease;
CRC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.16	25.71	0.82	1.07e-80	Triglycerides;
CRC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.6	9.0	0.44	1.86e-17	Lung cancer;
CRC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg13393036	chr8:95962371	TP53INP1	-0.5	-8.14	-0.41	8.28e-15	Alzheimer's disease (late onset);
CRC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.82	0.35	4.24e-11	Morning vs. evening chronotype;
CRC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.41	6.47	0.34	3.59e-10	Hemoglobin concentration;
CRC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.28	-0.42	3.06e-15	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02941859	chr7:99869835	GATS	0.42	6.03	0.32	4.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg00666640	chr1:248458726	OR2T12	0.39	6.9	0.36	2.61e-11	Common traits (Other);
CRC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.29	0.42	2.84e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12474201	0.650	rs56042410	chr2:46914082	A/T	cg06386533	chr2:46925753	SOCS5	0.7	8.64	0.43	2.4e-16	Height;
CRC	cis	rs6496667	0.779	rs10520687	chr15:90967749	C/G	cg04176472	chr15:90893244	GABARAPL3	-0.55	-7.99	-0.4	2.24e-14	Rheumatoid arthritis;
CRC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-12.44	-0.57	2.24e-29	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.37	-0.33	6.31e-10	Alzheimer's disease (late onset);
CRC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.39	0.46	1.06e-18	Parkinson's disease;
CRC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.96	-0.31	6.55e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.79	12.14	0.56	2.89e-28	Testicular germ cell tumor;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.88	0.35	3.02e-11	Obesity-related traits;
CRC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg21251018	chr6:28226885	NKAPL	0.4	6.06	0.32	3.66e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.67	8.87	0.44	4.81e-17	Alzheimer's disease;
CRC	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-6.67	-0.35	1.08e-10	Schizophrenia;
CRC	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.57	-5.87	-0.31	1.07e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	6.12	0.32	2.6e-9	Renal function-related traits (BUN);
CRC	cis	rs6988985	0.728	rs3753121	chr8:143926380	C/T	cg10324643	chr8:143916377	GML	-0.41	-6.8	-0.35	4.8e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.58	-9.43	-0.46	7.71e-19	Myopia (pathological);
CRC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg18512352	chr11:47633146	NA	-0.35	-6.84	-0.35	3.98e-11	Subjective well-being;
CRC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.7	10.63	0.51	6.78e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg23254163	chr1:152506842	NA	0.51	10.18	0.49	2.4e-21	Hair morphology;
CRC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-10.54	-0.5	1.4e-22	Personality dimensions;
CRC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.55	7.68	0.39	1.81e-13	Schizophrenia;
CRC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	7.85	0.4	6.11e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15920310	chr18:55297528	NA	0.41	6.79	0.35	5.41e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.92	-0.36	2.32e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08219700	chr8:58056026	NA	0.59	6.71	0.35	8.27e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg24463073	chr6:118973353	C6orf204	0.52	6.84	0.35	3.84e-11	Diastolic blood pressure;
CRC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg11003573	chr3:44754125	ZNF502	-0.35	-6.07	-0.32	3.43e-9	Depressive symptoms;
CRC	cis	rs4150161	0.656	rs2288025	chr16:84211735	A/C	cg10106505	chr16:84220380	TAF1C	-0.93	-7.93	-0.4	3.36e-14	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg09455208	chr3:40491958	NA	0.31	6.28	0.33	1.06e-9	Renal cell carcinoma;
CRC	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	cis	rs9992667	0.956	rs73232890	chr4:38685041	G/A	cg19726192	chr4:38663646	FLJ13197	-0.7	-8.3	-0.42	2.69e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.12	0.32	2.67e-9	Aortic root size;
CRC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg02018176	chr4:1364513	KIAA1530	0.4	5.77	0.3	1.82e-8	Obesity-related traits;
CRC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.67	8.83	0.44	6.17e-17	Coronary artery disease;
CRC	cis	rs742115	0.563	rs7762842	chr6:11303695	G/A	cg25250968	chr6:11318770	NEDD9	-0.4	-7.67	-0.39	2e-13	Coronary artery disease;
CRC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.83	-0.48	3.76e-20	Height;
CRC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.86	0.44	5.29e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg22532475	chr10:104410764	TRIM8	0.33	5.62	0.3	4e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.85e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg14458575	chr2:238380390	NA	0.53	7.38	0.38	1.29e-12	Prostate cancer;
CRC	cis	rs12760731	0.748	rs10158298	chr1:178470865	G/T	cg00404053	chr1:178313656	RASAL2	0.52	5.89	0.31	9.73e-9	Obesity-related traits;
CRC	trans	rs1607741	1.000	rs962227	chr4:72707517	A/G	cg06437464	chr6:127441704	RSPO3	0.29	6.11	0.32	2.86e-9	Vitamin D levels;
CRC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg13198984	chr17:80129470	CCDC57	0.41	7.18	0.37	4.69e-12	Life satisfaction;
CRC	trans	rs7671189	0.502	rs1114552	chr4:11739301	G/A	cg18054620	chr5:111191530	C5orf13	-0.3	-6.03	-0.32	4.39e-9	Obesity-related traits;
CRC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.81	-11.59	-0.54	2.88e-26	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15048802	chr2:200820651	C2orf60;C2orf47	0.38	6.03	0.32	4.51e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4684776	0.676	rs2067471	chr3:11299602	A/G	cg00170343	chr3:11313890	ATG7	-0.5	-5.87	-0.31	1.04e-8	Small vessel stroke;
CRC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.98	0.55	1.12e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.5	7.08	0.36	8.65e-12	Lymphocyte counts;
CRC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.03	-0.32	4.29e-9	Dupuytren's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09898070	chr2:48009866	MSH6	0.44	7.15	0.37	5.73e-12	Interleukin-6 levels;
CRC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.79	0.54	5.33e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg04110750	chr16:69646130	NFAT5	-0.55	-7.62	-0.39	2.72e-13	IgE levels;
CRC	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs55788414	0.932	rs55991107	chr16:81181066	G/A	cg06400318	chr16:81190750	PKD1L2	-0.66	-6.45	-0.33	4.06e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Parkinson's disease;
CRC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.67	-0.3	3.05e-8	Lung cancer;
CRC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.09	0.41	1.19e-14	Platelet count;
CRC	cis	rs7605827	0.930	rs7605274	chr2:15604269	A/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg05283184	chr6:79620031	NA	-0.43	-6.23	-0.32	1.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs73206853	0.764	rs73191812	chr12:110910279	G/A	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.43e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.84	0.35	3.93e-11	Bipolar disorder;
CRC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.52	0.54	4.92e-26	Prudent dietary pattern;
CRC	cis	rs6496667	0.865	rs62019279	chr15:90882334	G/A	cg04176472	chr15:90893244	GABARAPL3	0.57	6.62	0.34	1.45e-10	Rheumatoid arthritis;
CRC	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.71	-6.99	-0.36	1.58e-11	Non-glioblastoma glioma;Glioma;
CRC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg06636001	chr8:8085503	FLJ10661	0.52	7.83	0.4	6.67e-14	Retinal vascular caliber;
CRC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.46	-7.39	-0.38	1.26e-12	Monocyte count;
CRC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.79	-0.72	5.12e-54	Height;
CRC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg19635926	chr16:89946313	TCF25	0.59	5.8	0.3	1.57e-8	Skin colour saturation;
CRC	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.69	-0.35	9.83e-11	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13611783	chr6:71377394	SMAP1	0.43	6.13	0.32	2.45e-9	Response to antipsychotic treatment;
CRC	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg13491945	chr12:107078410	RFX4	0.34	5.85	0.31	1.21e-8	Heart rate;
CRC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.38	-5.82	-0.31	1.42e-8	Height;
CRC	cis	rs3736485	0.934	rs11635592	chr15:51859786	A/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.64	-0.3	3.67e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.53	6.84	0.35	3.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg21251018	chr6:28226885	NKAPL	0.58	10.15	0.49	3.17e-21	Pubertal anthropometrics;
CRC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg27534772	chr1:16042836	PLEKHM2	0.55	11.0	0.52	3.66e-24	Systolic blood pressure;
CRC	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02598441	chr17:62777298	LOC146880	0.53	7.13	0.37	6.28e-12	QT interval;
CRC	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.52	0.34	2.59e-10	Homocysteine levels;
CRC	cis	rs9462846	0.821	rs10223860	chr6:42875383	T/G	cg21280719	chr6:42927975	GNMT	-0.32	-6.21	-0.32	1.61e-9	Blood protein levels;
CRC	trans	rs10242455	0.702	rs17161700	chr7:98977067	A/G	cg09045935	chr12:6379348	NA	0.88	6.91	0.36	2.57e-11	Blood metabolite levels;
CRC	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.15	-0.37	5.73e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs1887596	0.705	rs541816	chr13:27204062	T/G	cg01312412	chr13:27282625	NA	0.43	5.67	0.3	3.21e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg10820045	chr2:198174542	NA	-0.55	-9.34	-0.46	1.53e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg20487152	chr13:99095054	FARP1	-0.45	-6.5	-0.34	2.99e-10	Neuroticism;
CRC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	10.12	0.49	3.96e-21	Cognitive test performance;
CRC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.77	10.56	0.5	1.17e-22	Height;
CRC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.95	0.4	2.96e-14	Lymphocyte percentage of white cells;
CRC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg24675056	chr1:15929824	NA	0.54	7.43	0.38	9.67e-13	Systolic blood pressure;
CRC	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.63	6.68	0.35	1.05e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.71	-0.3	2.47e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1320333	0.772	rs2867116	chr2:682363	C/A	cg00500140	chr2:691012	NA	0.63	7.01	0.36	1.37e-11	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.48	-7.62	-0.39	2.73e-13	Schizophrenia;
CRC	cis	rs80207740	1.000	rs17296501	chr8:21849566	C/T	cg25597362	chr8:21767310	DOK2	-0.55	-6.66	-0.34	1.14e-10	Mean corpuscular hemoglobin;
CRC	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.51	-9.31	-0.46	1.92e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.61	8.94	0.44	2.96e-17	Lymphocyte counts;
CRC	trans	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg18335740	chr13:41363409	SLC25A15	-0.49	-7.19	-0.37	4.47e-12	Lewy body disease;
CRC	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg15654264	chr1:150340011	RPRD2	-0.4	-5.9	-0.31	8.95e-9	Migraine;
CRC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.56	-8.06	-0.41	1.42e-14	Longevity;
CRC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.62	-11.15	-0.52	1.04e-24	Aortic root size;
CRC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg02527881	chr3:46936655	PTH1R	-0.41	-7.67	-0.39	1.91e-13	Colorectal cancer;
CRC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549328	0.670	rs35992827	chr13:113616752	G/A	cg17524180	chr13:113633600	MCF2L	0.5	9.0	0.44	1.86e-17	Systolic blood pressure;
CRC	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.87	16.53	0.67	4.21e-45	Metabolite levels;
CRC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.22	-0.37	3.72e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg00666640	chr1:248458726	OR2T12	-0.42	-7.56	-0.38	4.04e-13	Common traits (Other);
CRC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.64	6.66	0.34	1.16e-10	Axial length;
CRC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg27661571	chr11:113659931	NA	-0.88	-10.43	-0.5	3.41e-22	Hip circumference adjusted for BMI;
CRC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.38	6.08	0.32	3.31e-9	Major depressive disorder;
CRC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg07125278	chr16:67683757	RLTPR	-0.62	-7.07	-0.36	9.54e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.84	0.31	1.25e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.31	0.49	8.7e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	0.78	9.0	0.44	1.85e-17	Gout;Renal underexcretion gout;
CRC	cis	rs7945718	0.621	rs10831887	chr11:12665436	A/C	cg25843174	chr11:12811716	TEAD1	0.41	7.78	0.39	9.5e-14	Educational attainment (years of education);
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.46	-10.45	-0.5	2.96e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.71	-9.54	-0.47	3.41e-19	Coronary artery disease;
CRC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg07414643	chr4:187882934	NA	0.37	6.38	0.33	5.89e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.54e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.4	-8.88	-0.44	4.57e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs6662572	0.737	rs4660887	chr1:46275959	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.22	-0.32	1.52e-9	Blood protein levels;
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.4	-6.32	-0.33	8.58e-10	Neurofibrillary tangles;
CRC	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.24e-37	Hypertriglyceridemia;
CRC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg02683197	chr6:28174875	NA	0.59	8.33	0.42	2.18e-15	Parkinson's disease;
CRC	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg23229984	chr5:148520753	ABLIM3	0.48	6.89	0.36	2.84e-11	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15564972	chr6:79787561	PHIP	0.41	6.23	0.32	1.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.04e-12	Testicular germ cell tumor;
CRC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs4731207	0.735	rs17147494	chr7:124449835	G/A	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	13.45	0.6	3.62e-33	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17632124	chr6:41040243	C6orf130;NFYA	0.41	6.03	0.32	4.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg03030879	chr14:75389066	RPS6KL1	0.56	9.02	0.45	1.61e-17	Caffeine consumption;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.57	7.09	0.36	8.14e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.92	0.31	8.13e-9	Lung cancer;
CRC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg03013999	chr17:37608204	MED1	-0.47	-7.04	-0.36	1.1e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.08	18.97	0.72	9.43e-55	Dilated cardiomyopathy;
CRC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg04545296	chr12:48745243	ZNF641	0.35	6.09	0.32	3.12e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg08501292	chr6:25962987	TRIM38	0.64	6.31	0.33	8.99e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-6.98	-0.36	1.65e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.42	-6.0	-0.31	5.24e-9	Type 2 diabetes;
CRC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.19	-0.32	1.76e-9	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.14	0.41	8.26e-15	Lung cancer;
CRC	cis	rs55793580	1	rs55793580	chr9:127009395	C/T	cg14385362	chr9:127054095	NEK6	0.4	5.61	0.3	4.2e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;Monocyte count;
CRC	cis	rs8040855	0.627	rs12904238	chr15:85639841	A/T	cg10818794	chr15:86012489	AKAP13	-0.44	-5.97	-0.31	6.09e-9	Bulimia nervosa;
CRC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.63	9.49	0.46	4.71e-19	Lung cancer;
CRC	cis	rs116248771	0.549	rs9811858	chr3:158443093	T/C	cg16708174	chr3:158430962	RARRES1	0.44	5.8	0.3	1.57e-8	diarrhoeal disease at age 2;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg12047218	chr8:125740117	MTSS1	0.36	6.13	0.32	2.54e-9	Myopia;
CRC	cis	rs10486722	0.638	rs10807909	chr7:41796981	T/G	cg22138096	chr7:41772439	LOC285954	0.45	5.64	0.3	3.67e-8	Pit-and-Fissure caries;
CRC	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.59	-0.47	2.35e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.64	-6.18	-0.32	1.86e-9	Diabetic retinopathy;
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	0.7	7.84	0.4	6.44e-14	Body mass index;
CRC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.4	6.75	0.35	6.74e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.97	0.31	6.3e-9	Rheumatoid arthritis;
CRC	cis	rs7945718	0.621	rs10831895	chr11:12683327	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg25164649	chr6:28176230	NA	0.59	6.02	0.32	4.61e-9	Lung cancer in ever smokers;
CRC	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.11	-0.37	7.21e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.47	-6.49	-0.34	3.18e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg16235748	chr6:149772707	ZC3H12D	0.37	6.65	0.34	1.25e-10	Dupuytren's disease;
CRC	cis	rs7527798	0.592	rs2181694	chr1:207826776	G/A	cg09232269	chr1:207846808	CR1L	-0.48	-7.93	-0.4	3.35e-14	Erythrocyte sedimentation rate;
CRC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.48	-0.42	7.94e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.49e-12	Motion sickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17494855	chr1:43855675	C1orf84;MED8	0.4	6.75	0.35	6.5e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11817999	chr17:17655531	RAI1	0.42	6.51	0.34	2.74e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg07153921	chr17:41440717	NA	0.38	5.8	0.3	1.54e-8	Menopause (age at onset);
CRC	cis	rs891088	0.660	rs10413831	chr19:7198377	C/T	cg09779027	chr19:7224513	INSR	-0.53	-6.62	-0.34	1.44e-10	Hip circumference adjusted for BMI;Height;
CRC	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg15654264	chr1:150340011	RPRD2	0.42	6.2	0.32	1.68e-9	Migraine;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg04551154	chr10:95462393	C10orf4	-0.75	-6.36	-0.33	6.93e-10	Cognitive function;
CRC	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.58	8.5	0.42	6.79e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.63	-7.28	-0.37	2.42e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg14791747	chr16:20752902	THUMPD1	-0.67	-10.51	-0.5	1.78e-22	Cognitive test performance;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.49	8.51	0.42	6.42e-16	Hypertriglyceridemia;
CRC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.85	-0.31	1.2e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.54	-6.33	-0.33	8.22e-10	Obesity-related traits;
CRC	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.03	-0.4	1.76e-14	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg01505111	chr6:125621795	HDDC2	0.4	6.42	0.33	4.73e-10	DNA methylation (variation);
CRC	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.44	6.96	0.36	1.8e-11	Platelet count;
CRC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.48	7.43	0.38	9.4e-13	Corneal astigmatism;
CRC	cis	rs6545883	0.524	rs2593631	chr2:61572286	A/G	cg10580144	chr2:61372316	C2orf74	-0.35	-7.81	-0.4	7.8500000000000006e-14	Tuberculosis;
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs17095355	0.818	rs12571549	chr10:111770013	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.49	-5.77	-0.3	1.82e-8	Biliary atresia;
CRC	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg04586622	chr2:25135609	ADCY3	-0.48	-8.51	-0.42	6.11e-16	Body mass index in non-asthmatics;
CRC	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.62	-8.37	-0.42	1.71e-15	Blood pressure (smoking interaction);
CRC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg05342945	chr12:48394962	COL2A1	-0.39	-5.64	-0.3	3.6e-8	Lung cancer;
CRC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.56	8.34	0.42	2.09e-15	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.47	0.53	7.29e-26	Prudent dietary pattern;
CRC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg12046867	chr14:103022105	NA	-0.83	-11.44	-0.53	9.88e-26	Platelet count;
CRC	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg23202291	chr11:1979235	NA	-0.41	-6.01	-0.31	5.06e-9	DNA methylation (variation);
CRC	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg19077165	chr18:44547161	KATNAL2	0.39	5.97	0.31	6.24e-9	Educational attainment;
CRC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg15226275	chr6:116381976	FRK	0.31	8.79	0.44	8.52e-17	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2735413	0.958	rs11150034	chr16:78066369	G/A	cg04733911	chr16:78082701	NA	-0.37	-6.03	-0.32	4.33e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg03013999	chr17:37608204	MED1	-0.48	-7.42	-0.38	9.98e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-6.89	-0.36	2.87e-11	Eye color traits;
CRC	cis	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg18809830	chr7:99032528	PTCD1	-1.03	-7.68	-0.39	1.85e-13	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23394480	chr14:105487615	CDCA4	0.37	5.97	0.31	6.21e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13909320	chr9:125026858	MRRF;RBM18	0.39	6.07	0.32	3.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.41	-6.04	-0.32	4.18e-9	Gout;Renal underexcretion gout;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.56	6.92	0.36	2.3e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	9.35	0.46	1.38e-18	Alzheimer's disease;
CRC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.53	-6.5	-0.34	2.92e-10	Diastolic blood pressure;
CRC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.78	11.66	0.54	1.58e-26	Cognitive function;
CRC	cis	rs7209700	0.708	rs2292699	chr17:45362295	A/G	cg08085267	chr17:45401833	C17orf57	-0.47	-6.97	-0.36	1.73e-11	IgG glycosylation;
CRC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.51	-9.41	-0.46	9.04e-19	Intelligence (multi-trait analysis);
CRC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.99e-17	Schizophrenia;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.52	9.3	0.46	1.96e-18	Hypertriglyceridemia;
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.1	-0.32	3.04e-9	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06731162	chr10:75173949	ANXA7	0.43	5.97	0.31	5.99e-9	Response to antipsychotic treatment;
CRC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.47	-0.46	5.55e-19	Migraine;Coronary artery disease;
CRC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.54	-8.39	-0.42	1.46e-15	Height;
CRC	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.54	-8.14	-0.41	8.3e-15	Body mass index;
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg06494592	chr3:125709126	NA	-0.55	-6.43	-0.33	4.43e-10	Blood pressure (smoking interaction);
CRC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.64	10.28	0.49	1.11e-21	Dental caries;
CRC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg20848291	chr7:100343083	ZAN	0.4	6.19	0.32	1.83e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20712274	chr19:9946111	PIN1	0.39	6.02	0.31	4.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg19678392	chr7:94953810	PON1	-0.6	-7.5	-0.38	6.07e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16872918	chr9:101558330	ANKS6	0.49	6.38	0.33	5.91e-10	Thyroid stimulating hormone;
CRC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.63	9.56	0.47	2.79e-19	Corneal astigmatism;
CRC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg23136738	chr11:925521	AP2A2	-0.48	-7.66	-0.39	2.15e-13	Alzheimer's disease (late onset);
CRC	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg13590978	chr10:43134234	ZNF33B	0.71	5.64	0.3	3.71e-8	Blood protein levels;
CRC	cis	rs2737618	0.651	rs2816974	chr1:200082686	C/G	cg21825944	chr1:200113062	NR5A2	0.49	7.09	0.36	8.28e-12	Uric acid levels;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.44	0.33	4.2e-10	Bipolar disorder;
CRC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.16	23.69	0.79	4.09e-73	IgG glycosylation;
CRC	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.76	8.65	0.43	2.26e-16	Inflammatory bowel disease;
CRC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.48	6.71	0.35	8.29e-11	Lung cancer;
CRC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.45	0.42	9.39e-16	Homoarginine levels;
CRC	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.49	-7.24	-0.37	3.17e-12	Response to antidepressants in depression;
CRC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.6	8.76	0.44	1.02e-16	Monobrow;
CRC	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.3	-6.38	-0.33	6.1e-10	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg12927641	chr6:109611667	NA	-0.33	-5.62	-0.3	4.16e-8	Reticulocyte fraction of red cells;
CRC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg19622623	chr12:86230825	RASSF9	-0.36	-5.81	-0.3	1.51e-8	Major depressive disorder;
CRC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg24375607	chr4:120327624	NA	-0.41	-6.47	-0.34	3.58e-10	Corneal astigmatism;
CRC	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.6	-8.67	-0.43	1.96e-16	Menopause (age at onset);
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.48	-0.34	3.31e-10	Total body bone mineral density;
CRC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg00310523	chr12:86230176	RASSF9	0.43	7.32	0.37	1.97e-12	Major depressive disorder;
CRC	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.67	10.46	0.5	2.59e-22	Corneal astigmatism;
CRC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.43	8.65	0.43	2.24e-16	Renal cell carcinoma;
CRC	cis	rs2274273	0.624	rs7152390	chr14:55811701	C/T	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.82	-0.31	1.4e-8	Protein biomarker;
CRC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg19582491	chr16:67682965	RLTPR	-0.58	-6.89	-0.36	2.81e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.54	-8.22	-0.41	4.73e-15	Body mass index;
CRC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.81	12.32	0.56	6.11e-29	Menarche (age at onset);
CRC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.4	-0.33	5.31e-10	Aortic root size;
CRC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.51	-9.52	-0.46	3.91e-19	Longevity;
CRC	cis	rs11997175	0.967	rs60586868	chr8:33776585	A/G	cg04338863	chr8:33670619	NA	0.36	5.77	0.3	1.81e-8	Body mass index;
CRC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.57	0.39	3.83e-13	Lymphocyte percentage of white cells;
CRC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.53	7.56	0.38	3.97e-13	Cognitive function;
CRC	trans	rs2303319	0.504	rs2020027	chr2:162425878	C/T	cg19471553	chr17:41393123	NA	-0.65	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.68	5.99	0.31	5.43e-9	Breast cancer;
CRC	cis	rs12760731	0.623	rs12038759	chr1:178262700	A/C	cg00404053	chr1:178313656	RASAL2	0.69	8.84	0.44	5.95e-17	Obesity-related traits;
CRC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.76	-12.77	-0.58	1.31e-30	Breast cancer;
CRC	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.47	-6.57	-0.34	1.94e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.08	0.32	3.28e-9	Diabetic kidney disease;
CRC	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.47	7.3	0.37	2.17e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.4	-0.33	5.42e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg20169779	chr10:135381914	SYCE1	-0.64	-10.76	-0.51	2.42e-23	Obesity-related traits;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg26304593	chr6:42947056	PEX6	-0.4	-5.73	-0.3	2.22e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.42e-17	Morning vs. evening chronotype;
CRC	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-6.54	-0.34	2.38e-10	Schizophrenia;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.71	10.51	0.5	1.74e-22	Menarche (age at onset);
CRC	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	7.76	0.39	1.09e-13	Breast cancer;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg06470822	chr6:28175283	NA	0.67	9.07	0.45	1.1e-17	Parkinson's disease;
CRC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs7572644	0.640	rs4555299	chr2:28071190	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.22	0.32	1.48e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.42	0.53	1.15e-25	Bipolar disorder;
CRC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.14	0.45	6.57e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05301818	chr8:125385252	TMEM65	0.48	6.49	0.34	3.15e-10	Survival in pancreatic cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09636849	chr2:96658648	NA	0.52	6.67	0.35	1.09e-10	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg15845792	chr6:28175446	NA	0.76	11.18	0.52	8.44e-25	Parkinson's disease;
CRC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg13390004	chr1:15929781	NA	-0.52	-7.53	-0.38	4.95e-13	Systolic blood pressure;
CRC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.57	-5.9	-0.31	9.26e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	trans	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg07817883	chr1:32538562	TMEM39B	0.59	7.32	0.37	1.95e-12	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.6	8.81	0.44	7.43e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs12618769	0.652	rs3203856	chr2:99226021	C/T	cg18455616	chr2:99124870	INPP4A	0.36	5.96	0.31	6.63e-9	Bipolar disorder;
CRC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs4973397	0.774	rs12998237	chr2:232276651	T/C	cg18859089	chr2:232277014	NA	0.43	5.69	0.3	2.75e-8	Anti-saccade response;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08541953	chr1:6259338	RPL22	0.44	6.21	0.32	1.63e-9	Response to antipsychotic treatment;
CRC	trans	rs75246769	0.925	rs11971144	chr7:145647472	T/C	cg21982490	chr5:124845866	NA	-0.66	-6.12	-0.32	2.72e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00791764	chr4:53727839	RASL11B	0.49	6.55	0.34	2.15e-10	Optic nerve measurement (cup area);
CRC	trans	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg17903999	chr18:56338584	MALT1	0.42	6.97	0.36	1.75e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.59	8.81	0.44	7.33e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.75	11.02	0.52	3.09e-24	Breast cancer;
CRC	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg02811702	chr13:24901961	NA	-0.44	-6.15	-0.32	2.3e-9	Obesity-related traits;
CRC	cis	rs7274811	0.711	rs291691	chr20:32002878	G/C	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.89	0.31	9.59e-9	Height;
CRC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.89	-13.37	-0.59	7.34e-33	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.75	8.75	0.43	1.14e-16	Eosinophilic esophagitis;
CRC	cis	rs6694672	0.867	rs6656448	chr1:197143278	C/T	cg13682187	chr1:196946512	CFHR5	0.46	7.25	0.37	3.09e-12	Asthma;
CRC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.5	-6.75	-0.35	6.49e-11	Lymphocyte counts;Fibrinogen;
CRC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg02321871	chr13:50159138	RCBTB1	-0.42	-6.02	-0.32	4.62e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg21153622	chr11:89784906	NA	-0.51	-8.41	-0.42	1.28e-15	Height;
CRC	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.46	0.42	8.99e-16	Menopause (age at onset);
CRC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.7	-10.33	-0.49	7.33e-22	Intelligence (multi-trait analysis);
CRC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.55	6.17	0.32	1.98e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.67	9.02	0.45	1.59e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6735179	0.837	rs6745451	chr2:1776761	C/T	cg26137290	chr2:1776737	NA	-0.48	-6.3	-0.33	9.75e-10	Response to antipsychotic treatment;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.61	-10.59	-0.5	9.83e-23	Paraoxonase activity;
CRC	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.68	-8.2	-0.41	5.35e-15	Response to hepatitis C treatment;
CRC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg18761221	chr20:60518478	NA	0.46	7.58	0.39	3.55e-13	Body mass index;
CRC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.61	10.44	0.5	3.2e-22	Prudent dietary pattern;
CRC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.62	7.11	0.36	7.24e-12	Resting heart rate;
CRC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.6	8.58	0.43	3.68e-16	Tuberculosis;
CRC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.48	7.95	0.4	3.03e-14	Crohn's disease;
CRC	cis	rs1472147	0.955	rs3736614	chr7:128509048	T/G	cg00260937	chr7:128520193	KCP	0.49	7.31	0.37	2.07e-12	Calcium levels;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg04362960	chr10:104952993	NT5C2	-0.41	-5.69	-0.3	2.86e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg20354231	chr13:53171401	NA	-0.46	-7.38	-0.38	1.31e-12	Lewy body disease;
CRC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.39	-6.77	-0.35	5.85e-11	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg26373071	chr5:1325741	CLPTM1L	0.44	7.63	0.39	2.57e-13	Lung cancer;
CRC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.42	0.53	1.12e-25	Prudent dietary pattern;
CRC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg20243544	chr17:37824526	PNMT	0.44	6.69	0.35	9.8e-11	Self-reported allergy;
CRC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.56	8.89	0.44	4.23e-17	Type 2 diabetes;
CRC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.76	0.44	1.03e-16	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01719123	chr8:28244050	ZNF395	0.42	6.05	0.32	4.04e-9	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.64	11.86	0.55	3.03e-27	Bone mineral density;
CRC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.45	6.32	0.33	8.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4074493	1.000	rs4075892	chr1:231171807	G/A	cg22172038	chr1:231176991	FAM89A	0.35	5.92	0.31	7.89e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.75	0.68	5.43e-46	Chronic sinus infection;
CRC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05561993	chr7:140373033	ADCK2	0.46	6.41	0.33	5.06e-10	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26257210	chr1:6305348	HES3	0.43	6.9	0.36	2.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.55	7.68	0.39	1.78e-13	Triglycerides;
CRC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	7.73	0.39	1.29e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.37	5.73	0.3	2.28e-8	Longevity;Endometriosis;
CRC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.81	11.01	0.52	3.33e-24	Initial pursuit acceleration;
CRC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg21251018	chr6:28226885	NKAPL	0.53	8.87	0.44	4.63e-17	Depression;
CRC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26434548	chr7:129074607	FAM40B	0.38	6.19	0.32	1.79e-9	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.47e-8	Prudent dietary pattern;
CRC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.63	-0.3	3.92e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7313075	0.636	rs79850286	chr12:102471758	T/C	cg00456892	chr11:124629925	ESAM	-0.41	-5.97	-0.31	6.32e-9	Height;
CRC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.53	-7.79	-0.39	8.94e-14	Melanoma;
CRC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg11843238	chr5:131593191	PDLIM4	0.31	5.7	0.3	2.73e-8	Blood metabolite levels;
CRC	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.65	-10.13	-0.49	3.73e-21	Melanoma;
CRC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg26721908	chr21:47610096	LSS	0.4	6.17	0.32	1.96e-9	Testicular germ cell tumor;
CRC	cis	rs12541635	0.966	rs4734895	chr8:107002604	A/G	cg10147462	chr8:107024639	NA	0.45	7.28	0.37	2.44e-12	Age of smoking initiation;
CRC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.58	8.57	0.43	4.13e-16	Heart rate;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.26	-0.37	2.86e-12	Bipolar disorder;
CRC	cis	rs4664293	0.605	rs6745815	chr2:160550069	C/G	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.6200000000000003e-10	Monocyte percentage of white cells;
CRC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.5	0.38	5.84e-13	Mean platelet volume;
CRC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.71	0.43	1.53e-16	Morning vs. evening chronotype;
CRC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg16358738	chr2:241808595	AGXT	-0.39	-5.79	-0.3	1.68e-8	Urinary metabolites;
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.91	-0.48	2.03e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.61	-7.81	-0.4	7.54e-14	Gut microbiome composition (summer);
CRC	cis	rs755249	0.567	rs4660603	chr1:39736334	C/G	cg18385671	chr1:39797026	MACF1	0.41	5.83	0.31	1.33e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs775227	0.636	rs3773697	chr3:113023509	C/T	cg18753928	chr3:113234510	CCDC52	-0.6	-6.84	-0.35	3.84e-11	Dental caries;
CRC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.49	-0.34	3.24e-10	Aortic root size;
CRC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.53	-0.67	4.22e-45	Height;
CRC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg07074390	chr21:40555500	PSMG1	-0.43	-5.84	-0.31	1.23e-8	Cognitive function;
CRC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg02421172	chr7:1938701	MAD1L1	0.44	5.94	0.31	7.14e-9	Bipolar disorder;
CRC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.41	6.59	0.34	1.74e-10	Major depressive disorder;
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.81	12.68	0.57	2.94e-30	Menarche (age at onset);
CRC	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.13	-18.76	-0.72	6.3e-54	Ulcerative colitis;
CRC	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg00490450	chr3:139108681	COPB2	0.44	6.59	0.34	1.77e-10	Obesity-related traits;
CRC	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-6.94	-0.36	2.13e-11	Menarche (age at onset);
CRC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.42	-5.97	-0.31	6.08e-9	Daytime sleep phenotypes;
CRC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.67	10.89	0.51	8.79e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25722142	chr6:139695762	CITED2	0.48	6.3	0.33	9.5e-10	Thyroid stimulating hormone;
CRC	trans	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	3.08e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs4902562	0.838	rs6573823	chr14:68733632	A/G	cg08903604	chr17:2305559	MNT	0.46	5.96	0.31	6.43e-9	Systemic lupus erythematosus;
CRC	cis	rs354033	0.959	rs4727091	chr7:149267704	G/A	cg24335155	chr7:149193227	ZNF746	0.37	6.0	0.31	5.18e-9	Multiple sclerosis;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.37	0.5	5.38e-22	Prudent dietary pattern;
CRC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg16558177	chr4:4109446	NA	-0.56	-6.35	-0.33	7.02e-10	Blood pressure (smoking interaction);
CRC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg15147215	chr3:52552868	STAB1	-0.54	-8.89	-0.44	4.25e-17	Electroencephalogram traits;
CRC	cis	rs9287719	0.624	rs6740245	chr2:10760902	T/C	cg00105475	chr2:10696890	NA	0.44	6.89	0.36	2.83e-11	Prostate cancer;
CRC	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg14593290	chr7:50529359	DDC	-0.44	-6.39	-0.33	5.56e-10	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20609752	chr19:7894982	EVI5L	0.37	6.02	0.31	4.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.52	6.49	0.34	3.09e-10	Vitiligo;
CRC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.61	9.25	0.45	2.93e-18	Corneal astigmatism;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.83	-0.31	1.34e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	6.65	0.34	1.19e-10	Breast cancer;
CRC	cis	rs2274273	0.624	rs68138420	chr14:55777967	G/T	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.66	-0.3	3.28e-8	Protein biomarker;
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg21856205	chr7:94953877	PON1	-0.51	-6.52	-0.34	2.69e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.77	-10.49	-0.5	2.11e-22	White matter hyperintensity burden;
CRC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.53	7.46	0.38	7.87e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.69	9.64	0.47	1.56e-19	Lung cancer;
CRC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.49	7.46	0.38	7.86e-13	Corneal astigmatism;
CRC	cis	rs6952808	0.724	rs7792631	chr7:1982779	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	7.6	0.39	3.15e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.41	6.35	0.33	7.15e-10	Red blood cell count;
CRC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg15786705	chr6:28176104	NA	0.6	8.75	0.43	1.09e-16	Parkinson's disease;
CRC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg16476235	chr8:21771668	DOK2	-0.38	-6.39	-0.33	5.68e-10	Mean corpuscular volume;
CRC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.6	-0.39	3.09e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02636234	chr1:212781466	ATF3	0.49	6.96	0.36	1.87e-11	Response to antipsychotic treatment;
CRC	cis	rs3931020	0.745	rs10874274	chr1:75252134	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.41	5.66	0.3	3.25e-8	Resistin levels;
CRC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg09796270	chr17:17721594	SREBF1	-0.53	-9.09	-0.45	9.22e-18	Body mass index;
CRC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.54	7.42	0.38	1e-12	Height;
CRC	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.37	6.47e-12	Caudate activity during reward;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.67	7.71	0.39	1.48e-13	Body mass index;
CRC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg01692110	chr13:113365389	ATP11A	0.51	6.13	0.32	2.56e-9	Glycated hemoglobin levels;
CRC	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg18240653	chr6:144019428	PHACTR2	-0.55	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-5.81	-0.31	1.46e-8	Axial length;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg03623178	chr6:28175578	NA	0.79	11.69	0.54	1.22e-26	Cardiac Troponin-T levels;
CRC	cis	rs12913538	0.962	rs4775517	chr15:62885173	A/G	cg09983546	chr15:62884068	NA	0.63	10.01	0.48	9.15e-21	Sleep depth;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg21251018	chr6:28226885	NKAPL	0.47	6.38	0.33	6.15e-10	Parkinson's disease;
CRC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.27	-0.33	1.11e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs338389	0.516	rs6416484	chr15:68312776	T/C	cg22576950	chr15:68522787	CLN6	-0.34	-5.8	-0.3	1.53e-8	Survival in rectal cancer;
CRC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.76	0.3	1.92e-8	Coronary artery disease;
CRC	cis	rs11955398	0.625	rs34395679	chr5:59954716	A/G	cg02684056	chr5:59996105	DEPDC1B	0.4	5.83	0.31	1.31e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-7.42	-0.38	1.03e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.33	-0.33	8.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg05585544	chr11:47624801	NA	0.47	8.55	0.43	4.83e-16	Subjective well-being;
CRC	trans	rs4346635	0.528	rs6835442	chr4:81413207	G/C	cg13904968	chr20:56136012	PCK1	-0.18	-5.97	-0.31	6.28e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg15192750	chr16:69999425	NA	0.53	6.89	0.35	2.92e-11	IgE levels;
CRC	cis	rs12541635	0.966	rs6469028	chr8:107014552	C/T	cg10147462	chr8:107024639	NA	0.41	6.73	0.35	7.62e-11	Age of smoking initiation;
CRC	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.33e-10	Vitamin D levels;
CRC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.88	-0.48	2.44e-20	Bladder cancer;
CRC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.75	12.89	0.58	4.75e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.98	0.4	2.44e-14	Diabetic kidney disease;
CRC	cis	rs7202877	0.706	rs247438	chr16:75432649	C/G	cg03315344	chr16:75512273	CHST6	-0.47	-5.61	-0.3	4.29e-8	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08540010	chr20:48770450	TMEM189;TMEM189-UBE2V1	0.4	6.23	0.32	1.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.67	-11.62	-0.54	2.26e-26	Brugada syndrome;
CRC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-7.15	-0.37	5.76e-12	Neuroticism;
CRC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.63	-10.88	-0.51	9.62e-24	Coronary artery disease;
CRC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg14530993	chr4:882597	GAK	0.75	6.88	0.35	3.02e-11	Parkinson's disease;
CRC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.56	7.83	0.4	6.85e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg21132104	chr15:45694354	SPATA5L1	0.4	5.8	0.3	1.57e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.23e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg20607798	chr8:58055168	NA	0.51	5.79	0.3	1.66e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg02869306	chr7:64672164	INTS4L1	0.43	6.23	0.32	1.41e-9	Aortic root size;
CRC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.89	0.35	2.9e-11	Cognitive test performance;
CRC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg01721255	chr8:58191610	C8orf71	0.51	6.33	0.33	7.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg25985355	chr7:65971099	NA	-0.48	-5.75	-0.3	2e-8	Diabetic kidney disease;
CRC	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	1.2	9.69	0.47	1.09e-19	Arsenic metabolism;
CRC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.77	-0.72	6.17e-54	Height;
CRC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.73	14.07	0.61	1.56e-35	Body mass index;
CRC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.14	0.41	8.41e-15	Menopause (age at onset);
CRC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg04545296	chr12:48745243	ZNF641	0.33	5.73	0.3	2.26e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.52	8.48	0.42	7.77e-16	Prostate cancer;
CRC	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.81	12.33	0.56	5.67e-29	Testicular germ cell tumor;
CRC	cis	rs10208940	0.920	rs6742045	chr2:68811850	G/A	cg12452813	chr2:68675892	NA	0.48	6.0	0.31	5.28e-9	Urate levels in lean individuals;
CRC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.48	5.68	0.3	3.04e-8	Dental caries;
CRC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg10760299	chr15:45669010	GATM	0.49	7.74	0.39	1.23e-13	Homoarginine levels;
CRC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.51e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.51	7.19	0.37	4.25e-12	Melanoma;
CRC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg20684491	chr1:25596433	NA	-0.42	-7.64	-0.39	2.37e-13	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg08200770	chr17:80723486	TBCD	-0.49	-7.66	-0.39	2.08e-13	Glycated hemoglobin levels;
CRC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.59	-8.67	-0.43	2.02e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13338022	chr15:43029438	CDAN1	0.49	6.44	0.33	4.26e-10	Thyroid stimulating hormone;
CRC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18252515	chr7:66147081	NA	0.4	5.77	0.3	1.83e-8	Aortic root size;
CRC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.03	9.84	0.48	3.45e-20	Skin colour saturation;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg02683197	chr6:28174875	NA	0.65	9.06	0.45	1.22e-17	Cardiac Troponin-T levels;
CRC	cis	rs2559856	1.000	rs2695281	chr12:102089999	G/A	cg12924262	chr12:102091054	CHPT1	0.54	8.03	0.4	1.72e-14	Blood protein levels;
CRC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.61	-11.51	-0.54	5.37e-26	Educational attainment;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22012835	chr19:44598275	ZNF224	-0.4	-6.2	-0.32	1.71e-9	Aortic root size;
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.22	0.32	1.48e-9	Bipolar disorder;
CRC	cis	rs6000550	0.954	rs13055107	chr22:37469821	G/A	cg06230247	chr22:37420730	MPST	0.52	5.9	0.31	9.07e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
CRC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.64	10.72	0.51	3.48e-23	Platelet count;
CRC	cis	rs11212617	1.000	rs227088	chr11:108243755	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.58	0.34	1.85e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7703744	0.681	rs3797342	chr5:118691832	C/T	cg02283238	chr5:118691126	TNFAIP8	0.45	6.08	0.32	3.35e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg00531865	chr16:30841666	NA	-0.44	-5.68	-0.3	2.96e-8	Dementia with Lewy bodies;
CRC	cis	rs939584	1.000	rs7608050	chr2:652247	G/A	cg03610516	chr2:642275	NA	-0.42	-5.77	-0.3	1.82e-8	Body mass index;
CRC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg01721255	chr8:58191610	C8orf71	0.47	5.98	0.31	5.81e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.45	-0.62	5.56e-37	Body mass index;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.44	-0.38	8.72e-13	Body mass index;
CRC	cis	rs6499255	0.951	rs9788837	chr16:69688413	A/G	cg04110750	chr16:69646130	NFAT5	-0.57	-7.85	-0.4	6.01e-14	IgE levels;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12172441	chr6:28176163	NA	0.6	7.29	0.37	2.34e-12	Parkinson's disease;
CRC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.8	-11.42	-0.53	1.15e-25	Cognitive function;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02005709	chr14:92492924	TRIP11	-0.53	-7.26	-0.37	2.81e-12	Hip circumference;
CRC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg20243544	chr17:37824526	PNMT	0.55	8.74	0.43	1.17e-16	Asthma;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg21251018	chr6:28226885	NKAPL	0.39	6.08	0.32	3.31e-9	Hepatitis A;
CRC	cis	rs7258465	0.965	rs748609	chr19:18560282	T/C	cg06462663	chr19:18546047	ISYNA1	0.49	7.27	0.37	2.64e-12	Breast cancer;
CRC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.4	6.55	0.34	2.26e-10	Huntington's disease progression;
CRC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.1	0.32	2.98e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.37	6.51	0.34	2.89e-10	Crohn's disease;
CRC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-6.1	-0.32	3.01e-9	Carotid intima media thickness;
CRC	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.52	-0.71	6.06e-53	Schizophrenia;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	cis	rs6066835	1.000	rs6066830	chr20:47353897	C/T	cg18078177	chr20:47281410	PREX1	0.63	5.75	0.3	2.01e-8	Multiple myeloma;
CRC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.5	1.25e-22	Heart rate;
CRC	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.75	-0.3	2e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	1.08	9.82	0.48	3.92e-20	Arsenic metabolism;
CRC	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.54	-7.57	-0.39	3.76e-13	Coronary artery disease;
CRC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.04	-0.55	6.3e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg23461800	chr14:103021989	NA	0.68	7.81	0.4	7.79e-14	Platelet count;
CRC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.7	0.39	1.62e-13	Platelet count;
CRC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg23758597	chr6:163146217	PARK2	-0.68	-6.73	-0.35	7.44e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.32	-5.6	-0.3	4.51e-8	Personality dimensions;
CRC	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.51	-7.86	-0.4	5.42e-14	Diastolic blood pressure;
CRC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.57	-8.21	-0.41	5.2e-15	Menarche (age at onset);
CRC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.77	13.75	0.6	2.58e-34	Metabolic syndrome;
CRC	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg26576206	chr19:1064938	ABCA7	0.4	5.73	0.3	2.22e-8	Alzheimer's disease (late onset);
CRC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.67	-9.01	-0.44	1.73e-17	DNA methylation (variation);
CRC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.51	6.93	0.36	2.17e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.63	-0.39	2.51e-13	Psoriasis;
CRC	cis	rs75422866	0.867	rs73102201	chr12:48063052	G/A	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	trans	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg21153622	chr11:89784906	NA	-0.47	-7.5	-0.38	6.05e-13	HDL cholesterol;
CRC	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.5	-6.2	-0.32	1.65e-9	Height;
CRC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.62	11.46	0.53	7.93e-26	Bone mineral density;
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.81	-0.3	1.5e-8	Neuroticism;
CRC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.87	-12.12	-0.56	3.34e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.67	9.07	0.45	1.14e-17	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.76	8.07	0.41	1.31e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.47	-0.34	3.62e-10	Caffeine consumption;
CRC	cis	rs8049040	0.547	rs12934168	chr16:71436778	C/T	cg08717414	chr16:71523259	ZNF19	-0.41	-5.61	-0.3	4.4e-8	Blood protein levels;
CRC	trans	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg24644049	chr4:85504048	CDS1	0.84	7.48	0.38	6.98e-13	Skin colour saturation;
CRC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.9	-10.21	-0.49	1.89e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg20885578	chr2:198174922	NA	0.36	5.77	0.3	1.85e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg25600027	chr14:23388339	RBM23	-0.53	-8.37	-0.42	1.63e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.75	-7.61	-0.39	2.89e-13	Inflammatory biomarkers;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05657792	chr17:6899758	ALOX12	-0.45	-8.18	-0.41	6.45e-15	Tonsillectomy;
CRC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg19223190	chr17:80058835	NA	-0.44	-7.16	-0.37	5.41e-12	Life satisfaction;
CRC	cis	rs4728302	0.869	rs10255193	chr7:133608911	C/G	cg10665199	chr7:133106180	EXOC4	0.39	5.8	0.3	1.56e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.4	6.51	0.34	2.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3736485	0.578	rs2305716	chr15:51981291	C/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.86	-0.31	1.14e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg17810781	chr1:201082982	CACNA1S	0.4	6.73	0.35	7.7e-11	Permanent tooth development;
CRC	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg18196295	chr10:418757	DIP2C	0.54	8.05	0.41	1.52e-14	Psychosis in Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10070151	chr19:39881965	MED29;PAF1	0.44	6.46	0.34	3.78e-10	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	5.86	0.31	1.1e-8	Tonsillectomy;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg02683197	chr6:28174875	NA	0.85	10.69	0.51	4.25e-23	Depression;
CRC	trans	rs10021731	0.718	rs2199310	chr4:115413402	G/A	cg25927708	chr2:119603813	EN1	-0.33	-6.02	-0.31	4.78e-9	Optic disc area;
CRC	trans	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg17903999	chr18:56338584	MALT1	0.42	6.93	0.36	2.17e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.7	-0.39	1.65e-13	Psoriasis;
CRC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg21747405	chr11:67723411	NA	-0.49	-6.32	-0.33	8.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.84	18.44	0.71	1.21e-52	Breast cancer;
CRC	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg21064579	chr19:49206444	FUT2	0.47	8.18	0.41	6.16e-15	Dietary macronutrient intake;
CRC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.13	-0.49	3.47e-21	Monocyte count;
CRC	cis	rs12580194	0.593	rs12581959	chr12:55787311	G/A	cg19537932	chr12:55886519	OR6C68	-0.74	-8.88	-0.44	4.44e-17	Cancer;
CRC	cis	rs755249	0.567	rs112672438	chr1:39646787	C/T	cg18385671	chr1:39797026	MACF1	-0.41	-5.93	-0.31	7.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.44	-6.61	-0.34	1.56e-10	Response to fenofibrate (adiponectin levels);
CRC	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg24045832	chr17:1955481	NA	0.36	5.66	0.3	3.37e-8	Total body bone mineral density;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg22079747	chr2:228736145	WDR69	-0.42	-5.72	-0.3	2.37e-8	Blood pressure;
CRC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	0.53	8.92	0.44	3.38e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10861342	1.000	rs7305712	chr12:105519188	A/T	cg23923672	chr12:105501055	KIAA1033	-0.6	-5.73	-0.3	2.28e-8	IgG glycosylation;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg01874867	chr7:94954059	PON1	-0.54	-6.57	-0.34	1.99e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2108622	0.727	rs62106155	chr19:15980360	G/C	cg13772218	chr19:15982569	NA	0.48	6.82	0.35	4.37e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.53	7.54	0.38	4.74e-13	Testicular germ cell tumor;
CRC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.55	6.58	0.34	1.82e-10	Bipolar disorder;
CRC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.67	9.85	0.48	3.2e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.6	0.34	1.62e-10	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs12714668	0.502	rs6549114	chr3:86819661	C/T	cg13618939	chr10:46090486	MARCH8	-0.47	-6.06	-0.32	3.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.47	6.88	0.35	3.05e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2859741	0.565	rs11263962	chr1:37509239	C/T	cg09363841	chr1:37513479	NA	-0.47	-7.26	-0.37	2.72e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.67	-0.47	1.25e-19	Height;
CRC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.56	-7.76	-0.39	1.1e-13	DNA methylation (variation);
CRC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.47	7.0	0.36	1.48e-11	Menarche (age at onset);
CRC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	6.72	0.35	8.06e-11	Hip circumference adjusted for BMI;
CRC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.69	8.16	0.41	7.03e-15	Gut microbiome composition (summer);
CRC	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.47	8.04	0.41	1.64e-14	Testicular germ cell tumor;
CRC	cis	rs73200209	0.833	rs2161859	chr12:116455513	A/T	cg01776926	chr12:116560359	MED13L	-0.47	-5.9	-0.31	9.12e-9	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22715954	chr12:58146426	CDK4	0.43	6.05	0.32	3.91e-9	Response to antipsychotic treatment;
CRC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-14.42	-0.62	7.2e-37	Ulcerative colitis;
CRC	trans	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00938859	chr5:1591904	SDHAP3	0.67	6.13	0.32	2.45e-9	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12223105	chr20:4153034	SMOX	0.41	6.42	0.33	4.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg11766577	chr21:47581405	C21orf56	0.35	5.73	0.3	2.26e-8	Testicular germ cell tumor;
CRC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.54	8.85	0.44	5.52e-17	Coronary artery disease;
CRC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.54	-8.1	-0.41	1.07e-14	Blood protein levels;
CRC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.61	9.12	0.45	7.84e-18	Mean platelet volume;Platelet distribution width;
CRC	trans	rs10207628	1.000	rs76168490	chr2:127850618	C/G	cg22628694	chr19:58663362	ZNF329	0.57	6.08	0.32	3.36e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.59	8.97	0.44	2.24e-17	Monobrow;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg04553112	chr3:125709451	NA	-0.49	-5.69	-0.3	2.84e-8	Blood pressure (smoking interaction);
CRC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.12	-0.32	2.63e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.58	10.83	0.51	1.45e-23	Eye color traits;
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.29e-11	Alzheimer's disease;
CRC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	8.68	0.43	1.83e-16	Height;
CRC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-5.61	-0.3	4.23e-8	Coronary artery disease;
CRC	cis	rs6968419	0.755	rs17138486	chr7:115894403	C/G	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.48e-10	Intraocular pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11556929	chr2:240323605	HDAC4	0.45	6.28	0.33	1.06e-9	Anxiety disorder;
CRC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.17	-0.37	5.12e-12	Response to antipsychotic treatment;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg22385477	chr4:186392754	CCDC110	-0.42	-6.33	-0.33	8.12e-10	Birth weight;Height;
CRC	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg06307176	chr5:131281290	NA	-0.37	-5.78	-0.3	1.74e-8	Life satisfaction;
CRC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.48	-7.73	-0.39	1.36e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.68	10.49	0.5	2.15e-22	Corneal astigmatism;
CRC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.95	0.4	3.02e-14	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg12273811	chr6:28175739	NA	0.6	8.82	0.44	7e-17	Parkinson's disease;
CRC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.14	-0.32	2.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg06145435	chr7:1022769	CYP2W1	-0.41	-5.85	-0.31	1.22e-8	Bronchopulmonary dysplasia;
CRC	trans	rs6546324	0.625	rs6746394	chr2:67845021	A/C	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.21	-0.32	1.6e-9	Endometriosis;
CRC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.78	-11.7	-0.54	1.16e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.79	-0.3	1.67e-8	Ulcerative colitis;
CRC	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg13086574	chr8:135490821	ZFAT	-0.37	-6.36	-0.33	6.63e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.45	0.6	3.81e-33	Platelet count;
CRC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.21	-0.37	3.92e-12	Coronary artery disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17675882	chr20:35374068	NDRG3	-0.55	-6.78	-0.35	5.71e-11	Diisocyanate-induced asthma;
CRC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23200371	chr12:56367680	RAB5B	-0.4	-6.14	-0.32	2.33e-9	Myopia (pathological);
CRC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.52	5.71	0.3	2.5e-8	Menarche (age at onset);
CRC	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.82	-0.35	4.36e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.45	-6.57	-0.34	2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg01475377	chr6:109611718	NA	-0.33	-5.79	-0.3	1.62e-8	Reticulocyte fraction of red cells;
CRC	cis	rs17209837	1.000	rs2302385	chr7:87091826	T/C	cg00919237	chr7:87102261	ABCB4	-0.47	-5.63	-0.3	3.84e-8	Gallbladder cancer;
CRC	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.87	-16.95	-0.68	9.45e-47	Multiple myeloma;
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.24	-0.37	3.14e-12	Bipolar disorder;
CRC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg15744005	chr10:104629667	AS3MT	-0.3	-5.97	-0.31	6.19e-9	Arsenic metabolism;
CRC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg03013999	chr17:37608204	MED1	0.45	6.92	0.36	2.36e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.5	6.65	0.34	1.24e-10	Height;
CRC	cis	rs11264799	0.598	rs12567349	chr1:157731186	G/A	cg11810135	chr1:157771971	FCRL1	0.39	6.01	0.31	4.95e-9	IgA nephropathy;
CRC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.46	-6.36	-0.33	6.58e-10	Lung cancer;
CRC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.58	-7.83	-0.4	6.6e-14	Coronary artery disease;
CRC	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg04202892	chr2:111875749	ACOXL	0.43	6.94	0.36	2.09e-11	Chronic lymphocytic leukemia;
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.09	-0.32	3.23e-9	Total body bone mineral density;
CRC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.73	-0.3	2.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.47	0.46	5.5e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.15	-0.32	2.23e-9	Educational attainment (years of education);
CRC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg15445000	chr17:37608096	MED1	-0.35	-6.22	-0.32	1.48e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg12845895	chr18:77676008	PQLC1	0.43	6.17	0.32	2.04e-9	Schizophrenia;
CRC	cis	rs4750440	0.585	rs10508470	chr10:14021822	G/A	cg00551146	chr10:14014579	FRMD4A	0.47	7.47	0.38	7.45e-13	Adiponectin levels;
CRC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg06462663	chr19:18546047	ISYNA1	0.5	7.4	0.38	1.16e-12	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14035508	chr11:124543525	SIAE;SPA17	0.42	6.17	0.32	2.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg12315302	chr6:26189340	HIST1H4D	0.96	6.61	0.34	1.58e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.15	0.32	2.19e-9	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.33	-0.33	8.25e-10	Aortic root size;
CRC	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-5.7	-0.3	2.69e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.08	12.64	0.57	3.89e-30	Sexual dysfunction (female);
CRC	cis	rs2249694	1.000	rs2480258	chr10:135352100	T/C	cg16964102	chr10:135390573	NA	-0.38	-6.21	-0.32	1.57e-9	Obesity-related traits;
CRC	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.48	7.36	0.38	1.53e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-6.11	-0.32	2.84e-9	Cognitive function;
CRC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.74	-0.3	2.13e-8	Tonsillectomy;
CRC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg00343986	chr7:65444356	GUSB	0.49	7.42	0.38	1e-12	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00986762	chr1:36107072	PSMB2	0.48	6.21	0.32	1.56e-9	Thyroid stimulating hormone;
CRC	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.51	5.71	0.3	2.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.65	0.54	1.65e-26	Prudent dietary pattern;
CRC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg17810781	chr1:201082982	CACNA1S	0.41	6.79	0.35	5.16e-11	Permanent tooth development;
CRC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.1	-0.36	7.67e-12	Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22478328	chr22:32340140	C22orf24;YWHAH	0.56	7.38	0.38	1.3e-12	Thyroid stimulating hormone;
CRC	trans	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg10756647	chr7:56101905	PSPH	0.71	7.54	0.38	4.76e-13	Diabetic kidney disease;
CRC	cis	rs7487075	0.856	rs1079780	chr12:46736023	C/T	cg22049899	chr12:47219821	SLC38A4	0.33	6.15	0.32	2.23e-9	Itch intensity from mosquito bite;
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg21155852	chr7:2048760	MAD1L1	-0.47	-6.16	-0.32	2.14e-9	Neuroticism;
CRC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg12463550	chr7:65579703	CRCP	0.63	5.98	0.31	5.8e-9	Diabetic kidney disease;
CRC	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.51	-0.34	2.86e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg04362960	chr10:104952993	NT5C2	-0.43	-6.03	-0.32	4.4e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg06606381	chr12:133084897	FBRSL1	0.6	6.01	0.31	4.93e-9	Depression;
CRC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.46	-6.49	-0.34	3.17e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg21620606	chr4:1342894	KIAA1530	0.38	6.4	0.33	5.46e-10	Obesity-related traits;
CRC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg26762873	chr11:5879799	OR52E8	-0.48	-7.48	-0.38	6.84e-13	DNA methylation (variation);
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.64	-10.07	-0.49	5.74e-21	Lymphocyte counts;
CRC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.61	-9.74	-0.47	7.11e-20	Total body bone mineral density;
CRC	cis	rs863345	0.604	rs7518708	chr1:158504274	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg15786705	chr6:28176104	NA	0.49	6.99	0.36	1.5e-11	Parkinson's disease;
CRC	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.48	-6.18	-0.32	1.85e-9	Alopecia areata;
CRC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.82	0.31	1.43e-8	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04787407	chr4:99916511	METAP1	0.53	7.58	0.39	3.66e-13	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg27661571	chr11:113659931	NA	-0.95	-11.08	-0.52	1.91e-24	Hip circumference adjusted for BMI;
CRC	cis	rs4853036	0.597	rs1048165	chr2:70131964	A/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.96	-0.31	6.66e-9	Colorectal or endometrial cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10891888	chr12:46765615	SLC38A2	0.44	6.24	0.33	1.34e-9	Response to antipsychotic treatment;
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.84	10.23	0.49	1.71e-21	Lung function (FEV1/FVC);
CRC	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.47	0.65	6.02e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25517755	chr10:38738941	LOC399744	0.42	5.98	0.31	5.86e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.98	0.4	2.43e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.96	12.52	0.57	1.15e-29	Vitiligo;
CRC	cis	rs1950626	0.743	rs12884454	chr14:101465627	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	15.63	0.65	1.37e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-9.18	-0.45	4.75e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg23193639	chr7:45961078	IGFBP3	0.4	6.69	0.35	9.88e-11	Sitting height ratio;
CRC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg17321639	chr7:2759063	NA	-0.53	-7.11	-0.37	7.11e-12	Height;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg20540378	chr5:149340137	SLC26A2	0.44	6.11	0.32	2.88e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.92	-0.4	3.71e-14	Gut microbiome composition (summer);
CRC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	7.46	0.38	7.77e-13	Obesity-related traits;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.68	-9.26	-0.45	2.66e-18	Obesity-related traits;
CRC	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg06042504	chr8:55087323	NA	-0.37	-5.78	-0.3	1.71e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.62	-10.94	-0.52	5.68e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.56	-0.5	1.18e-22	Total cholesterol levels;
CRC	cis	rs7932354	0.583	rs3136447	chr11:46744368	T/C	cg19486271	chr11:47235900	DDB2	0.45	5.84	0.31	1.25e-8	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.61	0.5	8.45e-23	Hip circumference adjusted for BMI;
CRC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.87	-14.54	-0.63	2.49e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.5	-0.34	2.9e-10	Body mass index;
CRC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.67	6.98	0.36	1.65e-11	Axial length;
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.43	-0.38	9.22e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9443189	0.813	rs2647410	chr6:76433825	A/G	cg01950844	chr6:76311363	SENP6	-0.59	-7.6	-0.39	3.13e-13	Prostate cancer;
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.68	12.53	0.57	1.05e-29	Electroencephalogram traits;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.47	6.7	0.35	9.13e-11	Longevity;Endometriosis;
CRC	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.51	-6.58	-0.34	1.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.33	-6.05	-0.32	3.97e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg05623727	chr3:50126028	RBM5	0.53	6.97	0.36	1.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9292777	0.720	rs55937028	chr5:40412509	G/A	cg09067459	chr5:40385259	NA	-0.54	-8.68	-0.43	1.93e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs13161895	1.000	rs35135297	chr5:179469532	T/C	cg02702477	chr5:179499311	RNF130	0.55	6.26	0.33	1.18e-9	LDL cholesterol;
CRC	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg02023728	chr11:77925099	USP35	-0.35	-5.99	-0.31	5.35e-9	Alzheimer's disease (survival time);
CRC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.61	-9.59	-0.47	2.32e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg00383909	chr3:49044727	WDR6	0.44	5.69	0.3	2.8e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.41	-7.19	-0.37	4.5e-12	Eye color traits;
CRC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.44	-6.45	-0.33	4.09e-10	Response to amphetamines;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg07507251	chr3:52567010	NT5DC2	0.43	6.2	0.32	1.68e-9	Bipolar disorder;
CRC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.36	0.56	4.44e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-8.07	-0.41	1.3e-14	Major depressive disorder;
CRC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.52	7.32	0.37	1.86e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11574514	1.000	rs16957590	chr16:67934725	C/T	cg26727032	chr16:67993705	SLC12A4	0.61	5.6	0.3	4.43e-8	Crohn's disease;
CRC	cis	rs3996993	0.809	rs2397112	chr6:52684333	A/G	cg20803780	chr6:52668592	GSTA1	0.36	6.37	0.33	6.41e-10	Hemoglobin concentration;
CRC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.95	0.36	2.01e-11	Neuroticism;
CRC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.49	-6.99	-0.36	1.57e-11	Bipolar disorder;
CRC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg15962314	chr1:44399869	ARTN	0.3	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.49	0.46	5.04e-19	Coffee consumption (cups per day);
CRC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.07	-0.32	3.49e-9	Height;
CRC	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.6	8.05	0.41	1.5e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.91	0.36	2.46e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg07274523	chr3:49395745	GPX1	0.46	6.04	0.32	4.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.74	0.6	3e-34	Alzheimer's disease;
CRC	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.78	-0.3	1.7e-8	Blood pressure;
CRC	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg27083787	chr2:113543245	IL1A	0.45	6.23	0.33	1.39e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg06470822	chr6:28175283	NA	0.72	10.05	0.48	6.64e-21	Parkinson's disease;
CRC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg25985355	chr7:65971099	NA	-0.51	-5.89	-0.31	9.36e-9	Diabetic kidney disease;
CRC	cis	rs7487075	0.619	rs4768725	chr12:46848478	T/C	cg22049899	chr12:47219821	SLC38A4	0.32	5.83	0.31	1.35e-8	Itch intensity from mosquito bite;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00531400	chr12:125348358	SCARB1	0.39	6.5	0.34	2.93e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	1.25	15.16	0.64	9.75e-40	Lung disease severity in cystic fibrosis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	ch.2.235177505R	chr2:235512766	NA	-0.42	-6.16	-0.32	2.12e-9	HDL cholesterol;
CRC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg19812747	chr11:111475976	SIK2	-0.58	-10.08	-0.49	5.38e-21	Primary sclerosing cholangitis;
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.75	-0.35	6.69e-11	Total body bone mineral density;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg06470822	chr6:28175283	NA	1.01	15.38	0.65	1.29e-40	Depression;
CRC	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.57	8.53	0.43	5.24e-16	Multiple sclerosis;
CRC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-8.25	-0.41	3.9e-15	Schizophrenia;
CRC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.79	8.19	0.41	5.81e-15	Diabetic retinopathy;
CRC	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg10820045	chr2:198174542	NA	-0.54	-9.31	-0.46	1.82e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.55	8.13	0.41	8.91e-15	Response to temozolomide;
CRC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	18.05	0.71	4.12e-51	Smoking behavior;
CRC	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.63	10.28	0.49	1.11e-21	Mean platelet volume;
CRC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.62	9.69	0.47	1.1e-19	Tuberculosis;
CRC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.42	-0.5	3.78e-22	Breast cancer;
CRC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-12.42	-0.56	2.71e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	9.92e-18	Bladder cancer;
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg13880726	chr7:1868755	MAD1L1	-0.49	-5.99	-0.31	5.45e-9	Bipolar disorder;
CRC	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg08501292	chr6:25962987	TRIM38	1.14	9.98	0.48	1.12e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg06634786	chr22:41940651	POLR3H	-0.49	-6.22	-0.32	1.47e-9	Neuroticism;
CRC	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.37	-0.33	6.44e-10	Height;
CRC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg20354231	chr13:53171401	NA	-0.42	-6.75	-0.35	6.56e-11	Lewy body disease;
CRC	cis	rs10982256	0.905	rs4979417	chr9:117263878	C/T	cg13636371	chr9:117264095	DFNB31	0.37	7.09	0.36	8.1e-12	Bipolar disorder;
CRC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.53	7.32	0.37	1.86e-12	Height;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg25164649	chr6:28176230	NA	0.54	7.3	0.37	2.13e-12	Parkinson's disease;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12172441	chr6:28176163	NA	0.55	6.94	0.36	2.03e-11	Parkinson's disease;
CRC	cis	rs55702914	0.746	rs7588530	chr2:198146698	A/C	cg10820045	chr2:198174542	NA	-0.47	-8.68	-0.43	1.93e-16	Major depression and alcohol dependence;
CRC	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.5	-8.44	-0.42	1e-15	Testicular germ cell tumor;
CRC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.44	-6.53	-0.34	2.43e-10	Body mass index;
CRC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg09491104	chr22:46646882	C22orf40	-0.43	-6.6	-0.34	1.67e-10	LDL cholesterol;Cholesterol, total;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03745002	chr16:52581405	TOX3	0.43	6.02	0.31	4.63e-9	Hip circumference;
CRC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg04362960	chr10:104952993	NT5C2	-0.42	-5.85	-0.31	1.18e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.72	12.5	0.57	1.29e-29	Longevity;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27484876	chr20:33872021	EIF6	0.46	6.41	0.33	5.05e-10	Anxiety disorder;
CRC	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.46	-0.34	3.73e-10	Metabolite levels;
CRC	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.46	6.94	0.36	2.09e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	trans	rs2431623	0.675	rs2431621	chr10:12874715	T/G	cg01441497	chr3:167968476	C3orf50	-0.33	-6.06	-0.32	3.71e-9	Asymmetrical dimethylarginine levels;
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.99	18.2	0.71	1.09e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.61	-7.68	-0.39	1.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.42	7.51	0.38	5.6e-13	Blood metabolite ratios;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04780126	chr11:65029484	POLA2	0.42	6.12	0.32	2.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.58	-0.34	1.83e-10	Coronary artery disease;
CRC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg25985355	chr7:65971099	NA	-0.32	-5.66	-0.3	3.38e-8	Aortic root size;
CRC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.54	0.38	4.74e-13	Height;
CRC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg21918786	chr6:109611834	NA	-0.35	-6.05	-0.32	3.9e-9	Reticulocyte fraction of red cells;
CRC	cis	rs3736485	0.966	rs12592889	chr15:51795172	G/A	cg08986416	chr15:51914746	DMXL2	-0.41	-5.94	-0.31	7.26e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.57	-9.13	-0.45	6.89e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs948562	0.947	rs7482383	chr11:58369698	A/G	cg26660744	chr1:1573181	CDK11B	0.55	6.16	0.32	2.15e-9	Lymphoma;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg23161317	chr6:28129485	ZNF389	0.44	5.78	0.3	1.76e-8	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.63	10.63	0.51	7.05e-23	Prudent dietary pattern;
CRC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.93e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg22561889	chr6:118971681	C6orf204	0.52	6.58	0.34	1.91e-10	Diastolic blood pressure;
CRC	cis	rs12541635	0.966	rs62527363	chr8:107024258	A/G	cg10147462	chr8:107024639	NA	0.46	7.78	0.39	9.16e-14	Age of smoking initiation;
CRC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.65	10.23	0.49	1.61e-21	Huntington's disease progression;
CRC	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg04518342	chr5:131593106	PDLIM4	0.34	5.86	0.31	1.11e-8	Blood metabolite levels;
CRC	cis	rs2108622	0.711	rs113343664	chr19:15978993	G/C	cg13772218	chr19:15982569	NA	0.48	6.76	0.35	6.46e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.46	0.42	8.99e-16	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21788396	chr15:78423938	CIB2	0.41	6.76	0.35	6.37e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	cg04338863	chr8:33670619	NA	0.36	5.69	0.3	2.78e-8	Body mass index;
CRC	cis	rs73815153	0.546	rs6869019	chr5:180483973	G/T	cg00050152	chr5:180479829	BTNL9	0.56	5.97	0.31	6.11e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.44	-6.36	-0.33	6.77e-10	Platelet distribution width;
CRC	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.47	6.28	0.33	1.09e-9	Eye color traits;
CRC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.29	0.46	2.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.81	10.46	0.5	2.7e-22	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07035315	chr22:18483421	MICAL3	0.38	6.01	0.31	4.84e-9	Response to antipsychotic treatment;
CRC	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.9	-10.43	-0.5	3.52e-22	Orofacial clefts;
CRC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.39	0.42	1.45e-15	Height;
CRC	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg23711669	chr6:146136114	FBXO30	-0.73	-12.04	-0.55	6.8e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs863345	0.604	rs12133791	chr1:158506682	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg09264619	chr17:80180166	NA	0.35	5.86	0.31	1.12e-8	Life satisfaction;
CRC	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg22482690	chr17:47019901	SNF8	-0.43	-6.95	-0.36	2e-11	Type 2 diabetes;
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg00106254	chr7:1943704	MAD1L1	-0.38	-5.98	-0.31	5.92e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.65	6.84	0.35	3.95e-11	Axial length;
CRC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.44	6.49	0.34	3.25e-10	Menopause (age at onset);
CRC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.92	10.93	0.52	6.12e-24	Eosinophil percentage of granulocytes;
CRC	trans	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg09045935	chr12:6379348	NA	1.01	8.76	0.43	1.05e-16	Blood metabolite levels;
CRC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.98e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg02683197	chr6:28174875	NA	0.7	6.77	0.35	6.06e-11	Depression;
CRC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.54	8.62	0.43	2.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	cis	rs995000	0.931	rs1690766	chr1:62987289	T/C	cg19896129	chr1:63156450	NA	-0.45	-6.94	-0.36	2.07e-11	Triglyceride levels;
CRC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.51	6.12	0.32	2.66e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.57	8.36	0.42	1.78e-15	Autism;
CRC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg13777783	chr17:79615861	NA	-0.3	-5.7	-0.3	2.6e-8	Eye color traits;
CRC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.53e-12	Menopause (age at onset);
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.58	-0.47	2.49e-19	Heart rate;
CRC	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg09324608	chr17:30823087	MYO1D	-0.37	-6.43	-0.33	4.38e-10	Schizophrenia;
CRC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.13	0.32	2.52e-9	Lung cancer;
CRC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.38	0.53	1.54e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	0.99	12.34	0.56	5.12e-29	Type 2 diabetes nephropathy;
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.39e-26	Prudent dietary pattern;
CRC	cis	rs8023845	1.000	rs62019997	chr15:40443476	T/C	cg20259534	chr15:40453036	BUB1B	0.52	5.72	0.3	2.36e-8	Chronic lymphocytic leukemia;
CRC	cis	rs812925	0.512	rs1177309	chr2:61385248	A/G	cg10580144	chr2:61372316	C2orf74	0.35	7.9	0.4	4.33e-14	Immature fraction of reticulocytes;
CRC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.22	7.01	0.36	1.35e-11	Cutaneous nevi;
CRC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.52	-8.4	-0.42	1.33e-15	Neurofibrillary tangles;
CRC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	14.55	0.63	2.29e-37	Mean platelet volume;
CRC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg18165381	chr3:44552316	NA	-0.38	-5.64	-0.3	3.72e-8	Depressive symptoms;
CRC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.62	-8.04	-0.41	1.62e-14	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg12273811	chr6:28175739	NA	0.6	8.82	0.44	7e-17	Parkinson's disease;
CRC	trans	rs10496992	0.966	rs16825776	chr2:146683517	A/G	cg07441565	chr10:81107090	PPIF	-0.43	-6.18	-0.32	1.91e-9	Serum thyroid-stimulating hormone levels;
CRC	trans	rs1900442	0.536	rs1815346	chr13:42547580	A/G	cg16734191	chr21:40194848	ETS2	0.36	6.0	0.31	5.21e-9	Tuberculosis;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg02683197	chr6:28174875	NA	0.68	8.88	0.44	4.51e-17	Parkinson's disease;
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	6.54	0.34	2.3e-10	Bipolar disorder;
CRC	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.34	7.37	0.38	1.37e-12	Total body bone mineral density;
CRC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.45	6.11	0.32	2.74e-9	Total body bone mineral density;
CRC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-7.36	-0.38	1.51e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	15.53	0.65	3.42e-41	Primary sclerosing cholangitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19645734	chr12:49582919	TUBA1A	-0.39	-6.11	-0.32	2.78e-9	Myopia (pathological);
CRC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg21466736	chr12:48725269	NA	-0.55	-8.18	-0.41	6.36e-15	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6997458	0.606	rs1493302	chr8:86349280	T/C	cg21346043	chr8:86351067	CA3	-0.27	-5.97	-0.31	6.25e-9	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2257205	0.588	rs7219856	chr17:56941020	C/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.43e-8	Pancreatic cancer;
CRC	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.74	11.4	0.53	1.38e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs6950442	0.505	rs6953335	chr7:114341005	A/T	cg08672999	chr19:52675203	ZNF836	0.57	6.68	0.35	1.04e-10	Body mass index;
CRC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	17.07	0.69	3e-47	Platelet count;
CRC	cis	rs6662572	0.737	rs55765474	chr1:46401170	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.63	0.3	3.91e-8	Blood protein levels;
CRC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg15848620	chr12:58087721	OS9	-0.65	-8.97	-0.44	2.24e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.2	0.45	4.18e-18	Coffee consumption (cups per day);
CRC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg24879335	chr3:133465180	TF	0.32	5.88	0.31	9.98e-9	Iron status biomarkers;
CRC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06544989	chr22:39130855	UNC84B	0.47	7.62	0.39	2.69e-13	Menopause (age at onset);
CRC	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg06307176	chr5:131281290	NA	0.4	6.09	0.32	3.21e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.05	0.68	3.64e-47	Platelet count;
CRC	cis	rs7538876	1.000	rs2526828	chr1:17729903	G/A	cg07965774	chr1:17746286	RCC2	0.3	5.7	0.3	2.73e-8	Basal cell carcinoma;
CRC	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.58	0.39	3.54e-13	Motion sickness;
CRC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.66	-0.68	1.23e-45	Height;
CRC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.59	7.86	0.4	5.38e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-11.32	-0.53	2.59e-25	Alzheimer's disease;
CRC	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.45	7.86	0.4	5.45e-14	Schizophrenia;
CRC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.84	14.86	0.63	1.42e-38	Breast cancer;
CRC	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.06e-9	Red blood cell count;
CRC	cis	rs4363385	0.818	rs11205166	chr1:152988627	C/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.73	-0.35	7.68e-11	Inflammatory skin disease;
CRC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg12365402	chr11:9010492	NRIP3	0.53	9.03	0.45	1.53e-17	Hemoglobin concentration;
CRC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.39	-6.23	-0.32	1.41e-9	Iron status biomarkers;
CRC	cis	rs8040855	0.575	rs12912860	chr15:85573498	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.94	-0.31	7.37e-9	Bulimia nervosa;
CRC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.55	-8.65	-0.43	2.36e-16	Aortic root size;
CRC	trans	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.05e-13	Diabetic kidney disease;
CRC	cis	rs6735179	0.648	rs6706107	chr2:1761661	C/A	cg19300414	chr2:1746591	PXDN	0.35	6.13	0.32	2.51e-9	Response to antipsychotic treatment;
CRC	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg10263370	chr3:44754102	ZNF502	-0.38	-6.29	-0.33	9.93e-10	Depressive symptoms;
CRC	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.77	8.66	0.43	2.14e-16	Neuroticism;
CRC	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg25930673	chr12:123319894	HIP1R	-0.61	-6.08	-0.32	3.24e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04713951	chr22:38966166	DMC1	0.39	6.32	0.33	8.34e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.25	0.37	2.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-0.51	-6.4	-0.33	5.44e-10	Diastolic blood pressure;
CRC	cis	rs427941	0.632	rs201480	chr7:101747575	A/G	cg06246474	chr7:101738831	CUX1	0.44	6.75	0.35	6.62e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.42	5.96	0.31	6.41e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.44	-0.33	4.18e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27004975	chr16:87984542	BANP	0.43	6.18	0.32	1.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs950880	0.593	rs887971	chr2:103041167	T/C	cg03938978	chr2:103052716	IL18RAP	-0.41	-5.79	-0.3	1.63e-8	Serum protein levels (sST2);
CRC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	13.17	0.59	4.11e-32	Platelet count;
CRC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25517755	chr10:38738941	LOC399744	0.46	6.6	0.34	1.62e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16487852	chr16:83841511	HSBP1	0.42	6.89	0.36	2.86e-11	Interleukin-6 levels;
CRC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.3	12.44	0.57	2.13e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.47	-7.9	-0.4	4.26e-14	Endometriosis;
CRC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.04	0.52	2.57e-24	Cognitive ability;
CRC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14616479	chr3:155588124	GMPS	0.46	6.46	0.34	3.72e-10	Response to antipsychotic treatment;
CRC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	8.11	0.41	1.03e-14	Coronary artery disease;
CRC	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg12458913	chr13:53173898	NA	0.46	6.81	0.35	4.55e-11	Lewy body disease;
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg15382696	chr6:118971807	C6orf204	0.6	7.72	0.39	1.38e-13	Diastolic blood pressure;
CRC	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg05569086	chr8:143859399	LYNX1	0.52	8.93	0.44	3.06e-17	Urinary tract infection frequency;
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.06	-0.32	3.67e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.47	7.06	0.36	9.94e-12	Corneal astigmatism;
CRC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.7	0.35	8.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.61	11.1	0.52	1.51e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.15	-0.37	5.62e-12	Bipolar disorder;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg01758942	chr3:52551074	STAB1	0.31	6.01	0.31	4.9e-9	Electroencephalogram traits;
CRC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.13	-0.37	6.23e-12	Gut microbiome composition (summer);
CRC	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.0	-0.31	5.09e-9	Pubertal anthropometrics;
CRC	cis	rs9847710	0.901	rs2564937	chr3:53025859	C/T	cg18404041	chr3:52824283	ITIH1	0.3	5.94	0.31	7.34e-9	Ulcerative colitis;
CRC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.33	0.33	7.88e-10	Bladder cancer;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg21251018	chr6:28226885	NKAPL	-0.39	-6.15	-0.32	2.21e-9	Systemic lupus erythematosus;
CRC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg05941027	chr17:61774174	LIMD2	0.34	5.87	0.31	1.06e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-6.37	-0.33	6.54e-10	Lung cancer;
CRC	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.09	0.36	8.48e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.43	-0.38	9.36e-13	Bipolar disorder;
CRC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.59	6.96	0.36	1.81e-11	Type 2 diabetes nephropathy;
CRC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.56	-7.82	-0.4	7.24e-14	DNA methylation (variation);
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg10596483	chr8:143751796	JRK	-0.47	-6.21	-0.32	1.57e-9	Urinary tract infection frequency;
CRC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg22110888	chr17:80059540	CCDC57	0.39	6.16	0.32	2.09e-9	Life satisfaction;
CRC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg22349387	chr12:9600060	DDX12	-0.42	-6.75	-0.35	6.81e-11	Breast size;
CRC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-18.23	-0.71	8.22e-52	Height;
CRC	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-18.36	-0.71	2.61e-52	Schizophrenia;
CRC	cis	rs7553864	0.966	rs1886635	chr1:87614950	G/A	cg02083836	chr1:87617350	LOC339524	0.37	6.57	0.34	1.99e-10	Smoking behavior;
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg20356878	chr3:121714668	ILDR1	0.47	6.83	0.35	4.02e-11	Multiple sclerosis;
CRC	trans	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06834434	chr14:75079333	LTBP2	0.55	6.62	0.34	1.47e-10	Obesity-related traits;
CRC	cis	rs965469	0.779	rs6051771	chr20:3328271	A/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.61	0.34	1.52e-10	Subjective well-being;
CRC	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg09659197	chr4:152720779	NA	-0.41	-8.09	-0.41	1.14e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.31	5.13e-9	Hemoglobin concentration;
CRC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.78	0.44	9.08e-17	Morning vs. evening chronotype;
CRC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.28e-20	Ileal carcinoids;
CRC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg11843238	chr5:131593191	PDLIM4	0.3	5.64	0.3	3.74e-8	Blood metabolite levels;
CRC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg07507251	chr3:52567010	NT5DC2	0.39	5.83	0.31	1.3e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs35883536	1.000	rs12724990	chr1:101137030	G/A	cg14515779	chr1:101123966	NA	-0.41	-7.97	-0.4	2.69e-14	Monocyte count;
CRC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.5	5.82	0.31	1.41e-8	Vitiligo;
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-12.52	-0.57	1.11e-29	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	0.99	10.21	0.49	1.91e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg10356904	chr22:49881777	NA	-0.32	-6.05	-0.32	4.01e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.51	5.9	0.31	9e-9	Bipolar disorder (body mass index interaction);
CRC	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.39	6.75	0.35	6.73e-11	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.44	6.31	0.33	9e-10	Longevity;Endometriosis;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.33e-18	Blood pressure (smoking interaction);
CRC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.14	0.32	2.36e-9	Height;
CRC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.44	-8.66	-0.43	2.23e-16	Renal cell carcinoma;
CRC	cis	rs6499129	0.558	rs7203742	chr16:67605794	A/G	cg26727032	chr16:67993705	SLC12A4	0.61	7.97	0.4	2.61e-14	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.45	-7.13	-0.37	6.48e-12	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.49e-10	Depression;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.37	-6.23	-0.32	1.42e-9	Longevity;Endometriosis;
CRC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.53	7.17	0.37	5.1e-12	Height;
CRC	trans	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	7.28	0.37	2.55e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.31	-6.92	-0.36	2.34e-11	IgG glycosylation;
CRC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.59	7.23	0.37	3.44e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4509693	0.943	rs6584393	chr10:102497206	C/G	cg23167259	chr10:102495509	NA	-0.46	-6.27	-0.33	1.11e-9	Alzheimer's disease;
CRC	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.44	-7.13	-0.37	6.35e-12	Refractive error;
CRC	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	9.5	0.46	4.52e-19	Blood protein levels;
CRC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.58	-9.66	-0.47	1.33e-19	Monobrow;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg03623178	chr6:28175578	NA	0.84	9.0	0.44	1.86e-17	Lung cancer in ever smokers;
CRC	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.35	-5.78	-0.3	1.77e-8	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg04155289	chr7:94953770	PON1	-0.64	-7.75	-0.39	1.13e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12612619	0.732	rs11679069	chr2:27270311	G/A	cg00617064	chr2:27272375	NA	-0.39	-6.49	-0.34	3.17e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.55	9.01	0.44	1.68e-17	Gout;
CRC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.67	0.43	1.97e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg01483505	chr11:975446	AP2A2	0.41	6.23	0.32	1.46e-9	Alzheimer's disease (late onset);
CRC	cis	rs16867335	1.000	rs72884242	chr2:181465486	A/T	cg23363182	chr2:181467187	NA	-0.49	-6.62	-0.34	1.45e-10	Survival in rectal cancer;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg20041105	chr8:143859282	LYNX1	-0.43	-6.69	-0.35	9.5e-11	Urinary tract infection frequency;
CRC	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg12315302	chr6:26189340	HIST1H4D	0.9	6.56	0.34	2.06e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.74e-16	Alcohol dependence;
CRC	cis	rs1335587	0.582	rs3916910	chr13:102108308	A/G	cg03165014	chr13:102106348	ITGBL1	0.39	5.77	0.3	1.8e-8	Obesity-related traits;
CRC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.54	-7.24	-0.37	3.24e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.39	-5.93	-0.31	7.49e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.57	8.39	0.42	1.44e-15	Schizophrenia;
CRC	cis	rs4664293	0.867	rs6720304	chr2:160643832	G/A	cg08347373	chr2:160653686	CD302	-0.51	-7.99	-0.4	2.23e-14	Monocyte percentage of white cells;
CRC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.36	7.96	0.4	2.87e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.57	9.2	0.45	4.16e-18	Obesity-related traits;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg23071808	chr14:103021642	NA	-0.6	-7.14	-0.37	6.06e-12	Platelet count;
CRC	trans	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.4	-6.1	-0.32	2.98e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.51	7.67	0.39	1.99e-13	Corneal astigmatism;
CRC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	0.94	13.05	0.58	1.21e-31	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.73	11.07	0.52	1.97e-24	Menarche (age at onset);
CRC	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.58	10.66	0.51	5.31e-23	Age of smoking initiation;
CRC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.33	5.6	0.3	4.46e-8	Emphysema distribution in smoking;
CRC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg02569458	chr12:86230093	RASSF9	0.48	8.01	0.4	2.05e-14	Major depressive disorder;
CRC	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg14530993	chr4:882597	GAK	0.78	7.59	0.39	3.27e-13	Parkinson's disease;
CRC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.44	-8.09	-0.41	1.14e-14	Reticulocyte fraction of red cells;
CRC	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg04132472	chr17:19861366	AKAP10	0.38	6.02	0.32	4.61e-9	Schizophrenia;
CRC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.86	12.18	0.56	2.06e-28	Triglycerides;
CRC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.68	11.53	0.54	4.55e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.92	-19.57	-0.73	4.36e-57	Urate levels in lean individuals;
CRC	cis	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26784012	chr10:32216390	ARHGAP12	0.37	5.73	0.3	2.24e-8	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg20673091	chr1:2541236	MMEL1	-0.38	-6.01	-0.31	5.04e-9	Ulcerative colitis;
CRC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg05585544	chr11:47624801	NA	-0.55	-10.05	-0.48	6.9e-21	Subjective well-being;
CRC	cis	rs11212617	1.000	rs1003623	chr11:108152582	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.15	0.32	2.28e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-6.94	-0.36	2.07e-11	Tuberculosis;
CRC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.48	7.98	0.4	2.5e-14	Calcium levels;
CRC	cis	rs73200209	0.744	rs1136427	chr12:116608487	C/T	cg01776926	chr12:116560359	MED13L	-0.56	-6.19	-0.32	1.77e-9	Total body bone mineral density;
CRC	cis	rs6564851	0.506	rs11644611	chr16:81260494	T/G	cg05274606	chr16:81253692	PKD1L2	-0.37	-6.12	-0.32	2.61e-9	Carotenoid and tocopherol levels;
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.37	7.41	0.38	1.08e-12	Lung cancer;
CRC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.91	16.93	0.68	1.09e-46	Blood protein levels;
CRC	cis	rs2857891	0.817	rs2239733	chr11:6976666	T/C	cg12728517	chr11:6947552	ZNF215	0.48	5.71	0.3	2.48e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.31	6.3	0.33	9.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.46	6.22	0.32	1.49e-9	Cholesterol, total;
CRC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.58	6.53	0.34	2.52e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.04	0.32	4.21e-9	Glioblastoma;
CRC	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12606694	chr6:131520996	AKAP7	0.51	7.62	0.39	2.81e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06586915	chr7:65958596	NA	-0.42	-6.28	-0.33	1.05e-9	Aortic root size;
CRC	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.55	-7.7	-0.39	1.5700000000000001e-13	Type 1 diabetes;
CRC	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.69	-10.6	-0.5	9.1e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.69	9.94	0.48	1.56e-20	Blood protein levels;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.65	-0.34	1.25e-10	Breast cancer;
CRC	cis	rs6988985	0.765	rs7824229	chr8:143984064	A/C	cg10324643	chr8:143916377	GML	0.39	6.3	0.33	9.39e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7605827	0.930	rs4668904	chr2:15543642	C/G	cg19274914	chr2:15703543	NA	0.38	5.79	0.3	1.67e-8	Educational attainment (years of education);
CRC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg04545296	chr12:48745243	ZNF641	0.35	6.1	0.32	2.96e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.63	0.34	1.34e-10	Schizophrenia;
CRC	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.8	-0.35	4.84e-11	Coronary artery disease;
CRC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.45	6.93	0.36	2.26e-11	Colorectal cancer;
CRC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg21251018	chr6:28226885	NKAPL	0.4	6.09	0.32	3.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21972741	chr5:435613	AHRR	0.55	7.56	0.38	4.15e-13	Cystic fibrosis severity;
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.94	0.52	5.62e-24	Prudent dietary pattern;
CRC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg03623178	chr6:28175578	NA	0.77	6.33	0.33	7.87e-10	Depression;
CRC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.46	7.37	0.38	1.4e-12	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg27565382	chr3:53032988	SFMBT1	0.65	5.74	0.3	2.2e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12680326	chr20:2821316	VPS16;FAM113A	0.36	6.3	0.33	9.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg18721089	chr20:30220636	NA	-0.36	-5.86	-0.31	1.12e-8	Mean corpuscular hemoglobin;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00345270	chr16:29268157	NA	0.41	6.04	0.32	4.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.44	0.69	1.04e-48	Platelet count;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.98	17.67	0.7	1.29e-49	Menarche (age at onset);
CRC	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.33	-5.89	-0.31	9.38e-9	HIV-1 control;
CRC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg02007433	chr3:129722099	NA	-0.5	-6.22	-0.32	1.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg25985355	chr7:65971099	NA	-0.51	-5.87	-0.31	1.05e-8	Diabetic kidney disease;
CRC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.68	9.75	0.47	6.92e-20	Bladder cancer;
CRC	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.77	-0.3	1.86e-8	Blood pressure;
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.46	6.84	0.35	3.9e-11	Menarche (age at onset);
CRC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.57	9.23	0.45	3.32e-18	Gout;
CRC	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg14092988	chr3:52407081	DNAH1	0.38	6.67	0.35	1.06e-10	Bipolar disorder;
CRC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg19812747	chr11:111475976	SIK2	-0.49	-7.62	-0.39	2.75e-13	Primary sclerosing cholangitis;
CRC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg02569458	chr12:86230093	RASSF9	0.34	5.63	0.3	3.83e-8	Major depressive disorder;
CRC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.53	-7.62	-0.39	2.68e-13	Total body bone mineral density;
CRC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg03316587	chr8:142245164	NA	0.42	6.17	0.32	2.06e-9	Immature fraction of reticulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01089060	chr10:97050836	PDLIM1	0.35	6.14	0.32	2.41e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.89	-0.4	4.56e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg04362960	chr10:104952993	NT5C2	-0.42	-5.85	-0.31	1.18e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg13047869	chr3:10149882	C3orf24	0.51	7.0	0.36	1.47e-11	Alzheimer's disease;
CRC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.61	-11.06	-0.52	2.18e-24	Schizophrenia;
CRC	trans	rs11125721	0.788	rs11125718	chr2:57800605	A/G	cg20411671	chr10:1463014	ADARB2	0.4	6.22	0.32	1.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1223397	0.938	rs3817737	chr6:13279082	A/G	cg07912922	chr6:13274314	PHACTR1	0.51	6.09	0.32	3.22e-9	Blood pressure;
CRC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg25171089	chr10:5708825	ASB13	0.42	5.87	0.31	1.07e-8	Menopause (age at onset);
CRC	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00147160	chr1:26503991	CNKSR1	0.32	6.38	0.33	6.18e-10	Height;
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.55	7.44	0.38	8.73e-13	Menarche (age at onset);
CRC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg23996704	chr18:44553084	KATNAL2	-0.34	-6.78	-0.35	5.5e-11	Personality dimensions;
CRC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-7.3	-0.37	2.12e-12	Coronary artery disease;
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.16	0.37	5.41e-12	Alzheimer's disease;
CRC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.22	0.45	3.74e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.76	-10.48	-0.5	2.24e-22	Cognitive function;
CRC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	6.35	0.33	7.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.53	8.22	0.41	4.82e-15	Blood metabolite levels;
CRC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg05072774	chr3:49840536	C3orf54	-0.44	-5.71	-0.3	2.55e-8	Resting heart rate;
CRC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.63	10.62	0.51	7.72e-23	Body mass index;
CRC	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg04439458	chr5:138467593	SIL1	-0.35	-6.01	-0.31	4.95e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6076065	0.723	rs16985308	chr20:23359780	A/T	cg11657817	chr20:23433608	CST11	0.45	6.79	0.35	5.39e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.46	-6.46	-0.34	3.68e-10	Blood pressure (smoking interaction);
CRC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.47	-0.38	7.35e-13	Psoriasis;
CRC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-9.47	-0.46	5.45e-19	Chronic sinus infection;
CRC	cis	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17459225	chr2:239074497	NA	0.46	7.96	0.4	2.76e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.63	-0.51	7.02e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg20607287	chr7:12443886	VWDE	-0.67	-6.68	-0.35	1.01e-10	Coronary artery disease;
CRC	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg25922239	chr6:33757077	LEMD2	0.43	6.21	0.32	1.64e-9	Crohn's disease;
CRC	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg27398640	chr15:77910606	LINGO1	0.35	5.97	0.31	6.14e-9	Type 2 diabetes;
CRC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	7.08	0.36	8.68e-12	Mood instability;
CRC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.57	8.07	0.41	1.36e-14	Lung cancer;
CRC	cis	rs4750440	0.702	rs4750445	chr10:14030314	C/T	cg00551146	chr10:14014579	FRMD4A	0.37	5.9	0.31	8.89e-9	Adiponectin levels;
CRC	cis	rs11212617	1.000	rs650173	chr11:108174173	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.16	0.32	2.11e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg21620606	chr4:1342894	KIAA1530	0.38	6.61	0.34	1.59e-10	Obesity-related traits;
CRC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	10.54	0.5	1.48e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg12365402	chr11:9010492	NRIP3	-0.5	-8.06	-0.41	1.39e-14	Hemoglobin concentration;
CRC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.58	9.16	0.45	5.8e-18	Breast cancer;
CRC	cis	rs360798	0.512	rs6545973	chr2:63089434	C/T	cg17519650	chr2:63277830	OTX1	0.47	6.48	0.34	3.35e-10	Coronary artery disease;
CRC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.14	0.37	5.86e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg15845792	chr6:28175446	NA	0.97	13.08	0.58	8.89e-32	Depression;
CRC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	7.04	0.36	1.15e-11	Breast cancer;
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg15147215	chr3:52552868	STAB1	-0.64	-11.08	-0.52	1.85e-24	Bipolar disorder;
CRC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.54	-6.92	-0.36	2.31e-11	Platelet distribution width;
CRC	cis	rs9976767	0.932	rs3746924	chr21:43826391	T/C	cg23042151	chr21:43824109	UBASH3A	-0.37	-6.5	-0.34	2.96e-10	Type 1 diabetes;
CRC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg17346650	chr17:80929145	B3GNTL1	0.47	6.91	0.36	2.51e-11	Glycated hemoglobin levels;
CRC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00339695	chr16:24857497	SLC5A11	0.27	6.58	0.34	1.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg19077165	chr18:44547161	KATNAL2	0.42	6.22	0.32	1.54e-9	Educational attainment;
CRC	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg11189052	chr15:85197271	WDR73	0.53	7.08	0.36	8.9e-12	Alzheimer's disease (age of onset);
CRC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.64	9.31	0.46	1.85e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	9.74	0.47	7.14e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.58	0.54	3.17e-26	Bipolar disorder;
CRC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.35	-5.64	-0.3	3.69e-8	Total body bone mineral density;
CRC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg20885578	chr2:198174922	NA	0.37	6.57	0.34	1.95e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg11522145	chr4:3412961	RGS12	-0.38	-5.83	-0.31	1.35e-8	Serum sulfate level;
CRC	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.36	-0.42	1.79e-15	Reticulocyte fraction of red cells;
CRC	cis	rs501916	0.604	rs616871	chr15:48058259	T/A	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.78	-0.35	5.74e-11	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.52	6.56	0.34	2.07e-10	Monocyte percentage of white cells;
CRC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg19318889	chr4:1322082	MAEA	0.4	5.66	0.3	3.25e-8	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.33e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.38	-7.23	-0.37	3.34e-12	Ulcerative colitis;
CRC	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.6	8.79	0.44	8.19e-17	Multiple myeloma (IgH translocation);
CRC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg11693508	chr17:37793320	STARD3	0.62	7.08	0.36	8.79e-12	Bipolar disorder;
CRC	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.55	5.69	0.3	2.75e-8	Obesity-related traits;
CRC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-0.87	-13.94	-0.61	5.07e-35	Urate levels;
CRC	cis	rs6681460	0.932	rs523132	chr1:67174440	A/G	cg02459107	chr1:67143332	SGIP1	-0.37	-6.34	-0.33	7.67e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.02	0.4	1.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	1.13	13.93	0.61	5.38e-35	Uric acid levels;
CRC	cis	rs7487075	0.567	rs4768712	chr12:46811521	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05206762	chr4:8160379	ABLIM2	0.44	6.28	0.33	1.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.73	8.14	0.41	8.19e-15	Anti-saccade response;
CRC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.65	-7.9	-0.4	4.16e-14	Platelet count;
CRC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg03037974	chr15:76606532	NA	-0.54	-8.18	-0.41	6.47e-15	Blood metabolite levels;
CRC	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg08795948	chr3:128337044	NA	0.36	6.29	0.33	1.02e-9	Monocyte percentage of white cells;Monocyte count;
CRC	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.96	-0.55	1.28e-27	Exhaled nitric oxide output;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04362369	chr14:21905501	CHD8	-0.42	-6.73	-0.35	7.52e-11	Obesity-related traits;
CRC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.73	12.06	0.55	5.76e-28	Mean platelet volume;
CRC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.37	-5.67	-0.3	3.21e-8	Height;
CRC	cis	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg11143507	chr3:125485238	NA	-0.6	-7.66	-0.39	2.16e-13	Blood pressure (smoking interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04297258	chr16:88772664	RNF166;CTU2	-0.5	-6.14	-0.32	2.37e-9	Diisocyanate-induced asthma;
CRC	cis	rs17756712	0.725	rs3757122	chr6:611030	A/G	cg16786516	chr6:604617	EXOC2	0.45	5.75	0.3	2.07e-8	Vertical cup-disc ratio;
CRC	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.52	7.99	0.4	2.37e-14	Testicular germ cell tumor;
CRC	cis	rs8141797	0.901	rs5751804	chr22:24490105	A/C	cg20894457	chr22:24584366	SUSD2	-0.61	-7.58	-0.39	3.55e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg06172871	chr16:72088244	HP	0.43	6.27	0.33	1.12e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg02683197	chr6:28174875	NA	0.55	7.85	0.4	5.82e-14	Parkinson's disease;
CRC	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	1.0	18.87	0.72	2.33e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14119001	chr9:139324193	INPP5E	-0.44	-6.2	-0.32	1.68e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.78	-10.64	-0.51	6.51e-23	White matter hyperintensity burden;
CRC	trans	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg12560992	chr17:57184187	TRIM37	0.44	5.83	0.31	1.35e-8	Cognitive test performance;
CRC	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.69	8.78	0.44	9.31e-17	Obesity-related traits;
CRC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-11.39	-0.53	1.46e-25	Colorectal cancer;
CRC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg00631329	chr6:26305371	NA	0.41	6.88	0.35	3.05e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg25834613	chr7:1915315	MAD1L1	-0.5	-7.87	-0.4	5.27e-14	Bipolar disorder;
CRC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.47	6.22	0.32	1.47e-9	Obesity-related traits;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.0	-10.33	-0.49	7.51e-22	Body mass index;
CRC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.43	9.45	0.46	6.4e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.88	-0.4	4.73e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.65	-10.2	-0.49	2.03e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-6.02	-0.32	4.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg08200770	chr17:80723486	TBCD	-0.48	-7.37	-0.38	1.41e-12	Glycated hemoglobin levels;
CRC	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.8	-0.35	4.98e-11	Inflammatory skin disease;
CRC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.05	0.68	3.64e-47	Platelet count;
CRC	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg13615338	chr4:55094005	PDGFRA	0.4	5.95	0.31	6.86e-9	Corneal astigmatism;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg25164649	chr6:28176230	NA	0.47	6.95	0.36	2e-11	Pubertal anthropometrics;
CRC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg24289452	chr6:170231220	NA	-0.81	-7.0	-0.36	1.45e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11166629	1.000	rs7003870	chr8:135616586	A/G	cg27224718	chr8:135614730	ZFAT	0.54	7.84	0.4	6.28e-14	Smoking quantity;
CRC	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.44	6.72	0.35	7.81e-11	Sudden cardiac arrest;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs253959	0.672	rs4921056	chr5:115422934	A/G	cg23108291	chr5:115420582	COMMD10	0.45	6.39	0.33	5.67e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.48	-5.95	-0.31	7.02e-9	Adiposity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05445914	chr16:30134068	MAPK3	0.41	6.89	0.36	2.8e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.68	-8.98	-0.44	2.09e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg27534772	chr1:16042836	PLEKHM2	0.55	10.98	0.52	4.27e-24	Systolic blood pressure;
CRC	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.67	-0.35	1.09e-10	Metabolite levels;
CRC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.58	6.48	0.34	3.27e-10	Bipolar disorder;
CRC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-5.9	-0.31	9.14e-9	Carotid intima media thickness;
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.6	10.14	0.49	3.3e-21	Prudent dietary pattern;
CRC	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11646757	chr7:128095699	C7orf68	0.46	6.09	0.32	3.1e-9	Thyroid stimulating hormone;
CRC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-9.6	-0.47	2.12e-19	Multiple sclerosis;
CRC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-8.1	-0.41	1.06e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.42	0.46	8.23e-19	Migraine;Coronary artery disease;
CRC	cis	rs9463078	0.809	rs9357469	chr6:45049811	C/T	cg25276700	chr6:44698697	NA	-0.29	-6.93	-0.36	2.25e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-14.99	-0.64	4.54e-39	Vitiligo;
CRC	trans	rs12706411	0.571	rs35132220	chr7:122171197	A/G	cg04149356	chr5:158139306	EBF1	0.68	6.12	0.32	2.67e-9	Alzheimer disease and age of onset;
CRC	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-6.44	-0.33	4.2e-10	Capecitabine sensitivity;
CRC	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg23254163	chr1:152506842	NA	0.43	8.22	0.41	4.88e-15	Hair morphology;
CRC	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-14.7	-0.63	5.66e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg16342193	chr10:102329863	NA	-0.35	-5.92	-0.31	8e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg07211511	chr3:129823064	LOC729375	-0.61	-6.97	-0.36	1.73e-11	Blood pressure (smoking interaction);
CRC	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.33	-0.33	8e-10	Alzheimer's disease (late onset);
CRC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg08888203	chr3:10149979	C3orf24	0.47	7.23	0.37	3.47e-12	Alzheimer's disease;
CRC	cis	rs9928842	0.771	rs2870471	chr16:75274282	A/G	cg09066997	chr16:75300724	BCAR1	-0.61	-6.52	-0.34	2.6200000000000003e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs243505	0.661	rs887570	chr7:148505255	A/G	cg09806900	chr7:148480153	CUL1	0.49	7.08	0.36	9.04e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs713587	0.520	rs512419	chr2:25310155	G/T	cg22495460	chr2:25135724	ADCY3	0.44	6.5	0.34	3.04e-10	Body mass index in non-asthmatics;
CRC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.8	13.58	0.6	1.22e-33	Menopause (age at onset);
CRC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	1.000	rs7943165	chr11:108274890	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.52	0.34	2.61e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg04415270	chr2:102091202	RFX8	0.59	8.0	0.4	2.17e-14	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs17152411	0.793	rs12569669	chr10:126592671	A/G	cg07906193	chr10:126599966	NA	0.57	6.46	0.34	3.78e-10	Height;
CRC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.49	0.34	3.18e-10	Cognitive ability;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.38	6.73	0.35	7.37e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.47	8.97	0.44	2.23e-17	Educational attainment (years of education);
CRC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-6.92	-0.36	2.36e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.15	-0.45	6.36e-18	Total cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07889337	chr17:38257022	NR1D1	0.4	6.38	0.33	6.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.96	-0.4	2.88e-14	Magnesium levels;
CRC	cis	rs35883536	1.000	rs11586051	chr1:101096240	A/T	cg14515779	chr1:101123966	NA	0.42	7.95	0.4	3e-14	Monocyte count;
CRC	cis	rs9359856	0.518	rs11965790	chr6:90261621	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.59	-6.83	-0.35	4.11e-11	Bipolar disorder;
CRC	cis	rs7113874	0.569	rs11041978	chr11:8578150	T/C	cg17679104	chr11:8615758	STK33	-0.35	-5.9	-0.31	8.88e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.44	6.02	0.32	4.63e-9	Resistin levels;
CRC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.52	8.15	0.41	7.78e-15	Colorectal cancer;
CRC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.68	-0.3	2.96e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg21970626	chr13:21893289	NA	0.42	5.72	0.3	2.36e-8	White matter hyperintensity burden;
CRC	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg23417306	chr2:180868811	CWC22	-0.45	-6.09	-0.32	3.1e-9	Schizophrenia;
CRC	trans	rs16924631	0.818	rs10975595	chr9:6452555	G/A	cg18105767	chr19:41698548	CYP2S1	-0.47	-6.03	-0.32	4.35e-9	Periodontal microbiota;
CRC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.56	-9.87	-0.48	2.78e-20	Huntington's disease progression;
CRC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.42	6.86	0.35	3.36e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4731207	0.596	rs7802007	chr7:124638034	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.83e-9	Cutaneous malignant melanoma;
CRC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.13e-12	Corneal astigmatism;
CRC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.42	-7.07	-0.36	9.14e-12	Prostate cancer;
CRC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.37	-0.56	4.1e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg20356878	chr3:121714668	ILDR1	-0.49	-7.18	-0.37	4.66e-12	Multiple sclerosis;
CRC	trans	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.32	-0.37	1.93e-12	Endometrial cancer;
CRC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.49	8.04	0.41	1.63e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.32	-0.33	8.44e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.95	-17.37	-0.69	1.95e-48	IgG glycosylation;
CRC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-5.87	-0.31	1.05e-8	Body mass index;
CRC	cis	rs2070997	0.617	rs7848941	chr9:133744672	G/A	cg01000188	chr9:133769184	QRFP	0.53	7.21	0.37	3.75e-12	Response to amphetamines;
CRC	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg01993067	chr11:68851601	TPCN2	0.57	6.59	0.34	1.77e-10	Blond vs. brown hair color;
CRC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.25	-0.37	3.09e-12	Joint mobility (Beighton score);
CRC	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.53	-5.9	-0.31	9.26e-9	Obesity (extreme);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19403496	chr1:101491408	DPH5	0.39	6.57	0.34	1.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.66	8.84	0.44	5.96e-17	IgE levels in asthmatics (D.p. specific);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07898764	chr7:101847052	CUX1	0.4	6.03	0.32	4.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.54	-8.17	-0.41	6.53e-15	Height;
CRC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.54	-8.68	-0.43	1.88e-16	Neurofibrillary tangles;
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg16647868	chr5:131706066	SLC22A5	0.46	6.08	0.32	3.35e-9	Breast cancer;
CRC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.57	8.55	0.43	4.79e-16	Calcium levels;
CRC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg23262073	chr20:60523788	NA	-0.42	-7.08	-0.36	8.51e-12	Body mass index;
CRC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.56	-9.25	-0.45	2.97e-18	Height;
CRC	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg10437265	chr15:77819839	NA	0.59	9.95	0.48	1.46e-20	Type 2 diabetes;
CRC	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.09	-0.41	1.16e-14	Neuroticism;
CRC	cis	rs834811	0.602	rs4732183	chr7:135888513	G/T	cg01726295	chr7:135938950	NA	0.36	6.1	0.32	2.97e-9	Post-traumatic stress disorder;
CRC	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.5	5.74	0.3	2.18e-8	Dental caries;
CRC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-9.85	-0.48	3.04e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.62	-11.35	-0.53	2.08e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-9.31	-0.46	1.84e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg08314208	chr16:67682810	RLTPR	-0.59	-6.48	-0.34	3.31e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322817	0.691	rs2499664	chr6:105301484	C/G	cg02098413	chr6:105308735	HACE1	0.43	8.54	0.43	5.18e-16	Thyroid stimulating hormone;
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg25834613	chr7:1915315	MAD1L1	-0.46	-6.42	-0.33	4.64e-10	Bipolar disorder;
CRC	cis	rs12760731	0.565	rs6701832	chr1:178156775	A/G	cg00404053	chr1:178313656	RASAL2	1.02	10.74	0.51	2.85e-23	Obesity-related traits;
CRC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.57	8.29	0.42	2.95e-15	Aortic root size;
CRC	cis	rs728616	0.558	rs34268041	chr10:82148639	A/G	cg05935833	chr10:81318306	SFTPA2	-0.58	-7.06	-0.36	9.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6546324	0.959	rs2861694	chr2:67845739	A/G	cg15745817	chr2:67799979	NA	-0.29	-5.69	-0.3	2.76e-8	Endometriosis;
CRC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.75	-7.27	-0.37	2.58e-12	Type 2 diabetes;
CRC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg15147215	chr3:52552868	STAB1	0.53	9.24	0.45	3.04e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg16141378	chr3:129829833	LOC729375	0.43	6.13	0.32	2.53e-9	Triglycerides;
CRC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.66	11.6	0.54	2.57e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.64	0.34	1.3100000000000001e-10	Intraocular pressure;
CRC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg21770322	chr7:97807741	LMTK2	0.53	8.62	0.43	2.94e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.85	0.4	5.78e-14	Mean platelet volume;
CRC	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.79	0.3	1.64e-8	Metabolite levels;
CRC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.18	-26.8	-0.83	9.76e-85	IgG glycosylation;
CRC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg03037974	chr15:76606532	NA	-0.65	-11.12	-0.52	1.37e-24	Blood metabolite levels;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20877313	chr12:56881753	GLS2	0.42	6.39	0.33	5.79e-10	Intelligence (multi-trait analysis);
CRC	cis	rs77861329	0.748	rs9851576	chr3:52091254	C/T	cg08692210	chr3:52188851	WDR51A	-0.53	-6.41	-0.33	5.09e-10	Macrophage inflammatory protein 1b levels;
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.04	-0.32	4.25e-9	Total body bone mineral density;
CRC	cis	rs2298450	0.654	rs9984891	chr21:37626379	A/G	cg02919814	chr21:37666008	DOPEY2	-0.5	-6.58	-0.34	1.84e-10	Schizophrenia;
CRC	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.86	-0.31	1.11e-8	Height;
CRC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.47	8.55	0.43	4.69e-16	Height;
CRC	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg20885578	chr2:198174922	NA	-0.43	-6.95	-0.36	2.03e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.65	10.59	0.5	9.86e-23	Hemoglobin concentration;
CRC	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg10483660	chr13:112241077	NA	0.35	5.61	0.3	4.35e-8	Menarche (age at onset);
CRC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.39	-6.32	-0.33	8.45e-10	Height;
CRC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.68	11.79	0.55	5.13e-27	Resting heart rate;
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	10.51	0.5	1.75e-22	Alzheimer's disease;
CRC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.68	9.55	0.47	3.05e-19	Bladder cancer;
CRC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	0.97	13.58	0.6	1.14e-33	Breast cancer;
CRC	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg08999081	chr20:33150536	PIGU	0.46	5.77	0.3	1.8e-8	Neuroticism;
CRC	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.61	5.76	0.3	1.98e-8	IgG glycosylation;
CRC	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.61	7.32	0.37	1.88e-12	Carotid intima media thickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00959118	chr1:169455055	SLC19A2	0.4	6.08	0.32	3.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.31	0.75	5.05e-60	Prudent dietary pattern;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.46	0.34	3.85e-10	Bipolar disorder;
CRC	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.45	-11.79	-0.54	5.49e-27	Plateletcrit;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg15786705	chr6:28176104	NA	0.54	7.06	0.36	1.01e-11	Parkinson's disease;
CRC	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.53	8.58	0.43	3.78e-16	Endometrial cancer;
CRC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.5	8.29	0.42	2.85e-15	Aortic root size;
CRC	cis	rs6496667	0.738	rs16944500	chr15:91026973	A/T	cg04176472	chr15:90893244	GABARAPL3	-0.51	-7.61	-0.39	2.9e-13	Rheumatoid arthritis;
CRC	cis	rs4363385	0.747	rs1611760	chr1:152957573	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.07e-13	Inflammatory skin disease;
CRC	cis	rs9903692	0.954	rs3744346	chr17:46198876	G/C	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	3.09e-14	Pulse pressure;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.76	11.06	0.52	2.23e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.14	-0.32	2.33e-9	Diabetic kidney disease;
CRC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.56	7.72	0.39	1.42e-13	Lung cancer;
CRC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.82	0.51	1.51e-23	Motion sickness;
CRC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.19	-0.41	5.96e-15	Type 2 diabetes;
CRC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.21	-0.41	5.1e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.49	-6.74	-0.35	7.01e-11	Tuberculosis;
CRC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.66	10.3	0.49	9.34e-22	Total cholesterol levels;
CRC	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.64	8.34	0.42	2.01e-15	Uric acid levels;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg03160526	chr17:80928410	B3GNTL1	0.57	7.77	0.39	1.02e-13	Glycated hemoglobin levels;
CRC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg05072774	chr3:49840536	C3orf54	-0.44	-5.71	-0.3	2.55e-8	Resting heart rate;
CRC	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.96	-12.4	-0.56	3.23e-29	Exhaled nitric oxide output;
CRC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.83	10.68	0.51	4.72e-23	Monocyte percentage of white cells;
CRC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.45	-6.71	-0.35	8.58e-11	Blood metabolite levels;
CRC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.1	-12.3	-0.56	7.15e-29	Diabetic kidney disease;
CRC	cis	rs28655083	0.636	rs7194836	chr16:77066830	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-6.64	-0.34	1.28e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.49	9.81	0.48	4.4e-20	Ulcerative colitis;
CRC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.08	-0.32	3.33e-9	Height;
CRC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.65	9.63	0.47	1.69e-19	Breast cancer;
CRC	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.57	7.88	0.4	4.78e-14	Coronary artery disease;
CRC	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg02560186	chr11:3602584	NA	-0.71	-7.15	-0.37	5.68e-12	Blood pressure (smoking interaction);
CRC	cis	rs7605827	0.836	rs13009246	chr2:15640237	A/G	cg19274914	chr2:15703543	NA	0.4	6.15	0.32	2.27e-9	Educational attainment (years of education);
CRC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.88e-9	Hemoglobin concentration;
CRC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.44	6.33	0.33	8.22e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.68	-11.03	-0.52	2.77e-24	Hepatocellular carcinoma;
CRC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg18904891	chr8:8559673	CLDN23	0.48	6.6	0.34	1.63e-10	Obesity-related traits;
CRC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg05673287	chr15:77411982	SGK269	-0.52	-8.07	-0.41	1.36e-14	Type 2 diabetes;
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.4	18.86	0.72	2.63e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg27490568	chr2:178487706	NA	0.39	5.81	0.31	1.46e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.53	-0.34	2.44e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg22561889	chr6:118971681	C6orf204	0.51	6.55	0.34	2.25e-10	Renal cell carcinoma;
CRC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.55	-8.5	-0.42	6.69e-16	Aortic root size;
CRC	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.45	-7.75	-0.39	1.18e-13	Mitral valve prolapse;
CRC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.55	7.69	0.39	1.74e-13	Coronary artery disease;
CRC	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.0	0.36	1.46e-11	Ulcerative colitis;
CRC	cis	rs3018066	0.666	rs6816614	chr4:107049750	C/G	cg01869342	chr4:106983673	TBCK	0.44	5.8	0.3	1.57e-8	Cancer;
CRC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.59	0.47	2.2e-19	Cognitive test performance;
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.34	3.01e-10	Bipolar disorder;
CRC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.02	-0.32	4.61e-9	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02895995	chr19:7554069	PEX11G	0.46	5.97	0.31	6.14e-9	Thyroid stimulating hormone;
CRC	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.35	-0.33	7.16e-10	Metabolite levels (Pyroglutamine);
CRC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg00745463	chr17:30367425	LRRC37B	-0.46	-6.38	-0.33	5.95e-10	Hip circumference adjusted for BMI;
CRC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.91	0.44	3.53e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.52	5.91	0.31	8.35e-9	Diabetic retinopathy;
CRC	cis	rs2411233	0.967	rs7180968	chr15:39288527	C/G	cg23129342	chr15:39283510	NA	0.32	6.03	0.32	4.51e-9	Platelet count;
CRC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.59	8.79	0.44	8.4e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-5.98	-0.31	5.68e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08051231	chr16:19422492	TMC5	0.46	6.94	0.36	2.03e-11	Thyroid stimulating hormone;
CRC	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.52	-9.8	-0.48	4.49e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.76	14.17	0.62	6.69e-36	Prudent dietary pattern;
CRC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.39	6.39	0.33	5.56e-10	Dupuytren's disease;
CRC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	3.03e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.6	8.87	0.44	4.75e-17	Lymphocyte counts;
CRC	cis	rs6546550	0.743	rs6546548	chr2:70017022	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.86	-0.35	3.4e-11	Prevalent atrial fibrillation;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.4	-0.38	1.16e-12	Bipolar disorder;
CRC	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.52	8.82	0.44	7.03e-17	Dupuytren's disease;
CRC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.12	-0.32	2.6e-9	Post bronchodilator FEV1;
CRC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.41	6.61	0.34	1.55e-10	Platelet count;
CRC	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.62	-9.01	-0.44	1.68e-17	Coronary artery disease;
CRC	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.69	-11.3	-0.53	3.17e-25	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.48	-6.74	-0.35	7.03e-11	Corneal structure;
CRC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.78	12.26	0.56	1e-28	Breast cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17548431	chr4:160024475	NA	0.37	6.17	0.32	1.97e-9	Obesity-related traits;
CRC	cis	rs2457480	0.516	rs2035416	chr10:44649690	T/C	cg09554077	chr10:44749378	NA	0.46	5.89	0.31	9.39e-9	Coronary artery disease;
CRC	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg10820045	chr2:198174542	NA	0.38	6.31	0.33	9.24e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.3	-0.37	2.24e-12	Total body bone mineral density;
CRC	cis	rs1178968	1.000	rs13240408	chr7:72758023	T/C	cg25889504	chr7:72793014	NA	0.53	5.93	0.31	7.73e-9	Triglyceride levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01261044	chr14:35451962	SRP54	0.5	7.15	0.37	5.65e-12	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.62	-10.5	-0.5	1.99e-22	Prudent dietary pattern;
CRC	cis	rs16852403	0.583	rs10494510	chr1:178074581	A/G	cg00404053	chr1:178313656	RASAL2	0.58	7.28	0.37	2.45e-12	Childhood ear infection;
CRC	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.5	-7.96	-0.4	2.79e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg03647239	chr10:116582469	FAM160B1	-0.41	-5.71	-0.3	2.54e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.53	0.54	4.61e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.2e-25	Prostate cancer;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	6.0	0.31	5.35e-9	Obesity-related traits;
CRC	cis	rs12980942	0.591	rs11879435	chr19:41757603	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.62	0.34	1.46e-10	Coronary artery disease;
CRC	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.34	-0.33	7.59e-10	Breast cancer;
CRC	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.85	13.08	0.58	9.14e-32	Ulcerative colitis;
CRC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg07741184	chr6:167504864	NA	-0.36	-6.39	-0.33	5.77e-10	Crohn's disease;
CRC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.48	7.04	0.36	1.1e-11	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs6585424	1.000	rs12779955	chr10:81940864	C/T	cg11900509	chr10:81946545	ANXA11	0.76	9.35	0.46	1.43e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg00531865	chr16:30841666	NA	0.47	6.78	0.35	5.6e-11	Dementia with Lewy bodies;
CRC	cis	rs73206853	0.925	rs12318836	chr12:110642190	A/C	cg12870014	chr12:110450643	ANKRD13A	0.67	8.88	0.44	4.47e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12273811	chr6:28175739	NA	0.64	8.12	0.41	9.7e-15	Parkinson's disease;
CRC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.47	8.48	0.42	7.64e-16	Reticulocyte fraction of red cells;
CRC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.85	-0.35	3.57e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.33	-0.33	7.89e-10	Parkinson's disease;
CRC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.73	-0.35	7.76e-11	Alzheimer's disease (late onset);
CRC	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg02158880	chr13:53174818	NA	0.39	5.64	0.3	3.74e-8	Lewy body disease;
CRC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg07195577	chr17:27052828	TLCD1	0.42	6.05	0.32	4.01e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.34	-0.56	5.16e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg02336364	chr1:24764700	NIPAL3	0.46	8.16	0.41	6.97e-15	Response to interferon beta in multiple sclerosis;
CRC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.95	-0.31	6.9e-9	Life satisfaction;
CRC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg18612461	chr15:75251733	NA	0.38	5.96	0.31	6.56e-9	Breast cancer;
CRC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.9	16.58	0.67	2.73e-45	Intelligence (multi-trait analysis);
CRC	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.49	7.02	0.36	1.3e-11	Corneal astigmatism;
CRC	trans	rs4276421	0.806	rs12520124	chr5:45435019	T/C	cg04793272	chr11:119020941	ABCG4	-0.38	-6.23	-0.32	1.46e-9	P wave duration;
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg00343986	chr7:65444356	GUSB	-0.51	-7.61	-0.39	2.88e-13	Aortic root size;
CRC	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.42	6.03	0.32	4.4e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg06287003	chr12:125626642	AACS	-0.46	-7.18	-0.37	4.64e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.05	0.55	5.92e-28	Testicular germ cell tumor;
CRC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.95	18.2	0.71	1.07e-51	Intelligence (multi-trait analysis);
CRC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.46	-8.46	-0.42	8.68e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.95	-0.36	2.01e-11	Bipolar disorder;
CRC	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg04611788	chr3:186434169	KNG1	-0.58	-8.36	-0.42	1.79e-15	Blood protein levels;
CRC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.57	5.95	0.31	6.94e-9	Blood protein levels;
CRC	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.46	6.22	0.32	1.49e-9	Cholesterol, total;
CRC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.64	10.0	0.48	9.57e-21	Huntington's disease progression;
CRC	trans	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg07393940	chr7:158741817	NA	-0.51	-7.35	-0.38	1.61e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg06953865	chr19:18549723	ISYNA1	-0.37	-5.66	-0.3	3.38e-8	Breast cancer;
CRC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.93	-17.23	-0.69	7.15e-48	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.39	-0.42	1.48e-15	Total cholesterol levels;
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.82e-28	Alzheimer's disease;
CRC	cis	rs11608355	0.508	rs12817730	chr12:109799330	G/A	cg19025524	chr12:109796872	NA	-0.48	-7.15	-0.37	5.77e-12	Neuroticism;
CRC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg11245181	chr6:149772854	ZC3H12D	0.52	8.99	0.44	1.99e-17	Dupuytren's disease;
CRC	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.42	0.46	8.34e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg20041105	chr8:143859282	LYNX1	0.43	7.04	0.36	1.13e-11	Urinary tract infection frequency;
CRC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.46	-6.93	-0.36	2.25e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6844506	1.000	rs4862356	chr4:185220262	A/G	cg06915193	chr4:185205329	NA	0.41	5.74	0.3	2.13e-8	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
CRC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.76	0.3	1.92e-8	Coronary artery disease;
CRC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.63	0.39	2.57e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.47	-5.86	-0.31	1.15e-8	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CRC	trans	rs7976838	0.908	rs35203350	chr12:60143404	A/G	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	18.87	0.72	2.33e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.52	6.48	0.34	3.43e-10	White matter hyperintensity burden;
CRC	cis	rs117623576	0.941	rs11008775	chr10:32410307	T/C	cg03047570	chr10:32398778	NA	-0.76	-8.78	-0.44	8.91e-17	Anti-saccade response;
CRC	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.51	6.16	0.32	2.11e-9	Recombination rate (females);
CRC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06470822	chr6:28175283	NA	0.67	5.79	0.3	1.66e-8	Depression;
CRC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.63	12.61	0.57	5.15e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.47	-6.38	-0.33	6.09e-10	Schizophrenia;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.97	-0.44	2.23e-17	Bipolar disorder;
CRC	cis	rs7572644	0.621	rs4462754	chr2:28063994	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.23	0.32	1.43e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.62	-9.07	-0.45	1.09e-17	Subjective well-being;
CRC	cis	rs6838801	0.892	rs12647024	chr4:77575503	T/C	cg17476223	chr4:77663285	SHROOM3	0.42	5.92	0.31	8.27e-9	Cleft lip with or without cleft palate;
CRC	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.55	-7.28	-0.37	2.44e-12	Multiple sclerosis;
CRC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.51	-6.09	-0.32	3.15e-9	Diastolic blood pressure;
CRC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg21251018	chr6:28226885	NKAPL	0.56	9.56	0.47	2.8e-19	Pubertal anthropometrics;
CRC	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.4	-6.66	-0.34	1.15e-10	Eye color traits;
CRC	cis	rs883565	0.655	rs7649923	chr3:39102137	G/A	cg01426195	chr3:39028469	NA	-0.54	-8.77	-0.44	9.85e-17	Handedness;
CRC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.52	7.43	0.38	9.67e-13	Schizophrenia;
CRC	cis	rs17023223	0.537	rs12081585	chr1:119615956	A/C	cg05756136	chr1:119680316	WARS2	-0.54	-7.13	-0.37	6.21e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-15.27	-0.64	3.45e-40	Lymphocyte percentage of white cells;
CRC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Bladder cancer;
CRC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.06	0.41	1.47e-14	Menopause (age at onset);
CRC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.99	-0.4	2.23e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg01874867	chr7:94954059	PON1	-0.48	-6.19	-0.32	1.81e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.53	-0.38	5.03e-13	Colorectal cancer;
CRC	cis	rs8060686	0.858	rs7191129	chr16:67801391	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-11.1	-0.52	1.6e-24	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg18809830	chr7:99032528	PTCD1	-1.19	-8.64	-0.43	2.53e-16	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08472398	chr6:26156741	HIST1H1E	0.38	6.23	0.32	1.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.44	6.61e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.39e-26	Prudent dietary pattern;
CRC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.96	-0.31	6.58e-9	Educational attainment;
CRC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.55	-8.07	-0.41	1.36e-14	IgG glycosylation;
CRC	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg16950941	chr11:66035639	RAB1B	-0.61	-7.53	-0.38	5.06e-13	Electroencephalogram traits;
CRC	cis	rs7274811	0.711	rs293713	chr20:31942247	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.86	0.31	1.11e-8	Height;
CRC	cis	rs73206853	0.841	rs56306150	chr12:110716775	A/T	cg12870014	chr12:110450643	ANKRD13A	0.8	7.72	0.39	1.39e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.89	16.18	0.67	9.83e-44	Prostate cancer;
CRC	trans	rs6777098	0.793	rs4546146	chr3:166951314	C/T	cg07098314	chr17:39823360	NA	0.54	6.08	0.32	3.33e-9	Response to paliperidone in schizophrenia (positive Marder score);
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.59	8.68	0.43	1.83e-16	Lymphocyte counts;
CRC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.69	-0.6	4.65e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs185694	0.948	rs200512	chr13:30906446	C/T	cg07600127	chr13:30881527	KATNAL1	-0.56	-6.03	-0.32	4.39e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.85	-13.67	-0.6	5.3e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.09	-0.49	4.87e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.32	8.07	0.41	1.31e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.68	-7.01	-0.36	1.35e-11	Blood protein levels;
CRC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.55	8.02	0.4	1.89e-14	Melanoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.49	6.5	0.34	3e-10	Thyroid stimulating hormone;
CRC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.03	0.32	4.45e-9	Diabetic retinopathy;
CRC	cis	rs6604026	0.656	rs11164845	chr1:93416685	A/G	cg17283838	chr1:93427260	FAM69A	0.42	5.65	0.3	3.43e-8	Multiple sclerosis;
CRC	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg13385794	chr1:248469461	NA	0.4	7.09	0.36	8.35e-12	Common traits (Other);
CRC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg08213375	chr14:104286397	PPP1R13B	0.58	11.91	0.55	1.88e-27	Schizophrenia;
CRC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.47	6.3	0.33	9.71e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg04731861	chr2:219085781	ARPC2	0.34	6.8	0.35	5e-11	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.69	-0.43	1.8e-16	Aortic root size;
CRC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.51	-0.38	5.61e-13	Alzheimer's disease;
CRC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.68	-10.79	-0.51	1.94e-23	Coronary artery disease;
CRC	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg10820045	chr2:198174542	NA	0.42	7.34	0.38	1.71e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14051306	chr5:56248243	MIER3	0.4	6.22	0.32	1.55e-9	Interleukin-6 levels;
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14895029	chr7:2775587	GNA12	-0.43	-6.28	-0.33	1.05e-9	Height;
CRC	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.58	9.39	0.46	1.01e-18	Migraine;
CRC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.42	6.51	0.34	2.84e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs524281	0.773	rs10896105	chr11:66002260	A/G	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.63e-9	Rheumatoid arthritis;
CRC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.73	10.85	0.51	1.19e-23	Intelligence (multi-trait analysis);
CRC	trans	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg25214090	chr10:38739885	LOC399744	0.41	6.44	0.33	4.26e-10	Diastolic blood pressure;
CRC	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg19875578	chr6:126661172	C6orf173	0.41	5.92	0.31	8.17e-9	Male-pattern baldness;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01446983	chr17:47754976	SPOP	0.47	6.2	0.32	1.71e-9	Anxiety disorder;
CRC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.47	8.54	0.43	5.11e-16	Height;
CRC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.64	-8.87	-0.44	4.72e-17	DNA methylation (variation);
CRC	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.95	0.48	1.5e-20	Ileal carcinoids;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg12273811	chr6:28175739	NA	0.46	6.94	0.36	2.04e-11	Cardiac Troponin-T levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15235185	chr1:193028809	TROVE2;UCHL5	-0.52	-6.27	-0.33	1.16e-9	Diisocyanate-induced asthma;
CRC	cis	rs17443541	0.507	rs6435020	chr2:200448356	C/T	cg03741458	chr2:200468445	NA	-0.39	-6.04	-0.32	4.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.89	-14.84	-0.63	1.65e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	1.09	11.1	0.52	1.52e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.44	-5.92	-0.31	8.27e-9	Type 2 diabetes;
CRC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.77	11.31	0.53	2.78e-25	High light scatter reticulocyte count;
CRC	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.46	6.99	0.36	1.56e-11	Educational attainment;
CRC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.65	-10.62	-0.51	7.48e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.56	7.46	0.38	7.66e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.59	8.59	0.43	3.42e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg27098574	chr16:75285489	BCAR1	0.41	6.68	0.35	1.01e-10	Obesity-related traits;
CRC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.36	6.3	0.33	9.45e-10	Crohn's disease;
CRC	cis	rs3018066	0.748	rs7657962	chr4:106966715	G/A	cg01869342	chr4:106983673	TBCK	0.45	6.59	0.34	1.79e-10	Cancer;
CRC	trans	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.23	-0.32	1.39e-9	Tuberculosis;
CRC	cis	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg20159608	chr7:32802032	NA	-0.6	-7.13	-0.37	6.46e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-7.82	-0.4	7.04e-14	Colorectal cancer;
CRC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.59	-9.65	-0.47	1.4e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg18301423	chr5:131593218	PDLIM4	0.38	6.31	0.33	8.97e-10	Breast cancer;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg12516270	chr8:143859308	LYNX1	-0.39	-6.44	-0.33	4.18e-10	Urinary tract infection frequency;
CRC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.58	8.67	0.43	1.96e-16	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08021986	chr19:12777501	MORG1;MAN2B1	0.43	6.14	0.32	2.31e-9	Response to antipsychotic treatment;
CRC	cis	rs12476592	0.602	rs10469944	chr2:63816672	C/G	cg10828910	chr2:63850056	LOC388955	0.49	6.06	0.32	3.75e-9	Childhood ear infection;
CRC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg24375607	chr4:120327624	NA	0.48	7.74	0.39	1.2e-13	Corneal astigmatism;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg11235426	chr6:292522	DUSP22	-0.55	-7.8	-0.4	8.05e-14	Menopause (age at onset);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg14951734	chr2:208576279	CCNYL1	-0.41	-6.04	-0.32	4.18e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg18758796	chr5:131593413	PDLIM4	0.35	6.27	0.33	1.16e-9	Blood metabolite levels;
CRC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.62	-0.39	2.78e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	7.24	0.37	3.12e-12	Blood metabolite levels;
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg05192639	chr6:26864778	GUSBL1	-0.35	-6.05	-0.32	3.97e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg19407955	chr1:165599744	MGST3	-0.52	-6.62	-0.34	1.49e-10	Total ventricular volume;
CRC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.53e-10	Response to antipsychotic treatment;
CRC	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.52	7.45	0.38	8.29e-13	Testicular germ cell tumor;
CRC	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg10298567	chr3:47292165	KIF9	-0.41	-6.77	-0.35	5.84e-11	Colorectal cancer;
CRC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.46	7.43	0.38	9.61e-13	Major depressive disorder;
CRC	trans	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg13565492	chr6:43139072	SRF	-0.86	-6.3	-0.33	9.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs61996546	0.622	rs61998698	chr15:26868306	G/C	cg15066197	chr15:26874202	GABRB3	-0.44	-6.69	-0.35	9.44e-11	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs3764400	0.567	rs2325804	chr17:46218545	G/A	cg10706073	chr17:46328419	SKAP1	0.59	6.36	0.33	6.7e-10	Body mass index;
CRC	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.81	10.53	0.5	1.56e-22	Prostate cancer;
CRC	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.46	-7.18	-0.37	4.55e-12	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.66	-6.67	-0.35	1.09e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg10729496	chr3:10149963	C3orf24	0.48	5.63	0.3	3.81e-8	Alzheimer's disease;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg25164649	chr6:28176230	NA	0.64	9.01	0.45	1.66e-17	Cardiac Troponin-T levels;
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.38	5.68	0.3	2.92e-8	Lymphocyte counts;
CRC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-8.29	-0.42	2.85e-15	Intraocular pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25942691	chr19:36705733	ZNF565;ZNF146	0.43	6.05	0.32	4.04e-9	Response to antipsychotic treatment;
CRC	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-6.86	-0.35	3.42e-11	Putamen volume;
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.72	0.75	1.28e-61	Prudent dietary pattern;
CRC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg23018236	chr17:30244563	NA	-0.67	-8.04	-0.41	1.69e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg17545662	chr6:170176663	C6orf70	0.56	6.45	0.34	3.94e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.42	6.09	0.32	3.17e-9	Renal cell carcinoma;
CRC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg05585544	chr11:47624801	NA	-0.43	-6.8	-0.35	4.98e-11	Mean corpuscular hemoglobin;
CRC	cis	rs524281	0.773	rs10750781	chr11:66037270	A/G	cg16950941	chr11:66035639	RAB1B	-0.72	-8.1	-0.41	1.09e-14	Electroencephalogram traits;
CRC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-10.29	-0.49	1.07e-21	Breast cancer;
CRC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	10.43	0.5	3.54e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6445967	1.000	rs7622074	chr3:58312297	A/G	cg23715586	chr3:58305044	RPP14	0.36	6.0	0.31	5.12e-9	Platelet count;
CRC	cis	rs863345	0.604	rs2873594	chr1:158504790	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.47	-0.46	5.55e-19	Migraine;Coronary artery disease;
CRC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.49	10.24	0.49	1.5e-21	Alcohol dependence;
CRC	cis	rs737008	1.000	rs737008	chr16:11374866	G/T	cg00044050	chr16:11439710	C16orf75	-0.51	-6.79	-0.35	5.15e-11	Obesity-related traits;
CRC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.4	6.03	0.32	4.41e-9	Coronary artery disease;
CRC	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.81	-11.57	-0.54	3.36e-26	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.18	-0.32	1.91e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11229555	0.645	rs7945992	chr11:58187755	T/A	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.47	7.27	0.37	2.58e-12	Corneal astigmatism;
CRC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.62	9.38	0.46	1.1e-18	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6504622	0.537	rs7342957	chr17:44997356	G/A	cg16759221	chr17:45003025	GOSR2	0.6	9.66	0.47	1.33e-19	Orofacial clefts;
CRC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.59	-9.45	-0.46	6.53e-19	Aortic root size;
CRC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.44	-8.92	-0.44	3.33e-17	Renal cell carcinoma;
CRC	cis	rs7113874	0.543	rs7935708	chr11:8478545	C/A	cg17679104	chr11:8615758	STK33	-0.34	-5.71	-0.3	2.51e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.4	-8.72	-0.43	1.36e-16	Eye color traits;
CRC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.63	11.63	0.54	1.96e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.65	-0.3	3.52e-8	Lung cancer;
CRC	cis	rs10450586	0.932	rs11029915	chr11:27311468	G/A	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02290350	chr8:58132656	NA	-0.51	-6.39	-0.33	5.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.53	7.45	0.38	8.03e-13	Triglycerides;
CRC	cis	rs6662572	0.737	rs4660333	chr1:46462059	T/C	cg08644498	chr1:46502608	NA	-0.46	-7.38	-0.38	1.3e-12	Blood protein levels;
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.37	1.72e-12	Alzheimer's disease;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg25164649	chr6:28176230	NA	0.63	9.05	0.45	1.28e-17	Cardiac Troponin-T levels;
CRC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.59	8.67	0.43	2.07e-16	Lymphocyte counts;
CRC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.66	-0.3	3.38e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.63e-9	Life satisfaction;
CRC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.4	6.23	0.32	1.47e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-6.62	-0.34	1.49e-10	Insulin-like growth factors;
CRC	cis	rs12612619	0.761	rs7606840	chr2:27243364	A/G	cg00617064	chr2:27272375	NA	-0.37	-6.13	-0.32	2.51e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.58	-7.83	-0.4	6.76e-14	Extraversion;
CRC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.65	-10.66	-0.51	5.57e-23	Dental caries;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg10729496	chr3:10149963	C3orf24	0.45	6.08	0.32	3.26e-9	Alzheimer's disease;
CRC	cis	rs3764400	0.567	rs2325784	chr17:46212309	A/G	cg10706073	chr17:46328419	SKAP1	0.62	6.52	0.34	2.7e-10	Body mass index;
CRC	cis	rs9549328	0.520	rs36144023	chr13:113616592	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.43	0.33	4.47e-10	Systolic blood pressure;
CRC	cis	rs10946940	0.864	rs13201411	chr6:27498217	G/C	cg15845792	chr6:28175446	NA	-0.47	-6.3	-0.33	9.61e-10	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27109827	chr16:28936530	RABEP2	0.38	6.19	0.32	1.79e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16095951	chr6:108455178	NA	0.47	6.56	0.34	2.12e-10	Anxiety disorder;
CRC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg21251018	chr6:28226885	NKAPL	0.46	7.31	0.37	2.03e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14559774	chr8:87355871	WWP1	-0.55	-6.71	-0.35	8.51e-11	Monocyte percentage of white cells;
CRC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.57	8.11	0.41	1e-14	Carotid intima media thickness;
CRC	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.98	0.44	2.16e-17	Coffee consumption (cups per day);
CRC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.27	0.37	2.62e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.52	-0.38	5.19e-13	Aortic root size;
CRC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.8	0.51	1.8e-23	Motion sickness;
CRC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	9.85	0.48	3.23e-20	Cognitive test performance;
CRC	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.02	-0.32	4.61e-9	Height;
CRC	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg20885578	chr2:198174922	NA	-0.44	-6.99	-0.36	1.5e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-11.11	-0.52	1.44e-24	Personality dimensions;
CRC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.46	-6.99	-0.36	1.55e-11	Coronary artery disease;
CRC	cis	rs3736485	0.966	rs7170217	chr15:51890678	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.42	-0.33	4.76e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.8	0.4	8.17e-14	Lung cancer;
CRC	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-18.34	-0.71	3.1e-52	Schizophrenia;
CRC	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg18232548	chr7:50535776	DDC	0.39	5.78	0.3	1.71e-8	Systemic sclerosis;
CRC	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.72	-0.35	8e-11	Coronary artery disease;
CRC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.5	7.79	0.39	8.78e-14	Red blood cell count;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg18758796	chr5:131593413	PDLIM4	0.47	8.28	0.42	3.22e-15	Blood metabolite levels;
CRC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.52	8.99	0.44	2.01e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.39	8.85	0.44	5.65e-17	Multiple system atrophy;
CRC	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.58	10.47	0.5	2.54e-22	Blood metabolite ratios;
CRC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	13.08	0.58	9.08e-32	Chronic sinus infection;
CRC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.33e-13	Motion sickness;
CRC	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.82	-10.32	-0.49	8.21e-22	Height;
CRC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.95	12.4	0.56	3.22e-29	Triglycerides;
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-7.99	-0.4	2.23e-14	Type 2 diabetes;
CRC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06462663	chr19:18546047	ISYNA1	0.46	7.07	0.36	9.28e-12	Breast cancer;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg15786705	chr6:28176104	NA	0.48	7.16	0.37	5.37e-12	Cardiac Troponin-T levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23320034	chr20:60877648	ADRM1	0.4	6.04	0.32	4.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.51	8.07	0.41	1.34e-14	Red blood cell count;
CRC	trans	rs1979967	0.524	rs79248142	chr15:79657091	G/A	cg14802097	chr12:42970349	PRICKLE1	0.52	6.06	0.32	3.66e-9	Interleukin-18 levels;
CRC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-6.43	-0.33	4.49e-10	Response to antipsychotic treatment;
CRC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.37	7.19e-12	Menopause (age at onset);
CRC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-12.19	-0.56	1.89e-28	Prostate cancer;
CRC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.12	10.53	0.5	1.51e-22	Diabetic retinopathy;
CRC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg19318889	chr4:1322082	MAEA	0.4	5.66	0.3	3.25e-8	Obesity-related traits;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	7.42	0.38	1.04e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.52	9.0	0.44	1.8e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs737008	0.960	rs11640295	chr16:11390728	C/G	cg00044050	chr16:11439710	C16orf75	0.51	6.73	0.35	7.37e-11	Obesity-related traits;
CRC	cis	rs12580194	0.593	rs7488940	chr12:55802591	C/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.15	-0.45	6.31e-18	Cancer;
CRC	cis	rs600626	0.588	rs11236526	chr11:75467605	G/A	cg24262691	chr11:75473276	NA	0.51	7.77	0.39	1.02e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.27	0.37	2.65e-12	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.42	0.38	1.02e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1347297	0.756	rs10173183	chr2:179276427	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.42	-5.78	-0.3	1.69e-8	Alzheimer disease and age of onset;
CRC	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.53	8.16	0.41	7.18e-15	Vitiligo;
CRC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg17724175	chr1:150552817	MCL1	0.47	6.97	0.36	1.74e-11	Melanoma;
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg06494592	chr3:125709126	NA	-0.55	-6.43	-0.33	4.43e-10	Blood pressure (smoking interaction);
CRC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	17.33	0.69	2.96e-48	Platelet count;
CRC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.64	-0.3	3.64e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.59	11.8	0.55	4.99e-27	Birth weight;
CRC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.77	11.66	0.54	1.52e-26	Multiple sclerosis;
CRC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	5.87	0.31	1.08e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.07	-14.78	-0.63	2.8900000000000003e-38	Exhaled nitric oxide output;
CRC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.46	0.46	6.22e-19	Heart rate;
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.67	0.6	5.38e-34	Alzheimer's disease;
CRC	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs77861329	0.920	rs808787	chr3:52203249	G/A	cg08692210	chr3:52188851	WDR51A	0.87	8.16	0.41	7.07e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.52	-7.28	-0.37	2.48e-12	Dental caries;
CRC	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.02	-0.32	4.56e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04977951	chr14:99947745	SETD3;CCNK	0.39	6.36	0.33	6.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.56	-0.43	4.28e-16	Electroencephalogram traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04738279	chr17:46696432	NA	0.43	6.26	0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.7	-10.15	-0.49	3.08e-21	Lung cancer;
CRC	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.89	10.75	0.51	2.56e-23	Exhaled nitric oxide output;
CRC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.59	6.3	0.33	9.35e-10	Lung cancer;
CRC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg09658497	chr7:2847517	GNA12	-0.38	-5.91	-0.31	8.66e-9	Height;
CRC	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.72	-11.53	-0.54	4.62e-26	Neurofibrillary tangles;
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg04969067	chr8:143858791	LYNX1	0.44	7.59	0.39	3.29e-13	Urinary tract infection frequency;
CRC	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	0.89	7.75	0.39	1.18e-13	Fat distribution (HIV);
CRC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.77	-13.37	-0.59	7.52e-33	Intelligence (multi-trait analysis);
CRC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.5	7.54	0.38	4.76e-13	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	trans	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg01505111	chr6:125621795	HDDC2	0.38	6.04	0.32	4.06e-9	DNA methylation (variation);
CRC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.43	5.96	0.31	6.37e-9	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01131735	chr17:39968419	FKBP10;SC65	0.4	5.98	0.31	5.7e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07701084	chr6:150067640	NUP43	0.52	7.55	0.38	4.4e-13	Lung cancer;
CRC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.57	5.95	0.31	6.86e-9	Blood protein levels;
CRC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.46	0.38	7.95e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.5	-6.78	-0.35	5.72e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.42	0.33	4.71e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.7	-0.39	1.63e-13	Gut microbiome composition (summer);
CRC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-15.48	-0.65	5.67e-41	Prostate cancer;
CRC	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-7.64	-0.39	2.38e-13	Total body bone mineral density;
CRC	cis	rs910187	0.571	rs3746489	chr20:45801716	C/T	cg27589058	chr20:45804311	EYA2	-0.4	-7.54	-0.38	4.59e-13	Migraine;
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg16606324	chr3:10149918	C3orf24	0.61	8.03	0.4	1.7e-14	Alzheimer's disease;
CRC	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-7.02	-0.36	1.27e-11	Bipolar disorder;
CRC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg19682013	chr15:45996608	NA	0.33	6.78	0.35	5.7e-11	Waist circumference;Weight;
CRC	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.68	-0.51	4.62e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg00316803	chr15:76480434	C15orf27	-0.34	-5.61	-0.3	4.2e-8	Blood metabolite levels;
CRC	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.77	-10.24	-0.49	1.47e-21	Blood pressure (smoking interaction);
CRC	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.46	-6.04	-0.32	4.13e-9	Post bronchodilator FEV1;
CRC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg21770322	chr7:97807741	LMTK2	-0.69	-12.39	-0.56	3.3600000000000003e-29	Breast cancer;
CRC	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg12858261	chr2:113808755	IL1F8	0.46	6.68	0.35	1.02e-10	Protein quantitative trait loci;
CRC	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.45	-7.26	-0.37	2.87e-12	Alcohol dependence (age at onset);
CRC	cis	rs12745968	0.589	rs3936944	chr1:93106958	C/T	cg17283838	chr1:93427260	FAM69A	-0.47	-6.38	-0.33	6.1e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg25856811	chr1:152973957	SPRR3	-0.21	-5.62	-0.3	4.03e-8	Inflammatory skin disease;
CRC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg21155852	chr7:2048760	MAD1L1	-0.46	-6.39	-0.33	5.79e-10	Bipolar disorder;
CRC	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-9.92	-0.48	1.79e-20	Body mass index;
CRC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg04545296	chr12:48745243	ZNF641	0.35	6.07	0.32	3.57e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg15845792	chr6:28175446	NA	0.9	13.02	0.58	1.52e-31	Parkinson's disease;
CRC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.69	-10.95	-0.52	5.43e-24	Mean corpuscular hemoglobin;
CRC	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.4	5.76	0.3	1.91e-8	Platelet distribution width;
CRC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.31	0.33	9.03e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-11.83	-0.55	3.91e-27	Personality dimensions;
CRC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.29	0.37	2.37e-12	Motion sickness;
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.66	-0.51	5.33e-23	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.65	-0.43	2.29e-16	Aortic root size;
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.46	-0.38	7.96e-13	Lymphocyte counts;
CRC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.72	-0.3	2.45e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.2	-0.37	4.21e-12	Retinal vascular caliber;
CRC	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.13	24.16	0.8	7.25e-75	Schizophrenia;
CRC	cis	rs7113874	0.550	rs10840085	chr11:8613949	A/G	cg02811074	chr11:8615871	STK33	0.32	5.7	0.3	2.73e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.96	-12.66	-0.57	3.49e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs16867335	1.000	rs2113786	chr2:181483250	C/T	cg23363182	chr2:181467187	NA	-0.48	-6.49	-0.34	3.17e-10	Survival in rectal cancer;
CRC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.28	5.69	0.3	2.86e-8	Personality dimensions;
CRC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.07	0.32	3.47e-9	HDL cholesterol;
CRC	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.73	-9.61	-0.47	1.99e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.03	-0.36	1.17e-11	Menarche (age at onset);
CRC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.6	10.61	0.51	7.98e-23	Aortic root size;
CRC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg04362960	chr10:104952993	NT5C2	-0.44	-6.21	-0.32	1.59e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg02659138	chr7:134003124	SLC35B4	0.35	5.99	0.31	5.54e-9	Mean platelet volume;
CRC	cis	rs501120	0.584	rs11595946	chr10:44685695	C/T	cg09554077	chr10:44749378	NA	0.68	7.29	0.37	2.38e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.31	-6.92	-0.36	2.44e-11	IgG glycosylation;
CRC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg16928487	chr17:17741425	SREBF1	0.58	8.57	0.43	4.13e-16	Total body bone mineral density;
CRC	cis	rs35000415	1.000	rs35000415	chr7:128585616	C/T	cg19972273	chr7:128594194	NA	0.67	5.99	0.31	5.56e-9	Systemic lupus erythematosus;
CRC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg00343986	chr7:65444356	GUSB	0.43	6.08	0.32	3.31e-9	Aortic root size;
CRC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-9.76	-0.47	6.25e-20	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11178170	chr4:184427252	ING2	0.45	7.45	0.38	8.21e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.53	9.1	0.45	8.59e-18	Colorectal cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13896783	chr2:159313876	CCDC148;PKP4	0.39	6.22	0.32	1.49e-9	Obesity-related traits;
CRC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-8.73	-0.43	1.27e-16	Cognitive function;
CRC	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.76	11.08	0.52	1.92e-24	Plateletcrit;Platelet count;
CRC	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg23167259	chr10:102495509	NA	-0.47	-6.35	-0.33	6.97e-10	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12172441	chr6:28176163	NA	0.59	7.12	0.37	6.82e-12	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00076854	chr13:29233041	POMP	0.43	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.7	10.07	0.49	5.94e-21	Alzheimer's disease;
CRC	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.8	-0.3	1.57e-8	Alzheimer's disease (survival time);
CRC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.59	-8.1	-0.41	1.1e-14	Multiple sclerosis;
CRC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.36	7.01	0.36	1.35e-11	Renal cell carcinoma;
CRC	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.55	9.23	0.45	3.4e-18	Dupuytren's disease;
CRC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.7	12.46	0.57	1.8e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9447004	0.966	rs9343078	chr6:74489384	A/G	cg03014589	chr8:144965836	NA	0.2	5.98	0.31	5.91e-9	Blood protein levels;Calcium levels;
CRC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg21153622	chr11:89784906	NA	-0.38	-6.04	-0.32	4.13e-9	Height;
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs501120	1.000	rs604674	chr10:44756894	G/T	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.43	5.83	0.31	1.35e-8	Longevity;
CRC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.36	0.46	1.32e-18	Blood protein levels;
CRC	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	9.55	0.47	3e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg07617317	chr6:118971624	C6orf204	0.51	6.26	0.33	1.17e-9	Diastolic blood pressure;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.54	10.22	0.49	1.79e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg08885800	chr1:201084119	NA	0.42	7.42	0.38	9.88e-13	Permanent tooth development;
CRC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.76	-9.28	-0.46	2.34e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.54	7.25	0.37	2.93e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.32	-0.33	8.44e-10	Coronary artery disease;
CRC	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-1.05	-10.86	-0.51	1.12e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4728302	0.869	rs13228262	chr7:133598288	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.8e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.56	-7.09	-0.36	8.41e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-10.57	-0.5	1.15e-22	Schizophrenia;
CRC	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.58	7.91	0.4	3.85e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg17788362	chr6:86352627	SYNCRIP	0.49	6.76	0.35	6.43e-11	Smooth-surface caries;
CRC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.89	0.36	2.83e-11	HDL cholesterol;
CRC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.8	10.83	0.51	1.4e-23	Migraine;Coronary artery disease;
CRC	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.46	-0.34	3.72e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.51	6.99	0.36	1.51e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	7.1	0.36	7.9e-12	Mood instability;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg10729496	chr3:10149963	C3orf24	0.47	6.05	0.32	3.84e-9	Alzheimer's disease;
CRC	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg09695851	chr17:3907499	NA	-0.77	-13.83	-0.61	1.28e-34	Type 2 diabetes;
CRC	cis	rs4321325	0.733	rs74707659	chr2:127945469	T/C	cg11380483	chr2:127933992	NA	0.61	7.07	0.36	9.36e-12	Protein C levels;
CRC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg02683197	chr6:28174875	NA	-0.53	-7.32	-0.37	1.94e-12	Systemic lupus erythematosus;
CRC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.32	-6.83	-0.35	4.22e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs11825064	0.666	rs2000859	chr11:134485499	T/G	cg00033773	chr19:12779366	MORG1;C19orf56	0.45	6.17	0.32	1.97e-9	Seasonality;
CRC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.79	10.03	0.48	7.6e-21	Iron status biomarkers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10687823	chr19:36103576	HAUS5	0.48	6.73	0.35	7.6e-11	Anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13244110	chr17:40688572	NAGLU	0.42	6.02	0.31	4.64e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25130390	chr15:65810150	DPP8	0.4	6.67	0.35	1.08e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg23254163	chr1:152506842	NA	0.5	10.08	0.49	5.16e-21	Hair morphology;
CRC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.35	5.64	0.3	3.6e-8	Height;
CRC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.81	13.42	0.59	4.56e-33	Menopause (age at onset);
CRC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.17	11.46	0.53	8.2e-26	Intelligence (multi-trait analysis);
CRC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	7.82	0.4	7.38e-14	Schizophrenia;
CRC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.4	-0.38	1.16e-12	Chronic sinus infection;
CRC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg07718321	chr6:96025334	MANEA	0.48	5.7	0.3	2.64e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg17456097	chr1:26900765	RPS6KA1	0.42	6.28	0.33	1.08e-9	Glucose homeostasis traits;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.55	-9.17	-0.45	5.15e-18	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg10761708	chr20:43804764	PI3	0.51	5.65	0.3	3.57e-8	Blood protein levels;
CRC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.53	-7.16	-0.37	5.17e-12	Gut microbiome composition (summer);
CRC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.97	0.48	1.22e-20	Alzheimer's disease (late onset);
CRC	cis	rs4664293	0.867	rs6732987	chr2:160582429	C/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.62	-0.43	2.84e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-11.77	-0.54	6.3e-27	Cognitive function;
CRC	cis	rs75422866	0.867	rs73104144	chr12:48088173	G/T	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.65	10.16	0.49	2.75e-21	Type 2 diabetes;
CRC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	8.94	0.44	2.87e-17	Height;
CRC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.67	-12.51	-0.57	1.18e-29	Breast cancer;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.61	8.71	0.43	1.48e-16	Alcohol dependence;
CRC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg11189052	chr15:85197271	WDR73	0.59	8.58	0.43	3.73e-16	Schizophrenia;
CRC	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/G	cg26465532	chr10:79446426	NA	-0.71	-6.85	-0.35	3.61e-11	Mortality in heart failure;
CRC	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.95	-12.37	-0.56	4.11e-29	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08071915	chr8:12219732	FAM66A	0.34	5.94	0.31	7.07e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg09597638	chr17:3907349	NA	0.63	11.56	0.54	3.65e-26	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg02683197	chr6:28174875	NA	0.88	10.83	0.51	1.42e-23	Depression;
CRC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.85	-0.35	3.65e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.54	7.46	0.38	7.8e-13	Lung cancer;
CRC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.9	-16.34	-0.67	2.26e-44	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20470467	chr16:30886130	NA	0.5	7.02	0.36	1.3e-11	Response to antipsychotic treatment;
CRC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.5	7.07	0.36	9.58e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.14	-0.32	2.43e-9	Height;
CRC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg17948913	chr5:572064	NA	0.58	6.53	0.34	2.55e-10	Lung disease severity in cystic fibrosis;
CRC	trans	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.44	0.38	8.66e-13	Diabetic kidney disease;
CRC	trans	rs4276421	0.806	rs6451804	chr5:45492205	A/G	cg04793272	chr11:119020941	ABCG4	-0.38	-6.3	-0.33	9.3e-10	P wave duration;
CRC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	2.94e-11	Glioblastoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16275967	chr1:161172255	NDUFS2	0.47	6.87	0.35	3.32e-11	Response to antipsychotic treatment;
CRC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.58	11.05	0.52	2.45e-24	Eye color traits;
CRC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.61	11.23	0.53	5.62e-25	Immature fraction of reticulocytes;
CRC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.46	6.64	0.34	1.28e-10	Testicular germ cell tumor;
CRC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.78	13.21	0.59	2.86e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.42	6.42	0.33	4.86e-10	Social autistic-like traits;
CRC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg21918786	chr6:109611834	NA	-0.39	-6.91	-0.36	2.53e-11	Reticulocyte fraction of red cells;
CRC	cis	rs4601821	0.635	rs7114433	chr11:113208098	C/T	cg14159747	chr11:113255604	NA	0.43	8.1	0.41	1.11e-14	Alcoholic chronic pancreatitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23129613	chr7:150065255	REPIN1	0.47	6.85	0.35	3.72e-11	Response to antipsychotic treatment;
CRC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg02880119	chr16:3481970	NA	0.42	5.91	0.31	8.62e-9	Body mass index (adult);
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg27094323	chr7:1216898	NA	-0.37	-6.21	-0.32	1.63e-9	Longevity;Endometriosis;
CRC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.43	-9.63	-0.47	1.72e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.69	9.29	0.46	2.12e-18	Dilated cardiomyopathy;
CRC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.57	-6.0	-0.31	5.12e-9	White matter hyperintensity burden;
CRC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg21194808	chr1:2205498	SKI	0.4	5.91	0.31	8.73e-9	Height;
CRC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-6.11	-0.32	2.86e-9	Response to metformin (IC50);
CRC	cis	rs2882667	0.690	rs9327827	chr5:138182328	A/G	cg09476006	chr5:138032270	NA	0.54	9.77	0.47	5.67e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.02	-19.5	-0.73	8.13e-57	Prudent dietary pattern;
CRC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.5	6.35	0.33	6.96e-10	Obesity-related traits;
CRC	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.55	-8.93	-0.44	3.07e-17	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.43	-0.46	7.78e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.66	-0.3	3.3e-8	Aortic root size;
CRC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg07212818	chr11:638076	DRD4	-0.47	-5.9	-0.31	9.03e-9	Systemic lupus erythematosus;
CRC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg09127314	chr1:152161683	NA	0.49	6.18	0.32	1.88e-9	Atopic dermatitis;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg27615366	chr5:131592974	PDLIM4	0.33	5.78	0.3	1.7e-8	Acylcarnitine levels;
CRC	trans	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg26043149	chr18:55253948	FECH	0.53	7.85	0.4	5.73e-14	Bone mineral density;
CRC	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.18	0.41	6.46e-15	Body mass index;
CRC	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-7.98	-0.4	2.46e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg15845792	chr6:28175446	NA	0.97	13.87	0.61	8.9e-35	Depression;
CRC	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg08501292	chr6:25962987	TRIM38	0.85	5.77	0.3	1.79e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.54	8.75	0.43	1.13e-16	Obesity-related traits;
CRC	cis	rs728616	0.558	rs72817596	chr10:82151594	T/C	cg05935833	chr10:81318306	SFTPA2	-0.59	-7.28	-0.37	2.44e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.69	9.92	0.48	1.77e-20	Type 2 diabetes;
CRC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.56	-0.54	3.49e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg14139581	chr11:64358342	SLC22A12	-0.38	-6.12	-0.32	2.73e-9	Urate levels in obese individuals;
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.34	-0.33	7.77e-10	Lymphocyte counts;
CRC	cis	rs7072216	0.881	rs2147895	chr10:100148308	T/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-6.1	-0.32	2.89e-9	Metabolite levels;
CRC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-0.82	-8.83	-0.44	6.35e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.15	-0.56	2.56e-28	Idiopathic membranous nephropathy;
CRC	trans	rs7027930	0.524	rs7042862	chr9:612892	G/A	cg27061366	chr19:13044373	FARSA	0.51	6.32	0.33	8.75e-10	Pulmonary function decline;
CRC	cis	rs910873	0.505	rs2378249	chr20:33218090	G/A	cg08999081	chr20:33150536	PIGU	0.49	6.13	0.32	2.57e-9	Melanoma;
CRC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01200585	chr1:228362443	C1orf69	0.4	5.84	0.31	1.26e-8	Diastolic blood pressure;
CRC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-8.61	-0.43	2.97e-16	Gut microbiome composition (summer);
CRC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.42	6.34	0.33	7.67e-10	Menarche (age at onset);
CRC	trans	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.61	-0.34	1.59e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24274600	chr5:95066816	RHOBTB3	0.43	6.08	0.32	3.42e-9	Response to antipsychotic treatment;
CRC	trans	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg07817883	chr1:32538562	TMEM39B	0.64	7.23	0.37	3.41e-12	Monocyte percentage of white cells;
CRC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.59	9.79	0.47	5.12e-20	Breast cancer;
CRC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.91	16.29	0.67	3.68e-44	Intelligence (multi-trait analysis);
CRC	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-5.74	-0.3	2.13e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12817423	chr12:80329258	PPP1R12A	0.4	5.98	0.31	5.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg27398640	chr15:77910606	LINGO1	-0.4	-7.04	-0.36	1.11e-11	Type 2 diabetes;
CRC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg25459000	chr22:39777742	SYNGR1	-0.32	-5.66	-0.3	3.26e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11605275	1.000	rs11604681	chr11:20031042	G/A	cg14835545	chr11:20032148	NAV2	-0.83	-5.66	-0.3	3.35e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14119001	chr9:139324193	INPP5E	-0.46	-6.43	-0.33	4.44e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.62	0.39	2.73e-13	Body mass index;
CRC	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg09597638	chr17:3907349	NA	-0.68	-11.92	-0.55	1.86e-27	Type 2 diabetes;
CRC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.61	-0.34	1.51e-10	IgG glycosylation;
CRC	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg18232548	chr7:50535776	DDC	0.45	5.88	0.31	9.91e-9	Malaria;
CRC	trans	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg25214090	chr10:38739885	LOC399744	-0.41	-6.42	-0.33	4.69e-10	Diastolic blood pressure;
CRC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.38e-26	Bone mineral density;
CRC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.59	9.09	0.45	9.58e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg14345882	chr6:26364793	BTN3A2	0.4	6.33	0.33	7.96e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg08888203	chr3:10149979	C3orf24	0.48	7.32	0.37	1.9e-12	Alzheimer's disease;
CRC	cis	rs1322512	0.677	rs2695251	chr6:152927101	T/C	cg03415253	chr6:152958462	SYNE1	-0.4	-6.32	-0.33	8.64e-10	Tonometry;
CRC	cis	rs4731207	0.596	rs6967887	chr7:124609490	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg19025524	chr12:109796872	NA	-0.46	-5.88	-0.31	1.02e-8	Neuroticism;
CRC	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-8.71	-0.43	1.56e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.77	-13.2	-0.59	3.17e-32	Vitiligo;
CRC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.59	-11.64	-0.54	1.9e-26	Asthma (sex interaction);
CRC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.54	9.79	0.47	5.02e-20	Lung cancer;
CRC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg20203395	chr5:56204925	C5orf35	0.58	8.0	0.4	2.11e-14	Initial pursuit acceleration;
CRC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.54	-0.38	4.75e-13	Joint mobility (Beighton score);
CRC	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.48	8.98	0.44	2.14e-17	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08333703	chr19:35225315	ZNF181	0.38	6.52	0.34	2.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg24874828	chr4:187887005	NA	0.34	5.88	0.31	1.01e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg14352298	chr13:112236639	NA	0.29	6.78	0.35	5.66e-11	Hepatitis;
CRC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.93	-16.25	-0.67	5.44e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg12273811	chr6:28175739	NA	0.55	7.81	0.4	7.59e-14	Parkinson's disease;
CRC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	6.93	0.36	2.29e-11	Hip circumference adjusted for BMI;
CRC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg02683197	chr6:28174875	NA	0.73	10.76	0.51	2.46e-23	Cardiac Troponin-T levels;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg12500891	chr11:57225987	NA	-0.66	-6.1	-0.32	2.98e-9	Cognitive function;
CRC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.45	-8.25	-0.41	3.73e-15	Huntington's disease progression;
CRC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.42	-6.61	-0.34	1.56e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Parkinson's disease;
CRC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.58e-16	Menopause (age at onset);
CRC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.66	-11.59	-0.54	2.83e-26	Refractive error;
CRC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.43	6.55	0.34	2.26e-10	Menopause (age at onset);
CRC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	7.23	0.37	3.36e-12	Parkinson's disease;
CRC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.8	-14.93	-0.64	7.52e-39	Metabolic syndrome;
CRC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.54	8.48	0.42	7.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg06470822	chr6:28175283	NA	0.97	13.12	0.59	6.55e-32	Depression;
CRC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.52	-0.34	2.59e-10	Aortic root size;
CRC	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg20358437	chr6:27870759	NA	0.63	6.65	0.34	1.22e-10	Parkinson's disease;
CRC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-10.1	-0.49	4.59e-21	Personality dimensions;
CRC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg04545296	chr12:48745243	ZNF641	0.33	5.9	0.31	9.25e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs418053	0.648	rs204226	chr6:13706250	C/G	cg02206980	chr6:13574034	SIRT5	0.37	6.05	0.32	3.96e-9	Breast cancer;
CRC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.39	7.42	0.38	9.99e-13	Ulcerative colitis;
CRC	cis	rs13161895	1.000	rs394616	chr5:179418134	T/G	cg02702477	chr5:179499311	RNF130	0.56	6.46	0.34	3.77e-10	LDL cholesterol;
CRC	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07165851	chr6:158734300	TULP4	0.62	7.69	0.39	1.69e-13	Height;
CRC	cis	rs6893807	1.000	rs16903275	chr5:87950543	A/C	cg09002922	chr5:87956389	LOC645323	0.43	6.3	0.33	9.8e-10	Body mass index;
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.53	7.15	0.37	5.54e-12	Alzheimer's disease;
CRC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg23743428	chr13:21893420	NA	-0.39	-5.91	-0.31	8.78e-9	White matter hyperintensity burden;
CRC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.69	10.62	0.51	7.34e-23	Tonsillectomy;
CRC	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.52	8.3	0.42	2.78e-15	Corneal astigmatism;
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.28	-5.97	-0.31	6.03e-9	Schizophrenia;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg12172441	chr6:28176163	NA	0.55	7.12	0.37	6.62e-12	Parkinson's disease;
CRC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.47	6.13	0.32	2.46e-9	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03183882	chr3:15373315	SH3BP5	0.44	6.18	0.32	1.94e-9	Response to antipsychotic treatment;
CRC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.33	-0.33	8.12e-10	Total cholesterol levels;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg04969067	chr8:143858791	LYNX1	-0.41	-6.15	-0.32	2.21e-9	Urinary tract infection frequency;
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg04204079	chr8:58130323	NA	-0.44	-5.63	-0.3	3.87e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-5.7	-0.3	2.6e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg09184832	chr6:79620586	NA	-0.46	-8.03	-0.4	1.72e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.68	-9.86	-0.48	2.92e-20	Schizophrenia;
CRC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.88	-11.47	-0.53	7.5e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.46	5.66	0.3	3.39e-8	Renal function-related traits (BUN);
CRC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.53	-8.1	-0.41	1.07e-14	Aortic root size;
CRC	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	7.03	0.36	1.2e-11	Blood protein levels;
CRC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.69	10.46	0.5	2.77e-22	Corneal astigmatism;
CRC	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-12.35	-0.56	4.63e-29	Red cell distribution width;
CRC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.92	0.36	2.43e-11	Systolic blood pressure;
CRC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.48	-5.8	-0.3	1.55e-8	Bipolar disorder;
CRC	cis	rs727505	0.564	rs4731236	chr7:124827236	G/T	cg23710748	chr7:124431027	NA	-0.62	-10.31	-0.49	9e-22	Lewy body disease;
CRC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.03	-0.32	4.32e-9	Obesity-related traits;
CRC	trans	rs4714291	0.698	rs2983144	chr6:40046724	G/A	cg02267698	chr19:7991119	CTXN1	-0.45	-6.06	-0.32	3.81e-9	Strep throat;
CRC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.78	-9.29	-0.46	2.12e-18	Platelet count;
CRC	cis	rs7605827	0.930	rs11692646	chr2:15559198	C/G	cg19274914	chr2:15703543	NA	-0.38	-5.93	-0.31	7.65e-9	Educational attainment (years of education);
CRC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg00976097	chr5:421733	AHRR	-0.44	-6.02	-0.31	4.69e-9	Cystic fibrosis severity;
CRC	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg09469691	chr10:81107165	PPIF	0.52	7.97	0.4	2.58e-14	Height;
CRC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg01951491	chr16:67709440	GFOD2	-0.52	-5.75	-0.3	2.08e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	0.99	14.64	0.63	1.05e-37	Breast cancer;
CRC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg26805224	chr10:79626177	DLG5	-0.46	-6.78	-0.35	5.73e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg26688816	chr2:46740690	ATP6V1E2	0.58	8.91	0.44	3.68e-17	HDL cholesterol;
CRC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.51	-0.38	5.45e-13	Aortic root size;
CRC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg09473613	chr1:24152604	HMGCL	0.35	5.8	0.3	1.53e-8	Immature fraction of reticulocytes;
CRC	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.44	-8.42	-0.42	1.2e-15	Alcohol dependence;
CRC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-8.1	-0.41	1.09e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs12476592	0.602	rs262523	chr2:63892684	T/C	cg10828910	chr2:63850056	LOC388955	0.52	6.44	0.33	4.3e-10	Childhood ear infection;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16037806	chr7:91570105	AKAP9	0.43	6.11	0.32	2.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.62	-9.48	-0.46	5.23e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.57	-9.21	-0.45	3.98e-18	Intelligence (multi-trait analysis);
CRC	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.73	0.3	2.24e-8	Neuroticism;
CRC	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg25124228	chr12:125621409	AACS	-0.59	-6.73	-0.35	7.72e-11	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.75	12.1	0.55	4.03e-28	Autism spectrum disorder or schizophrenia;
CRC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.95	-0.68	9.06e-47	Height;
CRC	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-5.88	-0.31	9.83e-9	Yeast infection;
CRC	cis	rs728616	0.764	rs56196124	chr10:81902655	A/T	cg11900509	chr10:81946545	ANXA11	-0.69	-7.85	-0.4	6.11e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.22	-0.32	1.5e-9	Neuroticism;
CRC	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.47	-7.77	-0.39	9.81e-14	Prevalent atrial fibrillation;
CRC	cis	rs2421770	0.530	rs2421764	chr11:35364578	A/T	cg13971030	chr11:35366721	SLC1A2	-0.39	-6.75	-0.35	6.74e-11	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg21918786	chr6:109611834	NA	-0.33	-5.64	-0.3	3.67e-8	Reticulocyte fraction of red cells;
CRC	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg27205649	chr11:78285834	NARS2	-0.46	-5.6	-0.3	4.5e-8	Alzheimer's disease (survival time);
CRC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.75	9.55	0.47	3e-19	Psoriasis;
CRC	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.77	-0.35	5.83e-11	Inflammatory skin disease;
CRC	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-6.96	-0.36	1.86e-11	Coronary artery disease;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.66	-10.18	-0.49	2.36e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.51	-7.31	-0.37	2.08e-12	Longevity;Endometriosis;
CRC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg22601191	chr20:60968625	CABLES2	0.44	7.29	0.37	2.35e-12	Colorectal cancer;
CRC	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg13175173	chr14:55914753	NA	-0.52	-9.94	-0.48	1.57e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.94	-13.98	-0.61	3.5e-35	Systemic lupus erythematosus;
CRC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.13	-13.33	-0.59	1.06e-32	Diabetic kidney disease;
CRC	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14019695	chr9:139328340	INPP5E	0.37	5.62	0.3	4.11e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.64	8.75	0.43	1.13e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.2	0.41	5.3e-15	Cognitive performance;
CRC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	0.95	9.45	0.46	6.77e-19	Skin colour saturation;
CRC	cis	rs4321325	0.546	rs11886766	chr2:127948621	G/A	cg11380483	chr2:127933992	NA	0.53	6.7	0.35	8.84e-11	Protein C levels;
CRC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.39	0.46	1.02e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.98	-9.95	-0.48	1.42e-20	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.82	0.35	4.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.37	-5.63	-0.3	3.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12889267	0.770	rs2319627	chr14:21565189	C/T	cg02988727	chr14:21567520	ZNF219;C14orf176	-0.46	-6.81	-0.35	4.7e-11	Hematocrit;Resting heart rate;
CRC	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.62	9.92	0.48	1.79e-20	Smoking behavior;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg10251347	chr1:52344305	NRD1	-0.43	-6.53	-0.34	2.54e-10	Daytime sleep phenotypes;
CRC	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.6	9.36	0.46	1.25e-18	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23161317	chr6:28129485	ZNF389	0.52	6.36	0.33	6.6e-10	Depression;
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg26762873	chr11:5879799	OR52E8	-0.41	-5.95	-0.31	6.78e-9	DNA methylation (variation);
CRC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg00129232	chr17:37814104	STARD3	0.58	7.09	0.36	8.09e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.54e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.58	-10.0	-0.48	9.52e-21	Asthma;
CRC	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-6.28	-0.33	1.06e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1532331	0.548	rs6894506	chr5:43169096	C/T	cg09164108	chr5:43007320	NA	0.45	7.36	0.38	1.5e-12	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25462384	chr19:7985170	SNAPC2	0.39	6.34	0.33	7.56e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.66	6.96	0.36	1.9e-11	Axial length;
CRC	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.61	8.23	0.41	4.33e-15	Coronary artery disease;
CRC	cis	rs812925	0.553	rs1177307	chr2:61387388	T/C	cg10580144	chr2:61372316	C2orf74	0.36	8.05	0.41	1.56e-14	Immature fraction of reticulocytes;
CRC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg27523141	chr10:43048294	ZNF37B	0.48	6.88	0.35	3.06e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.76	0.35	6.41e-11	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12589749	chr1:54304061	TMEM48	0.46	6.4	0.33	5.51e-10	Response to antipsychotic treatment;
CRC	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Dilated cardiomyopathy;
CRC	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.6	-9.57	-0.47	2.75e-19	Vitiligo;
CRC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.54	-0.43	4.92e-16	Aortic root size;
CRC	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.18	-0.56	1.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.7	9.38	0.46	1.14e-18	Alzheimer's disease;
CRC	cis	rs61996546	0.622	rs12905999	chr15:26867460	A/G	cg15066197	chr15:26874202	GABRB3	-0.39	-5.99	-0.31	5.37e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs55788414	0.932	rs12103358	chr16:81185844	C/G	cg06400318	chr16:81190750	PKD1L2	-0.57	-6.7	-0.35	9.14e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	8.44	0.42	1.05e-15	Acylcarnitine levels;
CRC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.46	-6.04	-0.32	4.12e-9	Gut microbiome composition (summer);
CRC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg21285383	chr16:89894308	SPIRE2	0.35	5.84	0.31	1.25e-8	Vitiligo;
CRC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.48	-9.03	-0.45	1.51e-17	Reticulocyte fraction of red cells;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg22638593	chr5:131593259	PDLIM4	0.38	6.35	0.33	6.97e-10	Acylcarnitine levels;
CRC	cis	rs4728302	0.869	rs12707128	chr7:133589796	A/G	cg03336402	chr7:133662267	EXOC4	-0.49	-7.06	-0.36	9.68e-12	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg27535305	chr1:53392650	SCP2	-0.35	-6.22	-0.32	1.53e-9	Monocyte count;
CRC	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg10437265	chr15:77819839	NA	-0.58	-10.24	-0.49	1.49e-21	Type 2 diabetes;
CRC	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg16672083	chr15:72433130	SENP8	0.41	6.33	0.33	7.87e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.55	9.4	0.46	9.61e-19	Common traits (Other);
CRC	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.69	-0.43	1.8e-16	Coffee consumption (cups per day);
CRC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	11.0	0.52	3.46e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg23229984	chr5:148520753	ABLIM3	0.47	6.69	0.35	9.6e-11	Breast cancer;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.98	0.36	1.64e-11	Longevity;
CRC	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.29	6.07	0.32	3.56e-9	Height;
CRC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.6	-10.04	-0.48	6.97e-21	Calcium levels;
CRC	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14119001	chr9:139324193	INPP5E	-0.44	-6.2	-0.32	1.65e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.53	9.42	0.46	7.96e-19	Multiple system atrophy;
CRC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.64	10.86	0.51	1.07e-23	Prostate cancer;
CRC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.08	18.2	0.71	1.07e-51	Cognitive function;
CRC	cis	rs28829049	0.597	rs12566296	chr1:19498443	A/C	cg13387374	chr1:19411106	UBR4	0.41	6.06	0.32	3.81e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.57	8.09	0.41	1.18e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.74	-0.3	2.16e-8	Lung cancer;
CRC	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.36	-7.06	-0.36	1.01e-11	Arsenic metabolism;
CRC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.11	-0.32	2.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.97	11.86	0.55	2.94e-27	Gut microbiome composition (summer);
CRC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.39	-6.57	-0.34	1.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs1578862	0.872	rs1778550	chr1:247431329	C/T	cg06850283	chr5:44389769	FGF10	-0.25	-6.23	-0.32	1.46e-9	Monocyte percentage of white cells;
CRC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.49e-17	Bladder cancer;
CRC	cis	rs1868673	1.000	rs4681619	chr3:150160253	G/A	cg04908077	chr3:150187338	NA	-0.33	-5.64	-0.3	3.58e-8	Waist circumference;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.77	-0.39	9.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.43	6.37	0.33	6.47e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2969070	1.000	rs2895171	chr7:2514209	G/A	cg03277898	chr7:2518824	NA	-0.45	-6.63	-0.34	1.4e-10	Diastolic blood pressure;
CRC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.33	-0.42	2.21e-15	Bone mineral density;
CRC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.65	-0.43	2.33e-16	Bone mineral density;
CRC	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg12046867	chr14:103022105	NA	-0.43	-6.24	-0.33	1.32e-9	Platelet count;
CRC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.8	0.39	8.52e-14	Aortic root size;
CRC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.93	-0.4	3.56e-14	Intelligence (multi-trait analysis);
CRC	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg15704280	chr7:45808275	SEPT13	0.6	6.41	0.33	5.19e-10	Intraocular pressure;
CRC	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	0.79	9.61	0.47	1.96e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.54	7.14	0.37	5.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4478858	0.746	rs10798831	chr1:31688385	A/C	cg00250761	chr1:31883323	NA	0.31	5.82	0.31	1.42e-8	Alcohol dependence;
CRC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.47	-6.97	-0.36	1.73e-11	IgG glycosylation;
CRC	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.7	0.39	1.63e-13	Coronary heart disease;
CRC	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg01993067	chr11:68851601	TPCN2	0.56	6.32	0.33	8.39e-10	Blond vs. brown hair color;
CRC	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg20607287	chr7:12443886	VWDE	-0.55	-5.93	-0.31	7.55e-9	Coronary artery disease;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18301423	chr5:131593218	PDLIM4	0.37	6.78	0.35	5.43e-11	Breast cancer;
CRC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-7.4	-0.38	1.12e-12	Schizophrenia;
CRC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.49	7.31	0.37	2.02e-12	Emphysema distribution in smoking;
CRC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg24343755	chr10:26987087	PDSS1	-0.52	-6.86	-0.35	3.33e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13950403	chr5:153418565	MFAP3;FAM114A2	-0.4	-6.31	-0.33	9.04e-10	Myopia (pathological);
CRC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26850624	chr5:429559	AHRR	-0.71	-11.21	-0.53	6.2e-25	Cystic fibrosis severity;
CRC	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	0.61	5.91	0.31	8.52e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg08075719	chr14:103021372	NA	0.65	7.6	0.39	3.13e-13	Platelet count;
CRC	cis	rs6681460	1.000	rs4655647	chr1:67106077	C/G	cg02459107	chr1:67143332	SGIP1	0.45	7.67	0.39	2.01e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.33	-0.33	8.13e-10	Breast cancer;
CRC	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg22482690	chr17:47019901	SNF8	0.51	8.18	0.41	6.24e-15	Type 2 diabetes;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg15786705	chr6:28176104	NA	0.54	6.81	0.35	4.58e-11	Parkinson's disease;
CRC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.93	-0.48	1.71e-20	Chronic sinus infection;
CRC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.56	-9.87	-0.48	2.78e-20	Huntington's disease progression;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg10876282	chr6:28092338	ZSCAN16	0.4	5.7	0.3	2.67e-8	Pubertal anthropometrics;
CRC	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.35	5.7	0.3	2.66e-8	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16892046	chr8:119124311	EXT1	0.39	6.18	0.32	1.88e-9	Schizophrenia;
CRC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.4	7.53	0.38	4.77e-13	Ulcerative colitis;
CRC	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	cg04338863	chr8:33670619	NA	0.42	6.72	0.35	8.03e-11	Body mass index;
CRC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg10760299	chr15:45669010	GATM	0.52	7.86	0.4	5.56e-14	Homoarginine levels;
CRC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.58	8.72	0.43	1.44e-16	Aortic root size;
CRC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.88	-14.23	-0.62	4e-36	Blood metabolite levels;
CRC	trans	rs2383876	0.550	rs13252291	chr8:74068483	A/G	cg23880589	chr17:7826623	KCNAB3	-0.37	-6.17	-0.32	2e-9	Corneal curvature;
CRC	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.49	8.38	0.42	1.59e-15	Testicular germ cell tumor;
CRC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg08648136	chr8:956695	NA	0.32	5.83	0.31	1.34e-8	Schizophrenia;
CRC	trans	rs12940923	1.000	rs11867689	chr17:56370355	G/C	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.5	6.65	0.34	1.21e-10	IgG glycosylation;
CRC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.84	0.31	1.28e-8	Diabetic retinopathy;
CRC	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.54	-8.88	-0.44	4.55e-17	Breast cancer;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.59	8.96	0.44	2.49e-17	Longevity;Endometriosis;
CRC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.72	-9.98	-0.48	1.14e-20	Vitiligo;
CRC	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg16989086	chr20:62203971	PRIC285	-0.5	-6.38	-0.33	6.07e-10	Atopic dermatitis;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.42	-0.38	9.95e-13	Breast cancer;
CRC	cis	rs117623576	0.618	rs211416	chr10:32397591	T/A	cg03047570	chr10:32398778	NA	0.69	7.78	0.39	9.43e-14	Anti-saccade response;
CRC	cis	rs7623687	0.579	rs73082331	chr3:48994943	G/A	cg19401529	chr3:49056140	DALRD3	0.67	7.05	0.36	1.04e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CRC	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg19688584	chr6:167529678	CCR6	-0.32	-5.94	-0.31	7.23e-9	Rheumatoid arthritis;
CRC	trans	rs587242	1.000	rs60507779	chr1:96914875	C/A	cg10631902	chr5:14652156	NA	0.44	6.9	0.36	2.62e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.67	-9.83	-0.48	3.67e-20	Pancreatic cancer;
CRC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg21194808	chr1:2205498	SKI	0.37	5.63	0.3	3.82e-8	Height;
CRC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg25790453	chr13:113633590	MCF2L	-0.57	-10.07	-0.49	5.87e-21	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.47	-6.39	-0.33	5.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg04553112	chr3:125709451	NA	-0.51	-5.89	-0.31	9.55e-9	Blood pressure (smoking interaction);
CRC	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	7.76e-17	Dupuytren's disease;
CRC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg07153921	chr17:41440717	NA	-0.4	-5.97	-0.31	6.2e-9	Menopause (age at onset);
CRC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg21285383	chr16:89894308	SPIRE2	0.34	5.64	0.3	3.73e-8	Vitiligo;
CRC	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.53	6.43	0.33	4.39e-10	Bipolar disorder;
CRC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06634786	chr22:41940651	POLR3H	-0.46	-6.16	-0.32	2.08e-9	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01301935	chr16:69599904	NFAT5;MIR1538	0.47	6.86	0.35	3.34e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.33	-0.73	3.65e-56	Primary sclerosing cholangitis;
CRC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg18764771	chr6:116381957	FRK	0.25	6.97	0.36	1.74e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.52	8.21	0.41	5.13e-15	Corneal astigmatism;
CRC	cis	rs2811415	0.597	rs1007233	chr3:127801776	G/T	cg13719885	chr3:127795394	NA	-0.39	-5.85	-0.31	1.17e-8	Lung function (FEV1/FVC);
CRC	cis	rs1891275	0.515	rs7098763	chr10:93444827	C/T	cg07889827	chr10:93443413	NA	-0.39	-6.78	-0.35	5.48e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.47	7.27	0.37	2.57e-12	Bronchopulmonary dysplasia;
CRC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.34	-0.42	2.03e-15	Height;
CRC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.75	12.76	0.58	1.4e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg01843034	chr6:37503916	NA	-0.44	-8.24	-0.41	4.06e-15	Cognitive performance;
CRC	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.59	8.47	0.42	8.5e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12292205	chr6:26970375	C6orf41	0.5	7.34	0.38	1.63e-12	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.17	24.99	0.81	5.35e-78	IgG glycosylation;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.52	-9.55	-0.47	3.19e-19	Longevity;Endometriosis;
CRC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.57	8.32	0.42	2.37e-15	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00713605	chr2:232063387	ARMC9	0.48	6.58	0.34	1.81e-10	Anxiety disorder;
CRC	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.53	9.2	0.45	4.29e-18	Common traits (Other);
CRC	cis	rs1712517	0.771	rs11191666	chr10:105127278	A/G	cg05636881	chr10:105038444	INA	0.46	7.91	0.4	4.04e-14	Migraine;
CRC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.71	11.59	0.54	2.84e-26	Dental caries;
CRC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg05639522	chr1:247681581	NA	0.47	7.14	0.37	5.95e-12	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.68	10.66	0.51	5.61e-23	Intelligence (multi-trait analysis);
CRC	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.38	5.78	0.3	1.69e-8	PR interval;
CRC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	6.81	0.35	4.53e-11	Schizophrenia;
CRC	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.65e-24	Motion sickness;
CRC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.69	-8.74	-0.43	1.23e-16	Lung cancer in ever smokers;
CRC	cis	rs290268	0.502	rs1333633	chr9:93567572	G/A	cg02608019	chr9:93564028	SYK	0.47	7.29	0.37	2.3e-12	Platelet count;
CRC	cis	rs9649465	1.000	rs1506635	chr7:123317184	C/T	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.69e-8	Migraine;
CRC	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-9.89	-0.48	2.31e-20	Blood protein levels;
CRC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	trans	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	6.06	0.32	3.69e-9	Metabolite levels;
CRC	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.44	6.07	0.32	3.48e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-5.93	-0.31	7.74e-9	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00446684	chr2:64371646	PELI1	0.44	6.04	0.32	4.12e-9	Response to antipsychotic treatment;
CRC	cis	rs9311676	0.656	rs62258128	chr3:58397142	C/G	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.86	-14.97	-0.64	5.18e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg06219103	chr11:63990595	FERMT3	0.44	6.98	0.36	1.61e-11	Platelet count;
CRC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	11.64	0.54	1.83e-26	Platelet count;
CRC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.57	-11.53	-0.54	4.75e-26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12826942	0.605	rs7975932	chr12:42517967	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.19	0.32	1.78e-9	Coronary artery disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01711073	chr1:37980396	MEAF6	0.38	6.01	0.31	5e-9	Schizophrenia;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg03623178	chr6:28175578	NA	0.74	10.57	0.5	1.15e-22	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg18230493	chr5:56204884	C5orf35	0.41	5.64	0.3	3.65e-8	Type 2 diabetes;
CRC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg21970626	chr13:21893289	NA	-0.44	-6.59	-0.34	1.8e-10	White matter hyperintensity burden;
CRC	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg18758796	chr5:131593413	PDLIM4	0.34	5.97	0.31	6.14e-9	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg16606324	chr3:10149918	C3orf24	0.69	9.43	0.46	7.91e-19	Alzheimer's disease;
CRC	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.63	0.43	2.65e-16	Coffee consumption (cups per day);
CRC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.28	-0.46	2.38e-18	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg03233332	chr7:66118400	NA	-0.44	-6.23	-0.33	1.39e-9	Aortic root size;
CRC	cis	rs12594515	0.591	rs35554150	chr15:45990298	G/A	cg01629716	chr15:45996671	NA	0.4	6.64	0.34	1.32e-10	Waist circumference;Weight;
CRC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.56	-8.84	-0.44	5.83e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.63	9.16	0.45	5.61e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6922632	0.867	rs62400307	chr6:24114249	C/A	cg26194775	chr6:24126114	NRSN1	-0.62	-7.23	-0.37	3.37e-12	Information processing speed;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.69	-0.35	9.63e-11	Total body bone mineral density;
CRC	cis	rs6700896	0.864	rs56274111	chr1:66128511	A/C	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7113874	0.550	rs11042002	chr11:8616646	T/C	cg20771178	chr11:8615675	STK33	0.35	5.77	0.3	1.81e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.66	-8.88	-0.44	4.56e-17	Hypospadias;
CRC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.58	8.85	0.44	5.46e-17	Obesity-related traits;
CRC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.5	-0.34	2.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg02683197	chr6:28174875	NA	0.75	9.67	0.47	1.28e-19	Parkinson's disease;
CRC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.52	7.98	0.4	2.52e-14	Psychosis in Alzheimer's disease;
CRC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.01	15.81	0.66	2.82e-42	IgG glycosylation;
CRC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-10.71	-0.51	3.71e-23	Personality dimensions;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12172441	chr6:28176163	NA	0.53	7.17	0.37	5.02e-12	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03900353	chr1:212732456	NA	0.43	6.2	0.32	1.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7113874	0.569	rs11041962	chr11:8549623	C/T	cg20771178	chr11:8615675	STK33	-0.34	-5.69	-0.3	2.77e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4785204	1.000	rs7193487	chr16:50093406	G/A	cg07960154	chr17:37760198	NEUROD2	-0.66	-6.13	-0.32	2.45e-9	Esophageal cancer (squamous cell);
CRC	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.33	-6.23	-0.32	1.43e-9	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.62e-9	Life satisfaction;
CRC	cis	rs12745968	0.653	rs11164796	chr1:93144080	C/T	cg17283838	chr1:93427260	FAM69A	-0.41	-5.68	-0.3	2.97e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.37	-6.89	-0.35	2.92e-11	Iron status biomarkers;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.92	-0.36	2.44e-11	Blood metabolite levels;
CRC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.87	9.91	0.48	2.02e-20	Orofacial clefts;
CRC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-9.97	-0.48	1.25e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7215564	0.908	rs77750710	chr17:78717117	C/T	cg09596252	chr17:78655493	RPTOR	0.62	6.24	0.33	1.35e-9	Myopia (pathological);
CRC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-12.57	-0.57	7.63e-30	Prostate cancer;
CRC	cis	rs6681460	0.901	rs1570815	chr1:67139667	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.48	0.42	7.96e-16	Presence of antiphospholipid antibodies;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg19041857	chr6:27730383	NA	-0.44	-5.99	-0.31	5.36e-9	Parkinson's disease;
CRC	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg09659197	chr4:152720779	NA	0.52	11.24	0.53	4.87e-25	Intelligence (multi-trait analysis);
CRC	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.62	-9.76	-0.47	6.12e-20	Testicular germ cell tumor;
CRC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	9.63	0.47	1.72e-19	Height;
CRC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.0	-0.36	1.44e-11	Coronary artery disease;
CRC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg16060761	chr17:80687452	NA	0.45	6.55	0.34	2.23e-10	Breast cancer;
CRC	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg15654264	chr1:150340011	RPRD2	0.42	6.29	0.33	1.04e-9	Migraine;
CRC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.51	0.34	2.83e-10	Morning vs. evening chronotype;
CRC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.84	12.46	0.57	1.94e-29	Gut microbiome composition (summer);
CRC	cis	rs728616	0.867	rs61859008	chr10:81831711	C/G	cg11900509	chr10:81946545	ANXA11	-0.52	-5.7	-0.3	2.73e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Body mass index;
CRC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs673253	0.686	rs2842187	chr1:44014949	A/G	cg10881128	chr1:44031826	PTPRF	-0.21	-5.7	-0.3	2.61e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.98	-0.31	5.93e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-5.95	-0.31	6.97e-9	Arsenic metabolism;
CRC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.44	9.01	0.45	1.66e-17	Renal cell carcinoma;
CRC	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg00531865	chr16:30841666	NA	-0.43	-6.08	-0.32	3.34e-9	Dementia with Lewy bodies;
CRC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg02659138	chr7:134003124	SLC35B4	0.4	6.94	0.36	2.11e-11	Mean platelet volume;
CRC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.54	-8.14	-0.41	8.25e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.61	-6.74	-0.35	7.22e-11	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.36e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.5	6.1	0.32	2.99e-9	Vitiligo;
CRC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	0.58	6.16	0.32	2.08e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.94	-13.06	-0.58	1.13e-31	Platelet count;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg24634471	chr8:143751801	JRK	-0.5	-6.84	-0.35	3.91e-11	Urinary tract infection frequency;
CRC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.44	6.8	0.35	5.01e-11	Multiple system atrophy;
CRC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg24562669	chr7:97807699	LMTK2	0.42	7.0	0.36	1.45e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.61	0.43	3.09e-16	Homoarginine levels;
CRC	cis	rs289828	0.868	rs6757821	chr2:152138037	G/A	cg06191203	chr2:152266755	RIF1	-0.4	-5.72	-0.3	2.43e-8	Blood protein levels;
CRC	cis	rs6066835	1.000	rs6122720	chr20:47351095	G/A	cg18078177	chr20:47281410	PREX1	0.64	5.74	0.3	2.14e-8	Multiple myeloma;
CRC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.79	-8.7	-0.43	1.62e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg12365402	chr11:9010492	NRIP3	-0.57	-10.55	-0.5	1.29e-22	Hemoglobin concentration;
CRC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.63	6.82	0.35	4.49e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18591801	chr3:52553433	STAB1	-0.29	-5.64	-0.3	3.63e-8	Electroencephalogram traits;
CRC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg23071808	chr14:103021642	NA	0.61	6.55	0.34	2.28e-10	Platelet count;
CRC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.45	-9.62	-0.47	1.85e-19	Blood protein levels;
CRC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.4	-0.33	5.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.93	-0.31	7.52e-9	Pulmonary function;
CRC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg05874882	chr4:1763078	NA	-0.35	-6.55	-0.34	2.27e-10	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.48	7.3	0.37	2.2e-12	Corneal astigmatism;
CRC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg05304507	chr6:116381966	FRK	0.3	8.22	0.41	4.59e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-7.28	-0.37	2.53e-12	Obesity (extreme);
CRC	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg11038491	chr20:34638489	LOC647979	-0.59	-7.06	-0.36	9.96e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12249377	0.519	rs10881838	chr10:92590233	A/G	cg14313238	chr10:92632228	RPP30	0.47	6.51	0.34	2.88e-10	White matter microstructure (global fractional anisotropy);
CRC	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06307176	chr5:131281290	NA	0.44	6.45	0.34	3.9e-10	Life satisfaction;
CRC	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg06581033	chr10:766294	NA	-0.47	-5.71	-0.3	2.58e-8	Uric acid levels;
CRC	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg25649188	chr17:73499917	CASKIN2	0.63	6.35	0.33	7.18e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg14646075	chr2:228736089	WDR69	-0.43	-5.88	-0.31	1.03e-8	Blood pressure;
CRC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.58	8.13	0.41	8.73e-15	Resting heart rate;
CRC	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg21869046	chr19:41225005	ITPKC	0.42	6.19	0.32	1.79e-9	Kawasaki disease;
CRC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	11.95	0.55	1.38e-27	Mean platelet volume;
CRC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.94	11.01	0.52	3.17e-24	Eosinophil percentage of granulocytes;
CRC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.45	-21.41	-0.76	2.58e-64	Hemostatic factors and hematological phenotypes;
CRC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.12e-19	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg15845792	chr6:28175446	NA	-0.87	-12.77	-0.58	1.33e-30	Parkinson's disease;
CRC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.77	-0.3	1.8e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	10.73	0.51	3.02e-23	Hip circumference adjusted for BMI;
CRC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.71	0.47	9.15e-20	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg27398640	chr15:77910606	LINGO1	-0.41	-7.43	-0.38	9.4e-13	Type 2 diabetes;
CRC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg16141378	chr3:129829833	LOC729375	0.45	6.34	0.33	7.38e-10	Triglycerides;
CRC	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg07979401	chr6:33739406	LEMD2	-0.45	-5.92	-0.31	8e-9	Schizophrenia;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.75	-0.3	2.06e-8	Parkinson's disease;
CRC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg15786705	chr6:28176104	NA	0.64	6.42	0.33	4.71e-10	Depression;
CRC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg10494257	chr1:16342123	HSPB7	0.39	5.66	0.3	3.36e-8	Systolic blood pressure;
CRC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-5.82	-0.31	1.41e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03395546	chr19:41222599	ADCK4;ITPKC	0.39	6.04	0.32	4.14e-9	Obesity-related traits;
CRC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.39	5.71	0.3	2.49e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22704915	chr10:73079101	SLC29A3	0.36	6.33	0.33	8.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.62	9.19	0.45	4.5e-18	Breast cancer;
CRC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg27068330	chr11:65405492	SIPA1	-0.48	-6.76	-0.35	6.21e-11	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15646900	chr8:54755681	ATP6V1H	0.4	6.7	0.35	9.22e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg25456477	chr12:86230367	RASSF9	0.33	5.63	0.3	3.82e-8	Major depressive disorder;
CRC	cis	rs6504622	0.537	rs1662577	chr17:44996759	C/A	cg16759221	chr17:45003025	GOSR2	-0.65	-10.51	-0.5	1.84e-22	Orofacial clefts;
CRC	cis	rs7538876	0.935	rs1408420	chr1:17754815	A/G	cg01904812	chr1:17746340	RCC2	-0.41	-6.44	-0.33	4.15e-10	Basal cell carcinoma;
CRC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-0.71	-8.09	-0.41	1.2e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg22495460	chr2:25135724	ADCY3	-0.82	-13.4	-0.59	5.5e-33	Body mass index;
CRC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg19678392	chr7:94953810	PON1	-0.52	-6.58	-0.34	1.84e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.57	8.66	0.43	2.08e-16	Menopause (age at onset);
CRC	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg11887960	chr12:57824829	NA	0.62	6.76	0.35	6.26e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.63	-0.34	1.4e-10	Menopause (age at onset);
CRC	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg04748988	chr3:12329223	PPARG	0.59	7.69	0.39	1.69e-13	LDL cholesterol;
CRC	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-7.42	-0.38	1.03e-12	Coronary artery disease;
CRC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.78	-8.86	-0.44	5.21e-17	Bronchopulmonary dysplasia;
CRC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg20119798	chr7:94954144	PON1	-0.43	-5.99	-0.31	5.36e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.49	-9.24	-0.45	3.04e-18	Reticulocyte fraction of red cells;
CRC	trans	rs4130344	0.555	rs7664271	chr4:159865915	C/G	cg10773016	chr4:6690812	NA	0.4	6.1	0.32	3.04e-9	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg23590916	chr17:43697445	MGC57346	0.7	6.88	0.35	3.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg05501817	chr11:14380813	RRAS2	-0.45	-5.99	-0.31	5.42e-9	Sense of smell;
CRC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.2	-16.38	-0.67	1.6e-44	Breast cancer;
CRC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg12463550	chr7:65579703	CRCP	0.62	5.95	0.31	6.68e-9	Diabetic kidney disease;
CRC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg12458913	chr13:53173898	NA	0.76	13.84	0.61	1.2e-34	Lewy body disease;
CRC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.55	-0.43	4.59e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.45	-7.65	-0.39	2.3e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00400810	chr15:42066822	MAPKBP1	0.37	5.97	0.31	6.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6834538	0.520	rs34812023	chr4:113423634	A/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.36	-5.63	-0.3	3.97e-8	Free thyroxine concentration;
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.62	0.54	2.28e-26	Alzheimer's disease;
CRC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	6.92	0.36	2.33e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.46	7.2	0.37	4.11e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9649465	0.967	rs2286831	chr7:123303477	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-5.69	-0.3	2.82e-8	Migraine;
CRC	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.86	-0.48	2.81e-20	Blood protein levels;
CRC	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-5.78	-0.3	1.74e-8	Platelet distribution width;
CRC	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.73	-0.35	7.64e-11	Height;
CRC	cis	rs11212617	0.967	rs664982	chr11:108225483	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.68	0.35	1.03e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.39	-0.33	5.79e-10	Bipolar disorder;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03664139	chr6:101329504	ASCC3	-0.52	-6.32	-0.33	8.68e-10	Diisocyanate-induced asthma;
CRC	cis	rs7973719	1.000	rs7973719	chr12:7334813	C/T	cg07052231	chr12:7363540	PEX5	0.48	7.92	0.4	3.77e-14	IgG glycosylation;
CRC	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg12756093	chr1:115239321	AMPD1	0.48	7.13	0.37	6.23e-12	Autism;
CRC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07690219	chr3:49449608	TCTA;RHOA	0.5	5.67	0.3	3.16e-8	Menarche (age at onset);
CRC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg25767906	chr1:53392781	SCP2	-0.37	-5.96	-0.31	6.63e-9	Monocyte count;
CRC	cis	rs2814982	0.543	rs75776386	chr6:34465215	G/A	cg17674042	chr6:34482479	PACSIN1	-1.01	-11.11	-0.52	1.44e-24	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.74	0.39	1.24e-13	Motion sickness;
CRC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	10.9	0.51	8.2e-24	Mean corpuscular hemoglobin;
CRC	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	1.02	9.31	0.46	1.83e-18	Lymphocyte counts;
CRC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.59	-9.16	-0.45	5.75e-18	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg17903999	chr18:56338584	MALT1	0.41	6.54	0.34	2.39e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg15786705	chr6:28176104	NA	0.68	9.22	0.45	3.55e-18	Parkinson's disease;
CRC	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.61	-8.58	-0.43	3.93e-16	Waist circumference;Body mass index;
CRC	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg22546130	chr22:19950026	COMT	0.28	7.74	0.39	1.24e-13	Blood metabolite levels;
CRC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.56	9.13	0.45	7.33e-18	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25733915	chr17:40829168	PLEKHH3	0.43	6.0	0.31	5.29e-9	Response to antipsychotic treatment;
CRC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.79	-0.3	1.65e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-12.84	-0.58	7.05e-31	Cognitive function;
CRC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg23136738	chr11:925521	AP2A2	-0.48	-7.61	-0.39	2.91e-13	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.44	1.03e-16	Aortic root size;
CRC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.43	0.33	4.44e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.98	0.55	1.12e-27	Coffee consumption (cups per day);
CRC	cis	rs2415984	0.579	rs10151988	chr14:46955203	C/T	cg14871534	chr14:47121158	RPL10L	-0.41	-6.02	-0.31	4.74e-9	Number of children ever born;
CRC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg27535305	chr1:53392650	SCP2	0.39	7.03	0.36	1.21e-11	Monocyte count;
CRC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.47	6.43	0.33	4.4e-10	Schizophrenia;
CRC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.73	0.51	3.01e-23	Ileal carcinoids;
CRC	cis	rs4926298	1.000	rs11085829	chr19:13174312	G/A	cg04657146	chr19:12876947	HOOK2	-0.43	-5.79	-0.3	1.61e-8	Bipolar disorder;
CRC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.54	8.51	0.42	6.17e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.63	-0.47	1.66e-19	Heart rate;
CRC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.56	-7.76	-0.39	1.1e-13	DNA methylation (variation);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13411879	chr7:30068273	PLEKHA8	0.41	6.3	0.33	9.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.53	-9.09	-0.45	9.72e-18	Iron status biomarkers;
CRC	cis	rs9491140	0.539	rs911959	chr6:124688755	A/G	cg22366943	chr6:124882293	NKAIN2	0.51	7.73	0.39	1.31e-13	Neuroticism;
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg10729496	chr3:10149963	C3orf24	0.49	6.66	0.34	1.18e-10	Alzheimer's disease;
CRC	cis	rs4731207	0.698	rs12536575	chr7:124510276	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.5	8.93	0.44	3.14e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg21251018	chr6:28226885	NKAPL	0.57	9.8	0.48	4.44e-20	Cardiac Troponin-T levels;
CRC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.34	5.75	0.3	2.08e-8	Major depressive disorder;
CRC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.39	6.09	0.32	3.22e-9	Crohn's disease;
CRC	cis	rs2227564	0.761	rs2227552	chr10:75669319	C/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.23	-0.37	3.51e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs16867321	1.000	rs1358521	chr2:181444628	T/C	cg23363182	chr2:181467187	NA	-0.54	-6.87	-0.35	3.29e-11	Obesity;
CRC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.2	-14.36	-0.62	1.21e-36	Eosinophil percentage of granulocytes;
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg03623178	chr6:28175578	NA	0.75	5.99	0.31	5.52e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.59	-9.27	-0.46	2.5e-18	Corneal astigmatism;
CRC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.49	-6.76	-0.35	6.31e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.57	-9.13	-0.45	6.89e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16449816	chr17:55927528	MRPS23	0.37	6.1	0.32	2.99e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg26043149	chr18:55253948	FECH	0.51	7.95	0.4	3.02e-14	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24540109	chr1:32110960	PEF1	0.41	6.07	0.32	3.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg12273811	chr6:28175739	NA	0.54	7.72	0.39	1.43e-13	Parkinson's disease;
CRC	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.61	-0.34	1.57e-10	Multiple sclerosis;
CRC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg00999904	chr2:3704751	ALLC	0.49	6.72	0.35	7.97e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg14078730	chr11:63896557	MACROD1	0.35	5.62	0.3	4.08e-8	Platelet count;
CRC	cis	rs11030122	0.673	rs10835508	chr11:4045360	A/T	cg18678763	chr11:4115507	RRM1	-0.48	-7.96	-0.4	2.75e-14	Mean platelet volume;Platelet distribution width;
CRC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg03929089	chr4:120376271	NA	-0.49	-7.08	-0.36	8.76e-12	HDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19259146	chr1:26856420	RPS6KA1	0.41	6.07	0.32	3.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.45	-7.49	-0.38	6.22e-13	Height;
CRC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.82	15.11	0.64	1.57e-39	Mean platelet volume;
CRC	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg00564723	chr10:75632066	CAMK2G	0.24	6.13	0.32	2.51e-9	Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04981737	chr12:54383434	HOXC10	0.39	6.07	0.32	3.47e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.52	-9.01	-0.44	1.74e-17	Facial morphology (factor 20);
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.02	0.32	4.62e-9	Bipolar disorder;
CRC	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.61	-0.43	3.08e-16	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-8.01	-0.4	2.05e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg08314208	chr16:67682810	RLTPR	-0.6	-6.42	-0.33	4.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-12.43	-0.57	2.36e-29	Prostate cancer;
CRC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.9	-0.31	8.8e-9	Lung cancer;
CRC	cis	rs7215564	0.908	rs2316067	chr17:78659720	C/T	cg09596252	chr17:78655493	RPTOR	0.53	5.62	0.3	4.14e-8	Myopia (pathological);
CRC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg26893134	chr6:116381904	FRK	0.28	8.01	0.4	2e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.64	-9.09	-0.45	9.56e-18	Platelet count;
CRC	cis	rs1524976	1.000	rs62255280	chr3:65483527	T/C	cg16238336	chr3:65465873	MAGI1	-0.52	-6.76	-0.35	6.14e-11	PR interval;
CRC	cis	rs720844	1.000	rs16829006	chr2:149335661	C/T	cg09247360	chr2:149335327	NA	-0.61	-7.7	-0.39	1.5700000000000001e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.38	6.19	0.32	1.83e-9	Life satisfaction;
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4908768	0.501	rs12756257	chr1:8616933	C/A	cg20416874	chr1:8611966	RERE	-0.44	-6.31	-0.33	9.21e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.43	6.91	0.36	2.5e-11	Resting heart rate;
CRC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg00769240	chr8:12517080	NA	-0.57	-7.03	-0.36	1.23e-11	Blood pressure (smoking interaction);
CRC	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.42	0.42	1.15e-15	Endometrial cancer;
CRC	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.74	-11.97	-0.55	1.2100000000000001e-27	Idiopathic membranous nephropathy;
CRC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.01	0.48	9.19e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.61	-11.14	-0.52	1.13e-24	Height;
CRC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	1.06	12.97	0.58	2.26e-31	Iron status biomarkers;
CRC	cis	rs4853036	0.951	rs10185266	chr2:70152407	C/G	cg02498382	chr2:70120550	SNRNP27	-0.45	-6.9	-0.36	2.64e-11	Colorectal or endometrial cancer;
CRC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	11.16	0.52	9.41e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg11693508	chr17:37793320	STARD3	0.52	6.73	0.35	7.44e-11	Neuroticism;
CRC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg19257562	chr1:2043853	PRKCZ	0.44	7.09	0.36	8.3e-12	Height;
CRC	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg14515779	chr1:101123966	NA	-0.42	-8.04	-0.41	1.63e-14	Monocyte count;
CRC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	10.11	0.49	4.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.04	0.32	4.08e-9	Heart rate;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20092199	chr4:1342459	KIAA1530	0.41	7.49	0.38	6.31e-13	Obesity-related traits;
CRC	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	7.72	0.39	1.43e-13	Breast cancer;
CRC	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg12870014	chr12:110450643	ANKRD13A	0.86	9.64	0.47	1.53e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg08017880	chr11:407180	SIGIRR	-0.43	-6.17	-0.32	2e-9	Total cholesterol levels;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.03	0.32	4.33e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.29	0.42	2.95e-15	Height;
CRC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.73	0.35	7.5e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.51	-8.26	-0.41	3.63e-15	Testicular germ cell tumor;
CRC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.68	-8.5	-0.42	6.71e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.53	8.02	0.4	1.93e-14	Emphysema distribution in smoking;
CRC	trans	rs6918679	0.630	rs2353329	chr6:75549672	C/T	cg15161371	chr1:3613808	TP73	0.47	5.98	0.31	5.68e-9	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks);
CRC	cis	rs6743376	0.556	rs2441376	chr2:113817755	T/C	cg09040174	chr2:113837401	NA	0.44	6.37	0.33	6.46e-10	Inflammatory biomarkers;
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg10137463	chr15:23085908	NIPA1	0.47	6.01	0.31	4.89e-9	Plasma plasminogen activator levels;
CRC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.06	10.51	0.5	1.83e-22	Diabetic retinopathy;
CRC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02532999	chr21:38639929	DSCR3	0.38	6.04	0.32	4.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.52	-8.68	-0.43	1.83e-16	Sense of smell;
CRC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.43	-5.86	-0.31	1.13e-8	Diastolic blood pressure;
CRC	trans	rs2303319	0.504	rs16846026	chr2:162537691	T/C	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.55e-9	Cognitive function;
CRC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.39	-6.43	-0.33	4.56e-10	Hemoglobin concentration;
CRC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.42	7.2	0.37	4.22e-12	Primary biliary cholangitis;
CRC	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.58	10.17	0.49	2.54e-21	Age of smoking initiation;
CRC	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.53	9.43	0.46	7.35e-19	Schizophrenia;
CRC	cis	rs2179367	0.959	rs489551	chr6:149689457	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.35	-5.7	-0.3	2.65e-8	Dupuytren's disease;
CRC	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.73	-9.59	-0.47	2.23e-19	White matter hyperintensity burden;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11645453	chr3:52864694	ITIH4	0.36	6.55	0.34	2.22e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14684917	chr11:62380363	EML3;ROM1	-0.38	-6.17	-0.32	1.97e-9	Myopia (pathological);
CRC	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.56	6.63	0.34	1.42e-10	Lung function (FEV1/FVC);
CRC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.52	5.91	0.31	8.37e-9	Vitiligo;
CRC	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.5	-7.01	-0.36	1.35e-11	Educational attainment (college completion);
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.53	7.15	0.37	5.67e-12	Alzheimer's disease;
CRC	cis	rs4481887	0.504	rs4916107	chr1:248353621	A/G	cg00666640	chr1:248458726	OR2T12	-0.43	-7.09	-0.36	8.31e-12	Common traits (Other);
CRC	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg05714579	chr10:131428358	MGMT	0.54	7.69	0.39	1.76e-13	Response to temozolomide;
CRC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg26061582	chr7:22766209	IL6	0.53	8.03	0.4	1.77e-14	Lung cancer;
CRC	cis	rs7202877	0.706	rs4888375	chr16:75322356	T/C	cg03315344	chr16:75512273	CHST6	0.49	5.61	0.3	4.28e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg25344623	chr2:136566232	LCT	0.33	6.03	0.32	4.33e-9	Mosquito bite size;
CRC	cis	rs6743376	0.556	rs1374286	chr2:113819007	C/G	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.87	10.95	0.52	5.37e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.6	7.98	0.4	2.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.06	-0.45	1.19e-17	Triglycerides;
CRC	cis	rs2274471	0.699	rs73395341	chr9:5085549	A/G	cg03390472	chr9:5043263	JAK2	-0.57	-6.35	-0.33	7.01e-10	Crohn's disease;
CRC	cis	rs56313388	0.793	rs9937815	chr16:56330832	C/T	cg02433656	chr16:56322654	GNAO1	-0.51	-7.68	-0.39	1.78e-13	Pulse pressure;
CRC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.61	9.71	0.47	9.31e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg12317470	chr15:67143691	NA	0.78	6.68	0.35	9.98e-11	Lung cancer (smoking interaction);
CRC	cis	rs7692995	0.925	rs6843651	chr4:17995500	T/C	cg08925142	chr4:18023851	LCORL	-0.54	-5.97	-0.31	6.14e-9	Height;
CRC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-11.37	-0.53	1.7e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg01843034	chr6:37503916	NA	-0.38	-6.73	-0.35	7.53e-11	Cognitive performance;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12273811	chr6:28175739	NA	0.62	8.29	0.42	2.87e-15	Parkinson's disease;
CRC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.09	0.45	9.47e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.32	0.53	2.68e-25	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.68	-0.35	1.01e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg02126412	chr11:112831938	NCAM1	-0.32	-6.02	-0.31	4.7e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs17234274	0.585	rs2128494	chr11:23234390	A/G	cg05245346	chr11:23248277	NA	0.35	5.72	0.3	2.35e-8	Cancer;
CRC	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg23899408	chr19:12877188	HOOK2	-0.48	-6.54	-0.34	2.38e-10	Bipolar disorder;
CRC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.92e-30	Blood trace element (Zn levels);
CRC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.47	6.66	0.34	1.17e-10	Response to temozolomide;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.74	0.3	2.18e-8	Life satisfaction;
CRC	trans	rs1376359	0.673	rs35138045	chr1:103127474	G/A	cg16220183	chr17:56609687	SEPT4	-0.45	-6.04	-0.32	4.09e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.7	9.41	0.46	8.93e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15888301	chr15:73344233	NEO1	0.38	6.16	0.32	2.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.66	9.38	0.46	1.13e-18	Vitamin D levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00905170	chr8:67341306	RRS1	0.47	6.8	0.35	5.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.62	9.62	0.47	1.85e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.93	0.4	3.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg20628663	chr10:43360327	NA	0.57	6.62	0.34	1.43e-10	Blood protein levels;
CRC	cis	rs2625529	0.617	rs62023343	chr15:72174963	C/A	cg16672083	chr15:72433130	SENP8	0.46	7.01	0.36	1.39e-11	Red blood cell count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18809821	chr6:24403225	MRS2	0.49	6.3	0.33	9.53e-10	Thyroid stimulating hormone;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19884546	chr22:38082237	NOL12	0.54	7.48	0.38	6.82e-13	Thyroid stimulating hormone;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00665395	chr2:219575490	TTLL4	-0.53	-6.29	-0.33	1.03e-9	Diisocyanate-induced asthma;
CRC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.69	-0.74	1.42e-57	Primary sclerosing cholangitis;
CRC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg21251018	chr6:28226885	NKAPL	0.42	6.42	0.33	4.75e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-6.92	-0.36	2.35e-11	Breast cancer;
CRC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	11.65	0.54	1.75e-26	Tonsillectomy;
CRC	trans	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.65	0.34	1.25e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.88	11.77	0.54	6.18e-27	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.79	-13.66	-0.6	5.72e-34	Lewy body disease;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.5	6.93	0.36	2.25e-11	Menarche (age at onset);
CRC	cis	rs747650	0.504	rs7127741	chr11:47074479	T/C	cg19486271	chr11:47235900	DDB2	-0.44	-5.86	-0.31	1.11e-8	Acne (severe);
CRC	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg08779649	chr13:50194554	NA	0.33	6.48	0.34	3.38e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.51	-7.98	-0.4	2.51e-14	Monocyte count;
CRC	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg12564285	chr5:131593104	PDLIM4	0.32	5.6	0.3	4.5e-8	Blood metabolite levels;
CRC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17554472	chr22:41940697	POLR3H	-0.56	-6.06	-0.32	3.72e-9	Vitiligo;
CRC	trans	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg18335740	chr13:41363409	SLC25A15	0.61	9.83	0.48	3.67e-20	Lewy body disease;
CRC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.56	-6.96	-0.36	1.86e-11	Body mass index;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg07404485	chr7:94953653	PON1	0.46	6.03	0.32	4.41e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12760731	0.720	rs12026110	chr1:178410984	G/A	cg00404053	chr1:178313656	RASAL2	0.95	9.79	0.47	5.03e-20	Obesity-related traits;
CRC	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.5	-9.91	-0.48	2.02e-20	Urate levels in overweight individuals;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg23161317	chr6:28129485	ZNF389	0.45	6.32	0.33	8.63e-10	Parkinson's disease;
CRC	cis	rs868943	0.582	rs12209373	chr6:116488925	G/A	cg15226275	chr6:116381976	FRK	0.27	6.06	0.32	3.64e-9	Total cholesterol levels;
CRC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.68	10.35	0.5	6.44e-22	Corneal astigmatism;
CRC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.43	-7.05	-0.36	1.05e-11	Alcohol dependence;
CRC	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	7.45	0.38	8.46e-13	Mean corpuscular volume;
CRC	cis	rs6681460	0.576	rs7354930	chr1:66986377	T/C	cg02459107	chr1:67143332	SGIP1	0.36	5.62	0.3	4.16e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg13798780	chr7:105162888	PUS7	0.67	7.93	0.4	3.42e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg19773385	chr1:10388646	KIF1B	-0.57	-8.05	-0.41	1.55e-14	Hepatocellular carcinoma;
CRC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	11.09	0.52	1.7e-24	Monocyte percentage of white cells;
CRC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg05941027	chr17:61774174	LIMD2	0.34	6.27	0.33	1.15e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2342371	0.883	rs11185542	chr3:196187927	G/C	cg15048948	chr3:196158458	UBXN7	-0.52	-5.78	-0.3	1.77e-8	Fat distribution (HIV);
CRC	cis	rs995000	0.965	rs1690761	chr1:62955862	C/T	cg19896129	chr1:63156450	NA	-0.45	-6.98	-0.36	1.6e-11	Triglyceride levels;
CRC	trans	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg10756647	chr7:56101905	PSPH	0.67	6.83	0.35	4.13e-11	Diabetic kidney disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09226173	chr5:122111107	SNX2	0.42	6.14	0.32	2.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.46	-0.34	3.83e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs9925964	0.967	rs9936329	chr16:31140799	G/T	cg03418659	chr16:31128414	MYST1	0.54	7.86	0.4	5.55e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.44	6.5	0.34	2.93e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.09	-0.52	1.73e-24	Blood trace element (Zn levels);
CRC	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg09659197	chr4:152720779	NA	0.52	11.41	0.53	1.28e-25	Intelligence (multi-trait analysis);
CRC	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.47	7.49	0.38	6.26e-13	Schizophrenia;
CRC	cis	rs524281	0.731	rs2452682	chr11:65812609	C/T	cg16950941	chr11:66035639	RAB1B	-0.48	-5.76	-0.3	1.9e-8	Electroencephalogram traits;
CRC	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-5.87	-0.31	1.04e-8	Coronary artery disease;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg10596483	chr8:143751796	JRK	-0.46	-6.43	-0.33	4.58e-10	Urinary tract infection frequency;
CRC	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg04880052	chr2:219191631	PNKD	0.4	6.1	0.32	3.01e-9	Colorectal cancer;
CRC	trans	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.582	rs62187608	chr2:162431138	T/G	cg10498984	chr16:28874827	SH2B1	-0.73	-5.98	-0.31	5.81e-9	Cognitive function;
CRC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs1320333	0.772	rs17786120	chr2:700580	A/T	cg20966539	chr2:681320	NA	0.67	6.37	0.33	6.27e-10	Obesity-related traits;
CRC	cis	rs3956705	0.798	rs1045477	chr7:32908704	T/C	cg05721444	chr7:32995514	FKBP9	-0.44	-6.45	-0.34	3.92e-10	Red cell distribution width;
CRC	cis	rs3857067	1.000	rs115969971	chr4:95023550	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15617548	chr2:171785815	GORASP2	-0.42	-6.13	-0.32	2.49e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24562565	chr11:27494352	LGR4	0.5	7.4	0.38	1.12e-12	Response to antipsychotic treatment;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.42	0.33	4.73e-10	Diastolic blood pressure;
CRC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-9.79	-0.47	5.1e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.92	-9.42	-0.46	8.4e-19	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.68	-10.93	-0.52	6.36e-24	Motion sickness;
CRC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg22791324	chr7:157949174	PTPRN2	0.35	5.89	0.31	9.71e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.66	0.43	2.14e-16	Homoarginine levels;
CRC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg16358738	chr2:241808595	AGXT	-0.4	-6.24	-0.33	1.32e-9	Urinary metabolites;
CRC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.56	0.43	4.25e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.39	-6.21	-0.32	1.61e-9	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.16	26.05	0.82	5.8e-82	IgG glycosylation;
CRC	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg06606381	chr12:133084897	FBRSL1	-1.44	-10.94	-0.52	5.61e-24	Depression;
CRC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.54	-0.43	5.03e-16	Chronic sinus infection;
CRC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.21	-0.37	3.83e-12	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00309650	chr4:88312547	HSD17B11	0.43	6.13	0.32	2.45e-9	Response to antipsychotic treatment;
CRC	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.54	7.64	0.39	2.38e-13	Eye color traits;
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3087591	0.708	rs3785956	chr17:29647707	C/A	cg24425628	chr17:29625626	OMG;NF1	0.74	13.31	0.59	1.25e-32	Hip circumference;
CRC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.65	8.34	0.42	2.04e-15	Arsenic metabolism;
CRC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.75	0.3	2.05e-8	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg22561889	chr6:118971681	C6orf204	0.46	5.77	0.3	1.87e-8	Diastolic blood pressure;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	13.74	0.6	2.86e-34	Alzheimer's disease;
CRC	cis	rs230203	0.506	rs230195	chr20:55774426	C/A	cg13236649	chr20:55835020	BMP7	0.41	6.02	0.31	4.67e-9	Monobrow;
CRC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4654899	0.833	rs3816454	chr1:21191416	T/G	cg02927042	chr1:21476669	EIF4G3	0.45	7.18	0.37	4.62e-12	Superior frontal gyrus grey matter volume;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg21433313	chr16:3507492	NAT15	0.6	5.63	0.3	3.85e-8	Tuberculosis;
CRC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.51	-7.56	-0.38	3.93e-13	Height;
CRC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg15445000	chr17:37608096	MED1	-0.33	-5.69	-0.3	2.83e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg11189052	chr15:85197271	WDR73	0.61	9.04	0.45	1.35e-17	Schizophrenia;
CRC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.9e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.54	-10.0	-0.48	9.71e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22251877	chr8:125551349	TATDN1;NDUFB9	-0.42	-6.39	-0.33	5.6e-10	Myopia (pathological);
CRC	cis	rs1223397	0.938	rs9395602	chr6:13278753	C/T	cg00460589	chr6:13274354	PHACTR1	0.49	6.03	0.32	4.33e-9	Blood pressure;
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg21620606	chr4:1342894	KIAA1530	0.33	5.79	0.3	1.67e-8	Obesity-related traits;
CRC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg13607699	chr17:42295918	UBTF	-0.45	-5.82	-0.31	1.4e-8	Total body bone mineral density;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25595571	chr14:104029029	BAG5;C14orf153	0.37	6.09	0.32	3.09e-9	Obesity-related traits;
CRC	trans	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.25	0.33	1.28e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6662572	0.703	rs11580953	chr1:46387857	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.62	0.3	4.15e-8	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23080178	chr12:52463740	C12orf44	0.46	6.4	0.33	5.22e-10	Anxiety disorder;
CRC	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.75	13.62	0.6	8.5e-34	Lewy body disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01998682	chr6:151712546	ZBTB2	0.47	6.55	0.34	2.25e-10	Anxiety disorder;
CRC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.42	8.32	0.42	2.39e-15	Mean corpuscular volume;
CRC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07513332	chr6:167530253	CCR6	0.35	5.63	0.3	3.87e-8	Crohn's disease;
CRC	trans	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.45	6.29	0.33	1.04e-9	Cystic fibrosis severity;
CRC	cis	rs11650494	0.710	rs76651802	chr17:47473785	A/G	cg08112188	chr17:47440006	ZNF652	0.69	6.28	0.33	1.05e-9	Prostate cancer;
CRC	trans	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg17903999	chr18:56338584	MALT1	0.38	6.09	0.32	3.08e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.8	13.08	0.59	8.83e-32	Blood protein levels;
CRC	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg01268866	chr2:3683757	COLEC11	0.59	7.37	0.38	1.39e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.52	-8.3	-0.42	2.73e-15	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08938475	chr2:70313833	PCBP1	0.49	7.12	0.37	6.82e-12	Response to antipsychotic treatment;
CRC	cis	rs7901135	1.000	rs9415589	chr10:60586802	A/T	cg23799393	chr10:60588674	BICC1	0.36	5.66	0.3	3.26e-8	Morning vs. evening chronotype;
CRC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.52	9.07	0.45	1.11e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.45	8.8	0.44	8.12e-17	Intelligence (multi-trait analysis);
CRC	trans	rs1413885	1.000	rs1413885	chr1:65815659	C/T	cg26534493	chr8:28060551	NA	-0.37	-5.98	-0.31	5.72e-9	Anticoagulant levels;
CRC	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.65	9.6	0.47	2.15e-19	Schizophrenia;
CRC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg25972092	chr12:117363249	FBXW8	0.52	6.1	0.32	2.95e-9	Subcortical brain region volumes;Hippocampal volume;
CRC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.2	-15.67	-0.65	1.03e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-6.2	-0.32	1.65e-9	Height;
CRC	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.59	8.05	0.41	1.55e-14	White matter hyperintensity burden;
CRC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26587870	chr6:27730563	NA	-0.59	-5.95	-0.31	6.85e-9	Depression;
CRC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.54	0.47	3.23e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3018066	0.666	rs10002288	chr4:106961604	A/C	cg01869342	chr4:106983673	TBCK	0.49	6.27	0.33	1.17e-9	Cancer;
CRC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.82	9.16	0.45	5.68e-18	Breast cancer;
CRC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.67	10.09	0.49	4.73e-21	Lung cancer;
CRC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.42	5.95	0.31	7.03e-9	Aortic root size;
CRC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg27661571	chr11:113659931	NA	-0.95	-11.14	-0.52	1.11e-24	Hip circumference adjusted for BMI;
CRC	cis	rs6564851	0.506	rs11645428	chr16:81258896	C/T	cg05274606	chr16:81253692	PKD1L2	-0.37	-6.07	-0.32	3.46e-9	Carotenoid and tocopherol levels;
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg04969067	chr8:143858791	LYNX1	0.74	13.19	0.59	3.38e-32	Urinary tract infection frequency;
CRC	cis	rs13098911	0.540	rs6780028	chr3:46075090	A/C	cg12691230	chr3:46064611	XCR1	-0.52	-5.62	-0.3	4.01e-8	Celiac disease;
CRC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg05139728	chr16:28306816	SBK1	-0.33	-5.63	-0.3	3.77e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	11.01	0.52	3.4e-24	Coronary artery disease;
CRC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.59	6.66	0.34	1.17e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4789294	0.806	rs56239194	chr17:74403361	C/G	cg06840243	chr17:74442338	UBE2O	0.43	6.05	0.32	3.87e-9	Lymphocyte percentage of white cells;
CRC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg01788221	chr16:89496183	ANKRD11	-0.47	-7.26	-0.37	2.79e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg26061582	chr7:22766209	IL6	0.52	8.13	0.41	8.99e-15	Lung cancer;
CRC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.38	-6.57	-0.34	1.98e-10	Aortic root size;
CRC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.78	14.62	0.63	1.2e-37	Height;
CRC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg10589385	chr1:150898437	SETDB1	0.32	6.55	0.34	2.2e-10	Melanoma;
CRC	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.56	-0.38	4.08e-13	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24098516	chr3:122233880	KPNA1	0.4	6.25	0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.78	-0.3	1.75e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	cis	rs1192419	0.502	rs10493854	chr1:92055866	C/T	cg24006770	chr1:92056542	NA	-0.55	-9.26	-0.45	2.74e-18	Optic disc area;Optic nerve measurement (cup-to-disc ratio);
CRC	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.31	7.15	0.37	5.72e-12	Corneal astigmatism;
CRC	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg22495460	chr2:25135724	ADCY3	-0.82	-13.57	-0.6	1.31e-33	Body mass index;
CRC	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.55	-0.38	4.29e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.17	-0.37	5.09e-12	Colorectal cancer;
CRC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.64	9.69	0.47	1.04e-19	Lung cancer;
CRC	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.06	0.52	2.17e-24	Coffee consumption (cups per day);
CRC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg08761264	chr16:28874980	SH2B1	-0.42	-5.64	-0.3	3.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18121669	chr1:26560928	CCDC21	0.45	6.14	0.32	2.32e-9	Anxiety disorder;
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.83e-9	Life satisfaction;
CRC	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.46	-0.38	7.88e-13	Menarche (age at onset);
CRC	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.6	-8.58	-0.43	3.85e-16	Coronary artery disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14993530	chr1:245027115	HNRNPU	0.41	6.47	0.34	3.59e-10	Interleukin-6 levels;
CRC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.14	-0.32	2.42e-9	Morning vs. evening chronotype;
CRC	cis	rs6834538	0.637	rs11937201	chr4:113427458	A/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.41	-6.16	-0.32	2.14e-9	Free thyroxine concentration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06349174	chr11:3877476	STIM1	0.45	6.06	0.32	3.66e-9	Thyroid stimulating hormone;
CRC	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.58e-15	Lung cancer;
CRC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.75	10.24	0.49	1.47e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs12760731	0.565	rs34303391	chr1:178178126	T/A	cg00404053	chr1:178313656	RASAL2	1.05	10.96	0.52	4.8e-24	Obesity-related traits;
CRC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.6	6.76	0.35	6.25e-11	Bipolar disorder;
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00166722	chr3:10149974	C3orf24	0.72	8.26	0.41	3.63e-15	Alzheimer's disease;
CRC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.06	0.32	3.71e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.52e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg06470822	chr6:28175283	NA	0.62	8.81	0.44	7.28e-17	Parkinson's disease;
CRC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg09796270	chr17:17721594	SREBF1	-0.58	-10.2	-0.49	2.03e-21	Total body bone mineral density;
CRC	cis	rs2708977	0.637	rs675239	chr2:97076556	A/G	cg23100626	chr2:96804247	ASTL	0.22	5.62	0.3	4.09e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs11955398	0.625	rs11745077	chr5:59955716	C/T	cg02684056	chr5:59996105	DEPDC1B	0.4	5.69	0.3	2.74e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12516959	chr21:47718080	NA	-0.39	-6.63	-0.34	1.37e-10	Testicular germ cell tumor;
CRC	cis	rs73058052	0.569	rs2116922	chr19:50103252	G/A	cg15963326	chr19:50037085	RCN3	-0.37	-5.96	-0.31	6.58e-9	Fibrinogen levels;
CRC	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg20041105	chr8:143859282	LYNX1	-0.33	-5.76	-0.3	1.97e-8	Urinary tract infection frequency;
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.49	9.29	0.46	2.15e-18	Renal cell carcinoma;
CRC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.88e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6968419	0.747	rs1000966	chr7:115862902	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.58e-10	Intraocular pressure;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg20615401	chr6:28092323	ZSCAN16	0.46	6.16	0.32	2.14e-9	Parkinson's disease;
CRC	cis	rs6694672	0.867	rs7513826	chr1:197150638	A/G	cg13682187	chr1:196946512	CFHR5	0.51	7.66	0.39	2.06e-13	Asthma;
CRC	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.52	-0.5	1.6400000000000001e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6546324	0.625	rs6546317	chr2:67828793	C/G	cg15745817	chr2:67799979	NA	-0.54	-9.04	-0.45	1.4e-17	Endometriosis;
CRC	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.57	9.7	0.47	9.94e-20	Dupuytren's disease;
CRC	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg09873164	chr1:152488093	CRCT1	0.38	6.34	0.33	7.62e-10	Hair morphology;
CRC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg17633681	chr16:88106987	BANP	0.82	13.96	0.61	4.35e-35	Menopause (age at onset);
CRC	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.72	12.03	0.55	7.27e-28	Colorectal cancer;
CRC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.61	-9.54	-0.47	3.39e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-8.51	-0.42	6.46e-16	Coffee consumption (cups per day);
CRC	cis	rs12431939	0.947	rs55974960	chr14:51633742	T/C	cg23942311	chr14:51606299	NA	-0.55	-6.05	-0.32	3.96e-9	Cancer;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.41	5.72	0.3	2.46e-8	Longevity;
CRC	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.31	0.37	2.04e-12	Eye color traits;
CRC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.68	-0.3	2.96e-8	Total body bone mineral density;
CRC	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	trans	rs11673344	0.528	rs476194	chr19:37410733	T/C	cg18947437	chr10:1231002	ADARB2	-0.35	-6.28	-0.33	1.06e-9	Obesity-related traits;
CRC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.75	-0.6	2.69e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.79	-13.35	-0.59	8.41e-33	Obesity-related traits;
CRC	cis	rs7113874	0.569	rs11041983	chr11:8580619	A/G	cg17679104	chr11:8615758	STK33	-0.35	-5.84	-0.31	1.23e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.73	-8.36	-0.42	1.76e-15	Systolic blood pressure;
CRC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.53	-8.8	-0.44	8.04e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.7	-0.47	9.86e-20	Monocyte percentage of white cells;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg01662769	chr14:64932348	AKAP5	0.5	6.06	0.32	3.65e-9	Kashin-Beck disease;
CRC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg18016565	chr1:150552671	MCL1	0.44	6.04	0.32	4.07e-9	Melanoma;
CRC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.51	8.26	0.41	3.55e-15	Aortic root size;
CRC	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.67	7.03	0.36	1.21e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.76	0.39	1.11e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.54	6.72	0.35	7.95e-11	Mean platelet volume;
CRC	cis	rs9992667	0.955	rs28560778	chr4:38611289	G/A	cg19726192	chr4:38663646	FLJ13197	-0.59	-7.54	-0.38	4.61e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg15786705	chr6:28176104	NA	0.49	6.62	0.34	1.45e-10	Parkinson's disease;
CRC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.91	0.31	8.45e-9	Renal function-related traits (BUN);
CRC	trans	rs28673968	0.615	rs1603250	chr4:90513906	C/T	cg18438894	chr1:184377525	C1orf21	0.38	5.97	0.31	6.31e-9	Idiopathic pulmonary fibrosis;
CRC	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg08027265	chr7:2291960	NA	-0.43	-6.62	-0.34	1.47e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.91	-17.24	-0.69	6.89e-48	Coronary artery disease;
CRC	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg11693508	chr17:37793320	STARD3	0.58	6.73	0.35	7.63e-11	Neuroticism;
CRC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.61	-8.18	-0.41	6.29e-15	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14258675	chr14:75348443	DLST	0.51	6.74	0.35	6.92e-11	Thyroid stimulating hormone;
CRC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg20387954	chr3:183756860	HTR3D	0.42	7.17	0.37	5.04e-12	Anterior chamber depth;
CRC	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg04202892	chr2:111875749	ACOXL	0.46	7.5	0.38	6.02e-13	Chronic lymphocytic leukemia;
CRC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.72	-12.19	-0.56	1.83e-28	Breast cancer;
CRC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.44	6.15	0.32	2.3e-9	Tuberculosis;
CRC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.23	-0.37	3.45e-12	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20441175	chr10:75007251	DNAJC9	0.5	7.35	0.38	1.57e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.03	-11.25	-0.53	4.77e-25	Vitiligo;
CRC	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-0.66	-9.41	-0.46	8.66e-19	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09311052	chr1:154531418	UBE2Q1	0.44	6.16	0.32	2.16e-9	Response to antipsychotic treatment;
CRC	cis	rs7259376	0.818	rs8101997	chr19:22568432	A/T	cg02657401	chr19:22469223	NA	-0.33	-7.24	-0.37	3.3e-12	Menopause (age at onset);
CRC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.57	-8.49	-0.42	7.44e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg11269599	chr19:52391304	ZNF577	0.52	6.31	0.33	9.09e-10	Breast cancer;
CRC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg03060546	chr3:49711283	APEH	0.4	5.67	0.3	3.1e-8	Menarche (age at onset);
CRC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.83	10.52	0.5	1.73e-22	Obesity-related traits;
CRC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.66	7.02	0.36	1.27e-11	Axial length;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12977448	chr10:14920832	SUV39H2	0.49	7.55	0.38	4.19e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-6.33	-0.33	8.09e-10	Platelet distribution width;
CRC	cis	rs4908760	0.860	rs11121202	chr1:8639357	T/C	cg20416874	chr1:8611966	RERE	-0.43	-6.15	-0.32	2.28e-9	Vitiligo;
CRC	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.08	-12.43	-0.57	2.49e-29	Atopic dermatitis;
CRC	trans	rs12803066	0.505	rs17697327	chr11:99978855	A/G	cg22457238	chr19:58570995	ZNF135	-0.45	-6.03	-0.32	4.29e-9	Myopia (pathological);
CRC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.82	11.69	0.54	1.28e-26	Cognitive function;
CRC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg27661571	chr11:113659931	NA	-0.95	-11.09	-0.52	1.65e-24	Hip circumference adjusted for BMI;
CRC	cis	rs10924970	0.967	rs10802617	chr1:235485768	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	6.12	0.32	2.66e-9	Asthma;
CRC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.72	10.64	0.51	6.66e-23	Immature fraction of reticulocytes;
CRC	cis	rs7605827	0.930	rs2380652	chr2:15594926	T/C	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.51e-9	Educational attainment (years of education);
CRC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24533757	chr11:36615953	RAG2;C11orf74	0.4	6.18	0.32	1.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.43	-5.87	-0.31	1.05e-8	Parkinson's disease;
CRC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg11861562	chr11:117069780	TAGLN	0.41	9.37	0.46	1.17e-18	Blood protein levels;
CRC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg13072238	chr3:49761600	GMPPB	-0.48	-5.63	-0.3	3.86e-8	Menarche (age at onset);
CRC	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.29	6.08	0.32	3.25e-9	Height;
CRC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-1.11	-17.4	-0.69	1.56e-48	Blood pressure (smoking interaction);
CRC	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	8.79e-9	Red blood cell count;
CRC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.0	9.49	0.46	4.89e-19	Diabetic retinopathy;
CRC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg09876464	chr15:85330779	ZNF592	0.42	6.83	0.35	4.21e-11	P wave terminal force;
CRC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg13607699	chr17:42295918	UBTF	-0.5	-6.6	-0.34	1.68e-10	Total body bone mineral density;
CRC	cis	rs939584	0.932	rs2867108	chr2:650143	T/C	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg25164649	chr6:28176230	NA	0.77	10.66	0.51	5.59e-23	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03175635	chr2:203736521	ICA1L	0.4	6.17	0.32	2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.55	-7.97	-0.4	2.59e-14	QRS duration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26248908	chr17:4614115	ARRB2	0.37	6.12	0.32	2.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4700695	0.841	rs27132	chr5:65288791	A/G	cg21114390	chr5:65439923	SFRS12	0.56	6.95	0.36	2.02e-11	Facial morphology (factor 19);
CRC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.42	-5.88	-0.31	9.9e-9	Calcium levels;
CRC	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg09184832	chr6:79620586	NA	-0.43	-7.32	-0.37	1.87e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.66	0.75	2.3e-61	Primary sclerosing cholangitis;
CRC	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.68	9.95	0.48	1.42e-20	Schizophrenia;
CRC	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg26811252	chr16:29126840	RRN3P2	0.61	8.31	0.42	2.62e-15	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.5	-9.87	-0.48	2.73e-20	Ulcerative colitis;
CRC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.4	-6.33	-0.33	7.99e-10	Neurofibrillary tangles;
CRC	cis	rs12913538	0.862	rs1550053	chr15:62890532	G/C	cg09983546	chr15:62884068	NA	0.5	7.79	0.39	8.95e-14	Sleep depth;
CRC	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg15704280	chr7:45808275	SEPT13	0.44	5.99	0.31	5.47e-9	Height;
CRC	cis	rs6973256	0.569	rs13246174	chr7:133395004	C/T	cg10665199	chr7:133106180	EXOC4	0.48	7.53	0.38	4.98e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.69	10.65	0.51	5.73e-23	Intelligence (multi-trait analysis);
CRC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.75	10.14	0.49	3.41e-21	Gestational age at birth (maternal effect);
CRC	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.08e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg20607287	chr7:12443886	VWDE	-0.56	-6.04	-0.32	4.1e-9	Coronary artery disease;
CRC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.67	-7.86	-0.4	5.54e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.82	0.31	1.37e-8	Bipolar disorder;
CRC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg24881330	chr22:46731750	TRMU	0.59	5.74	0.3	2.2e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg00601450	chr5:74908170	NA	-0.37	-5.63	-0.3	3.82e-8	Age-related disease endophenotypes;
CRC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02772935	chr3:125709198	NA	-0.49	-5.68	-0.3	2.91e-8	Blood pressure (smoking interaction);
CRC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.31	-0.53	2.92e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.59	6.69	0.35	9.34e-11	Lymphocyte counts;
CRC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.53	7.86	0.4	5.49e-14	Blood protein levels;
CRC	cis	rs6988985	0.703	rs4736312	chr8:143953937	A/C	cg10324643	chr8:143916377	GML	0.35	5.84	0.31	1.23e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.65	-10.28	-0.49	1.08e-21	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05478295	chr8:61429204	RAB2A	0.4	6.42	0.33	4.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00255919	chr5:131827918	IRF1	-0.59	-11.53	-0.54	4.46e-26	Asthma (sex interaction);
CRC	cis	rs7725052	0.609	rs4957300	chr5:40463739	C/T	cg09067459	chr5:40385259	NA	-0.38	-6.29	-0.33	9.85e-10	Pediatric autoimmune diseases;
CRC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.51	7.32	0.37	1.97e-12	Colorectal cancer;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12172441	chr6:28176163	NA	0.6	7.2	0.37	4.23e-12	Depression;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg10876282	chr6:28092338	ZSCAN16	0.49	6.5	0.34	2.92e-10	Parkinson's disease;
CRC	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.58	9.24	0.45	3.06e-18	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03442064	chr6:41515050	FOXP4	0.51	7.2	0.37	4.07e-12	Response to antipsychotic treatment;
CRC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg24851651	chr11:66362959	CCS	-0.35	-5.8	-0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg19875578	chr6:126661172	C6orf173	-0.42	-5.83	-0.31	1.34e-8	Male-pattern baldness;
CRC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.39	6.06	0.32	3.72e-9	Schizophrenia;
CRC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.82	-12.95	-0.58	2.81e-31	Cognitive function;
CRC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg16482183	chr6:26056742	HIST1H1C	0.6	8.12	0.41	9.28e-15	Iron status biomarkers;
CRC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.01	0.4	1.95e-14	Menopause (age at onset);
CRC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.35	0.42	1.86e-15	Lymphocyte counts;
CRC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-6.01	-0.31	4.87e-9	Monocyte percentage of white cells;
CRC	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.5	7.36	0.38	1.5e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-7.28	-0.37	2.42e-12	Perceived unattractiveness to mosquitoes;
CRC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg20203395	chr5:56204925	C5orf35	0.5	6.5	0.34	2.91e-10	Type 2 diabetes;
CRC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg11861562	chr11:117069780	TAGLN	-0.42	-9.31	-0.46	1.9e-18	Blood protein levels;
CRC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.65	9.95	0.48	1.41e-20	Corneal astigmatism;
CRC	cis	rs8105895	0.935	rs7251884	chr19:22245530	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.62	8.91	0.44	3.53e-17	Birth weight;
CRC	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.99	12.26	0.56	1.03e-28	Ulcerative colitis;
CRC	cis	rs2860975	1.000	rs10159983	chr10:96774437	C/T	cg09036531	chr10:96991505	NA	-0.42	-5.64	-0.3	3.73e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.48	-9.61	-0.47	1.97e-19	Subjective well-being;
CRC	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg03938978	chr2:103052716	IL18RAP	0.4	6.31	0.33	9.13e-10	Blood protein levels;
CRC	cis	rs972578	0.936	rs4822237	chr22:43364655	G/A	cg01576275	chr22:43409880	NA	-0.45	-7.29	-0.37	2.37e-12	Mean platelet volume;
CRC	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg27534772	chr1:16042836	PLEKHM2	0.44	7.13	0.37	6.5e-12	Systolic blood pressure;
CRC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.43	5.92	0.31	8.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.18	0.52	8.09e-25	Prudent dietary pattern;
CRC	cis	rs7487075	0.619	rs10880968	chr12:46822960	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.66	0.3	3.29e-8	Itch intensity from mosquito bite;
CRC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	10.53	0.5	1.58e-22	Motion sickness;
CRC	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.31	5.63	0.3	3.95e-8	Heart rate;
CRC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.66	11.81	0.55	4.4e-27	Prostate cancer;
CRC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-10.43	-0.5	3.46e-22	Migraine;Coronary artery disease;
CRC	cis	rs2592394	0.626	rs711828	chr2:177000363	A/G	cg13092806	chr2:177043255	NA	0.51	5.79	0.3	1.64e-8	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg17903999	chr18:56338584	MALT1	-0.43	-6.88	-0.35	3.06e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.56	-6.96	-0.36	1.8e-11	Diastolic blood pressure;
CRC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.53	0.34	2.46e-10	Schizophrenia;
CRC	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	0.63	6.22	0.32	1.54e-9	Exhaled nitric oxide output;
CRC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.63	13.36	0.59	8.07e-33	Schizophrenia;
CRC	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	0.65	6.17	0.32	1.96e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg02158880	chr13:53174818	NA	0.4	5.69	0.3	2.86e-8	Lewy body disease;
CRC	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.57	-0.39	3.77e-13	Thrombosis;
CRC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.6	-8.99	-0.44	2e-17	Schizophrenia;
CRC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg18827107	chr12:86230957	RASSF9	0.39	5.98	0.31	5.88e-9	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg02741985	chr17:80059408	CCDC57	0.42	7.01	0.36	1.34e-11	Life satisfaction;
CRC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.38	5.62	0.3	4.15e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-9.89	-0.48	2.31e-20	Blood protein levels;
CRC	cis	rs12024301	0.557	rs12039982	chr1:183614998	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11064206	chr12:123459532	OGFOD2;ABCB9	0.46	6.47	0.34	3.63e-10	Response to antipsychotic treatment;
CRC	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg27552081	chr17:25621774	WSB1	-0.39	-6.07	-0.32	3.62e-9	Aortic root size;
CRC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg17545662	chr6:170176663	C6orf70	0.57	6.4	0.33	5.21e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.23	-0.37	3.36e-12	Response to antipsychotic treatment;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.57	8.08	0.41	1.22e-14	Menarche (age at onset);
CRC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.49	6.94	0.36	2.06e-11	Schizophrenia;
CRC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.72	-0.35	8.17e-11	Alzheimer's disease (late onset);
CRC	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg15145174	chr5:6755386	POLS	-0.42	-6.07	-0.32	3.6e-9	Menopause (age at onset);
CRC	cis	rs6961069	0.777	rs6961024	chr7:80249671	G/T	cg04458919	chr7:80252533	CD36	0.35	6.22	0.32	1.53e-9	Platelet count;
CRC	cis	rs6662572	0.737	rs72677530	chr1:46529677	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.33	0.33	7.85e-10	Blood protein levels;
CRC	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	0.79	8.09	0.41	1.18e-14	Severe influenza A (H1N1) infection;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10116431	chr3:143690928	C3orf58	-0.44	-6.67	-0.35	1.08e-10	Myopia (pathological);
CRC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg19635926	chr16:89946313	TCF25	0.65	6.59	0.34	1.7e-10	Skin colour saturation;
CRC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.2	0.67	8.61e-44	Chronic sinus infection;
CRC	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26714650	chr12:56694279	CS	-1.4	-10.71	-0.51	3.55e-23	Psoriasis vulgaris;
CRC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	8.67	0.43	2e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs4073416	0.518	rs10148529	chr14:66104703	A/T	cg03016385	chr14:66212404	NA	-0.45	-6.2	-0.32	1.67e-9	N-glycan levels;
CRC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.6	-5.91	-0.31	8.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg18512352	chr11:47633146	NA	-0.36	-6.8	-0.35	4.87e-11	Subjective well-being;
CRC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.64	-0.68	1.47e-45	Height;
CRC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-9.02	-0.45	1.64e-17	Initial pursuit acceleration;
CRC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.72	0.35	7.89e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12667521	chr19:29218732	NA	0.43	6.33	0.33	8.23e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs17767392	0.792	rs61991249	chr14:71869546	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.48	-6.13	-0.32	2.46e-9	Mitral valve prolapse;
CRC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.6	0.34	1.66e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	trans	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg10442358	chr7:100137102	AGFG2	0.38	6.15	0.32	2.28e-9	Breast cancer;
CRC	trans	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg04077850	chr5:125800366	GRAMD3	0.36	6.07	0.32	3.52e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg09659197	chr4:152720779	NA	0.52	10.98	0.52	4.12e-24	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg15744005	chr10:104629667	AS3MT	0.32	6.35	0.33	7.15e-10	Arsenic metabolism;
CRC	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg16540259	chr10:75572220	NDST2	0.38	5.74	0.3	2.13e-8	Inflammatory bowel disease;
CRC	cis	rs12143943	0.966	rs2169136	chr1:204564237	G/C	cg17419461	chr1:204415978	PIK3C2B	0.39	5.92	0.31	8.17e-9	Cognitive performance;
CRC	cis	rs2070997	0.702	rs7866565	chr9:133766545	C/T	cg01000188	chr9:133769184	QRFP	0.58	6.19	0.32	1.75e-9	Response to amphetamines;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11494149	chr3:20227091	SGOL1	0.44	6.52	0.34	2.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.99	13.33	0.59	1.01e-32	Breast cancer;
CRC	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.38e-11	Inflammatory skin disease;
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg10677697	chr7:45961126	IGFBP3	0.36	6.39	0.33	5.72e-10	Sitting height ratio;
CRC	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.49	6.45	0.33	4.04e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.43	6.91	0.36	2.51e-11	Monocyte count;
CRC	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.65	12.3	0.56	7.28e-29	Menarche (age at onset);
CRC	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.64	0.54	1.81e-26	Exhaled nitric oxide levels;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.49	-0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg02319466	chr17:76381040	PGS1	0.38	5.85	0.31	1.17e-8	HDL cholesterol;
CRC	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.61	-7.68	-0.39	1.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	1.13	13.15	0.59	5.07e-32	Obesity-related traits;
CRC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.29	-0.33	9.82e-10	Body mass index;
CRC	cis	rs55702914	0.628	rs11883902	chr2:198341325	A/T	cg10820045	chr2:198174542	NA	0.33	5.88	0.31	9.94e-9	Major depression and alcohol dependence;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg21251018	chr6:28226885	NKAPL	0.51	5.95	0.31	6.9e-9	Depression;
CRC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-10.06	-0.49	6.26e-21	Coronary artery disease;
CRC	cis	rs7705042	0.865	rs7709361	chr5:141513854	T/C	cg08523384	chr5:141488047	NDFIP1	-0.31	-5.68	-0.3	3.02e-8	Asthma;
CRC	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg18551225	chr6:44695536	NA	-0.4	-5.68	-0.3	3e-8	Total body bone mineral density;
CRC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg05341575	chr12:125625032	AACS	-0.35	-5.77	-0.3	1.85e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg00255919	chr5:131827918	IRF1	0.57	11.25	0.53	4.58e-25	Asthma (sex interaction);
CRC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.41	8.02	0.4	1.91e-14	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23161317	chr6:28129485	ZNF389	0.51	6.36	0.33	6.66e-10	Depression;
CRC	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.48e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24308560	chr3:49941425	MST1R	0.5	8.26	0.41	3.56e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-9.07	-0.45	1.1e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.55	9.45	0.46	6.49e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs6586163	0.967	rs10887877	chr10:90753038	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.51	-7.47	-0.38	7.23e-13	Chronic lymphocytic leukemia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22154562	chr7:100136517	AGFG2	0.44	7.14	0.37	6.16e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.9	-11.3	-0.53	3.04e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs12760731	0.668	rs12727134	chr1:178266794	T/C	cg00404053	chr1:178313656	RASAL2	0.68	8.74	0.43	1.25e-16	Obesity-related traits;
CRC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	6.05	0.32	4.01e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.8	0.35	4.8e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01928910	chr1:31194314	MATN1	-0.4	-6.59	-0.34	1.8e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.42	0.38	9.81e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	1.01	11.33	0.53	2.4e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg01339444	chr6:118972232	C6orf204	0.52	5.9	0.31	8.98e-9	Renal cell carcinoma;
CRC	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.49	-7.67	-0.39	1.95e-13	White blood cell count (basophil);
CRC	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg04586622	chr2:25135609	ADCY3	-0.58	-9.86	-0.48	3.02e-20	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14094333	chr4:38666051	KLF3;FLJ13197	0.43	6.76	0.35	6.48e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1570989	0.841	rs956598	chr6:12027635	A/G	cg17804551	chr6:12015979	HIVEP1	0.38	5.71	0.3	2.58e-8	Alcohol and nicotine co-dependence;
CRC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg18479299	chr3:125709523	NA	-0.55	-6.58	-0.34	1.86e-10	Blood pressure (smoking interaction);
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12963246	chr6:28129442	ZNF389	0.47	5.64	0.3	3.64e-8	Parkinson's disease;
CRC	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.98	-0.4	2.38e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.39	-5.9	-0.31	9.27e-9	Gout;Renal underexcretion gout;
CRC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.69	0.3	2.81e-8	Total body bone mineral density;
CRC	trans	rs7474896	0.778	rs11011310	chr10:37941911	C/T	cg16724811	chr16:15130678	PDXDC1	-0.62	-6.01	-0.31	4.96e-9	Obesity (extreme);
CRC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13198984	chr17:80129470	CCDC57	-0.46	-7.99	-0.4	2.25e-14	Life satisfaction;
CRC	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.54	7.22	0.37	3.54e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs860295	0.702	rs10796946	chr1:155429490	A/T	cg02153340	chr1:155202674	NA	-0.58	-6.88	-0.35	3.08e-11	Body mass index;
CRC	cis	rs3018066	0.748	rs62321365	chr4:107013723	C/T	cg01869342	chr4:106983673	TBCK	0.44	6.4	0.33	5.49e-10	Cancer;
CRC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.64	0.39	2.33e-13	Schizophrenia;
CRC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg05941027	chr17:61774174	LIMD2	0.36	6.63	0.34	1.41e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9937943	0.667	rs9938426	chr16:74523739	C/G	cg01733217	chr16:74700730	RFWD3	-0.69	-7.41	-0.38	1.07e-12	Neutrophil percentage of white cells;
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.4	-7.37	-0.38	1.38e-12	Lung cancer;
CRC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	9.23e-17	Morning vs. evening chronotype;
CRC	cis	rs524281	0.773	rs10791863	chr11:66027358	C/T	cg16950941	chr11:66035639	RAB1B	-0.72	-8.1	-0.41	1.09e-14	Electroencephalogram traits;
CRC	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.42	6.55	0.34	2.2e-10	Cystic fibrosis severity;
CRC	cis	rs863345	0.608	rs11265013	chr1:158499625	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.18	-0.32	1.88e-9	Pneumococcal bacteremia;
CRC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.57	7.56	0.38	4e-13	IgG glycosylation;
CRC	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.3	-0.37	2.17e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.49	8.97	0.44	2.24e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.56	0.47	2.77e-19	Morning vs. evening chronotype;
CRC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.96	17.45	0.69	9.71e-49	IgG glycosylation;
CRC	trans	rs1864585	0.520	rs17720365	chr8:10679499	C/G	cg26278703	chr11:58910052	FAM111A	-0.5	-6.07	-0.32	3.43e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17554472	chr22:41940697	POLR3H	0.56	5.64	0.3	3.71e-8	Vitiligo;
CRC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.75	-11.26	-0.53	4.13e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7487075	0.578	rs12319162	chr12:46837914	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.78	0.3	1.74e-8	Itch intensity from mosquito bite;
CRC	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg13919466	chr1:32135498	COL16A1	-0.32	-5.99	-0.31	5.37e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg15786705	chr6:28176104	NA	0.48	6.42	0.33	4.89e-10	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.58	-10.13	-0.49	3.58e-21	Body mass index;
CRC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.32	-0.49	8.14e-22	Total cholesterol levels;
CRC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.98	18.48	0.71	8.2e-53	Height;
CRC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg26061582	chr7:22766209	IL6	0.53	8.12	0.41	9.29e-15	Lung cancer;
CRC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.78	13.63	0.6	7.71e-34	Breast cancer;
CRC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.8	10.22	0.49	1.81e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg23234261	chr14:55582407	NA	-0.28	-5.71	-0.3	2.48e-8	Protein biomarker;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg02683197	chr6:28174875	NA	-0.49	-6.92	-0.36	2.32e-11	Cardiac Troponin-T levels;
CRC	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg03315344	chr16:75512273	CHST6	-0.5	-5.75	-0.3	2.04e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.07	0.32	3.47e-9	Asthma;
CRC	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.7	-0.3	2.6e-8	Electroencephalogram traits;
CRC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg08314208	chr16:67682810	RLTPR	-0.64	-6.74	-0.35	7.13e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.86	11.75	0.54	7.72e-27	Migraine;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.46	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.49	7.68	0.39	1.89e-13	Red blood cell count;
CRC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.41	0.53	1.28e-25	Bone mineral density;
CRC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.54	-0.34	2.38e-10	Inflammatory skin disease;
CRC	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.99	-0.31	5.4e-9	Cognitive function;
CRC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.4	-5.91	-0.31	8.77e-9	Prostate cancer;
CRC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg03037974	chr15:76606532	NA	-0.4	-5.91	-0.31	8.43e-9	Blood metabolite levels;
CRC	trans	rs4785204	1.000	rs8064089	chr16:50094482	A/G	cg07960154	chr17:37760198	NEUROD2	-0.65	-6.08	-0.32	3.38e-9	Esophageal cancer (squamous cell);
CRC	cis	rs6504622	0.557	rs1867237	chr17:45003829	A/G	cg16759221	chr17:45003025	GOSR2	-0.63	-10.24	-0.49	1.56e-21	Orofacial clefts;
CRC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.46	-6.05	-0.32	3.87e-9	Coronary artery disease;
CRC	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg15654264	chr1:150340011	RPRD2	0.43	6.39	0.33	5.75e-10	Migraine;
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg15145296	chr3:125709740	NA	-0.56	-6.71	-0.35	8.75e-11	Blood pressure (smoking interaction);
CRC	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-14.82	-0.63	2.1e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg03160526	chr17:80928410	B3GNTL1	0.51	6.94	0.36	2.14e-11	Glycated hemoglobin levels;
CRC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg08314208	chr16:67682810	RLTPR	-0.65	-7.04	-0.36	1.12e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	11.93	0.55	1.69e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg01629716	chr15:45996671	NA	0.41	8.48	0.42	7.63e-16	Waist circumference;Weight;
CRC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.57	6.82	0.35	4.48e-11	Diastolic blood pressure;
CRC	cis	rs8062405	0.690	rs4787458	chr16:28531287	A/G	cg16576597	chr16:28551801	NUPR1	0.45	5.99	0.31	5.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.29	0.75	6.44e-60	Prudent dietary pattern;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08695707	chr1:197871847	C1orf53	0.47	6.04	0.32	4.13e-9	Thyroid stimulating hormone;
CRC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-7.24	-0.37	3.1e-12	Self-reported allergy;
CRC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.78	0.3	1.73e-8	IgG glycosylation;
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg27532560	chr4:187881888	NA	0.54	9.67	0.47	1.2e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4700695	0.764	rs36300	chr5:65348153	C/T	cg21114390	chr5:65439923	SFRS12	0.64	7.06	0.36	1.02e-11	Facial morphology (factor 19);
CRC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.52	-8.67	-0.43	1.99e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.77	7.31	0.37	2.04e-12	Type 2 diabetes;
CRC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02228675	chr17:40259724	DHX58	-0.5	-6.96	-0.36	1.88e-11	Fibrinogen levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg03535439	chr6:42981950	MEA1;KLHDC3	0.41	6.36	0.33	6.88e-10	Interleukin-6 levels;
CRC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Corneal astigmatism;
CRC	trans	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-9.73	-0.47	7.84e-20	Coffee consumption (cups per day);
CRC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.63	11.95	0.55	1.43e-27	Total body bone mineral density;
CRC	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.63	-0.3	3.78e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4664293	0.867	rs3771719	chr2:160630964	C/T	cg08347373	chr2:160653686	CD302	0.42	7.09	0.36	8.13e-12	Monocyte percentage of white cells;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg07414643	chr4:187882934	NA	0.35	5.87	0.31	1.06e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.72	8.67	0.43	2.04e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.83	-13.03	-0.58	1.4e-31	Cognitive function;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg08224069	chr6:26365425	BTN3A2	-0.38	-6.08	-0.32	3.32e-9	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05470666	chr10:74856828	P4HA1	0.42	6.29	0.33	1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.51	-6.98	-0.36	1.65e-11	Response to antidepressants and depression;
CRC	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.55	-8.96	-0.44	2.48e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2252790	0.859	rs2640853	chr6:116677818	C/G	cg18764771	chr6:116381957	FRK	-0.23	-6.28	-0.33	1.07e-9	Fast beta electroencephalogram;
CRC	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg09264619	chr17:80180166	NA	0.51	7.28	0.37	2.5e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.43	6.66	0.34	1.14e-10	Red blood cell count;
CRC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.99	0.55	9.91e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06199907	chr16:71674507	MARVELD3	0.4	5.98	0.31	5.75e-9	Myopia (pathological);
CRC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg03030879	chr14:75389066	RPS6KL1	0.41	6.34	0.33	7.51e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10341310	chr8:66582206	MTFR1	-0.39	-6.38	-0.33	5.91e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.84	14.65	0.63	9e-38	Height;
CRC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.66	8.65	0.43	2.29e-16	Morning vs. evening chronotype;
CRC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.86	10.71	0.51	3.62e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg02741985	chr17:80059408	CCDC57	0.42	7.04	0.36	1.13e-11	Life satisfaction;
CRC	cis	rs55788414	0.932	rs12103403	chr16:81185904	C/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg14541582	chr5:601475	NA	-0.33	-6.36	-0.33	6.85e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.68	-9.89	-0.48	2.33e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.32	0.37	1.95e-12	Neuroticism;
CRC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-12.84	-0.58	7.06e-31	Glomerular filtration rate (creatinine);
CRC	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg19676328	chr12:49525230	TUBA1B	-0.48	-6.09	-0.32	3.08e-9	Total cholesterol levels;
CRC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.27	0.45	2.58e-18	Bladder cancer;
CRC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.7	-0.3	2.63e-8	Crohn's disease;
CRC	cis	rs8105895	0.935	rs2043316	chr19:22251204	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs7487075	0.567	rs7486580	chr12:46828348	C/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.69	0.3	2.89e-8	Itch intensity from mosquito bite;
CRC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.67	-9.46	-0.46	6.23e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.97	12.22	0.56	1.45e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs1215050	0.904	rs260898	chr4:98706492	C/G	cg05340658	chr4:99064831	C4orf37	-0.5	-6.83	-0.35	4.22e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.61	0.47	1.92e-19	Cognitive test performance;
CRC	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg20169779	chr10:135381914	SYCE1	0.56	9.17	0.45	5.46e-18	Obesity-related traits;
CRC	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg25008857	chr14:105974488	NA	0.4	5.63	0.3	3.95e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.57	-5.86	-0.31	1.11e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.59	9.88	0.48	2.41e-20	Prudent dietary pattern;
CRC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg25956985	chr22:39795188	MAP3K7IP1	0.45	5.8	0.3	1.56e-8	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10475689	chr16:12142335	RUNDC2A	-0.37	-6.48	-0.34	3.31e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.73e-20	Lung cancer;
CRC	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg13476313	chr9:127244764	NR5A1	-0.3	-5.95	-0.31	6.88e-9	Menarche (age at onset);
CRC	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.4	6.16	0.32	2.14e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg07507251	chr3:52567010	NT5DC2	0.43	6.18	0.32	1.88e-9	Bipolar disorder;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg10546040	chr5:78280163	ARSB	-0.41	-6.33	-0.33	8.2e-10	Aortic root size;
CRC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.78e-24	Bone mineral density;
CRC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.93	-0.31	7.48e-9	Crohn's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20784733	chr7:66205729	RABGEF1	0.36	6.31	0.33	9.23e-10	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-7.77	-0.39	9.87e-14	Total body bone mineral density;
CRC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg15445000	chr17:37608096	MED1	-0.35	-6.2	-0.32	1.71e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-8.05	-0.41	1.54e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.46	7.97	0.4	2.59e-14	Common traits (Other);
CRC	cis	rs16867321	0.950	rs16867322	chr2:181369403	A/G	cg23363182	chr2:181467187	NA	-0.49	-6.09	-0.32	3.16e-9	Obesity;
CRC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg08772003	chr10:104629869	AS3MT	-0.41	-6.82	-0.35	4.31e-11	Arsenic metabolism;
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg04518342	chr5:131593106	PDLIM4	-0.47	-8.79	-0.44	8.33e-17	Breast cancer;
CRC	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.7	11.28	0.53	3.68e-25	Type 2 diabetes;
CRC	cis	rs7926971	0.756	rs11826266	chr11:12659535	T/C	cg25843174	chr11:12811716	TEAD1	0.35	6.08	0.32	3.28e-9	Height;
CRC	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27149388	chr12:47473796	AMIGO2	0.39	6.46	0.34	3.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg23071808	chr14:103021642	NA	0.61	6.87	0.35	3.27e-11	Platelet count;
CRC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11645453	chr3:52864694	ITIH4	0.38	6.47	0.34	3.51e-10	Bipolar disorder;
CRC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.46	-6.94	-0.36	2.09e-11	Testicular germ cell tumor;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03923535	chr7:1197113	ZFAND2A	0.52	7.41	0.38	1.1e-12	Longevity;Endometriosis;
CRC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.59	8.44	0.42	9.97e-16	Arsenic metabolism;
CRC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg06470822	chr6:28175283	NA	0.81	6.57	0.34	2.03e-10	Depression;
CRC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.45	9.29	0.46	2.21e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.31	-12.31	-0.56	6.49e-29	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg11843238	chr5:131593191	PDLIM4	0.42	7.85	0.4	5.73e-14	Breast cancer;
CRC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.61	-9.21	-0.45	3.96e-18	Blood pressure (smoking interaction);
CRC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.41	7.97	0.4	2.57e-14	Mean corpuscular volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01402448	chr6:136571605	FAM54A	0.4	6.29	0.33	1.03e-9	Obesity-related traits;
CRC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg17633681	chr16:88106987	BANP	0.81	14.3	0.62	2.08e-36	Menopause (age at onset);
CRC	cis	rs1223397	0.530	rs2458313	chr6:13309789	C/T	cg20827128	chr6:13274284	PHACTR1	0.39	6.03	0.32	4.44e-9	Blood pressure;
CRC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.06	0.41	1.38e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-6.91	-0.36	2.58e-11	Glioblastoma;
CRC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.35	7.37	0.38	1.39e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15216925	chr5:179921655	CNOT6	0.5	8.62	0.43	2.83e-16	Liver disease severity in Alagille syndrome;
CRC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg23229984	chr5:148520753	ABLIM3	-0.55	-7.25	-0.37	3.09e-12	Breast cancer;
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.8	-0.3	1.57e-8	Life satisfaction;
CRC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06232999	chr12:96429744	LTA4H	0.4	6.01	0.31	4.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7113874	0.569	rs11041999	chr11:8605739	T/C	cg02811074	chr11:8615871	STK33	0.35	5.99	0.31	5.36e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15392845	chr14:73360933	DPF3	0.47	6.19	0.32	1.75e-9	Thyroid stimulating hormone;
CRC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-6.4	-0.33	5.37e-10	Platelet distribution width;
CRC	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.54	8.66	0.43	2.11e-16	Educational attainment;
CRC	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.58	8.58	0.43	3.77e-16	Smooth-surface caries;
CRC	trans	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg10756647	chr7:56101905	PSPH	0.71	7.67	0.39	1.99e-13	Diabetic kidney disease;
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.4	-6.99	-0.36	1.5e-11	Lung cancer;
CRC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg10911889	chr6:126070802	HEY2	0.39	6.03	0.32	4.49e-9	Brugada syndrome;
CRC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.56	7.83	0.4	6.85e-14	Melanoma;
CRC	trans	rs4933824	0.826	rs10884099	chr10:83815369	T/C	cg09212058	chr2:37543459	PRKD3	-0.67	-6.1	-0.32	2.94e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02018176	chr4:1364513	KIAA1530	-0.41	-7.01	-0.36	1.38e-11	Obesity-related traits;
CRC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.65	9.14	0.45	6.46e-18	Bronchopulmonary dysplasia;
CRC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.52	6.69	0.35	9.86e-11	Obesity-related traits;
CRC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg14844989	chr11:31128820	NA	-0.34	-6.1	-0.32	2.97e-9	Red blood cell count;
CRC	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.76	10.09	0.49	4.95e-21	Coronary artery disease;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.39	5.96	0.31	6.48e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.95	-0.4	2.92e-14	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18845289	chr12:121124611	MLEC	0.43	6.4	0.33	5.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11030122	0.547	rs4910865	chr11:3950546	T/C	cg18678763	chr11:4115507	RRM1	-0.38	-6.52	-0.34	2.58e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.66	0.3	3.38e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.59	9.05	0.45	1.29e-17	Obesity;
CRC	cis	rs524281	0.861	rs7931544	chr11:65917034	C/T	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.71	9.96	0.48	1.37e-20	Response to diuretic therapy;
CRC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02018176	chr4:1364513	KIAA1530	-0.48	-8.12	-0.41	9.57e-15	Obesity-related traits;
CRC	cis	rs10022260	1	rs10022260	chr4:83793921	C/T	cg00595051	chr4:83955429	COPS4	-0.38	-5.69	-0.3	2.89e-8	Adult asthma;
CRC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-5.97	-0.31	6.14e-9	Bipolar disorder;
CRC	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.62	8.05	0.41	1.55e-14	Body mass index;
CRC	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-9.21	-0.45	3.94e-18	Exhaled nitric oxide output;
CRC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg05585544	chr11:47624801	NA	-0.63	-11.5	-0.54	5.88e-26	Subjective well-being;
CRC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.51	-7.48	-0.38	6.84e-13	Type 2 diabetes;
CRC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.57	8.81	0.44	7.22e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg04117853	chr4:48832952	OCIAD1	0.43	6.41	0.33	5.08e-10	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs12403795	0.527	rs17648797	chr1:150338002	C/G	cg17724175	chr1:150552817	MCL1	0.66	5.87	0.31	1.07e-8	Illicit drug use;
CRC	cis	rs4700695	0.686	rs27075	chr5:65370379	C/T	cg21114390	chr5:65439923	SFRS12	-0.63	-7.08	-0.36	8.9e-12	Facial morphology (factor 19);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08619561	chr20:30311682	BCL2L1	0.38	6.03	0.32	4.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.07	-0.45	1.08e-17	Total cholesterol levels;
CRC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg06238570	chr21:40685208	BRWD1	0.79	10.83	0.51	1.41e-23	Cognitive function;
CRC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-6.35	-0.33	7.21e-10	Menarche (age at onset);
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.66	-0.34	1.18e-10	Bipolar disorder;
CRC	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	trans	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.65	-0.34	1.23e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs863345	0.625	rs6427439	chr1:158460357	C/A	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.62	-0.47	1.8e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01807202	chr4:130014778	C4orf33;SCLT1	0.47	6.38	0.33	5.91e-10	Anxiety disorder;
CRC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.3	-0.46	2.03e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.7e-8	Lung cancer;
CRC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg13319975	chr6:146136371	FBXO30	0.4	5.89	0.31	9.62e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg19025524	chr12:109796872	NA	-0.48	-7.06	-0.36	9.97e-12	Neuroticism;
CRC	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.49	-7.93	-0.4	3.51e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.09	-0.36	8.34e-12	Height;
CRC	trans	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg26043149	chr18:55253948	FECH	0.5	7.6	0.39	3.04e-13	Bone mineral density;
CRC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg21877656	chr19:58662188	ZNF329	0.7	7.66	0.39	2.13e-13	Cholesterol, total;
CRC	cis	rs7932354	0.710	rs10838621	chr11:46851459	C/T	cg19486271	chr11:47235900	DDB2	-0.47	-7.72	-0.39	1.36e-13	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg16898833	chr6:26189333	HIST1H4D	0.8	7.01	0.36	1.33e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs728616	0.558	rs61859215	chr10:82151148	G/A	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.97	-0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.47	-0.34	3.5e-10	Caffeine consumption;
CRC	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.91	-17.1	-0.69	2.35e-47	Coronary artery disease;
CRC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.39	-5.79	-0.3	1.62e-8	Primary biliary cholangitis;
CRC	cis	rs3736485	0.934	rs8038203	chr15:51870683	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.63	-0.34	1.41e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.98	-0.4	2.41e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-1.01	-12.7	-0.57	2.45e-30	Blood pressure (smoking interaction);
CRC	cis	rs6496667	0.779	rs28651333	chr15:91021718	C/T	cg04176472	chr15:90893244	GABARAPL3	0.51	7.33	0.37	1.77e-12	Rheumatoid arthritis;
CRC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.6	8.85	0.44	5.56e-17	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11645453	chr3:52864694	ITIH4	-0.39	-6.56	-0.34	2.15e-10	Bipolar disorder;
CRC	cis	rs4594175	0.926	rs11157804	chr14:51630340	A/G	cg23942311	chr14:51606299	NA	-0.59	-9.31	-0.46	1.83e-18	Cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01225317	chr1:205473878	CDK18	0.47	6.97	0.36	1.76e-11	Intelligence (multi-trait analysis);
CRC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.53	8.36	0.42	1.76e-15	Height;
CRC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.62	-0.3	4.05e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg27395922	chr11:50257633	LOC441601	0.49	6.2	0.32	1.71e-9	Axial length;
CRC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-7.12	-0.37	6.76e-12	Total body bone mineral density;
CRC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04221910	chr5:616842	CEP72	-0.41	-6.89	-0.36	2.85e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.64	-6.85	-0.35	3.56e-11	Axial length;
CRC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg20573242	chr4:122745356	CCNA2	0.43	6.47	0.34	3.46e-10	Type 2 diabetes;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20623943	chr1:47799834	CMPK1	-0.42	-6.25	-0.33	1.24e-9	Daytime sleep phenotypes;
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.72	9.48	0.46	5.05e-19	Alzheimer's disease;
CRC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.82	-0.31	1.43e-8	Obesity-related traits;
CRC	cis	rs7705042	0.865	rs7709361	chr5:141513854	T/C	cg07392085	chr5:141489673	NDFIP1	0.45	7.26	0.37	2.75e-12	Asthma;
CRC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.62	11.56	0.54	3.48e-26	Immature fraction of reticulocytes;
CRC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21643547	chr1:205240462	TMCC2	-0.44	-7.06	-0.36	1.01e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.48	5.91	0.31	8.64e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.36	-0.53	1.89e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.38	6.28	0.33	1.07e-9	Sitting height ratio;
CRC	cis	rs12630931	0.929	rs34652817	chr3:31983470	G/A	cg21375017	chr3:31988082	OSBPL10	0.44	5.96	0.31	6.63e-9	Periodontal disease-related phenotypes;
CRC	trans	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg18187862	chr3:45730750	SACM1L	0.46	6.62	0.34	1.49e-10	Primary sclerosing cholangitis;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg15147215	chr3:52552868	STAB1	-0.73	-14.49	-0.62	3.98e-37	Electroencephalogram traits;
CRC	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg23601416	chr22:19950040	COMT	0.29	7.79	0.39	8.98e-14	Blood metabolite levels;
CRC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.52	7.38	0.38	1.33e-12	Aortic root size;
CRC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07851057	chr5:70751686	BDP1	0.39	6.24	0.33	1.38e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.48	0.34	3.28e-10	Cognitive ability;
CRC	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg06581033	chr10:766294	NA	-0.5	-5.82	-0.31	1.4e-8	Uric acid levels;
CRC	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg21839984	chr17:30846986	MYO1D	0.33	5.76	0.3	1.93e-8	Schizophrenia;
CRC	trans	rs948562	1.000	rs11229535	chr11:58348386	A/G	cg26660744	chr1:1573181	CDK11B	0.53	6.19	0.32	1.83e-9	Lymphoma;
CRC	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg09324608	chr17:30823087	MYO1D	0.36	6.27	0.33	1.14e-9	Schizophrenia;
CRC	cis	rs7707921	1.000	rs749401	chr5:81561369	T/C	cg17942617	chr5:81327376	ATG10	0.39	5.8	0.3	1.53e-8	Breast cancer;
CRC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.6	10.74	0.51	2.99e-23	Aortic root size;
CRC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg21951975	chr1:209979733	IRF6	0.35	5.9	0.31	8.8e-9	Monobrow;
CRC	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg13385794	chr1:248469461	NA	-0.33	-5.7	-0.3	2.73e-8	Common traits (Other);
CRC	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.61	-6.71	-0.35	8.63e-11	Coronary artery disease;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.54	7.76	0.39	1.11e-13	Longevity;Endometriosis;
CRC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.54	7.24	0.37	3.15e-12	Height;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12214090	chr6:127741813	NA	-0.51	-6.06	-0.32	3.68e-9	Monocyte percentage of white cells;
CRC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.23	0.45	3.37e-18	Bladder cancer;
CRC	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.59	-7.34	-0.38	1.71e-12	Ulcerative colitis;
CRC	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg17182837	chr8:41585554	ANK1	-0.54	-7.61	-0.39	2.99e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg25164649	chr6:28176230	NA	0.57	6.14	0.32	2.32e-9	Parkinson's disease;
CRC	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.69	-0.39	1.74e-13	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24884940	chr4:84406509	FAM175A	0.46	6.57	0.34	2e-10	Response to antipsychotic treatment;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg04089111	chr2:74942655	NA	-0.54	-5.97	-0.31	6.18e-9	Lung adenocarcinoma;
CRC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.78	-13.59	-0.6	1.08e-33	Breast cancer;
CRC	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg05621596	chr22:47072043	GRAMD4	-0.7	-12.05	-0.55	6.09e-28	Urate levels in obese individuals;
CRC	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.8	-0.44	7.78e-17	Coffee consumption (cups per day);
CRC	cis	rs11191205	0.686	rs10786644	chr10:103396646	C/T	cg15320455	chr10:103880129	LDB1	0.56	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7781266	0.947	rs11971531	chr7:133538947	C/T	cg03336402	chr7:133662267	EXOC4	0.51	6.56	0.34	2.09e-10	Educational attainment (college completion);
CRC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-7.81	-0.4	7.62e-14	Coronary artery disease;
CRC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.62	9.78	0.47	5.54e-20	Height;
CRC	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg23387468	chr7:139079360	LUC7L2	-0.41	-7.04	-0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.33	-0.59	1.03e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg09127314	chr1:152161683	NA	-0.46	-5.86	-0.31	1.11e-8	Atopic dermatitis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01856985	chr12:6798404	ZNF384	0.4	6.21	0.32	1.62e-9	Schizophrenia;
CRC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.55	7.86	0.4	5.58e-14	Birth weight;
CRC	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.67	-7.56	-0.38	4.02e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-6.2	-0.32	1.68e-9	Inflammatory biomarkers;
CRC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.64	11.06	0.52	2.22e-24	Prostate cancer;
CRC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.64	-0.47	1.58e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.61	0.34	1.53e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg24634471	chr8:143751801	JRK	-0.44	-6.17	-0.32	1.99e-9	Urinary tract infection frequency;
CRC	cis	rs970548	0.954	rs12243153	chr10:46002060	T/A	cg15590007	chr10:45870220	ALOX5	0.48	6.02	0.31	4.76e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23378565	chr7:2036160	MAD1L1	-0.46	-6.37	-0.33	6.22e-10	Bipolar disorder;
CRC	cis	rs4731207	0.751	rs4584095	chr7:124500210	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.57	8.81	0.44	7.42e-17	Asthma (sex interaction);
CRC	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg11993925	chr19:44307056	LYPD5	0.47	7.79	0.39	9e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.08	0.32	3.28e-9	Obesity-related traits;
CRC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.45	-5.94	-0.31	7.45e-9	Gut microbiome composition (summer);
CRC	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-19.51	-0.73	6.95e-57	Schizophrenia;
CRC	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.86	15.89	0.66	1.36e-42	Hip circumference;
CRC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.59	12.98	0.58	2.14e-31	Airflow obstruction;
CRC	cis	rs9341808	0.600	rs668329	chr6:80968578	G/A	cg08355045	chr6:80787529	NA	-0.36	-5.92	-0.31	8.17e-9	Sitting height ratio;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.61	10.94	0.52	5.54e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs995000	0.931	rs6675401	chr1:63073975	C/T	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs6662572	0.703	rs9429090	chr1:46502393	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.79	0.3	1.69e-8	Blood protein levels;
CRC	cis	rs11958404	1.000	rs72816528	chr5:157410949	G/A	cg05962755	chr5:157440814	NA	0.83	10.82	0.51	1.57e-23	IgG glycosylation;
CRC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	10.0	0.48	9.99e-21	Monocyte percentage of white cells;
CRC	cis	rs4731207	0.698	rs4731218	chr7:124472015	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.03	-0.32	4.48e-9	Cutaneous malignant melanoma;
CRC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg17633681	chr16:88106987	BANP	-0.79	-14.0	-0.61	2.89e-35	Menopause (age at onset);
CRC	trans	rs587242	1.000	rs12036050	chr1:96917491	T/C	cg10631902	chr5:14652156	NA	0.45	7.05	0.36	1.08e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.52	7.88	0.4	4.96e-14	Alzheimer's disease (cognitive decline);
CRC	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.24	6.61	0.34	1.55e-10	Type 2 diabetes;
CRC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg14541582	chr5:601475	NA	-0.34	-6.61	-0.34	1.52e-10	Obesity-related traits;
CRC	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg13385794	chr1:248469461	NA	0.38	6.56	0.34	2.12e-10	Common traits (Other);
CRC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.41	6.37	0.33	6.38e-10	Monocyte count;
CRC	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.52	7.37	0.38	1.36e-12	Corneal astigmatism;
CRC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.91	17.27	0.69	4.82e-48	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17902383	chr17:36891499	PCGF2;CISD3	0.43	6.24	0.33	1.37e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.24e-11	Life satisfaction;
CRC	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg19688584	chr6:167529678	CCR6	-0.33	-5.98	-0.31	5.91e-9	Primary biliary cholangitis;
CRC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.54	-8.68	-0.43	1.88e-16	Neurofibrillary tangles;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.39	-5.81	-0.31	1.44e-8	IFN-related cytopenia;
CRC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.68	6.7	0.35	9.19e-11	Fat distribution (HIV);
CRC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.82	-14.31	-0.62	1.82e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg01843034	chr6:37503916	NA	0.45	8.38	0.42	1.57e-15	Cognitive performance;
CRC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.44	0.42	1.01e-15	Menarche (age at onset);
CRC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg21466736	chr12:48725269	NA	-0.56	-8.32	-0.42	2.36e-15	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.01e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.45	-6.22	-0.32	1.54e-9	Renal function-related traits (BUN);
CRC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg26762873	chr11:5879799	OR52E8	-0.42	-6.83	-0.35	4.15e-11	DNA methylation (variation);
CRC	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.49	7.0	0.36	1.48e-11	Large artery stroke;
CRC	cis	rs2933343	1.000	rs876755	chr3:128627933	C/T	cg11901034	chr3:128598214	ACAD9	-0.51	-6.12	-0.32	2.73e-9	IgG glycosylation;
CRC	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.02	8.71	0.43	1.46e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs6662572	0.737	rs55652826	chr1:46442678	T/C	cg08644498	chr1:46502608	NA	0.46	7.09	0.36	8.14e-12	Blood protein levels;
CRC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.92	10.64	0.51	6.63e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs6840360	0.547	rs9991859	chr4:152265572	T/C	cg09659197	chr4:152720779	NA	0.33	6.56	0.34	2.11e-10	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	0.97	10.08	0.49	5.26e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6988985	0.728	rs6471572	chr8:143965264	G/C	cg10324643	chr8:143916377	GML	0.38	6.14	0.32	2.44e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg23234261	chr14:55582407	NA	-0.29	-5.78	-0.3	1.75e-8	Protein biomarker;
CRC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.64	-0.47	1.58e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12172441	chr6:28176163	NA	-0.54	-6.65	-0.34	1.2e-10	Parkinson's disease;
CRC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.26	-0.45	2.66e-18	Type 2 diabetes;
CRC	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg17674042	chr6:34482479	PACSIN1	-0.63	-7.45	-0.38	8.35e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg25182066	chr10:30743637	MAP3K8	0.4	5.81	0.3	1.51e-8	Inflammatory bowel disease;
CRC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.49	-7.11	-0.36	7.38e-12	HDL cholesterol;
CRC	trans	rs9595908	0.802	rs2010997	chr13:33070506	G/A	cg07450633	chr5:172175321	NA	0.37	6.09	0.32	3.12e-9	Body mass index;
CRC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.99	14.96	0.64	5.61e-39	Lymphocyte percentage of white cells;
CRC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.67	9.35	0.46	1.35e-18	Coronary artery disease;
CRC	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.91	-0.4	3.97e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg12682573	chr17:27188876	MIR451;MIR144	-0.56	-8.47	-0.42	8.16e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.59	-7.04	-0.36	1.09e-11	Bronchopulmonary dysplasia;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg05802477	chr12:132629385	DDX51;NOC4L	-0.46	-6.0	-0.31	5.34e-9	Parkinson's disease;
CRC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.8	11.1	0.52	1.61e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.3	0.64	2.7e-40	Fuchs's corneal dystrophy;
CRC	cis	rs3126085	0.515	rs11204984	chr1:152331987	T/C	cg09127314	chr1:152161683	NA	-0.43	-5.68	-0.3	2.99e-8	Atopic dermatitis;
CRC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	1.99e-11	Morning vs. evening chronotype;
CRC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg16486109	chr11:613632	IRF7	0.59	10.51	0.5	1.82e-22	Systemic lupus erythematosus;
CRC	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-7.34	-0.38	1.72e-12	Menarche (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19455322	chr3:46735335	ALS2CL	-0.39	-6.04	-0.32	4.15e-9	Myopia (pathological);
CRC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg23172400	chr8:95962367	TP53INP1	-0.41	-6.41	-0.33	4.96e-10	Type 2 diabetes;
CRC	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.56	9.57	0.47	2.62e-19	Dupuytren's disease;
CRC	cis	rs7572644	0.640	rs11127126	chr2:28023284	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.2	0.32	1.7e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg05064044	chr6:292385	DUSP22	-0.57	-7.86	-0.4	5.4e-14	Menopause (age at onset);
CRC	trans	rs2270927	0.510	rs4352583	chr5:75576716	A/G	cg13563193	chr19:33072644	PDCD5	0.65	6.15	0.32	2.24e-9	Mean corpuscular volume;
CRC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.69	-10.34	-0.5	6.99e-22	Menarche (age at onset);
CRC	cis	rs2811415	0.597	rs13093679	chr3:127726005	T/C	cg13719885	chr3:127795394	NA	-0.4	-6.05	-0.32	3.97e-9	Lung function (FEV1/FVC);
CRC	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg09655341	chr17:79618100	PDE6G	0.54	6.37	0.33	6.24e-10	Dental caries;
CRC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.63	0.57	4.24e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg16745616	chr19:8428856	ANGPTL4	-0.46	-7.26	-0.37	2.88e-12	HDL cholesterol;
CRC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.64	-7.3	-0.37	2.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.62	9.5	0.46	4.59e-19	Corneal astigmatism;
CRC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg19913688	chr11:428466	ANO9	-0.73	-7.41	-0.38	1.08e-12	Body mass index;
CRC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.46	7.53	0.38	5.05e-13	Breast cancer;
CRC	cis	rs13144136	0.748	rs12502077	chr4:10667802	A/C	cg10242279	chr4:10666415	CLNK	-0.33	-5.67	-0.3	3.07e-8	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.23	-16.23	-0.67	6.43e-44	Breast cancer;
CRC	cis	rs6076065	0.723	rs6083099	chr20:23358233	A/G	cg11657817	chr20:23433608	CST11	-0.42	-6.35	-0.33	6.96e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg06917450	chr1:38156652	C1orf109	-0.52	-7.0	-0.36	1.47e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.5	9.78	0.47	5.49e-20	Renal cell carcinoma;
CRC	trans	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg18809830	chr7:99032528	PTCD1	-1.03	-7.68	-0.39	1.85e-13	Blood metabolite levels;
CRC	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg08213375	chr14:104286397	PPP1R13B	0.59	12.05	0.55	5.96e-28	Schizophrenia;
CRC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	ch.11.42038R	chr11:967971	AP2A2	0.57	9.76	0.47	6.08e-20	Alzheimer's disease (late onset);
CRC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-9.01	-0.44	1.69e-17	Urinary metabolites;
CRC	cis	rs2882667	0.728	rs10068766	chr5:138276784	G/A	cg09476006	chr5:138032270	NA	0.57	9.74	0.47	7.12e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.51	9.62	0.47	1.82e-19	Total body bone mineral density;
CRC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.58	8.52	0.42	6.03e-16	Schizophrenia;
CRC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.31	-6.9	-0.36	2.62e-11	IgG glycosylation;
CRC	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.59	9.65	0.47	1.47e-19	Itch intensity from mosquito bite;
CRC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.69	-9.12	-0.45	7.72e-18	Initial pursuit acceleration;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg15845792	chr6:28175446	NA	0.82	12.19	0.56	1.77e-28	Cardiac Troponin-T levels;
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.64	-8.81	-0.44	7.23e-17	Alzheimer's disease;
CRC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.67	7.85	0.4	5.78e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.46	6.53	0.34	2.53e-10	Tonsillectomy;
CRC	trans	rs6472827	0.645	rs2956052	chr8:75112658	A/G	cg16732884	chr16:2569654	AMDHD2;ATP6V0C	0.38	6.01	0.31	5.02e-9	Uterine fibroids;
CRC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.41	6.93	0.36	2.23e-11	Primary biliary cholangitis;
CRC	cis	rs7113874	0.610	rs11041924	chr11:8463107	C/T	cg17679104	chr11:8615758	STK33	-0.35	-5.87	-0.31	1.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.42	6.41	0.33	5.13e-10	Red blood cell count;
CRC	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.45	6.78	0.35	5.47e-11	Ovarian reserve;
CRC	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.98	-17.96	-0.7	9.76e-51	Headache;
CRC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	8.21	0.41	5.2e-15	Menarche (age at onset);
CRC	cis	rs4664293	0.609	rs10209829	chr2:160447624	A/T	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.54	-6.67	-0.35	1.05e-10	Obesity (extreme);
CRC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg14324370	chr2:177042789	NA	-0.69	-9.33	-0.46	1.62e-18	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.75	11.98	0.55	1.12e-27	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs7394190	0.748	rs3740293	chr10:75406141	A/C	cg07699608	chr10:75541558	CHCHD1	0.57	6.5	0.34	3.06e-10	Incident atrial fibrillation;
CRC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.68	10.39	0.5	4.73e-22	Corneal astigmatism;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg17147758	chr8:6949321	NA	-0.52	-7.2	-0.37	4.24e-12	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-8.31	-0.42	2.48e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg27534772	chr1:16042836	PLEKHM2	0.54	10.43	0.5	3.54e-22	Systolic blood pressure;
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg08213375	chr14:104286397	PPP1R13B	0.48	7.76	0.39	1.11e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg22532475	chr10:104410764	TRIM8	0.33	5.71	0.3	2.53e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.6	0.34	1.65e-10	Retinal vascular caliber;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.38	-6.81	-0.35	4.59e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.73	11.97	0.55	1.17e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg15468180	chr1:107600409	PRMT6	-0.44	-6.6	-0.34	1.65e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs58141407	1	rs58141407	chr8:21791772	C/T	cg12468850	chr8:21767224	DOK2	-0.55	-5.98	-0.31	5.93e-9	Red blood cell count;Mean corpuscular volume;
CRC	cis	rs9463078	0.764	rs9369513	chr6:44789476	T/C	cg25276700	chr6:44698697	NA	-0.26	-6.42	-0.33	4.75e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	6.29	0.33	1.01e-9	Menopause (age at onset);
CRC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.66	7.01	0.36	1.39e-11	Inflammatory bowel disease;
CRC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.79	13.4	0.59	5.5e-33	Menopause (age at onset);
CRC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg15110403	chr19:17392923	ANKLE1	-0.35	-5.65	-0.3	3.51e-8	Systemic lupus erythematosus;
CRC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.84	14.85	0.63	1.52e-38	Breast cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg01866215	chr16:3150293	NA	-0.48	-5.98	-0.31	5.94e-9	Hip circumference;
CRC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.49	6.85	0.35	3.59e-11	Type 1 diabetes nephropathy;
CRC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg08222913	chr3:52553049	STAB1	-0.35	-6.64	-0.34	1.29e-10	Electroencephalogram traits;
CRC	cis	rs4664293	0.625	rs7607394	chr2:160563797	G/A	cg08347373	chr2:160653686	CD302	0.39	6.53	0.34	2.44e-10	Monocyte percentage of white cells;
CRC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20092199	chr4:1342459	KIAA1530	0.45	8.15	0.41	7.71e-15	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11855759	chr17:9548802	USP43	0.47	7.76	0.39	1.06e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg19582491	chr16:67682965	RLTPR	-0.4	-5.69	-0.3	2.84e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.84	-10.52	-0.5	1.72e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.64	0.51	6.57e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10229583	0.527	rs6943219	chr7:127308386	A/G	cg01233922	chr7:127693937	SND1	-0.47	-7.34	-0.38	1.65e-12	Type 2 diabetes;
CRC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg02659138	chr7:134003124	SLC35B4	0.41	7.13	0.37	6.38e-12	Mean platelet volume;
CRC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.36	6.39	0.33	5.51e-10	Reticulocyte fraction of red cells;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg10876282	chr6:28092338	ZSCAN16	0.5	6.72	0.35	7.89e-11	Cardiac Troponin-T levels;
CRC	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	0.54	5.83	0.31	1.3e-8	Breast cancer (early onset);
CRC	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.27	5.82	0.31	1.38e-8	Educational attainment (years of education);
CRC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.54	-9.04	-0.45	1.35e-17	Age at first birth;
CRC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.66	-0.68	1.23e-45	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08316558	chr5:141229648	NA	0.43	6.3	0.33	9.48e-10	Intelligence (multi-trait analysis);
CRC	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.92	15.32	0.65	2.38e-40	Dupuytren's disease;
CRC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg02569458	chr12:86230093	RASSF9	0.35	5.84	0.31	1.25e-8	Major depressive disorder;
CRC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	8.87	0.44	4.6e-17	Platelet count;
CRC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.58	7.4	0.38	1.18e-12	Platelet distribution width;
CRC	cis	rs12476592	0.602	rs10865337	chr2:63720906	C/T	cg10828910	chr2:63850056	LOC388955	0.48	5.8	0.3	1.54e-8	Childhood ear infection;
CRC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.69	0.57	2.66e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg01493522	chr13:37497338	NA	-0.52	-7.16	-0.37	5.21e-12	Coronary artery disease;
CRC	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.08	-0.32	3.36e-9	Blood protein levels;
CRC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-7.02	-0.36	1.29e-11	Calcium levels;
CRC	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.98	0.52	4.29e-24	Bipolar disorder;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg00769240	chr8:12517080	NA	-0.74	-10.17	-0.49	2.71e-21	Blood pressure (smoking interaction);
CRC	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.41	6.9	0.36	2.69e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.57	-9.06	-0.45	1.16e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.86	16.02	0.66	4.32e-43	Menopause (age at onset);
CRC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.01	0.7	5.83e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg21770322	chr7:97807741	LMTK2	0.51	8.38	0.42	1.54e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6662572	0.703	rs4660890	chr1:46297452	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.09	-0.32	3.11e-9	Blood protein levels;
CRC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.54	9.0	0.44	1.91e-17	Huntington's disease progression;
CRC	cis	rs4731207	0.698	rs28409696	chr7:124562515	T/C	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.4	8.29	0.42	2.83e-15	Bipolar disorder;
CRC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.36	-6.61	-0.34	1.52e-10	Rheumatoid arthritis;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12554020	0.685	rs55893789	chr9:96170890	T/G	cg23291280	chr19:31847970	NA	-0.68	-6.24	-0.33	1.36e-9	Schizophrenia;
CRC	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06307176	chr5:131281290	NA	0.41	6.02	0.31	4.78e-9	Life satisfaction;
CRC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.38	-0.33	5.88e-10	Mood instability;
CRC	trans	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.54e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.55	7.87	0.4	5.15e-14	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18970754	chr14:74079533	NA	0.38	6.45	0.34	3.93e-10	Obesity-related traits;
CRC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg26893134	chr6:116381904	FRK	-0.25	-7.25	-0.37	2.94e-12	Cholesterol, total;LDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17841838	chr19:3626645	C19orf29	0.42	6.8	0.35	4.82e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.85	9.88	0.48	2.41e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.46	-7.97	-0.4	2.68e-14	Height;
CRC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.47	7.03	0.36	1.17e-11	Bone properties (heel);
CRC	trans	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg11693508	chr17:37793320	STARD3	0.45	6.15	0.32	2.21e-9	Neuroticism;
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg02018176	chr4:1364513	KIAA1530	0.41	6.91	0.36	2.47e-11	Obesity-related traits;
CRC	cis	rs1996152	0.543	rs4789658	chr17:72389526	A/T	cg23221732	chr17:72383708	NA	0.42	6.86	0.35	3.43e-11	Interleukin-12p70 levels;
CRC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.45	7.21	0.37	3.98e-12	Menopause (age at onset);
CRC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg07713946	chr22:31675144	LIMK2	-0.4	-5.68	-0.3	2.98e-8	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03498888	chr3:50649296	CISH	0.38	6.07	0.32	3.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.8	15.32	0.65	2.36e-40	Prudent dietary pattern;
CRC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-12.68	-0.57	2.92e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.85	15.48	0.65	5.3e-41	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.77	-0.3	1.85e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.47	-7.5	-0.38	6.17e-13	Platelet count;
CRC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.56	7.25	0.37	3.04e-12	Mean platelet volume;
CRC	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg00319359	chr11:70116639	PPFIA1	0.66	6.58	0.34	1.83e-10	Coronary artery disease;
CRC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.59	-0.47	2.22e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg17375396	chr11:67202808	RPS6KB2	0.33	5.65	0.3	3.4e-8	Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21525449	chr1:156571403	GPATCH4	0.5	6.51	0.34	2.81e-10	Thyroid stimulating hormone;
CRC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.51	7.06	0.36	1.01e-11	Schizophrenia;
CRC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg13798912	chr7:905769	UNC84A	0.51	5.81	0.31	1.45e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-8.15	-0.41	7.89e-15	Resting heart rate;
CRC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	15.74	0.66	5.29e-42	Platelet count;
CRC	cis	rs7072216	0.881	rs7916469	chr10:100148653	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.2	-0.32	1.72e-9	Metabolite levels;
CRC	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.58	8.32	0.42	2.36e-15	Glioblastoma;Glioma;
CRC	cis	rs9443189	0.901	rs2038625	chr6:76560968	G/A	cg01950844	chr6:76311363	SENP6	-0.62	-7.41	-0.38	1.04e-12	Prostate cancer;
CRC	cis	rs12476592	0.602	rs10865339	chr2:63811884	G/T	cg10828910	chr2:63850056	LOC388955	0.51	6.3	0.33	9.52e-10	Childhood ear infection;
CRC	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.13	0.37	6.27e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.53	5.76	0.3	1.88e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.86	-0.35	3.37e-11	Monocyte percentage of white cells;
CRC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.46	-5.8	-0.3	1.58e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg08888203	chr3:10149979	C3orf24	0.48	7.33	0.37	1.74e-12	Alzheimer's disease;
CRC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.77	11.59	0.54	2.93e-26	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21972741	chr5:435613	AHRR	0.55	7.44	0.38	9.07e-13	Cystic fibrosis severity;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs12476592	0.602	rs262485	chr2:63878413	T/G	cg10828910	chr2:63850056	LOC388955	0.5	6.31	0.33	8.92e-10	Childhood ear infection;
CRC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.94	-16.7	-0.68	8.87e-46	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.75	0.39	1.18e-13	Height;
CRC	cis	rs7901135	0.962	rs9416744	chr10:60567937	A/C	cg23799393	chr10:60588674	BICC1	0.37	5.74	0.3	2.13e-8	Morning vs. evening chronotype;
CRC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17554472	chr22:41940697	POLR3H	0.56	5.65	0.3	3.4e-8	Vitiligo;
CRC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	8.07e-9	Diabetic kidney disease;
CRC	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg23229984	chr5:148520753	ABLIM3	-0.5	-6.85	-0.35	3.59e-11	Breast cancer;
CRC	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	1.01	12.71	0.57	2.25e-30	Obesity-related traits;
CRC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg22815214	chr1:201083145	CACNA1S	0.63	10.44	0.5	3.06e-22	Permanent tooth development;
CRC	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.43	6.76	0.35	6.47e-11	Red blood cell count;
CRC	cis	rs11212617	0.967	rs1003624	chr11:108152645	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.15	0.32	2.28e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.88	13.16	0.59	4.72e-32	Diastolic blood pressure;
CRC	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.74	-15.71	-0.65	6.92e-42	Intelligence (multi-trait analysis);
CRC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.71	-12.09	-0.55	4.33e-28	Body mass index;
CRC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.77	13.58	0.6	1.21e-33	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg24786176	chr4:113153431	AP1AR	-0.52	-5.97	-0.31	6.27e-9	Hirschsprung disease;
CRC	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.45	5.83	0.31	1.31e-8	Educational attainment (years of education);
CRC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.34	-0.33	7.48e-10	Schizophrenia;
CRC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.59	-0.47	2.35e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.44	6.38	0.33	6.1e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12760731	0.565	rs10494511	chr1:178094265	A/G	cg00404053	chr1:178313656	RASAL2	0.92	9.95	0.48	1.46e-20	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13559099	chr11:62554740	TMEM179B;TAF6L	0.4	6.63	0.34	1.41e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs365302	1.000	rs369160	chr6:159638579	T/C	cg14500486	chr6:159655392	FNDC1	0.47	7.24	0.37	3.25e-12	Coronary heart disease;
CRC	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs4853036	0.951	rs13393656	chr2:70119255	C/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.57	-0.34	1.94e-10	Colorectal or endometrial cancer;
CRC	cis	rs6604026	0.656	rs2811597	chr1:93341153	G/A	cg17283838	chr1:93427260	FAM69A	-0.43	-5.6	-0.3	4.52e-8	Multiple sclerosis;
CRC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.75	-0.43	1.09e-16	Intelligence (multi-trait analysis);
CRC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.44	-6.81	-0.35	4.64e-11	Menarche (age at onset);
CRC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.4	-0.38	1.14e-12	Aortic root size;
CRC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.62	0.3	4.16e-8	Homoarginine levels;
CRC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.36	7.23	0.37	3.44e-12	Ewing sarcoma;
CRC	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.8e-9	Obesity-related traits;
CRC	cis	rs7605827	0.930	rs6431699	chr2:15540281	A/G	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.46	-6.77	-0.35	6.03e-11	Parkinson's disease;
CRC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.48	7.23	0.37	3.41e-12	Selective IgA deficiency;
CRC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg27124370	chr19:33622961	WDR88	0.47	6.88	0.35	3.01e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg20988775	chr15:25315425	SNORD116-8	-0.49	-6.1	-0.32	3.02e-9	Lymphocyte counts;
CRC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.11	13.18	0.59	3.94e-32	Psoriasis vulgaris;
CRC	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.39	-0.33	5.66e-10	Body mass index;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg05569086	chr8:143859399	LYNX1	0.47	7.61	0.39	2.83e-13	Urinary tract infection frequency;
CRC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06544989	chr22:39130855	UNC84B	0.42	6.28	0.33	1.1e-9	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.17	-0.56	2.25e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg00814883	chr7:100076585	TSC22D4	0.54	6.5	0.34	2.91e-10	Lung function (FEV1/FVC);
CRC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.02	0.45	1.6e-17	Mean platelet volume;
CRC	cis	rs10971721	0.731	rs72725388	chr9:33864622	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.48	-0.34	3.29e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.93	15.35	0.65	1.82e-40	Menarche (age at onset);
CRC	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.82	11.7	0.54	1.15e-26	Colorectal cancer;
CRC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.82	-0.55	4.13e-27	Type 2 diabetes;
CRC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.53	7.72	0.39	1.39e-13	IgG glycosylation;
CRC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.49	8.22	0.41	4.76e-15	Acylcarnitine levels;
CRC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.65	-0.34	1.23e-10	Height;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg07404485	chr7:94953653	PON1	-0.47	-6.14	-0.32	2.38e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7394190	0.810	rs7394152	chr10:75421446	C/T	cg07699608	chr10:75541558	CHCHD1	0.58	6.21	0.32	1.56e-9	Incident atrial fibrillation;
CRC	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg06223162	chr1:101003688	GPR88	0.39	7.14	0.37	5.91e-12	Breast cancer;
CRC	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg08501292	chr6:25962987	TRIM38	0.89	8.35	0.42	1.87e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs972578	0.747	rs5996242	chr22:43230627	T/C	cg01576275	chr22:43409880	NA	-0.4	-6.22	-0.32	1.49e-9	Mean platelet volume;
CRC	cis	rs4664293	0.967	rs2357526	chr2:160524596	C/T	cg08347373	chr2:160653686	CD302	0.38	6.17	0.32	1.95e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg04731861	chr2:219085781	ARPC2	-0.32	-6.8	-0.35	4.96e-11	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11570791	chr11:118186701	CD3E	0.4	6.38	0.33	5.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.85	0.31	1.18e-8	Axial length;
CRC	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.93	0.55	1.69e-27	Coffee consumption (cups per day);
CRC	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.38	-0.33	5.95e-10	Diastolic blood pressure;
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg12326244	chr17:78078995	GAA	-0.38	-5.77	-0.3	1.87e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg21095983	chr6:86352623	SYNCRIP	0.57	8.18	0.41	6.12e-15	Smooth-surface caries;
CRC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.38	6.83	0.35	4.16e-11	Sarcoidosis;
CRC	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.51	7.13	0.37	6.47e-12	Obesity-related traits;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg25164649	chr6:28176230	NA	0.6	7.91	0.4	3.87e-14	Parkinson's disease;
CRC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.68	-0.35	9.97e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12463550	chr7:65579703	CRCP	0.67	6.41	0.33	5.16e-10	Diabetic kidney disease;
CRC	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg05304507	chr6:116381966	FRK	0.29	6.5	0.34	2.98e-10	Total cholesterol levels;
CRC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.38	6.12	0.32	2.66e-9	Ulcerative colitis;
CRC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg21251018	chr6:28226885	NKAPL	0.49	7.78	0.39	9.18e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17152411	1.000	rs11245451	chr10:126661428	C/T	cg07906193	chr10:126599966	NA	0.58	5.68	0.3	3e-8	Height;
CRC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.85	13.55	0.6	1.57e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg09626299	chr10:82213104	TSPAN14	-0.35	-5.91	-0.31	8.69e-9	Post bronchodilator FEV1;
CRC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.65	7.33	0.37	1.83e-12	Body mass index;
CRC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.99	-0.44	2.04e-17	Bone mineral density;
CRC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-7.59	-0.39	3.23e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-0.9	-10.32	-0.49	8.19e-22	Breast cancer;
CRC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-11.29	-0.53	3.21e-25	Platelet distribution width;
CRC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg13385521	chr17:29058706	SUZ12P	0.48	6.09	0.32	3.17e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.39	0.62	9.24e-37	Fuchs's corneal dystrophy;
CRC	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg22495460	chr2:25135724	ADCY3	0.78	14.36	0.62	1.2e-36	Body mass index in non-asthmatics;
CRC	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.71	-8.94	-0.44	2.89e-17	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs10208712	0.525	rs56014028	chr2:4053971	A/G	cg00217080	chr2:4050767	NA	-0.26	-6.43	-0.33	4.58e-10	Restless legs syndrome;
CRC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.5	-8.2	-0.41	5.6e-15	Type 2 diabetes;
CRC	cis	rs4481887	0.504	rs7550630	chr1:248362311	C/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13579901	chr1:167905492	DCAF6;BRP44	0.44	6.28	0.33	1.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.72	8.26	0.41	3.59e-15	Body mass index;
CRC	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg14311320	chr7:124405732	GPR37	-0.38	-5.65	-0.3	3.56e-8	Lewy body disease;
CRC	cis	rs2486012	1.000	rs3011227	chr1:44325409	G/A	cg12908607	chr1:44402522	ARTN	-0.42	-6.04	-0.32	4.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-5.99	-0.31	5.53e-9	Pubertal anthropometrics;
CRC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.48	7.45	0.38	8.14e-13	Corneal astigmatism;
CRC	cis	rs2617583	0.679	rs2652511	chr5:1446389	A/G	cg07151155	chr5:1473589	LPCAT1	-0.4	-6.28	-0.33	1.06e-9	Breast cancer;
CRC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg07718321	chr6:96025334	MANEA	0.57	7.31	0.37	2.09e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg04553112	chr3:125709451	NA	-0.51	-5.94	-0.31	7.11e-9	Blood pressure (smoking interaction);
CRC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.6	-9.34	-0.46	1.53e-18	Body mass index;
CRC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.39e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg11494091	chr17:61959527	GH2	0.37	5.61	0.3	4.39e-8	Height;
CRC	cis	rs13088645	0.541	rs9842113	chr3:134192338	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-7.41	-0.38	1.07e-12	Coronary artery disease;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.6	-9.17	-0.45	5.16e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg22110888	chr17:80059540	CCDC57	0.4	6.45	0.34	3.95e-10	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27281285	chr12:120315368	CIT	0.44	6.14	0.32	2.32e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg03037974	chr15:76606532	NA	0.43	6.1	0.32	2.97e-9	Blood metabolite levels;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg15511327	chr8:143859410	LYNX1	-0.39	-6.51	-0.34	2.88e-10	Urinary tract infection frequency;
CRC	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.74	10.24	0.49	1.48e-21	Platelet distribution width;
CRC	cis	rs6968419	0.708	rs57321537	chr7:115883453	T/G	cg02561103	chr7:115862891	TES	-0.42	-6.31	-0.33	8.76e-10	Intraocular pressure;
CRC	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.9	-0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	10.03	0.48	7.55e-21	Myopia (pathological);
CRC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.52	-8.26	-0.41	3.63e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg03623178	chr6:28175578	NA	0.89	11.83	0.55	3.94e-27	Parkinson's disease;
CRC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.51	7.07	0.36	9.51e-12	Lymphocyte counts;
CRC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-11.47	-0.53	7.85e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.8	-10.3	-0.49	9.5e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs9467711	1.000	rs9467713	chr6:26338128	T/C	cg15845792	chr6:28175446	NA	0.67	6.72	0.35	8.17e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.67	-0.34	1.11e-10	Schizophrenia;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.69	-0.35	9.36e-11	Total body bone mineral density;
CRC	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg04202892	chr2:111875749	ACOXL	0.41	6.63	0.34	1.37e-10	Chronic lymphocytic leukemia;
CRC	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg04117972	chr1:227635322	NA	-0.52	-5.99	-0.31	5.61e-9	Major depressive disorder;
CRC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg23996704	chr18:44553084	KATNAL2	-0.3	-6.1	-0.32	2.96e-9	Educational attainment;
CRC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg26666090	chr16:58549219	SETD6	0.94	6.49	0.34	3.19e-10	Schizophrenia;
CRC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.09	-0.32	3.14e-9	Inflammatory bowel disease;
CRC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg20615401	chr6:28092323	ZSCAN16	0.44	5.77	0.3	1.82e-8	Parkinson's disease;
CRC	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg17545662	chr6:170176663	C6orf70	0.54	6.05	0.32	3.89e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg20933634	chr6:27740509	NA	-0.66	-9.43	-0.46	7.85e-19	Parkinson's disease;
CRC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.56	0.34	2.1e-10	Hip circumference adjusted for BMI;
CRC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.65	0.34	1.23e-10	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg06238570	chr21:40685208	BRWD1	0.78	10.76	0.51	2.51e-23	Cognitive function;
CRC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.76	-0.39	1.06e-13	Schizophrenia;
CRC	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.56	8.05	0.41	1.52e-14	Lung cancer;
CRC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.6	-0.47	2.06e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs294883	0.739	rs1504257	chr6:159727806	G/A	cg14500486	chr6:159655392	FNDC1	-0.37	-6.2	-0.32	1.69e-9	Coronary artery disease;
CRC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.45	-9.15	-0.45	6.27e-18	Renal cell carcinoma;
CRC	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	0.89	10.95	0.52	5.29e-24	Height;
CRC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.45	8.09	0.41	1.15e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.5	-7.77	-0.39	1.04e-13	Cognitive function;
CRC	cis	rs3751196	0.901	rs57173983	chr12:104207870	T/G	cg02344784	chr12:104178138	NT5DC3	0.7	7.12	0.37	6.87e-12	Sense of smell;
CRC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.48	9.43	0.46	7.53e-19	Ulcerative colitis;
CRC	cis	rs13144136	0.710	rs10516208	chr4:10661734	C/T	cg10242279	chr4:10666415	CLNK	0.38	6.6	0.34	1.6e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10208940	0.920	rs7576303	chr2:68838019	G/A	cg12452813	chr2:68675892	NA	0.48	5.93	0.31	7.66e-9	Urate levels in lean individuals;
CRC	cis	rs7259376	0.936	rs7255829	chr19:22537311	C/T	cg02657401	chr19:22469223	NA	-0.33	-7.45	-0.38	8.05e-13	Menopause (age at onset);
CRC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.53	-10.19	-0.49	2.21e-21	Height;
CRC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.51	6.03	0.32	4.31e-9	Pediatric autoimmune diseases;
CRC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14895029	chr7:2775587	GNA12	0.45	6.8	0.35	4.92e-11	Height;
CRC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.45	6.94	0.36	2.08e-11	Monocyte count;
CRC	cis	rs9469578	1.000	rs73743326	chr6:33709980	C/A	cg18708504	chr6:33715942	IP6K3	0.62	7.13	0.37	6.35e-12	Phosphorus levels;
CRC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.53	0.34	2.52e-10	Morning vs. evening chronotype;
CRC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.45	5.69	0.3	2.84e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.48	6.54	0.34	2.33e-10	Obesity-related traits;
CRC	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.41	6.39	0.33	5.78e-10	Recombination rate (males);
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.26	-6.53	-0.34	2.46e-10	Lymphocyte counts;
CRC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.3	-0.46	1.98e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg25804541	chr17:80189381	SLC16A3	0.32	5.98	0.31	5.75e-9	Life satisfaction;
CRC	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.49	9.35	0.46	1.43e-18	Educational attainment (years of education);
CRC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.55	8.48	0.42	7.72e-16	Aortic root size;
CRC	cis	rs11009175	0.556	rs1418540	chr10:33297667	C/T	cg00146027	chr10:33299147	NA	-0.28	-6.47	-0.34	3.48e-10	Depression (quantitative trait);
CRC	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs1223397	0.651	rs2496140	chr6:13309895	A/T	cg20827128	chr6:13274284	PHACTR1	0.39	6.04	0.32	4.1e-9	Blood pressure;
CRC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.52	9.6	0.47	2.18e-19	Height;
CRC	trans	rs12699921	0.632	rs2691601	chr7:17875431	C/T	cg15753394	chr6:17282781	RBM24	-0.38	-6.38	-0.33	6.02e-10	Fibrinogen levels;
CRC	trans	rs4346635	0.528	rs6534967	chr4:81412879	A/T	cg13904968	chr20:56136012	PCK1	-0.19	-6.03	-0.32	4.42e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.27	-0.33	1.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.35	-6.39	-0.33	5.71e-10	Menarche (age at onset);
CRC	cis	rs6504622	0.905	rs3809854	chr17:45029294	T/C	cg16759221	chr17:45003025	GOSR2	-0.54	-8.5	-0.42	6.64e-16	Orofacial clefts;
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg17330251	chr7:94953956	PON1	-0.61	-7.63	-0.39	2.5e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg27068330	chr11:65405492	SIPA1	-0.49	-6.7	-0.35	8.8e-11	Systemic lupus erythematosus;
CRC	cis	rs17767392	0.846	rs56180634	chr14:71989933	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.46	-6.1	-0.32	3.04e-9	Mitral valve prolapse;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg27615366	chr5:131592974	PDLIM4	-0.33	-5.81	-0.31	1.47e-8	Breast cancer;
CRC	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.68	-0.3	2.93e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-1.09	-10.61	-0.5	8.0700000000000006e-23	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
CRC	cis	rs7113874	0.589	rs10840058	chr11:8498399	G/T	cg17679104	chr11:8615758	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3018066	0.867	rs4600995	chr4:107049801	A/G	cg01869342	chr4:106983673	TBCK	0.37	5.77	0.3	1.81e-8	Cancer;
CRC	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.5	7.5	0.38	5.83e-13	Breast cancer;
CRC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.63	9.72	0.47	8.33e-20	Corneal astigmatism;
CRC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.96	0.4	2.85e-14	Aortic root size;
CRC	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.33	-0.62	1.56e-36	Colorectal cancer;
CRC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg00343986	chr7:65444356	GUSB	-0.47	-6.92	-0.36	2.32e-11	Aortic root size;
CRC	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg10279832	chr4:154682576	RNF175	0.37	5.66	0.3	3.37e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.57	8.69	0.43	1.71e-16	Schizophrenia;
CRC	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg15226275	chr6:116381976	FRK	0.31	7.36	0.38	1.45e-12	Total cholesterol levels;
CRC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-8.13	-0.41	8.75e-15	Arsenic metabolism;
CRC	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg12458913	chr13:53173898	NA	0.52	8.02	0.4	1.88e-14	Lewy body disease;
CRC	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.46	7.23	0.37	3.5e-12	Height;
CRC	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06307176	chr5:131281290	NA	0.43	6.14	0.32	2.41e-9	Life satisfaction;
CRC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.62	7.39	0.38	1.26e-12	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09851460	chr1:212964733	NSL1;TATDN3	0.5	6.87	0.35	3.3e-11	Response to antipsychotic treatment;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00226754	chr12:124068984	TMED2	-0.42	-6.03	-0.32	4.32e-9	Myopia (pathological);
CRC	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.69	-5.69	-0.3	2.75e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1511802	0.501	rs7661323	chr4:187115996	T/G	cg24794857	chr4:187113578	CYP4V2	0.41	5.84	0.31	1.28e-8	Blood protein levels;
CRC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.2	0.37	4.22e-12	Educational attainment;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg21782813	chr7:2030301	MAD1L1	0.39	7.17	0.37	4.83e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.59	8.81	0.44	7.57e-17	Aortic root size;
CRC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.77	9.89	0.48	2.3e-20	Initial pursuit acceleration;
CRC	cis	rs4867766	0.871	rs11747479	chr5:173955389	C/T	cg20434911	chr5:173954559	NA	-0.8	-9.17	-0.45	5.48e-18	Stroke;
CRC	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.54	-8.74	-0.43	1.19e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.47	5.61	0.3	4.26e-8	Depression;
CRC	cis	rs9914988	0.537	rs28448745	chr17:27188296	A/C	cg16670446	chr17:27188758	MIR451;MIR144	-0.56	-8.75	-0.43	1.11e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg21747405	chr11:67723411	NA	-0.49	-6.36	-0.33	6.71e-10	Blood pressure (smoking interaction);
CRC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.83	-11.99	-0.55	1.01e-27	Intelligence (multi-trait analysis);
CRC	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg20487152	chr13:99095054	FARP1	0.36	5.97	0.31	6.23e-9	Longevity;
CRC	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.36	0.53	1.83e-25	Bipolar disorder;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08989290	chr16:615782	NHLRC4	0.49	9.7	0.47	9.67e-20	Height;
CRC	trans	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg01505111	chr6:125621795	HDDC2	0.39	6.18	0.32	1.9e-9	DNA methylation (variation);
CRC	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.74	12.99	0.58	2.02e-31	Coronary artery disease;
CRC	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg25110126	chr1:46999211	NA	0.55	8.31	0.42	2.52e-15	Monobrow;
CRC	cis	rs4731207	0.596	rs1383751	chr7:124579721	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.71e-9	Cutaneous malignant melanoma;
CRC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.55	-8.23	-0.41	4.59e-15	Mean platelet volume;
CRC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.5	7.3	0.37	2.2e-12	Colorectal cancer;
CRC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg09455208	chr3:40491958	NA	0.32	6.43	0.33	4.4e-10	Renal cell carcinoma;
CRC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.75	-0.47	6.85e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.51	-7.26	-0.37	2.73e-12	Menarche (age at onset);
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.29	-0.33	1e-9	Total body bone mineral density;
CRC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-9.93	-0.48	1.67e-20	Total body bone mineral density;
CRC	cis	rs3736485	0.966	rs11070859	chr15:51890802	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.46	-0.34	3.79e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg02683197	chr6:28174875	NA	0.73	9.78	0.47	5.29e-20	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13903809	chr12:93964785	SOCS2	0.46	6.36	0.33	6.63e-10	Anxiety disorder;
CRC	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg26182253	chr13:112236782	NA	0.31	6.3	0.33	9.74e-10	Hepatitis;
CRC	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg00919237	chr7:87102261	ABCB4	-0.54	-7.09	-0.36	8.37e-12	Gallbladder cancer;
CRC	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg15654264	chr1:150340011	RPRD2	0.42	6.4	0.33	5.48e-10	Migraine;
CRC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.29	-0.56	7.94e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	7.45	0.38	8.23e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.29	-7.42	-0.38	1.04e-12	Mean corpuscular volume;
CRC	cis	rs362272	0.502	rs2857839	chr4:3036630	T/C	cg22930642	chr4:2936657	C4orf10;MFSD10	-0.4	-5.73	-0.3	2.21e-8	Serum sulfate level;
CRC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.37	-0.46	1.18e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08779779	chr2:200322566	SATB2	0.37	6.16	0.32	2.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.75	15.01	0.64	3.63e-39	Sjögren's syndrome;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg15056687	chr19:44079628	XRCC1	0.39	6.09	0.32	3.11e-9	Schizophrenia;
CRC	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.98	-0.31	5.95e-9	Blood protein levels;
CRC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.33	-5.85	-0.31	1.21e-8	Personality dimensions;
CRC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg10263370	chr3:44754102	ZNF502	-0.38	-6.46	-0.34	3.73e-10	Depressive symptoms;
CRC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.48	-6.78	-0.35	5.57e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.74	-12.09	-0.55	4.36e-28	Height;
CRC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	1.09	9.93	0.48	1.68e-20	Arsenic metabolism;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.33	0.37	1.85e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.55	-8.95	-0.44	2.57e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18297960	chr7:1142765	C7orf50	-0.44	-6.12	-0.32	2.61e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg03623178	chr6:28175578	NA	0.77	6.61	0.34	1.51e-10	Depression;
CRC	cis	rs10503871	0.545	rs13253760	chr8:30503792	C/T	cg26383811	chr8:30366931	RBPMS	-0.42	-5.96	-0.31	6.46e-9	Metabolite levels  (X-11787);
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg15845792	chr6:28175446	NA	0.68	8.92	0.44	3.35e-17	Parkinson's disease;
CRC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.48	-6.68	-0.35	1.03e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.68	0.35	1.04e-10	Tonsillectomy;
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.81	-0.3	1.5e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.66	-10.63	-0.51	6.86e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.47	7.53	0.38	4.96e-13	Schizophrenia;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg15786705	chr6:28176104	NA	0.61	8.73	0.43	1.35e-16	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.69	-11.35	-0.53	2.07e-25	Diastolic blood pressure;
CRC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-7.82	-0.4	7.38e-14	Colorectal cancer;
CRC	trans	rs6600671	0.934	rs12060031	chr1:121243450	A/G	cg09829573	chr1:144692074	NBPF9	0.43	6.54	0.34	2.36e-10	Hip geometry;
CRC	cis	rs55788414	0.932	rs9940186	chr16:81182199	A/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.88	-0.35	3.02e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg04969067	chr8:143858791	LYNX1	-0.35	-5.93	-0.31	7.87e-9	Urinary tract infection frequency;
CRC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg08772003	chr10:104629869	AS3MT	-0.39	-6.63	-0.34	1.38e-10	Arsenic metabolism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02825653	chr17:7383046	ZBTB4	0.44	7.06	0.36	9.71e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.68	11.14	0.52	1.13e-24	Colorectal cancer;
CRC	cis	rs524281	0.773	rs2155030	chr11:66030687	A/G	cg16950941	chr11:66035639	RAB1B	-0.72	-8.16	-0.41	7.42e-15	Electroencephalogram traits;
CRC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg03161606	chr19:29218774	NA	0.54	6.26	0.33	1.21e-9	Methadone dose in opioid dependence;
CRC	cis	rs9826463	0.582	rs73238186	chr3:142141180	A/C	cg20824294	chr3:142316082	PLS1	0.38	6.03	0.32	4.36e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	8.23	0.41	4.57e-15	Menarche (age at onset);
CRC	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.97	-0.31	6.18e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24087403	chr10:71078535	HK1	0.38	6.06	0.32	3.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7209460	0.518	rs9894634	chr17:1967501	C/T	cg15816464	chr17:2026533	SMG6	0.33	5.98	0.31	5.72e-9	Coronary artery disease;Total body bone mineral density;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg12273811	chr6:28175739	NA	0.54	7.72	0.39	1.42e-13	Parkinson's disease;
CRC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.29	0.37	2.3e-12	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05892773	chr1:112282121	C1orf183	0.45	6.36	0.33	6.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg09876464	chr15:85330779	ZNF592	0.48	8.28	0.42	3.21e-15	P wave terminal force;
CRC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10924970	0.613	rs12027933	chr1:235440411	A/T	cg09010748	chr1:235293032	TOMM20	-0.41	-5.72	-0.3	2.42e-8	Asthma;
CRC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.89	-0.48	2.25e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.95	0.31	6.77e-9	Morning vs. evening chronotype;
CRC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.57	-6.84	-0.35	3.98e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.69	-0.35	9.35e-11	Self-reported allergy;
CRC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.54	6.58	0.34	1.81e-10	Bipolar disorder (body mass index interaction);
CRC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.7	7.84	0.4	6.22e-14	Major depressive disorder;
CRC	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.86	10.35	0.5	6.48e-22	Exhaled nitric oxide output;
CRC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg23136738	chr11:925521	AP2A2	-0.4	-6.57	-0.34	1.96e-10	Alzheimer's disease (late onset);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg11455018	chr16:30709778	SRCAP	0.4	6.01	0.31	4.97e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.34	-6.68	-0.35	1.04e-10	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.53	-8.86	-0.44	5.09e-17	Airway imaging phenotypes;
CRC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.69	-0.35	9.45e-11	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18679886	chr7:107531975	DLD	0.43	6.06	0.32	3.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs7112136	chr11:108287131	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.34	0.33	7.39e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg01312482	chr5:178451176	ZNF879	-0.35	-5.87	-0.31	1.06e-8	Pubertal anthropometrics;
CRC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.57	0.34	1.97e-10	IgG glycosylation;
CRC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.54	-8.84	-0.44	5.71e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg21251018	chr6:28226885	NKAPL	-0.48	-6.21	-0.32	1.64e-9	Depression;
CRC	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg21918786	chr6:109611834	NA	-0.35	-6.06	-0.32	3.7e-9	Reticulocyte fraction of red cells;
CRC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.52	-0.43	5.73e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.45	6.82	0.35	4.26e-11	Menopause (age at onset);
CRC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.13	0.41	8.68e-15	Menarche (age at onset);
CRC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg20387954	chr3:183756860	HTR3D	0.46	7.77	0.39	1.04e-13	Anterior chamber depth;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg02927042	chr1:21476669	EIF4G3	-0.45	-7.22	-0.37	3.56e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg10589385	chr1:150898437	SETDB1	0.3	6.23	0.33	1.39e-9	Melanoma;
CRC	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.35	-5.79	-0.3	1.67e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	cis	rs9292777	0.901	rs7730591	chr5:40423280	G/A	cg09067459	chr5:40385259	NA	0.53	9.13	0.45	7.24e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs2637266	0.561	rs10824440	chr10:78489079	C/T	cg18941641	chr10:78392320	NA	-0.36	-6.11	-0.32	2.8e-9	Pulmonary function;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs117623576	0.590	rs2988084	chr10:32398653	C/T	cg03047570	chr10:32398778	NA	0.43	5.92	0.31	7.89e-9	Anti-saccade response;
CRC	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.33	0.49	7.63e-22	Asthma (childhood onset);
CRC	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.49	7.47	0.38	7.48e-13	Testicular germ cell tumor;
CRC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.41	-0.33	5.1e-10	Breast cancer;
CRC	cis	rs77633900	0.772	rs284898	chr15:76750695	A/G	cg21673338	chr15:77095150	SCAPER	-0.73	-6.45	-0.34	3.94e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-7.18	-0.37	4.56e-12	Aortic root size;
CRC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.54	8.81	0.44	7.1e-17	Breast cancer;
CRC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.91	-16.66	-0.68	1.33e-45	Body mass index;
CRC	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg08847533	chr14:75593920	NEK9	-0.4	-5.91	-0.31	8.46e-9	Caffeine consumption;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25130390	chr15:65810150	DPP8	-0.41	-6.22	-0.32	1.52e-9	Myopia (pathological);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01246254	chr10:124134882	PLEKHA1	0.46	7.15	0.37	5.56e-12	Interleukin-6 levels;
CRC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.74	12.81	0.58	9.33e-31	Mean platelet volume;
CRC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.66	-8.51	-0.42	6.22e-16	Mean platelet volume;
CRC	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.68	9.93	0.48	1.67e-20	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg03948781	chr1:205179583	DSTYK	-0.41	-5.83	-0.31	1.34e-8	Red blood cell count;
CRC	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg21970626	chr13:21893289	NA	0.45	5.91	0.31	8.56e-9	White matter hyperintensity burden;
CRC	trans	rs2898857	0.545	rs12602382	chr17:47356805	C/A	cg11430096	chr6:110968061	CDK19	0.51	7.8	0.4	8.44e-14	Cancer;
CRC	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg13385794	chr1:248469461	NA	0.4	6.87	0.35	3.23e-11	Common traits (Other);
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.61	7.3	0.37	2.21e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.11	-0.32	2.88e-9	Total body bone mineral density;
CRC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg01987224	chr1:201084466	NA	0.37	5.71	0.3	2.57e-8	Permanent tooth development;
CRC	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21659725	chr3:3221576	CRBN	0.55	7.0	0.36	1.45e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg24463073	chr6:118973353	C6orf204	0.52	6.91	0.36	2.52e-11	Diastolic blood pressure;
CRC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.7	0.47	9.7e-20	Cognitive test performance;
CRC	cis	rs6066835	1.000	rs6125446	chr20:47348161	C/G	cg18078177	chr20:47281410	PREX1	0.65	5.78	0.3	1.78e-8	Multiple myeloma;
CRC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg25767906	chr1:53392781	SCP2	0.43	6.72	0.35	7.95e-11	Monocyte count;
CRC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg05673287	chr15:77411982	SGK269	-0.54	-8.18	-0.41	6.41e-15	Type 2 diabetes;
CRC	cis	rs7772486	0.875	rs2777482	chr6:146320341	A/C	cg23711669	chr6:146136114	FBXO30	0.53	8.42	0.42	1.17e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.98	21.22	0.76	1.46e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.26e-11	Alzheimer's disease (late onset);
CRC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg15448220	chr1:150897856	SETDB1	0.44	6.27	0.33	1.12e-9	Tonsillectomy;
CRC	cis	rs335206	1.000	rs335206	chr5:122504566	T/C	cg16368670	chr5:122501738	PRDM6	-0.29	-5.65	-0.3	3.39e-8	QRS duration;
CRC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.47	7.91	0.4	3.89e-14	Childhood ear infection;
CRC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-6.0	-0.31	5.15e-9	Breast cancer;
CRC	cis	rs2077654	0.822	rs4148627	chr11:17436271	G/A	cg25308976	chr11:17434268	ABCC8	0.8	8.09	0.41	1.14e-14	Gout;
CRC	cis	rs10971721	0.731	rs12377117	chr9:33806584	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.82	0.31	1.38e-8	Body mass index;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg06470822	chr6:28175283	NA	0.59	8.61	0.43	3.17e-16	Parkinson's disease;
CRC	cis	rs6546324	0.625	rs980227	chr2:67864258	T/G	cg15745817	chr2:67799979	NA	-0.56	-9.78	-0.47	5.28e-20	Endometriosis;
CRC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.48	7.21	0.37	3.86e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.41	-6.85	-0.35	3.64e-11	Type 2 diabetes;
CRC	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg13385794	chr1:248469461	NA	-0.39	-7.0	-0.36	1.42e-11	Common traits (Other);
CRC	trans	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg26043149	chr18:55253948	FECH	-0.51	-7.11	-0.36	7.46e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.67	0.51	5.22e-23	Corneal astigmatism;
CRC	cis	rs727505	0.564	rs57841320	chr7:124847732	T/A	cg23710748	chr7:124431027	NA	-0.62	-10.33	-0.49	7.81e-22	Lewy body disease;
CRC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.42	-6.18	-0.32	1.89e-9	Motion sickness;
CRC	cis	rs6738485	0.588	rs12712247	chr2:106849382	C/T	cg16099169	chr2:106886729	NA	-0.36	-6.35	-0.33	6.97e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg21747405	chr11:67723411	NA	-0.43	-6.13	-0.32	2.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg19318889	chr4:1322082	MAEA	0.39	5.78	0.3	1.76e-8	Longevity;
CRC	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg23254163	chr1:152506842	NA	0.43	8.73	0.43	1.33e-16	Hair morphology;
CRC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.96	-0.4	2.87e-14	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.0	-0.36	1.43e-11	Bipolar disorder;
CRC	cis	rs75422866	0.867	rs73104148	chr12:48090515	A/G	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.58	7.79	0.39	9.12e-14	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07362569	chr17:61921086	SMARCD2	0.36	5.6	0.3	4.41e-8	Prudent dietary pattern;
CRC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.43	5.95	0.31	6.84e-9	Diastolic blood pressure;
CRC	cis	rs7113874	0.524	rs10840092	chr11:8624915	A/G	cg02811074	chr11:8615871	STK33	0.32	5.72	0.3	2.35e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2882667	0.690	rs3804199	chr5:138162129	T/C	cg09476006	chr5:138032270	NA	-0.58	-10.51	-0.5	1.8e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4964805	0.580	rs1866292	chr12:104174192	C/T	cg02344784	chr12:104178138	NT5DC3	0.55	8.12	0.41	9.52e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg02428538	chr16:24856791	SLC5A11	-0.54	-6.17	-0.32	2.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9463078	0.691	rs17288278	chr6:45298482	G/A	cg25276700	chr6:44698697	NA	0.25	6.11	0.32	2.89e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.24	0.33	1.34e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg21251018	chr6:28226885	NKAPL	0.57	9.8	0.48	4.44e-20	Cardiac Troponin-T levels;
CRC	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.72	11.3	0.53	3.17e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg27113153	chr11:123612418	ZNF202	-0.68	-6.06	-0.32	3.72e-9	Cognitive function;
CRC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.49	7.77	0.39	1.01e-13	Height;
CRC	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.64	9.43	0.46	7.47e-19	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	1.03	10.45	0.5	2.99e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg16797656	chr11:68205561	LRP5	0.37	5.76	0.3	1.97e-8	Total body bone mineral density;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.52	7.91	0.4	3.94e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.58e-24	Corneal astigmatism;
CRC	cis	rs3018066	0.836	rs9996093	chr4:107098543	T/C	cg01869342	chr4:106983673	TBCK	0.37	5.71	0.3	2.48e-8	Cancer;
CRC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.61	-0.3	4.22e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.44	6.02	0.32	4.6e-9	Platelet distribution width;
CRC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.87	-16.07	-0.66	2.67e-43	Coronary artery disease;
CRC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.45	7.13	0.37	6.35e-12	Hemoglobin concentration;
CRC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	0.54	9.02	0.45	1.63e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg14752227	chr20:34000481	UQCC	-0.38	-5.68	-0.3	2.91e-8	Height;
CRC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.84	-10.81	-0.51	1.64e-23	Gut microbiome composition (summer);
CRC	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg04132472	chr17:19861366	AKAP10	0.46	7.15	0.37	5.64e-12	Schizophrenia;
CRC	cis	rs9847710	0.670	rs36051354	chr3:52986012	T/C	cg15147215	chr3:52552868	STAB1	0.41	5.64	0.3	3.59e-8	Ulcerative colitis;
CRC	cis	rs16975963	0.843	rs11672163	chr19:38373856	G/A	cg15135657	chr19:38346511	NA	-0.42	-5.66	-0.3	3.26e-8	Longevity;
CRC	cis	rs10503871	0.690	rs4147357	chr8:30344444	T/C	cg26383811	chr8:30366931	RBPMS	0.49	7.91	0.4	3.91e-14	Metabolite levels  (X-11787);
CRC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	8.5	0.42	6.69e-16	Personality dimensions;
CRC	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.98	8.33	0.42	2.16e-15	Cerebrospinal fluid biomarker levels;
CRC	cis	rs17155006	0.664	rs387981	chr7:107741337	T/A	cg05962710	chr7:107745446	LAMB4	-0.43	-7.57	-0.39	3.74e-13	Pneumococcal bacteremia;
CRC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.77	10.63	0.51	7.11e-23	Orofacial clefts;
CRC	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.19	-0.37	4.38e-12	Schizophrenia;
CRC	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.46	6.73	0.35	7.69e-11	Pulmonary function decline;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.26	-0.37	2.81e-12	Longevity;Endometriosis;
CRC	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg05535760	chr7:792225	HEATR2	0.98	11.34	0.53	2.19e-25	Cerebrospinal P-tau181p levels;
CRC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg07211511	chr3:129823064	LOC729375	-0.53	-6.19	-0.32	1.83e-9	Blood pressure (smoking interaction);
CRC	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.22	-5.7	-0.3	2.6e-8	Type 2 diabetes;
CRC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg16486109	chr11:613632	IRF7	0.7	11.44	0.53	9.66e-26	Systemic lupus erythematosus;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12939425	chr5:130344188	NA	-0.39	-6.25	-0.33	1.24e-9	Thyroid stimulating hormone;
CRC	trans	rs783540	0.933	rs2567636	chr15:83263428	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.43	-0.33	4.53e-10	Schizophrenia;
CRC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg26162295	chr17:38119207	GSDMA	-0.34	-5.7	-0.3	2.63e-8	Asthma;
CRC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.67	-11.62	-0.54	2.26e-26	Brugada syndrome;
CRC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.86	-0.58	5.94e-31	Hemoglobin concentration;
CRC	cis	rs11212617	0.967	rs4754305	chr11:108075912	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.36	0.33	6.56e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs61883261	0.764	rs10833426	chr11:21008120	C/A	cg13263472	chr14:102593156	HSP90AA1	-0.63	-6.15	-0.32	2.31e-9	Response to amphetamines;
CRC	cis	rs501120	0.925	rs1657344	chr10:44781234	C/T	cg09554077	chr10:44749378	NA	0.86	10.71	0.51	3.77e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.71	-12.3	-0.56	7.51e-29	Body mass index;
CRC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.07	-12.49	-0.57	1.49e-29	Diabetic kidney disease;
CRC	cis	rs990171	0.955	rs3755268	chr2:103038527	C/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.78	0.3	1.69e-8	Lymphocyte counts;
CRC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.66	-0.51	5.51e-23	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00840926	chr19:58919549	ZNF584	0.48	6.22	0.32	1.54e-9	Thyroid stimulating hormone;
CRC	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.93	0.36	2.22e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.51	8.75	0.43	1.12e-16	Aortic root size;
CRC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg11632617	chr15:75315747	PPCDC	-0.53	-7.37	-0.38	1.35e-12	Blood trace element (Zn levels);
CRC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.65	8.55	0.43	4.61e-16	Gut microbiome composition (summer);
CRC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.32	5.85	0.31	1.21e-8	Huntington's disease progression;
CRC	cis	rs61160187	0.582	rs11739952	chr5:60275977	C/A	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.73	-0.3	2.26e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.55	8.23	0.41	4.57e-15	Body mass index;
CRC	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-7.72	-0.39	1.39e-13	Longevity;
CRC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg02880119	chr16:3481970	NA	0.44	6.24	0.33	1.32e-9	Body mass index (adult);
CRC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	0.39	5.98	0.31	5.76e-9	Alzheimer's disease (late onset);
CRC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.61	7.47	0.38	7.26e-13	Psoriasis;
CRC	trans	rs13221576	0.569	rs35899033	chr7:93973120	G/A	cg25582398	chr5:1217743	SLC6A19	0.55	6.14	0.32	2.34e-9	Intelligence;
CRC	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg06042504	chr8:55087323	NA	-0.42	-6.5	-0.34	2.97e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.42	-6.95	-0.36	1.94e-11	Childhood ear infection;
CRC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg24881330	chr22:46731750	TRMU	0.62	6.54	0.34	2.39e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg06581033	chr10:766294	NA	-0.52	-5.78	-0.3	1.71e-8	Uric acid levels;
CRC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.42	8.24	0.41	4.15e-15	Mean corpuscular volume;
CRC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-8.47	-0.42	8.34e-16	Vitiligo;
CRC	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg12856521	chr11:46389249	DGKZ	0.44	7.09	0.36	8.28e-12	Leprosy;
CRC	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	6.93	0.36	2.18e-11	Lymphocyte counts;
CRC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.34	-0.42	2.12e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.23	-0.32	1.42e-9	Fractional excretion of uric acid;
CRC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.54	9.81	0.48	4.43e-20	Huntington's disease progression;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26187342	chr17:65713858	NOL11	-0.46	-6.75	-0.35	6.5500000000000006e-11	Myopia (pathological);
CRC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.38	-6.97	-0.36	1.78e-11	Reticulocyte fraction of red cells;
CRC	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg25019722	chr6:37503610	NA	-0.47	-8.67	-0.43	2.05e-16	Cognitive performance;
CRC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.5	9.27	0.46	2.53e-18	Birth weight;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17017335	chr3:97540665	NA	0.41	6.04	0.32	4.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.67	0.39	2.02e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg15147215	chr3:52552868	STAB1	0.59	9.14	0.45	6.45e-18	Bipolar disorder;
CRC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.56	7.54	0.38	4.56e-13	Height;
CRC	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg19025524	chr12:109796872	NA	-0.48	-6.88	-0.35	2.94e-11	Neuroticism;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg13000219	chr12:21590632	PYROXD1	-0.44	-6.68	-0.35	1.03e-10	Underweight status;
CRC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-8.57	-0.43	4.12e-16	Chronic sinus infection;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.08	-0.36	9.04e-12	QT interval;
CRC	trans	rs11825064	0.606	rs2000858	chr11:134485458	A/G	cg00033773	chr19:12779366	MORG1;C19orf56	0.45	6.17	0.32	1.97e-9	Seasonality;
CRC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.38	-5.7	-0.3	2.61e-8	P wave terminal force;
CRC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.06	-0.36	9.84e-12	Mean corpuscular volume;
CRC	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg23356831	chr14:105996513	TMEM121	0.39	6.78	0.35	5.59e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.56	-0.34	2.14e-10	Breast cancer;
CRC	cis	rs11166629	1.000	rs1036820	chr8:135646571	C/T	cg27224718	chr8:135614730	ZFAT	-0.52	-7.74	-0.39	1.26e-13	Smoking quantity;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.3	-0.37	2.13e-12	Blood metabolite levels;
CRC	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg06632207	chr12:54070931	ATP5G2	0.49	8.61	0.43	3.04e-16	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14492347	chr15:85292323	ZNF592	0.48	6.18	0.32	1.92e-9	Thyroid stimulating hormone;
CRC	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg25182066	chr10:30743637	MAP3K8	0.43	5.82	0.31	1.42e-8	Inflammatory bowel disease;
CRC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.55	8.33	0.42	2.28e-15	High light scatter reticulocyte count;
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg06470822	chr6:28175283	NA	0.81	8.22	0.41	4.63e-15	Lung cancer in ever smokers;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.44	-0.33	4.3e-10	Breast cancer;
CRC	trans	rs9630182	0.561	rs10832042	chr11:13481424	T/C	cg13741668	chr9:85679694	NA	0.37	5.97	0.31	6.12e-9	Bone mineral density;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	cis	rs2195987	1.000	rs2195987	chr19:24149545	A/G	cg00460763	chr19:23944615	RPSAP58	-0.53	-5.9	-0.31	9.18e-9	Testicular germ cell tumor;
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg23193639	chr7:45961078	IGFBP3	0.38	6.38	0.33	6.18e-10	Sitting height ratio;
CRC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.73	0.39	1.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg19193384	chr17:30244184	NA	-0.55	-6.94	-0.36	2.07e-11	Hip circumference adjusted for BMI;
CRC	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg15848620	chr12:58087721	OS9	-0.49	-6.65	-0.34	1.19e-10	Multiple sclerosis;
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.42	-6.52	-0.34	2.72e-10	Platelet count;
CRC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	0.93	13.48	0.6	2.71e-33	Breast cancer;
CRC	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg19046167	chr17:80928561	B3GNTL1	0.44	7.46	0.38	7.74e-13	Breast cancer;
CRC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	10.62	0.51	7.85e-23	Motion sickness;
CRC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.7	12.42	0.57	2.56e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg16060761	chr17:80687452	NA	-0.49	-6.48	-0.34	3.41e-10	Glycated hemoglobin levels;
CRC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.51	-5.74	-0.3	2.13e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.52	7.27	0.37	2.64e-12	Alcohol dependence;Nicotine use;
CRC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	12.02	0.55	7.68e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.87	-13.3	-0.59	1.31e-32	Blood metabolite levels;
CRC	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.58	7.91	0.4	4.02e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.85	16.04	0.66	3.66e-43	Intelligence (multi-trait analysis);
CRC	cis	rs9903692	0.954	rs11079808	chr17:46180232	A/G	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg17775713	chr3:133465469	TF	0.35	6.23	0.32	1.41e-9	Iron status biomarkers (transferrin levels);
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg18653534	chr16:772142	FAM173A	-0.36	-5.69	-0.3	2.77e-8	Height;
CRC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.54	6.54	0.34	2.34e-10	Bipolar disorder;
CRC	cis	rs4936891	0.577	rs7945483	chr11:123903709	T/A	cg22125253	chr11:123886957	OR10G4	-0.33	-5.79	-0.3	1.63e-8	Male fertility;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg15786705	chr6:28176104	NA	0.76	9.45	0.46	6.35e-19	Parkinson's disease;
CRC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.71	8.08	0.41	1.27e-14	Major depressive disorder;
CRC	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21659725	chr3:3221576	CRBN	-0.61	-7.25	-0.37	3.08e-12	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.73	0.39	1.29e-13	Aortic root size;
CRC	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.99	18.15	0.71	1.62e-51	Gut microbiome composition (winter);
CRC	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.94	-0.44	2.9e-17	Rheumatoid arthritis;
CRC	cis	rs860295	0.812	rs11264413	chr1:155788656	G/A	cg02153340	chr1:155202674	NA	-0.52	-6.26	-0.33	1.18e-9	Body mass index;
CRC	cis	rs9467160	0.871	rs9461014	chr6:24449008	T/G	cg20631270	chr6:24437470	GPLD1	0.48	6.66	0.34	1.16e-10	Liver enzyme levels;
CRC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25517755	chr10:38738941	LOC399744	-0.43	-6.25	-0.33	1.26e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.48	-7.47	-0.38	7.05e-13	Corneal astigmatism;
CRC	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05903289	chr2:130345205	NA	-0.37	-7.04	-0.36	1.1e-11	Response to cytidine analogues (gemcitabine);
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg06700871	chr2:84686330	SUCLG1	0.48	7.02	0.36	1.25e-11	Monocyte count;
CRC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-7.05	-0.36	1.06e-11	Lung cancer;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg15382696	chr6:118971807	C6orf204	0.62	8.05	0.41	1.5e-14	Diastolic blood pressure;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24296761	chr19:42408458	ARHGEF1	0.31	6.27	0.33	1.17e-9	Survival in pancreatic cancer;
CRC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.72	7.85	0.4	6.07e-14	Diabetic retinopathy;
CRC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.84	-0.35	3.78e-11	Coronary artery disease;
CRC	trans	rs4276421	0.805	rs13354798	chr5:45457077	A/G	cg04793272	chr11:119020941	ABCG4	-0.39	-6.39	-0.33	5.62e-10	P wave duration;
CRC	cis	rs7705042	0.828	rs11750521	chr5:141500704	T/C	cg08523384	chr5:141488047	NDFIP1	-0.34	-6.08	-0.32	3.29e-9	Asthma;
CRC	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-7.32	-0.37	1.89e-12	Corneal astigmatism;
CRC	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.24	-0.33	1.31e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.5	-6.21	-0.32	1.64e-9	Schizophrenia;
CRC	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.57	8.41	0.42	1.25e-15	Dementia with Lewy bodies;
CRC	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg16589663	chr20:23618590	CST3	0.57	7.26	0.37	2.89e-12	Chronic kidney disease;
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.67	0.39	1.91e-13	Alzheimer's disease;
CRC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.62	9.67	0.47	1.23e-19	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.78	10.7	0.51	3.83e-23	Orofacial clefts;
CRC	trans	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.53	8.45	0.42	9.29e-16	Metabolite levels;
CRC	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.34	3.94e-10	Electroencephalogram traits;
CRC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg00129232	chr17:37814104	STARD3	-0.48	-7.52	-0.38	5.31e-13	Self-reported allergy;
CRC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg01483505	chr11:975446	AP2A2	0.46	7.62	0.39	2.71e-13	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12172441	chr6:28176163	NA	0.59	7.12	0.37	6.82e-12	Depression;
CRC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.72	8.18	0.41	6.46e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs4771996	0.508	rs9554404	chr13:98249364	T/C	cg03311339	chr17:64299562	PRKCA	-0.47	-6.17	-0.32	2.05e-9	Obesity-related traits;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.97	-0.52	4.6e-24	Electroencephalogram traits;
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs10502219	0.958	rs12362410	chr11:116422860	C/T	cg20778451	chr5:178368205	ZNF454	-0.34	-6.27	-0.33	1.15e-9	Mitochondrial DNA levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15818800	chr10:22292583	DNAJC1	0.47	6.09	0.32	3.06e-9	Thyroid stimulating hormone;
CRC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.31	-0.46	1.86e-18	Type 2 diabetes;
CRC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.66	-0.3	3.27e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6764363	0.504	rs4684335	chr3:283415	T/C	cg02057681	chr3:285234	CHL1	0.42	7.08	0.36	8.63e-12	Sudden cardiac arrest;
CRC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg14828511	chr1:107599125	PRMT6	0.45	6.57	0.34	1.97e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg00316803	chr15:76480434	C15orf27	-0.39	-6.66	-0.34	1.18e-10	Blood metabolite levels;
CRC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.66	8.73	0.43	1.33e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg03233332	chr7:66118400	NA	-0.43	-6.45	-0.34	3.89e-10	Aortic root size;
CRC	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg23167259	chr10:102495509	NA	-0.46	-6.28	-0.33	1.08e-9	Alzheimer's disease;
CRC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.43	0.33	4.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.94	-15.29	-0.64	3.07e-40	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22273042	chr8:81083829	TPD52	0.38	6.57	0.34	1.92e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.77	10.47	0.5	2.55e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg01951491	chr16:67709440	GFOD2	-0.46	-5.73	-0.3	2.28e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303280	0.617	rs4795406	chr17:38100134	G/C	cg24910161	chr17:38119198	GSDMA	-0.32	-5.62	-0.3	4.07e-8	Self-reported allergy;
CRC	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.69	10.97	0.52	4.49e-24	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.38	0.33	5.97e-10	Cognitive ability;
CRC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.84	12.34	0.56	5.1e-29	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.78	-14.54	-0.63	2.49e-37	Body mass index;
CRC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.45	-7.97	-0.4	2.71e-14	Reticulocyte fraction of red cells;
CRC	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.6	-8.31	-0.42	2.54e-15	Body mass index;
CRC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.41	-8.04	-0.41	1.69e-14	Mean corpuscular volume;
CRC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.61	8.44	0.42	1.03e-15	Arsenic metabolism;
CRC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.57	9.06	0.45	1.18e-17	Vitiligo;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg02683197	chr6:28174875	NA	0.63	7.22	0.37	3.55e-12	Depression;
CRC	cis	rs2692947	0.537	rs11688045	chr2:96243805	A/T	cg23100626	chr2:96804247	ASTL	0.23	5.69	0.3	2.84e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.39	0.33	5.77e-10	Aortic root size;
CRC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg13072238	chr3:49761600	GMPPB	0.52	5.65	0.3	3.46e-8	Menarche (age at onset);
CRC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg05044414	chr3:183734942	ABCC5	0.47	8.13	0.41	9.07e-15	Anterior chamber depth;
CRC	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	6.78	0.35	5.45e-11	Breast cancer;
CRC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.59	7.06	0.36	9.89e-12	Blood protein levels;
CRC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.56	6.73	0.35	7.73e-11	Gut microbiome composition (summer);
CRC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.38	6.34	0.33	7.78e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg07478791	chr1:31886160	SERINC2	-0.41	-5.86	-0.31	1.14e-8	Alcohol dependence;
CRC	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.7	-10.84	-0.51	1.34e-23	Type 2 diabetes;
CRC	cis	rs13315871	1.000	rs13317835	chr3:58383275	C/T	cg20936604	chr3:58311152	NA	-0.71	-6.53	-0.34	2.5e-10	Cholesterol, total;
CRC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.81	0.44	7.3e-17	Morning vs. evening chronotype;
CRC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.68	-0.43	1.91e-16	Coronary artery disease;
CRC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.82	-14.27	-0.62	2.62e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02290350	chr8:58132656	NA	-0.59	-7.8	-0.39	8.35e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg15845792	chr6:28175446	NA	0.68	8.99	0.44	2e-17	Parkinson's disease;
CRC	cis	rs9494145	0.667	rs1331309	chr6:135406178	T/G	cg22676075	chr6:135203613	NA	0.61	7.85	0.4	5.94e-14	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs13064447	0.753	rs9811396	chr3:12747915	A/G	cg07775309	chr3:12595852	NA	-0.37	-5.96	-0.31	6.46e-9	Major depression and alcohol dependence;
CRC	cis	rs11080107	0.542	rs894606	chr17:27909352	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.46	6.49	0.34	3.13e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01140101	chr1:202113040	ARL8A	0.48	6.97	0.36	1.79e-11	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg03623178	chr6:28175578	NA	0.49	5.8	0.3	1.56e-8	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.51	0.34	2.86e-10	Life satisfaction;
CRC	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg26816564	chr1:7831052	VAMP3	0.63	7.74	0.39	1.25e-13	Inflammatory bowel disease;
CRC	cis	rs4363385	0.693	rs576941	chr1:153040165	A/G	cg25856811	chr1:152973957	SPRR3	0.24	6.63	0.34	1.41e-10	Inflammatory skin disease;
CRC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-7.69	-0.39	1.7e-13	Aortic root size;
CRC	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.35	-5.77	-0.3	1.82e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	9.23	0.45	3.47e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.05	-14.84	-0.63	1.67e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg05192639	chr6:26864778	GUSBL1	0.3	5.7	0.3	2.71e-8	Schizophrenia;
CRC	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.78	-11.45	-0.53	9.15e-26	Multiple sclerosis;
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.69	7.77	0.39	9.92e-14	Body mass index;
CRC	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.59	-8.28	-0.42	3.11e-15	Personality dimensions;
CRC	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.4	0.46	9.58e-19	Height;
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg03623178	chr6:28175578	NA	0.75	7.86	0.4	5.45e-14	Depression;
CRC	cis	rs9612	1.000	rs347519	chr19:44273516	T/C	cg08581076	chr19:44259116	C19orf61	0.46	6.02	0.31	4.78e-9	Exhaled nitric oxide output;
CRC	cis	rs1790761	0.967	rs1638556	chr11:67213518	A/G	cg17375396	chr11:67202808	RPS6KB2	0.34	5.72	0.3	2.37e-8	Mean corpuscular volume;
CRC	trans	rs12797204	0.793	rs71465556	chr11:83461366	T/C	cg07421806	chr5:128301136	SLC27A6	-0.6	-5.97	-0.31	6.12e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CRC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-10.32	-0.49	8e-22	Personality dimensions;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05663122	chr19:59055778	TRIM28	0.41	6.35	0.33	6.97e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.55	-8.09	-0.41	1.2e-14	Coronary artery disease;
CRC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	10.52	0.5	1.69e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs938554	0.784	rs10939638	chr4:9977675	T/A	cg00071950	chr4:10020882	SLC2A9	0.47	6.65	0.34	1.21e-10	Blood metabolite levels;
CRC	trans	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.55	-0.34	2.27e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.48	4.77e-20	Bladder cancer;
CRC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg06219103	chr11:63990595	FERMT3	-0.38	-5.96	-0.31	6.56e-9	Platelet count;
CRC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.14	-0.37	6.14e-12	Eye color traits;
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs11212617	0.935	rs183459	chr11:108089197	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.68	0.3	2.91e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.65	11.16	0.52	9.82e-25	Cancer;
CRC	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.33	5.73	0.3	2.28e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.99	0.44	2.02e-17	Fuchs's corneal dystrophy;
CRC	trans	rs459571	0.606	rs457420	chr9:136909261	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.45	5.99	0.31	5.47e-9	Platelet distribution width;
CRC	cis	rs10046574	0.831	rs10261625	chr7:135173544	C/T	cg27474649	chr7:135195673	CNOT4	0.66	5.61	0.3	4.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00546594	chr21:35287829	ATP5O	0.41	6.28	0.33	1.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	0.58	6.16	0.32	2.08e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.63	9.56	0.47	2.91e-19	Lung cancer;
CRC	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.84	-0.35	3.76e-11	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-7.38	-0.38	1.34e-12	Menarche (age at onset);
CRC	cis	rs2179367	0.959	rs628488	chr6:149719400	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.0	-0.31	5.23e-9	Dupuytren's disease;
CRC	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.42	5.92	0.31	8.02e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.66	-10.19	-0.49	2.28e-21	Acne (severe);
CRC	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.95	-16.14	-0.66	1.48e-43	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-7.66	-0.39	2.06e-13	Total cholesterol levels;
CRC	cis	rs9648716	1.000	rs10272940	chr7:140569152	A/G	cg10747023	chr7:140774559	NA	0.43	5.66	0.3	3.34e-8	Type 2 diabetes;
CRC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.79	-13.04	-0.58	1.28e-31	Primary tooth development (time to first tooth eruption);
CRC	trans	rs1916521	0.519	rs2461900	chr10:57420539	T/C	cg16731318	chr1:94313343	NA	-0.43	-6.01	-0.31	4.85e-9	Cardiac hypertrophy;
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg20119798	chr7:94954144	PON1	0.47	6.05	0.32	4.04e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19904058	chr10:135279010	LOC619207	-0.37	-7.01	-0.36	1.33e-11	Systemic lupus erythematosus;
CRC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.66	9.7	0.47	9.87e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	8.9	0.44	3.69e-17	Menopause (age at onset);
CRC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg05585544	chr11:47624801	NA	-0.61	-10.79	-0.51	1.98e-23	Subjective well-being;
CRC	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-6.67	-0.35	1.06e-10	Coronary artery disease;
CRC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.68	10.09	0.49	4.78e-21	Corneal astigmatism;
CRC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.37	6.85	0.35	3.73e-11	Height;
CRC	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.43	-6.1	-0.32	2.95e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.55	9.11	0.45	8e-18	Prostate cancer;
CRC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.33	-0.46	1.67e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7692995	1.000	rs7692995	chr4:17936634	T/C	cg08925142	chr4:18023851	LCORL	-0.53	-5.83	-0.31	1.34e-8	Height;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.75	-0.35	6.69e-11	Total body bone mineral density;
CRC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.82	0.4	7.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.1	-10.57	-0.5	1.11e-22	Body mass index;
CRC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.14	-0.41	8.5e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-7.62	-0.39	2.81e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.16	0.41	7.02e-15	Menopause (age at onset);
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.54	10.42	0.5	3.71e-22	Acylcarnitine levels;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg23245007	chr3:195682326	NA	-0.4	-5.63	-0.3	3.81e-8	Pancreatic cancer;
CRC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.94	-0.36	2.14e-11	IgG glycosylation;
CRC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.43	6.14	0.32	2.35e-9	Aortic root size;
CRC	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.75	7.63	0.39	2.49e-13	Neuroticism;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg17958423	chr11:6947583	ZNF215	0.58	6.06	0.32	3.82e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.71	-11.55	-0.54	4.04e-26	Obesity-related traits;
CRC	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.47	-6.32	-0.33	8.68e-10	HDL cholesterol;
CRC	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.59	7.87	0.4	5.34e-14	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.73	-0.3	2.24e-8	Gout;Renal underexcretion gout;
CRC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg21399703	chr1:247681439	NA	-0.52	-9.06	-0.45	1.16e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg19980929	chr12:42632907	YAF2	0.43	6.3	0.33	9.74e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.34	7.76	0.39	1.11e-13	Corneal astigmatism;
CRC	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg10820045	chr2:198174542	NA	0.45	7.96	0.4	2.8e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg13736514	chr6:26305472	NA	-0.45	-7.3	-0.37	2.12e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.49	-6.25	-0.33	1.3e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg08600765	chr20:34638493	LOC647979	-0.64	-7.55	-0.38	4.2e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.45	9.0	0.44	1.85e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg09877947	chr5:131593287	PDLIM4	0.56	9.62	0.47	1.78e-19	Acylcarnitine levels;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.66	10.3	0.49	9.26e-22	Longevity;Endometriosis;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20164915	chr1:149871167	BOLA1	0.4	6.15	0.32	2.23e-9	Myopia (pathological);
CRC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.68	0.3	3.04e-8	Protein C levels;
CRC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-7.88	-0.4	4.75e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.1	22.12	0.77	4.7e-67	Schizophrenia;
CRC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg07952391	chr2:88470173	THNSL2	-0.44	-6.4	-0.33	5.21e-10	Response to metformin (IC50);
CRC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.4	6.28	0.33	1.08e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06688411	chr11:65153958	FRMD8	0.46	6.33	0.33	7.8e-10	Response to antipsychotic treatment;
CRC	cis	rs995000	0.965	rs1179765	chr1:63010110	G/C	cg19896129	chr1:63156450	NA	-0.44	-6.78	-0.35	5.74e-11	Triglyceride levels;
CRC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.87	15.26	0.64	3.78e-40	Coronary artery disease;
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.94	-0.31	7.25e-9	Life satisfaction;
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.48	-6.8	-0.35	5.07e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.74	-11.75	-0.54	7.63e-27	Plateletcrit;Platelet count;
CRC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.96	0.4	2.84e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.52	8.82	0.44	7.06e-17	Dupuytren's disease;
CRC	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.66	10.66	0.51	5.52e-23	White blood cell count (basophil);
CRC	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.75	-0.39	1.15e-13	Bipolar disorder;
CRC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.63	-10.88	-0.51	9.62e-24	Coronary artery disease;
CRC	cis	rs863345	0.604	rs11264977	chr1:158447852	G/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.92	-0.31	8.16e-9	Pneumococcal bacteremia;
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg19223190	chr17:80058835	NA	0.39	6.32	0.33	8.75e-10	Life satisfaction;
CRC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.72	-11.96	-0.55	1.24e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.72	10.0	0.48	9.57e-21	Alzheimer's disease;
CRC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.83	12.68	0.57	2.87e-30	Cognitive function;
CRC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.4	-6.69	-0.35	9.72e-11	Mean platelet volume;
CRC	cis	rs995000	0.899	rs1168031	chr1:62967987	C/T	cg19896129	chr1:63156450	NA	-0.39	-6.08	-0.32	3.29e-9	Triglyceride levels;
CRC	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-7.95	-0.4	2.94e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg16576597	chr16:28551801	NUPR1	-0.41	-5.97	-0.31	6.01e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05610379	chr10:123734658	NSMCE4A	0.43	7.02	0.36	1.27e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	9.47	0.46	5.46e-19	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.49	5.67	0.3	3.14e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg22535103	chr8:58192502	C8orf71	-0.53	-6.32	-0.33	8.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10512697	0.541	rs35183718	chr5:3498590	A/C	cg19473799	chr5:3511975	NA	-0.82	-6.32	-0.33	8.41e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs3996993	0.809	rs6910581	chr6:52735825	T/C	cg20803780	chr6:52668592	GSTA1	0.37	6.85	0.35	3.6e-11	Hemoglobin concentration;
CRC	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.5	-8.18	-0.41	6.15e-15	Huntington's disease progression;
CRC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	5.62	0.3	4e-8	Schizophrenia;
CRC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-9.74	-0.47	7.31e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.52	-8.34	-0.42	2.06e-15	Aortic root size;
CRC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg12935359	chr14:103987150	CKB	-0.4	-6.61	-0.34	1.55e-10	Body mass index;
CRC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.74	-12.94	-0.58	3.16e-31	Prostate cancer;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg03623178	chr6:28175578	NA	1.0	15.19	0.64	7.35e-40	Depression;
CRC	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.83	-14.63	-0.63	1.07e-37	Lewy body disease;
CRC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg02527881	chr3:46936655	PTH1R	0.4	7.2	0.37	4.17e-12	Colorectal cancer;
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	12.82	0.58	8.7e-31	Alzheimer's disease;
CRC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.48	7.48	0.38	6.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.45	-5.67	-0.3	3.09e-8	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21192376	chr14:53020168	GPR137C;TXNDC16	0.42	7.21	0.37	3.94e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.47e-8	Total body bone mineral density;
CRC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.62	0.34	1.49e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	0.96	10.01	0.48	9.1e-21	Body mass index;
CRC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-12.32	-0.56	5.95e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12630931	0.691	rs4637318	chr3:31994962	T/C	cg21375017	chr3:31988082	OSBPL10	0.46	7.12	0.37	6.74e-12	Periodontal disease-related phenotypes;
CRC	cis	rs9648716	1.000	rs9648696	chr7:140449150	T/C	cg10747023	chr7:140774559	NA	0.44	5.77	0.3	1.8e-8	Type 2 diabetes;
CRC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.48e-17	Bladder cancer;
CRC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg05585544	chr11:47624801	NA	-0.5	-8.98	-0.44	2.06e-17	Subjective well-being;
CRC	cis	rs11212617	0.967	rs227058	chr11:108265213	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.52	0.34	2.64e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg15485101	chr11:133734466	NA	-0.35	-5.6	-0.3	4.52e-8	Childhood ear infection;
CRC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.61	-9.64	-0.47	1.5e-19	Aortic root size;
CRC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.56	-8.78	-0.44	9.17e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	0.59	6.36	0.33	6.75e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg12751644	chr20:60527061	NA	-0.37	-5.62	-0.3	4.15e-8	Body mass index;
CRC	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs11250464	0.517	rs2892335	chr10:1432136	T/G	cg02408697	chr10:1416920	ADARB2	0.4	5.69	0.3	2.86e-8	Radiation response;
CRC	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.47	6.99	0.36	1.51e-11	Birth weight;
CRC	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.87	-0.31	1.07e-8	Height;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg23843100	chr6:142627231	GPR126	-0.38	-5.98	-0.31	5.7e-9	HDL cholesterol;
CRC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.73e-19	Corneal astigmatism;
CRC	cis	rs8105895	0.935	rs7254050	chr19:22286741	G/A	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.69	8.26	0.41	3.55e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg10298567	chr3:47292165	KIF9	0.35	5.74	0.3	2.15e-8	Colorectal cancer;
CRC	cis	rs9311676	0.656	rs11915190	chr3:58409700	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	trans	rs264162	0.655	rs1354813	chr18:11000418	C/T	cg03091010	chr18:73167894	NA	-0.32	-6.15	-0.32	2.2e-9	Stem cell growth factor beta levels;
CRC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg25985355	chr7:65971099	NA	0.5	5.84	0.31	1.28e-8	Diabetic kidney disease;
CRC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg10589385	chr1:150898437	SETDB1	0.29	6.19	0.32	1.81e-9	Melanoma;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg20615401	chr6:28092323	ZSCAN16	0.46	5.99	0.31	5.44e-9	Cardiac Troponin-T levels;
CRC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.94	0.48	1.59e-20	Cognitive test performance;
CRC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.47	-7.71	-0.39	1.46e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7932354	0.502	rs10769233	chr11:47072655	T/C	cg19486271	chr11:47235900	DDB2	-0.44	-6.59	-0.34	1.74e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg16589663	chr20:23618590	CST3	0.57	7.03	0.36	1.16e-11	Chronic kidney disease;
CRC	cis	rs6743226	0.811	rs10933537	chr2:242154930	C/G	cg10021735	chr2:242295487	FARP2	-0.46	-6.82	-0.35	4.49e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs17443541	0.507	rs1823489	chr2:200463825	C/G	cg03741458	chr2:200468445	NA	-0.36	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg14345882	chr6:26364793	BTN3A2	0.41	6.43	0.33	4.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg18827107	chr12:86230957	RASSF9	-0.39	-6.07	-0.32	3.59e-9	Major depressive disorder;
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs12024301	0.557	rs76617854	chr1:183608743	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.83	0.35	4.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.73	7.92	0.4	3.76e-14	Breast cancer;
CRC	cis	rs9491140	0.539	rs12204076	chr6:124693493	A/G	cg22366943	chr6:124882293	NKAIN2	0.56	8.01	0.4	2.05e-14	Neuroticism;
CRC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-5.84	-0.31	1.29e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.22e-22	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13710969	chr17:79393463	BAHCC1	0.27	6.25	0.33	1.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg13092806	chr2:177043255	NA	0.79	12.58	0.57	6.51e-30	IgG glycosylation;
CRC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg23461800	chr14:103021989	NA	-0.49	-6.48	-0.34	3.32e-10	Platelet count;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg04798930	chr2:37193060	STRN	-0.53	-6.06	-0.32	3.75e-9	Type 1 diabetes;
CRC	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.07	-0.41	1.29e-14	Body mass index;
CRC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.39	-5.66	-0.3	3.25e-8	Psychosis in Alzheimer's disease;
CRC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg02007433	chr3:129722099	NA	-0.47	-5.97	-0.31	6.04e-9	Blood pressure (smoking interaction);
CRC	cis	rs12024301	0.557	rs7526521	chr1:183590453	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg22561889	chr6:118971681	C6orf204	0.52	6.62	0.34	1.45e-10	Diastolic blood pressure;
CRC	cis	rs7835763	0.719	rs2956390	chr8:119104103	A/G	cg11592677	chr8:119110466	EXT1	-0.38	-6.18	-0.32	1.93e-9	Autism spectrum disorder;
CRC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.47	-8.07	-0.41	1.3e-14	Sense of smell;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03509965	chr14:75743987	FOS	0.44	6.23	0.32	1.42e-9	Anxiety disorder;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg12273811	chr6:28175739	NA	0.55	5.86	0.31	1.12e-8	Depression;
CRC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.65	-9.83	-0.48	3.54e-20	Breast cancer;
CRC	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.53	8.04	0.41	1.68e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.61	-9.33	-0.46	1.57e-18	Colorectal cancer;
CRC	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.57	6.23	0.32	1.43e-9	Coronary artery disease;
CRC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.63	-9.84	-0.48	3.31e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg05585544	chr11:47624801	NA	-0.61	-10.76	-0.51	2.45e-23	Subjective well-being;
CRC	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.61	-9.35	-0.46	1.35e-18	Hepatocellular carcinoma;
CRC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg01262667	chr19:19385393	TM6SF2	0.34	5.72	0.3	2.44e-8	Tonsillectomy;
CRC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.46	7.46	0.38	7.87e-13	Major depressive disorder;
CRC	cis	rs1223397	0.938	rs3734878	chr6:13288850	C/T	cg20827128	chr6:13274284	PHACTR1	0.56	6.6	0.34	1.67e-10	Blood pressure;
CRC	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg13385794	chr1:248469461	NA	0.39	6.7	0.35	8.96e-11	Common traits (Other);
CRC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.79	0.3	1.63e-8	Height;
CRC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.64	-0.3	3.6e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.55	-0.34	2.2e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2882667	0.690	rs160400	chr5:138063019	A/G	cg09476006	chr5:138032270	NA	-0.56	-9.91	-0.48	2.04e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg19554555	chr3:13937349	NA	0.43	6.15	0.32	2.3e-9	Ovarian reserve;
CRC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.77	13.51	0.6	2.08e-33	Metabolic syndrome;
CRC	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01516580	chr16:19179433	SYT17	0.41	6.02	0.31	4.76e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg13565492	chr6:43139072	SRF	-0.71	-7.27	-0.37	2.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.65	8.93	0.44	3.15e-17	Alcohol dependence;
CRC	cis	rs1007738	0.507	rs10742797	chr11:47240490	A/T	cg19486271	chr11:47235900	DDB2	0.48	6.86	0.35	3.49e-11	Bone mineral density (hip);
CRC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg25767906	chr1:53392781	SCP2	0.44	7.03	0.36	1.2e-11	Monocyte count;
CRC	cis	rs35520189	0.591	rs12618418	chr2:113707645	G/T	cg12858261	chr2:113808755	IL1F8	0.45	5.96	0.31	6.61e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg01629716	chr15:45996671	NA	-0.41	-8.29	-0.42	2.98e-15	Waist circumference;Weight;
CRC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.51	-0.38	5.56e-13	Neuroticism;
CRC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.33	6.87	0.35	3.29e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.703	rs9429090	chr1:46502393	A/G	cg08644498	chr1:46502608	NA	0.45	7.05	0.36	1.03e-11	Blood protein levels;
CRC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.14	0.37	5.9e-12	Life satisfaction;
CRC	cis	rs10743315	0.778	rs10841184	chr12:19370768	T/G	cg02471346	chr12:19282374	PLEKHA5	-0.62	-7.6	-0.39	3.03e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs11229555	0.645	rs35279927	chr11:58212129	G/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs629535	0.814	rs651985	chr8:70054966	G/A	cg26132723	chr8:70041827	NA	0.35	5.69	0.3	2.78e-8	Dupuytren's disease;
CRC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.82	-10.73	-0.51	3.13e-23	Gut microbiome composition (summer);
CRC	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.73	0.47	7.6e-20	Ileal carcinoids;
CRC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg24562669	chr7:97807699	LMTK2	0.44	7.28	0.37	2.52e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18912574	chr7:65842487	NCRNA00174	0.35	5.95	0.31	6.72e-9	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08943809	chr16:58059531	MMP15	0.36	5.96	0.31	6.45e-9	Obesity-related traits;
CRC	cis	rs4845875	0.557	rs6659541	chr1:11836442	G/A	cg02448276	chr1:11845238	NA	0.36	5.61	0.3	4.38e-8	Midregional pro atrial natriuretic peptide levels;
CRC	cis	rs1448094	0.617	rs952851	chr12:86477341	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.07	-0.36	9.59e-12	Major depressive disorder;
CRC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.72	-0.43	1.42e-16	Alcohol dependence;
CRC	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg20356878	chr3:121714668	ILDR1	0.51	7.85	0.4	5.79e-14	Cognitive performance;
CRC	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg23229984	chr5:148520753	ABLIM3	0.47	6.61	0.34	1.56e-10	Breast cancer;
CRC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.32	-5.92	-0.31	7.95e-9	Abdominal aortic aneurysm;
CRC	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs1223397	0.938	rs34505804	chr6:13292514	G/A	cg21538684	chr6:13274180	PHACTR1	0.48	5.63	0.3	3.89e-8	Blood pressure;
CRC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg15440763	chr7:158190612	PTPRN2	0.53	8.71	0.43	1.54e-16	Obesity-related traits;
CRC	trans	rs6693295	0.729	rs10802326	chr1:246216665	T/C	cg03680032	chr11:94965610	SESN3	0.49	6.12	0.32	2.68e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.46	6.07	0.32	3.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.48	6.11	0.32	2.78e-9	Response to diuretic therapy;
CRC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg03013999	chr17:37608204	MED1	-0.48	-7.42	-0.38	9.94e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs6496667	0.642	rs62019395	chr15:91066309	G/T	cg04176472	chr15:90893244	GABARAPL3	0.49	7.23	0.37	3.4e-12	Rheumatoid arthritis;
CRC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.99	-0.48	1.07e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	6.78	0.35	5.74e-11	Obesity-related traits;
CRC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg03037974	chr15:76606532	NA	-0.54	-7.78	-0.39	9.15e-14	Blood metabolite levels;
CRC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.72	-0.35	8.16e-11	Mean corpuscular volume;
CRC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	14.56	0.63	2.14e-37	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg08798685	chr6:27730294	NA	-0.42	-6.17	-0.32	2e-9	Parkinson's disease;
CRC	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.98	0.31	5.86e-9	Ovarian reserve;
CRC	trans	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.62	6.39	0.33	5.59e-10	Menarche (age at onset);
CRC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.43	-6.02	-0.31	4.73e-9	IgG glycosylation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03442064	chr6:41515050	FOXP4	0.48	6.19	0.32	1.81e-9	Thyroid stimulating hormone;
CRC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.22	-0.41	4.6e-15	Chronic sinus infection;
CRC	cis	rs9976767	0.861	rs9980448	chr21:43839730	T/C	cg23042151	chr21:43824109	UBASH3A	-0.33	-5.8	-0.3	1.55e-8	Type 1 diabetes;
CRC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.43	0.33	4.49e-10	Obesity-related traits;
CRC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.5	6.67	0.35	1.06e-10	IgG glycosylation;
CRC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg08999081	chr20:33150536	PIGU	0.41	5.71	0.3	2.53e-8	Protein C levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09085639	chr17:79670810	MRPL12	0.43	6.2	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.77	-0.3	1.85e-8	Educational attainment;
CRC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.66	-0.47	1.38e-19	Personality dimensions;
CRC	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg12856521	chr11:46389249	DGKZ	0.43	7.01	0.36	1.32e-11	Leprosy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02592615	chr6:12012261	HIVEP1	0.38	6.26	0.33	1.19e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.54	-6.49	-0.34	3.15e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg03909863	chr11:638404	DRD4	-0.51	-6.55	-0.34	2.17e-10	Systemic lupus erythematosus;
CRC	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg02466173	chr16:30829666	NA	0.62	9.32	0.46	1.78e-18	Dementia with Lewy bodies;
CRC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.36	5.72	0.3	2.34e-8	Height;
CRC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.55	6.19	0.32	1.82e-9	Vitiligo;
CRC	trans	rs56283067	0.887	rs7349931	chr6:44783674	C/T	cg16542424	chr3:61546472	PTPRG	0.54	6.15	0.32	2.28e-9	Total body bone mineral density;
CRC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.91	0.72	1.7e-54	Cognitive ability;
CRC	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.96	0.44	2.47e-17	Mean corpuscular volume;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg06470822	chr6:28175283	NA	0.67	9.07	0.45	1.1e-17	Parkinson's disease;
CRC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.3	5.86	0.31	1.11e-8	Personality dimensions;
CRC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	12.74	0.57	1.75e-30	Gut microbiome composition (summer);
CRC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg07153921	chr17:41440717	NA	-0.39	-5.9	-0.31	8.93e-9	Menopause (age at onset);
CRC	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg15282417	chr9:129245246	FAM125B	0.44	8.16	0.41	7.03e-15	Intraocular pressure;
CRC	cis	rs17818399	0.501	rs13413254	chr2:46802934	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.96	-0.36	1.85e-11	Height;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02290350	chr8:58132656	NA	-0.5	-6.19	-0.32	1.75e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg27427491	chr17:78079615	GAA	-0.38	-6.19	-0.32	1.76e-9	Yeast infection;
CRC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.57	-8.31	-0.42	2.46e-15	IgG glycosylation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25267957	chr22:32871051	FBXO7	0.37	5.97	0.31	6.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.59	10.04	0.48	7.33e-21	Prudent dietary pattern;
CRC	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.54	8.2	0.41	5.59e-15	Testicular germ cell tumor;
CRC	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.7	-0.39	1.61e-13	Bipolar disorder;
CRC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg21770322	chr7:97807741	LMTK2	-0.84	-18.42	-0.71	1.5e-52	Breast cancer;
CRC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs4731207	0.596	rs10275346	chr7:124610346	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs6557786	0.636	rs2445940	chr8:24787201	C/G	cg04118306	chr8:24772350	NEFM	0.36	5.96	0.31	6.52e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg10815400	chr1:65210420	RAVER2	0.43	6.37	0.33	6.4e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs12472274	0.941	rs36066920	chr2:239074480	T/G	cg17459225	chr2:239074497	NA	0.87	14.67	0.63	7.8e-38	Phospholipid levels (plasma);
CRC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.82	0.44	6.77e-17	Hip circumference adjusted for BMI;
CRC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.6	7.82	0.4	7.32e-14	Body mass index;
CRC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.16	0.32	2.15e-9	Aortic root size;
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.41	-0.33	5.15e-10	Total body bone mineral density;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg24655899	chr17:79519568	C17orf70	-0.7	-5.98	-0.31	5.92e-9	Cognitive function;
CRC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.91	0.4	3.93e-14	Mean corpuscular volume;
CRC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.78	-13.35	-0.59	8.43e-33	Breast cancer;
CRC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.5	-6.19	-0.32	1.8e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs758324	0.755	rs578637	chr5:131267609	G/A	cg25547332	chr5:131281432	NA	-0.37	-6.03	-0.32	4.5e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs10760158	0.832	rs4837821	chr9:124010519	T/C	cg14417974	chr9:124058376	GSN	-0.33	-5.64	-0.3	3.58e-8	Pulse pressure;
CRC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg10298567	chr3:47292165	KIF9	0.41	6.76	0.35	6.15e-11	Colorectal cancer;
CRC	cis	rs60871478	0.786	rs7807878	chr7:833878	T/C	cg13844804	chr7:814759	HEATR2	-0.65	-7.39	-0.38	1.25e-12	Cerebrospinal P-tau181p levels;
CRC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.61	-11.46	-0.53	8.56e-26	Educational attainment;
CRC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.38	0.38	1.32e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg07636037	chr3:49044803	WDR6	-0.66	-6.61	-0.34	1.51e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.63	10.87	0.51	1.04e-23	Prudent dietary pattern;
CRC	cis	rs7901135	0.962	rs4344442	chr10:60577393	A/G	cg23799393	chr10:60588674	BICC1	0.38	5.91	0.31	8.34e-9	Morning vs. evening chronotype;
CRC	cis	rs7539542	0.556	rs10753925	chr1:202854488	C/T	cg19681188	chr1:202830198	LOC148709	0.46	6.62	0.34	1.49e-10	Mean platelet volume;
CRC	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.88	14.38	0.62	9.75e-37	Dupuytren's disease;
CRC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg16342193	chr10:102329863	NA	-0.33	-5.7	-0.3	2.67e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.45	0.71	1.13e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6496667	0.779	rs8037260	chr15:91049960	C/T	cg04176472	chr15:90893244	GABARAPL3	0.57	8.28	0.42	3.18e-15	Rheumatoid arthritis;
CRC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.36	7.3	0.37	2.15e-12	Ewing sarcoma;
CRC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.44	-0.33	4.13e-10	Bipolar disorder;
CRC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.33	-0.33	7.89e-10	Menopause (age at onset);
CRC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg12639453	chr1:2035780	PRKCZ	-0.43	-8.04	-0.41	1.62e-14	Height;
CRC	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-8.64	-0.43	2.44e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg00631329	chr6:26305371	NA	-0.53	-8.81	-0.44	7.53e-17	Educational attainment;
CRC	cis	rs2882667	0.690	rs7722965	chr5:138100455	T/C	cg09476006	chr5:138032270	NA	-0.56	-9.6	-0.47	2.19e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.71	-9.12	-0.45	7.57e-18	Initial pursuit acceleration;
CRC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.65	-8.86	-0.44	5.29e-17	DNA methylation (variation);
CRC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.02	22.85	0.78	6.89e-70	Multiple system atrophy;
CRC	trans	rs4955793	0.585	rs9872496	chr3:178638752	C/T	cg11644478	chr21:40555479	PSMG1	0.66	6.14	0.32	2.36e-9	Post-traumatic stress disorder (asjusted for relatedness);
CRC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.96	0.31	6.59e-9	Rheumatoid arthritis;
CRC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.56	-7.36	-0.38	1.48e-12	Gut microbiome composition (summer);
CRC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.61	9.47	0.46	5.5e-19	Corneal astigmatism;
CRC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.52	-7.78	-0.39	9.76e-14	Platelet distribution width;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg02741985	chr17:80059408	CCDC57	-0.41	-6.76	-0.35	6.14e-11	Life satisfaction;
CRC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.5	10.21	0.49	1.89e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg16797656	chr11:68205561	LRP5	0.39	6.17	0.32	2.02e-9	Total body bone mineral density;
CRC	cis	rs744166	0.600	rs6503695	chr17:40499533	T/C	cg06270615	chr17:40516068	STAT3	-0.31	-6.74	-0.35	7.09e-11	Crohn's disease;Multiple sclerosis;Inflammatory bowel disease;
CRC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg04731861	chr2:219085781	ARPC2	0.33	6.91	0.36	2.49e-11	Colorectal cancer;
CRC	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.55	-8.02	-0.4	1.84e-14	Schizophrenia;
CRC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg05929019	chr1:183155154	LAMC2	-0.38	-6.95	-0.36	1.93e-11	Hypertriglyceridemia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15356674	chr10:79471309	NA	-0.53	-6.85	-0.35	3.68e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg18876405	chr7:65276391	NA	-0.44	-6.08	-0.32	3.36e-9	Aortic root size;
CRC	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg27053337	chr8:124217698	FAM83A	0.42	6.3	0.33	9.38e-10	Urinary uromodulin levels;
CRC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.8	0.48	4.74e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg25204440	chr1:209979598	IRF6	0.49	5.88	0.31	1.02e-8	Cleft lip with or without cleft palate;
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.65	-8.32	-0.42	2.32e-15	Platelet count;
CRC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.71	0.35	8.7e-11	Lung cancer;
CRC	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg15234197	chr11:68924956	NA	0.43	5.8	0.3	1.54e-8	Blond vs. brown hair color;
CRC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg17724175	chr1:150552817	MCL1	0.46	6.94	0.36	2.03e-11	Melanoma;
CRC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.93	14.17	0.62	6.79e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs17023223	0.537	rs2794310	chr1:119561930	C/G	cg05756136	chr1:119680316	WARS2	-0.51	-6.93	-0.36	2.19e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9462846	0.960	rs12194860	chr6:42862934	C/T	cg02353165	chr6:42928485	GNMT	0.48	6.57	0.34	2.03e-10	Blood protein levels;
CRC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-7.67	-0.39	1.95e-13	Inflammatory bowel disease;
CRC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.78	13.01	0.58	1.65e-31	Blood protein levels;
CRC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.69	0.3	2.81e-8	Total body bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05441541	chr16:1543911	TELO2	0.47	6.32	0.33	8.45e-10	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18330637	chr20:18548049	LOC388789	0.38	6.13	0.32	2.45e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.77	10.66	0.51	5.37e-23	Orofacial clefts;
CRC	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.46	-7.23	-0.37	3.36e-12	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.84	14.68	0.63	7.14e-38	Blood protein levels;
CRC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.89	-0.31	9.42e-9	Obesity-related traits;
CRC	cis	rs9992667	0.955	rs9998440	chr4:38607801	G/T	cg19726192	chr4:38663646	FLJ13197	0.56	7.36	0.38	1.47e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.8	-0.35	5.03e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.01	-0.44	1.73e-17	Schizophrenia;
CRC	cis	rs4664293	0.550	rs13388082	chr2:160472950	C/T	cg08347373	chr2:160653686	CD302	-0.39	-6.54	-0.34	2.38e-10	Monocyte percentage of white cells;
CRC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.45	6.31	0.33	9.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.59	8.58	0.43	3.83e-16	Response to temozolomide;
CRC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-5.67	-0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2580764	0.566	rs2968827	chr2:55297629	C/G	cg09592903	chr2:55203963	RTN4	0.65	10.48	0.5	2.32e-22	Mean platelet volume;
CRC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg23815491	chr16:72088622	HP	0.49	7.51	0.38	5.77e-13	Fibrinogen levels;
CRC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	0.74	8.14	0.41	8.28e-15	Gout;Renal underexcretion gout;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg15786705	chr6:28176104	NA	0.48	6.38	0.33	5.89e-10	Parkinson's disease;
CRC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg16447950	chr5:562315	NA	-0.81	-10.49	-0.5	2.1e-22	Obesity-related traits;
CRC	trans	rs9341835	0.772	rs4710254	chr6:64137609	C/T	cg13657004	chr13:50234944	EBPL	-0.37	-6.22	-0.32	1.48e-9	Schizophrenia;
CRC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.52e-18	Bladder cancer;
CRC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.24	-0.41	4.19e-15	Type 2 diabetes;
CRC	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	21.08	0.76	5.23e-63	Colorectal cancer;
CRC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.49	6.43	0.33	4.52e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-7.57	-0.39	3.67e-13	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-7.3	-0.37	2.24e-12	Response to antipsychotic treatment;
CRC	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg25797454	chr6:150327115	RAET1K	0.38	6.42	0.33	4.77e-10	Alopecia areata;
CRC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.96	-0.4	2.73e-14	Height;
CRC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.43	6.89	0.36	2.85e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02968854	chr7:30518406	NOD1	0.45	6.21	0.32	1.56e-9	Anxiety disorder;
CRC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.74	0.57	1.65e-30	Bone mineral density;
CRC	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.64	-10.81	-0.51	1.71e-23	Type 2 diabetes;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg02683197	chr6:28174875	NA	0.73	8.92	0.44	3.34e-17	Parkinson's disease;
CRC	cis	rs524281	0.861	rs3825067	chr11:65878419	A/G	cg16950941	chr11:66035639	RAB1B	0.6	7.43	0.38	9.71e-13	Electroencephalogram traits;
CRC	trans	rs67981189	0.593	rs221917	chr14:71590003	C/T	cg09414045	chr1:110162465	AMPD2	-0.4	-6.01	-0.31	4.92e-9	Schizophrenia;
CRC	cis	rs4716602	0.586	rs13224457	chr7:156161005	G/T	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.65e-11	Anti-saccade response;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Depression;
CRC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.53e-15	Height;
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg27432699	chr2:27873401	GPN1	-0.54	-8.36	-0.42	1.76e-15	Total body bone mineral density;
CRC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg16447950	chr5:562315	NA	-0.83	-11.24	-0.53	4.92e-25	Lung disease severity in cystic fibrosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16357719	chr16:2317538	RNPS1	0.4	6.68	0.35	1.03e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.57e-12	Life satisfaction;
CRC	cis	rs2882667	0.898	rs11950819	chr5:138397100	T/C	cg09476006	chr5:138032270	NA	0.44	7.44	0.38	8.99e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg15192750	chr16:69999425	NA	0.52	6.83	0.35	4.11e-11	IgE levels;
CRC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.64	10.86	0.51	1.07e-23	Prostate cancer;
CRC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.94	0.31	7.3e-9	Height;
CRC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg12855166	chr17:30846586	MYO1D	-0.57	-9.55	-0.47	3e-19	Schizophrenia;
CRC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.55	-7.18	-0.37	4.76e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg20607287	chr7:12443886	VWDE	-0.53	-5.68	-0.3	2.93e-8	Coronary artery disease;
CRC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.25	14.98	0.64	4.88e-39	Uric acid levels;
CRC	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.59	8.65	0.43	2.26e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.99	0.52	3.98e-24	Motion sickness;
CRC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg03948781	chr1:205179583	DSTYK	0.41	5.62	0.3	4.02e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.58	10.26	0.49	1.35e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs55788414	0.932	rs57461213	chr16:81185419	G/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs6893807	1.000	rs13163173	chr5:87943620	C/A	cg09002922	chr5:87956389	LOC645323	-0.42	-6.05	-0.32	3.83e-9	Body mass index;
CRC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg25985355	chr7:65971099	NA	-0.32	-5.67	-0.3	3.2e-8	Aortic root size;
CRC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.02	-19.76	-0.74	7.22e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.62	10.15	0.49	3.12e-21	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.49	8.29	0.42	3.01e-15	Common traits (Other);
CRC	trans	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg09045935	chr12:6379348	NA	0.94	6.53	0.34	2.52e-10	Blood metabolite levels;
CRC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.6	10.2	0.49	2.15e-21	Recombination rate (males);
CRC	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.48	7.61	0.39	2.87e-13	Red blood cell count;
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.6	-0.3	4.47e-8	Total body bone mineral density;
CRC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg19223190	chr17:80058835	NA	-0.46	-7.25	-0.37	3e-12	Life satisfaction;
CRC	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-8.69	-0.43	1.73e-16	Blood protein levels;
CRC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.6	8.47	0.42	8.24e-16	Arsenic metabolism;
CRC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.53	-7.89	-0.4	4.38e-14	Coronary artery disease;
CRC	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.61	8.62	0.43	2.78e-16	Breast cancer;
CRC	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg14631576	chr9:95140430	CENPP	-0.3	-5.63	-0.3	3.77e-8	Height;
CRC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg19812747	chr11:111475976	SIK2	0.44	6.37	0.33	6.53e-10	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11698816	chr16:19535587	CP110	0.39	6.65	0.34	1.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7546094	1.000	rs3103450	chr1:113197730	G/A	cg22162597	chr1:113214053	CAPZA1	-0.43	-5.88	-0.31	1.01e-8	Platelet distribution width;
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg05569086	chr8:143859399	LYNX1	0.38	6.64	0.34	1.27e-10	Urinary tract infection frequency;
CRC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.44	0.33	4.21e-10	Height;
CRC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.52	9.08	0.45	1.05e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.14	0.41	8.18e-15	Lung cancer;
CRC	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-6.13	-0.32	2.56e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.1	0.36	7.72e-12	Height;
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.62	9.99	0.48	1.03e-20	Prudent dietary pattern;
CRC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg08533674	chr1:46993347	NA	-0.61	-7.39	-0.38	1.24e-12	Monobrow;
CRC	cis	rs10512697	0.803	rs17637361	chr5:3580421	G/C	cg19473799	chr5:3511975	NA	-0.72	-5.71	-0.3	2.47e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.49	7.82	0.4	7.19e-14	Crohn's disease;
CRC	cis	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg18809830	chr7:99032528	PTCD1	-1.08	-7.98	-0.4	2.4e-14	Blood metabolite levels;
CRC	cis	rs365302	0.904	rs409843	chr6:159648832	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.87	0.35	3.15e-11	Coronary heart disease;
CRC	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.59	7.55	0.38	4.44e-13	Coronary artery disease;
CRC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-8.89	-0.44	4.19e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.7	-12.29	-0.56	8.14e-29	Prostate cancer;
CRC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg08270630	chr22:50330655	NA	-0.54	-5.77	-0.3	1.82e-8	Schizophrenia;
CRC	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07165851	chr6:158734300	TULP4	0.6	7.53	0.38	4.9e-13	Height;
CRC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.43	-0.33	4.46e-10	Total cholesterol levels;
CRC	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	cg04338863	chr8:33670619	NA	0.44	6.52	0.34	2.71e-10	Body mass index;
CRC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg05623727	chr3:50126028	RBM5	0.46	7.77	0.39	1.04e-13	Intelligence (multi-trait analysis);
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg14911132	chr11:61596755	FADS2	-0.56	-5.97	-0.31	6e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg20935933	chr6:143382018	AIG1	0.52	6.73	0.35	7.57e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.77	12.97	0.58	2.41e-31	Body mass index;
CRC	cis	rs4964805	0.594	rs954920	chr12:104173310	A/T	cg02344784	chr12:104178138	NT5DC3	0.42	6.14	0.32	2.32e-9	Attention deficit hyperactivity disorder;
CRC	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.71	7.9	0.4	4.14e-14	Eotaxin levels;
CRC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg19193384	chr17:30244184	NA	-0.58	-7.02	-0.36	1.3e-11	Hip circumference adjusted for BMI;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27619136	chr4:174291353	SAP30	0.47	6.21	0.32	1.63e-9	Thyroid stimulating hormone;
CRC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.56	0.38	3.94e-13	Menopause (age at onset);
CRC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.66	-0.34	1.15e-10	Morning vs. evening chronotype;
CRC	cis	rs9682041	0.569	rs4955724	chr3:170146532	A/G	cg11886554	chr3:170076028	SKIL	0.68	7.65	0.39	2.28e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.42	-0.5	3.56e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg15786705	chr6:28176104	NA	0.61	8.72	0.43	1.35e-16	Cardiac Troponin-T levels;
CRC	cis	rs6496667	0.779	rs16944431	chr15:90985403	G/T	cg04176472	chr15:90893244	GABARAPL3	0.59	8.13	0.41	8.73e-15	Rheumatoid arthritis;
CRC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg16102536	chr7:156981717	UBE3C	0.4	6.79	0.35	5.41e-11	Body mass index;
CRC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.16	0.37	5.31e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.49	7.12	0.37	6.71e-12	Testicular germ cell tumor;
CRC	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	6.35	0.33	7.2e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.52	-8.65	-0.43	2.24e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14599714	chr12:31226825	DDX11	-0.42	-6.06	-0.32	3.64e-9	Daytime sleep phenotypes;
CRC	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg15704280	chr7:45808275	SEPT13	0.65	6.25	0.33	1.26e-9	Intraocular pressure;
CRC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg03605463	chr16:89740564	NA	0.39	5.82	0.31	1.43e-8	Vitiligo;
CRC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg02089348	chr4:1724449	TMEM129;TACC3	-0.4	-5.76	-0.3	1.91e-8	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs11088226	0.581	rs1967870	chr21:33882858	A/G	cg09050820	chr6:167586206	TCP10L2	0.52	7.1	0.36	7.61e-12	Gastritis;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.24	-0.37	3.28e-12	Bipolar disorder;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25798026	chr22:32149910	DEPDC5	0.44	6.22	0.32	1.49e-9	Hip circumference;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg01525597	chr12:1739061	WNT5B	-0.44	-6.04	-0.32	4.26e-9	Protein C levels;
CRC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg09264619	chr17:80180166	NA	0.35	5.67	0.3	3.14e-8	Life satisfaction;
CRC	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.32	5.71	0.3	2.58e-8	Heart rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17365369	chr19:52773256	ZNF766	0.41	6.5	0.34	2.96e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12978357	chr2:114426529	NA	-0.37	-6.25	-0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg20356878	chr3:121714668	ILDR1	0.51	8.03	0.4	1.74e-14	Cognitive performance;
CRC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.15e-54	Parkinson's disease;
CRC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	7.04	0.36	1.12e-11	Obesity-related traits;
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.29	-0.37	2.31e-12	Total body bone mineral density;
CRC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg22535103	chr8:58192502	C8orf71	-0.44	-5.8	-0.3	1.55e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.5	6.59	0.34	1.74e-10	Bipolar disorder;
CRC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.83	-0.31	1.33e-8	Breast cancer;
CRC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.87	0.31	1.07e-8	Homoarginine levels;
CRC	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.52	8.85	0.44	5.37e-17	Dupuytren's disease;
CRC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg15145174	chr5:6755386	POLS	-0.43	-6.29	-0.33	1.04e-9	Menopause (age at onset);
CRC	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-5.62	-0.3	4.07e-8	Breast cancer;
CRC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg03030879	chr14:75389066	RPS6KL1	0.38	5.67	0.3	3.12e-8	Height;
CRC	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg04176472	chr15:90893244	GABARAPL3	-0.36	-5.64	-0.3	3.72e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.98	0.31	5.88e-9	Renal function-related traits (BUN);
CRC	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.59	9.45	0.46	6.46e-19	Type 2 diabetes;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.63	-8.71	-0.43	1.5e-16	Obesity-related traits;
CRC	cis	rs16924133	1.000	rs12293312	chr11:33224143	T/C	cg05567920	chr11:33183001	CSTF3	-0.78	-6.08	-0.32	3.39e-9	Anger;
CRC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.63	9.44	0.46	7.32e-19	Menopause (age at onset);
CRC	trans	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg26043149	chr18:55253948	FECH	0.51	7.92	0.4	3.79e-14	Bone mineral density;
CRC	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.59	-6.05	-0.32	3.88e-9	Night sleep phenotypes;
CRC	trans	rs9545047	0.716	rs6563096	chr13:79858235	C/T	cg07061582	chr15:90234082	PEX11A;WDR93	-0.42	-5.99	-0.31	5.41e-9	Schizophrenia;
CRC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	cis	rs2982552	0.805	rs2982557	chr6:152056369	G/A	cg22157087	chr6:152012887	ESR1	0.37	5.81	0.3	1.48e-8	Bone properties (heel);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26871885	chr11:207525	RIC8A;BET1L	0.43	7.03	0.36	1.21e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	cis	rs6694672	1.000	rs6428385	chr1:197048391	C/T	cg13682187	chr1:196946512	CFHR5	0.47	7.35	0.38	1.56e-12	Asthma;
CRC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.73	-9.98	-0.48	1.14e-20	Vitiligo;
CRC	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.57	9.74	0.47	7.49e-20	Facial morphology (factor 15, philtrum width);
CRC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg20684491	chr1:25596433	NA	0.42	7.43	0.38	9.61e-13	Erythrocyte sedimentation rate;
CRC	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.25	13.21	0.59	2.91e-32	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.35	-9.76	-0.47	6.27e-20	Mean corpuscular volume;
CRC	cis	rs727479	0.502	rs2289105	chr15:51507508	C/T	cg19946085	chr15:51559439	CYP19A1	0.28	5.69	0.3	2.88e-8	Estradiol levels;
CRC	cis	rs73206853	0.563	rs73194051	chr12:111204186	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	7.11	0.36	7.4e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg00343986	chr7:65444356	GUSB	-0.47	-6.92	-0.36	2.32e-11	Aortic root size;
CRC	cis	rs11212617	1.000	rs660429	chr11:108181511	A/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.94	0.31	7.36e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11229555	0.645	rs12294062	chr11:58175603	G/T	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.77	-9.14	-0.45	6.45e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.5	7.53	0.38	5e-13	Emphysema distribution in smoking;
CRC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.43	9.8	0.48	4.55e-20	Coronary artery disease;
CRC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg20129853	chr10:51489980	NA	-0.35	-5.81	-0.31	1.45e-8	Prostate-specific antigen levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05265988	chr5:180688748	TRIM52	0.39	6.56	0.34	2.1e-10	Obesity-related traits;
CRC	cis	rs41005	0.967	rs6752776	chr2:8104594	A/G	cg03155496	chr2:8117019	LOC339788	0.37	6.4	0.33	5.2400000000000005e-10	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.24	0.45	3.04e-18	Bladder cancer;
CRC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.66	9.55	0.47	3.03e-19	Lung cancer;
CRC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-14.8	-0.63	2.37e-38	Lymphocyte percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20712274	chr19:9946111	PIN1	0.44	6.13	0.32	2.51e-9	Anxiety disorder;
CRC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg19980929	chr12:42632907	YAF2	-0.39	-5.9	-0.31	9.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg09264619	chr17:80180166	NA	-0.5	-7.21	-0.37	3.98e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.4	6.3	0.33	9.71e-10	C-reactive protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11351475	chr10:75545401	KIAA0913	0.4	6.51	0.34	2.84e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.27	15.87	0.66	1.59e-42	Uric acid levels;
CRC	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.81	14.55	0.63	2.18e-37	Tonsillectomy;
CRC	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.61	-0.34	1.52e-10	Educational attainment (college completion);
CRC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21643547	chr1:205240462	TMCC2	-0.38	-6.15	-0.32	2.19e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.43	6.75	0.35	6.5500000000000006e-11	Schizophrenia;
CRC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.72	11.28	0.53	3.56e-25	Corneal astigmatism;
CRC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09995068	chr14:71288954	NA	0.45	6.13	0.32	2.57e-9	Anxiety disorder;
CRC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg23018236	chr17:30244563	NA	-0.47	-6.63	-0.34	1.42e-10	Hip circumference adjusted for BMI;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.48	7.2	0.37	4.22e-12	Longevity;Endometriosis;
CRC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.42	9.4	0.46	9.89e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22745781	chr7:16461244	ISPD	0.37	6.1	0.32	3e-9	Obesity-related traits;
CRC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08048268	chr3:133502702	NA	-0.33	-5.86	-0.31	1.15e-8	Iron status biomarkers;
CRC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg16102536	chr7:156981717	UBE3C	-0.39	-6.65	-0.34	1.24e-10	Body mass index;
CRC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.11	12.73	0.57	1.93e-30	Diabetic kidney disease;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg08888203	chr3:10149979	C3orf24	0.6	8.42	0.42	1.22e-15	Alzheimer's disease;
CRC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.79	0.35	5.15e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12476592	0.602	rs9789351	chr2:63740614	A/G	cg10828910	chr2:63850056	LOC388955	0.48	5.93	0.31	7.6e-9	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg11843238	chr5:131593191	PDLIM4	0.43	8.21	0.41	5.02e-15	Breast cancer;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.77	-11.74	-0.54	8.14e-27	Menarche (age at onset);
CRC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.03	-0.7	5.04e-51	Height;
CRC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg10760299	chr15:45669010	GATM	0.36	5.66	0.3	3.25e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg03959625	chr15:84868606	LOC388152	0.41	6.15	0.32	2.3e-9	Schizophrenia;
CRC	cis	rs7394190	0.748	rs34163229	chr10:75406912	G/T	cg07699608	chr10:75541558	CHCHD1	0.62	6.39	0.33	5.52e-10	Incident atrial fibrillation;
CRC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.61	-0.75	3.6e-61	Height;
CRC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.29	0.37	2.32e-12	Parkinson's disease;
CRC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.57	-9.25	-0.45	3.01e-18	P wave terminal force;
CRC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.57	-8.01	-0.4	1.99e-14	IgG glycosylation;
CRC	trans	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.44e-13	HDL cholesterol;
CRC	cis	rs2342406	0.825	rs1026062	chr2:45142078	G/A	cg23424933	chr2:45157613	NA	0.43	5.71	0.3	2.57e-8	Myopia;
CRC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.77e-11	Primary biliary cholangitis;
CRC	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.73	0.35	7.64e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.62	-9.21	-0.45	3.88e-18	Monocyte count;
CRC	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.74	-0.51	2.89e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.56	-0.34	2.06e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs559356	0.519	rs523810	chr3:34848023	G/A	cg19071035	chr6:20404090	E2F3	0.47	6.29	0.33	1.04e-9	Cognitive function;
CRC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.36	-7.47	-0.38	7.23e-13	Cutaneous nevi;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05972000	chr8:67525501	MYBL1	0.41	6.49	0.34	3.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.89	10.03	0.48	7.97e-21	Iron status biomarkers;
CRC	cis	rs1223397	0.651	rs2496147	chr6:13313233	C/T	cg07912922	chr6:13274314	PHACTR1	0.38	5.93	0.31	7.79e-9	Blood pressure;
CRC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.71	-12.09	-0.55	4.33e-28	Body mass index;
CRC	cis	rs12282928	1.000	rs1566730	chr11:48250854	G/A	cg20307385	chr11:47447363	PSMC3	0.47	5.81	0.31	1.45e-8	Migraine - clinic-based;
CRC	cis	rs17767392	0.957	rs7140354	chr14:71759616	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.82	-0.35	4.34e-11	Mitral valve prolapse;
CRC	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.54	-0.34	2.39e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6504950	0.800	rs9900816	chr17:53012057	G/A	cg26251398	chr17:52985966	TOM1L1	0.37	5.65	0.3	3.41e-8	Breast cancer;
CRC	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.3	0.42	2.76e-15	Coffee consumption (cups per day);
CRC	cis	rs863345	0.604	rs2054993	chr1:158505968	T/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.63	8.28	0.42	3.08e-15	Alzheimer's disease;
CRC	cis	rs16975963	0.843	rs2382624	chr19:38419025	A/G	cg15135657	chr19:38346511	NA	-0.43	-5.75	-0.3	2.01e-8	Longevity;
CRC	cis	rs2882667	0.931	rs10075039	chr5:138337854	A/G	cg09476006	chr5:138032270	NA	0.44	7.29	0.37	2.32e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	14.44	0.62	6.18e-37	Lewy body disease;
CRC	cis	rs9463078	0.774	rs4446571	chr6:45257662	T/C	cg25276700	chr6:44698697	NA	-0.27	-6.46	-0.34	3.81e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg27398640	chr15:77910606	LINGO1	0.43	7.3	0.37	2.21e-12	Type 2 diabetes;
CRC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.64	-0.34	1.28e-10	Intelligence (multi-trait analysis);
CRC	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.57	8.0	0.4	2.1e-14	Kawasaki disease;
CRC	cis	rs6066835	1.000	rs6063314	chr20:47353106	T/C	cg18078177	chr20:47281410	PREX1	0.63	5.78	0.3	1.7e-8	Multiple myeloma;
CRC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-9.26	-0.45	2.65e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.37	5.89	0.31	9.78e-9	Huntington's disease progression;
CRC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg19622623	chr12:86230825	RASSF9	0.37	5.89	0.31	9.4e-9	Major depressive disorder;
CRC	trans	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg12112058	chr1:224622605	WDR26	0.49	6.0	0.31	5.12e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.64	9.29	0.46	2.1e-18	Subjective well-being;
CRC	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.46	6.86	0.35	3.48e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.84	-10.39	-0.5	4.83e-22	Initial pursuit acceleration;
CRC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.49	-6.52	-0.34	2.64e-10	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.42	5.85	0.31	1.19e-8	Aortic root size;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12172441	chr6:28176163	NA	0.59	7.12	0.37	6.82e-12	Depression;
CRC	cis	rs4731207	0.596	rs13233978	chr7:124587620	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs6570726	0.559	rs11754523	chr6:145727951	A/G	cg23711669	chr6:146136114	FBXO30	-0.47	-7.17	-0.37	4.86e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7072216	0.881	rs4345897	chr10:100147060	A/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.24	-0.33	1.37e-9	Metabolite levels;
CRC	cis	rs61160187	0.582	rs3797559	chr5:60223741	A/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.94	-0.31	7.36e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg15962314	chr1:44399869	ARTN	0.3	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.72	11.24	0.53	5.04e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.41	-5.89	-0.31	9.67e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.39	6.08	0.32	3.4e-9	Migraine;
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.74	11.35	0.53	2.08e-25	Menarche (age at onset);
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg24560729	chr4:1342394	KIAA1530	0.32	5.74	0.3	2.11e-8	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.43	0.42	1.08e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6479527	0.904	rs2026917	chr9:96778644	C/T	cg14459158	chr9:96720562	NA	0.39	6.97	0.36	1.69e-11	Esophageal adenocarcinoma;
CRC	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.5	7.83	0.4	6.76e-14	Anxiety disorder;
CRC	cis	rs6534441	0.857	rs58568869	chr4:125459674	A/G	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-9.69	-0.47	1.08e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg23254163	chr1:152506842	NA	0.42	7.18	0.37	4.7e-12	Hair morphology;
CRC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-5.95	-0.31	6.94e-9	Bladder cancer;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-8.5	-0.42	6.62e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	ch.1.183610071R	chr1:185343448	NA	-0.41	-6.29	-0.33	1.01e-9	Aortic root size;
CRC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	5.97e-10	Red blood cell count;
CRC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg23461800	chr14:103021989	NA	-0.68	-7.83	-0.4	6.62e-14	Platelet count;
CRC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06656553	chr16:89960601	TCF25	-0.56	-5.7	-0.3	2.62e-8	Skin colour saturation;
CRC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.57	6.01	0.31	4.95e-9	Schizophrenia;
CRC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-10.65	-0.51	5.99e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15320075	chr8:145703422	NA	0.42	6.52	0.34	2.63e-10	Age at first birth;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg02683197	chr6:28174875	NA	0.75	9.78	0.47	5.25e-20	Parkinson's disease;
CRC	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.51	8.38	0.42	1.55e-15	Schizophrenia;
CRC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.49	8.42	0.42	1.18e-15	Coronary artery disease;
CRC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.62	10.1	0.49	4.48e-21	Breast cancer;
CRC	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.65	0.43	2.34e-16	Corneal astigmatism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12814969	chr4:83934274	LIN54	0.46	6.03	0.32	4.38e-9	Anxiety disorder;
CRC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.33	-7.1	-0.36	7.79e-12	IgG glycosylation;
CRC	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg17133734	chr15:86042851	AKAP13	0.4	6.35	0.33	6.95e-10	Coronary artery disease;
CRC	cis	rs56146971	0.670	rs12590074	chr14:91867390	T/G	cg16433844	chr14:91963127	SMEK1	-0.53	-5.65	-0.3	3.41e-8	Alzheimer disease and age of onset;
CRC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg17724175	chr1:150552817	MCL1	0.45	6.73	0.35	7.67e-11	Melanoma;
CRC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.9	10.55	0.5	1.36e-22	Psoriasis;
CRC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	5.76	0.3	1.93e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-5.98	-0.31	5.7e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.93	0.31	7.73e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg10761708	chr20:43804764	PI3	0.5	5.78	0.3	1.78e-8	Blood protein levels;
CRC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.65	-11.5	-0.54	5.99e-26	Educational attainment;
CRC	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-6.13	-0.32	2.49e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg11130432	chr3:121712080	ILDR1	-0.48	-6.2	-0.32	1.66e-9	Multiple sclerosis;
CRC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.68	11.23	0.53	5.29e-25	Mean platelet volume;
CRC	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.24	0.49	1.48e-21	Asthma;
CRC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.03	-0.32	4.36e-9	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.97	-0.31	6.08e-9	Diabetic kidney disease;
CRC	cis	rs7626444	0.625	rs1798635	chr3:196474289	C/T	cg12930392	chr3:196481615	PAK2	0.4	7.05	0.36	1.07e-11	Monocyte count;
CRC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.48	-9.45	-0.46	6.56e-19	Prostate cancer;
CRC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg15147215	chr3:52552868	STAB1	0.51	8.91	0.44	3.5e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18907495	chr17:53828548	PCTP	0.42	5.98	0.31	5.92e-9	Response to antipsychotic treatment;
CRC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-6.13	-0.32	2.56e-9	Menarche (age at onset);
CRC	cis	rs16975963	0.644	rs73031326	chr19:38043022	G/T	cg15135657	chr19:38346511	NA	-0.45	-6.25	-0.33	1.25e-9	Longevity;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.15	-0.32	2.31e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.34	-6.45	-0.34	3.94e-10	Colorectal cancer;
CRC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.49	7.43	0.38	9.59e-13	Blood metabolite levels;
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs9287663	chr2:15596076	T/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.14e-9	Educational attainment (years of education);
CRC	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.72	-9.47	-0.46	5.67e-19	Coronary artery disease;
CRC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.43	0.38	9.46e-13	Obesity-related traits;
CRC	cis	rs7731657	0.537	rs7709977	chr5:130367086	A/T	cg08523029	chr5:130500466	HINT1	-0.46	-5.98	-0.31	5.75e-9	Fasting plasma glucose;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg12273811	chr6:28175739	NA	0.55	7.84	0.4	6.19e-14	Parkinson's disease;
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.44	6.48	0.34	3.41e-10	Menarche (age at onset);
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.81	-0.35	4.67e-11	Electroencephalogram traits;
CRC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg22535103	chr8:58192502	C8orf71	-0.53	-6.32	-0.33	8.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.78	-12.76	-0.58	1.43e-30	Height;
CRC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	8.68	0.43	1.82e-16	Eosinophil percentage of white cells;
CRC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg21466736	chr12:48725269	NA	0.5	7.9	0.4	4.09e-14	Plateletcrit;
CRC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14008862	chr17:28927542	LRRC37B2	0.52	6.34	0.33	7.68e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.98	-0.31	5.97e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg19980929	chr12:42632907	YAF2	0.44	6.54	0.34	2.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.46	7.45	0.38	8.18e-13	Height;
CRC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg24011408	chr12:48396354	COL2A1	0.44	6.22	0.32	1.48e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.75	0.47	6.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3857067	1.000	rs7694820	chr4:95017026	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.06	-0.32	3.63e-9	QT interval;
CRC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.41	-6.02	-0.32	4.56e-9	Height;
CRC	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-13.8	-0.61	1.76e-34	Colorectal cancer;
CRC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.47	6.96	0.36	1.83e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.17	10.55	0.5	1.35e-22	Arsenic metabolism;
CRC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-9.09	-0.45	9.84e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg15534755	chr11:117069859	TAGLN	0.3	5.85	0.31	1.21e-8	Blood protein levels;
CRC	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.47	6.94	0.36	2.14e-11	Dialysis-related mortality;
CRC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg10589385	chr1:150898437	SETDB1	0.3	6.08	0.32	3.34e-9	Melanoma;
CRC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs62432291	0.681	rs2501177	chr6:159655593	C/T	cg14500486	chr6:159655392	FNDC1	-0.76	-10.4	-0.5	4.17e-22	Joint mobility (Beighton score);
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.85	-19.37	-0.73	2.52e-56	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.72	-0.72	9.51e-54	Schizophrenia;
CRC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg12046867	chr14:103022105	NA	-0.82	-11.41	-0.53	1.25e-25	Platelet count;
CRC	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg18551225	chr6:44695536	NA	-0.42	-5.87	-0.31	1.08e-8	Total body bone mineral density;
CRC	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.4	-6.08	-0.32	3.36e-9	Body mass index (alcohol intake interaction);
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.38	-8.69	-0.43	1.69e-16	Total body bone mineral density;
CRC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.6	-7.73	-0.39	1.32e-13	Gut microbiome composition (summer);
CRC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.35	-5.68	-0.3	2.92e-8	Huntington's disease progression;
CRC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg25809561	chr17:30822961	MYO1D	0.56	10.11	0.49	4.22e-21	Schizophrenia;
CRC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	8.52	0.43	5.67e-16	Response to antipsychotic treatment;
CRC	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg00260937	chr7:128520193	KCP	-0.46	-7.01	-0.36	1.35e-11	Calcium levels;
CRC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-5.83	-0.31	1.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.57	-9.02	-0.45	1.54e-17	Breast size;
CRC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.5	-6.63	-0.34	1.39e-10	Obesity-related traits;
CRC	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg00031303	chr3:195681400	NA	-0.47	-5.6	-0.3	4.5e-8	Red cell distribution width;
CRC	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.87	-0.31	1.05e-8	Metabolite levels;
CRC	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg16329197	chr12:53359506	NA	-1.05	-10.11	-0.49	4.31e-21	Prostate cancer;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.3	0.64	2.7e-40	Fuchs's corneal dystrophy;
CRC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.55	6.85	0.35	3.72e-11	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22345911	chr17:80231263	CSNK1D	0.32	6.36	0.33	6.74e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
CRC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg01483505	chr11:975446	AP2A2	0.42	6.71	0.35	8.38e-11	Alzheimer's disease (late onset);
CRC	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-7.42	-0.38	9.77e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg06204229	chr3:52865917	ITIH4	0.58	7.91	0.4	3.9e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.96	-0.31	6.44e-9	Life satisfaction;
CRC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-7.02	-0.36	1.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9649465	1.000	rs4588795	chr7:123349924	A/G	cg03229431	chr7:123269106	ASB15	0.36	5.61	0.3	4.34e-8	Migraine;
CRC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.86	14.22	0.62	4.14e-36	Alcohol dependence;
CRC	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.25	-0.45	2.96e-18	Rheumatoid arthritis;
CRC	cis	rs6545883	0.507	rs2442025	chr2:61571445	G/A	cg10580144	chr2:61372316	C2orf74	-0.35	-7.81	-0.4	7.8500000000000006e-14	Tuberculosis;
CRC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.68e-19	Educational attainment;
CRC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.59	7.23	0.37	3.39e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.6	9.31	0.46	1.81e-18	Tuberculosis;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12172441	chr6:28176163	NA	0.6	7.21	0.37	3.76e-12	Depression;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg26304593	chr6:42947056	PEX6	-0.45	-6.53	-0.34	2.47e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs243505	0.767	rs243530	chr7:148412618	T/C	cg09806900	chr7:148480153	CUL1	-0.46	-5.91	-0.31	8.78e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.46	7.02	0.36	1.26e-11	Migraine;Coronary artery disease;
CRC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.71	0.39	1.54e-13	Height;
CRC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.83	-9.93	-0.48	1.68e-20	Initial pursuit acceleration;
CRC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.7	-0.35	9.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.38	0.46	1.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.59	7.53	0.38	4.99e-13	Coronary artery disease;
CRC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg26176469	chr17:28951361	LRRC37B2	0.5	5.9	0.31	9.06e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg05192639	chr6:26864778	GUSBL1	0.34	6.21	0.32	1.59e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.87	-10.46	-0.5	2.68e-22	Gut microbiome composition (summer);
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.59	9.52	0.46	3.73e-19	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26294578	chr17:79319535	NA	0.46	6.62	0.34	1.45e-10	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	6.89	0.36	2.83e-11	Obesity-related traits;
CRC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.89	12.86	0.58	5.87e-31	Triglycerides;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg15786705	chr6:28176104	NA	0.58	7.07	0.36	9.12e-12	Parkinson's disease;
CRC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.42	6.55	0.34	2.25e-10	Hemoglobin concentration;
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.93	-0.31	7.62e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg15083037	chr5:83017644	HAPLN1	-0.53	-6.89	-0.36	2.82e-11	Prostate cancer;
CRC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg02935154	chr7:12443704	VWDE	-0.43	-6.05	-0.32	3.88e-9	Coronary artery disease;
CRC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.5	7.93	0.4	3.46e-14	Red blood cell count;
CRC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.5	-6.7	-0.35	9.24e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22388943	chr14:103799756	EIF5	0.42	5.98	0.31	5.92e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.24e-9	Life satisfaction;
CRC	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.72	-13.36	-0.59	7.88e-33	Hip circumference;
CRC	trans	rs6788895	1.000	rs6769917	chr3:150509604	A/T	cg12790874	chr13:100310405	CLYBL	0.64	6.21	0.32	1.58e-9	Breast cancer;
CRC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.26	-17.0	-0.68	5.78e-47	Breast cancer;
CRC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-7.56	-0.38	4.04e-13	Major depressive disorder;
CRC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg04545296	chr12:48745243	ZNF641	0.36	6.22	0.32	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg20684491	chr1:25596433	NA	-0.43	-7.39	-0.38	1.23e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg17133734	chr15:86042851	AKAP13	0.39	6.34	0.33	7.6e-10	Interstitial lung disease;
CRC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg16070018	chr6:26224392	HIST1H3E	0.6	5.83	0.31	1.32e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg25797454	chr6:150327115	RAET1K	0.36	6.49	0.34	3.1e-10	Alopecia areata;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	6.34	0.33	7.44e-10	Blood metabolite levels;
CRC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.84	0.51	1.3e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2274273	0.624	rs3783651	chr14:55850973	G/C	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.91	-0.31	8.32e-9	Protein biomarker;
CRC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg08314208	chr16:67682810	RLTPR	-0.54	-5.92	-0.31	7.89e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	6.55	0.34	2.26e-10	Mean corpuscular volume;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.69	-0.3	2.77e-8	Blood metabolite levels;
CRC	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.74	9.01	0.45	1.65e-17	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg03013636	chr16:1946785	NA	0.53	6.71	0.35	8.34e-11	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-6.77	-0.35	5.89e-11	Height;
CRC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs17152411	1.000	rs7077936	chr10:126650065	C/T	cg07906193	chr10:126599966	NA	0.61	6.81	0.35	4.73e-11	Height;
CRC	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg12856521	chr11:46389249	DGKZ	0.44	7.08	0.36	8.9e-12	Leprosy;
CRC	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.54	8.72	0.43	1.38e-16	Hemoglobin concentration;Hematocrit;
CRC	cis	rs9322817	0.691	rs2499666	chr6:105318576	A/G	cg02098413	chr6:105308735	HACE1	0.43	8.49	0.42	7.27e-16	Thyroid stimulating hormone;
CRC	trans	rs6485978	0.507	rs7128918	chr11:12641625	C/T	cg00122406	chr8:26431736	NA	-0.4	-6.5	-0.34	2.98e-10	Height;
CRC	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.72	9.64	0.47	1.6e-19	Prostate cancer;
CRC	cis	rs12983728	0.572	rs59114323	chr19:58649994	C/T	cg24884572	chr19:58661833	ZNF329	0.47	5.88	0.31	9.81e-9	Cholesterol, total;
CRC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-9.59	-0.47	2.27e-19	Alcohol dependence;
CRC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.22	-0.32	1.55e-9	Monocyte percentage of white cells;
CRC	cis	rs9549328	0.565	rs35371379	chr13:113616715	T/C	cg20742385	chr13:113633654	MCF2L	0.55	9.36	0.46	1.31e-18	Systolic blood pressure;
CRC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg25600027	chr14:23388339	RBM23	-0.53	-8.37	-0.42	1.63e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	6.65	0.34	1.23e-10	HIV-1 control;
CRC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.31	15.37	0.65	1.53e-40	Eosinophil percentage of granulocytes;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg03623178	chr6:28175578	NA	0.93	12.26	0.56	9.88e-29	Depression;
CRC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.5	6.33	0.33	7.9e-10	Recombination rate (females);
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.46	-8.04	-0.41	1.59e-14	Colorectal or endometrial cancer;
CRC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-7.48	-0.38	6.93e-13	Schizophrenia;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.32	-0.33	8.29e-10	Aortic root size;
CRC	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg20503657	chr10:835505	NA	0.69	8.01	0.4	2e-14	Eosinophil percentage of granulocytes;
CRC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.68	-0.63	7.09e-38	Diabetic kidney disease;
CRC	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg13736514	chr6:26305472	NA	-0.45	-7.24	-0.37	3.18e-12	Educational attainment;
CRC	trans	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg21153622	chr11:89784906	NA	-0.47	-7.57	-0.39	3.82e-13	HDL cholesterol;
CRC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-10.78	-0.51	2.03e-23	Colorectal cancer;
CRC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs12476592	0.714	rs262492	chr2:63844685	G/A	cg10828910	chr2:63850056	LOC388955	0.55	6.7	0.35	8.99e-11	Childhood ear infection;
CRC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.11	0.49	4.19e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.35	6.28	0.33	1.04e-9	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.82	-14.05	-0.61	1.82e-35	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg22676075	chr6:135203613	NA	0.44	6.86	0.35	3.38e-11	Red blood cell count;
CRC	cis	rs9303280	0.559	rs4795408	chr17:38107627	G/A	cg00129232	chr17:37814104	STARD3	0.38	5.64	0.3	3.76e-8	Self-reported allergy;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg15845792	chr6:28175446	NA	0.97	13.15	0.59	4.96e-32	Depression;
CRC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.4	-6.29	-0.33	9.84e-10	Neurofibrillary tangles;
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.79	13.0	0.58	1.77e-31	Height;
CRC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg04450456	chr4:17643702	FAM184B	0.38	5.89	0.31	9.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	0.74	8.28	0.42	3.17e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg01993067	chr11:68851601	TPCN2	0.48	6.31	0.33	8.94e-10	Blond vs. brown hair color;
CRC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.56	8.74	0.43	1.23e-16	Intelligence (multi-trait analysis);
CRC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg04880052	chr2:219191631	PNKD	0.43	6.8	0.35	5.08e-11	Colorectal cancer;
CRC	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.63	7.45	0.38	8.07e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7626444	0.625	rs1718410	chr3:196477660	A/G	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.96	0.36	1.82e-11	Morning vs. evening chronotype;
CRC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg08807892	chr2:162101083	NA	-0.44	-6.09	-0.32	3.2e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg25164649	chr6:28176230	NA	0.75	9.41	0.46	8.75e-19	Depression;
CRC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-6.43	-0.33	4.59e-10	Breast cancer;
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg17691542	chr6:26056736	HIST1H1C	0.41	5.66	0.3	3.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10924970	0.967	rs10754589	chr1:235439755	T/C	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.84e-9	Asthma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20770540	chr3:123304003	PTPLB	-0.45	-6.86	-0.35	3.41e-11	Myopia (pathological);
CRC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.14	-0.56	2.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg10729496	chr3:10149963	C3orf24	0.51	6.65	0.34	1.23e-10	Alzheimer's disease;
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.97	-0.4	2.56e-14	Electroencephalogram traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10143433	chr3:183353451	KLHL24	0.4	6.31	0.33	9.16e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.38	6.27	0.33	1.15e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.71	0.3	2.48e-8	Lung cancer;
CRC	cis	rs4731207	0.596	rs1006334	chr7:124628307	G/T	cg23710748	chr7:124431027	NA	-0.4	-6.37	-0.33	6.34e-10	Cutaneous malignant melanoma;
CRC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.52	-0.34	2.68e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg01483505	chr11:975446	AP2A2	0.4	5.77	0.3	1.84e-8	Alzheimer's disease (late onset);
CRC	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00495681	chr13:53174319	NA	0.59	8.79	0.44	8.25e-17	Lewy body disease;
CRC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.53	0.38	4.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.62	-10.51	-0.5	1.81e-22	Gout;
CRC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg02390115	chr1:21767211	NBPF3	0.55	8.35	0.42	1.92e-15	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19757154	chr17:74099924	EXOC7	0.45	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.58	-7.79	-0.39	8.6e-14	Response to antineoplastic agents;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05585129	chr12:132413985	PUS1	0.45	6.6	0.34	1.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.77	-0.39	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.92e-9	Prudent dietary pattern;
CRC	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.69	11.54	0.54	4.11e-26	Eosinophil percentage of white cells;
CRC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.53	0.38	4.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2257205	0.667	rs9912325	chr17:56873934	A/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg15147215	chr3:52552868	STAB1	-0.78	-15.83	-0.66	2.38e-42	Electroencephalogram traits;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg12273811	chr6:28175739	NA	0.68	5.73	0.3	2.22e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.78	12.03	0.55	6.93e-28	Schizophrenia;
CRC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs3018066	0.831	rs4470632	chr4:106946579	C/T	cg01869342	chr4:106983673	TBCK	0.41	6.22	0.32	1.47e-9	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07116851	chr12:58146173	CDK4	0.42	7.01	0.36	1.36e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg03609598	chr5:56110824	MAP3K1	0.57	7.5	0.38	5.84e-13	Type 2 diabetes;
CRC	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg18833306	chr6:118973337	C6orf204	0.43	5.63	0.3	3.92e-8	Diastolic blood pressure;
CRC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.58	9.55	0.47	3.07e-19	Dupuytren's disease;
CRC	cis	rs672059	0.806	rs3754524	chr1:183153267	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.96	0.4	2.88e-14	Hypertriglyceridemia;
CRC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.53	5.96	0.31	6.67e-9	Bipolar disorder;
CRC	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg14593290	chr7:50529359	DDC	0.58	7.92	0.4	3.64e-14	Malaria;
CRC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.7	0.47	9.94e-20	Blood protein levels;
CRC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.68	-10.33	-0.49	7.34e-22	Initial pursuit acceleration;
CRC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	10.64	0.51	6.48e-23	Motion sickness;
CRC	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg13385794	chr1:248469461	NA	0.38	6.56	0.34	2.08e-10	Common traits (Other);
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg21251018	chr6:28226885	NKAPL	0.45	6.89	0.36	2.83e-11	Parkinson's disease;
CRC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	cis	rs800160	0.777	rs2651783	chr11:2345890	C/T	cg09785033	chr11:2336066	TSPAN32	-0.47	-5.85	-0.31	1.16e-8	Bacteremia;
CRC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg18512352	chr11:47633146	NA	-0.37	-7.49	-0.38	6.59e-13	Subjective well-being;
CRC	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.07	-0.55	5.14e-28	Coffee consumption (cups per day);
CRC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.83	11.94	0.55	1.5e-27	Cognitive function;
CRC	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06307176	chr5:131281290	NA	0.43	6.4	0.33	5.5e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.49	6.91	0.36	2.53e-11	Type 1 diabetes nephropathy;
CRC	cis	rs2635047	0.542	rs11082567	chr18:44769820	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.76	-0.3	1.97e-8	Educational attainment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24932816	chr1:87794052	LMO4	0.39	6.37	0.33	6.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.53	8.73	0.43	1.3e-16	Thyroid hormone levels;
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	7.31	0.37	2e-12	Mood instability;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg08034379	chr2:228736324	WDR69	-0.54	-7.38	-0.38	1.28e-12	Blood pressure;
CRC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.5	-6.46	-0.34	3.84e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg03351412	chr1:154909251	PMVK	0.51	8.01	0.4	2.03e-14	Prostate cancer;
CRC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.09	9.7	0.47	9.72e-20	Diabetic retinopathy;
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs1105228	0.715	rs547269	chr6:165714538	A/T	cg20535254	chr6:165714960	C6orf118	-0.29	-6.03	-0.32	4.33e-9	Number of pregnancies;Number of children;
CRC	cis	rs1465370	0.682	rs62471720	chr7:130016359	C/G	cg03229158	chr7:130009420	NA	0.47	6.65	0.34	1.19e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.59	0.47	2.32e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg24562669	chr7:97807699	LMTK2	0.42	7.02	0.36	1.24e-11	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg16141378	chr3:129829833	LOC729375	-0.45	-7.0	-0.36	1.45e-11	Neuroticism;
CRC	cis	rs2415984	0.562	rs1389605	chr14:46964784	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.61	0.3	4.37e-8	Number of children ever born;
CRC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.43	-7.28	-0.37	2.44e-12	Schizophrenia;
CRC	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg25566285	chr7:158114605	PTPRN2	0.52	8.47	0.42	8.52e-16	Calcium levels;
CRC	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.32	-5.61	-0.3	4.34e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.62	-8.95	-0.44	2.72e-17	Menarche (age at onset);
CRC	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.42	5.97	0.31	6.27e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.63	8.68	0.43	1.88e-16	Coronary artery disease;
CRC	cis	rs12541635	0.833	rs4734130	chr8:107096458	A/G	cg10147462	chr8:107024639	NA	-0.41	-6.37	-0.33	6.34e-10	Age of smoking initiation;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.74	-0.35	7.19e-11	Longevity;Endometriosis;
CRC	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg12516270	chr8:143859308	LYNX1	-0.34	-5.87	-0.31	1.07e-8	Urinary tract infection frequency;
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg08200770	chr17:80723486	TBCD	-0.49	-7.45	-0.38	8.31e-13	Glycated hemoglobin levels;
CRC	trans	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg11693508	chr17:37793320	STARD3	0.7	8.7	0.43	1.62e-16	Bipolar disorder;
CRC	cis	rs2274273	0.638	rs58269011	chr14:55684388	A/G	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.83	-0.31	1.33e-8	Protein biomarker;
CRC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg22676075	chr6:135203613	NA	0.54	8.16	0.41	7.01e-15	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00613399	chr15:89010912	MRPL46;MRPS11	0.43	5.98	0.31	5.76e-9	Response to antipsychotic treatment;
CRC	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.59	-9.53	-0.47	3.6e-19	Breast cancer;
CRC	cis	rs7259376	0.875	rs1991830	chr19:22514730	G/A	cg02657401	chr19:22469223	NA	-0.37	-8.15	-0.41	7.51e-15	Menopause (age at onset);
CRC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.75e-11	Body mass index;
CRC	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.53	9.57	0.47	2.59e-19	Common traits (Other);
CRC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	6.89	0.36	2.77e-11	Reticulocyte count;
CRC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	11.99	0.55	1.01e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg00450029	chr8:599525	NA	0.63	5.65	0.3	3.52e-8	IgG glycosylation;
CRC	cis	rs1519814	1.000	rs6983133	chr8:121166682	T/G	cg22335954	chr8:121166405	COL14A1	-0.59	-6.84	-0.35	3.81e-11	Breast cancer;
CRC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.53	7.05	0.36	1.04e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg23254163	chr1:152506842	NA	0.49	9.72	0.47	8.37e-20	Hair morphology;
CRC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.46	7.16	0.37	5.18e-12	Corneal astigmatism;
CRC	cis	rs7212590	0.655	rs34687426	chr17:57997857	A/G	cg10252138	chr17:58120427	NA	-0.55	-5.93	-0.31	7.76e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01776903	chr15:38543564	SPRED1	0.43	6.17	0.32	2.06e-9	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.58	7.06	0.36	9.73e-12	Lymphocyte counts;
CRC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg08213375	chr14:104286397	PPP1R13B	0.58	11.71	0.54	1.04e-26	Schizophrenia;
CRC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.39	5.7	0.3	2.6e-8	Growth-regulated protein alpha levels;
CRC	cis	rs7113874	0.569	rs10160805	chr11:8600393	C/T	cg17679104	chr11:8615758	STK33	0.36	6.02	0.32	4.6e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.34	5.63	0.3	3.78e-8	Major depressive disorder;
CRC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.44	7.51	0.38	5.68e-13	Crohn's disease;
CRC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-16.54	-0.67	3.83e-45	Schizophrenia;
CRC	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg09127314	chr1:152161683	NA	0.49	6.33	0.33	7.87e-10	Atopic dermatitis;
CRC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.76	13.55	0.6	1.51e-33	Oral cavity cancer;
CRC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg20243544	chr17:37824526	PNMT	0.57	9.07	0.45	1.12e-17	Asthma;
CRC	cis	rs6460942	0.908	rs6979124	chr7:12232551	G/T	cg06484146	chr7:12443880	VWDE	-0.59	-6.19	-0.32	1.77e-9	Coronary artery disease;
CRC	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	0.94	9.9	0.48	2.13e-20	Gut microbiota (bacterial taxa);
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Depression;
CRC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg06243084	chr11:63990629	FERMT3	-0.4	-6.24	-0.33	1.31e-9	Platelet count;
CRC	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg01312482	chr5:178451176	ZNF879	-0.36	-6.11	-0.32	2.75e-9	Pubertal anthropometrics;
CRC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.69	-9.1	-0.45	8.57e-18	Pancreatic cancer;
CRC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.34	5.7	0.3	2.61e-8	Prostate-specific antigen levels;
CRC	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.19	-0.32	1.75e-9	Breast cancer;
CRC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.51	0.6	2.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg14541582	chr5:601475	NA	-0.27	-5.64	-0.3	3.72e-8	Obesity-related traits;
CRC	cis	rs17443541	0.507	rs6755597	chr2:200451440	A/G	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-13.85	-0.61	1.11e-34	Schizophrenia;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.55	6.65	0.34	1.19e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24308560	chr3:49941425	MST1R	0.42	6.52	0.34	2.65e-10	Body mass index;
CRC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.83	0.31	1.32e-8	Height;
CRC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8.07e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.53	8.07	0.41	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.89	-0.31	9.29e-9	Lung cancer;
CRC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.39	6.02	0.32	4.54e-9	Mean corpuscular volume;
CRC	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.73	8.98	0.44	2.2e-17	Diisocyanate-induced asthma;
CRC	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-12.68	-0.57	2.94e-30	Coffee consumption (cups per day);
CRC	cis	rs990171	1.000	rs6713618	chr2:103048437	A/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.9	0.31	9.09e-9	Lymphocyte counts;
CRC	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	19.25	0.73	7.84e-56	Colorectal cancer;
CRC	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.65	-10.84	-0.51	1.26e-23	Cancer;
CRC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-11.05	-0.52	2.43e-24	Dental caries;
CRC	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.8	10.45	0.5	2.88e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg15786705	chr6:28176104	NA	0.54	7.06	0.36	1.01e-11	Parkinson's disease;
CRC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.21	-0.56	1.57e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.37e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg19635926	chr16:89946313	TCF25	0.67	6.25	0.33	1.25e-9	Skin colour saturation;
CRC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.56	0.47	2.79e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg03623178	chr6:28175578	NA	0.84	6.98	0.36	1.68e-11	Depression;
CRC	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg05683857	chr10:124030795	BTBD16	0.33	5.92	0.31	7.98e-9	Total body bone mineral density;
CRC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	8.19	0.41	5.71e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19215386	chr18:72921446	TSHZ1;ZADH2	0.4	6.45	0.34	4e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.52	-7.55	-0.38	4.27e-13	Response to antidepressants in depression;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14543941	chr10:71079214	HK1	-0.41	-6.15	-0.32	2.25e-9	Daytime sleep phenotypes;
CRC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.98	-0.4	2.41e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2227564	0.729	rs2675675	chr10:75649048	G/A	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.63	-0.39	2.58e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.93	15.22	0.64	5.87e-40	Migraine;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.51	8.83	0.44	6.25e-17	Hypertriglyceridemia;
CRC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-20.05	-0.74	5.45e-59	Hemostatic factors and hematological phenotypes;
CRC	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.87	0.35	3.3e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.7	0.75	1.5e-61	Prudent dietary pattern;
CRC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg03233332	chr7:66118400	NA	0.45	6.22	0.32	1.49e-9	Aortic root size;
CRC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.23	-0.37	3.51e-12	Reticulocyte fraction of red cells;
CRC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.81	-0.3	1.51e-8	Gut microbiome composition (summer);
CRC	trans	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg20935933	chr6:143382018	AIG1	0.51	6.68	0.35	1.03e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.58	10.58	0.5	1.07e-22	Blood metabolite ratios;
CRC	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg14593290	chr7:50529359	DDC	0.52	7.11	0.36	7.42e-12	Malaria;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12588279	chr6:26043732	HIST1H2BB	0.48	6.84	0.35	3.97e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg25019722	chr6:37503610	NA	-0.47	-8.63	-0.43	2.66e-16	Cognitive performance;
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	3.99e-16	Life satisfaction;
CRC	cis	rs8032158	1.000	rs8024944	chr15:56125135	C/A	cg02198044	chr15:56286336	NEDD4	-0.38	-5.97	-0.31	6.31e-9	Keloid;
CRC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.66	-7.32	-0.37	1.88e-12	Lung disease severity in cystic fibrosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23139801	chr20:10414776	C20orf94;MKKS	0.47	6.61	0.34	1.57e-10	Response to antipsychotic treatment;
CRC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.52	-8.8	-0.44	7.82e-17	Huntington's disease progression;
CRC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg14541582	chr5:601475	NA	-0.37	-7.19	-0.37	4.49e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21643547	chr1:205240462	TMCC2	-0.38	-6.08	-0.32	3.27e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.47	-8.38	-0.42	1.56e-15	Migraine;
CRC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04731861	chr2:219085781	ARPC2	0.37	7.99	0.4	2.37e-14	Colorectal cancer;
CRC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.8	11.88	0.55	2.44e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg03423767	chr13:114876390	RASA3	0.37	6.32	0.33	8.4e-10	Facial morphology (factor 14, intercanthal width);
CRC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.14	-0.37	5.85e-12	Height;
CRC	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg01475377	chr6:109611718	NA	-0.34	-5.9	-0.31	9.23e-9	Reticulocyte fraction of red cells;
CRC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.82	-10.94	-0.52	5.83e-24	Initial pursuit acceleration;
CRC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.16	0.41	6.99e-15	Lung cancer;
CRC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.57	-9.65	-0.47	1.5e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs3789045	0.774	rs12028476	chr1:204476361	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.89	-0.4	4.47e-14	Educational attainment (college completion);
CRC	cis	rs7849270	0.959	rs3124509	chr9:131896999	C/T	cg13538475	chr9:131942899	NA	0.34	6.51	0.34	2.85e-10	Blood metabolite ratios;
CRC	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg07513332	chr6:167530253	CCR6	-0.43	-7.95	-0.4	2.96e-14	Primary biliary cholangitis;
CRC	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg00919237	chr7:87102261	ABCB4	-0.51	-6.7	-0.35	9.12e-11	Gallbladder cancer;
CRC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.71	9.71	0.47	8.9e-20	Cognitive function;
CRC	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-9.25	-0.45	2.92e-18	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.54	7.8	0.39	8.51e-14	Uric acid levels;
CRC	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg18198730	chr1:247681584	NA	0.63	6.91	0.36	2.52e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14431619	chr19:11266544	SPC24	0.49	6.94	0.36	2.08e-11	Response to antipsychotic treatment;
CRC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg02007433	chr3:129722099	NA	-0.51	-6.26	-0.33	1.19e-9	Blood pressure (smoking interaction);
CRC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.2	-0.41	5.3e-15	Bladder cancer;
CRC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.39	-6.26	-0.33	1.19e-9	Bone mineral density (spine);
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg12492157	chr7:27498310	NA	0.42	6.16	0.32	2.15e-9	Underweight status;
CRC	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg25649188	chr17:73499917	CASKIN2	0.44	6.35	0.33	7.2e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg10820045	chr2:198174542	NA	0.33	5.66	0.3	3.3e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-6.0	-0.31	5.18e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Dilated cardiomyopathy;
CRC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.61	8.11	0.41	9.84e-15	Breast cancer;
CRC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg25985355	chr7:65971099	NA	-0.5	-6.01	-0.31	4.91e-9	Diabetic kidney disease;
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.57	-0.39	3.83e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg09695851	chr17:3907499	NA	0.46	6.29	0.33	1.02e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00938859	chr5:1591904	SDHAP3	0.74	7.88	0.4	5e-14	Breast cancer;
CRC	cis	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg21251018	chr6:28226885	NKAPL	0.42	6.05	0.32	3.95e-9	Depression;
CRC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.71	-11.0	-0.52	3.56e-24	Pancreatic cancer;
CRC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.81	-13.63	-0.6	7.45e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.49	7.7	0.39	1.6e-13	Red blood cell count;
CRC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.68	9.87	0.48	2.66e-20	Cleft lip with or without cleft palate;
CRC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.99	0.48	1.08e-20	Alzheimer's disease (late onset);
CRC	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg18200150	chr17:30822561	MYO1D	0.44	8.56	0.43	4.28e-16	Schizophrenia;
CRC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.36	6.95	0.36	1.95e-11	Mean corpuscular volume;
CRC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg23533926	chr12:111358616	MYL2	-0.54	-8.21	-0.41	5e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.41	-6.34	-0.33	7.67e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs73206853	0.841	rs57726737	chr12:110843701	A/G	cg12870014	chr12:110450643	ANKRD13A	0.77	8.17	0.41	6.89e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.24	14.62	0.63	1.19e-37	Uric acid levels;
CRC	cis	rs2077654	0.822	rs7932122	chr11:17431361	A/G	cg25308976	chr11:17434268	ABCC8	-0.79	-8.3	-0.42	2.7e-15	Gout;
CRC	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.57	-6.26	-0.33	1.18e-9	Coronary artery disease;
CRC	cis	rs7429990	0.965	rs4858880	chr3:48104449	C/A	cg11946769	chr3:48343235	NME6	-0.44	-5.8	-0.3	1.58e-8	Educational attainment (years of education);
CRC	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg02466173	chr16:30829666	NA	0.66	9.98	0.48	1.15e-20	Dementia with Lewy bodies;
CRC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.78	0.35	5.69e-11	Body mass index;
CRC	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.61	9.88	0.48	2.43e-20	Itch intensity from mosquito bite;
CRC	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.55	8.05	0.41	1.54e-14	Sudden cardiac arrest;
CRC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.48	9.13	0.45	7.17e-18	Renal cell carcinoma;
CRC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg19774624	chr17:42201019	HDAC5	-0.66	-9.54	-0.47	3.41e-19	Total body bone mineral density;
CRC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.45	-5.96	-0.31	6.38e-9	Gut microbiome composition (summer);
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.77	-0.51	2.31e-23	Alzheimer's disease;
CRC	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs4481887	0.604	rs4642918	chr1:248411057	A/C	cg00666640	chr1:248458726	OR2T12	-0.39	-6.58	-0.34	1.82e-10	Common traits (Other);
CRC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.34	-0.62	1.52e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4964805	0.505	rs4981032	chr12:104165864	C/T	cg02344784	chr12:104178138	NT5DC3	0.47	7.23	0.37	3.35e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs6988985	0.818	rs3802230	chr8:143992864	C/A	cg10324643	chr8:143916377	GML	0.4	6.7	0.35	9.3e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	11.62	0.54	2.18e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07513332	chr6:167530253	CCR6	-0.36	-5.99	-0.31	5.55e-9	Primary biliary cholangitis;
CRC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.74	-10.5	-0.5	1.94e-22	Platelet distribution width;
CRC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.51	7.67	0.39	2.02e-13	Height;
CRC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.66	-8.46	-0.42	9.16e-16	Motion sickness;
CRC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.53	8.05	0.41	1.51e-14	Aortic root size;
CRC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	6.26	0.33	1.19e-9	Personality dimensions;
CRC	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.62	-0.39	2.64e-13	Caudate activity during reward;
CRC	cis	rs863345	0.565	rs2051665	chr1:158507157	A/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.17	-0.32	2.03e-9	Pneumococcal bacteremia;
CRC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.16	0.45	5.61e-18	Smoking initiation;
CRC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.68	11.33	0.53	2.49e-25	Alzheimer's disease (late onset);
CRC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.0	-22.38	-0.78	4.59e-68	Multiple system atrophy;
CRC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.7	9.61	0.47	1.95e-19	Breast cancer;
CRC	cis	rs17767392	1.000	rs35621718	chr14:71780758	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.9	-0.36	2.71e-11	Mitral valve prolapse;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg13324546	chr8:23564031	NKX2-6	-0.33	-5.98	-0.31	5.82e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-6.38	-0.33	6.16e-10	Response to bleomycin (chromatid breaks);
CRC	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg07274523	chr3:49395745	GPX1	0.46	5.89	0.31	9.41e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.64	6.03	0.32	4.33e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg03623178	chr6:28175578	NA	-0.97	-12.97	-0.58	2.44e-31	Depression;
CRC	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg25856811	chr1:152973957	SPRR3	-0.25	-7.1	-0.36	7.84e-12	Inflammatory skin disease;
CRC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.56	8.77	0.44	1.01e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg21770322	chr7:97807741	LMTK2	0.51	8.33	0.42	2.26e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.57	8.36	0.42	1.8e-15	Longevity;Endometriosis;
CRC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg15465823	chr12:48382534	COL2A1	-0.37	-6.14	-0.32	2.41e-9	Glycated hemoglobin levels;
CRC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg13319975	chr6:146136371	FBXO30	0.43	6.44	0.33	4.21e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.5	7.41	0.38	1.08e-12	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01301935	chr16:69599904	NFAT5;MIR1538	0.48	6.17	0.32	2.03e-9	Thyroid stimulating hormone;
CRC	trans	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg17903999	chr18:56338584	MALT1	0.41	6.54	0.34	2.33e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.49	7.88	0.4	4.73e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06498398	chr8:11627480	NEIL2	0.43	6.04	0.32	4.18e-9	Response to antipsychotic treatment;
CRC	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg11833968	chr6:79620685	NA	-0.35	-6.1	-0.32	2.98e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.45	0.34	3.97e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-7.41	-0.38	1.05e-12	Hemoglobin concentration;
CRC	trans	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg11693508	chr17:37793320	STARD3	0.5	6.69	0.35	9.65e-11	Neuroticism;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg15944457	chr8:30891341	WRN;PURG	0.5	6.51	0.34	2.76e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.31e-10	Bipolar disorder;
CRC	cis	rs7712401	0.686	rs154509	chr5:122198340	T/A	cg18764291	chr5:122110994	SNX2	0.35	5.67	0.3	3.2e-8	Mean platelet volume;
CRC	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.49	6.11	0.32	2.88e-9	Recombination rate (females);
CRC	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.49	7.68	0.39	1.88e-13	Red blood cell count;
CRC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.56	9.01	0.44	1.68e-17	Eosinophil percentage of white cells;
CRC	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-6.77	-0.35	6.01e-11	Body mass index;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg24201716	chr10:115933917	C10orf118;MIR2110	-0.42	-6.44	-0.33	4.17e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg20203395	chr5:56204925	C5orf35	-0.4	-5.64	-0.3	3.69e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.48	6.51	0.34	2.85e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.39	6.03	0.32	4.39e-9	Testicular germ cell tumor;
CRC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13198984	chr17:80129470	CCDC57	0.35	5.93	0.31	7.55e-9	Life satisfaction;
CRC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	0.55	6.67	0.34	1.12e-10	Prostate cancer;
CRC	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs9494145	0.680	rs11759553	chr6:135422296	A/T	cg22676075	chr6:135203613	NA	0.48	6.32	0.33	8.73e-10	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.94	0.31	7.14e-9	Lung cancer;
CRC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.49	-6.87	-0.35	3.31e-11	Gut microbiome composition (summer);
CRC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.93	15.77	0.66	3.98e-42	Parkinson's disease;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15216925	chr5:179921655	CNOT6	0.5	6.95	0.36	1.93e-11	Hip circumference;
CRC	cis	rs9648716	0.554	rs4726020	chr7:140603652	A/G	cg17554604	chr7:140774522	NA	0.44	5.96	0.31	6.32e-9	Type 2 diabetes;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Parkinson's disease;
CRC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.5	-7.63	-0.39	2.51e-13	Aortic root size;
CRC	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.81	-0.31	1.48e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.1	0.36	7.81e-12	Rheumatoid arthritis;
CRC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg24375607	chr4:120327624	NA	-0.46	-7.71	-0.39	1.52e-13	Corneal astigmatism;
CRC	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.76	-12.56	-0.57	7.88e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11255291	1.000	rs7917456	chr10:7732323	A/G	cg00997801	chr10:7671259	ITIH5	0.4	5.79	0.3	1.63e-8	Ovarian reserve;
CRC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.43	-6.85	-0.35	3.63e-11	Testicular germ cell tumor;
CRC	trans	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	cis	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg01251360	chr16:68772225	CDH1	-0.23	-5.63	-0.3	3.88e-8	Colorectal cancer;
CRC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs3736485	0.934	rs882385	chr15:51882369	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg11477977	chr8:29952662	LEPROTL1	-0.56	-6.06	-0.32	3.8e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-8.02	-0.4	1.89e-14	Height;
CRC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.34	-0.5	6.76e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs4908768	0.539	rs6675443	chr1:8651582	T/A	cg20416874	chr1:8611966	RERE	-0.42	-5.89	-0.31	9.7e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.08	-14.76	-0.63	3.56e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg07513332	chr6:167530253	CCR6	0.41	7.33	0.37	1.77e-12	Primary biliary cholangitis;
CRC	cis	rs9549328	0.565	rs35988856	chr13:113617427	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.5	0.46	4.44e-19	Systolic blood pressure;
CRC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.26	0.41	3.55e-15	Neuroticism;
CRC	cis	rs612683	0.862	rs12760924	chr1:100898600	A/T	cg06223162	chr1:101003688	GPR88	0.32	5.7	0.3	2.74e-8	Breast cancer;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg21784768	chr11:537496	LRRC56	-0.7	-6.63	-0.34	1.39e-10	Body mass index;
CRC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-0.99	-15.55	-0.65	3.02e-41	IgG glycosylation;
CRC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.9	-11.47	-0.53	7.58e-26	Dilated cardiomyopathy;
CRC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.93	17.17	0.69	1.26e-47	IgG glycosylation;
CRC	cis	rs2386661	0.826	rs2386651	chr10:5678031	C/A	cg26603656	chr10:5671107	NA	0.56	9.26	0.45	2.69e-18	Breast cancer;
CRC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.9	-15.52	-0.65	3.9e-41	Height;
CRC	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.99	-0.68	6.53e-47	Electrocardiographic conduction measures;
CRC	cis	rs2811415	0.597	rs9858267	chr3:127786551	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12317151	chr18:3012764	LPIN2	0.46	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs9311676	0.656	rs55692656	chr3:58383174	A/T	cg06643156	chr3:58380774	PXK	0.4	6.3	0.33	9.47e-10	Systemic lupus erythematosus;
CRC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.89	-15.36	-0.65	1.55e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg07856975	chr6:36356162	ETV7	0.45	5.64	0.3	3.62e-8	Platelet distribution width;
CRC	cis	rs3751196	0.901	rs117907031	chr12:104184317	G/C	cg02344784	chr12:104178138	NT5DC3	0.69	7.07	0.36	9.08e-12	Sense of smell;
CRC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.78	0.44	9.04e-17	Coronary artery disease;
CRC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.49	7.62	0.39	2.77e-13	Corneal astigmatism;
CRC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.6	-8.29	-0.42	2.83e-15	Obesity-related traits;
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg13126279	chr21:47581558	C21orf56	-0.38	-5.61	-0.3	4.21e-8	Testicular germ cell tumor;
CRC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.39	6.78	0.35	5.55e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg20684491	chr1:25596433	NA	0.45	7.96	0.4	2.75e-14	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.65	5.79	0.3	1.64e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22133161	chr19:49891603	CCDC155	0.52	6.65	0.34	1.22e-10	Multiple sclerosis;
CRC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg08213375	chr14:104286397	PPP1R13B	0.46	7.37	0.38	1.42e-12	Reticulocyte count;
CRC	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg25547332	chr5:131281432	NA	-0.36	-5.75	-0.3	1.99e-8	Life satisfaction;
CRC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg03623178	chr6:28175578	NA	0.58	8.66	0.43	2.08e-16	Pubertal anthropometrics;
CRC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.33	6.67	0.35	1.08e-10	Alzheimer's disease (late onset);
CRC	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.6	10.82	0.51	1.48e-23	Blood metabolite ratios;
CRC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.48	7.67	0.39	2e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02674588	chr19:17982716	SLC5A5	0.45	7.48	0.38	6.65e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg20488157	chr14:104394430	TDRD9	0.67	9.54	0.47	3.45e-19	Bipolar disorder;
CRC	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-12.38	-0.56	3.69e-29	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.68	-0.43	1.93e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg13047869	chr3:10149882	C3orf24	0.38	5.93	0.31	7.73e-9	Alzheimer's disease;
CRC	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg20243544	chr17:37824526	PNMT	-0.42	-6.47	-0.34	3.47e-10	Self-reported allergy;
CRC	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.57	6.29	0.33	1.02e-9	Type 2 diabetes;
CRC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.84	-0.35	3.77e-11	Urate levels in overweight individuals;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg15123519	chr2:136567270	LCT	-0.32	-6.26	-0.33	1.23e-9	Mosquito bite size;
CRC	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	7.44	0.38	9.11e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.82	9.27	0.46	2.54e-18	Inflammatory bowel disease;
CRC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg13722127	chr7:150037890	RARRES2	0.41	6.21	0.32	1.56e-9	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.25	0.33	1.26e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.97	-0.31	6.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg19318889	chr4:1322082	MAEA	0.4	5.9	0.31	8.95e-9	Obesity-related traits;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg15786705	chr6:28176104	NA	0.58	8.04	0.41	1.6e-14	Parkinson's disease;
CRC	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.42	-7.12	-0.37	6.88e-12	Vitamin D levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26277809	chr12:9102068	M6PR	0.44	6.44	0.33	4.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg07138768	chr7:917805	C7orf20	0.3	5.77	0.3	1.8e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs16975963	0.644	rs11083428	chr19:38083967	A/C	cg15135657	chr19:38346511	NA	-0.46	-6.28	-0.33	1.06e-9	Longevity;
CRC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.49	-0.42	7.09e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-10.37	-0.5	5.46e-22	Mood instability;
CRC	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg23032129	chr1:109941072	SORT1	-0.29	-6.02	-0.31	4.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7901135	0.962	rs1899979	chr10:60580635	A/G	cg23799393	chr10:60588674	BICC1	0.37	5.7	0.3	2.73e-8	Morning vs. evening chronotype;
CRC	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg03258749	chr1:151040405	MLLT11	-0.48	-7.45	-0.38	8.03e-13	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg20397358	chr22:38597902	MAFF	-0.73	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg26353448	chr1:248524236	OR2T4	-0.3	-5.68	-0.3	2.91e-8	Common traits (Other);
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg21155852	chr7:2048760	MAD1L1	-0.55	-6.99	-0.36	1.54e-11	Bipolar disorder;
CRC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.79	7.35	0.38	1.56e-12	Thyroid stimulating hormone;
CRC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.03e-9	Bladder cancer;
CRC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.94	18.94	0.72	1.24e-54	Multiple system atrophy;
CRC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.57	-8.27	-0.41	3.3e-15	IgG glycosylation;
CRC	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg04611788	chr3:186434169	KNG1	-0.53	-7.7	-0.39	1.64e-13	Blood protein levels;
CRC	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.5	0.5	1.96e-22	Corneal astigmatism;
CRC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.11	-0.32	2.77e-9	Monocyte percentage of white cells;
CRC	cis	rs6433857	0.505	rs12471899	chr2:181369856	C/T	cg23363182	chr2:181467187	NA	-0.55	-8.01	-0.4	2.01e-14	Body mass index;
CRC	cis	rs3790455	0.610	rs1171563	chr1:156456529	T/G	cg14087168	chr1:156450669	MEF2D	-0.37	-6.03	-0.32	4.45e-9	Migraine;
CRC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.74	-9.08	-0.45	1.03e-17	Behavioural disinhibition (generation interaction);
CRC	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.52	10.09	0.49	4.79e-21	Urate levels in lean individuals;
CRC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.05	-0.74	5.67e-59	Hip circumference adjusted for BMI;
CRC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17554472	chr22:41940697	POLR3H	0.56	5.76	0.3	1.93e-8	Vitiligo;
CRC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-7.34	-0.38	1.64e-12	Coronary artery disease;
CRC	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg11887960	chr12:57824829	NA	0.59	6.57	0.34	2e-10	Obesity-related traits;
CRC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.36	6.12	0.32	2.65e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.68	0.35	1.03e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.68	9.08	0.45	1.05e-17	Iron status biomarkers;
CRC	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg03258749	chr1:151040405	MLLT11	-0.48	-7.29	-0.37	2.33e-12	Childhood ear infection;
CRC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.61	-7.29	-0.37	2.32e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.41	-7.67	-0.39	1.97e-13	Ulcerative colitis;
CRC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg04719120	chr6:96025338	MANEA	0.52	6.41	0.33	5.19e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs4731207	0.564	rs10279816	chr7:124581580	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.25e-9	Cutaneous malignant melanoma;
CRC	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg06042504	chr8:55087323	NA	-0.43	-6.52	-0.34	2.57e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.57	-9.58	-0.47	2.42e-19	Body mass index;
CRC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.44	5.97	0.31	6.04e-9	Cognitive ability;
CRC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.6	-0.39	3.18e-13	Eye color traits;
CRC	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg09760422	chr2:128146352	NA	-0.36	-7.1	-0.36	7.68e-12	Protein C levels;
CRC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.56	7.82	0.4	7.02e-14	Lung cancer;
CRC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.44	5.81	0.31	1.48e-8	Heart rate;
CRC	cis	rs11212617	0.934	rs11212551	chr11:108078693	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.45	6.72	0.35	8e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg24140574	chr1:16342155	HSPB7	0.44	5.84	0.31	1.27e-8	Dilated cardiomyopathy;
CRC	cis	rs3790844	0.678	rs3790854	chr1:200000125	C/T	cg07208853	chr1:200005219	NR5A2	-0.34	-8.82	-0.44	6.83e-17	Pancreatic cancer;
CRC	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.6	0.34	1.64e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.83	-13.58	-0.6	1.16e-33	Plateletcrit;Platelet count;
CRC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg04362960	chr10:104952993	NT5C2	-0.43	-6.01	-0.31	4.81e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg03623178	chr6:28175578	NA	0.49	7.12	0.37	6.89e-12	Pubertal anthropometrics;
CRC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.63	-0.3	3.82e-8	Reticulocyte count;
CRC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.46	7.31	0.37	2.04e-12	Testicular germ cell tumor;
CRC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.58	-6.59	-0.34	1.74e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3736485	0.966	rs11070852	chr15:51782294	G/T	cg08986416	chr15:51914746	DMXL2	-0.44	-6.18	-0.32	1.91e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.52	-0.46	4e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9308731	0.583	rs10211562	chr2:111930796	G/T	cg04202892	chr2:111875749	ACOXL	0.42	6.62	0.34	1.44e-10	Chronic lymphocytic leukemia;
CRC	cis	rs6662572	0.737	rs4660887	chr1:46275959	A/G	cg08644498	chr1:46502608	NA	-0.44	-7.0	-0.36	1.4e-11	Blood protein levels;
CRC	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.75	11.24	0.53	4.86e-25	Testicular germ cell tumor;
CRC	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs860295	0.629	rs12026638	chr1:155401260	T/C	cg02153340	chr1:155202674	NA	-0.58	-6.85	-0.35	3.57e-11	Body mass index;
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.2	0.74	1.38e-59	Prudent dietary pattern;
CRC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs910187	0.537	rs1417452	chr20:45763350	T/C	cg27589058	chr20:45804311	EYA2	-0.36	-6.48	-0.34	3.26e-10	Migraine;
CRC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.89	16.24	0.67	6.02e-44	Coronary artery disease;
CRC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg06470822	chr6:28175283	NA	-0.43	-5.93	-0.31	7.6e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.85	-12.62	-0.57	4.71e-30	Gut microbiome composition (summer);
CRC	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.51	8.0	0.4	2.21e-14	Coronary artery disease;
CRC	cis	rs995000	0.868	rs1168113	chr1:63156098	T/C	cg19896129	chr1:63156450	NA	-0.45	-6.85	-0.35	3.72e-11	Triglyceride levels;
CRC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg11292332	chr7:45801988	SEPT13	-0.38	-7.02	-0.36	1.26e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03387256	chr10:90750898	FAS;ACTA2	0.47	6.55	0.34	2.28e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24031606	chr3:48229318	CDC25A	0.44	6.09	0.32	3.16e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.53	7.05	0.36	1.03e-11	Alzheimer's disease;
CRC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg14711859	chr11:8959438	ASCL3	-0.34	-5.76	-0.3	1.98e-8	Hemoglobin concentration;
CRC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg01941586	chr1:40203715	PPIE	-0.45	-6.21	-0.32	1.59e-9	Blood protein levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04328701	chr17:40761179	FAM134C;TUBG1	-0.41	-6.28	-0.33	1.08e-9	Aortic root size;
CRC	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg10494257	chr1:16342123	HSPB7	0.46	6.38	0.33	6.02e-10	Dilated cardiomyopathy;
CRC	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.33	-0.56	5.77e-29	Coffee consumption (cups per day);
CRC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.65	0.57	3.58e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg02397686	chr17:73851076	WBP2	0.75	6.28	0.33	1.07e-9	Psoriasis;
CRC	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg22482690	chr17:47019901	SNF8	0.5	8.19	0.41	5.69e-15	Type 2 diabetes;
CRC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg20684491	chr1:25596433	NA	0.38	6.59	0.34	1.8e-10	Erythrocyte sedimentation rate;
CRC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17507749	chr15:85114479	UBE2QP1	0.6	8.42	0.42	1.17e-15	Schizophrenia;
CRC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.72	0.39	1.45e-13	Motion sickness;
CRC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-7.4	-0.38	1.17e-12	Neuroticism;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg08322149	chr10:46222875	FAM21C	0.41	6.02	0.31	4.6e-9	Crohn's disease;
CRC	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.53	-8.65	-0.43	2.27e-16	Menarche (age at onset);
CRC	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	13.91	0.61	6.75e-35	Hypertriglyceridemia;
CRC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	8.31	0.42	2.49e-15	Height;
CRC	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.6	-0.47	2.04e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.47	6.74	0.35	7.16e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs13412757	0.646	rs184706	chr2:8457497	A/G	cg12167548	chr2:8464763	NA	0.35	6.59	0.34	1.79e-10	Asthma;Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs2811415	0.627	rs9820691	chr3:127750866	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg10483660	chr13:112241077	NA	0.36	5.78	0.3	1.76e-8	Menarche (age at onset);
CRC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg24375607	chr4:120327624	NA	0.49	7.67	0.39	1.91e-13	Corneal astigmatism;
CRC	cis	rs3018066	0.867	rs10017969	chr4:107054085	C/T	cg01869342	chr4:106983673	TBCK	0.37	5.7	0.3	2.61e-8	Cancer;
CRC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.17	-0.41	6.79e-15	Type 2 diabetes;
CRC	cis	rs2072510	0.643	rs2367755	chr12:96393082	T/C	cg09636302	chr12:96389483	HAL	-0.45	-6.34	-0.33	7.43e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	trans	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg15845792	chr6:28175446	NA	0.66	6.42	0.33	4.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.46	5.71	0.3	2.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg09184832	chr6:79620586	NA	-0.46	-8.03	-0.4	1.7e-14	Intelligence (multi-trait analysis);
CRC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg06207120	chr15:45996521	NA	0.32	7.7	0.39	1.59e-13	Waist circumference;Weight;
CRC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.45	-6.69	-0.35	9.48e-11	Breast size;
CRC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg05501817	chr11:14380813	RRAS2	-0.47	-6.5	-0.34	2.97e-10	Sense of smell;
CRC	cis	rs17401966	0.522	rs7368073	chr1:10314962	G/T	cg19773385	chr1:10388646	KIF1B	-0.48	-7.56	-0.38	4.13e-13	Hepatocellular carcinoma;
CRC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-6.12	-0.32	2.59e-9	Height;
CRC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.56	7.84	0.4	6.53e-14	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-9.28	-0.46	2.32e-18	Neuroticism;
CRC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg21496419	chr19:44306685	LYPD5	0.33	6.22	0.32	1.47e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.58	8.13	0.41	8.99e-15	Osteoporosis;
CRC	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.54	0.38	4.64e-13	Height;
CRC	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg21095983	chr6:86352623	SYNCRIP	0.54	7.76	0.39	1.11e-13	Smooth-surface caries;
CRC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.63	10.75	0.51	2.66e-23	Prudent dietary pattern;
CRC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg25985355	chr7:65971099	NA	0.32	5.67	0.3	3.12e-8	Aortic root size;
CRC	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.48	7.34	0.38	1.64e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.59	6.69	0.35	9.34e-11	Lymphocyte counts;
CRC	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.49	7.63	0.39	2.54e-13	Red blood cell count;
CRC	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg04132472	chr17:19861366	AKAP10	0.43	6.83	0.35	4.01e-11	Schizophrenia;
CRC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.6	-9.58	-0.47	2.46e-19	Intelligence (multi-trait analysis);
CRC	trans	rs12517041	1.000	rs10068478	chr5:23297003	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg22681709	chr2:178499509	PDE11A	-0.32	-5.94	-0.31	7.11e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.44	6.45	0.33	4.07e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.76	-0.39	1.05e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-8.74	-0.43	1.19e-16	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.79	0.35	5.37e-11	Body mass index;
CRC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.62	8.39	0.42	1.41e-15	High light scatter reticulocyte count;
CRC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.62	9.64	0.47	1.54e-19	Corneal astigmatism;
CRC	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg21153622	chr11:89784906	NA	-0.44	-7.11	-0.36	7.07e-12	HDL cholesterol;
CRC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.38	5.62	0.3	4.02e-8	Educational attainment;
CRC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.68	10.57	0.5	1.13e-22	Breast cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg01479122	chr15:32163262	NA	-0.39	-6.36	-0.33	6.57e-10	Aortic root size;
CRC	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.59	-5.97	-0.31	6.18e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs919433	0.714	rs2333855	chr2:198200213	T/G	cg20885578	chr2:198174922	NA	-0.36	-5.82	-0.31	1.41e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg16342193	chr10:102329863	NA	-0.35	-5.93	-0.31	7.54e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.38	-6.73	-0.35	7.55e-11	Reticulocyte fraction of red cells;
CRC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.22e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.36e-13	Red blood cell count;
CRC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.45	-7.28	-0.37	2.43e-12	Obesity-related traits;
CRC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg16447950	chr5:562315	NA	-0.86	-13.08	-0.58	9.48e-32	Lung disease severity in cystic fibrosis;
CRC	cis	rs12476592	0.602	rs1867849	chr2:63726932	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.44	5.73	0.3	2.29e-8	Total body bone mineral density;
CRC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.45	-7.42	-0.38	9.94e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9463078	0.691	rs4398713	chr6:45003928	C/T	cg25276700	chr6:44698697	NA	0.25	5.95	0.31	6.99e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.33	-0.33	7.88e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.12	-20.21	-0.74	1.25e-59	Ulcerative colitis;
CRC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	8.8	0.44	7.75e-17	Schizophrenia;
CRC	trans	rs9395066	0.545	rs4714828	chr6:44846008	A/G	cg04786201	chr1:17185605	NA	0.3	6.38	0.33	6.01e-10	Height;
CRC	cis	rs9925964	0.967	rs4889620	chr16:31131174	G/A	cg10396673	chr16:31104726	VKORC1	0.34	5.62	0.3	3.99e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg13722127	chr7:150037890	RARRES2	0.48	7.48	0.38	6.84e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19824897	chr13:79979916	RBM26	0.45	6.4	0.33	5.48e-10	Response to antipsychotic treatment;
CRC	trans	rs4586057	0.767	rs2901026	chr10:92615660	A/C	cg26894278	chr13:21016241	CRYL1	0.38	6.29	0.33	9.83e-10	Economic and political preferences (time);
CRC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.58	-8.96	-0.44	2.42e-17	Blood protein levels;
CRC	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg14631576	chr9:95140430	CENPP	-0.33	-6.09	-0.32	3.13e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9469578	0.892	rs6929527	chr6:33707976	G/T	cg18708504	chr6:33715942	IP6K3	0.65	7.42	0.38	9.77e-13	Phosphorus levels;
CRC	cis	rs4654899	0.897	rs3736880	chr1:21097727	G/A	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.45	-0.34	4e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs2814982	0.605	rs75152896	chr6:34477793	G/A	cg14254433	chr6:34482411	PACSIN1	-0.82	-8.7	-0.43	1.62e-16	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs4733781	0.509	rs6470811	chr8:131338933	G/T	cg21674704	chr8:131455249	NA	0.35	5.75	0.3	2.05e-8	Tuberculosis;
CRC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.66	-0.3	3.32e-8	Tonsillectomy;
CRC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.64	-9.54	-0.47	3.31e-19	Diastolic blood pressure;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg19238398	chr5:138775248	DNAJC18	-0.41	-6.27	-0.33	1.11e-9	Protein C levels;
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg17346650	chr17:80929145	B3GNTL1	0.48	7.14	0.37	5.94e-12	Glycated hemoglobin levels;
CRC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-14.84	-0.63	1.76e-38	Vitiligo;
CRC	cis	rs17401966	0.540	rs11121566	chr1:10472848	C/G	cg19773385	chr1:10388646	KIF1B	-0.49	-7.71	-0.39	1.47e-13	Hepatocellular carcinoma;
CRC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-6.1	-0.32	3.01e-9	Carotid intima media thickness;
CRC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.54	6.64	0.34	1.28e-10	Morning vs. evening chronotype;
CRC	trans	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg06791473	chr12:49259579	RND1	0.61	6.03	0.32	4.5e-9	Blood protein levels;
CRC	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg09659197	chr4:152720779	NA	0.3	5.62	0.3	4.07e-8	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Depression;
CRC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg07153921	chr17:41440717	NA	0.38	5.77	0.3	1.84e-8	Menopause (age at onset);
CRC	trans	rs7800418	0.723	rs1029558	chr7:26588391	C/T	cg14387656	chr2:233470847	EFHD1	-0.46	-6.32	-0.33	8.33e-10	Cognitive function;
CRC	cis	rs972578	0.715	rs5758969	chr22:43228969	A/C	cg01576275	chr22:43409880	NA	-0.35	-5.65	-0.3	3.42e-8	Mean platelet volume;
CRC	cis	rs8014671	0.532	rs12893988	chr14:70922142	C/A	cg25576086	chr14:70833871	SYNJ2BP	-0.35	-5.81	-0.3	1.51e-8	Prostate cancer;
CRC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg21970626	chr13:21893289	NA	0.43	5.68	0.3	2.9e-8	White matter hyperintensity burden;
CRC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.79	10.86	0.51	1.11e-23	Cognitive function;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.3	-0.37	2.19e-12	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.11	0.52	1.42e-24	Prudent dietary pattern;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg15786705	chr6:28176104	NA	0.47	6.86	0.35	3.43e-11	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26605996	chr7:102389191	FAM185A	0.41	6.81	0.35	4.56e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.7	-11.09	-0.52	1.71e-24	Prudent dietary pattern;
CRC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.02	-0.55	7.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2979489	0.891	rs17552243	chr8:30362627	T/C	cg26383811	chr8:30366931	RBPMS	-0.7	-10.1	-0.49	4.69e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-10.56	-0.5	1.21e-22	Cognitive function;
CRC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.43	7.45	0.38	8.2e-13	Childhood ear infection;
CRC	cis	rs1322512	1.000	rs2800626	chr6:153006340	T/A	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.18e-9	Tonometry;
CRC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg03013999	chr17:37608204	MED1	0.47	7.31	0.37	2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.66	7.76	0.39	1.06e-13	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.73	9.69	0.47	1.05e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs780094	0.500	rs13022873	chr2:27815510	A/C	cg27432699	chr2:27873401	GPN1	0.49	6.35	0.33	7.06e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.57	8.24	0.41	4.16e-15	Breast cancer;
CRC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.53	6.62	0.34	1.49e-10	Methadone dose in opioid dependence;
CRC	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.6	10.84	0.51	1.25e-23	Blood metabolite ratios;
CRC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg27233566	chr3:49894142	TRAIP	0.38	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg20645649	chr9:127624485	RPL35	-0.52	-6.35	-0.33	7.19e-10	Diisocyanate-induced asthma;
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg11519256	chr10:5708881	ASB13	0.51	7.64	0.39	2.34e-13	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22403971	chr6:119671423	MAN1A1	0.4	6.17	0.32	2.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.69	9.65	0.47	1.46e-19	Alzheimer's disease;
CRC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.61	-0.43	3.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03969138	chr6:7390163	RIOK1;CAGE1	0.49	6.3	0.33	9.81e-10	Thyroid stimulating hormone;
CRC	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.5	-9.18	-0.45	5.05e-18	Neuroticism;
CRC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.76	-12.48	-0.57	1.56e-29	Height;
CRC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.62	9.3	0.46	1.99e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg08071915	chr8:12219732	FAM66A	0.35	6.47	0.34	3.45e-10	Retinal vascular caliber;
CRC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.59	0.43	3.66e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-7.03	-0.36	1.21e-11	Electroencephalogram traits;
CRC	cis	rs501916	0.634	rs61333299	chr15:48066806	G/A	cg16110827	chr15:48056943	SEMA6D	-0.44	-6.43	-0.33	4.58e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.52e-15	Height;
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg00255919	chr5:131827918	IRF1	-0.35	-5.95	-0.31	6.84e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.86	-0.44	5.21e-17	Alcohol dependence;
CRC	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg13332499	chr17:408570	NA	0.38	8.53	0.43	5.38e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.84	-16.84	-0.68	2.56e-46	Post bronchodilator FEV1;
CRC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.62	-7.71	-0.39	1.5e-13	Schizophrenia;
CRC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg17401720	chr7:158221031	PTPRN2	0.47	7.76	0.39	1.09e-13	Obesity-related traits;
CRC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg12751644	chr20:60527061	NA	-0.34	-5.7	-0.3	2.62e-8	Body mass index;
CRC	cis	rs7259376	0.846	rs4024624	chr19:22568264	C/T	cg02657401	chr19:22469223	NA	-0.32	-7.06	-0.36	1.02e-11	Menopause (age at onset);
CRC	cis	rs243505	0.660	rs3807450	chr7:148522269	C/A	cg09806900	chr7:148480153	CUL1	0.53	6.69	0.35	9.4e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.52	0.43	5.78e-16	Menopause (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27660920	chr20:37554817	FAM83D	-0.43	-6.46	-0.34	3.69e-10	Myopia (pathological);
CRC	cis	rs447	0.806	rs12707615	chr7:83745349	T/C	cg22846510	chr7:83753280	SEMA3A	-0.41	-5.7	-0.3	2.65e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.66	-0.3	3.27e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs66569888	0.633	rs11124085	chr2:106758629	A/G	cg16099169	chr2:106886729	NA	-0.4	-6.04	-0.32	4.25e-9	Facial morphology (factor 23);
CRC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.19	0.41	5.89e-15	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00050312	chr17:64299065	PRKCA	0.48	6.85	0.35	3.66e-11	Response to antipsychotic treatment;
CRC	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-1.0	-10.74	-0.51	2.83e-23	Post bronchodilator FEV1;
CRC	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.93	10.45	0.5	2.97e-22	Iron status biomarkers;
CRC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	7.23	0.37	3.47e-12	Motion sickness;
CRC	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.6	6.6	0.34	1.68e-10	Opioid sensitivity;
CRC	trans	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.89	-0.4	4.47e-14	Diabetic kidney disease;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.43	9.02	0.45	1.59e-17	Renal cell carcinoma;
CRC	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.47	6.79	0.35	5.13e-11	Coronary heart disease;
CRC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	8.4	0.42	1.37e-15	Cognitive test performance;
CRC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.69	-12.2	-0.56	1.74e-28	Brugada syndrome;
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.52	6.58	0.34	1.8e-10	Exhaled nitric oxide output;
CRC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.68	0.3	3.04e-8	Protein C levels;
CRC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.6	8.15	0.41	7.76e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.58	9.81	0.48	4.38e-20	Menopause (age at onset);
CRC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg23136738	chr11:925521	AP2A2	0.47	7.57	0.39	3.69e-13	Alzheimer's disease (late onset);
CRC	cis	rs6694672	0.614	rs1556763	chr1:197152149	A/C	cg13682187	chr1:196946512	CFHR5	0.44	7.09	0.36	8.2e-12	Asthma;
CRC	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg14092571	chr14:90743983	NA	0.38	5.91	0.31	8.37e-9	Mortality in heart failure;
CRC	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.66	-9.8	-0.48	4.53e-20	Acne (severe);
CRC	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.4	6.09	0.32	3.15e-9	Red blood cell count;
CRC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.54	7.97	0.4	2.68e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg16060761	chr17:80687452	NA	-0.48	-6.26	-0.33	1.18e-9	Glycated hemoglobin levels;
CRC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.66	13.39	0.59	6.24e-33	Schizophrenia;
CRC	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.91	-0.36	2.49e-11	Metabolite levels;
CRC	cis	rs2160860	0.965	rs10085935	chr8:39806267	C/T	cg11363097	chr8:39792086	IDO2	-0.39	-6.51	-0.34	2.75e-10	Blood metabolite levels;
CRC	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-10.77	-0.51	2.35e-23	Exhaled nitric oxide output;
CRC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.54	-8.79	-0.44	8.63e-17	Coronary artery disease;
CRC	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.77	13.09	0.59	8.25e-32	Bipolar disorder;
CRC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.68	-7.99	-0.4	2.33e-14	Vitiligo;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg04025307	chr7:1156635	C7orf50	0.64	6.76	0.35	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-7.85	-0.4	6e-14	Monocyte count;
CRC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.06	0.64	2.3e-39	Primary sclerosing cholangitis;
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg04969067	chr8:143858791	LYNX1	0.58	10.06	0.48	6.39e-21	Urinary tract infection frequency;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg10729496	chr3:10149963	C3orf24	0.49	6.78	0.35	5.57e-11	Alzheimer's disease;
CRC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	12.12	0.56	3.32e-28	Monocyte percentage of white cells;
CRC	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.52	5.97	0.31	6.09e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CRC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.61	8.96	0.44	2.45e-17	Subjective well-being;
CRC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.36	-5.89	-0.31	9.72e-9	Granulocyte percentage of myeloid white cells;
CRC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.9	-0.72	1.77e-54	Height;
CRC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.9	0.31	8.91e-9	Tonsillectomy;
CRC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-8.32	-0.42	2.37e-15	Coronary artery disease;
CRC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.31	-6.05	-0.32	4.03e-9	Schizophrenia;
CRC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.33	0.46	1.58e-18	Parkinson's disease;
CRC	cis	rs427941	0.632	rs201471	chr7:101744145	T/G	cg06246474	chr7:101738831	CUX1	0.43	6.68	0.35	1.01e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.57	-10.06	-0.48	6.29e-21	Asthma;
CRC	trans	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg09045935	chr12:6379348	NA	1.06	8.4	0.42	1.36e-15	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg23247704	chr1:116518985	SLC22A15	-0.73	-6.21	-0.32	1.57e-9	Cognitive function;
CRC	cis	rs728616	0.867	rs7906286	chr10:81834035	T/C	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.93	-0.31	7.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg05585544	chr11:47624801	NA	-0.41	-6.35	-0.33	7.09e-10	Mean corpuscular hemoglobin;
CRC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.48	-7.69	-0.39	1.71e-13	Coronary artery disease;
CRC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.39	-5.71	-0.3	2.53e-8	Neurofibrillary tangles;
CRC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg03934865	chr2:198174659	NA	-0.42	-6.95	-0.36	1.93e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	6.71	0.35	8.52e-11	Lymphocyte counts;
CRC	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-0.65	-5.89	-0.31	9.49e-9	Pediatric areal bone mineral density (radius);
CRC	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-5.97	-0.31	6.13e-9	Coronary artery disease;
CRC	cis	rs909002	0.745	rs4949458	chr1:32142332	G/T	cg13919466	chr1:32135498	COL16A1	0.29	5.71	0.3	2.55e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.58	8.43	0.42	1.11e-15	Lung cancer;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg15786705	chr6:28176104	NA	0.77	9.73	0.47	8e-20	Depression;
CRC	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.67	10.67	0.51	4.99e-23	Tourette's syndrome or obsessive-compulsive disorder;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03930837	chr17:41132080	RUNDC1;AARSD1	-0.41	-6.1	-0.32	3.03e-9	HDL cholesterol;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25199208	chr2:109402912	CCDC138	-0.49	-6.2	-0.32	1.71e-9	Diisocyanate-induced asthma;
CRC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg13628971	chr7:2884303	GNA12	0.4	6.27	0.33	1.13e-9	Height;
CRC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg14828511	chr1:107599125	PRMT6	0.48	6.53	0.34	2.49e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-6.01	-0.31	4.85e-9	Lung cancer;
CRC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.44	-8.0	-0.4	2.1e-14	Reticulocyte fraction of red cells;
CRC	trans	rs6015450	1.000	rs75575888	chr20:57755060	A/G	cg22122715	chr13:96086023	CLDN10	-0.57	-6.2	-0.32	1.69e-9	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs11212617	1.000	rs7108522	chr11:108281004	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.66	0.34	1.13e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.2	0.53	6.98e-25	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06807126	chr1:46016862	AKR1A1	0.54	7.95	0.4	3.03e-14	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.59	-0.34	1.78e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.55	0.54	3.77e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg03030879	chr14:75389066	RPS6KL1	0.39	5.94	0.31	7.44e-9	Coronary artery disease;
CRC	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg10761708	chr20:43804764	PI3	0.47	5.62	0.3	4.05e-8	Blood protein levels;
CRC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.61	-8.89	-0.44	4.06e-17	Schizophrenia;
CRC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.59	-6.16	-0.32	2.17e-9	White matter hyperintensity burden;
CRC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.89	-16.29	-0.67	3.52e-44	Coronary artery disease;
CRC	cis	rs7705042	0.865	rs12653866	chr5:141489921	C/T	cg07392085	chr5:141489673	NDFIP1	0.46	7.25	0.37	2.98e-12	Asthma;
CRC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.6	8.5	0.42	6.55e-16	Longevity;
CRC	cis	rs3026101	0.671	rs56300366	chr17:5297839	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	6.62	0.34	1.43e-10	Body mass index;
CRC	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	0.92	13.95	0.61	4.4e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	9.36	0.46	1.34e-18	Blood protein levels;
CRC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.76	-0.35	6.31e-11	Platelet distribution width;
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.93	-0.36	2.2e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg12756093	chr1:115239321	AMPD1	0.54	7.28	0.37	2.54e-12	Autism;
CRC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.45	7.73	0.39	1.35e-13	Major depressive disorder;
CRC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	8.51	0.42	6.09e-16	Lymphocyte percentage of white cells;
CRC	cis	rs354033	0.837	rs4727075	chr7:149187738	G/T	cg24335155	chr7:149193227	ZNF746	0.42	6.51	0.34	2.84e-10	Multiple sclerosis;
CRC	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11446398	chr5:77624930	NA	0.46	6.26	0.33	1.21e-9	Triglycerides;
CRC	cis	rs4964805	0.802	rs11111778	chr12:104185431	G/A	cg02344784	chr12:104178138	NT5DC3	0.53	7.76	0.39	1.05e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg21466736	chr12:48725269	NA	-0.52	-7.98	-0.4	2.42e-14	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs73206853	0.841	rs57821814	chr12:110829254	A/C	cg12870014	chr12:110450643	ANKRD13A	0.82	8.81	0.44	7.43e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.16	-0.32	2.16e-9	Menopause (age at onset);
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.07	0.32	3.47e-9	Bipolar disorder;
CRC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.63	-9.62	-0.47	1.78e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.46	-6.51	-0.34	2.75e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.39	-6.07	-0.32	3.46e-9	Crohn's disease;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg15786705	chr6:28176104	NA	0.74	9.35	0.46	1.41e-18	Depression;
CRC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg11212589	chr17:38028394	ZPBP2	0.47	8.77	0.44	9.55e-17	Self-reported allergy;
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.46	6.9	0.36	2.72e-11	Menarche (age at onset);
CRC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.04	16.88	0.68	1.73e-46	IgG glycosylation;
CRC	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-0.67	-9.56	-0.47	2.93e-19	Type 2 diabetes;
CRC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.33	0.59	1.07e-32	Menarche (age at onset);
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg08200770	chr17:80723486	TBCD	-0.5	-7.57	-0.39	3.71e-13	Glycated hemoglobin levels;
CRC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.6	0.34	1.64e-10	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-8.48	-0.42	7.49e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs11627756	0.957	rs6575929	chr14:103149447	T/G	cg12046867	chr14:103022105	NA	0.41	5.83	0.31	1.29e-8	Mean platelet volume;
CRC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.58	-9.37	-0.46	1.21e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.98	-0.31	5.82e-9	Blood pressure (smoking interaction);
CRC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14895029	chr7:2775587	GNA12	-0.45	-6.41	-0.33	4.93e-10	Height;
CRC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg03013999	chr17:37608204	MED1	0.45	6.9	0.36	2.62e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.44	6.71	0.35	8.3e-11	Red blood cell count;
CRC	cis	rs12476592	0.602	rs1374308	chr2:63895436	G/C	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.31	-0.42	2.46e-15	Bipolar disorder;
CRC	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.55	-7.69	-0.39	1.76e-13	Adiposity;
CRC	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg00801512	chr17:28996047	NA	0.44	5.97	0.31	6.03e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.62	-10.15	-0.49	3.01e-21	Breast cancer;
CRC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg16447950	chr5:562315	NA	-0.82	-11.74	-0.54	8.27e-27	Lung disease severity in cystic fibrosis;
CRC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.73	11.26	0.53	4.14e-25	Tonsillectomy;
CRC	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg14003231	chr6:33640908	ITPR3	-0.4	-6.46	-0.34	3.83e-10	Plateletcrit;
CRC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	1.07	10.43	0.5	3.41e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00306426	chr1:70687415	SFRS11	0.42	6.44	0.33	4.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.9	-14.96	-0.64	5.82e-39	Migraine;
CRC	trans	rs2055729	0.677	rs6601389	chr8:9740636	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.7	0.35	8.84e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs11229555	0.645	rs12285111	chr11:58208385	T/G	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.58	6.47	0.34	3.47e-10	Bipolar disorder;
CRC	cis	rs4234798	1.000	rs4234797	chr4:7219907	C/T	cg18431297	chr4:7219810	SORCS2	0.62	10.8	0.51	1.81e-23	Insulin-like growth factors;
CRC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.82e-9	Aortic root size;
CRC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.71	0.57	2.17e-30	Platelet count;
CRC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg14671364	chr1:107599128	PRMT6	-0.61	-8.19	-0.41	5.85e-15	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	5.95	0.31	6.93e-9	Mean platelet volume;
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.15	0.61	8.13e-36	Alzheimer's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15527401	chr19:59071099	UBE2M;LOC100131691	-0.5	-6.14	-0.32	2.33e-9	Diisocyanate-induced asthma;
CRC	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.91	-0.36	2.58e-11	Putamen volume;
CRC	trans	rs800082	1.000	rs800084	chr3:144340494	C/T	cg24215973	chr2:240111563	HDAC4	0.52	7.07	0.36	9.59e-12	Smoking behavior;
CRC	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg18232548	chr7:50535776	DDC	0.45	5.84	0.31	1.26e-8	Malaria;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01656770	chr3:38496051	LOC100128640;ACVR2B	0.45	6.17	0.32	2.03e-9	Response to antipsychotic treatment;
CRC	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.09	0.32	3.15e-9	Bulimia nervosa;
CRC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.49	8.47	0.42	8.25e-16	Primary biliary cholangitis;
CRC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.22	0.37	3.55e-12	Calcium levels;
CRC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04731861	chr2:219085781	ARPC2	0.33	6.94	0.36	2.14e-11	Colorectal cancer;
CRC	cis	rs10046574	0.561	rs9656457	chr7:135202254	T/A	cg27474649	chr7:135195673	CNOT4	0.67	6.29	0.33	9.88e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.68	10.61	0.5	8.14e-23	Corneal astigmatism;
CRC	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg04110750	chr16:69646130	NFAT5	-0.56	-7.6	-0.39	3.05e-13	IgE levels;
CRC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.3	0.33	9.81e-10	Rheumatoid arthritis;
CRC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg12311346	chr5:56204834	C5orf35	-0.47	-7.03	-0.36	1.17e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.1	0.45	8.61e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.45	-6.78	-0.35	5.73e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.42	-7.48	-0.38	6.69e-13	Blood protein levels;
CRC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg24675056	chr1:15929824	NA	0.49	6.65	0.34	1.23e-10	Systolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25045127	chr20:23402051	NAPB	0.43	6.02	0.31	4.69e-9	Anxiety disorder;
CRC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.3	5.73	0.3	2.26e-8	Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-7.26	-0.37	2.87e-12	Aortic root size;
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg06096015	chr1:231504339	EGLN1	-0.43	-6.42	-0.33	4.83e-10	Hemoglobin concentration;
CRC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.35	-0.53	2.02e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.68	-8.56	-0.43	4.29e-16	Menarche (age at onset);
CRC	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg03315344	chr16:75512273	CHST6	0.49	5.85	0.31	1.16e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.71	-9.85	-0.48	3.17e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.46	8.1	0.41	1.12e-14	Information processing speed;
CRC	cis	rs6662572	0.737	rs4660893	chr1:46327532	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.13	0.32	2.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.71	0.35	8.74e-11	Lymphocyte counts;
CRC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.57	-9.19	-0.45	4.51e-18	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.17	0.32	1.95e-9	Diabetic retinopathy;
CRC	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.65e-9	Life satisfaction;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg10596483	chr8:143751796	JRK	-0.45	-6.37	-0.33	6.4e-10	Urinary tract infection frequency;
CRC	cis	rs1223397	0.938	rs35549743	chr6:13294354	C/T	cg20827128	chr6:13274284	PHACTR1	0.56	6.5	0.34	3.03e-10	Blood pressure;
CRC	trans	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg21302420	chr1:112162376	RAP1A	0.65	6.17	0.32	1.98e-9	Skin colour saturation;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg15786705	chr6:28176104	NA	0.78	9.7	0.47	1.01e-19	Depression;
CRC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg03037974	chr15:76606532	NA	0.81	15.52	0.65	3.8e-41	Blood metabolite levels;
CRC	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.65	10.02	0.48	8.28e-21	Corneal astigmatism;
CRC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.41	-5.69	-0.3	2.74e-8	Coronary artery disease;
CRC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-1.07	-9.67	-0.47	1.21e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg10494257	chr1:16342123	HSPB7	0.45	6.0	0.31	5.3e-9	Dilated cardiomyopathy;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg25164649	chr6:28176230	NA	0.58	8.3	0.42	2.7e-15	Parkinson's disease;
CRC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.54	-9.21	-0.45	3.95e-18	Systemic lupus erythematosus;
CRC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.66	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.45	6.57	0.34	1.93e-10	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25809215	chr3:16306823	OXNAD1;DPH3	0.49	6.27	0.33	1.12e-9	Thyroid stimulating hormone;
CRC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.44	-8.05	-0.41	1.5e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg23815491	chr16:72088622	HP	0.64	8.12	0.41	9.28e-15	Blood protein levels;
CRC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.78	9.46	0.46	6.15e-19	Body mass index;
CRC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg23625390	chr15:77176239	SCAPER	0.48	7.04	0.36	1.14e-11	Blood metabolite levels;
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.2e-9	Bipolar disorder;
CRC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.4	-0.38	1.17e-12	Self-reported allergy;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg02683197	chr6:28174875	NA	0.64	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.52	7.12	0.37	6.7e-12	Obesity-related traits;
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-11.43	-0.53	1.08e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10450586	0.932	rs10767626	chr11:27306545	G/A	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.98	8.33	0.42	2.16e-15	Cerebrospinal fluid biomarker levels;
CRC	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg25173405	chr17:45401733	C17orf57	-0.47	-7.23	-0.37	3.31e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.76	0.68	4.95e-46	Chronic sinus infection;
CRC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-11.2	-0.53	6.92e-25	Colorectal cancer;
CRC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.55	6.7	0.35	9.08e-11	Vitiligo;
CRC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.1	0.59	7.65e-32	Chronic sinus infection;
CRC	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.22	32.61	0.87	4.43e-105	Colorectal cancer;
CRC	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.11	-0.56	3.76e-28	Coffee consumption (cups per day);
CRC	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg03929089	chr4:120376271	NA	-0.64	-7.11	-0.36	7.43e-12	Axial length;
CRC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.17	-13.25	-0.59	2.03e-32	Diabetic kidney disease;
CRC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.82	-9.92	-0.48	1.82e-20	Initial pursuit acceleration;
CRC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.59	-8.3	-0.42	2.72e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.81	-0.31	1.45e-8	Neuroticism;
CRC	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs863345	0.604	rs975118	chr1:158511445	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.22e-13	QT interval;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18732869	chr19:6739680	TRIP10	0.37	6.09	0.32	3.24e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg04025307	chr7:1156635	C7orf50	0.68	7.22	0.37	3.65e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12059507	chr11:62606662	WDR74	0.39	6.22	0.32	1.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg25036284	chr2:26402008	FAM59B	0.45	5.93	0.31	7.55e-9	Gut microbiome composition (summer);
CRC	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg24463073	chr6:118973353	C6orf204	0.48	6.22	0.32	1.49e-9	Diastolic blood pressure;
CRC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.68	8.22	0.41	4.71e-15	Menarche (age at onset);
CRC	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.52	7.54	0.38	4.67e-13	Corneal astigmatism;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg17178900	chr1:205818956	PM20D1	-0.39	-5.69	-0.3	2.85e-8	Parkinson's disease;
CRC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.41	0.53	1.28e-25	Bone mineral density;
CRC	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg18232548	chr7:50535776	DDC	-0.46	-6.72	-0.35	8.19e-11	Systemic sclerosis;
CRC	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.71	0.3	2.58e-8	Heart rate;
CRC	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.92	11.59	0.54	2.7e-26	Exhaled nitric oxide levels;
CRC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-6.42	-0.33	4.69e-10	Total body bone mineral density;
CRC	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.81	-0.3	1.51e-8	Arsenic metabolism;
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.69	9.38	0.46	1.12e-18	Alzheimer's disease;
CRC	cis	rs713587	0.520	rs1530016	chr2:25305756	C/T	cg22495460	chr2:25135724	ADCY3	0.43	6.45	0.34	3.96e-10	Body mass index in non-asthmatics;
CRC	cis	rs28375034	1	rs28375034	chr7:132886052	G/A	cg10665199	chr7:133106180	EXOC4	0.56	5.83	0.31	1.3e-8	Schizophrenia;
CRC	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg02135003	chr7:105160482	PUS7	-0.52	-8.18	-0.41	6.39e-15	Bipolar disorder (body mass index interaction);
CRC	trans	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg26043149	chr18:55253948	FECH	0.48	7.06	0.36	1.01e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.98	0.36	1.63e-11	Diisocyanate-induced asthma;
CRC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.91	10.51	0.5	1.81e-22	Eosinophil percentage of granulocytes;
CRC	cis	rs394563	0.601	rs376269	chr6:149795154	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.45	-7.16	-0.37	5.41e-12	Dupuytren's disease;
CRC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg11843238	chr5:131593191	PDLIM4	0.43	7.01	0.36	1.4e-11	Blood metabolite levels;
CRC	cis	rs9491140	0.539	rs911959	chr6:124688755	A/G	cg05308643	chr6:124982296	NKAIN2	0.51	7.3	0.37	2.17e-12	Neuroticism;
CRC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.72	-0.3	2.33e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs394563	0.625	rs384306	chr6:149796140	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.23	-0.33	1.39e-9	Dupuytren's disease;
CRC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.39	5.87	0.31	1.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.16	-16.31	-0.67	2.94e-44	Breast cancer;
CRC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.4	6.43	0.33	4.52e-10	Testicular germ cell tumor;
CRC	cis	rs6840360	0.582	rs1372976	chr4:152451453	G/A	cg09659197	chr4:152720779	NA	0.33	6.47	0.34	3.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.75	-11.83	-0.55	3.74e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg14186256	chr22:23484241	RTDR1	0.46	5.87	0.31	1.06e-8	Serum parathyroid hormone levels;
CRC	cis	rs6988985	0.728	rs1134096	chr8:143954223	C/A	cg10324643	chr8:143916377	GML	0.35	5.84	0.31	1.25e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg15845792	chr6:28175446	NA	0.8	11.59	0.54	2.82e-26	Cardiac Troponin-T levels;
CRC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.48	9.47	0.46	5.67e-19	Ulcerative colitis;
CRC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.39	0.5	4.59e-22	Systolic blood pressure;
CRC	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.69	9.84	0.48	3.33e-20	Body mass index;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.75	12.76	0.58	1.46e-30	Body mass index;
CRC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.71e-20	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01773951	chr1:247094386	AHCTF1	0.45	6.24	0.33	1.36e-9	Response to antipsychotic treatment;
CRC	cis	rs3018066	0.867	rs4508971	chr4:107037815	C/T	cg01869342	chr4:106983673	TBCK	0.36	5.61	0.3	4.32e-8	Cancer;
CRC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg14883916	chr11:6947541	ZNF215	0.6	6.41	0.33	4.9e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg19223190	chr17:80058835	NA	-0.39	-6.06	-0.32	3.63e-9	Life satisfaction;
CRC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.71	-0.43	1.52e-16	Total cholesterol levels;
CRC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg15534755	chr11:117069859	TAGLN	0.33	6.09	0.32	3.09e-9	Blood protein levels;
CRC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.44	-0.42	1.03e-15	Hemoglobin concentration;
CRC	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg23740940	chr11:68924746	NA	0.44	5.77	0.3	1.82e-8	Blond vs. brown hair color;
CRC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs4700695	1.000	rs12518359	chr5:65397909	T/C	cg21114390	chr5:65439923	SFRS12	-0.49	-6.35	-0.33	7.17e-10	Facial morphology (factor 19);
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg10217327	chr6:118973057	C6orf204	0.51	5.75	0.3	2e-8	Diastolic blood pressure;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg01097406	chr16:89675127	NA	-0.38	-7.23	-0.37	3.43e-12	Hemoglobin concentration;
CRC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.94	10.72	0.51	3.35e-23	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21100532	chr2:192015514	STAT4	0.39	6.14	0.32	2.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.37	6.14	0.32	2.38e-9	Cardiovascular disease risk factors;
CRC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.25	-0.33	1.26e-9	Menopause (age at onset);
CRC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.39	-7.38	-0.38	1.3e-12	Iron status biomarkers;
CRC	cis	rs4731207	0.698	rs7794631	chr7:124551925	T/C	cg23710748	chr7:124431027	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Cutaneous malignant melanoma;
CRC	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.59	-8.97	-0.44	2.32e-17	Dementia with Lewy bodies;
CRC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg23711669	chr6:146136114	FBXO30	0.6	8.09	0.41	1.17e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg15147215	chr3:52552868	STAB1	-0.49	-6.49	-0.34	3.11e-10	Schizophrenia;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg24562669	chr7:97807699	LMTK2	0.42	7.02	0.36	1.3e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.48	7.72	0.39	1.38e-13	Endometrial cancer;
CRC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.59	-9.04	-0.45	1.41e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25749966	chr3:52443976	BAP1;PHF7	-0.39	-6.1	-0.32	3.03e-9	Myopia (pathological);
CRC	trans	rs800082	1.000	rs1405599	chr3:144328759	T/C	cg24215973	chr2:240111563	HDAC4	-0.54	-7.69	-0.39	1.75e-13	Smoking behavior;
CRC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	7.02	0.36	1.24e-11	Coronary artery disease;
CRC	trans	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.52	-0.34	2.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.95	-0.31	7e-9	Total body bone mineral density;
CRC	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	0.56	7.74	0.39	1.23e-13	Pulmonary function decline;
CRC	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.48e-12	Eye color traits;
CRC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg23109721	chr2:106886537	NA	0.49	6.83	0.35	4.18e-11	Facial morphology (factor 23);
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.51	-7.38	-0.38	1.33e-12	Caudate activity during reward;
CRC	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.56	8.8	0.44	7.93e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg27432699	chr2:27873401	GPN1	-0.55	-8.41	-0.42	1.31e-15	Total body bone mineral density;
CRC	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg08632701	chr21:37451849	NA	-0.42	-6.6	-0.34	1.68e-10	Mitral valve prolapse;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08348959	chr3:10290087	TATDN2	0.43	6.0	0.31	5.2e-9	Anxiety disorder;
CRC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.84	0.31	1.26e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12760731	0.720	rs12048459	chr1:178412702	T/C	cg00404053	chr1:178313656	RASAL2	0.95	9.76	0.47	6.35e-20	Obesity-related traits;
CRC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg09655341	chr17:79618100	PDE6G	0.36	6.23	0.32	1.46e-9	Eye color traits;
CRC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.01	10.65	0.51	5.86e-23	Diabetic retinopathy;
CRC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg09127314	chr1:152161683	NA	-0.5	-5.85	-0.31	1.21e-8	Atopic dermatitis;
CRC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg23758597	chr6:163146217	PARK2	-0.56	-6.32	-0.33	8.47e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs55788414	0.932	rs8059559	chr16:81185684	G/A	cg06400318	chr16:81190750	PKD1L2	0.55	6.75	0.35	6.88e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.36	-6.03	-0.32	4.38e-9	Childhood ear infection;
CRC	cis	rs12612619	0.732	rs2289360	chr2:27302165	T/C	cg00617064	chr2:27272375	NA	-0.38	-6.18	-0.32	1.91e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs78077440	0.932	rs78162562	chr5:40334428	A/C	cg09067459	chr5:40385259	NA	-0.53	-5.83	-0.31	1.32e-8	Multiple sclerosis;
CRC	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.68	-0.43	1.92e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03919779	chr17:16284127	UBB	0.44	7.05	0.36	1.03e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg20119798	chr7:94954144	PON1	-0.44	-5.61	-0.3	4.36e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	10.65	0.51	5.82e-23	Monocyte percentage of white cells;
CRC	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg27068330	chr11:65405492	SIPA1	-0.43	-5.91	-0.31	8.45e-9	Systemic lupus erythematosus;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg23123621	chr4:1343375	KIAA1530	0.36	6.19	0.32	1.82e-9	Longevity;
CRC	cis	rs1124376	1.000	rs17006623	chr3:20161043	G/T	cg05072819	chr3:20081367	KAT2B	0.51	6.15	0.32	2.22e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-9.11	-0.45	8.13e-18	Schizophrenia;
CRC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	9.54	0.47	3.31e-19	Lymphocyte counts;
CRC	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg21601837	chr3:125900065	ALDH1L1	-0.35	-5.62	-0.3	4.16e-8	Metabolite levels;
CRC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.69	-8.23	-0.41	4.32e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg03623178	chr6:28175578	NA	0.78	6.65	0.34	1.22e-10	Depression;
CRC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.83	0.44	6.53e-17	Neuroticism;
CRC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.33	-0.37	1.8e-12	Height;
CRC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2252790	1.000	rs12213442	chr6:116636907	G/A	cg18764771	chr6:116381957	FRK	0.21	5.76	0.3	1.94e-8	Fast beta electroencephalogram;
CRC	cis	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg05299278	chr17:33885742	SLFN14	-0.42	-6.31	-0.33	9.17e-10	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.37	-6.82	-0.35	4.25e-11	Colorectal cancer;
CRC	cis	rs3736485	0.966	rs4775958	chr15:51891562	G/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.37	-0.33	6.35e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg24324837	chr19:49891574	CCDC155	0.53	6.92	0.36	2.41e-11	Multiple sclerosis;
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg10729496	chr3:10149963	C3orf24	0.5	6.81	0.35	4.67e-11	Alzheimer's disease;
CRC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg00343986	chr7:65444356	GUSB	-0.48	-7.1	-0.36	7.51e-12	Aortic root size;
CRC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg24463073	chr6:118973353	C6orf204	0.55	7.27	0.37	2.59e-12	Diastolic blood pressure;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg26587870	chr6:27730563	NA	-0.56	-6.46	-0.34	3.67e-10	Lung cancer in ever smokers;
CRC	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.38	0.33	6e-10	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03535933	chr8:67974296	COPS5	0.45	6.67	0.35	1.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.69	-0.43	1.71e-16	Electroencephalogram traits;
CRC	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	15.89	0.66	1.42e-42	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs59104589	0.617	rs57696929	chr2:242380382	T/C	cg19488206	chr2:242435732	STK25	0.46	6.8	0.35	4.97e-11	Fibrinogen levels;
CRC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.44	-9.71	-0.47	9.36e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs4731207	0.596	rs6948283	chr7:124679523	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.52	-8.4	-0.42	1.4e-15	Testicular germ cell tumor;
CRC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.68	-10.64	-0.51	6.3e-23	Huntington's disease progression;
CRC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	0.91	11.17	0.52	8.7e-25	Hip circumference adjusted for BMI;
CRC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.85	-14.32	-0.62	1.68e-36	Ulcerative colitis;
CRC	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg04111102	chr1:66153794	NA	0.32	5.66	0.3	3.22e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.61	-0.47	1.96e-19	Morning vs. evening chronotype;
CRC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.33	6.61	0.34	1.54e-10	Lung cancer;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg03757145	chr4:76555832	CDKL2	-0.68	-6.04	-0.32	4.06e-9	Cognitive function;
CRC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg25251562	chr2:3704773	ALLC	-0.44	-6.37	-0.33	6.33e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.6	-0.43	3.28e-16	Alcohol dependence;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg18301423	chr5:131593218	PDLIM4	0.3	5.75	0.3	2e-8	Blood metabolite levels;
CRC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg13880726	chr7:1868755	MAD1L1	-0.46	-5.68	-0.3	2.95e-8	Bipolar disorder;
CRC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.05	0.55	6.15e-28	Chronic sinus infection;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.47	-0.42	8.56e-16	Bone mineral density;
CRC	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.73	0.63	4.72e-38	Lymphocyte percentage of white cells;
CRC	cis	rs12692738	0.526	rs355844	chr2:165623322	T/G	cg03182029	chr2:165697222	COBLL1	0.51	6.09	0.32	3.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.36	5.95	0.31	6.87e-9	Cardiovascular disease risk factors;
CRC	cis	rs7680126	0.632	rs11731464	chr4:10148376	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.0	-0.31	5.24e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.47	-5.86	-0.31	1.11e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	6.65	0.34	1.26e-10	Mean platelet volume;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12172441	chr6:28176163	NA	0.6	7.21	0.37	3.76e-12	Depression;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.66	7.62	0.39	2.69e-13	Body mass index;
CRC	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg23018236	chr17:30244563	NA	-0.58	-5.94	-0.31	7.07e-9	Height;
CRC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.17	-0.69	1.23e-47	Body mass index;
CRC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg14122633	chr5:456516	EXOC3	-0.48	-5.62	-0.3	4.15e-8	Fat distribution (HIV);
CRC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	8.06	0.41	1.41e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.9	-0.36	2.65e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.62	9.28	0.46	2.32e-18	Obesity-related traits;
CRC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.67	-0.3	3.15e-8	Neuroticism;
CRC	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11446398	chr5:77624930	NA	0.45	6.43	0.33	4.41e-10	Triglycerides;
CRC	cis	rs2882667	0.898	rs6882526	chr5:138382368	A/G	cg09476006	chr5:138032270	NA	0.44	7.4	0.38	1.12e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.52	-8.32	-0.42	2.35e-15	Menopause (age at onset);
CRC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.9	-14.68	-0.63	6.9e-38	Headache;
CRC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-7.41	-0.38	1.11e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	3.96e-9	Total body bone mineral density;
CRC	cis	rs4073416	0.542	rs7150094	chr14:65936361	A/G	cg03016385	chr14:66212404	NA	-0.44	-5.97	-0.31	6.12e-9	N-glycan levels;
CRC	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.52	0.43	5.64e-16	Schizophrenia;
CRC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.01	12.62	0.57	4.94e-30	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg00999904	chr2:3704751	ALLC	-0.53	-6.66	-0.34	1.15e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.81	12.04	0.55	6.78e-28	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.88	0.48	2.54e-20	Ileal carcinoids;
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.71	9.52	0.46	3.79e-19	Alzheimer's disease;
CRC	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg01000188	chr9:133769184	QRFP	0.59	8.56	0.43	4.32e-16	Response to amphetamines;
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg21577049	chr2:228736449	WDR69	-0.47	-6.22	-0.32	1.5e-9	Blood pressure;
CRC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg05585544	chr11:47624801	NA	-0.55	-9.79	-0.47	5.02e-20	Subjective well-being;
CRC	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.06	14.68	0.63	7.14e-38	Exhaled nitric oxide output;
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4.12e-17	Bipolar disorder;
CRC	cis	rs11625487	0.609	rs45493395	chr14:77976468	T/C	cg06469542	chr14:77965869	ISM2	-0.47	-5.61	-0.3	4.4e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	13.76	0.6	2.37e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9906695	0.846	rs4795902	chr17:32618701	T/C	cg12698626	chr17:32581466	CCL2	0.48	6.4	0.33	5.32e-10	Monocyte percentage of white cells;
CRC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-11.57	-0.54	3.3e-26	Menopause (age at onset);
CRC	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg01475377	chr6:109611718	NA	-0.35	-6.07	-0.32	3.56e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	trans	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg18335740	chr13:41363409	SLC25A15	-0.47	-7.12	-0.37	6.8e-12	Lewy body disease;
CRC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.44	-5.8	-0.3	1.59e-8	Height;
CRC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.45	-6.22	-0.32	1.5e-9	Calcium levels;
CRC	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.43	-6.17	-0.32	2.04e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs12431939	1.000	rs60593258	chr14:51662280	T/A	cg23942311	chr14:51606299	NA	-0.52	-6.25	-0.33	1.25e-9	Cancer;
CRC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.72	0.63	4.87e-38	Breast cancer;
CRC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg19193384	chr17:30244184	NA	-0.53	-6.73	-0.35	7.6e-11	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.84	-12.98	-0.58	2.2e-31	Blood metabolite levels;
CRC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg13010199	chr12:38710504	ALG10B	0.39	5.83	0.31	1.31e-8	Morning vs. evening chronotype;
CRC	cis	rs12024301	0.557	rs10911408	chr1:183660803	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7605827	0.897	rs11674618	chr2:15593035	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.14e-9	Educational attainment (years of education);
CRC	trans	rs492478	0.892	rs77364866	chr5:3926042	C/T	cg09199442	chr11:28132951	METT5D1	-0.7	-6.18	-0.32	1.95e-9	Cognitive performance;
CRC	cis	rs12476592	0.516	rs6546002	chr2:63593829	A/C	cg10828910	chr2:63850056	LOC388955	0.46	5.61	0.3	4.31e-8	Childhood ear infection;
CRC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.93	-0.48	1.71e-20	Chronic sinus infection;
CRC	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg12315302	chr6:26189340	HIST1H4D	0.96	6.61	0.34	1.58e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.83	0.4	6.6e-14	Breast cancer;
CRC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.67	-0.35	1.09e-10	Blood metabolite levels;
CRC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg13057898	chr1:3703894	LRRC47	0.54	7.11	0.37	7.06e-12	Red cell distribution width;
CRC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.73	13.08	0.58	8.86e-32	Oral cavity cancer;
CRC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.74	0.43	1.18e-16	Morning vs. evening chronotype;
CRC	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.9	-0.31	8.89e-9	Subjective well-being;
CRC	cis	rs1524976	1.000	rs1917531	chr3:65503221	A/G	cg16238336	chr3:65465873	MAGI1	0.45	5.94	0.31	7.44e-9	PR interval;
CRC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.57	-9.43	-0.46	7.8e-19	Total body bone mineral density;
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	1.04	11.25	0.53	4.81e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.76	-12.86	-0.58	6.21e-31	Height;
CRC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.58	-0.47	2.54e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2735413	0.918	rs4309408	chr16:78071507	G/A	cg04733911	chr16:78082701	NA	-0.42	-6.97	-0.36	1.72e-11	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs4684776	0.676	rs2067472	chr3:11299190	G/C	cg00170343	chr3:11313890	ATG7	-0.5	-5.87	-0.31	1.04e-8	Small vessel stroke;
CRC	cis	rs9469578	1.000	rs73743336	chr6:33715391	G/A	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2949837	0.603	rs1542818	chr7:45977656	G/T	cg06713098	chr7:45960367	IGFBP3	0.42	6.71	0.35	8.43e-11	Sitting height ratio;
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.75	8.8	0.44	8.08e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.3	6.24	0.33	1.36e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg11292332	chr7:45801988	SEPT13	0.36	6.24	0.33	1.37e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.4	6.52	0.34	2.6200000000000003e-10	Major depressive disorder;
CRC	cis	rs6546324	0.559	rs4671806	chr2:67777158	C/G	cg15745817	chr2:67799979	NA	-0.53	-8.68	-0.43	1.84e-16	Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11940773	chr11:63606512	MARK2	0.45	6.31	0.33	8.82e-10	Anxiety disorder;
CRC	cis	rs2786111	0.965	rs1764791	chr1:197281954	T/A	cg13682187	chr1:196946512	CFHR5	0.29	5.69	0.3	2.87e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg04545296	chr12:48745243	ZNF641	0.33	5.66	0.3	3.26e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.71e-11	Blood metabolite levels;
CRC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg22561889	chr6:118971681	C6orf204	0.5	6.39	0.33	5.8e-10	Diastolic blood pressure;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.69	-0.35	9.47e-11	Total body bone mineral density;
CRC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg02135003	chr7:105160482	PUS7	-0.95	-11.72	-0.54	9.39e-27	Bipolar disorder (body mass index interaction);
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg06470822	chr6:28175283	NA	-0.52	-7.21	-0.37	3.95e-12	Systemic lupus erythematosus;
CRC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.61	-0.43	2.98e-16	Hemoglobin concentration;
CRC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.44	-7.51	-0.38	5.49e-13	Facial morphology (factor 20);
CRC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11883161	chr10:99894664	C10orf28	0.47	6.45	0.34	3.95e-10	Anxiety disorder;
CRC	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.65	10.5	0.5	2.02e-22	Corneal astigmatism;
CRC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.57	-0.39	3.82e-13	Mean corpuscular volume;
CRC	cis	rs35520189	0.591	rs12105482	chr2:113697235	G/T	cg12858261	chr2:113808755	IL1F8	0.43	5.91	0.31	8.69e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg24201716	chr10:115933917	C10orf118;MIR2110	-0.42	-6.15	-0.32	2.19e-9	Birth weight;Height;
CRC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.56	0.54	3.46e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.42	6.96	0.36	1.83e-11	Lung cancer;
CRC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.24	6.64	0.34	1.28e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs16852403	0.548	rs316269	chr1:178107862	C/G	cg00404053	chr1:178313656	RASAL2	-0.5	-6.65	-0.34	1.22e-10	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10550416	chr2:36776323	CRIM1	0.38	5.98	0.31	5.75e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.67	9.02	0.45	1.59e-17	Breast cancer;
CRC	cis	rs12431939	0.546	rs4424815	chr14:51714360	C/A	cg23942311	chr14:51606299	NA	0.47	6.14	0.32	2.41e-9	Cancer;
CRC	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.51	8.02	0.4	1.82e-14	Height;
CRC	cis	rs1223397	0.651	rs402705	chr6:13296439	C/T	cg07912922	chr6:13274314	PHACTR1	0.36	5.62	0.3	4.18e-8	Blood pressure;
CRC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.43	6.84	0.35	3.95e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-8.95	-0.44	2.73e-17	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.83	11.41	0.53	1.29e-25	Testicular germ cell tumor;
CRC	trans	rs12432203	1.000	rs3935982	chr14:51730252	T/A	cg14592830	chr9:122318704	NA	0.59	6.12	0.32	2.62e-9	Cancer;
CRC	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.52	9.66	0.47	1.36e-19	Alcoholic chronic pancreatitis;
CRC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.57	10.46	0.5	2.76e-22	Coronary artery disease;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg12516270	chr8:143859308	LYNX1	0.42	6.92	0.36	2.42e-11	Urinary tract infection frequency;
CRC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg11070056	chr1:107600091	PRMT6	-0.4	-5.99	-0.31	5.5e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.69	11.95	0.55	1.36e-27	Resting heart rate;
CRC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.86	0.31	1.15e-8	HDL cholesterol;
CRC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg02776659	chr21:47717406	C21orf57	-0.35	-5.73	-0.3	2.33e-8	Testicular germ cell tumor;
CRC	cis	rs6662572	0.703	rs10789482	chr1:46396704	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.76	-0.3	1.98e-8	Blood protein levels;
CRC	cis	rs501916	0.605	rs11070612	chr15:48073174	C/G	cg16110827	chr15:48056943	SEMA6D	-0.46	-6.63	-0.34	1.4e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-8.23	-0.41	4.32e-15	Mean platelet volume;
CRC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.59	10.55	0.5	1.34e-22	Aortic root size;
CRC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.57	0.43	3.99e-16	Smoking initiation;
CRC	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.38	6.32	0.33	8.44e-10	Sitting height ratio;
CRC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.53	6.5	0.34	2.96e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-12.75	-0.58	1.57e-30	Blood metabolite levels;
CRC	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg02466173	chr16:30829666	NA	0.62	9.3	0.46	1.96e-18	Dementia with Lewy bodies;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04231340	chr16:50501845	NA	0.36	6.07	0.32	3.44e-9	Response to antipsychotic treatment;
CRC	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg05187965	chr10:45406764	TMEM72	-0.34	-6.71	-0.35	8.49e-11	Mean corpuscular volume;
CRC	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg00677455	chr12:58241039	CTDSP2	-0.51	-6.93	-0.36	2.29e-11	Multiple sclerosis;
CRC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.46	6.06	0.32	3.65e-9	Response to diuretic therapy;
CRC	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.95	-12.73	-0.57	1.82e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.91	17.27	0.69	4.82e-48	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.82	7.84	0.4	6.37e-14	Diabetic retinopathy;
CRC	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg16342193	chr10:102329863	NA	-0.35	-5.85	-0.31	1.18e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs910187	0.678	rs3818014	chr20:45816649	C/T	cg27589058	chr20:45804311	EYA2	-0.39	-7.51	-0.38	5.6e-13	Migraine;
CRC	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg07884673	chr3:53033167	SFMBT1	0.75	6.1	0.32	3.02e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg18721089	chr20:30220636	NA	-0.53	-7.98	-0.4	2.43e-14	Mean corpuscular hemoglobin;
CRC	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg06204229	chr3:52865917	ITIH4	0.43	5.95	0.31	6.94e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7945718	0.621	rs10831891	chr11:12676140	A/G	cg25843174	chr11:12811716	TEAD1	0.39	7.07	0.36	9.43e-12	Educational attainment (years of education);
CRC	trans	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	2.97e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.7	-10.77	-0.51	2.3e-23	Type 2 diabetes;
CRC	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg13390004	chr1:15929781	NA	0.43	5.7	0.3	2.6e-8	Systolic blood pressure;
CRC	cis	rs11628318	0.515	rs8009257	chr14:103155594	A/G	cg12046867	chr14:103022105	NA	0.44	6.0	0.31	5.2e-9	Platelet count;
CRC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg12590608	chr7:158785262	NA	-0.43	-7.8	-0.4	8.03e-14	Facial morphology (factor 20);
CRC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.96	0.66	7.1e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.83	-10.89	-0.51	8.82e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg01339444	chr6:118972232	C6orf204	0.52	5.82	0.31	1.41e-8	Diastolic blood pressure;
CRC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.49	6.77	0.35	5.99e-11	Total body bone mineral density;
CRC	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg03929089	chr4:120376271	NA	0.62	6.13	0.32	2.56e-9	Axial length;
CRC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	9.01	0.44	1.69e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.85	-0.35	3.57e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg20243544	chr17:37824526	PNMT	0.56	8.87	0.44	4.65e-17	Asthma;
CRC	trans	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg24644049	chr4:85504048	CDS1	0.9	7.92	0.4	3.58e-14	Skin colour saturation;
CRC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg02869306	chr7:64672164	INTS4L1	0.44	6.31	0.33	8.91e-10	Aortic root size;
CRC	trans	rs587242	1.000	rs2985639	chr1:96894735	C/T	cg10631902	chr5:14652156	NA	0.44	6.83	0.35	4.21e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.66	10.49	0.5	2.16e-22	Sudden cardiac arrest;
CRC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.7	10.58	0.5	1.02e-22	Cognitive function;
CRC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.3	0.33	9.4e-10	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7757969	0.500	rs9487731	chr6:112154848	T/C	cg08211895	chr2:48828358	STON1-GTF2A1L	0.31	6.04	0.32	4.14e-9	Schizophrenia;
CRC	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.91	14.41	0.62	8.15e-37	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.75	0.3	2.01e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg23123621	chr4:1343375	KIAA1530	0.36	6.36	0.33	6.62e-10	Obesity-related traits;
CRC	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg14458575	chr2:238380390	NA	0.52	7.24	0.37	3.16e-12	Prostate cancer;
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	6.75	0.35	6.8e-11	Lung function (FEV1/FVC);
CRC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg18761221	chr20:60518478	NA	0.48	7.84	0.4	6.23e-14	Body mass index;
CRC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg21466736	chr12:48725269	NA	0.46	7.12	0.37	6.99e-12	Glycated hemoglobin levels;
CRC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.37	6.29	0.33	1.02e-9	Height;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.46	5.61	0.3	4.24e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.39	0.46	9.96e-19	Monocyte percentage of white cells;
CRC	cis	rs4494114	0.967	rs1925677	chr1:39346905	T/G	cg25970120	chr1:39325951	RRAGC	-0.46	-6.38	-0.33	5.88e-10	Blood protein levels;
CRC	cis	rs6973256	0.897	rs7780456	chr7:133328782	C/T	cg10665199	chr7:133106180	EXOC4	-0.37	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs727479	0.502	rs2304463	chr15:51508120	A/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.03	-0.32	4.47e-9	Estradiol levels;
CRC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.12	-0.32	2.66e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg01475377	chr6:109611718	NA	-0.35	-6.07	-0.32	3.56e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.51	7.32	0.37	1.92e-12	Multiple sclerosis;
CRC	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.42	6.92	0.36	2.41e-11	Sitting height ratio;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg25164649	chr6:28176230	NA	0.56	7.44	0.38	9.1e-13	Parkinson's disease;
CRC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg06740227	chr12:86229804	RASSF9	0.37	5.62	0.3	4.02e-8	Major depressive disorder;
CRC	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.78	13.57	0.6	1.27e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg02741985	chr17:80059408	CCDC57	-0.46	-7.46	-0.38	7.96e-13	Life satisfaction;
CRC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.63	-9.3	-0.46	2e-18	Subjective well-being;
CRC	cis	rs2072510	0.569	rs7134860	chr12:96390358	C/A	cg15438951	chr12:96389694	HAL	-0.49	-5.92	-0.31	7.95e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-7.81	-0.4	7.92e-14	Vitiligo;
CRC	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.46	7.01	0.36	1.35e-11	QT interval;
CRC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.8	0.3	1.54e-8	HDL cholesterol;
CRC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.19	-0.32	1.79e-9	Axial length;
CRC	cis	rs1570989	0.841	rs9349054	chr6:12029312	C/T	cg17804551	chr6:12015979	HIVEP1	-0.38	-5.71	-0.3	2.46e-8	Alcohol and nicotine co-dependence;
CRC	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.48	-8.55	-0.43	4.82e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	9.27	0.46	2.46e-18	Menarche (age at onset);
CRC	cis	rs6681460	0.625	rs6679568	chr1:67074177	C/T	cg02459107	chr1:67143332	SGIP1	0.32	5.76	0.3	1.93e-8	Presence of antiphospholipid antibodies;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg11644585	chr17:8958019	NTN1	-0.43	-6.21	-0.32	1.62e-9	Parkinson's disease;
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.42	7.16	0.37	5.43e-12	Lung cancer;
CRC	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.53	-0.34	2.52e-10	Breast cancer;
CRC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg04880052	chr2:219191631	PNKD	-0.41	-6.17	-0.32	2.03e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23290343	chr5:107717310	FBXL17	0.4	6.29	0.33	1.01e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg08222913	chr3:52553049	STAB1	-0.39	-7.6	-0.39	3.17e-13	Bipolar disorder;
CRC	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg16141378	chr3:129829833	LOC729375	0.41	6.19	0.32	1.78e-9	Joint mobility (Beighton score);
CRC	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.56	9.58	0.47	2.43e-19	Dupuytren's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21558545	chr12:71834859	LGR5	0.49	6.76	0.35	6.13e-11	Thyroid stimulating hormone;
CRC	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.85	-13.0	-0.58	1.81e-31	Schizophrenia;
CRC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg15534755	chr11:117069859	TAGLN	0.33	6.01	0.31	4.96e-9	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05358025	chr19:4868071	PLIN3	0.46	6.05	0.32	3.9e-9	Thyroid stimulating hormone;
CRC	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg23100626	chr2:96804247	ASTL	-0.27	-6.87	-0.35	3.21e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs16867335	0.947	rs16867341	chr2:181488938	C/G	cg23363182	chr2:181467187	NA	-0.48	-6.47	-0.34	3.56e-10	Survival in rectal cancer;
CRC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.37	-6.85	-0.35	3.73e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12024301	0.557	rs12041999	chr1:183608393	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1178968	1.000	rs4717755	chr7:72761178	T/G	cg25889504	chr7:72793014	NA	0.49	5.83	0.31	1.32e-8	Triglyceride levels;
CRC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.74	-0.3	2.14e-8	Aortic root size;
CRC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	8.68	0.43	1.87e-16	Height;
CRC	cis	rs9323205	0.677	rs11620820	chr14:51734445	C/T	cg23942311	chr14:51606299	NA	-0.5	-5.8	-0.3	1.53e-8	Cancer;
CRC	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.5	-7.6	-0.39	3.09e-13	Uric acid levels;
CRC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg21609526	chr1:3105151	PRDM16	-0.57	-9.63	-0.47	1.69e-19	Migraine;
CRC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.64	7.34	0.38	1.63e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.46	5.8	0.3	1.55e-8	Metabolite levels;
CRC	cis	rs447921	0.953	rs16968964	chr17:74455272	C/T	cg20706315	chr17:74366578	NA	0.5	6.67	0.35	1.09e-10	Mitochondrial DNA levels;
CRC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.06	10.59	0.5	9.22e-23	Diabetic retinopathy;
CRC	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.4	-6.97	-0.36	1.79e-11	Hip circumference;Waist circumference;
CRC	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg26182253	chr13:112236782	NA	-0.31	-6.24	-0.33	1.35e-9	Hepatitis;
CRC	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.64	-7.77	-0.39	1.04e-13	Obesity (extreme);
CRC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg27535305	chr1:53392650	SCP2	0.39	7.07	0.36	9.17e-12	Monocyte count;
CRC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.3	6.41	0.33	5.02e-10	Alcohol dependence;
CRC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.58	8.69	0.43	1.8e-16	Aortic root size;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.54	8.33	0.42	2.27e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.78	-0.47	5.25e-20	P wave terminal force;
CRC	trans	rs2303319	0.504	rs12473497	chr2:162433766	T/C	cg10498984	chr16:28874827	SH2B1	-0.73	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.9	0.31	8.95e-9	IgG glycosylation;
CRC	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs4757319	0.554	rs11023520	chr11:15332935	A/G	cg03245590	chr11:15329459	NA	-0.53	-9.5	-0.46	4.5e-19	Breast cancer;
CRC	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.51	7.54	0.38	4.61e-13	Subjective well-being;
CRC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1223397	0.617	rs957176	chr6:13311526	C/T	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs4731207	0.596	rs1552119	chr7:124638876	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.94	-0.4	3.14e-14	Chronic sinus infection;
CRC	cis	rs447	0.806	rs933341	chr7:83743619	A/G	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.76	-0.3	1.95e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00713605	chr2:232063387	ARMC9	0.41	6.09	0.32	3.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.36	6.17	0.32	2.06e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs9584850	0.834	rs4294654	chr13:99119607	G/A	cg20487152	chr13:99095054	FARP1	0.41	6.0	0.31	5.28e-9	Neuroticism;
CRC	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.35	6.1	0.32	2.91e-9	Pneumonia;
CRC	cis	rs7301826	0.651	rs12228959	chr12:131296068	T/G	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26938348	chr10:121356513	TIAL1	0.42	6.18	0.32	1.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.5	-6.85	-0.35	3.74e-11	Superior crus of antihelix expression;
CRC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg11707556	chr5:10655725	ANKRD33B	0.35	6.48	0.34	3.32e-10	Coronary artery disease;
CRC	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.65	10.89	0.51	8.65e-24	White blood cell count (basophil);
CRC	cis	rs17209837	0.607	rs7789645	chr7:87122603	G/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.42	-0.33	4.66e-10	Gallbladder cancer;
CRC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.71	-9.19	-0.45	4.44e-18	Initial pursuit acceleration;
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg08222913	chr3:52553049	STAB1	-0.33	-6.24	-0.33	1.35e-9	Bipolar disorder;
CRC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-9.59	-0.47	2.32e-19	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg15845792	chr6:28175446	NA	0.64	9.63	0.47	1.66e-19	Cardiac Troponin-T levels;
CRC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg22495460	chr2:25135724	ADCY3	-0.81	-15.55	-0.65	2.97e-41	Body mass index;
CRC	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.41	6.52	0.34	2.57e-10	Left ventricle wall thickness;
CRC	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.43	6.12	0.32	2.65e-9	Body mass index;
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.83	12.87	0.58	5.56e-31	Menarche (age at onset);
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.59	8.85	0.44	5.43e-17	Aortic root size;
CRC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.62	-8.02	-0.4	1.89e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.77	11.71	0.54	1.07e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.57e-9	Colorectal cancer;
CRC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg00129232	chr17:37814104	STARD3	0.57	7.05	0.36	1.08e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.44	-6.28	-0.33	1.06e-9	Menarche (age at onset);
CRC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.99	0.36	1.5e-11	Morning vs. evening chronotype;
CRC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.45	5.78	0.3	1.77e-8	Heart rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01398415	chr1:226309536	NA	0.43	5.97	0.31	6.04e-9	Response to antipsychotic treatment;
CRC	cis	rs10046574	0.561	rs6966294	chr7:135196479	G/A	cg27474649	chr7:135195673	CNOT4	0.65	6.08	0.32	3.36e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.5	-9.32	-0.46	1.69e-18	Prostate cancer;
CRC	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg16540259	chr10:75572220	NDST2	0.52	7.65	0.39	2.22e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.79	8.04	0.41	1.68e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.51	7.12	0.37	6.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.39	5.97	0.31	6.3e-9	Red blood cell count;
CRC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4e-17	Bipolar disorder;
CRC	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.43	-5.84	-0.31	1.24e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.61	9.46	0.46	5.94e-19	Menopause (age at onset);
CRC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.07	0.36	9.28e-12	Hemoglobin concentration;
CRC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.39	6.33	0.33	8.21e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21926875	chr2:47596410	EPCAM	0.35	6.26	0.33	1.18e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.14	19.64	0.73	2.22e-57	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg16099169	chr2:106886729	NA	0.44	6.34	0.33	7.51e-10	Facial morphology (factor 23);
CRC	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg18099408	chr3:52552593	STAB1	0.43	7.22	0.37	3.73e-12	Electroencephalogram traits;
CRC	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01241850	chr9:138798996	CAMSAP1	0.46	6.44	0.33	4.21e-10	Anxiety disorder;
CRC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.64	-9.31	-0.46	1.83e-18	Subjective well-being;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-10.02	-0.48	8.3e-21	Dental caries;
CRC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.41	-0.33	4.98e-10	Dupuytren's disease;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg08798685	chr6:27730294	NA	-0.43	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg14646075	chr2:228736089	WDR69	0.44	5.88	0.31	9.9e-9	Blood pressure;
CRC	cis	rs12586317	0.576	rs12586302	chr14:35691074	G/C	cg07166546	chr14:35805898	NA	-0.31	-5.93	-0.31	7.48e-9	Psoriasis;
CRC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg13010199	chr12:38710504	ALG10B	-0.42	-5.93	-0.31	7.61e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.04	16.95	0.68	9.55e-47	IgG glycosylation;
CRC	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.53	-7.86	-0.4	5.7e-14	Blood protein levels;
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.83	-0.35	3.99e-11	Bipolar disorder;
CRC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs7394190	0.935	rs4746140	chr10:75417249	G/C	cg07699608	chr10:75541558	CHCHD1	0.55	6.36	0.33	6.61e-10	Incident atrial fibrillation;
CRC	cis	rs12024301	0.557	rs12067907	chr1:183658255	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.7	6.14	0.32	2.38e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.47	-7.1	-0.36	7.93e-12	Body mass index;
CRC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12463550	chr7:65579703	CRCP	0.69	6.4	0.33	5.42e-10	Diabetic kidney disease;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.46	-10.32	-0.49	8.35e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg04450456	chr4:17643702	FAM184B	0.39	6.31	0.33	8.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.18	-0.32	1.87e-9	Menopause (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04131734	chr11:102323536	TMEM123	0.39	6.11	0.32	2.82e-9	Obesity-related traits;
CRC	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.57	-7.02	-0.36	1.27e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.54	-8.27	-0.42	3.28e-15	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02820958	chr19:7099040	NA	0.41	6.67	0.35	1.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-12.2	-0.56	1.72e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.6	10.51	0.5	1.78e-22	Body mass index;
CRC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.59	-8.98	-0.44	2.17e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.0	-0.55	9.46e-28	Alzheimer's disease;
CRC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg21770322	chr7:97807741	LMTK2	0.52	8.51	0.42	6.16e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg16141378	chr3:129829833	LOC729375	0.46	6.83	0.35	4.18e-11	Neuroticism;
CRC	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.51	-0.38	5.8e-13	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10010189	chr2:60983202	PAPOLG	0.46	6.88	0.35	3.03e-11	Response to antipsychotic treatment;
CRC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	9.5	0.46	4.4e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.7	0.39	1.56e-13	Mean platelet volume;
CRC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.75	-11.35	-0.53	2.06e-25	Blood trace element (Zn levels);
CRC	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	8.16e-17	Dupuytren's disease;
CRC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg22535103	chr8:58192502	C8orf71	-0.44	-5.81	-0.3	1.49e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs150647904	1	rs150647904	chr1:54839485	T/TCAG	cg17417004	chr1:54819992	SSBP3	0.69	8.16	0.41	7.06e-15	Platelet distribution width;
CRC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.83	9.18	0.45	4.95e-18	Skin colour saturation;
CRC	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg02023728	chr11:77925099	USP35	-0.34	-5.64	-0.3	3.64e-8	Alzheimer's disease (survival time);
CRC	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02097616	chr17:62675921	NA	-0.52	-7.41	-0.38	1.07e-12	QT interval;
CRC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.85	-13.5	-0.6	2.41e-33	Cognitive function;
CRC	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.8	0.44	7.67e-17	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06905471	chr2:29092871	TRMT61B	0.49	6.91	0.36	2.54e-11	Response to antipsychotic treatment;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg26304593	chr6:42947056	PEX6	-0.41	-5.84	-0.31	1.24e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05704155	chr1:10459140	PGD	0.38	6.1	0.32	3.04e-9	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.73	-11.9	-0.55	2.13e-27	Neurofibrillary tangles;
CRC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg05623727	chr3:50126028	RBM5	-0.46	-7.63	-0.39	2.57e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6534441	0.697	rs58633746	chr4:125466433	A/G	cg21609808	chr4:125404261	NA	0.41	5.65	0.3	3.52e-8	Major depressive disorder;
CRC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.65	-10.26	-0.49	1.32e-21	Huntington's disease progression;
CRC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg17810781	chr1:201082982	CACNA1S	-0.49	-8.67	-0.43	2.04e-16	Permanent tooth development;
CRC	cis	rs1223397	1.000	rs1223402	chr6:13271640	G/A	cg00460589	chr6:13274354	PHACTR1	0.45	5.63	0.3	3.83e-8	Blood pressure;
CRC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.64	-9.27	-0.46	2.45e-18	Cognitive function;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.37	0.33	6.22e-10	Life satisfaction;
CRC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-5.93	-0.31	7.77e-9	Colorectal cancer;
CRC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.35	-0.46	1.43e-18	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.59	-8.2	-0.41	5.43e-15	Longevity;
CRC	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	0.85	7.78	0.39	9.33e-14	Economic and political preferences (immigration/crime);
CRC	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg24881330	chr22:46731750	TRMU	0.67	5.71	0.3	2.56e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.66	7.37	0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.44	6.08	0.32	3.36e-9	Schizophrenia;
CRC	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.56	9.81	0.48	4.21e-20	Age of smoking initiation;
CRC	cis	rs10207060	0.500	rs7600350	chr2:240716225	T/C	cg07506560	chr2:240697449	NA	0.42	5.62	0.3	4.17e-8	Obesity-related traits;
CRC	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.69	-0.39	1.69e-13	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg22110888	chr17:80059540	CCDC57	0.41	6.52	0.34	2.71e-10	Life satisfaction;
CRC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg00734567	chr1:86172782	ZNHIT6	-0.47	-7.23	-0.37	3.42e-12	Urate levels in overweight individuals;
CRC	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.49	-6.98	-0.36	1.6e-11	Coronary artery disease;
CRC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.91	-0.36	2.47e-11	Self-reported allergy;
CRC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	8.47	0.42	8.05e-16	Lymphocyte counts;
CRC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.58	-9.64	-0.47	1.54e-19	P wave terminal force;
CRC	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg23141183	chr17:80185318	SLC16A3	0.43	6.04	0.32	4.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg15763984	chr4:1342303	KIAA1530	0.36	6.15	0.32	2.21e-9	Longevity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07210462	chr1:39324918	RRAGC	0.48	6.96	0.36	1.83e-11	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.94	0.52	6e-24	Motion sickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10338082	chr3:124303555	KALRN	0.4	6.65	0.34	1.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg04176472	chr15:90893244	GABARAPL3	0.36	6.21	0.32	1.63e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs75920871	0.502	rs10790166	chr11:116779499	A/G	cg20608306	chr11:116969690	SIK3	-0.31	-5.74	-0.3	2.17e-8	Subjective well-being;
CRC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.79	0.39	8.63e-14	Major depressive disorder;
CRC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg02733842	chr7:1102375	C7orf50	-0.42	-5.77	-0.3	1.85e-8	Bronchopulmonary dysplasia;
CRC	cis	rs7215564	0.908	rs4889883	chr17:78664374	C/A	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg15786705	chr6:28176104	NA	0.49	6.99	0.36	1.58e-11	Parkinson's disease;
CRC	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg09659197	chr4:152720779	NA	0.4	7.93	0.4	3.4e-14	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg17903999	chr18:56338584	MALT1	0.43	7.12	0.37	6.83e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.75	7.95	0.4	3.04e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.44	0.38	9.04e-13	Height;
CRC	cis	rs1403694	1.000	rs1648716	chr3:186439529	C/T	cg04611788	chr3:186434169	KNG1	-0.45	-6.97	-0.36	1.69e-11	Blood protein levels;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.2	0.37	4.16e-12	Life satisfaction;
CRC	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.78	14.68	0.63	7.2e-38	Ulcerative colitis;
CRC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.48	7.17	0.37	4.97e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.61	8.8	0.44	7.65e-17	Red blood cell count;
CRC	trans	rs2303319	0.504	rs12467662	chr2:162386784	G/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg03609598	chr5:56110824	MAP3K1	-0.45	-6.23	-0.32	1.44e-9	Coronary artery disease;
CRC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.5	6.95	0.36	1.93e-11	Schizophrenia;
CRC	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.04	-0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.6	7.36	0.38	1.47e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.56	-6.72	-0.35	8.25e-11	Ulcerative colitis;
CRC	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-8.9	-0.44	3.78e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27391037	chr22:18560705	PEX26	0.39	6.02	0.31	4.57e-9	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06307176	chr5:131281290	NA	-0.39	-5.74	-0.3	2.1e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.53	-7.33	-0.37	1.78e-12	Schizophrenia;
CRC	cis	rs9648716	0.554	rs801093	chr7:140653145	T/G	cg10747023	chr7:140774559	NA	0.43	5.99	0.31	5.45e-9	Type 2 diabetes;
CRC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	7.96	0.4	2.84e-14	Height;
CRC	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	1.14	17.8	0.7	3.94e-50	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.5	-0.38	5.91e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07256732	chr16:621771	PIGQ	-0.36	-5.67	-0.3	3.05e-8	Height;
CRC	trans	rs2856321	0.874	rs1009951	chr12:11892896	C/T	cg04981696	chr16:16044519	ABCC1	0.42	6.0	0.31	5.21e-9	Height;
CRC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg04117972	chr1:227635322	NA	0.65	6.06	0.32	3.8e-9	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04686114	chr12:57081832	PTGES3	0.47	7.53	0.38	5.02e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.88	-0.31	1.02e-8	Life satisfaction;
CRC	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg11887960	chr12:57824829	NA	0.62	6.76	0.35	6.26e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg05304507	chr6:116381966	FRK	0.31	8.4	0.42	1.32e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6840360	0.642	rs2709819	chr4:152383832	A/G	cg09659197	chr4:152720779	NA	0.33	6.51	0.34	2.77e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.69	9.17	0.45	5.48e-18	Alzheimer's disease;
CRC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.44	6.07	0.32	3.46e-9	Aortic root size;
CRC	cis	rs11009175	0.556	rs7072034	chr10:33298617	A/G	cg00146027	chr10:33299147	NA	-0.28	-6.29	-0.33	1.02e-9	Depression (quantitative trait);
CRC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-6.04	-0.32	4.15e-9	Daytime sleep phenotypes;
CRC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg21153622	chr11:89784906	NA	0.43	7.12	0.37	6.72e-12	Coronary artery disease;
CRC	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg20988073	chr3:125900093	ALDH1L1	-0.35	-6.01	-0.31	4.92e-9	Metabolite levels;
CRC	cis	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg06470822	chr6:28175283	NA	-0.65	-6.69	-0.35	9.59e-11	Depression;
CRC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.31	-0.33	9.14e-10	Tonsillectomy;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.94	-0.31	7.43e-9	Depression;
CRC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg07884673	chr3:53033167	SFMBT1	0.77	6.17	0.32	2.05e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.95	-12.21	-0.56	1.58e-28	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25721516	chr17:42276931	ATXN7L3	0.43	6.99	0.36	1.53e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs253959	0.629	rs10054121	chr5:115419968	G/A	cg23108291	chr5:115420582	COMMD10	0.44	6.24	0.33	1.36e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg19554555	chr3:13937349	NA	-0.43	-6.22	-0.32	1.54e-9	Ovarian reserve;
CRC	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg18850127	chr7:39170497	POU6F2	0.43	5.77	0.3	1.8e-8	IgG glycosylation;
CRC	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.74	11.44	0.53	9.61e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9443189	1.000	rs3822957	chr6:76607280	A/G	cg01950844	chr6:76311363	SENP6	-0.59	-7.16	-0.37	5.17e-12	Prostate cancer;
CRC	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg03469862	chr11:68924853	NA	0.46	5.89	0.31	9.37e-9	Blond vs. brown hair color;
CRC	cis	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg15845792	chr6:28175446	NA	0.65	6.49	0.34	3.17e-10	Depression;
CRC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.83	12.68	0.57	2.87e-30	Cognitive function;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.46	5.74	0.3	2.13e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.4	-6.11	-0.32	2.87e-9	Monocyte count;
CRC	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg19338460	chr6:170058176	WDR27	-0.81	-8.27	-0.42	3.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.57	6.86	0.35	3.52e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg06470822	chr6:28175283	NA	0.59	6.47	0.34	3.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg09659197	chr4:152720779	NA	0.3	5.75	0.3	2.08e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg04990556	chr1:26633338	UBXN11	-0.47	-5.69	-0.3	2.78e-8	Obesity-related traits;
CRC	cis	rs6681460	0.966	rs2025595	chr1:67152499	G/A	cg02459107	chr1:67143332	SGIP1	0.4	7.03	0.36	1.18e-11	Presence of antiphospholipid antibodies;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08040170	chr16:18812977	ARL6IP1	0.49	6.85	0.35	3.62e-11	Response to antipsychotic treatment;
CRC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-6.59	-0.34	1.75e-10	Coronary artery disease;
CRC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.41	-5.78	-0.3	1.71e-8	Menarche (age at onset);
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.22	0.53	5.77e-25	Prudent dietary pattern;
CRC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.68	10.0	0.48	1e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.81	14.3	0.62	2.07e-36	Metabolic syndrome;
CRC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.84	-0.4	6.47e-14	Personality dimensions;
CRC	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	18.6	0.72	2.7e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg17903999	chr18:56338584	MALT1	-0.43	-6.74	-0.35	6.9e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg26576206	chr19:1064938	ABCA7	0.42	5.96	0.31	6.6e-9	Alzheimer's disease (late onset);
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.5	-8.44	-0.42	1.02e-15	Acylcarnitine levels;
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.56	-0.38	3.99e-13	Menopause (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12843872	chr7:90894352	FZD1	-0.51	-6.36	-0.33	6.57e-10	Diisocyanate-induced asthma;
CRC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.33	-5.67	-0.3	3.16e-8	Erythrocyte sedimentation rate;
CRC	cis	rs10991814	0.920	rs6479335	chr9:94108790	T/C	cg14446406	chr9:93919335	NA	0.59	6.66	0.34	1.13e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.75	13.9	0.61	7.15e-35	Metabolite levels;
CRC	cis	rs2346160	0.831	rs1467391	chr6:167690062	A/G	cg27333441	chr6:167680455	NA	-0.4	-6.63	-0.34	1.4e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.5	7.8	0.4	8.12e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.21	0.32	1.55e-9	Blood metabolite levels;
CRC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.51	-8.95	-0.44	2.72e-17	Height;
CRC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-9.66	-0.47	1.37e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs758324	0.812	rs4705839	chr5:131175258	G/A	cg25547332	chr5:131281432	NA	0.37	5.86	0.31	1.14e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg10729496	chr3:10149963	C3orf24	-0.5	-5.82	-0.31	1.4e-8	Alzheimer's disease;
CRC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.05	10.89	0.51	8.72e-24	Diabetic retinopathy;
CRC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg05623727	chr3:50126028	RBM5	-0.45	-7.38	-0.38	1.33e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.47	-0.6	3.03e-33	Blood metabolite levels;
CRC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.43	5.84	0.31	1.24e-8	Red blood cell count;
CRC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.46	7.21	0.37	3.82e-12	Eye color traits;
CRC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg02449762	chr10:5661741	NA	-0.33	-5.75	-0.3	2.06e-8	Breast cancer;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.41	-0.42	1.27e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4853036	0.951	rs6718298	chr2:70145450	A/C	cg02498382	chr2:70120550	SNRNP27	-0.46	-7.04	-0.36	1.09e-11	Colorectal or endometrial cancer;
CRC	cis	rs17767392	0.958	rs12889866	chr14:71937439	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.17	-0.37	5.11e-12	Mitral valve prolapse;
CRC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.97	-0.36	1.69e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.55	10.09	0.49	4.98e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg18758796	chr5:131593413	PDLIM4	0.39	6.24	0.33	1.32e-9	Breast cancer;
CRC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.53	8.58	0.43	3.87e-16	Menopause (age at onset);
CRC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg05639522	chr1:247681581	NA	0.49	7.15	0.37	5.55e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs728616	0.681	rs12413174	chr10:82062404	G/A	cg05935833	chr10:81318306	SFTPA2	-0.59	-7.03	-0.36	1.18e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg06896663	chr8:82754093	SNX16	-0.68	-6.1	-0.32	3.01e-9	Cognitive function;
CRC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.73	-12.19	-0.56	1.9e-28	Cognitive function;
CRC	cis	rs728616	0.681	rs36073865	chr10:81916055	C/T	cg11900509	chr10:81946545	ANXA11	-0.72	-8.65	-0.43	2.25e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.45	5.67	0.3	3.19e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16310774	chr5:64920439	C5orf44;TRIM23	0.43	6.0	0.31	5.25e-9	Response to antipsychotic treatment;
CRC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg18230493	chr5:56204884	C5orf35	0.73	10.02	0.48	8.53e-21	Initial pursuit acceleration;
CRC	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.55	-8.41	-0.42	1.29e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.71	-0.39	1.48e-13	Bipolar disorder;
CRC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.61	7.68	0.39	1.85e-13	Dilated cardiomyopathy;
CRC	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-7.53	-0.38	4.8e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg04155289	chr7:94953770	PON1	-0.63	-7.73	-0.39	1.32e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20887711	chr4:1340912	KIAA1530	0.41	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.66	6.13	0.32	2.58e-9	IgG glycosylation;
CRC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.56	-6.17	-0.32	2.01e-9	Vitiligo;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.45	-0.46	6.64e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.63	-7.89	-0.4	4.42e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9648716	1.000	rs11974112	chr7:140641544	G/A	cg10747023	chr7:140774559	NA	0.47	6.04	0.32	4.27e-9	Type 2 diabetes;
CRC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.14	-16.06	-0.66	2.87e-43	Hip circumference adjusted for BMI;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg25755261	chr14:35591781	PPP2R3C;KIAA0391	0.58	6.04	0.32	4.08e-9	Body mass index;
CRC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.53	-0.34	2.46e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg03929089	chr4:120376271	NA	-0.56	-6.48	-0.34	3.28e-10	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg16558177	chr4:4109446	NA	-0.62	-8.74	-0.43	1.23e-16	Blood pressure (smoking interaction);
CRC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg10790698	chr19:18539756	SSBP4	-0.46	-8.79	-0.44	8.55e-17	Breast cancer;
CRC	trans	rs264943	0.600	rs2257063	chr2:104092954	C/T	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.94e-9	HIV-1 viral setpoint;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.67	10.97	0.52	4.4e-24	Height;
CRC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.82	-6.89	-0.36	2.86e-11	Pediatric areal bone mineral density (radius);
CRC	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-6.25	-0.33	1.28e-9	Height;
CRC	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg14345882	chr6:26364793	BTN3A2	0.68	5.84	0.31	1.25e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.49	-0.38	6.38e-13	Aortic root size;
CRC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-10.28	-0.49	1.1e-21	Breast cancer;
CRC	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg14631576	chr9:95140430	CENPP	-0.4	-6.99	-0.36	1.57e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg24644049	chr4:85504048	CDS1	-0.9	-7.61	-0.39	2.99e-13	Skin colour saturation;
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg05569086	chr8:143859399	LYNX1	0.4	6.91	0.36	2.54e-11	Urinary tract infection frequency;
CRC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg07865391	chr16:88106882	BANP	0.47	5.94	0.31	7.09e-9	Menopause (age at onset);
CRC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg05639522	chr1:247681581	NA	0.51	7.43	0.38	9.57e-13	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.95	-0.44	2.57e-17	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17372494	chr2:27310078	KHK	0.43	6.46	0.34	3.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.97	-0.31	6.07e-9	Arsenic metabolism;
CRC	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.13	-9.56	-0.47	2.83e-19	Mitochondrial DNA levels;
CRC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.54	7.91	0.4	4.06e-14	Height;
CRC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg13722127	chr7:150037890	RARRES2	-0.46	-7.97	-0.4	2.65e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs354225	0.532	rs354211	chr2:54932516	C/T	cg26097391	chr2:54893211	SPTBN1	0.43	6.83	0.35	4.01e-11	Schizophrenia;
CRC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.55	-8.71	-0.43	1.53e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg22561889	chr6:118971681	C6orf204	0.53	6.5	0.34	3.03e-10	Diastolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01348121	chr10:43633961	CSGALNACT2	0.47	6.56	0.34	2.13e-10	Anxiety disorder;
CRC	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.46	-7.13	-0.37	6.29e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.48	-0.46	5.22e-19	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10240496	chr7:29724441	LOC646762	0.42	6.09	0.32	3.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.24	-16.67	-0.68	1.19e-45	Breast cancer;
CRC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.45	-5.86	-0.31	1.14e-8	Gut microbiome composition (summer);
CRC	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg14631576	chr9:95140430	CENPP	-0.39	-6.78	-0.35	5.43e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Colorectal cancer;
CRC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.6	-8.81	-0.44	7.25e-17	Height;
CRC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.35	-5.61	-0.3	4.25e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.47	5.97	0.31	6.14e-9	Bipolar disorder;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg18758796	chr5:131593413	PDLIM4	0.38	6.33	0.33	8.11e-10	Blood metabolite levels;
CRC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.69	0.3	2.77e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26667821	chr1:155099774	EFNA1	0.41	6.04	0.32	4.18e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20357023	chr2:178417605	TTC30B	0.49	6.89	0.36	2.77e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg00343986	chr7:65444356	GUSB	-0.5	-7.49	-0.38	6.35e-13	Aortic root size;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Parkinson's disease;
CRC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Body mass index;
CRC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg01629716	chr15:45996671	NA	0.38	7.6	0.39	3.03e-13	Waist circumference;Weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03888365	chr8:123792680	ZHX2	0.46	6.46	0.34	3.83e-10	Response to antipsychotic treatment;
CRC	trans	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg17903999	chr18:56338584	MALT1	-0.39	-6.44	-0.33	4.34e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg03030879	chr14:75389066	RPS6KL1	0.45	7.16	0.37	5.18e-12	Height;
CRC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-8.4	-0.42	1.31e-15	Total cholesterol levels;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg21620606	chr4:1342894	KIAA1530	0.51	8.72	0.43	1.44e-16	Longevity;
CRC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.4	-5.8	-0.3	1.57e-8	Aortic root size;
CRC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.08	-0.45	9.9e-18	Alzheimer's disease;
CRC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.77	0.51	2.25e-23	Ileal carcinoids;
CRC	trans	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg26043149	chr18:55253948	FECH	-0.56	-8.72	-0.43	1.42e-16	Bone mineral density;
CRC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.62	-11.66	-0.54	1.56e-26	Educational attainment;
CRC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg05683857	chr10:124030795	BTBD16	0.32	5.71	0.3	2.51e-8	Total body bone mineral density;
CRC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.57	-5.7	-0.3	2.64e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg23173402	chr1:227635558	NA	0.59	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.61	9.93	0.48	1.68e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg19537932	chr12:55886519	OR6C68	-0.66	-8.56	-0.43	4.26e-16	Cancer;
CRC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg27535305	chr1:53392650	SCP2	0.38	7.27	0.37	2.64e-12	Monocyte count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01399255	chr7:100271274	GNB2	-0.41	-6.09	-0.32	3.22e-9	Myopia (pathological);
CRC	cis	rs77972916	0.609	rs13414381	chr2:43567218	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.67	-0.3	3.08e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs11212617	0.935	rs227055	chr11:108261261	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.04	0.32	4.09e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08833169	chr11:810149	RPLP2	0.37	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg18335740	chr13:41363409	SLC25A15	-0.49	-7.69	-0.39	1.73e-13	Lewy body disease;
CRC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.41	6.83	0.35	4.19e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4728302	0.869	rs7805864	chr7:133610390	G/A	cg03336402	chr7:133662267	EXOC4	-0.44	-6.35	-0.33	7.32e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.64	9.04	0.45	1.38e-17	Menopause (age at onset);
CRC	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-7.1	-0.36	7.82e-12	Inflammatory skin disease;
CRC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg14828511	chr1:107599125	PRMT6	0.48	6.58	0.34	1.86e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs17881320	0.510	rs7221385	chr17:40562081	C/T	cg05878104	chr17:40932452	WNK4	-0.56	-6.8	-0.35	4.82e-11	Atopic dermatitis;
CRC	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.44	-0.33	4.15e-10	Prevalent atrial fibrillation;
CRC	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg00825309	chr19:58991885	ZNF446	0.41	5.91	0.31	8.32e-9	Uric acid clearance;
CRC	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg14631576	chr9:95140430	CENPP	0.34	6.48	0.34	3.3e-10	Height;
CRC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.72	-0.3	2.36e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg26695010	chr11:65641043	EFEMP2	0.48	7.46	0.38	7.59e-13	Eosinophil percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07921184	chr16:71880281	ATXN1L	0.44	6.53	0.34	2.43e-10	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg09877947	chr5:131593287	PDLIM4	0.44	7.15	0.37	5.73e-12	Acylcarnitine levels;
CRC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg24300038	chr13:113819356	PROZ	0.44	6.07	0.32	3.51e-9	Platelet distribution width;
CRC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg20811857	chr17:78079795	GAA	-0.41	-6.54	-0.34	2.33e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.85e-9	Arsenic metabolism;
CRC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-9.69	-0.47	1.08e-19	Personality dimensions;
CRC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.44	0.33	4.23e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg13926569	chr10:89418898	PAPSS2	-0.44	-6.49	-0.34	3.15e-10	Magnesium levels;
CRC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.33	-0.5	7.3e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs8070740	0.898	rs9895440	chr17:5325643	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	7.5	0.38	5.95e-13	Menopause (age at onset);
CRC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.68	10.3	0.49	9.17e-22	Corneal astigmatism;
CRC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.78	13.83	0.61	1.29e-34	Breast cancer;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12273811	chr6:28175739	NA	-0.7	-9.27	-0.46	2.52e-18	Depression;
CRC	cis	rs12760731	0.565	rs7536856	chr1:178057927	A/G	cg00404053	chr1:178313656	RASAL2	0.95	9.89	0.48	2.32e-20	Obesity-related traits;
CRC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-8.4	-0.42	1.37e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.73	-0.43	1.33e-16	Cerebrospinal fluid biomarker levels;
CRC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg27661571	chr11:113659931	NA	-0.67	-7.6	-0.39	3.07e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18912574	chr7:65842487	NCRNA00174	0.35	6.04	0.32	4.23e-9	Aortic root size;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.69	-10.73	-0.51	3.06e-23	Prudent dietary pattern;
CRC	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg03030879	chr14:75389066	RPS6KL1	0.55	9.14	0.45	6.51e-18	Caffeine consumption;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.38	-0.42	1.57e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg16589663	chr20:23618590	CST3	0.59	7.49	0.38	6.55e-13	Chronic kidney disease;
CRC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.75	11.07	0.52	1.97e-24	Menopause (age at onset);
CRC	cis	rs6834538	0.965	rs1580476	chr4:113493365	A/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.46	-6.48	-0.34	3.35e-10	Free thyroxine concentration;
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.49	-7.98	-0.4	2.5e-14	Platelet count;
CRC	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg01475377	chr6:109611718	NA	-0.34	-5.9	-0.31	9.23e-9	Reticulocyte fraction of red cells;
CRC	cis	rs698833	0.892	rs1067371	chr2:44651982	A/G	cg04920474	chr2:44395004	PPM1B	0.41	6.07	0.32	3.61e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	trans	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg19894588	chr14:64061835	NA	0.55	7.43	0.38	9.35e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg04731861	chr2:219085781	ARPC2	-0.31	-6.52	-0.34	2.57e-10	Colorectal cancer;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg06470822	chr6:28175283	NA	0.63	9.06	0.45	1.19e-17	Parkinson's disease;
CRC	cis	rs7539624	0.541	rs6674733	chr1:223906397	A/G	cg10100437	chr1:223903862	CAPN2	0.41	5.87	0.31	1.09e-8	Schizophrenia;
CRC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.22	0.64	5.89e-40	Lymphocyte percentage of white cells;
CRC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.38e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs6678914	1.000	rs12131882	chr1:202188264	A/G	cg19977628	chr5:1262072	TERT	0.41	6.13	0.32	2.54e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08496016	chr9:99181722	ZNF367	0.45	6.27	0.33	1.14e-9	Response to antipsychotic treatment;
CRC	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.43	-6.3	-0.33	9.74e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs2637266	0.600	rs11001843	chr10:78401949	T/A	cg18941641	chr10:78392320	NA	-0.38	-6.46	-0.34	3.78e-10	Pulmonary function;
CRC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg18404041	chr3:52824283	ITIH1	-0.41	-7.65	-0.39	2.25e-13	Schizophrenia;
CRC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg25767906	chr1:53392781	SCP2	-0.44	-6.81	-0.35	4.63e-11	Monocyte count;
CRC	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg16691251	chr5:66510806	NA	0.46	8.13	0.41	9.07e-15	Breast cancer;
CRC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg03623178	chr6:28175578	NA	0.45	6.04	0.32	4.21e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.67	6.61	0.34	1.57e-10	Neuroticism;
CRC	trans	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg17903999	chr18:56338584	MALT1	-0.43	-6.99	-0.36	1.49e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.92	-10.57	-0.5	1.08e-22	Orofacial clefts;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26708280	chr2:190649305	PMS1;ORMDL1	-0.4	-6.02	-0.31	4.66e-9	Aortic root size;
CRC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	0.74	6.94	0.36	2.05e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.65	8.73	0.43	1.35e-16	Alcohol dependence;
CRC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.61	9.78	0.47	5.57e-20	Dental caries;
CRC	cis	rs7605827	0.897	rs11675604	chr2:15672901	C/T	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.62e-8	Educational attainment (years of education);
CRC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.59	-8.08	-0.41	1.24e-14	Neutrophil percentage of white cells;
CRC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.08	-12.32	-0.56	5.94e-29	Diabetic kidney disease;
CRC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg24209194	chr3:40518798	ZNF619	0.42	6.5	0.34	2.97e-10	Renal cell carcinoma;
CRC	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg15192750	chr16:69999425	NA	0.55	7.48	0.38	6.96e-13	IgE levels;
CRC	cis	rs2745967	0.715	rs2724367	chr1:208067329	C/T	cg09788693	chr1:208063733	CD34	0.46	6.99	0.36	1.58e-11	Resting heart rate;
CRC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg16898833	chr6:26189333	HIST1H4D	0.86	7.12	0.37	6.73e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg20982606	chr12:109535391	UNG	-0.46	-6.88	-0.35	2.99e-11	Birth weight;Height;
CRC	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.43	5.67	0.3	3.15e-8	Body mass index;
CRC	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.52	6.36	0.33	6.59e-10	Cognitive test performance;
CRC	cis	rs7680126	0.672	rs10939819	chr4:10290661	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.02	-0.31	4.72e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.38	-8.92	-0.44	3.21e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs501120	0.584	rs11238911	chr10:44695862	A/G	cg09554077	chr10:44749378	NA	-0.66	-7.34	-0.38	1.71e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.21	0.37	3.99e-12	Lymphocyte counts;
CRC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.01	0.36	1.39e-11	Colorectal cancer;
CRC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.46	6.96	0.36	1.9e-11	Obesity-related traits;
CRC	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg20487152	chr13:99095054	FARP1	-0.46	-6.5	-0.34	2.92e-10	Neuroticism;
CRC	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	6.38	0.33	6.12e-10	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg19199531	chr22:20104664	TRMT2A;RANBP1	0.37	5.99	0.31	5.58e-9	Schizophrenia;
CRC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.83	-0.31	1.31e-8	Colorectal cancer;
CRC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.52e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11764359	chr7:65958608	NA	-0.46	-7.14	-0.37	6.02e-12	Aortic root size;
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.16	-0.32	2.13e-9	Bipolar disorder;
CRC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg19635926	chr16:89946313	TCF25	0.53	5.72	0.3	2.42e-8	Skin colour saturation;
CRC	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg10382835	chr6:42185730	MRPS10	0.74	7.07	0.36	9.07e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
CRC	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.61	8.49	0.42	7.33e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9928842	1.000	rs9928842	chr16:75242867	T/C	cg09066997	chr16:75300724	BCAR1	0.69	6.59	0.34	1.74e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs6988985	0.533	rs6391	chr8:143956965	A/G	cg10324643	chr8:143916377	GML	0.4	6.62	0.34	1.46e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg23161317	chr6:28129485	ZNF389	0.47	6.62	0.34	1.48e-10	Cardiac Troponin-T levels;
CRC	cis	rs11212617	0.870	rs227063	chr11:108207304	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.37	0.33	6.29e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg09695851	chr17:3907499	NA	0.47	5.62	0.3	4.09e-8	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06438056	chr1:33502433	AK2	0.44	6.49	0.34	3.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-11.88	-0.55	2.44e-27	Total body bone mineral density;
CRC	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg24304309	chr1:154577895	ADAR	0.36	6.0	0.31	5.3e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7932354	0.528	rs11039097	chr11:47131881	C/T	cg03339077	chr11:47165057	C11orf49	0.43	5.86	0.31	1.13e-8	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.47	-7.73	-0.39	1.34e-13	Type 2 diabetes;
CRC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.64	0.3	3.59e-8	Tonsillectomy;
CRC	cis	rs2289681	0.525	rs2277617	chr17:42977073	T/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.46	-5.81	-0.31	1.45e-8	Cognitive function;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg03790207	chr6:42947109	PEX6	-0.49	-6.92	-0.36	2.3e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.82	-0.35	4.36e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.44	6.29	0.33	1.01e-9	Coronary artery disease;
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.4	5.9	0.31	8.9e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	cis	rs12618769	0.652	rs2276603	chr2:99205962	C/T	cg18455616	chr2:99124870	INPP4A	-0.35	-5.66	-0.3	3.25e-8	Bipolar disorder;
CRC	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.82	-0.4	7.45e-14	Hemoglobin concentration;
CRC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.63	0.3	3.8e-8	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24965984	chr10:113943723	GPAM	0.45	6.14	0.32	2.36e-9	Response to antipsychotic treatment;
CRC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.48	-7.17	-0.37	4.89e-12	Monocyte percentage of white cells;
CRC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg25876840	chr17:41920477	NA	0.58	7.93	0.4	3.39e-14	Triglycerides;
CRC	trans	rs11088226	1.000	rs2833890	chr21:33927886	A/G	cg09050820	chr6:167586206	TCP10L2	-0.57	-6.44	-0.33	4.31e-10	Gastritis;
CRC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	0.97	9.0	0.44	1.78e-17	Pulse pressure;
CRC	cis	rs10046574	0.731	rs10270842	chr7:135163062	A/G	cg27474649	chr7:135195673	CNOT4	0.66	5.83	0.31	1.32e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.36	-0.59	8.31e-33	Systemic lupus erythematosus;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14007442	chr17:46048497	CDK5RAP3	0.49	6.92	0.36	2.36e-11	Response to antipsychotic treatment;
CRC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-10.03	-0.48	7.96e-21	Prostate cancer;
CRC	cis	rs6840360	0.548	rs4254751	chr4:152322571	C/T	cg09659197	chr4:152720779	NA	0.33	6.29	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	5.75	0.3	2.01e-8	IgG glycosylation;
CRC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.67	7.86	0.4	5.51e-14	Type 2 diabetes;
CRC	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.66	-10.92	-0.52	6.61e-24	White blood cell count (basophil);
CRC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.56	-8.13	-0.41	8.58e-15	Menarche (age at onset);
CRC	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-1.25	-10.12	-0.49	4.01e-21	Mitochondrial DNA levels;
CRC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.25	-0.33	1.27e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.6	10.84	0.51	1.3e-23	Blood metabolite ratios;
CRC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.97	0.36	1.75e-11	Mean platelet volume;
CRC	cis	rs990171	0.913	rs4851587	chr2:103073474	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.34e-9	Lymphocyte counts;
CRC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg12458913	chr13:53173898	NA	0.76	13.74	0.6	2.81e-34	Lewy body disease;
CRC	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.51	7.42	0.38	1e-12	Testicular germ cell tumor;
CRC	cis	rs10242455	1.000	rs73395547	chr7:98922746	C/A	cg18809830	chr7:99032528	PTCD1	-0.75	-6.52	-0.34	2.65e-10	Blood metabolite levels;
CRC	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.5	11.79	0.55	5.11e-27	Systolic blood pressure;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg19610905	chr11:61596333	FADS2	-0.63	-7.77	-0.39	1e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.6	-9.4	-0.46	9.21e-19	Aortic root size;
CRC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.33	0.46	1.67e-18	Parkinson's disease;
CRC	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg16576597	chr16:28551801	NUPR1	0.47	7.34	0.37	1.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2398893	0.774	rs35271736	chr9:96888786	A/G	cg14459158	chr9:96720562	NA	0.44	6.28	0.33	1.04e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22611817	chr5:60628016	ZSWIM6	0.44	5.97	0.31	6.05e-9	Anxiety disorder;
CRC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs9976767	0.608	rs11909987	chr21:43822402	C/A	cg23042151	chr21:43824109	UBASH3A	-0.4	-6.69	-0.35	9.5e-11	Type 1 diabetes;
CRC	cis	rs2637266	0.538	rs11510986	chr10:78415171	C/T	cg18941641	chr10:78392320	NA	-0.34	-5.73	-0.3	2.32e-8	Pulmonary function;
CRC	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg25885038	chr17:56607967	SEPT4	-0.37	-5.74	-0.3	2.15e-8	Vitamin D levels;
CRC	cis	rs375066	0.585	rs2195981	chr19:44352971	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs9463078	0.625	rs1329710	chr6:44969125	T/C	cg25276700	chr6:44698697	NA	-0.25	-6.14	-0.32	2.33e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg21155852	chr7:2048760	MAD1L1	-0.49	-6.51	-0.34	2.86e-10	Bipolar disorder;
CRC	trans	rs6686842	0.965	rs2802566	chr1:41551981	A/G	cg19787969	chr8:9763211	NA	0.29	6.13	0.32	2.57e-9	Height;
CRC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.87	-0.31	1.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4731207	0.565	rs1994022	chr7:124580877	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.09	-0.32	3.18e-9	Cutaneous malignant melanoma;
CRC	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.6	-10.6	-0.5	9.03e-23	Common traits (Other);
CRC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	6.07	0.32	3.46e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.86	11.75	0.54	7.34e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12101261	0.556	rs2300516	chr14:81446908	A/G	cg06600135	chr14:81408086	NA	0.39	5.68	0.3	3.01e-8	Graves' disease;
CRC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.55	9.93	0.48	1.64e-20	HDL cholesterol levels;
CRC	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg06484146	chr7:12443880	VWDE	-0.62	-6.51	-0.34	2.79e-10	Coronary artery disease;
CRC	cis	rs9311676	0.609	rs11921259	chr3:58368646	A/G	cg06643156	chr3:58380774	PXK	0.41	6.35	0.33	7.2e-10	Systemic lupus erythematosus;
CRC	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg13385794	chr1:248469461	NA	0.4	7.11	0.36	7.23e-12	Common traits (Other);
CRC	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg15382696	chr6:118971807	C6orf204	0.61	8.01	0.4	2.07e-14	Diastolic blood pressure;
CRC	cis	rs9534288	0.577	rs7999168	chr13:46680264	A/C	cg15192986	chr13:46630673	CPB2	-0.64	-8.59	-0.43	3.58e-16	Blood protein levels;
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.12	0.32	2.59e-9	Prudent dietary pattern;
CRC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.49	7.91	0.4	3.85e-14	Height;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07257037	chr12:70132348	RAB3IP	0.41	6.12	0.32	2.64e-9	Myopia (pathological);
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg15382696	chr6:118971807	C6orf204	0.6	7.67	0.39	1.9e-13	Diastolic blood pressure;
CRC	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg17133734	chr15:86042851	AKAP13	0.4	6.35	0.33	6.95e-10	Coronary artery disease;
CRC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.29	15.43	0.65	8.96e-41	Eosinophil percentage of granulocytes;
CRC	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	6.33	0.33	8.13e-10	Response to antipsychotic treatment;
CRC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg25459000	chr22:39777742	SYNGR1	-0.32	-5.77	-0.3	1.83e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg14036092	chr11:66035641	RAB1B	0.47	5.71	0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.61	9.3	0.46	1.99e-18	Testicular germ cell tumor;
CRC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg00603274	chr11:61596626	FADS2	-0.64	-7.77	-0.39	9.87e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.54	0.34	2.38e-10	Neuroticism;
CRC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.86	-9.85	-0.48	3.16e-20	Breast cancer;
CRC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.75	-0.39	1.12e-13	Chronic sinus infection;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07240673	chr16:3550908	CLUAP1	0.42	6.45	0.34	3.92e-10	Intelligence (multi-trait analysis);
CRC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.09	-0.32	3.1e-9	Acne (severe);
CRC	cis	rs12760731	0.565	rs12732507	chr1:178098296	A/G	cg00404053	chr1:178313656	RASAL2	1.1	11.41	0.53	1.2e-25	Obesity-related traits;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.63	0.57	4.38e-30	Alzheimer's disease;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.92	0.31	8.13e-9	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10251347	chr1:52344305	NRD1	0.46	6.57	0.34	1.94e-10	Response to antipsychotic treatment;
CRC	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.46	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.94	-0.36	2.04e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.63	8.63	0.43	2.64e-16	Coronary artery disease;
CRC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg10298567	chr3:47292165	KIF9	0.41	6.78	0.35	5.45e-11	Colorectal cancer;
CRC	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.75	-0.3	2.03e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.44	-6.29	-0.33	1e-9	Large artery stroke;
CRC	cis	rs75422866	0.510	rs73105845	chr12:48135607	T/C	cg14736327	chr12:48174669	SLC48A1	-0.84	-6.78	-0.35	5.63e-11	Pneumonia;
CRC	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.56e-21	Asthma (childhood onset);
CRC	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.5	-7.35	-0.38	1.62e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.89	-15.88	-0.66	1.45e-42	Height;
CRC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg03160526	chr17:80928410	B3GNTL1	-0.4	-5.79	-0.3	1.68e-8	Breast cancer;
CRC	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.51	6.71	0.35	8.67e-11	Coronary artery disease;
CRC	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg11038491	chr20:34638489	LOC647979	-0.61	-7.28	-0.37	2.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-5.64	-0.3	3.76e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.83	-12.01	-0.55	8.5e-28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg17788362	chr6:86352627	SYNCRIP	0.48	6.46	0.34	3.69e-10	Smooth-surface caries;
CRC	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.38	-5.7	-0.3	2.62e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.6	11.12	0.52	1.31e-24	Immature fraction of reticulocytes;
CRC	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.53	-7.02	-0.36	1.25e-11	Testicular germ cell tumor;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.82	10.64	0.51	6.26e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-6.08	-0.32	3.28e-9	Fibrinogen levels;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.07e-10	Life satisfaction;
CRC	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.11	-0.36	7.42e-12	Total cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27266479	chr1:9294882	H6PD	0.46	7.19	0.37	4.4e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.71	-10.23	-0.49	1.62e-21	Inflammatory bowel disease;
CRC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg19635926	chr16:89946313	TCF25	-0.61	-5.67	-0.3	3.07e-8	Skin colour saturation;
CRC	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.88	-16.73	-0.68	6.61e-46	Hip circumference;
CRC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg03623178	chr6:28175578	NA	0.88	9.15	0.45	6.03e-18	Lung cancer in ever smokers;
CRC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.9	16.65	0.68	1.4e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12541635	0.677	rs62527405	chr8:107058109	G/C	cg10147462	chr8:107024639	NA	0.6	10.5	0.5	2.01e-22	Age of smoking initiation;
CRC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.48	6.77	0.35	5.83e-11	Granulocyte percentage of myeloid white cells;
CRC	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.61	-0.63	1.29e-37	Exhaled nitric oxide output;
CRC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-8.36	-0.42	1.83e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg07809909	chr20:30433512	FOXS1	0.36	5.8	0.3	1.56e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.67	-0.3	3.14e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4926298	1.000	rs11085829	chr19:13174312	G/A	cg23899408	chr19:12877188	HOOK2	-0.46	-6.36	-0.33	6.73e-10	Bipolar disorder;
CRC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.47	-7.18	-0.37	4.56e-12	Calcium levels;
CRC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg11522145	chr4:3412961	RGS12	-0.37	-6.32	-0.33	8.31e-10	Parental longevity (mother's age at death);
CRC	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg01843034	chr6:37503916	NA	0.44	8.44	0.42	1.01e-15	Cognitive performance;
CRC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-0.56	-5.82	-0.31	1.4e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.39	6.66	0.34	1.17e-10	Crohn's disease;
CRC	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg00277334	chr10:82204260	NA	-0.37	-5.96	-0.31	6.48e-9	Sarcoidosis;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03923535	chr7:1197113	ZFAND2A	0.73	11.07	0.52	1.96e-24	Longevity;Endometriosis;
CRC	trans	rs12797204	0.793	rs36110284	chr11:83451753	T/C	cg07421806	chr5:128301136	SLC27A6	-0.6	-5.97	-0.31	6.12e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CRC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.97	0.4	2.64e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.64	10.0	0.48	9.88e-21	Huntington's disease progression;
CRC	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-7.88	-0.4	4.73e-14	Hepatocellular carcinoma;
CRC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.66	-0.43	2.18e-16	Body mass index;
CRC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.51	6.57	0.34	1.91e-10	Height;
CRC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.51	9.92	0.48	1.78e-20	Renal cell carcinoma;
CRC	cis	rs4700695	0.841	rs152933	chr5:65359530	A/G	cg21114390	chr5:65439923	SFRS12	-0.57	-6.84	-0.35	3.92e-11	Facial morphology (factor 19);
CRC	trans	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.43	6.11	0.32	2.74e-9	Cystic fibrosis severity;
CRC	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg07587117	chr16:2239488	CASKIN1	0.43	7.46	0.38	7.78e-13	Height;
CRC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.5	-5.73	-0.3	2.21e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6545883	0.525	rs2049747	chr2:61364154	G/A	cg10580144	chr2:61372316	C2orf74	-0.28	-5.7	-0.3	2.63e-8	Tuberculosis;
CRC	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21659725	chr3:3221576	CRBN	-0.67	-7.34	-0.38	1.72e-12	Menarche (age at onset);
CRC	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.53	9.56	0.47	2.89e-19	Common traits (Other);
CRC	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.44	6.97	0.36	1.78e-11	Breast cancer;
CRC	cis	rs9467160	0.765	rs793712	chr6:24446882	T/C	cg20631270	chr6:24437470	GPLD1	-0.44	-6.05	-0.32	4.04e-9	Liver enzyme levels;
CRC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg01262667	chr19:19385393	TM6SF2	0.37	6.23	0.33	1.39e-9	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06155979	chr2:232575824	PTMA	0.47	6.7	0.35	8.93e-11	Response to antipsychotic treatment;
CRC	cis	rs7605827	0.930	rs1035246	chr2:15512891	G/A	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.36e-9	Educational attainment (years of education);
CRC	cis	rs10991814	1.000	rs73650963	chr9:93943033	T/C	cg14446406	chr9:93919335	NA	0.59	7.26	0.37	2.8e-12	Neutrophil percentage of granulocytes;
CRC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.36	-0.46	1.27e-18	HDL cholesterol;
CRC	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg02927042	chr1:21476669	EIF4G3	0.45	7.24	0.37	3.12e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.39	-0.5	4.81e-22	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22696252	chr3:97540975	NA	0.4	6.58	0.34	1.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.47e-8	Total body bone mineral density;
CRC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.74	-0.35	7.11e-11	Cutaneous nevi;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg06470822	chr6:28175283	NA	0.81	12.29	0.56	7.97e-29	Parkinson's disease;
CRC	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.52	9.23	0.45	3.37e-18	Blood metabolite ratios;
CRC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg00343986	chr7:65444356	GUSB	-0.5	-7.51	-0.38	5.55e-13	Aortic root size;
CRC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.5	5.83	0.31	1.33e-8	Menarche (age at onset);
CRC	cis	rs11226613	0.547	rs7934144	chr11:104979884	C/T	cg04181079	chr11:104896587	CASP1	-0.42	-5.68	-0.3	2.96e-8	Bronchopulmonary dysplasia;
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.51	7.47	0.38	7.34e-13	Intelligence (multi-trait analysis);
CRC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.68	-8.05	-0.41	1.53e-14	Hip circumference adjusted for BMI;
CRC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.77	0.7	5.13e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg20636351	chr8:55087400	NA	-0.33	-5.9	-0.31	9.15e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg15123519	chr2:136567270	LCT	0.33	6.39	0.33	5.65e-10	Mosquito bite size;
CRC	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.82	15.8	0.66	3.09e-42	Hip circumference;
CRC	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.35	-0.46	1.43e-18	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.5	8.13	0.41	8.85e-15	Height;
CRC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.4	6.04	0.32	4.23e-9	Hemoglobin concentration;
CRC	cis	rs6662572	0.737	rs6700974	chr1:46371735	C/A	cg08644498	chr1:46502608	NA	-0.44	-6.85	-0.35	3.69e-11	Blood protein levels;
CRC	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs12745968	0.623	rs10874733	chr1:93123733	A/G	cg17283838	chr1:93427260	FAM69A	-0.46	-6.28	-0.33	1.08e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-11.69	-0.54	1.18e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg25767906	chr1:53392781	SCP2	0.37	5.86	0.31	1.12e-8	Monocyte count;
CRC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.38	-0.33	6.02e-10	Reticulocyte fraction of red cells;
CRC	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg02248941	chr16:2239361	CASKIN1	0.63	11.66	0.54	1.59e-26	Height;
CRC	cis	rs672059	1.000	rs566625	chr1:183161441	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	8.16	0.41	6.95e-15	Hypertriglyceridemia;
CRC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg05044414	chr3:183734942	ABCC5	0.46	8.02	0.4	1.82e-14	Anterior chamber depth;
CRC	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.42	6.86	0.35	3.38e-11	Sitting height ratio;
CRC	cis	rs4731207	0.596	rs10228686	chr7:124663086	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.11	-0.32	2.87e-9	Cutaneous malignant melanoma;
CRC	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.82	-14.49	-0.62	3.67e-37	Lewy body disease;
CRC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg19193384	chr17:30244184	NA	-0.65	-7.54	-0.38	4.67e-13	Hip circumference adjusted for BMI;
CRC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg23071808	chr14:103021642	NA	-0.64	-7.28	-0.37	2.45e-12	Platelet count;
CRC	trans	rs67073037	0.955	rs6734079	chr2:29160421	T/A	cg13899017	chr1:159158444	CADM3	-0.37	-6.14	-0.32	2.4e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.48	8.65e-21	Lung cancer;
CRC	trans	rs9914544	0.545	rs12452289	chr17:18781809	T/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.03	-0.32	4.38e-9	Educational attainment (years of education);
CRC	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg09659197	chr4:152720779	NA	0.5	10.68	0.51	4.69e-23	Intelligence (multi-trait analysis);
CRC	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg16388071	chr6:169726476	NA	-0.42	-6.61	-0.34	1.55e-10	Obesity-related traits;
CRC	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.88	17.02	0.68	4.81e-47	Hip circumference;
CRC	cis	rs2252521	0.553	rs2648659	chr7:29040952	A/T	cg11728747	chr7:29037910	CPVL	-0.47	-6.7	-0.35	8.96e-11	Cognitive performance;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22815056	chr20:4573300	NA	0.37	6.03	0.32	4.37e-9	Obesity-related traits;
CRC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.46	-6.11	-0.32	2.85e-9	Gut microbiome composition (summer);
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.63	11.52	0.54	4.85e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg08896387	chr1:24191740	FUCA1	0.46	5.77	0.3	1.81e-8	Immature fraction of reticulocytes;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-7.69	-0.39	1.77e-13	Blood metabolite levels;
CRC	cis	rs501916	0.605	rs2118917	chr15:48078992	C/T	cg16110827	chr15:48056943	SEMA6D	-0.47	-7.18	-0.37	4.81e-12	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg11245181	chr6:149772854	ZC3H12D	0.52	9.12	0.45	7.79e-18	Dupuytren's disease;
CRC	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg01721255	chr8:58191610	C8orf71	0.5	6.17	0.32	2.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.01	-0.36	1.35e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.87	0.4	5.04e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4561483	0.583	rs62038798	chr16:12001569	C/T	cg08843971	chr16:11963173	GSPT1	0.5	7.45	0.38	8.14e-13	Testicular germ cell tumor;
CRC	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.47	8.21	0.41	5.12e-15	Information processing speed;
CRC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg08741688	chr4:3415352	RGS12	-0.39	-5.82	-0.31	1.41e-8	Serum sulfate level;
CRC	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.49	7.3	0.37	2.15e-12	Night sleep phenotypes;
CRC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg10723962	chr6:26240782	HIST1H4F	0.4	6.03	0.32	4.38e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.76	0.35	6.27e-11	Tonsillectomy;
CRC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg01941586	chr1:40203715	PPIE	-0.45	-6.21	-0.32	1.59e-9	Blood protein levels;
CRC	cis	rs728616	0.614	rs35395602	chr10:81906770	A/G	cg05935833	chr10:81318306	SFTPA2	-0.57	-6.61	-0.34	1.59e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.74	11.17	0.52	8.95e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.53	-8.99	-0.44	2e-17	Airway imaging phenotypes;
CRC	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg15145174	chr5:6755386	POLS	-0.43	-6.21	-0.32	1.62e-9	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09831311	chr16:85833828	COX4NB;COX4I1	0.42	6.11	0.32	2.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.7	10.72	0.51	3.35e-23	Tonsillectomy;
CRC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.47	-6.89	-0.36	2.78e-11	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22127215	chr17:4613552	ARRB2	0.43	6.04	0.32	4.11e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.74	0.6	3e-34	Alzheimer's disease;
CRC	cis	rs9287719	0.649	rs6721857	chr2:10721210	C/T	cg00105475	chr2:10696890	NA	-0.42	-6.73	-0.35	7.63e-11	Prostate cancer;
CRC	cis	rs3018066	0.666	rs7662836	chr4:106997265	A/C	cg01869342	chr4:106983673	TBCK	0.48	6.23	0.33	1.39e-9	Cancer;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg08798685	chr6:27730294	NA	0.4	6.13	0.32	2.56e-9	Systemic lupus erythematosus;
CRC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.56	6.72	0.35	8.07e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.06	-0.52	2.27e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.99	-0.55	9.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.6	8.58	0.43	3.87e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-14.62	-0.63	1.16e-37	Chronic sinus infection;
CRC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.91	-17.84	-0.7	2.75e-50	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.6	-6.67	-0.35	1.06e-10	Menarche (age at onset);
CRC	cis	rs4481887	0.504	rs12025218	chr1:248356440	A/G	cg00666640	chr1:248458726	OR2T12	0.44	7.11	0.37	7.14e-12	Common traits (Other);
CRC	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.69	8.75	0.43	1.09e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.68	0.3	2.98e-8	Prudent dietary pattern;
CRC	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.57	-0.38	3.88e-13	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg23229984	chr5:148520753	ABLIM3	0.5	6.95	0.36	1.96e-11	Breast cancer;
CRC	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	1.13	17.87	0.7	2.24e-50	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.72	-0.3	2.41e-8	Crohn's disease;
CRC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.53	-0.34	2.46e-10	Alzheimer's disease (late onset);
CRC	cis	rs9303542	0.625	rs17703636	chr17:46566890	C/T	cg04904318	chr17:46607828	HOXB1	0.5	5.92	0.31	8.21e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.62	-9.75	-0.47	6.62e-20	Corneal astigmatism;
CRC	cis	rs2013441	0.965	rs8068720	chr17:20214171	G/T	cg13482628	chr17:19912719	NA	-0.4	-6.25	-0.33	1.28e-9	Obesity-related traits;
CRC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.52	-7.61	-0.39	2.92e-13	Asthma;
CRC	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.57	-5.91	-0.31	8.42e-9	Coronary artery disease;
CRC	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	5.63	0.3	3.93e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.28	0.75	7.02e-60	Prudent dietary pattern;
CRC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	8.83	0.44	6.56e-17	Cognitive test performance;
CRC	cis	rs995000	0.899	rs1748201	chr1:63045506	A/C	cg19896129	chr1:63156450	NA	-0.43	-6.7	-0.35	8.97e-11	Triglyceride levels;
CRC	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.78	11.79	0.54	5.53e-27	Fuchs's corneal dystrophy;
CRC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.66	0.39	2.13e-13	Major depressive disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg19092489	chr4:185375724	IRF2	-0.39	-5.97	-0.31	6.14e-9	Schizophrenia;
CRC	cis	rs12529935	0.737	rs11967697	chr6:90966364	G/A	cg06866423	chr6:90926672	BACH2	0.59	5.92	0.31	7.92e-9	Systemic lupus erythematosus;
CRC	trans	rs2303319	0.504	rs55650699	chr2:162388931	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg13491945	chr12:107078410	RFX4	0.36	6.21	0.32	1.63e-9	Heart rate;
CRC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.39	6.33	0.33	8.21e-10	Height;
CRC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg13611204	chr9:139324423	INPP5E	-0.41	-5.74	-0.3	2.13e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.66	-0.54	1.52e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2708977	0.698	rs772161	chr2:97043803	C/A	cg23100626	chr2:96804247	ASTL	0.23	5.86	0.31	1.1e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs7894051	1.000	rs11101723	chr10:135192139	C/A	cg24905316	chr10:135186343	ECHS1	0.78	6.87	0.35	3.18e-11	Lifespan;
CRC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.76	-11.51	-0.54	5.64e-26	Immature fraction of reticulocytes;
CRC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.48	6.79	0.35	5.24e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg15845792	chr6:28175446	NA	0.85	5.82	0.31	1.36e-8	Depression;
CRC	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	17.19	0.69	9.99e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.36	5.64	0.3	3.72e-8	Reticulocyte fraction of red cells;
CRC	trans	rs10243593	0.673	rs773393	chr7:40044282	A/G	cg13911576	chr9:84174038	NA	-0.34	-6.0	-0.31	5.21e-9	Lymphocyte counts;
CRC	cis	rs10888329	0.665	rs9662722	chr1:248385891	T/G	cg00666640	chr1:248458726	OR2T12	0.46	7.2	0.37	4.14e-12	Autism spectrum disorder;
CRC	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.22	-0.53	5.75e-25	Coffee consumption (cups per day);
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.61	9.47	0.46	5.55e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.56	0.38	3.94e-13	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23181591	chr8:123793873	ZHX2	0.49	6.32	0.33	8.51e-10	Thyroid stimulating hormone;
CRC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.63	-9.81	-0.48	4.13e-20	Body mass index;
CRC	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	0.98	14.44	0.62	6.21e-37	Breast cancer;
CRC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg21951975	chr1:209979733	IRF6	0.4	6.32	0.33	8.65e-10	Cleft lip with or without cleft palate;
CRC	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.42	6.31	0.33	9.16e-10	Testicular germ cell tumor;
CRC	cis	rs11958404	1.000	rs72816532	chr5:157413130	C/T	cg05962755	chr5:157440814	NA	0.78	10.75	0.51	2.66e-23	IgG glycosylation;
CRC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-11.03	-0.52	2.68e-24	Total cholesterol levels;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg22922770	chr7:98923339	ARPC1A	-0.68	-6.14	-0.32	2.35e-9	Cognitive function;
CRC	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06307176	chr5:131281290	NA	0.41	6.02	0.31	4.78e-9	Life satisfaction;
CRC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg13256891	chr4:100009986	ADH5	0.52	7.3	0.37	2.14e-12	Alcohol dependence;
CRC	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-6.18	-0.32	1.85e-9	Post bronchodilator FEV1;
CRC	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	7.77	0.39	1.04e-13	Breast cancer;
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg08888203	chr3:10149979	C3orf24	0.74	9.0	0.44	1.82e-17	Alzheimer's disease;
CRC	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.37	-5.64	-0.3	3.7e-8	Height;
CRC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.48	-6.84	-0.35	3.75e-11	Diastolic blood pressure;
CRC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg10862848	chr6:42927986	GNMT	0.34	6.48	0.34	3.34e-10	Blood protein levels;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.55	6.76	0.35	6.4e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10450586	0.677	rs7110359	chr11:27300429	A/T	cg10370305	chr11:27303972	NA	0.39	6.32	0.33	8.69e-10	Total body bone mineral density;
CRC	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.35	5.65	0.3	3.54e-8	Menarche (age at onset);
CRC	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg09141835	chr16:88988174	CBFA2T3	-0.28	-5.9	-0.31	8.9e-9	Social autistic-like traits;
CRC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05253283	chr3:195717344	SDHAP1	0.44	5.97	0.31	6.3e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13606994	chr1:44402422	ARTN	-0.34	-5.79	-0.3	1.65e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg10729496	chr3:10149963	C3orf24	0.53	6.93	0.36	2.25e-11	Alzheimer's disease;
CRC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg02007433	chr3:129722099	NA	-0.45	-6.08	-0.32	3.24e-9	Blood pressure (smoking interaction);
CRC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.79	10.18	0.49	2.52e-21	Iron status biomarkers;
CRC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.54	6.1	0.32	2.99e-9	Bipolar disorder;
CRC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.71	0.35	8.3e-11	Lung cancer;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07362569	chr17:61921086	SMARCD2	-0.38	-5.94	-0.31	7.14e-9	Prudent dietary pattern;
CRC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.43	6.21	0.32	1.61e-9	Aortic root size;
CRC	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg16476235	chr8:21771668	DOK2	0.4	6.51	0.34	2.78e-10	Mean corpuscular volume;
CRC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.86	15.42	0.65	9.15e-41	Height;
CRC	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.43	7.4	0.38	1.13e-12	Information processing speed;
CRC	cis	rs11212617	1.000	rs600329	chr11:108163733	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.02	0.32	4.58e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	6.02	0.32	4.53e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.95	-0.31	6.98e-9	Reticulocyte count;
CRC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg22029157	chr1:209979665	IRF6	0.62	6.79	0.35	5.36e-11	Coronary artery disease;
CRC	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg08461752	chr10:43522343	NA	-0.64	-5.93	-0.31	7.66e-9	Blood protein levels;
CRC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.68	-8.7	-0.43	1.67e-16	Psoriasis;
CRC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	0.99	11.19	0.53	7.36e-25	Type 2 diabetes nephropathy;
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.54	-10.17	-0.49	2.69e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.29e-9	Bipolar disorder;
CRC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg14558114	chr2:88469736	THNSL2	0.52	5.9	0.31	8.92e-9	Plasma clusterin levels;
CRC	cis	rs243505	0.660	rs1880358	chr7:148572504	C/T	cg09806900	chr7:148480153	CUL1	0.45	5.94	0.31	7.17e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07017275	chr14:55738748	FBXO34	-0.42	-6.63	-0.34	1.36e-10	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08450913	chr19:7694688	XAB2;LOC100131801	0.43	6.04	0.32	4.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.55	8.33	0.42	2.26e-15	Monocyte percentage of white cells;
CRC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.32	-0.37	1.88e-12	Self-reported allergy;
CRC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.36	-0.46	1.33e-18	HDL cholesterol;
CRC	cis	rs2279817	0.818	rs883379	chr1:17983789	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-5.69	-0.3	2.81e-8	Neuroticism;
CRC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.37	6.58	0.34	1.86e-10	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg09127314	chr1:152161683	NA	0.52	6.58	0.34	1.82e-10	Atopic dermatitis;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	7.1	0.36	7.67e-12	Breast cancer;
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.75	8.8	0.44	8.08e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06634786	chr22:41940651	POLR3H	-0.41	-5.75	-0.3	1.99e-8	Vitiligo;
CRC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.88	-17.1	-0.69	2.3e-47	Body mass index;
CRC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.58	7.65	0.39	2.27e-13	IgG glycosylation;
CRC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-1.03	-7.99	-0.4	2.28e-14	Breast cancer;
CRC	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg22777020	chr22:31556080	RNF185	-0.53	-6.2	-0.32	1.72e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.58	-9.6	-0.47	2.14e-19	Calcium levels;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Blood metabolite levels;
CRC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.68	10.17	0.49	2.64e-21	Lung cancer;
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.63	11.63	0.54	2.1e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg06818126	chr11:68850279	TPCN2	-0.51	-7.29	-0.37	2.38e-12	Hair color;
CRC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-6.76	-0.35	6.31e-11	Platelet distribution width;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20625393	chr4:95128694	SMARCAD1	-0.5	-6.2	-0.32	1.73e-9	Monocyte percentage of white cells;
CRC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.73	0.47	8.12e-20	Bladder cancer;
CRC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.5	7.19	0.37	4.47e-12	Lung cancer;
CRC	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg02811702	chr13:24901961	NA	0.43	5.96	0.31	6.58e-9	Obesity-related traits;
CRC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-6.08	-0.32	3.36e-9	Schizophrenia;
CRC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg02569458	chr12:86230093	RASSF9	0.39	6.65	0.34	1.25e-10	Major depressive disorder;
CRC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg03316587	chr8:142245164	NA	0.44	6.59	0.34	1.75e-10	Immature fraction of reticulocytes;
CRC	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg07125278	chr16:67683757	RLTPR	-0.58	-6.15	-0.32	2.26e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3750082	0.852	rs10260000	chr7:32898234	T/C	cg05721444	chr7:32995514	FKBP9	0.5	7.66	0.39	2.04e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.17	-0.41	6.9e-15	Platelet count;
CRC	cis	rs7605827	0.897	rs6431715	chr2:15717917	C/A	cg19274914	chr2:15703543	NA	0.41	6.15	0.32	2.25e-9	Educational attainment (years of education);
CRC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.72	0.47	8.43e-20	Colorectal cancer;
CRC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg13628971	chr7:2884303	GNA12	0.36	5.64	0.3	3.68e-8	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08208505	chr16:68119244	NFATC3	0.48	6.7	0.35	8.98e-11	Anxiety disorder;
CRC	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg12964065	chr18:77638022	KCNG2	0.68	6.81	0.35	4.68e-11	Opioid sensitivity;
CRC	cis	rs4731207	0.596	rs10275296	chr7:124681292	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.28	-0.33	1.06e-9	Cutaneous malignant melanoma;
CRC	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg08501292	chr6:25962987	TRIM38	0.84	6.5	0.34	2.97e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.69	-0.35	9.45e-11	Menopause (age at onset);
CRC	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg21399703	chr1:247681439	NA	0.46	7.61	0.39	2.97e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.42	6.44	0.33	4.24e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg02135003	chr7:105160482	PUS7	-0.73	-10.37	-0.5	5.48e-22	Bipolar disorder (body mass index interaction);
CRC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg00129232	chr17:37814104	STARD3	0.58	7.06	0.36	9.8e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.35	-5.64	-0.3	3.75e-8	Glycated hemoglobin levels;
CRC	trans	rs1549309	0.597	rs10454960	chr5:167240944	A/G	cg08634079	chr15:65478037	CLPX	0.44	6.08	0.32	3.34e-9	Dietary macronutrient intake;
CRC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.66	0.43	2.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.49	6.91	0.36	2.51e-11	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01156768	chr18:77439120	CTDP1	0.43	6.8	0.35	5.09e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg01639898	chr1:32083012	HCRTR1	0.3	6.1	0.32	3e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-6.9	-0.36	2.74e-11	Blood pressure (smoking interaction);
CRC	cis	rs1322512	0.760	rs818451	chr6:152924673	T/G	cg03415253	chr6:152958462	SYNE1	-0.41	-6.51	-0.34	2.81e-10	Tonometry;
CRC	cis	rs889398	0.641	rs7200258	chr16:69897469	T/G	cg00738113	chr16:70207722	CLEC18C	-0.42	-7.37	-0.38	1.43e-12	Body mass index;
CRC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	-0.51	-8.22	-0.41	4.87e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg05507819	chr15:63340323	TPM1	0.46	5.75	0.3	2.05e-8	HDL cholesterol;
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.21	0.37	3.95e-12	Life satisfaction;
CRC	cis	rs7932354	0.528	rs12224096	chr11:47174361	C/T	cg03339077	chr11:47165057	C11orf49	-0.46	-6.55	-0.34	2.18e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg27535305	chr1:53392650	SCP2	-0.36	-6.46	-0.34	3.73e-10	Monocyte count;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg15786705	chr6:28176104	NA	-0.57	-7.03	-0.36	1.22e-11	Parkinson's disease;
CRC	cis	rs7107770	0.663	rs2015290	chr11:125073825	T/C	cg27629782	chr11:125073726	PKNOX2	0.5	7.22	0.37	3.72e-12	Photic sneeze reflex;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21623771	chr12:116971139	NCRNA00173	0.35	6.26	0.33	1.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.51	7.22	0.37	3.6e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg09695851	chr17:3907499	NA	0.56	8.48	0.42	7.46e-16	Type 2 diabetes;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.14	-0.32	2.44e-9	Total body bone mineral density;
CRC	cis	rs6662572	0.737	rs9429179	chr1:46514198	A/G	cg08644498	chr1:46502608	NA	0.47	7.52	0.38	5.41e-13	Blood protein levels;
CRC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg24675056	chr1:15929824	NA	0.52	7.03	0.36	1.22e-11	Systolic blood pressure;
CRC	trans	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg18288967	chr1:45987694	PRDX1	0.7	7.9	0.4	4.22e-14	Obesity-related traits;
CRC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.88	10.34	0.5	6.76e-22	Psoriasis;
CRC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.92	-19.05	-0.72	4.62e-55	Urate levels in lean individuals;
CRC	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg02248941	chr16:2239361	CASKIN1	0.63	11.44	0.53	1.01e-25	Height;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-9.5	-0.46	4.59e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.52	6.35	0.33	7.25e-10	Allergy;
CRC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg18876405	chr7:65276391	NA	-0.44	-5.97	-0.31	6.3e-9	Aortic root size;
CRC	cis	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg02254774	chr11:50257496	LOC441601	0.41	5.62	0.3	4.12e-8	Coronary artery disease;
CRC	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg12845895	chr18:77676008	PQLC1	0.4	5.66	0.3	3.27e-8	Schizophrenia;
CRC	trans	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.19	0.32	1.75e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.69	-0.35	9.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.62	-11.12	-0.52	1.36e-24	Aortic root size;
CRC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg14558114	chr2:88469736	THNSL2	0.58	5.76	0.3	1.97e-8	Plasma clusterin levels;
CRC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.23	0.49	1.61e-21	Heart rate;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07555597	chr2:62423100	B3GNT2	-0.44	-6.23	-0.32	1.39e-9	Myopia (pathological);
CRC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.34	10.64	0.51	6.25e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs75246769	1.000	rs80293476	chr7:145644391	C/A	cg21982490	chr5:124845866	NA	-0.64	-5.96	-0.31	6.46e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs9283706	0.608	rs71626484	chr5:66334502	A/T	cg11590213	chr5:66331682	MAST4	0.4	5.62	0.3	4.06e-8	Coronary artery disease;
CRC	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08555112	chr17:48942811	TOB1	0.46	6.63	0.34	1.41e-10	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.58	8.38	0.42	1.56e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.62	10.16	0.49	2.95e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098699	0.821	rs931705	chr4:124205194	C/T	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs2072510	0.593	rs2247304	chr12:96424665	T/C	cg09636302	chr12:96389483	HAL	-0.52	-6.59	-0.34	1.77e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.01e-15	Platelet count;
CRC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.48	4.84e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.36	-0.33	6.91e-10	Total body bone mineral density;
CRC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.45	8.42	0.42	1.2e-15	Iron status biomarkers (transferrin levels);
CRC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.82	-12.92	-0.58	3.51e-31	Cognitive function;
CRC	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.56	6.76	0.35	6.37e-11	Lymphocyte counts;
CRC	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.78	11.25	0.53	4.49e-25	Height;
CRC	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg00495681	chr13:53174319	NA	-0.56	-8.09	-0.41	1.14e-14	Lewy body disease;
CRC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	16.33	0.67	2.62e-44	Lymphocyte percentage of white cells;
CRC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs7739232	0.920	rs79905210	chr6:53523634	T/C	cg15658676	chr6:53530538	KLHL31	-0.75	-5.88	-0.31	1.03e-8	Hip circumference adjusted for BMI;
CRC	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.22	-0.56	1.39e-28	Coffee consumption (cups per day);
CRC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.82	15.38	0.65	1.32e-40	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11588644	chr17:7761052	CYB5D1;LSMD1	0.44	6.33	0.33	8.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	11.03	0.52	2.82e-24	Motion sickness;
CRC	cis	rs4731207	0.591	rs11772336	chr7:124589796	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21086066	chr17:27920376	ANKRD13B	0.46	6.32	0.33	8.41e-10	Anxiety disorder;
CRC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.36	-6.22	-0.32	1.53e-9	Platelet count;
CRC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg15083037	chr5:83017644	HAPLN1	-0.46	-6.05	-0.32	4.03e-9	Prostate cancer;
CRC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.77	13.82	0.61	1.45e-34	Oral cavity cancer;
CRC	cis	rs11209185	0.509	rs1926279	chr1:68450681	A/G	cg22082780	chr1:68452167	NA	0.37	5.9	0.31	9.17e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg16070123	chr10:51489643	NA	-0.34	-5.76	-0.3	1.95e-8	Prostate-specific antigen levels;
CRC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.74	-0.35	7.32e-11	Lung cancer;
CRC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.55	0.43	4.62e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg23461800	chr14:103021989	NA	0.69	7.84	0.4	6.5e-14	Platelet count;
CRC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg14008862	chr17:28927542	LRRC37B2	0.5	6.01	0.31	4.94e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.36e-11	Lung cancer;
CRC	cis	rs17641971	0.684	rs1511367	chr8:49949412	T/C	cg00325661	chr8:49890786	NA	0.36	6.28	0.33	1.05e-9	Blood metabolite levels;
CRC	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg12160578	chr15:63334699	TPM1	0.63	7.53	0.38	5.02e-13	Orofacial clefts;
CRC	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg21918786	chr6:109611834	NA	-0.33	-5.61	-0.3	4.38e-8	Reticulocyte fraction of red cells;
CRC	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	8.05	0.41	1.58e-14	Iron status biomarkers;
CRC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.43	8.56	0.43	4.53e-16	Renal cell carcinoma;
CRC	trans	rs13434995	0.842	rs62305269	chr4:56373404	C/A	cg05873268	chr16:1290058	TPSAB1	-0.43	-6.24	-0.33	1.35e-9	Adiponectin levels;
CRC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.69	0.43	1.78e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-7.7	-0.39	1.58e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.52	7.64	0.39	2.44e-13	Lung cancer;
CRC	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg15845792	chr6:28175446	NA	0.55	7.82	0.4	7e-14	Parkinson's disease;
CRC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg25985355	chr7:65971099	NA	0.52	5.83	0.31	1.31e-8	Diabetic kidney disease;
CRC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.08	0.45	1.06e-17	Bladder cancer;
CRC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg12193833	chr17:30244370	NA	-0.75	-8.72	-0.43	1.4e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.59	9.01	0.45	1.66e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg20243544	chr17:37824526	PNMT	0.56	8.61	0.43	2.97e-16	Asthma;
CRC	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.63	-7.08	-0.36	8.79e-12	Coronary artery disease;
CRC	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg17182837	chr8:41585554	ANK1	-0.37	-5.75	-0.3	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg17298326	chr8:142245477	NA	-0.37	-5.71	-0.3	2.55e-8	Immature fraction of reticulocytes;
CRC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-11.05	-0.52	2.41e-24	Hepatocellular carcinoma;
CRC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4862307	0.836	rs13107384	chr4:185004073	C/T	cg06737308	chr4:185021514	ENPP6	-0.44	-6.99	-0.36	1.5e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.59	9.66	0.47	1.3e-19	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg18232548	chr7:50535776	DDC	-0.46	-6.3	-0.33	9.42e-10	Malaria;
CRC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.91	17.31	0.69	3.38e-48	Blood protein levels;
CRC	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.37	-6.88	-0.35	3.03e-11	Blood metabolite levels;
CRC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg22529645	chr1:3704559	LRRC47	0.43	5.81	0.3	1.5e-8	Red cell distribution width;
CRC	cis	rs6834538	0.538	rs6812859	chr4:113414100	A/C	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.77	-0.3	1.81e-8	Free thyroxine concentration;
CRC	trans	rs4591358	0.689	rs72927784	chr2:196415053	C/T	cg12742475	chr15:75233485	NA	0.3	5.96	0.31	6.4e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
CRC	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg10556349	chr10:835070	NA	-0.35	-6.69	-0.35	9.81e-11	Survival in rectal cancer;
CRC	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.1	-0.32	3.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-8.34	-0.42	2.1e-15	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10457504	chr17:19281708	MAPK7	0.45	6.46	0.34	3.72e-10	Response to antipsychotic treatment;
CRC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg25164649	chr6:28176230	NA	0.56	7.88	0.4	4.81e-14	Parkinson's disease;
CRC	cis	rs17065868	0.764	rs9533859	chr13:45032951	A/G	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.66	7.37	0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	trans	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg20064139	chr20:41823021	NA	-0.29	-6.09	-0.32	3.07e-9	Coronary artery disease;
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg02776659	chr21:47717406	C21orf57	-0.34	-5.75	-0.3	2.03e-8	Testicular germ cell tumor;
CRC	cis	rs12580194	0.593	rs12581060	chr12:55797484	A/C	cg19537932	chr12:55886519	OR6C68	-0.73	-9.21	-0.45	3.8e-18	Cancer;
CRC	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.62	-6.96	-0.36	1.8e-11	Coronary artery disease;
CRC	cis	rs56399783	0.901	rs12540539	chr7:2873294	C/T	cg19731401	chr7:2775893	GNA12	0.61	6.47	0.34	3.56e-10	Childhood ear infection;
CRC	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg13611204	chr9:139324423	INPP5E	-0.42	-5.92	-0.31	7.9e-9	White blood cell count;
CRC	cis	rs4731207	0.596	rs12537431	chr7:124586556	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.35e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.9e-8	Prostate cancer;
CRC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.82	8.98	0.44	2.19e-17	Breast cancer;
CRC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.5	7.58	0.39	3.65e-13	Asthma;
CRC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	0.65	7.6	0.39	3.17e-13	Lymphocyte counts;
CRC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg23298862	chr7:158159286	PTPRN2	0.37	5.82	0.31	1.43e-8	Calcium levels;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.49e-10	Depression;
CRC	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg12700464	chr11:78128424	GAB2	-0.47	-5.68	-0.3	3.03e-8	Testicular germ cell tumor;
CRC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.38	5.72	0.3	2.4e-8	Menarche (age at onset);
CRC	cis	rs1124376	0.935	rs6550307	chr3:20097885	G/A	cg05072819	chr3:20081367	KAT2B	0.57	6.85	0.35	3.61e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg04719120	chr6:96025338	MANEA	0.64	7.34	0.38	1.71e-12	Behavioural disinhibition (generation interaction);
CRC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.89	-16.04	-0.66	3.41e-43	Height;
CRC	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg25182066	chr10:30743637	MAP3K8	0.45	6.12	0.32	2.59e-9	Inflammatory bowel disease;
CRC	cis	rs2411233	1.000	rs8028720	chr15:39270787	C/G	cg23129342	chr15:39283510	NA	0.31	5.69	0.3	2.8e-8	Platelet count;
CRC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-7.89	-0.4	4.57e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9311474	0.652	rs352158	chr3:52217704	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.15	-0.32	2.31e-9	Electroencephalogram traits;
CRC	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.67	9.99	0.48	1.1e-20	Corneal astigmatism;
CRC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.6	8.11	0.41	9.79e-15	Multiple sclerosis;
CRC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.66	6.13	0.32	2.58e-9	IgG glycosylation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24356321	chr1:186344702	TPR;C1orf27;MIR548F1	0.41	6.16	0.32	2.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4920343	0.710	rs638256	chr1:19091182	C/A	cg19637330	chr1:19110922	NA	0.39	5.76	0.3	1.88e-8	Knee osteoarthritis;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg06964912	chr1:1173622	NA	0.25	6.03	0.32	4.41e-9	Myopia;
CRC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.85	15.03	0.64	3.23e-39	Height;
CRC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.32e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12936587	0.777	rs12951347	chr17:17534513	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.69	-0.3	2.74e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.8	-12.64	-0.57	3.93e-30	Hypospadias;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.6	-11.28	-0.53	3.75e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.32	-6.98	-0.36	1.65e-11	IgG glycosylation;
CRC	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg09127314	chr1:152161683	NA	0.47	6.02	0.31	4.75e-9	Atopic dermatitis;
CRC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg02766259	chr12:125626809	AACS	-0.45	-8.44	-0.42	1.01e-15	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.65	-10.71	-0.51	3.62e-23	Type 2 diabetes;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg15845792	chr6:28175446	NA	0.74	8.78	0.44	9.29e-17	Depression;
CRC	cis	rs939584	1.000	rs35628463	chr2:653581	G/A	cg03610516	chr2:642275	NA	-0.41	-5.64	-0.3	3.59e-8	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12580275	chr1:205744413	RAB7L1	0.47	6.63	0.34	1.4e-10	Response to antipsychotic treatment;
CRC	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg06632207	chr12:54070931	ATP5G2	0.41	7.12	0.37	6.7e-12	Height;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg15845792	chr6:28175446	NA	0.68	8.92	0.44	3.35e-17	Parkinson's disease;
CRC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.69	8.84	0.44	6.12e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg20488157	chr14:104394430	TDRD9	0.67	9.84	0.48	3.34e-20	Bipolar disorder;
CRC	cis	rs4700695	0.764	rs251327	chr5:65269464	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.24	0.37	3.26e-12	Facial morphology (factor 19);
CRC	cis	rs6662572	0.737	rs55652826	chr1:46442678	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.64	0.3	3.59e-8	Blood protein levels;
CRC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.57	7.95	0.4	3.1e-14	Lymphocyte percentage of white cells;
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	5.89	0.31	9.57e-9	Blood metabolite levels;
CRC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg07074390	chr21:40555500	PSMG1	-0.47	-6.29	-0.33	1.03e-9	Cognitive function;
CRC	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.6	-8.08	-0.41	1.22e-14	Waist circumference;Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04630321	chr11:74204613	LIPT2	0.44	6.0	0.31	5.22e-9	Anxiety disorder;
CRC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.54	8.73	0.43	1.29e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.72	-12.66	-0.57	3.39e-30	White blood cell count (basophil);
CRC	cis	rs11229555	0.645	rs12274866	chr11:58177129	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.64	8.81	0.44	7.53e-17	Response to diuretic therapy;
CRC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.53	-7.87	-0.4	5.27e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg04362960	chr10:104952993	NT5C2	-0.48	-6.34	-0.33	7.74e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.89	-14.73	-0.63	4.46e-38	Blood metabolite levels;
CRC	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02259255	chr5:176944032	DDX41	0.42	6.65	0.34	1.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.84	10.26	0.49	1.27e-21	Breast cancer;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg21251018	chr6:28226885	NKAPL	0.46	7.07	0.36	9.53e-12	Cardiac Troponin-T levels;
CRC	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.1	0.45	8.81e-18	Blood protein levels;
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	9.92e-11	Menopause (age at onset);
CRC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21643547	chr1:205240462	TMCC2	-0.38	-6.13	-0.32	2.58e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Depression;
CRC	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.6	-7.37	-0.38	1.37e-12	Post bronchodilator FEV1;
CRC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.62	9.08	0.45	1.04e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1519814	1.000	rs6469902	chr8:121171911	A/T	cg22335954	chr8:121166405	COL14A1	-0.55	-6.48	-0.34	3.34e-10	Breast cancer;
CRC	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.74	12.06	0.55	5.7e-28	Eosinophil percentage of white cells;
CRC	cis	rs2298450	0.717	rs2835330	chr21:37631173	G/A	cg02919814	chr21:37666008	DOPEY2	-0.51	-6.75	-0.35	6.68e-11	Schizophrenia;
CRC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.39	6.29	0.33	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.51	8.11	0.41	9.86e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.5	6.81	0.35	4.78e-11	Intelligence (multi-trait analysis);
CRC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg22777020	chr22:31556080	RNF185	0.46	5.65	0.3	3.54e-8	Colorectal cancer;
CRC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18011946	chr5:65440816	SFRS12	0.46	6.37	0.33	6.35e-10	Response to antipsychotic treatment;
CRC	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg20542592	chr8:11973495	FAM66D	0.34	5.9	0.31	8.92e-9	Retinal vascular caliber;
CRC	cis	rs4728302	0.934	rs4129572	chr7:133636888	T/C	cg03336402	chr7:133662267	EXOC4	0.46	6.93	0.36	2.21e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	6.06	0.32	3.77e-9	Putamen volume;
CRC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-16.76	-0.68	5.32e-46	Intelligence (multi-trait analysis);
CRC	cis	rs7680126	0.633	rs28378345	chr4:10209897	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-6.0	-0.31	5.27e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg17796960	chr10:135278976	LOC619207	-0.37	-5.61	-0.3	4.26e-8	Systemic lupus erythematosus;
CRC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	trans	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.5	-0.34	3.04e-10	Schizophrenia;
CRC	cis	rs4731207	0.591	rs12535300	chr7:124613907	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs6496667	0.908	rs12592935	chr15:90852437	T/C	cg04176472	chr15:90893244	GABARAPL3	0.55	7.4	0.38	1.18e-12	Rheumatoid arthritis;
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.65	0.57	3.81e-30	Alzheimer's disease;
CRC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.73	-0.35	7.48e-11	Obesity-related traits;
CRC	trans	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs7243821	0.921	rs1944360	chr18:52623560	C/T	cg16669619	chr18:52630472	NA	-0.42	-6.09	-0.32	3.12e-9	Chin dimples;
CRC	cis	rs365302	0.716	rs452441	chr6:159610622	C/T	cg14500486	chr6:159655392	FNDC1	0.52	7.91	0.4	3.92e-14	Coronary heart disease;
CRC	cis	rs1192419	0.502	rs12059556	chr1:92055995	C/T	cg24006770	chr1:92056542	NA	0.57	9.56	0.47	2.97e-19	Optic disc area;Optic nerve measurement (cup-to-disc ratio);
CRC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.0	10.93	0.52	6.37e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.63	9.02	0.45	1.63e-17	Birth weight;
CRC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.57	-9.18	-0.45	4.95e-18	Neuroticism;
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg04518342	chr5:131593106	PDLIM4	0.35	6.42	0.33	4.62e-10	Blood metabolite levels;
CRC	cis	rs17023223	0.509	rs10923740	chr1:119600287	C/T	cg05756136	chr1:119680316	WARS2	-0.5	-6.58	-0.34	1.87e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg23996704	chr18:44553084	KATNAL2	-0.41	-8.23	-0.41	4.43e-15	Personality dimensions;
CRC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.68	9.26	0.45	2.69e-18	Breast cancer;
CRC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.61	-9.16	-0.45	5.56e-18	Longevity;
CRC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-10.48	-0.5	2.33e-22	Menarche (age at onset);
CRC	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg15382696	chr6:118971807	C6orf204	0.59	7.5	0.38	6.18e-13	Diastolic blood pressure;
CRC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg25985355	chr7:65971099	NA	-0.5	-5.69	-0.3	2.86e-8	Diabetic kidney disease;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg21251018	chr6:28226885	NKAPL	0.41	5.88	0.31	1.02e-8	Parkinson's disease;
CRC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg23018236	chr17:30244563	NA	-0.59	-8.03	-0.4	1.76e-14	Hip circumference adjusted for BMI;
CRC	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.46	-0.42	8.98e-16	Alcohol dependence;
CRC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.79	-12.51	-0.57	1.22e-29	Cognitive function;
CRC	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	11.64	0.54	1.89e-26	Height;
CRC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg03233332	chr7:66118400	NA	-0.4	-5.77	-0.3	1.79e-8	Aortic root size;
CRC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	8.88	0.44	4.31e-17	Cognitive test performance;
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00166722	chr3:10149974	C3orf24	0.66	7.71	0.39	1.49e-13	Alzheimer's disease;
CRC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.11	-0.36	7.37e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Depression;
CRC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.55	6.9	0.36	2.67e-11	Lung cancer;
CRC	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.77	-10.08	-0.49	5.38e-21	Blood metabolite levels;
CRC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.58	-8.42	-0.42	1.14e-15	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22627950	chr7:44622302	TMED4	0.46	6.0	0.31	5.17e-9	Thyroid stimulating hormone;
CRC	cis	rs4664293	0.669	rs35299907	chr2:160418653	T/C	cg08347373	chr2:160653686	CD302	0.38	6.29	0.33	1.01e-9	Monocyte percentage of white cells;
CRC	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.36	-0.33	6.77e-10	IgE levels;
CRC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.69	9.74	0.47	7.38e-20	Platelet count;
CRC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.6	8.59	0.43	3.61e-16	Arsenic metabolism;
CRC	cis	rs524281	0.773	rs2236651	chr11:66001418	C/T	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs11229555	0.574	rs11229454	chr11:58203682	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg22974920	chr21:40686053	BRWD1	-0.42	-6.0	-0.31	5.34e-9	Cognitive function;
CRC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg15105060	chr4:7024189	TBC1D14	-0.68	-5.85	-0.31	1.21e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.09	0.55	4.14e-28	Testicular germ cell tumor;
CRC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.33e-12	Life satisfaction;
CRC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-7.66	-0.39	2.04e-13	Vitiligo;
CRC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.33	-0.46	1.66e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.06	-0.32	3.74e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6496667	0.642	rs58218975	chr15:91056798	C/G	cg04176472	chr15:90893244	GABARAPL3	0.62	7.87	0.4	5.06e-14	Rheumatoid arthritis;
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00166722	chr3:10149974	C3orf24	0.67	9.32	0.46	1.71e-18	Alzheimer's disease;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg08264704	chr1:228270414	ARF1	-0.41	-6.09	-0.32	3.11e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg06494592	chr3:125709126	NA	-0.52	-6.75	-0.35	6.66e-11	Blood pressure (smoking interaction);
CRC	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.59	7.58	0.39	3.57e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11861043	chr3:49131662	QRICH1	0.47	6.9	0.36	2.6e-11	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.69	0.3	2.82e-8	Cardiac Troponin-T levels;
CRC	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.87	-0.31	1.05e-8	Coronary artery disease;
CRC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.43	6.1	0.32	2.92e-9	Parkinson's disease;
CRC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.37	6.03	0.32	4.33e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11654801	0.812	rs11658722	chr17:20858686	G/A	cg23759823	chr7:139672531	TBXAS1	-0.39	-6.33	-0.33	8.17e-10	Mosquito bite size;
CRC	cis	rs2742417	0.967	rs1609553	chr3:45735142	T/C	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.95e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.63	-8.81	-0.44	7.27e-17	Coronary artery disease;
CRC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.67e-18	Bladder cancer;
CRC	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg13491945	chr12:107078410	RFX4	0.35	5.94	0.31	7.13e-9	Heart rate;
CRC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg26587870	chr6:27730563	NA	-0.6	-5.98	-0.31	5.78e-9	Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04407579	chr13:99228509	STK24	0.39	6.35	0.33	7.14e-10	Interleukin-6 levels;
CRC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.53	-9.31	-0.46	1.84e-18	Schizophrenia;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.49	9.93	0.48	1.67e-20	Lung cancer;
CRC	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.42	-6.57	-0.34	1.93e-10	Red blood cell count;
CRC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.75	12.89	0.58	4.55e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.533	rs1481340	chr7:124582051	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.25e-9	Cutaneous malignant melanoma;
CRC	trans	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-6.76	-0.35	6.2e-11	Response to antipsychotic treatment;
CRC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg07870213	chr5:140052090	DND1	0.64	8.34	0.42	2.01e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg02033258	chr5:131593261	PDLIM4	-0.33	-5.85	-0.31	1.17e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.86	-0.44	5.18e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs57590327	0.508	rs4399914	chr3:81965477	C/T	cg07356753	chr3:81810745	GBE1	-0.47	-6.25	-0.33	1.28e-9	Extraversion;
CRC	cis	rs4664293	0.769	rs1365798	chr2:160652364	A/G	cg08347373	chr2:160653686	CD302	0.43	6.59	0.34	1.78e-10	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.4	6.46	0.34	3.88e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs763356	chr2:15518816	G/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.62	0.34	1.49e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.36	-6.81	-0.35	4.74e-11	Iron status biomarkers;
CRC	cis	rs4865169	0.595	rs9998008	chr4:57766052	A/G	cg24291500	chr4:57773398	REST	0.29	5.62	0.3	4.08e-8	Breast cancer;
CRC	cis	rs17065868	0.764	rs61949796	chr13:45030199	T/C	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.19	-0.32	1.8e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg02007433	chr3:129722099	NA	-0.51	-6.19	-0.32	1.8e-9	Blood pressure (smoking interaction);
CRC	cis	rs1223397	0.651	rs2496144	chr6:13311941	A/G	cg07912922	chr6:13274314	PHACTR1	0.38	6.03	0.32	4.44e-9	Blood pressure;
CRC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.54	-8.39	-0.42	1.47e-15	Aortic root size;
CRC	cis	rs7512552	0.525	rs2298161	chr1:150237624	A/G	cg15654264	chr1:150340011	RPRD2	0.45	6.58	0.34	1.9e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.72	0.35	7.86e-11	Body mass index;
CRC	trans	rs9634489	0.648	rs4771946	chr13:97062424	C/T	cg20945253	chr2:157189510	NR4A2	0.38	6.03	0.32	4.5e-9	Body mass index;
CRC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.59	7.93	0.4	3.47e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08720519	chr16:70558200	SF3B3;COG4	0.46	6.81	0.35	4.6e-11	Schizophrenia;
CRC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.6	9.14	0.45	6.54e-18	Corneal astigmatism;
CRC	cis	rs4731207	0.596	rs7795218	chr7:124578380	C/A	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.79e-9	Cutaneous malignant melanoma;
CRC	cis	rs427941	0.703	rs201441	chr7:101737327	A/C	cg06246474	chr7:101738831	CUX1	0.45	7.16	0.37	5.44e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.64	-10.37	-0.5	5.29e-22	Body mass index;
CRC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg18375707	chr11:64034959	PLCB3	0.48	6.03	0.32	4.34e-9	Mean platelet volume;
CRC	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.4	7.55	0.38	4.22e-13	Ulcerative colitis;
CRC	trans	rs16957091	0.528	rs12908349	chr15:43086227	C/T	cg07673103	chr8:74277181	NA	0.54	5.97	0.31	6.29e-9	MGMT methylation in smokers;
CRC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg12855166	chr17:30846586	MYO1D	-0.39	-6.57	-0.34	1.92e-10	Schizophrenia;
CRC	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.72	-12.79	-0.58	1.14e-30	White blood cell count (basophil);
CRC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-10.14	-0.49	3.41e-21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.41	0.33	4.97e-10	Menopause (age at onset);
CRC	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg23260525	chr10:116636907	FAM160B1	0.32	6.81	0.35	4.75e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.37	0.33	6.54e-10	Diastolic blood pressure;
CRC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.42	-0.42	1.21e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg22110888	chr17:80059540	CCDC57	0.38	6.01	0.31	5.06e-9	Life satisfaction;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg25164649	chr6:28176230	NA	0.61	8.13	0.41	9.13e-15	Parkinson's disease;
CRC	cis	rs9311676	0.656	rs11915480	chr3:58377159	A/G	cg06643156	chr3:58380774	PXK	0.41	6.35	0.33	7.27e-10	Systemic lupus erythematosus;
CRC	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg24588162	chr13:113633484	MCF2L	-0.37	-6.67	-0.35	1.05e-10	Systolic blood pressure;
CRC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.18	-17.19	-0.69	1.02e-47	Hip circumference adjusted for BMI;
CRC	cis	rs75422866	0.867	rs73104104	chr12:48065769	C/T	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg08200582	chr11:442649	ANO9	-0.7	-7.07	-0.36	9.14e-12	Body mass index;
CRC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.12	-0.41	9.45e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10628982	chr1:33816091	PHC2	0.42	6.19	0.32	1.81e-9	Response to antipsychotic treatment;
CRC	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.73	10.06	0.49	6.14e-21	Systemic lupus erythematosus;
CRC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.39	-0.5	4.76e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.62	-9.99	-0.48	1.04e-20	Aortic root size;
CRC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	5.93	0.31	7.82e-9	Tonsillectomy;
CRC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9928842	0.823	rs6564243	chr16:75296001	A/C	cg09066997	chr16:75300724	BCAR1	0.62	5.86	0.31	1.1e-8	Alcoholic chronic pancreatitis;
CRC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.46	-8.83	-0.44	6.17e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	0.87	6.92	0.36	2.31e-11	Type 2 diabetes nephropathy;
CRC	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg09654669	chr8:57350985	NA	-0.44	-5.86	-0.31	1.12e-8	Obesity-related traits;
CRC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.6	9.56	0.47	2.91e-19	Vitiligo;
CRC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-21.08	-0.76	5.23e-63	Primary sclerosing cholangitis;
CRC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.72	11.83	0.55	3.82e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg19640130	chr10:64028056	RTKN2	-0.35	-5.66	-0.3	3.31e-8	Rheumatoid arthritis;
CRC	cis	rs2625529	0.730	rs7177242	chr15:72184114	A/G	cg16672083	chr15:72433130	SENP8	0.44	6.44	0.33	4.35e-10	Red blood cell count;
CRC	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.58e-11	Inflammatory skin disease;
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	trans	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.21	-0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-13.35	-0.59	8.55e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg09163369	chr1:210001066	C1orf107	0.4	5.75	0.3	2.08e-8	Orofacial clefts;
CRC	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.52	7.72	0.39	1.39e-13	HDL cholesterol;
CRC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.57	7.95	0.4	3.01e-14	Lung cancer;
CRC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.92	0.31	8.03e-9	Height;
CRC	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.48	-7.7	-0.39	1.56e-13	Schizophrenia;
CRC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs2282802	0.685	rs7717563	chr5:139689968	A/G	cg26211634	chr5:139558579	C5orf32	-0.43	-7.37	-0.38	1.41e-12	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg23123621	chr4:1343375	KIAA1530	0.36	6.35	0.33	7.02e-10	Obesity-related traits;
CRC	trans	rs4586057	0.812	rs10881841	chr10:92637153	G/A	cg26894278	chr13:21016241	CRYL1	0.38	6.34	0.33	7.64e-10	Economic and political preferences (time);
CRC	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.1	-22.43	-0.78	2.87e-68	Triglycerides;
CRC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	11.96	0.55	1.27e-27	Schizophrenia;
CRC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.16	0.41	7.39e-15	Lung cancer;
CRC	cis	rs9650315	0.530	rs35399441	chr8:57089431	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.45	6.4	0.33	5.2400000000000005e-10	Height;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg21251018	chr6:28226885	NKAPL	0.53	8.1	0.41	1.05e-14	Parkinson's disease;
CRC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.65	-10.7	-0.51	3.9e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.51	7.37	0.38	1.4e-12	Type 2 diabetes;
CRC	cis	rs3824347	0.771	rs10869477	chr9:77652604	A/G	cg01251476	chr9:77566080	C9orf40	0.37	5.83	0.31	1.29e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.1	0.32	2.91e-9	Hip circumference adjusted for BMI;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg03623178	chr6:28175578	NA	0.88	9.24	0.45	3.24e-18	Lung cancer in ever smokers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16688911	chr19:46010011	VASP	0.43	5.97	0.31	6.28e-9	Response to antipsychotic treatment;
CRC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg05527609	chr1:210001259	C1orf107	-0.5	-6.78	-0.35	5.44e-11	Monobrow;
CRC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.4	-0.33	5.41e-10	Aortic root size;
CRC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg25985355	chr7:65971099	NA	0.51	5.75	0.3	2.08e-8	Diabetic kidney disease;
CRC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.54	6.95	0.36	1.98e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg10437265	chr15:77819839	NA	-0.49	-8.54	-0.43	5.15e-16	Type 2 diabetes;
CRC	cis	rs10804591	0.848	rs6782700	chr3:129309147	G/A	cg21885638	chr3:129306552	PLXND1	-0.55	-6.78	-0.35	5.53e-11	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg27068330	chr11:65405492	SIPA1	-0.44	-6.63	-0.34	1.37e-10	Acne (severe);
CRC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07513332	chr6:167530253	CCR6	0.37	6.27	0.33	1.14e-9	Primary biliary cholangitis;
CRC	cis	rs3026445	0.887	rs10774601	chr12:110879831	T/C	cg12870014	chr12:110450643	ANKRD13A	0.38	5.93	0.31	7.53e-9	QT interval;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg27266060	chr8:22091797	NA	0.36	5.92	0.31	8.03e-9	Hypertriglyceridemia;
CRC	cis	rs672059	0.934	rs641057	chr1:183156859	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.13	0.37	6.54e-12	Hypertriglyceridemia;
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.67	-8.89	-0.44	3.98e-17	Alzheimer's disease;
CRC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg05036130	chr6:150231994	NA	0.27	5.69	0.3	2.85e-8	Lung cancer;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	5.93	0.31	7.64e-9	Prudent dietary pattern;
CRC	cis	rs17767392	0.918	rs8007068	chr14:71770710	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.69	-10.81	-0.51	1.67e-23	Blood protein levels;
CRC	cis	rs11212617	1.000	rs637064	chr11:108140909	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.29	0.33	1e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs720844	0.748	rs71413623	chr2:149324977	A/C	cg09247360	chr2:149335327	NA	-0.55	-5.98	-0.31	5.77e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.7	-12.16	-0.56	2.34e-28	Asthma;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg16800975	chr8:17434541	PDGFRL	-0.5	-6.08	-0.32	3.35e-9	Type 1 diabetes;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	5.62	0.3	3.97e-8	Bipolar disorder;
CRC	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.01	-0.31	4.89e-9	Metabolite levels (Pyroglutamine);
CRC	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg22134325	chr11:66188745	NPAS4	0.4	6.43	0.33	4.38e-10	Airway imaging phenotypes;
CRC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.35	-7.45	-0.38	8.4e-13	Urinary metabolites;
CRC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg14711859	chr11:8959438	ASCL3	0.45	7.52	0.38	5.21e-13	Hemoglobin concentration;
CRC	cis	rs7849270	1.000	rs1009242	chr9:131916832	A/G	cg13538475	chr9:131942899	NA	-0.31	-6.01	-0.31	4.82e-9	Blood metabolite ratios;
CRC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.3	0.42	2.69e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg00343986	chr7:65444356	GUSB	0.46	6.58	0.34	1.81e-10	Calcium levels;
CRC	cis	rs12620999	0.941	rs62183342	chr2:237979140	C/A	cg23555395	chr2:238036564	NA	0.54	8.35	0.42	1.91e-15	Systemic lupus erythematosus;
CRC	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.48	0.34	3.28e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.48	0.34	3.32e-10	Diabetic kidney disease;
CRC	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg23234261	chr14:55582407	NA	-0.3	-5.84	-0.31	1.28e-8	Protein biomarker;
CRC	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11547950	chr5:77652471	NA	0.52	7.59	0.39	3.37e-13	Triglycerides;
CRC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.48	-0.34	3.26e-10	Breast cancer;
CRC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg16339924	chr4:17578868	LAP3	-0.49	-5.94	-0.31	7.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6662572	1.000	rs6662572	chr1:46146812	A/G	cg08644498	chr1:46502608	NA	0.48	7.04	0.36	1.13e-11	Blood protein levels;
CRC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.62	8.95	0.44	2.59e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.6	-9.44	-0.46	6.93e-19	Body mass index;
CRC	cis	rs12580194	1.000	rs58332180	chr12:55711353	C/A	cg19537932	chr12:55886519	OR6C68	-0.6	-8.23	-0.41	4.29e-15	Cancer;
CRC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.57	-9.93	-0.48	1.73e-20	Lung function (FVC);
CRC	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg06223162	chr1:101003688	GPR88	0.37	6.75	0.35	6.64e-11	Monocyte count;
CRC	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.96	-0.31	6.39e-9	Vitamin D levels;
CRC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.53	0.34	2.55e-10	Tonsillectomy;
CRC	trans	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg18335740	chr13:41363409	SLC25A15	-0.56	-8.96	-0.44	2.5e-17	Lewy body disease;
CRC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.78	-0.44	9.13e-17	Bone mineral density;
CRC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.81	-0.48	4.22e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg01312482	chr5:178451176	ZNF879	-0.34	-5.66	-0.3	3.35e-8	Pubertal anthropometrics;
CRC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg13385521	chr17:29058706	SUZ12P	0.55	7.35	0.38	1.6e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.61	0.47	1.92e-19	Cognitive test performance;
CRC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.62	0.51	7.72e-23	Diabetic retinopathy;
CRC	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg04110750	chr16:69646130	NFAT5	-0.57	-7.82	-0.4	7.07e-14	IgE levels;
CRC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg25876840	chr17:41920477	NA	-0.46	-7.3	-0.37	2.21e-12	Triglycerides;
CRC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.57	8.29	0.42	2.85e-15	Homoarginine levels;
CRC	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.59	6.3	0.33	9.66e-10	RR interval (heart rate);
CRC	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.73	9.45	0.46	6.4e-19	Blood protein levels;
CRC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.62	10.73	0.51	3.1e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.62	-6.17	-0.32	2.02e-9	Response to haloperidol in psychosis;
CRC	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg00250761	chr1:31883323	NA	0.42	8.09	0.41	1.17e-14	Alcohol dependence;
CRC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.37	6.03	0.32	4.33e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg09659197	chr4:152720779	NA	-0.44	-9.46	-0.46	5.89e-19	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15188491	chr1:146644106	PRKAB2	0.52	6.99	0.36	1.57e-11	Thyroid stimulating hormone;
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.47	-6.38	-0.33	6.04e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.4	6.1	0.32	3.05e-9	Red blood cell count;
CRC	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	trans	rs10504390	0.656	rs78904368	chr8:66553761	C/T	cg26403416	chr21:43771339	TFF2	0.59	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.34e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01890681	chr17:635336	FAM57A	0.43	6.37	0.33	6.29e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.58	-8.0	-0.4	2.08e-14	DNA methylation (variation);
CRC	cis	rs11255291	1.000	rs7080828	chr10:7733770	G/A	cg00997801	chr10:7671259	ITIH5	0.4	5.86	0.31	1.15e-8	Ovarian reserve;
CRC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.92	10.92	0.52	6.74e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.51	7.15	0.37	5.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11212617	0.935	rs4623864	chr11:108051300	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.49	0.34	3.13e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg03037974	chr15:76606532	NA	-0.52	-7.72	-0.39	1.4e-13	Blood metabolite levels;
CRC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg04731861	chr2:219085781	ARPC2	-0.31	-6.57	-0.34	1.99e-10	Colorectal cancer;
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg22561889	chr6:118971681	C6orf204	0.53	6.83	0.35	4.16e-11	Diastolic blood pressure;
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18099408	chr3:52552593	STAB1	-0.46	-7.76	-0.39	1.07e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.39	6.59	0.34	1.73e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg09873164	chr1:152488093	CRCT1	0.39	6.57	0.34	1.98e-10	Hair morphology;
CRC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.91	17.37	0.69	2.05e-48	Blood protein levels;
CRC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.45	7.09	0.36	8.29e-12	Obesity-related traits;
CRC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg04553112	chr3:125709451	NA	-0.47	-5.69	-0.3	2.82e-8	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.27	0.41	3.32e-15	Alzheimer's disease;
CRC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.63	-10.27	-0.49	1.2e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	1.03	8.8	0.44	7.71e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.56	-8.41	-0.42	1.29e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06671706	chr8:8559999	CLDN23	0.61	9.04	0.45	1.35e-17	Obesity-related traits;
CRC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.46	-5.68	-0.3	2.98e-8	Bipolar disorder;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg25164649	chr6:28176230	NA	0.47	6.93	0.36	2.17e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.17	0.37	5.01e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.86	-0.44	4.97e-17	Bipolar disorder;
CRC	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06307176	chr5:131281290	NA	0.49	6.94	0.36	2.06e-11	Life satisfaction;
CRC	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg02158880	chr13:53174818	NA	0.5	7.51	0.38	5.53e-13	Lewy body disease;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.99	17.82	0.7	3.29e-50	Menarche (age at onset);
CRC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.5	7.88	0.4	4.7e-14	Coronary artery disease;
CRC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.41	0.56	2.76e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.38	7.23	0.37	3.35e-12	Tonsillectomy;
CRC	trans	rs2898857	0.524	rs11652146	chr17:47422363	G/A	cg11430096	chr6:110968061	CDK19	-0.49	-7.46	-0.38	8.01e-13	Cancer;
CRC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.69	0.7	1.13e-49	Platelet count;
CRC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg19223190	chr17:80058835	NA	0.41	6.7	0.35	8.79e-11	Life satisfaction;
CRC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.48	6.98	0.36	1.64e-11	Breast cancer;
CRC	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.1	-0.32	2.94e-9	Educational attainment;
CRC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.76	-10.4	-0.5	4.17e-22	IgG glycosylation;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	7.56	0.38	3.99e-13	Lymphocyte counts;
CRC	trans	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.84	0.35	3.81e-11	Mean corpuscular volume;
CRC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg05341575	chr12:125625032	AACS	-0.4	-5.74	-0.3	2.14e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs10503871	0.545	rs6991816	chr8:30487344	C/T	cg26383811	chr8:30366931	RBPMS	-0.39	-5.67	-0.3	3.08e-8	Metabolite levels  (X-11787);
CRC	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	8.78	0.44	8.93e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg11204139	chr17:3907470	NA	0.55	8.45	0.42	9.87e-16	Type 2 diabetes;
CRC	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.76	-12.7	-0.57	2.38e-30	Idiopathic membranous nephropathy;
CRC	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.48	-0.5	2.34e-22	Total cholesterol levels;
CRC	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	5.91	0.31	8.55e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.33	-6.81	-0.35	4.59e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-6.89	-0.35	2.92e-11	Cognitive test performance;
CRC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.66	-9.39	-0.46	1.04e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.27	0.64	3.58e-40	Platelet count;
CRC	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg15382696	chr6:118971807	C6orf204	0.48	6.52	0.34	2.65e-10	Renal cell carcinoma;
CRC	cis	rs3956705	0.830	rs7811609	chr7:32930597	A/G	cg05721444	chr7:32995514	FKBP9	0.43	6.29	0.33	9.83e-10	Red cell distribution width;
CRC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.45	-8.04	-0.41	1.58e-14	Reticulocyte fraction of red cells;
CRC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06544989	chr22:39130855	UNC84B	0.45	6.92	0.36	2.35e-11	Menopause (age at onset);
CRC	cis	rs2252790	1.000	rs10456907	chr6:116621036	T/C	cg18764771	chr6:116381957	FRK	0.22	5.92	0.31	8.17e-9	Fast beta electroencephalogram;
CRC	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.63	-6.71	-0.35	8.31e-11	Osteoarthritis;
CRC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.46	-6.81	-0.35	4.61e-11	Plateletcrit;
CRC	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.54	-8.23	-0.41	4.43e-15	Eosinophil percentage of white cells;
CRC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07234876	chr8:600039	NA	0.97	9.31	0.46	1.82e-18	IgG glycosylation;
CRC	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.45	7.35	0.38	1.56e-12	Sleep quality;
CRC	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.92	11.88	0.55	2.48e-27	Migraine;
CRC	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.7	-11.2	-0.53	6.86e-25	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.91	0.4	4.03e-14	Mean corpuscular volume;
CRC	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.88	-0.35	3.08e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.46	8.31	0.42	2.62e-15	Monocyte count;
CRC	cis	rs995000	0.899	rs1168099	chr1:63122859	C/A	cg19896129	chr1:63156450	NA	-0.41	-6.36	-0.33	6.93e-10	Triglyceride levels;
CRC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.63	8.09	0.41	1.17e-14	Cocaine dependence;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg16531660	chr3:141457093	RNF7	-0.41	-6.13	-0.32	2.5e-9	Protein C levels;
CRC	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg12590608	chr7:158785262	NA	0.38	6.56	0.34	2.1e-10	Facial morphology (factor 20);
CRC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	5.89	0.31	9.66e-9	Diabetic retinopathy;
CRC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21652505	chr19:40023540	EID2B	-0.47	-7.01	-0.36	1.33e-11	Myopia (pathological);
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg12564285	chr5:131593104	PDLIM4	0.46	8.78	0.44	8.9e-17	Breast cancer;
CRC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg00316803	chr15:76480434	C15orf27	-0.35	-5.64	-0.3	3.59e-8	Blood metabolite levels;
CRC	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.81	13.64	0.6	7.07e-34	Hypertriglyceridemia;
CRC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.69	9.2	0.45	4.17e-18	High light scatter reticulocyte count;
CRC	cis	rs6504950	0.679	rs9897646	chr17:52985351	G/C	cg26251398	chr17:52985966	TOM1L1	0.4	5.74	0.3	2.1e-8	Breast cancer;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02725872	chr8:58115012	NA	-0.59	-9.12	-0.45	7.59e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg17885191	chr8:135476712	NA	0.54	7.42	0.38	1.03e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.59	8.67	0.43	2.06e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.68	9.84	0.48	3.52e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.53	8.43	0.42	1.09e-15	Coronary artery disease;
CRC	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.67	10.79	0.51	1.99e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.63	14.52	0.63	2.81e-37	Airflow obstruction;
CRC	cis	rs6973256	0.543	rs13243553	chr7:133506955	A/G	cg10665199	chr7:133106180	EXOC4	-0.45	-6.67	-0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-7.29	-0.37	2.39e-12	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs720844	0.580	rs13009428	chr2:149296505	C/A	cg09247360	chr2:149335327	NA	-0.42	-5.7	-0.3	2.62e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.31	-0.37	1.99e-12	Longevity;Endometriosis;
CRC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.36e-10	Schizophrenia;
CRC	cis	rs12410462	0.551	rs2814091	chr1:227636367	G/T	cg23173402	chr1:227635558	NA	0.41	5.64	0.3	3.63e-8	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11540624	chr2:232573066	PTMA	0.47	6.58	0.34	1.85e-10	Anxiety disorder;
CRC	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg04132472	chr17:19861366	AKAP10	0.45	7.09	0.36	8.36e-12	Schizophrenia;
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg15382696	chr6:118971807	C6orf204	0.61	7.88	0.4	4.86e-14	Diastolic blood pressure;
CRC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	cis	rs9928842	0.765	rs6564222	chr16:75225044	A/G	cg09066997	chr16:75300724	BCAR1	0.63	6.0	0.31	5.3e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-7.51	-0.38	5.75e-13	Response to antipsychotic treatment;
CRC	cis	rs2013441	1.000	rs9915059	chr17:20177104	G/T	cg13482628	chr17:19912719	NA	-0.43	-6.28	-0.33	1.05e-9	Obesity-related traits;
CRC	cis	rs17209837	0.920	rs4148817	chr7:87087397	C/G	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	5.97	0.31	6.18e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg17133734	chr15:86042851	AKAP13	0.43	6.94	0.36	2.09e-11	Interstitial lung disease;
CRC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg03609598	chr5:56110824	MAP3K1	0.59	7.87	0.4	5.06e-14	Initial pursuit acceleration;
CRC	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.35	5.63	0.3	3.81e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.07	0.32	3.59e-9	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11901034	chr3:128598214	ACAD9	0.42	6.44	0.33	4.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg16005559	chr11:120040616	NA	-0.5	-7.21	-0.37	3.85e-12	Stroke (pediatric);
CRC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.67	8.91	0.44	3.47e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-7.43	-0.38	9.36e-13	Hemoglobin concentration;
CRC	cis	rs4662945	0.688	rs62174139	chr2:130202775	G/C	cg05903289	chr2:130345205	NA	-0.29	-5.74	-0.3	2.18e-8	Response to cytidine analogues (gemcitabine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21086878	chr14:90862960	CALM1	0.45	6.86	0.35	3.36e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg20363699	chr7:23626180	CLK2P	0.36	6.27	0.33	1.14e-9	Schizophrenia;
CRC	cis	rs9326248	0.516	rs6589577	chr11:116749977	C/T	cg26566898	chr11:117069891	TAGLN	0.41	5.67	0.3	3.21e-8	Blood protein levels;
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.92	-0.31	8.28e-9	Longevity;Endometriosis;
CRC	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.53	-8.76	-0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg20356878	chr3:121714668	ILDR1	0.51	7.99	0.4	2.27e-14	Cognitive performance;
CRC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	0.96	17.82	0.7	3.29e-50	Height;
CRC	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg01843034	chr6:37503916	NA	-0.47	-8.48	-0.42	7.75e-16	Cognitive performance;
CRC	trans	rs711355	0.872	rs785428	chr15:30185192	A/G	cg19414016	chr13:113697165	MCF2L	-0.42	-6.21	-0.32	1.63e-9	Response to antipsychotic treatment;
CRC	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17691542	chr6:26056736	HIST1H1C	0.67	7.56	0.38	4e-13	Iron status biomarkers;
CRC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg10570241	chr7:158785291	NA	0.39	6.88	0.35	3e-11	Facial morphology (factor 20);
CRC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg15848620	chr12:58087721	OS9	-0.65	-9.23	-0.45	3.43e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	8.06	0.41	1.41e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3736485	0.934	rs8036821	chr15:51861646	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg13385794	chr1:248469461	NA	0.38	6.66	0.34	1.14e-10	Common traits (Other);
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.39	5.72	0.3	2.34e-8	Growth-regulated protein alpha levels;
CRC	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg14352298	chr13:112236639	NA	-0.28	-6.38	-0.33	5.96e-10	Hepatitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13973351	chr11:60928923	VPS37C	0.38	6.39	0.33	5.8e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.4	5.71	0.3	2.52e-8	Aortic root size;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.45	5.82	0.31	1.38e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.64	9.59	0.47	2.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.63	11.64	0.54	1.89e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20988798	chr7:75677766	MDH2;STYXL1	0.45	6.84	0.35	3.82e-11	Intelligence (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03674076	chr20:524243	CSNK2A1	0.41	6.54	0.34	2.4e-10	Obesity-related traits;
CRC	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg19196414	chr17:27188595	MIR451;MIR144	-0.39	-5.69	-0.3	2.82e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.45	-6.99	-0.36	1.51e-11	Psychosis in Alzheimer's disease;
CRC	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.34e-36	Hypertriglyceridemia;
CRC	cis	rs7605827	0.930	rs6723785	chr2:15688314	T/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs61996546	0.622	rs45542840	chr15:26866738	C/T	cg15066197	chr15:26874202	GABRB3	-0.39	-5.99	-0.31	5.37e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg27053337	chr8:124217698	FAM83A	0.46	6.99	0.36	1.58e-11	Urinary uromodulin levels;
CRC	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	8.6	0.43	3.21e-16	Initial pursuit acceleration in psychotic disorders;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10880834	chr17:55927538	MRPS23	0.38	6.03	0.32	4.38e-9	Interleukin-6 levels;
CRC	cis	rs17767392	1.000	rs61991205	chr14:71771921	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.78	12.0	0.55	9.33e-28	Menarche (age at onset);
CRC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg11212589	chr17:38028394	ZPBP2	0.48	8.89	0.44	4.21e-17	Self-reported allergy;
CRC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.43	6.4	0.33	5.35e-10	Menopause (age at onset);
CRC	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg05925327	chr15:68127851	NA	0.29	5.62	0.3	3.98e-8	Restless legs syndrome;
CRC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.6	8.9	0.44	3.88e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg09417038	chr21:47716443	C21orf57	-0.41	-6.75	-0.35	6.54e-11	Testicular germ cell tumor;
CRC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.68	10.46	0.5	2.64e-22	Hemoglobin concentration;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg23235460	chr3:187871625	LPP	-0.43	-6.22	-0.32	1.52e-9	Schizophrenia;
CRC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.41	-8.75	-0.43	1.1e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg21851534	chr17:3907994	ZZEF1	0.37	6.4	0.33	5.35e-10	Type 2 diabetes;
CRC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	10.56	0.5	1.24e-22	Motion sickness;
CRC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.87	0.31	1.05e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.8	-13.61	-0.6	9.14e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs4586057	0.812	rs11186360	chr10:92667502	C/A	cg26894278	chr13:21016241	CRYL1	0.39	6.47	0.34	3.63e-10	Economic and political preferences (time);
CRC	cis	rs10760158	0.832	rs13292100	chr9:124040997	G/C	cg14417974	chr9:124058376	GSN	-0.34	-5.84	-0.31	1.26e-8	Pulse pressure;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg17437088	chr7:130698670	FLJ43663	0.37	5.96	0.31	6.48e-9	Interleukin-6 levels;
CRC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg27432699	chr2:27873401	GPN1	-0.52	-8.01	-0.4	1.99e-14	Total body bone mineral density;
CRC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.98	12.1	0.55	3.94e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.44	-6.42	-0.33	4.71e-10	Hip circumference adjusted for BMI;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.58	-0.39	3.52e-13	Total body bone mineral density;
CRC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4664293	0.647	rs7587700	chr2:160444320	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-1.06	-17.67	-0.7	1.31e-49	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.58	-8.49	-0.42	7.16e-16	Dental caries;
CRC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.51	8.27	0.41	3.33e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg09659197	chr4:152720779	NA	0.49	10.43	0.5	3.46e-22	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg08501292	chr6:25962987	TRIM38	0.66	6.4	0.33	5.3e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.67	9.53	0.47	3.52e-19	Bladder cancer;
CRC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.77	7.67	0.39	1.98e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.65	11.51	0.54	5.6e-26	Schizophrenia;
CRC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg04673462	chr1:38461896	NA	-0.4	-6.12	-0.32	2.66e-9	Coronary artery disease;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18591801	chr3:52553433	STAB1	-0.31	-6.1	-0.32	2.93e-9	Electroencephalogram traits;
CRC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.99	0.58	2.01e-31	Hip circumference adjusted for BMI;
CRC	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.09	-0.36	8.28e-12	Capecitabine sensitivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26072705	chr17:21454773	C17orf51	0.4	6.38	0.33	5.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-9.02	-0.45	1.54e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.44	6.28	0.33	1.06e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.48	-6.18	-0.32	1.92e-9	Type 2 diabetes;
CRC	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	cis	rs863345	0.526	rs10908669	chr1:158501938	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.14	0.37	6.14e-12	Hip circumference adjusted for BMI;
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg21268650	chr7:45961089	IGFBP3	0.38	6.44	0.33	4.3e-10	Sitting height ratio;
CRC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.58	-8.0	-0.4	2.08e-14	DNA methylation (variation);
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg15511327	chr8:143859410	LYNX1	-0.4	-6.64	-0.34	1.32e-10	Urinary tract infection frequency;
CRC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.51	6.86	0.35	3.51e-11	Height;
CRC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.67	8.88	0.44	4.28e-17	Morning vs. evening chronotype;
CRC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg26395211	chr5:140044315	WDR55	0.38	5.63	0.3	3.92e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9584850	0.834	rs12869627	chr13:99120452	G/A	cg20487152	chr13:99095054	FARP1	0.41	6.04	0.32	4.06e-9	Neuroticism;
CRC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.61	-0.3	4.31e-8	Lung cancer;
CRC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.49	9.02	0.45	1.55e-17	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.83	-0.44	6.2e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg24253500	chr15:84953950	NA	0.39	6.22	0.32	1.54e-9	Schizophrenia;
CRC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs16975963	0.843	rs7254809	chr19:38365695	A/G	cg15135657	chr19:38346511	NA	-0.42	-5.67	-0.3	3.21e-8	Longevity;
CRC	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.92	-7.56	-0.38	4e-13	Depression;
CRC	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.52	7.58	0.39	3.57e-13	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06723301	chr22:21213449	SNAP29;PI4KA	0.34	6.05	0.32	3.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.55	0.5	1.29e-22	Nonalcoholic fatty liver disease;
CRC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.76	16.5	0.67	5.36e-45	Breast cancer;
CRC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg08382946	chr5:1082689	SLC12A7	0.39	5.69	0.3	2.82e-8	QT interval;
CRC	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.93	-0.31	7.68e-9	Reticulocyte fraction of red cells;
CRC	cis	rs7932354	0.528	rs11039074	chr11:47081732	C/T	cg03339077	chr11:47165057	C11orf49	0.43	5.95	0.31	6.94e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.79	13.54	0.6	1.65e-33	Menopause (age at onset);
CRC	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg12856521	chr11:46389249	DGKZ	-0.41	-6.7	-0.35	9.14e-11	Leprosy;
CRC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg24375607	chr4:120327624	NA	0.47	7.59	0.39	3.42e-13	Corneal astigmatism;
CRC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg07713946	chr22:31675144	LIMK2	0.38	5.78	0.3	1.75e-8	Colorectal cancer;
CRC	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg27205649	chr11:78285834	NARS2	0.5	6.41	0.33	5.05e-10	Alzheimer's disease (survival time);
CRC	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.84	-15.15	-0.64	1.07e-39	Itch intensity from mosquito bite;
CRC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.61	0.3	4.39e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg04518342	chr5:131593106	PDLIM4	0.44	8.21	0.41	4.93e-15	Breast cancer;
CRC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-19.77	-0.74	7.1e-58	Height;
CRC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.02	-0.31	4.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.51	-10.09	-0.49	4.82e-21	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs11212617	chr11:108283161	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.08	0.32	3.27e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.54	-0.57	9.62e-30	Leprosy;
CRC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.28	-0.46	2.33e-18	Platelet count;
CRC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg23815491	chr16:72088622	HP	0.5	7.6	0.39	3.09e-13	Fibrinogen levels;
CRC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.72	-0.35	8.17e-11	Type 2 diabetes;
CRC	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg14356550	chr1:18808102	KLHDC7A	0.4	5.96	0.31	6.39e-9	Breast cancer;
CRC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg12365402	chr11:9010492	NRIP3	0.37	6.27	0.33	1.11e-9	Hemoglobin concentration;
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.49	-6.95	-0.36	1.96e-11	Intelligence (multi-trait analysis);
CRC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.59	10.59	0.5	9.88e-23	Multiple system atrophy;
CRC	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.53	7.49	0.38	6.35e-13	Schizophrenia;
CRC	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.4	-0.33	5.28e-10	Bipolar disorder;
CRC	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg22529645	chr1:3704559	LRRC47	0.43	5.86	0.31	1.11e-8	Red cell distribution width;
CRC	cis	rs2462686	0.930	rs2462687	chr7:45982306	C/T	cg15898840	chr7:45960834	IGFBP3	-0.41	-6.26	-0.33	1.23e-9	Major depressive disorder;
CRC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-6.48	-0.34	3.32e-10	Cognitive test performance;
CRC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.1	-0.32	2.96e-9	Inflammatory bowel disease;
CRC	cis	rs9584850	0.794	rs17470961	chr13:99135314	A/G	cg20487152	chr13:99095054	FARP1	0.41	5.96	0.31	6.44e-9	Neuroticism;
CRC	trans	rs10488031	1.000	rs10488031	chr7:37076854	A/G	cg14852736	chr1:3006329	PRDM16	-0.61	-6.42	-0.33	4.74e-10	QT interval;
CRC	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg12458913	chr13:53173898	NA	0.52	8.02	0.4	1.88e-14	Lewy body disease;
CRC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.85e-11	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26420413	chr1:93250872	EVI5	0.37	6.07	0.32	3.61e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs501120	0.584	rs7082177	chr10:44698630	G/A	cg09554077	chr10:44749378	NA	0.69	7.91	0.4	4.04e-14	Coronary artery disease;Coronary heart disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19596991	chr10:126432951	FAM53B	0.48	6.74	0.35	7.03e-11	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25903072	chr15:63334703	TPM1	0.4	6.61	0.34	1.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.82	-11.2	-0.53	7.25e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs889398	0.771	rs3790080	chr16:69902139	A/G	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.23	-0.32	1.4e-9	Body mass index;
CRC	cis	rs7201929	0.959	rs35725751	chr16:28845584	C/T	cg10436792	chr16:28889110	ATP2A1	0.43	5.72	0.3	2.37e-8	QT interval;
CRC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg15845792	chr6:28175446	NA	0.72	6.15	0.32	2.24e-9	Breast cancer;
CRC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.15	26.37	0.82	3.86e-83	IgG glycosylation;
CRC	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg11657817	chr20:23433608	CST11	0.44	6.56	0.34	2.11e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-6.27	-0.33	1.1e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.62	-8.54	-0.43	5.02e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.5	-6.22	-0.32	1.55e-9	Diastolic blood pressure;
CRC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg10978503	chr1:24200527	CNR2	0.48	8.68	0.43	1.93e-16	Immature fraction of reticulocytes;
CRC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg04553112	chr3:125709451	NA	-0.53	-6.09	-0.32	3.2e-9	Blood pressure (smoking interaction);
CRC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg15962314	chr1:44399869	ARTN	0.3	5.85	0.31	1.18e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6554196	0.895	rs7694422	chr4:55518877	T/A	cg18836493	chr4:55524333	KIT	-0.34	-5.65	-0.3	3.56e-8	Monocyte count;
CRC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	12.12	0.56	3.24e-28	Hip circumference adjusted for BMI;
CRC	cis	rs6764363	0.527	rs4684332	chr3:278420	A/G	cg02057681	chr3:285234	CHL1	0.42	7.22	0.37	3.62e-12	Sudden cardiac arrest;
CRC	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg04176472	chr15:90893244	GABARAPL3	0.38	6.52	0.34	2.59e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.6	-8.23	-0.41	4.37e-15	DNA methylation (variation);
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg23161317	chr6:28129485	ZNF389	0.47	6.09	0.32	3.14e-9	Depression;
CRC	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.55	6.44	0.33	4.32e-10	Menarche (age at onset);
CRC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.4	-0.33	5.41e-10	Aortic root size;
CRC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.64	9.28	0.46	2.36e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	cis	rs12431939	1.000	rs34063246	chr14:51663719	G/C	cg23942311	chr14:51606299	NA	-0.55	-6.24	-0.33	1.34e-9	Cancer;
CRC	cis	rs1178968	1.000	rs757939	chr7:72778108	T/C	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg09659197	chr4:152720779	NA	0.51	11.07	0.52	1.96e-24	Intelligence (multi-trait analysis);
CRC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.43	5.77	0.3	1.83e-8	Platelet distribution width;
CRC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-5.9	-0.31	8.86e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs17095355	0.642	rs57822924	chr10:111702078	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.59	-0.39	3.27e-13	Biliary atresia;
CRC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.68	0.39	1.78e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg06067394	chr11:133789110	IGSF9B	-0.39	-5.69	-0.3	2.87e-8	Parkinson's disease;
CRC	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06307176	chr5:131281290	NA	0.45	6.59	0.34	1.7e-10	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs1325195	1.000	rs1325195	chr1:179071756	G/A	cg11624085	chr17:8464688	MYH10	-0.39	-6.01	-0.31	4.97e-9	IgE grass sensitization;
CRC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.93	-17.29	-0.69	4.36e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.83	-0.55	3.9e-27	Type 2 diabetes;
CRC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg16235748	chr6:149772707	ZC3H12D	0.36	6.53	0.34	2.53e-10	Dupuytren's disease;
CRC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.54	0.38	4.76e-13	Eye color traits;
CRC	cis	rs10221833	0.636	rs355876	chr2:165632858	T/G	cg03182029	chr2:165697222	COBLL1	0.5	5.79	0.3	1.63e-8	Response to statin therapy;
CRC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg00738113	chr16:70207722	CLEC18C	0.46	7.83	0.4	6.56e-14	Sjögren's syndrome;
CRC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.65	-7.36	-0.38	1.45e-12	Menarche (age at onset);
CRC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.46	-0.34	3.7e-10	Electroencephalogram traits;
CRC	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.4	-6.76	-0.35	6.26e-11	Vitamin D levels;
CRC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.79	12.84	0.58	7.54e-31	Cognitive function;
CRC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg06172871	chr16:72088244	HP	0.39	5.74	0.3	2.14e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00003173	chr3:14166750	CHCHD4;TMEM43	0.43	6.38	0.33	5.94e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.62	-8.31	-0.42	2.53e-15	Hypospadias;
CRC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.39	5.63	0.3	3.89e-8	Heart rate;
CRC	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg27534772	chr1:16042836	PLEKHM2	0.43	7.26	0.37	2.74e-12	Systolic blood pressure;
CRC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.67	6.98	0.36	1.65e-11	Axial length;
CRC	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.85	-0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	9.43	0.46	7.75e-19	Eye color traits;
CRC	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.51	-7.86	-0.4	5.44e-14	Multiple myeloma (IgH translocation);
CRC	trans	rs10863936	0.558	rs7522330	chr1:212234104	A/T	cg16920991	chr12:100536345	UHRF1BP1L	-0.4	-5.96	-0.31	6.41e-9	Height;
CRC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	9.23	0.45	3.39e-18	Cognitive test performance;
CRC	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg00262122	chr8:11665843	FDFT1	-0.37	-5.73	-0.3	2.28e-8	Monocyte count;
CRC	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.38	5.92	0.31	7.94e-9	Endometrial cancer;
CRC	cis	rs7705042	0.647	rs10051379	chr5:141501662	T/G	cg07392085	chr5:141489673	NDFIP1	-0.42	-6.07	-0.32	3.62e-9	Asthma;
CRC	cis	rs7632954	0.900	rs6777857	chr3:8519329	C/T	cg03495237	chr3:8533978	NA	0.34	6.14	0.32	2.33e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.39	-6.33	-0.33	7.91e-10	Mean arterial pressure;
CRC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg14541582	chr5:601475	NA	-0.33	-6.45	-0.33	4.09e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7301826	0.651	rs1554807	chr12:131280417	C/T	cg11011512	chr12:131303247	STX2	-0.38	-5.77	-0.3	1.86e-8	Plasma plasminogen activator levels;
CRC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.63	-9.74	-0.47	7.21e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.96	14.11	0.61	1.14e-35	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs929596	0.564	rs2741029	chr2:234530160	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-5.74	-0.3	2.15e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.95	0.31	6.72e-9	Bladder cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04623168	chr12:112546260	NAA25	0.49	6.98	0.36	1.62e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg25985355	chr7:65971099	NA	-0.49	-5.74	-0.3	2.11e-8	Diabetic kidney disease;
CRC	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg22495460	chr2:25135724	ADCY3	-0.88	-15.06	-0.64	2.38e-39	Body mass index;
CRC	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.28	6.1	0.32	2.94e-9	Educational attainment (years of education);
CRC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.44	6.0	0.31	5.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.95	11.04	0.52	2.5300000000000002e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.72	-7.34	-0.38	1.64e-12	Systemic lupus erythematosus;
CRC	cis	rs7932354	0.502	rs10769233	chr11:47072655	T/C	cg03339077	chr11:47165057	C11orf49	0.44	6.23	0.32	1.44e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs113123495	0.609	rs2436499	chr19:5638054	C/T	cg26242866	chr19:5711310	LONP1	-0.65	-5.61	-0.3	4.24e-8	Obsessive-compulsive symptoms;
CRC	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.47	-6.15	-0.32	2.2e-9	Tuberculosis;
CRC	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg11901034	chr3:128598214	ACAD9	-0.47	-5.75	-0.3	2.07e-8	IgG glycosylation;
CRC	cis	rs10944	0.572	rs688180	chr5:78276747	C/T	cg13121490	chr5:78280331	ARSB	-0.44	-6.31	-0.33	9.23e-10	Blood and toenail selenium levels;
CRC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.44	-6.43	-0.33	4.43e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.52	-0.34	2.58e-10	Coronary artery calcification;
CRC	cis	rs6088813	0.767	rs4911179	chr20:33972899	A/C	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.36	6.11	0.32	2.78e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.68	10.34	0.5	6.75e-22	Menopause (age at onset);
CRC	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg23254163	chr1:152506842	NA	0.44	8.66	0.43	2.23e-16	Hair morphology;
CRC	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.71	0.39	1.55e-13	Breast cancer;
CRC	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.53	8.53	0.43	5.48e-16	Endometriosis;
CRC	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg00277334	chr10:82204260	NA	-0.37	-5.94	-0.31	7.31e-9	Sarcoidosis;
CRC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.41	6.49	0.34	3.21e-10	Monocyte count;
CRC	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg08795948	chr3:128337044	NA	-0.36	-6.15	-0.32	2.24e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.63e-12	Motion sickness;
CRC	cis	rs6479527	0.806	rs914296	chr9:96765974	A/G	cg14459158	chr9:96720562	NA	0.41	7.44	0.38	8.76e-13	Esophageal adenocarcinoma;
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg22687807	chr8:143858763	LYNX1	0.5	8.91	0.44	3.5e-17	Urinary tract infection frequency;
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.38	0.42	1.59e-15	Bipolar disorder and schizophrenia;
CRC	trans	rs7830371	0.545	rs2931311	chr8:62100551	T/A	cg27108154	chr4:96761377	PDHA2	0.34	6.01	0.31	4.92e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg09491104	chr22:46646882	C22orf40	-0.48	-7.59	-0.39	3.33e-13	LDL cholesterol;Cholesterol, total;
CRC	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.54	-0.43	5.19e-16	Triglycerides;
CRC	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg22495460	chr2:25135724	ADCY3	-0.84	-16.07	-0.66	2.78e-43	Body mass index in non-asthmatics;
CRC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.7	7.85	0.4	6.01e-14	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.5	5.86	0.31	1.15e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.46	7.15	0.37	5.79e-12	Calcium levels;
CRC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.58	-9.08	-0.45	1.03e-17	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.65	10.44	0.5	3.19e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.31	-0.42	2.54e-15	Type 2 diabetes;
CRC	cis	rs582297	1	rs582297	chr11:108165407	C/G	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.16	0.32	2.08e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.52	-0.34	2.58e-10	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03294028	chr2:242255774	SEPT2;HDLBP	0.44	6.13	0.32	2.5e-9	Response to antipsychotic treatment;
CRC	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.07	-15.45	-0.65	6.9e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.9e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs860295	0.702	rs12040100	chr1:155611847	G/T	cg02153340	chr1:155202674	NA	-0.54	-6.65	-0.34	1.25e-10	Body mass index;
CRC	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.4	0.33	5.48e-10	Tonsillectomy;
CRC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.95	-0.36	2.02e-11	Response to antipsychotic treatment;
CRC	cis	rs55702914	0.712	rs6730590	chr2:198148084	A/G	cg10820045	chr2:198174542	NA	-0.39	-7.04	-0.36	1.15e-11	Major depression and alcohol dependence;
CRC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4731207	0.536	rs13307657	chr7:124600864	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.86	-16.95	-0.68	8.89e-47	Oral cavity cancer;
CRC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.44	-5.88	-0.31	1.04e-8	Gut microbiome composition (summer);
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg23123621	chr4:1343375	KIAA1530	0.35	6.42	0.33	4.68e-10	Obesity-related traits;
CRC	trans	rs941823	0.951	rs4941977	chr13:41031535	C/T	cg25432738	chr13:21009861	CRYL1	-0.43	-6.07	-0.32	3.57e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	24.77	0.81	3.61e-77	Testicular germ cell tumor;
CRC	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.83e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.73	-11.8	-0.55	5.07e-27	Dental caries;
CRC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.41	-0.33	5.06e-10	Monocyte percentage of white cells;
CRC	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.5	-9.2	-0.45	4.31e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.42	5.79	0.3	1.65e-8	Educational attainment (years of education);
CRC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	6.6	0.34	1.63e-10	Diastolic blood pressure;
CRC	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.78	-13.16	-0.59	4.73e-32	Ear protrusion;
CRC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg18721089	chr20:30220636	NA	-0.51	-7.59	-0.39	3.31e-13	Mean corpuscular hemoglobin;
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg22110888	chr17:80059540	CCDC57	0.41	6.5	0.34	2.95e-10	Life satisfaction;
CRC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.88	11.77	0.54	6.18e-27	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.56	-8.73	-0.43	1.33e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs427941	0.632	rs201504	chr7:101759878	C/G	cg06246474	chr7:101738831	CUX1	0.44	6.72	0.35	7.85e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.33	0.33	7.92e-10	IgG glycosylation;
CRC	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.48	0.46	5.39e-19	Ileal carcinoids;
CRC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.37	-0.5	5.45e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.81	0.4	7.75e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2274273	0.615	rs67008693	chr14:55702693	T/C	cg10130446	chr14:55658398	DLGAP5	-0.44	-5.87	-0.31	1.06e-8	Protein biomarker;
CRC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.4	-7.0	-0.36	1.42e-11	Blood metabolite levels;
CRC	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg01843034	chr6:37503916	NA	-0.47	-8.91	-0.44	3.55e-17	Cognitive performance;
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02290350	chr8:58132656	NA	-0.58	-6.58	-0.34	1.82e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs13253111	0.687	rs7840565	chr8:28060783	C/T	cg26534493	chr8:28060551	NA	0.39	6.67	0.35	1.05e-10	Childhood body mass index;
CRC	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.3	0.49	9.74e-22	Corneal astigmatism;
CRC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg26666090	chr16:58549219	SETD6	0.9	6.11	0.32	2.86e-9	Schizophrenia;
CRC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.83	-0.48	3.75e-20	Total cholesterol levels;
CRC	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.89	-15.24	-0.64	4.88e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg02135003	chr7:105160482	PUS7	-0.93	-12.2	-0.56	1.77e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg13565492	chr6:43139072	SRF	-0.61	-6.28	-0.33	1.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs62458065	1.000	rs6462364	chr7:32464776	C/T	cg20159608	chr7:32802032	NA	-0.49	-6.2	-0.32	1.68e-9	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg12564285	chr5:131593104	PDLIM4	0.44	7.44	0.38	8.72e-13	Breast cancer;
CRC	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.76	10.02	0.48	8.47e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg05709478	chr1:6581295	PLEKHG5	0.61	6.08	0.32	3.42e-9	Body mass index;
CRC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-0.91	-17.78	-0.7	4.7e-50	Height;
CRC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg11344533	chr11:111475393	SIK2	-0.31	-5.94	-0.31	7.24e-9	Primary sclerosing cholangitis;
CRC	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17767392	0.918	rs35822724	chr14:71776934	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.99e-11	Mitral valve prolapse;
CRC	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg12856521	chr11:46389249	DGKZ	0.59	8.59	0.43	3.54e-16	Crohn's disease;
CRC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg02903104	chr8:1507517	DLGAP2	0.38	7.04	0.36	1.13e-11	Lung cancer;
CRC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.65	0.43	2.28e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg11189052	chr15:85197271	WDR73	0.65	9.56	0.47	2.8e-19	Schizophrenia;
CRC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.51	7.27	0.37	2.62e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.79	10.54	0.5	1.45e-22	Obesity-related traits;
CRC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.74	10.54	0.5	1.38e-22	Schizophrenia;
CRC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg04586622	chr2:25135609	ADCY3	-0.54	-10.08	-0.49	5.18e-21	Body mass index;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16868751	chr10:96162146	TBC1D12	0.44	6.64	0.34	1.3100000000000001e-10	Response to antipsychotic treatment;
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg06219103	chr11:63990595	FERMT3	0.47	7.65	0.39	2.17e-13	Platelet count;
CRC	cis	rs4804416	0.779	rs62112763	chr19:7220013	C/G	cg00428638	chr19:7224713	INSR	0.56	8.54	0.43	5.23e-16	Thyroid hormone levels;Hypothyroidism;
CRC	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.49	7.31	0.37	2.02e-12	Asthma;
CRC	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.22	0.45	3.65e-18	Blood protein levels;
CRC	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.78	-0.35	5.68e-11	Ulcerative colitis;
CRC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg09417038	chr21:47716443	C21orf57	-0.42	-6.88	-0.35	2.98e-11	Testicular germ cell tumor;
CRC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.84	10.83	0.51	1.37e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.96e-9	Body mass index;
CRC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.29	-0.46	2.16e-18	Type 2 diabetes;
CRC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16262614	chr3:133464971	TF	0.34	6.2	0.32	1.69e-9	Iron status biomarkers;
CRC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg05192639	chr6:26864778	GUSBL1	0.34	6.1	0.32	3e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.28	0.33	1.08e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs73200209	0.744	rs61939693	chr12:116540478	G/A	cg01776926	chr12:116560359	MED13L	-0.63	-7.46	-0.38	7.76e-13	Total body bone mineral density;
CRC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11645453	chr3:52864694	ITIH4	0.33	6.12	0.32	2.6e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg00246817	chr9:123691163	NA	-0.47	-5.94	-0.31	7.33e-9	Rheumatoid arthritis;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg20615401	chr6:28092323	ZSCAN16	0.47	6.25	0.33	1.28e-9	Parkinson's disease;
CRC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg05623727	chr3:50126028	RBM5	0.45	7.52	0.38	5.18e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.69	9.69	0.47	1.04e-19	Alzheimer's disease;
CRC	trans	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-7.98	-0.4	2.39e-14	Gut microbiome composition (summer);
CRC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.49	9.1	0.45	8.57e-18	Alcohol dependence;
CRC	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.14	0.45	6.4e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	14.94	0.64	7.12e-39	Smoking behavior;
CRC	cis	rs7692995	1.000	rs10516315	chr4:18016877	A/G	cg08925142	chr4:18023851	LCORL	-0.52	-5.87	-0.31	1.09e-8	Height;
CRC	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.51	7.14	0.37	5.89e-12	Obesity-related traits;
CRC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg13722127	chr7:150037890	RARRES2	0.39	5.69	0.3	2.86e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.37	-0.33	6.36e-10	Alzheimer's disease (late onset);
CRC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg18230493	chr5:56204884	C5orf35	-0.41	-5.93	-0.31	7.56e-9	Coronary artery disease;
CRC	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.68	-9.99	-0.48	1.09e-20	Blood protein levels;
CRC	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg18455616	chr2:99124870	INPP4A	0.33	5.64	0.3	3.64e-8	Bipolar disorder;
CRC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.81	13.0	0.58	1.74e-31	Breast cancer;
CRC	cis	rs12760731	0.720	rs10913540	chr1:178340060	T/C	cg00404053	chr1:178313656	RASAL2	0.94	9.89	0.48	2.37e-20	Obesity-related traits;
CRC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.8	-12.27	-0.56	9.65e-29	Acne (severe);
CRC	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg22134325	chr11:66188745	NPAS4	0.41	6.71	0.35	8.55e-11	Airway imaging phenotypes;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg13811448	chr19:12777509	MORG1;MAN2B1	-0.39	-5.99	-0.31	5.42e-9	Aortic root size;
CRC	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg23234261	chr14:55582407	NA	-0.29	-5.74	-0.3	2.13e-8	Protein biomarker;
CRC	cis	rs539096	0.602	rs2970610	chr1:44097530	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-6.7	-0.35	8.88e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.6	-8.39	-0.42	1.44e-15	Coronary artery disease;
CRC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg03929089	chr4:120376271	NA	-0.47	-6.61	-0.34	1.56e-10	HDL cholesterol;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16128701	chr8:82193449	FABP5	0.38	5.96	0.31	6.52e-9	Interleukin-6 levels;
CRC	cis	rs7212590	0.618	rs7219051	chr17:58032710	G/A	cg10252138	chr17:58120427	NA	-0.58	-6.28	-0.33	1.1e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs2415984	0.579	rs28636061	chr14:46959848	T/C	cg14871534	chr14:47121158	RPL10L	-0.43	-6.17	-0.32	1.95e-9	Number of children ever born;
CRC	trans	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.05	-0.32	4.02e-9	Aortic root size;
CRC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.71	-10.12	-0.49	4.01e-21	Ileal carcinoids;
CRC	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg21483461	chr5:81570383	RPS23	0.36	5.63	0.3	3.92e-8	Breast cancer;
CRC	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg22676075	chr6:135203613	NA	-0.67	-10.49	-0.5	2.18e-22	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.52	-7.05	-0.36	1.05e-11	Triglycerides;
CRC	trans	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg12026095	chr19:49468461	FTL	-0.39	-6.31	-0.33	8.77e-10	Breast cancer;
CRC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.46	7.35	0.38	1.63e-12	Neurofibrillary tangles;
CRC	cis	rs2857891	0.773	rs2857897	chr11:6982082	A/C	cg04053776	chr11:6947353	ZNF215	0.38	5.61	0.3	4.22e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.49	5.65	0.3	3.43e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04575325	chr6:160210070	MRPL18;TCP1	0.48	6.81	0.35	4.78e-11	Response to antipsychotic treatment;
CRC	cis	rs394563	0.601	rs431978	chr6:149793000	C/T	cg11245181	chr6:149772854	ZC3H12D	0.47	7.69	0.39	1.68e-13	Dupuytren's disease;
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg05569086	chr8:143859399	LYNX1	0.57	10.38	0.5	4.94e-22	Urinary tract infection frequency;
CRC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.37	6.35e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg23161317	chr6:28129485	ZNF389	0.38	5.69	0.3	2.8e-8	Cardiac Troponin-T levels;
CRC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg17294928	chr15:75287854	SCAMP5	-0.45	-6.78	-0.35	5.51e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.55	5.89	0.31	9.39e-9	Blood protein levels;
CRC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.97	-0.4	2.69e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs995000	0.965	rs11208004	chr1:63145439	G/A	cg19896129	chr1:63156450	NA	0.39	5.68	0.3	2.95e-8	Triglyceride levels;
CRC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9549328	0.700	rs4907570	chr13:113617651	T/C	cg20742385	chr13:113633654	MCF2L	0.56	9.53	0.46	3.7e-19	Systolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13452718	chr1:23670887	HNRNPR	0.48	6.17	0.32	2e-9	Thyroid stimulating hormone;
CRC	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg00935504	chr16:1863053	HAGH	0.31	5.62	0.3	4.07e-8	Blood metabolite levels;
CRC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.54	-0.38	4.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg15786705	chr6:28176104	NA	-0.55	-5.93	-0.31	7.64e-9	Depression;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg15786705	chr6:28176104	NA	0.48	6.42	0.33	4.89e-10	Parkinson's disease;
CRC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.56	-6.95	-0.36	1.97e-11	Body mass index;
CRC	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.97	11.41	0.53	1.27e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg21153622	chr11:89784906	NA	0.48	7.56	0.38	3.92e-13	HDL cholesterol;
CRC	trans	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	7.25	0.37	3.08e-12	Ulcerative colitis;
CRC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.55	8.47	0.42	8.58e-16	Calcium levels;
CRC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.1	-12.55	-0.57	9.03e-30	Diabetic kidney disease;
CRC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg24881330	chr22:46731750	TRMU	0.56	5.77	0.3	1.85e-8	LDL cholesterol;Cholesterol, total;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19442730	chr13:73634476	KLF5	0.41	6.24	0.33	1.33e-9	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20964256	chr4:146540759	MMAA	0.44	6.49	0.34	3.08e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.84	-9.73	-0.47	7.59e-20	Monocyte percentage of white cells;
CRC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.59	11.6	0.54	2.65e-26	Asthma (sex interaction);
CRC	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.54	-7.95	-0.4	2.96e-14	Homocysteine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14942134	chr8:94929220	PDP1	0.39	6.47	0.34	3.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg14541582	chr5:601475	NA	-0.34	-6.46	-0.34	3.71e-10	Obesity-related traits;
CRC	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg14458575	chr2:238380390	NA	0.43	6.22	0.32	1.51e-9	Prostate cancer;
CRC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.58	7.9	0.4	4.29e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10189230	0.546	rs6436266	chr2:222357235	T/C	cg14652038	chr2:222343519	EPHA4	0.39	6.06	0.32	3.76e-9	Urate levels in lean individuals;
CRC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.73	-0.54	9.04e-27	Type 2 diabetes;
CRC	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.51	6.11	0.32	2.85e-9	QRS duration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22233523	chr18:44497604	PIAS2	0.41	6.73	0.35	7.67e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg12964065	chr18:77638022	KCNG2	0.61	5.91	0.31	8.51e-9	Opioid sensitivity;
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.83	-0.31	1.3e-8	Life satisfaction;
CRC	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg19773385	chr1:10388646	KIF1B	-0.66	-10.78	-0.51	2.04e-23	Hepatocellular carcinoma;
CRC	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	16.59	0.67	2.38e-45	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.8	-13.26	-0.59	1.97e-32	Lung cancer;
CRC	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.52	7.63	0.39	2.49e-13	Blood metabolite levels;
CRC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.47	-5.86	-0.31	1.13e-8	Gut microbiome composition (summer);
CRC	trans	rs7821565	0.857	rs67281089	chr8:52173015	C/T	cg09187163	chr7:72721838	NSUN5	-0.42	-6.05	-0.32	4.04e-9	Tuberculosis;
CRC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg19980929	chr12:42632907	YAF2	0.41	6.27	0.33	1.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.72	-0.39	1.45e-13	Total body bone mineral density;
CRC	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-7.77	-0.39	9.78e-14	Body mass index;
CRC	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg07699608	chr10:75541558	CHCHD1	0.6	6.26	0.33	1.18e-9	Incident atrial fibrillation;
CRC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg19338460	chr6:170058176	WDR27	-0.88	-8.89	-0.44	4.03e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.16	0.32	2.15e-9	Tonsillectomy;
CRC	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.95	-0.36	1.91e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.82	14.42	0.62	6.93e-37	Coronary artery disease;
CRC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.4	5.68	0.3	2.96e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	trans	rs6956675	0.915	rs10232119	chr7:62638227	C/T	cg01314568	chr7:57830625	NA	-0.69	-9.27	-0.46	2.44e-18	Obesity-related traits;
CRC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.5	7.07	0.36	9.58e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.95	-0.31	7e-9	Body mass index;
CRC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.6	8.98	0.44	2.12e-17	Schizophrenia;
CRC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.6	13.48	0.6	2.9e-33	Airflow obstruction;
CRC	trans	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg10756647	chr7:56101905	PSPH	-0.77	-7.87	-0.4	5.06e-14	Diabetic kidney disease;
CRC	cis	rs1572438	1.000	rs873559	chr6:875336	G/A	cg21062780	chr6:887772	NA	0.37	5.88	0.31	1.02e-8	Aging;
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.56	0.34	2.08e-10	Bipolar disorder;
CRC	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg11441379	chr12:63026424	NA	0.54	5.65	0.3	3.47e-8	IgG glycosylation;
CRC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.58	-7.52	-0.38	5.39e-13	Gut microbiome composition (summer);
CRC	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26224664	chr14:101693935	NA	-0.5	-8.92	-0.44	3.32e-17	Body mass index (alcohol intake interaction);
CRC	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg09184832	chr6:79620586	NA	0.38	5.86	0.31	1.11e-8	Left atrial antero-posterior diameter;
CRC	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg12064134	chr16:90016061	DEF8	-0.51	-8.24	-0.41	4.17e-15	Melanoma;
CRC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.52	-9.57	-0.47	2.61e-19	Eye color traits;
CRC	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg10305451	chr2:177043427	NA	0.72	11.49	0.54	6.4e-26	IgG glycosylation;
CRC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg26893134	chr6:116381904	FRK	0.28	7.99	0.4	2.28e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.49	-7.41	-0.38	1.09e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.54	-0.34	2.35e-10	Menopause (age at onset);
CRC	cis	rs8037137	1.000	rs1105291	chr15:91502383	C/T	cg23684204	chr15:91497937	RCCD1	0.62	6.7	0.35	9.32e-11	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CRC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg26762873	chr11:5879799	OR52E8	-0.43	-5.98	-0.31	5.9e-9	DNA methylation (variation);
CRC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.22e-38	Intelligence (multi-trait analysis);
CRC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.67	-8.54	-0.43	4.97e-16	Immature fraction of reticulocytes;
CRC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.75	-9.89	-0.48	2.27e-20	Initial pursuit acceleration;
CRC	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.07	19.28	0.73	6.04e-56	Schizophrenia;
CRC	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.6	8.84	0.44	5.84e-17	Eosinophilic esophagitis;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg25164649	chr6:28176230	NA	0.54	7.8	0.4	8.18e-14	Hepatitis A;
CRC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg23283495	chr1:209979779	IRF6	0.42	5.89	0.31	9.56e-9	Cleft lip with or without cleft palate;
CRC	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg27083787	chr2:113543245	IL1A	0.47	6.57	0.34	1.92e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg03701575	chr16:83960119	NA	0.34	5.97	0.31	6.14e-9	Asthma;
CRC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg25834613	chr7:1915315	MAD1L1	0.44	6.52	0.34	2.61e-10	Bipolar disorder;
CRC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.65	10.65	0.51	6.04e-23	Personality dimensions;
CRC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.91	11.68	0.54	1.31e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.65	0.57	3.65e-30	Height;
CRC	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.16	-0.32	2.07e-9	Arsenic metabolism;
CRC	cis	rs524281	0.861	rs471484	chr11:65955144	A/G	cg14036092	chr11:66035641	RAB1B	-0.48	-6.01	-0.31	4.79e-9	Electroencephalogram traits;
CRC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1607741	1.000	rs1402155	chr4:72705908	C/T	cg06437464	chr6:127441704	RSPO3	-0.28	-6.07	-0.32	3.57e-9	Vitamin D levels;
CRC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.94	16.62	0.68	1.77e-45	Obesity (extreme);
CRC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.76e-24	Bone mineral density;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg11843238	chr5:131593191	PDLIM4	-0.45	-7.57	-0.38	3.9e-13	Breast cancer;
CRC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.78	12.04	0.55	6.36e-28	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18325920	chr2:27255615	TMEM214	0.44	6.27	0.33	1.14e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10607599	chr11:120382422	NA	0.32	6.49	0.34	3.24e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.57	8.6	0.43	3.2e-16	Longevity;Endometriosis;
CRC	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.63	9.89	0.48	2.39e-20	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.57	7.63	0.39	2.57e-13	Height;
CRC	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg09760422	chr2:128146352	NA	-0.37	-7.25	-0.37	2.97e-12	Protein C levels;
CRC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs35150201	0.529	rs7806221	chr7:135318779	T/C	cg23117316	chr7:135346802	PL-5283	-0.38	-6.61	-0.34	1.57e-10	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
CRC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.61	9.89	0.48	2.27e-20	Hemoglobin concentration;
CRC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.66	9.52	0.46	3.97e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00495681	chr13:53174319	NA	0.58	8.77	0.44	1.01e-16	Lewy body disease;
CRC	trans	rs75246769	0.706	rs75576122	chr7:145695402	A/G	cg14916917	chr5:81574294	RPS23	0.87	6.09	0.32	3.14e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg02683197	chr6:28174875	NA	0.61	5.74	0.3	2.19e-8	Depression;
CRC	cis	rs728616	0.510	rs34782759	chr10:82195219	T/C	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.34	-0.33	7.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07328115	chr20:25228580	PYGB	0.48	6.02	0.31	4.57e-9	Thyroid stimulating hormone;
CRC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg05540913	chr6:167530185	CCR6	-0.41	-7.45	-0.38	8.07e-13	Primary biliary cholangitis;
CRC	cis	rs10486722	0.606	rs2190337	chr7:41796420	C/T	cg22138096	chr7:41772439	LOC285954	0.44	5.67	0.3	3.12e-8	Pit-and-Fissure caries;
CRC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg24375607	chr4:120327624	NA	0.48	7.94	0.4	3.23e-14	Corneal astigmatism;
CRC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.52	-6.71	-0.35	8.33e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.88	0.4	4.95e-14	Height;
CRC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg09264619	chr17:80180166	NA	0.49	6.93	0.36	2.23e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15239263	chr16:31086047	ZNF668;ZNF646	0.46	6.47	0.34	3.64e-10	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.68	-10.62	-0.51	7.54e-23	Huntington's disease progression;
CRC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.36	0.33	6.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.56	-0.38	3.93e-13	Coronary artery disease;
CRC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.47	6.41	0.33	5.17e-10	Schizophrenia;
CRC	cis	rs6496667	0.865	rs7161929	chr15:90884009	G/A	cg04176472	chr15:90893244	GABARAPL3	0.58	6.58	0.34	1.83e-10	Rheumatoid arthritis;
CRC	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	1.06	14.71	0.63	5.2e-38	Exhaled nitric oxide output;
CRC	cis	rs9515203	1.000	rs9515203	chr13:111049623	C/T	cg15455643	chr13:111040242	COL4A2	0.44	6.18	0.32	1.92e-9	Coronary artery disease;
CRC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg21153622	chr11:89784906	NA	-0.53	-8.8	-0.44	8.03e-17	HDL cholesterol;
CRC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.56	-8.56	-0.43	4.27e-16	Height;
CRC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.77	-13.15	-0.59	4.78e-32	Breast cancer;
CRC	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.33e-15	Type 2 diabetes;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg15845792	chr6:28175446	NA	0.8	11.85	0.55	3.12e-27	Parkinson's disease;
CRC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg06987292	chr12:125626746	AACS	-0.37	-6.23	-0.32	1.46e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs73195822	0.667	rs59789826	chr12:111235110	T/C	cg12870014	chr12:110450643	ANKRD13A	0.56	5.66	0.3	3.22e-8	Itch intensity from mosquito bite;
CRC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg22535103	chr8:58192502	C8orf71	-0.44	-5.85	-0.31	1.21e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.62	-9.76	-0.47	6.15e-20	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.92	-0.48	1.84e-20	Height;
CRC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.25	-0.33	1.25e-9	Gout;Renal underexcretion gout;
CRC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.43	6.19	0.32	1.77e-9	Aortic root size;
CRC	cis	rs8005677	0.828	rs3794452	chr14:23386682	T/G	cg25600027	chr14:23388339	RBM23	-0.46	-6.92	-0.36	2.35e-11	Cognitive ability (multi-trait analysis);
CRC	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.51	-8.35	-0.42	1.95e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg09264619	chr17:80180166	NA	0.51	7.2	0.37	4.03e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.51	7.18	0.37	4.81e-12	Lymphocyte percentage of white cells;
CRC	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.71	8.37	0.42	1.67e-15	Lung function (FEV1/FVC);
CRC	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.4	-6.41	-0.33	4.9e-10	Testicular germ cell tumor;
CRC	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.56	0.5	1.18e-22	Corneal astigmatism;
CRC	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.84	13.84	0.61	1.2e-34	Height;
CRC	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg18455616	chr2:99124870	INPP4A	0.34	5.72	0.3	2.41e-8	Bipolar disorder;
CRC	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.54	-8.49	-0.42	7.4e-16	Intelligence (multi-trait analysis);
CRC	cis	rs117623576	0.941	rs7911845	chr10:32441827	T/C	cg03047570	chr10:32398778	NA	-0.66	-6.28	-0.33	1.04e-9	Anti-saccade response;
CRC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.24	0.53	4.97e-25	Tonsillectomy;
CRC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-5.85	-0.31	1.2e-8	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16057782	chr17:6347554	FAM64A	0.38	6.17	0.32	1.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg05754148	chr16:3507555	NAT15	-0.66	-6.1	-0.32	2.94e-9	Tuberculosis;
CRC	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	1.02	8.46	0.42	9.13e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.44	5.73	0.3	2.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12024301	0.557	rs12029676	chr1:183594057	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.72	6.52	0.34	2.64e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1223397	0.651	rs2919685	chr6:13311668	T/C	cg07912922	chr6:13274314	PHACTR1	0.38	5.96	0.31	6.61e-9	Blood pressure;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05350293	chr16:89119002	NA	0.32	6.0	0.31	5.23e-9	Survival in pancreatic cancer;
CRC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg20291162	chr17:40259547	DHX58	-0.55	-8.01	-0.4	2.06e-14	Fibrinogen levels;
CRC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.35	-0.38	1.62e-12	Alzheimer's disease;
CRC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	8.12	0.41	9.28e-15	Iron status biomarkers;
CRC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.76	12.46	0.57	1.81e-29	Breast cancer;
CRC	cis	rs524281	0.861	rs580891	chr11:65954681	A/C	cg16950941	chr11:66035639	RAB1B	-0.58	-7.35	-0.38	1.56e-12	Electroencephalogram traits;
CRC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg16358738	chr2:241808595	AGXT	-0.39	-5.82	-0.31	1.42e-8	Urinary metabolites;
CRC	cis	rs294883	0.686	rs7767003	chr6:159728138	T/C	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.48	7.87	0.4	5.33e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg15786705	chr6:28176104	NA	0.69	9.23	0.45	3.35e-18	Parkinson's disease;
CRC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.53	8.35	0.42	1.94e-15	Coronary artery disease;
CRC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg12365402	chr11:9010492	NRIP3	0.47	7.62	0.39	2.78e-13	Hemoglobin concentration;
CRC	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg21506790	chr11:5277210	HBG2	0.36	5.86	0.31	1.15e-8	Hemoglobin levels;
CRC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.57	-7.88	-0.4	4.86e-14	Gut microbiome composition (summer);
CRC	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.39	6.53	0.34	2.44e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.44	-5.8	-0.3	1.54e-8	Gut microbiome composition (summer);
CRC	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg08501292	chr6:25962987	TRIM38	0.58	6.52	0.34	2.58e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs802075	0.676	rs13204884	chr6:49791907	G/A	cg20364632	chr6:49636226	NA	0.35	5.91	0.31	8.66e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.14	0.49	3.45e-21	Birth weight;
CRC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.84	11.83	0.55	3.8e-27	Gut microbiome composition (summer);
CRC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.9	-0.36	2.62e-11	Lung cancer;
CRC	cis	rs11958404	1.000	rs9686690	chr5:157412103	C/T	cg05962755	chr5:157440814	NA	0.78	10.75	0.51	2.66e-23	IgG glycosylation;
CRC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg06219103	chr11:63990595	FERMT3	-0.41	-6.21	-0.32	1.56e-9	Platelet count;
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.19	-0.37	4.48e-12	Life satisfaction;
CRC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg23136738	chr11:925521	AP2A2	-0.48	-7.63	-0.39	2.49e-13	Alzheimer's disease (late onset);
CRC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.65	9.44	0.46	6.99e-19	Menopause (age at onset);
CRC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.07	-0.72	3.93e-55	Height;
CRC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.43	-6.08	-0.32	3.39e-9	Schizophrenia;
CRC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.37	-5.61	-0.3	4.4e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.37	-5.9	-0.31	8.89e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg26304593	chr6:42947056	PEX6	-0.42	-5.99	-0.31	5.62e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.52	0.38	5.15e-13	Lung cancer;
CRC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg20542592	chr8:11973495	FAM66D	0.32	5.72	0.3	2.44e-8	Retinal vascular caliber;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03258011	chr17:54857409	NA	0.51	6.87	0.35	3.16e-11	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13902498	chr15:75249203	RPP25	0.41	6.11	0.32	2.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.52	7.41	0.38	1.09e-12	Caudate activity during reward;
CRC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.96	14.1	0.61	1.2e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.6	0.47	2.05e-19	Cognitive test performance;
CRC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-9.29	-0.46	2.1e-18	Type 2 diabetes;
CRC	cis	rs2559856	1.000	rs2559856	chr12:102089561	A/G	cg12924262	chr12:102091054	CHPT1	0.54	7.98	0.4	2.41e-14	Blood protein levels;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13198984	chr17:80129470	CCDC57	0.45	8.12	0.41	9.48e-15	Life satisfaction;
CRC	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	1.19	11.1	0.52	1.64e-24	Prostate cancer;
CRC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs56146971	0.763	rs11160005	chr14:91872587	G/C	cg16433844	chr14:91963127	SMEK1	-0.55	-6.29	-0.33	9.97e-10	Alzheimer disease and age of onset;
CRC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.67	0.39	2.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7932354	0.528	rs4319472	chr11:47109514	G/C	cg19486271	chr11:47235900	DDB2	0.45	6.49	0.34	3.13e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	6.15	0.32	2.28e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg21153622	chr11:89784906	NA	-0.38	-6.17	-0.32	1.96e-9	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02386244	chr16:3030649	PKMYT1	0.47	6.67	0.35	1.08e-10	Anxiety disorder;
CRC	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg14139581	chr11:64358342	SLC22A12	0.38	6.04	0.32	4.13e-9	Urate levels in obese individuals;
CRC	cis	rs758970	0.523	rs887659	chr9:129184309	C/T	cg15282417	chr9:129245246	FAM125B	-0.34	-5.86	-0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.64	8.66	0.43	2.14e-16	Multiple sclerosis;
CRC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.49	0.54	6.51e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.75	6.9	0.36	2.75e-11	Paclitaxel disposition in epithelial ovarian cancer;
CRC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.83	-0.48	3.72e-20	Height;
CRC	cis	rs7429990	0.930	rs13072132	chr3:47866161	A/G	cg11946769	chr3:48343235	NME6	0.56	6.43	0.33	4.52e-10	Educational attainment (years of education);
CRC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.37	-5.9	-0.31	8.91e-9	Red cell distribution width;
CRC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.2	-0.32	1.67e-9	Alzheimer's disease (late onset);
CRC	cis	rs16852403	0.548	rs12410235	chr1:178184782	C/A	cg00404053	chr1:178313656	RASAL2	0.5	6.58	0.34	1.86e-10	Childhood ear infection;
CRC	cis	rs7264396	0.832	rs224361	chr20:34061578	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.81	-0.35	4.53e-11	Total cholesterol levels;
CRC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg16576597	chr16:28551801	NUPR1	0.48	7.0	0.36	1.44e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg17903999	chr18:56338584	MALT1	-0.39	-6.13	-0.32	2.47e-9	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18954434	chr22:46692881	CN5H6.4;GTSE1	0.47	6.71	0.35	8.43e-11	Anxiety disorder;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.77	14.59	0.63	1.54e-37	Prudent dietary pattern;
CRC	trans	rs12517041	1.000	rs4701362	chr5:23300849	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-5.96	-0.31	6.46e-9	Calcium levels;
CRC	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.51	7.26	0.37	2.85e-12	Pulmonary function decline;
CRC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.3	-0.33	9.32e-10	Arsenic metabolism;
CRC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.48	0.71	8.6e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.61	-0.39	2.96e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	6.16	0.32	2.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg17885791	chr6:149771845	ZC3H12D	0.31	5.66	0.3	3.32e-8	Dupuytren's disease;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	5.65	0.3	3.46e-8	Electroencephalogram traits;
CRC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.44	-6.14	-0.32	2.36e-9	Fibrinogen levels;
CRC	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.77	9.45	0.46	6.33e-19	Type 2 diabetes;
CRC	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg19338460	chr6:170058176	WDR27	-0.76	-8.3	-0.42	2.78e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg01874867	chr7:94954059	PON1	-0.5	-6.5	-0.34	2.92e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg08923669	chr16:420230	MRPL28	-0.45	-6.63	-0.34	1.4e-10	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.45	6.7	0.35	9.09e-11	Menopause (age at onset);
CRC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21582582	chr3:182698605	DCUN1D1	0.52	7.44	0.38	9.11e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg14541582	chr5:601475	NA	-0.37	-7.42	-0.38	1e-12	Obesity-related traits;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg03623178	chr6:28175578	NA	0.77	11.42	0.53	1.1e-25	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg15382696	chr6:118971807	C6orf204	0.59	7.5	0.38	6.18e-13	Diastolic blood pressure;
CRC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-11.96	-0.55	1.28e-27	Bone mineral density;
CRC	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg12458913	chr13:53173898	NA	0.46	6.81	0.35	4.53e-11	Lewy body disease;
CRC	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg03934865	chr2:198174659	NA	0.44	7.04	0.36	1.16e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.52	8.1	0.41	1.05e-14	Corneal astigmatism;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg22079747	chr2:228736145	WDR69	-0.41	-5.61	-0.3	4.24e-8	Blood pressure;
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg20119798	chr7:94954144	PON1	-0.52	-6.5	-0.34	3.03e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg15672331	chr15:85923765	AKAP13	-0.4	-6.1	-0.32	3.02e-9	Birth weight;Height;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.82	-0.4	7.21e-14	Total body bone mineral density;
CRC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.36	0.53	1.86e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.97	0.44	2.23e-17	Schizophrenia;
CRC	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26714650	chr12:56694279	CS	-1.4	-10.71	-0.51	3.55e-23	Psoriasis vulgaris;
CRC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.53	0.34	2.52e-10	Mean platelet volume;
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg04800585	chr6:26043546	HIST1H2BB	-0.48	-7.03	-0.36	1.21e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.97	0.36	1.78e-11	Response to antipsychotic treatment;
CRC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg10589385	chr1:150898437	SETDB1	0.33	7.02	0.36	1.26e-11	Melanoma;
CRC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.6	7.33	0.37	1.76e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.45	-5.61	-0.3	4.24e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs847649	0.692	rs7800548	chr7:102481842	C/T	cg18108683	chr7:102477205	FBXL13	0.66	11.07	0.52	1.99e-24	Morning vs. evening chronotype;
CRC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg10645314	chr2:3704589	ALLC	-0.54	-6.39	-0.33	5.78e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs1864585	0.520	rs7817252	chr8:10685932	C/A	cg26278703	chr11:58910052	FAM111A	0.51	6.03	0.32	4.33e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.68	7.58	0.39	3.63e-13	Anti-saccade response;
CRC	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.82	13.18	0.59	4e-32	Cognitive function;
CRC	trans	rs2303319	0.582	rs56315911	chr2:162560186	G/T	cg03774468	chr3:140950104	ACPL2	-0.64	-5.99	-0.31	5.37e-9	Cognitive function;
CRC	cis	rs4523957	0.579	rs903160	chr17:2091765	C/T	cg16513277	chr17:2031491	SMG6	-0.58	-9.67	-0.47	1.2e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.49	7.0	0.36	1.46e-11	Height;
CRC	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.27	-0.37	2.68e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg19913688	chr11:428466	ANO9	-0.56	-6.09	-0.32	3.22e-9	Body mass index;
CRC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.36	0.33	6.77e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.6	-9.66	-0.47	1.37e-19	IgG glycosylation;
CRC	trans	rs11654801	0.812	rs16962470	chr17:20854775	C/T	cg23759823	chr7:139672531	TBXAS1	-0.38	-6.19	-0.32	1.78e-9	Mosquito bite size;
CRC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.62	10.03	0.48	7.81e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg05569086	chr8:143859399	LYNX1	0.38	6.74	0.35	7.09e-11	Urinary tract infection frequency;
CRC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg20487152	chr13:99095054	FARP1	-0.49	-7.39	-0.38	1.23e-12	Neuroticism;
CRC	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.52	7.9	0.4	4.32e-14	Calcium levels;
CRC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg19622623	chr12:86230825	RASSF9	-0.38	-5.78	-0.3	1.71e-8	Major depressive disorder;
CRC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.9	16.6	0.68	2.13e-45	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg03013999	chr17:37608204	MED1	0.45	6.91	0.36	2.6e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg25886479	chr11:50257625	LOC441601	0.34	5.75	0.3	2.04e-8	Coronary artery disease;
CRC	cis	rs6496667	1.000	rs16944254	chr15:90898527	C/T	cg04176472	chr15:90893244	GABARAPL3	0.5	7.53	0.38	4.86e-13	Rheumatoid arthritis;
CRC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg20608306	chr11:116969690	SIK3	0.29	5.6	0.3	4.47e-8	Blood protein levels;
CRC	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.61	10.09	0.49	4.83e-21	Dupuytren's disease;
CRC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.15	0.49	3.05e-21	Systolic blood pressure;
CRC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.59e-17	Coronary artery disease;
CRC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.36	5.72	0.3	2.43e-8	Height;
CRC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg24531977	chr5:56204891	C5orf35	-0.43	-6.6	-0.34	1.69e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.53	7.53	0.38	5e-13	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.93	-0.36	2.29e-11	Bipolar disorder;
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.46	-0.38	7.92e-13	Lymphocyte counts;
CRC	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	0.75	8.48	0.42	7.49e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.68	9.05	0.45	1.27e-17	Platelet count;
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.71	-0.39	1.52e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.13	0.32	2.48e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg00631329	chr6:26305371	NA	-0.55	-9.44	-0.46	7.12e-19	Educational attainment;
CRC	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg02527881	chr3:46936655	PTH1R	0.37	6.81	0.35	4.54e-11	Colorectal cancer;
CRC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	4.06e-8	Major depressive disorder;
CRC	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.01	-0.4	1.96e-14	Body mass index;
CRC	trans	rs72991	0.740	rs297503	chr11:121264426	A/G	cg27192990	chr6:129479024	LAMA2	0.4	6.63	0.34	1.41e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg06470822	chr6:28175283	NA	0.98	13.17	0.59	4.07e-32	Depression;
CRC	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22677401	chr17:46026860	NA	-0.39	-5.97	-0.31	6.32e-9	Myopia (pathological);
CRC	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.66	-10.04	-0.48	7.38e-21	Multiple sclerosis;
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg23490090	chr17:78081364	GAA	-0.34	-5.88	-0.31	1.01e-8	Yeast infection;
CRC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.64	7.34	0.38	1.63e-12	Body mass index;
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.37	-0.33	6.46e-10	Total body bone mineral density;
CRC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.4	-0.33	5.46e-10	Daytime sleep phenotypes;
CRC	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.02	0.36	1.29e-11	Prostate cancer;
CRC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-6.42	-0.33	4.68e-10	Body mass index;
CRC	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.91	11.07	0.52	2.02e-24	Exhaled nitric oxide output;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg04586622	chr2:25135609	ADCY3	-0.56	-10.45	-0.5	2.87e-22	Body mass index;
CRC	cis	rs10982256	0.774	rs7034891	chr9:117245252	C/G	cg13636371	chr9:117264095	DFNB31	-0.31	-5.9	-0.31	9.26e-9	Bipolar disorder;
CRC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg27535305	chr1:53392650	SCP2	0.34	6.04	0.32	4.09e-9	Monocyte count;
CRC	cis	rs9287719	0.614	rs10929680	chr2:10723126	C/T	cg00105475	chr2:10696890	NA	0.45	7.07	0.36	9.46e-12	Prostate cancer;
CRC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.42	-6.66	-0.34	1.12e-10	Testicular germ cell tumor;
CRC	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	cg04338863	chr8:33670619	NA	0.44	7.06	0.36	9.65e-12	Body mass index;
CRC	trans	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg21153622	chr11:89784906	NA	-0.47	-7.42	-0.38	9.85e-13	HDL cholesterol;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.62	0.6	8.27e-34	Prudent dietary pattern;
CRC	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg12560992	chr17:57184187	TRIM37	0.53	6.19	0.32	1.79e-9	Vitamin D levels;
CRC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.94e-9	Melanoma;
CRC	cis	rs3736485	0.966	rs11070856	chr15:51853817	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.73e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg02527881	chr3:46936655	PTH1R	0.41	7.48	0.38	6.71e-13	Colorectal cancer;
CRC	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.47	9.52	0.46	3.79e-19	Schizophrenia;
CRC	cis	rs317865	0.609	rs28619251	chr4:16172024	A/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.51	5.77	0.3	1.8e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.6	-9.11	-0.45	8.21e-18	Schizophrenia;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.79	12.79	0.58	1.13e-30	Height;
CRC	cis	rs7113874	0.610	rs7947670	chr11:8525531	A/C	cg20771178	chr11:8615675	STK33	-0.36	-5.92	-0.31	8.31e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.77	-0.35	5.83e-11	Inflammatory skin disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22783262	chr22:45098346	PRR5-ARHGAP8;PRR5	0.48	6.97	0.36	1.76e-11	Response to antipsychotic treatment;
CRC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg23298862	chr7:158159286	PTPRN2	-0.37	-5.87	-0.31	1.07e-8	Calcium levels;
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg19223190	chr17:80058835	NA	0.39	6.3	0.33	9.57e-10	Life satisfaction;
CRC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg12193833	chr17:30244370	NA	0.45	5.97	0.31	6.25e-9	Hip circumference adjusted for BMI;
CRC	cis	rs12612619	0.732	rs3754734	chr2:27299598	G/T	cg00617064	chr2:27272375	NA	-0.39	-6.53	-0.34	2.54e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.74	8.59	0.43	3.5e-16	Educational attainment;
CRC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg15147215	chr3:52552868	STAB1	-0.61	-10.05	-0.48	6.91e-21	Bipolar disorder;
CRC	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.39	5.64	0.3	3.57e-8	Osteoporosis;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg03623178	chr6:28175578	NA	0.77	11.36	0.53	1.93e-25	Parkinson's disease;
CRC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.98	12.83	0.58	8.19e-31	Vitiligo;
CRC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.6	-0.6	1e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs8105895	0.935	rs62112362	chr19:22293113	A/G	cg02912127	chr19:22235281	ZNF257	-0.4	-5.6	-0.3	4.43e-8	Body mass index (change over time);
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.12	-0.32	2.73e-9	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09867184	chr1:153939684	SLC39A1;CREB3L4	0.48	6.5	0.34	2.89e-10	Anxiety disorder;
CRC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.75	-0.47	7e-20	Primary sclerosing cholangitis;
CRC	trans	rs28643277	0.671	rs878321	chr10:15557115	A/G	cg18315834	chr14:64909119	MTHFD1	-0.41	-5.98	-0.31	5.82e-9	Periodontitis (CDC/AAP);
CRC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.65	-10.22	-0.49	1.83e-21	Motion sickness;
CRC	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg00034003	chr16:88779146	CTU2	-0.45	-5.69	-0.3	2.75e-8	Autism spectrum disorder-related traits;
CRC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.51	-7.9	-0.4	4.16e-14	Height;
CRC	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.43	-6.83	-0.35	4.19e-11	Sleep quality;
CRC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.52	-0.38	5.38e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-6.48	-0.34	3.42e-10	Alzheimer's disease (late onset);
CRC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00492233	chr7:135242493	NUP205	0.43	6.13	0.32	2.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.08	13.02	0.58	1.57e-31	Vitiligo;
CRC	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.44	0.38	8.99e-13	Height;
CRC	cis	rs6681460	0.634	rs994396	chr1:67012236	G/A	cg02459107	chr1:67143332	SGIP1	0.4	6.28	0.33	1.04e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.83	12.42	0.57	2.6e-29	Cognitive function;
CRC	cis	rs7894407	0.760	rs1163072	chr10:105024378	C/T	cg05636881	chr10:105038444	INA	-0.35	-5.67	-0.3	3.1e-8	White matter hyperintensity burden;
CRC	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.6	-9.17	-0.45	5.47e-18	Itch intensity from mosquito bite;
CRC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg23229984	chr5:148520753	ABLIM3	0.53	6.85	0.35	3.56e-11	Breast cancer;
CRC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-7.81	-0.4	7.6e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg15571903	chr15:79123663	NA	0.31	5.95	0.31	6.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs4731207	0.536	rs1904971	chr7:124669695	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.15	-0.32	2.22e-9	Cutaneous malignant melanoma;
CRC	trans	rs596169	0.764	rs6691014	chr1:219127338	T/C	cg09853702	chr12:47665230	NA	0.77	6.43	0.33	4.58e-10	Intraocular pressure;
CRC	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg14768367	chr16:72042858	DHODH	-0.5	-5.83	-0.31	1.36e-8	Blood protein levels;
CRC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg25985355	chr7:65971099	NA	-0.49	-5.73	-0.3	2.27e-8	Diabetic kidney disease;
CRC	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg18131467	chr2:239335373	ASB1	-0.64	-7.7	-0.39	1.5700000000000001e-13	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.49	6.63	0.34	1.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4737010	0.715	rs7461534	chr8:41628650	C/T	cg17182837	chr8:41585554	ANK1	-0.54	-7.62	-0.39	2.72e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg03030879	chr14:75389066	RPS6KL1	0.55	8.77	0.44	9.78e-17	Caffeine consumption;
CRC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.83	10.41	0.5	4.02e-22	Eosinophil percentage of granulocytes;
CRC	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg20356878	chr3:121714668	ILDR1	-0.42	-6.01	-0.31	5.02e-9	Multiple sclerosis;
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.72	9.56	0.47	2.94e-19	Alzheimer's disease;
CRC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.59	10.82	0.51	1.58e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.89	-15.12	-0.64	1.35e-39	Body mass index;
CRC	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg02158880	chr13:53174818	NA	0.4	5.63	0.3	3.91e-8	Lewy body disease;
CRC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg00316803	chr15:76480434	C15orf27	-0.37	-6.15	-0.32	2.29e-9	Blood metabolite levels;
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.61	-11.09	-0.52	1.75e-24	Aortic root size;
CRC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.07	14.4	0.62	8.27e-37	Orofacial clefts;
CRC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.58	0.43	3.84e-16	Parkinson's disease;
CRC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20285263	chr6:41392403	NA	0.43	6.05	0.32	3.94e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-0.89	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg03959625	chr15:84868606	LOC388152	0.42	6.33	0.33	8.21e-10	Schizophrenia;
CRC	cis	rs972578	0.967	rs972579	chr22:43387711	T/C	cg01576275	chr22:43409880	NA	-0.49	-7.98	-0.4	2.48e-14	Mean platelet volume;
CRC	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.61	-11.1	-0.52	1.61e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07062780	chr6:112364987	NA	0.42	6.2	0.32	1.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.98	-0.4	2.38e-14	Caffeine consumption;
CRC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.63	8.48	0.42	7.48e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6499129	0.558	rs60626639	chr16:67625797	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-8.47	-0.42	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.43	6.3	0.33	9.35e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg27398640	chr15:77910606	LINGO1	-0.45	-7.75	-0.39	1.15e-13	Type 2 diabetes;
CRC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg20811857	chr17:78079795	GAA	-0.41	-6.53	-0.34	2.56e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.48	-7.25	-0.37	2.98e-12	High light scatter reticulocyte count;
CRC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.44	-6.48	-0.34	3.34e-10	Menarche (age at onset);
CRC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.8	12.98	0.58	2.09e-31	IgG glycosylation;
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.71	10.53	0.5	1.56e-22	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20095338	chr12:76478402	NAP1L1	0.45	6.97	0.36	1.7e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	12.03	0.55	7.05e-28	Coffee consumption (cups per day);
CRC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-6.78	-0.35	5.5e-11	Chronic sinus infection;
CRC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg26893134	chr6:116381904	FRK	0.27	7.33	0.37	1.77e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.89	0.36	2.79e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-6.49	-0.34	3.09e-10	Immature fraction of reticulocytes;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.39	-6.88	-0.35	2.96e-11	Height;
CRC	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	1.11	17.83	0.7	3.18e-50	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.75	11.03	0.52	2.72e-24	Neutrophil percentage of white cells;
CRC	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.55	-0.34	2.22e-10	Depression;
CRC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.71	9.57	0.47	2.67e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.4	0.42	1.35e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg08222913	chr3:52553049	STAB1	-0.35	-6.37	-0.33	6.35e-10	Bipolar disorder;
CRC	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg09184832	chr6:79620586	NA	-0.46	-8.04	-0.41	1.6e-14	Intelligence (multi-trait analysis);
CRC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg25459000	chr22:39777742	SYNGR1	-0.34	-6.05	-0.32	3.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs863345	0.526	rs863931	chr1:158612236	A/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.6	-0.34	1.62e-10	Pneumococcal bacteremia;
CRC	cis	rs17234274	0.584	rs11027058	chr11:23232320	A/G	cg05245346	chr11:23248277	NA	0.36	5.84	0.31	1.23e-8	Cancer;
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.64	10.8	0.51	1.84e-23	Prudent dietary pattern;
CRC	cis	rs7635838	0.827	rs4273358	chr3:11415160	T/G	cg00170343	chr3:11313890	ATG7	0.43	6.57	0.34	2.02e-10	HDL cholesterol;
CRC	cis	rs10982256	0.774	rs13286452	chr9:117246574	C/T	cg13636371	chr9:117264095	DFNB31	0.33	6.39	0.33	5.67e-10	Bipolar disorder;
CRC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Body mass index;
CRC	cis	rs9648716	1.000	rs6954652	chr7:140585871	A/C	cg10747023	chr7:140774559	NA	0.44	5.88	0.31	9.82e-9	Type 2 diabetes;
CRC	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg25182066	chr10:30743637	MAP3K8	-0.41	-6.01	-0.31	5.06e-9	Inflammatory bowel disease;
CRC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.54	0.43	5.02e-16	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11471939	chr15:72522966	PKM2	0.43	6.16	0.32	2.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg27068330	chr11:65405492	SIPA1	-0.48	-6.69	-0.35	9.69e-11	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00794038	chr20:48808334	CEBPB	0.42	6.24	0.33	1.34e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.71	9.86	0.48	2.86e-20	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg25985355	chr7:65971099	NA	-0.5	-6.01	-0.31	4.91e-9	Diabetic kidney disease;
CRC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg05585544	chr11:47624801	NA	-0.62	-10.93	-0.52	6.4e-24	Subjective well-being;
CRC	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg26870460	chr11:6947759	ZNF215	0.56	5.88	0.31	1.01e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg05044414	chr3:183734942	ABCC5	0.47	8.11	0.41	1.03e-14	Anterior chamber depth;
CRC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg00166722	chr3:10149974	C3orf24	0.43	6.36	0.33	6.73e-10	Alzheimer's disease;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg22734451	chr15:78219748	LOC645752	0.45	6.41	0.33	4.97e-10	Underweight status;
CRC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg16797656	chr11:68205561	LRP5	0.36	5.69	0.3	2.81e-8	Total body bone mineral density;
CRC	cis	rs7215564	0.908	rs4889879	chr17:78662573	A/T	cg09596252	chr17:78655493	RPTOR	-0.55	-5.91	-0.31	8.47e-9	Myopia (pathological);
CRC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg23815491	chr16:72088622	HP	0.51	7.64	0.39	2.4e-13	Fibrinogen levels;
CRC	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.18	-0.37	4.6e-12	Superior frontal gyrus grey matter volume;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09511246	chr2:172290755	DCAF17;METTL8	-0.43	-6.27	-0.33	1.11e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05989628	chr6:3458053	SLC22A23	0.41	6.24	0.33	1.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.49	-7.2	-0.37	4.11e-12	Menarche (age at onset);
CRC	cis	rs16852403	0.548	rs10798602	chr1:178226439	A/G	cg00404053	chr1:178313656	RASAL2	0.52	6.75	0.35	6.58e-11	Childhood ear infection;
CRC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.64	-0.43	2.57e-16	Neuroticism;
CRC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	5.96	0.31	6.33e-9	Rheumatoid arthritis;
CRC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg18827107	chr12:86230957	RASSF9	-0.38	-5.81	-0.3	1.5e-8	Major depressive disorder;
CRC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg00129232	chr17:37814104	STARD3	-0.46	-7.24	-0.37	3.23e-12	Self-reported allergy;
CRC	cis	rs6973256	0.583	rs2042000	chr7:133322697	T/C	cg10665199	chr7:133106180	EXOC4	0.48	7.6	0.39	3.19e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26850624	chr5:429559	AHRR	0.51	8.67	0.43	1.99e-16	Cystic fibrosis severity;
CRC	cis	rs1524976	0.698	rs9864728	chr3:65486793	A/C	cg16238336	chr3:65465873	MAGI1	0.5	6.43	0.33	4.59e-10	PR interval;
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.98	-0.31	5.97e-9	Life satisfaction;
CRC	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg09695851	chr17:3907499	NA	0.83	16.4	0.67	1.35e-44	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14591854	chr2:136287923	R3HDM1;ZRANB3	0.49	7.26	0.37	2.77e-12	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18043455	chr3:127771761	SEC61A1	0.43	6.08	0.32	3.35e-9	Response to antipsychotic treatment;
CRC	trans	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg07393940	chr7:158741817	NA	-0.53	-7.68	-0.39	1.81e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg12856521	chr11:46389249	DGKZ	0.44	7.2	0.37	4e-12	Leprosy;
CRC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.09	0.36	8.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg11833968	chr6:79620685	NA	-0.34	-5.97	-0.31	6.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9925964	0.967	rs2855475	chr16:31147548	G/A	cg03418659	chr16:31128414	MYST1	-0.45	-6.59	-0.34	1.72e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs684232	0.800	rs2002015	chr17:534525	G/T	cg15660573	chr17:549704	VPS53	0.45	6.97	0.36	1.75e-11	Prostate cancer;
CRC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg09127314	chr1:152161683	NA	0.52	6.52	0.34	2.67e-10	Atopic dermatitis;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23781003	chr4:120988207	MAD2L1	-0.39	-6.04	-0.32	4.06e-9	Aortic root size;
CRC	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.54	7.76	0.39	1.11e-13	Blood metabolite levels;
CRC	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.46	6.98	0.36	1.67e-11	Red blood cell count;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.65	8.99	0.44	1.92e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-10.93	-0.52	6.3e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs995000	0.931	rs10157265	chr1:63093617	C/T	cg19896129	chr1:63156450	NA	0.41	6.41	0.33	5.18e-10	Triglyceride levels;
CRC	cis	rs9549328	0.699	rs2993345	chr13:113617086	C/T	cg25790453	chr13:113633590	MCF2L	0.44	7.66	0.39	2.15e-13	Systolic blood pressure;
CRC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.58	9.91	0.48	2.01e-20	Mean corpuscular volume;
CRC	cis	rs4780355	0.877	rs243317	chr16:11357331	G/T	cg00044050	chr16:11439710	C16orf75	-0.42	-5.92	-0.31	8.12e-9	Crohn's disease and psoriasis;
CRC	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg12292205	chr6:26970375	C6orf41	-0.79	-8.68	-0.43	1.87e-16	Autism spectrum disorder or schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01813026	chr11:809279	RPLP2	0.45	6.14	0.32	2.31e-9	Anxiety disorder;
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.05	0.32	3.99e-9	Bipolar disorder;
CRC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.52	-9.86	-0.48	2.88e-20	Educational attainment (years of education);
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10337772	chr3:44803071	KIF15;KIAA1143	0.47	6.58	0.34	1.89e-10	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg02033258	chr5:131593261	PDLIM4	0.36	7.0	0.36	1.4e-11	Blood metabolite levels;
CRC	trans	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg20935933	chr6:143382018	AIG1	0.51	6.64	0.34	1.3e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	8.75	0.43	1.16e-16	Platelet count;
CRC	cis	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg02972257	chr16:68554789	NA	0.47	5.92	0.31	8.24e-9	Colorectal cancer;
CRC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg11189052	chr15:85197271	WDR73	0.62	9.17	0.45	5.26e-18	Schizophrenia;
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg04969067	chr8:143858791	LYNX1	0.45	7.58	0.39	3.66e-13	Urinary tract infection frequency;
CRC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.45	5.98	0.31	5.93e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-15.37	-0.65	1.46e-40	Schizophrenia;
CRC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg00769240	chr8:12517080	NA	-0.66	-7.32	-0.37	1.96e-12	Blood pressure (smoking interaction);
CRC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.39	-6.61	-0.34	1.54e-10	Total body bone mineral density;
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg01874867	chr7:94954059	PON1	-0.49	-6.23	-0.32	1.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.82	-10.94	-0.52	5.91e-24	IgG glycosylation;
CRC	trans	rs1490453	0.679	rs10434129	chr4:149245455	T/A	cg26605335	chr17:4689165	VMO1	-0.35	-6.02	-0.31	4.58e-9	Biochemical measures;
CRC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg15465823	chr12:48382534	COL2A1	0.38	6.36	0.33	6.94e-10	Glycated hemoglobin levels;
CRC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.97	-20.37	-0.75	3.02e-60	Myeloid white cell count;
CRC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.53	0.34	2.51e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.36e-34	Menopause (age at onset);
CRC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg20515095	chr8:8998461	PPP1R3B	-0.47	-5.81	-0.31	1.47e-8	Myopia (pathological);
CRC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.48	7.06	0.36	9.76e-12	Melanoma;
CRC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg11062466	chr8:58055876	NA	0.51	6.06	0.32	3.75e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	0.935	rs186591	chr11:108200142	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.94	0.31	7.36e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.43	-6.8	-0.35	5.03e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs60871478	0.786	rs7807878	chr7:833878	T/C	cg13798912	chr7:905769	UNC84A	-0.52	-5.84	-0.31	1.25e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs4073416	0.542	rs8007497	chr14:66044476	T/C	cg03016385	chr14:66212404	NA	-0.44	-6.14	-0.32	2.4e-9	N-glycan levels;
CRC	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg10761708	chr20:43804764	PI3	0.49	5.6	0.3	4.41e-8	Blood protein levels;
CRC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.61	8.93	0.44	2.98e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.1	-0.36	7.67e-12	Bipolar disorder;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg27635394	chr6:26043820	HIST1H2BB	0.44	6.3	0.33	9.65e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.6	-7.78	-0.39	9.32e-14	Body mass index;
CRC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.65	-8.1	-0.41	1.1e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.62	-8.14	-0.41	8.36e-15	Systemic lupus erythematosus;
CRC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.9	-0.44	3.88e-17	Aortic root size;
CRC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg11212589	chr17:38028394	ZPBP2	0.42	7.67	0.39	2e-13	Self-reported allergy;
CRC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.91e-9	Hemoglobin concentration;
CRC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.51	-7.26	-0.37	2.87e-12	White blood cell count (neutrophil);
CRC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg08314208	chr16:67682810	RLTPR	-0.58	-6.23	-0.32	1.47e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg15030294	chr4:139936825	CCRN4L	0.42	6.52	0.34	2.58e-10	Schizophrenia;
CRC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-7.67	-0.39	2e-13	Coronary artery disease;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg26587870	chr6:27730563	NA	-0.45	-6.59	-0.34	1.75e-10	Parkinson's disease;
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg22638593	chr5:131593259	PDLIM4	0.34	6.62	0.34	1.42e-10	Blood metabolite levels;
CRC	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg27053337	chr8:124217698	FAM83A	0.46	6.99	0.36	1.58e-11	Urinary uromodulin levels;
CRC	trans	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18288967	chr1:45987694	PRDX1	0.68	7.72	0.39	1.37e-13	Obesity-related traits;
CRC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg23565292	chr14:50234668	KLHDC2	0.39	5.7	0.3	2.62e-8	Carotid intima media thickness;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12676444	chr3:25825192	NGLY1	-0.43	-6.53	-0.34	2.44e-10	Myopia (pathological);
CRC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.81	13.51	0.6	2.08e-33	Menopause (age at onset);
CRC	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg20265528	chr2:105853269	NA	-0.34	-5.69	-0.3	2.81e-8	Type 2 diabetes;
CRC	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.41	-6.38	-0.33	5.94e-10	IFN-related cytopenia;
CRC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg15445000	chr17:37608096	MED1	-0.43	-8.28	-0.42	3.12e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.23e-20	Hip circumference adjusted for BMI;
CRC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	2e-33	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03217460	chr11:70117060	PPFIA1	0.4	6.1	0.32	2.92e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.97	-0.31	6.07e-9	Aortic root size;
CRC	cis	rs6586163	0.872	rs7082720	chr10:90742049	C/T	cg13456138	chr10:90753195	FAS	-0.44	-6.58	-0.34	1.84e-10	Chronic lymphocytic leukemia;
CRC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.56	8.64	0.43	2.47e-16	Methadone dose in opioid dependence;
CRC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.56	-10.15	-0.49	3.09e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.5	8.74	0.43	1.2e-16	Testicular germ cell tumor;
CRC	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	9.02	0.45	1.62e-17	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7212938	0.570	rs8071050	chr17:38106599	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.36	-5.76	-0.3	1.93e-8	Asthma and hay fever;
CRC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-6.58	-0.34	1.91e-10	Blood pressure (smoking interaction);
CRC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05733361	chr15:85524456	PDE8A	0.47	6.65	0.34	1.25e-10	Response to antipsychotic treatment;
CRC	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	9.83	0.48	3.62e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6747952	0.899	rs12731	chr2:239087912	G/A	cg07480446	chr2:239069576	NA	-0.37	-6.92	-0.36	2.38e-11	Mean corpuscular hemoglobin concentration;
CRC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.47	8.57	0.43	3.99e-16	Height;
CRC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg18016565	chr1:150552671	MCL1	0.49	7.15	0.37	5.59e-12	Tonsillectomy;
CRC	cis	rs812925	0.893	rs778160	chr2:61557164	A/G	cg10580144	chr2:61372316	C2orf74	0.3	6.08	0.32	3.31e-9	Immature fraction of reticulocytes;
CRC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.74	-12.61	-0.57	5.08e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.83	-14.77	-0.63	3.19e-38	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg13072238	chr3:49761600	GMPPB	-0.51	-5.86	-0.31	1.15e-8	Menarche (age at onset);
CRC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.77	-0.3	1.78e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg15786705	chr6:28176104	NA	0.74	9.47	0.46	5.74e-19	Depression;
CRC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-14.99	-0.64	4.42e-39	Vitiligo;
CRC	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.32	0.33	8.51e-10	Body mass index;
CRC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.25	-0.49	1.45e-21	Inflammatory bowel disease;
CRC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg01721255	chr8:58191610	C8orf71	0.44	5.77	0.3	1.84e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7259376	0.875	rs1975175	chr19:22515239	G/C	cg02657401	chr19:22469223	NA	-0.37	-8.1	-0.41	1.05e-14	Menopause (age at onset);
CRC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg03030879	chr14:75389066	RPS6KL1	0.55	9.04	0.45	1.33e-17	Caffeine consumption;
CRC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.63	11.63	0.54	1.96e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.41	6.32	0.33	8.57e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs11800820	0.510	rs3124120	chr1:246708990	C/T	cg26885821	chr6:124125002	NKAIN2	0.38	6.14	0.32	2.32e-9	Obesity-related traits;
CRC	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.79	0.44	8.7e-17	Dupuytren's disease;
CRC	cis	rs9914988	0.606	rs968726	chr17:27194634	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.41	6.43	0.33	4.43e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg02158880	chr13:53174818	NA	0.51	7.58	0.39	3.6e-13	Lewy body disease;
CRC	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg06795125	chr2:108905320	SULT1C2	-0.43	-6.63	-0.34	1.42e-10	Lobe size;
CRC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.52	6.69	0.35	9.86e-11	Obesity-related traits;
CRC	cis	rs1062746	0.502	rs76128303	chr16:87339236	T/C	cg02258303	chr16:87377426	FBXO31	-0.54	-7.68	-0.39	1.85e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs6743376	0.554	rs11123160	chr2:113836165	A/T	cg24553058	chr2:113831203	IL1F10	0.6	8.06	0.41	1.47e-14	Inflammatory biomarkers;
CRC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg00647820	chr17:40259828	DHX58	-0.46	-6.59	-0.34	1.78e-10	Fibrinogen levels;
CRC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.62	11.22	0.53	5.9e-25	Schizophrenia;
CRC	cis	rs2933343	1.000	rs1680790	chr3:128625853	G/T	cg11901034	chr3:128598214	ACAD9	-0.51	-6.12	-0.32	2.73e-9	IgG glycosylation;
CRC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg18876405	chr7:65276391	NA	0.45	6.13	0.32	2.5e-9	Aortic root size;
CRC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.37	-0.53	1.7e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.65	-0.57	3.57e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs12144094	0.882	rs10494229	chr1:120229117	A/G	cg20995928	chr1:120229863	NA	0.45	6.56	0.34	2.09e-10	Height;
CRC	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.58	-8.49	-0.42	7.15e-16	Autism;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg13047869	chr3:10149882	C3orf24	0.52	7.13	0.37	6.56e-12	Alzheimer's disease;
CRC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	15.67	0.65	9.79e-42	Platelet count;
CRC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.62	-7.77	-0.39	9.78e-14	Body mass index;
CRC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg17633681	chr16:88106987	BANP	0.84	15.51	0.65	4.08e-41	Menopause (age at onset);
CRC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.22	14.91	0.64	9.24e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs2270875	1.000	rs8859	chr8:133025671	C/G	cg24184792	chr8:132919238	EFR3A	-0.61	-5.9	-0.31	9.02e-9	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.95	-0.31	6.74e-9	Major depressive disorder;
CRC	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.3	3.18e-8	Diabetic retinopathy;
CRC	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-6.49	-0.34	3.21e-10	Systemic lupus erythematosus;
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.48	-6.22	-0.32	1.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	6.0	0.31	5.09e-9	Bipolar disorder;
CRC	cis	rs6735179	0.688	rs6745142	chr2:1763886	A/G	cg19300414	chr2:1746591	PXDN	0.34	6.14	0.32	2.41e-9	Response to antipsychotic treatment;
CRC	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs6681460	1.000	rs6681460	chr1:67123057	C/T	cg02459107	chr1:67143332	SGIP1	-0.48	-8.54	-0.43	5.15e-16	Presence of antiphospholipid antibodies;
CRC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.72	-9.33	-0.46	1.62e-18	Psoriasis;
CRC	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg25876840	chr17:41920477	NA	0.55	7.55	0.38	4.26e-13	Triglycerides;
CRC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.08	19.26	0.73	7.11e-56	Cognitive function;
CRC	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	1.0	18.29	0.71	4.67e-52	Gut microbiome composition (winter);
CRC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.34	5.68	0.3	3e-8	Major depressive disorder;
CRC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.82	-10.49	-0.5	2.08e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.38	6.1	0.32	2.92e-9	Left ventricle wall thickness;
CRC	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.66	10.38	0.5	5.02e-22	Lewy body disease;
CRC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-10.37	-0.5	5.54e-22	Personality dimensions;
CRC	trans	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg03973167	chr4:185394988	IRF2	-0.45	-6.46	-0.34	3.74e-10	Schizophrenia;
CRC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.19	-0.41	5.86e-15	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg22535103	chr8:58192502	C8orf71	-0.52	-6.05	-0.32	3.99e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07600127	chr13:30881527	KATNAL1	0.44	6.09	0.32	3.15e-9	Anxiety disorder;
CRC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	7.86	0.4	5.53e-14	Response to antipsychotic treatment;
CRC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.37	5.68	0.3	2.96e-8	Height;
CRC	cis	rs3996993	0.809	rs3756982	chr6:52670444	A/T	cg20803780	chr6:52668592	GSTA1	-0.37	-6.93	-0.36	2.26e-11	Hemoglobin concentration;
CRC	trans	rs7396835	0.551	rs10750098	chr11:116705568	G/T	cg17196713	chr15:62127170	NA	0.46	6.29	0.33	1.04e-9	Quantitative traits;
CRC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.66	13.89	0.61	7.63e-35	Schizophrenia;
CRC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.4	5.96	0.31	6.5e-9	Mean corpuscular volume;
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.42	-0.33	4.89e-10	Lymphocyte counts;
CRC	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg04289385	chr6:36355825	ETV7	0.39	5.69	0.3	2.86e-8	Platelet distribution width;
CRC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.98	14.11	0.61	1.13e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.39	0.42	1.45e-15	Height;
CRC	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg05925327	chr15:68127851	NA	-0.3	-5.87	-0.31	1.04e-8	Restless legs syndrome;
CRC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg27565382	chr3:53032988	SFMBT1	0.77	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.81	0.35	4.52e-11	Bipolar disorder;
CRC	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg16898833	chr6:26189333	HIST1H4D	0.68	5.69	0.3	2.78e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7849270	1.000	rs7020708	chr9:131885131	A/G	cg13538475	chr9:131942899	NA	-0.29	-5.86	-0.31	1.1e-8	Blood metabolite ratios;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg15845792	chr6:28175446	NA	0.51	7.2	0.37	4.07e-12	Parkinson's disease;
CRC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.58	7.35	0.38	1.57e-12	Neutrophil percentage of white cells;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg13370280	chr6:137539688	IFNGR1	-0.4	-6.09	-0.32	3.08e-9	Daytime sleep phenotypes;
CRC	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.81	-10.78	-0.51	2.12e-23	Hair shape;
CRC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.8	-11.42	-0.53	1.17e-25	Tonsillectomy;
CRC	cis	rs73206853	0.609	rs12311902	chr12:110883799	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	8.9	0.44	3.95e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg14711859	chr11:8959438	ASCL3	-0.49	-7.92	-0.4	3.73e-14	Hemoglobin concentration;
CRC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.76	14.25	0.62	3.36e-36	Prudent dietary pattern;
CRC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.81	14.42	0.62	7.35e-37	Vitiligo;
CRC	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg04850286	chr10:81895943	PLAC9	0.37	6.71	0.35	8.44e-11	Sarcoidosis;
CRC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg21238619	chr17:78079768	GAA	-0.35	-5.63	-0.3	3.91e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.67	9.41	0.46	8.8e-19	Gestational age at birth (maternal effect);
CRC	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.97	-0.48	1.29e-20	Height;
CRC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg00246817	chr9:123691163	NA	-0.47	-5.97	-0.31	6.22e-9	Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21188454	chr9:131549455	TBC1D13	0.38	6.07	0.32	3.57e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.83	0.31	1.29e-8	Hemoglobin concentration;
CRC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.66	-10.16	-0.49	2.79e-21	Diastolic blood pressure;
CRC	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.47	5.92	0.31	8.03e-9	Metabolite levels;
CRC	cis	rs10046574	0.731	rs10458299	chr7:135052348	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2677744	0.688	rs3784779	chr15:91453131	C/T	cg23684204	chr15:91497937	RCCD1	0.4	6.1	0.32	2.96e-9	Attention deficit hyperactivity disorder;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16664537	chr13:50366648	KPNA3	-0.41	-6.03	-0.32	4.48e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs11212617	0.967	rs4585	chr11:108239628	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.76	0.35	6.12e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.43	-5.95	-0.31	6.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	8.93	0.44	3.18e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.3	0.33	9.48e-10	Bipolar disorder;
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.44	-0.33	4.31e-10	Total body bone mineral density;
CRC	cis	rs2834256	0.646	rs6517193	chr21:35150756	A/G	cg14850771	chr21:34775459	IFNGR2	0.42	5.97	0.31	6.28e-9	Red cell distribution width;
CRC	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg04110750	chr16:69646130	NFAT5	-0.56	-7.71	-0.39	1.5e-13	IgE levels;
CRC	cis	rs12760731	0.720	rs10913557	chr1:178442190	C/T	cg00404053	chr1:178313656	RASAL2	0.96	10.06	0.49	6.17e-21	Obesity-related traits;
CRC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.33	5.99	0.31	5.5e-9	Rheumatoid arthritis;
CRC	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg02702477	chr5:179499311	RNF130	0.56	6.52	0.34	2.69e-10	LDL cholesterol;
CRC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg05709478	chr1:6581295	PLEKHG5	0.67	6.53	0.34	2.55e-10	Body mass index;
CRC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.71	10.1	0.49	4.55e-21	Alzheimer's disease;
CRC	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.82	12.31	0.56	6.86e-29	Gut microbiome composition (winter);
CRC	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg12560992	chr17:57184187	TRIM37	-0.57	-7.88	-0.4	4.98e-14	Testicular germ cell tumor;
CRC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.5	6.76	0.35	6.33e-11	Obesity-related traits;
CRC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.76	-12.1	-0.55	4e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.39	-5.69	-0.3	2.83e-8	Coronary artery disease;
CRC	trans	rs4386084	1.000	rs117184881	chr15:50258317	A/T	cg02453146	chr1:53068587	GPX7	-0.34	-6.05	-0.32	3.91e-9	Basophil percentage of white cells;Basophil percentage of granulocytes;
CRC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.9	-17.3	-0.69	3.95e-48	Intelligence (multi-trait analysis);
CRC	cis	rs17152411	0.901	rs7081640	chr10:126592522	C/T	cg07906193	chr10:126599966	NA	0.49	5.96	0.31	6.64e-9	Height;
CRC	trans	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.22	0.41	4.72e-15	Diabetic kidney disease;
CRC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.52	0.38	5.43e-13	Aortic root size;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg17346650	chr17:80929145	B3GNTL1	0.48	7.01	0.36	1.34e-11	Glycated hemoglobin levels;
CRC	cis	rs12760731	0.623	rs10913550	chr1:178408795	A/G	cg00404053	chr1:178313656	RASAL2	0.75	9.35	0.46	1.4e-18	Obesity-related traits;
CRC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.23	-0.53	5.54e-25	Chronic sinus infection;
CRC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg03037974	chr15:76606532	NA	-0.51	-7.66	-0.39	2.13e-13	Blood metabolite levels;
CRC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg05501817	chr11:14380813	RRAS2	-0.42	-5.89	-0.31	9.64e-9	Sense of smell;
CRC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.84	-14.63	-0.63	1.09e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.67	10.3	0.49	9.23e-22	Corneal astigmatism;
CRC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	trans	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs4660306	0.744	rs11211115	chr1:45926438	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.97	0.36	1.71e-11	Homocysteine levels;
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.32	-0.33	8.39e-10	Neuroticism;
CRC	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.94	0.31	7.35e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.55	0.34	2.22e-10	Diabetic kidney disease;
CRC	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.61	8.37	0.42	1.65e-15	Menopause (age at onset);
CRC	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.51	9.11	0.45	8.4e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17589437	chr7:87563717	ADAM22	0.39	7.06	0.36	9.93e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.46	-7.82	-0.4	7.35e-14	Major depressive disorder;
CRC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg15465823	chr12:48382534	COL2A1	-0.38	-6.26	-0.33	1.18e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg26394196	chr10:1453818	ADARB2	-0.33	-5.87	-0.31	1.04e-8	Radiation response;
CRC	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg17470449	chr10:769945	NA	0.5	7.06	0.36	9.9e-12	Uric acid levels;
CRC	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	15.32	0.65	2.24e-40	Mean corpuscular hemoglobin;
CRC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.61	10.28	0.49	1.15e-21	Prudent dietary pattern;
CRC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-7.91	-0.4	4.03e-14	Mean corpuscular volume;
CRC	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.57	-5.91	-0.31	8.42e-9	Coronary artery disease;
CRC	trans	rs6058526	1.000	rs8118061	chr20:30741664	C/T	cg13674914	chr7:14429205	DGKB	-0.52	-6.13	-0.32	2.57e-9	Chronic obstructive pulmonary disease;
CRC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.74	10.21	0.49	1.89e-21	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs863345	0.625	rs11264978	chr1:158447921	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.09	-0.32	3.07e-9	Pneumococcal bacteremia;
CRC	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.85	-15.06	-0.64	2.31e-39	Colorectal cancer;
CRC	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.81	-0.3	1.51e-8	Height;
CRC	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.62	-10.18	-0.49	2.53e-21	Neuroticism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03316107	chr7:5085477	RBAK	0.43	6.05	0.32	3.86e-9	Anxiety disorder;
CRC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg02869306	chr7:64672164	INTS4L1	0.44	6.22	0.32	1.5e-9	Aortic root size;
CRC	cis	rs9648716	1.000	rs1267625	chr7:140536739	A/C	cg10747023	chr7:140774559	NA	0.44	5.73	0.3	2.24e-8	Type 2 diabetes;
CRC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.6	-9.36	-0.46	1.25e-18	Aortic root size;
CRC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg11632617	chr15:75315747	PPCDC	-0.52	-6.98	-0.36	1.61e-11	Blood trace element (Zn levels);
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20589815	chr10:47656205	NA	0.41	6.92	0.36	2.33e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.59	7.46	0.38	7.53e-13	RR interval (heart rate);
CRC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg24562669	chr7:97807699	LMTK2	0.78	17.14	0.69	1.63e-47	Breast cancer;
CRC	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.98	11.64	0.54	1.87e-26	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-12.01	-0.55	8.36e-28	Asthma;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg27485189	chr12:124086218	DDX55	-0.42	-6.2	-0.32	1.64e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.59	6.0	0.31	5.24e-9	Plasma clusterin levels;
CRC	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg22256960	chr15:77711686	NA	-0.41	-5.95	-0.31	6.79e-9	Type 2 diabetes;
CRC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.62	-11.16	-0.52	1e-24	Aortic root size;
CRC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.6	8.55	0.43	4.62e-16	Lung cancer;
CRC	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.51	-7.67	-0.39	1.9e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg03689076	chr20:33865952	NA	0.46	6.64	0.34	1.3100000000000001e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg18479299	chr3:125709523	NA	-0.52	-6.22	-0.32	1.49e-9	Blood pressure (smoking interaction);
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg04969067	chr8:143858791	LYNX1	-0.71	-12.69	-0.57	2.67e-30	Urinary tract infection frequency;
CRC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.97	11.85	0.55	3.2e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.32	0.33	8.47e-10	Lung cancer;
CRC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.45	-6.03	-0.32	4.34e-9	Rheumatoid arthritis;
CRC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.84	0.35	3.81e-11	Neuroticism;
CRC	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg01422370	chr2:73384389	NA	0.38	6.05	0.32	3.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.75	12.28	0.56	8.4e-29	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.23e-23	Motion sickness;
CRC	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg19773385	chr1:10388646	KIF1B	-0.56	-7.63	-0.39	2.56e-13	Hepatocellular carcinoma;
CRC	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.74	-10.36	-0.5	5.94e-22	Blood protein levels;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.53	8.11	0.41	1.04e-14	Fibrinogen levels;
CRC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.43	6.94	0.36	2.11e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.51	-8.45	-0.42	9.25e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.48	-7.55	-0.38	4.25e-13	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs965469	0.779	rs6037568	chr20:3333245	C/T	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.75	-0.39	1.14e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.5	-11.07	-0.52	2.03e-24	Rheumatoid arthritis;
CRC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.7	-11.25	-0.53	4.79e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.58	-7.5	-0.38	6.08e-13	Gut microbiome composition (summer);
CRC	cis	rs863345	0.527	rs7514555	chr1:158445138	G/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.92	-0.31	8.16e-9	Pneumococcal bacteremia;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg11636714	chr8:42128950	IKBKB	0.48	6.15	0.32	2.22e-9	Plasma plasminogen activator levels;
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.45	-0.34	3.94e-10	Systemic lupus erythematosus;
CRC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.55	-0.38	4.32e-13	Aortic root size;
CRC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.44	-8.06	-0.41	1.45e-14	Reticulocyte fraction of red cells;
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.85	-0.44	5.68e-17	Bipolar disorder;
CRC	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg15147215	chr3:52552868	STAB1	0.43	6.92	0.36	2.38e-11	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15591513	chr8:142139310	DENND3	0.29	6.06	0.32	3.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg21251018	chr6:28226885	NKAPL	0.49	7.47	0.38	7.1e-13	Parkinson's disease;
CRC	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.29	-6.28	-0.33	1.06e-9	Mean corpuscular volume;
CRC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg12193833	chr17:30244370	NA	-0.75	-8.76	-0.43	1.09e-16	Hip circumference adjusted for BMI;
CRC	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.94	-0.64	7.14e-39	Exhaled nitric oxide output;
CRC	cis	rs7487075	0.828	rs2169030	chr12:46735056	A/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.45	0.34	4e-10	Itch intensity from mosquito bite;
CRC	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.97	0.36	1.74e-11	Diisocyanate-induced asthma;
CRC	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg14004847	chr7:1930337	MAD1L1	-0.44	-5.86	-0.31	1.15e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg01420254	chr6:26195488	NA	0.84	8.68	0.43	1.9e-16	Gout;Renal underexcretion gout;
CRC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	6.15	0.32	2.29e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.35	0.38	1.58e-12	Total body bone mineral density;
CRC	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	7.08	0.36	9e-12	Menarche (age at onset);
CRC	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.71	7.91	0.4	4.03e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.67	9.24	0.45	3.1e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02488887	chr5:176830915	F12	-0.42	-6.03	-0.32	4.38e-9	Daytime sleep phenotypes;
CRC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.41	-5.95	-0.31	7.01e-9	Response to metformin (IC50);
CRC	cis	rs6908034	0.607	rs113894708	chr6:19806066	G/T	cg02682789	chr6:19804855	NA	0.79	6.75	0.35	6.62e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs9287719	0.649	rs10207885	chr2:10733188	C/T	cg00105475	chr2:10696890	NA	0.45	7.1	0.36	7.51e-12	Prostate cancer;
CRC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.45	-5.6	-0.3	4.48e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	0.97	8.46	0.42	9.1e-16	Blood protein levels;
CRC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.46	7.17e-19	Bladder cancer;
CRC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg14008862	chr17:28927542	LRRC37B2	0.5	6.08	0.32	3.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.46	-7.06	-0.36	9.71e-12	Longevity;
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg15704280	chr7:45808275	SEPT13	0.52	6.07	0.32	3.56e-9	Intraocular pressure;
CRC	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.63	9.08	0.45	1.01e-17	Coronary artery disease;
CRC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.95	0.36	2e-11	Mean platelet volume;
CRC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.67	10.39	0.5	4.82e-22	Blood protein levels;
CRC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.82	-0.4	7.36e-14	Coronary artery disease;
CRC	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg02820901	chr13:113351484	ATP11A	0.61	6.65	0.34	1.2e-10	Glycated hemoglobin levels;
CRC	cis	rs941898	0.957	rs941900	chr14:100603399	C/A	cg14380774	chr14:101029898	BEGAIN	0.42	5.94	0.31	7.09e-9	White matter hyperintensity burden;
CRC	cis	rs5758511	0.573	rs2267439	chr22:42237769	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.37	-6.1	-0.32	2.99e-9	Birth weight;
CRC	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	0.9	7.79	0.39	8.85e-14	Fat distribution (HIV);
CRC	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.09	-0.32	3.11e-9	Metabolite levels;
CRC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.6	11.64	0.54	1.83e-26	Coronary artery disease;
CRC	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.15	-0.37	5.56e-12	Blood metabolite levels;
CRC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg00129232	chr17:37814104	STARD3	0.43	6.74	0.35	7.25e-11	Self-reported allergy;
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg01339444	chr6:118972232	C6orf204	0.55	6.23	0.32	1.43e-9	Diastolic blood pressure;
CRC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.29	15.45	0.65	7.32e-41	Uric acid levels;
CRC	trans	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg10756647	chr7:56101905	PSPH	0.72	7.98	0.4	2.39e-14	Diabetic kidney disease;
CRC	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.21	0.53	6.29e-25	Bipolar disorder;
CRC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg27532560	chr4:187881888	NA	-0.56	-10.24	-0.49	1.48e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.89	12.86	0.58	6.06e-31	IgG glycosylation;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg03301945	chr19:10764555	ILF3;LOC147727	0.39	6.18	0.32	1.85e-9	Schizophrenia;
CRC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.9	0.44	3.71e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg27615366	chr5:131592974	PDLIM4	0.33	5.81	0.3	1.49e-8	Breast cancer;
CRC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.61	9.41	0.46	8.75e-19	Corneal astigmatism;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.38	5.81	0.3	1.49e-8	Bipolar disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09560294	chr4:37892962	TBC1D1	0.5	6.62	0.34	1.44e-10	Thyroid stimulating hormone;
CRC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.77	13.29	0.59	1.42e-32	Prostate cancer;
CRC	cis	rs2179367	0.959	rs579789	chr6:149679371	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.17	-0.32	2e-9	Dupuytren's disease;
CRC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.03	-0.32	4.52e-9	Calcium levels;
CRC	cis	rs6066835	0.764	rs3091617	chr20:47386290	G/T	cg18078177	chr20:47281410	PREX1	0.69	6.17	0.32	2.06e-9	Multiple myeloma;
CRC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.62	9.21	0.45	3.8e-18	Subjective well-being;
CRC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg13390004	chr1:15929781	NA	0.53	7.44	0.38	9.04e-13	Systolic blood pressure;
CRC	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg05347473	chr6:146136440	FBXO30	0.5	6.69	0.35	9.63e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg27534772	chr1:16042836	PLEKHM2	0.56	10.64	0.51	6.42e-23	Systolic blood pressure;
CRC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.49	6.73	0.35	7.69e-11	Gut microbiome composition (summer);
CRC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.69	9.24	0.45	3.21e-18	High light scatter reticulocyte count;
CRC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.74	9.7	0.47	9.57e-20	Platelet count;
CRC	trans	rs875033	0.636	rs2818088	chr6:68287081	T/A	cg00112309	chr8:106787982	ZFPM2	-0.41	-6.01	-0.31	4.97e-9	Response to amphetamines;
CRC	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.03	0.68	4.35e-47	Electrocardiographic conduction measures;
CRC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg02659138	chr7:134003124	SLC35B4	0.34	5.8	0.3	1.57e-8	Mean platelet volume;
CRC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.79	-12.5	-0.57	1.36e-29	Blood trace element (Zn levels);
CRC	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg25856811	chr1:152973957	SPRR3	-0.27	-7.47	-0.38	7.2e-13	Inflammatory skin disease;
CRC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.49	-7.72	-0.39	1.45e-13	Eye color traits;
CRC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.63	9.63	0.47	1.67e-19	Corneal astigmatism;
CRC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06544989	chr22:39130855	UNC84B	0.46	6.99	0.36	1.53e-11	Menopause (age at onset);
CRC	cis	rs12044355	0.827	rs11583715	chr1:231829039	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.67	-0.34	1.11e-10	Alzheimer's disease;
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.67	-7.59	-0.39	3.28e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.46	-6.78	-0.35	5.7e-11	Uric acid clearance;
CRC	cis	rs2481665	0.617	rs12732781	chr1:62518459	T/C	cg18591186	chr1:62594603	INADL	-0.44	-6.27	-0.33	1.15e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs394563	0.556	rs398159	chr6:149792768	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.48	-7.48	-0.38	6.92e-13	Dupuytren's disease;
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.41	-0.38	1.09e-12	Lymphocyte counts;
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.65	0.54	1.65e-26	Prudent dietary pattern;
CRC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.74	-0.3	2.2e-8	Crohn's disease;
CRC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.66	-9.78	-0.47	5.44e-20	DNA methylation (variation);
CRC	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.2	-18.39	-0.71	1.85e-52	Blood pressure (smoking interaction);
CRC	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg09655341	chr17:79618100	PDE6G	0.59	6.82	0.35	4.44e-11	Dental caries;
CRC	cis	rs6681460	0.966	rs4655650	chr1:67142286	A/G	cg02459107	chr1:67143332	SGIP1	0.45	7.8	0.4	8.15e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs73200209	0.744	rs17426970	chr12:116665099	T/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.02	-0.36	1.3e-11	Total body bone mineral density;
CRC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.49	5.84	0.31	1.27e-8	Lung function (FEV1/FVC);
CRC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.42	6.1	0.32	2.95e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.81	11.48	0.53	6.81e-26	Gout;
CRC	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.42	6.11	0.32	2.8e-9	Red blood cell count;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg24560729	chr4:1342394	KIAA1530	-0.33	-5.89	-0.31	9.71e-9	Obesity-related traits;
CRC	cis	rs1868673	1.000	rs6770424	chr3:150174304	A/G	cg04908077	chr3:150187338	NA	-0.33	-5.64	-0.3	3.62e-8	Waist circumference;
CRC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	9.68	0.47	1.12e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.55	8.21	0.41	5.2e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.27e-19	Blood protein levels;
CRC	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.93	-0.36	2.29e-11	Depression;
CRC	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg01993067	chr11:68851601	TPCN2	0.56	6.33	0.33	7.99e-10	Blond vs. brown hair color;
CRC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.48	-7.87	-0.4	5.31e-14	Calcium levels;
CRC	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg26695010	chr11:65641043	EFEMP2	0.48	7.33	0.37	1.84e-12	Eosinophil percentage of white cells;
CRC	cis	rs9928842	0.771	rs4888363	chr16:75277344	A/T	cg08657710	chr16:75258780	CTRB1	-0.54	-6.97	-0.36	1.69e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs1971256	0.500	rs3912291	chr6:151818210	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.63	-5.74	-0.3	2.11e-8	Endometriosis;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.79	-0.35	5.16e-11	Type 2 diabetes;
CRC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg00383909	chr3:49044727	WDR6	0.44	5.75	0.3	2.02e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.89e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg16899823	chr10:58121153	ZWINT	-0.39	-6.09	-0.32	3.2e-9	Survival in rectal cancer;
CRC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.69	-0.35	9.67e-11	Mood instability;
CRC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-7.8	-0.4	8.09e-14	Coronary artery disease;
CRC	trans	rs2565722	0.622	rs10945704	chr6:161290926	C/T	cg01698392	chr17:76871734	TIMP2	-0.46	-6.02	-0.31	4.66e-9	Blood protein levels;
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg04155289	chr7:94953770	PON1	-0.63	-7.75	-0.39	1.17e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg13198984	chr17:80129470	CCDC57	0.43	7.56	0.38	3.92e-13	Life satisfaction;
CRC	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg14593290	chr7:50529359	DDC	0.51	7.0	0.36	1.45e-11	Malaria;
CRC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg03037974	chr15:76606532	NA	-0.66	-11.68	-0.54	1.33e-26	Blood metabolite levels;
CRC	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg21106136	chr3:194405973	FAM43A	0.44	6.5	0.34	3.04e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.94	0.44	2.77e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.35	-0.46	1.43e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg24046110	chr8:143859143	LYNX1	-0.43	-6.62	-0.34	1.48e-10	Urinary tract infection frequency;
CRC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg02007433	chr3:129722099	NA	-0.51	-6.2	-0.32	1.67e-9	Blood pressure (smoking interaction);
CRC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-8.16	-0.41	7.37e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18185028	chr3:154042079	DHX36	0.35	6.07	0.32	3.45e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg26566898	chr11:117069891	TAGLN	0.38	6.91	0.36	2.53e-11	Blood protein levels;
CRC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg07828024	chr6:149772892	ZC3H12D	-0.49	-9.21	-0.45	3.97e-18	Dupuytren's disease;
CRC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.67	-10.31	-0.49	9.02e-22	Other erythrocyte phenotypes;
CRC	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.2	0.32	1.65e-9	Vitamin D levels;
CRC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.53	8.36	0.42	1.81e-15	IgG glycosylation;
CRC	cis	rs11212617	0.967	rs396552	chr11:108221483	G/C	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.61	0.3	4.3e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.6	-10.83	-0.51	1.4e-23	Aortic root size;
CRC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg10760299	chr15:45669010	GATM	0.5	8.05	0.41	1.54e-14	Homoarginine levels;
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.34	-0.37	1.72e-12	Testicular germ cell tumor;
CRC	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.5	8.34	0.42	2e-15	Testicular germ cell tumor;
CRC	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.73	11.68	0.54	1.34e-26	Plateletcrit;Platelet count;
CRC	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg23100626	chr2:96804247	ASTL	0.29	8.04	0.41	1.63e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs73200209	0.744	rs61939697	chr12:116555491	T/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.41	-0.38	1.06e-12	Total body bone mineral density;
CRC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.44	7.02	0.36	1.31e-11	Height;
CRC	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.5	-7.66	-0.39	2.11e-13	Type 2 diabetes;
CRC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg07636037	chr3:49044803	WDR6	-0.68	-6.53	-0.34	2.57e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.65	-11.23	-0.53	5.35e-25	Brugada syndrome;
CRC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	7.1	0.36	7.93e-12	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.51e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.48	7.06	0.36	9.8e-12	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19078334	chr9:113019254	TXN	0.47	6.14	0.32	2.31e-9	Anxiety disorder;
CRC	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.59	8.71	0.43	1.54e-16	Adiposity;
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.63	-9.48	-0.46	5.11e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-15.34	-0.65	1.9e-40	Body mass index;
CRC	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.16	0.45	5.89e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	11.56	0.54	3.56e-26	Monocyte count;
CRC	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.49	7.63	0.39	2.54e-13	Red blood cell count;
CRC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.48	5.79	0.3	1.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.72	0.39	1.41e-13	Corneal astigmatism;
CRC	cis	rs7605827	0.930	rs11896745	chr2:15515373	C/T	cg19274914	chr2:15703543	NA	0.38	5.76	0.3	1.92e-8	Educational attainment (years of education);
CRC	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.2	-0.32	1.68e-9	Diastolic blood pressure;
CRC	cis	rs7122539	0.839	rs6591223	chr11:66609289	C/T	cg24851651	chr11:66362959	CCS	0.43	7.68	0.39	1.9e-13	HIV-1 susceptibility;
CRC	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-6.15	-0.32	2.27e-9	Schizophrenia;
CRC	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.5	7.36	0.38	1.51e-12	Pulmonary function decline;
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.48	-7.02	-0.36	1.3e-11	Caudate activity during reward;
CRC	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg21681030	chr2:46777652	RHOQ	0.45	6.07	0.32	3.47e-9	Height;
CRC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.68	-11.18	-0.52	8.18e-25	Hepatocellular carcinoma;
CRC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.26	0.37	2.78e-12	Motion sickness;
CRC	cis	rs1223397	1.000	rs1223402	chr6:13271640	G/A	cg21538684	chr6:13274180	PHACTR1	0.46	5.71	0.3	2.59e-8	Blood pressure;
CRC	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.62	-0.68	1.91e-45	Electrocardiographic conduction measures;
CRC	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.03	-17.09	-0.69	2.53e-47	Schizophrenia;
CRC	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.43	7.1	0.36	7.61e-12	Prevalent atrial fibrillation;
CRC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.95	0.36	2e-11	Platelet count;
CRC	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.75	12.35	0.56	4.75e-29	Plateletcrit;Platelet count;
CRC	trans	rs2303319	0.504	rs13417851	chr2:162559919	T/G	cg18122310	chr12:50236657	BCDIN3D	-0.68	-6.08	-0.32	3.35e-9	Cognitive function;
CRC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.77	-15.56	-0.65	2.56e-41	Prostate cancer;
CRC	cis	rs6691722	0.503	rs6667695	chr1:24707669	G/A	cg02336364	chr1:24764700	NIPAL3	0.38	6.25	0.33	1.28e-9	Response to interferon beta in multiple sclerosis;
CRC	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.37	0.46	1.17e-18	Endometrial cancer;
CRC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.47	8.59	0.43	3.48e-16	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1050846	0.564	rs1050863	chr16:87440895	C/T	cg27585878	chr16:87386489	FBXO31	-0.43	-6.96	-0.36	1.91e-11	Neuroticism;
CRC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.79	-11.48	-0.53	6.72e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.49	7.01	0.36	1.39e-11	Aortic root size;
CRC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg17401720	chr7:158221031	PTPRN2	-0.42	-6.98	-0.36	1.68e-11	Obesity-related traits;
CRC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.5	-7.48	-0.38	6.65e-13	Coronary artery disease;
CRC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.75	13.96	0.61	4.22e-35	Prudent dietary pattern;
CRC	cis	rs7429990	1.000	rs1665982	chr3:47905079	A/G	cg11946769	chr3:48343235	NME6	-0.54	-6.47	-0.34	3.55e-10	Educational attainment (years of education);
CRC	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.38	6.79	0.35	5.28e-11	Primary biliary cholangitis;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg26868354	chr6:35699952	LOC285847	0.38	6.05	0.32	3.96e-9	Myopia;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.65	6.77	0.35	5.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28493229	0.708	rs10407889	chr19:41161078	T/C	cg21869046	chr19:41225005	ITPKC	0.41	6.15	0.32	2.26e-9	Kawasaki disease;
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.99	-0.52	3.72e-24	Bipolar disorder;
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.58	9.04	0.45	1.36e-17	Electroencephalogram traits;
CRC	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.37	6.29	0.33	1e-9	Blood metabolite levels;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg17774305	chr12:50505649	C12orf62	0.57	5.97	0.31	6.15e-9	Airway imaging phenotypes;
CRC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg10398005	chr11:117014888	PAFAH1B2	-0.45	-6.75	-0.35	6.83e-11	Blood protein levels;
CRC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	9.85	0.48	3.17e-20	Hip circumference adjusted for BMI;
CRC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg18279126	chr7:2041391	MAD1L1	0.43	6.5	0.34	2.93e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.48	6.95	0.36	1.93e-11	Methadone dose in opioid dependence;
CRC	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg27068330	chr11:65405492	SIPA1	-0.43	-5.95	-0.31	6.87e-9	Systemic lupus erythematosus;
CRC	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg23100626	chr2:96804247	ASTL	0.32	8.72	0.43	1.36e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg02475695	chr16:616220	NHLRC4	0.45	7.25	0.37	3.06e-12	Height;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17404403	chr4:110737017	GAR1	0.41	6.61	0.34	1.55e-10	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06745235	chr1:180471494	ACBD6	0.47	6.04	0.32	4.2e-9	Thyroid stimulating hormone;
CRC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg17948913	chr5:572064	NA	0.51	5.91	0.31	8.58e-9	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11126068	chr11:67195806	RPS6KB2	0.5	6.41	0.33	5.03e-10	Thyroid stimulating hormone;
CRC	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.46	-7.22	-0.37	3.58e-12	Red blood cell count;
CRC	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.54	8.95	0.44	2.61e-17	Dupuytren's disease;
CRC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.39	6.39	0.33	5.64e-10	Sitting height ratio;
CRC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.45	6.72	0.35	8.23e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.31	-0.42	2.58e-15	Schizophrenia;
CRC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.85	14.04	0.61	2.06e-35	Blood metabolite levels;
CRC	cis	rs17641971	0.708	rs10957317	chr8:49888870	C/T	cg00325661	chr8:49890786	NA	-0.35	-6.13	-0.32	2.47e-9	Blood metabolite levels;
CRC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.97	-17.06	-0.69	3.26e-47	Headache;
CRC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.55	-8.21	-0.41	5.06e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.51	-8.12	-0.41	9.61e-15	Huntington's disease progression;
CRC	cis	rs12541635	1.000	rs7817197	chr8:107089633	T/G	cg10147462	chr8:107024639	NA	-0.37	-6.3	-0.33	9.62e-10	Age of smoking initiation;
CRC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	6.53	0.34	2.44e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.73	12.56	0.57	8.05e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs294883	0.739	rs1847482	chr6:159731324	A/C	cg14500486	chr6:159655392	FNDC1	-0.36	-6.27	-0.33	1.14e-9	Coronary artery disease;
CRC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg03037974	chr15:76606532	NA	0.59	9.98	0.48	1.18e-20	Blood metabolite levels;
CRC	cis	rs9296095	0.607	rs9366824	chr6:33521577	C/T	cg14003231	chr6:33640908	ITPR3	0.46	7.07	0.36	9.49e-12	Platelet count;
CRC	trans	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.64	-0.39	2.36e-13	HDL cholesterol;
CRC	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.72	-0.3	2.38e-8	Blood metabolite levels;
CRC	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.52	-0.46	4e-19	Capecitabine sensitivity;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg10876282	chr6:28092338	ZSCAN16	0.47	5.72	0.3	2.36e-8	Parkinson's disease;
CRC	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg11887960	chr12:57824829	NA	0.63	6.95	0.36	1.94e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs2333194	0.875	rs28716532	chr14:73769255	T/C	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.42	-6.36	-0.33	6.74e-10	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17691542	chr6:26056736	HIST1H1C	0.54	8.4	0.42	1.39e-15	Height;
CRC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.56	6.35	0.33	7.35e-10	Bipolar disorder;
CRC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg27661571	chr11:113659931	NA	-0.81	-10.15	-0.49	3.12e-21	Hip circumference adjusted for BMI;
CRC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.37	-0.42	1.7e-15	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14685339	chr14:77787351	POMT2;GSTZ1	0.45	6.45	0.34	4.05e-10	Response to antipsychotic treatment;
CRC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	18.19	0.71	1.14e-51	Smoking behavior;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04799218	chr12:7125780	LPCAT3	0.43	6.67	0.35	1.07e-10	Schizophrenia;
CRC	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg19537932	chr12:55886519	OR6C68	-0.64	-8.39	-0.42	1.46e-15	Cancer;
CRC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	8.59	0.43	3.46e-16	Lymphocyte counts;
CRC	cis	rs11212617	0.967	rs4754324	chr11:108325448	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.67	0.3	3.17e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.72	-0.3	2.44e-8	Inflammatory bowel disease;
CRC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg01629716	chr15:45996671	NA	0.41	8.34	0.42	2.13e-15	Waist circumference;Weight;
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.45	-8.36	-0.42	1.78e-15	Schizophrenia;
CRC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg02621376	chr1:85461303	MCOLN2	-0.41	-6.0	-0.31	5.19e-9	Serum sulfate level;
CRC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.76	-0.3	1.91e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	11.6	0.54	2.58e-26	High light scatter reticulocyte count;
CRC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.55	9.31	0.46	1.83e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.8	-0.4	8.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.14	0.64	1.12e-39	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.6	10.28	0.49	1.07e-21	Prudent dietary pattern;
CRC	cis	rs7705042	0.865	rs413214	chr5:141530157	G/A	cg07392085	chr5:141489673	NDFIP1	0.46	7.35	0.38	1.6e-12	Asthma;
CRC	cis	rs4731207	0.662	rs35630355	chr7:124549333	T/A	cg23710748	chr7:124431027	NA	-0.37	-5.98	-0.31	5.75e-9	Cutaneous malignant melanoma;
CRC	trans	rs7553035	0.850	rs7355220	chr1:211690029	T/C	cg04286297	chr15:83655119	FAM103A1	-0.66	-6.04	-0.32	4.08e-9	Retinopathy in non-diabetics;
CRC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.99	12.64	0.57	3.87e-30	Vitiligo;
CRC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs10486722	0.624	rs10155874	chr7:41765719	A/G	cg22138096	chr7:41772439	LOC285954	0.39	5.81	0.31	1.47e-8	Pit-and-Fissure caries;
CRC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.62	-0.34	1.46e-10	Inflammatory skin disease;
CRC	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.47	5.85	0.31	1.17e-8	Metabolite levels;
CRC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.73	14.67	0.63	7.41e-38	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05774672	chr2:208631916	FZD5	0.33	6.08	0.32	3.37e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg24628676	chr5:59189846	PDE4D	-0.3	-6.08	-0.32	3.3e-9	Urinary tract infection frequency;
CRC	cis	rs7781266	0.790	rs73148993	chr7:133178410	C/A	cg03336402	chr7:133662267	EXOC4	0.48	5.71	0.3	2.57e-8	Educational attainment (college completion);
CRC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.8	13.23	0.59	2.51e-32	Height;
CRC	cis	rs12913538	0.926	rs12438162	chr15:62884463	A/G	cg09983546	chr15:62884068	NA	0.52	7.99	0.4	2.33e-14	Sleep depth;
CRC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.65	-8.65	-0.43	2.28e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg03311606	chr2:173292277	ITGA6	-0.42	-6.08	-0.32	3.32e-9	Daytime sleep phenotypes;
CRC	cis	rs501120	0.584	rs966161	chr10:44712574	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg22988483	chr14:93581567	ITPK1	-0.67	-6.04	-0.32	4.16e-9	Cognitive function;
CRC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg13010199	chr12:38710504	ALG10B	-0.43	-5.9	-0.31	8.97e-9	Morning vs. evening chronotype;
CRC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.78	13.58	0.6	1.16e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.55	-0.34	2.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.53	-0.47	3.49e-19	Morning vs. evening chronotype;
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-7.23	-0.37	3.38e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.76	0.47	6.24e-20	Alzheimer's disease;
CRC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.17	-0.32	2.05e-9	Tonsillectomy;
CRC	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.34	6.19	0.32	1.83e-9	Neuroticism;
CRC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.39e-13	Corneal astigmatism;
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.75	-0.39	1.18e-13	Total body bone mineral density;
CRC	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.58	0.63	1.78e-37	Exhaled nitric oxide output;
CRC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.6	-8.41	-0.42	1.29e-15	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg26197690	chr5:139936946	SRA1	-0.42	-5.99	-0.31	5.61e-9	Birth weight;Height;
CRC	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	1.06	22.02	0.77	1.08e-66	Multiple myeloma;
CRC	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg08071915	chr8:12219732	FAM66A	0.35	6.26	0.33	1.23e-9	Retinal vascular caliber;
CRC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.24	0.41	4.06e-15	Homoarginine levels;
CRC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-11.98	-0.55	1.12e-27	Electrocardiographic conduction measures;
CRC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.74	-13.17	-0.59	4.24e-32	Multiple sclerosis;Ankylosing spondylitis;
CRC	trans	rs2303319	0.504	rs66761688	chr2:162578911	T/C	cg01422129	chr2:677375	TMEM18	-0.72	-6.01	-0.31	4.92e-9	Cognitive function;
CRC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.53	-7.54	-0.38	4.48e-13	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.05	-0.32	4.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg19223190	chr17:80058835	NA	0.4	6.4	0.33	5.26e-10	Life satisfaction;
CRC	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg09915433	chr19:53449742	NA	-0.49	-7.0	-0.36	1.44e-11	Psoriasis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03468541	chr14:89029199	ZC3H14	0.46	6.48	0.34	3.43e-10	Survival in pancreatic cancer;
CRC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg24505167	chr7:1915268	MAD1L1	-0.41	-5.63	-0.3	3.88e-8	Bipolar disorder;
CRC	cis	rs12760731	0.565	rs12048698	chr1:178136792	T/C	cg00404053	chr1:178313656	RASAL2	1.1	11.39	0.53	1.43e-25	Obesity-related traits;
CRC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4e-17	Electroencephalogram traits;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	7.08	0.36	8.99e-12	Breast cancer;
CRC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg11941060	chr3:133502564	NA	-0.42	-6.87	-0.35	3.25e-11	Iron status biomarkers;
CRC	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.8	-14.01	-0.61	2.61e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14022530	chr1:100598534	SASS6;CCDC76	0.4	6.01	0.31	5.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.47	5.61	0.3	4.26e-8	Depression;
CRC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg11522145	chr4:3412961	RGS12	-0.42	-6.43	-0.33	4.38e-10	Serum sulfate level;
CRC	cis	rs17209837	1.000	rs45502492	chr7:87089898	C/T	cg00919237	chr7:87102261	ABCB4	-0.47	-5.63	-0.3	3.84e-8	Gallbladder cancer;
CRC	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.6	8.43	0.42	1.1e-15	Uric acid levels;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.5	-10.38	-0.5	5.21e-22	Bipolar disorder;
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	0.7	7.84	0.4	6.44e-14	Body mass index;
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.76	-0.44	1.02e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg11915388	chr22:42470451	FAM109B	-0.43	-6.54	-0.34	2.3e-10	Schizophrenia;
CRC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.02	0.52	3.01e-24	Prudent dietary pattern;
CRC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.08	13.48	0.6	2.85e-33	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.81	12.35	0.56	4.95e-29	Cognitive function;
CRC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.53	8.43	0.42	1.07e-15	Prostate cancer;
CRC	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg04586622	chr2:25135609	ADCY3	-0.57	-9.53	-0.46	3.71e-19	Body mass index;
CRC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.53	7.92	0.4	3.8e-14	Tuberculosis;
CRC	cis	rs995000	0.868	rs1168114	chr1:63156043	C/T	cg19896129	chr1:63156450	NA	0.44	6.82	0.35	4.25e-11	Triglyceride levels;
CRC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.49	7.58	0.39	3.65e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.61	-9.86	-0.48	2.98e-20	Aortic root size;
CRC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.38	-0.33	5.97e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs3857067	1.000	rs2199603	chr4:95016174	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.21	0.45	3.84e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg08501292	chr6:25962987	TRIM38	0.98	9.41	0.46	8.79e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg15147215	chr3:52552868	STAB1	-0.61	-9.78	-0.47	5.21e-20	Bipolar disorder;
CRC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22133161	chr19:49891603	CCDC155	0.52	7.28	0.37	2.41e-12	Multiple sclerosis;
CRC	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.09	0.45	9.82e-18	Dupuytren's disease;
CRC	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.65	-10.4	-0.5	4.42e-22	Corneal astigmatism;
CRC	cis	rs6694672	0.850	rs1953064	chr1:197064826	A/G	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.74e-11	Asthma;
CRC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg27535305	chr1:53392650	SCP2	-0.33	-5.77	-0.3	1.84e-8	Monocyte count;
CRC	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.61	8.99	0.44	2.05e-17	Morning vs. evening chronotype;
CRC	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg26816564	chr1:7831052	VAMP3	0.57	6.07	0.32	3.61e-9	Inflammatory bowel disease;
CRC	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	trans	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.15	-0.32	2.28e-9	Aortic root size;
CRC	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.41	6.83	0.35	3.99e-11	Childhood ear infection;
CRC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.61	9.56	0.47	2.83e-19	Blood metabolite levels;
CRC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.76	12.91	0.58	4.08e-31	Menopause (age at onset);
CRC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg07587117	chr16:2239488	CASKIN1	-0.4	-7.17	-0.37	4.98e-12	Height;
CRC	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.21	0.32	1.64e-9	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02290350	chr8:58132656	NA	-0.44	-6.96	-0.36	1.82e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.2	-0.37	4.02e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.42	6.7	0.35	9.11e-11	Dupuytren's disease;
CRC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.67	8.37	0.42	1.68e-15	Cognitive test performance;
CRC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.61	-0.34	1.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.49	-6.98	-0.36	1.62e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.49	7.6	0.39	3.1400000000000003e-13	Corneal astigmatism;
CRC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.61	-0.47	1.92e-19	Heart rate;
CRC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.68	-0.3	2.9e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.87e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.5	-8.16	-0.41	6.96e-15	Post bronchodilator FEV1;
CRC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.45	-0.6	3.8e-33	Blood trace element (Zn levels);
CRC	cis	rs10788264	0.504	rs10749451	chr10:124028040	C/T	cg09507567	chr10:124027408	NA	0.36	7.65	0.39	2.24e-13	Total body bone mineral density;
CRC	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs12024301	0.557	rs11808304	chr1:183604095	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.47	6.5	0.34	2.94e-10	Lung cancer;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12273811	chr6:28175739	NA	0.76	10.93	0.52	6.19e-24	Depression;
CRC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg19688584	chr6:167529678	CCR6	0.36	6.7	0.35	9.07e-11	Primary biliary cholangitis;
CRC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.49	6.26	0.33	1.23e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg25767906	chr1:53392781	SCP2	0.47	7.49	0.38	6.24e-13	Monocyte count;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs12541635	0.677	rs1429681	chr8:107048808	A/C	cg10147462	chr8:107024639	NA	0.62	11.08	0.52	1.82e-24	Age of smoking initiation;
CRC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.45	6.64	0.34	1.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02228675	chr17:40259724	DHX58	-0.49	-6.87	-0.35	3.28e-11	Fibrinogen levels;
CRC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg00277769	chr7:97922759	BAIAP2L1	0.6	10.67	0.51	5.07e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.39	-5.95	-0.31	6.85e-9	Systemic lupus erythematosus;
CRC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.52	7.54	0.38	4.53e-13	Colorectal cancer;
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20814179	chr4:940893	TMEM175	0.58	10.55	0.5	1.35e-22	Sjögren's syndrome;
CRC	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.66	-9.58	-0.47	2.47e-19	Type 2 diabetes;
CRC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.52	6.73	0.35	7.38e-11	Height;
CRC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg03948781	chr1:205179583	DSTYK	-0.42	-5.72	-0.3	2.34e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs8010715	0.816	rs7153156	chr14:24598846	A/G	cg23112188	chr14:24563095	PCK2	-0.37	-7.24	-0.37	3.17e-12	IgG glycosylation;
CRC	cis	rs7945718	0.621	rs6485989	chr11:12695171	C/T	cg25843174	chr11:12811716	TEAD1	0.39	7.05	0.36	1.04e-11	Educational attainment (years of education);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00320862	chr3:170588302	RPL22L1	-0.42	-6.33	-0.33	8.1e-10	Myopia (pathological);
CRC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg03037974	chr15:76606532	NA	0.66	11.61	0.54	2.33e-26	Blood metabolite levels;
CRC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.29	-5.62	-0.3	4.11e-8	Colorectal cancer;
CRC	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.52	8.53	0.43	5.62e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg27239144	chr12:100661541	SCYL2;DEPDC4	-0.38	-5.97	-0.31	6.04e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg20041105	chr8:143859282	LYNX1	0.46	8.24	0.41	4.25e-15	Urinary tract infection frequency;
CRC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.59	-7.58	-0.39	3.46e-13	Gut microbiome composition (summer);
CRC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg11189052	chr15:85197271	WDR73	0.63	8.88	0.44	4.42e-17	Schizophrenia;
CRC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.51	7.32	0.37	1.88e-12	Pancreatic cancer;
CRC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13198984	chr17:80129470	CCDC57	-0.43	-7.09	-0.36	8.2e-12	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10367730	chr10:120938495	PRDX3	0.43	6.21	0.32	1.63e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6586163	0.872	rs7914490	chr10:90747447	A/G	cg13456138	chr10:90753195	FAS	-0.43	-6.53	-0.34	2.57e-10	Chronic lymphocytic leukemia;
CRC	cis	rs3741151	0.686	rs12276892	chr11:73283990	A/T	cg17517138	chr11:73019481	ARHGEF17	0.54	5.78	0.3	1.75e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg17633681	chr16:88106987	BANP	0.8	13.64	0.6	6.88e-34	Menopause (age at onset);
CRC	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.8	7.63	0.39	2.6e-13	Arsenic metabolism;
CRC	cis	rs59104589	0.570	rs73006397	chr2:242415523	C/T	cg19488206	chr2:242435732	STK25	0.47	7.44	0.38	8.73e-13	Fibrinogen levels;
CRC	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.35	-5.74	-0.3	2.19e-8	Mean arterial pressure;
CRC	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg00277334	chr10:82204260	NA	-0.45	-5.92	-0.31	7.95e-9	Post bronchodilator FEV1;
CRC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg23463467	chr20:60627584	TAF4	0.33	5.71	0.3	2.53e-8	Body mass index;
CRC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg26721908	chr21:47610096	LSS	0.41	6.47	0.34	3.65e-10	Testicular germ cell tumor;
CRC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.43	6.97	0.36	1.73e-11	Obesity-related traits;
CRC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.22	14.71	0.63	5.29e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg20684491	chr1:25596433	NA	0.45	7.96	0.4	2.75e-14	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs7215564	0.908	rs2340772	chr17:78752017	C/A	cg09596252	chr17:78655493	RPTOR	-0.58	-6.07	-0.32	3.43e-9	Myopia (pathological);
CRC	cis	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-6.18	-0.32	1.91e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.5e-8	Lung cancer;
CRC	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.55	-0.54	3.9e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-6.64	-0.34	1.26e-10	Breast cancer;
CRC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.74	9.75	0.47	6.69e-20	Platelet count;
CRC	cis	rs1887596	0.672	rs4771002	chr13:27201568	A/G	cg01312412	chr13:27282625	NA	0.45	5.72	0.3	2.43e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21194140	chr2:128568865	WDR33	0.38	5.99	0.31	5.48e-9	Schizophrenia;
CRC	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.13	0.32	2.5e-9	Ovarian reserve;
CRC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.44	5.96	0.31	6.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.39	5.89	0.31	9.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7264396	0.887	rs10359	chr20:34099789	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.9	-0.36	2.72e-11	Total cholesterol levels;
CRC	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.65	11.84	0.55	3.5e-27	Obesity-related traits;
CRC	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	1.06	12.52	0.57	1.15e-29	Obesity-related traits;
CRC	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.59	8.04	0.41	1.64e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs4400599	0.618	rs9943097	chr1:154205823	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.71	-0.3	2.49e-8	Platelet distribution width;
CRC	cis	rs2179367	0.919	rs4897124	chr6:149763209	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.4	-6.67	-0.35	1.06e-10	Dupuytren's disease;
CRC	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.53	-0.34	2.56e-10	Neuroticism;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Depression;
CRC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.81	13.62	0.6	8.16e-34	Menopause (age at onset);
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14159672	chr1:205819179	PM20D1	0.42	5.7	0.3	2.65e-8	Parkinson's disease;
CRC	cis	rs9914988	0.619	rs12451955	chr17:27314224	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.47	6.74	0.35	7.14e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg10756647	chr7:56101905	PSPH	0.74	7.77	0.39	9.91e-14	Diabetic kidney disease;
CRC	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.32	-6.22	-0.32	1.52e-9	Breast cancer;
CRC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg11843238	chr5:131593191	PDLIM4	0.33	6.08	0.32	3.27e-9	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.85	12.58	0.57	7e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-9.25	-0.45	3.03e-18	Coronary artery disease;
CRC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.54	8.3	0.42	2.76e-15	Sudden cardiac arrest;
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.26	-0.56	9.81e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg23463467	chr20:60627584	TAF4	0.34	5.96	0.31	6.58e-9	Body mass index;
CRC	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	7.87	0.4	5.32e-14	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs12580194	0.556	rs61957898	chr12:55730423	T/C	cg23425280	chr12:56401806	NA	0.47	5.93	0.31	7.72e-9	Cancer;
CRC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.5	-7.83	-0.4	6.78e-14	Calcium levels;
CRC	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00621029	chr21:35747559	FAM165B	0.46	6.71	0.35	8.39e-11	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.61	8.25	0.41	3.92e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.58	-8.7	-0.43	1.65e-16	Aortic root size;
CRC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg07936489	chr17:37558343	FBXL20	-0.46	-6.63	-0.34	1.4e-10	Asthma;
CRC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.76e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.0	0.31	5.13e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2415984	0.622	rs8022305	chr14:46946545	C/T	cg14871534	chr14:47121158	RPL10L	-0.44	-6.23	-0.32	1.44e-9	Number of children ever born;
CRC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.44	-0.53	9.35e-26	Ulcerative colitis;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg24560729	chr4:1342394	KIAA1530	0.43	7.81	0.4	7.72e-14	Longevity;
CRC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-12.11	-0.56	3.58e-28	Schizophrenia;
CRC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.32	0.42	2.32e-15	Coronary artery disease;
CRC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.35	-5.94	-0.31	7.3e-9	Childhood ear infection;
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg20041105	chr8:143859282	LYNX1	0.69	12.48	0.57	1.61e-29	Urinary tract infection frequency;
CRC	trans	rs12257178	0.532	rs12263857	chr10:113006704	A/G	cg23061718	chr2:73143321	EMX1	-0.45	-6.18	-0.32	1.89e-9	Longitudinal alcohol consumption;
CRC	cis	rs863345	0.604	rs6674656	chr1:158495431	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs600626	0.636	rs11236516	chr11:75451668	C/T	cg24262691	chr11:75473276	NA	-0.55	-7.57	-0.39	3.73e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.65e-24	Motion sickness;
CRC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg21770322	chr7:97807741	LMTK2	-0.69	-12.67	-0.57	3.21e-30	Breast cancer;
CRC	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.39	6.04	0.32	4.14e-9	Endometrial cancer;
CRC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.53	-0.38	5.05e-13	Alzheimer's disease;
CRC	cis	rs2415984	0.579	rs10135740	chr14:46957379	G/A	cg14871534	chr14:47121158	RPL10L	-0.41	-5.79	-0.3	1.63e-8	Number of children ever born;
CRC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.33	0.33	8.24e-10	Heart rate;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg02018176	chr4:1364513	KIAA1530	0.45	7.56	0.38	4.18e-13	Obesity-related traits;
CRC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.68	0.39	1.84e-13	Axial length;
CRC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.09	-0.32	3.11e-9	Menopause (age at onset);
CRC	cis	rs16867321	0.901	rs768116	chr2:181511012	A/G	cg23363182	chr2:181467187	NA	-0.5	-6.3	-0.33	9.76e-10	Obesity;
CRC	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg15711740	chr2:61764176	XPO1	-0.56	-7.72	-0.39	1.43e-13	Tuberculosis;
CRC	cis	rs17155006	0.746	rs370495	chr7:107746246	T/C	cg05962710	chr7:107745446	LAMB4	-0.41	-7.26	-0.37	2.9e-12	Pneumococcal bacteremia;
CRC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg02659138	chr7:134003124	SLC35B4	0.42	7.36	0.38	1.49e-12	Mean platelet volume;
CRC	cis	rs9462027	0.585	rs188190	chr6:34551086	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.92	-0.31	7.97e-9	Systemic lupus erythematosus;
CRC	cis	rs7394190	0.748	rs2306325	chr10:75506674	T/C	cg07699608	chr10:75541558	CHCHD1	0.62	6.37	0.33	6.37e-10	Incident atrial fibrillation;
CRC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg23758597	chr6:163146217	PARK2	-0.65	-6.52	-0.34	2.68e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02698620	chr7:45026579	C7orf40;SNORA9	0.43	6.06	0.32	3.77e-9	Response to antipsychotic treatment;
CRC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg24675056	chr1:15929824	NA	0.49	6.75	0.35	6.85e-11	Systolic blood pressure;
CRC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.59	-9.11	-0.45	8.17e-18	Monocyte count;
CRC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.6	-7.12	-0.37	6.96e-12	Blood protein levels;
CRC	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg14593290	chr7:50529359	DDC	-0.45	-6.52	-0.34	2.72e-10	Body mass index;
CRC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.63	-6.84	-0.35	3.98e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	cis	rs9468186	1	rs9468186	chr6:27626631	A/G	cg06470822	chr6:28175283	NA	0.51	6.12	0.32	2.69e-9	Neuroticism;
CRC	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg12458913	chr13:53173898	NA	0.59	9.3	0.46	1.98e-18	Lewy body disease;
CRC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg07274523	chr3:49395745	GPX1	0.45	6.05	0.32	4.03e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	8.04	0.41	1.62e-14	Cognitive ability;
CRC	cis	rs2160860	1.000	rs2160860	chr8:39823145	A/T	cg11363097	chr8:39792086	IDO2	0.34	5.62	0.3	4.12e-8	Blood metabolite levels;
CRC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.75	10.38	0.5	4.95e-22	Bronchopulmonary dysplasia;
CRC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.42	-7.74	-0.39	1.22e-13	Lung cancer;
CRC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.62	-12.21	-0.56	1.52e-28	Intelligence (multi-trait analysis);
CRC	cis	rs1867631	0.585	rs6670827	chr1:67127006	C/T	cg02459107	chr1:67143332	SGIP1	0.36	6.3	0.33	9.67e-10	Menopause (age at onset);
CRC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.42	-6.02	-0.31	4.69e-9	DNA methylation (variation);
CRC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg03233332	chr7:66118400	NA	-0.42	-5.89	-0.31	9.7e-9	Aortic root size;
CRC	cis	rs6968419	0.755	rs17138483	chr7:115893845	A/C	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.64e-10	Intraocular pressure;
CRC	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg09003973	chr2:102972529	NA	-0.73	-8.06	-0.41	1.39e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.59	-10.55	-0.5	1.35e-22	Aortic root size;
CRC	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.71	8.68	0.43	1.85e-16	Prostate cancer;
CRC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.97	18.04	0.71	4.72e-51	IgG glycosylation;
CRC	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.36	-0.33	6.85e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.8	10.66	0.51	5.55e-23	Vitiligo;
CRC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.64	8.94	0.44	2.9e-17	Cognitive function;
CRC	cis	rs6604026	0.883	rs10874745	chr1:93321541	G/A	cg22128645	chr1:93425802	FAM69A	-0.39	-5.91	-0.31	8.54e-9	Multiple sclerosis;
CRC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.27	-6.22	-0.32	1.48e-9	Total body bone mineral density;
CRC	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.52	-6.1	-0.32	2.93e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	8.44	0.42	1.06e-15	Body mass index;
CRC	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg09863266	chr14:51125203	SAV1	-0.31	-5.75	-0.3	2.08e-8	Mean platelet volume;
CRC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.14	-0.56	2.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.83	-0.31	1.31e-8	Depression;
CRC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.09	0.41	1.13e-14	Personality dimensions;
CRC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.17	0.45	5.14e-18	Lymphocyte counts;
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.14	-0.32	2.44e-9	Total body bone mineral density;
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.77e-17	Bipolar disorder;
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.65	8.51	0.42	6.42e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.12	-16.19	-0.67	9e-44	Platelet count;
CRC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.79	0.55	5.26e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.67	10.9	0.52	8.12e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg03690763	chr11:133734501	NA	-0.34	-5.73	-0.3	2.33e-8	Childhood ear infection;
CRC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.47	6.37	0.33	6.45e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	6.85	0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs6973256	0.897	rs17659708	chr7:133355098	A/G	cg10665199	chr7:133106180	EXOC4	-0.36	-5.68	-0.3	2.96e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg07617317	chr6:118971624	C6orf204	0.49	6.07	0.32	3.58e-9	Diastolic blood pressure;
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.73e-9	Life satisfaction;
CRC	cis	rs3812762	0.868	rs7934519	chr11:8791981	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.09	0.32	3.17e-9	Hypospadias;
CRC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.79	7.98	0.4	2.44e-14	Diabetic retinopathy;
CRC	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.42	-6.54	-0.34	2.3e-10	Asthma;
CRC	cis	rs7215564	0.822	rs2340771	chr17:78752947	A/C	cg09596252	chr17:78655493	RPTOR	-0.59	-6.2	-0.32	1.7e-9	Myopia (pathological);
CRC	cis	rs9648716	0.872	rs6964937	chr7:140609690	C/G	cg17554604	chr7:140774522	NA	0.45	5.67	0.3	3.12e-8	Type 2 diabetes;
CRC	cis	rs45544231	0.544	rs1420535	chr16:52578215	C/A	cg09051775	chr16:52580266	TOX3	-0.4	-6.51	-0.34	2.87e-10	Restless legs syndrome;
CRC	cis	rs3800461	0.509	rs73407707	chr6:34476644	T/G	cg17674042	chr6:34482479	PACSIN1	-0.99	-10.92	-0.52	6.77e-24	Chronic lymphocytic leukemia;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg03923535	chr7:1197113	ZFAND2A	-0.49	-6.99	-0.36	1.58e-11	Longevity;Endometriosis;
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg17788362	chr6:86352627	SYNCRIP	0.56	7.59	0.39	3.27e-13	Smooth-surface caries;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg23234261	chr14:55582407	NA	-0.28	-5.66	-0.3	3.3e-8	Protein biomarker;
CRC	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.63	-7.93	-0.4	3.48e-14	Coronary artery disease;
CRC	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs9296736	0.922	rs625899	chr6:53957588	C/T	cg04374786	chr6:53939321	C6orf142	-0.43	-7.11	-0.36	7.31e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg25164649	chr6:28176230	NA	0.59	8.38	0.42	1.56e-15	Parkinson's disease;
CRC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.6	0.34	1.68e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.78	0.35	5.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62187570	chr2:162373899	C/G	cg27113153	chr11:123612418	ZNF202	-0.72	-6.17	-0.32	1.96e-9	Cognitive function;
CRC	cis	rs4728302	0.869	rs10224575	chr7:133590875	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.85	0.31	1.22e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg04071446	chr10:115933849	C10orf118	-0.44	-6.46	-0.34	3.84e-10	Daytime sleep phenotypes;
CRC	cis	rs2160860	0.729	rs55992954	chr8:39801619	T/C	cg11363097	chr8:39792086	IDO2	-0.45	-7.58	-0.39	3.66e-13	Blood metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25356086	chr21:33764900	C21orf119;URB1	0.46	6.0	0.31	5.12e-9	Thyroid stimulating hormone;
CRC	cis	rs17095355	1.000	rs12570612	chr10:111717685	C/T	cg00817464	chr10:111662876	XPNPEP1	0.53	7.26	0.37	2.82e-12	Biliary atresia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03758392	chr3:184870408	C3orf70	-0.55	-6.72	-0.35	8.13e-11	Diisocyanate-induced asthma;
CRC	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg02491457	chr7:128862824	NA	-0.64	-8.78	-0.44	9.28e-17	White matter hyperintensity burden;
CRC	trans	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg21153622	chr11:89784906	NA	0.45	7.1	0.36	7.58e-12	HDL cholesterol;
CRC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.67	9.69	0.47	1.09e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg05874882	chr4:1763078	NA	-0.36	-6.63	-0.34	1.4e-10	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.54	9.79	0.48	4.84e-20	Electroencephalogram traits;
CRC	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.43	6.35	0.33	7.21e-10	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	1.13	13.26	0.59	1.97e-32	Obesity-related traits;
CRC	cis	rs1519814	0.654	rs1543201	chr8:121018888	A/T	cg22335954	chr8:121166405	COL14A1	0.51	5.64	0.3	3.75e-8	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08636040	chr1:151171017	PIP5K1A	0.46	6.25	0.33	1.28e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00349599	chr17:17184369	COPS3	0.48	6.78	0.35	5.5e-11	Response to antipsychotic treatment;
CRC	cis	rs6662572	0.737	rs9429179	chr1:46514198	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.12	0.32	2.7e-9	Blood protein levels;
CRC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.8	0.48	4.54e-20	Bladder cancer;
CRC	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg11003573	chr3:44754125	ZNF502	-0.36	-6.19	-0.32	1.74e-9	Depressive symptoms;
CRC	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.47	-5.73	-0.3	2.21e-8	Coronary artery calcification;
CRC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.71	-9.31	-0.46	1.89e-18	Coronary artery disease;
CRC	cis	rs9039	1.000	rs9932208	chr16:9218267	T/C	cg08831531	chr16:9218945	NA	-0.63	-8.89	-0.44	3.99e-17	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23333220	chr15:64679825	TRIP4	0.42	6.03	0.32	4.45e-9	Response to antipsychotic treatment;
CRC	cis	rs889398	0.802	rs2937121	chr16:69870409	T/G	cg00738113	chr16:70207722	CLEC18C	0.36	6.12	0.32	2.68e-9	Body mass index;
CRC	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.27	-0.33	1.11e-9	Coronary artery disease;
CRC	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs3018066	0.748	rs28897193	chr4:107005529	G/C	cg01869342	chr4:106983673	TBCK	0.42	6.28	0.33	1.07e-9	Cancer;
CRC	cis	rs2730260	0.800	rs73169218	chr7:158836906	T/A	cg02254261	chr7:158964346	NA	-0.57	-6.32	-0.33	8.37e-10	Myopia (pathological);
CRC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.46	0.42	8.9e-16	Homoarginine levels;
CRC	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg20312557	chr2:97357134	FER1L5	-0.61	-5.67	-0.3	3.19e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3825932	0.961	rs11856301	chr15:79232330	T/C	cg25744700	chr15:79237217	CTSH	0.39	6.07	0.32	3.61e-9	Type 1 diabetes;
CRC	trans	rs11031096	0.738	rs1980412	chr11:4148948	C/T	cg22978087	chr8:24814126	NEFL	0.33	6.06	0.32	3.75e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs3736485	0.932	rs2899477	chr15:51937701	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.55	-0.34	2.16e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.25	-0.59	2.04e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.71	-13.09	-0.59	8.66e-32	Bipolar disorder;
CRC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.52	8.25	0.41	3.91e-15	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg27615366	chr5:131592974	PDLIM4	0.33	5.65	0.3	3.56e-8	Blood metabolite levels;
CRC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg13393036	chr8:95962371	TP53INP1	0.49	8.08	0.41	1.26e-14	Alzheimer's disease (late onset);
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.62	-7.71	-0.39	1.5e-13	Schizophrenia;
CRC	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.39	-0.38	1.23e-12	Electroencephalogram traits;
CRC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.44	0.33	4.17e-10	Melanoma;
CRC	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.54	7.6	0.39	3.18e-13	Testicular germ cell tumor;
CRC	cis	rs3751196	0.901	rs12423994	chr12:104194263	A/G	cg02344784	chr12:104178138	NT5DC3	0.69	7.05	0.36	1.07e-11	Sense of smell;
CRC	cis	rs911119	0.955	rs8116859	chr20:23590703	A/T	cg16589663	chr20:23618590	CST3	0.45	6.27	0.33	1.12e-9	Chronic kidney disease;
CRC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.61	8.93	0.44	2.98e-17	Menarche (age at onset);
CRC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.94	-0.4	3.21e-14	Monocyte percentage of white cells;
CRC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg00631329	chr6:26305371	NA	-0.47	-7.89	-0.4	4.6e-14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs7300001	0.510	rs73205064	chr12:110512546	A/G	cg12870014	chr12:110450643	ANKRD13A	0.79	7.17	0.37	5.14e-12	Headache;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg11637544	chr11:66886765	KDM2A	-0.39	-6.17	-0.32	1.95e-9	Aortic root size;
CRC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.28	-0.37	2.51e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg20119798	chr7:94954144	PON1	-0.48	-6.18	-0.32	1.9e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg01262667	chr19:19385393	TM6SF2	0.36	5.73	0.3	2.22e-8	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24847481	chr1:100435557	SLC35A3	0.46	8.06	0.41	1.38e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	8.91	0.44	3.45e-17	Cognitive test performance;
CRC	cis	rs539514	0.690	rs776527	chr13:76317794	G/A	cg04757411	chr13:76259545	LMO7	-0.35	-5.91	-0.31	8.52e-9	Type 1 diabetes;
CRC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg27661571	chr11:113659931	NA	0.72	7.69	0.39	1.71e-13	Hip circumference adjusted for BMI;
CRC	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg02811702	chr13:24901961	NA	0.45	6.22	0.32	1.53e-9	Obesity-related traits;
CRC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg10760299	chr15:45669010	GATM	0.5	7.82	0.4	7.18e-14	Homoarginine levels;
CRC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg05754148	chr16:3507555	NAT15	0.46	6.56	0.34	2.06e-10	Tuberculosis;
CRC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11645453	chr3:52864694	ITIH4	0.37	6.55	0.34	2.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.46	8.32	0.42	2.45e-15	Reticulocyte fraction of red cells;
CRC	cis	rs9533799	1.000	rs9533798	chr13:44802505	C/G	cg19190762	chr13:44806055	NA	-0.63	-9.77	-0.47	5.97e-20	Amyotrophic lateral sclerosis;
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.68	-0.43	1.86e-16	Total body bone mineral density;
CRC	trans	rs7555117	0.510	rs12073874	chr1:61026145	G/A	cg16795821	chr3:142720237	SR140	-0.38	-6.4	-0.33	5.4e-10	Facial morphology (factor 19);
CRC	cis	rs806215	0.950	rs3735642	chr7:127224286	A/G	cg25922125	chr7:127225783	GCC1	-0.62	-6.67	-0.35	1.1e-10	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.6	10.23	0.49	1.6e-21	Prudent dietary pattern;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg03623178	chr6:28175578	NA	0.77	11.51	0.54	5.68e-26	Parkinson's disease;
CRC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg25834613	chr7:1915315	MAD1L1	-0.41	-5.89	-0.31	9.69e-9	Bipolar disorder;
CRC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg02007433	chr3:129722099	NA	-0.46	-6.25	-0.33	1.3e-9	Blood pressure (smoking interaction);
CRC	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg06470822	chr6:28175283	NA	0.82	9.31	0.46	1.94e-18	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.85	0.55	3.21e-27	Prudent dietary pattern;
CRC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.15	27.57	0.84	1.66e-87	Testicular germ cell tumor;
CRC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.29	6.47	0.34	3.48e-10	IgG glycosylation;
CRC	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.51	-6.93	-0.36	2.29e-11	Tuberculosis;
CRC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-10.98	-0.52	4.19e-24	Schizophrenia;
CRC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.87	12.32	0.56	6.03e-29	Menarche (age at onset);
CRC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.5	-8.13	-0.41	8.87e-15	Huntington's disease progression;
CRC	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.9	-16.28	-0.67	4.12e-44	Longevity;
CRC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.66	12.41	0.56	2.76e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	11.26	0.53	4.35e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18099408	chr3:52552593	STAB1	-0.49	-8.58	-0.43	3.69e-16	Electroencephalogram traits;
CRC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg03623178	chr6:28175578	NA	0.87	9.05	0.45	1.28e-17	Lung cancer in ever smokers;
CRC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.81	14.19	0.62	5.71e-36	Breast cancer;
CRC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.38	-8.99	-0.44	2.04e-17	Mean corpuscular volume;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Parkinson's disease;
CRC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.44	6.37	0.33	6.51e-10	Emphysema distribution in smoking;
CRC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.79	-14.21	-0.62	4.49e-36	Breast cancer;
CRC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg19682013	chr15:45996608	NA	0.32	6.6	0.34	1.6e-10	Waist circumference;Weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01839850	chr22:38240395	ANKRD54;MIR658	0.51	7.26	0.37	2.87e-12	Response to antipsychotic treatment;
CRC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.67	8.7	0.43	1.61e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs8105895	0.935	rs10405613	chr19:22244772	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.62	10.5	0.5	1.91e-22	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.48	-7.15	-0.37	5.52e-12	Menarche (age at onset);
CRC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-8.64	-0.43	2.49e-16	Menarche (age at onset);
CRC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs60871478	0.735	rs10950455	chr7:831451	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-6.25	-0.33	1.24e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs4929949	0.809	rs1900273	chr11:8483335	G/A	cg17679104	chr11:8615758	STK33	-0.35	-5.74	-0.3	2.17e-8	Body mass index;
CRC	cis	rs1712517	0.771	rs2292807	chr10:105155645	T/C	cg05636881	chr10:105038444	INA	0.47	8.01	0.4	2e-14	Migraine;
CRC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.32	5.6	0.3	4.46e-8	Lung cancer;
CRC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.49	-0.38	6.22e-13	Bladder cancer;
CRC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.6	0.39	3.1e-13	Mean platelet volume;
CRC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.59	-8.39	-0.42	1.44e-15	Carotid intima media thickness;
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg03469862	chr11:68924853	NA	0.46	5.88	0.31	1.02e-8	Blond vs. brown hair color;
CRC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg27661571	chr11:113659931	NA	-0.69	-7.73	-0.39	1.3e-13	Hip circumference adjusted for BMI;
CRC	trans	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg18335740	chr13:41363409	SLC25A15	0.55	8.43	0.42	1.09e-15	Lewy body disease;
CRC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.54	-0.38	4.7e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.74	13.0	0.58	1.77e-31	Menarche (age at onset);
CRC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	8.65	0.43	2.37e-16	Response to antipsychotic treatment;
CRC	cis	rs2412819	0.542	rs62018894	chr15:43912987	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	5.69	0.3	2.76e-8	Lung cancer;
CRC	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg11579758	chr4:1086637	RNF212	0.42	6.9	0.36	2.63e-11	Recombination rate (males);
CRC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.03	-0.32	4.35e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.44	6.58	0.34	1.88e-10	Pancreatic cancer;
CRC	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.42	7.95	0.4	3.1e-14	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.63	-0.34	1.35e-10	Bipolar disorder;
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.39	-0.42	1.45e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.69	-8.15	-0.41	7.67e-15	Body mass index;
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.14	0.59	5.55e-32	Prudent dietary pattern;
CRC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.96	12.86	0.58	5.93e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1572438	0.831	rs17139761	chr6:856766	A/G	cg21062780	chr6:887772	NA	-0.34	-5.64	-0.3	3.66e-8	Aging;
CRC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.95e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.42	-9.22	-0.45	3.61e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.6	8.46	0.42	9.02e-16	Arsenic metabolism;
CRC	cis	rs10905065	0.930	rs7096742	chr10:5735648	C/T	cg11519256	chr10:5708881	ASB13	0.46	6.65	0.34	1.22e-10	Menopause (age at onset);
CRC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg03909863	chr11:638404	DRD4	-0.4	-5.65	-0.3	3.39e-8	Systemic lupus erythematosus;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.48	-6.85	-0.35	3.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg10756647	chr7:56101905	PSPH	0.77	7.85	0.4	5.94e-14	Diabetic kidney disease;
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.64	8.48	0.42	8e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17774305	chr12:50505649	C12orf62	-0.51	-6.15	-0.32	2.21e-9	Diisocyanate-induced asthma;
CRC	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg08071915	chr8:12219732	FAM66A	0.35	6.11	0.32	2.75e-9	Morning vs. evening chronotype;
CRC	cis	rs7487075	0.786	rs1492892	chr12:46691487	C/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.95	0.31	7.01e-9	Itch intensity from mosquito bite;
CRC	cis	rs12580194	0.593	rs12580661	chr12:55803129	G/A	cg19537932	chr12:55886519	OR6C68	-0.72	-9.16	-0.45	5.6e-18	Cancer;
CRC	cis	rs12024301	0.557	rs6676348	chr1:183640787	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.99	0.36	1.52e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.74	9.21	0.45	4.07e-18	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.56	-0.43	4.26e-16	Blood metabolite levels;
CRC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	-0.66	-7.6	-0.39	3.02e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.73	-8.37	-0.42	1.66e-15	Obesity-related traits;
CRC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg13385794	chr1:248469461	NA	0.41	7.2	0.37	4.23e-12	Common traits (Other);
CRC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg19582491	chr16:67682965	RLTPR	-0.57	-6.53	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg18833306	chr6:118973337	C6orf204	0.45	5.82	0.31	1.44e-8	Diastolic blood pressure;
CRC	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.6	13.0	0.58	1.76e-31	Airflow obstruction;
CRC	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.19	-0.32	1.75e-9	Breast cancer;
CRC	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.5	5.62	0.3	4e-8	Hip circumference adjusted for BMI;
CRC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg17143192	chr8:8559678	CLDN23	0.47	6.15	0.32	2.21e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14024356	chr1:154934173	PYGO2	0.46	6.22	0.32	1.52e-9	Response to antipsychotic treatment;
CRC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.36	-6.05	-0.32	4.02e-9	Blood metabolite levels;
CRC	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.41	5.79	0.3	1.63e-8	Aortic root size;
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.65	-7.0	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	6.74	0.35	7.23e-11	Cystic fibrosis severity;
CRC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.53	-6.05	-0.32	3.98e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.91	-0.44	3.52e-17	Neuroticism;
CRC	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg18551225	chr6:44695536	NA	-0.43	-5.82	-0.31	1.37e-8	Total body bone mineral density;
CRC	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg17724175	chr1:150552817	MCL1	0.5	6.19	0.32	1.78e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.42	5.81	0.31	1.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg27563668	chr14:103995759	TRMT61A	-0.42	-5.97	-0.31	6.07e-9	Birth weight;Height;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.62	10.53	0.5	1.6e-22	Prudent dietary pattern;
CRC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.1	0.41	1.1e-14	Platelet count;
CRC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg13256891	chr4:100009986	ADH5	0.46	6.45	0.34	3.89e-10	Alcohol dependence;
CRC	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.44	6.57	0.34	1.99e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.71	-9.51	-0.46	4.13e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.47	7.18	0.37	4.8e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg04545296	chr12:48745243	ZNF641	-0.33	-5.73	-0.3	2.25e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.49	0.34	3.08e-10	Bladder cancer;
CRC	cis	rs2153904	1.000	rs2153904	chr1:205642790	A/C	cg23034840	chr1:205782522	SLC41A1	0.43	5.61	0.3	4.4e-8	Prostate-specific antigen levels;
CRC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg26762873	chr11:5879799	OR52E8	0.48	7.39	0.38	1.2e-12	DNA methylation (variation);
CRC	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg19508488	chr2:152266495	RIF1	0.52	6.49	0.34	3.15e-10	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25195193	chr3:195716626	SDHAP1	0.44	6.04	0.32	4.15e-9	Anxiety disorder;
CRC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.39	-0.33	5.68e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs427941	0.703	rs201457	chr7:101741338	C/A	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg06636001	chr8:8085503	FLJ10661	0.45	6.54	0.34	2.33e-10	Retinal vascular caliber;
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.73	-0.43	1.3e-16	Bipolar disorder;
CRC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.66	7.3	0.37	2.18e-12	Vitiligo;
CRC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.58	-5.94	-0.31	7.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.27	-7.15	-0.37	5.73e-12	Mean corpuscular volume;
CRC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.61	-11.47	-0.53	7.76e-26	Hemoglobin concentration;
CRC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.39	7.41	0.38	1.07e-12	Mean corpuscular volume;
CRC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.55	-9.35	-0.46	1.43e-18	Migraine;
CRC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.68	-12.02	-0.55	7.44e-28	Brugada syndrome;
CRC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.51	-6.87	-0.35	3.29e-11	Colorectal cancer;
CRC	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.53	-7.64	-0.39	2.46e-13	Multiple sclerosis;
CRC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg20790798	chr5:1857306	NA	-0.44	-6.66	-0.34	1.12e-10	Cardiovascular disease risk factors;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.97	-0.31	5.98e-9	Life satisfaction;
CRC	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.84	-0.31	1.29e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-1.01	-10.71	-0.51	3.79e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9868809	0.764	rs41290686	chr3:48604059	G/A	cg00383909	chr3:49044727	WDR6	1.13	7.77	0.39	1.04e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg16281234	chr15:35388805	NA	-0.51	-6.45	-0.34	4.08e-10	Longevity (90 years and older);
CRC	cis	rs1223397	0.938	rs3817742	chr6:13279552	T/C	cg06879394	chr6:13274151	PHACTR1	0.51	6.13	0.32	2.5e-9	Blood pressure;
CRC	cis	rs9595066	1.000	rs7981575	chr13:44710947	C/T	cg04068111	chr13:44716778	NA	-0.44	-6.11	-0.32	2.82e-9	Schizophrenia;
CRC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-6.57	-0.34	1.91e-10	Aortic root size;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg18827107	chr12:86230957	RASSF9	-0.5	-8.13	-0.41	8.79e-15	Major depressive disorder;
CRC	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.52	-7.36	-0.38	1.49e-12	Pulmonary function decline;
CRC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.15	0.49	3e-21	Alzheimer's disease (late onset);
CRC	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg02892189	chr1:6321676	GPR153	-0.64	-7.83	-0.4	6.64e-14	QT interval;
CRC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.66	7.96	0.4	2.73e-14	Menarche (age at onset);
CRC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.89	-0.51	8.94e-24	Total cholesterol levels;
CRC	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.68	-0.35	1.03e-10	Intraocular pressure;
CRC	trans	rs2962250	0.660	rs62368778	chr5:50346354	C/T	cg07611666	chr18:74729481	MBP	-0.62	-6.0	-0.31	5.2e-9	Schizophrenia;
CRC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	8.63	0.43	2.75e-16	Lung function (FEV1/FVC);
CRC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg06096015	chr1:231504339	EGLN1	0.41	6.27	0.33	1.15e-9	Hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg01422129	chr2:677375	TMEM18	-0.74	-6.01	-0.31	4.85e-9	Cognitive function;
CRC	cis	rs3849570	0.615	rs6778265	chr3:81985745	C/T	cg07356753	chr3:81810745	GBE1	0.47	6.36	0.33	6.74e-10	Waist circumference;Body mass index;
CRC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.94e-10	Lung cancer;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	6.92	0.36	2.34e-11	Obesity-related traits;
CRC	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.53	8.66	0.43	2.2e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00454932	chr1:171750547	METTL13	0.45	6.12	0.32	2.65e-9	Anxiety disorder;
CRC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.55	-8.6	-0.43	3.21e-16	Aortic root size;
CRC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs6662572	0.737	rs4388641	chr1:46522326	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.17	0.32	1.97e-9	Blood protein levels;
CRC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.81	13.48	0.6	2.7e-33	Menopause (age at onset);
CRC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.62	9.11	0.45	8.27e-18	Morning vs. evening chronotype;
CRC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.53	-7.61	-0.39	2.9e-13	Breast cancer;
CRC	cis	rs4654899	0.897	rs12121807	chr1:21069129	A/C	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.7	-0.35	9.13e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.58	6.03	0.32	4.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7932354	0.528	rs7947878	chr11:47028531	C/T	cg19486271	chr11:47235900	DDB2	-0.44	-6.53	-0.34	2.43e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs3790645	1.000	rs35245195	chr1:26884039	C/G	cg23229016	chr1:26872525	RPS6KA1	0.31	7.22	0.37	3.6e-12	Glucose homeostasis traits;
CRC	cis	rs7605827	0.930	rs3755129	chr2:15523549	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg20885578	chr2:198174922	NA	-0.41	-7.42	-0.38	1.04e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg27101125	chr19:17392770	ANKLE1	-0.33	-5.81	-0.3	1.5e-8	Systemic lupus erythematosus;
CRC	cis	rs7086803	1.000	rs7085406	chr10:114503496	G/C	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.59	-0.39	3.39e-13	Body mass index;
CRC	cis	rs1712517	0.526	rs113528138	chr10:105125451	C/A	cg04362960	chr10:104952993	NT5C2	-0.44	-5.71	-0.3	2.51e-8	Migraine;
CRC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.36	7.98	0.4	2.43e-14	Multiple system atrophy;
CRC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	8.01	0.4	1.97e-14	Cognitive test performance;
CRC	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.61	-6.92	-0.36	2.41e-11	Osteoarthritis;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg06470822	chr6:28175283	NA	0.68	9.12	0.45	7.67e-18	Parkinson's disease;
CRC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	11.89	0.55	2.31e-27	Nonalcoholic fatty liver disease;
CRC	trans	rs7179994	0.579	rs72712674	chr15:28300248	T/C	cg05237436	chr5:138533428	SIL1	0.7	6.28	0.33	1.1e-9	Shingles;
CRC	cis	rs4728302	0.869	rs6969899	chr7:133597490	A/G	cg10665199	chr7:133106180	EXOC4	0.37	5.62	0.3	4.01e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Depression;
CRC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.5	6.86	0.35	3.39e-11	Bronchopulmonary dysplasia;
CRC	trans	rs12517041	1.000	rs4701364	chr5:23301087	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.12	-0.32	2.66e-9	Calcium levels;
CRC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg00677455	chr12:58241039	CTDSP2	0.53	8.0	0.4	2.19e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg13777783	chr17:79615861	NA	0.3	5.72	0.3	2.44e-8	Eye color traits;
CRC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg12573674	chr2:1569213	NA	0.74	7.82	0.4	7.32e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.69	-0.3	2.84e-8	Monocyte percentage of white cells;
CRC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg18876405	chr7:65276391	NA	0.47	6.41	0.33	5.04e-10	Aortic root size;
CRC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.66	8.8	0.44	7.91e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg12273811	chr6:28175739	NA	0.46	6.93	0.36	2.18e-11	Cardiac Troponin-T levels;
CRC	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.48	-8.98	-0.44	2.09e-17	Hepatitis;
CRC	trans	rs4276421	0.776	rs7723380	chr5:45428535	T/C	cg04793272	chr11:119020941	ABCG4	-0.38	-6.22	-0.32	1.51e-9	P wave duration;
CRC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-12.21	-0.56	1.61e-28	Lung cancer;
CRC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.46	6.89	0.36	2.79e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-6.94	-0.36	2.07e-11	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.52	7.29	0.37	2.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.08e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg22654517	chr2:96458247	NA	0.32	5.72	0.3	2.43e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg15848620	chr12:58087721	OS9	-0.62	-8.73	-0.43	1.32e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.72	-11.78	-0.54	5.93e-27	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09188016	chr12:64798414	XPOT	0.42	6.87	0.35	3.17e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg22495460	chr2:25135724	ADCY3	-0.83	-13.9	-0.61	7.3e-35	Body mass index;
CRC	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.8	0.35	4.92e-11	Mammographic density (dense area);
CRC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-6.47	-0.34	3.5e-10	Height;
CRC	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg27534772	chr1:16042836	PLEKHM2	0.37	6.2	0.32	1.67e-9	Systolic blood pressure;
CRC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg21918786	chr6:109611834	NA	-0.42	-7.46	-0.38	7.91e-13	Reticulocyte fraction of red cells;
CRC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.5	0.34	2.99e-10	Total cholesterol levels;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Depression;
CRC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.43	-6.43	-0.33	4.49e-10	Electroencephalogram traits;
CRC	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg08501292	chr6:25962987	TRIM38	1.08	9.72	0.47	8.61e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg23202291	chr11:1979235	NA	0.47	6.57	0.34	1.99e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg24046110	chr8:143859143	LYNX1	-0.38	-6.6	-0.34	1.65e-10	Urinary tract infection frequency;
CRC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg15110403	chr19:17392923	ANKLE1	-0.36	-6.26	-0.33	1.21e-9	Systemic lupus erythematosus;
CRC	cis	rs6968419	0.747	rs3779509	chr7:115864889	C/A	cg02561103	chr7:115862891	TES	-0.43	-6.45	-0.33	4.1e-10	Intraocular pressure;
CRC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.46	9.14	0.45	6.48e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-8.16	-0.41	7.18e-15	Pancreatic cancer;
CRC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.64	-9.75	-0.47	6.97e-20	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9323205	0.834	rs12434435	chr14:51667524	G/T	cg23942311	chr14:51606299	NA	0.59	8.29	0.42	2.97e-15	Cancer;
CRC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.23	-0.41	4.39e-15	Personality dimensions;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.1	0.45	8.82e-18	Corneal astigmatism;
CRC	cis	rs1322512	1.000	rs2250632	chr6:153011126	C/A	cg03415253	chr6:152958462	SYNE1	0.42	6.47	0.34	3.47e-10	Tonometry;
CRC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg13206674	chr6:150067644	NUP43	0.48	6.88	0.35	2.98e-11	Testicular germ cell tumor;
CRC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.69	-0.39	1.72e-13	Arsenic metabolism;
CRC	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs9322817	0.691	rs2290515	chr6:105232204	C/T	cg02098413	chr6:105308735	HACE1	-0.44	-8.55	-0.43	4.67e-16	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6564851	0.506	rs56353925	chr16:81258368	A/G	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.66	-0.3	3.32e-8	Carotenoid and tocopherol levels;
CRC	trans	rs16846053	0.792	rs55893794	chr2:162418751	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Blood osmolality (transformed sodium);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08056012	chr3:130612679	ATP2C1	0.39	6.05	0.32	4.02e-9	Interleukin-6 levels;
CRC	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg27083787	chr2:113543245	IL1A	0.46	6.26	0.33	1.22e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	cis	rs4760636	0.648	rs12810487	chr12:48159571	T/C	cg13326926	chr12:48153388	RAPGEF3	0.6	5.98	0.31	5.66e-9	Urate levels;
CRC	cis	rs747650	0.504	rs4269876	chr11:47109463	T/A	cg19486271	chr11:47235900	DDB2	0.44	5.89	0.31	9.76e-9	Acne (severe);
CRC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg13390004	chr1:15929781	NA	0.5	6.91	0.36	2.53e-11	Systolic blood pressure;
CRC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg02135003	chr7:105160482	PUS7	-0.91	-11.94	-0.55	1.58e-27	Bipolar disorder (body mass index interaction);
CRC	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.39	5.84	0.31	1.25e-8	Essential tremor;
CRC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.47	-6.5	-0.34	2.89e-10	Lung cancer;
CRC	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.51	7.6	0.39	3.17e-13	Menopause (age at onset);
CRC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg12311346	chr5:56204834	C5orf35	-0.47	-6.98	-0.36	1.61e-11	Coronary artery disease;
CRC	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg19486271	chr11:47235900	DDB2	-0.47	-7.13	-0.37	6.33e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.55	-6.59	-0.34	1.76e-10	Body mass index;
CRC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.99e-24	Motion sickness;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19307233	chr1:231377017	C1orf131;GNPAT	0.46	6.39	0.33	5.79e-10	Anxiety disorder;
CRC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.97e-9	Hemoglobin concentration;
CRC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg19812747	chr11:111475976	SIK2	0.51	8.07	0.41	1.34e-14	Primary sclerosing cholangitis;
CRC	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11446398	chr5:77624930	NA	-0.47	-6.55	-0.34	2.15e-10	Triglycerides;
CRC	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg20607287	chr7:12443886	VWDE	-0.47	-6.11	-0.32	2.85e-9	Coronary artery disease;
CRC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg21461308	chr16:87754019	KLHDC4	-0.45	-6.34	-0.33	7.39e-10	Select biomarker traits;
CRC	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.59	6.31	0.33	9.06e-10	Coronary artery disease;
CRC	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg18232548	chr7:50535776	DDC	-0.4	-6.12	-0.32	2.64e-9	Body mass index;
CRC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.53	8.4	0.42	1.31e-15	Colorectal cancer;
CRC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-7.89	-0.4	4.57e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.9	-15.26	-0.64	3.95e-40	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00776160	chr1:149815087	HIST2H2AA3;HIST2H2AA4	0.49	6.86	0.35	3.53e-11	Response to antipsychotic treatment;
CRC	cis	rs3764400	0.508	rs12601350	chr17:46120419	T/C	cg10706073	chr17:46328419	SKAP1	-0.68	-7.28	-0.37	2.53e-12	Body mass index;
CRC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg03037974	chr15:76606532	NA	-0.49	-7.16	-0.37	5.34e-12	Blood metabolite levels;
CRC	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg08027265	chr7:2291960	NA	-0.4	-6.12	-0.32	2.59e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg01879757	chr17:41196368	BRCA1	-0.42	-6.24	-0.33	1.31e-9	Menopause (age at onset);
CRC	cis	rs8105895	0.935	rs8104144	chr19:22246913	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.33	1.26e-9	Heart rate;
CRC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.39	-7.11	-0.36	7.27e-12	Height;
CRC	cis	rs7215564	0.908	rs7501544	chr17:78660946	T/A	cg09596252	chr17:78655493	RPTOR	0.54	5.73	0.3	2.25e-8	Myopia (pathological);
CRC	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	6.3	0.33	9.59e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs10924970	0.870	rs2382569	chr1:235469032	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.0	0.31	5.32e-9	Asthma;
CRC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg12193833	chr17:30244370	NA	-0.61	-7.36	-0.38	1.5e-12	Hip circumference adjusted for BMI;
CRC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.56	7.26	0.37	2.84e-12	Gut microbiome composition (summer);
CRC	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.58	10.22	0.49	1.73e-21	Asthma;
CRC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.86	-0.48	3e-20	Body mass index;
CRC	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg05935833	chr10:81318306	SFTPA2	-0.73	-8.0	-0.4	2.14e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.66	-8.82	-0.44	6.63e-17	Hypospadias;
CRC	cis	rs12913538	0.641	rs12591920	chr15:62902495	A/C	cg09983546	chr15:62884068	NA	-0.52	-7.87	-0.4	5.33e-14	Sleep depth;
CRC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.52	-8.73	-0.43	1.34e-16	Brugada syndrome;
CRC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.59	9.4	0.46	9.55e-19	Vitiligo;
CRC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.53	8.94	0.44	2.94e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-7.48	-0.38	6.75e-13	Prevalent atrial fibrillation;
CRC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.97	12.22	0.56	1.49e-28	Eosinophil percentage of granulocytes;
CRC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg16141378	chr3:129829833	LOC729375	0.44	6.75	0.35	6.61e-11	Neuroticism;
CRC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.64	-11.02	-0.52	3.14e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg13491945	chr12:107078410	RFX4	0.34	5.67	0.3	3.16e-8	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01357671	chr17:3626806	ITGAE;GSG2	0.42	6.18	0.32	1.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.82e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.39	6.42	0.33	4.87e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05903289	chr2:130345205	NA	-0.41	-8.06	-0.41	1.47e-14	Response to cytidine analogues (gemcitabine);
CRC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg19980929	chr12:42632907	YAF2	0.4	5.78	0.3	1.77e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.58	-6.48	-0.34	3.43e-10	Schizophrenia;
CRC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04476341	chr5:669733	TPPP	0.42	6.88	0.35	3.1e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs2257205	0.667	rs16943147	chr17:56720752	C/A	cg25885038	chr17:56607967	SEPT4	-0.54	-5.85	-0.31	1.18e-8	Pancreatic cancer;
CRC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.31	5.82	0.31	1.42e-8	Blood protein levels;
CRC	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg02450064	chr17:40260053	DHX58	-0.43	-6.14	-0.32	2.42e-9	Fibrinogen levels;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.74	0.35	7.22e-11	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11829371	chr17:981724	ABR	0.42	6.62	0.34	1.43e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg01721255	chr8:58191610	C8orf71	0.46	5.82	0.31	1.38e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg11822372	chr1:151115635	SEMA6C	0.55	7.88	0.4	4.89e-14	Childhood ear infection;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg02683197	chr6:28174875	NA	0.65	8.86	0.44	4.95e-17	Parkinson's disease;
CRC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.09	-0.49	4.73e-21	Initial pursuit acceleration;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg12813394	chr14:69095057	NA	-0.36	-6.14	-0.32	2.33e-9	Lung cancer;
CRC	cis	rs10046574	0.831	rs77693675	chr7:135142402	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.72	0.3	2.41e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.09	-0.41	1.13e-14	Morning vs. evening chronotype;
CRC	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.4	-6.05	-0.32	3.84e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	trans	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg10756647	chr7:56101905	PSPH	0.74	7.72	0.39	1.43e-13	Diabetic kidney disease;
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs6534441	0.697	rs60743503	chr4:125443757	C/T	cg21609808	chr4:125404261	NA	0.39	5.63	0.3	3.77e-8	Major depressive disorder;
CRC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.41	6.35	0.33	6.96e-10	Coronary artery disease;
CRC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.5	6.84	0.35	3.86e-11	Optic nerve measurement (cup area);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26665246	chr5:179105570	CBY3	0.4	6.61	0.34	1.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-9.76	-0.47	6.41e-20	Dental caries;
CRC	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13736514	chr6:26305472	NA	-0.47	-7.64	-0.39	2.39e-13	Educational attainment;
CRC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-13.31	-0.59	1.24e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.9	-0.36	2.71e-11	Coronary artery disease;
CRC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.72	-0.43	1.38e-16	Total cholesterol levels;
CRC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.57	8.45	0.42	9.59e-16	Aortic root size;
CRC	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.64	8.24	0.41	4.01e-15	Breast cancer;
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.68	9.3	0.46	2.02e-18	Hair shape;
CRC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg19500275	chr17:80737654	TBCD	0.47	6.71	0.35	8.6e-11	Glycated hemoglobin levels;
CRC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	0.9	11.07	0.52	2.05e-24	Red blood cell traits;
CRC	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.77	0.35	5.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.66	10.3	0.49	9.26e-22	Longevity;Endometriosis;
CRC	trans	rs11825064	0.606	rs11821186	chr11:134487480	T/C	cg00033773	chr19:12779366	MORG1;C19orf56	0.43	5.97	0.31	6.19e-9	Seasonality;
CRC	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	0.6	6.16	0.32	2.07e-9	Left atrial antero-posterior diameter;
CRC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg16102536	chr7:156981717	UBE3C	-0.4	-6.79	-0.35	5.41e-11	Body mass index;
CRC	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.43	6.62	0.34	1.45e-10	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.4	6.32	0.33	8.37e-10	Monocyte count;
CRC	cis	rs356992	0.915	rs76674	chr2:60749109	C/T	cg08426369	chr2:60753602	BCL11A	-0.54	-7.77	-0.39	9.8e-14	Educational attainment (years of education);
CRC	cis	rs7605827	0.866	rs11689153	chr2:15533899	A/G	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.06e-8	Educational attainment (years of education);
CRC	cis	rs7258465	1.000	rs34010330	chr19:18559657	G/C	cg06462663	chr19:18546047	ISYNA1	0.44	6.42	0.33	4.66e-10	Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18565132	chr8:103613344	NA	0.38	6.25	0.33	1.28e-9	Interleukin-6 levels;
CRC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.44	0.42	1.06e-15	Height;
CRC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.81	12.33	0.56	5.83e-29	Cognitive function;
CRC	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.7	-0.3	2.62e-8	Schizophrenia;
CRC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.53	0.34	2.5e-10	Menarche (age at onset);
CRC	cis	rs72634501	0.622	rs4660416	chr1:39578986	A/G	cg18385671	chr1:39797026	MACF1	-0.43	-6.01	-0.31	5e-9	HDL cholesterol;
CRC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.45	5.98	0.31	5.68e-9	Schizophrenia;
CRC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.52	8.23	0.41	4.32e-15	Menopause (age at onset);
CRC	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg00631329	chr6:26305371	NA	-0.55	-9.42	-0.46	7.95e-19	Educational attainment;
CRC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.01	0.31	4.88e-9	Lung cancer;
CRC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.49	6.66	0.34	1.14e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11179286	chr13:115047994	UPF3A	0.4	5.98	0.31	5.66e-9	Intelligence (multi-trait analysis);
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg14315341	chr12:97346526	NEDD1	0.41	6.06	0.32	3.65e-9	Monocyte count;
CRC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.61	8.79	0.44	8.32e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs4437462	0.898	rs4711244	chr6:11309828	A/T	cg25250968	chr6:11318770	NEDD9	-0.4	-5.72	-0.3	2.45e-8	HIV-1 susceptibility;
CRC	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.48	7.59	0.39	3.37e-13	Red blood cell count;
CRC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	7.81	0.4	7.52e-14	Systolic blood pressure;
CRC	cis	rs12550646	0.652	rs13438989	chr8:41685845	T/G	cg12180191	chr8:41686706	ANK1	-0.45	-6.51	-0.34	2.81e-10	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.6	8.92	0.44	3.33e-17	Homoarginine levels;
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.6e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg23425280	chr12:56401806	NA	0.44	5.61	0.3	4.19e-8	Cancer;
CRC	trans	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg21153622	chr11:89784906	NA	-0.43	-6.97	-0.36	1.72e-11	HDL cholesterol;
CRC	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.54	8.09	0.41	1.18e-14	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11982332	chr8:96037194	C8orf38	0.5	6.86	0.35	3.44e-11	Anxiety disorder;
CRC	cis	rs1572438	0.931	rs13215634	chr6:866545	C/T	cg13447295	chr6:887704	NA	0.44	6.4	0.33	5.42e-10	Aging;
CRC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	7.3	0.37	2.14e-12	Headache;
CRC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg13206674	chr6:150067644	NUP43	0.66	9.38	0.46	1.12e-18	Lung cancer;
CRC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.03	0.45	1.53e-17	Alzheimer's disease;
CRC	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.54	-6.48	-0.34	3.45e-10	Obesity (extreme);
CRC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.43e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.36	-6.0	-0.31	5.24e-9	Mean arterial pressure;
CRC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg25204440	chr1:209979598	IRF6	0.5	7.08	0.36	8.78e-12	Cleft lip with or without cleft palate;
CRC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17554472	chr22:41940697	POLR3H	-0.55	-5.93	-0.31	7.73e-9	Vitiligo;
CRC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.9	-0.36	2.61e-11	Coronary artery disease;
CRC	cis	rs1124376	0.882	rs7618597	chr3:20134588	C/A	cg05072819	chr3:20081367	KAT2B	0.49	5.9	0.31	8.95e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg02741985	chr17:80059408	CCDC57	-0.42	-6.77	-0.35	5.9e-11	Life satisfaction;
CRC	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.52	-8.16	-0.41	6.97e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.65	-7.62	-0.39	2.71e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.0	9.49	0.46	4.89e-19	Diabetic retinopathy;
CRC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.05	-0.55	5.86e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.85	-0.35	3.55e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs16975963	0.843	rs241955	chr19:38278677	A/G	cg15135657	chr19:38346511	NA	-0.42	-5.68	-0.3	3.03e-8	Longevity;
CRC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.63	-0.39	2.54e-13	Morning vs. evening chronotype;
CRC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs896623	0.555	rs6837596	chr4:122131425	A/G	cg19463078	chr4:122099598	TNIP3	0.41	6.31	0.33	8.76e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2342371	0.715	rs9846106	chr3:196126539	G/A	cg15048948	chr3:196158458	UBXN7	0.51	6.26	0.33	1.18e-9	Fat distribution (HIV);
CRC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.76	11.1	0.52	1.61e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.39	-6.53	-0.34	2.45e-10	Mean arterial pressure;
CRC	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-0.71	-7.24	-0.37	3.25e-12	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11528995	chr1:117210575	IGSF3	0.39	6.44	0.33	4.26e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg06243084	chr11:63990629	FERMT3	0.46	7.28	0.37	2.41e-12	Platelet count;
CRC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg19682013	chr15:45996608	NA	0.32	6.62	0.34	1.46e-10	Waist circumference;Weight;
CRC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg24675056	chr1:15929824	NA	0.47	6.29	0.33	1.01e-9	Systolic blood pressure;
CRC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.6	-7.61	-0.39	2.97e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9925964	0.967	rs889548	chr16:31137712	A/G	cg03418659	chr16:31128414	MYST1	-0.53	-7.73	-0.39	1.31e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1324183	0.915	rs2224860	chr9:13550069	C/A	cg07050692	chr8:61664695	CHD7	-0.44	-5.98	-0.31	5.97e-9	Corneal structure;
CRC	trans	rs6708331	0.517	rs11692018	chr2:70369154	A/C	cg06926377	chr15:40443853	NA	0.41	6.08	0.32	3.4e-9	Obesity-related traits;
CRC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg11632617	chr15:75315747	PPCDC	-0.57	-7.79	-0.39	8.82e-14	Blood trace element (Zn levels);
CRC	trans	rs12517041	1.000	rs6891825	chr5:23299740	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg17346650	chr17:80929145	B3GNTL1	0.34	5.66	0.3	3.23e-8	Breast cancer;
CRC	cis	rs6585424	1.000	rs2228427	chr10:81926718	A/G	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.79	11.48	0.53	6.95e-26	Neutrophil percentage of white cells;
CRC	cis	rs939584	0.935	rs7569102	chr2:631335	G/T	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.55	-0.34	2.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.02	-0.31	4.69e-9	Inflammatory bowel disease;
CRC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg15110403	chr19:17392923	ANKLE1	-0.36	-6.0	-0.31	5.23e-9	Systemic lupus erythematosus;
CRC	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg15234197	chr11:68924956	NA	0.44	6.12	0.32	2.72e-9	Blond vs. brown hair color;
CRC	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg05585544	chr11:47624801	NA	0.41	6.31	0.33	8.88e-10	Mean corpuscular hemoglobin;
CRC	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	6.58	0.34	1.84e-10	Body mass index;
CRC	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.46	6.01	0.31	5.02e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.47	7.45	0.38	8.08e-13	Intelligence (multi-trait analysis);
CRC	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.48	5.8	0.3	1.59e-8	Schizophrenia;
CRC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.47	-8.73	-0.43	1.28e-16	Reticulocyte fraction of red cells;
CRC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.16	-0.32	2.14e-9	Hip circumference adjusted for BMI;
CRC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg16576597	chr16:28551801	NUPR1	0.49	7.13	0.37	6.53e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs3760982	1.000	rs4803658	chr19:44290013	T/A	cg21496419	chr19:44306685	LYPD5	0.35	6.54	0.34	2.31e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs4731207	0.698	rs10085888	chr7:124486391	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg19812747	chr11:111475976	SIK2	-0.45	-7.39	-0.38	1.22e-12	Primary sclerosing cholangitis;
CRC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.9	-0.55	2.11e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6694672	1.000	rs1332663	chr1:197109042	C/T	cg13682187	chr1:196946512	CFHR5	0.46	7.37	0.38	1.38e-12	Asthma;
CRC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg13722127	chr7:150037890	RARRES2	0.41	6.24	0.33	1.32e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.63	9.32	0.46	1.68e-18	Vitamin D levels;
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg22687807	chr8:143858763	LYNX1	0.51	9.13	0.45	7.1e-18	Urinary tract infection frequency;
CRC	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.39	-0.42	1.41e-15	Brugada syndrome;
CRC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.11	0.41	1.01e-14	Red blood cell count;
CRC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.76	-15.14	-0.64	1.14e-39	Refractive error;
CRC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.8	-11.54	-0.54	4.13e-26	Blood trace element (Zn levels);
CRC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg19193384	chr17:30244184	NA	-0.5	-6.85	-0.35	3.58e-11	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6496667	0.542	rs58182460	chr15:90897309	A/T	cg04176472	chr15:90893244	GABARAPL3	0.51	7.73	0.39	1.33e-13	Rheumatoid arthritis;
CRC	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.56	-8.12	-0.41	9.6e-15	Platelet distribution width;
CRC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.8	13.23	0.59	2.48e-32	Coronary artery disease;
CRC	trans	rs800082	1.000	rs9849975	chr3:144294530	A/G	cg24215973	chr2:240111563	HDAC4	-0.51	-7.1	-0.36	7.92e-12	Smoking behavior;
CRC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.38e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.09	-10.14	-0.49	3.36e-21	Diabetic retinopathy;
CRC	cis	rs6840360	0.904	rs6813516	chr4:152594407	C/G	cg09659197	chr4:152720779	NA	0.52	11.05	0.52	2.32e-24	Intelligence (multi-trait analysis);
CRC	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	0.56	6.74	0.35	6.93e-11	Prostate cancer;
CRC	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07165851	chr6:158734300	TULP4	0.6	7.58	0.39	3.46e-13	Height;
CRC	cis	rs2898681	0.581	rs10003908	chr4:53681089	T/C	cg00338735	chr4:53728038	RASL11B	0.39	5.92	0.31	8.08e-9	Optic nerve measurement (cup area);
CRC	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.82	-0.4	7.47e-14	Bipolar disorder;
CRC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg16447950	chr5:562315	NA	-0.85	-12.52	-0.57	1.1e-29	Obesity-related traits;
CRC	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-8.16	-0.41	7.26e-15	Mean corpuscular volume;
CRC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg18761221	chr20:60518478	NA	0.46	7.39	0.38	1.23e-12	Body mass index;
CRC	cis	rs7617773	1.000	rs11711766	chr3:48193170	G/C	cg11946769	chr3:48343235	NME6	-0.51	-6.85	-0.35	3.74e-11	Coronary artery disease;
CRC	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg14139581	chr11:64358342	SLC22A12	-0.38	-6.09	-0.32	3.14e-9	Urate levels in obese individuals;
CRC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.4	0.33	5.4e-10	Primary sclerosing cholangitis;
CRC	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.54	0.65	3.21e-41	Bipolar disorder;
CRC	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.44	6.23	0.32	1.46e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14517217	chr17:75447478	SEPT9	0.4	6.35	0.33	7.2e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.54	-9.08	-0.45	1.03e-17	Iron status biomarkers;
CRC	cis	rs2857891	0.817	rs2239732	chr11:6976689	C/G	cg04053776	chr11:6947353	ZNF215	0.41	5.88	0.31	1.01e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg24140574	chr1:16342155	HSPB7	0.43	6.24	0.33	1.35e-9	Systolic blood pressure;
CRC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.58	-9.34	-0.46	1.48e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.67	9.05	0.45	1.29e-17	IgE levels in asthmatics (D.p. specific);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05165064	chr20:18037039	OVOL2	0.4	6.05	0.32	3.97e-9	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.09	-0.32	3.21e-9	Height;
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.83	-0.31	1.3e-8	Life satisfaction;
CRC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.74	-11.63	-0.54	2.07e-26	Colorectal cancer;
CRC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.28	0.46	2.4e-18	Blood protein levels;
CRC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.42	8.55	0.43	4.59e-16	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05749548	chr13:48611855	NUDT15	0.45	6.34	0.33	7.46e-10	Anxiety disorder;
CRC	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.7	-9.79	-0.47	4.95e-20	Waist circumference;Body mass index;
CRC	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.46	-0.34	3.85e-10	Tonsillectomy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17886162	chr1:183440258	SMG7	0.42	6.1	0.32	3.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.46	7.3	0.37	2.22e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.71	-9.19	-0.45	4.44e-18	Initial pursuit acceleration;
CRC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.51	-8.24	-0.41	4.19e-15	Huntington's disease progression;
CRC	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.57	9.92	0.48	1.85e-20	Age of smoking initiation;
CRC	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-11.7	-0.54	1.14e-26	Urate levels in overweight individuals;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.64	9.98	0.48	1.2e-20	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11555878	chr7:7607056	MIOS	0.38	6.13	0.32	2.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2415984	0.579	rs8010773	chr14:46956863	T/C	cg14871534	chr14:47121158	RPL10L	-0.4	-5.83	-0.31	1.32e-8	Number of children ever born;
CRC	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.92	9.34	0.46	1.45e-18	Platelet distribution width;
CRC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg17948913	chr5:572064	NA	0.52	5.95	0.31	6.79e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg06238570	chr21:40685208	BRWD1	0.76	10.27	0.49	1.23e-21	Cognitive function;
CRC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.9e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs62432291	0.681	rs419836	chr6:159659481	C/T	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg25985355	chr7:65971099	NA	0.51	5.73	0.3	2.31e-8	Diabetic kidney disease;
CRC	cis	rs728616	0.764	rs61859016	chr10:81852500	C/A	cg11900509	chr10:81946545	ANXA11	-0.56	-5.83	-0.31	1.3e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25234159	chr3:184870893	C3orf70	0.41	6.04	0.32	4.08e-9	Response to antipsychotic treatment;
CRC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.85	0.55	3.28e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg20935933	chr6:143382018	AIG1	0.5	6.58	0.34	1.89e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg20885578	chr2:198174922	NA	-0.38	-5.65	-0.3	3.52e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	11.8	0.55	5.03e-27	Platelet count;
CRC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21643547	chr1:205240462	TMCC2	-0.45	-7.26	-0.37	2.84e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.56	8.42	0.42	1.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.39	5.61	0.3	4.37e-8	Aortic root size;
CRC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	6.37	0.33	6.26e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg15845792	chr6:28175446	NA	-0.46	-6.17	-0.32	2.06e-9	Systemic lupus erythematosus;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23161317	chr6:28129485	ZNF389	0.44	5.76	0.3	1.96e-8	Parkinson's disease;
CRC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg19682013	chr15:45996608	NA	-0.33	-6.83	-0.35	4.18e-11	Waist circumference;Weight;
CRC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.28	0.49	1.11e-21	Platelet count;
CRC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.5	-5.83	-0.31	1.33e-8	Vitiligo;
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.53	-7.09	-0.36	8.32e-12	Renal function-related traits (BUN);
CRC	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-6.91	-0.36	2.5e-11	HDL cholesterol;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.71	-13.4	-0.59	5.84e-33	Bipolar disorder;
CRC	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.67	11.04	0.52	2.51e-24	Breast cancer;
CRC	cis	rs28655083	0.529	rs4544253	chr16:77104774	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.59	0.34	1.76e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.25	-0.62	3.21e-36	Body mass index;
CRC	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.71	0.35	8.76e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	10.62	0.51	7.37e-23	Schizophrenia;
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.52	6.97	0.36	1.79e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.53	8.88	0.44	4.28e-17	Dupuytren's disease;
CRC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.59	6.26	0.33	1.23e-9	Axial length;
CRC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.26	-0.33	1.24e-9	Menopause (age at onset);
CRC	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.49	0.5	2.17e-22	Coffee consumption (cups per day);
CRC	cis	rs7626444	0.625	rs843539	chr3:196474856	T/C	cg12930392	chr3:196481615	PAK2	0.41	7.3	0.37	2.23e-12	Monocyte count;
CRC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.31	0.46	1.91e-18	Bladder cancer;
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.51	7.63	0.39	2.5e-13	Menarche (age at onset);
CRC	cis	rs459193	1.000	rs40271	chr5:55796319	A/G	cg00049729	chr5:55776345	NA	-0.38	-5.66	-0.3	3.3e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg09417038	chr21:47716443	C21orf57	-0.36	-6.11	-0.32	2.89e-9	Testicular germ cell tumor;
CRC	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.57	-6.92	-0.36	2.41e-11	Ulcerative colitis;
CRC	cis	rs16924133	0.557	rs66548785	chr11:33121605	T/C	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs12484776	0.735	rs6001799	chr22:40539200	G/A	cg21771250	chr22:40406049	FAM83F	0.32	5.82	0.31	1.43e-8	Uterine fibroids;
CRC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.4	5.75	0.3	1.99e-8	Obesity-related traits;
CRC	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.59	-9.11	-0.45	7.96e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg13789711	chr9:139743225	PHPT1	-0.42	-6.36	-0.33	6.67e-10	Aortic root size;
CRC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.49	-7.92	-0.4	3.65e-14	Coronary artery disease;
CRC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg18827107	chr12:86230957	RASSF9	-0.4	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Dilated cardiomyopathy;
CRC	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.99	18.42	0.71	1.51e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.97	-0.4	2.56e-14	Electroencephalogram traits;
CRC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg13198984	chr17:80129470	CCDC57	0.44	7.91	0.4	3.98e-14	Life satisfaction;
CRC	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg18232548	chr7:50535776	DDC	-0.43	-5.64	-0.3	3.76e-8	Malaria;
CRC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.95	-17.56	-0.7	3.48e-49	Coronary artery disease;
CRC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.84	12.66	0.57	3.49e-30	Menarche (age at onset);
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg15786705	chr6:28176104	NA	0.59	6.59	0.34	1.79e-10	Parkinson's disease;
CRC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.65	9.49	0.46	4.77e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-9.2	-0.45	4.09e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.7	-11.72	-0.54	9.46e-27	White blood cell count (basophil);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26438705	chr16:1661097	IFT140	0.37	6.13	0.32	2.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.47	6.43	0.33	4.56e-10	Breast cancer;
CRC	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.75	7.98	0.4	2.42e-14	Hypertension (SNP x SNP interaction);
CRC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.77	-12.15	-0.56	2.55e-28	Breast cancer;
CRC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.68	10.68	0.51	4.52e-23	Type 2 diabetes;
CRC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg23996704	chr18:44553084	KATNAL2	-0.37	-7.52	-0.38	5.23e-13	Personality dimensions;
CRC	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.11	-0.36	7.4e-12	QT interval;
CRC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg19635926	chr16:89946313	TCF25	0.67	5.67	0.3	3.14e-8	Skin colour saturation;
CRC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08751499	chr6:12290573	EDN1	0.53	6.96	0.36	1.84e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.26	-0.33	1.22e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11972953	chr2:30370168	YPEL5	0.43	5.96	0.31	6.53e-9	Anxiety disorder;
CRC	cis	rs3026101	0.671	rs3026109	chr17:5284480	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.44	-7.15	-0.37	5.6e-12	Body mass index;
CRC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.56	9.0	0.44	1.86e-17	Schizophrenia;
CRC	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	0.57	8.58	0.43	3.74e-16	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg09060608	chr5:178986726	RUFY1	0.39	6.06	0.32	3.77e-9	Lung cancer;
CRC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.52	-8.37	-0.42	1.63e-15	Monocyte count;
CRC	cis	rs6460942	0.908	rs6956500	chr7:12232120	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-6.0	-0.31	5.18e-9	Coronary artery disease;
CRC	cis	rs7605827	0.930	rs6431709	chr2:15638296	T/C	cg19274914	chr2:15703543	NA	0.39	6.0	0.31	5.1e-9	Educational attainment (years of education);
CRC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.92	-16.65	-0.68	1.44e-45	Coronary artery disease;
CRC	cis	rs10924970	0.934	rs10802572	chr1:235426121	A/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.76	0.3	1.93e-8	Asthma;
CRC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg25767906	chr1:53392781	SCP2	-0.44	-6.96	-0.36	1.88e-11	Monocyte count;
CRC	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.9	-13.02	-0.58	1.56e-31	Dupuytren's disease;
CRC	cis	rs9478638	0.507	rs2184406	chr6:155629678	T/C	cg07943832	chr6:155568918	TIAM2	-0.59	-7.64	-0.39	2.33e-13	Electroencephalogram traits;
CRC	cis	rs7487075	0.930	rs4076248	chr12:46833605	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	6.21	0.32	1.58e-9	Itch intensity from mosquito bite;
CRC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg05709478	chr1:6581295	PLEKHG5	0.64	7.44	0.38	8.99e-13	Body mass index;
CRC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	0.95	18.79	0.72	5e-54	Height;
CRC	trans	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.2	-0.37	4.18e-12	Endometrial cancer;
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder;
CRC	cis	rs4731207	0.596	rs7810643	chr7:124611410	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.07	-0.32	3.56e-9	Cutaneous malignant melanoma;
CRC	cis	rs9311676	0.632	rs56026131	chr3:58422483	C/G	cg06643156	chr3:58380774	PXK	0.43	6.53	0.34	2.5e-10	Systemic lupus erythematosus;
CRC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.75	-0.47	7e-20	Bladder cancer;
CRC	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg24851651	chr11:66362959	CCS	-0.39	-6.77	-0.35	6.08e-11	Educational attainment (years of education);
CRC	cis	rs2013441	0.613	rs888424	chr17:19985427	C/T	cg13482628	chr17:19912719	NA	0.38	5.89	0.31	9.43e-9	Obesity-related traits;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg02683197	chr6:28174875	NA	0.69	9.04	0.45	1.38e-17	Parkinson's disease;
CRC	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02598441	chr17:62777298	LOC146880	0.54	7.31	0.37	2.09e-12	QT interval;
CRC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.6	-8.77	-0.44	9.68e-17	Aortic root size;
CRC	cis	rs7626444	0.625	rs1798634	chr3:196474287	G/A	cg12930392	chr3:196481615	PAK2	0.4	7.05	0.36	1.07e-11	Monocyte count;
CRC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.67	11.52	0.54	5.1e-26	Prostate cancer;
CRC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg19223190	chr17:80058835	NA	0.42	6.63	0.34	1.37e-10	Life satisfaction;
CRC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.28	-0.37	2.49e-12	Height;
CRC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.72	-11.15	-0.52	1.05e-24	Cognitive function;
CRC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22133161	chr19:49891603	CCDC155	0.53	7.37	0.38	1.41e-12	Multiple sclerosis;
CRC	cis	rs9828933	0.577	rs832194	chr3:63857071	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.77	9.0	0.44	1.87e-17	Type 2 diabetes;
CRC	cis	rs4523957	0.855	rs216212	chr17:2134214	T/C	cg16513277	chr17:2031491	SMG6	0.52	8.69	0.43	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-10.32	-0.49	8.35e-22	Menarche (age at onset);
CRC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg04362960	chr10:104952993	NT5C2	-0.47	-5.98	-0.31	5.68e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10924970	0.649	rs6673756	chr1:235412134	G/A	cg09010748	chr1:235293032	TOMM20	-0.42	-5.77	-0.3	1.86e-8	Asthma;
CRC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.63	10.29	0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.5	6.71	0.35	8.27e-11	Optic nerve measurement (cup area);
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg12516270	chr8:143859308	LYNX1	0.42	7.54	0.38	4.55e-13	Urinary tract infection frequency;
CRC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.84	-0.63	1.63e-38	Diabetic kidney disease;
CRC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.55	8.03	0.4	1.77e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.42	6.76	0.35	6.46e-11	Monocyte count;
CRC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.29	0.33	1.04e-9	Lung cancer;
CRC	cis	rs8051149	0.688	rs3815559	chr16:87871366	G/C	cg01412419	chr16:87856264	NA	0.52	7.11	0.37	7.18e-12	Blood metabolite levels;
CRC	cis	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.0	-0.31	5.24e-9	LDL cholesterol levels;LDL cholesterol;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01213445	chr15:91537450	PRC1	-0.39	-6.05	-0.32	3.84e-9	Myopia (pathological);
CRC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.5	-8.04	-0.41	1.58e-14	Monocyte count;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.82	13.01	0.58	1.61e-31	Menarche (age at onset);
CRC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.43	0.33	4.41e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11168936	1.000	rs11168936	chr12:49645240	A/G	cg14846292	chr12:49726500	C1QL4	-0.34	-5.64	-0.3	3.65e-8	Cancer (pleiotropy);
CRC	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg14593290	chr7:50529359	DDC	0.55	7.71	0.39	1.52e-13	Malaria;
CRC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.52	-9.34	-0.46	1.52e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.83	0.44	6.35e-17	Hip circumference adjusted for BMI;
CRC	cis	rs889398	0.770	rs8052225	chr16:69883653	G/A	cg00738113	chr16:70207722	CLEC18C	-0.36	-6.18	-0.32	1.92e-9	Body mass index;
CRC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	8.99	0.44	1.94e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg25164649	chr6:28176230	NA	0.7	8.96	0.44	2.38e-17	Parkinson's disease;
CRC	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.67	-7.73	-0.39	1.28e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg02683197	chr6:28174875	NA	0.65	6.58	0.34	1.81e-10	Depression;
CRC	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.93	13.18	0.59	3.69e-32	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	10.64	0.51	6.54e-23	Coronary artery disease;
CRC	cis	rs9462846	0.881	rs34498470	chr6:42879551	C/T	cg05552183	chr6:42928497	GNMT	0.45	5.71	0.3	2.51e-8	Blood protein levels;
CRC	cis	rs4478137	0.824	rs10857353	chr4:164215835	A/G	cg06758707	chr4:164254230	NPY1R	-0.45	-6.97	-0.36	1.76e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs10450586	0.932	rs7483162	chr11:27316394	A/G	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.62	9.61	0.47	1.89e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.79	-0.35	5.14e-11	Dupuytren's disease;
CRC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.51	8.17	0.41	6.81e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.39	-5.92	-0.31	8.11e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg21251018	chr6:28226885	NKAPL	0.4	6.12	0.32	2.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.46	-6.1	-0.32	3.03e-9	Response to antidepressants and depression;
CRC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.91	-17.89	-0.7	1.83e-50	Obesity-related traits;
CRC	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg20356878	chr3:121714668	ILDR1	0.49	7.65	0.39	2.22e-13	Cognitive performance;
CRC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.45	8.97	0.44	2.29e-17	Renal cell carcinoma;
CRC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.11	-21.27	-0.76	9.42e-64	Cognitive function;
CRC	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-6.9	-0.36	2.72e-11	Caudate activity during reward;
CRC	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.69	-0.39	1.67e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-9.3	-0.46	2.07e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-6.46	-0.34	3.82e-10	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg20540378	chr5:149340137	SLC26A2	-0.52	-6.25	-0.33	1.29e-9	Diisocyanate-induced asthma;
CRC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.66	9.87	0.48	2.72e-20	Tonsillectomy;
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.23	-0.45	3.45e-18	Electroencephalogram traits;
CRC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg11292332	chr7:45801988	SEPT13	0.34	6.07	0.32	3.45e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs783540	1.000	rs6603033	chr15:83335875	A/C	cg18393722	chr15:85113863	UBE2QP1	0.38	6.32	0.33	8.58e-10	Schizophrenia;
CRC	cis	rs7932354	0.536	rs7929294	chr11:46776176	T/C	cg19486271	chr11:47235900	DDB2	-0.43	-6.51	-0.34	2.78e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.93	-0.36	2.19e-11	Inflammatory skin disease;
CRC	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.26	0.41	3.5e-15	Corneal astigmatism;
CRC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07701084	chr6:150067640	NUP43	0.5	7.24	0.37	3.15e-12	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19463885	chr2:242626846	DTYMK	0.45	6.34	0.33	7.75e-10	Response to antipsychotic treatment;
CRC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.86	-14.54	-0.63	2.36e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.9	0.55	2.17e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.75	0.39	1.14e-13	Menopause (age at onset);
CRC	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.54	0.38	4.64e-13	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00711773	chr3:40351057	EIF1B	0.41	6.53	0.34	2.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs17155006	0.746	rs402264	chr7:107748337	G/A	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs4074493	1.000	rs10864655	chr1:231172810	A/G	cg22172038	chr1:231176991	FAM89A	0.35	6.03	0.32	4.29e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.56	-8.35	-0.42	1.93e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03640568	chr22:38902623	DDX17	0.44	6.14	0.32	2.34e-9	Response to antipsychotic treatment;
CRC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg01483505	chr11:975446	AP2A2	0.4	6.05	0.32	4e-9	Alzheimer's disease (late onset);
CRC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.39	-0.33	5.68e-10	Tonsillectomy;
CRC	cis	rs9914988	0.667	rs11655019	chr17:27255191	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.49	6.25	0.33	1.27e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14588027	chr1:212872986	BATF3	0.41	6.37	0.33	6.51e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs883565	0.655	rs1608728	chr3:39089560	C/T	cg01426195	chr3:39028469	NA	-0.54	-8.7	-0.43	1.61e-16	Handedness;
CRC	cis	rs9311676	0.656	rs4681679	chr3:58332068	A/G	cg06643156	chr3:58380774	PXK	-0.44	-6.8	-0.35	4.99e-11	Systemic lupus erythematosus;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg15672331	chr15:85923765	AKAP13	0.39	6.16	0.32	2.15e-9	Schizophrenia;
CRC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.67	-12.17	-0.56	2.12e-28	Calcium levels;
CRC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.32	0.56	6.2e-29	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11861986	chr17:3572125	TMEM93;TAX1BP3	0.46	6.46	0.34	3.67e-10	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17047865	chr12:57824889	NA	0.44	6.29	0.33	1.01e-9	Anxiety disorder;
CRC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.67	10.01	0.48	9.22e-21	Menopause (age at onset);
CRC	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg07606381	chr6:8435919	SLC35B3	-0.64	-9.92	-0.48	1.82e-20	Motion sickness;
CRC	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11446398	chr5:77624930	NA	0.42	6.01	0.31	5.01e-9	Triglycerides;
CRC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg01788221	chr16:89496183	ANKRD11	-0.44	-6.81	-0.35	4.6e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg26805224	chr10:79626177	DLG5	-0.56	-8.34	-0.42	2.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-9.53	-0.47	3.66e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg07195577	chr17:27052828	TLCD1	0.42	6.06	0.32	3.63e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.64	-0.39	2.34e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs11212617	0.967	rs227068	chr11:108210109	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.99	0.31	5.41e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg20607287	chr7:12443886	VWDE	-0.48	-6.32	-0.33	8.6e-10	Coronary artery disease;
CRC	cis	rs4880487	0.888	rs10794731	chr10:1251905	T/A	cg03183215	chr10:1252341	ADARB2	-0.3	-6.32	-0.33	8.35e-10	Migraine;
CRC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.75e-11	Body mass index;
CRC	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.31	7.17	0.37	4.98e-12	Corneal astigmatism;
CRC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.77	-0.35	5.76e-11	Response to antipsychotic treatment;
CRC	cis	rs12618769	0.652	rs11537554	chr2:99216531	A/G	cg18455616	chr2:99124870	INPP4A	0.35	5.82	0.31	1.41e-8	Bipolar disorder;
CRC	cis	rs9443189	1.000	rs1280048	chr6:76529583	C/T	cg01950844	chr6:76311363	SENP6	0.58	6.9	0.36	2.63e-11	Prostate cancer;
CRC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	0.97	10.46	0.5	2.7e-22	Diabetic retinopathy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08659621	chr20:48552817	RNF114	0.5	6.51	0.34	2.8e-10	Thyroid stimulating hormone;
CRC	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.61	8.96	0.44	2.39e-17	Corneal astigmatism;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg21251018	chr6:28226885	NKAPL	0.51	6.21	0.32	1.58e-9	Depression;
CRC	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.5	-7.37	-0.38	1.36e-12	Response to antidepressants in depression;
CRC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.74	12.79	0.58	1.1e-30	Menarche (age at onset);
CRC	cis	rs501120	0.584	rs674746	chr10:44733522	A/T	cg09554077	chr10:44749378	NA	0.64	7.06	0.36	9.84e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.65	-10.71	-0.51	3.62e-23	P wave terminal force;
CRC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-18.2	-0.71	1.11e-51	Coronary artery disease;
CRC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg24209194	chr3:40518798	ZNF619	0.39	5.71	0.3	2.48e-8	Renal cell carcinoma;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg02766259	chr12:125626809	AACS	-0.45	-7.72	-0.39	1.42e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.6	-8.08	-0.41	1.22e-14	Waist circumference;Body mass index;
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00815214	chr21:47717953	NA	0.41	6.88	0.35	3.09e-11	Testicular germ cell tumor;
CRC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.68	9.44	0.46	7.19e-19	Bladder cancer;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.54	6.31	0.33	8.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg11843238	chr5:131593191	PDLIM4	-0.43	-7.33	-0.37	1.86e-12	Blood metabolite levels;
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg07404485	chr7:94953653	PON1	0.45	5.88	0.31	9.87e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.44	-7.86	-0.4	5.54e-14	Reticulocyte fraction of red cells;
CRC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.65	-9.06	-0.45	1.17e-17	Platelet count;
CRC	trans	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg05117785	chr10:94050880	CPEB3;MARCH5	0.46	6.07	0.32	3.48e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg21010569	chr2:103233596	NA	0.54	5.91	0.31	8.74e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs11212617	1.000	rs573890	chr11:108251363	C/G	cg01991180	chr11:108092276	ATM;NPAT	-0.39	-5.72	-0.3	2.44e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.64	-7.95	-0.4	2.99e-14	Mean platelet volume;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.73	0.35	7.48e-11	Bipolar disorder;
CRC	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg07513332	chr6:167530253	CCR6	-0.4	-7.14	-0.37	5.84e-12	Primary biliary cholangitis;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.47	5.61	0.3	4.26e-8	Depression;
CRC	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg26248373	chr2:1572462	NA	-0.86	-12.74	-0.57	1.68e-30	IgG glycosylation;
CRC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg23136738	chr11:925521	AP2A2	-0.5	-8.2	-0.41	5.64e-15	Alzheimer's disease (late onset);
CRC	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.92	9.75	0.47	6.58e-20	Gastritis;
CRC	trans	rs17126268	0.502	rs2185428	chr1:102880112	A/C	cg18468354	chr14:36993517	NA	0.38	6.12	0.32	2.65e-9	Glomerular filtration rate;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13770088	chr11:32851361	PRRG4	0.4	6.21	0.32	1.56e-9	Schizophrenia;
CRC	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.58	8.58	0.43	3.93e-16	Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18268492	chr10:99185986	PGAM1	0.39	6.41	0.33	5.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs16852403	0.548	rs2225586	chr1:178204132	C/T	cg00404053	chr1:178313656	RASAL2	0.48	6.35	0.33	7.32e-10	Childhood ear infection;
CRC	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.49	-5.86	-0.31	1.14e-8	Coronary artery calcification;
CRC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.61	0.3	4.23e-8	Homoarginine levels;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg01874867	chr7:94954059	PON1	-0.49	-6.35	-0.33	7e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.04e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.48	6.24	0.33	1.32e-9	Coronary artery disease;
CRC	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.83	-13.54	-0.6	1.73e-33	Hypospadias;
CRC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.17	-0.32	2.05e-9	Aortic root size;
CRC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.6	7.53	0.38	4.86e-13	Dilated cardiomyopathy;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg10708793	chr17:40264626	DHX58	-0.43	-6.35	-0.33	7.2e-10	Birth weight;Height;
CRC	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-8.94	-0.44	2.95e-17	Left ventricular obstructive tract defect (inherited effect);
CRC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17234274	0.644	rs10833967	chr11:23214978	G/A	cg05245346	chr11:23248277	NA	0.36	5.93	0.31	7.53e-9	Cancer;
CRC	cis	rs28489187	0.706	rs66811655	chr1:85831544	T/G	cg17737388	chr1:85724454	C1orf52	0.38	5.7	0.3	2.67e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs758324	0.773	rs10069521	chr5:131174215	A/G	cg25547332	chr5:131281432	NA	0.37	5.86	0.31	1.14e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.43	-6.11	-0.32	2.77e-9	DNA methylation (variation);
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.84e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg04518342	chr5:131593106	PDLIM4	0.46	8.48	0.42	7.92e-16	Breast cancer;
CRC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.93	12.35	0.56	4.81e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.78	0.51	2.09e-23	Cognitive function;
CRC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.8	-14.65	-0.63	9.59e-38	Vitiligo;
CRC	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg23587288	chr2:27483067	SLC30A3	-0.34	-5.75	-0.3	2e-8	Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs4668444	chr2:15515642	C/T	cg19274914	chr2:15703543	NA	0.4	6.03	0.32	4.33e-9	Educational attainment (years of education);
CRC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg03030879	chr14:75389066	RPS6KL1	0.41	5.7	0.3	2.71e-8	Height;
CRC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.33e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.61	9.6	0.47	2.11e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg11522145	chr4:3412961	RGS12	-0.42	-6.42	-0.33	4.87e-10	Serum sulfate level;
CRC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-6.8	-0.35	4.84e-11	Corneal structure;
CRC	trans	rs867743	0.512	rs6471810	chr8:60686056	A/C	cg01502296	chr2:241512254	RNPEPL1	0.44	5.97	0.31	6.23e-9	Schizophrenia;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.68	-7.76	-0.39	1.08e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.62	0.51	7.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	8.16e-11	Blood pressure (smoking interaction);
CRC	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.43	5.93	0.31	7.65e-9	Eye color traits;
CRC	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.87e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.54	7.98	0.4	2.5e-14	Platelet distribution width;
CRC	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.98	12.39	0.56	3.49e-29	Orofacial clefts;
CRC	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.61	-8.32	-0.42	2.45e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg09898070	chr2:48009866	MSH6	0.39	6.43	0.33	4.45e-10	Obesity-related traits;
CRC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.93	-0.36	2.27e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-8.12	-0.41	9.21e-15	Bipolar disorder;
CRC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.25	-0.41	3.89e-15	Chronic sinus infection;
CRC	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.56e-11	Opioid sensitivity;
CRC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.79	0.3	1.6e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.75	14.93	0.64	7.68e-39	Leprosy;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.8	0.3	1.53e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.6	-7.12	-0.37	6.96e-12	Blood protein levels;
CRC	cis	rs9311676	0.632	rs62258129	chr3:58397187	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg10760299	chr15:45669010	GATM	0.52	8.27	0.41	3.39e-15	Homoarginine levels;
CRC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg00620190	chr6:26240307	HIST1H4F	0.48	5.89	0.31	9.69e-9	Gout;Renal underexcretion gout;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.36	0.33	6.66e-10	Depression;
CRC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.43	5.68	0.3	3.01e-8	Heart rate;
CRC	cis	rs6735179	0.958	rs10048704	chr2:1777819	G/C	cg19300414	chr2:1746591	PXDN	0.4	6.63	0.34	1.38e-10	Response to antipsychotic treatment;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg24671235	chr10:45448095	NA	-0.53	-5.99	-0.31	5.38e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.77	0.3	1.8e-8	Parkinson's disease;
CRC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.84	0.51	1.3e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.45	-6.94	-0.36	2.06e-11	Psychosis in Alzheimer's disease;
CRC	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.93	-0.55	1.64e-27	Colorectal cancer;
CRC	trans	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.8	-0.35	4.96e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00767560	chr19:19887256	LOC284440	0.47	6.66	0.34	1.16e-10	Response to antipsychotic treatment;
CRC	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg14673194	chr17:80132900	CCDC57	0.49	6.34	0.33	7.73e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg11553311	chr5:66541588	NA	-0.46	-7.16	-0.37	5.19e-12	Breast cancer;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22194305	chr4:2264032	MXD4	0.55	6.01	0.31	4.97e-9	Interleukin-4 levels;
CRC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.84	-0.31	1.25e-8	Protein biomarker;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.08	-0.32	3.41e-9	Menopause (age at onset);
CRC	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.53	8.68	0.43	1.88e-16	Schizophrenia;
CRC	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-0.65	-5.89	-0.31	9.49e-9	Pediatric areal bone mineral density (radius);
CRC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-6.67	-0.35	1.06e-10	Chronic sinus infection;
CRC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.23	-0.41	4.41e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg09597638	chr17:3907349	NA	0.44	5.66	0.3	3.27e-8	Type 2 diabetes;
CRC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.36	1.32e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.84	-0.35	3.76e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	1.0	11.83	0.55	3.76e-27	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18099408	chr3:52552593	STAB1	-0.52	-9.11	-0.45	8.27e-18	Electroencephalogram traits;
CRC	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.78	15.75	0.66	4.75e-42	Leprosy;
CRC	cis	rs6694672	0.867	rs4915379	chr1:197161428	A/G	cg13682187	chr1:196946512	CFHR5	0.48	8.02	0.4	1.89e-14	Asthma;
CRC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.3	0.42	2.7e-15	Mean corpuscular volume;
CRC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg24881330	chr22:46731750	TRMU	0.67	7.71	0.39	1.55e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.38e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.41	7.55	0.38	4.34e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12292205	chr6:26970375	C6orf41	0.6	6.77	0.35	6.06e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.51	-6.8	-0.35	5.04e-11	Gut microbiome composition (summer);
CRC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.44	6.74	0.35	7.19e-11	Monocyte count;
CRC	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
CRC	cis	rs17152411	1.000	rs733401	chr10:126594158	A/T	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg04498913	chr7:1135747	C7orf50	-0.53	-6.38	-0.33	5.86e-10	Bronchopulmonary dysplasia;
CRC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.42	9.06	0.45	1.23e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg00310523	chr12:86230176	RASSF9	0.45	7.54	0.38	4.49e-13	Major depressive disorder;
CRC	cis	rs747650	0.892	rs7937101	chr11:47226488	A/G	cg03339077	chr11:47165057	C11orf49	0.47	6.83	0.35	4.03e-11	Acne (severe);
CRC	cis	rs6840360	0.606	rs10028035	chr4:152347825	T/G	cg09659197	chr4:152720779	NA	0.34	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.54	10.01	0.48	9.4499999999999992e-21	Eye color traits;
CRC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.5	6.49	0.34	3.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.89	-9.86	-0.48	2.8e-20	Cerebrospinal P-tau181p levels;
CRC	cis	rs6496667	0.865	rs7163144	chr15:90883962	C/T	cg04176472	chr15:90893244	GABARAPL3	0.56	6.49	0.34	3.13e-10	Rheumatoid arthritis;
CRC	cis	rs2949837	0.581	rs2960436	chr7:45977282	G/A	cg04796162	chr7:45961102	IGFBP3	0.4	6.83	0.35	4.07e-11	Sitting height ratio;
CRC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	cis	rs6496667	0.865	rs7163622	chr15:90884791	T/C	cg04176472	chr15:90893244	GABARAPL3	0.55	6.41	0.33	5.18e-10	Rheumatoid arthritis;
CRC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg00343986	chr7:65444356	GUSB	-0.49	-7.25	-0.37	2.93e-12	Aortic root size;
CRC	trans	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg04146151	chr16:2155961	PKD1	-0.46	-5.97	-0.31	6.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg15358701	chr1:161410459	NA	-0.65	-6.88	-0.35	2.96e-11	Rheumatoid arthritis;
CRC	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.41	-6.73	-0.35	7.51e-11	Mean arterial pressure;
CRC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.96e-8	Bladder cancer;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs802075	0.561	rs13198157	chr6:49602760	A/G	cg20364632	chr6:49636226	NA	0.34	5.72	0.3	2.41e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.77	-0.35	5.9e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs16975963	0.843	rs17249047	chr19:38336563	A/G	cg15135657	chr19:38346511	NA	-0.42	-5.72	-0.3	2.34e-8	Longevity;
CRC	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.46	6.8	0.35	4.96e-11	Carotid intima media thickness;
CRC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.48	0.42	7.63e-16	Retinal vascular caliber;
CRC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-7.99	-0.4	2.33e-14	Menarche (age at onset);
CRC	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg00666640	chr1:248458726	OR2T12	0.47	7.96	0.4	2.88e-14	Common traits (Other);
CRC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.84	0.44	5.84e-17	Hip circumference adjusted for BMI;
CRC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.74	-0.35	7.01e-11	Neuroticism;
CRC	cis	rs4363385	0.747	rs2339490	chr1:152984612	A/G	cg25856811	chr1:152973957	SPRR3	0.26	7.05	0.36	1.05e-11	Inflammatory skin disease;
CRC	cis	rs10046574	0.831	rs10276768	chr7:135064346	A/G	cg27474649	chr7:135195673	CNOT4	0.68	5.72	0.3	2.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00021576	chr1:244211966	NA	0.4	6.75	0.35	6.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.47	7.67	0.39	1.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9928842	0.882	rs3169330	chr16:75269267	A/G	cg08657710	chr16:75258780	CTRB1	-0.59	-6.9	-0.36	2.72e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.82e-9	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10145211	chr11:64885345	ZNHIT2	0.42	6.07	0.32	3.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.74	10.46	0.5	2.8e-22	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15260519	chr4:187113285	CYP4V2	0.44	6.17	0.32	1.99e-9	Response to antipsychotic treatment;
CRC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.63	12.4	0.56	3.23e-29	Coronary artery disease;
CRC	cis	rs755249	0.532	rs61779277	chr1:39833535	G/A	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.74	0.43	1.18e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.53	-7.23	-0.37	3.34e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18099408	chr3:52552593	STAB1	-0.52	-9.01	-0.44	1.69e-17	Electroencephalogram traits;
CRC	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.06e-12	HDL cholesterol;
CRC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg02007433	chr3:129722099	NA	-0.46	-6.25	-0.33	1.3e-9	Blood pressure (smoking interaction);
CRC	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.94	0.36	2.06e-11	Response to antipsychotic treatment;
CRC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.96	-0.31	6.52e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs41271951	0.512	rs41266632	chr1:151042980	C/T	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.73	-0.3	2.3e-8	Blood protein levels;
CRC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.15	0.45	6.1e-18	Bladder cancer;
CRC	cis	rs35883536	0.967	rs1855788	chr1:101118331	A/G	cg14515779	chr1:101123966	NA	-0.42	-8.12	-0.41	9.57e-15	Monocyte count;
CRC	cis	rs10919791	0.501	rs12024418	chr1:199916164	T/C	cg07208853	chr1:200005219	NR5A2	0.24	6.04	0.32	4.09e-9	Pancreatic cancer;
CRC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.89	-0.31	9.42e-9	Obesity-related traits;
CRC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.36	0.53	1.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.49	-7.15	-0.37	5.55e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs13315871	1.000	rs28626602	chr3:58409786	G/C	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs7517126	0.920	rs7552547	chr1:196836999	T/G	cg13682187	chr1:196946512	CFHR5	-0.37	-5.98	-0.31	5.67e-9	Blood protein levels;
CRC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-11.11	-0.52	1.43e-24	Total body bone mineral density;
CRC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.58	-0.39	3.52e-13	Coronary artery disease;
CRC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg21466736	chr12:48725269	NA	-0.51	-8.01	-0.4	2.01e-14	Plateletcrit;
CRC	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	1.09	19.01	0.72	7e-55	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22691505	chr7:6312217	CYTH3	0.38	6.07	0.32	3.51e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.91	0.44	3.63e-17	Morning vs. evening chronotype;
CRC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.23	-0.37	3.38e-12	Aortic root size;
CRC	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-8.51	-0.42	6.25e-16	Electroencephalogram traits;
CRC	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.61	7.13	0.37	6.38e-12	Coronary artery disease;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.5	5.92	0.31	7.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2303319	0.504	rs12467662	chr2:162386784	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	trans	rs10242455	0.867	rs3735453	chr7:99229435	C/T	cg09045935	chr12:6379348	NA	-0.55	-6.1	-0.32	3.01e-9	Blood metabolite levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12296218	chr15:48624389	DUT	0.45	6.25	0.33	1.27e-9	Anxiety disorder;
CRC	cis	rs11212617	0.967	rs583725	chr11:108165075	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.16	0.32	2.08e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg02158880	chr13:53174818	NA	0.49	6.82	0.35	4.26e-11	Lewy body disease;
CRC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.76	-0.39	1.08e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.47	6.52	0.34	2.61e-10	Response to antipsychotic treatment;
CRC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.58	9.76	0.47	6.18e-20	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.95	-0.4	3e-14	Total body bone mineral density;
CRC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.5	6.8	0.35	4.92e-11	Resistin levels;
CRC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg06287003	chr12:125626642	AACS	-0.5	-7.44	-0.38	9.1e-13	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19787033	chr11:77850962	ALG8	0.47	6.45	0.34	4e-10	Thyroid stimulating hormone;
CRC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg07636037	chr3:49044803	WDR6	-0.82	-6.67	-0.35	1.08e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.52	9.17	0.45	5.33e-18	Hypertriglyceridemia;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.75	-8.96	-0.44	2.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.14	26.91	0.83	3.96e-85	Testicular germ cell tumor;
CRC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.17e-8	Heart rate;
CRC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00794927	chr19:17187156	MYO9B;HAUS8	0.4	6.06	0.32	3.66e-9	Schizophrenia;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.37	6.16	0.32	2.12e-9	Mean arterial pressure;
CRC	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.81	14.07	0.61	1.53e-35	Hip circumference;
CRC	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	7.87	0.4	5.17e-14	Blood metabolite levels;
CRC	cis	rs1062746	0.528	rs11646030	chr16:87339278	T/C	cg02258303	chr16:87377426	FBXO31	-0.54	-7.87	-0.4	5.28e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7725052	0.609	rs10941507	chr5:40458916	T/C	cg09067459	chr5:40385259	NA	-0.4	-6.63	-0.34	1.4e-10	Pediatric autoimmune diseases;
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-6.91	-0.36	2.51e-11	Bipolar disorder;
CRC	trans	rs4276421	0.806	rs34666220	chr5:45435986	T/A	cg04793272	chr11:119020941	ABCG4	-0.38	-6.29	-0.33	1.02e-9	P wave duration;
CRC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.49	6.57	0.34	1.98e-10	Schizophrenia;
CRC	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.4	-6.06	-0.32	3.76e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.14e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg15744005	chr10:104629667	AS3MT	0.33	7.02	0.36	1.31e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7605827	0.930	rs2111453	chr2:15673248	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.97e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.36	-5.73	-0.3	2.25e-8	Ulcerative colitis;
CRC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.65	-9.92	-0.48	1.8899999999999998e-20	Testicular germ cell tumor;
CRC	cis	rs10911390	0.793	rs12040054	chr1:183639566	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Systemic lupus erythematosus;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27138088	chr11:842605	TSPAN4;POLR2L	-0.42	-6.51	-0.34	2.86e-10	Myopia (pathological);
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.3	0.53	2.97e-25	Prudent dietary pattern;
CRC	cis	rs34638657	0.518	rs7196560	chr16:82168162	A/T	cg07918374	chr16:82182319	MPHOSPH6	0.44	6.32	0.33	8.45e-10	Lung adenocarcinoma;
CRC	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.37	5.66	0.3	3.24e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg03609598	chr5:56110824	MAP3K1	0.59	8.1	0.41	1.09e-14	Initial pursuit acceleration;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg27049318	chr5:68514098	MRPS36	-0.59	-6.04	-0.32	4.07e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg05468064	chr22:46423449	NA	0.33	5.85	0.31	1.19e-8	Dupuytren's disease;Subjective well-being;
CRC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.48	-7.27	-0.37	2.61e-12	Corneal astigmatism;
CRC	cis	rs863345	0.604	rs1342954	chr1:158464548	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.35	-0.33	7.19e-10	Pneumococcal bacteremia;
CRC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.42	-6.09	-0.32	3.17e-9	Renal cell carcinoma;
CRC	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.38	6.11	0.32	2.86e-9	Sitting height ratio;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.75	10.75	0.51	2.64e-23	High light scatter reticulocyte count;
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg27432699	chr2:27873401	GPN1	-0.62	-9.48	-0.46	5.39e-19	Total body bone mineral density;
CRC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg20119798	chr7:94954144	PON1	-0.47	-5.88	-0.31	9.89e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.65	10.11	0.49	4.26e-21	Lymphocyte counts;
CRC	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.84	-12.73	-0.57	1.79e-30	Blood metabolite levels;
CRC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.74	-0.39	1.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.54	6.82	0.35	4.35e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.74	8.73	0.43	1.32e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.42	0.53	1.14e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06505273	chr16:24850292	NA	0.52	6.76	0.35	6.45e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.46	7.33	0.37	1.85e-12	Height;
CRC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.55	6.15	0.32	2.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2882667	0.690	rs274117	chr5:138065048	A/G	cg09476006	chr5:138032270	NA	0.58	10.42	0.5	3.74e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04923576	chr1:39956807	BMP8A	0.37	6.15	0.32	2.24e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.47	6.07	0.32	3.48e-9	Response to diuretic therapy;
CRC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.5	6.54	0.34	2.38e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.51	-0.34	2.82e-10	Coronary artery calcification;
CRC	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.38	-6.36	-0.33	6.87e-10	Mean arterial pressure;
CRC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.05	13.41	0.59	5.39e-33	Vitiligo;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08721347	chr1:95538652	ALG14	0.53	6.89	0.36	2.85e-11	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg03037974	chr15:76606532	NA	-0.52	-7.92	-0.4	3.64e-14	Blood metabolite levels;
CRC	cis	rs4141404	0.787	rs11913992	chr22:31585220	G/A	cg22777020	chr22:31556080	RNF185	-0.45	-5.86	-0.31	1.14e-8	Paclitaxel-induced neuropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09775628	chr19:1479573	C19orf25	0.42	6.85	0.35	3.65e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.42	6.48	0.34	3.34e-10	Ovarian reserve;
CRC	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.96	-0.31	6.58e-9	Metabolite levels;
CRC	cis	rs4700695	0.698	rs416369	chr5:65231058	C/T	cg21114390	chr5:65439923	SFRS12	0.5	6.18	0.32	1.95e-9	Facial morphology (factor 19);
CRC	cis	rs231513	0.813	rs231495	chr17:41976748	G/C	cg26893861	chr17:41843967	DUSP3	-0.63	-6.36	-0.33	6.63e-10	Cognitive function;
CRC	cis	rs6834538	0.520	rs7662311	chr4:113420584	G/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.8	-0.3	1.55e-8	Free thyroxine concentration;
CRC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	0.98	10.17	0.49	2.64e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.55	7.53	0.38	4.97e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16447950	chr5:562315	NA	-0.77	-10.08	-0.49	5.3e-21	Obesity-related traits;
CRC	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg14036092	chr11:66035641	RAB1B	-0.47	-5.74	-0.3	2.1e-8	Electroencephalogram traits;
CRC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-1.03	-13.2	-0.59	3.23e-32	Vitiligo;
CRC	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg05562828	chr17:3906858	NA	0.73	13.97	0.61	3.88e-35	Type 2 diabetes;
CRC	cis	rs9491140	0.539	rs980657	chr6:124690330	C/T	cg05308643	chr6:124982296	NKAIN2	0.47	6.57	0.34	1.98e-10	Neuroticism;
CRC	cis	rs4731207	0.596	rs10954062	chr7:124636460	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.26	-0.33	1.17e-9	Cutaneous malignant melanoma;
CRC	trans	rs1578862	0.901	rs2211273	chr1:247433959	A/G	cg06850283	chr5:44389769	FGF10	0.25	5.98	0.31	5.73e-9	Monocyte percentage of white cells;
CRC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs12476592	0.602	rs989527	chr2:63726791	G/T	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs972578	0.747	rs5758977	chr22:43236128	A/G	cg01576275	chr22:43409880	NA	-0.39	-6.08	-0.32	3.33e-9	Mean platelet volume;
CRC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.41	-5.68	-0.3	2.93e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12580194	1.000	rs73118926	chr12:55703335	A/G	cg19537932	chr12:55886519	OR6C68	-0.55	-6.37	-0.33	6.35e-10	Cancer;
CRC	cis	rs11212617	0.875	rs228597	chr11:108107009	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.7e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.32e-17	Bipolar disorder;
CRC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.52	7.75	0.39	1.14e-13	High light scatter reticulocyte count;
CRC	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.64	-7.51	-0.38	5.44e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg17724175	chr1:150552817	MCL1	0.51	7.5	0.38	6.07e-13	Melanoma;
CRC	trans	rs2303319	0.504	rs62187571	chr2:162374319	A/G	cg27113153	chr11:123612418	ZNF202	-0.72	-6.17	-0.32	1.96e-9	Cognitive function;
CRC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.6	-11.27	-0.53	3.97e-25	Educational attainment;
CRC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.53	0.38	4.88e-13	Menopause (age at onset);
CRC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.93	0.58	3.33e-31	Platelet count;
CRC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.49	7.1	0.36	7.66e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs11229555	0.645	rs12794534	chr11:58179568	C/A	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.36	0.46	1.32e-18	Blood protein levels;
CRC	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.38	12.69	0.57	2.63e-30	Granulocyte percentage of myeloid white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17861791	chr1:113162073	ST7L;CAPZA1	0.43	6.3	0.33	9.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg17328964	chr8:145687451	CYHR1	0.45	7.29	0.37	2.33e-12	Age at first birth;
CRC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18052984	chr12:51158439	ATF1	0.38	6.01	0.31	4.84e-9	Obesity-related traits;
CRC	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.63	8.94	0.44	2.78e-17	Psoriasis;
CRC	cis	rs427941	0.632	rs201469	chr7:101743932	C/G	cg06246474	chr7:101738831	CUX1	0.43	6.68	0.35	1.01e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	13.59	0.6	1.09e-33	Menopause (age at onset);
CRC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.65	9.47	0.46	5.59e-19	Subjective well-being;
CRC	cis	rs938554	0.826	rs7376960	chr4:9970570	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.02	-0.31	4.72e-9	Blood metabolite levels;
CRC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg25452165	chr22:42524984	CYP2D6	0.39	5.92	0.31	7.9e-9	Schizophrenia;
CRC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.58	5.84	0.31	1.29e-8	Obesity-related traits;
CRC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.66	8.78	0.44	9.08e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.39	6.0	0.31	5.17e-9	Hemoglobin concentration;
CRC	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.81	0.4	7.49e-14	Testicular germ cell tumor;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg22638593	chr5:131593259	PDLIM4	0.38	6.99	0.36	1.58e-11	Breast cancer;
CRC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.51	-7.04	-0.36	1.09e-11	Lymphocyte counts;
CRC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg20387954	chr3:183756860	HTR3D	0.46	7.74	0.39	1.26e-13	Anterior chamber depth;
CRC	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.44	0.46	7.24e-19	Blood protein levels;
CRC	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg07166546	chr14:35805898	NA	-0.3	-5.88	-0.31	9.97e-9	Psoriasis;
CRC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg03037974	chr15:76606532	NA	0.84	17.06	0.69	3.43e-47	Blood metabolite levels;
CRC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg24562669	chr7:97807699	LMTK2	-0.64	-12.0	-0.55	9.15e-28	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22435982	chr17:42441259	FAM171A2	0.45	6.11	0.32	2.74e-9	Anxiety disorder;
CRC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg19824325	chr16:58548873	SETD6	1.0	6.84	0.35	3.87e-11	Schizophrenia;
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg15962314	chr1:44399869	ARTN	0.31	6.03	0.32	4.31e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg21251018	chr6:28226885	NKAPL	0.46	6.56	0.34	2.04e-10	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	10.65	0.51	5.96e-23	Motion sickness;
CRC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.48	-6.39	-0.33	5.8e-10	Urate levels;
CRC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.82	0.44	6.6e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.46	6.26	0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00006884	chr7:23637030	CCDC126	0.46	6.39	0.33	5.51e-10	Response to antipsychotic treatment;
CRC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.61	7.01	0.36	1.34e-11	Height;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10955293	chr1:24117561	LYPLA2	0.42	6.55	0.34	2.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg16898833	chr6:26189333	HIST1H4D	0.77	6.47	0.34	3.51e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.16	0.32	2.14e-9	Self-reported allergy;
CRC	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg27398640	chr15:77910606	LINGO1	-0.45	-8.08	-0.41	1.22e-14	Type 2 diabetes;
CRC	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg16898833	chr6:26189333	HIST1H4D	0.63	5.78	0.3	1.77e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg11189052	chr15:85197271	WDR73	0.55	7.22	0.37	3.64e-12	Schizophrenia;
CRC	cis	rs7605827	0.930	rs1997305	chr2:15512383	T/C	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.36e-9	Educational attainment (years of education);
CRC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg00409905	chr10:38381863	ZNF37A	0.49	6.79	0.35	5.13e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg26043149	chr18:55253948	FECH	0.46	6.94	0.36	2.13e-11	Bone mineral density;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg02683197	chr6:28174875	NA	0.57	7.53	0.38	5.05e-13	Parkinson's disease;
CRC	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.77	10.14	0.49	3.42e-21	Bipolar disorder;
CRC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.38	5.87	0.31	1.04e-8	Lung cancer;
CRC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.59	-7.38	-0.38	1.3e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.54e-9	Arsenic metabolism;
CRC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.81	0.31	1.47e-8	Melanoma;
CRC	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.59	0.39	3.41e-13	Neuroticism;
CRC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.45	6.99	0.36	1.52e-11	Height;
CRC	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.95	12.02	0.55	7.47e-28	Exhaled nitric oxide levels;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	8.93	0.44	2.97e-17	Breast cancer;
CRC	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07165851	chr6:158734300	TULP4	-0.63	-7.93	-0.4	3.39e-14	Height;
CRC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg21153622	chr11:89784906	NA	-0.43	-6.88	-0.35	3.09e-11	Coronary artery disease;
CRC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg21153622	chr11:89784906	NA	-0.55	-9.28	-0.46	2.32e-18	Coronary artery disease;
CRC	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.57	0.63	1.8e-37	Hypertriglyceridemia;
CRC	cis	rs6460942	0.908	rs6978768	chr7:12232366	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.01	-0.31	4.8e-9	Coronary artery disease;
CRC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg23018236	chr17:30244563	NA	-0.65	-7.69	-0.39	1.73e-13	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.75	-0.35	6.53e-11	Height;
CRC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.44	9.68	0.47	1.12e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg03885332	chr11:832357	CD151	-0.42	-6.21	-0.32	1.59e-9	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02290350	chr8:58132656	NA	-0.61	-7.33	-0.37	1.81e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.41	0.33	5.11e-10	Heart rate;
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg06713098	chr7:45960367	IGFBP3	0.42	6.66	0.34	1.13e-10	Sitting height ratio;
CRC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg17298326	chr8:142245477	NA	0.37	5.65	0.3	3.49e-8	Immature fraction of reticulocytes;
CRC	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg13615338	chr4:55094005	PDGFRA	0.4	5.8	0.3	1.57e-8	Corneal astigmatism;
CRC	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.5	-7.12	-0.37	6.65e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.86	-15.06	-0.64	2.34e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17155006	0.655	rs430995	chr7:107727501	G/T	cg05962710	chr7:107745446	LAMB4	-0.34	-5.74	-0.3	2.13e-8	Pneumococcal bacteremia;
CRC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.15	-0.37	5.65e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg06138931	chr13:21896616	NA	0.56	7.14	0.37	6.03e-12	White matter hyperintensity burden;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg18758796	chr5:131593413	PDLIM4	0.4	6.46	0.34	3.83e-10	Acylcarnitine levels;
CRC	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.11	0.56	3.56e-28	Exhaled nitric oxide levels;
CRC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg11752832	chr7:134001865	SLC35B4	0.38	5.63	0.3	3.85e-8	Mean platelet volume;
CRC	cis	rs1403694	0.734	rs266723	chr3:186447047	A/C	cg04611788	chr3:186434169	KNG1	-0.45	-6.66	-0.34	1.14e-10	Blood protein levels;
CRC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.64	10.62	0.51	7.3e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-7.95	-0.4	2.95e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs12612619	0.732	rs1866654	chr2:27263122	A/G	cg00617064	chr2:27272375	NA	-0.42	-7.03	-0.36	1.22e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg03316587	chr8:142245164	NA	-0.4	-6.04	-0.32	4.16e-9	Immature fraction of reticulocytes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05513509	chr18:20513742	RBBP8	-0.44	-6.56	-0.34	2.06e-10	Myopia (pathological);
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg08354699	chr15:63796895	USP3	0.43	6.29	0.33	1.03e-9	Monocyte count;
CRC	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg25809561	chr17:30822961	MYO1D	0.51	9.18	0.45	5.03e-18	Schizophrenia;
CRC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.45	-7.47	-0.38	7.11e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg09655341	chr17:79618100	PDE6G	0.36	6.11	0.32	2.89e-9	Eye color traits;
CRC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg14671364	chr1:107599128	PRMT6	0.45	5.99	0.31	5.5e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg22535103	chr8:58192502	C8orf71	-0.44	-5.77	-0.3	1.85e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.55	8.26	0.41	3.58e-15	Blood protein levels;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg22079747	chr2:228736145	WDR69	-0.4	-5.72	-0.3	2.34e-8	Blood pressure;
CRC	cis	rs67981189	0.529	rs2810096	chr14:71435300	A/G	cg15910301	chr14:71632612	NA	-0.28	-5.67	-0.3	3.18e-8	Schizophrenia;
CRC	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.49	7.8	0.4	8.16e-14	Monocyte percentage of white cells;
CRC	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.67	0.35	1.06e-10	Corneal astigmatism;
CRC	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	ch.8.33884649F	chr8:33765107	NA	0.41	6.02	0.31	4.73e-9	Body mass index;
CRC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.24	0.33	1.33e-9	Mean platelet volume;
CRC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.32	-5.78	-0.3	1.75e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg04586622	chr2:25135609	ADCY3	-0.56	-10.38	-0.5	4.92e-22	Body mass index in non-asthmatics;
CRC	cis	rs1322512	0.760	rs2038615	chr6:152927267	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.11	0.32	2.76e-9	Tonometry;
CRC	cis	rs3790645	1.000	rs188158	chr1:26898142	A/G	cg23229016	chr1:26872525	RPS6KA1	0.25	5.96	0.31	6.66e-9	Glucose homeostasis traits;
CRC	cis	rs12550646	0.585	rs74887565	chr8:41681935	T/C	cg12180191	chr8:41686706	ANK1	-0.44	-6.29	-0.33	1.01e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg21665744	chr7:39171113	POU6F2	0.44	5.9	0.31	9.26e-9	IgG glycosylation;
CRC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs516243	0.841	rs6540944	chr1:10740405	C/T	cg02903756	chr1:10750680	CASZ1	-0.5	-8.76	-0.44	1.02e-16	Migraine - clinic-based;
CRC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.55	7.8	0.39	8.41e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	11.24	0.53	5.16e-25	Motion sickness;
CRC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.6	7.28	0.37	2.53e-12	Mean platelet volume;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25794979	chr16:2732314	KCTD5	-0.38	-5.97	-0.31	6.05e-9	Aortic root size;
CRC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.42	-7.04	-0.36	1.1e-11	Breast cancer;
CRC	cis	rs2882667	0.556	rs6873733	chr5:138403317	G/T	cg09476006	chr5:138032270	NA	0.36	6.0	0.31	5.24e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21643547	chr1:205240462	TMCC2	-0.47	-7.8	-0.4	8.33e-14	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.52	8.02	0.4	1.88e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01173912	chr12:1771358	NA	0.47	6.49	0.34	3.23e-10	Response to antipsychotic treatment;
CRC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.59	8.28	0.42	3.08e-15	Homoarginine levels;
CRC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.04	0.48	7.2e-21	Platelet count;
CRC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.53	6.76	0.35	6.43e-11	Morning vs. evening chronotype;
CRC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.53	-8.47	-0.42	8.09e-16	Breast cancer;
CRC	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg06632207	chr12:54070931	ATP5G2	0.37	6.52	0.34	2.67e-10	Height;
CRC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.17	0.49	2.66e-21	Platelet count;
CRC	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.74	9.8	0.48	4.62e-20	Prostate cancer;
CRC	cis	rs185694	1.000	rs202101	chr13:30897337	A/G	cg07600127	chr13:30881527	KATNAL1	-0.57	-5.99	-0.31	5.65e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.93	-0.55	1.67e-27	Alzheimer's disease;
CRC	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.44	-0.38	8.92e-13	Height;
CRC	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg19812747	chr11:111475976	SIK2	0.46	7.22	0.37	3.58e-12	Primary sclerosing cholangitis;
CRC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	11.94	0.55	1.48e-27	Platelet count;
CRC	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12560992	chr17:57184187	TRIM37	0.53	7.31	0.37	1.99e-12	Testicular germ cell tumor;
CRC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-6.56	-0.34	2.08e-10	Schizophrenia;
CRC	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.94	-15.18	-0.64	8.33e-40	Dupuytren's disease;
CRC	cis	rs4601821	0.895	rs2155464	chr11:113242448	T/C	cg14159747	chr11:113255604	NA	0.5	9.07	0.45	1.09e-17	Alcoholic chronic pancreatitis;
CRC	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs11958404	0.932	rs113264420	chr5:157437779	T/C	cg05962755	chr5:157440814	NA	0.95	12.34	0.56	5.17e-29	IgG glycosylation;
CRC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.64	-0.3	3.72e-8	Breast cancer;
CRC	cis	rs995000	0.931	rs61471917	chr1:63084030	G/A	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.56	8.43	0.42	1.12e-15	Inflammatory bowel disease;
CRC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg18876405	chr7:65276391	NA	0.45	6.17	0.32	1.96e-9	Aortic root size;
CRC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.79	-12.36	-0.56	4.49e-29	Multiple myeloma;
CRC	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg01339444	chr6:118972232	C6orf204	0.54	5.98	0.31	5.97e-9	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17825989	chr6:155635201	TFB1M	0.44	7.29	0.37	2.27e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.44	-6.4	-0.33	5.35e-10	Longevity;
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-6.25	-0.33	1.25e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.74	-11.85	-0.55	3.25e-27	Mean platelet volume;
CRC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.51	6.06	0.32	3.79e-9	Vitiligo;
CRC	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg09184832	chr6:79620586	NA	-0.45	-7.71	-0.39	1.52e-13	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.49	-0.38	6.2e-13	HDL cholesterol;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg19041857	chr6:27730383	NA	-0.73	-7.16	-0.37	5.2e-12	Depression;
CRC	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.37	6.29	0.33	1.01e-9	Testicular germ cell tumor;
CRC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.53	6.66	0.34	1.18e-10	Methadone dose in opioid dependence;
CRC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-5.81	-0.31	1.44e-8	Major depressive disorder;
CRC	cis	rs73200209	0.744	rs55819608	chr12:116578300	C/T	cg01776926	chr12:116560359	MED13L	-0.57	-6.28	-0.33	1.06e-9	Total body bone mineral density;
CRC	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.37	-5.84	-0.31	1.24e-8	Height;
CRC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.51	7.89	0.4	4.65e-14	Height;
CRC	cis	rs9847710	0.967	rs2244552	chr3:53055522	A/G	cg04503182	chr3:53078218	SFMBT1	0.41	6.55	0.34	2.16e-10	Ulcerative colitis;
CRC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-14.5	-0.62	3.48e-37	Blood metabolite levels;
CRC	cis	rs2625529	0.617	rs3784313	chr15:72187519	G/T	cg16672083	chr15:72433130	SENP8	0.47	7.18	0.37	4.54e-12	Red blood cell count;
CRC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14640386	chr17:5185735	RABEP1	0.38	6.25	0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-7.43	-0.38	9.58e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.74	-10.57	-0.5	1.09e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	8.73	0.43	1.3e-16	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.48	-0.38	6.72e-13	QT interval;
CRC	trans	rs800082	0.507	rs1121562	chr3:144259665	A/G	cg24215973	chr2:240111563	HDAC4	0.44	6.17	0.32	2.04e-9	Smoking behavior;
CRC	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	6.65	0.34	1.25e-10	Mean corpuscular volume;
CRC	cis	rs7605827	0.897	rs1468912	chr2:15662922	A/G	cg19274914	chr2:15703543	NA	0.39	5.84	0.31	1.23e-8	Educational attainment (years of education);
CRC	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.58	8.66	0.43	2.18e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.29	6.07	0.32	3.56e-9	Height;
CRC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.54	-0.43	5.22e-16	Monocyte count;
CRC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.43	5.6	0.3	4.52e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4663866	0.803	rs71426511	chr2:239180200	G/A	cg16914508	chr2:239161102	PER2	0.77	7.79	0.39	8.63e-14	Irritable bowel syndrome;
CRC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-8.95	-0.44	2.61e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.46	-0.34	3.75e-10	Aortic root size;
CRC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.37	-5.67	-0.3	3.18e-8	Crohn's disease;
CRC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2735413	0.914	rs2262658	chr16:78060267	A/G	cg04733911	chr16:78082701	NA	-0.37	-6.01	-0.31	4.89e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs6693295	0.711	rs4417032	chr1:246226428	G/A	cg03680032	chr11:94965610	SESN3	0.46	5.99	0.31	5.35e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg07052231	chr12:7363540	PEX5	0.52	8.4	0.42	1.39e-15	IgG glycosylation;
CRC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg13385794	chr1:248469461	NA	-0.38	-6.67	-0.35	1.07e-10	Common traits (Other);
CRC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg18512352	chr11:47633146	NA	-0.35	-6.74	-0.35	6.9e-11	Subjective well-being;
CRC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	9.06	0.45	1.2e-17	Colorectal cancer;
CRC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg04545296	chr12:48745243	ZNF641	0.36	6.18	0.32	1.85e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.54	-8.21	-0.41	5.1e-15	Monocyte count;
CRC	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.58	-9.22	-0.45	3.57e-18	Breast cancer;
CRC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg18876405	chr7:65276391	NA	0.46	6.45	0.34	3.96e-10	Aortic root size;
CRC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	11.79	0.54	5.38e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.43	-0.46	7.78e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.93	11.21	0.53	6.41e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.6	-7.41	-0.38	1.1e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs7845127	0.635	rs7357551	chr8:18142268	A/C	cg26673070	chr14:71828969	NA	0.51	6.01	0.31	4.92e-9	Night sleep phenotypes;
CRC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg05044414	chr3:183734942	ABCC5	0.48	8.26	0.41	3.58e-15	Anterior chamber depth;
CRC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg18761221	chr20:60518478	NA	0.45	7.21	0.37	3.8e-12	Body mass index;
CRC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.58	8.17	0.41	6.91e-15	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.51	13.3	0.59	1.33e-32	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg16606324	chr3:10149918	C3orf24	0.69	9.77	0.47	5.84e-20	Alzheimer's disease;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg15786705	chr6:28176104	NA	0.78	9.7	0.47	1.01e-19	Depression;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg04827747	chr7:134855666	C7orf49	0.42	6.04	0.32	4.24e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	7.15	0.37	5.62e-12	Schizophrenia;
CRC	cis	rs812925	0.537	rs2463097	chr2:61614301	G/C	cg10580144	chr2:61372316	C2orf74	-0.33	-7.18	-0.37	4.56e-12	Immature fraction of reticulocytes;
CRC	cis	rs17065868	0.764	rs73188732	chr13:45031653	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg26587870	chr6:27730563	NA	-0.54	-6.09	-0.32	3.1e-9	Lung cancer in ever smokers;
CRC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.23	-0.33	1.39e-9	Breast cancer;
CRC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg19980929	chr12:42632907	YAF2	-0.4	-6.19	-0.32	1.82e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.75	8.87	0.44	4.69e-17	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00930347	chr6:110012366	AKD1;FIG4	0.48	6.17	0.32	2.01e-9	Thyroid stimulating hormone;
CRC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg09829573	chr1:144692074	NBPF9	0.42	6.17	0.32	1.97e-9	Hip geometry;
CRC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.47	-7.25	-0.37	2.95e-12	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10660249	chr9:5833007	ERMP1	0.46	6.54	0.34	2.3e-10	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg03013999	chr17:37608204	MED1	-0.48	-7.35	-0.38	1.56e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs12230513	0.732	rs61956358	chr12:55852286	G/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.37	-0.46	1.17e-18	Contrast sensitivity;
CRC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.73	12.5	0.57	1.29e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7172809	0.796	rs4886870	chr15:77827471	A/C	cg10437265	chr15:77819839	NA	-0.4	-6.75	-0.35	6.52e-11	Glucose homeostasis traits;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg15511327	chr8:143859410	LYNX1	-0.39	-6.06	-0.32	3.74e-9	Urinary tract infection frequency;
CRC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.59	-9.64	-0.47	1.59e-19	Personality dimensions;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23392782	chr16:88772647	RNF166;CTU2	-0.6	-7.58	-0.39	3.59e-13	Diisocyanate-induced asthma;
CRC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17507749	chr15:85114479	UBE2QP1	0.62	8.8	0.44	7.93e-17	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09955859	chr1:40626914	RLF	0.53	7.68	0.39	1.89e-13	Response to antipsychotic treatment;
CRC	cis	rs4728142	0.584	rs7796963	chr7:128629001	T/C	cg06630958	chr7:128577819	IRF5	-0.35	-5.65	-0.3	3.55e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08301941	chr17:42148070	G6PC3	0.45	6.45	0.34	3.99e-10	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg19812747	chr11:111475976	SIK2	0.52	8.64	0.43	2.47e-16	Primary sclerosing cholangitis;
CRC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.8	0.3	1.56e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg14427527	chr5:176793960	RGS14	0.38	5.62	0.3	4.12e-8	Hemoglobin concentration;Hematocrit;
CRC	trans	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg14318858	chr19:50204862	CPT1C	-0.37	-6.04	-0.32	4.26e-9	Schizophrenia;
CRC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.49	8.87	0.44	4.69e-17	Birth weight;
CRC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.16	0.41	7.42e-15	Platelet count;
CRC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg18490616	chr2:88469792	THNSL2	-0.42	-6.12	-0.32	2.64e-9	Response to metformin (IC50);
CRC	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.69	-0.39	1.76e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.56e-12	Obesity-related traits;
CRC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07191003	chr1:1334791	CCNL2;LOC148413	0.46	6.17	0.32	1.96e-9	Anxiety disorder;
CRC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-11.92	-0.55	1.86e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.62	9.27	0.46	2.44e-18	Subjective well-being;
CRC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.69	-8.75	-0.43	1.11e-16	Skin colour saturation;
CRC	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg02811702	chr13:24901961	NA	0.41	5.73	0.3	2.33e-8	Obesity-related traits;
CRC	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	0.97	13.29	0.59	1.43e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.78	12.74	0.57	1.78e-30	Longevity;Endometriosis;
CRC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.81	-0.35	4.6e-11	Blood metabolite levels;
CRC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.72	9.93	0.48	1.66e-20	Heart rate;
CRC	cis	rs7487075	0.786	rs11183441	chr12:46715920	G/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.54	0.34	2.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.78	-0.44	9.17e-17	Cerebrospinal fluid biomarker levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26462404	chr19:2270807	OAZ1	0.45	6.34	0.33	7.52e-10	Response to antipsychotic treatment;
CRC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg16989719	chr2:238392110	NA	-0.46	-8.48	-0.42	7.82e-16	Prostate cancer;
CRC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg11189052	chr15:85197271	WDR73	0.65	9.32	0.46	1.75e-18	Schizophrenia;
CRC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.77	-0.44	9.74e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12024301	0.557	rs12032504	chr1:183602308	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.74	-6.53	-0.34	2.51e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs6546324	0.625	rs2861703	chr2:67861053	T/C	cg00907274	chr3:27498161	SLC4A7	-0.48	-6.11	-0.32	2.85e-9	Endometriosis;
CRC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.5	6.43	0.33	4.49e-10	Longevity;
CRC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg07074390	chr21:40555500	PSMG1	-0.45	-5.98	-0.31	5.86e-9	Cognitive function;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.86	-0.4	5.36e-14	Total body bone mineral density;
CRC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.39	-6.11	-0.32	2.85e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	1.24	14.35	0.62	1.29e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.67	5.73	0.3	2.3e-8	Depression;
CRC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12463550	chr7:65579703	CRCP	0.73	6.54	0.34	2.35e-10	Diabetic kidney disease;
CRC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg03929089	chr4:120376271	NA	-0.47	-6.72	-0.35	7.83e-11	HDL cholesterol;
CRC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg26695010	chr11:65641043	EFEMP2	-0.39	-5.95	-0.31	6.93e-9	Eosinophil percentage of white cells;
CRC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg15845792	chr6:28175446	NA	0.43	5.81	0.31	1.45e-8	Depression;
CRC	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.52	-5.87	-0.31	1.06e-8	Metabolite levels;
CRC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.68	9.7	0.47	9.56e-20	Vitamin D levels;
CRC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.95	-0.44	2.69e-17	Type 2 diabetes;
CRC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	8.97	0.44	2.27e-17	Cognitive test performance;
CRC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.09	0.41	1.16e-14	Platelet count;
CRC	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.46	-7.07	-0.36	9.32e-12	Testicular germ cell tumor;
CRC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.59	9.46	0.46	6.08e-19	Obesity-related traits;
CRC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.49	9.67	0.47	1.26e-19	Schizophrenia;
CRC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.51	8.98	0.44	2.07e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.96	17.13	0.69	1.83e-47	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg03160526	chr17:80928410	B3GNTL1	0.57	7.74	0.39	1.25e-13	Glycated hemoglobin levels;
CRC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.54	-9.38	-0.46	1.08e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3740540	0.530	rs10794163	chr10:126291398	A/G	cg04949429	chr10:126290192	LHPP	0.42	6.23	0.32	1.45e-9	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg17147758	chr8:6949321	NA	-0.52	-7.2	-0.37	4.24e-12	Blood pressure (smoking interaction);
CRC	trans	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg19894588	chr14:64061835	NA	-0.58	-7.64	-0.39	2.45e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.57	0.47	2.57e-19	Height;
CRC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg26248373	chr2:1572462	NA	-0.66	-7.1	-0.36	7.65e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs12144094	1.000	rs12144094	chr1:120264823	C/G	cg20995928	chr1:120229863	NA	0.48	5.73	0.3	2.31e-8	Height;
CRC	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.69	9.48	0.46	5.28e-19	Hair shape;
CRC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	8.43	0.42	1.08e-15	Height;
CRC	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.41	0.33	4.97e-10	Blood protein levels;
CRC	trans	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg26043149	chr18:55253948	FECH	0.53	8.22	0.41	4.65e-15	Bone mineral density;
CRC	trans	rs1864729	0.901	rs1348184	chr8:98276912	C/G	cg08679828	chr8:102218111	ZNF706	-0.61	-7.34	-0.38	1.67e-12	Estradiol plasma levels (breast cancer);
CRC	cis	rs45544231	0.544	rs4783780	chr16:52571436	G/T	cg09051775	chr16:52580266	TOX3	0.39	6.35	0.33	7.12e-10	Restless legs syndrome;
CRC	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	0.63	9.41	0.46	8.86e-19	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.09e-17	Dupuytren's disease;
CRC	cis	rs995000	0.895	rs1168124	chr1:63139730	C/T	cg19896129	chr1:63156450	NA	-0.43	-6.58	-0.34	1.88e-10	Triglyceride levels;
CRC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.64	7.32	0.37	1.94e-12	Vitiligo;
CRC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.43	0.42	1.1e-15	Height;
CRC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.57	-9.22	-0.45	3.7e-18	Obesity-related traits;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg02683197	chr6:28174875	NA	0.56	8.01	0.4	2.06e-14	Parkinson's disease;
CRC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg20542592	chr8:11973495	FAM66D	0.33	5.84	0.31	1.24e-8	Retinal vascular caliber;
CRC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	13.0	0.58	1.85e-31	Bone mineral density;
CRC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg08687515	chr19:58661962	ZNF329	0.76	8.26	0.41	3.58e-15	Cholesterol, total;
CRC	cis	rs6694672	0.867	rs1759013	chr1:197023411	T/G	cg13682187	chr1:196946512	CFHR5	0.43	6.92	0.36	2.35e-11	Asthma;
CRC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg16342193	chr10:102329863	NA	-0.36	-5.87	-0.31	1.07e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21937169	chr7:65541137	ASL	0.41	6.01	0.31	4.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg23283495	chr1:209979779	IRF6	0.48	6.82	0.35	4.28e-11	Cleft lip with or without cleft palate;
CRC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.79	-13.8	-0.61	1.73e-34	Breast cancer;
CRC	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.63	-9.83	-0.48	3.57e-20	Blood pressure (smoking interaction);
CRC	cis	rs9648716	1.000	rs1267602	chr7:140544404	C/T	cg10747023	chr7:140774559	NA	0.43	5.61	0.3	4.2e-8	Type 2 diabetes;
CRC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.46	7.14	0.37	5.89e-12	Height;
CRC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.69	-12.32	-0.56	6.28e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.54	-0.38	4.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.48	-7.53	-0.38	4.8e-13	Monocyte count;
CRC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.4	7.64	0.39	2.32e-13	Multiple sclerosis;
CRC	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg07979401	chr6:33739406	LEMD2	-0.46	-6.11	-0.32	2.79e-9	Schizophrenia;
CRC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.12	-0.56	3.28e-28	Ulcerative colitis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17422427	chr2:241507521	RNPEPL1	-0.52	-6.21	-0.32	1.57e-9	Diisocyanate-induced asthma;
CRC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	6.46	0.34	3.69e-10	Mean platelet volume;
CRC	cis	rs9826463	0.757	rs60001529	chr3:142282717	G/A	cg20824294	chr3:142316082	PLS1	0.42	6.99	0.36	1.54e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg19508488	chr2:152266495	RIF1	0.5	6.95	0.36	1.92e-11	Squamous cell lung carcinoma;
CRC	cis	rs282587	0.569	rs413110	chr13:113413755	A/G	cg04656015	chr13:113407548	ATP11A	-0.54	-6.62	-0.34	1.43e-10	Glycated hemoglobin levels;
CRC	cis	rs2386661	1.000	rs2386661	chr10:5670275	A/G	cg26603656	chr10:5671107	NA	0.48	7.95	0.4	2.95e-14	Breast cancer;
CRC	trans	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg13565492	chr6:43139072	SRF	-0.69	-7.37	-0.38	1.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.77	10.73	0.51	3.22e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2969070	1.000	rs1548594	chr7:2513281	G/C	cg03277898	chr7:2518824	NA	-0.45	-6.65	-0.34	1.21e-10	Diastolic blood pressure;
CRC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.39	5.7	0.3	2.61e-8	Breast cancer;
CRC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.52	-7.94	-0.4	3.25e-14	Cognitive ability;
CRC	cis	rs28829049	0.566	rs59681755	chr1:19528985	G/A	cg13387374	chr1:19411106	UBR4	0.41	6.06	0.32	3.79e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.43	-20.43	-0.75	1.7e-60	Hip circumference adjusted for BMI;
CRC	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-6.04	-0.32	4.08e-9	Eosinophil percentage of white cells;
CRC	cis	rs995000	0.868	rs1168029	chr1:62969402	G/A	cg19896129	chr1:63156450	NA	-0.39	-6.04	-0.32	4.19e-9	Triglyceride levels;
CRC	trans	rs783540	0.967	rs55972423	chr15:83258954	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.29	-0.33	1.04e-9	Schizophrenia;
CRC	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg19875535	chr5:140030758	IK	-0.51	-8.16	-0.41	7.11e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg06522879	chr11:64358276	SLC22A12	0.56	8.72	0.43	1.38e-16	Urate levels in obese individuals;
CRC	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg15867307	chr2:238110829	NA	-0.43	-7.18	-0.37	4.64e-12	Systemic lupus erythematosus;
CRC	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-6.42	-0.33	4.83e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.9	-0.31	8.87e-9	Longevity;Endometriosis;
CRC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.39	0.53	1.44e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg08501292	chr6:25962987	TRIM38	1.1	9.62	0.47	1.77e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.41	7.25	0.37	2.91e-12	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs41271951	0.512	rs7537292	chr1:151071038	C/G	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.72	-0.3	2.34e-8	Blood protein levels;
CRC	cis	rs10924970	0.649	rs12022924	chr1:235380147	G/T	cg09010748	chr1:235293032	TOMM20	-0.42	-5.87	-0.31	1.07e-8	Asthma;
CRC	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.27	-0.37	2.61e-12	Systemic lupus erythematosus;
CRC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.82	13.33	0.59	1e-32	Menopause (age at onset);
CRC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.3	-0.33	9.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.53	7.46	0.38	7.73e-13	Testicular germ cell tumor;
CRC	cis	rs75422866	0.867	rs73104116	chr12:48078806	A/G	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs6564851	0.506	rs56389890	chr16:81259266	G/T	cg05274606	chr16:81253692	PKD1L2	-0.38	-6.28	-0.33	1.05e-9	Carotenoid and tocopherol levels;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Parkinson's disease;
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg19913688	chr11:428466	ANO9	-0.68	-6.94	-0.36	2.06e-11	Body mass index;
CRC	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.05	21.31	0.76	6.21e-64	Multiple myeloma;
CRC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.61	-0.3	4.34e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.68	-0.3	2.96e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06614563	chr5:89770451	MBLAC2;POLR3G	0.45	6.31	0.33	8.98e-10	Response to antipsychotic treatment;
CRC	cis	rs12024301	0.557	rs16861298	chr1:183598181	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.85	8.6	0.43	3.26e-16	Major depressive disorder;
CRC	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.53	-0.54	4.75e-26	Psoriasis vulgaris;
CRC	trans	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.92	-0.36	2.32e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.59	8.32	0.42	2.38e-15	Blood protein levels;
CRC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.55	-0.47	3.01e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.61	-0.3	4.37e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21643547	chr1:205240462	TMCC2	-0.37	-6.06	-0.32	3.83e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg19025524	chr12:109796872	NA	-0.45	-5.96	-0.31	6.61e-9	Neuroticism;
CRC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7605827	0.930	rs11674824	chr2:15537429	G/A	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.66	-11.81	-0.55	4.56e-27	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06391473	chr2:238875301	UBE2F	0.43	6.85	0.35	3.64e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.56	-9.11	-0.45	8.18e-18	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04122601	chr12:10826785	STYK1	0.54	7.67	0.39	1.92e-13	Response to antipsychotic treatment;
CRC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg00343986	chr7:65444356	GUSB	-0.51	-7.61	-0.39	2.88e-13	Aortic root size;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg15763984	chr4:1342303	KIAA1530	0.35	6.17	0.32	2.06e-9	Obesity-related traits;
CRC	trans	rs6897795	1.000	rs72648830	chr5:177608542	C/T	cg19598605	chr2:70056955	GMCL1	-0.68	-7.68	-0.39	1.86e-13	Plateletcrit;
CRC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg27661571	chr11:113659931	NA	-0.94	-11.03	-0.52	2.83e-24	Hip circumference adjusted for BMI;
CRC	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.38	-6.55	-0.34	2.25e-10	Vitamin D levels;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.27	-0.37	2.7e-12	Bipolar disorder;
CRC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12311346	chr5:56204834	C5orf35	-0.51	-7.92	-0.4	3.59e-14	Coronary artery disease;
CRC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7605827	0.930	rs11694485	chr2:15676154	C/T	cg19274914	chr2:15703543	NA	0.39	5.8	0.3	1.53e-8	Educational attainment (years of education);
CRC	cis	rs17713451	0.555	rs111386955	chr7:151270268	A/G	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-8.88	-0.44	4.44e-17	Alzheimer's disease;
CRC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.69e-11	Prostate cancer;
CRC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.59	-9.38	-0.46	1.09e-18	Monocyte count;
CRC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.54	7.21	0.37	3.9e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4766566	0.501	rs3742004	chr12:111798553	A/G	cg10833066	chr12:111807467	FAM109A	0.55	7.38	0.38	1.28e-12	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
CRC	cis	rs58649573	0.574	rs10818907	chr9:126770250	C/G	cg14112217	chr9:126806003	NA	-0.41	-6.08	-0.32	3.36e-9	Post-traumatic stress disorder;
CRC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.39	6.42	0.33	4.87e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.7	11.11	0.52	1.51e-24	Longevity;Endometriosis;
CRC	cis	rs9463078	0.656	rs227838	chr6:44684621	C/A	cg25276700	chr6:44698697	NA	0.25	5.93	0.31	7.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7605827	0.897	rs4459705	chr2:15526584	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.42	7.04	0.36	1.13e-11	Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00311046	chr10:7830420	KIN;ATP5C1	0.41	6.03	0.32	4.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.49	7.49	0.38	6.36e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.02	0.52	2.92e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.5	8.73	0.43	1.26e-16	Facial morphology (factor 20);
CRC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg15147215	chr3:52552868	STAB1	0.52	9.04	0.45	1.36e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3764400	0.508	rs2240121	chr17:46152322	T/C	cg10706073	chr17:46328419	SKAP1	-0.62	-6.64	-0.34	1.33e-10	Body mass index;
CRC	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-6.67	-0.35	1.09e-10	Large artery stroke;
CRC	trans	rs10403021	0.960	rs10518279	chr19:30085145	C/T	cg22044635	chr17:76557109	DNAH17	0.46	6.27	0.33	1.14e-9	Diabetic retinopathy;
CRC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.69	12.41	0.56	2.75e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11654801	0.947	rs11541311	chr17:20911204	G/T	cg23759823	chr7:139672531	TBXAS1	-0.47	-6.78	-0.35	5.72e-11	Mosquito bite size;
CRC	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg23100626	chr2:96804247	ASTL	0.27	7.11	0.36	7.24e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.72	12.12	0.56	3.35e-28	Body mass index;
CRC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.1	0.64	1.66e-39	Fuchs's corneal dystrophy;
CRC	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.6	8.43	0.42	1.11e-15	Uric acid levels;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg03623178	chr6:28175578	NA	0.79	8.5	0.42	6.74e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg21251018	chr6:28226885	NKAPL	0.58	10.15	0.49	3.17e-21	Cardiac Troponin-T levels;
CRC	cis	rs11030122	0.547	rs12270732	chr11:3952901	C/A	cg18678763	chr11:4115507	RRM1	-0.39	-6.61	-0.34	1.59e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg08270630	chr22:50330655	NA	-0.43	-5.93	-0.31	7.59e-9	Schizophrenia;
CRC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17507749	chr15:85114479	UBE2QP1	0.62	8.6	0.43	3.39e-16	Schizophrenia;
CRC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg07074390	chr21:40555500	PSMG1	-0.46	-6.22	-0.32	1.54e-9	Cognitive function;
CRC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg22687807	chr8:143858763	LYNX1	-0.38	-6.64	-0.34	1.28e-10	Urinary tract infection frequency;
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg08888203	chr3:10149979	C3orf24	0.69	8.16	0.41	6.96e-15	Alzheimer's disease;
CRC	trans	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg26043149	chr18:55253948	FECH	-0.58	-8.96	-0.44	2.41e-17	Bone mineral density;
CRC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.74	10.8	0.51	1.73e-23	Cognitive function;
CRC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.55	-8.4	-0.42	1.36e-15	Tuberculosis;
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.55	0.75	5.84e-61	Prudent dietary pattern;
CRC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.27	0.46	2.53e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.63	-8.75	-0.43	1.13e-16	White matter hyperintensity burden;
CRC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.56	-6.12	-0.32	2.66e-9	Schizophrenia;
CRC	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.59	-10.36	-0.5	6e-22	Asthma;
CRC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg10802521	chr3:52805072	NEK4	0.46	6.12	0.32	2.64e-9	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01530797	chr7:139875863	LOC100134229;JHDM1D	0.47	6.48	0.34	3.33e-10	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.582	rs12464282	chr2:162448855	C/T	cg15664909	chr17:685709	GLOD4;RNMTL1	-0.67	-5.96	-0.31	6.48e-9	Cognitive function;
CRC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	cis	rs713587	0.571	rs475868	chr2:25318059	A/G	cg22495460	chr2:25135724	ADCY3	0.39	5.76	0.3	1.89e-8	Body mass index in non-asthmatics;
CRC	cis	rs2249694	1.000	rs4363513	chr10:135355534	A/G	cg16964102	chr10:135390573	NA	-0.43	-7.04	-0.36	1.11e-11	Obesity-related traits;
CRC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.61	-8.81	-0.44	7.38e-17	Menarche (age at onset);
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg06470822	chr6:28175283	NA	0.65	9.68	0.47	1.16e-19	Cardiac Troponin-T levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09920427	chr19:12777674	MORG1;MAN2B1	0.42	6.15	0.32	2.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.56	8.7	0.43	1.6e-16	Bipolar disorder;
CRC	trans	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.51	-0.38	5.79e-13	Endometrial cancer;
CRC	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs77861329	0.920	rs9860982	chr3:52096432	T/C	cg08692210	chr3:52188851	WDR51A	0.88	8.43	0.42	1.1e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg00092383	chr7:157075207	NA	0.23	5.65	0.3	3.43e-8	Type 2 diabetes;
CRC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs6479527	0.875	rs914297	chr9:96816506	T/A	cg14459158	chr9:96720562	NA	0.38	6.71	0.35	8.37e-11	Esophageal adenocarcinoma;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.42	0.42	1.18e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.51	-6.07	-0.32	3.47e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2252790	0.548	rs114094955	chr6:116521164	G/T	cg15226275	chr6:116381976	FRK	0.26	5.78	0.3	1.75e-8	Fast beta electroencephalogram;
CRC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg10298567	chr3:47292165	KIF9	0.39	6.28	0.33	1.08e-9	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15118204	chr17:79876231	MAFG;SIRT7	0.42	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg16964102	chr10:135390573	NA	0.49	6.77	0.35	5.9e-11	Gout;
CRC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.88	11.03	0.52	2.73e-24	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08306365	chr15:62543301	NA	-0.32	-5.97	-0.31	6.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6977940	0.558	rs11770455	chr7:2888014	G/A	cg19731401	chr7:2775893	GNA12	0.6	5.78	0.3	1.78e-8	White matter integrity;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.64e-18	Parkinson's disease;
CRC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg17294928	chr15:75287854	SCAMP5	-0.43	-6.38	-0.33	5.99e-10	Systemic lupus erythematosus;
CRC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.3	6.02	0.32	4.64e-9	Personality dimensions;
CRC	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.16	0.32	2.11e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.66	9.11	0.45	8.34e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.29	6.26	0.33	1.2e-9	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16487852	chr16:83841511	HSBP1	0.47	7.86	0.4	5.62e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg26958806	chr6:27640298	NA	0.93	6.09	0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.78	11.82	0.55	4.24e-27	Testicular germ cell tumor;
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg03623178	chr6:28175578	NA	0.85	12.48	0.57	1.55e-29	Parkinson's disease;
CRC	cis	rs12760731	0.582	rs2147031	chr1:178572474	T/G	cg00404053	chr1:178313656	RASAL2	0.65	7.01	0.36	1.36e-11	Obesity-related traits;
CRC	cis	rs7605827	0.930	rs13019216	chr2:15659539	A/G	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.8e-9	Educational attainment (years of education);
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg04562611	chr16:615315	C16orf11	0.36	6.07	0.32	3.6e-9	Height;
CRC	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-9.29	-0.46	2.24e-18	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs4731207	0.698	rs10250202	chr7:124465509	A/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs12692738	0.526	rs171392	chr2:165621464	T/C	cg03182029	chr2:165697222	COBLL1	0.51	6.09	0.32	3.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.61	-9.85	-0.48	3.19e-20	Intelligence (multi-trait analysis);
CRC	cis	rs10991814	0.920	rs61021072	chr9:94038021	T/C	cg14446406	chr9:93919335	NA	0.58	6.46	0.34	3.77e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.69	9.85	0.48	3.06e-20	Bronchopulmonary dysplasia;
CRC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg13628971	chr7:2884303	GNA12	0.39	6.07	0.32	3.52e-9	Height;
CRC	cis	rs720844	1.000	rs4972381	chr2:149336554	T/C	cg09247360	chr2:149335327	NA	-0.61	-7.7	-0.39	1.5700000000000001e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.43	6.4	0.33	5.5e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.1	0.49	4.69e-21	Asthma;
CRC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg21285383	chr16:89894308	SPIRE2	0.34	5.69	0.3	2.82e-8	Vitiligo;
CRC	cis	rs6691722	0.503	rs2274168	chr1:24707211	G/T	cg18323236	chr1:24743029	NIPAL3	0.39	5.71	0.3	2.55e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.69	-7.82	-0.4	7.03e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg06042504	chr8:55087323	NA	-0.37	-5.78	-0.3	1.71e-8	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs8064024	0.513	rs1049207	chr16:4934564	C/G	cg19252218	chr17:41477271	ARL4D	-0.41	-6.16	-0.32	2.08e-9	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16714432	chr6:75994713	TMEM30A	0.41	6.45	0.34	4.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs910187	0.678	rs6018329	chr20:45813184	A/G	cg27589058	chr20:45804311	EYA2	-0.39	-7.38	-0.38	1.29e-12	Migraine;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg19318889	chr4:1322082	MAEA	0.41	5.91	0.31	8.6e-9	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12463550	chr7:65579703	CRCP	0.68	6.5	0.34	2.96e-10	Diabetic kidney disease;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg15845792	chr6:28175446	NA	0.78	11.57	0.54	3.33e-26	Parkinson's disease;
CRC	cis	rs919433	0.756	rs7575389	chr2:198198489	A/G	cg10820045	chr2:198174542	NA	-0.47	-8.23	-0.41	4.3e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg02569458	chr12:86230093	RASSF9	0.41	6.82	0.35	4.31e-11	Major depressive disorder;
CRC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.71	-0.39	1.54e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg12100956	chr17:78086420	GAA	-0.36	-5.63	-0.3	3.92e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg08501292	chr6:25962987	TRIM38	0.64	7.15	0.37	5.48e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7635838	0.892	rs9838141	chr3:11488639	C/T	cg00170343	chr3:11313890	ATG7	0.42	6.37	0.33	6.45e-10	HDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27099978	chr3:48673001	SLC26A6	0.42	6.16	0.32	2.14e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00499509	chr1:149605515	LOC728855	0.42	6.8	0.35	5.05e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.51	10.19	0.49	2.3e-21	Alcohol dependence;
CRC	cis	rs2932538	0.583	rs2279500	chr1:113244433	T/C	cg22162597	chr1:113214053	CAPZA1	-0.62	-7.3	-0.37	2.19e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6496667	0.779	rs2238324	chr15:91006989	T/C	cg04176472	chr15:90893244	GABARAPL3	0.58	8.02	0.4	1.81e-14	Rheumatoid arthritis;
CRC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.48	-0.38	7.02e-13	Coronary artery disease;
CRC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.33	-0.53	2.45e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.2	-0.37	4.11e-12	Bipolar disorder;
CRC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.74	-11.47	-0.53	7.33e-26	Colorectal cancer;
CRC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.2	-0.37	4.22e-12	Educational attainment;
CRC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.4	-0.33	5.22e-10	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04131734	chr11:102323536	TMEM123	0.47	7.36	0.38	1.44e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg20608306	chr11:116969690	SIK3	-0.31	-5.78	-0.3	1.76e-8	Subjective well-being;
CRC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg17298326	chr8:142245477	NA	-0.38	-5.78	-0.3	1.78e-8	Immature fraction of reticulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20548716	chr17:7531197	SHBG;SAT2	0.45	6.36	0.33	6.75e-10	Response to antipsychotic treatment;
CRC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.78	-13.44	-0.6	3.88e-33	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg24300038	chr13:113819356	PROZ	0.43	5.78	0.3	1.74e-8	Platelet distribution width;
CRC	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.44	7.08	0.36	8.93e-12	Sitting height ratio;
CRC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.44	-0.33	4.3e-10	Dupuytren's disease;
CRC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18099408	chr3:52552593	STAB1	-0.49	-8.34	-0.42	1.99e-15	Electroencephalogram traits;
CRC	cis	rs6961069	0.742	rs1722502	chr7:80241874	A/C	cg04458919	chr7:80252533	CD36	-0.36	-6.37	-0.33	6.47e-10	Platelet count;
CRC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07570687	chr10:102243282	WNT8B	0.44	5.66	0.3	3.36e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs812925	0.859	rs2593624	chr2:61552484	T/A	cg10580144	chr2:61372316	C2orf74	-0.32	-6.64	-0.34	1.28e-10	Immature fraction of reticulocytes;
CRC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.77	-14.67	-0.63	7.87e-38	Body mass index;
CRC	cis	rs4523957	0.928	rs11869805	chr17:2176532	A/G	cg16513277	chr17:2031491	SMG6	-0.54	-9.12	-0.45	7.71e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg23425280	chr12:56401806	NA	0.47	5.72	0.3	2.44e-8	Cancer;
CRC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg12386194	chr3:101231763	SENP7	0.52	7.63	0.39	2.48e-13	Colorectal cancer;
CRC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.56	8.52	0.43	5.64e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.4	7.91	0.4	4.08e-14	Vitiligo;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg11326919	chr17:43324904	LOC100133991	-0.65	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07867325	chr3:73159953	NA	-0.42	-6.57	-0.34	1.95e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.62	-5.83	-0.31	1.33e-8	Yeast infection;
CRC	cis	rs231513	0.954	rs170766	chr17:41963407	C/G	cg26893861	chr17:41843967	DUSP3	-0.65	-6.62	-0.34	1.42e-10	Cognitive function;
CRC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	9.02	0.45	1.56e-17	Cognitive test performance;
CRC	cis	rs2274471	0.645	rs3824432	chr9:5091675	G/A	cg03390472	chr9:5043263	JAK2	-0.59	-7.03	-0.36	1.17e-11	Crohn's disease;
CRC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.05	11.85	0.55	3.18e-27	Hip circumference adjusted for BMI;
CRC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.39	-0.53	1.52e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.39	-0.56	3.47e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.72	0.35	7.83e-11	Tonsillectomy;
CRC	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg00425431	chr15:90792223	TTLL13	0.32	5.65	0.3	3.54e-8	Rheumatoid arthritis;
CRC	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.52	-6.87	-0.35	3.21e-11	Response to antidepressants and depression;
CRC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	1.99e-14	Type 2 diabetes;
CRC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg11189052	chr15:85197271	WDR73	0.54	7.2	0.37	4.12e-12	Schizophrenia;
CRC	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.72	7.19	0.37	4.45e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.52	-8.3	-0.42	2.73e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.03	0.32	4.51e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.13	10.47	0.5	2.49e-22	Prostate cancer;
CRC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	0.77	8.59	0.43	3.61e-16	Gout;Renal underexcretion gout;
CRC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg16558177	chr4:4109446	NA	-0.48	-6.22	-0.32	1.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg18230493	chr5:56204884	C5orf35	-0.6	-8.63	-0.43	2.68e-16	Initial pursuit acceleration;
CRC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20887711	chr4:1340912	KIAA1530	-0.44	-6.4	-0.33	5.31e-10	Obesity-related traits;
CRC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.86	-13.21	-0.59	2.97e-32	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.34	3.94e-10	Electroencephalogram traits;
CRC	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.38	5.85	0.31	1.19e-8	Multiple myeloma;
CRC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.3	10.52	0.5	1.69e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.48	0.34	3.37e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16447950	chr5:562315	NA	-0.77	-10.22	-0.49	1.75e-21	Obesity-related traits;
CRC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.41	5.73	0.3	2.26e-8	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05183487	chr16:89992959	TUBB3	0.44	6.74	0.35	6.96e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-9.1	-0.45	9.04e-18	Bone mineral density;
CRC	cis	rs3790844	0.515	rs35094784	chr1:199949274	T/C	cg13229857	chr1:200006247	NR5A2	0.51	7.36	0.38	1.44e-12	Pancreatic cancer;
CRC	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.12	9.65	0.47	1.47e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21137026	chr11:417246	SIGIRR	0.43	6.02	0.31	4.7e-9	Response to antipsychotic treatment;
CRC	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.18	-0.32	1.87e-9	Axial length;
CRC	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.07	9.18	0.45	5.01e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg23254163	chr1:152506842	NA	0.44	8.62	0.43	2.8e-16	Hair morphology;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23318986	chr2:149895139	LYPD6B	0.41	6.81	0.35	4.52e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.38	-6.17	-0.32	1.95e-9	Diastolic blood pressure;
CRC	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	8.96	0.44	2.45e-17	Ileal carcinoids;
CRC	cis	rs1124376	0.935	rs28716666	chr3:20148409	C/T	cg05072819	chr3:20081367	KAT2B	0.49	5.85	0.31	1.21e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs12024301	0.557	rs12045319	chr1:183608449	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.83	0.35	4.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg14784868	chr12:69753453	YEATS4	0.45	5.83	0.31	1.29e-8	Response to diuretic therapy;
CRC	cis	rs8099014	0.861	rs4940703	chr18:56115386	A/G	cg12907477	chr18:56117327	MIR122	0.46	5.96	0.31	6.58e-9	Platelet count;
CRC	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.66	-10.21	-0.49	1.97e-21	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg06581033	chr10:766294	NA	-0.47	-5.71	-0.3	2.58e-8	Uric acid levels;
CRC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.33	6.56	0.34	2.06e-10	Renal cell carcinoma;
CRC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	11.62	0.54	2.26e-26	High light scatter reticulocyte count;
CRC	cis	rs9992667	0.955	rs2078179	chr4:38664499	A/G	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.02	-0.45	1.62e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg15786705	chr6:28176104	NA	0.62	6.67	0.34	1.11e-10	Depression;
CRC	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.51	8.62	0.43	2.89e-16	Congenital heart disease (maternal effect);
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg23123621	chr4:1343375	KIAA1530	0.35	5.62	0.3	4.09e-8	Obesity-related traits;
CRC	cis	rs216303	0.841	rs2239160	chr12:6162754	A/G	cg19878637	chr12:6148451	VWF	-0.47	-5.9	-0.31	9.21e-9	Low vWF levels;
CRC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	10.53	0.5	1.51e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.46	7.78	0.39	9.74e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.2	-0.41	5.41e-15	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06222638	chr17:4542859	ALOX15	0.41	6.58	0.34	1.89e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg15848620	chr12:58087721	OS9	-0.63	-8.69	-0.43	1.73e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg18016565	chr1:150552671	MCL1	0.42	5.83	0.31	1.36e-8	Melanoma;
CRC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.56	-8.13	-0.41	8.82e-15	Response to temozolomide;
CRC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.56	8.36	0.42	1.76e-15	Type 2 diabetes;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.32	-5.79	-0.3	1.63e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs698833	0.886	rs786654	chr2:44581007	A/G	cg04920474	chr2:44395004	PPM1B	0.41	6.16	0.32	2.09e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.8	14.55	0.63	2.16e-37	Anterior chamber depth;
CRC	cis	rs6479527	0.875	rs10117457	chr9:96823684	A/G	cg14459158	chr9:96720562	NA	0.37	6.69	0.35	9.7e-11	Esophageal adenocarcinoma;
CRC	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg17375396	chr11:67202808	RPS6KB2	0.33	5.65	0.3	3.43e-8	Mean corpuscular volume;
CRC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.01	0.31	5.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.55	5.89	0.31	9.59e-9	Bipolar disorder;
CRC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.44	0.33	4.14e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg25251562	chr2:3704773	ALLC	0.49	7.31	0.37	1.98e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg26721908	chr21:47610096	LSS	0.45	7.39	0.38	1.21e-12	Testicular germ cell tumor;
CRC	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg05720666	chr2:69969591	ANXA4	0.45	6.06	0.32	3.75e-9	Type 2 diabetes (age of onset);
CRC	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.68	-9.89	-0.48	2.31e-20	Blood protein levels;
CRC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.38	0.33	5.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.67	0.39	2e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg05342945	chr12:48394962	COL2A1	-0.47	-6.59	-0.34	1.76e-10	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18004316	chr2:208634121	FZD5	0.36	6.04	0.32	4.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.6	9.46	0.46	5.94e-19	Schizophrenia;
CRC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	0.98	14.44	0.62	6.21e-37	Breast cancer;
CRC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-6.99	-0.36	1.55e-11	Coronary artery disease;
CRC	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.88	-0.31	1e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg15465823	chr12:48382534	COL2A1	-0.38	-6.32	-0.33	8.29e-10	Glycated hemoglobin levels;
CRC	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg26587870	chr6:27730563	NA	-0.6	-5.98	-0.31	5.78e-9	Breast cancer;
CRC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.62	8.33	0.42	2.27e-15	Smoking initiation;
CRC	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.46	6.79	0.35	5.11e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.53	8.71	0.43	1.53e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg11632617	chr15:75315747	PPCDC	0.51	6.8	0.35	4.91e-11	Blood trace element (Zn levels);
CRC	cis	rs6662572	0.703	rs4364819	chr1:46358510	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.85	-0.31	1.16e-8	Blood protein levels;
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.31	-0.33	9.22e-10	Neuroticism;
CRC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg16576597	chr16:28551801	NUPR1	0.48	6.9	0.36	2.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs2303319	0.504	rs2194732	chr2:162289156	G/A	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.86	-6.37	-0.33	6.37e-10	Cognitive function;
CRC	cis	rs501916	1.000	rs501916	chr15:48053229	C/A	cg16110827	chr15:48056943	SEMA6D	-0.36	-6.0	-0.31	5.08e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs1178968	0.901	rs4999954	chr7:72755520	A/G	cg25889504	chr7:72793014	NA	0.52	6.18	0.32	1.88e-9	Triglyceride levels;
CRC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.42e-8	Bladder cancer;
CRC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	5.97	0.31	5.99e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg07217954	chr7:1067459	C7orf50	0.47	5.62	0.3	3.99e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.41	6.25	0.33	1.31e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2346160	0.899	rs1736585	chr6:167688325	G/A	cg27333441	chr6:167680455	NA	-0.39	-6.36	-0.33	6.59e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg14433983	chr11:636460	DRD4	-0.45	-5.71	-0.3	2.54e-8	Systemic lupus erythematosus;
CRC	cis	rs6141769	0.518	rs28510728	chr20:31287891	G/A	cg13636640	chr20:31349939	DNMT3B	-0.4	-6.01	-0.31	4.9e-9	Subjective well-being;
CRC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.71	11.09	0.52	1.73e-24	Corneal astigmatism;
CRC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.6	8.71	0.43	1.5e-16	Breast cancer;
CRC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.69e-12	Obesity-related traits;
CRC	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg26816564	chr1:7831052	VAMP3	0.48	5.74	0.3	2.12e-8	Inflammatory bowel disease;
CRC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.58	-0.34	1.87e-10	Breast cancer;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.61	9.64	0.47	1.5700000000000001e-19	Height;
CRC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg09264619	chr17:80180166	NA	-0.49	-6.86	-0.35	3.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.76	0.3	1.89e-8	Prudent dietary pattern;
CRC	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.55	0.47	3.03e-19	Type 2 diabetes;
CRC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00815214	chr21:47717953	NA	-0.44	-7.48	-0.38	7.05e-13	Testicular germ cell tumor;
CRC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg13556452	chr1:2391241	NA	-0.37	-6.25	-0.33	1.27e-9	Non-obstructive azoospermia;
CRC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.16	0.32	2.1e-9	Menopause (age at onset);
CRC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-11.22	-0.53	5.86e-25	Colorectal cancer;
CRC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.45	8.99	0.44	1.98e-17	IgG glycosylation;
CRC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg27661571	chr11:113659931	NA	-0.95	-11.14	-0.52	1.11e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.64	-0.34	1.32e-10	Morning vs. evening chronotype;
CRC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.87	-0.4	5.11e-14	Body mass index;
CRC	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.7	-0.39	1.61e-13	Bipolar disorder;
CRC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.66	-0.3	3.24e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-0.65	-11.41	-0.53	1.25e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg04586622	chr2:25135609	ADCY3	-0.53	-9.7	-0.47	1.01e-19	Body mass index;
CRC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg20243544	chr17:37824526	PNMT	0.56	8.76	0.43	1.05e-16	Asthma;
CRC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.49	6.53	0.34	2.51e-10	Primary sclerosing cholangitis;
CRC	cis	rs4930103	0.904	rs2067051	chr11:2018168	C/T	cg23202291	chr11:1979235	NA	0.47	6.38	0.33	6.11e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.92	-19.28	-0.73	5.98e-56	Urate levels in lean individuals;
CRC	cis	rs10071761	0.513	rs10941504	chr5:40367355	G/A	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.62	-9.54	-0.47	3.24e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.64	12.25	0.56	1.07e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg00343986	chr7:65444356	GUSB	0.49	7.23	0.37	3.35e-12	Aortic root size;
CRC	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-7.75	-0.39	1.13e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.93	-11.91	-0.55	1.88e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	9.37	0.46	1.18e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.47	6.87	0.35	3.21e-11	Intelligence (multi-trait analysis);
CRC	cis	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg20027784	chr11:1520631	HCCA2	-0.42	-5.62	-0.3	3.98e-8	Myringotomy;
CRC	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.66	-8.22	-0.41	4.61e-15	Pursuit maintenance gain;
CRC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.84	-10.41	-0.5	4.07e-22	Initial pursuit acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24474701	chr18:55289098	NARS	0.43	6.32	0.33	8.61e-10	Anxiety disorder;
CRC	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg00490450	chr3:139108681	COPB2	0.45	6.65	0.34	1.19e-10	Obesity-related traits;
CRC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg18016565	chr1:150552671	MCL1	-0.47	-7.0	-0.36	1.4e-11	Tonsillectomy;
CRC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.48	9.43	0.46	7.65e-19	Ulcerative colitis;
CRC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.69	7.95	0.4	3.04e-14	Vitiligo;
CRC	cis	rs73206853	0.563	rs17682444	chr12:111154626	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	6.66	0.34	1.15e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.71	12.57	0.57	7.49e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs755249	0.567	rs16826038	chr1:39758634	G/A	cg18385671	chr1:39797026	MACF1	-0.42	-5.98	-0.31	5.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.48	0.71	8.6e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.5	6.84	0.35	3.95e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.83	-0.48	3.72e-20	Height;
CRC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.51	-6.33	-0.33	7.95e-10	Recombination rate (females);
CRC	trans	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg26043149	chr18:55253948	FECH	-0.48	-7.18	-0.37	4.7e-12	Bone mineral density;
CRC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.44	6.38	0.33	6.05e-10	Prostate cancer;
CRC	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.39	6.4	0.33	5.36e-10	Sitting height ratio;
CRC	cis	rs6076065	0.723	rs6137940	chr20:23397491	G/C	cg11657817	chr20:23433608	CST11	0.43	6.33	0.33	8.11e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.38	6.45	0.34	3.89e-10	Sitting height ratio;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04464559	chr6:107780641	PDSS2	0.45	6.43	0.33	4.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.72	0.65	6.5e-42	Fuchs's corneal dystrophy;
CRC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.28	-6.82	-0.35	4.43e-11	Urate levels in overweight individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07850863	chr19:508078	C19orf20	0.5	7.14	0.37	6.18e-12	Response to antipsychotic treatment;
CRC	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg19407955	chr1:165599744	MGST3	-0.52	-6.62	-0.34	1.49e-10	Total ventricular volume;
CRC	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.41	5.69	0.3	2.88e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.43	6.65	0.34	1.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg19041857	chr6:27730383	NA	-0.44	-5.93	-0.31	7.49e-9	Parkinson's disease;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg00597713	chr6:42947103	PEX6	-0.43	-6.05	-0.32	3.9e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg24562669	chr7:97807699	LMTK2	0.42	7.0	0.36	1.45e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg21132104	chr15:45694354	SPATA5L1	0.41	5.96	0.31	6.54e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg00277334	chr10:82204260	NA	-0.56	-6.12	-0.32	2.66e-9	Post bronchodilator FEV1;
CRC	cis	rs9925964	0.933	rs9929899	chr16:31062701	C/A	cg02466173	chr16:30829666	NA	0.41	5.65	0.3	3.53e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs910187	0.571	rs6124958	chr20:45801117	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-7.67	-0.39	2e-13	Migraine;
CRC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg15123519	chr2:136567270	LCT	0.33	6.39	0.33	5.56e-10	Mosquito bite size;
CRC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	7.21	0.37	3.93e-12	Menopause (age at onset);
CRC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.36	5.78	0.3	1.71e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg00603274	chr11:61596626	FADS2	-0.63	-7.77	-0.39	1.04e-13	Neutrophil count;Sum basophil neutrophil counts;
CRC	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg21110645	chr1:207815933	NA	-0.39	-5.83	-0.31	1.29e-8	Erythrocyte sedimentation rate;
CRC	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.37	-0.33	6.37e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs11212617	0.935	rs4623864	chr11:108051300	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.33	0.33	7.92e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.48	-7.64	-0.39	2.39e-13	Coronary artery disease;
CRC	cis	rs2252790	0.965	rs2501048	chr6:116663479	C/G	cg18764771	chr6:116381957	FRK	-0.22	-5.8	-0.3	1.59e-8	Fast beta electroencephalogram;
CRC	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.96	-0.31	6.51e-9	Educational attainment;
CRC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.54	8.82	0.44	7.06e-17	Coronary artery disease;
CRC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.78	-0.44	9.04e-17	Body mass index;
CRC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.63	-0.47	1.69e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.63	8.36	0.42	1.81e-15	Arsenic metabolism;
CRC	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg02296627	chr16:508045	RAB11FIP3	-0.38	-6.68	-0.35	9.99e-11	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.49	-8.2	-0.41	5.62e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9311676	0.632	rs56281646	chr3:58424917	G/A	cg06643156	chr3:58380774	PXK	0.43	6.53	0.34	2.5e-10	Systemic lupus erythematosus;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05388307	chr4:166248715	SC4MOL	0.46	6.16	0.32	2.09e-9	Anxiety disorder;
CRC	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs7849270	0.801	rs10819474	chr9:131930494	C/T	cg13538475	chr9:131942899	NA	-0.31	-6.06	-0.32	3.81e-9	Blood metabolite ratios;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10020897	chr1:167905730	BRP44;DCAF6	0.43	6.17	0.32	2.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.76	10.52	0.5	1.63e-22	Heart rate;
CRC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.17	11.73	0.54	8.82e-27	Intelligence (multi-trait analysis);
CRC	cis	rs6141769	0.542	rs6058819	chr20:31303942	T/C	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.92	-0.31	8.02e-9	Subjective well-being;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	1.02	19.31	0.73	4.47e-56	Menarche (age at onset);
CRC	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.55	8.48	0.42	7.98e-16	Diastolic blood pressure;
CRC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.26	14.39	0.62	9.53e-37	Diabetic kidney disease;
CRC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.42	6.71	0.35	8.36e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.56	8.35	0.42	1.88e-15	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.59	0.65	2.1e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.34	-5.69	-0.3	2.82e-8	Childhood ear infection;
CRC	cis	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.77	-0.3	1.87e-8	Asthma;
CRC	trans	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg26043149	chr18:55253948	FECH	0.45	6.86	0.35	3.43e-11	Bone mineral density;
CRC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	9.55	0.47	3.13e-19	Personality dimensions;
CRC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.83	-11.62	-0.54	2.25e-26	Asthma;
CRC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.34	8.03	0.4	1.72e-14	Diastolic blood pressure;
CRC	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.53	-8.33	-0.42	2.28e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-10.2	-0.49	2.1e-21	Colorectal cancer;
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.33	10.88	0.51	9.18e-24	Blood protein levels;
CRC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.11e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs1158570	0.564	rs2554372	chr8:131333913	A/G	cg21674704	chr8:131455249	NA	-0.38	-5.76	-0.3	1.95e-8	Platelet count;
CRC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.8	13.61	0.6	9.31e-34	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.49e-10	Depression;
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.45	6.39	0.33	5.62e-10	Parkinson's disease;
CRC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg13491945	chr12:107078410	RFX4	0.35	5.93	0.31	7.75e-9	Heart rate;
CRC	cis	rs75422866	0.510	rs73105812	chr12:48118187	C/A	cg14736327	chr12:48174669	SLC48A1	-0.72	-5.75	-0.3	2.05e-8	Pneumonia;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.75	11.55	0.54	3.93e-26	Longevity;Endometriosis;
CRC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.61	-7.8	-0.4	8.02e-14	Body mass index;
CRC	cis	rs10512697	0.803	rs13174189	chr5:3579174	G/T	cg19473799	chr5:3511975	NA	0.7	5.73	0.3	2.22e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.45	6.98	0.36	1.6e-11	Obesity-related traits;
CRC	cis	rs9903692	0.866	rs11079807	chr17:46176047	T/C	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs2637266	0.519	rs2395383	chr10:78300806	C/T	cg18941641	chr10:78392320	NA	-0.36	-6.02	-0.32	4.57e-9	Pulmonary function;
CRC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.5	-6.04	-0.32	4.1e-9	Diastolic blood pressure;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg07217954	chr7:1067459	C7orf50	0.5	5.77	0.3	1.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.05	0.32	3.99e-9	Bipolar disorder;
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	8.09e-9	Prudent dietary pattern;
CRC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.25	-0.41	3.77e-15	Gut microbiome composition (summer);
CRC	cis	rs4654899	0.895	rs10916866	chr1:21137768	C/A	cg02927042	chr1:21476669	EIF4G3	0.38	5.93	0.31	7.5e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg24289452	chr6:170231220	NA	-0.54	-5.94	-0.31	7.19e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.68	0.3	2.96e-8	Diabetic retinopathy;
CRC	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg14092571	chr14:90743983	NA	0.38	5.92	0.31	8.07e-9	Mortality in heart failure;
CRC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.74	-9.66	-0.47	1.31e-19	Body mass index;
CRC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-11.47	-0.53	7.52e-26	Vitiligo;
CRC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.81	10.57	0.5	1.1e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.59	9.48	0.46	5.11e-19	Anterior chamber depth;
CRC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.49	8.96	0.44	2.49e-17	Total body bone mineral density;
CRC	cis	rs3736485	0.873	rs7162563	chr15:51775067	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.44	-0.33	4.25e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.39	6.09	0.32	3.22e-9	Crohn's disease;
CRC	cis	rs7725052	0.609	rs4342370	chr5:40460902	A/G	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg08888203	chr3:10149979	C3orf24	0.74	9.0	0.44	1.82e-17	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.07	-0.36	9.29e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.13	0.37	6.31e-12	Life satisfaction;
CRC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.17	0.45	5.11e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7945718	0.870	rs3890064	chr11:12758766	C/A	cg25843174	chr11:12811716	TEAD1	0.45	8.45	0.42	9.44e-16	Educational attainment (years of education);
CRC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.62	-8.99	-0.44	1.94e-17	Coronary artery disease;
CRC	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg18833306	chr6:118973337	C6orf204	0.46	5.78	0.3	1.73e-8	Diastolic blood pressure;
CRC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.49	9.72	0.47	8.66e-20	Iron status biomarkers (transferrin levels);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07305049	chr22:21354332	THAP7	-0.38	-6.46	-0.34	3.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg09417038	chr21:47716443	C21orf57	0.41	6.86	0.35	3.43e-11	Testicular germ cell tumor;
CRC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07167872	chr1:205819463	PM20D1	0.4	6.0	0.31	5.27e-9	Prostate cancer;
CRC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.91	10.86	0.51	1.08e-23	Eosinophil percentage of granulocytes;
CRC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.18	-0.37	4.72e-12	Coronary artery disease;
CRC	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-7.52	-0.38	5.13e-13	Hepatocellular carcinoma;
CRC	cis	rs10986311	0.748	rs10986333	chr9:127168391	T/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.39	-5.72	-0.3	2.39e-8	Vitiligo;
CRC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg23463467	chr20:60627584	TAF4	0.41	7.55	0.38	4.31e-13	Body mass index;
CRC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.9	0.48	2.16e-20	Cognitive test performance;
CRC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.45	-7.11	-0.37	7.18e-12	Subjective well-being;Cardiovascular disease risk factors;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06936779	chr1:151171405	PIP5K1A	0.44	6.92	0.36	2.37e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg12639453	chr1:2035780	PRKCZ	-0.38	-7.27	-0.37	2.62e-12	Height;
CRC	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-15.19	-0.64	7.57e-40	Body mass index;
CRC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.44	-7.14	-0.37	5.96e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-7.0	-0.36	1.46e-11	Menarche (age at onset);
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg18301423	chr5:131593218	PDLIM4	0.37	6.25	0.33	1.29e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26933068	chr19:19976613	ZNF253	0.4	6.47	0.34	3.56e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg04121214	chr22:50244548	NA	-0.43	-6.66	-0.34	1.15e-10	Schizophrenia;
CRC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.49	9.63	0.47	1.66e-19	Renal cell carcinoma;
CRC	trans	rs5756813	0.668	rs5756805	chr22:38144618	A/G	cg19894588	chr14:64061835	NA	-0.47	-6.13	-0.32	2.55e-9	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.61	-0.39	2.88e-13	Bipolar disorder;
CRC	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg23254163	chr1:152506842	NA	0.5	10.17	0.49	2.65e-21	Hair morphology;
CRC	cis	rs4547160	0.606	rs36108998	chr12:63477075	T/C	cg26727693	chr12:63544175	AVPR1A	-0.43	-7.83	-0.4	6.9e-14	Morning vs. evening chronotype;
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.54	-9.75	-0.47	6.58e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-0.69	-7.19	-0.37	4.38e-12	Schizophrenia;
CRC	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg25838818	chr2:108905173	SULT1C2	-0.37	-5.94	-0.31	7.18e-9	Blood pressure;
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.74	11.35	0.53	2.08e-25	Menarche (age at onset);
CRC	cis	rs4870684	0.509	rs11763804	chr7:57702125	G/C	cg01314568	chr7:57830625	NA	-0.61	-7.28	-0.37	2.45e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	0.94	10.07	0.49	5.79e-21	Atopic dermatitis;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg17879804	chr3:44752500	NA	0.42	6.87	0.35	3.29e-11	Aortic root size;
CRC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg09417038	chr21:47716443	C21orf57	-0.38	-6.45	-0.33	4.03e-10	Testicular germ cell tumor;
CRC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.43	7.34	0.38	1.68e-12	Major depressive disorder;
CRC	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg25856811	chr1:152973957	SPRR3	0.26	7.28	0.37	2.51e-12	Inflammatory skin disease;
CRC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.37	-6.08	-0.32	3.3e-9	HDL cholesterol;
CRC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.95	13.75	0.6	2.59e-34	Breast cancer;
CRC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.97	14.26	0.62	2.99e-36	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11212617	0.967	rs11212616	chr11:108281322	T/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.09	0.32	3.2e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	16.89	0.68	1.56e-46	Testicular germ cell tumor;
CRC	cis	rs4481887	0.538	rs4916117	chr1:248387187	G/C	cg00666640	chr1:248458726	OR2T12	0.46	7.2	0.37	4.14e-12	Common traits (Other);
CRC	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.16	0.41	7.16e-15	Brugada syndrome;
CRC	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.8	10.48	0.5	2.22e-22	Diisocyanate-induced asthma;
CRC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.16	-12.11	-0.56	3.61e-28	Breast cancer;
CRC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12463550	chr7:65579703	CRCP	0.64	6.0	0.31	5.21e-9	Gout;
CRC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.53	7.99	0.4	2.29e-14	Morning vs. evening chronotype;
CRC	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg25721452	chr12:102133339	SYCP3	0.49	6.16	0.32	2.08e-9	Atopic dermatitis;
CRC	trans	rs12699921	0.632	rs2723494	chr7:17853983	C/T	cg15753394	chr6:17282781	RBM24	-0.36	-6.0	-0.31	5.32e-9	Fibrinogen levels;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.67	7.71	0.39	1.48e-13	Body mass index;
CRC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.4	-0.46	9.67e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.03	-0.45	1.45e-17	Bipolar disorder;
CRC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.56	-8.67	-0.43	1.98e-16	Motion sickness;
CRC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.44	0.33	4.24e-10	Tonsillectomy;
CRC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.84	11.0	0.52	3.6e-24	Gut microbiome composition (summer);
CRC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.04	23.48	0.79	2.69e-72	Multiple system atrophy;
CRC	cis	rs9463078	0.625	rs7742360	chr6:44998692	C/G	cg25276700	chr6:44698697	NA	-0.26	-6.22	-0.32	1.51e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs9928842	0.770	rs8048371	chr16:75275547	C/T	cg09066997	chr16:75300724	BCAR1	0.72	7.11	0.37	7.21e-12	Alcoholic chronic pancreatitis;
CRC	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg17133734	chr15:86042851	AKAP13	0.39	6.31	0.33	8.78e-10	Interstitial lung disease;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.87	11.29	0.53	3.27e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7165102	1.000	rs627804	chr15:65734040	A/C	cg22383888	chr3:27764816	EOMES	-0.29	-6.09	-0.32	3.11e-9	Mean corpuscular hemoglobin;
CRC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.7	8.53	0.43	5.36e-16	Bipolar disorder;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg26155979	chr10:105110866	PCGF6	0.34	6.04	0.32	4.24e-9	Interleukin-6 levels;
CRC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg05579598	chr16:88989069	CBFA2T3	0.36	7.1	0.36	7.62e-12	Social autistic-like traits;
CRC	cis	rs4400599	0.618	rs4845610	chr1:154205428	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.73	-0.3	2.22e-8	Platelet distribution width;
CRC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.38	-0.33	6.1e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9491140	0.539	rs980656	chr6:124690303	A/G	cg22366943	chr6:124882293	NKAIN2	0.53	7.98	0.4	2.46e-14	Neuroticism;
CRC	cis	rs17253792	0.545	rs34719936	chr14:56015134	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.17	-0.32	2.02e-9	Putamen volume;
CRC	cis	rs35000415	0.938	rs12536266	chr7:128611035	G/A	cg19972273	chr7:128594194	NA	0.66	6.03	0.32	4.32e-9	Systemic lupus erythematosus;
CRC	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.76	0.35	6.37e-11	Lymphocyte counts;
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg17346650	chr17:80929145	B3GNTL1	0.48	7.05	0.36	1.09e-11	Glycated hemoglobin levels;
CRC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.92	-0.31	8.12e-9	Lung cancer;
CRC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	0.73	8.07	0.41	1.31e-14	Gout;Renal underexcretion gout;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg18758796	chr5:131593413	PDLIM4	0.39	6.31	0.33	9.03e-10	Acylcarnitine levels;
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.61	-0.43	3.02e-16	Bipolar disorder;
CRC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.08	0.32	3.33e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7264396	0.887	rs6120954	chr20:34059536	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.2	-0.32	1.68e-9	Total cholesterol levels;
CRC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.3	0.37	2.2e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.62e-9	Bipolar disorder;
CRC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg03160526	chr17:80928410	B3GNTL1	0.44	6.35	0.33	7.27e-10	Breast cancer;
CRC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.45	-7.34	-0.38	1.69e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg18512352	chr11:47633146	NA	0.36	7.06	0.36	1.02e-11	Subjective well-being;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07362569	chr17:61921086	SMARCD2	0.36	5.6	0.3	4.41e-8	Prudent dietary pattern;
CRC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.84	9.32	0.46	1.7e-18	Inflammatory bowel disease;
CRC	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg13401533	chr1:37979913	MEAF6	0.42	5.95	0.31	6.99e-9	Axial length;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg08901578	chr4:187885870	NA	-0.33	-5.89	-0.31	9.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.47	-7.73	-0.39	1.33e-13	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14640751	chr11:111636595	PPP2R1B	0.49	6.47	0.34	3.49e-10	Thyroid stimulating hormone;
CRC	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg00631329	chr6:26305371	NA	-0.53	-8.86	-0.44	5.06e-17	Educational attainment;
CRC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg16486109	chr11:613632	IRF7	0.69	10.89	0.51	8.63e-24	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.43	5.92	0.31	8.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4499344	0.633	rs259258	chr19:33152523	A/G	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg17633681	chr16:88106987	BANP	0.8	13.72	0.6	3.32e-34	Menopause (age at onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25721516	chr17:42276931	ATXN7L3	0.39	6.08	0.32	3.39e-9	Interleukin-6 levels;
CRC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.76	0.58	1.47e-30	Bone mineral density;
CRC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.77	9.71	0.47	9.48e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg25856811	chr1:152973957	SPRR3	-0.25	-7.06	-0.36	9.83e-12	Inflammatory skin disease;
CRC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg23262073	chr20:60523788	NA	-0.41	-6.94	-0.36	2.1e-11	Body mass index;
CRC	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg22590775	chr19:49891494	CCDC155	0.61	5.85	0.31	1.21e-8	Multiple sclerosis;
CRC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.35	6.25	0.33	1.24e-9	Erythrocyte sedimentation rate;
CRC	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg04586622	chr2:25135609	ADCY3	-0.58	-9.93	-0.48	1.67e-20	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13645704	chr7:6522802	KDELR2	0.43	6.4	0.33	5.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.63	9.56	0.47	2.86e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01591470	chr14:39736043	CTAGE5	-0.41	-6.17	-0.32	2.03e-9	Myopia (pathological);
CRC	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-1.23	-10.17	-0.49	2.65e-21	Mitochondrial DNA levels;
CRC	trans	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg21153622	chr11:89784906	NA	-0.44	-7.05	-0.36	1.06e-11	HDL cholesterol;
CRC	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.46	6.71	0.35	8.6e-11	Pulmonary function decline;
CRC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.39	6.65	0.34	1.23e-10	Crohn's disease;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg03395511	chr6:291903	DUSP22	-0.51	-7.03	-0.36	1.19e-11	Menopause (age at onset);
CRC	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.52	8.81	0.44	7.42e-17	Dupuytren's disease;
CRC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg21620606	chr4:1342894	KIAA1530	0.4	7.06	0.36	9.95e-12	Longevity;
CRC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.64	8.0	0.4	2.14e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.57	8.56	0.43	4.54e-16	High light scatter reticulocyte count;
CRC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.36	5.65	0.3	3.55e-8	Total body bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26742440	chr11:73472391	RAB6A	0.51	6.81	0.35	4.58e-11	Thyroid stimulating hormone;
CRC	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.73	-11.89	-0.55	2.35e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.44	-0.42	1.04e-15	Bipolar disorder;
CRC	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	5.85	0.31	1.16e-8	Ovarian reserve;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16527794	chr11:47600580	NDUFS3;KBTBD4	0.37	6.16	0.32	2.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467711	0.516	rs548987	chr6:25869371	C/G	cg08501292	chr6:25962987	TRIM38	0.55	6.35	0.33	7.25e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.96	13.8	0.61	1.7e-34	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05790658	chr4:143748032	INPP4B	-0.37	-5.98	-0.31	5.89e-9	HDL cholesterol;
CRC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.7	-0.39	1.64e-13	Vitiligo;
CRC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-8.46	-0.42	8.99e-16	Menarche (age at onset);
CRC	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.47	-0.34	3.58e-10	Alcohol dependence;
CRC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.49	9.28	0.46	2.34e-18	Alcohol dependence;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.32	4.59e-9	Depression;
CRC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.6	9.03	0.45	1.47e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg01339444	chr6:118972232	C6orf204	0.5	6.12	0.32	2.72e-9	Renal cell carcinoma;
CRC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.76	6.91	0.36	2.55e-11	Paclitaxel disposition in epithelial ovarian cancer;
CRC	trans	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.01	-0.36	1.37e-11	Life satisfaction;
CRC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.76	-0.35	6.48e-11	Lung cancer;
CRC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg23392782	chr16:88772647	RNF166;CTU2	-0.53	-6.26	-0.33	1.21e-9	Hirschsprung disease;
CRC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg09417038	chr21:47716443	C21orf57	-0.38	-6.24	-0.33	1.36e-9	Testicular germ cell tumor;
CRC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	11.82	0.55	4.31e-27	Menopause (age at onset);
CRC	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg20356878	chr3:121714668	ILDR1	-0.42	-5.94	-0.31	7.35e-9	Multiple sclerosis;
CRC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.38	8.35	0.42	1.89e-15	Eye color traits;
CRC	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	17.36	0.69	2.15e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-7.03	-0.36	1.17e-11	Schizophrenia;
CRC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg22495460	chr2:25135724	ADCY3	-0.87	-17.16	-0.69	1.4e-47	Body mass index;
CRC	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.67	10.43	0.5	3.39e-22	Corneal astigmatism;
CRC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.44	0.53	9.85e-26	Hip circumference adjusted for BMI;
CRC	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.22e-37	Colorectal cancer;
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.84e-9	Life satisfaction;
CRC	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.41	0.33	5.11e-10	Life satisfaction;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23708337	chr7:1209742	NA	0.5	7.67	0.39	2.02e-13	Longevity;Endometriosis;
CRC	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg25809561	chr17:30822961	MYO1D	0.52	9.43	0.46	7.81e-19	Schizophrenia;
CRC	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg14458575	chr2:238380390	NA	-0.54	-7.08	-0.36	8.7e-12	Prostate cancer;
CRC	cis	rs2421770	0.530	rs7930134	chr11:35367017	A/C	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.68	-0.35	1.05e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg02683197	chr6:28174875	NA	-0.55	-5.86	-0.31	1.13e-8	Depression;
CRC	cis	rs7804356	0.953	rs73069539	chr7:26903661	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-5.93	-0.31	7.6e-9	Type 1 diabetes;
CRC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.73	-12.82	-0.58	8.7e-31	White blood cell count (basophil);
CRC	cis	rs282587	0.569	rs415552	chr13:113407564	A/C	cg04656015	chr13:113407548	ATP11A	0.62	7.97	0.4	2.63e-14	Glycated hemoglobin levels;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg20397358	chr22:38597902	MAFF	-0.71	-6.17	-0.32	2.03e-9	Cognitive function;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.69	-10.75	-0.51	2.74e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.81	0.35	4.7e-11	Aortic root size;
CRC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg09264619	chr17:80180166	NA	0.5	7.26	0.37	2.77e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.6	8.96	0.44	2.55e-17	Lung cancer;
CRC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg24849736	chr1:201084428	NA	-0.63	-12.04	-0.55	6.41e-28	Permanent tooth development;
CRC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.69	0.63	6.35e-38	Lymphocyte percentage of white cells;
CRC	cis	rs10046574	0.519	rs9656456	chr7:135202208	G/A	cg27474649	chr7:135195673	CNOT4	0.67	6.29	0.33	9.88e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg26043149	chr18:55253948	FECH	-0.49	-7.51	-0.38	5.78e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.57	-6.08	-0.32	3.3e-9	Vitiligo;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg11843238	chr5:131593191	PDLIM4	0.5	9.48	0.46	5.25e-19	Acylcarnitine levels;
CRC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26240231	chr7:1148101	C7orf50	-0.42	-5.99	-0.31	5.56e-9	Bronchopulmonary dysplasia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00867475	chr7:99746517	C7orf59	0.42	6.06	0.32	3.74e-9	Anxiety disorder;
CRC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.38	0.38	1.32e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.44	7.49	0.38	6.24e-13	Common traits (Other);
CRC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.32	-6.98	-0.36	1.63e-11	IgG glycosylation;
CRC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07513332	chr6:167530253	CCR6	-0.38	-6.58	-0.34	1.82e-10	Rheumatoid arthritis;
CRC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.46	-7.4	-0.38	1.15e-12	Type 2 diabetes;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24666276	chr8:128748214	MYC	0.42	6.2	0.32	1.66e-9	Myopia (pathological);
CRC	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.74	11.12	0.52	1.32e-24	Testicular germ cell tumor;
CRC	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.67	10.92	0.52	6.75e-24	Schizophrenia;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg02683197	chr6:28174875	NA	0.68	6.7	0.35	8.9e-11	Lung cancer in ever smokers;
CRC	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.82	0.4	7.25e-14	Blood metabolite levels;
CRC	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.96	-0.31	6.43e-9	Height;
CRC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.57	10.18	0.49	2.44e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.52	0.46	3.78e-19	Height;
CRC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg25985355	chr7:65971099	NA	-0.52	-5.9	-0.31	8.8e-9	Diabetic kidney disease;
CRC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg09876464	chr15:85330779	ZNF592	0.39	6.48	0.34	3.34e-10	P wave terminal force;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg15845792	chr6:28175446	NA	0.58	8.25	0.41	3.8e-15	Hepatitis A;
CRC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.3	-0.46	2.01e-18	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.21	0.37	3.97e-12	Breast cancer;
CRC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.74	11.17	0.52	8.95e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	10.3	0.49	9.14e-22	Schizophrenia;
CRC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg25767906	chr1:53392781	SCP2	0.4	6.54	0.34	2.35e-10	Monocyte count;
CRC	cis	rs501120	0.657	rs494207	chr10:44741256	G/A	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg00255919	chr5:131827918	IRF1	-0.35	-5.91	-0.31	8.6e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.96	-0.4	2.87e-14	Gut microbiome composition (summer);
CRC	trans	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.19	-0.32	1.82e-9	Aortic root size;
CRC	cis	rs4073416	0.518	rs11158595	chr14:65906369	A/G	cg03016385	chr14:66212404	NA	-0.44	-5.99	-0.31	5.49e-9	N-glycan levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg11361335	chr5:153653483	GALNT10	-0.37	-6.04	-0.32	4.1e-9	HDL cholesterol;
CRC	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-7.53	-0.38	4.9e-13	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.87	-13.87	-0.61	9.35e-35	Cognitive function;
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.82	-8.74	-0.43	1.18e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.88	-0.35	3.08e-11	Vitiligo;
CRC	cis	rs17767392	0.958	rs2332641	chr14:72044728	T/G	cg13720639	chr14:72061746	SIPA1L1	0.57	7.01	0.36	1.37e-11	Mitral valve prolapse;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27194998	chr19:47217554	PRKD2	0.36	5.98	0.31	5.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg27068330	chr11:65405492	SIPA1	-0.47	-6.55	-0.34	2.24e-10	Breast cancer;
CRC	cis	rs7692995	0.920	rs1380294	chr4:18024121	C/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs4132509	1.000	rs6660534	chr1:243791642	A/C	cg21452805	chr1:244014465	NA	0.5	6.92	0.36	2.35e-11	RR interval (heart rate);
CRC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.45	6.81	0.35	4.61e-11	Mean platelet volume;
CRC	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.53	-7.06	-0.36	1.01e-11	Triglycerides;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-11.87	-0.55	2.79e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg00343986	chr7:65444356	GUSB	0.49	7.27	0.37	2.71e-12	Aortic root size;
CRC	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.44	0.42	1.06e-15	Platelet distribution width;
CRC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.02	-0.32	4.63e-9	Alzheimer's disease (late onset);
CRC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg05044414	chr3:183734942	ABCC5	0.35	5.87	0.31	1.06e-8	Anterior chamber depth;
CRC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.79	-0.35	5.37e-11	Mean corpuscular volume;
CRC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs12931792	0.782	rs12927190	chr16:30169393	C/G	cg17640201	chr16:30407289	ZNF48	0.41	5.78	0.3	1.75e-8	Tonsillectomy;
CRC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg04110750	chr16:69646130	NFAT5	-0.49	-7.11	-0.37	7.06e-12	IgE levels;
CRC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.59	8.46	0.42	9.18e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.73	-8.36	-0.42	1.76e-15	Systolic blood pressure;
CRC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg04880052	chr2:219191631	PNKD	-0.39	-5.88	-0.31	1.03e-8	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.81	-0.44	7.57e-17	Aortic root size;
CRC	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.34	-0.38	1.63e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.4	-7.21	-0.37	3.78e-12	Childhood ear infection;
CRC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.67	0.43	2.05e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2421770	0.530	rs4756217	chr11:35366733	C/T	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.68	-0.35	1.05e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12149777	chr4:139937459	CCRN4L	0.37	5.97	0.31	6.08e-9	Obesity-related traits;
CRC	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.68	-8.92	-0.44	3.4e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.32	0.46	1.68e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.03	0.61	2.24e-35	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03552687	chr12:94071294	CRADD	0.42	6.02	0.31	4.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg15083037	chr5:83017644	HAPLN1	-0.46	-6.38	-0.33	6.15e-10	Prostate cancer;
CRC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg19193384	chr17:30244184	NA	-0.53	-6.73	-0.35	7.6e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg15654264	chr1:150340011	RPRD2	0.4	5.91	0.31	8.38e-9	Morning vs. evening chronotype;
CRC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	13.61	0.6	9.4e-34	Chronic sinus infection;
CRC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.67	0.54	1.44e-26	Prudent dietary pattern;
CRC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.58	-6.74	-0.35	7.1e-11	Red cell distribution width;
CRC	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.63	-8.52	-0.43	5.71e-16	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg00691999	chr4:55094011	PDGFRA	0.44	6.46	0.34	3.74e-10	Corneal astigmatism;
CRC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-7.58	-0.39	3.65e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.94	-0.31	7.29e-9	Educational attainment;
CRC	cis	rs7605827	0.930	rs2058867	chr2:15520153	T/C	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.05e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	6.09	0.32	3.22e-9	Neuroticism;
CRC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.22	-0.32	1.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg10729496	chr3:10149963	C3orf24	0.5	6.81	0.35	4.65e-11	Alzheimer's disease;
CRC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg10298567	chr3:47292165	KIF9	-0.38	-6.17	-0.32	1.99e-9	Colorectal cancer;
CRC	cis	rs9287719	0.624	rs10172926	chr2:10733254	A/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg12458913	chr13:53173898	NA	0.54	8.53	0.43	5.32e-16	Lewy body disease;
CRC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.56	7.98	0.4	2.47e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	6.06	0.32	3.74e-9	Mood instability;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.76	8.49	0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.14	-0.32	2.32e-9	Bipolar disorder;
CRC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-10.4	-0.5	4.18e-22	Neuroticism;
CRC	cis	rs427943	0.750	rs9974232	chr21:46617587	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	6.02	0.32	4.53e-9	Body mass index;
CRC	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.5	0.54	5.82e-26	Exhaled nitric oxide levels;
CRC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.59	6.66	0.34	1.17e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.39	-7.01	-0.36	1.37e-11	Dupuytren's disease;
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.54	7.92	0.4	3.75e-14	Testicular germ cell tumor;
CRC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.89	-0.48	2.26e-20	Bladder cancer;
CRC	cis	rs11212617	0.967	rs4754324	chr11:108325448	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.67	0.3	3.09e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg16060761	chr17:80687452	NA	-0.45	-5.8	-0.3	1.52e-8	Glycated hemoglobin levels;
CRC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.74e-21	Alzheimer's disease (late onset);
CRC	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.4	-7.13	-0.37	6.37e-12	Hepatitis;
CRC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.52	-6.58	-0.34	1.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.61	10.71	0.51	3.56e-23	Schizophrenia;
CRC	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.77	6.28	0.33	1.05e-9	Body mass index;
CRC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg27523141	chr10:43048294	ZNF37B	-0.48	-6.85	-0.35	3.72e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg15848620	chr12:58087721	OS9	-0.65	-9.11	-0.45	7.98e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg12193833	chr17:30244370	NA	-0.58	-7.81	-0.4	7.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.65	-7.78	-0.39	9.41e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg01874867	chr7:94954059	PON1	-0.51	-6.42	-0.33	4.74e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs853679	1.000	rs853676	chr6:28299687	C/T	cg15845792	chr6:28175446	NA	0.58	5.82	0.31	1.4e-8	Depression;
CRC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07587117	chr16:2239488	CASKIN1	0.49	9.24	0.45	3.12e-18	Height;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.89	-21.06	-0.76	5.88e-63	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4561483	0.798	rs456325	chr16:12012562	C/G	cg08843971	chr16:11963173	GSPT1	-0.63	-8.94	-0.44	2.82e-17	Testicular germ cell tumor;
CRC	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.53	-6.18	-0.32	1.86e-9	Coronary artery calcification;
CRC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg27523141	chr10:43048294	ZNF37B	0.5	7.22	0.37	3.55e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg15147215	chr3:52552868	STAB1	-0.43	-6.09	-0.32	3.17e-9	Bipolar disorder;
CRC	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.64	11.52	0.54	5.1e-26	Blood metabolite ratios;
CRC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.31	-0.46	1.84e-18	Aortic root size;
CRC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.2	-0.45	4.27e-18	Reticulocyte fraction of red cells;
CRC	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg17120908	chr11:65337727	SSSCA1	0.7	7.79	0.39	8.59e-14	Bone mineral density;
CRC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.12	-0.32	2.69e-9	Arsenic metabolism;
CRC	cis	rs3751196	0.521	rs17034637	chr12:104217600	A/C	cg02344784	chr12:104178138	NT5DC3	-0.7	-7.29	-0.37	2.29e-12	Sense of smell;
CRC	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs35000415	0.938	rs17424602	chr7:128687940	A/G	cg19972273	chr7:128594194	NA	0.72	6.27	0.33	1.16e-9	Systemic lupus erythematosus;
CRC	cis	rs7945718	0.650	rs4316494	chr11:12664541	C/T	cg25843174	chr11:12811716	TEAD1	-0.42	-7.65	-0.39	2.2e-13	Educational attainment (years of education);
CRC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.72	-0.3	2.36e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs7605827	0.897	rs7590963	chr2:15527888	T/C	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	7.9e-9	Educational attainment (years of education);
CRC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.62	-9.51	-0.46	4.31e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.8	12.86	0.58	6.31e-31	Height;
CRC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg12564285	chr5:131593104	PDLIM4	0.45	7.58	0.39	3.59e-13	Acylcarnitine levels;
CRC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.52	-0.34	2.61e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg01448155	chr10:3564782	NA	0.52	6.22	0.32	1.5e-9	Lymphocyte percentage of white cells;
CRC	cis	rs753955	0.554	rs2031587	chr13:24417335	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.39	5.83	0.31	1.33e-8	Lung cancer;
CRC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.72	8.0	0.4	2.21e-14	Vitiligo;
CRC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg19077165	chr18:44547161	KATNAL2	0.46	6.74	0.35	7.31e-11	Personality dimensions;
CRC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.26	-0.73	6.71e-56	Height;
CRC	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.45	7.25	0.37	3.03e-12	Response to radiotherapy in cancer (late toxicity);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10778407	chr1:6306850	NA	0.43	6.59	0.34	1.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg00666640	chr1:248458726	OR2T12	0.48	8.18	0.41	6.14e-15	Common traits (Other);
CRC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.75	9.08	0.45	1.03e-17	Body mass index;
CRC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.58	-9.08	-0.45	1.04e-17	Aortic root size;
CRC	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg09659197	chr4:152720779	NA	0.37	7.43	0.38	9.2e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4073416	0.542	rs9323461	chr14:66031405	T/C	cg03016385	chr14:66212404	NA	-0.45	-6.19	-0.32	1.78e-9	N-glycan levels;
CRC	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg00631329	chr6:26305371	NA	-0.54	-9.0	-0.44	1.83e-17	Educational attainment;
CRC	trans	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	6.12	0.32	2.71e-9	Menarche (age at onset);
CRC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.42	-6.82	-0.35	4.48e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.71	7.15	0.37	5.8e-12	Diabetic retinopathy;
CRC	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.23	0.45	3.27e-18	Mean corpuscular volume;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg11843238	chr5:131593191	PDLIM4	0.49	9.31	0.46	1.86e-18	Acylcarnitine levels;
CRC	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	7.14	0.37	5.92e-12	Body mass index;
CRC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.44	-5.85	-0.31	1.16e-8	Type 2 diabetes;
CRC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.63	0.3	3.88e-8	Bladder cancer;
CRC	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.89	0.31	9.33e-9	Ovarian reserve;
CRC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.06	0.69	3.29e-47	Platelet count;
CRC	cis	rs539096	0.624	rs11210892	chr1:44100084	A/G	cg12908607	chr1:44402522	ARTN	0.39	6.77	0.35	5.91e-11	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.32e-19	Blood protein levels;
CRC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg00129232	chr17:37814104	STARD3	0.57	7.04	0.36	1.14e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.9	-20.28	-0.75	7.02e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.46	6.85	0.35	3.63e-11	Crohn's disease;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.57	-8.02	-0.4	1.89e-14	Lung cancer;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs6988985	0.703	rs6988323	chr8:143946483	A/G	cg10324643	chr8:143916377	GML	0.36	5.87	0.31	1.06e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11344692	chr8:61429175	RAB2A	0.47	6.77	0.35	5.9e-11	Response to antipsychotic treatment;
CRC	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.57	-0.47	2.74e-19	Type 2 diabetes;
CRC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg13385521	chr17:29058706	SUZ12P	0.64	7.72	0.39	1.39e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.68	10.81	0.51	1.68e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.52	11.45	0.53	8.98e-26	Urate levels in overweight individuals;
CRC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.59	-0.5	9.83e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.55	9.44	0.46	6.87e-19	Common traits (Other);
CRC	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.66	8.78	0.44	9.36e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.57	-7.37	-0.38	1.42e-12	Gut microbiome composition (summer);
CRC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.53	-8.11	-0.41	1.01e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg09655341	chr17:79618100	PDE6G	-0.36	-6.24	-0.33	1.31e-9	Eye color traits;
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg08888203	chr3:10149979	C3orf24	0.61	8.51	0.42	6.11e-16	Alzheimer's disease;
CRC	cis	rs17234274	0.644	rs10767018	chr11:23221897	G/T	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.02e-8	Cancer;
CRC	cis	rs643506	1.000	rs612345	chr11:111639122	G/A	cg09085632	chr11:111637200	PPP2R1B	0.5	6.38	0.33	6.1e-10	Breast cancer;
CRC	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.4	6.1	0.32	3.05e-9	Essential tremor;
CRC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg10645314	chr2:3704589	ALLC	-0.69	-7.78	-0.39	9.55e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03676636	chr4:99064102	C4orf37	0.2	5.85	0.31	1.2e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.06e-10	Hepatitis;
CRC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.77	13.16	0.59	4.58e-32	Blood protein levels;
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.83e-9	Life satisfaction;
CRC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	8.72	0.43	1.36e-16	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12877462	chr4:100484858	RG9MTD2;MTTP	0.48	6.95	0.36	1.98e-11	Response to antipsychotic treatment;
CRC	cis	rs6840360	0.642	rs10454251	chr4:152383962	A/G	cg09659197	chr4:152720779	NA	0.33	6.47	0.34	3.6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg00246817	chr9:123691163	NA	-0.44	-5.6	-0.3	4.47e-8	Rheumatoid arthritis;
CRC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs447	0.806	rs12707617	chr7:83745474	G/A	cg22846510	chr7:83753280	SEMA3A	-0.41	-5.7	-0.3	2.65e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.79	14.22	0.62	4.13e-36	Breast cancer;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23161317	chr6:28129485	ZNF389	0.44	5.76	0.3	1.96e-8	Parkinson's disease;
CRC	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg14673194	chr17:80132900	CCDC57	-0.48	-6.02	-0.32	4.56e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg18404041	chr3:52824283	ITIH1	-0.33	-6.52	-0.34	2.72e-10	Schizophrenia;
CRC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-12.41	-0.56	2.85e-29	Asthma;
CRC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.99	0.31	5.64e-9	HDL cholesterol;
CRC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	7.31	0.37	2.06e-12	Neuroticism;
CRC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg25876840	chr17:41920477	NA	0.56	7.83	0.4	6.79e-14	Triglycerides;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg11843238	chr5:131593191	PDLIM4	0.46	7.66	0.39	2.03e-13	Breast cancer;
CRC	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.55	6.16	0.32	2.1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-7.61	-0.39	2.89e-13	Blood metabolite levels;
CRC	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.54	-7.93	-0.4	3.4e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2786111	0.965	rs1764788	chr1:197291306	A/G	cg13682187	chr1:196946512	CFHR5	0.29	5.74	0.3	2.17e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.43	-5.66	-0.3	3.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4523957	0.579	rs57130712	chr17:2089035	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-9.86	-0.48	2.86e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs728616	0.614	rs61859210	chr10:82131468	G/C	cg05935833	chr10:81318306	SFTPA2	-0.58	-7.02	-0.36	1.28e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg14092571	chr14:90743983	NA	0.38	5.92	0.31	8.07e-9	Mortality in heart failure;
CRC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.83	-14.18	-0.62	5.91e-36	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.83	11.47	0.53	7.37e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.51	-0.57	1.25e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.74	10.97	0.52	4.67e-24	Menarche (age at onset);
CRC	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg00531865	chr16:30841666	NA	0.49	6.82	0.35	4.32e-11	Dementia with Lewy bodies;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10681328	chr12:56915608	RBMS2	0.48	6.98	0.36	1.59e-11	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.44	5.66	0.3	3.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.41	5.92	0.31	8.07e-9	Osteoporosis;
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.68	-0.43	1.83e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs34435647	1	rs34435647	chr2:160518289	CT/C	cg08347373	chr2:160653686	CD302	-0.38	-6.2	-0.32	1.72e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;
CRC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.46	-6.05	-0.32	3.95e-9	Multiple sclerosis;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.64	8.97	0.44	2.38e-17	Parkinson's disease;
CRC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.61	8.82	0.44	6.62e-17	Response to temozolomide;
CRC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-6.64	-0.34	1.3e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	8.33	0.42	2.28e-15	Lymphocyte counts;
CRC	cis	rs11212617	0.869	rs4754299	chr11:108025214	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.38	5.62	0.3	4.08e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg26762873	chr11:5879799	OR52E8	-0.4	-5.88	-0.31	1.01e-8	DNA methylation (variation);
CRC	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg05585544	chr11:47624801	NA	0.41	6.23	0.33	1.4e-9	Mean corpuscular hemoglobin;
CRC	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.43	-8.38	-0.42	1.55e-15	Alcohol dependence;
CRC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.52	9.28	0.46	2.38e-18	Total body bone mineral density;
CRC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.63	9.55	0.47	3.07e-19	Night sleep phenotypes;
CRC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.55	8.15	0.41	7.91e-15	Resting heart rate;
CRC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.98	-0.52	4.01e-24	Testicular germ cell tumor;
CRC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.82	11.24	0.53	4.86e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4380275	1.000	rs4268954	chr2:772834	A/G	cg27237671	chr2:676223	TMEM18	-0.42	-6.06	-0.32	3.69e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs6141769	0.542	rs28542091	chr20:31301402	T/C	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.84	-0.31	1.27e-8	Subjective well-being;
CRC	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg06636001	chr8:8085503	FLJ10661	0.52	7.94	0.4	3.24e-14	Neuroticism;
CRC	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.41	0.53	1.28e-25	Coffee consumption (cups per day);
CRC	trans	rs4745661	0.564	rs1328523	chr9:80451693	C/A	cg02160872	chr5:212506	CCDC127	0.37	5.98	0.31	5.69e-9	IgG glycosylation;
CRC	cis	rs7945718	0.621	rs10765984	chr11:12672669	T/C	cg25843174	chr11:12811716	TEAD1	0.4	7.15	0.37	5.65e-12	Educational attainment (years of education);
CRC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.49	6.16	0.32	2.12e-9	Recombination rate (females);
CRC	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.4	-7.91	-0.4	3.86e-14	Migraine;
CRC	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.31	6.22	0.32	1.51e-9	Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.87	-0.55	2.74e-27	Colorectal cancer;
CRC	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.53	7.95	0.4	2.96e-14	Acylcarnitine levels;
CRC	trans	rs1957429	0.520	rs12435626	chr14:65295215	A/G	cg03748857	chr16:85658239	KIAA0182	-0.57	-6.13	-0.32	2.5e-9	Pediatric areal bone mineral density (radius);
CRC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	10.0	0.48	9.68e-21	Platelet count;
CRC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.81	-13.49	-0.6	2.52e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.52	0.6	2.03e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	cis	rs73206853	0.764	rs7960705	chr12:111084540	G/A	cg12870014	chr12:110450643	ANKRD13A	0.79	9.12	0.45	7.53e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-1.07	-7.92	-0.4	3.8e-14	Blood metabolite levels;
CRC	cis	rs6681460	0.837	rs6669023	chr1:67171868	G/T	cg02459107	chr1:67143332	SGIP1	0.35	5.89	0.31	9.71e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg26587870	chr6:27730563	NA	-0.39	-5.86	-0.31	1.13e-8	Cardiac Troponin-T levels;
CRC	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.6	-6.99	-0.36	1.5e-11	Blood trace element (Zn levels);
CRC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.7	-10.01	-0.48	9.18e-21	Heart rate;
CRC	cis	rs9463078	0.625	rs679713	chr6:44899632	T/C	cg25276700	chr6:44698697	NA	-0.25	-6.09	-0.32	3.08e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg22753661	chr15:79092743	ADAMTS7	0.42	5.95	0.31	7.04e-9	Coronary artery disease or large artery stroke;
CRC	trans	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg09324608	chr17:30823087	MYO1D	0.33	5.72	0.3	2.43e-8	Schizophrenia;
CRC	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11446398	chr5:77624930	NA	0.42	6.27	0.33	1.13e-9	Triglycerides;
CRC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-6.28	-0.33	1.06e-9	Blood protein levels;
CRC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.68	10.0	0.48	9.98e-21	Longevity;
CRC	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg22681709	chr2:178499509	PDE11A	-0.33	-6.07	-0.32	3.56e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12230513	0.732	rs60683621	chr12:55863224	C/G	cg19537932	chr12:55886519	OR6C68	-0.72	-9.14	-0.45	6.52e-18	Contrast sensitivity;
CRC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.5	7.68	0.39	1.82e-13	Red blood cell count;
CRC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.66	-0.34	1.15e-10	Menopause (age at onset);
CRC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.65	0.43	2.26e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg07166546	chr14:35805898	NA	-0.28	-5.6	-0.3	4.45e-8	Psoriasis;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg25164649	chr6:28176230	NA	0.65	8.59	0.43	3.64e-16	Parkinson's disease;
CRC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.38	0.33	6.11e-10	Heart rate;
CRC	trans	rs926326	0.866	rs35785909	chr6:25511309	G/A	cg25354657	chr11:129991445	APLP2	-0.42	-6.24	-0.33	1.31e-9	Platelet count;
CRC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.47	6.59	0.34	1.71e-10	Schizophrenia;
CRC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg27535305	chr1:53392650	SCP2	0.34	6.04	0.32	4.09e-9	Monocyte count;
CRC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.48	7.49	0.38	6.37e-13	Monobrow;
CRC	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg18196295	chr10:418757	DIP2C	-0.51	-7.78	-0.39	9.47e-14	Psychosis in Alzheimer's disease;
CRC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg03160526	chr17:80928410	B3GNTL1	-0.42	-6.07	-0.32	3.56e-9	Breast cancer;
CRC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg16358738	chr2:241808595	AGXT	-0.37	-5.67	-0.3	3.19e-8	Urinary metabolites;
CRC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg23590916	chr17:43697445	MGC57346	0.72	7.15	0.37	5.58e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg04362960	chr10:104952993	NT5C2	0.85	7.93	0.4	3.47e-14	Arsenic metabolism;
CRC	trans	rs3757458	0.546	rs73173757	chr7:101014265	A/G	cg01200482	chr7:62514477	NA	0.75	6.06	0.32	3.81e-9	QT interval;
CRC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.46	-9.09	-0.45	9.35e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00269115	chr1:23695530	C1orf213;ZNF436	0.48	6.73	0.35	7.6e-11	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11854871	chr1:110881943	RBM15	0.39	6.01	0.31	4.86e-9	Schizophrenia;
CRC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.6	-8.56	-0.43	4.53e-16	Lung cancer;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.73	0.43	1.29e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg22495460	chr2:25135724	ADCY3	-0.87	-16.95	-0.68	9.6e-47	Body mass index;
CRC	cis	rs11229555	0.645	rs12269745	chr11:58176875	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10986311	0.775	rs6478658	chr9:127127810	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.39	-5.97	-0.31	6.11e-9	Vitiligo;
CRC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	8.96	0.44	2.41e-17	Platelet count;
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23378565	chr7:2036160	MAD1L1	0.4	6.09	0.32	3.21e-9	Bipolar disorder;
CRC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.33	6.54	0.34	2.32e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.18	-0.37	4.6e-12	Capecitabine sensitivity;
CRC	cis	rs863345	0.604	rs11264976	chr1:158446927	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-5.92	-0.31	8.16e-9	Pneumococcal bacteremia;
CRC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.72	-11.82	-0.55	4.05e-27	DNA methylation (variation);
CRC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.53	8.2	0.41	5.57e-15	Intelligence (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg06204229	chr3:52865917	ITIH4	-0.42	-5.62	-0.3	4e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.68	-8.98	-0.44	2.09e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.8	-8.59	-0.43	3.55e-16	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg26587870	chr6:27730563	NA	-0.69	-6.4	-0.33	5.43e-10	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.2	-0.32	1.7e-9	Educational attainment;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.53	7.94	0.4	3.33e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.98	-19.36	-0.73	2.81e-56	Height;
CRC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs12541635	0.966	rs2059943	chr8:107071607	G/T	cg10147462	chr8:107024639	NA	0.43	7.14	0.37	5.97e-12	Age of smoking initiation;
CRC	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.48	7.38	0.38	1.32e-12	Malaria;
CRC	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.45	-7.1	-0.36	7.65e-12	Obesity-related traits;
CRC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.48	-7.76	-0.39	1.1e-13	Fat distribution (HIV);
CRC	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.55	0.47	3.03e-19	Type 2 diabetes;
CRC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg22974920	chr21:40686053	BRWD1	-0.45	-6.34	-0.33	7.6e-10	Cognitive function;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	0.7	10.59	0.5	9.61e-23	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg10483660	chr13:112241077	NA	0.37	5.96	0.31	6.48e-9	Menarche (age at onset);
CRC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg27535305	chr1:53392650	SCP2	-0.34	-5.88	-0.31	9.81e-9	Monocyte count;
CRC	cis	rs11696845	0.712	rs6130685	chr20:43366730	T/G	cg25301532	chr20:43378953	KCNK15	0.37	6.2	0.32	1.69e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07145255	chr5:59995354	DEPDC1B	0.5	7.18	0.37	4.6e-12	Response to antipsychotic treatment;
CRC	cis	rs2860975	0.967	rs7902572	chr10:96772717	C/A	cg09036531	chr10:96991505	NA	-0.42	-5.71	-0.3	2.48e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs737008	0.922	rs11074957	chr16:11378151	G/A	cg00044050	chr16:11439710	C16orf75	-0.45	-6.1	-0.32	3.03e-9	Obesity-related traits;
CRC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg08533674	chr1:46993347	NA	-0.82	-10.55	-0.5	1.33e-22	Monobrow;
CRC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.59	7.93	0.4	3.47e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-5.98	-0.31	5.77e-9	Height;
CRC	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	cg04338863	chr8:33670619	NA	0.44	6.96	0.36	1.8e-11	Body mass index;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg15786705	chr6:28176104	NA	0.59	8.76	0.43	1.05e-16	Parkinson's disease;
CRC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs910873	0.505	rs67260051	chr20:33448417	C/T	cg08999081	chr20:33150536	PIGU	-0.46	-5.68	-0.3	2.91e-8	Melanoma;
CRC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.52	6.84	0.35	3.98e-11	Obesity-related traits;
CRC	cis	rs11958404	0.932	rs72818127	chr5:157452227	C/T	cg05962755	chr5:157440814	NA	1.0	12.83	0.58	7.84e-31	IgG glycosylation;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.63	-12.52	-0.57	1.16e-29	Electroencephalogram traits;
CRC	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-7.77	-0.39	1.03e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg09592903	chr2:55203963	RTN4	0.71	11.4	0.53	1.35e-25	Mean platelet volume;
CRC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg13607699	chr17:42295918	UBTF	-0.49	-6.41	-0.33	5.11e-10	Total body bone mineral density;
CRC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.68	-11.49	-0.54	6.33e-26	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg08798685	chr6:27730294	NA	-0.42	-6.22	-0.32	1.51e-9	Parkinson's disease;
CRC	cis	rs459193	0.917	rs40270	chr5:55804552	A/C	cg18302225	chr5:55776401	NA	0.57	7.99	0.4	2.23e-14	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-11.37	-0.53	1.7e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.15	-0.41	7.84e-15	Recombination measurement;
CRC	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg21452805	chr1:244014465	NA	0.45	6.23	0.32	1.44e-9	RR interval (heart rate);
CRC	cis	rs6748734	0.625	rs4675792	chr2:241819526	A/G	cg16358738	chr2:241808595	AGXT	0.41	7.35	0.38	1.6e-12	Urinary metabolites;
CRC	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg19193384	chr17:30244184	NA	-0.49	-6.43	-0.33	4.49e-10	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	7.58	0.39	3.58e-13	Diisocyanate-induced asthma;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.43	6.0	0.31	5.26e-9	Breast cancer;
CRC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.53	-6.35	-0.33	7.35e-10	Diastolic blood pressure;
CRC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.05	20.08	0.74	4.12e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.59	-0.34	1.8e-10	Breast cancer;
CRC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.94	14.07	0.61	1.61e-35	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06235973	chr19:14183619	LOC113230	-0.47	-6.2	-0.32	1.7e-9	Diisocyanate-induced asthma;
CRC	cis	rs4722166	0.532	rs6461662	chr7:22757089	C/T	cg05472934	chr7:22766657	IL6	0.68	10.86	0.51	1.12e-23	Lung cancer;
CRC	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.51	6.85	0.35	3.54e-11	Breast cancer;
CRC	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg16898833	chr6:26189333	HIST1H4D	0.62	5.8	0.3	1.59e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.44	6.89	0.36	2.79e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.35	5.66	0.3	3.37e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.65e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20092199	chr4:1342459	KIAA1530	0.45	7.97	0.4	2.6e-14	Longevity;
CRC	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg25856811	chr1:152973957	SPRR3	-0.21	-5.62	-0.3	4.03e-8	Inflammatory skin disease;
CRC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	14.84	0.63	1.66e-38	Smoking behavior;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6445967	1.000	rs2292673	chr3:58301901	G/A	cg23715586	chr3:58305044	RPP14	0.35	5.82	0.31	1.39e-8	Platelet count;
CRC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.65	-7.66	-0.39	2.12e-13	Cleft lip with or without cleft palate;
CRC	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.35	-0.38	1.6e-12	Inflammatory skin disease;
CRC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.9e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg19678392	chr7:94953810	PON1	0.56	7.11	0.37	7.11e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.62	7.6	0.39	3.2e-13	Menarche (age at onset);
CRC	cis	rs9648716	0.608	rs1267610	chr7:140525883	C/T	cg17554604	chr7:140774522	NA	0.44	5.9	0.31	8.81e-9	Type 2 diabetes;
CRC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.11	-15.69	-0.65	8.5e-42	Hip circumference adjusted for BMI;
CRC	cis	rs534126	0.778	rs6464540	chr7:142954903	G/A	cg04039957	chr7:143013207	CLCN1	0.34	5.68	0.3	2.96e-8	Cancer;
CRC	cis	rs4731207	0.596	rs7802210	chr7:124632460	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.27	-0.33	1.15e-9	Cutaneous malignant melanoma;
CRC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.42	5.61	0.3	4.25e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg14828511	chr1:107599125	PRMT6	-0.57	-8.0	-0.4	2.11e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7487075	0.897	rs10880960	chr12:46761829	T/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.02	0.32	4.54e-9	Itch intensity from mosquito bite;
CRC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.15	0.32	2.26e-9	Morning vs. evening chronotype;
CRC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-13.07	-0.58	9.85e-32	Vitiligo;
CRC	cis	rs7692995	1.000	rs16896182	chr4:17973899	C/G	cg08925142	chr4:18023851	LCORL	-0.5	-5.65	-0.3	3.39e-8	Height;
CRC	cis	rs1950626	0.623	rs35947256	chr14:101460366	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.73	11.3	0.53	3.17e-25	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.52	8.82	0.44	6.79e-17	Dupuytren's disease;
CRC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.8	0.35	5.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg23815491	chr16:72088622	HP	0.51	7.93	0.4	3.44e-14	Fibrinogen levels;
CRC	cis	rs12760731	0.720	rs12691481	chr1:178392653	T/C	cg00404053	chr1:178313656	RASAL2	0.85	10.04	0.48	7.48e-21	Obesity-related traits;
CRC	trans	rs492478	0.892	rs78326948	chr5:3926201	A/G	cg09199442	chr11:28132951	METT5D1	-0.7	-6.18	-0.32	1.95e-9	Cognitive performance;
CRC	cis	rs2415984	0.622	rs7156466	chr14:46933384	A/G	cg14871534	chr14:47121158	RPL10L	-0.42	-5.97	-0.31	6.01e-9	Number of children ever born;
CRC	cis	rs1144713	0.531	rs1716941	chr12:32255094	A/G	cg01321189	chr12:32259338	BICD1	0.47	6.48	0.34	3.33e-10	Obesity-related traits;
CRC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.7	0.47	9.96e-20	Heart rate;
CRC	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg27205649	chr11:78285834	NARS2	0.49	6.26	0.33	1.22e-9	Alzheimer's disease (survival time);
CRC	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.39	-7.66	-0.39	2.09e-13	Alcohol dependence;
CRC	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.1	0.32	2.94e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg14458575	chr2:238380390	NA	0.45	6.46	0.34	3.83e-10	Prostate cancer;
CRC	cis	rs6908034	0.607	rs74573060	chr6:19806032	T/A	cg02682789	chr6:19804855	NA	0.79	6.75	0.35	6.62e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	trans	rs66573146	1.000	rs6852613	chr4:7035637	G/A	cg07817883	chr1:32538562	TMEM39B	1.23	10.66	0.51	5.52e-23	Granulocyte percentage of myeloid white cells;
CRC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.5	-0.34	2.92e-10	Cutaneous nevi;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg26587870	chr6:27730563	NA	-0.43	-6.69	-0.35	9.61e-11	Parkinson's disease;
CRC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.79	-7.97	-0.4	2.64e-14	Tuberculosis;
CRC	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.34	0.53	2.18e-25	Prudent dietary pattern;
CRC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.8	-0.4	8.04e-14	Hemoglobin concentration;
CRC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-16.17	-0.67	1.12e-43	Vitiligo;
CRC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.68	-0.39	1.86e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.98	-0.36	1.62e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.49	9.25	0.45	3.02e-18	Smoking initiation;
CRC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.64	-7.94	-0.4	3.25e-14	Platelet count;
CRC	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg10494257	chr1:16342123	HSPB7	0.46	6.38	0.33	6.11e-10	Dilated cardiomyopathy;
CRC	cis	rs9903692	0.648	rs35361214	chr17:46165091	G/A	cg21215337	chr17:46176117	CBX1	0.42	7.78	0.39	9.74e-14	Pulse pressure;
CRC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9292777	0.897	rs10473191	chr5:40412944	T/A	cg09067459	chr5:40385259	NA	0.51	8.86	0.44	4.94e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07165851	chr6:158734300	TULP4	-0.61	-7.85	-0.4	5.87e-14	Height;
CRC	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg24848437	chr7:2645542	IQCE	0.58	6.13	0.32	2.45e-9	Urate levels in lean individuals;
CRC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.52	-7.05	-0.36	1.03e-11	Height;Educational attainment;Head circumference (infant);
CRC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.16	-0.32	2.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.46	5.75	0.3	2.01e-8	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	11.0	0.52	3.61e-24	Mean corpuscular hemoglobin;
CRC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	15.15	0.64	1.08e-39	Electrocardiographic conduction measures;
CRC	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.72	-8.41	-0.42	1.25e-15	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs12517041	1.000	rs4701363	chr5:23301008	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-5.96	-0.31	6.46e-9	Calcium levels;
CRC	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg04586622	chr2:25135609	ADCY3	-0.43	-7.17	-0.37	5.06e-12	Body mass index;
CRC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg19582491	chr16:67682965	RLTPR	-0.4	-5.62	-0.3	4e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12172441	chr6:28176163	NA	0.62	7.28	0.37	2.53e-12	Parkinson's disease;
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07395648	chr5:131743802	NA	-0.41	-6.11	-0.32	2.84e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs7781266	0.741	rs1149555	chr7:133062665	G/A	cg03336402	chr7:133662267	EXOC4	-0.47	-5.7	-0.3	2.7e-8	Educational attainment (college completion);
CRC	cis	rs629535	0.911	rs627382	chr8:70014081	C/T	cg26132723	chr8:70041827	NA	-0.36	-5.99	-0.31	5.59e-9	Dupuytren's disease;
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg21747405	chr11:67723411	NA	-0.58	-9.13	-0.45	6.88e-18	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg13206674	chr6:150067644	NUP43	0.47	5.75	0.3	2.09e-8	Lung cancer;
CRC	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.48	6.07	0.32	3.51e-9	Recombination rate (females);
CRC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.27	-0.33	1.1e-9	Monocyte percentage of white cells;
CRC	cis	rs3857067	1.000	rs1588385	chr4:95017161	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg18252515	chr7:66147081	NA	0.41	6.04	0.32	4.07e-9	Aortic root size;
CRC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.09	-0.55	4.31e-28	Bone mineral density;
CRC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.91	18.08	0.71	3.1e-51	Bone mineral density;
CRC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.71	10.69	0.51	4.29e-23	Corneal astigmatism;
CRC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.79	-10.73	-0.51	3.02e-23	Initial pursuit acceleration;
CRC	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg14711859	chr11:8959438	ASCL3	-0.45	-7.25	-0.37	2.97e-12	Hemoglobin concentration;
CRC	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.43	6.56	0.34	2.06e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg00129232	chr17:37814104	STARD3	0.56	6.98	0.36	1.67e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg24463073	chr6:118973353	C6orf204	0.54	7.13	0.37	6.33e-12	Renal cell carcinoma;
CRC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.66	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.56	7.64	0.39	2.46e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7680126	0.633	rs887732	chr4:10183117	G/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.95	-0.31	6.92e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.78	-0.39	9.16e-14	Total cholesterol levels;
CRC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.42	8.03	0.4	1.74e-14	Mean corpuscular volume;
CRC	cis	rs2333194	0.875	rs7140876	chr14:73792938	A/G	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.42	-6.28	-0.33	1.07e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.78	-0.3	1.77e-8	Reticulocyte count;
CRC	trans	rs9914544	0.545	rs4924944	chr17:18810002	C/T	cg21372672	chr17:16614065	CCDC144A	-0.43	-6.9	-0.36	2.76e-11	Educational attainment (years of education);
CRC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg01941586	chr1:40203715	PPIE	-0.45	-6.18	-0.32	1.91e-9	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03640568	chr22:38902623	DDX17	0.44	6.26	0.33	1.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.88	-16.64	-0.68	1.55e-45	Height;
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21309049	chr7:43623222	STK17A	0.41	6.02	0.31	4.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.51	-6.35	-0.33	7.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg11941060	chr3:133502564	NA	-0.47	-7.65	-0.39	2.28e-13	Iron status biomarkers;
CRC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.66	-8.04	-0.41	1.66e-14	Bronchopulmonary dysplasia;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg04518342	chr5:131593106	PDLIM4	0.43	7.04	0.36	1.14e-11	Breast cancer;
CRC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.69	-10.81	-0.51	1.67e-23	Blood protein levels;
CRC	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-6.45	-0.34	4.01e-10	Metabolite levels;
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg12172441	chr6:28176163	NA	-0.54	-6.59	-0.34	1.74e-10	Parkinson's disease;
CRC	cis	rs73206853	0.534	rs73205059	chr12:110509947	G/A	cg12870014	chr12:110450643	ANKRD13A	0.86	8.88	0.44	4.53e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.57	7.26	0.37	2.88e-12	Morning vs. evening chronotype;
CRC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.71	12.44	0.57	2.31e-29	Prostate cancer;
CRC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.42	6.44	0.33	4.11e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.65	6.84	0.35	3.92e-11	Body mass index;
CRC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.5	8.68	0.43	1.87e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg16141378	chr3:129829833	LOC729375	-0.4	-6.02	-0.31	4.65e-9	Neuroticism;
CRC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.49	0.54	6.52e-26	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13435101	chr6:74171350	MTO1	-0.44	-6.78	-0.35	5.73e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.16	-0.56	2.28e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24308560	chr3:49941425	MST1R	0.48	7.73	0.39	1.29e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1572438	0.965	rs3799324	chr6:859376	G/A	cg21062780	chr6:887772	NA	-0.39	-5.98	-0.31	5.66e-9	Aging;
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg22495460	chr2:25135724	ADCY3	0.67	11.11	0.52	1.51e-24	Body mass index in non-asthmatics;
CRC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16515820	chr3:114866447	ZBTB20	0.47	6.14	0.32	2.39e-9	Thyroid stimulating hormone;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07286436	chr15:43425883	TMEM62	0.42	6.22	0.32	1.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-7.12	-0.37	6.98e-12	Major depressive disorder;
CRC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.6	0.39	3.11e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.43	6.68	0.35	1.04e-10	Corneal astigmatism;
CRC	cis	rs62408225	1.000	rs62408236	chr6:90980148	C/T	cg06866423	chr6:90926672	BACH2	0.48	7.9	0.4	4.25e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.78	14.61	0.63	1.36e-37	Prudent dietary pattern;
CRC	trans	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs897080	0.515	rs1085495	chr2:44608982	A/G	cg04920474	chr2:44395004	PPM1B	0.44	6.13	0.32	2.48e-9	Height;
CRC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.48	6.71	0.35	8.71e-11	Tuberculosis;
CRC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg08999081	chr20:33150536	PIGU	0.45	5.77	0.3	1.86e-8	Protein C levels;
CRC	cis	rs6758955	0.925	rs76748106	chr2:10480890	C/T	cg15773312	chr2:10472214	HPCAL1	-0.74	-8.88	-0.44	4.31e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.52	0.38	5.26e-13	Mean platelet volume;
CRC	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.59	-0.39	3.27e-13	HDL cholesterol;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg11321895	chr8:57123832	PLAG1;CHCHD7	-0.39	-6.05	-0.32	3.93e-9	Aortic root size;
CRC	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.66	8.59	0.43	3.44e-16	Uric acid levels;
CRC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.4	-6.37	-0.33	6.4e-10	Blood metabolite levels;
CRC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.26	14.89	0.63	1.11e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.62	9.74	0.47	7.41e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.48	7.29	0.37	2.28e-12	Menarche (age at onset);
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14895029	chr7:2775587	GNA12	-0.44	-6.33	-0.33	8.24e-10	Height;
CRC	cis	rs834811	0.563	rs834814	chr7:135887515	A/G	cg01726295	chr7:135938950	NA	0.35	6.05	0.32	3.94e-9	Post-traumatic stress disorder;
CRC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.52	0.38	5.18e-13	Motion sickness;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.81	12.99	0.58	1.94e-31	Menarche (age at onset);
CRC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.08	-0.41	1.29e-14	Height;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-0.58	-8.39	-0.42	1.5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7487075	0.780	rs12320197	chr12:46738883	A/G	cg17501823	chr12:47219793	SLC38A4	0.31	5.62	0.3	4.14e-8	Itch intensity from mosquito bite;
CRC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg02733842	chr7:1102375	C7orf50	-0.59	-7.7	-0.39	1.6e-13	Bronchopulmonary dysplasia;
CRC	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.68	7.93	0.4	3.39e-14	Systolic blood pressure;
CRC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg26762873	chr11:5879799	OR52E8	-0.49	-7.46	-0.38	7.84e-13	DNA methylation (variation);
CRC	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.85	-0.31	1.2e-8	Educational attainment;
CRC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.65	10.3	0.49	9.67e-22	Type 2 diabetes;
CRC	trans	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg07393940	chr7:158741817	NA	0.49	7.17	0.37	4.91e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg15147215	chr3:52552868	STAB1	0.53	9.17	0.45	5.31e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.64	-9.07	-0.45	1.09e-17	Cocaine dependence;
CRC	cis	rs4824093	0.544	rs7410274	chr22:50315928	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.85	-0.4	5.86e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg12273811	chr6:28175739	NA	0.54	7.7	0.39	1.59e-13	Parkinson's disease;
CRC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.54	8.16	0.41	7.11e-15	Morning vs. evening chronotype;
CRC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.14	0.74	2.41e-59	Prudent dietary pattern;
CRC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.62	-9.26	-0.45	2.75e-18	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg27535305	chr1:53392650	SCP2	0.39	7.07	0.36	9.43e-12	Monocyte count;
CRC	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.54	-7.26	-0.37	2.75e-12	Alzheimer's disease (age of onset);
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg15786705	chr6:28176104	NA	0.57	7.9	0.4	4.29e-14	Parkinson's disease;
CRC	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-7.64	-0.39	2.4e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg18683604	chr14:51561293	TRIM9	0.29	6.0	0.31	5.11e-9	Cancer;
CRC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.5	-7.13	-0.37	6.57e-12	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02323633	chr5:73937762	ENC1	0.48	6.88	0.35	3.03e-11	Response to antipsychotic treatment;
CRC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg15147215	chr3:52552868	STAB1	-0.43	-6.09	-0.32	3.12e-9	Schizophrenia;
CRC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.39	-0.33	5.59e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.82	-0.48	4.01e-20	Total cholesterol levels;
CRC	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.63	5.88	0.31	1.01e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17767392	0.958	rs4902938	chr14:72014778	T/C	cg13720639	chr14:72061746	SIPA1L1	0.56	7.14	0.37	6.03e-12	Mitral valve prolapse;
CRC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.44	0.33	4.23e-10	Renal cell carcinoma;
CRC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg18827107	chr12:86230957	RASSF9	-0.41	-6.23	-0.32	1.42e-9	Major depressive disorder;
CRC	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg16670446	chr17:27188758	MIR451;MIR144	-0.61	-10.48	-0.5	2.34e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.76	-0.3	1.89e-8	Breast cancer;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.32	5.68	0.3	2.94e-8	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.72	-0.39	1.41e-13	Hemoglobin concentration;
CRC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.13	-0.45	7.04e-18	Coronary artery disease;
CRC	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.24	-0.41	4.12e-15	Schizophrenia;
CRC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg25204440	chr1:209979598	IRF6	0.48	5.82	0.31	1.42e-8	Cleft lip with or without cleft palate;
CRC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.55	7.04	0.36	1.13e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg21010569	chr2:103233596	NA	0.49	5.67	0.3	3.15e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg12185399	chr6:27640341	NA	0.83	6.03	0.32	4.38e-9	Depression;
CRC	cis	rs77861329	1.000	rs352147	chr3:52208285	A/G	cg08692210	chr3:52188851	WDR51A	0.83	7.8	0.4	8.22e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-0.98	-21.08	-0.76	4.95e-63	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10512697	0.655	rs35451111	chr5:3466737	A/G	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16458507	chr12:113376293	OAS3	0.38	6.05	0.32	4.01e-9	Interleukin-6 levels;
CRC	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.78	-10.68	-0.51	4.86e-23	White matter hyperintensity burden;
CRC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.3	5.99	0.31	5.6e-9	Schizophrenia;
CRC	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg27534772	chr1:16042836	PLEKHM2	0.39	6.64	0.34	1.26e-10	Systolic blood pressure;
CRC	trans	rs12200782	0.649	rs12189870	chr6:26382765	T/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.49	-6.97	-0.36	1.7e-11	DNA methylation (variation);
CRC	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	9.26	0.45	2.75e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4750440	0.614	rs4750446	chr10:14030319	T/G	cg00551146	chr10:14014579	FRMD4A	0.43	6.9	0.36	2.66e-11	Adiponectin levels;
CRC	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.23	-0.56	1.28e-28	Coffee consumption (cups per day);
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg12273811	chr6:28175739	NA	0.54	5.81	0.3	1.5e-8	Depression;
CRC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-7.42	-0.38	9.92e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg20159608	chr7:32802032	NA	-0.63	-8.09	-0.41	1.13e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.66	10.7	0.51	3.9e-23	Schizophrenia;
CRC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.83	0.4	6.6e-14	Mean platelet volume;
CRC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9303542	0.625	rs9904760	chr17:46575031	C/T	cg04904318	chr17:46607828	HOXB1	-0.49	-6.47	-0.34	3.47e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg09796270	chr17:17721594	SREBF1	-0.47	-7.37	-0.38	1.43e-12	Total body bone mineral density;
CRC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.57	0.6	1.33e-33	Prudent dietary pattern;
CRC	cis	rs2346160	0.867	rs412495	chr6:167688940	C/G	cg27333441	chr6:167680455	NA	0.33	5.61	0.3	4.2e-8	Parental extreme longevity (95 years and older);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg06028048	chr5:175815674	HIGD2A;NOP16	0.46	6.61	0.34	1.59e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.38	-7.18	-0.37	4.8e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.51	-0.5	1.82e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.64	8.2	0.41	5.35e-15	Alzheimer's disease;
CRC	cis	rs3791556	0.741	rs3791542	chr2:240103955	A/G	cg03281426	chr2:240109471	HDAC4	-0.52	-6.08	-0.32	3.34e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg02569458	chr12:86230093	RASSF9	-0.47	-7.94	-0.4	3.16e-14	Major depressive disorder;
CRC	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.74	8.53	0.43	5.62e-16	Eotaxin levels;
CRC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg19046167	chr17:80928561	B3GNTL1	-0.44	-6.79	-0.35	5.24e-11	Breast cancer;
CRC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.5	8.55	0.43	4.73e-16	Schizophrenia;
CRC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-7.84	-0.4	6.48e-14	Colorectal cancer;
CRC	cis	rs501120	0.584	rs58540467	chr10:44705170	T/C	cg09554077	chr10:44749378	NA	0.66	7.65	0.39	2.25e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.02	-0.36	1.27e-11	Tuberculosis;
CRC	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.59	7.13	0.37	6.35e-12	Carotid intima media thickness;
CRC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08755283	chr5:118324104	DTWD2	-0.47	-7.13	-0.37	6.23e-12	Myopia (pathological);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg15921099	chr2:121010219	RALB	0.39	6.17	0.32	2.01e-9	Schizophrenia;
CRC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	11.86	0.55	3.03e-27	Bone mineral density;
CRC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.56	-7.2	-0.37	4.15e-12	DNA methylation (variation);
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20505218	chr17:80009845	GPS1;RFNG	0.48	6.14	0.32	2.36e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.52	8.59	0.43	3.65e-16	Aortic root size;
CRC	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg14003231	chr6:33640908	ITPR3	0.53	8.61	0.43	2.99e-16	Plateletcrit;
CRC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.13	-0.32	2.52e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg12516270	chr8:143859308	LYNX1	0.35	6.0	0.31	5.14e-9	Urinary tract infection frequency;
CRC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	trans	rs10411161	0.657	rs67462252	chr19:52382851	T/C	cg22319618	chr22:45562946	NUP50	-0.69	-7.57	-0.39	3.68e-13	Breast cancer;
CRC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.09	0.52	1.66e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.58	13.35	0.59	8.66e-33	Breast size;
CRC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.55	6.9	0.36	2.66e-11	Psoriasis;
CRC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06112835	chr11:68658793	MRPL21	0.44	6.86	0.35	3.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.59	7.92	0.4	3.72e-14	Birth weight;
CRC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14629032	chr9:94185528	NFIL3	0.42	6.37	0.33	6.3e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.86	-11.44	-0.53	9.42e-26	Asthma;
CRC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg05540913	chr6:167530185	CCR6	-0.41	-7.55	-0.38	4.2e-13	Primary biliary cholangitis;
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg15786705	chr6:28176104	NA	0.71	8.77	0.44	1.01e-16	Parkinson's disease;
CRC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg15848620	chr12:58087721	OS9	-0.65	-9.27	-0.46	2.46e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.38	6.45	0.33	4.1e-10	Sitting height ratio;
CRC	cis	rs12541635	0.966	rs2029881	chr8:107002226	A/G	cg10147462	chr8:107024639	NA	0.43	7.09	0.36	8.25e-12	Age of smoking initiation;
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02421172	chr7:1938701	MAD1L1	0.44	5.87	0.31	1.08e-8	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02084729	chr6:33589691	ITPR3	0.44	6.28	0.33	1.09e-9	Response to antipsychotic treatment;
CRC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg26528668	chr16:1614120	IFT140	0.36	5.6	0.3	4.46e-8	Coronary artery disease;
CRC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.6	-9.35	-0.46	1.35e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.84	14.68	0.63	7.14e-38	Blood protein levels;
CRC	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.7	-0.3	2.6e-8	Type 2 diabetes;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.77	-0.35	5.8200000000000003e-11	Longevity;Endometriosis;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg12273811	chr6:28175739	NA	0.45	5.63	0.3	3.81e-8	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01372608	chr1:116185223	VANGL1	0.51	6.55	0.34	2.21e-10	Thyroid stimulating hormone;
CRC	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-7.89	-0.4	4.57e-14	Extraversion;
CRC	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.53	8.89	0.44	4.14e-17	Dupuytren's disease;
CRC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.61	9.51	0.46	4.1e-19	Aortic root size;
CRC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	1.13	13.26	0.59	1.97e-32	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16414762	chr1:6845247	CAMTA1	0.39	6.42	0.33	4.64e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13972460	chr20:1165703	C20orf46	0.34	6.07	0.32	3.59e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13686799	chr11:60524194	MS4A15	0.29	6.04	0.32	4.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20092199	chr4:1342459	KIAA1530	0.45	7.89	0.4	4.62e-14	Longevity;
CRC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	11.08	0.52	1.85e-24	Schizophrenia;
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg21856205	chr7:94953877	PON1	-0.52	-6.62	-0.34	1.48e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg25985355	chr7:65971099	NA	0.32	5.69	0.3	2.75e-8	Aortic root size;
CRC	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.5	-6.02	-0.31	4.66e-9	Carotid intima media thickness;
CRC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.56	8.01	0.4	2.02e-14	Lymphocyte counts;
CRC	trans	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.66e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.9	-0.31	8.88e-9	Height;
CRC	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.39	-0.59	6.12e-33	Ulcerative colitis;
CRC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.51	-9.54	-0.47	3.36e-19	Menarche (age at onset);
CRC	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg00507830	chr2:103233733	NA	0.51	5.8	0.3	1.55e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.69	0.35	9.63e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4750440	0.702	rs11258775	chr10:14029742	T/C	cg00551146	chr10:14014579	FRMD4A	0.36	5.85	0.31	1.19e-8	Adiponectin levels;
CRC	cis	rs4321325	0.733	rs79995601	chr2:127947452	T/C	cg11380483	chr2:127933992	NA	0.53	6.72	0.35	7.96e-11	Protein C levels;
CRC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg05044414	chr3:183734942	ABCC5	0.48	8.33	0.42	2.17e-15	Anterior chamber depth;
CRC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.69	7.1	0.36	7.77e-12	Plasma clusterin levels;
CRC	cis	rs758324	0.812	rs2159243	chr5:131133900	G/A	cg25547332	chr5:131281432	NA	0.36	5.73	0.3	2.3e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg15704280	chr7:45808275	SEPT13	-0.47	-6.67	-0.35	1.08e-10	HDL cholesterol;
CRC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.75	-8.27	-0.42	3.26e-15	Coronary artery disease;
CRC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg13390004	chr1:15929781	NA	0.5	7.16	0.37	5.45e-12	Systolic blood pressure;
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12427896	chr2:111880694	BCL2L11	0.48	6.36	0.33	6.75e-10	Thyroid stimulating hormone;
CRC	cis	rs938554	0.735	rs12498742	chr4:9944052	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.84	-0.31	1.25e-8	Blood metabolite levels;
CRC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.81	13.64	0.6	6.79e-34	Blood protein levels;
CRC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg19223190	chr17:80058835	NA	0.38	6.09	0.32	3.15e-9	Life satisfaction;
CRC	cis	rs6433857	0.594	rs17455575	chr2:181524487	G/A	cg23363182	chr2:181467187	NA	-0.47	-7.31	-0.37	2.05e-12	Body mass index;
CRC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.53	0.54	4.48e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg05784532	chr1:230284198	GALNT2	0.42	5.74	0.3	2.11e-8	Coronary artery disease;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13047869	chr3:10149882	C3orf24	0.48	6.81	0.35	4.79e-11	Alzheimer's disease;
CRC	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg22561889	chr6:118971681	C6orf204	0.49	5.86	0.31	1.13e-8	Diastolic blood pressure;
CRC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.43	6.35	0.33	7.25e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9491140	0.514	rs11154227	chr6:124681816	G/A	cg22366943	chr6:124882293	NKAIN2	0.53	7.56	0.38	4.16e-13	Neuroticism;
CRC	cis	rs73200209	0.744	rs7133286	chr12:116483965	A/C	cg01776926	chr12:116560359	MED13L	-0.64	-7.68	-0.39	1.78e-13	Total body bone mineral density;
CRC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.39	6.23	0.32	1.46e-9	Total body bone mineral density;
CRC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.54	8.69	0.43	1.69e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.65	-7.79	-0.39	8.8e-14	Vitamin D levels;
CRC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.9	11.87	0.55	2.81e-27	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.29	0.33	9.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.96	-0.31	6.58e-9	Daytime sleep phenotypes;
CRC	cis	rs720844	0.748	rs10928406	chr2:149329952	G/T	cg09247360	chr2:149335327	NA	-0.58	-6.12	-0.32	2.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.94	15.45	0.65	7.21e-41	Primary sclerosing cholangitis;
CRC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.58	0.34	1.89e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg25164649	chr6:28176230	NA	-0.39	-5.74	-0.3	2.13e-8	Pubertal anthropometrics;
CRC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.61	-0.3	4.29e-8	Schizophrenia;
CRC	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.65	-0.34	1.21e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9584850	0.834	rs17574378	chr13:99116384	T/C	cg20750642	chr13:99100586	FARP1	-0.39	-5.64	-0.3	3.69e-8	Neuroticism;
CRC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.64	9.11	0.45	8.08e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2811415	0.597	rs9809087	chr3:127761128	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	cis	rs1465370	0.800	rs62471721	chr7:130016470	G/A	cg03229158	chr7:130009420	NA	0.48	6.92	0.36	2.3e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.45	8.05	0.41	1.51e-14	Immature fraction of reticulocytes;
CRC	cis	rs61160187	0.549	rs12518404	chr5:60341996	T/C	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.74	-0.3	2.2e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.98	-0.44	2.17e-17	Alcohol dependence;
CRC	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg00769240	chr8:12517080	NA	-0.56	-6.78	-0.35	5.57e-11	Blood pressure (smoking interaction);
CRC	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg04756594	chr16:24857601	SLC5A11	-0.23	-5.6	-0.3	4.48e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6717918	0.816	rs11901692	chr2:233149739	A/G	ch.2.233013039R	chr2:233304795	NA	-0.48	-6.57	-0.34	1.93e-10	Height;
CRC	cis	rs6499129	1.000	rs6499129	chr16:67458251	A/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.92	-0.31	8.25e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.74	10.58	0.5	1.04e-22	High light scatter reticulocyte count;
CRC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.61	-9.86	-0.48	2.98e-20	Aortic root size;
CRC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-6.19	-0.32	1.76e-9	Body mass index;
CRC	cis	rs7487075	0.797	rs12816358	chr12:46736646	A/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.13	0.32	2.49e-9	Itch intensity from mosquito bite;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11644746	chr12:13043866	GPRC5A	0.46	6.47	0.34	3.47e-10	Response to antipsychotic treatment;
CRC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg21466736	chr12:48725269	NA	-0.55	-8.18	-0.41	6.36e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.23	0.32	1.43e-9	Rheumatoid arthritis;
CRC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.44	6.45	0.34	3.97e-10	Mood instability;
CRC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.95e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.09	0.41	1.19e-14	Platelet count;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.73	12.87	0.58	5.38e-31	Prudent dietary pattern;
CRC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.09	-0.32	3.15e-9	IgG glycosylation;
CRC	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.44	7.03	0.36	1.19e-11	Sitting height ratio;
CRC	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07165851	chr6:158734300	TULP4	0.6	7.59	0.39	3.38e-13	Height;
CRC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.7	0.3	2.65e-8	Bladder cancer;
CRC	trans	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg14063357	chr9:79793314	VPS13A;LOC100286938	0.6	6.19	0.32	1.83e-9	Iron status biomarkers;
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.19	0.59	3.5e-32	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23995395	chr4:83821786	THAP9	0.44	6.35	0.33	7.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-0.99	-22.91	-0.78	4.2e-70	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.64	-7.42	-0.38	1.02e-12	Opioid sensitivity;
CRC	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.35	6.08	0.32	3.36e-9	Sitting height ratio;
CRC	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.54	0.47	3.31e-19	Type 2 diabetes;
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.01	-10.5	-0.5	2e-22	Body mass index;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12721145	chr4:109571876	OSTC	-0.41	-5.96	-0.31	6.4e-9	Myopia (pathological);
CRC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg24675056	chr1:15929824	NA	0.51	7.04	0.36	1.14e-11	Systolic blood pressure;
CRC	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	8.9	0.44	3.96e-17	Type 2 diabetes;
CRC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.48	8.04	0.41	1.67e-14	Breast cancer;
CRC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg06207120	chr15:45996521	NA	0.3	7.26	0.37	2.78e-12	Waist circumference;Weight;
CRC	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg19688584	chr6:167529678	CCR6	-0.36	-6.45	-0.33	4.08e-10	Primary biliary cholangitis;
CRC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.55	6.11	0.32	2.76e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg17948913	chr5:572064	NA	0.55	6.2	0.32	1.71e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs294883	0.858	rs9457584	chr6:159722282	G/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.76	-0.3	1.95e-8	Coronary artery disease;
CRC	cis	rs7705042	0.865	rs7733850	chr5:141515564	C/T	cg08523384	chr5:141488047	NDFIP1	-0.31	-5.68	-0.3	3.02e-8	Asthma;
CRC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.59	9.1	0.45	8.83e-18	Corneal astigmatism;
CRC	cis	rs7301826	0.651	rs4759517	chr12:131283698	G/A	cg11011512	chr12:131303247	STX2	0.39	5.76	0.3	1.98e-8	Plasma plasminogen activator levels;
CRC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-8.32	-0.42	2.44e-15	Vitiligo;
CRC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-6.91	-0.36	2.53e-11	Response to antipsychotic treatment;
CRC	trans	rs4714291	0.802	rs911818	chr6:39988816	C/A	cg02267698	chr19:7991119	CTXN1	-0.52	-7.19	-0.37	4.27e-12	Strep throat;
CRC	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg02569458	chr12:86230093	RASSF9	-0.43	-7.18	-0.37	4.54e-12	Major depressive disorder;
CRC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	-0.66	-7.6	-0.39	3.17e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg09324608	chr17:30823087	MYO1D	0.35	6.21	0.32	1.64e-9	Schizophrenia;
CRC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg12046867	chr14:103022105	NA	0.71	9.86	0.48	2.91e-20	Platelet count;
CRC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.48	7.36	0.38	1.51e-12	Mean platelet volume;
CRC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	7.78	0.39	9.29e-14	Body mass index;
CRC	cis	rs243505	0.660	rs10274701	chr7:148552456	C/T	cg09806900	chr7:148480153	CUL1	0.52	6.58	0.34	1.89e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg10217327	chr6:118973057	C6orf204	0.49	5.65	0.3	3.43e-8	Diastolic blood pressure;
CRC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.4	5.83	0.31	1.35e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.86	-15.13	-0.64	1.24e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.56	-0.34	2.11e-10	Aortic root size;
CRC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.57	-6.11	-0.32	2.77e-9	Vitiligo;
CRC	trans	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.72	8.24	0.41	4.21e-15	Ulcerative colitis;
CRC	cis	rs375066	0.623	rs239949	chr19:44356627	C/T	cg19542119	chr19:44331823	ZNF283	-0.41	-5.83	-0.31	1.31e-8	Breast cancer;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg12172441	chr6:28176163	NA	0.43	6.17	0.32	1.98e-9	Parkinson's disease;
CRC	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg23234261	chr14:55582407	NA	-0.29	-5.64	-0.3	3.62e-8	Protein biomarker;
CRC	cis	rs3857067	1.000	rs7685048	chr4:95027784	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.22	-0.32	1.55e-9	QT interval;
CRC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.27	-0.37	2.65e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.62	-0.43	2.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.4	5.8	0.3	1.54e-8	Obesity-related traits;
CRC	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg06781209	chr11:61594997	FADS2	-0.41	-5.91	-0.31	8.49e-9	Trans fatty acid levels;
CRC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.73	-0.3	2.33e-8	Tonsillectomy;
CRC	cis	rs2882667	0.690	rs160404	chr5:138084269	A/G	cg09476006	chr5:138032270	NA	0.56	9.8	0.48	4.45e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.6	8.6	0.43	3.27e-16	Homoarginine levels;
CRC	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.41	-6.21	-0.32	1.61e-9	Endometrial cancer;
CRC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.4	0.42	1.36e-15	Height;
CRC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17554472	chr22:41940697	POLR3H	0.55	5.61	0.3	4.29e-8	Vitiligo;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.64	-8.86	-0.44	5.02e-17	Menopause (age at onset);
CRC	cis	rs4663866	1.000	rs13026475	chr2:239178455	T/C	cg16914508	chr2:239161102	PER2	0.77	7.86	0.4	5.51e-14	Irritable bowel syndrome;
CRC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.68	0.39	1.88e-13	Aortic root size;
CRC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.6	-9.36	-0.46	1.24e-18	Colorectal cancer;
CRC	trans	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg26043149	chr18:55253948	FECH	0.49	7.28	0.37	2.55e-12	Bone mineral density;
CRC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.39	7.02	0.36	1.25e-11	Height;
CRC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-6.48	-0.34	3.41e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg24289452	chr6:170231220	NA	-0.58	-6.58	-0.34	1.81e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.38	5.65	0.3	3.47e-8	Diastolic blood pressure;
CRC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.83	-12.72	-0.57	2.09e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.36	6.2	0.32	1.72e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg15845792	chr6:28175446	NA	1.04	13.94	0.61	4.93e-35	Depression;
CRC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.2	-18.02	-0.7	5.43e-51	Blood pressure (smoking interaction);
CRC	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg00319359	chr11:70116639	PPFIA1	0.61	6.39	0.33	5.62e-10	Coronary artery disease;
CRC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg05623727	chr3:50126028	RBM5	0.43	6.99	0.36	1.58e-11	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg21709803	chr11:61594965	FADS2	-0.62	-6.97	-0.36	1.7e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.64	-9.98	-0.48	1.12e-20	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.45	6.12	0.32	2.63e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03513645	chr17:34891278	MYO19;PIGW	0.46	6.13	0.32	2.55e-9	Anxiety disorder;
CRC	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg08600765	chr20:34638493	LOC647979	-0.69	-8.89	-0.44	4.14e-17	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.65	-9.6	-0.47	2.14e-19	Type 2 diabetes;
CRC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.59	7.94	0.4	3.15e-14	Menopause (age at onset);
CRC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.5	-0.34	3.04e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.99	0.58	1.9e-31	Bone mineral density;
CRC	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.5	7.24	0.37	3.2e-12	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg03929089	chr4:120376271	NA	-0.62	-6.08	-0.32	3.34e-9	D-dimer levels;
CRC	cis	rs3789045	1.000	rs12046747	chr1:204593696	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.49	-7.06	-0.36	1.02e-11	Educational attainment (college completion);
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg26354017	chr1:205819088	PM20D1	0.42	5.91	0.31	8.72e-9	Parkinson's disease;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.93	15.46	0.65	6.71e-41	Menarche (age at onset);
CRC	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.38	5.94	0.31	7.2e-9	Mean corpuscular hemoglobin concentration;
CRC	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.42	-6.12	-0.32	2.67e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.6	8.49	0.42	6.99e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.36	5.78	0.3	1.75e-8	Sense of smell;
CRC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg15848620	chr12:58087721	OS9	-0.65	-9.09	-0.45	9.71e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-12.97	-0.58	2.42e-31	Cognitive function;
CRC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg27661571	chr11:113659931	NA	-0.77	-9.59	-0.47	2.24e-19	Hip circumference adjusted for BMI;
CRC	trans	rs17111396	0.627	rs61978744	chr14:81511484	T/C	cg22745369	chr6:3517953	NA	-0.43	-6.15	-0.32	2.19e-9	Uric acid levels;
CRC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.09	0.32	3.19e-9	Rheumatoid arthritis;
CRC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04111992	chr7:158790115	NA	-0.38	-6.21	-0.32	1.59e-9	Facial morphology (factor 20);
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.32	0.37	1.91e-12	Parkinson's disease;
CRC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg12193833	chr17:30244370	NA	0.44	6.14	0.32	2.38e-9	Hip circumference adjusted for BMI;
CRC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg27101125	chr19:17392770	ANKLE1	-0.33	-5.75	-0.3	1.99e-8	Systemic lupus erythematosus;
CRC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg03013999	chr17:37608204	MED1	0.48	7.33	0.37	1.82e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21159473	chr9:15510228	PSIP1	0.42	7.3	0.37	2.16e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.72	-9.04	-0.45	1.42e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.42	6.92	0.36	2.34e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg09127314	chr1:152161683	NA	0.49	6.25	0.33	1.26e-9	Atopic dermatitis;
CRC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg10298567	chr3:47292165	KIF9	-0.39	-6.15	-0.32	2.2e-9	Colorectal cancer;
CRC	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg23254163	chr1:152506842	NA	0.43	7.24	0.37	3.25e-12	Hair morphology;
CRC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg03037974	chr15:76606532	NA	-0.51	-7.48	-0.38	6.7e-13	Blood metabolite levels;
CRC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.58	8.08	0.41	1.29e-14	Lung cancer;
CRC	cis	rs4731207	0.596	rs723443	chr7:124659301	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.05	-0.32	3.97e-9	Cutaneous malignant melanoma;
CRC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18301423	chr5:131593218	PDLIM4	0.36	6.77	0.35	5.77e-11	Breast cancer;
CRC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.93	-17.42	-0.69	1.25e-48	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.6	-7.07	-0.36	9.45e-12	Gut microbiome composition (summer);
CRC	cis	rs365302	0.904	rs410879	chr6:159649747	T/C	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs4819143	0.517	rs439145	chr21:47373995	G/A	cg14185626	chr21:47401492	COL6A1	-0.49	-5.65	-0.3	3.43e-8	Insulin resistance/response;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg23161317	chr6:28129485	ZNF389	0.38	5.67	0.3	3.16e-8	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.41	5.69	0.3	2.88e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.62	8.99	0.44	1.92e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2294025	0.932	rs7836576	chr8:134164980	T/C	cg19857114	chr3:176741225	TBL1XR1	-0.39	-6.13	-0.32	2.51e-9	Graves' disease;
CRC	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg14593290	chr7:50529359	DDC	-0.47	-6.56	-0.34	2.11e-10	Systemic sclerosis;
CRC	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.68	-0.43	1.92e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.6	-9.33	-0.46	1.56e-18	Dementia with Lewy bodies;
CRC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg24112000	chr20:60950667	NA	-0.58	-9.91	-0.48	1.93e-20	Colorectal cancer;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg08352292	chr17:27503756	MYO18A	-0.42	-6.27	-0.33	1.13e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg09232269	chr1:207846808	CR1L	-0.43	-7.15	-0.37	5.82e-12	Erythrocyte sedimentation rate;
CRC	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg21038819	chr17:73507788	CASKIN2	0.6	5.61	0.3	4.4e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs4731207	0.535	rs1351471	chr7:124672015	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.2	-0.32	1.72e-9	Cutaneous malignant melanoma;
CRC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.33	-5.75	-0.3	2.08e-8	Blood protein levels;
CRC	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	14.84	0.63	1.71e-38	Mean corpuscular hemoglobin;
CRC	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs73206853	0.841	rs7956963	chr12:110947783	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	7.86	0.4	5.56e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg11189052	chr15:85197271	WDR73	0.64	8.98	0.44	2.11e-17	Schizophrenia;
CRC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07513332	chr6:167530253	CCR6	-0.41	-7.13	-0.37	6.45e-12	Primary biliary cholangitis;
CRC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.09	13.38	0.59	6.59e-33	Vitiligo;
CRC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg27535305	chr1:53392650	SCP2	0.38	7.1	0.36	7.9e-12	Monocyte count;
CRC	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.52	-7.54	-0.38	4.52e-13	Response to antidepressants in depression;
CRC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg19223190	chr17:80058835	NA	-0.42	-6.61	-0.34	1.56e-10	Life satisfaction;
CRC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg11212589	chr17:38028394	ZPBP2	0.42	7.8	0.4	8.14e-14	Self-reported allergy;
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.8	11.8	0.55	4.89e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-6.38	-0.33	6.05e-10	Migraine;Coronary artery disease;
CRC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.52	0.5	1.73e-22	Menopause (age at onset);
CRC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.47	-6.12	-0.32	2.62e-9	Putamen volume;
CRC	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.04	-0.32	4.23e-9	Educational attainment;
CRC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.96	12.13	0.56	3.18e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg16892393	chr17:41919603	NA	0.55	7.95	0.4	2.94e-14	Triglycerides;
CRC	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.73	-0.43	1.32e-16	Coffee consumption (cups per day);
CRC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.9	8.26	0.41	3.61e-15	Platelet distribution width;
CRC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-7.81	-0.4	7.78e-14	Type 2 diabetes;
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg03844506	chr4:4109441	NA	-0.51	-7.62	-0.39	2.75e-13	Blood pressure (smoking interaction);
CRC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-10.38	-0.5	4.9e-22	Menarche (age at onset);
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.51	-5.99	-0.31	5.58e-9	Obesity-related traits;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg04073608	chr11:65268100	MALAT1	-0.46	-6.66	-0.34	1.14e-10	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg00631329	chr6:26305371	NA	-0.55	-9.4	-0.46	9.9e-19	Educational attainment;
CRC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.78	11.45	0.53	9.28e-26	Neutrophil percentage of white cells;
CRC	cis	rs7680126	0.596	rs10939835	chr4:10313750	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.55	-0.34	2.24e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.37	6.13	0.32	2.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2213920	0.679	rs4979534	chr9:118211159	T/C	cg13918206	chr9:118159781	DEC1	0.59	5.8	0.3	1.58e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs12753569	0.748	rs1340689	chr1:76506409	T/A	cg00791851	chr1:76518896	NA	0.36	6.54	0.34	2.34e-10	Personality dimensions;
CRC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	16.87	0.68	1.85e-46	Smoking behavior;
CRC	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg12856521	chr11:46389249	DGKZ	0.44	7.26	0.37	2.78e-12	Leprosy;
CRC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.67	8.23	0.41	4.3e-15	Cognitive test performance;
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.52	6.18	0.32	1.88e-9	Blood protein levels;
CRC	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.65	-11.2	-0.53	7.06e-25	Dental caries;
CRC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.17	25.84	0.82	3.41e-81	IgG glycosylation;
CRC	cis	rs2786111	0.965	rs664767	chr1:197280295	A/C	cg13682187	chr1:196946512	CFHR5	0.29	5.71	0.3	2.47e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.85	-14.55	-0.63	2.21e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg25173405	chr17:45401733	C17orf57	0.43	6.75	0.35	6.58e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg19223190	chr17:80058835	NA	0.43	6.73	0.35	7.49e-11	Life satisfaction;
CRC	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.51	-5.65	-0.3	3.42e-8	Lymphocyte percentage of white cells;
CRC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.73	0.3	2.21e-8	Life satisfaction;
CRC	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg22495460	chr2:25135724	ADCY3	-0.82	-13.76	-0.6	2.5e-34	Body mass index;
CRC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.6	6.95	0.36	1.93e-11	Vitiligo;
CRC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00339695	chr16:24857497	SLC5A11	0.28	6.6	0.34	1.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12692738	0.526	rs355873	chr2:165632464	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.94	-0.36	2.07e-11	Menopause (age at onset);
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.0	-0.36	1.41e-11	Body mass index;
CRC	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg07606381	chr6:8435919	SLC35B3	-0.43	-6.25	-0.33	1.28e-9	Motion sickness;
CRC	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.67	10.3	0.49	9.23e-22	Corneal astigmatism;
CRC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.31	5.13e-9	Hemoglobin concentration;
CRC	cis	rs59104589	0.617	rs73002114	chr2:242280924	G/A	cg19488206	chr2:242435732	STK25	0.47	6.8	0.35	4.97e-11	Fibrinogen levels;
CRC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg21251018	chr6:28226885	NKAPL	0.47	6.66	0.34	1.12e-10	Depression;
CRC	cis	rs11723261	0.582	rs11248005	chr4:166615	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	6.64	0.34	1.28e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11813246	chr1:42846740	RIMKLA	0.44	6.92	0.36	2.31e-11	Schizophrenia;
CRC	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg09655341	chr17:79618100	PDE6G	0.55	6.53	0.34	2.57e-10	Dental caries;
CRC	cis	rs3824347	0.839	rs3758184	chr9:77568392	C/G	cg01251476	chr9:77566080	C9orf40	0.39	6.05	0.32	3.87e-9	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg03623178	chr6:28175578	NA	0.99	12.74	0.57	1.72e-30	Depression;
CRC	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.95	-0.31	6.9e-9	Educational attainment;
CRC	cis	rs62458065	1.000	rs10275978	chr7:32466719	G/T	cg20159608	chr7:32802032	NA	-0.5	-6.35	-0.33	7.34e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.58	7.84	0.4	6.14e-14	Birth weight;
CRC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.8	12.54	0.57	9.7e-30	Cognitive function;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.2	-17.22	-0.69	8.08e-48	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07227728	chr7:131012528	MKLN1	0.38	6.41	0.33	5.04e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg27661571	chr11:113659931	NA	-0.7	-8.87	-0.44	4.79e-17	Hip circumference adjusted for BMI;
CRC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.52	-8.94	-0.44	2.87e-17	Aortic root size;
CRC	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.61	-7.37	-0.38	1.39e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.34	-9.66	-0.47	1.35e-19	Mean corpuscular volume;
CRC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.42	-7.36	-0.38	1.46e-12	Height;
CRC	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.54	6.0	0.31	5.25e-9	Pulse pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19272713	chr11:66247337	DPP3	0.48	6.76	0.35	6.25e-11	Response to antipsychotic treatment;
CRC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.55	-7.76	-0.39	1.06e-13	IgG glycosylation;
CRC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.58	-0.34	1.82e-10	Systemic lupus erythematosus;
CRC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.54	7.14	0.37	5.84e-12	Obesity-related traits;
CRC	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.73	-11.23	-0.53	5.48e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.45	-6.87	-0.35	3.13e-11	Response to antineoplastic agents;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07817097	chr1:179851575	TOR1AIP1	-0.42	-6.0	-0.31	5.19e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05010219	chr10:134210111	PWWP2B	0.45	7.38	0.38	1.3e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs688181	0.646	rs6903041	chr6:158111700	C/G	cg11843673	chr2:239699222	NA	0.37	6.0	0.31	5.12e-9	Platelet distribution width;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18297960	chr7:1142765	C7orf50	-0.42	-5.72	-0.3	2.39e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-1.04	-21.0	-0.76	1.07e-62	Headache;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26459430	chr19:680063	FSTL3	0.4	6.64	0.34	1.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10971721	0.822	rs56274755	chr9:33934271	T/C	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg03929089	chr4:120376271	NA	-0.51	-6.16	-0.32	2.11e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.17	-0.56	2.14e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs926938	0.841	rs11588144	chr1:115239355	G/A	cg12756093	chr1:115239321	AMPD1	-0.79	-13.75	-0.6	2.63e-34	Autism;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg25987502	chr17:6899865	ALOX12	-0.32	-5.83	-0.31	1.36e-8	Tonsillectomy;
CRC	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.56	8.21	0.41	5.11e-15	Autism;
CRC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg18230493	chr5:56204884	C5orf35	-0.49	-7.2	-0.37	4.19e-12	Coronary artery disease;
CRC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	13.48	0.6	2.73e-33	Platelet count;
CRC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.13	-0.49	3.56e-21	Body mass index;
CRC	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	6.24	0.33	1.31e-9	Menarche (age at onset);
CRC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg03609598	chr5:56110824	MAP3K1	0.44	5.88	0.31	1.03e-8	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg18833306	chr6:118973337	C6orf204	0.45	6.01	0.31	4.81e-9	Diastolic blood pressure;
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.18	-0.32	1.9e-9	Total body bone mineral density;
CRC	trans	rs2898857	0.524	rs2960172	chr17:47379581	G/A	cg11430096	chr6:110968061	CDK19	0.54	8.06	0.41	1.47e-14	Cancer;
CRC	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.63	-8.64	-0.43	2.52e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg20203395	chr5:56204925	C5orf35	-0.41	-5.63	-0.3	3.93e-8	Coronary artery disease;
CRC	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg12560992	chr17:57184187	TRIM37	0.53	6.15	0.32	2.28e-9	Vitamin D levels;
CRC	cis	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg02972257	chr16:68554789	NA	0.51	6.21	0.32	1.62e-9	Colorectal cancer;
CRC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.58	-0.34	1.86e-10	Fibrinogen levels;
CRC	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.85	-14.9	-0.63	9.69e-39	Monocyte count;
CRC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.65	7.88	0.4	4.79e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14777817	chr13:80055594	NDFIP2	-0.41	-5.99	-0.31	5.39e-9	Myopia (pathological);
CRC	trans	rs10050311	0.698	rs67867077	chr4:87643746	G/A	cg00004207	chr2:38977301	SFRS7	0.51	6.16	0.32	2.08e-9	Insulin-related traits;
CRC	cis	rs4481887	0.508	rs4916115	chr1:248383316	T/G	cg00666640	chr1:248458726	OR2T12	0.37	6.31	0.33	8.95e-10	Common traits (Other);
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.28	0.75	7.02e-60	Prudent dietary pattern;
CRC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	8.67	0.43	2e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.34	-0.38	1.68e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.67	10.41	0.5	4.15e-22	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6908034	0.607	rs80355837	chr6:19808343	C/G	cg02682789	chr6:19804855	NA	0.78	6.83	0.35	4.16e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg11271282	chr2:238384023	NA	0.48	5.61	0.3	4.25e-8	Prostate cancer;
CRC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg04315214	chr1:2043799	PRKCZ	0.39	6.74	0.35	7.09e-11	Height;
CRC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.81	-10.49	-0.5	2.06e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.53	0.34	2.47e-10	Coronary artery disease;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg03623178	chr6:28175578	NA	0.74	7.82	0.4	7.43e-14	Depression;
CRC	cis	rs7107174	0.901	rs7937277	chr11:78114977	C/G	cg12700464	chr11:78128424	GAB2	-0.53	-6.03	-0.32	4.53e-9	Testicular germ cell tumor;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14479329	chr6:167370587	RNASET2	0.49	6.31	0.33	9.08e-10	Hip circumference;
CRC	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg12458913	chr13:53173898	NA	0.54	8.47	0.42	8.35e-16	Lewy body disease;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg21251018	chr6:28226885	NKAPL	0.46	6.53	0.34	2.56e-10	Parkinson's disease;
CRC	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.93	15.32	0.65	2.37e-40	Dupuytren's disease;
CRC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg10802521	chr3:52805072	NEK4	-0.47	-6.52	-0.34	2.64e-10	Schizophrenia;
CRC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02450064	chr17:40260053	DHX58	-0.42	-6.11	-0.32	2.75e-9	Fibrinogen levels;
CRC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg20243544	chr17:37824526	PNMT	0.43	6.63	0.34	1.41e-10	Self-reported allergy;
CRC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-5.98	-0.31	5.74e-9	Height;
CRC	cis	rs939574	0.512	rs908197	chr2:220144410	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.57	6.51	0.34	2.77e-10	Platelet distribution width;
CRC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02359409	chr6:42947317	PEX6	-0.69	-11.52	-0.54	5.04e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-8.86	-0.44	5.13e-17	Brugada syndrome;
CRC	cis	rs4926298	1.000	rs931068	chr19:13158678	A/G	cg11738485	chr19:12877000	HOOK2	-0.41	-5.68	-0.3	2.91e-8	Bipolar disorder;
CRC	cis	rs995000	0.899	rs1305521	chr1:62949034	A/G	cg19896129	chr1:63156450	NA	-0.45	-6.89	-0.36	2.83e-11	Triglyceride levels;
CRC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg25767906	chr1:53392781	SCP2	0.42	6.62	0.34	1.48e-10	Monocyte count;
CRC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.72	11.42	0.53	1.1e-25	Colorectal cancer;
CRC	cis	rs365302	0.517	rs294876	chr6:159606982	A/C	cg14500486	chr6:159655392	FNDC1	-0.43	-6.65	-0.34	1.21e-10	Coronary heart disease;
CRC	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	6.28	0.33	1.05e-9	Mean corpuscular volume;
CRC	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg02811702	chr13:24901961	NA	0.43	5.97	0.31	6.02e-9	Obesity-related traits;
CRC	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg09873164	chr1:152488093	CRCT1	0.41	6.79	0.35	5.18e-11	Hair morphology;
CRC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.68	9.78	0.47	5.23e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.46	-6.41	-0.33	5.14e-10	Blood pressure (smoking interaction);
CRC	cis	rs4654899	0.897	rs6670897	chr1:21066376	T/C	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.82	-0.35	4.42e-11	Superior frontal gyrus grey matter volume;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03044510	chr21:27107978	ATP5J;GABPA	-0.43	-6.4	-0.33	5.21e-10	Myopia (pathological);
CRC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08219700	chr8:58056026	NA	0.56	6.29	0.33	9.91e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.51	8.94	0.44	2.87e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19500275	chr17:80737654	TBCD	0.5	6.76	0.35	6.19e-11	Glycated hemoglobin levels;
CRC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.12	0.52	1.36e-24	Colorectal cancer;
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg08347473	chr17:78092826	GAA	-0.37	-6.3	-0.33	9.48e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg01951491	chr16:67709440	GFOD2	-0.45	-5.9	-0.31	9.09e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.06	-14.8	-0.63	2.51e-38	Exhaled nitric oxide output;
CRC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.77	0.3	1.84e-8	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.58	9.28	0.46	2.42e-18	Schizophrenia;
CRC	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg12046867	chr14:103022105	NA	0.76	9.03	0.45	1.44e-17	Platelet count;
CRC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	5.64	0.3	3.63e-8	Schizophrenia;
CRC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-9.77	-0.47	5.87e-20	Cognitive function;
CRC	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.69e-9	Corneal astigmatism;
CRC	cis	rs4523957	0.928	rs1122645	chr17:2170858	A/G	cg16513277	chr17:2031491	SMG6	-0.54	-9.27	-0.45	2.58e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7429990	0.965	rs4858887	chr3:48092017	G/T	cg11946769	chr3:48343235	NME6	-0.5	-6.37	-0.33	6.43e-10	Educational attainment (years of education);
CRC	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.34e-36	Hypertriglyceridemia;
CRC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	13.13	0.59	5.98e-32	Electrocardiographic conduction measures;
CRC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg06484146	chr7:12443880	VWDE	-0.64	-6.83	-0.35	4.2e-11	Coronary artery disease;
CRC	cis	rs6921919	0.789	rs6912584	chr6:28309590	T/C	cg21251018	chr6:28226885	NKAPL	0.4	5.7	0.3	2.68e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg23758597	chr6:163146217	PARK2	-0.66	-6.64	-0.34	1.29e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.53	8.54	0.43	5.14e-16	Coronary artery disease;
CRC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-8.08	-0.41	1.25e-14	Height;
CRC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg18479299	chr3:125709523	NA	-0.55	-6.59	-0.34	1.75e-10	Blood pressure (smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17166282	chr13:103249241	TPP2	0.44	6.29	0.33	1.04e-9	Anxiety disorder;
CRC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-7.43	-0.38	9.26e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg18827107	chr12:86230957	RASSF9	-0.38	-5.74	-0.3	2.17e-8	Major depressive disorder;
CRC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.43	6.65	0.34	1.26e-10	Mean platelet volume;
CRC	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg12870014	chr12:110450643	ANKRD13A	0.82	10.57	0.5	1.09e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.8	-13.87	-0.61	9.07e-35	Dementia with Lewy bodies;
CRC	cis	rs2013441	0.965	rs2386485	chr17:20095246	G/A	cg13482628	chr17:19912719	NA	-0.4	-6.07	-0.32	3.43e-9	Obesity-related traits;
CRC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.69	8.77	0.44	9.72e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.09	8.88	0.44	4.36e-17	Plateletcrit;
CRC	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.57	0.34	1.99e-10	Intraocular pressure;
CRC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg26566898	chr11:117069891	TAGLN	0.42	8.52	0.43	5.95e-16	Blood protein levels;
CRC	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.17	0.32	2.01e-9	Ovarian reserve;
CRC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	13.03	0.58	1.38e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.58	-10.81	-0.51	1.71e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs990171	0.913	rs6718157	chr2:103079814	A/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Lymphocyte counts;
CRC	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.52	8.65	0.43	2.27e-16	Dupuytren's disease;
CRC	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.81	-0.4	7.95e-14	Mean platelet volume;
CRC	cis	rs35883536	1.000	rs12410168	chr1:101115321	G/A	cg14515779	chr1:101123966	NA	-0.42	-8.2	-0.41	5.63e-15	Monocyte count;
CRC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.52	-6.9	-0.36	2.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs73195822	0.614	rs73194056	chr12:111216325	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	7.46	0.38	8e-13	Itch intensity from mosquito bite;
CRC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.77	0.54	6.32e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.85	-0.31	1.21e-8	Alcohol dependence;
CRC	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.44	6.31	0.33	8.95e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs7274811	0.625	rs211041	chr20:31932068	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.4	5.97	0.31	6.18e-9	Height;
CRC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	7.46	0.38	7.92e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.75	-11.86	-0.55	3e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg02683197	chr6:28174875	NA	0.88	10.83	0.51	1.42e-23	Depression;
CRC	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.66	-10.92	-0.52	6.61e-24	White blood cell count (basophil);
CRC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.49	11.09	0.52	1.75e-24	Rheumatoid arthritis;
CRC	cis	rs1178968	0.901	rs7795782	chr7:72766817	T/G	cg25889504	chr7:72793014	NA	0.53	6.03	0.32	4.48e-9	Triglyceride levels;
CRC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.33	-0.33	8.15e-10	Menarche (age at onset);
CRC	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg14631576	chr9:95140430	CENPP	0.39	6.91	0.36	2.59e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.38	0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs891088	0.677	rs11670960	chr19:7185504	C/T	cg00428638	chr19:7224713	INSR	-0.59	-6.17	-0.32	1.99e-9	Hip circumference adjusted for BMI;Height;
CRC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg17321639	chr7:2759063	NA	0.46	6.2	0.32	1.69e-9	Height;
CRC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.46	-6.26	-0.33	1.17e-9	Cognitive ability;
CRC	cis	rs4481887	0.636	rs6672981	chr1:248407200	C/T	cg00666640	chr1:248458726	OR2T12	0.47	7.63	0.39	2.6e-13	Common traits (Other);
CRC	cis	rs7626444	0.625	rs9826214	chr3:196478213	C/T	cg12930392	chr3:196481615	PAK2	0.38	6.86	0.35	3.49e-11	Monocyte count;
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg15511327	chr8:143859410	LYNX1	0.39	6.85	0.35	3.62e-11	Urinary tract infection frequency;
CRC	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.54	-8.5	-0.42	6.85e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6840360	0.582	rs4473638	chr4:152322146	C/T	cg09659197	chr4:152720779	NA	0.33	6.29	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.46	-6.4	-0.33	5.31e-10	Intelligence (multi-trait analysis);
CRC	cis	rs73195822	0.614	rs11065717	chr12:111208823	A/C	cg12870014	chr12:110450643	ANKRD13A	0.71	8.13	0.41	8.65e-15	Itch intensity from mosquito bite;
CRC	cis	rs11229555	0.598	rs12276438	chr11:58185419	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.33	6.14	0.32	2.42e-9	QRS complex (12-leadsum);
CRC	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-10.87	-0.51	1.01e-23	Response to temozolomide;
CRC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.49	6.6	0.34	1.66e-10	Cleft lip with or without cleft palate;
CRC	cis	rs1867631	0.585	rs12062570	chr1:67086285	T/C	cg02459107	chr1:67143332	SGIP1	0.35	6.32	0.33	8.4e-10	Menopause (age at onset);
CRC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.42	0.46	8.19e-19	Monocyte percentage of white cells;
CRC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg17948913	chr5:572064	NA	0.51	5.89	0.31	9.53e-9	Obesity-related traits;
CRC	cis	rs4594175	0.926	rs4414399	chr14:51596929	G/T	cg23942311	chr14:51606299	NA	0.67	10.71	0.51	3.62e-23	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10656664	chr5:853447	NA	-0.4	-6.57	-0.34	1.93e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.56	-7.22	-0.37	3.65e-12	Platelet distribution width;
CRC	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.64	9.99	0.48	1.03e-20	Corneal astigmatism;
CRC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg14061069	chr19:46274453	DMPK	0.69	12.71	0.57	2.2e-30	Coronary artery disease;
CRC	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.7	-0.3	2.62e-8	Breast cancer;
CRC	trans	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg26043149	chr18:55253948	FECH	0.51	7.95	0.4	3.02e-14	Bone mineral density;
CRC	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.8	10.45	0.5	2.88e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg03160526	chr17:80928410	B3GNTL1	0.63	8.74	0.43	1.25e-16	Glycated hemoglobin levels;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg02033258	chr5:131593261	PDLIM4	0.35	6.89	0.36	2.78e-11	Blood metabolite levels;
CRC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg17333051	chr19:2783644	SGTA	0.45	6.89	0.35	2.92e-11	Total cholesterol levels;
CRC	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02290350	chr8:58132656	NA	-0.59	-7.11	-0.36	7.43e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg21770322	chr7:97807741	LMTK2	0.53	8.62	0.43	2.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.61	9.06	0.45	1.18e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs17601876	0.814	rs28520437	chr15:51553277	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-6.73	-0.35	7.76e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.3e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6968419	0.755	rs3807983	chr7:115898991	T/C	cg02561103	chr7:115862891	TES	-0.44	-6.61	-0.34	1.58e-10	Intraocular pressure;
CRC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg11245181	chr6:149772854	ZC3H12D	0.53	9.38	0.46	1.09e-18	Dupuytren's disease;
CRC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg10820045	chr2:198174542	NA	0.46	8.21	0.41	5.04e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg12193833	chr17:30244370	NA	-0.63	-8.19	-0.41	5.67e-15	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16271524	chr11:66139231	SLC29A2	0.4	6.03	0.32	4.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17767392	0.958	rs8014349	chr14:72046496	C/A	cg13720639	chr14:72061746	SIPA1L1	0.55	6.82	0.35	4.27e-11	Mitral valve prolapse;
CRC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.26	14.46	0.62	5.09e-37	Diabetic kidney disease;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.74	10.72	0.51	3.31e-23	Menarche (age at onset);
CRC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.53	-6.2	-0.32	1.74e-9	Bipolar disorder;
CRC	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs9409565	0.586	rs9409764	chr9:97219391	C/T	cg04523069	chr9:97136363	HIATL1	0.43	6.06	0.32	3.75e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.48	-0.34	3.27e-10	Bipolar disorder;
CRC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg10578991	chr7:12443926	VWDE	-0.44	-5.74	-0.3	2.1e-8	Coronary artery disease;
CRC	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.49	7.05	0.36	1.07e-11	Primary sclerosing cholangitis;
CRC	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-1.07	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17796897	chr19:18403201	NA	0.45	6.77	0.35	5.89e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.48	7.75	0.39	1.17e-13	Uric acid clearance;
CRC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.4	0.42	1.39e-15	Smoking initiation;
CRC	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.52	-8.83	-0.44	6.26e-17	Testicular germ cell tumor;
CRC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-5.67	-0.3	3.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.56	8.36	0.42	1.77e-15	Schizophrenia;
CRC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg17298326	chr8:142245477	NA	0.4	6.15	0.32	2.29e-9	Immature fraction of reticulocytes;
CRC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.34	-0.42	2.08e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.66	10.38	0.5	5.1e-22	Lewy body disease;
CRC	cis	rs501120	0.925	rs1657345	chr10:44779078	A/G	cg09554077	chr10:44749378	NA	0.81	10.36	0.5	5.84e-22	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.53	7.53	0.38	4.81e-13	Graves' disease;
CRC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.0	-0.36	1.49e-11	IgG glycosylation;
CRC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	8.42	0.42	1.15e-15	Platelet count;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg05127153	chr1:6452942	ACOT7	0.51	6.15	0.32	2.28e-9	Kashin-Beck disease;
CRC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.78	-13.21	-0.59	3e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg17294928	chr15:75287854	SCAMP5	0.37	5.66	0.3	3.29e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.49	-9.49	-0.46	5.02e-19	Subjective well-being;
CRC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg20203395	chr5:56204925	C5orf35	-0.57	-6.54	-0.34	2.34e-10	Initial pursuit acceleration;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.58	6.56	0.34	2.06e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4363385	0.574	rs61813182	chr1:152943868	T/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.6	-0.34	1.64e-10	Inflammatory skin disease;
CRC	cis	rs7692995	1.000	rs6449345	chr4:17934394	A/T	cg08925142	chr4:18023851	LCORL	-0.52	-5.85	-0.31	1.21e-8	Height;
CRC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.17	-0.37	4.87e-12	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06563602	chr4:130014800	C4orf33;SCLT1	0.43	6.18	0.32	1.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21643547	chr1:205240462	TMCC2	-0.38	-6.13	-0.32	2.58e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg16606324	chr3:10149918	C3orf24	0.62	7.1	0.36	7.6e-12	Alzheimer's disease;
CRC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.6	-0.68	2.12e-45	Electrocardiographic conduction measures;
CRC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.55	7.98	0.4	2.43e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	16.02	0.66	4.12e-43	Platelet count;
CRC	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.58	-8.91	-0.44	3.45e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.46	-7.69	-0.39	1.78e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs6546324	0.625	rs2902023	chr2:67830279	A/G	cg15745817	chr2:67799979	NA	-0.55	-9.07	-0.45	1.1e-17	Endometriosis;
CRC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.95	-0.31	6.68e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.56	-9.75	-0.47	6.66e-20	Body mass index;
CRC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.53	-8.5	-0.42	6.79e-16	Aortic root size;
CRC	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.56	8.73	0.43	1.29e-16	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.5	6.97	0.36	1.7e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.36	5.66	0.3	3.28e-8	Educational attainment;
CRC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.85	0.35	3.54e-11	Neuroticism;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg08307039	chr5:64920116	TRIM23;C5orf44	0.44	6.08	0.32	3.38e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6580110	0.793	rs9324792	chr5:154078564	A/G	cg11923914	chr5:154071666	NA	-0.49	-7.69	-0.39	1.71e-13	Facial morphology (factor 9, facial height related to vertical position of nasion);
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.64	8.64	0.43	2.5e-16	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2882667	0.690	rs288018	chr5:138192416	G/A	cg09476006	chr5:138032270	NA	-0.54	-8.92	-0.44	3.39e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	7.77	0.39	9.86e-14	Intelligence (multi-trait analysis);
CRC	trans	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg01134436	chr17:81009848	B3GNTL1	0.56	6.11	0.32	2.87e-9	Lung function (FEV1/FVC);
CRC	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.39	-7.35	-0.38	1.62e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.69	0.39	1.73e-13	Cognitive ability;
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.64	-0.3	3.67e-8	Life satisfaction;
CRC	cis	rs12431939	1.000	rs11850391	chr14:51639759	A/G	cg23942311	chr14:51606299	NA	-0.49	-5.62	-0.3	4.18e-8	Cancer;
CRC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg24375607	chr4:120327624	NA	0.43	6.82	0.35	4.49e-11	Corneal astigmatism;
CRC	cis	rs12476592	0.543	rs4671510	chr2:63742880	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.07	0.32	3.6e-9	Childhood ear infection;
CRC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.78	-10.99	-0.52	3.95e-24	Vitiligo;
CRC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-8.37	-0.42	1.68e-15	Arsenic metabolism;
CRC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.65	-0.39	2.3e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14008862	chr17:28927542	LRRC37B2	0.5	5.92	0.31	8.28e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.33	-0.33	7.86e-10	IgG glycosylation;
CRC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg21512124	chr14:70655805	SLC8A3	-0.31	-6.01	-0.31	4.95e-9	Prostate cancer;
CRC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg21153622	chr11:89784906	NA	0.43	6.9	0.36	2.64e-11	Coronary artery disease;
CRC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.38	-0.33	6.18e-10	Daytime sleep phenotypes;
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.01	-0.4	2.01e-14	Bipolar disorder;
CRC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.49	-7.69	-0.39	1.68e-13	Coronary artery disease;
CRC	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.57	-9.16	-0.45	5.54e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg03623178	chr6:28175578	NA	0.77	11.36	0.53	1.93e-25	Parkinson's disease;
CRC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	8.79	0.44	8.66e-17	Eosinophil percentage of white cells;
CRC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg08210727	chr20:33865349	NA	-0.49	-6.32	-0.33	8.63e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs61160187	0.556	rs55738840	chr5:60273414	G/C	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.73	-0.3	2.26e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02335971	chr8:121457381	MTBP;MRPL13	0.4	6.3	0.33	9.68e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.8	9.97	0.48	1.2e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg18827107	chr12:86230957	RASSF9	0.36	5.72	0.3	2.36e-8	Major depressive disorder;
CRC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.44	7.11	0.36	7.26e-12	Menopause (age at onset);
CRC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.47	7.33	0.37	1.83e-12	Motion sickness;
CRC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.58e-24	Corneal astigmatism;
CRC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.83	12.88	0.58	5.05e-31	Cognitive function;
CRC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.69	-0.3	2.86e-8	Diabetic kidney disease;
CRC	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.89	-0.36	2.87e-11	Putamen volume;
CRC	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.57	-9.19	-0.45	4.64e-18	Neuroticism;
CRC	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg15131784	chr3:139108705	COPB2	0.39	5.63	0.3	3.89e-8	Obesity-related traits;
CRC	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.83	-14.62	-0.63	1.2e-37	Lewy body disease;
CRC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17554472	chr22:41940697	POLR3H	-0.55	-5.84	-0.31	1.23e-8	Vitiligo;
CRC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.12	-0.32	2.64e-9	Alzheimer's disease (late onset);
CRC	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg17133734	chr15:86042851	AKAP13	0.4	6.51	0.34	2.8e-10	Interstitial lung disease;
CRC	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.61	-9.52	-0.46	3.86e-19	Ulcerative colitis;
CRC	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg04803921	chr20:30102855	HM13	-0.41	-5.96	-0.31	6.35e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs4664293	0.934	rs7604482	chr2:160513826	T/C	cg08347373	chr2:160653686	CD302	-0.37	-6.15	-0.32	2.21e-9	Monocyte percentage of white cells;
CRC	cis	rs4867766	0.585	rs10043212	chr5:173949740	C/T	cg20434911	chr5:173954559	NA	0.61	6.83	0.35	4.03e-11	Stroke;
CRC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.17	0.32	2.01e-9	Renal function-related traits (BUN);
CRC	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.48	-7.87	-0.4	5.15e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	trans	rs6011368	0.678	rs6062359	chr20:62900380	G/T	cg13869341	chr1:15865	WASH5P	-0.42	-6.48	-0.34	3.31e-10	Clozapine-induced cytotoxicity;
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg22638593	chr5:131593259	PDLIM4	0.38	6.21	0.32	1.59e-9	Breast cancer;
CRC	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.38	-6.14	-0.32	2.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.68	-8.56	-0.43	4.4e-16	Lung adenocarcinoma;
CRC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-5.95	-0.31	6.81e-9	Axial length;
CRC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.62	-11.4	-0.53	1.39e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	5.94	0.31	7.16e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg08807892	chr2:162101083	NA	-0.45	-6.05	-0.32	4.03e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.39	6.01	0.31	5e-9	Height;
CRC	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg09659197	chr4:152720779	NA	0.31	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16758041	chr9:32573371	NDUFB6	0.42	6.15	0.32	2.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1320333	0.772	rs111825088	chr2:695785	T/G	cg20966539	chr2:681320	NA	0.62	5.88	0.31	1.01e-8	Obesity-related traits;
CRC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.51	7.08	0.36	8.64e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1075232	0.649	rs7170850	chr15:32123445	A/C	cg08481732	chr15:32323009	CHRNA7	0.65	5.67	0.3	3.13e-8	Survival in colorectal cancer (non-distant metastatic);
CRC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.91	10.73	0.51	3.18e-23	Psoriasis;
CRC	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs16852403	0.548	rs7547504	chr1:178201312	G/C	cg00404053	chr1:178313656	RASAL2	0.5	6.55	0.34	2.21e-10	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24028381	chr8:145133668	EXOSC4	0.4	6.52	0.34	2.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg20936604	chr3:58311152	NA	-0.75	-6.89	-0.35	2.89e-11	Cholesterol, total;
CRC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg13607699	chr17:42295918	UBTF	-0.48	-6.3	-0.33	9.39e-10	Total body bone mineral density;
CRC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.56	-0.43	4.41e-16	Chronic sinus infection;
CRC	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.69	9.5	0.46	4.47e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-10.83	-0.51	1.4e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs12745968	0.623	rs4847432	chr1:93118884	C/G	cg17283838	chr1:93427260	FAM69A	-0.44	-6.15	-0.32	2.26e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.87	-0.44	4.63e-17	Bipolar disorder;
CRC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.89	0.4	4.49e-14	Aortic root size;
CRC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.38	-6.97	-0.36	1.78e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7527798	0.592	rs960087	chr1:207826858	C/G	cg21110645	chr1:207815933	NA	-0.41	-6.27	-0.33	1.14e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.36	0.42	1.81e-15	Arsenic metabolism;
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-13.08	-0.58	9.29e-32	Alzheimer's disease;
CRC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg25204440	chr1:209979598	IRF6	0.49	5.88	0.31	1.01e-8	Cleft lip with or without cleft palate;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10959773	chr22:24951920	C22orf13;SNRPD3	0.49	6.27	0.33	1.13e-9	Thyroid stimulating hormone;
CRC	cis	rs1192419	0.502	rs6686665	chr1:92056435	C/T	cg24006770	chr1:92056542	NA	0.57	9.56	0.47	2.97e-19	Optic disc area;Optic nerve measurement (cup-to-disc ratio);
CRC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.24	0.41	4.06e-15	Homoarginine levels;
CRC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.57	9.06	0.45	1.19e-17	Vitiligo;
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-7.23	-0.37	3.47e-12	Lymphocyte counts;
CRC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.46	5.77	0.3	1.83e-8	Aortic root size;
CRC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.84	10.25	0.49	1.36e-21	Monocyte percentage of white cells;
CRC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.84	0.31	1.23e-8	Tonsillectomy;
CRC	cis	rs995000	0.931	rs10889339	chr1:63012056	A/G	cg19896129	chr1:63156450	NA	-0.44	-6.92	-0.36	2.4e-11	Triglyceride levels;
CRC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg26162295	chr17:38119207	GSDMA	-0.34	-5.67	-0.3	3.09e-8	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-7.96	-0.4	2.77e-14	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.52	-9.23	-0.45	3.44e-18	Height;
CRC	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.44	-6.2	-0.32	1.73e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.91	15.03	0.64	2.98e-39	Longevity;
CRC	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.46	7.56	0.38	3.94e-13	Refractive error;
CRC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.1	-0.36	7.73e-12	Height;
CRC	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.78	-14.34	-0.62	1.42e-36	Hip circumference;
CRC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.51	7.02	0.36	1.26e-11	Melanoma;
CRC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.32	4.61e-9	Morning vs. evening chronotype;
CRC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg23018236	chr17:30244563	NA	0.53	6.72	0.35	7.79e-11	Hip circumference adjusted for BMI;
CRC	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.84	11.22	0.53	5.68e-25	IgG glycosylation;
CRC	cis	rs4965359	0.750	rs2995904	chr15:101595898	A/G	cg01350081	chr15:101592003	LRRK1	0.36	6.23	0.32	1.46e-9	Central corneal thickness;
CRC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.01e-12	Alzheimer's disease (late onset);
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03576123	chr11:487126	PTDSS2	-1.1	-10.87	-0.51	1.04e-23	Body mass index;
CRC	cis	rs2811415	0.597	rs9833838	chr3:127741134	C/G	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.1e-8	Lung function (FEV1/FVC);
CRC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg23517279	chr6:96025343	MANEA	-0.5	-5.72	-0.3	2.42e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs9549328	0.544	rs66893681	chr13:113617499	A/G	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.7e-13	Systolic blood pressure;
CRC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.81	14.22	0.62	4.3e-36	Breast cancer;
CRC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.91	-0.52	7.49e-24	Chronic sinus infection;
CRC	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.93	-0.31	7.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg21620606	chr4:1342894	KIAA1530	-0.41	-7.26	-0.37	2.84e-12	Obesity-related traits;
CRC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.4	6.07	0.32	3.43e-9	Hemoglobin concentration;
CRC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg22676075	chr6:135203613	NA	0.41	6.22	0.32	1.47e-9	Red blood cell count;
CRC	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.97	12.38	0.56	3.56e-29	Exhaled nitric oxide levels;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg21251018	chr6:28226885	NKAPL	0.53	8.06	0.41	1.42e-14	Parkinson's disease;
CRC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.88	-15.94	-0.66	8.97e-43	Body mass index;
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg12855166	chr17:30846586	MYO1D	-0.35	-5.67	-0.3	3.14e-8	Schizophrenia;
CRC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg09264619	chr17:80180166	NA	-0.37	-6.2	-0.32	1.72e-9	Life satisfaction;
CRC	cis	rs4908768	0.539	rs6663123	chr1:8642931	T/C	cg20416874	chr1:8611966	RERE	-0.43	-6.11	-0.32	2.81e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-9.51	-0.46	4.03e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg18131467	chr2:239335373	ASB1	-0.7	-6.06	-0.32	3.71e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.67	-0.3	3.15e-8	Neuroticism;
CRC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg24562669	chr7:97807699	LMTK2	0.44	7.28	0.37	2.45e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.6	7.45	0.38	8.41e-13	Body mass index;
CRC	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.52	-7.2	-0.37	4.03e-12	Tuberculosis;
CRC	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.79	14.71	0.63	5.35e-38	Metabolic syndrome;
CRC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.16	-0.69	1.36e-47	Body mass index in non-asthmatics;
CRC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.16	25.81	0.82	4.38e-81	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13917047	chr17:15406213	FAM18B2	0.38	6.01	0.31	4.96e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg23123621	chr4:1343375	KIAA1530	0.35	6.42	0.33	4.68e-10	Obesity-related traits;
CRC	cis	rs17021463	0.615	rs4626213	chr4:95297241	G/A	cg11021082	chr4:95130006	SMARCAD1	0.48	7.28	0.37	2.52e-12	Testicular germ cell tumor;
CRC	trans	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs4929949	0.932	rs10840087	chr11:8616255	G/A	cg17679104	chr11:8615758	STK33	0.38	6.41	0.33	5.17e-10	Body mass index;
CRC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.24	0.33	1.33e-9	Heart rate;
CRC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg07294406	chr7:64700536	NA	-0.39	-6.36	-0.33	6.66e-10	Calcium levels;
CRC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg15123519	chr2:136567270	LCT	-0.35	-6.78	-0.35	5.44e-11	Mosquito bite size;
CRC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	0.98	15.98	0.66	6.1e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.72	-11.33	-0.53	2.37e-25	Lung cancer;
CRC	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17340548	chr19:46185070	GIPR	0.36	6.0	0.31	5.21e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.8	-14.48	-0.62	4.33e-37	Itch intensity from mosquito bite;
CRC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13198984	chr17:80129470	CCDC57	0.47	8.18	0.41	6.33e-15	Life satisfaction;
CRC	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.6	-5.99	-0.31	5.54e-9	Night sleep phenotypes;
CRC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.54	7.28	0.37	2.42e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-0.58	-8.39	-0.42	1.5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg16691251	chr5:66510806	NA	0.59	11.66	0.54	1.6e-26	Breast cancer;
CRC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.61	-8.96	-0.44	2.54e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg03037974	chr15:76606532	NA	-0.53	-7.45	-0.38	8.24e-13	Blood metabolite levels;
CRC	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.52	9.28	0.46	2.31e-18	Blood metabolite ratios;
CRC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.82	15.11	0.64	1.57e-39	Mean platelet volume;
CRC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.64	0.34	1.3100000000000001e-10	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12463199	chr20:49126897	PTPN1	0.44	6.07	0.32	3.48e-9	Response to antipsychotic treatment;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg24669129	chr7:155089712	INSIG1	0.47	5.97	0.31	6.26e-9	Kashin-Beck disease;
CRC	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.44	-7.1	-0.36	7.68e-12	Refractive error;
CRC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.53	0.34	2.53e-10	Melanoma;
CRC	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-0.89	-7.94	-0.4	3.26e-14	Left atrial antero-posterior diameter;
CRC	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.48	6.12	0.32	2.64e-9	Exhaled nitric oxide output;
CRC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.75	8.35	0.42	1.93e-15	Tuberculosis;
CRC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg22777020	chr22:31556080	RNF185	-0.51	-5.82	-0.31	1.42e-8	Colorectal cancer;
CRC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.67	0.35	1.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.45	6.51	0.34	2.78e-10	Activated partial thromboplastin time;
CRC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg02880119	chr16:3481970	NA	0.42	6.0	0.31	5.3e-9	Body mass index (adult);
CRC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg17948913	chr5:572064	NA	0.55	6.42	0.33	4.65e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.57	8.18	0.41	6.29e-15	Primary sclerosing cholangitis;
CRC	cis	rs6024905	0.595	rs2022499	chr20:36966531	G/T	cg07053727	chr20:36965646	BPI	0.74	14.21	0.62	4.54e-36	Bipolar disorder and schizophrenia;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg27588902	chr6:42928151	GNMT	-0.38	-6.72	-0.35	8.19e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	7.55	0.38	4.29e-13	Height;
CRC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.46	6.94	0.36	2.07e-11	Menopause (age at onset);
CRC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg15226275	chr6:116381976	FRK	0.3	8.49	0.42	7.39e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg03339077	chr11:47165057	C11orf49	0.5	7.25	0.37	3.06e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.95	17.67	0.7	1.31e-49	Cognitive ability;
CRC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.5	7.28	0.37	2.47e-12	Schizophrenia;
CRC	trans	rs11466653	1.000	rs10002420	chr4:38779213	T/A	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs889398	0.802	rs8050414	chr16:69886813	T/A	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.23	-0.32	1.41e-9	Body mass index;
CRC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs4731207	0.565	rs2402760	chr7:124595920	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.34e-9	Cutaneous malignant melanoma;
CRC	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.95	0.48	1.5e-20	Corneal astigmatism;
CRC	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg05342945	chr12:48394962	COL2A1	-0.43	-6.03	-0.32	4.36e-9	Lung cancer;
CRC	cis	rs7113874	0.550	rs4929949	chr11:8604593	T/C	cg02811074	chr11:8615871	STK33	0.35	6.06	0.32	3.76e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.76	14.25	0.62	3.31e-36	Prudent dietary pattern;
CRC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.46	-6.38	-0.33	6.06e-10	Mean platelet volume;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.4	6.98	0.36	1.59e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.01	-0.4	1.96e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg20041105	chr8:143859282	LYNX1	0.44	7.87	0.4	5.27e-14	Urinary tract infection frequency;
CRC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.85	-15.69	-0.65	8.63e-42	Menopause (age at onset);
CRC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.66	-10.08	-0.49	5.12e-21	Corneal astigmatism;
CRC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg03030879	chr14:75389066	RPS6KL1	0.46	7.29	0.37	2.27e-12	Height;
CRC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	10.23	0.49	1.68e-21	Platelet count;
CRC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg04719120	chr6:96025338	MANEA	0.63	7.21	0.37	3.84e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.56	7.95	0.4	2.97e-14	Lung cancer;
CRC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.65	0.34	1.21e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.55	-0.34	2.27e-10	Electroencephalogram traits;
CRC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg00129232	chr17:37814104	STARD3	0.58	7.21	0.37	3.86e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.6	9.96	0.48	1.36e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.42	-0.33	4.72e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.52	-0.5	1.62e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs3015497	0.653	rs2356455	chr14:51093142	G/A	cg09863266	chr14:51125203	SAV1	-0.3	-5.75	-0.3	2.09e-8	Mean platelet volume;
CRC	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.87	7.31	0.37	2.08e-12	Alzheimer's disease (late onset);
CRC	cis	rs7739232	0.920	rs7748828	chr6:53517643	A/C	cg15658676	chr6:53530538	KLHL31	-0.75	-5.88	-0.31	1.03e-8	Hip circumference adjusted for BMI;
CRC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.81	14.72	0.63	4.99e-38	Mean platelet volume;
CRC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-10.63	-0.51	7.02e-23	Personality dimensions;
CRC	cis	rs7580658	0.613	rs12478656	chr2:128196520	G/T	cg09760422	chr2:128146352	NA	-0.31	-5.67	-0.3	3.15e-8	Protein C levels;
CRC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.65	-11.53	-0.54	4.59e-26	Prudent dietary pattern;
CRC	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.9	9.58	0.47	2.4e-19	Gastritis;
CRC	trans	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg26043149	chr18:55253948	FECH	0.51	7.5	0.38	5.85e-13	Bone mineral density;
CRC	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.57	7.68	0.39	1.79e-13	Adiposity;
CRC	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.59	9.22	0.45	3.77e-18	HDL cholesterol;
CRC	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg09184832	chr6:79620586	NA	-0.46	-8.03	-0.4	1.7e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg13844804	chr7:814759	HEATR2	0.6	7.94	0.4	3.33e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.54	8.98	0.44	2.07e-17	Prevalent atrial fibrillation;
CRC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17848003	chr1:3704513	LRRC47	0.42	6.01	0.31	4.81e-9	Red cell distribution width;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17302176	chr4:139936680	CCRN4L	0.41	6.11	0.32	2.88e-9	Myopia (pathological);
CRC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17554472	chr22:41940697	POLR3H	-0.6	-6.08	-0.32	3.24e-9	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16237672	chr18:74534576	NA	0.37	6.43	0.33	4.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg04415270	chr2:102091202	RFX8	0.59	8.0	0.4	2.17e-14	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs4930103	0.904	rs2067051	chr11:2018168	C/T	cg06197492	chr11:2016605	H19	0.42	6.51	0.34	2.78e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg00290994	chr1:41848739	NA	0.53	7.99	0.4	2.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs16936870	0.543	rs877181	chr8:71077288	G/A	cg14232793	chr8:71155543	NCOA2	-0.46	-5.72	-0.3	2.36e-8	QT interval;
CRC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg09473613	chr1:24152604	HMGCL	0.35	5.75	0.3	1.99e-8	Immature fraction of reticulocytes;
CRC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.48	-9.49	-0.46	4.89e-19	Subjective well-being;
CRC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-8.04	-0.41	1.69e-14	Uric acid levels;
CRC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.33	-6.93	-0.36	2.24e-11	Cutaneous nevi;
CRC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.32	-0.46	1.72e-18	Migraine;Coronary artery disease;
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.78	-0.51	2.09e-23	Body mass index;
CRC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.65	10.96	0.52	4.79e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg23298862	chr7:158159286	PTPRN2	-0.47	-7.86	-0.4	5.65e-14	Calcium levels;
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.13	-0.37	6.28e-12	Total body bone mineral density;
CRC	cis	rs1223397	0.702	rs1223400	chr6:13271242	T/C	cg00460589	chr6:13274354	PHACTR1	0.47	5.79	0.3	1.61e-8	Blood pressure;
CRC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.46	7.2	0.37	4.14e-12	Height;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.95	-0.31	6.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg22561889	chr6:118971681	C6orf204	0.47	5.9	0.31	9.09e-9	Diastolic blood pressure;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg06470822	chr6:28175283	NA	0.94	12.75	0.58	1.6e-30	Parkinson's disease;
CRC	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.67	11.92	0.55	1.86e-27	Eye color traits;
CRC	cis	rs12760731	0.623	rs721289	chr1:178395682	A/G	cg00404053	chr1:178313656	RASAL2	0.72	8.51	0.42	6.38e-16	Obesity-related traits;
CRC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-9.45	-0.46	6.37e-19	Pancreatic cancer;
CRC	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.62	-7.53	-0.38	4.9e-13	Pursuit maintenance gain;
CRC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.06	0.41	1.43e-14	Cystic fibrosis severity;
CRC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.98	-0.31	5.95e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg15654264	chr1:150340011	RPRD2	0.42	6.25	0.33	1.29e-9	Migraine;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22159483	chr17:1588198	PRPF8	0.52	6.78	0.35	5.61e-11	Thyroid stimulating hormone;
CRC	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg14550559	chr2:240039617	HDAC4	-0.52	-7.81	-0.4	7.89e-14	Skin aging (microtopography measurement);
CRC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.22e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg13119609	chr19:45449297	APOC2	0.31	5.81	0.3	1.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1958560	0.932	rs61987992	chr14:66070731	C/T	cg03016385	chr14:66212404	NA	-0.45	-6.19	-0.32	1.81e-9	Menarche (age at onset);
CRC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.84	13.2	0.59	3.12e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.4	-0.46	9.54e-19	Platelet count;
CRC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.52	7.89	0.4	4.4e-14	Corneal astigmatism;
CRC	cis	rs7605827	0.930	rs7598196	chr2:15596662	A/G	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.51e-9	Educational attainment (years of education);
CRC	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg13172432	chr1:205912842	SLC26A9	-0.35	-6.11	-0.32	2.76e-9	Cystic fibrosis-related diabetes;
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg05569086	chr8:143859399	LYNX1	0.51	8.88	0.44	4.46e-17	Urinary tract infection frequency;
CRC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg02569458	chr12:86230093	RASSF9	0.46	7.79	0.39	8.84e-14	Major depressive disorder;
CRC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.86	-15.33	-0.65	2.13e-40	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.46	6.79	0.35	5.38e-11	Cleft lip with or without cleft palate;
CRC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.38	0.46	1.08e-18	Parkinson's disease;
CRC	trans	rs12517041	1.000	rs10054160	chr5:23297609	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg20935368	chr5:178288625	ZNF354B	0.44	7.21	0.37	3.91e-12	Sleep duration;
CRC	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.72	-12.02	-0.55	7.94e-28	Ear protrusion;
CRC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.18	10.92	0.52	6.58e-24	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21411534	chr10:93558674	TNKS2	0.47	6.59	0.34	1.78e-10	Response to antipsychotic treatment;
CRC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.87	-0.44	4.81e-17	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.68	6.55	0.34	2.28e-10	Diabetic retinopathy;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.51	7.85	0.4	6.08e-14	Corneal astigmatism;
CRC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg06363034	chr20:62225388	GMEB2	-0.43	-6.49	-0.34	3.14e-10	Glioblastoma;
CRC	cis	rs9311676	0.681	rs4681846	chr3:58332543	T/C	cg06643156	chr3:58380774	PXK	-0.44	-6.8	-0.35	4.99e-11	Systemic lupus erythematosus;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.64	-11.7	-0.54	1.09e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg12935359	chr14:103987150	CKB	-0.38	-5.82	-0.31	1.4e-8	Body mass index;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg00343986	chr7:65444356	GUSB	0.48	7.11	0.36	7.45e-12	Aortic root size;
CRC	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.92	-0.36	2.43e-11	Multiple sclerosis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21354621	chr12:46384284	SFRS2IP	-0.49	-5.98	-0.31	5.95e-9	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11501976	chr4:186064568	SLC25A4	0.45	6.42	0.33	4.67e-10	Response to antipsychotic treatment;
CRC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.56	6.15	0.32	2.25e-9	Schizophrenia;
CRC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.46	-6.83	-0.35	4.02e-11	Menarche (age at onset);
CRC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg05627522	chr15:75251581	NA	0.41	6.27	0.33	1.16e-9	Breast cancer;
CRC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.48	-5.66	-0.3	3.34e-8	Menarche (age at onset);
CRC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.73	0.43	1.3e-16	Morning vs. evening chronotype;
CRC	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.61	-12.57	-0.57	7.51e-30	Neuroticism;
CRC	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.47	-6.57	-0.34	1.95e-10	Hair color;
CRC	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.83	-11.8	-0.55	5e-27	Platelet distribution width;
CRC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.59	8.1	0.41	1.06e-14	Lung cancer;
CRC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.44	-9.91	-0.48	1.94e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs858239	0.899	rs28635122	chr7:23310181	C/T	cg00469287	chr7:23338798	C7orf30	0.49	6.19	0.32	1.77e-9	Cerebrospinal fluid biomarker levels;
CRC	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.75	-0.43	1.1e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11212617	0.905	rs6589007	chr11:108040104	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.72	0.35	8.15e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12172441	chr6:28176163	NA	0.59	8.52	0.43	5.68e-16	Cardiac Troponin-T levels;
CRC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg18230493	chr5:56204884	C5orf35	0.59	8.86	0.44	5.12e-17	Initial pursuit acceleration;
CRC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.66	-10.29	-0.49	1.01e-21	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10651637	chr15:45315642	SORD	0.43	6.55	0.34	2.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.77	12.62	0.57	4.9e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.39	5.73	0.3	2.22e-8	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs7760949	0.963	rs1467729	chr6:13911167	C/T	cg27413430	chr6:13925136	RNF182	-0.3	-5.62	-0.3	4.18e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg02158880	chr13:53174818	NA	0.49	7.37	0.38	1.37e-12	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04591119	chr6:111197245	AMD1	0.47	6.52	0.34	2.65e-10	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg00484396	chr16:3507460	NAT15	-0.65	-6.48	-0.34	3.26e-10	Tuberculosis;
CRC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.7	9.41	0.46	9.09e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs73200209	0.626	rs56178625	chr12:116578048	A/G	cg01776926	chr12:116560359	MED13L	-0.62	-7.14	-0.37	6.18e-12	Total body bone mineral density;
CRC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-6.77	-0.35	5.8e-11	Body mass index;
CRC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.23	0.67	6.36e-44	Chronic sinus infection;
CRC	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg14664628	chr15:75095509	CSK	0.45	6.26	0.33	1.23e-9	Systemic lupus erythematosus;
CRC	cis	rs9648716	1.000	rs10255130	chr7:140587633	C/T	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-6.14	-0.32	2.44e-9	IgG glycosylation;
CRC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.7	-8.56	-0.43	4.37e-16	Diabetic retinopathy;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.75	-0.3	2.07e-8	Depression;
CRC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.39	6.89	0.35	2.89e-11	Cardiovascular disease risk factors;
CRC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	6.98	0.36	1.64e-11	Platelet count;
CRC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.31	-0.33	9.17e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs16846053	0.786	rs72877309	chr2:162587828	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.11	-0.32	2.78e-9	Blood osmolality (transformed sodium);
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.51	5.83	0.31	1.36e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.51	-0.46	4.33e-19	Subjective well-being;
CRC	cis	rs7953508	0.580	rs10859534	chr12:93975208	G/A	cg18151635	chr12:93972918	NA	-0.83	-11.23	-0.53	5.43e-25	Pubertal anthropometrics;
CRC	trans	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg10756647	chr7:56101905	PSPH	-0.77	-7.87	-0.4	5.06e-14	Diabetic kidney disease;
CRC	cis	rs282587	0.569	rs378432	chr13:113398048	A/C	cg04656015	chr13:113407548	ATP11A	0.64	8.02	0.4	1.83e-14	Glycated hemoglobin levels;
CRC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg13319975	chr6:146136371	FBXO30	0.4	6.16	0.32	2.17e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.18	0.32	1.89e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg00750074	chr16:89608354	SPG7	-0.5	-7.53	-0.38	4.85e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.43e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.48	6.96	0.36	1.9e-11	Longevity;
CRC	cis	rs2415984	0.500	rs12323609	chr14:46976023	C/G	cg14871534	chr14:47121158	RPL10L	-0.41	-5.93	-0.31	7.74e-9	Number of children ever born;
CRC	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.63	-7.06	-0.36	1.01e-11	Osteoarthritis;
CRC	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	8.16	0.41	7.14e-15	Testicular germ cell tumor;
CRC	cis	rs12760731	0.623	rs12023044	chr1:178407772	G/A	cg00404053	chr1:178313656	RASAL2	0.75	9.35	0.46	1.4e-18	Obesity-related traits;
CRC	cis	rs7487075	1.000	rs7487075	chr12:46828918	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	6.33	0.33	8.14e-10	Itch intensity from mosquito bite;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.46	-8.71	-0.43	1.55e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.91	-0.31	8.42e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.64	-8.98	-0.44	2.17e-17	Obesity-related traits;
CRC	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg18806716	chr10:30721971	MAP3K8	0.46	6.94	0.36	2.06e-11	Inflammatory bowel disease;
CRC	trans	rs1864585	0.520	rs12155811	chr8:10673513	C/T	cg26278703	chr11:58910052	FAM111A	0.56	6.63	0.34	1.42e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.77	16.27	0.67	4.38e-44	Age-related hearing impairment;
CRC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg01262667	chr19:19385393	TM6SF2	0.35	5.79	0.3	1.6e-8	Tonsillectomy;
CRC	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg11130432	chr3:121712080	ILDR1	-0.51	-6.64	-0.34	1.28e-10	Multiple sclerosis;
CRC	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.54	5.99	0.31	5.41e-9	Pulse pressure;
CRC	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.43	6.92	0.36	2.33e-11	Schizophrenia;
CRC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.17	-0.37	5.06e-12	Blood metabolite levels;
CRC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.68	8.28	0.42	3.22e-15	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12554051	chr12:665863	B4GALNT3	-0.39	-6.83	-0.35	4.08e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg14310730	chr9:100685193	C9orf156	0.52	6.02	0.31	4.57e-9	Kashin-Beck disease;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.63	6.54	0.34	2.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10345131	chr15:91475918	UNC45A;HDDC3	0.44	6.09	0.32	3.09e-9	Survival in pancreatic cancer;
CRC	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.49	7.65	0.39	2.23e-13	Schizophrenia;
CRC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg12573674	chr2:1569213	NA	-0.74	-7.89	-0.4	4.59e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs2303319	0.504	rs62187611	chr2:162431946	A/G	cg00039960	chr17:7142925	PHF23	-0.73	-6.0	-0.31	5.26e-9	Cognitive function;
CRC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.51	8.24	0.41	4.19e-15	Aortic root size;
CRC	cis	rs4731207	0.698	rs11978656	chr7:124449965	C/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs6988985	0.678	rs28659182	chr8:143999919	T/A	cg10324643	chr8:143916377	GML	0.39	6.54	0.34	2.34e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.51	7.0	0.36	1.49e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg08034379	chr2:228736324	WDR69	-0.51	-6.9	-0.36	2.65e-11	Blood pressure;
CRC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.91	-0.31	8.52e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg20243544	chr17:37824526	PNMT	-0.46	-5.77	-0.3	1.86e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg13880726	chr7:1868755	MAD1L1	-0.43	-5.71	-0.3	2.54e-8	Bipolar disorder;
CRC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.5	-6.97	-0.36	1.72e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-8.16	-0.41	6.96e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.4	-6.2	-0.32	1.69e-9	Breast cancer;
CRC	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.4	6.74	0.35	7.01e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17767392	0.958	rs10135680	chr14:72030809	G/A	cg13720639	chr14:72061746	SIPA1L1	0.56	6.88	0.35	3.04e-11	Mitral valve prolapse;
CRC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.53	-7.11	-0.37	7.16e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04682787	chr11:65339779	FAM89B	0.46	6.47	0.34	3.46e-10	Response to antipsychotic treatment;
CRC	cis	rs5498	0.839	rs62130688	chr19:10409007	T/C	cg10604476	chr19:10403908	ICAM5	0.3	5.66	0.3	3.3e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CRC	cis	rs17023223	0.537	rs12092807	chr1:119750644	A/G	cg05756136	chr1:119680316	WARS2	0.48	6.56	0.34	2.09e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg25767906	chr1:53392781	SCP2	-0.41	-6.67	-0.35	1.08e-10	Monocyte count;
CRC	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.64	7.75	0.39	1.13e-13	Obesity (extreme);
CRC	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.76	13.75	0.6	2.69e-34	Lewy body disease;
CRC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg02175503	chr12:58329896	NA	0.51	5.88	0.31	1.02e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7394190	0.748	rs11000766	chr10:75512952	C/T	cg07699608	chr10:75541558	CHCHD1	0.61	6.36	0.33	6.64e-10	Incident atrial fibrillation;
CRC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	12.12	0.56	3.32e-28	Monocyte percentage of white cells;
CRC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg22638593	chr5:131593259	PDLIM4	0.4	7.55	0.38	4.31e-13	Breast cancer;
CRC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.36	5.85	0.31	1.18e-8	Huntington's disease progression;
CRC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.6	6.1	0.32	2.96e-9	Plasma clusterin levels;
CRC	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg20628663	chr10:43360327	NA	0.56	6.77	0.35	5.97e-11	Blood protein levels;
CRC	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.47	8.97	0.44	2.23e-17	Educational attainment (years of education);
CRC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.53	-8.56	-0.43	4.37e-16	Aortic root size;
CRC	trans	rs6693295	0.729	rs10737782	chr1:246215358	C/T	cg03680032	chr11:94965610	SESN3	0.49	6.12	0.32	2.68e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.46	6.42	0.33	4.71e-10	Uric acid levels;
CRC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.38	-6.27	-0.33	1.15e-9	HDL cholesterol;
CRC	trans	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.49	0.34	3.21e-10	Diastolic blood pressure;
CRC	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg08314208	chr16:67682810	RLTPR	-0.47	-5.69	-0.3	2.75e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22819616	chr8:144952622	NA	0.35	5.98	0.31	5.96e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.63	8.56	0.43	4.43e-16	Behavioural disinhibition (generation interaction);
CRC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg04731861	chr2:219085781	ARPC2	0.34	6.94	0.36	2.13e-11	Colorectal cancer;
CRC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.34	-0.46	1.5e-18	HDL cholesterol;
CRC	cis	rs6662572	0.737	rs77017199	chr1:46532407	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.94	0.31	7.12e-9	Blood protein levels;
CRC	trans	rs7200786	0.546	rs11643622	chr16:11225515	A/G	cg24513522	chr17:77393929	HRNBP3	-0.33	-5.99	-0.31	5.42e-9	Multiple sclerosis;Systemic lupus erythematosus;
CRC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-7.06	-0.36	9.7e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23378565	chr7:2036160	MAD1L1	-0.42	-5.8	-0.3	1.52e-8	Neuroticism;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	9.28	0.46	2.34e-18	Lymphocyte counts;
CRC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.53	-0.34	2.54e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.67	-11.18	-0.52	8.28e-25	Dental caries;
CRC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.36	5.75	0.3	2.02e-8	Type 2 diabetes;
CRC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.56	0.6	1.35e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.67	9.41	0.46	8.94e-19	Multiple sclerosis;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg14329157	chr2:228736135	WDR69	-0.45	-6.24	-0.33	1.36e-9	Blood pressure;
CRC	cis	rs554111	0.510	rs10916863	chr1:21120592	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.62	-0.3	3.97e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	trans	rs1945380	0.964	rs4315098	chr11:80389928	T/C	cg00859112	chr14:99736559	BCL11B	0.44	6.0	0.31	5.16e-9	Diabetic kidney disease;
CRC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg03361068	chr14:51561562	TRIM9	0.28	5.94	0.31	7.26e-9	Cancer;
CRC	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg07636037	chr3:49044803	WDR6	-0.72	-6.08	-0.32	3.38e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4760636	0.648	rs12815462	chr12:48160252	G/A	cg13326926	chr12:48153388	RAPGEF3	0.61	6.06	0.32	3.63e-9	Urate levels;
CRC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg10760299	chr15:45669010	GATM	0.5	7.97	0.4	2.72e-14	Homoarginine levels;
CRC	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-8.45	-0.42	9.41e-16	HDL cholesterol;
CRC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg14673194	chr17:80132900	CCDC57	0.49	6.35	0.33	7.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.7	9.9	0.48	2.22e-20	Alzheimer's disease;
CRC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.94	0.4	3.33e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg24562669	chr7:97807699	LMTK2	-0.63	-11.76	-0.54	6.99e-27	Breast cancer;
CRC	cis	rs7394190	0.748	rs4746146	chr10:75527197	C/T	cg07699608	chr10:75541558	CHCHD1	0.6	6.34	0.33	7.42e-10	Incident atrial fibrillation;
CRC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21951070	chr3:185826924	ETV5	0.38	6.32	0.33	8.31e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13704678	chr3:10362667	SEC13	-0.44	-6.31	-0.33	8.83e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	1.95e-33	Vitiligo;
CRC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.68	9.96	0.48	1.37e-20	Longevity;
CRC	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21659725	chr3:3221576	CRBN	-0.69	-7.14	-0.37	6.11e-12	Menarche (age at onset);
CRC	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.7	-9.16	-0.45	5.5e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.53	-0.34	2.57e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11547950	chr5:77652471	NA	-0.49	-6.56	-0.34	2.11e-10	Triglycerides;
CRC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.75	11.72	0.54	9.87e-27	Immature fraction of reticulocytes;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg26875233	chr11:93583750	C11orf90	-0.33	-6.46	-0.34	3.85e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.81	0.68	3.37e-46	Electrocardiographic conduction measures;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12694820	chr6:41041189	NFYA;C6orf130	0.47	6.01	0.31	4.88e-9	Thyroid stimulating hormone;
CRC	cis	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg04733911	chr16:78082701	NA	-0.45	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg19894588	chr14:64061835	NA	0.42	6.02	0.31	4.58e-9	Glioblastoma;Glioma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02608292	chr19:55897501	RPL28	0.51	6.56	0.34	2.13e-10	Thyroid stimulating hormone;
CRC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.43	6.67	0.35	1.05e-10	Red blood cell count;
CRC	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg10437265	chr15:77819839	NA	-0.54	-9.36	-0.46	1.31e-18	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24180569	chr12:6309517	CD9	0.42	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.36	-6.9	-0.36	2.67e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12463550	chr7:65579703	CRCP	0.69	6.43	0.33	4.37e-10	Diabetic kidney disease;
CRC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.66	9.52	0.46	3.79e-19	Lung cancer;
CRC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.51	-8.48	-0.42	7.58e-16	Brugada syndrome;
CRC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg18612461	chr15:75251733	NA	0.48	7.25	0.37	2.91e-12	Breast cancer;
CRC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.94	-0.4	3.16e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg24375607	chr4:120327624	NA	0.46	7.28	0.37	2.54e-12	Corneal astigmatism;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-7.82	-0.4	7.11e-14	Total body bone mineral density;
CRC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.65	-10.33	-0.49	7.7e-22	Glaucoma (primary open-angle);
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.34	0.53	2.15e-25	Prudent dietary pattern;
CRC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-9.5	-0.46	4.6e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.54	-0.34	2.38e-10	Blood protein levels;
CRC	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.59	-8.97	-0.44	2.32e-17	Dementia with Lewy bodies;
CRC	cis	rs9648716	0.873	rs10251793	chr7:140587169	C/T	cg10747023	chr7:140774559	NA	0.44	5.88	0.31	9.82e-9	Type 2 diabetes;
CRC	trans	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg03037974	chr15:76606532	NA	-0.41	-6.14	-0.32	2.36e-9	Blood metabolite levels;
CRC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.31	0.42	2.51e-15	Colorectal cancer;
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.73	10.11	0.49	4.07e-21	White matter hyperintensity burden;
CRC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg12193833	chr17:30244370	NA	-0.67	-8.19	-0.41	5.7e-15	Hip circumference adjusted for BMI;
CRC	cis	rs2252521	0.583	rs317763	chr7:29082303	A/G	cg11728747	chr7:29037910	CPVL	-0.52	-7.22	-0.37	3.69e-12	Cognitive performance;
CRC	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.49	0.38	6.44e-13	Eye color traits;
CRC	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.48	-6.09	-0.32	3.2e-9	Orofacial clefts;
CRC	cis	rs6496667	0.865	rs62019349	chr15:90921658	C/T	cg04176472	chr15:90893244	GABARAPL3	0.6	7.88	0.4	4.77e-14	Rheumatoid arthritis;
CRC	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.11	0.45	8.15e-18	Dupuytren's disease;
CRC	trans	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.46	8.33	0.42	2.2e-15	Birth weight;
CRC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg03623178	chr6:28175578	NA	0.66	9.07	0.45	1.07e-17	Parkinson's disease;
CRC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.78	-0.35	5.43e-11	Breast cancer;
CRC	trans	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.09	-0.32	3.09e-9	Educational attainment (years of education);
CRC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.51	7.95	0.4	3.02e-14	Aortic root size;
CRC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.72	-0.35	8.01e-11	Aortic root size;
CRC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.35	-5.75	-0.3	2.04e-8	Childhood ear infection;
CRC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.82	13.53	0.6	1.81e-33	Cognitive function;
CRC	trans	rs6472235	0.749	rs62506641	chr8:66903691	C/T	cg07884673	chr3:53033167	SFMBT1	-0.44	-6.06	-0.32	3.78e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.48	7.29	0.37	2.3e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.1	-0.45	9.11e-18	Cancer;
CRC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.22	0.37	3.66e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13069244	1.000	rs13069244	chr3:180441172	G/A	cg07959070	chr22:50026188	C22orf34	0.69	6.23	0.32	1.42e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI in smokers;BMI (adjusted for smoking behaviour);
CRC	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.56	9.58	0.47	2.47e-19	Dupuytren's disease;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.65	-0.34	1.24e-10	Tonsillectomy;
CRC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg20243544	chr17:37824526	PNMT	-0.43	-5.66	-0.3	3.28e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	8.13	0.41	8.86e-15	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20018225	chr2:85555517	TGOLN2	0.42	6.0	0.31	5.35e-9	Response to antipsychotic treatment;
CRC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg05585544	chr11:47624801	NA	-0.58	-9.88	-0.48	2.4e-20	Neuroticism;
CRC	cis	rs6088813	0.961	rs6060373	chr20:33914208	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.37	6.18	0.32	1.86e-9	Height;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.64	-10.11	-0.49	4.22e-21	Monocyte percentage of white cells;
CRC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.73	-11.84	-0.55	3.64e-27	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00147160	chr1:26503991	CNKSR1	0.31	6.5	0.34	3.04e-10	Height;
CRC	cis	rs720844	0.628	rs13003132	chr2:149295930	C/T	cg09247360	chr2:149335327	NA	-0.56	-5.83	-0.31	1.32e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.68	11.12	0.52	1.36e-24	Colorectal cancer;
CRC	cis	rs4743820	0.651	rs10820838	chr9:93930913	G/A	cg14446406	chr9:93919335	NA	-0.75	-13.54	-0.6	1.69e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.42	6.14	0.32	2.32e-9	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06834434	chr14:75079333	LTBP2	0.52	6.06	0.32	3.72e-9	Obesity-related traits;
CRC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00338735	chr4:53728038	RASL11B	0.46	6.27	0.33	1.12e-9	Optic nerve measurement (cup area);
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg13198984	chr17:80129470	CCDC57	0.47	8.27	0.41	3.34e-15	Life satisfaction;
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.8	0.3	1.53e-8	Prudent dietary pattern;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18935937	chr14:105293067	NA	0.5	6.56	0.34	2.05e-10	Thyroid stimulating hormone;
CRC	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg12908607	chr1:44402522	ARTN	-0.33	-5.68	-0.3	3.03e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg09659197	chr4:152720779	NA	0.4	7.82	0.4	7.07e-14	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.52	-9.92	-0.48	1.9e-20	Acylcarnitine levels;
CRC	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg02466173	chr16:30829666	NA	0.4	5.65	0.3	3.43e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.2	-0.37	3.99e-12	Systolic blood pressure;
CRC	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.42	-6.99	-0.36	1.56e-11	IgG glycosylation;
CRC	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.53	-8.8	-0.44	8.05e-17	Brugada syndrome;
CRC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	6.78	0.35	5.45e-11	Lung function (FEV1/FVC);
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.44	6.35	0.33	7.09e-10	Obesity-related traits;
CRC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.44	-6.84	-0.35	3.96e-11	Height;
CRC	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06529477	chr17:56709497	TEX14	-0.41	-6.56	-0.34	2.13e-10	Aortic root size;
CRC	cis	rs3996993	0.809	rs10948722	chr6:52663813	A/G	cg20803780	chr6:52668592	GSTA1	0.37	6.56	0.34	2.11e-10	Hemoglobin concentration;
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg05055821	chr7:2758924	NA	-0.36	-5.76	-0.3	1.98e-8	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18730023	chr12:44199730	TWF1	0.45	6.21	0.32	1.63e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.56	-9.19	-0.45	4.52e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.4	7.74	0.39	1.22e-13	Ulcerative colitis;
CRC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	7.92	0.4	3.58e-14	Aortic root size;
CRC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.49	-9.51	-0.46	4.05e-19	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.4	5.88	0.31	9.81e-9	Obesity-related traits;
CRC	cis	rs7731657	0.537	rs10073197	chr5:130373090	C/T	cg08523029	chr5:130500466	HINT1	-0.47	-6.06	-0.32	3.68e-9	Fasting plasma glucose;
CRC	trans	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg08397747	chr2:29038986	SPDYA	0.36	5.96	0.31	6.42e-9	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg03013999	chr17:37608204	MED1	-0.47	-7.4	-0.38	1.14e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg02158880	chr13:53174818	NA	0.44	6.65	0.34	1.22e-10	Lewy body disease;
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.51	0.57	1.19e-29	Alzheimer's disease;
CRC	cis	rs7617773	0.851	rs13068288	chr3:48331751	A/T	cg11946769	chr3:48343235	NME6	0.64	8.59	0.43	3.47e-16	Coronary artery disease;
CRC	cis	rs4234798	0.933	rs10020957	chr4:7222436	C/T	cg18431297	chr4:7219810	SORCS2	-0.56	-10.49	-0.5	2.2e-22	Insulin-like growth factors;
CRC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.51	7.04	0.36	1.12e-11	IgG glycosylation;
CRC	cis	rs6725806	1.000	rs6725806	chr2:103216172	T/G	cg00507830	chr2:103233733	NA	0.47	6.34	0.33	7.73e-10	Blood protein levels;
CRC	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg25714306	chr4:1656736	FAM53A	-0.31	-5.67	-0.3	3.16e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.65	5.74	0.3	2.15e-8	Yeast infection;
CRC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.61	10.29	0.49	1.05e-21	Resting heart rate;
CRC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.82	18.06	0.71	3.69e-51	Breast cancer;
CRC	cis	rs9469578	0.710	rs77213792	chr6:33713952	C/G	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs12042938	0.622	rs61707606	chr1:231813446	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.65	0.3	3.49e-8	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.55	9.02	0.45	1.56e-17	Colorectal cancer;
CRC	cis	rs6662572	0.703	rs4420029	chr1:46425500	G/A	cg08644498	chr1:46502608	NA	-0.41	-6.8	-0.35	4.88e-11	Blood protein levels;
CRC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-7.7	-0.39	1.56e-13	Coronary artery disease;
CRC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.55	7.42	0.38	9.97e-13	Obesity-related traits;
CRC	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.44	5.87	0.31	1.08e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	12.11	0.56	3.6e-28	Nonalcoholic fatty liver disease;
CRC	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.45	7.31	0.37	2.08e-12	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.62	9.65	0.47	1.46e-19	Corneal astigmatism;
CRC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg17321639	chr7:2759063	NA	-0.38	-5.86	-0.31	1.1e-8	Height;
CRC	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.49	6.96	0.36	1.8e-11	Eye color traits;
CRC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.64	-7.53	-0.38	4.81e-13	Vitiligo;
CRC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.51	9.82	0.48	3.86e-20	Renal cell carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03939875	chr1:46016565	AKR1A1	0.42	6.29	0.33	1e-9	Response to antipsychotic treatment;
CRC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg25204440	chr1:209979598	IRF6	0.48	5.75	0.3	2.01e-8	Cleft lip with or without cleft palate;
CRC	cis	rs4727963	0.846	rs12670195	chr7:122712925	T/G	cg03640110	chr7:122635026	TAS2R16	0.33	5.86	0.31	1.15e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg11887960	chr12:57824829	NA	0.63	6.79	0.35	5.32e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs10946940	0.864	rs13201411	chr6:27498217	G/C	cg02683197	chr6:28174875	NA	-0.55	-7.49	-0.38	6.34e-13	Systemic lupus erythematosus;
CRC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.18	-16.27	-0.67	4.43e-44	Breast cancer;
CRC	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.81	-10.76	-0.51	2.42e-23	IgG glycosylation;
CRC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.31	0.37	2.03e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg17133734	chr15:86042851	AKAP13	0.43	7.03	0.36	1.22e-11	Interstitial lung disease;
CRC	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs2179367	0.553	rs7762222	chr6:149765982	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.4	-5.63	-0.3	3.91e-8	Dupuytren's disease;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg08798685	chr6:27730294	NA	-0.43	-6.3	-0.33	9.81e-10	Parkinson's disease;
CRC	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.73	12.0	0.55	9.35e-28	Anterior chamber depth;
CRC	cis	rs7605827	0.930	rs13033762	chr2:15592295	T/C	cg19274914	chr2:15703543	NA	0.38	5.76	0.3	1.92e-8	Educational attainment (years of education);
CRC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg27535305	chr1:53392650	SCP2	-0.37	-6.59	-0.34	1.77e-10	Monocyte count;
CRC	cis	rs9943465	0.688	rs318929	chr10:132071772	T/C	cg12765123	chr10:132100019	NA	0.57	6.07	0.32	3.48e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.67	-8.52	-0.43	5.74e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.71	-9.28	-0.46	2.35e-18	IgG glycosylation;
CRC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg03030879	chr14:75389066	RPS6KL1	0.41	6.35	0.33	7.25e-10	Coronary artery disease;
CRC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.74	6.87	0.35	3.27e-11	Diabetic retinopathy;
CRC	trans	rs10242455	0.702	rs28753399	chr7:98997259	C/T	cg09045935	chr12:6379348	NA	1.0	7.62	0.39	2.79e-13	Blood metabolite levels;
CRC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg21620606	chr4:1342894	KIAA1530	0.5	7.9	0.4	4.2e-14	Obesity-related traits;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.82	0.44	7.03e-17	Hip circumference adjusted for BMI;
CRC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.08	0.41	1.27e-14	Cystic fibrosis severity;
CRC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.46	8.02	0.4	1.89e-14	Schizophrenia;
CRC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.46	7.83e-19	Bladder cancer;
CRC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg04121214	chr22:50244548	NA	0.4	5.76	0.3	1.9e-8	Schizophrenia;
CRC	cis	rs35000415	0.938	rs34725944	chr7:128641653	T/C	cg19972273	chr7:128594194	NA	0.68	6.31	0.33	8.75e-10	Systemic lupus erythematosus;
CRC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg24375607	chr4:120327624	NA	0.44	6.86	0.35	3.46e-11	Corneal astigmatism;
CRC	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	0.75	8.14	0.41	8.26e-15	Systolic blood pressure;
CRC	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.52	8.65	0.43	2.38e-16	Dupuytren's disease;
CRC	trans	rs3914167	0.881	rs3849759	chr5:39406098	C/T	cg21800284	chr12:115107215	NA	0.43	6.02	0.31	4.71e-9	Systemic lupus erythematosus;
CRC	cis	rs12760731	0.669	rs10798609	chr1:178431648	C/T	cg00404053	chr1:178313656	RASAL2	0.85	10.04	0.48	7.24e-21	Obesity-related traits;
CRC	cis	rs73206853	0.841	rs73191824	chr12:110936564	T/C	cg12870014	chr12:110450643	ANKRD13A	0.76	6.63	0.34	1.34e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.68	8.33	0.42	2.21e-15	Menarche (age at onset);
CRC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-1.02	-12.9	-0.58	4.34e-31	Orofacial clefts;
CRC	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.49	7.32	0.37	1.86e-12	Corneal astigmatism;
CRC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.33	0.33	8.16e-10	Morning vs. evening chronotype;
CRC	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	6.8	0.35	4.95e-11	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7113874	0.513	rs2015629	chr11:8564426	A/T	cg20771178	chr11:8615675	STK33	-0.36	-5.88	-0.31	1.01e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7011507	1.000	rs79249191	chr8:49193683	A/G	cg04544946	chr8:978226	NA	0.45	6.45	0.34	4.09e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.81	-0.3	1.49e-8	Alzheimer's disease (survival time);
CRC	cis	rs713587	0.520	rs483428	chr2:25305136	A/G	cg22495460	chr2:25135724	ADCY3	-0.43	-6.32	-0.33	8.67e-10	Body mass index in non-asthmatics;
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg21155852	chr7:2048760	MAD1L1	-0.52	-6.98	-0.36	1.63e-11	Bipolar disorder;
CRC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg23018236	chr17:30244563	NA	-0.67	-8.02	-0.4	1.83e-14	Hip circumference adjusted for BMI;
CRC	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg21466736	chr12:48725269	NA	0.46	7.32	0.37	1.86e-12	Plateletcrit;
CRC	cis	rs6973256	0.834	rs10244670	chr7:133323417	A/G	cg10665199	chr7:133106180	EXOC4	-0.37	-5.68	-0.3	2.95e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02772935	chr3:125709198	NA	-0.49	-5.74	-0.3	2.11e-8	Blood pressure (smoking interaction);
CRC	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.82	11.67	0.54	1.47e-26	Cognitive function;
CRC	cis	rs73206853	0.620	rs17682644	chr12:111156008	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.48	0.34	3.28e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs11825064	0.945	rs56296358	chr11:134478665	C/T	cg00033773	chr19:12779366	MORG1;C19orf56	0.52	6.14	0.32	2.43e-9	Seasonality;
CRC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.73	0.3	2.32e-8	Personality dimensions;
CRC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.82	0.31	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg21153622	chr11:89784906	NA	-0.48	-7.67	-0.39	2.02e-13	HDL cholesterol;
CRC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.16	27.12	0.83	6.77e-86	IgG glycosylation;
CRC	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	11.6	0.54	2.58e-26	Height;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg17836132	chr15:51201076	AP4E1	-0.49	-6.2	-0.32	1.65e-9	Type 1 diabetes;
CRC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02450064	chr17:40260053	DHX58	-0.42	-6.13	-0.32	2.54e-9	Fibrinogen levels;
CRC	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg05585544	chr11:47624801	NA	0.4	6.17	0.32	2.02e-9	Mean corpuscular hemoglobin;
CRC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.76	16.59	0.67	2.42e-45	Breast cancer;
CRC	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg08501292	chr6:25962987	TRIM38	0.87	6.75	0.35	6.7e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7254114	0.578	rs4804574	chr19:11317482	G/A	cg02815516	chr19:11306319	KANK2	0.34	6.3	0.33	9.57e-10	Immature fraction of reticulocytes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.42	6.01	0.31	5.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.59	-7.04	-0.36	1.11e-11	Body mass index;
CRC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.48	8.76	0.43	1.04e-16	Longevity;
CRC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.86	-14.85	-0.63	1.53e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7072216	0.666	rs11189592	chr10:100155642	C/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-5.95	-0.31	6.92e-9	Metabolite levels;
CRC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg24163568	chr5:669837	TPPP	-0.43	-6.86	-0.35	3.32e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg19193384	chr17:30244184	NA	-0.65	-7.51	-0.38	5.62e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg22907277	chr7:1156413	C7orf50	0.66	6.96	0.36	1.87e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.61	-9.44	-0.46	7.26e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.73	0.3	2.31e-8	Depression;
CRC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.48	0.53	6.94e-26	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.61	10.3	0.49	9.23e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-6.27	-0.33	1.17e-9	Height;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg06470822	chr6:28175283	NA	0.98	13.17	0.59	4.07e-32	Depression;
CRC	cis	rs10971721	0.822	rs72727342	chr9:33938082	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg03037974	chr15:76606532	NA	-0.51	-7.25	-0.37	2.95e-12	Blood metabolite levels;
CRC	cis	rs55788414	0.789	rs4630561	chr16:81183108	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-8.04	-0.41	1.65e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg12172441	chr6:28176163	NA	0.58	5.72	0.3	2.35e-8	Depression;
CRC	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg01656853	chr19:49199172	FUT2	0.23	5.61	0.3	4.3e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg08999081	chr20:33150536	PIGU	-0.35	-5.68	-0.3	2.95e-8	Height;
CRC	cis	rs6662572	1.000	rs11587982	chr1:46161868	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	6.12	0.32	2.64e-9	Blood protein levels;
CRC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.4	-6.91	-0.36	2.46e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9287719	0.578	rs7598541	chr2:10700516	G/A	cg00105475	chr2:10696890	NA	0.48	7.31	0.37	2.11e-12	Prostate cancer;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg23807890	chr2:228736357	WDR69	-0.51	-6.99	-0.36	1.56e-11	Blood pressure;
CRC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16262614	chr3:133464971	TF	-0.32	-5.69	-0.3	2.82e-8	Iron status biomarkers;
CRC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.12	21.01	0.76	9.29e-63	Cognitive function;
CRC	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	14.66	0.63	8.2e-38	Mean corpuscular hemoglobin;
CRC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg05623727	chr3:50126028	RBM5	0.46	7.82	0.4	7.12e-14	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26933736	chr6:83902998	RWDD2A;PGM3	0.4	6.38	0.33	6.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.68	7.77	0.39	1.04e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11716640	chr1:113933411	MAGI3	0.46	6.16	0.32	2.17e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.52	8.38	0.42	1.6e-15	Aortic root size;
CRC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg04043695	chr12:129287642	SLC15A4	0.39	5.95	0.31	6.95e-9	Systemic lupus erythematosus;
CRC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-7.44	-0.38	8.92e-13	Chronic sinus infection;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Bladder cancer;
CRC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg06470822	chr6:28175283	NA	0.92	13.0	0.58	1.83e-31	Parkinson's disease;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-7.41	-0.38	1.09e-12	Longevity;Endometriosis;
CRC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	-0.56	-6.33	-0.33	8.02e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	8.8	0.44	8.11e-17	Cognitive test performance;
CRC	cis	rs3996993	0.809	rs12528332	chr6:52687392	G/A	cg20803780	chr6:52668592	GSTA1	0.36	6.48	0.34	3.44e-10	Hemoglobin concentration;
CRC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg05925327	chr15:68127851	NA	-0.31	-6.01	-0.31	4.84e-9	Restless legs syndrome;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg11235426	chr6:292522	DUSP22	-0.54	-7.7	-0.39	1.62e-13	Menopause (age at onset);
CRC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-5.98	-0.31	5.75e-9	Type 2 diabetes;
CRC	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.52	9.36	0.46	1.32e-18	Blood metabolite ratios;
CRC	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2252790	1.000	rs10456906	chr6:116621035	C/A	cg18764771	chr6:116381957	FRK	0.22	5.92	0.31	8.17e-9	Fast beta electroencephalogram;
CRC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.76	-10.57	-0.5	1.13e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs12922317	0.538	rs442234	chr16:12072161	A/G	cg02368508	chr16:12060182	TNFRSF17	0.43	6.87	0.35	3.16e-11	Schizophrenia;
CRC	cis	rs1873147	1.000	rs4774470	chr15:63312119	G/A	cg12160578	chr15:63334699	TPM1	-0.4	-5.74	-0.3	2.13e-8	Orofacial clefts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21468385	chr11:120207433	ARHGEF12	0.4	6.22	0.32	1.47e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs10221833	0.602	rs355882	chr2:165633761	T/C	cg03182029	chr2:165697222	COBLL1	0.49	5.8	0.3	1.56e-8	Response to statin therapy;
CRC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.01	-0.31	4.81e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg13402217	chr1:151584375	SNX27	0.39	6.16	0.32	2.07e-9	Age-related macular degeneration;
CRC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.38	7.24	0.37	3.19e-12	Iron status biomarkers;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23708337	chr7:1209742	NA	0.41	5.9	0.31	9.03e-9	Longevity;Endometriosis;
CRC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.87	-0.4	5.24e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.1	-0.36	7.91e-12	Breast cancer;
CRC	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg23254163	chr1:152506842	NA	0.51	10.12	0.49	3.97e-21	Hair morphology;
CRC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.67	11.32	0.53	2.72e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.8e-8	Colorectal cancer;
CRC	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg18232548	chr7:50535776	DDC	0.45	5.89	0.31	9.48e-9	Malaria;
CRC	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg17507749	chr15:85114479	UBE2QP1	0.62	7.77	0.39	1.02e-13	Schizophrenia;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg25164649	chr6:28176230	NA	0.59	6.31	0.33	8.79e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.43	8.75	0.43	1.15e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-6.86	-0.35	3.38e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11547950	chr5:77652471	NA	-0.48	-7.04	-0.36	1.14e-11	Triglycerides;
CRC	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-11.2	-0.53	6.79e-25	Colorectal cancer;
CRC	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg20542592	chr8:11973495	FAM66D	0.35	5.62	0.3	4.02e-8	Retinal vascular caliber;
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.88	0.31	1.03e-8	Systemic lupus erythematosus;
CRC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.82	11.22	0.53	5.97e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	8.74	0.43	1.19e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05940971	chr14:93651131	MOAP1;C14orf109	0.42	6.61	0.34	1.6e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.48	-5.84	-0.31	1.26e-8	Diastolic blood pressure;
CRC	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg19418318	chr19:17219073	MYO9B	0.5	8.52	0.43	5.69e-16	Reticulocyte fraction of red cells;
CRC	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.07e-11	Common traits (Other);
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.74	-0.3	2.2e-8	Life satisfaction;
CRC	cis	rs8105895	0.935	rs10408150	chr19:22245225	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs8005677	0.798	rs4536383	chr14:23410926	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-6.3	-0.33	9.66e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.68	12.43	0.57	2.44e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.42e-25	Intelligence (multi-trait analysis);
CRC	trans	rs2797369	0.771	rs2813643	chr6:101575509	G/T	cg26346621	chr12:6873348	NA	0.38	6.12	0.32	2.66e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.98	-17.93	-0.7	1.26e-50	Headache;
CRC	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.98	0.4	2.49e-14	Breast cancer;
CRC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.5	7.45	0.38	8.37e-13	Menarche (age at onset);
CRC	cis	rs727505	0.607	rs17387591	chr7:124799471	A/G	cg23710748	chr7:124431027	NA	-0.58	-9.67	-0.47	1.27e-19	Lewy body disease;
CRC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.74	-12.28	-0.56	8.57e-29	Breast cancer;
CRC	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.31	6.59	0.34	1.73e-10	Educational attainment (years of education);
CRC	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg18200150	chr17:30822561	MYO1D	0.44	8.52	0.43	5.79e-16	Schizophrenia;
CRC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg21466736	chr12:48725269	NA	-0.49	-7.62	-0.39	2.7e-13	Plateletcrit;
CRC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.26	0.45	2.71e-18	Height;
CRC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.96	0.48	1.32e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.43	8.24	0.41	4.1e-15	Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.37	5.66	0.3	3.34e-8	Height;
CRC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.61	-9.24	-0.45	3.08e-18	Blood pressure (smoking interaction);
CRC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.75	-0.3	2.09e-8	Crohn's disease;
CRC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg14074117	chr16:1909714	C16orf73	0.42	5.85	0.31	1.2e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.61	8.03	0.4	1.8e-14	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16421803	chr2:25194856	DNAJC27	0.42	6.34	0.33	7.77e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17756712	0.725	rs17135679	chr6:614787	T/C	cg16786516	chr6:604617	EXOC2	0.46	5.71	0.3	2.46e-8	Vertical cup-disc ratio;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.57	-7.93	-0.4	3.53e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.74	-0.47	7.41e-20	Bladder cancer;
CRC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.6	8.44	0.42	1.02e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.4	-7.8	-0.39	8.38e-14	Migraine;
CRC	cis	rs2213920	0.679	rs9409160	chr9:118227046	G/A	cg13918206	chr9:118159781	DEC1	0.64	6.07	0.32	3.49e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg15845792	chr6:28175446	NA	0.48	6.96	0.36	1.82e-11	Pubertal anthropometrics;
CRC	cis	rs11625487	0.915	rs11845826	chr14:77966145	C/A	cg16049707	chr14:77965284	ISM2	0.43	5.84	0.31	1.23e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg11993925	chr19:44307056	LYPD5	0.47	7.82	0.4	7.09e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs3736485	0.932	rs2278990	chr15:51914662	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.53	-0.34	2.49e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs365302	1.000	rs444245	chr6:159642963	C/T	cg14500486	chr6:159655392	FNDC1	0.45	6.73	0.35	7.76e-11	Coronary heart disease;
CRC	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg05714579	chr10:131428358	MGMT	-0.5	-6.88	-0.35	2.97e-11	Response to temozolomide;
CRC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg25876840	chr17:41920477	NA	0.48	6.9	0.36	2.67e-11	Triglycerides;
CRC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg09264619	chr17:80180166	NA	-0.38	-6.46	-0.34	3.81e-10	Life satisfaction;
CRC	trans	rs1945380	1.000	rs4118071	chr11:80425472	A/T	cg01496416	chr19:45147715	PVR	0.45	5.97	0.31	5.99e-9	Diabetic kidney disease;
CRC	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg14530993	chr4:882597	GAK	0.78	7.44	0.38	9.04e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.43e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.62	-0.3	4.04e-8	Ovarian reserve;
CRC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.75	13.33	0.59	1.05e-32	Oral cavity cancer;
CRC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.38	-6.2	-0.32	1.71e-9	Bone mineral density (spine);
CRC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.52	6.86	0.35	3.35e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25974723	chr19:50119415	PRR12	-0.37	-5.98	-0.31	5.88e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05019311	chr17:4807065	CHRNE	0.45	6.62	0.34	1.48e-10	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.99	-0.36	1.5e-11	Lung cancer;
CRC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.5	6.44	0.33	4.22e-10	Obesity-related traits;
CRC	cis	rs7705042	0.759	rs3765011	chr5:141517665	G/C	cg07392085	chr5:141489673	NDFIP1	0.45	7.29	0.37	2.34e-12	Asthma;
CRC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.92	-18.09	-0.71	2.95e-51	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.81	13.51	0.6	2.08e-33	Menopause (age at onset);
CRC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.44	-6.53	-0.34	2.43e-10	Body mass index;
CRC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.34	-5.85	-0.31	1.18e-8	White matter hyperintensity burden;
CRC	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.67	6.4	0.33	5.39e-10	Axial length;
CRC	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.67	-0.47	1.26e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.67	-0.47	1.21e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.76	-10.55	-0.5	1.32e-22	Initial pursuit acceleration;
CRC	cis	rs911119	0.954	rs116786204	chr20:23599918	T/G	cg16589663	chr20:23618590	CST3	0.44	6.16	0.32	2.12e-9	Chronic kidney disease;
CRC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.45	-5.86	-0.31	1.14e-8	Gut microbiome composition (summer);
CRC	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12292205	chr6:26970375	C6orf41	-0.77	-8.23	-0.41	4.37e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg21620606	chr4:1342894	KIAA1530	0.36	5.89	0.31	9.62e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04215179	chr7:23719682	C7orf46	0.43	6.98	0.36	1.63e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	1.05	10.14	0.49	3.36e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg02776659	chr21:47717406	C21orf57	-0.33	-5.63	-0.3	3.79e-8	Testicular germ cell tumor;
CRC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.45	-7.86	-0.4	5.54e-14	Eye color traits;
CRC	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-9.67	-0.47	1.24e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg12756093	chr1:115239321	AMPD1	0.48	6.99	0.36	1.51e-11	Autism;
CRC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg26248373	chr2:1572462	NA	-0.83	-12.38	-0.56	3.62e-29	IgG glycosylation;
CRC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg23625390	chr15:77176239	SCAPER	0.5	7.22	0.37	3.66e-12	Blood metabolite levels;
CRC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.8	-0.3	1.54e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs11212617	0.967	rs3781868	chr11:108059569	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.43	0.33	4.44e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs863345	0.604	rs12118446	chr1:158496235	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg21466736	chr12:48725269	NA	0.51	8.01	0.4	1.96e-14	Plateletcrit;
CRC	cis	rs8105895	0.935	rs62111028	chr19:22272397	A/T	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	1.05	21.04	0.76	7.53e-63	Multiple myeloma;
CRC	cis	rs600626	0.588	rs10160802	chr11:75457950	A/C	cg24262691	chr11:75473276	NA	0.5	7.27	0.37	2.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-6.85	-0.35	3.68e-11	Vitiligo;
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg05279229	chr7:1896384	MAD1L1	-0.35	-5.67	-0.3	3.15e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.38	-6.2	-0.32	1.69e-9	Glycated hemoglobin levels;
CRC	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg23815491	chr16:72088622	HP	0.54	5.84	0.31	1.22e-8	Coronary artery disease;
CRC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.66	0.39	2.16e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	6.33	0.33	8.21e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7623687	0.786	rs73082337	chr3:49009570	C/G	cg19401529	chr3:49056140	DALRD3	0.55	6.05	0.32	4.03e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CRC	cis	rs2223471	0.754	rs2744490	chr6:50765876	T/A	cg03432817	chr6:50765336	NA	0.43	6.93	0.36	2.24e-11	Subcutaneous adipose tissue;
CRC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg06243084	chr11:63990629	FERMT3	-0.4	-6.17	-0.32	2e-9	Platelet count;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg15786705	chr6:28176104	NA	0.55	7.78	0.39	9.76e-14	Parkinson's disease;
CRC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.58	-6.13	-0.32	2.54e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg08779649	chr13:50194554	NA	0.35	6.62	0.34	1.46e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.61	8.81	0.44	7.23e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs12519773	0.501	rs4449514	chr5:92521022	T/C	cg18783429	chr5:92414398	NA	0.27	5.73	0.3	2.25e-8	Migraine;
CRC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.58	-8.57	-0.43	4.21e-16	Aortic root size;
CRC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.31	0.53	2.81e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg15123572	chr13:114911570	NA	-0.39	-6.1	-0.32	3.04e-9	HDL cholesterol;
CRC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.56	0.43	4.43e-16	Lymphocyte counts;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23156475	chr20:18269111	ZNF133	-0.38	-6.11	-0.32	2.82e-9	Aortic root size;
CRC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.62	7.58	0.39	3.59e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.43	5.72	0.3	2.43e-8	Coronary artery disease;
CRC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.89	-0.36	2.85e-11	Schizophrenia;
CRC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-9.85	-0.48	3.23e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg18753928	chr3:113234510	CCDC52	-0.48	-7.72	-0.39	1.42e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs243505	0.762	rs3779036	chr7:148488507	C/T	cg09806900	chr7:148480153	CUL1	0.52	7.56	0.38	3.94e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.52	-7.82	-0.4	7.45e-14	Asthma;
CRC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg15269541	chr15:43626905	ADAL	-0.62	-6.32	-0.33	8.41e-10	Lung cancer in ever smokers;
CRC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00166722	chr3:10149974	C3orf24	0.42	6.28	0.33	1.1e-9	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00789034	chr6:158245090	SNX9	0.46	6.35	0.33	7.1e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg03623178	chr6:28175578	NA	0.96	12.36	0.56	4.32e-29	Depression;
CRC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.22	-0.53	5.81e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2415984	0.583	rs2642090	chr14:46968788	C/T	cg14871534	chr14:47121158	RPL10L	0.39	5.93	0.31	7.78e-9	Number of children ever born;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24419099	chr11:47270565	NR1H3;ACP2	0.42	5.96	0.31	6.45e-9	Response to antipsychotic treatment;
CRC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs1223397	0.651	rs2439537	chr6:13307824	C/T	cg20827128	chr6:13274284	PHACTR1	0.39	5.99	0.31	5.56e-9	Blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02273769	chr5:171433860	FBXW11	0.45	6.17	0.32	2.03e-9	Response to antipsychotic treatment;
CRC	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg00469287	chr7:23338798	C7orf30	0.45	6.23	0.32	1.4e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.67	10.62	0.51	7.51e-23	Sudden cardiac arrest;
CRC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg19980929	chr12:42632907	YAF2	0.44	6.54	0.34	2.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.59	-9.23	-0.45	3.46e-18	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03664139	chr6:101329504	ASCC3	0.48	6.88	0.35	3.07e-11	Response to antipsychotic treatment;
CRC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg22676075	chr6:135203613	NA	0.39	6.03	0.32	4.51e-9	Red blood cell count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20093577	chr11:65819742	SF3B2	0.45	6.36	0.33	6.82e-10	Anxiety disorder;
CRC	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06307176	chr5:131281290	NA	0.45	6.65	0.34	1.22e-10	Life satisfaction;
CRC	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.44	6.47	0.34	3.45e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg10729496	chr3:10149963	C3orf24	0.52	6.93	0.36	2.21e-11	Alzheimer's disease;
CRC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17767392	0.918	rs61991201	chr14:71762623	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.8	0.35	4.85e-11	Rheumatoid arthritis;
CRC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg08213375	chr14:104286397	PPP1R13B	0.36	5.86	0.31	1.11e-8	Reticulocyte count;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg18301423	chr5:131593218	PDLIM4	0.31	5.76	0.3	1.95e-8	Blood metabolite levels;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg00166722	chr3:10149974	C3orf24	0.68	7.84	0.4	6.29e-14	Alzheimer's disease;
CRC	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.74	13.74	0.6	2.84e-34	Metabolite levels;
CRC	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg10437265	chr15:77819839	NA	-0.58	-9.75	-0.47	6.92e-20	Type 2 diabetes;
CRC	trans	rs4576506	0.536	rs13299549	chr9:31495659	A/G	cg26940518	chr16:1593766	IFT140;TMEM204	-0.65	-6.02	-0.31	4.71e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg13319975	chr6:146136371	FBXO30	0.43	6.46	0.34	3.71e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9659323	1.000	rs11584380	chr1:119517420	C/T	cg26570165	chr1:119541833	NA	-0.38	-6.38	-0.33	6.02e-10	Body mass index;
CRC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.68e-9	Colorectal cancer;
CRC	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.67	6.82	0.35	4.47e-11	Pediatric areal bone mineral density (radius);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02002494	chr3:119013045	CDGAP	-0.53	-6.42	-0.33	4.78e-10	Diisocyanate-induced asthma;
CRC	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.68	6.19	0.32	1.8e-9	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20822818	chr11:119235062	USP2	0.36	7.09	0.36	8.12e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg10437265	chr15:77819839	NA	0.67	12.77	0.58	1.34e-30	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.59	9.97	0.48	1.2e-20	Prudent dietary pattern;
CRC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.73	-12.01	-0.55	8.66e-28	Breast cancer;
CRC	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg21064579	chr19:49206444	FUT2	-0.47	-8.21	-0.41	5.15e-15	Dietary macronutrient intake;
CRC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.68	-0.3	2.97e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.79	-11.65	-0.54	1.69e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.32	-6.94	-0.36	2.03e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08974500	chr6:170863287	PSMB1;TBP	0.4	5.97	0.31	6.29e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.03	-0.36	1.22e-11	Psoriasis;
CRC	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.74	0.3	2.21e-8	Prostate cancer;
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.1	9.37	0.46	1.21e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs41005	1.000	rs798450	chr2:8107093	C/T	cg03155496	chr2:8117019	LOC339788	0.42	7.54	0.38	4.56e-13	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.76e-9	Life satisfaction;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs9341808	0.667	rs3828753	chr6:80912746	C/T	cg08355045	chr6:80787529	NA	0.34	5.79	0.3	1.63e-8	Sitting height ratio;
CRC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.21	-16.45	-0.67	8.87e-45	Breast cancer;
CRC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.87	-16.07	-0.66	2.73e-43	Coronary artery disease;
CRC	trans	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.94	-0.36	2.04e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.37	-0.38	1.36e-12	Aortic root size;
CRC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.68	11.79	0.55	5.18e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg12193833	chr17:30244370	NA	-0.62	-7.94	-0.4	3.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg03623178	chr6:28175578	NA	-0.71	-7.85	-0.4	6.11e-14	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg11292332	chr7:45801988	SEPT13	-0.39	-7.1	-0.36	7.68e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-0.97	-16.28	-0.67	4.02e-44	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.49	7.62	0.39	2.77e-13	Corneal astigmatism;
CRC	trans	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg21167628	chr1:45308625	PTCH2	0.38	6.52	0.34	2.66e-10	Facial morphology (factor 20);
CRC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg17524180	chr13:113633600	MCF2L	-0.56	-8.9	-0.44	3.83e-17	Systolic blood pressure;
CRC	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.55	8.66	0.43	2.13e-16	Testicular germ cell tumor;
CRC	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg11266682	chr4:10021025	SLC2A9	0.3	5.61	0.3	4.21e-8	Cardiovascular disease risk factors;
CRC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg19980929	chr12:42632907	YAF2	0.44	6.57	0.34	1.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.76	11.62	0.54	2.24e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs4731207	0.596	rs1600739	chr7:124639606	A/G	cg23710748	chr7:124431027	NA	0.4	6.43	0.33	4.38e-10	Cutaneous malignant melanoma;
CRC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.68	-0.3	2.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.43	5.83	0.31	1.34e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12541635	0.677	rs4734892	chr8:106990088	G/C	cg10147462	chr8:107024639	NA	0.59	10.0	0.48	1e-20	Age of smoking initiation;
CRC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.46	0.42	9.09e-16	Arsenic metabolism;
CRC	cis	rs7107770	0.640	rs2874374	chr11:125073691	A/G	cg27629782	chr11:125073726	PKNOX2	0.49	7.19	0.37	4.37e-12	Photic sneeze reflex;
CRC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.4	5.61	0.3	4.26e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg09127314	chr1:152161683	NA	-0.52	-6.61	-0.34	1.54e-10	Atopic dermatitis;
CRC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.49	7.17	0.37	4.95e-12	Response to antineoplastic agents;
CRC	trans	rs771998	0.909	rs2252526	chr12:52381230	G/T	cg04286455	chr5:77803462	LHFPL2	-0.39	-6.1	-0.32	3.04e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.09	-0.32	3.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg24375607	chr4:120327624	NA	0.51	7.75	0.39	1.12e-13	Corneal astigmatism;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg22561889	chr6:118971681	C6orf204	0.53	6.83	0.35	4.16e-11	Diastolic blood pressure;
CRC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg05623727	chr3:50126028	RBM5	-0.41	-6.89	-0.36	2.81e-11	Menarche (age at onset);
CRC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.98	-0.4	2.45e-14	Schizophrenia;
CRC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	8.11	0.41	1.04e-14	Monocyte count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13009927	chr2:242254519	SEPT2;HDLBP	0.38	6.04	0.32	4.27e-9	Obesity-related traits;
CRC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg12639453	chr1:2035780	PRKCZ	0.33	6.39	0.33	5.54e-10	Height;
CRC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.64	7.84	0.4	6.51e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-14.75	-0.63	3.94e-38	Colorectal cancer;
CRC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.74	12.32	0.56	5.91e-29	Primary sclerosing cholangitis;
CRC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	7.47	0.38	7.22e-13	Obesity-related traits;
CRC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-5.91	-0.31	8.46e-9	Alzheimer's disease (late onset);
CRC	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg09003973	chr2:102972529	NA	0.66	6.59	0.34	1.76e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.71	9.52	0.46	3.79e-19	Alzheimer's disease;
CRC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg00316803	chr15:76480434	C15orf27	-0.34	-5.69	-0.3	2.75e-8	Blood metabolite levels;
CRC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg24253500	chr15:84953950	NA	0.35	5.95	0.31	6.74e-9	Schizophrenia;
CRC	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.47	6.77	0.35	6.1e-11	Primary sclerosing cholangitis;
CRC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg24505167	chr7:1915268	MAD1L1	-0.43	-6.06	-0.32	3.69e-9	Bipolar disorder;
CRC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg20243544	chr17:37824526	PNMT	0.55	8.95	0.44	2.66e-17	Asthma;
CRC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg15534755	chr11:117069859	TAGLN	0.34	6.48	0.34	3.29e-10	Blood protein levels;
CRC	cis	rs7849270	0.959	rs10988233	chr9:131915926	C/A	cg13538475	chr9:131942899	NA	-0.3	-5.87	-0.31	1.04e-8	Blood metabolite ratios;
CRC	trans	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg26043149	chr18:55253948	FECH	-0.46	-6.95	-0.36	1.96e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12128893	chr10:75255807	PPP3CB	0.47	6.83	0.35	4.09e-11	Response to antipsychotic treatment;
CRC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.69	-10.81	-0.51	1.67e-23	Blood protein levels;
CRC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg21153622	chr11:89784906	NA	-0.37	-5.97	-0.31	6.15e-9	Height;
CRC	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.23	0.53	5.6e-25	Bipolar disorder;
CRC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.71	-12.02	-0.55	7.57e-28	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg07617317	chr6:118971624	C6orf204	0.47	5.68	0.3	2.91e-8	Diastolic blood pressure;
CRC	cis	rs7703744	0.634	rs6884061	chr5:118683431	C/T	cg07086380	chr5:118691033	TNFAIP8	0.4	5.75	0.3	2e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.71	-8.02	-0.4	1.83e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg11900509	chr10:81946545	ANXA11	-0.66	-6.6	-0.34	1.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg14593290	chr7:50529359	DDC	-0.44	-6.35	-0.33	7e-10	Body mass index;
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.64	12.66	0.57	3.37e-30	HDL cholesterol;
CRC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.45	6.44	0.33	4.32e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.66	0.57	3.43e-30	Alzheimer's disease;
CRC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.83	0.35	4e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.47	-6.45	-0.34	3.99e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs73206853	0.841	rs56017652	chr12:110931054	C/T	cg12870014	chr12:110450643	ANKRD13A	0.75	8.1	0.41	1.08e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.29	-6.08	-0.32	3.3e-9	Educational attainment (years of education);
CRC	cis	rs1322512	0.917	rs2758778	chr6:153007802	T/C	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.57	-0.34	1.92e-10	Educational attainment (years of education);
CRC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.6	-0.47	2.14e-19	Monocyte percentage of white cells;
CRC	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg18709589	chr6:96969512	KIAA0776	0.5	5.8	0.3	1.53e-8	Migraine;Coronary artery disease;
CRC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.97	-0.31	6.03e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.46	7.0	0.36	1.42e-11	Menopause (age at onset);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01044127	chr13:77566253	CLN5	-0.43	-6.17	-0.32	2.05e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9491140	0.539	rs11154226	chr6:124681785	G/A	cg05308643	chr6:124982296	NKAIN2	0.45	5.91	0.31	8.78e-9	Neuroticism;
CRC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.28	0.33	1.06e-9	Aortic root size;
CRC	trans	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg06834434	chr14:75079333	LTBP2	0.55	6.55	0.34	2.28e-10	Obesity-related traits;
CRC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.41	5.71	0.3	2.59e-8	Eosinophil percentage of white cells;
CRC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.4	-7.46	-0.38	7.66e-13	Monocyte percentage of white cells;
CRC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24308560	chr3:49941425	MST1R	-0.44	-6.81	-0.35	4.6e-11	Body mass index;
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.15	0.74	2.13e-59	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.56	-9.35	-0.46	1.43e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.81	-11.14	-0.52	1.12e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg23032129	chr1:109941072	SORT1	-0.29	-6.08	-0.32	3.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.03	10.1	0.49	4.66e-21	Lymphocyte counts;
CRC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs7091068	0.616	rs1890657	chr10:95506087	G/A	cg20715218	chr10:95462985	C10orf4	0.55	5.74	0.3	2.19e-8	Urinary tract infection frequency;
CRC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12172441	chr6:28176163	NA	0.54	6.99	0.36	1.58e-11	Parkinson's disease;
CRC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-5.65	-0.3	3.48e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08748207	chr12:46777589	NA	0.44	6.13	0.32	2.46e-9	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.58	9.24	0.45	3.06e-18	Lewy body disease;
CRC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.56	-7.86	-0.4	5.4e-14	Urate levels in lean individuals;
CRC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg15445000	chr17:37608096	MED1	-0.37	-6.53	-0.34	2.49e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg00750074	chr16:89608354	SPG7	-0.51	-7.76	-0.39	1.1e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.81	-13.65	-0.6	6.41e-34	Menarche (age at onset);
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg21251018	chr6:28226885	NKAPL	0.4	6.28	0.33	1.08e-9	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01653354	chr6:74230425	EEF1A1	0.44	5.99	0.31	5.36e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.14	0.32	2.41e-9	Aortic root size;
CRC	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg00919237	chr7:87102261	ABCB4	0.56	7.34	0.38	1.68e-12	Gallbladder cancer;
CRC	cis	rs10221833	0.636	rs355890	chr2:165634976	T/G	cg03182029	chr2:165697222	COBLL1	0.52	6.09	0.32	3.22e-9	Response to statin therapy;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg19528231	chr10:74451771	CCDC109A	-0.44	-6.4	-0.33	5.2e-10	Daytime sleep phenotypes;
CRC	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.63	-11.56	-0.54	3.75e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.57	7.8	0.39	8.39e-14	Menopause (age at onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg20566942	chr11:28129866	METT5D1;KIF18A	0.38	5.99	0.31	5.64e-9	Interleukin-6 levels;
CRC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg02033258	chr5:131593261	PDLIM4	-0.33	-6.27	-0.33	1.11e-9	Breast cancer;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.95	0.31	7.04e-9	Parkinson's disease;
CRC	cis	rs3736485	0.966	rs4775961	chr15:51892959	A/G	cg08986416	chr15:51914746	DMXL2	-0.48	-6.74	-0.35	7.06e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.7	-10.15	-0.49	3.09e-21	Lung cancer;
CRC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.26	0.45	2.71e-18	Height;
CRC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.73	-11.56	-0.54	3.63e-26	Lung cancer;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg08200770	chr17:80723486	TBCD	-0.5	-7.61	-0.39	2.97e-13	Glycated hemoglobin levels;
CRC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.43	-7.53	-0.38	5.08e-13	Type 1 diabetes;
CRC	cis	rs6840360	0.642	rs4263379	chr4:152399131	G/A	cg09659197	chr4:152720779	NA	0.34	6.64	0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-5.67	-0.3	3.09e-8	Electroencephalogram traits;
CRC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	8.74	0.43	1.23e-16	Hip circumference adjusted for BMI;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.77	11.4	0.53	1.33e-25	Menarche (age at onset);
CRC	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg23461800	chr14:103021989	NA	0.69	7.84	0.4	6.5e-14	Platelet count;
CRC	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.36	-0.38	1.45e-12	Inflammatory skin disease;
CRC	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.59	-6.98	-0.36	1.59e-11	Dental caries;
CRC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.63	11.52	0.54	5.02e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg00603274	chr11:61596626	FADS2	-0.44	-6.4	-0.33	5.33e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	trans	rs2303319	0.504	rs62188147	chr2:162286552	G/T	cg19471553	chr17:41393123	NA	-0.68	-6.05	-0.32	4e-9	Cognitive function;
CRC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg02659138	chr7:134003124	SLC35B4	0.36	6.31	0.33	8.99e-10	Mean platelet volume;
CRC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.6	9.82	0.48	3.86e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.52	9.2	0.45	4.34e-18	Schizophrenia;
CRC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	7.92	0.4	3.76e-14	Rheumatoid arthritis;
CRC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.72	-0.3	2.42e-8	Bipolar disorder;
CRC	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	0.89	7.75	0.39	1.18e-13	Fat distribution (HIV);
CRC	cis	rs4964805	0.586	rs934846	chr12:104185297	C/T	cg02344784	chr12:104178138	NT5DC3	0.81	16.03	0.66	4e-43	Attention deficit hyperactivity disorder;
CRC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg09163369	chr1:210001066	C1orf107	0.42	6.2	0.32	1.73e-9	Orofacial clefts;
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.94	-0.31	7.17e-9	Total body bone mineral density;
CRC	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.38	6.34	0.33	7.63e-10	Sitting height ratio;
CRC	cis	rs539514	0.612	rs9573648	chr13:76309279	A/G	cg04757411	chr13:76259545	LMO7	-0.35	-5.95	-0.31	6.79e-9	Type 1 diabetes;
CRC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.9	13.04	0.58	1.29e-31	Triglycerides;
CRC	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg09915433	chr19:53449742	NA	-0.6	-8.96	-0.44	2.5e-17	Psoriasis;
CRC	cis	rs62229266	0.625	rs2051395	chr21:37431265	A/C	cg12218747	chr21:37451666	NA	0.33	5.7	0.3	2.73e-8	Mitral valve prolapse;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg25164649	chr6:28176230	NA	0.59	8.33	0.42	2.26e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	7.58	0.39	3.58e-13	Diisocyanate-induced asthma;
CRC	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg09659197	chr4:152720779	NA	0.5	10.71	0.51	3.59e-23	Intelligence (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26655295	chr2:677162	TMEM18	0.42	6.32	0.33	8.3e-10	Schizophrenia;
CRC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg24209194	chr3:40518798	ZNF619	0.42	6.33	0.33	8.25e-10	Renal cell carcinoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01744215	chr16:9056616	USP7	0.48	6.49	0.34	3.14e-10	Anxiety disorder;
CRC	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-6.49	-0.34	3.1e-10	Coronary artery disease;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg10729496	chr3:10149963	C3orf24	0.61	7.18	0.37	4.55e-12	Alzheimer's disease;
CRC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.54	7.25	0.37	3.01e-12	Total body bone mineral density;
CRC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.79	-12.86	-0.58	6.21e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.57	8.26	0.41	3.58e-15	Lymphocyte counts;
CRC	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg13736514	chr6:26305472	NA	-0.45	-7.28	-0.37	2.43e-12	Educational attainment;
CRC	cis	rs73206853	0.841	rs7967246	chr12:110756569	G/A	cg12870014	chr12:110450643	ANKRD13A	0.84	8.88	0.44	4.54e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27274463	chr12:110338238	TCHP	0.39	6.14	0.32	2.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02725872	chr8:58115012	NA	-0.38	-6.36	-0.33	6.56e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9462027	0.607	rs205259	chr6:34564066	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.98	-0.31	5.86e-9	Systemic lupus erythematosus;
CRC	cis	rs4132462	0.924	rs6749448	chr2:212607990	C/T	cg15635483	chr2:212618994	ERBB4	0.41	6.03	0.32	4.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg25164649	chr6:28176230	NA	0.66	8.76	0.43	1.08e-16	Parkinson's disease;
CRC	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.56	-5.91	-0.31	8.79e-9	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.09	-12.2	-0.56	1.65e-28	Diabetic kidney disease;
CRC	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.46	6.78	0.35	5.55e-11	Carotid intima media thickness;
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg12516270	chr8:143859308	LYNX1	0.67	12.03	0.55	7.18e-28	Urinary tract infection frequency;
CRC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.94	15.0	0.64	3.89e-39	Primary sclerosing cholangitis;
CRC	trans	rs6544773	0.668	rs572753	chr2:45072029	T/G	cg10208897	chr5:178548229	ADAMTS2	0.35	5.97	0.31	6.17e-9	Mosquito bite size;
CRC	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg25838465	chr1:92012736	NA	0.42	5.72	0.3	2.37e-8	Eosinophil percentage of white cells;
CRC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg14324370	chr2:177042789	NA	-0.69	-9.35	-0.46	1.34e-18	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.68e-21	Asthma;
CRC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg07636037	chr3:49044803	WDR6	-0.66	-7.01	-0.36	1.35e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.8	11.31	0.53	2.79e-25	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.34	16.86	0.68	2.17e-46	Uric acid levels;
CRC	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg16797656	chr11:68205561	LRP5	0.46	6.53	0.34	2.44e-10	Total body bone mineral density (age 45-60);
CRC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.03	-0.32	4.32e-9	Gout;Renal underexcretion gout;
CRC	cis	rs11229555	0.645	rs11229430	chr11:58181104	G/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3736485	0.844	rs55981933	chr15:51785436	C/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.66	-0.34	1.14e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20092199	chr4:1342459	KIAA1530	0.37	6.5	0.34	2.89e-10	Obesity-related traits;
CRC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-11.54	-0.54	4.29e-26	Asthma;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.03	-0.36	1.18e-11	Breast cancer;
CRC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg18479299	chr3:125709523	NA	-0.47	-5.64	-0.3	3.58e-8	Blood pressure (smoking interaction);
CRC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.21	0.53	6.56e-25	Tonsillectomy;
CRC	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.42	-7.14	-0.37	6.07e-12	Mean arterial pressure;
CRC	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.06	10.21	0.49	1.86e-21	Diabetic retinopathy;
CRC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.86	0.35	3.42e-11	Dupuytren's disease;
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02290350	chr8:58132656	NA	-0.58	-7.89	-0.4	4.38e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg12458913	chr13:53173898	NA	0.75	13.79	0.61	1.85e-34	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00692763	chr18:47088373	LIPG	0.46	6.65	0.34	1.19e-10	Response to antipsychotic treatment;
CRC	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.43	-0.33	4.49e-10	Self-reported allergy;
CRC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-5.88	-0.31	9.81e-9	Aortic root size;
CRC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.14	0.45	6.45e-18	Cognitive test performance;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-7.57	-0.39	3.87e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.5	6.7	0.35	9.05e-11	Caudate activity during reward;
CRC	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.71	-8.3	-0.42	2.69e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.8	-11.39	-0.53	1.51e-25	Gut microbiome composition (winter);
CRC	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.44	0.33	4.15e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.24	-0.33	1.38e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19819135	chr1:70710422	SFRS11	-0.4	-6.74	-0.35	6.94e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.58	-8.85	-0.44	5.42e-17	Uric acid levels;
CRC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.56	0.6	1.37e-33	Platelet count;
CRC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.78	12.05	0.55	5.95e-28	Monocyte count;
CRC	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.23	-0.45	3.34e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg11212589	chr17:38028394	ZPBP2	0.46	8.74	0.43	1.21e-16	Self-reported allergy;
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg15845792	chr6:28175446	NA	0.82	7.87	0.4	5.26e-14	Depression;
CRC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.46	-6.95	-0.36	2.03e-11	Psoriasis;
CRC	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.73	8.29	0.42	2.83e-15	Eotaxin levels;
CRC	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg06522879	chr11:64358276	SLC22A12	0.57	8.83	0.44	6.21e-17	Urate levels in obese individuals;
CRC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.66	11.67	0.54	1.48e-26	Height;
CRC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.05	-0.41	1.5e-14	Height;
CRC	trans	rs2303319	0.582	rs12464282	chr2:162448855	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.72	-5.97	-0.31	6.06e-9	Cognitive function;
CRC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.27	15.87	0.66	1.59e-42	Uric acid levels;
CRC	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.1	11.91	0.55	1.96e-27	Granulocyte percentage of myeloid white cells;
CRC	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.58	8.33	0.42	2.17e-15	Mean platelet volume;
CRC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-7.38	-0.38	1.26e-12	Menarche (age at onset);
CRC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg06970220	chr1:156163860	SLC25A44	0.5	7.13	0.37	6.42e-12	Testicular germ cell tumor;
CRC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg11632617	chr15:75315747	PPCDC	-0.55	-7.39	-0.38	1.23e-12	Blood trace element (Zn levels);
CRC	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg20356878	chr3:121714668	ILDR1	-0.43	-6.09	-0.32	3.08e-9	Multiple sclerosis;
CRC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.61	8.4	0.42	1.37e-15	Arsenic metabolism;
CRC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.45	6.94	0.36	2.08e-11	Monocyte count;
CRC	cis	rs9287719	0.649	rs12617968	chr2:10721945	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08859206	chr1:53392774	SCP2	-0.4	-6.13	-0.32	2.45e-9	Monocyte count;
CRC	cis	rs7692995	1.000	rs6830062	chr4:18017730	A/G	cg08925142	chr4:18023851	LCORL	-0.5	-5.66	-0.3	3.31e-8	Height;
CRC	cis	rs3736485	0.934	rs2899476	chr15:51903874	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.53	-0.34	2.56e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs3889199	0.924	rs12739904	chr1:59669488	T/C	cg25881383	chr1:59680599	NA	-0.38	-6.08	-0.32	3.36e-9	Pulse pressure;
CRC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg23461800	chr14:103021989	NA	-0.68	-7.83	-0.4	6.62e-14	Platelet count;
CRC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg19223190	chr17:80058835	NA	0.41	6.43	0.33	4.51e-10	Life satisfaction;
CRC	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	7.7	0.39	1.63e-13	Coronary heart disease;
CRC	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.53	-8.08	-0.41	1.25e-14	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg16606324	chr3:10149918	C3orf24	0.48	7.09	0.36	8.29e-12	Alzheimer's disease;
CRC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.73e-9	Major depressive disorder;
CRC	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg26741380	chr15:41871084	TYRO3	-0.5	-7.09	-0.36	8.25e-12	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.56	8.09	0.41	1.14e-14	Lymphocyte counts;
CRC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Corneal astigmatism;
CRC	cis	rs6735179	0.532	rs6756670	chr2:1761496	A/G	cg19300414	chr2:1746591	PXDN	0.36	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.57	8.76	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.12	-0.32	2.68e-9	Schizophrenia;
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.33e-12	Life satisfaction;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	trans	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg17903999	chr18:56338584	MALT1	0.42	6.94	0.36	2.1e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00706505	chr3:49142215	QARS	0.46	6.42	0.33	4.88e-10	Response to antipsychotic treatment;
CRC	trans	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.55	-0.38	4.4e-13	Endometrial cancer;
CRC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.89	-0.51	8.51e-24	Eye color traits;
CRC	cis	rs13315871	0.929	rs6769216	chr3:58238877	C/T	cg20936604	chr3:58311152	NA	-0.67	-6.76	-0.35	6.41e-11	Cholesterol, total;
CRC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg00129232	chr17:37814104	STARD3	0.56	6.67	0.35	1.07e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg09264619	chr17:80180166	NA	-0.35	-5.81	-0.31	1.48e-8	Life satisfaction;
CRC	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.71	-10.88	-0.51	9.56e-24	Response to temozolomide;
CRC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.78	-10.61	-0.5	8.24e-23	Coronary artery disease;
CRC	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg00318322	chr16:67708822	GFOD2	-0.31	-5.98	-0.31	5.88e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8010715	0.785	rs2877611	chr14:24595430	C/T	cg23112188	chr14:24563095	PCK2	-0.37	-7.27	-0.37	2.69e-12	IgG glycosylation;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04139749	chr14:77786727	GSTZ1;POMT2	-0.44	-6.42	-0.33	4.78e-10	Myopia (pathological);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06231882	chr16:81040594	CENPN;C16orf61	-0.42	-6.46	-0.34	3.66e-10	Aortic root size;
CRC	cis	rs4731207	0.565	rs10227119	chr7:124593780	T/A	cg23710748	chr7:124431027	NA	-0.38	-6.05	-0.32	4e-9	Cutaneous malignant melanoma;
CRC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.95	0.58	2.91e-31	Hip circumference adjusted for BMI;
CRC	cis	rs995000	0.931	rs11207986	chr1:63018170	T/C	cg19896129	chr1:63156450	NA	-0.44	-6.78	-0.35	5.74e-11	Triglyceride levels;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg09080729	chr16:81069740	ATMIN	0.49	7.12	0.37	6.79e-12	Body mass index;
CRC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.07	0.32	3.61e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs747650	0.504	rs11039081	chr11:47093465	C/G	cg19486271	chr11:47235900	DDB2	0.44	5.77	0.3	1.79e-8	Acne (severe);
CRC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.76	-12.36	-0.56	4.46e-29	Height;
CRC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg05502645	chr19:1971281	CSNK1G2	-0.41	-6.46	-0.34	3.68e-10	Coronary artery disease;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.67	9.7	0.47	9.69e-20	Menarche (age at onset);
CRC	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-12.17	-0.56	2.23e-28	Colorectal cancer;
CRC	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-25.23	-0.81	6.72e-79	Exhaled nitric oxide output;
CRC	cis	rs3015497	0.616	rs11157759	chr14:51087263	A/G	cg09863266	chr14:51125203	SAV1	-0.32	-6.16	-0.32	2.11e-9	Mean platelet volume;
CRC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.86	-0.31	1.1e-8	Heart rate;
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg10729496	chr3:10149963	C3orf24	0.56	5.95	0.31	6.98e-9	Alzheimer's disease;
CRC	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg04110750	chr16:69646130	NFAT5	-0.51	-6.68	-0.35	1.05e-10	IgE levels;
CRC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg11843238	chr5:131593191	PDLIM4	0.33	5.83	0.31	1.32e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.69	9.63	0.47	1.74e-19	Multiple sclerosis;
CRC	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.88	-17.12	-0.69	1.95e-47	Urate levels in lean individuals;
CRC	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.15	-0.45	6.04e-18	Triglycerides;
CRC	trans	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs9462027	0.583	rs6937784	chr6:34644276	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-6.33	-0.33	8.25e-10	Systemic lupus erythematosus;
CRC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg18876405	chr7:65276391	NA	0.45	6.23	0.32	1.44e-9	Aortic root size;
CRC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-11.06	-0.52	2.26e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.4	-6.29	-0.33	1.01e-9	Neurofibrillary tangles;
CRC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.65	0.57	3.59e-30	Bone mineral density;
CRC	cis	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg04523069	chr9:97136363	HIATL1	0.37	5.67	0.3	3.05e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	11.22	0.53	5.91e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.45	6.55	0.34	2.16e-10	Menopause (age at onset);
CRC	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg00677455	chr12:58241039	CTDSP2	-0.52	-7.26	-0.37	2.82e-12	Multiple sclerosis;
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.4	5.92	0.31	8.02e-9	Longevity;Endometriosis;
CRC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.8	12.77	0.58	1.33e-30	Height;
CRC	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06307176	chr5:131281290	NA	-0.44	-6.4	-0.33	5.2400000000000005e-10	Life satisfaction;
CRC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg03233332	chr7:66118400	NA	-0.43	-6.11	-0.32	2.75e-9	Aortic root size;
CRC	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.74	-16.26	-0.67	4.76e-44	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.24	-0.37	3.29e-12	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.59	-0.34	1.74e-10	Systemic lupus erythematosus;
CRC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.61	-7.65	-0.39	2.26e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13824859	chr6:109804376	ZBTB24	0.46	6.56	0.34	2.12e-10	Anxiety disorder;
CRC	cis	rs883565	0.569	rs1274969	chr3:39169712	T/C	cg01426195	chr3:39028469	NA	0.4	6.64	0.34	1.29e-10	Handedness;
CRC	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.46	-8.39	-0.42	1.48e-15	Pediatric bone mineral content (femoral neck);
CRC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg14847009	chr1:175162515	KIAA0040	0.27	5.89	0.31	9.5e-9	Alcohol dependence;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg00063174	chr2:228736253	WDR69	-0.51	-6.86	-0.35	3.49e-11	Blood pressure;
CRC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.56	-10.42	-0.5	3.62e-22	Schizophrenia;
CRC	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.73	11.68	0.54	1.34e-26	Plateletcrit;Platelet count;
CRC	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.0	-0.48	1.01e-20	Bipolar disorder;
CRC	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg23260525	chr10:116636907	FAM160B1	0.31	6.73	0.35	7.51e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg00086871	chr4:6988644	TBC1D14	0.89	7.15	0.37	5.48e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-17.88	-0.7	1.91e-50	Coronary artery disease;
CRC	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg07862535	chr7:139043722	LUC7L2	0.58	7.4	0.38	1.16e-12	Diisocyanate-induced asthma;
CRC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.41	-5.74	-0.3	2.14e-8	Corneal structure;
CRC	cis	rs10878977	0.542	rs60964256	chr12:69815151	A/G	cg20891283	chr12:69753455	YEATS4	-0.6	-5.92	-0.31	8.13e-9	Colorectal cancer;
CRC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.92	0.31	8.29e-9	Total body bone mineral density;
CRC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg22777020	chr22:31556080	RNF185	0.5	5.98	0.31	5.84e-9	Colorectal cancer;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.7e-8	Prudent dietary pattern;
CRC	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.05	0.32	3.86e-9	Vitamin D levels;
CRC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	12.45	0.57	2.06e-29	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.56	9.44	0.46	7.12e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs4654899	0.931	rs7520481	chr1:21140385	T/G	cg02927042	chr1:21476669	EIF4G3	0.47	7.47	0.38	7.51e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.44	6.6	0.34	1.68e-10	Calcium levels;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.65	9.22	0.45	3.61e-18	Parkinson's disease;
CRC	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.22	-0.67	6.97e-44	Hip circumference;
CRC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.51	8.49	0.42	7.17e-16	Aortic root size;
CRC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24308560	chr3:49941425	MST1R	0.45	7.01	0.36	1.32e-11	Intelligence (multi-trait analysis);
CRC	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg06606381	chr12:133084897	FBRSL1	-0.92	-7.56	-0.38	4e-13	Depression;
CRC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.85	-0.44	5.49e-17	Platelet count;
CRC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.65	-11.74	-0.54	8.01e-27	Breast cancer;
CRC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.47	8.45	0.42	9.75e-16	Weight;
CRC	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.42	6.84	0.35	3.96e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-14.54	-0.63	2.42e-37	Height;
CRC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.52	5.91	0.31	8.37e-9	Vitiligo;
CRC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.82	-0.44	7e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg05084668	chr3:125655381	ALG1L	-0.44	-6.16	-0.32	2.09e-9	Blood pressure (smoking interaction);
CRC	cis	rs2882667	0.931	rs6596457	chr5:138323379	T/C	cg09476006	chr5:138032270	NA	0.42	6.94	0.36	2.1e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg00769240	chr8:12517080	NA	0.62	7.18	0.37	4.61e-12	Blood pressure (smoking interaction);
CRC	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.41	-6.39	-0.33	5.78e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg25164649	chr6:28176230	NA	0.59	8.33	0.42	2.22e-15	Parkinson's disease;
CRC	cis	rs10450586	0.830	rs10450590	chr11:27310339	G/A	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg00919237	chr7:87102261	ABCB4	-0.54	-7.15	-0.37	5.78e-12	Gallbladder cancer;
CRC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg07718321	chr6:96025334	MANEA	0.51	5.93	0.31	7.65e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07491357	chr18:9914943	VAPA	0.46	6.61	0.34	1.56e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12476592	0.571	rs10171223	chr2:63687700	A/G	cg10828910	chr2:63850056	LOC388955	0.46	5.7	0.3	2.6e-8	Childhood ear infection;
CRC	cis	rs17601876	0.545	rs17523270	chr15:51538280	A/C	cg19946085	chr15:51559439	CYP19A1	0.3	5.9	0.31	9.25e-9	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26018965	chr1:183604789	ARPC5;RGL1	0.38	6.08	0.32	3.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg11843238	chr5:131593191	PDLIM4	-0.45	-7.56	-0.38	3.94e-13	Breast cancer;
CRC	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg19773385	chr1:10388646	KIF1B	-0.63	-9.36	-0.46	1.24e-18	Hepatocellular carcinoma;
CRC	cis	rs12594515	0.600	rs12903858	chr15:45972166	A/G	cg19682013	chr15:45996608	NA	0.28	5.6	0.3	4.5e-8	Waist circumference;Weight;
CRC	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg17710535	chr19:10819994	QTRT1	0.45	6.61	0.34	1.54e-10	Inflammatory skin disease;
CRC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.59	-10.42	-0.5	3.75e-22	Iron status biomarkers;
CRC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06634786	chr22:41940651	POLR3H	0.47	5.98	0.31	5.79e-9	Vitiligo;
CRC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg05139728	chr16:28306816	SBK1	-0.37	-5.99	-0.31	5.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg09417038	chr21:47716443	C21orf57	-0.39	-6.43	-0.33	4.49e-10	Testicular germ cell tumor;
CRC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.71	-0.35	8.31e-11	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.72	15.1	0.64	1.65e-39	Sjögren's syndrome;
CRC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.45	0.38	8.33e-13	Lung cancer;
CRC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.31	-6.91	-0.36	2.53e-11	IgG glycosylation;
CRC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.08e-19	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs7605827	0.930	rs3796002	chr2:15567649	T/C	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.78e-9	Educational attainment (years of education);
CRC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.45	-5.81	-0.31	1.48e-8	Menarche (age at onset);
CRC	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.6	-0.34	1.64e-10	Coronary artery disease;
CRC	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.53	6.88	0.35	2.99e-11	Alzheimer's disease (survival time);
CRC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg12639453	chr1:2035780	PRKCZ	0.31	5.7	0.3	2.67e-8	Height;
CRC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg11887960	chr12:57824829	NA	0.58	6.42	0.33	4.87e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-20.7	-0.75	1.55e-61	Primary sclerosing cholangitis;
CRC	cis	rs2411233	1.000	rs13379846	chr15:39272413	T/A	cg23129342	chr15:39283510	NA	0.31	5.71	0.3	2.48e-8	Platelet count;
CRC	cis	rs17155006	0.655	rs380046	chr7:107728315	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-5.85	-0.31	1.16e-8	Pneumococcal bacteremia;
CRC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.87e-12	Aortic root size;
CRC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs7605827	0.930	rs12692265	chr2:15544998	T/C	cg19274914	chr2:15703543	NA	0.4	5.9	0.31	9.12e-9	Educational attainment (years of education);
CRC	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg16989719	chr2:238392110	NA	-0.4	-8.2	-0.41	5.58e-15	Prostate cancer;
CRC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg05941027	chr17:61774174	LIMD2	0.35	6.38	0.33	5.92e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.23	-0.37	3.42e-12	Inflammatory skin disease;
CRC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg00343986	chr7:65444356	GUSB	-0.49	-7.42	-0.38	1e-12	Aortic root size;
CRC	cis	rs867529	1.000	rs11681299	chr2:88901732	C/T	cg26627705	chr2:89060884	NA	-0.51	-6.46	-0.34	3.73e-10	Height;
CRC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.77	0.47	5.8e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2072510	0.593	rs2247304	chr12:96424665	T/C	cg22491680	chr12:96389547	HAL	-0.48	-6.04	-0.32	4.14e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.59	9.26	0.45	2.73e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.52	6.69	0.35	9.44e-11	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11949945	chr9:123342512	CDK5RAP2	0.43	6.16	0.32	2.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg17330251	chr7:94953956	PON1	-0.59	-7.65	-0.39	2.27e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.73	-11.68	-0.54	1.35e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	27.07	0.83	1.05e-85	Testicular germ cell tumor;
CRC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg14541582	chr5:601475	NA	-0.33	-6.53	-0.34	2.53e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs3736485	0.966	rs10467924	chr15:51787579	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.53	-0.34	2.48e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.5	8.19	0.41	6.01e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.63	10.59	0.5	9.85e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.65	8.71	0.43	1.48e-16	Body mass index;
CRC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.23	-0.49	1.66e-21	Initial pursuit acceleration;
CRC	cis	rs2179367	0.959	rs652807	chr6:149737495	A/G	cg11245181	chr6:149772854	ZC3H12D	0.38	5.89	0.31	9.47e-9	Dupuytren's disease;
CRC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg02766259	chr12:125626809	AACS	0.44	7.1	0.36	7.94e-12	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03900353	chr1:212732456	NA	0.49	6.94	0.36	2.13e-11	Response to antipsychotic treatment;
CRC	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.55	-8.42	-0.42	1.21e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-11.1	-0.52	1.53e-24	Platelet distribution width;
CRC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg15269541	chr15:43626905	ADAL	-0.37	-5.63	-0.3	3.93e-8	Lung cancer;
CRC	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.44	5.86	0.31	1.13e-8	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06537201	chr12:58330115	NA	0.45	6.89	0.36	2.79e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.61e-14	Height;
CRC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12315302	chr6:26189340	HIST1H4D	0.82	6.33	0.33	8.12e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17391141	chr20:49575376	MOCS3;DPM1	0.48	6.85	0.35	3.75e-11	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.44	6.82	0.35	4.49e-11	Corneal astigmatism;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02772935	chr3:125709198	NA	-0.51	-6.07	-0.32	3.5e-9	Blood pressure (smoking interaction);
CRC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg12365402	chr11:9010492	NRIP3	-0.58	-10.71	-0.51	3.66e-23	Hemoglobin concentration;
CRC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.63	10.43	0.5	3.39e-22	Colorectal cancer;
CRC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.04	0.32	4.05e-9	IgG glycosylation;
CRC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.51	7.65	0.39	2.21e-13	Platelet distribution width;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	trans	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg24644049	chr4:85504048	CDS1	0.8	6.98	0.36	1.66e-11	Skin colour saturation;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg02683197	chr6:28174875	NA	0.69	9.49	0.46	4.74e-19	Parkinson's disease;
CRC	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.74	-11.82	-0.55	4.13e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg10483660	chr13:112241077	NA	0.35	5.65	0.3	3.57e-8	Menarche (age at onset);
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.73	-0.51	3.19e-23	Alzheimer's disease;
CRC	cis	rs2421770	0.530	rs4756218	chr11:35370113	G/A	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.59	-0.34	1.75e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.6	-8.27	-0.42	3.28e-15	Extraversion;
CRC	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg05805236	chr11:65401703	PCNXL3	-0.42	-6.69	-0.35	9.75e-11	Acne (severe);
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg18758796	chr5:131593413	PDLIM4	0.32	5.94	0.31	7.16e-9	Blood metabolite levels;
CRC	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.94	-15.18	-0.64	8.33e-40	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg25164649	chr6:28176230	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.87	8.88	0.44	4.34e-17	Major depressive disorder;
CRC	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg06781209	chr11:61594997	FADS2	-0.41	-6.02	-0.32	4.6e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg07125278	chr16:67683757	RLTPR	-0.63	-7.25	-0.37	3.09e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.28	0.42	3.08e-15	Rheumatoid arthritis;
CRC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-6.77	-0.35	5.79e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg05192639	chr6:26864778	GUSBL1	0.31	6.05	0.32	4.01e-9	Schizophrenia;
CRC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.67	9.15	0.45	6.18e-18	Alcohol dependence;
CRC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.63	-9.33	-0.46	1.66e-18	Acne (severe);
CRC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-10.74	-0.51	2.93e-23	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg15320455	chr10:103880129	LDB1	0.73	6.76	0.35	6.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs243505	1.000	rs243502	chr7:148437205	C/T	cg09806900	chr7:148480153	CUL1	-0.47	-6.61	-0.34	1.6e-10	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg09184832	chr6:79620586	NA	-0.46	-7.96	-0.4	2.81e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg11915388	chr22:42470451	FAM109B	-0.42	-6.36	-0.33	6.8e-10	Schizophrenia;
CRC	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg27395922	chr11:50257633	LOC441601	0.41	6.9	0.36	2.65e-11	Height;
CRC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-11.66	-0.54	1.52e-26	Asthma;
CRC	cis	rs12431939	0.947	rs68164178	chr14:51679003	A/C	cg23942311	chr14:51606299	NA	-0.53	-6.31	-0.33	8.91e-10	Cancer;
CRC	cis	rs12042938	0.622	rs58403453	chr1:231813438	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.65	0.3	3.49e-8	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs17213078	0.505	rs3795909	chr2:106754734	A/G	cg15412446	chr2:106886593	NA	0.36	5.7	0.3	2.65e-8	Facial morphology (factor 23);
CRC	cis	rs4561483	0.583	rs1029285	chr16:11987118	G/A	cg08843971	chr16:11963173	GSPT1	0.51	7.6	0.39	3.07e-13	Testicular germ cell tumor;
CRC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.66	9.76	0.47	6.05e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.41	6.45	0.34	3.9e-10	Obesity;
CRC	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.83	-0.48	3.53e-20	Height;
CRC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.17	-13.55	-0.6	1.59e-33	Diabetic kidney disease;
CRC	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg05507819	chr15:63340323	TPM1	0.46	5.75	0.3	2.05e-8	HDL cholesterol;
CRC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg11833968	chr6:79620685	NA	-0.35	-6.04	-0.32	4.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.43	6.52	0.34	2.68e-10	Resting heart rate;
CRC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.12	-0.32	2.59e-9	Morning vs. evening chronotype;
CRC	cis	rs7827545	1.000	rs6578235	chr8:135568022	C/T	cg17885191	chr8:135476712	NA	0.51	7.16	0.37	5.21e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg15107132	chr11:63991130	FERMT3	0.43	7.38	0.38	1.27e-12	Platelet count;
CRC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.42e-25	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg21724239	chr8:58056113	NA	0.4	5.94	0.31	7.28e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.72	-0.3	2.36e-8	Life satisfaction;
CRC	cis	rs17767392	0.681	rs4899390	chr14:71680348	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.19	-0.32	1.75e-9	Mitral valve prolapse;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	7.49	0.38	6.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11233250	0.502	rs59617763	chr11:82402396	A/G	cg17391194	chr11:82401662	NA	0.44	6.77	0.35	5.77e-11	Glioblastoma;Glioma;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.84	-18.71	-0.72	1.08e-53	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.49	-7.33	-0.37	1.8e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.53	8.53	0.43	5.46e-16	Coronary artery disease;
CRC	cis	rs17155006	0.561	rs22783	chr7:107743243	G/T	cg05962710	chr7:107745446	LAMB4	-0.43	-7.63	-0.39	2.54e-13	Pneumococcal bacteremia;
CRC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg00343986	chr7:65444356	GUSB	-0.47	-7.04	-0.36	1.15e-11	Aortic root size;
CRC	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.57	6.39	0.33	5.6e-10	Childhood ear infection;
CRC	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg10517650	chr3:113235015	CCDC52	0.42	7.32	0.37	1.9e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg14664628	chr15:75095509	CSK	-0.47	-6.59	-0.34	1.78e-10	Airflow obstruction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03869194	chr19:59031081	ZBTB45	0.46	6.62	0.34	1.47e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.43	-8.43	-0.42	1.12e-15	Alcohol dependence;
CRC	cis	rs10512697	0.655	rs35912980	chr5:3458039	G/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.18	-0.37	4.56e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.48	6.49	0.34	3.07e-10	Aortic root size;
CRC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-14.09	-0.61	1.27e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.6	-7.12	-0.37	6.96e-12	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02683314	chr19:4182606	SIRT6;ANKRD24	0.38	6.38	0.33	5.99e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-10.86	-0.51	1.08e-23	Coronary artery disease;
CRC	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg02353165	chr6:42928485	GNMT	0.47	6.42	0.33	4.81e-10	Blood protein levels;
CRC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg17764715	chr19:33622953	WDR88	0.47	6.84	0.35	3.89e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.72	-9.19	-0.45	4.45e-18	Initial pursuit acceleration;
CRC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2735413	0.881	rs12919818	chr16:78082862	C/T	cg04733911	chr16:78082701	NA	-0.46	-7.58	-0.39	3.46e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.73	-12.87	-0.58	5.73e-31	White blood cell count (basophil);
CRC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.89e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg10589385	chr1:150898437	SETDB1	-0.26	-5.83	-0.31	1.36e-8	Tonsillectomy;
CRC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	18.49	0.71	7.34e-53	Cognitive ability;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02725872	chr8:58115012	NA	-0.59	-9.18	-0.45	4.97e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-14.68	-0.63	7.23e-38	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07649646	chr14:73525051	RBM25	0.42	6.06	0.32	3.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.52	7.64	0.39	2.37e-13	Coronary heart disease;
CRC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.46	6.82	0.35	4.44e-11	Menopause (age at onset);
CRC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.48	5.76	0.3	1.93e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg15226275	chr6:116381976	FRK	0.31	7.31	0.37	2.09e-12	Total cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13886636	chr9:130679606	ST6GALNAC4	0.43	6.17	0.32	2.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.5	-7.31	-0.37	2.07e-12	Blood metabolite levels;
CRC	cis	rs4973397	0.921	rs12622248	chr2:232289127	G/A	cg13347044	chr2:232276743	NA	0.5	6.9	0.36	2.74e-11	Anti-saccade response;
CRC	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg23100626	chr2:96804247	ASTL	0.3	8.18	0.41	6.43e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03425468	chr1:155164676	MIR92B	0.38	6.08	0.32	3.37e-9	Obesity-related traits;
CRC	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg09045935	chr12:6379348	NA	1.14	8.88	0.44	4.43e-17	Blood metabolite levels;
CRC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg05941027	chr17:61774174	LIMD2	0.35	6.31	0.33	8.87e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07151155	chr5:1473589	LPCAT1	-0.42	-6.5	-0.34	2.9e-10	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11521799	chr20:2451663	SNRPB	0.44	6.4	0.33	5.51e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.59	8.75	0.43	1.14e-16	Lung cancer;
CRC	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	8.79e-9	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23141096	chr10:98347050	TM9SF3	0.42	5.99	0.31	5.48e-9	Response to antipsychotic treatment;
CRC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-17.1	-0.69	2.31e-47	Intelligence (multi-trait analysis);
CRC	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	7.66	0.39	2.16e-13	Mean corpuscular volume;
CRC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg16141378	chr3:129829833	LOC729375	0.47	6.94	0.36	2.06e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-19.44	-0.73	1.33e-56	Primary sclerosing cholangitis;
CRC	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg26805224	chr10:79626177	DLG5	-0.41	-5.9	-0.31	8.91e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.61	-0.34	1.58e-10	Vitamin D levels;
CRC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.89	12.22	0.56	1.43e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.57	-9.65	-0.47	1.46e-19	Breast cancer;
CRC	trans	rs587242	1.000	rs509770	chr1:96891615	G/A	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	8.04	0.41	1.68e-14	Coronary artery disease;
CRC	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-7.17	-0.37	4.95e-12	Hepatocellular carcinoma;
CRC	trans	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.98	-19.1	-0.73	2.86e-55	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg18165381	chr3:44552316	NA	-0.38	-5.69	-0.3	2.8e-8	Depressive symptoms;
CRC	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg01692110	chr13:113365389	ATP11A	-0.45	-5.61	-0.3	4.24e-8	Glycated hemoglobin levels;
CRC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	13.84	0.61	1.22e-34	Electrocardiographic conduction measures;
CRC	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.66	-11.12	-0.52	1.36e-24	Type 2 diabetes;
CRC	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.68	12.63	0.57	4.45e-30	Obesity-related traits;
CRC	cis	rs7209700	0.692	rs11652097	chr17:45316717	C/T	cg08085267	chr17:45401833	C17orf57	0.48	6.9	0.36	2.69e-11	IgG glycosylation;
CRC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.59	9.52	0.46	3.76e-19	Schizophrenia;
CRC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.53	0.47	3.57e-19	Cognitive test performance;
CRC	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.58	0.39	3.56e-13	Eye color traits;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05518842	chr16:1823291	MRPS34;EME2	0.34	5.97	0.31	6.15e-9	Interleukin-6 levels;
CRC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.88	-0.31	1e-8	Lung cancer;
CRC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.78	-13.5	-0.6	2.35e-33	Dental caries;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26883264	chr1:151483574	CGN	0.43	6.25	0.33	1.24e-9	Response to antipsychotic treatment;
CRC	cis	rs1322512	1.000	rs1405694	chr6:152946561	C/T	cg03415253	chr6:152958462	SYNE1	-0.43	-6.83	-0.35	4.14e-11	Tonometry;
CRC	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.68	-8.39	-0.42	1.44e-15	Response to hepatitis C treatment;
CRC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg07274523	chr3:49395745	GPX1	0.45	6.05	0.32	4.03e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg09184832	chr6:79620586	NA	-0.46	-7.86	-0.4	5.67e-14	Intelligence (multi-trait analysis);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19927065	chr19:1122678	SBNO2	0.35	5.98	0.31	5.79e-9	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21584983	chr19:11640070	ECSIT	0.5	6.44	0.33	4.15e-10	Thyroid stimulating hormone;
CRC	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg11204139	chr17:3907470	NA	-0.75	-14.15	-0.62	7.84e-36	Type 2 diabetes;
CRC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18912574	chr7:65842487	NCRNA00174	0.33	5.64	0.3	3.58e-8	Aortic root size;
CRC	cis	rs1256061	0.624	rs944046	chr14:64700299	G/A	cg23250157	chr14:64679961	SYNE2	0.46	7.13	0.37	6.4e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg08314208	chr16:67682810	RLTPR	-0.61	-6.63	-0.34	1.37e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.39	5.8	0.3	1.56e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.4	-6.75	-0.35	6.85e-11	Vitamin D levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18548362	chr4:1857197	LETM1	0.38	6.34	0.33	7.52e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-6.01	-0.31	4.84e-9	Pulmonary function;
CRC	cis	rs6761276	0.649	rs10184259	chr2:113838628	T/C	cg09040174	chr2:113837401	NA	0.58	9.05	0.45	1.31e-17	Protein quantitative trait loci;
CRC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13198984	chr17:80129470	CCDC57	-0.46	-7.93	-0.4	3.38e-14	Life satisfaction;
CRC	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-6.14	-0.32	2.36e-9	Alzheimer's disease (survival time);
CRC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.5	-9.61	-0.47	1.95e-19	Alcohol dependence;
CRC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg08222913	chr3:52553049	STAB1	-0.37	-6.81	-0.35	4.61e-11	Electroencephalogram traits;
CRC	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg25190513	chr12:123201362	GPR109B	-0.5	-6.32	-0.33	8.41e-10	Adiponectin levels;
CRC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.8	9.27	0.45	2.6e-18	Inflammatory bowel disease;
CRC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.47	-6.35	-0.33	7.18e-10	IgG glycosylation;
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs524281	1.000	rs524281	chr11:65886662	C/A	cg14036092	chr11:66035641	RAB1B	0.5	6.84	0.35	3.83e-11	Electroencephalogram traits;
CRC	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4731207	0.596	rs12534466	chr7:124668423	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.02	-0.32	4.58e-9	Cutaneous malignant melanoma;
CRC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.48	7.19	0.37	4.25e-12	Height;
CRC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg01529538	chr14:23388837	RBM23	0.38	5.91	0.31	8.78e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg04121214	chr22:50244548	NA	0.41	5.79	0.3	1.68e-8	Schizophrenia;
CRC	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.56	-6.74	-0.35	6.96e-11	Carotid intima media thickness;
CRC	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.96	-0.31	6.49e-9	Retinal vascular caliber;
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.71	-9.75	-0.47	6.72e-20	Alzheimer's disease;
CRC	trans	rs6546324	0.580	rs4410279	chr2:67850620	A/C	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.26	-0.33	1.21e-9	Endometriosis;
CRC	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg02258303	chr16:87377426	FBXO31	-0.53	-8.19	-0.41	5.91e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.45	0.46	6.45e-19	Platelet count;
CRC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.08	-0.59	8.78e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs12999616	0.817	rs17695937	chr2:98327875	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	6.43	0.33	4.6e-10	Colorectal cancer;
CRC	trans	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.2	-0.37	4.18e-12	Endometrial cancer;
CRC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.69	-10.36	-0.5	6e-22	Intelligence (multi-trait analysis);
CRC	cis	rs9400239	0.661	rs1268163	chr6:109008998	C/T	cg11073813	chr6:109029018	NA	-0.4	-6.23	-0.32	1.41e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg18099408	chr3:52552593	STAB1	0.35	6.03	0.32	4.48e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.05	-0.32	3.97e-9	Arsenic metabolism;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.56	-0.38	4.08e-13	Longevity;Endometriosis;
CRC	trans	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg16141378	chr3:129829833	LOC729375	0.39	6.08	0.32	3.42e-9	Neuroticism;
CRC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.64	-0.3	3.64e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6504950	0.830	rs17817877	chr17:53034628	T/A	cg26251398	chr17:52985966	TOM1L1	0.43	5.75	0.3	2.02e-8	Breast cancer;
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg07404485	chr7:94953653	PON1	-0.45	-5.94	-0.31	7.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg07162820	chr14:24837146	NFATC4	0.55	7.62	0.39	2.74e-13	Height;
CRC	cis	rs4716602	0.622	rs57131976	chr7:156167072	A/C	cg16983916	chr7:156159713	NA	-0.33	-5.62	-0.3	4e-8	Anti-saccade response;
CRC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.38	0.33	6.05e-10	Tonsillectomy;
CRC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.16	0.69	1.38e-47	Platelet count;
CRC	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.8	-0.3	1.57e-8	Alzheimer's disease (survival time);
CRC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs863345	0.584	rs1342949	chr1:158463295	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.31	-0.33	8.84e-10	Pneumococcal bacteremia;
CRC	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.93	0.4	3.44e-14	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02437376	chr10:76969880	VDAC2	0.42	5.99	0.31	5.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6838801	0.588	rs344140	chr4:77660162	G/C	cg17476223	chr4:77663285	SHROOM3	-0.43	-5.72	-0.3	2.43e-8	Cleft lip with or without cleft palate;
CRC	cis	rs7705042	0.865	rs4912804	chr5:141493614	T/C	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.88	-0.31	9.9e-9	Asthma;
CRC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg19318889	chr4:1322082	MAEA	0.41	5.73	0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs597583	0.951	rs599411	chr11:117422262	T/G	cg27161313	chr11:117392002	DSCAML1	-0.39	-5.75	-0.3	2.09e-8	Putamen volume;
CRC	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.85	8.83	0.44	6.23e-17	Gastritis;
CRC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.47	6.82	0.35	4.42e-11	Methadone dose in opioid dependence;
CRC	cis	rs7605827	0.930	rs12692261	chr2:15511967	T/G	cg19274914	chr2:15703543	NA	0.38	5.79	0.3	1.62e-8	Educational attainment (years of education);
CRC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.59	-8.82	-0.44	6.94e-17	Body mass index;
CRC	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.65	6.54	0.34	2.39e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.65	10.16	0.49	2.75e-21	Type 2 diabetes;
CRC	cis	rs4692589	0.581	rs12646523	chr4:170944698	C/T	cg19918862	chr4:170955249	NA	0.54	7.4	0.38	1.18e-12	Anxiety disorder;
CRC	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.67	-10.94	-0.52	5.75e-24	Mean platelet volume;
CRC	cis	rs9341808	0.667	rs3805919	chr6:80906809	C/G	cg08355045	chr6:80787529	NA	0.33	5.68	0.3	2.89e-8	Sitting height ratio;
CRC	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	1.04	14.54	0.63	2.35e-37	Exhaled nitric oxide output;
CRC	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	trans	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg18335740	chr13:41363409	SLC25A15	0.49	7.57	0.39	3.71e-13	Lewy body disease;
CRC	cis	rs4803480	0.554	rs12150975	chr19:42070360	C/T	cg08478046	chr19:42093086	CEACAM21	-0.28	-5.93	-0.31	7.55e-9	Schizophrenia;
CRC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.09	0.32	3.16e-9	Bladder cancer;
CRC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.65	-9.39	-0.46	1.07e-18	Lung cancer;
CRC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.6	9.33	0.46	1.67e-18	Diastolic blood pressure;
CRC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.78	7.84	0.4	6.45e-14	Diabetic retinopathy;
CRC	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.31	0.49	8.56e-22	Corneal astigmatism;
CRC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg21665744	chr7:39171113	POU6F2	0.44	5.9	0.31	9.26e-9	IgG glycosylation;
CRC	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	1.08	9.42	0.46	8.08e-19	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.5	-6.22	-0.32	1.51e-9	Height;
CRC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.72	7.33	0.37	1.77e-12	Diabetic retinopathy;
CRC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg10272801	chr16:14013773	ERCC4	-0.67	-6.07	-0.32	3.6e-9	Blood osmolality (transformed sodium);
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg25987502	chr17:6899865	ALOX12	0.36	6.67	0.35	1.1e-10	Tonsillectomy;
CRC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	8.66	0.43	2.21e-16	Cognitive test performance;
CRC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg17724175	chr1:150552817	MCL1	0.44	6.96	0.36	1.82e-11	Melanoma;
CRC	cis	rs7712401	0.755	rs1545697	chr5:122102277	T/C	cg18764291	chr5:122110994	SNX2	0.42	6.68	0.35	1.03e-10	Mean platelet volume;
CRC	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg15455643	chr13:111040242	COL4A2	0.35	5.87	0.31	1.04e-8	White matter hyperintensity burden;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.67	-10.38	-0.5	5.2e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.53	7.45	0.38	8.15e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.61	10.76	0.51	2.52e-23	Aortic root size;
CRC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg00601450	chr5:74908170	NA	0.39	5.61	0.3	4.34e-8	Age-related disease endophenotypes;
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	5.78	0.3	1.77e-8	Lung function (FEV1/FVC);
CRC	cis	rs7605827	0.930	rs11903302	chr2:15706286	C/T	cg19274914	chr2:15703543	NA	0.38	5.81	0.31	1.48e-8	Educational attainment (years of education);
CRC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.45	7.1	0.36	7.79e-12	Longevity;
CRC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.36	6.13	0.32	2.46e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.76	-12.63	-0.57	4.22e-30	Height;
CRC	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-8.13	-0.41	9.08e-15	Height;
CRC	cis	rs12024301	0.557	rs10911388	chr1:183616781	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.59	0.34	1.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg10217327	chr6:118973057	C6orf204	0.51	5.76	0.3	1.93e-8	Diastolic blood pressure;
CRC	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.55	-6.17	-0.32	2.02e-9	Neutrophil percentage of white cells;
CRC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.91	-17.13	-0.69	1.81e-47	Intelligence (multi-trait analysis);
CRC	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg19537932	chr12:55886519	OR6C68	-0.66	-8.56	-0.43	4.26e-16	Cancer;
CRC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.63	-0.39	2.48e-13	Heart rate;
CRC	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.85	-0.72	2.83e-54	Schizophrenia;
CRC	trans	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.39	0.53	1.47e-25	Bone mineral density;
CRC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15369054	chr17:80825471	TBCD	0.34	5.74	0.3	2.15e-8	Breast cancer;
CRC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg20203395	chr5:56204925	C5orf35	0.56	7.62	0.39	2.75e-13	Initial pursuit acceleration;
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02772935	chr3:125709198	NA	-0.5	-5.71	-0.3	2.53e-8	Blood pressure (smoking interaction);
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg04778178	chr7:27162294	HOXA3	0.26	5.97	0.31	6.08e-9	Kashin-Beck disease;
CRC	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg09003973	chr2:102972529	NA	0.41	5.86	0.31	1.11e-8	Blood protein levels;
CRC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	2.94e-11	Glioblastoma;
CRC	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.72	14.0	0.61	2.87e-35	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.27	-14.59	-0.63	1.57e-37	Diabetic kidney disease;
CRC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.63	-10.43	-0.5	3.38e-22	Colorectal cancer;
CRC	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.7	13.25	0.59	2.06e-32	Mean corpuscular hemoglobin;
CRC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.39	-7.07	-0.36	9.53e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs73206853	0.620	rs73194027	chr12:111144317	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	6.48	0.34	3.4e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.41	-0.71	1.63e-52	Height;
CRC	cis	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg15786705	chr6:28176104	NA	0.58	6.15	0.32	2.29e-9	Depression;
CRC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.42	6.9	0.36	2.61e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12744310	0.887	rs72667610	chr1:41794810	G/A	cg19175123	chr10:103411746	FBXW4	0.46	6.13	0.32	2.55e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs1656402	0.953	rs1190456	chr2:233435104	T/C	cg03852847	chr2:233439513	NA	-0.42	-6.85	-0.35	3.73e-11	Non-small cell lung cancer (survival);
CRC	cis	rs6141769	0.542	rs6058840	chr20:31319116	A/T	cg13636640	chr20:31349939	DNMT3B	0.42	6.05	0.32	3.93e-9	Subjective well-being;
CRC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.56	8.49	0.42	6.99e-16	Aortic root size;
CRC	cis	rs501120	0.584	rs10900000	chr10:44694892	G/A	cg09554077	chr10:44749378	NA	0.71	7.85	0.4	5.98e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.76	11.12	0.52	1.37e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg10760299	chr15:45669010	GATM	0.49	7.81	0.4	7.8500000000000006e-14	Homoarginine levels;
CRC	trans	rs11466653	1.000	rs9998678	chr4:38777520	T/A	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14640712	chr21:45526961	PWP2	0.43	6.37	0.33	6.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.47	0.34	3.5e-10	Diabetic kidney disease;
CRC	trans	rs10242455	0.702	rs74416635	chr7:99180569	G/A	cg09045935	chr12:6379348	NA	1.15	8.87	0.44	4.69e-17	Blood metabolite levels;
CRC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.43	-0.42	1.12e-15	Height;
CRC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg12639453	chr1:2035780	PRKCZ	-0.3	-5.6	-0.3	4.47e-8	Height;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13393204	chr11:86748738	TMEM135	0.44	7.39	0.38	1.25e-12	Obesity-related traits;
CRC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.47	-8.22	-0.41	4.84e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg07299736	chr8:135490787	ZFAT	-0.37	-6.19	-0.32	1.77e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	5.97	0.31	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.66	10.19	0.49	2.19e-21	Initial pursuit acceleration;
CRC	cis	rs2346160	0.831	rs1467391	chr6:167690062	A/G	cg04673565	chr6:167680447	NA	-0.41	-6.79	-0.35	5.22e-11	Parental extreme longevity (95 years and older);
CRC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.45	6.43	0.33	4.53e-10	Longevity;Endometriosis;
CRC	trans	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg10756647	chr7:56101905	PSPH	-0.73	-7.84	-0.4	6.49e-14	Diabetic kidney disease;
CRC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.61e-24	Motion sickness;
CRC	trans	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.46	-0.38	7.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg04110750	chr16:69646130	NFAT5	-0.58	-7.54	-0.38	4.6e-13	IgE levels;
CRC	cis	rs10463316	0.779	rs6896444	chr5:150777357	T/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.14	-0.37	5.85e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.77	-9.34	-0.46	1.55e-18	Body mass index;
CRC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg20203395	chr5:56204925	C5orf35	0.58	8.0	0.4	2.11e-14	Initial pursuit acceleration;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.49	-0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15947007	chr7:64023509	ZNF680	0.43	6.78	0.35	5.55e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.71	0.51	3.63e-23	Motion sickness;
CRC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.75	9.13	0.45	7.08e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.23	0.56	1.36e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.43	-6.24	-0.33	1.34e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs12143943	0.934	rs12567161	chr1:204577832	G/A	cg17419461	chr1:204415978	PIK3C2B	0.37	5.76	0.3	1.95e-8	Cognitive performance;
CRC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.79	-0.47	5.05e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4731207	0.698	rs3919896	chr7:124553007	A/T	cg23710748	chr7:124431027	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Cutaneous malignant melanoma;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.73	11.0	0.52	3.69e-24	Menarche (age at onset);
CRC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26240231	chr7:1148101	C7orf50	-0.37	-5.66	-0.3	3.39e-8	Bronchopulmonary dysplasia;
CRC	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg08890418	chr1:21044141	KIF17	0.32	5.98	0.31	5.88e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.45	-7.49	-0.38	6.37e-13	Refractive error;
CRC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg16989086	chr20:62203971	PRIC285	0.46	5.83	0.31	1.31e-8	Glioblastoma;
CRC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.91	-0.31	8.77e-9	Vitiligo;
CRC	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.28	-0.42	3.06e-15	Idiopathic membranous nephropathy;
CRC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	10.5	0.5	1.96e-22	Prudent dietary pattern;
CRC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.81	0.44	7.32e-17	Rheumatoid arthritis;
CRC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg17948913	chr5:572064	NA	0.51	5.89	0.31	9.53e-9	Obesity-related traits;
CRC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	8.62	0.43	2.86e-16	Colorectal cancer;
CRC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg20573242	chr4:122745356	CCNA2	-0.42	-6.32	-0.33	8.59e-10	Type 2 diabetes;
CRC	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.63	8.43	0.42	1.11e-15	Uric acid levels;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg21251018	chr6:28226885	NKAPL	-0.52	-8.82	-0.44	6.72e-17	Cardiac Troponin-T levels;
CRC	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.48	6.63	0.34	1.37e-10	Eye color traits;
CRC	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg27398640	chr15:77910606	LINGO1	0.44	7.68	0.39	1.88e-13	Type 2 diabetes;
CRC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.52	-0.34	2.69e-10	Body mass index;
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg24046110	chr8:143859143	LYNX1	0.62	10.81	0.51	1.67e-23	Urinary tract infection frequency;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16098923	chr2:88927231	EIF2AK3	0.38	6.41	0.33	5.14e-10	Obesity-related traits;
CRC	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg14550559	chr2:240039617	HDAC4	-0.52	-7.81	-0.4	7.89e-14	Skin aging (microtopography measurement);
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg15147215	chr3:52552868	STAB1	-0.78	-15.97	-0.66	6.82e-43	Electroencephalogram traits;
CRC	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.52	9.19	0.45	4.48e-18	Common traits (Other);
CRC	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.94	-0.31	7.26e-9	Vitamin D levels;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.55	9.42	0.46	8.34e-19	Lung cancer;
CRC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.53	0.47	3.52e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.74	-11.24	-0.53	4.83e-25	Platelet distribution width;
CRC	trans	rs4667466	0.727	rs12622595	chr2:163661011	A/G	cg06147758	chr7:100487180	UFSP1	-0.51	-6.31	-0.33	8.84e-10	Diabetic kidney disease;
CRC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28655083	0.785	rs7404856	chr16:77130339	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.57	7.84	0.4	6.47e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-14.96	-0.64	5.87e-39	Vitiligo;
CRC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-5.68	-0.3	2.97e-8	Aortic root size;
CRC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.58	10.03	0.48	7.71e-21	Intelligence (multi-trait analysis);
CRC	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.06	0.52	2.21e-24	Exhaled nitric oxide output;
CRC	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.88	-8.43	-0.42	1.06e-15	Platelet distribution width;
CRC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.89	0.55	2.39e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg07636037	chr3:49044803	WDR6	-0.81	-5.71	-0.3	2.55e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.28	-0.42	3.08e-15	Hemoglobin concentration;
CRC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.38	7.14	0.37	5.93e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.53	-6.58	-0.34	1.8e-10	Body mass index;
CRC	cis	rs9928842	0.770	rs4888364	chr16:75279510	A/G	cg08657710	chr16:75258780	CTRB1	-0.54	-6.35	-0.33	7.2e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg25164649	chr6:28176230	NA	0.65	8.58	0.43	3.87e-16	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00668182	chr20:30795591	POFUT1;PLAGL2	0.41	6.06	0.32	3.81e-9	Response to antipsychotic treatment;
CRC	trans	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg21153622	chr11:89784906	NA	-0.48	-7.74	-0.39	1.26e-13	HDL cholesterol;
CRC	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.37e-19	Blood protein levels;
CRC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg05623727	chr3:50126028	RBM5	0.53	6.97	0.36	1.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.28	5.71	0.3	2.51e-8	Lung cancer;
CRC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-9.77	-0.47	5.6e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.01	0.31	4.89e-9	Tonsillectomy;
CRC	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.5	-7.78	-0.39	9.28e-14	Type 2 diabetes;
CRC	cis	rs501120	0.810	rs498810	chr10:44740776	A/C	cg09554077	chr10:44749378	NA	0.89	13.18	0.59	3.84e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs8062405	0.558	rs231976	chr16:28545587	C/G	cg05139728	chr16:28306816	SBK1	-0.32	-5.72	-0.3	2.43e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.61	11.36	0.53	1.92e-25	Immature fraction of reticulocytes;
CRC	cis	rs12889267	0.722	rs2319625	chr14:21565146	C/T	cg02988727	chr14:21567520	ZNF219;C14orf176	0.46	6.93	0.36	2.24e-11	Hematocrit;Resting heart rate;
CRC	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.73	7.13	0.37	6.38e-12	Neuroticism;
CRC	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.52	8.01	0.4	1.95e-14	Diastolic blood pressure;
CRC	cis	rs12230513	0.732	rs61547125	chr12:55814082	C/G	cg19537932	chr12:55886519	OR6C68	-0.74	-9.46	-0.46	5.95e-19	Contrast sensitivity;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-9.79	-0.48	4.93e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.69	8.76	0.43	1.04e-16	Coronary artery disease;
CRC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg24675056	chr1:15929824	NA	0.51	7.06	0.36	9.73e-12	Systolic blood pressure;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.54	10.11	0.49	4.27e-21	Acylcarnitine levels;
CRC	cis	rs2160860	0.965	rs2543049	chr8:39820209	C/T	cg11363097	chr8:39792086	IDO2	-0.35	-5.65	-0.3	3.51e-8	Blood metabolite levels;
CRC	cis	rs1223397	0.651	rs202017	chr6:13301051	C/G	cg20827128	chr6:13274284	PHACTR1	0.37	5.69	0.3	2.8e-8	Blood pressure;
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.76	-14.26	-0.62	2.84e-36	Prudent dietary pattern;
CRC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg07713946	chr22:31675144	LIMK2	-0.41	-5.78	-0.3	1.69e-8	Colorectal cancer;
CRC	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.62	-7.82	-0.4	7.46e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg10437265	chr15:77819839	NA	-0.49	-8.18	-0.41	6.44e-15	Type 2 diabetes;
CRC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.37	-6.22	-0.32	1.49e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.69	8.73	0.43	1.34e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.77	-0.3	1.87e-8	Asthma;
CRC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.85	-0.35	3.69e-11	Retinal vascular caliber;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12214673	chr3:196159430	UBXN7	0.4	6.13	0.32	2.49e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.61	10.95	0.52	5.43e-24	Aortic root size;
CRC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.42	0.5	3.63e-22	Systolic blood pressure;
CRC	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.86e-12	Prostate cancer;
CRC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.48	-6.58	-0.34	1.88e-10	Lymphocyte counts;
CRC	cis	rs863345	0.604	rs1112915	chr1:158444447	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.24	-0.33	1.35e-9	Pneumococcal bacteremia;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.77	11.67	0.54	1.44e-26	Menarche (age at onset);
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02359409	chr6:42947317	PEX6	-0.67	-10.75	-0.51	2.72e-23	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.69	9.78	0.47	5.24e-20	Bone mineral density;
CRC	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.52	5.74	0.3	2.2e-8	Mean platelet volume;
CRC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.55	7.18	0.37	4.71e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.46	-6.55	-0.34	2.28e-10	Tonsillectomy;
CRC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-8.64	-0.43	2.49e-16	Menarche (age at onset);
CRC	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg04656015	chr13:113407548	ATP11A	-0.49	-5.68	-0.3	2.99e-8	Glycated hemoglobin levels;
CRC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.41	0.33	5.15e-10	Cognitive test performance;
CRC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg04990556	chr1:26633338	UBXN11	-0.46	-5.74	-0.3	2.2e-8	Monocyte percentage of white cells;
CRC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.58	10.66	0.51	5.53e-23	Glomerular filtration rate (creatinine);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16725050	chr2:220117771	TUBA4B;TUBA4A	0.37	5.99	0.31	5.41e-9	Obesity-related traits;
CRC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg20203395	chr5:56204925	C5orf35	-0.69	-8.03	-0.4	1.75e-14	Initial pursuit acceleration;
CRC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.31	-0.42	2.61e-15	Mean platelet volume;
CRC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.47	8.28	0.42	3.24e-15	Red cell distribution width;
CRC	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg21466736	chr12:48725269	NA	0.47	7.37	0.38	1.4e-12	Plateletcrit;
CRC	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.82	-0.4	7.01e-14	QT interval;
CRC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	9.36	0.46	1.31e-18	Schizophrenia;
CRC	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.6	-7.51	-0.38	5.77e-13	Body mass index;
CRC	cis	rs459193	0.912	rs27984	chr5:55802419	C/T	cg18302225	chr5:55776401	NA	0.59	8.67	0.43	1.98e-16	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg27565382	chr3:53032988	SFMBT1	0.77	6.23	0.32	1.41e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6963495	0.510	rs73192157	chr7:105225862	A/T	cg02135003	chr7:105160482	PUS7	-0.72	-7.76	-0.39	1.11e-13	Bipolar disorder (body mass index interaction);
CRC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.75	10.46	0.5	2.69e-22	Heart rate;
CRC	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.37	6.77	0.35	5.8e-11	Glucocorticoid-induced osteonecrosis (age 10 years and older);
CRC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.54	0.47	3.27e-19	Lymphocyte counts;
CRC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg07274523	chr3:49395745	GPX1	-0.43	-5.86	-0.31	1.12e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg08533674	chr1:46993347	NA	0.6	7.96	0.4	2.9e-14	Monobrow;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02567788	chr10:71992279	PPA1	-0.44	-6.44	-0.33	4.27e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg03623178	chr6:28175578	NA	0.58	6.4	0.33	5.28e-10	Parkinson's disease;
CRC	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-17.23	-0.69	7.44e-48	Ulcerative colitis;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.64	-9.29	-0.46	2.17e-18	Menopause (age at onset);
CRC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.61	-8.43	-0.42	1.09e-15	DNA methylation (variation);
CRC	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.46	6.03	0.32	4.34e-9	Putamen volume;
CRC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16447950	chr5:562315	NA	-0.74	-9.75	-0.47	6.56e-20	Obesity-related traits;
CRC	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.49	-8.14	-0.41	8.51e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06505273	chr16:24850292	NA	-0.52	-6.74	-0.35	7.17e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg04969067	chr8:143858791	LYNX1	0.59	10.11	0.49	4.25e-21	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23102962	chr12:110011481	MMAB;MVK	0.51	7.31	0.37	1.99e-12	Response to antipsychotic treatment;
CRC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.61	10.01	0.48	9.04e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.74	-9.84	-0.48	3.35e-20	Prostate cancer;
CRC	trans	rs8098244	0.708	rs1262340	chr18:21475153	A/G	cg15462349	chr14:37116296	NA	0.49	6.0	0.31	5.23e-9	Epithelial ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg22638593	chr5:131593259	PDLIM4	0.31	5.66	0.3	3.25e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.51	8.99	0.44	1.92e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-7.77	-0.39	1.03e-13	Type 2 diabetes;
CRC	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg16342193	chr10:102329863	NA	-0.38	-6.02	-0.31	4.68e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	0.97	9.26	0.45	2.8e-18	Severe influenza A (H1N1) infection;
CRC	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.87	-0.35	3.19e-11	Bipolar disorder;
CRC	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg18232548	chr7:50535776	DDC	0.44	6.26	0.33	1.23e-9	Malaria;
CRC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.49	9.91	0.48	2.04e-20	Ulcerative colitis;
CRC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg14711859	chr11:8959438	ASCL3	0.57	10.18	0.49	2.4e-21	Hematocrit;
CRC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg13777783	chr17:79615861	NA	-0.3	-5.73	-0.3	2.27e-8	Eye color traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26771998	chr10:75490334	BMS1P4	0.46	6.94	0.36	2.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg20628663	chr10:43360327	NA	0.57	6.62	0.34	1.43e-10	Blood protein levels;
CRC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg06740227	chr12:86229804	RASSF9	0.37	5.62	0.3	4.02e-8	Major depressive disorder;
CRC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg21251018	chr6:28226885	NKAPL	0.5	8.61	0.43	3.05e-16	Pubertal anthropometrics;
CRC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.23e-8	Protein C levels;
CRC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.37	6.33	0.33	7.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.56	6.66	0.34	1.14e-10	Body mass index;
CRC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg00531865	chr16:30841666	NA	-0.5	-5.8	-0.3	1.59e-8	Diastolic blood pressure;
CRC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.0	0.31	5.06e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.48	-5.62	-0.3	4.01e-8	Neutrophil percentage of white cells;
CRC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.6	10.98	0.52	4.03e-24	Schizophrenia;
CRC	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.39	5.99	0.31	5.39e-9	Red blood cell count;
CRC	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg07587117	chr16:2239488	CASKIN1	0.43	7.63	0.39	2.59e-13	Height;
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.73	-0.43	1.34e-16	Bipolar disorder;
CRC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.55	-8.01	-0.4	2.06e-14	Fibrinogen levels;
CRC	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.45	7.03	0.36	1.17e-11	Coronary artery disease;
CRC	cis	rs6662572	0.737	rs2067635	chr1:46537946	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.22	0.32	1.54e-9	Blood protein levels;
CRC	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26714650	chr12:56694279	CS	-1.41	-11.34	-0.53	2.29e-25	Psoriasis vulgaris;
CRC	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	0.7	10.59	0.5	9.61e-23	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs727505	0.866	rs67724276	chr7:124719719	G/A	cg23710748	chr7:124431027	NA	-0.72	-12.17	-0.56	2.14e-28	Lewy body disease;
CRC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg25767906	chr1:53392781	SCP2	0.42	6.6	0.34	1.6e-10	Monocyte count;
CRC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.46	-7.44	-0.38	8.66e-13	Hemoglobin concentration;
CRC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.61	-6.42	-0.33	4.65e-10	Schizophrenia;
CRC	trans	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7703744	0.681	rs73239280	chr5:118695579	G/A	cg17471836	chr5:118691007	TNFAIP8	0.43	5.97	0.31	6.09e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg13607699	chr17:42295918	UBTF	0.47	6.27	0.33	1.13e-9	Total body bone mineral density;
CRC	cis	rs11212617	1.000	rs11212619	chr11:108289167	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.12	0.32	2.61e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.46	6.56	0.34	2.14e-10	Response to temozolomide;
CRC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.69e-10	HDL cholesterol;
CRC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.47	7.91	0.4	4.07e-14	Breast cancer;
CRC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg19077165	chr18:44547161	KATNAL2	0.5	8.13	0.41	9.13e-15	Educational attainment;
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg04796162	chr7:45961102	IGFBP3	0.41	7.06	0.36	9.63e-12	Sitting height ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13968099	chr5:162864768	CCNG1	0.36	6.03	0.32	4.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-6.82	-0.35	4.32e-11	Platelet distribution width;
CRC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.39	-6.89	-0.36	2.77e-11	Reticulocyte fraction of red cells;
CRC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.57	9.16	0.45	5.56e-18	Caffeine consumption;
CRC	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg03623178	chr6:28175578	NA	0.73	6.97	0.36	1.75e-11	Depression;
CRC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.51	0.34	2.81e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg21268650	chr7:45961089	IGFBP3	0.38	6.59	0.34	1.78e-10	Sitting height ratio;
CRC	cis	rs775227	1.000	rs13093350	chr3:112993063	A/G	cg18753928	chr3:113234510	CCDC52	0.44	5.61	0.3	4.32e-8	Dental caries;
CRC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.97	11.5	0.54	6.08e-26	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg24375607	chr4:120327624	NA	0.48	7.67	0.39	1.92e-13	Corneal astigmatism;
CRC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.51	-7.52	-0.38	5.22e-13	Dementia with Lewy bodies;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.62	7.9	0.4	4.15e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.46	6.59	0.34	1.71e-10	Corneal astigmatism;
CRC	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26539663	chr17:7590939	WRAP53;TP53	0.38	6.12	0.32	2.72e-9	Obesity-related traits;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.56	8.75	0.43	1.1e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.56	0.38	4.03e-13	Obesity-related traits;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg19318889	chr4:1322082	MAEA	0.41	5.95	0.31	6.97e-9	Obesity-related traits;
CRC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.78	-0.44	8.89e-17	Hip circumference adjusted for BMI;
CRC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.87	12.74	0.57	1.71e-30	Diastolic blood pressure;
CRC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.53	0.75	6.95e-61	Prudent dietary pattern;
CRC	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg00677455	chr12:58241039	CTDSP2	0.49	6.62	0.34	1.48e-10	Multiple sclerosis;
CRC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.61	-10.81	-0.51	1.58e-23	Aortic root size;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	0.84	8.53	0.43	5.41e-16	Gut microbiota (bacterial taxa);
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.02	-0.36	1.26e-11	Bipolar disorder;
CRC	cis	rs6694672	1.000	rs6695300	chr1:197098143	G/C	cg13682187	chr1:196946512	CFHR5	0.54	8.03	0.4	1.73e-14	Asthma;
CRC	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg19438565	chr8:143695827	ARC	-0.48	-6.78	-0.35	5.68e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg08888203	chr3:10149979	C3orf24	0.72	8.86	0.44	5.2e-17	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.58	-8.26	-0.41	3.57e-15	Arsenic metabolism;
CRC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.4	-5.91	-0.31	8.39e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs3020333	0.653	rs851982	chr6:152024985	T/C	cg22157087	chr6:152012887	ESR1	0.49	7.21	0.37	3.93e-12	Total body bone mineral density;
CRC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.6	-9.58	-0.47	2.54e-19	Sudden cardiac arrest;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg08798685	chr6:27730294	NA	0.44	6.48	0.34	3.28e-10	Parkinson's disease;
CRC	cis	rs7712401	0.686	rs246305	chr5:122199606	A/T	cg18764291	chr5:122110994	SNX2	0.35	5.61	0.3	4.3e-8	Mean platelet volume;
CRC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.43	6.8	0.35	5.08e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg19622623	chr12:86230825	RASSF9	0.41	6.62	0.34	1.49e-10	Major depressive disorder;
CRC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.95	-17.85	-0.7	2.63e-50	Intelligence (multi-trait analysis);
CRC	trans	rs8064024	0.513	rs1049208	chr16:4934549	G/A	cg19252218	chr17:41477271	ARL4D	-0.42	-6.21	-0.32	1.57e-9	Cancer;
CRC	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.82	13.05	0.58	1.18e-31	Blood metabolite levels;
CRC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-0.99	-10.94	-0.52	5.9e-24	Diabetic retinopathy;
CRC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.42	-6.65	-0.34	1.24e-10	Bone mineral density (spine);
CRC	cis	rs972578	0.905	rs56026835	chr22:43363122	A/C	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.57	7.5	0.38	6.15e-13	Breast cancer;
CRC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.36	-0.38	1.48e-12	Monocyte percentage of white cells;
CRC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.7	-10.31	-0.49	8.61e-22	Menopause (age at onset);
CRC	cis	rs672059	1.000	rs549844	chr1:183158143	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.52	-7.58	-0.39	3.59e-13	Hypertriglyceridemia;
CRC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.36	-6.6	-0.34	1.66e-10	Menarche (age at onset);
CRC	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg26727032	chr16:67993705	SLC12A4	0.67	10.35	0.5	6.47e-22	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-8.42	-0.42	1.15e-15	Morning vs. evening chronotype;
CRC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.89	-10.02	-0.48	8.61e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg20488157	chr14:104394430	TDRD9	0.54	7.54	0.38	4.52e-13	Bipolar disorder;
CRC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.24	0.53	4.97e-25	Tonsillectomy;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23708337	chr7:1209742	NA	0.5	7.73	0.39	1.32e-13	Longevity;Endometriosis;
CRC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.63	-0.34	1.39e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg17385448	chr1:15911702	AGMAT	0.29	5.86	0.31	1.14e-8	Systolic blood pressure;
CRC	cis	rs7082209	0.540	rs800310	chr10:44815048	A/T	cg09554077	chr10:44749378	NA	-0.4	-6.11	-0.32	2.83e-9	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
CRC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	1.1	10.48	0.5	2.33e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg05064044	chr6:292385	DUSP22	-0.59	-8.1	-0.41	1.06e-14	Menopause (age at onset);
CRC	cis	rs11212617	0.967	rs2356802	chr11:108282169	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.63	0.34	1.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg27053337	chr8:124217698	FAM83A	0.42	6.36	0.33	6.62e-10	Urinary uromodulin levels;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg17346650	chr17:80929145	B3GNTL1	0.49	7.36	0.38	1.48e-12	Glycated hemoglobin levels;
CRC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.58	8.11	0.41	1.04e-14	Arsenic metabolism;
CRC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg22110888	chr17:80059540	CCDC57	0.41	6.7	0.35	8.86e-11	Life satisfaction;
CRC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg11070056	chr1:107600091	PRMT6	-0.4	-5.74	-0.3	2.19e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg21153622	chr11:89784906	NA	0.45	7.1	0.36	7.58e-12	HDL cholesterol;
CRC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.95	-0.48	1.49e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.43	6.89	0.36	2.82e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.41	-0.42	1.29e-15	Monocyte count;
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs4728302	0.871	rs10259686	chr7:133633152	A/G	cg03336402	chr7:133662267	EXOC4	0.43	6.35	0.33	6.96e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24308560	chr3:49941425	MST1R	0.42	6.52	0.34	2.66e-10	Body mass index;
CRC	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.48	-7.4	-0.38	1.17e-12	Schizophrenia;
CRC	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.84	0.4	6.2e-14	Diabetic kidney disease;
CRC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.5	7.14	0.37	5.95e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg00601450	chr5:74908170	NA	0.41	5.76	0.3	1.95e-8	Age-related disease endophenotypes;
CRC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.8	0.35	5.08e-11	Educational attainment;
CRC	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.58	10.17	0.49	2.54e-21	Age of smoking initiation;
CRC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg18721089	chr20:30220636	NA	-0.53	-8.01	-0.4	2.02e-14	Mean corpuscular hemoglobin;
CRC	cis	rs2282802	0.685	rs13170475	chr5:139671062	C/T	cg26211634	chr5:139558579	C5orf32	0.44	7.61	0.39	2.83e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.52	9.95	0.48	1.42e-20	HIV-1 susceptibility;
CRC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.06	0.36	9.69e-12	Menopause (age at onset);
CRC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg19913688	chr11:428466	ANO9	0.71	7.28	0.37	2.5e-12	Body mass index;
CRC	cis	rs12580194	0.593	rs11171416	chr12:55731490	A/G	cg23425280	chr12:56401806	NA	0.47	5.93	0.31	7.65e-9	Cancer;
CRC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.18	-25.84	-0.82	3.4e-81	IgG glycosylation;
CRC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.61	-8.09	-0.41	1.2e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs2055729	0.645	rs7828229	chr8:9742841	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.01	-0.31	5.02e-9	Multiple myeloma (hyperdiploidy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01096752	chr19:49468454	FTL	0.37	5.96	0.31	6.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.57	0.38	3.88e-13	Lung cancer in ever smokers;
CRC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.25	-0.41	3.82e-15	Type 2 diabetes;
CRC	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.66	-11.79	-0.54	5.4e-27	Lewy body disease;
CRC	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg24140574	chr1:16342155	HSPB7	0.46	6.53	0.34	2.46e-10	Dilated cardiomyopathy;
CRC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.18	-0.41	6.47e-15	Chronic sinus infection;
CRC	cis	rs2811415	0.597	rs13094149	chr3:127795569	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.86	-0.31	1.12e-8	Lung function (FEV1/FVC);
CRC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.54	-9.01	-0.45	1.66e-17	Brugada syndrome;
CRC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg08772003	chr10:104629869	AS3MT	-0.34	-5.76	-0.3	1.95e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg04727332	chr7:45960243	IGFBP3	0.36	5.85	0.31	1.18e-8	Sitting height ratio;
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg01422370	chr2:73384389	NA	0.37	5.82	0.31	1.39e-8	Intelligence (multi-trait analysis);
CRC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.37	6.02	0.31	4.78e-9	Ulcerative colitis;
CRC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.58	-0.75	4.39e-61	Height;
CRC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.74e-12	Obesity-related traits;
CRC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	10.14	0.49	3.29e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11098699	0.784	rs11098701	chr4:124216461	C/G	cg09941581	chr4:124220074	SPATA5	0.42	6.28	0.33	1.05e-9	Mosquito bite size;
CRC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg19223190	chr17:80058835	NA	0.42	6.89	0.35	2.92e-11	Life satisfaction;
CRC	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-8.76	-0.43	1.09e-16	Pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25229157	chr1:51426110	FAF1	0.43	6.03	0.32	4.45e-9	Response to antipsychotic treatment;
CRC	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg02466173	chr16:30829666	NA	-0.74	-9.15	-0.45	6.04e-18	Diastolic blood pressure;
CRC	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.49	-7.9	-0.4	4.31e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4731207	0.596	rs10081226	chr7:124575529	C/A	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs73206853	0.660	rs12313068	chr12:110597304	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	9.75	0.47	6.84e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.37	5.83	0.31	1.34e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-0.89	-19.74	-0.74	8.98e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg02390115	chr1:21767211	NBPF3	0.53	7.84	0.4	6.46e-14	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.51	-9.69	-0.47	1.04e-19	Hip circumference;Waist circumference;
CRC	cis	rs17756712	0.725	rs57440245	chr6:616855	G/C	cg16786516	chr6:604617	EXOC2	0.46	5.66	0.3	3.35e-8	Vertical cup-disc ratio;
CRC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02018176	chr4:1364513	KIAA1530	0.39	6.62	0.34	1.46e-10	Longevity;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg20615401	chr6:28092323	ZSCAN16	0.43	5.62	0.3	4.13e-8	Parkinson's disease;
CRC	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.61	7.18	0.37	4.7e-12	Bipolar disorder;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg15845792	chr6:28175446	NA	0.86	13.56	0.6	1.46e-33	Cardiac Troponin-T levels;
CRC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.68	-0.47	1.15e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6066835	0.867	rs73118616	chr20:47364704	G/C	cg18078177	chr20:47281410	PREX1	0.62	5.72	0.3	2.35e-8	Multiple myeloma;
CRC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg23018236	chr17:30244563	NA	-0.66	-7.82	-0.4	7.05e-14	Hip circumference adjusted for BMI;
CRC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg06386533	chr2:46925753	SOCS5	0.48	6.0	0.31	5.21e-9	Height;
CRC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-13.02	-0.58	1.57e-31	Ulcerative colitis;
CRC	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-8.97	-0.44	2.24e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.39	-0.33	5.63e-10	Bipolar disorder;
CRC	cis	rs9549328	0.616	rs35086993	chr13:113617305	G/A	cg25790453	chr13:113633590	MCF2L	0.44	7.65	0.39	2.22e-13	Systolic blood pressure;
CRC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.55	10.04	0.48	7.22e-21	HDL cholesterol levels;
CRC	trans	rs12200782	0.649	rs9467746	chr6:26387405	A/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23359706	chr19:11491839	EPOR	0.45	6.37	0.33	6.34e-10	Response to antipsychotic treatment;
CRC	cis	rs4700695	0.697	rs251319	chr5:65239468	A/G	cg21114390	chr5:65439923	SFRS12	0.5	6.18	0.32	1.95e-9	Facial morphology (factor 19);
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg03623178	chr6:28175578	NA	0.68	9.43	0.46	7.56e-19	Parkinson's disease;
CRC	cis	rs6479527	0.710	rs2226117	chr9:96750661	G/A	cg14459158	chr9:96720562	NA	0.41	7.52	0.38	5.11e-13	Esophageal adenocarcinoma;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg02683197	chr6:28174875	NA	0.82	10.11	0.49	4.09e-21	Depression;
CRC	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.23	0.41	4.38e-15	Osteoporosis;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.75	-0.35	6.68e-11	Colorectal cancer;
CRC	cis	rs2257205	0.667	rs7342841	chr17:56916156	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.43e-8	Pancreatic cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01016553	chr1:51810627	TTC39A	-0.39	-6.06	-0.32	3.75e-9	Myopia (pathological);
CRC	cis	rs9341808	0.667	rs2490241	chr6:80846342	T/C	cg08355045	chr6:80787529	NA	0.34	5.81	0.31	1.47e-8	Sitting height ratio;
CRC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.69	-0.35	9.77e-11	Aortic root size;
CRC	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.6	-7.93	-0.4	3.43e-14	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.49	8.27	0.41	3.45e-15	Common traits (Other);
CRC	cis	rs12541635	0.653	rs7014265	chr8:107026412	G/A	cg10147462	chr8:107024639	NA	0.59	9.85	0.48	3.11e-20	Age of smoking initiation;
CRC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.43	6.59	0.34	1.74e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.49	6.51	0.34	2.89e-10	IgG glycosylation;
CRC	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.25	6.8	0.35	4.84e-11	Type 2 diabetes;
CRC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg17330251	chr7:94953956	PON1	-0.54	-6.78	-0.35	5.59e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08722104	chr11:47448306	PSMC3	0.52	7.3	0.37	2.12e-12	Response to antipsychotic treatment;
CRC	trans	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs73200209	0.625	rs11611787	chr12:116644886	G/T	cg01776926	chr12:116560359	MED13L	-0.61	-7.08	-0.36	8.97e-12	Total body bone mineral density;
CRC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.56	10.29	0.49	1.01e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.45	6.61	0.34	1.53e-10	Menopause (age at onset);
CRC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg00255919	chr5:131827918	IRF1	-0.37	-6.29	-0.33	9.98e-10	Breast cancer;Mosquito bite size;
CRC	cis	rs910187	0.678	rs1046661	chr20:45817149	G/A	cg27589058	chr20:45804311	EYA2	-0.4	-7.66	-0.39	2.09e-13	Migraine;
CRC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg03037974	chr15:76606532	NA	0.57	9.63	0.47	1.67e-19	Blood metabolite levels;
CRC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg02659138	chr7:134003124	SLC35B4	0.41	6.71	0.35	8.55e-11	Mean platelet volume;
CRC	cis	rs939584	1.000	rs35796073	chr2:636819	C/A	cg03610516	chr2:642275	NA	-0.42	-5.7	-0.3	2.72e-8	Body mass index;
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.98	-0.55	1.09e-27	Alzheimer's disease;
CRC	cis	rs4664293	0.867	rs35196716	chr2:160589777	T/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.25	-0.56	1.09e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.89	0.31	9.73e-9	Heart rate;
CRC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.18	27.23	0.83	2.73e-86	IgG glycosylation;
CRC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.17	-0.32	2.04e-9	Height;
CRC	cis	rs7605827	0.930	rs7590458	chr2:15601574	A/G	cg19274914	chr2:15703543	NA	-0.37	-5.69	-0.3	2.85e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-7.85	-0.4	6e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg06346307	chr22:19949965	COMT	0.25	6.36	0.33	6.56e-10	Blood metabolite levels;
CRC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.72	0.68	7.16e-46	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-7.44	-0.38	8.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.0	-23.15	-0.79	4.87e-71	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.55	-0.38	4.39e-13	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.42	-0.5	3.63e-22	Initial pursuit acceleration;
CRC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.27	16.78	0.68	4.34e-46	Breast cancer;
CRC	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg13482628	chr17:19912719	NA	-0.38	-5.62	-0.3	4.04e-8	Obesity-related traits;
CRC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.04	0.45	1.4e-17	Bladder cancer;
CRC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.36	-0.33	6.7e-10	Breast cancer;
CRC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.79	-0.47	5.05e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-12.87	-0.58	5.64e-31	Vitiligo;
CRC	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg16589663	chr20:23618590	CST3	0.58	6.97	0.36	1.71e-11	Chronic kidney disease;
CRC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.65	10.16	0.49	2.75e-21	Type 2 diabetes;
CRC	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.44	-9.21	-0.45	3.84e-18	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.6	8.18	0.41	6.43e-15	Neutrophil percentage of white cells;
CRC	cis	rs12044355	0.892	rs1538974	chr1:231828596	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.45	-6.26	-0.33	1.21e-9	Alzheimer's disease;
CRC	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.37	5.89	0.31	9.36e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.47	-7.63	-0.39	2.58e-13	Body mass index;
CRC	trans	rs4621152	1.000	rs11894340	chr2:217917167	A/G	cg03559682	chr11:6439864	APBB1	-0.31	-5.97	-0.31	6.17e-9	Gut microbiota (bacterial taxa);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13348770	chr6:122720548	HSF2	0.47	6.26	0.33	1.17e-9	Anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01241850	chr9:138798996	CAMSAP1	0.39	6.04	0.32	4.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3018066	0.666	rs6844324	chr4:107046619	C/T	cg01869342	chr4:106983673	TBCK	0.47	6.08	0.32	3.3e-9	Cancer;
CRC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg08222913	chr3:52553049	STAB1	0.34	6.48	0.34	3.35e-10	Electroencephalogram traits;
CRC	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.45	-0.42	9.83e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.45	-6.93	-0.36	2.29e-11	Menarche (age at onset);
CRC	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg21153622	chr11:89784906	NA	-0.44	-7.0	-0.36	1.47e-11	HDL cholesterol;
CRC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg00343986	chr7:65444356	GUSB	0.42	5.94	0.31	7.35e-9	Aortic root size;
CRC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.7	-11.49	-0.54	6.38e-26	Hepatocellular carcinoma;
CRC	trans	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg18288967	chr1:45987694	PRDX1	0.68	6.59	0.34	1.79e-10	Obesity-related traits;
CRC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.64	0.54	1.85e-26	Asthma (sex interaction);
CRC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.29	0.46	2.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.29	-6.51	-0.34	2.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg05304507	chr6:116381966	FRK	0.31	8.43	0.42	1.09e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16262614	chr3:133464971	TF	0.33	5.85	0.31	1.17e-8	Iron status biomarkers;
CRC	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.65	-10.66	-0.51	5.45e-23	Hepatocellular carcinoma;
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg20041105	chr8:143859282	LYNX1	-0.45	-7.97	-0.4	2.56e-14	Urinary tract infection frequency;
CRC	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.43	-6.2	-0.32	1.71e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18996663	chr14:55595768	LGALS3	0.39	6.06	0.32	3.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg16606324	chr3:10149918	C3orf24	0.76	8.82	0.44	6.99e-17	Alzheimer's disease;
CRC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg11292332	chr7:45801988	SEPT13	-0.38	-7.02	-0.36	1.26e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.83	-0.44	6.2e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10971721	0.643	rs10971702	chr9:33784102	C/T	cg13495928	chr9:33750294	PRSS3	0.66	5.92	0.31	8.05e-9	Body mass index;
CRC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.34e-38	Intelligence (multi-trait analysis);
CRC	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg13931752	chr15:40660718	DISP2	0.48	6.0	0.31	5.3300000000000004e-09	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg00587665	chr15:100533223	ADAMTS17	-0.45	-7.75	-0.39	1.16e-13	Height;
CRC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	10.17	0.49	2.56e-21	Schizophrenia;
CRC	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.41	5.96	0.31	6.63e-9	Neuroticism;
CRC	cis	rs10229583	0.527	rs6979634	chr7:127323965	A/C	cg01233922	chr7:127693937	SND1	0.46	6.86	0.35	3.51e-11	Type 2 diabetes;
CRC	cis	rs2213920	0.568	rs6478166	chr9:118213548	T/C	cg13918206	chr9:118159781	DEC1	0.6	5.85	0.31	1.16e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	7.85	0.4	5.88e-14	Schizophrenia;
CRC	cis	rs7951870	0.673	rs4606447	chr11:46691737	A/G	cg19486271	chr11:47235900	DDB2	-0.43	-6.61	-0.34	1.59e-10	Schizophrenia;
CRC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-9.68	-0.47	1.16e-19	Dental caries;
CRC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.34	-0.42	2.07e-15	Gut microbiome composition (summer);
CRC	cis	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg06470822	chr6:28175283	NA	0.65	6.64	0.34	1.26e-10	Depression;
CRC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22805796	chr17:79829393	ARHGDIA	0.45	6.39	0.33	5.77e-10	Response to antipsychotic treatment;
CRC	cis	rs4658101	0.815	rs11165013	chr1:92051419	G/A	cg24006770	chr1:92056542	NA	0.43	5.68	0.3	2.9e-8	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.5	8.12	0.41	9.57e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg07807695	chr5:81608485	ATP6AP1L	-0.48	-7.66	-0.39	2.16e-13	Breast cancer;
CRC	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.6	9.67	0.47	1.27e-19	Itch intensity from mosquito bite;
CRC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-7.76	-0.39	1.11e-13	Type 2 diabetes;
CRC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.56	8.04	0.41	1.61e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21036854	chr14:77506705	NA	0.5	6.55	0.34	2.19e-10	Thyroid stimulating hormone;
CRC	cis	rs7264396	0.887	rs6060431	chr20:34059337	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-5.93	-0.31	7.54e-9	Total cholesterol levels;
CRC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.63	-10.64	-0.51	6.55e-23	Depressive symptoms (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19794706	chr14:75643232	TMED10	0.43	6.66	0.34	1.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg06470822	chr6:28175283	NA	-1.02	-16.08	-0.66	2.35e-43	Depression;
CRC	cis	rs17166499	0.634	rs73070122	chr7:12887318	A/G	cg12945054	chr7:12841881	NA	0.45	5.81	0.31	1.46e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.89	-14.83	-0.63	1.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11212617	1.000	rs652311	chr11:108240069	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.76	0.35	6.12e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.2	-0.41	5.35e-15	Bone mineral density;
CRC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.49	0.42	7.03e-16	Height;
CRC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg11833968	chr6:79620685	NA	-0.35	-6.04	-0.32	4.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.73	-0.3	2.31e-8	Migraine;Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23182539	chr10:121355708	TIAL1	0.46	6.68	0.35	9.92e-11	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.48	-6.7	-0.35	8.83e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg23161317	chr6:28129485	ZNF389	0.4	6.06	0.32	3.64e-9	Cardiac Troponin-T levels;
CRC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.76	11.37	0.53	1.69e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10274279	1.000	rs6459798	chr7:157381735	C/T	cg26886268	chr7:157387156	PTPRN2	-0.48	-5.84	-0.31	1.23e-8	Myopia (pathological);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg00694336	chr1:114301873	PHTF1	-0.44	-6.3	-0.33	9.67e-10	HDL cholesterol;
CRC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg12193833	chr17:30244370	NA	-0.63	-8.06	-0.41	1.39e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.92	-0.31	8.18e-9	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.66	-0.3	3.25e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg17420585	chr12:42539391	GXYLT1	-0.44	-6.32	-0.33	8.41e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2237234	0.848	rs2237235	chr6:26391395	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	6.09	0.32	3.07e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg21176127	chr14:100795263	C14orf68	0.21	5.96	0.31	6.42e-9	Menarche (age at onset);
CRC	cis	rs7781266	0.793	rs62470021	chr7:133273036	T/A	cg03336402	chr7:133662267	EXOC4	0.49	5.75	0.3	2.02e-8	Educational attainment (college completion);
CRC	cis	rs9846480	0.598	rs35219044	chr3:138056177	T/C	cg25476813	chr3:138050155	TXNDC6	-0.4	-5.91	-0.31	8.37e-9	Whole-brain volume (Alzheimer's disease interaction);
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.38	-5.6	-0.3	4.42e-8	Lymphocyte counts;
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.21	-0.32	1.57e-9	Bipolar disorder;
CRC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg05926586	chr15:74592786	CCDC33	0.32	5.64	0.3	3.66e-8	Airflow obstruction;
CRC	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	1.11	10.4	0.5	4.45e-22	Arsenic metabolism;
CRC	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg16540259	chr10:75572220	NDST2	0.38	6.1	0.32	2.99e-9	Inflammatory bowel disease;
CRC	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.39	5.72	0.3	2.41e-8	Growth-regulated protein alpha levels;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg26587870	chr6:27730563	NA	-0.44	-6.83	-0.35	4.18e-11	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.94	0.44	2.79e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.83	0.4	6.96e-14	Alzheimer's disease;
CRC	cis	rs12692738	0.526	rs355866	chr2:165630823	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.54	-7.5	-0.38	6.06e-13	Homocysteine levels;
CRC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.59	8.42	0.42	1.14e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.49	7.82	0.4	7.47e-14	Dental caries;
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg24560729	chr4:1342394	KIAA1530	0.38	6.18	0.32	1.86e-9	Obesity-related traits;
CRC	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.74	-10.26	-0.49	1.29e-21	Blood protein levels;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-5.75	-0.3	2.08e-8	Alzheimer's disease (late onset);
CRC	cis	rs9648716	0.766	rs534348	chr7:140782235	A/G	cg10747023	chr7:140774559	NA	0.44	5.9	0.31	8.86e-9	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg06781209	chr11:61594997	FADS2	-0.6	-7.57	-0.39	3.83e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg24438145	chr17:48624694	SPATA20	0.44	6.26	0.33	1.2e-9	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.81	0.48	4.27e-20	Lung cancer;
CRC	trans	rs6472235	0.837	rs60520895	chr8:66930290	C/T	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs4731207	0.564	rs1011721	chr7:124605159	G/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg11212589	chr17:38028394	ZPBP2	0.41	7.59	0.39	3.28e-13	Self-reported allergy;
CRC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.63	-0.34	1.35e-10	Bipolar disorder;
CRC	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.79	-13.99	-0.61	3.22e-35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs77861329	1.000	rs6781635	chr3:52125343	A/G	cg08692210	chr3:52188851	WDR51A	0.87	8.26	0.41	3.7e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12463550	chr7:65579703	CRCP	-0.68	-6.08	-0.32	3.29e-9	Diabetic kidney disease;
CRC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.08	0.32	3.28e-9	Schizophrenia;
CRC	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.62	-7.68	-0.39	1.84e-13	Extraversion;
CRC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.92	-0.48	1.82e-20	Total cholesterol levels;
CRC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.24e-10	Dupuytren's disease;
CRC	cis	rs7707921	1.000	rs6888977	chr5:81533735	C/T	cg17942617	chr5:81327376	ATG10	-0.4	-5.99	-0.31	5.46e-9	Breast cancer;
CRC	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.68	0.43	1.93e-16	Morning vs. evening chronotype;
CRC	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg10483660	chr13:112241077	NA	-0.39	-6.48	-0.34	3.45e-10	Menarche (age at onset);
CRC	cis	rs7259376	0.936	rs8111537	chr19:22535545	C/G	cg02657401	chr19:22469223	NA	-0.31	-7.05	-0.36	1.08e-11	Menopause (age at onset);
CRC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.08	0.36	8.6e-12	Breast cancer;
CRC	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg21747405	chr11:67723411	NA	-0.58	-9.13	-0.45	6.88e-18	Blood pressure (smoking interaction);
CRC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04978709	chr7:75101039	POM121C	0.4	5.75	0.3	2.03e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17767392	0.881	rs34061264	chr14:71785276	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.0	-0.31	5.14e-9	Mitral valve prolapse;
CRC	trans	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	trans	rs2303319	0.504	rs41267437	chr2:162627391	G/A	cg04551154	chr10:95462393	C10orf4	-0.74	-5.98	-0.31	5.91e-9	Cognitive function;
CRC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.56	-9.51	-0.46	4.19e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.67	8.78	0.44	9.2e-17	Gut microbiome composition (summer);
CRC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg07074390	chr21:40555500	PSMG1	-0.47	-6.29	-0.33	1.03e-9	Cognitive function;
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13047869	chr3:10149882	C3orf24	0.51	7.07	0.36	9.31e-12	Alzheimer's disease;
CRC	cis	rs3741151	0.686	rs7944346	chr11:73244230	C/T	cg17517138	chr11:73019481	ARHGEF17	0.52	5.65	0.3	3.55e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.36	-6.67	-0.34	1.11e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg20119798	chr7:94954144	PON1	-0.52	-6.48	-0.34	3.39e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4926298	1.000	rs10423745	chr19:13176815	T/C	cg11738485	chr19:12877000	HOOK2	-0.43	-5.92	-0.31	8.27e-9	Bipolar disorder;
CRC	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	12.97	0.58	2.37e-31	Hip circumference;
CRC	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	6.22	0.32	1.54e-9	Ovarian reserve;
CRC	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.84e-10	Breast cancer;
CRC	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg25922125	chr7:127225783	GCC1	0.54	6.12	0.32	2.7e-9	Type 2 diabetes;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg15845792	chr6:28175446	NA	0.78	11.62	0.54	2.13e-26	Cardiac Troponin-T levels;
CRC	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg11993925	chr19:44307056	LYPD5	0.47	7.76	0.39	1.07e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.62	-0.39	2.71e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.43	-6.6	-0.34	1.63e-10	Colorectal cancer;
CRC	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.58	-6.5	-0.34	2.94e-10	Red blood cell count;
CRC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.69	0.3	2.78e-8	Tonsillectomy;
CRC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.45	-8.17	-0.41	6.8e-15	Total body bone mineral density;
CRC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.52	-9.28	-0.46	2.26e-18	Height;
CRC	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02097616	chr17:62675921	NA	-0.5	-7.07	-0.36	9.46e-12	QT interval;
CRC	cis	rs7781266	0.895	rs17658042	chr7:133302371	G/T	cg03336402	chr7:133662267	EXOC4	0.52	5.94	0.31	7.23e-9	Educational attainment (college completion);
CRC	cis	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg07480446	chr2:239069576	NA	-0.36	-6.74	-0.35	7.04e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg23071808	chr14:103021642	NA	-0.64	-7.25	-0.37	2.99e-12	Platelet count;
CRC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.73	-11.12	-0.52	1.37e-24	Lung cancer;
CRC	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.45	8.25	0.41	3.92e-15	Blood metabolite ratios;
CRC	cis	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg01991180	chr11:108092276	ATM;NPAT	-0.41	-6.02	-0.32	4.56e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg02033258	chr5:131593261	PDLIM4	0.32	5.83	0.31	1.32e-8	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14363992	chr6:27776350	HIST1H2AI;HIST1H3H;HIST1H2BL	0.44	6.31	0.33	9.11e-10	Response to antipsychotic treatment;
CRC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.58	8.02	0.4	1.87e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.44e-13	HDL cholesterol;
CRC	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg26353448	chr1:248524236	OR2T4	0.3	5.78	0.3	1.77e-8	Common traits (Other);
CRC	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.58	9.19	0.45	4.44e-18	Corneal astigmatism;
CRC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-5.86	-0.31	1.15e-8	Schizophrenia;
CRC	cis	rs11212617	0.967	rs662578	chr11:108194557	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.43	0.33	4.62e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-5.83	-0.31	1.32e-8	Alzheimer's disease (survival time);
CRC	cis	rs4654899	0.931	rs7543140	chr1:21180250	G/A	cg02927042	chr1:21476669	EIF4G3	0.4	6.42	0.33	4.83e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs10221833	0.602	rs429376	chr2:165634361	A/G	cg03182029	chr2:165697222	COBLL1	0.5	5.77	0.3	1.79e-8	Response to statin therapy;
CRC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-20.57	-0.75	5.09e-61	Height;
CRC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02290350	chr8:58132656	NA	-0.41	-5.86	-0.31	1.12e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs1549309	0.767	rs9313387	chr5:167173269	C/T	cg15316583	chr2:169312568	LASS6	0.53	6.39	0.33	5.6e-10	Dietary macronutrient intake;
CRC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.57	-8.73	-0.43	1.27e-16	Height;
CRC	trans	rs4955793	0.585	rs9854435	chr3:178624727	G/A	cg11644478	chr21:40555479	PSMG1	0.66	6.15	0.32	2.24e-9	Post-traumatic stress disorder (asjusted for relatedness);
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg19678392	chr7:94953810	PON1	-0.59	-7.31	-0.37	2.09e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs800082	0.516	rs1182797	chr3:144241495	T/C	cg24215973	chr2:240111563	HDAC4	0.46	6.54	0.34	2.34e-10	Smoking behavior;
CRC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.55	7.39	0.38	1.19e-12	Obesity-related traits;
CRC	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.76	-12.67	-0.57	3.03e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg06470822	chr6:28175283	NA	-0.52	-7.15	-0.37	5.64e-12	Systemic lupus erythematosus;
CRC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	7.79	0.39	8.63e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7113874	0.655	rs7945659	chr11:8529925	A/T	cg17679104	chr11:8615758	STK33	-0.35	-5.71	-0.3	2.58e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4728302	0.838	rs755664	chr7:133596671	C/G	cg10665199	chr7:133106180	EXOC4	0.39	5.79	0.3	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.95e-9	Depression;
CRC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.41	6.01	0.31	4.95e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg05569086	chr8:143859399	LYNX1	-0.54	-9.38	-0.46	1.12e-18	Urinary tract infection frequency;
CRC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg10760299	chr15:45669010	GATM	0.51	8.12	0.41	9.48e-15	Homoarginine levels;
CRC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.51	-7.95	-0.4	2.93e-14	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24543526	chr10:75911479	ADK;AP3M1	0.51	7.29	0.37	2.36e-12	Response to antipsychotic treatment;
CRC	trans	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg13751927	chr19:17000885	F2RL3	-0.36	-5.97	-0.31	6.08e-9	Primary biliary cholangitis;
CRC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	1.17	10.93	0.52	6.24e-24	Arsenic metabolism;
CRC	cis	rs7804356	1.000	rs12535784	chr7:26882067	G/A	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.09e-8	Type 1 diabetes;
CRC	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.06	0.52	2.21e-24	Exhaled nitric oxide output;
CRC	cis	rs703980	0.786	rs703982	chr10:80942721	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.37	-6.55	-0.34	2.19e-10	Type 2 diabetes;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03923535	chr7:1197113	ZFAND2A	0.67	9.45	0.46	6.77e-19	Longevity;Endometriosis;
CRC	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.52	6.6	0.34	1.67e-10	IgG glycosylation;
CRC	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-7.45	-0.38	8.43e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg25164649	chr6:28176230	NA	0.55	5.75	0.3	2e-8	Depression;
CRC	cis	rs10971721	0.822	rs72725377	chr9:33842226	T/C	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.92	-17.28	-0.69	4.8e-48	Height;
CRC	trans	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg09045935	chr12:6379348	NA	1.16	9.03	0.45	1.47e-17	Blood metabolite levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18073423	chr4:9514864	NA	0.39	6.29	0.33	1.01e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05602987	chr16:28834702	ATXN2L	0.44	7.13	0.37	6.33e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.47	6.76	0.35	6.36e-11	Pulse pressure;
CRC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg15744005	chr10:104629667	AS3MT	0.29	5.89	0.31	9.79e-9	Arsenic metabolism;
CRC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg12590608	chr7:158785262	NA	-0.36	-6.37	-0.33	6.33e-10	Facial morphology (factor 20);
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg03160526	chr17:80928410	B3GNTL1	0.59	8.04	0.41	1.69e-14	Glycated hemoglobin levels;
CRC	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.56	-8.28	-0.42	3.04e-15	Birth weight;
CRC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.52	-6.92	-0.36	2.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg06138931	chr13:21896616	NA	0.48	5.63	0.3	3.91e-8	White matter hyperintensity burden;
CRC	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.51	7.03	0.36	1.17e-11	Tuberculosis;
CRC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.99	0.36	1.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg01339444	chr6:118972232	C6orf204	0.53	5.86	0.31	1.12e-8	Diastolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25392384	chr7:150102268	LOC728743	0.43	6.14	0.32	2.38e-9	Anxiety disorder;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg20041105	chr8:143859282	LYNX1	-0.43	-7.16	-0.37	5.22e-12	Urinary tract infection frequency;
CRC	cis	rs12024301	0.557	rs12042704	chr1:183614433	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg24463073	chr6:118973353	C6orf204	0.49	6.37	0.33	6.29e-10	Diastolic blood pressure;
CRC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.75	13.72	0.6	3.47e-34	Cancer;
CRC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.99	0.68	6.28e-47	Platelet count;
CRC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.4	-6.1	-0.32	2.96e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	8.18	0.41	6.44e-15	Menarche (age at onset);
CRC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg21972741	chr5:435613	AHRR	0.47	6.46	0.34	3.73e-10	Cystic fibrosis severity;
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.8	15.25	0.64	4.21e-40	Prudent dietary pattern;
CRC	cis	rs6973256	0.543	rs13243553	chr7:133506955	A/G	cg03336402	chr7:133662267	EXOC4	0.41	5.74	0.3	2.15e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg18683604	chr14:51561293	TRIM9	0.29	6.0	0.31	5.11e-9	Cancer;
CRC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs7429990	0.932	rs9862913	chr3:48016172	T/C	cg11946769	chr3:48343235	NME6	0.43	5.71	0.3	2.58e-8	Educational attainment (years of education);
CRC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.46	6.78	0.35	5.42e-11	Melanoma;
CRC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.8e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg22561889	chr6:118971681	C6orf204	0.51	6.65	0.34	1.26e-10	Diastolic blood pressure;
CRC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.5	0.46	4.38e-19	Monocyte percentage of white cells;
CRC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.4	5.94	0.31	7.37e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs17234274	0.622	rs1947941	chr11:23237051	T/C	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.55	8.02	0.4	1.91e-14	Lung cancer;
CRC	cis	rs7527798	0.592	rs11118282	chr1:207832402	G/A	cg21110645	chr1:207815933	NA	-0.37	-5.88	-0.31	1.03e-8	Erythrocyte sedimentation rate;
CRC	cis	rs3087591	0.639	rs757378	chr17:29722619	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.69	-12.27	-0.56	9.06e-29	Hip circumference;
CRC	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg22677401	chr17:46026860	NA	-0.69	-6.05	-0.32	4e-9	Cognitive function;
CRC	trans	rs10504390	0.656	rs80115097	chr8:66551520	T/G	cg26403416	chr21:43771339	TFF2	0.59	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	trans	rs6600671	0.899	rs6674392	chr1:121260662	C/G	cg09829573	chr1:144692074	NBPF9	-0.41	-6.12	-0.32	2.69e-9	Hip geometry;
CRC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg18761221	chr20:60518478	NA	0.43	6.94	0.36	2.12e-11	Body mass index;
CRC	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.95	18.15	0.71	1.64e-51	Intelligence (multi-trait analysis);
CRC	cis	rs7712401	0.755	rs4283786	chr5:122101050	T/C	cg18764291	chr5:122110994	SNX2	0.41	6.5	0.34	3.02e-10	Mean platelet volume;
CRC	cis	rs12476592	0.571	rs112194	chr2:63876872	T/G	cg10828910	chr2:63850056	LOC388955	0.49	6.15	0.32	2.22e-9	Childhood ear infection;
CRC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.37	0.38	1.4e-12	Menopause (age at onset);
CRC	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	trans	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg17903999	chr18:56338584	MALT1	0.42	7.02	0.36	1.24e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06544989	chr22:39130855	UNC84B	0.49	7.99	0.4	2.25e-14	Menopause (age at onset);
CRC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-7.16	-0.37	5.15e-12	Colorectal cancer;
CRC	cis	rs10746514	1.000	rs1576618	chr1:232244331	A/G	cg09506761	chr1:232265262	NA	-0.43	-5.66	-0.3	3.34e-8	Response to statin therapy;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg07617317	chr6:118971624	C6orf204	0.5	6.21	0.32	1.56e-9	Diastolic blood pressure;
CRC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.72	-12.34	-0.56	5.16e-29	Age at first birth;
CRC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg14711859	chr11:8959438	ASCL3	-0.42	-6.81	-0.35	4.67e-11	Hemoglobin concentration;
CRC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	ch.11.42038R	chr11:967971	AP2A2	0.61	10.34	0.5	6.76e-22	Alzheimer's disease (late onset);
CRC	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg09324608	chr17:30823087	MYO1D	0.33	5.73	0.3	2.31e-8	Schizophrenia;
CRC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg14844989	chr11:31128820	NA	-0.35	-6.21	-0.32	1.64e-9	Red blood cell count;
CRC	cis	rs10887265	1	rs10887265	chr10:86015573	G/C	cg04757499	chr10:86016597	RGR	0.62	11.1	0.52	1.61e-24	Myopia;
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg07617317	chr6:118971624	C6orf204	0.49	6.07	0.32	3.58e-9	Diastolic blood pressure;
CRC	cis	rs73200209	0.744	rs7974638	chr12:116462700	C/G	cg01776926	chr12:116560359	MED13L	-0.62	-7.54	-0.38	4.72e-13	Total body bone mineral density;
CRC	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.69	12.32	0.56	5.96e-29	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.25	-0.53	4.65e-25	Coffee consumption (cups per day);
CRC	cis	rs7553864	0.518	rs10747341	chr1:87627331	G/A	cg09121047	chr1:87617328	LOC339524	0.51	8.4	0.42	1.33e-15	Smoking behavior;
CRC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg00383909	chr3:49044727	WDR6	0.44	5.68	0.3	2.91e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg09264619	chr17:80180166	NA	-0.36	-6.08	-0.32	3.37e-9	Life satisfaction;
CRC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.63	-10.35	-0.5	6.58e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9287719	0.649	rs12104950	chr2:10732105	G/A	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.3	-0.33	9.49e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.52	7.8	0.4	8.27e-14	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04611479	chr17:41910366	MPP3	0.47	6.14	0.32	2.41e-9	Anxiety disorder;
CRC	trans	rs800082	0.839	rs17282884	chr3:144319905	C/T	cg24215973	chr2:240111563	HDAC4	0.51	6.67	0.35	1.1e-10	Smoking behavior;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14425428	chr9:130743818	FAM102A	0.44	6.61	0.34	1.56e-10	Response to antipsychotic treatment;
CRC	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg01388757	chr2:102091195	RFX8	-0.37	-5.67	-0.3	3.21e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg20356878	chr3:121714668	ILDR1	0.51	6.7	0.35	8.97e-11	Multiple sclerosis;
CRC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.05	0.36	1.04e-11	Rheumatoid arthritis;
CRC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg15845792	chr6:28175446	NA	0.73	6.16	0.32	2.08e-9	Depression;
CRC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	11.09	0.52	1.77e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.69	0.43	1.78e-16	Height;
CRC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.73	9.65	0.47	1.43e-19	Bladder cancer;
CRC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg17948913	chr5:572064	NA	0.51	5.88	0.31	1.01e-8	Obesity-related traits;
CRC	cis	rs7587476	0.505	rs777323	chr2:215738485	A/G	cg04004882	chr2:215674386	BARD1	-0.58	-8.03	-0.4	1.73e-14	Neuroblastoma;
CRC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	1.01	9.56	0.47	2.83e-19	Lymphocyte counts;
CRC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.66e-23	Aortic root size;
CRC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.61	-11.52	-0.54	4.94e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.25	-0.37	3.02e-12	Morning vs. evening chronotype;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg00331096	chr20:22564947	FOXA2	-0.43	-6.54	-0.34	2.36e-10	Daytime sleep phenotypes;
CRC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.65	8.16	0.41	7.21e-15	Menarche (age at onset);
CRC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.94	0.36	2.08e-11	Mean platelet volume;
CRC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg21770322	chr7:97807741	LMTK2	0.51	8.38	0.42	1.54e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg00531865	chr16:30841666	NA	-0.44	-6.28	-0.33	1.05e-9	Dementia with Lewy bodies;
CRC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg15412446	chr2:106886593	NA	-0.5	-6.97	-0.36	1.7e-11	Facial morphology (factor 23);
CRC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg22482690	chr17:47019901	SNF8	0.49	8.19	0.41	5.85e-15	Type 2 diabetes;
CRC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.42	-9.05	-0.45	1.25e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20227976	chr9:35757314	NA	0.45	6.85	0.35	3.59e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg27427491	chr17:78079615	GAA	-0.44	-7.01	-0.36	1.4e-11	Yeast infection;
CRC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.67	-10.1	-0.49	4.48e-21	Diastolic blood pressure;
CRC	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg16589663	chr20:23618590	CST3	0.57	7.3	0.37	2.16e-12	Chronic kidney disease;
CRC	cis	rs6429082	0.967	rs704709	chr1:235620964	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	6.56	0.34	2.14e-10	Adiposity;
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.43	-6.4	-0.33	5.2e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.52	0.46	3.92e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.6	8.73	0.43	1.35e-16	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01956147	chr2:17935879	GEN1;SMC6	0.36	6.04	0.32	4.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7705042	0.865	rs249641	chr5:141525305	A/G	cg07392085	chr5:141489673	NDFIP1	0.45	7.25	0.37	2.94e-12	Asthma;
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02290350	chr8:58132656	NA	-0.59	-8.03	-0.4	1.7e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg15845792	chr6:28175446	NA	0.49	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2227564	0.700	rs12413039	chr10:75524759	C/G	cg00564723	chr10:75632066	CAMK2G	0.31	7.09	0.36	8.28e-12	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs983332	0.512	rs17130136	chr1:88213827	A/C	cg09221037	chr5:1523205	LPCAT1	0.63	6.12	0.32	2.65e-9	Response to TNF antagonist treatment;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.37	6.4	0.33	5.31e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.68	7.59	0.39	3.38e-13	Iron status biomarkers;
CRC	cis	rs216303	1.000	rs216294	chr12:6153750	A/G	cg19878637	chr12:6148451	VWF	-0.6	-6.47	-0.34	3.58e-10	Low vWF levels;
CRC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.95	0.52	5.37e-24	Systolic blood pressure;
CRC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.27	-0.37	2.58e-12	Bipolar disorder;
CRC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.63	10.91	0.52	7.24e-24	Schizophrenia;
CRC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.4	0.42	1.4e-15	Smoking initiation;
CRC	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg27534772	chr1:16042836	PLEKHM2	0.42	6.95	0.36	2.02e-11	Systolic blood pressure;
CRC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg18016565	chr1:150552671	MCL1	-0.45	-6.73	-0.35	7.71e-11	Tonsillectomy;
CRC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg14008862	chr17:28927542	LRRC37B2	0.49	6.1	0.32	2.96e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.88e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg04362960	chr10:104952993	NT5C2	-0.49	-6.19	-0.32	1.81e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.31	7.57	0.38	3.91e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.03e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs995000	0.931	rs7548877	chr1:63005950	T/C	cg19896129	chr1:63156450	NA	-0.45	-7.04	-0.36	1.15e-11	Triglyceride levels;
CRC	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-6.21	-0.32	1.6e-9	Blood pressure;
CRC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.36	-6.33	-0.33	8.18e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12745968	0.587	rs1034218	chr1:93049131	A/G	cg17283838	chr1:93427260	FAM69A	-0.45	-6.17	-0.32	2.06e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.71	-11.66	-0.54	1.6e-26	Cognitive function;
CRC	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg16898833	chr6:26189333	HIST1H4D	0.89	7.28	0.37	2.4e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg15226275	chr6:116381976	FRK	0.29	8.15	0.41	7.73e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg18867708	chr6:26865862	GUSBL1	0.38	5.78	0.3	1.69e-8	Schizophrenia;
CRC	cis	rs6893300	0.560	rs1019443	chr5:179207547	A/G	cg14593053	chr5:179126677	CANX	-0.51	-8.15	-0.41	7.69e-15	Resting heart rate;
CRC	trans	rs7302981	0.667	rs7136648	chr12:50624822	A/G	cg00474734	chr12:53645975	MFSD5	-0.38	-6.04	-0.32	4.17e-9	Systolic blood pressure;
CRC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.86	-10.18	-0.49	2.47e-21	Breast cancer;
CRC	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	15.05	0.64	2.65e-39	Intelligence (multi-trait analysis);
CRC	cis	rs2424590	1.000	rs2424590	chr20:23636980	C/T	cg16589663	chr20:23618590	CST3	-0.54	-6.72	-0.35	7.93e-11	Blood protein levels;
CRC	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg15845792	chr6:28175446	NA	0.7	7.6	0.39	3.02e-13	Parkinson's disease;
CRC	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.51	0.54	5.29e-26	Bipolar disorder;
CRC	cis	rs9322817	0.691	rs2486135	chr6:105282263	C/T	cg02098413	chr6:105308735	HACE1	0.44	8.72	0.43	1.41e-16	Thyroid stimulating hormone;
CRC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.54	-8.36	-0.42	1.76e-15	Asthma (sex interaction);
CRC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	8.31	0.42	2.51e-15	LDL cholesterol;Cholesterol, total;
CRC	trans	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg24644049	chr4:85504048	CDS1	0.74	7.25	0.37	2.95e-12	Skin colour saturation;
CRC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.49	6.55	0.34	2.24e-10	Cleft lip with or without cleft palate;
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg20041105	chr8:143859282	LYNX1	0.47	8.27	0.41	3.43e-15	Urinary tract infection frequency;
CRC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.92	-0.4	3.73e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs75804782	0.625	rs11889723	chr2:239471469	A/G	cg21861151	chr2:239478365	NA	-0.46	-6.23	-0.32	1.44e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs6066835	0.572	rs6066809	chr20:47273119	T/C	cg18078177	chr20:47281410	PREX1	0.8	6.04	0.32	4.22e-9	Multiple myeloma;
CRC	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg09760422	chr2:128146352	NA	-0.37	-7.24	-0.37	3.17e-12	Protein C levels;
CRC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-11.03	-0.52	2.77e-24	Hepatocellular carcinoma;
CRC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.66	12.14	0.56	2.9e-28	Aortic root size;
CRC	cis	rs4700695	0.764	rs37018	chr5:65366645	A/G	cg21114390	chr5:65439923	SFRS12	0.56	6.6	0.34	1.63e-10	Facial morphology (factor 19);
CRC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.77	-0.3	1.8e-8	Monocyte percentage of white cells;
CRC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.56	-8.54	-0.43	4.98e-16	Height;
CRC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg12365402	chr11:9010492	NRIP3	0.47	7.5	0.38	6.18e-13	Hemoglobin concentration;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.98	0.31	5.78e-9	Electroencephalogram traits;
CRC	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.86	-0.31	1.14e-8	Neuroticism;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00166722	chr3:10149974	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.89	-0.48	2.25e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7517126	1.000	rs35445694	chr1:196838865	A/T	cg13682187	chr1:196946512	CFHR5	-0.4	-6.26	-0.33	1.17e-9	Blood protein levels;
CRC	cis	rs2860975	1.000	rs11188133	chr10:96772015	G/A	cg09036531	chr10:96991505	NA	-0.44	-5.85	-0.31	1.18e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg11130432	chr3:121712080	ILDR1	-0.51	-6.64	-0.34	1.28e-10	Multiple sclerosis;
CRC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.6	-9.31	-0.46	1.85e-18	Intelligence (multi-trait analysis);
CRC	cis	rs449789	0.857	rs9346784	chr6:159703757	G/T	cg14500486	chr6:159655392	FNDC1	-0.48	-7.37	-0.38	1.36e-12	Pulse pressure;
CRC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.07	0.32	3.5e-9	Monocyte percentage of white cells;
CRC	cis	rs8016982	0.589	rs4640110	chr14:81692191	A/G	cg01989461	chr14:81687754	GTF2A1	-0.43	-5.68	-0.3	2.97e-8	Schizophrenia;
CRC	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg20312557	chr2:97357134	FER1L5	-0.6	-5.6	-0.3	4.5e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.89	-0.31	9.31e-9	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02712401	chr12:6961946	USP5;CDCA3	0.45	6.26	0.33	1.17e-9	Response to antipsychotic treatment;
CRC	cis	rs7192380	0.737	rs7204433	chr16:69589924	A/G	cg00738113	chr16:70207722	CLEC18C	-0.33	-5.81	-0.3	1.5e-8	Sjögren's syndrome;
CRC	cis	rs3106136	0.609	rs11097406	chr4:95146042	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.74	-0.35	6.98e-11	Capecitabine sensitivity;
CRC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20887711	chr4:1340912	KIAA1530	0.39	5.68	0.3	2.91e-8	Obesity-related traits;
CRC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg12311346	chr5:56204834	C5orf35	0.45	6.92	0.36	2.43e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-9.18	-0.45	4.84e-18	HDL cholesterol;
CRC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.82	12.72	0.57	2.08e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.86	0.44	5.07e-17	Bladder cancer;
CRC	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	5.6	0.3	4.47e-8	Height;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg21548813	chr6:291882	DUSP22	-0.51	-7.11	-0.36	7.24e-12	Menopause (age at onset);
CRC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.71	-13.47	-0.6	2.98e-33	Breast cancer;
CRC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.46	6.01	0.31	4.83e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.45	-6.44	-0.33	4.13e-10	Lymphocyte counts;
CRC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06636001	chr8:8085503	FLJ10661	0.46	5.91	0.31	8.32e-9	Obesity-related traits;
CRC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.57	7.54	0.38	4.59e-13	Mean platelet volume;
CRC	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12560992	chr17:57184187	TRIM37	0.52	7.25	0.37	2.94e-12	Testicular germ cell tumor;
CRC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-6.71	-0.35	8.58e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-7.85	-0.4	6.01e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.61e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs12580194	0.593	rs61957924	chr12:55744100	T/C	cg19537932	chr12:55886519	OR6C68	-0.66	-8.57	-0.43	4.1e-16	Cancer;
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.48	6.41	0.33	5e-10	Height;
CRC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg01483505	chr11:975446	AP2A2	0.41	6.29	0.33	1.03e-9	Alzheimer's disease (late onset);
CRC	trans	rs8097070	0.661	rs9966711	chr18:23171413	C/G	cg10330149	chr12:112820238	NA	0.53	5.97	0.31	6.24e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg07713946	chr22:31675144	LIMK2	-0.4	-5.75	-0.3	2e-8	Colorectal cancer;
CRC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.37	0.46	1.23e-18	Lymphocyte counts;
CRC	cis	rs910187	0.596	rs6066222	chr20:45801917	G/A	cg27589058	chr20:45804311	EYA2	-0.44	-8.76	-0.44	1.02e-16	Migraine;
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.66	7.53	0.38	4.88e-13	Body mass index;
CRC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.6	-0.39	3.13e-13	Eye color traits;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.42	5.64	0.3	3.6e-8	Longevity;Endometriosis;
CRC	cis	rs10760158	0.800	rs4837829	chr9:124045958	T/C	cg14417974	chr9:124058376	GSN	-0.33	-5.63	-0.3	3.83e-8	Pulse pressure;
CRC	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg21452805	chr1:244014465	NA	0.46	6.15	0.32	2.27e-9	RR interval (heart rate);
CRC	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	0.94	10.19	0.49	2.23e-21	Mitochondrial DNA levels;
CRC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg18016565	chr1:150552671	MCL1	0.42	5.94	0.31	7.1e-9	Melanoma;
CRC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.51	9.06	0.45	1.19e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.38	-11.34	-0.53	2.14e-25	Psoriasis vulgaris;
CRC	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.71	7.96	0.4	2.75e-14	Systolic blood pressure;
CRC	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg12315302	chr6:26189340	HIST1H4D	0.8	6.29	0.33	1.02e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg05585544	chr11:47624801	NA	0.61	11.2	0.53	7.1e-25	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12531003	chr19:56152621	ZNF580	0.45	6.72	0.35	7.82e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3996993	0.809	rs3957357	chr6:52668687	A/G	cg20803780	chr6:52668592	GSTA1	-0.38	-7.01	-0.36	1.38e-11	Hemoglobin concentration;
CRC	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Corneal astigmatism;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg18301423	chr5:131593218	PDLIM4	0.38	6.35	0.33	6.95e-10	Breast cancer;
CRC	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.73	-8.37	-0.42	1.72e-15	Systolic blood pressure;
CRC	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	11.16	0.52	9.41e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.86	0.35	3.42e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	ch.11.42038R	chr11:967971	AP2A2	0.58	10.03	0.48	7.98e-21	Alzheimer's disease (late onset);
CRC	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.38	-5.63	-0.3	3.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg09417038	chr21:47716443	C21orf57	0.38	6.21	0.32	1.6e-9	Testicular germ cell tumor;
CRC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.82	8.7	0.43	1.59e-16	Plasma clusterin levels;
CRC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.02	0.4	1.83e-14	Platelet count;
CRC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.36	5.77	0.3	1.79e-8	Total body bone mineral density;
CRC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.43	5.89	0.31	9.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.81	-12.16	-0.56	2.29e-28	Multiple sclerosis;
CRC	trans	rs72862334	0.684	rs72861062	chr2:146556359	C/A	cg04759376	chr10:77190437	NA	0.59	5.96	0.31	6.43e-9	Coronary artery disease;
CRC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.54	-8.69	-0.43	1.73e-16	Testicular germ cell tumor;
CRC	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg13615338	chr4:55094005	PDGFRA	0.42	6.19	0.32	1.81e-9	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs62187611	chr2:162431946	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.24	-0.33	1.33e-9	Cognitive function;
CRC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.07	0.45	1.11e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg18404041	chr3:52824283	ITIH1	0.38	7.02	0.36	1.3e-11	Schizophrenia;
CRC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.32	-6.46	-0.34	3.77e-10	Renal cell carcinoma;
CRC	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.69	5.66	0.3	3.36e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6838801	1.000	rs6838801	chr4:77549559	G/T	cg17476223	chr4:77663285	SHROOM3	0.41	5.63	0.3	3.93e-8	Cleft lip with or without cleft palate;
CRC	cis	rs4664293	0.867	rs6432554	chr2:160579084	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.72	12.05	0.55	5.88e-28	Mean platelet volume;
CRC	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.34	-9.25	-0.45	2.91e-18	Mean corpuscular volume;
CRC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg05044414	chr3:183734942	ABCC5	0.48	8.31	0.42	2.56e-15	Anterior chamber depth;
CRC	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg20503657	chr10:835505	NA	0.59	7.57	0.39	3.84e-13	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg01874867	chr7:94954059	PON1	-0.5	-6.33	-0.33	8.15e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	0.84	7.64	0.39	2.34e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-12.09	-0.55	4.31e-28	Developmental language disorder (linguistic errors);
CRC	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg17145862	chr1:211918768	LPGAT1	-0.5	-8.2	-0.41	5.35e-15	Leprosy;
CRC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg24140574	chr1:16342155	HSPB7	0.44	5.8	0.3	1.57e-8	Dilated cardiomyopathy;
CRC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.15	0.45	6.02e-18	Monocyte percentage of white cells;
CRC	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.46	-5.82	-0.31	1.43e-8	Alopecia areata;
CRC	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg09659197	chr4:152720779	NA	0.51	10.85	0.51	1.17e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs11687702	chr2:15682857	T/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.34	3.01e-10	Bipolar disorder;
CRC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.41	6.01	0.31	4.89e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.68	6.74	0.35	7.29e-11	Fat distribution (HIV);
CRC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.7	9.7	0.47	9.68e-20	Bladder cancer;
CRC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.35	5.71	0.3	2.59e-8	Colonoscopy-negative controls vs population controls;
CRC	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.02	-14.1	-0.61	1.25e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg25600027	chr14:23388339	RBM23	-0.54	-8.4	-0.42	1.34e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs10097731	0.901	rs4398860	chr8:82041753	C/T	cg25230327	chr8:82042993	NA	-0.94	-13.46	-0.6	3.4e-33	Serum total protein level;
CRC	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.63	-9.72	-0.47	8.4e-20	Testicular germ cell tumor;
CRC	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.46	0.34	3.82e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg11843238	chr5:131593191	PDLIM4	0.3	5.64	0.3	3.74e-8	Blood metabolite levels;
CRC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg14074117	chr16:1909714	C16orf73	-0.4	-5.66	-0.3	3.37e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs3018066	0.867	rs13101612	chr4:107128360	A/G	cg01869342	chr4:106983673	TBCK	-0.36	-5.63	-0.3	3.76e-8	Cancer;
CRC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.49	6.52	0.34	2.58e-10	White matter hyperintensity burden;
CRC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg16817229	chr21:42798199	MX1	-0.39	-5.63	-0.3	3.89e-8	IgG glycosylation;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg25164649	chr6:28176230	NA	0.78	9.69	0.47	1.04e-19	Depression;
CRC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg11518657	chr1:67396239	MIER1	0.55	5.93	0.31	7.58e-9	Lymphocyte percentage of white cells;
CRC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.76	-0.3	1.96e-8	Schizophrenia;
CRC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.57	-8.48	-0.42	7.87e-16	Sudden cardiac arrest;
CRC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.44	-6.48	-0.34	3.34e-10	Menarche (age at onset);
CRC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.81	0.35	4.57e-11	Mean platelet volume;
CRC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-9.96	-0.48	1.35e-20	Coronary artery disease;
CRC	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg01493522	chr13:37497338	NA	-0.52	-7.16	-0.37	5.21e-12	Coronary artery disease;
CRC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg22753661	chr15:79092743	ADAMTS7	0.43	5.9	0.31	9.09e-9	Coronary artery disease or large artery stroke;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg19913688	chr11:428466	ANO9	-0.68	-7.0	-0.36	1.44e-11	Body mass index;
CRC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.85	0.58	6.71e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.3	-0.49	9.43e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22038928	chr6:166756117	SFT2D1	0.4	6.27	0.33	1.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg06470822	chr6:28175283	NA	0.96	13.78	0.6	2.07e-34	Depression;
CRC	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg05540913	chr6:167530185	CCR6	-0.41	-7.4	-0.38	1.18e-12	Primary biliary cholangitis;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg11843238	chr5:131593191	PDLIM4	0.51	8.91	0.44	3.46e-17	Acylcarnitine levels;
CRC	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg27053337	chr8:124217698	FAM83A	0.47	6.97	0.36	1.78e-11	Urinary uromodulin levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17958798	chr17:7200008	NA	0.45	6.26	0.33	1.21e-9	Survival in pancreatic cancer;
CRC	cis	rs9292777	0.777	rs1992662	chr5:40393852	A/G	cg09067459	chr5:40385259	NA	-0.57	-9.39	-0.46	1.01e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.22	-0.41	4.63e-15	Gut microbiome composition (summer);
CRC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.65	12.05	0.55	5.91e-28	Prostate cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03403966	chr4:85504051	CDS1	0.43	6.05	0.32	3.99e-9	Anxiety disorder;
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg22638593	chr5:131593259	PDLIM4	0.41	7.61	0.39	2.95e-13	Breast cancer;
CRC	trans	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg17145862	chr1:211918768	LPGAT1	-0.67	-12.37	-0.56	3.86e-29	Leprosy;
CRC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.98	-0.36	1.62e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg15845792	chr6:28175446	NA	0.79	11.66	0.54	1.55e-26	Parkinson's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06370862	chr6:50680748	TFAP2D	-0.42	-6.66	-0.34	1.12e-10	Aortic root size;
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg20119798	chr7:94954144	PON1	-0.49	-6.26	-0.33	1.21e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.68	-0.51	4.62e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.68	-11.53	-0.54	4.57e-26	White blood cell count (basophil);
CRC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg03160526	chr17:80928410	B3GNTL1	0.51	8.34	0.42	2.09e-15	Breast cancer;
CRC	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg11204139	chr17:3907470	NA	0.47	5.69	0.3	2.8e-8	Type 2 diabetes;
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.37	-0.33	6.46e-10	Total body bone mineral density;
CRC	cis	rs10924970	0.625	rs2789370	chr1:235503256	A/G	cg09010748	chr1:235293032	TOMM20	-0.44	-6.14	-0.32	2.39e-9	Asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14496862	chr7:100888369	FIS1	0.4	6.11	0.32	2.85e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.47	-0.38	7.34e-13	Major depressive disorder;
CRC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.94	14.72	0.63	5.16e-38	Primary sclerosing cholangitis;
CRC	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.45	0.5	2.84e-22	Corneal astigmatism;
CRC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.61	9.28	0.46	2.3e-18	Corneal astigmatism;
CRC	cis	rs992157	0.644	rs6741757	chr2:219182748	T/C	cg04880052	chr2:219191631	PNKD	0.41	6.15	0.32	2.3e-9	Colorectal cancer;
CRC	trans	rs10858396	0.957	rs7029858	chr9:138273821	C/T	cg05258489	chr8:61593179	CHD7	0.5	6.35	0.33	7.17e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00215801	chr6:34855797	TAF11;ANKS1A	0.41	6.8	0.35	5.01e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15459742	chr9:111775564	CTNNAL1	0.48	6.92	0.36	2.39e-11	Response to antipsychotic treatment;
CRC	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg18551225	chr6:44695536	NA	-0.42	-6.07	-0.32	3.55e-9	Total body bone mineral density;
CRC	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.24	-0.37	3.19e-12	Crohn's disease;
CRC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs3026101	0.671	rs739767	chr17:5290681	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.43	6.95	0.36	1.94e-11	Sitting height ratio;
CRC	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-7.41	-0.38	1.04e-12	Hepatocellular carcinoma;
CRC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg27398640	chr15:77910606	LINGO1	-0.45	-7.78	-0.39	9.51e-14	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08348959	chr3:10290087	TATDN2	0.4	6.21	0.32	1.63e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg15511327	chr8:143859410	LYNX1	-0.38	-6.0	-0.31	5.14e-9	Urinary tract infection frequency;
CRC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.44	6.62	0.34	1.49e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.61	-9.81	-0.48	4.3e-20	Dental caries;
CRC	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.74	11.44	0.53	9.57e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.68	-0.47	1.14e-19	Hip circumference adjusted for BMI;
CRC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg06634786	chr22:41940651	POLR3H	-0.44	-5.61	-0.3	4.24e-8	Neuroticism;
CRC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg04117972	chr1:227635322	NA	0.68	7.58	0.39	3.61e-13	Major depressive disorder;
CRC	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.63	-9.6	-0.47	2.13e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6604026	0.698	rs2492294	chr1:93346566	C/G	cg17283838	chr1:93427260	FAM69A	-0.44	-5.69	-0.3	2.76e-8	Multiple sclerosis;
CRC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	13.22	0.59	2.72e-32	Mean platelet volume;
CRC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.01	-0.31	4.86e-9	Gut microbiome composition (summer);
CRC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.8	0.51	1.8e-23	Motion sickness;
CRC	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg25856811	chr1:152973957	SPRR3	-0.23	-6.16	-0.32	2.09e-9	Inflammatory skin disease;
CRC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg11657440	chr19:46296263	DMWD	0.71	12.29	0.56	7.64e-29	Coronary artery disease;
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg07414643	chr4:187882934	NA	-0.43	-7.13	-0.37	6.45e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07211739	chr21:34914437	SON;GART	0.46	6.38	0.33	5.9e-10	Anxiety disorder;
CRC	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg08501292	chr6:25962987	TRIM38	0.99	9.48	0.46	5.43e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg05941027	chr17:61774174	LIMD2	-0.37	-6.49	-0.34	3.1e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs863345	0.604	rs7549581	chr1:158489704	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.48	5.87	0.31	1.08e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg18761221	chr20:60518478	NA	0.46	7.44	0.38	9e-13	Body mass index;
CRC	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg06172871	chr16:72088244	HP	0.43	6.27	0.33	1.15e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg17691542	chr6:26056736	HIST1H1C	0.41	5.64	0.3	3.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-13.79	-0.61	1.94e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.5	-8.0	-0.4	2.13e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg06470822	chr6:28175283	NA	-0.74	-10.77	-0.51	2.23e-23	Parkinson's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11190155	chr3:9975447	CRELD1	-0.55	-6.7	-0.35	9.25e-11	Diisocyanate-induced asthma;
CRC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.5	0.34	2.92e-10	Body mass index;
CRC	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-1.04	-14.75	-0.63	3.79e-38	Exhaled nitric oxide output;
CRC	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg01388757	chr2:102091195	RFX8	0.65	8.7	0.43	1.61e-16	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs965469	0.947	rs56689368	chr20:3332921	G/A	cg25506879	chr20:3388711	C20orf194	-0.39	-5.81	-0.31	1.44e-8	IFN-related cytopenia;
CRC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.47	7.49	0.38	6.54e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.54	-7.49	-0.38	6.31e-13	Body mass index;
CRC	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.76	-8.02	-0.4	1.83e-14	Recalcitrant atopic dermatitis;
CRC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.41	7.84	0.4	6.48e-14	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18202627	chr2:200776533	C2orf69	0.47	6.45	0.34	3.95e-10	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04971341	chr1:52607910	ZFYVE9	0.45	6.42	0.33	4.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.63	9.41	0.46	9.14e-19	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.69	-11.09	-0.52	1.72e-24	Lung cancer;
CRC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.69	-7.76	-0.39	1.08e-13	Body mass index;
CRC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg13206674	chr6:150067644	NUP43	0.51	6.81	0.35	4.79e-11	Testicular germ cell tumor;
CRC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg08270630	chr22:50330655	NA	-0.41	-6.29	-0.33	1.03e-9	Schizophrenia;
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.51	-7.23	-0.37	3.32e-12	Lymphocyte counts;
CRC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-7.01	-0.36	1.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-8.99	-0.44	2.02e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.63	-7.19	-0.37	4.38e-12	Hip circumference adjusted for BMI;
CRC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.71	-7.34	-0.37	1.74e-12	Magnesium levels;
CRC	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.1	-0.45	9.11e-18	Cancer;
CRC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.09	-0.32	3.08e-9	Menopause (age at onset);
CRC	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.55	-0.38	4.26e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.54	-9.39	-0.46	1.05e-18	Lung function (FVC);
CRC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.75	10.75	0.51	2.64e-23	High light scatter reticulocyte count;
CRC	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg01620082	chr3:125678407	NA	-0.85	-6.73	-0.35	7.41e-11	Depression;
CRC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.37	-0.38	1.41e-12	Mean corpuscular volume;
CRC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.85	15.01	0.64	3.63e-39	Blood protein levels;
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs2257205	0.667	rs8081074	chr17:56836596	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.47	-6.55	-0.34	2.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.42	-0.38	1e-12	Lymphocyte counts;
CRC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.72	-10.82	-0.51	1.47e-23	Platelet distribution width;
CRC	cis	rs10068717	1	rs10068717	chr5:141494934	C/T	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.88	-0.31	9.9e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18110333	chr6:292329	DUSP22	-0.57	-8.37	-0.42	1.68e-15	Menopause (age at onset);
CRC	trans	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg24628676	chr5:59189846	PDE4D	-0.3	-6.05	-0.32	4.05e-9	Urinary tract infection frequency;
CRC	cis	rs728616	0.510	rs17679603	chr10:82181434	C/T	cg05935833	chr10:81318306	SFTPA2	-0.56	-6.44	-0.33	4.24e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.42	-6.12	-0.32	2.71e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02794174	chr8:61564980	NA	0.43	6.61	0.34	1.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	0.38	5.83	0.31	1.31e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2786111	0.898	rs1764792	chr1:197281941	A/G	cg13682187	chr1:196946512	CFHR5	0.29	5.71	0.3	2.51e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg21251018	chr6:28226885	NKAPL	0.45	7.14	0.37	5.87e-12	Depression;
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg21155852	chr7:2048760	MAD1L1	-0.46	-5.98	-0.31	5.77e-9	Neuroticism;
CRC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg18764771	chr6:116381957	FRK	0.25	7.1	0.36	7.67e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg24463073	chr6:118973353	C6orf204	0.52	6.55	0.34	2.24e-10	Diastolic blood pressure;
CRC	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg20737812	chr15:86336631	KLHL25	-0.34	-5.64	-0.3	3.74e-8	Coronary artery disease;
CRC	cis	rs364477	0.904	rs279897	chr9:966257	T/G	cg13952963	chr9:998547	NA	0.57	6.21	0.32	1.61e-9	Major depressive disorder;
CRC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.64	-0.3	3.67e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.87	0.44	4.67e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2415984	0.622	rs2415998	chr14:46930712	A/G	cg14871534	chr14:47121158	RPL10L	-0.43	-6.16	-0.32	2.17e-9	Number of children ever born;
CRC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.54	5.81	0.3	1.49e-8	Vitiligo;
CRC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.59	-8.21	-0.41	5.1e-15	Platelet distribution width;
CRC	trans	rs4538475	0.790	rs11934811	chr4:15738253	A/G	cg13752949	chr16:19535313	CP110	0.57	6.03	0.32	4.53e-9	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.29	0.37	2.3e-12	Life satisfaction;
CRC	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.79	0.39	8.9e-14	Height;
CRC	cis	rs995000	0.965	rs10889332	chr1:62950858	A/G	cg19896129	chr1:63156450	NA	-0.41	-6.13	-0.32	2.46e-9	Triglyceride levels;
CRC	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.54	0.38	4.76e-13	Eye color traits;
CRC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-6.1	-0.32	2.9e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.56	-11.51	-0.54	5.49e-26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00295448	chr5:140044129	WDR55	0.58	8.39	0.42	1.42e-15	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.32	-0.49	8e-22	Bipolar disorder;
CRC	cis	rs9409565	0.586	rs9409547	chr9:97212196	A/C	cg04523069	chr9:97136363	HIATL1	0.43	5.98	0.31	5.7e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs12760731	0.565	rs12027723	chr1:178090271	A/T	cg00404053	chr1:178313656	RASAL2	1.07	11.38	0.53	1.64e-25	Obesity-related traits;
CRC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg24011408	chr12:48396354	COL2A1	0.44	6.1	0.32	3.03e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	6.09	0.32	3.23e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg22638593	chr5:131593259	PDLIM4	0.48	8.69	0.43	1.74e-16	Blood metabolite levels;
CRC	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-10.27	-0.49	1.25e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.89	-0.31	9.48e-9	Alcohol dependence;
CRC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	13.69	0.6	4.67e-34	Platelet count;
CRC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.93	0.31	7.84e-9	Heart rate;
CRC	cis	rs4925540	0.724	rs2453407	chr1:247172257	A/G	cg22502715	chr1:247171572	ZNF695	-0.44	-6.5	-0.34	2.93e-10	Response to taxane treatment (docetaxel);
CRC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg15845792	chr6:28175446	NA	0.77	6.27	0.33	1.12e-9	Depression;
CRC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.97	11.69	0.54	1.21e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.72	-11.3	-0.53	3.12e-25	Menarche (age at onset);
CRC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.11	-0.36	7.33e-12	Gut microbiome composition (summer);
CRC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.55	6.11	0.32	2.76e-9	Cannabis dependence symptom count;
CRC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg23758597	chr6:163146217	PARK2	-0.68	-6.91	-0.36	2.46e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.4	5.77	0.3	1.86e-8	Diastolic blood pressure;
CRC	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.4	6.1	0.32	3.05e-9	Red blood cell count;
CRC	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg11204139	chr17:3907470	NA	0.74	13.48	0.6	2.91e-33	Type 2 diabetes;
CRC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.55	8.93	0.44	2.99e-17	Mean corpuscular volume;
CRC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg21399703	chr1:247681439	NA	0.52	8.38	0.42	1.59e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.9	15.78	0.66	3.81e-42	Fuchs's corneal dystrophy;
CRC	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg08917208	chr2:24149416	ATAD2B	0.9	8.35	0.42	1.92e-15	Lymphocyte counts;
CRC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg10935138	chr17:73851978	WBP2	0.52	6.56	0.34	2.08e-10	Psoriasis;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg27094323	chr7:1216898	NA	0.38	6.21	0.32	1.58e-9	Longevity;Endometriosis;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11081941	chr7:30518533	NOD1	0.38	6.32	0.33	8.67e-10	Obesity-related traits;
CRC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg17545662	chr6:170176663	C6orf70	0.54	5.98	0.31	5.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.63	8.13	0.41	8.77e-15	Gut microbiome composition (summer);
CRC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.64	9.08	0.45	1.02e-17	Height;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	6.21	0.32	1.55e-9	Renal function-related traits (BUN);
CRC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.44	5.79	0.3	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10189230	0.643	rs2710503	chr2:222374699	C/G	cg14652038	chr2:222343519	EPHA4	-0.33	-5.66	-0.3	3.35e-8	Urate levels in lean individuals;
CRC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.43	6.62	0.34	1.48e-10	High light scatter reticulocyte count;
CRC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-8.86	-0.44	5.04e-17	Extrinsic epigenetic age acceleration;
CRC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg24343755	chr10:26987087	PDSS1	-0.5	-6.4	-0.33	5.22e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg16447950	chr5:562315	NA	-0.84	-11.42	-0.53	1.19e-25	Lung disease severity in cystic fibrosis;
CRC	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.55	10.01	0.48	9.31e-21	Blood metabolite ratios;
CRC	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg25008857	chr14:105974488	NA	0.52	7.88	0.4	4.91e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg23202291	chr11:1979235	NA	0.51	7.5	0.38	5.92e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.34	-6.18	-0.32	1.91e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6896969	0.510	rs10042027	chr5:40428811	G/A	cg09067459	chr5:40385259	NA	0.45	7.75	0.39	1.19e-13	Multiple sclerosis;
CRC	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.46	6.72	0.35	8.23e-11	Body mass index;
CRC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	11.6	0.54	2.54e-26	Mean platelet volume;
CRC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.71	0.63	5.5e-38	Lymphocyte percentage of white cells;
CRC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.77	10.29	0.49	1.06e-21	Platelet count;
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg15511327	chr8:143859410	LYNX1	0.41	7.15	0.37	5.7e-12	Urinary tract infection frequency;
CRC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg03894339	chr8:19674705	INTS10	0.42	5.73	0.3	2.21e-8	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14872888	chr22:39189885	DNAL4	0.45	6.36	0.33	6.56e-10	Survival in pancreatic cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg03086376	chr16:1876114	HAGH;FAHD1	-0.42	-6.73	-0.35	7.36e-11	Aortic root size;
CRC	cis	rs2179367	0.959	rs9285519	chr6:149692935	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.42	-6.62	-0.34	1.48e-10	Dupuytren's disease;
CRC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.38	6.36	0.33	6.76e-10	Height;
CRC	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.6	6.07	0.32	3.44e-9	Thyroid stimulating hormone;
CRC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.1	12.65	0.57	3.66e-30	Psoriasis vulgaris;
CRC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14895029	chr7:2775587	GNA12	-0.4	-5.97	-0.31	6.15e-9	Height;
CRC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.14	0.32	2.38e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg11707556	chr5:10655725	ANKRD33B	0.38	6.96	0.36	1.88e-11	Coronary artery disease;
CRC	cis	rs2380220	0.808	rs2386669	chr6:95902121	C/T	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg23172400	chr8:95962367	TP53INP1	-0.42	-6.83	-0.35	4.1e-11	Type 2 diabetes;
CRC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-7.54	-0.38	4.63e-13	Major depressive disorder;
CRC	cis	rs17713451	0.593	rs7807134	chr7:151268590	T/C	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06671352	chr3:128399555	NA	0.47	6.63	0.34	1.34e-10	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01084379	chr5:179160712	MAML1	0.4	6.41	0.33	5.12e-10	Obesity-related traits;
CRC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.57	8.88	0.44	4.34e-17	Asthma (sex interaction);
CRC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg15848620	chr12:58087721	OS9	-0.63	-8.58	-0.43	3.87e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.85	11.78	0.54	5.91e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.58	0.39	3.54e-13	Motion sickness;
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02807482	chr3:125708958	NA	-0.45	-5.65	-0.3	3.39e-8	Blood pressure (smoking interaction);
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg20041105	chr8:143859282	LYNX1	-0.42	-6.94	-0.36	2.06e-11	Urinary tract infection frequency;
CRC	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-1.14	-10.91	-0.52	7.62e-24	Post bronchodilator FEV1;
CRC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.8e-27	Asthma (sex interaction);
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg15107132	chr11:63991130	FERMT3	0.45	7.73	0.39	1.33e-13	Platelet count;
CRC	cis	rs4523957	0.820	rs7212249	chr17:2135980	A/T	cg16513277	chr17:2031491	SMG6	-0.52	-8.9	-0.44	3.78e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08744461	chr12:108079556	PWP1	0.44	6.08	0.32	3.36e-9	Anxiety disorder;
CRC	cis	rs1465370	0.682	rs741486	chr7:130024010	C/T	cg03229158	chr7:130009420	NA	-0.42	-6.2	-0.32	1.71e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-17.22	-0.69	7.71e-48	Height;
CRC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	7.02	0.36	1.28e-11	Coronary artery disease;
CRC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.52	8.02	0.4	1.83e-14	Fibrinogen levels;
CRC	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.17	0.45	5.23e-18	Mean corpuscular volume;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg14640751	chr11:111636595	PPP2R1B	-0.39	-6.11	-0.32	2.76e-9	Aortic root size;
CRC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.42	6.48	0.34	3.31e-10	Monocyte count;
CRC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg25985355	chr7:65971099	NA	-0.48	-5.67	-0.3	3.15e-8	Diabetic kidney disease;
CRC	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.74	8.4	0.42	1.4e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.41	-0.42	1.27e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6662572	0.737	rs9429091	chr1:46513088	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.12	0.32	2.63e-9	Blood protein levels;
CRC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.67	-10.77	-0.51	2.26e-23	Menarche (age at onset);
CRC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.72	11.24	0.53	5.19e-25	Intelligence (multi-trait analysis);
CRC	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.93	-0.31	7.7e-9	Type 2 diabetes;
CRC	cis	rs939584	1.000	rs13412194	chr2:653245	A/C	cg03610516	chr2:642275	NA	-0.42	-5.74	-0.3	2.18e-8	Body mass index;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg02683197	chr6:28174875	NA	0.73	10.73	0.51	3.07e-23	Cardiac Troponin-T levels;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20092199	chr4:1342459	KIAA1530	-0.39	-6.88	-0.35	2.94e-11	Obesity-related traits;
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.93	-0.44	3.01e-17	Electroencephalogram traits;
CRC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg24209194	chr3:40518798	ZNF619	0.42	6.46	0.34	3.75e-10	Renal cell carcinoma;
CRC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.7	-0.39	1.63e-13	Coronary artery disease;
CRC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-10.92	-0.52	6.55e-24	Glomerular filtration rate (creatinine);
CRC	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.42	-6.72	-0.35	7.89e-11	Corneal astigmatism;
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18591801	chr3:52553433	STAB1	-0.31	-5.89	-0.31	9.5e-9	Electroencephalogram traits;
CRC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.48	-6.5	-0.34	3.02e-10	Colorectal cancer;
CRC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg10305451	chr2:177043427	NA	-0.53	-6.85	-0.35	3.71e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.82	14.69	0.63	6.75e-38	Dental caries;
CRC	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.39e-22	Corneal astigmatism;
CRC	cis	rs728616	0.867	rs55690691	chr10:81658942	G/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.74	-0.39	1.21e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg09184832	chr6:79620586	NA	-0.45	-7.75	-0.39	1.19e-13	Intelligence (multi-trait analysis);
CRC	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg23815491	chr16:72088622	HP	0.45	6.59	0.34	1.79e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.83	-0.31	1.31e-8	Lung cancer;
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg15790184	chr11:494944	RNH1	-0.6	-6.28	-0.33	1.06e-9	Body mass index;
CRC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.4	6.41	0.33	5.03e-10	Testicular germ cell tumor;
CRC	cis	rs12505749	0.542	rs12505939	chr4:57364210	T/C	cg06922635	chr4:57371607	ARL9	-0.54	-5.71	-0.3	2.54e-8	Airflow obstruction;
CRC	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26378065	chr17:18585709	ZNF286B	-0.43	-6.76	-0.35	6.42e-11	Educational attainment (years of education);
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg14196790	chr5:131705035	SLC22A5	0.35	6.12	0.32	2.66e-9	Blood metabolite levels;
CRC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.22	14.86	0.63	1.43e-38	Lung disease severity in cystic fibrosis;
CRC	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.43	-8.38	-0.42	1.55e-15	Alcohol dependence;
CRC	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg03929089	chr4:120376271	NA	0.66	5.96	0.31	6.38e-9	Myopia (pathological);
CRC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg04880052	chr2:219191631	PNKD	-0.39	-5.89	-0.31	9.54e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg05585544	chr11:47624801	NA	0.53	9.3	0.46	2.09e-18	Subjective well-being;
CRC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.68	-0.39	1.83e-13	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12111933	chr18:72265022	LOC400657	0.49	7.21	0.37	3.81e-12	Response to antipsychotic treatment;
CRC	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.56	-9.33	-0.46	1.58e-18	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-20.96	-0.76	1.47e-62	Primary sclerosing cholangitis;
CRC	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.65	-8.0	-0.4	2.19e-14	Blood protein levels;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.48	6.77	0.35	6.1e-11	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07780856	chr3:183967543	ALG3;ECE2	0.48	6.43	0.33	4.43e-10	Anxiety disorder;
CRC	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg17788362	chr6:86352627	SYNCRIP	0.51	7.41	0.38	1.06e-12	Smooth-surface caries;
CRC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.1	-0.49	4.6e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.59	-8.95	-0.44	2.63e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07472398	chr5:130501141	HINT1	0.43	6.11	0.32	2.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.44	7.76	0.39	1.07e-13	Perceived unattractiveness to mosquitoes;
CRC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-6.42	-0.33	4.63e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg00343986	chr7:65444356	GUSB	-0.54	-7.9	-0.4	4.2e-14	Calcium levels;
CRC	cis	rs13315871	1.000	rs9864824	chr3:58394835	A/G	cg20936604	chr3:58311152	NA	0.73	7.0	0.36	1.49e-11	Cholesterol, total;
CRC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.58	-8.79	-0.44	8.37e-17	Body mass index;
CRC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.8	13.63	0.6	7.81e-34	Menopause (age at onset);
CRC	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg03938978	chr2:103052716	IL18RAP	0.36	5.84	0.31	1.23e-8	Asthma;
CRC	cis	rs17127169	0.536	rs74860172	chr1:65497547	T/A	cg11989330	chr1:65468827	NA	0.89	6.32	0.33	8.3e-10	Sitting height ratio;
CRC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.21	-0.37	3.78e-12	Educational attainment;
CRC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.03	-0.7	5.04e-51	Height;
CRC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.69	0.39	1.74e-13	Height;
CRC	cis	rs17155006	0.691	rs403731	chr7:107744217	C/T	cg05962710	chr7:107745446	LAMB4	0.41	7.36	0.38	1.48e-12	Pneumococcal bacteremia;
CRC	cis	rs995000	0.931	rs624660	chr1:62920388	C/A	cg19896129	chr1:63156450	NA	0.44	6.78	0.35	5.59e-11	Triglyceride levels;
CRC	cis	rs4731207	0.671	rs7811607	chr7:124447843	T/G	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.79	12.13	0.56	2.97e-28	Multiple sclerosis;
CRC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg19193384	chr17:30244184	NA	-0.51	-6.72	-0.35	8.04e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg16989719	chr2:238392110	NA	-0.43	-6.12	-0.32	2.72e-9	Prostate cancer;
CRC	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg05935833	chr10:81318306	SFTPA2	-0.75	-8.19	-0.41	5.8e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.81	-0.4	7.69e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg19338460	chr6:170058176	WDR27	-0.74	-8.09	-0.41	1.14e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg23254163	chr1:152506842	NA	0.45	9.13	0.45	6.92e-18	Hair morphology;
CRC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	9.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.91	-0.31	8.33e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.65	8.78	0.44	9.01e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.64	-0.39	2.43e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.81	0.35	4.77e-11	Red blood cell count;
CRC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg15534755	chr11:117069859	TAGLN	0.35	6.73	0.35	7.5e-11	Blood protein levels;
CRC	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.45	7.29	0.37	2.35e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg21951975	chr1:209979733	IRF6	0.46	6.16	0.32	2.12e-9	Cleft lip with or without cleft palate;
CRC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.39	6.48	0.34	3.35e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-9.1	-0.45	9.11e-18	Type 2 diabetes;
CRC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.9	16.39	0.67	1.5e-44	Intelligence (multi-trait analysis);
CRC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.36	-0.42	1.75e-15	Schizophrenia;
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg18070033	chr2:220025364	NHEJ1	0.45	6.45	0.34	4.06e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg09877947	chr5:131593287	PDLIM4	-0.41	-6.85	-0.35	3.63e-11	Breast cancer;
CRC	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.37	6.83	0.35	4.05e-11	Breast cancer;
CRC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg18512352	chr11:47633146	NA	-0.36	-7.08	-0.36	8.58e-12	Subjective well-being;
CRC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg22777020	chr22:31556080	RNF185	0.53	6.25	0.33	1.25e-9	Colorectal cancer;
CRC	cis	rs539514	0.627	rs9544035	chr13:76293789	C/T	cg04757411	chr13:76259545	LMO7	-0.36	-6.08	-0.32	3.38e-9	Type 1 diabetes;
CRC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.84	12.67	0.57	3.24e-30	Cognitive function;
CRC	trans	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg11693508	chr17:37793320	STARD3	0.56	6.95	0.36	2.01e-11	Bipolar disorder;
CRC	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-6.13	-0.32	2.55e-9	Metabolite levels;
CRC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.37	6.22	0.32	1.51e-9	Blood metabolite levels;
CRC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.43	5.86	0.31	1.11e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg14593290	chr7:50529359	DDC	-0.45	-6.36	-0.33	6.92e-10	Systemic sclerosis;
CRC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02018176	chr4:1364513	KIAA1530	0.48	7.88	0.4	4.67e-14	Obesity-related traits;
CRC	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg07884673	chr3:53033167	SFMBT1	0.67	5.89	0.31	9.73e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.63	-10.37	-0.5	5.49e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.53	-8.77	-0.44	9.71e-17	Type 2 diabetes;
CRC	cis	rs12476592	0.602	rs2292793	chr2:63661280	A/G	cg10828910	chr2:63850056	LOC388955	0.53	6.5	0.34	3.06e-10	Childhood ear infection;
CRC	cis	rs6496044	0.568	rs11632326	chr15:86079834	A/C	cg17133734	chr15:86042851	AKAP13	0.42	6.96	0.36	1.9e-11	Interstitial lung disease;
CRC	cis	rs2179367	0.959	rs4895789	chr6:149764654	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.43	-6.82	-0.35	4.39e-11	Dupuytren's disease;
CRC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.61	-6.43	-0.33	4.44e-10	Axial length;
CRC	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.36	5.78	0.3	1.71e-8	Carotid intima media thickness;
CRC	cis	rs79387448	0.745	rs723292	chr2:103166804	A/G	cg09003973	chr2:102972529	NA	0.7	7.77	0.39	1.03e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05301359	chr2:27886888	SUPT7L;SLC4A1AP	-0.41	-5.97	-0.31	6.15e-9	HDL cholesterol;
CRC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.75	0.47	6.87e-20	Cognitive test performance;
CRC	trans	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.51	-0.38	5.79e-13	Endometrial cancer;
CRC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.51	6.7	0.35	9.07e-11	Obesity-related traits;
CRC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg15786705	chr6:28176104	NA	-0.81	-11.74	-0.54	8.03e-27	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12946690	chr17:2206740	SMG6;SRR	0.44	7.1	0.36	7.81e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.92	0.31	7.89e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.41	6.57	0.34	1.92e-10	Mean platelet volume;
CRC	cis	rs11212617	0.967	rs227068	chr11:108210109	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.37	0.33	6.43e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.69	-11.24	-0.53	4.89e-25	Bone mineral density;
CRC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.64	11.81	0.55	4.32e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs7300001	0.667	rs7302198	chr12:110506280	T/C	cg12870014	chr12:110450643	ANKRD13A	0.94	9.82	0.48	3.97e-20	Headache;
CRC	cis	rs4660531	1.000	rs4660532	chr1:41840197	C/T	cg19619003	chr1:41846758	NA	-0.37	-5.88	-0.31	9.98e-9	Bipolar disorder;
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.14	-0.37	6.2e-12	Bipolar disorder;
CRC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-6.59	-0.34	1.79e-10	Menarche (age at onset);
CRC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg19500275	chr17:80737654	TBCD	0.47	6.52	0.34	2.6e-10	Glycated hemoglobin levels;
CRC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.23	0.37	3.41e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg25985355	chr7:65971099	NA	0.32	5.64	0.3	3.68e-8	Aortic root size;
CRC	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg15234197	chr11:68924956	NA	0.42	5.77	0.3	1.87e-8	Blond vs. brown hair color;
CRC	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.49	7.11	0.37	7.16e-12	Schizophrenia;
CRC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.56	-7.77	-0.39	1.01e-13	Longevity;
CRC	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.5	0.46	4.36e-19	Blood protein levels;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg07617317	chr6:118971624	C6orf204	0.5	6.23	0.32	1.44e-9	Diastolic blood pressure;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg25164649	chr6:28176230	NA	0.54	7.26	0.37	2.82e-12	Parkinson's disease;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg06470822	chr6:28175283	NA	0.8	12.1	0.55	4.08e-28	Parkinson's disease;
CRC	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.63	9.58	0.47	2.42e-19	Dementia with Lewy bodies;
CRC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg27523141	chr10:43048294	ZNF37B	0.47	6.89	0.36	2.87e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg10437265	chr15:77819839	NA	0.59	9.97	0.48	1.23e-20	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19733847	chr19:8571072	NA	0.48	6.94	0.36	2.07e-11	Response to antipsychotic treatment;
CRC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16262614	chr3:133464971	TF	0.35	5.97	0.31	6.2e-9	Iron status biomarkers;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg25164649	chr6:28176230	NA	0.58	8.0	0.4	2.09e-14	Parkinson's disease;
CRC	cis	rs4561483	0.603	rs11544193	chr16:12009304	C/A	cg08843971	chr16:11963173	GSPT1	0.5	7.46	0.38	7.59e-13	Testicular germ cell tumor;
CRC	cis	rs9494145	0.680	rs9402686	chr6:135427817	G/A	cg22676075	chr6:135203613	NA	0.57	7.26	0.37	2.81e-12	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg06145435	chr7:1022769	CYP2W1	0.32	5.62	0.3	4e-8	Bronchopulmonary dysplasia;
CRC	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.27	11.79	0.54	5.43e-27	Prostate cancer;
CRC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.42e-10	Breast cancer;
CRC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.53	8.26	0.41	3.66e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.42	0.33	4.78e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs305851	0.818	rs6458122	chr6:39769455	C/T	cg02386599	chr6:39769542	DAAM2	0.42	6.73	0.35	7.43e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.98	17.95	0.7	1.01e-50	Gut microbiome composition (winter);
CRC	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.52	8.04	0.41	1.58e-14	Corneal astigmatism;
CRC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg06634786	chr22:41940651	POLR3H	-0.44	-5.61	-0.3	4.24e-8	Neuroticism;
CRC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.55e-27	Cognitive function;
CRC	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.93	-0.58	3.24e-31	Brugada syndrome;
CRC	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.4	-6.83	-0.35	4.13e-11	Hip circumference;Waist circumference;
CRC	cis	rs10484885	0.553	rs16881936	chr6:90265665	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-6.56	-0.34	2.04e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs8014671	0.553	rs34866539	chr14:70873763	T/C	cg25576086	chr14:70833871	SYNJ2BP	-0.37	-6.25	-0.33	1.27e-9	Prostate cancer;
CRC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.85	-9.83	-0.48	3.67e-20	Breast cancer;
CRC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.88	0.68	1.67e-46	Platelet count;
CRC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.63	-0.51	7.02e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.75e-13	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.25	-0.45	2.96e-18	Rheumatoid arthritis;
CRC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06544989	chr22:39130855	UNC84B	0.44	6.26	0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg10876282	chr6:28092338	ZSCAN16	0.4	5.76	0.3	1.93e-8	Cardiac Troponin-T levels;
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.14e-9	Prudent dietary pattern;
CRC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-19.08	-0.72	3.46e-55	Primary sclerosing cholangitis;
CRC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.54	5.66	0.3	3.33e-8	Schizophrenia;
CRC	cis	rs17023223	0.581	rs61808932	chr1:119643820	T/C	cg05756136	chr1:119680316	WARS2	-0.55	-6.94	-0.36	2.06e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg23018236	chr17:30244563	NA	-0.65	-7.74	-0.39	1.21e-13	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.05	-0.32	3.92e-9	Obesity-related traits;
CRC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg08027265	chr7:2291960	NA	-0.36	-6.33	-0.33	8.23e-10	Schizophrenia;
CRC	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.37	-8.18	-0.41	6.21e-15	Mean corpuscular volume;
CRC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs3751196	0.708	rs17034464	chr12:104144852	A/T	cg02344784	chr12:104178138	NT5DC3	0.69	6.75	0.35	6.79e-11	Sense of smell;
CRC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg03609598	chr5:56110824	MAP3K1	-0.56	-6.8	-0.35	4.81e-11	Type 2 diabetes;
CRC	trans	rs2303319	0.504	rs60824222	chr2:162368719	A/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.11	-0.32	2.75e-9	Cognitive function;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg03623178	chr6:28175578	NA	0.68	9.47	0.46	5.85e-19	Parkinson's disease;
CRC	cis	rs6088813	1.000	rs735531	chr20:33947730	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.81	-0.3	1.49e-8	Height;
CRC	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.35	6.27	0.33	1.13e-9	Neuroticism;
CRC	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.72	-9.94	-0.48	1.58e-20	Coronary artery disease;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.43	6.0	0.31	5.26e-9	Blood metabolite levels;
CRC	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.55	7.45	0.38	8.12e-13	Type 2 diabetes;
CRC	cis	rs6741819	0.956	rs4669126	chr2:7152120	T/C	cg27144453	chr2:7172511	RNF144A	-0.4	-5.93	-0.31	7.48e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17064520	chr10:98591758	LCOR	0.4	6.47	0.34	3.56e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg16914508	chr2:239161102	PER2	0.74	7.99	0.4	2.26e-14	Irritable bowel syndrome;
CRC	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.45	-6.36	-0.33	6.59e-10	Testicular germ cell tumor;
CRC	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-6.27	-0.33	1.11e-9	Prion diseases;
CRC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.8	-0.3	1.59e-8	Heart rate;
CRC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	8.13	0.41	9.05e-15	Cognitive test performance;
CRC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.85	-0.35	3.69e-11	Lung cancer;
CRC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.77	11.99	0.55	1.01e-27	Blood metabolite levels;
CRC	cis	rs7605827	1.000	rs7605827	chr2:15598740	A/T	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.58e-9	Educational attainment (years of education);
CRC	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.41	6.56	0.34	2.07e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.49	7.95	0.4	3.03e-14	Testicular germ cell tumor;
CRC	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg10517650	chr3:113235015	CCDC52	-0.39	-5.63	-0.3	3.88e-8	Dental caries;
CRC	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.08	-14.86	-0.63	1.46e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.66	-9.73	-0.47	7.89e-20	Initial pursuit acceleration;
CRC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.4	-5.62	-0.3	4.05e-8	Calcium levels;
CRC	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.66	-9.2	-0.45	4.38e-18	White matter hyperintensity burden;
CRC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.42	6.33	0.33	7.89e-10	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	4.94e-12	Life satisfaction;
CRC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg16928487	chr17:17741425	SREBF1	0.48	8.23	0.41	4.36e-15	Total body bone mineral density;
CRC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	10.29	0.49	1e-21	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.5	8.2	0.41	5.29e-15	Height;
CRC	cis	rs501120	0.525	rs1704229	chr10:44689529	G/A	cg09554077	chr10:44749378	NA	0.57	7.99	0.4	2.25e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-7.06	-0.36	1e-11	Dental caries;
CRC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg13072238	chr3:49761600	GMPPB	-0.52	-5.75	-0.3	2.05e-8	Menarche (age at onset);
CRC	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.61	8.77	0.44	9.58e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.94	0.44	2.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9549328	0.670	rs35992827	chr13:113616752	G/A	cg20742385	chr13:113633654	MCF2L	0.53	8.95	0.44	2.61e-17	Systolic blood pressure;
CRC	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg23254163	chr1:152506842	NA	0.44	8.62	0.43	2.8e-16	Hair morphology;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg26608667	chr7:1196370	ZFAND2A	0.41	6.51	0.34	2.82e-10	Longevity;Endometriosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25377726	chr2:45838438	SRBD1	0.42	6.26	0.33	1.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.17e-35	Mean platelet volume;
CRC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.48	-9.34	-0.46	1.52e-18	Prostate cancer;
CRC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.53	8.61	0.43	3.05e-16	Testicular germ cell tumor;
CRC	cis	rs9462846	0.821	rs2092554	chr6:42863921	G/A	cg21280719	chr6:42927975	GNMT	-0.33	-6.49	-0.34	3.09e-10	Blood protein levels;
CRC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.56	6.35	0.33	7.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.5	6.98	0.36	1.66e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs16975963	0.644	rs2290999	chr19:38138887	T/C	cg15135657	chr19:38346511	NA	-0.44	-6.15	-0.32	2.21e-9	Longevity;
CRC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.8	9.72	0.47	8.83e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02450064	chr17:40260053	DHX58	-0.43	-6.24	-0.33	1.38e-9	Fibrinogen levels;
CRC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.8	13.7	0.6	4.08e-34	Menopause (age at onset);
CRC	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg08071915	chr8:12219732	FAM66A	-0.34	-6.38	-0.33	5.98e-10	Retinal vascular caliber;
CRC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg01721255	chr8:58191610	C8orf71	0.53	6.6	0.34	1.69e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.5	7.85	0.4	5.87e-14	Carotid intima media thickness;
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.9	0.31	9.05e-9	Self-reported allergy;
CRC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.81	-13.83	-0.61	1.3e-34	Cystic fibrosis severity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14813019	chr8:90996956	NBN	0.42	6.07	0.32	3.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg16606324	chr3:10149918	C3orf24	0.45	6.82	0.35	4.25e-11	Alzheimer's disease;
CRC	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.64	-0.34	1.29e-10	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07656362	chr1:32688117	C1orf91;EIF3I	0.48	6.58	0.34	1.88e-10	Response to antipsychotic treatment;
CRC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.5	6.73	0.35	7.54e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs12580194	0.593	rs7487419	chr12:55769801	C/G	cg23425280	chr12:56401806	NA	0.47	5.83	0.31	1.34e-8	Cancer;
CRC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.64	-7.39	-0.38	1.25e-12	Menarche (age at onset);
CRC	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.49	7.89	0.4	4.61e-14	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs7172809	0.643	rs75334741	chr15:77841492	T/C	cg10437265	chr15:77819839	NA	-0.39	-6.6	-0.34	1.6e-10	Glucose homeostasis traits;
CRC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.54	-7.08	-0.36	8.56e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.49	6.1	0.32	3.05e-9	Red blood cell count;
CRC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.94	0.44	2.79e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1472147	0.955	rs3736611	chr7:128509243	C/G	cg00260937	chr7:128520193	KCP	0.49	7.31	0.37	2.07e-12	Calcium levels;
CRC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.54	-0.34	2.4e-10	Blood metabolite levels;
CRC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.36	-6.78	-0.35	5.63e-11	Colorectal cancer;
CRC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	9.23	0.45	3.49e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-9.15	-0.45	6.25e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.71	10.98	0.52	4.03e-24	Immature fraction of reticulocytes;
CRC	cis	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg21667061	chr15:60772094	NARG2	0.31	6.24	0.33	1.38e-9	Menarche (age at onset);
CRC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	7.21	0.37	3.98e-12	Schizophrenia;
CRC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.52	-8.9	-0.44	3.88e-17	Aortic root size;
CRC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	8.61	0.43	3.05e-16	Cognitive test performance;
CRC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.98	-17.81	-0.7	3.7e-50	Cognitive ability;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25341789	chr19:3506185	FZR1	0.45	6.2	0.32	1.7e-9	Response to antipsychotic treatment;
CRC	cis	rs4731207	0.596	rs719972	chr7:124631797	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	2.06e-9	Cutaneous malignant melanoma;
CRC	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	5.65	0.3	3.57e-8	Lung function (FEV1/FVC);
CRC	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.49	-7.74	-0.39	1.25e-13	Type 2 diabetes;
CRC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.13	11.6	0.54	2.58e-26	Intelligence (multi-trait analysis);
CRC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.61	7.32	0.37	1.88e-12	Carotid intima media thickness;
CRC	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg13919466	chr1:32135498	COL16A1	-0.3	-5.73	-0.3	2.27e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12760731	0.720	rs12039605	chr1:178433368	C/T	cg00404053	chr1:178313656	RASAL2	0.95	9.93	0.48	1.66e-20	Obesity-related traits;
CRC	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg15654264	chr1:150340011	RPRD2	0.37	5.64	0.3	3.71e-8	Migraine;
CRC	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg24848437	chr7:2645542	IQCE	0.58	6.02	0.32	4.54e-9	Urate levels in lean individuals;
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg27411370	chr8:25316735	KCTD9;CDCA2	0.5	6.75	0.35	6.61e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.57	-9.2	-0.45	4.14e-18	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.61	-10.95	-0.52	5.42e-24	Aortic root size;
CRC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.56	8.78	0.44	9.18e-17	Vitiligo;
CRC	cis	rs3736485	0.966	rs11070855	chr15:51850283	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.6	-0.34	1.65e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-6.92	-0.36	2.41e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6499129	0.867	rs7196853	chr16:67560613	T/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-7.72	-0.39	1.43e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.76	-12.47	-0.57	1.71e-29	Lung cancer;
CRC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.67	-10.14	-0.49	3.2e-21	Acne (severe);
CRC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.39	6.59	0.34	1.73e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg26805224	chr10:79626177	DLG5	-0.56	-8.34	-0.42	2.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06231882	chr16:81040594	CENPN;C16orf61	0.46	6.51	0.34	2.82e-10	Response to antipsychotic treatment;
CRC	cis	rs12580194	0.593	rs61956275	chr12:55786423	G/A	cg19537932	chr12:55886519	OR6C68	-0.72	-9.08	-0.45	9.94e-18	Cancer;
CRC	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-7.08	-0.36	8.77e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.43	-6.18	-0.32	1.93e-9	Platelet distribution width;
CRC	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.98	-17.27	-0.69	5.1e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.14	0.32	2.38e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.68	8.13	0.41	8.87e-15	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09241033	chr17:7893344	NA	0.46	6.33	0.33	8.14e-10	Anxiety disorder;
CRC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.53	8.01	0.4	2.06e-14	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.8	13.69	0.6	4.46e-34	Menopause (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17487170	chr5:133451259	TCF7	0.37	6.39	0.33	5.61e-10	Obesity-related traits;
CRC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.61	9.4	0.46	9.75e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	15.3	0.64	2.86e-40	Platelet count;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21715088	chr18:74534568	NA	0.39	6.0	0.31	5.18e-9	Myopia (pathological);
CRC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.36	-0.56	4.47e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.73	-12.91	-0.58	3.88e-31	Prostate cancer;
CRC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.39	5.89	0.31	9.68e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg20487152	chr13:99095054	FARP1	0.35	5.85	0.31	1.21e-8	Longevity;
CRC	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg03938978	chr2:103052716	IL18RAP	0.42	6.65	0.34	1.19e-10	Blood protein levels;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.76	11.99	0.55	9.8e-28	Height;
CRC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.76	0.35	6.44e-11	Melanoma;
CRC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-7.95	-0.4	2.98e-14	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05181282	chr17:2496653	PAFAH1B1	0.41	5.97	0.31	6.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg00738113	chr16:70207722	CLEC18C	-0.41	-5.92	-0.31	7.99e-9	IgE levels;
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.8	0.44	7.68e-17	Alzheimer's disease;
CRC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.57	7.56	0.38	4e-13	IgG glycosylation;
CRC	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.81	0.51	1.63e-23	Exhaled nitric oxide output;
CRC	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.51	8.11	0.41	1.04e-14	Airflow obstruction;
CRC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.37	6.35e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.96	0.31	6.61e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14671666	chr5:41904456	C5orf51	-0.37	-6.01	-0.31	4.96e-9	Obesity-related traits;
CRC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.56	7.41	0.38	1.07e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.11	-0.32	2.87e-9	Gout;Renal underexcretion gout;
CRC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg17775713	chr3:133465469	TF	0.34	5.9	0.31	9.24e-9	Iron status biomarkers;
CRC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg18512352	chr11:47633146	NA	0.36	7.07	0.36	9.23e-12	Subjective well-being;
CRC	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.45	6.64	0.34	1.28e-10	Red blood cell count;
CRC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.26	12.25	0.56	1.14e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg00850481	chr1:228891306	NA	-0.44	-6.83	-0.35	4.01e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.96	0.48	1.32e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg23167259	chr10:102495509	NA	-0.49	-6.83	-0.35	4.04e-11	Alzheimer's disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18604133	chr13:27746144	USP12	0.38	6.05	0.32	4e-9	Schizophrenia;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16672449	chr3:127842622	RUVBL1	-0.41	-6.39	-0.33	5.51e-10	Aortic root size;
CRC	cis	rs4588572	0.561	rs12697887	chr5:77804729	A/G	cg11547950	chr5:77652471	NA	-0.43	-6.18	-0.32	1.87e-9	Triglycerides;
CRC	cis	rs236352	0.576	rs3778017	chr6:36842183	C/T	cg10099585	chr6:36853529	C6orf89	-0.45	-6.34	-0.33	7.47e-10	Heart rate;
CRC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.44	9.77	0.47	5.91e-20	Blood protein levels;
CRC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg23298862	chr7:158159286	PTPRN2	-0.47	-7.64	-0.39	2.47e-13	Calcium levels;
CRC	cis	rs932541	0.955	rs6034488	chr20:16456611	G/A	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.52	8.45	0.42	9.3e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.7	9.61	0.47	1.95e-19	Breast cancer;
CRC	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.13	0.64	1.23e-39	Bipolar disorder;
CRC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.65	-8.27	-0.41	3.45e-15	Hemostatic factors and hematological phenotypes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25660386	chr3:13009126	IQSEC1	0.39	6.11	0.32	2.83e-9	Interleukin-6 levels;
CRC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.41	5.76	0.3	1.93e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.51	7.49	0.38	6.31e-13	Intelligence (multi-trait analysis);
CRC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.87	-13.64	-0.6	7.1e-34	Multiple myeloma;
CRC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.5	7.15	0.37	5.71e-12	Height;
CRC	cis	rs7680126	0.500	rs4697717	chr4:10149784	C/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.13	-0.32	2.55e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.63	-9.5	-0.46	4.54e-19	Ulcerative colitis;
CRC	cis	rs10971721	0.731	rs72727303	chr9:33878376	G/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg21153622	chr11:89784906	NA	-0.46	-7.31	-0.37	2.06e-12	HDL cholesterol;
CRC	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg24110177	chr3:50126178	RBM5	-0.49	-5.82	-0.31	1.4e-8	Intelligence (multi-trait analysis);
CRC	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.58	-8.19	-0.41	6e-15	Personality dimensions;
CRC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.69	8.73	0.43	1.31e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00166722	chr3:10149974	C3orf24	0.43	6.47	0.34	3.6e-10	Alzheimer's disease;
CRC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.08	-0.32	3.33e-9	Height;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg15845792	chr6:28175446	NA	0.74	7.97	0.4	2.64e-14	Parkinson's disease;
CRC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.85	-0.35	3.68e-11	Type 2 diabetes;
CRC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.41	0.38	1.1e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.66	-0.47	1.38e-19	Primary sclerosing cholangitis;
CRC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	9.24	0.45	3.07e-18	Schizophrenia;
CRC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.63	10.27	0.49	1.21e-21	Aortic root size;
CRC	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.52	-9.41	-0.46	8.91e-19	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.63	10.35	0.5	6.65e-22	Eosinophil percentage of white cells;
CRC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.68	10.24	0.49	1.49e-21	Menarche (age at onset);
CRC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-8.27	-0.41	3.44e-15	Total body bone mineral density;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg00843398	chr6:24403479	MRS2	0.48	6.13	0.32	2.47e-9	Resistin levels;
CRC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.6	-8.44	-0.42	1.05e-15	Carotid intima media thickness;
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.48	-0.34	3.45e-10	Bipolar disorder;
CRC	cis	rs7849270	0.921	rs7868476	chr9:131918133	A/G	cg13538475	chr9:131942899	NA	-0.34	-6.34	-0.33	7.58e-10	Blood metabolite ratios;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg16060761	chr17:80687452	NA	0.53	8.12	0.41	9.73e-15	Glycated hemoglobin levels;
CRC	cis	rs629535	0.773	rs568159	chr8:70032908	C/G	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9463078	0.507	rs1023089	chr6:45012346	G/A	cg25276700	chr6:44698697	NA	0.24	5.67	0.3	3.13e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.52	-6.96	-0.36	1.86e-11	Gut microbiome composition (summer);
CRC	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.47	7.54	0.38	4.53e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg21782813	chr7:2030301	MAD1L1	0.38	7.09	0.36	8.15e-12	Schizophrenia;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.59	6.11	0.32	2.74e-9	Fat distribution (HIV);
CRC	cis	rs727479	0.523	rs700518	chr15:51529112	C/T	cg19946085	chr15:51559439	CYP19A1	0.29	5.74	0.3	2.17e-8	Estradiol levels;
CRC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.24	-0.33	1.33e-9	Renal cell carcinoma;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg22638593	chr5:131593259	PDLIM4	0.35	6.43	0.33	4.46e-10	Blood metabolite levels;
CRC	cis	rs6694672	0.867	rs1115247	chr1:197037667	A/G	cg13682187	chr1:196946512	CFHR5	0.49	7.62	0.39	2.79e-13	Asthma;
CRC	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.56	-8.32	-0.42	2.39e-15	Psoriasis;
CRC	trans	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg05376469	chr2:102649931	NA	-0.37	-6.23	-0.32	1.42e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20430870	chr10:52487619	NA	-0.42	-6.87	-0.35	3.25e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02421172	chr7:1938701	MAD1L1	0.47	6.25	0.33	1.3e-9	Neuroticism;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.33	-0.33	7.89e-10	Parkinson's disease;
CRC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.78	-0.3	1.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-12.01	-0.55	8.36e-28	Asthma;
CRC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg03233332	chr7:66118400	NA	0.44	6.08	0.32	3.42e-9	Aortic root size;
CRC	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	0.96	7.46	0.38	8.01e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.43	6.05	0.32	3.97e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg17133734	chr15:86042851	AKAP13	0.42	6.72	0.35	7.92e-11	Coronary artery disease;
CRC	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.62	-5.76	-0.3	1.94e-8	Alzheimer's disease (late onset);
CRC	trans	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg18335740	chr13:41363409	SLC25A15	0.54	8.15	0.41	7.69e-15	Lewy body disease;
CRC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03074839	chr11:107436493	ALKBH8	0.4	6.4	0.33	5.38e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24992181	chr8:110657174	GOLSYN	0.38	6.11	0.32	2.84e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.25	-0.33	1.27e-9	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg13057898	chr1:3703894	LRRC47	0.55	7.3	0.37	2.21e-12	Red cell distribution width;
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.53	7.08	0.36	8.52e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg02683197	chr6:28174875	NA	0.73	9.78	0.47	5.29e-20	Parkinson's disease;
CRC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.54	7.1	0.36	7.95e-12	Alzheimer's disease (survival time);
CRC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.55	7.65	0.39	2.28e-13	Lung cancer;
CRC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.38	8.81	0.44	7.56e-17	Multiple system atrophy;
CRC	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.1	0.32	2.98e-9	Hair morphology;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15353389	chr12:120525027	CCDC64	0.5	7.08	0.36	8.92e-12	Response to antipsychotic treatment;
CRC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.55	9.29	0.46	2.14e-18	Systemic lupus erythematosus;
CRC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.62	-11.75	-0.54	7.27e-27	Immature fraction of reticulocytes;
CRC	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-0.84	-9.2	-0.45	4.32e-18	Post bronchodilator FEV1;
CRC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-7.58	-0.39	3.52e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.58	8.1	0.41	1.08e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.66	-0.39	2.16e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.02	-0.4	1.84e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-13.32	-0.59	1.14e-32	Colorectal cancer;
CRC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.91	17.35	0.69	2.44e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.53	-6.76	-0.35	6.26e-11	Vitamin D levels;
CRC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.6	-9.54	-0.47	3.39e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg16141378	chr3:129829833	LOC729375	-0.47	-7.29	-0.37	2.27e-12	Mood instability;
CRC	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg13385794	chr1:248469461	NA	-0.38	-6.77	-0.35	5.83e-11	Common traits (Other);
CRC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.5	6.44	0.33	4.22e-10	IgG glycosylation;
CRC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.85	10.26	0.49	1.29e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.57	8.97	0.44	2.23e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.93	-0.31	7.62e-9	Pulmonary function;
CRC	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg19773385	chr1:10388646	KIF1B	0.47	7.44	0.38	9.07e-13	Hepatocellular carcinoma;
CRC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.74	7.27	0.37	2.58e-12	Plasma clusterin levels;
CRC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg20387954	chr3:183756860	HTR3D	0.46	7.93	0.4	3.43e-14	Anterior chamber depth;
CRC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg24560729	chr4:1342394	KIAA1530	-0.34	-6.25	-0.33	1.25e-9	Obesity-related traits;
CRC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.54	6.31	0.33	8.85e-10	Menarche (age at onset);
CRC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.4	6.25	0.33	1.27e-9	Red blood cell count;
CRC	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.56	-0.38	4.12e-13	Capecitabine sensitivity;
CRC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.23	0.37	3.4e-12	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg09760422	chr2:128146352	NA	-0.37	-7.24	-0.37	3.17e-12	Protein C levels;
CRC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.3	0.37	2.21e-12	Motion sickness;
CRC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg01320579	chr17:75405842	SEPT9	0.35	5.65	0.3	3.53e-8	Airflow obstruction;
CRC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.61	-8.68	-0.43	1.87e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2457480	0.778	rs11238901	chr10:44681012	C/A	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;
CRC	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.68	-9.59	-0.47	2.37e-19	Personality dimensions;
CRC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.34	-0.46	1.49e-18	Platelet count;
CRC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.43	8.78	0.44	8.99e-17	Renal cell carcinoma;
CRC	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.54	8.4	0.42	1.32e-15	Diastolic blood pressure;
CRC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.36	-6.59	-0.34	1.77e-10	Menarche (age at onset);
CRC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.99	-0.4	2.26e-14	Response to antipsychotic treatment;
CRC	cis	rs55986470	0.817	rs6710301	chr2:239441308	A/C	cg18131467	chr2:239335373	ASB1	0.55	5.77	0.3	1.8e-8	Chronotype;
CRC	cis	rs6496667	1.000	rs3803539	chr15:90891982	A/G	cg04176472	chr15:90893244	GABARAPL3	0.59	8.33	0.42	2.24e-15	Rheumatoid arthritis;
CRC	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.21	0.41	5.11e-15	Cognitive performance;
CRC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.72	-10.47	-0.5	2.51e-22	Blood metabolite levels;
CRC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg05501817	chr11:14380813	RRAS2	-0.47	-6.58	-0.34	1.87e-10	Sense of smell;
CRC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.38	-6.43	-0.33	4.43e-10	Schizophrenia;
CRC	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.53	-7.94	-0.4	3.23e-14	Liver enzyme levels;
CRC	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.48	7.74	0.39	1.27e-13	Body mass index;
CRC	cis	rs72799341	0.706	rs889555	chr16:31122571	C/T	cg02466173	chr16:30829666	NA	-0.46	-6.22	-0.32	1.51e-9	Diastolic blood pressure;
CRC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.92	-0.31	8.02e-9	Gout;Renal underexcretion gout;
CRC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.65	9.63	0.47	1.7e-19	Longevity;
CRC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg24849736	chr1:201084428	NA	0.65	12.36	0.56	4.27e-29	Permanent tooth development;
CRC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.36	6.02	0.32	4.53e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.58	-9.78	-0.47	5.38e-20	Personality dimensions;
CRC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.39	-6.04	-0.32	4.22e-9	Height;
CRC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.68	10.68	0.51	4.61e-23	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01657511	chr8:142318170	NA	0.41	6.81	0.35	4.57e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.26	0.49	1.35e-21	Corneal astigmatism;
CRC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.37	-5.78	-0.3	1.73e-8	Mean corpuscular volume;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.72	-0.43	1.39e-16	Bipolar disorder;
CRC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.5	8.13	0.41	8.69e-15	Aortic root size;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Blood metabolite levels;
CRC	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg05540913	chr6:167530185	CCR6	0.4	7.35	0.38	1.53e-12	Primary biliary cholangitis;
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.74	9.41	0.46	8.98e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.54	-6.88	-0.35	2.95e-11	Personality dimensions;
CRC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.26	0.37	2.79e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs17767392	0.846	rs34281405	chr14:71780587	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.04	-0.32	4.17e-9	Mitral valve prolapse;
CRC	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.38	-0.33	5.93e-10	Caffeine consumption;
CRC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.67	9.83	0.48	3.62e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.81	-0.31	1.45e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs72627123	0.867	rs58102735	chr14:74467531	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.92	0.31	8.3e-9	Morning vs. evening chronotype;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg27635394	chr6:26043820	HIST1H2BB	0.4	5.83	0.31	1.35e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.01	0.31	5.05e-9	Renal function-related traits (BUN);
CRC	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.51	7.88	0.4	4.77e-14	Corneal astigmatism;
CRC	cis	rs2579500	0.807	rs4907200	chr2:97320737	T/G	cg23100626	chr2:96804247	ASTL	-0.23	-5.62	-0.3	3.97e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.69	9.08	0.45	1.03e-17	Platelet count;
CRC	cis	rs911119	0.913	rs3004139	chr20:23578674	C/T	cg16589663	chr20:23618590	CST3	-0.44	-6.28	-0.33	1.1e-9	Chronic kidney disease;
CRC	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.86	-16.9	-0.68	1.49e-46	Oral cavity cancer;
CRC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	6.9	0.36	2.72e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg12100956	chr17:78086420	GAA	-0.38	-5.83	-0.31	1.33e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg05585544	chr11:47624801	NA	-0.62	-11.43	-0.53	1.09e-25	Subjective well-being;
CRC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	2.94e-11	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.48	-7.97	-0.4	2.65e-14	Lung cancer;
CRC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.18	0.32	1.89e-9	Cognitive ability;
CRC	cis	rs728616	0.867	rs2152550	chr10:81818509	G/A	cg05935833	chr10:81318306	SFTPA2	-0.51	-6.25	-0.33	1.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.37	-0.46	1.23e-18	Subjective well-being;
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg10677697	chr7:45961126	IGFBP3	0.36	6.37	0.33	6.28e-10	Sitting height ratio;
CRC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg19980929	chr12:42632907	YAF2	0.42	6.29	0.33	1.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	6.0	0.31	5.16e-9	Menarche (age at onset);
CRC	trans	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs10788264	0.504	rs7090214	chr10:124036494	T/C	cg09507567	chr10:124027408	NA	0.36	7.65	0.39	2.2e-13	Total body bone mineral density;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	cis	rs62408225	1.000	rs17513531	chr6:90951239	C/T	cg06866423	chr6:90926672	BACH2	0.46	7.45	0.38	8.19e-13	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.39	-5.83	-0.31	1.32e-8	Total body bone mineral density;
CRC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs863345	0.604	rs4584390	chr1:158505975	T/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-5.62	-0.3	4.03e-8	Schizophrenia;
CRC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg03690763	chr11:133734501	NA	-0.39	-6.32	-0.33	8.29e-10	Childhood ear infection;
CRC	cis	rs7259376	1.000	rs2163846	chr19:22505844	C/T	cg02657401	chr19:22469223	NA	-0.36	-8.17	-0.41	6.65e-15	Menopause (age at onset);
CRC	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg23425280	chr12:56401806	NA	0.47	5.72	0.3	2.44e-8	Cancer;
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.01	-0.31	5.01e-9	Total body bone mineral density;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg02683197	chr6:28174875	NA	0.7	8.9	0.44	3.85e-17	Parkinson's disease;
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12900413	0.687	rs28428808	chr15:90315516	C/T	cg24249390	chr15:90295951	MESP1	-0.56	-8.9	-0.44	3.84e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg27661571	chr11:113659931	NA	-0.88	-10.42	-0.5	3.71e-22	Hip circumference adjusted for BMI;
CRC	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg03690763	chr11:133734501	NA	-0.36	-5.97	-0.31	6.24e-9	Childhood ear infection;
CRC	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	ch.8.33884649F	chr8:33765107	NA	0.39	5.76	0.3	1.9e-8	Body mass index;
CRC	cis	rs6662572	0.737	rs6687316	chr1:46581449	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.3	0.33	9.58e-10	Blood protein levels;
CRC	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg22561889	chr6:118971681	C6orf204	0.48	5.8	0.3	1.6e-8	Diastolic blood pressure;
CRC	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs17767392	0.881	rs1029570	chr14:72043200	A/G	cg13720639	chr14:72061746	SIPA1L1	0.57	7.02	0.36	1.25e-11	Mitral valve prolapse;
CRC	trans	rs711355	0.902	rs1085232	chr15:30189454	G/A	cg19414016	chr13:113697165	MCF2L	-0.42	-6.24	-0.33	1.37e-9	Response to antipsychotic treatment;
CRC	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-5.85	-0.31	1.21e-8	Mood instability;
CRC	cis	rs6988985	0.728	rs10105643	chr8:143957886	A/C	cg10324643	chr8:143916377	GML	0.4	6.6	0.34	1.68e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.85	0.66	1.97e-42	Fuchs's corneal dystrophy;
CRC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06505273	chr16:24850292	NA	0.51	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.57	-8.8	-0.44	7.95e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10982256	0.567	rs10817620	chr9:117238405	C/T	cg13636371	chr9:117264095	DFNB31	0.33	6.32	0.33	8.35e-10	Bipolar disorder;
CRC	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.62	11.23	0.53	5.31e-25	Blood metabolite ratios;
CRC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.98	-0.4	2.5e-14	Height;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.13	-0.37	6.23e-12	Breast cancer;
CRC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg26260408	chr4:53727979	RASL11B	0.5	5.73	0.3	2.29e-8	Optic nerve measurement (cup area);
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg13957321	chr17:43675089	NA	0.5	6.23	0.32	1.45e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Bladder cancer;
CRC	cis	rs71227278	1	rs71227278	chr12:54358047	C/CTTAA	cg19188855	chr12:54355476	NA	0.33	6.82	0.35	4.49e-11	Urinary tract infection frequency;
CRC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	trans	rs6544773	0.668	rs543541	chr2:45071204	G/A	cg10208897	chr5:178548229	ADAMTS2	0.35	6.03	0.32	4.53e-9	Mosquito bite size;
CRC	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.43	6.25	0.33	1.29e-9	Rheumatoid arthritis;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg09855544	chr8:135498122	ZFAT	-0.43	-5.75	-0.3	2.09e-8	Hypertension (SNP x SNP interaction);
CRC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.63	-11.14	-0.52	1.15e-24	Coronary artery disease;
CRC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.8	12.35	0.56	4.76e-29	Breast cancer;
CRC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-6.36	-0.33	6.6e-10	Diabetic retinopathy;
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg13206674	chr6:150067644	NUP43	0.51	6.81	0.35	4.79e-11	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13826618	chr2:11828697	NA	0.42	6.22	0.32	1.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg09264619	chr17:80180166	NA	-0.35	-5.97	-0.31	5.98e-9	Life satisfaction;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18864399	chr15:73345368	NEO1	0.47	6.31	0.33	9e-10	Survival in pancreatic cancer;
CRC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg12856521	chr11:46389249	DGKZ	-0.5	-8.2	-0.41	5.3e-15	Leprosy;
CRC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.68	-11.28	-0.53	3.5e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.46	6.63	0.34	1.38e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg04800585	chr6:26043546	HIST1H2BB	0.41	6.18	0.32	1.86e-9	Intelligence (multi-trait analysis);
CRC	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.07	-14.34	-0.62	1.5e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg24343755	chr10:26987087	PDSS1	-0.53	-7.07	-0.36	9.24e-12	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.58	7.9	0.4	4.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.23	-0.53	5.57e-25	Chronic sinus infection;
CRC	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg09003973	chr2:102972529	NA	0.41	5.68	0.3	2.96e-8	Blood protein levels;
CRC	trans	rs72991	0.595	rs10892742	chr11:121229932	G/A	cg27192990	chr6:129479024	LAMA2	-0.44	-6.32	-0.33	8.49e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.18	-0.49	2.49e-21	Inflammatory bowel disease;
CRC	cis	rs6586163	0.872	rs7910825	chr10:90743341	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.08	-0.36	8.67e-12	Chronic lymphocytic leukemia;
CRC	cis	rs2062225	1.000	rs1483535	chr2:111759661	G/T	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs9648716	1.000	rs6964724	chr7:140501936	G/A	cg10747023	chr7:140774559	NA	0.46	5.98	0.31	5.69e-9	Type 2 diabetes;
CRC	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg09127314	chr1:152161683	NA	-0.49	-6.34	-0.33	7.41e-10	Atopic dermatitis;
CRC	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.53	-7.67	-0.39	1.96e-13	Pulmonary function decline;
CRC	cis	rs4728302	0.869	rs13233690	chr7:133587328	C/T	cg03336402	chr7:133662267	EXOC4	-0.44	-6.37	-0.33	6.27e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.53	-8.21	-0.41	4.93e-15	Paraoxonase activity;
CRC	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.67	-0.39	2.02e-13	HDL cholesterol;
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.62	8.26	0.41	3.67e-15	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11786013	chr1:36622167	MAP7D1	0.41	6.32	0.33	8.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.39	-5.8	-0.3	1.55e-8	Mean corpuscular volume;
CRC	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg09596252	chr17:78655493	RPTOR	-0.64	-5.79	-0.3	1.68e-8	Myopia (pathological);
CRC	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	1.02	8.98	0.44	2.1e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs12024301	0.557	rs11803516	chr1:183640687	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.73	10.2	0.49	2.1e-21	Heart rate;
CRC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.54	-6.05	-0.32	3.96e-9	Initial pursuit acceleration;
CRC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.57	9.91	0.48	1.97e-20	Menarche (age at onset);
CRC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.6	-7.79	-0.39	8.72e-14	Schizophrenia;
CRC	cis	rs6604026	0.656	rs2481713	chr1:93354889	G/T	cg17283838	chr1:93427260	FAM69A	-0.45	-5.87	-0.31	1.07e-8	Multiple sclerosis;
CRC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.5	7.41	0.38	1.05e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg07195577	chr17:27052828	TLCD1	0.42	6.03	0.32	4.32e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg06606381	chr12:133084897	FBRSL1	-0.93	-7.09	-0.36	8.01e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4728302	0.869	rs10954434	chr7:133597864	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.8e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.69	-8.85	-0.44	5.66e-17	Blood pressure (smoking interaction);
CRC	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.84	10.26	0.49	1.32e-21	Exhaled nitric oxide output;
CRC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.67	-12.36	-0.56	4.39e-29	Height;
CRC	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.24	0.53	5.04e-25	Coffee consumption (cups per day);
CRC	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.12	-0.45	7.41e-18	Rheumatoid arthritis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19602773	chr3:52007747	ABHD14B;ABHD14A	-0.43	-6.73	-0.35	7.64e-11	Myopia (pathological);
CRC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg10298567	chr3:47292165	KIF9	-0.37	-5.88	-0.31	1.03e-8	Colorectal cancer;
CRC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.44	-0.33	4.3e-10	Dupuytren's disease;
CRC	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.56	-8.93	-0.44	2.99e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.07	0.52	2e-24	Prudent dietary pattern;
CRC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.83	-13.32	-0.59	1.12e-32	Cognitive function;
CRC	cis	rs12580194	0.593	rs7971053	chr12:55729947	A/C	cg19537932	chr12:55886519	OR6C68	-0.66	-8.59	-0.43	3.63e-16	Cancer;
CRC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.47	5.88	0.31	1.02e-8	Body mass index;
CRC	trans	rs17665859	0.669	rs56187424	chr8:447194	A/G	cg18996590	chr8:30890583	WRN;PURG	-0.45	-6.26	-0.33	1.19e-9	Bilirubin levels;
CRC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.43	6.19	0.32	1.76e-9	HIV-1 control;
CRC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.37	6.03	0.32	4.33e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.48	7.05	0.36	1.04e-11	Blood metabolite levels;
CRC	trans	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.92	0.36	2.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.44	-6.67	-0.35	1.07e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg24463073	chr6:118973353	C6orf204	0.48	6.21	0.32	1.61e-9	Diastolic blood pressure;
CRC	cis	rs6504622	0.577	rs197925	chr17:45010721	C/T	cg16759221	chr17:45003025	GOSR2	-0.62	-10.09	-0.49	4.82e-21	Orofacial clefts;
CRC	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.47	-8.93	-0.44	2.98e-17	Educational attainment (years of education);
CRC	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11446398	chr5:77624930	NA	0.43	6.32	0.33	8.52e-10	Triglycerides;
CRC	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.61	-8.75	-0.43	1.11e-16	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.36	0.46	1.26e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg05313129	chr8:58192883	C8orf71	-0.44	-6.12	-0.32	2.72e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.75	-0.3	2e-8	Height;
CRC	trans	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.97	-0.36	1.74e-11	Primary sclerosing cholangitis;
CRC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.61	7.72	0.39	1.4e-13	Gut microbiome composition (summer);
CRC	cis	rs2734839	0.964	rs12808482	chr11:113294998	T/A	cg14159747	chr11:113255604	NA	0.46	7.95	0.4	2.96e-14	Information processing speed;
CRC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg16060761	chr17:80687452	NA	0.42	6.07	0.32	3.46e-9	Breast cancer;
CRC	cis	rs1109861	0.593	rs658681	chr10:11218580	A/G	cg24910943	chr10:11206320	CUGBP2	0.27	7.59	0.39	3.34e-13	Urinary albumin-to-creatinine ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20609493	chr15:60420227	NA	0.49	6.48	0.34	3.38e-10	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg21204522	chr6:27730016	NA	-0.4	-5.64	-0.3	3.64e-8	Parkinson's disease;
CRC	cis	rs6534441	0.727	rs74953168	chr4:125466534	A/G	cg21609808	chr4:125404261	NA	0.41	5.64	0.3	3.68e-8	Major depressive disorder;
CRC	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg10790698	chr19:18539756	SSBP4	-0.47	-8.61	-0.43	3.06e-16	Breast cancer;
CRC	cis	rs6586163	1.000	rs1324551	chr10:90751516	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.51	-7.41	-0.38	1.05e-12	Chronic lymphocytic leukemia;
CRC	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg24996280	chr8:143481281	TSNARE1	0.36	5.97	0.31	6e-9	Schizophrenia;
CRC	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.51	8.16	0.41	7.15e-15	Plateletcrit;Platelet count;
CRC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.62	-9.41	-0.46	8.62e-19	Body mass index;
CRC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.43	6.54	0.34	2.4e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-7.42	-0.38	1e-12	Menarche (age at onset);
CRC	cis	rs16975963	0.793	rs73041034	chr19:38286272	G/A	cg15135657	chr19:38346511	NA	-0.44	-5.89	-0.31	9.55e-9	Longevity;
CRC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.41	8.08	0.41	1.22e-14	Mean corpuscular volume;
CRC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-9.32	-0.46	1.73e-18	Cognitive function;
CRC	cis	rs6604026	0.883	rs7514280	chr1:93320869	C/T	cg22128645	chr1:93425802	FAM69A	-0.39	-5.81	-0.31	1.47e-8	Multiple sclerosis;
CRC	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs6499255	0.951	rs7186002	chr16:69751065	C/G	cg04110750	chr16:69646130	NFAT5	-0.54	-7.34	-0.38	1.66e-12	IgE levels;
CRC	cis	rs1223397	0.938	rs17767967	chr6:13282067	C/T	cg07912922	chr6:13274314	PHACTR1	0.53	6.44	0.33	4.2e-10	Blood pressure;
CRC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg20811857	chr17:78079795	GAA	-0.45	-6.4	-0.33	5.45e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.04	-0.41	1.65e-14	Longevity;
CRC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.25	0.53	4.47e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11645453	chr3:52864694	ITIH4	0.4	6.72	0.35	8.18e-11	Bipolar disorder;
CRC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	6.58	0.34	1.85e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.47	6.37	0.33	6.53e-10	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11531628	chr1:27930643	AHDC1	0.39	6.17	0.32	2.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg05139728	chr16:28306816	SBK1	-0.34	-5.82	-0.31	1.4e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg08614441	chr13:113633676	MCF2L	-0.4	-7.0	-0.36	1.42e-11	Systolic blood pressure;
CRC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.83	14.9	0.63	1.04e-38	Breast cancer;
CRC	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg14345882	chr6:26364793	BTN3A2	0.64	6.12	0.32	2.66e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg26618903	chr10:100175079	PYROXD2	-0.41	-6.89	-0.36	2.8e-11	Metabolite levels;
CRC	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg03352830	chr11:487213	PTDSS2	0.44	5.63	0.3	3.77e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.02	-0.36	1.25e-11	Schizophrenia;
CRC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs7665939	1.000	rs72727639	chr4:190107992	G/C	cg09826759	chr4:190284978	NA	-0.74	-6.21	-0.32	1.61e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg15786705	chr6:28176104	NA	0.55	7.73	0.39	1.34e-13	Parkinson's disease;
CRC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg17911788	chr17:44343683	NA	0.55	6.63	0.34	1.41e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02290350	chr8:58132656	NA	-0.57	-8.09	-0.41	1.2e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg17724175	chr1:150552817	MCL1	0.47	6.95	0.36	1.93e-11	Melanoma;
CRC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.26	-0.62	2.92e-36	Body mass index;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg02475695	chr16:616220	NHLRC4	0.44	7.22	0.37	3.6e-12	Height;
CRC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.68	-0.57	2.77e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7776786	0.870	rs12540224	chr7:18830489	C/T	cg13420273	chr7:18810212	HDAC9	-0.31	-6.15	-0.32	2.2e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-6.04	-0.32	4.2e-9	Menarche (age at onset);
CRC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.84	-11.01	-0.52	3.21e-24	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg09218773	chr11:619014	MUPCDH	-0.36	-5.68	-0.3	2.94e-8	Systemic lupus erythematosus;
CRC	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.69	-9.38	-0.46	1.14e-18	Prostate cancer;
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4478858	0.746	rs7520468	chr1:31688812	G/A	cg00250761	chr1:31883323	NA	0.31	5.82	0.31	1.4e-8	Alcohol dependence;
CRC	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.38	-5.73	-0.3	2.22e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.55	8.72	0.43	1.41e-16	Type 2 diabetes;
CRC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.6	-0.43	3.21e-16	Hemoglobin concentration;
CRC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.9	-0.48	2.17e-20	Total cholesterol levels;
CRC	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.55	8.86	0.44	5.28e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.56e-11	Opioid sensitivity;
CRC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.7	-0.35	8.8e-11	Response to antipsychotic treatment;
CRC	cis	rs9303542	0.559	rs12602539	chr17:46617459	T/A	cg04904318	chr17:46607828	HOXB1	-0.52	-6.11	-0.32	2.82e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs12620999	0.774	rs2875726	chr2:237954576	T/C	cg23555395	chr2:238036564	NA	0.49	7.79	0.39	8.85e-14	Systemic lupus erythematosus;
CRC	cis	rs2415984	0.579	rs2100337	chr14:46966088	T/C	cg14871534	chr14:47121158	RPL10L	-0.4	-6.01	-0.31	5.05e-9	Number of children ever born;
CRC	cis	rs2268667	0.511	rs1874807	chr1:85779393	A/G	cg27183818	chr1:85764021	NA	0.43	6.69	0.35	9.81e-11	Asymmetrical dimethylarginine levels;
CRC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.61	-8.66	-0.43	2.18e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.48	-6.81	-0.35	4.64e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.81	0.51	1.64e-23	Platelet count;
CRC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs9937943	0.614	rs35148538	chr16:74613575	G/C	cg01733217	chr16:74700730	RFWD3	0.72	7.56	0.38	4e-13	Neutrophil percentage of white cells;
CRC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.06	-0.32	3.76e-9	Aortic root size;
CRC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.86	-0.31	1.13e-8	Colorectal cancer;
CRC	cis	rs6496667	0.865	rs10438436	chr15:90908781	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.59	-8.14	-0.41	7.97e-15	Rheumatoid arthritis;
CRC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.74	12.62	0.57	4.66e-30	Mean platelet volume;
CRC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.98	-0.44	2.2e-17	Neuroticism;
CRC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs939584	1.000	rs4854347	chr2:641159	A/C	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19717773	chr7:2847554	GNA12	-0.35	-5.62	-0.3	4.15e-8	Height;
CRC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.07	-0.36	9.23e-12	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03069383	chr2:18741691	RDH14	0.39	6.01	0.31	4.91e-9	Obesity-related traits;
CRC	cis	rs11212617	1.000	rs11212615	chr11:108281267	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.25	0.33	1.26e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg16606324	chr3:10149918	C3orf24	0.48	7.03	0.36	1.23e-11	Alzheimer's disease;
CRC	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.83	-14.75	-0.63	3.72e-38	Itch intensity from mosquito bite;
CRC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.77	0.3	1.84e-8	Eosinophil percentage of white cells;
CRC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.57	9.24	0.45	3.09e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6479527	0.875	rs10435924	chr9:96781571	T/C	cg14459158	chr9:96720562	NA	0.36	6.49	0.34	3.12e-10	Esophageal adenocarcinoma;
CRC	cis	rs4074493	1.000	rs4460622	chr1:231173033	C/T	cg22172038	chr1:231176991	FAM89A	0.34	5.88	0.31	1.02e-8	Carotid plaque burden (smoking interaction);
CRC	cis	rs4731207	0.596	rs1481333	chr7:124643059	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.7	-11.43	-0.53	1.07e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.08	0.41	1.26e-14	Life satisfaction;
CRC	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.73	8.59	0.43	3.57e-16	Response to hepatitis C treatment;
CRC	cis	rs12760731	0.843	rs12023718	chr1:178491879	C/T	cg00404053	chr1:178313656	RASAL2	-0.63	-7.09	-0.36	8.36e-12	Obesity-related traits;
CRC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.45	5.8	0.3	1.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11229555	0.609	rs7927730	chr11:58187906	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.22	-0.49	1.74e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.8	7.84	0.4	6.5e-14	Diabetic retinopathy;
CRC	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.68	10.6	0.5	8.67e-23	Intelligence (multi-trait analysis);
CRC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	2.98e-9	Heart rate;
CRC	cis	rs4654899	0.865	rs12130841	chr1:21067051	C/T	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.76	-0.35	6.22e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.81	0.55	4.39e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg22013790	chr1:91990662	CDC7	-0.47	-5.66	-0.3	3.38e-8	Eosinophil percentage of white cells;
CRC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-8.77	-0.44	9.74e-17	Vitamin D levels;
CRC	cis	rs4728302	0.869	rs6962865	chr7:133599433	T/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.5	-0.34	2.97e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg00507830	chr2:103233733	NA	0.54	6.04	0.32	4.13e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.34	-0.33	7.79e-10	Renal cell carcinoma;
CRC	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-7.05	-0.36	1.07e-11	Intelligence (multi-trait analysis);
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01638175	chr3:49171179	LAMB2	0.43	6.94	0.36	2.15e-11	Intelligence (multi-trait analysis);
CRC	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.61	-6.72	-0.35	7.94e-11	Coronary artery disease;
CRC	cis	rs6764363	0.504	rs13072223	chr3:279586	G/C	cg02057681	chr3:285234	CHL1	0.42	7.12	0.37	6.65e-12	Sudden cardiac arrest;
CRC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.74	12.1	0.55	3.9e-28	Monocyte count;
CRC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg06363034	chr20:62225388	GMEB2	0.44	6.84	0.35	3.81e-11	Glioblastoma;
CRC	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg18850127	chr7:39170497	POU6F2	0.46	5.91	0.31	8.42e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.52	-0.43	5.73e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.86	0.35	3.38e-11	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg04518342	chr5:131593106	PDLIM4	0.42	6.87	0.35	3.15e-11	Breast cancer;
CRC	cis	rs2179367	0.887	rs2143076	chr6:149746451	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.37	-5.85	-0.31	1.2e-8	Dupuytren's disease;
CRC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.9	12.69	0.57	2.59e-30	Triglycerides;
CRC	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-6.86	-0.35	3.42e-11	Putamen volume;
CRC	cis	rs4664293	0.631	rs13024749	chr2:160656117	T/G	cg08347373	chr2:160653686	CD302	0.44	7.37	0.38	1.41e-12	Monocyte percentage of white cells;
CRC	cis	rs863345	0.564	rs11264988	chr1:158466912	A/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.59	-0.34	1.78e-10	Pneumococcal bacteremia;
CRC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	16.24	0.67	5.94e-44	Testicular germ cell tumor;
CRC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.65	10.01	0.48	9.21e-21	Birth weight;
CRC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Body mass index;
CRC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.54	7.85	0.4	5.97e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.92	-0.31	8.18e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17401966	0.522	rs12133617	chr1:10288463	C/T	cg19773385	chr1:10388646	KIF1B	-0.48	-7.46	-0.38	7.55e-13	Hepatocellular carcinoma;
CRC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg13628971	chr7:2884303	GNA12	0.52	6.89	0.36	2.8e-11	Height;
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	5.83	0.31	1.3e-8	Prudent dietary pattern;
CRC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.93	0.48	1.76e-20	Alzheimer's disease (late onset);
CRC	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg18232548	chr7:50535776	DDC	-0.46	-6.54	-0.34	2.31e-10	Malaria;
CRC	cis	rs7264396	0.887	rs2236160	chr20:34101821	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.31	-0.33	8.97e-10	Total cholesterol levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03229959	chr8:38089560	DDHD2	0.49	6.24	0.33	1.36e-9	Thyroid stimulating hormone;
CRC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg10790698	chr19:18539756	SSBP4	-0.46	-8.84	-0.44	5.78e-17	Breast cancer;
CRC	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg00290994	chr1:41848739	NA	0.52	7.87	0.4	5.2e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg00631329	chr6:26305371	NA	-0.52	-8.72	-0.43	1.42e-16	Educational attainment;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08354699	chr15:63796895	USP3	0.41	6.28	0.33	1.09e-9	Myopia (pathological);
CRC	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg20636351	chr8:55087400	NA	-0.32	-5.76	-0.3	1.92e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg03623178	chr6:28175578	NA	0.54	7.81	0.4	7.52e-14	Parkinson's disease;
CRC	cis	rs6585424	1.000	rs34332933	chr10:81926750	G/C	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg13264159	chr8:625131	ERICH1	0.59	6.44	0.33	4.21e-10	IgG glycosylation;
CRC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.47	7.34	0.38	1.67e-12	Longevity;
CRC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.6	-9.43	-0.46	7.76e-19	Body mass index;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.52e-18	Parkinson's disease;
CRC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24308560	chr3:49941425	MST1R	0.5	8.31	0.42	2.51e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg11212589	chr17:38028394	ZPBP2	0.45	8.28	0.42	3.21e-15	Self-reported allergy;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.68e-40	Colorectal cancer;
CRC	cis	rs731174	0.797	rs586252	chr1:38155265	G/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.3	-5.63	-0.3	3.94e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs16852403	0.517	rs12047029	chr1:178179717	C/T	cg00404053	chr1:178313656	RASAL2	0.5	6.58	0.34	1.86e-10	Childhood ear infection;
CRC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.34	0.53	2.25e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.66	-0.47	1.3e-19	Body mass index;
CRC	cis	rs1007738	0.507	rs4752969	chr11:47185510	A/G	cg19486271	chr11:47235900	DDB2	0.42	5.68	0.3	2.89e-8	Bone mineral density (hip);
CRC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg25456477	chr12:86230367	RASSF9	0.37	6.34	0.33	7.4e-10	Major depressive disorder;
CRC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg03037974	chr15:76606532	NA	0.55	8.45	0.42	9.42e-16	Blood metabolite levels;
CRC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.0	9.41	0.46	9.08e-19	Diabetic retinopathy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23633679	chr1:173793655	CENPL;DARS2	0.55	7.26	0.37	2.84e-12	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.53	6.58	0.34	1.85e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05966498	chr5:10761293	DAP	0.49	6.68	0.35	1e-10	Hip circumference;
CRC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.97	-0.36	1.73e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.98	0.48	1.19e-20	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9903692	0.954	rs8065670	chr17:46173840	G/A	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs3018066	0.738	rs12639678	chr4:106952765	A/T	cg01869342	chr4:106983673	TBCK	0.45	6.06	0.32	3.73e-9	Cancer;
CRC	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.51	7.25	0.37	2.99e-12	Intelligence (multi-trait analysis);
CRC	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.58	-8.15	-0.41	7.46e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.42	6.21	0.32	1.57e-9	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05045343	chr2:219232747	C2orf62	0.35	6.15	0.32	2.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-6.21	-0.32	1.62e-9	Colorectal cancer;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg18301423	chr5:131593218	PDLIM4	0.31	5.82	0.31	1.4e-8	Blood metabolite levels;
CRC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg20811857	chr17:78079795	GAA	-0.52	-7.94	-0.4	3.3e-14	Yeast infection;
CRC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg12564285	chr5:131593104	PDLIM4	0.31	5.64	0.3	3.69e-8	Blood metabolite levels;
CRC	cis	rs1712517	0.773	rs1063461	chr10:105049105	C/G	cg05636881	chr10:105038444	INA	0.47	8.08	0.41	1.23e-14	Migraine;
CRC	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.31	0.82	6.44e-83	Schizophrenia;
CRC	cis	rs11203032	0.831	rs4078488	chr10:90966546	C/T	cg16672925	chr10:90967113	CH25H	0.46	5.8	0.3	1.55e-8	Heart failure;
CRC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.59	8.83	0.44	6.44e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.72	-11.98	-0.55	1.11e-27	Cognitive function;
CRC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.61	-0.3	4.24e-8	Aortic root size;
CRC	trans	rs6472235	0.837	rs6996761	chr8:66911571	T/A	cg07884673	chr3:53033167	SFMBT1	-0.46	-6.27	-0.33	1.11e-9	Myopia (pathological);Plateletcrit;
CRC	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.58	-9.13	-0.45	7.28e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs9462027	0.628	rs2395598	chr6:34640686	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.69	-10.34	-0.5	6.93e-22	Corneal astigmatism;
CRC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.49	-7.64	-0.39	2.34e-13	Corneal astigmatism;
CRC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg04110750	chr16:69646130	NFAT5	-0.51	-6.75	-0.35	6.72e-11	IgE levels;
CRC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.82	15.06	0.64	2.47e-39	Vitiligo;
CRC	cis	rs12692738	0.526	rs355853	chr2:165627618	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.26	-6.16	-0.32	2.11e-9	Coronary artery disease;
CRC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.57	-5.9	-0.31	9.26e-9	Hip circumference adjusted for BMI;
CRC	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.19	-0.53	7.33e-25	Colorectal cancer;
CRC	cis	rs6662572	0.737	rs4423055	chr1:46259980	T/C	cg08644498	chr1:46502608	NA	-0.44	-7.0	-0.36	1.4e-11	Blood protein levels;
CRC	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.54	-0.47	3.23e-19	Prevalent atrial fibrillation;
CRC	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	12.65	0.57	3.69e-30	Electrocardiographic conduction measures;
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg15511327	chr8:143859410	LYNX1	0.39	6.87	0.35	3.13e-11	Urinary tract infection frequency;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26313349	chr1:145589328	NUDT17	0.36	6.01	0.31	4.8e-9	Obesity-related traits;
CRC	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.43	7.39	0.38	1.26e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.62	0.34	1.49e-10	Depression;
CRC	cis	rs4926298	1.000	rs10423745	chr19:13176815	T/C	cg23899408	chr19:12877188	HOOK2	-0.45	-6.33	-0.33	8.13e-10	Bipolar disorder;
CRC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg15786705	chr6:28176104	NA	0.47	6.9	0.36	2.66e-11	Cardiac Troponin-T levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00029397	chr12:57940957	DCTN2	0.48	6.33	0.33	8.12e-10	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20652787	chr6:41863119	USP49	0.39	6.35	0.33	7.25e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1050846	0.603	rs1050847	chr16:87443734	A/G	cg27585878	chr16:87386489	FBXO31	0.43	7.13	0.37	6.59e-12	Neuroticism;
CRC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.76	10.92	0.52	6.64e-24	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.74	11.74	0.54	8.14e-27	Longevity;Endometriosis;
CRC	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg21918786	chr6:109611834	NA	-0.36	-6.18	-0.32	1.85e-9	Reticulocyte fraction of red cells;
CRC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.86	-13.85	-0.61	1.1e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9462027	0.628	rs2814957	chr6:34702689	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.46	-6.93	-0.36	2.27e-11	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10919791	0.501	rs12029406	chr1:199905828	A/G	cg13229857	chr1:200006247	NR5A2	-0.43	-6.46	-0.34	3.88e-10	Pancreatic cancer;
CRC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-1.08	-12.81	-0.58	9.04e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.65	11.13	0.52	1.27e-24	Prostate cancer;
CRC	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg03689076	chr20:33865952	NA	-0.49	-7.14	-0.37	6.06e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-5.95	-0.31	6.74e-9	Diabetic retinopathy;
CRC	cis	rs939584	1.000	rs13386517	chr2:650479	G/C	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs1545257	0.538	rs729921	chr2:24633124	T/G	cg06627628	chr2:24431161	ITSN2	-0.45	-6.63	-0.34	1.34e-10	Sjögren's syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11940663	chr21:46962454	SLC19A1	0.43	6.85	0.35	3.56e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4731207	0.698	rs12538333	chr7:124508357	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.47	-5.91	-0.31	8.49e-9	Bipolar disorder;
CRC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.52	-6.48	-0.34	3.25e-10	Body mass index;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs6681460	0.899	rs1280280	chr1:67173903	G/A	cg02459107	chr1:67143332	SGIP1	0.34	5.88	0.31	1.03e-8	Presence of antiphospholipid antibodies;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03748352	chr10:182365	ZMYND11	-0.42	-6.28	-0.33	1.09e-9	HDL cholesterol;
CRC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.52	-7.79	-0.39	8.56e-14	Body mass index;
CRC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg06462663	chr19:18546047	ISYNA1	0.48	7.28	0.37	2.43e-12	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21190381	chr2:53994763	LOC100302652;ASB3;CHAC2	0.42	6.21	0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.588	rs11158037	chr14:55832152	C/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.03	-0.32	4.48e-9	Protein biomarker;
CRC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.63	-0.34	1.36e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.62	9.45	0.46	6.67e-19	Menopause (age at onset);
CRC	trans	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19862616	chr7:65841803	NCRNA00174	0.56	8.31	0.42	2.61e-15	Eotaxin levels;
CRC	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.77	-0.3	1.81e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.82	11.61	0.54	2.44e-26	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.07	-0.32	3.54e-9	Alzheimer's disease (late onset);
CRC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.53	8.69	0.43	1.75e-16	Platelet count;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23708337	chr7:1209742	NA	0.49	7.58	0.39	3.45e-13	Longevity;Endometriosis;
CRC	cis	rs7705042	0.865	rs12656877	chr5:141490091	T/C	cg07392085	chr5:141489673	NDFIP1	0.47	7.25	0.37	2.95e-12	Asthma;
CRC	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg23018236	chr17:30244563	NA	-0.6	-7.82	-0.4	7.2e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.62	10.56	0.5	1.25e-22	Body mass index;
CRC	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00938859	chr5:1591904	SDHAP3	0.7	7.62	0.39	2.78e-13	Breast cancer;
CRC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.46	5.95	0.31	6.73e-9	Cocaine dependence;
CRC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.49	6.15	0.32	2.28e-9	Schizophrenia;
CRC	cis	rs7923609	1.000	rs10761742	chr10:65085048	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.78	-0.3	1.73e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.75	12.16	0.56	2.41e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs7710178	0.680	rs280462	chr5:156043586	G/A	cg05270082	chr4:166307089	MIR578;CPE	0.43	5.97	0.31	6.04e-9	Airway responsiveness in chronic obstructive pulmonary disease;
CRC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg27535305	chr1:53392650	SCP2	0.46	8.19	0.41	6e-15	Monocyte count;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg15447715	chr7:150725397	ABCB8	0.45	6.82	0.35	4.34e-11	Schizophrenia;
CRC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.89	-0.36	2.79e-11	Mean platelet volume;
CRC	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg10437265	chr15:77819839	NA	0.65	11.54	0.54	4.4e-26	Type 2 diabetes;
CRC	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	0.82	8.19	0.41	5.86e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.72	-0.3	2.33e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9879311	0.966	rs28113	chr3:10400643	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.38	6.25	0.33	1.25e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.49	6.82	0.35	4.29e-11	Superior crus of antihelix expression;
CRC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.65	-11.78	-0.54	6.03e-27	Breast cancer;
CRC	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg06470822	chr6:28175283	NA	0.88	8.32	0.42	2.3e-15	Parkinson's disease;
CRC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.35	6.44	0.33	4.28e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.58	8.13	0.41	9.05e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg08772003	chr10:104629869	AS3MT	-0.35	-6.02	-0.32	4.59e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg18758796	chr5:131593413	PDLIM4	0.33	5.64	0.3	3.59e-8	Blood metabolite levels;
CRC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.37	-6.43	-0.33	4.4e-10	Height;
CRC	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.56	8.29	0.42	3.02e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17507749	chr15:85114479	UBE2QP1	0.62	8.97	0.44	2.36e-17	Schizophrenia;
CRC	cis	rs1983170	0.668	rs77687738	chr1:92016191	C/G	cg21854759	chr1:92012499	NA	0.5	5.63	0.3	3.91e-8	Eosinophil percentage of white cells;
CRC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.43	-6.36	-0.33	6.92e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.61	-10.07	-0.49	5.72e-21	Calcium levels;
CRC	cis	rs6834538	0.637	rs923237	chr4:113429731	C/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.4	-5.98	-0.31	5.97e-9	Free thyroxine concentration;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg04562611	chr16:615315	C16orf11	0.37	6.32	0.33	8.54e-10	Height;
CRC	cis	rs12936587	0.692	rs35660942	chr17:17527185	G/A	cg09796270	chr17:17721594	SREBF1	-0.4	-5.88	-0.31	9.95e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.41	-0.38	1.05e-12	Cystic fibrosis severity;
CRC	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.74	-11.74	-0.54	8.39e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2303319	0.582	rs56094729	chr2:162464835	C/T	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.55e-9	Cognitive function;
CRC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.42e-13	Schizophrenia;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg26358599	chr1:24018029	RPL11	-0.74	-6.02	-0.31	4.71e-9	Cognitive function;
CRC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.68	-0.43	1.92e-16	HDL cholesterol;
CRC	cis	rs370915	0.542	rs6838849	chr4:187790684	T/C	cg12892747	chr4:187813459	NA	-0.41	-6.2	-0.32	1.67e-9	Gout;
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18887142	chr20:47835750	DDX27	0.41	6.15	0.32	2.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.97	-0.31	6.07e-9	Arsenic metabolism;
CRC	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.39	5.61	0.3	4.28e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.76	-12.96	-0.58	2.5e-31	Body mass index;
CRC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.73	10.69	0.51	4.25e-23	High light scatter reticulocyte count;
CRC	trans	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg11693508	chr17:37793320	STARD3	0.46	6.19	0.32	1.8e-9	Neuroticism;
CRC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07685180	chr8:600429	NA	-0.81	-7.53	-0.38	4.99e-13	IgG glycosylation;
CRC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.42	9.27	0.46	2.47e-18	Lung function (FEV1);
CRC	trans	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg01505111	chr6:125621795	HDDC2	-0.39	-6.0	-0.31	5.07e-9	DNA methylation (variation);
CRC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.7	0.35	9.14e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-13.4	-0.59	5.76e-33	Vitiligo;
CRC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.23	-0.53	5.3e-25	Chronic sinus infection;
CRC	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg26353448	chr1:248524236	OR2T4	-0.35	-6.68	-0.35	1.02e-10	Common traits (Other);
CRC	cis	rs62229266	0.609	rs2835253	chr21:37419745	T/C	cg08632701	chr21:37451849	NA	-0.4	-6.27	-0.33	1.14e-9	Mitral valve prolapse;
CRC	cis	rs62458065	0.850	rs7804998	chr7:32461197	T/C	cg20159608	chr7:32802032	NA	-0.54	-6.62	-0.34	1.47e-10	Metabolite levels (HVA/MHPG ratio);
CRC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.86	-0.48	2.97e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.61	-9.46	-0.46	6.24e-19	Body mass index;
CRC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg18225595	chr11:63971243	STIP1	-0.43	-6.65	-0.34	1.19e-10	Platelet count;
CRC	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.38	-5.93	-0.31	7.46e-9	Endometrial cancer;
CRC	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-7.09	-0.36	8.03e-12	Response to antipsychotic treatment;
CRC	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg06470822	chr6:28175283	NA	0.63	6.69	0.35	9.4e-11	Depression;
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg08200582	chr11:442649	ANO9	-0.71	-7.44	-0.38	8.72e-13	Body mass index;
CRC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.48	-0.34	3.31e-10	Lung cancer;
CRC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-0.68	-8.31	-0.42	2.63e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.69	8.99	0.44	2.01e-17	Platelet count;
CRC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.47	6.22	0.32	1.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.15	0.37	5.5e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg24375607	chr4:120327624	NA	0.44	7.02	0.36	1.25e-11	Corneal astigmatism;
CRC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.38e-59	Hip circumference adjusted for BMI;
CRC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.17	-0.59	4e-32	Diabetic kidney disease;
CRC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg21132104	chr15:45694354	SPATA5L1	0.44	6.43	0.33	4.42e-10	Response to fenofibrate (adiponectin levels);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg21501234	chr15:64683155	TRIP4	0.45	6.68	0.35	1e-10	Interleukin-6 levels;
CRC	cis	rs4380275	0.965	rs4375894	chr2:772567	G/C	cg27237671	chr2:676223	TMEM18	-0.41	-5.72	-0.3	2.41e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.53	-8.21	-0.41	5.25e-15	Sudden cardiac arrest;
CRC	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.48	7.44	0.38	8.57e-13	Red blood cell count;
CRC	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.49	7.59	0.39	3.23e-13	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg21784768	chr11:537496	LRRC56	-0.59	-5.64	-0.3	3.67e-8	Body mass index;
CRC	trans	rs875971	0.528	rs801213	chr7:66014918	C/T	cg02869306	chr7:64672164	INTS4L1	0.43	6.28	0.33	1.08e-9	Aortic root size;
CRC	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg11887960	chr12:57824829	NA	0.65	7.25	0.37	3.08e-12	Obesity-related traits;
CRC	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.55	9.02	0.45	1.61e-17	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg05562828	chr17:3906858	NA	0.48	6.29	0.33	1e-9	Type 2 diabetes;
CRC	cis	rs7215564	0.908	rs61707349	chr17:78665255	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.13	0.32	2.57e-9	Myopia (pathological);
CRC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.76	11.06	0.52	2.15e-24	High light scatter reticulocyte count;
CRC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.71	-0.51	3.59e-23	Total cholesterol levels;
CRC	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.46	9.35	0.46	1.4e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-7.54	-0.38	4.68e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.0	0.31	5.22e-9	Diabetic kidney disease;
CRC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.84	-11.01	-0.52	3.21e-24	Ulcerative colitis;
CRC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg17948913	chr5:572064	NA	0.56	6.25	0.33	1.28e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.92	-0.4	3.73e-14	Gut microbiome composition (summer);
CRC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.59	-7.51	-0.38	5.49e-13	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg24879335	chr3:133465180	TF	0.37	6.81	0.35	4.56e-11	Iron status biomarkers;
CRC	cis	rs41005	1.000	rs798449	chr2:8106533	G/A	cg03155496	chr2:8117019	LOC339788	0.41	7.18	0.37	4.69e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.6	-9.25	-0.45	2.96e-18	Body mass index;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg03623178	chr6:28175578	NA	0.89	11.83	0.55	3.94e-27	Parkinson's disease;
CRC	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.74	-9.68	-0.47	1.12e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg09655341	chr17:79618100	PDE6G	0.49	5.95	0.31	6.78e-9	Dental caries;
CRC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.56	8.02	0.4	1.83e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.17	-10.08	-0.49	5.18e-21	Mitochondrial DNA levels;
CRC	cis	rs7487075	1.000	rs10880966	chr12:46801782	C/G	cg17501823	chr12:47219793	SLC38A4	0.32	5.64	0.3	3.58e-8	Itch intensity from mosquito bite;
CRC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.88	10.92	0.52	6.63e-24	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01786828	chr11:9685521	SWAP70	0.49	6.68	0.35	1.01e-10	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.24	6.66	0.34	1.17e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	11.95	0.55	1.44e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs990171	0.607	rs10153578	chr2:102764609	C/T	cg22835712	chr2:102737379	NA	-0.44	-5.68	-0.3	2.9e-8	Lymphocyte counts;
CRC	cis	rs7725052	0.609	rs4532399	chr5:40467272	T/C	cg09067459	chr5:40385259	NA	0.4	6.57	0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg26805224	chr10:79626177	DLG5	-0.5	-7.18	-0.37	4.67e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.71	-9.09	-0.45	9.28e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.41	6.23	0.32	1.46e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.38	6.44	0.33	4.17e-10	Cardiovascular disease risk factors;
CRC	trans	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg05376469	chr2:102649931	NA	0.37	6.04	0.32	4.2e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg09655341	chr17:79618100	PDE6G	0.5	6.32	0.33	8.48e-10	Dental caries;
CRC	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg09659197	chr4:152720779	NA	0.41	8.46	0.42	8.74e-16	Intelligence (multi-trait analysis);
CRC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.71	11.09	0.52	1.73e-24	Corneal astigmatism;
CRC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.49	-0.34	3.2e-10	Schizophrenia;
CRC	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	0.9	6.76	0.35	6.12e-11	Fat distribution (HIV);
CRC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs9992667	0.955	rs10025499	chr4:38620994	T/C	cg19726192	chr4:38663646	FLJ13197	-0.6	-7.79	-0.39	9.02e-14	Eosinophil percentage of granulocytes;
CRC	cis	rs11212617	0.967	rs7118967	chr11:108057856	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.16	0.32	2.16e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.5	0.42	6.71e-16	Cognitive test performance;
CRC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.68	-10.56	-0.5	1.18e-22	Metabolic syndrome;
CRC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-6.36	-0.33	6.81e-10	Height;
CRC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	7.93	0.4	3.55e-14	Neuroticism;
CRC	cis	rs9847710	0.733	rs2581808	chr3:53089445	C/T	cg18099408	chr3:52552593	STAB1	0.41	6.14	0.32	2.4e-9	Ulcerative colitis;
CRC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.05	-0.32	3.98e-9	Menopause (age at onset);
CRC	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg14631576	chr9:95140430	CENPP	-0.39	-7.33	-0.37	1.78e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.43	-5.82	-0.31	1.39e-8	Schizophrenia;
CRC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.47	6.64	0.34	1.32e-10	Lung cancer;
CRC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg23533926	chr12:111358616	MYL2	-0.56	-8.7	-0.43	1.6e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	0.55	6.07	0.32	3.59e-9	Tonsillectomy;
CRC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.62	-7.68	-0.39	1.9e-13	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20607318	chr19:36391512	NFKBID	0.46	6.66	0.34	1.16e-10	Response to antipsychotic treatment;
CRC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.9	0.4	4.33e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.67	8.46	0.42	8.68e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.58	7.82	0.4	7.34e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.7	-8.67	-0.43	2.06e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4727963	0.765	rs6971635	chr7:122704188	C/T	cg03640110	chr7:122635026	TAS2R16	0.36	6.56	0.34	2.09e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg21918786	chr6:109611834	NA	-0.35	-6.05	-0.32	3.9e-9	Reticulocyte fraction of red cells;
CRC	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.51	7.6	0.39	3.17e-13	Menopause (age at onset);
CRC	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg22495460	chr2:25135724	ADCY3	-0.89	-15.33	-0.65	2.07e-40	Body mass index;
CRC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg21153622	chr11:89784906	NA	-0.5	-8.3	-0.42	2.71e-15	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10501049	chr6:105630323	NA	0.39	6.16	0.32	2.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg23123621	chr4:1343375	KIAA1530	0.32	5.64	0.3	3.65e-8	Obesity-related traits;
CRC	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.3	0.37	2.21e-12	Diisocyanate-induced asthma;
CRC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.51	-6.67	-0.35	1.06e-10	Bipolar disorder;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.5	8.09	0.41	1.15e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.49	7.67	0.39	1.97e-13	Red blood cell count;
CRC	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.31	5.88e-9	Heart rate;
CRC	cis	rs7429990	0.965	rs796566	chr3:47938354	G/C	cg11946769	chr3:48343235	NME6	0.44	5.7	0.3	2.69e-8	Educational attainment (years of education);
CRC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12530845	0.887	rs78641973	chr7:135324311	C/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.73	-0.3	2.27e-8	Red blood cell traits;
CRC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	1.01	13.49	0.6	2.68e-33	Psoriasis;
CRC	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.44	6.25	0.33	1.31e-9	Life satisfaction;
CRC	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.72	9.71	0.47	9.21e-20	Menopause (age at onset);
CRC	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg10483660	chr13:112241077	NA	0.37	5.98	0.31	5.85e-9	Menarche (age at onset);
CRC	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg14593290	chr7:50529359	DDC	0.62	8.12	0.41	9.4e-15	Malaria;
CRC	cis	rs10971721	0.822	rs72727329	chr9:33921664	C/A	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.67	-7.23	-0.37	3.31e-12	Obesity;Body mass index;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg14487702	chr8:22132665	PIWIL2	0.39	5.89	0.31	9.46e-9	Hypertriglyceridemia;
CRC	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.53	-7.19	-0.37	4.31e-12	Pulmonary function decline;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15766557	chr19:46234224	FBXO46	0.43	6.24	0.33	1.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.52	8.82	0.44	6.64e-17	Aortic root size;
CRC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs1656402	0.954	rs11676436	chr2:233453063	A/G	cg03852847	chr2:233439513	NA	-0.39	-6.64	-0.34	1.27e-10	Non-small cell lung cancer (survival);
CRC	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg13919466	chr1:32135498	COL16A1	-0.31	-5.79	-0.3	1.67e-8	Intelligence (multi-trait analysis);
CRC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.48	-7.49	-0.38	6.23e-13	Coronary artery disease;
CRC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.85	15.96	0.66	7.24e-43	Dental caries;
CRC	cis	rs2227564	0.678	rs2242256	chr10:75597546	C/G	cg00564723	chr10:75632066	CAMK2G	0.37	8.8	0.44	8.01e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg22561889	chr6:118971681	C6orf204	0.53	6.87	0.35	3.16e-11	Diastolic blood pressure;
CRC	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.49	8.29	0.42	3.01e-15	Common traits (Other);
CRC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05013783	chr12:56652058	ANKRD52	0.49	7.01	0.36	1.37e-11	Response to antipsychotic treatment;
CRC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg26754761	chr2:177040938	NA	-0.45	-6.68	-0.35	1.01e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24770856	chr10:127512017	BCCIP;UROS	0.45	6.48	0.34	3.27e-10	Response to antipsychotic treatment;
CRC	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.54	-8.93	-0.44	3.11e-17	Dupuytren's disease;
CRC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.63	10.0	0.48	9.8e-21	Height;
CRC	trans	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg21659725	chr3:3221576	CRBN	-0.64	-6.07	-0.32	3.52e-9	Menarche (age at onset);
CRC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg19812747	chr11:111475976	SIK2	0.44	6.34	0.33	7.7e-10	Primary sclerosing cholangitis;
CRC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg23533926	chr12:111358616	MYL2	-0.51	-7.68	-0.39	1.84e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26714650	chr12:56694279	CS	-1.43	-11.59	-0.54	2.88e-26	Psoriasis vulgaris;
CRC	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.88	10.95	0.52	5.48e-24	Diisocyanate-induced asthma;
CRC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-9.99	-0.48	1.08e-20	Schizophrenia;
CRC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-10.1	-0.49	4.6e-21	Personality dimensions;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17539315	chr12:50794919	LARP4	0.55	7.14	0.37	6.1e-12	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.5	-8.78	-0.44	9.1e-17	Blood metabolite levels;
CRC	trans	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg11693508	chr17:37793320	STARD3	0.5	6.61	0.34	1.52e-10	Neuroticism;
CRC	cis	rs17092148	0.887	rs6059936	chr20:33184249	C/T	cg08999081	chr20:33150536	PIGU	0.49	6.3	0.33	9.31e-10	Neuroticism;
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.14e-9	Prudent dietary pattern;
CRC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.85	-13.6	-0.6	9.92e-34	Cognitive function;
CRC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.67	-7.08	-0.36	8.63e-12	Psoriasis;
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.58	-7.84	-0.4	6.35e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg21784768	chr11:537496	LRRC56	-0.58	-5.87	-0.31	1.08e-8	Body mass index;
CRC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg11900509	chr10:81946545	ANXA11	0.38	6.17	0.32	2.04e-9	Sarcoidosis;
CRC	cis	rs747650	0.892	rs7937101	chr11:47226488	A/G	cg19486271	chr11:47235900	DDB2	-0.52	-8.11	-0.41	1e-14	Acne (severe);
CRC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg25985355	chr7:65971099	NA	-0.52	-6.1	-0.32	3.05e-9	Diabetic kidney disease;
CRC	trans	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.0	-0.31	5.08e-9	Tuberculosis;
CRC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-6.92	-0.36	2.38e-11	Neuroticism;
CRC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.88	-0.48	2.55e-20	Body mass index;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	10.3	0.49	9.51e-22	Systolic blood pressure;
CRC	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg13919466	chr1:32135498	COL16A1	-0.3	-5.73	-0.3	2.3e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7625357	1.000	rs7625357	chr3:169347832	C/T	cg04414509	chr3:169351419	MECOM	0.59	8.95	0.44	2.73e-17	Childhood and early adolescence aggressive behavior;
CRC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.9	-0.4	4.18e-14	Height;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg15845792	chr6:28175446	NA	0.76	10.78	0.51	2.11e-23	Parkinson's disease;
CRC	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.67	9.67	0.47	1.23e-19	Bipolar disorder;
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.67	9.7	0.47	9.79e-20	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21963583	chr11:68658836	MRPL21	0.64	11.61	0.54	2.3e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs231513	0.911	rs124720	chr17:41960141	A/G	cg26893861	chr17:41843967	DUSP3	-0.72	-6.5	-0.34	3.05e-10	Cognitive function;
CRC	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.74	0.63	4.18e-38	Exhaled nitric oxide output;
CRC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.69	-0.39	1.68e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg10790698	chr19:18539756	SSBP4	-0.44	-8.38	-0.42	1.59e-15	Breast cancer;
CRC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.39	-5.61	-0.3	4.36e-8	Daytime sleep phenotypes;
CRC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.61	9.58	0.47	2.56e-19	Systemic lupus erythematosus;
CRC	trans	rs12699921	0.632	rs2691615	chr7:17887180	C/G	cg02066331	chr6:17282778	RBM24	-0.35	-6.05	-0.32	3.99e-9	Fibrinogen levels;
CRC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.57	-8.22	-0.41	4.85e-15	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10297971	chr15:93426637	NA	0.38	6.01	0.31	4.79e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg01500633	chr6:86387148	SNORD50A;SNHG5	-0.38	-5.97	-0.31	6.24e-9	Aortic root size;
CRC	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	23.24	0.79	2.2e-71	Schizophrenia;
CRC	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg00250761	chr1:31883323	NA	0.41	7.62	0.39	2.81e-13	Alcohol dependence;
CRC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg16797656	chr11:68205561	LRP5	0.37	5.75	0.3	2.05e-8	Total body bone mineral density;
CRC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.54	-7.88	-0.4	4.89e-14	Cisplatin-induced ototoxicity;
CRC	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg17133734	chr15:86042851	AKAP13	0.39	6.19	0.32	1.82e-9	Coronary artery disease;
CRC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg01629716	chr15:45996671	NA	0.4	8.35	0.42	1.89e-15	Waist circumference;Weight;
CRC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.34	0.59	9.15e-33	Bone mineral density;
CRC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg16342193	chr10:102329863	NA	-0.37	-6.01	-0.31	5.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04911280	chr6:44281184	AARS2	0.37	6.09	0.32	3.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.74	-7.43	-0.38	9.68e-13	Non-glioblastoma glioma;Glioma;
CRC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.51	9.78	0.47	5.53e-20	Renal cell carcinoma;
CRC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg03037974	chr15:76606532	NA	-0.43	-5.99	-0.31	5.44e-9	Blood metabolite levels;
CRC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	10.53	0.5	1.58e-22	Motion sickness;
CRC	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg26394196	chr10:1453818	ADARB2	-0.33	-5.83	-0.31	1.34e-8	Radiation response;
CRC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg00359181	chr2:38893519	GALM	-0.55	-5.89	-0.31	9.3e-9	5-HTT brain serotonin transporter levels;
CRC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.03	0.52	2.69e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3126085	0.515	rs11204998	chr1:152365655	A/C	cg09127314	chr1:152161683	NA	-0.44	-5.87	-0.31	1.06e-8	Atopic dermatitis;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg07217954	chr7:1067459	C7orf50	0.55	5.61	0.3	4.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.4e-8	Lung cancer;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20092199	chr4:1342459	KIAA1530	-0.38	-6.8	-0.35	4.94e-11	Obesity-related traits;
CRC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.7	-0.39	1.62e-13	Gut microbiome composition (summer);
CRC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.35	-0.46	1.35e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	7.33	0.37	1.77e-12	Iron status biomarkers;
CRC	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg06632207	chr12:54070931	ATP5G2	-0.41	-7.26	-0.37	2.89e-12	Height;
CRC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.73	11.32	0.53	2.66e-25	Tonsillectomy;
CRC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg18490616	chr2:88469792	THNSL2	-0.44	-6.39	-0.33	5.61e-10	Response to metformin (IC50);
CRC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg21770322	chr7:97807741	LMTK2	0.85	19.36	0.73	2.8e-56	Breast cancer;
CRC	cis	rs2971970	0.539	rs2971972	chr7:133644200	A/G	cg03336402	chr7:133662267	EXOC4	-0.66	-10.33	-0.5	7.31e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.56	-9.86	-0.48	2.94e-20	Lung function (FVC);
CRC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-18.95	-0.72	1.19e-54	Height;
CRC	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg04239558	chr2:103089729	SLC9A4	0.38	6.64	0.34	1.29e-10	Blood protein levels;
CRC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-6.89	-0.36	2.83e-11	Type 2 diabetes;
CRC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.95	0.31	6.72e-9	Axial length;
CRC	trans	rs62295889	0.602	rs62293667	chr4:12539018	T/C	cg03490839	chr16:73082051	ZFHX3	0.59	6.38	0.33	5.96e-10	Obesity-related traits;
CRC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.49	-7.22	-0.37	3.74e-12	Corneal astigmatism;
CRC	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg09264619	chr17:80180166	NA	0.47	6.51	0.34	2.73e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.52	-0.42	6.03e-16	Alcohol dependence;
CRC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.19	0.41	5.93e-15	Retinal vascular caliber;
CRC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.61	9.07	0.45	1.13e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.91e-9	Arsenic metabolism;
CRC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg16141378	chr3:129829833	LOC729375	-0.42	-6.11	-0.32	2.78e-9	Retinal vascular caliber;
CRC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.54	-5.65	-0.3	3.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12144094	0.882	rs1441011	chr1:120245374	T/C	cg20995928	chr1:120229863	NA	0.46	6.61	0.34	1.56e-10	Height;
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.38	0.38	1.3e-12	Eye color traits;
CRC	cis	rs12024301	0.557	rs10157789	chr1:183654973	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.54	7.29	0.37	2.36e-12	Height;
CRC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.45	5.71	0.3	2.52e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs6600671	1.000	rs1856572	chr1:121169579	A/C	cg09829573	chr1:144692074	NBPF9	-0.4	-6.07	-0.32	3.49e-9	Hip geometry;
CRC	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-1.1	-12.97	-0.58	2.41e-31	Blood pressure (smoking interaction);
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.59	-8.22	-0.41	4.67e-15	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.92	-0.31	8.02e-9	Gout;Renal underexcretion gout;
CRC	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.7	9.71	0.47	9.08e-20	Hair shape;
CRC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.42	6.11	0.32	2.83e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.49	8.35	0.42	1.98e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.44	6.66	0.34	1.13e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.39	-5.83	-0.31	1.32e-8	Total body bone mineral density;
CRC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.33	-0.46	1.67e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.09	0.74	3.8e-59	Prudent dietary pattern;
CRC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.06	0.36	9.8e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs863345	0.604	rs1342945	chr1:158512912	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.42	-0.33	4.84e-10	Pneumococcal bacteremia;
CRC	cis	rs7527798	0.592	rs12119104	chr1:207861207	A/G	cg09232269	chr1:207846808	CR1L	-0.48	-7.85	-0.4	5.98e-14	Erythrocyte sedimentation rate;
CRC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.65	7.33	0.37	1.83e-12	Body mass index;
CRC	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.62	9.08	0.45	1.03e-17	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.49	-0.34	3.07e-10	Mean corpuscular volume;
CRC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg10790698	chr19:18539756	SSBP4	-0.43	-8.13	-0.41	8.79e-15	Breast cancer;
CRC	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.86	-0.35	3.43e-11	Menopause (age at onset);
CRC	cis	rs1511802	0.666	rs28698123	chr4:187123189	C/T	cg24794857	chr4:187113578	CYP4V2	0.39	5.69	0.3	2.86e-8	Blood protein levels;
CRC	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.77	-12.69	-0.57	2.61e-30	Survival in pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03885414	chr19:54240196	NA	0.29	6.12	0.32	2.69e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.5	6.56	0.34	2.03e-10	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02970425	chr20:48552805	RNF114	0.44	6.4	0.33	5.47e-10	Response to antipsychotic treatment;
CRC	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg12964065	chr18:77638022	KCNG2	0.62	6.64	0.34	1.3100000000000001e-10	Opioid sensitivity;
CRC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg23018236	chr17:30244563	NA	-0.47	-6.62	-0.34	1.5e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg11143507	chr3:125485238	NA	-0.57	-7.35	-0.38	1.55e-12	Blood pressure (smoking interaction);
CRC	trans	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg24644049	chr4:85504048	CDS1	0.84	7.48	0.38	6.98e-13	Skin colour saturation;
CRC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg09876464	chr15:85330779	ZNF592	0.39	6.48	0.34	3.34e-10	P wave terminal force;
CRC	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.57	7.99	0.4	2.26e-14	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-7.48	-0.38	6.83e-13	Menarche (age at onset);
CRC	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg20608306	chr11:116969690	SIK3	-0.34	-6.41	-0.33	5.09e-10	Subjective well-being;
CRC	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg26741380	chr15:41871084	TYRO3	0.44	6.93	0.36	2.24e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.6	-9.4	-0.46	9.45e-19	Aortic root size;
CRC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-9.7	-0.47	9.86e-20	Monocyte percentage of white cells;
CRC	cis	rs911119	0.913	rs6048929	chr20:23588855	T/C	cg16589663	chr20:23618590	CST3	0.45	6.44	0.33	4.34e-10	Chronic kidney disease;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg22638593	chr5:131593259	PDLIM4	0.52	9.14	0.45	6.39e-18	Acylcarnitine levels;
CRC	cis	rs7619833	0.620	rs2370946	chr3:27260283	A/G	cg02860705	chr3:27208620	NA	-0.38	-6.04	-0.32	4.06e-9	Breast cancer;
CRC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.99	0.7	7.42e-51	Platelet count;
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.4	-0.33	5.43e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.41	6.15	0.32	2.25e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.35	0.33	7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg15511327	chr8:143859410	LYNX1	-0.41	-6.32	-0.33	8.38e-10	Urinary tract infection frequency;
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.31	0.56	6.9e-29	Height;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.45	-9.97	-0.48	1.25e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.38	6.5	0.34	2.98e-10	Alcohol dependence;
CRC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.43	-6.44	-0.33	4.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	11.19	0.53	7.45e-25	Bone mineral density;
CRC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-6.23	-0.32	1.4e-9	Response to bleomycin (chromatid breaks);
CRC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg23463467	chr20:60627584	TAF4	0.3	5.62	0.3	4.12e-8	Body mass index;
CRC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.63	6.99	0.36	1.58e-11	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01140101	chr1:202113040	ARL8A	0.45	6.84	0.35	3.81e-11	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg08314208	chr16:67682810	RLTPR	-0.6	-6.42	-0.33	4.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1519814	1.000	rs7826920	chr8:121121010	T/C	cg22335954	chr8:121166405	COL14A1	-0.49	-6.1	-0.32	3.06e-9	Breast cancer;
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.66	0.39	2.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1784692	1.000	rs1784692	chr11:113949232	A/G	cg07057617	chr6:170405951	NA	0.52	6.03	0.32	4.37e-9	Polycystic ovary syndrome;
CRC	cis	rs12476592	0.602	rs262514	chr2:63890920	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg24607948	chr9:100459097	XPA	-0.41	-6.16	-0.32	2.18e-9	Daytime sleep phenotypes;
CRC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.42	-0.33	4.8e-10	Aortic root size;
CRC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg26762873	chr11:5879799	OR52E8	-0.39	-5.72	-0.3	2.35e-8	DNA methylation (variation);
CRC	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.09	0.49	4.8e-21	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21041329	chr8:56686126	TMEM68;TGS1	0.39	6.61	0.34	1.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg20356878	chr3:121714668	ILDR1	-0.42	-6.08	-0.32	3.25e-9	Multiple sclerosis;
CRC	cis	rs802075	1.000	rs4711935	chr6:49647822	C/T	cg20364632	chr6:49636226	NA	-0.36	-5.71	-0.3	2.53e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg20291162	chr17:40259547	DHX58	-0.56	-8.24	-0.41	4.27e-15	Fibrinogen levels;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.7	7.14	0.37	6.14e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg05207973	chr5:176823642	SLC34A1	0.35	5.88	0.31	1.03e-8	Hemoglobin concentration;Hematocrit;
CRC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.6	8.27	0.41	3.47e-15	Lung cancer;
CRC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg12464048	chr2:102091129	RFX8	0.44	6.18	0.32	1.86e-9	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg10396713	chr8:602097	NA	-0.47	-5.66	-0.3	3.34e-8	IgG glycosylation;
CRC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.35	-9.74	-0.47	7.52e-20	Mean corpuscular volume;
CRC	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.85	-0.35	3.58e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs12760731	0.582	rs35304375	chr1:178539180	A/G	cg00404053	chr1:178313656	RASAL2	0.63	7.09	0.36	8.37e-12	Obesity-related traits;
CRC	trans	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg18543242	chr14:23290393	SLC7A7	0.43	5.98	0.31	5.79e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.46	-7.18	-0.37	4.6e-12	Hip circumference adjusted for BMI;
CRC	trans	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg11693508	chr17:37793320	STARD3	0.53	7.03	0.36	1.22e-11	Neuroticism;
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.65	-0.3	3.41e-8	Neuroticism;
CRC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.32	-0.56	6.35e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg04110750	chr16:69646130	NFAT5	-0.5	-6.87	-0.35	3.16e-11	IgE levels;
CRC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.91	-11.53	-0.54	4.59e-26	Bronchopulmonary dysplasia;
CRC	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.64	11.37	0.53	1.73e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg16511076	chr4:48887480	OCIAD2	-0.41	-6.64	-0.34	1.26e-10	HDL cholesterol;
CRC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.7	-10.92	-0.52	7.03e-24	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.4	6.18	0.32	1.94e-9	Red blood cell count;
CRC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg02527881	chr3:46936655	PTH1R	0.39	7.1	0.36	7.61e-12	Colorectal cancer;
CRC	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11446398	chr5:77624930	NA	0.47	6.3	0.33	9.63e-10	Triglycerides;
CRC	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.47	0.34	3.49e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-11.29	-0.53	3.45e-25	Colorectal cancer;
CRC	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.59	-8.01	-0.4	2e-14	Extraversion;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14358451	chr1:156698811	C1orf66;ISG20L2	0.42	6.13	0.32	2.57e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg03623178	chr6:28175578	NA	0.63	8.4	0.42	1.36e-15	Parkinson's disease;
CRC	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.73	-11.74	-0.54	7.95e-27	Plateletcrit;Platelet count;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg02336364	chr1:24764700	NIPAL3	0.37	6.23	0.32	1.44e-9	Response to interferon beta in multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09414045	chr1:110162465	AMPD2	0.48	8.07	0.41	1.36e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.34	5.78	0.3	1.77e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.53	-7.92	-0.4	3.8e-14	Blood protein levels;
CRC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.83	-9.93	-0.48	1.74e-20	Inflammatory bowel disease;
CRC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.5	-6.82	-0.35	4.3e-11	Body mass index;
CRC	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.5	6.34	0.33	7.74e-10	Alzheimer's disease (survival time);
CRC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.9	-0.52	7.9e-24	Pancreatic cancer;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg02683197	chr6:28174875	NA	0.63	8.19	0.41	5.64e-15	Parkinson's disease;
CRC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.62	10.09	0.49	4.83e-21	Aortic root size;
CRC	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.46	7.42	0.38	9.93e-13	Schizophrenia;
CRC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.61	10.46	0.5	2.59e-22	Resting heart rate;
CRC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg05709478	chr1:6581295	PLEKHG5	-0.5	-5.69	-0.3	2.83e-8	Body mass index;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27161523	chr12:51591966	POU6F1	0.44	6.24	0.33	1.36e-9	Monocyte percentage of white cells;
CRC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg00246817	chr9:123691163	NA	-0.43	-5.6	-0.3	4.53e-8	Rheumatoid arthritis;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02807482	chr3:125708958	NA	-0.46	-6.0	-0.31	5.14e-9	Blood pressure (smoking interaction);
CRC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg23625390	chr15:77176239	SCAPER	0.5	7.18	0.37	4.65e-12	Blood metabolite levels;
CRC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg09659197	chr4:152720779	NA	0.4	8.23	0.41	4.47e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.62	-7.16	-0.37	5.24e-12	Ulcerative colitis;
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11645453	chr3:52864694	ITIH4	0.35	6.13	0.32	2.58e-9	Bipolar disorder;
CRC	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg06606381	chr12:133084897	FBRSL1	-0.91	-6.95	-0.36	1.91e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.54	-8.38	-0.42	1.58e-15	Asthma (sex interaction);
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg05064044	chr6:292385	DUSP22	-0.6	-8.22	-0.41	4.88e-15	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.19	0.37	4.48e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg23032129	chr1:109941072	SORT1	-0.27	-5.76	-0.3	1.94e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9463078	0.547	rs2038555	chr6:44744033	A/G	cg25276700	chr6:44698697	NA	0.3	7.76	0.39	1.09e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9903692	0.954	rs4794448	chr17:46180807	C/T	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.71	-8.24	-0.41	4.02e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.55	-5.74	-0.3	2.15e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.57	9.73	0.47	7.95e-20	Dupuytren's disease;
CRC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg22815214	chr1:201083145	CACNA1S	0.63	10.32	0.49	8.07e-22	Permanent tooth development;
CRC	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11547950	chr5:77652471	NA	-0.48	-7.03	-0.36	1.19e-11	Triglycerides;
CRC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.29	0.33	9.93e-10	Asthma;
CRC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.51	-9.28	-0.46	2.3e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.39	-5.69	-0.3	2.76e-8	Coronary artery disease;
CRC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg21466736	chr12:48725269	NA	0.52	8.13	0.41	8.75e-15	Plateletcrit;
CRC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.92	0.36	2.4e-11	Rheumatoid arthritis;
CRC	trans	rs10242455	0.702	rs73713507	chr7:99138603	G/A	cg09045935	chr12:6379348	NA	1.13	8.15	0.41	7.74e-15	Blood metabolite levels;
CRC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02290350	chr8:58132656	NA	-0.43	-6.03	-0.32	4.3e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.51	8.16	0.41	7.28e-15	Menopause (age at onset);
CRC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	15.5	0.65	4.4e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.26	-0.33	1.23e-9	Height;
CRC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.46	7.26	0.37	2.81e-12	Eye color traits;
CRC	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.87	15.38	0.65	1.31e-40	Phospholipid levels (plasma);
CRC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.39	7.37	0.38	1.4e-12	Subjective well-being;
CRC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg20203395	chr5:56204925	C5orf35	-0.73	-8.6	-0.43	3.41e-16	Initial pursuit acceleration;
CRC	cis	rs9462027	0.583	rs2744974	chr6:34579431	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.05	-0.32	3.88e-9	Systemic lupus erythematosus;
CRC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs6586163	0.872	rs7069841	chr10:90741955	T/C	cg13456138	chr10:90753195	FAS	-0.44	-6.58	-0.34	1.84e-10	Chronic lymphocytic leukemia;
CRC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.01	11.83	0.55	3.79e-27	Diabetic kidney disease;
CRC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.65	-10.22	-0.49	1.84e-21	Huntington's disease progression;
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.72	-9.6	-0.47	2.14e-19	Alzheimer's disease;
CRC	cis	rs965469	1.000	rs6051807	chr20:3350485	A/G	cg25506879	chr20:3388711	C20orf194	-0.41	-5.85	-0.31	1.19e-8	IFN-related cytopenia;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.0	-0.31	5.29e-9	Total body bone mineral density;
CRC	cis	rs2811415	0.597	rs9822021	chr3:127735238	T/C	cg13719885	chr3:127795394	NA	-0.38	-5.75	-0.3	2.06e-8	Lung function (FEV1/FVC);
CRC	cis	rs4803480	0.872	rs10420470	chr19:42073433	A/G	cg08478046	chr19:42093086	CEACAM21	-0.39	-6.6	-0.34	1.64e-10	Schizophrenia;
CRC	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.58	-8.11	-0.41	1.05e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.73	-0.39	1.33e-13	Colorectal cancer;
CRC	cis	rs117623576	0.816	rs72784871	chr10:32445169	T/A	cg03047570	chr10:32398778	NA	-0.66	-6.17	-0.32	1.98e-9	Anti-saccade response;
CRC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg23758597	chr6:163146217	PARK2	-0.51	-5.9	-0.31	8.81e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.66	-0.3	3.3e-8	Breast cancer;
CRC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.76	14.57	0.63	1.95e-37	Body mass index;
CRC	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.45	-6.41	-0.33	5e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.75	-12.86	-0.58	6.25e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg02811702	chr13:24901961	NA	0.47	6.62	0.34	1.49e-10	Obesity-related traits;
CRC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg24289452	chr6:170231220	NA	-0.54	-6.01	-0.31	5.05e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg15448220	chr1:150897856	SETDB1	0.46	6.54	0.34	2.29e-10	Tonsillectomy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12176476	chr15:75747445	SIN3A	0.43	6.05	0.32	4.02e-9	Anxiety disorder;
CRC	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg11693508	chr17:37793320	STARD3	0.56	6.66	0.34	1.12e-10	Bipolar disorder;
CRC	cis	rs1572438	0.862	rs4959467	chr6:857977	G/C	cg13447295	chr6:887704	NA	-0.42	-6.18	-0.32	1.88e-9	Aging;
CRC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.61	9.34	0.46	1.48e-18	Corneal astigmatism;
CRC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.55	7.8	0.4	8.21e-14	Melanoma;
CRC	cis	rs2019216	0.967	rs2342216	chr17:21910379	A/C	cg05591447	chr17:21909280	FLJ36000	-0.33	-6.74	-0.35	7.1e-11	Pelvic organ prolapse;
CRC	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.4	5.69	0.3	2.87e-8	Blood pressure (smoking interaction);
CRC	cis	rs6735179	0.648	rs10469992	chr2:1760091	A/G	cg19300414	chr2:1746591	PXDN	-0.34	-5.97	-0.31	6.16e-9	Response to antipsychotic treatment;
CRC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg16102536	chr7:156981717	UBE3C	-0.37	-6.3	-0.33	9.6e-10	Body mass index;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg02683197	chr6:28174875	NA	0.66	8.47	0.42	8.25e-16	Parkinson's disease;
CRC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.74	-11.98	-0.55	1.11e-27	Idiopathic membranous nephropathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12218697	chr1:86042661	DDAH1	0.43	5.96	0.31	6.46e-9	Response to antipsychotic treatment;
CRC	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg03929089	chr4:120376271	NA	-0.68	-6.64	-0.34	1.34e-10	Intraocular pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15573783	chr19:45927056	ERCC1	0.39	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.89	17.69	0.7	1.08e-49	Metabolic syndrome;
CRC	cis	rs6662572	0.703	rs7548617	chr1:46365489	C/A	cg08644498	chr1:46502608	NA	-0.44	-6.85	-0.35	3.69e-11	Blood protein levels;
CRC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.3	0.42	2.68e-15	Mean corpuscular volume;
CRC	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.96	-12.6	-0.57	5.5e-30	Educational attainment;
CRC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg21153622	chr11:89784906	NA	-0.44	-7.16	-0.37	5.41e-12	Height;
CRC	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.62	9.2	0.45	4.08e-18	Hemoglobin concentration;
CRC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs6840360	0.573	rs10024721	chr4:152265331	G/A	cg09659197	chr4:152720779	NA	0.32	6.31	0.33	8.78e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.07	-0.45	1.13e-17	Bipolar disorder;
CRC	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg00086871	chr4:6988644	TBC1D14	1.01	7.58	0.39	3.49e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.58	0.54	2.93e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg09045935	chr12:6379348	NA	1.14	8.91	0.44	3.66e-17	Blood metabolite levels;
CRC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.95	10.6	0.5	8.78e-23	Eosinophil percentage of granulocytes;
CRC	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg06606381	chr12:133084897	FBRSL1	-1.01	-7.01	-0.36	1.36e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2882667	0.898	rs10058347	chr5:138361358	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-6.01	-0.31	4.85e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.54	9.83	0.48	3.58e-20	Height;
CRC	cis	rs59104589	0.959	rs3771555	chr2:242322680	C/T	cg10021735	chr2:242295487	FARP2	-0.42	-5.96	-0.31	6.5e-9	Fibrinogen levels;
CRC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.67	-9.82	-0.48	4.01e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg10298567	chr3:47292165	KIF9	0.39	6.01	0.31	4.97e-9	Colorectal cancer;
CRC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.48	-6.64	-0.34	1.3e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-10.15	-0.49	3.07e-21	Blood protein levels;
CRC	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-6.02	-0.32	4.6e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.14	-0.37	6.04e-12	Pulmonary function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26732287	chr11:102322742	TMEM123	0.44	6.5	0.34	3.03e-10	Intelligence (multi-trait analysis);
CRC	trans	rs10208940	0.843	rs7608248	chr2:68851403	C/T	cg00078746	chr14:91700401	GPR68	0.44	6.01	0.31	4.8e-9	Urate levels in lean individuals;
CRC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.63	-0.3	3.86e-8	Reticulocyte count;
CRC	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg02702477	chr5:179499311	RNF130	0.83	8.39	0.42	1.43e-15	LDL cholesterol;
CRC	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.96	-16.27	-0.67	4.46e-44	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs10512697	0.803	rs34134373	chr5:3574462	C/A	cg19473799	chr5:3511975	NA	-0.74	-5.72	-0.3	2.46e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg03804128	chr16:635623	NA	0.29	6.75	0.35	6.86e-11	Height;
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	trans	rs2303319	0.582	rs62187608	chr2:162431138	T/G	cg12500891	chr11:57225987	NA	-0.67	-5.97	-0.31	6e-9	Cognitive function;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11645453	chr3:52864694	ITIH4	0.36	6.21	0.32	1.64e-9	Bipolar disorder;
CRC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.2	-0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	8.11	0.41	1e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9549328	0.565	rs35371379	chr13:113616715	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.35	0.46	1.43e-18	Systolic blood pressure;
CRC	trans	rs11088226	0.581	rs2833862	chr21:33884390	A/G	cg09050820	chr6:167586206	TCP10L2	0.52	7.32	0.37	1.93e-12	Gastritis;
CRC	trans	rs9561329	0.800	rs12430278	chr13:94035424	C/T	cg23072629	chr2:239195537	PER2	0.34	6.41	0.33	4.99e-10	Neuroticism (age interaction);
CRC	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs780094	0.500	rs4666002	chr2:27840640	G/C	cg27432699	chr2:27873401	GPN1	0.46	5.97	0.31	6.14e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.46	6.85	0.35	3.63e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-6.48	-0.34	3.39e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs860295	0.702	rs12239100	chr1:155428476	C/A	cg02153340	chr1:155202674	NA	-0.58	-6.92	-0.36	2.44e-11	Body mass index;
CRC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.61	8.83	0.44	6.28e-17	Lymphocyte counts;
CRC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.63	10.07	0.49	5.55e-21	Height;
CRC	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg08501292	chr6:25962987	TRIM38	1.09	9.37	0.46	1.2e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg08314208	chr16:67682810	RLTPR	-0.5	-6.04	-0.32	4.22e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-12.7	-0.57	2.5e-30	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10894147	0.709	rs1030467	chr11:129744252	T/C	cg27255275	chr11:129766154	NFRKB	0.4	5.79	0.3	1.64e-8	Obesity-related traits;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.18	-0.32	1.87e-9	Parkinson's disease;
CRC	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.62	10.92	0.52	6.69e-24	Superior crus of antihelix expression;
CRC	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.89	-16.85	-0.68	2.31e-46	Hip circumference;
CRC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.47	-6.27	-0.33	1.15e-9	Gut microbiome composition (summer);
CRC	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.41	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.55	-0.5	1.36e-22	Alzheimer's disease;
CRC	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.59	-6.22	-0.32	1.52e-9	Coronary artery disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04180668	chr6:163148903	PARK2;PACRG	-0.41	-6.3	-0.33	9.29e-10	Aortic root size;
CRC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.42	0.46	8.51e-19	Lymphocyte counts;
CRC	cis	rs12476592	0.602	rs262506	chr2:63863022	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.03	0.32	4.37e-9	Childhood ear infection;
CRC	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.38	-5.65	-0.3	3.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1223397	0.938	rs3734878	chr6:13288850	C/T	cg06879394	chr6:13274151	PHACTR1	0.53	6.22	0.32	1.54e-9	Blood pressure;
CRC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg25344623	chr2:136566232	LCT	0.34	6.15	0.32	2.2e-9	Mosquito bite size;
CRC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg23229984	chr5:148520753	ABLIM3	0.5	6.95	0.36	1.96e-11	Breast cancer;
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.94	-0.31	7.17e-9	Total body bone mineral density;
CRC	cis	rs2997447	0.846	rs61775422	chr1:26395898	C/T	cg24519413	chr1:26490540	NA	0.46	5.66	0.3	3.22e-8	QRS complex (12-leadsum);
CRC	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.66	-6.84	-0.35	3.88e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6479527	0.806	rs6479522	chr9:96748822	G/A	cg14459158	chr9:96720562	NA	0.41	7.52	0.38	5.11e-13	Esophageal adenocarcinoma;
CRC	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.78	-0.3	1.74e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.8	-0.39	8.41e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs7487075	0.751	rs7310869	chr12:46665386	G/C	cg22049899	chr12:47219821	SLC38A4	0.32	6.12	0.32	2.65e-9	Itch intensity from mosquito bite;
CRC	cis	rs12541635	0.966	rs12544362	chr8:106976344	A/C	cg10147462	chr8:107024639	NA	0.41	6.62	0.34	1.5e-10	Age of smoking initiation;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.76	11.43	0.53	1.01e-25	Menarche (age at onset);
CRC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg03006477	chr6:74432658	CD109	0.36	6.34	0.33	7.53e-10	Blood protein levels;Calcium levels;
CRC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.5	7.82	0.4	7.14e-14	Red blood cell count;
CRC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.39	-5.65	-0.3	3.48e-8	Neurofibrillary tangles;
CRC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.53	-7.5	-0.38	6.01e-13	Neuroticism;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg08034379	chr2:228736324	WDR69	-0.49	-6.75	-0.35	6.78e-11	Blood pressure;
CRC	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.52	0.46	3.84e-19	Corneal astigmatism;
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.12	0.32	2.65e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.54	-8.11	-0.41	9.81e-15	Obesity-related traits;
CRC	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.53	7.84	0.4	6.36e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg25985355	chr7:65971099	NA	0.51	5.72	0.3	2.46e-8	Diabetic kidney disease;
CRC	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.44	0.42	1.06e-15	Platelet distribution width;
CRC	cis	rs3772130	0.961	rs34667636	chr3:121353291	G/A	cg20356878	chr3:121714668	ILDR1	0.49	7.65	0.39	2.22e-13	Cognitive performance;
CRC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg05585544	chr11:47624801	NA	0.32	5.61	0.3	4.27e-8	Neuroticism;Neuroticism (multi-trait analysis);
CRC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg05941027	chr17:61774174	LIMD2	0.36	6.31	0.33	9.08e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg13010199	chr12:38710504	ALG10B	0.44	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.47	2.63e-19	Intelligence (multi-trait analysis);
CRC	cis	rs76993477	0.666	rs80355141	chr1:169712598	G/A	cg03211132	chr1:169703751	SELE	0.58	5.7	0.3	2.72e-8	Tonsillectomy;
CRC	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	0.95	10.12	0.49	3.91e-21	Gut microbiota (bacterial taxa);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01956158	chr8:132916947	EFR3A	0.49	6.21	0.32	1.62e-9	Thyroid stimulating hormone;
CRC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.65	-0.34	1.25e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2075064	0.900	rs10760309	chr9:126792005	A/G	cg14112217	chr9:126806003	NA	0.39	5.78	0.3	1.71e-8	Waist circumference;
CRC	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg15382696	chr6:118971807	C6orf204	0.48	6.4	0.33	5.33e-10	Diastolic blood pressure;
CRC	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-14.4	-0.62	8.72e-37	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.49	-6.65	-0.34	1.19e-10	Bipolar disorder;
CRC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.58	9.04	0.45	1.39e-17	Aortic root size;
CRC	trans	rs2303319	0.504	rs60495163	chr2:162408807	C/T	cg27113153	chr11:123612418	ZNF202	-0.72	-6.16	-0.32	2.09e-9	Cognitive function;
CRC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-7.44	-0.38	8.8e-13	Hemoglobin concentration;
CRC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.57	7.32	0.37	1.97e-12	Neutrophil percentage of white cells;
CRC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg12463550	chr7:65579703	CRCP	0.69	6.46	0.34	3.72e-10	Diabetic kidney disease;
CRC	cis	rs2811415	0.597	rs9820563	chr3:127780871	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.98	-0.31	5.78e-9	Lung function (FEV1/FVC);
CRC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.75	-8.34	-0.42	1.99e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs983332	0.512	rs17130131	chr1:88210458	G/A	cg09221037	chr5:1523205	LPCAT1	-0.65	-6.12	-0.32	2.6e-9	Response to TNF antagonist treatment;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg25010444	chr12:123717480	C12orf65	0.43	5.99	0.31	5.58e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-5.94	-0.31	7.31e-9	Axial length;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg03623178	chr6:28175578	NA	0.8	7.45	0.38	8.56e-13	Depression;
CRC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-6.97	-0.36	1.78e-11	Gut microbiome composition (summer);
CRC	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.32e-22	Corneal astigmatism;
CRC	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.45	0.5	2.9e-22	Corneal astigmatism;
CRC	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.41	-0.42	1.29e-15	Mean corpuscular volume;
CRC	cis	rs6604026	0.656	rs2774952	chr1:93355246	A/C	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.49	-0.38	6.52e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg07870213	chr5:140052090	DND1	0.62	8.01	0.4	1.98e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.74	-12.54	-0.57	9.67e-30	Eosinophil percentage of white cells;
CRC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.76	13.22	0.59	2.65e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg15468180	chr1:107600409	PRMT6	0.38	5.6	0.3	4.48e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06028605	chr16:24865363	SLC5A11	-0.4	-7.72	-0.39	1.44e-13	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.18	-0.37	4.6e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.42	0.38	9.79e-13	Lung cancer;
CRC	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg25110126	chr1:46999211	NA	0.41	6.35	0.33	7.02e-10	Monobrow;
CRC	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg17885191	chr8:135476712	NA	0.53	7.53	0.38	4.92e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.48	-8.98	-0.44	2.09e-17	Hepatitis;
CRC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg15763984	chr4:1342303	KIAA1530	0.44	6.84	0.35	3.99e-11	Obesity-related traits;
CRC	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.56	-0.38	4.15e-13	Bipolar disorder;
CRC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.62	-8.01	-0.4	2.04e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg19554555	chr3:13937349	NA	0.44	6.62	0.34	1.48e-10	Ovarian reserve;
CRC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-5.99	-0.31	5.48e-9	Coronary artery disease;
CRC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.79	-0.39	8.68e-14	Morning vs. evening chronotype;
CRC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg01420254	chr6:26195488	NA	0.49	6.02	0.31	4.73e-9	Gout;Renal underexcretion gout;
CRC	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg06470822	chr6:28175283	NA	0.98	13.08	0.59	8.77e-32	Depression;
CRC	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg02927042	chr1:21476669	EIF4G3	-0.5	-8.03	-0.4	1.78e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.29	-0.33	1.03e-9	Total body bone mineral density;
CRC	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.66	7.73	0.39	1.35e-13	Response to hepatitis C treatment;
CRC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.08	0.32	3.39e-9	Morning vs. evening chronotype;
CRC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.54	6.9	0.36	2.76e-11	Morning vs. evening chronotype;
CRC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.37	-6.32	-0.33	8.69e-10	Personality dimensions;
CRC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.49	6.83	0.35	4.08e-11	Lung cancer;
CRC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg25985355	chr7:65971099	NA	-0.49	-5.7	-0.3	2.69e-8	Diabetic kidney disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13993802	chr11:107880029	CUL5	0.41	6.29	0.33	1.02e-9	Schizophrenia;
CRC	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg20356878	chr3:121714668	ILDR1	-0.45	-6.55	-0.34	2.23e-10	Multiple sclerosis;
CRC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.74	-0.57	1.76e-30	Hemoglobin concentration;
CRC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg17948913	chr5:572064	NA	0.5	5.75	0.3	2.02e-8	Obesity-related traits;
CRC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.53	8.45	0.42	9.24e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg08798685	chr6:27730294	NA	-0.45	-5.89	-0.31	9.48e-9	Parkinson's disease;
CRC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.25	0.41	3.86e-15	Height;
CRC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.53	-7.55	-0.38	4.25e-13	Neuroticism;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg18758796	chr5:131593413	PDLIM4	0.41	6.58	0.34	1.83e-10	Breast cancer;
CRC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.4	-6.42	-0.33	4.66e-10	Bone mineral density (spine);
CRC	cis	rs954108	0.809	rs1792022	chr13:29367967	A/G	cg11788234	chr13:29393811	NA	-0.42	-6.6	-0.34	1.64e-10	Obesity-related traits;
CRC	cis	rs524281	0.817	rs10896097	chr11:65967953	A/C	cg14036092	chr11:66035641	RAB1B	-0.46	-5.63	-0.3	3.8e-8	Electroencephalogram traits;
CRC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7259376	0.846	rs5014503	chr19:22568340	A/T	cg02657401	chr19:22469223	NA	-0.33	-7.24	-0.37	3.3e-12	Menopause (age at onset);
CRC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	10.17	0.49	2.64e-21	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17507749	chr15:85114479	UBE2QP1	0.61	8.82	0.44	6.96e-17	Schizophrenia;
CRC	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.24	-0.33	1.37e-9	Breast cancer;
CRC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.74	-13.22	-0.59	2.63e-32	Asthma;
CRC	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.54	-0.38	4.6e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.61	0.43	3.01e-16	Menopause (age at onset);
CRC	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg04969067	chr8:143858791	LYNX1	-0.35	-5.92	-0.31	8.2e-9	Urinary tract infection frequency;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg01305625	chr5:131593812	PDLIM4	0.33	5.93	0.31	7.67e-9	Acylcarnitine levels;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.93	0.74	1.63e-58	Prudent dietary pattern;
CRC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.78	11.2	0.53	7.25e-25	Neutrophil percentage of white cells;
CRC	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.62	9.67	0.47	1.28e-19	Crohn's disease;
CRC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.67	9.99	0.48	1.1e-20	Corneal astigmatism;
CRC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.62	-0.43	2.84e-16	Body mass index;
CRC	cis	rs6662572	0.737	rs4557909	chr1:46316949	T/C	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.43	-6.42	-0.33	4.72e-10	Asthma;
CRC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg16060761	chr17:80687452	NA	0.43	6.28	0.33	1.05e-9	Breast cancer;
CRC	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.42	-6.5	-0.34	2.99e-10	Body mass index (alcohol intake interaction);
CRC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.91	-0.31	8.44e-9	Lung cancer;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12273811	chr6:28175739	NA	0.72	9.33	0.46	1.66e-18	Depression;
CRC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.97	-0.4	2.57e-14	Monocyte percentage of white cells;
CRC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.41	0.5	3.87e-22	Systolic blood pressure;
CRC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg05585544	chr11:47624801	NA	-0.61	-10.84	-0.51	1.25e-23	Subjective well-being;
CRC	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg23387468	chr7:139079360	LUC7L2	0.4	7.04	0.36	1.16e-11	Diisocyanate-induced asthma;
CRC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.32	-6.48	-0.34	3.25e-10	Alzheimer's disease (late onset);
CRC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg23996704	chr18:44553084	KATNAL2	-0.37	-7.53	-0.38	5.06e-13	Personality dimensions;
CRC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13844804	chr7:814759	HEATR2	0.7	8.25	0.41	3.79e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg00334542	chr7:100209784	MOSPD3	-0.52	-6.69	-0.35	9.79e-11	Other erythrocyte phenotypes;
CRC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.22	0.45	3.74e-18	Bladder cancer;
CRC	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs3751196	0.708	rs74600793	chr12:104183718	T/C	cg02344784	chr12:104178138	NT5DC3	0.7	7.16	0.37	5.23e-12	Sense of smell;
CRC	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.7	0.35	8.98e-11	Subjective well-being;
CRC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.02	-14.18	-0.62	5.79e-36	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg21251018	chr6:28226885	NKAPL	0.47	6.48	0.34	3.39e-10	Parkinson's disease;
CRC	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.5	7.55	0.38	4.38e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg02033258	chr5:131593261	PDLIM4	0.35	6.8	0.35	5.03e-11	Blood metabolite levels;
CRC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.51	-6.67	-0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.6	8.66	0.43	2.1e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg03160526	chr17:80928410	B3GNTL1	0.46	7.06	0.36	1.01e-11	Breast cancer;
CRC	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg11271282	chr2:238384023	NA	0.44	5.6	0.3	4.52e-8	Prostate cancer;
CRC	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.55	-6.61	-0.34	1.51e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.61	6.59	0.34	1.76e-10	RR interval (heart rate);
CRC	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-7.85	-0.4	5.87e-14	Facial morphology (factor 19);
CRC	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg19773385	chr1:10388646	KIF1B	-0.55	-7.35	-0.38	1.53e-12	Hepatocellular carcinoma;
CRC	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg00383167	chr18:77616694	NA	0.54	6.02	0.31	4.69e-9	Opioid sensitivity;
CRC	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg02319466	chr17:76381040	PGS1	-0.39	-6.12	-0.32	2.66e-9	HDL cholesterol levels;
CRC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs7923609	0.902	rs10733793	chr10:65323809	T/G	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.81	-0.3	1.51e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs73200209	0.703	rs17427025	chr12:116677033	C/G	cg01776926	chr12:116560359	MED13L	-0.57	-6.83	-0.35	4.16e-11	Total body bone mineral density;
CRC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg26566898	chr11:117069891	TAGLN	0.38	6.86	0.35	3.51e-11	Blood protein levels;
CRC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg18972013	chr17:78078605	GAA	-0.41	-5.92	-0.31	8.23e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg21620606	chr4:1342894	KIAA1530	0.34	5.67	0.3	3.06e-8	Obesity-related traits;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg16015499	chr1:159888603	TAGLN2	-0.52	-6.88	-0.35	3.09e-11	Hip circumference;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg23161317	chr6:28129485	ZNF389	0.46	5.91	0.31	8.7e-9	Parkinson's disease;
CRC	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.55	9.29	0.46	2.2e-18	Facial morphology (factor 15, philtrum width);
CRC	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg12856521	chr11:46389249	DGKZ	0.45	7.33	0.37	1.83e-12	Leprosy;
CRC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.29	-5.89	-0.31	9.34e-9	Alzheimer's disease (late onset);
CRC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg00343986	chr7:65444356	GUSB	-0.47	-6.94	-0.36	2.05e-11	Aortic root size;
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.92	-0.4	3.81e-14	Bipolar disorder;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.73	-0.39	1.28e-13	Longevity;Endometriosis;
CRC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.59	-8.4	-0.42	1.38e-15	Hip circumference adjusted for BMI;
CRC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.39	0.42	1.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.34	-0.37	1.72e-12	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00633736	chr17:15164050	PMP22	0.4	6.48	0.34	3.3e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.6	0.39	3.17e-13	Blood metabolite levels;
CRC	cis	rs11233250	0.502	rs11233281	chr11:82414527	C/G	cg17391194	chr11:82401662	NA	-0.39	-6.08	-0.32	3.33e-9	Glioblastoma;Glioma;
CRC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.33	-0.46	1.57e-18	Migraine;Coronary artery disease;
CRC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.79	-0.47	5.01e-20	Schizophrenia;
CRC	cis	rs847649	0.732	rs6465876	chr7:102497569	G/T	cg18108683	chr7:102477205	FBXL13	-0.62	-10.63	-0.51	6.86e-23	Morning vs. evening chronotype;
CRC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg10298567	chr3:47292165	KIF9	0.39	6.09	0.32	3.21e-9	Colorectal cancer;
CRC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.65	11.28	0.53	3.52e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg25173405	chr17:45401733	C17orf57	0.44	6.78	0.35	5.44e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	7.13	0.37	6.22e-12	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25371088	chr1:156710915	MRPL24	0.43	6.14	0.32	2.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.773	rs7925123	chr11:65993213	G/C	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.07	-28.27	-0.84	4.63e-90	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg26248373	chr2:1572462	NA	-0.62	-7.08	-0.36	9.04e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.54	0.34	2.42e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.61	12.43	0.57	2.32e-29	Asthma (sex interaction);
CRC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.79	13.4	0.59	5.5e-33	Menopause (age at onset);
CRC	cis	rs883565	0.655	rs9837975	chr3:39064293	T/C	cg01426195	chr3:39028469	NA	-0.47	-7.84	-0.4	6.17e-14	Handedness;
CRC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.65	10.66	0.51	5.33e-23	Calcium levels;
CRC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.14	0.37	5.89e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21643547	chr1:205240462	TMCC2	-0.37	-6.04	-0.32	4.25e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.46	-0.5	2.79e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.49	7.23	0.37	3.34e-12	Body mass index;
CRC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.67	9.51	0.46	4.2e-19	Vitamin D levels;
CRC	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.36	6.08	0.32	3.24e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.46	6.31	0.33	8.93e-10	Parkinson's disease;
CRC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg00786952	chr1:21763130	NA	0.49	8.4	0.42	1.33e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.45	7.23	0.37	3.39e-12	Platelet count;
CRC	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.49	-7.26	-0.37	2.74e-12	Uric acid levels;
CRC	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg19637330	chr1:19110922	NA	0.43	5.97	0.31	6.27e-9	Drug-induced liver injury (nitrofurantoin);
CRC	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.58	6.54	0.34	2.3e-10	Glioblastoma;
CRC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.54	8.15	0.41	7.84e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs17641971	0.899	rs818557	chr8:49984515	G/C	cg18784943	chr17:79371681	NA	0.41	6.18	0.32	1.87e-9	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00140910	chr6:131384370	EPB41L2	0.44	6.45	0.34	3.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg06470822	chr6:28175283	NA	0.48	6.63	0.34	1.39e-10	Depression;
CRC	trans	rs10242455	0.702	rs1045012	chr7:98984354	G/C	cg09045935	chr12:6379348	NA	0.99	7.44	0.38	8.57e-13	Blood metabolite levels;
CRC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.06	-0.45	1.18e-17	Chronic sinus infection;
CRC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg14711859	chr11:8959438	ASCL3	-0.51	-8.28	-0.42	3.03e-15	Hemoglobin concentration;
CRC	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.47	7.18	0.37	4.53e-12	Carotid intima media thickness;
CRC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.04	14.56	0.63	2.01e-37	Vitiligo;
CRC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg19824325	chr16:58548873	SETD6	0.96	6.28	0.33	1.08e-9	Schizophrenia;
CRC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.9	-11.92	-0.55	1.83e-27	Platelet count;
CRC	trans	rs4853036	0.540	rs55941844	chr2:69999728	T/A	cg14633329	chr9:139640053	LCN6	-0.38	-6.34	-0.33	7.43e-10	Colorectal or endometrial cancer;
CRC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.5	8.64	0.43	2.48e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg15845792	chr6:28175446	NA	0.51	5.93	0.31	7.51e-9	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.44	7.41	0.38	1.11e-12	Crohn's disease;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg15123149	chr5:14485252	TRIO	-0.37	-6.18	-0.32	1.85e-9	HDL cholesterol;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.59	9.33	0.46	1.55e-18	Glycated hemoglobin levels;
CRC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg23093090	chr10:104574429	C10orf26	-0.41	-5.76	-0.3	1.94e-8	Arsenic metabolism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10815483	chr17:16394899	C17orf76	0.46	6.8	0.35	4.92e-11	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.55	8.18	0.41	6.45e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	7.87	0.4	5.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-9.41	-0.46	9.12e-19	Platelet distribution width;
CRC	trans	rs11661542	0.967	rs11082043	chr18:20222985	C/G	cg01231434	chr16:23607392	NDUFAB1	-0.44	-6.07	-0.32	3.62e-9	Intracranial aneurysm;
CRC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.56	8.9	0.44	3.69e-17	Type 2 diabetes;
CRC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.38	-6.68	-0.35	1.01e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.86	-0.55	2.96e-27	Colorectal cancer;
CRC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.33	-5.62	-0.3	4.18e-8	Calcium levels;
CRC	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-8.31	-0.42	2.6e-15	Homocysteine levels;
CRC	cis	rs4731207	0.596	rs6466982	chr7:124656788	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.88	18.11	0.71	2.38e-51	White blood cell count;
CRC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg12046867	chr14:103022105	NA	0.76	8.98	0.44	2.2e-17	Platelet count;
CRC	cis	rs2302190	0.882	rs3744111	chr17:56607959	G/A	cg25885038	chr17:56607967	SEPT4	-0.52	-7.86	-0.4	5.41e-14	Vitamin D levels;
CRC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg24977027	chr2:88469347	THNSL2	0.52	6.13	0.32	2.47e-9	Plasma clusterin levels;
CRC	cis	rs10919791	0.501	rs12024418	chr1:199916164	T/C	cg13229857	chr1:200006247	NR5A2	0.44	6.49	0.34	3.13e-10	Pancreatic cancer;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg03623178	chr6:28175578	NA	0.77	9.26	0.45	2.74e-18	Depression;
CRC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.58	-9.48	-0.46	5.29e-19	Schizophrenia;
CRC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.46	-6.79	-0.35	5.37e-11	Systemic lupus erythematosus;
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.93	-0.36	2.25e-11	Menopause (age at onset);
CRC	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg25547332	chr5:131281432	NA	-0.38	-5.61	-0.3	4.32e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	9.96	0.48	1.37e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.77	-10.83	-0.51	1.37e-23	Blood pressure (smoking interaction);
CRC	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs3790645	1.000	rs3790645	chr1:26884864	G/A	cg17456097	chr1:26900765	RPS6KA1	0.39	5.78	0.3	1.74e-8	Glucose homeostasis traits;
CRC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-5.9	-0.31	9.15e-9	Cognitive function;
CRC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg03037974	chr15:76606532	NA	0.83	16.68	0.68	1.06e-45	Blood metabolite levels;
CRC	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.14e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.61	10.19	0.49	2.26e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.56	0.6	1.38e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.64	9.64	0.47	1.5700000000000001e-19	Dementia with Lewy bodies;
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.45	19.89	0.74	2.22e-58	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10971721	0.822	rs10971788	chr9:33915085	G/A	cg13495928	chr9:33750294	PRSS3	0.57	6.22	0.32	1.52e-9	Body mass index;
CRC	cis	rs9311676	0.656	rs56384862	chr3:58395863	A/G	cg06643156	chr3:58380774	PXK	0.4	6.11	0.32	2.85e-9	Systemic lupus erythematosus;
CRC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-7.93	-0.4	3.55e-14	Aortic root size;
CRC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.52	-0.34	2.68e-10	Menopause (age at onset);
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-6.97	-0.36	1.77e-11	Longevity;Endometriosis;
CRC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs728616	0.614	rs57342950	chr10:82105081	G/A	cg05935833	chr10:81318306	SFTPA2	-0.46	-6.14	-0.32	2.43e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg09127314	chr1:152161683	NA	0.48	6.29	0.33	9.91e-10	Atopic dermatitis;
CRC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.4	-0.56	3.24e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.42	7.21	0.37	3.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10888329	0.741	rs4328104	chr1:248373326	A/G	cg00666640	chr1:248458726	OR2T12	0.43	6.77	0.35	5.91e-11	Autism spectrum disorder;
CRC	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.56	-8.19	-0.41	5.82e-15	Vitiligo;
CRC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.48	-7.74	-0.39	1.23e-13	Post bronchodilator FEV1;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09273779	chr9:35605990	TESK1	0.49	6.38	0.33	5.88e-10	Thyroid stimulating hormone;
CRC	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg04110750	chr16:69646130	NFAT5	-0.52	-7.25	-0.37	2.97e-12	IgE levels;
CRC	trans	rs2303319	0.504	rs56405014	chr2:162497603	C/T	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.55e-9	Cognitive function;
CRC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.56	-5.99	-0.31	5.41e-9	Vitiligo;
CRC	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg16898833	chr6:26189333	HIST1H4D	0.75	6.46	0.34	3.82e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7180079	0.844	rs11071791	chr15:64602270	C/A	cg22857141	chr5:123707481	NA	0.48	6.1	0.32	2.89e-9	Monocyte count;
CRC	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	27.18	0.83	4.1e-86	Schizophrenia;
CRC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg13798780	chr7:105162888	PUS7	0.67	7.78	0.39	9.18e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.93	0.4	3.47e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01604592	chr1:44679056	DMAP1	0.41	6.78	0.35	5.52e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.61	10.19	0.49	2.32e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.38	-0.33	5.89e-10	Aortic root size;
CRC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg07274523	chr3:49395745	GPX1	0.48	6.41	0.33	5.06e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	9.92	0.48	1.85e-20	Bone mineral density;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.65	10.68	0.51	4.85e-23	Height;
CRC	cis	rs6586163	0.527	rs12775501	chr10:90750909	C/T	cg13456138	chr10:90753195	FAS	0.41	5.77	0.3	1.84e-8	Chronic lymphocytic leukemia;
CRC	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg16482183	chr6:26056742	HIST1H1C	0.41	5.66	0.3	3.35e-8	Blood metabolite levels;
CRC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-8.66	-0.43	2.16e-16	Monocyte percentage of white cells;
CRC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg11245181	chr6:149772854	ZC3H12D	0.52	9.09	0.45	9.67e-18	Dupuytren's disease;
CRC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.42	6.03	0.32	4.34e-9	Renal cell carcinoma;
CRC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.0	-0.31	5.15e-9	Gut microbiome composition (summer);
CRC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.53	0.34	2.5e-10	HDL cholesterol;
CRC	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg27171509	chr10:82033454	MAT1A	-0.48	-8.56	-0.43	4.23e-16	Borderline personality disorder;
CRC	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.23	-0.56	1.3e-28	Idiopathic membranous nephropathy;
CRC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg25804541	chr17:80189381	SLC16A3	0.32	6.12	0.32	2.72e-9	Life satisfaction;
CRC	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg20356878	chr3:121714668	ILDR1	-0.47	-7.57	-0.39	3.67e-13	Multiple sclerosis;
CRC	trans	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg20935933	chr6:143382018	AIG1	0.5	6.47	0.34	3.65e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg09003973	chr2:102972529	NA	0.41	5.84	0.31	1.26e-8	Blood protein levels;
CRC	cis	rs992157	0.764	rs3731861	chr2:219191256	T/C	cg00012203	chr2:219082015	ARPC2	-0.4	-5.63	-0.3	3.9e-8	Colorectal cancer;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.55	-10.03	-0.48	8.07e-21	Bipolar disorder;
CRC	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.66	10.3	0.49	9.52e-22	Corneal astigmatism;
CRC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.61	0.3	4.35e-8	Bladder cancer;
CRC	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg27499820	chr13:21296301	IL17D	-0.36	-5.81	-0.31	1.45e-8	Dental caries;
CRC	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg03929089	chr4:120376271	NA	-0.54	-6.61	-0.34	1.56e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02097616	chr17:62675921	NA	0.48	5.85	0.31	1.2e-8	QT interval;
CRC	cis	rs62408225	0.962	rs2325292	chr6:90986749	T/C	cg06866423	chr6:90926672	BACH2	0.48	7.87	0.4	5.02e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11039100	0.527	rs10769249	chr11:5839326	C/T	cg03895540	chr11:5841482	OR52N2	-0.31	-5.68	-0.3	2.9e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-0.86	-9.9	-0.48	2.13e-20	Breast cancer;
CRC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.13	0.32	2.46e-9	Bladder cancer;
CRC	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg07195197	chr16:1662150	IFT140	-0.7	-5.98	-0.31	5.91e-9	Cognitive function;
CRC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg18288967	chr1:45987694	PRDX1	0.62	6.85	0.35	3.65e-11	Obesity-related traits;
CRC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.62	9.26	0.45	2.66e-18	Schizophrenia;
CRC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg18279126	chr7:2041391	MAD1L1	0.41	6.02	0.32	4.56e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2737618	0.674	rs2258280	chr1:200097648	G/A	cg21825944	chr1:200113062	NR5A2	-0.51	-7.35	-0.38	1.57e-12	Uric acid levels;
CRC	cis	rs6838801	0.823	rs13139112	chr4:77584089	G/A	cg17476223	chr4:77663285	SHROOM3	0.41	5.75	0.3	1.99e-8	Cleft lip with or without cleft palate;
CRC	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg19875578	chr6:126661172	C6orf173	0.43	5.87	0.31	1.08e-8	Male-pattern baldness;
CRC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.17	-0.45	5.32e-18	Aortic root size;
CRC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.84	-11.13	-0.52	1.21e-24	Gut microbiome composition (summer);
CRC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.73	10.92	0.52	6.54e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	7.79	0.39	8.63e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-6.61	-0.34	1.56e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.44	6.26	0.33	1.19e-9	Menarche (age at onset);
CRC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.51	7.37	0.38	1.4e-12	Homoarginine levels;
CRC	trans	rs11165623	0.602	rs11165667	chr1:97013509	A/C	cg10631902	chr5:14652156	NA	-0.36	-6.17	-0.32	2.05e-9	Hip circumference;Waist circumference;
CRC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg01420254	chr6:26195488	NA	0.86	9.08	0.45	1.06e-17	Gout;Renal underexcretion gout;
CRC	trans	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg24644049	chr4:85504048	CDS1	-0.55	-6.11	-0.32	2.75e-9	Skin colour saturation;
CRC	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg06470822	chr6:28175283	NA	-0.5	-6.77	-0.35	5.88e-11	Systemic lupus erythematosus;
CRC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-9.18	-0.45	4.78e-18	Monocyte count;
CRC	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg18850127	chr7:39170497	POU6F2	0.44	5.71	0.3	2.53e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.85	10.08	0.49	5.15e-21	Psoriasis;
CRC	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg18198730	chr1:247681584	NA	0.62	6.91	0.36	2.55e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-7.16	-0.37	5.39e-12	Lung cancer;
CRC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.53	7.83	0.4	6.67e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-0.74	-7.66	-0.39	2.13e-13	Blood protein levels;
CRC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg22096450	chr11:6947773	ZNF215	0.58	6.01	0.31	4.99e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25517755	chr10:38738941	LOC399744	-0.42	-6.1	-0.32	3.03e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2625529	0.730	rs2957737	chr15:72265410	A/G	cg16672083	chr15:72433130	SENP8	0.43	6.18	0.32	1.93e-9	Red blood cell count;
CRC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.45	6.73	0.35	7.5e-11	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs4731207	0.596	rs6961441	chr7:124590871	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.13	0.32	2.52e-9	Renal function-related traits (BUN);
CRC	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg08645402	chr16:4508243	NA	0.5	6.32	0.33	8.57e-10	Schizophrenia;
CRC	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.7	-0.3	2.67e-8	Pulmonary function;
CRC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.3	18.06	0.71	3.71e-51	Hemostatic factors and hematological phenotypes;
CRC	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.8	9.78	0.47	5.36e-20	Exhaled nitric oxide output;
CRC	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.99	-0.31	5.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.65	-0.3	3.44e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.57	-8.49	-0.42	7.31e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg16850897	chr7:100343110	ZAN	0.44	6.62	0.34	1.45e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.74	0.39	1.2e-13	Parkinson's disease;
CRC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.77	0.68	4.92e-46	Platelet count;
CRC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg17120908	chr11:65337727	SSSCA1	-0.69	-7.49	-0.38	6.51e-13	Bone mineral density;
CRC	cis	rs6681460	0.549	rs1156618	chr1:67031564	T/C	cg02459107	chr1:67143332	SGIP1	0.34	5.61	0.3	4.28e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.55	-7.99	-0.4	2.31e-14	Fibrinogen levels;
CRC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.77	-12.6	-0.57	5.52e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	cis	rs6810498	0.899	rs7661937	chr4:26062131	A/G	cg12925881	chr4:26050407	NA	-0.38	-6.58	-0.34	1.89e-10	Alcohol dependence;
CRC	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs5498	0.803	rs62130687	chr19:10408995	G/A	cg10604476	chr19:10403908	ICAM5	0.3	5.72	0.3	2.42e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CRC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.48	-8.04	-0.41	1.68e-14	Mean platelet volume;Platelet distribution width;
CRC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-18.05	-0.71	4.27e-51	Coronary artery disease;
CRC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.59	-0.34	1.8e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	7.24e-16	Aortic root size;
CRC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-12.81	-0.58	9.31e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.94	0.31	7.31e-9	Diabetic retinopathy;
CRC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg22676075	chr6:135203613	NA	0.38	5.89	0.31	9.75e-9	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09564133	chr5:176738847	MXD3	0.47	6.69	0.35	9.33e-11	Response to antipsychotic treatment;
CRC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg27534772	chr1:16042836	PLEKHM2	0.56	10.56	0.5	1.18e-22	Systolic blood pressure;
CRC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.66	0.3	3.25e-8	Tonsillectomy;
CRC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-5.96	-0.31	6.57e-9	Vitiligo;
CRC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.57	-7.84	-0.4	6.2e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg02825527	chr7:2087843	MAD1L1	-0.49	-5.83	-0.31	1.34e-8	Bipolar disorder;
CRC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.45	6.94	0.36	2.08e-11	Longevity;Endometriosis;
CRC	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg15038512	chr6:170123185	PHF10	0.47	5.67	0.3	3.07e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10242455	0.571	rs45527841	chr7:99310965	C/T	cg18809830	chr7:99032528	PTCD1	-0.94	-7.27	-0.37	2.7e-12	Blood metabolite levels;
CRC	cis	rs216303	0.841	rs2283333	chr12:6162852	T/C	cg19878637	chr12:6148451	VWF	-0.55	-6.61	-0.34	1.52e-10	Low vWF levels;
CRC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg03013999	chr17:37608204	MED1	0.47	7.28	0.37	2.46e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.92	16.88	0.68	1.74e-46	Intelligence (multi-trait analysis);
CRC	cis	rs2249694	1.000	rs8192781	chr10:135354251	T/G	cg16964102	chr10:135390573	NA	-0.37	-5.99	-0.31	5.38e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00472393	chr6:97730957	C6orf167;MIR548H3	0.41	6.43	0.33	4.49e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-7.29	-0.37	2.31e-12	Bipolar disorder;
CRC	cis	rs6840360	0.642	rs2709833	chr4:152377622	A/G	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	trans	rs10502219	0.918	rs7947659	chr11:116419981	A/C	cg20778451	chr5:178368205	ZNF454	-0.34	-6.03	-0.32	4.33e-9	Mitochondrial DNA levels;
CRC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-8.57	-0.43	4.12e-16	Platelet count;
CRC	cis	rs9303542	0.625	rs6504340	chr17:46617019	A/G	cg04904318	chr17:46607828	HOXB1	0.44	6.15	0.32	2.22e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.62	-0.39	2.73e-13	Blood metabolite levels;
CRC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.54	9.76	0.47	6.28e-20	Multiple system atrophy;
CRC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.81	9.29	0.46	2.14e-18	Iron status biomarkers;
CRC	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-8.07	-0.41	1.37e-14	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg21724239	chr8:58056113	NA	0.8	8.66	0.43	2.13e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.42	0.42	1.15e-15	Homoarginine levels;
CRC	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.52	7.41	0.38	1.09e-12	Caudate activity during reward;
CRC	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.71	8.44	0.42	1.03e-15	Eotaxin levels;
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.89	-19.66	-0.73	1.85e-57	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	trans	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg07393940	chr7:158741817	NA	-0.51	-7.4	-0.38	1.15e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2462686	1.000	rs1534150	chr7:45985290	T/C	cg23193639	chr7:45961078	IGFBP3	-0.37	-5.69	-0.3	2.76e-8	Major depressive disorder;
CRC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-9.25	-0.45	2.86e-18	Breast cancer;
CRC	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg18551225	chr6:44695536	NA	-0.4	-5.8	-0.3	1.6e-8	Total body bone mineral density;
CRC	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	7.7	0.39	1.63e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7113874	0.589	rs725502	chr11:8503743	A/G	cg02811074	chr11:8615871	STK33	0.36	6.04	0.32	4.27e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.54	0.34	2.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.85	11.3	0.53	2.96e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.46	7.93	0.4	3.55e-14	Common traits (Other);
CRC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.37	5.98	0.31	5.77e-9	Blood metabolite levels;
CRC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg27535305	chr1:53392650	SCP2	-0.36	-6.46	-0.34	3.78e-10	Monocyte count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14218504	chr3:133380807	TOPBP1	0.47	6.4	0.33	5.48e-10	Anxiety disorder;
CRC	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg26958806	chr6:27640298	NA	0.99	6.89	0.35	2.89e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	9.76	0.47	6.46e-20	Schizophrenia;
CRC	cis	rs55726902	0.761	rs2544029	chr12:48194957	C/T	cg14736327	chr12:48174669	SLC48A1	-0.41	-5.61	-0.3	4.35e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg23161317	chr6:28129485	ZNF389	0.45	6.38	0.33	5.99e-10	Parkinson's disease;
CRC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.66	9.43	0.46	7.42e-19	Vitamin D levels;
CRC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.44	0.38	9.04e-13	Height;
CRC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.83	-0.31	1.3e-8	Daytime sleep phenotypes;
CRC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg13798912	chr7:905769	UNC84A	0.53	5.96	0.31	6.63e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.45	0.53	8.88e-26	Alzheimer's disease;
CRC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.44	6.34	0.33	7.63e-10	Obesity-related traits;
CRC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg15440763	chr7:158190612	PTPRN2	0.53	8.63	0.43	2.66e-16	Obesity-related traits;
CRC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg19318889	chr4:1322082	MAEA	0.41	6.2	0.32	1.66e-9	Longevity;
CRC	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	5.95	0.31	6.74e-9	Ovarian reserve;
CRC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.7	10.61	0.5	8.43e-23	Menopause (age at onset);
CRC	cis	rs9648428	0.515	rs17172276	chr7:36202416	A/G	cg14708893	chr7:36124863	NA	-0.41	-6.1	-0.32	3.03e-9	Obesity-related traits;
CRC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	trans	rs2321882	0.794	rs55800294	chr13:59468828	A/G	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2274273	0.588	rs9919923	chr14:55813899	A/G	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.82	-0.31	1.4e-8	Protein biomarker;
CRC	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.72	7.76	0.39	1.08e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9928842	0.771	rs4888363	chr16:75277344	A/T	cg09066997	chr16:75300724	BCAR1	0.68	7.18	0.37	4.66e-12	Alcoholic chronic pancreatitis;
CRC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.53	11.2	0.53	6.74e-25	Alcohol dependence;
CRC	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.44	-6.8	-0.35	4.87e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg19041857	chr6:27730383	NA	-0.73	-7.06	-0.36	9.84e-12	Breast cancer;
CRC	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.16	-24.69	-0.81	7.19e-77	Exhaled nitric oxide output;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08267591	chr2:165693745	COBLL1	0.39	6.26	0.33	1.21e-9	Interleukin-6 levels;
CRC	cis	rs732072	0.826	rs605952	chr11:65475111	A/G	cg21033440	chr11:65409861	SIPA1	-0.67	-5.7	-0.3	2.7e-8	Inflammatory bowel disease;
CRC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.51	0.54	5.66e-26	Monocyte percentage of white cells;
CRC	cis	rs4731207	0.698	rs10252039	chr7:124539537	T/C	cg23710748	chr7:124431027	NA	-0.37	-5.86	-0.31	1.15e-8	Cutaneous malignant melanoma;
CRC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.18	-0.49	2.39e-21	Inflammatory bowel disease;
CRC	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg26353448	chr1:248524236	OR2T4	-0.31	-6.18	-0.32	1.94e-9	Common traits (Other);
CRC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.54	8.62	0.43	2.96e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.51	6.72	0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.49	7.57	0.38	3.88e-13	Total body bone mineral density;
CRC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg09473613	chr1:24152604	HMGCL	-0.34	-5.93	-0.31	7.87e-9	Immature fraction of reticulocytes;
CRC	cis	rs12760731	0.565	rs71628268	chr1:178151908	T/C	cg00404053	chr1:178313656	RASAL2	1.12	11.36	0.53	1.89e-25	Obesity-related traits;
CRC	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.4	-6.65	-0.34	1.2e-10	Resting heart rate;
CRC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg00316803	chr15:76480434	C15orf27	-0.36	-6.23	-0.32	1.45e-9	Blood metabolite levels;
CRC	cis	rs7587476	0.599	rs61073893	chr2:215744814	C/T	cg04004882	chr2:215674386	BARD1	0.68	8.38	0.42	1.6e-15	Neuroblastoma;
CRC	cis	rs6589219	0.954	rs3802842	chr11:111171709	C/A	cg25129781	chr11:111156908	C11orf53	-0.31	-5.77	-0.3	1.82e-8	Colorectal cancer;
CRC	cis	rs4731207	0.596	rs7799712	chr7:124649717	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs7707921	0.767	rs226199	chr5:81572464	G/C	cg07807695	chr5:81608485	ATP6AP1L	-0.49	-7.75	-0.39	1.17e-13	Breast cancer;
CRC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.78	12.68	0.57	2.8e-30	Type 2 diabetes;
CRC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg06363034	chr20:62225388	GMEB2	-0.44	-6.77	-0.35	5.94e-11	Glioblastoma;
CRC	trans	rs2303319	0.504	rs62188728	chr2:162335701	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.02	-0.31	4.69e-9	Cognitive function;
CRC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg03923535	chr7:1197113	ZFAND2A	0.42	5.71	0.3	2.5e-8	Longevity;Endometriosis;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.22	-0.49	1.8e-21	Bipolar disorder;
CRC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-8.9	-0.44	3.71e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14431266	chr11:67057003	ANKRD13D	0.51	6.67	0.35	1.06e-10	Thyroid stimulating hormone;
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg24505167	chr7:1915268	MAD1L1	-0.45	-6.28	-0.33	1.09e-9	Bipolar disorder;
CRC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.46	5.95	0.31	6.92e-9	Aortic root size;
CRC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.04	-0.48	7.5e-21	Bone mineral density;
CRC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg13835894	chr2:219148914	PNKD;TMBIM1	0.32	6.16	0.32	2.16e-9	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15090714	chr17:60142985	MED13	0.45	7.32	0.37	1.93e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg11271282	chr2:238384023	NA	0.48	5.6	0.3	4.45e-8	Prostate cancer;
CRC	cis	rs1322512	0.677	rs2695254	chr6:152926021	A/C	cg03415253	chr6:152958462	SYNE1	-0.38	-5.92	-0.31	8.15e-9	Tonometry;
CRC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs10911390	0.793	rs112313734	chr1:183605035	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.51	0.34	2.73e-10	Systemic lupus erythematosus;
CRC	cis	rs10924970	0.649	rs10925128	chr1:235378767	T/G	cg09010748	chr1:235293032	TOMM20	-0.42	-5.87	-0.31	1.07e-8	Asthma;
CRC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg25876840	chr17:41920477	NA	0.51	7.63	0.39	2.62e-13	Triglycerides;
CRC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.54	-7.43	-0.38	9.17e-13	Schizophrenia;
CRC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg20243544	chr17:37824526	PNMT	0.52	8.26	0.41	3.53e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg20041105	chr8:143859282	LYNX1	-0.32	-5.65	-0.3	3.45e-8	Urinary tract infection frequency;
CRC	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.51	8.17	0.41	6.92e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg03623178	chr6:28175578	NA	0.92	12.95	0.58	2.82e-31	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00585572	chr22:41347381	RBX1	0.45	6.3	0.33	9.33e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.78	9.79	0.47	5.01e-20	Developmental language disorder (linguistic errors);
CRC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg16141378	chr3:129829833	LOC729375	0.48	7.0	0.36	1.42e-11	Neuroticism;
CRC	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.87	-0.4	5.17e-14	Height;
CRC	cis	rs6662572	0.641	rs4660891	chr1:46319447	T/A	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs11627756	0.958	rs2146430	chr14:103071825	G/T	cg12046867	chr14:103022105	NA	-0.42	-5.77	-0.3	1.81e-8	Mean platelet volume;
CRC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	0.82	8.71	0.43	1.55e-16	Gout;Renal underexcretion gout;
CRC	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.77	-0.3	1.8e-8	Triglycerides;
CRC	cis	rs73206853	0.841	rs59698293	chr12:111054455	C/G	cg12870014	chr12:110450643	ANKRD13A	0.77	7.23	0.37	3.44e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.68	9.25	0.45	2.82e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4662945	0.688	rs10496679	chr2:130201113	G/A	cg05903289	chr2:130345205	NA	-0.3	-5.75	-0.3	2.02e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg24011408	chr12:48396354	COL2A1	0.46	6.5	0.34	2.93e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs77633900	0.772	rs284897	chr15:76750722	T/C	cg21673338	chr15:77095150	SCAPER	-0.71	-6.48	-0.34	3.41e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.46	-7.08	-0.36	9.02e-12	Renal cell carcinoma;
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.28	-0.69	4.62e-48	Schizophrenia;
CRC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.17	-0.32	2.01e-9	Morning vs. evening chronotype;
CRC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.67	9.25	0.45	2.84e-18	Lung cancer;
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.26e-26	Prudent dietary pattern;
CRC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.74	-9.21	-0.45	3.91e-18	Body mass index;
CRC	cis	rs2380220	0.810	rs877096	chr6:95937046	A/G	cg04719120	chr6:96025338	MANEA	-0.55	-6.04	-0.32	4.15e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.97	0.4	2.62e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg21251018	chr6:28226885	NKAPL	0.46	6.53	0.34	2.56e-10	Parkinson's disease;
CRC	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg20119798	chr7:94954144	PON1	-0.5	-6.52	-0.34	2.65e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6838801	0.523	rs344123	chr4:77638013	T/C	cg17476223	chr4:77663285	SHROOM3	-0.44	-5.76	-0.3	1.93e-8	Cleft lip with or without cleft palate;
CRC	cis	rs2041840	0.618	rs11124581	chr2:37576638	C/T	cg25727520	chr2:37576821	QPCT	-0.32	-5.72	-0.3	2.38e-8	Chronic lymphocytic leukemia;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.63	13.35	0.59	8.5e-33	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7487075	0.820	rs35497251	chr12:46692481	C/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.88	0.31	9.94e-9	Itch intensity from mosquito bite;
CRC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.6	10.32	0.49	8.33e-22	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.99e-24	Motion sickness;
CRC	cis	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg27395922	chr11:50257633	LOC441601	0.35	5.71	0.3	2.58e-8	Coronary artery disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05800723	chr4:79103126	FRAS1	0.47	7.77	0.39	1e-13	Interleukin-6 levels;
CRC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg07074390	chr21:40555500	PSMG1	-0.46	-6.18	-0.32	1.87e-9	Cognitive function;
CRC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.93	-0.31	7.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.68	0.47	1.15e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.8	-14.83	-0.63	1.83e-38	Hip circumference;
CRC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.35	-0.33	7.23e-10	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00619347	chr3:149688574	PFN2	0.37	6.26	0.33	1.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.39	0.33	5.83e-10	Lung cancer;
CRC	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg21854759	chr1:92012499	NA	0.51	6.07	0.32	3.52e-9	Eosinophil percentage of white cells;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	8.01	0.4	2.02e-14	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26500707	chr16:50100227	HEATR3	0.39	6.04	0.32	4.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg09835421	chr16:68378352	PRMT7	-0.7	-7.62	-0.39	2.69e-13	Schizophrenia;
CRC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.68	10.2	0.49	2.03e-21	Corneal astigmatism;
CRC	cis	rs9462846	0.919	rs9462844	chr6:42856502	T/G	cg02353165	chr6:42928485	GNMT	0.45	6.24	0.33	1.38e-9	Blood protein levels;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg03623178	chr6:28175578	NA	0.65	9.79	0.47	5.02e-20	Cardiac Troponin-T levels;
CRC	cis	rs1656402	1.000	rs1190437	chr2:233423796	C/G	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg04117972	chr1:227635322	NA	0.67	6.22	0.32	1.54e-9	Major depressive disorder;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg21251018	chr6:28226885	NKAPL	0.45	6.89	0.36	2.83e-11	Parkinson's disease;
CRC	cis	rs995000	0.931	rs2366636	chr1:63056670	G/A	cg19896129	chr1:63156450	NA	0.42	6.53	0.34	2.48e-10	Triglyceride levels;
CRC	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.61	7.7	0.39	1.62e-13	Post bronchodilator FEV1;
CRC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.77	-10.09	-0.49	4.8e-21	Initial pursuit acceleration;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg04497992	chr16:616212	NHLRC4	0.44	7.17	0.37	5.02e-12	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07595909	chr18:61089263	VPS4B	0.52	7.26	0.37	2.87e-12	Response to antipsychotic treatment;
CRC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.74	-0.35	7.09e-11	Response to antipsychotic treatment;
CRC	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.49	8.09	0.41	1.2e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2592394	0.596	rs711829	chr2:177001292	C/A	cg13092806	chr2:177043255	NA	0.5	5.73	0.3	2.31e-8	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg21138405	chr5:131827807	IRF1	0.34	5.77	0.3	1.86e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs8141797	0.901	rs4306797	chr22:24453375	C/T	cg20894457	chr22:24584366	SUSD2	-0.62	-7.39	-0.38	1.21e-12	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	5.88	0.31	1.03e-8	Diabetic retinopathy;
CRC	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08144172	chr1:41849203	NA	0.33	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2274471	0.699	rs10758672	chr9:5116369	T/C	cg03390472	chr9:5043263	JAK2	-0.53	-6.32	-0.33	8.34e-10	Crohn's disease;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.94	0.52	5.62e-24	Prudent dietary pattern;
CRC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04476341	chr5:669733	TPPP	0.42	6.9	0.36	2.63e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.3e-9	Heart rate;
CRC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.07	-0.32	3.62e-9	Life satisfaction;
CRC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg08888203	chr3:10149979	C3orf24	0.48	7.32	0.37	1.9e-12	Alzheimer's disease;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg12172441	chr6:28176163	NA	0.6	6.3	0.33	9.49e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg17031739	chr1:67600172	NA	-0.38	-6.04	-0.32	4.19e-9	Psoriasis;
CRC	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.77	-10.7	-0.51	4.06e-23	White matter hyperintensity burden;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg01056903	chr20:44601024	ZNF335	0.46	6.24	0.33	1.33e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02808110	chr17:34957846	MRM1	0.45	6.09	0.32	3.17e-9	Response to antipsychotic treatment;
CRC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg16989086	chr20:62203971	PRIC285	0.51	6.53	0.34	2.55e-10	Glioblastoma;
CRC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.3	0.37	2.17e-12	Total body bone mineral density;
CRC	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs2310173	0.575	rs2110563	chr2:102628433	T/G	cg20856504	chr2:102616538	IL1R2	0.39	6.12	0.32	2.68e-9	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	1.01	12.23	0.56	1.28e-28	Obesity-related traits;
CRC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-10.35	-0.5	6.5600000000000005e-22	IgG glycosylation;
CRC	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg26248373	chr2:1572462	NA	-0.67	-8.54	-0.43	5.23e-16	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg02683197	chr6:28174875	NA	0.42	6.0	0.31	5.2e-9	Pubertal anthropometrics;
CRC	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.68	0.35	1e-10	Resistin levels;
CRC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11645453	chr3:52864694	ITIH4	-0.36	-6.72	-0.35	7.94e-11	Body mass index;
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.88	-0.51	9.7e-24	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13198984	chr17:80129470	CCDC57	0.49	8.52	0.43	5.65e-16	Life satisfaction;
CRC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.65	-10.49	-0.5	2.14e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01490821	chr2:170684022	UBR3	0.45	6.14	0.32	2.44e-9	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	trans	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.75	-0.35	6.68e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01804284	chr1:41157659	NFYC;LOC100130557	-0.43	-6.82	-0.35	4.27e-11	Myopia (pathological);
CRC	cis	rs2982552	0.773	rs11155809	chr6:152056058	A/G	cg22157087	chr6:152012887	ESR1	0.37	5.66	0.3	3.31e-8	Bone properties (heel);
CRC	cis	rs990171	1.000	rs7559479	chr2:103068787	C/T	cg03938978	chr2:103052716	IL18RAP	0.48	6.1	0.32	3.03e-9	Lymphocyte counts;
CRC	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-8.96	-0.44	2.56e-17	Educational attainment (college completion);
CRC	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.78	-12.65	-0.57	3.66e-30	Hypospadias;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg25164649	chr6:28176230	NA	0.79	11.02	0.52	2.91e-24	Depression;
CRC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg24699146	chr1:24152579	HMGCL	0.32	5.64	0.3	3.62e-8	Immature fraction of reticulocytes;
CRC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.25	15.13	0.64	1.26e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs11958404	1.000	rs72816523	chr5:157403168	G/C	cg05962755	chr5:157440814	NA	0.96	12.22	0.56	1.42e-28	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18663498	chr6:27487068	NA	0.52	7.35	0.38	1.61e-12	Response to antipsychotic treatment;
CRC	cis	rs10971721	0.642	rs114466241	chr9:33835729	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.76	-0.3	1.95e-8	Rheumatoid arthritis;
CRC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.48	7.44	0.38	9.13e-13	Corneal astigmatism;
CRC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg18758796	chr5:131593413	PDLIM4	0.33	6.18	0.32	1.94e-9	Blood metabolite levels;
CRC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.69	-10.81	-0.51	1.67e-23	Blood protein levels;
CRC	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg13919466	chr1:32135498	COL16A1	-0.31	-5.79	-0.3	1.67e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.85	-14.5	-0.62	3.46e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	0.94	13.54	0.6	1.62e-33	Breast cancer;
CRC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg18827107	chr12:86230957	RASSF9	-0.43	-6.82	-0.35	4.31e-11	Major depressive disorder;
CRC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.88	0.35	2.98e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg18479299	chr3:125709523	NA	-0.54	-6.41	-0.33	4.96e-10	Blood pressure (smoking interaction);
CRC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.88	0.31	1.01e-8	Heart rate;
CRC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.26	-0.49	1.3e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg15786705	chr6:28176104	NA	0.62	6.67	0.34	1.11e-10	Depression;
CRC	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.57	7.91	0.4	3.9e-14	Pulmonary function decline;
CRC	cis	rs2834256	0.625	rs2834246	chr21:35050225	C/T	cg14850771	chr21:34775459	IFNGR2	-0.47	-6.99	-0.36	1.5e-11	Red cell distribution width;
CRC	cis	rs2072510	0.569	rs61937880	chr12:96390867	C/A	cg09636302	chr12:96389483	HAL	-0.52	-6.37	-0.33	6.21e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.62	9.27	0.46	2.44e-18	Subjective well-being;
CRC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg11833968	chr6:79620685	NA	0.37	6.5	0.34	2.97e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg11833968	chr6:79620685	NA	-0.35	-6.05	-0.32	3.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12315302	chr6:26189340	HIST1H4D	0.75	6.29	0.33	9.83e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.65	0.47	1.48e-19	Ileal carcinoids;
CRC	cis	rs2457480	0.733	rs1545845	chr10:44679802	A/C	cg09554077	chr10:44749378	NA	0.5	6.98	0.36	1.62e-11	Coronary artery disease;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00802000	chr16:706648	WDR90	-0.39	-5.62	-0.3	4.12e-8	Height;
CRC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.46	0.42	8.79e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	9.18	0.45	5.08e-18	Personality dimensions;
CRC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.87	9.59	0.47	2.33e-19	Breast cancer;
CRC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25517755	chr10:38738941	LOC399744	-0.45	-6.61	-0.34	1.53e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg02560186	chr11:3602584	NA	-0.57	-6.89	-0.36	2.85e-11	Blood pressure (smoking interaction);
CRC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.69	-9.74	-0.47	7.15e-20	Blood metabolite levels;
CRC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.64	0.3	3.7e-8	Lung cancer;
CRC	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.56	8.18	0.41	6.15e-15	Autism;
CRC	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg20387954	chr3:183756860	HTR3D	0.36	6.05	0.32	3.95e-9	Anterior chamber depth;
CRC	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg02527881	chr3:46936655	PTH1R	0.35	5.99	0.31	5.4e-9	Colorectal cancer;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.78	-0.39	9.16e-14	Total cholesterol levels;
CRC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.39	-6.66	-0.34	1.13e-10	Childhood ear infection;
CRC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.63	0.54	1.94e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.76	0.35	6.4e-11	Menarche (age at onset);
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg20542592	chr8:11973495	FAM66D	0.35	6.15	0.32	2.28e-9	Retinal vascular caliber;
CRC	trans	rs9528384	0.599	rs9645948	chr13:62269878	T/C	cg08375866	chr1:50799151	NA	-0.32	-6.0	-0.31	5.08e-9	Verbal declarative memory;
CRC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.66	7.69	0.39	1.69e-13	Menarche (age at onset);
CRC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.08	0.32	3.29e-9	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03366677	chr14:77495018	C14orf4	0.42	6.11	0.32	2.89e-9	Response to antipsychotic treatment;
CRC	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-9.18	-0.45	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs59104589	0.517	rs1064767	chr2:242167337	T/C	cg19488206	chr2:242435732	STK25	0.39	6.07	0.32	3.49e-9	Fibrinogen levels;
CRC	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.52	7.96	0.4	2.91e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.67	10.45	0.5	2.98e-22	Colorectal cancer;
CRC	trans	rs12495832	0.778	rs56373533	chr3:147940311	G/A	cg10221266	chr7:153579447	NA	0.59	6.34	0.33	7.77e-10	Chin dimples;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12525736	chr1:228269915	ARF1	0.45	7.35	0.38	1.57e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.45	-7.38	-0.38	1.34e-12	Refractive error;
CRC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.36	-0.33	6.72e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7074356	0.688	rs34894697	chr10:82169888	T/C	cg27171509	chr10:82033454	MAT1A	-0.45	-7.75	-0.39	1.18e-13	Borderline personality disorder;
CRC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.44	9.59	0.47	2.25e-19	Blood protein levels;
CRC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.61	-9.15	-0.45	6.31e-18	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.09	-0.41	1.15e-14	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00757413	chr9:130160153	SLC2A8	0.41	6.3	0.33	9.79e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.59	10.67	0.51	5.2e-23	Coronary artery disease;
CRC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.46	0.34	3.84e-10	Aortic root size;
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08219700	chr8:58056026	NA	0.55	6.56	0.34	2.15e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06451949	chr17:48942959	NA	0.43	6.0	0.31	5.1e-9	Response to antipsychotic treatment;
CRC	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-15.22	-0.64	5.66e-40	Cognitive function;
CRC	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.6	-6.85	-0.35	3.54e-11	Verbal memory performance (residualized delayed recall change);
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs3764400	0.567	rs741058	chr17:46205353	T/C	cg10706073	chr17:46328419	SKAP1	0.58	6.26	0.33	1.22e-9	Body mass index;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	0.99	12.66	0.57	3.33e-30	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16075951	chr14:24899050	CBLN3;KHNYN	0.37	6.03	0.32	4.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg00409905	chr10:38381863	ZNF37A	0.5	7.62	0.39	2.78e-13	Hemostatic factors and hematological phenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.49	7.06	0.36	1.02e-11	Response to antipsychotic treatment;
CRC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.65	7.85	0.4	5.8e-14	Psoriasis;
CRC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.44	0.33	4.25e-10	Morning vs. evening chronotype;
CRC	cis	rs1552172	0.853	rs11587821	chr1:145599038	G/T	cg11743829	chr1:145714124	CD160	-0.41	-6.14	-0.32	2.34e-9	Breast cancer;
CRC	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	trans	rs10180663	0.649	rs10189164	chr2:25633368	C/G	cg26118698	chr21:47599972	C21orf56	0.4	6.37	0.33	6.55e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg12223502	chr10:5658492	NA	-0.36	-5.9	-0.31	9.03e-9	Breast cancer;
CRC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.68	-0.35	1.01e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg12700464	chr11:78128424	GAB2	-0.5	-5.8	-0.3	1.52e-8	Testicular germ cell tumor;
CRC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.66	-10.71	-0.51	3.73e-23	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg06470822	chr6:28175283	NA	0.7	5.93	0.31	7.71e-9	Depression;
CRC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg01941586	chr1:40203715	PPIE	-0.42	-5.94	-0.31	7.23e-9	Blood protein levels;
CRC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.4	5.78	0.3	1.74e-8	Obesity-related traits;
CRC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg13844804	chr7:814759	HEATR2	0.65	8.52	0.42	6.01e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.42	7.02	0.36	1.27e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.5	8.94	0.44	2.84e-17	Blood metabolite levels;
CRC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2882667	0.867	rs11749045	chr5:138420960	C/T	cg09476006	chr5:138032270	NA	0.4	6.68	0.35	9.91e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.46	5.89	0.31	9.34e-9	Aortic root size;
CRC	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg04586622	chr2:25135609	ADCY3	-0.56	-10.26	-0.49	1.3e-21	Body mass index in non-asthmatics;
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg15898840	chr7:45960834	IGFBP3	0.42	7.09	0.36	8.2e-12	Sitting height ratio;
CRC	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.49	6.39	0.33	5.64e-10	Alzheimer's disease (survival time);
CRC	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.6	-9.12	-0.45	7.49e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.53	7.02	0.36	1.26e-11	Obesity-related traits;
CRC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg13390004	chr1:15929781	NA	0.5	7.07	0.36	9.19e-12	Systolic blood pressure;
CRC	trans	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg01134436	chr17:81009848	B3GNTL1	0.77	7.02	0.36	1.24e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.45	6.78	0.35	5.68e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg21466736	chr12:48725269	NA	0.51	7.7	0.39	1.6e-13	Glycated hemoglobin levels;
CRC	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.64	8.24	0.41	4.16e-15	Bipolar disorder;
CRC	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.56	-5.78	-0.3	1.77e-8	Vitamin D levels;
CRC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg02094049	chr14:103021097	NA	-0.57	-7.51	-0.38	5.56e-13	Platelet count;
CRC	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.56e-11	Opioid sensitivity;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20092199	chr4:1342459	KIAA1530	0.34	5.95	0.31	6.74e-9	Obesity-related traits;
CRC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg15445000	chr17:37608096	MED1	-0.35	-6.12	-0.32	2.59e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.88	10.19	0.49	2.18e-21	Psoriasis;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.33e-12	Cardiac Troponin-T levels;
CRC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.55	7.14	0.37	6.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.08	18.29	0.71	4.62e-52	Cognitive function;
CRC	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.68	-10.39	-0.5	4.54e-22	Colorectal cancer;
CRC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.54	-8.74	-0.43	1.24e-16	Aortic root size;
CRC	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.66	10.55	0.5	1.3e-22	Intelligence (multi-trait analysis);
CRC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	8.02	0.4	1.87e-14	Schizophrenia;
CRC	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.03	0.32	4.35e-9	Ovarian reserve;
CRC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg19223190	chr17:80058835	NA	0.41	6.57	0.34	1.93e-10	Life satisfaction;
CRC	cis	rs9311676	0.618	rs12152337	chr3:58365271	T/C	cg06643156	chr3:58380774	PXK	0.42	6.55	0.34	2.17e-10	Systemic lupus erythematosus;
CRC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg24562669	chr7:97807699	LMTK2	-0.68	-12.73	-0.57	1.88e-30	Breast cancer;
CRC	cis	rs9462027	0.628	rs9368832	chr6:34679587	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.37	6.63	0.34	1.35e-10	Systemic lupus erythematosus;
CRC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.52	8.58	0.43	3.77e-16	Calcium levels;
CRC	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg23234261	chr14:55582407	NA	-0.3	-5.97	-0.31	6.17e-9	Protein biomarker;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg14329157	chr2:228736135	WDR69	-0.47	-6.53	-0.34	2.48e-10	Blood pressure;
CRC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.51	-8.36	-0.42	1.77e-15	Huntington's disease progression;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.52	-0.34	2.6200000000000003e-10	Alzheimer's disease (late onset);
CRC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.78	13.53	0.6	1.81e-33	Breast cancer;
CRC	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg09659197	chr4:152720779	NA	0.4	7.98	0.4	2.49e-14	Intelligence (multi-trait analysis);
CRC	cis	rs727505	0.563	rs73227531	chr7:124800221	T/A	cg23710748	chr7:124431027	NA	-0.64	-10.42	-0.5	3.58e-22	Lewy body disease;
CRC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.21	-0.41	4.98e-15	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.88	0.51	9.5e-24	Exhaled nitric oxide output;
CRC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg26816564	chr1:7831052	VAMP3	0.55	6.14	0.32	2.36e-9	Inflammatory bowel disease;
CRC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.52	-8.41	-0.42	1.27e-15	Aortic root size;
CRC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.83	-13.07	-0.58	9.83e-32	Cognitive function;
CRC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.15	10.84	0.51	1.3e-23	Skin colour saturation;
CRC	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	6.68	0.35	1.01e-10	Body mass index;
CRC	cis	rs12541635	0.934	rs11776139	chr8:106983966	A/G	cg10147462	chr8:107024639	NA	0.47	7.67	0.39	2.02e-13	Age of smoking initiation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08541953	chr1:6259338	RPL22	0.51	6.68	0.35	1.02e-10	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg22110888	chr17:80059540	CCDC57	-0.43	-6.69	-0.35	9.52e-11	Life satisfaction;
CRC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	8.22	0.41	4.83e-15	Rheumatoid arthritis;
CRC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.94	-14.89	-0.63	1.09e-38	Gout;
CRC	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg20469991	chr17:27169893	C17orf63	0.47	5.85	0.31	1.2e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.66	-0.3	3.31e-8	Height;
CRC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg12923728	chr3:195709715	SDHAP1	-0.6	-6.28	-0.33	1.07e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg00310523	chr12:86230176	RASSF9	-0.38	-6.14	-0.32	2.4e-9	Major depressive disorder;
CRC	cis	rs7804356	0.861	rs115453073	chr7:26852741	A/T	cg03456212	chr7:26904342	SKAP2	-0.52	-5.68	-0.3	2.98e-8	Type 1 diabetes;
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.67	9.77	0.47	6.02e-20	Alzheimer's disease;
CRC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg27535305	chr1:53392650	SCP2	-0.39	-7.18	-0.37	4.66e-12	Monocyte count;
CRC	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.56	8.41	0.42	1.25e-15	HDL cholesterol;
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.76	9.15	0.45	6.19e-18	Response to hepatitis C treatment;
CRC	trans	rs2303319	0.504	rs12474470	chr2:162535336	T/C	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.55e-9	Cognitive function;
CRC	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.6	10.23	0.49	1.66e-21	Dupuytren's disease;
CRC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg16342193	chr10:102329863	NA	-0.4	-6.49	-0.34	3.23e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.63	10.3	0.49	9.29e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.51	-7.09	-0.36	8.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg12756093	chr1:115239321	AMPD1	0.47	6.84	0.35	3.86e-11	Autism;
CRC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg13092806	chr2:177043255	NA	0.8	13.09	0.59	8.21e-32	IgG glycosylation;
CRC	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.32	5.65	0.3	3.42e-8	Heart rate;
CRC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg00334542	chr7:100209784	MOSPD3	-0.52	-6.69	-0.35	9.7e-11	Other erythrocyte phenotypes;
CRC	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.37	-0.33	6.37e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs997295	0.570	rs737226	chr15:67840773	T/C	cg24247231	chr15:67904302	MAP2K5	-0.34	-5.96	-0.31	6.63e-9	Motion sickness;
CRC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.83	14.89	0.63	1.05e-38	Breast cancer;
CRC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.77	0.35	5.89e-11	Mean platelet volume;
CRC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.81	-15.04	-0.64	2.87e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1532331	0.864	rs6414900	chr5:43126528	G/A	cg09164108	chr5:43007320	NA	0.37	5.68	0.3	3e-8	Menarche (age at onset);
CRC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg17848003	chr1:3704513	LRRC47	0.4	5.95	0.31	6.97e-9	Red cell distribution width;
CRC	trans	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	7.7	0.39	1.64e-13	Endometrial cancer;
CRC	cis	rs4728302	0.703	rs3823572	chr7:133680601	G/A	cg03336402	chr7:133662267	EXOC4	-0.47	-7.07	-0.36	9.59e-12	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6743376	0.556	rs2472188	chr2:113820814	C/G	cg09040174	chr2:113837401	NA	0.4	5.84	0.31	1.22e-8	Inflammatory biomarkers;
CRC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg15445000	chr17:37608096	MED1	0.37	6.68	0.35	1e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02290350	chr8:58132656	NA	-0.5	-6.21	-0.32	1.6e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11446398	chr5:77624930	NA	0.42	6.06	0.32	3.65e-9	Triglycerides;
CRC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.48	-8.42	-0.42	1.15e-15	Dupuytren's disease;
CRC	cis	rs6788895	0.661	rs57869178	chr3:150492826	G/C	cg09723797	chr3:150481914	SIAH2	0.87	6.77	0.35	5.91e-11	Breast cancer;
CRC	cis	rs1545257	0.537	rs2339948	chr2:24641012	A/T	cg06627628	chr2:24431161	ITSN2	-0.45	-6.59	-0.34	1.71e-10	Sjögren's syndrome;
CRC	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg09344028	chr17:70110421	NA	0.44	6.65	0.34	1.2e-10	Thyroid hormone levels;
CRC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg15309053	chr8:964076	NA	0.41	7.27	0.37	2.64e-12	Schizophrenia;
CRC	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.55	8.96	0.44	2.55e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs883565	0.612	rs784512	chr3:39165110	G/T	cg01426195	chr3:39028469	NA	0.42	6.99	0.36	1.52e-11	Handedness;
CRC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.48	8.05	0.41	1.48e-14	Major depressive disorder;
CRC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg26721908	chr21:47610096	LSS	-0.46	-6.56	-0.34	2.09e-10	Testicular germ cell tumor;
CRC	cis	rs7626444	0.626	rs5021325	chr3:196477629	A/T	cg12930392	chr3:196481615	PAK2	0.39	6.88	0.35	3.06e-11	Monocyte count;
CRC	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg11204139	chr17:3907470	NA	0.76	14.68	0.63	7.35e-38	Type 2 diabetes;
CRC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.43	-7.17	-0.37	4.86e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.85	-12.69	-0.57	2.69e-30	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.74	0.47	7.29e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg07617317	chr6:118971624	C6orf204	0.5	6.25	0.33	1.27e-9	Renal cell carcinoma;
CRC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.43	0.33	4.6e-10	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.76	10.23	0.49	1.69e-21	Height;
CRC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.72	-11.39	-0.53	1.46e-25	Colorectal cancer;
CRC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.27e-19	Corneal astigmatism;
CRC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-8.57	-0.43	3.98e-16	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.47	7.36	0.38	1.48e-12	Corneal astigmatism;
CRC	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.94	-0.31	7.18e-9	Type 2 diabetes;
CRC	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg05044414	chr3:183734942	ABCC5	0.41	7.28	0.37	2.5e-12	Anterior chamber depth;
CRC	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-8.02	-0.4	1.86e-14	Body mass index;
CRC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.88	17.29	0.69	4.28e-48	Metabolic syndrome;
CRC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.24	0.41	4.24e-15	Rheumatoid arthritis;
CRC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.69	11.91	0.55	1.96e-27	Prostate cancer;
CRC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg13206674	chr6:150067644	NUP43	0.42	6.03	0.32	4.35e-9	Testicular germ cell tumor;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22146484	chr8:57123862	CHCHD7;PLAG1	-0.48	-5.99	-0.31	5.37e-9	Diisocyanate-induced asthma;
CRC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.08	0.36	8.96e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.35	5.71	0.3	2.54e-8	Menarche (age at onset);
CRC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.07	-0.49	5.56e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg14631576	chr9:95140430	CENPP	-0.3	-5.62	-0.3	3.97e-8	Height;
CRC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.45	-0.34	3.99e-10	Aortic root size;
CRC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04013166	chr16:89971882	TCF25	0.62	6.09	0.32	3.22e-9	Skin colour saturation;
CRC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg14828511	chr1:107599125	PRMT6	0.56	7.71	0.39	1.46e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.52	-7.94	-0.4	3.17e-14	Diastolic blood pressure;
CRC	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.63	-7.93	-0.4	3.34e-14	Height;
CRC	cis	rs9549328	0.542	rs36172983	chr13:113616582	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.43	0.33	4.47e-10	Systolic blood pressure;
CRC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-18.01	-0.7	6.09e-51	Height;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg14358282	chr2:219866628	MIR375	-0.55	-5.97	-0.31	6.05e-9	Lung adenocarcinoma;
CRC	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.56	-6.81	-0.35	4.76e-11	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06620269	chr17:2952258	NA	0.43	6.38	0.33	6.14e-10	Response to antipsychotic treatment;
CRC	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.36	-5.85	-0.31	1.18e-8	Menopause (age at onset);
CRC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.5	7.97	0.4	2.72e-14	Height;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.95e-9	Depression;
CRC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.06	0.36	1.02e-11	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg13047869	chr3:10149882	C3orf24	0.53	7.31	0.37	2.04e-12	Alzheimer's disease;
CRC	cis	rs9378357	1.000	rs7750434	chr6:3281726	G/T	cg08754725	chr6:3293098	SLC22A23	-0.57	-5.94	-0.31	7.12e-9	Obesity-related traits;
CRC	cis	rs1971762	0.509	rs784567	chr12:53894465	C/T	cg06632207	chr12:54070931	ATP5G2	-0.48	-8.03	-0.4	1.8e-14	Height;
CRC	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-7.61	-0.39	2.98e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.81	-14.37	-0.62	1.11e-36	Coronary artery disease;
CRC	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.71	-10.82	-0.51	1.47e-23	Response to temozolomide;
CRC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg02825527	chr7:2087843	MAD1L1	-0.4	-5.68	-0.3	3.03e-8	Bipolar disorder;
CRC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.46	-6.72	-0.35	8.25e-11	Menarche (age at onset);
CRC	cis	rs4664293	0.647	rs4665090	chr2:160453907	A/C	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	cis	rs12137294	0.794	rs1172160	chr1:205207015	G/A	cg24159697	chr1:205181237	DSTYK	-0.34	-6.25	-0.33	1.31e-9	Red cell distribution width;
CRC	cis	rs2307022	0.586	rs1465467	chr16:68398432	A/G	cg02226672	chr16:68398533	SMPD3	-0.29	-5.68	-0.3	2.9e-8	Body mass index;
CRC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.62	13.95	0.61	4.63e-35	Airflow obstruction;
CRC	cis	rs4731207	0.596	rs10081290	chr7:124575508	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21248554	chr2:27665150	KRTCAP3	0.3	6.97	0.36	1.7e-11	Total body bone mineral density;
CRC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.48	6.75	0.35	6.71e-11	Pulse pressure;
CRC	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.6	6.43	0.33	4.56e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg21251018	chr6:28226885	NKAPL	0.42	6.06	0.32	3.81e-9	Parkinson's disease;
CRC	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.83	-0.31	1.29e-8	Alzheimer's disease (late onset);
CRC	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.82	8.28	0.42	3.17e-15	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11522767	chr6:157342961	ARID1B	0.52	7.11	0.36	7.33e-12	Thyroid stimulating hormone;
CRC	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.98	-0.48	1.14e-20	Colorectal cancer;
CRC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	13.32	0.59	1.1e-32	Cognitive ability;
CRC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.84	13.68	0.6	5.07e-34	Cognitive function;
CRC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-1.01	-14.49	-0.62	3.9e-37	Initial pursuit acceleration;
CRC	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	cis	rs17023223	0.537	rs1325940	chr1:119586687	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-6.26	-0.33	1.2e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.57	8.39	0.42	1.5e-15	Menopause (age at onset);
CRC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-6.39	-0.33	5.65e-10	Cognitive function;
CRC	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg24463073	chr6:118973353	C6orf204	0.52	6.83	0.35	4.24e-11	Diastolic blood pressure;
CRC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.81	13.76	0.6	2.44e-34	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03732293	chr1:179335087	C1orf125	0.5	6.5	0.34	3.05e-10	Thyroid stimulating hormone;
CRC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.15	0.45	6.08e-18	Bladder cancer;
CRC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	8.02	0.4	1.87e-14	Schizophrenia;
CRC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg09839279	chr12:125627357	AACS	-0.38	-5.76	-0.3	1.9e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7703744	0.681	rs73239278	chr5:118695051	G/A	cg23985447	chr5:118691066	TNFAIP8	0.43	6.04	0.32	4.11e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.38	-6.85	-0.35	3.7e-11	Reticulocyte fraction of red cells;
CRC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.33	-5.91	-0.31	8.75e-9	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.53	0.34	2.47e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg14250997	chr9:106856677	SMC2	0.39	5.67	0.3	3.15e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-0.86	-9.9	-0.48	2.13e-20	Breast cancer;
CRC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-9.35	-0.46	1.38e-18	Prostate cancer;
CRC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.4	-6.05	-0.32	4.02e-9	Monocyte count;
CRC	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg18198730	chr1:247681584	NA	0.62	6.91	0.36	2.55e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.21	0.53	6.56e-25	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00926192	chr17:42297085	UBTF	0.36	6.11	0.32	2.82e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.57	-8.54	-0.43	5.02e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22062239	chr16:31106011	VKORC1	-0.52	-6.31	-0.33	9.05e-10	Diisocyanate-induced asthma;
CRC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.85	-0.35	3.64e-11	HDL cholesterol;
CRC	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.66	-0.34	1.12e-10	Height;
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg27532560	chr4:187881888	NA	-0.54	-10.04	-0.48	7.11e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.58	8.63	0.43	2.69e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.51	-0.46	4.1e-19	Bipolar disorder and schizophrenia;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01516881	chr6:292596	DUSP22	-0.57	-8.23	-0.41	4.48e-15	Menopause (age at onset);
CRC	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.6	-7.71	-0.39	1.5e-13	Ileal carcinoids;
CRC	trans	rs2303319	0.504	rs12463509	chr2:162347948	C/T	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.77	-6.04	-0.32	4.18e-9	Cognitive function;
CRC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	10.62	0.51	7.35e-23	Hip circumference adjusted for BMI;
CRC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg11292332	chr7:45801988	SEPT13	-0.38	-6.81	-0.35	4.75e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg08330183	chr15:22892184	CYFIP1	0.45	6.28	0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs910187	0.678	rs3818013	chr20:45816639	A/G	cg27589058	chr20:45804311	EYA2	-0.39	-7.51	-0.38	5.6e-13	Migraine;
CRC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg25456477	chr12:86230367	RASSF9	-0.35	-6.08	-0.32	3.39e-9	Major depressive disorder;
CRC	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg24046110	chr8:143859143	LYNX1	0.47	8.18	0.41	6.48e-15	Urinary tract infection frequency;
CRC	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07698384	chr15:25684465	UBE3A	0.49	6.9	0.36	2.7e-11	Response to antipsychotic treatment;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01363902	chr12:121022439	NA	-0.51	-6.39	-0.33	5.58e-10	Diisocyanate-induced asthma;
CRC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg07125278	chr16:67683757	RLTPR	-0.49	-6.81	-0.35	4.54e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00938859	chr5:1591904	SDHAP3	0.71	7.59	0.39	3.23e-13	Breast cancer;
CRC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.5	6.62	0.34	1.45e-10	Obesity-related traits;
CRC	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg09344028	chr17:70110421	NA	0.49	7.78	0.39	9.37e-14	Thyroid hormone levels;
CRC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg25767906	chr1:53392781	SCP2	0.4	6.53	0.34	2.55e-10	Monocyte count;
CRC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.61	-7.5	-0.38	6.14e-13	Bipolar disorder;
CRC	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg04110750	chr16:69646130	NFAT5	-0.54	-7.12	-0.37	6.73e-12	IgE levels;
CRC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-17.3	-0.69	3.95e-48	Intelligence (multi-trait analysis);
CRC	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.55	-6.1	-0.32	3.01e-9	Blood protein levels;
CRC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.54	-9.01	-0.44	1.69e-17	Brugada syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09423085	chr2:68478351	PPP3R1	0.41	6.12	0.32	2.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs6662572	0.737	rs111970066	chr1:46572817	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.38	0.33	6.09e-10	Blood protein levels;
CRC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.67	10.95	0.52	5.48e-24	Mean corpuscular hemoglobin;
CRC	cis	rs10413329	1.000	rs10403210	chr19:13103638	C/T	cg13338734	chr19:13113668	NFIX	-0.33	-5.69	-0.3	2.78e-8	Intelligence (multi-trait analysis);
CRC	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.37	-7.53	-0.38	5.01e-13	Cutaneous nevi;
CRC	cis	rs3026101	0.671	rs2285746	chr17:5311742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05665937	chr4:1216051	CTBP1	-0.39	-5.87	-0.31	1.06e-8	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.4	6.72	0.35	7.82e-11	Resting heart rate;
CRC	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.47	-6.8	-0.35	4.81e-11	Body mass index;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg00393283	chr10:92984646	PCGF5	-0.58	-6.62	-0.34	1.49e-10	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.51	-9.1	-0.45	8.85e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg18512352	chr11:47633146	NA	-0.35	-6.84	-0.35	3.98e-11	Subjective well-being;
CRC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06656553	chr16:89960601	TCF25	0.54	5.71	0.3	2.49e-8	Skin colour saturation;
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.7	0.35	8.83e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs6728302	0.557	rs7600132	chr2:233248198	C/A	cg09490371	chr2:233253024	ECEL1P2	-0.72	-6.37	-0.33	6.5e-10	Height;
CRC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.54	6.96	0.36	1.84e-11	Bronchopulmonary dysplasia;
CRC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17554472	chr22:41940697	POLR3H	-0.57	-6.08	-0.32	3.28e-9	Vitiligo;
CRC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.9	-9.96	-0.48	1.36e-20	Cerebrospinal P-tau181p levels;
CRC	cis	rs7605827	0.930	rs1469016	chr2:15687627	A/G	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.02e-15	Morning vs. evening chronotype;
CRC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.48	7.19	0.37	4.29e-12	Corneal astigmatism;
CRC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.13	-0.41	8.96e-15	Monocyte count;
CRC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.92	0.31	8.04e-9	Depression;
CRC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.15e-23	Motion sickness;
CRC	cis	rs12753569	0.748	rs1013629	chr1:76513759	A/G	cg00791851	chr1:76518896	NA	0.37	6.87	0.35	3.18e-11	Personality dimensions;
CRC	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18452880	chr6:170151829	C6orf70;TCTE3	0.42	6.83	0.35	4.01e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.41	-0.38	1.05e-12	Total body bone mineral density;
CRC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.18	-0.32	1.86e-9	Menopause (age at onset);
CRC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.64	0.63	9.85e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17023223	0.537	rs10802075	chr1:119627227	C/T	cg05756136	chr1:119680316	WARS2	-0.51	-6.87	-0.35	3.32e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13837895	chr19:50145301	SCAF1	0.46	6.38	0.33	6.06e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.92	14.18	0.62	5.85e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07165851	chr6:158734300	TULP4	0.58	7.19	0.37	4.51e-12	Height;
CRC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12580194	0.593	rs4448777	chr12:55724981	T/C	cg23425280	chr12:56401806	NA	0.48	5.81	0.31	1.45e-8	Cancer;
CRC	cis	rs4664293	0.899	rs7588710	chr2:160529522	T/A	cg08347373	chr2:160653686	CD302	-0.46	-7.36	-0.38	1.51e-12	Monocyte percentage of white cells;
CRC	cis	rs2288912	0.808	rs35670684	chr19:45455985	A/C	cg13119609	chr19:45449297	APOC2	0.31	5.76	0.3	1.92e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs669446	0.528	rs4660743	chr1:44195404	C/T	cg12908607	chr1:44402522	ARTN	-0.33	-5.7	-0.3	2.72e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs10888329	0.720	rs4428922	chr1:248406894	C/T	cg00666640	chr1:248458726	OR2T12	0.4	6.79	0.35	5.19e-11	Autism spectrum disorder;
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.25	-0.33	1.24e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.5	8.73	0.43	1.28e-16	Dietary macronutrient intake;
CRC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.75	12.76	0.58	1.4e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.58	6.27	0.33	1.12e-9	Schizophrenia;
CRC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.04	0.41	1.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.55	-7.4	-0.38	1.15e-12	Glycated hemoglobin levels;
CRC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-7.38	-0.38	1.34e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg20935933	chr6:143382018	AIG1	0.5	6.46	0.34	3.66e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.5	-7.88	-0.4	4.97e-14	Migraine;Coronary artery disease;
CRC	cis	rs965469	1.000	rs6139088	chr20:3329063	G/A	cg25506879	chr20:3388711	C20orf194	-0.37	-5.6	-0.3	4.41e-8	IFN-related cytopenia;
CRC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.57	7.29	0.37	2.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.06	-0.32	3.74e-9	Life satisfaction;
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg15898840	chr7:45960834	IGFBP3	-0.49	-7.82	-0.4	7.33e-14	Sitting height ratio;
CRC	cis	rs7605827	0.930	rs10208972	chr2:15676686	G/A	cg19274914	chr2:15703543	NA	0.39	5.83	0.31	1.33e-8	Educational attainment (years of education);
CRC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.36	5.68	0.3	2.89e-8	Height;
CRC	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.34	-6.68	-0.35	1.04e-10	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6840360	0.582	rs11733820	chr4:152316139	T/C	cg09659197	chr4:152720779	NA	0.33	6.34	0.33	7.38e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg20307385	chr11:47447363	PSMC3	0.48	6.02	0.31	4.66e-9	Migraine - clinic-based;
CRC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.65	6.72	0.35	8.24e-11	Axial length;
CRC	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.58	-9.23	-0.45	3.3e-18	Breast cancer;
CRC	cis	rs377457	0.856	rs11117268	chr16:85738269	A/T	cg02758499	chr16:85682440	KIAA0182	0.33	5.88	0.31	9.83e-9	Type 2 diabetes;
CRC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.18	-0.32	1.93e-9	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13051058	chr15:34629706	SLC12A6	0.46	6.69	0.35	9.87e-11	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	9.41	0.46	9.13e-19	Rheumatoid arthritis;
CRC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.4	-6.78	-0.35	5.67e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.41e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg10298567	chr3:47292165	KIF9	-0.38	-6.24	-0.33	1.35e-9	Colorectal cancer;
CRC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.14e-30	Bone mineral density;
CRC	cis	rs3849570	0.533	rs4440144	chr3:81988359	A/G	cg07356753	chr3:81810745	GBE1	-0.46	-6.34	-0.33	7.76e-10	Waist circumference;Body mass index;
CRC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.65	8.03	0.4	1.72e-14	Menarche (age at onset);
CRC	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg03929089	chr4:120376271	NA	0.64	6.22	0.32	1.53e-9	Axial length;
CRC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.71	0.51	3.63e-23	Motion sickness;
CRC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.75	0.39	1.16e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.39	-0.46	1.02e-18	Platelet count;
CRC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.15e-23	Motion sickness;
CRC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg12046867	chr14:103022105	NA	-0.7	-8.69	-0.43	1.71e-16	Platelet count;
CRC	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg12458913	chr13:53173898	NA	0.51	8.14	0.41	8.49e-15	Lewy body disease;
CRC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.45	6.87	0.35	3.14e-11	Menarche (age at onset);
CRC	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg04969067	chr8:143858791	LYNX1	-0.34	-5.82	-0.31	1.38e-8	Urinary tract infection frequency;
CRC	cis	rs10924970	0.967	rs1933246	chr1:235391446	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.79	0.3	1.64e-8	Asthma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11151929	chr3:120068323	LRRC58	0.47	6.15	0.32	2.25e-9	Thyroid stimulating hormone;
CRC	cis	rs28489187	0.706	rs4949890	chr1:85830632	T/C	cg17737388	chr1:85724454	C1orf52	0.38	5.7	0.3	2.67e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg22676075	chr6:135203613	NA	0.38	5.95	0.31	6.75e-9	Red blood cell count;
CRC	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.63	8.43	0.42	1.11e-15	Uric acid levels;
CRC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.94	14.39	0.62	9.68e-37	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.33	-0.56	5.77e-29	Coffee consumption (cups per day);
CRC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.53	-9.51	-0.46	4.11e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	0.9	11.06	0.52	2.16e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.76	-0.35	6.37e-11	Multiple sclerosis;
CRC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.75	0.39	1.19e-13	Mean platelet volume;
CRC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg09876464	chr15:85330779	ZNF592	0.39	6.54	0.34	2.32e-10	P wave terminal force;
CRC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-0.84	-9.3	-0.46	2.06e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.26	0.53	4.14e-25	Bone mineral density;
CRC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg23533926	chr12:111358616	MYL2	-0.54	-8.21	-0.41	5e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-6.16	-0.32	2.13e-9	Metabolite levels;
CRC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.36	-5.65	-0.3	3.55e-8	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08874598	chr8:102217901	ZNF706	0.41	7.41	0.38	1.06e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.49	-7.86	-0.4	5.5e-14	Height;
CRC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.75	11.04	0.52	2.5300000000000002e-24	Schizophrenia;
CRC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	9.86	0.48	2.8e-20	Cognitive test performance;
CRC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg24289452	chr6:170231220	NA	-0.81	-7.18	-0.37	4.55e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg16486109	chr11:613632	IRF7	0.73	12.38	0.56	3.58e-29	Systemic lupus erythematosus;
CRC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.37	-0.42	1.72e-15	Height;
CRC	cis	rs3736485	0.844	rs12593979	chr15:51741579	A/G	cg08986416	chr15:51914746	DMXL2	0.44	6.4	0.33	5.23e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7731657	0.537	rs6867710	chr5:130201260	A/C	cg08523029	chr5:130500466	HINT1	-0.46	-5.86	-0.31	1.11e-8	Fasting plasma glucose;
CRC	trans	rs559356	0.519	rs604721	chr3:34839735	T/C	cg18960307	chr17:4699574	PSMB6	0.41	6.06	0.32	3.72e-9	Cognitive function;
CRC	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.53	6.01	0.31	4.81e-9	Recalcitrant atopic dermatitis;
CRC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg14828511	chr1:107599125	PRMT6	0.55	7.5	0.38	5.91e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg20203395	chr5:56204925	C5orf35	-0.41	-5.83	-0.31	1.35e-8	Coronary artery disease;
CRC	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg04611788	chr3:186434169	KNG1	-0.58	-8.32	-0.42	2.31e-15	Blood protein levels;
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg11843238	chr5:131593191	PDLIM4	0.33	5.69	0.3	2.87e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16092991	chr4:15004611	CPEB2	0.45	6.53	0.34	2.43e-10	Response to antipsychotic treatment;
CRC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg19678392	chr7:94953810	PON1	-0.55	-6.72	-0.35	8.11e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.2	-0.41	5.41e-15	Chronic sinus infection;
CRC	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg09654669	chr8:57350985	NA	-0.45	-6.56	-0.34	2.12e-10	Obesity-related traits;
CRC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.58	9.45	0.46	6.54e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg18512352	chr11:47633146	NA	-0.35	-6.84	-0.35	3.98e-11	Subjective well-being;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg20607287	chr7:12443886	VWDE	-0.55	-5.89	-0.31	9.31e-9	Coronary artery disease;
CRC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-8.64	-0.43	2.45e-16	Platelet count;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-8.78	-0.44	9.2e-17	Lymphocyte counts;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg09877947	chr5:131593287	PDLIM4	0.55	10.25	0.49	1.41e-21	Acylcarnitine levels;
CRC	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.54	-8.25	-0.41	3.85e-15	Male sexual orientation;
CRC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.45	8.95	0.44	2.73e-17	Bipolar disorder;
CRC	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg18196295	chr10:418757	DIP2C	-0.42	-5.75	-0.3	2.01e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.8	14.0	0.61	3.05e-35	Vitiligo;
CRC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.67	0.54	1.44e-26	Prudent dietary pattern;
CRC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg21770322	chr7:97807741	LMTK2	0.54	9.09	0.45	9.85e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.57	8.31	0.42	2.63e-15	Response to temozolomide;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.83	-18.47	-0.71	8.93e-53	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17200204	chr3:43732323	ABHD5	0.4	6.12	0.32	2.68e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00552226	chr2:70475288	TIA1	0.48	6.87	0.35	3.24e-11	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.41	6.96	0.36	1.86e-11	Major depressive disorder;
CRC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.63	10.72	0.51	3.39e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22133161	chr19:49891603	CCDC155	0.5	6.43	0.33	4.39e-10	Multiple sclerosis;
CRC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	9.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.39	-6.88	-0.35	2.96e-11	Dilated cardiomyopathy;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg25164649	chr6:28176230	NA	0.63	9.02	0.45	1.62e-17	Parkinson's disease;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.54	10.01	0.48	9.16e-21	Age-related hearing impairment;
CRC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg12064134	chr16:90016061	DEF8	-0.56	-5.78	-0.3	1.78e-8	Skin colour saturation;
CRC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.44	0.53	9.63e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs629535	0.814	rs571682	chr8:70062793	A/G	cg26132723	chr8:70041827	NA	0.34	5.69	0.3	2.82e-8	Dupuytren's disease;
CRC	cis	rs8130944	0.859	rs35729571	chr21:44110493	T/C	cg23590273	chr21:44105265	PDE9A	-0.35	-5.62	-0.3	3.99e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg00601450	chr5:74908170	NA	0.44	6.22	0.32	1.48e-9	Age-related disease endophenotypes;
CRC	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg09695851	chr17:3907499	NA	-0.78	-14.11	-0.61	1.13e-35	Type 2 diabetes;
CRC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg11070056	chr1:107600091	PRMT6	0.38	5.62	0.3	4.13e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9378357	0.850	rs9392474	chr6:3293731	G/A	cg08754725	chr6:3293098	SLC22A23	-0.75	-6.9	-0.36	2.74e-11	Obesity-related traits;
CRC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	9.46	0.46	6.17e-19	Mean platelet volume;
CRC	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg23229984	chr5:148520753	ABLIM3	0.48	6.84	0.35	3.94e-11	Breast cancer;
CRC	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.66	9.33	0.46	1.6e-18	Body mass index;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02290350	chr8:58132656	NA	-0.55	-6.35	-0.33	7.04e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg06042504	chr8:55087323	NA	0.41	6.61	0.34	1.55e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.81	-14.3	-0.62	2.04e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25553015	chr19:39109861	MAP4K1;EIF3K	0.49	6.21	0.32	1.57e-9	Thyroid stimulating hormone;
CRC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.47	6.62	0.34	1.47e-10	Diastolic blood pressure;
CRC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.93	0.4	3.35e-14	Obesity-related traits;
CRC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.68	-6.59	-0.34	1.77e-10	Tuberculosis;
CRC	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Colorectal cancer;
CRC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.05	11.41	0.53	1.21e-25	Skin colour saturation;
CRC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	0.98	21.08	0.76	5.11e-63	Multiple system atrophy;
CRC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg01849466	chr14:104193079	ZFYVE21	0.39	5.64	0.3	3.71e-8	Body mass index;
CRC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-7.36	-0.38	1.48e-12	Primary sclerosing cholangitis;
CRC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg11189052	chr15:85197271	WDR73	0.58	8.47	0.42	8.01e-16	Schizophrenia;
CRC	cis	rs1062746	0.520	rs17698303	chr16:87329543	C/G	cg02258303	chr16:87377426	FBXO31	-0.51	-7.32	-0.37	1.9e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg15816464	chr17:2026533	SMG6	0.37	6.38	0.33	6.08e-10	Total body bone mineral density;
CRC	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.79	13.3	0.59	1.32e-32	Menopause (age at onset);
CRC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg07718321	chr6:96025334	MANEA	0.43	5.67	0.3	3.18e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg03623178	chr6:28175578	NA	0.78	11.64	0.54	1.87e-26	Parkinson's disease;
CRC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.23	0.37	3.49e-12	Hemoglobin concentration;
CRC	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg05194412	chr2:137003533	NA	0.44	6.82	0.35	4.38e-11	Colorectal cancer;
CRC	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.71	-11.93	-0.55	1.6e-27	Plateletcrit;Platelet count;
CRC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	9.04	0.45	1.39e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.65	0.39	2.28e-13	Lymphocyte percentage of white cells;
CRC	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.46	6.91	0.36	2.5e-11	Asthma;
CRC	cis	rs17152411	1.000	rs17152377	chr10:126592852	T/G	cg07906193	chr10:126599966	NA	0.58	6.48	0.34	3.33e-10	Height;
CRC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4731207	0.541	rs6960027	chr7:124543011	G/T	cg23710748	chr7:124431027	NA	-0.37	-5.98	-0.31	5.75e-9	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.8	-10.22	-0.49	1.85e-21	Initial pursuit acceleration;
CRC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.53	5.94	0.31	7.35e-9	Initial pursuit acceleration;
CRC	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg00531865	chr16:30841666	NA	0.48	6.81	0.35	4.58e-11	Dementia with Lewy bodies;
CRC	cis	rs6141769	0.542	rs4425162	chr20:31312916	A/G	cg13636640	chr20:31349939	DNMT3B	-0.38	-5.6	-0.3	4.44e-8	Subjective well-being;
CRC	cis	rs4731207	0.698	rs10263573	chr7:124469267	A/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7487075	1.000	rs7301001	chr12:46830841	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	6.09	0.32	3.12e-9	Itch intensity from mosquito bite;
CRC	cis	rs972578	0.765	rs7286299	chr22:43392856	C/T	cg01576275	chr22:43409880	NA	-0.38	-5.84	-0.31	1.25e-8	Mean platelet volume;
CRC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.65	-11.81	-0.55	4.33e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.45	7.29	0.37	2.29e-12	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.55	8.16	0.41	6.96e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.82	-0.48	3.96e-20	Blood protein levels;
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg01191114	chr3:48936118	SLC25A20	-0.69	-6.0	-0.31	5.27e-9	Cognitive function;
CRC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg08648136	chr8:956695	NA	0.32	6.26	0.33	1.19e-9	Schizophrenia;
CRC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-7.2	-0.37	4.13e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg23262073	chr20:60523788	NA	-0.42	-6.63	-0.34	1.38e-10	Body mass index;
CRC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	10.5	0.5	1.99e-22	Mean corpuscular hemoglobin;
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg12273811	chr6:28175739	NA	0.51	5.66	0.3	3.27e-8	Parkinson's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03462115	chr16:29801729	KIF22	-0.45	-6.5	-0.34	2.98e-10	Myopia (pathological);
CRC	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg13919466	chr1:32135498	COL16A1	-0.3	-5.73	-0.3	2.27e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg00122941	chr17:4613640	ARRB2	0.63	7.57	0.39	3.83e-13	Lymphocyte counts;
CRC	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.55	9.45	0.46	6.4e-19	Dupuytren's disease;
CRC	trans	rs6129564	0.731	rs6016332	chr20:38988846	A/T	cg12409982	chr3:137489312	NA	-0.44	-5.97	-0.31	6e-9	Cranial base width;
CRC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.99	12.4	0.56	2.99e-29	Vitiligo;
CRC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.8	-11.67	-0.54	1.47e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.87	-0.31	1.06e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
CRC	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.48	6.99	0.36	1.49e-11	Testicular germ cell tumor;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.73	9.74	0.47	7.36e-20	Alzheimer's disease;
CRC	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.56	5.87	0.31	1.04e-8	Blood protein levels;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.57	8.48	0.42	7.82e-16	Longevity;Endometriosis;
CRC	cis	rs7870657	0.535	rs7019370	chr9:71743826	A/G	cg14326805	chr9:71737756	TJP2	0.31	6.44	0.33	4.31e-10	Seasonality;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01546243	chr14:61748019	TMEM30B	0.43	6.03	0.32	4.52e-9	Thyroid stimulating hormone;
CRC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg21155852	chr7:2048760	MAD1L1	-0.43	-6.01	-0.31	4.92e-9	Bipolar disorder;
CRC	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg08501292	chr6:25962987	TRIM38	0.6	6.03	0.32	4.4e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-6.4	-0.33	5.46e-10	Migraine;Coronary artery disease;
CRC	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.45	6.2	0.32	1.66e-9	Diastolic blood pressure;
CRC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.09	-0.32	3.14e-9	Bipolar disorder;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg15845792	chr6:28175446	NA	0.78	11.57	0.54	3.33e-26	Parkinson's disease;
CRC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.68	-10.18	-0.49	2.43e-21	Intelligence (multi-trait analysis);
CRC	cis	rs3823572	0.542	rs28529474	chr7:133634908	C/T	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.6	0.43	3.33e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.41	-6.13	-0.32	2.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.53	8.08	0.41	1.24e-14	Breast cancer;
CRC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.46	7.41	0.38	1.07e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14317554	chr3:184870948	C3orf70	0.35	6.24	0.33	1.38e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg06042504	chr8:55087323	NA	-0.36	-5.76	-0.3	1.95e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.58	10.26	0.49	1.31e-21	Common traits (Other);
CRC	cis	rs6662572	0.686	rs59091734	chr1:46285809	A/G	cg08644498	chr1:46502608	NA	0.44	6.92	0.36	2.37e-11	Blood protein levels;
CRC	cis	rs7951870	0.645	rs2070852	chr11:46744925	C/G	cg19486271	chr11:47235900	DDB2	-0.46	-7.26	-0.37	2.86e-12	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25789511	chr20:60757919	GTPBP5	0.38	6.1	0.32	2.94e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.05	-0.36	1.05e-11	Coronary artery disease;
CRC	cis	rs7781266	0.790	rs11772553	chr7:133123204	G/A	cg03336402	chr7:133662267	EXOC4	0.49	5.81	0.31	1.47e-8	Educational attainment (college completion);
CRC	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.42	7.18	0.37	4.56e-12	Testicular germ cell tumor;
CRC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.52	-8.8	-0.44	7.82e-17	Huntington's disease progression;
CRC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.34	-5.83	-0.31	1.31e-8	White matter hyperintensity burden;
CRC	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.58	-7.23	-0.37	3.43e-12	Ulcerative colitis;
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27620946	chr8:42011116	AP3M2	-0.54	-6.74	-0.35	6.97e-11	Diisocyanate-induced asthma;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.44	-6.3	-0.33	9.35e-10	Adiposity;
CRC	cis	rs6445967	1.000	rs13082844	chr3:58318261	G/A	cg23715586	chr3:58305044	RPP14	0.36	5.96	0.31	6.64e-9	Platelet count;
CRC	trans	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg05376469	chr2:102649931	NA	0.37	6.1	0.32	2.94e-9	LDL cholesterol levels;LDL cholesterol;
CRC	trans	rs7830939	1.000	rs7830939	chr8:9380132	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.76	-0.35	6.38e-11	Neuroticism;
CRC	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.42	-0.33	4.68e-10	Homocysteine levels;
CRC	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00938859	chr5:1591904	SDHAP3	0.73	7.81	0.4	7.59e-14	Breast cancer;
CRC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.02	-0.45	1.57e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg20255370	chr15:40268687	EIF2AK4	-0.78	-7.12	-0.37	6.86e-12	Response to haloperidol in psychosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19978540	chr12:3409405	NA	0.46	6.65	0.34	1.23e-10	Response to antipsychotic treatment;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.55	-10.47	-0.5	2.47e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.84	0.4	6.26e-14	Menopause (age at onset);
CRC	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg19784903	chr17:45786737	TBKBP1	-0.36	-5.89	-0.31	9.61e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.64	-8.55	-0.43	4.64e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	10.95	0.52	5.42e-24	Prudent dietary pattern;
CRC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.66	10.64	0.51	6.47e-23	Sudden cardiac arrest;
CRC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	10.84	0.51	1.3e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7605827	0.930	rs4668898	chr2:15511502	T/C	cg19274914	chr2:15703543	NA	0.39	6.01	0.31	4.81e-9	Educational attainment (years of education);
CRC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.59	-0.43	3.56e-16	Gut microbiome composition (summer);
CRC	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.52	9.22	0.45	3.57e-18	Common traits (Other);
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00166722	chr3:10149974	C3orf24	0.67	9.26	0.45	2.71e-18	Alzheimer's disease;
CRC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg04553112	chr3:125709451	NA	-0.52	-6.02	-0.32	4.56e-9	Blood pressure (smoking interaction);
CRC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg07138768	chr7:917805	C7orf20	-0.3	-5.83	-0.31	1.33e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs9891119	0.965	rs17886724	chr17:40496163	A/G	cg06270615	chr17:40516068	STAT3	-0.27	-5.97	-0.31	6.21e-9	Multiple sclerosis;Crohn's disease;
CRC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg19824325	chr16:58548873	SETD6	1.0	6.84	0.35	3.87e-11	Schizophrenia;
CRC	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.49	11.88	0.55	2.41e-27	Systolic blood pressure;
CRC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.37	-6.72	-0.35	7.79e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.86	0.44	4.96e-17	Coffee consumption (cups per day);
CRC	cis	rs62432291	0.681	rs385438	chr6:159656213	A/G	cg14500486	chr6:159655392	FNDC1	-0.69	-9.66	-0.47	1.33e-19	Joint mobility (Beighton score);
CRC	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.54	7.42	0.38	9.98e-13	Tuberculosis;
CRC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg11843238	chr5:131593191	PDLIM4	0.31	5.7	0.3	2.73e-8	Blood metabolite levels;
CRC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg23625390	chr15:77176239	SCAPER	0.41	5.95	0.31	6.81e-9	Blood metabolite levels;
CRC	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg27068330	chr11:65405492	SIPA1	-0.44	-6.06	-0.32	3.8e-9	Systemic lupus erythematosus;
CRC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.18	-0.56	1.94e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg09877947	chr5:131593287	PDLIM4	0.33	6.13	0.32	2.55e-9	Blood metabolite levels;
CRC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.54	6.75	0.35	6.65e-11	Colorectal cancer;
CRC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.52	8.24	0.41	4.2e-15	Aortic root size;
CRC	cis	rs6662572	0.737	rs72690901	chr1:46378028	C/T	cg08644498	chr1:46502608	NA	0.43	6.77	0.35	6.1e-11	Blood protein levels;
CRC	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.27	6.11	0.32	2.75e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg15192750	chr16:69999425	NA	0.64	8.28	0.42	3.19e-15	IgE levels;
CRC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.86	0.31	1.12e-8	Gout;
CRC	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.53	7.26	0.37	2.77e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.72	-11.96	-0.55	1.31e-27	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.94	12.19	0.56	1.79e-28	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19850565	chr19:35168394	ZNF302	0.42	6.13	0.32	2.5e-9	Response to antipsychotic treatment;
CRC	cis	rs17155006	0.783	rs410286	chr7:107749257	A/T	cg05962710	chr7:107745446	LAMB4	-0.41	-7.36	-0.38	1.46e-12	Pneumococcal bacteremia;
CRC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.76	10.2	0.49	2.06e-21	Vitiligo;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	8.62	0.43	2.88e-16	Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.84	0.51	1.29e-23	Ileal carcinoids;
CRC	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg05562828	chr17:3906858	NA	0.67	12.55	0.57	8.33e-30	Type 2 diabetes;
CRC	cis	rs7605827	0.836	rs9287662	chr2:15595994	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.14e-9	Educational attainment (years of education);
CRC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.21	0.32	1.56e-9	Diabetic retinopathy;
CRC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.46	6.34	0.33	7.68e-10	Cardiac Troponin-T levels;
CRC	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg17145862	chr1:211918768	LPGAT1	-0.47	-6.38	-0.33	5.86e-10	Crohn's disease;
CRC	cis	rs76993477	0.666	rs77749308	chr1:169713467	A/G	cg03211132	chr1:169703751	SELE	0.58	5.7	0.3	2.72e-8	Tonsillectomy;
CRC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.68	9.97	0.48	1.2e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.4	6.71	0.35	8.7e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10779981	chr1:207925104	CD46	0.43	5.98	0.31	5.67e-9	Response to antipsychotic treatment;
CRC	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-5.81	-0.31	1.47e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.65	9.73	0.47	8.1e-20	Bladder cancer;
CRC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.51	-8.34	-0.42	2e-15	Aortic root size;
CRC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg03959625	chr15:84868606	LOC388152	0.42	6.36	0.33	6.88e-10	Schizophrenia;
CRC	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg24851651	chr11:66362959	CCS	-0.39	-6.86	-0.35	3.45e-11	Educational attainment (years of education);
CRC	cis	rs755249	0.532	rs61779278	chr1:39834617	A/G	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg07718321	chr6:96025334	MANEA	0.58	7.27	0.37	2.68e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg02820901	chr13:113351484	ATP11A	-0.55	-6.38	-0.33	6e-10	Glycated hemoglobin levels;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg03757145	chr4:76555832	CDKL2	-0.68	-6.04	-0.32	4.06e-9	Cognitive function;
CRC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.52	-6.9	-0.36	2.72e-11	Bronchopulmonary dysplasia;
CRC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg14829360	chr17:73884958	NA	-0.46	-7.27	-0.37	2.64e-12	Psoriasis;
CRC	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.59	-10.07	-0.49	5.95e-21	Obesity-related traits;
CRC	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg00531865	chr16:30841666	NA	-0.42	-5.95	-0.31	6.87e-9	Dementia with Lewy bodies;
CRC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.07	-0.32	3.56e-9	Menopause (age at onset);
CRC	cis	rs526821	0.595	rs629948	chr11:55356448	G/A	cg04317927	chr11:55418816	OR4S2	0.4	6.85	0.35	3.57e-11	Pediatric bone mineral density (spine);
CRC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-8.09	-0.41	1.13e-14	Major depressive disorder;
CRC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.31e-12	Putamen volume;
CRC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg19223190	chr17:80058835	NA	-0.45	-7.16	-0.37	5.41e-12	Life satisfaction;
CRC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.35	-5.66	-0.3	3.23e-8	Self-reported allergy;
CRC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12667521	chr19:29218732	NA	0.46	6.48	0.34	3.42e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg18809830	chr7:99032528	PTCD1	-0.94	-7.34	-0.38	1.69e-12	Blood metabolite levels;
CRC	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg16964102	chr10:135390573	NA	0.53	7.42	0.38	1.01e-12	Gout;
CRC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-0.67	-8.15	-0.41	7.53e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.53	8.52	0.43	5.74e-16	Platelet count;
CRC	cis	rs7932354	0.528	rs11039074	chr11:47081732	C/T	cg19486271	chr11:47235900	DDB2	-0.45	-6.46	-0.34	3.8e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.46	-6.3	-0.33	9.34e-10	Schizophrenia;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.51	-0.38	5.66e-13	Blood metabolite levels;
CRC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.85	0.44	5.65e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.37	-6.75	-0.35	6.53e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7539542	0.556	rs3820152	chr1:202878492	A/T	cg19681188	chr1:202830198	LOC148709	-0.41	-6.01	-0.31	5.01e-9	Mean platelet volume;
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.57	10.55	0.5	1.31e-22	Sjögren's syndrome;
CRC	cis	rs7605827	0.897	rs1996518	chr2:15517419	A/G	cg19274914	chr2:15703543	NA	0.39	5.93	0.31	7.51e-9	Educational attainment (years of education);
CRC	cis	rs6504622	0.720	rs4968304	chr17:45140601	A/C	cg16759221	chr17:45003025	GOSR2	0.44	6.8	0.35	5.08e-11	Orofacial clefts;
CRC	cis	rs902774	0.818	rs55958994	chr12:53301019	C/T	cg14581129	chr12:53358946	NA	-0.54	-6.16	-0.32	2.14e-9	Prostate cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01111397	chr2:172967676	DLX2	0.46	6.26	0.33	1.21e-9	Anxiety disorder;
CRC	cis	rs6988985	0.589	rs6471580	chr8:143986701	A/G	cg10324643	chr8:143916377	GML	0.37	6.38	0.33	6.06e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.36	-7.58	-0.39	3.6e-13	Schizophrenia;
CRC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23262073	chr20:60523788	NA	-0.42	-6.73	-0.35	7.35e-11	Body mass index;
CRC	cis	rs2857891	1.000	rs2595500	chr11:6963165	C/T	cg12728517	chr11:6947552	ZNF215	-0.56	-6.41	-0.33	4.95e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.42	0.33	4.76e-10	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19199531	chr22:20104664	TRMT2A;RANBP1	0.47	6.69	0.35	9.75e-11	Anxiety disorder;
CRC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.52	8.22	0.41	4.86e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06335251	chr10:31320888	ZNF438	0.43	6.39	0.33	5.62e-10	Response to antipsychotic treatment;
CRC	cis	rs9976767	0.637	rs9325635	chr21:43823289	G/A	cg23042151	chr21:43824109	UBASH3A	-0.41	-7.02	-0.36	1.31e-11	Type 1 diabetes;
CRC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.67	-0.47	1.25e-19	Height;
CRC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg06470822	chr6:28175283	NA	0.54	6.23	0.32	1.45e-9	Breast cancer;
CRC	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.65	0.51	5.97e-23	Iron status biomarkers;
CRC	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg27121462	chr16:89883253	FANCA	0.44	6.54	0.34	2.41e-10	Vitiligo;
CRC	cis	rs3823572	0.542	rs2953634	chr7:133640386	C/T	cg03336402	chr7:133662267	EXOC4	0.66	10.01	0.48	9.19e-21	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-6.02	-0.32	4.58e-9	Total body bone mineral density;
CRC	cis	rs16859517	0.546	rs56772456	chr2:220190457	G/C	cg00436969	chr2:220197716	RESP18	-0.46	-7.0	-0.36	1.46e-11	Height;
CRC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.63	-6.58	-0.34	1.86e-10	Axial length;
CRC	cis	rs9463078	0.774	rs10948222	chr6:45244415	T/C	cg25276700	chr6:44698697	NA	-0.27	-6.49	-0.34	3.14e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.8	12.98	0.58	2.25e-31	Breast cancer;
CRC	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11645453	chr3:52864694	ITIH4	-0.43	-8.39	-0.42	1.42e-15	Body mass index;
CRC	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg10517650	chr3:113235015	CCDC52	-0.38	-6.09	-0.32	3.13e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg27565382	chr3:53032988	SFMBT1	0.7	6.19	0.32	1.76e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg09127314	chr1:152161683	NA	0.52	6.82	0.35	4.45e-11	Atopic dermatitis;
CRC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg05627522	chr15:75251581	NA	0.4	6.02	0.32	4.6e-9	Breast cancer;
CRC	trans	rs9630182	0.561	rs10832036	chr11:13462853	G/T	cg13741668	chr9:85679694	NA	0.37	6.02	0.31	4.78e-9	Bone mineral density;
CRC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg15110403	chr19:17392923	ANKLE1	-0.36	-5.74	-0.3	2.11e-8	Systemic lupus erythematosus;
CRC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	0.84	7.63	0.39	2.54e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9847710	0.733	rs2581809	chr3:53089683	G/C	cg18099408	chr3:52552593	STAB1	0.4	6.03	0.32	4.53e-9	Ulcerative colitis;
CRC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.05	-0.32	3.95e-9	Bipolar disorder;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg04562611	chr16:615315	C16orf11	0.35	5.96	0.31	6.41e-9	Height;
CRC	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.49	8.34	0.42	2.08e-15	Common traits (Other);
CRC	trans	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg21153622	chr11:89784906	NA	0.45	6.91	0.36	2.46e-11	HDL cholesterol;
CRC	cis	rs7725052	0.609	rs10213846	chr5:40442869	A/C	cg09067459	chr5:40385259	NA	0.4	6.7	0.35	8.85e-11	Pediatric autoimmune diseases;
CRC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.47	8.24	0.41	4.26e-15	Lung cancer;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-10.53	-0.5	1.49e-22	Longevity;Endometriosis;
CRC	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.9	-0.61	6.99e-35	Ulcerative colitis;
CRC	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.66	-10.34	-0.5	6.91e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.89	0.31	9.49e-9	Rheumatoid arthritis;
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.63	11.43	0.53	1.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09372928	chr1:6845395	CAMTA1	0.4	6.41	0.33	5.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	9.09	0.45	9.54e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2292864	0.764	rs72825627	chr17:45386289	C/G	cg18085866	chr17:45331354	ITGB3	-0.58	-5.61	-0.3	4.39e-8	Left atrial antero-posterior diameter;
CRC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.61	-0.34	1.51e-10	IgG glycosylation;
CRC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.57	-9.09	-0.45	9.73e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-7.88	-0.4	4.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg09659197	chr4:152720779	NA	0.53	11.47	0.53	7.79e-26	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	8.69	0.43	1.75e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg15845792	chr6:28175446	NA	0.68	8.96	0.44	2.46e-17	Parkinson's disease;
CRC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.06e-15	Menopause (age at onset);
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Parkinson's disease;
CRC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.59	10.18	0.49	2.42e-21	Alzheimer's disease (late onset);
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00567696	chr6:46097521	ENPP4	0.45	6.64	0.34	1.33e-10	Response to antipsychotic treatment;
CRC	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.57	-0.43	4.09e-16	Biliary atresia;
CRC	trans	rs800082	0.516	rs9811286	chr3:144230367	T/C	cg24215973	chr2:240111563	HDAC4	0.46	6.44	0.33	4.18e-10	Smoking behavior;
CRC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg07195577	chr17:27052828	TLCD1	0.41	5.95	0.31	6.86e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9914988	0.667	rs11652544	chr17:27252989	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.48	6.19	0.32	1.8e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.42	-5.76	-0.3	1.9e-8	Diastolic blood pressure;
CRC	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.44	-6.89	-0.36	2.77e-11	C-reactive protein levels;
CRC	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg06935464	chr4:38784597	TLR10	0.55	5.74	0.3	2.12e-8	Breast cancer;
CRC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.07	0.49	5.64e-21	Heart rate;
CRC	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.19	0.45	4.45e-18	Mean corpuscular volume;
CRC	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg01557791	chr16:72042693	DHODH	-0.56	-5.84	-0.31	1.28e-8	Coronary artery disease;
CRC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.4	5.61	0.3	4.24e-8	Erythrocyte sedimentation rate;
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg01874867	chr7:94954059	PON1	-0.51	-6.39	-0.33	5.66e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9462027	0.606	rs12201281	chr6:34681091	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.37	6.63	0.34	1.35e-10	Systemic lupus erythematosus;
CRC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.1	-0.32	3e-9	Blood protein levels;
CRC	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.08	-0.32	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4073416	0.542	rs1953415	chr14:65988034	A/G	cg03016385	chr14:66212404	NA	-0.42	-5.93	-0.31	7.71e-9	N-glycan levels;
CRC	cis	rs7131987	0.644	rs1436323	chr12:29554741	A/G	cg09582351	chr12:29534625	ERGIC2	0.27	5.74	0.3	2.17e-8	QT interval;
CRC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.72	-0.3	2.4e-8	Lung cancer;
CRC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.8	-11.05	-0.52	2.32e-24	Type 2 diabetes;
CRC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg08075719	chr14:103021372	NA	-0.67	-7.87	-0.4	5.07e-14	Platelet count;
CRC	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.23	6.22	0.32	1.55e-9	Type 2 diabetes;
CRC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16405210	chr4:1374714	KIAA1530	0.42	5.94	0.31	7.07e-9	Obesity-related traits;
CRC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.52	-8.45	-0.42	9.38e-16	Breast cancer;
CRC	cis	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.66	-7.9	-0.4	4.32e-14	Rheumatoid arthritis;
CRC	trans	rs80346118	0.673	rs6012535	chr20:47423191	G/A	cg14297966	chr9:35101708	STOML2	0.45	5.98	0.31	5.89e-9	Diastolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09514589	chr15:76603992	ETFA	0.47	6.06	0.32	3.67e-9	Thyroid stimulating hormone;
CRC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg23463467	chr20:60627584	TAF4	0.38	7.45	0.38	8.36e-13	Body mass index;
CRC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.41	-0.33	5.06e-10	Alzheimer's disease (late onset);
CRC	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.54	9.58	0.47	2.43e-19	Blood metabolite ratios;
CRC	cis	rs8170	1.000	rs10418362	chr19:17386107	A/T	cg04749549	chr19:17459798	NA	-0.44	-5.95	-0.31	6.82e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.39	6.31	0.33	9.19e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg23758597	chr6:163146217	PARK2	-0.67	-6.77	-0.35	6.05e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.01	-0.4	1.95e-14	Gut microbiome composition (summer);
CRC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.68	-0.47	1.14e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-7.46	-0.38	7.73e-13	Coronary artery disease;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg21204522	chr6:27730016	NA	-0.4	-5.67	-0.3	3.2e-8	Parkinson's disease;
CRC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.13	-0.41	8.85e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs728616	0.558	rs12767261	chr10:82162323	G/A	cg11900509	chr10:81946545	ANXA11	-0.56	-6.24	-0.33	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.85	0.31	1.22e-8	IgG glycosylation;
CRC	cis	rs7487075	0.619	rs10880970	chr12:46830420	A/G	cg22049899	chr12:47219821	SLC38A4	0.31	5.74	0.3	2.12e-8	Itch intensity from mosquito bite;
CRC	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg22495460	chr2:25135724	ADCY3	-0.66	-11.09	-0.52	1.77e-24	Body mass index in non-asthmatics;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25026703	chr17:78429138	NA	0.37	6.0	0.31	5.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg01843034	chr6:37503916	NA	-0.48	-8.8	-0.44	7.73e-17	Cognitive performance;
CRC	trans	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.94	0.36	2.03e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg02198044	chr15:56286336	NEDD4	-0.38	-5.74	-0.3	2.1e-8	Keloid;
CRC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg22110888	chr17:80059540	CCDC57	0.4	6.25	0.33	1.3e-9	Life satisfaction;
CRC	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.44	5.97	0.31	6.26e-9	Pulse pressure;
CRC	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.65	0.34	1.21e-10	Subjective well-being;
CRC	cis	rs12928939	0.954	rs34998650	chr16:71829329	T/C	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.02	-0.31	4.78e-9	Post bronchodilator FEV1;
CRC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.4	0.33	5.2e-10	Diabetic kidney disease;
CRC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.8	12.22	0.56	1.46e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.84	-0.31	1.28e-8	Blood pressure;
CRC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.34	6.35	0.33	6.98e-10	QRS complex (12-leadsum);
CRC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg20360395	chr12:132671235	NA	0.38	6.2	0.32	1.72e-9	Anti-saccade response;
CRC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.05	0.68	3.64e-47	Platelet count;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.67	9.77	0.47	6.02e-20	Alzheimer's disease;
CRC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.9	10.55	0.5	1.36e-22	Psoriasis;
CRC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.49	-5.91	-0.31	8.42e-9	Smoking behavior;
CRC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg02766259	chr12:125626809	AACS	-0.48	-7.72	-0.39	1.43e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg14671364	chr1:107599128	PRMT6	0.52	7.19	0.37	4.49e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs35000415	0.938	rs12531711	chr7:128617466	A/G	cg19972273	chr7:128594194	NA	0.64	5.94	0.31	7.22e-9	Systemic lupus erythematosus;
CRC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.66	7.27	0.37	2.62e-12	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00184235	chr8:126442434	TRIB1	0.41	6.79	0.35	5.35e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-6.96	-0.36	1.82e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.53	7.54	0.38	4.74e-13	Testicular germ cell tumor;
CRC	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	0.57	6.19	0.32	1.78e-9	Coronary artery disease;
CRC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13871588	chr6:42981948	MEA1;KLHDC3	0.41	6.11	0.32	2.74e-9	Intelligence (multi-trait analysis);
CRC	cis	rs868943	0.582	rs12203393	chr6:116461404	C/A	cg15226275	chr6:116381976	FRK	0.25	5.87	0.31	1.06e-8	Total cholesterol levels;
CRC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.89	8.66	0.43	2.19e-16	Lymphocyte counts;
CRC	cis	rs7113874	0.550	rs10840084	chr11:8609274	G/A	cg17679104	chr11:8615758	STK33	0.36	6.06	0.32	3.63e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.55	6.6	0.34	1.62e-10	Alzheimer's disease;
CRC	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg15145174	chr5:6755386	POLS	0.45	6.33	0.33	7.99e-10	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16907344	chr1:16174671	SPEN;FLJ37453	0.44	6.25	0.33	1.26e-9	Anxiety disorder;
CRC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.68	10.42	0.5	3.69e-22	Tonsillectomy;
CRC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.45	-5.73	-0.3	2.26e-8	Longevity;
CRC	cis	rs1975991	0.503	rs9844744	chr3:187980503	G/C	cg17585528	chr3:187988060	LPP	-0.44	-5.87	-0.31	1.07e-8	White matter integrity (bipolar disorder risk interaction);
CRC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	13.17	0.59	4.13e-32	Menopause (age at onset);
CRC	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg14844989	chr11:31128820	NA	-0.33	-5.92	-0.31	8.25e-9	Red blood cell count;
CRC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.75	-0.57	1.61e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19500275	chr17:80737654	TBCD	0.5	6.73	0.35	7.77e-11	Glycated hemoglobin levels;
CRC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	5.99	0.31	5.42e-9	Retinal vascular caliber;
CRC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.69	-10.32	-0.49	8.12e-22	Menopause (age at onset);
CRC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg05044414	chr3:183734942	ABCC5	0.47	8.13	0.41	8.85e-15	Anterior chamber depth;
CRC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.22	0.56	1.46e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg11204139	chr17:3907470	NA	0.48	6.22	0.32	1.49e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	cis	rs12760731	0.623	rs10465514	chr1:178334035	G/T	cg00404053	chr1:178313656	RASAL2	0.75	9.45	0.46	6.61e-19	Obesity-related traits;
CRC	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.0	-0.31	5.32e-9	Schizophrenia;
CRC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.72	11.95	0.55	1.38e-27	Mean platelet volume;
CRC	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs17767392	0.834	rs61991193	chr14:71743789	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.08	-0.32	3.3e-9	Mitral valve prolapse;
CRC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg26248373	chr2:1572462	NA	-0.66	-7.2	-0.37	4.09e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs8141797	0.901	rs738808	chr22:24488461	C/T	cg20894457	chr22:24584366	SUSD2	0.68	6.43	0.33	4.61e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs939584	1.000	rs6749375	chr2:636017	C/T	cg03610516	chr2:642275	NA	0.43	5.76	0.3	1.91e-8	Body mass index;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg21251018	chr6:28226885	NKAPL	0.48	7.63	0.39	2.57e-13	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02018176	chr4:1364513	KIAA1530	-0.44	-7.43	-0.38	9.44e-13	Obesity-related traits;
CRC	cis	rs12541635	0.967	rs11997513	chr8:107093325	C/T	cg10147462	chr8:107024639	NA	-0.38	-6.31	-0.33	9.22e-10	Age of smoking initiation;
CRC	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.74	11.48	0.53	7.1e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg19193384	chr17:30244184	NA	-0.63	-7.17	-0.37	5.09e-12	Hip circumference adjusted for BMI;
CRC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-0.94	-18.08	-0.71	3.26e-51	Coronary artery disease;
CRC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.49	-8.74	-0.43	1.19e-16	Birth weight;
CRC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.28	-0.42	3.2e-15	Neuroticism;
CRC	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg25019722	chr6:37503610	NA	-0.41	-7.37	-0.38	1.4e-12	Cognitive performance;
CRC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg02741985	chr17:80059408	CCDC57	0.44	7.29	0.37	2.34e-12	Life satisfaction;
CRC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.57	-8.93	-0.44	3.12e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs12024301	0.557	rs16861402	chr1:183620178	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.97	0.4	2.61e-14	Rheumatoid arthritis;
CRC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg03037974	chr15:76606532	NA	-0.54	-8.23	-0.41	4.33e-15	Blood metabolite levels;
CRC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.36	-0.33	6.71e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4889855	0.614	rs6565694	chr17:78501101	T/C	cg16591659	chr17:78472290	NA	-0.61	-7.54	-0.38	4.48e-13	Fractional excretion of uric acid;
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg04204079	chr8:58130323	NA	-0.47	-5.89	-0.31	9.76e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.44	6.65	0.34	1.22e-10	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs10208940	0.920	rs10164780	chr2:68766250	A/T	cg12452813	chr2:68675892	NA	0.48	6.01	0.31	4.94e-9	Urate levels in lean individuals;
CRC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.19	-0.37	4.31e-12	Mean corpuscular volume;
CRC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg20573242	chr4:122745356	CCNA2	0.4	6.01	0.31	4.92e-9	Type 2 diabetes;
CRC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.62	-0.3	4.03e-8	Life satisfaction;
CRC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.84	15.25	0.64	4.31e-40	Body mass index;
CRC	cis	rs2811415	0.597	rs13092555	chr3:127738638	T/A	cg13719885	chr3:127795394	NA	-0.4	-6.06	-0.32	3.67e-9	Lung function (FEV1/FVC);
CRC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.28	14.87	0.63	1.28e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.73	10.19	0.49	2.29e-21	Alcohol dependence;
CRC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.38	-7.15	-0.37	5.58e-12	Iron status biomarkers;
CRC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg19688584	chr6:167529678	CCR6	-0.36	-6.53	-0.34	2.52e-10	Primary biliary cholangitis;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12172441	chr6:28176163	NA	0.59	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.7	0.39	1.62e-13	Platelet count;
CRC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.42	0.5	3.63e-22	Systolic blood pressure;
CRC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg01943577	chr7:158741284	NA	-0.44	-6.4	-0.33	5.39e-10	Height;
CRC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg15845792	chr6:28175446	NA	0.67	5.67	0.3	3.13e-8	Depression;
CRC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.21	-0.37	3.81e-12	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17465130	chr10:135192054	PAOX	0.47	6.77	0.35	6.03e-11	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.43	-5.78	-0.3	1.73e-8	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CRC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.74	9.06	0.45	1.22e-17	Iron status biomarkers;
CRC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.27	-0.33	1.15e-9	Aortic root size;
CRC	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	6.53	0.34	2.5e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs6015450	1.000	rs74715624	chr20:57753203	T/C	cg22122715	chr13:96086023	CLDN10	-0.55	-6.07	-0.32	3.48e-9	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07036775	chr1:145470395	ANKRD34A;POLR3GL	0.43	5.97	0.31	6.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10924970	0.967	rs4659654	chr1:235383188	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.82	0.31	1.43e-8	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27488370	chr7:128046294	IMPDH1	-0.41	-6.16	-0.32	2.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4728302	0.869	rs13233715	chr7:133617471	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.76	0.3	1.92e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.42	-0.33	4.66e-10	Height;
CRC	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.48	6.88	0.35	2.99e-11	Coronary artery disease;
CRC	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.41	6.38	0.33	6.15e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg01312482	chr5:178451176	ZNF879	0.34	5.72	0.3	2.45e-8	Pubertal anthropometrics;
CRC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.21e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.8	-0.3	1.57e-8	Alzheimer's disease (survival time);
CRC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-9.92	-0.48	1.8899999999999998e-20	Menarche (age at onset);
CRC	cis	rs17401966	0.540	rs4846221	chr1:10472026	C/A	cg19773385	chr1:10388646	KIF1B	-0.48	-7.58	-0.39	3.64e-13	Hepatocellular carcinoma;
CRC	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg06581033	chr10:766294	NA	-0.52	-5.78	-0.3	1.71e-8	Uric acid levels;
CRC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg20908204	chr19:46285434	DMPK	-0.34	-6.84	-0.35	3.97e-11	Coronary artery disease;
CRC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-15.78	-0.66	3.69e-42	Intelligence (multi-trait analysis);
CRC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.61	11.98	0.55	1.11e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg26875233	chr11:93583750	C11orf90	-0.33	-6.27	-0.33	1.11e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.61	-9.84	-0.48	3.32e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs995000	0.931	rs1168042	chr1:62974150	A/T	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.5e-11	Triglyceride levels;
CRC	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.49	6.91	0.36	2.58e-11	Height;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg26587870	chr6:27730563	NA	-0.42	-6.28	-0.33	1.05e-9	Parkinson's disease;
CRC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.0	-0.31	5.12e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.76	-0.3	1.9e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4688759	0.764	rs11716961	chr3:49908338	G/A	cg01304814	chr3:48885189	PRKAR2A	0.94	6.36	0.33	6.7e-10	Blood protein levels;
CRC	cis	rs775227	0.574	rs3732809	chr3:113045561	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-6.61	-0.34	1.56e-10	Dental caries;
CRC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg12365402	chr11:9010492	NRIP3	-0.48	-8.04	-0.41	1.59e-14	Hemoglobin concentration;
CRC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg14711859	chr11:8959438	ASCL3	-0.52	-8.42	-0.42	1.16e-15	Hemoglobin concentration;
CRC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07702255	chr11:46143461	PHF21A	0.41	6.08	0.32	3.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.85	-15.77	-0.66	4.06e-42	Dental caries;
CRC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.7	-8.54	-0.43	5.2e-16	Initial pursuit acceleration;
CRC	trans	rs1864729	1.000	rs2567773	chr8:98279182	G/A	cg08679828	chr8:102218111	ZNF706	-0.58	-7.05	-0.36	1.06e-11	Estradiol plasma levels (breast cancer);
CRC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.94	-0.31	7.26e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7487075	0.828	rs7132228	chr12:46731961	G/A	cg22049899	chr12:47219821	SLC38A4	0.35	6.82	0.35	4.45e-11	Itch intensity from mosquito bite;
CRC	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg13057898	chr1:3703894	LRRC47	0.58	7.81	0.4	7.7e-14	Red cell distribution width;
CRC	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg04117972	chr1:227635322	NA	0.62	7.24	0.37	3.24e-12	Major depressive disorder;
CRC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.72	-9.4	-0.46	9.79e-19	Birth weight;
CRC	cis	rs812925	0.511	rs11886950	chr2:61399317	A/C	cg10580144	chr2:61372316	C2orf74	0.34	7.69	0.39	1.7e-13	Immature fraction of reticulocytes;
CRC	cis	rs9879311	0.932	rs7427473	chr3:10413197	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.37	5.7	0.3	2.68e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg25790453	chr13:113633590	MCF2L	-0.57	-10.09	-0.49	5.03e-21	Systolic blood pressure;
CRC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.88e-13	Corneal astigmatism;
CRC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25382265	chr19:50169375	BCL2L12;IRF3	0.43	6.01	0.31	4.79e-9	Response to antipsychotic treatment;
CRC	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.43	6.72	0.35	7.86e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CRC	cis	rs16852403	0.548	rs482269	chr1:178226624	T/C	cg00404053	chr1:178313656	RASAL2	-0.5	-6.57	-0.34	1.92e-10	Childhood ear infection;
CRC	cis	rs4073416	0.527	rs1959144	chr14:65946051	T/G	cg03016385	chr14:66212404	NA	-0.45	-6.21	-0.32	1.56e-9	N-glycan levels;
CRC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.65	-8.75	-0.43	1.12e-16	Gut microbiome composition (summer);
CRC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.68	5.79	0.3	1.68e-8	Putamen volume;
CRC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg25876840	chr17:41920477	NA	0.44	6.45	0.33	4.07e-10	Triglycerides;
CRC	cis	rs17767392	1.000	rs34528131	chr14:71861278	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.89	-0.35	2.93e-11	Mitral valve prolapse;
CRC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.54	11.14	0.52	1.12e-24	Alcohol dependence;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg10868875	chr11:61596307	FADS2	-0.53	-6.86	-0.35	3.41e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.68	9.51	0.46	4.14e-19	Bladder cancer;
CRC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg07884673	chr3:53033167	SFMBT1	0.76	6.13	0.32	2.45e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.6	8.86	0.44	5.24e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs970548	1.000	rs11239545	chr10:46012245	A/T	cg15590007	chr10:45870220	ALOX5	-0.46	-5.92	-0.31	7.89e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg10263370	chr3:44754102	ZNF502	-0.42	-5.78	-0.3	1.74e-8	IgG glycosylation;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.69	-8.68	-0.43	1.89e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.57	10.21	0.49	1.9e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11212617	1.000	rs227094	chr11:108233800	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.45	6.71	0.35	8.52e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.64	-10.44	-0.5	3.11e-22	Colorectal cancer;
CRC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.48	7.27	0.37	2.69e-12	Breast cancer;
CRC	cis	rs364477	0.855	rs279894	chr9:968334	G/A	cg13952963	chr9:998547	NA	0.58	6.28	0.33	1.06e-9	Major depressive disorder;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.56	0.34	2.03e-10	Bipolar disorder;
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.84	-0.51	1.32e-23	Bipolar disorder;
CRC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.66	-7.99	-0.4	2.28e-14	Menarche (age at onset);
CRC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg26805224	chr10:79626177	DLG5	-0.48	-7.09	-0.36	8.5e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.22	0.74	1.2e-59	Prudent dietary pattern;
CRC	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.43	6.95	0.36	1.94e-11	Sitting height ratio;
CRC	cis	rs454510	0.542	rs10754417	chr1:120177454	G/T	cg11530693	chr1:120165357	ZNF697	0.43	6.22	0.32	1.48e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.38	-6.03	-0.32	4.36e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.11	0.32	2.8e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg02741985	chr17:80059408	CCDC57	-0.42	-6.77	-0.35	5.8e-11	Life satisfaction;
CRC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg19812747	chr11:111475976	SIK2	-0.47	-7.77	-0.39	9.89e-14	Primary sclerosing cholangitis;
CRC	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.59	-5.94	-0.31	7.37e-9	Thyroid stimulating hormone;
CRC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.75	12.58	0.57	6.82e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.68e-21	Asthma (childhood onset);
CRC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg24209194	chr3:40518798	ZNF619	0.41	6.1	0.32	2.94e-9	Renal cell carcinoma;
CRC	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.75	13.53	0.6	1.74e-33	Lewy body disease;
CRC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.54	9.02	0.45	1.65e-17	Calcium levels;
CRC	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg21836586	chr14:55907198	TBPL2	0.31	5.62	0.3	4.1e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg22495460	chr2:25135724	ADCY3	-0.99	-22.82	-0.78	8.91e-70	Body mass index in non-asthmatics;
CRC	cis	rs990171	1.000	rs2058660	chr2:103054449	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	0.92	15.32	0.65	2.38e-40	Dupuytren's disease;
CRC	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.52	9.23	0.45	3.37e-18	Blood metabolite ratios;
CRC	cis	rs6585424	1.000	rs12769115	chr10:81933501	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.31	-0.46	1.92e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.37	-0.46	1.19e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	12.26	0.56	9.9e-29	Lymphocyte percentage of white cells;
CRC	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.39	-5.87	-0.31	1.09e-8	Red blood cell count;Hematocrit;Red blood cell traits;
CRC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.44	-6.21	-0.32	1.57e-9	Lymphocyte counts;
CRC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.98	-0.36	1.62e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6546324	1.000	rs1430787	chr2:67868498	A/T	cg15745817	chr2:67799979	NA	-0.29	-5.7	-0.3	2.7e-8	Endometriosis;
CRC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg20203395	chr5:56204925	C5orf35	0.57	7.78	0.39	9.41e-14	Initial pursuit acceleration;
CRC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.38	5.95	0.31	6.73e-9	Height;
CRC	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.4	-6.02	-0.32	4.58e-9	Height;
CRC	cis	rs17767392	0.834	rs61991191	chr14:71739204	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.46	-0.34	3.77e-10	Mitral valve prolapse;
CRC	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.72	0.35	8.12e-11	Homocysteine levels;
CRC	cis	rs6804368	0.531	rs12107637	chr3:30758448	T/C	cg06106510	chr3:30762233	NA	0.39	6.42	0.33	4.77e-10	Blood metabolite levels;
CRC	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.71	-7.48	-0.38	6.99e-13	Type 2 diabetes;
CRC	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs728616	0.510	rs61860860	chr10:81758572	G/A	cg05935833	chr10:81318306	SFTPA2	-0.55	-7.16	-0.37	5.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.47	7.16	0.37	5.18e-12	Mood instability;
CRC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg15123519	chr2:136567270	LCT	-0.35	-6.78	-0.35	5.71e-11	Mosquito bite size;
CRC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10118547	chr2:206547064	NRP2	0.39	6.36	0.33	6.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs34638657	0.536	rs2967327	chr16:82188657	C/T	cg07918374	chr16:82182319	MPHOSPH6	0.44	6.43	0.33	4.46e-10	Lung adenocarcinoma;
CRC	cis	rs8005677	0.828	rs12437151	chr14:23372913	G/A	cg25600027	chr14:23388339	RBM23	-0.43	-6.46	-0.34	3.78e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg12172441	chr6:28176163	NA	0.6	8.57	0.43	4.23e-16	Cardiac Troponin-T levels;
CRC	cis	rs7394190	0.748	rs11000764	chr10:75506864	A/G	cg07699608	chr10:75541558	CHCHD1	0.62	6.37	0.33	6.37e-10	Incident atrial fibrillation;
CRC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.02	-0.31	4.7e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18099408	chr3:52552593	STAB1	0.34	5.81	0.31	1.46e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg27588902	chr6:42928151	GNMT	-0.41	-7.41	-0.38	1.06e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.69	9.71	0.47	9.26e-20	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.62	9.06	0.45	1.2e-17	Response to temozolomide;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg24046110	chr8:143859143	LYNX1	-0.39	-6.72	-0.35	7.84e-11	Urinary tract infection frequency;
CRC	cis	rs6545883	0.931	rs778756	chr2:61781994	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-5.68	-0.3	2.91e-8	Tuberculosis;
CRC	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg01312482	chr5:178451176	ZNF879	-0.36	-5.97	-0.31	6.26e-9	Pubertal anthropometrics;
CRC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.7	-0.39	1.64e-13	Neuroticism;
CRC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.12e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9322817	0.691	rs2168394	chr6:105259152	C/T	cg02098413	chr6:105308735	HACE1	-0.44	-8.6	-0.43	3.29e-16	Thyroid stimulating hormone;
CRC	cis	rs9992667	0.910	rs17428945	chr4:38689745	T/C	cg19726192	chr4:38663646	FLJ13197	-0.7	-8.8	-0.44	7.71e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs35000415	0.938	rs13236009	chr7:128663173	T/G	cg19972273	chr7:128594194	NA	0.68	6.32	0.33	8.52e-10	Systemic lupus erythematosus;
CRC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg04498913	chr7:1135747	C7orf50	-0.61	-6.93	-0.36	2.21e-11	Bronchopulmonary dysplasia;
CRC	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.72	0.39	1.45e-13	Breast cancer;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg15786705	chr6:28176104	NA	0.76	9.49	0.46	4.97e-19	Depression;
CRC	cis	rs3026101	0.671	rs929262	chr17:5312271	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg08222618	chr4:941054	TMEM175	-0.35	-6.23	-0.32	1.44e-9	Systemic sclerosis;
CRC	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg00691999	chr4:55094011	PDGFRA	0.42	6.03	0.32	4.4e-9	Corneal astigmatism;
CRC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.83	-0.35	4.24e-11	Asthma and hay fever;
CRC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06636001	chr8:8085503	FLJ10661	0.46	5.82	0.31	1.39e-8	Obesity-related traits;
CRC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.48	7.34	0.38	1.69e-12	Corneal astigmatism;
CRC	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg19508488	chr2:152266495	RIF1	0.49	6.22	0.32	1.52e-9	Squamous cell lung carcinoma;
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg25164649	chr6:28176230	NA	-0.79	-11.28	-0.53	3.57e-25	Depression;
CRC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.69	10.14	0.49	3.2e-21	Longevity;
CRC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg11440486	chr17:48585216	MYCBPAP	-0.43	-5.83	-0.31	1.33e-8	Visceral fat;
CRC	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.77	0.44	9.82e-17	Coffee consumption (cups per day);
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.49	6.84	0.35	3.75e-11	Height;
CRC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.13	0.41	8.68e-15	Menarche (age at onset);
CRC	trans	rs1972460	0.506	rs62012050	chr15:82532274	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.82	-0.35	4.4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs660899	0.857	rs7520053	chr1:44226657	C/T	cg10881128	chr1:44031826	PTPRF	-0.21	-5.62	-0.3	4.11e-8	Hypertension risk in short sleep duration;
CRC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	10.34	0.5	6.72e-22	Motion sickness;
CRC	cis	rs4663866	1.000	rs4663300	chr2:239181491	T/C	cg16914508	chr2:239161102	PER2	0.78	7.98	0.4	2.41e-14	Irritable bowel syndrome;
CRC	cis	rs13098911	0.540	rs13097556	chr3:46061997	T/C	cg12691230	chr3:46064611	XCR1	-0.53	-5.77	-0.3	1.83e-8	Celiac disease;
CRC	cis	rs2882667	0.537	rs7704790	chr5:138410096	A/C	cg09476006	chr5:138032270	NA	0.35	5.72	0.3	2.41e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16262614	chr3:133464971	TF	0.35	6.22	0.32	1.49e-9	Iron status biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01240483	chr11:93861934	PANX1	0.42	6.2	0.32	1.73e-9	Response to antipsychotic treatment;
CRC	cis	rs3736485	0.934	rs1077361	chr15:51880919	T/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg00531865	chr16:30841666	NA	-0.4	-5.66	-0.3	3.22e-8	Dementia with Lewy bodies;
CRC	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-7.77	-0.39	1.03e-13	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-19.52	-0.73	6.34e-57	Height;
CRC	cis	rs4731207	0.698	rs10236403	chr7:124539542	C/T	cg23710748	chr7:124431027	NA	-0.36	-5.77	-0.3	1.79e-8	Cutaneous malignant melanoma;
CRC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.59	9.68	0.47	1.17e-19	Colorectal cancer;
CRC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg17298326	chr8:142245477	NA	-0.38	-5.79	-0.3	1.64e-8	Immature fraction of reticulocytes;
CRC	trans	rs11825709	1.000	rs2460047	chr11:93678936	A/G	cg08642771	chr1:198392758	NA	-0.59	-6.51	-0.34	2.78e-10	Obesity-related traits;
CRC	cis	rs6969780	0.915	rs11983200	chr7:27186596	A/G	cg26364809	chr7:27145159	NA	-0.74	-6.92	-0.36	2.31e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.31	0.37	1.99e-12	Testicular germ cell tumor;
CRC	cis	rs3750082	0.852	rs2392152	chr7:32900549	A/G	cg05721444	chr7:32995514	FKBP9	-0.49	-7.74	-0.39	1.24e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.54	-8.68	-0.43	1.87e-16	Huntington's disease progression;
CRC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.56	9.18	0.45	4.87e-18	Huntington's disease progression;
CRC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg03609598	chr5:56110824	MAP3K1	-0.56	-7.56	-0.38	4.09e-13	Coronary artery disease;
CRC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.36	5.83	0.31	1.29e-8	Cardiovascular disease risk factors;
CRC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.51	-6.55	-0.34	2.27e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg14458575	chr2:238380390	NA	0.46	6.51	0.34	2.8e-10	Prostate cancer;
CRC	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.57	-7.5	-0.38	6e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs282587	0.569	rs7326827	chr13:113408866	T/C	cg04656015	chr13:113407548	ATP11A	0.62	7.97	0.4	2.63e-14	Glycated hemoglobin levels;
CRC	trans	rs10021731	0.718	rs17678686	chr4:115410256	G/A	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg12172441	chr6:28176163	NA	0.54	7.43	0.38	9.55e-13	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs2882667	0.861	rs11242445	chr5:138417054	G/T	cg09476006	chr5:138032270	NA	0.4	6.65	0.34	1.19e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19894588	chr14:64061835	NA	0.43	6.14	0.32	2.32e-9	Glioblastoma;Glioma;
CRC	cis	rs243505	0.762	rs734004	chr7:148505460	C/G	cg09806900	chr7:148480153	CUL1	0.47	6.8	0.35	5.08e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg25972092	chr12:117363249	FBXW8	0.55	6.33	0.33	8.06e-10	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs4728302	0.838	rs6974143	chr7:133603550	G/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.52	-0.34	2.61e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.44	-7.23	-0.37	3.34e-12	Refractive error;
CRC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.8	-12.39	-0.56	3.3600000000000003e-29	Cognitive function;
CRC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.35	-0.79	8.31e-72	Myeloid white cell count;
CRC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.84	-14.3	-0.62	2.08e-36	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg21770322	chr7:97807741	LMTK2	0.48	7.92	0.4	3.8e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg03037974	chr15:76606532	NA	0.7	12.57	0.57	7.07e-30	Blood metabolite levels;
CRC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg18230493	chr5:56204884	C5orf35	-0.39	-5.77	-0.3	1.87e-8	Breast cancer;Breast cancer (early onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10064079	chr20:44600917	ZNF335	0.45	6.16	0.32	2.08e-9	Response to antipsychotic treatment;
CRC	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.51	6.37	0.33	6.52e-10	Recombination rate (females);
CRC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.07	-0.36	9.19e-12	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17315135	chr7:29234965	CHN2	0.38	6.02	0.31	4.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	3.04e-10	Fibrinogen levels;
CRC	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.6	-0.3	4.45e-8	Educational attainment (years of education);
CRC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.66	-0.39	2.1e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.74	-0.35	7.09e-11	Subjective well-being;
CRC	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-8.63	-0.43	2.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	11.22	0.53	6.05e-25	Systolic blood pressure;
CRC	cis	rs7605827	0.866	rs34815739	chr2:15533375	A/G	cg19274914	chr2:15703543	NA	0.4	5.9	0.31	9.25e-9	Educational attainment (years of education);
CRC	cis	rs73200209	0.665	rs17498599	chr12:116597253	C/T	cg01776926	chr12:116560359	MED13L	-0.63	-7.28	-0.37	2.52e-12	Total body bone mineral density;
CRC	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.66	8.77	0.44	9.95e-17	Uric acid levels;
CRC	cis	rs995000	0.931	rs12062275	chr1:62991905	T/C	cg19896129	chr1:63156450	NA	-0.45	-7.0	-0.36	1.48e-11	Triglyceride levels;
CRC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg26721908	chr21:47610096	LSS	-0.44	-7.0	-0.36	1.46e-11	Testicular germ cell tumor;
CRC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.84	-0.4	6.21e-14	Gut microbiome composition (summer);
CRC	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.27	-0.37	2.58e-12	HDL cholesterol;
CRC	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11446398	chr5:77624930	NA	0.45	6.26	0.33	1.17e-9	Triglycerides;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00441754	chr19:45394894	TOMM40	0.46	6.82	0.35	4.4e-11	Interleukin-6 levels;
CRC	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg23920097	chr1:209922102	NA	-0.53	-6.72	-0.35	7.86e-11	Red blood cell count;
CRC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.61e-11	Aortic root size;
CRC	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.49	-6.8	-0.35	4.79e-11	Corneal structure;
CRC	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg12856521	chr11:46389249	DGKZ	0.43	6.88	0.35	3.1e-11	Leprosy;
CRC	cis	rs7725052	0.609	rs60960096	chr5:40445914	A/G	cg09067459	chr5:40385259	NA	-0.39	-6.57	-0.34	1.96e-10	Pediatric autoimmune diseases;
CRC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-6.95	-0.36	1.97e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg11843238	chr5:131593191	PDLIM4	0.35	6.51	0.34	2.8e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-9.17	-0.45	5.34e-18	Idiopathic membranous nephropathy;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg09877947	chr5:131593287	PDLIM4	0.43	7.05	0.36	1.05e-11	Breast cancer;
CRC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.73	12.28	0.56	8.98e-29	Cognitive function;
CRC	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	6.35	0.33	7.2e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.51	7.02	0.36	1.27e-11	Longevity;Endometriosis;
CRC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg26752003	chr8:145688521	CYHR1	-0.36	-5.84	-0.31	1.28e-8	Age at first birth;
CRC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.01e-20	Bladder cancer;
CRC	cis	rs7312933	0.509	rs12831750	chr12:42466477	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.15	0.32	2.26e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25725117	chr1:228871303	RHOU	0.42	5.97	0.31	6.29e-9	Anxiety disorder;
CRC	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.5	-6.04	-0.32	4.28e-9	Carotid intima media thickness;
CRC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.72	-7.9	-0.4	4.17e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg25856811	chr1:152973957	SPRR3	-0.21	-5.86	-0.31	1.14e-8	Inflammatory skin disease;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.89	0.44	4.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.22	0.32	1.51e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.42	-0.42	1.2e-15	Bladder cancer;
CRC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.87	10.95	0.52	5.37e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.66	10.27	0.49	1.24e-21	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13627451	chr15:52043674	TMOD2;LYSMD2	0.38	6.19	0.32	1.75e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	13.46	0.6	3.35e-33	Menopause (age at onset);
CRC	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg14593290	chr7:50529359	DDC	0.52	7.24	0.37	3.11e-12	Malaria;
CRC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.36	-0.33	6.91e-10	Total body bone mineral density;
CRC	cis	rs863345	0.967	rs7512117	chr1:158532064	C/T	cg12129480	chr1:158549410	OR10X1	-0.26	-5.66	-0.3	3.32e-8	Pneumococcal bacteremia;
CRC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.5e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.84	-0.31	1.22e-8	Life satisfaction;
CRC	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-10.94	-0.52	5.67e-24	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.74	-10.54	-0.5	1.38e-22	Platelet distribution width;
CRC	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg05925327	chr15:68127851	NA	-0.3	-5.88	-0.31	9.91e-9	Restless legs syndrome;
CRC	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.61	-11.15	-0.52	1.02e-24	Blood metabolite ratios;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.56	-8.05	-0.41	1.55e-14	Menopause (age at onset);
CRC	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg04989706	chr14:50066350	PPIL5	0.47	6.56	0.34	2.11e-10	Carotid intima media thickness;
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.18	-0.32	1.9e-9	Total body bone mineral density;
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.85	-0.51	1.15e-23	Bipolar disorder;
CRC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.7	9.74	0.47	7.38e-20	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26611836	chr5:126112609	LMNB1	0.45	6.34	0.33	7.78e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00171161	chr4:88343636	NUDT9	0.46	6.48	0.34	3.38e-10	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg22110888	chr17:80059540	CCDC57	0.38	6.07	0.32	3.61e-9	Life satisfaction;
CRC	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.38	6.12	0.32	2.69e-9	Blood metabolite levels;
CRC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.42	6.33	0.33	7.89e-10	Menopause (age at onset);
CRC	cis	rs728616	0.867	rs726289	chr10:81706951	C/T	cg11900509	chr10:81946545	ANXA11	-0.71	-7.14	-0.37	6.18e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1950626	0.833	rs72700524	chr14:101417309	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	16.09	0.66	2.16e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs812925	0.519	rs10199672	chr2:61627634	T/G	cg10580144	chr2:61372316	C2orf74	-0.33	-7.2	-0.37	4.21e-12	Immature fraction of reticulocytes;
CRC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	10.53	0.5	1.58e-22	Motion sickness;
CRC	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.6	-9.67	-0.47	1.25e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg18850127	chr7:39170497	POU6F2	0.45	5.81	0.31	1.47e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9783347	1.000	rs4150575	chr11:18356466	C/T	cg15585147	chr11:18324498	HPS5	0.43	6.02	0.31	4.67e-9	Pancreatic cancer;
CRC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.79	8.19	0.41	5.81e-15	Diabetic retinopathy;
CRC	cis	rs7605827	0.897	rs763355	chr2:15518838	A/G	cg19274914	chr2:15703543	NA	0.38	5.63	0.3	3.81e-8	Educational attainment (years of education);
CRC	cis	rs7781266	0.895	rs7779631	chr7:133303907	G/C	cg03336402	chr7:133662267	EXOC4	0.49	6.02	0.31	4.7e-9	Educational attainment (college completion);
CRC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	10.28	0.49	1.13e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14390580	chr17:35873008	DUSP14	-0.41	-6.67	-0.35	1.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.08	13.41	0.59	5.35e-33	Vitiligo;
CRC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	1.0	15.69	0.65	8.44e-42	IgG glycosylation;
CRC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg02449762	chr10:5661741	NA	-0.32	-5.71	-0.3	2.57e-8	Breast cancer;
CRC	trans	rs16846053	0.786	rs62187647	chr2:162446018	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Blood osmolality (transformed sodium);
CRC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.57	-6.84	-0.35	3.8e-11	Mean platelet volume;
CRC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.53	-0.38	4.85e-13	Coronary artery disease;
CRC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.49	5.1e-21	Hip circumference adjusted for BMI;
CRC	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.33	-0.37	1.84e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.52	-7.47	-0.38	7.07e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.52	-0.34	2.58e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.81	0.4	7.93e-14	Lung cancer;
CRC	trans	rs2303319	0.504	rs62187611	chr2:162431946	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.14	-0.32	2.36e-9	Cognitive function;
CRC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.47	-7.98	-0.4	2.49e-14	Major depressive disorder;
CRC	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg01843034	chr6:37503916	NA	-0.36	-5.96	-0.31	6.34e-9	Cognitive performance;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg15763984	chr4:1342303	KIAA1530	0.34	5.69	0.3	2.83e-8	Obesity-related traits;
CRC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.77	-11.46	-0.53	8.05e-26	Menopause (age at onset);
CRC	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg16591659	chr17:78472290	NA	0.4	5.73	0.3	2.32e-8	Fractional excretion of uric acid;
CRC	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.52	9.2	0.45	4.37e-18	Blood metabolite ratios;
CRC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.56	7.89	0.4	4.44e-14	Alcohol dependence;
CRC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg23018236	chr17:30244563	NA	0.52	6.64	0.34	1.3100000000000001e-10	Hip circumference adjusted for BMI;
CRC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.52	7.0	0.36	1.45e-11	Methadone dose in opioid dependence;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg15763984	chr4:1342303	KIAA1530	0.51	8.58	0.43	3.72e-16	Longevity;
CRC	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.57	-8.03	-0.4	1.74e-14	Diisocyanate-induced asthma;
CRC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg23100626	chr2:96804247	ASTL	0.26	7.07	0.36	9.21e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg09877947	chr5:131593287	PDLIM4	0.46	7.49	0.38	6.3e-13	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15481787	chr19:18303865	MPV17L2	0.48	6.83	0.35	4.24e-11	Response to antipsychotic treatment;
CRC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.57	-0.34	2.02e-10	Bipolar disorder;
CRC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg27068330	chr11:65405492	SIPA1	-0.46	-6.31	-0.33	9.09e-10	Breast cancer;
CRC	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.67	9.78	0.47	5.45e-20	Blood protein levels;
CRC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.07	-18.09	-0.71	2.95e-51	Cognitive function;
CRC	trans	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs4664293	0.625	rs35481084	chr2:160634240	G/A	cg08347373	chr2:160653686	CD302	0.43	7.42	0.38	1.03e-12	Monocyte percentage of white cells;
CRC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.51	-0.75	8.67e-61	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.69	9.45	0.46	6.61e-19	Alzheimer's disease;
CRC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg03030879	chr14:75389066	RPS6KL1	0.54	8.72	0.43	1.39e-16	Caffeine consumption;
CRC	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg11887960	chr12:57824829	NA	0.62	6.77	0.35	5.9e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.54	-0.38	4.73e-13	Putamen volume;
CRC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg06740227	chr12:86229804	RASSF9	0.36	5.76	0.3	1.95e-8	Major depressive disorder;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.14	0.32	2.4e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10743315	0.778	rs7399032	chr12:19371546	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.63	-8.0	-0.4	2.18e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs1669338	0.588	rs62228634	chr3:3184985	A/G	cg16797762	chr3:3221439	CRBN	-0.6	-6.1	-0.32	2.9e-9	White matter integrity;
CRC	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	6.88	0.35	2.97e-11	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.45	-0.42	9.75e-16	Neuroticism;
CRC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.74	-12.96	-0.58	2.46e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.54	8.95	0.44	2.67e-17	Dupuytren's disease;
CRC	cis	rs4664293	0.867	rs1427329	chr2:160604812	C/T	cg08347373	chr2:160653686	CD302	-0.43	-6.85	-0.35	3.64e-11	Monocyte percentage of white cells;
CRC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg23815491	chr16:72088622	HP	0.5	7.6	0.39	3.09e-13	Fibrinogen levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19056506	chr17:79633562	CCDC137;C17orf90	0.43	6.07	0.32	3.61e-9	Anxiety disorder;
CRC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.75e-11	Body mass index;
CRC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.86	0.44	5.2e-17	Morning vs. evening chronotype;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21742872	chr21:43373869	C2CD2	0.44	6.2	0.32	1.64e-9	Anxiety disorder;
CRC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.44	6.66	0.34	1.16e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg15845792	chr6:28175446	NA	0.9	13.11	0.59	6.83e-32	Parkinson's disease;
CRC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.77	7.8	0.4	8.13e-14	Diabetic retinopathy;
CRC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-6.57	-0.34	1.95e-10	Menarche (age at onset);
CRC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg05309399	chr4:106552544	FLJ20184	-0.45	-5.61	-0.3	4.31e-8	Post bronchodilator FEV1;
CRC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.52	8.58	0.43	3.77e-16	Calcium levels;
CRC	trans	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg06791473	chr12:49259579	RND1	0.61	5.99	0.31	5.45e-9	Blood protein levels;
CRC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.34	5.7	0.3	2.66e-8	Emphysema distribution in smoking;
CRC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.48	-0.71	8.6e-53	Height;
CRC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.9	-17.41	-0.69	1.45e-48	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.77	-0.35	5.94e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg00531865	chr16:30841666	NA	-0.45	-6.38	-0.33	6.05e-10	Dementia with Lewy bodies;
CRC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-6.15	-0.32	2.26e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg17401720	chr7:158221031	PTPRN2	0.41	6.54	0.34	2.3e-10	Obesity-related traits;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg09877947	chr5:131593287	PDLIM4	0.46	8.42	0.42	1.2e-15	Breast cancer;
CRC	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs10106298	0.846	rs2099408	chr8:103680416	A/C	cg10187029	chr8:103597600	NA	0.42	5.86	0.31	1.12e-8	Schizophrenia;
CRC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg25985355	chr7:65971099	NA	0.51	5.75	0.3	2.08e-8	Diabetic kidney disease;
CRC	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.1e-17	Dupuytren's disease;
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg13047869	chr3:10149882	C3orf24	0.49	6.66	0.34	1.18e-10	Alzheimer's disease;
CRC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.44	6.15	0.32	2.19e-9	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05484920	chr19:49588520	SNRNP70	0.44	6.14	0.32	2.34e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09901735	chr16:19729769	C16orf88;IQCK	0.49	6.86	0.35	3.46e-11	Response to antipsychotic treatment;
CRC	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	0.84	7.59	0.39	3.31e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Bone mineral density;
CRC	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg06462663	chr19:18546047	ISYNA1	0.42	6.04	0.32	4.1e-9	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09092174	chr22:39190118	DNAL4	0.47	6.59	0.34	1.77e-10	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3736594	1.000	rs3792252	chr2:27995931	A/G	cg27432699	chr2:27873401	GPN1	0.55	7.65	0.39	2.31e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.66	6.77	0.35	5.88e-11	Plasma clusterin levels;
CRC	cis	rs7605827	0.930	rs6722963	chr2:15527105	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.35	-5.74	-0.3	2.2e-8	Diastolic blood pressure;
CRC	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg09659197	chr4:152720779	NA	0.52	11.24	0.53	4.87e-25	Intelligence (multi-trait analysis);
CRC	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.31	-0.33	9.21e-10	Caffeine consumption;
CRC	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-7.55	-0.38	4.35e-13	Mood instability;
CRC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.67	11.42	0.53	1.15e-25	Anterior chamber depth;
CRC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.47	7.14	0.37	5.87e-12	Motion sickness;
CRC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.73	12.68	0.57	2.78e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.61	10.44	0.5	3.17e-22	Calcium levels;
CRC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.5	-7.68	-0.39	1.89e-13	Monocyte count;
CRC	cis	rs6681460	0.966	rs10789215	chr1:67151185	C/T	cg02459107	chr1:67143332	SGIP1	-0.4	-7.08	-0.36	8.94e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg03623178	chr6:28175578	NA	0.84	6.98	0.36	1.68e-11	Depression;
CRC	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg25876840	chr17:41920477	NA	0.55	7.52	0.38	5.14e-13	Triglycerides;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.14	0.59	5.55e-32	Prudent dietary pattern;
CRC	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.23	0.37	3.45e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.65	6.68	0.35	1.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6840360	0.642	rs7676059	chr4:152393267	T/C	cg09659197	chr4:152720779	NA	0.33	6.56	0.34	2.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.88	-0.48	2.46e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.47	-7.4	-0.38	1.11e-12	Testicular germ cell tumor;
CRC	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg14139581	chr11:64358342	SLC22A12	-0.39	-6.19	-0.32	1.81e-9	Urate levels in obese individuals;
CRC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg10130564	chr11:117069849	TAGLN	0.35	6.7	0.35	8.95e-11	Blood protein levels;
CRC	cis	rs75422866	0.558	rs73104190	chr12:48109823	G/A	cg14736327	chr12:48174669	SLC48A1	-0.73	-5.76	-0.3	1.94e-8	Pneumonia;
CRC	trans	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.74	-0.3	2.11e-8	Pulmonary function;
CRC	cis	rs7107770	0.629	rs4936993	chr11:125071752	G/A	cg27629782	chr11:125073726	PKNOX2	0.48	6.84	0.35	3.93e-11	Photic sneeze reflex;
CRC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-6.09	-0.32	3.12e-9	Schizophrenia;
CRC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.08	-0.36	8.63e-12	IgG glycosylation;
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg10729496	chr3:10149963	C3orf24	0.52	6.41	0.33	5.07e-10	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00969988	chr3:142297747	ATR	0.39	6.52	0.34	2.61e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.71	-11.46	-0.53	8.48e-26	Height;
CRC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.69	9.27	0.46	2.56e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.34	5.71	0.3	2.58e-8	Emphysema distribution in smoking;
CRC	cis	rs2384207	0.818	rs34326408	chr12:113647337	T/C	cg22376712	chr12:113623594	C12orf52;DDX54	0.48	6.03	0.32	4.44e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs73206853	0.841	rs7971568	chr12:110780612	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	7.71	0.39	1.55e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg10729496	chr3:10149963	C3orf24	0.49	5.77	0.3	1.84e-8	Alzheimer's disease;
CRC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.5	0.38	6.12e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	8.93	0.44	3.11e-17	Eosinophil percentage of white cells;
CRC	cis	rs365302	0.868	rs381639	chr6:159653635	C/G	cg14500486	chr6:159655392	FNDC1	-0.45	-6.81	-0.35	4.7e-11	Coronary heart disease;
CRC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg10589385	chr1:150898437	SETDB1	0.33	7.02	0.36	1.26e-11	Melanoma;
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-6.95	-0.36	1.92e-11	Inflammatory bowel disease;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Parkinson's disease;
CRC	trans	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg19862616	chr7:65841803	NCRNA00174	0.44	6.13	0.32	2.46e-9	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.4	6.78	0.35	5.58e-11	Crohn's disease;
CRC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.45	5.82	0.31	1.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg14593290	chr7:50529359	DDC	-0.52	-7.69	-0.39	1.76e-13	Malaria;
CRC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.52	8.41	0.42	1.24e-15	Coronary artery disease;
CRC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.49	10.23	0.49	1.62e-21	Alcohol dependence;
CRC	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg11993925	chr19:44307056	LYPD5	-0.47	-7.78	-0.39	9.23e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.07	-0.36	9.23e-12	Aortic root size;
CRC	cis	rs4700695	0.841	rs36301	chr5:65348940	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.19	0.37	4.36e-12	Facial morphology (factor 19);
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-9.05	-0.45	1.26e-17	Bipolar disorder;
CRC	cis	rs17092148	0.652	rs61341205	chr20:33072578	A/G	cg08999081	chr20:33150536	PIGU	-0.45	-5.67	-0.3	3.18e-8	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01069104	chr3:18467441	SATB1	0.38	6.17	0.32	2.05e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg27661571	chr11:113659931	NA	-0.96	-11.11	-0.52	1.42e-24	Hip circumference adjusted for BMI;
CRC	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg01472538	chr16:58549086	SETD6	1.12	7.16	0.37	5.33e-12	Schizophrenia;
CRC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.98	0.44	2.18e-17	Morning vs. evening chronotype;
CRC	cis	rs4700695	0.841	rs152995	chr5:65323172	G/A	cg21114390	chr5:65439923	SFRS12	0.62	6.83	0.35	4.03e-11	Facial morphology (factor 19);
CRC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.65	9.32	0.46	1.8e-18	Vitamin D levels;
CRC	trans	rs6600671	1.000	rs10794671	chr1:121168242	A/C	cg00646200	chr1:148855367	NA	0.35	6.35	0.33	7.24e-10	Hip geometry;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg03790207	chr6:42947109	PEX6	-0.49	-7.07	-0.36	9.39e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.7	7.77	0.39	1.03e-13	Vitiligo;
CRC	cis	rs4073416	0.518	rs2149839	chr14:65983448	G/A	cg03016385	chr14:66212404	NA	-0.42	-5.94	-0.31	7.06e-9	N-glycan levels;
CRC	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.46	5.9	0.31	9.23e-9	Exhaled nitric oxide output;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00323266	chr2:26256363	RAB10	0.48	6.23	0.32	1.45e-9	Anxiety disorder;
CRC	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.1e-10	Hepatitis;
CRC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg09264619	chr17:80180166	NA	-0.34	-5.72	-0.3	2.39e-8	Life satisfaction;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs1223397	0.938	rs17700321	chr6:13280666	G/T	cg00460589	chr6:13274354	PHACTR1	0.48	5.96	0.31	6.59e-9	Blood pressure;
CRC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.6	9.4	0.46	9.61e-19	Asthma (sex interaction);
CRC	cis	rs7605827	0.897	rs12692271	chr2:15640317	T/C	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs12580194	1.000	rs4491341	chr12:55697838	G/A	cg19537932	chr12:55886519	OR6C68	-0.57	-7.92	-0.4	3.6e-14	Cancer;
CRC	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.25	15.72	0.65	6.58e-42	Lung disease severity in cystic fibrosis;
CRC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.04	-0.36	1.13e-11	IgG glycosylation;
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.28	0.42	3.08e-15	Alzheimer's disease;
CRC	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg19582491	chr16:67682965	RLTPR	-0.4	-5.74	-0.3	2.13e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.63	9.6	0.47	2.1e-19	Lung cancer;
CRC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.34	-0.33	7.44e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.79	6.79	0.35	5.1e-11	LDL cholesterol;
CRC	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.89	-0.4	4.61e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.72	9.89	0.48	2.32e-20	Alzheimer's disease;
CRC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.71	-12.52	-0.57	1.09e-29	Dental caries;
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg19678392	chr7:94953810	PON1	-0.6	-7.37	-0.38	1.35e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6479527	0.806	rs12351292	chr9:96763271	G/A	cg14459158	chr9:96720562	NA	0.41	7.49	0.38	6.39e-13	Esophageal adenocarcinoma;
CRC	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.28	-0.33	1.08e-9	QT interval;
CRC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.47	7.83	0.4	6.76e-14	Breast cancer;
CRC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg05709478	chr1:6581295	PLEKHG5	0.54	6.67	0.35	1.08e-10	Body mass index;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg23136738	chr11:925521	AP2A2	-0.52	-8.43	-0.42	1.11e-15	Alzheimer's disease (late onset);
CRC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.42	-20.26	-0.75	8.39e-60	Hip circumference adjusted for BMI;
CRC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.69	10.56	0.5	1.2e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs56292044	1.000	rs56292044	chr8:138776547	G/T	cg00605270	chr1:28261552	SMPDL3B	0.43	6.31	0.33	8.81e-10	Post bronchodilator FEV1/FVC ratio in COPD;
CRC	trans	rs11466653	0.744	rs6856416	chr4:38778573	T/C	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.25e-12	HDL cholesterol;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg02488288	chr5:141705351	SPRY4	-0.41	-6.06	-0.32	3.71e-9	HDL cholesterol;
CRC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.58	8.77	0.44	1.01e-16	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21437766	chr7:73498314	LIMK1	0.5	7.2	0.37	4.17e-12	Response to antipsychotic treatment;
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg15147215	chr3:52552868	STAB1	0.55	8.99	0.44	1.93e-17	Bipolar disorder;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs1950626	0.787	rs34857222	chr14:101391354	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.94	15.2	0.64	6.77e-40	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	20.06	0.74	4.98e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg00677455	chr12:58241039	CTDSP2	-0.49	-6.64	-0.34	1.26e-10	Multiple sclerosis;
CRC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.34	-6.73	-0.35	7.41e-11	Social autistic-like traits;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg25164649	chr6:28176230	NA	-0.73	-9.49	-0.46	4.87e-19	Depression;
CRC	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-6.64	-0.34	1.29e-10	Caudate activity during reward;
CRC	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg12218747	chr21:37451666	NA	-0.37	-6.24	-0.33	1.35e-9	Mitral valve prolapse;
CRC	cis	rs25422	0.540	rs9481842	chr6:118974798	A/C	cg24463073	chr6:118973353	C6orf204	0.44	6.68	0.35	9.97e-11	Renal cell carcinoma;
CRC	cis	rs78077440	1.000	rs78077440	chr5:40323767	G/A	cg09067459	chr5:40385259	NA	-0.54	-5.86	-0.31	1.11e-8	Multiple sclerosis;
CRC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.81	0.4	7.78e-14	Morning vs. evening chronotype;
CRC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.99	-0.4	2.3e-14	Gut microbiome composition (summer);
CRC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.77	0.54	6.32e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.27	-0.33	1.15e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg05279229	chr7:1896384	MAD1L1	-0.37	-5.91	-0.31	8.66e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.98	-0.66	6.12e-43	Height;
CRC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs9287719	0.649	rs2024433	chr2:10731504	G/C	cg00105475	chr2:10696890	NA	0.45	7.14	0.37	6.18e-12	Prostate cancer;
CRC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg23625390	chr15:77176239	SCAPER	0.39	5.79	0.3	1.63e-8	Blood metabolite levels;
CRC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.38	6.27	0.33	1.12e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	trans	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg16141378	chr3:129829833	LOC729375	-0.43	-6.53	-0.34	2.55e-10	Mood instability;
CRC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	8.81e-11	Major depressive disorder;
CRC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.79	-13.39	-0.59	5.94e-33	Obesity-related traits;
CRC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.33	0.37	1.78e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg22110888	chr17:80059540	CCDC57	0.4	6.32	0.33	8.27e-10	Life satisfaction;
CRC	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.76	-0.35	6.26e-11	Morning vs. evening chronotype;
CRC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg10298567	chr3:47292165	KIF9	-0.36	-5.86	-0.31	1.12e-8	Colorectal cancer;
CRC	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.89	-0.35	2.9100000000000002e-11	Schizophrenia;
CRC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg16512390	chr1:228756714	NA	0.39	5.67	0.3	3.13e-8	Chronic lymphocytic leukemia;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05737526	chr18:3454175	TGIF1	-0.52	-6.33	-0.33	7.81e-10	Monocyte percentage of white cells;
CRC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.7	-0.51	4.06e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12667521	chr19:29218732	NA	0.48	6.82	0.35	4.27e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.36	6.03	0.32	4.44e-9	Menopause (age at onset);
CRC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg00484396	chr16:3507460	NAT15	0.6	5.61	0.3	4.38e-8	Tuberculosis;
CRC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg24140574	chr1:16342155	HSPB7	0.44	5.88	0.31	1.03e-8	Dilated cardiomyopathy;
CRC	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg02811702	chr13:24901961	NA	0.45	6.24	0.33	1.31e-9	Obesity-related traits;
CRC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg03929089	chr4:120376271	NA	0.61	6.01	0.31	4.8e-9	Axial length;
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg07404485	chr7:94953653	PON1	-0.48	-6.19	-0.32	1.84e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9938149	0.674	rs7201034	chr16:88298705	A/G	cg05435882	chr16:88311214	NA	-0.48	-6.28	-0.33	1.05e-9	Corneal structure;Central corneal thickness;
CRC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.41	-0.42	1.3e-15	Neuroticism;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.46	-0.38	7.69e-13	Breast cancer;
CRC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg20119798	chr7:94954144	PON1	-0.44	-5.66	-0.3	3.37e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.54	-9.16	-0.45	5.87e-18	Iron status biomarkers;
CRC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg20573242	chr4:122745356	CCNA2	0.41	6.15	0.32	2.26e-9	Type 2 diabetes;
CRC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.44	-0.42	1.01e-15	Schizophrenia;
CRC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.56	6.21	0.32	1.59e-9	Initial pursuit acceleration;
CRC	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	cis	rs73200209	0.744	rs55643039	chr12:116609355	T/G	cg01776926	chr12:116560359	MED13L	-0.61	-7.04	-0.36	1.14e-11	Total body bone mineral density;
CRC	cis	rs3812762	0.833	rs35670750	chr11:8782444	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.24	-0.33	1.35e-9	Hypospadias;
CRC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.78	-0.3	1.74e-8	Gout;Renal underexcretion gout;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-7.76	-0.39	1.08e-13	Axial length;
CRC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.59	0.43	3.59e-16	Homoarginine levels;
CRC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.4	6.56	0.34	2.1e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.47	-5.82	-0.31	1.36e-8	Coronary artery calcification;
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.6	8.25	0.41	3.81e-15	Arsenic metabolism;
CRC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.69	0.39	1.71e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.65	7.91	0.4	3.86e-14	Eotaxin levels;
CRC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.4	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.25	-0.53	4.47e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.55	-10.11	-0.49	4.23e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.33	0.33	8.09e-10	Obesity-related traits;
CRC	trans	rs7227892	0.659	rs9959212	chr18:46342442	C/T	cg04876465	chr9:35605902	TESK1	0.49	6.06	0.32	3.7e-9	Migraine with aura;
CRC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs10486722	0.606	rs13237727	chr7:41802205	A/G	cg22138096	chr7:41772439	LOC285954	-0.45	-6.31	-0.33	9.14e-10	Pit-and-Fissure caries;
CRC	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.5	7.06	0.36	1e-11	Autism;
CRC	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg03929089	chr4:120376271	NA	0.65	6.38	0.33	6.18e-10	Axial length;
CRC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.35	-0.38	1.61e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.71	9.04	0.45	1.4e-17	Body mass index;
CRC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg09835421	chr16:68378352	PRMT7	-0.7	-7.76	-0.39	1.09e-13	Schizophrenia;
CRC	cis	rs12928939	0.911	rs8051878	chr16:71818431	C/G	cg08717414	chr16:71523259	ZNF19	-0.51	-6.35	-0.33	7.13e-10	Post bronchodilator FEV1;
CRC	cis	rs8105895	0.932	rs28600030	chr19:22268443	G/A	cg02657401	chr19:22469223	NA	-0.35	-5.76	-0.3	1.94e-8	Body mass index (change over time);
CRC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	5.9	0.31	8.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.27	-14.44	-0.62	5.83e-37	Diabetic kidney disease;
CRC	trans	rs6472235	0.778	rs6472242	chr8:66910613	T/G	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.24	-0.33	1.38e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg02527881	chr3:46936655	PTH1R	0.38	6.85	0.35	3.65e-11	Colorectal cancer;
CRC	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg12458913	chr13:53173898	NA	0.49	7.64	0.39	2.41e-13	Lewy body disease;
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg22561889	chr6:118971681	C6orf204	-0.49	-6.45	-0.33	4.11e-10	Diastolic blood pressure;
CRC	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.6	-9.41	-0.46	8.63e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg18478394	chr8:109455254	TTC35	0.42	6.24	0.33	1.36e-9	Dupuytren's disease;
CRC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.06	-12.43	-0.57	2.43e-29	Diabetic kidney disease;
CRC	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.68	-0.35	1.05e-10	Depression;
CRC	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19717773	chr7:2847554	GNA12	-0.36	-5.72	-0.3	2.41e-8	Height;
CRC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg05501817	chr11:14380813	RRAS2	-0.45	-5.91	-0.31	8.48e-9	Sense of smell;
CRC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.68	0.3	2.97e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg00383909	chr3:49044727	WDR6	0.44	5.68	0.3	2.91e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs78761021	0.867	rs17676067	chr17:9791375	C/T	cg26853458	chr17:9805074	RCVRN	-0.44	-7.96	-0.4	2.78e-14	Type 2 diabetes;
CRC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg13777783	chr17:79615861	NA	-0.3	-5.64	-0.3	3.71e-8	Eye color traits;
CRC	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.37	-5.89	-0.31	9.32e-9	Inflammatory bowel disease;
CRC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg20243544	chr17:37824526	PNMT	0.58	8.89	0.44	4.24e-17	Asthma;
CRC	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.84	0.4	6.2e-14	Diabetic kidney disease;
CRC	trans	rs7690467	0.794	rs4365738	chr4:133404953	C/T	cg19296258	chr17:78878799	RPTOR	0.47	6.17	0.32	2.03e-9	Eating disorders;
CRC	cis	rs3789045	1.000	rs3789045	chr1:204586812	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.49	-6.94	-0.36	2.05e-11	Educational attainment (college completion);
CRC	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.47	6.99	0.36	1.55e-11	Red blood cell count;
CRC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.39	-5.65	-0.3	3.48e-8	Neurofibrillary tangles;
CRC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.6e-12	Motion sickness;
CRC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.54	8.27	0.41	3.47e-15	Aortic root size;
CRC	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.5	6.72	0.35	7.91e-11	Caudate activity during reward;
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.9	0.58	4.44e-31	Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.89	-0.44	4.01e-17	Bipolar disorder;
CRC	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.55	9.05	0.45	1.26e-17	Mean corpuscular volume;
CRC	cis	rs7605827	0.930	rs4668923	chr2:15681227	G/A	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.52	8.27	0.41	3.34e-15	Intelligence (multi-trait analysis);
CRC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.47	7.22	0.37	3.55e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs7705042	0.897	rs249681	chr5:141538017	G/C	cg07392085	chr5:141489673	NDFIP1	0.46	7.31	0.37	2.01e-12	Asthma;
CRC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg03609598	chr5:56110824	MAP3K1	0.58	7.81	0.4	7.56e-14	Initial pursuit acceleration;
CRC	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.89	10.86	0.51	1.07e-23	Neuroticism (multi-trait analysis);Neuroticism;
CRC	trans	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.52	-0.34	2.68e-10	Aortic root size;
CRC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg07884673	chr3:53033167	SFMBT1	0.77	6.21	0.32	1.64e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs16852403	0.619	rs6685876	chr1:178135119	G/A	cg00404053	chr1:178313656	RASAL2	0.6	7.64	0.39	2.36e-13	Childhood ear infection;
CRC	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.32	16.01	0.66	4.44e-43	Uric acid levels;
CRC	trans	rs6472235	0.807	rs2357566	chr8:66911221	C/T	cg07884673	chr3:53033167	SFMBT1	-0.46	-6.27	-0.33	1.11e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.77e-10	Bladder cancer;
CRC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.37	5.87	0.31	1.04e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.54	7.05	0.36	1.08e-11	Neutrophil percentage of white cells;
CRC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03752689	chr1:209958185	C1orf74	0.49	7.15	0.37	5.58e-12	Response to antipsychotic treatment;
CRC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.95	-0.4	3.02e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.8	0.44	8.01e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	11.93	0.55	1.68e-27	Platelet count;
CRC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.55	-8.07	-0.41	1.34e-14	Headache;
CRC	cis	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg01251360	chr16:68772225	CDH1	-0.23	-5.62	-0.3	4.03e-8	Colorectal cancer;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.84	0.31	1.26e-8	Depression;
CRC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11645453	chr3:52864694	ITIH4	0.44	7.17	0.37	4.9e-12	Bipolar disorder;
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg17848003	chr1:3704513	LRRC47	0.41	6.06	0.32	3.71e-9	Red cell distribution width;
CRC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	7.87	0.4	5.05e-14	Intelligence (multi-trait analysis);
CRC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.31	-0.37	1.99e-12	Coronary artery disease;
CRC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.54	-8.15	-0.41	7.47e-15	Blood protein levels;
CRC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.83	11.8	0.55	4.76e-27	Gut microbiome composition (summer);
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg15845792	chr6:28175446	NA	0.6	6.2	0.32	1.65e-9	Depression;
CRC	cis	rs9517320	0.967	rs9517337	chr13:99181647	A/C	cg07423050	chr13:99094983	FARP1	0.44	6.7	0.35	8.79e-11	Longevity;
CRC	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.48	7.54	0.38	4.6e-13	Testicular germ cell tumor;
CRC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs7712401	0.791	rs10059964	chr5:122118293	A/G	cg18764291	chr5:122110994	SNX2	0.43	6.88	0.35	2.96e-11	Mean platelet volume;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.71	0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.58	6.71	0.35	8.6e-11	Coronary artery disease;
CRC	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg12870014	chr12:110450643	ANKRD13A	0.84	9.77	0.47	5.69e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.09	-0.32	3.15e-9	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26063087	chr22:35695661	TOM1	0.47	7.05	0.36	1.03e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.35	-5.73	-0.3	2.28e-8	Menopause (age at onset);
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	ch.1.64660926R	chr1:64888338	NA	-0.4	-5.99	-0.31	5.6e-9	Brain structure;
CRC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg19980929	chr12:42632907	YAF2	-0.38	-5.82	-0.31	1.43e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.54	0.34	2.32e-10	Renal cell carcinoma;
CRC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.58e-12	Height;
CRC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.73	-9.2	-0.45	4.31e-18	Body mass index;
CRC	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.55	-8.32	-0.42	2.43e-15	Coronary artery disease;
CRC	cis	rs11191205	0.686	rs61382490	chr10:103454402	A/T	cg15320455	chr10:103880129	LDB1	0.56	6.0	0.31	5.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.44	-6.24	-0.33	1.36e-9	Lymphocyte counts;
CRC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.78	12.78	0.58	1.22e-30	IgG glycosylation;
CRC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.53	-7.26	-0.37	2.87e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.37	-6.09	-0.32	3.09e-9	Blood metabolite levels;
CRC	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.55	8.73	0.43	1.35e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs17767392	0.836	rs17178387	chr14:71997723	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.47	-6.24	-0.33	1.37e-9	Mitral valve prolapse;
CRC	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg18404041	chr3:52824283	ITIH1	0.38	7.47	0.38	7.45e-13	Schizophrenia;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17421506	chr11:18656159	SPTY2D1	0.4	6.01	0.31	5.01e-9	Myopia (pathological);
CRC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.45	-5.61	-0.3	4.37e-8	Aortic root size;
CRC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.78	12.3	0.56	7.34e-29	Breast cancer;
CRC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.71	-9.2	-0.45	4.39e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2024825	1	rs2024825	chr1:67597977	T/C	cg17031739	chr1:67600172	NA	0.5	6.21	0.32	1.58e-9	Leprosy;
CRC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.73	10.92	0.52	6.54e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.36	-6.19	-0.32	1.8e-9	Height;
CRC	cis	rs2084637	1.000	rs12224773	chr11:122417079	T/C	cg21585512	chr11:122030076	LOC399959	-0.38	-6.78	-0.35	5.47e-11	Stroke;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19972591	chr12:120966863	COQ5	0.4	6.53	0.34	2.47e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	10.53	0.5	1.54e-22	Motion sickness;
CRC	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.25e-10	Alzheimer's disease (late onset);
CRC	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	8.9	0.44	3.77e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.07e-10	Menopause (age at onset);
CRC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-9.94	-0.48	1.53e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg04523069	chr9:97136363	HIATL1	0.37	5.71	0.3	2.55e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.84	10.69	0.51	4.32e-23	Gut microbiome composition (summer);
CRC	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.9	-0.31	9.15e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs17767392	1.000	rs725673	chr14:71878468	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.74	11.48	0.53	7.1e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg13919466	chr1:32135498	COL16A1	-0.31	-5.95	-0.31	6.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.95	10.61	0.5	8.04e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg24140574	chr1:16342155	HSPB7	0.43	5.74	0.3	2.11e-8	Dilated cardiomyopathy;
CRC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.65	-0.34	1.25e-10	Monocyte count;
CRC	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.78	-0.3	1.78e-8	Morning vs. evening chronotype;
CRC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg20387954	chr3:183756860	HTR3D	0.46	7.76	0.39	1.1e-13	Anterior chamber depth;
CRC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg18721089	chr20:30220636	NA	-0.36	-5.86	-0.31	1.12e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18099408	chr3:52552593	STAB1	-0.57	-10.94	-0.52	5.59e-24	Electroencephalogram traits;
CRC	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.59	-0.34	1.75e-10	Putamen volume;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg20567499	chr11:107730432	SLC35F2	-0.4	-6.23	-0.32	1.42e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.98	0.52	4.28e-24	Bone mineral density;
CRC	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg09264619	chr17:80180166	NA	-0.49	-6.9	-0.36	2.63e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.82	0.31	1.39e-8	Diabetic retinopathy;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23161317	chr6:28129485	ZNF389	0.46	6.02	0.31	4.79e-9	Depression;
CRC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	-0.61	-7.07	-0.36	9.53e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.59	-8.56	-0.43	4.54e-16	Menarche (age at onset);
CRC	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.56	-6.9	-0.36	2.65e-11	Ulcerative colitis;
CRC	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.67	-8.04	-0.41	1.67e-14	Vitamin D levels;
CRC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.62	12.81	0.58	9.17e-31	Schizophrenia;
CRC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.91	-17.21	-0.69	8.57e-48	Body mass index;
CRC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg11204139	chr17:3907470	NA	0.5	6.38	0.33	6.16e-10	Type 2 diabetes;
CRC	cis	rs10888329	0.708	rs6587435	chr1:248355585	T/C	cg00666640	chr1:248458726	OR2T12	0.43	7.05	0.36	1.05e-11	Autism spectrum disorder;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg24675056	chr1:15929824	NA	0.53	7.04	0.36	1.16e-11	Systolic blood pressure;
CRC	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.46	7.2	0.37	4.04e-12	Red blood cell count;
CRC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.07	-0.36	9.26e-12	IgG glycosylation;
CRC	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.93	-0.58	3.24e-31	Brugada syndrome;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg02033258	chr5:131593261	PDLIM4	-0.39	-6.61	-0.34	1.52e-10	Breast cancer;
CRC	cis	rs10486722	0.606	rs6949797	chr7:41802301	C/T	cg22138096	chr7:41772439	LOC285954	-0.52	-6.38	-0.33	5.92e-10	Pit-and-Fissure caries;
CRC	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-8.21	-0.41	5.07e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.5	-6.85	-0.35	3.7e-11	Total body bone mineral density;
CRC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.55	6.15	0.32	2.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.35e-10	Bladder cancer;
CRC	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg20936604	chr3:58311152	NA	-0.7	-6.72	-0.35	8.01e-11	Cholesterol, total;
CRC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	14.81	0.63	2.25e-38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.41	6.34	0.33	7.53e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.94	0.31	7.24e-9	Tonsillectomy;
CRC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.77	0.39	1.01e-13	Resting heart rate;
CRC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.57	9.43	0.46	7.72e-19	Total body bone mineral density;
CRC	trans	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.52	7.52	0.38	5.17e-13	Endometrial cancer;
CRC	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.5	-7.23	-0.37	3.45e-12	Educational attainment;
CRC	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg15654264	chr1:150340011	RPRD2	-0.39	-5.7	-0.3	2.6e-8	Migraine;
CRC	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.48	7.95	0.4	3.05e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs9783347	1.000	rs1520884	chr11:18309700	C/T	cg15585147	chr11:18324498	HPS5	-0.45	-6.52	-0.34	2.72e-10	Pancreatic cancer;
CRC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg10760299	chr15:45669010	GATM	0.47	7.42	0.38	9.84e-13	Homoarginine levels;
CRC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.59	-8.4	-0.42	1.34e-15	Menarche (age at onset);
CRC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.69	9.77	0.47	5.61e-20	Vitamin D levels;
CRC	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.16	0.62	6.98e-36	Hypertriglyceridemia;
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.35	-0.38	1.59e-12	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.71	-13.31	-0.59	1.24e-32	Prudent dietary pattern;
CRC	cis	rs4731207	0.596	rs7788458	chr7:124630141	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.28	-0.33	1.09e-9	Cutaneous malignant melanoma;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg21620606	chr4:1342894	KIAA1530	0.37	6.34	0.33	7.55e-10	Obesity-related traits;
CRC	cis	rs7212590	0.748	rs7211208	chr17:57957109	A/C	cg10252138	chr17:58120427	NA	-0.57	-5.83	-0.31	1.34e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-7.55	-0.38	4.24e-13	Dilated cardiomyopathy;
CRC	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.67	8.63	0.43	2.6e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg02574844	chr11:5959923	NA	-0.43	-5.69	-0.3	2.86e-8	DNA methylation (variation);
CRC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-7.77	-0.39	1.04e-13	Colorectal cancer;
CRC	cis	rs9322817	0.691	rs2499652	chr6:105269959	G/A	cg02098413	chr6:105308735	HACE1	0.43	8.52	0.43	5.85e-16	Thyroid stimulating hormone;
CRC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.6	8.0	0.4	2.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2235544	0.579	rs11804837	chr1:54482915	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.22	-6.32	-0.33	8.74e-10	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg11833968	chr6:79620685	NA	-0.36	-6.35	-0.33	7.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	8.08	0.41	1.25e-14	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22128035	chr2:47168977	MCFD2;TTC7A	0.45	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11377484	chr7:128578176	IRF5	0.42	6.11	0.32	2.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.75	-0.3	2.03e-8	Life satisfaction;
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.3	-6.13	-0.32	2.58e-9	Bipolar disorder;
CRC	trans	rs963731	0.649	rs7571052	chr2:39189831	C/T	cg13401531	chr11:70333281	SHANK2	-0.73	-6.08	-0.32	3.42e-9	Corticobasal degeneration;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg27615366	chr5:131592974	PDLIM4	0.32	5.62	0.3	4.1e-8	Breast cancer;
CRC	cis	rs2992756	0.663	rs1360916	chr1:18801697	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.4	-5.69	-0.3	2.74e-8	Breast cancer;
CRC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg24675658	chr1:53192096	ZYG11B	0.8	12.23	0.56	1.36e-28	Monocyte count;
CRC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.83	12.88	0.58	5.05e-31	Cognitive function;
CRC	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.58	7.37	0.38	1.41e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2949837	0.603	rs1542818	chr7:45977656	G/T	cg10677697	chr7:45961126	IGFBP3	0.36	6.3	0.33	9.38e-10	Sitting height ratio;
CRC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.07	-0.32	3.48e-9	Mean corpuscular volume;
CRC	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21659725	chr3:3221576	CRBN	-0.65	-8.96	-0.44	2.56e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg09835421	chr16:68378352	PRMT7	0.74	7.62	0.39	2.74e-13	Schizophrenia;
CRC	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs11212617	1.000	rs7112136	chr11:108287131	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.61	0.34	1.52e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.75	-12.81	-0.58	9.21e-31	Breast cancer;
CRC	cis	rs4716602	0.542	rs13224561	chr7:156161063	G/A	cg16983916	chr7:156159713	NA	-0.39	-6.81	-0.35	4.57e-11	Anti-saccade response;
CRC	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-11.25	-0.53	4.7e-25	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.88	-0.31	9.99e-9	Response to antipsychotic treatment;
CRC	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg21169611	chr9:106856078	SMC2	0.44	6.13	0.32	2.5e-9	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg11245181	chr6:149772854	ZC3H12D	0.52	9.02	0.45	1.58e-17	Dupuytren's disease;
CRC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg20203395	chr5:56204925	C5orf35	-0.42	-5.82	-0.31	1.41e-8	Coronary artery disease;
CRC	cis	rs7487075	0.606	rs4768714	chr12:46814245	T/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.8	0.3	1.58e-8	Itch intensity from mosquito bite;
CRC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.54	8.55	0.43	4.7e-16	Type 2 diabetes;
CRC	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.55	7.95	0.4	2.94e-14	Testicular germ cell tumor;
CRC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	11.74	0.54	7.83e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.62	5.85	0.31	1.21e-8	IgG glycosylation;
CRC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.56	-8.18	-0.41	6.46e-15	IgG glycosylation;
CRC	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg27087555	chr16:88793112	FAM38A	-0.51	-5.86	-0.31	1.1e-8	Autism spectrum disorder-related traits;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.83	13.04	0.58	1.3e-31	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.43	6.83	0.35	4.12e-11	Methadone dose in opioid dependence;
CRC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg27121462	chr16:89883253	FANCA	-0.39	-5.75	-0.3	1.99e-8	Vitiligo;
CRC	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.06	-14.8	-0.63	2.51e-38	Exhaled nitric oxide output;
CRC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.97	-0.4	2.58e-14	Gut microbiome composition (summer);
CRC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.35	5.83	0.31	1.3e-8	Blood metabolite levels;
CRC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.58	7.53	0.38	4.96e-13	Platelet distribution width;
CRC	cis	rs1186222	0.902	rs1179629	chr7:75262613	G/T	cg05145297	chr7:75264568	HIP1	0.54	9.86	0.48	2.81e-20	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg13722127	chr7:150037890	RARRES2	0.49	7.68	0.39	1.82e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-0.76	-7.78	-0.39	9.23e-14	Schizophrenia;
CRC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.37	6.27	0.33	1.12e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.59	8.19	0.41	5.66e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.54	7.8	0.4	8.28e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.64	9.07	0.45	1.13e-17	Lung cancer;
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.53	-6.33	-0.33	8.02e-10	Vitiligo;
CRC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg08314208	chr16:67682810	RLTPR	-0.58	-6.23	-0.32	1.47e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.14	0.49	3.45e-21	Birth weight;
CRC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.54	-9.42	-0.46	8.33e-19	Iron status biomarkers;
CRC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20307385	chr11:47447363	PSMC3	-0.55	-7.75	-0.39	1.19e-13	Subjective well-being;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs2735413	0.875	rs12925138	chr16:78083923	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.54	-0.38	4.5e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.69	8.24	0.41	4.22e-15	Major depressive disorder;
CRC	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg20933634	chr6:27740509	NA	0.58	6.89	0.36	2.86e-11	Depression;
CRC	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.45	-7.3	-0.37	2.14e-12	Refractive error;
CRC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg24253500	chr15:84953950	NA	0.38	6.42	0.33	4.71e-10	Schizophrenia;
CRC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.03e-9	Bladder cancer;
CRC	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg13385794	chr1:248469461	NA	0.35	6.39	0.33	5.79e-10	Common traits (Other);
CRC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.12	-0.32	2.7e-9	Morning vs. evening chronotype;
CRC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.98e-15	Lung cancer;
CRC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg15269541	chr15:43626905	ADAL	-0.56	-6.66	-0.34	1.14e-10	Lung cancer in ever smokers;
CRC	cis	rs4240897	1.000	rs4240897	chr1:12042755	A/G	cg13216073	chr1:12042593	MFN2	-0.54	-8.45	-0.42	9.54e-16	Tuberculosis;
CRC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg02741985	chr17:80059408	CCDC57	-0.45	-7.27	-0.37	2.63e-12	Life satisfaction;
CRC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.5	6.84	0.35	3.99e-11	Bronchopulmonary dysplasia;
CRC	trans	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg18288967	chr1:45987694	PRDX1	0.68	7.43	0.38	9.51e-13	Obesity-related traits;
CRC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24308560	chr3:49941425	MST1R	-0.4	-6.21	-0.32	1.6e-9	Body mass index;
CRC	trans	rs75246769	1.000	rs6954312	chr7:145604258	A/G	cg14916917	chr5:81574294	RPS23	0.8	5.97	0.31	6.06e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.06	20.23	0.74	1.04e-59	Schizophrenia;
CRC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.67	9.53	0.46	3.69e-19	Vitamin D levels;
CRC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.66	10.23	0.49	1.71e-21	Initial pursuit acceleration;
CRC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.5	8.04	0.41	1.65e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-7.52	-0.38	5.31e-13	Self-reported allergy;
CRC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg12064134	chr16:90016061	DEF8	-0.57	-5.63	-0.3	3.85e-8	Skin colour saturation;
CRC	cis	rs4664293	0.867	rs13428679	chr2:160593198	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs354033	0.959	rs4727082	chr7:149228110	C/T	cg24335155	chr7:149193227	ZNF746	0.39	6.19	0.32	1.82e-9	Multiple sclerosis;
CRC	cis	rs62229266	0.652	rs7280551	chr21:37409609	T/A	cg08632701	chr21:37451849	NA	-0.4	-6.27	-0.33	1.16e-9	Mitral valve prolapse;
CRC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.62	-8.12	-0.41	9.36e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg14074117	chr16:1909714	C16orf73	-0.35	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	11.32	0.53	2.51e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.41	-6.55	-0.34	2.17e-10	Iron status biomarkers;
CRC	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg06156847	chr2:113672199	IL1F7	-0.39	-5.96	-0.31	6.34e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.94	-0.36	2.15e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.5	8.41	0.42	1.26e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.54	-0.38	4.74e-13	Height;
CRC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.81	-9.0	-0.44	1.79e-17	Monocyte percentage of white cells;
CRC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg11189052	chr15:85197271	WDR73	0.61	9.0	0.44	1.87e-17	Schizophrenia;
CRC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.01	21.01	0.76	9.38e-63	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg16576597	chr16:28551801	NUPR1	0.48	6.87	0.35	3.31e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg04315214	chr1:2043799	PRKCZ	-0.34	-5.9	-0.31	9.15e-9	Height;
CRC	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.96	11.01	0.52	3.29e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg05139728	chr16:28306816	SBK1	-0.33	-5.63	-0.3	3.77e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.66	8.78	0.44	9.11e-17	Menopause (age at onset);
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs73200209	0.744	rs61939683	chr12:116508474	T/G	cg01776926	chr12:116560359	MED13L	-0.65	-7.69	-0.39	1.71e-13	Total body bone mineral density;
CRC	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.7	-7.65	-0.39	2.19e-13	Plateletcrit;
CRC	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg17545662	chr6:170176663	C6orf70	0.55	6.11	0.32	2.88e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.36	1.32e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.36	5.93	0.31	7.76e-9	Ulcerative colitis;
CRC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.09	-0.66	2.29e-43	Intelligence (multi-trait analysis);
CRC	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg27053337	chr8:124217698	FAM83A	0.46	7.02	0.36	1.3e-11	Urinary uromodulin levels;
CRC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg13628971	chr7:2884303	GNA12	0.44	6.79	0.35	5.26e-11	Height;
CRC	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.39	-5.96	-0.31	6.61e-9	Obesity;
CRC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg03037974	chr15:76606532	NA	0.6	9.93	0.48	1.7e-20	Blood metabolite levels;
CRC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.22	0.37	3.68e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	7.11	0.36	7.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.37	6.33	0.33	8.26e-10	Lung cancer;
CRC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.1	21.19	0.76	1.86e-63	Cognitive function;
CRC	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.44	-6.89	-0.36	2.81e-11	Large artery stroke;
CRC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26797661	chr1:151138516	LYSMD1;SCNM1	0.41	6.03	0.32	4.41e-9	Response to antipsychotic treatment;
CRC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-12.44	-0.57	2.29e-29	Electrocardiographic conduction measures;
CRC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.49	6.08	0.32	3.24e-9	Bipolar disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21222826	chr3:69062762	C3orf64	-0.4	-6.1	-0.32	2.93e-9	Myopia (pathological);
CRC	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.38	-6.49	-0.34	3.18e-10	Vitamin D levels;
CRC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.57	9.06	0.45	1.21e-17	Hemoglobin concentration;
CRC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg19500275	chr17:80737654	TBCD	0.5	6.85	0.35	3.53e-11	Glycated hemoglobin levels;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-7.91	-0.4	4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg23758597	chr6:163146217	PARK2	-0.68	-7.02	-0.36	1.29e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-7.14	-0.37	6.04e-12	Morning vs. evening chronotype;
CRC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.38	0.33	5.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs868943	0.512	rs72953957	chr6:116546543	A/G	cg18764771	chr6:116381957	FRK	0.24	5.67	0.3	3.18e-8	Total cholesterol levels;
CRC	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg03938978	chr2:103052716	IL18RAP	0.41	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	7.99	0.4	2.25e-14	Height;
CRC	trans	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg01505111	chr6:125621795	HDDC2	0.38	6.0	0.31	5.3300000000000004e-09	DNA methylation (variation);
CRC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.65	8.78	0.44	9.01e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.57	6.86	0.35	3.5e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	trans	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.99	-18.63	-0.72	2.21e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.56	-8.3	-0.42	2.8e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2077654	0.556	rs2299638	chr11:17443587	A/G	cg25308976	chr11:17434268	ABCC8	-0.6	-6.81	-0.35	4.56e-11	Gout;
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg04155289	chr7:94953770	PON1	-0.62	-7.79	-0.39	9.1e-14	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg19688584	chr6:167529678	CCR6	-0.35	-6.37	-0.33	6.33e-10	Primary biliary cholangitis;
CRC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.47	6.93	0.36	2.17e-11	Response to antineoplastic agents;
CRC	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg06042504	chr8:55087323	NA	-0.37	-5.86	-0.31	1.14e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.82	9.39	0.46	1.03e-18	Inflammatory bowel disease;
CRC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.71	0.3	2.57e-8	Educational attainment;
CRC	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.81	-0.35	4.67e-11	Menarche (age at onset);
CRC	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21659725	chr3:3221576	CRBN	0.44	6.7	0.35	9.28e-11	Menarche (age at onset);
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg23161317	chr6:28129485	ZNF389	0.46	6.46	0.34	3.68e-10	Cardiac Troponin-T levels;
CRC	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.19	0.45	4.51e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.59	8.56	0.43	4.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.37	5.94	0.31	7.18e-9	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03130627	chr6:159240554	EZR	0.41	6.41	0.33	4.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg02094049	chr14:103021097	NA	-0.51	-6.48	-0.34	3.44e-10	Platelet count;
CRC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.38	5.66	0.3	3.22e-8	Alzheimer's disease (late onset);
CRC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.87	0.51	9.81e-24	Motion sickness;
CRC	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.8	-0.35	4.93e-11	Dilated cardiomyopathy;
CRC	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.6	-0.34	1.66e-10	Depression;
CRC	cis	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg04317927	chr11:55418816	OR4S2	0.39	6.54	0.34	2.35e-10	Pediatric bone mineral density (spine);
CRC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg20885578	chr2:198174922	NA	-0.39	-6.94	-0.36	2.14e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.36	6.47	0.34	3.49e-10	Breast cancer;
CRC	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.33	5.76	0.3	1.91e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.37	7.19e-12	Menopause (age at onset);
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.13	-0.49	3.46e-21	Bipolar disorder;
CRC	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg23378565	chr7:2036160	MAD1L1	-0.38	-6.34	-0.33	7.47e-10	Bipolar disorder;
CRC	cis	rs3996993	0.621	rs60120296	chr6:52732547	G/T	cg20803780	chr6:52668592	GSTA1	0.39	6.77	0.35	5.79e-11	Hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17967426	chr5:168006763	PANK3	0.43	6.14	0.32	2.44e-9	Response to antipsychotic treatment;
CRC	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.44	5.91	0.31	8.59e-9	Tuberculosis;
CRC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs1619661	0.530	rs1623851	chr10:44691241	C/T	cg09554077	chr10:44749378	NA	-0.52	-7.8	-0.4	8.18e-14	QT interval (ambient particulate matter interaction);
CRC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg01629716	chr15:45996671	NA	0.41	8.34	0.42	2.13e-15	Waist circumference;Weight;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.4	-8.69	-0.43	1.77e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg17948913	chr5:572064	NA	0.5	5.79	0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-5.66	-0.3	3.28e-8	Schizophrenia;
CRC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.4	-20.09	-0.74	3.83e-59	Hip circumference adjusted for BMI;
CRC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg13880726	chr7:1868755	MAD1L1	-0.42	-5.66	-0.3	3.31e-8	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.16	0.37	5.31e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	cis	rs7072216	0.881	rs2182169	chr10:100148004	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.2	-0.32	1.72e-9	Metabolite levels;
CRC	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg08222913	chr3:52553049	STAB1	0.34	6.26	0.33	1.21e-9	Electroencephalogram traits;
CRC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	0.71	6.7	0.35	9.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg03934865	chr2:198174659	NA	0.36	5.85	0.31	1.21e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg04155289	chr7:94953770	PON1	-0.6	-7.67	-0.39	1.96e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.4	-0.5	4.49e-22	Initial pursuit acceleration;
CRC	cis	rs12541635	0.737	rs736627	chr8:107100285	C/T	cg10147462	chr8:107024639	NA	-0.38	-6.07	-0.32	3.56e-9	Age of smoking initiation;
CRC	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-8.11	-0.41	1e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.61	-5.8	-0.3	1.55e-8	Alzheimer's disease (late onset);
CRC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.36	6.06	0.32	3.83e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg25456477	chr12:86230367	RASSF9	0.36	6.23	0.32	1.46e-9	Major depressive disorder;
CRC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.54	6.9	0.36	2.66e-11	Bipolar disorder;
CRC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-7.0	-0.36	1.45e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.5	8.15	0.41	7.48e-15	Lipoprotein (a) levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07279281	chr3:46735319	ALS2CL	0.4	6.25	0.33	1.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2072510	0.900	rs2110762	chr12:96402534	T/C	cg22491680	chr12:96389547	HAL	-0.39	-6.05	-0.32	4.03e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs10128264	0.902	rs1250588	chr10:80980169	T/C	cg20744163	chr10:80999841	ZMIZ1	-0.43	-7.39	-0.38	1.19e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16447950	chr5:562315	NA	-0.8	-10.38	-0.5	4.94e-22	Lung disease severity in cystic fibrosis;
CRC	cis	rs6988985	0.560	rs4736346	chr8:143951849	G/T	cg10324643	chr8:143916377	GML	0.39	6.71	0.35	8.43e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08475953	chr5:178004091	COL23A1	0.23	6.61	0.34	1.56e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg19041857	chr6:27730383	NA	-0.44	-5.94	-0.31	7.12e-9	Parkinson's disease;
CRC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.92	-16.19	-0.67	9.15e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg15226275	chr6:116381976	FRK	0.31	8.8	0.44	8.03e-17	Cholesterol, total;LDL cholesterol;
CRC	trans	rs2303319	0.504	rs55821334	chr2:162452014	A/G	cg10272801	chr16:14013773	ERCC4	-0.68	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs457287	0.614	rs531122	chr9:4830849	A/G	cg14182974	chr9:4791918	RCL1	-0.35	-5.71	-0.3	2.5e-8	Platelet count;
CRC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.55	8.16	0.41	6.95e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.53	-7.61	-0.39	2.87e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg07392085	chr5:141489673	NDFIP1	0.46	7.23	0.37	3.48e-12	Asthma;
CRC	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.81	10.68	0.51	4.56e-23	Prostate cancer;
CRC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.57	7.83	0.4	6.56e-14	Lung cancer;
CRC	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.53	8.44	0.42	9.98e-16	Sum neutrophil eosinophil counts;
CRC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-11.74	-0.54	7.93e-27	Gut microbiome composition (summer);
CRC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.48	6.22	0.32	1.52e-9	Cleft lip with or without cleft palate;
CRC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.19e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.48	6.94	0.36	2.08e-11	Pancreatic cancer;
CRC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13198984	chr17:80129470	CCDC57	-0.46	-7.99	-0.4	2.25e-14	Life satisfaction;
CRC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.67	10.79	0.51	1.89e-23	Sudden cardiac arrest;
CRC	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.72	12.02	0.55	7.7e-28	Colorectal cancer;
CRC	cis	rs834811	0.865	rs844327	chr7:135898043	G/T	cg01726295	chr7:135938950	NA	0.36	6.36	0.33	6.68e-10	Post-traumatic stress disorder;
CRC	cis	rs501120	1.000	rs487465	chr10:44758197	A/C	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.28	-0.33	1.05e-9	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17864206	chr1:43855683	C1orf84;MED8	0.39	6.01	0.31	4.91e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2737618	0.722	rs2737673	chr1:200081710	T/C	cg21825944	chr1:200113062	NR5A2	-0.47	-6.5	-0.34	3.06e-10	Uric acid levels;
CRC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.46	-9.15	-0.45	6.06e-18	Subjective well-being;
CRC	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.63	-0.3	3.78e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs55702914	0.650	rs6715690	chr2:198148371	C/T	cg03934865	chr2:198174659	NA	-0.36	-6.17	-0.32	1.95e-9	Major depression and alcohol dependence;
CRC	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	9.51	0.46	4.18e-19	Bone mineral density;
CRC	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.64	-9.35	-0.46	1.38e-18	Blood protein levels;
CRC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.67	0.39	1.94e-13	Height;
CRC	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.51	-0.42	6.38e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.63	11.44	0.53	9.84e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg00631329	chr6:26305371	NA	-0.4	-6.89	-0.36	2.86e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.43	-20.42	-0.75	2e-60	Hip circumference adjusted for BMI;
CRC	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.74	-10.36	-0.5	6.08e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.75	-13.35	-0.59	8.81e-33	Paraoxonase activity;
CRC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-10.54	-0.5	1.41e-22	Platelet distribution width;
CRC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.4	18.15	0.71	1.65e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.6	-9.04	-0.45	1.4e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12560992	chr17:57184187	TRIM37	-0.57	-7.99	-0.4	2.28e-14	Testicular germ cell tumor;
CRC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg20400248	chr8:9005257	PPP1R3B	-0.38	-5.91	-0.31	8.44e-9	Joint mobility (Beighton score);
CRC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	13.14	0.59	5.3e-32	Electrocardiographic conduction measures;
CRC	cis	rs2882667	0.690	rs700623	chr5:138098682	A/G	cg09476006	chr5:138032270	NA	-0.59	-10.73	-0.51	3.06e-23	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.59	-0.39	3.43e-13	HDL cholesterol;
CRC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.42	-9.25	-0.45	2.82e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg24416660	chr17:73865998	NA	-0.38	-5.76	-0.3	1.91e-8	Psoriasis;
CRC	cis	rs970548	1.000	rs58865519	chr10:46010891	C/A	cg15590007	chr10:45870220	ALOX5	0.51	6.5	0.34	3e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg17330251	chr7:94953956	PON1	-0.6	-7.49	-0.38	6.26e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.7	0.39	1.5700000000000001e-13	Obesity-related traits;
CRC	cis	rs7527798	0.592	rs10863461	chr1:207840776	C/T	cg21110645	chr1:207815933	NA	-0.42	-6.61	-0.34	1.57e-10	Erythrocyte sedimentation rate;
CRC	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.48	6.73	0.35	7.66e-11	Coronary artery disease;
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.4	0.42	1.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg25237894	chr2:233734115	C2orf82	-0.4	-5.71	-0.3	2.48e-8	Schizophrenia;
CRC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.52	-7.81	-0.4	7.99e-14	Dementia with Lewy bodies;
CRC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg20243544	chr17:37824526	PNMT	0.39	5.84	0.31	1.24e-8	Self-reported allergy;
CRC	cis	rs7113874	0.589	rs1374262	chr11:8458749	A/G	cg02811074	chr11:8615871	STK33	0.35	6.0	0.31	5.28e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.49	6.91	0.36	2.53e-11	Type 1 diabetes nephropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16655837	chr10:32636197	EPC1	0.4	6.42	0.33	4.63e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.91	-14.72	-0.63	4.79e-38	Cognitive ability;
CRC	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-6.7	-0.35	9.16e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg00129232	chr17:37814104	STARD3	0.43	6.74	0.35	7.25e-11	Self-reported allergy;
CRC	cis	rs3018066	0.867	rs12650692	chr4:107199842	C/T	cg01869342	chr4:106983673	TBCK	0.37	5.79	0.3	1.61e-8	Cancer;
CRC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg04121214	chr22:50244548	NA	0.41	6.27	0.33	1.16e-9	Schizophrenia;
CRC	cis	rs8105895	0.877	rs9973249	chr19:22242160	T/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg10818794	chr15:86012489	AKAP13	0.41	6.4	0.33	5.3e-10	Bulimia nervosa;
CRC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.83	-0.48	3.71e-20	Aortic root size;
CRC	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.49	7.26	0.37	2.84e-12	Autism;
CRC	trans	rs9822411	0.623	rs17016204	chr3:25367141	C/T	cg06260789	chr22:41741977	ZC3H7B	-0.48	-6.02	-0.31	4.77e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg03934865	chr2:198174659	NA	-0.39	-6.14	-0.32	2.41e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.7	-0.51	4.06e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.88	0.35	3.02e-11	Obesity-related traits;
CRC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.72	7.0	0.36	1.4e-11	Fat distribution (HIV);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10858225	chr5:141303120	KIAA0141	0.44	6.04	0.32	4.22e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01751188	chr22:23412225	RTDR1;GNAZ	0.47	6.03	0.32	4.5e-9	Thyroid stimulating hormone;
CRC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.67	10.3	0.49	9.15e-22	Corneal astigmatism;
CRC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg13606994	chr1:44402422	ARTN	-0.36	-5.99	-0.31	5.5e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.79	10.83	0.51	1.41e-23	Cognitive function;
CRC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg06784218	chr1:46089804	CCDC17	-0.34	-5.66	-0.3	3.25e-8	Red blood cell count;Reticulocyte count;
CRC	cis	rs10865541	1.000	rs11684337	chr2:3395287	A/G	cg22182287	chr2:3452347	TTC15	-0.37	-5.76	-0.3	1.95e-8	Obesity-related traits;
CRC	cis	rs7120118	0.517	rs3758668	chr11:47270775	C/T	cg25783544	chr11:47291846	MADD	0.64	5.76	0.3	1.92e-8	HDL cholesterol;
CRC	cis	rs12620999	0.941	rs1986830	chr2:237978320	C/T	cg23555395	chr2:238036564	NA	0.55	8.41	0.42	1.29e-15	Systemic lupus erythematosus;
CRC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.59	-10.62	-0.51	7.52e-23	Aortic root size;
CRC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg07713946	chr22:31675144	LIMK2	-0.39	-5.63	-0.3	3.94e-8	Colorectal cancer;
CRC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg03160526	chr17:80928410	B3GNTL1	0.58	7.68	0.39	1.81e-13	Glycated hemoglobin levels;
CRC	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.38	-6.06	-0.32	3.75e-9	Life satisfaction;
CRC	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-11.28	-0.53	3.66e-25	Exhaled nitric oxide output;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06577604	chr3:184279443	EPHB3	0.45	6.12	0.32	2.64e-9	Response to antipsychotic treatment;
CRC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-8.05	-0.41	1.55e-14	Insulin-like growth factors;
CRC	cis	rs9682041	0.561	rs1477211	chr3:170140792	A/G	cg11886554	chr3:170076028	SKIL	0.66	7.53	0.38	5.03e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.16	0.52	9.37e-25	Prudent dietary pattern;
CRC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.35	0.53	2.09e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg20265528	chr2:105853269	NA	-0.32	-5.68	-0.3	2.96e-8	Type 2 diabetes;
CRC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.54	10.31	0.49	8.68e-22	Urate levels in lean individuals;
CRC	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg12756093	chr1:115239321	AMPD1	0.48	7.09	0.36	8.36e-12	Autism;
CRC	cis	rs4499344	0.604	rs259275	chr19:33159693	A/G	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.82e-9	Mean platelet volume;
CRC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.58	8.29	0.42	2.82e-15	Arsenic metabolism;
CRC	cis	rs4290604	0.748	rs80306906	chr2:237998886	T/G	cg23555395	chr2:238036564	NA	0.65	6.67	0.35	1.09e-10	Asthma;
CRC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg20243544	chr17:37824526	PNMT	0.54	8.08	0.41	1.23e-14	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25842470	chr1:2472373	NA	-0.46	-7.23	-0.37	3.3e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.81	-14.46	-0.62	5.16e-37	Breast cancer;
CRC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.61	-9.45	-0.46	6.61e-19	Body mass index;
CRC	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.18	-0.37	4.6e-12	Capecitabine sensitivity;
CRC	cis	rs2249694	0.922	rs8192780	chr10:135354125	T/G	cg16964102	chr10:135390573	NA	-0.37	-6.0	-0.31	5.18e-9	Obesity-related traits;
CRC	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.81	8.55	0.43	4.61e-16	Gastritis;
CRC	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg04837898	chr3:45731254	SACM1L	-0.35	-5.73	-0.3	2.26e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.37	-5.97	-0.31	6.11e-9	Blood metabolite levels;
CRC	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.92e-31	White blood cell count (basophil);
CRC	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg25588852	chr2:216877276	MREG	-0.32	-6.05	-0.32	4.01e-9	Alcohol dependence;
CRC	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg11038491	chr20:34638489	LOC647979	-0.63	-7.36	-0.38	1.53e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg27535305	chr1:53392650	SCP2	-0.36	-6.48	-0.34	3.31e-10	Monocyte count;
CRC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg23815491	chr16:72088622	HP	0.47	5.98	0.31	5.93e-9	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01290701	chr5:82373336	XRCC4;TMEM167A	0.43	6.12	0.32	2.6e-9	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.66	-11.0	-0.52	3.68e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.68	-0.35	1.02e-10	Educational attainment (years of education);
CRC	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.99	-0.36	1.52e-11	Bone mineral density;
CRC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg07952391	chr2:88470173	THNSL2	0.62	5.95	0.31	7.01e-9	Plasma clusterin levels;
CRC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.49	6.56	0.34	2.06e-10	Lymphocyte counts;
CRC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.27	-14.59	-0.63	1.57e-37	Diabetic kidney disease;
CRC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.87	0.4	5.09e-14	Lung cancer;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.53	0.43	5.33e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.53	0.34	2.51e-10	Morning vs. evening chronotype;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg06470822	chr6:28175283	NA	1.01	15.38	0.65	1.29e-40	Depression;
CRC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg25767906	chr1:53392781	SCP2	-0.42	-6.76	-0.35	6.19e-11	Monocyte count;
CRC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg11843238	chr5:131593191	PDLIM4	0.33	6.09	0.32	3.16e-9	Blood metabolite levels;
CRC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg08648136	chr8:956695	NA	0.32	6.35	0.33	7.03e-10	Schizophrenia;
CRC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.83	0.31	1.34e-8	Self-reported allergy;
CRC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.17	24.9	0.81	1.13e-77	IgG glycosylation;
CRC	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg09654669	chr8:57350985	NA	-0.41	-5.71	-0.3	2.51e-8	Obesity-related traits;
CRC	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg00042356	chr1:8021962	PARK7	-0.58	-7.01	-0.36	1.35e-11	Inflammatory bowel disease;
CRC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.55	-8.22	-0.41	4.76e-15	Sudden cardiac arrest;
CRC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg11833968	chr6:79620685	NA	-0.37	-6.4	-0.33	5.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-17.08	-0.69	2.88e-47	Height;
CRC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.39	6.74	0.35	7.22e-11	Coronary artery disease;
CRC	trans	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg13565492	chr6:43139072	SRF	-0.71	-7.12	-0.37	7.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.69	-12.31	-0.56	6.7200000000000006e-29	Endometriosis;
CRC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.53	-0.5	1.53e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10986311	0.706	rs7854989	chr9:127133584	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.45	0.33	4.04e-10	Vitiligo;
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.7	9.58	0.47	2.4e-19	Alzheimer's disease;
CRC	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.85	-0.35	3.55e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg02880119	chr16:3481970	NA	0.44	6.07	0.32	3.57e-9	Body mass index (adult);
CRC	trans	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg09872104	chr7:134855509	C7orf49	-0.85	-7.57	-0.39	3.81e-13	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg10589385	chr1:150898437	SETDB1	0.32	6.88	0.35	3.04e-11	Melanoma;
CRC	cis	rs12936587	0.692	rs35660942	chr17:17527185	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-5.72	-0.3	2.44e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-7.72	-0.39	1.38e-13	Aortic root size;
CRC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg05941027	chr17:61774174	LIMD2	0.37	6.75	0.35	6.81e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.71	-11.29	-0.53	3.44e-25	Height;
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.68	-11.12	-0.52	1.32e-24	Monocyte percentage of white cells;
CRC	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg16127683	chr15:40268777	EIF2AK4	-0.68	-6.39	-0.33	5.69e-10	Response to haloperidol in psychosis;
CRC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.85	-0.31	1.2e-8	Cognitive function;
CRC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.48	-0.38	6.89e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.73	-0.3	2.28e-8	Life satisfaction;
CRC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.42	0.53	1.12e-25	Prudent dietary pattern;
CRC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.62	10.57	0.5	1.09e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.53	-0.38	5.05e-13	Alzheimer's disease;
CRC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.14	-0.32	2.34e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2857891	1.000	rs2857891	chr11:6962957	C/T	cg22096450	chr11:6947773	ZNF215	0.61	6.43	0.33	4.36e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.54	-7.06	-0.36	1.02e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06441946	chr5:145583671	RBM27	0.49	6.43	0.33	4.37e-10	Thyroid stimulating hormone;
CRC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.86	-0.31	1.11e-8	Heart rate;
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg22687807	chr8:143858763	LYNX1	-0.73	-13.91	-0.61	6.6e-35	Urinary tract infection frequency;
CRC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.47	7.51	0.38	5.48e-13	Major depressive disorder;
CRC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg02725872	chr8:58115012	NA	-0.35	-5.99	-0.31	5.5e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12476592	0.602	rs1348806	chr2:63895884	A/T	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.31	-0.37	2.04e-12	Mean corpuscular volume;
CRC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	6.08e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.51	-7.37	-0.38	1.41e-12	Systemic lupus erythematosus;
CRC	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.51	6.5	0.34	2.99e-10	Serum parathyroid hormone levels;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg15845792	chr6:28175446	NA	0.66	9.05	0.45	1.24e-17	Parkinson's disease;
CRC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-6.57	-0.34	1.97e-10	Height;
CRC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.57	6.4	0.33	5.49e-10	Skin colour saturation;
CRC	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.85	0.35	3.63e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg08896387	chr1:24191740	FUCA1	0.53	6.94	0.36	2.12e-11	Immature fraction of reticulocytes;
CRC	cis	rs9925964	0.900	rs56813533	chr16:31070481	A/T	cg03418659	chr16:31128414	MYST1	0.47	6.75	0.35	6.57e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs365302	1.000	rs401578	chr6:159645783	A/G	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.76e-10	Coronary heart disease;
CRC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg20908204	chr19:46285434	DMPK	0.34	7.41	0.38	1.05e-12	Coronary artery disease;
CRC	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-9.41	-0.46	8.93e-19	Type 2 diabetes;
CRC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.75	-0.3	2.01e-8	Blood pressure;
CRC	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.52	0.34	2.58e-10	Intraocular pressure;
CRC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg19812747	chr11:111475976	SIK2	-0.58	-9.93	-0.48	1.68e-20	Primary sclerosing cholangitis;
CRC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.4	-5.71	-0.3	2.52e-8	Rheumatoid arthritis;
CRC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.43	7.04	0.36	1.12e-11	Sitting height ratio;
CRC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.5	-0.34	2.97e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg22676075	chr6:135203613	NA	0.4	6.11	0.32	2.85e-9	Red blood cell count;
CRC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18252515	chr7:66147081	NA	0.43	6.27	0.33	1.14e-9	Aortic root size;
CRC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.68	11.35	0.53	2.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00166722	chr3:10149974	C3orf24	0.42	6.3	0.33	9.75e-10	Alzheimer's disease;
CRC	cis	rs11212617	1.000	rs227088	chr11:108243755	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.55	0.34	2.19e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.56	-0.47	2.9e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg09835421	chr16:68378352	PRMT7	-0.44	-5.69	-0.3	2.78e-8	Schizophrenia;
CRC	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	11.68	0.54	1.36e-26	Height;
CRC	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	7.27	0.37	2.59e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13561157	chr9:139922545	C9orf139;ABCA2	0.44	6.12	0.32	2.65e-9	Response to antipsychotic treatment;
CRC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg16102536	chr7:156981717	UBE3C	-0.39	-6.52	-0.34	2.72e-10	Body mass index;
CRC	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg09695851	chr17:3907499	NA	0.49	6.19	0.32	1.76e-9	Type 2 diabetes;
CRC	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.54	8.95	0.44	2.67e-17	Dupuytren's disease;
CRC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.6	7.98	0.4	2.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9287719	0.601	rs9287718	chr2:10701629	A/T	cg00105475	chr2:10696890	NA	-0.47	-7.27	-0.37	2.6e-12	Prostate cancer;
CRC	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg25856811	chr1:152973957	SPRR3	0.25	7.06	0.36	1.01e-11	Inflammatory skin disease;
CRC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg11062466	chr8:58055876	NA	0.45	5.6	0.3	4.45e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg24011408	chr12:48396354	COL2A1	0.45	6.08	0.32	3.24e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20646317	chr12:50794494	LARP4	0.45	6.25	0.33	1.29e-9	Response to antipsychotic treatment;
CRC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.98	-0.44	2.17e-17	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27060912	chr19:6517005	NA	0.47	7.4	0.38	1.14e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.47	-7.35	-0.38	1.56e-12	Schizophrenia;
CRC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-14.02	-0.61	2.54e-35	Exhaled nitric oxide output;
CRC	cis	rs17767392	0.958	rs2877729	chr14:71887868	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.63	-0.34	1.42e-10	Breast cancer;
CRC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.64	11.48	0.53	6.92e-26	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26872475	chr11:119039430	NLRX1	0.5	7.23	0.37	3.48e-12	Response to antipsychotic treatment;
CRC	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.46	6.9	0.36	2.68e-11	Asthma;
CRC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.48	8.74	0.43	1.23e-16	Prostate cancer;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg26587870	chr6:27730563	NA	-0.42	-6.22	-0.32	1.54e-9	Parkinson's disease;
CRC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.52	9.44	0.46	6.87e-19	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11875500	chr19:36391588	NFKBID	0.41	6.22	0.32	1.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.89	0.4	4.59e-14	Blood metabolite levels;
CRC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-6.56	-0.34	2.08e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs727505	0.564	rs56068095	chr7:124831906	A/T	cg23710748	chr7:124431027	NA	-0.62	-10.33	-0.49	7.81e-22	Lewy body disease;
CRC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.72	11.66	0.54	1.57e-26	Breast cancer;
CRC	cis	rs501120	0.564	rs11238905	chr10:44685136	T/A	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	trans	rs10411161	0.702	rs8113685	chr19:52383890	C/T	cg22319618	chr22:45562946	NUP50	-0.68	-7.53	-0.38	4.85e-13	Breast cancer;
CRC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.29	0.42	2.85e-15	Homoarginine levels;
CRC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-7.14	-0.37	6.07e-12	Aortic root size;
CRC	cis	rs17067123	0.539	rs79352031	chr4:180066810	C/T	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	7.28e-11	Response to hepatitis C treatment;
CRC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.39	5.93	0.31	7.57e-9	Hemoglobin concentration;
CRC	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg15711740	chr2:61764176	XPO1	0.43	5.61	0.3	4.27e-8	Tuberculosis;
CRC	cis	rs2108622	0.727	rs7251296	chr19:15983736	A/G	cg13772218	chr19:15982569	NA	0.46	6.55	0.34	2.23e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.48	0.38	6.76e-13	Eosinophil percentage of white cells;
CRC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg18230493	chr5:56204884	C5orf35	-0.59	-8.63	-0.43	2.72e-16	Initial pursuit acceleration;
CRC	cis	rs600806	0.888	rs12046539	chr1:109875415	C/T	cg23032129	chr1:109941072	SORT1	-0.27	-5.73	-0.3	2.21e-8	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-6.3	-0.33	9.42e-10	Myopia (pathological);
CRC	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.05	0.58	1.15e-31	Hip circumference;
CRC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.36	-5.72	-0.3	2.39e-8	Breast size;
CRC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.56e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.04	-0.32	4.18e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08744727	chr4:206112	ZNF876P	-0.39	-6.42	-0.33	4.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg02741985	chr17:80059408	CCDC57	0.43	6.97	0.36	1.71e-11	Life satisfaction;
CRC	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.84	15.28	0.64	3.3e-40	Vitiligo;
CRC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.54	-7.63	-0.39	2.58e-13	Corneal structure;
CRC	cis	rs77861329	0.670	rs9828327	chr3:52120209	T/C	cg08692210	chr3:52188851	WDR51A	0.53	6.01	0.31	4.85e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg00976097	chr5:421733	AHRR	-0.45	-6.02	-0.31	4.76e-9	Cystic fibrosis severity;
CRC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.43	-0.5	3.3e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.82	10.3	0.49	9.84e-22	Eosinophil percentage of granulocytes;
CRC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.93	0.4	3.43e-14	Lymphocyte percentage of white cells;
CRC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg16342193	chr10:102329863	NA	-0.37	-6.11	-0.32	2.8e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.52	-7.3	-0.37	2.21e-12	Schizophrenia;
CRC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg20203395	chr5:56204925	C5orf35	0.57	7.85	0.4	5.99e-14	Initial pursuit acceleration;
CRC	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.6	-7.97	-0.4	2.63e-14	Post bronchodilator FEV1;
CRC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.54	7.24	0.37	3.29e-12	Height;
CRC	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg16512390	chr1:228756714	NA	0.64	6.7	0.35	8.82e-11	Chronic lymphocytic leukemia;
CRC	cis	rs4481887	0.504	rs11204608	chr1:248360379	C/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	trans	rs855408	0.959	rs526759	chr6:62897695	G/A	cg21737066	chr3:72495901	RYBP	0.49	5.96	0.31	6.43e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg00074818	chr8:8560427	CLDN23	0.41	7.36	0.38	1.45e-12	Obesity-related traits;
CRC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	-0.42	-5.86	-0.31	1.12e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg14122300	chr14:69446504	ACTN1	-0.49	-6.24	-0.33	1.34e-9	Diisocyanate-induced asthma;
CRC	cis	rs2062225	0.877	rs4849340	chr2:111774116	G/A	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.84	15.48	0.65	5.55e-41	Dental caries;
CRC	cis	rs713477	0.654	rs12886848	chr14:55911138	G/A	cg13175173	chr14:55914753	NA	-0.43	-7.48	-0.38	7e-13	Pediatric bone mineral content (femoral neck);
CRC	trans	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6908034	0.607	rs73376680	chr6:19808099	G/A	cg02682789	chr6:19804855	NA	0.78	6.83	0.35	4.16e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg08501292	chr6:25962987	TRIM38	0.58	6.48	0.34	3.36e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.49	0.34	3.25e-10	Height;
CRC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-8.2	-0.41	5.4e-15	Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02290350	chr8:58132656	NA	-0.57	-8.08	-0.41	1.22e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.46	6.42	0.33	4.79e-10	Pulse pressure;
CRC	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.51	-9.58	-0.47	2.51e-19	Hip circumference;Waist circumference;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg19318889	chr4:1322082	MAEA	0.41	6.24	0.33	1.33e-9	Obesity-related traits;
CRC	cis	rs12745968	0.589	rs10782936	chr1:93041906	A/G	cg17283838	chr1:93427260	FAM69A	-0.43	-6.0	-0.31	5.14e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.45	-6.96	-0.36	1.8e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.56	7.66	0.39	2.16e-13	Bronchopulmonary dysplasia;
CRC	cis	rs6679356	0.789	rs4655698	chr1:67798327	T/G	cg24364144	chr1:67875067	SERBP1	0.41	5.81	0.3	1.5e-8	Primary biliary cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05970768	chr5:171682616	UBTD2	-0.41	-6.36	-0.33	6.77e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.39	-6.07	-0.32	3.52e-9	Crohn's disease;
CRC	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	8.61	0.43	2.98e-16	Response to antipsychotic treatment;
CRC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.77	13.64	0.6	7.11e-34	Oral cavity cancer;
CRC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.61	-11.45	-0.53	8.96e-26	Educational attainment;
CRC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	8.87	0.44	4.84e-17	Mean platelet volume;
CRC	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg01858014	chr14:56050164	KTN1	-0.89	-6.86	-0.35	3.42e-11	Putamen volume;
CRC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.72	-0.39	1.4e-13	Hemoglobin concentration;
CRC	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg02083836	chr1:87617350	LOC339524	-0.35	-6.28	-0.33	1.07e-9	Smoking behavior;
CRC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-6.26	-0.33	1.21e-9	Response to bleomycin (chromatid breaks);
CRC	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.13	17.37	0.69	1.99e-48	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.71	-0.47	8.9e-20	Intelligence (multi-trait analysis);
CRC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.48	7.63	0.39	2.53e-13	Tumor biomarkers;
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00166722	chr3:10149974	C3orf24	0.66	9.02	0.45	1.59e-17	Alzheimer's disease;
CRC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.5	-0.34	2.99e-10	Major depressive disorder;
CRC	trans	rs8005962	0.724	rs28589908	chr14:96105511	C/T	cg21678461	chr11:20180700	DBX1	0.31	6.2	0.32	1.65e-9	Tuberculosis;
CRC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.59	0.34	1.77e-10	Cognitive test performance;
CRC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.93	-0.36	2.23e-11	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10512748	chr1:28844557	SNHG3-RCC1;RCC1	0.53	7.48	0.38	6.88e-13	Response to antipsychotic treatment;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg17084751	chr11:6953558	ZNF215	-0.51	-5.81	-0.31	1.47e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.82	-12.79	-0.58	1.11e-30	Height;
CRC	cis	rs7705042	0.865	rs249643	chr5:141524746	C/G	cg07392085	chr5:141489673	NDFIP1	0.45	7.25	0.37	2.94e-12	Asthma;
CRC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg02033258	chr5:131593261	PDLIM4	-0.33	-5.79	-0.3	1.68e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg08307039	chr5:64920116	TRIM23;C5orf44	-0.41	-6.0	-0.31	5.28e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.49	-9.29	-0.46	2.13e-18	Reticulocyte fraction of red cells;
CRC	cis	rs12618769	0.597	rs3754892	chr2:99063318	T/A	cg18455616	chr2:99124870	INPP4A	0.37	5.73	0.3	2.26e-8	Bipolar disorder;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	-0.41	-6.29	-0.33	9.87e-10	Daytime sleep phenotypes;
CRC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.49	7.19	0.37	4.34e-12	Cognitive test performance;
CRC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.8	0.48	4.59e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.49	7.93	0.4	3.46e-14	Osteoporosis;
CRC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg02569458	chr12:86230093	RASSF9	0.47	7.83	0.4	6.86e-14	Major depressive disorder;
CRC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.81	-0.35	4.73e-11	Aortic root size;
CRC	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg27053337	chr8:124217698	FAM83A	0.45	6.82	0.35	4.48e-11	Urinary uromodulin levels;
CRC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg14515779	chr1:101123966	NA	-0.45	-8.46	-0.42	9.07e-16	Monocyte count;
CRC	cis	rs9903692	0.954	rs875066	chr17:46139732	T/G	cg21215337	chr17:46176117	CBX1	0.42	7.67	0.39	1.99e-13	Pulse pressure;
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg15790184	chr11:494944	RNH1	0.62	6.92	0.36	2.36e-11	Body mass index;
CRC	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.45	-6.46	-0.34	3.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.83	11.94	0.55	1.55e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.75	-9.92	-0.48	1.77e-20	White matter hyperintensity burden;
CRC	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.17e-12	Putamen volume;
CRC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.24e-10	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg15448220	chr1:150897856	SETDB1	0.49	7.01	0.36	1.35e-11	Tonsillectomy;
CRC	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg17133734	chr15:86042851	AKAP13	0.42	6.78	0.35	5.62e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05315670	chr11:64037304	BAD	0.42	6.7	0.35	9.27e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.47	6.81	0.35	4.69e-11	Aortic root size;
CRC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	10.09	0.49	4.82e-21	Menarche (age at onset);
CRC	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg17133734	chr15:86042851	AKAP13	0.43	6.82	0.35	4.43e-11	Coronary artery disease;
CRC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.77	-9.18	-0.45	4.96e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.53	6.32	0.33	8.44e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma (childhood onset);
CRC	cis	rs6504622	0.755	rs7219544	chr17:45166928	G/T	cg16759221	chr17:45003025	GOSR2	0.42	6.69	0.35	9.76e-11	Orofacial clefts;
CRC	cis	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg18809830	chr7:99032528	PTCD1	-0.81	-6.2	-0.32	1.67e-9	Blood metabolite levels;
CRC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg08923669	chr16:420230	MRPL28	-0.59	-7.6	-0.39	3.02e-13	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13476105	chr17:7819425	LOC284023	0.45	6.36	0.33	6.86e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg02725872	chr8:58115012	NA	-0.32	-5.72	-0.3	2.39e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.61	8.99	0.44	1.99e-17	Schizophrenia;
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg04969067	chr8:143858791	LYNX1	0.45	7.59	0.39	3.34e-13	Urinary tract infection frequency;
CRC	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg18165381	chr3:44552316	NA	-0.39	-5.86	-0.31	1.1e-8	Depressive symptoms;
CRC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.39	9.26	0.45	2.7e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.41	8.52	0.43	5.73e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.47	9.17	0.45	5.39e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.89	-0.44	4.01e-17	Bipolar disorder;
CRC	trans	rs62295889	0.602	rs62293670	chr4:12542220	C/T	cg03490839	chr16:73082051	ZFHX3	0.57	6.0	0.31	5.21e-9	Obesity-related traits;
CRC	cis	rs7632954	0.567	rs6808372	chr3:8534693	T/C	cg03495237	chr3:8533978	NA	0.35	6.38	0.33	5.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10274279	1.000	rs73163814	chr7:157388012	A/G	cg26886268	chr7:157387156	PTPRN2	-0.48	-5.89	-0.31	9.62e-9	Myopia (pathological);
CRC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg19682013	chr15:45996608	NA	0.32	6.62	0.34	1.48e-10	Waist circumference;Weight;
CRC	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg25482853	chr8:67687455	SGK3	1.22	13.74	0.6	2.86e-34	Lung disease severity in cystic fibrosis;
CRC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.25	0.33	1.28e-9	Rheumatoid arthritis;
CRC	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.59	-7.48	-0.38	7.02e-13	Obesity (extreme);
CRC	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.45	6.8	0.35	5.03e-11	Neutrophil percentage of white cells;
CRC	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.71	-9.71	-0.47	9.38e-20	Blood pressure (smoking interaction);
CRC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.44	-6.95	-0.36	1.99e-11	Menopause (age at onset);
CRC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg27535305	chr1:53392650	SCP2	0.33	6.17	0.32	2.03e-9	Monocyte count;
CRC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg02527881	chr3:46936655	PTH1R	0.39	6.98	0.36	1.59e-11	Colorectal cancer;
CRC	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg15212455	chr7:39170539	POU6F2	0.45	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.66	-10.95	-0.52	5.35e-24	White blood cell count (basophil);
CRC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.86	-0.48	2.97e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.51	-7.53	-0.38	4.95e-13	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs11191205	0.686	rs11191088	chr10:103437266	C/G	cg15320455	chr10:103880129	LDB1	-0.62	-6.85	-0.35	3.68e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg21856205	chr7:94953877	PON1	-0.45	-5.9	-0.31	9.09e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.42	9.27	0.46	2.47e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg19046167	chr17:80928561	B3GNTL1	-0.43	-7.29	-0.37	2.26e-12	Breast cancer;
CRC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg11833968	chr6:79620685	NA	-0.37	-6.48	-0.34	3.34e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16155655	chr2:158485694	ACVR1C	0.45	6.36	0.33	6.68e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7671266	0.589	rs10938772	chr4:10375328	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.92	-0.31	8.28e-9	Cardiovascular disease risk factors;
CRC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21467203	chr3:49911342	NA	-0.25	-6.05	-0.32	4.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7677751	1.000	rs73252946	chr4:55125992	G/A	cg17187183	chr4:55093834	PDGFRA	0.48	5.92	0.31	8.21e-9	Corneal astigmatism;
CRC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.57	8.62	0.43	2.85e-16	Aortic root size;
CRC	trans	rs2321882	0.794	rs75393184	chr13:59477960	T/C	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-6.97	-0.36	1.78e-11	Gut microbiome composition (summer);
CRC	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.73	-13.05	-0.58	1.14e-31	White blood cell count (basophil);
CRC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.65	-0.3	3.44e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs73200209	0.744	rs61936954	chr12:116473408	T/A	cg01776926	chr12:116560359	MED13L	-0.65	-7.58	-0.39	3.57e-13	Total body bone mineral density;
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.56	-7.4	-0.38	1.17e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	15.65	0.65	1.22e-41	Subjective well-being;
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02772935	chr3:125709198	NA	-0.52	-5.93	-0.31	7.7e-9	Blood pressure (smoking interaction);
CRC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.94	-15.38	-0.65	1.29e-40	Gut microbiota (bacterial taxa);
CRC	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg17524180	chr13:113633600	MCF2L	-0.53	-9.77	-0.47	5.86e-20	Systolic blood pressure;
CRC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.6	-6.49	-0.34	3.08e-10	Schizophrenia;
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.03	-25.44	-0.81	1.08e-79	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.26	0.33	1.23e-9	Self-reported allergy;
CRC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	0.59	6.15	0.32	2.19e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.14	-13.85	-0.61	1.06e-34	Diabetic kidney disease;
CRC	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg14458575	chr2:238380390	NA	0.53	6.94	0.36	2.06e-11	Prostate cancer;
CRC	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg01422370	chr2:73384389	NA	0.37	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6838801	0.752	rs13138237	chr4:77616562	C/G	cg17476223	chr4:77663285	SHROOM3	0.44	5.89	0.31	9.8e-9	Cleft lip with or without cleft palate;
CRC	cis	rs9311676	0.656	rs11917529	chr3:58382158	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.58	-7.32	-0.37	1.98e-12	Platelet distribution width;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.78	10.85	0.51	1.24e-23	Obesity-related traits;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg09877947	chr5:131593287	PDLIM4	0.57	10.02	0.48	8.74e-21	Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05505450	chr2:58273643	VRK2	0.46	6.68	0.35	1.05e-10	Response to antipsychotic treatment;
CRC	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.48	7.5	0.38	5.88e-13	HDL cholesterol;
CRC	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.68	7.7	0.39	1.58e-13	Breast cancer;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	9.17	0.45	5.23e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.13	-0.32	2.54e-9	Daytime sleep phenotypes;
CRC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.31	-0.33	9.1e-10	Schizophrenia;
CRC	cis	rs7635838	0.859	rs9875414	chr3:11453559	A/G	cg00170343	chr3:11313890	ATG7	0.42	6.38	0.33	6.06e-10	HDL cholesterol;
CRC	cis	rs9826463	0.702	rs9683274	chr3:142332110	A/G	cg20824294	chr3:142316082	PLS1	0.37	5.8	0.3	1.57e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg04415270	chr2:102091202	RFX8	-0.37	-5.86	-0.31	1.12e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg19193384	chr17:30244184	NA	-0.66	-7.59	-0.39	3.4e-13	Hip circumference adjusted for BMI;
CRC	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.57	8.54	0.43	5.01e-16	Corneal astigmatism;
CRC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.44	-6.92	-0.36	2.35e-11	Height;
CRC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg17724175	chr1:150552817	MCL1	0.47	7.0	0.36	1.46e-11	Melanoma;
CRC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.43	6.02	0.32	4.55e-9	Aortic root size;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg03623178	chr6:28175578	NA	0.63	8.41	0.42	1.3e-15	Parkinson's disease;
CRC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg06238570	chr21:40685208	BRWD1	0.78	10.82	0.51	1.48e-23	Cognitive function;
CRC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.11	-14.17	-0.62	6.47e-36	Breast cancer;
CRC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.6	10.73	0.51	3.03e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg17470449	chr10:769945	NA	0.57	7.89	0.4	4.66e-14	Uric acid levels;
CRC	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.58	-10.81	-0.51	1.71e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs883565	0.528	rs4428122	chr3:38972603	C/A	cg01426195	chr3:39028469	NA	0.42	7.09	0.36	8.22e-12	Handedness;
CRC	trans	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg14791747	chr16:20752902	THUMPD1	0.53	6.58	0.34	1.84e-10	Cognitive test performance;
CRC	cis	rs9469578	1.000	rs16869466	chr6:33715265	A/G	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.66	9.21	0.45	4.01e-18	Menarche (age at onset);
CRC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.74	-14.08	-0.61	1.46e-35	Body mass index;
CRC	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.39	-6.55	-0.34	2.21e-10	Mean arterial pressure;
CRC	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.7	9.11	0.45	8.49e-18	Dementia with Lewy bodies;
CRC	cis	rs10046574	0.831	rs28399231	chr7:135093154	G/A	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.59	0.47	2.22e-19	Common traits (Other);
CRC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg19318889	chr4:1322082	MAEA	0.41	6.27	0.33	1.15e-9	Obesity-related traits;
CRC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.67	13.14	0.59	5.45e-32	Educational attainment;
CRC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg24829409	chr8:58192753	C8orf71	-0.41	-5.67	-0.3	3.07e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg02560186	chr11:3602584	NA	-0.45	-6.12	-0.32	2.62e-9	Blood pressure (smoking interaction);
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg00750074	chr16:89608354	SPG7	-0.49	-7.56	-0.38	4.07e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.57	-10.15	-0.49	3.16e-21	Height;
CRC	cis	rs6662572	0.671	rs12047120	chr1:46478496	A/G	cg08644498	chr1:46502608	NA	-0.46	-7.37	-0.38	1.4e-12	Blood protein levels;
CRC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg23093090	chr10:104574429	C10orf26	0.4	6.58	0.34	1.91e-10	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs2013441	0.866	rs12949485	chr17:20021661	A/G	cg13482628	chr17:19912719	NA	0.41	6.0	0.31	5.14e-9	Obesity-related traits;
CRC	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg20636351	chr8:55087400	NA	-0.34	-6.01	-0.31	4.88e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.43	-0.33	4.55e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05780616	chr12:96252764	SNRPF	0.46	6.6	0.34	1.67e-10	Response to antipsychotic treatment;
CRC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.55	7.81	0.4	7.72e-14	Breast cancer;
CRC	cis	rs7632954	0.605	rs9824908	chr3:8524647	G/A	cg03495237	chr3:8533978	NA	0.37	6.69	0.35	9.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg03160526	chr17:80928410	B3GNTL1	0.62	8.45	0.42	9.66e-16	Glycated hemoglobin levels;
CRC	trans	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06834434	chr14:75079333	LTBP2	0.56	7.06	0.36	9.8e-12	Obesity-related traits;
CRC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg22495460	chr2:25135724	ADCY3	-0.88	-17.58	-0.7	2.99e-49	Body mass index;
CRC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg20243544	chr17:37824526	PNMT	-0.56	-9.04	-0.45	1.36e-17	Asthma;
CRC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg23533926	chr12:111358616	MYL2	-0.53	-8.19	-0.41	5.92e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs11209185	0.503	rs4655573	chr1:68438778	C/T	cg22082780	chr1:68452167	NA	-0.38	-5.78	-0.3	1.72e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs7274811	0.711	rs657040	chr20:32001292	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.8	0.3	1.59e-8	Height;
CRC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.8	-13.22	-0.59	2.6e-32	Body mass index;
CRC	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.42	6.3	0.33	9.33e-10	Testicular germ cell tumor;
CRC	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.51	-0.57	1.18e-29	Idiopathic membranous nephropathy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09844983	chr1:28240714	RPA2	0.47	6.15	0.32	2.27e-9	Thyroid stimulating hormone;
CRC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.63	9.71	0.47	9.04e-20	Corneal astigmatism;
CRC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.44	0.33	4.12e-10	Lung cancer;
CRC	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.52	7.37	0.38	1.43e-12	Testicular germ cell tumor;
CRC	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.42	-6.12	-0.32	2.61e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg08501292	chr6:25962987	TRIM38	1.11	9.48	0.46	5.15e-19	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.53	8.46	0.42	8.78e-16	Corneal astigmatism;
CRC	cis	rs12928939	0.768	rs71386932	chr16:71816191	G/A	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.06	-0.32	3.75e-9	Post bronchodilator FEV1;
CRC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg07636037	chr3:49044803	WDR6	-0.66	-6.41	-0.33	5.06e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.22	0.41	4.81e-15	Platelet count;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.61	9.36	0.46	1.32e-18	Lung cancer;
CRC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.76	-10.99	-0.52	3.81e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.5	10.96	0.52	4.83e-24	Alcohol dependence;
CRC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-7.34	-0.38	1.69e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.59	-8.66	-0.43	2.23e-16	Longevity;
CRC	cis	rs16867321	0.853	rs12464199	chr2:181333307	A/G	cg23363182	chr2:181467187	NA	0.51	6.15	0.32	2.26e-9	Obesity;
CRC	cis	rs6743376	0.556	rs768627	chr2:113821653	C/T	cg24553058	chr2:113831203	IL1F10	-0.43	-7.09	-0.36	8.16e-12	Inflammatory biomarkers;
CRC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.81	-11.54	-0.54	4.13e-26	Cognitive function;
CRC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.51	7.51	0.38	5.52e-13	Lymphocyte counts;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg14593290	chr7:50529359	DDC	0.6	8.0	0.4	2.18e-14	Malaria;
CRC	trans	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg01134436	chr17:81009848	B3GNTL1	0.76	7.09	0.36	8.43e-12	Chronotype;
CRC	cis	rs6968419	0.609	rs73716710	chr7:115905744	G/A	cg02561103	chr7:115862891	TES	-0.41	-6.14	-0.32	2.35e-9	Intraocular pressure;
CRC	cis	rs6662572	0.703	rs7556472	chr1:46339811	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs9549260	0.564	rs7997896	chr13:41268823	T/A	cg21288729	chr13:41239152	FOXO1	0.44	6.71	0.35	8.37e-11	Red blood cell count;
CRC	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12463110	chr4:54930242	CHIC2	0.49	7.18	0.37	4.81e-12	Response to antipsychotic treatment;
CRC	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.62	-8.77	-0.44	9.83e-17	Coronary artery disease;
CRC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.8	12.0	0.55	9.25e-28	Response to antineoplastic agents;
CRC	cis	rs6793245	0.845	rs4073796	chr3:38590849	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-8.3	-0.42	2.77e-15	QT interval;
CRC	trans	rs9903692	0.954	rs12450620	chr17:46130254	G/T	cg13910583	chr8:56987998	RPS20	-0.44	-5.99	-0.31	5.63e-9	Pulse pressure;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.83	0.44	6.45e-17	Rheumatoid arthritis;
CRC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17675882	chr20:35374068	NDRG3	0.54	7.26	0.37	2.86e-12	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-0.59	-11.12	-0.52	1.3e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.72	-0.35	8.24e-11	IgG glycosylation;
CRC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs661713	0.734	rs2655387	chr6:90947998	T/C	cg06866423	chr6:90926672	BACH2	0.39	5.69	0.3	2.77e-8	Hypothyroidism;
CRC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.52	8.69	0.43	1.77e-16	Menarche (age at onset);
CRC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg03030879	chr14:75389066	RPS6KL1	0.4	6.11	0.32	2.86e-9	Height;
CRC	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg18200150	chr17:30822561	MYO1D	0.47	9.17	0.45	5.17e-18	Schizophrenia;
CRC	trans	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg09695851	chr17:3907499	NA	-0.79	-14.43	-0.62	6.36e-37	Type 2 diabetes;
CRC	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg19537932	chr12:55886519	OR6C68	0.7	9.09	0.45	9.41e-18	Cancer;
CRC	cis	rs501120	0.925	rs494045	chr10:44773498	C/T	cg09554077	chr10:44749378	NA	0.73	10.63	0.51	7e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.4	-7.58	-0.39	3.64e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs4664293	0.967	rs1346325	chr2:160542506	C/T	cg08347373	chr2:160653686	CD302	-0.44	-7.09	-0.36	8.07e-12	Monocyte percentage of white cells;
CRC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.55	-5.9	-0.31	9.22e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.34	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.65	-0.3	3.47e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg08999081	chr20:33150536	PIGU	0.45	5.79	0.3	1.66e-8	Protein C levels;
CRC	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg10298567	chr3:47292165	KIF9	-0.41	-6.66	-0.34	1.14e-10	Colorectal cancer;
CRC	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg15192750	chr16:69999425	NA	0.57	7.69	0.39	1.75e-13	IgE levels;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.34	-6.46	-0.34	3.81e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-10.11	-0.49	4.17e-21	Total cholesterol levels;
CRC	cis	rs4321325	0.733	rs78593261	chr2:127947044	G/A	cg11380483	chr2:127933992	NA	0.62	7.02	0.36	1.25e-11	Protein C levels;
CRC	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-9.97	-0.48	1.28e-20	Menarche (age at onset);
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-8.97	-0.44	2.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.63	9.57	0.47	2.74e-19	Menopause (age at onset);
CRC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.67	-10.33	-0.49	7.34e-22	Initial pursuit acceleration;
CRC	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.58	8.25	0.41	3.75e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg04192923	chr4:3473232	DOK7	0.38	6.01	0.31	4.88e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg18833306	chr6:118973337	C6orf204	0.45	6.01	0.31	4.81e-9	Diastolic blood pressure;
CRC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-8.12	-0.41	9.7e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.63	11.63	0.54	1.96e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg25834613	chr7:1915315	MAD1L1	-0.42	-5.95	-0.31	7.03e-9	Bipolar disorder;
CRC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	10.62	0.51	7.77e-23	Neutrophil percentage of white cells;
CRC	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.01	-0.31	4.97e-9	Blood metabolite levels;
CRC	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg15131784	chr3:139108705	COPB2	-0.41	-5.95	-0.31	6.93e-9	Obesity-related traits;
CRC	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.19	-0.32	1.75e-9	Systemic lupus erythematosus;
CRC	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.89	-0.36	2.89e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.46	-9.13	-0.45	6.9e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs56037433	1	rs56037433	chr2:162575985	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.78	-6.1	-0.32	3.05e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.98	0.44	2.15e-17	Mean platelet volume;
CRC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.75	0.51	2.57e-23	Bone mineral density;
CRC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg08314208	chr16:67682810	RLTPR	-0.65	-6.8	-0.35	5.04e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg11522145	chr4:3412961	RGS12	-0.36	-5.69	-0.3	2.85e-8	Serum sulfate level;
CRC	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.66	-11.06	-0.52	2.15e-24	Type 2 diabetes;
CRC	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.48	8.14	0.41	7.98e-15	Common traits (Other);
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.35	-0.42	1.9e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.32	5.66	0.3	3.37e-8	Heart rate;
CRC	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.48	-7.14	-0.37	5.92e-12	Subjective well-being;
CRC	cis	rs4731207	0.596	rs1600745	chr7:124585183	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.73	-9.95	-0.48	1.42e-20	Coronary artery disease;
CRC	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-1.0	-9.05	-0.45	1.24e-17	Post bronchodilator FEV1;
CRC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.44	5.74	0.3	2.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.69	-0.72	1.26e-53	Height;
CRC	cis	rs892085	0.681	rs873016	chr19:10894728	G/A	cg17710535	chr19:10819994	QTRT1	0.39	5.8	0.3	1.56e-8	Psoriasis vulgaris;Psoriasis;
CRC	cis	rs6662572	0.686	rs72677546	chr1:46577716	C/T	cg08644498	chr1:46502608	NA	0.46	7.31	0.37	2.11e-12	Blood protein levels;
CRC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.44	7.82	0.4	7.3e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.23	0.32	1.47e-9	Parkinson's disease;
CRC	cis	rs698833	0.828	rs786623	chr2:44606171	C/T	cg04920474	chr2:44395004	PPM1B	0.42	6.23	0.32	1.4e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-8.85	-0.44	5.35e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs4731207	0.724	rs35535003	chr7:124442464	A/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.91	17.77	0.7	5.22e-50	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.24	0.41	4.27e-15	Platelet count;
CRC	cis	rs6662572	0.901	rs58692133	chr1:46067269	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.7	0.3	2.6e-8	Blood protein levels;
CRC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.65	-8.97	-0.44	2.3e-17	Metabolic syndrome;
CRC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.33e-29	Prostate cancer;
CRC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.82	-0.31	1.43e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12143943	0.934	rs1563827	chr1:204579139	C/T	cg17419461	chr1:204415978	PIK3C2B	0.37	5.81	0.3	1.51e-8	Cognitive performance;
CRC	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.56	8.72	0.43	1.42e-16	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.09	0.32	3.07e-9	Bipolar disorder;
CRC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.45	6.25	0.33	1.3e-9	Red blood cell count;
CRC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.25	-0.33	1.25e-9	QT interval;
CRC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.61	9.09	0.45	9.33e-18	Morning vs. evening chronotype;
CRC	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg25834613	chr7:1915315	MAD1L1	0.4	5.92	0.31	8.25e-9	Bipolar disorder;
CRC	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg13175173	chr14:55914753	NA	-0.52	-9.94	-0.48	1.57e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg18683604	chr14:51561293	TRIM9	0.29	5.87	0.31	1.08e-8	Cancer;
CRC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.27	0.41	3.38e-15	Homoarginine levels;
CRC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.31	0.37	2.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.7	-0.3	2.73e-8	Daytime sleep phenotypes;
CRC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.41	6.43	0.33	4.42e-10	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07410086	chr14:35515858	FAM177A1	0.46	6.28	0.33	1.08e-9	Response to antipsychotic treatment;
CRC	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.01	-0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02001571	chr14:50319805	SDCCAG1	-0.41	-6.0	-0.31	5.32e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.55	-0.38	4.4e-13	Endometrial cancer;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.41	5.77	0.3	1.81e-8	Breast cancer;
CRC	cis	rs995000	0.931	rs2366638	chr1:63099577	G/A	cg19896129	chr1:63156450	NA	0.41	6.41	0.33	5.18e-10	Triglyceride levels;
CRC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg24550644	chr17:30846204	MYO1D	-0.35	-5.69	-0.3	2.81e-8	Schizophrenia;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00137828	chr10:105881754	C10orf78	0.39	6.2	0.32	1.69e-9	Obesity-related traits;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.51	6.93	0.36	2.23e-11	Longevity;Endometriosis;
CRC	cis	rs6662572	0.737	rs6429592	chr1:46472153	G/A	cg08644498	chr1:46502608	NA	-0.47	-7.46	-0.38	7.64e-13	Blood protein levels;
CRC	cis	rs73206853	0.698	rs56327628	chr12:111117931	A/C	cg12870014	chr12:110450643	ANKRD13A	0.78	8.0	0.4	2.15e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg15845792	chr6:28175446	NA	1.03	15.85	0.66	1.9e-42	Depression;
CRC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.37	6.02	0.31	4.78e-9	Ulcerative colitis;
CRC	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.09	0.41	1.15e-14	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11249215	chr1:110036563	CYB561D1	0.41	6.58	0.34	1.91e-10	Response to antipsychotic treatment;
CRC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21028142	chr17:79581711	NPLOC4	0.38	8.32	0.42	2.38e-15	Eye color traits;
CRC	cis	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.53	6.96	0.36	1.87e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.72	6.77	0.35	5.97e-11	Major depressive disorder;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg27615366	chr5:131592974	PDLIM4	0.33	5.77	0.3	1.8e-8	Breast cancer;
CRC	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.51	6.9	0.36	2.75e-11	Caudate activity during reward;
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg04269497	chr6:167369491	RNASET2	-0.74	-6.06	-0.32	3.72e-9	Cognitive function;
CRC	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.59	7.56	0.38	4.04e-13	Height;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.76	10.91	0.52	7.4e-24	Menarche (age at onset);
CRC	cis	rs6545883	0.524	rs4599092	chr2:61498968	T/G	cg10580144	chr2:61372316	C2orf74	-0.35	-7.81	-0.4	7.78e-14	Tuberculosis;
CRC	trans	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg17903999	chr18:56338584	MALT1	0.42	6.86	0.35	3.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg04450456	chr4:17643702	FAM184B	-0.37	-5.85	-0.31	1.19e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg15440763	chr7:158190612	PTPRN2	-0.52	-8.31	-0.42	2.58e-15	Obesity-related traits;
CRC	trans	rs783540	0.934	rs1594511	chr15:83307063	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.48	-0.34	3.4e-10	Schizophrenia;
CRC	cis	rs12519773	0.526	rs4869415	chr5:92522764	A/G	cg18783429	chr5:92414398	NA	0.29	6.13	0.32	2.58e-9	Migraine;
CRC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.9	11.41	0.53	1.21e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.55	8.87	0.44	4.67e-17	Asthma;
CRC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.78	-0.44	9.14e-17	Menarche (age at onset);
CRC	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	7.31	0.37	2.02e-12	Schizophrenia;
CRC	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.61	8.2	0.41	5.38e-15	Coronary artery disease;
CRC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.8	13.98	0.61	3.58e-35	Breast cancer;
CRC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.47	-6.88	-0.35	2.94e-11	Hemoglobin concentration;
CRC	trans	rs1642645	0.831	rs2886564	chr1:42496924	G/A	cg16926213	chr1:1841314	NA	-0.43	-6.05	-0.32	3.88e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.02	-0.36	1.31e-11	IgG glycosylation;
CRC	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.48	0.42	7.88e-16	Schizophrenia;
CRC	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.55	8.02	0.4	1.93e-14	Cancer;
CRC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg18225595	chr11:63971243	STIP1	0.54	7.05	0.36	1.04e-11	Mean platelet volume;
CRC	cis	rs17152411	0.895	rs7094381	chr10:126585848	G/A	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24125890	chr12:21654287	RECQL;GOLT1B	0.46	5.96	0.31	6.37e-9	Thyroid stimulating hormone;
CRC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.63	0.3	3.9e-8	Homoarginine levels;
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.07	-0.45	1.13e-17	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.98	-0.31	5.89e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.69	12.14	0.56	2.85e-28	Inhibitory control;
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.31	-0.37	2.1e-12	Total body bone mineral density;
CRC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg13777783	chr17:79615861	NA	0.3	5.72	0.3	2.44e-8	Eye color traits;
CRC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg12458913	chr13:53173898	NA	0.79	15.21	0.64	6.06e-40	Lewy body disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14067770	chr11:615950	IRF7	0.49	6.85	0.35	3.72e-11	Survival in pancreatic cancer;
CRC	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18252515	chr7:66147081	NA	0.4	5.9	0.31	9.26e-9	Aortic root size;
CRC	cis	rs4731207	0.596	rs1481329	chr7:124631334	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.34	-0.33	7.73e-10	Cutaneous malignant melanoma;
CRC	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.59	-0.54	2.74e-26	Colorectal cancer;
CRC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-7.08	-0.36	8.67e-12	Colorectal cancer;
CRC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.57	9.93	0.48	1.72e-20	Aortic root size;
CRC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg24253500	chr15:84953950	NA	0.38	6.01	0.31	4.96e-9	Schizophrenia;
CRC	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.49	-7.88	-0.4	4.7e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs812925	0.533	rs35507645	chr2:61396766	A/G	cg10580144	chr2:61372316	C2orf74	0.35	7.81	0.4	7.58e-14	Immature fraction of reticulocytes;
CRC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.75	-0.43	1.1e-16	Hemoglobin concentration;
CRC	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.14	0.37	6.12e-12	Diisocyanate-induced asthma;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg03395511	chr6:291903	DUSP22	-0.5	-6.85	-0.35	3.75e-11	Menopause (age at onset);
CRC	cis	rs6504622	0.818	rs3851784	chr17:45040117	C/T	cg16759221	chr17:45003025	GOSR2	-0.5	-7.66	-0.39	2.15e-13	Orofacial clefts;
CRC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg18876405	chr7:65276391	NA	-0.46	-6.34	-0.33	7.55e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06185924	chr10:27529785	ACBD5	0.41	6.87	0.35	3.13e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.48	-5.69	-0.3	2.75e-8	Coronary artery calcification;
CRC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.37	-0.33	6.47e-10	Blood metabolite levels;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg02683197	chr6:28174875	NA	0.67	9.18	0.45	4.91e-18	Cardiac Troponin-T levels;
CRC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.6	-9.78	-0.47	5.4e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11212617	1.000	rs660429	chr11:108181511	A/C	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.4	0.33	5.41e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.46	-6.6	-0.34	1.66e-10	Longevity;Endometriosis;
CRC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	14.38	0.62	1.03e-36	Body mass index (adult);
CRC	cis	rs9296095	0.607	rs10947409	chr6:33515191	G/C	cg14003231	chr6:33640908	ITPR3	0.46	7.01	0.36	1.36e-11	Platelet count;
CRC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg03152288	chr2:177042942	NA	-0.57	-7.34	-0.38	1.71e-12	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.78	0.66	3.78e-42	Intelligence (multi-trait analysis);
CRC	cis	rs9462027	0.606	rs2744959	chr6:34616654	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.29	-0.33	1.01e-9	Systemic lupus erythematosus;
CRC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.8	13.37	0.59	7.61e-33	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg11833968	chr6:79620685	NA	-0.35	-6.15	-0.32	2.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg13628971	chr7:2884303	GNA12	0.39	6.08	0.32	3.3e-9	Height;
CRC	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.52	8.74	0.43	1.18e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.37	0.38	1.35e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.72	-0.35	7.94e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.65	8.52	0.43	5.72e-16	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.47e-12	Eye color traits;
CRC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.07	0.32	3.61e-9	Renal cell carcinoma;
CRC	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg06581033	chr10:766294	NA	-0.51	-5.61	-0.3	4.23e-8	Uric acid levels;
CRC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg18288967	chr1:45987694	PRDX1	0.65	7.13	0.37	6.35e-12	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.5e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg01262667	chr19:19385393	TM6SF2	0.36	6.03	0.32	4.4e-9	Tonsillectomy;
CRC	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.93	15.84	0.66	2.1e-42	Dupuytren's disease;
CRC	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.54	7.67	0.39	1.99e-13	Response to antidepressants and depression;
CRC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	1.02	12.44	0.57	2.13e-29	Iron status biomarkers;
CRC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.51	10.74	0.51	2.85e-23	Rheumatoid arthritis;
CRC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.72	-11.91	-0.55	1.97e-27	Ear protrusion;
CRC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.64	-0.3	3.59e-8	Daytime sleep phenotypes;
CRC	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg18551225	chr6:44695536	NA	-0.4	-5.72	-0.3	2.42e-8	Total body bone mineral density;
CRC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg15147215	chr3:52552868	STAB1	-0.53	-9.26	-0.45	2.7e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs28493229	0.708	rs80003555	chr19:41160612	C/G	cg21869046	chr19:41225005	ITPKC	0.41	6.19	0.32	1.81e-9	Kawasaki disease;
CRC	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.38	-0.33	5.96e-10	Lymphocyte counts;
CRC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	trans	rs783540	0.846	rs783534	chr15:83250243	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.31	-0.33	9.14e-10	Schizophrenia;
CRC	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.09	-14.83	-0.63	1.79e-38	Exhaled nitric oxide output;
CRC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.12	-0.41	9.62e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.51	7.67	0.39	1.97e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.83	15.7	0.65	7.76e-42	Hip circumference;
CRC	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-8.2	-0.41	5.32e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.37	0.5	5.35e-22	Corneal astigmatism;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg24046110	chr8:143859143	LYNX1	0.45	7.75	0.39	1.14e-13	Urinary tract infection frequency;
CRC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.76e-9	Ulcerative colitis;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg15786705	chr6:28176104	NA	0.7	9.88	0.48	2.51e-20	Parkinson's disease;
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.22e-9	Life satisfaction;
CRC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg11070056	chr1:107600091	PRMT6	-0.4	-6.11	-0.32	2.74e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.18	-0.32	1.88e-9	Cognitive function;
CRC	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg02158880	chr13:53174818	NA	0.41	6.15	0.32	2.22e-9	Lewy body disease;
CRC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.33	-0.37	1.8e-12	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00812502	chr22:19109875	DGCR2	0.48	6.64	0.34	1.28e-10	Anxiety disorder;
CRC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.63	-0.3	3.84e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	7.8e-17	Dupuytren's disease;
CRC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg26754761	chr2:177040938	NA	-0.44	-6.62	-0.34	1.46e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15216925	chr5:179921655	CNOT6	0.38	6.36	0.33	6.83e-10	Obesity-related traits;
CRC	cis	rs7894051	0.681	rs2185747	chr10:135191460	T/G	cg20534287	chr10:135191450	PAOX	-0.88	-7.75	-0.39	1.14e-13	Lifespan;
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.76	14.12	0.61	1.01e-35	Prudent dietary pattern;
CRC	cis	rs10503871	1.000	rs10503871	chr8:30436852	A/G	cg26383811	chr8:30366931	RBPMS	-0.4	-6.52	-0.34	2.61e-10	Metabolite levels  (X-11787);
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12273811	chr6:28175739	NA	-0.72	-9.22	-0.45	3.59e-18	Depression;
CRC	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.66	-11.12	-0.52	1.31e-24	White blood cell count (basophil);
CRC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.7	7.82	0.4	7.38e-14	Vitiligo;
CRC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.48	7.37	0.38	1.42e-12	Red blood cell count;
CRC	cis	rs1555895	0.633	rs7913077	chr10:845969	T/C	cg10556349	chr10:835070	NA	-0.39	-7.6	-0.39	3.03e-13	Survival in rectal cancer;
CRC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17554472	chr22:41940697	POLR3H	-0.56	-5.76	-0.3	1.93e-8	Vitiligo;
CRC	trans	rs2303319	0.504	rs12476631	chr2:162566936	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18912574	chr7:65842487	NCRNA00174	0.4	6.88	0.35	2.94e-11	Aortic root size;
CRC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.73	11.58	0.54	3.04e-26	Tonsillectomy;
CRC	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.45	9.12	0.45	7.39e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.45	-7.69	-0.39	1.69e-13	Response to cytidine analogues (gemcitabine);
CRC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.49	6.92	0.36	2.35e-11	Schizophrenia;
CRC	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.62	8.69	0.43	1.73e-16	Arsenic metabolism;
CRC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.52	10.52	0.5	1.61e-22	Bone mineral density;
CRC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.58	8.76	0.43	1.03e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.62	9.36	0.46	1.27e-18	Methadone dose in opioid dependence;
CRC	trans	rs7800418	0.817	rs882541	chr7:26590298	C/T	cg14387656	chr2:233470847	EFHD1	0.45	6.07	0.32	3.58e-9	Cognitive function;
CRC	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg11271282	chr2:238384023	NA	0.45	5.7	0.3	2.72e-8	Prostate cancer;
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg01339444	chr6:118972232	C6orf204	0.53	6.0	0.31	5.22e-9	Diastolic blood pressure;
CRC	cis	rs7712401	0.791	rs4835897	chr5:122121504	C/G	cg18764291	chr5:122110994	SNX2	0.4	6.46	0.34	3.87e-10	Mean platelet volume;
CRC	cis	rs2811415	0.597	rs12695503	chr3:127769174	C/A	cg13719885	chr3:127795394	NA	-0.37	-5.69	-0.3	2.76e-8	Lung function (FEV1/FVC);
CRC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg03395651	chr16:88107091	BANP	0.57	7.37	0.38	1.39e-12	Menopause (age at onset);
CRC	cis	rs4750440	0.735	rs2447014	chr10:14010122	C/T	cg00551146	chr10:14014579	FRMD4A	-0.41	-6.71	-0.35	8.38e-11	Adiponectin levels;
CRC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.66	8.78	0.44	9.07e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg04731861	chr2:219085781	ARPC2	-0.32	-6.81	-0.35	4.61e-11	Colorectal cancer;
CRC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	0.98	8.0	0.4	2.12e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs954108	0.809	rs1592060	chr13:29368944	T/C	cg11788234	chr13:29393811	NA	-0.42	-6.6	-0.34	1.64e-10	Obesity-related traits;
CRC	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.74	-9.19	-0.45	4.48e-18	Iron status biomarkers;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.72	12.06	0.55	5.55e-28	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs73200209	0.744	rs58471589	chr12:116573035	A/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.06	-0.36	9.8e-12	Total body bone mineral density;
CRC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.88e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.52	-7.03	-0.36	1.19e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24536114	chr1:89448405	RBMXL1;CCBL2	-0.4	-6.28	-0.33	1.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg24011408	chr12:48396354	COL2A1	0.45	6.32	0.33	8.27e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.6	8.95	0.44	2.6e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.44	7.36	0.38	1.44e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.62	7.16	0.37	5.44e-12	Vitiligo;
CRC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18867708	chr6:26865862	GUSBL1	0.42	6.14	0.32	2.39e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17234274	0.644	rs10833964	chr11:23214853	A/T	cg05245346	chr11:23248277	NA	0.36	5.93	0.31	7.53e-9	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08798492	chr16:3070269	TNFRSF12A	0.44	7.81	0.4	7.81e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg04497992	chr16:616212	NHLRC4	0.43	6.7	0.35	8.91e-11	Height;
CRC	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.09	-0.36	8.08e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13315871	1.000	rs13317400	chr3:58408792	T/G	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.49	-10.75	-0.51	2.71e-23	Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs16852403	0.583	rs4440820	chr1:178088698	T/C	cg00404053	chr1:178313656	RASAL2	0.6	7.71	0.39	1.48e-13	Childhood ear infection;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15716185	chr18:60190644	ZCCHC2	0.46	6.22	0.32	1.5e-9	Thyroid stimulating hormone;
CRC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.73	-0.3	2.24e-8	Gout;Renal underexcretion gout;
CRC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.61	6.6	0.34	1.6e-10	Initial pursuit acceleration;
CRC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.44	7.19	0.37	4.31e-12	Tumor biomarkers;
CRC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.63	-8.43	-0.42	1.12e-15	Gestational age at birth (maternal effect);
CRC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.75	12.51	0.57	1.2e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-5.68	-0.3	3.02e-8	Alzheimer's disease (survival time);
CRC	cis	rs11212617	0.967	rs172895	chr11:108265876	C/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.45	0.34	3.92e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02670133	chr5:65440111	SFRS12	0.4	6.22	0.32	1.53e-9	Interleukin-6 levels;
CRC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg07636037	chr3:49044803	WDR6	-0.86	-6.08	-0.32	3.37e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.32	0.33	8.64e-10	Life satisfaction;
CRC	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.77	12.41	0.56	2.91e-29	Height;
CRC	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.63	6.45	0.33	4.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	12.32	0.56	6.09e-29	Platelet count;
CRC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.41	-7.24	-0.37	3.2e-12	Schizophrenia;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg26155979	chr10:105110866	PCGF6	-0.5	-6.15	-0.32	2.27e-9	Lung adenocarcinoma;
CRC	cis	rs9925964	1.000	rs9925964	chr16:31129895	A/G	cg10396673	chr16:31104726	VKORC1	0.34	5.62	0.3	4.05e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.56	-0.43	4.43e-16	Hemoglobin concentration;
CRC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.81	8.56	0.43	4.31e-16	Plasma clusterin levels;
CRC	trans	rs10021731	0.718	rs7698790	chr4:115413803	C/T	cg25927708	chr2:119603813	EN1	0.33	6.01	0.31	4.98e-9	Optic disc area;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15133363	chr7:128096265	C7orf68	0.44	6.2	0.32	1.66e-9	Response to antipsychotic treatment;
CRC	cis	rs3020333	0.653	rs851985	chr6:152020390	G/T	cg22157087	chr6:152012887	ESR1	-0.5	-7.59	-0.39	3.23e-13	Total body bone mineral density;
CRC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	1.0	18.93	0.72	1.43e-54	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	16.55	0.67	3.38e-45	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.86	0.4	5.53e-14	Motion sickness;
CRC	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg11752769	chr1:207818423	CR1L	-0.57	-5.68	-0.3	2.96e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
CRC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.76	0.51	2.5e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.47	6.91	0.36	2.59e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs7178572	0.633	rs12907746	chr15:77843326	A/G	cg22256960	chr15:77711686	NA	-0.65	-9.27	-0.46	2.47e-18	Type 2 diabetes;
CRC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.7	-9.88	-0.48	2.56e-20	Pancreatic cancer;
CRC	cis	rs7804356	1.000	rs10486485	chr7:26900356	C/A	cg03456212	chr7:26904342	SKAP2	-0.5	-5.74	-0.3	2.17e-8	Type 1 diabetes;
CRC	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.58	6.84	0.35	3.9e-11	Neutrophil percentage of white cells;
CRC	cis	rs4654899	0.931	rs4654727	chr1:21214735	C/T	cg02927042	chr1:21476669	EIF4G3	0.41	6.5	0.34	3.06e-10	Superior frontal gyrus grey matter volume;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01362921	chr17:5015082	ZNF232	-0.41	-6.01	-0.31	4.9e-9	Daytime sleep phenotypes;
CRC	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.58	7.55	0.38	4.25e-13	Body mass index;
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg16606324	chr3:10149918	C3orf24	0.68	9.31	0.46	1.85e-18	Alzheimer's disease;
CRC	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.47	7.5	0.38	5.81e-13	Schizophrenia;
CRC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.91	12.83	0.58	8.2e-31	Orofacial clefts;
CRC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg03623178	chr6:28175578	NA	0.78	6.65	0.34	1.22e-10	Depression;
CRC	cis	rs9322817	0.902	rs963949	chr6:105174273	A/G	cg02098413	chr6:105308735	HACE1	-0.37	-6.67	-0.35	1.09e-10	Thyroid stimulating hormone;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg22902534	chr3:183892754	AP2M1	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06656553	chr16:89960601	TCF25	-0.65	-5.89	-0.31	9.76e-9	Skin colour saturation;
CRC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.62	8.87	0.44	4.65e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.44	-6.64	-0.34	1.29e-10	Blood metabolite levels;
CRC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.96	-0.44	2.42e-17	Bone mineral density;
CRC	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-7.33	-0.37	1.82e-12	Response to antipsychotic treatment;
CRC	cis	rs6973256	0.897	rs1041621	chr7:133353965	A/G	cg10665199	chr7:133106180	EXOC4	0.37	5.88	0.31	9.92e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg20356878	chr3:121714668	ILDR1	0.52	8.08	0.41	1.25e-14	Cognitive performance;
CRC	cis	rs10971721	0.822	rs10971791	chr9:33920910	G/C	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs73206853	0.563	rs74869743	chr12:111204031	T/C	cg12870014	chr12:110450643	ANKRD13A	0.71	8.08	0.41	1.25e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg02321871	chr13:50159138	RCBTB1	-0.42	-6.08	-0.32	3.34e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs457287	1.000	rs7048839	chr9:4835444	T/G	cg14182974	chr9:4791918	RCL1	0.43	6.51	0.34	2.75e-10	Platelet count;
CRC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.12	-0.37	7.02e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.39	6.19	0.32	1.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.83	0.44	6.18e-17	Total body bone mineral density;
CRC	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.92	-0.36	2.34e-11	Neuroticism;
CRC	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.34	-7.84	-0.4	6.33e-14	Corneal astigmatism;
CRC	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01084379	chr5:179160712	MAML1	0.41	6.5	0.34	2.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-6.0	-0.31	5.09e-9	Total body bone mineral density;
CRC	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.95	-17.32	-0.69	3.07e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9463078	0.845	rs6458419	chr6:45085038	T/C	cg25276700	chr6:44698697	NA	-0.29	-6.81	-0.35	4.6e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs990171	1.000	rs990171	chr2:103086770	A/C	cg03938978	chr2:103052716	IL18RAP	0.45	5.67	0.3	3.09e-8	Lymphocyte counts;
CRC	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg17145862	chr1:211918768	LPGAT1	-0.49	-8.14	-0.41	8.12e-15	Leprosy;
CRC	trans	rs6693295	0.729	rs10802325	chr1:246213454	C/A	cg08881680	chr11:94965469	SESN3	0.49	6.02	0.31	4.7e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.82	14.6	0.63	1.49e-37	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.12	0.41	9.2e-15	Menopause (age at onset);
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	5.1e-12	Life satisfaction;
CRC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.46	-7.7	-0.39	1.6e-13	Age at first birth;
CRC	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.39	0.33	5.69e-10	Blood protein levels;
CRC	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.54	-9.55	-0.47	3.08e-19	Lung function (FVC);
CRC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.41	-6.9	-0.36	2.7e-11	Mean platelet volume;
CRC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.33	-5.6	-0.3	4.44e-8	Childhood ear infection;
CRC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.47	8.16	0.41	7.34e-15	Systemic lupus erythematosus;
CRC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.83	-12.83	-0.58	7.83e-31	Glomerular filtration rate (creatinine);
CRC	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg11693508	chr17:37793320	STARD3	0.67	7.86	0.4	5.51e-14	Bipolar disorder;
CRC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21659725	chr3:3221576	CRBN	-0.63	-8.55	-0.43	4.61e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10046574	0.908	rs28418917	chr7:135124905	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05301818	chr8:125385252	TMEM65	0.4	5.97	0.31	6.17e-9	Myopia (pathological);
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg18653534	chr16:772142	FAM173A	-0.37	-5.87	-0.31	1.06e-8	Height;
CRC	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.48	8.19	0.41	5.74e-15	Testicular germ cell tumor;
CRC	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.35	0.53	2e-25	Height;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg26856583	chr16:87425887	MAP1LC3B;FBXO31	-0.53	-6.6	-0.34	1.6e-10	Diisocyanate-induced asthma;
CRC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.42	-8.78	-0.44	9.16e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.69	0.39	1.77e-13	Mean platelet volume;
CRC	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.14e-9	Hair morphology;
CRC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.14	0.45	6.68e-18	Cognitive test performance;
CRC	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.84	-0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.21	-0.37	3.89e-12	Hemoglobin concentration;
CRC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.06	-0.49	6.19e-21	Height;
CRC	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg27053337	chr8:124217698	FAM83A	0.41	5.63	0.3	3.93e-8	Urinary uromodulin levels;
CRC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	8.23	0.41	4.39e-15	Aortic root size;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg12273811	chr6:28175739	NA	-0.51	-7.32	-0.37	1.95e-12	Parkinson's disease;
CRC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.67	-11.87	-0.55	2.65e-27	Mean corpuscular volume;
CRC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.71	-9.87	-0.48	2.79e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg16540259	chr10:75572220	NDST2	0.38	6.13	0.32	2.54e-9	Inflammatory bowel disease;
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg20119798	chr7:94954144	PON1	-0.49	-6.17	-0.32	2.01e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg25985355	chr7:65971099	NA	0.51	6.02	0.32	4.65e-9	Diabetic kidney disease;
CRC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.39	-0.38	1.25e-12	Headache;
CRC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.76	-0.35	6.21e-11	Mean platelet volume;
CRC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.58	-0.43	3.7e-16	Aortic root size;
CRC	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.36	-6.49	-0.34	3.21e-10	Breast cancer;
CRC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg12935359	chr14:103987150	CKB	-0.37	-6.14	-0.32	2.44e-9	Body mass index;
CRC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-9.35	-0.46	1.34e-18	Menarche (age at onset);
CRC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.62	-11.75	-0.54	7.66e-27	Educational attainment;
CRC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.44	0.33	4.33e-10	Diabetic kidney disease;
CRC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.55	7.94	0.4	3.16e-14	Pancreatic cancer;
CRC	cis	rs72772090	0.539	rs72773986	chr5:96159717	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-5.66	-0.3	3.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.73	-12.78	-0.58	1.24e-30	Mean platelet volume;
CRC	cis	rs9900062	0.586	rs6504249	chr17:62676149	A/G	cg02598441	chr17:62777298	LOC146880	-0.53	-6.77	-0.35	5.81e-11	QT interval;
CRC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.65	-8.83	-0.44	6.24e-17	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.6	-0.3	4.43e-8	Reticulocyte count;
CRC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.69	-8.7	-0.43	1.66e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg10298567	chr3:47292165	KIF9	0.4	6.25	0.33	1.3e-9	Colorectal cancer;
CRC	cis	rs12023718	0.588	rs6674606	chr1:178599017	T/C	cg00404053	chr1:178313656	RASAL2	0.59	7.07	0.36	9.37e-12	Obesity-related traits;
CRC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-6.59	-0.34	1.71e-10	Cognitive test performance;
CRC	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg15123519	chr2:136567270	LCT	-0.35	-6.75	-0.35	6.67e-11	Mosquito bite size;
CRC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg21153622	chr11:89784906	NA	0.4	6.49	0.34	3.14e-10	Height;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg23161317	chr6:28129485	ZNF389	0.44	6.13	0.32	2.57e-9	Parkinson's disease;
CRC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.2	-16.29	-0.67	3.63e-44	Breast cancer;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.1	-0.32	2.97e-9	Total body bone mineral density;
CRC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.94	-0.48	1.61e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.95	0.44	2.75e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs375066	0.870	rs7258418	chr19:44383083	G/C	cg12072164	chr19:44306565	LYPD5	0.37	5.74	0.3	2.18e-8	Breast cancer;
CRC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.74	10.67	0.51	5.16e-23	High light scatter reticulocyte count;
CRC	trans	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg24644049	chr4:85504048	CDS1	0.89	6.68	0.35	1.01e-10	Skin colour saturation;
CRC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.5	-0.38	5.82e-13	Aortic root size;
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.79	9.65	0.47	1.4e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13798912	chr7:905769	UNC84A	0.54	6.18	0.32	1.93e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.24	11.46	0.53	8.41e-26	Alzheimer's disease (late onset);
CRC	trans	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg26043149	chr18:55253948	FECH	-0.51	-8.09	-0.41	1.18e-14	Bone mineral density;
CRC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.78	9.74	0.47	7.53e-20	Body mass index;
CRC	trans	rs6479874	0.510	rs2248908	chr10:52750665	C/T	cg15483030	chr1:5935144	NPHP4	-0.69	-6.23	-0.32	1.43e-9	Migraine;
CRC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.17	-0.69	1.29e-47	Coronary artery disease;
CRC	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg27395922	chr11:50257633	LOC441601	0.49	6.11	0.32	2.8e-9	Intraocular pressure;
CRC	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.74	-16.42	-0.67	1.09e-44	Intelligence (multi-trait analysis);
CRC	trans	rs6956675	0.915	rs1608134	chr7:62653607	A/C	cg01314568	chr7:57830625	NA	-0.6	-8.97	-0.44	2.37e-17	Obesity-related traits;
CRC	cis	rs9810259	0.522	rs9875338	chr3:12296469	A/G	cg04748988	chr3:12329223	PPARG	0.4	6.1	0.32	3.05e-9	Platelet count;
CRC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg23625390	chr15:77176239	SCAPER	0.39	5.65	0.3	3.44e-8	Blood metabolite levels;
CRC	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	15.43	0.65	8.47e-41	Subcortical brain region volumes;Putamen volume;
CRC	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.63	8.26	0.41	3.58e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.81	14.36	0.62	1.19e-36	Anterior chamber depth;
CRC	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.54	-6.07	-0.32	3.44e-9	Type 2 diabetes;
CRC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg10298567	chr3:47292165	KIF9	0.39	6.19	0.32	1.81e-9	Colorectal cancer;
CRC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg01788221	chr16:89496183	ANKRD11	-0.42	-6.34	-0.33	7.49e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.42	6.54	0.34	2.36e-10	Dupuytren's disease;
CRC	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.51	8.14	0.41	8.32e-15	Migraine;
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg20041105	chr8:143859282	LYNX1	0.46	8.31	0.42	2.48e-15	Urinary tract infection frequency;
CRC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.03	-22.54	-0.78	1.1e-68	Myeloid white cell count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24170415	chr4:185747632	ACSL1	0.48	6.27	0.33	1.12e-9	Thyroid stimulating hormone;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg11503833	chr11:492997	NA	0.56	5.89	0.31	9.64e-9	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07025548	chr5:74632477	HMGCR	0.44	7.13	0.37	6.27e-12	Obesity-related traits;
CRC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg25767906	chr1:53392781	SCP2	-0.36	-5.75	-0.3	2.05e-8	Monocyte count;
CRC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.54	-0.38	4.67e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6804368	0.649	rs7647948	chr3:30760602	C/T	cg06106510	chr3:30762233	NA	0.41	7.46	0.38	7.59e-13	Blood metabolite levels;
CRC	cis	rs11212617	1.000	rs609261	chr11:108158134	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.04e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11673344	0.583	rs10421436	chr19:37885503	T/C	cg11720556	chr19:37764088	NA	-0.41	-5.85	-0.31	1.17e-8	Obesity-related traits;
CRC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.86	13.91	0.61	6.45e-35	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22015966	chr11:47198573	ARFGAP2	-0.37	-6.2	-0.32	1.7e-9	Myopia (pathological);
CRC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.4	5.87	0.31	1.08e-8	Obesity-related traits;
CRC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.66	9.38	0.46	1.12e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.54	8.14	0.41	8.27e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg24046110	chr8:143859143	LYNX1	0.45	7.75	0.39	1.17e-13	Urinary tract infection frequency;
CRC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.33	-5.6	-0.3	4.44e-8	Childhood ear infection;
CRC	trans	rs783540	0.900	rs55924160	chr15:83282196	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.39	-0.38	1.25e-12	Schizophrenia;
CRC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.47	0.38	7.15e-13	Height;
CRC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg19318889	chr4:1322082	MAEA	0.39	5.85	0.31	1.17e-8	Longevity;
CRC	cis	rs3789045	0.688	rs6668637	chr1:204452295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.61	-8.51	-0.42	6.26e-16	Educational attainment (college completion);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03923535	chr7:1197113	ZFAND2A	0.68	10.26	0.49	1.31e-21	Longevity;Endometriosis;
CRC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg25985355	chr7:65971099	NA	-0.32	-5.62	-0.3	3.97e-8	Aortic root size;
CRC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs62408225	1.000	rs1504215	chr6:91006227	G/A	cg06866423	chr6:90926672	BACH2	0.5	8.12	0.41	9.66e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg08071915	chr8:12219732	FAM66A	0.32	5.74	0.3	2.13e-8	Retinal vascular caliber;
CRC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	11.46	0.53	7.95e-26	Tonsillectomy;
CRC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.24	-0.33	1.33e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.4	7.52	0.38	5.14e-13	Alcohol dependence;
CRC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.58	10.65	0.51	6.08e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg07979401	chr6:33739406	LEMD2	-0.46	-5.98	-0.31	5.7e-9	Schizophrenia;
CRC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg03623178	chr6:28175578	NA	-0.67	-7.39	-0.38	1.23e-12	Depression;
CRC	trans	rs783540	1.000	rs783540	chr15:83254708	C/T	cg18393722	chr15:85113863	UBE2QP1	0.36	6.51	0.34	2.75e-10	Schizophrenia;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.17	-0.37	5.01e-12	Breast cancer;
CRC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.89	-0.36	2.78e-11	Colorectal cancer;
CRC	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.53	7.86	0.4	5.62e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.61	8.96	0.44	2.53e-17	Corneal astigmatism;
CRC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.8	-12.38	-0.56	3.66e-29	Cognitive function;
CRC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg18827107	chr12:86230957	RASSF9	-0.41	-6.23	-0.32	1.42e-9	Major depressive disorder;
CRC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg11710851	chr12:130765858	NA	-0.41	-5.77	-0.3	1.83e-8	Menopause (age at onset);
CRC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg23625390	chr15:77176239	SCAPER	-0.68	-9.64	-0.47	1.54e-19	Blood metabolite levels;
CRC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg19680485	chr15:31195859	MTMR15	0.47	6.6	0.34	1.68e-10	Huntington's disease progression;
CRC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.69	-0.35	9.64e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.49	-7.11	-0.37	7.12e-12	White blood cell count;
CRC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.71	9.89	0.48	2.3e-20	Platelet count;
CRC	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.52	-8.49	-0.42	7.22e-16	Menarche (age at onset);
CRC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.25	-0.37	3.08e-12	Systolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22074242	chr16:4321640	TFAP4	0.42	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-10.03	-0.48	7.68e-21	Dental caries;
CRC	cis	rs6499255	0.951	rs11075728	chr16:69611582	A/G	cg15192750	chr16:69999425	NA	0.59	7.79	0.39	8.66e-14	IgE levels;
CRC	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.51	-7.12	-0.37	6.94e-12	Iron status biomarkers;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg19041857	chr6:27730383	NA	-0.62	-6.77	-0.35	6.1e-11	Lung cancer in ever smokers;
CRC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-7.12	-0.37	6.9e-12	Pulmonary function;
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	1.0	10.88	0.51	9.64e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg00343986	chr7:65444356	GUSB	0.49	7.15	0.37	5.6e-12	Aortic root size;
CRC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.81e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.73	0.35	7.42e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	5.96	0.31	6.47e-9	Asthma;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12273811	chr6:28175739	NA	0.62	9.07	0.45	1.1e-17	Cardiac Troponin-T levels;
CRC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	8.21	0.41	5.23e-15	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg16964102	chr10:135390573	NA	-0.49	-6.82	-0.35	4.41e-11	Gout;
CRC	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	trans	rs2303319	0.504	rs56145818	chr2:162403778	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.64	9.09	0.45	9.47e-18	Body mass index;
CRC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.65	-0.3	3.39e-8	Type 2 diabetes;
CRC	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg03929089	chr4:120376271	NA	-0.58	-6.76	-0.35	6.34e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg23293999	chr7:106826042	HBP1	-0.49	-5.66	-0.3	3.33e-8	Coronary artery disease;
CRC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg07809909	chr20:30433512	FOXS1	0.35	5.7	0.3	2.6e-8	Mean corpuscular hemoglobin;
CRC	cis	rs17155006	0.691	rs413412	chr7:107745399	A/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.32	-0.37	1.93e-12	Pneumococcal bacteremia;
CRC	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg10437265	chr15:77819839	NA	0.64	11.52	0.54	4.83e-26	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16572859	chr19:18263815	PIK3R2	0.38	6.03	0.32	4.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	8.02	0.4	1.81e-14	Schizophrenia;
CRC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg01262667	chr19:19385393	TM6SF2	0.37	6.17	0.32	2.05e-9	Tonsillectomy;
CRC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-17.19	-0.69	1.03e-47	Height;
CRC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.72	-11.81	-0.55	4.67e-27	Height;
CRC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	cis	rs10804591	0.666	rs13079843	chr3:129308096	G/A	cg21885638	chr3:129306552	PLXND1	0.4	5.96	0.31	6.41e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg05527609	chr1:210001259	C1orf107	-0.56	-6.21	-0.32	1.56e-9	Red blood cell count;
CRC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.55	0.43	4.74e-16	Schizophrenia;
CRC	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.57	-0.34	1.98e-10	Subjective well-being;
CRC	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg00042356	chr1:8021962	PARK7	0.71	7.83	0.4	6.78e-14	Inflammatory bowel disease;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg02683197	chr6:28174875	NA	0.64	8.9	0.44	3.89e-17	Cardiac Troponin-T levels;
CRC	cis	rs12476592	0.602	rs2592388	chr2:63896096	A/C	cg10828910	chr2:63850056	LOC388955	0.52	6.44	0.33	4.3e-10	Childhood ear infection;
CRC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.64	11.34	0.53	2.24e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.82	12.72	0.57	2.09e-30	Blood metabolite levels;
CRC	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.58	8.44	0.42	1.01e-15	Autism;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.46	6.02	0.32	4.61e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg17948913	chr5:572064	NA	0.55	6.25	0.33	1.29e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg06781209	chr11:61594997	FADS2	-0.39	-5.73	-0.3	2.25e-8	Trans fatty acid levels;
CRC	cis	rs2223471	0.754	rs2817361	chr6:50771563	C/T	cg03432817	chr6:50765336	NA	0.43	6.93	0.36	2.24e-11	Subcutaneous adipose tissue;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20566420	chr12:122327043	PSMD9	0.49	6.97	0.36	1.79e-11	Response to antipsychotic treatment;
CRC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.38	-5.78	-0.3	1.72e-8	Platelet count;
CRC	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.6	-7.07	-0.36	9.15e-12	Dental caries;
CRC	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg04202892	chr2:111875749	ACOXL	0.43	6.89	0.36	2.84e-11	Chronic lymphocytic leukemia;
CRC	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg04176472	chr15:90893244	GABARAPL3	0.36	6.29	0.33	9.98e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.58	-9.16	-0.45	5.85e-18	Type 2 diabetes;
CRC	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.48	-8.78	-0.44	8.87e-17	Hip circumference;Waist circumference;
CRC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg01483505	chr11:975446	AP2A2	0.45	7.39	0.38	1.21e-12	Alzheimer's disease (late onset);
CRC	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.23	-6.1	-0.32	2.94e-9	Type 2 diabetes;
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg10729496	chr3:10149963	C3orf24	0.58	6.59	0.34	1.74e-10	Alzheimer's disease;
CRC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.57	-9.14	-0.45	6.69e-18	Intelligence (multi-trait analysis);
CRC	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.95	-13.35	-0.59	8.39e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg06238570	chr21:40685208	BRWD1	0.71	10.11	0.49	4.09e-21	Cognitive function;
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.89	0.36	2.77e-11	Diastolic blood pressure;
CRC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg00166722	chr3:10149974	C3orf24	0.43	6.36	0.33	6.73e-10	Alzheimer's disease;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12273811	chr6:28175739	NA	0.62	8.29	0.42	2.87e-15	Parkinson's disease;
CRC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg19678392	chr7:94953810	PON1	-0.53	-6.67	-0.35	1.08e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.78	-0.44	9.24e-17	Aortic root size;
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.41	-7.34	-0.38	1.69e-12	Blood metabolite levels;
CRC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.4	0.56	3.13e-29	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	5.88e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg05569086	chr8:143859399	LYNX1	-0.34	-5.93	-0.31	7.5e-9	Urinary tract infection frequency;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04718306	chr1:68151105	GADD45A	0.41	6.12	0.32	2.63e-9	Intelligence (multi-trait analysis);
CRC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-5.99	-0.31	5.44e-9	Eosinophil percentage of white cells;
CRC	cis	rs10242455	0.702	rs59574285	chr7:99236151	C/T	cg18809830	chr7:99032528	PTCD1	-1.04	-7.34	-0.38	1.68e-12	Blood metabolite levels;
CRC	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.46	-0.34	3.86e-10	Subjective well-being;
CRC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.63	-8.02	-0.4	1.91e-14	Mean platelet volume;
CRC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.4	-0.33	5.21e-10	Aortic root size;
CRC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.58	7.14	0.37	6.02e-12	Mean platelet volume;
CRC	cis	rs7113874	0.569	rs10160430	chr11:8599876	G/T	cg02811074	chr11:8615871	STK33	0.35	6.04	0.32	4.21e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg21399703	chr1:247681439	NA	-0.53	-9.84	-0.48	3.35e-20	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs800082	0.507	rs2222701	chr3:144258813	C/T	cg24215973	chr2:240111563	HDAC4	0.44	6.19	0.32	1.82e-9	Smoking behavior;
CRC	cis	rs11255291	0.668	rs4749169	chr10:7737661	G/C	cg13340899	chr10:7670827	ITIH5	0.39	5.72	0.3	2.33e-8	Ovarian reserve;
CRC	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.71	0.43	1.49e-16	Mean corpuscular volume;
CRC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg00495681	chr13:53174319	NA	0.56	8.05	0.41	1.54e-14	Lewy body disease;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.69	-0.35	9.34e-11	Breast cancer;
CRC	cis	rs860295	0.702	rs10796945	chr1:155427688	G/A	cg02153340	chr1:155202674	NA	-0.53	-7.01	-0.36	1.36e-11	Body mass index;
CRC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.39	5.72	0.3	2.41e-8	Educational attainment;
CRC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00339695	chr16:24857497	SLC5A11	0.32	6.47	0.34	3.57e-10	Intelligence (multi-trait analysis);
CRC	trans	rs783540	0.934	rs8043401	chr15:83356259	A/G	cg18393722	chr15:85113863	UBE2QP1	0.36	6.24	0.33	1.36e-9	Schizophrenia;
CRC	cis	rs4731207	0.596	rs1871771	chr7:124679051	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg10483660	chr13:112241077	NA	0.35	5.65	0.3	3.57e-8	Menarche (age at onset);
CRC	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg25834613	chr7:1915315	MAD1L1	-0.5	-7.85	-0.4	6.08e-14	Bipolar disorder;
CRC	cis	rs4731207	0.698	rs2286173	chr7:124465951	A/C	cg23710748	chr7:124431027	NA	0.37	5.93	0.31	7.72e-9	Cutaneous malignant melanoma;
CRC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.52	7.52	0.38	5.41e-13	Uric acid levels;
CRC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.46	0.42	8.76e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs11233250	0.528	rs58791004	chr11:82402167	C/T	cg17391194	chr11:82401662	NA	0.44	6.73	0.35	7.69e-11	Glioblastoma;Glioma;
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14533885	chr3:146262700	PLSCR1	0.4	6.01	0.31	4.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg15465823	chr12:48382534	COL2A1	-0.39	-6.34	-0.33	7.48e-10	Glycated hemoglobin levels;
CRC	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.87	-0.31	1.06e-8	Alcohol dependence;
CRC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg21665744	chr7:39171113	POU6F2	0.45	5.96	0.31	6.67e-9	IgG glycosylation;
CRC	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.47	-6.34	-0.33	7.66e-10	Adiposity;
CRC	cis	rs12780046	0.536	rs1892507	chr10:101082348	G/A	cg26459859	chr10:101118273	CNNM1	-0.46	-6.34	-0.33	7.68e-10	Non-glioblastoma glioma;
CRC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg20933634	chr6:27740509	NA	0.56	7.74	0.39	1.26e-13	Parkinson's disease;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.6	-9.38	-0.46	1.13e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11645453	chr3:52864694	ITIH4	0.37	6.51	0.34	2.83e-10	Bipolar disorder;
CRC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.2	0.41	5.31e-15	Rheumatoid arthritis;
CRC	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.58	-9.41	-0.46	8.73e-19	Myopia (pathological);
CRC	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.36	0.42	1.79e-15	Arsenic metabolism;
CRC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.68	11.36	0.53	1.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10155981	0.510	rs4719705	chr7:22592707	C/T	cg05062323	chr7:22590069	NA	-0.56	-5.85	-0.31	1.16e-8	Bilirubin levels;
CRC	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.38	-5.77	-0.3	1.87e-8	Obesity;
CRC	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg04111992	chr7:158790115	NA	-0.39	-6.36	-0.33	6.88e-10	Facial morphology (factor 20);
CRC	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg00852783	chr1:26633632	UBXN11	-0.49	-5.81	-0.31	1.45e-8	Obesity-related traits;
CRC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-15.56	-0.65	2.56e-41	Prostate cancer;
CRC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.5	-0.42	6.59e-16	Monocyte count;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23161317	chr6:28129485	ZNF389	-0.48	-6.12	-0.32	2.63e-9	Parkinson's disease;
CRC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-7.36	-0.38	1.51e-12	Schizophrenia;
CRC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.52	8.66	0.43	2.13e-16	Systemic lupus erythematosus;
CRC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg24879335	chr3:133465180	TF	0.33	5.78	0.3	1.71e-8	Iron status biomarkers;
CRC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg24011408	chr12:48396354	COL2A1	0.46	6.35	0.33	7.23e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	8.0	0.4	2.16e-14	Schizophrenia;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.53	6.11	0.32	2.81e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.11	-0.32	2.89e-9	Depression;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.55	-0.38	4.37e-13	Breast cancer;
CRC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.49	8.09	0.41	1.16e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.52	0.46	3.82e-19	Corneal astigmatism;
CRC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-11.43	-0.53	1.09e-25	Asthma;
CRC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.89	9.65	0.47	1.5e-19	Skin colour saturation;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg02033258	chr5:131593261	PDLIM4	-0.39	-6.76	-0.35	6.12e-11	Breast cancer;
CRC	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.43	6.9	0.36	2.64e-11	Sitting height ratio;
CRC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.72	9.18	0.45	4.77e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12760731	0.720	rs12741848	chr1:178334941	A/G	cg00404053	chr1:178313656	RASAL2	0.9	10.59	0.5	9.85e-23	Obesity-related traits;
CRC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.4	-5.91	-0.31	8.73e-9	Primary biliary cholangitis;
CRC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.59	0.39	3.33e-13	Lymphocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg26587870	chr6:27730563	NA	-0.6	-5.98	-0.31	5.78e-9	Breast cancer;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg24560729	chr4:1342394	KIAA1530	0.43	7.84	0.4	6.44e-14	Longevity;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg20933634	chr6:27740509	NA	0.43	6.37	0.33	6.55e-10	Parkinson's disease;
CRC	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg21095983	chr6:86352623	SYNCRIP	0.56	8.07	0.41	1.35e-14	Smooth-surface caries;
CRC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-9.98	-0.48	1.14e-20	Coronary artery disease;
CRC	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg06917450	chr1:38156652	C1orf109	-0.5	-7.07	-0.36	9.37e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.78	12.0	0.55	9.33e-28	Menarche (age at onset);
CRC	cis	rs17152411	1.000	rs2241541	chr10:126671673	T/C	cg07906193	chr10:126599966	NA	0.63	6.82	0.35	4.46e-11	Height;
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg23260525	chr10:116636907	FAM160B1	0.31	6.82	0.35	4.38e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21659725	chr3:3221576	CRBN	0.46	6.63	0.34	1.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.62	9.6	0.47	2.12e-19	Corneal astigmatism;
CRC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.69	8.75	0.43	1.15e-16	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7605827	0.897	rs6745917	chr2:15537924	G/C	cg19274914	chr2:15703543	NA	0.4	5.98	0.31	5.84e-9	Educational attainment (years of education);
CRC	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20115266	chr19:51416517	NA	-0.4	-6.0	-0.31	5.18e-9	Energy expenditure (24h);
CRC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	9.06	0.45	1.22e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg25767906	chr1:53392781	SCP2	0.47	7.48	0.38	6.61e-13	Monocyte count;
CRC	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.84	9.9	0.48	2.17e-20	Obesity-related traits;
CRC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.23e-13	Bladder cancer;
CRC	cis	rs12024301	0.557	rs114491252	chr1:183605243	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7487075	0.780	rs12296120	chr12:46737591	G/A	cg07601320	chr12:47219841	SLC38A4	0.28	5.78	0.3	1.77e-8	Itch intensity from mosquito bite;
CRC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.02	-0.32	4.64e-9	Diabetic kidney disease;
CRC	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.24	-0.41	4.05e-15	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs35000415	0.745	rs117473643	chr7:128698186	G/C	cg19972273	chr7:128594194	NA	0.71	6.15	0.32	2.2e-9	Systemic lupus erythematosus;
CRC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.97	-0.36	1.7e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg10876282	chr6:28092338	ZSCAN16	0.47	6.4	0.33	5.35e-10	Parkinson's disease;
CRC	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.73e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg24209194	chr3:40518798	ZNF619	-0.4	-5.93	-0.31	7.86e-9	Renal cell carcinoma;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg11843238	chr5:131593191	PDLIM4	0.49	9.31	0.46	1.86e-18	Acylcarnitine levels;
CRC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.75	-9.78	-0.47	5.18e-20	Initial pursuit acceleration;
CRC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.77	-8.04	-0.41	1.69e-14	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.32	6.34	0.33	7.63e-10	Lung cancer;
CRC	trans	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.68	-12.3	-0.56	7.58e-29	Hip circumference;
CRC	cis	rs1223397	0.651	rs202017	chr6:13301051	C/G	cg07912922	chr6:13274314	PHACTR1	0.37	5.71	0.3	2.53e-8	Blood pressure;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-7.56	-0.38	4.12e-13	Total body bone mineral density;
CRC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-6.72	-0.35	8.04e-11	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.66	9.44	0.46	6.83e-19	Alzheimer's disease;
CRC	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	7.35	0.38	1.54e-12	Blood protein levels;
CRC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.8	-13.28	-0.59	1.68e-32	Obesity-related traits;
CRC	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.58	7.32	0.37	1.9e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.52	9.31	0.46	1.85e-18	Common traits (Other);
CRC	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg00129232	chr17:37814104	STARD3	-0.6	-6.58	-0.34	1.9e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13490635	chr8:30242021	RBPMS	0.46	6.74	0.35	7.01e-11	Response to antipsychotic treatment;
CRC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.56	-7.27	-0.37	2.6e-12	Body mass index;
CRC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.59	9.15	0.45	5.93e-18	Height;
CRC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.72	-12.86	-0.58	6.04e-31	Educational attainment;
CRC	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.5	6.34	0.33	7.74e-10	Alzheimer's disease (survival time);
CRC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.58	0.47	2.43e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9649465	0.967	rs12538876	chr7:123296320	C/A	cg03229431	chr7:123269106	ASB15	-0.37	-5.61	-0.3	4.36e-8	Migraine;
CRC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	trans	rs9914544	0.545	rs68046274	chr17:18785126	G/A	cg21372672	chr17:16614065	CCDC144A	-0.38	-5.98	-0.31	5.67e-9	Educational attainment (years of education);
CRC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.22	-0.37	3.69e-12	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13580471	chr1:104068704	RNPC3	0.43	6.0	0.31	5.14e-9	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.5	7.39	0.38	1.24e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06382698	chr2:54015232	LOC100302652;ERLEC1;ASB3	0.45	6.6	0.34	1.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.59	10.51	0.5	1.79e-22	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23137483	chr22:41682341	RANGAP1	0.46	6.01	0.31	5.03e-9	Anxiety disorder;
CRC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg07617317	chr6:118971624	C6orf204	0.51	6.26	0.33	1.21e-9	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04393905	chr3:53381207	DCP1A	0.46	6.4	0.33	5.28e-10	Response to antipsychotic treatment;
CRC	cis	rs11212617	0.967	rs4987982	chr11:108151269	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.71	0.3	2.54e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.96	-0.31	6.46e-9	Lung cancer;
CRC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg06453172	chr10:134556979	INPP5A	0.49	7.63	0.39	2.51e-13	Migraine;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.39	-5.73	-0.3	2.3e-8	Pancreatic cancer;
CRC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.52	-7.93	-0.4	3.47e-14	Menarche (age at onset);
CRC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.79	10.97	0.52	4.45e-24	Cognitive function;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.99	-0.31	5.49e-9	Total body bone mineral density;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg06470822	chr6:28175283	NA	0.8	11.86	0.55	3.05e-27	Cardiac Troponin-T levels;
CRC	cis	rs939584	1.000	rs11127491	chr2:646145	T/C	cg03610516	chr2:642275	NA	0.42	5.87	0.31	1.06e-8	Body mass index;
CRC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.91	-17.91	-0.7	1.52e-50	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg03037974	chr15:76606532	NA	0.66	11.44	0.53	9.38e-26	Blood metabolite levels;
CRC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg00769240	chr8:12517080	NA	-0.56	-6.95	-0.36	1.92e-11	Blood pressure (smoking interaction);
CRC	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg23609528	chr2:113191194	RGPD5;RGPD8	0.66	5.67	0.3	3.18e-8	Yeast infection;
CRC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.48e-24	Motion sickness;
CRC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.96	-0.44	2.44e-17	Total cholesterol levels;
CRC	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.25	0.45	3.01e-18	Coffee consumption (cups per day);
CRC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.61	-9.47	-0.46	5.59e-19	Aortic root size;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.71	-0.3	2.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs3750082	0.748	rs10248427	chr7:32898969	C/G	cg05721444	chr7:32995514	FKBP9	0.49	7.63	0.39	2.57e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	10.89	0.51	8.93e-24	Bone mineral density;
CRC	cis	rs6496667	0.865	rs8043146	chr15:90850373	C/T	cg04176472	chr15:90893244	GABARAPL3	0.56	7.23	0.37	3.37e-12	Rheumatoid arthritis;
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg02683197	chr6:28174875	NA	0.54	7.31	0.37	1.98e-12	Parkinson's disease;
CRC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	7.39	0.38	1.24e-12	Height;
CRC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.67	9.22	0.45	3.63e-18	Lung cancer;
CRC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.41	6.26	0.33	1.18e-9	HDL cholesterol levels;
CRC	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.85	0.31	1.18e-8	Coronary artery disease;
CRC	trans	rs17742757	0.522	rs899364	chr8:11329544	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.98	-0.31	5.78e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.47e-12	Eye color traits;
CRC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.05	10.85	0.51	1.16e-23	Diabetic retinopathy;
CRC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.83	10.29	0.49	1.02e-21	Glomerular filtration rate (creatinine);
CRC	cis	rs12541635	0.966	rs55762012	chr8:107033218	T/C	cg10147462	chr8:107024639	NA	0.44	7.27	0.37	2.6e-12	Age of smoking initiation;
CRC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.52	0.34	2.64e-10	Life satisfaction;
CRC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.58	7.73	0.39	1.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg21285383	chr16:89894308	SPIRE2	-0.37	-6.21	-0.32	1.55e-9	Vitiligo;
CRC	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.52	7.46	0.38	7.93e-13	Testicular germ cell tumor;
CRC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.87	0.35	3.27e-11	Neuroticism;
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg24578937	chr1:2090814	PRKCZ	0.45	8.18	0.41	6.2e-15	Coronary artery disease;
CRC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs2737618	0.674	rs2260033	chr1:200086074	G/A	cg21825944	chr1:200113062	NR5A2	-0.52	-7.66	-0.39	2.11e-13	Uric acid levels;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg12172441	chr6:28176163	NA	0.51	6.24	0.33	1.34e-9	Parkinson's disease;
CRC	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg07828024	chr6:149772892	ZC3H12D	0.41	6.6	0.34	1.69e-10	Dupuytren's disease;
CRC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-5.98	-0.31	5.91e-9	Major depressive disorder;
CRC	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.51	6.38	0.33	5.93e-10	White matter hyperintensity burden;
CRC	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21659725	chr3:3221576	CRBN	0.68	7.91	0.4	3.82e-14	Menarche (age at onset);
CRC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.3	0.53	3.03e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26378065	chr17:18585709	ZNF286B	0.42	5.78	0.3	1.76e-8	Pancreatic cancer;
CRC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.63	-0.43	2.69e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg26695010	chr11:65641043	EFEMP2	0.43	6.17	0.32	1.97e-9	DNA methylation (variation);
CRC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.66	8.38	0.42	1.61e-15	Arsenic metabolism;
CRC	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.58	0.39	3.51e-13	Lung cancer;
CRC	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.59	0.34	1.72e-10	Blood protein levels;
CRC	cis	rs3767633	0.800	rs2341479	chr1:161885352	C/A	cg09175582	chr1:161736000	ATF6	0.61	5.9	0.31	9.26e-9	IgG glycosylation;
CRC	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-5.9	-0.31	8.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg04586622	chr2:25135609	ADCY3	-0.57	-9.61	-0.47	1.91e-19	Body mass index;
CRC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13099106	chr12:120525172	CCDC64	0.45	6.47	0.34	3.49e-10	Response to antipsychotic treatment;
CRC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.36	-5.6	-0.3	4.53e-8	Testicular germ cell tumor;
CRC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.66	-11.87	-0.55	2.74e-27	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02537909	chr2:165697595	COBLL1	0.44	6.36	0.33	6.77e-10	Response to antipsychotic treatment;
CRC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg24562669	chr7:97807699	LMTK2	0.42	6.95	0.36	2.01e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.09	-19.9	-0.74	2.19e-58	Exhaled nitric oxide output;
CRC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.11	0.45	8.26e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-9.5	-0.46	4.65e-19	Prostate cancer;
CRC	cis	rs2307022	0.586	rs1562479	chr16:68387373	C/T	cg02226672	chr16:68398533	SMPD3	0.28	5.62	0.3	4.12e-8	Body mass index;
CRC	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.66	8.6	0.43	3.26e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-6.67	-0.35	1.06e-10	Blood pressure (smoking interaction);
CRC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.73	13.08	0.58	9.49e-32	Oral cavity cancer;
CRC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.47	-7.45	-0.38	8.08e-13	Coronary artery disease;
CRC	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg27326032	chr3:127006922	NA	-0.46	-6.95	-0.36	2.02e-11	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CRC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg17948913	chr5:572064	NA	0.5	5.79	0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg08989290	chr16:615782	NHLRC4	0.47	9.1	0.45	9.05e-18	Height;
CRC	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.07	0.32	3.6e-9	Asthma;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg10729496	chr3:10149963	C3orf24	0.58	6.07	0.32	3.62e-9	Alzheimer's disease;
CRC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.66	-7.34	-0.38	1.64e-12	Menarche (age at onset);
CRC	cis	rs9311676	0.632	rs56288363	chr3:58374533	A/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs2274273	0.837	rs8011329	chr14:55677255	G/A	cg23234261	chr14:55582407	NA	-0.29	-5.66	-0.3	3.29e-8	Protein biomarker;
CRC	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.77	-11.69	-0.54	1.18e-26	Acne (severe);
CRC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.19e-10	Dupuytren's disease;
CRC	cis	rs9311676	0.656	rs12495490	chr3:58373251	A/G	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg00677455	chr12:58241039	CTDSP2	0.56	6.73	0.35	7.33e-11	Multiple sclerosis;
CRC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.61e-11	Aortic root size;
CRC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.81	-0.35	4.55e-11	Breast cancer;
CRC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.37	12.07	0.55	5.27e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-0.89	-6.88	-0.35	2.95e-11	Putamen volume;
CRC	cis	rs9993810	1	rs9993810	chr4:77614640	G/A	cg17476223	chr4:77663285	SHROOM3	0.43	5.77	0.3	1.88e-8	Magnesium levels;
CRC	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.5	7.61	0.39	2.92e-13	Testicular germ cell tumor;
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.83	-11.79	-0.55	5.27e-27	Gut microbiome composition (summer);
CRC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.86	10.36	0.5	5.75e-22	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10332367	chr16:2075476	SLC9A3R2	-0.4	-6.75	-0.35	6.56e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.78	0.35	5.63e-11	Interstitial lung disease;
CRC	cis	rs7487075	0.820	rs12311507	chr12:46723190	T/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.65	0.34	1.21e-10	Itch intensity from mosquito bite;
CRC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg18479299	chr3:125709523	NA	-0.55	-6.64	-0.34	1.27e-10	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.65	-6.72	-0.35	7.9e-11	Depression;
CRC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.76	-11.1	-0.52	1.61e-24	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg02018176	chr4:1364513	KIAA1530	0.49	7.96	0.4	2.77e-14	Obesity-related traits;
CRC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg27535305	chr1:53392650	SCP2	0.39	7.01	0.36	1.34e-11	Monocyte count;
CRC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg03929089	chr4:120376271	NA	-0.46	-6.58	-0.34	1.88e-10	HDL cholesterol;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg15786705	chr6:28176104	NA	0.72	9.36	0.46	1.33e-18	Parkinson's disease;
CRC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.61	7.5	0.38	6.16e-13	Obesity (extreme);
CRC	cis	rs72730918	0.590	rs6493514	chr15:51914778	T/G	cg14296394	chr15:51910925	DMXL2	-0.47	-6.33	-0.33	8.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.15	-0.37	5.79e-12	Height;
CRC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-0.89	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.48	5.82	0.31	1.37e-8	Parkinson's disease;
CRC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg26666090	chr16:58549219	SETD6	1.01	6.67	0.35	1.06e-10	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25798026	chr22:32149910	DEPDC5	0.44	7.57	0.39	3.68e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.53	-8.05	-0.41	1.5e-14	Coronary artery disease;
CRC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.56	-8.76	-0.44	1.02e-16	Tuberculosis;
CRC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.44	-7.79	-0.39	8.87e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.57	7.65	0.39	2.28e-13	Colorectal cancer;
CRC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.43	0.33	4.41e-10	Diastolic blood pressure;
CRC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6662572	0.737	rs10789477	chr1:46306583	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.08	-0.32	3.31e-9	Blood protein levels;
CRC	cis	rs863345	0.526	rs857676	chr1:158615702	G/A	cg12129480	chr1:158549410	OR10X1	-0.31	-6.66	-0.34	1.17e-10	Pneumococcal bacteremia;
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.26e-10	Bipolar disorder;
CRC	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg20607287	chr7:12443886	VWDE	-0.46	-6.15	-0.32	2.27e-9	Coronary artery disease;
CRC	trans	rs587242	1.000	rs663771	chr1:96891855	C/G	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.99	-0.48	1.07e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.47	-6.92	-0.36	2.38e-11	Coffee consumption (cups per day);
CRC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.53	0.34	2.52e-10	Melanoma;
CRC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.58	0.34	1.89e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.55	8.08	0.41	1.25e-14	Cognitive ability;
CRC	cis	rs11203032	0.634	rs3802658	chr10:90965691	C/T	cg16672925	chr10:90967113	CH25H	-0.45	-6.13	-0.32	2.47e-9	Heart failure;
CRC	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg15038512	chr6:170123185	PHF10	-0.38	-5.9	-0.31	8.96e-9	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.69	-11.27	-0.53	3.85e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.55	8.41	0.42	1.24e-15	Diastolic blood pressure;
CRC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg23702412	chr14:70655803	SLC8A3	-0.31	-5.96	-0.31	6.49e-9	Prostate cancer;
CRC	cis	rs2386661	0.523	rs2386663	chr10:5652739	C/T	cg26603656	chr10:5671107	NA	0.4	7.28	0.37	2.44e-12	Breast cancer;
CRC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.76	-0.39	1.1e-13	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.58	-9.03	-0.45	1.52e-17	Ulcerative colitis;
CRC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13844804	chr7:814759	HEATR2	-0.55	-5.81	-0.3	1.49e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.47	6.86	0.35	3.36e-11	High light scatter reticulocyte count;
CRC	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg06935464	chr4:38784597	TLR10	0.6	6.07	0.32	3.5e-9	Breast cancer;
CRC	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg14593290	chr7:50529359	DDC	-0.56	-7.81	-0.4	7.68e-14	Malaria;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.34	0.53	2.15e-25	Prudent dietary pattern;
CRC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	11.3	0.53	3.08e-25	Motion sickness;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg14711859	chr11:8959438	ASCL3	0.35	6.01	0.31	4.93e-9	Hemoglobin concentration;
CRC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg16558177	chr4:4109446	NA	-0.56	-6.43	-0.33	4.42e-10	Blood pressure (smoking interaction);
CRC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.31	-0.46	1.84e-18	Migraine;Coronary artery disease;
CRC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.46	6.16	0.32	2.13e-9	Gut microbiome composition (summer);
CRC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.68	-9.11	-0.45	8.37e-18	Dilated cardiomyopathy;
CRC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	7.99	0.4	2.23e-14	Monocyte percentage of white cells;
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg16486109	chr11:613632	IRF7	0.73	12.38	0.56	3.59e-29	Systemic lupus erythematosus;
CRC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg08533674	chr1:46993347	NA	0.72	9.17	0.45	5.32e-18	Monobrow;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Parkinson's disease;
CRC	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.7	-10.84	-0.51	1.26e-23	Neurofibrillary tangles;
CRC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg10544611	chr16:67998164	SLC12A4	-0.53	-5.64	-0.3	3.66e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4700695	0.764	rs251593	chr5:65313889	G/A	cg21114390	chr5:65439923	SFRS12	0.57	6.99	0.36	1.58e-11	Facial morphology (factor 19);
CRC	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg14092571	chr14:90743983	NA	0.38	5.85	0.31	1.17e-8	Mortality in heart failure;
CRC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.75	10.32	0.49	7.92e-22	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg15845792	chr6:28175446	NA	0.58	8.54	0.43	5.14e-16	Pubertal anthropometrics;
CRC	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.52	7.76	0.39	1.1e-13	Testicular germ cell tumor;
CRC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.77	-0.72	5.95e-54	Height;
CRC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.71	-8.48	-0.42	7.97e-16	Body mass index;
CRC	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg03929089	chr4:120376271	NA	0.62	6.09	0.32	3.17e-9	Axial length;
CRC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.25	0.33	1.28e-9	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.64	-10.41	-0.5	4.06e-22	Aortic root size;
CRC	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.68	8.23	0.41	4.31e-15	Obesity (extreme);
CRC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.31	-0.33	9.17e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg11212589	chr17:38028394	ZPBP2	0.36	6.71	0.35	8.34e-11	Self-reported allergy;
CRC	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.63	-10.14	-0.49	3.37e-21	Motion sickness;
CRC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.39	6.34	0.33	7.36e-10	Blood metabolite levels;
CRC	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.51e-34	Menopause (age at onset);
CRC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.47	-7.07	-0.36	9.32e-12	Motion sickness;
CRC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.96	0.31	6.35e-9	Tonsillectomy;
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.67	-7.98	-0.4	2.44e-14	Rheumatoid arthritis;
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg02018176	chr4:1364513	KIAA1530	0.38	5.63	0.3	3.87e-8	Obesity-related traits;
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.49	-7.67	-0.39	1.96e-13	Bipolar disorder;
CRC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.42	-20.11	-0.74	3.29e-59	Hip circumference adjusted for BMI;
CRC	cis	rs12024301	0.557	rs12021522	chr1:183600257	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.84	0.35	3.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.73	-0.51	3.19e-23	Alzheimer's disease;
CRC	cis	rs1550532	0.632	rs1441093	chr2:234272484	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.53	-6.29	-0.33	1.03e-9	Calcium levels;Bilirubin levels;
CRC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13939156	chr17:80058883	NA	0.39	5.99	0.31	5.37e-9	Life satisfaction;
CRC	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.9	-11.81	-0.55	4.4e-27	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.75	9.94	0.48	1.54e-20	Bronchopulmonary dysplasia;
CRC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.85	0.31	1.16e-8	Homoarginine levels;
CRC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.48	7.17	0.37	4.97e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-6.71	-0.35	8.44e-11	Alzheimer's disease (late onset);
CRC	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg18232548	chr7:50535776	DDC	-0.44	-5.8	-0.3	1.57e-8	Malaria;
CRC	cis	rs7804356	0.954	rs3801809	chr7:26895456	G/A	cg03456212	chr7:26904342	SKAP2	-0.49	-5.61	-0.3	4.33e-8	Type 1 diabetes;
CRC	cis	rs28493229	0.500	rs45545932	chr19:41190875	G/A	cg21869046	chr19:41225005	ITPKC	0.38	5.94	0.31	7.17e-9	Kawasaki disease;
CRC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	cis	rs9359856	0.957	rs9342201	chr6:90310356	G/T	cg13799429	chr6:90582589	CASP8AP2	0.44	6.33	0.33	7.84e-10	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.82	12.31	0.56	6.59e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.62	-8.86	-0.44	5.12e-17	Cognitive function;
CRC	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.83	-14.8	-0.63	2.33e-38	Itch intensity from mosquito bite;
CRC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg22974920	chr21:40686053	BRWD1	-0.44	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.73	-12.4	-0.56	3.05e-29	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02830023	chr6:15575773	DTNBP1	0.35	6.38	0.33	6.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.51	-9.4	-0.46	9.26e-19	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.25e-12	HDL cholesterol;
CRC	cis	rs10503871	0.967	rs4403367	chr8:30439724	A/G	cg26383811	chr8:30366931	RBPMS	0.46	7.41	0.38	1.09e-12	Metabolite levels  (X-11787);
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.19	0.59	3.5e-32	Alzheimer's disease;
CRC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.5	-8.01	-0.4	2.02e-14	Body mass index;
CRC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.05	0.32	4e-9	Dupuytren's disease;
CRC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-12.66	-0.57	3.31e-30	Gut microbiome composition (summer);
CRC	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.55	8.76	0.43	1.03e-16	Hyperactive-impulsive symptoms;
CRC	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.43	6.35	0.33	7.13e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.73	-0.35	7.51e-11	Prevalent atrial fibrillation;
CRC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.05e-14	Resting heart rate;
CRC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-8.76	-0.44	1.02e-16	Body mass index;
CRC	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg04586622	chr2:25135609	ADCY3	-0.55	-9.37	-0.46	1.22e-18	Body mass index;
CRC	cis	rs372883	0.509	rs28462110	chr21:30544318	C/T	cg24692254	chr21:30365293	RNF160	-0.38	-5.61	-0.3	4.3e-8	Pancreatic cancer;
CRC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.45	6.64	0.34	1.29e-10	Menopause (age at onset);
CRC	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.69	8.92	0.44	3.19e-17	Coronary artery disease;
CRC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.49	7.19	0.37	4.52e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	8.85	0.44	5.5e-17	Menarche (age at onset);
CRC	cis	rs11212617	0.967	rs3781869	chr11:108059000	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.87	0.31	1.07e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04498913	chr7:1135747	C7orf50	-0.49	-5.92	-0.31	8.04e-9	Bronchopulmonary dysplasia;
CRC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.7	10.79	0.51	1.87e-23	Corneal astigmatism;
CRC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21963583	chr11:68658836	MRPL21	0.55	9.67	0.47	1.27e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs62408225	1.000	rs72925996	chr6:90930513	T/C	cg06866423	chr6:90926672	BACH2	0.48	7.55	0.38	4.29e-13	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs17713451	0.593	rs17642575	chr7:151261450	T/C	cg18404559	chr7:151322523	PRKAG2	-0.56	-6.28	-0.33	1.04e-9	Interleukin-4 levels;
CRC	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.7	-0.3	2.67e-8	Pulmonary function;
CRC	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.86e-12	Prostate cancer;
CRC	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.48	-6.98	-0.36	1.59e-11	Coronary artery disease;
CRC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.8	0.55	5e-27	Prudent dietary pattern;
CRC	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg09003973	chr2:102972529	NA	0.74	8.07	0.41	1.3e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.53	-7.33	-0.37	1.83e-12	Coronary artery disease;
CRC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.85	-0.48	3.12e-20	Height;
CRC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg10130564	chr11:117069849	TAGLN	0.38	7.08	0.36	8.52e-12	Blood protein levels;
CRC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.38	5.68	0.3	2.95e-8	HDL cholesterol levels;
CRC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.66	-12.02	-0.55	8.04e-28	Educational attainment;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.58	9.18	0.45	4.73e-18	Corneal astigmatism;
CRC	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.47	-7.61	-0.39	2.91e-13	Platelet count;
CRC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.02	-0.32	4.54e-9	Arsenic metabolism;
CRC	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.66	9.35	0.46	1.38e-18	Body mass index;
CRC	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg10756647	chr7:56101905	PSPH	0.76	7.92	0.4	3.72e-14	Diabetic kidney disease;
CRC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.69	0.51	4.25e-23	Sudden cardiac arrest;
CRC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.73	-0.39	1.33e-13	Colorectal cancer;
CRC	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-1.04	-10.76	-0.51	2.48e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg25809561	chr17:30822961	MYO1D	0.51	9.19	0.45	4.68e-18	Schizophrenia;
CRC	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.69	-9.11	-0.45	8.3e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.88	0.55	2.57e-27	Asthma (sex interaction);
CRC	cis	rs9992667	0.826	rs7656708	chr4:38641662	G/A	cg19726192	chr4:38663646	FLJ13197	-0.67	-8.73	-0.43	1.31e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg20203395	chr5:56204925	C5orf35	-0.43	-5.87	-0.31	1.06e-8	Coronary artery disease;
CRC	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06307176	chr5:131281290	NA	0.43	6.36	0.33	6.62e-10	Life satisfaction;
CRC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-6.66	-0.34	1.15e-10	Morning vs. evening chronotype;
CRC	cis	rs17065868	1.000	rs9533938	chr13:45222796	T/A	cg10246903	chr13:45222710	NA	0.53	6.39	0.33	5.55e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7605827	0.897	rs6431713	chr2:15691382	C/T	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.65	7.93	0.4	3.4e-14	Diabetic retinopathy;
CRC	cis	rs11622475	1.000	rs56060232	chr14:104386165	G/C	cg12183467	chr14:104352244	NA	-0.52	-7.12	-0.37	6.8e-12	Bipolar disorder;
CRC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.39	-6.82	-0.35	4.51e-11	Height;
CRC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.94e-39	Prudent dietary pattern;
CRC	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.55	8.45	0.42	9.32e-16	Itch intensity from mosquito bite;
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg20541178	chr8:143858627	LYNX1	0.34	6.13	0.32	2.5e-9	Urinary tract infection frequency;
CRC	cis	rs995000	0.899	rs1184865	chr1:62973795	A/G	cg19896129	chr1:63156450	NA	-0.38	-5.9	-0.31	9.28e-9	Triglyceride levels;
CRC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.66	-0.3	3.28e-8	Blood protein levels;
CRC	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.5	-7.84	-0.4	6.13e-14	Corneal astigmatism;
CRC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.69	-0.39	1.7e-13	Vitiligo;
CRC	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.86	-0.55	2.96e-27	Colorectal cancer;
CRC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs995000	0.931	rs659656	chr1:62912120	C/G	cg19896129	chr1:63156450	NA	0.44	6.8	0.35	4.87e-11	Triglyceride levels;
CRC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.39	6.0	0.31	5.11e-9	Hemoglobin concentration;
CRC	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.72	-8.82	-0.44	6.75e-17	Inflammatory bowel disease;
CRC	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-7.61	-0.39	2.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg06470822	chr6:28175283	NA	1.0	13.03	0.58	1.36e-31	Depression;
CRC	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.46	-0.34	3.86e-10	DNA methylation (variation);
CRC	cis	rs4700695	0.641	rs386949	chr5:65231061	G/A	cg21114390	chr5:65439923	SFRS12	0.61	6.3	0.33	9.74e-10	Facial morphology (factor 19);
CRC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.53	5.7	0.3	2.65e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.5	7.27	0.37	2.58e-12	Height;
CRC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-9.77	-0.47	5.99e-20	Total body bone mineral density;
CRC	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg15282417	chr9:129245246	FAM125B	0.44	8.03	0.4	1.73e-14	Intraocular pressure;
CRC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.78	12.92	0.58	3.75e-31	Lung cancer;
CRC	cis	rs6479527	0.840	rs4282631	chr9:96764410	T/C	cg14459158	chr9:96720562	NA	0.41	7.49	0.38	6.39e-13	Esophageal adenocarcinoma;
CRC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg23461800	chr14:103021989	NA	-0.76	-10.02	-0.48	8.31e-21	Platelet count;
CRC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.62	-0.57	4.86e-30	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.66	7.32	0.37	1.94e-12	Coronary artery disease;
CRC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.82	-0.31	1.42e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg24531977	chr5:56204891	C5orf35	-0.42	-6.34	-0.33	7.79e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.32e-11	Menopause (age at onset);
CRC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.15	-0.32	2.28e-9	Life satisfaction;
CRC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg00074818	chr8:8560427	CLDN23	0.41	7.36	0.38	1.45e-12	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg22561889	chr6:118971681	C6orf204	0.48	5.95	0.31	7.02e-9	Diastolic blood pressure;
CRC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25517755	chr10:38738941	LOC399744	0.43	6.29	0.33	1e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.4	-6.16	-0.32	2.11e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.56	8.52	0.43	5.66e-16	Aortic root size;
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.54	10.03	0.48	7.63e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.46	-7.39	-0.38	1.25e-12	Monocyte count;
CRC	cis	rs4728302	0.934	rs4129572	chr7:133636888	T/C	cg10665199	chr7:133106180	EXOC4	-0.39	-6.14	-0.32	2.34e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.63	10.38	0.5	5.13e-22	Cancer;
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg21357108	chr17:15164082	PMP22	-0.49	-6.01	-0.31	4.79e-9	Hirschsprung disease;
CRC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs863345	0.604	rs7544134	chr1:158475421	G/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.33	-0.33	7.99e-10	Pneumococcal bacteremia;
CRC	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.39	5.87	0.31	1.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.03	23.34	0.79	9.54e-72	Multiple system atrophy;
CRC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.34	-0.42	2.09e-15	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26143326	chr5:218493	SDHA;CCDC127	0.49	6.92	0.36	2.4e-11	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16699849	chr7:98923489	ARPC1A	0.37	6.31	0.33	9.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.54	7.38	0.38	1.28e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2421770	0.530	rs3847622	chr11:35368700	A/G	cg13971030	chr11:35366721	SLC1A2	0.37	6.49	0.34	3.08e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg10494973	chr17:80897199	TBCD	0.36	5.77	0.3	1.83e-8	Breast cancer;
CRC	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg13057898	chr1:3703894	LRRC47	0.52	6.91	0.36	2.46e-11	Red cell distribution width;
CRC	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg27205649	chr11:78285834	NARS2	0.47	5.68	0.3	3e-8	Alzheimer's disease (survival time);
CRC	cis	rs7731657	0.537	rs4637539	chr5:130311944	T/C	cg08523029	chr5:130500466	HINT1	-0.49	-6.16	-0.32	2.1e-9	Fasting plasma glucose;
CRC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg01788221	chr16:89496183	ANKRD11	-0.44	-6.52	-0.34	2.59e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-0.95	-9.72	-0.47	8.33e-20	Schizophrenia;
CRC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.85	14.88	0.63	1.17e-38	Intelligence (multi-trait analysis);
CRC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.91	0.44	3.56e-17	Morning vs. evening chronotype;
CRC	trans	rs6546324	0.625	rs2861700	chr2:67855441	A/G	cg00907274	chr3:27498161	SLC4A7	0.49	6.21	0.32	1.59e-9	Endometriosis;
CRC	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.56	8.28	0.42	3.09e-15	Lewy body disease;
CRC	cis	rs4743820	0.603	rs1887370	chr9:93927076	G/A	cg14446406	chr9:93919335	NA	-0.44	-7.7	-0.39	1.56e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg19257562	chr1:2043853	PRKCZ	0.38	6.46	0.34	3.74e-10	Height;
CRC	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.25	0.37	3.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg18551225	chr6:44695536	NA	0.43	5.82	0.31	1.42e-8	Total body bone mineral density;
CRC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg24879335	chr3:133465180	TF	0.33	5.93	0.31	7.53e-9	Iron status biomarkers;
CRC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	13.27	0.59	1.76e-32	Cognitive ability;
CRC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.52	7.29	0.37	2.34e-12	Lymphocyte counts;
CRC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.4	-7.67	-0.39	1.91e-13	Ulcerative colitis;
CRC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	0.89	10.4	0.5	4.49e-22	Diabetic kidney disease;
CRC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg12193833	chr17:30244370	NA	-0.75	-8.76	-0.44	1.01e-16	Hip circumference adjusted for BMI;
CRC	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg13414629	chr9:132935646	FREQ	0.43	6.28	0.33	1.07e-9	Alzheimer's disease (cognitive decline);
CRC	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg13482628	chr17:19912719	NA	0.4	6.08	0.32	3.35e-9	Schizophrenia;
CRC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.75	12.47	0.57	1.65e-29	Menopause (age at onset);
CRC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg23625390	chr15:77176239	SCAPER	0.48	6.92	0.36	2.35e-11	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg04110750	chr16:69646130	NFAT5	-0.51	-6.75	-0.35	6.72e-11	IgE levels;
CRC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs755249	0.567	rs4660546	chr1:39679402	T/C	cg18385671	chr1:39797026	MACF1	-0.44	-6.23	-0.32	1.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.61	-9.45	-0.46	6.78e-19	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25876406	chr19:33864478	CEBPG	0.41	6.26	0.33	1.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6496667	1.000	rs6496668	chr15:90893704	A/T	cg04176472	chr15:90893244	GABARAPL3	0.62	8.52	0.43	5.63e-16	Rheumatoid arthritis;
CRC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.79	-12.44	-0.57	2.14e-29	Menopause (age at onset);
CRC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.77	0.3	1.88e-8	Homoarginine levels;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.61	-9.81	-0.48	4.12e-20	Obesity-related traits;
CRC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.54	0.34	2.36e-10	Renal cell carcinoma;
CRC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg00255919	chr5:131827918	IRF1	-0.38	-6.43	-0.33	4.57e-10	Breast cancer;Mosquito bite size;
CRC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.48	7.36	0.38	1.5e-12	Corneal astigmatism;
CRC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.88	0.66	1.52e-42	Primary sclerosing cholangitis;
CRC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.45	7.7	0.39	1.65e-13	Childhood ear infection;
CRC	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.66	-10.57	-0.5	1.1e-22	Motion sickness;
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg10217327	chr6:118973057	C6orf204	0.51	5.75	0.3	2e-8	Renal cell carcinoma;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg22638593	chr5:131593259	PDLIM4	0.36	6.95	0.36	2.01e-11	Blood metabolite levels;
CRC	cis	rs1552172	0.922	rs2231375	chr1:145696694	G/A	cg11743829	chr1:145714124	CD160	-0.42	-6.2	-0.32	1.74e-9	Breast cancer;
CRC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.44	0.53	9.33e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs17713451	0.593	rs7788234	chr7:151268657	A/C	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg04969067	chr8:143858791	LYNX1	-0.43	-6.76	-0.35	6.44e-11	Urinary tract infection frequency;
CRC	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg22182287	chr2:3452347	TTC15	0.38	5.94	0.31	7.44e-9	Obesity-related traits;
CRC	cis	rs12580194	0.593	rs7485053	chr12:55770126	T/C	cg19537932	chr12:55886519	OR6C68	-0.7	-9.02	-0.45	1.54e-17	Cancer;
CRC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.89	-0.4	4.6e-14	Height;
CRC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg20684491	chr1:25596433	NA	0.42	7.29	0.37	2.37e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg12292205	chr6:26970375	C6orf41	-0.48	-6.76	-0.35	6.15e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.72	-10.94	-0.52	5.62e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg22638593	chr5:131593259	PDLIM4	0.38	6.26	0.33	1.19e-9	Breast cancer;
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.68	9.07	0.45	1.08e-17	Alzheimer's disease;
CRC	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg21839984	chr17:30846986	MYO1D	-0.33	-5.74	-0.3	2.15e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10657986	chr3:53381858	DCP1A	0.47	6.63	0.34	1.4e-10	Response to antipsychotic treatment;
CRC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.53	7.07	0.36	9.56e-12	Resting heart rate;
CRC	cis	rs9903692	0.954	rs4794451	chr17:46184781	A/G	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg02683197	chr6:28174875	NA	0.81	9.98	0.48	1.15e-20	Depression;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs732072	0.826	rs617980	chr11:65475503	G/C	cg21033440	chr11:65409861	SIPA1	-0.67	-5.7	-0.3	2.7e-8	Inflammatory bowel disease;
CRC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.76	13.16	0.59	4.67e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.23	-0.32	1.44e-9	Menopause (age at onset);
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg21204522	chr6:27730016	NA	-0.4	-5.6	-0.3	4.48e-8	Parkinson's disease;
CRC	cis	rs61160187	0.577	rs34741733	chr5:60139548	C/T	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.91	-0.31	8.75e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.69	0.51	4.33e-23	Motion sickness;
CRC	cis	rs2386661	0.784	rs2386652	chr10:5676326	G/A	cg26603656	chr10:5671107	NA	0.56	9.2	0.45	4.1e-18	Breast cancer;
CRC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.46	8.62	0.43	2.86e-16	Renal cell carcinoma;
CRC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg01788221	chr16:89496183	ANKRD11	-0.4	-5.82	-0.31	1.43e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg12395012	chr8:11607386	GATA4	-0.37	-5.98	-0.31	5.84e-9	Myopia (pathological);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg13897947	chr1:113390019	NA	-0.39	-6.17	-0.32	1.96e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg26754761	chr2:177040938	NA	-0.44	-6.62	-0.34	1.46e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.42	-0.33	4.82e-10	Cognitive function;
CRC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg25281562	chr12:121454272	C12orf43	0.39	5.62	0.3	3.99e-8	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12463550	chr7:65579703	CRCP	0.69	6.42	0.33	4.89e-10	Diabetic kidney disease;
CRC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.56	8.29	0.42	2.95e-15	Homoarginine levels;
CRC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-10.62	-0.51	7.77e-23	Monocyte percentage of white cells;
CRC	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.47	7.33	0.37	1.82e-12	Height;
CRC	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	10.93	0.52	6.38e-24	High light scatter reticulocyte count;
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19853194	chr18:9913725	VAPA	0.49	6.4	0.33	5.37e-10	Thyroid stimulating hormone;
CRC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.7	0.47	1.02e-19	Platelet count;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg27053337	chr8:124217698	FAM83A	-0.44	-6.66	-0.34	1.16e-10	Urinary uromodulin levels;
CRC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg00074818	chr8:8560427	CLDN23	0.42	7.66	0.39	2.09e-13	Obesity-related traits;
CRC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.06	-0.36	9.93e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-8.89	-0.44	3.97e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	7.53	0.38	4.83e-13	Mean platelet volume;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.65	9.93	0.48	1.68e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.67	-10.35	-0.5	6.29e-22	Blood pressure (smoking interaction);
CRC	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.67	6.53	0.34	2.51e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg21620606	chr4:1342894	KIAA1530	0.38	6.42	0.33	4.82e-10	Obesity-related traits;
CRC	cis	rs11628318	0.563	rs1190344	chr14:103097912	A/G	cg12046867	chr14:103022105	NA	-0.39	-5.71	-0.3	2.5e-8	Platelet count;
CRC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg25456477	chr12:86230367	RASSF9	0.32	5.64	0.3	3.58e-8	Major depressive disorder;
CRC	cis	rs143000161	1	rs143000161	chr2:165710540	A/T	cg03182029	chr2:165697222	COBLL1	0.98	9.58	0.47	2.49e-19	Heschl's gyrus morphology;
CRC	cis	rs7487075	0.780	rs12320197	chr12:46738883	A/G	cg22049899	chr12:47219821	SLC38A4	0.35	7.1	0.36	7.7e-12	Itch intensity from mosquito bite;
CRC	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.6	8.04	0.41	1.68e-14	Coronary artery disease;
CRC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg03013999	chr17:37608204	MED1	0.43	6.41	0.33	4.96e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg21918786	chr6:109611834	NA	-0.35	-6.05	-0.32	3.9e-9	Reticulocyte fraction of red cells;
CRC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-9.27	-0.46	2.46e-18	Monocyte count;
CRC	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.78	-11.46	-0.53	8.24e-26	Gout;
CRC	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.89	-11.28	-0.53	3.61e-25	Hair shape;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04232466	chr8:21988724	HR	-0.52	-6.43	-0.33	4.49e-10	Diisocyanate-induced asthma;
CRC	cis	rs990171	1.000	rs2110734	chr2:103052206	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	5.8	0.3	1.53e-8	Lymphocyte counts;
CRC	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg04165759	chr1:150448943	RPRD2	-0.36	-5.94	-0.31	7.41e-9	Migraine;
CRC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.89	-0.51	8.51e-24	Eye color traits;
CRC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg19761014	chr17:28927070	LRRC37B2	0.59	5.89	0.31	9.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2708977	0.698	rs772159	chr2:97036439	G/A	cg23100626	chr2:96804247	ASTL	0.23	5.88	0.31	9.81e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-6.75	-0.35	6.66e-11	Putamen volume;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg03623178	chr6:28175578	NA	0.7	9.29	0.46	2.17e-18	Parkinson's disease;
CRC	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	9.15	0.45	6.1e-18	Type 2 diabetes;
CRC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.88	15.31	0.65	2.55e-40	Coronary artery disease;
CRC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.18	0.59	3.84e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-12.65	-0.57	3.73e-30	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.52	7.41	0.38	1.09e-12	Testicular germ cell tumor;
CRC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg12573674	chr2:1569213	NA	-0.68	-7.74	-0.39	1.22e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-7.02	-0.36	1.25e-11	Hemostatic factors and hematological phenotypes;
CRC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.83	-0.48	3.75e-20	Total cholesterol levels;
CRC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg16482183	chr6:26056742	HIST1H1C	0.59	7.97	0.4	2.64e-14	Iron status biomarkers;
CRC	trans	rs247929	0.642	rs11525670	chr12:46451692	A/G	cg11832793	chr4:24212454	NA	0.36	5.99	0.31	5.63e-9	Educational attainment;
CRC	cis	rs73200209	0.744	rs56350518	chr12:116556775	A/G	cg01776926	chr12:116560359	MED13L	-0.62	-7.42	-0.38	9.81e-13	Total body bone mineral density;
CRC	cis	rs4750440	0.706	rs10796148	chr10:14016900	G/A	cg00551146	chr10:14014579	FRMD4A	0.35	5.71	0.3	2.57e-8	Adiponectin levels;
CRC	cis	rs73206853	0.841	rs74503171	chr12:111061652	A/G	cg12870014	chr12:110450643	ANKRD13A	0.72	7.58	0.39	3.64e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.26e-11	Alzheimer's disease (late onset);
CRC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.51	-5.74	-0.3	2.13e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.8	-0.63	2.42e-38	Exhaled nitric oxide output;
CRC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.51	8.36	0.42	1.74e-15	Testicular germ cell tumor;
CRC	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.19	0.53	7.53e-25	Bipolar disorder;
CRC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg23461800	chr14:103021989	NA	0.67	7.58	0.39	3.58e-13	Platelet count;
CRC	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.49	-6.24	-0.33	1.35e-9	Red blood cell traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21411490	chr22:31739936	PATZ1	0.35	6.07	0.32	3.46e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.96	17.78	0.7	4.99e-50	Lewy body disease;
CRC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00339695	chr16:24857497	SLC5A11	0.25	5.89	0.31	9.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.11e-9	Life satisfaction;
CRC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg02659138	chr7:134003124	SLC35B4	0.38	6.53	0.34	2.52e-10	Mean platelet volume;
CRC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.5	7.58	0.39	3.58e-13	Emphysema distribution in smoking;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07038191	chr16:29801882	KIF22	0.4	6.27	0.33	1.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-10.03	-0.48	7.78e-21	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.42	6.05	0.32	4.03e-9	Red cell distribution width;
CRC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.67	10.78	0.51	2.04e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.62	-10.33	-0.49	7.59e-22	Myopia (pathological);
CRC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.81	0.3	1.51e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.46	6.14	0.32	2.4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.62	-9.01	-0.45	1.66e-17	Response to temozolomide;
CRC	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.86	16.18	0.67	9.55e-44	Hip circumference;
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19046167	chr17:80928561	B3GNTL1	0.51	7.14	0.37	6.01e-12	Glycated hemoglobin levels;
CRC	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.28	14.21	0.62	4.48e-36	Uric acid levels;
CRC	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.7	-11.19	-0.53	7.26e-25	Obesity-related traits;
CRC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.01	16.01	0.66	4.5e-43	Cognitive function;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg03623178	chr6:28175578	NA	0.68	9.59	0.47	2.31e-19	Parkinson's disease;
CRC	cis	rs4073416	0.542	rs2183277	chr14:66035429	T/C	cg03016385	chr14:66212404	NA	-0.45	-6.19	-0.32	1.78e-9	N-glycan levels;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg10596483	chr8:143751796	JRK	-0.43	-6.12	-0.32	2.65e-9	Urinary tract infection frequency;
CRC	cis	rs939584	0.932	rs2867111	chr2:651286	A/C	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs4700695	0.925	rs6878011	chr5:65392465	G/A	cg21114390	chr5:65439923	SFRS12	-0.6	-6.98	-0.36	1.6e-11	Facial morphology (factor 19);
CRC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.84	-0.31	1.25e-8	Colorectal cancer;
CRC	cis	rs9487051	0.724	rs11751953	chr6:109635986	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.69	-0.3	2.86e-8	Reticulocyte fraction of red cells;
CRC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.44	-0.46	7.01e-19	Platelet count;
CRC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.41	8.13	0.41	8.94e-15	Mean corpuscular volume;
CRC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.79	-0.3	1.6e-8	Lung cancer;
CRC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	0.98	12.25	0.56	1.12e-28	Type 2 diabetes nephropathy;
CRC	cis	rs7605827	0.930	rs3792579	chr2:15534723	A/G	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.98	-0.31	5.95e-9	Reticulocyte count;
CRC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg18016565	chr1:150552671	MCL1	0.42	6.02	0.31	4.66e-9	Melanoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27529569	chr19:2977348	TLE6	0.47	6.53	0.34	2.5e-10	Anxiety disorder;
CRC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.04	13.3	0.59	1.34e-32	Vitiligo;
CRC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg23018236	chr17:30244563	NA	-0.68	-8.1	-0.41	1.12e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-9.94	-0.48	1.53e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.6	-0.47	2.1e-19	Hip circumference adjusted for BMI;
CRC	cis	rs7527798	0.592	rs11118282	chr1:207832402	G/A	cg09232269	chr1:207846808	CR1L	-0.44	-7.15	-0.37	5.54e-12	Erythrocyte sedimentation rate;
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.4	-0.46	9.29e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg10589385	chr1:150898437	SETDB1	-0.26	-5.64	-0.3	3.65e-8	Tonsillectomy;
CRC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.77	0.3	1.82e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6761276	0.649	rs12711751	chr2:113837765	T/G	cg09040174	chr2:113837401	NA	0.59	8.88	0.44	4.43e-17	Protein quantitative trait loci;
CRC	trans	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.51	0.38	5.8e-13	Endometrial cancer;
CRC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg21770322	chr7:97807741	LMTK2	0.54	9.08	0.45	1.02e-17	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.52	8.02	0.4	1.82e-14	Coronary artery disease;
CRC	cis	rs4664293	0.605	rs7556888	chr2:160540261	T/C	cg08347373	chr2:160653686	CD302	0.36	5.92	0.31	8.09e-9	Monocyte percentage of white cells;
CRC	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.44	-6.55	-0.34	2.19e-10	Breast size;
CRC	cis	rs9322817	0.691	rs9377679	chr6:105345036	C/T	cg02098413	chr6:105308735	HACE1	0.45	9.05	0.45	1.23e-17	Thyroid stimulating hormone;
CRC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg07212818	chr11:638076	DRD4	-0.46	-5.96	-0.31	6.32e-9	Systemic lupus erythematosus;
CRC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.0	12.12	0.56	3.24e-28	Nonalcoholic fatty liver disease;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg00316803	chr15:76480434	C15orf27	-0.35	-5.81	-0.31	1.46e-8	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.1	0.32	3.03e-9	Menopause (age at onset);
CRC	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-5.92	-0.31	7.98e-9	Arsenic metabolism;
CRC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.09	-0.49	4.8e-21	Body mass index;
CRC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.82	0.7	3.44e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.78	-0.39	9.49e-14	Blood metabolite levels;
CRC	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg13722127	chr7:150037890	RARRES2	-0.49	-7.77	-0.39	1.04e-13	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs11105468	1.000	rs10777206	chr12:90260046	C/T	cg23572944	chr11:60720130	SLC15A3	-0.45	-6.38	-0.33	5.97e-10	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.55	8.4	0.42	1.32e-15	Calcium levels;
CRC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.44	6.8	0.35	4.89e-11	Red blood cell count;
CRC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.58	-0.34	1.82e-10	Systemic lupus erythematosus;
CRC	cis	rs965469	1.000	rs6051809	chr20:3352551	A/C	cg25506879	chr20:3388711	C20orf194	-0.4	-5.83	-0.31	1.35e-8	IFN-related cytopenia;
CRC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.6	8.14	0.41	8.07e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.32	0.33	8.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.83	8.44	0.42	1.04e-15	Fat distribution (HIV);
CRC	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.39	-11.42	-0.53	1.14e-25	Psoriasis vulgaris;
CRC	cis	rs6076065	0.723	rs2251145	chr20:23399998	G/A	cg11657817	chr20:23433608	CST11	0.43	6.4	0.33	5.36e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.91	0.31	8.63e-9	Bladder cancer;
CRC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg19682013	chr15:45996608	NA	0.32	6.71	0.35	8.73e-11	Waist circumference;Weight;
CRC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg11861562	chr11:117069780	TAGLN	0.41	9.25	0.45	2.85e-18	Blood protein levels;
CRC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.81	0.48	4.17e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6772849	0.804	rs4857920	chr3:128407623	C/T	cg08795948	chr3:128337044	NA	0.34	5.75	0.3	2.07e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg09877947	chr5:131593287	PDLIM4	0.35	6.36	0.33	6.71e-10	Blood metabolite levels;
CRC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21028142	chr17:79581711	NPLOC4	0.34	7.17	0.37	5.11e-12	Eye color traits;
CRC	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	12.03	0.55	7.05e-28	Coffee consumption (cups per day);
CRC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.76	13.25	0.59	2.17e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.79	10.06	0.49	6.22e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.72	-0.35	7.94e-11	Dupuytren's disease;
CRC	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.23	-0.32	1.4e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.6	7.34	0.37	1.73e-12	Obesity (extreme);
CRC	cis	rs2252521	0.524	rs317745	chr7:29068114	T/C	cg11728747	chr7:29037910	CPVL	-0.5	-7.21	-0.37	3.86e-12	Cognitive performance;
CRC	cis	rs10426930	0.621	rs10409229	chr19:5009545	C/T	cg18473234	chr19:5097819	KDM4B	0.5	5.73	0.3	2.31e-8	Monocyte percentage of white cells;
CRC	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	15.08	0.64	2.03e-39	Mean corpuscular hemoglobin;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	8.59	0.43	3.61e-16	Lymphocyte counts;
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg13047869	chr3:10149882	C3orf24	0.53	7.31	0.37	2.04e-12	Alzheimer's disease;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	9.13	0.45	7.19e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.61	6.78	0.35	5.54e-11	Type 2 diabetes;
CRC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.32	-0.33	8.39e-10	Reticulocyte fraction of red cells;
CRC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg25956985	chr22:39795188	MAP3K7IP1	0.47	6.49	0.34	3.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg15845792	chr6:28175446	NA	0.85	8.72	0.43	1.38e-16	Lung cancer in ever smokers;
CRC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.32	-0.33	8.45e-10	Height;
CRC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-5.93	-0.31	7.79e-9	Aortic root size;
CRC	cis	rs9409565	0.559	rs9409762	chr9:97215040	A/C	cg04523069	chr9:97136363	HIATL1	0.43	6.02	0.32	4.58e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.37	-6.93	-0.36	2.22e-11	Iron status biomarkers;
CRC	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg03037974	chr15:76606532	NA	-0.53	-7.62	-0.39	2.7e-13	Blood metabolite levels;
CRC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.46	6.26	0.33	1.23e-9	Height;
CRC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.0	-0.48	9.78e-21	Type 2 diabetes;
CRC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	11.16	0.52	9.46e-25	Alzheimer's disease;
CRC	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.6	-7.52	-0.38	5.1e-13	Ulcerative colitis;
CRC	trans	rs4714291	0.832	rs6936016	chr6:40097013	A/G	cg02267698	chr19:7991119	CTXN1	-0.51	-6.92	-0.36	2.37e-11	Strep throat;
CRC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg02766259	chr12:125626809	AACS	-0.47	-7.64	-0.39	2.44e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.51	7.5	0.38	5.93e-13	Obesity-related traits;
CRC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg23533926	chr12:111358616	MYL2	-0.45	-6.65	-0.34	1.23e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.77	-12.69	-0.57	2.55e-30	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-8.56	-0.43	4.45e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.58	-0.47	2.54e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.44	7.18	0.37	4.75e-12	Refractive error;
CRC	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs4664293	0.764	rs1425044	chr2:160474937	C/T	cg08347373	chr2:160653686	CD302	-0.45	-7.83	-0.4	6.65e-14	Monocyte percentage of white cells;
CRC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-8.13	-0.41	8.57e-15	Gut microbiome composition (summer);
CRC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg08999081	chr20:33150536	PIGU	0.46	5.98	0.31	5.87e-9	Protein C levels;
CRC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.47	0.38	7.26e-13	Mean platelet volume;
CRC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.55	-7.93	-0.4	3.42e-14	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22269526	chr2:47630224	MSH2	0.39	5.98	0.31	5.95e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.84	14.14	0.61	8.83e-36	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs6658393	chr1:183621477	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.79	-0.3	1.67e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.67	6.93	0.36	2.21e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12711979	0.566	rs1111281	chr2:3855896	C/T	cg17052675	chr2:3827356	NA	-0.37	-5.87	-0.31	1.07e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4908760	0.899	rs61783642	chr1:8591397	T/C	cg20416874	chr1:8611966	RERE	-0.45	-6.44	-0.33	4.15e-10	Vitiligo;
CRC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg21620606	chr4:1342894	KIAA1530	-0.34	-5.93	-0.31	7.65e-9	Obesity-related traits;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg12172441	chr6:28176163	NA	0.54	7.32	0.37	1.87e-12	Cardiac Troponin-T levels;
CRC	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.5	-6.15	-0.32	2.21e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.53	-7.21	-0.37	3.91e-12	DNA methylation (variation);
CRC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.67	11.22	0.53	5.87e-25	Cancer;
CRC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.54	7.98	0.4	2.43e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.53	7.44	0.38	8.94e-13	Triglycerides;
CRC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.66	10.65	0.51	5.92e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg23127183	chr11:57508653	C11orf31	-0.53	-7.1	-0.36	7.6e-12	Schizophrenia;
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg15511327	chr8:143859410	LYNX1	-0.39	-6.52	-0.34	2.65e-10	Urinary tract infection frequency;
CRC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.33	6.07e-10	Vitiligo;
CRC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg13390004	chr1:15929781	NA	0.51	6.96	0.36	1.88e-11	Systolic blood pressure;
CRC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.8	14.23	0.62	3.81e-36	Breast cancer;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.47	6.67	0.35	1.08e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.51	7.61	0.39	2.89e-13	Night sleep phenotypes;
CRC	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.68	-10.13	-0.49	3.7e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2249625	0.523	rs2463702	chr6:72853778	A/G	cg18830697	chr6:72922368	RIMS1	0.3	5.95	0.31	6.71e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.68	-10.25	-0.49	1.44e-21	Total body bone mineral density;
CRC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-5.77	-0.3	1.79e-8	Joint mobility (Beighton score);
CRC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.5	7.92	0.4	3.76e-14	Red blood cell count;
CRC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	1.03	20.52	0.75	7.72e-61	Headache;
CRC	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.54	-7.88	-0.4	4.77e-14	Diisocyanate-induced asthma;
CRC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg09655341	chr17:79618100	PDE6G	-0.35	-6.03	-0.32	4.46e-9	Eye color traits;
CRC	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.66	-9.58	-0.47	2.5e-19	Type 2 diabetes;
CRC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.66	0.43	2.23e-16	Schizophrenia;
CRC	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.11	20.77	0.75	8.49e-62	Exhaled nitric oxide output;
CRC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.4	6.26	0.33	1.19e-9	Red blood cell count;
CRC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.77	-12.86	-0.58	6.13e-31	Glaucoma (primary open-angle);
CRC	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.61	9.83	0.48	3.56e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.34	6.5	0.34	2.98e-10	Ulcerative colitis;
CRC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.25e-10	Alzheimer's disease (late onset);
CRC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.8	14.15	0.62	7.64e-36	Breast cancer;
CRC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.53	-0.34	2.47e-10	Total body bone mineral density;
CRC	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.55	-8.89	-0.44	4.13e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.62	6.89	0.36	2.82e-11	Coronary artery disease;
CRC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg15234197	chr11:68924956	NA	0.43	6.19	0.32	1.79e-9	Blond vs. brown hair color;
CRC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.74	0.35	7.16e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.63	9.16	0.45	5.61e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg17724175	chr1:150552817	MCL1	0.44	6.54	0.34	2.34e-10	Melanoma;
CRC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg02269571	chr22:50332266	NA	-0.57	-8.03	-0.4	1.78e-14	Schizophrenia;
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg27635394	chr6:26043820	HIST1H2BB	0.39	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg14828511	chr1:107599125	PRMT6	-0.54	-7.45	-0.38	8.11e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg11632617	chr15:75315747	PPCDC	-0.57	-7.85	-0.4	5.77e-14	Blood trace element (Zn levels);
CRC	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.83	10.31	0.49	8.89e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.33	-0.33	7.93e-10	Aortic root size;
CRC	cis	rs972578	0.875	rs4822250	chr22:43409058	C/A	cg01576275	chr22:43409880	NA	-0.48	-7.62	-0.39	2.78e-13	Mean platelet volume;
CRC	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.52	9.22	0.45	3.57e-18	Common traits (Other);
CRC	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg06238570	chr21:40685208	BRWD1	0.7	9.24	0.45	3.12e-18	Cognitive function;
CRC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.72	9.34	0.46	1.48e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.16	0.32	2.1e-9	Menopause (age at onset);
CRC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.13	0.64	1.23e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg05527609	chr1:210001259	C1orf107	-0.65	-6.21	-0.32	1.59e-9	Red blood cell count;
CRC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	10.93	0.52	6.03e-24	Personality dimensions;
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.65	8.61	0.43	2.97e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00531307	chr14:50998683	MAP4K5;ATL1	0.49	6.31	0.33	8.8e-10	Thyroid stimulating hormone;
CRC	cis	rs4731207	0.596	rs4507709	chr7:124651533	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs8032158	1.000	rs7176225	chr15:56126857	G/A	cg02198044	chr15:56286336	NEDD4	-0.39	-6.04	-0.32	4.06e-9	Keloid;
CRC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.91	0.31	8.63e-9	Prudent dietary pattern;
CRC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.41	-5.97	-0.31	6.13e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs2742417	0.935	rs2742442	chr3:45748599	T/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.83	-0.31	1.34e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs3750082	0.889	rs13230763	chr7:32912965	C/T	cg05721444	chr7:32995514	FKBP9	0.51	7.87	0.4	5.33e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2380220	0.808	rs2613547	chr6:95910311	C/T	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.74	-0.3	2.18e-8	Breast cancer;
CRC	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.54	-7.88	-0.4	4.79e-14	Heschl's gyrus morphology;
CRC	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg20811857	chr17:78079795	GAA	-0.5	-7.13	-0.37	6.22e-12	Yeast infection;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23780514	chr18:71959249	CYB5A	0.45	6.78	0.35	5.66e-11	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03352657	chr17:26684557	POLDIP2;TMEM199	-0.39	-6.17	-0.32	1.98e-9	Myopia (pathological);
CRC	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.7	7.14	0.37	5.83e-12	Blood protein levels;
CRC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.47	7.13	0.37	6.32e-12	Red blood cell count;
CRC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.81	11.47	0.53	7.41e-26	Cognitive function;
CRC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg22974920	chr21:40686053	BRWD1	0.41	5.75	0.3	2.01e-8	Cognitive function;
CRC	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg11693508	chr17:37793320	STARD3	0.61	7.23	0.37	3.36e-12	Bipolar disorder;
CRC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg11833968	chr6:79620685	NA	-0.36	-6.04	-0.32	4.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg22134325	chr11:66188745	NPAS4	0.28	5.8	0.3	1.55e-8	Airway imaging phenotypes;
CRC	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.46	7.08	0.36	8.84e-12	HDL cholesterol;
CRC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg21153622	chr11:89784906	NA	-0.49	-8.28	-0.42	3.23e-15	Coronary artery disease;
CRC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.61	-9.75	-0.47	6.99e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1105228	0.819	rs561112	chr6:165715891	T/C	cg20535254	chr6:165714960	C6orf118	-0.28	-5.66	-0.3	3.22e-8	Number of pregnancies;Number of children;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg15786705	chr6:28176104	NA	-0.46	-6.74	-0.35	7.2e-11	Cardiac Troponin-T levels;
CRC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg01448562	chr3:133502909	NA	0.44	6.6	0.34	1.6e-10	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.66	11.79	0.54	5.46e-27	Height;
CRC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.71	10.35	0.5	6.24e-22	Menopause (age at onset);
CRC	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.46	-6.49	-0.34	3.16e-10	Large artery stroke;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.85	15.13	0.64	1.22e-39	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.59	0.34	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.49	-8.58	-0.43	3.88e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg05132306	chr1:1846340	CALML6	-0.48	-7.32	-0.37	1.9e-12	Body mass index;
CRC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.45	-6.03	-0.32	4.4e-9	Gut microbiome composition (summer);
CRC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.77	-13.1	-0.59	7.96e-32	Breast cancer;
CRC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg24308560	chr3:49941425	MST1R	-0.44	-6.09	-0.32	3.15e-9	Resting heart rate;
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.44	-6.02	-0.31	4.67e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.28	0.73	5.63e-56	Prudent dietary pattern;
CRC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.66	7.23	0.37	3.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg00105475	chr2:10696890	NA	0.45	7.11	0.36	7.28e-12	Prostate cancer;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg04518342	chr5:131593106	PDLIM4	0.46	8.52	0.43	5.95e-16	Breast cancer;
CRC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.57	-6.28	-0.33	1.07e-9	Schizophrenia;
CRC	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg17143192	chr8:8559678	CLDN23	0.48	6.25	0.33	1.26e-9	Obesity-related traits;
CRC	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg16898833	chr6:26189333	HIST1H4D	0.84	6.86	0.35	3.32e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6743226	0.901	rs4675968	chr2:242222492	T/C	cg10021735	chr2:242295487	FARP2	0.46	6.55	0.34	2.22e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.88	0.48	2.47e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.94	0.4	3.21e-14	Colorectal cancer;
CRC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.54	-9.05	-0.45	1.28e-17	Calcium levels;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-9.05	-0.45	1.26e-17	Bipolar disorder;
CRC	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-7.14	-0.37	5.85e-12	Menarche (age at onset);
CRC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg27523141	chr10:43048294	ZNF37B	0.45	6.39	0.33	5.67e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg26182253	chr13:112236782	NA	0.31	6.23	0.32	1.4e-9	Hepatitis;
CRC	cis	rs11039100	0.688	rs1993225	chr11:5841068	C/T	cg03895540	chr11:5841482	OR52N2	-0.31	-5.66	-0.3	3.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg02741985	chr17:80059408	CCDC57	0.44	7.2	0.37	4.08e-12	Life satisfaction;
CRC	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg00063174	chr2:228736253	WDR69	0.45	5.99	0.31	5.44e-9	Blood pressure;
CRC	cis	rs17767392	0.813	rs8003478	chr14:72120363	C/G	cg13720639	chr14:72061746	SIPA1L1	0.56	7.1	0.36	7.5e-12	Mitral valve prolapse;
CRC	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs9462027	0.628	rs2814970	chr6:34713500	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.5	5.78	0.3	1.75e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg02033258	chr5:131593261	PDLIM4	0.46	8.73	0.43	1.28e-16	Acylcarnitine levels;
CRC	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-6.41	-0.33	4.95e-10	Subjective well-being;
CRC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.59	8.11	0.41	1.02e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.62	12.64	0.57	4.07e-30	Neuroticism;
CRC	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg19582491	chr16:67682965	RLTPR	-0.58	-6.55	-0.34	2.26e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.51	-8.43	-0.42	1.09e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	1.04	11.74	0.54	8.07e-27	Iron status biomarkers;
CRC	trans	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg17903999	chr18:56338584	MALT1	0.4	6.54	0.34	2.32e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.65	0.51	5.81e-23	Systolic blood pressure;
CRC	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.24	-9.92	-0.48	1.84e-20	Mitochondrial DNA levels;
CRC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.94	0.48	1.59e-20	Cognitive test performance;
CRC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.55	-7.65	-0.39	2.19e-13	Corneal structure;
CRC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg05941027	chr17:61774174	LIMD2	0.35	6.31	0.33	8.87e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.46	7.35	0.38	1.59e-12	Testicular germ cell tumor;
CRC	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg05623727	chr3:50126028	RBM5	0.43	6.61	0.34	1.6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.44	-5.89	-0.31	9.6e-9	Gut microbiome composition (summer);
CRC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.54	-8.74	-0.43	1.22e-16	Huntington's disease progression;
CRC	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg20487152	chr13:99095054	FARP1	0.36	5.67	0.3	3.09e-8	Longevity;
CRC	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.44	-7.11	-0.36	7.4e-12	Caffeine consumption;
CRC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg16486109	chr11:613632	IRF7	0.73	11.8	0.55	4.83e-27	Systemic lupus erythematosus;
CRC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.35	0.38	1.59e-12	Height;
CRC	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	0.94	9.9	0.48	2.13e-20	Gut microbiota (bacterial taxa);
CRC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.64	8.89	0.44	4.1e-17	Alcohol dependence;
CRC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-6.61	-0.34	1.56e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg25834613	chr7:1915315	MAD1L1	-0.38	-6.42	-0.33	4.82e-10	Bipolar disorder;
CRC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.91	15.21	0.64	5.95e-40	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg20615401	chr6:28092323	ZSCAN16	0.44	5.77	0.3	1.82e-8	Parkinson's disease;
CRC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	0.38	5.77	0.3	1.87e-8	Breast cancer;
CRC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg23609528	chr2:113191194	RGPD5;RGPD8	0.68	5.68	0.3	2.9e-8	Yeast infection;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs17592366	0.517	rs60007157	chr14:35312272	A/G	cg09327582	chr14:35236912	BAZ1A	0.49	6.87	0.35	3.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16447950	chr5:562315	NA	-0.73	-9.65	-0.47	1.41e-19	Obesity-related traits;
CRC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg15205204	chr1:6545172	PLEKHG5	0.39	5.75	0.3	1.99e-8	Body mass index;
CRC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg24011408	chr12:48396354	COL2A1	0.46	6.28	0.33	1.1e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg07513332	chr6:167530253	CCR6	-0.48	-8.74	-0.43	1.21e-16	Primary biliary cholangitis;
CRC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.56	-6.96	-0.36	1.82e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.69	0.3	2.82e-8	Prudent dietary pattern;
CRC	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg14292368	chr19:18793705	CRTC1	-0.38	-5.64	-0.3	3.71e-8	Menarche (age at onset);
CRC	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.61	-6.22	-0.32	1.51e-9	Vitamin D levels;
CRC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.98	0.48	1.15e-20	Cognitive test performance;
CRC	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.64	8.88	0.44	4.55e-17	Coronary artery disease;
CRC	cis	rs6445967	0.933	rs6796069	chr3:58332508	C/T	cg23715586	chr3:58305044	RPP14	0.36	5.78	0.3	1.74e-8	Platelet count;
CRC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.76	11.16	0.52	9.43e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg25886479	chr11:50257625	LOC441601	0.39	6.76	0.35	6.13e-11	Height;
CRC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	7.44	0.38	8.72e-13	Mean platelet volume;
CRC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.56	-7.15	-0.37	5.77e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.02	-0.45	1.59e-17	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg18016565	chr1:150552671	MCL1	0.43	6.14	0.32	2.37e-9	Tonsillectomy;
CRC	cis	rs11212617	1.000	rs7108522	chr11:108281004	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.45	6.95	0.36	1.97e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg00495681	chr13:53174319	NA	0.6	9.1	0.45	8.68e-18	Lewy body disease;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg06900573	chr10:5978347	FBXO18	-0.41	-6.73	-0.35	7.66e-11	HDL cholesterol;
CRC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.8	-10.79	-0.51	1.88e-23	Asthma;
CRC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.56	-7.28	-0.37	2.46e-12	Gut microbiome composition (summer);
CRC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg27635394	chr6:26043820	HIST1H2BB	0.39	5.75	0.3	2e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6.25e-9	Gut microbiome composition (summer);
CRC	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.73	9.78	0.47	5.46e-20	Coronary artery disease;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03923535	chr7:1197113	ZFAND2A	0.62	8.93	0.44	3.01e-17	Longevity;Endometriosis;
CRC	cis	rs7173389	1.000	rs7173389	chr15:73663903	A/T	cg01796676	chr15:73680284	NA	0.5	6.69	0.35	9.74e-11	Resting heart rate;
CRC	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.06	-14.8	-0.63	2.51e-38	Exhaled nitric oxide output;
CRC	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.89	0.36	2.9100000000000002e-11	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg15790184	chr11:494944	RNH1	0.59	6.1	0.32	2.93e-9	Body mass index;
CRC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg18827107	chr12:86230957	RASSF9	-0.42	-6.64	-0.34	1.32e-10	Major depressive disorder;
CRC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.76	-11.94	-0.55	1.56e-27	Multiple myeloma;
CRC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg12365402	chr11:9010492	NRIP3	0.48	7.75	0.39	1.13e-13	Hemoglobin concentration;
CRC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.74	-0.35	7e-11	Lung cancer;
CRC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.45	-0.5	2.89e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.6	-10.19	-0.49	2.28e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1552172	0.845	rs17354594	chr1:145632500	A/G	cg11743829	chr1:145714124	CD160	-0.42	-6.35	-0.33	7.05e-10	Breast cancer;
CRC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13198984	chr17:80129470	CCDC57	0.48	8.5	0.42	6.51e-16	Life satisfaction;
CRC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.39	6.29	0.33	9.86e-10	Height;
CRC	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg24355006	chr19:1969744	CSNK1G2	0.5	8.15	0.41	7.62e-15	Coronary artery disease;
CRC	cis	rs4363385	0.818	rs10888524	chr1:153000125	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.8	-0.35	5.09e-11	Inflammatory skin disease;
CRC	cis	rs7932354	0.528	rs11039105	chr11:47157677	A/T	cg03339077	chr11:47165057	C11orf49	-0.45	-6.19	-0.32	1.75e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.83	13.36	0.59	8.29e-33	Menarche (age at onset);
CRC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.67e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-9.35	-0.46	1.4e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs783540	0.900	rs12916980	chr15:83306447	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.41	-7.25	-0.37	3.05e-12	Schizophrenia;
CRC	cis	rs10991814	0.920	rs16907323	chr9:94025459	A/G	cg14446406	chr9:93919335	NA	0.5	5.68	0.3	3.01e-8	Neutrophil percentage of granulocytes;
CRC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.45	9.19	0.45	4.49e-18	Renal cell carcinoma;
CRC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg09491104	chr22:46646882	C22orf40	0.42	6.42	0.33	4.87e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.68	8.2	0.41	5.37e-15	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03793131	chr1:43833547	ELOVL1	0.44	6.51	0.34	2.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.42	7.01	0.36	1.36e-11	Melanoma;
CRC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25517755	chr10:38738941	LOC399744	0.41	5.99	0.31	5.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	trans	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg25214090	chr10:38739885	LOC399744	0.42	6.47	0.34	3.65e-10	Diastolic blood pressure;
CRC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	9.23e-17	Morning vs. evening chronotype;
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.41	5.84	0.31	1.24e-8	Bipolar disorder;
CRC	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.92	15.29	0.64	2.9e-40	Dupuytren's disease;
CRC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.3	6.01	0.31	5.03e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.58	9.66	0.47	1.3e-19	Total body bone mineral density;
CRC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.76	11.44	0.53	9.62e-26	Breast cancer;
CRC	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.85	10.98	0.52	4.2e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg20608306	chr11:116969690	SIK3	-0.33	-6.4	-0.33	5.32e-10	Subjective well-being;
CRC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-10.38	-0.5	5.17e-22	Colorectal cancer;
CRC	trans	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg17903999	chr18:56338584	MALT1	0.41	6.64	0.34	1.27e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs938554	0.779	rs4639073	chr4:9973781	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.02	-0.32	4.54e-9	Blood metabolite levels;
CRC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg00383909	chr3:49044727	WDR6	0.46	5.62	0.3	4.12e-8	Educational attainment;
CRC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.17	-0.37	4.9e-12	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19947233	chr4:90032727	TIGD2	0.37	6.42	0.33	4.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg00814883	chr7:100076585	TSC22D4	-0.51	-6.11	-0.32	2.82e-9	Lung function (FEV1/FVC);
CRC	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.83	-10.59	-0.5	9.91e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.21	-0.32	1.63e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.43	5.81	0.31	1.47e-8	Tuberculosis;
CRC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.18	-0.32	1.9e-9	Menopause (age at onset);
CRC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.56	8.9	0.44	3.69e-17	Type 2 diabetes;
CRC	cis	rs3750082	0.632	rs7811630	chr7:32960718	C/A	cg05721444	chr7:32995514	FKBP9	0.5	6.37	0.33	6.34e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-8.11	-0.41	1.01e-14	Bone mineral density;
CRC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.48	7.89	0.4	4.48e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.63	11.61	0.54	2.34e-26	Prostate cancer;
CRC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.96	-0.36	1.82e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.54	9.07	0.45	1.14e-17	Prevalent atrial fibrillation;
CRC	cis	rs4690686	0.538	rs11730551	chr4:177259182	A/G	cg17059388	chr4:177262070	NA	0.38	5.71	0.3	2.52e-8	Essential tremor;
CRC	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.58	-6.02	-0.31	4.67e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17241999	chr3:171758173	FNDC3B	0.4	6.56	0.34	2.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg18016565	chr1:150552671	MCL1	-0.43	-6.3	-0.33	9.32e-10	Tonsillectomy;
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg12273811	chr6:28175739	NA	0.55	6.09	0.32	3.19e-9	Depression;
CRC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg11833968	chr6:79620685	NA	-0.36	-6.39	-0.33	5.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg22110888	chr17:80059540	CCDC57	0.39	6.22	0.32	1.51e-9	Life satisfaction;
CRC	cis	rs3902035	0.964	rs17349133	chr6:118998633	C/T	cg01339444	chr6:118972232	C6orf204	0.44	5.61	0.3	4.4e-8	QT interval;
CRC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg12193833	chr17:30244370	NA	-0.75	-8.73	-0.43	1.27e-16	Hip circumference adjusted for BMI;
CRC	trans	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-7.0	-0.36	1.41e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.26	-0.33	1.23e-9	Gout;Renal underexcretion gout;
CRC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.69	11.87	0.55	2.67e-27	Resting heart rate;
CRC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.03	-0.45	1.53e-17	Height;
CRC	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.86	0.35	3.4e-11	Brugada syndrome;
CRC	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg11130432	chr3:121712080	ILDR1	-0.5	-6.5	-0.34	2.97e-10	Multiple sclerosis;
CRC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.54	7.05	0.36	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.75	0.35	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.2	-0.32	1.73e-9	Neuroticism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24677674	chr10:113943468	GPAM	0.51	6.58	0.34	1.81e-10	Thyroid stimulating hormone;
CRC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.46	6.66	0.34	1.13e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.82	9.29	0.46	2.24e-18	Menarche (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21703068	chr21:35015322	ITSN1;CRYZL1	0.46	6.49	0.34	3.1e-10	Anxiety disorder;
CRC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.43	6.87	0.35	3.18e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.04	0.32	4.19e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13896783	chr2:159313876	CCDC148;PKP4	0.53	7.17	0.37	5.11e-12	Hip circumference;
CRC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.25	0.33	1.3e-9	Height;
CRC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg00717180	chr2:96193071	NA	-0.37	-6.1	-0.32	2.94e-9	HDL cholesterol;
CRC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg07134254	chr20:33865797	NA	0.45	5.69	0.3	2.84e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.58	-11.78	-0.54	5.97e-27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.37	-5.61	-0.3	4.4e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12743425	chr17:29877216	NA	0.47	6.71	0.35	8.53e-11	Response to antipsychotic treatment;
CRC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.23	5.61	0.3	4.32e-8	Coronary artery disease;
CRC	cis	rs73206853	0.686	rs73206895	chr12:110879968	A/G	cg12870014	chr12:110450643	ANKRD13A	0.83	9.88	0.48	2.46e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.85	9.89	0.48	2.35e-20	Inflammatory bowel disease;
CRC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg05368731	chr17:41323189	NBR1	0.67	9.76	0.47	6.24e-20	Menopause (age at onset);
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03909863	chr11:638404	DRD4	-0.45	-5.73	-0.3	2.26e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.38	6.62	0.34	1.43e-10	Cardiovascular disease risk factors;
CRC	cis	rs524281	0.731	rs11227433	chr11:66004693	G/A	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.08	-0.32	3.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.74	12.02	0.55	8.05e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.5	7.74	0.39	1.22e-13	Corneal astigmatism;
CRC	cis	rs7692995	1.000	rs6813340	chr4:17922866	A/G	cg08925142	chr4:18023851	LCORL	-0.53	-5.77	-0.3	1.83e-8	Height;
CRC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.96	-0.4	2.78e-14	Height;
CRC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.35	-6.1	-0.32	2.92e-9	Mean corpuscular volume;
CRC	cis	rs9783347	0.754	rs4757637	chr11:18307575	G/T	cg15585147	chr11:18324498	HPS5	0.43	6.36	0.33	6.74e-10	Pancreatic cancer;
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.47	6.83	0.35	4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.62	-8.46	-0.42	9.19e-16	Arsenic metabolism;
CRC	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg05925327	chr15:68127851	NA	0.29	5.9	0.31	9.15e-9	Restless legs syndrome;
CRC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.9	0.44	3.91e-17	Homoarginine levels;
CRC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg21972741	chr5:435613	AHRR	-0.48	-5.61	-0.3	4.35e-8	Cystic fibrosis severity;
CRC	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.73	-9.33	-0.46	1.61e-18	Body mass index;
CRC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.13e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg11693508	chr17:37793320	STARD3	0.58	7.25	0.37	3.07e-12	Bipolar disorder;
CRC	cis	rs12900463	0.813	rs187316	chr15:85405995	T/C	cg17507749	chr15:85114479	UBE2QP1	0.43	5.65	0.3	3.45e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.88	-15.84	-0.66	2.12e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.75	-0.47	6.86e-20	Monocyte count;
CRC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg16447950	chr5:562315	NA	-0.83	-11.04	-0.52	2.6e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.42	6.28	0.33	1.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs932287	1.000	rs932287	chr11:9044767	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-7.0	-0.36	1.4e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg00769240	chr8:12517080	NA	-0.74	-10.23	-0.49	1.64e-21	Blood pressure (smoking interaction);
CRC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.53	8.15	0.41	7.6e-15	Aortic root size;
CRC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.42	8.63	0.43	2.73e-16	Renal cell carcinoma;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.46	-0.34	3.76e-10	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00974835	chr14:74960278	NPC2;ISCA2	-0.45	-6.95	-0.36	2.01e-11	Myopia (pathological);
CRC	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.69	0.43	1.78e-16	Coffee consumption (cups per day);
CRC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.74	-11.66	-0.54	1.53e-26	Tonsillectomy;
CRC	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.44	7.1	0.36	7.6e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg18612461	chr15:75251733	NA	-0.38	-5.9	-0.31	8.98e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.81	14.49	0.62	3.74e-37	Breast cancer;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg06470822	chr6:28175283	NA	0.79	12.11	0.56	3.51e-28	Parkinson's disease;
CRC	cis	rs71403859	0.667	rs12924650	chr16:71705908	C/T	cg08717414	chr16:71523259	ZNF19	-0.97	-8.88	-0.44	4.45e-17	Post bronchodilator FEV1;
CRC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	7.15	0.37	5.52e-12	Motion sickness;
CRC	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.52	7.85	0.4	5.82e-14	Hyperactive-impulsive symptoms;
CRC	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02097616	chr17:62675921	NA	0.53	7.69	0.39	1.69e-13	QT interval;
CRC	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.48	7.27	0.37	2.68e-12	Diastolic blood pressure;
CRC	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-7.79	-0.39	9.08e-14	Homocysteine levels;
CRC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg11212589	chr17:38028394	ZPBP2	0.34	5.93	0.31	7.48e-9	Asthma;
CRC	cis	rs12230513	0.732	rs7310335	chr12:55884439	C/T	cg19537932	chr12:55886519	OR6C68	-0.71	-9.09	-0.45	9.57e-18	Contrast sensitivity;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg10096052	chr16:615709	NHLRC4	-0.34	-5.71	-0.3	2.55e-8	Height;
CRC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg00745463	chr17:30367425	LRRC37B	-0.6	-7.87	-0.4	5.24e-14	Hip circumference adjusted for BMI;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg03804128	chr16:635623	NA	0.31	7.37	0.38	1.39e-12	Height;
CRC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.65	11.02	0.52	3e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.9	-0.44	3.87e-17	Prostate cancer;
CRC	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.38	-0.38	1.34e-12	QT interval;
CRC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg09695851	chr17:3907499	NA	-0.78	-13.71	-0.6	3.91e-34	Type 2 diabetes;
CRC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.61	-0.34	1.59e-10	Red cell distribution width;
CRC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.68	9.29	0.46	2.24e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.46	5.8	0.3	1.56e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.32	0.46	1.69e-18	Heart rate;
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.64	-0.3	3.69e-8	Tonsillectomy;
CRC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.47	-8.0	-0.4	2.16e-14	Diastolic blood pressure;
CRC	cis	rs57466243	1	rs57466243	chr17:27059666	T/A	cg12682573	chr17:27188876	MIR451;MIR144	-0.37	-5.76	-0.3	1.96e-8	Reticulocyte count;
CRC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg19041857	chr6:27730383	NA	-0.43	-5.99	-0.31	5.63e-9	Parkinson's disease;
CRC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.59	9.58	0.47	2.51e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg00383909	chr3:49044727	WDR6	0.47	5.9	0.31	9.07e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.66	-10.07	-0.49	5.83e-21	Diastolic blood pressure;
CRC	trans	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg19188899	chr13:112838565	NA	-0.38	-6.02	-0.31	4.65e-9	Systemic lupus erythematosus;
CRC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	cis	rs891088	0.622	rs10426094	chr19:7205240	C/T	cg09779027	chr19:7224513	INSR	-0.58	-7.17	-0.37	4.92e-12	Hip circumference adjusted for BMI;Height;
CRC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.47	6.77	0.35	5.86e-11	Tonsillectomy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20299236	chr22:32870557	FBXO7	0.49	6.41	0.33	5.09e-10	Thyroid stimulating hormone;
CRC	cis	rs6717918	0.620	rs76788222	chr2:233152479	T/G	ch.2.233013039R	chr2:233304795	NA	0.58	6.58	0.34	1.88e-10	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12171159	chr11:72504902	STARD10	-0.38	-6.11	-0.32	2.76e-9	Myopia (pathological);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02970425	chr20:48552805	RNF114	-0.44	-6.84	-0.35	3.84e-11	Daytime sleep phenotypes;
CRC	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg22561889	chr6:118971681	C6orf204	0.47	5.9	0.31	9.09e-9	Diastolic blood pressure;
CRC	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg07713946	chr22:31675144	LIMK2	0.37	5.67	0.3	3.1e-8	Colorectal cancer;
CRC	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.44	6.44	0.33	4.35e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg04545296	chr12:48745243	ZNF641	-0.38	-6.46	-0.34	3.67e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.65	-9.79	-0.47	5.14e-20	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23325948	chr5:169011174	CCDC99	0.48	6.96	0.36	1.82e-11	Response to antipsychotic treatment;
CRC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.4	7.74	0.39	1.22e-13	Ulcerative colitis;
CRC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.51	-7.18	-0.37	4.57e-12	Fibrinogen levels;
CRC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg20243544	chr17:37824526	PNMT	0.53	8.53	0.43	5.41e-16	Asthma;
CRC	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.98	12.17	0.56	2.19e-28	Ulcerative colitis;
CRC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg17724175	chr1:150552817	MCL1	0.45	6.77	0.35	6.07e-11	Melanoma;
CRC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg03623178	chr6:28175578	NA	0.48	6.95	0.36	1.94e-11	Pubertal anthropometrics;
CRC	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg27053337	chr8:124217698	FAM83A	0.4	5.65	0.3	3.42e-8	Urinary uromodulin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05672380	chr19:36505394	ALKBH6	0.45	6.54	0.34	2.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.76	-16.61	-0.68	2.03e-45	Breast cancer;
CRC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.49	8.14	0.41	8e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.09	0.41	1.2e-14	Menopause (age at onset);
CRC	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg00086871	chr4:6988644	TBC1D14	1.02	7.68	0.39	1.81e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.61	13.71	0.6	3.82e-34	Airflow obstruction;
CRC	trans	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg17903999	chr18:56338584	MALT1	0.4	6.59	0.34	1.78e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.84	0.51	1.3e-23	Motion sickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01109508	chr10:135187068	ECHS1	0.39	6.35	0.33	7.15e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg27043427	chr17:65362820	PSMD12	-0.44	-6.36	-0.33	6.67e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs629535	0.862	rs598548	chr8:70032438	C/T	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11234017	chr17:42767172	CCDC43	0.56	7.46	0.38	7.76e-13	Thyroid stimulating hormone;
CRC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.5	-5.65	-0.3	3.45e-8	Initial pursuit acceleration;
CRC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg00750074	chr16:89608354	SPG7	-0.5	-7.64	-0.39	2.39e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.75	-0.3	1.99e-8	Coronary artery disease;
CRC	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.59	-8.37	-0.42	1.73e-15	Personality dimensions;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.57	-0.39	3.7e-13	Longevity;Endometriosis;
CRC	trans	rs747334	0.713	rs7078592	chr10:92727797	A/T	cg19856520	chr1:39696676	MACF1	-0.33	-5.96	-0.31	6.4e-9	Fibroblast growth factor basic levels;
CRC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.07	0.45	1.07e-17	Alzheimer's disease;
CRC	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.51	-0.54	5.47e-26	Colorectal cancer;
CRC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.21	0.32	1.64e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg23205692	chr1:25664452	TMEM50A	0.42	5.93	0.31	7.74e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.61	8.51	0.42	6.45e-16	Arsenic metabolism;
CRC	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.5	8.74	0.43	1.25e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.27	-0.49	1.2e-21	Bipolar disorder;
CRC	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.45	-6.25	-0.33	1.29e-9	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09968765	chr19:3985171	EEF2	0.48	6.68	0.35	1.03e-10	Response to antipsychotic treatment;
CRC	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.15	19.38	0.73	2.36e-56	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	8.27	0.41	3.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10760158	0.832	rs10760169	chr9:124057682	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.75	-0.3	2.04e-8	Pulse pressure;
CRC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.72	12.3	0.56	7.5e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23068124	chr14:58711505	PSMA3	0.45	6.33	0.33	7.91e-10	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-5.97	-0.31	6.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg15786705	chr6:28176104	NA	0.49	7.03	0.36	1.18e-11	Hepatitis A;
CRC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.97e-22	Menopause (age at onset);
CRC	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.51	-0.42	6.38e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6968419	0.755	rs4730720	chr7:115895235	C/T	cg02561103	chr7:115862891	TES	0.44	6.61	0.34	1.6e-10	Intraocular pressure;
CRC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.6	0.34	1.64e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.75	-7.82	-0.4	7.28e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.79	13.42	0.59	4.56e-33	Menopause (age at onset);
CRC	trans	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg15845792	chr6:28175446	NA	0.67	6.52	0.34	2.71e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.57	6.02	0.32	4.62e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg18809830	chr7:99032528	PTCD1	-1.18	-8.59	-0.43	3.66e-16	Blood metabolite levels;
CRC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.33	-0.33	8.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg25456477	chr12:86230367	RASSF9	0.4	6.71	0.35	8.75e-11	Major depressive disorder;
CRC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.62	0.39	2.68e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.39	-0.33	5.65e-10	Sense of smell;
CRC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.62	11.22	0.53	5.75e-25	Schizophrenia;
CRC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg02659138	chr7:134003124	SLC35B4	0.38	6.23	0.32	1.47e-9	Mean platelet volume;
CRC	trans	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg24375607	chr4:120327624	NA	0.48	7.75	0.39	1.16e-13	Corneal astigmatism;
CRC	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.57	-0.43	3.99e-16	Biliary atresia;
CRC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.07	0.41	1.35e-14	Life satisfaction;
CRC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	7.71	0.39	1.54e-13	Gut microbiome composition (summer);
CRC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg01262667	chr19:19385393	TM6SF2	-0.36	-5.95	-0.31	6.7e-9	Tonsillectomy;
CRC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.1	19.92	0.74	1.84e-58	Ulcerative colitis;
CRC	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.61	9.64	0.47	1.54e-19	Systemic lupus erythematosus;
CRC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg09127314	chr1:152161683	NA	0.5	6.31	0.33	9.03e-10	Atopic dermatitis;
CRC	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg00291366	chr1:12616550	NA	0.6	10.78	0.51	2.11e-23	Optic cup area;
CRC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	1.03	9.71	0.47	9.22e-20	Birth weight;
CRC	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.7	-6.31	-0.33	8.86e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11122148	chr13:45150705	TSC22D1	0.37	6.7	0.35	9.23e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-7.1	-0.36	7.84e-12	Inflammatory skin disease;
CRC	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.47	-0.34	3.6e-10	Retinal vascular caliber;
CRC	trans	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg10756647	chr7:56101905	PSPH	0.74	7.99	0.4	2.29e-14	Diabetic kidney disease;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg09877947	chr5:131593287	PDLIM4	0.54	10.07	0.49	5.53e-21	Acylcarnitine levels;
CRC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-8.29	-0.42	2.99e-15	Hemoglobin concentration;
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.46	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg12458913	chr13:53173898	NA	0.75	13.66	0.6	5.78e-34	Lewy body disease;
CRC	cis	rs12024301	0.557	rs12045516	chr1:183625631	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23819836	chr6:15663134	DTNBP1	0.46	6.08	0.32	3.26e-9	Hip circumference;
CRC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.6	9.01	0.44	1.71e-17	Aortic root size;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.5	5.74	0.3	2.2e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs11692377	chr2:15659848	C/T	cg19274914	chr2:15703543	NA	0.39	5.86	0.31	1.13e-8	Educational attainment (years of education);
CRC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.59	8.32	0.42	2.34e-15	Lung cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02711976	chr1:36023590	NCDN;KIAA0319L	0.47	6.16	0.32	2.07e-9	Survival in pancreatic cancer;
CRC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.74	11.25	0.53	4.76e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.18	10.89	0.51	8.81e-24	Alzheimer's disease (late onset);
CRC	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11446398	chr5:77624930	NA	0.41	5.98	0.31	5.91e-9	Triglycerides;
CRC	cis	rs4731207	0.596	rs6980448	chr7:124569418	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg10802521	chr3:52805072	NEK4	0.45	6.2	0.32	1.7e-9	Schizophrenia;
CRC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.35	6.05	0.32	3.88e-9	Erythrocyte sedimentation rate;
CRC	cis	rs16856186	0.520	rs73082334	chr1:205800125	T/C	cg07157834	chr1:205819609	PM20D1	-0.57	-5.65	-0.3	3.44e-8	Pulmonary function decline;
CRC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg15468180	chr1:107600409	PRMT6	0.38	5.72	0.3	2.45e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-8.51	-0.42	6.45e-16	Intelligence (multi-trait analysis);
CRC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.63	8.52	0.43	5.84e-16	Multiple sclerosis;
CRC	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.33	-0.37	1.76e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.61	-9.72	-0.47	8.51e-20	Motion sickness;
CRC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg05623727	chr3:50126028	RBM5	-0.43	-7.27	-0.37	2.72e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-8.69	-0.43	1.71e-16	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.35	6.14	0.32	2.35e-9	Erythrocyte sedimentation rate;
CRC	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.72	-9.46	-0.46	6.22e-19	Cisplatin-induced ototoxicity;
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.82	12.53	0.57	1.02e-29	Menarche (age at onset);
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg03160526	chr17:80928410	B3GNTL1	0.57	7.72	0.39	1.37e-13	Glycated hemoglobin levels;
CRC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.6	-10.52	-0.5	1.72e-22	Immature fraction of reticulocytes;
CRC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.33	6.74	0.35	7.09e-11	Lung cancer;
CRC	trans	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.74	0.35	7.12e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.58	11.05	0.52	2.45e-24	Eye color traits;
CRC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.98	-18.85	-0.72	2.78e-54	Gut microbiome composition (winter);
CRC	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg15711740	chr2:61764176	XPO1	-0.53	-7.17	-0.37	5e-12	Tuberculosis;
CRC	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.45	6.21	0.32	1.64e-9	Height;
CRC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.62	9.62	0.47	1.88e-19	Corneal astigmatism;
CRC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.84	-0.31	1.27e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg03162506	chr22:38580953	NA	0.28	6.0	0.31	5.31e-9	Cutaneous nevi;
CRC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	1.12	10.64	0.51	6.59e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg25767906	chr1:53392781	SCP2	-0.47	-7.43	-0.38	9.49e-13	Monocyte count;
CRC	cis	rs7635838	0.927	rs13082150	chr3:11437813	T/C	cg00170343	chr3:11313890	ATG7	0.41	6.28	0.33	1.08e-9	HDL cholesterol;
CRC	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.34e-11	Prostate cancer;
CRC	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.49	7.22	0.37	3.61e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs11212617	0.967	rs11212616	chr11:108281322	T/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.43	0.33	4.4e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.38	-5.87	-0.31	1.08e-8	IgG glycosylation;
CRC	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.39	-7.4	-0.38	1.11e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	10.01	0.48	8.88e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.93	-10.49	-0.5	2.11e-22	Cerebrospinal P-tau181p levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21694044	chr22:41215540	SLC25A17	0.4	6.75	0.35	6.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7254114	0.618	rs7250652	chr19:11302606	A/G	cg02815516	chr19:11306319	KANK2	-0.34	-6.62	-0.34	1.48e-10	Immature fraction of reticulocytes;
CRC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.65	-0.68	1.36e-45	Height;
CRC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.49	0.46	4.96e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26051060	chr21:43916302	RSPH1	0.43	6.09	0.32	3.21e-9	Response to antipsychotic treatment;
CRC	cis	rs6504622	1.000	rs1047779	chr17:45019243	T/G	cg16759221	chr17:45003025	GOSR2	0.45	7.1	0.36	7.68e-12	Orofacial clefts;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg21251018	chr6:28226885	NKAPL	0.47	7.26	0.37	2.83e-12	Cardiac Troponin-T levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01038479	chr17:35767307	TADA2A;ACACA	0.45	6.16	0.32	2.17e-9	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.59	6.16	0.32	2.16e-9	Cognitive function;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg14875093	chr19:38398164	WDR87;SIPA1L3	-0.59	-7.09	-0.36	8.05e-12	Diisocyanate-induced asthma;
CRC	cis	rs2276314	0.512	rs1789515	chr18:33635893	G/A	cg05985134	chr18:33552581	C18orf21	-0.37	-5.83	-0.31	1.3e-8	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg12927641	chr6:109611667	NA	-0.38	-6.62	-0.34	1.42e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg11212589	chr17:38028394	ZPBP2	-0.43	-7.94	-0.4	3.25e-14	Self-reported allergy;
CRC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.67	9.35	0.46	1.35e-18	Coronary artery disease;
CRC	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg21251018	chr6:28226885	NKAPL	0.46	6.57	0.34	1.97e-10	Depression;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg06470822	chr6:28175283	NA	0.78	8.18	0.41	6.06e-15	Lung cancer in ever smokers;
CRC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.77	-10.19	-0.49	2.27e-21	Blood metabolite levels;
CRC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.79	13.94	0.61	4.99e-35	Metabolic syndrome;
CRC	cis	rs12024301	0.557	rs77882972	chr1:183609281	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.8	6.63	0.34	1.39e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.33	-0.33	8.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.14	0.61	8.48e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4276421	0.869	rs11741075	chr5:45556378	C/T	cg04793272	chr11:119020941	ABCG4	0.38	5.97	0.31	6.24e-9	P wave duration;
CRC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.44	-0.38	8.76e-13	Retinal vascular caliber;
CRC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.4	-0.33	5.31e-10	Aortic root size;
CRC	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.67	0.39	1.95e-13	Corneal astigmatism;
CRC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg08755490	chr11:65554678	OVOL1	0.44	6.34	0.33	7.57e-10	Acne (severe);
CRC	cis	rs970548	0.954	rs72796498	chr10:45982219	C/T	cg15590007	chr10:45870220	ALOX5	0.47	5.98	0.31	5.8e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.06	0.41	1.48e-14	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.29	-0.37	2.34e-12	Morning vs. evening chronotype;
CRC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.06	-0.32	3.68e-9	Alzheimer's disease (late onset);
CRC	trans	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.68	0.3	2.98e-8	Prudent dietary pattern;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg19041857	chr6:27730383	NA	-0.42	-5.94	-0.31	7.29e-9	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.45	-10.17	-0.49	2.57e-21	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg04731861	chr2:219085781	ARPC2	0.32	6.74	0.35	7.23e-11	Colorectal cancer;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg12273811	chr6:28175739	NA	0.45	6.71	0.35	8.28e-11	Cardiac Troponin-T levels;
CRC	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg15382696	chr6:118971807	C6orf204	0.6	7.78	0.39	9.5e-14	Diastolic blood pressure;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.57	7.38	0.38	1.33e-12	Body mass index;
CRC	trans	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg24849736	chr1:201084428	NA	-0.46	-6.26	-0.33	1.17e-9	Permanent tooth development;
CRC	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.37	-5.85	-0.31	1.17e-8	Reticulocyte count;High light scatter reticulocyte count;
CRC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.59	10.17	0.49	2.62e-21	Iron status biomarkers;
CRC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg03037974	chr15:76606532	NA	0.72	12.85	0.58	6.38e-31	Blood metabolite levels;
CRC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.43	-7.97	-0.4	2.7e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6735179	0.641	rs2382558	chr2:1752229	A/G	cg19300414	chr2:1746591	PXDN	0.44	7.6	0.39	3.1400000000000003e-13	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-10.97	-0.52	4.52e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12612619	0.677	rs3754733	chr2:27249245	A/G	cg00617064	chr2:27272375	NA	-0.38	-6.21	-0.32	1.6e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg25482853	chr8:67687455	SGK3	0.9	11.12	0.52	1.3e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.64e-9	Bipolar disorder;
CRC	cis	rs2252790	0.859	rs3053	chr6:116679751	A/T	cg18764771	chr6:116381957	FRK	-0.22	-6.03	-0.32	4.34e-9	Fast beta electroencephalogram;
CRC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.79	13.24	0.59	2.36e-32	Menopause (age at onset);
CRC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg16950941	chr11:66035639	RAB1B	-0.62	-7.57	-0.39	3.74e-13	Electroencephalogram traits;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.44	-9.07	-0.45	1.09e-17	Bipolar disorder;
CRC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg24253500	chr15:84953950	NA	0.38	6.49	0.34	3.23e-10	Schizophrenia;
CRC	cis	rs7259376	0.902	rs11669353	chr19:22605103	G/C	cg02657401	chr19:22469223	NA	0.3	6.54	0.34	2.3e-10	Menopause (age at onset);
CRC	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.4	6.05	0.32	3.83e-9	Endometrial cancer;
CRC	cis	rs3018066	0.867	rs4569824	chr4:107186200	A/T	cg01869342	chr4:106983673	TBCK	-0.38	-5.92	-0.31	8.01e-9	Cancer;
CRC	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg00319359	chr11:70116639	PPFIA1	0.66	6.56	0.34	2.1e-10	Coronary artery disease;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg15786705	chr6:28176104	NA	-0.45	-6.6	-0.34	1.64e-10	Cardiac Troponin-T levels;
CRC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	6.71	0.35	8.31e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.69	-13.45	-0.6	3.75e-33	Educational attainment;
CRC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.52	-10.87	-0.51	1.04e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg23533926	chr12:111358616	MYL2	-0.51	-7.67	-0.39	1.95e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs981844	0.796	rs11099904	chr4:154681861	A/G	cg10279832	chr4:154682576	RNF175	-0.39	-5.71	-0.3	2.54e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.39	7.57	0.39	3.7e-13	Mean corpuscular volume;
CRC	cis	rs17162190	0.698	rs3816539	chr1:26786627	G/A	cg17456097	chr1:26900765	RPS6KA1	0.47	6.62	0.34	1.5e-10	Mean corpuscular volume;
CRC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg03013999	chr17:37608204	MED1	0.48	7.43	0.38	9.6e-13	Glomerular filtration rate (creatinine);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg22039215	chr3:195716632	SDHAP1	0.43	6.04	0.32	4.1e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg11189052	chr15:85197271	WDR73	0.64	8.93	0.44	3.1e-17	Schizophrenia;
CRC	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.02	0.36	1.3e-11	Diisocyanate-induced asthma;
CRC	cis	rs720844	0.554	rs16828786	chr2:149296672	A/G	cg09247360	chr2:149335327	NA	-0.42	-5.7	-0.3	2.62e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.39	-0.33	5.79e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.86	15.9	0.66	1.21e-42	Hip circumference;
CRC	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg11003573	chr3:44754125	ZNF502	-0.37	-6.36	-0.33	6.86e-10	Depressive symptoms;
CRC	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.66	-9.8	-0.48	4.52e-20	Non-response to antidepressants and depression;
CRC	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.64	8.48	0.42	8e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.26	0.33	1.17e-9	Body mass index;
CRC	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg06307176	chr5:131281290	NA	0.43	6.19	0.32	1.79e-9	Life satisfaction;
CRC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg24851651	chr11:66362959	CCS	-0.38	-6.54	-0.34	2.3e-10	Educational attainment (years of education);
CRC	cis	rs12024301	0.557	rs2231241	chr1:183596703	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.72	6.52	0.34	2.64e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg21856205	chr7:94953877	PON1	-0.49	-6.29	-0.33	1.03e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.41	-6.34	-0.33	7.6e-10	Refractive error;
CRC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg19824325	chr16:58548873	SETD6	0.96	6.28	0.33	1.08e-9	Schizophrenia;
CRC	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg15744005	chr10:104629667	AS3MT	0.29	5.83	0.31	1.32e-8	Arsenic metabolism;
CRC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	cis	rs9311676	0.656	rs3191903	chr3:58382846	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs11677416	1.000	rs11677416	chr2:113529240	A/G	cg27083787	chr2:113543245	IL1A	0.47	6.58	0.34	1.82e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.74	-0.39	1.24e-13	Developmental language disorder (linguistic errors);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg17169982	chr17:80787973	TBCD;ZNF750	0.42	6.43	0.33	4.39e-10	Interleukin-6 levels;
CRC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23992470	chr4:843637	GAK	0.47	7.27	0.37	2.64e-12	Parkinson's disease;
CRC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg03037974	chr15:76606532	NA	-0.53	-7.26	-0.37	2.8e-12	Blood metabolite levels;
CRC	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.59	7.13	0.37	6.35e-12	Carotid intima media thickness;
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.3	-0.37	2.2e-12	Testicular germ cell tumor;
CRC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg04117972	chr1:227635322	NA	0.66	6.06	0.32	3.81e-9	Major depressive disorder;
CRC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg16342193	chr10:102329863	NA	-0.36	-5.93	-0.31	7.45e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.52	7.91	0.4	4.04e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.89	-0.4	4.42e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	5.05e-15	Red blood cell count;
CRC	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.16	-0.32	2.11e-9	Blood protein levels;
CRC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.84	15.17	0.64	8.56e-40	Prudent dietary pattern;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg11859384	chr17:80120422	CCDC57	0.36	5.71	0.3	2.59e-8	Life satisfaction;
CRC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg25251562	chr2:3704773	ALLC	-0.49	-6.16	-0.32	2.09e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.83	15.37	0.65	1.41e-40	Hip circumference;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg21251018	chr6:28226885	NKAPL	0.38	5.63	0.3	3.79e-8	Parkinson's disease;
CRC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.54	-0.38	4.59e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.63	-0.34	1.34e-10	Total body bone mineral density;
CRC	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.64	0.43	2.42e-16	Mean corpuscular volume;
CRC	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.84	9.01	0.44	1.66e-17	Gastritis;
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg09873164	chr1:152488093	CRCT1	0.38	6.3	0.33	9.41e-10	Plantar warts;
CRC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg16141378	chr3:129829833	LOC729375	-0.46	-7.14	-0.37	6.09e-12	Neuroticism;
CRC	cis	rs7259376	0.902	rs11879678	chr19:22607312	C/A	cg02657401	chr19:22469223	NA	0.31	6.67	0.35	1.07e-10	Menopause (age at onset);
CRC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12292205	chr6:26970375	C6orf41	-0.49	-6.74	-0.35	6.97e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.59	0.63	1.52e-37	Colorectal cancer;
CRC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.5	-6.51	-0.34	2.87e-10	Gut microbiome composition (summer);
CRC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.51	9.08	0.45	1.02e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1930961	1.000	rs6004667	chr22:25874464	A/G	cg13472656	chr22:25960710	ADRBK2	-0.52	-5.7	-0.3	2.65e-8	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg04562611	chr16:615315	C16orf11	0.35	5.88	0.31	9.85e-9	Height;
CRC	cis	rs12519773	0.501	rs4321736	chr5:92533363	C/T	cg18783429	chr5:92414398	NA	0.28	5.9	0.31	9.09e-9	Migraine;
CRC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	1.07	10.66	0.51	5.43e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.62	10.32	0.49	8.41e-22	Personality dimensions;
CRC	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.06	-16.04	-0.66	3.67e-43	Colorectal cancer;
CRC	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.78	14.28	0.62	2.41e-36	Oral cavity cancer;
CRC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.39	7.05	0.36	1.04e-11	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27238079	chr10:33247273	ITGB1	-0.37	-5.98	-0.31	5.72e-9	Myopia (pathological);
CRC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24308560	chr3:49941425	MST1R	0.48	7.6	0.39	3.19e-13	Intelligence (multi-trait analysis);
CRC	cis	rs400736	0.859	rs379920	chr1:8028865	G/C	cg25007680	chr1:8021821	PARK7	0.56	7.59	0.39	3.32e-13	Response to antidepressants and depression;
CRC	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg00277334	chr10:82204260	NA	-0.44	-5.8	-0.3	1.55e-8	Post bronchodilator FEV1;
CRC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.88	-0.48	2.55e-20	Body mass index;
CRC	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg07699608	chr10:75541558	CHCHD1	0.61	6.37	0.33	6.53e-10	Incident atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09514589	chr15:76603992	ETFA	0.43	6.08	0.32	3.38e-9	Response to antipsychotic treatment;
CRC	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg01475377	chr6:109611718	NA	-0.34	-5.9	-0.31	9.23e-9	Reticulocyte fraction of red cells;
CRC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.73	8.06	0.41	1.38e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	7.47	0.38	7.26e-13	Response to antipsychotic treatment;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg22438603	chr5:127418940	SLC12A2;FLJ33630	-0.56	-6.05	-0.32	3.96e-9	Lung adenocarcinoma;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.44	-6.77	-0.35	6.04e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.59	6.83	0.35	4.23e-11	Height;Educational attainment;Head circumference (infant);
CRC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg19041857	chr6:27730383	NA	-0.77	-6.96	-0.36	1.81e-11	Depression;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.29	-0.37	2.32e-12	Lymphocyte counts;
CRC	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg24463073	chr6:118973353	C6orf204	0.48	5.85	0.31	1.18e-8	Diastolic blood pressure;
CRC	cis	rs6662572	0.806	rs56067046	chr1:46044314	C/T	cg08644498	chr1:46502608	NA	0.49	7.02	0.36	1.26e-11	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22595711	chr4:83351836	ENOPH1;HNRPDL	0.47	6.65	0.34	1.24e-10	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg02158880	chr13:53174818	NA	0.49	7.37	0.38	1.37e-12	Lewy body disease;
CRC	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg23254163	chr1:152506842	NA	0.46	9.0	0.44	1.84e-17	Hair morphology;
CRC	cis	rs9549260	0.753	rs9549243	chr13:41217205	G/A	cg21288729	chr13:41239152	FOXO1	0.49	6.26	0.33	1.19e-9	Red blood cell count;
CRC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.86	-11.11	-0.52	1.51e-24	Initial pursuit acceleration;
CRC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg00834779	chr19:12036415	ZNF700	-0.41	-6.23	-0.32	1.42e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg23408836	chr2:170590490	KLHL23	-0.42	-6.25	-0.33	1.26e-9	Daytime sleep phenotypes;
CRC	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg08501292	chr6:25962987	TRIM38	0.64	6.68	0.35	1.04e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg07817883	chr1:32538562	TMEM39B	1.68	13.33	0.59	1.01e-32	Granulocyte percentage of myeloid white cells;
CRC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.88	0.35	3.1e-11	Morning vs. evening chronotype;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22212156	chr20:32031449	SNTA1	-0.39	-5.99	-0.31	5.53e-9	Myopia (pathological);
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg08034379	chr2:228736324	WDR69	-0.49	-6.75	-0.35	6.83e-11	Blood pressure;
CRC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-11.95	-0.55	1.38e-27	Prostate cancer;
CRC	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg11901034	chr3:128598214	ACAD9	-0.59	-7.83	-0.4	6.55e-14	IgG glycosylation;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00852613	chr13:50159829	RCBTB1	0.39	6.29	0.33	1.03e-9	Obesity-related traits;
CRC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg27426351	chr10:43362370	NA	0.49	6.18	0.32	1.89e-9	Blood protein levels;
CRC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg03623178	chr6:28175578	NA	0.74	7.48	0.38	6.79e-13	Depression;
CRC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.62	7.65	0.39	2.23e-13	Dilated cardiomyopathy;
CRC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg27121462	chr16:89883253	FANCA	0.56	8.66	0.43	2.17e-16	Vitiligo;
CRC	cis	rs4936891	0.577	rs1453650	chr11:123921929	A/G	cg22125253	chr11:123886957	OR10G4	-0.34	-6.17	-0.32	2e-9	Male fertility;
CRC	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg22495460	chr2:25135724	ADCY3	-0.76	-13.74	-0.6	2.77e-34	Body mass index in non-asthmatics;
CRC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.83	11.82	0.55	4.02e-27	Cognitive function;
CRC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3736485	0.934	rs17609812	chr15:51879260	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.75	-12.26	-0.56	1.02e-28	Height;
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg02683197	chr6:28174875	NA	0.55	7.76	0.39	1.05e-13	Parkinson's disease;
CRC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.74	11.1	0.52	1.62e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs17234274	0.644	rs7949847	chr11:23222440	C/G	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.02e-8	Cancer;
CRC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.56	8.16	0.41	7e-15	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg26043149	chr18:55253948	FECH	-0.49	-7.51	-0.38	5.78e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg05585544	chr11:47624801	NA	-0.61	-10.64	-0.51	6.26e-23	Subjective well-being;
CRC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.63	6.5	0.34	2.94e-10	Axial length;
CRC	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg07979401	chr6:33739406	LEMD2	0.48	6.09	0.32	3.16e-9	Schizophrenia;
CRC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.86	14.23	0.62	3.68e-36	Alcohol dependence;
CRC	cis	rs17095355	1.000	rs17126877	chr10:111672786	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.53	-6.06	-0.32	3.66e-9	Biliary atresia;
CRC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.52	-0.78	1.34e-68	Myeloid white cell count;
CRC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Bladder cancer;
CRC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.53	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.22	-0.37	3.6e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.45	6.71	0.35	8.7e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.49	-8.36	-0.42	1.84e-15	Electroencephalogram traits;
CRC	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg18764771	chr6:116381957	FRK	0.26	6.25	0.33	1.26e-9	Total cholesterol levels;
CRC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.81	-0.55	4.53e-27	Type 2 diabetes;
CRC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	14.36	0.62	1.17e-36	Platelet count;
CRC	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg11130432	chr3:121712080	ILDR1	0.5	6.15	0.32	2.19e-9	Multiple sclerosis;
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg20933634	chr6:27740509	NA	0.39	5.65	0.3	3.39e-8	Parkinson's disease;
CRC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.5	-0.38	6e-13	Intelligence (multi-trait analysis);
CRC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.1	-0.36	7.67e-12	Mean corpuscular volume;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12273811	chr6:28175739	NA	0.63	8.16	0.41	7.43e-15	Parkinson's disease;
CRC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27570636	chr1:214454189	SMYD2	0.43	6.22	0.32	1.49e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02290350	chr8:58132656	NA	-0.6	-8.4	-0.42	1.33e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg06307176	chr5:131281290	NA	0.45	6.48	0.34	3.34e-10	Life satisfaction;
CRC	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.09	-0.41	1.18e-14	Morning vs. evening chronotype;
CRC	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.48	7.0	0.36	1.42e-11	Coronary heart disease;
CRC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.11	0.69	2.18e-47	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.44	7.51	0.38	5.6e-13	HDL cholesterol;
CRC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.88	-15.94	-0.66	8.97e-43	Body mass index;
CRC	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	1.06	14.77	0.63	3.26e-38	Exhaled nitric oxide output;
CRC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg18876405	chr7:65276391	NA	-0.45	-6.06	-0.32	3.74e-9	Aortic root size;
CRC	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.55	9.83	0.48	3.7e-20	Common traits (Other);
CRC	cis	rs1519814	1.000	rs4871045	chr8:121167814	T/C	cg22335954	chr8:121166405	COL14A1	-0.58	-6.73	-0.35	7.65e-11	Breast cancer;
CRC	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-18.76	-0.72	6.3e-54	Ulcerative colitis;
CRC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	11.1	0.52	1.62e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg25797454	chr6:150327115	RAET1K	0.38	6.49	0.34	3.13e-10	Alopecia areata;
CRC	cis	rs12474201	0.630	rs897529	chr2:46948175	T/C	cg06386533	chr2:46925753	SOCS5	0.66	10.72	0.51	3.5e-23	Height;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.21	0.41	4.97e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.7	-7.89	-0.4	4.52e-14	Body mass index;
CRC	cis	rs9311676	0.632	rs62259780	chr3:58428078	T/G	cg06643156	chr3:58380774	PXK	0.43	6.53	0.34	2.5e-10	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-10.96	-0.52	4.78e-24	Developmental language disorder (linguistic errors);
CRC	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	8.2	0.41	5.27e-15	Obesity-related traits;
CRC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.4	-0.38	1.12e-12	Colorectal cancer;
CRC	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg01312482	chr5:178451176	ZNF879	-0.35	-5.93	-0.31	7.85e-9	Pubertal anthropometrics;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20791669	chr3:190232025	IL1RAP	0.48	6.2	0.32	1.74e-9	Thyroid stimulating hormone;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25385272	chr1:222763149	TAF1A	0.48	6.13	0.32	2.57e-9	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg03037974	chr15:76606532	NA	-0.54	-8.08	-0.41	1.29e-14	Blood metabolite levels;
CRC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg20291162	chr17:40259547	DHX58	-0.55	-7.98	-0.4	2.46e-14	Fibrinogen levels;
CRC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	0.8	7.17	0.37	4.9e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.57	8.79	0.44	8.75e-17	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00596521	chr2:175260560	CIR1;SCRN3	0.39	6.69	0.35	9.37e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg23920097	chr1:209922102	NA	-0.47	-5.67	-0.3	3.11e-8	Red blood cell count;
CRC	cis	rs10503871	0.545	rs7822088	chr8:30498193	G/A	cg26383811	chr8:30366931	RBPMS	0.4	5.65	0.3	3.4e-8	Metabolite levels  (X-11787);
CRC	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg14631576	chr9:95140430	CENPP	0.31	5.81	0.31	1.47e-8	Height;
CRC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	0.79	8.63	0.43	2.66e-16	Gout;Renal underexcretion gout;
CRC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.51	6.57	0.34	2.01e-10	Obesity-related traits;
CRC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.03	0.32	4.29e-9	Prudent dietary pattern;
CRC	cis	rs2630709	0.562	rs3097267	chr2:8466157	A/G	cg12167548	chr2:8464763	NA	-0.35	-6.85	-0.35	3.59e-11	Monocyte percentage of white cells;
CRC	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.92	0.44	3.34e-17	Fuchs's corneal dystrophy;
CRC	cis	rs1992660	0.528	rs6883302	chr5:40411414	C/T	cg09067459	chr5:40385259	NA	0.44	7.59	0.39	3.31e-13	Crohn's disease;
CRC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.44	-7.99	-0.4	2.28e-14	Huntington's disease progression;
CRC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.56	6.51	0.34	2.74e-10	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26807643	chr1:11741683	MAD2L2	0.41	6.14	0.32	2.39e-9	Response to antipsychotic treatment;
CRC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.81	8.17	0.41	6.68e-15	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15793563	chr11:910950	CHID1	0.4	7.06	0.36	1.01e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.49	7.69	0.39	1.73e-13	Monocyte percentage of white cells;
CRC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.61	-8.76	-0.43	1.05e-16	Inflammatory bowel disease;
CRC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.64	-0.57	3.92e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg20607287	chr7:12443886	VWDE	-0.5	-7.0	-0.36	1.47e-11	Coronary artery disease;
CRC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.83	9.66	0.47	1.31e-19	Psoriasis;
CRC	cis	rs17270561	0.636	rs3922681	chr6:25698481	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	7.57	0.39	3.68e-13	Iron status biomarkers;
CRC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.1	18.48	0.71	8.34e-53	Total cholesterol levels;
CRC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.49	7.04	0.36	1.15e-11	Aortic root size;
CRC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10021731	0.718	rs28766989	chr4:115410908	C/T	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.46	7.41	0.38	1.07e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02132760	chr11:18416547	LDHA	0.47	6.6	0.34	1.7e-10	Response to antipsychotic treatment;
CRC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	6.08	0.32	3.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3736485	0.934	rs4775955	chr15:51873449	C/T	cg08986416	chr15:51914746	DMXL2	0.45	6.47	0.34	3.47e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.7	-0.39	1.63e-13	Cholesterol, total;
CRC	trans	rs2303319	0.504	rs62187613	chr2:162434474	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.05	-0.32	3.89e-9	Cognitive function;
CRC	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg12700464	chr11:78128424	GAB2	-0.47	-5.63	-0.3	3.87e-8	Testicular germ cell tumor;
CRC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg04731861	chr2:219085781	ARPC2	-0.32	-6.79	-0.35	5.3e-11	Colorectal cancer;
CRC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg07274523	chr3:49395745	GPX1	0.45	6.11	0.32	2.89e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.89	-0.31	9.59e-9	Schizophrenia;
CRC	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg11204139	chr17:3907470	NA	0.82	16.22	0.67	7.11e-44	Type 2 diabetes;
CRC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.77	-0.3	1.87e-8	Mean platelet volume;
CRC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg18478394	chr8:109455254	TTC35	0.38	5.8	0.3	1.53e-8	Dupuytren's disease;
CRC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs41271951	0.512	rs12070256	chr1:151070090	C/T	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.72	-0.3	2.34e-8	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02679291	chr19:48248902	GLTSCR2	0.4	6.14	0.32	2.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.14	-0.37	5.85e-12	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06157335	chr1:53164003	C1orf163	0.5	6.95	0.36	1.98e-11	Response to antipsychotic treatment;
CRC	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs800160	0.777	rs11022289	chr11:2345417	T/G	cg09785033	chr11:2336066	TSPAN32	-0.48	-5.74	-0.3	2.13e-8	Bacteremia;
CRC	cis	rs11212617	0.905	rs1893813	chr11:108054604	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.69	0.3	2.86e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	12.0	0.55	9.05e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4664293	0.647	rs1425039	chr2:160428123	A/C	cg08347373	chr2:160653686	CD302	-0.38	-6.42	-0.33	4.72e-10	Monocyte percentage of white cells;
CRC	cis	rs9783347	1.000	rs12286683	chr11:18348662	G/T	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.03	0.58	1.44e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	10.83	0.51	1.45e-23	Platelet count;
CRC	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00321850	chr1:175162397	KIAA0040	-0.39	-6.19	-0.32	1.82e-9	Alcohol dependence;
CRC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg21132104	chr15:45694354	SPATA5L1	0.42	6.18	0.32	1.89e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg07212818	chr11:638076	DRD4	-0.44	-5.66	-0.3	3.23e-8	Systemic lupus erythematosus;
CRC	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.48	6.96	0.36	1.9e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.76	10.18	0.49	2.37e-21	Vitiligo;
CRC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.53	0.46	3.69e-19	Vitamin D levels;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg10760299	chr15:45669010	GATM	-0.37	-5.83	-0.31	1.3e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.65	0.34	1.22e-10	Morning vs. evening chronotype;
CRC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.42	-6.2	-0.32	1.72e-9	Ulcerative colitis;
CRC	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-1.04	-13.29	-0.59	1.46e-32	Educational attainment;
CRC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	10.21	0.49	1.96e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.66	9.19	0.45	4.59e-18	White matter hyperintensity burden;
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg06713098	chr7:45960367	IGFBP3	-0.45	-6.84	-0.35	3.81e-11	Sitting height ratio;
CRC	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.38	6.34	0.33	7.65e-10	Mean arterial pressure;
CRC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg14828511	chr1:107599125	PRMT6	0.48	6.6	0.34	1.61e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg14780466	chr2:20870812	GDF7	0.31	6.51	0.34	2.8e-10	Abdominal aortic aneurysm;
CRC	cis	rs9303280	0.901	rs7216558	chr17:38070071	C/T	cg00129232	chr17:37814104	STARD3	0.44	6.83	0.35	4.16e-11	Self-reported allergy;
CRC	cis	rs7212590	0.529	rs60283440	chr17:57994248	T/C	cg10252138	chr17:58120427	NA	-0.61	-6.29	-0.33	1.02e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.47	-6.82	-0.35	4.34e-11	Longevity;Endometriosis;
CRC	trans	rs4762326	0.509	rs6538615	chr12:95587856	T/C	cg16511708	chr18:23671264	SS18	0.42	5.98	0.31	5.85e-9	Endometriosis;
CRC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.4	5.78	0.3	1.74e-8	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg22687807	chr8:143858763	LYNX1	0.51	9.17	0.45	5.35e-18	Urinary tract infection frequency;
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg10729496	chr3:10149963	C3orf24	0.58	7.52	0.38	5.23e-13	Alzheimer's disease;
CRC	cis	rs17767392	0.767	rs61989382	chr14:71983638	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.46	-6.15	-0.32	2.22e-9	Mitral valve prolapse;
CRC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.76	0.39	1.1e-13	Height;
CRC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16803707	chr20:1099736	PSMF1	0.41	5.97	0.31	6.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg13854012	chr2:162103682	NA	0.49	7.86	0.4	5.69e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg21399703	chr1:247681439	NA	0.47	7.65	0.39	2.24e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1891275	0.515	rs10786010	chr10:93443773	G/A	cg07889827	chr10:93443413	NA	-0.39	-6.65	-0.34	1.2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.53	8.57	0.43	4.11e-16	Coronary artery disease;
CRC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg16606324	chr3:10149918	C3orf24	0.56	7.96	0.4	2.73e-14	Alzheimer's disease;
CRC	trans	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg26043149	chr18:55253948	FECH	-0.56	-7.91	-0.4	4.03e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.43	-0.79	4.22e-72	Myeloid white cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05966498	chr5:10761293	DAP	0.47	7.73	0.39	1.3e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.71	0.3	2.57e-8	Educational attainment;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00166722	chr3:10149974	C3orf24	0.61	7.88	0.4	4.95e-14	Alzheimer's disease;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg06470822	chr6:28175283	NA	0.73	10.3	0.49	9.62e-22	Parkinson's disease;
CRC	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg16540259	chr10:75572220	NDST2	0.38	6.0	0.31	5.25e-9	Inflammatory bowel disease;
CRC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.91e-9	Hemoglobin concentration;
CRC	cis	rs939317	0.635	rs843371	chr3:183994536	A/G	cg09405238	chr3:183994500	ECE2	0.51	6.19	0.32	1.74e-9	Menarche (age at onset);
CRC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg00383909	chr3:49044727	WDR6	0.49	6.05	0.32	3.86e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09242721	chr3:3168535	TRNT1	-0.39	-6.34	-0.33	7.53e-10	Myopia (pathological);
CRC	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.98	-0.31	5.91e-9	Pulmonary function;
CRC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.56	8.26	0.41	3.67e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23633635	chr17:7297619	PLSCR3	0.37	5.98	0.31	5.8e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg25214090	chr10:38739885	LOC399744	-0.41	-6.38	-0.33	6e-10	Diastolic blood pressure;
CRC	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg20885578	chr2:198174922	NA	0.41	6.73	0.35	7.63e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg00343986	chr7:65444356	GUSB	-0.5	-7.51	-0.38	5.55e-13	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04686114	chr12:57081832	PTGES3	0.42	6.58	0.34	1.81e-10	Obesity-related traits;
CRC	cis	rs12024301	0.557	rs58620414	chr1:183621957	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg09676794	chr13:100310162	CLYBL	0.61	6.03	0.32	4.42e-9	Breast cancer;
CRC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-9.27	-0.46	2.46e-18	Monocyte count;
CRC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.39	6.11	0.32	2.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg06470822	chr6:28175283	NA	0.73	10.51	0.5	1.74e-22	Parkinson's disease;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg02683197	chr6:28174875	NA	0.62	8.75	0.43	1.11e-16	Parkinson's disease;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.83	12.64	0.57	3.88e-30	Menarche (age at onset);
CRC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.45	-21.36	-0.76	3.94e-64	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27006547	chr11:62606509	WDR74	0.5	6.99	0.36	1.56e-11	Thyroid stimulating hormone;
CRC	trans	rs9341835	0.584	rs1741801	chr6:64145375	T/C	cg13657004	chr13:50234944	EBPL	-0.38	-6.45	-0.34	4.07e-10	Schizophrenia;
CRC	cis	rs889398	0.771	rs1566454	chr16:69900083	C/T	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.3	-0.33	9.79e-10	Body mass index;
CRC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.69	9.65	0.47	1.44e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-6.89	-0.36	2.82e-11	Body mass index (adult);
CRC	cis	rs600806	0.888	rs461200	chr1:109855404	G/A	cg23032129	chr1:109941072	SORT1	-0.27	-5.86	-0.31	1.14e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23019037	chr1:224622598	WDR26	0.5	7.11	0.36	7.39e-12	Response to antipsychotic treatment;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.13	-0.41	8.62e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg13072238	chr3:49761600	GMPPB	0.5	5.84	0.31	1.25e-8	Menarche (age at onset);
CRC	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.74	9.47	0.46	5.46e-19	Iron status biomarkers;
CRC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg02158880	chr13:53174818	NA	0.68	10.35	0.5	6.61e-22	Lewy body disease;
CRC	cis	rs4728302	0.869	rs7779370	chr7:133595702	T/C	cg03336402	chr7:133662267	EXOC4	-0.45	-6.51	-0.34	2.78e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.58	8.54	0.43	4.99e-16	Uric acid levels;
CRC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	13.58	0.6	1.17e-33	Menopause (age at onset);
CRC	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.73	11.05	0.52	2.33e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.8	13.69	0.6	4.46e-34	Menopause (age at onset);
CRC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg02993699	chr4:3415135	RGS12	-0.39	-6.5	-0.34	3.04e-10	Serum sulfate level;
CRC	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg20744362	chr22:50050164	C22orf34	0.33	5.92	0.31	8.07e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg15448220	chr1:150897856	SETDB1	0.46	6.57	0.34	1.93e-10	Tonsillectomy;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg23123621	chr4:1343375	KIAA1530	0.35	6.48	0.34	3.4e-10	Obesity-related traits;
CRC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.39	6.72	0.35	8.06e-11	Crohn's disease;
CRC	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.51	-8.65	-0.43	2.29e-16	Testicular germ cell tumor;
CRC	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.54	-9.55	-0.47	3.1400000000000002e-19	Post-traumatic stress disorder;
CRC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.45	6.04	0.32	4.07e-9	Gut microbiome composition (summer);
CRC	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.35	5.67	0.3	3.18e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.5	7.98	0.4	2.38e-14	Calcium levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21344124	chr8:22857393	RHOBTB2	0.39	5.97	0.31	6.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.76	12.84	0.58	7.22e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs635808	0.561	rs491700	chr6:167171838	A/G	cg27626620	chr6:167171727	RPS6KA2	-0.37	-6.33	-0.33	7.97e-10	Dental caries;
CRC	cis	rs34293785	0.565	rs59710023	chr1:66137193	T/C	cg04111102	chr1:66153794	NA	0.35	6.02	0.31	4.67e-9	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
CRC	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg16989719	chr2:238392110	NA	-0.41	-7.98	-0.4	2.46e-14	Prostate cancer;
CRC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	10.88	0.51	9.36e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg00738113	chr16:70207722	CLEC18C	-0.38	-5.62	-0.3	4.13e-8	IgE levels;
CRC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12516959	chr21:47718080	NA	0.34	6.1	0.32	2.91e-9	Testicular germ cell tumor;
CRC	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg01422370	chr2:73384389	NA	0.38	5.98	0.31	5.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.82	-0.31	1.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.7	-10.29	-0.49	1.01e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg04289385	chr6:36355825	ETV7	-0.44	-5.62	-0.3	4.11e-8	Platelet distribution width;
CRC	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	10.68	0.51	4.57e-23	Bipolar disorder;
CRC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	0.95	7.98	0.4	2.46e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg15786705	chr6:28176104	NA	0.66	9.73	0.47	7.63e-20	Cardiac Troponin-T levels;
CRC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-9.36	-0.46	1.27e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-6.87	-0.35	3.18e-11	Gut microbiome composition (summer);
CRC	cis	rs372883	0.530	rs11088110	chr21:30543373	G/A	cg24692254	chr21:30365293	RNF160	-0.38	-5.61	-0.3	4.3e-8	Pancreatic cancer;
CRC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.95	-0.44	2.58e-17	Hemoglobin concentration;
CRC	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.52	-0.46	3.84e-19	QT interval;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10757027	chr7:150783788	AGAP3	0.4	7.35	0.38	1.63e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2384207	0.818	rs7962969	chr12:113674461	C/T	cg22376712	chr12:113623594	C12orf52;DDX54	0.48	5.9	0.31	8.94e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.12	-0.32	2.68e-9	Monocyte percentage of white cells;
CRC	trans	rs16846053	0.681	rs62187569	chr2:162373517	A/G	cg27113153	chr11:123612418	ZNF202	-0.72	-6.17	-0.32	1.96e-9	Blood osmolality (transformed sodium);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11522767	chr6:157342961	ARID1B	0.49	7.23	0.37	3.44e-12	Response to antipsychotic treatment;
CRC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg01788221	chr16:89496183	ANKRD11	0.39	5.93	0.31	7.77e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg25809561	chr17:30822961	MYO1D	0.52	9.42	0.46	8.1e-19	Schizophrenia;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	7.95e-11	Blood pressure (smoking interaction);
CRC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.52	-11.8	-0.55	5.08e-27	Prostate cancer;
CRC	cis	rs6504622	0.755	rs11079750	chr17:45149515	T/C	cg16759221	chr17:45003025	GOSR2	0.44	6.74	0.35	7.12e-11	Orofacial clefts;
CRC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.56	5.66	0.3	3.38e-8	Fat distribution (HIV);
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg07414643	chr4:187882934	NA	0.36	6.24	0.33	1.33e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.62	-10.36	-0.5	6.05e-22	Neuroticism;
CRC	trans	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg25214090	chr10:38739885	LOC399744	0.52	7.92	0.4	3.7e-14	Corneal astigmatism;
CRC	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.62	9.14	0.45	6.61e-18	Schizophrenia;
CRC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.37	6.71	0.35	8.38e-11	Erythrocyte sedimentation rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01945793	chr7:10979586	NDUFA4	0.4	6.36	0.33	6.74e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.2e-12	Prostate cancer;
CRC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	6.36	0.33	6.58e-10	Lymphocyte counts;
CRC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.44	-0.38	8.68e-13	Total body bone mineral density;
CRC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.98	-0.31	5.73e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg15105011	chr4:940614	TMEM175	0.55	8.33	0.42	2.24e-15	Sjögren's syndrome;
CRC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg26260408	chr4:53727979	RASL11B	0.53	6.29	0.33	1.04e-9	Optic nerve measurement (cup area);
CRC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg05342945	chr12:48394962	COL2A1	0.44	6.18	0.32	1.9e-9	Lung cancer;
CRC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-5.72	-0.3	2.4e-8	Height;
CRC	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg21155852	chr7:2048760	MAD1L1	-0.46	-6.45	-0.34	3.99e-10	Neuroticism;
CRC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg25767906	chr1:53392781	SCP2	0.36	5.82	0.31	1.41e-8	Monocyte count;
CRC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.46e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.5	6.45	0.33	4.05e-10	Alzheimer's disease (survival time);
CRC	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-10.78	-0.51	2.07e-23	Colorectal cancer;
CRC	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.49	6.79	0.35	5.25e-11	Coronary artery disease;
CRC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	13.35	0.59	8.54e-33	Menopause (age at onset);
CRC	cis	rs11098699	0.750	rs1500122	chr4:124220060	A/C	cg09941581	chr4:124220074	SPATA5	0.43	6.36	0.33	6.83e-10	Mosquito bite size;
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.43	-7.44	-0.38	8.69e-13	Height;
CRC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg23590916	chr17:43697445	MGC57346	-0.56	-6.07	-0.32	3.56e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs860295	0.676	rs11264374	chr1:155421512	A/C	cg02153340	chr1:155202674	NA	-0.56	-6.67	-0.34	1.11e-10	Body mass index;
CRC	cis	rs3018066	0.748	rs7677248	chr4:106960497	C/T	cg01869342	chr4:106983673	TBCK	-0.45	-6.85	-0.35	3.75e-11	Cancer;
CRC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.64	0.39	2.42e-13	Axial length;
CRC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg02428538	chr16:24856791	SLC5A11	0.73	8.62	0.43	2.93e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9906695	0.846	rs4795904	chr17:32618981	C/T	cg12698626	chr17:32581466	CCL2	0.47	6.33	0.33	7.82e-10	Monocyte percentage of white cells;
CRC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.54	-8.38	-0.42	1.53e-15	Aortic root size;
CRC	cis	rs9391253	0.571	rs1475120	chr6:105389953	G/A	cg02098413	chr6:105308735	HACE1	0.31	5.61	0.3	4.24e-8	Height;Age at voice drop;Puberty onset (breast development);
CRC	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.48	7.39	0.38	1.25e-12	Red blood cell count;
CRC	trans	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.36	-0.33	6.84e-10	Schizophrenia;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg10243681	chr15:73925924	NPTN	0.37	5.99	0.31	5.55e-9	Myopia;
CRC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg15135914	chr11:65430544	RELA	0.52	6.48	0.34	3.31e-10	Kashin-Beck disease;
CRC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.32	-6.03	-0.32	4.39e-9	Cerebrospinal fluid biomarker levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23029363	chr5:137803326	EGR1	0.39	6.05	0.32	3.85e-9	Aortic root size;
CRC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg07130601	chr7:158766826	NA	0.42	5.99	0.31	5.43e-9	Facial morphology (factor 20);
CRC	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.53	6.91	0.36	2.54e-11	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg07125278	chr16:67683757	RLTPR	0.44	5.9	0.31	8.8e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.53	6.93	0.36	2.18e-11	Alzheimer's disease (survival time);
CRC	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs5756931	0.503	rs2076112	chr22:38538822	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.38	-0.33	6.07e-10	Triglycerides;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg10813610	chr7:150783881	AGAP3	-0.48	-6.67	-0.35	1.09e-10	Protein C levels;
CRC	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02598441	chr17:62777298	LOC146880	-0.58	-6.85	-0.35	3.6e-11	QT interval;
CRC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.26	-0.45	2.63e-18	Type 2 diabetes;
CRC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.74	10.87	0.51	1.05e-23	Response to antineoplastic agents;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg08798685	chr6:27730294	NA	-0.63	-6.15	-0.32	2.23e-9	Depression;
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg14487702	chr8:22132665	PIWIL2	0.37	5.65	0.3	3.54e-8	Hypertriglyceridemia;
CRC	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg09998033	chr7:158218633	PTPRN2	-0.54	-7.3	-0.37	2.11e-12	Obesity-related traits;
CRC	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.58	8.89	0.44	4.16e-17	HDL cholesterol;
CRC	cis	rs7487075	0.619	rs4076247	chr12:46833450	A/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.74	0.3	2.12e-8	Itch intensity from mosquito bite;
CRC	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04733989	chr22:42467013	NAGA	0.41	5.81	0.3	1.51e-8	Cognitive function;
CRC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.47	7.06	0.36	1.01e-11	Menarche (age at onset);
CRC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.97	0.52	4.44e-24	Personality dimensions;
CRC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.66	-0.34	1.16e-10	Mean platelet volume;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg15786705	chr6:28176104	NA	0.52	7.23	0.37	3.44e-12	Parkinson's disease;
CRC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.59	8.99	0.44	1.93e-17	Asthma (sex interaction);
CRC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg11833968	chr6:79620685	NA	-0.35	-6.05	-0.32	3.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1105228	0.759	rs581335	chr6:165709371	C/T	cg20535254	chr6:165714960	C6orf118	-0.3	-6.27	-0.33	1.13e-9	Number of pregnancies;Number of children;
CRC	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.52	7.99	0.4	2.37e-14	Testicular germ cell tumor;
CRC	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg11547950	chr5:77652471	NA	-0.5	-7.07	-0.36	9.09e-12	Triglycerides;
CRC	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.67	9.41	0.46	8.78e-19	Neuroblastoma;
CRC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.58	7.51	0.38	5.57e-13	Body mass index;
CRC	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27171280	chr4:89205853	PPM1K	-0.39	-6.0	-0.31	5.27e-9	Myopia (pathological);
CRC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.39	-6.48	-0.34	3.33e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg21251018	chr6:28226885	NKAPL	0.47	6.37	0.33	6.33e-10	Parkinson's disease;
CRC	cis	rs7625357	1.000	rs7653417	chr3:169350023	G/A	cg04414509	chr3:169351419	MECOM	0.63	8.9	0.44	3.88e-17	Childhood and early adolescence aggressive behavior;
CRC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.65	10.3	0.49	9.6e-22	Colorectal cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09219451	chr7:27224123	HOXA11AS;HOXA11	0.47	6.59	0.34	1.76e-10	Anxiety disorder;
CRC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.58	9.17	0.45	5.3e-18	Vitiligo;
CRC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.61	10.38	0.5	5.17e-22	Colorectal cancer;
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg04204079	chr8:58130323	NA	-0.44	-5.69	-0.3	2.78e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	6.68	0.35	1.01e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg14036092	chr11:66035641	RAB1B	-0.48	-5.77	-0.3	1.79e-8	Electroencephalogram traits;
CRC	cis	rs3772130	0.926	rs66653099	chr3:121393089	T/G	cg20356878	chr3:121714668	ILDR1	0.49	7.33	0.37	1.82e-12	Cognitive performance;
CRC	cis	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg11143507	chr3:125485238	NA	0.51	5.67	0.3	3.17e-8	Blood pressure (smoking interaction);
CRC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.95	13.72	0.6	3.35e-34	Breast cancer;
CRC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	0.99	14.65	0.63	8.94e-38	Breast cancer;
CRC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-6.94	-0.36	2.09e-11	Height;
CRC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.65	0.43	2.27e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7539624	0.588	rs10916598	chr1:223895559	G/A	cg10100437	chr1:223903862	CAPN2	0.42	5.7	0.3	2.67e-8	Schizophrenia;
CRC	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.75	8.73	0.43	1.31e-16	Inflammatory bowel disease;
CRC	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.84	-15.97	-0.66	6.48e-43	Hip circumference;
CRC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg17401720	chr7:158221031	PTPRN2	-0.4	-6.8	-0.35	4.94e-11	Obesity-related traits;
CRC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.79	14.66	0.63	8.12e-38	Prudent dietary pattern;
CRC	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.58	-8.07	-0.41	1.31e-14	Cancer;
CRC	cis	rs4964805	0.641	rs10861094	chr12:104159716	C/A	cg02344784	chr12:104178138	NT5DC3	0.49	7.66	0.39	2.17e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg07195577	chr17:27052828	TLCD1	-0.41	-5.91	-0.31	8.66e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.95	12.31	0.56	6.63e-29	Triglycerides;
CRC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.98	-20.34	-0.75	3.97e-60	Myeloid white cell count;
CRC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.9	12.86	0.58	6.25e-31	Triglycerides;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20471045	chr19:49568214	NTF4	0.42	6.89	0.36	2.88e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01070657	chr2:207988837	KLF7	0.43	6.88	0.35	2.94e-11	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.56	8.03	0.4	1.72e-14	Resting heart rate;
CRC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.41	5.93	0.31	7.71e-9	Renal cell carcinoma;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07936541	chr2:98206095	ANKRD36B	-0.42	-6.71	-0.35	8.5e-11	Aortic root size;
CRC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.44	8.38	0.42	1.53e-15	Breast cancer;Mosquito bite size;
CRC	cis	rs938554	0.736	rs4697699	chr4:9945722	T/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.69	-0.3	2.74e-8	Blood metabolite levels;
CRC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.94	-0.55	1.47e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg21153622	chr11:89784906	NA	-0.43	-7.1	-0.36	7.73e-12	Height;
CRC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.31	12.52	0.57	1.13e-29	Cognitive function;
CRC	cis	rs6662572	0.578	rs6662307	chr1:46287287	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.87	0.31	1.04e-8	Blood protein levels;
CRC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.78	0.39	9.42e-14	Cognitive ability;
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18591801	chr3:52553433	STAB1	-0.3	-5.6	-0.3	4.5e-8	Electroencephalogram traits;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02290350	chr8:58132656	NA	-0.59	-8.33	-0.42	2.25e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs990171	1.000	rs4851584	chr2:103060313	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	5.76	0.3	1.88e-8	Lymphocyte counts;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07228441	chr8:681215	ERICH1	-0.44	-7.0	-0.36	1.48e-11	Myopia (pathological);
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg19913688	chr11:428466	ANO9	-0.69	-7.03	-0.36	1.22e-11	Body mass index;
CRC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.57	0.43	4.05e-16	Gut microbiome composition (summer);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17589437	chr7:87563717	ADAM22	-0.38	-6.17	-0.32	2.05e-9	Myopia (pathological);
CRC	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.12	0.37	6.72e-12	Red blood cell count;
CRC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg09264619	chr17:80180166	NA	-0.5	-7.24	-0.37	3.21e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.54	-0.43	5.03e-16	Chronic sinus infection;
CRC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.67	11.23	0.53	5.25e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6445967	1.000	rs12637163	chr3:58317692	A/G	cg23715586	chr3:58305044	RPP14	0.36	6.07	0.32	3.44e-9	Platelet count;
CRC	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.6	-0.3	4.42e-8	Axial length;
CRC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.84	-12.06	-0.55	5.65e-28	Gut microbiome composition (summer);
CRC	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg06784218	chr1:46089804	CCDC17	-0.52	-9.08	-0.45	1e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg22192744	chr12:123187474	GPR109A	-0.39	-5.61	-0.3	4.26e-8	Adiponectin levels;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg15845792	chr6:28175446	NA	0.64	8.94	0.44	2.95e-17	Parkinson's disease;
CRC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.52	8.14	0.41	8.36e-15	Red blood cell count;
CRC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.54e-15	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg01304814	chr3:48885189	PRKAR2A	-0.78	-6.35	-0.33	7.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4363385	0.776	rs1415957	chr1:152948909	A/G	cg25856811	chr1:152973957	SPRR3	-0.22	-6.15	-0.32	2.22e-9	Inflammatory skin disease;
CRC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs9826463	0.757	rs73238195	chr3:142171525	A/C	cg20824294	chr3:142316082	PLS1	0.36	6.28	0.33	1.05e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2632516	1.000	rs2526378	chr17:56404349	A/G	cg12560992	chr17:57184187	TRIM37	0.4	5.67	0.3	3.16e-8	Alzheimer's disease;Alzheimer's disease in APOE e4- carriers;Monocyte count;
CRC	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.63	8.46	0.42	8.85e-16	Uric acid levels;
CRC	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.44	-6.31	-0.33	9.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.39	6.76	0.35	6.46e-11	Primary biliary cholangitis;
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03647317	chr4:187891568	NA	-0.49	-8.78	-0.44	9.39e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs56313388	0.521	rs62039274	chr16:56328813	G/T	cg02433656	chr16:56322654	GNAO1	0.52	7.57	0.39	3.79e-13	Pulse pressure;
CRC	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	6.18	0.32	1.89e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.53	-6.86	-0.35	3.39e-11	DNA methylation (variation);
CRC	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg15145296	chr3:125709740	NA	-0.56	-6.72	-0.35	8.17e-11	Blood pressure (smoking interaction);
CRC	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	0.8	9.92	0.48	1.87e-20	Prostate cancer;
CRC	cis	rs294883	0.821	rs9365036	chr6:159703779	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg08798685	chr6:27730294	NA	-0.48	-6.81	-0.35	4.53e-11	Parkinson's disease;
CRC	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.91	-0.31	8.38e-9	Type 2 diabetes;
CRC	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	0.9	10.14	0.49	3.28e-21	Type 2 diabetes nephropathy;
CRC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	5.99	0.31	5.6e-9	Obesity-related traits;
CRC	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.52	10.02	0.48	8.14e-21	Urate levels in lean individuals;
CRC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg07423050	chr13:99094983	FARP1	-0.43	-6.37	-0.33	6.4e-10	Educational attainment (years of education);
CRC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.2	-0.41	5.27e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.48	-6.77	-0.35	5.91e-11	Diastolic blood pressure;
CRC	cis	rs7605827	0.836	rs9287659	chr2:15595755	C/T	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.51e-9	Educational attainment (years of education);
CRC	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.7	8.02	0.4	1.91e-14	Major depressive disorder;
CRC	cis	rs7546094	1.000	rs12126277	chr1:113106369	A/G	cg22162597	chr1:113214053	CAPZA1	0.43	5.94	0.31	7.2e-9	Platelet distribution width;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.71	0.51	3.81e-23	Prudent dietary pattern;
CRC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.46	6.18	0.32	1.91e-9	Protein C levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02299360	chr1:203275326	BTG2	0.45	6.26	0.33	1.2e-9	Response to antipsychotic treatment;
CRC	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	1.06	14.77	0.63	3.26e-38	Exhaled nitric oxide output;
CRC	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg20356878	chr3:121714668	ILDR1	-0.49	-7.18	-0.37	4.66e-12	Multiple sclerosis;
CRC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.68	-0.35	1.01e-10	Major depressive disorder;
CRC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.16	-0.37	5.45e-12	Gut microbiome composition (summer);
CRC	cis	rs4925540	0.550	rs7519943	chr1:247175127	A/G	cg22502715	chr1:247171572	ZNF695	0.42	6.09	0.32	3.1e-9	Response to taxane treatment (docetaxel);
CRC	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	cg04338863	chr8:33670619	NA	0.4	6.84	0.35	3.8e-11	Body mass index;
CRC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg21747405	chr11:67723411	NA	-0.5	-6.6	-0.34	1.69e-10	Blood pressure (smoking interaction);
CRC	cis	rs9818941	0.824	rs2712318	chr3:157776053	C/T	cg08654915	chr3:157813417	NA	-0.32	-5.95	-0.31	7.04e-9	Height;
CRC	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg27534772	chr1:16042836	PLEKHM2	0.43	7.02	0.36	1.25e-11	Systolic blood pressure;
CRC	cis	rs7705042	0.828	rs249638	chr5:141530696	G/C	cg07392085	chr5:141489673	NDFIP1	0.46	7.35	0.38	1.6e-12	Asthma;
CRC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg16102536	chr7:156981717	UBE3C	0.41	6.91	0.36	2.57e-11	Body mass index;
CRC	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg20356878	chr3:121714668	ILDR1	0.51	7.75	0.39	1.19e-13	Cognitive performance;
CRC	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg13401533	chr1:37979913	MEAF6	0.45	6.28	0.33	1.05e-9	Axial length;
CRC	cis	rs1712517	0.844	rs1163087	chr10:105043289	G/A	cg05636881	chr10:105038444	INA	0.48	8.1	0.41	1.07e-14	Migraine;
CRC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10971721	0.822	rs10971793	chr9:33922626	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs71403859	0.554	rs12373065	chr16:71870032	T/A	cg03805757	chr16:71968109	PKD1L3	-0.66	-5.62	-0.3	4.14e-8	Post bronchodilator FEV1;
CRC	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.49	6.31	0.33	9.24e-10	Cholesterol, total;
CRC	cis	rs995000	0.899	rs11207976	chr1:62976751	G/A	cg19896129	chr1:63156450	NA	0.42	6.36	0.33	6.74e-10	Triglyceride levels;
CRC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg05304507	chr6:116381966	FRK	0.31	8.37	0.42	1.67e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg10820045	chr2:198174542	NA	-0.53	-9.12	-0.45	7.78e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg26528668	chr16:1614120	IFT140	0.36	5.6	0.3	4.46e-8	Coronary artery disease;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12172441	chr6:28176163	NA	0.63	7.45	0.38	8.49e-13	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04924415	chr12:100661456	SCYL2;DEPDC4	0.39	6.35	0.33	7.17e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19603390	chr7:7222222	C1GALT1	0.46	6.47	0.34	3.57e-10	Anxiety disorder;
CRC	trans	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.26	0.33	1.23e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs427941	0.609	rs4729776	chr7:101830064	A/G	cg06246474	chr7:101738831	CUX1	0.41	6.03	0.32	4.4e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10659575	chr11:102188233	BIRC3	0.46	6.59	0.34	1.74e-10	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.63	9.71	0.47	9.06e-20	Corneal astigmatism;
CRC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg06238570	chr21:40685208	BRWD1	0.59	8.51	0.42	6.3e-16	Menarche (age at onset);
CRC	cis	rs2742417	1.000	rs938362	chr3:45746365	T/C	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg24505167	chr7:1915268	MAD1L1	-0.42	-5.89	-0.31	9.29e-9	Bipolar disorder;
CRC	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12292205	chr6:26970375	C6orf41	-0.76	-8.08	-0.41	1.29e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.33e-11	Prostate cancer;
CRC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.62	-8.91	-0.44	3.54e-17	Inflammatory bowel disease;
CRC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06544989	chr22:39130855	UNC84B	0.48	7.77	0.39	1.03e-13	Menopause (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10490227	chr1:40348903	TRIT1	0.4	6.43	0.33	4.57e-10	Obesity-related traits;
CRC	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.81	-0.55	4.43e-27	Colorectal cancer;
CRC	cis	rs12900413	0.687	rs62023459	chr15:90308231	A/T	cg24249390	chr15:90295951	MESP1	-0.57	-9.13	-0.45	7.11e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-12.97	-0.58	2.26e-31	Systemic lupus erythematosus;
CRC	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.63	-7.33	-0.37	1.75e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.28	0.73	5.63e-56	Prudent dietary pattern;
CRC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.36	0.5	5.76e-22	Systolic blood pressure;
CRC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg04880052	chr2:219191631	PNKD	-0.43	-6.8	-0.35	4.82e-11	Colorectal cancer;
CRC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg07809909	chr20:30433512	FOXS1	0.35	5.75	0.3	2.09e-8	Mean corpuscular hemoglobin;
CRC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-8.57	-0.43	4.11e-16	Lung cancer in ever smokers;
CRC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.53	0.47	3.55e-19	Monocyte percentage of white cells;
CRC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.58	-0.47	2.4e-19	Mood instability;
CRC	cis	rs932541	0.955	rs6043995	chr20:16457916	T/C	cg17003395	chr20:16555519	KIF16B	0.41	5.7	0.3	2.7e-8	Intelligence;
CRC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.48	5.81	0.31	1.44e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs9491140	0.539	rs11154230	chr6:124686156	A/G	cg22366943	chr6:124882293	NKAIN2	0.56	8.42	0.42	1.21e-15	Neuroticism;
CRC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.59	8.5	0.42	6.65e-16	Response to temozolomide;
CRC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.91	-17.12	-0.69	1.97e-47	Intelligence (multi-trait analysis);
CRC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.43	-0.42	1.13e-15	Total cholesterol levels;
CRC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.64	-0.57	3.91e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.67	11.31	0.53	2.88e-25	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.2	0.69	9.93e-48	Electrocardiographic conduction measures;
CRC	trans	rs34102591	0.826	rs71458829	chr12:124470747	G/A	cg07736115	chr13:113771937	F7	0.53	6.27	0.33	1.15e-9	Schizophrenia;
CRC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-0.65	-6.29	-0.33	1.02e-9	Lung cancer;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg06470822	chr6:28175283	NA	0.8	11.86	0.55	2.9e-27	Cardiac Troponin-T levels;
CRC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg03037974	chr15:76606532	NA	0.84	17.29	0.69	4.28e-48	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.78	0.3	1.73e-8	Renal cell carcinoma;
CRC	cis	rs2302190	0.941	rs6503865	chr17:56549672	A/C	cg25885038	chr17:56607967	SEPT4	-0.42	-6.16	-0.32	2.09e-9	Vitamin D levels;
CRC	trans	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	9.87	0.48	2.74e-20	Exhaled nitric oxide output;
CRC	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24080313	chr3:55522631	WNT5A	-0.44	-6.08	-0.32	3.27e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs2625529	0.730	rs6494990	chr15:72401074	T/A	cg16672083	chr15:72433130	SENP8	0.41	6.05	0.32	3.96e-9	Red blood cell count;
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg20041105	chr8:143859282	LYNX1	0.43	7.62	0.39	2.65e-13	Urinary tract infection frequency;
CRC	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	trans	rs7027930	0.520	rs11790989	chr9:606602	G/A	cg27061366	chr19:13044373	FARSA	0.5	6.06	0.32	3.74e-9	Pulmonary function decline;
CRC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.51	8.26	0.41	3.52e-15	Aortic root size;
CRC	cis	rs7626444	0.628	rs1684464	chr3:196485514	A/C	cg12930392	chr3:196481615	PAK2	0.39	7.11	0.36	7.25e-12	Monocyte count;
CRC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg07884673	chr3:53033167	SFMBT1	0.69	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2346160	0.899	rs206977	chr6:167690746	G/C	cg04673565	chr6:167680447	NA	-0.39	-6.31	-0.33	8.78e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.27	-0.53	3.82e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.9	-11.17	-0.52	9.15e-25	Exhaled nitric oxide output;
CRC	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.58	-7.26	-0.37	2.8e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs73200209	1.000	rs73200209	chr12:116555786	A/T	cg01776926	chr12:116560359	MED13L	-0.5	-6.19	-0.32	1.83e-9	Total body bone mineral density;
CRC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.02	0.52	3.04e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.54	7.42	0.38	9.77e-13	Fibrinogen levels;
CRC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.7	-12.86	-0.58	5.87e-31	Lymphocyte percentage of white cells;
CRC	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg13334819	chr7:99746414	C7orf59	-0.47	-5.7	-0.3	2.65e-8	Coronary artery disease;
CRC	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.57	6.23	0.32	1.43e-9	Coronary artery disease;
CRC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg13385521	chr17:29058706	SUZ12P	0.55	7.33	0.37	1.79e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.03	-0.36	1.17e-11	HDL cholesterol;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.7	10.69	0.51	4.39e-23	Longevity;Endometriosis;
CRC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg18876405	chr7:65276391	NA	-0.45	-6.31	-0.33	8.92e-10	Aortic root size;
CRC	cis	rs4728302	0.838	rs10225115	chr7:133591435	C/T	cg03336402	chr7:133662267	EXOC4	-0.44	-6.43	-0.33	4.45e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.04	0.52	2.63e-24	Alzheimer's disease;
CRC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.95	-0.4	2.97e-14	Height;
CRC	cis	rs12760731	0.720	rs35781686	chr1:178261262	G/A	cg00404053	chr1:178313656	RASAL2	1.1	11.2	0.53	7.14e-25	Obesity-related traits;
CRC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.12	0.32	2.72e-9	Hemoglobin concentration;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	8.69	0.43	1.73e-16	Lymphocyte counts;
CRC	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg20636351	chr8:55087400	NA	-0.33	-5.9	-0.31	9.15e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.39	6.22	0.32	1.52e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs679582	0.864	rs4896468	chr6:139838710	T/C	cg24871798	chr6:50817450	NA	-0.36	-6.35	-0.33	7.05e-10	Blood trace element (Se levels);
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.88	-0.31	1e-8	Aortic root size;
CRC	cis	rs41271951	0.512	rs79122717	chr1:151093526	G/A	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.69	-0.3	2.75e-8	Blood protein levels;
CRC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.65	9.3	0.46	2.09e-18	Multiple sclerosis;
CRC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.18	-0.45	4.89e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg24375607	chr4:120327624	NA	0.44	6.5	0.34	2.89e-10	Corneal astigmatism;
CRC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.41	-5.93	-0.31	7.6e-9	Mean platelet volume;
CRC	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.79	7.65	0.39	2.23e-13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg15368822	chr1:226070397	TMEM63A	0.41	5.98	0.31	5.86e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.77	0.39	9.99e-14	Alzheimer's disease;
CRC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg10820045	chr2:198174542	NA	0.45	8.01	0.4	1.99e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg10544611	chr16:67998164	SLC12A4	-0.53	-5.64	-0.3	3.66e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9491140	0.539	rs11154232	chr6:124691494	G/A	cg05308643	chr6:124982296	NKAIN2	0.54	7.08	0.36	8.52e-12	Neuroticism;
CRC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg11212589	chr17:38028394	ZPBP2	0.34	5.96	0.31	6.5e-9	Asthma;
CRC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.36	-0.62	1.17e-36	Body mass index;
CRC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.67	-9.72	-0.47	8.26e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-8.43	-0.42	1.11e-15	Blood pressure (smoking interaction);
CRC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.82	14.81	0.63	2.23e-38	Vitiligo;
CRC	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg27398640	chr15:77910606	LINGO1	-0.46	-7.98	-0.4	2.48e-14	Type 2 diabetes;
CRC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.47	-5.99	-0.31	5.52e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.91	-15.32	-0.65	2.25e-40	Height;
CRC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.75	10.78	0.51	2.06e-23	Blood metabolite levels;
CRC	cis	rs1383484	0.545	rs7171383	chr15:84644839	T/A	cg11189052	chr15:85197271	WDR73	-0.48	-5.71	-0.3	2.49e-8	Height;
CRC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.47	-7.41	-0.38	1.09e-12	Menopause (age at onset);
CRC	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.56	-7.93	-0.4	3.49e-14	Personality dimensions;
CRC	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.52	9.0	0.44	1.87e-17	Schizophrenia;
CRC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.55	8.04	0.41	1.61e-14	Schizophrenia;
CRC	cis	rs9463078	0.547	rs1418434	chr6:44748365	C/T	cg25276700	chr6:44698697	NA	-0.3	-7.64	-0.39	2.33e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4658101	0.774	rs11165008	chr1:92050615	T/C	cg24006770	chr1:92056542	NA	0.46	6.84	0.35	3.97e-11	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs4750440	0.576	rs2447011	chr10:14032199	C/T	cg00551146	chr10:14014579	FRMD4A	0.45	8.0	0.4	2.18e-14	Adiponectin levels;
CRC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.65	15.42	0.65	9.31e-41	Airflow obstruction;
CRC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.28	-0.53	3.61e-25	Ulcerative colitis;
CRC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	16.9	0.68	1.41e-46	Testicular germ cell tumor;
CRC	cis	rs490234	0.702	rs12553882	chr9:128195044	G/A	cg14078157	chr9:128172775	NA	-0.4	-6.25	-0.33	1.29e-9	Mean arterial pressure;
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg04727332	chr7:45960243	IGFBP3	0.36	5.74	0.3	2.18e-8	Sitting height ratio;
CRC	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.47	-6.48	-0.34	3.39e-10	Height;
CRC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17261708	chr5:176794207	RGS14	0.57	8.47	0.42	8.56e-16	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg12172441	chr6:28176163	NA	0.49	6.04	0.32	4.14e-9	Parkinson's disease;
CRC	trans	rs10090774	0.841	rs13438888	chr8:141841942	A/T	cg14360659	chr9:137029702	RNU6ATAC	-0.46	-6.05	-0.32	3.96e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.79	10.27	0.49	1.23e-21	Diisocyanate-induced asthma;
CRC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.46	-6.87	-0.35	3.26e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg23018236	chr17:30244563	NA	-0.57	-7.09	-0.36	8e-12	Hip circumference adjusted for BMI;
CRC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.7e-9	Rheumatoid arthritis;
CRC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg19622623	chr12:86230825	RASSF9	-0.36	-5.81	-0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.92	-10.39	-0.5	4.8e-22	HIV-1 control;
CRC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.25	-0.41	3.91e-15	Gut microbiome composition (summer);
CRC	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg02927042	chr1:21476669	EIF4G3	0.37	5.6	0.3	4.51e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg26875233	chr11:93583750	C11orf90	-0.33	-6.26	-0.33	1.2e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.47	-5.82	-0.31	1.42e-8	Response to bleomycin (chromatid breaks);
CRC	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg12963866	chr19:57752005	ZNF805	-0.42	-6.22	-0.32	1.5e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.62	-0.34	1.45e-10	Subjective well-being;
CRC	trans	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg17903999	chr18:56338584	MALT1	0.41	6.7	0.35	8.89e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02290350	chr8:58132656	NA	-0.58	-7.96	-0.4	2.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.71	-9.45	-0.46	6.55e-19	Developmental language disorder (linguistic errors);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg18960307	chr17:4699574	PSMB6	-0.48	-6.17	-0.32	2.02e-9	Type 1 diabetes;
CRC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-6.0	-0.31	5.15e-9	Gut microbiome composition (summer);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25563616	chr16:8962190	CARHSP1	0.47	6.19	0.32	1.75e-9	Thyroid stimulating hormone;
CRC	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.36	0.46	1.29e-18	Lymphocyte counts;Red cell distribution width;
CRC	trans	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg16724585	chr3:197361211	NA	-0.46	-6.81	-0.35	4.75e-11	Pancreatic cancer;
CRC	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.49	7.24	0.37	3.29e-12	Testicular germ cell tumor;
CRC	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg03162506	chr22:38580953	NA	-0.3	-6.14	-0.32	2.42e-9	Cutaneous nevi;
CRC	cis	rs4363385	0.654	rs1129654	chr1:152958238	A/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.07e-13	Inflammatory skin disease;
CRC	trans	rs7180079	0.620	rs12442852	chr15:64677413	A/G	cg07470598	chr14:107239068	NA	0.42	5.99	0.31	5.46e-9	Monocyte count;
CRC	cis	rs3018066	0.867	rs3113252	chr4:107252402	G/T	cg01869342	chr4:106983673	TBCK	0.36	5.61	0.3	4.25e-8	Cancer;
CRC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg15786705	chr6:28176104	NA	0.7	5.78	0.3	1.74e-8	Depression;
CRC	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.31	0.42	2.61e-15	Mean corpuscular volume;
CRC	trans	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	3.09e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.7	12.39	0.56	3.35e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.59	5.98	0.31	5.79e-9	Plasma clusterin levels;
CRC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg03030879	chr14:75389066	RPS6KL1	0.42	6.39	0.33	5.64e-10	Height;
CRC	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg19077165	chr18:44547161	KATNAL2	-0.38	-6.1	-0.32	3.03e-9	Educational attainment;
CRC	cis	rs720844	0.748	rs6430323	chr2:149318579	G/C	cg09247360	chr2:149335327	NA	-0.56	-6.03	-0.32	4.49e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.63	-8.02	-0.4	1.82e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs55788414	1.000	rs28395434	chr16:81182222	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.88	-0.35	3.02e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.51	8.79	0.44	8.39e-17	Aortic root size;
CRC	cis	rs6504950	0.830	rs12150038	chr17:53041520	T/G	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg00105475	chr2:10696890	NA	0.46	7.18	0.37	4.56e-12	Prostate cancer;
CRC	cis	rs7517126	1.000	rs2336503	chr1:196843420	G/T	cg13682187	chr1:196946512	CFHR5	-0.34	-5.72	-0.3	2.41e-8	Blood protein levels;
CRC	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg14003231	chr6:33640908	ITPR3	0.51	8.38	0.42	1.52e-15	Plateletcrit;
CRC	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg02569219	chr17:2266849	SGSM2	0.4	6.65	0.34	1.2e-10	Proinsulin levels;
CRC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-7.52	-0.38	5.17e-13	Schizophrenia;
CRC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-8.23	-0.41	4.39e-15	Hemoglobin concentration;
CRC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17507749	chr15:85114479	UBE2QP1	0.58	7.77	0.39	1.03e-13	Schizophrenia;
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg20119798	chr7:94954144	PON1	-0.47	-5.98	-0.31	5.95e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.58	-0.34	1.87e-10	Lymphocyte counts;
CRC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.66	11.99	0.55	9.84e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2797369	0.713	rs943909	chr6:101579289	A/C	cg26346621	chr12:6873348	NA	0.4	6.24	0.33	1.36e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.27	-0.49	1.24e-21	Monocyte count;
CRC	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14119001	chr9:139324193	INPP5E	-0.46	-6.45	-0.34	3.99e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.59e-18	Platelet count;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-7.69	-0.39	1.71e-13	Monocyte percentage of white cells;
CRC	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg10820045	chr2:198174542	NA	0.38	6.38	0.33	5.88e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.85	-0.35	3.57e-11	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg04518342	chr5:131593106	PDLIM4	0.43	6.95	0.36	1.98e-11	Breast cancer;
CRC	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	10.1	0.49	4.52e-21	Exhaled nitric oxide output;
CRC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg14784868	chr12:69753453	YEATS4	0.44	5.71	0.3	2.49e-8	Response to diuretic therapy;
CRC	cis	rs9925964	0.933	rs11150604	chr16:31037020	A/T	cg02466173	chr16:30829666	NA	0.44	6.04	0.32	4.22e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.16	0.52	9.86e-25	Bone mineral density;
CRC	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg10437265	chr15:77819839	NA	0.66	11.62	0.54	2.13e-26	Type 2 diabetes;
CRC	cis	rs6534441	0.512	rs962939	chr4:125404239	A/G	cg21609808	chr4:125404261	NA	0.5	7.48	0.38	6.66e-13	Major depressive disorder;
CRC	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg20487152	chr13:99095054	FARP1	0.36	5.92	0.31	8.14e-9	Longevity;
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.49	-7.27	-0.37	2.64e-12	Triglycerides;
CRC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg01721255	chr8:58191610	C8orf71	0.51	6.37	0.33	6.37e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.83	-0.31	1.3e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.41	0.53	1.23e-25	Height;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg04025307	chr7:1156635	C7orf50	0.54	6.34	0.33	7.56e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs72991	0.639	rs1529579	chr11:121235871	G/T	cg27192990	chr6:129479024	LAMA2	-0.44	-6.45	-0.34	4.07e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.31	5.89	0.31	9.4e-9	Ulcerative colitis;
CRC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.69	0.3	2.74e-8	Self-reported allergy;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20349076	chr11:118992192	HINFP	0.4	6.55	0.34	2.22e-10	Obesity-related traits;
CRC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.41	-7.01	-0.36	1.32e-11	Height;
CRC	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg10517650	chr3:113235015	CCDC52	-0.38	-5.94	-0.31	7.08e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.67	10.12	0.49	3.79e-21	Menopause (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13972460	chr20:1165703	C20orf46	-0.39	-6.36	-0.33	6.86e-10	Myopia (pathological);
CRC	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.53	8.88	0.44	4.53e-17	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg19812747	chr11:111475976	SIK2	0.52	7.61	0.39	2.94e-13	Primary sclerosing cholangitis;
CRC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-11.56	-0.54	3.59e-26	Asthma;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02934500	chr4:142557404	IL15	0.45	6.08	0.32	3.4e-9	Survival in pancreatic cancer;
CRC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.67	8.7	0.43	1.61e-16	Morning vs. evening chronotype;
CRC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.82	-0.35	4.4e-11	Response to antipsychotic treatment;
CRC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-5.63	-0.3	3.83e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	10.98	0.52	4.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.47	5.78	0.3	1.76e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.56	-8.68	-0.43	1.93e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg20119798	chr7:94954144	PON1	-0.53	-6.61	-0.34	1.52e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.34	-0.33	7.41e-10	Aortic root size;
CRC	cis	rs6662572	0.737	rs4660893	chr1:46327532	T/C	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs2882667	0.931	rs10077896	chr5:138356756	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-5.92	-0.31	8.28e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg16724585	chr3:197361211	NA	-0.48	-7.08	-0.36	8.94e-12	Pancreatic cancer;
CRC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.45	6.55	0.34	2.16e-10	Menopause (age at onset);
CRC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg06287003	chr12:125626642	AACS	-0.58	-7.49	-0.38	6.42e-13	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg26399773	chr5:74633655	HMGCR	-0.55	-6.39	-0.33	5.81e-10	Lung adenocarcinoma;
CRC	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.62	11.23	0.53	5.31e-25	Blood metabolite ratios;
CRC	trans	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.01	0.31	4.82e-9	Breast cancer;
CRC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.77e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.49	7.39	0.38	1.24e-12	Emphysema distribution in smoking;
CRC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs2213920	0.679	rs10759786	chr9:118241188	A/G	cg13918206	chr9:118159781	DEC1	0.55	5.63	0.3	3.83e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs9584850	0.834	rs7339274	chr13:99120272	A/G	cg07423050	chr13:99094983	FARP1	-0.45	-6.33	-0.33	8.13e-10	Neuroticism;
CRC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-5.92	-0.31	7.93e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs28829049	0.597	rs34219832	chr1:19502432	C/T	cg13387374	chr1:19411106	UBR4	0.42	6.14	0.32	2.39e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg14711859	chr11:8959438	ASCL3	0.37	6.21	0.32	1.59e-9	Hemoglobin concentration;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg06470822	chr6:28175283	NA	0.74	10.0	0.48	9.56e-21	Parkinson's disease;
CRC	cis	rs12541635	0.833	rs4099936	chr8:107099297	G/A	cg10147462	chr8:107024639	NA	-0.39	-5.97	-0.31	6.01e-9	Age of smoking initiation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00694302	chr12:47609865	LOC100233209;FAM113B	0.45	6.81	0.35	4.63e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg05507819	chr15:63340323	TPM1	0.46	5.99	0.31	5.46e-9	HDL cholesterol;
CRC	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.1	-14.99	-0.64	4.56e-39	Exhaled nitric oxide output;
CRC	cis	rs10944	0.598	rs9293761	chr5:78290215	C/T	cg13121490	chr5:78280331	ARSB	-0.51	-6.99	-0.36	1.55e-11	Blood and toenail selenium levels;
CRC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.0	0.31	5.1e-9	Educational attainment (years of education);
CRC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg20673091	chr1:2541236	MMEL1	0.36	5.82	0.31	1.43e-8	Ulcerative colitis;
CRC	cis	rs883565	0.740	rs7624734	chr3:39108503	G/A	cg01426195	chr3:39028469	NA	-0.54	-8.65	-0.43	2.36e-16	Handedness;
CRC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.68	-10.04	-0.48	7.25e-21	DNA methylation (variation);
CRC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.64	11.47	0.53	7.3e-26	Schizophrenia;
CRC	cis	rs4664293	0.625	rs6760931	chr2:160559111	C/G	cg08347373	chr2:160653686	CD302	0.39	6.53	0.34	2.44e-10	Monocyte percentage of white cells;
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.53	-0.43	5.53e-16	Bipolar disorder;
CRC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.64	11.09	0.52	1.76e-24	Cancer;
CRC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.74	-0.3	2.19e-8	Reticulocyte count;
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg21251018	chr6:28226885	NKAPL	0.54	6.46	0.34	3.7e-10	Depression;
CRC	cis	rs3771570	0.901	rs6757876	chr2:242245570	T/C	cg21155796	chr2:242212141	HDLBP	0.58	6.95	0.36	2.02e-11	Prostate cancer;
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.97	-0.31	5.98e-9	Life satisfaction;
CRC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.36	-7.63	-0.39	2.49e-13	Schizophrenia;
CRC	cis	rs4692589	1.000	rs11727880	chr4:170937467	C/T	cg19918862	chr4:170955249	NA	0.39	6.4	0.33	5.33e-10	Anxiety disorder;
CRC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.22	-0.49	1.8e-21	Bipolar disorder;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.88	14.49	0.62	3.96e-37	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05704155	chr1:10459140	PGD	0.38	6.1	0.32	2.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.82	9.35	0.46	1.36e-18	Menarche (age at onset);
CRC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.87	11.85	0.55	3.24e-27	Gut microbiome composition (summer);
CRC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg24130564	chr14:104152367	KLC1	0.44	5.96	0.31	6.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-0.64	-6.91	-0.36	2.45e-11	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.39	5.93	0.31	7.46e-9	Red blood cell count;
CRC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg10760299	chr15:45669010	GATM	0.51	8.11	0.41	1.03e-14	Homoarginine levels;
CRC	cis	rs7731657	0.537	rs12516770	chr5:130222575	T/C	cg08523029	chr5:130500466	HINT1	-0.47	-6.13	-0.32	2.45e-9	Fasting plasma glucose;
CRC	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg11130432	chr3:121712080	ILDR1	-0.53	-6.88	-0.35	3.03e-11	Multiple sclerosis;
CRC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.38	6.06	0.32	3.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3736485	0.899	rs7183479	chr15:51942207	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.46	-0.34	3.87e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg19812747	chr11:111475976	SIK2	-0.57	-9.75	-0.47	7e-20	Primary sclerosing cholangitis;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg14196790	chr5:131705035	SLC22A5	0.31	5.62	0.3	4.1e-8	Blood metabolite levels;
CRC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.32	0.56	6.2e-29	Menopause (age at onset);
CRC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.58	9.42	0.46	8.53e-19	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.02	-0.31	4.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2070997	0.816	rs1800609	chr9:133731184	A/G	cg01000188	chr9:133769184	QRFP	0.51	5.67	0.3	3.1e-8	Response to amphetamines;
CRC	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg20811857	chr17:78079795	GAA	-0.49	-6.11	-0.32	2.81e-9	Yeast infection;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg12273811	chr6:28175739	NA	0.45	5.63	0.3	3.81e-8	Parkinson's disease;
CRC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.57	-8.95	-0.44	2.69e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.38e-32	Glomerular filtration rate (creatinine);
CRC	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.76	-10.61	-0.5	8.13e-23	Obesity-related traits;
CRC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.2	-0.41	5.6e-15	Chronic sinus infection;
CRC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg21320455	chr17:78086503	GAA	-0.36	-6.09	-0.32	3.09e-9	Yeast infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09188322	chr1:113258477	PPM1J	0.43	5.99	0.31	5.52e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg10729496	chr3:10149963	C3orf24	0.52	6.93	0.36	2.21e-11	Alzheimer's disease;
CRC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	13.23	0.59	2.47e-32	Platelet count;
CRC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08219700	chr8:58056026	NA	0.54	6.15	0.32	2.27e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg12458913	chr13:53173898	NA	-0.47	-7.1	-0.36	7.64e-12	Lewy body disease;
CRC	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.5	-8.34	-0.42	2.08e-15	Airway imaging phenotypes;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24839693	chr17:43212892	ACBD4	0.44	6.11	0.32	2.76e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9522267	0.966	rs9515443	chr13:112197387	T/C	cg10483660	chr13:112241077	NA	-0.36	-6.15	-0.32	2.26e-9	Hepatitis;
CRC	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.24	-0.37	3.29e-12	Inflammatory skin disease;
CRC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg14829360	chr17:73884958	NA	-0.43	-6.67	-0.34	1.11e-10	Psoriasis;
CRC	cis	rs4803480	0.573	rs2302188	chr19:42085873	C/T	cg08478046	chr19:42093086	CEACAM21	0.3	6.48	0.34	3.27e-10	Schizophrenia;
CRC	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.59	7.58	0.39	3.47e-13	Diisocyanate-induced asthma;
CRC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.61	-9.91	-0.48	1.97e-20	P wave terminal force;
CRC	cis	rs3751196	0.808	rs117214801	chr12:104215022	G/A	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg11292332	chr7:45801988	SEPT13	-0.38	-6.75	-0.35	6.61e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.59	-8.44	-0.42	1.04e-15	Arsenic metabolism;
CRC	cis	rs7259376	0.936	rs12151261	chr19:22587929	C/T	cg02657401	chr19:22469223	NA	0.31	6.72	0.35	8.02e-11	Menopause (age at onset);
CRC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg21747405	chr11:67723411	NA	0.44	6.51	0.34	2.8e-10	Blood pressure (smoking interaction);
CRC	cis	rs3750965	0.839	rs921670	chr11:68871639	C/T	cg06818126	chr11:68850279	TPCN2	-0.4	-5.64	-0.3	3.65e-8	Hair color;
CRC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg21153622	chr11:89784906	NA	0.46	7.39	0.38	1.26e-12	HDL cholesterol;
CRC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.44	8.08	0.41	1.21e-14	Prostate cancer;
CRC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	10.44	0.5	3.2e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg26554054	chr8:600488	NA	0.59	5.7	0.3	2.66e-8	IgG glycosylation;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.32	-5.89	-0.31	9.29e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.43	-6.3	-0.33	9.47e-10	Ulcerative colitis;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg21115120	chr5:157158441	THG1L	-0.46	-6.35	-0.33	7.07e-10	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.46	-6.57	-0.34	1.99e-10	Type 2 diabetes;
CRC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.16	11.41	0.53	1.27e-25	Skin colour saturation;
CRC	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg00531865	chr16:30841666	NA	-0.44	-6.37	-0.33	6.54e-10	Dementia with Lewy bodies;
CRC	cis	rs9462846	0.881	rs34498470	chr6:42879551	C/T	cg02353165	chr6:42928485	GNMT	0.57	7.48	0.38	6.83e-13	Blood protein levels;
CRC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.4	-6.19	-0.32	1.79e-9	Blood metabolite levels;
CRC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg20684491	chr1:25596433	NA	0.43	7.91	0.4	3.97e-14	Erythrocyte sedimentation rate;
CRC	cis	rs1801251	0.928	rs4458205	chr2:233557646	C/T	cg25237894	chr2:233734115	C2orf82	0.53	8.45	0.42	9.770000000000001e-16	Coronary artery disease;
CRC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.68	0.39	1.88e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.74	-0.35	7.01e-11	Total body bone mineral density;
CRC	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg14631576	chr9:95140430	CENPP	-0.4	-7.13	-0.37	6.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg17330251	chr7:94953956	PON1	-0.58	-7.45	-0.38	8.55e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08240007	chr2:220407822	CHPF;TMEM198	0.46	6.79	0.35	5.15e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.51	-9.09	-0.45	9.77e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.22	-0.32	1.47e-9	Bipolar disorder;
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16932098	chr10:97321215	SORBS1	0.44	6.53	0.34	2.46e-10	Intelligence (multi-trait analysis);
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.67	-11.13	-0.52	1.19e-24	Monocyte percentage of white cells;
CRC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.6	0.47	2.05e-19	Cognitive test performance;
CRC	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-8.92	-0.44	3.27e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.32	-0.46	1.72e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.38	-5.81	-0.31	1.46e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.63	0.34	1.4e-10	Rheumatoid arthritis;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.47	-6.77	-0.35	5.76e-11	Menopause (age at onset);
CRC	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.46	6.56	0.34	2.05e-10	Red cell distribution width;
CRC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg26666090	chr16:58549219	SETD6	1.01	6.67	0.35	1.06e-10	Schizophrenia;
CRC	cis	rs11212617	0.967	rs11605442	chr11:108077857	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.46	0.34	3.72e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2282802	0.635	rs199152	chr5:139539235	C/T	cg26211634	chr5:139558579	C5orf32	-0.37	-6.4	-0.33	5.28e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg10556349	chr10:835070	NA	-0.36	-6.84	-0.35	3.92e-11	Survival in rectal cancer;
CRC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-9.67	-0.47	1.21e-19	Body mass index;
CRC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.68	-8.92	-0.44	3.28e-17	Bronchopulmonary dysplasia;
CRC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21028142	chr17:79581711	NPLOC4	0.35	7.23	0.37	3.33e-12	Eye color traits;
CRC	cis	rs6546324	0.625	rs2861701	chr2:67855980	T/G	cg15745817	chr2:67799979	NA	-0.57	-9.88	-0.48	2.49e-20	Endometriosis;
CRC	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.52	-0.43	5.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.78	-0.39	9.74e-14	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00539716	chr2:48541921	FOXN2	0.43	6.44	0.33	4.11e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.55	-7.81	-0.4	7.8e-14	Cocaine dependence;
CRC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.72	-11.33	-0.53	2.38e-25	Lung cancer;
CRC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	11.3	0.53	3.03e-25	Tonsillectomy;
CRC	trans	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg17903999	chr18:56338584	MALT1	0.4	6.63	0.34	1.37e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.69	-8.22	-0.41	4.68e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg12463550	chr7:65579703	CRCP	0.62	5.99	0.31	5.58e-9	Diabetic kidney disease;
CRC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.01	-0.36	1.39e-11	Total cholesterol levels;
CRC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.07	-0.45	1.08e-17	Hip circumference adjusted for BMI;
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg12516270	chr8:143859308	LYNX1	0.43	7.44	0.38	9.08e-13	Urinary tract infection frequency;
CRC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.76	13.18	0.59	3.84e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.04	14.39	0.62	9.58e-37	Exhaled nitric oxide output;
CRC	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-6.18	-0.32	1.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg08200770	chr17:80723486	TBCD	-0.45	-6.85	-0.35	3.66e-11	Glycated hemoglobin levels;
CRC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg02741985	chr17:80059408	CCDC57	-0.45	-7.15	-0.37	5.7e-12	Life satisfaction;
CRC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.79	-0.3	1.66e-8	Calcium levels;
CRC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg08923669	chr16:420230	MRPL28	-0.59	-7.5	-0.38	6.1e-13	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg27053337	chr8:124217698	FAM83A	0.46	6.99	0.36	1.58e-11	Urinary uromodulin levels;
CRC	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.59	-8.74	-0.43	1.2e-16	Aortic root size;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg15786705	chr6:28176104	NA	0.62	8.95	0.44	2.67e-17	Cardiac Troponin-T levels;
CRC	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.06	-0.41	1.43e-14	Biliary atresia;
CRC	cis	rs2898681	0.581	rs11938140	chr4:53678057	T/A	cg00338735	chr4:53728038	RASL11B	0.39	5.92	0.31	8.08e-9	Optic nerve measurement (cup area);
CRC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.49	-9.15	-0.45	5.96e-18	Reticulocyte fraction of red cells;
CRC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.39	6.41	0.33	4.92e-10	Height;
CRC	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg04672837	chr16:48644449	N4BP1	0.42	5.79	0.3	1.63e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg06238570	chr21:40685208	BRWD1	0.71	9.26	0.45	2.78e-18	Cognitive function;
CRC	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-8.88	-0.44	4.41e-17	Coffee consumption (cups per day);
CRC	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg09659197	chr4:152720779	NA	0.39	7.73	0.39	1.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg16670446	chr17:27188758	MIR451;MIR144	0.6	10.35	0.5	6.34e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	1.97e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg09659197	chr4:152720779	NA	0.41	8.62	0.43	2.82e-16	Intelligence (multi-trait analysis);
CRC	trans	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.93	-0.31	7.53e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CRC	cis	rs4731207	0.698	rs10954048	chr7:124533740	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.57	7.65	0.39	2.26e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg13777783	chr17:79615861	NA	-0.3	-5.63	-0.3	3.79e-8	Eye color traits;
CRC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.82	13.04	0.58	1.27e-31	Body mass index (adult);
CRC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.45	5.74	0.3	2.1e-8	Aortic root size;
CRC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.55	-7.86	-0.4	5.47e-14	Height;
CRC	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg20608306	chr11:116969690	SIK3	-0.31	-5.67	-0.3	3.13e-8	Subjective well-being;
CRC	cis	rs8062405	0.540	rs151226	chr16:28549823	A/C	cg05139728	chr16:28306816	SBK1	-0.32	-5.83	-0.31	1.32e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.46	-6.51	-0.34	2.83e-10	Lung cancer;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.53e-18	Parkinson's disease;
CRC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg24375607	chr4:120327624	NA	0.44	6.84	0.35	3.83e-11	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg05163923	chr11:71159392	DHCR7	-0.54	-5.78	-0.3	1.69e-8	Vitamin D levels;
CRC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg10978503	chr1:24200527	CNR2	0.44	7.43	0.38	9.38e-13	Immature fraction of reticulocytes;
CRC	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.15	-0.32	2.29e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg14191688	chr11:70257035	CTTN	0.45	6.05	0.32	3.99e-9	Coronary artery disease;
CRC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-11.58	-0.54	3.01e-26	Asthma;
CRC	cis	rs4523957	0.579	rs4790883	chr17:2087605	T/C	cg16513277	chr17:2031491	SMG6	-0.58	-9.76	-0.47	6.2e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs972578	0.811	rs2284091	chr22:43271504	G/T	cg01576275	chr22:43409880	NA	-0.4	-6.21	-0.32	1.57e-9	Mean platelet volume;
CRC	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.59	-0.34	1.79e-10	Retinal vascular caliber;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.7	-0.35	8.97e-11	Height;
CRC	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-5.75	-0.3	2.02e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.92e-9	Life satisfaction;
CRC	cis	rs478222	1.000	rs567359	chr2:25304574	C/T	cg22495460	chr2:25135724	ADCY3	-0.41	-6.09	-0.32	3.12e-9	Type 1 diabetes;
CRC	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.83	0.31	1.32e-8	Male-pattern baldness;
CRC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.82	-0.35	4.36e-11	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-0.61	-10.07	-0.49	5.73e-21	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.73	8.98	0.44	2.2e-17	Diisocyanate-induced asthma;
CRC	cis	rs3823572	0.564	rs2971983	chr7:133652537	A/G	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-8.63	-0.43	2.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-7.86	-0.4	5.41e-14	Vitiligo;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg25164649	chr6:28176230	NA	0.47	6.93	0.36	2.17e-11	Cardiac Troponin-T levels;
CRC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.49	-7.7	-0.39	1.58e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03786933	chr16:69760418	NQO1	-0.4	-6.21	-0.32	1.62e-9	Myopia (pathological);
CRC	trans	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	6.98	0.36	1.59e-11	Ulcerative colitis;
CRC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg03037974	chr15:76606532	NA	0.75	13.64	0.6	6.96e-34	Blood metabolite levels;
CRC	cis	rs11191205	0.644	rs3095791	chr10:103383836	T/C	cg15320455	chr10:103880129	LDB1	0.55	6.09	0.32	3.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.86	-14.97	-0.64	5.18e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.52	-9.74	-0.47	7.24e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.71	-0.47	9.33e-20	Mood instability;
CRC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg24011408	chr12:48396354	COL2A1	-0.42	-6.13	-0.32	2.46e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12963312	chr6:52441723	TRAM2	0.44	6.32	0.33	8.62e-10	Response to antipsychotic treatment;
CRC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02421172	chr7:1938701	MAD1L1	0.42	5.62	0.3	4.11e-8	Bipolar disorder;
CRC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs2233152	0.656	rs2287691	chr19:41286163	C/G	cg21869046	chr19:41225005	ITPKC	0.41	6.4	0.33	5.25e-10	Kawasaki disease;
CRC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	-0.53	-8.78	-0.44	9.28e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg20356878	chr3:121714668	ILDR1	-0.43	-6.06	-0.32	3.83e-9	Multiple sclerosis;
CRC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.56	7.74	0.39	1.21e-13	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13641043	chr17:43198610	PLCD3	0.22	6.16	0.32	2.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.74	0.7	7.11e-50	Platelet count;
CRC	cis	rs531930	0.587	rs332611	chr6:124713527	C/T	cg22366943	chr6:124882293	NKAIN2	-0.44	-6.6	-0.34	1.69e-10	Celiac disease;
CRC	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-8.1	-0.41	1.07e-14	Mitochondrial DNA levels;
CRC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.61	-9.19	-0.45	4.71e-18	Diastolic blood pressure;
CRC	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg24046110	chr8:143859143	LYNX1	-0.35	-6.01	-0.31	4.96e-9	Urinary tract infection frequency;
CRC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg18478394	chr8:109455254	TTC35	0.38	5.82	0.31	1.38e-8	Dupuytren's disease;
CRC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.52	6.24	0.33	1.36e-9	Gut microbiome composition (summer);
CRC	cis	rs10905065	0.610	rs72774056	chr10:5737065	C/T	cg11519256	chr10:5708881	ASB13	-0.42	-5.88	-0.31	9.88e-9	Menopause (age at onset);
CRC	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.63	10.28	0.49	1.11e-21	Schizophrenia;
CRC	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	7.54	0.38	4.61e-13	Mean corpuscular volume;
CRC	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg20608306	chr11:116969690	SIK3	-0.31	-5.74	-0.3	2.13e-8	Subjective well-being;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg04392234	chr4:74608458	IL8	-0.55	-6.01	-0.31	4.82e-9	Plasma thyroid-stimulating hormone levels;
CRC	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.42	0.33	4.85e-10	Myopia (pathological);
CRC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.83	-12.97	-0.58	2.42e-31	Cognitive function;
CRC	cis	rs938554	0.868	rs734553	chr4:9923004	G/T	cg00071950	chr4:10020882	SLC2A9	0.41	5.71	0.3	2.59e-8	Blood metabolite levels;
CRC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.6	0.34	1.67e-10	Morning vs. evening chronotype;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17783671	chr19:59070436	UBE2M;LOC100131691	0.38	6.17	0.32	2.05e-9	Obesity-related traits;
CRC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg16342193	chr10:102329863	NA	-0.35	-5.9	-0.31	9.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	cis	rs71386933	0.509	rs34400689	chr16:72003454	T/G	cg08717414	chr16:71523259	ZNF19	-0.68	-5.89	-0.31	9.39e-9	Post bronchodilator FEV1;
CRC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-9.9	-0.48	2.13e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg13722127	chr7:150037890	RARRES2	0.39	5.6	0.3	4.51e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.36	-0.33	6.85e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg06970220	chr1:156163860	SLC25A44	0.5	7.13	0.37	6.42e-12	Testicular germ cell tumor;
CRC	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.74	-8.66	-0.43	2.16e-16	Iron status biomarkers;
CRC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg27535305	chr1:53392650	SCP2	0.38	7.27	0.37	2.57e-12	Monocyte count;
CRC	cis	rs3087591	0.600	rs2905808	chr17:29493993	A/T	cg24425628	chr17:29625626	OMG;NF1	0.67	8.78	0.44	9.02e-17	Hip circumference;
CRC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.51	9.67	0.47	1.24e-19	Alcohol dependence;
CRC	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.69	12.57	0.57	7.09e-30	Blood protein levels;
CRC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.5	8.03	0.4	1.71e-14	Bronchopulmonary dysplasia;
CRC	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.38	5.85	0.31	1.21e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12044355	0.927	rs11585981	chr1:231833962	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.21	0.32	1.6e-9	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18247638	chr13:103451366	KDELC1;BIVM	0.49	6.93	0.36	2.29e-11	Response to antipsychotic treatment;
CRC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.26	-0.45	2.63e-18	Type 2 diabetes;
CRC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-8.02	-0.4	1.92e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.24	-14.68	-0.63	7.09e-38	Diabetic kidney disease;
CRC	trans	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg02674126	chr19:40336878	FBL	0.43	6.91	0.36	2.58e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.5	7.94	0.4	3.2e-14	Red blood cell count;
CRC	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-5.94	-0.31	7.15e-9	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.44	-6.78	-0.35	5.46e-11	Asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01495663	chr14:21945285	RAB2B;TOX4	0.41	5.96	0.31	6.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12463550	chr7:65579703	CRCP	0.75	6.82	0.35	4.5e-11	Diabetic kidney disease;
CRC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg08888203	chr3:10149979	C3orf24	0.46	6.69	0.35	9.43e-11	Alzheimer's disease;
CRC	trans	rs4386084	0.890	rs12373013	chr15:50251620	A/T	cg02453146	chr1:53068587	GPX7	-0.33	-5.98	-0.31	5.92e-9	Basophil percentage of white cells;Basophil percentage of granulocytes;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.61	9.6	0.47	2.15e-19	Longevity;Endometriosis;
CRC	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.54e-21	Asthma;
CRC	cis	rs10267593	0.516	rs62435159	chr7:1911281	G/A	cg23422044	chr7:1970798	MAD1L1	-0.46	-6.14	-0.32	2.4e-9	Coronary artery disease;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23161317	chr6:28129485	ZNF389	0.44	5.76	0.3	1.96e-8	Parkinson's disease;
CRC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.79	10.17	0.49	2.69e-21	Monocyte percentage of white cells;
CRC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg03013999	chr17:37608204	MED1	0.45	6.91	0.36	2.6e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs2302612	0.514	rs7572853	chr2:102853783	G/A	cg25110734	chr5:149535650	PDGFRB	-0.48	-6.58	-0.34	1.9e-10	Serum protein levels (sST2);
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.8	-0.3	1.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.64	-8.92	-0.44	3.24e-17	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg16558177	chr4:4109446	NA	-0.48	-6.29	-0.33	1.03e-9	Blood pressure (smoking interaction);
CRC	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.48	7.46	0.38	7.66e-13	HDL cholesterol;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12826942	0.571	rs17224156	chr12:42446725	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.15	0.32	2.21e-9	Coronary artery disease;
CRC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.49	-6.65	-0.34	1.21e-10	Aortic root size;
CRC	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg17885191	chr8:135476712	NA	0.57	7.64	0.39	2.45e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-7.83	-0.4	6.97e-14	Granulocyte percentage of myeloid white cells;
CRC	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.44	6.34	0.33	7.43e-10	Primary sclerosing cholangitis;
CRC	cis	rs4731207	0.596	rs922711	chr7:124604304	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg09264619	chr17:80180166	NA	-0.5	-7.28	-0.37	2.49e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.59	-6.16	-0.32	2.17e-9	White matter hyperintensity burden;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.43e-10	Bipolar disorder;
CRC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.6	-9.27	-0.46	2.46e-18	Height;
CRC	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg14003231	chr6:33640908	ITPR3	0.54	7.73	0.39	1.28e-13	Platelet count;
CRC	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	5.72	0.3	2.34e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.29	-6.08	-0.32	3.33e-9	Homoarginine levels;
CRC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.65	-0.3	3.44e-8	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.59	8.96	0.44	2.41e-17	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11786582	chr17:57233134	PRR11;SKA2	0.37	5.98	0.31	5.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg18761221	chr20:60518478	NA	0.48	7.78	0.39	9.42e-14	Body mass index;
CRC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.45	7.31	0.37	2.04e-12	Obesity-related traits;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg10799186	chr3:139396487	NMNAT3	0.49	6.02	0.31	4.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg02683197	chr6:28174875	NA	0.6	6.8	0.35	4.81e-11	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13370280	chr6:137539688	IFNGR1	0.45	6.54	0.34	2.31e-10	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.46	6.57	0.34	1.92e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg19875578	chr6:126661172	C6orf173	0.42	5.92	0.31	8.1e-9	Male-pattern baldness;
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg06470822	chr6:28175283	NA	-0.73	-9.03	-0.45	1.49e-17	Parkinson's disease;
CRC	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.37	-6.72	-0.35	8.23e-11	Dilated cardiomyopathy;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16908901	chr1:94054835	BCAR3	0.36	5.99	0.31	5.53e-9	Aortic root size;
CRC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg19812747	chr11:111475976	SIK2	-0.58	-9.73	-0.47	8.16e-20	Primary sclerosing cholangitis;
CRC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	9.06e-9	Red blood cell count;
CRC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg21625146	chr5:486483	SLC9A3	0.37	5.79	0.3	1.67e-8	Cystic fibrosis severity;
CRC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	14.08	0.61	1.51e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.29	5.89	0.31	9.67e-9	Ewing sarcoma;
CRC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.65	0.43	2.39e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.43	6.71	0.35	8.45e-11	Red blood cell count;
CRC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg24375607	chr4:120327624	NA	0.47	7.72	0.39	1.42e-13	Corneal astigmatism;
CRC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.4	0.33	5.47e-10	Hemoglobin concentration;
CRC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.54	8.07	0.41	1.34e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02772935	chr3:125709198	NA	-0.5	-5.83	-0.31	1.3e-8	Blood pressure (smoking interaction);
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.4	7.28	0.37	2.55e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.76	0.35	6.27e-11	Obesity-related traits;
CRC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg11189052	chr15:85197271	WDR73	0.63	8.71	0.43	1.51e-16	Schizophrenia;
CRC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.86	14.87	0.63	1.27e-38	Intelligence (multi-trait analysis);
CRC	trans	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg00352043	chr22:38863594	KDELR3	0.33	6.05	0.32	3.98e-9	Schizophrenia;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg02033258	chr5:131593261	PDLIM4	0.35	6.76	0.35	6.29e-11	Blood metabolite levels;
CRC	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.61	-6.8	-0.35	5e-11	Red blood cell count;
CRC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.51	8.99	0.44	1.94e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg24675056	chr1:15929824	NA	0.49	6.66	0.34	1.12e-10	Systolic blood pressure;
CRC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.67	0.39	1.95e-13	Height;
CRC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.55	-6.7	-0.35	9.14e-11	Body mass index;
CRC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.25	-16.79	-0.68	4.1e-46	Breast cancer;
CRC	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg08133631	chr1:26527909	CATSPER4	-0.35	-5.76	-0.3	1.91e-8	Obesity-related traits;
CRC	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.75	-10.92	-0.52	6.95e-24	Blood protein levels;
CRC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25517755	chr10:38738941	LOC399744	-0.45	-6.6	-0.34	1.61e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7705042	0.828	rs249638	chr5:141530696	G/C	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.48e-8	Asthma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09564133	chr5:176738847	MXD3	-0.54	-6.63	-0.34	1.4e-10	Diisocyanate-induced asthma;
CRC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs7259376	0.936	rs2099354	chr19:22539532	C/A	cg02657401	chr19:22469223	NA	-0.34	-7.62	-0.39	2.73e-13	Menopause (age at onset);
CRC	cis	rs2274471	0.699	rs10815160	chr9:5116616	A/C	cg03390472	chr9:5043263	JAK2	-0.5	-5.93	-0.31	7.49e-9	Crohn's disease;
CRC	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	7.23	0.37	3.38e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.44	7.39	0.38	1.2e-12	Crohn's disease;
CRC	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg21918786	chr6:109611834	NA	-0.34	-5.84	-0.31	1.28e-8	Reticulocyte fraction of red cells;
CRC	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.58	8.6	0.43	3.29e-16	Autism;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12273811	chr6:28175739	NA	0.59	8.64	0.43	2.56e-16	Cardiac Troponin-T levels;
CRC	cis	rs477692	0.549	rs7079744	chr10:131454790	G/A	cg05714579	chr10:131428358	MGMT	-0.48	-6.48	-0.34	3.42e-10	Response to temozolomide;
CRC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.38	5.69	0.3	2.87e-8	HDL cholesterol;
CRC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-6.35	-0.33	7.15e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg05072774	chr3:49840536	C3orf54	-0.43	-5.64	-0.3	3.59e-8	Resting heart rate;
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.64e-9	Bipolar disorder;
CRC	cis	rs600626	0.529	rs2008476	chr11:75470813	C/T	cg24262691	chr11:75473276	NA	0.53	7.9	0.4	4.18e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	9.52	0.46	3.87e-19	Type 2 diabetes;
CRC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.54	6.75	0.35	6.64e-11	Bipolar disorder (body mass index interaction);
CRC	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.47	-0.34	3.5e-10	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25222319	chr17:3500274	TRPV1	-0.33	-6.02	-0.31	4.61e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs354033	1.000	rs354034	chr7:149290497	G/A	cg24335155	chr7:149193227	ZNF746	0.38	6.19	0.32	1.8e-9	Multiple sclerosis;
CRC	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.7	8.18	0.41	6.05e-15	Phospholipid levels (plasma);
CRC	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-6.83	-0.35	4.05e-11	Coronary artery disease;
CRC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.53	-0.38	4.91e-13	Mean corpuscular volume;
CRC	cis	rs427941	0.703	rs201442	chr7:101737627	C/T	cg06246474	chr7:101738831	CUX1	-0.45	-7.02	-0.36	1.25e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.47	-6.41	-0.33	5.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	6.82	0.35	4.38e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00167275	chr10:88854588	FAM35A;GLUD1	0.39	6.43	0.33	4.54e-10	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01973771	chr19:2740143	SLC39A3	0.41	6.0	0.31	5.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.0	0.4	2.15e-14	Menopause (age at onset);
CRC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24013378	chr11:69480958	ORAOV1	0.42	6.73	0.35	7.46e-11	Asthma;
CRC	cis	rs9903692	0.908	rs11079809	chr17:46198221	T/C	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	3.09e-14	Pulse pressure;
CRC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.7	11.21	0.53	6.36e-25	DNA methylation (variation);
CRC	cis	rs6681460	0.634	rs4142763	chr1:66998036	A/G	cg02459107	chr1:67143332	SGIP1	0.37	5.7	0.3	2.6e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs6681460	0.604	rs7546825	chr1:67101802	A/G	cg02459107	chr1:67143332	SGIP1	0.32	5.72	0.3	2.39e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.95	0.36	2.01e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.5	6.46	0.34	3.66e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.58	7.65	0.39	2.23e-13	Alzheimer's disease;
CRC	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.5	7.56	0.38	4.15e-13	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11227075	chr10:52750930	PRKG1	0.39	6.04	0.32	4.18e-9	Response to antipsychotic treatment;
CRC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg21854759	chr1:92012499	NA	-0.49	-6.69	-0.35	9.54e-11	Eosinophil percentage of white cells;
CRC	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg12560992	chr17:57184187	TRIM37	0.56	7.65	0.39	2.25e-13	Testicular germ cell tumor;
CRC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.76	10.02	0.48	8.6e-21	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09278885	chr1:2126389	C1orf86;LOC100128003	0.49	6.74	0.35	7.06e-11	Response to antipsychotic treatment;
CRC	cis	rs7224610	0.898	rs4299205	chr17:53366146	T/G	cg02383154	chr17:53343283	HLF	-0.34	-5.76	-0.3	1.93e-8	Urate levels;
CRC	cis	rs12692738	0.526	rs446315	chr2:165609194	T/C	cg03182029	chr2:165697222	COBLL1	0.48	5.6	0.3	4.46e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.1	-11.67	-0.54	1.45e-26	Intelligence (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg27565382	chr3:53032988	SFMBT1	0.65	5.68	0.3	2.94e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.64	0.63	9.82e-38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.53	8.17	0.41	6.81e-15	Testicular germ cell tumor;
CRC	cis	rs7259376	0.905	rs2082480	chr19:22538650	G/A	cg02657401	chr19:22469223	NA	-0.34	-7.62	-0.39	2.73e-13	Menopause (age at onset);
CRC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.65	-11.48	-0.53	6.9e-26	Schizophrenia;
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.38	-7.22	-0.37	3.61e-12	Abdominal aortic aneurysm;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	5.66	0.3	3.29e-8	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.95	-13.38	-0.59	6.93e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.63	9.96	0.48	1.38e-20	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19871494	chr1:1310280	AURKAIP1	0.39	6.31	0.33	8.77e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg04969067	chr8:143858791	LYNX1	-0.35	-5.98	-0.31	5.67e-9	Urinary tract infection frequency;
CRC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.79	10.86	0.51	1.11e-23	Cognitive function;
CRC	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.63	10.3	0.49	9.81e-22	Schizophrenia;
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg08888203	chr3:10149979	C3orf24	0.7	8.5	0.42	6.51e-16	Alzheimer's disease;
CRC	trans	rs11885103	0.543	rs1320362	chr2:564079	G/T	cg12228919	chr15:44955936	SPG11	-0.45	-6.66	-0.34	1.13e-10	Heschl's gyrus morphology;
CRC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.44	-6.19	-0.32	1.77e-9	Schizophrenia;
CRC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-6.97	-0.36	1.78e-11	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25002044	chr14:68141349	VTI1B	0.4	6.15	0.32	2.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.69	-11.46	-0.53	8.09e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.58	7.52	0.38	5.14e-13	RR interval (heart rate);
CRC	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg20936604	chr3:58311152	NA	-0.72	-6.86	-0.35	3.51e-11	Cholesterol, total;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg22687807	chr8:143858763	LYNX1	-0.47	-7.77	-0.39	9.95e-14	Urinary tract infection frequency;
CRC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	1.07	10.94	0.52	5.69e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg15704280	chr7:45808275	SEPT13	0.56	6.32	0.33	8.44e-10	Intraocular pressure;
CRC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.28	0.42	3.2e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.67	7.26	0.37	2.84e-12	Childhood ear infection;
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.4	-5.92	-0.31	8.29e-9	Lymphocyte counts;
CRC	cis	rs10946940	0.896	rs12208078	chr6:27498581	G/A	cg15845792	chr6:28175446	NA	-0.45	-6.16	-0.32	2.14e-9	Systemic lupus erythematosus;
CRC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.63	11.77	0.54	6.19e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.35	-5.61	-0.3	4.28e-8	Mean platelet volume;
CRC	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg12365402	chr11:9010492	NRIP3	0.36	5.97	0.31	6.18e-9	Hemoglobin concentration;
CRC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg02421172	chr7:1938701	MAD1L1	0.45	6.05	0.32	3.98e-9	Bipolar disorder;
CRC	trans	rs17641971	1.000	rs73579360	chr8:49920586	C/T	cg25069010	chr20:34828328	C20orf4	-0.42	-6.09	-0.32	3.23e-9	Blood metabolite levels;
CRC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.62	0.6	8.2e-34	Chronic sinus infection;
CRC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg05192639	chr6:26864778	GUSBL1	-0.35	-6.11	-0.32	2.79e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg21577049	chr2:228736449	WDR69	-0.47	-6.22	-0.32	1.5e-9	Blood pressure;
CRC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg25456477	chr12:86230367	RASSF9	-0.36	-6.16	-0.32	2.13e-9	Major depressive disorder;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg02683197	chr6:28174875	NA	0.68	9.43	0.46	7.91e-19	Parkinson's disease;
CRC	cis	rs11212617	0.934	rs172896	chr11:108217049	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.22	0.32	1.51e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg04362960	chr10:104952993	NT5C2	-0.41	-5.72	-0.3	2.37e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.17	0.41	6.81e-15	Lung cancer;
CRC	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.35	-0.33	7.08e-10	Caffeine consumption;
CRC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.44	-7.23	-0.37	3.36e-12	Coronary artery disease;
CRC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.38	0.33	6.09e-10	Tonsillectomy;
CRC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg09163369	chr1:210001066	C1orf107	0.41	5.76	0.3	1.91e-8	Orofacial clefts;
CRC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.49	7.81	0.4	7.96e-14	Obesity-related traits;
CRC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.67	10.08	0.49	5.26e-21	Menopause (age at onset);
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg25193742	chr10:104614220	C10orf32	-0.79	-6.47	-0.34	3.54e-10	Blood osmolality (transformed sodium);
CRC	cis	rs4903604	0.581	rs4899658	chr14:78035392	A/T	cg18872420	chr14:78023429	SPTLC2	-0.34	-5.8	-0.3	1.58e-8	Gut microbiome composition (winter);
CRC	cis	rs12745968	0.589	rs10874725	chr1:93090850	G/A	cg17283838	chr1:93427260	FAM69A	-0.46	-6.32	-0.33	8.45e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21227347	chr9:117374170	C9orf91	0.49	7.11	0.36	7.04e-12	Response to antipsychotic treatment;
CRC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.27	-0.42	3.24e-15	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.05	-0.32	3.87e-9	Depression;
CRC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg22834771	chr12:69754056	YEATS4	-0.42	-5.98	-0.31	5.69e-9	Blood protein levels;
CRC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.92	-0.48	1.82e-20	Total cholesterol levels;
CRC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.64	-10.22	-0.49	1.74e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-7.57	-0.39	3.81e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.03	-0.32	4.3e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.88	0.4	4.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.46	6.27	0.33	1.14e-9	Red blood cell count;
CRC	cis	rs7901135	0.924	rs2393501	chr10:60563326	C/A	cg23799393	chr10:60588674	BICC1	0.37	5.63	0.3	3.87e-8	Morning vs. evening chronotype;
CRC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.61	-0.43	3.14e-16	Monocyte percentage of white cells;
CRC	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg01420254	chr6:26195488	NA	0.73	6.04	0.32	4.13e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.67	-11.91	-0.55	2.01e-27	Eye color traits;
CRC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.25	-0.53	4.55e-25	Blood trace element (Zn levels);
CRC	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	cg04338863	chr8:33670619	NA	0.37	6.44	0.33	4.22e-10	Body mass index;
CRC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.14	0.37	6.06e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-7.91	-0.4	4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg19025524	chr12:109796872	NA	-0.46	-6.52	-0.34	2.61e-10	Neuroticism;
CRC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.76	10.83	0.51	1.42e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs7781266	0.842	rs73150821	chr7:133244026	C/T	cg03336402	chr7:133662267	EXOC4	0.49	5.78	0.3	1.74e-8	Educational attainment (college completion);
CRC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg05501817	chr11:14380813	RRAS2	-0.47	-6.57	-0.34	1.92e-10	Sense of smell;
CRC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.65	-10.29	-0.49	1.06e-21	Motion sickness;
CRC	cis	rs7626444	0.565	rs7613010	chr3:196490221	G/T	cg12930392	chr3:196481615	PAK2	0.39	6.92	0.36	2.43e-11	Monocyte count;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg00010168	chr10:99258642	MMS19;UBTD1	-0.41	-6.16	-0.32	2.18e-9	HDL cholesterol;
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	0.94	10.32	0.49	7.94e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.57	0.34	1.99e-10	Morning vs. evening chronotype;
CRC	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg08015503	chr16:89190385	ACSF3	-0.95	-7.53	-0.38	4.9e-13	Red blood cell count;
CRC	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg04110750	chr16:69646130	NFAT5	-0.56	-7.67	-0.39	1.9e-13	IgE levels;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg15763984	chr4:1342303	KIAA1530	0.48	8.33	0.42	2.25e-15	Longevity;
CRC	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg01475377	chr6:109611718	NA	-0.34	-5.93	-0.31	7.68e-9	Reticulocyte fraction of red cells;
CRC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.79	13.41	0.59	4.99e-33	Menopause (age at onset);
CRC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.59	8.25	0.41	3.86e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg01489032	chr8:143877656	NA	0.37	6.12	0.32	2.73e-9	Urinary tract infection frequency;
CRC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs2304069	0.729	rs2066934	chr5:149433596	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	8.2	0.41	5.64e-15	HIV-1 control;
CRC	cis	rs4731207	0.596	rs1525612	chr7:124684047	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs6429082	0.508	rs4233473	chr1:235488052	C/G	cg26050004	chr1:235667680	B3GALNT2	0.41	6.11	0.32	2.75e-9	Adiposity;
CRC	cis	rs9649465	0.967	rs13244694	chr7:123329879	T/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12463550	chr7:65579703	CRCP	0.62	5.91	0.31	8.39e-9	Diabetic kidney disease;
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.67	9.14	0.45	6.46e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg02493740	chr2:85810744	VAMP5	0.37	5.95	0.31	6.94e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06307176	chr5:131281290	NA	0.41	6.02	0.31	4.78e-9	Life satisfaction;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.63	11.52	0.54	4.85e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.59	8.91	0.44	3.63e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6840360	0.582	rs2709823	chr4:152340446	T/C	cg09659197	chr4:152720779	NA	0.33	6.53	0.34	2.52e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.58	8.85	0.44	5.47e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02450064	chr17:40260053	DHX58	-0.42	-6.13	-0.32	2.54e-9	Fibrinogen levels;
CRC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.55	-6.46	-0.34	3.83e-10	Lymphocyte counts;
CRC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg10760299	chr15:45669010	GATM	-0.49	-7.69	-0.39	1.77e-13	Homoarginine levels;
CRC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.58	7.67	0.39	1.97e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	0.99	8.46	0.42	8.98e-16	Blood protein levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20961037	chr17:43096356	NA	0.35	5.97	0.31	6.31e-9	Obesity-related traits;
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.81	12.67	0.57	3.04e-30	Menarche (age at onset);
CRC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.69	-9.07	-0.45	1.1e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.45	7.07	0.36	9.36e-12	Platelet count;
CRC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg05585544	chr11:47624801	NA	0.47	8.54	0.43	4.96e-16	Subjective well-being;
CRC	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18436758	chr1:21113190	HP1BP3	0.38	6.82	0.35	4.33e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-5.7	-0.3	2.66e-8	Inflammatory bowel disease;
CRC	cis	rs7626444	0.647	rs844546	chr3:196475274	T/G	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.74e-12	Monocyte count;
CRC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11764359	chr7:65958608	NA	0.51	7.69	0.39	1.74e-13	Aortic root size;
CRC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg00428638	chr19:7224713	INSR	0.95	19.59	0.73	3.59e-57	Hypothyroidism;
CRC	cis	rs12760731	0.565	rs77024410	chr1:178164121	A/C	cg00404053	chr1:178313656	RASAL2	1.05	10.93	0.52	6.36e-24	Obesity-related traits;
CRC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.97	-0.36	1.7e-11	Total cholesterol levels;
CRC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg05585544	chr11:47624801	NA	-0.52	-9.43	-0.46	7.53e-19	Subjective well-being;
CRC	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.42	7.95	0.4	3.02e-14	Ulcerative colitis;
CRC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.38	0.38	1.34e-12	Breast cancer;
CRC	cis	rs1639906	0.729	rs17186614	chr7:2231002	G/A	cg19897017	chr7:2163380	MAD1L1	-0.62	-8.34	-0.42	2.04e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.98	0.31	5.9e-9	Lung cancer;
CRC	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg02811702	chr13:24901961	NA	0.47	6.5	0.34	2.96e-10	Obesity-related traits;
CRC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.34	0.56	5.08e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4700695	0.841	rs36302	chr5:65349061	T/A	cg21114390	chr5:65439923	SFRS12	0.67	6.88	0.35	2.96e-11	Facial morphology (factor 19);
CRC	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg27147174	chr7:100797783	AP1S1	-0.4	-6.62	-0.34	1.47e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg09779027	chr19:7224513	INSR	1.01	22.54	0.78	1.1e-68	Hypothyroidism;
CRC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs10911390	0.744	rs116730615	chr1:183652731	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Systemic lupus erythematosus;
CRC	cis	rs36715	1.000	rs36715	chr5:127562880	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	5.87	0.31	1.04e-8	Breast cancer;
CRC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-10.0	-0.48	1.01e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.58	9.94	0.48	1.6e-20	Breast cancer;
CRC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-8.17	-0.41	6.77e-15	IgG glycosylation;
CRC	cis	rs7104764	0.507	rs7111364	chr11:258542	G/C	cg00562011	chr11:252351	PSMD13	-0.54	-6.33	-0.33	8.18e-10	Menarche (age at onset);
CRC	cis	rs62458065	1.000	rs10250808	chr7:32466153	T/C	cg20159608	chr7:32802032	NA	-0.5	-6.31	-0.33	8.83e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg18709589	chr6:96969512	KIAA0776	0.5	5.67	0.3	3.2e-8	Migraine;Coronary artery disease;
CRC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.83	-14.53	-0.63	2.8e-37	Coronary artery disease;
CRC	cis	rs7943203	0.962	rs10749918	chr11:108354874	C/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.67	0.3	3.11e-8	Red blood cell count;Mean corpuscular volume;
CRC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.52	-7.3	-0.37	2.23e-12	Pancreatic cancer;
CRC	cis	rs7113874	0.569	rs9300093	chr11:8590825	T/G	cg17679104	chr11:8615758	STK33	-0.35	-5.88	-0.31	9.95e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs62432291	0.681	rs294912	chr6:159667337	A/G	cg14500486	chr6:159655392	FNDC1	-0.74	-9.0	-0.44	1.91e-17	Joint mobility (Beighton score);
CRC	trans	rs12699921	0.573	rs2723562	chr7:17846620	C/G	cg02066331	chr6:17282778	RBM24	-0.36	-6.11	-0.32	2.79e-9	Fibrinogen levels;
CRC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs6968419	0.747	rs6953050	chr7:115888162	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.28	-0.33	1.06e-9	Intraocular pressure;
CRC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg21285383	chr16:89894308	SPIRE2	0.36	6.19	0.32	1.81e-9	Vitiligo;
CRC	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.35	16.39	0.67	1.43e-44	Uric acid levels;
CRC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-9.21	-0.45	3.85e-18	Sudden cardiac arrest;
CRC	cis	rs1223397	0.938	rs17700321	chr6:13280666	G/T	cg07912922	chr6:13274314	PHACTR1	0.52	6.39	0.33	5.83e-10	Blood pressure;
CRC	trans	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	6.44	0.33	4.33e-10	Mean corpuscular volume;
CRC	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg04850286	chr10:81895943	PLAC9	0.38	6.72	0.35	7.9e-11	Sarcoidosis;
CRC	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.54	8.14	0.41	8.3e-15	Smoking behavior;
CRC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.75	-0.47	7e-20	Primary sclerosing cholangitis;
CRC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.41	5.7	0.3	2.6e-8	Renal cell carcinoma;
CRC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-6.42	-0.33	4.75e-10	Schizophrenia;
CRC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.56	0.57	8.3e-30	Bone mineral density;
CRC	cis	rs728616	0.614	rs61859209	chr10:82128309	G/A	cg05935833	chr10:81318306	SFTPA2	-0.58	-7.02	-0.36	1.28e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.32	5.7	0.3	2.64e-8	Heart rate;
CRC	cis	rs11212617	1.000	rs609429	chr11:108196509	G/C	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.55	0.34	2.19e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-9.05	-0.45	1.24e-17	Mean corpuscular hemoglobin concentration;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg24560729	chr4:1342394	KIAA1530	-0.32	-5.85	-0.31	1.17e-8	Obesity-related traits;
CRC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg20684491	chr1:25596433	NA	-0.44	-7.88	-0.4	4.79e-14	Erythrocyte sedimentation rate;
CRC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg25456477	chr12:86230367	RASSF9	0.34	5.77	0.3	1.82e-8	Major depressive disorder;
CRC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg25985355	chr7:65971099	NA	-0.56	-6.28	-0.33	1.04e-9	Diabetic kidney disease;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.64	-9.62	-0.47	1.81e-19	Menarche (age at onset);
CRC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.42	-0.33	4.74e-10	Aortic root size;
CRC	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11446398	chr5:77624930	NA	0.46	6.33	0.33	8.15e-10	Triglycerides;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.81	-0.44	7.22e-17	Bipolar disorder;
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs7215564	0.908	rs56078934	chr17:78658849	A/C	cg09596252	chr17:78655493	RPTOR	0.53	5.66	0.3	3.26e-8	Myopia (pathological);
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg07423050	chr13:99094983	FARP1	0.41	6.6	0.34	1.63e-10	Longevity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16761550	chr16:3029823	PKMYT1	0.43	6.18	0.32	1.91e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg02869306	chr7:64672164	INTS4L1	0.44	6.86	0.35	3.53e-11	Aortic root size;
CRC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg20092199	chr4:1342459	KIAA1530	0.45	7.32	0.37	1.95e-12	Obesity-related traits;
CRC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.47	6.44	0.33	4.23e-10	Pulse pressure;
CRC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.74	10.45	0.5	2.97e-22	Response to antineoplastic agents;
CRC	cis	rs4731207	0.596	rs12113765	chr7:124589684	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.61	-8.76	-0.43	1.06e-16	Coronary artery disease;
CRC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.55	0.47	3.04e-19	Cognitive test performance;
CRC	trans	rs329674	0.516	rs329650	chr11:133765897	C/T	cg05324519	chr17:62770765	LOC146880	0.46	6.04	0.32	4.24e-9	Bipolar disorder;
CRC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.65	9.39	0.46	1.03e-18	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03352657	chr17:26684557	POLDIP2;TMEM199	0.46	8.12	0.41	9.42e-15	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06772644	chr1:40997203	ZNF684	0.39	6.22	0.32	1.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg24011408	chr12:48396354	COL2A1	0.45	6.32	0.33	8.27e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.74	-0.3	2.15e-8	Migraine;Coronary artery disease;
CRC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg16558177	chr4:4109446	NA	-0.56	-6.43	-0.33	4.42e-10	Blood pressure (smoking interaction);
CRC	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	cg04338863	chr8:33670619	NA	0.44	6.9	0.36	2.68e-11	Body mass index;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18802567	chr5:171433913	FBXW11	0.4	6.1	0.32	3.01e-9	Myopia (pathological);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07584320	chr11:94964503	SESN3	0.42	6.58	0.34	1.91e-10	Interleukin-6 levels;
CRC	trans	rs333332	1.000	rs333332	chr3:124328494	C/T	cg08451243	chr11:1273788	MUC5B	0.41	6.51	0.34	2.89e-10	Heschl's gyrus morphology;
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.54	-9.8	-0.48	4.49e-20	Bipolar disorder;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg01779806	chr5:160279389	ATP10B	-0.38	-5.99	-0.31	5.44e-9	HDL cholesterol;
CRC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg21620606	chr4:1342894	KIAA1530	0.34	5.65	0.3	3.53e-8	Obesity-related traits;
CRC	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.48	6.72	0.35	8.11e-11	Eye color traits;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg22627826	chr19:1240265	ATP5D	-0.72	-6.18	-0.32	1.86e-9	Cognitive function;
CRC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg14008862	chr17:28927542	LRRC37B2	0.56	5.8	0.3	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7605827	0.897	rs9973344	chr2:15632583	G/T	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.17e-9	Educational attainment (years of education);
CRC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27010576	chr16:21964792	UQCRC2	0.48	6.8	0.35	4.99e-11	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.55	0.38	4.42e-13	Motion sickness;
CRC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg02659138	chr7:134003124	SLC35B4	0.38	6.51	0.34	2.85e-10	Mean platelet volume;
CRC	cis	rs3791406	0.654	rs3791409	chr2:240030606	C/G	cg14550559	chr2:240039617	HDAC4	-0.47	-6.88	-0.35	3.04e-11	Skin aging (microtopography measurement);
CRC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg16606324	chr3:10149918	C3orf24	0.48	7.03	0.36	1.19e-11	Alzheimer's disease;
CRC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.36	5.98	0.31	5.84e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.14	-0.32	2.36e-9	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12273811	chr6:28175739	NA	0.69	8.83	0.44	6.17e-17	Depression;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04355093	chr4:85887382	WDFY3;C4orf12	-0.41	-6.16	-0.32	2.17e-9	Myopia (pathological);
CRC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs728616	0.717	rs17098169	chr10:81816134	C/T	cg11900509	chr10:81946545	ANXA11	0.53	5.78	0.3	1.76e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.42	-5.78	-0.3	1.75e-8	Corneal structure;
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-8.4	-0.42	1.36e-15	Bipolar disorder;
CRC	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-1.0	-10.42	-0.5	3.76e-22	Post bronchodilator FEV1;
CRC	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg20935368	chr5:178288625	ZNF354B	0.43	7.03	0.36	1.16e-11	Sleep duration;
CRC	cis	rs12476592	0.543	rs262532	chr2:63906020	G/A	cg10828910	chr2:63850056	LOC388955	0.5	6.3	0.33	9.56e-10	Childhood ear infection;
CRC	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg06632207	chr12:54070931	ATP5G2	0.45	7.69	0.39	1.73e-13	Height;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05954884	chr1:155279053	FDPS	0.43	6.01	0.31	4.98e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg11843238	chr5:131593191	PDLIM4	0.36	6.97	0.36	1.77e-11	Blood metabolite levels;
CRC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg02741985	chr17:80059408	CCDC57	-0.43	-7.0	-0.36	1.43e-11	Life satisfaction;
CRC	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg09659197	chr4:152720779	NA	-0.42	-8.66	-0.43	2.18e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.51	-6.37	-0.33	6.44e-10	Recombination rate (females);
CRC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.7	-0.35	9.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.48	-6.13	-0.32	2.49e-9	Longevity;
CRC	cis	rs755249	0.567	rs16825921	chr1:39649198	A/T	cg18385671	chr1:39797026	MACF1	-0.41	-5.93	-0.31	7.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9549328	0.520	rs36144023	chr13:113616592	T/C	cg20742385	chr13:113633654	MCF2L	0.55	9.39	0.46	1.01e-18	Systolic blood pressure;
CRC	cis	rs3736485	0.934	rs17609924	chr15:51911592	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.33	-0.33	8.13e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.73	11.82	0.55	4.15e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.19	0.53	7.36e-25	Bipolar disorder;
CRC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.39	5.9	0.31	8.8e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs2462686	0.965	rs1534151	chr7:45984645	A/G	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.83	-0.31	1.29e-8	Major depressive disorder;
CRC	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.33	-5.71	-0.3	2.56e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg12185399	chr6:27640341	NA	0.82	5.85	0.31	1.21e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7725052	0.605	rs10941510	chr5:40462426	T/C	cg09067459	chr5:40385259	NA	0.4	6.57	0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.83	-0.44	6.38e-17	Aortic root size;
CRC	cis	rs758324	0.812	rs13170176	chr5:131138736	G/C	cg25547332	chr5:131281432	NA	0.36	5.72	0.3	2.34e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.84	0.66	2.15e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.3e-40	Prostate cancer;
CRC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg03013999	chr17:37608204	MED1	-0.48	-7.51	-0.38	5.62e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs1223397	0.651	rs957175	chr6:13311243	C/T	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg14324370	chr2:177042789	NA	0.8	13.08	0.58	9.34e-32	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02445447	chr2:106015594	FHL2	0.39	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3751196	0.808	rs79014697	chr12:104213856	G/T	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-6.0	-0.31	5.13e-9	Life satisfaction;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07734359	chr17:618044	VPS53	0.4	6.04	0.32	4.08e-9	Schizophrenia;
CRC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.67	10.2	0.49	2.1e-21	Corneal astigmatism;
CRC	trans	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg24375607	chr4:120327624	NA	-0.47	-7.75	-0.39	1.14e-13	Corneal astigmatism;
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.08	-0.32	3.4e-9	Bipolar disorder;
CRC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.61	-0.43	3.05e-16	Platelet count;
CRC	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.99	0.44	1.96e-17	Fuchs's corneal dystrophy;
CRC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.63	-11.38	-0.53	1.63e-25	Aortic root size;
CRC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.87	-16.13	-0.66	1.52e-43	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.12	0.32	2.71e-9	Personality dimensions;
CRC	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.67	-10.02	-0.48	8.37e-21	Acne (severe);
CRC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg19223190	chr17:80058835	NA	0.4	6.33	0.33	8.04e-10	Life satisfaction;
CRC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.74	-10.43	-0.5	3.45e-22	Platelet distribution width;
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg02741985	chr17:80059408	CCDC57	0.42	7.02	0.36	1.25e-11	Life satisfaction;
CRC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg06627628	chr2:24431161	ITSN2	-0.53	-5.87	-0.31	1.07e-8	Lymphocyte counts;
CRC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.2	0.37	4.21e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.63	-9.81	-0.48	4.18e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.63	8.94	0.44	2.92e-17	Homoarginine levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg03241287	chr5:118324324	DTWD2	0.41	6.05	0.32	3.88e-9	Schizophrenia;
CRC	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.54	7.91	0.4	3.94e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.0	9.8	0.48	4.7e-20	Diabetic retinopathy;
CRC	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-6.03	-0.32	4.44e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg22110888	chr17:80059540	CCDC57	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg08885800	chr1:201084119	NA	0.48	8.91	0.44	3.5e-17	Permanent tooth development;
CRC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.72	-0.3	2.38e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg05896524	chr21:47604654	C21orf56	0.46	6.88	0.35	3.03e-11	Testicular germ cell tumor;
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.0	-0.44	1.8e-17	Alzheimer's disease;
CRC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.99	-0.31	5.54e-9	Bladder cancer;
CRC	cis	rs75804782	1.000	rs75804782	chr2:239316043	T/C	cg18131467	chr2:239335373	ASB1	-0.67	-5.71	-0.3	2.57e-8	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.36	-5.74	-0.3	2.19e-8	Breast size;
CRC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg00769240	chr8:12517080	NA	-0.57	-7.05	-0.36	1.04e-11	Blood pressure (smoking interaction);
CRC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	trans	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg17903999	chr18:56338584	MALT1	0.42	6.68	0.35	1.05e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3812762	0.871	rs11042068	chr11:8815599	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.42	-6.78	-0.35	5.52e-11	Hypospadias;
CRC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg12751644	chr20:60527061	NA	-0.4	-6.32	-0.33	8.66e-10	Body mass index;
CRC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.39	-0.69	1.75e-48	Body mass index;
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.64e-9	Bipolar disorder;
CRC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg19318889	chr4:1322082	MAEA	0.41	5.78	0.3	1.71e-8	Obesity-related traits;
CRC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.51	7.73	0.39	1.36e-13	Corneal astigmatism;
CRC	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.71	7.6	0.39	3.16e-13	Breast cancer;
CRC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg20811857	chr17:78079795	GAA	0.37	6.19	0.32	1.78e-9	Yeast infection;
CRC	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-0.74	-7.66	-0.39	2.1e-13	Blood protein levels;
CRC	cis	rs2857891	0.695	rs2857896	chr11:6982825	A/T	cg04053776	chr11:6947353	ZNF215	0.38	5.83	0.31	1.35e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs629535	0.862	rs655028	chr8:70049047	T/C	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg05562828	chr17:3906858	NA	0.67	12.41	0.56	2.83e-29	Type 2 diabetes;
CRC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.51	-0.34	2.79e-10	Educational attainment;
CRC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-8.23	-0.41	4.54e-15	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25503565	chr17:38264529	NA	-0.42	-6.87	-0.35	3.28e-11	Myopia (pathological);
CRC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.65	-0.51	5.8e-23	Total cholesterol levels;
CRC	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg26528668	chr16:1614120	IFT140	0.38	5.88	0.31	1.03e-8	Coronary artery disease;
CRC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.75	-10.19	-0.49	2.26e-21	White matter hyperintensity burden;
CRC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg10298567	chr3:47292165	KIF9	-0.38	-6.14	-0.32	2.39e-9	Colorectal cancer;
CRC	cis	rs3924048	0.574	rs34494202	chr1:12612868	G/A	cg00291366	chr1:12616550	NA	0.59	10.73	0.51	3.06e-23	Optic cup area;
CRC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.74	-0.3	2.13e-8	Tonsillectomy;
CRC	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.83	-13.54	-0.6	1.73e-33	Hypospadias;
CRC	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	8.2	0.41	5.45e-15	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg02018176	chr4:1364513	KIAA1530	0.39	5.73	0.3	2.22e-8	Obesity-related traits;
CRC	cis	rs10274279	0.660	rs9638055	chr7:157379914	A/G	cg26886268	chr7:157387156	PTPRN2	-0.46	-6.43	-0.33	4.5e-10	Myopia (pathological);
CRC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.39	-6.59	-0.34	1.73e-10	Height;
CRC	cis	rs4750440	0.637	rs2457859	chr10:14032099	T/G	cg04819048	chr10:14014548	FRMD4A	0.37	6.11	0.32	2.82e-9	Adiponectin levels;
CRC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg22777020	chr22:31556080	RNF185	0.48	5.76	0.3	1.9e-8	Colorectal cancer;
CRC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.69	11.25	0.53	4.54e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.32	-6.6	-0.34	1.6e-10	Cutaneous nevi;
CRC	cis	rs883565	0.502	rs9839582	chr3:38943120	G/A	cg01426195	chr3:39028469	NA	0.38	6.37	0.33	6.34e-10	Handedness;
CRC	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg15571903	chr15:79123663	NA	-0.3	-5.96	-0.31	6.61e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs4719841	0.662	rs6980357	chr7:25994009	A/G	cg24254488	chr7:25991654	NA	0.29	6.02	0.31	4.75e-9	Triglyceride levels;
CRC	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.48	9.43	0.46	7.45e-19	Hand grip strength;
CRC	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.46	5.68	0.3	2.95e-8	Metabolite levels;
CRC	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-0.65	-5.89	-0.31	9.49e-9	Pediatric areal bone mineral density (radius);
CRC	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.55	10.17	0.49	2.62e-21	Cognitive performance;
CRC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	10.91	0.52	7.22e-24	Body mass index;
CRC	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.59	-6.54	-0.34	2.4e-10	Blood protein levels;
CRC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.58	-0.43	3.79e-16	Total cholesterol levels;
CRC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.53	9.14	0.45	6.4e-18	Coronary artery disease;
CRC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg09455208	chr3:40491958	NA	-0.29	-5.86	-0.31	1.15e-8	Renal cell carcinoma;
CRC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.52	7.15	0.37	5.72e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04136173	chr3:38065951	PLCD1	0.38	6.07	0.32	3.44e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.48	6.82	0.35	4.43e-11	Malaria;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04698434	chr2:25265145	EFR3B	0.36	6.11	0.32	2.75e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg09836344	chr4:1243392	C4orf42;CTBP1	0.55	6.14	0.32	2.33e-9	Mosquito bite size;
CRC	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.48	6.76	0.35	6.35e-11	Mammographic density (dense area);
CRC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	14.78	0.63	2.93e-38	Platelet count;
CRC	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	13.8	0.61	1.68e-34	Colorectal cancer;
CRC	cis	rs2077654	0.556	rs4756888	chr11:17442658	T/C	cg25308976	chr11:17434268	ABCC8	0.6	6.9	0.36	2.68e-11	Gout;
CRC	trans	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg17903999	chr18:56338584	MALT1	0.43	6.96	0.36	1.85e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.38	-7.72	-0.39	1.39e-13	Lung cancer;
CRC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.93	-0.4	3.43e-14	Height;
CRC	trans	rs492478	0.892	rs80288101	chr5:3929135	A/G	cg09199442	chr11:28132951	METT5D1	-0.7	-6.1	-0.32	3.05e-9	Cognitive performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06590470	chr9:34523253	ENHO	0.5	6.94	0.36	2.13e-11	Response to antipsychotic treatment;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg04497992	chr16:616212	NHLRC4	0.42	6.56	0.34	2.04e-10	Height;
CRC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.43	-0.38	9.17e-13	Calcium levels;
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18301423	chr5:131593218	PDLIM4	-0.37	-6.86	-0.35	3.34e-11	Breast cancer;
CRC	cis	rs17152411	0.947	rs733400	chr10:126594340	G/A	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs7113874	0.524	rs9704586	chr11:8578530	T/G	cg17679104	chr11:8615758	STK33	-0.35	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07804711	chr19:46142647	MIR330;EML2	0.45	6.57	0.34	2.01e-10	Response to antipsychotic treatment;
CRC	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg17145862	chr1:211918768	LPGAT1	0.56	9.41	0.46	8.55e-19	Leprosy;
CRC	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg16898833	chr6:26189333	HIST1H4D	0.75	6.28	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11030122	0.547	rs750525	chr11:3948894	G/A	cg18678763	chr11:4115507	RRM1	-0.39	-6.61	-0.34	1.59e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg17948913	chr5:572064	NA	0.55	6.2	0.32	1.71e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.38	5.87	0.31	1.07e-8	HDL cholesterol levels;
CRC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12315302	chr6:26189340	HIST1H4D	0.81	6.23	0.32	1.45e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg00343986	chr7:65444356	GUSB	0.42	5.99	0.31	5.46e-9	Aortic root size;
CRC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg07424746	chr4:185654737	MLF1IP	-0.57	-5.78	-0.3	1.78e-8	Blood protein levels;
CRC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.8	12.11	0.56	3.57e-28	Coronary artery disease;
CRC	cis	rs9303280	0.806	rs9303279	chr17:38073968	G/C	cg11212589	chr17:38028394	ZPBP2	-0.39	-6.93	-0.36	2.22e-11	Self-reported allergy;
CRC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.4	-0.46	9.54e-19	Platelet count;
CRC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02228675	chr17:40259724	DHX58	-0.48	-6.78	-0.35	5.67e-11	Fibrinogen levels;
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.07	-14.92	-0.64	8.16e-39	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-11.85	-0.55	3.29e-27	Dental caries;
CRC	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg16950941	chr11:66035639	RAB1B	0.6	7.43	0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.57	0.43	4e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg15309053	chr8:964076	NA	0.41	7.29	0.37	2.37e-12	Schizophrenia;
CRC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.24	0.37	3.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1465370	0.682	rs6972781	chr7:130023179	A/G	cg03229158	chr7:130009420	NA	0.43	6.2	0.32	1.73e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20092199	chr4:1342459	KIAA1530	0.42	7.71	0.39	1.52e-13	Obesity-related traits;
CRC	cis	rs10512697	1.000	rs62335224	chr5:3568744	A/G	cg19473799	chr5:3511975	NA	-0.76	-5.81	-0.31	1.44e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	10.78	0.51	2.1e-23	Platelet count;
CRC	cis	rs3020333	0.703	rs862346	chr6:152016369	A/T	cg22157087	chr6:152012887	ESR1	0.48	7.41	0.38	1.08e-12	Total body bone mineral density;
CRC	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-5.75	-0.3	2.04e-8	Alzheimer's disease (survival time);
CRC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.53	7.07	0.36	9.14e-12	Height;
CRC	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.39	-0.42	1.43e-15	Biliary atresia;
CRC	trans	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.7	-8.34	-0.42	2e-15	Pursuit maintenance gain;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg26587870	chr6:27730563	NA	-0.47	-6.94	-0.36	2.08e-11	Parkinson's disease;
CRC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.35	-5.64	-0.3	3.6e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24739457	chr1:205821442	NA	0.43	6.18	0.32	1.86e-9	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04185037	chr6:159239164	EZR	0.41	6.05	0.32	4.02e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs4308415	0.726	rs13122686	chr4:67810818	C/A	cg19648955	chr2:177134095	MTX2	-0.41	-6.14	-0.32	2.4e-9	Educational attainment (years of education);
CRC	trans	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-6.7	-0.35	8.79e-11	Monocyte count;
CRC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg13844804	chr7:814759	HEATR2	0.61	8.01	0.4	1.98e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.67	0.3	3.15e-8	Lung cancer;
CRC	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	9.48	0.46	5.36e-19	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-7.91	-0.4	4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.51	7.63	0.39	2.56e-13	Lymphocyte counts;
CRC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.22	0.37	3.57e-12	Educational attainment;
CRC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg07718321	chr6:96025334	MANEA	0.52	6.11	0.32	2.82e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.57	-8.73	-0.43	1.32e-16	Bipolar disorder;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg02683197	chr6:28174875	NA	0.71	9.02	0.45	1.64e-17	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07747515	chr11:61659326	FADS3	0.4	6.2	0.32	1.7e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg26116260	chr4:7069785	GRPEL1	-0.6	-5.81	-0.31	1.48e-8	Granulocyte percentage of myeloid white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07545714	chr3:122135128	WDR5B	0.45	6.33	0.33	8.17e-10	Response to antipsychotic treatment;
CRC	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg16964102	chr10:135390573	NA	0.45	7.56	0.38	4e-13	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.43	5.76	0.3	1.93e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7923609	0.967	rs4486511	chr10:65264266	C/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.94	-0.31	7.27e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.83	-0.44	6.2e-17	Bipolar disorder;
CRC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.57	0.34	1.99e-10	Major depressive disorder;
CRC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.6	-10.65	-0.51	5.83e-23	Aortic root size;
CRC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.69	11.99	0.55	1.02e-27	Resting heart rate;
CRC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-14.98	-0.64	4.69e-39	Lymphocyte percentage of white cells;
CRC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	6.5	0.34	2.92e-10	Monocyte percentage of white cells;
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg10729496	chr3:10149963	C3orf24	0.6	7.06	0.36	9.86e-12	Alzheimer's disease;
CRC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	11.31	0.53	2.93e-25	Neutrophil percentage of white cells;
CRC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg25164649	chr6:28176230	NA	0.4	5.72	0.3	2.42e-8	Pubertal anthropometrics;
CRC	trans	rs7619427	0.643	rs6791785	chr3:44093101	G/A	cg09408571	chr1:101003634	GPR88	0.55	6.09	0.32	3.13e-9	Schizophrenia;
CRC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.2	-0.49	2.06e-21	Body mass index;
CRC	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.56	-7.48	-0.38	6.72e-13	Waist circumference;Body mass index;
CRC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.53	7.75	0.39	1.13e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg22134325	chr11:66188745	NPAS4	0.4	6.66	0.34	1.13e-10	Airway imaging phenotypes;
CRC	cis	rs7172809	0.643	rs4243046	chr15:77834746	T/C	cg10437265	chr15:77819839	NA	-0.39	-6.56	-0.34	2.08e-10	Glucose homeostasis traits;
CRC	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg20356878	chr3:121714668	ILDR1	-0.42	-6.01	-0.31	5.02e-9	Multiple sclerosis;
CRC	cis	rs939584	1.000	rs7567368	chr2:645082	T/C	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs17234274	0.622	rs1586075	chr11:23237399	A/G	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.48	-8.2	-0.41	5.43e-15	P wave terminal force;
CRC	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.75e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs943466	0.614	rs4713677	chr6:33731225	C/G	cg11713064	chr6:33730089	NA	-0.24	-5.89	-0.31	9.3e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
CRC	cis	rs282587	0.569	rs419334	chr13:113415346	G/A	cg04656015	chr13:113407548	ATP11A	0.59	7.56	0.38	3.96e-13	Glycated hemoglobin levels;
CRC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.67	7.46	0.38	7.85e-13	Vitiligo;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.55	-10.09	-0.49	4.95e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.16	-0.32	2.07e-9	IgE levels;
CRC	cis	rs9522267	0.511	rs4773397	chr13:112245044	T/C	cg10483660	chr13:112241077	NA	-0.47	-8.9	-0.44	3.78e-17	Hepatitis;
CRC	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.08	-0.36	8.95e-12	Colorectal cancer;
CRC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.52	-8.67	-0.43	2.01e-16	Menarche (age at onset);
CRC	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.43	7.05	0.36	1.04e-11	Sitting height ratio;
CRC	cis	rs6968419	0.649	rs58624059	chr7:115868798	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.43	-0.33	4.62e-10	Intraocular pressure;
CRC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.66	9.87	0.48	2.7e-20	Gestational age at birth (maternal effect);
CRC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg07952391	chr2:88470173	THNSL2	0.52	6.04	0.32	4.23e-9	Plasma clusterin levels;
CRC	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.82	-14.48	-0.62	4.14e-37	Height;
CRC	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.07	-0.52	2.04e-24	Colorectal cancer;
CRC	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.52	9.72	0.47	8.7e-20	Age-related hearing impairment;
CRC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.65	0.39	2.24e-13	Height;
CRC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.17	-0.37	5.08e-12	Type 2 diabetes;
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.69	-0.3	2.88e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9361491	0.657	rs2321773	chr6:79476243	G/A	cg09184832	chr6:79620586	NA	-0.33	-5.69	-0.3	2.76e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.41	6.14	0.32	2.36e-9	Renal cell carcinoma;
CRC	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg11189052	chr15:85197271	WDR73	0.52	6.77	0.35	5.8200000000000003e-11	Schizophrenia;
CRC	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.96	16.82	0.68	3.12e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg01420254	chr6:26195488	NA	0.73	6.04	0.32	4.13e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00166722	chr3:10149974	C3orf24	0.68	9.46	0.46	6.2e-19	Alzheimer's disease;
CRC	trans	rs10269006	0.613	rs12704744	chr7:94373916	A/T	cg05903386	chr2:217555456	IGFBP5	-0.39	-6.47	-0.34	3.64e-10	Breast cancer;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12172441	chr6:28176163	NA	0.63	7.43	0.38	9.41e-13	Depression;
CRC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg12963866	chr19:57752005	ZNF805	-0.44	-6.65	-0.34	1.2e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23161317	chr6:28129485	ZNF389	0.5	6.21	0.32	1.57e-9	Depression;
CRC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.8	13.28	0.59	1.59e-32	Blood metabolite levels;
CRC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.47	7.92	0.4	3.78e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs243505	0.898	rs243544	chr7:148402710	T/A	cg09806900	chr7:148480153	CUL1	-0.42	-5.84	-0.31	1.28e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs16882447	0.514	rs27677	chr5:53484164	C/G	cg06461071	chr5:53490839	ARL15	-0.35	-5.67	-0.3	3.12e-8	Systolic blood pressure (dietary potassium intake interaction);
CRC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.4	-8.06	-0.41	1.47e-14	Renal cell carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09230774	chr11:67169262	PPP1CA	0.41	6.37	0.33	6.51e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-8.09	-0.41	1.15e-14	Personality dimensions;
CRC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.6	8.68	0.43	1.87e-16	Primary sclerosing cholangitis;
CRC	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-8.04	-0.41	1.67e-14	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs2298450	0.717	rs2835324	chr21:37610551	C/G	cg02919814	chr21:37666008	DOPEY2	0.46	6.16	0.32	2.11e-9	Schizophrenia;
CRC	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-17.95	-0.7	1.01e-50	Schizophrenia;
CRC	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-6.53	-0.34	2.53e-10	Eosinophil percentage of white cells;
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg13047869	chr3:10149882	C3orf24	0.54	7.5	0.38	6.09e-13	Alzheimer's disease;
CRC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg03609598	chr5:56110824	MAP3K1	0.74	8.83	0.44	6.52e-17	Initial pursuit acceleration;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg10130564	chr11:117069849	TAGLN	0.31	5.93	0.31	7.66e-9	Blood protein levels;
CRC	cis	rs77861329	1.000	rs9868101	chr3:52138377	T/C	cg08692210	chr3:52188851	WDR51A	0.86	7.96	0.4	2.79e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2274273	0.624	rs10141396	chr14:55816925	A/C	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.82	-0.31	1.38e-8	Protein biomarker;
CRC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.62	8.34	0.42	2.1e-15	Migraine;
CRC	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.54	-8.02	-0.4	1.86e-14	Bone mineral density;
CRC	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-8.98	-0.44	2.07e-17	Coronary artery disease;
CRC	cis	rs62229266	0.609	rs12482541	chr21:37419743	A/G	cg12218747	chr21:37451666	NA	-0.37	-6.24	-0.33	1.31e-9	Mitral valve prolapse;
CRC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.35	5.7	0.3	2.69e-8	Sitting height ratio;
CRC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.16	11.81	0.55	4.52e-27	Plateletcrit;
CRC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.66	-0.3	3.38e-8	Gout;Renal underexcretion gout;
CRC	trans	rs877282	0.583	rs11253429	chr10:823234	A/C	cg22713356	chr15:30763199	NA	0.78	8.63	0.43	2.75e-16	Uric acid levels;
CRC	cis	rs2882667	0.598	rs288020	chr5:138224298	A/G	cg09476006	chr5:138032270	NA	0.57	10.13	0.49	3.47e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	1.04	10.12	0.49	3.79e-21	Mean corpuscular hemoglobin;
CRC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.78	-0.3	1.7e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Parkinson's disease;
CRC	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg11887960	chr12:57824829	NA	0.64	7.2	0.37	4.1e-12	Obesity-related traits;
CRC	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg14458575	chr2:238380390	NA	0.47	8.37	0.42	1.64e-15	Prostate cancer;
CRC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.37	-0.42	1.65e-15	Neuroticism;
CRC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.47	6.39	0.33	5.75e-10	Schizophrenia;
CRC	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.43	-7.45	-0.38	8.5e-13	Venous thromboembolism;
CRC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.41	-6.1	-0.32	2.97e-9	Tonsillectomy;
CRC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.78	-0.66	3.79e-42	Intelligence (multi-trait analysis);
CRC	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg03689076	chr20:33865952	NA	0.49	6.94	0.36	2.06e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs6662572	0.737	rs9429093	chr1:46555252	T/C	cg08644498	chr1:46502608	NA	0.43	7.13	0.37	6.51e-12	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08079518	chr17:73775869	H3F3B	0.39	6.34	0.33	7.46e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.1	-17.5	-0.69	5.96e-49	Blood pressure (smoking interaction);
CRC	cis	rs6142102	0.923	rs6059635	chr20:32613493	A/T	cg08999081	chr20:33150536	PIGU	0.4	5.92	0.31	8.15e-9	Skin pigmentation;
CRC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.59	7.88	0.4	4.97e-14	Methadone dose in opioid dependence;
CRC	cis	rs7605827	0.930	rs4668921	chr2:15672071	T/C	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs9847710	0.670	rs36051354	chr3:52986012	T/C	cg18099408	chr3:52552593	STAB1	0.39	5.7	0.3	2.73e-8	Ulcerative colitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19187145	chr15:49338251	SECISBP2L	0.42	6.22	0.32	1.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.55	-8.47	-0.42	8.04e-16	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22727761	chr1:24286270	PNRC2	0.41	6.79	0.35	5.28e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16308101	chr1:67895914	SERBP1	0.57	9.7	0.47	9.56e-20	Liver disease severity in Alagille syndrome;
CRC	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.51	7.93	0.4	3.39e-14	Coronary artery disease;
CRC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	13.76	0.6	2.35e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.22	28.81	0.85	5.44e-92	Schizophrenia;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg15786705	chr6:28176104	NA	0.73	9.31	0.46	1.85e-18	Depression;
CRC	trans	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.54	-0.34	2.33e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12541635	0.934	rs7008840	chr8:107016404	T/C	cg10147462	chr8:107024639	NA	0.44	7.15	0.37	5.49e-12	Age of smoking initiation;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg06470822	chr6:28175283	NA	0.66	10.12	0.49	3.83e-21	Cardiac Troponin-T levels;
CRC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.38	5.87	0.31	1.04e-8	Crohn's disease;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg24768116	chr2:27665128	KRTCAP3	0.34	7.66	0.39	2.15e-13	Total body bone mineral density;
CRC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.39	-6.79	-0.35	5.39e-11	Reticulocyte fraction of red cells;
CRC	cis	rs6479527	0.933	rs10993058	chr9:96873151	C/A	cg14459158	chr9:96720562	NA	0.43	7.43	0.38	9.65e-13	Esophageal adenocarcinoma;
CRC	trans	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg05376469	chr2:102649931	NA	-0.37	-6.11	-0.32	2.81e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs8070740	0.898	rs4493114	chr17:5324207	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	7.46	0.38	7.92e-13	Menopause (age at onset);
CRC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.5	7.45	0.38	8.26e-13	Longevity;
CRC	cis	rs7616330	0.790	rs73118209	chr3:71040857	A/C	cg01511742	chr3:71112437	FOXP1	-0.56	-6.56	-0.34	2.12e-10	QT interval;
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.15	-0.32	2.29e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.6	7.68	0.39	1.79e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg02927042	chr1:21476669	EIF4G3	0.38	5.71	0.3	2.5e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Educational attainment;
CRC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02290350	chr8:58132656	NA	-0.43	-5.99	-0.31	5.63e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3015497	0.789	rs3015500	chr14:51108877	C/T	cg09863266	chr14:51125203	SAV1	-0.31	-5.77	-0.3	1.81e-8	Mean platelet volume;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24106215	chr1:202927166	ADIPOR1	0.43	6.0	0.31	5.3300000000000004e-09	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-7.38	-0.38	1.27e-12	Type 2 diabetes;
CRC	cis	rs73206853	0.841	rs74728497	chr12:111020179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.81	8.35	0.42	1.88e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	11.47	0.53	7.61e-26	Menopause (age at onset);
CRC	cis	rs4926298	0.926	rs8111617	chr19:13191461	C/T	cg23899408	chr19:12877188	HOOK2	-0.47	-6.52	-0.34	2.66e-10	Bipolar disorder;
CRC	cis	rs7527798	0.592	rs960086	chr1:207827069	A/G	cg21110645	chr1:207815933	NA	-0.39	-6.18	-0.32	1.9e-9	Erythrocyte sedimentation rate;
CRC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.68	-11.74	-0.54	8.34e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.76	-0.3	1.97e-8	Arsenic metabolism;
CRC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.9	-11.71	-0.54	1.01e-26	Vitiligo;
CRC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.58	-8.3	-0.42	2.69e-15	Schizophrenia;
CRC	cis	rs77972916	0.561	rs72788900	chr2:43559087	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.93	-0.31	7.64e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-1.41	-11.34	-0.53	2.29e-25	Psoriasis vulgaris;
CRC	cis	rs972578	1.000	rs2092214	chr22:43363923	G/A	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.76	-0.3	1.93e-8	Total body bone mineral density;
CRC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg17321639	chr7:2759063	NA	-0.37	-5.65	-0.3	3.55e-8	Height;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs1165668	0.755	rs2583283	chr12:104313643	G/A	cg21863207	chr12:104234989	NT5DC3	0.48	7.15	0.37	5.76e-12	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.43	-7.34	-0.38	1.64e-12	Huntington's disease progression;
CRC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.79	-13.8	-0.61	1.73e-34	Breast cancer;
CRC	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21659725	chr3:3221576	CRBN	-0.67	-7.42	-0.38	1e-12	Menarche (age at onset);
CRC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.49e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.4	5.88	0.31	1.01e-8	Coronary artery disease;
CRC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.61	9.94	0.48	1.57e-20	Colorectal cancer;
CRC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.72	-8.29	-0.42	2.99e-15	Obesity-related traits;
CRC	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.94e-40	Hypertriglyceridemia;
CRC	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg20356878	chr3:121714668	ILDR1	-0.47	-6.74	-0.35	7.19e-11	Multiple sclerosis;
CRC	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.17	-10.08	-0.49	5.18e-21	Mitochondrial DNA levels;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg13628971	chr7:2884303	GNA12	0.54	7.23	0.37	3.43e-12	Height;
CRC	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg25019722	chr6:37503610	NA	-0.38	-6.59	-0.34	1.73e-10	Cognitive performance;
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.9	-0.31	8.89e-9	Life satisfaction;
CRC	cis	rs860295	0.702	rs4971095	chr1:155606224	G/A	cg02153340	chr1:155202674	NA	0.53	6.92	0.36	2.43e-11	Body mass index;
CRC	cis	rs17767392	1.000	rs61991248	chr14:71860529	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.89	-0.35	2.93e-11	Mitral valve prolapse;
CRC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.12	-0.52	1.3e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.72	-0.35	8.16e-11	Reticulocyte fraction of red cells;
CRC	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.25	-0.37	2.91e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg15147215	chr3:52552868	STAB1	0.45	6.29	0.33	9.84e-10	Schizophrenia;
CRC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.45	-7.86	-0.4	5.48e-14	Breast cancer;
CRC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.75	8.33	0.42	2.17e-15	Systolic blood pressure;
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg16606324	chr3:10149918	C3orf24	0.58	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.82	12.79	0.58	1.11e-30	Menarche (age at onset);
CRC	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-9.37	-0.46	1.22e-18	Blood protein levels;
CRC	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.5	6.72	0.35	7.91e-11	Caudate activity during reward;
CRC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.64	0.34	1.3e-10	Mean platelet volume;
CRC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.55	-0.34	2.28e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.53	6.53	0.34	2.52e-10	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg17321639	chr7:2759063	NA	-0.41	-6.1	-0.32	2.92e-9	Height;
CRC	cis	rs62229266	0.682	rs11700546	chr21:37371139	A/C	cg08632701	chr21:37451849	NA	-0.37	-5.67	-0.3	3.16e-8	Mitral valve prolapse;
CRC	trans	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg26043149	chr18:55253948	FECH	-0.52	-8.01	-0.4	2.03e-14	Bone mineral density;
CRC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17554472	chr22:41940697	POLR3H	-0.52	-5.62	-0.3	4.11e-8	Vitiligo;
CRC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.76	-0.3	1.92e-8	Arsenic metabolism;
CRC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.93	11.02	0.52	3e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs7605827	0.930	rs2010881	chr2:15624646	T/A	cg19274914	chr2:15703543	NA	0.39	6.05	0.32	3.96e-9	Educational attainment (years of education);
CRC	trans	rs9813712	0.574	rs62281647	chr3:129961513	C/T	cg23942268	chr17:6347992	FAM64A	-0.41	-6.01	-0.31	5.03e-9	Response to amphetamines;
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.79	-0.3	1.64e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs3736485	0.932	rs28795073	chr15:51927562	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.55	-0.34	2.21e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	14.95	0.64	6.32e-39	Platelet count;
CRC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.94	-16.76	-0.68	5.27e-46	Height;
CRC	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg26605046	chr4:2439731	NA	-0.4	-7.1	-0.36	7.6e-12	Cognitive function;
CRC	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.93	-0.55	1.6e-27	Exhaled nitric oxide output;
CRC	cis	rs995000	0.965	rs10889334	chr1:62957199	C/G	cg19896129	chr1:63156450	NA	0.4	5.84	0.31	1.26e-8	Triglyceride levels;
CRC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.66	10.67	0.51	5.25e-23	Mean platelet volume;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.01	-0.31	4.81e-9	Total body bone mineral density;
CRC	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.44	-6.6	-0.34	1.65e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg03609598	chr5:56110824	MAP3K1	-0.59	-7.88	-0.4	4.77e-14	Initial pursuit acceleration;
CRC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.5	-0.54	5.96e-26	Psoriasis vulgaris;
CRC	cis	rs73206853	0.841	rs60013768	chr12:110576095	A/G	cg12870014	chr12:110450643	ANKRD13A	0.79	8.0	0.4	2.21e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs8130944	0.822	rs1515756	chr21:44114770	A/C	cg23590273	chr21:44105265	PDE9A	-0.37	-5.8	-0.3	1.56e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg25797454	chr6:150327115	RAET1K	0.37	6.37	0.33	6.45e-10	Alopecia areata;
CRC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	7.83	0.4	6.85e-14	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.46	0.34	3.74e-10	Diabetic retinopathy;
CRC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.0	0.48	9.92e-21	Platelet count;
CRC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	20.95	0.76	1.6e-62	Cognitive ability;
CRC	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.63	-8.67	-0.43	1.95e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.43	-7.71	-0.39	1.51e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-8.63	-0.43	2.73e-16	Urinary metabolites;
CRC	cis	rs863345	0.604	rs59427353	chr1:158500621	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs9462027	0.540	rs4282407	chr6:34830162	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.04	-0.32	4.22e-9	Systemic lupus erythematosus;
CRC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.35	6.2	0.32	1.71e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg16691251	chr5:66510806	NA	0.6	11.91	0.55	1.94e-27	Breast cancer;
CRC	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.68	-9.91	-0.48	2e-20	Multiple sclerosis;
CRC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02725872	chr8:58115012	NA	-0.39	-6.52	-0.34	2.64e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7274811	0.625	rs293722	chr20:31927361	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.45	-6.43	-0.33	4.52e-10	Height;
CRC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.49	7.03	0.36	1.18e-11	Bone mineral density (spine);
CRC	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.62	-9.58	-0.47	2.43e-19	Testicular germ cell tumor;
CRC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16974379	chr10:38146505	ZNF248	0.5	6.51	0.34	2.87e-10	Thyroid stimulating hormone;
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-5.93	-0.31	7.82e-9	Total body bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10039051	chr12:123756720	CDK2AP1	0.51	6.64	0.34	1.33e-10	Thyroid stimulating hormone;
CRC	cis	rs7107770	0.663	rs7111751	chr11:125075288	A/T	cg27629782	chr11:125073726	PKNOX2	-0.49	-7.15	-0.37	5.62e-12	Photic sneeze reflex;
CRC	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21659725	chr3:3221576	CRBN	0.63	7.06	0.36	1.01e-11	Menarche (age at onset);
CRC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.26	-0.33	1.21e-9	Gout;Renal underexcretion gout;
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg22687807	chr8:143858763	LYNX1	-0.46	-7.56	-0.38	4.09e-13	Urinary tract infection frequency;
CRC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg20243544	chr17:37824526	PNMT	0.44	6.77	0.35	5.85e-11	Self-reported allergy;
CRC	trans	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.25	-0.37	2.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg13264159	chr8:625131	ERICH1	-0.77	-7.15	-0.37	5.63e-12	IgG glycosylation;
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg19041857	chr6:27730383	NA	-0.76	-7.48	-0.38	6.83e-13	Depression;
CRC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg18827107	chr12:86230957	RASSF9	-0.47	-7.55	-0.38	4.22e-13	Major depressive disorder;
CRC	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg02072170	chr3:194406190	FAM43A	0.43	7.35	0.38	1.59e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg14673194	chr17:80132900	CCDC57	0.49	6.35	0.33	7.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.66	6.72	0.35	7.79e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2882667	0.690	rs160405	chr5:138084076	A/G	cg09476006	chr5:138032270	NA	0.56	9.64	0.47	1.58e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.06	-0.32	3.79e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.55	8.59	0.43	3.55e-16	Blood metabolite levels;
CRC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.61	8.46	0.42	8.85e-16	Arsenic metabolism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22627950	chr7:44622302	TMED4	-0.53	-6.45	-0.34	3.94e-10	Diisocyanate-induced asthma;
CRC	cis	rs975722	0.646	rs43032	chr7:117107284	A/C	cg09181792	chr7:117119393	CFTR	0.27	5.6	0.3	4.51e-8	Coronary artery disease;
CRC	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg25811766	chr13:21894605	NA	-0.59	-6.07	-0.32	3.57e-9	White matter hyperintensity burden;
CRC	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg04586622	chr2:25135609	ADCY3	-0.58	-9.66	-0.47	1.35e-19	Body mass index;
CRC	cis	rs356992	1.000	rs356992	chr2:60753593	C/G	cg08426369	chr2:60753602	BCL11A	0.52	6.94	0.36	2.15e-11	Educational attainment (years of education);
CRC	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.51	8.26	0.41	3.49e-15	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.15	0.59	4.98e-32	Hip circumference;
CRC	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	10.19	0.49	2.21e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg08761264	chr16:28874980	SH2B1	-0.42	-5.64	-0.3	3.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs995000	0.931	rs10789114	chr1:63034222	T/C	cg19896129	chr1:63156450	NA	0.39	5.67	0.3	3.14e-8	Triglyceride levels;
CRC	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	1.14	10.04	0.48	7.37e-21	Mitochondrial DNA levels;
CRC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.67	10.25	0.49	1.46e-21	Monocyte count;
CRC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.56	0.6	1.37e-33	Platelet count;
CRC	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg04571233	chr2:111982156	NA	-0.34	-5.72	-0.3	2.42e-8	Chronic lymphocytic leukemia;
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.7	9.56	0.47	2.85e-19	Alzheimer's disease;
CRC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.38e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg04166393	chr7:2884313	GNA12	0.39	5.8	0.3	1.53e-8	Height;
CRC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs72862334	0.554	rs6723151	chr2:146592034	C/G	cg22809798	chr19:15284853	NOTCH3	-0.42	-6.19	-0.32	1.79e-9	Coronary artery disease;
CRC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg17948913	chr5:572064	NA	0.51	5.89	0.31	9.53e-9	Obesity-related traits;
CRC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.67	7.88	0.4	4.86e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.87	-0.35	3.15e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.62	8.6	0.43	3.24e-16	Type 2 diabetes;
CRC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.83	-0.72	3.41e-54	Height;
CRC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg05585544	chr11:47624801	NA	-0.55	-10.01	-0.48	9.16e-21	Subjective well-being;
CRC	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.65	-6.09	-0.32	3.14e-9	Alzheimer's disease (late onset);
CRC	cis	rs12431939	1.000	rs66806841	chr14:51670524	G/C	cg23942311	chr14:51606299	NA	-0.53	-6.36	-0.33	6.89e-10	Cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21942256	chr3:156892528	NA	0.45	5.98	0.31	5.76e-9	Survival in pancreatic cancer;
CRC	cis	rs9303542	0.625	rs7207109	chr17:46607817	C/T	cg04904318	chr17:46607828	HOXB1	-0.54	-6.57	-0.34	1.94e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.75	-12.63	-0.57	4.47e-30	Breast cancer;
CRC	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.63e-17	Dupuytren's disease;
CRC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg15145296	chr3:125709740	NA	-0.58	-6.77	-0.35	6.05e-11	Blood pressure (smoking interaction);
CRC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.79	-13.14	-0.59	5.56e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.66	10.63	0.51	6.8e-23	Obesity-related traits;
CRC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.63	-0.39	2.48e-13	Intelligence (multi-trait analysis);
CRC	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.6	-8.68	-0.43	1.91e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.73	-0.54	8.45e-27	Alzheimer's disease;
CRC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.74	7.56	0.38	4.17e-13	Diabetic retinopathy;
CRC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg02527881	chr3:46936655	PTH1R	0.36	6.31	0.33	9.13e-10	Colorectal cancer;
CRC	cis	rs7804356	0.953	rs3823928	chr7:26893317	T/C	cg03456212	chr7:26904342	SKAP2	-0.49	-5.63	-0.3	3.96e-8	Type 1 diabetes;
CRC	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	0.57	8.58	0.43	3.74e-16	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg19196414	chr17:27188595	MIR451;MIR144	0.38	5.69	0.3	2.8e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.33	-5.93	-0.31	7.78e-9	Rheumatoid arthritis;
CRC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.6	10.62	0.51	7.84e-23	Aortic root size;
CRC	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.74	9.88	0.48	2.56e-20	Coronary artery disease;
CRC	cis	rs10971721	0.642	rs10971736	chr9:33854374	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs2802369	1	rs2802369	chr10:80960828	C/A	cg20744163	chr10:80999841	ZMIZ1	-0.43	-7.37	-0.38	1.37e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.6	-10.8	-0.51	1.85e-23	Prudent dietary pattern;
CRC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.64	7.89	0.4	4.37e-14	Menarche (age at onset);
CRC	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg26182253	chr13:112236782	NA	0.31	6.25	0.33	1.26e-9	Hepatitis;
CRC	trans	rs12699921	0.598	rs2723505	chr7:17854849	C/T	cg15753394	chr6:17282781	RBM24	-0.36	-6.03	-0.32	4.5e-9	Fibrinogen levels;
CRC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.31	-0.33	8.94e-10	Reticulocyte fraction of red cells;
CRC	cis	rs11630290	1.000	rs72750990	chr15:64005333	C/T	cg12036633	chr15:63758958	NA	-0.56	-5.81	-0.3	1.51e-8	Iris characteristics;
CRC	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg06878361	chr19:52390810	ZNF577	0.47	5.61	0.3	4.31e-8	Breast cancer;
CRC	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.17	-0.41	6.61e-15	Metabolite levels;
CRC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.53	7.97	0.4	2.64e-14	Body mass index;
CRC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg21153622	chr11:89784906	NA	-0.42	-6.98	-0.36	1.64e-11	Height;
CRC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	7.52	0.38	5.38e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.86	9.89	0.48	2.29e-20	Psoriasis;
CRC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.54	-9.01	-0.44	1.69e-17	Brugada syndrome;
CRC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.72	11.62	0.54	2.14e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg00852783	chr1:26633632	UBXN11	0.48	5.84	0.31	1.24e-8	Obesity-related traits;
CRC	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg04202892	chr2:111875749	ACOXL	0.47	7.64	0.39	2.32e-13	Chronic lymphocytic leukemia;
CRC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.49	-9.0	-0.44	1.83e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6694672	1.000	rs1412639	chr1:197003593	G/A	cg13682187	chr1:196946512	CFHR5	0.6	8.91	0.44	3.68e-17	Asthma;
CRC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.99	0.52	3.99e-24	Motion sickness;
CRC	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg09127314	chr1:152161683	NA	0.49	6.15	0.32	2.29e-9	Atopic dermatitis;
CRC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	6.79	0.35	5.23e-11	Obesity-related traits;
CRC	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg00540400	chr15:79124168	NA	0.3	5.61	0.3	4.41e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg24375607	chr4:120327624	NA	-0.41	-6.58	-0.34	1.9e-10	Corneal astigmatism;
CRC	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.31	7.17	0.37	4.98e-12	Corneal astigmatism;
CRC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg12193833	chr17:30244370	NA	-0.73	-8.62	-0.43	2.95e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg22529645	chr1:3704559	LRRC47	0.43	5.79	0.3	1.68e-8	Red cell distribution width;
CRC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.69	10.57	0.5	1.12e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6433857	0.534	rs1157535	chr2:181361736	T/A	cg23363182	chr2:181467187	NA	-0.55	-8.03	-0.4	1.74e-14	Body mass index;
CRC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.61	7.58	0.39	3.6e-13	Dilated cardiomyopathy;
CRC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.89	-0.4	4.41e-14	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.65	10.37	0.5	5.64e-22	Corneal astigmatism;
CRC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg04362960	chr10:104952993	NT5C2	-0.5	-6.13	-0.32	2.57e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg02319466	chr17:76381040	PGS1	0.37	5.78	0.3	1.78e-8	HDL cholesterol levels;
CRC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	0.94	11.44	0.53	9.89e-26	IgG glycosylation;
CRC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.11e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs55702914	0.650	rs6715690	chr2:198148371	C/T	cg20885578	chr2:198174922	NA	-0.34	-5.96	-0.31	6.49e-9	Major depression and alcohol dependence;
CRC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg15468180	chr1:107600409	PRMT6	0.45	6.73	0.35	7.76e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs4724055	0.557	rs539401	chr7:41620806	G/A	cg21883598	chr15:45404157	DUOX2	0.48	5.96	0.31	6.55e-9	Non-substance related behavioral disinhibition;
CRC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.22	-0.32	1.51e-9	Arsenic metabolism;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23075269	chr19:18304032	MPV17L2	0.38	6.04	0.32	4.25e-9	Schizophrenia;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.03	-25.58	-0.82	3.3e-80	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17155006	0.746	rs435125	chr7:107748934	A/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.71	0.43	1.53e-16	Fuchs's corneal dystrophy;
CRC	cis	rs4234284	0.556	rs4679147	chr3:126955702	C/T	cg27326032	chr3:127006922	NA	-0.52	-7.49	-0.38	6.52e-13	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17728987	chr19:36485959	SDHAF1	0.46	6.71	0.35	8.39e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.51	7.66	0.39	2.08e-13	Coronary artery disease;
CRC	trans	rs16846053	0.681	rs62187563	chr2:162354653	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.53e-9	Blood osmolality (transformed sodium);
CRC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.34	6.78	0.35	5.64e-11	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg00814883	chr7:100076585	TSC22D4	-0.51	-6.11	-0.32	2.82e-9	Lung function (FEV1/FVC);
CRC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.78	13.93	0.61	5.21e-35	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs2814331	0.607	rs1902678	chr10:88006634	C/G	cg11798182	chr14:98444513	C14orf64	0.65	5.99	0.31	5.62e-9	Balding;
CRC	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.4	5.77	0.3	1.79e-8	Diastolic blood pressure;
CRC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.57	-8.46	-0.42	8.72e-16	Migraine;Coronary artery disease;
CRC	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-25.31	-0.81	3.19e-79	Exhaled nitric oxide output;
CRC	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	9.16	0.45	5.85e-18	Lymphocyte counts;
CRC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.91	0.36	2.58e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.45	0.33	4.09e-10	Neuroticism;
CRC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs2737618	0.674	rs2737684	chr1:200092951	C/T	cg21825944	chr1:200113062	NR5A2	-0.52	-7.5	-0.38	6.06e-13	Uric acid levels;
CRC	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg04990556	chr1:26633338	UBXN11	0.55	5.94	0.31	7.29e-9	Obesity-related traits;
CRC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.48	7.09	0.36	8.2e-12	Cognitive function;
CRC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.3	-0.33	9.38e-10	Aortic root size;
CRC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg25182066	chr10:30743637	MAP3K8	-0.41	-6.02	-0.31	4.72e-9	Inflammatory bowel disease;
CRC	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.52	7.77	0.39	1.04e-13	Menopause (age at onset);
CRC	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.34	-5.93	-0.31	7.82e-9	Pneumonia;
CRC	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.57	-0.39	3.73e-13	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg00579200	chr11:133705235	NA	-0.41	-5.96	-0.31	6.32e-9	Childhood ear infection;
CRC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.49	8.05	0.41	1.48e-14	Major depressive disorder;
CRC	trans	rs4308415	0.781	rs6857547	chr4:67808453	A/G	cg19648955	chr2:177134095	MTX2	-0.42	-6.2	-0.32	1.68e-9	Educational attainment (years of education);
CRC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.95	17.24	0.69	6.44e-48	IgG glycosylation;
CRC	trans	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg18806716	chr10:30721971	MAP3K8	0.45	6.99	0.36	1.51e-11	Inflammatory bowel disease;
CRC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.95	-0.36	2e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.89	-0.44	4.01e-17	Bipolar disorder;
CRC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.67	9.83	0.48	3.62e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-7.4	-0.38	1.16e-12	Height;
CRC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg15845792	chr6:28175446	NA	0.8	11.85	0.55	3.12e-27	Parkinson's disease;
CRC	cis	rs6662572	0.737	rs6429579	chr1:46258193	T/C	cg08644498	chr1:46502608	NA	-0.36	-5.98	-0.31	5.91e-9	Blood protein levels;
CRC	trans	rs11581859	0.950	rs72728601	chr1:99369685	C/T	cg12183875	chr3:169587454	LRRC31	0.26	6.13	0.32	2.55e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12963246	chr6:28129442	ZNF389	0.51	5.86	0.31	1.13e-8	Depression;
CRC	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.6e-15	Type 2 diabetes;
CRC	cis	rs9992667	0.955	rs12507197	chr4:38663660	T/C	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.02	-0.45	1.62e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.65	-7.81	-0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.53	8.22	0.41	4.91e-15	Diastolic blood pressure;
CRC	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-7.85	-0.4	5.73e-14	Hepatocellular carcinoma;
CRC	cis	rs3823572	0.542	rs10271889	chr7:133635846	A/G	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Intelligence (multi-trait analysis);
CRC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.43	6.31	0.33	9.27e-10	Morning vs. evening chronotype;
CRC	cis	rs5758511	0.573	rs2267438	chr22:42237565	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.37	-6.06	-0.32	3.82e-9	Birth weight;
CRC	cis	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg18131467	chr2:239335373	ASB1	-0.64	-6.76	-0.35	6.4e-11	Lung function (FEV1/FVC);
CRC	cis	rs877282	0.682	rs2265092	chr10:780293	C/T	cg17470449	chr10:769945	NA	-0.38	-6.28	-0.33	1.08e-9	Uric acid levels;
CRC	trans	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg26043149	chr18:55253948	FECH	-0.49	-7.5	-0.38	6.14e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs728616	0.681	rs36073865	chr10:81916055	C/T	cg05935833	chr10:81318306	SFTPA2	-0.49	-5.94	-0.31	7.29e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-0.48	-6.82	-0.35	4.38e-11	Blood protein levels;
CRC	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.54	8.27	0.41	3.36e-15	Diastolic blood pressure;
CRC	trans	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg10756647	chr7:56101905	PSPH	0.74	7.48	0.38	7.04e-13	Diabetic kidney disease;
CRC	trans	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg24644049	chr4:85504048	CDS1	0.87	7.11	0.36	7.24e-12	Skin colour saturation;
CRC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.76	11.12	0.52	1.31e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6662572	1.000	rs11587982	chr1:46161868	A/T	cg08644498	chr1:46502608	NA	0.45	6.56	0.34	2.15e-10	Blood protein levels;
CRC	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.93	15.32	0.65	2.37e-40	Dupuytren's disease;
CRC	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.35	-0.33	7.03e-10	Breast cancer;
CRC	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg16540259	chr10:75572220	NDST2	0.38	5.98	0.31	5.91e-9	Inflammatory bowel disease;
CRC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	9.14	0.45	6.79e-18	Platelet count;
CRC	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.76	-8.03	-0.4	1.79e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs929596	0.564	rs2741024	chr2:234517745	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.7	-0.3	2.62e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.07e-11	Common traits (Other);
CRC	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg14092571	chr14:90743983	NA	-0.46	-7.02	-0.36	1.24e-11	Longevity;
CRC	cis	rs939584	0.866	rs13387090	chr2:650974	G/T	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.46e-9	Body mass index;
CRC	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg11833968	chr6:79620685	NA	-0.35	-6.08	-0.32	3.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg25011176	chr20:3776985	CDC25B	-0.39	-5.65	-0.3	3.5e-8	Bipolar disorder;
CRC	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg09659197	chr4:152720779	NA	0.53	11.62	0.54	2.26e-26	Intelligence (multi-trait analysis);
CRC	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.43	7.24	0.37	3.27e-12	Testicular germ cell tumor;
CRC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.52	-5.67	-0.3	3.18e-8	Lung cancer (smoking interaction);
CRC	cis	rs16852403	0.502	rs6682970	chr1:178170520	A/G	cg00404053	chr1:178313656	RASAL2	0.5	6.59	0.34	1.75e-10	Childhood ear infection;
CRC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.24	-0.33	1.34e-9	Aortic root size;
CRC	trans	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg26043149	chr18:55253948	FECH	0.56	8.72	0.43	1.38e-16	Bone mineral density;
CRC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.27	0.56	9.17e-29	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg15786705	chr6:28176104	NA	0.59	6.05	0.32	3.84e-9	Depression;
CRC	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.34	6.15	0.32	2.24e-9	Neuroticism;
CRC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.61	-10.17	-0.49	2.72e-21	Body mass index;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg03790207	chr6:42947109	PEX6	-0.53	-7.76	-0.39	1.1e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg08314208	chr16:67682810	RLTPR	-0.57	-6.12	-0.32	2.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09440018	chr17:7475963	EIF4A1	0.45	6.34	0.33	7.37e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg07636037	chr3:49044803	WDR6	-0.7	-6.07	-0.32	3.56e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg25985355	chr7:65971099	NA	0.51	5.72	0.3	2.46e-8	Diabetic kidney disease;
CRC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	trans	rs800082	0.867	rs2717393	chr3:144280290	T/C	cg24215973	chr2:240111563	HDAC4	0.52	6.94	0.36	2.11e-11	Smoking behavior;
CRC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.49	-0.54	6.3e-26	Type 2 diabetes;
CRC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg08270630	chr22:50330655	NA	-0.4	-5.71	-0.3	2.47e-8	Schizophrenia;
CRC	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.73	7.92	0.4	3.76e-14	Breast cancer;
CRC	cis	rs4722166	0.598	rs4722178	chr7:22798650	T/C	cg05472934	chr7:22766657	IL6	0.64	10.52	0.5	1.65e-22	Lung cancer;
CRC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.85	-0.35	3.68e-11	Retinal vascular caliber;
CRC	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg24289452	chr6:170231220	NA	-0.6	-6.56	-0.34	2.09e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Depression;
CRC	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg18827107	chr12:86230957	RASSF9	-0.36	-5.77	-0.3	1.83e-8	Major depressive disorder;
CRC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-0.6	-11.24	-0.53	5.19e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.43	9.46	0.46	6.14e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	7.39	0.38	1.23e-12	Homocysteine levels;
CRC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.56	9.22	0.45	3.74e-18	Total body bone mineral density;
CRC	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-9.98	-0.48	1.13e-20	Colorectal cancer;
CRC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.72	10.13	0.49	3.57e-21	Coronary artery disease;
CRC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg12560992	chr17:57184187	TRIM37	-0.48	-6.42	-0.33	4.82e-10	Primary tooth development (time to first tooth eruption);
CRC	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.76	8.35	0.42	1.89e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs10924970	0.601	rs12024609	chr1:235452167	G/A	cg09010748	chr1:235293032	TOMM20	-0.4	-5.66	-0.3	3.26e-8	Asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08204369	chr17:73150733	HN1	0.51	7.27	0.37	2.56e-12	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg10729496	chr3:10149963	C3orf24	0.5	6.74	0.35	7.23e-11	Alzheimer's disease;
CRC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.85	0.55	3.12e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg24560729	chr4:1342394	KIAA1530	-0.33	-6.18	-0.32	1.84e-9	Obesity-related traits;
CRC	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.77	8.64	0.43	2.48e-16	Neuroticism;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg10354845	chr8:30013713	DCTN6	0.47	6.08	0.32	3.32e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.65	-10.31	-0.49	9.01e-22	Monocyte percentage of white cells;
CRC	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	1.01	8.32	0.42	2.41e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-9.29	-0.46	2.2e-18	Menarche (age at onset);
CRC	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.57	-6.27	-0.33	1.11e-9	Red cell distribution width;
CRC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	8.31	0.42	2.55e-15	Lung cancer in ever smokers;
CRC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.54	7.12	0.37	6.68e-12	Obesity-related traits;
CRC	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg20503657	chr10:835505	NA	0.61	8.16	0.41	6.98e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.28	-0.46	2.28e-18	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16529440	chr12:93323219	EEA1	0.36	6.0	0.31	5.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6743376	0.556	rs6748448	chr2:113819419	A/G	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs10242455	1.000	rs2301889	chr7:98931105	A/G	cg18809830	chr7:99032528	PTCD1	-0.71	-6.2	-0.32	1.67e-9	Blood metabolite levels;
CRC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.63	7.11	0.37	7.11e-12	Vitiligo;
CRC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.84	18.44	0.71	1.18e-52	Breast cancer;
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.9	13.45	0.6	3.5e-33	Longevity;
CRC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.62	8.89	0.44	4.06e-17	Schizophrenia;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg02033258	chr5:131593261	PDLIM4	0.37	6.38	0.33	6.02e-10	Breast cancer;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.46	-0.34	3.73e-10	Longevity;Endometriosis;
CRC	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.49	-7.34	-0.38	1.65e-12	Tonsillectomy;
CRC	cis	rs1124376	0.816	rs62243131	chr3:20141308	A/G	cg05072819	chr3:20081367	KAT2B	0.46	5.76	0.3	1.91e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.74	11.84	0.55	3.57e-27	Cognitive function;
CRC	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.34	7.54	0.38	4.55e-13	Total body bone mineral density;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg24253500	chr15:84953950	NA	0.37	6.18	0.32	1.92e-9	Schizophrenia;
CRC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.72	-0.35	7.94e-11	Dupuytren's disease;
CRC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.6	0.47	2.14e-19	Cognitive test performance;
CRC	cis	rs17234274	0.622	rs4598669	chr11:23236615	C/G	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg04317927	chr11:55418816	OR4S2	0.39	6.56	0.34	2.06e-10	Pediatric bone mineral density (spine);
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.46	-7.6	-0.39	3.1e-13	Acylcarnitine levels;
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.64e-9	Bipolar disorder;
CRC	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg01656853	chr19:49199172	FUT2	0.23	5.79	0.3	1.65e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs9649465	0.967	rs11765790	chr7:123293152	A/C	cg03229431	chr7:123269106	ASB15	-0.38	-5.77	-0.3	1.82e-8	Migraine;
CRC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg05540913	chr6:167530185	CCR6	-0.34	-5.85	-0.31	1.2e-8	Primary biliary cholangitis;
CRC	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.7	7.53	0.38	4.95e-13	Breast cancer;
CRC	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.87	-0.44	4.81e-17	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs4750440	0.585	rs35982189	chr10:14029875	T/C	cg00551146	chr10:14014579	FRMD4A	0.44	6.92	0.36	2.32e-11	Adiponectin levels;
CRC	cis	rs17767392	0.846	rs17767398	chr14:71770485	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-5.91	-0.31	8.35e-9	Mitral valve prolapse;
CRC	cis	rs10924970	0.967	rs2185021	chr1:235452744	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.77	0.3	1.87e-8	Asthma;
CRC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.72	0.3	2.45e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg13615338	chr4:55094005	PDGFRA	0.41	5.83	0.31	1.29e-8	Corneal astigmatism;
CRC	cis	rs11627756	0.957	rs11846451	chr14:103131723	T/C	cg12046867	chr14:103022105	NA	0.44	6.05	0.32	3.97e-9	Mean platelet volume;
CRC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg12311346	chr5:56204834	C5orf35	-0.46	-6.99	-0.36	1.52e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.5	5.9	0.31	9.16e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10439911	chr2:85766251	MAT2A	0.4	6.15	0.32	2.2e-9	Schizophrenia;
CRC	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.1	-0.32	2.9e-9	Diastolic blood pressure;
CRC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.85e-20	Corneal astigmatism;
CRC	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg18585273	chr17:66197086	NA	-0.49	-7.4	-0.38	1.11e-12	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.53	-9.1	-0.45	8.68e-18	Iron status biomarkers;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.59	0.43	3.53e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.55	-7.68	-0.39	1.88e-13	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.46	6.24	0.33	1.38e-9	Aortic root size;
CRC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.43	8.68	0.43	1.83e-16	Renal cell carcinoma;
CRC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.06	-0.74	5.05e-59	Height;
CRC	cis	rs4654899	0.931	rs4654887	chr1:21234923	A/G	cg02927042	chr1:21476669	EIF4G3	0.46	7.37	0.38	1.41e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11645453	chr3:52864694	ITIH4	0.35	6.05	0.32	3.99e-9	Bipolar disorder;
CRC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg25456477	chr12:86230367	RASSF9	0.38	6.3	0.33	9.43e-10	Major depressive disorder;
CRC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.74	12.1	0.55	3.95e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6445525	1.000	rs6445525	chr3:65993104	C/G	cg06109867	chr3:66002991	MAGI1	0.38	6.4	0.33	5.46e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs9659323	1.000	rs12073056	chr1:119508400	C/T	cg26570165	chr1:119541833	NA	-0.38	-6.48	-0.34	3.44e-10	Body mass index;
CRC	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.48	6.29	0.33	9.83e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg12792011	chr19:58661915	ZNF329	0.75	8.19	0.41	5.94e-15	Cholesterol, total;
CRC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg24253500	chr15:84953950	NA	0.38	6.44	0.33	4.32e-10	Schizophrenia;
CRC	cis	rs11212617	1.000	rs652311	chr11:108240069	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.64	0.34	1.27e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg25019722	chr6:37503610	NA	-0.41	-6.91	-0.36	2.57e-11	Cognitive performance;
CRC	cis	rs66573146	0.901	rs55659111	chr4:7012338	G/T	cg00086871	chr4:6988644	TBC1D14	0.95	5.87	0.31	1.06e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.92	-0.44	3.3e-17	Type 2 diabetes;
CRC	cis	rs2179367	0.920	rs560051	chr6:149666977	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.42	-6.51	-0.34	2.89e-10	Dupuytren's disease;
CRC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.6	-8.77	-0.44	9.96e-17	Menarche (age at onset);
CRC	cis	rs6445967	1.000	rs62259324	chr3:58291107	T/C	cg23715586	chr3:58305044	RPP14	0.35	5.84	0.31	1.24e-8	Platelet count;
CRC	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg14541582	chr5:601475	NA	-0.36	-7.3	-0.37	2.24e-12	Obesity-related traits;
CRC	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg09659197	chr4:152720779	NA	0.39	7.99	0.4	2.29e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	5.97	0.31	5.99e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs2108622	0.683	rs111388185	chr19:15977414	T/C	cg13772218	chr19:15982569	NA	0.47	6.59	0.34	1.74e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.59	8.97	0.44	2.31e-17	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg21132104	chr15:45694354	SPATA5L1	0.4	5.66	0.3	3.3e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg00531865	chr16:30841666	NA	-0.42	-6.09	-0.32	3.15e-9	Dementia with Lewy bodies;
CRC	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg04611788	chr3:186434169	KNG1	-0.6	-8.83	-0.44	6.23e-17	Blood protein levels;
CRC	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.71	-0.39	1.48e-13	Bipolar disorder;
CRC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.75	9.88	0.48	2.48e-20	Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02737830	chr12:64616354	C12orf66	0.42	5.97	0.31	6.28e-9	Response to antipsychotic treatment;
CRC	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.99	-15.33	-0.65	2.07e-40	Gout;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17289057	chr17:74473006	RHBDF2	0.39	6.29	0.33	1.02e-9	Myopia (pathological);
CRC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.38	0.46	1.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2882667	0.654	rs1095374	chr5:138095206	A/G	cg09476006	chr5:138032270	NA	-0.58	-10.46	-0.5	2.61e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6662572	1.000	rs28433203	chr1:46196813	G/T	cg08644498	chr1:46502608	NA	0.46	6.64	0.34	1.32e-10	Blood protein levels;
CRC	trans	rs6561151	1.000	rs6561151	chr13:44484706	G/A	cg17145862	chr1:211918768	LPGAT1	0.5	7.15	0.37	5.78e-12	Crohn's disease;
CRC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg13722127	chr7:150037890	RARRES2	0.39	5.65	0.3	3.43e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12292205	chr6:26970375	C6orf41	-0.5	-6.68	-0.35	1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg24308560	chr3:49941425	MST1R	-0.42	-6.08	-0.32	3.34e-9	Resting heart rate;
CRC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.44	6.29	0.33	9.93e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.4	7.34	0.37	1.74e-12	Obesity-related traits;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.67	10.71	0.51	3.79e-23	Longevity;Endometriosis;
CRC	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.62	-9.16	-0.45	5.5e-18	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.46	6.11	0.32	2.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.62	-6.97	-0.36	1.78e-11	Menarche (age at onset);
CRC	cis	rs12618769	0.652	rs4851144	chr2:99220707	T/C	cg18455616	chr2:99124870	INPP4A	0.35	5.92	0.31	8.22e-9	Bipolar disorder;
CRC	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg24289452	chr6:170231220	NA	-0.67	-6.79	-0.35	5.28e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg08075719	chr14:103021372	NA	-0.72	-9.49	-0.46	4.8e-19	Platelet count;
CRC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.58	-0.34	1.82e-10	Lung cancer;
CRC	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg18646521	chr2:111875858	NA	0.36	5.63	0.3	3.96e-8	Chronic lymphocytic leukemia;
CRC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	cis	rs4750440	0.702	rs11258774	chr10:14029701	G/A	cg00551146	chr10:14014579	FRMD4A	0.36	5.85	0.31	1.19e-8	Adiponectin levels;
CRC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.56	-0.43	4.3e-16	Aortic root size;
CRC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.48	7.48	0.38	7.02e-13	Longevity;
CRC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.85	9.29	0.46	2.12e-18	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05995172	chr11:57434667	ZDHHC5	0.46	7.19	0.37	4.51e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.05	0.45	1.25e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4733781	0.509	rs12550365	chr8:131136046	A/T	cg21674704	chr8:131455249	NA	-0.37	-6.04	-0.32	4.27e-9	Tuberculosis;
CRC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-12.34	-0.56	5.21e-29	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs995000	0.899	rs4495740	chr1:63124465	T/G	cg19896129	chr1:63156450	NA	0.39	5.61	0.3	4.35e-8	Triglyceride levels;
CRC	cis	rs12900463	0.813	rs306198	chr15:85405369	C/T	cg11189052	chr15:85197271	WDR73	-0.48	-6.64	-0.34	1.3e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg03037974	chr15:76606532	NA	0.58	9.6	0.47	2.16e-19	Blood metabolite levels;
CRC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.46	-6.61	-0.34	1.57e-10	Diastolic blood pressure;
CRC	trans	rs75246769	1.000	rs74441628	chr7:145588168	A/G	cg14916917	chr5:81574294	RPS23	0.8	5.97	0.31	6.06e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.47	-7.58	-0.39	3.48e-13	Post bronchodilator FEV1;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.83	-0.35	3.99e-11	Bipolar disorder;
CRC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg13390004	chr1:15929781	NA	0.5	6.98	0.36	1.61e-11	Systolic blood pressure;
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.78	-0.51	2.09e-23	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07083384	chr2:75836410	NA	0.41	5.99	0.31	5.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1539053	0.932	rs7544337	chr1:58108645	T/C	cg20292791	chr1:58089357	DAB1	-0.32	-5.67	-0.3	3.13e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs7712401	0.791	rs4836244	chr5:122116232	A/G	cg18764291	chr5:122110994	SNX2	0.39	6.35	0.33	7.19e-10	Mean platelet volume;
CRC	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg17133734	chr15:86042851	AKAP13	-0.4	-6.34	-0.33	7.51e-10	Coronary artery disease;
CRC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg07718321	chr6:96025334	MANEA	0.57	7.18	0.37	4.73e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.79	11.32	0.53	2.59e-25	Gout;
CRC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.82	-0.35	4.44e-11	Cutaneous nevi;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg06470822	chr6:28175283	NA	0.95	13.56	0.6	1.43e-33	Parkinson's disease;
CRC	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg17885191	chr8:135476712	NA	0.51	7.22	0.37	3.7e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.4	6.15	0.32	2.2e-9	Red blood cell count;
CRC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.39	5.95	0.31	6.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.44	6.85	0.35	3.66e-11	C-reactive protein levels;
CRC	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg01843034	chr6:37503916	NA	-0.39	-6.98	-0.36	1.68e-11	Cognitive performance;
CRC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06656553	chr16:89960601	TCF25	-0.69	-6.06	-0.32	3.75e-9	Skin colour saturation;
CRC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg16558177	chr4:4109446	NA	0.45	6.03	0.32	4.49e-9	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-11.8	-0.55	4.73e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg23071808	chr14:103021642	NA	0.56	5.98	0.31	5.91e-9	Platelet count;
CRC	cis	rs728616	0.867	rs41297151	chr10:81807167	A/T	cg05935833	chr10:81318306	SFTPA2	-0.57	-6.93	-0.36	2.27e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21490755	chr8:66754279	PDE7A	0.41	6.16	0.32	2.17e-9	Anxiety disorder;
CRC	cis	rs7121446	0.521	rs4084215	chr11:121867511	T/C	cg13820391	chr11:121835505	NA	0.33	5.97	0.31	6.2e-9	Cardiovascular risk factors (age interaction);
CRC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.47	-0.34	3.6e-10	Life satisfaction;
CRC	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	1.04	8.62	0.43	2.85e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9311676	0.656	rs4681682	chr3:58337833	A/G	cg06643156	chr3:58380774	PXK	-0.44	-6.79	-0.35	5.2e-11	Systemic lupus erythematosus;
CRC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	10.97	0.52	4.37e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.75	11.36	0.53	1.81e-25	Testicular germ cell tumor;
CRC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.38	6.12	0.32	2.61e-9	Height;
CRC	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.69	-5.97	-0.31	5.99e-9	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.88e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg10802521	chr3:52805072	NEK4	-0.47	-6.38	-0.33	5.99e-10	Schizophrenia;
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.29	-5.99	-0.31	5.59e-9	Bipolar disorder;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.4	-7.68	-0.39	1.88e-13	Mean corpuscular volume;
CRC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.81	-0.35	4.66e-11	Colorectal cancer;
CRC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg07636037	chr3:49044803	WDR6	-0.76	-5.68	-0.3	3.02e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.65	-0.34	1.24e-10	Tonsillectomy;
CRC	cis	rs7546094	1.000	rs7546094	chr1:113154400	C/T	cg22162597	chr1:113214053	CAPZA1	0.44	6.03	0.32	4.39e-9	Platelet distribution width;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08228715	chr17:79895357	PYCR1	0.39	6.11	0.32	2.85e-9	Schizophrenia;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg25164649	chr6:28176230	NA	0.59	6.14	0.32	2.33e-9	Depression;
CRC	cis	rs1519814	1.000	rs4588897	chr8:121139142	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-6.44	-0.33	4.13e-10	Breast cancer;
CRC	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.13e-17	Dupuytren's disease;
CRC	cis	rs216303	0.554	rs216320	chr12:6143356	T/C	cg19878637	chr12:6148451	VWF	-0.64	-6.96	-0.36	1.87e-11	Low vWF levels;
CRC	cis	rs7849270	0.959	rs7039031	chr9:131899395	A/G	cg13538475	chr9:131942899	NA	-0.32	-6.38	-0.33	6.13e-10	Blood metabolite ratios;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.42	-6.26	-0.33	1.17e-9	Platelet distribution width;
CRC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.76	-13.0	-0.58	1.74e-31	Breast cancer;
CRC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-11.4	-0.53	1.32e-25	Colorectal cancer;
CRC	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.47	-6.58	-0.34	1.81e-10	Coronary artery disease;
CRC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.59	8.83	0.44	6.44e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.4	-0.38	1.12e-12	Colorectal cancer;
CRC	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.47	-8.74	-0.43	1.17e-16	Hepatitis;
CRC	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.54	-9.11	-0.45	8.28e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.69	-8.86	-0.44	5.25e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs72730918	0.564	rs956171	chr15:51837138	C/T	cg14296394	chr15:51910925	DMXL2	-0.45	-5.99	-0.31	5.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.38	5.68	0.3	2.94e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03188948	chr7:1209495	NA	0.44	6.39	0.33	5.59e-10	Longevity;Endometriosis;
CRC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg01472538	chr16:58549086	SETD6	1.12	7.38	0.38	1.28e-12	Schizophrenia;
CRC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.73	-9.48	-0.46	5.09e-19	Initial pursuit acceleration;
CRC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.6	9.73	0.47	7.71e-20	Obesity-related traits;
CRC	cis	rs8014671	0.519	rs12884918	chr14:70890778	T/C	cg25576086	chr14:70833871	SYNJ2BP	-0.35	-5.88	-0.31	9.99e-9	Prostate cancer;
CRC	cis	rs11195062	0.766	rs1891375	chr10:112001009	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.36	-5.62	-0.3	4.04e-8	Multiple myeloma;
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg21268650	chr7:45961089	IGFBP3	0.38	6.52	0.34	2.64e-10	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02855924	chr3:50402563	CACNA2D2	0.43	6.02	0.31	4.54e-9	Response to antipsychotic treatment;
CRC	cis	rs12913538	0.862	rs7162434	chr15:62888070	A/G	cg09983546	chr15:62884068	NA	0.54	8.62	0.43	2.82e-16	Sleep depth;
CRC	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg00071950	chr4:10020882	SLC2A9	0.41	6.54	0.34	2.39e-10	Cardiovascular disease risk factors;
CRC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.54	8.31	0.42	2.48e-15	Aortic root size;
CRC	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.37	5.62	0.3	4.05e-8	Rheumatoid arthritis;
CRC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg15145296	chr3:125709740	NA	-0.57	-6.75	-0.35	6.67e-11	Blood pressure (smoking interaction);
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg02319466	chr17:76381040	PGS1	0.37	5.87	0.31	1.06e-8	HDL cholesterol levels;
CRC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.61	8.97	0.44	2.38e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.86	15.39	0.65	1.18e-40	Blood protein levels;
CRC	trans	rs73162807	0.655	rs114655191	chr3:146439760	G/A	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg10494257	chr1:16342123	HSPB7	0.45	5.95	0.31	6.71e-9	Dilated cardiomyopathy;
CRC	cis	rs2108622	0.727	rs12609468	chr19:15977814	A/G	cg13772218	chr19:15982569	NA	0.48	6.66	0.34	1.18e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.79	-11.74	-0.54	8.11e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs644148	0.679	rs2204119	chr19:44970975	T/C	cg15540054	chr19:45004280	ZNF180	-0.55	-7.01	-0.36	1.33e-11	Personality dimensions;
CRC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg15147215	chr3:52552868	STAB1	-0.43	-6.05	-0.32	3.92e-9	Schizophrenia;
CRC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.55	-0.38	4.23e-13	Headache;
CRC	cis	rs3018066	0.831	rs7668276	chr4:107156365	C/G	cg01869342	chr4:106983673	TBCK	-0.36	-5.67	-0.3	3.05e-8	Cancer;
CRC	cis	rs2077654	0.556	rs4148624	chr11:17444024	A/G	cg25308976	chr11:17434268	ABCC8	0.52	5.96	0.31	6.61e-9	Gout;
CRC	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.38	6.06	0.32	3.79e-9	Reticulocyte fraction of red cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11617147	chr7:105517689	ATXN7L1	0.4	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg10790698	chr19:18539756	SSBP4	-0.4	-7.27	-0.37	2.56e-12	Breast cancer;
CRC	trans	rs3932549	1	rs3932549	chr9:97073588	A/C	cg05679027	chr9:99775184	HIATL2	0.4	6.07	0.32	3.5e-9	Body mass index;
CRC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.54	-8.82	-0.44	7.06e-17	Coronary artery disease;
CRC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.71	0.39	1.49e-13	Colorectal cancer;
CRC	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg08761264	chr16:28874980	SH2B1	-0.42	-5.66	-0.3	3.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.4	-5.93	-0.31	7.5e-9	Monocyte percentage of white cells;
CRC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.77	10.16	0.49	2.76e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05947596	chr6:99969103	NA	0.46	6.63	0.34	1.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs2890487	chr2:15594938	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.14e-9	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15039414	chr2:43454687	ZFP36L2;LOC100129726	0.38	6.12	0.32	2.6e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg07217954	chr7:1067459	C7orf50	0.55	5.71	0.3	2.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21159241	chr7:39662930	RALA	0.44	6.06	0.32	3.73e-9	Anxiety disorder;
CRC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.04	13.22	0.59	2.71e-32	Vitiligo;
CRC	cis	rs55702914	1.000	rs55702914	chr2:198214396	C/G	cg10820045	chr2:198174542	NA	0.34	6.08	0.32	3.36e-9	Major depression and alcohol dependence;
CRC	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.61	-9.28	-0.46	2.26e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs12580194	0.598	rs12582005	chr12:55772837	A/T	cg23425280	chr12:56401806	NA	0.48	5.88	0.31	1.03e-8	Cancer;
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.75	-0.35	6.69e-11	Total body bone mineral density;
CRC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg08314208	chr16:67682810	RLTPR	-0.54	-5.9	-0.31	8.84e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.88	-14.03	-0.61	2.32e-35	Blood metabolite levels;
CRC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.67	10.31	0.49	8.87e-22	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17956079	chr11:73358572	PLEKHB1	0.5	7.66	0.39	2.08e-13	Response to antipsychotic treatment;
CRC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.26	-15.13	-0.64	1.25e-39	Gout;
CRC	cis	rs4731207	0.565	rs1552118	chr7:124628858	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.55	8.58	0.43	3.76e-16	Aortic root size;
CRC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.51	-7.77	-0.39	9.97e-14	Systemic sclerosis;
CRC	cis	rs9296095	0.519	rs6918046	chr6:33514567	T/A	cg14003231	chr6:33640908	ITPR3	0.37	5.65	0.3	3.4e-8	Platelet count;
CRC	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.34	6.19	0.32	1.83e-9	Neuroticism;
CRC	trans	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg02741985	chr17:80059408	CCDC57	-0.41	-6.66	-0.34	1.12e-10	Life satisfaction;
CRC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.75	6.79	0.35	5.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.6	-9.4	-0.46	9.21e-19	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14969671	chr10:131934538	GLRX3	0.39	6.5	0.34	3e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg06470822	chr6:28175283	NA	0.81	12.09	0.55	4.31e-28	Cardiac Troponin-T levels;
CRC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.65	10.41	0.5	4.11e-22	Colorectal cancer;
CRC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.52	0.34	2.59e-10	Melanoma;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15067376	chr9:139257843	DNLZ	-0.52	-6.08	-0.32	3.4e-9	Monocyte percentage of white cells;
CRC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg10820045	chr2:198174542	NA	0.46	8.26	0.41	3.67e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.57	-10.07	-0.49	5.72e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg00601450	chr5:74908170	NA	0.42	5.99	0.31	5.6e-9	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CRC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-7.26	-0.37	2.84e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.25	-0.41	3.97e-15	Mean corpuscular volume;
CRC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg16102536	chr7:156981717	UBE3C	-0.4	-6.79	-0.35	5.41e-11	Body mass index;
CRC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.71	-8.49	-0.42	6.98e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03923535	chr7:1197113	ZFAND2A	0.73	11.15	0.52	1.04e-24	Longevity;Endometriosis;
CRC	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.62	7.72	0.39	1.39e-13	Post bronchodilator FEV1;
CRC	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.47	-6.05	-0.32	3.87e-9	Alopecia areata;
CRC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg13798780	chr7:105162888	PUS7	0.67	7.94	0.4	3.29e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.65	9.85	0.48	3.04e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.59	7.86	0.4	5.39e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	0.65	7.25	0.37	3.03e-12	Prostate cancer;
CRC	cis	rs7849270	1.000	rs10819469	chr9:131882067	G/T	cg13538475	chr9:131942899	NA	-0.31	-6.07	-0.32	3.48e-9	Blood metabolite ratios;
CRC	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg09127314	chr1:152161683	NA	-0.45	-5.86	-0.31	1.14e-8	Atopic dermatitis;
CRC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.96e-9	Schizophrenia;
CRC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.46	6.62	0.34	1.49e-10	Emphysema distribution in smoking;
CRC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.94	-17.74	-0.7	6.97e-50	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62187613	chr2:162434474	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.01	-0.31	4.88e-9	Cognitive function;
CRC	cis	rs7731657	0.537	rs112876284	chr5:130293884	G/C	cg08523029	chr5:130500466	HINT1	-0.49	-6.19	-0.32	1.83e-9	Fasting plasma glucose;
CRC	cis	rs10499694	0.697	rs3779074	chr7:50612202	A/G	cg14593290	chr7:50529359	DDC	-0.47	-6.59	-0.34	1.73e-10	Body mass index;
CRC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg00310523	chr12:86230176	RASSF9	0.43	7.32	0.37	1.93e-12	Major depressive disorder;
CRC	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.57	7.45	0.38	8.11e-13	Response to hepatitis C treatment;
CRC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg16447950	chr5:562315	NA	-0.83	-11.29	-0.53	3.41e-25	Lung disease severity in cystic fibrosis;
CRC	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs11191205	0.644	rs10883665	chr10:103374233	G/A	cg15320455	chr10:103880129	LDB1	0.58	6.4	0.33	5.47e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.73	-0.39	1.33e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.56	7.74	0.39	1.22e-13	Lewy body disease;
CRC	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-6.81	-0.35	4.67e-11	Coronary artery disease;
CRC	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.57	-8.03	-0.4	1.71e-14	Diisocyanate-induced asthma;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.36	0.38	1.44e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.71	10.45	0.5	2.87e-22	Gestational age at birth (maternal effect);
CRC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg05072774	chr3:49840536	C3orf54	-0.43	-5.74	-0.3	2.15e-8	Resting heart rate;
CRC	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.37	6.91	0.36	2.48e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.67	7.86	0.4	5.71e-14	Body mass index;
CRC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	7.87	0.4	5.28e-14	Menarche (age at onset);
CRC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg02158880	chr13:53174818	NA	0.55	8.69	0.43	1.73e-16	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22050555	chr5:171615449	STK10	0.36	6.26	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16725723	chr3:68925535	FAM19A4	-0.37	-6.01	-0.31	4.79e-9	Aortic root size;
CRC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.55	0.47	3.06e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.52	-8.14	-0.41	8.01e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.71	12.23	0.56	1.33e-28	Height;
CRC	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.84	0.35	3.85e-11	Mean corpuscular volume;
CRC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.45	7.54	0.38	4.47e-13	Alcohol dependence;
CRC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.76	7.66	0.39	2.03e-13	Parkinson's disease;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-9.84	-0.48	3.39e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg25251562	chr2:3704773	ALLC	-0.49	-6.12	-0.32	2.62e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs501120	1.000	rs522293	chr10:44756703	G/A	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs6546324	0.625	rs2861698	chr2:67854808	A/G	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.21	-0.32	1.6e-9	Endometriosis;
CRC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.34	0.33	7.68e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.37	5.94	0.31	7.45e-9	IgG glycosylation;
CRC	trans	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg18335740	chr13:41363409	SLC25A15	0.53	8.03	0.4	1.73e-14	Lewy body disease;
CRC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg15147215	chr3:52552868	STAB1	0.51	8.9	0.44	3.79e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.65	8.78	0.44	9.01e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.6	-9.29	-0.46	2.22e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.61	-11.28	-0.53	3.72e-25	Educational attainment;
CRC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.71	-10.73	-0.51	3.17e-23	Acne (severe);
CRC	trans	rs3793427	0.877	rs3213600	chr8:17074640	C/G	cg09855739	chr12:58027032	B4GALNT1	-0.41	-6.14	-0.32	2.36e-9	Tonometry;
CRC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.42	7.41	0.38	1.11e-12	Age at first birth;
CRC	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg04110750	chr16:69646130	NFAT5	-0.52	-6.99	-0.36	1.58e-11	IgE levels;
CRC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13198984	chr17:80129470	CCDC57	-0.46	-7.98	-0.4	2.39e-14	Life satisfaction;
CRC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg23018236	chr17:30244563	NA	-0.43	-5.69	-0.3	2.83e-8	Hip circumference adjusted for BMI;
CRC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs365302	1.000	rs475074	chr6:159648058	G/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.48	7.42	0.38	9.78e-13	Longevity;
CRC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.31	12.52	0.57	1.13e-29	Cognitive function;
CRC	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.4	-6.67	-0.35	1.06e-10	Resting heart rate;
CRC	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.44	-6.31	-0.33	8.81e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.56	8.88	0.44	4.36e-17	Mean corpuscular volume;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.73	-11.46	-0.53	8.21e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.47	7.72	0.39	1.42e-13	Major depressive disorder;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.5	6.85	0.35	3.56e-11	Height;
CRC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.34	-0.33	7.49e-10	Tonsillectomy;
CRC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg18099408	chr3:52552593	STAB1	0.33	5.63	0.3	3.95e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.1	27.58	0.84	1.48e-87	Testicular germ cell tumor;
CRC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.27	-0.37	2.68e-12	Chronic sinus infection;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.89	-19.92	-0.74	1.75e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.61	8.89	0.44	4.24e-17	Lymphocyte counts;
CRC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg22535103	chr8:58192502	C8orf71	-0.44	-5.8	-0.3	1.55e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01600621	chr19:42681426	NA	0.37	6.05	0.32	3.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg01475377	chr6:109611718	NA	-0.34	-5.84	-0.31	1.24e-8	Reticulocyte fraction of red cells;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg12172441	chr6:28176163	NA	0.53	7.27	0.37	2.63e-12	Parkinson's disease;
CRC	cis	rs9322817	0.691	rs17680345	chr6:105337409	A/T	cg02098413	chr6:105308735	HACE1	0.46	9.22	0.45	3.78e-18	Thyroid stimulating hormone;
CRC	cis	rs4731207	0.596	rs922712	chr7:124607050	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg11900509	chr10:81946545	ANXA11	-0.68	-6.79	-0.35	5.37e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.55	8.52	0.43	5.93e-16	N-glycan levels;
CRC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.9	9.0	0.44	1.88e-17	Breast cancer;
CRC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.65	11.35	0.53	1.97e-25	Prostate cancer;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg19385725	chr18:21166173	NPC1	0.53	6.14	0.32	2.43e-9	Body mass index;
CRC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg16797656	chr11:68205561	LRP5	0.38	6.07	0.32	3.52e-9	Total body bone mineral density;
CRC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.4	6.25	0.33	1.31e-9	Obesity;
CRC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.56	8.18	0.41	6.17e-15	Response to temozolomide;
CRC	cis	rs863345	0.604	rs11264997	chr1:158485482	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.24	-0.33	1.32e-9	Pneumococcal bacteremia;
CRC	cis	rs11203032	0.831	rs4399251	chr10:90943634	A/C	cg16672925	chr10:90967113	CH25H	0.44	5.67	0.3	3.13e-8	Heart failure;
CRC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg23815491	chr16:72088622	HP	0.51	7.78	0.39	9.45e-14	Fibrinogen levels;
CRC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg15168958	chr13:99100528	FARP1	0.4	6.39	0.33	5.65e-10	Educational attainment (years of education);
CRC	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg12458913	chr13:53173898	NA	0.46	6.77	0.35	5.99e-11	Lewy body disease;
CRC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.54	0.47	3.46e-19	Platelet count;
CRC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.73	-11.69	-0.54	1.22e-26	Height;
CRC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.57	-8.35	-0.42	1.92e-15	IgG glycosylation;
CRC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	13.37	0.59	7.59e-33	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02921350	chr14:69260300	ZFP36L1	0.39	6.77	0.35	5.85e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.43	6.28	0.33	1.07e-9	Mean platelet volume;
CRC	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg02158880	chr13:53174818	NA	0.47	6.82	0.35	4.38e-11	Lewy body disease;
CRC	cis	rs4711336	1.000	rs2296738	chr6:33656850	C/T	cg14003231	chr6:33640908	ITPR3	0.53	8.33	0.42	2.26e-15	Height;
CRC	cis	rs6604026	0.656	rs34389767	chr1:93373780	T/G	cg17283838	chr1:93427260	FAM69A	0.43	5.79	0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.88	-0.4	4.86e-14	Gut microbiome composition (summer);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02062003	chr11:117187060	BACE1	-0.43	-6.47	-0.34	3.52e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg00383909	chr3:49044727	WDR6	1.03	9.52	0.46	3.94e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.55	-7.76	-0.39	1.11e-13	Lymphocyte percentage of white cells;
CRC	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.28	0.46	2.4e-18	Blood protein levels;
CRC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.54	8.16	0.41	7.11e-15	Morning vs. evening chronotype;
CRC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-6.1	-0.32	3.03e-9	Alzheimer's disease (late onset);
CRC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.39	6.66	0.34	1.15e-10	Major depressive disorder;
CRC	cis	rs6793245	0.845	rs4073797	chr3:38590850	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-8.26	-0.41	3.53e-15	QT interval;
CRC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg14003231	chr6:33640908	ITPR3	0.5	8.15	0.41	7.53e-15	Plateletcrit;
CRC	cis	rs10924970	0.967	rs10925192	chr1:235400826	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.66	0.3	3.27e-8	Electroencephalogram traits;
CRC	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.57	10.25	0.49	1.36e-21	Blood metabolite ratios;
CRC	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg24045832	chr17:1955481	NA	0.39	6.29	0.33	1.02e-9	Total body bone mineral density;
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.51	7.76	0.39	1.08e-13	Bipolar disorder;
CRC	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	7.32	0.37	1.94e-12	Obesity-related traits;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg15845792	chr6:28175446	NA	0.5	5.83	0.31	1.32e-8	Breast cancer;
CRC	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	cg25843174	chr11:12811716	TEAD1	0.45	8.4	0.42	1.35e-15	Educational attainment (years of education);
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg04110750	chr16:69646130	NFAT5	-0.54	-7.21	-0.37	3.78e-12	IgE levels;
CRC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.45	-0.33	4.06e-10	Platelet distribution width;
CRC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.91	0.66	1.13e-42	Chronic sinus infection;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.7	0.54	1.1e-26	Prudent dietary pattern;
CRC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.84	15.82	0.66	2.67e-42	Dental caries;
CRC	cis	rs1887596	0.705	rs498498	chr13:27221206	G/A	cg01312412	chr13:27282625	NA	0.43	5.83	0.31	1.32e-8	Facial morphology (factor 3, length of philtrum);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08052428	chr9:135996421	RALGDS	-0.51	-6.32	-0.33	8.69e-10	Diisocyanate-induced asthma;
CRC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-7.24	-0.37	3.1e-12	Self-reported allergy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14538439	chr10:90750381	FAS;ACTA2	0.38	6.29	0.33	1.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	15.91	0.66	1.15e-42	Mean corpuscular hemoglobin;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10721359	chr6:26538456	HMGN4	0.48	6.75	0.35	6.82e-11	Response to antipsychotic treatment;
CRC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.38	-6.35	-0.33	6.97e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.14	-0.37	6.11e-12	Joint mobility (Beighton score);
CRC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.43	6.96	0.36	1.89e-11	Obesity-related traits;
CRC	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	0.95	12.54	0.57	9.76e-30	IgG glycosylation;
CRC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg25344623	chr2:136566232	LCT	0.32	5.93	0.31	7.48e-9	Mosquito bite size;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg16606324	chr3:10149918	C3orf24	0.62	7.91	0.4	3.93e-14	Alzheimer's disease;
CRC	trans	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.5	-6.05	-0.32	4.04e-9	Obesity-related traits;
CRC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.65	-11.22	-0.53	5.83e-25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.53	7.88	0.4	4.86e-14	Lymphocyte counts;
CRC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg18758796	chr5:131593413	PDLIM4	-0.33	-5.79	-0.3	1.63e-8	Blood metabolite levels;
CRC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-9.27	-0.46	2.49e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg05527609	chr1:210001259	C1orf107	0.54	6.19	0.32	1.8e-9	Red blood cell count;
CRC	cis	rs883565	0.606	rs883349	chr3:39067925	T/C	cg01426195	chr3:39028469	NA	-0.47	-7.85	-0.4	5.9e-14	Handedness;
CRC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.81	-8.98	-0.44	2.13e-17	Tuberculosis;
CRC	cis	rs9659323	0.745	rs10923723	chr1:119544002	G/A	cg26570165	chr1:119541833	NA	-0.43	-7.15	-0.37	5.81e-12	Body mass index;
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.49	-9.24	-0.45	3.1e-18	Intelligence (multi-trait analysis);
CRC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg16892393	chr17:41919603	NA	0.47	7.24	0.37	3.23e-12	Triglycerides;
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.42	-7.85	-0.4	5.76e-14	Colorectal or endometrial cancer;
CRC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	9.45	0.46	6.46e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.47	0.38	7.32e-13	Endometrial cancer;
CRC	cis	rs2062225	1.000	rs11679341	chr2:111758579	T/C	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-8.3	-0.42	2.69e-15	HDL cholesterol;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg24634471	chr8:143751801	JRK	-0.43	-6.06	-0.32	3.64e-9	Urinary tract infection frequency;
CRC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.55	9.4	0.46	9.53e-19	Iron status biomarkers;
CRC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.06	10.59	0.5	9.22e-23	Diabetic retinopathy;
CRC	trans	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg20935933	chr6:143382018	AIG1	0.49	6.46	0.34	3.8e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16447950	chr5:562315	NA	-0.73	-9.65	-0.47	1.41e-19	Obesity-related traits;
CRC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.43	6.78	0.35	5.55e-11	Testicular germ cell tumor;
CRC	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.45	-7.44	-0.38	8.86e-13	Weight;
CRC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.31	12.52	0.57	1.13e-29	Cognitive function;
CRC	cis	rs4654899	0.931	rs12723255	chr1:21233570	C/T	cg02927042	chr1:21476669	EIF4G3	0.43	6.84	0.35	3.77e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.42	9.27	0.46	2.47e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.91	-0.4	3.86e-14	Gut microbiome composition (summer);
CRC	cis	rs501916	0.634	rs531596	chr15:48058214	C/T	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.78	-0.35	5.74e-11	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg05569086	chr8:143859399	LYNX1	0.38	6.61	0.34	1.58e-10	Urinary tract infection frequency;
CRC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.58	-9.34	-0.46	1.48e-18	Intelligence (multi-trait analysis);
CRC	cis	rs10208940	0.920	rs35859673	chr2:68735718	G/A	cg12452813	chr2:68675892	NA	0.47	5.81	0.31	1.44e-8	Urate levels in lean individuals;
CRC	cis	rs12295403	1.000	rs12789252	chr11:18690389	C/T	cg07538406	chr11:18686895	NA	-0.41	-6.15	-0.32	2.22e-9	Ovarian reserve;
CRC	cis	rs4073416	0.542	rs2898814	chr14:66023961	T/C	cg03016385	chr14:66212404	NA	-0.44	-6.12	-0.32	2.62e-9	N-glycan levels;
CRC	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg00250761	chr1:31883323	NA	-0.39	-7.34	-0.38	1.65e-12	Alcohol dependence;
CRC	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg25547332	chr5:131281432	NA	0.4	5.61	0.3	4.28e-8	Life satisfaction;
CRC	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.52	-7.75	-0.39	1.15e-13	Systemic sclerosis;
CRC	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg02702477	chr5:179499311	RNF130	0.69	7.58	0.39	3.54e-13	LDL cholesterol;
CRC	cis	rs2811415	0.597	rs11706281	chr3:127803922	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.9	-0.31	9.25e-9	Lung function (FEV1/FVC);
CRC	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.34	7.81	0.4	7.59e-14	Corneal astigmatism;
CRC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.62	9.83	0.48	3.65e-20	Height;
CRC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.35	6.22	0.32	1.51e-9	Crohn's disease;
CRC	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.83	-10.59	-0.5	9.91e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7932354	0.528	rs11039097	chr11:47131881	C/T	cg19486271	chr11:47235900	DDB2	-0.47	-6.85	-0.35	3.69e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg02896835	chr1:92012615	NA	0.52	6.26	0.33	1.2e-9	Eosinophil percentage of white cells;
CRC	cis	rs4903604	0.581	rs4903606	chr14:78036935	A/G	cg18872420	chr14:78023429	SPTLC2	0.35	6.03	0.32	4.42e-9	Gut microbiome composition (winter);
CRC	cis	rs62229266	0.652	rs7280551	chr21:37409609	T/A	cg12218747	chr21:37451666	NA	-0.36	-6.2	-0.32	1.71e-9	Mitral valve prolapse;
CRC	cis	rs6840360	0.642	rs2709825	chr4:152365563	C/A	cg09659197	chr4:152720779	NA	0.34	6.7	0.35	8.91e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.35	0.42	1.89e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg07701084	chr6:150067640	NUP43	0.47	5.78	0.3	1.69e-8	Lung cancer;
CRC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.7	0.54	1.15e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.58	-0.34	1.83e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20691617	chr2:85142974	NA	0.45	6.91	0.36	2.59e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.62	0.34	1.47e-10	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg20933634	chr6:27740509	NA	-0.56	-8.26	-0.41	3.58e-15	Parkinson's disease;
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.05	-0.41	1.48e-14	Bipolar disorder;
CRC	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg26182253	chr13:112236782	NA	0.31	6.39	0.33	5.57e-10	Hepatitis;
CRC	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.71	0.35	8.34e-11	Mean corpuscular volume;
CRC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.35	6.14	0.32	2.35e-9	Erythrocyte sedimentation rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20930618	chr1:151162157	VPS72	0.45	6.7	0.35	8.88e-11	Response to antipsychotic treatment;
CRC	cis	rs9463078	0.715	rs9463076	chr6:45171362	C/T	cg25276700	chr6:44698697	NA	0.24	5.91	0.31	8.62e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.82	-0.4	7.31e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg04362960	chr10:104952993	NT5C2	0.48	7.06	0.36	9.76e-12	Waist circumference;Hip circumference;
CRC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg00129232	chr17:37814104	STARD3	-0.47	-7.61	-0.39	2.93e-13	Self-reported allergy;
CRC	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.4	-0.33	5.45e-10	Diastolic blood pressure;
CRC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.2	0.32	1.67e-9	Lung cancer;
CRC	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg23920097	chr1:209922102	NA	0.51	6.53	0.34	2.51e-10	Red blood cell count;
CRC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.65	-12.09	-0.55	4.37e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.0	0.31	5.18e-9	Prudent dietary pattern;
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg16606324	chr3:10149918	C3orf24	0.59	7.21	0.37	3.78e-12	Alzheimer's disease;
CRC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.35	5.87	0.31	1.06e-8	Mean platelet volume;Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24423424	chr22:36718563	MYH9	-0.36	-6.13	-0.32	2.5e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg24655899	chr17:79519568	C17orf70	-0.7	-5.98	-0.31	5.92e-9	Cognitive function;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg18833306	chr6:118973337	C6orf204	0.44	5.86	0.31	1.14e-8	Diastolic blood pressure;
CRC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-10.22	-0.49	1.73e-21	Colorectal cancer;
CRC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg22535103	chr8:58192502	C8orf71	-0.52	-6.32	-0.33	8.67e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs294883	0.865	rs426497	chr6:159698455	G/A	cg14500486	chr6:159655392	FNDC1	-0.36	-5.82	-0.31	1.4e-8	Coronary artery disease;
CRC	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	8.61	0.43	3.13e-16	Eotaxin levels;
CRC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.62	0.39	2.66e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	ch.11.42038R	chr11:967971	AP2A2	0.57	9.04	0.45	1.37e-17	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16664859	chr1:226309452	NA	0.39	6.06	0.32	3.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg23609528	chr2:113191194	RGPD5;RGPD8	0.66	5.67	0.3	3.18e-8	Yeast infection;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.4	-5.69	-0.3	2.83e-8	Intelligence (multi-trait analysis);
CRC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-0.63	-5.62	-0.3	3.98e-8	Lung cancer;
CRC	cis	rs863345	0.604	rs10908658	chr1:158465256	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	9.9e-10	Pneumococcal bacteremia;
CRC	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-9.04	-0.45	1.37e-17	Blood protein levels;
CRC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	cis	rs55675132	0.510	rs12136319	chr1:115298525	T/C	cg12756093	chr1:115239321	AMPD1	0.52	6.24	0.33	1.34e-9	Schizophrenia;
CRC	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.34	-8.12	-0.41	9.28e-15	Diastolic blood pressure;
CRC	cis	rs7538876	0.935	rs4920607	chr1:17760098	A/G	cg07965774	chr1:17746286	RCC2	0.35	6.31	0.33	8.95e-10	Basal cell carcinoma;
CRC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.53	10.92	0.52	6.76e-24	Alcohol dependence;
CRC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.07	10.71	0.51	3.56e-23	Diabetic retinopathy;
CRC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.29	-6.37	-0.33	6.33e-10	Diastolic blood pressure;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.1	-0.32	2.91e-9	Obesity-related traits;
CRC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00207794	chr3:24161207	THRB	0.38	6.06	0.32	3.73e-9	Interleukin-6 levels;
CRC	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg06092702	chr1:163392909	NA	-0.54	-8.53	-0.43	5.46e-16	Motion sickness;
CRC	cis	rs12745968	0.589	rs10874710	chr1:93017763	A/G	cg17283838	chr1:93427260	FAM69A	-0.48	-6.36	-0.33	6.91e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13591723	chr12:46765135	SLC38A2	0.45	6.34	0.33	7.48e-10	Response to antipsychotic treatment;
CRC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.27	-0.33	1.15e-9	Gout;Renal underexcretion gout;
CRC	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.37	-7.03	-0.36	1.23e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.79e-13	Motion sickness;
CRC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.45	-8.37	-0.42	1.65e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.83	-13.72	-0.6	3.57e-34	Hypospadias;
CRC	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg17133734	chr15:86042851	AKAP13	0.42	6.66	0.34	1.17e-10	Coronary artery disease;
CRC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.24	-0.33	1.37e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.99	-0.36	1.5e-11	Monocyte count;
CRC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.68	11.12	0.52	1.36e-24	Colorectal cancer;
CRC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.85	15.74	0.66	5.45e-42	Menopause (age at onset);
CRC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg23625390	chr15:77176239	SCAPER	0.39	5.72	0.3	2.34e-8	Blood metabolite levels;
CRC	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-7.42	-0.38	1.03e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg26043149	chr18:55253948	FECH	-0.54	-7.56	-0.38	4.16e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7690467	0.757	rs55661838	chr4:133404548	C/A	cg19296258	chr17:78878799	RPTOR	-0.47	-6.34	-0.33	7.41e-10	Eating disorders;
CRC	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.63	10.01	0.48	9.3e-21	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.87	0.4	5.16e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.63	9.04	0.45	1.35e-17	Birth weight;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg25008156	chr6:170893875	PDCD2	0.56	6.02	0.31	4.72e-9	Body mass index;
CRC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg02683197	chr6:28174875	NA	0.61	8.37	0.42	1.68e-15	Parkinson's disease;
CRC	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.39	-7.01	-0.36	1.32e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.7	-0.35	9.1e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg22689833	chr10:102415991	NA	0.35	6.83	0.35	4.24e-11	Body mass index;
CRC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.76	-0.39	1.08e-13	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.98	12.41	0.56	2.86e-29	Eosinophil percentage of granulocytes;
CRC	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.42	6.89	0.36	2.89e-11	Menopause (age at onset);
CRC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.83	-14.64	-0.63	1.03e-37	Coronary artery disease;
CRC	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg15147215	chr3:52552868	STAB1	0.46	7.67	0.39	2.02e-13	Body mass index;
CRC	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.46	5.68	0.3	2.95e-8	Metabolite levels;
CRC	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-0.88	-6.61	-0.34	1.51e-10	Fat distribution (HIV);
CRC	cis	rs2084637	1.000	rs11218651	chr11:122384336	A/C	cg21585512	chr11:122030076	LOC399959	0.36	6.45	0.33	4.05e-10	Stroke;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.47	-6.75	-0.35	6.89e-11	Longevity;Endometriosis;
CRC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.03	-0.52	2.84e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	7.99e-9	Prudent dietary pattern;
CRC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-9.22	-0.45	3.73e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.69	-9.34	-0.46	1.49e-18	Platelet count;
CRC	cis	rs73206853	0.534	rs13313211	chr12:110509616	A/T	cg12870014	chr12:110450643	ANKRD13A	0.86	8.88	0.44	4.53e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs698833	0.886	rs698766	chr2:44574277	C/G	cg04920474	chr2:44395004	PPM1B	0.42	6.3	0.33	9.57e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.47	0.42	8.36e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg27523141	chr10:43048294	ZNF37B	0.44	6.35	0.33	7.32e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.78	-14.8	-0.63	2.51e-38	Prostate cancer;
CRC	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-6.27	-0.33	1.12e-9	D-dimer levels;
CRC	cis	rs7781557	1.000	rs7781557	chr7:102481891	A/G	cg18108683	chr7:102477205	FBXL13	0.55	6.9	0.36	2.68e-11	Colorectal adenoma (advanced);
CRC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.29	0.67	3.54e-44	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.55	7.79	0.39	8.97e-14	Melanoma;
CRC	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg09659197	chr4:152720779	NA	0.53	11.67	0.54	1.49e-26	Intelligence (multi-trait analysis);
CRC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg15962314	chr1:44399869	ARTN	0.3	5.85	0.31	1.18e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg23262073	chr20:60523788	NA	-0.49	-7.69	-0.39	1.73e-13	Body mass index;
CRC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.07	0.45	1.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.26	-0.37	2.74e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.36	5.62	0.3	4.05e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.86	16.78	0.68	4.17e-46	White blood cell count;
CRC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.74	-0.43	1.24e-16	Schizophrenia;
CRC	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg11578532	chr1:161008127	TSTD1	0.28	5.76	0.3	1.94e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg23758597	chr6:163146217	PARK2	-0.6	-6.71	-0.35	8.55e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg02683197	chr6:28174875	NA	0.79	9.73	0.47	8.12e-20	Depression;
CRC	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg14847009	chr1:175162515	KIAA0040	0.27	5.86	0.31	1.11e-8	Alcohol dependence;
CRC	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg07979401	chr6:33739406	LEMD2	-0.46	-5.98	-0.31	5.7e-9	Schizophrenia;
CRC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg16892393	chr17:41919603	NA	-0.36	-5.72	-0.3	2.37e-8	Triglycerides;
CRC	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.7	9.61	0.47	1.95e-19	Breast cancer;
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00166722	chr3:10149974	C3orf24	0.65	7.67	0.39	1.91e-13	Alzheimer's disease;
CRC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg21770322	chr7:97807741	LMTK2	0.59	9.85	0.48	3.14e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg24585782	chr17:78113791	EIF4A3	-0.53	-7.38	-0.38	1.3e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.26	-0.37	2.78e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12983728	0.536	rs34380569	chr19:58648528	A/G	cg06882758	chr19:58662330	ZNF329	0.47	5.62	0.3	4.04e-8	Cholesterol, total;
CRC	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg10437265	chr15:77819839	NA	0.59	9.99	0.48	1.03e-20	Type 2 diabetes;
CRC	cis	rs720844	0.507	rs4972377	chr2:149335154	T/C	cg09247360	chr2:149335327	NA	0.48	6.28	0.33	1.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg19622623	chr12:86230825	RASSF9	-0.42	-6.76	-0.35	6.29e-11	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.78	-12.94	-0.58	2.94e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.42	-20.09	-0.74	3.82e-59	Hip circumference adjusted for BMI;
CRC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.44	6.57	0.34	2.03e-10	Calcium levels;
CRC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.76	10.6	0.5	8.9e-23	Heart rate;
CRC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.39	5.7	0.3	2.73e-8	Aortic root size;
CRC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg27661571	chr11:113659931	NA	-0.52	-6.25	-0.33	1.25e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.68e-17	Bipolar disorder;
CRC	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.52	-8.41	-0.42	1.3e-15	Mean platelet volume;Platelet distribution width;
CRC	trans	rs7604735	0.824	rs1830318	chr2:145819803	C/T	cg26010734	chr19:15344046	EPHX3	0.36	6.2	0.32	1.73e-9	Coronary artery disease;
CRC	cis	rs6772849	0.930	rs12630379	chr3:128370204	G/C	cg08795948	chr3:128337044	NA	0.35	6.2	0.32	1.73e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.69	-8.22	-0.41	4.62e-15	LDL cholesterol;Cholesterol, total;
CRC	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg22482690	chr17:47019901	SNF8	0.43	6.98	0.36	1.67e-11	Type 2 diabetes;
CRC	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.93	-0.58	3.26e-31	Brugada syndrome;
CRC	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.3	0.64	2.79e-40	Fuchs's corneal dystrophy;
CRC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg22495460	chr2:25135724	ADCY3	-0.87	-16.95	-0.68	9.6e-47	Body mass index;
CRC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.15	-0.52	1.03e-24	Blood trace element (Zn levels);
CRC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-6.92	-0.36	2.43e-11	Renal cell carcinoma;
CRC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.86	10.71	0.51	3.67e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg19338460	chr6:170058176	WDR27	-0.67	-7.38	-0.38	1.32e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11212617	0.967	rs664982	chr11:108225483	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.56	0.34	2.08e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs6561151	0.957	rs9316058	chr13:44485076	G/C	cg12856521	chr11:46389249	DGKZ	0.63	9.51	0.46	4.18e-19	Crohn's disease;
CRC	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-5.77	-0.3	1.87e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg21521518	chr4:53727714	RASL11B	0.41	6.07	0.32	3.56e-9	Optic nerve measurement (cup area);
CRC	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.73	-0.3	2.31e-8	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04633058	chr17:48474099	LRRC59	0.41	6.05	0.32	3.84e-9	Response to antipsychotic treatment;
CRC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg13770691	chr19:1021866	C19orf6	0.42	6.78	0.35	5.63e-11	Eosinophil percentage of granulocytes;
CRC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg20573242	chr4:122745356	CCNA2	0.43	6.47	0.34	3.46e-10	Type 2 diabetes;
CRC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg18827107	chr12:86230957	RASSF9	-0.38	-6.22	-0.32	1.48e-9	Major depressive disorder;
CRC	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.21	-0.37	3.79e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg12927641	chr6:109611667	NA	-0.37	-6.61	-0.34	1.58e-10	Reticulocyte fraction of red cells;
CRC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.06	0.32	3.82e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg03623178	chr6:28175578	NA	0.71	9.48	0.46	5.31e-19	Parkinson's disease;
CRC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.41	6.35	0.33	7.09e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs12476592	0.571	rs262517	chr2:63891261	G/T	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	cis	rs4664293	0.647	rs10192408	chr2:160424594	G/T	cg08347373	chr2:160653686	CD302	-0.39	-6.59	-0.34	1.76e-10	Monocyte percentage of white cells;
CRC	cis	rs4237845	0.611	rs11172387	chr12:58332351	C/G	cg02175503	chr12:58329896	NA	0.78	12.46	0.57	1.9e-29	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg10756647	chr7:56101905	PSPH	-0.77	-7.87	-0.4	5.06e-14	Diabetic kidney disease;
CRC	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.19	0.67	8.88e-44	Electrocardiographic conduction measures;
CRC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.12e-11	Major depressive disorder;
CRC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg05941027	chr17:61774174	LIMD2	0.36	6.61	0.34	1.54e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.44	0.33	4.34e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.62	-0.39	2.76e-13	Bipolar disorder;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg20512303	chr5:131592959	PDLIM4	0.38	6.56	0.34	2.09e-10	Acylcarnitine levels;
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg10729496	chr3:10149963	C3orf24	0.5	6.43	0.33	4.41e-10	Alzheimer's disease;
CRC	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.67	6.82	0.35	4.47e-11	Pediatric areal bone mineral density (radius);
CRC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.8	10.57	0.5	1.09e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.97	17.8	0.7	4.16e-50	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.59	6.0	0.31	5.24e-9	Plasma clusterin levels;
CRC	cis	rs243505	0.624	rs6975291	chr7:148548393	C/G	cg09806900	chr7:148480153	CUL1	0.52	6.65	0.34	1.22e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.74	7.56	0.38	4.17e-13	Diabetic retinopathy;
CRC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	-0.52	-8.75	-0.43	1.11e-16	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg02560186	chr11:3602584	NA	-0.56	-6.98	-0.36	1.63e-11	Blood pressure (smoking interaction);
CRC	cis	rs8010715	0.816	rs8015168	chr14:24599872	A/T	cg23112188	chr14:24563095	PCK2	-0.37	-7.24	-0.37	3.17e-12	IgG glycosylation;
CRC	cis	rs2882667	0.690	rs288029	chr5:138217305	A/G	cg09476006	chr5:138032270	NA	0.53	8.73	0.43	1.34e-16	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs902774	0.818	rs73110464	chr12:53312612	C/T	cg14581129	chr12:53358946	NA	-0.5	-5.82	-0.31	1.43e-8	Prostate cancer;
CRC	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg18232548	chr7:50535776	DDC	-0.41	-6.2	-0.32	1.67e-9	Body mass index;
CRC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs10849893	0.576	rs7296507	chr12:121847135	A/G	cg01154721	chr12:121881891	KDM2B	-0.42	-6.1	-0.32	3.02e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11427898	chr15:38544983	SPRED1	0.4	7.32	0.37	1.95e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.47	-8.26	-0.41	3.62e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.92	-15.93	-0.66	9.45e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg06766960	chr11:133703094	NA	-0.36	-5.96	-0.31	6.6e-9	Childhood ear infection;
CRC	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.58	7.71	0.39	1.49e-13	Height;
CRC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.45	6.33	0.33	8.02e-10	Alzheimer's disease (late onset);
CRC	trans	rs9545047	0.716	rs2265377	chr13:79999620	G/A	cg07061582	chr15:90234082	PEX11A;WDR93	-0.41	-5.97	-0.31	6.15e-9	Schizophrenia;
CRC	cis	rs2310173	0.575	rs13022757	chr2:102613546	G/C	cg20856504	chr2:102616538	IL1R2	0.41	6.69	0.35	9.34e-11	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.87e-12	Aortic root size;
CRC	cis	rs6810498	0.932	rs7676659	chr4:26057613	C/T	cg12925881	chr4:26050407	NA	0.43	8.09	0.41	1.16e-14	Alcohol dependence;
CRC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.57	9.38	0.46	1.08e-18	Schizophrenia;
CRC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.57	8.73	0.43	1.29e-16	Blood metabolite levels;
CRC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg05540913	chr6:167530185	CCR6	-0.38	-6.99	-0.36	1.5e-11	Primary biliary cholangitis;
CRC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs9341835	0.741	rs6929702	chr6:64144114	T/C	cg13657004	chr13:50234944	EBPL	-0.36	-6.1	-0.32	2.93e-9	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16919356	chr7:150780878	TMUB1	0.56	7.55	0.38	4.35e-13	Thyroid stimulating hormone;
CRC	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg02811702	chr13:24901961	NA	0.41	5.74	0.3	2.15e-8	Obesity-related traits;
CRC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	11.41	0.53	1.2e-25	High light scatter reticulocyte count;
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.18e-26	Prudent dietary pattern;
CRC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.65	-8.34	-0.42	2.12e-15	Bronchopulmonary dysplasia;
CRC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg21033440	chr11:65409861	SIPA1	-0.44	-5.64	-0.3	3.69e-8	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.56	10.23	0.49	1.71e-21	Coronary artery disease;
CRC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.94	-0.36	2.06e-11	IgG glycosylation;
CRC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg24977027	chr2:88469347	THNSL2	0.64	7.72	0.39	1.37e-13	Plasma clusterin levels;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg15786705	chr6:28176104	NA	0.64	9.23	0.45	3.27e-18	Parkinson's disease;
CRC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.61	9.21	0.45	3.95e-18	Testicular germ cell tumor;
CRC	cis	rs6694672	1.000	rs1571964	chr1:197113073	G/A	cg13682187	chr1:196946512	CFHR5	0.42	6.72	0.35	8.15e-11	Asthma;
CRC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg07514618	chr14:103979422	NA	0.45	6.9	0.36	2.73e-11	Bone mineral density;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.48	-6.32	-0.33	8.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg13010199	chr12:38710504	ALG10B	0.39	5.72	0.3	2.42e-8	Bladder cancer;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.92	-21.7	-0.77	2.01e-65	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04742505	chr7:72936528	BAZ1B	-0.53	-6.45	-0.34	4.08e-10	Diisocyanate-induced asthma;
CRC	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg14668889	chr17:73230827	NUP85	-0.51	-7.53	-0.38	4.81e-13	Systemic lupus erythematosus;
CRC	cis	rs2871473	1.000	rs2871473	chr2:103107280	A/C	cg09003973	chr2:102972529	NA	0.48	6.29	0.33	9.94e-10	Blood protein levels;
CRC	cis	rs7113874	0.589	rs2028882	chr11:8504854	A/C	cg02811074	chr11:8615871	STK33	-0.36	-6.16	-0.32	2.08e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg26587870	chr6:27730563	NA	-0.37	-5.76	-0.3	1.96e-8	Cardiac Troponin-T levels;
CRC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.49	-0.38	6.44e-13	Blood metabolite levels;
CRC	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg04239558	chr2:103089729	SLC9A4	0.38	6.64	0.34	1.29e-10	Blood protein levels;
CRC	cis	rs6973256	0.897	rs2345941	chr7:133337635	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.87	0.31	1.09e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.55	-9.12	-0.45	7.42e-18	Congenital heart disease (maternal effect);
CRC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg17724175	chr1:150552817	MCL1	-0.54	-9.28	-0.46	2.39e-18	Tonsillectomy;
CRC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.44	-0.42	1.04e-15	Morning vs. evening chronotype;
CRC	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg26116260	chr4:7069785	GRPEL1	0.56	8.33	0.42	2.14e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.41	6.38	0.33	6.15e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.83	11.91	0.55	1.9e-27	Cognitive function;
CRC	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.36	6.02	0.31	4.74e-9	Sitting height ratio;
CRC	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.98	-0.31	5.7e-9	Height;
CRC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.87	0.48	2.61e-20	Cognitive test performance;
CRC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.74	0.39	1.21e-13	Morning vs. evening chronotype;
CRC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	cis	rs524281	0.773	rs2155031	chr11:66030927	C/T	cg16950941	chr11:66035639	RAB1B	-0.72	-8.16	-0.41	7.42e-15	Electroencephalogram traits;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.42	0.42	1.21e-15	Arsenic metabolism;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg21747405	chr11:67723411	NA	-0.55	-8.7	-0.43	1.61e-16	Blood pressure (smoking interaction);
CRC	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.7	-10.27	-0.49	1.16e-21	Serum albumin level;
CRC	cis	rs7605827	0.930	rs12993042	chr2:15708218	A/T	cg19274914	chr2:15703543	NA	0.37	5.76	0.3	1.96e-8	Educational attainment (years of education);
CRC	cis	rs4077468	0.963	rs4951271	chr1:205913848	A/G	cg13172432	chr1:205912842	SLC26A9	-0.33	-5.71	-0.3	2.55e-8	Cystic fibrosis-related diabetes;
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.87	-0.44	4.63e-17	Bipolar disorder;
CRC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.16	-0.37	5.45e-12	Gut microbiome composition (summer);
CRC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.31	-6.85	-0.35	3.57e-11	Total body bone mineral density;
CRC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.96	-16.33	-0.67	2.45e-44	Height;
CRC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.79	14.73	0.63	4.46e-38	Metabolic syndrome;
CRC	cis	rs10392	0.543	rs1733	chr20:37581506	G/A	cg27552599	chr20:37590471	DHX35	0.37	5.81	0.3	1.5e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg27094323	chr7:1216898	NA	-0.36	-5.91	-0.31	8.37e-9	Longevity;Endometriosis;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-0.57	-8.0	-0.4	2.17e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.52	-8.1	-0.41	1.09e-14	Height;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10516465	chr14:102695515	RAGE	0.46	6.52	0.34	2.72e-10	Survival in pancreatic cancer;
CRC	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg27053337	chr8:124217698	FAM83A	0.45	6.81	0.35	4.55e-11	Urinary uromodulin levels;
CRC	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.6	-10.51	-0.5	1.76e-22	Asthma;
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.39	5.98	0.31	5.82e-9	Obesity;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.52	6.17	0.32	1.98e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.7	9.81	0.48	4.41e-20	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15555727	chr8:144692268	PYCRL	0.46	6.59	0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs9311676	0.656	rs66793022	chr3:58391565	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg00246817	chr9:123691163	NA	-0.44	-5.62	-0.3	4.08e-8	Rheumatoid arthritis;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18099408	chr3:52552593	STAB1	0.44	7.41	0.38	1.07e-12	Bipolar disorder;
CRC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14364472	chr9:139394549	NOTCH1	-0.44	-6.3	-0.33	9.78e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs3823572	0.503	rs4731990	chr7:133689074	C/T	cg03336402	chr7:133662267	EXOC4	-0.66	-9.66	-0.47	1.38e-19	Intelligence (multi-trait analysis);
CRC	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.71	-0.3	2.54e-8	Daytime sleep phenotypes;
CRC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.88	-12.11	-0.56	3.55e-28	Triglycerides;
CRC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg02269571	chr22:50332266	NA	-0.64	-8.62	-0.43	2.89e-16	Schizophrenia;
CRC	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.7	-0.35	9.24e-11	Subjective well-being;
CRC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg10978503	chr1:24200527	CNR2	-0.45	-7.5	-0.38	5.98e-13	Immature fraction of reticulocytes;
CRC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg25985355	chr7:65971099	NA	0.51	5.79	0.3	1.6e-8	Diabetic kidney disease;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.38	1.68e-12	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27362927	chr21:43299497	PRDM15	0.44	6.1	0.32	2.9e-9	Anxiety disorder;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg21251018	chr6:28226885	NKAPL	0.45	6.89	0.36	2.83e-11	Parkinson's disease;
CRC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.56	-8.5	-0.42	6.78e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs909002	0.759	rs10914454	chr1:32078940	G/A	cg01639898	chr1:32083012	HCRTR1	0.31	6.4	0.33	5.33e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.24	0.45	3.04e-18	Bladder cancer;
CRC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg03181118	chr3:128483840	RAB7A	-0.46	-6.7	-0.35	9.01e-11	Attention deficit hyperactivity disorder and conduct disorder;
CRC	trans	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.89	-0.36	2.82e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.38	-0.42	1.57e-15	Monocyte count;
CRC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg13010199	chr12:38710504	ALG10B	0.44	6.33	0.33	8.16e-10	Morning vs. evening chronotype;
CRC	trans	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.46	0.42	8.72e-16	Ulcerative colitis;
CRC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.72	-7.9	-0.4	4.17e-14	Lung disease severity in cystic fibrosis;
CRC	trans	rs6600671	1.000	rs2319969	chr1:121207335	A/G	cg00646200	chr1:148855367	NA	0.34	6.03	0.32	4.48e-9	Hip geometry;
CRC	cis	rs6973256	0.604	rs6975134	chr7:133531432	T/C	cg10665199	chr7:133106180	EXOC4	0.45	6.84	0.35	3.79e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg04518342	chr5:131593106	PDLIM4	0.47	8.6	0.43	3.41e-16	Breast cancer;
CRC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.25e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.45	-7.3	-0.37	2.2e-12	Refractive error;
CRC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg21251018	chr6:28226885	NKAPL	0.48	8.26	0.41	3.67e-15	Pubertal anthropometrics;
CRC	cis	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg18131467	chr2:239335373	ASB1	-0.73	-6.26	-0.33	1.18e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs427941	0.632	rs201526	chr7:101774333	T/G	cg06246474	chr7:101738831	CUX1	0.45	6.95	0.36	1.98e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg14711859	chr11:8959438	ASCL3	0.45	7.53	0.38	4.98e-13	Hemoglobin concentration;
CRC	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.81	14.77	0.63	3.22e-38	Metabolite levels;
CRC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26240231	chr7:1148101	C7orf50	-0.46	-6.7	-0.35	8.85e-11	Bronchopulmonary dysplasia;
CRC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.52	0.46	3.78e-19	Height;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg10272801	chr16:14013773	ERCC4	-0.69	-6.16	-0.32	2.15e-9	Cognitive function;
CRC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.74	11.76	0.54	6.75e-27	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02603434	chr19:49122389	RPL18;SPHK2	0.48	6.6	0.34	1.63e-10	Anxiety disorder;
CRC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.51	8.36	0.42	1.74e-15	Aortic root size;
CRC	cis	rs6066835	1.000	rs6095270	chr20:47356062	T/C	cg18078177	chr20:47281410	PREX1	0.64	6.0	0.31	5.07e-9	Multiple myeloma;
CRC	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.08	18.6	0.72	2.69e-53	Cognitive function;
CRC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.67	10.52	0.5	1.65e-22	Age at first birth;
CRC	cis	rs7487075	0.619	rs7485580	chr12:46830374	A/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.74	0.3	2.12e-8	Itch intensity from mosquito bite;
CRC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.7	-8.35	-0.42	1.98e-15	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg19223190	chr17:80058835	NA	-0.4	-6.29	-0.33	1.03e-9	Life satisfaction;
CRC	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.6	-9.71	-0.47	9.03e-20	Itch intensity from mosquito bite;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21685266	chr3:184971652	EHHADH	0.39	6.02	0.31	4.63e-9	Myopia (pathological);
CRC	cis	rs4774899	0.752	rs2962992	chr15:57346505	T/C	cg08128148	chr15:57256372	TCF12	-0.39	-5.67	-0.3	3.19e-8	Urinary tract infection frequency;
CRC	trans	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg13565492	chr6:43139072	SRF	-0.86	-6.34	-0.33	7.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2252790	1.000	rs2498710	chr6:116670636	G/A	cg18764771	chr6:116381957	FRK	-0.22	-5.8	-0.3	1.59e-8	Fast beta electroencephalogram;
CRC	trans	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-7.62	-0.39	2.71e-13	Endometrial cancer;
CRC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.57	8.73	0.43	1.35e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.98	-0.44	2.11e-17	Bipolar disorder;
CRC	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.79	-10.98	-0.52	4.05e-24	Blood pressure (smoking interaction);
CRC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.43	5.6	0.3	4.46e-8	Heart rate;
CRC	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg16950941	chr11:66035639	RAB1B	-0.61	-7.66	-0.39	2.13e-13	Electroencephalogram traits;
CRC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.38	8.81	0.44	7.54e-17	Multiple system atrophy;
CRC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.37	0.38	1.42e-12	Calcium levels;
CRC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.57	-9.78	-0.47	5.21e-20	Type 2 diabetes;
CRC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.57	7.92	0.4	3.7e-14	Alcohol dependence;
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.24e-12	Life satisfaction;
CRC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02725872	chr8:58115012	NA	-0.4	-6.84	-0.35	3.79e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.16	-12.12	-0.56	3.3e-28	Breast cancer;
CRC	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.42	-6.73	-0.35	7.39e-11	Corneal astigmatism;
CRC	cis	rs9925964	0.967	rs14235	chr16:31121793	G/A	cg03418659	chr16:31128414	MYST1	0.52	7.51	0.38	5.49e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.55	-8.65	-0.43	2.36e-16	Aortic root size;
CRC	cis	rs294883	0.739	rs4709294	chr6:159730544	C/T	cg14500486	chr6:159655392	FNDC1	0.37	6.43	0.33	4.45e-10	Coronary artery disease;
CRC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.57	10.13	0.49	3.69e-21	Aortic root size;
CRC	cis	rs4731207	0.698	rs6956638	chr7:124530115	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg04202892	chr2:111875749	ACOXL	0.39	6.13	0.32	2.52e-9	Chronic lymphocytic leukemia;
CRC	cis	rs7394190	0.748	rs11000775	chr10:75539010	T/C	cg07699608	chr10:75541558	CHCHD1	0.59	6.26	0.33	1.18e-9	Incident atrial fibrillation;
CRC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.69	9.42	0.46	8.11e-19	Breast cancer;
CRC	cis	rs1223397	0.938	rs3817738	chr6:13279388	G/T	cg06879394	chr6:13274151	PHACTR1	0.57	6.49	0.34	3.21e-10	Blood pressure;
CRC	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.62	-0.3	4.1e-8	Psychosis and Alzheimer's disease;
CRC	cis	rs3823572	0.564	rs3735050	chr7:133682181	T/C	cg03336402	chr7:133662267	EXOC4	-0.65	-9.53	-0.47	3.48e-19	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg24375607	chr4:120327624	NA	0.47	7.62	0.39	2.78e-13	Corneal astigmatism;
CRC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg00631329	chr6:26305371	NA	-0.5	-8.72	-0.43	1.42e-16	Educational attainment;
CRC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg21155852	chr7:2048760	MAD1L1	0.42	6.09	0.32	3.14e-9	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.43	-7.21	-0.37	3.83e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24308560	chr3:49941425	MST1R	0.45	6.84	0.35	3.9e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.91	0.36	2.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg04289385	chr6:36355825	ETV7	0.38	5.61	0.3	4.25e-8	Platelet distribution width;
CRC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.84	-0.44	5.88e-17	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg15845792	chr6:28175446	NA	1.04	13.81	0.61	1.6e-34	Depression;
CRC	cis	rs7725052	0.609	rs4527650	chr5:40460205	T/C	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14008862	chr17:28927542	LRRC37B2	0.51	6.03	0.32	4.44e-9	Body mass index;
CRC	cis	rs9549328	0.611	rs72661939	chr13:113617498	C/T	cg08614441	chr13:113633676	MCF2L	0.4	7.06	0.36	9.78e-12	Systolic blood pressure;
CRC	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg12856521	chr11:46389249	DGKZ	-0.5	-8.3	-0.42	2.64e-15	Leprosy;
CRC	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.5	-0.34	3.06e-10	Neuroticism;
CRC	cis	rs2072510	0.593	rs2540498	chr12:96400569	T/A	cg22491680	chr12:96389547	HAL	-0.47	-6.1	-0.32	2.9e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg06470822	chr6:28175283	NA	0.62	9.04	0.45	1.42e-17	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg04204079	chr8:58130323	NA	0.44	5.61	0.3	4.39e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.75	10.7	0.51	3.93e-23	Neutrophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17417193	chr6:45983110	CLIC5	0.39	6.27	0.33	1.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg00791764	chr4:53727839	RASL11B	0.59	6.29	0.33	1.02e-9	Optic nerve measurement (cup area);
CRC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.59	9.93	0.48	1.66e-20	Prudent dietary pattern;
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.04	0.52	2.63e-24	Alzheimer's disease;
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg03909863	chr11:638404	DRD4	-0.52	-6.89	-0.36	2.83e-11	Systemic lupus erythematosus;
CRC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.41	-6.33	-0.33	8.16e-10	Gout;Renal underexcretion gout;
CRC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.67	-7.98	-0.4	2.48e-14	Rheumatoid arthritis;
CRC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-15.54	-0.65	3.27e-41	Cognitive function;
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs9469578	1.000	rs16869464	chr6:33715127	A/G	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.56	0.43	4.53e-16	Coffee consumption (cups per day);
CRC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.55	-7.4	-0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.55	6.15	0.32	2.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4664293	0.625	rs35241460	chr2:160508200	T/A	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15072625	chr6:86302950	SNX14	0.56	8.24	0.41	4.25e-15	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg19223190	chr17:80058835	NA	0.38	6.09	0.32	3.16e-9	Life satisfaction;
CRC	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg09659197	chr4:152720779	NA	0.5	10.63	0.51	6.99e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.65e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1223397	1.000	rs1223399	chr6:13271220	G/A	cg06879394	chr6:13274151	PHACTR1	0.53	6.48	0.34	3.3e-10	Blood pressure;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.41	-0.33	5.06e-10	Total body bone mineral density;
CRC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.52	8.1	0.41	1.09e-14	LDL cholesterol;Cholesterol, total;
CRC	trans	rs2055729	0.645	rs6989793	chr8:9744650	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.13	-0.37	6.42e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	9.46	0.46	6.16e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.62	-8.74	-0.43	1.18e-16	Coronary artery disease;
CRC	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.52	-11.7	-0.54	1.14e-26	Urate levels in overweight individuals;
CRC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.59	9.49	0.46	4.81e-19	Systemic lupus erythematosus;
CRC	cis	rs728616	0.558	rs72817596	chr10:82151594	T/C	cg11900509	chr10:81946545	ANXA11	-0.53	-6.06	-0.32	3.81e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.94	-0.31	7.38e-9	Cognitive function;
CRC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg27534772	chr1:16042836	PLEKHM2	0.54	10.12	0.49	3.78e-21	Systolic blood pressure;
CRC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.37	-6.44	-0.33	4.2e-10	Erythrocyte sedimentation rate;
CRC	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13198984	chr17:80129470	CCDC57	0.45	8.07	0.41	1.3e-14	Life satisfaction;
CRC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26289871	chr20:39969385	LPIN3	-0.43	-7.67	-0.39	1.94e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg22676075	chr6:135203613	NA	-0.39	-6.02	-0.31	4.73e-9	Red blood cell count;
CRC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg03690763	chr11:133734501	NA	-0.35	-5.85	-0.31	1.22e-8	Childhood ear infection;
CRC	cis	rs11212617	0.967	rs227076	chr11:108218905	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.33	0.33	8.07e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.09	0.52	1.7e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg02972257	chr16:68554789	NA	0.48	5.77	0.3	1.83e-8	Colorectal cancer;
CRC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.63	-9.1	-0.45	9.04e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg01420254	chr6:26195488	NA	0.73	6.04	0.32	4.13e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg17764715	chr19:33622953	WDR88	0.44	6.41	0.33	5.15e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs13315871	0.615	rs13066167	chr3:58340175	G/A	cg25250853	chr2:85822726	RNF181	0.53	6.37	0.33	6.23e-10	Cholesterol, total;
CRC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg15017067	chr4:17643749	FAM184B	0.36	5.73	0.3	2.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.02	14.65	0.63	9.17e-38	Gut microbiome composition (summer);
CRC	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.14e-26	Coffee consumption (cups per day);
CRC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-11.05	-0.52	2.43e-24	Dental caries;
CRC	cis	rs6496667	0.779	rs8035817	chr15:90974327	G/A	cg04176472	chr15:90893244	GABARAPL3	0.59	8.16	0.41	7.28e-15	Rheumatoid arthritis;
CRC	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.86	-0.31	1.1e-8	Metabolite levels;
CRC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.8	-11.63	-0.54	2.08e-26	Mean platelet volume;Platelet distribution width;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18241048	chr10:5855009	GDI2	0.47	6.64	0.34	1.27e-10	Anxiety disorder;
CRC	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg08992911	chr2:238395768	MLPH	0.47	5.83	0.31	1.3e-8	Prostate cancer;
CRC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.48	-8.03	-0.4	1.7e-14	Height;
CRC	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg16540259	chr10:75572220	NDST2	0.38	5.91	0.31	8.64e-9	Inflammatory bowel disease;
CRC	cis	rs10512697	0.772	rs62336081	chr5:3528961	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.37	-0.33	6.34e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg04562611	chr16:615315	C16orf11	0.35	5.93	0.31	7.76e-9	Height;
CRC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.44	-6.87	-0.35	3.13e-11	Monocyte count;
CRC	cis	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg07460842	chr6:66804631	NA	-0.42	-5.7	-0.3	2.64e-8	Blood trace element (Cu levels);
CRC	cis	rs9311676	0.632	rs7643057	chr3:58374015	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.6	7.9	0.4	4.13e-14	Mammographic density (dense area);
CRC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.48	7.33	0.37	1.81e-12	Response to antineoplastic agents;
CRC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg21839984	chr17:30846986	MYO1D	-0.36	-5.94	-0.31	7.4e-9	Schizophrenia;
CRC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.43	-6.05	-0.32	3.84e-9	Aortic root size;
CRC	cis	rs59104589	0.583	rs62186377	chr2:242211450	A/G	cg19488206	chr2:242435732	STK25	0.48	6.86	0.35	3.48e-11	Fibrinogen levels;
CRC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	0.93	12.47	0.57	1.75e-29	Red blood cell traits;
CRC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg03030879	chr14:75389066	RPS6KL1	0.47	7.31	0.37	2.03e-12	Height;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8099014	0.859	rs11152072	chr18:56098912	A/G	cg19312305	chr18:56117016	MIR122	-0.38	-5.8	-0.3	1.54e-8	Platelet count;
CRC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-6.17	-0.32	2.04e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg11693508	chr17:37793320	STARD3	0.6	6.88	0.35	3.01e-11	Neuroticism;
CRC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.79	14.07	0.61	1.57e-35	Oral cavity cancer;
CRC	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg00490450	chr3:139108681	COPB2	0.43	6.4	0.33	5.37e-10	Obesity-related traits;
CRC	cis	rs73206853	0.764	rs68087637	chr12:110619797	T/C	cg12870014	chr12:110450643	ANKRD13A	0.83	10.86	0.51	1.07e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-6.93	-0.36	2.26e-11	Prudent dietary pattern;
CRC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.71	0.68	8.48e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.39	0.42	1.5e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.99	20.9	0.76	2.54e-62	Metabolite levels;
CRC	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.46	-5.98	-0.31	5.81e-9	Tuberculosis;
CRC	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg18806716	chr10:30721971	MAP3K8	0.46	6.98	0.36	1.65e-11	Inflammatory bowel disease;
CRC	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.66	8.08	0.41	1.25e-14	Eotaxin levels;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg25164649	chr6:28176230	NA	0.58	5.91	0.31	8.68e-9	Lung cancer in ever smokers;
CRC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.49	-8.65	-0.43	2.24e-16	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.49	-0.46	4.98e-19	Prevalent atrial fibrillation;
CRC	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.5	6.77	0.35	5.8e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	8.82	0.44	6.86e-17	Type 2 diabetes;
CRC	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg25588852	chr2:216877276	MREG	-0.35	-6.85	-0.35	3.63e-11	Alcohol dependence;
CRC	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.46	6.11	0.32	2.81e-9	Tuberculosis;
CRC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-7.3	-0.37	2.24e-12	Bladder cancer;
CRC	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.05	-14.41	-0.62	7.5e-37	Exhaled nitric oxide output;
CRC	cis	rs7572733	0.592	rs113964240	chr2:198456310	C/A	cg10820045	chr2:198174542	NA	0.35	6.28	0.33	1.04e-9	Dermatomyositis;
CRC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-13.11	-0.59	6.81e-32	Body mass index;
CRC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.46	6.14	0.32	2.4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03805410	chr22:42487359	NDUFA6	0.42	6.14	0.32	2.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.43	6.48	0.34	3.44e-10	Resting heart rate;
CRC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.92	-19.28	-0.73	5.98e-56	Urate levels in lean individuals;
CRC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.47	-8.01	-0.4	1.98e-14	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12404182	chr2:132250324	FAM128A;LOC150776	0.47	5.99	0.31	5.58e-9	Thyroid stimulating hormone;
CRC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg07153921	chr17:41440717	NA	-0.4	-6.15	-0.32	2.3e-9	Menopause (age at onset);
CRC	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13736514	chr6:26305472	NA	-0.47	-7.64	-0.39	2.39e-13	Educational attainment;
CRC	cis	rs1223397	0.938	rs3817738	chr6:13279388	G/T	cg20827128	chr6:13274284	PHACTR1	0.59	6.79	0.35	5.21e-11	Blood pressure;
CRC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.34	-6.82	-0.35	4.25e-11	Alzheimer's disease (late onset);
CRC	cis	rs7705042	0.865	rs4912622	chr5:141490587	A/G	cg07392085	chr5:141489673	NDFIP1	-0.48	-7.57	-0.39	3.71e-13	Asthma;
CRC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.6	-7.92	-0.4	3.75e-14	Post bronchodilator FEV1;
CRC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.41	-0.33	5.06e-10	Monocyte percentage of white cells;
CRC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-12.11	-0.56	3.71e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg25809561	chr17:30822961	MYO1D	0.6	10.68	0.51	4.6e-23	Schizophrenia;
CRC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.52	-8.02	-0.4	1.83e-14	Body mass index;
CRC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02551244	chr2:23608357	KLHL29	0.47	6.04	0.32	4.19e-9	Thyroid stimulating hormone;
CRC	cis	rs887797	0.518	rs8075979	chr17:64576138	C/T	cg27019712	chr17:64599478	PRKCA	-0.38	-5.79	-0.3	1.66e-8	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
CRC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.3	0.46	2.03e-18	High light scatter reticulocyte count;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.41	5.65	0.3	3.47e-8	Longevity;Endometriosis;
CRC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.4	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.49	7.6	0.39	3.09e-13	Obesity-related traits;
CRC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg21132104	chr15:45694354	SPATA5L1	0.44	6.45	0.34	4.01e-10	Response to fenofibrate (adiponectin levels);
CRC	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.22	-5.91	-0.31	8.61e-9	Type 2 diabetes;
CRC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.42	-5.64	-0.3	3.71e-8	Menarche (age at onset);
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.65	-0.3	3.45e-8	Total body bone mineral density;
CRC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg27130406	chr16:89901659	SPIRE2	-1.03	-12.41	-0.56	2.81e-29	Vitiligo;
CRC	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg11189052	chr15:85197271	WDR73	-0.62	-9.86	-0.48	3.01e-20	P wave terminal force;
CRC	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.5	7.73	0.39	1.33e-13	Red cell distribution width;
CRC	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.69	-0.35	9.45e-11	Educational attainment (years of education);
CRC	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.4	-6.14	-0.32	2.34e-9	Testicular germ cell tumor;
CRC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	16.15	0.66	1.32e-43	Platelet count;
CRC	trans	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg02674126	chr19:40336878	FBL	0.42	6.83	0.35	4.23e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg15845792	chr6:28175446	NA	0.8	6.52	0.34	2.67e-10	Depression;
CRC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.66	8.82	0.44	6.68e-17	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs11581859	0.950	rs60534017	chr1:99370528	C/T	cg12183875	chr3:169587454	LRRC31	0.26	6.13	0.32	2.55e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs6694672	1.000	rs6677082	chr1:197112533	G/A	cg13682187	chr1:196946512	CFHR5	0.42	6.72	0.35	8.15e-11	Asthma;
CRC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.47	7.34	0.38	1.71e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.5	8.5	0.42	6.74e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02069519	chr1:51985103	EPS15	0.4	6.27	0.33	1.16e-9	Schizophrenia;
CRC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg27661571	chr11:113659931	NA	0.71	7.84	0.4	6.31e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	10.19	0.49	2.25e-21	Total cholesterol levels;
CRC	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg25019722	chr6:37503610	NA	-0.46	-8.49	-0.42	7e-16	Cognitive performance;
CRC	trans	rs14057	0.827	rs6682920	chr1:6645867	C/T	cg13000219	chr12:21590632	PYROXD1	0.4	6.14	0.32	2.38e-9	Systolic blood pressure;
CRC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.32	-0.33	8.27e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20306533	chr22:18507404	MICAL3	0.43	6.22	0.32	1.5e-9	Response to antipsychotic treatment;
CRC	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg25547332	chr5:131281432	NA	0.36	5.65	0.3	3.56e-8	Life satisfaction;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg12172441	chr6:28176163	NA	0.55	6.53	0.34	2.43e-10	Parkinson's disease;
CRC	cis	rs11748023	0.605	rs156090	chr5:139521684	T/C	cg26211634	chr5:139558579	C5orf32	0.35	6.03	0.32	4.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg12172441	chr6:28176163	NA	0.57	7.51	0.38	5.5e-13	Parkinson's disease;
CRC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg23463467	chr20:60627584	TAF4	0.43	8.13	0.41	8.67e-15	Body mass index;
CRC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.51	6.3	0.33	9.48e-10	Recombination rate (females);
CRC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.84	0.48	3.28e-20	Cognitive test performance;
CRC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.49	9.36	0.46	1.28e-18	Renal cell carcinoma;
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07157834	chr1:205819609	PM20D1	0.44	6.1	0.32	2.99e-9	Parkinson's disease;
CRC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.86	-10.87	-0.51	9.9e-24	Obesity-related traits;
CRC	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.36e-11	Prostate cancer;
CRC	cis	rs61996546	0.622	rs2873027	chr15:26867409	C/T	cg15066197	chr15:26874202	GABRB3	-0.39	-5.99	-0.31	5.37e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.52	-0.38	5.37e-13	Psoriasis;
CRC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.37	5.6	0.3	4.48e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg20935933	chr6:143382018	AIG1	0.53	6.8	0.35	5e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.61	8.17	0.41	6.59e-15	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg03929089	chr4:120376271	NA	0.67	6.62	0.34	1.45e-10	Intraocular pressure;
CRC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02725872	chr8:58115012	NA	-0.38	-6.31	-0.33	9.08e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.53	6.91	0.36	2.48e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.65	-11.69	-0.54	1.25e-26	Hematocrit;
CRC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg25459000	chr22:39777742	SYNGR1	0.32	5.87	0.31	1.05e-8	IgG glycosylation;
CRC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.29	5.97	0.31	6.07e-9	Homoarginine levels;
CRC	cis	rs10982256	0.774	rs998548	chr9:117275182	C/T	cg13636371	chr9:117264095	DFNB31	0.35	6.82	0.35	4.37e-11	Bipolar disorder;
CRC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.61	9.0	0.44	1.84e-17	Schizophrenia;
CRC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.59	9.17	0.45	5.19e-18	Height;
CRC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.67	-0.3	3.16e-8	Life satisfaction;
CRC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.66	-7.96	-0.4	2.76e-14	Menarche (age at onset);
CRC	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg26727032	chr16:67993705	SLC12A4	-0.74	-12.24	-0.56	1.22e-28	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg04662943	chr10:102668895	NA	0.65	7.45	0.38	8.54e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg21836586	chr14:55907198	TBPL2	0.3	5.6	0.3	4.51e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.57	-8.65	-0.43	2.25e-16	Body mass index;
CRC	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.53	-6.59	-0.34	1.73e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	12.3	0.56	7.06e-29	Coffee consumption (cups per day);
CRC	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg20312557	chr2:97357134	FER1L5	-0.61	-5.63	-0.3	3.87e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.05	0.41	1.54e-14	Resting heart rate;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04652621	chr7:150671807	KCNH2	0.38	6.01	0.31	4.83e-9	Obesity-related traits;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.63	-8.76	-0.43	1.03e-16	Blood pressure (smoking interaction);
CRC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.43	-7.16	-0.37	5.19e-12	Type 2 diabetes;
CRC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg17306686	chr7:157230923	NA	0.46	6.64	0.34	1.29e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.41	-6.1	-0.32	3.02e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg22687807	chr8:143858763	LYNX1	0.51	8.99	0.44	2.05e-17	Urinary tract infection frequency;
CRC	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg17133734	chr15:86042851	AKAP13	0.4	6.34	0.33	7.51e-10	Coronary artery disease;
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg12273811	chr6:28175739	NA	0.55	5.86	0.31	1.12e-8	Depression;
CRC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.78	14.78	0.63	3.03e-38	Cancer;
CRC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-0.94	-16.18	-0.67	9.6e-44	Body mass index;
CRC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.55	-0.38	4.37e-13	Coronary artery disease;
CRC	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-1.0	-11.37	-0.53	1.79e-25	Blood protein levels;
CRC	cis	rs6546324	0.625	rs1430791	chr2:67864800	A/C	cg15745817	chr2:67799979	NA	-0.55	-9.57	-0.47	2.68e-19	Endometriosis;
CRC	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg00603274	chr11:61596626	FADS2	0.45	6.64	0.34	1.29e-10	Trans fatty acid levels;
CRC	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.68	-10.49	-0.5	2.2e-22	Systemic sclerosis;
CRC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg09491104	chr22:46646882	C22orf40	-0.48	-7.51	-0.38	5.72e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.46	5.94	0.31	7.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.68	10.19	0.49	2.28e-21	Schizophrenia;
CRC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg21770322	chr7:97807741	LMTK2	-0.55	-8.78	-0.44	8.91e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.57e-16	Chronic sinus infection;
CRC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.24e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3751196	0.901	rs117053620	chr12:104191196	G/A	cg02344784	chr12:104178138	NT5DC3	0.68	6.96	0.36	1.91e-11	Sense of smell;
CRC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-16.47	-0.67	7.23e-45	Electrocardiographic conduction measures;
CRC	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg06042504	chr8:55087323	NA	-0.42	-6.44	-0.33	4.21e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.62	7.62	0.39	2.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.28	-0.33	1.09e-9	Lymphocyte counts;
CRC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	6.42	0.33	4.85e-10	IgG glycosylation;
CRC	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg23202291	chr11:1979235	NA	0.48	6.59	0.34	1.78e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.82	-15.23	-0.64	5.3e-40	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01353139	chr8:124170018	NA	0.38	6.12	0.32	2.6e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.71	-10.36	-0.5	5.74e-22	Type 2 diabetes;
CRC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.25	-14.84	-0.63	1.63e-38	Diabetic kidney disease;
CRC	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.39	-5.88	-0.31	9.87e-9	Large artery stroke;
CRC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg12183467	chr14:104352244	NA	0.49	6.73	0.35	7.65e-11	Bipolar disorder;
CRC	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.48	7.72	0.39	1.38e-13	Endometrial cancer;
CRC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.79	-0.35	5.15e-11	Schizophrenia;
CRC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.66	9.07	0.45	1.13e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6973256	0.762	rs11768260	chr7:133430482	T/C	cg10665199	chr7:133106180	EXOC4	-0.39	-5.8	-0.3	1.58e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.92	0.44	3.3e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg08501292	chr6:25962987	TRIM38	0.83	6.43	0.33	4.44e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.37	-0.38	1.39e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg20354231	chr13:53171401	NA	-0.43	-6.87	-0.35	3.22e-11	Lewy body disease;
CRC	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg15123519	chr2:136567270	LCT	-0.32	-6.11	-0.32	2.8e-9	Mosquito bite size;
CRC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.4	-0.5	4.45e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg13264159	chr8:625131	ERICH1	-0.77	-7.18	-0.37	4.69e-12	IgG glycosylation;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15312298	chr8:127570908	FAM84B	-0.51	-6.45	-0.34	4.01e-10	Diisocyanate-induced asthma;
CRC	cis	rs7605827	0.964	rs6733847	chr2:15564930	G/A	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.62e-9	Educational attainment (years of education);
CRC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	1.03	19.74	0.74	8.73e-58	Menarche (age at onset);
CRC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.31e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.22	0.49	1.8e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.56	8.9	0.44	3.69e-17	Type 2 diabetes;
CRC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg01126855	chr4:183727586	NA	0.63	6.07	0.32	3.57e-9	Pediatric autoimmune diseases;
CRC	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.04	-0.32	4.15e-9	Metabolite levels;
CRC	cis	rs4664293	1.000	rs10204535	chr2:160463692	C/T	cg08347373	chr2:160653686	CD302	-0.38	-6.31	-0.33	9.11e-10	Monocyte percentage of white cells;
CRC	trans	rs16846053	0.792	rs56374905	chr2:162631445	G/C	cg18226098	chr19:917109	KISS1R	-0.64	-6.03	-0.32	4.46e-9	Blood osmolality (transformed sodium);
CRC	cis	rs7605827	0.930	rs11676730	chr2:15563573	C/T	cg19274914	chr2:15703543	NA	0.38	5.76	0.3	1.9e-8	Educational attainment (years of education);
CRC	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.51	8.55	0.43	4.7e-16	Schizophrenia;
CRC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	0.96	14.14	0.61	8.42e-36	Initial pursuit acceleration;
CRC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg19812747	chr11:111475976	SIK2	-0.5	-7.92	-0.4	3.82e-14	Primary sclerosing cholangitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21871735	chr16:2015157	SNHG9;RPS2;SNORA78	0.47	6.62	0.34	1.46e-10	Response to antipsychotic treatment;
CRC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg24209194	chr3:40518798	ZNF619	0.42	6.51	0.34	2.8e-10	Renal cell carcinoma;
CRC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-9.89	-0.48	2.38e-20	Prostate cancer;
CRC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.03	-0.32	4.49e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6504622	0.905	rs736604	chr17:45024809	C/T	cg16759221	chr17:45003025	GOSR2	-0.54	-8.45	-0.42	9.25e-16	Orofacial clefts;
CRC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	0.92	18.17	0.71	1.46e-51	Myeloid white cell count;
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	0.78	8.67	0.43	1.97e-16	Gout;Renal underexcretion gout;
CRC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.42	-6.37	-0.33	6.31e-10	Renal cell carcinoma;
CRC	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg17545662	chr6:170176663	C6orf70	0.55	6.02	0.31	4.78e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg03885332	chr11:832357	CD151	-0.42	-6.21	-0.32	1.61e-9	Mean platelet volume;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.7	9.86	0.48	2.94e-20	Menarche (age at onset);
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg22687807	chr8:143858763	LYNX1	-0.48	-7.87	-0.4	5.12e-14	Urinary tract infection frequency;
CRC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.08	0.41	1.22e-14	Platelet count;
CRC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.39	-6.68	-0.35	9.9e-11	Frontotemporal dementia;
CRC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.72	-11.64	-0.54	1.91e-26	Personality dimensions;
CRC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.08e-23	Motion sickness;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg13575638	chr3:9440081	SETD5;LOC440944	0.39	6.08	0.32	3.36e-9	Interleukin-6 levels;
CRC	cis	rs9549328	0.614	rs35299896	chr13:113617229	G/T	cg24588162	chr13:113633484	MCF2L	0.36	6.51	0.34	2.89e-10	Systolic blood pressure;
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.81	-14.19	-0.62	5.26e-36	Lewy body disease;
CRC	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg14191688	chr11:70257035	CTTN	0.57	6.99	0.36	1.55e-11	Coronary artery disease;
CRC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.57	8.81	0.44	7.39e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg07952391	chr2:88470173	THNSL2	0.63	6.38	0.33	5.99e-10	Plasma clusterin levels;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg15845792	chr6:28175446	NA	0.95	13.73	0.6	3.05e-34	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg17724175	chr1:150552817	MCL1	0.47	6.97	0.36	1.7e-11	Melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18635645	chr1:85667791	SYDE2	0.44	6.53	0.34	2.47e-10	Response to antipsychotic treatment;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg17147758	chr8:6949321	NA	-0.52	-7.2	-0.37	4.24e-12	Blood pressure (smoking interaction);
CRC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-6.81	-0.35	4.77e-11	Colorectal cancer;
CRC	cis	rs4692589	1.000	rs4692783	chr4:170935407	G/A	cg19918862	chr4:170955249	NA	0.38	6.29	0.33	1.03e-9	Anxiety disorder;
CRC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg17796960	chr10:135278976	LOC619207	-0.37	-5.65	-0.3	3.53e-8	Systemic lupus erythematosus;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg23161317	chr6:28129485	ZNF389	0.45	6.5	0.34	3.01e-10	Parkinson's disease;
CRC	cis	rs972578	1.000	rs2267481	chr22:43363889	A/G	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	trans	rs4714291	0.802	rs2983143	chr6:40044850	G/T	cg02267698	chr19:7991119	CTXN1	-0.45	-6.09	-0.32	3.09e-9	Strep throat;
CRC	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.5	0.38	6.05e-13	Coronary artery disease;
CRC	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.45	6.4	0.33	5.31e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25229015	chr15:78591883	WDR61	0.46	6.01	0.31	4.97e-9	Survival in pancreatic cancer;
CRC	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg18232548	chr7:50535776	DDC	0.45	5.86	0.31	1.12e-8	Malaria;
CRC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.16	-0.49	2.82e-21	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04696171	chr16:89787876	C16orf7;ZNF276	0.39	6.3	0.33	9.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.68	10.86	0.51	1.14e-23	Myopia (pathological);
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15560884	chr1:710097	NA	-0.46	-8.76	-0.43	1.08e-16	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg16898833	chr6:26189333	HIST1H4D	0.65	5.76	0.3	1.88e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg04990556	chr1:26633338	UBXN11	0.54	5.81	0.3	1.51e-8	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01524359	chr1:46049306	NASP	0.48	6.65	0.34	1.21e-10	Response to antipsychotic treatment;
CRC	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg24848437	chr7:2645542	IQCE	0.59	6.06	0.32	3.66e-9	Urate levels in lean individuals;
CRC	cis	rs2737618	0.674	rs2821334	chr1:200093887	G/T	cg21825944	chr1:200113062	NR5A2	-0.52	-7.51	-0.38	5.67e-13	Uric acid levels;
CRC	cis	rs974417	0.508	rs17743380	chr6:97312271	C/T	cg14723344	chr6:97285662	GPR63	0.41	5.91	0.31	8.7e-9	Body mass index;
CRC	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	trans	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.76	-0.39	1.07e-13	HDL cholesterol;
CRC	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.85e-18	Iron status biomarkers;
CRC	cis	rs12692738	0.526	rs355872	chr2:165632206	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.4	0.42	1.31e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-9.77	-0.47	5.75e-20	Blood protein levels;
CRC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.55	8.16	0.41	7.39e-15	Response to temozolomide;
CRC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.15e-12	Motion sickness;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.72	11.31	0.53	2.77e-25	Colorectal cancer;
CRC	cis	rs12024301	0.557	rs6661715	chr1:183622314	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.66	0.34	1.14e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg15786705	chr6:28176104	NA	0.48	7.18	0.37	4.74e-12	Cardiac Troponin-T levels;
CRC	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.53	8.62	0.43	2.82e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.17	-0.32	2.04e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	6.25	0.33	1.3e-9	Blood metabolite levels;
CRC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.69	10.06	0.48	6.26e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6445967	0.898	rs4336086	chr3:58297390	C/T	cg23715586	chr3:58305044	RPP14	0.35	5.84	0.31	1.25e-8	Platelet count;
CRC	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg00935504	chr16:1863053	HAGH	0.3	5.65	0.3	3.44e-8	Blood metabolite levels;
CRC	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg13385794	chr1:248469461	NA	0.39	6.74	0.35	7.28e-11	Common traits (Other);
CRC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	6.6	0.34	1.61e-10	Diastolic blood pressure;
CRC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.61e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg02119577	chr21:40195074	ETS2	0.38	6.48	0.34	3.31e-10	Non-small cell lung cancer (survival);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14792983	chr20:18447909	C20orf12;POLR3F	0.46	6.12	0.32	2.6e-9	Survival in pancreatic cancer;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg03623178	chr6:28175578	NA	-0.7	-9.95	-0.48	1.46e-20	Parkinson's disease;
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.55	6.19	0.32	1.82e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.61	10.28	0.49	1.16e-21	Resting heart rate;
CRC	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg13460858	chr9:96720652	NA	0.31	5.95	0.31	6.83e-9	Esophageal adenocarcinoma;
CRC	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.51	-7.86	-0.4	5.42e-14	Diastolic blood pressure;
CRC	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg11861562	chr11:117069780	TAGLN	0.35	6.4	0.33	5.38e-10	Blood protein levels;
CRC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.36	6.8	0.35	4.82e-11	Lung cancer;
CRC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.51	6.46	0.34	3.72e-10	Morning vs. evening chronotype;
CRC	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg18232548	chr7:50535776	DDC	-0.43	-5.61	-0.3	4.27e-8	Malaria;
CRC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg02158880	chr13:53174818	NA	-0.49	-7.46	-0.38	7.58e-13	Lewy body disease;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg12172441	chr6:28176163	NA	0.6	6.56	0.34	2.1e-10	Parkinson's disease;
CRC	cis	rs8141797	0.901	rs34247969	chr22:24555965	G/A	cg20894457	chr22:24584366	SUSD2	0.67	6.98	0.36	1.59e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.61	-9.43	-0.46	7.73e-19	Corneal astigmatism;
CRC	trans	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg07393940	chr7:158741817	NA	-0.56	-7.84	-0.4	6.47e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg07274523	chr3:49395745	GPX1	0.45	6.05	0.32	4.03e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs10760158	0.800	rs4556152	chr9:124016909	G/A	cg14417974	chr9:124058376	GSN	-0.33	-5.66	-0.3	3.3e-8	Pulse pressure;
CRC	trans	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg18288967	chr1:45987694	PRDX1	0.66	7.29	0.37	2.3e-12	Obesity-related traits;
CRC	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg02927042	chr1:21476669	EIF4G3	0.45	7.26	0.37	2.81e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.14	-0.32	2.43e-9	Alzheimer's disease (late onset);
CRC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.78	-0.3	1.73e-8	Neuroticism;
CRC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.44	5.91	0.31	8.55e-9	Resistin levels;
CRC	cis	rs10971721	0.643	rs12378415	chr9:33797333	G/T	cg13495928	chr9:33750294	PRSS3	0.67	5.94	0.31	7.14e-9	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03457587	chr19:54694791	MBOAT7;TSEN34	0.44	6.28	0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12273811	chr6:28175739	NA	0.76	10.93	0.52	6.19e-24	Depression;
CRC	cis	rs10971721	0.822	rs72727327	chr9:33918816	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19138325	chr12:129429698	GLT1D1	-0.37	-6.08	-0.32	3.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	15.09	0.64	1.79e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.05	-25.27	-0.81	4.48e-79	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.39	-6.59	-0.34	1.73e-10	Height;
CRC	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.44	-6.81	-0.35	4.61e-11	Platelet count;
CRC	cis	rs7527798	0.592	rs10746386	chr1:207855095	C/T	cg09232269	chr1:207846808	CR1L	-0.45	-7.33	-0.37	1.84e-12	Erythrocyte sedimentation rate;
CRC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.23	6.32	0.33	8.59e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.86	19.01	0.72	6.63e-55	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.74	8.89	0.44	4.07e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.47	6.32	0.33	8.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17067123	0.539	rs75564322	chr4:180066838	A/G	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	7.28e-11	Response to hepatitis C treatment;
CRC	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg11204139	chr17:3907470	NA	0.83	16.53	0.67	4.27e-45	Type 2 diabetes;
CRC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg13390004	chr1:15929781	NA	0.5	6.88	0.35	3.01e-11	Systolic blood pressure;
CRC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg17948913	chr5:572064	NA	0.51	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.64	-0.47	1.51e-19	Hip circumference adjusted for BMI;
CRC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-8.89	-0.44	4.2e-17	Immature fraction of reticulocytes;
CRC	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg11693508	chr17:37793320	STARD3	0.57	6.66	0.34	1.17e-10	Neuroticism;
CRC	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.37	-5.92	-0.31	7.91e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	0.83	6.66	0.34	1.16e-10	LDL cholesterol;
CRC	trans	rs75246769	0.636	rs74730677	chr7:145681220	G/C	cg14916917	chr5:81574294	RPS23	0.91	6.2	0.32	1.7e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.43	-0.33	4.58e-10	Gout;Renal underexcretion gout;
CRC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.67e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg15448220	chr1:150897856	SETDB1	0.42	6.0	0.31	5.2e-9	Melanoma;
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg12516270	chr8:143859308	LYNX1	-0.69	-12.96	-0.58	2.57e-31	Urinary tract infection frequency;
CRC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg12855166	chr17:30846586	MYO1D	-0.49	-7.62	-0.39	2.67e-13	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04324509	chr3:101295624	PCNP	-0.41	-6.77	-0.35	5.91e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.74	14.82	0.63	2.04e-38	Leprosy;
CRC	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9969804	0.818	rs10992439	chr9:95495134	T/A	cg14631576	chr9:95140430	CENPP	-0.32	-5.97	-0.31	6.03e-9	Height;
CRC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25517755	chr10:38738941	LOC399744	-0.45	-6.49	-0.34	3.24e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.83	14.17	0.62	6.55e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg20744362	chr22:50050164	C22orf34	0.34	6.2	0.32	1.69e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg08798685	chr6:27730294	NA	-0.57	-6.27	-0.33	1.15e-9	Lung cancer in ever smokers;
CRC	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-9.02	-0.45	1.59e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.42	6.58	0.34	1.81e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.67	10.79	0.51	2e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.4	5.77	0.3	1.79e-8	Schizophrenia;
CRC	cis	rs73206853	0.841	rs4131851	chr12:110812345	T/C	cg12870014	chr12:110450643	ANKRD13A	0.77	8.38	0.42	1.59e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs755249	0.567	rs61779279	chr1:39837102	C/T	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.07	9.71	0.47	9.45e-20	Diabetic retinopathy;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.79	-0.3	1.61e-8	Longevity;Endometriosis;
CRC	cis	rs16867321	0.950	rs4667223	chr2:181498302	C/G	cg23363182	chr2:181467187	NA	-0.51	-6.65	-0.34	1.21e-10	Obesity;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg09781304	chr17:80887954	TBCD	-0.43	-6.05	-0.32	4.05e-9	Lung cancer;
CRC	cis	rs73200209	0.744	rs56187732	chr12:116688042	C/T	cg01776926	chr12:116560359	MED13L	-0.61	-7.28	-0.37	2.56e-12	Total body bone mineral density;
CRC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.58	8.36	0.42	1.79e-15	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs17095355	1.000	rs17095355	chr10:111735750	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.44	-0.42	1.06e-15	Biliary atresia;
CRC	trans	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg09872104	chr7:134855509	C7orf49	-0.84	-7.34	-0.38	1.66e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.78	-0.35	5.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.51	6.71	0.35	8.67e-11	Coronary artery disease;
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.72	-0.43	1.36e-16	Bipolar disorder;
CRC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg24588162	chr13:113633484	MCF2L	-0.36	-5.72	-0.3	2.46e-8	Systolic blood pressure;
CRC	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg23298862	chr7:158159286	PTPRN2	0.37	5.88	0.31	9.96e-9	Calcium levels;
CRC	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.55	7.74	0.39	1.2e-13	Testicular germ cell tumor;
CRC	cis	rs10046574	0.831	rs7455447	chr7:135062056	C/T	cg27474649	chr7:135195673	CNOT4	0.66	5.64	0.3	3.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2882667	0.861	rs10037106	chr5:138365490	G/T	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.44e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.38	6.22	0.32	1.55e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.18	-0.32	1.93e-9	Obesity-related traits;
CRC	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.46	6.82	0.35	4.28e-11	Neutrophil percentage of white cells;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.04	22.99	0.79	2.02e-70	Myeloid white cell count;
CRC	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.82	11.79	0.55	5.2e-27	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg25036284	chr2:26402008	FAM59B	0.54	6.41	0.33	5.04e-10	Gut microbiome composition (summer);
CRC	cis	rs16975963	0.604	rs17305326	chr19:38119547	T/C	cg15135657	chr19:38346511	NA	-0.46	-6.28	-0.33	1.04e-9	Longevity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02114728	chr2:169102929	STK39	0.44	6.16	0.32	2.15e-9	Response to antipsychotic treatment;
CRC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.45	8.7	0.43	1.65e-16	Alcohol dependence;
CRC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19500275	chr17:80737654	TBCD	-0.51	-8.5	-0.42	6.82e-16	Glycated hemoglobin levels;
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.73	9.99	0.48	1.03e-20	Alzheimer's disease;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg15786705	chr6:28176104	NA	0.6	8.79	0.44	8.25e-17	Parkinson's disease;
CRC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	13.38	0.59	6.48e-33	Chronic sinus infection;
CRC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	10.55	0.5	1.29e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.23e-8	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg17321639	chr7:2759063	NA	-0.48	-6.13	-0.32	2.58e-9	Height;
CRC	cis	rs3751196	0.808	rs17034662	chr12:104221904	A/G	cg02344784	chr12:104178138	NT5DC3	0.68	7.18	0.37	4.7e-12	Sense of smell;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07120806	chr4:1873451	WHSC1	0.42	6.63	0.34	1.37e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12588279	chr6:26043732	HIST1H2BB	0.44	6.29	0.33	9.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg21251018	chr6:28226885	NKAPL	0.42	6.05	0.32	3.84e-9	Parkinson's disease;
CRC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.39	6.53	0.34	2.53e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.0	15.36	0.65	1.68e-40	Cognitive function;
CRC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.85	9.91	0.48	2.03e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.69	-11.3	-0.53	3.08e-25	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.67	-8.63	-0.43	2.76e-16	Mean platelet volume;
CRC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.68	0.39	1.85e-13	Mean corpuscular volume;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.76	8.78	0.44	9.43e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-1.03	-10.56	-0.5	1.18e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6123683	0.964	rs8116259	chr20:55826168	A/G	cg13236649	chr20:55835020	BMP7	0.43	6.21	0.32	1.6e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.43	6.12	0.32	2.62e-9	Aortic root size;
CRC	cis	rs6546324	0.615	rs7598280	chr2:67815313	A/T	cg15745817	chr2:67799979	NA	-0.55	-9.24	-0.45	3.14e-18	Endometriosis;
CRC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.16	25.92	0.82	1.73e-81	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.98	-0.31	5.97e-9	Life satisfaction;
CRC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg21466736	chr12:48725269	NA	-0.6	-9.02	-0.45	1.63e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.78	11.66	0.54	1.58e-26	Cognitive function;
CRC	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.11	-0.36	7.49e-12	Total bilirubin levels in HIV-1 infection;
CRC	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg12856521	chr11:46389249	DGKZ	-0.41	-6.53	-0.34	2.49e-10	Leprosy;
CRC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.36	0.42	1.74e-15	Menarche (age at onset);
CRC	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.57	6.62	0.34	1.48e-10	Blood trace element (Cu levels);
CRC	cis	rs939584	0.825	rs62105327	chr2:639060	T/A	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.67e-8	Body mass index;
CRC	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.57	-9.04	-0.45	1.38e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.74	-0.3	2.18e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg02428538	chr16:24856791	SLC5A11	0.45	6.13	0.32	2.56e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16595404	chr10:12238160	CDC123;NUDT5	0.46	6.62	0.34	1.5e-10	Response to antipsychotic treatment;
CRC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.5	-7.88	-0.4	4.98e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.29	0.33	9.88e-10	Life satisfaction;
CRC	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg12884169	chr21:40033163	ERG	0.41	9.16	0.45	5.88e-18	Coronary artery disease;
CRC	cis	rs7487075	0.619	rs2220727	chr12:46805069	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12501888	chr15:85177176	SCAND2	-0.37	-5.94	-0.31	7.09e-9	P wave terminal force;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11203927	chr22:41032991	MKL1	0.41	5.96	0.31	6.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.41	0.53	1.23e-25	Height;
CRC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-13.39	-0.59	5.94e-33	Asthma;
CRC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.4	-6.93	-0.36	2.29e-11	Crohn's disease;
CRC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.51	0.57	1.24e-29	Platelet count;
CRC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.67	8.7	0.43	1.67e-16	Bladder cancer;
CRC	cis	rs2880765	0.525	rs2062234	chr15:86054490	A/G	cg10818794	chr15:86012489	AKAP13	-0.48	-7.14	-0.37	5.88e-12	Coronary artery disease;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	7.2	0.37	4.06e-12	Breast cancer;
CRC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.08e-8	Morning vs. evening chronotype;
CRC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg03013999	chr17:37608204	MED1	0.47	7.35	0.38	1.61e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.03	-0.4	1.73e-14	Hemoglobin concentration;
CRC	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.47	-8.67	-0.43	1.97e-16	Hepatitis;
CRC	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.24	-9.92	-0.48	1.84e-20	Mitochondrial DNA levels;
CRC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg03929089	chr4:120376271	NA	0.53	6.26	0.33	1.22e-9	Intraocular pressure;
CRC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg16606324	chr3:10149918	C3orf24	-0.49	-7.32	-0.37	1.93e-12	Alzheimer's disease;
CRC	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg13385794	chr1:248469461	NA	0.4	7.05	0.36	1.06e-11	Common traits (Other);
CRC	cis	rs2252790	0.605	rs12193974	chr6:116542500	T/C	cg26893134	chr6:116381904	FRK	0.23	5.64	0.3	3.74e-8	Fast beta electroencephalogram;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15334456	chr3:10290272	TATDN2	-0.41	-6.2	-0.32	1.66e-9	Myopia (pathological);
CRC	cis	rs7692995	1.000	rs1380293	chr4:18027235	T/C	cg08925142	chr4:18023851	LCORL	-0.53	-5.97	-0.31	6.12e-9	Height;
CRC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.44	5.82	0.31	1.37e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.35	-0.33	7.1e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	7.24	0.37	3.15e-12	Lipoprotein (a) levels;
CRC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg03233332	chr7:66118400	NA	-0.44	-6.32	-0.33	8.49e-10	Aortic root size;
CRC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg00316803	chr15:76480434	C15orf27	-0.4	-6.84	-0.35	3.83e-11	Blood metabolite levels;
CRC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg12458913	chr13:53173898	NA	0.9	17.04	0.68	4.06e-47	Lewy body disease;
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.5	-0.34	2.99e-10	Height;
CRC	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg19773385	chr1:10388646	KIF1B	-0.64	-10.41	-0.5	4.11e-22	Hepatocellular carcinoma;
CRC	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.87	-0.31	1.07e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg07979401	chr6:33739406	LEMD2	-0.47	-5.89	-0.31	9.76e-9	Schizophrenia;
CRC	cis	rs12431939	1.000	rs60818073	chr14:51696649	T/C	cg23942311	chr14:51606299	NA	-0.54	-6.24	-0.33	1.34e-9	Cancer;
CRC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.4	5.63	0.3	3.78e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs243505	1.000	rs243520	chr7:148423560	C/T	cg09806900	chr7:148480153	CUL1	-0.46	-6.51	-0.34	2.74e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg04121214	chr22:50244548	NA	0.4	6.12	0.32	2.63e-9	Schizophrenia;
CRC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.29	-0.46	2.19e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg10876282	chr6:28092338	ZSCAN16	0.45	6.08	0.32	3.26e-9	Cardiac Troponin-T levels;
CRC	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg19338460	chr6:170058176	WDR27	-0.54	-6.18	-0.32	1.86e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.54	-7.18	-0.37	4.78e-12	Neutrophil percentage of white cells;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.84	-0.58	7.52e-31	Alzheimer's disease;
CRC	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.46	-7.91	-0.4	3.96e-14	Response to cytidine analogues (gemcitabine);
CRC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.66	-10.42	-0.5	3.82e-22	Height;
CRC	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.07	-14.34	-0.62	1.5e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.76	-0.3	1.93e-8	Schizophrenia;
CRC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.19	-0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg24046110	chr8:143859143	LYNX1	0.48	8.32	0.42	2.3e-15	Urinary tract infection frequency;
CRC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.64	-13.32	-0.59	1.1e-32	Schizophrenia;
CRC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg00255919	chr5:131827918	IRF1	-0.34	-5.74	-0.3	2.13e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07866137	chr8:67579786	VCPIP1	0.46	6.11	0.32	2.85e-9	Thyroid stimulating hormone;
CRC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.54	8.55	0.43	4.7e-16	Type 2 diabetes;
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.26	-0.56	1.03e-28	Alzheimer's disease;
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg01339444	chr6:118972232	C6orf204	0.52	5.92	0.31	8.31e-9	Diastolic blood pressure;
CRC	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.87	0.31	1.07e-8	Migraine;
CRC	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg21153622	chr11:89784906	NA	-0.45	-7.18	-0.37	4.68e-12	HDL cholesterol;
CRC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg02549819	chr16:58548995	SETD6	1.13	7.37	0.38	1.43e-12	Schizophrenia;
CRC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.33	-0.33	8.03e-10	Gout;Renal underexcretion gout;
CRC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.57	0.54	3.44e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.81	11.89	0.55	2.36e-27	Cognitive function;
CRC	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg13482628	chr17:19912719	NA	-0.4	-6.29	-0.33	1.04e-9	Obesity-related traits;
CRC	cis	rs12519773	0.526	rs4632783	chr5:92528309	A/G	cg18783429	chr5:92414398	NA	0.27	5.8	0.3	1.58e-8	Migraine;
CRC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.65	-8.05	-0.41	1.49e-14	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.27	-0.37	2.7e-12	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.12	-0.41	9.26e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg27205649	chr11:78285834	NARS2	0.49	6.26	0.33	1.22e-9	Alzheimer's disease (survival time);
CRC	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.87	-0.35	3.15e-11	Ulcerative colitis;
CRC	cis	rs7605827	0.808	rs13001585	chr2:15517790	T/C	cg19274914	chr2:15703543	NA	0.39	5.93	0.31	7.51e-9	Educational attainment (years of education);
CRC	cis	rs77956314	0.711	rs4767492	chr12:117436861	C/T	cg02017074	chr12:117425053	FBXW8	0.65	5.6	0.3	4.41e-8	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs73206853	0.841	rs73194013	chr12:111100677	T/C	cg12870014	chr12:110450643	ANKRD13A	0.79	8.35	0.42	1.94e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.6	8.47	0.42	8.42e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg22117107	chr15:45993392	NA	-0.45	-9.16	-0.45	5.85e-18	Waist circumference;Weight;
CRC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20135002	chr11:47629003	NA	-0.35	-5.89	-0.31	9.33e-9	Subjective well-being;
CRC	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.64	0.34	1.29e-10	Blood protein levels;
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs7731657	0.537	rs2107334	chr5:130292773	T/C	cg08523029	chr5:130500466	HINT1	-0.49	-6.19	-0.32	1.83e-9	Fasting plasma glucose;
CRC	cis	rs7827545	1.000	rs7846013	chr8:135569967	C/T	cg17885191	chr8:135476712	NA	0.41	5.8	0.3	1.56e-8	Hypertension (SNP x SNP interaction);
CRC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.67	11.72	0.54	9.53e-27	Height;
CRC	cis	rs2298450	1.000	rs2298450	chr21:37623447	C/T	cg02919814	chr21:37666008	DOPEY2	-0.4	-5.97	-0.31	6.32e-9	Schizophrenia;
CRC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg08270630	chr22:50330655	NA	-0.4	-5.63	-0.3	3.78e-8	Schizophrenia;
CRC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.52	7.12	0.37	6.7e-12	Obesity-related traits;
CRC	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg15644404	chr18:77186268	NFATC1	-0.83	-6.41	-0.33	5.05e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs524281	0.861	rs2889313	chr11:65966066	G/C	cg16950941	chr11:66035639	RAB1B	-0.62	-7.59	-0.39	3.28e-13	Electroencephalogram traits;
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.66	-8.96	-0.44	2.38e-17	Systemic lupus erythematosus;
CRC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.14	-0.32	2.44e-9	Gout;Renal underexcretion gout;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.69	0.3	2.82e-8	Cardiac Troponin-T levels;
CRC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg15147215	chr3:52552868	STAB1	-0.53	-9.22	-0.45	3.79e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs8032158	0.963	rs12102020	chr15:56125578	G/A	cg02198044	chr15:56286336	NEDD4	-0.39	-6.04	-0.32	4.06e-9	Keloid;
CRC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.32	-5.62	-0.3	4.02e-8	Heart rate;
CRC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.77	-10.76	-0.51	2.5e-23	Cognitive function;
CRC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.77	11.59	0.54	2.75e-26	Neutrophil percentage of white cells;
CRC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.49	7.67	0.39	2.01e-13	Corneal astigmatism;
CRC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.57	-0.47	2.61e-19	Heart rate;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01560739	chr3:32023198	OSBPL10;ZNF860	-0.39	-5.98	-0.31	5.78e-9	Myopia (pathological);
CRC	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.49	-6.88	-0.35	2.98e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	10.27	0.49	1.21e-21	Total cholesterol levels;
CRC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.34	6.24	0.33	1.36e-9	Menarche (age at onset);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-6.57	-0.34	1.95e-10	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12128876	chr20:46131028	NCOA3	0.4	6.24	0.33	1.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg11901034	chr3:128598214	ACAD9	-0.53	-6.27	-0.33	1.13e-9	IgG glycosylation;
CRC	cis	rs6662572	0.737	rs4660901	chr1:46445257	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.7	-0.3	2.71e-8	Blood protein levels;
CRC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.51	-7.71	-0.39	1.5e-13	Serum sulfate level;
CRC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg08075719	chr14:103021372	NA	-0.68	-7.94	-0.4	3.23e-14	Platelet count;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg09414045	chr1:110162465	AMPD2	0.56	6.44	0.33	4.16e-10	Body mass index;
CRC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.58	7.65	0.39	2.27e-13	IgG glycosylation;
CRC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.16	0.32	2.16e-9	Rheumatoid arthritis;
CRC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.57	-9.47	-0.46	5.6e-19	Body mass index;
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.47e-10	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03311606	chr2:173292277	ITGA6	0.46	6.33	0.33	7.82e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00388479	chr19:47354305	AP2S1	0.5	7.03	0.36	1.16e-11	Response to antipsychotic treatment;
CRC	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.61	9.99	0.48	1.05e-20	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg12964065	chr18:77638022	KCNG2	0.62	6.64	0.34	1.27e-10	Opioid sensitivity;
CRC	cis	rs747650	0.892	rs1976143	chr11:47225534	G/A	cg19486271	chr11:47235900	DDB2	-0.51	-7.71	-0.39	1.54e-13	Acne (severe);
CRC	trans	rs4714291	0.862	rs2984433	chr6:39973445	T/G	cg02267698	chr19:7991119	CTXN1	-0.48	-6.5	-0.34	2.9e-10	Strep throat;
CRC	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg11900509	chr10:81946545	ANXA11	-0.72	-7.26	-0.37	2.88e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9311676	0.656	rs11712139	chr3:58384775	C/T	cg06643156	chr3:58380774	PXK	0.41	6.26	0.33	1.18e-9	Systemic lupus erythematosus;
CRC	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.81	-0.31	1.48e-8	Response to antipsychotic treatment;
CRC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.76	9.74	0.47	7.11e-20	Monocyte percentage of white cells;
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg13957321	chr17:43675089	NA	0.49	6.15	0.32	2.22e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.57	-9.83	-0.48	3.73e-20	Breast cancer;
CRC	cis	rs2160860	0.773	rs7839881	chr8:39799228	G/A	cg11363097	chr8:39792086	IDO2	-0.42	-7.27	-0.37	2.68e-12	Blood metabolite levels;
CRC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg24300038	chr13:113819356	PROZ	0.49	6.47	0.34	3.58e-10	Platelet distribution width;
CRC	cis	rs939584	1.000	rs4854344	chr2:638144	G/T	cg03610516	chr2:642275	NA	0.42	5.98	0.31	5.93e-9	Body mass index;
CRC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00338735	chr4:53728038	RASL11B	0.46	6.17	0.32	1.95e-9	Optic nerve measurement (cup area);
CRC	trans	rs6956675	0.915	rs7787116	chr7:62654060	G/A	cg01314568	chr7:57830625	NA	-0.62	-8.88	-0.44	4.41e-17	Obesity-related traits;
CRC	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg22495460	chr2:25135724	ADCY3	-0.87	-14.69	-0.63	6.35e-38	Body mass index;
CRC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg02527881	chr3:46936655	PTH1R	0.33	5.89	0.31	9.44e-9	Colorectal cancer;
CRC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.8	10.66	0.51	5.61e-23	Cerebrospinal P-tau181p levels;
CRC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.57	8.56	0.43	4.54e-16	Blood protein levels;
CRC	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.76	9.16	0.45	5.84e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.54	7.57	0.39	3.81e-13	Testicular germ cell tumor;
CRC	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.67	0.3	3.15e-8	Heart rate;
CRC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.45	6.19	0.32	1.8e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22691340	chr12:62997631	C12orf61	0.37	6.13	0.32	2.47e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.63	10.26	0.49	1.26e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg00601450	chr5:74908170	NA	0.41	5.94	0.31	7.09e-9	Age-related disease endophenotypes;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.76	11.43	0.53	1.01e-25	Menarche (age at onset);
CRC	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.36	6.42	0.33	4.84e-10	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.86e-19	Prevalent atrial fibrillation;
CRC	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg13919466	chr1:32135498	COL16A1	-0.31	-5.89	-0.31	9.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.737	rs72677533	chr1:46536558	T/C	cg08644498	chr1:46502608	NA	0.45	7.25	0.37	3.09e-12	Blood protein levels;
CRC	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.56	8.86	0.44	5.09e-17	Ulcerative colitis;
CRC	cis	rs6772849	0.662	rs12494372	chr3:128401693	A/C	cg08795948	chr3:128337044	NA	0.35	5.79	0.3	1.63e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg17470449	chr10:769945	NA	0.5	7.23	0.37	3.5e-12	Uric acid levels;
CRC	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg06632207	chr12:54070931	ATP5G2	0.4	6.91	0.36	2.6e-11	Height;
CRC	cis	rs860295	0.812	rs6657670	chr1:155787867	C/T	cg02153340	chr1:155202674	NA	-0.52	-6.21	-0.32	1.57e-9	Body mass index;
CRC	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	cis	rs61160187	0.582	rs11740632	chr5:60141245	G/A	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.8	-0.3	1.58e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.58	7.08	0.36	8.66e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg06484146	chr7:12443880	VWDE	-0.56	-7.22	-0.37	3.67e-12	Coronary artery disease;
CRC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg11271282	chr2:238384023	NA	0.44	5.73	0.3	2.26e-8	Prostate cancer;
CRC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.37	5.79	0.3	1.64e-8	Height;
CRC	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg21153622	chr11:89784906	NA	-0.45	-7.18	-0.37	4.68e-12	HDL cholesterol;
CRC	trans	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs6586163	0.872	rs1926197	chr10:90748626	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.21	-0.37	3.77e-12	Chronic lymphocytic leukemia;
CRC	trans	rs56823429	0.634	rs2966097	chr16:81549708	A/G	cg26655873	chr3:72818019	SHQ1	0.44	6.05	0.32	3.88e-9	HDL cholesterol;
CRC	cis	rs7781266	0.793	rs2991227	chr7:133283772	A/T	cg03336402	chr7:133662267	EXOC4	0.49	5.75	0.3	1.99e-8	Educational attainment (college completion);
CRC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	11.25	0.53	4.77e-25	Menopause (age at onset);
CRC	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.35	-0.38	1.6e-12	QT interval;
CRC	cis	rs6564851	0.506	rs72831377	chr16:81257141	A/T	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.65	-0.3	3.43e-8	Carotenoid and tocopherol levels;
CRC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	13.83	0.61	1.26e-34	Platelet count;
CRC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	13.6	0.6	9.82e-34	Schizophrenia;
CRC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	7.2	0.37	4e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs7737355	0.673	rs26006	chr5:130982768	A/G	cg25547332	chr5:131281432	NA	0.36	5.75	0.3	2.06e-8	Life satisfaction;
CRC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg21798802	chr22:38057573	PDXP	0.35	5.62	0.3	3.99e-8	Fat distribution (HIV);
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.71	0.51	3.81e-23	Prudent dietary pattern;
CRC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.49	9.1	0.45	8.64e-18	Iron status biomarkers (transferrin levels);
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg14004847	chr7:1930337	MAD1L1	0.41	5.67	0.3	3.2e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10779184	chr7:92462706	CDK6	0.37	6.2	0.32	1.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.61	7.18	0.37	4.75e-12	Lymphocyte counts;
CRC	trans	rs2303319	0.504	rs62187613	chr2:162434474	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.02	-0.31	4.72e-9	Cognitive function;
CRC	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.48	5.68	0.3	2.98e-8	QRS duration;
CRC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.38	7.23	0.37	3.35e-12	Tonsillectomy;
CRC	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.62	9.68	0.47	1.13e-19	Crohn's disease;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg19041857	chr6:27730383	NA	-0.61	-6.8	-0.35	4.94e-11	Lung cancer in ever smokers;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25220896	chr1:11004296	NA	-0.44	-5.99	-0.31	5.43e-9	Diisocyanate-induced asthma;
CRC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.06	10.59	0.5	9.22e-23	Diabetic retinopathy;
CRC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg03732007	chr1:2071316	PRKCZ	-0.36	-5.64	-0.3	3.74e-8	Height;
CRC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.97	-0.36	1.79e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.92	0.4	3.66e-14	Platelet count;
CRC	cis	rs1178968	1.000	rs3108462	chr7:72739455	T/C	cg25889504	chr7:72793014	NA	0.53	6.04	0.32	4.16e-9	Triglyceride levels;
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-8.31	-0.42	2.48e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.5	8.62	0.43	2.89e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	6.24	0.33	1.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	8.18	0.41	6.07e-15	Height;
CRC	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.68	-10.11	-0.49	4.06e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13284007	chr3:53381865	DCP1A	0.41	6.09	0.32	3.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.85	0.68	2.34e-46	Platelet count;
CRC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.81	14.73	0.63	4.66e-38	Anterior chamber depth;
CRC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.54	6.65	0.34	1.21e-10	Vitiligo;
CRC	cis	rs1865063	1.000	rs1865063	chr19:11341029	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.9	9.17	0.45	5.38e-18	HDL cholesterol levels;
CRC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.52	-9.2	-0.45	4.27e-18	Schizophrenia;
CRC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.47	-5.86	-0.31	1.14e-8	Gut microbiome composition (summer);
CRC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.96	-0.36	1.87e-11	Morning vs. evening chronotype;
CRC	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.0	0.64	4.16e-39	Bipolar disorder;
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg19913688	chr11:428466	ANO9	-0.69	-7.09	-0.36	8.4e-12	Body mass index;
CRC	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.4	-6.63	-0.34	1.38e-10	Airway imaging phenotypes;
CRC	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg24289452	chr6:170231220	NA	-0.99	-8.06	-0.41	1.46e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg10542027	chr5:78532229	JMY	-0.41	-6.38	-0.33	6.12e-10	Daytime sleep phenotypes;
CRC	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	9.79	0.47	4.91e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.53	-8.55	-0.43	4.8e-16	Aortic root size;
CRC	trans	rs800082	0.839	rs11714177	chr3:144312862	T/C	cg24215973	chr2:240111563	HDAC4	-0.54	-6.89	-0.36	2.83e-11	Smoking behavior;
CRC	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	0.79	8.09	0.41	1.18e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	8.53	0.43	5.46e-16	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20659025	chr11:126173961	DCPS	0.39	6.16	0.32	2.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7703744	0.634	rs112352373	chr5:118687625	C/G	cg23985447	chr5:118691066	TNFAIP8	0.4	5.63	0.3	3.87e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17234274	0.644	rs10833966	chr11:23214937	C/G	cg05245346	chr11:23248277	NA	0.37	6.1	0.32	3.04e-9	Cancer;
CRC	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11446398	chr5:77624930	NA	0.46	6.27	0.33	1.14e-9	Triglycerides;
CRC	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.11	-0.32	2.86e-9	Monocyte count;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.96	-0.44	2.53e-17	Bipolar disorder;
CRC	trans	rs12699921	0.598	rs2723505	chr7:17854849	C/T	cg02066331	chr6:17282778	RBM24	-0.35	-6.1	-0.32	2.9e-9	Fibrinogen levels;
CRC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.08e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-8.55	-0.43	4.74e-16	Menarche (age at onset);
CRC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.87	-14.46	-0.62	5.11e-37	Blood metabolite levels;
CRC	cis	rs10503871	0.690	rs7840384	chr8:30349914	A/G	cg26383811	chr8:30366931	RBPMS	0.49	7.79	0.39	8.93e-14	Metabolite levels  (X-11787);
CRC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.38	-0.33	5.85e-10	Blood metabolite levels;
CRC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.16	-0.37	5.45e-12	Height;
CRC	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.46	7.18	0.37	4.55e-12	Platelet count;
CRC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.15	0.32	2.26e-9	Asthma;
CRC	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg12501888	chr15:85177176	SCAND2	-0.37	-5.93	-0.31	7.57e-9	P wave terminal force;
CRC	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.76	-0.3	1.98e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.46	9.38	0.46	1.08e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.43	-6.66	-0.34	1.17e-10	Hemoglobin concentration;
CRC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.69	-0.3	2.87e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.58	8.7	0.43	1.58e-16	High light scatter reticulocyte count;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg21251018	chr6:28226885	NKAPL	0.51	5.98	0.31	5.84e-9	Depression;
CRC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.41	5.63	0.3	3.93e-8	Eosinophil percentage of white cells;
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg27635394	chr6:26043820	HIST1H2BB	0.4	5.97	0.31	6.09e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg18335740	chr13:41363409	SLC25A15	-0.52	-7.73	-0.39	1.34e-13	Lewy body disease;
CRC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.86	-14.51	-0.62	3.15e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs972578	1.000	rs738389	chr22:43332516	T/C	cg01576275	chr22:43409880	NA	-0.44	-7.09	-0.36	8.01e-12	Mean platelet volume;
CRC	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg14191688	chr11:70257035	CTTN	0.52	6.49	0.34	3.11e-10	Coronary artery disease;
CRC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.85	-13.11	-0.59	7.08e-32	Blood metabolite levels;
CRC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.52	0.38	5.26e-13	Aortic root size;
CRC	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg20542592	chr8:11973495	FAM66D	0.32	5.69	0.3	2.81e-8	Retinal vascular caliber;
CRC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg25204440	chr1:209979598	IRF6	0.5	6.58	0.34	1.9e-10	Cleft lip with or without cleft palate;
CRC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg04155289	chr7:94953770	PON1	-0.59	-7.29	-0.37	2.26e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg26875233	chr11:93583750	C11orf90	0.31	5.9	0.31	9.1e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg19041857	chr6:27730383	NA	-0.46	-6.03	-0.32	4.35e-9	Breast cancer;
CRC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg13844804	chr7:814759	HEATR2	0.61	8.04	0.41	1.61e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs2732480	0.967	rs2732469	chr12:48712932	T/A	cg21466736	chr12:48725269	NA	-0.48	-7.41	-0.38	1.06e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7429990	0.965	rs4858810	chr3:48043737	G/A	cg11946769	chr3:48343235	NME6	-0.5	-6.34	-0.33	7.42e-10	Educational attainment (years of education);
CRC	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.29	6.03	0.32	4.49e-9	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10744248	chr7:76009385	NA	0.43	6.04	0.32	4.12e-9	Response to antipsychotic treatment;
CRC	cis	rs11212617	0.967	rs4753833	chr11:108057430	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.7	0.3	2.71e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.92	-0.36	2.31e-11	IgG glycosylation;
CRC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg26061582	chr7:22766209	IL6	0.5	8.0	0.4	2.17e-14	Lung cancer;
CRC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.57	0.57	7.11e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.7	10.82	0.51	1.47e-23	Corneal astigmatism;
CRC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.65	-11.68	-0.54	1.32e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	5.74	0.3	2.18e-8	Electroencephalogram traits;
CRC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.46	5.77	0.3	1.83e-8	Aortic root size;
CRC	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg13385794	chr1:248469461	NA	0.37	6.58	0.34	1.88e-10	Common traits (Other);
CRC	trans	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	7.27	0.37	2.64e-12	Ulcerative colitis;
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg15790184	chr11:494944	RNH1	0.57	5.71	0.3	2.59e-8	Body mass index;
CRC	cis	rs12476592	0.602	rs171901	chr2:63901700	C/G	cg10828910	chr2:63850056	LOC388955	-0.5	-6.29	-0.33	1.02e-9	Childhood ear infection;
CRC	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg16898833	chr6:26189333	HIST1H4D	0.76	6.57	0.34	2e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.76	-0.39	1.09e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg03623178	chr6:28175578	NA	0.77	6.69	0.35	9.81e-11	Depression;
CRC	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg02527881	chr3:46936655	PTH1R	0.36	6.37	0.33	6.24e-10	Colorectal cancer;
CRC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.26	-0.33	1.2e-9	Lung cancer;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.68	11.35	0.53	1.98e-25	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.55	-7.79	-0.39	8.78e-14	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg21620606	chr4:1342894	KIAA1530	0.38	6.45	0.33	4.07e-10	Obesity-related traits;
CRC	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-7.45	-0.38	8.18e-13	Schizophrenia;
CRC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg10298567	chr3:47292165	KIF9	0.39	6.13	0.32	2.46e-9	Colorectal cancer;
CRC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.02	-0.36	1.31e-11	IgG glycosylation;
CRC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00495681	chr13:53174319	NA	0.54	7.88	0.4	4.93e-14	Lewy body disease;
CRC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.59	-8.5	-0.42	6.54e-16	Platelet distribution width;
CRC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.6	8.14	0.41	8.07e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg03037974	chr15:76606532	NA	-0.52	-7.31	-0.37	2.04e-12	Blood metabolite levels;
CRC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-14.65	-0.63	9.16e-38	Height;
CRC	trans	rs6479874	0.681	rs9415727	chr10:52886136	G/T	cg20384632	chr7:106508080	PIK3CG	-0.47	-5.96	-0.31	6.48e-9	Migraine;
CRC	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg04239562	chr7:158767014	NA	0.36	5.66	0.3	3.23e-8	Facial morphology (factor 20);
CRC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.65	-12.16	-0.56	2.29e-28	Prostate cancer;
CRC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.53	-8.86	-0.44	4.96e-17	Menarche (age at onset);
CRC	cis	rs4728302	0.869	rs6966403	chr7:133614421	A/C	cg03336402	chr7:133662267	EXOC4	0.41	5.94	0.31	7.18e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg01629716	chr15:45996671	NA	0.41	8.42	0.42	1.19e-15	Waist circumference;Weight;
CRC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.72	10.31	0.49	8.65e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg07404485	chr7:94953653	PON1	-0.47	-6.14	-0.32	2.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg26587870	chr6:27730563	NA	-0.36	-5.62	-0.3	4.14e-8	Cardiac Troponin-T levels;
CRC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.47	-8.5	-0.42	6.64e-16	Prostate cancer;
CRC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.96	0.61	4.23e-35	Prudent dietary pattern;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.83	0.35	4.11e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07404363	chr5:112197029	SRP19	0.39	6.15	0.32	2.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9491140	0.539	rs11755888	chr6:124693042	A/G	cg05308643	chr6:124982296	NKAIN2	0.51	6.83	0.35	4.05e-11	Neuroticism;
CRC	cis	rs10944	0.598	rs688286	chr5:78276665	G/A	cg13121490	chr5:78280331	ARSB	-0.44	-6.31	-0.33	9.23e-10	Blood and toenail selenium levels;
CRC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.53e-10	Response to antipsychotic treatment;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-8.93	-0.44	3.17e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-18.86	-0.72	2.59e-54	Height;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg21251018	chr6:28226885	NKAPL	0.42	5.96	0.31	6.51e-9	Parkinson's disease;
CRC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.39	-0.69	1.75e-48	Body mass index;
CRC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24308560	chr3:49941425	MST1R	-0.49	-7.65	-0.39	2.21e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.48	7.08	0.36	8.6e-12	Menarche (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26335527	chr1:155100185	EFNA1	0.45	6.2	0.32	1.65e-9	Anxiety disorder;
CRC	trans	rs6066835	0.572	rs6125413	chr20:47257145	G/A	cg21109867	chr19:55897418	RPL28	-0.84	-6.29	-0.33	1.01e-9	Multiple myeloma;
CRC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg00579200	chr11:133705235	NA	0.42	6.18	0.32	1.93e-9	Childhood ear infection;
CRC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg19193384	chr17:30244184	NA	-0.66	-7.6	-0.39	3.18e-13	Hip circumference adjusted for BMI;
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.11e-22	Prudent dietary pattern;
CRC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.12	-0.41	9.45e-15	Morning vs. evening chronotype;
CRC	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14119001	chr9:139324193	INPP5E	-0.45	-6.39	-0.33	5.69e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs73200209	0.912	rs10507268	chr12:116540227	G/A	cg01776926	chr12:116560359	MED13L	-0.51	-6.27	-0.33	1.11e-9	Total body bone mineral density;
CRC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.96	0.31	6.55e-9	Bladder cancer;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22710661	chr11:17411071	KCNJ11	0.54	6.06	0.32	3.7e-9	Interleukin-4 levels;
CRC	cis	rs6764363	0.587	rs459980	chr3:285569	A/G	cg02057681	chr3:285234	CHL1	-0.44	-7.59	-0.39	3.29e-13	Sudden cardiac arrest;
CRC	cis	rs4728302	0.869	rs2042456	chr7:133580447	G/A	cg03336402	chr7:133662267	EXOC4	-0.43	-6.15	-0.32	2.23e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.49	-6.05	-0.32	3.93e-9	Coronary artery calcification;
CRC	cis	rs6694672	1.000	rs2026429	chr1:197079671	A/C	cg13682187	chr1:196946512	CFHR5	-0.46	-7.74	-0.39	1.25e-13	Asthma;
CRC	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.02	0.31	4.69e-9	Asthma;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.53	-9.92	-0.48	1.77e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg21251018	chr6:28226885	NKAPL	0.45	6.89	0.36	2.83e-11	Parkinson's disease;
CRC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.4	6.1	0.32	2.96e-9	Lung cancer;
CRC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg04719120	chr6:96025338	MANEA	0.59	6.72	0.35	8.02e-11	Behavioural disinhibition (generation interaction);
CRC	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.52	-9.33	-0.46	1.59e-18	Common traits (Other);
CRC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	2.94e-11	Glioblastoma;
CRC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg15832292	chr6:96025679	MANEA	0.61	6.63	0.34	1.41e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs10905065	0.610	rs4748307	chr10:5747701	C/T	cg11519256	chr10:5708881	ASB13	-0.44	-6.04	-0.32	4.21e-9	Menopause (age at onset);
CRC	cis	rs3736485	0.868	rs4774597	chr15:51919656	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.38	-0.33	6.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg25459000	chr22:39777742	SYNGR1	-0.34	-6.05	-0.32	3.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg01304814	chr3:48885189	PRKAR2A	0.9	6.38	0.33	6.15e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg03623178	chr6:28175578	NA	0.97	12.38	0.56	3.55e-29	Depression;
CRC	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.78	-12.69	-0.57	2.61e-30	Ear protrusion;
CRC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14193886	chr22:30642728	LIF	0.45	6.55	0.34	2.19e-10	Response to antipsychotic treatment;
CRC	cis	rs7712401	0.791	rs6872932	chr5:122145636	A/G	cg18764291	chr5:122110994	SNX2	0.39	6.11	0.32	2.74e-9	Mean platelet volume;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00166722	chr3:10149974	C3orf24	0.61	7.88	0.4	4.95e-14	Alzheimer's disease;
CRC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.7	0.35	8.92e-11	Coronary artery disease;
CRC	trans	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg04077850	chr5:125800366	GRAMD3	0.38	6.2	0.32	1.73e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1864585	0.520	rs73208785	chr8:10678120	T/C	cg26278703	chr11:58910052	FAM111A	0.55	6.39	0.33	5.72e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs231513	0.911	rs124719	chr17:41960343	T/C	cg26893861	chr17:41843967	DUSP3	-0.65	-6.53	-0.34	2.46e-10	Cognitive function;
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg18876405	chr7:65276391	NA	0.46	6.26	0.33	1.21e-9	Aortic root size;
CRC	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg22903471	chr2:27725779	GCKR	-0.34	-5.64	-0.3	3.62e-8	Oral cavity cancer;
CRC	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg16964102	chr10:135390573	NA	-0.49	-6.88	-0.35	3.09e-11	Gout;
CRC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.69	-0.3	2.87e-8	Migraine;Coronary artery disease;
CRC	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.38	-5.64	-0.3	3.67e-8	Growth-regulated protein alpha levels;
CRC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06505273	chr16:24850292	NA	0.53	6.53	0.34	2.48e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	-0.53	-9.0	-0.44	1.8e-17	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.58	-10.13	-0.49	3.47e-21	Iron status biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00562905	chr17:42634144	FZD2	0.47	6.6	0.34	1.63e-10	Response to antipsychotic treatment;
CRC	cis	rs4664293	0.967	rs7597482	chr2:160547091	T/A	cg08347373	chr2:160653686	CD302	-0.38	-6.18	-0.32	1.9e-9	Monocyte percentage of white cells;
CRC	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs1552172	0.853	rs4970859	chr1:145605318	A/G	cg11743829	chr1:145714124	CD160	0.41	6.25	0.33	1.26e-9	Breast cancer;
CRC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.71	-0.43	1.52e-16	Intelligence (multi-trait analysis);
CRC	cis	rs10746514	0.833	rs11122428	chr1:232261417	A/G	cg09506761	chr1:232265262	NA	-0.47	-6.79	-0.35	5.33e-11	Response to statin therapy;
CRC	cis	rs12630931	0.929	rs11708350	chr3:31983244	A/G	cg21375017	chr3:31988082	OSBPL10	0.43	5.79	0.3	1.6e-8	Periodontal disease-related phenotypes;
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	6.11	0.32	2.89e-9	Life satisfaction;
CRC	trans	rs6902257	0.744	rs2496683	chr6:81329501	T/C	cg16210497	chr6:85474188	TBX18	0.6	6.05	0.32	3.89e-9	Obesity-related traits;
CRC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.48	9.21	0.45	3.8e-18	Renal cell carcinoma;
CRC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.5	6.23	0.32	1.46e-9	Recombination rate (females);
CRC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.45	-8.62	-0.43	2.91e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.69	11.26	0.53	4.28e-25	Osteoporosis;
CRC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.71	-0.35	8.48e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg09127314	chr1:152161683	NA	0.51	6.52	0.34	2.66e-10	Atopic dermatitis;
CRC	cis	rs9826463	0.582	rs73238152	chr3:142071081	C/T	cg20824294	chr3:142316082	PLS1	0.36	5.73	0.3	2.32e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-5.64	-0.3	3.76e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.99	0.48	1.07e-20	Platelet count;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg02683197	chr6:28174875	NA	0.66	8.65	0.43	2.3e-16	Parkinson's disease;
CRC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg08896387	chr1:24191740	FUCA1	0.51	6.75	0.35	6.58e-11	Immature fraction of reticulocytes;
CRC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.76	10.13	0.49	3.67e-21	Height;
CRC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.58	-9.79	-0.47	5.12e-20	Intelligence (multi-trait analysis);
CRC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.52	8.07	0.41	1.37e-14	Breast cancer;
CRC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.42	5.84	0.31	1.28e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.64	10.06	0.49	6.01e-21	Body mass index;
CRC	cis	rs4716602	0.596	rs10258969	chr7:156157753	A/G	cg16983916	chr7:156159713	NA	-0.39	-6.92	-0.36	2.36e-11	Anti-saccade response;
CRC	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.44	6.11	0.32	2.75e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12760731	0.623	rs6701584	chr1:178290509	C/T	cg00404053	chr1:178313656	RASAL2	0.7	8.89	0.44	4.09e-17	Obesity-related traits;
CRC	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.86	-0.48	2.81e-20	Blood protein levels;
CRC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.42	0.33	4.82e-10	Renal cell carcinoma;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03871162	chr6:17611359	FAM8A1	0.31	6.11	0.32	2.85e-9	Hip circumference;
CRC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.57	9.82	0.48	4e-20	Age at first birth;
CRC	cis	rs6060717	0.702	rs6060756	chr20:34608479	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.4	6.38	0.33	6.1e-10	Hip circumference adjusted for BMI;
CRC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	0.77	8.59	0.43	3.61e-16	Gout;Renal underexcretion gout;
CRC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg24300038	chr13:113819356	PROZ	-0.47	-5.86	-0.31	1.13e-8	Platelet distribution width;
CRC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.56	8.23	0.41	4.44e-15	Melanoma;
CRC	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.3	5.66	0.3	3.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.4	-5.66	-0.3	3.23e-8	Uric acid clearance;
CRC	cis	rs7737355	0.853	rs6596024	chr5:130769785	A/C	cg25547332	chr5:131281432	NA	0.36	5.69	0.3	2.82e-8	Life satisfaction;
CRC	trans	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg02671819	chr17:62778370	LOC146880	-0.46	-6.11	-0.32	2.79e-9	Menarche (age at onset);
CRC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.41	7.5	0.38	6.19e-13	Bipolar disorder;
CRC	trans	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg14063357	chr9:79793314	VPS13A;LOC100286938	0.6	6.19	0.32	1.83e-9	Iron status biomarkers;
CRC	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg05283184	chr6:79620031	NA	-0.45	-6.44	-0.33	4.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg12183467	chr14:104352244	NA	-0.52	-7.01	-0.36	1.34e-11	Bipolar disorder;
CRC	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11645453	chr3:52864694	ITIH4	0.4	7.44	0.38	8.58e-13	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24662107	chr5:139135835	NA	0.43	6.11	0.32	2.74e-9	Anxiety disorder;
CRC	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.77	-16.17	-0.67	1.04e-43	Leprosy;
CRC	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.91	11.21	0.53	6.36e-25	Orofacial clefts;
CRC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.69	0.57	2.66e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg09582351	chr12:29534625	ERGIC2	-0.28	-6.02	-0.31	4.66e-9	QT interval;
CRC	cis	rs12024301	0.557	rs115277680	chr1:183614362	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg18722847	chr3:44754129	ZNF502	-0.34	-5.63	-0.3	3.82e-8	Depressive symptoms;
CRC	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.76	-10.46	-0.5	2.65e-22	White matter hyperintensity burden;
CRC	cis	rs6988985	0.728	rs7003782	chr8:143974828	C/T	cg10324643	chr8:143916377	GML	0.39	6.4	0.33	5.45e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg17545662	chr6:170176663	C6orf70	0.56	6.45	0.34	3.94e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs4290604	0.748	rs10164697	chr2:238032560	G/A	cg23555395	chr2:238036564	NA	-0.66	-6.71	-0.35	8.36e-11	Asthma;
CRC	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.47	-7.03	-0.36	1.21e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CRC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.09	-0.32	3.12e-9	Axial length;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.57	-8.52	-0.43	5.74e-16	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27114727	chr14:74227186	C14orf43	0.38	6.04	0.32	4.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.45	-6.46	-0.34	3.66e-10	Type 2 diabetes;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.35	-0.59	9.02e-33	Alzheimer's disease;
CRC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg06634786	chr22:41940651	POLR3H	-0.47	-6.13	-0.32	2.44e-9	Neuroticism;
CRC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.51	-8.34	-0.42	2.03e-15	Schizophrenia;
CRC	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg11887960	chr12:57824829	NA	0.66	7.1	0.36	7.76e-12	Obesity-related traits;
CRC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-8.19	-0.41	5.93e-15	Axial length;
CRC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg24675056	chr1:15929824	NA	0.52	6.9	0.36	2.64e-11	Systolic blood pressure;
CRC	cis	rs447	0.945	rs4141151	chr7:83737361	A/G	cg22846510	chr7:83753280	SEMA3A	-0.55	-6.93	-0.36	2.28e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.17	-0.32	2.02e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.39	0.5	4.64e-22	Mean corpuscular volume;
CRC	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.22e-13	QT interval;
CRC	cis	rs10426930	0.621	rs6510833	chr19:5008399	G/A	cg18473234	chr19:5097819	KDM4B	0.59	6.32	0.33	8.28e-10	Monocyte percentage of white cells;
CRC	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.52	6.58	0.34	1.8e-10	Exhaled nitric oxide output;
CRC	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.9	-11.45	-0.53	8.8e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs10242455	0.702	rs73397481	chr7:99030108	C/T	cg18809830	chr7:99032528	PTCD1	-1.19	-8.57	-0.43	4.21e-16	Blood metabolite levels;
CRC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.0	0.52	3.58e-24	Monocyte percentage of white cells;
CRC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.91	-11.3	-0.53	3.11e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs2569991	0.636	rs2600222	chr3:12937617	C/G	cg22481960	chr3:13008800	IQSEC1	-0.51	-6.3	-0.33	9.63e-10	Periodontitis (DPAL);
CRC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg14671364	chr1:107599128	PRMT6	0.55	7.42	0.38	1e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.7	9.59	0.47	2.33e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg12172441	chr6:28176163	NA	0.42	5.73	0.3	2.29e-8	Parkinson's disease;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.4	6.24	0.33	1.35e-9	Hemoglobin concentration;
CRC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.92	15.42	0.65	9.76e-41	Height;
CRC	trans	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg02936872	chr9:99801550	CTSL2	0.47	6.13	0.32	2.48e-9	Iron status biomarkers;
CRC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.18	-0.37	4.61e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.41e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg07426533	chr8:59803705	TOX	-0.32	-5.61	-0.3	4.27e-8	Pneumonia;
CRC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs860295	0.651	rs6677385	chr1:155304581	C/A	cg02153340	chr1:155202674	NA	-0.51	-6.24	-0.33	1.36e-9	Body mass index;
CRC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	8.15	0.41	7.77e-15	Menarche (age at onset);
CRC	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg08975724	chr8:8085496	FLJ10661	0.45	6.38	0.33	5.96e-10	Schizophrenia;
CRC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.46	0.71	9.75e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23151374	chr4:164415611	C4orf43	0.51	6.66	0.34	1.12e-10	Thyroid stimulating hormone;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19082920	chr1:202830751	LOC148709	0.43	6.19	0.32	1.84e-9	Response to antipsychotic treatment;
CRC	cis	rs9463078	0.550	rs7769231	chr6:45284921	A/G	cg25276700	chr6:44698697	NA	-0.25	-6.02	-0.31	4.74e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.68	0.65	9.43e-42	Lymphocyte percentage of white cells;
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.83	-0.58	7.64e-31	Alzheimer's disease;
CRC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.91	17.05	0.69	3.57e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.81	14.27	0.62	2.66e-36	Vitiligo;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00619347	chr3:149688574	PFN2	0.36	6.0	0.31	5.1e-9	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25623535	chr19:41196524	NUMBL	0.47	6.66	0.34	1.16e-10	Anxiety disorder;
CRC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.31	6.05	0.32	4.02e-9	Personality dimensions;
CRC	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.44	-0.38	8.88e-13	HDL cholesterol;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06463010	chr2:42795624	MTA3	-0.42	-6.27	-0.33	1.12e-9	Myopia (pathological);
CRC	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	1.07	11.84	0.55	3.54e-27	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.89	-11.28	-0.53	3.61e-25	Hair shape;
CRC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.48	-8.23	-0.41	4.55e-15	Facial morphology (factor 20);
CRC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.62	11.01	0.52	3.29e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.2	-0.37	4.03e-12	Eye color traits;
CRC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg15123519	chr2:136567270	LCT	0.31	5.9	0.31	9.24e-9	Mosquito bite size;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg06470822	chr6:28175283	NA	0.64	9.43	0.46	7.89e-19	Cardiac Troponin-T levels;
CRC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg23815491	chr16:72088622	HP	0.54	8.13	0.41	8.69e-15	Fibrinogen levels;
CRC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.12	-0.37	7.03e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05873873	chr17:30771297	PSMD11	0.43	6.04	0.32	4.12e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.93	11.22	0.53	5.92e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg09659197	chr4:152720779	NA	-0.41	-8.15	-0.41	7.55e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg00631329	chr6:26305371	NA	-0.56	-9.48	-0.46	5.3e-19	Educational attainment;
CRC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.38	6.15	0.32	2.2e-9	Major depressive disorder;
CRC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.59	6.52	0.34	2.68e-10	Skin colour saturation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17129141	chr2:47629949	MSH2	0.45	6.32	0.33	8.34e-10	Response to antipsychotic treatment;
CRC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg17724175	chr1:150552817	MCL1	0.46	6.99	0.36	1.55e-11	Melanoma;
CRC	cis	rs10486722	0.651	rs10951655	chr7:41776877	A/C	cg22138096	chr7:41772439	LOC285954	-0.5	-6.58	-0.34	1.85e-10	Pit-and-Fissure caries;
CRC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.45	-6.47	-0.34	3.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg19875578	chr6:126661172	C6orf173	0.41	5.7	0.3	2.6e-8	Male-pattern baldness;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg00307073	chr7:116502428	CAPZA2	-0.43	-6.28	-0.33	1.08e-9	Daytime sleep phenotypes;
CRC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.49	7.48	0.38	6.71e-13	Methadone dose in opioid dependence;
CRC	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.52	10.02	0.48	8.14e-21	Urate levels in lean individuals;
CRC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.33	-5.92	-0.31	8.24e-9	Rheumatoid arthritis;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.47	7.78	0.39	9.77e-14	Major depressive disorder;
CRC	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg08501292	chr6:25962987	TRIM38	0.84	7.76	0.39	1.1e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.11	0.32	2.82e-9	Vitamin D levels;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg03623178	chr6:28175578	NA	0.75	7.86	0.4	5.45e-14	Depression;
CRC	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.51	-7.54	-0.38	4.54e-13	Response to antidepressants in depression;
CRC	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	5.93	0.31	7.72e-9	Response to antipsychotic treatment;
CRC	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.61	7.17	0.37	5.13e-12	Bitter taste perception;
CRC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.55	8.25	0.41	3.93e-15	Morning vs. evening chronotype;
CRC	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg15212455	chr7:39170539	POU6F2	0.45	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.75	0.43	1.16e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.82	0.44	6.8e-17	Morning vs. evening chronotype;
CRC	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg12193833	chr17:30244370	NA	-0.71	-7.23	-0.37	3.45e-12	Height;
CRC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.1	-0.32	2.94e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-0.84	-8.02	-0.4	1.85e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg08075719	chr14:103021372	NA	-0.7	-9.66	-0.47	1.36e-19	Platelet count;
CRC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.59	-8.95	-0.44	2.63e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg02560186	chr11:3602584	NA	-0.45	-6.12	-0.32	2.64e-9	Blood pressure (smoking interaction);
CRC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.35	5.63	0.3	3.95e-8	Total body bone mineral density;
CRC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.51	8.14	0.41	8.43e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.47	7.4	0.38	1.12e-12	Corneal astigmatism;
CRC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.68	9.35	0.46	1.41e-18	Coronary artery disease;
CRC	cis	rs965469	1.000	rs6051827	chr20:3372007	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.84	-0.31	1.28e-8	IFN-related cytopenia;
CRC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.52	-8.62	-0.43	2.96e-16	Sense of smell;
CRC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.71	-7.34	-0.37	1.74e-12	Schizophrenia;
CRC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg16060761	chr17:80687452	NA	-0.55	-7.95	-0.4	3.08e-14	Glycated hemoglobin levels;
CRC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.24e-19	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.94	-0.31	7.33e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.92	-19.57	-0.73	4.36e-57	Urate levels in lean individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07590406	chr3:58292066	RPP14	0.52	7.54	0.38	4.66e-13	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25109009	chr16:69760305	NQO1	0.45	6.71	0.35	8.42e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	10.72	0.51	3.36e-23	Personality dimensions;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg04969067	chr8:143858791	LYNX1	-0.42	-6.66	-0.34	1.14e-10	Urinary tract infection frequency;
CRC	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-7.04	-0.36	1.16e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs867529	1.000	rs1606803	chr2:88933316	C/T	cg26627705	chr2:89060884	NA	-0.51	-6.48	-0.34	3.35e-10	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06394476	chr2:65454602	ACTR2	0.4	6.23	0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg17724175	chr1:150552817	MCL1	-0.51	-8.22	-0.41	4.74e-15	Tonsillectomy;
CRC	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.71	-0.3	2.56e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.6	8.43	0.42	1.1e-15	Uric acid levels;
CRC	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg10382835	chr6:42185730	MRPS10	0.66	6.5	0.34	2.92e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
CRC	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.68	10.99	0.52	3.93e-24	Cognitive test performance;
CRC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg08501292	chr6:25962987	TRIM38	0.83	6.43	0.33	4.44e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg17633681	chr16:88106987	BANP	0.87	16.24	0.67	5.81e-44	Menopause (age at onset);
CRC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-19.24	-0.73	8.17e-56	Ulcerative colitis;
CRC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.63	-9.26	-0.45	2.81e-18	Menarche (age at onset);
CRC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg09491104	chr22:46646882	C22orf40	-0.48	-7.51	-0.38	5.72e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.54	-0.38	4.67e-13	Hip circumference adjusted for BMI;
CRC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.64	13.5	0.6	2.33e-33	Schizophrenia;
CRC	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.8	8.68	0.43	1.83e-16	Anti-saccade response;
CRC	trans	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg26043149	chr18:55253948	FECH	-0.49	-7.48	-0.38	6.69e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg21302420	chr1:112162376	RAP1A	0.77	6.26	0.33	1.19e-9	Skin colour saturation;
CRC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg19193384	chr17:30244184	NA	-0.65	-7.51	-0.38	5.54e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-10.07	-0.49	5.53e-21	Mood instability;
CRC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.72	-7.81	-0.4	7.98e-14	Psoriasis;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	6.84	0.35	3.84e-11	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs1524976	1.000	rs7612710	chr3:65476581	C/T	cg16238336	chr3:65465873	MAGI1	-0.52	-7.72	-0.39	1.44e-13	PR interval;
CRC	cis	rs7258465	1.000	rs8111708	chr19:18558876	A/G	cg10790698	chr19:18539756	SSBP4	-0.44	-8.12	-0.41	9.46e-15	Breast cancer;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg10596483	chr8:143751796	JRK	-0.5	-6.79	-0.35	5.12e-11	Urinary tract infection frequency;
CRC	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg10437265	chr15:77819839	NA	0.66	11.29	0.53	3.25e-25	Type 2 diabetes;
CRC	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg11887960	chr12:57824829	NA	0.63	6.95	0.36	1.94e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.12	-0.52	1.37e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs501120	1.000	rs501120	chr10:44753867	T/C	cg09554077	chr10:44749378	NA	0.89	13.31	0.59	1.23e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10905065	0.898	rs2892078	chr10:5831138	A/G	cg11519256	chr10:5708881	ASB13	-0.44	-6.27	-0.33	1.11e-9	Menopause (age at onset);
CRC	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg00601450	chr5:74908170	NA	0.49	6.12	0.32	2.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg26816564	chr1:7831052	VAMP3	0.63	7.65	0.39	2.3e-13	Inflammatory bowel disease;
CRC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.34	-0.38	1.73e-12	Retinal vascular caliber;
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg04155289	chr7:94953770	PON1	-0.6	-7.44	-0.38	8.8e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.07	-28.67	-0.85	1.81e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg07636037	chr3:49044803	WDR6	-0.85	-6.5	-0.34	3.06e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.35	-0.5	6.22e-22	Alzheimer's disease;
CRC	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.61	-8.97	-0.44	2.36e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.76	-0.43	1.08e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs282587	0.502	rs393320	chr13:113396469	C/A	cg04656015	chr13:113407548	ATP11A	0.63	7.8	0.4	8.04e-14	Glycated hemoglobin levels;
CRC	cis	rs3823572	0.504	rs2346266	chr7:133639533	A/G	cg03336402	chr7:133662267	EXOC4	0.66	10.14	0.49	3.29e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg10589385	chr1:150898437	SETDB1	-0.32	-5.71	-0.3	2.46e-8	Urate levels;
CRC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.63	0.39	2.52e-13	Mean platelet volume;
CRC	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.97	11.02	0.52	3.12e-24	Mitochondrial DNA levels;
CRC	cis	rs6840360	0.558	rs2709821	chr4:152342190	C/T	cg09659197	chr4:152720779	NA	0.35	6.96	0.36	1.89e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg15465823	chr12:48382534	COL2A1	-0.38	-6.17	-0.32	2.04e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg19773385	chr1:10388646	KIF1B	-0.62	-9.42	-0.46	8.14e-19	Hepatocellular carcinoma;
CRC	cis	rs2108622	0.727	rs77780918	chr19:15982707	T/C	cg13772218	chr19:15982569	NA	0.49	7.01	0.36	1.39e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg01843034	chr6:37503916	NA	-0.39	-7.12	-0.37	6.8e-12	Cognitive performance;
CRC	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.43	-6.45	-0.34	4.01e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs55702914	0.712	rs12619296	chr2:198148767	A/G	cg10820045	chr2:198174542	NA	-0.39	-7.11	-0.36	7.22e-12	Major depression and alcohol dependence;
CRC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03934478	chr11:495069	RNH1	0.69	7.12	0.37	6.61e-12	Body mass index;
CRC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg13722127	chr7:150037890	RARRES2	0.36	5.84	0.31	1.28e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.54	8.15	0.41	7.85e-15	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07556773	chr1:155294010	RUSC1;C1orf104	0.4	6.47	0.34	3.56e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00764470	chr14:31495561	AP4S1;STRN3	0.44	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03676636	chr4:99064102	C4orf37	0.22	5.91	0.31	8.47e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12476592	0.602	rs262495	chr2:63848607	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.19	0.32	1.76e-9	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.34	-0.33	7.73e-10	Cognitive function;
CRC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg10760299	chr15:45669010	GATM	0.51	8.14	0.41	8.37e-15	Homoarginine levels;
CRC	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg07130601	chr7:158766826	NA	0.42	6.02	0.32	4.59e-9	Facial morphology (factor 20);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25595571	chr14:104029029	BAG5;C14orf153	-0.41	-6.13	-0.32	2.45e-9	Myopia (pathological);
CRC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-0.67	-8.16	-0.41	7.34e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-8.87	-0.44	4.84e-17	Bipolar disorder;
CRC	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.83	11.72	0.54	9.59e-27	Height;
CRC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.29e-10	Childhood ear infection;
CRC	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.46	6.58	0.34	1.83e-10	Subjective well-being;
CRC	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.44	6.87	0.35	3.3e-11	Testicular germ cell tumor;
CRC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.3	0.33	9.5e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.95	0.31	7.04e-9	Tonsillectomy;
CRC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg15147215	chr3:52552868	STAB1	-0.65	-11.29	-0.53	3.36e-25	Electroencephalogram traits;
CRC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.44	-9.74	-0.47	7.41e-20	Blood protein levels;
CRC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg24209194	chr3:40518798	ZNF619	0.43	6.54	0.34	2.32e-10	Renal cell carcinoma;
CRC	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg04611788	chr3:186434169	KNG1	-0.59	-8.78	-0.44	8.92e-17	Blood protein levels;
CRC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg03037974	chr15:76606532	NA	0.69	11.69	0.54	1.23e-26	Blood metabolite levels;
CRC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg19635926	chr16:89946313	TCF25	0.67	6.25	0.33	1.25e-9	Skin colour saturation;
CRC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Body mass index;
CRC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.5	6.44	0.33	4.22e-10	Obesity-related traits;
CRC	cis	rs35520189	0.591	rs6723582	chr2:113708102	A/G	cg12858261	chr2:113808755	IL1F8	0.42	5.74	0.3	2.16e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg22687807	chr8:143858763	LYNX1	0.48	8.58	0.43	3.68e-16	Urinary tract infection frequency;
CRC	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.73	13.08	0.58	9.12e-32	Hip circumference;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09623457	chr3:183735666	ABCC5	0.43	6.72	0.35	7.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.81	0.31	1.47e-8	Rheumatoid arthritis;
CRC	cis	rs12928939	0.911	rs11645704	chr16:71826611	G/T	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.06	-0.32	3.75e-9	Post bronchodilator FEV1;
CRC	cis	rs4780401	0.933	rs8058003	chr16:11815178	C/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.61	-0.3	4.32e-8	Rheumatoid arthritis;
CRC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg15147215	chr3:52552868	STAB1	-0.51	-8.24	-0.41	4e-15	Electroencephalogram traits;
CRC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg12365402	chr11:9010492	NRIP3	-0.44	-7.06	-0.36	9.72e-12	Hemoglobin concentration;
CRC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.51	8.22	0.41	4.65e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4676482	0.836	rs75370740	chr3:39233198	G/T	cg02254461	chr3:39195904	CSRNP1	0.53	6.57	0.34	1.93e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4664293	0.625	rs62171654	chr2:160531618	T/A	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.67e-10	Monocyte percentage of white cells;
CRC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-6.15	-0.32	2.27e-9	Gut microbiome composition (summer);
CRC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7619833	0.542	rs11129287	chr3:27497310	C/T	cg02860705	chr3:27208620	NA	0.43	6.75	0.35	6.64e-11	Breast cancer;
CRC	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.38	-7.0	-0.36	1.46e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs447	0.945	rs13310638	chr7:83761086	A/G	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.79	-0.39	8.68e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg19793718	chr12:125473601	DHX37	-0.44	-6.27	-0.33	1.12e-9	Schizophrenia;
CRC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.5	7.72	0.39	1.4e-13	Crohn's disease;
CRC	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	0.87	9.74	0.47	7.25e-20	Uric acid levels;
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg00012762	chr17:72744649	SLC9A3R1	0.42	6.41	0.33	5.05e-10	Body mass index;
CRC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.41e-18	Platelet count;
CRC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.64	-0.34	1.27e-10	Aortic root size;
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg20041105	chr8:143859282	LYNX1	0.43	7.62	0.39	2.65e-13	Urinary tract infection frequency;
CRC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.85	-11.06	-0.52	2.21e-24	Ulcerative colitis;
CRC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	11.98	0.55	1.11e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-8.17	-0.41	6.79e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs747650	0.504	rs7130947	chr11:47002005	C/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.49	-0.34	3.13e-10	Acne (severe);
CRC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.49	7.82	0.4	7.21e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.55	8.43	0.42	1.12e-15	Aortic root size;
CRC	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	10.25	0.49	1.43e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs447	1.000	rs6964546	chr7:83750271	T/C	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.79	-0.39	8.91e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.61	0.34	1.51e-10	Blood protein levels;
CRC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.64	10.03	0.48	7.72e-21	Huntington's disease progression;
CRC	cis	rs12580194	0.593	rs61957946	chr12:55755778	T/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.07	-0.45	1.12e-17	Cancer;
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.79	-8.9	-0.44	3.86e-17	IgG glycosylation;
CRC	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.8	-0.3	1.58e-8	Protein biomarker;
CRC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg11212589	chr17:38028394	ZPBP2	0.35	5.94	0.31	7.37e-9	Asthma;
CRC	cis	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg17948913	chr5:572064	NA	0.55	6.3	0.33	9.64e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18252515	chr7:66147081	NA	0.4	5.68	0.3	2.92e-8	Aortic root size;
CRC	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.4	7.52	0.38	5.1e-13	Ulcerative colitis;
CRC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.56	6.73	0.35	7.73e-11	Gut microbiome composition (summer);
CRC	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg06223162	chr1:101003688	GPR88	-0.35	-6.38	-0.33	5.94e-10	Monocyte count;
CRC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.3	-0.33	9.6e-10	Tonsillectomy;
CRC	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	0.94	11.43	0.53	1.05e-25	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06169648	chr16:85646832	KIAA0182	0.49	6.25	0.33	1.28e-9	Thyroid stimulating hormone;
CRC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg05501817	chr11:14380813	RRAS2	-0.45	-5.96	-0.31	6.43e-9	Sense of smell;
CRC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	1.99e-11	Morning vs. evening chronotype;
CRC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.46	6.92	0.36	2.36e-11	Colorectal cancer;
CRC	cis	rs16975963	0.895	rs8103383	chr19:38327701	A/C	cg15135657	chr19:38346511	NA	-0.43	-5.9	-0.31	8.84e-9	Longevity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18805835	chr5:138775054	DNAJC18	0.5	6.77	0.35	5.89e-11	Thyroid stimulating hormone;
CRC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.69	10.4	0.5	4.27e-22	Corneal astigmatism;
CRC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.58	-8.7	-0.43	1.66e-16	Longevity;
CRC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg22638593	chr5:131593259	PDLIM4	0.53	9.23	0.45	3.51e-18	Acylcarnitine levels;
CRC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.48	9.09	0.45	9.58e-18	Smoking initiation;
CRC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.87	0.4	5.25e-14	Aortic root size;
CRC	cis	rs2530545	0.502	rs76161392	chr7:34680367	T/C	cg14401837	chr7:34697493	NPSR1	0.6	5.78	0.3	1.74e-8	IgG glycosylation;
CRC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg07936489	chr17:37558343	FBXL20	-0.42	-5.97	-0.31	6.2e-9	Asthma;
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.82	-10.92	-0.52	6.6e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10993769	chr22:39928308	RPS19BP1	0.45	6.32	0.33	8.38e-10	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.65	-0.3	3.4e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs11466653	1.000	rs9999985	chr4:38779091	A/G	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg10760299	chr15:45669010	GATM	0.5	7.9	0.4	4.16e-14	Homoarginine levels;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.61	6.48	0.34	3.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2415984	0.622	rs12437018	chr14:46937149	A/G	cg14871534	chr14:47121158	RPL10L	-0.41	-6.04	-0.32	4.2e-9	Number of children ever born;
CRC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	10.54	0.5	1.46e-22	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.16	-0.32	2.16e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg16141378	chr3:129829833	LOC729375	-0.44	-6.64	-0.34	1.27e-10	Retinal vascular caliber;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.56	7.75	0.39	1.12e-13	Alzheimer's disease;
CRC	trans	rs9545047	0.716	rs9545067	chr13:79897564	A/G	cg07061582	chr15:90234082	PEX11A;WDR93	0.42	6.07	0.32	3.47e-9	Schizophrenia;
CRC	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg09760422	chr2:128146352	NA	0.38	7.47	0.38	7.36e-13	Protein C levels;
CRC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.63	10.26	0.49	1.35e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg02733842	chr7:1102375	C7orf50	-0.44	-5.95	-0.31	6.68e-9	Bronchopulmonary dysplasia;
CRC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04768630	chr22:35696543	TOM1	0.48	7.01	0.36	1.35e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2160860	0.765	rs55818481	chr8:39800041	A/C	cg11363097	chr8:39792086	IDO2	-0.45	-7.65	-0.39	2.28e-13	Blood metabolite levels;
CRC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg16989719	chr2:238392110	NA	-0.4	-6.45	-0.34	3.92e-10	Prostate cancer;
CRC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-0.83	-12.75	-0.58	1.52e-30	Blood trace element (Zn levels);
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg10217327	chr6:118973057	C6orf204	0.52	5.92	0.31	8.31e-9	Diastolic blood pressure;
CRC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.4	0.53	1.3e-25	Exhaled nitric oxide levels;
CRC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.42	6.21	0.32	1.6e-9	Ulcerative colitis;
CRC	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.8	0.44	7.81e-17	Coffee consumption (cups per day);
CRC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.92	-0.31	8.18e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.37	-5.79	-0.3	1.65e-8	Type 1 diabetes;
CRC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.8	14.08	0.61	1.48e-35	Breast cancer;
CRC	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg13491945	chr12:107078410	RFX4	0.37	6.28	0.33	1.08e-9	Heart rate;
CRC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.65	10.63	0.51	6.76e-23	Hepatocellular carcinoma;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg24874828	chr4:187887005	NA	0.34	5.76	0.3	1.95e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg19025524	chr12:109796872	NA	-0.45	-5.97	-0.31	6.14e-9	Neuroticism;
CRC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.92	-0.31	8.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	8.78	0.44	9.26e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg21251018	chr6:28226885	NKAPL	0.38	5.74	0.3	2.13e-8	Parkinson's disease;
CRC	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg20045696	chr14:77926864	AHSA1	0.36	5.6	0.3	4.51e-8	Myeloid white cell count;
CRC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.42	0.5	3.69e-22	Personality dimensions;
CRC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg24977027	chr2:88469347	THNSL2	0.62	7.48	0.38	6.78e-13	Plasma clusterin levels;
CRC	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.8	-14.11	-0.61	1.15e-35	Lewy body disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01777103	chr8:145550585	DGAT1	-0.4	-6.17	-0.32	2.04e-9	Myopia (pathological);
CRC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg15468180	chr1:107600409	PRMT6	0.43	6.44	0.33	4.32e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1186222	0.521	rs4731230	chr7:75264429	C/T	cg05145297	chr7:75264568	HIP1	0.68	12.17	0.56	2.23e-28	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.85	0.44	5.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.17	0.37	5.06e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35000415	0.873	rs62478615	chr7:128684316	G/C	cg19972273	chr7:128594194	NA	0.68	6.15	0.32	2.28e-9	Systemic lupus erythematosus;
CRC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg19193384	chr17:30244184	NA	-0.59	-7.01	-0.36	1.33e-11	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.39	6.18	0.32	1.85e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.04	-0.41	1.64e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.85	0.44	5.66e-17	Dupuytren's disease;
CRC	cis	rs728616	0.614	rs61859189	chr10:82089250	T/C	cg05935833	chr10:81318306	SFTPA2	-0.48	-6.57	-0.34	1.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	8.29	0.42	2.9e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.53	-8.48	-0.42	7.89e-16	Coronary artery disease;
CRC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	0.98	8.14	0.41	8.47e-15	Granulocyte percentage of myeloid white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03545677	chr2:47403996	CALM2	0.42	5.98	0.31	5.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35520189	0.592	rs12471839	chr2:113712489	G/C	cg12858261	chr2:113808755	IL1F8	0.46	6.23	0.32	1.41e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg26893134	chr6:116381904	FRK	0.27	6.45	0.33	4.06e-10	Total cholesterol levels;
CRC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.23	-0.32	1.45e-9	Aortic root size;
CRC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00815214	chr21:47717953	NA	-0.39	-6.38	-0.33	5.84e-10	Testicular germ cell tumor;
CRC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	0.35	5.65	0.3	3.47e-8	Personality dimensions;
CRC	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg10724054	chr17:3904396	NA	-0.47	-7.93	-0.4	3.5e-14	Type 2 diabetes;
CRC	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg06156847	chr2:113672199	IL1F7	-0.4	-6.03	-0.32	4.38e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.73	0.3	2.25e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg19223190	chr17:80058835	NA	-0.39	-6.17	-0.32	2.01e-9	Life satisfaction;
CRC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.44	6.75	0.35	6.58e-11	Monocyte count;
CRC	cis	rs990171	0.955	rs10165460	chr2:103085631	C/T	cg03938978	chr2:103052716	IL18RAP	0.47	5.93	0.31	7.82e-9	Lymphocyte counts;
CRC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.68	-8.19	-0.41	5.77e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg10820045	chr2:198174542	NA	0.44	7.73	0.39	1.33e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.64	11.16	0.52	9.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg02869306	chr7:64672164	INTS4L1	0.46	6.6	0.34	1.6e-10	Aortic root size;
CRC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.55	-8.98	-0.44	2.11e-17	P wave terminal force;
CRC	cis	rs7605827	0.930	rs6704723	chr2:15599895	A/G	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg05562828	chr17:3906858	NA	0.73	13.99	0.61	3.12e-35	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00748821	chr4:83932227	LIN54	0.48	6.89	0.36	2.87e-11	Response to antipsychotic treatment;
CRC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	7.95	0.4	3e-14	Colorectal cancer;
CRC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg06470822	chr6:28175283	NA	0.64	6.55	0.34	2.24e-10	Depression;
CRC	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	0.83	9.87	0.48	2.67e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00566492	chr22:39096679	JOSD1	-0.38	-6.02	-0.31	4.7e-9	Myopia (pathological);
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs747650	0.504	rs6485715	chr11:46975125	C/T	cg19486271	chr11:47235900	DDB2	0.43	6.61	0.34	1.54e-10	Acne (severe);
CRC	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.65e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg20512303	chr5:131592959	PDLIM4	0.34	6.33	0.33	8.21e-10	Breast cancer;
CRC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-14.45	-0.62	5.64e-37	Chronic sinus infection;
CRC	cis	rs6662572	0.737	rs72690901	chr1:46378028	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.71	0.3	2.56e-8	Blood protein levels;
CRC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg18230493	chr5:56204884	C5orf35	0.58	8.84	0.44	5.7e-17	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10335543	chr14:102829157	TECPR2;CINP	0.39	6.24	0.33	1.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-10.78	-0.51	2.18e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg02475695	chr16:616220	NHLRC4	0.44	7.15	0.37	5.54e-12	Height;
CRC	cis	rs995000	0.931	rs1168098	chr1:63121294	G/A	cg19896129	chr1:63156450	NA	-0.41	-6.36	-0.33	6.93e-10	Triglyceride levels;
CRC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.47	-6.43	-0.33	4.44e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.34	5.75	0.3	2.08e-8	Major depressive disorder;
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg21784768	chr11:537496	LRRC56	-0.7	-6.67	-0.35	1.07e-10	Body mass index;
CRC	trans	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg18755114	chr2:209119030	IDH1	-0.41	-6.18	-0.32	1.9e-9	Blood protein levels;
CRC	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg16898833	chr6:26189333	HIST1H4D	0.72	6.45	0.34	4.08e-10	Depression;
CRC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.76	0.35	6.47e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.62	-8.67	-0.43	1.94e-16	DNA methylation (variation);
CRC	cis	rs7580658	0.864	rs1566823	chr2:128018192	A/G	cg09760422	chr2:128146352	NA	-0.3	-5.91	-0.31	8.53e-9	Protein C levels;
CRC	cis	rs7619833	0.593	rs7626742	chr3:27268398	G/T	cg02860705	chr3:27208620	NA	0.36	5.68	0.3	2.98e-8	Breast cancer;
CRC	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg13385794	chr1:248469461	NA	0.39	6.7	0.35	8.96e-11	Common traits (Other);
CRC	cis	rs12024301	0.557	rs6663499	chr1:183640764	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.99	0.36	1.52e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg14711859	chr11:8959438	ASCL3	0.39	6.67	0.34	1.11e-10	Hemoglobin concentration;
CRC	trans	rs12517041	1.000	rs74322845	chr5:23293404	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.21	0.37	3.84e-12	Mean corpuscular volume;
CRC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.67	8.93	0.44	3.04e-17	Bladder cancer;
CRC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.43	0.42	1.08e-15	Schizophrenia;
CRC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.37	-6.05	-0.32	3.95e-9	Diastolic blood pressure;
CRC	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.61	10.17	0.49	2.66e-21	Leprosy;
CRC	trans	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg24644049	chr4:85504048	CDS1	0.75	6.82	0.35	4.42e-11	Skin colour saturation;
CRC	cis	rs7617773	1.000	rs6442108	chr3:48192959	G/C	cg11946769	chr3:48343235	NME6	-0.5	-6.73	-0.35	7.49e-11	Coronary artery disease;
CRC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.57e-27	Cognitive function;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.54	-0.38	4.5e-13	Breast cancer;
CRC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.33e-16	Response to antipsychotic treatment;
CRC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.14	0.41	8.01e-15	Cystic fibrosis severity;
CRC	cis	rs703980	0.750	rs703974	chr10:80948593	A/G	cg20744163	chr10:80999841	ZMIZ1	0.37	6.6	0.34	1.67e-10	Type 2 diabetes;
CRC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.69	-0.57	2.71e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg06470822	chr6:28175283	NA	0.95	13.58	0.6	1.14e-33	Parkinson's disease;
CRC	cis	rs17155006	0.664	rs6974722	chr7:107738836	T/C	cg05962710	chr7:107745446	LAMB4	-0.43	-7.53	-0.38	4.79e-13	Pneumococcal bacteremia;
CRC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.66	7.81	0.4	7.66e-14	Bipolar disorder;
CRC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.79	8.4	0.42	1.33e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.6	8.59	0.43	3.65e-16	Longevity;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.18	0.49	2.53e-21	Asthma;
CRC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.47	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg24463073	chr6:118973353	C6orf204	0.48	6.22	0.32	1.49e-9	Diastolic blood pressure;
CRC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.09	0.32	3.16e-9	IgG glycosylation;
CRC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.33	-6.23	-0.32	1.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.5	7.78	0.39	9.21e-14	Monocyte percentage of white cells;
CRC	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg24463073	chr6:118973353	C6orf204	0.51	6.47	0.34	3.56e-10	Diastolic blood pressure;
CRC	trans	rs2303319	0.504	rs12476631	chr2:162566936	A/G	cg03774468	chr3:140950104	ACPL2	-0.67	-6.17	-0.32	2.06e-9	Cognitive function;
CRC	cis	rs12630931	1.000	rs11713199	chr3:31975321	C/G	cg21375017	chr3:31988082	OSBPL10	0.45	6.15	0.32	2.25e-9	Periodontal disease-related phenotypes;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg15786705	chr6:28176104	NA	0.72	9.36	0.46	1.33e-18	Parkinson's disease;
CRC	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg08015503	chr16:89190385	ACSF3	-0.93	-7.33	-0.37	1.79e-12	Red blood cell count;
CRC	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.06	20.76	0.75	8.99e-62	Schizophrenia;
CRC	trans	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg15845792	chr6:28175446	NA	0.66	6.42	0.33	4.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.78	0.63	2.88e-38	Lymphocyte percentage of white cells;
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	7.44	0.38	8.63e-13	Blood metabolite levels;
CRC	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg06156847	chr2:113672199	IL1F7	-0.4	-6.0	-0.31	5.18e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.65	-8.64	-0.43	2.48e-16	Facial morphology (factor 19);
CRC	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.44	-7.68	-0.39	1.82e-13	Intelligence (multi-trait analysis);
CRC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.77	10.8	0.51	1.84e-23	Heart rate;
CRC	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.82	-9.99	-0.48	1.04e-20	Blood pressure (smoking interaction);
CRC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg00745463	chr17:30367425	LRRC37B	-0.43	-5.72	-0.3	2.4e-8	Height;
CRC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.27	0.75	7.46e-60	Headache;
CRC	cis	rs12630931	0.928	rs13093442	chr3:31978144	T/C	cg21375017	chr3:31988082	OSBPL10	0.43	5.87	0.31	1.05e-8	Periodontal disease-related phenotypes;
CRC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.48	7.18	0.37	4.78e-12	N-glycan levels;
CRC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.52	0.38	5.13e-13	Height;
CRC	cis	rs7129220	0.512	rs1867138	chr11:10228728	A/G	cg23875677	chr11:10229755	SBF2	-0.59	-6.3	-0.33	9.74e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.83	13.69	0.6	4.43e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.46e-9	Cognitive function;
CRC	trans	rs6687430	0.512	rs34575776	chr1:10621061	A/G	cg20645065	chr1:21836138	ALPL	-0.4	-6.0	-0.31	5.25e-9	Hand grip strength;
CRC	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.96	0.4	2.85e-14	Corneal astigmatism;
CRC	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.69	9.01	0.44	1.69e-17	Breast cancer;
CRC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.19	0.45	4.43e-18	Bladder cancer;
CRC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg15445000	chr17:37608096	MED1	-0.35	-6.23	-0.32	1.43e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs9914544	0.564	rs4334348	chr17:18787004	G/T	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.1	-0.32	2.93e-9	Educational attainment (years of education);
CRC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	5.78	0.3	1.73e-8	Obesity-related traits;
CRC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.7	9.49	0.46	4.97e-19	Alzheimer's disease;
CRC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg05527609	chr1:210001259	C1orf107	0.5	6.93	0.36	2.18e-11	Monobrow;
CRC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12999616	0.571	rs35263587	chr2:98506906	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	5.66	0.3	3.25e-8	Colorectal cancer;
CRC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	7.82	0.4	7e-14	Menopause (age at onset);
CRC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg00343986	chr7:65444356	GUSB	-0.51	-7.62	-0.39	2.66e-13	Aortic root size;
CRC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.9e-12	Aortic root size;
CRC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg16928487	chr17:17741425	SREBF1	-0.42	-7.48	-0.38	6.76e-13	Total body bone mineral density;
CRC	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg16989719	chr2:238392110	NA	-0.39	-7.81	-0.4	7.82e-14	Prostate cancer;
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs4965869	0.866	rs4965865	chr15:101975597	C/T	cg12371147	chr15:101978424	PCSK6	-0.4	-5.7	-0.3	2.73e-8	Platelet-derived growth factor BB levels;
CRC	cis	rs9826463	0.759	rs56161530	chr3:142332376	C/A	cg20824294	chr3:142316082	PLS1	0.43	6.06	0.32	3.64e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.5	-6.14	-0.32	2.35e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg20203395	chr5:56204925	C5orf35	-0.73	-8.59	-0.43	3.57e-16	Initial pursuit acceleration;
CRC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-9.14	-0.45	6.78e-18	Bronchopulmonary dysplasia;
CRC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.37	-6.33	-0.33	8.02e-10	Personality dimensions;
CRC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg15845792	chr6:28175446	NA	0.78	8.05	0.41	1.56e-14	Parkinson's disease;
CRC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.27	6.97	0.36	1.71e-11	Iron status biomarkers;
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.66	0.54	1.55e-26	Prudent dietary pattern;
CRC	cis	rs7932354	0.528	rs2018527	chr11:47175809	A/G	cg19486271	chr11:47235900	DDB2	0.44	6.47	0.34	3.48e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	cg04338863	chr8:33670619	NA	0.42	6.3	0.33	9.78e-10	Body mass index;
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	0.84	7.69	0.39	1.73e-13	IgG glycosylation;
CRC	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg17710535	chr19:10819994	QTRT1	0.44	6.51	0.34	2.8e-10	Inflammatory skin disease;
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg01339444	chr6:118972232	C6orf204	-0.54	-6.35	-0.33	7.34e-10	Diastolic blood pressure;
CRC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg14711859	chr11:8959438	ASCL3	-0.5	-8.07	-0.41	1.35e-14	Hemoglobin concentration;
CRC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg21770322	chr7:97807741	LMTK2	0.52	8.53	0.43	5.61e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.18	-14.56	-0.63	2e-37	Eosinophil percentage of granulocytes;
CRC	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.56	11.19	0.53	7.28e-25	Neuroticism;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg22988483	chr14:93581567	ITPK1	-0.67	-6.04	-0.32	4.16e-9	Cognitive function;
CRC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.66	-10.84	-0.51	1.31e-23	Mean platelet volume;
CRC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-6.9	-0.36	2.66e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.47	7.87	0.4	5.02e-14	Childhood ear infection;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg13987078	chr10:38691799	CDC10L	-0.39	-5.65	-0.3	3.53e-8	Breast cancer;
CRC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.08	-0.36	9.04e-12	QT interval;
CRC	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg18876405	chr7:65276391	NA	0.47	6.41	0.33	5.04e-10	Aortic root size;
CRC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.51	-9.16	-0.45	5.55e-18	Alcohol dependence;
CRC	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.56	5.85	0.31	1.16e-8	Blood protein levels;
CRC	cis	rs524281	0.861	rs10791858	chr11:65978396	A/G	cg14036092	chr11:66035641	RAB1B	-0.52	-6.11	-0.32	2.89e-9	Electroencephalogram traits;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg13319975	chr6:146136371	FBXO30	0.43	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.36	5.63	0.3	3.91e-8	Retinal vascular caliber;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21192376	chr14:53020168	GPR137C;TXNDC16	-0.42	-6.56	-0.34	2.12e-10	Myopia (pathological);
CRC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.95	9.56	0.47	2.87e-19	Breast cancer;
CRC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg26762873	chr11:5879799	OR52E8	-0.41	-5.66	-0.3	3.24e-8	DNA methylation (variation);
CRC	cis	rs3751196	0.808	rs17034625	chr12:104215308	A/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	trans	rs10207628	0.943	rs10207708	chr2:127852056	G/A	cg22628694	chr19:58663362	ZNF329	0.56	6.01	0.31	5.05e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.58	-7.75	-0.39	1.19e-13	Diabetic retinopathy;
CRC	trans	rs16846053	0.786	rs115562071	chr2:162493241	C/T	cg04269497	chr6:167369491	RNASET2	-0.74	-5.97	-0.31	6.27e-9	Blood osmolality (transformed sodium);
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.16	-0.37	5.43e-12	Breast cancer;
CRC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.55	-6.34	-0.33	7.47e-10	Bipolar disorder;
CRC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.38	5.85	0.31	1.2e-8	Height;
CRC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.35	-5.65	-0.3	3.48e-8	Height;
CRC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.57	8.01	0.4	2.01e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17554472	chr22:41940697	POLR3H	-0.52	-5.62	-0.3	4.11e-8	Vitiligo;
CRC	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.39	-5.7	-0.3	2.63e-8	Mean corpuscular hemoglobin;
CRC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.39	-6.06	-0.32	3.72e-9	Menopause (age at onset);
CRC	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg13086574	chr8:135490821	ZFAT	-0.38	-6.4	-0.33	5.48e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.6	9.2	0.45	4.15e-18	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg00666640	chr1:248458726	OR2T12	0.34	6.48	0.34	3.3e-10	Common traits (Other);
CRC	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.52	10.09	0.49	4.8e-21	Urate levels in lean individuals;
CRC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.6	11.52	0.54	5.19e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs755249	0.567	rs17264671	chr1:39818052	A/C	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.66	0.34	1.13e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg24375607	chr4:120327624	NA	0.48	7.74	0.39	1.2e-13	Corneal astigmatism;
CRC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg00601486	chr12:48723148	H1FNT	-0.34	-6.67	-0.35	1.09e-10	Glycated hemoglobin levels;
CRC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.94	11.22	0.53	6.04e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13547250	chr16:30107791	YPEL3	0.37	6.16	0.32	2.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.68e-12	Life satisfaction;
CRC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.69	-0.35	9.86e-11	Mean platelet volume;
CRC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.45	9.18	0.45	4.89e-18	Renal cell carcinoma;
CRC	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.77	-10.61	-0.5	8.14e-23	White matter hyperintensity burden;
CRC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.46	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.33	-0.33	8.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.98	-0.31	5.76e-9	High light scatter reticulocyte count;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.61	7.94	0.4	3.22e-14	Alzheimer's disease;
CRC	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.86e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-7.14	-0.37	6.05e-12	Colorectal cancer;
CRC	trans	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg07817883	chr1:32538562	TMEM39B	-0.6	-7.55	-0.38	4.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg10838469	chr11:2211741	NA	0.47	6.69	0.35	9.6e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.84	-0.31	1.27e-8	Life satisfaction;
CRC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.51	6.77	0.35	5.91e-11	Corneal structure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17150678	chr19:49617435	LIN7B	0.44	6.29	0.33	1.03e-9	Response to antipsychotic treatment;
CRC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.41	8.12	0.41	9.76e-15	Mean corpuscular volume;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00802000	chr16:706648	WDR90	-0.44	-6.33	-0.33	7.87e-10	Height;
CRC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.47	6.78	0.35	5.49e-11	Tonsillectomy;
CRC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.73	12.07	0.55	5.24e-28	Blood protein levels;
CRC	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg13385794	chr1:248469461	NA	0.38	6.67	0.35	1.09e-10	Common traits (Other);
CRC	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.64	-8.87	-0.44	4.71e-17	Autism;
CRC	cis	rs10924970	0.649	rs4659763	chr1:235447779	T/C	cg09010748	chr1:235293032	TOMM20	-0.42	-5.87	-0.31	1.04e-8	Asthma;
CRC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.06	10.8	0.51	1.79e-23	Skin colour saturation;
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-7.96	-0.4	2.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.99	0.31	5.35e-9	Prudent dietary pattern;
CRC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.54	8.66	0.43	2.22e-16	Gout;
CRC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg24675056	chr1:15929824	NA	0.51	7.06	0.36	9.73e-12	Systolic blood pressure;
CRC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg03013999	chr17:37608204	MED1	0.43	6.6	0.34	1.68e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13884470	chr9:86595151	HNRNPK;RMI1	-0.4	-6.34	-0.33	7.48e-10	Myopia (pathological);
CRC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.66	8.11	0.41	1.03e-14	Obesity (extreme);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03837750	chr1:74664160	LRRIQ3;TNNI3K;FPGT	-0.56	-6.75	-0.35	6.72e-11	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26117622	chr2:242042254	MTERFD2	0.4	6.18	0.32	1.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.06	-12.44	-0.57	2.13e-29	Diabetic kidney disease;
CRC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.56	10.13	0.49	3.7e-21	HDL cholesterol levels;
CRC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.51	-7.02	-0.36	1.26e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg24249390	chr15:90295951	MESP1	-0.59	-9.61	-0.47	1.93e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs12913538	1.000	rs4265758	chr15:62896297	T/G	cg09983546	chr15:62884068	NA	0.61	9.68	0.47	1.12e-19	Sleep depth;
CRC	cis	rs12760731	0.720	rs3791023	chr1:178398092	A/C	cg00404053	chr1:178313656	RASAL2	0.98	10.15	0.49	3.04e-21	Obesity-related traits;
CRC	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg18833306	chr6:118973337	C6orf204	0.46	5.67	0.3	3.14e-8	Diastolic blood pressure;
CRC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.63	9.2	0.45	4.09e-18	Breast cancer;
CRC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg08632701	chr21:37451849	NA	-0.41	-6.36	-0.33	6.77e-10	Mitral valve prolapse;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09858208	chr3:50283852	GNAI2	0.43	6.01	0.31	5.05e-9	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg20119798	chr7:94954144	PON1	-0.5	-6.28	-0.33	1.1e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.78	10.49	0.5	2.11e-22	Bipolar disorder;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg10876282	chr6:28092338	ZSCAN16	0.48	6.6	0.34	1.68e-10	Cardiac Troponin-T levels;
CRC	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	5.69	0.3	2.78e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs990171	1.000	rs7561487	chr2:103077894	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.34e-9	Lymphocyte counts;
CRC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.24e-8	Aortic root size;
CRC	cis	rs281302	0.621	rs392572	chr15:47743625	A/G	cg13159054	chr15:47721715	NA	-0.44	-6.49	-0.34	3.1e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.47	-5.92	-0.31	8.27e-9	Orofacial clefts;
CRC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.43	0.33	4.44e-10	Morning vs. evening chronotype;
CRC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg21153622	chr11:89784906	NA	-0.49	-8.02	-0.4	1.88e-14	Height;
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg25452165	chr22:42524984	CYP2D6	-0.41	-5.77	-0.3	1.84e-8	Cognitive function;
CRC	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.46	7.08	0.36	8.84e-12	HDL cholesterol;
CRC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.67	10.11	0.49	4.35e-21	Corneal astigmatism;
CRC	cis	rs6604026	0.848	rs2893226	chr1:93288437	G/A	cg22128645	chr1:93425802	FAM69A	-0.4	-5.93	-0.31	7.66e-9	Multiple sclerosis;
CRC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.45	7.04	0.36	1.1e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-7.15	-0.37	5.53e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg15845792	chr6:28175446	NA	0.72	6.15	0.32	2.24e-9	Breast cancer;
CRC	cis	rs727505	0.564	rs68107250	chr7:124870200	G/A	cg23710748	chr7:124431027	NA	-0.62	-10.29	-0.49	1.04e-21	Lewy body disease;
CRC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.49	8.49	0.42	7.33e-16	Primary biliary cholangitis;
CRC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.55	-8.6	-0.43	3.21e-16	Aortic root size;
CRC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg21153622	chr11:89784906	NA	-0.44	-6.93	-0.36	2.28e-11	Coronary artery disease;
CRC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.54	8.81	0.44	7.41e-17	Platelet count;
CRC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.75	0.39	1.14e-13	Height;
CRC	cis	rs10221833	0.602	rs355893	chr2:165635147	A/G	cg03182029	chr2:165697222	COBLL1	0.52	6.09	0.32	3.22e-9	Response to statin therapy;
CRC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	13.94	0.61	4.84e-35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.71	9.58	0.47	2.51e-19	Coronary artery disease;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg20994686	chr17:71306668	CDC42EP4	-0.4	-6.0	-0.31	5.11e-9	Schizophrenia;
CRC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.64	-0.47	1.52e-19	Bladder cancer;
CRC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.41	-7.4	-0.38	1.11e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.44	-0.38	8.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.95	-0.31	6.72e-9	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03993376	chr5:172386357	LOC100268168;RPL26L1	0.42	6.19	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.4	5.9	0.31	9.03e-9	Renal cell carcinoma;
CRC	trans	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.69	0.35	9.85e-11	Mean corpuscular volume;
CRC	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg13385794	chr1:248469461	NA	0.37	6.42	0.33	4.78e-10	Common traits (Other);
CRC	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg11204139	chr17:3907470	NA	0.54	8.71	0.43	1.51e-16	Type 2 diabetes;
CRC	cis	rs10242455	0.702	rs6956305	chr7:99241310	A/G	cg18809830	chr7:99032528	PTCD1	-1.04	-7.34	-0.38	1.68e-12	Blood metabolite levels;
CRC	trans	rs7485210	0.673	rs78606016	chr12:131632805	T/A	cg23037403	chr5:178368183	ZNF454	-0.46	-5.99	-0.31	5.5e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg06155606	chr11:6704862	MRPL17	0.41	5.97	0.31	6.04e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.24	-0.37	3.14e-12	Height;
CRC	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.58	-7.83	-0.4	6.8e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9341808	0.667	rs806783	chr6:80942943	A/C	cg08355045	chr6:80787529	NA	-0.36	-5.95	-0.31	6.71e-9	Sitting height ratio;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Parkinson's disease;
CRC	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg21174375	chr14:64681225	SYNE2	-0.4	-6.42	-0.33	4.84e-10	Atrial fibrillation;
CRC	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.44	-6.44	-0.33	4.33e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.26	14.76	0.63	3.35e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.45	6.91	0.36	2.46e-11	Cleft lip with or without cleft palate;
CRC	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.62	11.23	0.53	5.31e-25	Blood metabolite ratios;
CRC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.48	6.17	0.32	1.99e-9	Blood metabolite levels;
CRC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.51	7.62	0.39	2.76e-13	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg25547332	chr5:131281432	NA	0.37	5.76	0.3	1.98e-8	Life satisfaction;
CRC	cis	rs6565180	0.926	rs4788413	chr16:30410445	C/T	cg01392867	chr16:30410429	ZNF48	0.38	5.98	0.31	5.88e-9	Tonsillectomy;
CRC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.84	-11.67	-0.54	1.49e-26	Asthma;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg19628164	chr3:143689916	C3orf58	-0.59	-6.45	-0.34	3.9e-10	Lung adenocarcinoma;
CRC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.65	0.34	1.19e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16102016	chr17:8126456	C17orf44	0.43	5.97	0.31	6.1e-9	Anxiety disorder;
CRC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.66	8.82	0.44	6.68e-17	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25184507	chr17:7760147	CYB5D1;LSMD1	0.55	7.39	0.38	1.2e-12	Thyroid stimulating hormone;
CRC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.54	8.97	0.44	2.36e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.57	8.86	0.44	5.07e-17	Neurofibrillary tangles;
CRC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg21153622	chr11:89784906	NA	-0.38	-6.0	-0.31	5.28e-9	Height;
CRC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg08888203	chr3:10149979	C3orf24	0.65	7.55	0.38	4.33e-13	Alzheimer's disease;
CRC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg21620606	chr4:1342894	KIAA1530	0.36	5.97	0.31	6.06e-9	Obesity-related traits;
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	12.33	0.56	5.56e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg08501292	chr6:25962987	TRIM38	1.11	10.79	0.51	1.97e-23	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.08	0.32	3.33e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.18	-0.56	1.94e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.31	0.46	1.88e-18	Bladder cancer;
CRC	cis	rs1712517	0.771	rs11191676	chr10:105155066	C/A	cg05636881	chr10:105038444	INA	0.48	8.18	0.41	6.1e-15	Migraine;
CRC	cis	rs6717918	0.672	rs2853359	chr2:233118874	C/G	ch.2.233013039R	chr2:233304795	NA	0.5	6.29	0.33	1.02e-9	Height;
CRC	cis	rs4478858	0.718	rs10914329	chr1:31688441	T/A	cg00250761	chr1:31883323	NA	0.31	5.82	0.31	1.42e-8	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26483432	chr1:149815043	HIST2H2AA3;HIST2H2AA4	0.5	7.64	0.39	2.36e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.39	-5.69	-0.3	2.75e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.6	0.39	3.13e-13	Endometrial cancer;
CRC	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.69	9.73	0.47	7.59e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09535168	chr19:19431582	KIAA0892;SF4	0.45	6.35	0.33	7.2e-10	Response to antipsychotic treatment;
CRC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg00601486	chr12:48723148	H1FNT	-0.33	-6.31	-0.33	9.26e-10	Glycated hemoglobin levels;
CRC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.54	8.11	0.41	1.02e-14	Lymphocyte counts;
CRC	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.91	0.52	7.06e-24	Bipolar disorder;
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.24	0.37	3.11e-12	Alzheimer's disease;
CRC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg04369109	chr6:150039330	LATS1	-0.44	-6.17	-0.32	1.95e-9	Lung cancer;
CRC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.62	0.57	4.78e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.72	-0.39	1.41e-13	Psoriasis;
CRC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg10911889	chr6:126070802	HEY2	0.38	5.76	0.3	1.91e-8	Brugada syndrome;
CRC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	1.01	20.07	0.74	4.5e-59	Headache;
CRC	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.47	-8.67	-0.43	1.97e-16	Hepatitis;
CRC	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08498830	chr11:832797	CD151	-0.61	-6.23	-0.32	1.39e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.99	15.25	0.64	4.17e-40	Testicular germ cell tumor;
CRC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	0.57	7.09	0.36	8.47e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg01737554	chr17:33866071	SLFN12L	-0.37	-6.23	-0.32	1.42e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	1.37	10.78	0.51	2.1e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.48	6.5	0.34	2.92e-10	Total body bone mineral density;
CRC	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.13	0.32	2.46e-9	Systemic lupus erythematosus;
CRC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07513332	chr6:167530253	CCR6	-0.44	-8.21	-0.41	5.06e-15	Primary biliary cholangitis;
CRC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.66	-9.08	-0.45	1.06e-17	Breast cancer;
CRC	cis	rs370915	0.542	rs13124558	chr4:187794175	T/C	cg12892747	chr4:187813459	NA	-0.56	-8.06	-0.41	1.4e-14	Gout;
CRC	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.42	-8.2	-0.41	5.38e-15	Migraine;
CRC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.4	5.96	0.31	6.44e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.35	-6.03	-0.32	4.47e-9	Intelligence (multi-trait analysis);
CRC	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.58	9.77	0.47	5.6e-20	Dupuytren's disease;
CRC	cis	rs1639906	0.560	rs1108036	chr7:2263354	A/G	cg19897017	chr7:2163380	MAD1L1	0.43	6.32	0.33	8.51e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg10570241	chr7:158785291	NA	-0.45	-7.83	-0.4	6.74e-14	Facial morphology (factor 20);
CRC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.53	8.2	0.41	5.53e-15	Red blood cell count;
CRC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg08847533	chr14:75593920	NEK9	0.42	5.7	0.3	2.63e-8	IgG glycosylation;
CRC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.59	-8.74	-0.43	1.22e-16	Menarche (age at onset);
CRC	cis	rs7705042	0.826	rs13184323	chr5:141494719	T/G	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.9	-0.31	9e-9	Asthma;
CRC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.16e-13	Motion sickness;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.83e-9	Life satisfaction;
CRC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.62	-7.95	-0.4	2.94e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7635879	0.533	rs12486721	chr3:193744854	A/G	cg01524723	chr3:193718032	NA	-0.54	-7.55	-0.38	4.43e-13	Breastfeeding duration;
CRC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.72	-0.35	8.01e-11	Aortic root size;
CRC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	11.92	0.55	1.78e-27	Schizophrenia;
CRC	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg13043300	chr11:71146211	DHCR7	-0.42	-5.82	-0.31	1.37e-8	Vitamin D levels;
CRC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.41e-11	Aortic root size;
CRC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.85	-15.89	-0.66	1.31e-42	Menopause (age at onset);
CRC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg15445000	chr17:37608096	MED1	-0.35	-6.17	-0.32	2.02e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.66	7.87	0.4	5.31e-14	Triglycerides;
CRC	cis	rs4664293	0.967	rs10803758	chr2:160548219	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.18	-0.32	1.9e-9	Monocyte percentage of white cells;
CRC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.52	7.52	0.38	5.33e-13	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17114402	chr2:97778470	ANKRD36	-0.42	-6.0	-0.31	5.25e-9	Myopia (pathological);
CRC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.36	-6.68	-0.35	1.05e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.95	0.31	6.77e-9	Depression;
CRC	cis	rs2421770	0.530	rs7945809	chr11:35369253	G/A	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.66	-0.34	1.16e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg09264619	chr17:80180166	NA	0.49	7.08	0.36	8.59e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs459193	1.000	rs40271	chr5:55796319	A/G	cg26646659	chr5:55776364	NA	-0.48	-6.6	-0.34	1.65e-10	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.82	0.44	6.9e-17	Morning vs. evening chronotype;
CRC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.64	-10.44	-0.5	3.06e-22	Dental caries;
CRC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12516959	chr21:47718080	NA	-0.36	-6.11	-0.32	2.86e-9	Testicular germ cell tumor;
CRC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.45	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg12365402	chr11:9010492	NRIP3	0.48	7.74	0.39	1.26e-13	Hemoglobin concentration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07756108	chr2:203130955	NOP58	0.47	6.1	0.32	2.92e-9	Thyroid stimulating hormone;
CRC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.7	-9.58	-0.47	2.54e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6694672	1.000	rs7541429	chr1:197099485	A/G	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.69e-11	Asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18641478	chr19:17970431	RPL18AP3;RPL18A	0.46	6.35	0.33	7.29e-10	Anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20899340	chr17:60143175	MED13	0.42	6.37	0.33	6.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg06470822	chr6:28175283	NA	0.62	6.84	0.35	3.92e-11	Depression;
CRC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.81	-0.51	1.7e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	7.87	0.4	5.17e-14	Blood metabolite levels;
CRC	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	9.98	0.48	1.18e-20	Blood protein levels;
CRC	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.81	12.19	0.56	1.9e-28	Obesity-related traits;
CRC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.78	-0.39	9.18e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs16867321	0.901	rs2368168	chr2:181355888	G/T	cg23363182	chr2:181467187	NA	-0.49	-5.96	-0.31	6.54e-9	Obesity;
CRC	trans	rs7976838	0.831	rs61935606	chr12:60242347	A/G	cg16974014	chr22:22007515	MIR130B	0.49	5.96	0.31	6.46e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.82	0.66	2.48e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.92	0.31	8.07e-9	Breast cancer;
CRC	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg19537932	chr12:55886519	OR6C68	-0.7	-8.89	-0.44	4.2e-17	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09254823	chr19:13885429	C19orf53	0.39	6.14	0.32	2.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.59	11.17	0.52	8.72e-25	Bone mineral density;
CRC	cis	rs3219474	0.505	rs487174	chr1:46009536	C/T	cg06784218	chr1:46089804	CCDC17	0.64	6.64	0.34	1.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.99	16.47	0.67	7.39e-45	Diastolic blood pressure;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg20933634	chr6:27740509	NA	0.53	6.86	0.35	3.39e-11	Parkinson's disease;
CRC	trans	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	0.96	16.34	0.67	2.42e-44	Triglycerides;
CRC	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg25838465	chr1:92012736	NA	-0.41	-5.91	-0.31	8.72e-9	Eosinophil percentage of white cells;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.41	-5.97	-0.31	6.12e-9	Daytime sleep phenotypes;
CRC	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.17	-0.37	5.08e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs1639906	0.527	rs1639919	chr7:2262934	C/G	cg19897017	chr7:2163380	MAD1L1	0.4	5.88	0.31	1.02e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.52	7.62	0.39	2.76e-13	Lung cancer;
CRC	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.46	0.34	3.83e-10	Acne (severe);
CRC	cis	rs7113874	0.589	rs10769907	chr11:8457237	G/A	cg17679104	chr11:8615758	STK33	-0.34	-5.61	-0.3	4.37e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.27	-0.42	3.24e-15	Mean corpuscular volume;
CRC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.68	11.61	0.54	2.31e-26	Dental caries;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.2	-0.56	1.65e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg23743428	chr13:21893420	NA	-0.39	-5.92	-0.31	8.02e-9	White matter hyperintensity burden;
CRC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.47	6.64	0.34	1.27e-10	Lung cancer;
CRC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.16	11.41	0.53	1.27e-25	Skin colour saturation;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg10876282	chr6:28092338	ZSCAN16	0.46	6.34	0.33	7.76e-10	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.63	9.23	0.45	3.51e-18	Blood protein levels;
CRC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.39	6.64	0.34	1.3100000000000001e-10	Crohn's disease;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg12273811	chr6:28175739	NA	0.53	7.19	0.37	4.49e-12	Parkinson's disease;
CRC	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs9467160	1.000	rs9467157	chr6:24440644	C/T	cg16211469	chr6:24423932	MRS2	0.36	5.74	0.3	2.19e-8	Liver enzyme levels;
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.77	9.69	0.47	1.05e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.58	6.32	0.33	8.27e-10	Type 2 diabetes;
CRC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg19193384	chr17:30244184	NA	-0.63	-7.33	-0.37	1.82e-12	Hip circumference adjusted for BMI;
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.93	9.84	0.48	3.44e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg01483505	chr11:975446	AP2A2	0.39	5.85	0.31	1.2e-8	Alzheimer's disease (late onset);
CRC	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.59	-7.14	-0.37	6.03e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg09659197	chr4:152720779	NA	0.42	8.61	0.43	3.01e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.57	-8.11	-0.41	1.02e-14	Monobrow;
CRC	cis	rs4731207	0.569	rs1986124	chr7:124641717	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs7259376	0.936	rs10423736	chr19:22596132	C/T	cg02657401	chr19:22469223	NA	0.31	6.82	0.35	4.25e-11	Menopause (age at onset);
CRC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg17633681	chr16:88106987	BANP	0.85	14.76	0.63	3.48e-38	Menopause (age at onset);
CRC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.63	9.51	0.46	4.15e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg18827107	chr12:86230957	RASSF9	0.38	5.99	0.31	5.49e-9	Major depressive disorder;
CRC	cis	rs9322817	0.902	rs4336470	chr6:105180785	C/T	cg02098413	chr6:105308735	HACE1	-0.36	-6.61	-0.34	1.51e-10	Thyroid stimulating hormone;
CRC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.76	14.03	0.61	2.19e-35	Prudent dietary pattern;
CRC	cis	rs972578	0.967	rs738392	chr22:43340279	G/T	cg01576275	chr22:43409880	NA	-0.45	-7.23	-0.37	3.48e-12	Mean platelet volume;
CRC	cis	rs9491140	0.539	rs11755888	chr6:124693042	A/G	cg19267163	chr6:125004984	NKAIN2	0.47	6.08	0.32	3.38e-9	Neuroticism;
CRC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg06287003	chr12:125626642	AACS	-0.52	-7.1	-0.36	7.89e-12	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.64	-9.99	-0.48	1.1e-20	Coronary artery disease;
CRC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	0.67	7.46	0.38	7.61e-13	Body mass index;
CRC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.59	7.01	0.36	1.33e-11	Type 2 diabetes nephropathy;
CRC	trans	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg21302420	chr1:112162376	RAP1A	0.83	7.41	0.38	1.07e-12	Skin colour saturation;
CRC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.5e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.2	-0.37	4.13e-12	Life satisfaction;
CRC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.52	8.1	0.41	1.05e-14	Monocyte count;
CRC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg02018176	chr4:1364513	KIAA1530	0.35	5.84	0.31	1.26e-8	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs72873603	chr2:162469665	C/T	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.43e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	trans	rs4714291	0.802	rs3008833	chr6:39986303	G/A	cg02267698	chr19:7991119	CTXN1	-0.52	-7.19	-0.37	4.27e-12	Strep throat;
CRC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.43	6.25	0.33	1.26e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.54	8.16	0.41	7.11e-15	Morning vs. evening chronotype;
CRC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.66	10.99	0.52	4e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4363385	0.782	rs10788857	chr1:153024941	T/G	cg25856811	chr1:152973957	SPRR3	-0.28	-7.58	-0.39	3.63e-13	Inflammatory skin disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16527794	chr11:47600580	NDUFS3;KBTBD4	-0.39	-6.11	-0.32	2.78e-9	Myopia (pathological);
CRC	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg22687807	chr8:143858763	LYNX1	-0.38	-6.63	-0.34	1.36e-10	Urinary tract infection frequency;
CRC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg02560186	chr11:3602584	NA	-0.57	-6.97	-0.36	1.73e-11	Blood pressure (smoking interaction);
CRC	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg00507830	chr2:103233733	NA	-0.5	-5.63	-0.3	3.81e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg05861140	chr6:150128134	PCMT1	0.37	5.81	0.31	1.45e-8	Lung cancer;
CRC	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.34	-0.33	7.67e-10	Height;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.55	6.62	0.34	1.5e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.39	-7.01	-0.36	1.37e-11	Dupuytren's disease;
CRC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.52	7.69	0.39	1.67e-13	Platelet distribution width;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12273811	chr6:28175739	NA	0.71	9.14	0.45	6.45e-18	Depression;
CRC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.43	5.66	0.3	3.28e-8	Heart rate;
CRC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs2708240	0.666	rs1861010	chr7:147601401	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.44	-6.42	-0.33	4.87e-10	QT interval (drug interaction);
CRC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.96	-0.36	1.8e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.93	-0.31	7.57e-9	Neuroticism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25764190	chr19:44037015	ZNF575	0.58	7.72	0.39	1.39e-13	Thyroid stimulating hormone;
CRC	cis	rs12476592	0.602	rs262536	chr2:63906926	T/C	cg10828910	chr2:63850056	LOC388955	0.52	6.39	0.33	5.59e-10	Childhood ear infection;
CRC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	5.82	0.31	1.37e-8	Breast cancer;
CRC	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.48	-8.69	-0.43	1.8e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.54	7.21	0.37	3.76e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21582570	chr1:113257894	PPM1J	0.39	6.19	0.32	1.76e-9	Schizophrenia;
CRC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.75	-12.59	-0.57	6.29e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg10820045	chr2:198174542	NA	0.38	6.31	0.33	9.24e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.58	8.51	0.42	6.24e-16	Lymphocyte counts;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg03623178	chr6:28175578	NA	0.63	8.32	0.42	2.44e-15	Parkinson's disease;
CRC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.58	-0.72	3.48e-53	Primary sclerosing cholangitis;
CRC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg10570241	chr7:158785291	NA	0.38	6.44	0.33	4.26e-10	Facial morphology (factor 20);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11837215	chr10:13344517	NA	0.5	6.84	0.35	3.81e-11	Response to antipsychotic treatment;
CRC	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg10437265	chr15:77819839	NA	-0.68	-12.94	-0.58	3.03e-31	Type 2 diabetes;
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg18833306	chr6:118973337	C6orf204	0.45	5.84	0.31	1.24e-8	Diastolic blood pressure;
CRC	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.65	-0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04238871	chr10:126431886	FAM53B	0.48	6.71	0.35	8.35e-11	Response to antipsychotic treatment;
CRC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.56	0.57	7.8e-30	Coronary artery disease;
CRC	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.53	8.07	0.41	1.33e-14	Body mass index;
CRC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.06	0.36	9.91e-12	Menopause (age at onset);
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs1465370	0.644	rs1558919	chr7:130029508	A/T	cg03229158	chr7:130009420	NA	0.42	6.09	0.32	3.13e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18402987	chr7:1209562	NA	0.53	7.8	0.4	8.32e-14	Longevity;Endometriosis;
CRC	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg14139581	chr11:64358342	SLC22A12	0.37	5.88	0.31	1.03e-8	Urate levels in obese individuals;
CRC	cis	rs4237845	0.637	rs7299249	chr12:58343710	C/T	cg02175503	chr12:58329896	NA	0.76	11.97	0.55	1.2100000000000001e-27	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.39	-6.99	-0.36	1.54e-11	Reticulocyte fraction of red cells;
CRC	cis	rs12541635	0.966	rs6987512	chr8:106998770	C/T	cg10147462	chr8:107024639	NA	0.42	6.93	0.36	2.16e-11	Age of smoking initiation;
CRC	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.58	-7.23	-0.37	3.43e-12	Ulcerative colitis;
CRC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.4	-0.33	5.2400000000000005e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.65	0.3	3.46e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11371493	chr20:30795352	POFUT1;PLAGL2	0.43	6.61	0.34	1.53e-10	Schizophrenia;
CRC	cis	rs4400599	0.606	rs7542975	chr1:154204813	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.74	-0.3	2.21e-8	Platelet distribution width;
CRC	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.51	6.32	0.33	8.62e-10	Neuroticism;
CRC	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.92	0.52	6.98e-24	Coffee consumption (cups per day);
CRC	cis	rs1223397	0.938	rs34505804	chr6:13292514	G/A	cg07912922	chr6:13274314	PHACTR1	0.54	6.46	0.34	3.68e-10	Blood pressure;
CRC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15369054	chr17:80825471	TBCD	-0.36	-6.02	-0.31	4.68e-9	Breast cancer;
CRC	cis	rs7487075	0.820	rs7953659	chr12:46698683	A/G	cg22049899	chr12:47219821	SLC38A4	0.32	6.18	0.32	1.92e-9	Itch intensity from mosquito bite;
CRC	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg09179987	chr1:167433047	CD247	0.49	7.18	0.37	4.58e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg10089145	chr11:130030103	ST14	-0.55	-6.97	-0.36	1.77e-11	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg12856521	chr11:46389249	DGKZ	-0.42	-6.88	-0.35	2.99e-11	Leprosy;
CRC	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.53	6.81	0.35	4.75e-11	Alzheimer's disease (survival time);
CRC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.65	-10.82	-0.51	1.55e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.58	8.95	0.44	2.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg00601486	chr12:48723148	H1FNT	-0.3	-5.71	-0.3	2.58e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.51	7.31	0.37	2.03e-12	Testicular germ cell tumor;
CRC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg25956985	chr22:39795188	MAP3K7IP1	-0.42	-6.2	-0.32	1.69e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.39	0.38	1.21e-12	Aortic root size;
CRC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.4	6.25	0.33	1.29e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.56	8.86	0.44	5.26e-17	Colorectal cancer;
CRC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-8.66	-0.43	2.21e-16	Blood metabolite levels;
CRC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.4	7.86	0.4	5.7e-14	Mean corpuscular volume;
CRC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.58	-7.56	-0.38	4.04e-13	DNA methylation (variation);
CRC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.5	-10.94	-0.52	5.95e-24	Rheumatoid arthritis;
CRC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06505273	chr16:24850292	NA	0.47	5.65	0.3	3.39e-8	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.65	-0.43	2.39e-16	Uric acid levels;
CRC	trans	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg11693508	chr17:37793320	STARD3	0.51	6.74	0.35	6.9e-11	Neuroticism;
CRC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.41	6.71	0.35	8.57e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg13491945	chr12:107078410	RFX4	0.35	6.15	0.32	2.21e-9	Heart rate;
CRC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.58	8.84	0.44	5.8e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.36	-0.56	4.3e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9287719	0.649	rs6717431	chr2:10726046	A/G	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-12.95	-0.58	2.8e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-8.0	-0.4	2.1e-14	Chronic sinus infection;
CRC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8070740	1.000	rs8066928	chr17:5328155	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.98	0.36	1.65e-11	Menopause (age at onset);
CRC	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.51	8.01	0.4	1.98e-14	Anterior chamber depth;
CRC	cis	rs3750082	0.505	rs7807550	chr7:32984472	C/T	cg05721444	chr7:32995514	FKBP9	0.52	6.53	0.34	2.44e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7605827	0.930	rs1549015	chr2:15616458	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.85	-0.44	5.49e-17	Personality dimensions;
CRC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg05132306	chr1:1846340	CALML6	-0.49	-7.66	-0.39	2.07e-13	Body mass index;
CRC	cis	rs6499129	1.000	rs12935253	chr16:67466430	T/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.92	-0.36	2.34e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7113874	0.513	rs2015629	chr11:8564426	A/T	cg17679104	chr11:8615758	STK33	-0.37	-6.18	-0.32	1.86e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	10.21	0.49	1.91e-21	Hip circumference adjusted for BMI;
CRC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.95	-11.82	-0.55	4.14e-27	Vitiligo;
CRC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg03037974	chr15:76606532	NA	0.57	9.51	0.46	4.32e-19	Blood metabolite levels;
CRC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg07130601	chr7:158766826	NA	0.44	6.42	0.33	4.64e-10	Facial morphology (factor 20);
CRC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.69	-8.46	-0.42	9.02e-16	Bronchopulmonary dysplasia;
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.51	-0.5	1.86e-22	Total cholesterol levels;
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.46	-6.79	-0.35	5.28e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04731861	chr2:219085781	ARPC2	0.33	6.88	0.35	2.94e-11	Colorectal cancer;
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.85	0.31	1.22e-8	Prudent dietary pattern;
CRC	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg02825527	chr7:2087843	MAD1L1	-0.54	-6.58	-0.34	1.88e-10	Neuroticism;
CRC	cis	rs12745968	0.589	rs12025792	chr1:93107408	C/T	cg17283838	chr1:93427260	FAM69A	-0.44	-5.92	-0.31	8.27e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00997172	chr20:32399000	CHMP4B	0.41	6.29	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg05207973	chr5:176823642	SLC34A1	0.48	7.47	0.38	7.1e-13	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg04239558	chr2:103089729	SLC9A4	0.37	6.6	0.34	1.67e-10	Blood protein levels;
CRC	cis	rs4803480	0.554	rs12983999	chr19:42070528	G/C	cg08478046	chr19:42093086	CEACAM21	-0.29	-6.04	-0.32	4.23e-9	Schizophrenia;
CRC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6496667	0.865	rs4622491	chr15:90885481	C/T	cg04176472	chr15:90893244	GABARAPL3	0.57	6.73	0.35	7.68e-11	Rheumatoid arthritis;
CRC	trans	rs974471	0.736	rs1956246	chr14:29669291	C/G	cg01759126	chr2:68870892	NA	-0.34	-5.96	-0.31	6.48e-9	Intelligence (multi-trait analysis);Body mass index in physically active individuals;Body mass index;Cognitive ability (multi-trait analysis);Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg10820045	chr2:198174542	NA	-0.52	-9.11	-0.45	8.5e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg26043149	chr18:55253948	FECH	0.55	8.53	0.43	5.58e-16	Bone mineral density;
CRC	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg27205649	chr11:78285834	NARS2	0.49	6.23	0.32	1.45e-9	Alzheimer's disease (survival time);
CRC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg16576597	chr16:28551801	NUPR1	0.52	7.67	0.39	1.92e-13	Mosquito bite size;
CRC	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.47	6.4	0.33	5.47e-10	Eye color traits;
CRC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.53	7.93	0.4	3.43e-14	Body mass index;
CRC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg15017067	chr4:17643749	FAM184B	0.36	5.7	0.3	2.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1891275	0.515	rs7092884	chr10:93483872	A/C	cg07889827	chr10:93443413	NA	0.39	6.52	0.34	2.66e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.88	10.85	0.51	1.2e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.46	-5.63	-0.3	3.84e-8	Coronary artery calcification;
CRC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.74	13.53	0.6	1.76e-33	Prostate cancer;
CRC	cis	rs7113874	0.524	rs6484485	chr11:8620740	A/G	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg15786705	chr6:28176104	NA	0.7	5.78	0.3	1.74e-8	Depression;
CRC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg19635926	chr16:89946313	TCF25	0.68	6.14	0.32	2.35e-9	Skin colour saturation;
CRC	cis	rs10450586	0.796	rs10437624	chr11:27307345	C/G	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.74	9.46	0.46	6.05e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.09	-0.32	3.19e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.68	0.63	7.35e-38	Chronic sinus infection;
CRC	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.03	-0.36	1.17e-11	Menarche (age at onset);
CRC	cis	rs1124376	1.000	rs73038113	chr3:20139025	T/A	cg05072819	chr3:20081367	KAT2B	0.54	6.27	0.33	1.15e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00282216	chr8:145823653	KIAA1688	-0.47	-7.7	-0.39	1.5700000000000001e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07283595	chr17:5372003	DHX33	0.42	6.21	0.32	1.57e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06080224	chr7:107204581	COG5;DUS4L	0.45	6.18	0.32	1.86e-9	Anxiety disorder;
CRC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.48	-7.69	-0.39	1.74e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.57	-9.12	-0.45	7.85e-18	Neuroticism;
CRC	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.95	0.31	6.83e-9	Axial length;
CRC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.77	7.8	0.4	8.13e-14	Diabetic retinopathy;
CRC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.44	-0.42	1.04e-15	Bipolar disorder;
CRC	trans	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg21302420	chr1:112162376	RAP1A	0.69	5.96	0.31	6.37e-9	Skin colour saturation;
CRC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.55	-9.54	-0.47	3.37e-19	Iron status biomarkers;
CRC	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.95	0.36	1.93e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs6557786	0.636	rs2445940	chr8:24787201	C/G	cg10207787	chr8:26148195	PPP2R2A	-0.55	-6.64	-0.34	1.3100000000000001e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg09998033	chr7:158218633	PTPRN2	0.52	7.0	0.36	1.44e-11	Obesity-related traits;
CRC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg15358701	chr1:161410459	NA	-0.62	-6.63	-0.34	1.39e-10	Rheumatoid arthritis;
CRC	cis	rs4237845	0.611	rs4509811	chr12:58335142	A/G	cg02175503	chr12:58329896	NA	0.76	11.93	0.55	1.64e-27	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg25767906	chr1:53392781	SCP2	0.37	5.86	0.31	1.12e-8	Monocyte count;
CRC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.45	7.12	0.37	6.83e-12	Calcium levels;
CRC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg15110403	chr19:17392923	ANKLE1	-0.36	-5.92	-0.31	8.17e-9	Systemic lupus erythematosus;
CRC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	10.67	0.51	5.17e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-10.93	-0.52	6.14e-24	Colorectal cancer;
CRC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18912574	chr7:65842487	NCRNA00174	0.35	5.95	0.31	6.85e-9	Aortic root size;
CRC	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg24140574	chr1:16342155	HSPB7	0.47	6.66	0.34	1.13e-10	Dilated cardiomyopathy;
CRC	cis	rs12431939	1.000	rs12433445	chr14:51666091	G/A	cg23942311	chr14:51606299	NA	-0.54	-6.19	-0.32	1.76e-9	Cancer;
CRC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg05725404	chr16:58534157	NDRG4	-0.6	-5.6	-0.3	4.45e-8	Schizophrenia;
CRC	trans	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.55	-6.03	-0.32	4.3e-9	Ulcerative colitis;
CRC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13198984	chr17:80129470	CCDC57	-0.41	-7.01	-0.36	1.37e-11	Life satisfaction;
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg15147215	chr3:52552868	STAB1	-0.61	-10.4	-0.5	4.17e-22	Bipolar disorder;
CRC	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg10517650	chr3:113235015	CCDC52	-0.36	-5.92	-0.31	8.19e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.85	9.86	0.48	2.83e-20	Psoriasis;
CRC	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.77	10.57	0.5	1.14e-22	Blood pressure (smoking interaction);
CRC	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.56	-7.82	-0.4	7.17e-14	Carotid intima media thickness;
CRC	trans	rs7027930	0.524	rs7023618	chr9:612425	C/G	cg27061366	chr19:13044373	FARSA	0.51	6.21	0.32	1.59e-9	Pulmonary function decline;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg19041857	chr6:27730383	NA	-0.62	-6.88	-0.35	3.09e-11	Lung cancer in ever smokers;
CRC	cis	rs740160	0.558	rs68164591	chr7:98904440	C/T	cg24650262	chr7:98904301	NA	0.55	5.72	0.3	2.42e-8	Dehydroepiandrosterone sulphate levels;
CRC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.44	-6.71	-0.35	8.49e-11	Body mass index;
CRC	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.43	6.33	0.33	7.86e-10	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.73	-12.69	-0.57	2.58e-30	P wave terminal force;
CRC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.44	5.61	0.3	4.23e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg15845792	chr6:28175446	NA	-0.64	-9.49	-0.46	5.01e-19	Cardiac Troponin-T levels;
CRC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.85	10.08	0.49	5.15e-21	Psoriasis;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg11248668	chr11:45826493	SLC35C1	0.4	6.01	0.31	4.93e-9	Crohn's disease;
CRC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.85	-0.35	3.69e-11	Breast cancer;
CRC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.68	-9.23	-0.45	3.49e-18	Platelet count;
CRC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.02	-0.55	8.02e-28	Bipolar disorder and schizophrenia;
CRC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.7	8.62	0.43	2.86e-16	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.73	-9.76	-0.47	6.36e-20	Prostate cancer;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.41	-0.5	3.94e-22	Alzheimer's disease;
CRC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg19223190	chr17:80058835	NA	0.4	6.52	0.34	2.63e-10	Life satisfaction;
CRC	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg27398640	chr15:77910606	LINGO1	-0.44	-7.57	-0.39	3.81e-13	Type 2 diabetes;
CRC	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg16576597	chr16:28551801	NUPR1	0.47	7.34	0.37	1.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24438655	chr17:45727598	KPNB1	0.41	6.07	0.32	3.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.88	10.88	0.51	9.53e-24	Exhaled nitric oxide output;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg23161317	chr6:28129485	ZNF389	0.46	6.61	0.34	1.52e-10	Cardiac Troponin-T levels;
CRC	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg13798912	chr7:905769	UNC84A	0.57	6.13	0.32	2.48e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.6	-9.32	-0.46	1.76e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.59	9.31	0.46	1.84e-18	Intelligence (multi-trait analysis);
CRC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.33	-6.14	-0.32	2.35e-9	Menarche (age at onset);
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg07617317	chr6:118971624	C6orf204	0.52	6.4	0.33	5.29e-10	Diastolic blood pressure;
CRC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.49	6.92	0.36	2.33e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.73	-0.3	2.32e-8	Reticulocyte count;
CRC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.99	16.28	0.67	4.1e-44	Diastolic blood pressure;
CRC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.46	-6.07	-0.32	3.46e-9	Gut microbiome composition (summer);
CRC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.56	7.9	0.4	4.25e-14	Lung cancer;
CRC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg12193833	chr17:30244370	NA	0.55	6.82	0.35	4.32e-11	Hip circumference adjusted for BMI;
CRC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.17	-13.25	-0.59	2.03e-32	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs243505	0.726	rs734005	chr7:148505864	G/A	cg09806900	chr7:148480153	CUL1	0.51	7.34	0.37	1.74e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7091068	0.754	rs6583903	chr10:95422174	T/C	cg20715218	chr10:95462985	C10orf4	0.5	5.94	0.31	7.22e-9	Urinary tract infection frequency;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.71	8.88	0.44	4.51e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg04117972	chr1:227635322	NA	0.59	5.95	0.31	6.95e-9	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20002729	chr12:110318525	GLTP	0.44	6.18	0.32	1.87e-9	Anxiety disorder;
CRC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.39	-6.17	-0.32	1.99e-9	Testicular germ cell tumor;
CRC	cis	rs9903692	0.909	rs1468270	chr17:46125191	C/T	cg21215337	chr17:46176117	CBX1	0.43	7.8	0.4	8.28e-14	Pulse pressure;
CRC	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-0.96	-12.13	-0.56	2.99e-28	Height;
CRC	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-6.99	-0.36	1.56e-11	IgG glycosylation;
CRC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.39	5.87	0.31	1.04e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg20503657	chr10:835505	NA	0.69	8.16	0.41	7.33e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg19052272	chr2:3704530	ALLC	-0.44	-6.44	-0.33	4.15e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.34	0.38	1.68e-12	Platelet count;
CRC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.22e-10	Lung cancer;
CRC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.58	-8.77	-0.44	9.45e-17	Body mass index;
CRC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.39	-7.32	-0.37	1.91e-12	Ulcerative colitis;
CRC	cis	rs10760158	0.832	rs4240466	chr9:124039734	A/T	cg14417974	chr9:124058376	GSN	-0.33	-5.64	-0.3	3.71e-8	Pulse pressure;
CRC	cis	rs10991814	0.920	rs7857020	chr9:94035272	G/T	cg14446406	chr9:93919335	NA	0.58	6.41	0.33	5.03e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.25e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg14883916	chr11:6947541	ZNF215	0.63	6.87	0.35	3.29e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg16680214	chr1:154839983	KCNN3	0.37	6.64	0.34	1.29e-10	Prostate cancer;
CRC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.37	0.38	1.43e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg25214090	chr10:38739885	LOC399744	0.43	6.7	0.35	9.29e-11	Diastolic blood pressure;
CRC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg02527881	chr3:46936655	PTH1R	0.37	6.83	0.35	4.11e-11	Colorectal cancer;
CRC	cis	rs7804356	1.000	rs6461980	chr7:26894123	T/G	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.06e-8	Type 1 diabetes;
CRC	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg02023728	chr11:77925099	USP35	-0.36	-6.07	-0.32	3.46e-9	Alzheimer's disease (survival time);
CRC	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.21	28.58	0.84	3.59e-91	Schizophrenia;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.57	8.29	0.42	2.86e-15	Parkinson's disease;
CRC	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-8.34	-0.42	2.03e-15	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15693898	chr3:183602556	PARL	0.41	6.07	0.32	3.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg24675056	chr1:15929824	NA	0.51	7.03	0.36	1.19e-11	Systolic blood pressure;
CRC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-6.0	-0.31	5.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.05	-0.32	4.03e-9	Menopause (age at onset);
CRC	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg16964102	chr10:135390573	NA	0.49	6.63	0.34	1.38e-10	Gout;
CRC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.52	7.59	0.39	3.32e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6662572	1.000	rs28584711	chr1:46212631	C/T	cg08644498	chr1:46502608	NA	0.45	6.31	0.33	8.91e-10	Blood protein levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg21365899	chr1:231558446	EGLN1	-0.41	-6.2	-0.32	1.69e-9	Daytime sleep phenotypes;
CRC	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.48	-8.3	-0.42	2.73e-15	Testicular germ cell tumor;
CRC	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg26703956	chr19:39260304	NA	-0.37	-5.96	-0.31	6.65e-9	Heart rate;
CRC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.14e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg20615401	chr6:28092323	ZSCAN16	0.45	5.98	0.31	5.68e-9	Cardiac Troponin-T levels;
CRC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.34e-13	Melanoma;
CRC	cis	rs17767392	0.914	rs10139519	chr14:72109270	C/A	cg13720639	chr14:72061746	SIPA1L1	0.56	7.04	0.36	1.15e-11	Mitral valve prolapse;
CRC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.66	10.04	0.48	7.39e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg05725404	chr16:58534157	NDRG4	-0.6	-5.6	-0.3	4.45e-8	Schizophrenia;
CRC	trans	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06834434	chr14:75079333	LTBP2	0.51	6.08	0.32	3.39e-9	Obesity-related traits;
CRC	cis	rs4400599	0.805	rs10908739	chr1:154160655	T/C	cg05139571	chr1:154127138	NUP210L	0.44	6.62	0.34	1.43e-10	Platelet distribution width;
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg19678392	chr7:94953810	PON1	-0.56	-7.03	-0.36	1.18e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg21251018	chr6:28226885	NKAPL	0.41	6.24	0.33	1.35e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.55	-8.54	-0.43	5.11e-16	Corneal structure;
CRC	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg27205649	chr11:78285834	NARS2	0.47	5.79	0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.2	0.32	1.65e-9	Breast cancer;
CRC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.53	7.82	0.4	7.01e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.08	-12.52	-0.57	1.16e-29	Metabolite levels (HVA/5-HIAA ratio);
CRC	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg27661571	chr11:113659931	NA	-0.95	-11.1	-0.52	1.64e-24	Hip circumference adjusted for BMI;
CRC	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.52	0.46	3.85e-19	Common traits (Other);
CRC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg16822035	chr13:113633379	MCF2L	-0.29	-5.91	-0.31	8.41e-9	Systolic blood pressure;
CRC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs185694	0.779	rs639234	chr13:30893984	G/A	cg07600127	chr13:30881527	KATNAL1	-0.51	-5.61	-0.3	4.21e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg10820045	chr2:198174542	NA	0.54	9.54	0.47	3.29e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg18876405	chr7:65276391	NA	0.46	6.46	0.34	3.7e-10	Aortic root size;
CRC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.37	0.5	5.36e-22	Sudden cardiac arrest;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22024508	chr19:16771032	TMEM38A;C19orf42	-0.5	-6.0	-0.31	5.13e-9	Diisocyanate-induced asthma;
CRC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.47	0.34	3.46e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs10426930	0.700	rs10413045	chr19:5024099	G/T	cg25246084	chr19:4971487	KDM4B	-0.34	-5.76	-0.3	1.9e-8	Monocyte percentage of white cells;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg18663513	chr1:53793486	LRP8	0.39	5.98	0.31	5.82e-9	Menarche (age at onset);
CRC	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg16964102	chr10:135390573	NA	-0.5	-6.94	-0.36	2.16e-11	Gout;
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.82	15.03	0.64	3.17e-39	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg02725872	chr8:58115012	NA	-0.32	-5.72	-0.3	2.39e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1519814	1.000	rs4504680	chr8:121132175	T/C	cg22335954	chr8:121166405	COL14A1	-0.56	-6.3	-0.33	9.33e-10	Breast cancer;
CRC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg16102536	chr7:156981717	UBE3C	0.42	6.88	0.35	3.12e-11	Body mass index;
CRC	trans	rs783540	1.000	rs7496954	chr15:83345536	T/G	cg18393722	chr15:85113863	UBE2QP1	0.35	5.97	0.31	6.08e-9	Schizophrenia;
CRC	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg09455208	chr3:40491958	NA	-0.33	-6.78	-0.35	5.48e-11	Renal cell carcinoma;
CRC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.73	-8.35	-0.42	1.9e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13198984	chr17:80129470	CCDC57	-0.37	-6.17	-0.32	2.05e-9	Life satisfaction;
CRC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.9	16.44	0.67	9.63e-45	Prostate cancer;
CRC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg02527881	chr3:46936655	PTH1R	-0.41	-7.84	-0.4	6.52e-14	Colorectal cancer;
CRC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.5	-6.75	-0.35	6.63e-11	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.11	-0.41	1.04e-14	Biliary atresia;
CRC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.64	9.58	0.47	2.37e-19	Breast cancer;
CRC	cis	rs1474256	0.630	rs79015977	chr15:79450147	G/A	cg17916960	chr15:79447300	NA	0.42	5.64	0.3	3.67e-8	Bronchopulmonary dysplasia;
CRC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.37	6.19	0.32	1.75e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4803480	1.000	rs7255679	chr19:42063981	G/T	cg08478046	chr19:42093086	CEACAM21	-0.34	-6.08	-0.32	3.34e-9	Schizophrenia;
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.88	-0.51	9.24e-24	Alzheimer's disease;
CRC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg04450456	chr4:17643702	FAM184B	0.39	6.22	0.32	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.88	16.83	0.68	2.64e-46	Metabolic syndrome;
CRC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.36	-5.69	-0.3	2.8e-8	Esophageal squamous cell carcinoma;
CRC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.35	-7.38	-0.38	1.29e-12	Cutaneous nevi;
CRC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg09417038	chr21:47716443	C21orf57	-0.39	-6.37	-0.33	6.55e-10	Testicular germ cell tumor;
CRC	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.63	0.39	2.55e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.36	-0.33	6.7e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6586163	0.872	rs1926197	chr10:90748626	A/G	cg13456138	chr10:90753195	FAS	-0.44	-6.61	-0.34	1.54e-10	Chronic lymphocytic leukemia;
CRC	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg11204139	chr17:3907470	NA	-0.43	-6.32	-0.33	8.35e-10	Type 2 diabetes;
CRC	cis	rs10097731	0.908	rs77317991	chr8:82032468	C/T	cg25230327	chr8:82042993	NA	-0.78	-11.22	-0.53	5.85e-25	Serum total protein level;
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-0.68	-8.29	-0.42	2.95e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.02	10.31	0.49	8.6e-22	Diabetic retinopathy;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.36	-5.93	-0.31	7.84e-9	Lymphocyte counts;
CRC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg15465823	chr12:48382534	COL2A1	0.37	6.05	0.32	3.94e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.47	7.97	0.4	2.63e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg19792802	chr11:65647270	CTSW	0.62	7.41	0.38	1.09e-12	Crohn's disease;
CRC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.83	8.33	0.42	2.26e-15	Major depressive disorder;
CRC	cis	rs7072216	0.770	rs7896828	chr10:100170507	A/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.74	-0.35	6.96e-11	Metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20180059	chr1:109584182	WDR47	0.45	6.4	0.33	5.32e-10	Response to antipsychotic treatment;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg26710055	chr3:15468825	EAF1;METTL6	0.51	6.33	0.33	8.21e-10	Kashin-Beck disease;
CRC	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.63	-8.51	-0.42	6.42e-16	Uric acid levels;
CRC	trans	rs2565722	0.622	rs2489944	chr6:161292913	C/T	cg01698392	chr17:76871734	TIMP2	-0.46	-6.06	-0.32	3.66e-9	Blood protein levels;
CRC	cis	rs1030268	1.000	rs1030268	chr7:133606631	C/T	cg03336402	chr7:133662267	EXOC4	0.58	7.71	0.39	1.47e-13	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.24	-0.33	1.36e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg10815483	chr17:16394899	C17orf76	-0.54	-6.78	-0.35	5.48e-11	Diisocyanate-induced asthma;
CRC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.47	6.44	0.33	4.28e-10	Alzheimer's disease (late onset);
CRC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	10.77	0.51	2.19e-23	Schizophrenia;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg25164649	chr6:28176230	NA	0.73	9.32	0.46	1.74e-18	Parkinson's disease;
CRC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.44	-7.47	-0.38	7.28e-13	Height;
CRC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-6.14	-0.32	2.35e-9	Type 2 diabetes;
CRC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg08807101	chr21:30365312	RNF160	-0.38	-5.61	-0.3	4.32e-8	Pancreatic cancer;
CRC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.32	6.07	0.32	3.58e-9	Mean corpuscular volume;
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.02	-0.36	1.24e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.7	8.33	0.42	2.21e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg11887960	chr12:57824829	NA	0.59	6.57	0.34	2e-10	Obesity-related traits;
CRC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg14844989	chr11:31128820	NA	-0.34	-5.98	-0.31	5.89e-9	Red blood cell count;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18305333	chr11:62439274	C11orf83;C11orf48	0.47	6.66	0.34	1.13e-10	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	17.31	0.69	3.51e-48	Electrocardiographic conduction measures;
CRC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg06636001	chr8:8085503	FLJ10661	0.46	6.77	0.35	5.95e-11	Neuroticism;
CRC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.39	6.92	0.36	2.42e-11	Primary biliary cholangitis;
CRC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.96	0.31	6.41e-9	HDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11970843	chr2:203736525	ICA1L	0.39	6.14	0.32	2.44e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.43	-6.23	-0.32	1.44e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.54	6.28	0.33	1.07e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.54	11.96	0.55	1.3e-27	Alcohol dependence;
CRC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg24910161	chr17:38119198	GSDMA	-0.42	-7.45	-0.38	8.14e-13	Asthma and hay fever;
CRC	trans	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg24952240	chr4:169567560	PALLD	-0.4	-5.97	-0.31	6.28e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01301935	chr16:69599904	NFAT5;MIR1538	0.49	6.4	0.33	5.42e-10	Anxiety disorder;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg23161317	chr6:28129485	ZNF389	0.43	6.05	0.32	3.88e-9	Parkinson's disease;
CRC	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.74	9.37	0.46	1.19e-18	Iron status biomarkers;
CRC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.25	15.72	0.65	6.58e-42	Lung disease severity in cystic fibrosis;
CRC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg08859206	chr1:53392774	SCP2	-0.45	-7.08	-0.36	8.9e-12	Monocyte count;
CRC	cis	rs8105895	0.935	rs2043315	chr19:22252823	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg17321639	chr7:2759063	NA	-0.4	-6.09	-0.32	3.18e-9	Height;
CRC	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.59	-0.34	1.75e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16120927	chr11:63536330	C11orf95	0.48	6.8	0.35	4.9e-11	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00339695	chr16:24857497	SLC5A11	0.26	5.9	0.31	9.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.74	11.31	0.53	2.8e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg21153622	chr11:89784906	NA	-0.47	-7.42	-0.38	9.85e-13	HDL cholesterol;
CRC	cis	rs11212617	0.869	rs12801988	chr11:108357747	C/T	cg12106634	chr11:108092400	ATM;NPAT	-0.39	-5.63	-0.3	3.86e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00006032	chr14:66974439	GPHN	-0.53	-6.5	-0.34	2.91e-10	Diisocyanate-induced asthma;
CRC	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg21153622	chr11:89784906	NA	-0.51	-8.55	-0.43	4.82e-16	HDL cholesterol;
CRC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg02659138	chr7:134003124	SLC35B4	0.4	6.94	0.36	2.16e-11	Mean platelet volume;
CRC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.91	-17.25	-0.69	6.27e-48	Coronary artery disease;
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.4e-9	Prudent dietary pattern;
CRC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg17633681	chr16:88106987	BANP	0.85	14.64	0.63	1.05e-37	Menopause (age at onset);
CRC	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.54	0.34	2.38e-10	HDL cholesterol;
CRC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.54	-7.95	-0.4	2.94e-14	Mean platelet volume;
CRC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.26	12.25	0.56	1.14e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg00343986	chr7:65444356	GUSB	0.52	7.75	0.39	1.15e-13	Aortic root size;
CRC	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg20512303	chr5:131592959	PDLIM4	-0.36	-5.63	-0.3	3.85e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs7968440	0.651	rs7309519	chr12:50652280	G/A	cg12020201	chr12:50017283	PRPF40B	0.35	5.78	0.3	1.71e-8	Fibrinogen;
CRC	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.31	-0.33	9.21e-10	Caffeine consumption;
CRC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.48	8.73	0.43	1.31e-16	Height;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	trans	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-6.92	-0.36	2.33e-11	Menarche (age at onset);
CRC	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.07	9.25	0.45	2.99e-18	Mitochondrial DNA levels;
CRC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg15848620	chr12:58087721	OS9	-0.65	-9.09	-0.45	9.71e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.67	0.43	1.98e-16	Homoarginine levels;
CRC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.68	0.54	1.28e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.8	14.51	0.62	3.2e-37	Anterior chamber depth;
CRC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg05192639	chr6:26864778	GUSBL1	0.3	5.78	0.3	1.74e-8	Schizophrenia;
CRC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.47	7.18	0.37	4.66e-12	Corneal astigmatism;
CRC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	9.88	0.48	2.5e-20	Bone mineral density;
CRC	cis	rs7680126	0.596	rs11731652	chr4:10292984	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.04	-0.32	4.23e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.11	0.52	1.39e-24	Bone mineral density;
CRC	cis	rs7463659	1.000	rs7463659	chr8:135432140	T/C	cg09855544	chr8:135498122	ZFAT	-0.38	-5.81	-0.3	1.51e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.36	5.88	0.31	9.88e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.56	8.02	0.4	1.88e-14	Uric acid levels;
CRC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.61	6.72	0.35	8.09e-11	Cleft lip with or without cleft palate;
CRC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	10.68	0.51	4.78e-23	Motion sickness;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg11843238	chr5:131593191	PDLIM4	0.43	6.98	0.36	1.59e-11	Blood metabolite levels;
CRC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg19980929	chr12:42632907	YAF2	0.45	6.61	0.34	1.59e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23944232	chr2:86948118	RMND5A	0.4	6.48	0.34	3.37e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7605827	0.930	rs1997307	chr2:15512588	T/C	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.36e-9	Educational attainment (years of education);
CRC	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.63	10.14	0.49	3.38e-21	Anterior chamber depth;
CRC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-6.8	-0.35	4.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs858239	0.932	rs1728313	chr7:23271031	A/C	cg00469287	chr7:23338798	C7orf30	0.43	5.78	0.3	1.77e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.54	8.19	0.41	5.77e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.72	10.11	0.49	4.11e-21	Blood metabolite levels;
CRC	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.46	9.22	0.45	3.54e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10450586	0.932	rs10835155	chr11:27317812	C/T	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18297960	chr7:1142765	C7orf50	-0.45	-6.1	-0.32	2.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.1	-0.41	1.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg10876282	chr6:28092338	ZSCAN16	0.44	5.88	0.31	9.85e-9	Parkinson's disease;
CRC	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.73	0.3	2.3e-8	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04474326	chr20:57556688	TH1L	0.44	5.97	0.31	6.19e-9	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.27	-0.75	7.14e-60	Height;
CRC	trans	rs1941687	0.800	rs1845387	chr18:31358940	T/G	cg27147174	chr7:100797783	AP1S1	-0.36	-6.06	-0.32	3.67e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.43	6.46	0.34	3.69e-10	Blood metabolite levels;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg22777020	chr22:31556080	RNF185	-0.52	-6.0	-0.31	5.35e-9	Colorectal cancer;
CRC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg13628971	chr7:2884303	GNA12	0.4	6.33	0.33	7.82e-10	Height;
CRC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg21399703	chr1:247681439	NA	0.47	7.69	0.39	1.68e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.66	-7.46	-0.38	7.85e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.6	-9.39	-0.46	1.03e-18	Aortic root size;
CRC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.46	6.85	0.35	3.55e-11	Type 2 diabetes;
CRC	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14119001	chr9:139324193	INPP5E	-0.44	-6.18	-0.32	1.9e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg03929089	chr4:120376271	NA	-0.46	-6.58	-0.34	1.83e-10	Height;
CRC	cis	rs16867321	1.000	rs1358520	chr2:181440081	C/T	cg23363182	chr2:181467187	NA	-0.52	-6.54	-0.34	2.3e-10	Obesity;
CRC	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-7.75	-0.39	1.12e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg08213375	chr14:104286397	PPP1R13B	0.37	5.81	0.31	1.46e-8	Reticulocyte count;
CRC	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	8.06	0.41	1.43e-14	Blood protein levels;
CRC	cis	rs9400239	0.622	rs1268170	chr6:109007522	A/G	cg11073813	chr6:109029018	NA	-0.4	-6.33	-0.33	7.89e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.78	-13.29	-0.59	1.43e-32	Breast cancer;
CRC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg19773385	chr1:10388646	KIF1B	0.47	7.31	0.37	2.04e-12	Hepatocellular carcinoma;
CRC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.79	12.03	0.55	7.39e-28	Cognitive function;
CRC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.39	7.55	0.38	4.23e-13	Mean corpuscular volume;
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.68	-0.3	3.01e-8	Neuroticism;
CRC	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	7.65	0.39	2.18e-13	Neuroticism;
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg04553112	chr3:125709451	NA	-0.51	-5.71	-0.3	2.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.7	-0.3	2.73e-8	Migraine;Coronary artery disease;
CRC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.4	7.14	0.37	6.1e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg18678763	chr11:4115507	RRM1	-0.48	-7.56	-0.38	4.05e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-15.92	-0.66	1.01e-42	Cognitive function;
CRC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.39	-5.85	-0.31	1.2e-8	Total body bone mineral density;
CRC	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg09659197	chr4:152720779	NA	0.43	8.36	0.42	1.76e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg15845792	chr6:28175446	NA	0.48	7.17	0.37	5.1e-12	Pubertal anthropometrics;
CRC	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	1.01	12.33	0.56	5.53e-29	Eosinophil percentage of granulocytes;
CRC	trans	rs1390943	1.000	rs13253777	chr8:20071770	C/G	cg24796471	chr19:6737389	GPR108	-0.44	-6.15	-0.32	2.27e-9	Circulating myeloperoxidase levels (serum);
CRC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.49	7.27	0.37	2.72e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg02158880	chr13:53174818	NA	-0.45	-6.61	-0.34	1.52e-10	Lewy body disease;
CRC	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg26566898	chr11:117069891	TAGLN	0.39	6.99	0.36	1.54e-11	Blood protein levels;
CRC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.02	-0.32	4.63e-9	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23706161	chr2:109336669	RANBP2	0.43	6.71	0.35	8.51e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.86	14.03	0.61	2.31e-35	Multiple system atrophy;
CRC	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg13926569	chr10:89418898	PAPSS2	-0.44	-6.49	-0.34	3.15e-10	Magnesium levels;
CRC	cis	rs6433857	0.505	rs7561255	chr2:181369216	A/G	cg23363182	chr2:181467187	NA	-0.53	-7.87	-0.4	5.01e-14	Body mass index;
CRC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.37	6.95	0.36	2e-11	Mean corpuscular volume;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg12682573	chr17:27188876	MIR451;MIR144	-0.61	-9.06	-0.45	1.15e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.4	6.22	0.32	1.47e-9	HDL cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06838869	chr7:140098259	SLC37A3	0.38	6.57	0.34	2.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs2933343	1.000	rs789237	chr3:128636961	A/C	cg11901034	chr3:128598214	ACAD9	-0.53	-6.53	-0.34	2.43e-10	IgG glycosylation;
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.26	-0.56	1.03e-28	Alzheimer's disease;
CRC	cis	rs7120118	0.517	rs10838694	chr11:47351760	G/A	cg25783544	chr11:47291846	MADD	0.62	5.68	0.3	2.93e-8	HDL cholesterol;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg23161317	chr6:28129485	ZNF389	0.45	6.47	0.34	3.55e-10	Cardiac Troponin-T levels;
CRC	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.36	-0.38	1.44e-12	Superior frontal gyrus grey matter volume;
CRC	trans	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg16724585	chr3:197361211	NA	-0.5	-6.54	-0.34	2.3e-10	Pancreatic cancer;
CRC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.72	0.75	1.28e-61	Prudent dietary pattern;
CRC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.8	-0.3	1.54e-8	Coronary artery disease;
CRC	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.57	7.87	0.4	5.32e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.34	-0.33	7.78e-10	Lymphocyte counts;
CRC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.6	8.59	0.43	3.56e-16	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg10494257	chr1:16342123	HSPB7	0.45	6.06	0.32	3.72e-9	Dilated cardiomyopathy;
CRC	cis	rs9837602	0.688	rs793492	chr3:99499736	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.88	0.31	9.99e-9	Breast cancer;
CRC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.66	9.45	0.46	6.37e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.18e-13	Motion sickness;
CRC	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.75	0.54	7.56e-27	Exhaled nitric oxide levels;
CRC	trans	rs11654801	0.947	rs16962375	chr17:20910984	G/T	cg23759823	chr7:139672531	TBXAS1	-0.46	-6.81	-0.35	4.78e-11	Mosquito bite size;
CRC	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.77	11.37	0.53	1.67e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18758796	chr5:131593413	PDLIM4	0.45	8.28	0.42	3.11e-15	Breast cancer;
CRC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.78	13.95	0.61	4.55e-35	Oral cavity cancer;
CRC	cis	rs10760158	0.865	rs10760165	chr9:124021254	C/T	cg14417974	chr9:124058376	GSN	-0.33	-5.63	-0.3	3.9e-8	Pulse pressure;
CRC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.32	5.68	0.3	2.94e-8	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.41	6.15	0.32	2.29e-9	Hemoglobin concentration;
CRC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	8.94	0.44	2.94e-17	Height;
CRC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs3750082	0.574	rs9639668	chr7:32912635	G/A	cg05721444	chr7:32995514	FKBP9	0.52	6.49	0.34	3.15e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.65	12.81	0.58	9.66e-31	HDL cholesterol levels;
CRC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.62	9.58	0.47	2.46e-19	Corneal astigmatism;
CRC	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.18	-24.86	-0.81	1.65e-77	Exhaled nitric oxide output;
CRC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.76	10.35	0.5	6.42e-22	Cognitive function;
CRC	cis	rs9303542	0.694	rs8071207	chr17:46584016	T/C	cg04904318	chr17:46607828	HOXB1	0.45	5.97	0.31	5.99e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9463078	0.691	rs1041332	chr6:45012811	A/T	cg25276700	chr6:44698697	NA	0.24	5.82	0.31	1.37e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg15845792	chr6:28175446	NA	0.47	6.46	0.34	3.69e-10	Depression;
CRC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.52	6.86	0.35	3.52e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg18827107	chr12:86230957	RASSF9	-0.37	-5.73	-0.3	2.23e-8	Major depressive disorder;
CRC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.73	11.82	0.55	4.15e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.43	-7.51	-0.38	5.75e-13	Venous thromboembolism;
CRC	cis	rs6684514	0.778	rs11264477	chr1:156321154	C/T	cg16558208	chr1:156270281	VHLL	0.5	7.63	0.39	2.62e-13	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg11887960	chr12:57824829	NA	0.63	6.95	0.36	1.94e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19717773	chr7:2847554	GNA12	-0.45	-6.27	-0.33	1.13e-9	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21636432	chr6:35887842	SRPK1	0.46	6.45	0.34	4.08e-10	Response to antipsychotic treatment;
CRC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.88	-0.4	4.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg08888203	chr3:10149979	C3orf24	0.7	8.54	0.43	5.12e-16	Alzheimer's disease;
CRC	cis	rs7539624	0.588	rs1892076	chr1:223899417	T/A	cg10100437	chr1:223903862	CAPN2	0.46	6.46	0.34	3.84e-10	Schizophrenia;
CRC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.39	-0.38	1.25e-12	Morning vs. evening chronotype;
CRC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg07865391	chr16:88106882	BANP	0.46	6.05	0.32	3.86e-9	Menopause (age at onset);
CRC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.27	0.33	1.1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.44	6.9	0.36	2.74e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	trans	rs800082	1.000	rs4681378	chr3:144308005	C/T	cg24215973	chr2:240111563	HDAC4	-0.52	-6.95	-0.36	1.95e-11	Smoking behavior;
CRC	cis	rs990171	0.913	rs2241117	chr2:103003043	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.37e-8	Lymphocyte counts;
CRC	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.45	-0.42	9.35e-16	Alcohol dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01566955	chr10:71211468	TSPAN15	0.43	6.08	0.32	3.31e-9	Response to antipsychotic treatment;
CRC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg18230493	chr5:56204884	C5orf35	-0.39	-5.96	-0.31	6.51e-9	Coronary artery disease;
CRC	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.48	-7.81	-0.4	7.98e-14	Red cell distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26435092	chr3:133292540	CDV3	0.38	6.1	0.32	2.91e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.92	15.32	0.65	2.38e-40	Dupuytren's disease;
CRC	cis	rs6840360	0.608	rs6831644	chr4:152283746	A/G	cg09659197	chr4:152720779	NA	0.37	7.31	0.37	2.06e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg06470822	chr6:28175283	NA	0.81	11.77	0.54	6.35e-27	Cardiac Troponin-T levels;
CRC	cis	rs9625935	0.518	rs713718	chr22:30314092	A/C	cg01021169	chr22:30184971	ASCC2	0.37	5.73	0.3	2.25e-8	Tonsillectomy;
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.76	-0.3	1.94e-8	Menopause (age at onset);
CRC	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg24463073	chr6:118973353	C6orf204	0.54	7.24	0.37	3.26e-12	Diastolic blood pressure;
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg16060761	chr17:80687452	NA	0.53	8.09	0.41	1.18e-14	Glycated hemoglobin levels;
CRC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13198984	chr17:80129470	CCDC57	0.43	7.4	0.38	1.18e-12	Life satisfaction;
CRC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.85	-11.56	-0.54	3.46e-26	Asthma;
CRC	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.41	-0.33	5.18e-10	Neuroticism;
CRC	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.39	-0.33	5.73e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.62	8.62	0.43	2.91e-16	Arsenic metabolism;
CRC	cis	rs2982552	0.873	rs2152750	chr6:152070145	C/T	cg22157087	chr6:152012887	ESR1	-0.37	-5.66	-0.3	3.35e-8	Bone properties (heel);
CRC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.92	17.22	0.69	8.3e-48	Intelligence (multi-trait analysis);
CRC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.57	6.65	0.34	1.23e-10	Bipolar disorder;
CRC	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.48	-8.99	-0.44	2.04e-17	Hepatitis;
CRC	cis	rs1355223	0.934	rs11602669	chr11:34695114	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.68	-0.3	2.99e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg15382696	chr6:118971807	C6orf204	0.6	7.53	0.38	5.03e-13	Diastolic blood pressure;
CRC	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg13385794	chr1:248469461	NA	0.37	6.53	0.34	2.56e-10	Common traits (Other);
CRC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg14541582	chr5:601475	NA	-0.33	-6.54	-0.34	2.39e-10	Obesity-related traits;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.62	9.81	0.48	4.29e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg04155289	chr7:94953770	PON1	-0.59	-7.53	-0.38	5.06e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs1376359	0.673	rs1868828	chr1:103152118	A/C	cg16220183	chr17:56609687	SEPT4	0.45	6.26	0.33	1.23e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg03233332	chr7:66118400	NA	-0.42	-5.83	-0.31	1.34e-8	Aortic root size;
CRC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.55	8.58	0.43	3.76e-16	Aortic root size;
CRC	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.56	-5.73	-0.3	2.25e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg20062050	chr1:227730881	NA	0.36	6.08	0.32	3.31e-9	Menopause (age at onset);
CRC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg11212589	chr17:38028394	ZPBP2	0.34	6.02	0.32	4.65e-9	Asthma;
CRC	trans	rs4785204	1.000	rs7186983	chr16:50098852	C/T	cg07960154	chr17:37760198	NEUROD2	-0.65	-6.05	-0.32	3.98e-9	Esophageal cancer (squamous cell);
CRC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.83	-15.79	-0.66	3.46e-42	Lewy body disease;
CRC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.63	8.51	0.42	6.43e-16	Gut microbiome composition (summer);
CRC	cis	rs11212617	1.000	rs186595	chr11:108251211	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.62	0.34	1.45e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg07076509	chr9:96720819	NA	0.36	5.98	0.31	5.71e-9	Esophageal adenocarcinoma;
CRC	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg22495460	chr2:25135724	ADCY3	-0.83	-13.9	-0.61	7.3e-35	Body mass index;
CRC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.66	9.53	0.47	3.5e-19	Subjective well-being;
CRC	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg02353165	chr6:42928485	GNMT	0.56	7.15	0.37	5.78e-12	Blood protein levels;
CRC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg19223190	chr17:80058835	NA	0.39	6.22	0.32	1.53e-9	Life satisfaction;
CRC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg19622623	chr12:86230825	RASSF9	-0.37	-6.03	-0.32	4.3e-9	Major depressive disorder;
CRC	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	1.04	12.44	0.57	2.17e-29	Diisocyanate-induced asthma;
CRC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.48	-8.32	-0.42	2.35e-15	Blood metabolite levels;
CRC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg27535305	chr1:53392650	SCP2	-0.32	-5.71	-0.3	2.49e-8	Monocyte count;
CRC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.6	7.79	0.39	8.81e-14	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17482927	chr17:63133259	RGS9	0.46	6.24	0.33	1.37e-9	Thyroid stimulating hormone;
CRC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.64	8.2	0.41	5.39e-15	Arsenic metabolism;
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg02033258	chr5:131593261	PDLIM4	0.36	7.0	0.36	1.4e-11	Blood metabolite levels;
CRC	cis	rs9462027	0.651	rs13220394	chr6:34810172	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.02	-0.32	4.63e-9	Systemic lupus erythematosus;
CRC	cis	rs11212617	0.967	rs227074	chr11:108215095	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.47	0.34	3.66e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.93	11.91	0.55	2.03e-27	Migraine;
CRC	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.51	6.77	0.35	5.79e-11	Caudate activity during reward;
CRC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg08314208	chr16:67682810	RLTPR	-0.53	-5.81	-0.3	1.5e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.69	-0.39	1.69e-13	HDL cholesterol;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.94	-0.44	2.77e-17	Bipolar disorder;
CRC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg04362960	chr10:104952993	NT5C2	-0.46	-6.15	-0.32	2.29e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg03523603	chr1:150241529	APH1A	0.4	6.04	0.32	4.07e-9	Interleukin-6 levels;
CRC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.15	-0.32	2.26e-9	Bipolar disorder;
CRC	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg09163369	chr1:210001066	C1orf107	0.6	7.72	0.39	1.38e-13	Orofacial clefts;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg02683197	chr6:28174875	NA	0.71	8.72	0.43	1.39e-16	Parkinson's disease;
CRC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg25173405	chr17:45401733	C17orf57	0.44	6.92	0.36	2.4e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg23260525	chr10:116636907	FAM160B1	0.32	6.87	0.35	3.2e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.63	7.89	0.4	4.66e-14	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.54	-6.96	-0.36	1.9e-11	DNA methylation (variation);
CRC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg16035780	chr5:759353	NA	0.42	5.68	0.3	3e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg20356878	chr3:121714668	ILDR1	-0.45	-6.59	-0.34	1.71e-10	Multiple sclerosis;
CRC	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg10263370	chr3:44754102	ZNF502	-0.37	-6.12	-0.32	2.66e-9	Depressive symptoms;
CRC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	8.09	0.41	1.17e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1223397	0.589	rs364493	chr6:13297020	C/T	cg07912922	chr6:13274314	PHACTR1	-0.46	-6.78	-0.35	5.54e-11	Blood pressure;
CRC	cis	rs11958404	0.517	rs13154764	chr5:157305206	T/C	cg05962755	chr5:157440814	NA	0.79	8.71	0.43	1.54e-16	IgG glycosylation;
CRC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.99	-0.55	1.01e-27	Body mass index;
CRC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.71	-0.43	1.48e-16	Platelet count;
CRC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg21724239	chr8:58056113	NA	0.57	7.58	0.39	3.59e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg00745463	chr17:30367425	LRRC37B	0.54	6.66	0.34	1.12e-10	Hip circumference adjusted for BMI;
CRC	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg25856811	chr1:152973957	SPRR3	-0.23	-6.18	-0.32	1.87e-9	Inflammatory skin disease;
CRC	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg25457927	chr22:38595422	NA	-0.31	-6.23	-0.32	1.44e-9	Cutaneous nevi;
CRC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg03037974	chr15:76606532	NA	0.69	11.69	0.54	1.23e-26	Blood metabolite levels;
CRC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg10589385	chr1:150898437	SETDB1	0.3	6.25	0.33	1.26e-9	Tonsillectomy;
CRC	cis	rs11690462	0.926	rs12615704	chr2:26551903	G/C	cg22920501	chr2:26401640	FAM59B	0.4	5.7	0.3	2.63e-8	Coronary artery disease;
CRC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.43	6.44	0.33	4.32e-10	Menopause (age at onset);
CRC	cis	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg06988349	chr10:69991859	ATOH7	0.36	5.69	0.3	2.76e-8	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02884346	chr4:6271501	WFS1	0.39	6.34	0.33	7.55e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	0.98	10.06	0.49	6.35e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg10437265	chr15:77819839	NA	0.68	12.38	0.56	3.64e-29	Type 2 diabetes;
CRC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg25767906	chr1:53392781	SCP2	0.36	5.7	0.3	2.62e-8	Monocyte count;
CRC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg03885332	chr11:832357	CD151	-0.42	-6.23	-0.32	1.46e-9	Mean platelet volume;
CRC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.47	0.42	8.46e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg25164649	chr6:28176230	NA	0.49	7.14	0.37	6.11e-12	Parkinson's disease;
CRC	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg15131784	chr3:139108705	COPB2	0.39	5.64	0.3	3.61e-8	Obesity-related traits;
CRC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs12249377	0.519	rs66650915	chr10:92592468	T/C	cg14313238	chr10:92632228	RPP30	0.47	6.51	0.34	2.88e-10	White matter microstructure (global fractional anisotropy);
CRC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg24562669	chr7:97807699	LMTK2	0.44	7.25	0.37	3.09e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.36	-6.4	-0.33	5.33e-10	Height;
CRC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.91	11.11	0.52	1.41e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.15	0.32	2.31e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg21155852	chr7:2048760	MAD1L1	-0.4	-5.62	-0.3	4.03e-8	Bipolar disorder;
CRC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.54	7.2	0.37	4.14e-12	Tourette syndrome;
CRC	cis	rs9303280	0.806	rs9303279	chr17:38073968	G/C	cg00129232	chr17:37814104	STARD3	0.45	6.84	0.35	3.82e-11	Self-reported allergy;
CRC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16262614	chr3:133464971	TF	0.35	6.31	0.33	8.85e-10	Iron status biomarkers;
CRC	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.46	-7.25	-0.37	3.02e-12	Obesity-related traits;
CRC	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg06935464	chr4:38784597	TLR10	0.6	6.07	0.32	3.5e-9	Breast cancer;
CRC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.09	18.67	0.72	1.44e-53	Cognitive function;
CRC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.5	7.36	0.38	1.48e-12	Longevity;Endometriosis;
CRC	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.76	-10.27	-0.49	1.23e-21	Coronary artery disease;
CRC	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg14458575	chr2:238380390	NA	0.53	6.92	0.36	2.44e-11	Prostate cancer;
CRC	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg05562828	chr17:3906858	NA	0.46	6.07	0.32	3.47e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.6	9.31	0.46	1.81e-18	Tuberculosis;
CRC	cis	rs728616	0.867	rs78131725	chr10:81820919	C/G	cg05935833	chr10:81318306	SFTPA2	-0.56	-6.36	-0.33	6.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg20684491	chr1:25596433	NA	-0.43	-7.44	-0.38	9.12e-13	Erythrocyte sedimentation rate;
CRC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.22e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.56	6.74	0.35	7.02e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.45	-0.33	4.03e-10	Aortic root size;
CRC	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25008156	chr6:170893875	PDCD2	0.45	6.86	0.35	3.36e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.78	-0.35	5.43e-11	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7781557	0.640	rs55681588	chr7:102577338	C/G	cg18108683	chr7:102477205	FBXL13	-0.49	-5.74	-0.3	2.14e-8	Colorectal adenoma (advanced);
CRC	cis	rs6066835	0.764	rs2426103	chr20:47394490	A/C	cg18078177	chr20:47281410	PREX1	-0.59	-5.99	-0.31	5.58e-9	Multiple myeloma;
CRC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.44	-7.88	-0.4	4.9e-14	Monocyte count;
CRC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.92	-16.74	-0.68	6.08e-46	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg08314208	chr16:67682810	RLTPR	-0.5	-5.82	-0.31	1.37e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7605827	0.930	rs7596969	chr2:15513615	C/G	cg19274914	chr2:15703543	NA	-0.4	-6.16	-0.32	2.14e-9	Educational attainment (years of education);
CRC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-8.63	-0.43	2.6e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-6.63	-0.34	1.4e-10	Lung cancer;
CRC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.45	-6.71	-0.35	8.44e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.64	-8.02	-0.4	1.93e-14	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.56	7.55	0.38	4.38e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24786176	chr4:113153431	AP1AR	0.49	6.84	0.35	3.84e-11	Response to antipsychotic treatment;
CRC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-8.99	-0.44	2.04e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.73	11.32	0.53	2.66e-25	Tonsillectomy;
CRC	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg02696742	chr7:106810147	HBP1	-0.56	-5.79	-0.3	1.63e-8	Coronary artery disease;
CRC	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg24596788	chr1:163392923	NA	-0.5	-7.84	-0.4	6.28e-14	Motion sickness;
CRC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.33	-6.08	-0.32	3.37e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg20607287	chr7:12443886	VWDE	-0.55	-6.26	-0.33	1.2e-9	Coronary artery disease;
CRC	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg16850897	chr7:100343110	ZAN	0.44	6.65	0.34	1.26e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.21	-0.32	1.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg03804128	chr16:635623	NA	0.29	6.78	0.35	5.49e-11	Height;
CRC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.81	-11.2	-0.53	6.69e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.49	-0.34	3.13e-10	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16203911	chr17:7590731	WRAP53;TP53	0.41	6.25	0.33	1.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.19	-0.32	1.83e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.5	6.96	0.36	1.83e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.67	8.89	0.44	4.04e-17	Platelet count;
CRC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-9.98	-0.48	1.12e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24308560	chr3:49941425	MST1R	0.48	7.49	0.38	6.49e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9323205	0.871	rs8008599	chr14:51670057	A/G	cg23942311	chr14:51606299	NA	0.57	7.82	0.4	7.23e-14	Cancer;
CRC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.04	-0.45	1.38e-17	Gut microbiome composition (summer);
CRC	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.65	0.39	2.25e-13	Testicular germ cell tumor;
CRC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.11	-0.32	2.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.4	6.3	0.33	9.55e-10	Obesity;
CRC	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg23100626	chr2:96804247	ASTL	0.29	7.97	0.4	2.58e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.76	-0.3	1.92e-8	Arsenic metabolism;
CRC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.59	8.65	0.43	2.31e-16	Lung cancer;
CRC	cis	rs2227564	0.649	rs2948689	chr10:75657860	A/G	cg16540259	chr10:75572220	NDST2	0.41	5.71	0.3	2.51e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.45	5.78	0.3	1.77e-8	Aortic root size;
CRC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.77	10.14	0.49	3.29e-21	Monocyte percentage of white cells;
CRC	cis	rs2630709	0.562	rs3097266	chr2:8463495	T/C	cg12167548	chr2:8464763	NA	0.35	6.67	0.34	1.11e-10	Monocyte percentage of white cells;
CRC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.52	0.34	2.6e-10	Aortic root size;
CRC	cis	rs7923609	0.934	rs7923544	chr10:65182256	T/G	cg08743896	chr10:65200160	JMJD1C	-0.43	-6.16	-0.32	2.18e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs59104589	0.920	rs1476698	chr2:242296449	A/G	cg10021735	chr2:242295487	FARP2	0.4	5.78	0.3	1.7e-8	Fibrinogen levels;
CRC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg20243544	chr17:37824526	PNMT	0.37	5.74	0.3	2.17e-8	Self-reported allergy;
CRC	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.08	-0.36	8.64e-12	IgG glycosylation;
CRC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs11212617	1.000	rs11212579	chr11:108150664	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.12	0.32	2.71e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg12172441	chr6:28176163	NA	0.52	7.11	0.37	7.2e-12	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.26e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-5.87	-0.31	1.08e-8	Vitiligo;
CRC	cis	rs10924970	0.967	rs2152955	chr1:235417773	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.8	0.3	1.54e-8	Asthma;
CRC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.41	-19.91	-0.74	1.98e-58	Hip circumference adjusted for BMI;
CRC	trans	rs2303319	0.504	rs56405014	chr2:162497603	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.16	-0.32	2.13e-9	Cognitive function;
CRC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.97	12.28	0.56	8.55e-29	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24179850	chr19:56154938	ZNF581	0.39	6.19	0.32	1.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg26816564	chr1:7831052	VAMP3	0.55	5.91	0.31	8.49e-9	Inflammatory bowel disease;
CRC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.47	-8.33	-0.42	2.19e-15	Dupuytren's disease;
CRC	cis	rs7259376	0.905	rs1975172	chr19:22534603	A/G	cg02657401	chr19:22469223	NA	-0.32	-7.02	-0.36	1.27e-11	Menopause (age at onset);
CRC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.46	-6.95	-0.36	1.91e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.08	-0.32	3.42e-9	High light scatter reticulocyte count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11011774	chr17:19266179	B9D1	0.49	6.81	0.35	4.65e-11	Anxiety disorder;
CRC	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	7.9	0.4	4.16e-14	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg09835421	chr16:68378352	PRMT7	-0.48	-5.66	-0.3	3.37e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.62	-11.19	-0.52	7.76e-25	Aortic root size;
CRC	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg16486109	chr11:613632	IRF7	0.58	10.24	0.49	1.53e-21	Systemic lupus erythematosus;
CRC	cis	rs11627756	0.958	rs2146431	chr14:103071861	A/G	cg12046867	chr14:103022105	NA	0.41	5.74	0.3	2.16e-8	Mean platelet volume;
CRC	cis	rs6764363	0.527	rs115329276	chr3:282338	T/A	cg02057681	chr3:285234	CHL1	0.42	7.08	0.36	8.63e-12	Sudden cardiac arrest;
CRC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.11	0.32	2.82e-9	Height;
CRC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.62	-0.3	4.05e-8	Multiple myeloma (IgH translocation);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg07899956	chr17:74261249	FAM100B	0.59	6.48	0.34	3.39e-10	Body mass index;
CRC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.68	11.51	0.54	5.32e-26	Lung cancer;
CRC	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.65	-7.5	-0.38	5.89e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.46	9.05	0.45	1.3e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs13070584	1.000	rs16841339	chr3:99263041	C/T	cg16683008	chr14:23494327	NA	-0.71	-6.04	-0.32	4.15e-9	Chronic kidney disease and serum creatinine levels;
CRC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.65	-10.57	-0.5	1.15e-22	Motion sickness;
CRC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg06505273	chr16:24850292	NA	0.37	5.68	0.3	3.02e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4728302	0.869	rs6963032	chr7:133599527	T/C	cg03336402	chr7:133662267	EXOC4	-0.45	-6.57	-0.34	1.93e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.65	0.57	3.77e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.75	0.43	1.14e-16	Menopause (age at onset);
CRC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.51	7.26	0.37	2.88e-12	Colorectal cancer;
CRC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	11.8	0.55	5.03e-27	Platelet count;
CRC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg06138931	chr13:21896616	NA	0.56	7.14	0.37	6.03e-12	White matter hyperintensity burden;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg06470822	chr6:28175283	NA	0.72	10.35	0.5	6.55e-22	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg19041857	chr6:27730383	NA	-0.74	-7.3	-0.37	2.23e-12	Depression;
CRC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24308560	chr3:49941425	MST1R	0.51	8.25	0.41	3.73e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg14003231	chr6:33640908	ITPR3	0.49	7.85	0.4	5.97e-14	Plateletcrit;
CRC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.45	-6.69	-0.35	9.48e-11	Breast size;
CRC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg07870213	chr5:140052090	DND1	0.64	8.34	0.42	2.01e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs9648716	0.810	rs2706775	chr7:140518968	C/T	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15356780	chr14:90422831	TDP1	0.5	6.56	0.34	2.09e-10	Thyroid stimulating hormone;
CRC	cis	rs1223397	0.651	rs2439545	chr6:13313844	C/T	cg07912922	chr6:13274314	PHACTR1	-0.37	-5.67	-0.3	3.17e-8	Blood pressure;
CRC	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.23	0.53	5.39e-25	Prudent dietary pattern;
CRC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg24851651	chr11:66362959	CCS	0.34	5.67	0.3	3.17e-8	Educational attainment (years of education);
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg27094323	chr7:1216898	NA	-0.38	-6.12	-0.32	2.65e-9	Longevity;Endometriosis;
CRC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.6	-8.58	-0.43	3.86e-16	Inflammatory bowel disease;
CRC	trans	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg12790874	chr13:100310405	CLYBL	0.62	6.51	0.34	2.86e-10	Breast cancer;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.9	-20.37	-0.75	2.89e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg21724239	chr8:58056113	NA	-0.51	-6.7	-0.35	9.03e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.54	-7.27	-0.37	2.63e-12	Post bronchodilator FEV1;
CRC	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.34	-5.75	-0.3	2.08e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.5	-0.46	4.59e-19	Prevalent atrial fibrillation;
CRC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.21	-0.37	3.76e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16262614	chr3:133464971	TF	0.35	6.03	0.32	4.47e-9	Iron status biomarkers;
CRC	cis	rs2227564	0.700	rs2688612	chr10:75653205	G/T	cg00564723	chr10:75632066	CAMK2G	-0.3	-7.04	-0.36	1.15e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	1.14	10.25	0.49	1.46e-21	Arsenic metabolism;
CRC	cis	rs11212617	1.000	rs600329	chr11:108163733	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.13	0.32	2.48e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10512697	0.655	rs35249343	chr5:3463116	G/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00166722	chr3:10149974	C3orf24	-0.44	-6.51	-0.34	2.8e-10	Alzheimer's disease;
CRC	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.41	5.96	0.31	6.66e-9	Lymphocyte percentage of white cells;
CRC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.14	-0.32	2.38e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs847649	0.842	rs1608651	chr7:102624192	C/T	cg18108683	chr7:102477205	FBXL13	0.54	8.57	0.43	4.09e-16	Morning vs. evening chronotype;
CRC	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg12908607	chr1:44402522	ARTN	-0.35	-6.16	-0.32	2.12e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	7.42	0.38	1.02e-12	Schizophrenia;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg24596729	chr1:165345813	NA	-0.54	-6.42	-0.33	4.78e-10	Lung adenocarcinoma;
CRC	trans	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg26043149	chr18:55253948	FECH	0.52	7.88	0.4	4.98e-14	Bone mineral density;
CRC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.26	-0.41	3.59e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs6141769	0.542	rs6057627	chr20:31306728	C/G	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.92	-0.31	8.02e-9	Subjective well-being;
CRC	cis	rs728616	0.867	rs56000427	chr10:81986946	A/G	cg11900509	chr10:81946545	ANXA11	-0.73	-6.9	-0.36	2.69e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.52	8.49	0.42	7.41e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg15131784	chr3:139108705	COPB2	0.41	5.93	0.31	7.87e-9	Obesity-related traits;
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg20608306	chr11:116969690	SIK3	0.31	6.27	0.33	1.12e-9	Blood protein levels;
CRC	cis	rs1322512	1.000	rs2800631	chr6:153008631	T/C	cg03415253	chr6:152958462	SYNE1	0.39	6.01	0.31	4.94e-9	Tonometry;
CRC	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.4	-0.33	5.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1545257	0.537	rs4581852	chr2:24638256	C/A	cg06627628	chr2:24431161	ITSN2	-0.47	-7.02	-0.36	1.27e-11	Sjögren's syndrome;
CRC	cis	rs11574514	1.000	rs8049622	chr16:67800927	G/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-5.88	-0.31	1e-8	Crohn's disease;
CRC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg12590608	chr7:158785262	NA	0.44	7.46	0.38	7.7e-13	Facial morphology (factor 20);
CRC	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg17545662	chr6:170176663	C6orf70	0.53	5.91	0.31	8.6e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg22974920	chr21:40686053	BRWD1	0.43	5.96	0.31	6.52e-9	Cognitive function;
CRC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.94e-15	Life satisfaction;
CRC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.66	10.96	0.52	4.98e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg06363034	chr20:62225388	GMEB2	-0.44	-6.76	-0.35	6.44e-11	Glioblastoma;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.04	-0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22133161	chr19:49891603	CCDC155	0.46	6.43	0.33	4.58e-10	Multiple sclerosis;
CRC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.78	13.66	0.6	6e-34	Breast cancer;
CRC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg15845792	chr6:28175446	NA	0.89	12.53	0.57	1.03e-29	Parkinson's disease;
CRC	cis	rs6546324	0.625	rs2861695	chr2:67846727	A/G	cg15745817	chr2:67799979	NA	-0.57	-9.7	-0.47	1.01e-19	Endometriosis;
CRC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.44	7.13	0.37	6.26e-12	Resting heart rate;
CRC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg12927641	chr6:109611667	NA	-0.38	-6.74	-0.35	7.22e-11	Reticulocyte fraction of red cells;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9359856	1.000	rs9359856	chr6:90307985	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.44	-6.45	-0.34	3.95e-10	Bipolar disorder;
CRC	cis	rs11212617	0.840	rs228599	chr11:108107660	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.65	0.3	3.46e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.45	-7.11	-0.36	7.26e-12	Cardiovascular disease risk factors;
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.57	0.75	5.01e-61	Prudent dietary pattern;
CRC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.54	8.83	0.44	6.51e-17	Colorectal cancer;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg20933634	chr6:27740509	NA	0.53	6.39	0.33	5.74e-10	Depression;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg23161317	chr6:28129485	ZNF389	0.43	5.71	0.3	2.46e-8	Parkinson's disease;
CRC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.43	-7.49	-0.38	6.55e-13	Facial morphology (factor 20);
CRC	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg09597638	chr17:3907349	NA	0.56	9.64	0.47	1.55e-19	Type 2 diabetes;
CRC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.94	-0.4	3.24e-14	Height;
CRC	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-8.05	-0.41	1.57e-14	QT interval;
CRC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.05	0.45	1.31e-17	Alzheimer's disease (late onset);
CRC	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.34	-6.83	-0.35	4.15e-11	Cutaneous nevi;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23784313	chr12:15942613	EPS8	0.44	6.44	0.33	4.28e-10	Response to antipsychotic treatment;
CRC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.18	11.57	0.54	3.24e-26	Skin colour saturation;
CRC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg03037974	chr15:76606532	NA	-0.49	-7.2	-0.37	4.24e-12	Blood metabolite levels;
CRC	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg04731861	chr2:219085781	ARPC2	0.3	6.22	0.32	1.49e-9	Ulcerative colitis;
CRC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.7	0.39	1.62e-13	Lymphocyte percentage of white cells;
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg04969067	chr8:143858791	LYNX1	0.46	7.76	0.39	1.05e-13	Urinary tract infection frequency;
CRC	cis	rs10743315	0.643	rs16915128	chr12:19304286	G/T	cg02471346	chr12:19282374	PLEKHA5	-0.7	-6.65	-0.34	1.2e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg06470822	chr6:28175283	NA	0.8	11.76	0.54	6.84e-27	Parkinson's disease;
CRC	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.49	7.7	0.39	1.63e-13	Red blood cell count;
CRC	cis	rs6681460	0.966	rs9659879	chr1:67121434	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.38	0.42	1.54e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg08888203	chr3:10149979	C3orf24	0.69	9.74	0.47	7.48e-20	Alzheimer's disease;
CRC	cis	rs1030268	1.000	rs748754	chr7:133509069	G/A	cg03336402	chr7:133662267	EXOC4	-0.55	-7.07	-0.36	9.2e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-9.51	-0.46	4.03e-19	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg04121214	chr22:50244548	NA	0.39	5.78	0.3	1.75e-8	Schizophrenia;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg06701443	chr5:173043757	BOD1	-0.41	-6.01	-0.31	4.9e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.15	-0.37	5.66e-12	Total body bone mineral density;
CRC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	10.63	0.51	7.23e-23	Chronic sinus infection;
CRC	cis	rs12913538	0.962	rs10851714	chr15:62897029	A/G	cg09983546	chr15:62884068	NA	-0.61	-9.87	-0.48	2.74e-20	Sleep depth;
CRC	cis	rs13315871	1.000	rs4585221	chr3:58415567	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	8.33	0.42	2.18e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.47	-6.18	-0.32	1.93e-9	Type 2 diabetes;
CRC	cis	rs4074493	1.000	rs4658875	chr1:231168994	C/T	cg22172038	chr1:231176991	FAM89A	-0.35	-6.15	-0.32	2.21e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs17681684	0.541	rs12150176	chr17:9764547	C/T	cg26853458	chr17:9805074	RCVRN	0.53	9.33	0.46	1.66e-18	GIP levels in response to oral glucose tolerance test (fasting);
CRC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	cis	rs6804368	0.649	rs1350784	chr3:30754016	C/T	cg06106510	chr3:30762233	NA	0.42	7.59	0.39	3.41e-13	Blood metabolite levels;
CRC	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs2055729	0.645	rs12056944	chr8:9742525	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.02	0.36	1.24e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.78	10.71	0.51	3.64e-23	Cognitive function;
CRC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	8.47	0.42	8.18e-16	Height;
CRC	cis	rs11212617	1.000	rs227077	chr11:108253252	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.42	0.33	4.67e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg09877947	chr5:131593287	PDLIM4	0.44	7.23	0.37	3.46e-12	Blood metabolite levels;
CRC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.43	-8.67	-0.43	2.03e-16	Renal cell carcinoma;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02725872	chr8:58115012	NA	-0.59	-9.18	-0.45	4.97e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.41e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs12618769	0.597	rs2278208	chr2:99154229	C/T	cg18455616	chr2:99124870	INPP4A	0.36	5.92	0.31	8.23e-9	Bipolar disorder;
CRC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.8	-14.02	-0.61	2.53e-35	Dementia with Lewy bodies;
CRC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.53	-7.72	-0.39	1.39e-13	Lung cancer;
CRC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.85	16.11	0.66	1.88e-43	Dental caries;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg00978845	chr7:104752077	MLL5	-0.39	-6.82	-0.35	4.45e-11	HDL cholesterol;
CRC	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.3	1.5e-8	Metabolite levels;
CRC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.76	14.24	0.62	3.45e-36	Prudent dietary pattern;
CRC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.86	-0.44	5.1e-17	Prostate cancer;
CRC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg21466736	chr12:48725269	NA	0.51	7.72	0.39	1.45e-13	Glycated hemoglobin levels;
CRC	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg03162506	chr22:38580953	NA	-0.27	-5.79	-0.3	1.69e-8	Cutaneous nevi;
CRC	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.71	9.65	0.47	1.42e-19	Menopause (age at onset);
CRC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg08992911	chr2:238395768	MLPH	0.63	6.31	0.33	9.11e-10	Prostate cancer;
CRC	cis	rs2179367	0.959	rs480034	chr6:149735430	C/T	cg07828024	chr6:149772892	ZC3H12D	0.39	6.17	0.32	2.04e-9	Dupuytren's disease;
CRC	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg02466173	chr16:30829666	NA	-0.56	-7.96	-0.4	2.74e-14	Dementia with Lewy bodies;
CRC	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg23505145	chr19:12996616	KLF1	0.51	7.92	0.4	3.69e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg20243544	chr17:37824526	PNMT	0.53	8.38	0.42	1.59e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg00490450	chr3:139108681	COPB2	0.43	6.43	0.33	4.53e-10	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg25985355	chr7:65971099	NA	-0.5	-5.73	-0.3	2.25e-8	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24730871	chr19:19516902	GATAD2A	0.37	6.19	0.32	1.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.43	0.38	9.25e-13	Motion sickness;
CRC	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg00260937	chr7:128520193	KCP	-0.39	-6.09	-0.32	3.2e-9	Calcium levels;
CRC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.59	6.66	0.34	1.17e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	10.98	0.52	4.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg23229016	chr1:26872525	RPS6KA1	-0.3	-7.21	-0.37	3.89e-12	Glucose homeostasis traits;
CRC	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.19	-0.37	4.5e-12	Multiple myeloma (hyperdiploidy);
CRC	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.58	-0.34	1.86e-10	Neuroticism;
CRC	trans	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.65	-9.46	-0.46	6.05e-19	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00563090	chr7:148680266	NA	0.37	5.99	0.31	5.42e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25947998	chr8:42948467	SGK196	0.5	6.45	0.34	4.02e-10	Thyroid stimulating hormone;
CRC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg23205692	chr1:25664452	TMEM50A	0.43	6.17	0.32	1.98e-9	Erythrocyte sedimentation rate;
CRC	cis	rs6968419	0.674	rs6466571	chr7:115910045	A/G	cg02561103	chr7:115862891	TES	0.42	6.25	0.33	1.29e-9	Intraocular pressure;
CRC	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.57	7.07	0.36	9.46e-12	Ulcerative colitis;
CRC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.83	0.4	6.61e-14	Lung cancer;
CRC	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg22482690	chr17:47019901	SNF8	0.49	8.09	0.41	1.16e-14	Type 2 diabetes;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg16576620	chr11:61596068	FADS2	-0.51	-6.68	-0.35	1.05e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.98	15.85	0.66	1.96e-42	Primary sclerosing cholangitis;
CRC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.85	0.35	3.56e-11	Major depressive disorder;
CRC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.84	-0.31	1.26e-8	Carotid intima media thickness;
CRC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.28	0.42	3.22e-15	Menopause (age at onset);
CRC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg18721089	chr20:30220636	NA	-0.36	-5.82	-0.31	1.39e-8	Mean corpuscular hemoglobin;
CRC	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.88	-0.31	9.84e-9	Migraine - clinic-based;
CRC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.58	-0.39	3.62e-13	QT interval;
CRC	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.51	-7.59	-0.39	3.4e-13	DNA methylation (variation);
CRC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06953865	chr19:18549723	ISYNA1	-0.37	-5.65	-0.3	3.56e-8	Breast cancer;
CRC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.03	-14.17	-0.62	6.58e-36	Hemostatic factors and hematological phenotypes;
CRC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.39	-5.86	-0.31	1.11e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1945380	0.964	rs1970728	chr11:80394267	C/G	cg07625156	chr15:43426262	TMEM62	0.47	6.01	0.31	5.01e-9	Diabetic kidney disease;
CRC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg10298567	chr3:47292165	KIF9	0.37	5.84	0.31	1.28e-8	Colorectal cancer;
CRC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	10.27	0.49	1.21e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.96	-0.48	1.31e-20	Total cholesterol levels;
CRC	cis	rs1519814	0.956	rs11774123	chr8:121119274	C/T	cg22335954	chr8:121166405	COL14A1	0.52	6.28	0.33	1.05e-9	Breast cancer;
CRC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.62	-0.34	1.45e-10	Total body bone mineral density;
CRC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.64	9.86	0.48	2.92e-20	Bipolar disorder;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg16558177	chr4:4109446	NA	-0.62	-8.71	-0.43	1.55e-16	Blood pressure (smoking interaction);
CRC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.76	-9.38	-0.46	1.13e-18	Body mass index;
CRC	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.46	-7.82	-0.4	7.4e-14	Congenital heart disease (maternal effect);
CRC	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg09659197	chr4:152720779	NA	0.3	5.62	0.3	4.07e-8	Intelligence (multi-trait analysis);
CRC	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg23815491	chr16:72088622	HP	0.5	7.23	0.37	3.35e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07796735	chr12:49932860	KCNH3	0.4	6.22	0.32	1.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg19875578	chr6:126661172	C6orf173	0.43	5.94	0.31	7.11e-9	Male-pattern baldness;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.25	0.37	2.91e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.55	9.01	0.44	1.69e-17	Corneal astigmatism;
CRC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg15845792	chr6:28175446	NA	0.58	5.88	0.31	9.81e-9	Depression;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg12172441	chr6:28176163	NA	0.45	6.35	0.33	7.19e-10	Parkinson's disease;
CRC	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg15192750	chr16:69999425	NA	0.55	7.1	0.36	7.79e-12	IgE levels;
CRC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	cis	rs9584850	0.834	rs745639	chr13:99119279	C/T	cg07423050	chr13:99094983	FARP1	0.46	6.58	0.34	1.84e-10	Neuroticism;
CRC	trans	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.0	0.36	1.46e-11	Ulcerative colitis;
CRC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.04e-11	Lung cancer;
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg21784768	chr11:537496	LRRC56	-0.68	-6.43	-0.33	4.37e-10	Body mass index;
CRC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.71	-11.82	-0.55	4.26e-27	Breast cancer;
CRC	cis	rs11748023	0.605	rs155948	chr5:139519181	A/G	cg26211634	chr5:139558579	C5orf32	-0.36	-6.2	-0.32	1.7e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6686842	0.932	rs1008505	chr1:41560235	C/T	cg19787969	chr8:9763211	NA	0.28	6.05	0.32	3.99e-9	Height;
CRC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.89	12.19	0.56	1.87e-28	Height;
CRC	trans	rs7227892	0.659	rs9959212	chr18:46342442	C/T	cg16735821	chr18:13727230	C18orf19;RNMT	0.51	6.52	0.34	2.6200000000000003e-10	Migraine with aura;
CRC	cis	rs282587	0.569	rs377748	chr13:113405482	C/T	cg04656015	chr13:113407548	ATP11A	0.58	7.04	0.36	1.15e-11	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03744954	chr7:23637556	CCDC126	0.39	6.11	0.32	2.79e-9	Response to antipsychotic treatment;
CRC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.98	-0.44	2.14e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.49	-9.79	-0.48	4.94e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.33	-5.9	-0.31	8.83e-9	Monocyte percentage of white cells;
CRC	cis	rs7945718	0.621	rs4606460	chr11:12687781	A/G	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	5.06e-12	Educational attainment (years of education);
CRC	trans	rs800082	1.000	rs9289678	chr3:144307096	C/T	cg24215973	chr2:240111563	HDAC4	0.51	6.9	0.36	2.73e-11	Smoking behavior;
CRC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.36	6.38	0.33	6.18e-10	Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08998414	chr7:129483134	UBE2H	0.42	6.28	0.33	1.07e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg16591659	chr17:78472290	NA	-0.43	-6.23	-0.32	1.42e-9	Fractional excretion of uric acid;
CRC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1178968	0.748	rs10248063	chr7:72776008	T/G	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.59	-0.34	1.76e-10	Bipolar disorder;
CRC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.81	-14.39	-0.62	9.31e-37	Breast cancer;
CRC	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg00734567	chr1:86172782	ZNHIT6	0.4	6.08	0.32	3.39e-9	Urate levels in overweight individuals;
CRC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.58	0.34	1.87e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg00564723	chr10:75632066	CAMK2G	0.24	5.95	0.31	7.02e-9	Inflammatory bowel disease;
CRC	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.68	9.73	0.47	7.94e-20	Body mass index;
CRC	cis	rs747650	0.504	rs7112854	chr11:47116823	T/C	cg19486271	chr11:47235900	DDB2	0.44	5.89	0.31	9.76e-9	Acne (severe);
CRC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.62	8.03	0.4	1.74e-14	Gut microbiome composition (summer);
CRC	cis	rs2708977	0.730	rs596069	chr2:97076642	C/T	cg23100626	chr2:96804247	ASTL	-0.24	-6.37	-0.33	6.53e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.33	5.67	0.3	3.17e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.1	-0.32	2.98e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.98	-0.44	2.07e-17	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg12927641	chr6:109611667	NA	-0.35	-6.25	-0.33	1.25e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2179367	0.919	rs577001	chr6:149646308	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.14	-0.32	2.39e-9	Dupuytren's disease;
CRC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.35	-0.42	1.91e-15	Aortic root size;
CRC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.84	12.46	0.57	1.94e-29	Gut microbiome composition (summer);
CRC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg04518342	chr5:131593106	PDLIM4	0.33	5.82	0.31	1.39e-8	Blood metabolite levels;
CRC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.5	0.38	5.94e-13	Aortic root size;
CRC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.79	0.66	3.5e-42	Intelligence (multi-trait analysis);
CRC	trans	rs7619427	0.544	rs9872382	chr3:44021964	C/A	cg09408571	chr1:101003634	GPR88	0.44	6.05	0.32	3.96e-9	Schizophrenia;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.34	0.42	2.13e-15	Menopause (age at onset);
CRC	cis	rs755249	0.567	rs4660208	chr1:39722214	A/G	cg18385671	chr1:39797026	MACF1	-0.43	-6.01	-0.31	4.86e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg17321639	chr7:2759063	NA	-0.43	-6.34	-0.33	7.77e-10	Height;
CRC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg23625390	chr15:77176239	SCAPER	0.48	7.06	0.36	9.99e-12	Blood metabolite levels;
CRC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.53	7.08	0.36	8.88e-12	Obesity-related traits;
CRC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.58	0.34	1.9e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.46	-7.11	-0.36	7.29e-12	Large artery stroke;
CRC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs501120	1.000	rs552794	chr10:44771666	G/A	cg09554077	chr10:44749378	NA	0.78	11.91	0.55	1.96e-27	Coronary artery disease;Coronary heart disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21646186	chr1:110052458	AMIGO1	0.43	6.23	0.32	1.46e-9	Anxiety disorder;
CRC	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg24505167	chr7:1915268	MAD1L1	-0.49	-7.44	-0.38	8.84e-13	Bipolar disorder;
CRC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.95	-15.03	-0.64	3.21e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg23071808	chr14:103021642	NA	0.62	6.96	0.36	1.82e-11	Platelet count;
CRC	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg14119001	chr9:139324193	INPP5E	-0.44	-5.89	-0.31	9.75e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg00086871	chr4:6988644	TBC1D14	1.06	7.57	0.39	3.68e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.71	-0.39	1.46e-13	Blood metabolite levels;
CRC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.45	-6.38	-0.33	5.99e-10	Cognitive ability;
CRC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.83	-13.35	-0.59	8.98e-33	Body mass index (adult);
CRC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.58	9.89	0.48	2.32e-20	Total body bone mineral density;
CRC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg14593290	chr7:50529359	DDC	0.55	7.57	0.38	3.88e-13	Malaria;
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.43	-6.12	-0.32	2.63e-9	Lymphocyte counts;
CRC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-8.31	-0.42	2.59e-15	Personality dimensions;
CRC	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg06632207	chr12:54070931	ATP5G2	0.36	6.14	0.32	2.36e-9	Height;
CRC	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg21770322	chr7:97807741	LMTK2	0.53	8.69	0.43	1.73e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.92	-15.22	-0.64	5.67e-40	Gut microbiota (bacterial taxa);
CRC	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22228296	chr3:141457315	RNF7	0.46	6.43	0.33	4.39e-10	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.76	0.47	6.41e-20	Corneal astigmatism;
CRC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07701084	chr6:150067640	NUP43	0.49	7.17	0.37	4.95e-12	Testicular germ cell tumor;
CRC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.34	6.35	0.33	6.98e-10	QRS complex (12-leadsum);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17436946	chr4:39699568	UBE2K	-0.4	-6.05	-0.32	3.85e-9	Myopia (pathological);
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11645453	chr3:52864694	ITIH4	0.34	6.32	0.33	8.61e-10	Electroencephalogram traits;
CRC	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.46	7.01	0.36	1.37e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.61	-0.43	3.03e-16	IgG glycosylation;
CRC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg04731861	chr2:219085781	ARPC2	-0.3	-6.22	-0.32	1.47e-9	Colorectal cancer;
CRC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg25456477	chr12:86230367	RASSF9	0.38	6.43	0.33	4.41e-10	Major depressive disorder;
CRC	trans	rs1864729	1.000	rs2053481	chr8:98278923	C/T	cg08679828	chr8:102218111	ZNF706	-0.6	-7.23	-0.37	3.37e-12	Estradiol plasma levels (breast cancer);
CRC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.1	0.45	8.64e-18	Cognitive test performance;
CRC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.69	9.42	0.46	8.11e-19	Breast cancer;
CRC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.65	8.12	0.41	9.7e-15	Gut microbiome composition (summer);
CRC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.61	11.58	0.54	2.94e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs17126268	0.502	rs2185432	chr1:102878478	T/G	cg18468354	chr14:36993517	NA	0.38	6.12	0.32	2.65e-9	Glomerular filtration rate;
CRC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.78	-0.3	1.75e-8	Bipolar disorder;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.63	7.28	0.37	2.52e-12	Parkinson's disease;
CRC	cis	rs17065868	0.764	rs61949769	chr13:45023064	C/G	cg10246903	chr13:45222710	NA	0.57	6.28	0.33	1.06e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.26	0.33	1.22e-9	Tonsillectomy;
CRC	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg07807695	chr5:81608485	ATP6AP1L	-0.47	-7.38	-0.38	1.3e-12	Breast cancer;
CRC	cis	rs6554196	0.932	rs6825657	chr4:55515359	A/G	cg18836493	chr4:55524333	KIT	-0.34	-5.73	-0.3	2.22e-8	Monocyte count;
CRC	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg23034840	chr1:205782522	SLC41A1	0.48	6.47	0.34	3.51e-10	White blood cell types;
CRC	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.69	-0.35	9.81e-11	Putamen volume;
CRC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.08	0.32	3.28e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.66	9.92	0.48	1.79e-20	Selective IgA deficiency;
CRC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-18.93	-0.72	1.46e-54	Height;
CRC	trans	rs2303319	0.582	rs12464282	chr2:162448855	C/T	cg27113153	chr11:123612418	ZNF202	-0.7	-6.15	-0.32	2.28e-9	Cognitive function;
CRC	cis	rs7680126	0.596	rs17418533	chr4:10316941	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.12	-0.32	2.69e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.56	-8.47	-0.42	8.21e-16	Height;
CRC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.27	0.64	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.37	6.7	0.35	8.94e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg19131313	chr8:1704013	NA	-0.48	-5.74	-0.3	2.17e-8	Systolic blood pressure;
CRC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg16892393	chr17:41919603	NA	0.44	6.45	0.33	4.09e-10	Triglycerides;
CRC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.29	0.33	9.9e-10	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09888562	chr16:54318314	IRX3	0.29	6.02	0.31	4.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	10.98	0.52	4.18e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg04166393	chr7:2884313	GNA12	0.38	5.79	0.3	1.67e-8	Height;
CRC	trans	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.66	0.34	1.14e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.41	-0.33	4.97e-10	Alzheimer's disease (late onset);
CRC	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.38	5.62	0.3	4.13e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.77	14.36	0.62	1.2e-36	Hip circumference;
CRC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.29	6.39	0.33	5.54e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	7.23	0.37	3.34e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	9.04	0.45	1.36e-17	Fuchs's corneal dystrophy;
CRC	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.13	0.49	3.7e-21	Corneal astigmatism;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.37	7.09	0.36	8.48e-12	Longevity;Endometriosis;
CRC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.82	-0.31	1.42e-8	Aortic root size;
CRC	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	6.53	0.34	2.51e-10	Blood protein levels;
CRC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.26	0.53	4.24e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.58	-7.37	-0.38	1.43e-12	Gut microbiome composition (summer);
CRC	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	8.57	0.43	4.12e-16	High light scatter reticulocyte percentage of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12243255	chr3:39194549	CSRNP1	0.45	6.29	0.33	1.01e-9	Response to antipsychotic treatment;
CRC	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.5	6.48	0.34	3.4e-10	Age-related disease endophenotypes;
CRC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.12	-0.37	6.68e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.6	-8.03	-0.4	1.77e-14	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.23	0.37	3.32e-12	Aortic root size;
CRC	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg09455208	chr3:40491958	NA	0.31	6.06	0.32	3.74e-9	Renal cell carcinoma;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22137448	chr16:2318988	RNPS1	0.41	6.24	0.33	1.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.66	0.34	1.12e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.65	12.97	0.58	2.28e-31	HDL cholesterol levels;
CRC	cis	rs10982256	0.567	rs11791072	chr9:117238655	C/T	cg13636371	chr9:117264095	DFNB31	0.33	6.32	0.33	8.46e-10	Bipolar disorder;
CRC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-15.91	-0.66	1.12e-42	Body mass index;
CRC	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10802521	chr3:52805072	NEK4	-0.43	-6.66	-0.34	1.13e-10	Electroencephalogram traits;
CRC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.61	-9.78	-0.47	5.44e-20	Height;
CRC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.77	-12.9	-0.58	4.46e-31	Coronary artery disease;
CRC	cis	rs7107770	0.514	rs7938677	chr11:125072861	A/G	cg27629782	chr11:125073726	PKNOX2	0.51	7.27	0.37	2.57e-12	Photic sneeze reflex;
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg22687807	chr8:143858763	LYNX1	0.52	9.22	0.45	3.78e-18	Urinary tract infection frequency;
CRC	trans	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.54	-8.61	-0.43	2.99e-16	DNA methylation (variation);
CRC	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06771106	chr2:113671356	IL1F7	-0.39	-5.7	-0.3	2.62e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-6.96	-0.36	1.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.67	7.14	0.37	5.9e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549328	0.700	rs3011473	chr13:113618096	A/G	cg25790453	chr13:113633590	MCF2L	0.45	7.84	0.4	6.24e-14	Systolic blood pressure;
CRC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.82	15.29	0.64	2.97e-40	Mean platelet volume;
CRC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.38	6.27	0.33	1.16e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg13385794	chr1:248469461	NA	0.39	6.98	0.36	1.62e-11	Common traits (Other);
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.69	-0.3	2.82e-8	Longevity;Endometriosis;
CRC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.57	8.69	0.43	1.68e-16	Obesity-related traits;
CRC	trans	rs8097070	0.661	rs9966711	chr18:23171413	C/G	cg10708793	chr17:40264626	DHX58	0.56	6.02	0.31	4.66e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.45	-7.1	-0.36	7.84e-12	Vitiligo;
CRC	cis	rs12760731	0.686	rs12749597	chr1:178578227	A/T	cg00404053	chr1:178313656	RASAL2	0.76	7.14	0.37	6.19e-12	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs10046574	0.561	rs9656458	chr7:135202300	G/A	cg27474649	chr7:135195673	CNOT4	0.66	6.21	0.32	1.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-8.9	-0.44	3.82e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.34	0.33	7.42e-10	Melanoma;
CRC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg00334542	chr7:100209784	MOSPD3	-0.57	-6.99	-0.36	1.58e-11	Other erythrocyte phenotypes;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg03623178	chr6:28175578	NA	0.93	12.3	0.56	7.59e-29	Depression;
CRC	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg01843034	chr6:37503916	NA	-0.37	-6.34	-0.33	7.43e-10	Cognitive performance;
CRC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.47	0.53	7.73e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg03037974	chr15:76606532	NA	-0.51	-7.27	-0.37	2.66e-12	Blood metabolite levels;
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12648201	chr2:27665141	KRTCAP3	0.29	5.67	0.3	3.14e-8	Total body bone mineral density;
CRC	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	0.78	15.73	0.66	5.89e-42	Leprosy;
CRC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.2	0.32	1.73e-9	Asthma;
CRC	cis	rs12620999	0.555	rs10199274	chr2:238111864	G/C	cg15867307	chr2:238110829	NA	0.44	7.17	0.37	4.87e-12	Systemic lupus erythematosus;
CRC	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg25019722	chr6:37503610	NA	-0.42	-7.43	-0.38	9.32e-13	Cognitive performance;
CRC	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg14631576	chr9:95140430	CENPP	-0.32	-6.11	-0.32	2.86e-9	Height;
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.72	-14.08	-0.61	1.45e-35	Leprosy;
CRC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22133161	chr19:49891603	CCDC155	-0.5	-6.37	-0.33	6.41e-10	Multiple sclerosis;
CRC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg18761221	chr20:60518478	NA	0.44	7.14	0.37	5.92e-12	Body mass index;
CRC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg26354017	chr1:205819088	PM20D1	0.42	6.26	0.33	1.17e-9	Prostate cancer;
CRC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.99	0.31	5.4e-9	Height;
CRC	cis	rs7192380	0.964	rs55780735	chr16:69740374	A/G	cg00738113	chr16:70207722	CLEC18C	0.32	5.68	0.3	2.91e-8	Sjögren's syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24806126	chr5:14581620	FAM105A	0.39	6.08	0.32	3.42e-9	Response to antipsychotic treatment;
CRC	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg08632701	chr21:37451849	NA	-0.42	-6.6	-0.34	1.68e-10	Mitral valve prolapse;
CRC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.37	0.33	6.52e-10	Aortic root size;
CRC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.38	5.6	0.3	4.48e-8	Electroencephalogram traits;
CRC	cis	rs4594175	0.892	rs10135768	chr14:51671017	G/T	cg23942311	chr14:51606299	NA	0.54	8.44	0.42	9.9e-16	Cancer;
CRC	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.69	-0.47	1.11e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg08798685	chr6:27730294	NA	0.39	5.91	0.31	8.56e-9	Systemic lupus erythematosus;
CRC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-18.77	-0.72	5.86e-54	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17270843	chr10:99079074	FRAT1	0.3	6.25	0.33	1.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4237845	0.611	rs6581159	chr12:58323876	C/T	cg02175503	chr12:58329896	NA	-0.54	-7.59	-0.39	3.24e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg10498984	chr16:28874827	SH2B1	-0.73	-6.25	-0.33	1.3e-9	Cognitive function;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg01191114	chr3:48936118	SLC25A20	-0.68	-5.96	-0.31	6.49e-9	Cognitive function;
CRC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.3	6.36	0.33	6.66e-10	Lung cancer;
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg19913688	chr11:428466	ANO9	-0.68	-6.98	-0.36	1.65e-11	Body mass index;
CRC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09174674	chr1:9884042	CLSTN1	0.37	6.15	0.32	2.27e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.79	-12.51	-0.57	1.27e-29	Blood pressure (smoking interaction);
CRC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs73206853	0.764	rs28569834	chr12:110826208	T/G	cg12870014	chr12:110450643	ANKRD13A	0.63	8.1	0.41	1.06e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg00631329	chr6:26305371	NA	-0.53	-8.86	-0.44	5.06e-17	Educational attainment;
CRC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg24375607	chr4:120327624	NA	-0.47	-7.88	-0.4	4.89e-14	Corneal astigmatism;
CRC	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.6	-6.61	-0.34	1.55e-10	Body mass index;
CRC	cis	rs57590327	0.527	rs7610703	chr3:81613942	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-6.77	-0.35	5.78e-11	Extraversion;
CRC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg13844804	chr7:814759	HEATR2	0.66	8.51	0.42	6.07e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.56	-8.45	-0.42	9.3e-16	Uric acid levels;
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg12516270	chr8:143859308	LYNX1	0.43	7.56	0.38	4.03e-13	Urinary tract infection frequency;
CRC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg00450029	chr8:599525	NA	0.64	5.86	0.31	1.12e-8	IgG glycosylation;
CRC	cis	rs78663649	0.708	rs115656720	chr19:16622921	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	-0.85	-6.16	-0.32	2.12e-9	White blood cell count;
CRC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.77	11.71	0.54	1.07e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs672059	1.000	rs547905	chr1:183157924	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.51	7.25	0.37	3e-12	Hypertriglyceridemia;
CRC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.55	8.02	0.4	1.89e-14	Melanoma;
CRC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.76	0.51	2.41e-23	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.09	0.32	3.21e-9	Life satisfaction;
CRC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.65	8.74	0.43	1.2e-16	Methadone dose in opioid dependence;
CRC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.96	14.12	0.61	1.02e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.45	-7.71	-0.39	1.52e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.52	7.45	0.38	8.29e-13	Testicular germ cell tumor;
CRC	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.92	-11.43	-0.53	1.04e-25	Exhaled nitric oxide output;
CRC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.69	10.33	0.5	7.26e-22	Corneal astigmatism;
CRC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.48	-8.96	-0.44	2.53e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg06632207	chr12:54070931	ATP5G2	-0.42	-7.24	-0.37	3.13e-12	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03756640	chr12:102091773	CHPT1	0.42	5.99	0.31	5.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-7.57	-0.39	3.74e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.4	6.47	0.34	3.57e-10	Survival in rectal cancer;
CRC	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-6.05	-0.32	3.91e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.53	-8.49	-0.42	7.27e-16	Prostate cancer;
CRC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.59	-8.93	-0.44	3.17e-17	Obesity-related traits;
CRC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.44	6.9	0.36	2.64e-11	Vitiligo;
CRC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.39	6.44	0.33	4.25e-10	Major depressive disorder;
CRC	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	6.71	0.35	8.44e-11	Lymphocyte counts;
CRC	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg11189052	chr15:85197271	WDR73	-0.51	-6.94	-0.36	2.14e-11	Alzheimer's disease (age of onset);
CRC	trans	rs855408	0.959	rs208994	chr6:62870244	C/T	cg21737066	chr3:72495901	RYBP	0.51	6.14	0.32	2.43e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	9.92	0.48	1.87e-20	Bipolar disorder;
CRC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.69	11.98	0.55	1.09e-27	Gout;
CRC	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-8.01	-0.4	2.06e-14	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg25985355	chr7:65971099	NA	-0.51	-5.9	-0.31	9.27e-9	Diabetic kidney disease;
CRC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg20534287	chr10:135191450	PAOX	0.68	6.25	0.33	1.25e-9	Lifespan;
CRC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.15	0.74	2.12e-59	Prudent dietary pattern;
CRC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.44	-6.62	-0.34	1.45e-10	Monocyte count;
CRC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.96	14.11	0.61	1.11e-35	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg03046705	chr5:131746062	C5orf56	0.49	6.85	0.35	3.58e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.65	-9.95	-0.48	1.46e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg01339444	chr6:118972232	C6orf204	0.53	5.87	0.31	1.04e-8	Renal cell carcinoma;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20092199	chr4:1342459	KIAA1530	-0.42	-7.77	-0.39	1.02e-13	Obesity-related traits;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg27094323	chr7:1216898	NA	-0.4	-6.31	-0.33	9.11e-10	Longevity;Endometriosis;
CRC	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-0.65	-6.43	-0.33	4.6e-10	Mean corpuscular volume;
CRC	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.12	-0.32	2.71e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08821792	chr21:34144507	C21orf49;C21orf66	0.41	6.31	0.33	9.21e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9646303	0.830	rs9924961	chr16:87511467	G/A	cg01301660	chr5:110886711	NA	0.57	6.23	0.32	1.43e-9	Major depressive disorder;
CRC	cis	rs1465370	0.720	rs3823579	chr7:130017374	T/C	cg03229158	chr7:130009420	NA	0.44	6.29	0.33	1.01e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.92	9.34	0.46	1.45e-18	Platelet distribution width;
CRC	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00938859	chr5:1591904	SDHAP3	0.72	7.67	0.39	1.91e-13	Breast cancer;
CRC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg25985355	chr7:65971099	NA	-0.5	-5.67	-0.3	3.15e-8	Diabetic kidney disease;
CRC	cis	rs2811415	0.597	rs9837457	chr3:127777040	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg23463467	chr20:60627584	TAF4	0.33	5.68	0.3	2.91e-8	Body mass index;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.46	-0.34	3.7e-10	Breast cancer;
CRC	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg15711740	chr2:61764176	XPO1	-0.52	-7.04	-0.36	1.13e-11	Tuberculosis;
CRC	cis	rs972578	0.967	rs1040427	chr22:43373570	A/C	cg01576275	chr22:43409880	NA	0.48	7.75	0.39	1.17e-13	Mean platelet volume;
CRC	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg21169611	chr9:106856078	SMC2	0.42	5.83	0.31	1.31e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.52	-6.7	-0.35	9.09e-11	Morning vs. evening chronotype;
CRC	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg08501292	chr6:25962987	TRIM38	0.85	7.85	0.4	5.77e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.96	-0.31	6.46e-9	Lung cancer;
CRC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.39	6.59	0.34	1.73e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.34	-5.72	-0.3	2.41e-8	White matter hyperintensity burden;
CRC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.79	-13.3	-0.59	1.36e-32	Obesity-related traits;
CRC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.44	6.45	0.33	4.1e-10	Alzheimer's disease (late onset);
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.98	-19.36	-0.73	2.81e-56	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23709988	chr14:23772096	PPP1R3E	-0.41	-6.35	-0.33	7.03e-10	Myopia (pathological);
CRC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.73	-0.35	7.39e-11	Reticulocyte fraction of red cells;
CRC	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.52	6.89	0.35	2.9e-11	Coronary artery disease;
CRC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.87	14.08	0.61	1.47e-35	Multiple system atrophy;
CRC	cis	rs9992667	0.955	rs12499028	chr4:38639708	C/A	cg19726192	chr4:38663646	FLJ13197	-0.67	-8.57	-0.43	3.95e-16	Eosinophil percentage of granulocytes;
CRC	trans	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg07817883	chr1:32538562	TMEM39B	0.64	7.18	0.37	4.78e-12	Monocyte percentage of white cells;
CRC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg16482183	chr6:26056742	HIST1H1C	0.51	7.58	0.39	3.61e-13	Height;
CRC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.44	7.96	0.4	2.8e-14	Reticulocyte fraction of red cells;
CRC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.83	14.4	0.62	8.26e-37	Coronary artery disease;
CRC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.45	8.43	0.42	1.06e-15	Monocyte count;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06154111	chr16:89627682	RPL13;SNORD68	0.46	6.14	0.32	2.33e-9	Survival in pancreatic cancer;
CRC	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg23127183	chr11:57508653	C11orf31	-0.49	-6.6	-0.34	1.65e-10	Schizophrenia;
CRC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.42	6.48	0.34	3.33e-10	Mean platelet volume;
CRC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.62	-7.86	-0.4	5.36e-14	Response to diuretic therapy;
CRC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.73	-8.33	-0.42	2.19e-15	Obesity-related traits;
CRC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.89	0.63	1.08e-38	Chronic sinus infection;
CRC	cis	rs12476592	0.602	rs262519	chr2:63891464	G/A	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	trans	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg26043149	chr18:55253948	FECH	-0.53	-7.25	-0.37	3.06e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg00105475	chr2:10696890	NA	0.45	7.12	0.37	6.81e-12	Prostate cancer;
CRC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.53	0.6	1.83e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.17	0.32	1.95e-9	Aortic root size;
CRC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg20608306	chr11:116969690	SIK3	0.31	5.66	0.3	3.29e-8	Blood protein levels;
CRC	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg10494257	chr1:16342123	HSPB7	0.45	6.33	0.33	7.97e-10	Dilated cardiomyopathy;
CRC	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-0.58	-5.71	-0.3	2.54e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-0.77	-9.82	-0.48	3.82e-20	Platelet distribution width;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Parkinson's disease;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg15845792	chr6:28175446	NA	0.96	12.98	0.58	2.14e-31	Depression;
CRC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg17321639	chr7:2759063	NA	-0.52	-7.43	-0.38	9.17e-13	Height;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg26028573	chr6:26043587	HIST1H2BB	0.44	6.66	0.34	1.12e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2062225	1.000	rs6542248	chr2:111753228	A/C	cg11729679	chr2:111877065	BCL2L11	0.56	5.63	0.3	3.78e-8	Monocyte count;
CRC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17219203	chr10:38645113	HSD17B7P2	0.41	5.8	0.3	1.54e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-12.83	-0.58	8.13e-31	Menarche (age at onset);
CRC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.73	11.82	0.55	4.15e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.48	-7.3	-0.37	2.19e-12	Coffee consumption (cups per day);
CRC	cis	rs6968419	0.755	rs2896181	chr7:115897884	A/G	cg02561103	chr7:115862891	TES	0.44	6.76	0.35	6.28e-11	Intraocular pressure;
CRC	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.02	-0.31	4.78e-9	Blood protein levels;
CRC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.41	6.77	0.35	5.85e-11	Diastolic blood pressure;
CRC	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.07	0.32	3.47e-9	Asthma;
CRC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-8.17	-0.41	6.73e-15	Arsenic metabolism;
CRC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.25	-0.37	3e-12	Reticulocyte fraction of red cells;
CRC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.92	-0.36	2.41e-11	IgG glycosylation;
CRC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg11212589	chr17:38028394	ZPBP2	0.33	5.7	0.3	2.71e-8	Asthma;
CRC	cis	rs9311676	0.656	rs11923253	chr3:58376992	G/A	cg06643156	chr3:58380774	PXK	0.41	6.22	0.32	1.55e-9	Systemic lupus erythematosus;
CRC	cis	rs3099143	0.901	rs76036665	chr15:77232720	A/G	cg21673338	chr15:77095150	SCAPER	-0.75	-6.1	-0.32	2.98e-9	Recalcitrant atopic dermatitis;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg02683197	chr6:28174875	NA	0.88	12.35	0.56	4.59e-29	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17351385	chr19:36505139	ALKBH6	0.47	6.54	0.34	2.3e-10	Response to antipsychotic treatment;
CRC	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg05527609	chr1:210001259	C1orf107	-0.56	-6.13	-0.32	2.52e-9	Red blood cell count;
CRC	cis	rs891088	0.660	rs10413831	chr19:7198377	C/T	cg00428638	chr19:7224713	INSR	-0.53	-6.73	-0.35	7.54e-11	Hip circumference adjusted for BMI;Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06583696	chr2:26101536	ASXL2	0.43	6.1	0.32	2.98e-9	Response to antipsychotic treatment;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.39	-5.79	-0.3	1.63e-8	Bipolar disorder;
CRC	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.88	0.35	3.05e-11	Neuroticism;
CRC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg04155289	chr7:94953770	PON1	-0.55	-6.95	-0.36	1.91e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-7.9	-0.4	4.11e-14	Coronary artery disease;
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg16268157	chr7:99778414	STAG3	-0.43	-5.72	-0.3	2.45e-8	Lung function (FEV1/FVC);
CRC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	0.53	8.88	0.44	4.51e-17	Intelligence (multi-trait analysis);
CRC	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.48	7.04	0.36	1.1e-11	Schizophrenia;
CRC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg23093090	chr10:104574429	C10orf26	-0.41	-5.77	-0.3	1.86e-8	Arsenic metabolism;
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.15	-0.45	5.92e-18	Bipolar disorder;
CRC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.74	-12.12	-0.56	3.45e-28	Breast cancer;
CRC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.94	-0.31	7.45e-9	Life satisfaction;
CRC	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.39	0.62	9.24e-37	Fuchs's corneal dystrophy;
CRC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.49e-16	Homoarginine levels;
CRC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg05623727	chr3:50126028	RBM5	-0.44	-7.47	-0.38	7.19e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	6.58	0.34	1.88e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.31	-0.33	9.13e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	0.96	12.99	0.58	2.02e-31	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg00691999	chr4:55094011	PDGFRA	0.44	6.27	0.33	1.15e-9	Corneal astigmatism;
CRC	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.44	0.5	3.12e-22	Corneal astigmatism;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02018176	chr4:1364513	KIAA1530	0.41	7.01	0.36	1.39e-11	Obesity-related traits;
CRC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.66	-0.47	1.38e-19	Personality dimensions;
CRC	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg05562828	chr17:3906858	NA	0.66	11.71	0.54	1.03e-26	Type 2 diabetes;
CRC	cis	rs6076065	0.723	rs6083087	chr20:23341529	C/T	cg11657817	chr20:23433608	CST11	0.43	6.49	0.34	3.16e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.54	7.64	0.39	2.41e-13	Triglycerides;
CRC	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.7	11.37	0.53	1.67e-25	Mean platelet volume;
CRC	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.55	-6.99	-0.36	1.51e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6496667	0.779	rs8027211	chr15:90983706	A/G	cg04176472	chr15:90893244	GABARAPL3	0.58	8.2	0.41	5.58e-15	Rheumatoid arthritis;
CRC	cis	rs4073416	0.542	rs10873191	chr14:66110628	T/C	cg03016385	chr14:66212404	NA	-0.45	-6.23	-0.33	1.39e-9	N-glycan levels;
CRC	cis	rs7394190	1.000	rs7394190	chr10:75421648	G/A	cg07699608	chr10:75541558	CHCHD1	0.56	6.48	0.34	3.39e-10	Incident atrial fibrillation;
CRC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-10.4	-0.5	4.29e-22	Tonsillectomy;
CRC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	cis	rs72730918	0.564	rs1902596	chr15:51910875	A/G	cg14296394	chr15:51910925	DMXL2	-0.46	-6.03	-0.32	4.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.39	-5.91	-0.31	8.62e-9	Blood metabolite levels;
CRC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.6	0.54	2.52e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs427941	0.655	rs2734782	chr7:101749667	T/C	cg06246474	chr7:101738831	CUX1	0.44	6.72	0.35	8.09e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25517755	chr10:38738941	LOC399744	0.43	6.3	0.33	9.39e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg23254163	chr1:152506842	NA	0.46	9.04	0.45	1.41e-17	Hair morphology;
CRC	cis	rs12230513	0.732	rs61957763	chr12:55867540	G/A	cg19537932	chr12:55886519	OR6C68	-0.71	-8.93	-0.44	3.12e-17	Contrast sensitivity;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	13.79	0.61	1.81e-34	Alzheimer's disease;
CRC	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg17674042	chr6:34482479	PACSIN1	-0.92	-9.2	-0.45	4.09e-18	Chronic lymphocytic leukemia;
CRC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.88	10.74	0.51	2.86e-23	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.23	-0.37	3.35e-12	Inflammatory skin disease;
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg03623178	chr6:28175578	NA	0.75	5.94	0.31	7.28e-9	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09069694	chr16:67571370	FAM65A	0.35	6.34	0.33	7.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7705042	0.865	rs6580223	chr5:141489027	G/T	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.84	-0.31	1.24e-8	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02948236	chr16:66864732	NAE1	0.4	6.15	0.32	2.25e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13862983	chr9:73028130	KLF9	0.4	6.04	0.32	4.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.49	-6.94	-0.36	2.04e-11	Coronary artery disease;
CRC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg24675056	chr1:15929824	NA	0.51	7.0	0.36	1.45e-11	Systolic blood pressure;
CRC	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.61	8.8	0.44	7.61e-17	Schizophrenia;
CRC	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.84	-10.45	-0.5	3.01e-22	Blood pressure (smoking interaction);
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00166722	chr3:10149974	C3orf24	0.71	9.38	0.46	1.13e-18	Alzheimer's disease;
CRC	cis	rs2882667	0.898	rs11956089	chr5:138394604	G/T	cg09476006	chr5:138032270	NA	-0.45	-7.61	-0.39	2.85e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-14.42	-0.62	6.96e-37	Exhaled nitric oxide output;
CRC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg05585544	chr11:47624801	NA	-0.62	-11.39	-0.53	1.48e-25	Subjective well-being;
CRC	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg06197492	chr11:2016605	H19	-0.41	-6.28	-0.33	1.09e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.39	5.64	0.3	3.65e-8	Body mass index;
CRC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02290350	chr8:58132656	NA	-0.44	-6.39	-0.33	5.52e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.25	14.41	0.62	8.1e-37	Diabetic kidney disease;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg06470822	chr6:28175283	NA	0.79	11.82	0.55	4.2e-27	Cardiac Troponin-T levels;
CRC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg20542592	chr8:11973495	FAM66D	-0.32	-5.68	-0.3	3e-8	Retinal vascular caliber;
CRC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.65	10.59	0.5	9.81e-23	Height;
CRC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.66e-15	Menopause (age at onset);
CRC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.92	-0.31	7.96e-9	Lung cancer;
CRC	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.85	14.33	0.62	1.53e-36	Monocyte count;
CRC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-9.86	-0.48	2.99e-20	Pancreatic cancer;
CRC	cis	rs10450586	0.863	rs10767625	chr11:27304965	A/C	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg24560729	chr4:1342394	KIAA1530	-0.32	-5.79	-0.3	1.63e-8	Obesity-related traits;
CRC	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.83	-10.55	-0.5	1.33e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs524281	0.861	rs7941431	chr11:65960157	C/T	cg16950941	chr11:66035639	RAB1B	-0.59	-7.28	-0.37	2.53e-12	Electroencephalogram traits;
CRC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.84	-12.86	-0.58	6.09e-31	Blood metabolite levels;
CRC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.21	-16.57	-0.67	2.78e-45	Breast cancer;
CRC	trans	rs6544773	0.668	rs341600	chr2:45065683	A/G	cg10208897	chr5:178548229	ADAMTS2	0.35	6.03	0.32	4.4e-9	Mosquito bite size;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg22687807	chr8:143858763	LYNX1	-0.45	-7.44	-0.38	8.84e-13	Urinary tract infection frequency;
CRC	cis	rs11212617	0.901	rs10789656	chr11:108024336	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.71	0.3	2.58e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.46e-8	Morning vs. evening chronotype;
CRC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg13387374	chr1:19411106	UBR4	0.41	6.17	0.32	1.97e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.5	0.34	3.06e-10	Lung cancer;
CRC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.7	8.1	0.41	1.05e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.94	-0.36	2.06e-11	Aortic root size;
CRC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.78	-12.98	-0.58	2.25e-31	Body mass index;
CRC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.63	11.62	0.54	2.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs4731207	0.564	rs2127972	chr7:124665545	A/T	cg23710748	chr7:124431027	NA	-0.4	-6.3	-0.33	9.7e-10	Cutaneous malignant melanoma;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg03623178	chr6:28175578	NA	0.93	12.17	0.56	2.25e-28	Depression;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.1	-0.36	7.92e-12	Bipolar disorder;
CRC	cis	rs7072216	0.881	rs6584192	chr10:100152373	T/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.26	-0.33	1.22e-9	Metabolite levels;
CRC	cis	rs1524976	0.943	rs62255325	chr3:65509446	T/A	cg16238336	chr3:65465873	MAGI1	-0.46	-5.99	-0.31	5.57e-9	PR interval;
CRC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.81	-8.07	-0.41	1.31e-14	Plateletcrit;
CRC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg09582351	chr12:29534625	ERGIC2	-0.28	-5.84	-0.31	1.25e-8	QT interval;
CRC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.71	9.67	0.47	1.29e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.82	11.69	0.54	1.28e-26	Cognitive function;
CRC	cis	rs17767392	1.000	rs17767523	chr14:71880739	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs11212617	0.967	rs7110127	chr11:108329125	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.76	0.3	1.96e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.47	-0.34	3.64e-10	Total cholesterol levels;
CRC	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.63	11.47	0.53	7.59e-26	Blood metabolite ratios;
CRC	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.39	5.72	0.3	2.41e-8	Metabolic traits;
CRC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg19193384	chr17:30244184	NA	0.47	5.81	0.31	1.47e-8	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18255008	chr19:11908503	ZNF491	0.42	6.32	0.33	8.51e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.2	-0.32	1.71e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1536827	0.748	rs9418986	chr10:135324276	T/C	cg20169779	chr10:135381914	SYCE1	0.5	6.01	0.31	4.9e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.51	-6.01	-0.31	4.85e-9	Obesity-related traits;
CRC	cis	rs713477	0.654	rs7143800	chr14:55917734	A/G	cg21836586	chr14:55907198	TBPL2	0.34	6.18	0.32	1.91e-9	Pediatric bone mineral content (femoral neck);
CRC	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.24e-10	Common traits (Other);
CRC	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.5	-7.41	-0.38	1.08e-12	Systemic sclerosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21830413	chr10:70884251	VPS26A	0.43	6.05	0.32	3.85e-9	Anxiety disorder;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Parkinson's disease;
CRC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg24209194	chr3:40518798	ZNF619	0.41	6.12	0.32	2.63e-9	Renal cell carcinoma;
CRC	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	5.98	0.31	5.73e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.76	0.39	1.11e-13	Motion sickness;
CRC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.85	-12.1	-0.55	3.96e-28	Gut microbiome composition (summer);
CRC	cis	rs7517126	0.688	rs73080175	chr1:196937331	G/A	cg13682187	chr1:196946512	CFHR5	-0.45	-5.87	-0.31	1.08e-8	Blood protein levels;
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg21856205	chr7:94953877	PON1	-0.5	-6.49	-0.34	3.25e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.58	-8.73	-0.43	1.26e-16	Height;
CRC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.82	8.7	0.43	1.59e-16	Plasma clusterin levels;
CRC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12983728	0.505	rs35511051	chr19:58665817	C/A	cg24884572	chr19:58661833	ZNF329	0.45	5.64	0.3	3.65e-8	Cholesterol, total;
CRC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	0.35	5.85	0.31	1.16e-8	Personality dimensions;
CRC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg20243544	chr17:37824526	PNMT	0.56	8.62	0.43	2.83e-16	Asthma;
CRC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.69	-11.77	-0.54	6.24e-27	Breast cancer;
CRC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.93	-11.84	-0.55	3.62e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.37	-6.11	-0.32	2.81e-9	HDL cholesterol;
CRC	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg05805236	chr11:65401703	PCNXL3	-0.42	-6.65	-0.34	1.19e-10	Acne (severe);
CRC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.61	8.84	0.44	5.88e-17	Lymphocyte counts;
CRC	cis	rs7605827	0.780	rs34739027	chr2:15532146	C/A	cg19274914	chr2:15703543	NA	0.38	5.61	0.3	4.27e-8	Educational attainment (years of education);
CRC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17507749	chr15:85114479	UBE2QP1	0.52	7.68	0.39	1.82e-13	Schizophrenia;
CRC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	10.43	0.5	3.42e-22	HIV-1 control;
CRC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.88	-0.31	1e-8	Crohn's disease;
CRC	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg17145862	chr1:211918768	LPGAT1	-0.49	-8.11	-0.41	1.04e-14	Leprosy;
CRC	cis	rs9976767	0.861	rs9974339	chr21:43838054	T/C	cg23042151	chr21:43824109	UBASH3A	-0.33	-5.88	-0.31	1.02e-8	Type 1 diabetes;
CRC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg07274523	chr3:49395745	GPX1	0.47	6.11	0.32	2.77e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg10494257	chr1:16342123	HSPB7	0.44	5.77	0.3	1.85e-8	Dilated cardiomyopathy;
CRC	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.35	0.46	1.38e-18	Blood protein levels;
CRC	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg23650765	chr1:12612165	NA	0.35	6.62	0.34	1.48e-10	Optic cup area;
CRC	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.63	-7.3	-0.37	2.18e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.33	-0.37	1.8e-12	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23359706	chr19:11491839	EPOR	0.43	6.2	0.32	1.66e-9	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg02683197	chr6:28174875	NA	0.47	6.66	0.34	1.15e-10	Cardiac Troponin-T levels;
CRC	trans	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg26043149	chr18:55253948	FECH	0.49	7.67	0.39	1.93e-13	Bone mineral density;
CRC	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.31	-5.88	-0.31	1.01e-8	Cutaneous nevi;
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg13777783	chr17:79615861	NA	0.3	5.72	0.3	2.44e-8	Eye color traits;
CRC	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg02896835	chr1:92012615	NA	-0.48	-6.25	-0.33	1.27e-9	Eosinophil percentage of white cells;
CRC	cis	rs501120	0.657	rs1619661	chr10:44733383	T/C	cg09554077	chr10:44749378	NA	0.64	7.06	0.36	9.84e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6427782	0.602	rs9782959	chr1:199821515	G/A	cg07208853	chr1:200005219	NR5A2	0.23	6.09	0.32	3.13e-9	Menarche (age at onset);
CRC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.52	-7.04	-0.36	1.15e-11	Colorectal cancer;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg12648201	chr2:27665141	KRTCAP3	0.3	6.03	0.32	4.49e-9	Body mass index;
CRC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.92	-0.48	1.83e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs9813712	0.574	rs35856399	chr3:129960804	C/T	cg23942268	chr17:6347992	FAM64A	-0.41	-6.01	-0.31	5.05e-9	Response to amphetamines;
CRC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.53	7.83	0.4	6.73e-14	Menopause (age at onset);
CRC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.59	9.38	0.46	1.08e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg21466736	chr12:48725269	NA	-0.54	-7.92	-0.4	3.66e-14	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.46	7.97	0.4	2.59e-14	Common traits (Other);
CRC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2227564	0.729	rs2688616	chr10:75650652	G/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.63	-0.39	2.58e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9322817	0.691	rs9486015	chr6:105254000	C/T	cg02098413	chr6:105308735	HACE1	-0.44	-8.6	-0.43	3.29e-16	Thyroid stimulating hormone;
CRC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg09324608	chr17:30823087	MYO1D	-0.4	-6.79	-0.35	5.14e-11	Schizophrenia;
CRC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.45	5.83	0.31	1.32e-8	Platelet distribution width;
CRC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.75	12.86	0.58	6.3e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg16797656	chr11:68205561	LRP5	0.38	5.9	0.31	9.09e-9	Total body bone mineral density;
CRC	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg02927042	chr1:21476669	EIF4G3	0.37	5.6	0.3	4.51e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs7781266	0.793	rs57352738	chr7:133304694	T/A	cg03336402	chr7:133662267	EXOC4	0.46	5.62	0.3	4.05e-8	Educational attainment (college completion);
CRC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.36e-34	Menopause (age at onset);
CRC	cis	rs1881396	0.531	rs76586169	chr2:27897835	G/A	cg27432699	chr2:27873401	GPN1	0.58	6.45	0.34	3.93e-10	Nonalcoholic fatty liver disease;
CRC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.23	14.5	0.62	3.54e-37	Eosinophil percentage of granulocytes;
CRC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg10298567	chr3:47292165	KIF9	-0.37	-5.7	-0.3	2.6e-8	Colorectal cancer;
CRC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg12564285	chr5:131593104	PDLIM4	-0.34	-6.28	-0.33	1.09e-9	Blood metabolite levels;
CRC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-9.71	-0.47	9.34e-20	Alcohol dependence;
CRC	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.95	-12.54	-0.57	9.07e-30	Educational attainment;
CRC	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.24	14.62	0.63	1.19e-37	Uric acid levels;
CRC	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.51	10.05	0.48	6.83e-21	Alcoholic chronic pancreatitis;
CRC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.28	14.8	0.63	2.39e-38	Diabetic kidney disease;
CRC	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.74	11.38	0.53	1.54e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07312556	chr10:61666263	CCDC6	0.34	6.05	0.32	3.94e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.55	12.54	0.57	9.14e-30	Breast cancer;
CRC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.41	-5.98	-0.31	5.84e-9	Breast cancer;
CRC	cis	rs9491140	0.539	rs10872287	chr6:124694573	T/G	cg05308643	chr6:124982296	NKAIN2	0.56	7.02	0.36	1.29e-11	Neuroticism;
CRC	cis	rs745570	0.833	rs1696757	chr17:77800743	C/T	cg04986373	chr17:77768687	CBX8	-0.38	-5.94	-0.31	7.17e-9	Breast cancer;
CRC	trans	rs867371	0.502	rs7176926	chr15:82538094	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.05	-0.32	3.92e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg06204229	chr3:52865917	ITIH4	0.5	5.74	0.3	2.19e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg18301423	chr5:131593218	PDLIM4	0.37	6.06	0.32	3.79e-9	Breast cancer;
CRC	cis	rs965469	0.724	rs6051818	chr20:3362033	T/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.73	-0.3	2.22e-8	IFN-related cytopenia;
CRC	cis	rs6504622	0.557	rs7225428	chr17:45000997	G/A	cg16759221	chr17:45003025	GOSR2	0.6	9.66	0.47	1.39e-19	Orofacial clefts;
CRC	cis	rs3790645	0.831	rs873151	chr1:26880989	T/C	cg23229016	chr1:26872525	RPS6KA1	0.28	6.43	0.33	4.47e-10	Glucose homeostasis traits;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg25164649	chr6:28176230	NA	0.54	7.3	0.37	2.13e-12	Parkinson's disease;
CRC	trans	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg19894588	chr14:64061835	NA	-0.59	-7.75	-0.39	1.19e-13	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15412250	chr17:21828178	NA	-0.36	-6.21	-0.32	1.59e-9	Obesity-related traits;
CRC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.67	-10.25	-0.49	1.41e-21	Total body bone mineral density;
CRC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.47	-0.34	3.52e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs17095355	1.000	rs921348	chr10:111707498	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.21	-0.41	5.08e-15	Biliary atresia;
CRC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.8	14.06	0.61	1.68e-35	Breast cancer;
CRC	cis	rs7617773	0.962	rs6797587	chr3:48197614	A/G	cg11946769	chr3:48343235	NME6	-0.52	-6.86	-0.35	3.49e-11	Coronary artery disease;
CRC	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg14844989	chr11:31128820	NA	0.35	6.07	0.32	3.58e-9	Red blood cell count;
CRC	cis	rs55788414	0.932	rs4365300	chr16:81184460	C/T	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs1223397	0.651	rs2458310	chr6:13310308	G/C	cg07912922	chr6:13274314	PHACTR1	0.39	6.07	0.32	3.52e-9	Blood pressure;
CRC	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.53	6.82	0.35	4.31e-11	Alzheimer's disease (survival time);
CRC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.61	-9.33	-0.46	1.58e-18	Height;
CRC	cis	rs427943	0.750	rs8133307	chr21:46599714	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.43	5.76	0.3	1.92e-8	Body mass index;
CRC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-12.88	-0.58	5.11e-31	Asthma;
CRC	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.6	-9.44	-0.46	7.22e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg24463073	chr6:118973353	C6orf204	0.52	6.97	0.36	1.69e-11	Diastolic blood pressure;
CRC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.54	8.38	0.42	1.56e-15	Lymphocyte counts;
CRC	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.58	-0.72	3.5e-53	Schizophrenia;
CRC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.86	-0.48	2.97e-20	Bladder cancer;
CRC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.1	0.41	1.05e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Melanoma;
CRC	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.79	-0.3	1.68e-8	Blood pressure;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.39	-9.42	-0.46	8.3e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg25804541	chr17:80189381	SLC16A3	-0.33	-6.2	-0.32	1.68e-9	Life satisfaction;
CRC	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg03929089	chr4:120376271	NA	-0.57	-6.46	-0.34	3.86e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg19223190	chr17:80058835	NA	0.39	6.19	0.32	1.82e-9	Life satisfaction;
CRC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg18016565	chr1:150552671	MCL1	-0.43	-6.27	-0.33	1.13e-9	Tonsillectomy;
CRC	cis	rs1320333	0.772	rs35181861	chr2:679483	A/G	cg00500140	chr2:691012	NA	0.63	6.71	0.35	8.7e-11	Obesity-related traits;
CRC	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.1	0.45	9.09e-18	Alzheimer's disease (late onset);
CRC	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	1.11	12.99	0.58	2.06e-31	Obesity-related traits;
CRC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.95	-13.86	-0.61	9.81e-35	Blood pressure (smoking interaction);
CRC	cis	rs995000	0.931	rs6587976	chr1:62945631	C/T	cg19896129	chr1:63156450	NA	0.41	6.2	0.32	1.68e-9	Triglyceride levels;
CRC	cis	rs938554	0.784	rs7439210	chr4:9971749	C/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.21	-0.32	1.57e-9	Blood metabolite levels;
CRC	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.63	0.43	2.7e-16	Coffee consumption (cups per day);
CRC	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.69	0.35	9.63e-11	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.37	5.9	0.31	8.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03676636	chr4:99064102	C4orf37	0.22	5.85	0.31	1.17e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-5.78	-0.3	1.72e-8	Obesity (extreme);
CRC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.4	0.5	4.25e-22	Ileal carcinoids;
CRC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.02	-19.76	-0.74	7.22e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.36	-0.42	1.84e-15	Alzheimer's disease (late onset);
CRC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg20933634	chr6:27740509	NA	0.44	6.44	0.33	4.32e-10	Parkinson's disease;
CRC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.61	9.59	0.47	2.31e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.77	13.64	0.6	7.11e-34	Oral cavity cancer;
CRC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	10.02	0.48	8.46e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg23229984	chr5:148520753	ABLIM3	0.5	6.93	0.36	2.16e-11	Breast cancer;
CRC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-10.27	-0.49	1.25e-21	Platelet distribution width;
CRC	cis	rs2933343	1.000	rs1683782	chr3:128640277	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-6.32	-0.33	8.5e-10	IgG glycosylation;
CRC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.51	6.19	0.32	1.79e-9	Diastolic blood pressure;
CRC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.48	0.38	6.66e-13	Height;
CRC	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg18850127	chr7:39170497	POU6F2	0.5	6.43	0.33	4.42e-10	IgG glycosylation;
CRC	cis	rs3018066	0.666	rs12508552	chr4:107030624	G/A	cg01869342	chr4:106983673	TBCK	0.46	6.01	0.31	4.84e-9	Cancer;
CRC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.55	-8.99	-0.44	2e-17	P wave terminal force;
CRC	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-6.35	-0.33	7.08e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg16482183	chr6:26056742	HIST1H1C	0.75	9.16	0.45	5.85e-18	Iron status biomarkers;
CRC	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs55675132	0.548	rs75634202	chr1:115375464	C/G	cg25493687	chr8:27288214	PTK2B	0.5	6.06	0.32	3.77e-9	Schizophrenia;
CRC	cis	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg06470822	chr6:28175283	NA	0.67	6.62	0.34	1.48e-10	Depression;
CRC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.51	7.4	0.38	1.14e-12	Colorectal cancer;
CRC	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg06581033	chr10:766294	NA	-0.5	-5.81	-0.31	1.47e-8	Uric acid levels;
CRC	cis	rs7605827	0.930	rs2111456	chr2:15560118	A/G	cg19274914	chr2:15703543	NA	0.39	5.86	0.31	1.13e-8	Educational attainment (years of education);
CRC	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.62	-8.69	-0.43	1.68e-16	Blood pressure (smoking interaction);
CRC	cis	rs11098699	0.821	rs12500715	chr4:124230078	T/C	cg09941581	chr4:124220074	SPATA5	0.4	5.94	0.31	7.44e-9	Mosquito bite size;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.05	-0.32	3.91e-9	Longevity;Endometriosis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19296258	chr17:78878799	RPTOR	0.47	6.33	0.33	8e-10	Survival in pancreatic cancer;
CRC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.42	7.65	0.39	2.27e-13	Height;
CRC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg05342945	chr12:48394962	COL2A1	-0.47	-6.59	-0.34	1.76e-10	Lung cancer;
CRC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg21038819	chr17:73507788	CASKIN2	0.6	5.61	0.3	4.4e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.51	9.94	0.48	1.54e-20	Urate levels in lean individuals;
CRC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg00310523	chr12:86230176	RASSF9	0.44	7.53	0.38	5.05e-13	Major depressive disorder;
CRC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.36	8.08e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.537	rs6466974	chr7:124609510	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.16	-0.32	2.1e-9	Cutaneous malignant melanoma;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01221484	chr19:58920079	ZNF584	0.4	6.26	0.33	1.18e-9	Schizophrenia;
CRC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.49	8.13	0.41	8.93e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.49	7.34	0.38	1.66e-12	Response to antineoplastic agents;
CRC	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.65	6.75	0.35	6.76e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-5.8	-0.3	1.53e-8	Blood metabolite levels;
CRC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.15	-0.32	2.29e-9	Arsenic metabolism;
CRC	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-6.2	-0.32	1.72e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs13178541	0.551	rs4315919	chr5:135108794	G/A	cg07557560	chr5:134914642	CXCL14	-0.35	-6.09	-0.32	3.09e-9	IgG glycosylation;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.66	-9.52	-0.46	3.93e-19	Menopause (age at onset);
CRC	cis	rs6788895	1.000	rs73010967	chr3:150498056	T/C	cg09723797	chr3:150481914	SIAH2	0.87	5.61	0.3	4.26e-8	Breast cancer;
CRC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg07130601	chr7:158766826	NA	0.4	5.73	0.3	2.23e-8	Facial morphology (factor 20);
CRC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg19812747	chr11:111475976	SIK2	-0.58	-9.91	-0.48	2e-20	Primary sclerosing cholangitis;
CRC	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.47	6.23	0.32	1.45e-9	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg12273811	chr6:28175739	NA	-0.53	-6.68	-0.35	1.03e-10	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	10.58	0.5	1.07e-22	Coronary artery disease;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg19913688	chr11:428466	ANO9	-0.68	-7.01	-0.36	1.33e-11	Body mass index;
CRC	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.53	7.71	0.39	1.49e-13	Uric acid levels;
CRC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg10437265	chr15:77819839	NA	0.59	9.97	0.48	1.23e-20	Type 2 diabetes;
CRC	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg15845792	chr6:28175446	NA	0.7	7.57	0.39	3.75e-13	Parkinson's disease;
CRC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs6694672	1.000	rs1627765	chr1:197033043	C/T	cg13682187	chr1:196946512	CFHR5	0.48	7.56	0.38	4.1e-13	Asthma;
CRC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs873549	0.877	rs7550876	chr1:222280229	G/T	cg13387374	chr1:19411106	UBR4	0.44	6.0	0.31	5.11e-9	Keloid;
CRC	cis	rs727505	0.819	rs4142718	chr7:124731688	T/A	cg23710748	chr7:124431027	NA	-0.72	-12.33	-0.56	5.7e-29	Lewy body disease;
CRC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg09835421	chr16:68378352	PRMT7	-0.76	-8.0	-0.4	2.11e-14	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07639959	chr1:242011162	EXO1	0.45	6.51	0.34	2.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.65	-8.48	-0.42	7.52e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.56	0.38	3.93e-13	Height;
CRC	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00495681	chr13:53174319	NA	0.54	8.26	0.41	3.61e-15	Lewy body disease;
CRC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.5	7.37	0.38	1.36e-12	Height;
CRC	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.75	9.38	0.46	1.07e-18	Type 2 diabetes;
CRC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.18	-0.49	2.43e-21	Inflammatory bowel disease;
CRC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.79	-8.5	-0.42	6.76e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.62	-8.96	-0.44	2.48e-17	Testicular germ cell tumor;
CRC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.09	0.36	8.41e-12	Hip circumference adjusted for BMI;
CRC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.83	-0.4	6.57e-14	Putamen volume;
CRC	cis	rs12523822	0.913	rs9479916	chr6:154960939	G/A	cg20019720	chr6:154832845	CNKSR3	0.26	5.66	0.3	3.37e-8	Diabetic kidney disease;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg18301423	chr5:131593218	PDLIM4	-0.38	-6.41	-0.33	5.02e-10	Blood metabolite levels;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.79e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg04837898	chr3:45731254	SACM1L	-0.34	-5.69	-0.3	2.77e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg01420254	chr6:26195488	NA	0.75	8.47	0.42	8.46e-16	Gout;Renal underexcretion gout;
CRC	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg14191688	chr11:70257035	CTTN	0.4	5.65	0.3	3.55e-8	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs11800820	0.521	rs3120699	chr1:246705509	A/G	cg26885821	chr6:124125002	NKAIN2	-0.38	-6.05	-0.32	3.96e-9	Obesity-related traits;
CRC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.4	6.52	0.34	2.7e-10	Major depressive disorder;
CRC	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.61	-7.47	-0.38	7.48e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.55	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	6.3	0.33	9.41e-10	Depressive episodes in bipolar disorder;
CRC	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.68	11.33	0.53	2.39e-25	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-9.25	-0.45	2.98e-18	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg26805224	chr10:79626177	DLG5	-0.49	-7.31	-0.37	2.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.62	-7.27	-0.37	2.57e-12	Ulcerative colitis;
CRC	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.44	6.86	0.35	3.5e-11	Testicular germ cell tumor;
CRC	cis	rs7120118	0.517	rs56177220	chr11:47328377	C/T	cg25783544	chr11:47291846	MADD	0.62	5.77	0.3	1.81e-8	HDL cholesterol;
CRC	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.59	-0.43	3.49e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.58	-9.57	-0.47	2.73e-19	Calcium levels;
CRC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg02869306	chr7:64672164	INTS4L1	0.44	6.36	0.33	6.94e-10	Aortic root size;
CRC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.73	-0.39	1.35e-13	Height;
CRC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.19	-13.16	-0.59	4.5e-32	Diabetic kidney disease;
CRC	cis	rs6662572	0.737	rs10789476	chr1:46305362	G/A	cg08644498	chr1:46502608	NA	-0.44	-6.82	-0.35	4.37e-11	Blood protein levels;
CRC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25517755	chr10:38738941	LOC399744	-0.45	-6.56	-0.34	2.14e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg13010199	chr12:38710504	ALG10B	-0.42	-6.09	-0.32	3.23e-9	Bladder cancer;
CRC	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg14352298	chr13:112236639	NA	0.27	6.11	0.32	2.87e-9	Hepatitis;
CRC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.58	-10.28	-0.49	1.07e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	0.64	8.93	0.44	3.1e-17	Vitamin D levels;
CRC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg11518657	chr1:67396239	MIER1	0.57	6.17	0.32	1.98e-9	Lymphocyte percentage of white cells;
CRC	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21028142	chr17:79581711	NPLOC4	0.3	5.68	0.3	2.89e-8	Myopia;
CRC	cis	rs1223397	0.651	rs2458314	chr6:13309224	C/T	cg07912922	chr6:13274314	PHACTR1	0.43	6.94	0.36	2.05e-11	Blood pressure;
CRC	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.17	0.32	1.95e-9	Hair morphology;
CRC	cis	rs501120	1.000	rs579058	chr10:44755104	A/G	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.34	-5.68	-0.3	3.02e-8	DNA methylation (variation);
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.16	0.32	2.07e-9	Depression;
CRC	cis	rs4400599	0.618	rs2220390	chr1:154233016	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-6.21	-0.32	1.64e-9	Platelet distribution width;
CRC	trans	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.45	-0.34	4.03e-10	Aortic root size;
CRC	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg19897017	chr7:2163380	MAD1L1	-0.6	-8.81	-0.44	7.45e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1161463	0.834	rs1161457	chr13:29434854	G/A	cg16311697	chr3:124249497	KALRN	-0.45	-6.15	-0.32	2.25e-9	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
CRC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.34	0.37	1.73e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.19	-0.37	4.27e-12	Height;
CRC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.79	-12.13	-0.56	3.16e-28	Cognitive function;
CRC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.82	14.1	0.61	1.17e-35	Coronary artery disease;
CRC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg23107878	chr1:152161397	NA	0.42	6.14	0.32	2.38e-9	Inflammatory skin disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18281101	chr1:157015843	ARHGEF11	0.39	6.24	0.33	1.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.53	9.39	0.46	1.01e-18	Huntington's disease progression;
CRC	cis	rs62097350	0.877	rs11659895	chr18:13301705	A/G	cg23768505	chr18:13262434	C18orf1	0.59	5.64	0.3	3.69e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg02683197	chr6:28174875	NA	0.87	10.72	0.51	3.38e-23	Depression;
CRC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.64	-11.11	-0.52	1.43e-24	Dental caries;
CRC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg06781209	chr11:61594997	FADS2	-0.38	-5.74	-0.3	2.11e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.59	-8.41	-0.42	1.29e-15	Arsenic metabolism;
CRC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg18876405	chr7:65276391	NA	0.45	6.19	0.32	1.77e-9	Aortic root size;
CRC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.44	-6.5	-0.34	2.92e-10	Gout;Renal underexcretion gout;
CRC	cis	rs727505	0.551	rs2293346	chr7:124783849	C/T	cg23710748	chr7:124431027	NA	-0.55	-9.11	-0.45	8.47e-18	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07522440	chr7:143317300	FAM115C	0.4	6.34	0.33	7.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.71	0.39	1.5e-13	Morning vs. evening chronotype;
CRC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.68	0.39	1.83e-13	Axial length;
CRC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.4	-6.61	-0.34	1.53e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg17803054	chr19:40927068	NA	0.54	6.21	0.32	1.59e-9	Body mass index;
CRC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	0.99	14.58	0.63	1.75e-37	Breast cancer;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.7	-0.54	1.12e-26	Alzheimer's disease;
CRC	cis	rs4757319	0.515	rs10832403	chr11:15334129	A/G	cg03245590	chr11:15329459	NA	-0.53	-9.43	-0.46	7.68e-19	Breast cancer;
CRC	cis	rs519973	0.775	rs6768827	chr3:187639162	A/T	cg10168494	chr3:187635183	NA	0.5	8.26	0.41	3.57e-15	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs10512697	0.655	rs62337684	chr5:3491889	G/C	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg00531865	chr16:30841666	NA	0.42	5.73	0.3	2.32e-8	Mean corpuscular hemoglobin;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07555182	chr11:82782896	RAB30	0.47	6.53	0.34	2.51e-10	Response to antipsychotic treatment;
CRC	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.01	-0.31	4.89e-9	Blood metabolite levels;
CRC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.33	-0.42	2.23e-15	Schizophrenia;
CRC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.75	-0.39	1.12e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.65	-11.18	-0.52	8.11e-25	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg24343755	chr10:26987087	PDSS1	-0.52	-6.84	-0.35	3.88e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg25797454	chr6:150327115	RAET1K	0.37	6.46	0.34	3.71e-10	Alopecia areata;
CRC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	8.58	0.43	3.72e-16	Neuroticism;
CRC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.36	0.59	7.79e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.65	-0.3	3.57e-8	Morning vs. evening chronotype;
CRC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg13047869	chr3:10149882	C3orf24	0.38	5.93	0.31	7.73e-9	Alzheimer's disease;
CRC	cis	rs1511802	0.501	rs7683132	chr4:187116039	A/G	cg24794857	chr4:187113578	CYP4V2	0.42	6.11	0.32	2.75e-9	Blood protein levels;
CRC	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	0.88	7.3	0.37	2.18e-12	Fat distribution (HIV);
CRC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.52	-0.54	5.1e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.92	-0.48	1.82e-20	Total cholesterol levels;
CRC	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg26446133	chr18:72167187	CNDP2	-0.61	-6.54	-0.34	2.33e-10	Refractive error;
CRC	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg01843034	chr6:37503916	NA	-0.4	-7.4	-0.38	1.12e-12	Cognitive performance;
CRC	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.94	0.36	2.06e-11	Response to antipsychotic treatment;
CRC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.59	0.47	2.24e-19	Cognitive test performance;
CRC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.63	0.51	7.1e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.6	10.33	0.49	7.77e-22	Prudent dietary pattern;
CRC	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9847710	0.967	rs2581824	chr3:53022408	A/C	cg18404041	chr3:52824283	ITIH1	-0.3	-5.92	-0.31	8.21e-9	Ulcerative colitis;
CRC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg16358738	chr2:241808595	AGXT	-0.4	-6.27	-0.33	1.14e-9	Urinary metabolites;
CRC	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.41	5.82	0.31	1.42e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.52	8.13	0.41	9.02e-15	Corneal astigmatism;
CRC	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg00691999	chr4:55094011	PDGFRA	0.44	6.33	0.33	8.1e-10	Corneal astigmatism;
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13047869	chr3:10149882	C3orf24	0.48	6.8	0.35	4.99e-11	Alzheimer's disease;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg24634471	chr8:143751801	JRK	0.41	5.7	0.3	2.61e-8	Urinary tract infection frequency;
CRC	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg09873164	chr1:152488093	CRCT1	-0.37	-6.25	-0.33	1.29e-9	Hair morphology;
CRC	cis	rs9847710	0.733	rs2581790	chr3:53101780	A/G	cg18099408	chr3:52552593	STAB1	0.4	6.14	0.32	2.37e-9	Ulcerative colitis;
CRC	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.59	6.72	0.35	8.06e-11	Glioblastoma;
CRC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.35	0.33	7.01e-10	Menopause (age at onset);
CRC	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.7	7.8	0.4	8.16e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.75	9.38	0.46	1.07e-18	Type 2 diabetes;
CRC	cis	rs2811415	0.597	rs9814694	chr3:127792615	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.89	-0.31	9.75e-9	Lung function (FEV1/FVC);
CRC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.71	9.58	0.47	2.43e-19	Bladder cancer;
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.4e-10	Bipolar disorder;
CRC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg26816564	chr1:7831052	VAMP3	0.84	9.11	0.45	8.28e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.51	7.04	0.36	1.09e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg04586622	chr2:25135609	ADCY3	-0.48	-8.49	-0.42	7.33e-16	Body mass index in non-asthmatics;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg20933634	chr6:27740509	NA	0.59	5.72	0.3	2.43e-8	Depression;
CRC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.47	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.78	-0.3	1.76e-8	Ulcerative colitis;
CRC	cis	rs6758955	1.000	rs6758955	chr2:10480637	G/T	cg15773312	chr2:10472214	HPCAL1	0.73	9.57	0.47	2.59e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs995000	0.931	rs11207990	chr1:63041086	T/C	cg19896129	chr1:63156450	NA	-0.43	-6.7	-0.35	8.85e-11	Triglyceride levels;
CRC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.07	-0.32	3.61e-9	Bipolar disorder;
CRC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	0.94	18.28	0.71	5.31e-52	Height;
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18099408	chr3:52552593	STAB1	-0.52	-9.18	-0.45	4.91e-18	Electroencephalogram traits;
CRC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg23461800	chr14:103021989	NA	-0.69	-7.65	-0.39	2.28e-13	Platelet count;
CRC	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.28	-0.33	1.06e-9	Eye color traits;
CRC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg14092571	chr14:90743983	NA	0.39	6.02	0.31	4.76e-9	Mortality in heart failure;
CRC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg00601486	chr12:48723148	H1FNT	-0.34	-6.62	-0.34	1.42e-10	Glycated hemoglobin levels;
CRC	cis	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg04523069	chr9:97136363	HIATL1	0.37	5.69	0.3	2.84e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.54	10.35	0.5	6.27e-22	Urate levels in lean individuals;
CRC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.57	-0.5	1.12e-22	Testicular germ cell tumor;
CRC	cis	rs11212617	0.967	rs583725	chr11:108165075	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.04e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.53	-7.56	-0.38	3.92e-13	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.94	0.44	2.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.5	-6.07	-0.32	3.62e-9	Recombination rate (females);
CRC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.61	10.36	0.5	5.88e-22	Prostate cancer;
CRC	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-5.65	-0.3	3.39e-8	Neuroticism;
CRC	cis	rs524281	0.773	rs10791863	chr11:66027358	C/T	cg14036092	chr11:66035641	RAB1B	-0.56	-6.13	-0.32	2.56e-9	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26783523	chr19:18043562	CCDC124	0.46	5.99	0.31	5.42e-9	Thyroid stimulating hormone;
CRC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg04267008	chr7:1944627	MAD1L1	0.6	7.75	0.39	1.15e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg13611204	chr9:139324423	INPP5E	-0.43	-6.05	-0.32	3.84e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs58649573	0.552	rs7049157	chr9:126787006	A/G	cg14112217	chr9:126806003	NA	0.4	5.81	0.31	1.44e-8	Post-traumatic stress disorder;
CRC	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	1.11	9.62	0.47	1.8e-19	Mitochondrial DNA levels;
CRC	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.06	-28.15	-0.84	1.27e-89	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.06	-0.32	3.72e-9	Monocyte count;
CRC	cis	rs3772130	0.560	rs7649585	chr3:121562300	G/C	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	cis	rs17767392	1.000	rs34011442	chr14:71779083	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.9	-0.36	2.71e-11	Mitral valve prolapse;
CRC	cis	rs6504950	0.720	rs9913784	chr17:52989071	A/T	cg26251398	chr17:52985966	TOM1L1	0.43	6.53	0.34	2.5e-10	Breast cancer;
CRC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.68	0.3	2.96e-8	Lung cancer;
CRC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.26	0.33	1.18e-9	Height;
CRC	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg00691999	chr4:55094011	PDGFRA	0.41	5.76	0.3	1.89e-8	Corneal astigmatism;
CRC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.1	11.49	0.54	6.24e-26	Intelligence (multi-trait analysis);
CRC	trans	rs4853036	0.629	rs7577864	chr2:70017435	A/G	cg14633329	chr9:139640053	LCN6	-0.37	-6.21	-0.32	1.58e-9	Colorectal or endometrial cancer;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg21784768	chr11:537496	LRRC56	-0.7	-6.6	-0.34	1.65e-10	Body mass index;
CRC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.65	9.59	0.47	2.27e-19	Menopause (age at onset);
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg08200582	chr11:442649	ANO9	-0.7	-7.3	-0.37	2.23e-12	Body mass index;
CRC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.45	5.67	0.3	3.06e-8	Aortic root size;
CRC	trans	rs9358372	0.671	rs10946416	chr6:20883616	T/G	cg14519598	chr9:36906608	PAX5	-0.45	-6.06	-0.32	3.71e-9	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18450072	chr4:40058936	LOC344967;N4BP2	0.4	6.24	0.33	1.34e-9	Obesity-related traits;
CRC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.56	-6.9	-0.36	2.69e-11	Platelet distribution width;
CRC	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	0.56	8.76	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.2	0.62	5.08e-36	Fuchs's corneal dystrophy;
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.8	10.17	0.49	2.64e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4789294	0.806	rs898085	chr17:74393681	A/G	cg06840243	chr17:74442338	UBE2O	0.41	6.05	0.32	3.88e-9	Lymphocyte percentage of white cells;
CRC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.68e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.48	-0.42	7.6e-16	Smoking initiation;
CRC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.77	-0.44	9.93e-17	Prostate cancer;
CRC	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.73	0.35	7.64e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.88	-0.35	2.98e-11	Total body bone mineral density;
CRC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.56	6.54	0.34	2.38e-10	Vitiligo;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs7487075	0.786	rs7966288	chr12:46674970	C/T	cg22049899	chr12:47219821	SLC38A4	0.32	5.77	0.3	1.84e-8	Itch intensity from mosquito bite;
CRC	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.55	8.98	0.44	2.06e-17	Corneal astigmatism;
CRC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-10.97	-0.52	4.45e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.62	0.39	2.68e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.69	-13.58	-0.6	1.15e-33	Educational attainment;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.58	-0.34	1.83e-10	Total body bone mineral density;
CRC	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.67	-8.95	-0.44	2.67e-17	IgE levels;
CRC	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.49	8.22	0.41	4.76e-15	Endometriosis;
CRC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg12193833	chr17:30244370	NA	-0.64	-8.32	-0.42	2.33e-15	Hip circumference adjusted for BMI;
CRC	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.47	5.83	0.31	1.29e-8	Metabolite levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06766450	chr1:16766999	NECAP2	0.5	6.54	0.34	2.38e-10	Thyroid stimulating hormone;
CRC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.54	6.92	0.36	2.31e-11	Morning vs. evening chronotype;
CRC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.69	-11.73	-0.54	8.82e-27	Breast cancer;
CRC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg19223190	chr17:80058835	NA	0.39	6.14	0.32	2.39e-9	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62187657	chr2:162488091	G/A	cg12500891	chr11:57225987	NA	-0.69	-6.05	-0.32	4.05e-9	Cognitive function;
CRC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.2	-0.45	4.18e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.7	-10.42	-0.5	3.81e-22	Menarche (age at onset);
CRC	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.59	8.23	0.41	4.43e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg05941027	chr17:61774174	LIMD2	0.35	6.3	0.33	9.71e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.07	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-0.61	-8.58	-0.43	3.85e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg15845792	chr6:28175446	NA	0.62	8.29	0.42	2.97e-15	Parkinson's disease;
CRC	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.44	6.68	0.35	1.03e-10	Red blood cell count;
CRC	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.2	10.77	0.51	2.33e-23	Prostate cancer;
CRC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.76	-15.24	-0.64	4.77e-40	Refractive error;
CRC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.39	0.69	1.62e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg19683494	chr5:74908142	NA	-0.49	-6.27	-0.33	1.15e-9	Age-related disease endophenotypes;
CRC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg04450456	chr4:17643702	FAM184B	0.41	6.7	0.35	8.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.48	-9.1	-0.45	9.18e-18	Hepatitis;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg01373691	chr16:71917765	ZNF821;ATXN1L	0.45	6.61	0.34	1.51e-10	Body mass index;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg12273811	chr6:28175739	NA	0.63	7.72	0.39	1.37e-13	Depression;
CRC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-7.1	-0.36	7.64e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-0.88	-10.67	-0.51	5.23e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg06494592	chr3:125709126	NA	-0.56	-6.52	-0.34	2.66e-10	Blood pressure (smoking interaction);
CRC	cis	rs2072510	0.593	rs2660900	chr12:96405077	T/C	cg22491680	chr12:96389547	HAL	-0.46	-5.73	-0.3	2.23e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg12273811	chr6:28175739	NA	0.51	6.69	0.35	9.56e-11	Parkinson's disease;
CRC	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.09	0.32	3.15e-9	Bulimia nervosa;
CRC	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.74	8.75	0.43	1.11e-16	Eotaxin levels;
CRC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg15962314	chr1:44399869	ARTN	0.32	6.28	0.33	1.1e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg02733842	chr7:1102375	C7orf50	-0.56	-6.97	-0.36	1.69e-11	Bronchopulmonary dysplasia;
CRC	cis	rs6546324	0.625	rs1430790	chr2:67864912	G/T	cg15745817	chr2:67799979	NA	0.51	9.03	0.45	1.52e-17	Endometriosis;
CRC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.58	-9.81	-0.48	4.37e-20	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.74	-11.47	-0.53	7.3e-26	Blood metabolite levels;
CRC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	13.81	0.61	1.57e-34	Mean platelet volume;
CRC	trans	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06834434	chr14:75079333	LTBP2	0.55	6.88	0.35	3.04e-11	Obesity-related traits;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg06470822	chr6:28175283	NA	0.84	9.56	0.47	2.85e-19	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01297674	chr2:122406765	CLASP1	0.54	6.91	0.36	2.6e-11	Thyroid stimulating hormone;
CRC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	5.73	0.3	2.33e-8	Schizophrenia;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.47	-6.64	-0.34	1.32e-10	Blood pressure (smoking interaction);
CRC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	12.28	0.56	8.32e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.31	-0.33	8.78e-10	Bipolar disorder;
CRC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-10.98	-0.52	4.07e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.81	14.74	0.63	4.18e-38	Anterior chamber depth;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg08034379	chr2:228736324	WDR69	-0.53	-7.22	-0.37	3.59e-12	Blood pressure;
CRC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg20607287	chr7:12443886	VWDE	-0.64	-6.41	-0.33	5.11e-10	Coronary artery disease;
CRC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-10.07	-0.49	5.83e-21	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17274771	chr17:7465072	SENP3	0.41	7.2	0.37	4.12e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg21770322	chr7:97807741	LMTK2	0.52	8.48	0.42	7.59e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.77	-0.35	6.03e-11	Total cholesterol levels;
CRC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	5.67	0.3	3.14e-8	Menarche (age at onset);
CRC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.55	-8.45	-0.42	9.79e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.67	11.34	0.53	2.15e-25	Mean corpuscular volume;
CRC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg08085267	chr17:45401833	C17orf57	-0.74	-12.84	-0.58	6.94e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg07299736	chr8:135490787	ZFAT	-0.37	-6.23	-0.32	1.46e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.4	6.41	0.33	5.03e-10	Cystic fibrosis severity;
CRC	cis	rs10045504	0.502	rs17352898	chr5:38745498	C/T	cg15396434	chr5:38725168	NA	-0.6	-6.01	-0.31	4.86e-9	Night sleep phenotypes;
CRC	cis	rs73206853	0.841	rs3026479	chr12:110779034	A/G	cg12870014	chr12:110450643	ANKRD13A	0.78	6.73	0.35	7.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.68	7.33	0.37	1.76e-12	Childhood ear infection;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14584865	chr2:128615641	POLR2D	0.38	5.97	0.31	5.99e-9	Schizophrenia;
CRC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.44	-6.32	-0.33	8.71e-10	Birth weight;
CRC	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-8.43	-0.42	1.08e-15	Metabolite levels;
CRC	cis	rs2302190	0.882	rs8073754	chr17:56618030	C/T	cg12560992	chr17:57184187	TRIM37	0.51	5.99	0.31	5.48e-9	Vitamin D levels;
CRC	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.85	-14.36	-0.62	1.21e-36	Gut microbiome composition (winter);
CRC	cis	rs1572438	0.792	rs17139759	chr6:856754	G/A	cg13447295	chr6:887704	NA	-0.42	-6.12	-0.32	2.66e-9	Aging;
CRC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.63	-11.92	-0.55	1.8e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg17346650	chr17:80929145	B3GNTL1	0.37	6.01	0.31	4.92e-9	Glycated hemoglobin levels;
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.04	0.36	1.09e-11	Life satisfaction;
CRC	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.4	-0.33	5.41e-10	Educational attainment;
CRC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.08	24.97	0.81	6.05e-78	Testicular germ cell tumor;
CRC	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.28	6.1	0.32	2.94e-9	Educational attainment (years of education);
CRC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg11861562	chr11:117069780	TAGLN	0.4	9.0	0.44	1.79e-17	Blood protein levels;
CRC	trans	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.39	0.38	1.19e-12	Skin colour saturation;
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.92	-0.36	2.44e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg02725872	chr8:58115012	NA	-0.35	-5.99	-0.31	5.51e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.49	0.42	7.31e-16	Parkinson's disease;
CRC	cis	rs9391253	0.571	rs11156429	chr6:105364421	T/G	cg02098413	chr6:105308735	HACE1	0.31	5.6	0.3	4.51e-8	Height;Age at voice drop;Puberty onset (breast development);
CRC	cis	rs990171	0.913	rs2075185	chr2:103070988	A/G	cg03938978	chr2:103052716	IL18RAP	0.48	6.2	0.32	1.72e-9	Lymphocyte counts;
CRC	cis	rs12190007	0.604	rs7382308	chr6:169732276	A/C	cg16388071	chr6:169726476	NA	-0.38	-5.72	-0.3	2.45e-8	Obesity-related traits;
CRC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.82e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg12964065	chr18:77638022	KCNG2	0.66	6.96	0.36	1.88e-11	Opioid sensitivity;
CRC	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.61	-9.68	-0.47	1.17e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg26353448	chr1:248524236	OR2T4	-0.35	-7.08	-0.36	8.96e-12	Common traits (Other);
CRC	cis	rs55788414	0.932	rs2317122	chr16:81182819	A/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs3753275	0.564	rs6676113	chr1:8910544	T/C	cg25376875	chr2:9459453	ASAP2	0.51	6.04	0.32	4.06e-9	Educational attainment;
CRC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.39	-0.33	5.65e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.82	9.97	0.48	1.25e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-7.61	-0.39	2.98e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.46	6.89	0.35	2.92e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg11130432	chr3:121712080	ILDR1	0.52	6.35	0.33	6.99e-10	Multiple sclerosis;
CRC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.96	-0.31	6.62e-9	Neuroticism;
CRC	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg26805224	chr10:79626177	DLG5	-0.49	-7.29	-0.37	2.37e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.4	7.36	0.38	1.47e-12	Monocyte count;
CRC	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.49	-7.9	-0.4	4.31e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.7	12.46	0.57	1.8e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg18217622	chr6:170732253	NA	0.59	5.73	0.3	2.31e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21028142	chr17:79581711	NPLOC4	0.33	6.98	0.36	1.68e-11	Eye color traits;
CRC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs12024301	0.557	rs12029647	chr1:183593968	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.68	-10.35	-0.5	6.27e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-7.9	-0.4	4.16e-14	Menarche (age at onset);
CRC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.67	-8.01	-0.4	1.96e-14	Lymphocyte counts;
CRC	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.76	9.15	0.45	6.19e-18	Response to hepatitis C treatment;
CRC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg13385521	chr17:29058706	SUZ12P	0.53	7.27	0.37	2.64e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg24130564	chr14:104152367	KLC1	0.43	5.94	0.31	7.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2657888	0.628	rs7314242	chr12:56876372	C/A	cg23002907	chr12:56915593	RBMS2	-0.38	-5.89	-0.31	9.4e-9	Adiponectin levels;
CRC	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.49	7.58	0.39	3.51e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	1.02	11.31	0.53	2.92e-25	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg25547332	chr5:131281432	NA	0.41	5.72	0.3	2.42e-8	Life satisfaction;
CRC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-1.1	-12.97	-0.58	2.41e-31	Blood pressure (smoking interaction);
CRC	cis	rs6546324	0.625	rs1023693	chr2:67868732	T/C	cg15745817	chr2:67799979	NA	-0.55	-9.54	-0.47	3.34e-19	Endometriosis;
CRC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.62	-12.21	-0.56	1.51e-28	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26399773	chr5:74633655	HMGCR	-0.38	-6.03	-0.32	4.3e-9	Myopia (pathological);
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.83	-0.35	3.99e-11	Bipolar disorder;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.34e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.6	8.29	0.42	2.84e-15	Menarche (age at onset);
CRC	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg21399703	chr1:247681439	NA	0.49	5.7	0.3	2.61e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.41	6.26	0.33	1.17e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.46	-6.67	-0.35	1.06e-10	Primary sclerosing cholangitis;
CRC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.4	6.92	0.36	2.33e-11	Coronary artery disease;
CRC	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg09324608	chr17:30823087	MYO1D	0.35	6.0	0.31	5.14e-9	Schizophrenia;
CRC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.03	0.66	3.98e-43	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05910615	chr19:36248877	HSPB6;C19orf55	0.4	6.29	0.33	1.03e-9	Obesity-related traits;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.64	0.47	1.51e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1186222	0.501	rs12534422	chr7:75263792	A/G	cg05145297	chr7:75264568	HIP1	-0.67	-12.17	-0.56	2.15e-28	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06210147	chr17:40428290	STAT5B	0.46	7.48	0.38	6.86e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg04450456	chr4:17643702	FAM184B	0.36	5.81	0.31	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4664293	0.585	rs35293435	chr2:160518907	T/C	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	ch.11.42038R	chr11:967971	AP2A2	0.7	11.77	0.54	6.25e-27	Alzheimer's disease (late onset);
CRC	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg18721089	chr20:30220636	NA	-0.32	-5.73	-0.3	2.23e-8	Mean corpuscular hemoglobin;
CRC	cis	rs8040855	0.599	rs1964724	chr15:85726500	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.37	5.7	0.3	2.71e-8	Bulimia nervosa;
CRC	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.71	-11.45	-0.53	9.05e-26	Breast cancer;
CRC	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg14515779	chr1:101123966	NA	0.34	5.7	0.3	2.73e-8	Monocyte count;
CRC	cis	rs9311676	0.632	rs11924677	chr3:58420542	T/C	cg06643156	chr3:58380774	PXK	0.42	6.47	0.34	3.46e-10	Systemic lupus erythematosus;
CRC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.52	8.0	0.4	2.09e-14	Corneal astigmatism;
CRC	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.82	-0.31	1.4e-8	Blood pressure;
CRC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	15.82	0.66	2.55e-42	Electrocardiographic conduction measures;
CRC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02066222	chr1:114354688	RSBN1	0.47	6.45	0.34	4.01e-10	Survival in pancreatic cancer;
CRC	cis	rs965469	1.000	rs6051790	chr20:3342994	C/T	cg25506879	chr20:3388711	C20orf194	-0.39	-5.75	-0.3	2.07e-8	IFN-related cytopenia;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.69	10.65	0.51	6.08e-23	Pancreatic cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18629615	chr19:18794107	CRTC1	0.43	6.15	0.32	2.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.44	-6.22	-0.32	1.49e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11645453	chr3:52864694	ITIH4	0.36	6.39	0.33	5.61e-10	Bipolar disorder;
CRC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg05139728	chr16:28306816	SBK1	-0.38	-6.23	-0.32	1.41e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02359409	chr6:42947317	PEX6	-0.65	-10.29	-0.49	1.06e-21	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.02	0.52	2.9e-24	Prudent dietary pattern;
CRC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.49	0.34	3.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg01444801	chr10:135216882	MTG1	-0.55	-7.82	-0.4	7.4e-14	Systemic lupus erythematosus;
CRC	cis	rs12541635	0.801	rs12155858	chr8:107105205	G/A	cg10147462	chr8:107024639	NA	-0.39	-6.05	-0.32	3.92e-9	Age of smoking initiation;
CRC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg20573242	chr4:122745356	CCNA2	-0.4	-5.8	-0.3	1.56e-8	Type 2 diabetes;
CRC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg27535305	chr1:53392650	SCP2	0.39	7.01	0.36	1.34e-11	Monocyte count;
CRC	cis	rs7113874	0.589	rs7120065	chr11:8484896	C/T	cg20771178	chr11:8615675	STK33	-0.34	-5.67	-0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.59	-9.99	-0.48	1.07e-20	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.79	14.79	0.63	2.66e-38	Prudent dietary pattern;
CRC	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg27365978	chr10:106093659	ITPRIP	-0.41	-6.32	-0.33	8.47e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.73	-8.03	-0.4	1.74e-14	Diabetic retinopathy;
CRC	cis	rs12913538	0.890	rs4326998	chr15:62896609	A/G	cg09983546	chr15:62884068	NA	0.54	7.9	0.4	4.36e-14	Sleep depth;
CRC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.87	-0.31	1.06e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01903903	chr12:82752704	CCDC59;C12orf26	0.38	6.33	0.33	8.14e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.56	8.34	0.42	2.09e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.55	-0.38	4.38e-13	Headache;
CRC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.36	7.96	0.4	2.81e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.55	-10.1	-0.49	4.61e-21	Intelligence (multi-trait analysis);
CRC	cis	rs501916	0.634	rs1561480	chr15:48070050	C/G	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.48	-0.34	3.43e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs294883	0.858	rs1394231	chr6:159718921	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg15786705	chr6:28176104	NA	0.56	7.3	0.37	2.19e-12	Parkinson's disease;
CRC	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-7.45	-0.38	8.37e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.49	6.88	0.35	3.07e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21042902	chr5:176873577	PRR7	0.39	6.47	0.34	3.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.66	-0.39	2.06e-13	Hemoglobin concentration;
CRC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg19622623	chr12:86230825	RASSF9	0.41	6.57	0.34	1.93e-10	Major depressive disorder;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02045355	chr6:26365194	BTN3A2	-0.38	-6.06	-0.32	3.73e-9	Aortic root size;
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.43	6.47	0.34	3.61e-10	Obesity-related traits;
CRC	cis	rs9400239	0.547	rs473268	chr6:109019323	C/A	cg11073813	chr6:109029018	NA	-0.39	-6.11	-0.32	2.77e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs1007738	0.507	rs7940240	chr11:47203068	T/C	cg19486271	chr11:47235900	DDB2	-0.44	-5.94	-0.31	7.12e-9	Bone mineral density (hip);
CRC	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg00490450	chr3:139108681	COPB2	-0.48	-7.21	-0.37	3.77e-12	Obesity-related traits;
CRC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.66	7.78	0.39	9.36e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.44	-6.92	-0.36	2.35e-11	Menopause (age at onset);
CRC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14895029	chr7:2775587	GNA12	-0.44	-6.28	-0.33	1.05e-9	Height;
CRC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09835421	chr16:68378352	PRMT7	-0.6	-5.76	-0.3	1.93e-8	Schizophrenia;
CRC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06505273	chr16:24850292	NA	0.52	6.7	0.35	9.01e-11	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	0.99	10.09	0.49	4.77e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.13e-12	Corneal astigmatism;
CRC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-8.92	-0.44	3.38e-17	Menarche (age at onset);
CRC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.75	-12.4	-0.56	3.21e-29	Height;
CRC	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.93	11.84	0.55	3.43e-27	Exhaled nitric oxide levels;
CRC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.45	-9.46	-0.46	6.18e-19	Intelligence (multi-trait analysis);
CRC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.61	8.14	0.41	7.99e-15	Mean platelet volume;
CRC	cis	rs9908102	0.740	rs56375019	chr17:12909790	G/A	cg26162695	chr17:12921313	ELAC2	0.43	5.81	0.31	1.48e-8	Schizophrenia;
CRC	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg00700412	chr12:58011837	NA	0.37	5.69	0.3	2.8e-8	Multiple sclerosis;
CRC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	8.67	0.43	2.03e-16	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.9	17.3	0.69	3.68e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.45	6.96	0.36	1.8e-11	Red blood cell count;
CRC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg02766259	chr12:125626809	AACS	-0.46	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.03	-16.91	-0.68	1.31e-46	IgG glycosylation;
CRC	cis	rs977987	0.864	rs40446	chr16:75496658	T/C	cg03315344	chr16:75512273	CHST6	-0.58	-9.63	-0.47	1.69e-19	Dupuytren's disease;
CRC	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg18317788	chr4:185205197	NA	-0.39	-6.2	-0.32	1.72e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
CRC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.87e-13	Corneal astigmatism;
CRC	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.06	-0.32	3.7e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg12560992	chr17:57184187	TRIM37	0.53	6.17	0.32	1.98e-9	Vitamin D levels;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg23161317	chr6:28129485	ZNF389	0.44	6.3	0.33	9.6e-10	Cardiac Troponin-T levels;
CRC	cis	rs77861329	1.000	rs171294	chr3:52203599	C/G	cg08692210	chr3:52188851	WDR51A	0.87	8.16	0.41	7.07e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6076065	0.723	rs6083104	chr20:23366038	C/T	cg11657817	chr20:23433608	CST11	0.44	6.63	0.34	1.37e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.85	0.4	5.74e-14	Blood metabolite levels;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.51	-0.38	5.66e-13	Breast cancer;
CRC	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg01422370	chr2:73384389	NA	0.39	6.13	0.32	2.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3996993	0.597	rs62412889	chr6:52703158	G/A	cg20803780	chr6:52668592	GSTA1	0.39	6.59	0.34	1.76e-10	Hemoglobin concentration;
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg03037974	chr15:76606532	NA	0.73	13.13	0.59	5.83e-32	Blood metabolite levels;
CRC	cis	rs365302	1.000	rs474108	chr6:159648154	A/G	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs2252790	1.000	rs2252790	chr6:116663323	G/A	cg18764771	chr6:116381957	FRK	-0.22	-5.8	-0.3	1.59e-8	Fast beta electroencephalogram;
CRC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.86	-9.91	-0.48	2.03e-20	Initial pursuit acceleration;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.2	0.59	3.17e-32	Alzheimer's disease;
CRC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.15	-0.32	2.23e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00071751	chr10:91461194	KIF20B	0.51	7.02	0.36	1.27e-11	Anxiety disorder;
CRC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.4	6.49	0.34	3.11e-10	Obesity-related traits;
CRC	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.73	-11.9	-0.55	2.12e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg05941027	chr17:61774174	LIMD2	0.35	6.12	0.32	2.64e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6840360	0.642	rs2709816	chr4:152380269	T/C	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.16	-0.45	5.56e-18	Prevalent atrial fibrillation;
CRC	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg26587870	chr6:27730563	NA	-0.67	-6.29	-0.33	1.04e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg11130432	chr3:121712080	ILDR1	-0.5	-6.35	-0.33	7.22e-10	Multiple sclerosis;
CRC	trans	rs2294025	0.932	rs7816892	chr8:134169898	A/G	cg19857114	chr3:176741225	TBL1XR1	0.4	6.41	0.33	4.93e-10	Graves' disease;
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.39	-0.33	5.78e-10	Electroencephalogram traits;
CRC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02807482	chr3:125708958	NA	-0.41	-5.61	-0.3	4.25e-8	Blood pressure (smoking interaction);
CRC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.4	6.22	0.32	1.53e-9	Blood protein levels;
CRC	trans	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg26043149	chr18:55253948	FECH	-0.52	-8.17	-0.41	6.72e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06296021	chr5:133702588	CDKL3	0.43	6.29	0.33	9.86e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19927028	chr5:64777838	ADAMTS6	0.52	7.44	0.38	8.87e-13	Response to antipsychotic treatment;
CRC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.6	-8.76	-0.43	1.07e-16	Longevity;
CRC	cis	rs6662572	0.737	rs11211214	chr1:46347328	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.67	-0.3	3.11e-8	Blood protein levels;
CRC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.75	0.39	1.15e-13	Morning vs. evening chronotype;
CRC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.49	7.74	0.39	1.21e-13	Red blood cell count;
CRC	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.34e-13	Melanoma;
CRC	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07741184	chr6:167504864	NA	0.35	6.12	0.32	2.68e-9	Primary biliary cholangitis;
CRC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.62	6.66	0.34	1.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03923535	chr7:1197113	ZFAND2A	0.52	7.67	0.39	2.01e-13	Longevity;Endometriosis;
CRC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.02	0.7	5.41e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg21251018	chr6:28226885	NKAPL	0.52	6.06	0.32	3.7e-9	Depression;
CRC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.74	10.05	0.48	6.48e-21	Cognitive function;
CRC	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg04117972	chr1:227635322	NA	-0.51	-5.83	-0.31	1.32e-8	Major depressive disorder;
CRC	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg20936604	chr3:58311152	NA	-0.59	-5.66	-0.3	3.23e-8	Cholesterol, total;
CRC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.86	14.88	0.63	1.23e-38	Height;
CRC	cis	rs977987	0.864	rs37592	chr16:75496791	G/C	cg03315344	chr16:75512273	CHST6	-0.58	-9.63	-0.47	1.69e-19	Dupuytren's disease;
CRC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.76	-10.09	-0.49	4.98e-21	Coronary artery disease;
CRC	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg02980000	chr4:1222292	CTBP1	0.54	6.3	0.33	9.38e-10	Systolic blood pressure;
CRC	cis	rs17152411	1.000	rs7082846	chr10:126593310	C/A	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs6604026	0.666	rs11164830	chr1:93356823	C/A	cg17283838	chr1:93427260	FAM69A	-0.5	-6.92	-0.36	2.36e-11	Multiple sclerosis;
CRC	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg09003973	chr2:102972529	NA	0.43	6.05	0.32	4.05e-9	Blood protein levels;
CRC	trans	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	6.26	0.33	1.2e-9	Mean corpuscular volume;
CRC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-6.85	-0.35	3.54e-11	Aortic root size;
CRC	cis	rs4594175	0.677	rs7149846	chr14:51739654	A/C	cg23942311	chr14:51606299	NA	0.47	6.97	0.36	1.78e-11	Cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24351916	chr3:39452635	SNORA62;RPSA	-0.48	-6.26	-0.33	1.17e-9	Hip circumference;
CRC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.72	11.92	0.55	1.85e-27	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21548788	chr4:77997565	CCNI	0.46	6.48	0.34	3.38e-10	Response to antipsychotic treatment;
CRC	cis	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg09363841	chr1:37513479	NA	-0.56	-9.48	-0.46	5.07e-19	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23378565	chr7:2036160	MAD1L1	-0.41	-6.28	-0.33	1.04e-9	Bipolar disorder;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02772935	chr3:125709198	NA	-0.5	-5.71	-0.3	2.53e-8	Blood pressure (smoking interaction);
CRC	cis	rs6479527	0.904	rs6479529	chr9:96883386	T/C	cg14459158	chr9:96720562	NA	0.37	6.14	0.32	2.38e-9	Esophageal adenocarcinoma;
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.95	-0.36	2.01e-11	Electroencephalogram traits;
CRC	cis	rs11212617	0.967	rs4753833	chr11:108057430	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.93	0.31	7.67e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.58	9.18	0.45	4.73e-18	Corneal astigmatism;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.86	0.44	5.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.55	-8.6	-0.43	3.28e-16	Motion sickness;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.74	-10.52	-0.5	1.7e-22	Menopause (age at onset);
CRC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg08888203	chr3:10149979	C3orf24	0.47	7.23	0.37	3.47e-12	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21180178	chr1:10093010	UBE4B	0.46	6.71	0.35	8.27e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19046167	chr17:80928561	B3GNTL1	-0.5	-7.2	-0.37	4.1e-12	Glycated hemoglobin levels;
CRC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.4	7.79	0.39	8.72e-14	Mean corpuscular volume;
CRC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg05941027	chr17:61774174	LIMD2	0.35	6.24	0.33	1.32e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg10756647	chr7:56101905	PSPH	-0.74	-7.57	-0.39	3.76e-13	Diabetic kidney disease;
CRC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.7	-0.35	8.88e-11	Coronary artery disease;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.5	-7.5	-0.38	6.16e-13	Longevity;Endometriosis;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg26304593	chr6:42947056	PEX6	0.45	6.58	0.34	1.86e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg14094063	chr7:140624470	BRAF	-0.46	-6.01	-0.31	4.82e-9	Parkinson's disease;
CRC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg00750074	chr16:89608354	SPG7	-0.55	-8.44	-0.42	1.01e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs7605827	0.930	rs2287273	chr2:15658523	T/C	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.8e-9	Educational attainment (years of education);
CRC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg16928487	chr17:17741425	SREBF1	-0.52	-8.65	-0.43	2.24e-16	Total body bone mineral density;
CRC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.49	-7.36	-0.38	1.46e-12	Coronary artery disease;
CRC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-5.97	-0.31	6.28e-9	Alzheimer's disease (late onset);
CRC	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	cg04338863	chr8:33670619	NA	0.44	6.49	0.34	3.25e-10	Body mass index;
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.8	15.29	0.64	2.98e-40	Prudent dietary pattern;
CRC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-8.07	-0.41	1.29e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	5.68	0.3	3.03e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.64	-0.3	3.7e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg20356878	chr3:121714668	ILDR1	0.47	6.23	0.32	1.45e-9	Multiple sclerosis;
CRC	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	0.92	7.18	0.37	4.8e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.55	-8.42	-0.42	1.15e-15	Bipolar disorder;
CRC	trans	rs7718446	0.622	rs12653353	chr5:145780135	A/G	cg27662633	chr7:30395138	ZNRF2	0.33	6.09	0.32	3.18e-9	Migraine without aura;
CRC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg04013166	chr16:89971882	TCF25	0.58	5.9	0.31	8.96e-9	Skin colour saturation;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg04562611	chr16:615315	C16orf11	0.37	6.16	0.32	2.06e-9	Height;
CRC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.38	-5.81	-0.3	1.49e-8	Ulcerative colitis;
CRC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg00343986	chr7:65444356	GUSB	-0.47	-6.45	-0.33	4.05e-10	Aortic root size;
CRC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.1	10.17	0.49	2.54e-21	Opioid sensitivity;
CRC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.62	8.18	0.41	6.25e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg02725872	chr8:58115012	NA	-0.53	-7.09	-0.36	8.33e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.95	0.44	2.75e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg18099408	chr3:52552593	STAB1	0.34	5.61	0.3	4.36e-8	Electroencephalogram traits;
CRC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.38	-5.8	-0.3	1.57e-8	Ulcerative colitis;
CRC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.44	5.66	0.3	3.28e-8	Response to diuretic therapy;
CRC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.83	11.55	0.54	4.04e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg00601486	chr12:48723148	H1FNT	0.3	5.69	0.3	2.82e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg14844989	chr11:31128820	NA	-0.34	-6.02	-0.32	4.55e-9	Bone mineral density (spine);
CRC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.57	8.63	0.43	2.72e-16	Aortic root size;
CRC	cis	rs77633900	0.772	rs77582696	chr15:76669153	A/G	cg21673338	chr15:77095150	SCAPER	-0.69	-6.08	-0.32	3.31e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs747650	0.504	rs7945558	chr11:46957808	G/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.64	-0.34	1.27e-10	Acne (severe);
CRC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.84	-11.23	-0.53	5.23e-25	Gut microbiome composition (summer);
CRC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.95	-14.46	-0.62	5.12e-37	Systemic lupus erythematosus;
CRC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.42	-9.14	-0.45	6.65e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.51	9.59	0.47	2.22e-19	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06567423	chr11:125462867	STT3A	0.41	6.02	0.31	4.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.66	6.83	0.35	4.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg19025524	chr12:109796872	NA	-0.47	-6.72	-0.35	8e-11	Neuroticism;
CRC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.89	11.06	0.52	2.27e-24	Exhaled nitric oxide output;
CRC	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg06042504	chr8:55087323	NA	-0.44	-6.56	-0.34	2.05e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.07	-0.32	3.55e-9	Pubertal anthropometrics;
CRC	cis	rs9584850	0.609	rs7983408	chr13:99155593	G/C	cg20487152	chr13:99095054	FARP1	0.44	5.65	0.3	3.44e-8	Neuroticism;
CRC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.5	7.52	0.38	5.43e-13	Lymphocyte counts;
CRC	cis	rs1971762	0.712	rs7302232	chr12:53965423	A/T	cg06632207	chr12:54070931	ATP5G2	0.39	6.57	0.34	1.93e-10	Height;
CRC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.76e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12172441	chr6:28176163	NA	0.64	7.46	0.38	7.95e-13	Depression;
CRC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-5.62	-0.3	4.13e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg19894588	chr14:64061835	NA	-0.58	-7.64	-0.39	2.45e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-11.17	-0.52	9.13e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs12760731	0.565	rs11583144	chr1:178222070	C/G	cg00404053	chr1:178313656	RASAL2	1.03	10.81	0.51	1.61e-23	Obesity-related traits;
CRC	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg11900509	chr10:81946545	ANXA11	-0.71	-7.16	-0.37	5.2e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.95	15.1	0.64	1.71e-39	Primary sclerosing cholangitis;
CRC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06544989	chr22:39130855	UNC84B	0.42	6.09	0.32	3.08e-9	Menopause (age at onset);
CRC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg19193384	chr17:30244184	NA	-0.46	-5.95	-0.31	6.81e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.78	11.33	0.53	2.49e-25	Neutrophil percentage of white cells;
CRC	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	7.44	0.38	8.7e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg11003573	chr3:44754125	ZNF502	-0.34	-5.72	-0.3	2.34e-8	Depressive symptoms;
CRC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.6	8.89	0.44	4.09e-17	Lung cancer;
CRC	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.35	-0.38	1.6e-12	Inflammatory skin disease;
CRC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.38	0.38	1.28e-12	Lung cancer in ever smokers;
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.45	-0.38	8.52e-13	Bipolar disorder;
CRC	cis	rs6545883	0.524	rs2694618	chr2:61536984	A/G	cg10580144	chr2:61372316	C2orf74	0.35	7.79	0.39	8.83e-14	Tuberculosis;
CRC	cis	rs7264396	0.887	rs224354	chr20:34054609	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.51	-0.34	2.83e-10	Total cholesterol levels;
CRC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.51	-6.69	-0.35	9.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.69	-11.85	-0.55	3.36e-27	Dental caries;
CRC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.77	13.42	0.59	4.55e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg20885578	chr2:198174922	NA	-0.36	-6.39	-0.33	5.6e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.61	8.84	0.44	5.97e-17	Uric acid levels;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg25164649	chr6:28176230	NA	0.57	7.84	0.4	6.13e-14	Parkinson's disease;
CRC	cis	rs4973397	0.765	rs13025087	chr2:232264914	A/C	cg13347044	chr2:232276743	NA	-0.41	-5.8	-0.3	1.57e-8	Anti-saccade response;
CRC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.4	-0.46	9.26e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.06	-0.49	6.21e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.72	9.59	0.47	2.28e-19	Coronary artery disease;
CRC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.63	11.84	0.55	3.6e-27	Prostate cancer;
CRC	cis	rs1322512	0.796	rs1744391	chr6:152936761	A/G	cg03415253	chr6:152958462	SYNE1	-0.42	-6.57	-0.34	1.99e-10	Tonometry;
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.39	-0.42	1.43e-15	Biliary atresia;
CRC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg19635926	chr16:89946313	TCF25	0.64	5.76	0.3	1.96e-8	Skin colour saturation;
CRC	cis	rs231513	0.822	rs231520	chr17:41956983	T/C	cg26893861	chr17:41843967	DUSP3	-0.67	-6.76	-0.35	6.29e-11	Cognitive function;
CRC	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.5	5.7	0.3	2.69e-8	Dental caries;
CRC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.28	-0.46	2.3e-18	Alcohol dependence;
CRC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.82	11.31	0.53	2.87e-25	Initial pursuit acceleration;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg02683197	chr6:28174875	NA	0.68	6.86	0.35	3.37e-11	Lung cancer in ever smokers;
CRC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.36	-0.33	6.68e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg03160526	chr17:80928410	B3GNTL1	0.49	7.91	0.4	3.82e-14	Breast cancer;
CRC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	9.15	0.45	6.02e-18	Schizophrenia;
CRC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.68	-10.12	-0.49	3.88e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg01339444	chr6:118972232	C6orf204	0.55	6.23	0.32	1.43e-9	Diastolic blood pressure;
CRC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.31	0.53	2.81e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7550918	1	rs7550918	chr1:247675559	C/T	cg05639522	chr1:247681581	NA	-0.5	-8.42	-0.42	1.17e-15	Platelet count;
CRC	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg05139728	chr16:28306816	SBK1	-0.36	-5.91	-0.31	8.38e-9	Mosquito bite size;
CRC	cis	rs1950626	0.751	rs12883799	chr14:101396850	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.97	0.66	6.72e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.76	-0.3	1.95e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9807841	0.670	rs2569512	chr19:10790162	A/G	cg17710535	chr19:10819994	QTRT1	0.43	5.77	0.3	1.87e-8	Inflammatory skin disease;
CRC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.68	-0.43	1.91e-16	HDL cholesterol;
CRC	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	1.06	14.77	0.63	3.26e-38	Exhaled nitric oxide output;
CRC	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.79	16.07	0.66	2.57e-43	Leprosy;
CRC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.69	8.76	0.43	1.09e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7800418	0.723	rs1029557	chr7:26588258	C/T	cg14387656	chr2:233470847	EFHD1	0.46	6.37	0.33	6.36e-10	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02619135	chr3:51428440	RBM15B	0.5	7.12	0.37	6.71e-12	Response to antipsychotic treatment;
CRC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.21e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg18002602	chr11:66138449	SLC29A2	0.28	5.9	0.31	8.88e-9	Educational attainment (years of education);
CRC	cis	rs9323205	0.634	rs61987266	chr14:51734909	C/T	cg23942311	chr14:51606299	NA	-0.5	-5.92	-0.31	8.17e-9	Cancer;
CRC	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.82	0.4	7.23e-14	Schizophrenia;
CRC	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg06766960	chr11:133703094	NA	-0.34	-5.61	-0.3	4.26e-8	Childhood ear infection;
CRC	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	7.11	0.36	7.23e-12	Breast cancer;
CRC	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg05673287	chr15:77411982	SGK269	-0.52	-6.73	-0.35	7.67e-11	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.51	6.04	0.32	4.16e-9	Bipolar disorder (body mass index interaction);
CRC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-6.0	-0.31	5.27e-9	Gut microbiome composition (summer);
CRC	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.47	-5.87	-0.31	1.07e-8	Alzheimer's disease (survival time);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18485485	chr8:91013687	DECR1	0.39	6.11	0.32	2.88e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg02135003	chr7:105160482	PUS7	-0.53	-8.2	-0.41	5.44e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.37	0.5	5.66e-22	Alzheimer's disease (late onset);
CRC	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.67	-0.47	1.27e-19	Breast cancer;
CRC	cis	rs8141797	0.748	rs2051199	chr22:24465845	A/G	cg20894457	chr22:24584366	SUSD2	-0.64	-6.65	-0.34	1.2e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-1.01	-8.94	-0.44	2.95e-17	Post bronchodilator FEV1;
CRC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.83	12.75	0.58	1.59e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.19	-16.2	-0.67	7.98e-44	Breast cancer;
CRC	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.51	7.7	0.39	1.5700000000000001e-13	Corneal astigmatism;
CRC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.97	-0.36	1.7e-11	QT interval;
CRC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.75	-10.26	-0.49	1.3e-21	QT interval;
CRC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25517755	chr10:38738941	LOC399744	-0.43	-6.25	-0.33	1.27e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.87	-0.35	3.28e-11	Body mass index;
CRC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.4	6.13	0.32	2.5e-9	Mean corpuscular volume;
CRC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.03e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.54	8.03	0.4	1.73e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs4664293	0.967	rs4665103	chr2:160532312	G/A	cg08347373	chr2:160653686	CD302	-0.46	-7.29	-0.37	2.26e-12	Monocyte percentage of white cells;
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg02033258	chr5:131593261	PDLIM4	0.38	6.37	0.33	6.32e-10	Breast cancer;
CRC	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.87e-24	Motion sickness;
CRC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.74	9.47	0.46	5.44e-19	Cleft lip with or without cleft palate;
CRC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg24289452	chr6:170231220	NA	-0.78	-6.96	-0.36	1.86e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg27661571	chr11:113659931	NA	-0.95	-11.14	-0.52	1.11e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg18833306	chr6:118973337	C6orf204	0.43	5.63	0.3	3.92e-8	Diastolic blood pressure;
CRC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	1.03	9.75	0.47	6.62e-20	Lymphocyte counts;
CRC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.94	-0.36	2.06e-11	Colorectal cancer;
CRC	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.57	7.9	0.4	4.3e-14	Coronary artery disease;
CRC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-6.62	-0.34	1.49e-10	Bipolar disorder;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg09163369	chr1:210001066	C1orf107	0.41	5.77	0.3	1.85e-8	Orofacial clefts;
CRC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.49	7.93	0.4	3.45e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11446398	chr5:77624930	NA	-0.48	-6.71	-0.35	8.28e-11	Triglycerides;
CRC	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.47	-6.05	-0.32	3.87e-9	Alopecia areata;
CRC	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.46	7.02	0.36	1.28e-11	Red blood cell count;
CRC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.44	8.19	0.41	5.85e-15	Iron status biomarkers (transferrin levels);
CRC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.38	6.49	0.34	3.07e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.74	-0.3	2.14e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg08215318	chr16:86016387	NA	-0.77	-11.2	-0.53	6.71e-25	Multiple sclerosis;
CRC	cis	rs12024301	0.557	rs78343928	chr1:183598832	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs2013441	1.000	rs2703801	chr17:20100600	T/C	cg13482628	chr17:19912719	NA	-0.41	-6.22	-0.32	1.48e-9	Obesity-related traits;
CRC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-6.26	-0.33	1.21e-9	Diabetic retinopathy;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.73	11.49	0.54	6.18e-26	Longevity;Endometriosis;
CRC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg23298862	chr7:158159286	PTPRN2	0.5	7.11	0.37	7.06e-12	Response to amphetamines;
CRC	cis	rs2444240	0.935	rs4936509	chr11:120041444	C/T	cg04390734	chr11:120039366	NA	0.28	5.74	0.3	2.14e-8	Corneal curvature;
CRC	cis	rs117623576	1.000	rs117623576	chr10:32387808	C/T	cg03047570	chr10:32398778	NA	-0.74	-7.29	-0.37	2.25e-12	Anti-saccade response;
CRC	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.68	-8.05	-0.41	1.5e-14	Arsenic metabolism;
CRC	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg15382696	chr6:118971807	C6orf204	0.59	7.46	0.38	7.96e-13	Renal cell carcinoma;
CRC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.66	0.39	2.06e-13	Intelligence (multi-trait analysis);
CRC	trans	rs587242	1.000	rs2968487	chr1:96887370	C/T	cg10631902	chr5:14652156	NA	0.45	6.97	0.36	1.71e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.87	10.11	0.49	4.22e-21	Psoriasis;
CRC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.6	-8.97	-0.44	2.31e-17	Breast cancer;
CRC	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.79	-12.79	-0.58	1.07e-30	Hypospadias;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg22687807	chr8:143858763	LYNX1	-0.47	-7.51	-0.38	5.57e-13	Urinary tract infection frequency;
CRC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.84	-0.31	1.29e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3996993	0.809	rs6458892	chr6:52737138	C/T	cg20803780	chr6:52668592	GSTA1	-0.36	-6.83	-0.35	4.19e-11	Hemoglobin concentration;
CRC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.87	-14.52	-0.62	2.97e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs12692738	0.526	rs355848	chr2:165625277	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.46	5.96	0.31	6.49e-9	Aortic root size;
CRC	cis	rs13333054	0.950	rs68143182	chr16:86005838	C/T	cg08215318	chr16:86016387	NA	0.75	10.56	0.5	1.25e-22	Multiple sclerosis;
CRC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg21466736	chr12:48725269	NA	-0.53	-8.06	-0.41	1.47e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg02569458	chr12:86230093	RASSF9	0.39	6.55	0.34	2.2e-10	Major depressive disorder;
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.74	10.97	0.52	4.39e-24	Menarche (age at onset);
CRC	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.51	-8.12	-0.41	9.45e-15	Caffeine consumption;
CRC	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.29	0.42	2.87e-15	Arsenic metabolism;
CRC	cis	rs4728302	0.869	rs13221033	chr7:133617487	T/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.5	-0.34	2.92e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.54	8.7	0.43	1.57e-16	Aortic root size;
CRC	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	1.16	10.74	0.51	2.86e-23	Arsenic metabolism;
CRC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22133161	chr19:49891603	CCDC155	0.52	7.21	0.37	3.98e-12	Multiple sclerosis;
CRC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg18709589	chr6:96969512	KIAA0776	0.49	6.24	0.33	1.37e-9	Migraine;Coronary artery disease;
CRC	cis	rs4727963	0.846	rs2402626	chr7:122712358	C/T	cg03640110	chr7:122635026	TAS2R16	0.33	5.86	0.31	1.14e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	6.12	0.32	2.72e-9	Life satisfaction;
CRC	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.9	-0.4	4.13e-14	Biliary atresia;
CRC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg25344623	chr2:136566232	LCT	0.32	5.78	0.3	1.69e-8	Mosquito bite size;
CRC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.51	8.36	0.42	1.82e-15	Aortic root size;
CRC	cis	rs427941	0.632	rs201505	chr7:101760287	T/C	cg06246474	chr7:101738831	CUX1	0.45	6.89	0.36	2.79e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs375066	0.551	rs10408461	chr19:44330772	A/G	cg19542119	chr19:44331823	ZNF283	0.41	5.74	0.3	2.1e-8	Breast cancer;
CRC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg03605463	chr16:89740564	NA	0.39	5.72	0.3	2.39e-8	Vitiligo;
CRC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg18876405	chr7:65276391	NA	0.46	6.31	0.33	9.12e-10	Aortic root size;
CRC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.39	-5.98	-0.31	5.72e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg03013999	chr17:37608204	MED1	0.47	7.26	0.37	2.88e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs3751196	0.901	rs117932686	chr12:104197523	G/A	cg02344784	chr12:104178138	NT5DC3	0.69	7.0	0.36	1.45e-11	Sense of smell;
CRC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg11707556	chr5:10655725	ANKRD33B	0.48	7.75	0.39	1.15e-13	Coronary artery disease;
CRC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.56	-7.03	-0.36	1.18e-11	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	7.54	0.38	4.62e-13	Personality dimensions;
CRC	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.29	-0.37	2.4e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg04518342	chr5:131593106	PDLIM4	0.51	9.31	0.46	1.85e-18	Blood metabolite levels;
CRC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11645453	chr3:52864694	ITIH4	-0.42	-8.07	-0.41	1.32e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg22638593	chr5:131593259	PDLIM4	0.4	6.43	0.33	4.55e-10	Blood metabolite levels;
CRC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg21972741	chr5:435613	AHRR	0.42	5.63	0.3	3.79e-8	Cystic fibrosis severity;
CRC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.05	-21.5	-0.76	1.18e-64	Colorectal cancer;
CRC	trans	rs6472235	0.837	rs11988360	chr8:66931379	G/A	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.62	8.98	0.44	2.12e-17	Obesity-related traits;
CRC	cis	rs9826463	0.757	rs73238202	chr3:142205344	C/T	cg20824294	chr3:142316082	PLS1	0.41	6.82	0.35	4.41e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2811415	0.597	rs2053014	chr3:127760006	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	trans	rs7027930	0.520	rs10975385	chr9:607178	C/G	cg27061366	chr19:13044373	FARSA	0.51	6.25	0.33	1.26e-9	Pulmonary function decline;
CRC	cis	rs1545257	0.537	rs2702088	chr2:24642535	G/C	cg06627628	chr2:24431161	ITSN2	-0.47	-6.88	-0.35	3.03e-11	Sjögren's syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14178696	chr11:47291038	MADD	0.45	6.28	0.33	1.09e-9	Response to antipsychotic treatment;
CRC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg15147215	chr3:52552868	STAB1	0.53	9.17	0.45	5.29e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.67	10.06	0.49	6.21e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg21770322	chr7:97807741	LMTK2	0.87	19.64	0.73	2.25e-57	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CRC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.62	7.72	0.39	1.42e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs17767392	1.000	rs34748537	chr14:71831683	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-7.43	-0.38	9.56e-13	Chronic sinus infection;
CRC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	8.87	0.44	4.71e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.25	0.45	2.87e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.61	8.88	0.44	4.33e-17	Cognitive function;
CRC	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.94	-13.85	-0.61	1.15e-34	Ulcerative colitis;
CRC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg15845792	chr6:28175446	NA	0.8	6.52	0.34	2.67e-10	Depression;
CRC	trans	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.44e-13	HDL cholesterol;
CRC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.63	-0.34	1.37e-10	Menarche (age at onset);
CRC	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.76	-14.52	-0.62	2.89e-37	Ulcerative colitis;
CRC	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.57	-6.45	-0.33	4.1e-10	Blood protein levels;
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.42	-0.33	4.89e-10	Obesity-related traits;
CRC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg04553112	chr3:125709451	NA	-0.53	-6.09	-0.32	3.2e-9	Blood pressure (smoking interaction);
CRC	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.37	0.5	5.64e-22	Corneal astigmatism;
CRC	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.73	-11.05	-0.52	2.37e-24	Waist circumference;Body mass index;
CRC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-6.77	-0.35	5.8e-11	Body mass index;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.88	11.33	0.53	2.35e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.59	8.98	0.44	2.15e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.66	-9.67	-0.47	1.28e-19	Waist circumference;Body mass index;
CRC	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.41	7.1	0.36	7.96e-12	Obesity-related traits;
CRC	cis	rs6586163	0.843	rs1926199	chr10:90746660	G/T	cg13456138	chr10:90753195	FAS	-0.44	-6.61	-0.34	1.54e-10	Chronic lymphocytic leukemia;
CRC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.4	-5.94	-0.31	7.33e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs910187	0.537	rs2154035	chr20:45760083	T/G	cg27589058	chr20:45804311	EYA2	-0.35	-6.28	-0.33	1.04e-9	Migraine;
CRC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.55	7.21	0.37	3.82e-12	Height;
CRC	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.53	-7.37	-0.38	1.37e-12	Tuberculosis;
CRC	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.84	-0.35	3.93e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.75	13.72	0.6	3.41e-34	Cancer;
CRC	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06307176	chr5:131281290	NA	-0.39	-5.65	-0.3	3.39e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.08e-13	Alzheimer's disease;
CRC	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg16486109	chr11:613632	IRF7	0.59	10.47	0.5	2.42e-22	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.46	-6.77	-0.35	6.01e-11	Body mass index;
CRC	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	0.55	6.0	0.31	5.09e-9	Coronary artery disease;
CRC	cis	rs8018967	1.000	rs8018967	chr14:73976934	A/G	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.49	-7.26	-0.37	2.89e-12	Blood metabolite ratios;
CRC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.35	-0.33	7.29e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.95	15.98	0.66	5.8e-43	Dupuytren's disease;
CRC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11645453	chr3:52864694	ITIH4	0.4	6.56	0.34	2.05e-10	Bipolar disorder;
CRC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg16342193	chr10:102329863	NA	-0.37	-5.95	-0.31	6.76e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.2	0.37	4.02e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs10924970	0.967	rs3845566	chr1:235449757	T/A	cg26050004	chr1:235667680	B3GALNT2	0.4	5.97	0.31	6.04e-9	Asthma;
CRC	cis	rs73206853	0.841	rs57726856	chr12:110961123	T/C	cg12870014	chr12:110450643	ANKRD13A	0.71	7.68	0.39	1.86e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.38	5.91	0.31	8.63e-9	Crohn's disease;
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.18	-0.37	4.68e-12	Lymphocyte counts;
CRC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg09835421	chr16:68378352	PRMT7	-0.49	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg09372928	chr1:6845395	CAMTA1	0.42	6.71	0.35	8.64e-11	Obesity-related traits;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.19	0.32	1.83e-9	Electroencephalogram traits;
CRC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg00531865	chr16:30841666	NA	-0.49	-7.07	-0.36	9.24e-12	Dementia with Lewy bodies;
CRC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.51	-8.22	-0.41	4.9e-15	Breast cancer;
CRC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.63	8.89	0.44	4.11e-17	Chronic sinus infection;
CRC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.58	9.87	0.48	2.75e-20	Prudent dietary pattern;
CRC	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.01	0.31	4.96e-9	Heart rate;
CRC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.54	-8.04	-0.41	1.69e-14	Menarche (age at onset);
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg05569086	chr8:143859399	LYNX1	-0.4	-6.53	-0.34	2.51e-10	Urinary tract infection frequency;
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg27532560	chr4:187881888	NA	-0.56	-10.23	-0.49	1.63e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.05	-0.32	3.85e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.54	-6.48	-0.34	3.38e-10	Coronary artery calcification;
CRC	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.54e-21	Asthma;
CRC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg24562669	chr7:97807699	LMTK2	0.44	7.25	0.37	3.02e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06656553	chr16:89960601	TCF25	-0.61	-5.66	-0.3	3.27e-8	Skin colour saturation;
CRC	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.02	-15.06	-0.64	2.38e-39	Schizophrenia;
CRC	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg27205649	chr11:78285834	NARS2	0.49	6.05	0.32	3.86e-9	Alzheimer's disease (survival time);
CRC	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.3	0.53	2.99e-25	Bipolar disorder;
CRC	cis	rs16858210	0.874	rs35717944	chr3:183607361	C/A	cg25686905	chr3:183603175	PARL	-0.49	-6.71	-0.35	8.39e-11	Menopause (age at onset);
CRC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg12927641	chr6:109611667	NA	0.37	6.48	0.34	3.39e-10	Reticulocyte fraction of red cells;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14471455	chr9:80332956	NA	0.4	5.98	0.31	5.87e-9	Myopia (pathological);
CRC	trans	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg07817883	chr1:32538562	TMEM39B	0.68	7.46	0.38	7.66e-13	Monocyte percentage of white cells;
CRC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.63	9.58	0.47	2.53e-19	Cleft lip with or without cleft palate;
CRC	cis	rs10982256	0.774	rs1535960	chr9:117251352	C/T	cg13636371	chr9:117264095	DFNB31	0.34	6.62	0.34	1.47e-10	Bipolar disorder;
CRC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg00612595	chr21:47717864	NA	-0.37	-6.18	-0.32	1.89e-9	Testicular germ cell tumor;
CRC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg24375607	chr4:120327624	NA	-0.4	-6.32	-0.33	8.41e-10	Corneal astigmatism;
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	7.06	0.36	9.71e-12	Blood protein levels;
CRC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs11229555	0.645	rs12289985	chr11:58185436	C/G	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg25164649	chr6:28176230	NA	0.47	6.88	0.35	2.98e-11	Cardiac Troponin-T levels;
CRC	trans	rs4918814	0.955	rs7090377	chr10:115107258	A/G	cg25339052	chr2:196399403	NA	0.38	6.1	0.32	2.91e-9	Neuroticism (multi-trait analysis);
CRC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.45	5.73	0.3	2.31e-8	Bronchopulmonary dysplasia;
CRC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	7.27	0.37	2.6e-12	Aortic root size;
CRC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-6.09	-0.32	3.12e-9	Schizophrenia;
CRC	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.63	8.2	0.41	5.64e-15	Alzheimer's disease;
CRC	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg21153622	chr11:89784906	NA	-0.49	-8.17	-0.41	6.55e-15	HDL cholesterol;
CRC	cis	rs12541635	0.966	rs7812766	chr8:107057033	G/A	cg10147462	chr8:107024639	NA	0.47	7.82	0.4	7.24e-14	Age of smoking initiation;
CRC	cis	rs4908768	0.501	rs11121201	chr1:8632791	A/T	cg20416874	chr1:8611966	RERE	-0.45	-6.35	-0.33	7.29e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.58	-9.7	-0.47	9.59e-20	DNA methylation (variation);
CRC	cis	rs2836754	1.000	rs11701117	chr21:40292512	C/T	cg20434300	chr21:40194735	ETS2	-0.34	-5.87	-0.31	1.04e-8	Crohn's disease;Body mass index;
CRC	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.38	5.93	0.31	7.56e-9	Longevity;
CRC	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.18	-0.37	4.65e-12	Body mass index;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.48	5.61	0.3	4.24e-8	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03900353	chr1:212732456	NA	0.53	7.03	0.36	1.21e-11	Thyroid stimulating hormone;
CRC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.4	-5.83	-0.31	1.35e-8	Alzheimer's disease (late onset);
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00802000	chr16:706648	WDR90	-0.44	-6.46	-0.34	3.68e-10	Height;
CRC	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.34	-9.3	-0.46	1.99e-18	Mean corpuscular volume;
CRC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-6.0	-0.31	5.16e-9	Menarche (age at onset);
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg04155289	chr7:94953770	PON1	-0.65	-7.85	-0.4	6.09e-14	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02725872	chr8:58115012	NA	-0.4	-7.16	-0.37	5.44e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.94	13.69	0.6	4.55e-34	Breast cancer;
CRC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg16540259	chr10:75572220	NDST2	0.38	5.98	0.31	5.77e-9	Inflammatory bowel disease;
CRC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.75e-11	Body mass index;
CRC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.3	-0.49	9.77e-22	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7011507	1.000	rs13270488	chr8:49196047	T/A	cg04544946	chr8:978226	NA	0.44	6.09	0.32	3.18e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.44	-0.42	9.94e-16	Heart rate;
CRC	cis	rs9914988	0.619	rs9898529	chr17:27318861	A/T	cg16670446	chr17:27188758	MIR451;MIR144	0.46	6.31	0.33	9.19e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6681460	0.932	rs4655640	chr1:67089220	T/C	cg02459107	chr1:67143332	SGIP1	0.43	7.14	0.37	6.19e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs7487075	0.820	rs6582625	chr12:46698317	C/T	cg22049899	chr12:47219821	SLC38A4	0.33	5.99	0.31	5.61e-9	Itch intensity from mosquito bite;
CRC	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.35	-0.33	6.99e-10	Breast cancer;
CRC	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	5.75	0.3	2.09e-8	Breast cancer;
CRC	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg18830697	chr6:72922368	RIMS1	-0.39	-7.9	-0.4	4.11e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.73	8.05	0.41	1.48e-14	Eosinophil percentage of granulocytes;
CRC	cis	rs490234	0.932	rs577026	chr9:128341023	C/T	cg14078157	chr9:128172775	NA	-0.37	-6.23	-0.32	1.43e-9	Mean arterial pressure;
CRC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg16931447	chr4:875861	GAK	0.35	5.69	0.3	2.83e-8	Systemic sclerosis;
CRC	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.57	-0.34	1.95e-10	Height;
CRC	cis	rs10450586	0.932	rs10082678	chr11:27320448	C/T	cg10370305	chr11:27303972	NA	-0.36	-5.9	-0.31	9.02e-9	Total body bone mineral density;
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02290350	chr8:58132656	NA	-0.5	-6.19	-0.32	1.75e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.63	7.13	0.37	6.4e-12	Psoriasis;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.51	5.9	0.31	9e-9	Bipolar disorder (body mass index interaction);
CRC	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.94	0.36	2.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	9.26	0.45	2.68e-18	Migraine;Coronary artery disease;
CRC	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.89	-0.35	2.9e-11	Prevalent atrial fibrillation;
CRC	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	6.22	0.32	1.53e-9	Ovarian reserve;
CRC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.04	-0.55	6.65e-28	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.51	6.91	0.36	2.59e-11	Bronchopulmonary dysplasia;
CRC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.94	-17.93	-0.7	1.24e-50	Intelligence (multi-trait analysis);
CRC	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg14003231	chr6:33640908	ITPR3	0.48	7.69	0.39	1.67e-13	Height;
CRC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.0	15.53	0.65	3.62e-41	IgG glycosylation;
CRC	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg06581033	chr10:766294	NA	-0.5	-5.73	-0.3	2.28e-8	Uric acid levels;
CRC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	8.82	0.44	6.95e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs847649	0.699	rs10241865	chr7:102527517	G/A	cg18108683	chr7:102477205	FBXL13	-0.63	-10.87	-0.51	9.92e-24	Morning vs. evening chronotype;
CRC	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.79	-0.35	5.26e-11	Breast cancer;
CRC	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg21153622	chr11:89784906	NA	-0.45	-7.21	-0.37	3.98e-12	HDL cholesterol;
CRC	cis	rs4964805	1.000	rs11111791	chr12:104193271	C/G	cg02344784	chr12:104178138	NT5DC3	0.5	7.05	0.36	1.03e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.93	-0.31	7.61e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.63	12.66	0.57	3.46e-30	HDL cholesterol levels;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.52	5.93	0.31	7.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg12756093	chr1:115239321	AMPD1	0.48	7.02	0.36	1.3e-11	Autism;
CRC	cis	rs6694672	1.000	rs1170880	chr1:196947314	C/T	cg13682187	chr1:196946512	CFHR5	0.51	7.98	0.4	2.41e-14	Asthma;
CRC	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.37	-6.25	-0.33	1.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.53	8.86	0.44	5.25e-17	Breast cancer;
CRC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.72	0.35	8.13e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs2249625	0.523	rs2496554	chr6:72855840	A/T	cg18830697	chr6:72922368	RIMS1	-0.31	-6.17	-0.32	1.97e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.57	-0.34	2.02e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6880778	0.505	rs6891952	chr5:40400885	C/T	cg09067459	chr5:40385259	NA	0.45	7.75	0.39	1.13e-13	Inflammatory bowel disease;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.4	-0.38	1.13e-12	Aortic root size;
CRC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12292205	chr6:26970375	C6orf41	-0.47	-6.45	-0.34	3.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.5	7.16	0.37	5.15e-12	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14963534	chr19:17420130	DDA1	0.4	6.54	0.34	2.37e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.4	6.37	0.33	6.44e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.42	-0.33	4.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	10.21	0.49	1.93e-21	Cognitive test performance;
CRC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg00383909	chr3:49044727	WDR6	0.48	5.92	0.31	7.98e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg23254163	chr1:152506842	NA	0.44	8.58	0.43	3.71e-16	Hair morphology;
CRC	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg24058013	chr18:77568902	NA	-0.46	-7.86	-0.4	5.48e-14	Schizophrenia;
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg08200582	chr11:442649	ANO9	-0.73	-7.6	-0.39	3.19e-13	Body mass index;
CRC	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.51	0.62	3.17e-37	Exhaled nitric oxide output;
CRC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg05935833	chr10:81318306	SFTPA2	-0.75	-8.24	-0.41	4.02e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.98	-0.4	2.4e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs9462846	0.881	rs9296402	chr6:42875650	G/A	cg10862848	chr6:42927986	GNMT	-0.28	-5.63	-0.3	3.9e-8	Blood protein levels;
CRC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.67	-0.63	7.63e-38	Height;
CRC	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.7	-0.3	2.71e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.63	9.68	0.47	1.11e-19	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00885901	chr1:10459695	PGD	0.5	6.69	0.35	9.35e-11	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg03623178	chr6:28175578	NA	0.87	11.46	0.53	8.46e-26	Parkinson's disease;
CRC	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.61	-9.38	-0.46	1.14e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-7.07	-0.36	9.17e-12	Schizophrenia;
CRC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	0.54	9.05	0.45	1.28e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg08992911	chr2:238395768	MLPH	0.59	5.91	0.31	8.33e-9	Prostate cancer;
CRC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg25985355	chr7:65971099	NA	-0.32	-5.63	-0.3	3.82e-8	Aortic root size;
CRC	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06307176	chr5:131281290	NA	0.42	6.23	0.32	1.45e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4731207	0.596	rs6942997	chr7:124648479	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.73e-9	Cutaneous malignant melanoma;
CRC	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.67	11.52	0.54	5.1e-26	Prostate cancer;
CRC	cis	rs863345	0.967	rs5009954	chr1:158530417	A/G	cg12129480	chr1:158549410	OR10X1	-0.26	-5.66	-0.3	3.35e-8	Pneumococcal bacteremia;
CRC	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg02751453	chr18:77725136	HSBP1L1	0.46	5.74	0.3	2.16e-8	Opioid sensitivity;
CRC	cis	rs6834538	0.558	rs6839861	chr4:113416629	C/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.77	-0.3	1.81e-8	Free thyroxine concentration;
CRC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.55	7.41	0.38	1.08e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg08890418	chr1:21044141	KIF17	-0.34	-5.75	-0.3	2.01e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	trans	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06834434	chr14:75079333	LTBP2	0.55	7.02	0.36	1.25e-11	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg22687807	chr8:143858763	LYNX1	0.5	8.91	0.44	3.5e-17	Urinary tract infection frequency;
CRC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.44	0.42	1.04e-15	Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.95	0.31	6.79e-9	Parkinson's disease;
CRC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg13385521	chr17:29058706	SUZ12P	0.56	7.32	0.37	1.98e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg23758597	chr6:163146217	PARK2	-0.55	-5.6	-0.3	4.45e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.4	-6.9	-0.36	2.75e-11	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.76	9.51	0.46	4.31e-19	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs501120	0.584	rs11238892	chr10:44671194	A/G	cg09554077	chr10:44749378	NA	-0.73	-8.2	-0.41	5.35e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg08075719	chr14:103021372	NA	-0.71	-9.73	-0.47	7.79e-20	Platelet count;
CRC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.43	9.48	0.46	5.3e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg25164649	chr6:28176230	NA	0.65	8.57	0.43	4.18e-16	Parkinson's disease;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg00063174	chr2:228736253	WDR69	-0.45	-6.35	-0.33	7.29e-10	Blood pressure;
CRC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.76	-0.35	6.15e-11	Type 2 diabetes;
CRC	cis	rs34779708	0.733	rs4102764	chr10:35545392	T/C	cg03585969	chr10:35415529	CREM	0.54	6.86	0.35	3.46e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	6.22	0.32	1.48e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.64	8.23	0.41	4.31e-15	Response to diuretic therapy;
CRC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg23815491	chr16:72088622	HP	0.51	7.86	0.4	5.56e-14	Fibrinogen levels;
CRC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.9	0.31	9e-9	Diabetic retinopathy;
CRC	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg27535305	chr1:53392650	SCP2	-0.37	-6.7	-0.35	9.3e-11	Monocyte count;
CRC	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.61	-8.47	-0.42	8.14e-16	Blood protein levels;
CRC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.3	-0.33	9.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.61	6.85	0.35	3.63e-11	Gut microbiota (bacterial taxa);
CRC	cis	rs73206853	0.841	rs7297096	chr12:110798322	G/C	cg12870014	chr12:110450643	ANKRD13A	0.79	7.51	0.38	5.56e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04633058	chr17:48474099	LRRC59	0.51	7.04	0.36	1.12e-11	Thyroid stimulating hormone;
CRC	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.46	6.8	0.35	5.02e-11	Body mass index;
CRC	cis	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg03623178	chr6:28175578	NA	0.79	6.36	0.33	6.62e-10	Depression;
CRC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.67	-0.3	3.19e-8	Neuroticism;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg03923535	chr7:1197113	ZFAND2A	0.48	6.58	0.34	1.89e-10	Longevity;Endometriosis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09188840	chr17:4699533	PSMB6	-0.4	-6.01	-0.31	5.04e-9	Myopia (pathological);
CRC	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.08	-14.73	-0.63	4.38e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.83	-0.4	6.65e-14	Schizophrenia;
CRC	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.75	0.35	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.88	-0.31	1e-8	Coronary artery disease;
CRC	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg10437265	chr15:77819839	NA	0.68	12.17	0.56	2.11e-28	Type 2 diabetes;
CRC	cis	rs11195062	0.521	rs6584977	chr10:111954970	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.93	-0.36	2.18e-11	Multiple myeloma;
CRC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.31	0.33	8.92e-10	IgG glycosylation;
CRC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.75	0.35	6.85e-11	Lung cancer;
CRC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.41	5.6	0.3	4.46e-8	Renal cell carcinoma;
CRC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.46	-12.25	-0.56	1.11e-28	Plateletcrit;
CRC	trans	rs9650657	0.615	rs4840519	chr8:10693113	T/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.02	-0.31	4.72e-9	Neuroticism;
CRC	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-13.84	-0.61	1.25e-34	Ulcerative colitis;
CRC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.66	-10.19	-0.49	2.28e-21	Acne (severe);
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-0.54	-7.49	-0.38	6.34e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.49	-8.95	-0.44	2.62e-17	Immature fraction of reticulocytes;
CRC	cis	rs5167	0.566	rs5120	chr19:45451620	T/A	cg13119609	chr19:45449297	APOC2	0.36	6.67	0.35	1.09e-10	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10330149	chr12:112820238	NA	0.42	6.56	0.34	2.06e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg26248373	chr2:1572462	NA	-0.65	-7.15	-0.37	5.76e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg03623178	chr6:28175578	NA	0.56	8.11	0.41	1.04e-14	Pubertal anthropometrics;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.91	-11.62	-0.54	2.25e-26	Bronchopulmonary dysplasia;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg21620606	chr4:1342894	KIAA1530	0.53	9.69	0.47	1.04e-19	Longevity;
CRC	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.46	6.35	0.33	7.26e-10	Uric acid levels;
CRC	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg00531865	chr16:30841666	NA	0.5	7.03	0.36	1.2e-11	Dementia with Lewy bodies;
CRC	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.06	-0.32	3.75e-9	Post bronchodilator FEV1;
CRC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg10356904	chr22:49881777	NA	-0.34	-6.49	-0.34	3.12e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4664293	0.647	rs7595044	chr2:160446205	T/A	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs365302	1.000	rs485557	chr6:159651303	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.78	0.35	5.7e-11	Coronary heart disease;
CRC	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.51	5.73	0.3	2.21e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg04586622	chr2:25135609	ADCY3	-0.56	-10.58	-0.5	1.06e-22	Body mass index in non-asthmatics;
CRC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	1.99e-11	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg22110888	chr17:80059540	CCDC57	-0.45	-6.88	-0.35	2.95e-11	Life satisfaction;
CRC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.58	-0.39	3.49e-13	Schizophrenia;
CRC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	11.97	0.55	1.2100000000000001e-27	Schizophrenia;
CRC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.12	10.91	0.52	7.06e-24	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.46	-0.34	3.8e-10	Aortic root size;
CRC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.57	8.55	0.43	4.76e-16	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09081385	chr12:120972070	RNF10	-0.46	-7.13	-0.37	6.58e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.96	-0.36	1.84e-11	Total body bone mineral density;
CRC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg10802521	chr3:52805072	NEK4	-0.45	-6.0	-0.31	5.32e-9	Schizophrenia;
CRC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.94	-17.86	-0.7	2.28e-50	Height;
CRC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.36	0.46	1.25e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.9	-0.36	2.74e-11	Mood instability;
CRC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.01	-0.31	4.89e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs2274273	0.624	rs8014540	chr14:55841688	C/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.14	-0.32	2.41e-9	Protein biomarker;
CRC	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg01475377	chr6:109611718	NA	-0.34	-5.91	-0.31	8.78e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13272327	chr3:137906213	ARMC8	0.48	6.28	0.33	1.05e-9	Thyroid stimulating hormone;
CRC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.38	0.33	5.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.49	7.25	0.37	3.04e-12	Obesity-related traits;
CRC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.46	0.5	2.7e-22	Platelet count;
CRC	cis	rs16882447	0.607	rs13435967	chr5:53490881	G/T	cg06461071	chr5:53490839	ARL15	-0.35	-5.75	-0.3	2e-8	Systolic blood pressure (dietary potassium intake interaction);
CRC	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.66	-8.98	-0.44	2.07e-17	Blood trace element (Cu levels);
CRC	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.74	0.43	1.18e-16	Coffee consumption (cups per day);
CRC	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg08501292	chr6:25962987	TRIM38	0.84	7.85	0.4	6.01e-14	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16856342	chr1:67895909	SERBP1	0.47	7.94	0.4	3.3e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs12476592	0.602	rs262503	chr2:63860437	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.19	0.32	1.76e-9	Childhood ear infection;
CRC	cis	rs17095355	1.000	rs13377046	chr10:111729228	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.2	-0.41	5.59e-15	Biliary atresia;
CRC	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00376283	chr12:123451042	ABCB9	-0.51	-5.86	-0.31	1.14e-8	Neutrophil percentage of white cells;
CRC	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.51	7.45	0.38	8.03e-13	Hemoglobin concentration;
CRC	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.18	-0.37	4.6e-12	QT interval;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24321774	chr2:27193835	MAPRE3	0.45	6.61	0.34	1.52e-10	Hip circumference;
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.95	-0.36	2.01e-11	Bipolar disorder;
CRC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.87	-12.79	-0.58	1.08e-30	Blood metabolite levels;
CRC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.75	0.35	6.5e-11	Tonsillectomy;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg26868354	chr6:35699952	LOC285847	-0.46	-6.75	-0.35	6.62e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.44	-6.3	-0.33	9.57e-10	Height;
CRC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.11	0.52	1.44e-24	Colorectal cancer;
CRC	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12075659	chr20:19738521	NA	0.41	6.1	0.32	2.92e-9	Response to antipsychotic treatment;
CRC	cis	rs11628318	0.515	rs11627756	chr14:103096606	C/T	cg12046867	chr14:103022105	NA	-0.41	-5.62	-0.3	4.02e-8	Platelet count;
CRC	cis	rs1322512	0.920	rs2695246	chr6:152948466	T/C	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.64	11.17	0.52	8.66e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	0.58	8.92	0.44	3.2e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.68	10.55	0.5	1.35e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.63	11.75	0.54	7.28e-27	Menarche (age at onset);
CRC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.2e-12	Corneal astigmatism;
CRC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.64	0.3	3.63e-8	Depression;
CRC	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg04969067	chr8:143858791	LYNX1	-0.34	-5.82	-0.31	1.38e-8	Urinary tract infection frequency;
CRC	trans	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.7	-0.35	9.14e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.6e-9	Aortic root size;
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg21856205	chr7:94953877	PON1	0.48	6.29	0.33	1.02e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23365554	chr19:54975006	LENG9	0.43	6.39	0.33	5.62e-10	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12557418	chr8:110552613	EBAG9	0.45	6.45	0.34	3.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg23202291	chr11:1979235	NA	0.47	6.57	0.34	1.99e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.83	8.82	0.44	6.75e-17	Gastritis;
CRC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.71e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.16	0.37	5.47e-12	Life satisfaction;
CRC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.52	-9.65	-0.47	1.42e-19	Alcohol dependence;
CRC	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.52	0.34	2.6200000000000003e-10	Parkinson's disease;
CRC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.5	7.06	0.36	1.03e-11	Height;
CRC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.6	7.14	0.37	6.2e-12	White matter hyperintensity burden;
CRC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.53	-0.38	4.79e-13	Alzheimer's disease;
CRC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.61	8.27	0.41	3.39e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	11.07	0.52	1.94e-24	Motion sickness;
CRC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.73	-12.81	-0.58	9.6e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs356992	0.957	rs356979	chr2:60747743	T/C	cg08426369	chr2:60753602	BCL11A	0.54	7.53	0.38	4.88e-13	Educational attainment (years of education);
CRC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg01420254	chr6:26195488	NA	0.81	8.51	0.42	6.08e-16	Gout;Renal underexcretion gout;
CRC	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg23229984	chr5:148520753	ABLIM3	0.53	7.51	0.38	5.62e-13	Breast cancer;
CRC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.52	0.54	5.15e-26	Alzheimer's disease;
CRC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.69	10.67	0.51	4.93e-23	Corneal astigmatism;
CRC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	1.13	10.33	0.5	7.24e-22	Skin colour saturation;
CRC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg03690763	chr11:133734501	NA	-0.35	-5.86	-0.31	1.13e-8	Childhood ear infection;
CRC	trans	rs9527727	0.876	rs9537923	chr13:58606355	T/C	cg06608599	chr10:101381392	SLC25A28	0.44	6.1	0.32	2.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.37	-0.5	5.45e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.84	0.4	6.31e-14	Cognitive ability;
CRC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.83e-9	Life satisfaction;
CRC	cis	rs10760158	0.832	rs10739593	chr9:124021025	A/G	cg14417974	chr9:124058376	GSN	-0.33	-5.63	-0.3	3.9e-8	Pulse pressure;
CRC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	1.02	20.45	0.75	1.42e-60	Headache;
CRC	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.34	0.65	1.9e-40	Colorectal cancer;
CRC	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg16540259	chr10:75572220	NDST2	0.51	7.68	0.39	1.78e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7605827	0.866	rs6717492	chr2:15538171	A/G	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.0	12.36	0.56	4.57e-29	Uric acid levels;
CRC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.38	0.5	5.21e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.61	8.93	0.44	3.02e-17	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.62	8.32	0.42	2.43e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.69	10.61	0.5	8.49e-23	Monocyte count;
CRC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.97	15.18	0.64	7.94e-40	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09417774	chr12:112037791	ATXN2	0.48	6.9	0.36	2.6e-11	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg20933634	chr6:27740509	NA	0.57	7.9	0.4	4.13e-14	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03205208	chr10:7830848	KIN;ATP5C1	0.44	6.43	0.33	4.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.73	0.39	1.29e-13	Aortic root size;
CRC	trans	rs11885103	0.543	rs1320365	chr2:563182	A/G	cg12228919	chr15:44955936	SPG11	-0.46	-6.87	-0.35	3.13e-11	Heschl's gyrus morphology;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.57	7.3	0.37	2.13e-12	RR interval (heart rate);
CRC	cis	rs7849270	1.000	rs1360172	chr9:131907980	A/G	cg13538475	chr9:131942899	NA	-0.32	-6.36	-0.33	6.63e-10	Blood metabolite ratios;
CRC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.37	-6.33	-0.33	8.25e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs2270927	0.510	rs6876070	chr5:75579237	T/A	cg13563193	chr19:33072644	PDCD5	0.68	6.15	0.32	2.29e-9	Mean corpuscular volume;
CRC	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.69	12.32	0.56	5.96e-29	Blood protein levels;
CRC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-7.07	-0.36	9.43e-12	Life satisfaction;
CRC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.3	-0.53	2.97e-25	Coffee consumption (cups per day);
CRC	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.57	0.47	2.71e-19	Common traits (Other);
CRC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.4	-0.38	1.13e-12	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.91	-0.4	3.95e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg04498913	chr7:1135747	C7orf50	-0.61	-6.73	-0.35	7.67e-11	Bronchopulmonary dysplasia;
CRC	cis	rs6694672	1.000	rs1412634	chr1:197023156	T/C	cg13682187	chr1:196946512	CFHR5	0.5	7.67	0.39	1.96e-13	Asthma;
CRC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg00852783	chr1:26633632	UBXN11	0.42	6.73	0.35	7.74e-11	Obesity-related traits;
CRC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.63	0.34	1.34e-10	Schizophrenia;
CRC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.53	8.46	0.42	8.75e-16	Breast cancer;
CRC	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.77	-10.28	-0.49	1.08e-21	Blood metabolite levels;
CRC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.65	-8.8	-0.44	7.63e-17	Alcohol dependence;
CRC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg25456477	chr12:86230367	RASSF9	0.38	6.32	0.33	8.37e-10	Major depressive disorder;
CRC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.85	-0.31	1.17e-8	Gout;Renal underexcretion gout;
CRC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	5.72	0.3	2.38e-8	Height;
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.57	-7.27	-0.37	2.7e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg14515779	chr1:101123966	NA	-0.43	-8.37	-0.42	1.68e-15	Monocyte count;
CRC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg02527881	chr3:46936655	PTH1R	0.37	6.68	0.35	1e-10	Colorectal cancer;
CRC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.56	7.49	0.38	6.51e-13	Height;
CRC	trans	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg17903999	chr18:56338584	MALT1	0.41	6.81	0.35	4.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25452974	chr10:89621984	PTEN;KILLIN	0.48	6.22	0.32	1.55e-9	Thyroid stimulating hormone;
CRC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.95	-14.97	-0.64	5.46e-39	Gout;
CRC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-6.2	-0.32	1.67e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.57	7.78	0.39	9.59e-14	Multiple sclerosis;
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg18110333	chr6:292329	DUSP22	-0.58	-8.32	-0.42	2.35e-15	Menopause (age at onset);
CRC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	0.82	10.02	0.48	8.31e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.87	0.35	3.22e-11	Rheumatoid arthritis;
CRC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.74e-21	Alzheimer's disease (late onset);
CRC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.73	0.47	7.72e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg19318889	chr4:1322082	MAEA	0.42	6.43	0.33	4.57e-10	Obesity-related traits;
CRC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.69	-8.4	-0.42	1.38e-15	Hip circumference adjusted for BMI;
CRC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.48	9.24	0.45	3.26e-18	Renal cell carcinoma;
CRC	cis	rs4363385	0.818	rs4284210	chr1:152985711	G/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	0.93	8.91	0.44	3.48e-17	Type 2 diabetes nephropathy;
CRC	cis	rs11229555	0.645	rs11229460	chr11:58208343	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs375066	0.551	rs11879541	chr19:44331443	C/T	cg19542119	chr19:44331823	ZNF283	0.41	5.74	0.3	2.1e-8	Breast cancer;
CRC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg08075719	chr14:103021372	NA	-0.69	-9.17	-0.45	5.19e-18	Platelet count;
CRC	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-10.01	-0.48	8.86e-21	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.75	-13.76	-0.6	2.5e-34	Prostate cancer;
CRC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.73	0.3	2.3e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	0.77	14.24	0.62	3.41e-36	Prostate cancer;
CRC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg26721908	chr21:47610096	LSS	-0.41	-6.31	-0.33	9.17e-10	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14107159	chr12:56652285	ANKRD52	0.41	6.01	0.31	4.98e-9	Response to antipsychotic treatment;
CRC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.43	-5.92	-0.31	7.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg15131784	chr3:139108705	COPB2	0.39	5.69	0.3	2.79e-8	Obesity-related traits;
CRC	cis	rs4964805	0.657	rs1866293	chr12:104186655	C/T	cg02344784	chr12:104178138	NT5DC3	0.79	15.03	0.64	3.07e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg12458913	chr13:53173898	NA	0.5	7.33	0.37	1.82e-12	Lewy body disease;
CRC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.14	-0.32	2.33e-9	Diabetic kidney disease;
CRC	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.73	-10.43	-0.5	3.53e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs11723261	0.582	rs116471062	chr4:163522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	6.87	0.35	3.27e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02450064	chr17:40260053	DHX58	-0.42	-6.12	-0.32	2.7e-9	Fibrinogen levels;
CRC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.67	-10.88	-0.51	9.32e-24	Asthma;
CRC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.39	0.33	5.77e-10	Aortic root size;
CRC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.66	10.96	0.52	4.98e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.6	11.62	0.54	2.22e-26	Schizophrenia;
CRC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.52	8.14	0.41	8.41e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.68	9.48	0.46	5.23e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.69	-11.39	-0.53	1.46e-25	Cognitive function;
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.77	14.5	0.62	3.51e-37	Prudent dietary pattern;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.17	-0.49	2.64e-21	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02406285	chr3:67048577	KBTBD8	0.42	6.82	0.35	4.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg15590007	chr10:45870220	ALOX5	0.57	5.96	0.31	6.43e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.82	-11.03	-0.52	2.73e-24	Initial pursuit acceleration;
CRC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg02569458	chr12:86230093	RASSF9	-0.4	-6.79	-0.35	5.22e-11	Major depressive disorder;
CRC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg18612461	chr15:75251733	NA	0.4	6.18	0.32	1.94e-9	Breast cancer;
CRC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.26	14.99	0.64	4.41e-39	Eosinophil percentage of granulocytes;
CRC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.76	-10.09	-0.49	4.98e-21	Coronary artery disease;
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg27635394	chr6:26043820	HIST1H2BB	0.44	6.34	0.33	7.52e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.89	-0.36	2.82e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg21856205	chr7:94953877	PON1	-0.53	-6.67	-0.35	1.1e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7632954	0.669	rs7642129	chr3:8530748	C/T	cg03495237	chr3:8533978	NA	0.36	6.61	0.34	1.54e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.46	6.18	0.32	1.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.6	0.34	1.64e-10	Blood protein levels;
CRC	cis	rs9467603	0.547	rs7774567	chr6:25425526	C/T	cg16898833	chr6:26189333	HIST1H4D	0.69	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7626444	0.563	rs2686598	chr3:196487719	C/T	cg12930392	chr3:196481615	PAK2	0.4	7.13	0.37	6.28e-12	Monocyte count;
CRC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs7937840	0.581	rs4963286	chr11:61887232	C/A	cg01969543	chr11:61895209	INCENP	-0.47	-6.47	-0.34	3.51e-10	Breast cancer;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg14631576	chr9:95140430	CENPP	-0.41	-7.24	-0.37	3.14e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.89	9.9	0.48	2.2e-20	Inflammatory bowel disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09378111	chr2:211036309	C2orf67	0.45	6.41	0.33	5.14e-10	Response to antipsychotic treatment;
CRC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg08741688	chr4:3415352	RGS12	-0.4	-5.74	-0.3	2.19e-8	Serum sulfate level;
CRC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.55	8.85	0.44	5.5e-17	Prostate cancer;
CRC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg08885800	chr1:201084119	NA	0.43	6.19	0.32	1.83e-9	Permanent tooth development;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg10272801	chr16:14013773	ERCC4	-0.69	-6.02	-0.31	4.59e-9	Cognitive function;
CRC	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.65	8.28	0.42	3.1e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17065868	0.764	rs61949798	chr13:45034464	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14119001	chr9:139324193	INPP5E	-0.41	-6.02	-0.32	4.58e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.51	-8.13	-0.41	8.85e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg12588638	chr12:83080208	TMTC2	0.44	6.4	0.33	5.28e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs995000	0.965	rs1168022	chr1:63007721	A/T	cg19896129	chr1:63156450	NA	-0.44	-6.81	-0.35	4.6e-11	Triglyceride levels;
CRC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.71	-0.47	9.27e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.81	14.97	0.64	5.47e-39	Metabolic syndrome;
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.43	-7.79	-0.39	8.82e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg02936872	chr9:99801550	CTSL2	0.48	6.18	0.32	1.85e-9	Iron status biomarkers;
CRC	cis	rs73200209	0.744	rs3214009	chr12:116486852	C/T	cg01776926	chr12:116560359	MED13L	0.64	7.3	0.37	2.19e-12	Total body bone mineral density;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg15786705	chr6:28176104	NA	0.59	8.47	0.42	8.49e-16	Parkinson's disease;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01516881	chr6:292596	DUSP22	-0.57	-8.31	-0.42	2.59e-15	Menopause (age at onset);
CRC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.69	10.51	0.5	1.78e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg03690763	chr11:133734501	NA	-0.35	-5.86	-0.31	1.13e-8	Childhood ear infection;
CRC	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.5	-6.41	-0.33	5.04e-10	Red blood cell traits;
CRC	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.81	10.71	0.51	3.6e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg06307176	chr5:131281290	NA	0.41	5.97	0.31	6.2e-9	Life satisfaction;
CRC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.76	0.39	1.05e-13	Aortic root size;
CRC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	6.15	0.32	2.29e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.59	-8.75	-0.43	1.16e-16	Longevity;
CRC	trans	rs6600671	0.902	rs2222371	chr1:121289118	T/C	cg09829573	chr1:144692074	NBPF9	0.41	6.1	0.32	3.03e-9	Hip geometry;
CRC	cis	rs9303542	0.625	rs7222242	chr17:46565486	C/A	cg04904318	chr17:46607828	HOXB1	-0.5	-5.75	-0.3	2.04e-8	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg09264619	chr17:80180166	NA	-0.36	-5.91	-0.31	8.79e-9	Life satisfaction;
CRC	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.35	-0.33	6.99e-10	Breast cancer;
CRC	cis	rs11212617	0.840	rs172894	chr11:108262090	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.72	0.3	2.43e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg20799917	chr2:38894198	GALM	-0.47	-5.64	-0.3	3.66e-8	5-HTT brain serotonin transporter levels;
CRC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	15.42	0.65	9.52e-41	Lymphocyte percentage of white cells;
CRC	trans	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.7e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.58	0.34	1.87e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs524281	0.773	rs2236651	chr11:66001418	C/T	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00838150	chr3:69788442	MITF	0.44	6.38	0.33	6.05e-10	Response to antipsychotic treatment;
CRC	trans	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.51	0.38	5.69e-13	Endometrial cancer;
CRC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg02880119	chr16:3481970	NA	0.49	5.62	0.3	4.08e-8	Tuberculosis;
CRC	cis	rs2882667	0.931	rs10038799	chr5:138362283	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-6.0	-0.31	5.3300000000000004e-09	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7212590	0.748	rs9904374	chr17:57908096	T/C	cg10252138	chr17:58120427	NA	-0.55	-5.84	-0.31	1.24e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg00631329	chr6:26305371	NA	-0.54	-9.24	-0.45	3.04e-18	Educational attainment;
CRC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.63	10.62	0.51	7.75e-23	Platelet count;
CRC	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.45	6.79	0.35	5.1e-11	Neutrophil percentage of white cells;
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg02683197	chr6:28174875	NA	0.67	6.55	0.34	2.27e-10	Lung cancer in ever smokers;
CRC	cis	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg15845792	chr6:28175446	NA	0.86	5.61	0.3	4.22e-8	Intelligence (multi-trait analysis);
CRC	cis	rs62158211	0.565	rs2121243	chr2:114099346	C/T	cg17784749	chr2:114082611	LOC440839	0.47	6.23	0.33	1.39e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4664293	1.000	rs6753181	chr2:160492438	C/A	cg08347373	chr2:160653686	CD302	-0.45	-7.25	-0.37	2.93e-12	Monocyte percentage of white cells;
CRC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs9303280	0.617	rs8079416	chr17:38092713	T/C	cg24910161	chr17:38119198	GSDMA	-0.32	-5.72	-0.3	2.4e-8	Self-reported allergy;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg12172441	chr6:28176163	NA	0.51	7.26	0.37	2.76e-12	Parkinson's disease;
CRC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-14.43	-0.62	6.63e-37	Height;
CRC	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg12072164	chr19:44306565	LYPD5	0.41	6.45	0.34	3.97e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00760200	chr1:115053833	TRIM33	0.44	6.86	0.35	3.37e-11	Interleukin-6 levels;
CRC	cis	rs4731207	0.596	rs2127971	chr7:124595309	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.43	-0.33	4.51e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	7.69	0.39	1.69e-13	Mean platelet volume;
CRC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-9.53	-0.47	3.6e-19	Body mass index;
CRC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.7	10.55	0.5	1.35e-22	Corneal astigmatism;
CRC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.67	-0.39	1.91e-13	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07573057	chr8:82754234	SNX16	0.52	6.75	0.35	6.76e-11	Thyroid stimulating hormone;
CRC	cis	rs2745967	0.740	rs2785645	chr1:208067420	A/G	cg09788693	chr1:208063733	CD34	0.47	7.04	0.36	1.13e-11	Resting heart rate;
CRC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.57	-9.62	-0.47	1.8e-19	Personality dimensions;
CRC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg23127183	chr11:57508653	C11orf31	-0.53	-7.16	-0.37	5.32e-12	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10260072	chr6:42421084	TRERF1	0.41	6.65	0.34	1.2e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs6472235	0.837	rs7465415	chr8:66920522	T/G	cg07884673	chr3:53033167	SFMBT1	-0.46	-6.15	-0.32	2.31e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.66	-6.4	-0.33	5.32e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.78	-12.81	-0.58	9.06e-31	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-0.64	-11.39	-0.53	1.41e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg23740940	chr11:68924746	NA	0.44	5.75	0.3	2.04e-8	Blond vs. brown hair color;
CRC	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg17218026	chr1:154582156	ADAR	0.57	9.01	0.44	1.68e-17	Blood protein levels;
CRC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.42	-5.85	-0.31	1.16e-8	Corneal structure;
CRC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-8.05	-0.41	1.56e-14	Colorectal cancer;
CRC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.76	-0.35	6.26e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg08773314	chr2:239334832	ASB1	0.37	7.76	0.39	1.11e-13	Multiple system atrophy;
CRC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.95	11.2	0.53	6.98e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.24	-0.37	3.22e-12	Inflammatory skin disease;
CRC	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg06781209	chr11:61594997	FADS2	-0.39	-5.86	-0.31	1.15e-8	Trans fatty acid levels;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12963246	chr6:28129442	ZNF389	0.5	5.75	0.3	2e-8	Depression;
CRC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.25	6.92	0.36	2.44e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.37	-9.0	-0.44	1.81e-17	Diastolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17559213	chr10:80827237	LOC283050	0.42	6.36	0.33	6.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.861	rs7124165	chr11:65901218	C/T	cg16950941	chr11:66035639	RAB1B	-0.61	-7.52	-0.38	5.31e-13	Electroencephalogram traits;
CRC	cis	rs10242455	1.000	rs73395557	chr7:98934424	C/A	cg18809830	chr7:99032528	PTCD1	-0.75	-6.5	-0.34	2.96e-10	Blood metabolite levels;
CRC	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.37	-5.97	-0.31	6.22e-9	Reticulocyte count;High light scatter reticulocyte count;
CRC	trans	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg11693508	chr17:37793320	STARD3	0.51	6.57	0.34	1.93e-10	Neuroticism;
CRC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.45	6.26	0.33	1.2e-9	Red blood cell count;
CRC	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.51	-8.78	-0.44	8.95e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.34	6.35	0.33	6.98e-10	QRS complex (12-leadsum);
CRC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.88	-0.31	1.03e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.66	9.62	0.47	1.77e-19	Total body bone mineral density;
CRC	trans	rs6693295	0.729	rs12022431	chr1:246216636	A/T	cg03680032	chr11:94965610	SESN3	0.49	6.12	0.32	2.68e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg01335087	chr22:19950166	COMT	0.21	5.69	0.3	2.75e-8	Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs7593184	chr2:15598461	T/G	cg19274914	chr2:15703543	NA	0.4	5.97	0.31	6.3e-9	Educational attainment (years of education);
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg02683197	chr6:28174875	NA	0.59	7.88	0.4	4.83e-14	Parkinson's disease;
CRC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg09491104	chr22:46646882	C22orf40	-0.48	-7.52	-0.38	5.38e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs45544231	0.569	rs1420530	chr16:52558729	C/T	cg09051775	chr16:52580266	TOX3	-0.38	-6.09	-0.32	3.13e-9	Restless legs syndrome;
CRC	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.77	-17.11	-0.69	2.18e-47	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.73e-9	Life satisfaction;
CRC	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-8.49	-0.42	7.04e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg10978503	chr1:24200527	CNR2	0.46	7.72	0.39	1.43e-13	Immature fraction of reticulocytes;
CRC	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-6.73	-0.35	7.49e-11	Capecitabine sensitivity;
CRC	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg09476006	chr5:138032270	NA	0.44	6.74	0.35	6.92e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg08632701	chr21:37451849	NA	-0.42	-6.64	-0.34	1.27e-10	Mitral valve prolapse;
CRC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.15	0.37	5.77e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg07030052	chr1:162531143	UAP1	-0.41	-6.26	-0.33	1.18e-9	Birth weight;Height;
CRC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.63	5.71	0.3	2.48e-8	Schizophrenia;
CRC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg27053337	chr8:124217698	FAM83A	0.46	6.99	0.36	1.58e-11	Urinary uromodulin levels;
CRC	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	6.09	0.32	3.11e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.68	9.68	0.47	1.19e-19	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12677436	chr2:54785476	SPTBN1	0.43	5.96	0.31	6.42e-9	Response to antipsychotic treatment;
CRC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.66	-0.39	2.12e-13	Hemoglobin concentration;
CRC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	trans	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.0	-0.31	5.11e-9	Educational attainment (years of education);
CRC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg21194808	chr1:2205498	SKI	0.38	5.95	0.31	6.8e-9	Height;
CRC	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.73	-9.92	-0.48	1.8899999999999998e-20	Pubertal anthropometrics;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07466433	chr2:7005728	CMPK2	0.39	6.2	0.32	1.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	6.62	0.34	1.47e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23681243	chr15:25684088	UBE3A	0.45	6.37	0.33	6.55e-10	Response to antipsychotic treatment;
CRC	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.34	-5.95	-0.31	6.69e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.77	-0.72	5.95e-54	Height;
CRC	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg13482628	chr17:19912719	NA	-0.41	-6.3	-0.33	9.69e-10	Obesity-related traits;
CRC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.52	-7.58	-0.39	3.46e-13	Response to temozolomide;
CRC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.23	0.37	3.38e-12	Aortic root size;
CRC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg05044414	chr3:183734942	ABCC5	0.44	7.76	0.39	1.06e-13	Anterior chamber depth;
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.95	-0.36	2.01e-11	Bipolar disorder;
CRC	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	6.02	0.32	4.63e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.83	9.88	0.48	2.57e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	8.01	0.4	1.98e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.39	-5.85	-0.31	1.16e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.5	8.08	0.41	1.22e-14	Total body bone mineral density;
CRC	cis	rs1223397	0.651	rs2439543	chr6:13312153	A/C	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.98	-0.48	1.19e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.54	8.61	0.43	3.01e-16	Coronary artery disease;
CRC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	14.29	0.62	2.28e-36	Electrocardiographic conduction measures;
CRC	cis	rs7113874	0.569	rs2871753	chr11:8486650	A/T	cg17679104	chr11:8615758	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9649465	0.967	rs11769381	chr7:123264804	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-6.01	-0.31	4.86e-9	Migraine;
CRC	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-7.2	-0.37	4.19e-12	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20809690	chr4:2757764	TNIP2	0.39	6.08	0.32	3.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.61	10.52	0.5	1.62e-22	Intelligence (multi-trait analysis);
CRC	cis	rs10411161	0.579	rs59305384	chr19:52387064	A/G	cg11269599	chr19:52391304	ZNF577	0.44	5.65	0.3	3.48e-8	Breast cancer;
CRC	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.38	-5.93	-0.31	7.46e-9	Endometrial cancer;
CRC	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.62	-10.8	-0.51	1.82e-23	Dupuytren's disease;
CRC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg18479299	chr3:125709523	NA	-0.55	-6.63	-0.34	1.4e-10	Blood pressure (smoking interaction);
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.95	-0.4	3.03e-14	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.25e-36	Prudent dietary pattern;
CRC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07400628	chr1:6761934	DNAJC11	0.39	6.03	0.32	4.51e-9	Schizophrenia;
CRC	cis	rs7692995	1.000	rs6449346	chr4:17934461	T/C	cg08925142	chr4:18023851	LCORL	-0.52	-5.85	-0.31	1.21e-8	Height;
CRC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16447950	chr5:562315	NA	-0.74	-9.79	-0.47	4.96e-20	Obesity-related traits;
CRC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.46	-7.1	-0.36	7.51e-12	Coronary artery disease;
CRC	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-5.94	-0.31	7.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg23234261	chr14:55582407	NA	-0.3	-5.92	-0.31	8.14e-9	Protein biomarker;
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.65	-0.3	3.45e-8	Cognitive function;
CRC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.71	-0.35	8.57e-11	Urate levels in overweight individuals;
CRC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	16.1	0.66	1.97e-43	Body mass index (adult);
CRC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.18	-13.88	-0.61	8.21e-35	Diabetic kidney disease;
CRC	cis	rs73206853	0.764	rs56205958	chr12:111027361	G/C	cg12870014	chr12:110450643	ANKRD13A	0.8	9.18	0.45	5.09e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg03790207	chr6:42947109	PEX6	-0.49	-6.91	-0.36	2.51e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12580194	1.000	rs60206376	chr12:55703375	C/A	cg19537932	chr12:55886519	OR6C68	-0.57	-7.02	-0.36	1.31e-11	Cancer;
CRC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.6	8.87	0.44	4.85e-17	Homoarginine levels;
CRC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg20607287	chr7:12443886	VWDE	-0.68	-7.35	-0.38	1.59e-12	Coronary artery disease;
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg07404485	chr7:94953653	PON1	-0.45	-5.94	-0.31	7.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22075671	chr5:133747798	CDKN2AIPNL	0.4	6.05	0.32	3.92e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.39	-9.12	-0.45	7.84e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.85	15.52	0.65	3.75e-41	Lewy body disease;
CRC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.67	10.86	0.51	1.14e-23	Lung cancer;
CRC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.32	-5.8	-0.3	1.53e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg11271282	chr2:238384023	NA	0.45	5.7	0.3	2.72e-8	Prostate cancer;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10819733	chr22:24237672	NA	-0.35	-5.92	-0.31	8.17e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.46	-6.57	-0.34	1.99e-10	Type 2 diabetes;
CRC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	8.0	0.4	2.09e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13378284	chr11:616089	IRF7	0.46	7.62	0.39	2.82e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.74	10.02	0.48	8.29e-21	Cognitive function;
CRC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.13	-0.32	2.49e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12528403	chr1:40997196	ZNF684	0.4	6.27	0.33	1.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.9	-0.36	2.68e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs59104589	0.521	rs3771584	chr2:242399493	C/G	cg19488206	chr2:242435732	STK25	0.47	7.51	0.38	5.68e-13	Fibrinogen levels;
CRC	cis	rs73198271	0.531	rs3827812	chr8:8654898	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	6.38	0.33	6.13e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.16	0.37	5.47e-12	Life satisfaction;
CRC	cis	rs12024301	0.557	rs10911390	chr1:183616884	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg12560992	chr17:57184187	TRIM37	0.53	6.15	0.32	2.28e-9	Vitamin D levels;
CRC	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg11901034	chr3:128598214	ACAD9	-0.5	-6.12	-0.32	2.64e-9	IgG glycosylation;
CRC	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg25007680	chr1:8021821	PARK7	0.56	7.6	0.39	3.06e-13	Response to antidepressants and depression;
CRC	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg19773385	chr1:10388646	KIF1B	-0.62	-9.88	-0.48	2.48e-20	Hepatocellular carcinoma;
CRC	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-12.38	-0.56	3.63e-29	Leprosy;
CRC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg27523141	chr10:43048294	ZNF37B	0.45	6.37	0.33	6.19e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.58	5.73	0.3	2.25e-8	Fat distribution (HIV);
CRC	trans	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg04077850	chr5:125800366	GRAMD3	0.36	6.11	0.32	2.89e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-5.99	-0.31	5.62e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.59	10.38	0.5	5.06e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs78472555	0.789	rs2603229	chr15:100263499	T/C	cg18869061	chr15:100272053	LYSMD4	0.48	6.62	0.34	1.48e-10	Post bronchodilator FEV1/FVC ratio in COPD;
CRC	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.77	-10.24	-0.49	1.47e-21	Blood pressure (smoking interaction);
CRC	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg18721089	chr20:30220636	NA	-0.32	-5.78	-0.3	1.69e-8	Mean corpuscular hemoglobin;
CRC	cis	rs12745968	0.589	rs10874711	chr1:93017988	C/T	cg17283838	chr1:93427260	FAM69A	-0.48	-6.36	-0.33	6.91e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg06470822	chr6:28175283	NA	0.54	8.08	0.41	1.24e-14	Pubertal anthropometrics;
CRC	cis	rs2070997	0.702	rs7021981	chr9:133739735	G/T	cg01000188	chr9:133769184	QRFP	0.65	7.17	0.37	5.08e-12	Response to amphetamines;
CRC	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.59	-8.6	-0.43	3.28e-16	Coronary artery disease;
CRC	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg27083787	chr2:113543245	IL1A	0.44	6.24	0.33	1.32e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs17401966	0.593	rs11121523	chr1:10214442	T/A	cg19773385	chr1:10388646	KIF1B	-0.47	-6.4	-0.33	5.48e-10	Hepatocellular carcinoma;
CRC	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6604026	0.922	rs34244251	chr1:93297180	G/A	cg17283838	chr1:93427260	FAM69A	0.44	5.62	0.3	4.13e-8	Multiple sclerosis;
CRC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg10760299	chr15:45669010	GATM	0.49	7.65	0.39	2.19e-13	Homoarginine levels;
CRC	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg00318322	chr16:67708822	GFOD2	-0.31	-5.84	-0.31	1.23e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.49	-0.38	6.35e-13	Asthma;
CRC	cis	rs7703744	0.681	rs17145294	chr5:118701433	G/T	cg23917399	chr5:118691751	TNFAIP8	0.42	5.87	0.31	1.09e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs16975963	0.644	rs12459013	chr19:38129497	C/G	cg15135657	chr19:38346511	NA	-0.47	-6.34	-0.33	7.4e-10	Longevity;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.4	-5.68	-0.3	2.95e-8	Longevity;Endometriosis;
CRC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.3e-9	Life satisfaction;
CRC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg20302533	chr7:39170763	POU6F2	0.43	6.08	0.32	3.26e-9	IgG glycosylation;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg03790207	chr6:42947109	PEX6	-0.44	-6.26	-0.33	1.22e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.47	7.15	0.37	5.74e-12	Testicular germ cell tumor;
CRC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.39	6.24	0.33	1.36e-9	Total body bone mineral density;
CRC	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.81	-11.64	-0.54	1.78e-26	Pubertal anthropometrics;
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.47	-6.68	-0.35	9.96e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.61	-0.39	2.84e-13	Vitiligo;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.78	14.66	0.63	8.44e-38	Prudent dietary pattern;
CRC	cis	rs2072510	0.569	rs61937880	chr12:96390867	C/A	cg15438951	chr12:96389694	HAL	-0.48	-5.84	-0.31	1.22e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.56	0.54	3.69e-26	Prudent dietary pattern;
CRC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg21251018	chr6:28226885	NKAPL	0.4	6.07	0.32	3.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg18655438	chr5:1077845	SLC12A7	0.46	6.67	0.35	1.08e-10	Mean corpuscular hemoglobin concentration;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg08206623	chr11:2907334	CDKN1C	-0.41	-6.27	-0.33	1.12e-9	Birth weight;Height;
CRC	cis	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg04523069	chr9:97136363	HIATL1	0.37	5.67	0.3	3.05e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg11843238	chr5:131593191	PDLIM4	0.36	6.62	0.34	1.49e-10	Blood metabolite levels;
CRC	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.73	0.66	5.66e-42	Fuchs's corneal dystrophy;
CRC	cis	rs995000	0.899	rs7518497	chr1:63177696	G/T	cg19896129	chr1:63156450	NA	-0.4	-5.75	-0.3	2.01e-8	Triglyceride levels;
CRC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.79	-12.14	-0.56	2.88e-28	Body mass index;
CRC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.38	6.29	0.33	9.84e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3018066	0.867	rs3113250	chr4:107207049	G/A	cg01869342	chr4:106983673	TBCK	0.37	5.79	0.3	1.61e-8	Cancer;
CRC	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.54	0.47	3.36e-19	Migraine;Coronary artery disease;
CRC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg24562669	chr7:97807699	LMTK2	0.79	17.7	0.7	1.05e-49	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CRC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg19622623	chr12:86230825	RASSF9	-0.37	-5.95	-0.31	7.02e-9	Major depressive disorder;
CRC	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg02811702	chr13:24901961	NA	0.43	5.97	0.31	5.99e-9	Obesity-related traits;
CRC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg27068330	chr11:65405492	SIPA1	0.48	7.0	0.36	1.45e-11	Acne (severe);
CRC	cis	rs7112925	1.000	rs7112925	chr11:66826160	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.43	-0.33	4.57e-10	Height;
CRC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.65	10.29	0.49	9.94e-22	Colorectal cancer;
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg15763984	chr4:1342303	KIAA1530	-0.46	-8.27	-0.41	3.44e-15	Obesity-related traits;
CRC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.48	6.9	0.36	2.75e-11	Lymphocyte counts;
CRC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.85	-11.77	-0.54	6.07e-27	Platelet distribution width;
CRC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-0.75	-7.78	-0.39	9.72e-14	Schizophrenia;
CRC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg06238570	chr21:40685208	BRWD1	0.79	10.84	0.51	1.29e-23	Cognitive function;
CRC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.56	7.69	0.39	1.68e-13	Bronchopulmonary dysplasia;
CRC	cis	rs8141797	0.901	rs5760201	chr22:24474704	A/G	cg20894457	chr22:24584366	SUSD2	0.63	7.58	0.39	3.55e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.52	7.37	0.38	1.36e-12	Corneal astigmatism;
CRC	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.41	-5.72	-0.3	2.36e-8	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.6	-8.58	-0.43	3.93e-16	Total body bone mineral density;
CRC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg03609598	chr5:56110824	MAP3K1	-0.59	-7.88	-0.4	4.77e-14	Initial pursuit acceleration;
CRC	cis	rs9462027	0.628	rs6925623	chr6:34800896	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-0.62	-6.88	-0.35	3.08e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg04586622	chr2:25135609	ADCY3	-0.57	-10.96	-0.52	5.04e-24	Body mass index in non-asthmatics;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26719024	chr10:105156444	PDCD11;USMG5	0.47	6.13	0.32	2.57e-9	Thyroid stimulating hormone;
CRC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.1	18.95	0.72	1.18e-54	Ulcerative colitis;
CRC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-5.66	-0.3	3.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-6.91	-0.36	2.59e-11	Height;
CRC	cis	rs4731207	0.698	rs4731223	chr7:124483272	A/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.28e-9	Cutaneous malignant melanoma;
CRC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.57	-9.61	-0.47	2.02e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.09	9.24	0.45	3.09e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs728616	0.681	rs12412762	chr10:81907470	A/G	cg11900509	chr10:81946545	ANXA11	0.78	8.89	0.44	4.08e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.76	9.94	0.48	1.51e-20	Iron status biomarkers;
CRC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.2	-0.32	1.68e-9	Aortic root size;
CRC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.54	7.98	0.4	2.39e-14	Lymphocyte counts;
CRC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.57	7.08	0.36	8.52e-12	Cleft lip with or without cleft palate;
CRC	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12560992	chr17:57184187	TRIM37	0.53	7.31	0.37	1.99e-12	Testicular germ cell tumor;
CRC	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg07587117	chr16:2239488	CASKIN1	0.43	7.63	0.39	2.59e-13	Height;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg20552752	chr15:90895281	ZNF774	-0.5	-6.22	-0.32	1.48e-9	Diisocyanate-induced asthma;
CRC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs806215	0.813	rs2582717	chr7:127311863	A/G	cg25922125	chr7:127225783	GCC1	0.49	5.98	0.31	5.92e-9	Type 2 diabetes;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg06470822	chr6:28175283	NA	0.84	12.77	0.58	1.28e-30	Parkinson's disease;
CRC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	12.02	0.55	7.68e-28	Chronic sinus infection;
CRC	cis	rs3018066	0.666	rs7662806	chr4:106997167	C/A	cg01869342	chr4:106983673	TBCK	0.48	6.23	0.33	1.39e-9	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02458384	chr16:2021763	TBL3	0.44	7.18	0.37	4.61e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg04990556	chr1:26633338	UBXN11	-0.46	-5.76	-0.3	1.98e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.44	-0.46	7.16e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg22110888	chr17:80059540	CCDC57	0.41	6.46	0.34	3.82e-10	Life satisfaction;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg21251018	chr6:28226885	NKAPL	0.5	7.66	0.39	2.12e-13	Parkinson's disease;
CRC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg03013999	chr17:37608204	MED1	0.43	6.6	0.34	1.68e-10	Lung function (FEV1);
CRC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.56	8.13	0.41	8.63e-15	Breast cancer;
CRC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.71	-0.3	2.47e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.28	0.46	2.4e-18	Blood protein levels;
CRC	trans	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17712092	chr4:129076599	LARP1B	-0.75	-12.36	-0.56	4.56e-29	Eosinophil percentage of white cells;
CRC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.5	-0.67	5.63e-45	Height;
CRC	cis	rs6564851	0.506	rs11641417	chr16:81257783	G/A	cg05274606	chr16:81253692	PKD1L2	-0.38	-6.16	-0.32	2.15e-9	Carotenoid and tocopherol levels;
CRC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.29	-0.42	2.95e-15	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Parkinson's disease;
CRC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	6.02	0.31	4.75e-9	IgG glycosylation;
CRC	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg13482628	chr17:19912719	NA	0.54	8.62	0.43	2.95e-16	Schizophrenia;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.52	7.93	0.4	3.49e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg08741688	chr4:3415352	RGS12	-0.39	-5.6	-0.3	4.47e-8	Serum sulfate level;
CRC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.24	0.45	3.14e-18	Cognitive test performance;
CRC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg14530993	chr4:882597	GAK	0.8	7.31	0.37	1.99e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.72	8.18	0.41	6.4e-15	Systolic blood pressure;
CRC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.67	10.14	0.49	3.45e-21	Menopause (age at onset);
CRC	cis	rs3126085	0.515	rs1923503	chr1:152360820	G/A	cg09127314	chr1:152161683	NA	-0.44	-5.86	-0.31	1.13e-8	Atopic dermatitis;
CRC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg07636037	chr3:49044803	WDR6	-0.7	-6.77	-0.35	6.09e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.35	6.28	0.33	1.1e-9	Crohn's disease;
CRC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.62	9.36	0.46	1.33e-18	Testicular germ cell tumor;
CRC	cis	rs17065868	1.000	rs73190824	chr13:45108587	G/C	cg10246903	chr13:45222710	NA	0.53	5.67	0.3	3.14e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-9.18	-0.45	4.97e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.97	12.22	0.56	1.45e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs4523957	0.928	rs9905529	chr17:2177732	T/C	cg16513277	chr17:2031491	SMG6	-0.54	-9.12	-0.45	7.71e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-12.49	-0.57	1.49e-29	Electrocardiographic conduction measures;
CRC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.51	-7.91	-0.4	3.85e-14	Body mass index;
CRC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.4	0.42	1.31e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6662572	0.737	rs9429187	chr1:46558927	C/A	cg08644498	chr1:46502608	NA	0.44	7.12	0.37	6.76e-12	Blood protein levels;
CRC	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.24	-0.41	4.07e-15	Brugada syndrome;
CRC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.29	-0.71	4.7e-52	Height;
CRC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs6976053	0.935	rs4727470	chr7:100509201	A/G	cg10426581	chr7:100472382	SRRT	0.38	5.79	0.3	1.62e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.74	-12.03	-0.55	7.03e-28	Pancreatic cancer;
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg06470822	chr6:28175283	NA	0.65	9.31	0.46	1.84e-18	Parkinson's disease;
CRC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.65e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-10.96	-0.52	4.79e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.6	-8.33	-0.42	2.2e-15	DNA methylation (variation);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07283595	chr17:5372003	DHX33	0.44	6.07	0.32	3.5e-9	Survival in pancreatic cancer;
CRC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-6.46	-0.34	3.84e-10	Personality dimensions;
CRC	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.65	-10.3	-0.49	9.46e-22	Ulcerative colitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00006884	chr7:23637030	CCDC126	0.52	6.62	0.34	1.5e-10	Thyroid stimulating hormone;
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.56	-0.34	2.03e-10	Bipolar disorder;
CRC	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.41	5.84	0.31	1.23e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg13607699	chr17:42295918	UBTF	-0.47	-6.16	-0.32	2.07e-9	Total body bone mineral density;
CRC	cis	rs9462846	0.692	rs1819325	chr6:42859748	C/A	cg10862848	chr6:42927986	GNMT	-0.27	-5.7	-0.3	2.71e-8	Blood protein levels;
CRC	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg21918786	chr6:109611834	NA	-0.33	-5.64	-0.3	3.67e-8	Reticulocyte fraction of red cells;
CRC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.55	8.52	0.43	5.79e-16	Aortic root size;
CRC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.6	0.39	3.1e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg13385794	chr1:248469461	NA	0.38	6.56	0.34	2.08e-10	Common traits (Other);
CRC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.51	8.83	0.44	6.18e-17	Schizophrenia;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg24407065	chr1:169335802	BLZF1;NME7	0.45	6.44	0.33	4.25e-10	Underweight status;
CRC	cis	rs9462027	0.628	rs7774697	chr6:34791027	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.02	0.32	4.62e-9	Systemic lupus erythematosus;
CRC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.69	-0.35	9.81e-11	Putamen volume;
CRC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg21466736	chr12:48725269	NA	0.45	7.07	0.36	9.6e-12	Glycated hemoglobin levels;
CRC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.31	-0.42	2.47e-15	Bone mineral density;
CRC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.22	-0.56	1.44e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.94	14.87	0.63	1.28e-38	Primary sclerosing cholangitis;
CRC	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.86	8.43	0.42	1.07e-15	Type 2 diabetes nephropathy;
CRC	cis	rs10950821	0.806	rs28645540	chr7:20647637	T/A	cg02470904	chr7:20686108	ABCB5	0.38	5.6	0.3	4.46e-8	Response to statin therapy;
CRC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.25	0.45	3e-18	Height;
CRC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.06	9.97	0.48	1.21e-20	Opioid sensitivity;
CRC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.55	-8.65	-0.43	2.34e-16	Aortic root size;
CRC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.32	-0.37	1.89e-12	IgG glycosylation;
CRC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.86	0.31	1.11e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.73	-0.39	1.28e-13	Blood metabolite levels;
CRC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22133161	chr19:49891603	CCDC155	0.52	7.07	0.36	9.14e-12	Multiple sclerosis;
CRC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.9	0.48	2.11e-20	Ileal carcinoids;
CRC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.59	-0.34	1.7e-10	Lung cancer;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg02033258	chr5:131593261	PDLIM4	0.47	8.87	0.44	4.83e-17	Acylcarnitine levels;
CRC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg15083037	chr5:83017644	HAPLN1	-0.5	-6.38	-0.33	5.91e-10	Prostate cancer;
CRC	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.75	12.49	0.57	1.48e-29	Selective IgA deficiency;
CRC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg11212589	chr17:38028394	ZPBP2	0.34	5.93	0.31	7.48e-9	Asthma;
CRC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs4964805	0.505	rs15918	chr12:104167024	T/C	cg02344784	chr12:104178138	NT5DC3	0.42	6.28	0.33	1.09e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1.01e-20	HDL cholesterol levels;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.59	8.96	0.44	2.49e-17	Longevity;Endometriosis;
CRC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.43	6.89	0.36	2.8e-11	Height;
CRC	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg00343986	chr7:65444356	GUSB	-0.49	-6.71	-0.35	8.36e-11	Aortic root size;
CRC	cis	rs469568	0.562	rs11746802	chr5:178665185	C/T	cg08999896	chr5:178685787	ADAMTS2	0.31	5.66	0.3	3.26e-8	Stroke (pediatric);
CRC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.31	5.69	0.3	2.87e-8	Menarche (age at onset);
CRC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13606994	chr1:44402422	ARTN	-0.34	-5.76	-0.3	1.94e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.84	-9.73	-0.47	7.72e-20	Breast cancer;
CRC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.58	-0.34	1.91e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.52	0.54	5.08e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.55	-7.92	-0.4	3.78e-14	Birth weight;
CRC	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.5	0.54	5.74e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.68	9.13	0.45	7.23e-18	High light scatter reticulocyte count;
CRC	cis	rs17767392	0.756	rs61989256	chr14:71729964	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.36	-0.33	6.63e-10	Mitral valve prolapse;
CRC	cis	rs6076065	0.723	rs2051093	chr20:23371349	G/A	cg11657817	chr20:23433608	CST11	0.45	6.69	0.35	9.76e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg12516270	chr8:143859308	LYNX1	0.41	7.42	0.38	1e-12	Urinary tract infection frequency;
CRC	trans	rs34308817	0.509	rs7426901	chr3:181361312	C/G	cg10852698	chr6:46375852	NA	-0.45	-5.97	-0.31	6.03e-9	Ankle injury;
CRC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg03732007	chr1:2071316	PRKCZ	-0.36	-5.73	-0.3	2.28e-8	Height;
CRC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg17724175	chr1:150552817	MCL1	0.43	6.6	0.34	1.63e-10	Melanoma;
CRC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg20387954	chr3:183756860	HTR3D	0.45	7.6	0.39	3.11e-13	Anterior chamber depth;
CRC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.83	-0.35	4.07e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-8.73	-0.43	1.33e-16	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7635838	0.573	rs73019547	chr3:11493323	A/C	cg00170343	chr3:11313890	ATG7	0.46	7.12	0.37	6.84e-12	HDL cholesterol;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg19223190	chr17:80058835	NA	0.38	6.17	0.32	2e-9	Life satisfaction;
CRC	cis	rs57590327	0.508	rs4605572	chr3:81965751	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-6.26	-0.33	1.2e-9	Extraversion;
CRC	cis	rs8170	1.000	rs8170	chr19:17389704	G/A	cg04749549	chr19:17459798	NA	-0.45	-6.11	-0.32	2.76e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.68	10.42	0.5	3.68e-22	Menopause (age at onset);
CRC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.51	-0.42	6.33e-16	Bone mineral density;
CRC	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.51	7.67	0.39	1.95e-13	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.75	14.88	0.63	1.14e-38	Leprosy;
CRC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-6.05	-0.32	4e-9	Aortic root size;
CRC	trans	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg03771185	chr4:775700	NA	0.52	6.2	0.32	1.68e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.62	11.61	0.54	2.35e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.52	-6.09	-0.32	3.16e-9	Coronary artery calcification;
CRC	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.16	0.41	7.17e-15	Lung cancer;
CRC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.61	-0.43	3.09e-16	Monocyte percentage of white cells;
CRC	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.62	-9.24	-0.45	3.08e-18	Initial pursuit acceleration in psychotic disorders;
CRC	trans	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.67	-0.35	1.1e-10	Breast cancer;
CRC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.52	1.55e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.34	0.53	2.15e-25	Prudent dietary pattern;
CRC	cis	rs2252521	0.526	rs317704	chr7:29087343	T/G	cg11728747	chr7:29037910	CPVL	-0.47	-6.68	-0.35	1.02e-10	Cognitive performance;
CRC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.62	0.34	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
CRC	cis	rs6604026	0.656	rs2811596	chr1:93341223	A/G	cg17283838	chr1:93427260	FAM69A	-0.43	-5.6	-0.3	4.52e-8	Multiple sclerosis;
CRC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg26304593	chr6:42947056	PEX6	-0.45	-6.65	-0.34	1.24e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.78	0.54	5.79e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg05585544	chr11:47624801	NA	-0.61	-11.31	-0.53	2.74e-25	Subjective well-being;
CRC	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	6.77	0.35	6.02e-11	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg15763984	chr4:1342303	KIAA1530	-0.35	-6.05	-0.32	3.95e-9	Obesity-related traits;
CRC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.8	8.03	0.4	1.79e-14	Major depressive disorder;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg08798685	chr6:27730294	NA	-0.43	-6.2	-0.32	1.66e-9	Parkinson's disease;
CRC	cis	rs12476592	0.516	rs1348804	chr2:63895672	C/T	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.69	-7.78	-0.39	9.14e-14	Vitiligo;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06596689	chr7:139875956	LOC100134229;JHDM1D	-0.4	-6.47	-0.34	3.49e-10	Myopia (pathological);
CRC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.27	-14.68	-0.63	7.35e-38	Diabetic kidney disease;
CRC	cis	rs939584	0.877	rs6548240	chr2:636929	C/A	cg03610516	chr2:642275	NA	0.43	5.77	0.3	1.8e-8	Body mass index;
CRC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	26.88	0.83	5.33e-85	IgG glycosylation;
CRC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg23136738	chr11:925521	AP2A2	-0.5	-7.9	-0.4	4.34e-14	Alzheimer's disease (late onset);
CRC	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.83	-13.43	-0.6	4.27e-33	Hypospadias;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18800192	chr19:42388471	ARHGEF1	0.39	6.01	0.31	5.04e-9	Interleukin-6 levels;
CRC	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.42	6.42	0.33	4.85e-10	Recombination rate (males);
CRC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.51	8.07	0.41	1.34e-14	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15846643	chr11:94964345	SESN3	0.41	7.64	0.39	2.42e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.8	-11.41	-0.53	1.22e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	14.89	0.63	1.05e-38	Mean platelet volume;
CRC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.47	-7.63	-0.39	2.56e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.51	8.57	0.43	4.13e-16	Schizophrenia;
CRC	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.59	-5.95	-0.31	6.77e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.6	-10.65	-0.51	5.8e-23	Aortic root size;
CRC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	7.14	0.37	6.05e-12	Platelet count;
CRC	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.69	9.97	0.48	1.28e-20	Body mass index;
CRC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.49	-0.62	3.8e-37	Body mass index;
CRC	cis	rs6735179	0.607	rs10202812	chr2:1746468	A/T	cg19300414	chr2:1746591	PXDN	0.43	7.01	0.36	1.34e-11	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.46	0.6	3.42e-33	Alzheimer's disease;
CRC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg19622623	chr12:86230825	RASSF9	0.4	6.39	0.33	5.55e-10	Major depressive disorder;
CRC	trans	rs4942242	0.583	rs1027413	chr13:44224212	C/T	cg19169023	chr15:41853346	TYRO3	0.44	6.45	0.34	3.91e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.02	0.58	1.48e-31	Platelet count;
CRC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg20114781	chr15:43622253	ADAL;LCMT2	0.56	6.0	0.31	5.11e-9	Lung cancer in ever smokers;
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.28	-0.33	1.07e-9	Electroencephalogram traits;
CRC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.61	-9.68	-0.47	1.16e-19	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.899	rs1167998	chr1:62931632	C/A	cg19896129	chr1:63156450	NA	-0.39	-5.91	-0.31	8.5e-9	Triglyceride levels;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg08546805	chr12:8549446	NA	-0.43	-6.55	-0.34	2.26e-10	Blood pressure (smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03546505	chr14:105266900	ZBTB42	0.44	5.98	0.31	5.71e-9	Anxiety disorder;
CRC	cis	rs7113874	0.569	rs2289921	chr11:8496611	G/C	cg02811074	chr11:8615871	STK33	0.36	6.13	0.32	2.48e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.62	9.29	0.46	2.19e-18	Subjective well-being;
CRC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.39	6.25	0.33	1.25e-9	Blood metabolite levels;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg15845792	chr6:28175446	NA	0.82	12.17	0.56	2.24e-28	Cardiac Troponin-T levels;
CRC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg19223190	chr17:80058835	NA	-0.43	-6.81	-0.35	4.54e-11	Life satisfaction;
CRC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg00343986	chr7:65444356	GUSB	-0.41	-5.85	-0.31	1.2e-8	Aortic root size;
CRC	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg04239558	chr2:103089729	SLC9A4	0.35	6.11	0.32	2.84e-9	Blood protein levels;
CRC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.69	9.31	0.46	1.85e-18	High light scatter reticulocyte count;
CRC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.17	-0.32	2.01e-9	Morning vs. evening chronotype;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15351736	chr11:111808104	DIXDC1	-0.48	-5.97	-0.31	6.13e-9	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02941376	chr17:1613939	TLCD2	0.46	6.63	0.34	1.36e-10	Response to antipsychotic treatment;
CRC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.17	0.49	2.71e-21	Birth weight;
CRC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.65	-0.39	2.25e-13	Coronary artery disease;
CRC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.7	-12.42	-0.56	2.63e-29	Dental caries;
CRC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg19812747	chr11:111475976	SIK2	0.5	8.05	0.41	1.5e-14	Primary sclerosing cholangitis;
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	13.78	0.6	2e-34	Alzheimer's disease;
CRC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12172441	chr6:28176163	NA	-0.65	-8.54	-0.43	5.04e-16	Depression;
CRC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.38	-5.71	-0.3	2.59e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	1.08	9.22	0.45	3.7e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg04800585	chr6:26043546	HIST1H2BB	0.57	8.39	0.42	1.48e-15	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.58	8.69	0.43	1.8e-16	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26339992	chr1:28241106	RPA2	0.41	7.04	0.36	1.13e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg12193833	chr17:30244370	NA	-0.57	-7.99	-0.4	2.3e-14	Hip circumference adjusted for BMI;
CRC	trans	rs10411161	0.702	rs16983200	chr19:52386723	G/A	cg22319618	chr22:45562946	NUP50	-0.67	-7.41	-0.38	1.06e-12	Breast cancer;
CRC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.83	-14.28	-0.62	2.38e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20607769	chr12:53491735	IGFBP6	0.44	6.62	0.34	1.48e-10	Anxiety disorder;
CRC	cis	rs4654899	0.549	rs4654873	chr1:21152384	G/A	cg02927042	chr1:21476669	EIF4G3	-0.42	-6.3	-0.33	9.59e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.62	-8.24	-0.41	4.18e-15	Multiple sclerosis;
CRC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-0.9	-15.55	-0.65	2.87e-41	Body mass index;
CRC	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.5	7.61	0.39	2.92e-13	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.97	-0.4	2.65e-14	Life satisfaction;
CRC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg21194808	chr1:2205498	SKI	-0.36	-5.74	-0.3	2.12e-8	Height;
CRC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.16	0.37	5.31e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg02569458	chr12:86230093	RASSF9	-0.4	-6.64	-0.34	1.33e-10	Major depressive disorder;
CRC	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.43	8.54	0.43	5.08e-16	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg07870213	chr5:140052090	DND1	-0.61	-7.72	-0.39	1.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg12516270	chr8:143859308	LYNX1	-0.4	-6.6	-0.34	1.65e-10	Urinary tract infection frequency;
CRC	trans	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg06206626	chr22:26825900	ASPHD2	0.41	6.18	0.32	1.94e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9463078	0.677	rs7739928	chr6:45068053	G/C	cg25276700	chr6:44698697	NA	-0.25	-5.96	-0.31	6.63e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	6.81	0.35	4.56e-11	Aortic root size;
CRC	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.14	8.76	0.43	1.03e-16	Economic and political preferences (immigration/crime);
CRC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg04586622	chr2:25135609	ADCY3	-0.54	-10.18	-0.49	2.43e-21	Body mass index;
CRC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.7	9.24	0.45	3.24e-18	High light scatter reticulocyte count;
CRC	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.02	20.87	0.75	3.48e-62	Multiple myeloma;
CRC	trans	rs11088226	0.538	rs4816436	chr21:33880251	A/G	cg09050820	chr6:167586206	TCP10L2	0.54	7.42	0.38	9.76e-13	Gastritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20972416	chr2:220025218	NHEJ1	0.41	6.01	0.31	5.04e-9	Response to antipsychotic treatment;
CRC	cis	rs9491140	0.539	rs10872283	chr6:124685919	G/A	cg05308643	chr6:124982296	NKAIN2	0.49	6.76	0.35	6.19e-11	Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10719100	chr8:146078187	COMMD5	-0.39	-6.12	-0.32	2.64e-9	Myopia (pathological);
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg10729496	chr3:10149963	C3orf24	0.5	6.65	0.34	1.22e-10	Alzheimer's disease;
CRC	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.64	7.9	0.4	4.18e-14	Arsenic metabolism;
CRC	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.71	8.44	0.42	1.03e-15	Eotaxin levels;
CRC	cis	rs243505	1.000	rs243511	chr7:148430148	A/C	cg09806900	chr7:148480153	CUL1	-0.44	-6.26	-0.33	1.17e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.66	9.02	0.45	1.57e-17	Response to diuretic therapy;
CRC	trans	rs11581859	0.901	rs72730328	chr1:99395309	C/A	cg12183875	chr3:169587454	LRRC31	0.28	6.34	0.33	7.78e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.65	-12.44	-0.57	2.16e-29	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.31	-6.31	-0.33	8.93e-10	Bipolar disorder;
CRC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg12564285	chr5:131593104	PDLIM4	0.32	5.82	0.31	1.36e-8	Blood metabolite levels;
CRC	cis	rs6681460	0.966	rs10789214	chr1:67146817	C/T	cg02459107	chr1:67143332	SGIP1	0.45	7.97	0.4	2.56e-14	Presence of antiphospholipid antibodies;
CRC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.55	7.06	0.36	1e-11	Morning vs. evening chronotype;
CRC	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg20488157	chr14:104394430	TDRD9	0.68	9.82	0.48	3.87e-20	Bipolar disorder;
CRC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.51	-7.09	-0.36	8.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg10263370	chr3:44754102	ZNF502	-0.35	-5.86	-0.31	1.12e-8	Depressive symptoms;
CRC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.58	8.46	0.42	9.1e-16	Lung cancer;
CRC	trans	rs9650657	0.615	rs6601534	chr8:10691993	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.17	-0.32	2.04e-9	Neuroticism;
CRC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.47	6.32	0.33	8.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.33	-6.33	-0.33	8.16e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg04450456	chr4:17643702	FAM184B	0.41	6.7	0.35	9.11e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	1.0	14.46	0.62	4.91e-37	Initial pursuit acceleration;
CRC	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.69	9.57	0.47	2.6e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06470822	chr6:28175283	NA	0.67	5.85	0.31	1.22e-8	Depression;
CRC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.6	9.02	0.45	1.6e-17	Lung cancer;
CRC	cis	rs4789693	0.872	rs28612648	chr17:80403386	G/A	cg04308225	chr17:80449738	NA	0.53	6.87	0.35	3.3e-11	Glucocorticoid-induced osteonecrosis;
CRC	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg25664220	chr3:72788482	NA	-0.4	-6.01	-0.31	4.94e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	trans	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg10756647	chr7:56101905	PSPH	0.78	8.1	0.41	1.08e-14	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15993354	chr19:12912590	PRDX2	0.37	6.02	0.31	4.67e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.91	-15.71	-0.65	6.72e-42	Height;
CRC	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg25856811	chr1:152973957	SPRR3	-0.21	-5.69	-0.3	2.74e-8	Inflammatory skin disease;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.3	-5.81	-0.31	1.46e-8	Lung cancer;
CRC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18912574	chr7:65842487	NCRNA00174	0.37	6.3	0.33	9.63e-10	Aortic root size;
CRC	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-8.84	-0.44	6.03e-17	Rheumatoid arthritis;
CRC	cis	rs910187	0.538	rs2868849	chr20:45802273	G/A	cg27589058	chr20:45804311	EYA2	-0.44	-8.79	-0.44	8.22e-17	Migraine;
CRC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.44	-0.38	8.78e-13	Joint mobility (Beighton score);
CRC	cis	rs447	0.806	rs6974494	chr7:83743961	A/G	cg22846510	chr7:83753280	SEMA3A	0.41	5.72	0.3	2.43e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg17885191	chr8:135476712	NA	0.51	7.2	0.37	4e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.44	0.42	1.03e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg15145296	chr3:125709740	NA	-0.57	-6.5	-0.34	2.98e-10	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.61	9.06	0.45	1.15e-17	Lung cancer;
CRC	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.34	-0.33	7.38e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg14828511	chr1:107599125	PRMT6	0.45	6.54	0.34	2.32e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.69	0.43	1.78e-16	Menopause (age at onset);
CRC	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.89	-12.03	-0.55	7.14e-28	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.59	8.45	0.42	9.26e-16	Arsenic metabolism;
CRC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.56	8.83	0.44	6.58e-17	Motion sickness;
CRC	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.54	7.6	0.39	3.18e-13	Testicular germ cell tumor;
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.06	-0.32	3.81e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg20512303	chr5:131592959	PDLIM4	-0.38	-6.69	-0.35	9.62e-11	Breast cancer;
CRC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg20608306	chr11:116969690	SIK3	-0.31	-5.69	-0.3	2.78e-8	Subjective well-being;
CRC	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-7.73	-0.39	1.32e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00166722	chr3:10149974	C3orf24	0.66	9.0	0.44	1.85e-17	Alzheimer's disease;
CRC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg08213375	chr14:104286397	PPP1R13B	0.39	6.23	0.32	1.41e-9	Reticulocyte count;
CRC	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.61	-9.84	-0.48	3.49e-20	Itch intensity from mosquito bite;
CRC	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.39	-11.42	-0.53	1.14e-25	Psoriasis vulgaris;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg07217954	chr7:1067459	C7orf50	0.56	5.75	0.3	2.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.7	-7.9	-0.4	4.3e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7201929	1.000	rs7201929	chr16:28871966	C/T	cg10436792	chr16:28889110	ATP2A1	-0.41	-5.93	-0.31	7.72e-9	QT interval;
CRC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.38	6.28	0.33	1.06e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.7	0.35	8.88e-11	Cognitive ability;
CRC	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg25184248	chr3:123813393	KALRN	0.47	6.17	0.32	2.02e-9	Parkinson's disease;
CRC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg03030879	chr14:75389066	RPS6KL1	0.44	6.69	0.35	9.82e-11	Height;
CRC	cis	rs10971721	0.822	rs72725368	chr9:33815455	G/A	cg13495928	chr9:33750294	PRSS3	0.55	5.89	0.31	9.66e-9	Body mass index;
CRC	cis	rs6496667	0.779	rs6496673	chr15:90976106	C/T	cg04176472	chr15:90893244	GABARAPL3	0.59	7.97	0.4	2.62e-14	Rheumatoid arthritis;
CRC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg18479299	chr3:125709523	NA	-0.55	-6.53	-0.34	2.45e-10	Blood pressure (smoking interaction);
CRC	cis	rs136211	0.929	rs6000262	chr22:36770038	A/G	cg16924664	chr22:36878180	TXN2	0.39	5.71	0.3	2.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg23461800	chr14:103021989	NA	-0.75	-10.23	-0.49	1.7e-21	Platelet count;
CRC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.64	8.53	0.43	5.53e-16	Iron status biomarkers;
CRC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.55	8.27	0.41	3.41e-15	Obesity-related traits;
CRC	cis	rs427941	0.562	rs6950791	chr7:101780458	C/T	cg06246474	chr7:101738831	CUX1	0.45	6.9	0.36	2.63e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14777817	chr13:80055594	NDFIP2	0.46	7.42	0.38	1.01e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.9	0.4	4.29e-14	Arsenic metabolism;
CRC	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.73	0.35	7.51e-11	Retinal vascular caliber;
CRC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-6.06	-0.32	3.81e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.68	10.81	0.51	1.7e-23	Cognitive function;
CRC	trans	rs783540	0.934	rs783532	chr15:83249367	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.37	-0.33	6.54e-10	Schizophrenia;
CRC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.35	0.42	1.86e-15	Lymphocyte counts;
CRC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.54	8.67	0.43	2.05e-16	Type 2 diabetes;
CRC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.71	11.51	0.54	5.4e-26	Dental caries;
CRC	cis	rs9903692	0.954	rs68175794	chr17:46181104	G/T	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.29	-6.07	-0.32	3.51e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.29	-0.33	9.96e-10	Colorectal cancer;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02725872	chr8:58115012	NA	-0.6	-9.12	-0.45	7.55e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg04586622	chr2:25135609	ADCY3	-0.57	-9.72	-0.47	8.37e-20	Body mass index;
CRC	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.58	9.28	0.46	2.37e-18	Myopia (pathological);
CRC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.69	-0.51	4.39e-23	Bone mineral density;
CRC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09065629	chr16:1709722	CRAMP1L	0.36	5.62	0.3	4.09e-8	Coronary artery disease;
CRC	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-5.93	-0.31	7.46e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg18827107	chr12:86230957	RASSF9	0.37	5.78	0.3	1.72e-8	Major depressive disorder;
CRC	cis	rs1891498	0.516	rs12037169	chr1:147248057	A/G	cg17941330	chr1:147245494	GJA5	-0.37	-5.64	-0.3	3.67e-8	Cognitive performance;
CRC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg12193833	chr17:30244370	NA	-0.62	-7.99	-0.4	2.27e-14	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19387228	chr4:8442570	ACOX3	0.51	7.41	0.38	1.05e-12	Response to antipsychotic treatment;
CRC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.11	-0.49	4.18e-21	Monocyte count;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg04969067	chr8:143858791	LYNX1	0.45	7.68	0.39	1.84e-13	Urinary tract infection frequency;
CRC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.67	10.38	0.5	4.96e-22	Birth weight;
CRC	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg24642844	chr7:1081250	C7orf50	-0.84	-7.41	-0.38	1.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	7.89	0.4	4.64e-14	Platelet count;
CRC	cis	rs12711979	0.904	rs12329356	chr2:3868533	G/C	cg17052675	chr2:3827356	NA	-0.51	-9.22	-0.45	3.74e-18	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.57	-0.75	5.09e-61	Height;
CRC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.41	-0.33	5.19e-10	Cognitive test performance;
CRC	cis	rs2179367	0.959	rs504985	chr6:149658978	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.08	-0.32	3.4e-9	Dupuytren's disease;
CRC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.85	-14.8	-0.63	2.36e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.4e-11	Lung cancer;
CRC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.14	0.32	2.4e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.92	0.55	1.8e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.6	8.94	0.44	2.9e-17	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	17.02	0.68	4.75e-47	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg07865391	chr16:88106882	BANP	0.47	6.09	0.32	3.1e-9	Menopause (age at onset);
CRC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg09998033	chr7:158218633	PTPRN2	0.51	7.27	0.37	2.72e-12	Obesity-related traits;
CRC	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.07	-0.45	1.11e-17	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25350635	chr12:49182847	ADCY6	0.39	6.39	0.33	5.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.58	6.47	0.34	3.47e-10	Bipolar disorder;
CRC	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-6.07	-0.32	3.46e-9	Prion diseases;
CRC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.68	0.35	1.02e-10	Mean platelet volume;
CRC	cis	rs7605827	0.930	rs11687986	chr2:15591308	G/T	cg19274914	chr2:15703543	NA	0.39	6.01	0.31	4.94e-9	Educational attainment (years of education);
CRC	cis	rs1465370	0.720	rs5011387	chr7:130017149	C/T	cg03229158	chr7:130009420	NA	0.44	6.26	0.33	1.23e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	trans	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg21153622	chr11:89784906	NA	-0.48	-7.73	-0.39	1.35e-13	HDL cholesterol;
CRC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.76	12.91	0.58	3.91e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs6956675	0.915	rs6977279	chr7:62630625	C/G	cg01314568	chr7:57830625	NA	-0.66	-9.15	-0.45	5.98e-18	Obesity-related traits;
CRC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg16447950	chr5:562315	NA	-0.85	-12.55	-0.57	8.97e-30	Obesity-related traits;
CRC	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg01993067	chr11:68851601	TPCN2	0.58	6.66	0.34	1.13e-10	Blond vs. brown hair color;
CRC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg10589385	chr1:150898437	SETDB1	0.32	6.87	0.35	3.16e-11	Melanoma;
CRC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg19792802	chr11:65647270	CTSW	0.5	7.55	0.38	4.23e-13	Crohn's disease;
CRC	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.5	9.32	0.46	1.77e-18	Educational attainment (years of education);
CRC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-18.43	-0.71	1.34e-52	Coronary artery disease;
CRC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.5	9.46	0.46	6.16e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg12365402	chr11:9010492	NRIP3	-0.51	-8.41	-0.42	1.28e-15	Hemoglobin concentration;
CRC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.47	-6.4	-0.33	5.5e-10	Multiple myeloma;
CRC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.42	5.84	0.31	1.23e-8	Heart rate;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12588279	chr6:26043732	HIST1H2BB	-0.49	-7.09	-0.36	8.06e-12	Intelligence (multi-trait analysis);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg08990514	chr17:48672483	CACNA1G	-0.37	-6.26	-0.33	1.18e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.39	-0.42	1.42e-15	Height;
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.66	0.3	3.23e-8	Prudent dietary pattern;
CRC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.62	-7.7	-0.39	1.5700000000000001e-13	Schizophrenia;
CRC	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg00042356	chr1:8021962	PARK7	0.53	6.53	0.34	2.48e-10	Inflammatory bowel disease;
CRC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.72	0.47	8.32e-20	Heart rate;
CRC	cis	rs11203032	0.831	rs3923282	chr10:90946752	C/T	cg16672925	chr10:90967113	CH25H	0.45	5.73	0.3	2.31e-8	Heart failure;
CRC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07701084	chr6:150067640	NUP43	0.54	7.59	0.39	3.3e-13	Lung cancer;
CRC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-10.87	-0.51	1.03e-23	Prostate cancer;
CRC	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.59	-8.69	-0.43	1.75e-16	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg26597838	chr10:835615	NA	0.52	7.06	0.36	9.84e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.66	8.17	0.41	6.84e-15	Type 2 diabetes nephropathy;
CRC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.63	-0.39	2.58e-13	Gut microbiome composition (summer);
CRC	cis	rs7605827	0.930	rs1019358	chr2:15524042	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.6	-0.47	2.1e-19	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14964934	chr19:4723942	DPP9	0.43	6.03	0.32	4.36e-9	Anxiety disorder;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg02683197	chr6:28174875	NA	0.68	8.32	0.42	2.36e-15	Parkinson's disease;
CRC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.41	-6.29	-0.33	1.03e-9	Blood metabolite levels;
CRC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.97	14.26	0.62	2.99e-36	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7692995	1.000	rs1585333	chr4:18019025	T/C	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	trans	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	6.06	0.32	3.69e-9	Metabolite levels;
CRC	cis	rs12980942	0.591	rs1946613	chr19:41767785	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.49	0.34	3.13e-10	Coronary artery disease;
CRC	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.0	-0.4	2.1e-14	Biliary atresia;
CRC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.41	-0.38	1.1e-12	Type 2 diabetes;
CRC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg10589385	chr1:150898437	SETDB1	0.3	6.23	0.33	1.39e-9	Melanoma;
CRC	cis	rs9847710	0.967	rs4687694	chr3:53049047	T/C	cg04503182	chr3:53078218	SFMBT1	0.41	6.6	0.34	1.69e-10	Ulcerative colitis;
CRC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.77	0.3	1.85e-8	Tonsillectomy;
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.65	-6.65	-0.34	1.21e-10	Depression;
CRC	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.41	5.76	0.3	1.96e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs12230513	0.732	rs61957765	chr12:55868561	T/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.15	-0.45	6.05e-18	Contrast sensitivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02977761	chr19:42901279	NA	0.43	6.64	0.34	1.33e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3026445	0.761	rs67917264	chr12:110554818	A/G	cg12870014	chr12:110450643	ANKRD13A	0.43	6.91	0.36	2.5e-11	QT interval;
CRC	cis	rs73200209	0.744	rs61562746	chr12:116456445	A/C	cg01776926	chr12:116560359	MED13L	-0.63	-7.37	-0.38	1.4e-12	Total body bone mineral density;
CRC	cis	rs9786986	0.609	rs12401387	chr1:235701314	C/T	cg08848088	chr1:235714526	GNG4	0.52	6.4	0.33	5.2400000000000005e-10	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16365086	chr5:150603689	CCDC69	0.45	6.33	0.33	7.87e-10	Response to antipsychotic treatment;
CRC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15541040	chr2:3486749	NA	-0.53	-8.4	-0.42	1.35e-15	Neurofibrillary tangles;
CRC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.89	0.58	4.51e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.5	7.44	0.38	8.89e-13	Blood metabolite levels;
CRC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.62	9.26	0.45	2.68e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.52	-7.13	-0.37	6.25e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs62432291	0.614	rs420339	chr6:159657195	G/T	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.42	6.48	0.34	3.29e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07560096	chr11:86383182	ME3	0.42	5.98	0.31	5.72e-9	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.73	12.3	0.56	7.53e-29	Cognitive function;
CRC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.6	8.11	0.41	9.98e-15	Multiple sclerosis;
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.9	-20.29	-0.75	6.11e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg05141711	chr1:15912213	AGMAT	0.33	5.9	0.31	9.02e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	12.06	0.55	5.66e-28	Monocyte percentage of white cells;
CRC	cis	rs6586163	1.000	rs7097572	chr10:90753260	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.52	-7.44	-0.38	9.09e-13	Chronic lymphocytic leukemia;
CRC	cis	rs365302	1.000	rs416321	chr6:159648907	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg03938978	chr2:103052716	IL18RAP	0.37	6.1	0.32	3.01e-9	Asthma;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.4	-5.66	-0.3	3.27e-8	Breast cancer;
CRC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.09	-19.31	-0.73	4.6e-56	Dilated cardiomyopathy;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg10272801	chr16:14013773	ERCC4	-0.69	-6.06	-0.32	3.8e-9	Cognitive function;
CRC	trans	rs4714291	0.832	rs1923462	chr6:39976100	T/C	cg02267698	chr19:7991119	CTXN1	-0.5	-6.82	-0.35	4.25e-11	Strep throat;
CRC	cis	rs6504950	0.800	rs12952253	chr17:53005716	A/G	cg26251398	chr17:52985966	TOM1L1	0.4	5.66	0.3	3.24e-8	Breast cancer;
CRC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg27068330	chr11:65405492	SIPA1	-0.48	-6.69	-0.35	9.69e-11	Breast cancer;
CRC	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.83	-0.55	3.66e-27	Colorectal cancer;
CRC	cis	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg25886479	chr11:50257625	LOC441601	0.36	6.23	0.32	1.4e-9	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09611793	chr4:48833193	OCIAD1	0.38	5.98	0.31	5.77e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	8.43	0.42	1.12e-15	Neuroticism;
CRC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.44	9.41	0.46	8.85e-19	Cutaneous nevi;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20913372	chr9:140190455	NA	0.45	6.33	0.33	8.22e-10	Response to antipsychotic treatment;
CRC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.99	-0.31	5.62e-9	Mean corpuscular volume;
CRC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg19193384	chr17:30244184	NA	-0.53	-6.89	-0.36	2.85e-11	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.49	7.63	0.39	2.49e-13	Corneal astigmatism;
CRC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.89	-0.36	2.84e-11	Colorectal cancer;
CRC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.84	-0.35	3.9e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg15445000	chr17:37608096	MED1	-0.36	-6.18	-0.32	1.86e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg09835421	chr16:68378352	PRMT7	-0.78	-8.1	-0.41	1.12e-14	Magnesium levels;
CRC	cis	rs72634258	0.519	rs4908487	chr1:7937437	C/T	cg26816564	chr1:7831052	VAMP3	0.78	8.68	0.43	1.81e-16	Inflammatory bowel disease;
CRC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.53	8.57	0.43	4.16e-16	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg03623178	chr6:28175578	NA	0.92	12.95	0.58	2.82e-31	Parkinson's disease;
CRC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.73	-12.72	-0.57	1.94e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs4604732	0.812	rs6663238	chr1:247624971	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.41	-6.24	-0.33	1.34e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.76	0.47	6.46e-20	Alzheimer's disease (late onset);
CRC	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	11.17	0.52	9e-25	Nonalcoholic fatty liver disease;
CRC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.59	8.89	0.44	4.18e-17	Lung cancer;
CRC	cis	rs3790645	1.000	rs897641	chr1:26881806	C/A	cg17456097	chr1:26900765	RPS6KA1	0.41	6.16	0.32	2.08e-9	Glucose homeostasis traits;
CRC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg00129232	chr17:37814104	STARD3	0.6	7.21	0.37	3.94e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.88	11.78	0.54	5.62e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.53	8.6	0.43	3.32e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs6700896	0.864	rs11208718	chr1:66158995	G/A	cg04111102	chr1:66153794	NA	0.34	5.87	0.31	1.04e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg16447950	chr5:562315	NA	-0.81	-10.62	-0.51	7.76e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs9462027	0.561	rs3798348	chr6:34771892	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.47e-9	Systemic lupus erythematosus;
CRC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.18	0.32	1.9e-9	Menopause (age at onset);
CRC	cis	rs997295	0.570	rs7172298	chr15:67872983	T/C	cg24247231	chr15:67904302	MAP2K5	-0.33	-5.62	-0.3	4.16e-8	Motion sickness;
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg19678392	chr7:94953810	PON1	-0.56	-7.06	-0.36	9.89e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.61	9.1	0.45	8.96e-18	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00129774	chr12:56360414	CDK2;SILV	0.41	6.03	0.32	4.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.47	0.46	5.5e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3026101	0.671	rs2107151	chr17:5297338	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	6.91	0.36	2.49e-11	Body mass index;
CRC	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.48	-8.82	-0.44	6.68e-17	Educational attainment (years of education);
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.67	-9.06	-0.45	1.17e-17	Alzheimer's disease;
CRC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-5.92	-0.31	7.93e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.64	9.72	0.47	8.47e-20	Initial pursuit acceleration;
CRC	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg18032046	chr6:28092343	ZSCAN16	0.49	5.65	0.3	3.5e-8	Depression;
CRC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00339695	chr16:24857497	SLC5A11	0.28	6.6	0.34	1.61e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08592733	chr4:140374542	RAB33B	0.43	6.26	0.33	1.23e-9	Schizophrenia;
CRC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.52	7.15	0.37	5.69e-12	Schizophrenia;
CRC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.66	8.73	0.43	1.33e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg27534772	chr1:16042836	PLEKHM2	0.53	10.02	0.48	8.15e-21	Systolic blood pressure;
CRC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.34	-0.33	7.54e-10	Obesity-related traits;
CRC	trans	rs6472235	0.837	rs10098417	chr8:66918380	A/G	cg07884673	chr3:53033167	SFMBT1	-0.46	-6.15	-0.32	2.31e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg21285383	chr16:89894308	SPIRE2	0.34	5.64	0.3	3.73e-8	Vitiligo;
CRC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	-0.53	-9.0	-0.44	1.8e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.53	-7.23	-0.37	3.32e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.78	9.46	0.46	6.15e-19	Body mass index;
CRC	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg08125733	chr17:73851984	WBP2	0.47	6.0	0.31	5.15e-9	White matter hyperintensity burden;
CRC	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.47	6.74	0.35	6.94e-11	Response to statin therapy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02056921	chr1:901892	PLEKHN1	0.48	6.39	0.33	5.72e-10	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15531788	chr10:38146671	ZNF248	0.42	6.92	0.36	2.35e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9914988	0.537	rs28448745	chr17:27188296	A/C	cg12682573	chr17:27188876	MIR451;MIR144	-0.52	-7.01	-0.36	1.37e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.45	0.38	8.19e-13	Rheumatoid arthritis;
CRC	trans	rs747334	0.558	rs7897249	chr10:92772368	C/T	cg05202497	chr5:154317929	GEMIN5	0.53	6.3	0.33	9.57e-10	Fibroblast growth factor basic levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06056004	chr5:44809616	MRPS30	0.49	6.42	0.33	4.86e-10	Thyroid stimulating hormone;
CRC	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs6557786	0.636	rs2445940	chr8:24787201	C/G	cg20585869	chr8:24772333	NEFM	0.37	5.8	0.3	1.58e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.48	-0.34	3.27e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6586163	0.872	rs7069841	chr10:90741955	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.08	-0.36	8.67e-12	Chronic lymphocytic leukemia;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-8.28	-0.42	3.17e-15	Lymphocyte counts;
CRC	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg11176159	chr1:28213800	NA	0.3	5.8	0.3	1.56e-8	Corneal astigmatism;
CRC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.72	11.1	0.52	1.56e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2692947	0.794	rs2692949	chr2:96673525	G/A	cg23100626	chr2:96804247	ASTL	0.25	6.73	0.35	7.51e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg15168958	chr13:99100528	FARP1	0.38	6.2	0.32	1.67e-9	Educational attainment (years of education);
CRC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14893161	chr1:205819251	PM20D1	0.41	6.1	0.32	2.92e-9	Prostate cancer;
CRC	trans	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg10756647	chr7:56101905	PSPH	0.71	7.57	0.39	3.91e-13	Diabetic kidney disease;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.35	-5.65	-0.3	3.41e-8	Glycated hemoglobin levels;
CRC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.62	6.66	0.34	1.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg04586622	chr2:25135609	ADCY3	-0.54	-10.01	-0.48	9.31e-21	Body mass index;
CRC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg01420254	chr6:26195488	NA	0.79	8.84	0.44	6.05e-17	Gout;Renal underexcretion gout;
CRC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.66	-11.52	-0.54	4.87e-26	Refractive error;
CRC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.43	-8.26	-0.41	3.48e-15	Systolic blood pressure;
CRC	cis	rs6534441	0.727	rs78433352	chr4:125458401	A/G	cg21609808	chr4:125404261	NA	0.41	5.76	0.3	1.95e-8	Major depressive disorder;
CRC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.84	13.09	0.59	8.21e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.52	9.29	0.46	2.23e-18	Common traits (Other);
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12172441	chr6:28176163	NA	0.51	6.99	0.36	1.58e-11	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.47	-7.08	-0.36	8.99e-12	Response to antineoplastic agents;
CRC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg23815491	chr16:72088622	HP	0.47	6.95	0.36	1.94e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.66	-10.25	-0.49	1.43e-21	Platelet count;
CRC	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.53	6.52	0.34	2.7e-10	Neuroticism;
CRC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.7	7.91	0.4	3.83e-14	Major depressive disorder;
CRC	cis	rs4664293	0.647	rs10202352	chr2:160427608	G/A	cg08347373	chr2:160653686	CD302	-0.38	-6.41	-0.33	4.95e-10	Monocyte percentage of white cells;
CRC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-6.98	-0.36	1.68e-11	Height;
CRC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.52	7.21	0.37	3.82e-12	Height;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Depression;
CRC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-15.11	-0.64	1.52e-39	Prostate cancer;
CRC	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg09597638	chr17:3907349	NA	0.71	13.19	0.59	3.41e-32	Type 2 diabetes;
CRC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg16892393	chr17:41919603	NA	0.4	5.92	0.31	7.88e-9	Triglycerides;
CRC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.59	-10.59	-0.5	9.39e-23	Intelligence (multi-trait analysis);
CRC	cis	rs11031096	0.542	rs11030404	chr11:3980638	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-6.85	-0.35	3.61e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.34	5.83	0.31	1.31e-8	Lung cancer;
CRC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.7e-8	Lung cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14383135	chr2:101436923	NPAS2	-0.4	-6.17	-0.32	2.03e-9	Myopia (pathological);
CRC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg25193494	chr16:90016004	DEF8	0.48	7.37	0.38	1.38e-12	Squamous cell carcinoma;
CRC	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.66	-0.47	1.32e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg23298862	chr7:158159286	PTPRN2	0.38	5.98	0.31	5.8e-9	Calcium levels;
CRC	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg23127183	chr11:57508653	C11orf31	0.53	7.47	0.38	7.36e-13	Schizophrenia;
CRC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg05941027	chr17:61774174	LIMD2	0.37	6.71	0.35	8.59e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Parkinson's disease;
CRC	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg13385794	chr1:248469461	NA	0.39	6.68	0.35	1.01e-10	Common traits (Other);
CRC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg10645314	chr2:3704589	ALLC	-0.54	-6.32	-0.33	8.33e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg14078730	chr11:63896557	MACROD1	-0.35	-5.63	-0.3	3.83e-8	Platelet count;
CRC	cis	rs10242455	0.571	rs45532337	chr7:99310319	A/G	cg18809830	chr7:99032528	PTCD1	-0.87	-6.82	-0.35	4.39e-11	Blood metabolite levels;
CRC	trans	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg25985355	chr7:65971099	NA	-0.52	-5.93	-0.31	7.51e-9	Gout;
CRC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.42	6.19	0.32	1.81e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03038816	chr19:49149549	SEC1;CA11	0.51	6.51	0.34	2.84e-10	Thyroid stimulating hormone;
CRC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg21770322	chr7:97807741	LMTK2	0.58	9.64	0.47	1.56e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.52	6.94	0.36	2.14e-11	Height;
CRC	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs11212617	0.967	rs2356802	chr11:108282169	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.51	0.34	2.74e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9292777	0.897	rs6883964	chr5:40411910	A/G	cg09067459	chr5:40385259	NA	0.51	8.86	0.44	5.15e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.46	-6.72	-0.35	8.16e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg19913688	chr11:428466	ANO9	-0.74	-7.16	-0.37	5.3e-12	Body mass index;
CRC	trans	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg10756647	chr7:56101905	PSPH	0.69	7.49	0.38	6.21e-13	Diabetic kidney disease;
CRC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg19193384	chr17:30244184	NA	-0.53	-6.66	-0.34	1.15e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.66	-9.12	-0.45	7.82e-18	Multiple sclerosis;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.66	0.57	3.43e-30	Alzheimer's disease;
CRC	cis	rs4731207	0.596	rs10255638	chr7:124576255	C/T	cg23710748	chr7:124431027	NA	0.39	6.14	0.32	2.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.1	24.82	0.81	2.18e-77	Testicular germ cell tumor;
CRC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg03013999	chr17:37608204	MED1	-0.47	-7.03	-0.36	1.18e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.43	-6.12	-0.32	2.68e-9	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12830829	chr14:51707081	TMX1	-0.42	-6.04	-0.32	4.21e-9	Myopia (pathological);
CRC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-7.27	-0.37	2.61e-12	Hemoglobin concentration;
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00166722	chr3:10149974	C3orf24	0.65	8.87	0.44	4.92e-17	Alzheimer's disease;
CRC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg19052272	chr2:3704530	ALLC	0.5	7.04	0.36	1.14e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.47	-6.31	-0.33	8.9e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.19	-0.32	1.76e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs3849570	0.555	rs4452351	chr3:82007977	C/T	cg07356753	chr3:81810745	GBE1	-0.5	-6.94	-0.36	2.07e-11	Waist circumference;Body mass index;
CRC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.67	11.72	0.54	9.53e-27	Height;
CRC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24308560	chr3:49941425	MST1R	-0.45	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.55	7.85	0.4	5.74e-14	Alcohol dependence;
CRC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg11707556	chr5:10655725	ANKRD33B	0.37	6.72	0.35	7.94e-11	Coronary artery disease;
CRC	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.64	8.41	0.42	1.26e-15	Uric acid levels;
CRC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg24140574	chr1:16342155	HSPB7	0.42	5.67	0.3	3.09e-8	Dilated cardiomyopathy;
CRC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg24562669	chr7:97807699	LMTK2	0.45	7.52	0.38	5.11e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.64	7.89	0.4	4.4e-14	Response to hepatitis C treatment;
CRC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg12193833	chr17:30244370	NA	0.55	6.88	0.35	2.98e-11	Hip circumference adjusted for BMI;
CRC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg01788221	chr16:89496183	ANKRD11	-0.47	-7.26	-0.37	2.9e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg09473613	chr1:24152604	HMGCL	-0.34	-5.88	-0.31	1.03e-8	Immature fraction of reticulocytes;
CRC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.97e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs11628318	0.563	rs4906234	chr14:103076928	G/C	cg12046867	chr14:103022105	NA	-0.44	-5.82	-0.31	1.38e-8	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16974379	chr10:38146505	ZNF248	0.51	7.28	0.37	2.41e-12	Response to antipsychotic treatment;
CRC	trans	rs1973993	0.662	rs6593607	chr1:96968116	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.81	-0.35	4.61e-11	Weight;
CRC	cis	rs7703744	0.634	rs73237292	chr5:118688520	A/T	cg02283238	chr5:118691126	TNFAIP8	0.45	6.28	0.33	1.08e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.55	0.38	4.28e-13	Motion sickness;
CRC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2737618	0.722	rs2816978	chr1:200078773	A/G	cg21825944	chr1:200113062	NR5A2	-0.48	-6.62	-0.34	1.49e-10	Uric acid levels;
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.52	6.97	0.36	1.79e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs77972916	0.609	rs72790907	chr2:43575195	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.66	-0.3	3.33e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.42	-6.29	-0.33	1.03e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.49	-7.1	-0.36	7.57e-12	Height;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.56	8.11	0.41	1.01e-14	Menopause (age at onset);
CRC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.99	-0.31	5.54e-9	Bladder cancer;
CRC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.81	-13.09	-0.59	8.69e-32	Cognitive function;
CRC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.48	7.34	0.38	1.64e-12	Red blood cell count;
CRC	cis	rs4731207	0.596	rs1531718	chr7:124644777	T/A	cg23710748	chr7:124431027	NA	-0.39	-6.16	-0.32	2.17e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.4	5.73	0.3	2.21e-8	Aortic root size;
CRC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.78	11.69	0.54	1.26e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.5	0.54	5.69e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg20368463	chr18:77673604	PQLC1	-0.58	-6.56	-0.34	2.05e-10	Opioid sensitivity;
CRC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.77	9.08	0.45	1.02e-17	Eosinophilic esophagitis;
CRC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg12193833	chr17:30244370	NA	0.55	6.85	0.35	3.57e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.01	0.31	4.87e-9	Ovarian reserve;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.78	-0.39	9.4e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.41	-0.5	3.95e-22	Total cholesterol levels;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.43	7.15	0.37	5.79e-12	Testicular germ cell tumor;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.39	6.86	0.35	3.35e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.62	8.29	0.42	2.98e-15	Menopause (age at onset);
CRC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg25790453	chr13:113633590	MCF2L	-0.57	-10.02	-0.48	8.77e-21	Systolic blood pressure;
CRC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.51	8.53	0.43	5.36e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg22687807	chr8:143858763	LYNX1	0.51	9.19	0.45	4.69e-18	Urinary tract infection frequency;
CRC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.5	7.74	0.39	1.22e-13	Corneal astigmatism;
CRC	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.97	-19.27	-0.73	6.27e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg20573242	chr4:122745356	CCNA2	0.43	6.31	0.33	8.9e-10	Type 2 diabetes;
CRC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg10437265	chr15:77819839	NA	0.46	8.12	0.41	9.66e-15	Type 2 diabetes;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg22638593	chr5:131593259	PDLIM4	-0.35	-5.87	-0.31	1.08e-8	Breast cancer;
CRC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.54	8.53	0.43	5.26e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.41	6.2	0.32	1.66e-9	Endometrial cancer;
CRC	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	1.0	9.15	0.45	5.97e-18	Blood protein levels;
CRC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.72	0.3	2.41e-8	Educational attainment;
CRC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg07507251	chr3:52567010	NT5DC2	-0.38	-5.84	-0.31	1.24e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6066835	1.000	rs3746819	chr20:47307934	A/G	cg18078177	chr20:47281410	PREX1	0.78	6.04	0.32	4.27e-9	Multiple myeloma;
CRC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg22777020	chr22:31556080	RNF185	0.48	5.88	0.31	9.99e-9	Colorectal cancer;
CRC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg12458913	chr13:53173898	NA	0.76	13.97	0.61	3.98e-35	Lewy body disease;
CRC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24308560	chr3:49941425	MST1R	0.47	7.37	0.38	1.42e-12	Intelligence (multi-trait analysis);
CRC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg25382214	chr1:3105252	PRDM16	0.4	6.53	0.34	2.48e-10	Migraine;
CRC	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.89	0.31	9.77e-9	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.08	19.02	0.72	5.97e-55	Cognitive function;
CRC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.39	6.89	0.35	2.93e-11	Primary biliary cholangitis;
CRC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Urate levels;
CRC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-14.17	-0.62	6.71e-36	Schizophrenia;
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-6.0	-0.31	5.32e-9	Schizophrenia;
CRC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg09127314	chr1:152161683	NA	0.5	6.36	0.33	6.64e-10	Atopic dermatitis;
CRC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.66	-11.08	-0.52	1.82e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg03689076	chr20:33865952	NA	-0.56	-7.52	-0.38	5.2e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.99e-9	Aortic root size;
CRC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.46	-0.34	3.81e-10	Life satisfaction;
CRC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.61	-10.65	-0.51	5.71e-23	Aortic root size;
CRC	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-7.84	-0.4	6.43e-14	Coronary artery disease;
CRC	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg13385794	chr1:248469461	NA	0.38	6.66	0.34	1.14e-10	Common traits (Other);
CRC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.44	0.57	2.26e-29	Hip circumference adjusted for BMI;
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg01191114	chr3:48936118	SLC25A20	-0.67	-6.08	-0.32	3.35e-9	Cognitive function;
CRC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-7.66	-0.39	2.07e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg13722127	chr7:150037890	RARRES2	0.45	7.7	0.39	1.62e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.52	6.94	0.36	2.06e-11	Alzheimer's disease (survival time);
CRC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.74	-9.38	-0.46	1.14e-18	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21097105	chr17:19265900	B9D1	0.42	7.03	0.36	1.21e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg10756647	chr7:56101905	PSPH	0.68	7.3	0.37	2.14e-12	Diabetic kidney disease;
CRC	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.64	7.09	0.36	8.38e-12	Major depressive disorder;
CRC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.74	11.31	0.53	2.74e-25	Intelligence (multi-trait analysis);
CRC	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.33	12.72	0.57	2.04e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.39	-5.9	-0.31	9.14e-9	Crohn's disease;
CRC	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg15903213	chr10:43522190	NA	-0.74	-5.75	-0.3	2.01e-8	Pediatric bone mineral content (radius);
CRC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.62	6.19	0.32	1.8e-9	Plasma clusterin levels;
CRC	trans	rs4714291	0.722	rs9296320	chr6:40118298	C/G	cg02267698	chr19:7991119	CTXN1	0.44	6.09	0.32	3.19e-9	Strep throat;
CRC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-8.13	-0.41	8.78e-15	Height;
CRC	cis	rs11650494	0.710	rs2233666	chr17:47484286	T/C	cg08112188	chr17:47440006	ZNF652	0.91	7.24	0.37	3.19e-12	Prostate cancer;
CRC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.75	-9.49	-0.46	4.75e-19	Type 2 diabetes;
CRC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.58	0.47	2.48e-19	Lung cancer;
CRC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.62	-7.86	-0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.11	-0.37	7.2e-12	Aortic root size;
CRC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.42	-8.28	-0.42	3.18e-15	Vitiligo;
CRC	cis	rs2692947	0.537	rs11685849	chr2:96243804	C/A	cg23100626	chr2:96804247	ASTL	0.23	5.69	0.3	2.84e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9311676	0.656	rs55668308	chr3:58388453	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.43	-6.52	-0.34	2.59e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.79	-13.66	-0.6	5.72e-34	Lewy body disease;
CRC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.44	0.33	4.12e-10	Lung cancer;
CRC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	9.68	0.47	1.19e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.53	7.94	0.4	3.23e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.35	5.7	0.3	2.69e-8	Sitting height ratio;
CRC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.98	21.22	0.76	1.46e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg03609598	chr5:56110824	MAP3K1	0.58	7.81	0.4	7.56e-14	Initial pursuit acceleration;
CRC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.85	-14.55	-0.63	2.21e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-5.73	-0.3	2.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.46	0.65	6.33e-41	Colorectal cancer;
CRC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.51	7.95	0.4	3e-14	Corneal astigmatism;
CRC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg03844506	chr4:4109441	NA	-0.51	-7.57	-0.39	3.88e-13	Blood pressure (smoking interaction);
CRC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.43	0.33	4.6e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	0.73	5.87	0.31	1.04e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03861200	chr5:133340900	VDAC1	0.45	5.99	0.31	5.53e-9	Thyroid stimulating hormone;
CRC	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12315302	chr6:26189340	HIST1H4D	0.75	6.33	0.33	7.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.14e-26	Coffee consumption (cups per day);
CRC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.04	-0.32	4.07e-9	Diabetic kidney disease;
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg06494592	chr3:125709126	NA	-0.55	-6.43	-0.33	4.43e-10	Blood pressure (smoking interaction);
CRC	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.23	6.27	0.33	1.13e-9	Type 2 diabetes;
CRC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg20203395	chr5:56204925	C5orf35	-0.59	-6.9	-0.36	2.63e-11	Initial pursuit acceleration;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg25164649	chr6:28176230	NA	0.58	8.02	0.4	1.86e-14	Parkinson's disease;
CRC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg21922841	chr17:72744131	SLC9A3R1	0.28	5.86	0.31	1.13e-8	Monocyte count;
CRC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg24881330	chr22:46731750	TRMU	0.57	6.81	0.35	4.78e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.6	-8.86	-0.44	4.97e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg06238570	chr21:40685208	BRWD1	0.75	10.49	0.5	2.08e-22	Cognitive function;
CRC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.79	0.35	5.37e-11	Bone mineral density (spine);
CRC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.39	0.38	1.21e-12	Breast cancer;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Parkinson's disease;
CRC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg04166393	chr7:2884313	GNA12	0.38	5.82	0.31	1.4e-8	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16523653	chr20:31350394	DNMT3B	0.43	6.08	0.32	3.29e-9	Anxiety disorder;
CRC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg03013999	chr17:37608204	MED1	-0.47	-7.21	-0.37	3.87e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.39	7.37	0.38	1.4e-12	Subjective well-being;
CRC	trans	rs35391	1.000	rs35391	chr5:33955673	C/T	cg25815124	chr19:18434238	LSM4	0.7	6.24	0.33	1.34e-9	Tanning;
CRC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.68	0.39	1.83e-13	Lung cancer;
CRC	cis	rs7259376	0.875	rs10409520	chr19:22512477	C/T	cg02657401	chr19:22469223	NA	-0.37	-8.08	-0.41	1.23e-14	Menopause (age at onset);
CRC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.1	10.7	0.51	3.99e-23	Diabetic retinopathy;
CRC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.34	-0.56	5.38e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7523050	1.000	rs7523050	chr1:109417679	C/A	cg08274380	chr1:109419600	GPSM2	0.53	5.82	0.31	1.41e-8	Fat distribution (HIV);
CRC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.56	10.25	0.49	1.41e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg03160526	chr17:80928410	B3GNTL1	0.57	7.68	0.39	1.81e-13	Glycated hemoglobin levels;
CRC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.93	-17.24	-0.69	6.74e-48	Height;
CRC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.65	-11.04	-0.52	2.48e-24	White blood cell count (basophil);
CRC	trans	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg23517279	chr6:96025343	MANEA	0.55	6.23	0.33	1.4e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.54	-5.67	-0.3	3.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.7	8.95	0.44	2.64e-17	Vitiligo;
CRC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.42	5.7	0.3	2.74e-8	IgG glycosylation;
CRC	cis	rs9311676	0.632	rs11130646	chr3:58447013	C/G	cg06643156	chr3:58380774	PXK	0.44	6.78	0.35	5.59e-11	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.89	-0.31	9.4e-9	Life satisfaction;
CRC	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-7.62	-0.39	2.66e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-0.58	-8.39	-0.42	1.5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4481887	0.508	rs7349159	chr1:248386242	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.09	0.32	3.21e-9	Common traits (Other);
CRC	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.9e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.71	9.39	0.46	1e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg19812747	chr11:111475976	SIK2	0.53	8.43	0.42	1.1e-15	Primary sclerosing cholangitis;
CRC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	1.03	20.52	0.75	7.72e-61	Headache;
CRC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	13.87	0.61	9.07e-35	Platelet count;
CRC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.69	-13.43	-0.59	4.53e-33	Educational attainment;
CRC	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.53	9.48	0.46	5.15e-19	Blood metabolite ratios;
CRC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg13198984	chr17:80129470	CCDC57	0.43	7.56	0.38	3.92e-13	Life satisfaction;
CRC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6743376	0.556	rs3180235	chr2:113820672	C/T	cg24553058	chr2:113831203	IL1F10	-0.42	-6.99	-0.36	1.57e-11	Inflammatory biomarkers;
CRC	cis	rs4664293	0.867	rs1126842	chr2:160627317	C/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.6	10.66	0.51	5.67e-23	Intelligence (multi-trait analysis);
CRC	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg21153622	chr11:89784906	NA	-0.42	-6.55	-0.34	2.22e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12227505	chr17:78194145	SLC26A11;SGSH	0.44	7.28	0.37	2.46e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.48e-13	Type 2 diabetes;
CRC	cis	rs3026101	0.671	rs2309372	chr17:5298396	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.66	-0.57	3.37e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.55	8.11	0.41	1.05e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.44	6.66	0.34	1.14e-10	Mean platelet volume;
CRC	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg01312482	chr5:178451176	ZNF879	-0.35	-5.91	-0.31	8.6e-9	Pubertal anthropometrics;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11234017	chr17:42767172	CCDC43	-0.54	-6.63	-0.34	1.37e-10	Diisocyanate-induced asthma;
CRC	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg10978503	chr1:24200527	CNR2	0.37	5.87	0.31	1.09e-8	Immature fraction of reticulocytes;
CRC	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg16486109	chr11:613632	IRF7	0.59	10.43	0.5	3.53e-22	Systemic lupus erythematosus;
CRC	cis	rs231513	0.954	rs231498	chr17:41975251	C/G	cg26893861	chr17:41843967	DUSP3	-0.6	-6.19	-0.32	1.76e-9	Cognitive function;
CRC	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.19	27.04	0.83	1.29e-85	Schizophrenia;
CRC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.8	13.41	0.59	5.12e-33	Blood protein levels;
CRC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg07130601	chr7:158766826	NA	0.41	5.84	0.31	1.27e-8	Facial morphology (factor 20);
CRC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.83	14.94	0.64	6.89e-39	Breast cancer;
CRC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.49	7.07	0.36	9.63e-12	Methadone dose in opioid dependence;
CRC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.1	-0.41	1.08e-14	Height;
CRC	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg20936604	chr3:58311152	NA	0.68	6.95	0.36	1.95e-11	Cholesterol, total;
CRC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg05313129	chr8:58192883	C8orf71	-0.5	-5.89	-0.31	9.4e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.4	-0.46	9.71e-19	Subjective well-being;
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.04	-0.32	4.23e-9	Total body bone mineral density;
CRC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	7.69	0.39	1.71e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg12160578	chr15:63334699	TPM1	-0.59	-7.44	-0.38	8.86e-13	Orofacial clefts;
CRC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.37	0.46	1.23e-18	Lymphocyte counts;
CRC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.57	6.47	0.34	3.61e-10	Initial pursuit acceleration;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg00597713	chr6:42947103	PEX6	-0.42	-5.98	-0.31	5.7e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.46	-6.18	-0.32	1.94e-9	Height;
CRC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.54	8.25	0.41	3.96e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7264396	0.887	rs2281849	chr20:34060286	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.18	-0.32	1.88e-9	Total cholesterol levels;
CRC	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.58	9.83	0.48	3.66e-20	Dupuytren's disease;
CRC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.44	-6.1	-0.32	2.92e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg06572093	chr14:69095231	NA	-0.42	-7.02	-0.36	1.27e-11	Lung cancer;
CRC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	10.22	0.49	1.72e-21	Total cholesterol levels;
CRC	cis	rs4664293	0.585	rs1991372	chr2:160516067	G/C	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.76	0.43	1.06e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.4	-0.33	5.49e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg25456477	chr12:86230367	RASSF9	-0.34	-5.87	-0.31	1.09e-8	Major depressive disorder;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg03623178	chr6:28175578	NA	0.56	6.6	0.34	1.63e-10	Breast cancer;
CRC	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.66	-8.82	-0.44	6.63e-17	Hypospadias;
CRC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.79	11.75	0.54	7.54e-27	Gestational age at birth (maternal effect);
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-8.02	-0.4	1.92e-14	Longevity;Endometriosis;
CRC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.67	7.05	0.36	1.06e-11	Axial length;
CRC	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg13057898	chr1:3703894	LRRC47	0.41	6.01	0.31	4.98e-9	Mean corpuscular volume;
CRC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06656553	chr16:89960601	TCF25	-0.7	-5.81	-0.3	1.51e-8	Skin colour saturation;
CRC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.59	0.57	5.99e-30	Body mass index;
CRC	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	5.75	0.3	2.02e-8	Schizophrenia;
CRC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.67	-8.69	-0.43	1.69e-16	Cognitive test performance;
CRC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg14433983	chr11:636460	DRD4	-0.44	-6.25	-0.33	1.26e-9	Systemic lupus erythematosus;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.47	7.07	0.36	9.54e-12	Menarche (age at onset);
CRC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.63	9.02	0.45	1.63e-17	Birth weight;
CRC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg24011408	chr12:48396354	COL2A1	0.46	6.32	0.33	8.67e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.46	9.17	0.45	5.42e-18	Prostate cancer;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.09	0.32	3.1e-9	Depression;
CRC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13051202	chr11:67887978	CHKA	0.4	6.07	0.32	3.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg02741985	chr17:80059408	CCDC57	-0.42	-6.84	-0.35	3.98e-11	Life satisfaction;
CRC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.59	-0.39	3.4e-13	Height;
CRC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg05527609	chr1:210001259	C1orf107	-0.45	-5.85	-0.31	1.19e-8	Monobrow;
CRC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.0	-0.31	5.06e-9	Gout;Renal underexcretion gout;
CRC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.39e-13	Methadone dose in opioid dependence;
CRC	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.52	7.66	0.39	2.11e-13	Menopause (age at onset);
CRC	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg00507830	chr2:103233733	NA	-0.51	-5.66	-0.3	3.26e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.42	0.38	1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.0	-0.31	5.3300000000000004e-09	Subjective well-being;
CRC	cis	rs1124376	1.000	rs61138004	chr3:20145855	C/G	cg05072819	chr3:20081367	KAT2B	0.51	5.85	0.31	1.19e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.7	-0.72	1.09e-53	Height;
CRC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.49	7.52	0.38	5.23e-13	Corneal astigmatism;
CRC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.46	6.82	0.35	4.34e-11	Motion sickness;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13896783	chr2:159313876	CCDC148;PKP4	-0.42	-6.25	-0.33	1.3e-9	Myopia (pathological);
CRC	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.96	0.4	2.72e-14	Breast cancer;
CRC	cis	rs62408225	0.722	rs10944481	chr6:90917314	A/G	cg06866423	chr6:90926672	BACH2	-0.66	-12.37	-0.56	4.01e-29	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.46	7.07	0.36	9.09e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	1.99e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	9.78	0.47	5.39e-20	Platelet count;
CRC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.88	0.31	1.03e-8	Diabetic retinopathy;
CRC	cis	rs12822507	0.783	rs10772586	chr12:12772866	C/A	cg11838227	chr12:12764436	CREBL2	0.41	5.62	0.3	4.09e-8	Systemic lupus erythematosus;
CRC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.59	-0.34	1.71e-10	Total body bone mineral density;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg25164649	chr6:28176230	NA	0.65	8.58	0.43	3.87e-16	Parkinson's disease;
CRC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.64	-8.7	-0.43	1.62e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3736485	0.966	rs12443007	chr15:51892192	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.4	-0.33	5.32e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.37	-6.32	-0.33	8.39e-10	Longevity;Endometriosis;
CRC	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg10862848	chr6:42927986	GNMT	-0.3	-5.64	-0.3	3.75e-8	Blood protein levels;
CRC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg04450456	chr4:17643702	FAM184B	0.43	6.86	0.35	3.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-1.24	-11.41	-0.53	1.23e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.83	-0.31	1.33e-8	Longevity;
CRC	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.58	10.72	0.51	3.27e-23	Blood metabolite ratios;
CRC	trans	rs12517041	1.000	rs71611219	chr5:23280981	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-5.99	-0.31	5.61e-9	Calcium levels;
CRC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg25281562	chr12:121454272	C12orf43	0.39	5.69	0.3	2.83e-8	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-6.52	-0.34	2.6e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.37	6.3	0.33	9.54e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs4276421	0.806	rs6892290	chr5:45427137	A/G	cg04793272	chr11:119020941	ABCG4	-0.38	-6.21	-0.32	1.61e-9	P wave duration;
CRC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.71	12.52	0.57	1.15e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.67	9.32	0.46	1.7e-18	Lung cancer;
CRC	cis	rs2257205	0.667	rs79155614	chr17:56722496	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.77	-0.3	1.85e-8	Pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19858671	chr8:130951373	FAM49B	0.41	6.37	0.33	6.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.56	0.75	5.27e-61	Prudent dietary pattern;
CRC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	5.91	0.31	8.61e-9	Life satisfaction;
CRC	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.59	7.7	0.39	1.58e-13	Body mass index;
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.78	8.94	0.44	2.87e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11817309	chr1:249152443	ZNF692	0.46	6.86	0.35	3.43e-11	Anxiety disorder;
CRC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	6.03	0.32	4.45e-9	Aortic root size;
CRC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.66	-0.39	2.05e-13	Body mass index;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.71	-8.45	-0.42	9.58e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg00531865	chr16:30841666	NA	-0.45	-6.36	-0.33	6.79e-10	Dementia with Lewy bodies;
CRC	trans	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg16006296	chr10:38738647	LOC399744	0.4	6.01	0.31	4.8e-9	Diastolic blood pressure;
CRC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24308560	chr3:49941425	MST1R	0.45	7.07	0.36	9.52e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg26182253	chr13:112236782	NA	0.32	6.34	0.33	7.71e-10	Hepatitis;
CRC	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.36e-10	Alzheimer's disease;
CRC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.46	6.47	0.34	3.53e-10	Huntington's disease progression;
CRC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15066777	chr18:66382427	CCDC102B;TMX3	0.44	6.14	0.32	2.33e-9	Anxiety disorder;
CRC	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-11.02	-0.52	2.99e-24	Coronary artery disease;
CRC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.66	-8.04	-0.41	1.69e-14	Iron status biomarkers;
CRC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.83	12.78	0.58	1.24e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs253959	0.672	rs1133186	chr5:115420415	A/C	cg23108291	chr5:115420582	COMMD10	0.45	6.3	0.33	9.67e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.8	8.99	0.44	1.99e-17	Skin colour saturation;
CRC	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.5	7.11	0.36	7.29e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.78	13.45	0.6	3.76e-33	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4728302	0.838	rs13231095	chr7:133604436	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.67	0.3	3.13e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.06	-0.32	3.78e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg11342046	chr2:242641489	ING5	-0.44	-7.04	-0.36	1.14e-11	Aortic root size;
CRC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.43	-6.63	-0.34	1.35e-10	Monocyte count;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg12500891	chr11:57225987	NA	-0.67	-6.27	-0.33	1.14e-9	Cognitive function;
CRC	cis	rs245880	0.740	rs245898	chr7:29194143	G/A	cg17163760	chr7:29186267	CPVL	-0.39	-6.88	-0.35	3.05e-11	Warfarin maintenance dose;
CRC	cis	rs3812762	0.826	rs2292045	chr11:8806709	G/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-6.85	-0.35	3.66e-11	Hypospadias;
CRC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg07138768	chr7:917805	C7orf20	0.3	5.81	0.31	1.46e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.54	-10.05	-0.48	6.85e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg06581033	chr10:766294	NA	-0.54	-6.32	-0.33	8.41e-10	Uric acid levels;
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.6	-0.3	4.41e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.66	10.87	0.51	9.76e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.69	7.82	0.4	7.23e-14	Major depressive disorder;
CRC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.18	-0.32	1.91e-9	Aortic root size;
CRC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.8	-0.48	4.49e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1322512	0.760	rs2695252	chr6:152926834	C/T	cg03415253	chr6:152958462	SYNE1	-0.41	-6.48	-0.34	3.42e-10	Tonometry;
CRC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	1.25	14.71	0.63	5.39e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.95	-15.0	-0.64	4.17e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.76	-10.11	-0.49	4.31e-21	Coronary artery disease;
CRC	cis	rs7527798	0.592	rs11118278	chr1:207831357	C/G	cg21110645	chr1:207815933	NA	-0.37	-5.85	-0.31	1.19e-8	Erythrocyte sedimentation rate;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03884976	chr16:577621	SOLH;C16orf10	0.39	6.1	0.32	2.98e-9	Obesity-related traits;
CRC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.14	-0.64	1.2e-39	Gut microbiome composition (summer);
CRC	cis	rs8105895	0.935	rs10405673	chr19:22244890	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg16540259	chr10:75572220	NDST2	0.38	5.98	0.31	5.91e-9	Inflammatory bowel disease;
CRC	cis	rs9478638	0.507	rs335368	chr6:155640881	C/T	cg07943832	chr6:155568918	TIAM2	-0.46	-6.22	-0.32	1.48e-9	Electroencephalogram traits;
CRC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.95	12.33	0.56	5.74e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.86	0.44	5.13e-17	Bladder cancer;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.71	-0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.42	6.96	0.36	1.86e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9903692	0.908	rs8066391	chr17:46195296	C/G	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	3.09e-14	Pulse pressure;
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg15790184	chr11:494944	RNH1	0.59	6.37	0.33	6.38e-10	Body mass index;
CRC	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.47	-6.96	-0.36	1.88e-11	Neutrophil percentage of white cells;
CRC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.06	-12.27	-0.56	9.34e-29	Diabetic kidney disease;
CRC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.11	-0.32	2.74e-9	Type 2 diabetes;
CRC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05299703	chr18:43678513	ATP5A1	0.45	6.06	0.32	3.71e-9	Thyroid stimulating hormone;
CRC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.47	-0.46	5.82e-19	Body mass index;
CRC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.45	5.87	0.31	1.05e-8	Large artery stroke;
CRC	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.48	7.46	0.38	7.97e-13	Eye color traits;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg01490821	chr2:170684022	UBR3	0.41	6.01	0.31	4.96e-9	Crohn's disease;
CRC	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	0.82	9.95	0.48	1.43e-20	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg21747405	chr11:67723411	NA	-0.5	-6.24	-0.33	1.34e-9	Blood pressure (smoking interaction);
CRC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg14711859	chr11:8959438	ASCL3	0.4	6.76	0.35	6.23e-11	Hemoglobin concentration;
CRC	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg24289452	chr6:170231220	NA	-0.58	-6.3	-0.33	9.43e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs3757247	0.631	rs2501716	chr6:90892399	C/G	cg06866423	chr6:90926672	BACH2	-0.42	-6.69	-0.35	9.81e-11	Vitiligo;Type 1 diabetes;
CRC	cis	rs9648716	0.938	rs11981790	chr7:140588384	A/C	cg10747023	chr7:140774559	NA	0.45	5.96	0.31	6.33e-9	Type 2 diabetes;
CRC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.56	-7.53	-0.38	4.95e-13	Schizophrenia;
CRC	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	0.88	10.36	0.5	6.12e-22	Type 2 diabetes nephropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18149689	chr3:193721164	NA	0.39	6.39	0.33	5.6e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg20387954	chr3:183756860	HTR3D	0.45	7.86	0.4	5.7e-14	Anterior chamber depth;
CRC	cis	rs427941	0.703	rs1734879	chr7:101740610	C/A	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg24849736	chr1:201084428	NA	0.59	10.5	0.5	1.91e-22	Permanent tooth development;
CRC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.53	8.96	0.44	2.49e-17	Coronary artery disease;
CRC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.88	0.35	2.99e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9549328	0.700	rs34890317	chr13:113617245	G/C	cg20742385	chr13:113633654	MCF2L	0.56	9.52	0.46	3.92e-19	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.44	-6.62	-0.34	1.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.91	-0.31	8.38e-9	Type 2 diabetes;
CRC	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.4	6.06	0.32	3.72e-9	Diastolic blood pressure;
CRC	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg23234261	chr14:55582407	NA	-0.29	-5.72	-0.3	2.41e-8	Protein biomarker;
CRC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.67	0.47	1.21e-19	Heart rate;
CRC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.68	10.6	0.5	8.86e-23	Huntington's disease progression;
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.57	6.86	0.35	3.5e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9925964	0.933	rs2303223	chr16:31075175	G/A	cg02466173	chr16:30829666	NA	0.43	5.8	0.3	1.53e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.69	8.63	0.43	2.69e-16	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.43	6.25	0.33	1.27e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs13315871	0.929	rs35557787	chr3:58234536	T/C	cg20936604	chr3:58311152	NA	-0.67	-6.73	-0.35	7.62e-11	Cholesterol, total;
CRC	cis	rs62408225	0.569	rs2174281	chr6:90987872	T/C	cg06866423	chr6:90926672	BACH2	0.37	6.32	0.33	8.36e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs8099014	0.861	rs6566969	chr18:56118999	A/G	cg12907477	chr18:56117327	MIR122	0.43	5.64	0.3	3.72e-8	Platelet count;
CRC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.24	-0.37	3.13e-12	Major depressive disorder;
CRC	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg16482183	chr6:26056742	HIST1H1C	0.75	9.53	0.47	3.48e-19	Iron status biomarkers;
CRC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	11.14	0.52	1.18e-24	Bone mineral density;
CRC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs501120	0.564	rs1704214	chr10:44682729	A/G	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.58	9.01	0.44	1.72e-17	HDL cholesterol;
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.63	11.51	0.54	5.41e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.44	-9.54	-0.47	3.3e-19	Urinary metabolites;
CRC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg22561889	chr6:118971681	C6orf204	0.47	5.93	0.31	7.61e-9	Diastolic blood pressure;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg06470822	chr6:28175283	NA	0.66	5.61	0.3	4.35e-8	Breast cancer;
CRC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.5	7.19	0.37	4.4e-12	Aortic root size;
CRC	cis	rs7259376	0.837	rs16999542	chr19:22573092	A/C	cg02657401	chr19:22469223	NA	-0.31	-6.81	-0.35	4.64e-11	Menopause (age at onset);
CRC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.69	11.62	0.54	2.27e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19046167	chr17:80928561	B3GNTL1	0.51	7.12	0.37	6.91e-12	Glycated hemoglobin levels;
CRC	cis	rs449789	0.711	rs7765794	chr6:159704925	T/C	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg14593290	chr7:50529359	DDC	0.64	8.51	0.42	6.25e-16	Malaria;
CRC	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.37	-0.42	1.69e-15	Brugada syndrome;
CRC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg25319279	chr11:5960081	NA	-0.37	-5.77	-0.3	1.83e-8	DNA methylation (variation);
CRC	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.88	-0.44	4.48e-17	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.98	21.22	0.76	1.46e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg07828024	chr6:149772892	ZC3H12D	0.47	8.76	0.43	1.05e-16	Dupuytren's disease;
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.26e-26	Prudent dietary pattern;
CRC	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.6	9.67	0.47	1.23e-19	Itch intensity from mosquito bite;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19357178	chr21:45527350	PWP2	0.43	6.42	0.33	4.66e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.59	-10.73	-0.51	3.05e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.86	0.48	2.81e-20	Cognitive test performance;
CRC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.47	-6.97	-0.36	1.75e-11	Motion sickness;
CRC	cis	rs812925	0.537	rs778146	chr2:61606475	A/G	cg10580144	chr2:61372316	C2orf74	-0.33	-7.37	-0.38	1.38e-12	Immature fraction of reticulocytes;
CRC	cis	rs2415984	0.579	rs61993338	chr14:46969142	T/C	cg14871534	chr14:47121158	RPL10L	-0.43	-6.25	-0.33	1.24e-9	Number of children ever born;
CRC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.42	6.82	0.35	4.38e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg10756647	chr7:56101905	PSPH	0.69	7.49	0.38	6.21e-13	Diabetic kidney disease;
CRC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg03013999	chr17:37608204	MED1	0.49	7.54	0.38	4.62e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.06	0.36	9.79e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-10.48	-0.5	2.33e-22	Menarche (age at onset);
CRC	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09915433	chr19:53449742	NA	-0.59	-8.85	-0.44	5.69e-17	Psoriasis;
CRC	cis	rs747650	0.859	rs4567413	chr11:47232184	A/G	cg03339077	chr11:47165057	C11orf49	0.47	6.61	0.34	1.57e-10	Acne (severe);
CRC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.76	10.28	0.49	1.08e-21	Platelet count;
CRC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.73	12.78	0.58	1.17e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.49	8.22	0.41	4.68e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.8	-11.62	-0.54	2.27e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-8.04	-0.41	1.58e-14	Hepatocellular carcinoma;
CRC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg02527881	chr3:46936655	PTH1R	-0.34	-5.95	-0.31	6.84e-9	Colorectal cancer;
CRC	cis	rs447	0.806	rs4732545	chr7:83745971	C/T	cg22846510	chr7:83753280	SEMA3A	-0.41	-5.67	-0.3	3.21e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.74	8.94	0.44	2.83e-17	Body mass index;
CRC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.01	-10.24	-0.49	1.49e-21	Body mass index;
CRC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.01	0.4	2.05e-14	Lung cancer in ever smokers;
CRC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg17810781	chr1:201082982	CACNA1S	0.49	8.22	0.41	4.71e-15	Permanent tooth development;
CRC	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg09344028	chr17:70110421	NA	0.48	7.72	0.39	1.41e-13	Thyroid hormone levels;
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.52	7.31	0.37	2.02e-12	Alzheimer's disease;
CRC	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg14092571	chr14:90743983	NA	0.38	5.72	0.3	2.38e-8	Mortality in heart failure;
CRC	cis	rs7202877	0.611	rs7187263	chr16:75308978	C/A	cg03315344	chr16:75512273	CHST6	0.51	6.01	0.31	5.01e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.78	12.17	0.56	2.2e-28	Menarche (age at onset);
CRC	trans	rs7324845	0.688	rs1980830	chr13:46712587	C/T	cg15277906	chr8:97170364	GDF6	-0.54	-6.15	-0.32	2.19e-9	Non-alcoholic fatty liver disease histology (other);
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.55	-0.38	4.36e-13	Bipolar disorder;
CRC	cis	rs7737355	0.812	rs11242083	chr5:130927526	A/T	cg25547332	chr5:131281432	NA	0.37	5.73	0.3	2.28e-8	Life satisfaction;
CRC	cis	rs4908768	0.501	rs12046643	chr1:8547866	A/C	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.18	0.52	8.51e-25	Prudent dietary pattern;
CRC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg20684491	chr1:25596433	NA	0.41	7.15	0.37	5.82e-12	Erythrocyte sedimentation rate;
CRC	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.39	5.78	0.3	1.71e-8	Essential tremor;
CRC	cis	rs11690462	0.926	rs11689086	chr2:26549127	C/T	cg22920501	chr2:26401640	FAM59B	0.4	5.71	0.3	2.57e-8	Coronary artery disease;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.31	0.33	9.16e-10	Depression;
CRC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.8	-10.81	-0.51	1.69e-23	Initial pursuit acceleration;
CRC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.8	0.63	2.35e-38	Chronic sinus infection;
CRC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.96	0.4	2.82e-14	Menopause (age at onset);
CRC	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.75	-12.09	-0.55	4.23e-28	Plateletcrit;Platelet count;
CRC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.69	-10.56	-0.5	1.23e-22	Breast cancer;
CRC	cis	rs7781557	0.646	rs12113759	chr7:102440914	C/T	cg18108683	chr7:102477205	FBXL13	-0.51	-6.61	-0.34	1.53e-10	Colorectal adenoma (advanced);
CRC	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.75	-10.76	-0.51	2.39e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22133161	chr19:49891603	CCDC155	0.52	6.65	0.34	1.22e-10	Multiple sclerosis;
CRC	cis	rs7766336	0.533	rs11754600	chr6:105388718	C/T	cg02098413	chr6:105308735	HACE1	0.31	5.61	0.3	4.24e-8	Menarche (age at onset);
CRC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.31	0.33	8.83e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.36	-0.42	1.77e-15	Monocyte percentage of white cells;
CRC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.47	7.38	0.38	1.32e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.57	-9.48	-0.46	5.15e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.45	-5.61	-0.3	4.33e-8	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs2228213	0.585	rs9296258	chr6:12084445	C/G	cg07575407	chr15:66541975	MEGF11	0.38	6.09	0.32	3.15e-9	Body mass index;
CRC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.93	-0.31	7.58e-9	Depression;
CRC	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg25809561	chr17:30822961	MYO1D	0.51	9.05	0.45	1.27e-17	Schizophrenia;
CRC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg12365402	chr11:9010492	NRIP3	-0.51	-8.99	-0.44	2e-17	Hemoglobin concentration;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg27615366	chr5:131592974	PDLIM4	0.32	5.7	0.3	2.69e-8	Breast cancer;
CRC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.61	8.68	0.43	1.9e-16	Tuberculosis;
CRC	cis	rs703970	0.521	rs1574190	chr10:80992381	A/G	cg20744163	chr10:80999841	ZMIZ1	0.33	5.63	0.3	3.79e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg26769984	chr7:1090371	C7orf50	0.5	7.1	0.36	7.82e-12	Bronchopulmonary dysplasia;
CRC	cis	rs911119	0.913	rs1158167	chr20:23578189	G/A	cg16589663	chr20:23618590	CST3	-0.43	-6.16	-0.32	2.07e-9	Chronic kidney disease;
CRC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.71	0.39	1.54e-13	Colorectal cancer;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	5.8	0.3	1.55e-8	Electroencephalogram traits;
CRC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.42	6.83	0.35	4.15e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.51	7.64	0.39	2.46e-13	Monocyte percentage of white cells;
CRC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.89	-0.31	9.48e-9	Alcohol dependence;
CRC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.68	-11.76	-0.54	6.97e-27	Lewy body disease;
CRC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.49	7.32	0.37	1.94e-12	Obesity-related traits;
CRC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.98	-0.31	5.86e-9	Acne (severe);
CRC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.59	6.96	0.36	1.81e-11	Type 2 diabetes nephropathy;
CRC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.39	-6.17	-0.32	1.98e-9	Hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg03774468	chr3:140950104	ACPL2	-0.66	-6.1	-0.32	3.01e-9	Cognitive function;
CRC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs12760731	0.582	rs4607830	chr1:178535152	A/G	cg00404053	chr1:178313656	RASAL2	0.57	6.69	0.35	9.74e-11	Obesity-related traits;
CRC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg20243544	chr17:37824526	PNMT	0.56	8.61	0.43	2.97e-16	Asthma;
CRC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.55	7.3	0.37	2.12e-12	Obesity-related traits;
CRC	cis	rs2249694	0.520	rs7077457	chr10:135324370	G/T	cg20169779	chr10:135381914	SYCE1	-0.49	-6.92	-0.36	2.43e-11	Obesity-related traits;
CRC	cis	rs2257205	0.667	rs8075108	chr17:56657248	G/A	cg25885038	chr17:56607967	SEPT4	-0.56	-6.15	-0.32	2.19e-9	Pancreatic cancer;
CRC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	0.81	7.38	0.38	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-5.73	-0.3	2.31e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	0.66	5.63	0.3	3.96e-8	Parkinson's disease;
CRC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg23609528	chr2:113191194	RGPD5;RGPD8	0.66	5.67	0.3	3.18e-8	Yeast infection;
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.7	-0.35	9.17e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-8.56	-0.43	4.48e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	10.34	0.5	7.21e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs720844	1.000	rs720844	chr2:149350128	G/A	cg09247360	chr2:149335327	NA	-0.63	-7.74	-0.39	1.21e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.61	-7.61	-0.39	2.89e-13	Ulcerative colitis;
CRC	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.58	8.47	0.42	8.12e-16	Corneal astigmatism;
CRC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.59	10.54	0.5	1.44e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05370860	chr19:10514434	MIR1181;CDC37	0.42	6.23	0.32	1.46e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19537317	chr19:36337105	NPHS1	0.4	6.29	0.33	9.89e-10	Response to antipsychotic treatment;
CRC	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.42	6.7	0.35	8.85e-11	Sitting height ratio;
CRC	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg00334542	chr7:100209784	MOSPD3	-0.7	-7.99	-0.4	2.24e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.54	-0.34	2.29e-10	Acne (severe);
CRC	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.71	-9.44	-0.46	6.94e-19	Blood protein levels;
CRC	cis	rs1656402	1.000	rs2077975	chr2:233425877	C/A	cg03852847	chr2:233439513	NA	0.45	7.66	0.39	2.12e-13	Non-small cell lung cancer (survival);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16261398	chr11:1410750	BRSK2	0.36	6.26	0.33	1.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.77	0.35	6.02e-11	Lymphocyte counts;
CRC	cis	rs77633900	0.772	rs75253262	chr15:76657124	G/A	cg21673338	chr15:77095150	SCAPER	-0.74	-6.88	-0.35	3e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.53	5.78	0.3	1.72e-8	Vitiligo;
CRC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg13385794	chr1:248469461	NA	0.35	6.39	0.33	5.79e-10	Common traits (Other);
CRC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.57	-8.81	-0.44	7.32e-17	Sudden cardiac arrest;
CRC	cis	rs8141797	0.892	rs176158	chr22:24513337	T/A	cg20894457	chr22:24584366	SUSD2	0.61	8.07	0.41	1.3e-14	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg20203395	chr5:56204925	C5orf35	-0.59	-7.99	-0.4	2.32e-14	Initial pursuit acceleration;
CRC	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.42	0.71	1.48e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.9	16.41	0.67	1.28e-44	Prostate cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09755102	chr1:33283495	S100PBP;YARS	-0.55	-6.64	-0.34	1.27e-10	Diisocyanate-induced asthma;
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.43	0.53	1.09e-25	Alzheimer's disease;
CRC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.03	9.79	0.47	4.96e-20	Diabetic retinopathy;
CRC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.5	6.22	0.32	1.51e-9	Recombination rate (females);
CRC	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.7	11.79	0.54	5.48e-27	Eosinophil percentage of white cells;
CRC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.46	-7.6	-0.39	3.02e-13	Type 2 diabetes;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.39	-0.42	1.48e-15	Longevity;Endometriosis;
CRC	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	cg04338863	chr8:33670619	NA	0.44	7.01	0.36	1.36e-11	Body mass index;
CRC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.84	13.47	0.6	3.09e-33	Cognitive function;
CRC	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.54	9.12	0.45	7.66e-18	Dupuytren's disease;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08219700	chr8:58056026	NA	0.52	6.09	0.32	3.18e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs73162807	0.655	rs73160912	chr3:146421626	A/G	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07685180	chr8:600429	NA	-0.81	-7.53	-0.38	4.99e-13	IgG glycosylation;
CRC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	8.02	0.4	1.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22856972	chr6:134275178	TBPL1	0.43	6.02	0.31	4.55e-9	Thyroid stimulating hormone;
CRC	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.83	0.35	4.14e-11	Lymphocyte counts;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg15534755	chr11:117069859	TAGLN	0.3	5.88	0.31	1.01e-8	Blood protein levels;
CRC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.14	0.45	6.75e-18	Bladder cancer;
CRC	cis	rs4908768	0.501	rs35865480	chr1:8603777	C/T	cg20416874	chr1:8611966	RERE	-0.46	-6.69	-0.35	9.65e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.37	6.83	0.35	4.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.82	-15.79	-0.66	3.32e-42	Hip circumference;
CRC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.67	-9.87	-0.48	2.79e-20	Multiple myeloma;
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg03160526	chr17:80928410	B3GNTL1	-0.57	-7.88	-0.4	4.74e-14	Glycated hemoglobin levels;
CRC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg20487152	chr13:99095054	FARP1	-0.45	-6.57	-0.34	1.97e-10	Longevity;
CRC	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg10724054	chr17:3904396	NA	0.47	7.59	0.39	3.36e-13	Type 2 diabetes;
CRC	cis	rs4400599	0.618	rs4393149	chr1:154195753	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.71	-0.3	2.49e-8	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19036007	chr3:38496311	LOC100128640;ACVR2B	0.45	6.47	0.34	3.55e-10	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	7.37	0.38	1.42e-12	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09938328	chr1:39325620	RRAGC	0.34	6.75	0.35	6.63e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg25834613	chr7:1915315	MAD1L1	0.4	6.25	0.33	1.28e-9	Bipolar disorder;
CRC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.28	0.46	2.4e-18	Blood protein levels;
CRC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.09e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.46	-7.23	-0.37	3.33e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg23071808	chr14:103021642	NA	-0.68	-8.98	-0.44	2.12e-17	Platelet count;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg20933634	chr6:27740509	NA	0.57	8.08	0.41	1.24e-14	Parkinson's disease;
CRC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.39	0.38	1.19e-12	Mean platelet volume;
CRC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.63	-8.98	-0.44	2.09e-17	Platelet count;
CRC	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.44	-0.33	4.18e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.84	19.12	0.73	2.59e-55	Breast cancer;
CRC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.04	24.15	0.8	7.29e-75	Myeloid white cell count;
CRC	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.08	-15.68	-0.65	8.88e-42	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg14844989	chr11:31128820	NA	-0.34	-6.14	-0.32	2.42e-9	Red blood cell count;
CRC	cis	rs812925	0.519	rs2922089	chr2:61625129	T/G	cg10580144	chr2:61372316	C2orf74	-0.33	-7.08	-0.36	8.84e-12	Immature fraction of reticulocytes;
CRC	cis	rs6961069	0.777	rs4731643	chr7:80248029	A/G	cg04458919	chr7:80252533	CD36	-0.35	-6.35	-0.33	7.36e-10	Platelet count;
CRC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-9.5	-0.46	4.43e-19	Chronic sinus infection;
CRC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg05585544	chr11:47624801	NA	0.47	8.48	0.42	7.86e-16	Subjective well-being;
CRC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg15448220	chr1:150897856	SETDB1	0.44	6.12	0.32	2.73e-9	Blood protein levels;
CRC	trans	rs3747547	0.792	rs11790106	chr9:38047710	G/A	cg15100947	chr1:6333867	ACOT7	0.76	5.97	0.31	6.2e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.78	12.17	0.56	2.2e-28	Menarche (age at onset);
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg19223190	chr17:80058835	NA	0.38	6.17	0.32	2e-9	Life satisfaction;
CRC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.9	0.4	4.13e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.51	-7.63	-0.39	2.58e-13	Neuroticism;
CRC	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg14092571	chr14:90743983	NA	0.39	5.98	0.31	5.81e-9	Mortality in heart failure;
CRC	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.55	9.59	0.47	2.33e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.51	8.34	0.42	2.12e-15	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs10045504	0.502	rs10512692	chr5:38762993	G/A	cg15396434	chr5:38725168	NA	-0.63	-6.14	-0.32	2.32e-9	Night sleep phenotypes;
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg25164649	chr6:28176230	NA	0.4	5.84	0.31	1.26e-8	Pubertal anthropometrics;
CRC	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.31	-0.33	8.76e-10	Breast cancer;
CRC	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.38	-5.92	-0.31	7.93e-9	Red blood cell count;
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.8	15.29	0.64	2.98e-40	Prudent dietary pattern;
CRC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.28	-0.33	1.07e-9	Alzheimer's disease (late onset);
CRC	cis	rs9914988	0.606	rs968726	chr17:27194634	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.41	7.4	0.38	1.15e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.8	10.6	0.5	8.79e-23	Cerebrospinal P-tau181p levels;
CRC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.54	-0.34	2.41e-10	Blood pressure (smoking interaction);
CRC	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.08	0.36	9.03e-12	Morning vs. evening chronotype;
CRC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg04545296	chr12:48745243	ZNF641	0.36	6.0	0.31	5.27e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.53	6.58	0.34	1.85e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14019695	chr9:139328340	INPP5E	0.42	6.21	0.32	1.61e-9	Monocyte percentage of white cells;
CRC	cis	rs10865541	0.869	rs6711292	chr2:3422170	A/T	cg22182287	chr2:3452347	TTC15	0.38	5.92	0.31	7.94e-9	Obesity-related traits;
CRC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-10.71	-0.51	3.73e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-6.27	-0.33	1.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8141797	0.901	rs176159	chr22:24514352	A/G	cg20894457	chr22:24584366	SUSD2	-0.6	-7.21	-0.37	3.78e-12	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	5.74	0.3	2.21e-8	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.56	-8.22	-0.41	4.69e-15	Vitiligo;
CRC	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	0.8	6.87	0.35	3.15e-11	Pediatric areal bone mineral density (radius);
CRC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg21153622	chr11:89784906	NA	-0.5	-8.29	-0.42	2.93e-15	Height;
CRC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs16975963	0.644	rs73035164	chr19:38146720	G/C	cg15135657	chr19:38346511	NA	-0.46	-6.33	-0.33	7.87e-10	Longevity;
CRC	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.43	-7.04	-0.36	1.09e-11	Refractive error;
CRC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	trans	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.28	-0.37	2.51e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg19913688	chr11:428466	ANO9	-0.69	-7.03	-0.36	1.22e-11	Body mass index;
CRC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.84	-0.55	3.39e-27	Hemoglobin concentration;
CRC	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.03	-12.61	-0.57	5.01e-30	Blood pressure (smoking interaction);
CRC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg16342193	chr10:102329863	NA	-0.35	-5.84	-0.31	1.25e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.65	8.87	0.44	4.59e-17	Alcohol dependence;
CRC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg25876840	chr17:41920477	NA	0.53	7.43	0.38	9.37e-13	Triglycerides;
CRC	trans	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg25214090	chr10:38739885	LOC399744	0.4	6.32	0.33	8.52e-10	Corneal astigmatism;
CRC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg14541582	chr5:601475	NA	-0.37	-7.38	-0.38	1.27e-12	Obesity-related traits;
CRC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg13390004	chr1:15929781	NA	0.5	7.08	0.36	8.59e-12	Systolic blood pressure;
CRC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.2	-0.41	5.44e-15	Monocyte percentage of white cells;
CRC	cis	rs6840360	0.642	rs12647555	chr4:152401098	A/T	cg09659197	chr4:152720779	NA	0.34	6.65	0.34	1.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12745968	0.589	rs912796	chr1:92961410	C/T	cg17283838	chr1:93427260	FAM69A	-0.46	-6.27	-0.33	1.11e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.7	0.39	1.63e-13	Height;
CRC	cis	rs68170813	0.559	rs56933300	chr7:106953278	A/AGGACCTCGGCAGAAGCC	cg02696742	chr7:106810147	HBP1	-0.58	-6.08	-0.32	3.41e-9	Coronary artery disease;
CRC	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg06392426	chr19:10676186	KRI1	0.56	6.44	0.33	4.25e-10	Red cell distribution width;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.13	-0.37	6.36e-12	Breast cancer;
CRC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.14	0.37	6.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.11	-15.12	-0.64	1.43e-39	Vitiligo;
CRC	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg21452805	chr1:244014465	NA	0.51	6.89	0.36	2.87e-11	RR interval (heart rate);
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.49	-9.18	-0.45	5e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.68	10.29	0.49	1.05e-21	Menopause (age at onset);
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg11843238	chr5:131593191	PDLIM4	0.35	6.64	0.34	1.28e-10	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20227886	chr18:48405353	ME2	0.37	6.08	0.32	3.38e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07326768	chr15:86337453	KLHL25	0.51	7.35	0.38	1.55e-12	Response to antipsychotic treatment;
CRC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg15790184	chr11:494944	RNH1	0.62	5.96	0.31	6.67e-9	Body mass index;
CRC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.99	-19.5	-0.73	7.89e-57	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-8.55	-0.43	4.67e-16	Uric acid levels;
CRC	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-1.02	-19.87	-0.74	2.83e-58	Gut microbiome composition (winter);
CRC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-15.85	-0.66	2.02e-42	Body mass index;
CRC	cis	rs9326248	0.813	rs4938350	chr11:117022276	A/G	cg26566898	chr11:117069891	TAGLN	0.39	7.02	0.36	1.24e-11	Blood protein levels;
CRC	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.33	-0.37	1.83e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg06872519	chr11:6947619	ZNF215	0.6	5.9	0.31	9.15e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.64	11.14	0.52	1.17e-24	Brugada syndrome;
CRC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	8.02	0.4	1.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.53	-0.34	2.45e-10	Coronary artery disease;
CRC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg15269541	chr15:43626905	ADAL	-0.51	-5.82	-0.31	1.36e-8	Lung cancer in ever smokers;
CRC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg01721255	chr8:58191610	C8orf71	0.5	6.17	0.32	2.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.39	-5.97	-0.31	6.15e-9	Endometrial cancer;
CRC	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg18764771	chr6:116381957	FRK	0.26	6.14	0.32	2.4e-9	Total cholesterol levels;
CRC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.39	12.45	0.57	2.08e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.61	-0.34	1.59e-10	Bipolar disorder;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11645453	chr3:52864694	ITIH4	0.34	6.21	0.32	1.57e-9	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	10.77	0.51	2.35e-23	Menopause (age at onset);
CRC	cis	rs3760982	1.000	rs4803658	chr19:44290013	T/A	cg12072164	chr19:44306565	LYPD5	0.41	6.47	0.34	3.62e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.12e-18	Blood protein levels;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg05865860	chr7:158649142	WDR60	-0.71	-5.97	-0.31	6.26e-9	Cognitive function;
CRC	cis	rs4731207	0.596	rs7795611	chr7:124578456	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.1	-0.32	2.94e-9	Cutaneous malignant melanoma;
CRC	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg22089800	chr15:90895588	ZNF774	0.48	7.82	0.4	7.27e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16280098	chr14:23790882	PABPN1	0.41	7.0	0.36	1.41e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23161317	chr6:28129485	ZNF389	0.49	6.11	0.32	2.81e-9	Parkinson's disease;
CRC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.01	-0.31	5.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.36	-6.81	-0.35	4.74e-11	Iron status biomarkers;
CRC	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.46	8.1	0.41	1.12e-14	Information processing speed;
CRC	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.78	13.15	0.59	4.86e-32	Height;
CRC	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg08729031	chr10:102416179	NA	-0.42	-7.56	-0.38	3.98e-13	Body mass index;
CRC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.95	-0.48	1.5e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs12898370	0.561	rs11630770	chr15:77469643	A/G	cg10437265	chr15:77819839	NA	-0.56	-6.37	-0.33	6.26e-10	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.39	-0.38	1.2e-12	Body mass index;
CRC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg25304816	chr1:36627734	MAP7D1	0.41	6.39	0.33	5.79e-10	Schizophrenia;
CRC	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.15	-19.39	-0.73	2.19e-56	Ulcerative colitis;
CRC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.63	-9.39	-0.46	1.04e-18	Menarche (age at onset);
CRC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.46	-9.31	-0.46	1.92e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05255807	chr6:88411528	NCRNA00120;AKIRIN2	-0.44	-6.55	-0.34	2.17e-10	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26821823	chr11:75875926	NA	-0.37	-6.48	-0.34	3.42e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg14530993	chr4:882597	GAK	0.82	7.7	0.39	1.64e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.5	7.63	0.39	2.56e-13	Red cell distribution width;
CRC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.6	-9.35	-0.46	1.35e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg08992911	chr2:238395768	MLPH	0.61	6.27	0.33	1.13e-9	Prostate cancer;
CRC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-8.12	-0.41	9.36e-15	Educational attainment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02769794	chr10:79686682	LOC100128292;DLG5	0.41	6.3	0.33	9.81e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.63	7.98	0.4	2.4e-14	Cocaine dependence;
CRC	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.7	-7.9	-0.4	4.3e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.04	-0.32	4.13e-9	Height;
CRC	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.64	10.35	0.5	6.24e-22	Corneal astigmatism;
CRC	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.27	-0.46	2.44e-18	Rheumatoid arthritis;
CRC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-6.17	-0.32	2.06e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6604026	0.656	rs2811591	chr1:93363951	C/A	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12857786	chr4:83934023	LIN54	0.42	6.15	0.32	2.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg20243544	chr17:37824526	PNMT	0.43	6.64	0.34	1.3e-10	Self-reported allergy;
CRC	cis	rs4903604	0.513	rs12880891	chr14:78035233	T/C	cg18872420	chr14:78023429	SPTLC2	0.34	5.92	0.31	7.9e-9	Gut microbiome composition (winter);
CRC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.2	0.45	4.13e-18	Smoking initiation;
CRC	cis	rs79387448	0.745	rs6749440	chr2:103101846	C/T	cg09003973	chr2:102972529	NA	0.68	7.37	0.38	1.36e-12	Gut microbiota (bacterial taxa);
CRC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.44	8.82	0.44	6.83e-17	Renal cell carcinoma;
CRC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.54	-5.87	-0.31	1.04e-8	Schizophrenia;
CRC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg25073967	chr14:105360327	KIAA0284	-0.36	-5.64	-0.3	3.69e-8	IgG glycosylation;
CRC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.56	9.0	0.44	1.79e-17	Type 2 diabetes;
CRC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.82	-14.97	-0.64	5.33e-39	Body mass index;
CRC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.43	6.23	0.32	1.44e-9	Aortic root size;
CRC	trans	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.13	0.37	6.23e-12	Ulcerative colitis;
CRC	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-7.01	-0.36	1.32e-11	Coronary artery disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg22833807	chr22:36925177	EIF3D	-0.43	-6.41	-0.33	4.94e-10	Daytime sleep phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23469188	chr7:108166441	PNPLA8	0.4	6.95	0.36	2e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg18032046	chr6:28092343	ZSCAN16	0.55	6.35	0.33	7.07e-10	Depression;
CRC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg18833306	chr6:118973337	C6orf204	0.44	5.7	0.3	2.66e-8	Renal cell carcinoma;
CRC	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-0.99	-9.52	-0.46	3.9e-19	Post bronchodilator FEV1;
CRC	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.77	-14.7	-0.63	5.9e-38	Itch intensity from mosquito bite;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	8.25	0.41	3.98e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.81	-8.88	-0.44	4.38e-17	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.59	9.35	0.46	1.41e-18	Height;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.69	-8.06	-0.41	1.47e-14	Systolic blood pressure;
CRC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.79	13.4	0.59	5.5e-33	Menopause (age at onset);
CRC	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.36	0.33	6.73e-10	Rheumatoid arthritis;
CRC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.92	-0.52	6.61e-24	Blood trace element (Zn levels);
CRC	trans	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.79e-15	Bone mineral density;
CRC	cis	rs891088	0.622	rs11670932	chr19:7206790	A/G	cg00428638	chr19:7224713	INSR	-0.62	-7.6	-0.39	3.11e-13	Hip circumference adjusted for BMI;Height;
CRC	cis	rs1816752	0.905	rs8002309	chr13:24976355	C/T	cg02811702	chr13:24901961	NA	0.42	5.82	0.31	1.41e-8	Obesity-related traits;
CRC	cis	rs2252790	1.000	rs2501050	chr6:116663206	G/A	cg18764771	chr6:116381957	FRK	-0.22	-5.8	-0.3	1.59e-8	Fast beta electroencephalogram;
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs16846053	0.786	rs62187567	chr2:162363066	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.11	-0.32	2.75e-9	Blood osmolality (transformed sodium);
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg15763984	chr4:1342303	KIAA1530	0.51	9.0	0.44	1.82e-17	Longevity;
CRC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.15	-0.45	6.28e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2882667	0.690	rs700620	chr5:138097936	C/T	cg09476006	chr5:138032270	NA	-0.59	-10.52	-0.5	1.7e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.47	-6.93	-0.36	2.18e-11	Type 2 diabetes;
CRC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.09e-12	Headache;
CRC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	11.63	0.54	2.1e-26	Tonsillectomy;
CRC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.19	0.37	4.44e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg18833306	chr6:118973337	C6orf204	0.44	5.81	0.31	1.48e-8	Diastolic blood pressure;
CRC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg25456477	chr12:86230367	RASSF9	0.34	6.01	0.31	4.96e-9	Major depressive disorder;
CRC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg24578937	chr1:2090814	PRKCZ	-0.45	-7.92	-0.4	3.76e-14	Height;
CRC	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	-0.55	-8.62	-0.43	2.83e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06470822	chr6:28175283	NA	-0.77	-7.39	-0.38	1.19e-12	Depression;
CRC	cis	rs17166499	0.634	rs73070111	chr7:12874767	A/C	cg12945054	chr7:12841881	NA	0.48	5.91	0.31	8.55e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.09	-15.3	-0.64	2.69e-40	Exhaled nitric oxide output;
CRC	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.35	6.49	0.34	3.08e-10	Obesity-related traits;
CRC	cis	rs9549328	0.700	rs3011473	chr13:113618096	A/G	cg08614441	chr13:113633676	MCF2L	0.42	7.31	0.37	1.98e-12	Systolic blood pressure;
CRC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15369054	chr17:80825471	TBCD	-0.35	-5.8	-0.3	1.55e-8	Breast cancer;
CRC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.74	12.89	0.58	4.51e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg10820045	chr2:198174542	NA	-0.57	-11.41	-0.53	1.23e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.92	-11.43	-0.53	1.04e-25	Exhaled nitric oxide output;
CRC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.58	-8.04	-0.41	1.67e-14	DNA methylation (variation);
CRC	cis	rs17362650	0.653	rs35968355	chr2:9551713	G/A	cg12832956	chr2:9616023	IAH1	-0.51	-6.64	-0.34	1.27e-10	Alcohol dependence (age at onset);
CRC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-10.01	-0.48	9.09e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-9.43	-0.46	7.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.37	5.67	0.3	3.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg07404485	chr7:94953653	PON1	-0.47	-6.09	-0.32	3.16e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2562152	0.744	rs216597	chr16:106777	G/C	cg02949481	chr16:131562	MPG	0.53	6.05	0.32	3.86e-9	Glioblastoma;
CRC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.702	rs78734698	chr10:81756449	G/A	cg11900509	chr10:81946545	ANXA11	-0.69	-6.76	-0.35	6.43e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.63	10.07	0.49	5.89e-21	Huntington's disease progression;
CRC	cis	rs9303542	0.527	rs8074125	chr17:46610060	G/T	cg04904318	chr17:46607828	HOXB1	-0.54	-6.26	-0.33	1.18e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.51	-6.77	-0.35	5.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.34	-0.33	7.54e-10	Obesity-related traits;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg06470822	chr6:28175283	NA	-1.01	-13.81	-0.61	1.54e-34	Depression;
CRC	cis	rs9925964	0.900	rs9934438	chr16:31104878	G/A	cg02466173	chr16:30829666	NA	0.41	5.65	0.3	3.43e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg14593290	chr7:50529359	DDC	0.57	7.3	0.37	2.24e-12	Malaria;
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.32	-0.33	8.48e-10	Blood metabolite levels;
CRC	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.67	6.72	0.35	8.07e-11	Lymphocyte counts;
CRC	cis	rs2969070	1.000	rs2969070	chr7:2512545	C/T	cg03277898	chr7:2518824	NA	-0.45	-6.95	-0.36	2.02e-11	Diastolic blood pressure;
CRC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.82	-9.19	-0.45	4.62e-18	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11292385	chr22:29138453	CHEK2;HSCB	0.47	6.11	0.32	2.83e-9	Thyroid stimulating hormone;
CRC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.75	0.39	1.19e-13	Mean platelet volume;
CRC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.66	9.79	0.48	4.93e-20	Menopause (age at onset);
CRC	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg08795948	chr3:128337044	NA	0.35	6.19	0.32	1.75e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.65	11.52	0.54	4.89e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7572644	0.640	rs4666024	chr2:28072979	C/G	cg27432699	chr2:27873401	GPN1	-0.46	-6.39	-0.33	5.58e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.65	9.51	0.46	4.29e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4731207	0.596	rs7806807	chr7:124611300	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.82e-9	Height;
CRC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg27534772	chr1:16042836	PLEKHM2	0.52	9.74	0.47	7.51e-20	Systolic blood pressure;
CRC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg20607287	chr7:12443886	VWDE	-0.56	-6.15	-0.32	2.21e-9	Coronary artery disease;
CRC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg20243544	chr17:37824526	PNMT	0.54	8.71	0.43	1.46e-16	Asthma;
CRC	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	0.83	6.52	0.34	2.6e-10	Fat distribution (HIV);
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.19	-0.32	1.77e-9	Bipolar disorder;
CRC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.47	-8.88	-0.44	4.51e-17	Prostate cancer;
CRC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.5	-6.75	-0.35	6.85e-11	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.7	9.11	0.45	8.49e-18	Dementia with Lewy bodies;
CRC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.98	-0.36	1.62e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.74	-13.23	-0.59	2.59e-32	Asthma;
CRC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg08075719	chr14:103021372	NA	0.64	7.38	0.38	1.31e-12	Platelet count;
CRC	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	0.89	7.75	0.39	1.18e-13	Fat distribution (HIV);
CRC	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	cg04338863	chr8:33670619	NA	0.39	6.84	0.35	3.92e-11	Body mass index;
CRC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.75	13.95	0.61	4.46e-35	Cancer;
CRC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.62	0.43	2.87e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1403694	1.000	rs2304451	chr3:186437661	G/C	cg04611788	chr3:186434169	KNG1	-0.45	-6.97	-0.36	1.69e-11	Blood protein levels;
CRC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04239562	chr7:158767014	NA	0.36	5.61	0.3	4.19e-8	Facial morphology (factor 20);
CRC	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21659725	chr3:3221576	CRBN	-0.58	-7.88	-0.4	4.87e-14	Educational attainment;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.67	9.77	0.47	6.02e-20	Alzheimer's disease;
CRC	cis	rs28655083	0.529	rs285019	chr16:77099450	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.49	6.91	0.36	2.51e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs800160	0.777	rs10765944	chr11:2348194	A/G	cg09785033	chr11:2336066	TSPAN32	-0.55	-6.32	-0.33	8.6e-10	Bacteremia;
CRC	cis	rs9287719	0.614	rs12329184	chr2:10722764	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.46	6.99	0.36	1.51e-11	Monocyte count;
CRC	cis	rs427941	0.703	rs201451	chr7:101739550	G/A	cg06246474	chr7:101738831	CUX1	0.46	7.23	0.37	3.35e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.22	0.41	4.72e-15	Diabetic kidney disease;
CRC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs12913538	0.715	rs955529	chr15:62881864	A/T	cg09983546	chr15:62884068	NA	-0.47	-6.95	-0.36	1.92e-11	Sleep depth;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg15511327	chr8:143859410	LYNX1	-0.42	-6.85	-0.35	3.68e-11	Urinary tract infection frequency;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08113034	chr14:59655386	DAAM1	0.47	6.0	0.31	5.08e-9	Thyroid stimulating hormone;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09934056	chr19:8400203	KANK3	0.43	6.22	0.32	1.51e-9	Anxiety disorder;
CRC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg14074117	chr16:1909714	C16orf73	0.49	6.52	0.34	2.59e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg23018236	chr17:30244563	NA	-0.67	-7.99	-0.4	2.29e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg15962314	chr1:44399869	ARTN	0.3	5.84	0.31	1.28e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg14458575	chr2:238380390	NA	0.46	8.07	0.41	1.32e-14	Prostate cancer;
CRC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11645453	chr3:52864694	ITIH4	0.49	8.6	0.43	3.23e-16	Bipolar disorder;
CRC	cis	rs9467603	1.000	rs1892250	chr6:25769024	T/C	cg08501292	chr6:25962987	TRIM38	-0.96	-8.66	-0.43	2.18e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7122539	0.768	rs7931485	chr11:66578635	G/A	cg24851651	chr11:66362959	CCS	0.45	7.9	0.4	4.36e-14	HIV-1 susceptibility;
CRC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.23	14.38	0.62	9.77e-37	Diabetic kidney disease;
CRC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.73	8.75	0.43	1.11e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.78e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7113874	0.589	rs7112153	chr11:8461178	T/C	cg02811074	chr11:8615871	STK33	-0.35	-5.89	-0.31	9.34e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.39	7.22	0.37	3.71e-12	Mean platelet volume;Platelet distribution width;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg15879533	chr17:56709523	TEX14	-0.41	-6.62	-0.34	1.44e-10	Aortic root size;
CRC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg21153622	chr11:89784906	NA	-0.43	-7.2	-0.37	4.08e-12	Height;
CRC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.66	0.54	1.6e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.1	-0.32	3.05e-9	Total body bone mineral density;
CRC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg14844989	chr11:31128820	NA	-0.34	-6.0	-0.31	5.16e-9	Red blood cell count;
CRC	cis	rs453193	0.789	rs2630707	chr2:8447203	A/C	cg12167548	chr2:8464763	NA	-0.29	-5.86	-0.31	1.09e-8	Granulocyte percentage of myeloid white cells;
CRC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-16.27	-0.67	4.29e-44	Coronary artery disease;
CRC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.63	-0.68	1.69e-45	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12868349	chr11:71639594	RNF121;LOC100133315	0.49	6.43	0.33	4.4e-10	Thyroid stimulating hormone;
CRC	cis	rs6968419	0.747	rs2030978	chr7:115874560	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.28	-0.33	1.09e-9	Intraocular pressure;
CRC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg11189052	chr15:85197271	WDR73	0.59	8.47	0.42	8.06e-16	Schizophrenia;
CRC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg16797656	chr11:68205561	LRP5	0.37	5.94	0.31	7.34e-9	Total body bone mineral density;
CRC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.02	-0.52	2.92e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.63	-11.73	-0.54	8.94e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.58	7.65	0.39	2.27e-13	IgG glycosylation;
CRC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.64	8.98	0.44	2.11e-17	Lung cancer;
CRC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.57	7.54	0.38	4.69e-13	Menopause (age at onset);
CRC	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg12935359	chr14:103987150	CKB	0.51	7.84	0.4	6.26e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg14593290	chr7:50529359	DDC	0.62	8.04	0.41	1.62e-14	Malaria;
CRC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.54	0.43	5.08e-16	Height;
CRC	cis	rs6504950	0.830	rs12951542	chr17:53041965	T/C	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.45	6.69	0.35	9.84e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18402987	chr7:1209562	NA	0.5	7.56	0.38	4.07e-13	Longevity;Endometriosis;
CRC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.39	-5.78	-0.3	1.69e-8	Aortic root size;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg15511327	chr8:143859410	LYNX1	-0.39	-6.52	-0.34	2.6e-10	Urinary tract infection frequency;
CRC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.66	-9.37	-0.46	1.21e-18	Refractive error;
CRC	cis	rs1552172	0.887	rs12732381	chr1:145630536	T/A	cg11743829	chr1:145714124	CD160	-0.4	-6.06	-0.32	3.69e-9	Breast cancer;
CRC	cis	rs11229555	0.645	rs6591475	chr11:58193551	G/T	cg15696309	chr11:58395628	NA	0.83	10.45	0.5	2.98e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg18016565	chr1:150552671	MCL1	0.43	5.92	0.31	8.32e-9	Melanoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20996918	chr1:155243486	CLK2	0.45	6.06	0.32	3.62e-9	Thyroid stimulating hormone;
CRC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-6.74	-0.35	7.29e-11	Blood metabolite levels;
CRC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.5	8.44	0.42	1e-15	Coronary artery disease;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg17823892	chr15:85525171	PDE8A	0.49	5.99	0.31	5.65e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.44	-6.27	-0.33	1.11e-9	Inflammatory bowel disease;
CRC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.75	-11.89	-0.55	2.27e-27	Dilated cardiomyopathy;
CRC	cis	rs868943	0.582	rs9488861	chr6:116502405	A/G	cg15226275	chr6:116381976	FRK	0.23	5.83	0.31	1.3e-8	Total cholesterol levels;
CRC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.94	-17.69	-0.7	1.09e-49	Height;
CRC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.85	-0.4	5.92e-14	Bipolar disorder;
CRC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg21153622	chr11:89784906	NA	-0.37	-6.01	-0.31	4.83e-9	Height;
CRC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg09597638	chr17:3907349	NA	-0.67	-11.49	-0.53	6.64e-26	Type 2 diabetes;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.59	-0.34	1.75e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.62	9.25	0.45	2.96e-18	Total body bone mineral density;
CRC	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.47	6.83	0.35	4.16e-11	Body mass index;
CRC	cis	rs41005	0.967	rs193928	chr2:8107899	T/C	cg03155496	chr2:8117019	LOC339788	0.41	7.29	0.37	2.4e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.74	0.39	1.22e-13	Lung cancer in ever smokers;
CRC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.4	-5.68	-0.3	3.03e-8	Diastolic blood pressure;
CRC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.79	14.36	0.62	1.22e-36	Anterior chamber depth;
CRC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg11212589	chr17:38028394	ZPBP2	0.4	7.36	0.38	1.45e-12	Self-reported allergy;
CRC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg21153622	chr11:89784906	NA	-0.5	-8.21	-0.41	5.26e-15	Height;
CRC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.4	5.98	0.31	5.84e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.59	-9.41	-0.46	8.55e-19	Breast cancer;
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.45	7.7	0.39	1.65e-13	Childhood ear infection;
CRC	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	3.01e-9	Axial length;
CRC	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg08992911	chr2:238395768	MLPH	0.6	5.8	0.3	1.58e-8	Prostate cancer;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg15845792	chr6:28175446	NA	0.8	11.59	0.54	2.82e-26	Cardiac Troponin-T levels;
CRC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-12.08	-0.55	4.59e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.44	5.6	0.3	4.52e-8	Aortic root size;
CRC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	11.97	0.55	1.17e-27	Platelet count;
CRC	cis	rs929596	0.564	rs2602373	chr2:234561953	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-5.83	-0.31	1.3e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs10982256	0.870	rs998547	chr9:117275012	G/A	cg13636371	chr9:117264095	DFNB31	0.37	7.2	0.37	4.2e-12	Bipolar disorder;
CRC	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.5	7.29	0.37	2.36e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg22689833	chr10:102415991	NA	-0.34	-6.57	-0.34	2.01e-10	Body mass index;
CRC	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg08501292	chr6:25962987	TRIM38	0.58	6.55	0.34	2.18e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-8.9	-0.44	3.82e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.44	0.33	4.33e-10	Diabetic kidney disease;
CRC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.83	-11.3	-0.53	3.14e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6662572	0.737	rs9429091	chr1:46513088	C/T	cg08644498	chr1:46502608	NA	0.46	7.34	0.38	1.65e-12	Blood protein levels;
CRC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.58	-0.34	1.82e-10	Menopause (age at onset);
CRC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.52	0.38	5.39e-13	Calcium levels;
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.7	-0.7	1.01e-49	Height;
CRC	trans	rs16846053	0.681	rs62187563	chr2:162354653	G/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.16	-0.32	2.13e-9	Blood osmolality (transformed sodium);
CRC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.81	-9.73	-0.47	7.64e-20	Breast cancer;
CRC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	12.25	0.56	1.11e-28	Platelet count;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10819733	chr22:24237672	NA	-0.36	-6.08	-0.32	3.35e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1971762	0.527	rs11170590	chr12:53938913	G/A	cg06632207	chr12:54070931	ATP5G2	0.45	7.64	0.39	2.44e-13	Height;
CRC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg24154853	chr7:158122151	PTPRN2	0.66	10.88	0.51	9.33e-24	Calcium levels;
CRC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.91	16.9	0.68	1.4e-46	Cognitive ability;
CRC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg20387954	chr3:183756860	HTR3D	0.35	5.79	0.3	1.63e-8	Anterior chamber depth;
CRC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.64	-17.43	-0.69	1.16e-48	Urate levels in overweight individuals;
CRC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3804749	0.966	rs3792376	chr3:122844951	T/G	cg26084141	chr3:122786895	PDIA5	0.23	6.08	0.32	3.42e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.61	9.5	0.46	4.35e-19	Lewy body disease;
CRC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg08200582	chr11:442649	ANO9	-0.67	-6.38	-0.33	5.84e-10	Body mass index;
CRC	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg14458575	chr2:238380390	NA	0.44	6.11	0.32	2.77e-9	Prostate cancer;
CRC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.78	-0.39	9.43e-14	Blood metabolite levels;
CRC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18099408	chr3:52552593	STAB1	0.43	7.03	0.36	1.19e-11	Bipolar disorder;
CRC	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.63	-0.34	1.39e-10	Neuroticism;
CRC	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12560992	chr17:57184187	TRIM37	0.56	7.73	0.39	1.29e-13	Testicular germ cell tumor;
CRC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.79	-9.88	-0.48	2.44e-20	Platelet count;
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.62	11.6	0.54	2.53e-26	Immature fraction of reticulocytes;
CRC	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.91	-0.31	8.54e-9	Schizophrenia;
CRC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg21285383	chr16:89894308	SPIRE2	0.34	5.69	0.3	2.82e-8	Vitiligo;
CRC	cis	rs9303542	0.571	rs2202895	chr17:46584657	T/C	cg04904318	chr17:46607828	HOXB1	0.45	5.95	0.31	6.86e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.58	9.24	0.45	3.17e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.52	-7.78	-0.39	9.57e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg10729496	chr3:10149963	C3orf24	0.5	6.74	0.35	7.23e-11	Alzheimer's disease;
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.9	-21.04	-0.76	7.13e-63	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-18.54	-0.71	4.92e-53	Primary sclerosing cholangitis;
CRC	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.12	-0.32	2.72e-9	Neuroticism;
CRC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg16260113	chr12:107380972	MTERFD3	-0.4	-5.67	-0.3	3.11e-8	Total body bone mineral density;
CRC	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg20936604	chr3:58311152	NA	-0.74	-7.75	-0.39	1.17e-13	Cholesterol, total;
CRC	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	7.9	0.4	4.11e-14	Hemoglobin concentration;
CRC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-10.54	-0.5	1.41e-22	Platelet distribution width;
CRC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.51	-6.54	-0.34	2.39e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg24300038	chr13:113819356	PROZ	0.49	6.45	0.34	4e-10	Platelet distribution width;
CRC	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.42	-5.69	-0.3	2.78e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.4	-5.73	-0.3	2.32e-8	Strep throat;
CRC	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.14	8.9	0.44	3.71e-17	Mitochondrial DNA levels;
CRC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.53	-11.09	-0.52	1.75e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	11.91	0.55	1.9e-27	Platelet count;
CRC	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg03929089	chr4:120376271	NA	0.63	6.01	0.31	4.92e-9	Axial length;
CRC	cis	rs7487075	1.000	rs12814341	chr12:46823272	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	6.02	0.32	4.63e-9	Itch intensity from mosquito bite;
CRC	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.79	-13.59	-0.6	1.08e-33	Lewy body disease;
CRC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.65	10.65	0.51	5.77e-23	Lung cancer;
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.55	7.24	0.37	3.11e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg16898833	chr6:26189333	HIST1H4D	0.74	6.35	0.33	7.32e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg09855544	chr8:135498122	ZFAT	-0.43	-5.61	-0.3	4.2e-8	Hypertension (SNP x SNP interaction);
CRC	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.45	5.9	0.31	9.05e-9	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13556659	chr11:94276960	FUT4	-0.43	-6.37	-0.33	6.33e-10	Myopia (pathological);
CRC	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.72	-0.47	8.4e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg13507429	chr1:18807550	KLHDC7A	-0.36	-6.48	-0.34	3.28e-10	Breast cancer;
CRC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.85	-0.44	5.38e-17	Hemoglobin concentration;
CRC	cis	rs929596	0.531	rs2741021	chr2:234511883	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	5.92	0.31	8.09e-9	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs863345	0.565	rs6679056	chr1:158450314	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-6.17	-0.32	2.03e-9	Pneumococcal bacteremia;
CRC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.75	0.35	6.69e-11	Tonsillectomy;
CRC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24308560	chr3:49941425	MST1R	0.44	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs834811	0.563	rs2033093	chr7:135874334	T/C	cg01726295	chr7:135938950	NA	0.33	5.63	0.3	3.85e-8	Post-traumatic stress disorder;
CRC	cis	rs10946940	0.632	rs9366698	chr6:27672035	C/G	cg03623178	chr6:28175578	NA	0.55	6.74	0.35	6.97e-11	Systemic lupus erythematosus;
CRC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.53	-9.34	-0.46	1.44e-18	Dupuytren's disease;
CRC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.11	-0.36	7.38e-12	Putamen volume;
CRC	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.46	7.91	0.4	3.93e-14	HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13587582	chr20:61847585	YTHDF1	0.46	6.62	0.34	1.47e-10	Anxiety disorder;
CRC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3764400	0.567	rs8071199	chr17:46195335	A/T	cg10706073	chr17:46328419	SKAP1	0.57	6.12	0.32	2.59e-9	Body mass index;
CRC	cis	rs728616	0.510	rs34817075	chr10:81749740	A/G	cg05935833	chr10:81318306	SFTPA2	-0.53	-6.97	-0.36	1.72e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.41	0.53	1.23e-25	Height;
CRC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.15	-0.41	7.72e-15	Monocyte percentage of white cells;
CRC	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.83	-0.4	6.72e-14	Caffeine consumption;
CRC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.73	-0.43	1.3e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.27e-13	Hip circumference adjusted for BMI;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg02657892	chr1:62190594	TM2D1	0.44	6.06	0.32	3.66e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9287719	0.625	rs12473787	chr2:10717194	G/C	cg00105475	chr2:10696890	NA	0.45	7.08	0.36	8.74e-12	Prostate cancer;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg27555944	chr3:49056208	DALRD3	0.6	6.66	0.34	1.15e-10	Body mass index;
CRC	cis	rs4290604	0.667	rs62183331	chr2:237952212	T/C	cg23555395	chr2:238036564	NA	0.65	6.42	0.33	4.89e-10	Asthma;
CRC	trans	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg26043149	chr18:55253948	FECH	0.54	8.44	0.42	9.9e-16	Bone mineral density;
CRC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.64	7.95	0.4	2.94e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19741408	chr1:90460434	ZNF326;LOC492303	0.48	6.91	0.36	2.58e-11	Response to antipsychotic treatment;
CRC	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-1.25	-10.26	-0.49	1.27e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.68	-0.3	2.93e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.69	9.03	0.45	1.51e-17	Uric acid levels;
CRC	cis	rs8105895	0.733	rs10423457	chr19:22279267	G/C	cg02657401	chr19:22469223	NA	-0.35	-5.67	-0.3	3.06e-8	Body mass index (change over time);
CRC	cis	rs4731207	0.596	rs1481331	chr7:124577325	C/G	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.99	-0.4	2.32e-14	HDL cholesterol;
CRC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.71	7.23	0.37	3.48e-12	Initial pursuit acceleration;
CRC	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.27	5.82	0.31	1.38e-8	Educational attainment (years of education);
CRC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg20959480	chr12:125599568	AACS	0.39	5.8	0.3	1.59e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.35	6.35	0.33	6.99e-10	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.69	-10.65	-0.51	5.92e-23	Type 2 diabetes;
CRC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.49	7.53	0.38	5.03e-13	Corneal astigmatism;
CRC	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.65	0.34	1.25e-10	Lymphocyte counts;
CRC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.45	6.61	0.34	1.53e-10	Menopause (age at onset);
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.38	6.54	0.34	2.32e-10	Lung cancer;
CRC	trans	rs8058130	0.566	rs9926510	chr16:64327067	A/C	cg10373645	chr2:74007265	DUSP11	0.38	6.01	0.31	5e-9	Schizophrenia;
CRC	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.38	-5.63	-0.3	3.77e-8	IFN-related cytopenia;
CRC	trans	rs2892463	0.504	rs4769777	chr13:30415200	A/G	cg13931752	chr15:40660718	DISP2	-0.4	-6.19	-0.32	1.81e-9	Non-word repetition;
CRC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg20573242	chr4:122745356	CCNA2	0.43	6.47	0.34	3.46e-10	Type 2 diabetes;
CRC	cis	rs9463078	0.715	rs7768521	chr6:45060938	C/G	cg25276700	chr6:44698697	NA	-0.25	-6.05	-0.32	4e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg03315344	chr16:75512273	CHST6	0.49	5.7	0.3	2.71e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.56	-0.34	2.12e-10	Fibrinogen levels;
CRC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.47	7.02	0.36	1.26e-11	Menopause (age at onset);
CRC	cis	rs4757319	0.515	rs7126103	chr11:15337892	T/C	cg03245590	chr11:15329459	NA	0.53	9.37	0.46	1.17e-18	Breast cancer;
CRC	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg12183467	chr14:104352244	NA	-0.47	-6.42	-0.33	4.79e-10	Bipolar disorder;
CRC	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg25547332	chr5:131281432	NA	-0.38	-5.62	-0.3	4.04e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9583531	0.760	rs9521916	chr13:111385509	A/G	cg24331049	chr13:111365604	ING1	-0.49	-5.86	-0.31	1.15e-8	Coronary artery disease;
CRC	cis	rs6546324	0.539	rs4671192	chr2:67841855	A/G	cg15745817	chr2:67799979	NA	-0.56	-9.54	-0.47	3.44e-19	Endometriosis;
CRC	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.6	8.72	0.43	1.44e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9491140	0.539	rs11755888	chr6:124693042	A/G	cg22366943	chr6:124882293	NKAIN2	0.56	8.01	0.4	2.05e-14	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08831002	chr7:20826153	SP8	0.41	6.98	0.36	1.6e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.47	-6.58	-0.34	1.87e-10	Multiple sclerosis;
CRC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg03929089	chr4:120376271	NA	0.68	6.72	0.35	8.24e-11	Intraocular pressure;
CRC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg01262667	chr19:19385393	TM6SF2	0.37	6.2	0.32	1.7e-9	Tonsillectomy;
CRC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg16746620	chr16:89178589	ACSF3	-0.41	-6.3	-0.33	9.75e-10	HDL cholesterol;
CRC	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg08533674	chr1:46993347	NA	-0.63	-8.25	-0.41	3.82e-15	Monobrow;
CRC	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.55	8.34	0.42	2.03e-15	Smoking behavior;
CRC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.6e-39	Lymphocyte percentage of white cells;
CRC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.23	-0.32	1.46e-9	Neuroticism;
CRC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.11	-0.32	2.82e-9	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09019002	chr7:102715232	ARMC10;FBXL13	0.39	5.96	0.31	6.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.51	9.18	0.45	5.07e-18	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.65	-7.51	-0.38	5.48e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.61	10.41	0.5	4e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg15110403	chr19:17392923	ANKLE1	-0.36	-6.01	-0.31	4.81e-9	Systemic lupus erythematosus;
CRC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.57	8.64	0.43	2.56e-16	Height;
CRC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	7.96	0.4	2.84e-14	Height;
CRC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.49	7.53	0.38	5.09e-13	Red blood cell count;
CRC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.92	0.52	6.76e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-5.88	-0.31	1.02e-8	Lung disease severity in cystic fibrosis;
CRC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.83	-0.48	3.65e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg15192750	chr16:69999425	NA	0.55	7.1	0.36	7.76e-12	IgE levels;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23708337	chr7:1209742	NA	0.43	6.47	0.34	3.46e-10	Longevity;Endometriosis;
CRC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.5	8.02	0.4	1.85e-14	Gout;
CRC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg08057103	chr13:110438916	IRS2	-0.38	-5.96	-0.31	6.56e-9	HDL cholesterol;
CRC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg01472538	chr16:58549086	SETD6	1.2	7.61	0.39	2.9e-13	Schizophrenia;
CRC	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.36	-0.42	1.75e-15	Alcohol dependence;
CRC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg01262667	chr19:19385393	TM6SF2	-0.36	-5.9	-0.31	9.11e-9	Tonsillectomy;
CRC	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	1.12	9.65	0.47	1.47e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2842126	0.518	rs1865749	chr10:52013434	A/C	cg13488930	chr10:51784648	NA	0.44	5.94	0.31	7.41e-9	Blood protein levels;
CRC	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg16898833	chr6:26189333	HIST1H4D	0.8	6.7	0.35	8.78e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7312933	0.558	rs11181403	chr12:42682902	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.56	0.43	4.24e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg09695851	chr17:3907499	NA	0.76	14.24	0.62	3.62e-36	Type 2 diabetes;
CRC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.2	11.07	0.52	1.95e-24	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.38	-0.33	5.89e-10	Aortic root size;
CRC	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.41	6.4	0.33	5.44e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.06	-0.32	3.74e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7539624	0.588	rs6669046	chr1:223906309	T/C	cg10100437	chr1:223903862	CAPN2	0.4	5.8	0.3	1.54e-8	Schizophrenia;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.88	0.44	4.45e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	5.84	0.31	1.27e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.8	13.4	0.59	5.54e-33	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.99	0.31	5.47e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2380220	0.808	rs2613548	chr6:95910559	C/T	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg16434002	chr17:42200994	HDAC5	-0.45	-6.12	-0.32	2.66e-9	Total body bone mineral density;
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.37	-0.38	1.37e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23378565	chr7:2036160	MAD1L1	-0.44	-6.34	-0.33	7.61e-10	Neuroticism;
CRC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.87	-14.35	-0.62	1.38e-36	Blood metabolite levels;
CRC	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs6694672	0.681	rs6670056	chr1:196982776	T/C	cg13682187	chr1:196946512	CFHR5	0.52	8.05	0.41	1.56e-14	Asthma;
CRC	trans	rs2303319	0.504	rs41267437	chr2:162627391	G/A	cg27342122	chr8:133787442	PHF20L1	-0.74	-6.0	-0.31	5.3300000000000004e-09	Cognitive function;
CRC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-5.88	-0.31	1.01e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg16077055	chr2:106428750	NCK2	-0.4	-5.77	-0.3	1.87e-8	Addiction;
CRC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.57	8.71	0.43	1.56e-16	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg22079747	chr2:228736145	WDR69	-0.44	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs938554	0.657	rs7679724	chr4:9985376	G/T	cg00071950	chr4:10020882	SLC2A9	0.41	6.13	0.32	2.45e-9	Blood metabolite levels;
CRC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	6.02	0.32	4.54e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.74	13.53	0.6	1.76e-33	Prostate cancer;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg21577049	chr2:228736449	WDR69	-0.44	-5.88	-0.31	9.88e-9	Blood pressure;
CRC	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	0.9	13.68	0.6	5e-34	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.68	0.3	2.9e-8	Depression;
CRC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs524281	0.861	rs7941469	chr11:65900152	A/G	cg16950941	chr11:66035639	RAB1B	0.57	7.45	0.38	8.35e-13	Electroencephalogram traits;
CRC	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.46	7.9	0.4	4.19e-14	Common traits (Other);
CRC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.63	-8.83	-0.44	6.39e-17	DNA methylation (variation);
CRC	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09915433	chr19:53449742	NA	-0.6	-9.1	-0.45	8.63e-18	Psoriasis;
CRC	cis	rs9462027	0.628	rs2744949	chr6:34633862	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.42	-0.33	4.87e-10	Coronary artery disease;
CRC	cis	rs727479	0.502	rs2289106	chr15:51507782	T/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.08	-0.32	3.38e-9	Estradiol levels;
CRC	cis	rs2625529	0.689	rs12898868	chr15:72112918	A/G	cg16672083	chr15:72433130	SENP8	0.43	6.41	0.33	5.11e-10	Red blood cell count;
CRC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.46e-13	Schizophrenia;
CRC	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg12845895	chr18:77676008	PQLC1	0.41	5.94	0.31	7.32e-9	Schizophrenia;
CRC	cis	rs16975963	0.843	rs77895245	chr19:38419780	G/C	cg15135657	chr19:38346511	NA	-0.44	-5.92	-0.31	7.99e-9	Longevity;
CRC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg24011408	chr12:48396354	COL2A1	0.43	6.33	0.33	8.06e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09466831	chr16:47071686	NA	0.42	6.95	0.36	1.93e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg23463467	chr20:60627584	TAF4	0.39	7.44	0.38	8.93e-13	Body mass index;
CRC	cis	rs13082711	0.501	rs428239	chr3:27555566	G/C	cg02860705	chr3:27208620	NA	-0.41	-6.08	-0.32	3.34e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg13385794	chr1:248469461	NA	0.38	6.57	0.34	1.93e-10	Common traits (Other);
CRC	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00338735	chr4:53728038	RASL11B	0.41	6.48	0.34	3.25e-10	Optic nerve measurement (cup area);
CRC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.59	9.47	0.46	5.5e-19	Tonsillectomy;
CRC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.46	6.11	0.32	2.81e-9	Tuberculosis;
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.74	-0.3	2.11e-8	Total body bone mineral density;
CRC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.66e-8	Bladder cancer;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg03623178	chr6:28175578	NA	0.67	9.54	0.47	3.41e-19	Parkinson's disease;
CRC	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	7.19	0.37	4.36e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.58	-9.16	-0.45	5.49e-18	Hyperactive-impulsive symptoms;
CRC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg13072238	chr3:49761600	GMPPB	0.51	5.81	0.31	1.48e-8	Menarche (age at onset);
CRC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.94	13.66	0.6	5.88e-34	Breast cancer;
CRC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.52	8.23	0.41	4.42e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10242455	0.702	rs1045012	chr7:98984354	G/C	cg18809830	chr7:99032528	PTCD1	-1.11	-7.97	-0.4	2.72e-14	Blood metabolite levels;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg06470822	chr6:28175283	NA	0.75	10.09	0.49	5.07e-21	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.19	0.49	2.19e-21	Alzheimer's disease;
CRC	cis	rs2004318	1.000	rs2004318	chr19:55138232	C/T	cg03320607	chr19:54800032	LILRA3	-0.75	-6.0	-0.31	5.26e-9	Blood protein levels;
CRC	cis	rs965469	0.779	rs6037528	chr20:3260978	A/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.78	-0.3	1.75e-8	IFN-related cytopenia;
CRC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.45	-0.5	3e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.43	5.61	0.3	4.3e-8	Cholesterol, total;
CRC	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg23740940	chr11:68924746	NA	0.44	5.77	0.3	1.82e-8	Blond vs. brown hair color;
CRC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg03037974	chr15:76606532	NA	0.58	9.59	0.47	2.34e-19	Blood metabolite levels;
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.37	0.42	1.72e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.67	10.82	0.51	1.55e-23	Lung cancer;
CRC	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg03339077	chr11:47165057	C11orf49	0.43	6.1	0.32	2.96e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	1.03	8.08	0.41	1.28e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg17788362	chr6:86352627	SYNCRIP	0.47	6.55	0.34	2.17e-10	Smooth-surface caries;
CRC	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.46	-0.46	6.05e-19	Capecitabine sensitivity;
CRC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.48	-7.35	-0.38	1.54e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs1490453	0.629	rs6829009	chr4:149247221	G/C	cg26605335	chr17:4689165	VMO1	-0.35	-6.12	-0.32	2.7e-9	Biochemical measures;
CRC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.55	8.02	0.4	1.84e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg25457927	chr22:38595422	NA	-0.3	-5.99	-0.31	5.36e-9	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs7635838	0.859	rs7632040	chr3:11427455	A/G	cg00170343	chr3:11313890	ATG7	0.4	6.15	0.32	2.28e-9	HDL cholesterol;
CRC	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg04586622	chr2:25135609	ADCY3	-0.42	-6.95	-0.36	1.92e-11	Body mass index;
CRC	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.46	6.96	0.36	1.83e-11	Asthma;
CRC	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.51	0.62	3.17e-37	Exhaled nitric oxide output;
CRC	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.77	13.12	0.59	6.42e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.56	0.54	3.61e-26	Monocyte percentage of white cells;
CRC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.12	0.37	6.81e-12	Heart rate;
CRC	cis	rs6604026	0.656	rs2255723	chr1:93368309	A/C	cg22128645	chr1:93425802	FAM69A	-0.37	-5.7	-0.3	2.64e-8	Multiple sclerosis;
CRC	cis	rs6479527	1.000	rs6479527	chr9:96858411	G/A	cg14459158	chr9:96720562	NA	0.43	7.52	0.38	5.12e-13	Esophageal adenocarcinoma;
CRC	cis	rs6429082	1.000	rs6429082	chr1:235600129	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.9	0.31	9.24e-9	Adiposity;
CRC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.56	-9.14	-0.45	6.69e-18	Type 2 diabetes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01593552	chr13:22185680	NA	-0.35	-6.0	-0.31	5.12e-9	Obesity-related traits;
CRC	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.96	-12.47	-0.57	1.73e-29	Exhaled nitric oxide output;
CRC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.16	0.41	7.36e-15	Arsenic metabolism;
CRC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.91	-0.4	3.99e-14	Triglycerides;
CRC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg10802521	chr3:52805072	NEK4	0.44	5.99	0.31	5.39e-9	Schizophrenia;
CRC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.72	0.39	1.37e-13	Lymphocyte percentage of white cells;
CRC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.66	9.31	0.46	1.9e-18	Vitiligo;
CRC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.61	10.29	0.49	1.05e-21	Resting heart rate;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs858239	1.000	rs199357	chr7:23288309	A/G	cg18081818	chr7:23246105	NA	0.34	5.89	0.31	9.74e-9	Cerebrospinal fluid biomarker levels;
CRC	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg21153622	chr11:89784906	NA	-0.45	-7.17	-0.37	5.01e-12	HDL cholesterol;
CRC	cis	rs17209837	0.915	rs17149637	chr7:87085209	G/A	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.46	-5.72	-0.3	2.41e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.47	-7.52	-0.38	5.29e-13	Schizophrenia;
CRC	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg00852783	chr1:26633632	UBXN11	-0.5	-5.87	-0.31	1.08e-8	Obesity-related traits;
CRC	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.32e-12	HDL cholesterol;
CRC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs7259376	0.840	rs3862494	chr19:22519522	G/A	cg02657401	chr19:22469223	NA	-0.37	-8.2	-0.41	5.42e-15	Menopause (age at onset);
CRC	trans	rs10242455	1.000	rs73395547	chr7:98922746	C/A	cg09045935	chr12:6379348	NA	0.74	6.98	0.36	1.67e-11	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg11887960	chr12:57824829	NA	0.55	6.59	0.34	1.75e-10	Obesity-related traits;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.45	6.18	0.32	1.91e-9	Longevity;Endometriosis;
CRC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg25985355	chr7:65971099	NA	-0.54	-6.09	-0.32	3.18e-9	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02825527	chr7:2087843	MAD1L1	-0.5	-6.07	-0.32	3.49e-9	Neuroticism;
CRC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg12193833	chr17:30244370	NA	0.56	6.92	0.36	2.32e-11	Hip circumference adjusted for BMI;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05485520	chr3:45883628	LZTFL1	-0.52	-6.4	-0.33	5.31e-10	Diisocyanate-induced asthma;
CRC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-13.34	-0.59	9.28e-33	Cognitive function;
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.68	-0.51	4.84e-23	Electroencephalogram traits;
CRC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.22e-11	Morning vs. evening chronotype;
CRC	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	0.96	8.96	0.44	2.53e-17	Pulse pressure;
CRC	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	7.76	0.39	1.11e-13	Response to antipsychotic treatment;
CRC	cis	rs6479527	0.806	rs2153058	chr9:96746126	A/G	cg14459158	chr9:96720562	NA	-0.41	-7.57	-0.39	3.8e-13	Esophageal adenocarcinoma;
CRC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-7.1	-0.36	7.83e-12	Colorectal cancer;
CRC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.55	9.92	0.48	1.8e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.41	-8.67	-0.43	2.01e-16	Urinary metabolites;
CRC	cis	rs17767392	0.846	rs12884929	chr14:71788946	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.47	-6.18	-0.32	1.93e-9	Mitral valve prolapse;
CRC	cis	rs990171	1.000	rs6746271	chr2:103052995	G/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.43e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.13	-0.32	2.53e-9	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01753003	chr11:85565989	CCDC83	0.37	6.72	0.35	8.22e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03952484	chr1:149899818	SF3B4	-0.53	-6.32	-0.33	8.31e-10	Diisocyanate-induced asthma;
CRC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.23	14.8	0.63	2.42e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03262242	chr1:28559476	DNAJC8	0.4	6.13	0.32	2.56e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg06494592	chr3:125709126	NA	-0.57	-6.78	-0.35	5.61e-11	Blood pressure (smoking interaction);
CRC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.68	9.37	0.46	1.2e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3767633	0.925	rs924777	chr1:161848904	G/A	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.59	-7.42	-0.38	1.03e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.61	9.65	0.47	1.47e-19	Height;
CRC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.4	7.33	0.37	1.84e-12	Mean corpuscular volume;
CRC	cis	rs17065868	0.764	rs12146918	chr13:45035819	T/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.42	6.67	0.35	1.05e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03680250	chr13:111567502	ANKRD10	0.41	6.02	0.31	4.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.4	-6.26	-0.33	1.22e-9	Breast cancer;
CRC	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.76	-0.3	1.94e-8	Coronary artery disease;
CRC	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg00738113	chr16:70207722	CLEC18C	-0.39	-6.14	-0.32	2.38e-9	IgE levels;
CRC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg20243544	chr17:37824526	PNMT	0.42	6.57	0.34	1.97e-10	Self-reported allergy;
CRC	cis	rs4363385	0.693	rs821755	chr1:153036245	G/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.87e-10	Inflammatory skin disease;
CRC	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.85	-0.35	3.72e-11	Schizophrenia;
CRC	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.56	7.88	0.4	4.97e-14	Lewy body disease;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-9.4	-0.46	9.42e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.43	-5.81	-0.3	1.48e-8	Monocyte count;
CRC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.43	-0.38	9.66e-13	Colorectal cancer;
CRC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.37	-6.03	-0.32	4.31e-9	Ulcerative colitis;
CRC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.16	0.32	2.17e-9	Monocyte percentage of white cells;
CRC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.63	-10.37	-0.5	5.49e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.67	12.26	0.56	1.01e-28	Calcium levels;
CRC	cis	rs73198271	0.531	rs11985640	chr8:8652504	C/T	cg01851573	chr8:8652454	MFHAS1	0.55	6.84	0.35	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	0.95	7.78	0.39	9.74e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2030401	0.603	rs1727301	chr12:123664514	G/A	cg00376283	chr12:123451042	ABCB9	0.43	5.67	0.3	3.08e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.11	-0.41	1.03e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg17321639	chr7:2759063	NA	-0.47	-6.21	-0.32	1.59e-9	Height;
CRC	cis	rs12936587	0.595	rs9911672	chr17:17528670	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.42	5.85	0.31	1.21e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.82e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.62	-7.95	-0.4	2.94e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg19188899	chr13:112838565	NA	-0.41	-6.26	-0.33	1.19e-9	Systemic lupus erythematosus;
CRC	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.48	-5.92	-0.31	7.95e-9	Crohn's disease;
CRC	cis	rs61160187	0.549	rs56031340	chr5:60253870	A/G	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.74	-0.3	2.17e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg24463073	chr6:118973353	C6orf204	0.51	6.81	0.35	4.64e-11	Diastolic blood pressure;
CRC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.54	9.04	0.45	1.4e-17	Breast cancer;
CRC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.57	8.64	0.43	2.52e-16	Methadone dose in opioid dependence;
CRC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.29	0.37	2.34e-12	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.51	-0.57	1.22e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12024301	0.557	rs75330230	chr1:183592353	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.87	-0.35	3.17e-11	Coronary artery disease;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.79	9.61	0.47	1.91e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.56	-5.83	-0.31	1.32e-8	Systemic lupus erythematosus;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg03623178	chr6:28175578	NA	0.78	6.95	0.36	1.99e-11	Depression;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18758796	chr5:131593413	PDLIM4	0.49	8.21	0.41	5.05e-15	Acylcarnitine levels;
CRC	cis	rs365302	1.000	rs294918	chr6:159626072	C/T	cg14500486	chr6:159655392	FNDC1	0.53	8.0	0.4	2.18e-14	Coronary heart disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16311773	chr6:167313693	NA	-0.46	-7.21	-0.37	3.8e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg15848620	chr12:58087721	OS9	-0.65	-8.89	-0.44	4.22e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg00074818	chr8:8560427	CLDN23	-0.38	-7.01	-0.36	1.34e-11	Obesity-related traits;
CRC	trans	rs11075138	0.893	rs2865585	chr16:12728587	A/G	cg24572153	chr13:21047387	CRYL1	0.42	6.16	0.32	2.09e-9	Cerebral amyloid angiopathy;
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg07507251	chr3:52567010	NT5DC2	0.43	6.2	0.32	1.68e-9	Bipolar disorder;
CRC	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.45	-0.38	8.03e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.5	6.67	0.34	1.11e-10	Schizophrenia;
CRC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.71	0.35	8.57e-11	Coronary artery disease;
CRC	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg19773385	chr1:10388646	KIF1B	-0.55	-7.09	-0.36	8e-12	Hepatocellular carcinoma;
CRC	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg26248373	chr2:1572462	NA	-0.67	-8.15	-0.41	7.66e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs7176508	0.660	rs7180247	chr15:70046036	G/T	cg06571387	chr2:176964101	HOXD12	-0.32	-5.98	-0.31	5.84e-9	Chronic lymphocytic leukemia;
CRC	trans	rs800082	1.000	rs6440259	chr3:144286614	C/T	cg24215973	chr2:240111563	HDAC4	0.46	6.62	0.34	1.43e-10	Smoking behavior;
CRC	trans	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg24644049	chr4:85504048	CDS1	0.83	6.97	0.36	1.69e-11	Skin colour saturation;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20092199	chr4:1342459	KIAA1530	0.45	7.63	0.39	2.49e-13	Longevity;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.43	6.98	0.36	1.61e-11	Sitting height ratio;
CRC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.72	0.3	2.41e-8	Homoarginine levels;
CRC	cis	rs2734839	0.964	rs12798900	chr11:113298996	G/T	cg14159747	chr11:113255604	NA	0.48	8.52	0.43	5.75e-16	Information processing speed;
CRC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg10298567	chr3:47292165	KIF9	0.4	6.29	0.33	9.86e-10	Colorectal cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01546243	chr14:61748019	TMEM30B	-0.46	-5.96	-0.31	6.4e-9	Diisocyanate-induced asthma;
CRC	trans	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs73200209	0.626	rs56159711	chr12:116578050	T/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.14	-0.37	6.18e-12	Total body bone mineral density;
CRC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg14433983	chr11:636460	DRD4	-0.42	-5.92	-0.31	8.17e-9	Systemic lupus erythematosus;
CRC	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.73	0.35	7.46e-11	Axial length;
CRC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.49	6.36	0.33	6.74e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs16846053	0.681	rs62187569	chr2:162373517	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.54e-9	Blood osmolality (transformed sodium);
CRC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg14008862	chr17:28927542	LRRC37B2	0.51	6.17	0.32	1.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg23123621	chr4:1343375	KIAA1530	0.38	6.09	0.32	3.1e-9	Obesity-related traits;
CRC	cis	rs911119	0.955	rs8121405	chr20:23605226	G/A	cg16589663	chr20:23618590	CST3	0.45	6.35	0.33	7.25e-10	Chronic kidney disease;
CRC	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.7	0.47	1.03e-19	Coffee consumption (cups per day);
CRC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-15.37	-0.65	1.53e-40	Height;
CRC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	5.78	0.3	1.77e-8	Obesity-related traits;
CRC	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg07478791	chr1:31886160	SERINC2	-0.41	-5.79	-0.3	1.61e-8	Alcohol dependence;
CRC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.0	-0.31	5.06e-9	Gout;Renal underexcretion gout;
CRC	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.73	-8.55	-0.43	4.66e-16	Diisocyanate-induced asthma;
CRC	trans	rs10411161	0.640	rs7252303	chr19:52389357	G/A	cg22319618	chr22:45562946	NUP50	-0.62	-6.51	-0.34	2.78e-10	Breast cancer;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.72	8.23	0.41	4.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	8.96	0.44	2.53e-17	Alzheimer's disease (late onset);
CRC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.72	9.42	0.46	8.49e-19	High light scatter reticulocyte count;
CRC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.06	0.32	3.69e-9	Lung cancer;
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.73	8.88	0.44	4.57e-17	Alzheimer's disease;
CRC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03558299	chr20:47662597	CSE1L	0.49	6.91	0.36	2.56e-11	Response to antipsychotic treatment;
CRC	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.46	0.38	7.62e-13	Eye color traits;
CRC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.95	11.44	0.53	9.53e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16447950	chr5:562315	NA	-0.83	-11.08	-0.52	1.82e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.61e-11	Aortic root size;
CRC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg06766960	chr11:133703094	NA	-0.38	-6.28	-0.33	1.1e-9	Childhood ear infection;
CRC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.51	7.04	0.36	1.13e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg01657329	chr11:68192670	LRP5	0.45	6.42	0.33	4.82e-10	Total body bone mineral density;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02243342	chr3:69129635	UBA3	-0.4	-6.03	-0.32	4.33e-9	Aortic root size;
CRC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg26805224	chr10:79626177	DLG5	-0.5	-7.43	-0.38	9.72e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7487075	0.619	rs4768710	chr12:46808104	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs7692995	1.000	rs12511600	chr4:17939921	C/T	cg08925142	chr4:18023851	LCORL	-0.52	-5.81	-0.31	1.45e-8	Height;
CRC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg08533674	chr1:46993347	NA	-0.8	-10.42	-0.5	3.71e-22	Monobrow;
CRC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.53	-8.56	-0.43	4.37e-16	Aortic root size;
CRC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.82	-13.93	-0.61	5.67e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.26	-0.33	1.17e-9	Mood instability;
CRC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.68	7.08	0.36	8.84e-12	Diabetic retinopathy;
CRC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Corneal astigmatism;
CRC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg16358738	chr2:241808595	AGXT	-0.39	-5.82	-0.31	1.4e-8	Urinary metabolites;
CRC	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg16342193	chr10:102329863	NA	-0.37	-5.95	-0.31	6.68e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.72	13.4	0.59	5.89e-33	Prudent dietary pattern;
CRC	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.4	6.07	0.32	3.52e-9	Testicular germ cell tumor;
CRC	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.4	-7.63	-0.39	2.5e-13	Migraine;
CRC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.25	-0.37	3.06e-12	Chronic sinus infection;
CRC	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.54	-7.52	-0.38	5.37e-13	Carotid intima media thickness;
CRC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg21194808	chr1:2205498	SKI	0.39	5.75	0.3	2.06e-8	Height;
CRC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.99	21.36	0.76	4.12e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.45	6.41	0.33	5.01e-10	Pulse pressure;
CRC	trans	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06834434	chr14:75079333	LTBP2	0.53	5.96	0.31	6.34e-9	Obesity-related traits;
CRC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	0.96	17.82	0.7	3.29e-50	Height;
CRC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.51	8.81	0.44	7.58e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs526821	0.595	rs504661	chr11:55312683	A/G	cg04317927	chr11:55418816	OR4S2	0.39	6.51	0.34	2.83e-10	Pediatric bone mineral density (spine);
CRC	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg22561889	chr6:118971681	C6orf204	0.52	6.62	0.34	1.45e-10	Diastolic blood pressure;
CRC	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg19486271	chr11:47235900	DDB2	-0.47	-7.07	-0.36	9.57e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4757319	0.515	rs7109366	chr11:15438964	T/C	cg03245590	chr11:15329459	NA	0.52	9.0	0.44	1.88e-17	Breast cancer;
CRC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg17911788	chr17:44343683	NA	0.57	7.02	0.36	1.27e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03573702	chr19:44669354	ZNF226	0.41	6.07	0.32	3.53e-9	Response to antipsychotic treatment;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12888358	chr2:86668281	KDM3A	-0.55	-8.3	-0.42	2.75e-15	Interleukin-6 levels;
CRC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.44	6.13	0.32	2.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12692738	0.526	rs355874	chr2:165632668	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	12.36	0.56	4.57e-29	Chronic sinus infection;
CRC	cis	rs7917772	0.690	rs11191369	chr10:104457456	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.94	0.4	3.3e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg03623178	chr6:28175578	NA	0.83	6.72	0.35	7.91e-11	Depression;
CRC	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.66	10.6	0.5	8.91e-23	Schizophrenia;
CRC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.37	5.9	0.31	8.79e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg02725872	chr8:58115012	NA	-0.36	-6.18	-0.32	1.91e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.94	-0.31	7.16e-9	Lung cancer;
CRC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.48	6.77	0.35	5.98e-11	Height;
CRC	cis	rs6743376	0.556	rs2515394	chr2:113817765	C/T	cg24553058	chr2:113831203	IL1F10	0.42	6.9	0.36	2.69e-11	Inflammatory biomarkers;
CRC	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg06172871	chr16:72088244	HP	0.42	6.1	0.32	2.97e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.69	-13.61	-0.6	8.87e-34	Educational attainment;
CRC	cis	rs77861329	1.000	rs1237830	chr3:52202820	T/C	cg08692210	chr3:52188851	WDR51A	0.87	8.15	0.41	7.44e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs7212590	0.748	rs62081818	chr17:57890629	C/T	cg10252138	chr17:58120427	NA	-0.54	-5.64	-0.3	3.73e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-10.15	-0.49	3.05e-21	Breast cancer;
CRC	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.44	5.83	0.31	1.3e-8	Tuberculosis;
CRC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.45	-6.0	-0.31	5.3e-9	Lung cancer;
CRC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.98	-19.31	-0.73	4.62e-56	Height;
CRC	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.46	9.37	0.46	1.23e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.49	6.08	0.32	3.24e-9	Bipolar disorder;
CRC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.53	7.99	0.4	2.36e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.68	-0.35	1.02e-10	Vitamin D levels;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg23161317	chr6:28129485	ZNF389	0.44	6.41	0.33	5.12e-10	Parkinson's disease;
CRC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	9.16	0.45	5.56e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.43	-6.28	-0.33	1.06e-9	Longevity;Endometriosis;
CRC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-11.15	-0.52	1.05e-24	Cognitive function;
CRC	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.44	6.44	0.33	4.35e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg04155289	chr7:94953770	PON1	-0.57	-7.1	-0.36	7.6e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.27	0.56	9.17e-29	Hip circumference adjusted for BMI;
CRC	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg00601450	chr5:74908170	NA	-0.47	-5.82	-0.31	1.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.51	9.05	0.45	1.32e-17	Body mass index;
CRC	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg19046167	chr17:80928561	B3GNTL1	0.44	6.59	0.34	1.78e-10	Breast cancer;
CRC	cis	rs12760731	0.565	rs34041572	chr1:178184493	T/C	cg00404053	chr1:178313656	RASAL2	1.11	11.47	0.53	7.73e-26	Obesity-related traits;
CRC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.67	8.86	0.44	4.96e-17	Bronchopulmonary dysplasia;
CRC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	0.95	18.81	0.72	4.15e-54	Height;
CRC	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg14191688	chr11:70257035	CTTN	0.4	5.69	0.3	2.8e-8	Coronary artery disease;
CRC	cis	rs11212617	0.905	rs6589007	chr11:108040104	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.56	0.34	2.07e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.43	-6.13	-0.32	2.58e-9	Body mass index;
CRC	cis	rs2737618	0.722	rs2821333	chr1:200093253	A/C	cg21825944	chr1:200113062	NR5A2	-0.53	-7.42	-0.38	9.78e-13	Uric acid levels;
CRC	cis	rs73206853	0.764	rs60339427	chr12:110824471	G/A	cg12870014	chr12:110450643	ANKRD13A	0.84	10.0	0.48	1e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9816226	0.591	rs4234589	chr3:185818882	A/G	cg00760338	chr3:185826511	ETV5	-0.64	-5.63	-0.3	3.93e-8	Obesity;Body mass index;
CRC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.51	8.91	0.44	3.49e-17	Aortic root size;
CRC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.41	7.92	0.4	3.73e-14	Mean corpuscular volume;
CRC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.03	19.12	0.73	2.56e-55	Primary sclerosing cholangitis;
CRC	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.4	6.3	0.33	9.49e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg13607699	chr17:42295918	UBTF	-0.54	-7.28	-0.37	2.54e-12	Total body bone mineral density;
CRC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.79	12.38	0.56	3.72e-29	Breast cancer;
CRC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.42	-6.28	-0.33	1.09e-9	Neutrophil percentage of white cells;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg20615401	chr6:28092323	ZSCAN16	0.45	5.89	0.31	9.65e-9	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13919496	chr22:42915677	RRP7A	0.44	6.19	0.32	1.76e-9	Anxiety disorder;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-9.02	-0.45	1.64e-17	Bipolar disorder;
CRC	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.56	9.44	0.46	6.91e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09728486	chr1:110577640	FAM40A	0.44	6.38	0.33	5.96e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12612619	0.677	rs2053386	chr2:27244712	C/T	cg00617064	chr2:27272375	NA	-0.36	-5.84	-0.31	1.26e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs8005677	0.828	rs712486	chr14:23425041	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-6.42	-0.33	4.82e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs9292777	0.777	rs12523046	chr5:40385241	A/T	cg09067459	chr5:40385259	NA	-0.56	-9.28	-0.46	2.31e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7705042	0.897	rs4912807	chr5:141519296	G/C	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.5e-8	Asthma;
CRC	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.35	0.38	1.62e-12	Lung cancer;
CRC	cis	rs78707713	0.531	rs12411720	chr10:71192471	T/G	cg12610070	chr10:71211762	TSPAN15	-0.4	-7.21	-0.37	3.85e-12	Venous thromboembolism;
CRC	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12172441	chr6:28176163	NA	0.6	7.19	0.37	4.46e-12	Depression;
CRC	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.77	-12.63	-0.57	4.22e-30	Ear protrusion;
CRC	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.74	-0.3	2.14e-8	Vascular endothelial growth factor levels;
CRC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	8.54	0.43	5.13e-16	Cognitive test performance;
CRC	cis	rs9379832	1	rs9379832	chr6:26186200	A/G	cg13736514	chr6:26305472	NA	-0.45	-7.03	-0.36	1.23e-11	Birth weight;
CRC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.37	7.19e-12	Menopause (age at onset);
CRC	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.87	7.47	0.38	7.52e-13	Alzheimer's disease (late onset);
CRC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg27565382	chr3:53032988	SFMBT1	0.77	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.64	-9.91	-0.48	1.94e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.88	11.27	0.53	3.84e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.18	0.41	6.2e-15	Menarche (age at onset);
CRC	cis	rs11212617	0.967	rs183460	chr11:108090710	A/C	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.33	0.33	7.9e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12760731	0.565	rs12028024	chr1:178087423	G/T	cg00404053	chr1:178313656	RASAL2	1.07	11.37	0.53	1.67e-25	Obesity-related traits;
CRC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.52	-7.08	-0.36	8.59e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.84	-0.31	1.26e-8	Arsenic metabolism;
CRC	cis	rs3924048	0.574	rs34494202	chr1:12612868	G/A	cg23650765	chr1:12612165	NA	0.38	7.34	0.38	1.65e-12	Optic cup area;
CRC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.73	-10.87	-0.51	9.87e-24	Obesity-related traits;
CRC	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.33	-0.46	1.63e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.98	-0.4	2.4e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.39	6.19	0.32	1.78e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.83	13.27	0.59	1.78e-32	Platelet distribution width;
CRC	trans	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04565464	chr8:145669602	NFKBIL2	0.41	6.21	0.32	1.55e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.61	-0.3	4.38e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.58	-8.86	-0.44	5.26e-17	Height;
CRC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.4	-0.46	9.54e-19	Platelet count;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg08989290	chr16:615782	NHLRC4	0.45	8.52	0.43	5.87e-16	Height;
CRC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.8	-14.01	-0.61	2.73e-35	Vitiligo;
CRC	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	1.19	10.18	0.49	2.51e-21	Skin colour saturation;
CRC	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.43	0.62	6.62e-37	Chronic sinus infection;
CRC	cis	rs965469	0.901	rs7270135	chr20:3247922	T/C	cg25506879	chr20:3388711	C20orf194	-0.38	-5.66	-0.3	3.29e-8	IFN-related cytopenia;
CRC	cis	rs10924970	0.870	rs7531130	chr1:235440556	C/G	cg26050004	chr1:235667680	B3GALNT2	0.41	6.1	0.32	2.96e-9	Asthma;
CRC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.86	-0.31	1.13e-8	Diastolic blood pressure;
CRC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg07713946	chr22:31675144	LIMK2	-0.4	-5.79	-0.3	1.63e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg08314208	chr16:67682810	RLTPR	-0.47	-5.71	-0.3	2.55e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.79	-0.75	6.66e-62	Height;
CRC	cis	rs77972916	0.561	rs17406174	chr2:43557484	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.93	-0.31	7.64e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.57	9.32	0.46	1.74e-18	Mean corpuscular volume;
CRC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.98	18.17	0.71	1.44e-51	Headache;
CRC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	6.14	0.32	2.35e-9	Putamen volume;
CRC	cis	rs8170	1.000	rs67412075	chr19:17385502	A/G	cg04749549	chr19:17459798	NA	-0.43	-5.88	-0.31	1.01e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-7.12	-0.37	6.65e-12	Body mass index (adult);
CRC	cis	rs3015497	0.789	rs3015502	chr14:51108427	T/C	cg09863266	chr14:51125203	SAV1	-0.31	-5.8	-0.3	1.53e-8	Mean platelet volume;
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.65	7.42	0.38	1.03e-12	Body mass index;
CRC	cis	rs6684514	1.000	rs7522948	chr1:156275308	C/T	cg16558208	chr1:156270281	VHLL	0.49	7.59	0.39	3.23e-13	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6662572	0.774	rs9429188	chr1:46570879	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.38	0.33	6.09e-10	Blood protein levels;
CRC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.34	-5.88	-0.31	1.01e-8	Cognitive function;
CRC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.21	-0.69	8.36e-48	Height;
CRC	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg08071915	chr8:12219732	FAM66A	0.34	6.01	0.31	4.92e-9	Morning vs. evening chronotype;
CRC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	8.11	0.41	1.04e-14	Monocyte count;
CRC	cis	rs939584	1.000	rs4854346	chr2:638918	A/C	cg03610516	chr2:642275	NA	0.43	5.76	0.3	1.96e-8	Body mass index;
CRC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.65	-0.34	1.26e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.92	8.58	0.43	3.87e-16	Type 2 diabetes nephropathy;
CRC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.61	-6.93	-0.36	2.17e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24308560	chr3:49941425	MST1R	-0.38	-5.73	-0.3	2.23e-8	Body mass index;
CRC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg18827107	chr12:86230957	RASSF9	-0.44	-7.14	-0.37	6.2e-12	Major depressive disorder;
CRC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg21251018	chr6:28226885	NKAPL	0.5	5.86	0.31	1.15e-8	Depression;
CRC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.05	13.07	0.58	1.02e-31	Vitiligo;
CRC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg11861562	chr11:117069780	TAGLN	0.38	7.98	0.4	2.4e-14	Blood protein levels;
CRC	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg08501292	chr6:25962987	TRIM38	0.79	7.15	0.37	5.67e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.68	7.25	0.37	3e-12	D-dimer levels;
CRC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	10.08	0.49	5.46e-21	Alzheimer's disease (late onset);
CRC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg06145435	chr7:1022769	CYP2W1	0.4	6.16	0.32	2.11e-9	Bronchopulmonary dysplasia;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.41	6.25	0.33	1.25e-9	Electroencephalogram traits;
CRC	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg23100626	chr2:96804247	ASTL	0.26	7.14	0.37	6.05e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.69	-0.47	1.05e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11645453	chr3:52864694	ITIH4	0.35	6.14	0.32	2.31e-9	Bipolar disorder;
CRC	cis	rs1215050	0.655	rs6842706	chr4:98499037	A/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.96	-0.31	6.47e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.96	0.4	2.84e-14	Height;
CRC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.04	-11.6	-0.54	2.54e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.57	0.34	1.97e-10	Bipolar disorder;
CRC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-6.95	-0.36	1.94e-11	Glioblastoma;
CRC	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-1.37	-15.11	-0.64	1.47e-39	Height;
CRC	cis	rs10924970	0.649	rs12745603	chr1:235405211	G/A	cg09010748	chr1:235293032	TOMM20	-0.41	-5.65	-0.3	3.48e-8	Asthma;
CRC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.97	0.31	6.21e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.52	-8.08	-0.41	1.27e-14	Fibrinogen levels;
CRC	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.52	-7.13	-0.37	6.21e-12	Tuberculosis;
CRC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg01472538	chr16:58549086	SETD6	0.98	6.32	0.33	8.72e-10	Schizophrenia;
CRC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-16.12	-0.66	1.73e-43	Coronary artery disease;
CRC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.12	-0.37	6.79e-12	Eye color traits;
CRC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg16102536	chr7:156981717	UBE3C	0.41	6.79	0.35	5.35e-11	Body mass index;
CRC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.62	0.51	7.54e-23	Systolic blood pressure;
CRC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg05623727	chr3:50126028	RBM5	0.45	7.63	0.39	2.55e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.52	8.01	0.4	1.97e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	11.94	0.55	1.5e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-8.31	-0.42	2.53e-15	Hypospadias;
CRC	cis	rs728616	0.558	rs34268041	chr10:82148639	A/G	cg11900509	chr10:81946545	ANXA11	-0.56	-6.26	-0.33	1.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg15660573	chr17:549704	VPS53	-0.92	-16.58	-0.67	2.73e-45	Prostate cancer;
CRC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.83e-8	Major depressive disorder;
CRC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.47	-0.38	7.14e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg05340658	chr4:99064831	C4orf37	0.51	6.33	0.33	7.96e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.5	7.56	0.38	4.13e-13	Immature fraction of reticulocytes;
CRC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.5	0.54	5.69e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg02158880	chr13:53174818	NA	0.44	6.39	0.33	5.73e-10	Lewy body disease;
CRC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.76	12.59	0.57	6.24e-30	Selective IgA deficiency;
CRC	cis	rs7072216	0.621	rs3750605	chr10:100175654	C/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-7.9	-0.4	4.35e-14	Metabolite levels;
CRC	cis	rs2565722	0.622	rs2465834	chr6:161301868	T/C	cg03159191	chr6:161285451	NA	-0.46	-6.28	-0.33	1.07e-9	Blood protein levels;
CRC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.0	-0.4	2.12e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.68	-0.35	1.02e-10	Lymphocyte counts;
CRC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.47	-0.46	5.45e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-7.7	-0.39	1.64e-13	Vitiligo;
CRC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg27432699	chr2:27873401	GPN1	-0.53	-8.04	-0.41	1.59e-14	Total body bone mineral density;
CRC	cis	rs9786986	0.665	rs12401438	chr1:235701732	C/T	cg08848088	chr1:235714526	GNG4	0.52	5.89	0.31	9.54e-9	Body mass index;
CRC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg02527881	chr3:46936655	PTH1R	-0.38	-7.12	-0.37	6.9e-12	Colorectal cancer;
CRC	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg05304507	chr6:116381966	FRK	0.26	6.03	0.32	4.37e-9	Total cholesterol levels;
CRC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26958806	chr6:27640298	NA	0.65	5.6	0.3	4.48e-8	Depression;
CRC	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg20935368	chr5:178288625	ZNF354B	0.43	7.02	0.36	1.31e-11	Sleep duration;
CRC	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg09537434	chr19:41945824	ATP5SL	-0.52	-6.6	-0.34	1.66e-10	Colorectal cancer;
CRC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.38	-6.08	-0.32	3.38e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.86e-17	Aortic root size;
CRC	cis	rs4700695	0.764	rs251301	chr5:65300017	G/C	cg21114390	chr5:65439923	SFRS12	0.59	6.61	0.34	1.57e-10	Facial morphology (factor 19);
CRC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.38e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg16606324	chr3:10149918	C3orf24	0.48	7.09	0.36	8.29e-12	Alzheimer's disease;
CRC	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-8.38	-0.42	1.51e-15	Hypospadias;
CRC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.39	6.02	0.31	4.66e-9	Hemoglobin concentration;
CRC	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg06042504	chr8:55087323	NA	-0.37	-5.77	-0.3	1.79e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg12160578	chr15:63334699	TPM1	0.63	7.53	0.38	5.02e-13	Orofacial clefts;
CRC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.66	11.83	0.55	3.97e-27	Eye color traits;
CRC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18099408	chr3:52552593	STAB1	-0.48	-8.3	-0.42	2.81e-15	Electroencephalogram traits;
CRC	cis	rs17092148	0.887	rs6059937	chr20:33186200	G/C	cg08999081	chr20:33150536	PIGU	0.5	6.35	0.33	6.96e-10	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21870244	chr1:198125992	NEK7	0.45	6.55	0.34	2.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg24011408	chr12:48396354	COL2A1	-0.44	-6.48	-0.34	3.35e-10	Glycated hemoglobin levels;
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg07507251	chr3:52567010	NT5DC2	0.49	7.45	0.38	8.12e-13	Electroencephalogram traits;
CRC	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.66	-9.54	-0.47	3.38e-19	Type 2 diabetes;
CRC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.16	0.45	5.82e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs954108	0.809	rs1592059	chr13:29368961	G/A	cg11788234	chr13:29393811	NA	-0.42	-6.6	-0.34	1.64e-10	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.01	-19.92	-0.74	1.74e-58	Prudent dietary pattern;
CRC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg14711859	chr11:8959438	ASCL3	-0.51	-8.2	-0.41	5.31e-15	Hemoglobin concentration;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg27635394	chr6:26043820	HIST1H2BB	-0.45	-6.54	-0.34	2.38e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.61	8.87	0.44	4.71e-17	Obesity-related traits;
CRC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.62	7.61	0.39	2.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7945718	0.592	rs10765985	chr11:12676468	G/A	cg25843174	chr11:12811716	TEAD1	0.39	7.07	0.36	9.43e-12	Educational attainment (years of education);
CRC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg14593290	chr7:50529359	DDC	-0.47	-6.67	-0.35	1.08e-10	Systemic sclerosis;
CRC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.54	8.48	0.42	7.53e-16	Aortic root size;
CRC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.73	16.52	0.67	4.49e-45	Sjögren's syndrome;
CRC	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-7.76	-0.39	1.12e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg13798780	chr7:105162888	PUS7	0.64	7.27	0.37	2.7e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.65	9.58	0.47	2.53e-19	Menopause (age at onset);
CRC	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.74	8.28	0.42	3.18e-15	Systolic blood pressure;
CRC	cis	rs9311676	0.656	rs11718352	chr3:58401480	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg02527881	chr3:46936655	PTH1R	0.36	6.19	0.32	1.75e-9	Colorectal cancer;
CRC	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.75	-10.85	-0.51	1.21e-23	Bipolar disorder;
CRC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.66	8.8	0.44	7.91e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17601876	0.814	rs8038715	chr15:51561120	T/A	cg19946085	chr15:51559439	CYP19A1	-0.34	-6.93	-0.36	2.21e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs6763159	1.000	rs1447807	chr3:59648681	A/G	cg07069742	chr3:59644285	NA	-0.35	-7.13	-0.37	6.34e-12	Conotruncal heart defects;
CRC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg22110888	chr17:80059540	CCDC57	-0.43	-6.63	-0.34	1.35e-10	Life satisfaction;
CRC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg04545296	chr12:48745243	ZNF641	0.36	6.19	0.32	1.81e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs62229266	0.659	rs2835242	chr21:37413532	A/C	cg12218747	chr21:37451666	NA	-0.36	-6.18	-0.32	1.86e-9	Mitral valve prolapse;
CRC	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.41	-11.53	-0.54	4.75e-26	Psoriasis vulgaris;
CRC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.65	0.6	6.38e-34	Schizophrenia;
CRC	cis	rs9903692	0.954	rs12936731	chr17:46128359	G/C	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.39	6.25	0.33	1.25e-9	Blood metabolite levels;
CRC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.66	6.99	0.36	1.54e-11	Axial length;
CRC	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.63	10.41	0.5	3.89e-22	Schizophrenia;
CRC	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.47	8.12	0.41	9.23e-15	Primary biliary cholangitis;
CRC	cis	rs889398	0.741	rs7192213	chr16:69926280	G/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.81	-0.3	1.49e-8	Body mass index;
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.77	14.59	0.63	1.54e-37	Prudent dietary pattern;
CRC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg20607287	chr7:12443886	VWDE	-0.64	-6.41	-0.33	5.11e-10	Coronary artery disease;
CRC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.78	-0.35	5.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg21452805	chr1:244014465	NA	0.52	6.9	0.36	2.76e-11	RR interval (heart rate);
CRC	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.76	0.63	3.56e-38	Exhaled nitric oxide output;
CRC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.46	5.96	0.31	6.64e-9	Aortic root size;
CRC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.57	9.58	0.47	2.44e-19	Prostate cancer;
CRC	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg13736514	chr6:26305472	NA	-0.46	-7.54	-0.38	4.65e-13	Educational attainment;
CRC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg20203395	chr5:56204925	C5orf35	-0.72	-8.55	-0.43	4.67e-16	Initial pursuit acceleration;
CRC	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs12580194	0.593	rs12581916	chr12:55764409	A/C	cg23425280	chr12:56401806	NA	0.47	5.7	0.3	2.71e-8	Cancer;
CRC	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg03315344	chr16:75512273	CHST6	0.55	9.29	0.46	2.16e-18	Dupuytren's disease;
CRC	trans	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg19046167	chr17:80928561	B3GNTL1	0.46	8.04	0.41	1.64e-14	Breast cancer;
CRC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg13736514	chr6:26305472	NA	-0.41	-6.79	-0.35	5.12e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg14036092	chr11:66035641	RAB1B	0.49	6.65	0.34	1.21e-10	Electroencephalogram traits;
CRC	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.47	7.02	0.36	1.24e-11	Mean platelet volume;
CRC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.87	-16.67	-0.68	1.16e-45	Hip circumference;
CRC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.54	8.03	0.4	1.78e-14	Body mass index;
CRC	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.98	0.44	2.16e-17	Coffee consumption (cups per day);
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg23161317	chr6:28129485	ZNF389	0.46	6.49	0.34	3.25e-10	Parkinson's disease;
CRC	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg20368463	chr18:77673604	PQLC1	-0.6	-5.89	-0.31	9.33e-9	Opioid sensitivity;
CRC	trans	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg14557552	chr3:187012559	NA	0.53	6.0	0.31	5.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.48	-7.61	-0.39	2.96e-13	Schizophrenia;
CRC	cis	rs61677309	1.000	rs1945765	chr11:118182829	T/A	cg06090739	chr11:118230722	UBE4A	0.42	5.72	0.3	2.34e-8	Lung cancer in ever smokers;
CRC	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.57	-8.2	-0.41	5.44e-15	Rheumatoid arthritis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00983485	chr15:31284262	MTMR10	-0.51	-6.37	-0.33	6.39e-10	Diisocyanate-induced asthma;
CRC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19091366	chr12:94853648	CCDC41;LOC144486	0.51	7.24	0.37	3.21e-12	Anxiety disorder;
CRC	cis	rs4654899	0.802	rs10737452	chr1:21199764	C/T	cg02927042	chr1:21476669	EIF4G3	0.44	6.99	0.36	1.58e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.17	-0.32	2.03e-9	Total body bone mineral density;
CRC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg24011408	chr12:48396354	COL2A1	0.44	6.23	0.32	1.44e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.32	-0.37	1.97e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg04110750	chr16:69646130	NFAT5	0.41	6.19	0.32	1.8e-9	Sjögren's syndrome;
CRC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14895029	chr7:2775587	GNA12	-0.43	-6.11	-0.32	2.85e-9	Height;
CRC	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.42	6.59	0.34	1.8e-10	Red blood cell count;
CRC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg06238570	chr21:40685208	BRWD1	0.76	10.62	0.51	7.3e-23	Cognitive function;
CRC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg10760299	chr15:45669010	GATM	0.36	5.81	0.31	1.44e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21283714	chr1:205196967	TMCC2	0.4	6.19	0.32	1.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg01950434	chr2:97203154	ARID5A	-0.4	-5.92	-0.31	8.29e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.82	9.53	0.47	3.52e-19	Obesity-related traits;
CRC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg21285383	chr16:89894308	SPIRE2	0.35	5.85	0.31	1.18e-8	Vitiligo;
CRC	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-10.74	-0.51	2.94e-23	Colorectal cancer;
CRC	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg00947319	chr17:47005597	UBE2Z	-0.35	-6.17	-0.32	2e-9	Type 2 diabetes;
CRC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.7e-9	Rheumatoid arthritis;
CRC	cis	rs9462027	0.628	rs2038839	chr6:34777791	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.93	-0.31	7.48e-9	Systemic lupus erythematosus;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg18301423	chr5:131593218	PDLIM4	0.39	6.42	0.33	4.65e-10	Breast cancer;
CRC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.44	6.52	0.34	2.72e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.74	-11.97	-0.55	1.16e-27	Lung cancer;
CRC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.82	0.7	3.44e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.71	10.43	0.5	3.4e-22	Longevity;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27665823	chr16:460516	DECR2	-0.45	-6.18	-0.32	1.91e-9	Hip circumference;
CRC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.61	-0.39	3e-13	Gut microbiome composition (summer);
CRC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.64	0.3	3.7e-8	Multiple sclerosis;
CRC	cis	rs11723261	0.621	rs7440274	chr4:155713	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.46	-6.15	-0.32	2.24e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.73	0.35	7.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-5.77	-0.3	1.84e-8	Alzheimer's disease (late onset);
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.36	-0.38	1.5e-12	Lymphocyte counts;
CRC	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8141797	0.792	rs12484557	chr22:24555861	A/G	cg20894457	chr22:24584366	SUSD2	0.63	6.09	0.32	3.22e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.51	-5.97	-0.31	6.15e-9	Bronchopulmonary dysplasia;
CRC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07701084	chr6:150067640	NUP43	0.54	7.65	0.39	2.22e-13	Testicular germ cell tumor;
CRC	cis	rs990171	1.000	rs6543141	chr2:103076351	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.34e-9	Lymphocyte counts;
CRC	cis	rs10046574	0.561	rs7789858	chr7:135212285	A/G	cg27474649	chr7:135195673	CNOT4	0.61	5.95	0.31	7.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.9	17.61	0.7	2.32e-49	Metabolic syndrome;
CRC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg14541582	chr5:601475	NA	-0.34	-6.46	-0.34	3.71e-10	Obesity-related traits;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg21251018	chr6:28226885	NKAPL	0.42	6.06	0.32	3.81e-9	Parkinson's disease;
CRC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.5	-7.42	-0.38	9.89e-13	Longevity;
CRC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.48	-0.34	3.29e-10	Total body bone mineral density;
CRC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.38	5.93	0.31	7.87e-9	Height;
CRC	cis	rs4757319	0.515	rs4757316	chr11:15432094	A/G	cg03245590	chr11:15329459	NA	0.53	9.27	0.46	2.49e-18	Breast cancer;
CRC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.99	18.32	0.71	3.48e-52	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	0.96	10.71	0.51	3.72e-23	Diabetic retinopathy;
CRC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs55788414	0.932	rs9929066	chr16:81182157	G/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg00734567	chr1:86172782	ZNHIT6	-0.44	-6.74	-0.35	6.92e-11	Urate levels in overweight individuals;
CRC	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.5	7.92	0.4	3.77e-14	Red blood cell count;
CRC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.44	-6.93	-0.36	2.19e-11	LDL cholesterol;Cholesterol, total;
CRC	trans	rs2797369	0.769	rs12199600	chr6:101594847	C/T	cg26346621	chr12:6873348	NA	0.39	6.15	0.32	2.19e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24308560	chr3:49941425	MST1R	-0.48	-7.5	-0.38	5.97e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-0.9	-15.66	-0.65	1.12e-41	Body mass index;
CRC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	8.36	0.42	1.85e-15	Prudent dietary pattern;
CRC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.7	12.49	0.57	1.45e-29	Diastolic blood pressure;
CRC	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg06935464	chr4:38784597	TLR10	-0.62	-8.08	-0.41	1.21e-14	Breast cancer;
CRC	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.73	-10.04	-0.48	7.16e-21	Coronary artery disease;
CRC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.82	11.28	0.53	3.49e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.55	-8.48	-0.42	7.64e-16	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg00383167	chr18:77616694	NA	0.54	6.02	0.31	4.69e-9	Opioid sensitivity;
CRC	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg16691251	chr5:66510806	NA	0.42	7.36	0.38	1.53e-12	Breast cancer;
CRC	cis	rs4664293	0.836	rs13032500	chr2:160606251	G/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.57e-13	Monocyte percentage of white cells;
CRC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.83	-0.35	4.07e-11	Bipolar disorder;
CRC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.54	7.43	0.38	9.47e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.76	0.43	1.09e-16	Coronary artery disease;
CRC	cis	rs56146971	0.763	rs2064961	chr14:91868814	A/G	cg16433844	chr14:91963127	SMEK1	-0.62	-6.61	-0.34	1.59e-10	Alzheimer disease and age of onset;
CRC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.74	11.25	0.53	4.8e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.38	5.66	0.3	3.25e-8	Mood instability;
CRC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.4	6.21	0.32	1.62e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg16540259	chr10:75572220	NDST2	-0.39	-6.24	-0.33	1.37e-9	Inflammatory bowel disease;
CRC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.51	7.12	0.37	6.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6961069	0.773	rs1761661	chr7:80238041	A/C	cg04458919	chr7:80252533	CD36	-0.34	-6.18	-0.32	1.85e-9	Platelet count;
CRC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.67	10.11	0.49	4.05e-21	Gestational age at birth (maternal effect);
CRC	trans	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.65	-0.34	1.22e-10	Depression;
CRC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.52	-7.87	-0.4	5.16e-14	Menarche (age at onset);
CRC	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg20573242	chr4:122745356	CCNA2	0.44	6.52	0.34	2.59e-10	Type 2 diabetes;
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.49	8.07	0.41	1.29e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg15845792	chr6:28175446	NA	-0.64	-6.13	-0.32	2.45e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.4	-0.33	5.39e-10	Monocyte percentage of white cells;
CRC	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.53	7.69	0.39	1.72e-13	Multiple sclerosis;
CRC	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.66	-10.84	-0.51	1.31e-23	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.61	9.68	0.47	1.19e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg22777020	chr22:31556080	RNF185	0.53	6.27	0.33	1.11e-9	Colorectal cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07811750	chr17:4890503	CAMTA2	0.46	7.24	0.37	3.11e-12	Interleukin-6 levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06636527	chr1:144932473	PDE4DIP	0.44	6.19	0.32	1.76e-9	Anxiety disorder;
CRC	cis	rs501120	0.929	rs2576355	chr10:44750362	A/G	cg09554077	chr10:44749378	NA	0.89	13.17	0.59	4.18e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg19913688	chr11:428466	ANO9	-0.73	-7.65	-0.39	2.19e-13	Body mass index;
CRC	cis	rs972578	0.936	rs738394	chr22:43366896	C/T	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.7	0.63	6.15e-38	Chronic sinus infection;
CRC	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-6.99	-0.36	1.55e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg22256960	chr15:77711686	NA	-0.61	-9.03	-0.45	1.48e-17	Type 2 diabetes;
CRC	trans	rs6693295	0.605	rs4396095	chr1:246213270	A/G	cg03680032	chr11:94965610	SESN3	0.53	6.57	0.34	2e-10	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs6504950	0.720	rs2877634	chr17:52987545	A/G	cg26251398	chr17:52985966	TOM1L1	0.37	5.66	0.3	3.33e-8	Breast cancer;
CRC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.5	-9.12	-0.45	7.58e-18	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.6	9.53	0.46	3.71e-19	Corneal astigmatism;
CRC	cis	rs7705042	0.828	rs1835966	chr5:141501508	C/T	cg07392085	chr5:141489673	NDFIP1	0.47	7.37	0.38	1.41e-12	Asthma;
CRC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.65	0.43	2.28e-16	Prostate cancer;
CRC	cis	rs17152411	0.947	rs61873270	chr10:126595923	C/A	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13909412	chr9:125703662	RABGAP1	0.47	6.56	0.34	2.03e-10	Response to antipsychotic treatment;
CRC	cis	rs3751196	0.901	rs55932227	chr12:104193086	T/C	cg02344784	chr12:104178138	NT5DC3	0.7	7.21	0.37	3.83e-12	Sense of smell;
CRC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg19980929	chr12:42632907	YAF2	0.42	6.29	0.33	1.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.45	-5.61	-0.3	4.26e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg00507830	chr2:103233733	NA	0.68	6.58	0.34	1.85e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.36	5.7	0.3	2.73e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	8.86e-20	Hair morphology;
CRC	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.63	9.83	0.48	3.61e-20	Corneal astigmatism;
CRC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg03623178	chr6:28175578	NA	0.46	6.47	0.34	3.65e-10	Depression;
CRC	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.44	-6.52	-0.34	2.58e-10	Rheumatoid arthritis;
CRC	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.54	-6.91	-0.36	2.6e-11	Obesity-related traits;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg25164649	chr6:28176230	NA	0.79	11.08	0.52	1.9e-24	Depression;
CRC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.82	-17.97	-0.7	8.33e-51	Breast cancer;
CRC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.6	-0.34	1.64e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7173389	1.000	rs7172808	chr15:73663632	A/G	cg01796676	chr15:73680284	NA	0.51	6.84	0.35	3.86e-11	Resting heart rate;
CRC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.5	6.23	0.32	1.43e-9	Recombination rate (females);
CRC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg20119798	chr7:94954144	PON1	-0.45	-5.67	-0.3	3.18e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg00531865	chr16:30841666	NA	-0.42	-6.09	-0.32	3.15e-9	Dementia with Lewy bodies;
CRC	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.53	9.53	0.47	3.48e-19	Common traits (Other);
CRC	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.54	6.94	0.36	2.04e-11	Alzheimer's disease (survival time);
CRC	cis	rs6662572	0.737	rs9429184	chr1:46524739	G/A	cg08644498	chr1:46502608	NA	0.46	7.32	0.37	1.96e-12	Blood protein levels;
CRC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg20129853	chr10:51489980	NA	-0.42	-7.03	-0.36	1.21e-11	Prostate-specific antigen levels;
CRC	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08877624	chr8:141521446	CHRAC1	0.38	6.24	0.33	1.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg24046110	chr8:143859143	LYNX1	0.46	7.99	0.4	2.24e-14	Urinary tract infection frequency;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02951344	chr11:85522279	SYTL2	0.36	6.2	0.32	1.66e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg13491945	chr12:107078410	RFX4	0.35	6.04	0.32	4.23e-9	Heart rate;
CRC	cis	rs10045504	0.502	rs72746038	chr5:38753999	G/A	cg15396434	chr5:38725168	NA	-0.61	-6.15	-0.32	2.24e-9	Night sleep phenotypes;
CRC	cis	rs644148	0.872	rs2686780	chr19:44974126	G/C	cg15540054	chr19:45004280	ZNF180	-0.55	-7.1	-0.36	7.5e-12	Personality dimensions;
CRC	trans	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.9e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.38	5.65	0.3	3.56e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.86	-0.35	3.35e-11	Type 2 diabetes;
CRC	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.8	-0.63	2.42e-38	Exhaled nitric oxide output;
CRC	cis	rs7550918	1	rs7550918	chr1:247675559	C/T	cg11166453	chr1:247681781	NA	-0.49	-8.97	-0.44	2.3e-17	Platelet count;
CRC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.5	-6.85	-0.35	3.72e-11	Gut microbiome composition (summer);
CRC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	9.96	0.48	1.37e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.27	0.33	1.16e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg18016565	chr1:150552671	MCL1	-0.43	-6.05	-0.32	3.98e-9	Melanoma;
CRC	cis	rs17209837	1.000	rs2072383	chr7:87081349	A/G	cg00919237	chr7:87102261	ABCB4	-0.48	-5.73	-0.3	2.31e-8	Gallbladder cancer;
CRC	trans	rs2303319	0.504	rs56145818	chr2:162403778	G/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.14	-0.32	2.44e-9	Gout;Renal underexcretion gout;
CRC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg21155852	chr7:2048760	MAD1L1	0.45	6.23	0.32	1.42e-9	Bipolar disorder;
CRC	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.28	16.24	0.67	5.85e-44	Uric acid levels;
CRC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg25456477	chr12:86230367	RASSF9	0.34	5.68	0.3	2.94e-8	Major depressive disorder;
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.03	-0.32	4.35e-9	Total body bone mineral density;
CRC	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg11579758	chr4:1086637	RNF212	0.41	6.65	0.34	1.19e-10	Recombination rate (males);
CRC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg17294928	chr15:75287854	SCAMP5	-0.43	-6.39	-0.33	5.71e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.5	-7.23	-0.37	3.31e-12	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00252654	chr19:36980732	ZNF566	0.43	6.07	0.32	3.51e-9	Response to antipsychotic treatment;
CRC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.59	9.46	0.46	6.13e-19	Height;
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.63	-8.76	-0.43	1.03e-16	Blood pressure (smoking interaction);
CRC	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg04202892	chr2:111875749	ACOXL	0.46	7.54	0.38	4.63e-13	Chronic lymphocytic leukemia;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.51	-7.53	-0.38	4.89e-13	Longevity;Endometriosis;
CRC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg05110241	chr16:68378359	PRMT7	-0.74	-7.76	-0.39	1.06e-13	Schizophrenia;
CRC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg14324370	chr2:177042789	NA	0.79	12.99	0.58	1.91e-31	IgG glycosylation;
CRC	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.49	7.61	0.39	2.96e-13	Corneal astigmatism;
CRC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.49	-7.08	-0.36	8.79e-12	Height;
CRC	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg00666640	chr1:248458726	OR2T12	0.41	7.5	0.38	5.96e-13	Common traits (Other);
CRC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.67	-10.33	-0.49	7.74e-22	Cognitive function;
CRC	cis	rs4731207	0.596	rs10274820	chr7:124629664	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.16	-0.32	2.16e-9	Cutaneous malignant melanoma;
CRC	cis	rs11750568	1.000	rs11750568	chr5:178535713	A/G	cg10208897	chr5:178548229	ADAMTS2	0.35	5.63	0.3	3.9e-8	Height;
CRC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.37e-8	Bladder cancer;
CRC	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.77	15.89	0.66	1.3e-42	Leprosy;
CRC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.84	13.32	0.59	1.18e-32	Coronary artery disease;
CRC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg11189052	chr15:85197271	WDR73	-0.63	-8.98	-0.44	2.21e-17	Schizophrenia;
CRC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg13332499	chr17:408570	NA	0.41	8.45	0.42	9.5e-16	Hip circumference adjusted for BMI;
CRC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.03	0.45	1.53e-17	Alzheimer's disease (late onset);
CRC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg08772003	chr10:104629869	AS3MT	-0.35	-6.01	-0.31	5.05e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.5	-5.89	-0.31	9.34e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	17.67	0.7	1.39e-49	Electrocardiographic conduction measures;
CRC	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.49	-0.38	6.22e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.32	5.61	0.3	4.22e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.68	-0.3	2.9e-8	Recombination rate (females);
CRC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg02269571	chr22:50332266	NA	-0.64	-8.62	-0.43	2.89e-16	Schizophrenia;
CRC	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg11900509	chr10:81946545	ANXA11	-0.65	-6.57	-0.34	1.94e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg08501292	chr6:25962987	TRIM38	0.94	8.44	0.42	1.05e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg18809830	chr7:99032528	PTCD1	-1.12	-8.14	-0.41	7.97e-15	Blood metabolite levels;
CRC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.5	8.39	0.42	1.5e-15	Coronary artery disease;
CRC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg10494257	chr1:16342123	HSPB7	0.39	5.65	0.3	3.54e-8	Systolic blood pressure;
CRC	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg10437265	chr15:77819839	NA	0.64	11.28	0.53	3.67e-25	Type 2 diabetes;
CRC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.83	-0.48	3.8e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs3823572	0.525	rs2002866	chr7:133690378	C/T	cg03336402	chr7:133662267	EXOC4	0.67	9.81	0.48	4.3e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg27170947	chr2:26402098	FAM59B	0.61	7.28	0.37	2.49e-12	Gut microbiome composition (summer);
CRC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07157834	chr1:205819609	PM20D1	0.42	5.69	0.3	2.84e-8	Parkinson's disease;
CRC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg02683197	chr6:28174875	NA	0.48	6.72	0.35	8e-11	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10173275	chr17:77783551	NA	0.38	6.11	0.32	2.74e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg11204139	chr17:3907470	NA	-0.78	-14.23	-0.62	3.89e-36	Type 2 diabetes;
CRC	cis	rs1223397	0.689	rs2439539	chr6:13308833	G/A	cg07912922	chr6:13274314	PHACTR1	0.4	6.12	0.32	2.64e-9	Blood pressure;
CRC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg00383909	chr3:49044727	WDR6	0.47	5.82	0.31	1.39e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19046167	chr17:80928561	B3GNTL1	0.52	7.25	0.37	2.97e-12	Glycated hemoglobin levels;
CRC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.48	-7.97	-0.4	2.72e-14	Coronary artery disease;
CRC	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.63	9.85	0.48	3.24e-20	Corneal astigmatism;
CRC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-10.4	-0.5	4.39e-22	Initial pursuit acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11590700	chr3:169381241	MECOM	0.47	7.35	0.38	1.54e-12	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.71	8.08	0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs7572644	0.640	rs4632296	chr2:28024984	T/C	cg27432699	chr2:27873401	GPN1	0.45	5.68	0.3	2.92e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg19622623	chr12:86230825	RASSF9	-0.37	-5.99	-0.31	5.51e-9	Major depressive disorder;
CRC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg01126855	chr4:183727586	NA	0.54	5.67	0.3	3.08e-8	Pediatric autoimmune diseases;
CRC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-9.0	-0.44	1.85e-17	Total body bone mineral density;
CRC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.48	6.53	0.34	2.43e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg20542592	chr8:11973495	FAM66D	0.32	5.62	0.3	3.98e-8	Retinal vascular caliber;
CRC	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg03162506	chr22:38580953	NA	0.28	6.02	0.32	4.63e-9	Cutaneous nevi;
CRC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.78	0.35	5.58e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.56	9.1	0.45	8.9e-18	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.6	-0.3	4.47e-8	Bladder cancer;
CRC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.78	0.66	3.68e-42	Lymphocyte percentage of white cells;
CRC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.59	8.19	0.41	5.68e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.39e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg06713098	chr7:45960367	IGFBP3	0.42	6.79	0.35	5.11e-11	Sitting height ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26397265	chr12:25348258	LYRM5;CASC1	0.46	7.78	0.39	9.71e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs11212617	0.967	rs625120	chr11:108095220	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.27	0.33	1.14e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.36	-7.57	-0.39	3.83e-13	Cutaneous nevi;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00234608	chr9:139702971	C9orf86;LOC100131193	0.37	6.02	0.31	4.63e-9	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.82	0.31	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09302848	chr2:48667639	KLRAQ1	0.48	6.87	0.35	3.31e-11	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.67	9.92	0.48	1.88e-20	Corneal astigmatism;
CRC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.66	10.26	0.49	1.28e-21	Methadone dose in opioid dependence;
CRC	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg07274523	chr3:49395745	GPX1	0.46	5.93	0.31	7.68e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.48	0.38	6.67e-13	Response to temozolomide;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17492891	chr22:41843204	TOB2	0.47	6.11	0.32	2.8e-9	Thyroid stimulating hormone;
CRC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.42	-9.05	-0.45	1.25e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.43	-0.42	1.12e-15	Monocyte percentage of white cells;
CRC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg16928487	chr17:17741425	SREBF1	0.55	9.05	0.45	1.26e-17	Total body bone mineral density;
CRC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg14541582	chr5:601475	NA	-0.33	-6.59	-0.34	1.73e-10	Obesity-related traits;
CRC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.39	-0.46	1.06e-18	Aortic root size;
CRC	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.62	10.13	0.49	3.53e-21	Subjective well-being (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	5.72	0.3	2.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.71	8.03	0.4	1.71e-14	Major depressive disorder;
CRC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.48	-7.75	-0.39	1.19e-13	Monocyte count;
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg08200770	chr17:80723486	TBCD	-0.51	-7.97	-0.4	2.67e-14	Glycated hemoglobin levels;
CRC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06505273	chr16:24850292	NA	-0.51	-6.68	-0.35	1.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg15145296	chr3:125709740	NA	-0.58	-6.77	-0.35	6.05e-11	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05448504	chr18:72924030	TSHZ1	0.43	6.07	0.32	3.5e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03662217	chr21:35747882	FAM165B	0.43	6.03	0.32	4.44e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.63	6.72	0.35	7.89e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg17085576	chr10:5658249	NA	0.48	6.83	0.35	4.23e-11	Breast cancer;
CRC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg02980000	chr4:1222292	CTBP1	0.76	8.21	0.41	5.06e-15	Systolic blood pressure;
CRC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	0.7	6.19	0.32	1.77e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4664293	0.867	rs12692562	chr2:160595710	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.27	-0.71	5.57e-52	Schizophrenia;
CRC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.5	7.74	0.39	1.26e-13	Corneal astigmatism;
CRC	cis	rs6066835	0.764	rs3091540	chr20:47391481	A/G	cg18078177	chr20:47281410	PREX1	0.69	6.14	0.32	2.39e-9	Multiple myeloma;
CRC	cis	rs4499344	0.633	rs166311	chr19:33161246	A/G	cg08127369	chr19:33164662	ANKRD27	0.39	5.93	0.31	7.51e-9	Mean platelet volume;
CRC	cis	rs10743315	0.557	rs1552750	chr12:19356505	A/T	cg02471346	chr12:19282374	PLEKHA5	0.77	6.04	0.32	4.2e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.18e-35	Mean platelet volume;
CRC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.67	-11.83	-0.55	3.89e-27	Asthma;
CRC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg21856205	chr7:94953877	PON1	-0.45	-5.89	-0.31	9.63e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.56	-0.57	8.3e-30	Blood trace element (Zn levels);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07772128	chr15:75095447	CSK	-0.38	-6.38	-0.33	6.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.57	-8.2	-0.41	5.57e-15	Menarche (age at onset);
CRC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg13753209	chr17:57696993	CLTC	0.46	5.85	0.31	1.16e-8	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16504641	chr6:137143711	PEX7	-0.4	-6.08	-0.32	3.25e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07881982	chr3:156878112	CCNL1	0.43	5.98	0.31	5.92e-9	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.67	10.11	0.49	4.23e-21	Lung cancer;
CRC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg04362960	chr10:104952993	NT5C2	0.41	5.67	0.3	3.17e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.57	8.86	0.44	5.1e-17	Endometrial cancer;
CRC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg23136738	chr11:925521	AP2A2	-0.42	-7.2	-0.37	4.09e-12	Alzheimer's disease (late onset);
CRC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.72	-0.47	8.45e-20	Heart rate;
CRC	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg07513332	chr6:167530253	CCR6	-0.46	-8.45	-0.42	9.59e-16	Primary biliary cholangitis;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg01305625	chr5:131593812	PDLIM4	0.32	5.63	0.3	3.85e-8	Blood metabolite levels;
CRC	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg27068330	chr11:65405492	SIPA1	0.45	5.89	0.31	9.73e-9	Urate levels;
CRC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.2	-24.25	-0.8	3.14e-75	IgG glycosylation;
CRC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.38	6.51	0.34	2.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6504622	0.875	rs2316330	chr17:45040032	G/T	cg16759221	chr17:45003025	GOSR2	-0.55	-8.68	-0.43	1.85e-16	Orofacial clefts;
CRC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.78	-10.56	-0.5	1.19e-22	IgG glycosylation;
CRC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg00750074	chr16:89608354	SPG7	-0.53	-8.24	-0.41	4.11e-15	Multiple myeloma (IgH translocation);
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg23887129	chr19:46234375	FBXO46	-0.43	-6.03	-0.32	4.5e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs4654899	0.714	rs12133972	chr1:21091338	A/T	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.19	-0.37	4.43e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.47	-0.34	3.57e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.55	8.77	0.44	9.71e-17	Menopause (age at onset);
CRC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.18	-0.41	6.35e-15	Bone mineral density;
CRC	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg02135003	chr7:105160482	PUS7	-0.52	-8.08	-0.41	1.22e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7932354	0.528	rs10466478	chr11:47162604	A/C	cg03339077	chr11:47165057	C11orf49	0.45	6.58	0.34	1.82e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg05527609	chr1:210001259	C1orf107	-0.48	-5.73	-0.3	2.23e-8	Red blood cell count;
CRC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.41	6.58	0.34	1.83e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	1.12	10.16	0.49	2.88e-21	Arsenic metabolism;
CRC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.25	-0.41	3.82e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13893634	chr17:48229117	PPP1R9B	-0.42	-6.41	-0.33	5.07e-10	Temporomandibular joint disorder;
CRC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.87	-0.31	1.05e-8	Carotid intima media thickness;
CRC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.74	11.31	0.53	2.74e-25	Intelligence (multi-trait analysis);
CRC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg24163568	chr5:669837	TPPP	-0.43	-6.97	-0.36	1.77e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs2637266	0.714	rs11594217	chr10:78385088	G/T	cg18941641	chr10:78392320	NA	-0.37	-6.49	-0.34	3.11e-10	Pulmonary function;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	9.35	0.46	1.35e-18	Blood protein levels;
CRC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.37	2.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.82e-9	Height;
CRC	cis	rs4731207	0.596	rs6466987	chr7:124677731	C/A	cg23710748	chr7:124431027	NA	-0.39	-6.11	-0.32	2.83e-9	Cutaneous malignant melanoma;
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg23247704	chr1:116518985	SLC22A15	-0.7	-6.04	-0.32	4.14e-9	Cognitive function;
CRC	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg06042504	chr8:55087323	NA	-0.43	-6.75	-0.35	6.71e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.56	8.42	0.42	1.16e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg26248373	chr2:1572462	NA	-0.84	-12.17	-0.56	2.14e-28	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg01483505	chr11:975446	AP2A2	0.43	6.82	0.35	4.37e-11	Alzheimer's disease (late onset);
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.57	-9.12	-0.45	7.78e-18	Electroencephalogram traits;
CRC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.12	0.32	2.69e-9	Aortic root size;
CRC	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	0.76	7.34	0.37	1.72e-12	Type 2 diabetes nephropathy;
CRC	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.59	-6.01	-0.31	4.98e-9	Vitamin D levels;
CRC	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg04132472	chr17:19861366	AKAP10	0.44	6.9	0.36	2.7e-11	Schizophrenia;
CRC	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.61	-0.3	4.35e-8	Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.03	0.32	4.35e-9	Depression;
CRC	cis	rs6662572	0.737	rs6659064	chr1:46346724	G/C	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg09476006	chr5:138032270	NA	0.45	6.9	0.36	2.69e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg09455208	chr3:40491958	NA	0.32	6.41	0.33	5.19e-10	Renal cell carcinoma;
CRC	cis	rs995000	0.931	rs1168009	chr1:62943954	G/A	cg19896129	chr1:63156450	NA	-0.39	-6.02	-0.31	4.78e-9	Triglyceride levels;
CRC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg26528668	chr16:1614120	IFT140	0.38	5.86	0.31	1.11e-8	Coronary artery disease;
CRC	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.98	0.52	4.29e-24	Bipolar disorder;
CRC	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.62	7.19	0.37	4.42e-12	Vitiligo;
CRC	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.79	-0.35	5.1e-11	Coronary artery disease;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.83	-13.34	-0.59	9.52e-33	Cognitive function;
CRC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.53	-9.35	-0.46	1.37e-18	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24515799	chr6:149867235	PPIL4	0.44	6.18	0.32	1.95e-9	Anxiety disorder;
CRC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.51	7.52	0.38	5.21e-13	Height;
CRC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg11189052	chr15:85197271	WDR73	0.58	8.57	0.43	4.05e-16	Schizophrenia;
CRC	trans	rs2303319	0.504	rs57464189	chr2:162419312	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.49	6.7	0.35	8.88e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg13010199	chr12:38710504	ALG10B	0.43	6.26	0.33	1.19e-9	Heart rate;
CRC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.66	0.3	3.28e-8	Tonsillectomy;
CRC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.9	10.55	0.5	1.36e-22	Psoriasis;
CRC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg16358738	chr2:241808595	AGXT	-0.39	-5.79	-0.3	1.68e-8	Urinary metabolites;
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg10729496	chr3:10149963	C3orf24	0.46	6.18	0.32	1.87e-9	Alzheimer's disease;
CRC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.91	16.61	0.68	1.98e-45	Intelligence (multi-trait analysis);
CRC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg20387954	chr3:183756860	HTR3D	0.44	7.55	0.38	4.43e-13	Anterior chamber depth;
CRC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg21155852	chr7:2048760	MAD1L1	-0.41	-6.01	-0.31	4.98e-9	Bipolar disorder;
CRC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.85	12.55	0.57	8.88e-30	Response to antineoplastic agents;
CRC	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.45	-6.73	-0.35	7.67e-11	Body mass index;
CRC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	1.06	12.96	0.58	2.67e-31	Iron status biomarkers;
CRC	cis	rs7113874	0.569	rs2871753	chr11:8486650	A/T	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.54	-0.47	3.3e-19	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.17	-0.32	1.99e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05142140	chr3:49055321	DALRD3	0.44	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.36	1.32e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11948739	0.501	rs971699	chr5:130361558	A/G	cg08523029	chr5:130500466	HINT1	-0.45	-5.91	-0.31	8.77e-9	Pediatric bone mineral content (hip);
CRC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg06713675	chr4:122721982	EXOSC9	-0.38	-5.88	-0.31	1.01e-8	Type 2 diabetes;
CRC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg19223190	chr17:80058835	NA	-0.42	-6.68	-0.35	1.04e-10	Life satisfaction;
CRC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.89	0.51	8.58e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.8	-0.3	1.53e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg27534772	chr1:16042836	PLEKHM2	0.42	7.07	0.36	9.23e-12	Systolic blood pressure;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg15845792	chr6:28175446	NA	0.7	7.65	0.39	2.28e-13	Parkinson's disease;
CRC	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.5	-6.8	-0.35	4.81e-11	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27366207	chr19:28287704	NA	0.43	6.57	0.34	1.95e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17783671	chr19:59070436	UBE2M;LOC100131691	0.43	6.91	0.36	2.54e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg27454412	chr7:1067447	C7orf50	0.5	5.65	0.3	3.55e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg23018236	chr17:30244563	NA	-0.61	-7.89	-0.4	4.49e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.44	8.72	0.43	1.37e-16	Alcohol dependence;
CRC	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-5.77	-0.3	1.8e-8	Mean platelet volume;
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.71	11.77	0.54	6.27e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9323205	0.634	rs56043194	chr14:51726066	A/C	cg23942311	chr14:51606299	NA	-0.52	-6.18	-0.32	1.9e-9	Cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17907730	chr7:35077704	DPY19L1	0.46	6.48	0.34	3.31e-10	Anxiety disorder;
CRC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.76	-0.35	6.48e-11	Lung cancer;
CRC	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.44	-6.49	-0.34	3.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.3	-0.42	2.81e-15	Electroencephalogram traits;
CRC	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.35	-0.33	7.13e-10	Diastolic blood pressure;
CRC	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg04586622	chr2:25135609	ADCY3	-0.43	-7.29	-0.37	2.34e-12	Body mass index;
CRC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.56	-8.77	-0.44	9.77e-17	Alzheimer's disease (late onset);
CRC	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.71	0.39	1.47e-13	Corneal astigmatism;
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.39	-6.07	-0.32	3.52e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.09	18.69	0.72	1.25e-53	Cognitive function;
CRC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg15147215	chr3:52552868	STAB1	0.51	8.9	0.44	3.79e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg01612440	chr4:3296283	NA	0.39	5.67	0.3	3.19e-8	Serum sulfate level;
CRC	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	10.05	0.48	6.62e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.23	0.37	3.31e-12	Lung cancer;
CRC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.6	9.59	0.47	2.37e-19	Tonsillectomy;
CRC	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.05	-0.48	6.56e-21	Body mass index in non-asthmatics;
CRC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.5	6.56	0.34	2.03e-10	IgG glycosylation;
CRC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg08614441	chr13:113633676	MCF2L	-0.53	-9.34	-0.46	1.48e-18	Systolic blood pressure;
CRC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.19	0.52	7.73e-25	Heart rate;
CRC	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.6	8.4	0.42	1.35e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.6	9.78	0.47	5.3e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	0.58	9.0	0.44	1.9e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6662572	0.737	rs11211247	chr1:46476587	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.18	0.32	1.94e-9	Blood protein levels;
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.43	-0.33	4.54e-10	Total body bone mineral density;
CRC	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg01426195	chr3:39028469	NA	-0.53	-8.56	-0.43	4.52e-16	Handedness;
CRC	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg00383909	chr3:49044727	WDR6	0.44	5.67	0.3	3.07e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);
CRC	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.77	8.54	0.43	4.88e-16	Eotaxin levels;
CRC	cis	rs10242455	1.000	rs28468623	chr7:98922812	C/G	cg18809830	chr7:99032528	PTCD1	-0.74	-6.39	-0.33	5.68e-10	Blood metabolite levels;
CRC	cis	rs3740540	0.530	rs4297414	chr10:126292116	T/G	cg04949429	chr10:126290192	LHPP	0.43	6.44	0.33	4.28e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	8.8	0.44	7.81e-17	Bone mineral density;
CRC	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg09873164	chr1:152488093	CRCT1	0.38	6.34	0.33	7.57e-10	Hair morphology;
CRC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg15786705	chr6:28176104	NA	0.48	7.21	0.37	3.76e-12	Cardiac Troponin-T levels;
CRC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.85	-0.31	1.16e-8	Gut microbiome composition (summer);
CRC	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg27499820	chr13:21296301	IL17D	-0.36	-5.94	-0.31	7.21e-9	Dental caries;
CRC	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg01312482	chr5:178451176	ZNF879	-0.36	-6.03	-0.32	4.3e-9	Pubertal anthropometrics;
CRC	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.37	-5.88	-0.31	1.02e-8	Breast cancer;
CRC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.52	-8.06	-0.41	1.43e-14	Body mass index;
CRC	cis	rs9359856	0.518	rs10944451	chr6:90262341	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.59	-6.83	-0.35	4.2e-11	Bipolar disorder;
CRC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg00343986	chr7:65444356	GUSB	0.47	6.95	0.36	1.99e-11	Aortic root size;
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.99	-0.4	2.25e-14	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg04204079	chr8:58130323	NA	0.42	5.62	0.3	4.18e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.45	-6.37	-0.33	6.21e-10	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.93	18.62	0.72	2.45e-53	Bone mineral density;
CRC	cis	rs61996546	0.622	rs17560717	chr15:26834211	G/C	cg15066197	chr15:26874202	GABRB3	-0.4	-5.99	-0.31	5.41e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-5.7	-0.3	2.68e-8	Menarche (age at onset);
CRC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.5	-7.47	-0.38	7.31e-13	Total body bone mineral density;
CRC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.95	0.44	2.73e-17	Schizophrenia;
CRC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.77	0.35	5.85e-11	Morning vs. evening chronotype;
CRC	cis	rs8028182	0.636	rs4545784	chr15:75755651	A/G	cg20655648	chr15:75932815	IMP3	0.42	6.39	0.33	5.72e-10	Sudden cardiac arrest;
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.22	-0.56	1.48e-28	Alzheimer's disease;
CRC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.26	0.62	2.87e-36	Chronic sinus infection;
CRC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.68	7.81	0.4	7.71e-14	Cleft lip with or without cleft palate;
CRC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.48	-7.17	-0.37	4.87e-12	Body mass index;
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.52	6.89	0.36	2.84e-11	Height;
CRC	cis	rs354225	0.554	rs10166844	chr2:54798272	T/C	cg26097391	chr2:54893211	SPTBN1	0.38	5.7	0.3	2.73e-8	Schizophrenia;
CRC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18357526	chr6:26021779	HIST1H4A	0.41	5.77	0.3	1.8e-8	Height;
CRC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg19193384	chr17:30244184	NA	-0.65	-7.58	-0.39	3.51e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9549328	0.700	rs34890317	chr13:113617245	G/C	cg24588162	chr13:113633484	MCF2L	0.36	6.49	0.34	3.22e-10	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.4	-6.95	-0.36	2e-11	Primary biliary cholangitis;
CRC	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.31	1.47e-8	Metabolite levels;
CRC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.04	-0.32	4.07e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7605827	0.897	rs1919292	chr2:15567236	A/G	cg19274914	chr2:15703543	NA	0.37	5.74	0.3	2.14e-8	Educational attainment (years of education);
CRC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.58	8.11	0.41	1.02e-14	Pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09015484	chr9:96929106	NA	0.45	6.37	0.33	6.46e-10	Response to antipsychotic treatment;
CRC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg26061582	chr7:22766209	IL6	0.49	7.62	0.39	2.76e-13	Lung cancer;
CRC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	1.04	10.29	0.49	9.91e-22	Lymphocyte counts;
CRC	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.59	8.34	0.42	2.11e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg03315344	chr16:75512273	CHST6	0.49	5.65	0.3	3.51e-8	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg23107878	chr1:152161397	NA	0.4	5.84	0.31	1.22e-8	Inflammatory skin disease;
CRC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.5	6.65	0.34	1.21e-10	IgG glycosylation;
CRC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.61	-7.97	-0.4	2.66e-14	Platelet count;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.48	-0.34	3.29e-10	Total body bone mineral density;
CRC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.44	6.17	0.32	2.01e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.48	-10.51	-0.5	1.82e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	7.9e-11	Colorectal cancer;
CRC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.58	8.71	0.43	1.55e-16	Aortic root size;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.66	9.52	0.46	3.79e-19	Lung cancer;
CRC	cis	rs72772090	0.539	rs56395748	chr5:96176893	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-5.77	-0.3	1.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00399650	chr7:141402322	KIAA1147	0.45	6.32	0.33	8.27e-10	Response to antipsychotic treatment;
CRC	cis	rs9292777	0.966	rs6861824	chr5:40432412	A/G	cg09067459	chr5:40385259	NA	0.51	8.91	0.44	3.5e-17	Crohn's disease;Multiple sclerosis;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.56	-8.06	-0.41	1.45e-14	Menopause (age at onset);
CRC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.38	-6.55	-0.34	2.24e-10	Height;
CRC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg11861562	chr11:117069780	TAGLN	0.26	5.89	0.31	9.34e-9	Blood protein levels;
CRC	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-7.55	-0.38	4.42e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs17443541	0.516	rs1450569	chr2:200443111	A/T	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.79	0.39	8.74e-14	Height;
CRC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg00484396	chr16:3507460	NAT15	-0.6	-6.09	-0.32	3.2e-9	Tuberculosis;
CRC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.61	-7.16	-0.37	5.28e-12	Type 2 diabetes nephropathy;
CRC	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.71	11.65	0.54	1.7e-26	Gut microbiome composition (winter);
CRC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.41	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.62	7.11	0.36	7.24e-12	Resting heart rate;
CRC	cis	rs4926298	1.000	rs11085829	chr19:13174312	G/A	cg11738485	chr19:12877000	HOOK2	-0.43	-5.93	-0.31	7.58e-9	Bipolar disorder;
CRC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.17	-0.45	5.38e-18	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg18187862	chr3:45730750	SACM1L	0.46	6.63	0.34	1.35e-10	Primary sclerosing cholangitis;
CRC	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.59	-10.45	-0.5	2.99e-22	Asthma;
CRC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg25804541	chr17:80189381	SLC16A3	0.32	6.12	0.32	2.72e-9	Life satisfaction;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02725872	chr8:58115012	NA	-0.51	-7.09	-0.36	8.18e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.63	5.85	0.31	1.2e-8	Body mass index;
CRC	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg01843034	chr6:37503916	NA	-0.41	-7.59	-0.39	3.3e-13	Cognitive performance;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.7	-0.54	1.11e-26	Alzheimer's disease;
CRC	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.84	-12.01	-0.55	8.64e-28	Platelet distribution width;
CRC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.63	-0.47	1.62e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg04202892	chr2:111875749	ACOXL	0.43	6.97	0.36	1.74e-11	Chronic lymphocytic leukemia;
CRC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.63	-10.27	-0.49	1.2e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.39	6.13	0.32	2.57e-9	Recombination rate (males);
CRC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.93	-0.31	7.87e-9	Major depressive disorder;
CRC	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg15192750	chr16:69999425	NA	0.56	7.44	0.38	9.02e-13	IgE levels;
CRC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.68	10.55	0.5	1.34e-22	Diastolic blood pressure;
CRC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.72	14.34	0.62	1.46e-36	Leprosy;
CRC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.83	12.53	0.57	1.06e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.83	-11.28	-0.53	3.7e-25	Initial pursuit acceleration;
CRC	cis	rs6504340	0.793	rs12946855	chr17:46608030	G/A	cg04904318	chr17:46607828	HOXB1	-0.54	-6.63	-0.34	1.37e-10	Primary tooth development (number of teeth);
CRC	trans	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg18187862	chr3:45730750	SACM1L	-0.49	-6.74	-0.35	7.05e-11	Primary sclerosing cholangitis;
CRC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.67	8.88	0.44	4.54e-17	Morning vs. evening chronotype;
CRC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.24	0.45	3.24e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11837864	chr2:220043521	FAM134A	0.5	6.8	0.35	4.82e-11	Thyroid stimulating hormone;
CRC	cis	rs6764363	0.733	rs193071	chr3:294358	A/C	cg02057681	chr3:285234	CHL1	-0.36	-5.94	-0.31	7.14e-9	Sudden cardiac arrest;
CRC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.46	-6.69	-0.35	9.71e-11	Menarche (age at onset);
CRC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg00769240	chr8:12517080	NA	-0.54	-6.72	-0.35	8.02e-11	Blood pressure (smoking interaction);
CRC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg05709478	chr1:6581295	PLEKHG5	0.56	6.08	0.32	3.27e-9	Body mass index;
CRC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg03623178	chr6:28175578	NA	0.86	13.64	0.6	7.14e-34	Cardiac Troponin-T levels;
CRC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs2802369	1	rs2802369	chr10:80960828	C/A	cg18737081	chr10:80999807	ZMIZ1	-0.34	-6.03	-0.32	4.52e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	15.64	0.65	1.34e-41	Bipolar disorder;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg02683197	chr6:28174875	NA	0.7	9.75	0.47	6.54e-20	Cardiac Troponin-T levels;
CRC	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.61	8.8	0.44	7.61e-17	Schizophrenia;
CRC	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs73206853	0.688	rs55805203	chr12:110819142	G/T	cg12870014	chr12:110450643	ANKRD13A	0.78	7.41	0.38	1.07e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	0.73	6.08	0.32	3.38e-9	Type 2 diabetes nephropathy;
CRC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.58	-9.69	-0.47	1.08e-19	Schizophrenia;
CRC	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg04850286	chr10:81895943	PLAC9	-0.38	-6.8	-0.35	4.94e-11	Sarcoidosis;
CRC	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg17470449	chr10:769945	NA	0.58	7.88	0.4	4.89e-14	Uric acid levels;
CRC	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.79	-0.35	5.33e-11	Inflammatory skin disease;
CRC	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.5	0.38	6.05e-13	Coronary artery disease;
CRC	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.44	-8.03	-0.4	1.74e-14	Reticulocyte fraction of red cells;
CRC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.51	-0.34	2.73e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg02741985	chr17:80059408	CCDC57	-0.43	-5.81	-0.31	1.46e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.41	-0.42	1.31e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3804749	0.966	rs726681	chr3:122837648	C/T	cg26084141	chr3:122786895	PDIA5	0.22	6.11	0.32	2.78e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg12573674	chr2:1569213	NA	-0.76	-7.84	-0.4	6.48e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.58	10.26	0.49	1.35e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.48	7.57	0.39	3.85e-13	Uric acid clearance;
CRC	trans	rs1979967	0.524	rs8034825	chr15:79655761	A/G	cg14802097	chr12:42970349	PRICKLE1	0.51	6.02	0.31	4.69e-9	Interleukin-18 levels;
CRC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.99e-9	Aortic root size;
CRC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-8.0	-0.4	2.17e-14	Pancreatic cancer;
CRC	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg17674042	chr6:34482479	PACSIN1	-0.63	-7.45	-0.38	8.35e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.97	-0.36	1.77e-11	IgG glycosylation;
CRC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.63	-0.3	3.89e-8	Lung cancer;
CRC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.01	0.4	2.07e-14	Resting heart rate;
CRC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg10298567	chr3:47292165	KIF9	-0.37	-5.88	-0.31	1.01e-8	Colorectal cancer;
CRC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.45	-8.23	-0.41	4.4e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs965469	0.947	rs6051692	chr20:3244098	T/C	cg25506879	chr20:3388711	C20orf194	-0.38	-5.68	-0.3	2.94e-8	IFN-related cytopenia;
CRC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	13.76	0.6	2.45e-34	Menarche (age at onset);
CRC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.53	-0.38	4.79e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg01251360	chr16:68772225	CDH1	-0.23	-5.68	-0.3	2.91e-8	Colorectal cancer;
CRC	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.6	-0.43	3.27e-16	Coffee consumption (cups per day);
CRC	cis	rs41005	1.000	rs41003	chr2:8111772	A/C	cg03155496	chr2:8117019	LOC339788	0.4	7.11	0.36	7.35e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg22777020	chr22:31556080	RNF185	0.53	6.25	0.33	1.25e-9	Colorectal cancer;
CRC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.79	10.89	0.51	8.5e-24	Cognitive function;
CRC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07294406	chr7:64700536	NA	0.35	5.69	0.3	2.87e-8	Calcium levels;
CRC	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.42	-0.33	4.73e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.72	-12.82	-0.58	8.7e-31	Inhibitory control;
CRC	cis	rs9928842	0.765	rs6564220	chr16:75224194	T/C	cg09066997	chr16:75300724	BCAR1	0.65	6.14	0.32	2.33e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.22e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.71	0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.21	-0.32	1.56e-9	Menopause (age at onset);
CRC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.47	-6.94	-0.36	2.05e-11	IgG glycosylation;
CRC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.83	14.57	0.63	1.95e-37	Breast cancer;
CRC	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg12560992	chr17:57184187	TRIM37	0.56	7.64	0.39	2.46e-13	Testicular germ cell tumor;
CRC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.82	-11.99	-0.55	1.01e-27	Mean platelet volume;Platelet distribution width;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14886145	chr10:74451829	CCDC109A	0.44	6.37	0.33	6.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.33	0.33	8.02e-10	Bladder cancer;
CRC	cis	rs8066384	1	rs8066384	chr17:78625756	T/C	cg16591659	chr17:78472290	NA	-0.41	-6.09	-0.32	3.1e-9	Schizophrenia;
CRC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.15	-0.32	2.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg22561889	chr6:118971681	C6orf204	0.5	6.39	0.33	5.81e-10	Diastolic blood pressure;
CRC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg12193833	chr17:30244370	NA	-0.57	-8.0	-0.4	2.11e-14	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg23123621	chr4:1343375	KIAA1530	0.32	5.68	0.3	2.92e-8	Obesity-related traits;
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg25164649	chr6:28176230	NA	0.72	7.25	0.37	2.94e-12	Depression;
CRC	cis	rs4925540	0.724	rs4971301	chr1:247172140	G/C	cg22502715	chr1:247171572	ZNF695	0.41	6.07	0.32	3.46e-9	Response to taxane treatment (docetaxel);
CRC	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg11822372	chr1:151115635	SEMA6C	0.53	7.59	0.39	3.39e-13	Childhood ear infection;
CRC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.6e-39	Lymphocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06431905	chr5:148931119	CSNK1A1	0.41	6.49	0.34	3.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs965469	1.000	rs6037579	chr20:3347980	G/A	cg25506879	chr20:3388711	C20orf194	-0.39	-5.62	-0.3	4.02e-8	IFN-related cytopenia;
CRC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06636001	chr8:8085503	FLJ10661	0.47	5.8	0.3	1.53e-8	Obesity-related traits;
CRC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.45	6.87	0.35	3.22e-11	Platelet count;
CRC	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg09659197	chr4:152720779	NA	0.5	10.63	0.51	6.99e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-15.22	-0.64	5.69e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.29	-0.37	2.32e-12	Type 2 diabetes;
CRC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.36	-0.56	4.47e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs7605827	0.930	rs6431706	chr2:15600019	C/T	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.58e-9	Educational attainment (years of education);
CRC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.63	-0.43	2.57e-16	Platelet count;
CRC	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.7	12.79	0.58	1.13e-30	Hip circumference;
CRC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.43	6.27	0.33	1.15e-9	Obesity-related traits;
CRC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.04	21.13	0.76	3.18e-63	Testicular germ cell tumor;
CRC	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg23254163	chr1:152506842	NA	0.38	6.55	0.34	2.28e-10	Hair morphology;
CRC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.82	15.1	0.64	1.61e-39	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-9.23	-0.45	3.5e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.8	-10.88	-0.51	9.63e-24	Initial pursuit acceleration;
CRC	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-7.51	-0.38	5.79e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg00691999	chr4:55094011	PDGFRA	0.45	6.47	0.34	3.57e-10	Corneal astigmatism;
CRC	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	6.47	0.34	3.49e-10	Lymphocyte counts;
CRC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.08	-0.45	1.04e-17	Migraine;Coronary artery disease;
CRC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.55	8.16	0.41	7.26e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9659323	0.931	rs113197996	chr1:119522426	G/A	cg26570165	chr1:119541833	NA	-0.37	-6.21	-0.32	1.64e-9	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10524192	chr9:34637478	SIGMAR1	0.47	6.6	0.34	1.66e-10	Anxiety disorder;
CRC	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.81	-0.4	7.95e-14	Homocysteine levels;
CRC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.63	11.49	0.54	6.33e-26	Bone mineral density;
CRC	cis	rs3924048	0.547	rs72642661	chr1:12612873	C/G	cg00291366	chr1:12616550	NA	0.59	10.73	0.51	3.06e-23	Optic cup area;
CRC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.69	11.6	0.54	2.49e-26	Lung cancer;
CRC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10802521	chr3:52805072	NEK4	0.48	6.8	0.35	4.98e-11	Bipolar disorder;
CRC	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.59	9.57	0.47	2.62e-19	Migraine;
CRC	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.71	11.12	0.52	1.28e-24	Neurofibrillary tangles;
CRC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-8.16	-0.41	7.25e-15	IgG glycosylation;
CRC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.51	5.79	0.3	1.64e-8	Menarche (age at onset);
CRC	cis	rs972578	1.000	rs2284098	chr22:43401772	A/G	cg01576275	chr22:43409880	NA	-0.49	-8.14	-0.41	8.5e-15	Mean platelet volume;
CRC	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.48	-7.36	-0.38	1.47e-12	HDL cholesterol;
CRC	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	0.65	9.87	0.48	2.72e-20	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.44	5.73	0.3	2.3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	9.52	0.46	3.89e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg15845792	chr6:28175446	NA	0.74	7.78	0.39	9.45e-14	Depression;
CRC	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.98	-19.23	-0.73	8.84e-56	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03341697	chr11:94277138	FUT4	0.47	5.99	0.31	5.56e-9	Thyroid stimulating hormone;
CRC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.77	-10.93	-0.52	6.15e-24	Intelligence (multi-trait analysis);
CRC	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.58	-6.45	-0.34	3.96e-10	Blood protein levels;
CRC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs67981189	0.529	rs8181986	chr14:71582244	G/A	cg15910301	chr14:71632612	NA	0.31	6.06	0.32	3.78e-9	Schizophrenia;
CRC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.88	0.31	1.02e-8	Total body bone mineral density;
CRC	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg14003231	chr6:33640908	ITPR3	0.46	7.5	0.38	6.17e-13	Plateletcrit;
CRC	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg06470822	chr6:28175283	NA	0.69	6.48	0.34	3.33e-10	Depression;
CRC	cis	rs11166629	1.000	rs4909330	chr8:135644369	T/C	cg27224718	chr8:135614730	ZFAT	0.52	7.68	0.39	1.82e-13	Smoking quantity;
CRC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg05941027	chr17:61774174	LIMD2	0.37	6.71	0.35	8.59e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs35771425	0.619	rs6689078	chr1:211476423	C/G	cg25617285	chr1:211431773	RCOR3	-0.39	-5.61	-0.3	4.39e-8	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27583997	chr6:64346064	NA	0.43	5.96	0.31	6.38e-9	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg03037974	chr15:76606532	NA	0.66	11.45	0.53	8.74e-26	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23365554	chr19:54975006	LENG9	0.42	5.98	0.31	5.7e-9	Response to antipsychotic treatment;
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg20041105	chr8:143859282	LYNX1	0.46	8.2	0.41	5.52e-15	Urinary tract infection frequency;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05902063	chr12:96794315	CDK17	0.34	6.1	0.32	2.94e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg11833968	chr6:79620685	NA	-0.36	-6.37	-0.33	6.31e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-8.65	-0.43	2.38e-16	Menarche (age at onset);
CRC	cis	rs6496667	0.865	rs12592226	chr15:90926190	C/T	cg04176472	chr15:90893244	GABARAPL3	0.58	7.51	0.38	5.73e-13	Rheumatoid arthritis;
CRC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg10790698	chr19:18539756	SSBP4	-0.46	-8.81	-0.44	7.26e-17	Breast cancer;
CRC	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.55	9.38	0.46	1.1e-18	Common traits (Other);
CRC	trans	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg17712092	chr4:129076599	LARP1B	-0.49	-7.33	-0.37	1.77e-12	Eosinophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00218620	chr2:219866460	MIR375	0.42	6.95	0.36	1.93e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7610312	0.681	rs7610449	chr3:58319958	G/A	cg06643156	chr3:58380774	PXK	-0.39	-5.63	-0.3	3.78e-8	Red blood cell count;
CRC	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.27	-0.56	9.46e-29	Idiopathic membranous nephropathy;
CRC	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg00579200	chr11:133705235	NA	0.41	5.83	0.31	1.29e-8	Childhood ear infection;
CRC	cis	rs501120	0.584	rs11238925	chr10:44703730	A/G	cg09554077	chr10:44749378	NA	0.67	7.47	0.38	7.27e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.17	-0.32	2.03e-9	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg02683197	chr6:28174875	NA	-0.87	-10.47	-0.5	2.53e-22	Depression;
CRC	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg06042504	chr8:55087323	NA	-0.44	-6.86	-0.35	3.42e-11	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05790999	chr2:20850809	HS1BP3	0.38	6.11	0.32	2.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.46	7.44	0.38	8.89e-13	Brain structure;
CRC	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.63	-6.5	-0.34	2.97e-10	Pediatric areal bone mineral density (radius);
CRC	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.92	-0.31	8.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.66	8.79	0.44	8.33e-17	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26303861	chr1:20988122	DDOST	0.38	6.02	0.31	4.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.55	0.34	2.2e-10	Lung cancer;
CRC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.27	0.33	1.13e-9	Aortic root size;
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg09877947	chr5:131593287	PDLIM4	0.46	8.47	0.42	8.27e-16	Breast cancer;
CRC	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.61	9.58	0.47	2.38e-19	Corneal astigmatism;
CRC	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-5.63	-0.3	3.87e-8	Pulmonary function;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg23088508	chr4:20729211	PACRGL	-0.54	-6.11	-0.32	2.85e-9	Plasma thyroid-stimulating hormone levels;
CRC	trans	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.58	0.39	3.52e-13	Endometrial cancer;
CRC	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.61	-8.41	-0.42	1.24e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.42	6.11	0.32	2.89e-9	Blood metabolite levels;
CRC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	7.13	0.37	6.31e-12	Lung cancer;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg02869364	chr7:1081709	C7orf50	-0.43	-6.95	-0.36	1.95e-11	Longevity;Endometriosis;
CRC	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.69e-9	Corneal astigmatism;
CRC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	1.06	10.39	0.5	4.64e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.38	-6.25	-0.33	1.24e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg00127047	chr5:142150919	ARHGAP26	0.51	6.28	0.33	1.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs9658691	0.920	rs72809352	chr10:90742624	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-6.3	-0.33	9.75e-10	Mosquito bite size;
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.45	0.34	3.95e-10	Life satisfaction;
CRC	cis	rs77861329	0.669	rs2878438	chr3:52103045	A/G	cg08692210	chr3:52188851	WDR51A	0.54	6.35	0.33	7.31e-10	Macrophage inflammatory protein 1b levels;
CRC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg22532475	chr10:104410764	TRIM8	0.34	5.8	0.3	1.58e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.32	4.59e-9	Parkinson's disease;
CRC	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg18385501	chr17:73401976	GRB2	-0.43	-6.04	-0.32	4.17e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs2708977	0.692	rs17685766	chr2:97319534	G/C	cg01950434	chr2:97203154	ARID5A	0.48	6.74	0.35	7.1e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.63	0.34	1.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.42	0.42	1.2e-15	Colorectal cancer;
CRC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13198984	chr17:80129470	CCDC57	-0.45	-8.04	-0.41	1.63e-14	Life satisfaction;
CRC	cis	rs2036402	1.000	rs12515585	chr5:156430150	A/G	cg21915449	chr5:156456672	HAVCR1	-0.46	-5.62	-0.3	3.99e-8	Hypertriglyceridemia;
CRC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.72	0.68	7.62e-46	Platelet count;
CRC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.51	8.35	0.42	1.88e-15	Aortic root size;
CRC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.97	-18.93	-0.72	1.36e-54	Height;
CRC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.43	5.84	0.31	1.22e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.44	8.08	0.41	1.28e-14	Childhood ear infection;
CRC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg00334542	chr7:100209784	MOSPD3	-0.68	-8.02	-0.4	1.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs4073416	0.542	rs10145146	chr14:66075004	C/T	cg03016385	chr14:66212404	NA	-0.45	-6.17	-0.32	2.05e-9	N-glycan levels;
CRC	cis	rs10128264	0.934	rs1250590	chr10:80983786	A/C	cg18737081	chr10:80999807	ZMIZ1	0.38	6.75	0.35	6.52e-11	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.44	-8.0	-0.4	2.15e-14	Huntington's disease progression;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-10.04	-0.48	7.46e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.63	-9.23	-0.45	3.36e-18	Subjective well-being;
CRC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.79	14.73	0.63	4.42e-38	Prudent dietary pattern;
CRC	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg25856811	chr1:152973957	SPRR3	-0.27	-7.37	-0.38	1.43e-12	Inflammatory skin disease;
CRC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-16.81	-0.68	3.37e-46	Intelligence (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09423994	chr12:56660919	COQ10A	0.39	6.04	0.32	4.15e-9	Schizophrenia;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.44	-6.92	-0.36	2.31e-11	C-reactive protein levels;
CRC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.77	10.66	0.51	5.37e-23	Orofacial clefts;
CRC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs6840360	0.573	rs7692939	chr4:152258455	C/T	cg09659197	chr4:152720779	NA	0.33	6.47	0.34	3.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.39	6.13	0.32	2.58e-9	Recombination rate (males);
CRC	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg27411982	chr8:10470053	RP1L1	0.37	5.82	0.31	1.42e-8	Neuroticism;
CRC	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg09127314	chr1:152161683	NA	0.46	5.85	0.31	1.17e-8	Atopic dermatitis;
CRC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06544989	chr22:39130855	UNC84B	-0.45	-6.64	-0.34	1.32e-10	Menopause (age at onset);
CRC	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg11003573	chr3:44754125	ZNF502	-0.33	-5.68	-0.3	2.97e-8	Depressive symptoms;
CRC	trans	rs7604735	0.824	rs1881409	chr2:145821520	A/G	cg26010734	chr19:15344046	EPHX3	-0.36	-6.25	-0.33	1.29e-9	Coronary artery disease;
CRC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.65	8.97	0.44	2.25e-17	Morning vs. evening chronotype;
CRC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.66	11.46	0.53	8.58e-26	Glycated hemoglobin levels;
CRC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.77	0.51	2.22e-23	Hip circumference adjusted for BMI;
CRC	cis	rs4743820	0.651	rs73494917	chr9:93923120	T/G	cg14446406	chr9:93919335	NA	0.81	14.88	0.63	1.24e-38	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.79	12.04	0.55	6.69e-28	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	6.14	0.32	2.33e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	8.08	0.41	1.28e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.58	-8.49	-0.42	7.15e-16	Autism;
CRC	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.56	9.68	0.47	1.19e-19	Prevalent atrial fibrillation;
CRC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.44	-8.13	-0.41	8.67e-15	Reticulocyte fraction of red cells;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg19025524	chr12:109796872	NA	-0.45	-5.96	-0.31	6.61e-9	Neuroticism;
CRC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-1.04	-21.1	-0.76	4.07e-63	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.73	11.63	0.54	1.98e-26	Myeloid white cell count;
CRC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.56	8.62	0.43	2.81e-16	Breast cancer;
CRC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-7.62	-0.39	2.66e-13	Vitiligo;
CRC	cis	rs2013441	1.000	rs2703802	chr17:20101039	T/C	cg13482628	chr17:19912719	NA	-0.41	-6.22	-0.32	1.48e-9	Obesity-related traits;
CRC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.43	-5.62	-0.3	4.05e-8	Visceral fat;
CRC	cis	rs7635838	0.859	rs6779840	chr3:11425423	A/G	cg00170343	chr3:11313890	ATG7	0.42	6.33	0.33	8.01e-10	HDL cholesterol;
CRC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg00129232	chr17:37814104	STARD3	-0.5	-6.18	-0.32	1.94e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs1515184	chr2:162561347	A/G	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.11	0.45	8.31e-18	Mean platelet volume;
CRC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.15	-0.41	7.48e-15	Morning vs. evening chronotype;
CRC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-8.27	-0.41	3.35e-15	Systemic lupus erythematosus;
CRC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.4	-7.18	-0.37	4.65e-12	Monocyte count;
CRC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.55	8.92	0.44	3.38e-17	Type 2 diabetes;
CRC	cis	rs10512697	0.655	rs13166953	chr5:3472213	A/G	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg24675056	chr1:15929824	NA	0.54	7.17	0.37	5.01e-12	Systolic blood pressure;
CRC	cis	rs73206853	0.764	rs16940881	chr12:110937818	G/C	cg12870014	chr12:110450643	ANKRD13A	0.84	9.78	0.47	5.3e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg20243544	chr17:37824526	PNMT	0.44	6.83	0.35	4.21e-11	Self-reported allergy;
CRC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.84	-0.35	3.78e-11	Aortic root size;
CRC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.89	-0.31	9.39e-9	Cognitive function;
CRC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.57	0.34	1.94e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg00646200	chr1:148855367	NA	0.33	5.98	0.31	5.68e-9	Hip geometry;
CRC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg19223190	chr17:80058835	NA	0.43	6.93	0.36	2.16e-11	Life satisfaction;
CRC	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg09127314	chr1:152161683	NA	-0.45	-5.86	-0.31	1.14e-8	Atopic dermatitis;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.43	-6.29	-0.33	1.03e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00338735	chr4:53728038	RASL11B	0.37	6.15	0.32	2.27e-9	Optic nerve measurement (cup area);
CRC	cis	rs375066	0.935	rs396973	chr19:44399306	C/T	cg12072164	chr19:44306565	LYPD5	-0.37	-5.68	-0.3	2.93e-8	Breast cancer;
CRC	cis	rs4728302	0.869	rs13221033	chr7:133617487	T/A	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.83e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23104823	chr14:45553408	PRPF39	0.5	7.24	0.37	3.18e-12	Response to antipsychotic treatment;
CRC	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.62	-9.92	-0.48	1.77e-20	Breast cancer;
CRC	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.11	9.49	0.46	4.91e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg02569458	chr12:86230093	RASSF9	0.4	6.78	0.35	5.53e-11	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.79e-16	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24865406	chr1:230203041	GALNT2	0.36	5.97	0.31	6.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.35	0.46	1.35e-18	Coffee consumption (cups per day);
CRC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.67	8.07	0.41	1.36e-14	Gut microbiome composition (summer);
CRC	cis	rs8014671	0.553	rs2877661	chr14:70916559	G/T	cg25576086	chr14:70833871	SYNJ2BP	-0.34	-5.81	-0.31	1.46e-8	Prostate cancer;
CRC	cis	rs9549328	0.544	rs66893681	chr13:113617499	A/G	cg24588162	chr13:113633484	MCF2L	0.36	6.52	0.34	2.68e-10	Systolic blood pressure;
CRC	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.45	-0.38	8.03e-13	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.51	8.36	0.42	1.78e-15	Thyroid hormone levels;
CRC	cis	rs7487075	1.000	rs12832425	chr12:46822818	A/T	cg22049899	chr12:47219821	SLC38A4	0.31	6.02	0.32	4.63e-9	Itch intensity from mosquito bite;
CRC	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg02569458	chr12:86230093	RASSF9	0.37	6.42	0.33	4.74e-10	Major depressive disorder;
CRC	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg00186954	chr11:8933980	ST5;C11orf17	0.44	6.6	0.34	1.66e-10	Hemoglobin concentration;
CRC	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg05585544	chr11:47624801	NA	-0.4	-6.35	-0.33	7.06e-10	Mean corpuscular hemoglobin;
CRC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.9	0.36	2.73e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	11.03	0.52	2.86e-24	Coronary artery disease;
CRC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.24	0.33	1.32e-9	Bladder cancer;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07513332	chr6:167530253	CCR6	0.36	5.65	0.3	3.42e-8	Crohn's disease;
CRC	cis	rs9494145	0.567	rs35786788	chr6:135419042	G/A	cg22676075	chr6:135203613	NA	0.57	7.19	0.37	4.42e-12	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg17885791	chr6:149771845	ZC3H12D	-0.32	-5.77	-0.3	1.85e-8	Dupuytren's disease;
CRC	trans	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.4	-6.18	-0.32	1.88e-9	Mean corpuscular volume;
CRC	trans	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg09070855	chr12:133302174	NA	0.4	6.08	0.32	3.4e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs1619661	0.530	rs1509929	chr10:44682829	A/C	cg09554077	chr10:44749378	NA	0.47	7.12	0.37	6.99e-12	QT interval (ambient particulate matter interaction);
CRC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.96	0.4	2.75e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.79	0.35	5.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.41	-5.67	-0.3	3.13e-8	Corneal structure;
CRC	cis	rs972578	0.791	rs713776	chr22:43396094	A/G	cg01576275	chr22:43409880	NA	-0.39	-6.13	-0.32	2.48e-9	Mean platelet volume;
CRC	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.52	9.16	0.45	5.86e-18	Common traits (Other);
CRC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.12	0.49	3.9e-21	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.8	-11.03	-0.52	2.89e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4363385	0.818	rs11205164	chr1:152986023	A/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.82	-12.37	-0.56	4.14e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62187571	chr2:162374319	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.11	-0.32	2.75e-9	Cognitive function;
CRC	cis	rs7595037	0.663	rs7421075	chr2:68656342	T/C	cg12452813	chr2:68675892	NA	-0.43	-6.38	-0.33	5.96e-10	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25369027	chr8:103666178	KLF10	0.46	6.37	0.33	6.38e-10	Response to antipsychotic treatment;
CRC	trans	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg03060546	chr3:49711283	APEH	-0.56	-6.14	-0.32	2.37e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6743376	0.556	rs1530548	chr2:113817402	G/A	cg09040174	chr2:113837401	NA	0.44	6.43	0.33	4.61e-10	Inflammatory biomarkers;
CRC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg24920358	chr1:40204285	PPIE	0.56	8.37	0.42	1.62e-15	Blood protein levels;
CRC	cis	rs9392556	0.600	rs2326408	chr6:4119516	A/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.24	5.92	0.31	8.27e-9	Blood metabolite levels;
CRC	cis	rs7849270	0.959	rs2297111	chr9:131904294	G/A	cg13538475	chr9:131942899	NA	-0.31	-6.27	-0.33	1.15e-9	Blood metabolite ratios;
CRC	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	6.8	0.35	5e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg16606324	chr3:10149918	C3orf24	0.7	9.74	0.47	7.03e-20	Alzheimer's disease;
CRC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg05623727	chr3:50126028	RBM5	-0.45	-7.46	-0.38	7.82e-13	Menarche (age at onset);
CRC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg13206674	chr6:150067644	NUP43	0.48	6.82	0.35	4.48e-11	Testicular germ cell tumor;
CRC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.51	8.08	0.41	1.26e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg09264619	chr17:80180166	NA	0.49	6.97	0.36	1.73e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6433857	0.536	rs12474658	chr2:181352992	G/T	cg23363182	chr2:181467187	NA	-0.54	-8.13	-0.41	8.84e-15	Body mass index;
CRC	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.5	7.61	0.39	2.92e-13	Testicular germ cell tumor;
CRC	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-7.67	-0.39	2.01e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg17385448	chr1:15911702	AGMAT	0.29	5.84	0.31	1.22e-8	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25568297	chr16:30077541	ALDOA	0.46	6.56	0.34	2.1e-10	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.78	10.69	0.51	4.36e-23	Cognitive function;
CRC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.64	6.78	0.35	5.59e-11	Chronic lymphocytic leukemia;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs3751196	0.708	rs55810720	chr12:104188770	A/G	cg02344784	chr12:104178138	NT5DC3	0.69	7.05	0.36	1.06e-11	Sense of smell;
CRC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.56	9.16	0.45	5.74e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.46	6.11	0.32	2.86e-9	HDL cholesterol;
CRC	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.93	0.4	3.38e-14	Intelligence (multi-trait analysis);
CRC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.88	-0.35	2.99e-11	Breast cancer;
CRC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.42	-8.01	-0.4	2.06e-14	Prostate cancer;
CRC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.79	14.51	0.62	3.29e-37	Metabolic syndrome;
CRC	cis	rs7680126	0.633	rs17389602	chr4:10206926	T/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-6.56	-0.34	2.06e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg18288967	chr1:45987694	PRDX1	0.67	6.68	0.35	1.03e-10	Obesity-related traits;
CRC	cis	rs9925964	0.967	rs749767	chr16:31124407	C/T	cg03418659	chr16:31128414	MYST1	-0.53	-7.78	-0.39	9.39e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.42	-20.11	-0.74	3.29e-59	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.75	-0.54	7.67e-27	Alzheimer's disease;
CRC	cis	rs10512697	0.655	rs35450818	chr5:3491486	T/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.5e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.44	0.46	6.92e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	5.75	0.3	2.04e-8	Bipolar disorder;
CRC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.69	-13.61	-0.6	8.87e-34	Educational attainment;
CRC	cis	rs7692995	1.000	rs2085683	chr4:18007435	C/G	cg08925142	chr4:18023851	LCORL	-0.55	-6.06	-0.32	3.73e-9	Height;
CRC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg14122633	chr5:456516	EXOC3	-0.4	-7.17	-0.37	5e-12	Cystic fibrosis severity;
CRC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.54	-0.43	4.97e-16	Platelet count;
CRC	cis	rs12550646	0.600	rs10089948	chr8:41672453	C/T	cg12180191	chr8:41686706	ANK1	0.45	6.89	0.35	2.92e-11	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	trans	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg23387109	chr10:94051229	MARCH5;CPEB3	0.47	6.19	0.32	1.78e-9	Extraversion;
CRC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.31e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg04611788	chr3:186434169	KNG1	-0.58	-8.36	-0.42	1.79e-15	Adiponectin levels;
CRC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.56	7.93	0.4	3.57e-14	Lung cancer;
CRC	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg16928487	chr17:17741425	SREBF1	-0.46	-7.89	-0.4	4.56e-14	Total body bone mineral density;
CRC	cis	rs4356975	0.545	rs35297888	chr4:69949573	G/A	cg25583503	chr4:69962676	UGT2B7	-0.31	-5.68	-0.3	2.92e-8	Obesity-related traits;
CRC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg01420254	chr6:26195488	NA	0.79	8.86	0.44	5.19e-17	Gout;Renal underexcretion gout;
CRC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs427941	0.703	rs201456	chr7:101741059	C/G	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.7	7.61	0.39	2.85e-13	Breast cancer;
CRC	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24308560	chr3:49941425	MST1R	0.43	6.68	0.35	1.04e-10	Body mass index;
CRC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg01392867	chr16:30410429	ZNF48	-0.4	-5.84	-0.31	1.26e-8	Tonsillectomy;
CRC	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.65	-10.44	-0.5	3.23e-22	Hepatocellular carcinoma;
CRC	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.05	-0.32	4.03e-9	Axial length;
CRC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg05044414	chr3:183734942	ABCC5	0.48	8.31	0.42	2.56e-15	Anterior chamber depth;
CRC	cis	rs12431939	0.626	rs7160810	chr14:51716467	G/A	cg23942311	chr14:51606299	NA	0.54	6.95	0.36	1.93e-11	Cancer;
CRC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.73	9.51	0.46	4.11e-19	Cleft lip with or without cleft palate;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.38	-0.33	5.88e-10	Height;
CRC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.91	9.42	0.46	7.94e-19	Arsenic metabolism;
CRC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg15445000	chr17:37608096	MED1	0.36	6.27	0.33	1.14e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs7605827	0.930	rs11676198	chr2:15603097	G/A	cg19274914	chr2:15703543	NA	0.39	6.01	0.31	4.96e-9	Educational attainment (years of education);
CRC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.42e-8	Bladder cancer;
CRC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.94	0.48	1.52e-20	Cognitive test performance;
CRC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg12437481	chr16:420112	MRPL28	-0.65	-8.86	-0.44	4.97e-17	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.64	8.12	0.41	9.7e-15	Cocaine dependence;
CRC	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.76	-0.43	1.05e-16	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27150171	chr12:49961253	MCRS1	0.44	6.12	0.32	2.61e-9	Response to antipsychotic treatment;
CRC	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.37	-0.38	1.43e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.43	6.18	0.32	1.94e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.36	-5.81	-0.31	1.48e-8	High light scatter reticulocyte count;
CRC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.64	-10.46	-0.5	2.64e-22	Dental caries;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14559774	chr8:87355871	WWP1	0.47	6.79	0.35	5.18e-11	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.76	-12.31	-0.56	6.62e-29	Height;
CRC	cis	rs73198271	0.531	rs17154758	chr8:8653343	G/A	cg01851573	chr8:8652454	MFHAS1	0.55	6.84	0.35	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2108622	1.000	rs2108622	chr19:15990431	C/T	cg13772218	chr19:15982569	NA	0.43	6.06	0.32	3.77e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-12.93	-0.58	3.44e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.57	-8.87	-0.44	4.78e-17	Motion sickness;
CRC	cis	rs728616	0.867	rs41297151	chr10:81807167	A/T	cg11900509	chr10:81946545	ANXA11	-0.52	-5.81	-0.3	1.52e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.24	-0.33	1.34e-9	Lung cancer;
CRC	cis	rs3996993	0.809	rs11969435	chr6:52664956	C/T	cg20803780	chr6:52668592	GSTA1	0.36	6.46	0.34	3.74e-10	Hemoglobin concentration;
CRC	cis	rs77861329	1.000	rs114209632	chr3:52188361	C/T	cg08692210	chr3:52188851	WDR51A	0.83	7.17	0.37	4.84e-12	Macrophage inflammatory protein 1b levels;
CRC	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	6.6	0.34	1.68e-10	Body mass index;
CRC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg18404041	chr3:52824283	ITIH1	-0.33	-6.3	-0.33	9.67e-10	Schizophrenia;
CRC	cis	rs17767392	0.846	rs4453405	chr14:71757251	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.06	-0.32	3.75e-9	Mitral valve prolapse;
CRC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.25	-0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7707921	1.000	rs6884232	chr5:81550043	G/A	cg17942617	chr5:81327376	ATG10	-0.39	-5.82	-0.31	1.38e-8	Breast cancer;
CRC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.74	0.35	7.18e-11	Lung cancer;
CRC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.32	-18.35	-0.71	2.64e-52	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.55	8.6	0.43	3.21e-16	Aortic root size;
CRC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg01721255	chr8:58191610	C8orf71	0.5	6.21	0.32	1.63e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-6.08	-0.32	3.3e-9	Longevity;Endometriosis;
CRC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg11833968	chr6:79620685	NA	-0.36	-6.22	-0.32	1.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.46	6.74	0.35	7.17e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg19677607	chr8:24772270	NEFM	-0.38	-6.72	-0.35	8.24e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.44	8.99	0.44	1.96e-17	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.29	0.37	2.38e-12	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg15845792	chr6:28175446	NA	1.02	13.74	0.6	2.86e-34	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17434043	chr11:2907123	CDKN1C	0.43	6.11	0.32	2.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.64	10.2	0.49	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg12573674	chr2:1569213	NA	-0.67	-7.6	-0.39	3.07e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg19856771	chr13:42780042	DGKH	0.43	6.91	0.36	2.48e-11	Interleukin-6 levels;
CRC	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg20159608	chr7:32802032	NA	-0.58	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.51	6.78	0.35	5.63e-11	Height;
CRC	cis	rs6496667	1.000	rs3803538	chr15:90891771	A/G	cg04176472	chr15:90893244	GABARAPL3	0.55	8.54	0.43	5.23e-16	Rheumatoid arthritis;
CRC	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-7.47	-0.38	7.49e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	9.55	0.47	3.01e-19	Schizophrenia;
CRC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.37	0.38	1.39e-12	Motion sickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08713367	chr6:37225473	TMEM217;TBC1D22B	0.37	6.04	0.32	4.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg12458913	chr13:53173898	NA	0.85	15.84	0.66	2.22e-42	Lewy body disease;
CRC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.15	-16.84	-0.68	2.44e-46	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.49	5.61	0.3	4.23e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	6.0	0.31	5.11e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs1223397	0.651	rs2919686	chr6:13312641	A/G	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs3731896	0.700	rs2271593	chr2:220168607	C/T	cg00436969	chr2:220197716	RESP18	-0.46	-5.95	-0.31	6.7e-9	Educational attainment;
CRC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg08885800	chr1:201084119	NA	0.48	8.69	0.43	1.75e-16	Permanent tooth development;
CRC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg18478394	chr8:109455254	TTC35	0.38	5.89	0.31	9.79e-9	Dupuytren's disease;
CRC	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-6.02	-0.31	4.68e-9	Morning vs. evening chronotype;
CRC	cis	rs7901135	0.962	rs7087585	chr10:60569229	G/A	cg23799393	chr10:60588674	BICC1	0.36	5.61	0.3	4.25e-8	Morning vs. evening chronotype;
CRC	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6735179	0.643	rs10200618	chr2:1746140	A/C	cg19300414	chr2:1746591	PXDN	0.43	7.25	0.37	3.04e-12	Response to antipsychotic treatment;
CRC	trans	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs4757319	0.532	rs10766251	chr11:15443681	A/G	cg03245590	chr11:15329459	NA	-0.39	-6.7	-0.35	9.09e-11	Breast cancer;
CRC	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12667521	chr19:29218732	NA	0.52	7.16	0.37	5.18e-12	Methadone dose in opioid dependence;
CRC	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg20356878	chr3:121714668	ILDR1	0.51	8.03	0.4	1.74e-14	Cognitive performance;
CRC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-9.42	-0.46	8.29e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.7	0.47	1.03e-19	Coffee consumption (cups per day);
CRC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg26875233	chr11:93583750	C11orf90	0.31	6.09	0.32	3.11e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.44	6.33	0.33	7.98e-10	Height;
CRC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.06	0.69	3.29e-47	Platelet count;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg08092331	chr12:121019201	POP5	0.44	5.99	0.31	5.57e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs524281	0.817	rs10896092	chr11:65958046	A/C	cg16950941	chr11:66035639	RAB1B	-0.57	-7.14	-0.37	5.84e-12	Electroencephalogram traits;
CRC	cis	rs7107770	0.739	rs12793744	chr11:125079871	G/T	cg27629782	chr11:125073726	PKNOX2	0.54	7.87	0.4	5.23e-14	Photic sneeze reflex;
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-9.05	-0.45	1.29e-17	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07660663	chr8:117886887	RAD21	0.47	6.62	0.34	1.44e-10	Response to antipsychotic treatment;
CRC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.47	7.02	0.36	1.27e-11	Menopause (age at onset);
CRC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs459193	1.000	rs256904	chr5:55810305	A/T	cg18302225	chr5:55776401	NA	0.43	5.73	0.3	2.28e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.28	6.41	0.33	5e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.28	-0.37	2.47e-12	Coronary artery disease;
CRC	trans	rs17111230	0.675	rs1349568	chr14:41315945	A/C	cg26721700	chr19:35645598	FXYD5	0.41	6.05	0.32	3.96e-9	Congenital heart disease (inherited effect);
CRC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.54e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	8.84	0.44	5.76e-17	Mean platelet volume;
CRC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg11843238	chr5:131593191	PDLIM4	0.3	5.64	0.3	3.74e-8	Blood metabolite levels;
CRC	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.58	9.83	0.48	3.71e-20	Breast cancer;
CRC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.69	-7.26	-0.37	2.86e-12	Systemic lupus erythematosus;
CRC	cis	rs737337	0.623	rs4804154	chr19:11334179	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.79	8.85	0.44	5.52e-17	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.81	-9.05	-0.45	1.25e-17	Breast cancer;
CRC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.5	0.57	1.36e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.53	6.04	0.32	4.19e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.46	6.54	0.34	2.35e-10	Height;
CRC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.61	0.34	1.57e-10	Cognitive test performance;
CRC	trans	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.22	-0.32	1.51e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs4668451	chr2:15675285	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg19223190	chr17:80058835	NA	0.41	6.7	0.35	8.79e-11	Life satisfaction;
CRC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.63	0.6	7.53e-34	Breast cancer;
CRC	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg18230493	chr5:56204884	C5orf35	-0.39	-5.83	-0.31	1.33e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.79	-13.39	-0.59	6.36e-33	Obesity-related traits;
CRC	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.27	5.85	0.31	1.22e-8	Educational attainment (years of education);
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg00063174	chr2:228736253	WDR69	-0.47	-6.32	-0.33	8.42e-10	Blood pressure;
CRC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg27053337	chr8:124217698	FAM83A	0.35	5.77	0.3	1.87e-8	Urinary uromodulin levels;
CRC	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.59	-7.34	-0.38	1.71e-12	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00253204	chr17:16118700	NCOR1	0.43	6.07	0.32	3.5e-9	Response to antipsychotic treatment;
CRC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.66	-8.15	-0.41	7.67e-15	Body mass index;
CRC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg25459000	chr22:39777742	SYNGR1	-0.32	-5.61	-0.3	4.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.25	14.7	0.63	6.01e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg12273811	chr6:28175739	NA	0.46	7.02	0.36	1.31e-11	Cardiac Troponin-T levels;
CRC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.43	1.09e-16	Aortic root size;
CRC	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	6.96	0.36	1.83e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-12.39	-0.56	3.29e-29	Dental caries;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15068520	chr10:79789178	POLR3A	0.42	6.1	0.32	2.95e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.703	rs4364819	chr1:46358510	G/A	cg08644498	chr1:46502608	NA	-0.44	-6.92	-0.36	2.32e-11	Blood protein levels;
CRC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.53	-8.45	-0.42	9.73e-16	Type 2 diabetes;
CRC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg11204139	chr17:3907470	NA	-0.76	-13.98	-0.61	3.52e-35	Type 2 diabetes;
CRC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.52	0.46	3.93e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.37	6.22	0.32	1.51e-9	Blood metabolite levels;
CRC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.74	-9.13	-0.45	6.98e-18	Initial pursuit acceleration;
CRC	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg12856521	chr11:46389249	DGKZ	-0.43	-6.87	-0.35	3.13e-11	Leprosy;
CRC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.6	-7.73	-0.39	1.33e-13	Schizophrenia;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg15845792	chr6:28175446	NA	0.84	8.84	0.44	5.86e-17	Lung cancer in ever smokers;
CRC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.81	8.56	0.43	4.31e-16	Plasma clusterin levels;
CRC	trans	rs2303319	0.504	rs56384808	chr2:162347755	G/T	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.77	-6.04	-0.32	4.18e-9	Cognitive function;
CRC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-15.08	-0.64	1.96e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.4	-0.33	5.49e-10	Total body bone mineral density;
CRC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.61	7.85	0.4	5.9e-14	Mean platelet volume;
CRC	cis	rs6604026	0.883	rs77741804	chr1:93324038	C/T	cg22128645	chr1:93425802	FAM69A	-0.4	-5.91	-0.31	8.78e-9	Multiple sclerosis;
CRC	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.38	-6.96	-0.36	1.8e-11	Mean corpuscular volume;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.64	-9.09	-0.45	9.33e-18	Alzheimer's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02562419	chr6:159049626	TMEM181	0.4	6.0	0.31	5.24e-9	Myopia (pathological);
CRC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.68	13.43	0.6	4.24e-33	Educational attainment;
CRC	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg06522879	chr11:64358276	SLC22A12	-0.58	-9.08	-0.45	1.05e-17	Urate levels in obese individuals;
CRC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.36	-0.33	6.81e-10	Bipolar disorder;
CRC	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.43	6.44	0.33	4.34e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.5	8.84	0.44	5.92e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs7487075	0.820	rs1586905	chr12:46707618	T/A	cg22049899	chr12:47219821	SLC38A4	0.33	6.24	0.33	1.36e-9	Itch intensity from mosquito bite;
CRC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg16476235	chr8:21771668	DOK2	0.41	7.01	0.36	1.38e-11	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01145398	chr10:135075451	NA	0.39	6.43	0.33	4.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg02023728	chr11:77925099	USP35	-0.38	-6.39	-0.33	5.54e-10	Alzheimer's disease (survival time);
CRC	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.38	0.56	3.75e-29	Height;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg26608667	chr7:1196370	ZFAND2A	0.36	5.62	0.3	3.99e-8	Longevity;Endometriosis;
CRC	cis	rs3823572	0.586	rs2971969	chr7:133656264	G/T	cg03336402	chr7:133662267	EXOC4	-0.66	-10.27	-0.49	1.24e-21	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg00343986	chr7:65444356	GUSB	-0.44	-6.42	-0.33	4.74e-10	Aortic root size;
CRC	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-7.03	-0.36	1.19e-11	Schizophrenia;
CRC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.6	9.84	0.48	3.48e-20	Permanent tooth development;
CRC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg03037974	chr15:76606532	NA	0.68	11.55	0.54	4.06e-26	Blood metabolite levels;
CRC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-6.94	-0.36	2.09e-11	Type 2 diabetes;
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg18833306	chr6:118973337	C6orf204	0.44	5.74	0.3	2.12e-8	Renal cell carcinoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15807180	chr15:74907231	CLK3	0.46	6.46	0.34	3.75e-10	Anxiety disorder;
CRC	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14119001	chr9:139324193	INPP5E	-0.47	-6.72	-0.35	7.96e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.64	10.41	0.5	3.86e-22	Breast cancer;
CRC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.12	0.37	6.76e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	0.8	6.57	0.34	1.97e-10	Prostate cancer;
CRC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.74	9.35	0.46	1.35e-18	Behavioural disinhibition (generation interaction);
CRC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.59	-8.06	-0.41	1.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.68	0.35	1.02e-10	HIV-1 control;
CRC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	2e-33	Vitiligo;
CRC	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg16358738	chr2:241808595	AGXT	-0.4	-6.98	-0.36	1.59e-11	Urinary metabolites;
CRC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.44	-7.41	-0.38	1.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg18473234	chr19:5097819	KDM4B	-0.48	-6.08	-0.32	3.36e-9	Monocyte percentage of white cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20099147	chr19:56652066	ZNF444	0.51	6.56	0.34	2.08e-10	Thyroid stimulating hormone;
CRC	trans	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	0.44	6.25	0.33	1.29e-9	Monocyte count;
CRC	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg19582491	chr16:67682965	RLTPR	-0.41	-5.9	-0.31	8.82e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg14593290	chr7:50529359	DDC	-0.52	-7.21	-0.37	3.96e-12	Malaria;
CRC	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	15.89	0.66	1.42e-42	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.62	-7.63	-0.39	2.62e-13	Blood trace element (Zn levels);
CRC	cis	rs12230513	0.793	rs1896044	chr12:55953670	T/A	cg19537932	chr12:55886519	OR6C68	-0.42	-5.65	-0.3	3.56e-8	Contrast sensitivity;
CRC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.17e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg07274523	chr3:49395745	GPX1	0.45	5.75	0.3	2.06e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	11.95	0.55	1.38e-27	Mean platelet volume;
CRC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.25	15.02	0.64	3.34e-39	Uric acid levels;
CRC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.54	-9.47	-0.46	5.49e-19	Lung cancer;
CRC	cis	rs12541635	1.000	rs1896919	chr8:107090357	C/G	cg10147462	chr8:107024639	NA	-0.36	-6.12	-0.32	2.68e-9	Age of smoking initiation;
CRC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.6	0.43	3.31e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.36	0.38	1.5e-12	Life satisfaction;
CRC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.61	-11.09	-0.52	1.75e-24	Aortic root size;
CRC	trans	rs4308415	0.726	rs12509233	chr4:67811618	C/T	cg19648955	chr2:177134095	MTX2	-0.42	-6.36	-0.33	6.7e-10	Educational attainment (years of education);
CRC	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg14631576	chr9:95140430	CENPP	0.31	5.68	0.3	3.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg13565492	chr6:43139072	SRF	-0.7	-7.31	-0.37	2.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.68	-9.94	-0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg12183467	chr14:104352244	NA	-0.47	-6.57	-0.34	2e-10	Bipolar disorder;
CRC	cis	rs2857891	1.000	rs2638092	chr11:6961746	G/A	cg12728517	chr11:6947552	ZNF215	0.57	6.16	0.32	2.17e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	10.25	0.49	1.43e-21	HIV-1 control;
CRC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs7113874	0.569	rs10769915	chr11:8597449	C/G	cg20771178	chr11:8615675	STK33	-0.35	-5.75	-0.3	2.02e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg17321639	chr7:2759063	NA	-0.52	-7.05	-0.36	1.08e-11	Height;
CRC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.24	-0.37	3.28e-12	Type 2 diabetes;
CRC	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.66	10.44	0.5	3.09e-22	Lewy body disease;
CRC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.53	7.99	0.4	2.23e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg04176472	chr15:90893244	GABARAPL3	-0.38	-5.92	-0.31	8.09e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.54	8.31	0.42	2.47e-15	Ulcerative colitis;
CRC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.47	0.42	8.03e-16	Rheumatoid arthritis;
CRC	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.84	-12.85	-0.58	6.69e-31	Longevity;
CRC	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.83	-0.4	6.93e-14	Prevalent atrial fibrillation;
CRC	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.34	-0.33	7.79e-10	Breast cancer;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg12172441	chr6:28176163	NA	0.52	7.29	0.37	2.27e-12	Parkinson's disease;
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.76	14.24	0.62	3.62e-36	Prudent dietary pattern;
CRC	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg23461800	chr14:103021989	NA	-0.61	-7.24	-0.37	3.28e-12	Platelet count;
CRC	cis	rs6496667	1.000	rs6496667	chr15:90893668	C/A	cg04176472	chr15:90893244	GABARAPL3	0.52	7.94	0.4	3.26e-14	Rheumatoid arthritis;
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg01339444	chr6:118972232	C6orf204	0.58	6.24	0.33	1.35e-9	Diastolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17994379	chr17:43025264	KIF18B	0.46	6.21	0.32	1.64e-9	Thyroid stimulating hormone;
CRC	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.46	6.43	0.33	4.54e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.37	-6.28	-0.33	1.07e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	0.96	12.91	0.58	3.84e-31	Vitiligo;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg15845792	chr6:28175446	NA	-0.99	-13.35	-0.59	9.01e-33	Depression;
CRC	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg15192750	chr16:69999425	NA	0.55	7.17	0.37	4.99e-12	IgE levels;
CRC	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	6.82	0.35	4.24e-11	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.82	0.31	1.41e-8	HDL cholesterol;
CRC	cis	rs365302	1.000	rs433171	chr6:159645378	C/T	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.76e-10	Coronary heart disease;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg03623178	chr6:28175578	NA	0.92	13.02	0.58	1.52e-31	Parkinson's disease;
CRC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg15848620	chr12:58087721	OS9	-0.62	-8.68	-0.43	1.92e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.75	0.47	6.97e-20	Alzheimer's disease;
CRC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.37	-6.72	-0.35	7.97e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.87	0.31	1.07e-8	Homoarginine levels;
CRC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-8.82	-0.44	6.97e-17	Uric acid levels;
CRC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.32	-0.33	8.51e-10	Diabetic kidney disease;
CRC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.64	-8.52	-0.43	5.91e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.99	-0.4	2.23e-14	Schizophrenia;
CRC	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg05527609	chr1:210001259	C1orf107	-0.56	-6.21	-0.32	1.56e-9	Red blood cell count;
CRC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.65	-11.77	-0.54	6.3e-27	Hematocrit;
CRC	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg12560992	chr17:57184187	TRIM37	0.47	5.94	0.31	7.16e-9	Vitamin D levels;
CRC	trans	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg02674126	chr19:40336878	FBL	-0.41	-6.56	-0.34	2.06e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-1.03	-20.89	-0.76	2.86e-62	Headache;
CRC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.07	-17.43	-0.69	1.18e-48	Dilated cardiomyopathy;
CRC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.09	-0.45	9.8e-18	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg03037974	chr15:76606532	NA	0.59	9.78	0.47	5.24e-20	Blood metabolite levels;
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg09659197	chr4:152720779	NA	0.4	7.84	0.4	6.54e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.99	-0.31	5.59e-9	Life satisfaction;
CRC	cis	rs2380220	0.751	rs117986000	chr6:95923454	A/C	cg04719120	chr6:96025338	MANEA	-0.53	-5.81	-0.31	1.44e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg14646075	chr2:228736089	WDR69	-0.45	-6.14	-0.32	2.43e-9	Blood pressure;
CRC	cis	rs6668534	1.000	rs6668534	chr1:161671995	C/T	cg17887793	chr1:161494110	HSPA6	-0.69	-8.48	-0.42	7.95e-16	Blood protein levels;
CRC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.06	0.41	1.48e-14	Type 2 diabetes;
CRC	cis	rs6496667	1.000	rs4261510	chr15:90890606	G/A	cg04176472	chr15:90893244	GABARAPL3	0.65	8.93	0.44	3.16e-17	Rheumatoid arthritis;
CRC	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.59	10.66	0.51	5.37e-23	Blood metabolite ratios;
CRC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.85	16.8	0.68	3.47e-46	White blood cell count (basophil);White blood cell count;
CRC	cis	rs11209185	0.509	rs1938424	chr1:68431722	A/G	cg22082780	chr1:68452167	NA	-0.38	-5.77	-0.3	1.85e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg25885038	chr17:56607967	SEPT4	-0.51	-7.52	-0.38	5.36e-13	Vitamin D levels;
CRC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.53	-7.21	-0.37	3.9e-12	Tuberculosis;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs2811415	0.597	rs9857492	chr3:127763522	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	trans	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg14520829	chr3:18390388	SATB1	0.4	6.25	0.33	1.29e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.51	8.0	0.4	2.21e-14	Coronary artery disease;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.42	6.05	0.32	3.98e-9	Longevity;Endometriosis;
CRC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	9.04	0.45	1.4e-17	Lymphocyte counts;
CRC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg00129232	chr17:37814104	STARD3	-0.46	-7.19	-0.37	4.44e-12	Self-reported allergy;
CRC	trans	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg24644049	chr4:85504048	CDS1	0.89	7.31	0.37	2.07e-12	Skin colour saturation;
CRC	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg09476006	chr5:138032270	NA	0.44	6.78	0.35	5.56e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg24505167	chr7:1915268	MAD1L1	-0.48	-7.31	-0.37	2.08e-12	Bipolar disorder;
CRC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.57	-7.64	-0.39	2.34e-13	Urate levels in lean individuals;
CRC	cis	rs755249	0.532	rs2296173	chr1:39913351	A/G	cg18385671	chr1:39797026	MACF1	-0.4	-5.7	-0.3	2.71e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.61e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.57	-8.27	-0.41	3.38e-15	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg24505167	chr7:1915268	MAD1L1	-0.42	-5.92	-0.31	8.3e-9	Neuroticism;
CRC	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.45	-0.34	3.96e-10	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.99	-0.31	5.54e-9	Bladder cancer;
CRC	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg26353448	chr1:248524236	OR2T4	-0.31	-5.81	-0.31	1.47e-8	Common traits (Other);
CRC	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.48	8.02	0.4	1.9e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-6.0	-0.31	5.19e-9	Schizophrenia;
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	10.13	0.49	3.62e-21	Total body bone mineral density;
CRC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.91	-0.36	2.51e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg15845792	chr6:28175446	NA	0.68	8.93	0.44	2.99e-17	Parkinson's disease;
CRC	cis	rs59104589	0.517	rs3821281	chr2:242385340	A/G	cg19488206	chr2:242435732	STK25	0.49	7.12	0.37	6.65e-12	Fibrinogen levels;
CRC	cis	rs10208940	0.920	rs35005506	chr2:68814238	A/T	cg12452813	chr2:68675892	NA	0.48	6.0	0.31	5.28e-9	Urate levels in lean individuals;
CRC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.69	-10.21	-0.49	1.87e-21	Gut microbiome composition (summer);
CRC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg03934865	chr2:198174659	NA	-0.44	-7.77	-0.39	1.01e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2457480	0.866	rs7079375	chr10:44730310	T/C	cg09554077	chr10:44749378	NA	0.65	7.41	0.38	1.07e-12	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg09264619	chr17:80180166	NA	0.38	6.44	0.33	4.28e-10	Life satisfaction;
CRC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14895029	chr7:2775587	GNA12	-0.48	-6.96	-0.36	1.87e-11	Height;
CRC	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg21251018	chr6:28226885	NKAPL	0.5	8.2	0.41	5.34e-15	Depression;
CRC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.58	0.5	1.02e-22	Platelet count;
CRC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg04362960	chr10:104952993	NT5C2	-0.4	-5.6	-0.3	4.46e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02867650	chr6:11094066	LOC221710	0.47	6.51	0.34	2.79e-10	Response to antipsychotic treatment;
CRC	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg12160578	chr15:63334699	TPM1	0.61	7.22	0.37	3.62e-12	Orofacial clefts;
CRC	cis	rs7632954	0.867	rs11715189	chr3:8517861	C/T	cg03495237	chr3:8533978	NA	0.34	5.87	0.31	1.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg25452165	chr22:42524984	CYP2D6	-0.4	-5.72	-0.3	2.34e-8	Cognitive function;
CRC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.39	-8.52	-0.43	5.72e-16	Alcohol dependence;
CRC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg14844989	chr11:31128820	NA	-0.34	-6.02	-0.31	4.75e-9	Red blood cell count;
CRC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.39	0.33	5.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.82	14.34	0.62	1.44e-36	Intelligence (multi-trait analysis);
CRC	trans	rs6600671	1.000	rs12047116	chr1:121185770	G/A	cg09829573	chr1:144692074	NBPF9	-0.4	-5.99	-0.31	5.47e-9	Hip geometry;
CRC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.09	-0.36	8.02e-12	Glycated hemoglobin levels;
CRC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg18279126	chr7:2041391	MAD1L1	0.39	5.75	0.3	2.04e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg12856521	chr11:46389249	DGKZ	-0.72	-10.85	-0.51	1.18e-23	Crohn's disease;
CRC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.58	-0.47	2.45e-19	Bladder cancer;
CRC	cis	rs1209950	0.512	rs374575	chr21:40193914	C/T	cg02119577	chr21:40195074	ETS2	-0.37	-5.74	-0.3	2.2e-8	Non-small cell lung cancer (survival);
CRC	cis	rs6585424	0.778	rs12257082	chr10:81922121	C/G	cg11900509	chr10:81946545	ANXA11	-0.72	-8.81	-0.44	7.22e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.42	-6.28	-0.33	1.08e-9	Platelet distribution width;
CRC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg05192639	chr6:26864778	GUSBL1	0.33	6.01	0.31	4.96e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.76	13.11	0.59	6.83e-32	Colorectal cancer;
CRC	cis	rs4728302	0.869	rs10808273	chr7:133597691	G/C	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.8e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2565722	0.622	rs2489944	chr6:161292913	C/T	cg03159191	chr6:161285451	NA	-0.45	-6.0	-0.31	5.24e-9	Blood protein levels;
CRC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.28	-0.33	1.1e-9	Morning vs. evening chronotype;
CRC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21963583	chr11:68658836	MRPL21	0.59	10.22	0.49	1.74e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.59	-8.39	-0.42	1.42e-15	Breast cancer;
CRC	cis	rs3736485	0.932	rs8037167	chr15:51918126	G/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.62	-0.34	1.47e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg10802521	chr3:52805072	NEK4	-0.43	-5.92	-0.31	8.06e-9	Schizophrenia;
CRC	cis	rs6662572	0.737	rs10789477	chr1:46306583	A/G	cg08644498	chr1:46502608	NA	-0.42	-6.49	-0.34	3.22e-10	Blood protein levels;
CRC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.44	-9.44	-0.46	6.83e-19	Blood protein levels;
CRC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg24675056	chr1:15929824	NA	0.48	6.62	0.34	1.49e-10	Systolic blood pressure;
CRC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.6	-7.31	-0.37	2.09e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02725872	chr8:58115012	NA	-0.39	-6.78	-0.35	5.63e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9992667	0.955	rs1962053	chr4:38612357	A/C	cg19726192	chr4:38663646	FLJ13197	-0.59	-7.67	-0.39	1.95e-13	Eosinophil percentage of granulocytes;
CRC	trans	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg09045935	chr12:6379348	NA	0.9	7.86	0.4	5.68e-14	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04824595	chr19:58987622	ZNF446	0.47	6.56	0.34	2.09e-10	Response to antipsychotic treatment;
CRC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.85	-0.44	5.31e-17	IgG glycosylation;
CRC	cis	rs10450586	0.829	rs7105320	chr11:27306168	A/G	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg20713130	chr11:46260756	NA	0.41	6.21	0.32	1.59e-9	Interleukin-6 levels;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg10596483	chr8:143751796	JRK	-0.44	-6.27	-0.33	1.15e-9	Urinary tract infection frequency;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg08546805	chr12:8549446	NA	-0.43	-6.55	-0.34	2.26e-10	Blood pressure (smoking interaction);
CRC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-6.21	-0.32	1.55e-9	Alzheimer's disease (late onset);
CRC	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg27398640	chr15:77910606	LINGO1	-0.45	-7.97	-0.4	2.6e-14	Type 2 diabetes;
CRC	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.35	7.52	0.38	5.1e-13	Total body bone mineral density;
CRC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.66	10.99	0.52	3.81e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4908768	0.501	rs11121199	chr1:8600192	G/A	cg20416874	chr1:8611966	RERE	-0.44	-6.4	-0.33	5.26e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.43	-5.79	-0.3	1.61e-8	Diastolic blood pressure;
CRC	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00495681	chr13:53174319	NA	0.51	7.75	0.39	1.15e-13	Lewy body disease;
CRC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg18876405	chr7:65276391	NA	0.46	6.44	0.33	4.29e-10	Aortic root size;
CRC	trans	rs2055729	0.645	rs12543996	chr8:9742666	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.55	-0.38	4.23e-13	Multiple myeloma (hyperdiploidy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10722636	chr22:41252884	XPNPEP3;ST13	0.42	6.37	0.33	6.27e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.75	0.35	6.57e-11	Neuroticism;
CRC	trans	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.7	-7.68	-0.39	1.86e-13	Vitiligo;
CRC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.79	10.85	0.51	1.17e-23	Cognitive function;
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.04	0.32	4.06e-9	Prudent dietary pattern;
CRC	cis	rs3956705	0.798	rs6462427	chr7:32907344	T/C	cg05721444	chr7:32995514	FKBP9	-0.45	-6.49	-0.34	3.24e-10	Red cell distribution width;
CRC	cis	rs11212617	0.967	rs3781869	chr11:108059000	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.69	0.3	2.86e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg19338460	chr6:170058176	WDR27	-0.72	-7.83	-0.4	6.94e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1178968	1.000	rs4273741	chr7:72773966	C/A	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs2160860	0.773	rs10958574	chr8:39798041	G/A	cg11363097	chr8:39792086	IDO2	-0.43	-7.3	-0.37	2.19e-12	Blood metabolite levels;
CRC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.4	6.86	0.35	3.45e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg24159697	chr1:205181237	DSTYK	-0.33	-5.91	-0.31	8.33e-9	Schizophrenia;
CRC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg07713946	chr22:31675144	LIMK2	-0.39	-5.62	-0.3	4e-8	Colorectal cancer;
CRC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg23131131	chr22:24373011	LOC391322	0.53	5.63	0.3	3.79e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CRC	cis	rs9584850	0.834	rs7339274	chr13:99120272	A/G	cg20487152	chr13:99095054	FARP1	-0.41	-5.99	-0.31	5.42e-9	Neuroticism;
CRC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg00080972	chr5:178986291	RUFY1	0.46	7.92	0.4	3.64e-14	Lung cancer;
CRC	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.44	6.45	0.34	4.01e-10	Pulmonary function decline;
CRC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.67	-11.17	-0.52	8.81e-25	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs55702914	0.712	rs10931778	chr2:198148922	C/T	cg10820045	chr2:198174542	NA	-0.43	-7.93	-0.4	3.51e-14	Major depression and alcohol dependence;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09698166	chr20:21106763	PLK1S1	-0.5	-6.14	-0.32	2.44e-9	Diisocyanate-induced asthma;
CRC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	0.55	5.76	0.3	1.95e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.67	-0.43	1.94e-16	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.46	0.38	7.85e-13	Motion sickness;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15747848	chr15:40074985	FSIP1	0.45	6.24	0.33	1.32e-9	Response to antipsychotic treatment;
CRC	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.48	-6.22	-0.32	1.53e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg26102564	chr10:131424627	MGMT	0.38	5.63	0.3	3.9e-8	Response to temozolomide;
CRC	cis	rs1223397	0.651	rs2439541	chr6:13310567	T/C	cg20827128	chr6:13274284	PHACTR1	0.38	5.8	0.3	1.52e-8	Blood pressure;
CRC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg06781209	chr11:61594997	FADS2	-0.38	-5.74	-0.3	2.11e-8	LDL cholesterol;
CRC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.88	-16.34	-0.67	2.41e-44	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.65	8.4	0.42	1.31e-15	Uric acid levels;
CRC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.42	6.27	0.33	1.14e-9	Menopause (age at onset);
CRC	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.05	14.56	0.63	2.04e-37	Exhaled nitric oxide output;
CRC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.4	-7.52	-0.38	5.19e-13	Ulcerative colitis;
CRC	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.73	-15.81	-0.66	2.74e-42	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.72	0.35	7.91e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg22732515	chr19:44031385	ETHE1	0.61	9.07	0.45	1.1e-17	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.38	-7.27	-0.37	2.57e-12	Iron status biomarkers;
CRC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.55	-0.38	4.32e-13	Aortic root size;
CRC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.4	-6.29	-0.33	9.97e-10	Neurofibrillary tangles;
CRC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.51	7.72	0.39	1.36e-13	Calcium levels;
CRC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg02725872	chr8:58115012	NA	-0.53	-7.09	-0.36	8.33e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.54	7.11	0.36	7.46e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.48	7.71	0.39	1.53e-13	Coronary artery disease;
CRC	cis	rs7680126	0.596	rs4697714	chr4:10143786	A/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.05	-0.32	4.04e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12195820	chr8:42698243	THAP1	0.4	6.04	0.32	4.12e-9	Myopia (pathological);
CRC	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg14458575	chr2:238380390	NA	0.52	6.86	0.35	3.51e-11	Prostate cancer;
CRC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.7e-20	Bladder cancer;
CRC	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.66	9.03	0.45	1.48e-17	Coronary artery disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg24949396	chr16:68877816	TMCO7	-0.41	-6.18	-0.32	1.92e-9	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26085966	chr14:64319812	SYNE2	0.37	6.33	0.33	8.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg26721908	chr21:47610096	LSS	-0.36	-5.61	-0.3	4.33e-8	Testicular germ cell tumor;
CRC	cis	rs4692589	1.000	rs4692784	chr4:170938581	A/G	cg19918862	chr4:170955249	NA	0.39	6.29	0.33	9.93e-10	Anxiety disorder;
CRC	cis	rs910187	0.591	rs13041142	chr20:45788979	C/T	cg27589058	chr20:45804311	EYA2	-0.34	-6.26	-0.33	1.21e-9	Migraine;
CRC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.37	-5.91	-0.31	8.35e-9	Blood metabolite levels;
CRC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.41	6.49	0.34	3.23e-10	Monocyte count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12187437	chr12:66524584	LLPH	0.46	6.04	0.32	4.15e-9	Thyroid stimulating hormone;
CRC	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg16898833	chr6:26189333	HIST1H4D	0.63	5.78	0.3	1.77e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.53	-8.12	-0.41	9.37e-15	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02878701	chr21:47706221	MCM3AP;C21orf57	0.37	6.19	0.32	1.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.57	-7.9	-0.4	4.3e-14	Height;
CRC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.66	13.79	0.61	1.86e-34	Schizophrenia;
CRC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.6	11.01	0.52	3.33e-24	Immature fraction of reticulocytes;
CRC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg11522145	chr4:3412961	RGS12	-0.39	-5.99	-0.31	5.6e-9	Serum sulfate level;
CRC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg12573674	chr2:1569213	NA	-0.74	-7.89	-0.4	4.59e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.56	7.84	0.4	6.16e-14	Alzheimer's disease;
CRC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.66	0.3	3.25e-8	Height;
CRC	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg26353448	chr1:248524236	OR2T4	-0.3	-5.71	-0.3	2.55e-8	Common traits (Other);
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-8.61	-0.43	3.02e-16	Bipolar disorder;
CRC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg18225595	chr11:63971243	STIP1	-0.59	-7.67	-0.39	1.92e-13	Mean platelet volume;
CRC	cis	rs6810498	0.800	rs2007354	chr4:26052969	C/T	cg12925881	chr4:26050407	NA	-0.41	-7.66	-0.39	2.09e-13	Alcohol dependence;
CRC	cis	rs1832871	0.521	rs878585	chr6:158815897	C/T	cg14153777	chr6:158651016	NA	0.4	5.63	0.3	3.93e-8	Height;
CRC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs370915	0.928	rs433477	chr4:187814866	C/G	cg12892747	chr4:187813459	NA	0.38	5.8	0.3	1.58e-8	Gout;
CRC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.67	8.21	0.41	5.05e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg24628676	chr5:59189846	PDE4D	-0.3	-6.08	-0.32	3.3e-9	Urinary tract infection frequency;
CRC	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.05e-14	Type 2 diabetes;
CRC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg24675056	chr1:15929824	NA	0.53	7.06	0.36	1.02e-11	Systolic blood pressure;
CRC	cis	rs7209700	0.547	rs7219925	chr17:45341640	G/C	cg17185639	chr17:45330862	ITGB3	0.37	5.73	0.3	2.25e-8	IgG glycosylation;
CRC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.78	-12.32	-0.56	6.09e-29	Multiple myeloma;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14743055	chr21:43430222	ZNF295	0.44	6.15	0.32	2.24e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11158239	chr12:7037742	ATN1	0.42	6.57	0.34	1.95e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.59	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.49	8.34	0.42	2.08e-15	Common traits (Other);
CRC	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.4	-6.27	-0.33	1.12e-9	Refractive error;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-6.84	-0.35	3.95e-11	Hemoglobin concentration;
CRC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.38	16.84	0.68	2.53e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg20119798	chr7:94954144	PON1	-0.48	-6.19	-0.32	1.83e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.84	10.25	0.49	1.42e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17091793	chr13:49684397	FNDC3A	-0.49	-6.02	-0.31	4.58e-9	Monocyte percentage of white cells;
CRC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.47	-7.4	-0.38	1.13e-12	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25704110	chr12:4967040	NA	0.47	6.63	0.34	1.34e-10	Response to antipsychotic treatment;
CRC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-11.74	-0.54	8.22e-27	Body mass index;
CRC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	11.68	0.54	1.38e-26	Mean corpuscular hemoglobin;
CRC	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	8.97	0.44	2.38e-17	Neuroticism;
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.93	10.18	0.49	2.4e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7517126	1.000	rs6428368	chr1:196844310	T/C	cg13682187	chr1:196946512	CFHR5	-0.41	-6.51	-0.34	2.85e-10	Blood protein levels;
CRC	cis	rs2811415	0.597	rs9848345	chr3:127779220	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.46	6.78	0.35	5.42e-11	Melanoma;
CRC	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg20936604	chr3:58311152	NA	-0.74	-7.74	-0.39	1.2e-13	Cholesterol, total;
CRC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs6763159	1.000	rs6808992	chr3:59649558	A/G	cg07069742	chr3:59644285	NA	-0.36	-7.27	-0.37	2.58e-12	Conotruncal heart defects;
CRC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.63	9.14	0.45	6.38e-18	Obesity-related traits;
CRC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-9.36	-0.46	1.29e-18	Response to antipsychotic treatment;
CRC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.43	-8.04	-0.41	1.58e-14	Colorectal cancer;
CRC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.51	-6.07	-0.32	3.47e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11446398	chr5:77624930	NA	0.47	6.3	0.33	9.63e-10	Triglycerides;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19440955	chr10:99609836	GOLGA7B	0.46	6.21	0.32	1.58e-9	Survival in pancreatic cancer;
CRC	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg23229984	chr5:148520753	ABLIM3	0.49	6.8	0.35	4.85e-11	Breast cancer;
CRC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.7	-10.17	-0.49	2.64e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.49	7.62	0.39	2.73e-13	Response to antineoplastic agents;
CRC	cis	rs3736485	0.934	rs28410165	chr15:51875019	C/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04731861	chr2:219085781	ARPC2	0.38	8.04	0.41	1.6e-14	Colorectal cancer;
CRC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg03923535	chr7:1197113	ZFAND2A	0.45	6.81	0.35	4.63e-11	Longevity;Endometriosis;
CRC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00801512	chr17:28996047	NA	0.53	6.04	0.32	4.22e-9	Hip circumference adjusted for BMI;
CRC	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	5.04e-11	Prostate cancer;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.67	7.26	0.37	2.83e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.74e-9	Aortic root size;
CRC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.48	-6.09	-0.32	3.21e-9	DNA methylation (variation);
CRC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg27535305	chr1:53392650	SCP2	0.34	6.17	0.32	2.03e-9	Monocyte count;
CRC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.42e-25	Intelligence (multi-trait analysis);
CRC	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg09040174	chr2:113837401	NA	0.65	10.31	0.49	9.07e-22	Protein quantitative trait loci;
CRC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02725872	chr8:58115012	NA	-0.39	-6.77	-0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg05072774	chr3:49840536	C3orf54	-0.45	-5.83	-0.31	1.35e-8	Resting heart rate;
CRC	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg13491945	chr12:107078410	RFX4	0.34	5.65	0.3	3.45e-8	Heart rate;
CRC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg13319975	chr6:146136371	FBXO30	0.39	5.93	0.31	7.81e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11365449	chr11:66313673	ZDHHC24;ACTN3	-0.42	-6.07	-0.32	3.57e-9	Myopia (pathological);
CRC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.38	5.68	0.3	2.95e-8	HDL cholesterol levels;
CRC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.76	13.55	0.6	1.51e-33	Oral cavity cancer;
CRC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg24375607	chr4:120327624	NA	0.48	7.74	0.39	1.2e-13	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg21251018	chr6:28226885	NKAPL	0.47	6.14	0.32	2.42e-9	Depression;
CRC	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.9	0.36	2.62e-11	Retinal vascular caliber;
CRC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.71	-12.68	-0.57	2.93e-30	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.67	-8.08	-0.41	1.22e-14	Initial pursuit acceleration;
CRC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.72	-10.25	-0.49	1.45e-21	Lung cancer;
CRC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.75	11.79	0.55	5.18e-27	Intelligence (multi-trait analysis);
CRC	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.49	7.82	0.4	7.04e-14	Body mass index;
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg03623178	chr6:28175578	NA	0.64	9.66	0.47	1.3e-19	Cardiac Troponin-T levels;
CRC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg21681030	chr2:46777652	RHOQ	0.45	6.05	0.32	3.98e-9	Height;
CRC	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.67	-6.14	-0.32	2.33e-9	IgG glycosylation;
CRC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.08	13.41	0.59	5.35e-33	Vitiligo;
CRC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg06494592	chr3:125709126	NA	-0.53	-6.49	-0.34	3.08e-10	Blood pressure (smoking interaction);
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg15511327	chr8:143859410	LYNX1	0.39	6.76	0.35	6.25e-11	Urinary tract infection frequency;
CRC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg27068330	chr11:65405492	SIPA1	0.61	9.06	0.45	1.23e-17	Acne (severe);
CRC	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.52	-8.45	-0.42	9.5e-16	Depressive symptoms (multi-trait analysis);
CRC	trans	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.27	-0.37	2.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.41	-7.48	-0.38	7e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs877282	0.583	rs11253428	chr10:823233	C/T	cg22713356	chr15:30763199	NA	0.78	8.63	0.43	2.75e-16	Uric acid levels;
CRC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.64	12.43	0.57	2.39e-29	Coronary artery disease;
CRC	cis	rs2708240	0.666	rs2538962	chr7:147600604	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.44	-6.44	-0.33	4.25e-10	QT interval (drug interaction);
CRC	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	0.87	10.71	0.51	3.67e-23	Breast cancer;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.48	-6.65	-0.34	1.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg14593290	chr7:50529359	DDC	-0.43	-6.34	-0.33	7.62e-10	Body mass index;
CRC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	11.2	0.53	6.87e-25	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg07817883	chr1:32538562	TMEM39B	-0.62	-8.11	-0.41	1.03e-14	Monocyte percentage of white cells;
CRC	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.42	-6.09	-0.32	3.07e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs10905065	0.930	rs9423726	chr10:5737979	A/G	cg11519256	chr10:5708881	ASB13	-0.45	-6.47	-0.34	3.6e-10	Menopause (age at onset);
CRC	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-8.08	-0.41	1.22e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.78	13.56	0.6	1.41e-33	Breast cancer;
CRC	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.7	-7.95	-0.4	2.96e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.85	-0.35	3.74e-11	Height;
CRC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.49	0.34	3.18e-10	HIV-1 control;
CRC	cis	rs7680126	0.633	rs55766779	chr4:10287039	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.68	-0.35	1.04e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.54	5.79	0.3	1.66e-8	Schizophrenia;
CRC	trans	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.73	-0.39	1.31e-13	HDL cholesterol;
CRC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.66	7.3	0.37	2.18e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.42	-7.26	-0.37	2.74e-12	Height;
CRC	cis	rs236352	0.576	rs3778016	chr6:36842192	C/T	cg10099585	chr6:36853529	C6orf89	-0.45	-6.34	-0.33	7.47e-10	Heart rate;
CRC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.58	6.38	0.33	6.18e-10	Bipolar disorder;
CRC	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-7.79	-0.39	8.69e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg03041920	chr13:100310311	CLYBL	0.39	5.62	0.3	4e-8	Obesity-related traits;
CRC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.41	6.63	0.34	1.4e-10	High light scatter reticulocyte count;
CRC	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.08	-0.36	8.55e-12	Body mass index;
CRC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg00343986	chr7:65444356	GUSB	-0.47	-7.07	-0.36	9.53e-12	Aortic root size;
CRC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.71	-12.84	-0.58	7e-31	Dental caries;
CRC	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.65	8.4	0.42	1.31e-15	Uric acid levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07907917	chr19:40949191	SERTAD3	0.48	6.12	0.32	2.59e-9	Thyroid stimulating hormone;
CRC	cis	rs3751196	0.808	rs1437505	chr12:104216214	G/A	cg02344784	chr12:104178138	NT5DC3	0.7	8.24	0.41	4.16e-15	Sense of smell;
CRC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.58	9.27	0.45	2.57e-18	Vitiligo;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	cis	rs4290604	0.667	rs62183333	chr2:237953460	T/C	cg23555395	chr2:238036564	NA	0.66	6.54	0.34	2.37e-10	Asthma;
CRC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.39	0.42	1.47e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.55	9.77	0.47	5.65e-20	Optic cup area;
CRC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.82	11.68	0.54	1.3e-26	Cognitive function;
CRC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.84	0.4	6.51e-14	Diabetic retinopathy;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.43	-9.47	-0.46	5.47e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9549328	0.527	rs9549622	chr13:113640064	A/C	cg20742385	chr13:113633654	MCF2L	-0.55	-6.56	-0.34	2.03e-10	Systolic blood pressure;
CRC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-1.39	-13.15	-0.59	4.95e-32	Plateletcrit;
CRC	cis	rs720844	0.671	rs10928399	chr2:149277896	C/T	cg09247360	chr2:149335327	NA	-0.51	-6.01	-0.31	4.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg24163568	chr5:669837	TPPP	0.43	6.83	0.35	4.09e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.72	-0.39	1.41e-13	Breast cancer;
CRC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.6	10.61	0.51	7.98e-23	Aortic root size;
CRC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.63	10.05	0.48	6.78e-21	Colorectal cancer;
CRC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04221910	chr5:616842	CEP72	0.41	6.77	0.35	5.99e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.49	7.57	0.39	3.7e-13	Corneal astigmatism;
CRC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.64	6.6	0.34	1.62e-10	Axial length;
CRC	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg02569458	chr12:86230093	RASSF9	0.39	6.55	0.34	2.18e-10	Major depressive disorder;
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.53	-0.38	4.84e-13	Alzheimer's disease;
CRC	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg08717414	chr16:71523259	ZNF19	-0.46	-5.81	-0.31	1.45e-8	Post bronchodilator FEV1;
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23378565	chr7:2036160	MAD1L1	-0.5	-7.03	-0.36	1.17e-11	Bipolar disorder;
CRC	trans	rs11818462	0.522	rs72821972	chr10:107167108	C/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.62	-6.0	-0.31	5.07e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg01657329	chr11:68192670	LRP5	-0.45	-6.42	-0.33	4.63e-10	Total body bone mineral density (age 0-15);
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.85	-0.31	1.16e-8	Neuroticism;
CRC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.68e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.6	-8.81	-0.44	7.55e-17	Menarche (age at onset);
CRC	cis	rs3751196	0.708	rs55724382	chr12:104155075	T/C	cg02344784	chr12:104178138	NT5DC3	0.66	6.21	0.32	1.63e-9	Sense of smell;
CRC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.31	-0.33	9.08e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.43	6.83	0.35	4.07e-11	Dupuytren's disease;
CRC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.43	-5.9	-0.31	8.99e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.79	0.3	1.65e-8	Heart rate;
CRC	cis	rs1223397	0.651	rs2496146	chr6:13312474	A/G	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg10298567	chr3:47292165	KIF9	-0.35	-5.82	-0.31	1.36e-8	Colorectal cancer;
CRC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.43	5.8	0.3	1.59e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.53	-7.63	-0.39	2.56e-13	High light scatter reticulocyte count;
CRC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg14433983	chr11:636460	DRD4	-0.42	-6.17	-0.32	2.01e-9	Systemic lupus erythematosus;
CRC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.79	0.51	1.94e-23	Motion sickness;
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.07	-0.36	9.16e-12	IgG glycosylation;
CRC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.9	-11.41	-0.53	1.27e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.65	11.25	0.53	4.57e-25	Blood protein levels;
CRC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.79	-13.29	-0.59	1.53e-32	Obesity-related traits;
CRC	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.67	0.3	3.07e-8	Tuberculosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02002494	chr3:119013045	CDGAP	0.52	7.53	0.38	4.97e-13	Response to antipsychotic treatment;
CRC	trans	rs7474896	0.887	rs12570864	chr10:37937293	T/C	cg16724811	chr16:15130678	PDXDC1	-0.62	-6.01	-0.31	4.96e-9	Obesity (extreme);
CRC	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.4	5.76	0.3	1.91e-8	Platelet distribution width;
CRC	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg27534772	chr1:16042836	PLEKHM2	0.44	7.16	0.37	5.35e-12	Systolic blood pressure;
CRC	trans	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02228675	chr17:40259724	DHX58	-0.48	-6.78	-0.35	5.51e-11	Fibrinogen levels;
CRC	cis	rs731174	0.840	rs525379	chr1:38151705	T/C	cg06917450	chr1:38156652	C1orf109	-0.51	-7.18	-0.37	4.74e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7546094	1.000	rs7513716	chr1:113089320	A/T	cg22162597	chr1:113214053	CAPZA1	0.43	5.93	0.31	7.67e-9	Platelet distribution width;
CRC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.5	7.54	0.38	4.65e-13	Emphysema distribution in smoking;
CRC	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.1	0.49	4.49e-21	Asthma;
CRC	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.56	-9.28	-0.46	2.35e-18	Graves' disease;
CRC	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.62	-8.56	-0.43	4.31e-16	Type 2 diabetes;
CRC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.69	9.42	0.46	8.11e-19	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05805736	chr6:42952517	PPP2R5D	0.43	6.11	0.32	2.89e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02577203	chr11:47869805	NUP160	-0.51	-6.17	-0.32	1.95e-9	Diisocyanate-induced asthma;
CRC	cis	rs7605827	0.866	rs4668901	chr2:15521677	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg25204440	chr1:209979598	IRF6	0.49	5.92	0.31	8.29e-9	Cleft lip with or without cleft palate;
CRC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.44	8.77	0.44	1.01e-16	Renal cell carcinoma;
CRC	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.2	-0.32	1.66e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg15571903	chr15:79123663	NA	0.3	5.99	0.31	5.5e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.67	-11.85	-0.55	3.21e-27	Eye color traits;
CRC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.75	-0.35	6.74e-11	Response to antipsychotic treatment;
CRC	cis	rs7619833	0.592	rs7615829	chr3:27252196	C/G	cg02860705	chr3:27208620	NA	0.37	5.82	0.31	1.42e-8	Breast cancer;
CRC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.73	-7.26	-0.37	2.89e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg23565292	chr14:50234668	KLHDC2	-0.44	-6.21	-0.32	1.57e-9	Carotid intima media thickness;
CRC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.87	13.1	0.59	7.35e-32	Cognitive function;
CRC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg20608306	chr11:116969690	SIK3	-0.3	-5.78	-0.3	1.71e-8	Blood protein levels;
CRC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg18200150	chr17:30822561	MYO1D	0.45	8.6	0.43	3.29e-16	Schizophrenia;
CRC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-8.49	-0.42	7.36e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.92	17.77	0.7	5.25e-50	Obesity-related traits;
CRC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.52	-8.74	-0.43	1.2e-16	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11969144	chr1:87797684	LMO4	0.37	6.26	0.33	1.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.51	-9.43	-0.46	7.73e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	0.67	5.89	0.31	9.73e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.71	-12.09	-0.55	4.36e-28	Lung cancer;
CRC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg01480708	chr17:30846118	MYO1D	-0.38	-6.38	-0.33	6.03e-10	Schizophrenia;
CRC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Urate levels;
CRC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs853679	1.000	rs853678	chr6:28297313	T/A	cg03623178	chr6:28175578	NA	0.64	6.81	0.35	4.77e-11	Depression;
CRC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg11707556	chr5:10655725	ANKRD33B	0.35	6.53	0.34	2.45e-10	Coronary artery disease;
CRC	cis	rs802075	1.000	rs802075	chr6:49654166	A/G	cg20364632	chr6:49636226	NA	-0.35	-5.73	-0.3	2.27e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.52	5.91	0.31	8.7e-9	Type 2 diabetes nephropathy;
CRC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.37e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.54	9.7	0.47	1.01e-19	Common traits (Other);
CRC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.6	9.8	0.48	4.77e-20	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.66	7.06	0.36	1.02e-11	Axial length;
CRC	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg08075719	chr14:103021372	NA	-0.65	-8.48	-0.42	7.7e-16	Platelet count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15365320	chr11:17373302	DKFZp686O24166	0.44	6.2	0.32	1.69e-9	Anxiety disorder;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07580707	chr3:14220061	XPC;LSM3	0.4	6.36	0.33	6.66e-10	Obesity-related traits;
CRC	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.79	-0.35	5.1e-11	Coronary artery disease;
CRC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.4	-7.36	-0.38	1.48e-12	Bipolar disorder;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg01758942	chr3:52551074	STAB1	0.3	5.95	0.31	6.96e-9	Electroencephalogram traits;
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg27635394	chr6:26043820	HIST1H2BB	-0.38	-5.7	-0.3	2.61e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4908768	0.539	rs11121204	chr1:8654305	A/G	cg20416874	chr1:8611966	RERE	0.45	6.02	0.31	4.77e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg25809561	chr17:30822961	MYO1D	0.52	9.52	0.46	3.97e-19	Schizophrenia;
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg15511327	chr8:143859410	LYNX1	0.4	7.25	0.37	2.95e-12	Urinary tract infection frequency;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg03804128	chr16:635623	NA	0.3	6.93	0.36	2.25e-11	Height;
CRC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg19046167	chr17:80928561	B3GNTL1	0.47	8.04	0.41	1.66e-14	Breast cancer;
CRC	cis	rs4728302	0.869	rs6966403	chr7:133614421	A/C	cg10665199	chr7:133106180	EXOC4	-0.4	-6.0	-0.31	5.18e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	11.32	0.53	2.63e-25	Bone mineral density;
CRC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	0.93	8.88	0.44	4.4e-17	IgG glycosylation;
CRC	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.59	8.77	0.44	9.48e-17	Schizophrenia;
CRC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.46	-0.46	6.05e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs3849570	0.615	rs1851918	chr3:81980557	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-6.62	-0.34	1.46e-10	Waist circumference;Body mass index;
CRC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.51	-6.96	-0.36	1.83e-11	IgG glycosylation;
CRC	cis	rs698833	0.892	rs1067322	chr2:44630107	C/T	cg04920474	chr2:44395004	PPM1B	0.39	5.65	0.3	3.51e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg24308560	chr3:49941425	MST1R	-0.43	-6.18	-0.32	1.85e-9	Resting heart rate;
CRC	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg16898833	chr6:26189333	HIST1H4D	1.0	7.2	0.37	4.15e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07513332	chr6:167530253	CCR6	0.38	6.25	0.33	1.27e-9	Primary biliary cholangitis;
CRC	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg14752227	chr20:34000481	UQCC	-0.37	-5.72	-0.3	2.33e-8	Height;
CRC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.76	-9.02	-0.45	1.57e-17	Hemostatic factors and hematological phenotypes;
CRC	trans	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06456258	chr22:39898429	SMCR7L	0.45	6.29	0.33	1.02e-9	Anxiety disorder;
CRC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.68	-11.18	-0.52	8.14e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	10.67	0.51	4.93e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.51	7.84	0.4	6.25e-14	Testicular germ cell tumor;
CRC	cis	rs3018066	0.777	rs11725254	chr4:106943155	G/C	cg01869342	chr4:106983673	TBCK	0.44	6.04	0.32	4.23e-9	Cancer;
CRC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.56	7.89	0.4	4.44e-14	Alcohol dependence;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14810013	chr4:66535412	EPHA5	0.29	6.36	0.33	6.93e-10	Myopia (pathological);
CRC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.75	0.39	1.19e-13	Colorectal cancer;
CRC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	6.04	0.32	4.24e-9	IgG glycosylation;
CRC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg10760299	chr15:45669010	GATM	0.48	7.63	0.39	2.56e-13	Homoarginine levels;
CRC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.5	7.53	0.38	5e-13	Emphysema distribution in smoking;
CRC	cis	rs10071761	0.513	rs4957277	chr5:40361734	A/G	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.03	-0.4	1.74e-14	Response to antipsychotic treatment;
CRC	cis	rs73206853	0.697	rs56084592	chr12:110577910	T/A	cg12870014	chr12:110450643	ANKRD13A	0.82	10.31	0.49	8.97e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg00666640	chr1:248458726	OR2T12	0.51	8.99	0.44	1.98e-17	Common traits (Other);
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.56	7.88	0.4	4.96e-14	Resting heart rate;
CRC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.8	12.06	0.55	5.56e-28	Cognitive function;
CRC	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.58	-0.39	3.44e-13	Bipolar disorder;
CRC	cis	rs13333054	1.000	rs13333054	chr16:86011033	C/T	cg08215318	chr16:86016387	NA	0.81	11.69	0.54	1.18e-26	Multiple sclerosis;
CRC	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.43	5.88	0.31	1.02e-8	Educational attainment (years of education);
CRC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-17.13	-0.69	1.81e-47	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.42	-0.33	4.72e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg11503833	chr11:492997	NA	0.54	6.09	0.32	3.13e-9	Body mass index;
CRC	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.75	-10.28	-0.49	1.09e-21	White matter hyperintensity burden;
CRC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg21747405	chr11:67723411	NA	-0.44	-6.29	-0.33	9.96e-10	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17864040	chr1:78148524	ZZZ3	0.43	6.09	0.32	3.14e-9	Response to antipsychotic treatment;
CRC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.69	-0.43	1.78e-16	Coronary artery disease;
CRC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.67	-9.17	-0.45	5.2e-18	Metabolic syndrome;
CRC	cis	rs3736485	0.966	rs8042289	chr15:51899884	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.49	-0.34	3.08e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.56	10.95	0.52	5.37e-24	Asthma (sex interaction);
CRC	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg14668889	chr17:73230827	NUP85	-0.51	-7.44	-0.38	8.84e-13	Systemic lupus erythematosus;
CRC	cis	rs7731657	0.537	rs4705917	chr5:130206326	A/G	cg08523029	chr5:130500466	HINT1	-0.42	-5.7	-0.3	2.67e-8	Fasting plasma glucose;
CRC	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg09455208	chr3:40491958	NA	0.31	6.31	0.33	8.76e-10	Renal cell carcinoma;
CRC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.78e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg05585544	chr11:47624801	NA	-0.62	-10.84	-0.51	1.26e-23	Body mass index;
CRC	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.72	-0.3	2.33e-8	Height;
CRC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.78	9.82	0.48	4.08e-20	Initial pursuit acceleration;
CRC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.51	7.2	0.37	4.11e-12	High light scatter reticulocyte count;
CRC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.69	9.48	0.46	5.06e-19	Vitiligo;
CRC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Red blood cell count;
CRC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.15	0.37	5.49e-12	Menopause (age at onset);
CRC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg11833968	chr6:79620685	NA	0.36	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	5.82	0.31	1.4e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg04518342	chr5:131593106	PDLIM4	0.57	9.82	0.48	3.86e-20	Acylcarnitine levels;
CRC	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg12856521	chr11:46389249	DGKZ	-0.42	-6.64	-0.34	1.3100000000000001e-10	Leprosy;
CRC	cis	rs7680126	0.562	rs4698036	chr4:10331294	T/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.76	-0.35	6.34e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	13.74	0.6	2.92e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.4	-7.44	-0.38	9e-13	Iron status biomarkers;
CRC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.65	9.55	0.47	3.16e-19	Menopause (age at onset);
CRC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.0	0.44	1.84e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.44	-7.37	-0.38	1.39e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7605827	0.930	rs10189403	chr2:15635664	T/A	cg19274914	chr2:15703543	NA	0.4	6.09	0.32	3.22e-9	Educational attainment (years of education);
CRC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.65	8.55	0.43	4.55e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	7.62	0.39	2.82e-13	Schizophrenia;
CRC	cis	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg26958806	chr6:27640298	NA	0.93	6.61	0.34	1.55e-10	Depression;
CRC	cis	rs7605827	0.930	rs1986279	chr2:15617390	G/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs4975616	1.000	rs4975616	chr5:1315660	G/A	cg26373071	chr5:1325741	CLPTM1L	-0.5	-8.59	-0.43	3.61e-16	Lung cancer;
CRC	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.15	-0.37	5.52e-12	Inflammatory bowel disease;
CRC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg07195577	chr17:27052828	TLCD1	0.4	5.66	0.3	3.36e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.49	-7.77	-0.39	9.77e-14	Schizophrenia;
CRC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.32	0.33	8.64e-10	Life satisfaction;
CRC	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.35	6.66	0.34	1.16e-10	QRS complex (12-leadsum);
CRC	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.57	6.56	0.34	2.11e-10	Osteoarthritis;
CRC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg03146154	chr1:46216737	IPP	-0.54	-7.23	-0.37	3.4e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs501120	1.000	rs559580	chr10:44752078	C/T	cg09554077	chr10:44749378	NA	-0.84	-11.48	-0.53	6.8e-26	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg02972257	chr16:68554789	NA	-0.54	-6.69	-0.35	9.59e-11	Ulcerative colitis;
CRC	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg02072170	chr3:194406190	FAM43A	0.42	7.22	0.37	3.71e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg15845792	chr6:28175446	NA	0.7	6.22	0.32	1.51e-9	Depression;
CRC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.92	17.11	0.69	2.18e-47	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11310629	chr13:45991975	SLC25A30	0.48	6.31	0.33	8.78e-10	Thyroid stimulating hormone;
CRC	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.48	9.18	0.45	5.01e-18	Educational attainment (years of education);
CRC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	7.2	0.37	4.04e-12	Hemoglobin concentration;
CRC	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.24	14.83	0.63	1.93e-38	Lung disease severity in cystic fibrosis;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg08245425	chr17:34957834	MRM1	0.45	6.65	0.34	1.2e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.56	-7.17	-0.37	4.95e-12	Neuroticism;
CRC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.79	-12.05	-0.55	5.82e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg05043794	chr9:111880884	C9orf5	0.33	6.12	0.32	2.7e-9	Menarche (age at onset);
CRC	cis	rs6534441	0.697	rs75752108	chr4:125428768	A/G	cg21609808	chr4:125404261	NA	0.45	6.32	0.33	8.42e-10	Major depressive disorder;
CRC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.44	6.71	0.35	8.71e-11	Coronary artery disease;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.59	8.26	0.41	3.54e-15	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	1.04	14.64	0.63	1.04e-37	Exhaled nitric oxide output;
CRC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg17031739	chr1:67600172	NA	0.45	7.23	0.37	3.38e-12	Psoriasis;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18402987	chr7:1209562	NA	0.39	5.83	0.31	1.31e-8	Longevity;Endometriosis;
CRC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.86	-11.63	-0.54	1.94e-26	Asthma;
CRC	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg23234261	chr14:55582407	NA	-0.3	-5.98	-0.31	5.76e-9	Protein biomarker;
CRC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg03037974	chr15:76606532	NA	0.56	8.23	0.41	4.37e-15	Blood metabolite levels;
CRC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.57	7.45	0.38	8.18e-13	Gut microbiome composition (summer);
CRC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-7.05	-0.36	1.03e-11	Alzheimer's disease (late onset);
CRC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.56	8.18	0.41	6.37e-15	Schizophrenia;
CRC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg16342193	chr10:102329863	NA	-0.34	-5.82	-0.31	1.37e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2223471	0.870	rs2817422	chr6:50750240	G/C	cg03432817	chr6:50765336	NA	0.37	5.92	0.31	8.1e-9	Subcutaneous adipose tissue;
CRC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.81	14.7	0.63	6.14e-38	Anterior chamber depth;
CRC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.55	-8.77	-0.44	9.81e-17	Huntington's disease progression;
CRC	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-8.01	-0.4	1.94e-14	Mean platelet volume;Platelet distribution width;
CRC	trans	rs16957091	0.528	rs34920950	chr15:43109479	T/A	cg07673103	chr8:74277181	NA	0.56	6.12	0.32	2.74e-9	MGMT methylation in smokers;
CRC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.71	0.3	2.59e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.66	0.43	2.12e-16	Height;
CRC	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.64	-8.17	-0.41	6.86e-15	Alcohol dependence;Nicotine use;
CRC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg24849736	chr1:201084428	NA	0.46	6.05	0.32	3.87e-9	Permanent tooth development;
CRC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.36	-0.38	1.48e-12	Monocyte percentage of white cells;
CRC	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.3	-0.33	9.56e-10	Fractional excretion of uric acid;
CRC	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.89	0.44	4.14e-17	Coffee consumption (cups per day);
CRC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg15145296	chr3:125709740	NA	-0.57	-6.72	-0.35	8.25e-11	Blood pressure (smoking interaction);
CRC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.5	10.34	0.5	6.86e-22	Bone mineral density;
CRC	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.38	5.95	0.31	6.74e-9	Endometrial cancer;
CRC	cis	rs9462027	0.628	rs9348950	chr6:34673678	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.28	0.33	1.09e-9	Systemic lupus erythematosus;
CRC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.93	-17.12	-0.69	1.91e-47	Intelligence (multi-trait analysis);
CRC	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.47	-6.69	-0.35	9.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	8.1	0.41	1.09e-14	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9311676	0.632	rs6777066	chr3:58361603	T/C	cg06643156	chr3:58380774	PXK	0.43	6.73	0.35	7.6e-11	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9359856	0.956	rs6934804	chr6:90316020	A/G	cg13799429	chr6:90582589	CASP8AP2	0.45	6.37	0.33	6.31e-10	Bipolar disorder;
CRC	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg08461752	chr10:43522343	NA	-0.63	-5.9	-0.31	9.27e-9	Blood protein levels;
CRC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.44	5.75	0.3	2.04e-8	Post bronchodilator FEV1;
CRC	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.53	6.93	0.36	2.22e-11	Alzheimer's disease (survival time);
CRC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00339695	chr16:24857497	SLC5A11	0.26	6.01	0.31	5.01e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg21747405	chr11:67723411	NA	-0.49	-6.42	-0.33	4.84e-10	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg07392085	chr5:141489673	NDFIP1	0.46	7.24	0.37	3.17e-12	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10659886	chr19:58629719	ZSCAN18	0.23	6.7	0.35	9.19e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs55638078	chr2:162524997	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.58e-9	Cognitive function;
CRC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.36	-5.93	-0.31	7.76e-9	Red cell distribution width;
CRC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	8.95	0.44	2.66e-17	Cognitive test performance;
CRC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	5.98	0.31	5.97e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4750440	0.671	rs1809305	chr10:14026780	G/A	cg00551146	chr10:14014579	FRMD4A	0.4	6.35	0.33	7.14e-10	Adiponectin levels;
CRC	cis	rs13315871	1.000	rs9860970	chr3:58353781	C/T	cg20936604	chr3:58311152	NA	-0.75	-6.89	-0.35	2.89e-11	Cholesterol, total;
CRC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg18876405	chr7:65276391	NA	0.47	6.47	0.34	3.62e-10	Aortic root size;
CRC	cis	rs9532580	0.778	rs34373380	chr13:41244217	T/A	cg21288729	chr13:41239152	FOXO1	0.5	7.6	0.39	3.04e-13	Mean corpuscular hemoglobin;
CRC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg14541582	chr5:601475	NA	-0.33	-6.35	-0.33	7.09e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs28829049	0.597	rs1009806	chr1:19500551	T/C	cg13387374	chr1:19411106	UBR4	0.41	6.06	0.32	3.81e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.75	14.32	0.62	1.76e-36	Body mass index;
CRC	trans	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg17401720	chr7:158221031	PTPRN2	0.46	7.56	0.38	3.95e-13	Obesity-related traits;
CRC	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg23093090	chr10:104574429	C10orf26	0.44	5.86	0.31	1.13e-8	Arsenic metabolism;
CRC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.29	0.33	1.02e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.58	9.13	0.45	6.99e-18	Body mass index;
CRC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg12463550	chr7:65579703	CRCP	0.64	6.1	0.32	3.01e-9	Diabetic kidney disease;
CRC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.51	-0.34	2.82e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.52	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.37	6.58	0.34	1.86e-10	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.45e-10	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4838594	0.563	rs730509	chr10:49679153	C/A	cg17291251	chr10:49678358	ARHGAP22	0.44	7.02	0.36	1.29e-11	Daytime sleep phenotypes;
CRC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg22117107	chr15:45993392	NA	0.44	8.82	0.44	6.78e-17	Waist circumference;Weight;
CRC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.71	10.46	0.5	2.79e-22	Immature fraction of reticulocytes;
CRC	cis	rs997295	0.570	rs28730805	chr15:67879418	G/A	cg24247231	chr15:67904302	MAP2K5	-0.33	-5.75	-0.3	2e-8	Motion sickness;
CRC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg26893134	chr6:116381904	FRK	0.26	7.6	0.39	3.02e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.76	0.39	1.08e-13	Lung cancer;
CRC	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.68	-10.39	-0.5	4.52e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.52	7.07	0.36	9.2e-12	Morning vs. evening chronotype;
CRC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.57	9.04	0.45	1.41e-17	Vitiligo;
CRC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.14	0.37	6.01e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.61	7.7	0.39	1.6e-13	Gut microbiome composition (summer);
CRC	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-7.06	-0.36	9.8e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.4	-6.51	-0.34	2.74e-10	Gout;Renal underexcretion gout;
CRC	cis	rs7113874	0.569	rs11041978	chr11:8578150	T/C	cg02811074	chr11:8615871	STK33	-0.34	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2580764	0.517	rs2972070	chr2:55301691	G/A	cg09592903	chr2:55203963	RTN4	0.65	10.46	0.5	2.72e-22	Mean platelet volume;
CRC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-6.67	-0.35	1.07e-10	Axial length;
CRC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.72	7.69	0.39	1.69e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.14	-0.37	5.89e-12	Personality dimensions;
CRC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.59	-0.34	1.72e-10	Acylcarnitine levels;
CRC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg23071808	chr14:103021642	NA	-0.67	-8.62	-0.43	2.84e-16	Platelet count;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16870442	chr8:6264181	MCPH1	0.45	6.33	0.33	7.95e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg11189052	chr15:85197271	WDR73	0.65	9.56	0.47	2.9e-19	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05885012	chr17:55980673	CUEDC1	0.45	6.47	0.34	3.6e-10	Response to antipsychotic treatment;
CRC	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg15131784	chr3:139108705	COPB2	0.39	5.69	0.3	2.79e-8	Obesity-related traits;
CRC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.56	-8.26	-0.41	3.62e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6504950	0.800	rs9916547	chr17:53006890	G/A	cg26251398	chr17:52985966	TOM1L1	0.37	5.65	0.3	3.48e-8	Breast cancer;
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.1	0.36	7.93e-12	Alzheimer's disease;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02359409	chr6:42947317	PEX6	-0.61	-9.76	-0.47	6.45e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.8	-0.55	5.04e-27	Type 2 diabetes;
CRC	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.52	13.22	0.59	2.77e-32	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.08	-0.41	1.22e-14	Bipolar disorder;
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.2	-0.37	4.14e-12	Total body bone mineral density;
CRC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-18.86	-0.72	2.59e-54	Height;
CRC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.6	8.74	0.43	1.23e-16	Total body bone mineral density;
CRC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.43	6.62	0.34	1.48e-10	High light scatter reticulocyte count;
CRC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.57	-8.34	-0.42	2.04e-15	Dental caries;
CRC	cis	rs12230513	0.732	rs60643523	chr12:55842928	A/G	cg19537932	chr12:55886519	OR6C68	-0.73	-9.5	-0.46	4.47e-19	Contrast sensitivity;
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-10.78	-0.51	2.03e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20092199	chr4:1342459	KIAA1530	0.36	6.35	0.33	7.29e-10	Obesity-related traits;
CRC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.43	0.42	1.11e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.63	7.32	0.37	1.91e-12	Response to hepatitis C treatment;
CRC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.51	-7.43	-0.38	9.18e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4363385	0.818	rs472076	chr1:153013742	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.9	-0.36	2.64e-11	Inflammatory skin disease;
CRC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Bone mineral density;
CRC	trans	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg26043149	chr18:55253948	FECH	-0.72	-10.47	-0.5	2.51e-22	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg14092571	chr14:90743983	NA	0.39	5.88	0.31	1.02e-8	Mortality in heart failure;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.1	-0.45	8.89e-18	Bipolar disorder;
CRC	cis	rs7259376	0.694	rs75653200	chr19:22579503	G/T	cg02657401	chr19:22469223	NA	0.31	6.79	0.35	5.21e-11	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03729288	chr17:7232752	NEURL4	0.39	6.24	0.33	1.35e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs28489187	0.706	rs2300637	chr1:85822772	T/C	cg17737388	chr1:85724454	C1orf52	0.38	5.7	0.3	2.67e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-6.75	-0.35	6.56e-11	Schizophrenia;
CRC	trans	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg19847866	chr10:1019161	NA	0.4	5.75	0.3	1.99e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg00034003	chr16:88779146	CTU2	0.66	6.56	0.34	2.09e-10	Autism spectrum disorder-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16071359	chr2:169312933	LASS6	0.48	6.7	0.35	9.22e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.73	0.39	1.29e-13	Aortic root size;
CRC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.52	7.09	0.36	8.45e-12	Iron status biomarkers;
CRC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.2	-0.37	4.04e-12	Hemoglobin concentration;
CRC	cis	rs28655083	0.636	rs61117898	chr16:77050736	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.6	-7.15	-0.37	5.7e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.7	10.33	0.49	7.6e-22	Corneal astigmatism;
CRC	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg08533674	chr1:46993347	NA	-0.39	-5.67	-0.3	3.21e-8	Monobrow;
CRC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg09473613	chr1:24152604	HMGCL	0.35	5.67	0.3	3.18e-8	Immature fraction of reticulocytes;
CRC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg13385521	chr17:29058706	SUZ12P	0.5	6.2	0.32	1.67e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.38	6.08	0.32	3.29e-9	Lung cancer;
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.3	0.33	9.46e-10	Electroencephalogram traits;
CRC	cis	rs6743226	0.934	rs4234100	chr2:242265273	A/G	cg10021735	chr2:242295487	FARP2	-0.45	-6.65	-0.34	1.24e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg08314208	chr16:67682810	RLTPR	-0.6	-6.5	-0.34	2.93e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs854555	0.581	rs854537	chr7:94910248	C/T	cg19678392	chr7:94953810	PON1	-0.46	-6.08	-0.32	3.38e-9	Response to TNF antagonist treatment;
CRC	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.07	-0.36	9.35e-12	Caudate activity during reward;
CRC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.19	-0.32	1.79e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.14	-0.37	5.94e-12	Total body bone mineral density;
CRC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.82	-0.44	6.85e-17	Chronic sinus infection;
CRC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.48e-9	Homoarginine levels;
CRC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.37	-0.42	1.7e-15	Gut microbiome composition (summer);
CRC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.22	-6.0	-0.31	5.26e-9	Urinary metabolites;
CRC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.5	8.21	0.41	5.03e-15	Lipoprotein (a) levels;
CRC	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.01	19.29	0.73	5.52e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.9	20.85	0.75	4.04e-62	Longevity;
CRC	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.64	9.15	0.45	6.22e-18	Coronary artery disease;
CRC	cis	rs4867766	0.789	rs17781920	chr5:173955939	G/A	cg20434911	chr5:173954559	NA	-0.8	-9.1	-0.45	8.58e-18	Stroke;
CRC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-7.11	-0.36	7.48e-12	Vitiligo;
CRC	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg04202892	chr2:111875749	ACOXL	0.44	7.07	0.36	9.17e-12	Chronic lymphocytic leukemia;
CRC	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg03929089	chr4:120376271	NA	0.65	6.38	0.33	6.18e-10	Axial length;
CRC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.72	-0.3	2.33e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg05341575	chr12:125625032	AACS	-0.39	-5.95	-0.31	6.85e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs478222	1.000	rs478222	chr2:25301755	A/T	cg22495460	chr2:25135724	ADCY3	0.43	6.4	0.33	5.39e-10	Type 1 diabetes;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.1	-0.32	3.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg08755490	chr11:65554678	OVOL1	0.42	6.15	0.32	2.24e-9	Acne (severe);
CRC	cis	rs11212617	1.000	rs227092	chr11:108236783	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.32	0.33	8.53e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12581662	chr19:36706085	ZNF565;ZNF146	0.45	6.78	0.35	5.62e-11	Response to antipsychotic treatment;
CRC	cis	rs965469	1.000	rs6051672	chr20:3224819	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.7	-0.3	2.61e-8	IFN-related cytopenia;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	8.21	0.41	5.01e-15	Lymphocyte counts;
CRC	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg24463073	chr6:118973353	C6orf204	0.53	6.55	0.34	2.2e-10	Diastolic blood pressure;
CRC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg05355328	chr19:33096524	ANKRD27	0.51	5.7	0.3	2.63e-8	Eosinophilic esophagitis;
CRC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-6.61	-0.34	1.54e-10	Arsenic metabolism;
CRC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.59	-8.67	-0.43	2.02e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.83	13.16	0.59	4.6e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.47	0.34	3.58e-10	Lung cancer;
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-11.04	-0.52	2.57e-24	Bipolar disorder;
CRC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.78	-0.3	1.69e-8	Aortic root size;
CRC	trans	rs2321882	0.834	rs61953982	chr13:59466140	T/G	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs1712517	0.771	rs11191672	chr10:105138961	C/T	cg05636881	chr10:105038444	INA	0.45	7.84	0.4	6.48e-14	Migraine;
CRC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.78	-13.48	-0.6	2.8e-33	Breast cancer;
CRC	cis	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg20159608	chr7:32802032	NA	-0.5	-6.44	-0.33	4.3e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.63	-0.43	2.69e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7113874	0.569	rs10840072	chr11:8569360	T/C	cg02811074	chr11:8615871	STK33	-0.34	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.01	-0.31	5e-9	Eosinophil percentage of white cells;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.65	0.54	1.76e-26	Prudent dietary pattern;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg04238871	chr10:126431886	FAM53B	-0.4	-6.06	-0.32	3.74e-9	Aortic root size;
CRC	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.56	-5.93	-0.31	7.62e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.77	-0.3	1.87e-8	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16841147	chr20:33543707	GSS	0.37	6.04	0.32	4.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg06470822	chr6:28175283	NA	-0.62	-9.19	-0.45	4.67e-18	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12351856	chr18:19192308	SNRPD1	0.39	6.58	0.34	1.9e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.72	10.65	0.51	5.84e-23	Neutrophil percentage of white cells;
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg26958806	chr6:27640298	NA	0.67	5.75	0.3	1.99e-8	Breast cancer;
CRC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-20.32	-0.75	4.68e-60	Hemostatic factors and hematological phenotypes;
CRC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.66	-0.43	2.12e-16	Neuroticism;
CRC	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.63	6.6	0.34	1.67e-10	Childhood ear infection;
CRC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.48	-7.19	-0.37	4.49e-12	Subjective well-being;
CRC	cis	rs55702914	0.742	rs34555121	chr2:198166053	C/T	cg03934865	chr2:198174659	NA	0.41	7.18	0.37	4.76e-12	Major depression and alcohol dependence;
CRC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.95	13.72	0.6	3.35e-34	Breast cancer;
CRC	trans	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6788895	1.000	rs1991781	chr3:150468433	G/A	cg09723797	chr3:150481914	SIAH2	0.88	5.98	0.31	5.81e-9	Breast cancer;
CRC	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.74	13.63	0.6	7.51e-34	Metabolite levels;
CRC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.58	-9.07	-0.45	1.14e-17	Vitiligo;
CRC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.06	-0.36	9.71e-12	Aortic root size;
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.23e-26	Prudent dietary pattern;
CRC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.41	-0.33	5.17e-10	Aortic root size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21413108	chr3:122233679	KPNA1	0.43	6.11	0.32	2.81e-9	Anxiety disorder;
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.49	-6.69	-0.35	9.66e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3736485	0.873	rs12442725	chr15:51874412	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs5756813	0.668	rs4821704	chr22:38146585	A/G	cg19894588	chr14:64061835	NA	-0.48	-6.41	-0.33	5.14e-10	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs9987353	0.876	rs73199666	chr8:9125730	C/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.29	-0.33	1e-9	Recombination measurement;
CRC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.68	-0.3	2.97e-8	Mean platelet volume;
CRC	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg06484146	chr7:12443880	VWDE	-0.61	-6.43	-0.33	4.5e-10	Coronary artery disease;
CRC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-9.42	-0.46	8.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg20998090	chr9:86536513	KIF27	-0.51	-6.29	-0.33	9.92e-10	Intelligence (multi-trait analysis);
CRC	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.76	0.35	6.21e-11	Resting heart rate;
CRC	cis	rs9925964	0.933	rs11150604	chr16:31037020	A/T	cg03418659	chr16:31128414	MYST1	0.46	6.66	0.34	1.16e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg15465823	chr12:48382534	COL2A1	-0.38	-6.3	-0.33	9.61e-10	Glycated hemoglobin levels;
CRC	trans	rs11581859	0.950	rs72730330	chr1:99395692	G/A	cg12183875	chr3:169587454	LRRC31	0.28	6.34	0.33	7.78e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.92	10.93	0.52	6.12e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-0.89	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs10733682	0.524	rs10987418	chr9:129462563	A/G	cg00232160	chr9:129468157	NA	0.33	5.66	0.3	3.32e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.73	-9.79	-0.48	4.91e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg01166180	chr19:36606541	POLR2I;TBCB	-0.4	-6.01	-0.31	4.93e-9	Aortic root size;
CRC	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.67	9.38	0.46	1.15e-18	White matter hyperintensity burden;
CRC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.97	0.44	2.31e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02825527	chr7:2087843	MAD1L1	-0.49	-5.82	-0.31	1.38e-8	Neuroticism;
CRC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.4	6.94	0.36	2.06e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.83	-0.44	6.26e-17	Bipolar disorder;
CRC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-8.1	-0.41	1.1e-14	Gut microbiome composition (summer);
CRC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg21251018	chr6:28226885	NKAPL	0.56	9.47	0.46	5.53e-19	Pulmonary function;
CRC	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.52	-0.43	5.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.72	0.68	7.3e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6585424	1.000	rs34386571	chr10:81939432	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-9.33	-0.46	1.56e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.18	-0.32	1.86e-9	Menopause (age at onset);
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.54	-9.41	-0.46	8.95e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg04518342	chr5:131593106	PDLIM4	0.47	8.61	0.43	3.09e-16	Breast cancer;
CRC	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-7.47	-0.38	7.31e-13	Adiposity;
CRC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg18761221	chr20:60518478	NA	0.47	7.72	0.39	1.37e-13	Body mass index;
CRC	cis	rs7781266	0.739	rs6949831	chr7:133081470	G/C	cg03336402	chr7:133662267	EXOC4	-0.47	-5.65	-0.3	3.5e-8	Educational attainment (college completion);
CRC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg15790184	chr11:494944	RNH1	0.62	5.89	0.31	9.5e-9	Body mass index;
CRC	cis	rs11229555	0.645	rs10896778	chr11:58193925	T/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg05639522	chr1:247681581	NA	0.48	7.3	0.37	2.15e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.6	-10.11	-0.49	4.19e-21	Dental caries;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs6804368	0.649	rs9850620	chr3:30767114	C/T	cg06106510	chr3:30762233	NA	-0.39	-6.93	-0.36	2.22e-11	Blood metabolite levels;
CRC	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	1.0	18.78	0.72	5.56e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.33	-0.37	1.79e-12	Morning vs. evening chronotype;
CRC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg24675056	chr1:15929824	NA	0.5	6.97	0.36	1.76e-11	Systolic blood pressure;
CRC	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	trans	rs10411161	0.702	rs10423835	chr19:52387322	A/G	cg22319618	chr22:45562946	NUP50	-0.66	-7.28	-0.37	2.41e-12	Breast cancer;
CRC	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg21153622	chr11:89784906	NA	-0.44	-7.12	-0.37	6.86e-12	HDL cholesterol;
CRC	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.81	-14.68	-0.63	7.12e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.55	-6.21	-0.32	1.63e-9	Neutrophil percentage of white cells;
CRC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg02569458	chr12:86230093	RASSF9	0.39	6.34	0.33	7.77e-10	Major depressive disorder;
CRC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-0.87	-9.28	-0.46	2.3e-18	Diabetic retinopathy;
CRC	trans	rs1864729	1.000	rs2583506	chr8:98281847	G/A	cg08679828	chr8:102218111	ZNF706	-0.63	-7.62	-0.39	2.77e-13	Estradiol plasma levels (breast cancer);
CRC	cis	rs7586879	0.663	rs6760328	chr2:25077991	T/C	cg22495460	chr2:25135724	ADCY3	-0.8	-12.82	-0.58	8.81e-31	Body mass index;
CRC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.88e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg26816564	chr1:7831052	VAMP3	0.78	8.78	0.44	9.39e-17	Inflammatory bowel disease;
CRC	trans	rs8089364	0.917	rs11660069	chr18:57885413	A/G	cg05871254	chr17:14213225	HS3ST3B1	-0.45	-6.45	-0.34	3.97e-10	Type 2 diabetes;Body mass index;
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.29	0.42	2.85e-15	Homoarginine levels;
CRC	cis	rs11212617	1.000	rs7931930	chr11:108268286	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.41	5.94	0.31	7.41e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11645453	chr3:52864694	ITIH4	0.35	6.2	0.32	1.73e-9	Bipolar disorder;
CRC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.53	-7.8	-0.39	8.34e-14	Blood protein levels;
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg08798685	chr6:27730294	NA	-0.74	-6.65	-0.34	1.22e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06505273	chr16:24850292	NA	0.38	5.81	0.3	1.5e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	17.44	0.69	1.06e-48	Platelet count;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.07	-0.32	3.44e-9	Obesity-related traits;
CRC	cis	rs6662572	0.906	rs11590549	chr1:46086329	C/T	cg06784218	chr1:46089804	CCDC17	-0.39	-6.07	-0.32	3.61e-9	Blood protein levels;
CRC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg27523141	chr10:43048294	ZNF37B	0.45	6.46	0.34	3.84e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.03	-0.7	5.04e-51	Height;
CRC	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg00507830	chr2:103233733	NA	0.53	5.83	0.31	1.31e-8	Gut microbiota (bacterial taxa);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg05236530	chr12:7362357	PEX5	-0.56	-6.33	-0.33	8e-10	Body mass index;
CRC	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-5.85	-0.31	1.19e-8	Type 2 diabetes;
CRC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg13256891	chr4:100009986	ADH5	0.48	6.58	0.34	1.88e-10	Alcohol dependence;
CRC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.51	7.32	0.37	1.88e-12	Pancreatic cancer;
CRC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.71	11.35	0.53	2.05e-25	Dental caries;
CRC	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.9	-13.04	-0.58	1.25e-31	Dupuytren's disease;
CRC	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11446398	chr5:77624930	NA	0.46	6.38	0.33	6.05e-10	Triglycerides;
CRC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.99	0.44	1.95e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.42	6.14	0.32	2.4e-9	Height;
CRC	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.98	-0.36	1.65e-11	Myopia (pathological);
CRC	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.43	6.99	0.36	1.53e-11	Sitting height ratio;
CRC	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg16141378	chr3:129829833	LOC729375	-0.42	-6.31	-0.33	8.95e-10	Retinal vascular caliber;
CRC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.72	0.35	8e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg24163568	chr5:669837	TPPP	0.43	6.83	0.35	4.09e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.46	-0.71	9.7e-53	Primary sclerosing cholangitis;
CRC	trans	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.21	-0.32	1.57e-9	Aortic root size;
CRC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.66	-0.34	1.12e-10	Aortic root size;
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.04	-0.32	4.13e-9	Bipolar disorder;
CRC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.55	6.09	0.32	3.2e-9	Cannabis dependence symptom count;
CRC	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg17145862	chr1:211918768	LPGAT1	0.5	7.15	0.37	5.78e-12	Crohn's disease;
CRC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-18.3	-0.71	4.49e-52	Primary sclerosing cholangitis;
CRC	cis	rs10242455	0.571	rs13438288	chr7:98916414	T/G	cg18809830	chr7:99032528	PTCD1	-0.93	-6.72	-0.35	8.13e-11	Blood metabolite levels;
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.63	11.26	0.53	4.31e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg00343986	chr7:65444356	GUSB	-0.47	-6.49	-0.34	3.11e-10	Aortic root size;
CRC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs6921919	0.525	rs16894095	chr6:28390230	C/T	cg21251018	chr6:28226885	NKAPL	0.41	5.85	0.31	1.19e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.13	0.32	2.54e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7932354	0.666	rs6485696	chr11:46842045	C/T	cg19486271	chr11:47235900	DDB2	-0.47	-7.71	-0.39	1.5e-13	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs531930	1.000	rs486550	chr6:124738091	A/G	cg22366943	chr6:124882293	NKAIN2	-0.43	-6.16	-0.32	2.09e-9	Celiac disease;
CRC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.83	-0.48	3.7799999999999997e-20	Total cholesterol levels;
CRC	cis	rs3812762	0.783	rs11042070	chr11:8819367	C/T	cg14711859	chr11:8959438	ASCL3	0.43	6.41	0.33	4.96e-10	Hypospadias;
CRC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg19635926	chr16:89946313	TCF25	0.63	5.61	0.3	4.35e-8	Skin colour saturation;
CRC	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.18	-0.32	1.91e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.39	6.03	0.32	4.46e-9	Endometrial cancer;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.64e-9	Bipolar disorder;
CRC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.8	11.85	0.55	3.11e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.17	0.45	5.47e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.72	-6.86	-0.35	3.44e-11	Diabetic retinopathy;
CRC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.68	-13.44	-0.6	3.92e-33	Educational attainment;
CRC	trans	rs12940923	1.000	rs12451466	chr17:56378067	G/A	cg16900910	chr15:72789182	ARIH1	0.54	6.08	0.32	3.25e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs7605827	0.866	rs6745922	chr2:15537931	G/C	cg19274914	chr2:15703543	NA	0.4	6.02	0.31	4.77e-9	Educational attainment (years of education);
CRC	cis	rs7605827	0.930	rs6745731	chr2:15537915	C/T	cg19274914	chr2:15703543	NA	0.4	6.0	0.31	5.17e-9	Educational attainment (years of education);
CRC	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.52	6.03	0.32	4.41e-9	Recombination rate (females);
CRC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.68	10.3	0.49	9.6e-22	Menopause (age at onset);
CRC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.54	-5.71	-0.3	2.49e-8	Hip circumference adjusted for BMI;
CRC	trans	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg17903999	chr18:56338584	MALT1	0.38	6.3	0.33	9.77e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.97	16.17	0.67	1.12e-43	Ewing sarcoma;
CRC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.73	-0.39	1.29e-13	Aortic root size;
CRC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.61	0.34	1.58e-10	Retinal vascular caliber;
CRC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.84	10.35	0.5	6.46e-22	Menarche (age at onset);
CRC	cis	rs7932354	0.710	rs2306032	chr11:46897253	G/C	cg19486271	chr11:47235900	DDB2	-0.46	-7.38	-0.38	1.29e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.02e-22	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12655729	chr3:194393122	LSG1	0.54	7.0	0.36	1.41e-11	Thyroid stimulating hormone;
CRC	cis	rs12760731	0.623	rs2300300	chr1:178419387	G/C	cg00404053	chr1:178313656	RASAL2	0.78	9.09	0.45	9.39e-18	Obesity-related traits;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	7.69	0.39	1.71e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.78	-0.35	5.63e-11	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.82	15.11	0.64	1.57e-39	Mean platelet volume;
CRC	cis	rs6504622	0.934	rs3760377	chr17:45042079	G/A	cg16759221	chr17:45003025	GOSR2	0.47	7.46	0.38	7.87e-13	Orofacial clefts;
CRC	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.92	-11.69	-0.54	1.19e-26	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.79	12.29	0.56	7.87e-29	Breast cancer;
CRC	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7705042	0.826	rs11749731	chr5:141500436	A/C	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.98	-0.31	5.83e-9	Asthma;
CRC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	9.27	0.45	2.61e-18	Mean platelet volume;
CRC	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg09547119	chr19:52391367	ZNF577	0.48	5.85	0.31	1.2e-8	Breast cancer;
CRC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.66	9.61	0.47	1.95e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7923609	0.846	rs7075901	chr10:65280994	C/A	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.95	-0.31	6.97e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg23425280	chr12:56401806	NA	0.47	6.02	0.32	4.57e-9	Cancer;
CRC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg16262614	chr3:133464971	TF	-0.33	-5.77	-0.3	1.87e-8	Iron status biomarkers (transferrin levels);
CRC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	trans	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06834434	chr14:75079333	LTBP2	0.55	6.62	0.34	1.47e-10	Obesity-related traits;
CRC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.8	14.21	0.62	4.48e-36	Breast cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05790982	chr4:4861404	MSX1	0.37	5.98	0.31	5.72e-9	Obesity-related traits;
CRC	trans	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.33	0.33	8.13e-10	Endometrial cancer;
CRC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.42	7.02	0.36	1.26e-11	Schizophrenia;
CRC	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.08	0.32	3.36e-9	Blood protein levels;
CRC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg17243654	chr1:109816280	CELSR2	-0.43	-5.81	-0.3	1.5e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs863345	0.604	rs7525362	chr1:158493890	G/C	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	7e-9	Pneumococcal bacteremia;
CRC	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.72	-0.39	1.45e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.5	9.14	0.45	6.38e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15604051	chr3:44754201	ZNF502	-0.36	-5.69	-0.3	2.8e-8	Depressive symptoms;
CRC	trans	rs820077	0.557	rs4713840	chr6:35143168	C/T	cg23173586	chr14:20945319	PNP	-0.29	-6.03	-0.32	4.43e-9	Systemic lupus erythematosus;
CRC	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.74	0.63	4.18e-38	Exhaled nitric oxide output;
CRC	cis	rs7487075	0.897	rs7979418	chr12:46774771	A/G	cg22049899	chr12:47219821	SLC38A4	0.32	5.94	0.31	7.14e-9	Itch intensity from mosquito bite;
CRC	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.61	8.19	0.41	5.84e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs3736485	0.966	rs7174435	chr15:51895065	G/A	cg08986416	chr15:51914746	DMXL2	-0.48	-6.74	-0.35	7.06e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.87	-0.31	1.04e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg03623178	chr6:28175578	NA	0.45	6.09	0.32	3.07e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-7.48	-0.38	6.74e-13	Bipolar disorder;
CRC	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-11.75	-0.54	7.63e-27	Plateletcrit;Platelet count;
CRC	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.47	7.8	0.4	8.33e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg01629716	chr15:45996671	NA	0.41	8.5	0.42	6.75e-16	Waist circumference;Weight;
CRC	trans	rs6472827	0.645	rs2977070	chr8:75112770	A/G	cg16732884	chr16:2569654	AMDHD2;ATP6V0C	-0.39	-6.07	-0.32	3.62e-9	Uterine fibroids;
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg19678392	chr7:94953810	PON1	0.56	7.05	0.36	1.07e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-6.09	-0.32	3.09e-9	Putamen volume;
CRC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.6	-8.23	-0.41	4.37e-15	DNA methylation (variation);
CRC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg03030879	chr14:75389066	RPS6KL1	0.5	8.04	0.41	1.68e-14	Caffeine consumption;
CRC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.52	7.55	0.38	4.24e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.81	-0.3	1.51e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-8.35	-0.42	1.89e-15	Blood metabolite levels;
CRC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg17633681	chr16:88106987	BANP	0.88	15.38	0.65	1.3e-40	Menopause (age at onset);
CRC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg21770322	chr7:97807741	LMTK2	0.56	9.32	0.46	1.72e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.73	12.61	0.57	5.41e-30	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19424343	chr3:16306684	OXNAD1;DPH3	0.47	6.77	0.35	5.84e-11	Anxiety disorder;
CRC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.66	-7.73	-0.39	1.31e-13	Vitiligo;
CRC	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg12856521	chr11:46389249	DGKZ	0.44	7.21	0.37	3.98e-12	Leprosy;
CRC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.11e-15	Lung cancer;
CRC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg02089348	chr4:1724449	TMEM129;TACC3	-0.4	-5.76	-0.3	1.91e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3736594	0.513	rs62138965	chr2:27816593	T/C	cg27432699	chr2:27873401	GPN1	0.65	8.0	0.4	2.1e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08593074	chr19:55678419	C19orf51	0.44	6.37	0.33	6.39e-10	Response to antipsychotic treatment;
CRC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg27523141	chr10:43048294	ZNF37B	0.44	6.42	0.33	4.7e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg16989086	chr20:62203971	PRIC285	0.51	6.41	0.33	5.08e-10	Glioblastoma;
CRC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.71	12.56	0.57	7.83e-30	Dental caries;
CRC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg18876405	chr7:65276391	NA	0.46	6.45	0.34	3.96e-10	Aortic root size;
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.67	9.82	0.48	3.97e-20	Menarche (age at onset);
CRC	cis	rs17065868	0.764	rs73188711	chr13:45015814	A/G	cg10246903	chr13:45222710	NA	0.58	5.65	0.3	3.45e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg12573674	chr2:1569213	NA	-0.73	-8.07	-0.41	1.38e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.16e-13	Corneal astigmatism;
CRC	cis	rs540254	0.551	rs2271967	chr1:160787705	T/C	cg20255094	chr1:160771763	LY9	0.48	6.31	0.33	9.12e-10	Blood protein levels;
CRC	cis	rs73206853	0.563	rs7301769	chr12:111171026	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	8.89	0.44	4.07e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.65	8.51	0.42	6.25e-16	Uric acid levels;
CRC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.47	8.52	0.43	5.75e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg12463550	chr7:65579703	CRCP	0.69	6.35	0.33	7.16e-10	Diabetic kidney disease;
CRC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg05585544	chr11:47624801	NA	-0.46	-8.26	-0.41	3.69e-15	Subjective well-being;
CRC	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.43	6.76	0.35	6.47e-11	Red blood cell count;
CRC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.67	-0.3	3.06e-8	Heart rate;
CRC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.51	8.57	0.43	4.2e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs10411161	0.702	rs8113584	chr19:52383874	A/G	cg22319618	chr22:45562946	NUP50	-0.68	-7.53	-0.38	4.85e-13	Breast cancer;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.69	-0.35	9.47e-11	Total body bone mineral density;
CRC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg11003573	chr3:44754125	ZNF502	-0.37	-6.38	-0.33	6.1e-10	Depressive symptoms;
CRC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	0.98	12.25	0.56	1.12e-28	Type 2 diabetes nephropathy;
CRC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.89	-15.24	-0.64	4.88e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg16540259	chr10:75572220	NDST2	0.38	5.91	0.31	8.5e-9	Psoriasis vulgaris;Psoriasis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00098451	chr1:16370634	CLCNKB	-0.41	-6.67	-0.35	1.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9903692	0.505	rs208008	chr17:46230838	C/T	cg10706073	chr17:46328419	SKAP1	0.59	6.37	0.33	6.25e-10	Pulse pressure;
CRC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.53	0.34	2.55e-10	Tonsillectomy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02702510	chr10:46090551	MARCH8	0.46	6.6	0.34	1.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17554472	chr22:41940697	POLR3H	-0.54	-5.75	-0.3	2.09e-8	Vitiligo;
CRC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.42	6.46	0.34	3.7e-10	Monocyte count;
CRC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.7	10.8	0.51	1.76e-23	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.7	9.2	0.45	4.13e-18	Height;
CRC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.92	-16.19	-0.67	9.15e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg06494592	chr3:125709126	NA	-0.55	-6.43	-0.33	4.43e-10	Blood pressure (smoking interaction);
CRC	cis	rs7209700	0.962	rs56327427	chr17:45354746	C/T	cg17185639	chr17:45330862	ITGB3	0.35	5.94	0.31	7.37e-9	IgG glycosylation;
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.44	-0.33	4.21e-10	Lymphocyte counts;
CRC	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg24046110	chr8:143859143	LYNX1	-0.36	-6.13	-0.32	2.54e-9	Urinary tract infection frequency;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.73	-0.51	3.19e-23	Alzheimer's disease;
CRC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06634786	chr22:41940651	POLR3H	-0.46	-6.01	-0.31	4.93e-9	Vitiligo;
CRC	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg20487152	chr13:99095054	FARP1	-0.44	-6.26	-0.33	1.17e-9	Longevity;
CRC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.7	-0.72	1.17e-53	Height;
CRC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.39	5.86	0.31	1.14e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg16342193	chr10:102329863	NA	-0.35	-5.88	-0.31	1.03e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	8.31	0.42	2.52e-15	LDL cholesterol;Cholesterol, total;
CRC	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.45	-0.34	4.03e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg20356878	chr3:121714668	ILDR1	-0.51	-6.59	-0.34	1.73e-10	Multiple sclerosis;
CRC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.74	11.16	0.52	9.92e-25	Menopause (age at onset);
CRC	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.85	8.31	0.42	2.62e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg21466736	chr12:48725269	NA	0.47	7.25	0.37	3.03e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.4	6.16	0.32	2.09e-9	Recombination rate (males);
CRC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.37	5.67	0.3	3.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.72	11.22	0.53	5.85e-25	Corneal astigmatism;
CRC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg19046167	chr17:80928561	B3GNTL1	0.39	5.86	0.31	1.14e-8	Breast cancer;
CRC	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.67	-9.72	-0.47	8.52e-20	Type 2 diabetes;
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg19041857	chr6:27730383	NA	-0.72	-7.05	-0.36	1.07e-11	Depression;
CRC	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg00277334	chr10:82204260	NA	-0.37	-5.95	-0.31	6.79e-9	Sarcoidosis;
CRC	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg03894339	chr8:19674705	INTS10	-0.42	-5.77	-0.3	1.85e-8	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17424859	chr6:71319002	NA	0.45	6.63	0.34	1.39e-10	Myopia (pathological);
CRC	cis	rs12523822	0.826	rs866993	chr6:154969004	G/A	cg20019720	chr6:154832845	CNKSR3	0.28	5.95	0.31	6.91e-9	Diabetic kidney disease;
CRC	cis	rs1322512	1.000	rs2800623	chr6:153003720	A/G	cg03415253	chr6:152958462	SYNE1	0.44	6.85	0.35	3.74e-11	Tonometry;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07284132	chr22:36462314	NA	0.42	6.1	0.32	3.01e-9	Response to antipsychotic treatment;
CRC	trans	rs712068	0.935	rs10916640	chr1:224747597	C/G	cg04390004	chr19:39279324	LGALS7B	0.42	6.3	0.33	9.78e-10	Cancer;
CRC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.6	9.0	0.44	1.79e-17	Lung cancer;
CRC	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.81	-14.87	-0.63	1.3e-38	Hip circumference;
CRC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.44	5.8	0.3	1.52e-8	Heart rate;
CRC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.56e-12	Obesity-related traits;
CRC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.11	0.56	3.76e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.67	-11.63	-0.54	1.99e-26	Brugada syndrome;
CRC	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.93	-15.84	-0.66	2.13e-42	Bipolar disorder;
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.5	-0.38	6.08e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.19	-0.41	5.98e-15	Type 2 diabetes;
CRC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	7.4	0.38	1.14e-12	Aortic root size;
CRC	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-8.65	-0.43	2.3e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs12464559	0.522	rs11676866	chr2:152628858	G/C	cg01189475	chr2:152685088	ARL5A	0.51	5.72	0.3	2.44e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07513332	chr6:167530253	CCR6	-0.45	-8.36	-0.42	1.79e-15	Primary biliary cholangitis;
CRC	trans	rs1569175	1.000	rs1509830	chr2:200908143	G/A	cg12143499	chr12:27615389	NA	0.68	6.15	0.32	2.25e-9	Response to treatment for acute lymphoblastic leukemia;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg20512303	chr5:131592959	PDLIM4	0.42	7.82	0.4	7.04e-14	Acylcarnitine levels;
CRC	cis	rs3750082	0.855	rs6462430	chr7:32921831	G/A	cg05721444	chr7:32995514	FKBP9	0.5	7.76	0.39	1.12e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.48	8.69	0.43	1.75e-16	Testicular germ cell tumor;
CRC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.14	0.37	5.92e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.62	0.57	4.92e-30	Body mass index;
CRC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg11271282	chr2:238384023	NA	0.48	5.72	0.3	2.36e-8	Prostate cancer;
CRC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg08798685	chr6:27730294	NA	-0.59	-5.61	-0.3	4.26e-8	Depression;
CRC	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-6.01	-0.31	4.8e-9	Superior frontal gyrus grey matter volume;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg15496871	chr19:36208495	MLL4	0.51	6.59	0.34	1.74e-10	Resistin levels;
CRC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	0.77	10.67	0.51	5.18e-23	Heart rate;
CRC	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg13482628	chr17:19912719	NA	-0.4	-6.18	-0.32	1.92e-9	Obesity-related traits;
CRC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.45	6.87	0.35	3.14e-11	Asthma;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg12172441	chr6:28176163	NA	0.5	6.73	0.35	7.38e-11	Parkinson's disease;
CRC	cis	rs7605827	0.930	rs13410044	chr2:15602535	A/G	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs4853036	0.859	rs10196546	chr2:70157158	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-7.54	-0.38	4.53e-13	Colorectal or endometrial cancer;
CRC	trans	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg02674126	chr19:40336878	FBL	0.42	6.67	0.35	1.09e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg20356878	chr3:121714668	ILDR1	-0.43	-6.09	-0.32	3.08e-9	Multiple sclerosis;
CRC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg21770322	chr7:97807741	LMTK2	0.53	8.62	0.43	2.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs9914544	0.545	rs8077775	chr17:18809543	A/G	cg21372672	chr17:16614065	CCDC144A	-0.4	-6.35	-0.33	6.98e-10	Educational attainment (years of education);
CRC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.66	-8.02	-0.4	1.9e-14	Diabetic retinopathy;
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	6.72	0.35	8.1e-11	Height;
CRC	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg15903213	chr10:43522190	NA	-0.7	-5.63	-0.3	3.83e-8	Blood protein levels;
CRC	cis	rs11212617	0.967	rs4237579	chr11:108279201	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.52	0.34	2.61e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.99	0.52	3.71e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.48	7.72	0.39	1.44e-13	Schizophrenia;
CRC	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	0.8	7.16	0.37	5.39e-12	Type 2 diabetes nephropathy;
CRC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.41	6.15	0.32	2.25e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg19338460	chr6:170058176	WDR27	-0.67	-7.38	-0.38	1.32e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs73206853	0.841	rs11065663	chr12:110988886	G/T	cg12870014	chr12:110450643	ANKRD13A	0.66	7.95	0.4	2.96e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04718306	chr1:68151105	GADD45A	0.46	6.1	0.32	2.94e-9	Anxiety disorder;
CRC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg14008862	chr17:28927542	LRRC37B2	0.54	5.68	0.3	2.91e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg08992911	chr2:238395768	MLPH	0.59	5.91	0.31	8.33e-9	Prostate cancer;
CRC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg06470822	chr6:28175283	NA	-0.46	-6.35	-0.33	7.28e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.73e-9	Life satisfaction;
CRC	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.11	21.04	0.76	7.33e-63	Exhaled nitric oxide output;
CRC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.84	-10.38	-0.5	4.97e-22	Initial pursuit acceleration;
CRC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg02659138	chr7:134003124	SLC35B4	0.4	7.09	0.36	8.32e-12	Mean platelet volume;
CRC	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.5	6.71	0.35	8.35e-11	Red blood cell count;
CRC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.45	-7.04	-0.36	1.16e-11	Monocyte count;
CRC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg16989719	chr2:238392110	NA	-0.38	-6.87	-0.35	3.19e-11	Prostate cancer;
CRC	cis	rs4853036	0.951	rs3755391	chr2:70141519	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.17	-0.32	2.04e-9	Colorectal or endometrial cancer;
CRC	cis	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.7	-0.3	2.64e-8	Blood trace element (Cu levels);
CRC	cis	rs4964805	0.683	rs12424737	chr12:104196221	A/C	cg02344784	chr12:104178138	NT5DC3	0.79	14.62	0.63	1.17e-37	Attention deficit hyperactivity disorder;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.82	-14.04	-0.61	2.03e-35	Height;
CRC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	7.85	0.4	5.96e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06307176	chr5:131281290	NA	-0.46	-6.68	-0.35	9.95e-11	Life satisfaction;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	7.01	0.36	1.33e-11	Breast cancer;
CRC	cis	rs7527798	0.592	rs1323720	chr1:207823161	T/C	cg09232269	chr1:207846808	CR1L	-0.46	-7.45	-0.38	8.05e-13	Erythrocyte sedimentation rate;
CRC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.62	-9.76	-0.47	6.07e-20	Intelligence (multi-trait analysis);
CRC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.35	-7.73	-0.39	1.32e-13	Inflammatory skin disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25062812	chr14:25519484	STXBP6	-0.44	-6.26	-0.33	1.19e-9	Myopia (pathological);
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg02683197	chr6:28174875	NA	0.7	9.6	0.47	2.15e-19	Parkinson's disease;
CRC	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.67	10.27	0.49	1.21e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg01262667	chr19:19385393	TM6SF2	0.36	5.86	0.31	1.1e-8	Tonsillectomy;
CRC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	7.92	0.4	3.58e-14	Aortic root size;
CRC	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg00383909	chr3:49044727	WDR6	0.58	6.62	0.34	1.46e-10	Cognitive function;
CRC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg12218747	chr21:37451666	NA	-0.45	-7.72	-0.39	1.41e-13	Mitral valve prolapse;
CRC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.68	10.67	0.51	5.19e-23	Diastolic blood pressure;
CRC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.4	-6.42	-0.33	4.83e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.63	9.53	0.46	3.73e-19	Menopause (age at onset);
CRC	cis	rs965469	0.947	rs965468	chr20:3381443	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.8	-0.3	1.54e-8	IFN-related cytopenia;
CRC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02772935	chr3:125709198	NA	-0.49	-5.68	-0.3	2.91e-8	Blood pressure (smoking interaction);
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg09983326	chr2:43451308	ZFP36L2	-0.45	-6.3	-0.33	9.63e-10	Underweight status;
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.09	-0.32	3.23e-9	Total body bone mineral density;
CRC	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.04	-0.32	4.15e-9	Schizophrenia;
CRC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	10.68	0.51	4.6e-23	Motion sickness;
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19910922	chr7:139025279	C7orf55	0.37	5.99	0.31	5.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs713477	0.505	rs10131672	chr14:55905091	A/T	cg13175173	chr14:55914753	NA	-0.42	-6.87	-0.35	3.16e-11	Pediatric bone mineral content (femoral neck);
CRC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.3	0.46	2.01e-18	Lymphocyte counts;
CRC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg19980929	chr12:42632907	YAF2	-0.4	-6.08	-0.32	3.29e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03700121	chr11:60610004	CCDC86	0.44	6.86	0.35	3.52e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.59	-0.34	1.77e-10	Multiple sclerosis;
CRC	cis	rs2415984	0.600	rs2084823	chr14:46966454	C/G	cg14871534	chr14:47121158	RPL10L	0.39	5.93	0.31	7.78e-9	Number of children ever born;
CRC	cis	rs9937943	0.667	rs35253850	chr16:74599103	T/C	cg01733217	chr16:74700730	RFWD3	0.72	8.19	0.41	5.71e-15	Neutrophil percentage of white cells;
CRC	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.59	-10.14	-0.49	3.2e-21	Asthma;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg15024055	chr5:81267935	ATG10	0.49	7.31	0.37	2.06e-12	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.62	12.68	0.57	2.86e-30	Neuroticism;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg20615401	chr6:28092323	ZSCAN16	0.47	6.24	0.33	1.34e-9	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.41	6.0	0.31	5.3300000000000004e-09	Metabolic traits;
CRC	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.68	-8.43	-0.42	1.1e-15	Blood protein levels;
CRC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.79	10.85	0.51	1.23e-23	Cognitive function;
CRC	cis	rs9903692	0.954	rs2109984	chr17:46171099	G/T	cg21215337	chr17:46176117	CBX1	0.42	7.59	0.39	3.24e-13	Pulse pressure;
CRC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.65	0.3	3.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg06206626	chr22:26825900	ASPHD2	0.41	6.11	0.32	2.84e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	0.67	6.83	0.35	4.21e-11	Body mass index;
CRC	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.77	-0.51	2.24e-23	Migraine;Coronary artery disease;
CRC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg12682573	chr17:27188876	MIR451;MIR144	-0.57	-7.9	-0.4	4.32e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02010868	chr19:4067159	ZBTB7A	0.42	6.3	0.33	9.43e-10	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.931	rs1168021	chr1:63009900	A/G	cg19896129	chr1:63156450	NA	-0.44	-6.78	-0.35	5.74e-11	Triglyceride levels;
CRC	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg25547332	chr5:131281432	NA	0.38	5.79	0.3	1.64e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg12564285	chr5:131593104	PDLIM4	0.39	7.34	0.38	1.63e-12	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00243897	chr12:122326549	PSMD9	0.39	6.28	0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7113874	0.610	rs1446462	chr11:8566343	C/T	cg02811074	chr11:8615871	STK33	-0.36	-6.14	-0.32	2.44e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.69	-12.91	-0.58	3.86e-31	Bipolar disorder;
CRC	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg20737812	chr15:86336631	KLHL25	-0.44	-7.08	-0.36	8.51e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.4	6.34	0.33	7.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg20356878	chr3:121714668	ILDR1	-0.51	-7.11	-0.36	7.34e-12	Multiple sclerosis;
CRC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg25985355	chr7:65971099	NA	-0.48	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
CRC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.47	6.91	0.36	2.53e-11	Menopause (age at onset);
CRC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.56	-9.38	-0.46	1.11e-18	Eye color traits;
CRC	trans	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg16141378	chr3:129829833	LOC729375	-0.47	-6.14	-0.32	2.33e-9	Red cell distribution width;
CRC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg00106254	chr7:1943704	MAD1L1	0.43	6.12	0.32	2.59e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16616022	chr6:57086293	RAB23	0.44	6.4	0.33	5.27e-10	Response to antipsychotic treatment;
CRC	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg26875233	chr11:93583750	C11orf90	-0.34	-6.59	-0.34	1.7e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.21	0.69	8.33e-48	Platelet count;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.31	-5.77	-0.3	1.82e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.18	-0.32	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.58	-0.34	1.85e-10	Breast cancer;
CRC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.43	0.33	4.59e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.77	-7.65	-0.39	2.2e-13	Coronary artery disease;
CRC	cis	rs231513	0.954	rs231506	chr17:41970191	A/G	cg26893861	chr17:41843967	DUSP3	-0.63	-6.32	-0.33	8.53e-10	Cognitive function;
CRC	cis	rs2274273	0.840	rs10136596	chr14:55836773	A/G	cg23234261	chr14:55582407	NA	-0.28	-5.61	-0.3	4.38e-8	Protein biomarker;
CRC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	6.31	0.33	9.01e-10	Diabetic retinopathy;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.43	7.36	0.38	1.5e-12	Lung cancer;
CRC	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg07617317	chr6:118971624	C6orf204	0.47	5.68	0.3	2.91e-8	Diastolic blood pressure;
CRC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg05425664	chr17:57184151	TRIM37	0.43	6.82	0.35	4.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg03469862	chr11:68924853	NA	0.45	5.74	0.3	2.17e-8	Blond vs. brown hair color;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.87	-19.96	-0.74	1.28e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg17133734	chr15:86042851	AKAP13	0.43	7.07	0.36	9.28e-12	Interstitial lung disease;
CRC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.7	10.29	0.49	1.01e-21	Menopause (age at onset);
CRC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.93	0.52	6.5e-24	Motion sickness;
CRC	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.42	6.34	0.33	7.64e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.49	-6.62	-0.34	1.42e-10	Obesity-related traits;
CRC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Depression;
CRC	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.5	9.42	0.46	8.39e-19	Educational attainment (years of education);
CRC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg14671364	chr1:107599128	PRMT6	-0.53	-7.57	-0.39	3.7e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.42	-5.64	-0.3	3.71e-8	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10444037	chr6:42531637	UBR2	0.48	6.12	0.32	2.67e-9	Thyroid stimulating hormone;
CRC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg22495460	chr2:25135724	ADCY3	-0.8	-14.5	-0.62	3.65e-37	Breast cancer;
CRC	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.71	0.54	1.03e-26	Coffee consumption (cups per day);
CRC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-7.31	-0.37	2.06e-12	Cognitive test performance;
CRC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg16898833	chr6:26189333	HIST1H4D	0.73	6.4	0.33	5.36e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.79	7.67	0.39	2.01e-13	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.45	-0.53	8.92e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs6585424	1.000	rs56190825	chr10:81934736	C/T	cg11900509	chr10:81946545	ANXA11	-0.72	-8.83	-0.44	6.14e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg20487152	chr13:99095054	FARP1	-0.39	-6.03	-0.32	4.32e-9	Alzheimer's disease;
CRC	cis	rs7394190	1.000	rs7394190	chr10:75421648	G/A	cg26549892	chr10:75416844	SYNPO2L	-0.48	-6.06	-0.32	3.74e-9	Incident atrial fibrillation;
CRC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.64	7.7	0.39	1.66e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.72	8.71	0.43	1.51e-16	Mean platelet volume;
CRC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.38	-5.73	-0.3	2.24e-8	Ulcerative colitis;
CRC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.79	-13.15	-0.59	4.94e-32	Obesity-related traits;
CRC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.8	0.7	4.05e-50	Platelet count;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.0	15.6	0.65	1.81e-41	Cognitive function;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg02683197	chr6:28174875	NA	0.63	8.92	0.44	3.22e-17	Parkinson's disease;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.32	-5.77	-0.3	1.86e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.63	0.3	3.79e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.44	6.91	0.36	2.46e-11	Platelet count;
CRC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-7.07	-0.36	9.12e-12	Colorectal cancer;
CRC	cis	rs12476592	0.602	rs10176522	chr2:63722433	T/C	cg10828910	chr2:63850056	LOC388955	0.48	5.8	0.3	1.54e-8	Childhood ear infection;
CRC	trans	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg18393722	chr15:85113863	UBE2QP1	0.37	6.08	0.32	3.32e-9	Schizophrenia;
CRC	trans	rs596169	0.655	rs12087006	chr1:219203397	T/C	cg00778190	chr1:95068029	NA	0.76	6.6	0.34	1.67e-10	Intraocular pressure;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-6.77	-0.35	5.81e-11	Lymphocyte counts;
CRC	cis	rs2730260	0.611	rs73169221	chr7:158846316	T/A	cg02254261	chr7:158964346	NA	-0.56	-6.2	-0.32	1.68e-9	Myopia (pathological);
CRC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg14191688	chr11:70257035	CTTN	0.47	6.24	0.33	1.33e-9	Coronary artery disease;
CRC	cis	rs4676482	0.841	rs34810344	chr3:39226114	G/A	cg02254461	chr3:39195904	CSRNP1	0.51	6.24	0.33	1.36e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs315934	0.664	rs10199363	chr2:113840791	A/G	cg24553058	chr2:113831203	IL1F10	-0.49	-5.62	-0.3	4.16e-8	Dysmenorrheic pain;
CRC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.78	-0.44	9.2e-17	Type 2 diabetes;
CRC	trans	rs6780569	0.655	rs17012829	chr3:23261334	C/T	cg12985929	chr17:75370611	SEPT9	-0.52	-6.1	-0.32	2.96e-9	Type 2 diabetes;
CRC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.83	-0.44	6.23e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg23029597	chr12:123009494	RSRC2	0.58	6.55	0.34	2.22e-10	Body mass index;
CRC	cis	rs11212617	0.934	rs694376	chr11:108119048	C/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.72	0.3	2.35e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.66	-0.47	1.31e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.45	8.03	0.4	1.78e-14	Blood metabolite ratios;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13056269	chr2:136633607	MCM6	0.44	6.28	0.33	1.06e-9	Response to antipsychotic treatment;
CRC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.47	6.4	0.33	5.25e-10	Schizophrenia;
CRC	cis	rs9469578	0.710	rs73743330	chr6:33713971	G/A	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.54	-8.39	-0.42	1.47e-15	Aortic root size;
CRC	trans	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg24644049	chr4:85504048	CDS1	0.77	7.55	0.38	4.3e-13	Skin colour saturation;
CRC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Melanoma;
CRC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.5	7.12	0.37	7e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.57	7.54	0.38	4.64e-13	Adiposity;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg24046110	chr8:143859143	LYNX1	-0.47	-7.47	-0.38	7.4e-13	Urinary tract infection frequency;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg04518342	chr5:131593106	PDLIM4	0.33	5.88	0.31	1.03e-8	Lung function (FEV1/FVC);
CRC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.52	7.63	0.39	2.54e-13	Lung cancer;
CRC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.57	-0.39	3.68e-13	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04569364	chr19:57922590	ZNF17	0.48	6.71	0.35	8.55e-11	Response to antipsychotic treatment;
CRC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.49	7.23	0.37	3.36e-12	N-glycan levels;
CRC	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.57	-5.67	-0.3	3.17e-8	Night sleep phenotypes;
CRC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.14	-0.45	6.39e-18	Intelligence (multi-trait analysis);
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg09192942	chr16:75682004	KARS;TERF2IP	0.38	6.01	0.31	4.98e-9	Age-related macular degeneration;
CRC	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.85	10.97	0.52	4.7e-24	Schizophrenia;
CRC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.49	6.29	0.33	1.02e-9	Obesity-related traits;
CRC	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg14191688	chr11:70257035	CTTN	0.44	6.76	0.35	6.42e-11	Coronary artery disease;
CRC	trans	rs559356	0.561	rs44338	chr3:34834586	G/A	cg19071035	chr6:20404090	E2F3	0.46	6.2	0.32	1.67e-9	Cognitive function;
CRC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.8	13.49	0.6	2.61e-33	Menopause (age at onset);
CRC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.55e-18	Parkinson's disease;
CRC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.47e-10	Breast cancer;
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg19678392	chr7:94953810	PON1	-0.57	-7.35	-0.38	1.56e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.36	-5.67	-0.3	3.11e-8	Platelet distribution width;
CRC	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg25164649	chr6:28176230	NA	-0.41	-5.62	-0.3	4.07e-8	Systemic lupus erythematosus;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19891435	chr13:114145178	DCUN1D2;TMCO3	0.39	6.15	0.32	2.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.22	0.32	1.48e-9	Self-reported allergy;
CRC	trans	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg10756647	chr7:56101905	PSPH	0.66	6.96	0.36	1.9e-11	Diabetic kidney disease;
CRC	cis	rs9463078	0.801	rs9395079	chr6:45154433	C/T	cg25276700	chr6:44698697	NA	-0.29	-6.88	-0.35	3.1e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3996993	0.809	rs58912740	chr6:52669759	G/C	cg20803780	chr6:52668592	GSTA1	0.35	6.28	0.33	1.08e-9	Hemoglobin concentration;
CRC	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg09040174	chr2:113837401	NA	0.43	5.79	0.3	1.64e-8	Protein quantitative trait loci;
CRC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.43	-0.38	9.24e-13	Reticulocyte fraction of red cells;
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs13315871	1.000	rs11706420	chr3:58392411	C/T	cg20936604	chr3:58311152	NA	0.68	6.74	0.35	7.11e-11	Cholesterol, total;
CRC	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.08	-12.52	-0.57	1.15e-29	Mitochondrial DNA levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16641818	chr10:45869619	ALOX5	0.38	6.37	0.33	6.5e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.29	-0.37	2.39e-12	Mean corpuscular volume;
CRC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg01788221	chr16:89496183	ANKRD11	0.4	5.88	0.31	1.01e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.51	8.18	0.41	6.31e-15	Aortic root size;
CRC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg02869306	chr7:64672164	INTS4L1	-0.46	-7.96	-0.4	2.83e-14	Calcium levels;
CRC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg19980929	chr12:42632907	YAF2	0.44	6.55	0.34	2.22e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9584850	0.520	rs10508036	chr13:99157398	C/G	cg20487152	chr13:99095054	FARP1	-0.44	-5.7	-0.3	2.64e-8	Neuroticism;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.21	-0.49	1.97e-21	Bipolar disorder;
CRC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-6.65	-0.34	1.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg27068330	chr11:65405492	SIPA1	-0.45	-6.65	-0.34	1.2e-10	Urate levels;
CRC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg04539111	chr16:67997858	SLC12A4	-0.51	-5.91	-0.31	8.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4664293	0.647	rs2042775	chr2:160510092	T/G	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.53	-8.3	-0.42	2.75e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg10820045	chr2:198174542	NA	0.42	7.16	0.37	5.45e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg17675882	chr20:35374068	NDRG3	-0.4	-6.19	-0.32	1.75e-9	Aortic root size;
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg24046110	chr8:143859143	LYNX1	0.49	8.49	0.42	7.22e-16	Urinary tract infection frequency;
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.4	-0.42	1.36e-15	Bipolar disorder;
CRC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.65	-11.75	-0.54	7.23e-27	Educational attainment;
CRC	cis	rs243505	0.660	rs7785022	chr7:148533384	C/T	cg09806900	chr7:148480153	CUL1	0.52	6.77	0.35	5.78e-11	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg21153622	chr11:89784906	NA	-0.37	-6.0	-0.31	5.16e-9	Height;
CRC	cis	rs2274273	0.662	rs67092614	chr14:55672055	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.81	-0.31	1.46e-8	Protein biomarker;
CRC	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs4727963	0.792	rs12665913	chr7:122741302	T/C	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.25e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg14673194	chr17:80132900	CCDC57	0.49	6.35	0.33	7.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.53	-8.6	-0.43	3.31e-16	Endometrial cancer;
CRC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	8.23	0.41	4.49e-15	Schizophrenia;
CRC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-9.04	-0.45	1.36e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg21466736	chr12:48725269	NA	-0.55	-8.18	-0.41	6.36e-15	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.46	6.02	0.32	4.65e-9	Heart rate;
CRC	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg00507830	chr2:103233733	NA	0.62	6.53	0.34	2.46e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.35	-5.72	-0.3	2.39e-8	IgG glycosylation;
CRC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.47	6.91	0.36	2.53e-11	Menopause (age at onset);
CRC	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.52	7.35	0.38	1.62e-12	Testicular germ cell tumor;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05002732	chr11:19262474	E2F8	0.41	5.98	0.31	5.9e-9	Myopia (pathological);
CRC	trans	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg25214090	chr10:38739885	LOC399744	0.41	6.44	0.33	4.19e-10	Diastolic blood pressure;
CRC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.57	-7.83	-0.4	6.63e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14503987	chr14:102786530	ZNF839	0.39	6.03	0.32	4.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg25174290	chr11:3078921	CARS	-0.4	-5.65	-0.3	3.5e-8	Calcium levels;
CRC	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.38	-0.38	1.27e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08767708	chr16:73082503	ZFHX3	0.41	6.66	0.34	1.15e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.56	-0.43	4.28e-16	Chronic sinus infection;
CRC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.4	0.33	5.2e-10	Morning vs. evening chronotype;
CRC	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg11204139	chr17:3907470	NA	0.82	16.33	0.67	2.53e-44	Type 2 diabetes;
CRC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.5	-6.31	-0.33	9.15e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.65	-10.13	-0.49	3.72e-21	Height;
CRC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.63	-0.3	3.77e-8	Blood protein levels;
CRC	trans	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg02674126	chr19:40336878	FBL	0.42	6.69	0.35	9.76e-11	Hyperactive-impulsive symptoms;
CRC	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg27395922	chr11:50257633	LOC441601	0.48	6.05	0.32	3.87e-9	Axial length;
CRC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12292205	chr6:26970375	C6orf41	-0.71	-9.09	-0.45	9.43e-18	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01951308	chr20:30865502	KIF3B	0.41	6.25	0.33	1.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.73	-12.1	-0.55	4.12e-28	Breast cancer;
CRC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.56	7.2	0.37	4.24e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.44	8.74	0.43	1.17e-16	Vitiligo;
CRC	cis	rs2077654	0.822	rs7939973	chr11:17433291	G/T	cg25308976	chr11:17434268	ABCC8	0.81	8.39	0.42	1.48e-15	Gout;
CRC	trans	rs12660387	1.000	rs12664313	chr6:65271611	A/G	cg13393512	chr9:135749454	C9orf98	0.51	5.98	0.31	5.97e-9	Schizophrenia;
CRC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.59	9.61	0.47	2.03e-19	Tonsillectomy;
CRC	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg22777020	chr22:31556080	RNF185	0.47	5.72	0.3	2.4e-8	Colorectal cancer;
CRC	cis	rs3026445	0.925	rs3759384	chr12:110888857	C/T	cg12870014	chr12:110450643	ANKRD13A	0.38	5.94	0.31	7.23e-9	QT interval;
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.75	10.02	0.48	8.78e-21	Prostate cancer;
CRC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.44	6.65	0.34	1.19e-10	Cleft lip with or without cleft palate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06476344	chr2:26396290	FAM59B	0.4	6.24	0.33	1.38e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.21	-0.32	1.56e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg20129853	chr10:51489980	NA	-0.36	-5.85	-0.31	1.16e-8	Prostate-specific antigen levels;
CRC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg27535305	chr1:53392650	SCP2	-0.34	-6.08	-0.32	3.26e-9	Monocyte count;
CRC	cis	rs9409565	0.787	rs11789704	chr9:97233408	C/T	cg04523069	chr9:97136363	HIATL1	0.4	6.12	0.32	2.68e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6545883	0.507	rs62149712	chr2:61601272	T/C	cg10580144	chr2:61372316	C2orf74	-0.37	-8.37	-0.42	1.64e-15	Tuberculosis;
CRC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.01	0.4	1.94e-14	Lung cancer;
CRC	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.31	0.37	2.04e-12	Lung cancer;
CRC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.7	11.38	0.53	1.63e-25	Osteoporosis;
CRC	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg22089800	chr15:90895588	ZNF774	0.48	7.69	0.39	1.73e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs540254	0.578	rs3817407	chr1:160788131	T/C	cg20255094	chr1:160771763	LY9	0.49	6.7	0.35	9.16e-11	Blood protein levels;
CRC	cis	rs12980942	0.810	rs8103839	chr19:41781493	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.52	6.02	0.31	4.73e-9	Coronary artery disease;
CRC	trans	rs7299538	1.000	rs7299538	chr12:46085330	C/T	cg20672981	chr7:27242161	NA	-0.44	-6.03	-0.32	4.43e-9	Gut microbiome composition (winter);
CRC	cis	rs1355223	1.000	rs2221720	chr11:34754921	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	7.06	0.36	1.02e-11	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.83	0.31	1.36e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	7.97	0.4	2.55e-14	Height;
CRC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.22	-0.32	1.54e-9	Tonsillectomy;
CRC	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.9	0.44	3.69e-17	Mean corpuscular volume;
CRC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg09876464	chr15:85330779	ZNF592	0.39	6.51	0.34	2.74e-10	P wave terminal force;
CRC	cis	rs7215564	0.908	rs2873059	chr17:78663874	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.12	0.59	6.59e-32	Bone mineral density;
CRC	trans	rs12530266	0.523	rs11154200	chr6:124275316	A/G	cg11555228	chr19:21324807	ZNF431	0.41	5.99	0.31	5.41e-9	Gut microbiome composition (summer);
CRC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-10.36	-0.5	5.9e-22	Dental caries;
CRC	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.32	0.49	7.98e-22	Hemoglobin concentration;
CRC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.24	0.33	1.32e-9	Diabetic kidney disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18313106	chr1:229694614	ABCB10	0.41	6.6	0.34	1.68e-10	Obesity-related traits;
CRC	cis	rs4716602	0.596	rs10253193	chr7:156157801	C/T	cg16983916	chr7:156159713	NA	-0.39	-7.03	-0.36	1.21e-11	Anti-saccade response;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18990761	chr12:123756318	CDK2AP1	0.44	6.13	0.32	2.54e-9	Anxiety disorder;
CRC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg24140574	chr1:16342155	HSPB7	0.42	5.63	0.3	3.96e-8	Dilated cardiomyopathy;
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg24634471	chr8:143751801	JRK	-0.47	-6.66	-0.34	1.16e-10	Urinary tract infection frequency;
CRC	cis	rs17209837	1.000	rs4148815	chr7:87087834	A/T	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.49	6.82	0.35	4.34e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.15	0.37	5.83e-12	Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26220259	chr1:44444688	B4GALT2	0.39	6.23	0.32	1.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.9e-14	Obesity-related traits;
CRC	cis	rs9549328	0.700	rs3011473	chr13:113618096	A/G	cg24588162	chr13:113633484	MCF2L	0.37	6.62	0.34	1.46e-10	Systolic blood pressure;
CRC	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.47	-7.19	-0.37	4.35e-12	HDL cholesterol;
CRC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.64	12.02	0.55	7.86e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.82	-0.35	4.41e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.5	7.62	0.39	2.77e-13	Methadone dose in opioid dependence;
CRC	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	12.76	0.58	1.47e-30	Platelet count;
CRC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg18512352	chr11:47633146	NA	0.35	6.91	0.36	2.48e-11	Subjective well-being;
CRC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.55	-9.5	-0.46	4.68e-19	Type 2 diabetes;
CRC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.51	6.44	0.33	4.17e-10	Recombination rate (females);
CRC	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.44	6.61	0.34	1.51e-10	Red blood cell count;
CRC	cis	rs9469913	0.542	rs114863007	chr6:34729158	G/A	cg14254433	chr6:34482411	PACSIN1	-0.68	-5.93	-0.31	7.51e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg20615401	chr6:28092323	ZSCAN16	0.47	6.32	0.33	8.57e-10	Parkinson's disease;
CRC	cis	rs9549328	0.589	rs36164841	chr13:113616579	A/G	cg20742385	chr13:113633654	MCF2L	0.55	9.39	0.46	1.01e-18	Systolic blood pressure;
CRC	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-9.24	-0.45	3.06e-18	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.44	6.74	0.35	7.14e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg24675056	chr1:15929824	NA	0.49	6.65	0.34	1.23e-10	Systolic blood pressure;
CRC	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.49	7.6	0.39	3.02e-13	Atrial fibrillation;
CRC	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-0.68	-6.24	-0.33	1.36e-9	Inflammatory biomarkers;
CRC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.65	-0.47	1.4e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.56	7.67	0.39	1.99e-13	Height;
CRC	cis	rs10971721	0.908	rs10971787	chr9:33914412	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.48	7.57	0.39	3.72e-13	Corneal astigmatism;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg22638593	chr5:131593259	PDLIM4	-0.47	-8.12	-0.41	9.75e-15	Acylcarnitine levels;
CRC	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.09	0.49	4.82e-21	Asthma;
CRC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.63	-0.47	1.65e-19	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.61	10.2	0.49	2.05e-21	Prudent dietary pattern;
CRC	trans	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.32	-0.37	1.91e-12	Endometrial cancer;
CRC	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-6.27	-0.33	1.11e-9	Coronary artery disease;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.23	-0.45	3.45e-18	Electroencephalogram traits;
CRC	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.62	-0.34	1.48e-10	Educational attainment;
CRC	trans	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg09045935	chr12:6379348	NA	1.15	8.8	0.44	7.62e-17	Blood metabolite levels;
CRC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg14979609	chr8:8086686	FLJ10661	0.37	6.02	0.32	4.61e-9	Joint mobility (Beighton score);
CRC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.36	6.88	0.35	2.97e-11	Multiple sclerosis;
CRC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.8	-0.48	4.44e-20	Monocyte count;
CRC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.47	0.5	2.42e-22	Diabetic retinopathy;
CRC	cis	rs911119	0.908	rs8114619	chr20:23601813	G/T	cg16589663	chr20:23618590	CST3	0.47	6.5	0.34	2.92e-10	Chronic kidney disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23350065	chr19:4909600	UHRF1	0.45	6.57	0.34	1.95e-10	Anxiety disorder;
CRC	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg05925327	chr15:68127851	NA	-0.31	-5.94	-0.31	7.1e-9	Restless legs syndrome;
CRC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.18	-17.22	-0.69	7.98e-48	Hip circumference adjusted for BMI;
CRC	cis	rs6539288	0.630	rs10778519	chr12:107357329	A/G	cg15890332	chr12:107067104	RFX4	0.32	5.64	0.3	3.65e-8	Total body bone mineral density;
CRC	cis	rs2000999	0.514	rs17604662	chr16:72221464	A/G	cg04254540	chr16:71951199	KIAA0174	-0.73	-6.24	-0.33	1.38e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	trans	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg20064139	chr20:41823021	NA	-0.29	-6.14	-0.32	2.32e-9	Coronary artery disease;
CRC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg10298567	chr3:47292165	KIF9	-0.4	-6.5	-0.34	2.94e-10	Colorectal cancer;
CRC	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.42	-6.45	-0.34	3.91e-10	Asthma;
CRC	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.79	-13.86	-0.61	9.98e-35	Lewy body disease;
CRC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg05623727	chr3:50126028	RBM5	0.46	7.55	0.38	4.42e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06771106	chr2:113671356	IL1F7	0.43	6.19	0.32	1.83e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg11212589	chr17:38028394	ZPBP2	0.34	5.74	0.3	2.13e-8	Asthma;
CRC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg18478394	chr8:109455254	TTC35	0.38	5.95	0.31	6.87e-9	Dupuytren's disease;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg12273811	chr6:28175739	NA	0.51	5.71	0.3	2.51e-8	Parkinson's disease;
CRC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg21466736	chr12:48725269	NA	0.49	7.63	0.39	2.51e-13	Glycated hemoglobin levels;
CRC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg13334819	chr7:99746414	C7orf59	0.42	5.82	0.31	1.38e-8	Coronary artery disease;
CRC	cis	rs9549328	0.589	rs34144481	chr13:113617322	T/G	cg20742385	chr13:113633654	MCF2L	0.55	9.27	0.46	2.54e-18	Systolic blood pressure;
CRC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.92e-13	Motion sickness;
CRC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.63	9.28	0.46	2.36e-18	Schizophrenia;
CRC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.76	-7.62	-0.39	2.69e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.67	11.51	0.54	5.44e-26	Hip circumference;
CRC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.26	-0.45	2.63e-18	Type 2 diabetes;
CRC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg04545296	chr12:48745243	ZNF641	0.33	5.66	0.3	3.24e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg27534772	chr1:16042836	PLEKHM2	-0.41	-6.81	-0.35	4.65e-11	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03301945	chr19:10764555	ILF3;LOC147727	0.4	6.02	0.31	4.72e-9	Response to antipsychotic treatment;
CRC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.99	-0.36	1.51e-11	IgG glycosylation;
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.66	0.54	1.57e-26	Alzheimer's disease;
CRC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg00310523	chr12:86230176	RASSF9	-0.43	-7.24	-0.37	3.15e-12	Major depressive disorder;
CRC	cis	rs1656402	1.000	rs3108614	chr2:233425485	T/G	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	3e-23	Immature fraction of reticulocytes;
CRC	cis	rs28655083	0.509	rs679263	chr16:77103829	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.85	0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg20503657	chr10:835505	NA	0.66	8.84	0.44	6.03e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs17155006	0.655	rs450722	chr7:107726014	G/A	cg05962710	chr7:107745446	LAMB4	-0.35	-5.85	-0.31	1.21e-8	Pneumococcal bacteremia;
CRC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs501120	0.564	rs2624682	chr10:44678240	C/T	cg09554077	chr10:44749378	NA	0.5	6.98	0.36	1.62e-11	Coronary artery disease;Coronary heart disease;
CRC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.71	-0.47	9.16e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs524281	0.861	rs7937281	chr11:65950074	T/C	cg14036092	chr11:66035641	RAB1B	-0.45	-5.61	-0.3	4.26e-8	Electroencephalogram traits;
CRC	trans	rs6950442	0.556	rs617433	chr7:114348653	T/G	cg08672999	chr19:52675203	ZNF836	-0.54	-6.86	-0.35	3.37e-11	Body mass index;
CRC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.39	-5.73	-0.3	2.28e-8	Neurofibrillary tangles;
CRC	cis	rs9648716	1.000	rs62484301	chr7:140573382	A/T	cg10747023	chr7:140774559	NA	0.45	5.82	0.31	1.36e-8	Type 2 diabetes;
CRC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.6	9.96	0.48	1.3e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.58	-9.2	-0.45	4.09e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.6	7.52	0.38	5.41e-13	Body mass index;
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.59	8.87	0.44	4.9e-17	Longevity;Endometriosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02521036	chr11:62554803	TAF6L;TMEM179B	0.45	6.36	0.33	6.68e-10	Intelligence (multi-trait analysis);
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg03395511	chr6:291903	DUSP22	-0.5	-6.89	-0.36	2.76e-11	Menopause (age at onset);
CRC	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.7	8.04	0.41	1.59e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03923535	chr7:1197113	ZFAND2A	0.54	7.64	0.39	2.37e-13	Longevity;Endometriosis;
CRC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-6.97	-0.36	1.76e-11	Subjective well-being;
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg15511327	chr8:143859410	LYNX1	0.39	6.85	0.35	3.62e-11	Urinary tract infection frequency;
CRC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.98	-0.31	5.67e-9	Lung cancer;
CRC	trans	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg01134436	chr17:81009848	B3GNTL1	0.7	6.46	0.34	3.8e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg00343986	chr7:65444356	GUSB	0.43	6.16	0.32	2.18e-9	Aortic root size;
CRC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.33	0.53	2.39e-25	Asthma (sex interaction);
CRC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.58	8.95	0.44	2.66e-17	Blood protein levels;
CRC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.42	6.01	0.31	4.83e-9	Erythrocyte sedimentation rate;
CRC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.46	5.93	0.31	7.66e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15564865	chr6:4021423	PRPF4B	0.51	6.77	0.35	5.87e-11	Thyroid stimulating hormone;
CRC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.84	-0.48	3.32e-20	Schizophrenia;
CRC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg13010199	chr12:38710504	ALG10B	0.39	5.82	0.31	1.43e-8	Morning vs. evening chronotype;
CRC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.71	10.48	0.5	2.38e-22	Gestational age at birth (maternal effect);
CRC	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.52	10.09	0.49	4.79e-21	Urate levels in lean individuals;
CRC	trans	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.82	-0.35	4.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.39	-0.59	5.93e-33	Blood trace element (Zn levels);
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg04518342	chr5:131593106	PDLIM4	0.46	7.29	0.37	2.36e-12	Breast cancer;
CRC	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.48	-7.59	-0.39	3.31e-13	Schizophrenia;
CRC	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg00490450	chr3:139108681	COPB2	0.43	6.43	0.33	4.53e-10	Obesity-related traits;
CRC	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg05925327	chr15:68127851	NA	0.29	5.65	0.3	3.5e-8	Restless legs syndrome;
CRC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg04450456	chr4:17643702	FAM184B	0.41	6.65	0.34	1.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.47	6.67	0.35	1.07e-10	Response to temozolomide;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04931582	chr4:140477720	SETD7	0.42	6.56	0.34	2.09e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.56	-9.93	-0.48	1.74e-20	Breast cancer;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.53	7.44	0.38	8.8e-13	Longevity;Endometriosis;
CRC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg25876840	chr17:41920477	NA	-0.51	-7.26	-0.37	2.84e-12	Triglycerides;
CRC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.67	11.98	0.55	1.13e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.2e-12	Corneal astigmatism;
CRC	cis	rs728616	0.614	rs61859196	chr10:82109048	A/G	cg11900509	chr10:81946545	ANXA11	-0.56	-6.38	-0.33	5.97e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06462663	chr19:18546047	ISYNA1	0.48	7.39	0.38	1.21e-12	Breast cancer;
CRC	cis	rs6662572	0.950	rs111971542	chr1:46235998	A/T	cg08644498	chr1:46502608	NA	0.44	6.12	0.32	2.69e-9	Blood protein levels;
CRC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.0	9.8	0.48	4.7e-20	Diabetic retinopathy;
CRC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.89	0.51	8.51e-24	Cognitive function;
CRC	cis	rs12024301	0.557	rs114508153	chr1:183632551	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.96	0.36	1.86e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3015497	0.789	rs3015498	chr14:51112824	T/C	cg09863266	chr14:51125203	SAV1	-0.31	-5.77	-0.3	1.82e-8	Mean platelet volume;
CRC	cis	rs9462846	0.960	rs10807284	chr6:42868133	C/A	cg21280719	chr6:42927975	GNMT	-0.33	-6.49	-0.34	3.09e-10	Blood protein levels;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg22719782	chr11:114310057	REXO2	-0.45	-6.51	-0.34	2.76e-10	Birth weight;Height;
CRC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.1	0.32	2.97e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.98e-10	Lung cancer;
CRC	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.81	-14.26	-0.62	2.88e-36	Lewy body disease;
CRC	cis	rs3823572	0.564	rs2346276	chr7:133664901	G/T	cg03336402	chr7:133662267	EXOC4	-0.66	-10.38	-0.5	5.04e-22	Intelligence (multi-trait analysis);
CRC	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg21251018	chr6:28226885	NKAPL	-0.48	-5.86	-0.31	1.1e-8	Depression;
CRC	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg21280719	chr6:42927975	GNMT	-0.34	-5.89	-0.31	9.37e-9	Blood protein levels;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg02033258	chr5:131593261	PDLIM4	0.35	6.15	0.32	2.25e-9	Blood metabolite levels;
CRC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.87	0.4	5.26e-14	Cognitive ability;
CRC	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg00246817	chr9:123691163	NA	-0.44	-5.65	-0.3	3.44e-8	Rheumatoid arthritis;
CRC	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02951883	chr7:2050386	MAD1L1	0.41	5.61	0.3	4.38e-8	Neuroticism;
CRC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.55	-6.37	-0.33	6.35e-10	Bipolar disorder;
CRC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.66	-10.89	-0.51	8.55e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	8.11	0.41	9.84e-15	HIV-1 control;
CRC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.79	-8.63	-0.43	2.67e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.98	-0.31	5.7e-9	Height;
CRC	cis	rs2882667	0.690	rs288009	chr5:138228662	G/A	cg09476006	chr5:138032270	NA	0.55	9.14	0.45	6.76e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12431939	0.598	rs8012074	chr14:51732101	C/G	cg23942311	chr14:51606299	NA	0.49	6.56	0.34	2.07e-10	Cancer;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.65	9.15	0.45	5.95e-18	Parkinson's disease;
CRC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.28	-0.46	2.3e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.59	8.65	0.43	2.26e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2811415	0.569	rs9829877	chr3:127787969	A/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg05673287	chr15:77411982	SGK269	-0.51	-7.99	-0.4	2.34e-14	Type 2 diabetes;
CRC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.56	8.51	0.42	6.33e-16	Height;
CRC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.4	8.14	0.41	8.41e-15	Renal cell carcinoma;
CRC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg00647820	chr17:40259828	DHX58	0.45	6.43	0.33	4.38e-10	Fibrinogen levels;
CRC	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-7.39	-0.38	1.25e-12	Electroencephalogram traits;
CRC	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.55	-8.24	-0.41	4.13e-15	Bone mineral density;
CRC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg13880726	chr7:1868755	MAD1L1	-0.42	-5.66	-0.3	3.31e-8	Bipolar disorder;
CRC	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.98	0.4	2.46e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.5	-5.79	-0.3	1.62e-8	Vitiligo;
CRC	cis	rs7705042	0.828	rs6877864	chr5:141503839	A/G	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.83	-0.31	1.31e-8	Asthma;
CRC	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg01339444	chr6:118972232	C6orf204	0.54	5.98	0.31	5.97e-9	Diastolic blood pressure;
CRC	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	0.77	5.87	0.31	1.07e-8	Cannabis dependence symptom count;
CRC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg12927641	chr6:109611667	NA	-0.33	-5.6	-0.3	4.52e-8	Reticulocyte fraction of red cells;
CRC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.74	-11.13	-0.52	1.21e-24	Refractive error;
CRC	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg24046110	chr8:143859143	LYNX1	-0.37	-6.32	-0.33	8.7e-10	Urinary tract infection frequency;
CRC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg01518246	chr11:63870912	FLRT1;MACROD1	0.45	6.21	0.32	1.57e-9	Mean platelet volume;
CRC	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.43	6.96	0.36	1.82e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.67	-9.87	-0.48	2.79e-20	Multiple myeloma;
CRC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.38	0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg25164649	chr6:28176230	NA	0.7	8.85	0.44	5.59e-17	Parkinson's disease;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.56	-0.34	2.04e-10	Lymphocyte counts;
CRC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.42	-0.38	9.97e-13	Aortic root size;
CRC	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.61	-9.38	-0.46	1.15e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg03623178	chr6:28175578	NA	0.61	8.65	0.43	2.24e-16	Parkinson's disease;
CRC	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.67	10.32	0.49	8.44e-22	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.56	7.34	0.38	1.67e-12	Height;
CRC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.48	-8.65	-0.43	2.39e-16	Age at first birth;
CRC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	7.99	0.4	2.33e-14	Mean corpuscular volume;
CRC	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.96	0.31	6.63e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.64	10.95	0.52	5.16e-24	Mean corpuscular volume;
CRC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg10298567	chr3:47292165	KIF9	0.37	5.64	0.3	3.75e-8	Colorectal cancer;
CRC	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.69	9.79	0.47	5.06e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs13315871	0.858	rs4075404	chr3:58411419	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.83	0.35	4.16e-11	Diastolic blood pressure;
CRC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg21399703	chr1:247681439	NA	0.49	7.62	0.39	2.71e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.62	-9.96	-0.48	1.35e-20	Aortic root size;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg20615401	chr6:28092323	ZSCAN16	0.45	6.09	0.32	3.06e-9	Parkinson's disease;
CRC	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg14593290	chr7:50529359	DDC	-0.56	-7.64	-0.39	2.45e-13	Malaria;
CRC	cis	rs939574	0.512	rs6730612	chr2:220146196	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.52	6.04	0.32	4.21e-9	Platelet distribution width;
CRC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.92	17.0	0.68	6.03e-47	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.35e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg10862848	chr6:42927986	GNMT	-0.3	-5.64	-0.3	3.62e-8	Blood protein levels;
CRC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.71	8.88	0.44	4.56e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.39	-5.89	-0.31	9.73e-9	Crohn's disease;
CRC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.96	0.31	6.36e-9	IgG glycosylation;
CRC	cis	rs11650494	0.710	rs11653775	chr17:47472365	A/G	cg08112188	chr17:47440006	ZNF652	0.67	5.99	0.31	5.63e-9	Prostate cancer;
CRC	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.81	8.48	0.42	7.74e-16	Gastritis;
CRC	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	11.73	0.54	8.6e-27	Alzheimer's disease;
CRC	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg08717414	chr16:71523259	ZNF19	-0.47	-5.71	-0.3	2.47e-8	Post bronchodilator FEV1;
CRC	cis	rs698833	0.798	rs1067391	chr2:44639434	T/G	cg04920474	chr2:44395004	PPM1B	0.4	5.96	0.31	6.35e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13198984	chr17:80129470	CCDC57	0.44	7.73	0.39	1.34e-13	Life satisfaction;
CRC	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg10756647	chr7:56101905	PSPH	0.76	8.08	0.41	1.26e-14	Gout;
CRC	cis	rs2652834	0.718	rs2729829	chr15:63395484	C/T	cg05507819	chr15:63340323	TPM1	0.43	5.65	0.3	3.46e-8	HDL cholesterol;
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg21153622	chr11:89784906	NA	-0.51	-8.11	-0.41	1.04e-14	HDL cholesterol;
CRC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.93	16.26	0.67	4.71e-44	Headache;
CRC	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg00490450	chr3:139108681	COPB2	-0.45	-6.76	-0.35	6.31e-11	Obesity-related traits;
CRC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.48	8.0	0.4	2.1e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg11189052	chr15:85197271	WDR73	0.55	7.32	0.37	1.88e-12	Schizophrenia;
CRC	cis	rs9847710	1.000	rs2581817	chr3:53071797	G/C	cg04503182	chr3:53078218	SFMBT1	0.44	7.05	0.36	1.06e-11	Ulcerative colitis;
CRC	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg02869306	chr7:64672164	INTS4L1	0.43	6.3	0.33	9.49e-10	Aortic root size;
CRC	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.54	9.24	0.45	3.17e-18	Dupuytren's disease;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg19683494	chr5:74908142	NA	0.48	6.2	0.32	1.74e-9	Age-related disease endophenotypes;
CRC	trans	rs2403907	0.758	rs2823132	chr21:16568856	T/C	cg00407105	chr4:90231041	NA	-0.4	-6.11	-0.32	2.8e-9	Breast cancer;
CRC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg17298326	chr8:142245477	NA	-0.38	-5.79	-0.3	1.61e-8	Immature fraction of reticulocytes;
CRC	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.63	8.91	0.44	3.63e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.62	-10.34	-0.5	6.92e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	9.71	0.47	8.87e-20	Metabolite levels;
CRC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg15845792	chr6:28175446	NA	0.58	5.94	0.31	7.09e-9	Depression;
CRC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.46	-6.5	-0.34	2.96e-10	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.899	rs10889340	chr1:63012071	A/C	cg19896129	chr1:63156450	NA	-0.44	-6.82	-0.35	4.3e-11	Triglyceride levels;
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg04969067	chr8:143858791	LYNX1	0.45	7.67	0.39	1.97e-13	Urinary tract infection frequency;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.8	12.76	0.58	1.4e-30	Height;
CRC	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.43	5.69	0.3	2.76e-8	Tuberculosis;
CRC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.72	9.67	0.47	1.22e-19	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg18827107	chr12:86230957	RASSF9	-0.38	-6.25	-0.33	1.3e-9	Major depressive disorder;
CRC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.56	-9.86	-0.48	2.86e-20	Huntington's disease progression;
CRC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg21681030	chr2:46777652	RHOQ	0.41	5.77	0.3	1.88e-8	Height;
CRC	cis	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg08831531	chr16:9218945	NA	-0.64	-9.0	-0.44	1.84e-17	Menopause (age at onset);
CRC	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.43	5.87	0.31	1.09e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02290350	chr8:58132656	NA	-0.57	-8.04	-0.41	1.59e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs10208940	0.920	rs6714976	chr2:68764873	G/T	cg12452813	chr2:68675892	NA	0.48	6.01	0.31	4.94e-9	Urate levels in lean individuals;
CRC	cis	rs73206853	0.841	rs3026456	chr12:110748735	G/C	cg12870014	chr12:110450643	ANKRD13A	0.8	7.76	0.39	1.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg07979401	chr6:33739406	LEMD2	-0.46	-5.98	-0.31	5.72e-9	Schizophrenia;
CRC	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.36	6.52	0.34	2.58e-10	Panic disorder;
CRC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.84	-0.55	3.39e-27	Hemoglobin concentration;
CRC	cis	rs6840360	0.642	rs2709838	chr4:152371364	G/A	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.69	11.12	0.52	1.34e-24	Corneal astigmatism;
CRC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg18683604	chr14:51561293	TRIM9	0.29	6.0	0.31	5.11e-9	Cancer;
CRC	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.73	-7.53	-0.38	4.81e-13	Recalcitrant atopic dermatitis;
CRC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.72	11.57	0.54	3.37e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12679910	chr17:73900713	MRPL38	0.44	6.29	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.5	-7.24	-0.37	3.16e-12	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg02527881	chr3:46936655	PTH1R	0.33	5.64	0.3	3.75e-8	Colorectal cancer;
CRC	cis	rs747650	0.504	rs4394802	chr11:46990587	C/T	cg19486271	chr11:47235900	DDB2	-0.43	-6.51	-0.34	2.76e-10	Acne (severe);
CRC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.42e-10	Breast cancer;
CRC	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.77	-0.3	1.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg07195577	chr17:27052828	TLCD1	0.42	5.99	0.31	5.47e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.69	9.31	0.46	1.85e-18	High light scatter reticulocyte count;
CRC	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg12483005	chr1:23474871	LUZP1	0.44	6.39	0.33	5.6e-10	Height;
CRC	cis	rs12692738	0.526	rs355852	chr2:165626304	C/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12963246	chr6:28129442	ZNF389	0.5	5.73	0.3	2.3e-8	Depression;
CRC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02290350	chr8:58132656	NA	-0.44	-6.24	-0.33	1.36e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.65	6.8	0.35	4.82e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg07979401	chr6:33739406	LEMD2	-0.47	-5.89	-0.31	9.29e-9	Schizophrenia;
CRC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	6.03	0.32	4.38e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg19041857	chr6:27730383	NA	-0.44	-5.99	-0.31	5.36e-9	Parkinson's disease;
CRC	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.47	6.76	0.35	6.18e-11	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07393655	chr5:43122148	ZNF131	0.43	6.11	0.32	2.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg25809561	chr17:30822961	MYO1D	0.52	9.16	0.45	5.75e-18	Schizophrenia;
CRC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg18833306	chr6:118973337	C6orf204	0.44	5.64	0.3	3.67e-8	Diastolic blood pressure;
CRC	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.75	-0.43	1.1e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.55	8.8	0.44	7.77e-17	Prostate cancer;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg02683197	chr6:28174875	NA	0.75	9.78	0.47	5.25e-20	Parkinson's disease;
CRC	cis	rs11761441	0.602	rs35256056	chr7:87035	G/C	cg12845006	chr7:82380	NA	-0.23	-5.64	-0.3	3.63e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg12172441	chr6:28176163	NA	0.58	7.75	0.39	1.13e-13	Parkinson's disease;
CRC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.16	0.52	9.91e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9828933	0.701	rs7621544	chr3:63928681	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-5.97	-0.31	6.26e-9	Type 2 diabetes;
CRC	cis	rs62408225	1.000	rs56106243	chr6:90975990	C/T	cg06866423	chr6:90926672	BACH2	0.5	8.23	0.41	4.55e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.39	6.81	0.35	4.61e-11	Coronary artery disease;
CRC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.69	10.17	0.49	2.66e-21	Corneal astigmatism;
CRC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg08533674	chr1:46993347	NA	-0.77	-10.37	-0.5	5.43e-22	Monobrow;
CRC	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.54	-9.72	-0.47	8.19e-20	Schizophrenia;
CRC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg26695010	chr11:65641043	EFEMP2	-0.38	-5.76	-0.3	1.96e-8	Eosinophil percentage of white cells;
CRC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.5	-0.34	3.05e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg17401720	chr7:158221031	PTPRN2	0.46	7.36	0.38	1.51e-12	Obesity-related traits;
CRC	cis	rs972578	1.000	rs5759067	chr22:43372799	T/C	cg01576275	chr22:43409880	NA	-0.47	-7.6	-0.39	3.1e-13	Mean platelet volume;
CRC	cis	rs1009181	0.585	rs4486004	chr6:26167710	G/T	cg00631329	chr6:26305371	NA	-0.42	-6.08	-0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs7605827	0.866	rs4668917	chr2:15661815	G/C	cg19274914	chr2:15703543	NA	0.39	5.84	0.31	1.23e-8	Educational attainment (years of education);
CRC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02228675	chr17:40259724	DHX58	-0.48	-6.8	-0.35	5.05e-11	Fibrinogen levels;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg19678392	chr7:94953810	PON1	-0.52	-6.59	-0.34	1.77e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.28	-0.37	2.5e-12	Chronic sinus infection;
CRC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg26695010	chr11:65641043	EFEMP2	0.48	7.46	0.38	7.59e-13	Eosinophil percentage of white cells;
CRC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.68	-8.09	-0.41	1.14e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.99	-10.2	-0.49	2.1e-21	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17554472	chr22:41940697	POLR3H	-0.55	-5.84	-0.31	1.23e-8	Vitiligo;
CRC	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg15436123	chr4:3390332	RGS12	-0.35	-6.83	-0.35	4.14e-11	Blood protein levels;
CRC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.39e-12	Bipolar disorder;
CRC	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg05472934	chr7:22766657	IL6	0.45	6.85	0.35	3.61e-11	Lung cancer;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg09324608	chr17:30823087	MYO1D	0.34	5.98	0.31	5.72e-9	Schizophrenia;
CRC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-6.54	-0.34	2.29e-10	Coronary artery disease;
CRC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.52	7.7	0.39	1.6e-13	Blood protein levels;
CRC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	trans	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.52e-13	Bone mineral density;
CRC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg27565382	chr3:53032988	SFMBT1	0.65	5.68	0.3	2.94e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg00490450	chr3:139108681	COPB2	0.41	6.13	0.32	2.48e-9	Obesity-related traits;
CRC	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.65	0.34	1.23e-10	Coronary artery disease;
CRC	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg12856521	chr11:46389249	DGKZ	0.76	10.57	0.5	1.14e-22	Crohn's disease;
CRC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.54	0.34	2.3e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4594175	0.707	rs12432912	chr14:51739395	T/C	cg23942311	chr14:51606299	NA	0.47	7.03	0.36	1.21e-11	Cancer;
CRC	cis	rs524281	0.773	rs11227448	chr11:66048491	G/A	cg14036092	chr11:66035641	RAB1B	-0.56	-6.1	-0.32	3e-9	Electroencephalogram traits;
CRC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg21251018	chr6:28226885	NKAPL	-0.41	-6.21	-0.32	1.63e-9	Parkinson's disease;
CRC	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.05	-0.32	3.87e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.57	7.79	0.39	8.83e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7259376	0.936	rs8108630	chr19:22535177	G/T	cg02657401	chr19:22469223	NA	-0.33	-7.39	-0.38	1.19e-12	Menopause (age at onset);
CRC	cis	rs7703744	0.681	rs17145294	chr5:118701433	G/T	cg19893178	chr5:118692011	TNFAIP8	0.44	5.94	0.31	7.41e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6662572	1.000	rs6662999	chr1:46119351	C/G	cg08644498	chr1:46502608	NA	0.44	6.4	0.33	5.46e-10	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02849769	chr1:110527541	AHCYL1	0.44	6.04	0.32	4.09e-9	Anxiety disorder;
CRC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg23262073	chr20:60523788	NA	-0.42	-7.08	-0.36	8.81e-12	Body mass index;
CRC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.78	-13.54	-0.6	1.65e-33	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4869931	0.790	rs17080108	chr6:151006643	T/C	cg01367992	chr1:160766535	LY9	0.37	6.06	0.32	3.76e-9	Systolic blood pressure in sickle cell anemia;
CRC	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.52	8.85	0.44	5.42e-17	Dupuytren's disease;
CRC	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.53	-8.78	-0.44	9.08e-17	Metabolite levels;
CRC	cis	rs965469	0.779	rs6051820	chr20:3365301	A/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.96e-8	IFN-related cytopenia;
CRC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg12639453	chr1:2035780	PRKCZ	-0.39	-7.55	-0.38	4.45e-13	Height;
CRC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.55	-8.22	-0.41	4.76e-15	Sudden cardiac arrest;
CRC	cis	rs6840360	0.667	rs9994482	chr4:152391230	T/C	cg09659197	chr4:152720779	NA	0.34	6.63	0.34	1.34e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11851522	chr11:71791722	LRTOMT;NUMA1	0.44	5.99	0.31	5.51e-9	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg12172441	chr6:28176163	NA	-0.54	-6.76	-0.35	6.28e-11	Parkinson's disease;
CRC	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.6	11.82	0.55	4.17e-27	Neuroticism;
CRC	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	1.0	20.15	0.74	2.27e-59	Alcohol dependence;
CRC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.34	0.33	7.69e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.41	-8.79	-0.44	8.46e-17	Urinary metabolites;
CRC	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg26394196	chr10:1453818	ADARB2	-0.32	-5.84	-0.31	1.29e-8	Radiation response;
CRC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.48	9.32	0.46	1.75e-18	Renal cell carcinoma;
CRC	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.66	-9.71	-0.47	9.07e-20	Bipolar disorder;
CRC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg24011408	chr12:48396354	COL2A1	0.47	6.39	0.33	5.64e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	12.13	0.56	3.1e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.58	8.87	0.44	4.65e-17	Vitiligo;
CRC	cis	rs3018066	0.666	rs79026220	chr4:107037655	A/G	cg01869342	chr4:106983673	TBCK	0.46	6.03	0.32	4.52e-9	Cancer;
CRC	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.55	-0.38	4.36e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.66	8.79	0.44	8.68e-17	Bladder cancer;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	0.71	7.87	0.4	5.25e-14	Body mass index;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.72	8.75	0.43	1.16e-16	Chronic sinus infection;
CRC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.47	-6.52	-0.34	2.6e-10	Platelet distribution width;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg04497992	chr16:616212	NHLRC4	0.41	6.45	0.33	4.07e-10	Height;
CRC	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.43	5.81	0.31	1.47e-8	Tuberculosis;
CRC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-12.57	-0.57	7.21e-30	Electrocardiographic conduction measures;
CRC	cis	rs282587	0.502	rs382758	chr13:113400169	C/T	cg04656015	chr13:113407548	ATP11A	0.61	7.68	0.39	1.83e-13	Glycated hemoglobin levels;
CRC	cis	rs2737618	0.722	rs2258675	chr1:200091548	G/C	cg21825944	chr1:200113062	NR5A2	-0.52	-7.36	-0.38	1.46e-12	Uric acid levels;
CRC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	6.87	0.35	3.28e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.46	7.05	0.36	1.09e-11	Red blood cell count;
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-10.54	-0.5	1.37e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.48	8.88	0.44	4.49e-17	Lung cancer;
CRC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.98	-0.36	1.66e-11	Colorectal cancer;
CRC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.05	0.32	3.87e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.31	0.37	1.98e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.48	5.79	0.3	1.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg06238570	chr21:40685208	BRWD1	0.78	10.78	0.51	2.06e-23	Cognitive function;
CRC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg17775713	chr3:133465469	TF	0.37	6.76	0.35	6.35e-11	Iron status biomarkers (transferrin levels);
CRC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-5.77	-0.3	1.79e-8	Tonsillectomy;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg03623178	chr6:28175578	NA	0.79	11.41	0.53	1.22e-25	Cardiac Troponin-T levels;
CRC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-15.06	-0.64	2.43e-39	Height;
CRC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.5	-5.66	-0.3	3.31e-8	Vitiligo;
CRC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.74	7.68	0.39	1.83e-13	Fat distribution (HIV);
CRC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-13.91	-0.61	6.28e-35	Blood metabolite levels;
CRC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.6	-9.27	-0.45	2.59e-18	Colorectal cancer;
CRC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg17948913	chr5:572064	NA	0.5	5.79	0.3	1.61e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs6546324	0.625	rs2861645	chr2:67800338	T/A	cg15745817	chr2:67799979	NA	-0.57	-9.8	-0.48	4.45e-20	Endometriosis;
CRC	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg16576597	chr16:28551801	NUPR1	0.41	5.97	0.31	6.26e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg01483505	chr11:975446	AP2A2	0.45	7.38	0.38	1.34e-12	Alzheimer's disease (late onset);
CRC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.52	7.75	0.39	1.17e-13	Lymphocyte counts;
CRC	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.56	-9.0	-0.44	1.78e-17	Neuroticism;
CRC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg24375607	chr4:120327624	NA	0.48	7.41	0.38	1.07e-12	Corneal astigmatism;
CRC	cis	rs1223397	0.938	rs13205692	chr6:13291560	C/T	cg07912922	chr6:13274314	PHACTR1	0.54	6.46	0.34	3.68e-10	Blood pressure;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.58	7.82	0.4	7.34e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.49	7.51	0.38	5.7e-13	Bone properties (heel);
CRC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.8	0.55	5.06e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.92	11.89	0.55	2.27e-27	Exhaled nitric oxide output;
CRC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.57	8.32	0.42	2.37e-15	Type 2 diabetes;
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	0.33	6.31	0.33	8.82e-10	Colorectal cancer;
CRC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03676636	chr4:99064102	C4orf37	0.22	6.26	0.33	1.17e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.96	-17.56	-0.7	3.66e-49	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg12564285	chr5:131593104	PDLIM4	0.5	9.69	0.47	1.1e-19	Breast cancer;
CRC	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg15845792	chr6:28175446	NA	0.8	6.39	0.33	5.67e-10	Depression;
CRC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.56	-9.06	-0.45	1.17e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.06	-0.32	3.82e-9	Blood pressure;
CRC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.59	-6.38	-0.33	6.07e-10	Lung cancer;
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.95	-0.4	3.02e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-9.91	-0.48	1.96e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9469578	1.000	rs9469580	chr6:33715837	A/G	cg18708504	chr6:33715942	IP6K3	-0.65	-7.64	-0.39	2.34e-13	Phosphorus levels;
CRC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	0.98	13.85	0.61	1.08e-34	Breast cancer;
CRC	trans	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.61	-0.39	2.96e-13	HDL cholesterol;
CRC	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.48	-6.66	-0.34	1.14e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.29	0.42	2.85e-15	Homoarginine levels;
CRC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.53	8.18	0.41	6.35e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg18490616	chr2:88469792	THNSL2	-0.39	-5.7	-0.3	2.67e-8	Response to metformin (IC50);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04585517	chr2:37899444	CDC42EP3	-0.41	-6.02	-0.31	4.67e-9	Myopia (pathological);
CRC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	9.56	0.47	2.81e-19	Coronary artery disease;
CRC	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.84e-8	Putamen volume;
CRC	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-0.75	-7.57	-0.39	3.76e-13	Severe influenza A (H1N1) infection;
CRC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.66	8.27	0.41	3.38e-15	Coronary artery disease;
CRC	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-5.73	-0.3	2.29e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4664293	0.609	rs10167143	chr2:160463396	T/A	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg03030879	chr14:75389066	RPS6KL1	0.55	9.13	0.45	6.87e-18	Caffeine consumption;
CRC	cis	rs883565	0.569	rs1274970	chr3:39163252	A/G	cg01426195	chr3:39028469	NA	0.41	6.76	0.35	6.21e-11	Handedness;
CRC	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg20636351	chr8:55087400	NA	-0.33	-5.9	-0.31	9.15e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.18	0.74	1.67e-59	Prudent dietary pattern;
CRC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.95	0.31	6.9e-9	Tonsillectomy;
CRC	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-0.71	-7.24	-0.37	3.25e-12	Blood protein levels;
CRC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.73	-0.35	7.4e-11	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3015497	0.789	rs2934688	chr14:51112360	G/A	cg09863266	chr14:51125203	SAV1	-0.32	-6.13	-0.32	2.51e-9	Mean platelet volume;
CRC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.95	-0.31	6.78e-9	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25486472	chr5:141348514	RNF14	0.44	6.26	0.33	1.18e-9	Response to antipsychotic treatment;
CRC	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.53	7.66	0.39	2.09e-13	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.35	0.33	7.02e-10	Tonsillectomy;
CRC	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.92	0.31	8.2e-9	Refractive astigmatism;
CRC	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.78	14.12	0.61	9.75e-36	Hip circumference;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.73	10.36	0.5	5.76e-22	Menarche (age at onset);
CRC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.66	0.43	2.13e-16	Menopause (age at onset);
CRC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.7	-8.15	-0.41	7.66e-15	Vitiligo;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg15365588	chr7:7681016	RPA3	0.5	6.12	0.32	2.63e-9	Kashin-Beck disease;
CRC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	8.61	0.43	3.04e-16	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.83	13.21	0.59	2.89e-32	Cognitive function;
CRC	cis	rs59104589	0.617	rs60614486	chr2:242274998	C/G	cg19488206	chr2:242435732	STK25	0.46	6.42	0.33	4.67e-10	Fibrinogen levels;
CRC	cis	rs755249	0.567	rs61779275	chr1:39820310	C/T	cg18385671	chr1:39797026	MACF1	-0.4	-5.71	-0.3	2.59e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.56	-0.5	1.25e-22	Bipolar disorder;
CRC	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.16	-0.37	5.15e-12	Capecitabine sensitivity;
CRC	cis	rs2415984	0.579	rs2254846	chr14:46973394	G/A	cg14871534	chr14:47121158	RPL10L	0.39	5.92	0.31	8.03e-9	Number of children ever born;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10452531	chr12:6493278	LTBR	0.38	6.71	0.35	8.48e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.25	0.41	3.86e-15	Lung cancer;
CRC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg10760299	chr15:45669010	GATM	0.37	5.78	0.3	1.73e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg20512303	chr5:131592959	PDLIM4	0.31	5.89	0.31	9.49e-9	Lung function (FEV1/FVC);
CRC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.67	9.0	0.44	1.88e-17	Breast cancer;
CRC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.75	10.01	0.48	8.82e-21	Platelet count;
CRC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.31	0.37	2.09e-12	Motion sickness;
CRC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.44	0.42	1.04e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7517126	1.000	rs13375150	chr1:196841839	C/T	cg13682187	chr1:196946512	CFHR5	-0.37	-5.97	-0.31	6.03e-9	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14575559	chr19:18111766	ARRDC2	0.45	6.29	0.33	1.03e-9	Anxiety disorder;
CRC	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.65	-8.85	-0.44	5.59e-17	Autism;
CRC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.47	-6.86	-0.35	3.43e-11	Lymphocyte counts;
CRC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg15763984	chr4:1342303	KIAA1530	0.35	5.95	0.31	7.01e-9	Longevity;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg03623178	chr6:28175578	NA	0.7	9.33	0.46	1.61e-18	Parkinson's disease;
CRC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.12	13.67	0.6	5.31e-34	Vitiligo;
CRC	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.54	8.35	0.42	1.97e-15	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs12745968	0.623	rs1886684	chr1:92975938	T/C	cg17283838	chr1:93427260	FAM69A	-0.47	-6.3	-0.33	9.41e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.94e-10	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24838029	chr1:43833615	ELOVL1	0.36	5.97	0.31	6.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.73	-11.58	-0.54	3.03e-26	Cognitive function;
CRC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs711830	1.000	rs6433571	chr2:177039578	G/T	cg13092806	chr2:177043255	NA	0.74	9.21	0.45	3.97e-18	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.77	-9.67	-0.47	1.27e-19	Mean platelet volume;
CRC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.51	7.9	0.4	4.18e-14	Lipoprotein (a) levels;
CRC	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	6.99	0.36	1.5e-11	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27238079	chr10:33247273	ITGB1	0.36	6.2	0.32	1.66e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.62	11.23	0.53	5.31e-25	Aortic root size;
CRC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.98	12.07	0.55	5.12e-28	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg19223190	chr17:80058835	NA	0.4	6.42	0.33	4.82e-10	Life satisfaction;
CRC	cis	rs17092148	0.887	rs2295443	chr20:33173827	T/C	cg08999081	chr20:33150536	PIGU	0.49	6.3	0.33	9.31e-10	Neuroticism;
CRC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.43	-8.69	-0.43	1.74e-16	Renal cell carcinoma;
CRC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-9.75	-0.47	6.55e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.99	0.4	2.27e-14	Height;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg03804128	chr16:635623	NA	0.3	7.06	0.36	9.96e-12	Height;
CRC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg10298567	chr3:47292165	KIF9	-0.38	-5.82	-0.31	1.39e-8	Colorectal cancer;
CRC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.42	6.14	0.32	2.32e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg08807101	chr21:30365312	RNF160	0.5	7.17	0.37	5.08e-12	Pancreatic cancer;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg20397358	chr22:38597902	MAFF	-0.73	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg08755490	chr11:65554678	OVOL1	0.42	6.15	0.32	2.24e-9	Acne (severe);
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	1.0	20.24	0.74	9.46e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4834770	1.000	rs878374	chr4:120237564	A/G	cg24375607	chr4:120327624	NA	0.34	5.63	0.3	3.94e-8	Blood protein levels;
CRC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs10746514	0.833	rs1888601	chr1:232266922	C/T	cg09506761	chr1:232265262	NA	-0.46	-6.72	-0.35	8.24e-11	Response to statin therapy;
CRC	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.87	14.5	0.62	3.51e-37	Monocyte count;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.46	-0.34	3.78e-10	Breast cancer;
CRC	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg10935138	chr17:73851978	WBP2	0.56	6.98	0.36	1.59e-11	Psoriasis;
CRC	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.93	14.33	0.62	1.57e-36	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.93	-16.96	-0.68	8.53e-47	Height;
CRC	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg08075719	chr14:103021372	NA	0.56	6.65	0.34	1.24e-10	Platelet count;
CRC	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.54	-6.46	-0.34	3.68e-10	Coronary artery calcification;
CRC	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg06223162	chr1:101003688	GPR88	-0.35	-5.9	-0.31	9.16e-9	Monocyte count;
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs1852612	0.932	rs1852614	chr7:45404785	C/T	cg16479323	chr14:93406498	ITPK1	-0.43	-5.97	-0.31	6.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	trans	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg21747405	chr11:67723411	NA	-0.5	-6.24	-0.33	1.31e-9	Blood pressure (smoking interaction);
CRC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg22117107	chr15:45993392	NA	-0.44	-8.91	-0.44	3.43e-17	Waist circumference;Weight;
CRC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.5	-0.42	6.82e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.57	8.54	0.43	5.12e-16	Blood protein levels;
CRC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg14711859	chr11:8959438	ASCL3	0.57	10.21	0.49	1.91e-21	Hematocrit;
CRC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-16.04	-0.66	3.41e-43	Intelligence (multi-trait analysis);
CRC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.41	6.81	0.35	4.65e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.42	0.53	1.13e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs9462027	0.628	rs9469917	chr6:34831369	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.11	-0.32	2.79e-9	Systemic lupus erythematosus;
CRC	cis	rs9992667	1.000	rs68191221	chr4:38677062	A/G	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.0	-0.44	1.9e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	8.92	0.44	3.37e-17	Alzheimer's disease (late onset);
CRC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-7.43	-0.38	9.24e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.56	-7.94	-0.4	3.18e-14	Educational attainment (college completion);
CRC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg25600027	chr14:23388339	RBM23	0.5	7.93	0.4	3.55e-14	Cognitive ability (multi-trait analysis);
CRC	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-0.67	-9.56	-0.47	2.93e-19	Type 2 diabetes;
CRC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg00129232	chr17:37814104	STARD3	-0.51	-6.43	-0.33	4.45e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg10217327	chr6:118973057	C6orf204	0.51	5.86	0.31	1.12e-8	Diastolic blood pressure;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg26587870	chr6:27730563	NA	-0.36	-5.73	-0.3	2.22e-8	Parkinson's disease;
CRC	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	0.93	12.19	0.56	1.88e-28	Blood protein levels;
CRC	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.5	-7.21	-0.37	3.84e-12	Breast cancer;
CRC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.59	-9.0	-0.44	1.82e-17	Colorectal cancer;
CRC	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.72	-0.35	7.81e-11	Putamen volume;
CRC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.46	6.15	0.32	2.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06766273	chr11:62521983	ZBTB3	-0.53	-6.39	-0.33	5.54e-10	Diisocyanate-induced asthma;
CRC	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.41	-11.53	-0.54	4.75e-26	Psoriasis vulgaris;
CRC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.47	-6.09	-0.32	3.07e-9	Obesity-related traits;
CRC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg11833968	chr6:79620685	NA	-0.37	-6.4	-0.33	5.3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs10486722	0.607	rs6463037	chr7:41760000	A/G	cg22138096	chr7:41772439	LOC285954	0.55	7.45	0.38	8.27e-13	Pit-and-Fissure caries;
CRC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.66	11.96	0.55	1.3e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.12	-0.45	7.41e-18	Rheumatoid arthritis;
CRC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.74	12.79	0.58	1.1e-30	Menarche (age at onset);
CRC	cis	rs501120	0.564	rs61855758	chr10:44684854	T/C	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.98	-0.31	5.68e-9	Monocyte percentage of white cells;
CRC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-5.68	-0.3	2.94e-8	Heart rate;
CRC	cis	rs6564851	0.508	rs7199144	chr16:81251846	A/T	cg00908271	chr16:81254010	PKD1L2	-0.37	-6.03	-0.32	4.48e-9	Carotenoid and tocopherol levels;
CRC	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg14036092	chr11:66035641	RAB1B	-0.46	-5.66	-0.3	3.32e-8	Electroencephalogram traits;
CRC	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-0.72	-5.74	-0.3	2.18e-8	Lung cancer;
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg21138405	chr5:131827807	IRF1	-0.37	-6.27	-0.33	1.12e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	10.66	0.51	5.38e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg25456477	chr12:86230367	RASSF9	0.38	6.32	0.33	8.37e-10	Major depressive disorder;
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.47	6.73	0.35	7.59e-11	Parkinson's disease;
CRC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.38	-8.22	-0.41	4.73e-15	Schizophrenia;
CRC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.6	7.74	0.39	1.21e-13	Gut microbiome composition (summer);
CRC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.5	-6.78	-0.35	5.72e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs420259	0.510	rs12921516	chr16:23521403	T/G	cg00143387	chr16:23521605	GGA2	-0.47	-5.9	-0.31	9.27e-9	Bipolar disorder;
CRC	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-14.15	-0.62	7.62e-36	Exhaled nitric oxide output;
CRC	cis	rs2730260	0.736	rs73169215	chr7:158833701	T/C	cg02254261	chr7:158964346	NA	-0.57	-6.36	-0.33	6.6e-10	Myopia (pathological);
CRC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg24140574	chr1:16342155	HSPB7	-0.41	-5.67	-0.3	3.06e-8	Dilated cardiomyopathy;
CRC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg01483505	chr11:975446	AP2A2	0.45	7.39	0.38	1.24e-12	Alzheimer's disease (late onset);
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20823940	chr1:95007489	F3	0.47	6.6	0.34	1.69e-10	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17121955	chr11:6411382	SMPD1	0.38	6.2	0.32	1.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.68	-6.94	-0.36	2.15e-11	Tuberculosis;
CRC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg14541582	chr5:601475	NA	-0.34	-6.71	-0.35	8.72e-11	Lung disease severity in cystic fibrosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20531166	chr11:82782814	RAB30	0.4	5.99	0.31	5.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.59	9.13	0.45	7.14e-18	Schizophrenia;
CRC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.63	13.04	0.58	1.24e-31	Schizophrenia;
CRC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.96	-0.31	6.41e-9	Bipolar disorder;
CRC	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg00490450	chr3:139108681	COPB2	0.43	6.43	0.33	4.53e-10	Obesity-related traits;
CRC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.42	-6.43	-0.33	4.43e-10	Type 2 diabetes;
CRC	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.34e-36	Hypertriglyceridemia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24306924	chr16:46918433	GPT2	0.42	6.29	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.78	10.9	0.51	8.27e-24	Orofacial clefts;
CRC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.06	0.64	2.3e-39	Primary sclerosing cholangitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03226425	chr6:170151538	C6orf70;TCTE3	0.48	6.31	0.33	9.05e-10	Thyroid stimulating hormone;
CRC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.65	0.34	1.21e-10	Mean platelet volume;
CRC	cis	rs7731657	0.537	rs13355768	chr5:130360245	C/T	cg08523029	chr5:130500466	HINT1	-0.46	-5.95	-0.31	6.9e-9	Fasting plasma glucose;
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg19678392	chr7:94953810	PON1	-0.57	-7.2	-0.37	4.21e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.42	6.62	0.34	1.45e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.21	-0.45	3.83e-18	Mood instability;
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.43	0.42	1.09e-15	Life satisfaction;
CRC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.79	0.63	2.66e-38	Prudent dietary pattern;
CRC	trans	rs67073037	0.955	rs11677283	chr2:29151035	C/T	cg13899017	chr1:159158444	CADM3	-0.36	-6.17	-0.32	2.06e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs4973397	0.774	rs12998237	chr2:232276651	T/C	cg13347044	chr2:232276743	NA	0.54	7.67	0.39	1.93e-13	Anti-saccade response;
CRC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18357526	chr6:26021779	HIST1H4A	0.41	5.81	0.3	1.5e-8	Height;
CRC	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg02569458	chr12:86230093	RASSF9	-0.4	-6.81	-0.35	4.55e-11	Major depressive disorder;
CRC	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.42e-12	Life satisfaction;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.72	-11.46	-0.53	8.24e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.79	12.27	0.56	9.28e-29	Breast cancer;
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.56	6.81	0.35	4.74e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg05241839	chr16:53537463	AKTIP	0.48	6.19	0.32	1.84e-9	Plasma plasminogen activator levels;
CRC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.56	8.87	0.44	4.7e-17	Schizophrenia;
CRC	cis	rs17401966	1.000	rs17396382	chr1:10290268	T/C	cg19773385	chr1:10388646	KIF1B	-0.54	-6.89	-0.35	2.92e-11	Hepatocellular carcinoma;
CRC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg03146154	chr1:46216737	IPP	-0.49	-6.36	-0.33	6.79e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-7.61	-0.39	2.92e-13	Renal function-related traits (BUN);
CRC	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.64	-8.89	-0.44	4.13e-17	Blood protein levels;
CRC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg20243544	chr17:37824526	PNMT	0.4	6.34	0.33	7.54e-10	Self-reported allergy;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg18758796	chr5:131593413	PDLIM4	0.4	6.42	0.33	4.64e-10	Breast cancer;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg18301423	chr5:131593218	PDLIM4	0.39	6.52	0.34	2.57e-10	Breast cancer;
CRC	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.03	0.52	2.83e-24	Bipolar disorder;
CRC	cis	rs4917833	0.764	rs1925644	chr10:100220488	C/T	cg19043522	chr10:100227446	HPSE2	0.37	5.7	0.3	2.71e-8	Pediatric bone mineral density (femoral neck);
CRC	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.6	9.79	0.48	4.86e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs672059	1.000	rs625917	chr1:183157991	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.29	0.37	2.38e-12	Hypertriglyceridemia;
CRC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.87	-10.18	-0.49	2.47e-21	Initial pursuit acceleration;
CRC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.45	6.36	0.33	6.91e-10	Lymphocyte counts;
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg24463073	chr6:118973353	C6orf204	0.51	6.73	0.35	7.61e-11	Diastolic blood pressure;
CRC	cis	rs11212617	0.967	rs419716	chr11:108221099	G/T	cg01991180	chr11:108092276	ATM;NPAT	-0.41	-6.14	-0.32	2.43e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-8.19	-0.41	6.02e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.39	5.75	0.3	2.09e-8	Menarche (age at onset);
CRC	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	12.33	0.56	5.45e-29	Platelet count;
CRC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.46	0.5	2.69e-22	Heart rate;
CRC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.43	-6.18	-0.32	1.93e-9	Aortic root size;
CRC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	6.76	0.35	6.39e-11	Cognitive test performance;
CRC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.72	11.33	0.53	2.45e-25	Corneal astigmatism;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg06470822	chr6:28175283	NA	0.82	8.4	0.42	1.4e-15	Lung cancer in ever smokers;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.5	7.36	0.38	1.46e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg15382696	chr6:118971807	C6orf204	0.57	7.15	0.37	5.49e-12	Diastolic blood pressure;
CRC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.63	-8.52	-0.43	5.65e-16	Refractive error;
CRC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-6.14	-0.32	2.44e-9	Lung cancer;
CRC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.59	-0.34	1.72e-10	Dupuytren's disease;
CRC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.1e-16	Alcohol dependence;
CRC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.45	-6.39	-0.33	5.72e-10	Blood pressure (smoking interaction);
CRC	cis	rs7121446	0.521	rs12278577	chr11:121861838	A/G	cg13820391	chr11:121835505	NA	0.32	5.82	0.31	1.4e-8	Cardiovascular risk factors (age interaction);
CRC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.42	6.46	0.34	3.7e-10	Monocyte count;
CRC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.82	10.06	0.48	6.39e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.77	12.72	0.57	2.09e-30	Height;
CRC	cis	rs17065868	1.000	rs17065995	chr13:45222314	C/T	cg10246903	chr13:45222710	NA	0.51	6.21	0.32	1.55e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.4	-0.46	9.67e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4780401	0.728	rs4781136	chr16:11767978	G/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.65	-0.3	3.55e-8	Rheumatoid arthritis;
CRC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.62	-0.3	4.07e-8	Aortic root size;
CRC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.8	-13.49	-0.6	2.49e-33	Coronary artery disease;
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.56	8.17	0.41	6.75e-15	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	0.98	14.5	0.62	3.57e-37	IgG glycosylation;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg12172441	chr6:28176163	NA	0.53	7.42	0.38	9.91e-13	Parkinson's disease;
CRC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.42e-12	Colorectal cancer;
CRC	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.8	-0.48	4.79e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg24562669	chr7:97807699	LMTK2	0.44	7.2	0.37	3.99e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.72	10.55	0.5	1.35e-22	Neutrophil percentage of white cells;
CRC	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	1.01	12.16	0.56	2.48e-28	Obesity-related traits;
CRC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg14711859	chr11:8959438	ASCL3	-0.43	-6.93	-0.36	2.21e-11	Hemoglobin concentration;
CRC	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.54	6.35	0.33	7.21e-10	Blood protein levels;
CRC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	2e-33	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.73	-9.8	-0.48	4.69e-20	Coronary artery disease;
CRC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	9.21	0.45	3.91e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.54	0.43	5.08e-16	Colonoscopy-negative controls vs population controls;
CRC	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.78	-0.63	3.02e-38	Exhaled nitric oxide output;
CRC	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.47	7.85	0.4	5.77e-14	Refractive error;
CRC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg24011408	chr12:48396354	COL2A1	-0.43	-6.38	-0.33	6e-10	Glycated hemoglobin levels;
CRC	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-0.7	-7.22	-0.37	3.69e-12	Blood protein levels;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg06470822	chr6:28175283	NA	0.82	12.33	0.56	5.58e-29	Parkinson's disease;
CRC	cis	rs16852403	0.548	rs1018706	chr1:178209895	T/G	cg00404053	chr1:178313656	RASAL2	0.5	6.53	0.34	2.55e-10	Childhood ear infection;
CRC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.71	11.12	0.52	1.39e-24	Corneal astigmatism;
CRC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.51	7.12	0.37	6.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.62	-9.08	-0.45	1e-17	Testicular germ cell tumor;
CRC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-6.77	-0.35	5.93e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-10.13	-0.49	3.64e-21	Intelligence (multi-trait analysis);
CRC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12501888	chr15:85177176	SCAND2	-0.37	-6.18	-0.32	1.9e-9	P wave terminal force;
CRC	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.47	9.52	0.46	3.96e-19	Schizophrenia;
CRC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg05132306	chr1:1846340	CALML6	-0.44	-6.74	-0.35	6.98e-11	Body mass index;
CRC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.61	-0.34	1.58e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.81	14.97	0.64	5.12e-39	Mean platelet volume;
CRC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.64	-10.71	-0.51	3.54e-23	Depressive symptoms (multi-trait analysis);
CRC	trans	rs67073037	0.955	rs4371318	chr2:29156360	T/C	cg13899017	chr1:159158444	CADM3	-0.37	-6.23	-0.32	1.39e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs7923609	0.967	rs7082470	chr10:65277026	G/A	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.96	-0.31	6.65e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-6.7	-0.35	9.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.6	10.61	0.51	7.98e-23	Aortic root size;
CRC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.42	-0.46	8.23e-19	Bladder cancer;
CRC	cis	rs28655083	0.529	rs285027	chr16:77100932	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.47	6.6	0.34	1.64e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.91	11.3	0.53	2.97e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.12	-12.24	-0.56	1.17e-28	Breast cancer;
CRC	cis	rs12143943	0.934	rs1870551	chr1:204581014	A/G	cg17419461	chr1:204415978	PIK3C2B	0.4	6.08	0.32	3.25e-9	Cognitive performance;
CRC	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.4	-5.74	-0.3	2.13e-8	Fractional excretion of uric acid;
CRC	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.02	-0.32	4.6e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg16447950	chr5:562315	NA	-0.64	-9.17	-0.45	5.11e-18	Lung disease severity in cystic fibrosis;
CRC	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg03060546	chr3:49711283	APEH	0.46	6.28	0.33	1.04e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00804031	chr19:4007535	PIAS4	0.42	6.27	0.33	1.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg21251018	chr6:28226885	NKAPL	-0.46	-6.58	-0.34	1.88e-10	Depression;
CRC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24308560	chr3:49941425	MST1R	0.49	8.19	0.41	5.98e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.31	5.86	0.31	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.48	8.09	0.41	1.17e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.48	-7.78	-0.39	9.72e-14	Testicular germ cell tumor;
CRC	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.42	-6.32	-0.33	8.63e-10	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.61e-9	Height;
CRC	cis	rs1322512	0.917	rs2623956	chr6:152971617	G/A	cg03415253	chr6:152958462	SYNE1	-0.44	-6.75	-0.35	6.68e-11	Tonometry;
CRC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg03037974	chr15:76606532	NA	0.72	13.12	0.59	6.35e-32	Blood metabolite levels;
CRC	cis	rs7527798	0.592	rs12411037	chr1:207857158	T/C	cg09232269	chr1:207846808	CR1L	-0.48	-7.87	-0.4	5.04e-14	Erythrocyte sedimentation rate;
CRC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.45	5.73	0.3	2.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs802075	0.905	rs7746868	chr6:49642763	A/C	cg20364632	chr6:49636226	NA	0.36	6.01	0.31	4.86e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.66	-10.07	-0.49	5.76e-21	Longevity;
CRC	cis	rs7113874	0.524	rs10743076	chr11:8560571	C/A	cg17679104	chr11:8615758	STK33	-0.36	-5.96	-0.31	6.52e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg21335942	chr16:58549945	SETD6	0.86	5.72	0.3	2.39e-8	Schizophrenia;
CRC	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg15654264	chr1:150340011	RPRD2	0.38	5.95	0.31	7.02e-9	Migraine;
CRC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.38	6.08	0.32	3.31e-9	Major depressive disorder;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.48	7.44	0.38	8.79e-13	Corneal astigmatism;
CRC	cis	rs71227278	1	rs71227278	chr12:54358047	C/CTTAA	cg01524278	chr12:54355460	NA	0.39	7.69	0.39	1.75e-13	Urinary tract infection frequency;
CRC	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.56	8.36	0.42	1.79e-15	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg09455208	chr3:40491958	NA	-0.31	-6.3	-0.33	9.41e-10	Renal cell carcinoma;
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.81	13.72	0.6	3.54e-34	Menopause (age at onset);
CRC	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg02811702	chr13:24901961	NA	0.47	6.6	0.34	1.64e-10	Obesity-related traits;
CRC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.81	-11.52	-0.54	4.9e-26	Gut microbiome composition (summer);
CRC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.42	-6.32	-0.33	8.47e-10	Obesity-related traits;
CRC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg19223190	chr17:80058835	NA	0.48	7.69	0.39	1.75e-13	Life satisfaction;
CRC	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.38	-5.74	-0.3	2.16e-8	Endometrial cancer;
CRC	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.53	-9.11	-0.45	8.28e-18	Aortic root size;
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg20119798	chr7:94954144	PON1	-0.51	-6.4	-0.33	5.35e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg03013999	chr17:37608204	MED1	0.48	7.39	0.38	1.24e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-7.46	-0.38	7.55e-13	Colorectal cancer;
CRC	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.71	-9.44	-0.46	6.94e-19	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22129074	chr11:74204105	LIPT2	0.47	6.1	0.32	3.04e-9	Thyroid stimulating hormone;
CRC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs62229266	0.659	rs2835243	chr21:37413946	C/T	cg12218747	chr21:37451666	NA	-0.37	-6.21	-0.32	1.62e-9	Mitral valve prolapse;
CRC	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	7.9	0.4	4.2e-14	Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04720635	chr5:118604540	TNFAIP8	0.39	6.19	0.32	1.76e-9	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg27661571	chr11:113659931	NA	-0.96	-11.1	-0.52	1.56e-24	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg06470822	chr6:28175283	NA	0.72	9.7	0.47	1e-19	Parkinson's disease;
CRC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23378565	chr7:2036160	MAD1L1	-0.42	-5.9	-0.31	8.98e-9	Bipolar disorder;
CRC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.1	11.62	0.54	2.23e-26	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg11900509	chr10:81946545	ANXA11	-0.71	-7.17	-0.37	4.83e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.4	6.43	0.33	4.41e-10	Life satisfaction;
CRC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.67	-12.39	-0.56	3.32e-29	Breast cancer;
CRC	trans	rs4478147	0.591	rs56353461	chr4:87470983	A/G	cg01215037	chr19:50083917	PRRG2;NOSIP	0.45	5.97	0.31	6.1e-9	Migraine - clinic-based;
CRC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.52	6.98	0.36	1.62e-11	Anxiety disorder;
CRC	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.59	9.97	0.48	1.28e-20	Breast cancer;
CRC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.49	0.5	2.13e-22	Systolic blood pressure;
CRC	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.32	-6.22	-0.32	1.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.91	-17.1	-0.69	2.38e-47	Body mass index;
CRC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	4.94e-12	Life satisfaction;
CRC	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12516959	chr21:47718080	NA	-0.33	-5.65	-0.3	3.57e-8	Testicular germ cell tumor;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg10217327	chr6:118973057	C6orf204	0.5	5.69	0.3	2.83e-8	Diastolic blood pressure;
CRC	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.5	-9.77	-0.47	5.89e-20	Hepatitis;
CRC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.67	9.67	0.47	1.21e-19	Corneal astigmatism;
CRC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.93	11.11	0.52	1.43e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg10217327	chr6:118973057	C6orf204	0.5	5.69	0.3	2.83e-8	Diastolic blood pressure;
CRC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-7.23	-0.37	3.34e-12	Lung cancer;
CRC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.66	8.35	0.42	1.93e-15	Mean platelet volume;
CRC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	0.64	6.34	0.33	7.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24340285	chr19:1095545	POLR2E	0.37	6.08	0.32	3.25e-9	Obesity-related traits;
CRC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.29	-0.46	2.17e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.81e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.65	9.23	0.45	3.51e-18	Alzheimer's disease;
CRC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-7.58	-0.39	3.48e-13	Menarche (age at onset);
CRC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg12193833	chr17:30244370	NA	0.46	6.12	0.32	2.61e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg03804128	chr16:635623	NA	0.31	7.07	0.36	9.35e-12	Height;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23161317	chr6:28129485	ZNF389	-0.5	-6.16	-0.32	2.15e-9	Depression;
CRC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg18827107	chr12:86230957	RASSF9	0.37	6.09	0.32	3.19e-9	Major depressive disorder;
CRC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.7	12.98	0.58	2.14e-31	Developmental language disorder (linguistic errors);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03924805	chr2:242211663	HDLBP	0.44	6.32	0.33	8.53e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.12e-9	Depression;
CRC	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg16068336	chr17:48637367	CACNA1G	-0.51	-7.4	-0.38	1.12e-12	Type 2 diabetes;
CRC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg14074117	chr16:1909714	C16orf73	0.41	5.79	0.3	1.63e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.04	12.82	0.58	8.95e-31	Vitiligo;
CRC	cis	rs11212617	1.000	rs680113	chr11:108165406	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.07	0.32	3.56e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.01	-0.31	4.8e-9	Subjective well-being;
CRC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg10760299	chr15:45669010	GATM	0.37	5.69	0.3	2.74e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs797680	0.856	rs6541404	chr1:93743434	A/T	cg10096100	chr1:26503862	CNKSR1	0.25	6.8	0.35	4.95e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CRC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.46	6.19	0.32	1.81e-9	Aortic root size;
CRC	trans	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg26043149	chr18:55253948	FECH	-0.51	-7.85	-0.4	5.93e-14	Bone mineral density;
CRC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.7	-0.35	9.01e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.6	8.24	0.41	4.15e-15	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05878849	chr19:40971639	SPTBN4;BLVRB	0.47	6.44	0.33	4.24e-10	Anxiety disorder;
CRC	cis	rs863345	0.604	rs11264983	chr1:158462218	A/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.7	-11.77	-0.54	6.33e-27	Paraoxonase activity;
CRC	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg23555395	chr2:238036564	NA	-0.47	-7.4	-0.38	1.13e-12	Systemic lupus erythematosus;
CRC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.95e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.38	-5.65	-0.3	3.47e-8	Educational attainment;
CRC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg18016565	chr1:150552671	MCL1	-0.42	-6.22	-0.32	1.5e-9	Tonsillectomy;
CRC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.57	-9.86	-0.48	2.99e-20	Intelligence (multi-trait analysis);
CRC	cis	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg27395922	chr11:50257633	LOC441601	0.36	5.87	0.31	1.07e-8	Coronary artery disease;
CRC	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg21452805	chr1:244014465	NA	0.47	6.38	0.33	5.99e-10	RR interval (heart rate);
CRC	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs4954585	0.683	rs11678502	chr2:136994454	C/T	cg05194412	chr2:137003533	NA	0.42	6.7	0.35	8.98e-11	Colorectal cancer;
CRC	cis	rs17095355	1.000	rs734165	chr10:111697789	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.53	-6.47	-0.34	3.59e-10	Biliary atresia;
CRC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg21523564	chr15:75251491	NA	0.42	6.12	0.32	2.65e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg24562669	chr7:97807699	LMTK2	0.79	17.53	0.69	4.85e-49	Breast cancer;
CRC	trans	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.47	-0.34	3.62e-10	Aortic root size;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14293776	chr19:12371199	NA	0.41	6.11	0.32	2.89e-9	Interleukin-6 levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00984370	chr22:50946470	LMF2;NCAPH2	0.43	6.16	0.32	2.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.33	4.06e-10	Electroencephalogram traits;
CRC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.68	0.39	1.84e-13	Axial length;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16215968	chr13:30995686	NA	0.42	6.48	0.34	3.26e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.32	-0.33	8.51e-10	Mood instability;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.2	0.59	3.17e-32	Alzheimer's disease;
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23422044	chr7:1970798	MAD1L1	-0.58	-6.92	-0.36	2.34e-11	Bipolar disorder;
CRC	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-7.32	-0.37	1.94e-12	Coronary artery disease;
CRC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.01	-19.49	-0.73	8.97e-57	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg13385794	chr1:248469461	NA	0.4	6.85	0.35	3.58e-11	Common traits (Other);
CRC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg21399703	chr1:247681439	NA	0.47	7.65	0.39	2.24e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg02527881	chr3:46936655	PTH1R	0.41	7.36	0.38	1.49e-12	Colorectal cancer;
CRC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.46	6.31	0.33	8.9e-10	Red blood cell count;
CRC	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.68	-9.39	-0.46	1.02e-18	Hypospadias;
CRC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.13	0.32	2.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6834538	0.559	rs10434014	chr4:113401357	C/A	cg10021238	chr4:113569128	MIR367;LARP7	-0.39	-5.75	-0.3	2.02e-8	Free thyroxine concentration;
CRC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-13.22	-0.59	2.59e-32	Blood metabolite levels;
CRC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.77	-0.3	1.87e-8	Mean platelet volume;
CRC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.67	-9.41	-0.46	8.91e-19	DNA methylation (variation);
CRC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg02135003	chr7:105160482	PUS7	-0.97	-12.57	-0.57	7.19e-30	Bipolar disorder (body mass index interaction);
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg19041857	chr6:27730383	NA	-0.41	-5.93	-0.31	7.57e-9	Parkinson's disease;
CRC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.94	-0.31	7.41e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs1326986	0.702	rs12252209	chr10:19825426	T/G	cg02718124	chr11:6502648	FXC1;ARFIP2	0.58	5.97	0.31	6e-9	Ankylosing spondylitis;
CRC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.59	9.01	0.45	1.66e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19148051	chr1:3713096	LRRC47	0.43	6.05	0.32	3.88e-9	Response to antipsychotic treatment;
CRC	trans	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg25214090	chr10:38739885	LOC399744	-0.42	-6.54	-0.34	2.37e-10	Diastolic blood pressure;
CRC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.57	-8.87	-0.44	4.62e-17	Aortic root size;
CRC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.36	5.7	0.3	2.73e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13047869	chr3:10149882	C3orf24	0.48	6.81	0.35	4.79e-11	Alzheimer's disease;
CRC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.1	-0.36	7.88e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.73	-9.48	-0.46	5.09e-19	Initial pursuit acceleration;
CRC	trans	rs2303319	0.504	rs62187653	chr2:162469128	T/C	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.43e-9	Cognitive function;
CRC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg01879757	chr17:41196368	BRCA1	-0.42	-6.24	-0.33	1.31e-9	Menopause (age at onset);
CRC	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.59	-0.39	3.33e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg16606324	chr3:10149918	C3orf24	0.48	6.93	0.36	2.29e-11	Alzheimer's disease;
CRC	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.71	-0.6	3.9e-34	Hypospadias;
CRC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.11	-9.85	-0.48	3.19e-20	Gout;
CRC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.78	-0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg16077055	chr2:106428750	NCK2	0.41	5.97	0.31	5.98e-9	Addiction;
CRC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.77	0.3	1.85e-8	Lung cancer;
CRC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.63	10.33	0.49	7.51e-22	Ulcerative colitis;
CRC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04476341	chr5:669733	TPPP	0.42	6.88	0.35	3.1e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.78	-10.48	-0.5	2.37e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs3750082	0.889	rs11766608	chr7:32940086	C/T	cg05721444	chr7:32995514	FKBP9	0.48	7.22	0.37	3.62e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.58	-9.34	-0.46	1.48e-18	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg21475434	chr5:93447410	FAM172A	0.46	5.9	0.31	9.03e-9	Diabetic retinopathy;
CRC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	11.96	0.55	1.27e-27	Schizophrenia;
CRC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.66	10.22	0.49	1.78e-21	Blood protein levels;
CRC	trans	rs10944	0.598	rs9293761	chr5:78290215	C/T	cg10777881	chr1:144044138	NA	0.45	6.32	0.33	8.37e-10	Blood and toenail selenium levels;
CRC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.42	6.27	0.33	1.15e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	7.59	0.39	3.43e-13	Obesity-related traits;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg18758796	chr5:131593413	PDLIM4	0.46	8.26	0.41	3.59e-15	Blood metabolite levels;
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.46	-0.5	2.78e-22	Alzheimer's disease;
CRC	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg18232548	chr7:50535776	DDC	0.49	6.86	0.35	3.4e-11	Malaria;
CRC	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.94	-0.31	7.21e-9	Type 2 diabetes;
CRC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-17.08	-0.69	2.88e-47	Height;
CRC	cis	rs3736485	0.934	rs4775952	chr15:51869056	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.64	-0.34	1.3e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg27094323	chr7:1216898	NA	-0.35	-5.78	-0.3	1.77e-8	Longevity;Endometriosis;
CRC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23463467	chr20:60627584	TAF4	0.36	6.39	0.33	5.67e-10	Body mass index;
CRC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	7.87	0.4	5.26e-14	Menopause (age at onset);
CRC	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg13611204	chr9:139324423	INPP5E	-0.4	-5.7	-0.3	2.73e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs3087591	0.639	rs1048317	chr17:29704002	T/C	cg24425628	chr17:29625626	OMG;NF1	0.64	10.9	0.52	8.01e-24	Hip circumference;
CRC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-8.43	-0.42	1.13e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.85	-0.31	1.17e-8	Gout;Renal underexcretion gout;
CRC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.89	17.25	0.69	6.26e-48	Bone mineral density;
CRC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19717773	chr7:2847554	GNA12	-0.4	-5.81	-0.3	1.51e-8	Height;
CRC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.92	-0.36	2.38e-11	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	11.59	0.54	2.88e-26	Prudent dietary pattern;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15884411	chr2:96932403	CIAO1;TMEM127	0.42	6.14	0.32	2.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.74	9.66	0.47	1.33e-19	Blood protein levels;
CRC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.4	-5.89	-0.31	9.65e-9	Response to metformin (IC50);
CRC	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.61	-7.68	-0.39	1.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs739496	0.542	rs7316698	chr12:111790511	C/T	cg10833066	chr12:111807467	FAM109A	0.56	7.25	0.37	3.06e-12	Platelet count;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg25885038	chr17:56607967	SEPT4	-0.5	-7.55	-0.38	4.26e-13	Vitamin D levels;
CRC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.44	5.82	0.31	1.37e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.74	-0.3	2.18e-8	Lung cancer;
CRC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.47	6.49	0.34	3.11e-10	Schizophrenia;
CRC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg22903471	chr2:27725779	GCKR	0.35	5.63	0.3	3.83e-8	Oral cavity cancer;
CRC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.91	-0.4	3.96e-14	Height;
CRC	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.46	-6.56	-0.34	2.1e-10	Schizophrenia;
CRC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg13722127	chr7:150037890	RARRES2	0.49	7.66	0.39	2.06e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.6	0.63	1.5e-37	Chronic sinus infection;
CRC	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.18	-0.32	1.86e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.63	10.64	0.51	6.32e-23	Prudent dietary pattern;
CRC	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.3	-6.58	-0.34	1.83e-10	Corneal astigmatism;
CRC	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.59	-0.34	1.7e-10	Monocyte count;
CRC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.42	-6.5	-0.34	3.05e-10	Blood metabolite levels;
CRC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.85	15.01	0.64	3.63e-39	Blood protein levels;
CRC	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.33	16.07	0.66	2.6e-43	Uric acid levels;
CRC	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg09659197	chr4:152720779	NA	0.31	5.69	0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.56	-8.24	-0.41	4.25e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.57	8.32	0.42	2.45e-15	Response to temozolomide;
CRC	cis	rs62432291	0.681	rs450538	chr6:159659523	A/G	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.39	-8.62	-0.43	2.89e-16	Eye color traits;
CRC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.68	0.6	4.96e-34	Platelet count;
CRC	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02598441	chr17:62777298	LOC146880	-0.52	-6.7	-0.35	8.99e-11	QT interval;
CRC	cis	rs3823572	0.564	rs2971953	chr7:133663576	C/T	cg03336402	chr7:133662267	EXOC4	-0.66	-10.4	-0.5	4.2e-22	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	9.52	0.46	4e-19	Prudent dietary pattern;
CRC	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg01251360	chr16:68772225	CDH1	-0.25	-6.15	-0.32	2.28e-9	Colorectal cancer;
CRC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg00343986	chr7:65444356	GUSB	-0.47	-7.02	-0.36	1.28e-11	Aortic root size;
CRC	cis	rs55702914	0.742	rs6744206	chr2:198148522	A/G	cg20885578	chr2:198174922	NA	-0.35	-6.0	-0.31	5.07e-9	Major depression and alcohol dependence;
CRC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.51	-8.67	-0.43	1.98e-16	Schizophrenia;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg15790184	chr11:494944	RNH1	0.61	6.25	0.33	1.27e-9	Body mass index;
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.92	-0.4	3.73e-14	Gut microbiome composition (summer);
CRC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16447950	chr5:562315	NA	-0.78	-10.31	-0.49	9.11e-22	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19199142	chr21:30671683	BACH1	0.46	6.25	0.33	1.3e-9	Anxiety disorder;
CRC	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.72	11.24	0.53	5.04e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.49	6.48	0.34	3.28e-10	Type 1 diabetes nephropathy;
CRC	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.67	-8.57	-0.43	4.16e-16	Iron status biomarkers;
CRC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.41	7.64	0.39	2.36e-13	Mean corpuscular volume;
CRC	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.63	-9.18	-0.45	5.04e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4743820	0.620	rs7046632	chr9:93919341	C/T	cg14446406	chr9:93919335	NA	0.81	15.07	0.64	2.19e-39	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-11.09	-0.52	1.74e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg17712092	chr4:129076599	LARP1B	0.66	7.21	0.37	3.93e-12	Inflammatory bowel disease;
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.31	0.33	9.05e-10	Life satisfaction;
CRC	cis	rs7487075	0.808	rs10880961	chr12:46765228	C/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.32	0.33	8.41e-10	Itch intensity from mosquito bite;
CRC	cis	rs7173389	0.530	rs11636535	chr15:73681648	T/C	cg01796676	chr15:73680284	NA	0.53	8.18	0.41	6.23e-15	Resting heart rate;
CRC	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.92	11.17	0.52	9.12e-25	Exhaled nitric oxide output;
CRC	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg27417294	chr10:81904244	PLAC9	-0.37	-5.82	-0.31	1.38e-8	Sarcoidosis;
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.08	-0.36	8.77e-12	Lymphocyte counts;
CRC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.03	16.43	0.67	1.02e-44	Cognitive function;
CRC	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg18678763	chr11:4115507	RRM1	-0.36	-5.82	-0.31	1.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9925964	0.869	rs2288004	chr16:31054040	G/C	cg02466173	chr16:30829666	NA	0.42	5.82	0.31	1.39e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	0.99	10.61	0.5	8.17e-23	Diabetic retinopathy;
CRC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.43	5.86	0.31	1.11e-8	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.76	12.37	0.56	3.97e-29	Selective IgA deficiency;
CRC	cis	rs11212617	0.901	rs4754301	chr11:108048541	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.15	0.32	2.21e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	5.81	0.3	1.5e-8	Electroencephalogram traits;
CRC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg09473613	chr1:24152604	HMGCL	-0.36	-6.16	-0.32	2.18e-9	Immature fraction of reticulocytes;
CRC	cis	rs35883536	0.967	rs4908091	chr1:101138171	G/A	cg14515779	chr1:101123966	NA	-0.39	-7.56	-0.38	4.11e-13	Monocyte count;
CRC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	8.71	0.43	1.53e-16	Colorectal cancer;
CRC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	17.67	0.7	1.31e-49	Platelet count;
CRC	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg20608306	chr11:116969690	SIK3	-0.32	-5.87	-0.31	1.06e-8	Subjective well-being;
CRC	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg03037974	chr15:76606532	NA	-0.52	-7.5	-0.38	5.99e-13	Blood metabolite levels;
CRC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-13.39	-0.59	6.18e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-5.65	-0.3	3.51e-8	Cognitive function;
CRC	cis	rs2677744	0.626	rs12915155	chr15:91490894	G/T	cg23684204	chr15:91497937	RCCD1	0.43	6.51	0.34	2.8e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs6997458	0.742	rs9969643	chr8:86365987	C/T	cg21346043	chr8:86351067	CA3	-0.26	-5.72	-0.3	2.37e-8	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.56	-9.16	-0.45	5.83e-18	Depressive symptoms (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13837552	chr12:112819996	NA	0.39	6.39	0.33	5.63e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02420406	chr7:7606596	MIOS	0.48	6.63	0.34	1.37e-10	Response to antipsychotic treatment;
CRC	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.6	-6.01	-0.31	4.86e-9	Night sleep phenotypes;
CRC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.75	0.3	2.04e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.57	-7.16	-0.37	5.24e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.6	7.97	0.4	2.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg15309053	chr8:964076	NA	0.4	7.37	0.38	1.39e-12	Schizophrenia;
CRC	cis	rs3823572	0.586	rs2001282	chr7:133663287	A/G	cg03336402	chr7:133662267	EXOC4	-0.66	-10.4	-0.5	4.2e-22	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg27661571	chr11:113659931	NA	-0.62	-8.16	-0.41	7.01e-15	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.55	6.46	0.34	3.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg21851534	chr17:3907994	ZZEF1	0.36	6.07	0.32	3.57e-9	Type 2 diabetes;
CRC	cis	rs3825932	0.778	rs11072817	chr15:79236815	G/A	cg25744700	chr15:79237217	CTSH	0.38	5.71	0.3	2.5e-8	Type 1 diabetes;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg12172441	chr6:28176163	NA	0.64	5.99	0.31	5.4e-9	Depression;
CRC	cis	rs294883	0.827	rs294906	chr6:159670303	G/A	cg14500486	chr6:159655392	FNDC1	-0.39	-6.5	-0.34	2.91e-10	Coronary artery disease;
CRC	cis	rs4731207	0.596	rs7782410	chr7:124571104	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.25	-0.33	1.28e-9	Cutaneous malignant melanoma;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg03623178	chr6:28175578	NA	0.7	9.29	0.46	2.21e-18	Parkinson's disease;
CRC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.62	7.98	0.4	2.51e-14	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg21620606	chr4:1342894	KIAA1530	0.34	5.7	0.3	2.7e-8	Obesity-related traits;
CRC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg15845792	chr6:28175446	NA	-0.49	-7.24	-0.37	3.14e-12	Pubertal anthropometrics;
CRC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg06470822	chr6:28175283	NA	0.54	8.11	0.41	1.04e-14	Pubertal anthropometrics;
CRC	cis	rs9549328	0.614	rs35299896	chr13:113617229	G/T	cg25790453	chr13:113633590	MCF2L	0.44	7.65	0.39	2.22e-13	Systolic blood pressure;
CRC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.5	7.15	0.37	5.68e-12	Prostate cancer;
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.49	-0.54	6.26e-26	Alzheimer's disease;
CRC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg19824325	chr16:58548873	SETD6	0.92	6.21	0.32	1.62e-9	Schizophrenia;
CRC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.71	-7.28	-0.37	2.56e-12	Coronary artery disease;
CRC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.7	-0.51	4.12e-23	Monocyte count;
CRC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.4	-7.38	-0.38	1.29e-12	Ulcerative colitis;
CRC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg10298567	chr3:47292165	KIF9	0.38	6.11	0.32	2.74e-9	Colorectal cancer;
CRC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.36	-6.04	-0.32	4.19e-9	Schizophrenia;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg12564285	chr5:131593104	PDLIM4	0.45	7.37	0.38	1.41e-12	Blood metabolite levels;
CRC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.54	9.35	0.46	1.39e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.49	-7.04	-0.36	1.14e-11	Height;
CRC	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-7.01	-0.36	1.38e-11	Coronary artery disease;
CRC	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg14673194	chr17:80132900	CCDC57	0.46	5.79	0.3	1.67e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.67	-8.77	-0.44	9.78e-17	Blood protein levels;
CRC	cis	rs3812762	0.871	rs10734637	chr11:8788225	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.37	6.22	0.32	1.51e-9	Hypospadias;
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg05569086	chr8:143859399	LYNX1	-0.43	-7.08	-0.36	8.53e-12	Urinary tract infection frequency;
CRC	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.6	10.19	0.49	2.21e-21	Dupuytren's disease;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Parkinson's disease;
CRC	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.62	-12.6	-0.57	5.43e-30	Monocyte count;
CRC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.97e-9	Life satisfaction;
CRC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.31	0.46	1.85e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg19257562	chr1:2043853	PRKCZ	0.37	6.32	0.33	8.75e-10	Height;
CRC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.58	7.78	0.39	9.45e-14	Behavioural disinhibition (generation interaction);
CRC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.38	0.5	4.9e-22	Diabetic retinopathy;
CRC	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg08600765	chr20:34638493	LOC647979	-0.62	-7.47	-0.38	7.09e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg25809561	chr17:30822961	MYO1D	0.51	9.16	0.45	5.77e-18	Schizophrenia;
CRC	trans	rs7821565	0.904	rs73573847	chr8:52166881	G/A	cg09187163	chr7:72721838	NSUN5	-0.41	-6.0	-0.31	5.31e-9	Tuberculosis;
CRC	cis	rs1832871	0.521	rs878585	chr6:158815897	C/T	cg07165851	chr6:158734300	TULP4	0.46	5.95	0.31	6.95e-9	Height;
CRC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg01483505	chr11:975446	AP2A2	0.42	6.78	0.35	5.69e-11	Alzheimer's disease (late onset);
CRC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg03037974	chr15:76606532	NA	0.52	7.92	0.4	3.57e-14	Blood metabolite levels;
CRC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.48	6.9	0.36	2.76e-11	Cleft lip with or without cleft palate;
CRC	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg09695851	chr17:3907499	NA	0.78	14.84	0.63	1.69e-38	Type 2 diabetes;
CRC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg26805224	chr10:79626177	DLG5	-0.5	-7.11	-0.37	7.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs938554	0.784	rs13131257	chr4:9981889	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	5.65	0.3	3.4e-8	Blood metabolite levels;
CRC	cis	rs4321325	0.733	rs4510165	chr2:127936284	C/T	cg11380483	chr2:127933992	NA	0.64	7.76	0.39	1.04e-13	Protein C levels;
CRC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.81	13.86	0.61	9.83e-35	Breast cancer;
CRC	cis	rs1347297	0.666	rs2114581	chr2:179269678	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.42	-5.93	-0.31	7.66e-9	Alzheimer disease and age of onset;
CRC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	14.6	0.63	1.38e-37	Gut microbiome composition (summer);
CRC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg10858369	chr11:6476139	TRIM3	-0.38	-6.0	-0.31	5.31e-9	Iris heterochromicity;
CRC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.21	-0.37	3.78e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9837602	0.935	rs17392948	chr3:99754498	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.19	-0.32	1.82e-9	Breast cancer;
CRC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg11279151	chr3:101281821	RG9MTD1	0.57	7.83	0.4	6.55e-14	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04999270	chr1:14076291	PRDM2	0.46	6.31	0.33	9.23e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg02683197	chr6:28174875	NA	-0.84	-10.42	-0.5	3.83e-22	Depression;
CRC	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-7.66	-0.39	2.04e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.5	-7.48	-0.38	6.92e-13	Dementia with Lewy bodies;
CRC	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg13926569	chr10:89418898	PAPSS2	-0.44	-6.49	-0.34	3.15e-10	Magnesium levels;
CRC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.44	5.73	0.3	2.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9847710	0.967	rs2564931	chr3:53020559	G/A	cg04503182	chr3:53078218	SFMBT1	0.42	6.32	0.33	8.32e-10	Ulcerative colitis;
CRC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.55	7.74	0.39	1.24e-13	Inflammatory bowel disease;
CRC	cis	rs9303542	0.625	rs9905940	chr17:46614102	A/C	cg04904318	chr17:46607828	HOXB1	0.45	5.99	0.31	5.42e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.98	-0.52	4.02e-24	Electroencephalogram traits;
CRC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.42	-7.18	-0.37	4.57e-12	Height;
CRC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.31	-0.33	9.16e-10	Aortic root size;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.24	-0.33	1.36e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg25985355	chr7:65971099	NA	-0.49	-5.85	-0.31	1.19e-8	Diabetic kidney disease;
CRC	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.44	-0.33	4.13e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.88	-0.51	9.29e-24	Pancreatic cancer;
CRC	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.76	-8.02	-0.4	1.83e-14	Recalcitrant atopic dermatitis;
CRC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg11993925	chr19:44307056	LYPD5	-0.38	-6.18	-0.32	1.9e-9	Breast cancer;
CRC	cis	rs672059	1.000	rs559476	chr1:183160704	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.28	0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg03938978	chr2:103052716	IL18RAP	-0.36	-5.79	-0.3	1.66e-8	Asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02285715	chr20:61493179	TCFL5	0.43	6.03	0.32	4.29e-9	Anxiety disorder;
CRC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.47	6.82	0.35	4.42e-11	Methadone dose in opioid dependence;
CRC	cis	rs4731207	0.596	rs10274384	chr7:124650437	T/A	cg23710748	chr7:124431027	NA	-0.39	-6.24	-0.33	1.36e-9	Cutaneous malignant melanoma;
CRC	cis	rs4731207	0.698	rs10245872	chr7:124535253	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-6.02	-0.32	4.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.43	0.42	1.08e-15	Height;
CRC	cis	rs812925	0.515	rs1177308	chr2:61387254	C/G	cg10580144	chr2:61372316	C2orf74	0.36	8.04	0.41	1.61e-14	Immature fraction of reticulocytes;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.38	6.49	0.34	3.19e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg00106254	chr7:1943704	MAD1L1	0.41	6.28	0.33	1.08e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.43	6.09	0.32	3.14e-9	Alzheimer's disease (late onset);
CRC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.43	-0.33	4.61e-10	Coronary artery disease;
CRC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05585630	chr7:157510462	PTPRN2	-0.41	-6.53	-0.34	2.49e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17164693	chr10:124913828	BUB3	0.42	6.01	0.31	4.92e-9	Response to antipsychotic treatment;
CRC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.8	-13.38	-0.59	6.77e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13126279	chr21:47581558	C21orf56	-0.38	-5.88	-0.31	9.83e-9	Testicular germ cell tumor;
CRC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg15440763	chr7:158190612	PTPRN2	-0.39	-6.37	-0.33	6.52e-10	Obesity-related traits;
CRC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	9.13	0.45	7.25e-18	Systolic blood pressure;
CRC	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg25019722	chr6:37503610	NA	0.39	6.43	0.33	4.62e-10	Cognitive performance;
CRC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.15	0.32	2.22e-9	Renal function-related traits (BUN);
CRC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.44	-9.71	-0.47	9.39e-20	Glomerular filtration rate (creatinine);
CRC	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21587861	chr12:32260103	BICD1	-0.57	-6.01	-0.31	4.94e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg02683197	chr6:28174875	NA	-0.64	-6.82	-0.35	4.46e-11	Parkinson's disease;
CRC	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg15660573	chr17:549704	VPS53	-0.87	-15.84	-0.66	2.22e-42	Prostate cancer;
CRC	trans	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.3	0.37	2.11e-12	Endometrial cancer;
CRC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg19041857	chr6:27730383	NA	-0.71	-6.71	-0.35	8.65e-11	Depression;
CRC	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg24375607	chr4:120327624	NA	0.46	7.05	0.36	1.03e-11	Educational attainment;
CRC	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.54	6.82	0.35	4.27e-11	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06406294	chr21:34915161	GART;SON	0.41	6.68	0.35	1.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.78	15.87	0.66	1.66e-42	Leprosy;
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg24747557	chr10:131355152	MGMT	-0.41	-5.85	-0.31	1.16e-8	Response to temozolomide;
CRC	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-7.88	-0.4	4.78e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18912574	chr7:65842487	NCRNA00174	0.35	6.08	0.32	3.34e-9	Aortic root size;
CRC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.35	-7.33	-0.37	1.79e-12	Schizophrenia;
CRC	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.82	14.5	0.62	3.4e-37	Hip circumference;
CRC	cis	rs4478858	0.735	rs10914368	chr1:31847937	A/G	cg00250761	chr1:31883323	NA	-0.41	-7.64	-0.39	2.33e-13	Alcohol dependence;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	1.11	9.82	0.48	4.02e-20	Mitochondrial DNA levels;
CRC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.41	7.91	0.4	3.93e-14	Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08541772	chr1:209958162	C1orf74	0.43	5.97	0.31	6.13e-9	Response to antipsychotic treatment;
CRC	cis	rs12692738	0.526	rs355860	chr2:165629911	T/G	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.57	10.13	0.49	3.61e-21	Age of smoking initiation;
CRC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.14	-0.41	8.11e-15	Type 2 diabetes;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg03790207	chr6:42947109	PEX6	-0.52	-7.56	-0.38	4e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.68	0.3	2.95e-8	Diabetic retinopathy;
CRC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.75	10.75	0.51	2.64e-23	High light scatter reticulocyte count;
CRC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.83	-11.3	-0.53	3.14e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg09344028	chr17:70110421	NA	0.45	6.85	0.35	3.58e-11	Thyroid hormone levels;
CRC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.85	-0.44	5.49e-17	Platelet count;
CRC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.4	-0.53	1.31e-25	Ulcerative colitis;
CRC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.49	7.03	0.36	1.18e-11	Bone mineral density (spine);
CRC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg03934865	chr2:198174659	NA	-0.44	-7.9	-0.4	4.24e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.09	0.32	3.17e-9	Depression;
CRC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg10494257	chr1:16342123	HSPB7	0.45	5.91	0.31	8.55e-9	Dilated cardiomyopathy;
CRC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.55	8.72	0.43	1.43e-16	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.08	10.13	0.49	3.66e-21	Diabetic retinopathy;
CRC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	13.21	0.59	2.91e-32	Chronic sinus infection;
CRC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg17724175	chr1:150552817	MCL1	-0.51	-8.17	-0.41	6.89e-15	Tonsillectomy;
CRC	cis	rs3849570	0.576	rs4425286	chr3:81992365	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-6.41	-0.33	5.15e-10	Waist circumference;Body mass index;
CRC	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg20542592	chr8:11973495	FAM66D	0.32	5.69	0.3	2.76e-8	Retinal vascular caliber;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.84	14.87	0.63	1.26e-38	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.68	9.75	0.47	6.81e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.46	-6.49	-0.34	3.08e-10	Breast cancer;
CRC	cis	rs6662572	0.686	rs72677546	chr1:46577716	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.4	0.33	5.26e-10	Blood protein levels;
CRC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg11843238	chr5:131593191	PDLIM4	-0.32	-5.92	-0.31	8.13e-9	Blood metabolite levels;
CRC	cis	rs6743376	0.556	rs957201	chr2:113821200	T/C	cg09040174	chr2:113837401	NA	0.4	5.85	0.31	1.18e-8	Inflammatory biomarkers;
CRC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-7.25	-0.37	3.05e-12	Neuroticism;
CRC	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-6.91	-0.36	2.45e-11	Eye color traits;
CRC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.22e-10	Lung cancer;
CRC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.63	8.79	0.44	8.21e-17	Arsenic metabolism;
CRC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.3	-0.46	1.98e-18	Intelligence (multi-trait analysis);
CRC	cis	rs3736485	0.808	rs4462537	chr15:51826518	A/G	cg08986416	chr15:51914746	DMXL2	-0.49	-7.06	-0.36	9.93e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.49	-9.3	-0.46	1.98e-18	Reticulocyte fraction of red cells;
CRC	cis	rs7605827	0.930	rs11687253	chr2:15655869	A/G	cg19274914	chr2:15703543	NA	-0.38	-5.81	-0.3	1.51e-8	Educational attainment (years of education);
CRC	trans	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg10756647	chr7:56101905	PSPH	0.62	6.56	0.34	2.04e-10	Diabetic kidney disease;
CRC	trans	rs9540294	1.000	rs2175688	chr13:65541333	A/C	cg18771126	chr3:119150634	TMEM39A	0.56	6.12	0.32	2.69e-9	Recalcitrant atopic dermatitis;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.77	14.58	0.63	1.65e-37	Prudent dietary pattern;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg22561889	chr6:118971681	C6orf204	0.5	6.52	0.34	2.71e-10	Diastolic blood pressure;
CRC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.75	12.98	0.58	2.25e-31	Breast cancer;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg22766770	chr17:18218566	TOP3A;SMCR8	-0.59	-6.14	-0.32	2.35e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.57	8.28	0.42	3.18e-15	Uric acid levels;
CRC	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg17145862	chr1:211918768	LPGAT1	0.59	10.07	0.49	5.64e-21	Leprosy;
CRC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.61	-8.65	-0.43	2.36e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg02659138	chr7:134003124	SLC35B4	0.36	5.74	0.3	2.16e-8	Mean platelet volume;
CRC	cis	rs4713675	0.584	rs560111	chr6:33706277	C/T	cg14003231	chr6:33640908	ITPR3	0.36	5.86	0.31	1.11e-8	Plateletcrit;
CRC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.3	5.69	0.3	2.8e-8	Mean corpuscular volume;
CRC	cis	rs7131987	0.676	rs10843407	chr12:29550244	A/G	cg09582351	chr12:29534625	ERGIC2	0.34	7.26	0.37	2.83e-12	QT interval;
CRC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg06386533	chr2:46925753	SOCS5	0.48	6.45	0.33	4.05e-10	Height;
CRC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.75	0.35	6.84e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg27532560	chr4:187881888	NA	0.55	10.22	0.49	1.75e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9311676	0.656	rs62258093	chr3:58371745	T/C	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg08444004	chr2:240086178	HDAC4	0.36	5.96	0.31	6.57e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg15845792	chr6:28175446	NA	0.97	13.03	0.58	1.43e-31	Depression;
CRC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.91	17.35	0.69	2.44e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg04562611	chr16:615315	C16orf11	0.38	6.33	0.33	7.96e-10	Height;
CRC	cis	rs11958404	1.000	rs72816531	chr5:157413079	A/G	cg05962755	chr5:157440814	NA	0.78	10.75	0.51	2.66e-23	IgG glycosylation;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg20512303	chr5:131592959	PDLIM4	0.39	6.69	0.35	9.86e-11	Blood metabolite levels;
CRC	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg08600765	chr20:34638493	LOC647979	-0.64	-7.73	-0.39	1.36e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.91	0.52	7.25e-24	Prudent dietary pattern;
CRC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg08347473	chr17:78092826	GAA	-0.37	-6.13	-0.32	2.53e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs7595037	0.663	rs11126185	chr2:68652580	G/A	cg12452813	chr2:68675892	NA	-0.44	-6.48	-0.34	3.39e-10	Multiple sclerosis;
CRC	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.53	-0.54	4.75e-26	Psoriasis vulgaris;
CRC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.56	-8.68	-0.43	1.93e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.37	-5.99	-0.31	5.48e-9	Total body bone mineral density;
CRC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16447950	chr5:562315	NA	-0.74	-9.74	-0.47	7.34e-20	Obesity-related traits;
CRC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg25456477	chr12:86230367	RASSF9	0.34	5.75	0.3	2.02e-8	Major depressive disorder;
CRC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.62	-0.3	4.03e-8	Mean corpuscular volume;
CRC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	11.6	0.54	2.58e-26	High light scatter reticulocyte count;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg04558362	chr11:64863611	C11orf2	-0.45	-6.13	-0.32	2.53e-9	Protein C levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19650755	chr12:68617143	IL26	0.41	6.45	0.34	4.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4731207	0.596	rs900047	chr7:124673373	A/G	cg23710748	chr7:124431027	NA	0.38	5.98	0.31	5.71e-9	Cutaneous malignant melanoma;
CRC	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.63	-12.4	-0.56	3.06e-29	Menarche (age at onset);
CRC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.59	0.6	1.05e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21005948	chr18:46065258	KIAA0427	0.4	6.41	0.33	5.06e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6662572	0.737	rs6693222	chr1:46461178	A/G	cg08644498	chr1:46502608	NA	0.46	7.3	0.37	2.19e-12	Blood protein levels;
CRC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs473651	0.935	rs508483	chr2:239339709	T/C	cg13521940	chr21:36262239	RUNX1	-0.41	-6.2	-0.32	1.71e-9	Multiple system atrophy;
CRC	cis	rs883565	0.528	rs4504116	chr3:38953768	A/G	cg01426195	chr3:39028469	NA	0.38	6.37	0.33	6.41e-10	Handedness;
CRC	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.51	-6.11	-0.32	2.82e-9	Bipolar disorder;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-12.19	-0.56	1.9e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.5	5.8	0.3	1.58e-8	Vitiligo;
CRC	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.47	-6.48	-0.34	3.4e-10	Eye color traits;
CRC	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.55	-9.06	-0.45	1.15e-17	Congenital heart disease (maternal effect);
CRC	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	8.94	0.44	2.89e-17	Menarche (age at onset);
CRC	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	6.1	0.32	3.01e-9	Asthma;
CRC	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	1.02	9.31	0.46	1.83e-18	Lymphocyte counts;
CRC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.78	11.71	0.54	1.02e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg21153622	chr11:89784906	NA	0.46	7.39	0.38	1.25e-12	HDL cholesterol;
CRC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.64	8.62	0.43	2.84e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs8010715	0.816	rs6573565	chr14:24594733	A/G	cg23112188	chr14:24563095	PCK2	0.35	7.04	0.36	1.14e-11	IgG glycosylation;
CRC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg03395651	chr16:88107091	BANP	0.59	8.01	0.4	1.97e-14	Menopause (age at onset);
CRC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg20243544	chr17:37824526	PNMT	0.45	6.82	0.35	4.48e-11	Self-reported allergy;
CRC	trans	rs587242	1.000	rs61786491	chr1:96904651	G/C	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg04117972	chr1:227635322	NA	-0.51	-5.83	-0.31	1.32e-8	Major depressive disorder;
CRC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.69	8.21	0.41	5.02e-15	Bipolar disorder;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg13385794	chr1:248469461	NA	0.37	6.4	0.33	5.27e-10	Common traits (Other);
CRC	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.59	0.34	1.71e-10	Systolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01078248	chr7:123197661	NDUFA5	0.47	5.98	0.31	5.94e-9	Thyroid stimulating hormone;
CRC	cis	rs995000	0.965	rs7520810	chr1:63095711	C/T	cg19896129	chr1:63156450	NA	0.42	6.44	0.33	4.16e-10	Triglyceride levels;
CRC	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.39	5.75	0.3	2e-8	Growth-regulated protein alpha levels;
CRC	cis	rs800160	0.777	rs962903	chr11:2352341	A/G	cg09785033	chr11:2336066	TSPAN32	-0.54	-5.82	-0.31	1.38e-8	Bacteremia;
CRC	trans	rs16957091	0.528	rs12908349	chr15:43086227	C/T	cg15973384	chr6:168817498	NA	0.53	6.15	0.32	2.27e-9	MGMT methylation in smokers;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.43	6.0	0.31	5.28e-9	Blood metabolite levels;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg12172441	chr6:28176163	NA	0.49	6.29	0.33	9.97e-10	Parkinson's disease;
CRC	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12463550	chr7:65579703	CRCP	-0.68	-6.04	-0.32	4.07e-9	Diabetic kidney disease;
CRC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg11168104	chr5:1857477	NA	-0.38	-6.67	-0.34	1.11e-10	Cardiovascular disease risk factors;
CRC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.55	8.13	0.41	8.91e-15	Response to temozolomide;
CRC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-11.33	-0.53	2.45e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg09417038	chr21:47716443	C21orf57	-0.41	-6.8	-0.35	4.94e-11	Testicular germ cell tumor;
CRC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.9	-15.72	-0.65	6.15e-42	Body mass index;
CRC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg14541582	chr5:601475	NA	-0.36	-7.25	-0.37	2.91e-12	Obesity-related traits;
CRC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.49	6.33	0.33	7.83e-10	Obesity-related traits;
CRC	cis	rs12024301	0.557	rs116821993	chr1:183641049	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.82	6.81	0.35	4.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02176678	chr2:219576539	TTLL4	0.48	7.48	0.38	6.73e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-9.71	-0.47	9.03e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.64	10.38	0.5	5.13e-22	Height;
CRC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg15147215	chr3:52552868	STAB1	-0.42	-5.84	-0.31	1.28e-8	Schizophrenia;
CRC	cis	rs17767392	0.871	rs2108706	chr14:71799175	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.5	-0.34	3.06e-10	Mitral valve prolapse;
CRC	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.68	9.1	0.45	8.9e-18	Platelet count;
CRC	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	0.89	10.69	0.51	4.31e-23	Nonalcoholic fatty liver disease;
CRC	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.53	-9.51	-0.46	4.11e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.41	-6.17	-0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.72	9.73	0.47	8.11e-20	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg15744005	chr10:104629667	AS3MT	-0.35	-6.33	-0.33	8.02e-10	Arsenic metabolism;
CRC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-10.68	-0.51	4.75e-23	Personality dimensions;
CRC	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.82	15.9	0.66	1.22e-42	Hip circumference;
CRC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.74	10.05	0.48	6.51e-21	Platelet count;
CRC	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.39	6.56	0.34	2.04e-10	Sitting height ratio;
CRC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.56	-7.29	-0.37	2.3e-12	Body mass index;
CRC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.48	-0.38	7.02e-13	Hemoglobin concentration;
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg24463073	chr6:118973353	C6orf204	0.52	6.91	0.36	2.52e-11	Diastolic blood pressure;
CRC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	8.33	0.42	2.18e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.58	-8.85	-0.44	5.42e-17	Uric acid levels;
CRC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.53	7.56	0.38	4.11e-13	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07630649	chr16:75600717	GABARAPL2	0.44	6.16	0.32	2.13e-9	Anxiety disorder;
CRC	trans	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg18335740	chr13:41363409	SLC25A15	0.54	8.26	0.41	3.51e-15	Lewy body disease;
CRC	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg14515779	chr1:101123966	NA	-0.35	-6.18	-0.32	1.9e-9	Monocyte count;
CRC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.39	0.38	1.19e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.11	-21.23	-0.76	1.26e-63	Dilated cardiomyopathy;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.58	-0.5	1.08e-22	Alzheimer's disease;
CRC	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg14092571	chr14:90743983	NA	0.38	5.85	0.31	1.17e-8	Mortality in heart failure;
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg13047869	chr3:10149882	C3orf24	0.55	6.66	0.34	1.17e-10	Alzheimer's disease;
CRC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg17724175	chr1:150552817	MCL1	0.48	7.08	0.36	8.66e-12	Melanoma;
CRC	trans	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg18335740	chr13:41363409	SLC25A15	0.48	7.16	0.37	5.27e-12	Lewy body disease;
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg27432699	chr2:27873401	GPN1	-0.48	-7.24	-0.37	3.27e-12	Total body bone mineral density;
CRC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.34	-5.63	-0.3	3.8e-8	Cognitive function;
CRC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.78	-0.66	3.79e-42	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.74	-11.77	-0.54	6.3e-27	Cognitive function;
CRC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.55	-7.67	-0.39	2.02e-13	Lymphocyte percentage of white cells;
CRC	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.53	7.94	0.4	3.33e-14	Coronary artery disease;
CRC	trans	rs7690467	0.794	rs35848947	chr4:133393124	C/A	cg19296258	chr17:78878799	RPTOR	-0.48	-6.49	-0.34	3.24e-10	Eating disorders;
CRC	cis	rs11212617	0.902	rs599406	chr11:108118234	T/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.26	0.33	1.23e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.05e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.67	-10.58	-0.5	1.05e-22	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs6840360	0.642	rs4696089	chr4:152395733	A/G	cg09659197	chr4:152720779	NA	0.34	6.64	0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6694672	0.867	rs568757	chr1:197218051	G/A	cg13682187	chr1:196946512	CFHR5	0.49	7.01	0.36	1.39e-11	Asthma;
CRC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.43	6.56	0.34	2.06e-10	Systemic lupus erythematosus;
CRC	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-8.71	-0.43	1.52e-16	Ulcerative colitis;
CRC	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg25547332	chr5:131281432	NA	0.38	5.64	0.3	3.67e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24124398	chr17:40075096	ACLY	0.5	7.36	0.38	1.48e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.23	-0.32	1.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6662572	0.737	rs6702764	chr1:46252717	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-6.05	-0.32	4.02e-9	Blood protein levels;
CRC	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg10761708	chr20:43804764	PI3	0.48	5.64	0.3	3.58e-8	Blood protein levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09041756	chr7:5570314	ACTB	-0.43	-6.51	-0.34	2.79e-10	Myopia (pathological);
CRC	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.62	-0.3	4.15e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.52	6.18	0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17942371	chr19:796826	PTBP1	0.4	6.03	0.32	4.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.69	-0.6	4.51e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg00738113	chr16:70207722	CLEC18C	-0.4	-5.78	-0.3	1.72e-8	IgE levels;
CRC	cis	rs28655083	0.529	rs285023	chr16:77099783	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.81	0.35	4.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.44	-6.48	-0.34	3.33e-10	Ulcerative colitis;
CRC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg25811766	chr13:21894605	NA	-0.56	-6.01	-0.31	4.93e-9	White matter hyperintensity burden;
CRC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg21251018	chr6:28226885	NKAPL	0.47	7.09	0.36	8.23e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19644449	chr12:46385886	SFRS2IP	0.43	6.22	0.32	1.47e-9	Intelligence (multi-trait analysis);
CRC	trans	rs349114	0.501	rs9554396	chr13:98115192	G/C	cg04366385	chr4:78980382	FRAS1	-0.46	-6.03	-0.32	4.43e-9	Obesity-related traits;
CRC	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.89	11.13	0.52	1.21e-24	Prostate cancer;
CRC	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.07	-16.55	-0.67	3.48e-45	Colorectal cancer;
CRC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-0.82	-9.05	-0.45	1.27e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.79	8.65	0.43	2.34e-16	Skin colour saturation;
CRC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.66	-9.5	-0.46	4.65e-19	Subjective well-being;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.09	-0.52	1.77e-24	Bipolar disorder and schizophrenia;
CRC	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00938859	chr5:1591904	SDHAP3	0.69	6.09	0.32	3.22e-9	Breast cancer;
CRC	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.8	-0.58	1.0500000000000001e-30	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00166722	chr3:10149974	C3orf24	0.66	7.67	0.39	1.96e-13	Alzheimer's disease;
CRC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg18230493	chr5:56204884	C5orf35	-0.39	-5.92	-0.31	7.95e-9	Coronary artery disease;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4576506	0.536	rs13302490	chr9:31501013	C/T	cg26940518	chr16:1593766	IFT140;TMEM204	-0.65	-5.97	-0.31	6.1e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00791764	chr4:53727839	RASL11B	0.47	6.16	0.32	2.15e-9	Optic nerve measurement (cup area);
CRC	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.03	-0.32	4.3e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg13206674	chr6:150067644	NUP43	0.66	9.7	0.47	1.02e-19	Lung cancer;
CRC	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg04362960	chr10:104952993	NT5C2	0.52	6.25	0.33	1.3e-9	Waist circumference;Hip circumference;
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.6	9.84	0.48	3.35e-20	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03157738	chr19:11308118	KANK2	0.46	6.41	0.33	5.04e-10	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.99	12.49	0.57	1.47e-29	Vitiligo;
CRC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg15147215	chr3:52552868	STAB1	-0.57	-9.06	-0.45	1.17e-17	Bipolar disorder;
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg04155289	chr7:94953770	PON1	-0.59	-7.48	-0.38	6.83e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs860295	0.702	rs11264381	chr1:155522572	C/T	cg02153340	chr1:155202674	NA	0.55	6.57	0.34	1.93e-10	Body mass index;
CRC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.45	0.42	9.23e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1223397	0.651	rs2458311	chr6:13310012	T/C	cg07912922	chr6:13274314	PHACTR1	0.39	6.07	0.32	3.52e-9	Blood pressure;
CRC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.62	-9.7	-0.47	9.85e-20	Height;
CRC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.84	-0.35	3.81e-11	Cutaneous nevi;
CRC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.94e-10	Lung cancer;
CRC	cis	rs4363385	0.747	rs1577962	chr1:152962013	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.32	-0.37	1.93e-12	Inflammatory skin disease;
CRC	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg12315302	chr6:26189340	HIST1H4D	0.72	5.76	0.3	1.96e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.29	7.71	0.39	1.5e-13	Blood metabolite levels;
CRC	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.7	0.35	9.03e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg06766960	chr11:133703094	NA	-0.32	-5.75	-0.3	2.05e-8	Childhood ear infection;
CRC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.49	8.1	0.41	1.07e-14	Crohn's disease;
CRC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg17321639	chr7:2759063	NA	0.5	6.46	0.34	3.86e-10	Height;
CRC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.61	-10.34	-0.5	7.09e-22	Colorectal cancer;
CRC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg03609598	chr5:56110824	MAP3K1	-0.45	-5.9	-0.31	9.09e-9	Coronary artery disease;
CRC	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-0.89	-9.63	-0.47	1.67e-19	Post bronchodilator FEV1;
CRC	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg12072164	chr19:44306565	LYPD5	-0.41	-6.4	-0.33	5.49e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.59	-0.39	3.28e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg25767906	chr1:53392781	SCP2	0.37	5.83	0.31	1.3e-8	Monocyte count;
CRC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.45	6.78	0.35	5.51e-11	N-glycan levels;
CRC	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg08034379	chr2:228736324	WDR69	0.48	6.35	0.33	7.05e-10	Blood pressure;
CRC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg07930552	chr6:133119739	C6orf192	0.74	6.09	0.32	3.13e-9	Type 2 diabetes nephropathy;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22625903	chr11:62313283	AHNAK	-0.51	-6.1	-0.32	2.96e-9	Diisocyanate-induced asthma;
CRC	cis	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg15845792	chr6:28175446	NA	0.65	6.49	0.34	3.17e-10	Depression;
CRC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.42	5.77	0.3	1.81e-8	Bronchopulmonary dysplasia;
CRC	trans	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg21302420	chr1:112162376	RAP1A	0.81	7.43	0.38	9.4e-13	Skin colour saturation;
CRC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-5.94	-0.31	7.29e-9	Schizophrenia;
CRC	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.59	0.63	1.55e-37	Hypertriglyceridemia;
CRC	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg23254163	chr1:152506842	NA	0.5	10.23	0.49	1.62e-21	Plantar warts;
CRC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.64	9.11	0.45	8.07e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg06767701	chr1:152008878	S100A11	0.61	6.38	0.33	6.04e-10	Body mass index;
CRC	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.08	-0.32	3.34e-9	Total body bone mineral density;
CRC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	14.53	0.63	2.62e-37	Multiple sclerosis;
CRC	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.44	-0.38	9.1e-13	Schizophrenia;
CRC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.56	-9.87	-0.48	2.78e-20	Huntington's disease progression;
CRC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.39	-7.27	-0.37	2.56e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg25164649	chr6:28176230	NA	0.59	8.33	0.42	2.22e-15	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2708977	0.666	rs17685664	chr2:97315570	C/T	cg01950434	chr2:97203154	ARID5A	0.48	6.74	0.35	7.1e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.46	0.38	7.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs400736	0.930	rs225119	chr1:8044361	T/C	cg25007680	chr1:8021821	PARK7	0.55	7.71	0.39	1.48e-13	Response to antidepressants and depression;
CRC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-5.67	-0.3	3.06e-8	Heart rate;
CRC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.66	-12.15	-0.56	2.54e-28	Aortic root size;
CRC	cis	rs741668	0.897	rs17429573	chr13:46570058	T/C	cg06018095	chr13:46550134	ZC3H13	0.41	5.73	0.3	2.21e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.43	-0.33	4.61e-10	Dupuytren's disease;
CRC	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg10820045	chr2:198174542	NA	0.39	6.33	0.33	7.85e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.51	7.54	0.38	4.63e-13	Night sleep phenotypes;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg10499166	chr1:23345815	KDM1A	-0.44	-6.51	-0.34	2.87e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4728302	0.869	rs13233690	chr7:133587328	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.8	0.3	1.54e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs3087591	0.683	rs7502556	chr17:29642430	T/C	cg24425628	chr17:29625626	OMG;NF1	0.73	13.11	0.59	6.95e-32	Hip circumference;
CRC	cis	rs9323205	0.798	rs2999391	chr14:51655109	A/G	cg23942311	chr14:51606299	NA	0.61	9.08	0.45	1.01e-17	Cancer;
CRC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.71	11.29	0.53	3.36e-25	Colorectal cancer;
CRC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.45	0.38	8.08e-13	Hip circumference adjusted for BMI;
CRC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg12573674	chr2:1569213	NA	-0.74	-7.7	-0.39	1.59e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs17234274	0.549	rs4922645	chr11:23233722	G/A	cg05245346	chr11:23248277	NA	0.35	5.66	0.3	3.29e-8	Cancer;
CRC	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.6	8.69	0.43	1.75e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.56	9.26	0.45	2.75e-18	Eye color traits;
CRC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.16	14.93	0.64	7.8e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.84	-0.48	3.52e-20	P wave terminal force;
CRC	cis	rs3026101	0.723	rs1806248	chr17:5310411	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg05754148	chr16:3507555	NAT15	0.61	5.7	0.3	2.65e-8	Tuberculosis;
CRC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.31	-7.31	-0.37	2e-12	Lymphocyte counts;
CRC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.46	-7.02	-0.36	1.32e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs16852403	0.548	rs387917	chr1:178117542	G/A	cg00404053	chr1:178313656	RASAL2	-0.49	-6.43	-0.33	4.48e-10	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06247283	chr18:29302528	NA	0.44	6.38	0.33	5.86e-10	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.52	0.34	2.6200000000000003e-10	Parkinson's disease;
CRC	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg14593290	chr7:50529359	DDC	-0.47	-6.61	-0.34	1.56e-10	Systemic sclerosis;
CRC	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.85	-10.19	-0.49	2.32e-21	Blood protein levels;
CRC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg21854759	chr1:92012499	NA	-0.54	-8.81	-0.44	7.17e-17	Breast cancer;
CRC	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.77	0.35	6.06e-11	Mean corpuscular volume;
CRC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.46	5.8	0.3	1.52e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.47	-7.2	-0.37	4e-12	Breast cancer;
CRC	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg20307385	chr11:47447363	PSMC3	0.49	6.02	0.31	4.78e-9	Migraine - clinic-based;
CRC	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.55	8.31	0.42	2.54e-15	Ulcerative colitis;
CRC	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg04586622	chr2:25135609	ADCY3	-0.54	-9.97	-0.48	1.25e-20	Body mass index;
CRC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg02527881	chr3:46936655	PTH1R	-0.43	-7.79	-0.39	8.88e-14	Colorectal cancer;
CRC	cis	rs10512697	0.655	rs35099902	chr5:3473373	T/C	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.6	-8.3	-0.42	2.65e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.58	-8.81	-0.44	7.37e-17	Body mass index;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.14	0.32	2.31e-9	Bipolar disorder;
CRC	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.68	5.6	0.3	4.45e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs847649	1.000	rs11514917	chr7:102609221	A/C	cg18108683	chr7:102477205	FBXL13	-0.56	-9.19	-0.45	4.6e-18	Morning vs. evening chronotype;
CRC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg10130564	chr11:117069849	TAGLN	0.37	6.84	0.35	3.76e-11	Blood protein levels;
CRC	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.63	-10.52	-0.5	1.68e-22	Itch intensity from mosquito bite;
CRC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.31	-0.33	9.02e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2252521	0.583	rs317732	chr7:29089183	A/G	cg11728747	chr7:29037910	CPVL	-0.48	-6.75	-0.35	6.72e-11	Cognitive performance;
CRC	cis	rs972578	1.000	rs5759071	chr22:43375950	C/T	cg01576275	chr22:43409880	NA	-0.47	-7.45	-0.38	8.05e-13	Mean platelet volume;
CRC	cis	rs4700695	0.925	rs12518262	chr5:65414004	A/G	cg21114390	chr5:65439923	SFRS12	-0.59	-6.94	-0.36	2.09e-11	Facial morphology (factor 19);
CRC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.65	6.72	0.35	8.24e-11	Axial length;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17677112	chr7:77428730	PHTF2;TMEM60	0.46	6.55	0.34	2.17e-10	Response to antipsychotic treatment;
CRC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.48	-9.61	-0.47	1.97e-19	Subjective well-being;
CRC	cis	rs4766646	0.619	rs4766637	chr12:110292155	A/C	cg01252219	chr12:110302105	GLTP	0.4	6.17	0.32	2.06e-9	Metabolite levels (MHPG);
CRC	cis	rs3764400	0.567	rs2109983	chr17:46207148	A/G	cg10706073	chr17:46328419	SKAP1	0.58	6.26	0.33	1.22e-9	Body mass index;
CRC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.62	8.7	0.43	1.66e-16	Arsenic metabolism;
CRC	cis	rs863345	0.604	rs11265003	chr1:158490631	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs9287719	0.649	rs12621977	chr2:10721931	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs9494145	0.648	rs7758845	chr6:135428537	A/C	cg22676075	chr6:135203613	NA	0.49	6.43	0.33	4.36e-10	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.54	8.57	0.43	3.97e-16	Testicular germ cell tumor;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.73	0.3	2.27e-8	Prudent dietary pattern;
CRC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.47	6.7	0.35	9.25e-11	Lung cancer;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.62	-0.54	2.25e-26	Alzheimer's disease;
CRC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.4	6.12	0.32	2.6e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.76	-12.96	-0.58	2.5e-31	Body mass index;
CRC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.19	0.41	5.89e-15	Bladder cancer;
CRC	cis	rs7605827	0.930	rs7574879	chr2:15698083	C/G	cg19274914	chr2:15703543	NA	0.37	5.65	0.3	3.57e-8	Educational attainment (years of education);
CRC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15704304	chr12:68881427	NA	-0.4	-6.57	-0.34	2.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.67	-0.43	1.93e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg16964102	chr10:135390573	NA	0.52	7.05	0.36	1.04e-11	Gout;
CRC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg27534772	chr1:16042836	PLEKHM2	-0.55	-10.71	-0.51	3.71e-23	Systolic blood pressure;
CRC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.43	7.0	0.36	1.48e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg25164649	chr6:28176230	NA	0.52	7.43	0.38	9.73e-13	Parkinson's disease;
CRC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg02776659	chr21:47717406	C21orf57	-0.36	-5.95	-0.31	7e-9	Testicular germ cell tumor;
CRC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19623624	chr10:135278901	LOC619207	-0.35	-5.83	-0.31	1.33e-8	Systemic lupus erythematosus;
CRC	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.57	-6.13	-0.32	2.49e-9	Coronary artery disease;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg15147215	chr3:52552868	STAB1	-0.61	-9.99	-0.48	1.06e-20	Bipolar disorder;
CRC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg09355771	chr2:177043147	NA	-0.51	-6.49	-0.34	3.14e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.4	6.16	0.32	2.14e-9	Cognitive ability (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19202786	chr6:166797286	BRP44L	0.45	6.25	0.33	1.28e-9	Response to antipsychotic treatment;
CRC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.59	-6.14	-0.32	2.33e-9	White matter hyperintensity burden;
CRC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.63	9.38	0.46	1.09e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs59104589	0.583	rs57576464	chr2:242240697	C/T	cg19488206	chr2:242435732	STK25	0.48	6.72	0.35	7.88e-11	Fibrinogen levels;
CRC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.47	-7.34	-0.37	1.74e-12	LDL cholesterol;Cholesterol, total;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg25336731	chr2:70520884	SNRPG	-0.42	-6.18	-0.32	1.88e-9	Protein C levels;
CRC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.09	13.48	0.6	2.82e-33	Vitiligo;
CRC	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.32	-0.33	8.72e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.67	-9.94	-0.48	1.62e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg03623178	chr6:28175578	NA	-0.86	-12.65	-0.57	3.81e-30	Parkinson's disease;
CRC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg21466736	chr12:48725269	NA	-0.52	-7.69	-0.39	1.78e-13	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.5	-6.6	-0.34	1.67e-10	Glioblastoma;
CRC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg07513332	chr6:167530253	CCR6	0.44	8.3	0.42	2.73e-15	Primary biliary cholangitis;
CRC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.59	10.38	0.5	4.93e-22	Schizophrenia;
CRC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.43	-7.96	-0.4	2.86e-14	Vitiligo;
CRC	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.74	9.8	0.48	4.62e-20	Prostate cancer;
CRC	trans	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg06791473	chr12:49259579	RND1	0.62	6.04	0.32	4.13e-9	Blood protein levels;
CRC	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	6.78	0.35	5.43e-11	Homocysteine levels;
CRC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.72	11.42	0.53	1.1e-25	Colorectal cancer;
CRC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04731861	chr2:219085781	ARPC2	0.37	7.99	0.4	2.37e-14	Colorectal cancer;
CRC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	6.22	0.32	1.51e-9	Mean platelet volume;
CRC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.52	6.53	0.34	2.52e-10	Morning vs. evening chronotype;
CRC	cis	rs17023223	0.537	rs6662165	chr1:119614071	T/G	cg05756136	chr1:119680316	WARS2	-0.54	-7.24	-0.37	3.25e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-8.96	-0.44	2.47e-17	Bipolar disorder;
CRC	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05658717	chr12:118407033	KSR2	0.39	6.32	0.33	8.68e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06544989	chr22:39130855	UNC84B	-0.42	-6.57	-0.34	2.02e-10	Menopause (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14824382	chr8:144680115	EEF1D;TIGD5	-0.43	-6.9	-0.36	2.76e-11	Myopia (pathological);
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.58	0.54	3.07e-26	Hip circumference adjusted for BMI;
CRC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg26769984	chr7:1090371	C7orf50	0.51	7.29	0.37	2.32e-12	Bronchopulmonary dysplasia;
CRC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg20203395	chr5:56204925	C5orf35	-0.73	-8.59	-0.43	3.57e-16	Initial pursuit acceleration;
CRC	cis	rs11209185	0.509	rs2419044	chr1:68421087	C/T	cg22082780	chr1:68452167	NA	0.38	5.83	0.31	1.3e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.47	-9.17	-0.45	5.15e-18	Multiple sclerosis;
CRC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.22	0.37	3.68e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.29	-0.33	1.01e-9	Depression;
CRC	cis	rs6662572	0.737	rs11211211	chr1:46340554	G/T	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg25019722	chr6:37503610	NA	-0.47	-8.68	-0.43	1.86e-16	Cognitive performance;
CRC	trans	rs3118914	1.000	rs3118912	chr13:51111464	C/T	cg09222023	chr3:138669322	C3orf72	0.35	6.0	0.31	5.26e-9	Height;
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg01339444	chr6:118972232	C6orf204	0.55	6.19	0.32	1.77e-9	Diastolic blood pressure;
CRC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg11843238	chr5:131593191	PDLIM4	-0.32	-5.63	-0.3	3.9e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs4363385	0.818	rs4576617	chr1:152985729	G/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-8.1	-0.41	1.07e-14	Response to bleomycin (chromatid breaks);
CRC	cis	rs3018066	0.720	rs7662592	chr4:107004079	G/A	cg01869342	chr4:106983673	TBCK	0.46	6.79	0.35	5.15e-11	Cancer;
CRC	cis	rs12692738	0.526	rs422265	chr2:165630796	C/T	cg03182029	chr2:165697222	COBLL1	0.51	6.07	0.32	3.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg06781209	chr11:61594997	FADS2	-0.76	-9.24	-0.45	3.13e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15005908	chr6:114292723	HDAC2	0.36	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.47	-7.57	-0.39	3.78e-13	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.5	8.31	0.42	2.49e-15	Aortic root size;
CRC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.62	10.4	0.5	4.44e-22	Resting heart rate;
CRC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.74	10.05	0.48	6.51e-21	Platelet count;
CRC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	12.37	0.56	4.01e-29	Hip circumference adjusted for BMI;
CRC	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.65	7.48	0.38	6.7e-13	Eotaxin levels;
CRC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.5	-7.69	-0.39	1.68e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	15.45	0.65	7.21e-41	Primary sclerosing cholangitis;
CRC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.46	8.66	0.43	2.2e-16	Renal cell carcinoma;
CRC	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.68	-11.92	-0.55	1.83e-27	Lewy body disease;
CRC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg16447950	chr5:562315	NA	-0.85	-12.55	-0.57	8.97e-30	Obesity-related traits;
CRC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.87	17.43	0.69	1.19e-48	White blood cell count;
CRC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.6	-9.59	-0.47	2.34e-19	Aortic root size;
CRC	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.77	-9.26	-0.45	2.73e-18	Body mass index;
CRC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.91	-15.75	-0.66	4.73e-42	Height;
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.48	-6.6	-0.34	1.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	cg04338863	chr8:33670619	NA	0.38	6.49	0.34	3.15e-10	Body mass index;
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg19913688	chr11:428466	ANO9	-0.68	-6.56	-0.34	2.03e-10	Body mass index;
CRC	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg06671706	chr8:8559999	CLDN23	0.51	7.46	0.38	7.94e-13	Obesity-related traits;
CRC	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs910187	0.678	rs1046664	chr20:45817223	G/A	cg27589058	chr20:45804311	EYA2	-0.4	-7.63	-0.39	2.53e-13	Migraine;
CRC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg17948913	chr5:572064	NA	0.52	5.94	0.31	7.29e-9	Obesity-related traits;
CRC	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg15192750	chr16:69999425	NA	0.58	7.46	0.38	7.89e-13	IgE levels;
CRC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg21153622	chr11:89784906	NA	-0.51	-8.52	-0.43	5.87e-16	HDL cholesterol;
CRC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00322946	chr10:22605631	COMMD3	0.42	5.97	0.31	6.27e-9	Response to antipsychotic treatment;
CRC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.59	8.19	0.41	5.82e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.45	-7.71	-0.39	1.5e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs995000	0.899	rs1305520	chr1:62926057	A/T	cg19896129	chr1:63156450	NA	-0.38	-5.91	-0.31	8.34e-9	Triglyceride levels;
CRC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.55	8.45	0.42	9.3e-16	Diastolic blood pressure;
CRC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.52	-6.96	-0.36	1.83e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg26666090	chr16:58549219	SETD6	0.94	6.4	0.33	5.36e-10	Schizophrenia;
CRC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg07507251	chr3:52567010	NT5DC2	0.4	5.98	0.31	5.9e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.53	-6.19	-0.32	1.74e-9	Vitiligo;
CRC	cis	rs9292777	0.901	rs6878370	chr5:40433552	G/A	cg09067459	chr5:40385259	NA	0.51	8.87	0.44	4.77e-17	Crohn's disease;Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04355093	chr4:85887382	WDFY3;C4orf12	0.39	6.45	0.34	3.92e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg26462404	chr19:2270807	OAZ1	-0.5	-5.98	-0.31	5.66e-9	Diisocyanate-induced asthma;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	17.84	0.7	2.77e-50	Prudent dietary pattern;
CRC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg10760299	chr15:45669010	GATM	0.52	7.94	0.4	3.27e-14	Homoarginine levels;
CRC	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.82	-10.49	-0.5	2.08e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.98	-19.27	-0.73	6.62e-56	Height;
CRC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg02659138	chr7:134003124	SLC35B4	0.41	7.2	0.37	4.14e-12	Mean platelet volume;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg15786705	chr6:28176104	NA	0.49	6.44	0.33	4.26e-10	Parkinson's disease;
CRC	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.18	0.49	2.44e-21	Asthma;
CRC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-9.8	-0.48	4.52e-20	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.11e-22	Prudent dietary pattern;
CRC	cis	rs17767392	1.000	rs34674149	chr14:71777093	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.9	-0.36	2.71e-11	Mitral valve prolapse;
CRC	cis	rs9649465	1.000	rs56396297	chr7:123350535	T/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.62	-0.3	4.05e-8	Migraine;
CRC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.0	-0.52	3.58e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.13	-0.37	6.28e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.68	-11.89	-0.55	2.39e-27	Eye color traits;
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-8.25	-0.41	3.95e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-1.0	-22.68	-0.78	3.05e-69	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.52	8.39	0.42	1.49e-15	Schizophrenia;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg08200582	chr11:442649	ANO9	-0.69	-7.21	-0.37	3.75e-12	Body mass index;
CRC	cis	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg11143507	chr3:125485238	NA	-0.52	-5.71	-0.3	2.53e-8	Blood pressure (smoking interaction);
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg08200582	chr11:442649	ANO9	-0.68	-7.65	-0.39	2.26e-13	Body mass index;
CRC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.63	9.41	0.46	8.71e-19	Breast cancer;
CRC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg14711859	chr11:8959438	ASCL3	-0.51	-8.24	-0.41	4.27e-15	Hemoglobin concentration;
CRC	cis	rs10512697	0.764	rs13155882	chr5:3543787	C/G	cg19473799	chr5:3511975	NA	-0.77	-5.97	-0.31	6.25e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.88	-14.26	-0.62	2.94e-36	Mean platelet volume;
CRC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.88	15.73	0.66	5.92e-42	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.26	-14.48	-0.62	4.06e-37	Diabetic kidney disease;
CRC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg12311346	chr5:56204834	C5orf35	-0.45	-6.72	-0.35	7.99e-11	Coronary artery disease;
CRC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.51	-7.48	-0.38	7.02e-13	White blood cell count;
CRC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21028142	chr17:79581711	NPLOC4	-0.33	-7.05	-0.36	1.09e-11	Eye color traits;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg08600765	chr20:34638493	LOC647979	-0.59	-7.27	-0.37	2.69e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.3	-0.33	9.77e-10	Aortic root size;
CRC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg03030879	chr14:75389066	RPS6KL1	0.4	5.94	0.31	7.17e-9	Height;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg15845792	chr6:28175446	NA	0.78	8.35	0.42	1.98e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11587400	0.514	rs222499	chr1:115146488	C/A	cg12756093	chr1:115239321	AMPD1	-0.44	-5.97	-0.31	6.06e-9	Autism;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg00222291	chr16:22385662	CDR2	0.42	6.11	0.32	2.77e-9	Body mass index;
CRC	cis	rs6961069	0.777	rs1953299	chr7:80265625	T/G	cg04458919	chr7:80252533	CD36	0.33	5.87	0.31	1.06e-8	Platelet count;
CRC	cis	rs6738485	0.763	rs11681976	chr2:106841591	C/A	cg16099169	chr2:106886729	NA	-0.39	-6.78	-0.35	5.5e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.5	-7.45	-0.38	8.26e-13	Response to antineoplastic agents;
CRC	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.5	7.78	0.39	9.2e-14	Monocyte percentage of white cells;
CRC	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg00490450	chr3:139108681	COPB2	0.45	6.65	0.34	1.19e-10	Obesity-related traits;
CRC	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-7.82	-0.4	7.14e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.51	7.63	0.39	2.5e-13	Menarche (age at onset);
CRC	cis	rs2421770	0.530	rs3847621	chr11:35364435	G/A	cg13971030	chr11:35366721	SLC1A2	-0.39	-6.75	-0.35	6.74e-11	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg01879757	chr17:41196368	BRCA1	-0.42	-6.24	-0.33	1.31e-9	Menopause (age at onset);
CRC	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.81	13.92	0.61	5.8e-35	Lewy body disease;
CRC	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.72	-9.27	-0.46	2.47e-18	Blood protein levels;
CRC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.36	-0.33	6.77e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.35	-6.08	-0.32	3.34e-9	Mean corpuscular volume;
CRC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.75	-14.06	-0.61	1.78e-35	Body mass index;
CRC	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.38	-6.22	-0.32	1.52e-9	Eosinophil percentage of granulocytes;
CRC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg26248373	chr2:1572462	NA	-0.69	-7.52	-0.38	5.13e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs17227506	0.679	rs34216318	chr8:13444780	T/C	cg03566418	chr8:13424080	C8orf48	0.34	5.79	0.3	1.65e-8	Nonsyndromic cleft lip with cleft palate;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg03152577	chr1:54411898	LRRC42;HSPB11	0.42	6.66	0.34	1.13e-10	Interleukin-6 levels;
CRC	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg10130446	chr14:55658398	DLGAP5	-0.39	-5.61	-0.3	4.23e-8	Protein biomarker;
CRC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.33	-0.79	9.69e-72	Myeloid white cell count;
CRC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.65	6.84	0.35	3.8e-11	Body mass index;
CRC	trans	rs1404872	0.717	rs73049436	chr7:3329350	T/C	cg25123566	chr12:47610734	FAM113B;LOC100233209	-0.52	-6.0	-0.31	5.16e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.59	9.17	0.45	5.34e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.82e-28	Alzheimer's disease;
CRC	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg20744362	chr22:50050164	C22orf34	0.34	5.98	0.31	5.93e-9	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04857149	chr18:24237060	NA	0.44	6.73	0.35	7.4e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.36	-5.62	-0.3	4.13e-8	Axial length;
CRC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.12	-0.74	2.91e-59	Height;
CRC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.39	7.07	0.36	9.58e-12	Bipolar disorder;
CRC	cis	rs943466	0.614	rs4713677	chr6:33731225	C/G	cg25922239	chr6:33757077	LEMD2	-0.39	-5.8	-0.3	1.54e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
CRC	cis	rs7605827	0.930	rs9287660	chr2:15595767	C/A	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.37	-5.74	-0.3	2.1e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.95	-0.36	2.02e-11	Response to antipsychotic treatment;
CRC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg18016565	chr1:150552671	MCL1	0.42	6.06	0.32	3.63e-9	Melanoma;
CRC	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.54	9.27	0.46	2.55e-18	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.56	8.85	0.44	5.4e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.42	-6.04	-0.32	4.22e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.51	7.1	0.36	7.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.57	9.43	0.46	7.8e-19	Total body bone mineral density;
CRC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-10.91	-0.52	7.56e-24	Menopause (age at onset);
CRC	cis	rs236352	0.515	rs9380610	chr6:36805885	A/C	cg10099585	chr6:36853529	C6orf89	-0.43	-6.27	-0.33	1.12e-9	Heart rate;
CRC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.72	11.92	0.55	1.85e-27	Monocyte count;
CRC	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.37	-5.64	-0.3	3.64e-8	Inflammatory bowel disease;
CRC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-7.19	-0.37	4.29e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg24910161	chr17:38119198	GSDMA	-0.36	-5.94	-0.31	7.28e-9	Myeloid white cell count;
CRC	cis	rs354033	1.000	rs56707870	chr7:149265728	T/C	cg24335155	chr7:149193227	ZNF746	0.37	5.7	0.3	2.64e-8	Multiple sclerosis;
CRC	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg15704280	chr7:45808275	SEPT13	0.58	7.96	0.4	2.77e-14	Intraocular pressure;
CRC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg17724175	chr1:150552817	MCL1	0.5	7.33	0.37	1.83e-12	Melanoma;
CRC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.6	-6.78	-0.35	5.49e-11	Blood protein levels;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.64	-10.4	-0.5	4.3e-22	Hepatocellular carcinoma;
CRC	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.06e-9	Red blood cell count;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg20615401	chr6:28092323	ZSCAN16	0.47	5.9	0.31	9.13e-9	Parkinson's disease;
CRC	cis	rs11229555	0.645	rs4594017	chr11:58194788	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.62	8.82	0.44	6.82e-17	Vitamin D levels;
CRC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs6968419	0.714	rs7811984	chr7:115886079	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.31	-0.33	8.9e-10	Intraocular pressure;
CRC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg13390004	chr1:15929781	NA	0.53	7.43	0.38	9.43e-13	Systolic blood pressure;
CRC	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg05194412	chr2:137003533	NA	0.44	6.84	0.35	3.76e-11	Colorectal cancer;
CRC	cis	rs6076065	0.723	rs2424539	chr20:23384904	C/T	cg11657817	chr20:23433608	CST11	-0.4	-5.89	-0.31	9.33e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg13798780	chr7:105162888	PUS7	0.67	7.97	0.4	2.72e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg26666090	chr16:58549219	SETD6	0.94	6.49	0.34	3.19e-10	Schizophrenia;
CRC	cis	rs7932354	0.583	rs7107778	chr11:46860855	C/T	cg19486271	chr11:47235900	DDB2	-0.44	-6.62	-0.34	1.45e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9494145	0.531	rs9399136	chr6:135402339	T/C	cg22676075	chr6:135203613	NA	0.61	7.85	0.4	5.94e-14	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs12024301	0.557	rs75344054	chr1:183598479	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.6	-9.29	-0.46	2.12e-18	Colorectal cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17373656	chr21:45196239	CSTB	0.44	6.22	0.32	1.51e-9	Anxiety disorder;
CRC	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	9.61	0.47	1.99e-19	Platelet distribution width;
CRC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.06	-15.38	-0.65	1.35e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg18721089	chr20:30220636	NA	0.35	5.77	0.3	1.82e-8	Mean corpuscular hemoglobin;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20946600	chr2:27294721	LOC100128731	0.51	6.91	0.36	2.56e-11	Anxiety disorder;
CRC	cis	rs73206853	0.620	rs17682482	chr12:111154788	C/G	cg12870014	chr12:110450643	ANKRD13A	0.74	6.8	0.35	5.04e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg18187862	chr3:45730750	SACM1L	-0.52	-6.88	-0.35	3.12e-11	Primary sclerosing cholangitis;
CRC	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.04	-0.36	1.11e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.2	0.49	2.05e-21	Platelet count;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs12760731	0.565	rs7541122	chr1:178199214	G/C	cg00404053	chr1:178313656	RASAL2	1.05	10.89	0.51	8.62e-24	Obesity-related traits;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg05569086	chr8:143859399	LYNX1	-0.4	-6.12	-0.32	2.59e-9	Urinary tract infection frequency;
CRC	trans	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg18187862	chr3:45730750	SACM1L	0.46	6.7	0.35	9.15e-11	Primary sclerosing cholangitis;
CRC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg11212589	chr17:38028394	ZPBP2	0.33	5.92	0.31	8.01e-9	Asthma;
CRC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg06494592	chr3:125709126	NA	-0.56	-6.73	-0.35	7.33e-11	Blood pressure (smoking interaction);
CRC	cis	rs755249	0.530	rs16826087	chr1:39812518	C/T	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg17076921	chr10:75634595	CAMK2G	0.42	6.09	0.32	3.18e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg00631329	chr6:26305371	NA	-0.42	-6.94	-0.36	2.03e-11	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CRC	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.42	-8.2	-0.41	5.51e-15	Alcohol dependence;
CRC	cis	rs10982256	0.774	rs13286280	chr9:117246504	C/T	cg13636371	chr9:117264095	DFNB31	0.33	6.39	0.33	5.67e-10	Bipolar disorder;
CRC	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.0	-0.31	5.09e-9	Pubertal anthropometrics;
CRC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs1656402	1.000	rs6761056	chr2:233437045	T/A	cg03852847	chr2:233439513	NA	-0.44	-7.51	-0.38	5.71e-13	Non-small cell lung cancer (survival);
CRC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	8.27	0.41	3.45e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07028284	chr17:4871281	SPAG7	0.44	6.11	0.32	2.74e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg22182287	chr2:3452347	TTC15	0.39	6.07	0.32	3.57e-9	Obesity-related traits;
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg15147215	chr3:52552868	STAB1	-0.64	-11.04	-0.52	2.62e-24	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27309920	chr12:6798957	ZNF384	0.5	6.66	0.34	1.16e-10	Thyroid stimulating hormone;
CRC	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg09760422	chr2:128146352	NA	-0.36	-6.94	-0.36	2.05e-11	Protein C levels;
CRC	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.72	9.21	0.45	3.86e-18	Iron status biomarkers;
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.39	-0.33	5.78e-10	Electroencephalogram traits;
CRC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg18404041	chr3:52824283	ITIH1	0.36	6.63	0.34	1.38e-10	Schizophrenia;
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.39	-0.38	1.22e-12	Total body bone mineral density;
CRC	cis	rs2108622	0.727	rs8104311	chr19:15982760	T/C	cg13772218	chr19:15982569	NA	0.49	7.01	0.36	1.39e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs995000	0.826	rs7555577	chr1:63034363	A/C	cg19896129	chr1:63156450	NA	-0.44	-6.81	-0.35	4.73e-11	Triglyceride levels;
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.61	7.68	0.39	1.85e-13	Dilated cardiomyopathy;
CRC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	0.99	9.37	0.46	1.21e-18	Lymphocyte counts;
CRC	cis	rs6681460	0.966	rs7519747	chr1:67140723	T/C	cg02459107	chr1:67143332	SGIP1	0.5	8.84	0.44	6.04e-17	Presence of antiphospholipid antibodies;
CRC	cis	rs754466	0.561	rs11002343	chr10:79705871	G/A	cg17075019	chr10:79541650	NA	-0.61	-6.82	-0.35	4.31e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	14.91	0.63	9.46e-39	Menarche (age at onset);
CRC	cis	rs59104589	0.583	rs62186399	chr2:242225325	G/C	cg19488206	chr2:242435732	STK25	0.49	6.91	0.36	2.45e-11	Fibrinogen levels;
CRC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.53	7.69	0.39	1.73e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.47	8.07	0.41	1.36e-14	Common traits (Other);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17738503	chr17:49244158	NME2;NME1-NME2	0.37	6.02	0.31	4.58e-9	Obesity-related traits;
CRC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg03037974	chr15:76606532	NA	-0.75	-14.36	-0.62	1.27e-36	Blood metabolite levels;
CRC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.27	-0.46	2.49e-18	Type 2 diabetes;
CRC	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.09	0.49	4.8e-21	Asthma (childhood onset);
CRC	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg24848437	chr7:2645542	IQCE	0.59	6.27	0.33	1.17e-9	Urate levels in lean individuals;
CRC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.56	-9.34	-0.46	1.51e-18	Iron status biomarkers;
CRC	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg20356878	chr3:121714668	ILDR1	-0.42	-6.01	-0.31	5.02e-9	Multiple sclerosis;
CRC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.66	0.63	8.22e-38	Chronic sinus infection;
CRC	cis	rs61160187	0.582	rs12516995	chr5:60308274	C/T	cg16298547	chr5:60138761	ELOVL7	-0.26	-5.76	-0.3	1.88e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.83	0.31	1.33e-8	Prudent dietary pattern;
CRC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.53	-9.0	-0.44	1.79e-17	Menarche (age at onset);
CRC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.42	-0.38	9.97e-13	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14393411	chr19:13067586	GADD45GIP1	0.45	6.25	0.33	1.25e-9	Response to antipsychotic treatment;
CRC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg13722127	chr7:150037890	RARRES2	0.49	7.66	0.39	2.06e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg08270630	chr22:50330655	NA	-0.4	-5.62	-0.3	4.04e-8	Schizophrenia;
CRC	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg26597838	chr10:835615	NA	0.73	8.13	0.41	9.08e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs7707921	1.000	rs7707921	chr5:81538046	T/A	cg17942617	chr5:81327376	ATG10	-0.38	-5.78	-0.3	1.76e-8	Breast cancer;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg23161317	chr6:28129485	ZNF389	0.43	6.03	0.32	4.45e-9	Parkinson's disease;
CRC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-9.95	-0.48	1.43e-20	Breast cancer;
CRC	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.12	10.53	0.5	1.51e-22	Diabetic retinopathy;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg02033258	chr5:131593261	PDLIM4	0.38	6.41	0.33	4.9e-10	Breast cancer;
CRC	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.45	7.07	0.36	9.6e-12	C-reactive protein levels;
CRC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg11189052	chr15:85197271	WDR73	-0.64	-8.78	-0.44	8.95e-17	Schizophrenia;
CRC	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg12855166	chr17:30846586	MYO1D	-0.37	-6.0	-0.31	5.19e-9	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62187657	chr2:162488091	G/A	cg25193742	chr10:104614220	C10orf32	-0.78	-6.16	-0.32	2.17e-9	Cognitive function;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.51	-0.34	2.86e-10	Breast cancer;
CRC	cis	rs500492	0.508	rs2744147	chr16:1073146	C/G	cg09791621	chr16:1078722	NA	0.45	6.12	0.32	2.7e-9	Polycystic ovary syndrome;
CRC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	10.67	0.51	5.21e-23	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.46	-6.24	-0.33	1.38e-9	Airflow obstruction;
CRC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.66	11.63	0.54	2.04e-26	Brugada syndrome;
CRC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.75	-11.08	-0.52	1.9e-24	Schizophrenia;
CRC	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg02158880	chr13:53174818	NA	0.45	6.41	0.33	5.02e-10	Lewy body disease;
CRC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg24562669	chr7:97807699	LMTK2	0.42	7.03	0.36	1.18e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2249694	0.537	rs751945	chr10:135329939	G/A	cg20169779	chr10:135381914	SYCE1	0.51	6.48	0.34	3.27e-10	Obesity-related traits;
CRC	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	6.19e-10	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	trans	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.14	-0.37	5.96e-12	Monocyte percentage of white cells;
CRC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.38	6.28	0.33	1.08e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.66	-0.34	1.15e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	7.99	0.4	2.25e-14	Height;
CRC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.14	-0.32	2.33e-9	Menopause (age at onset);
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02359409	chr6:42947317	PEX6	-0.69	-11.48	-0.53	7.02e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9912789	0.687	rs9892874	chr17:79188303	G/C	cg14413466	chr17:79170920	AZI1	-0.38	-6.57	-0.34	2e-10	Frontotemporal dementia;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.15	-0.32	2.29e-9	Height;
CRC	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	0.72	6.4	0.33	5.31e-10	Fat distribution (HIV);
CRC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07701084	chr6:150067640	NUP43	0.48	6.93	0.36	2.3e-11	Testicular germ cell tumor;
CRC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.46	-6.45	-0.33	4.08e-10	DNA methylation (variation);
CRC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.49e-17	Bladder cancer;
CRC	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-6.73	-0.35	7.49e-11	Capecitabine sensitivity;
CRC	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.48	-7.03	-0.36	1.16e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg15786705	chr6:28176104	NA	0.63	6.77	0.35	5.94e-11	Depression;
CRC	cis	rs7932354	0.583	rs10734548	chr11:46787573	T/C	cg19486271	chr11:47235900	DDB2	-0.43	-6.5	-0.34	2.99e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg22495460	chr2:25135724	ADCY3	-0.83	-15.86	-0.66	1.83e-42	Body mass index;
CRC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.5e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg06470822	chr6:28175283	NA	0.58	8.35	0.42	1.95e-15	Parkinson's disease;
CRC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.55	7.88	0.4	4.99e-14	Lung cancer;
CRC	cis	rs2457480	0.516	rs3900567	chr10:44651421	C/T	cg09554077	chr10:44749378	NA	0.46	5.94	0.31	7.3e-9	Coronary artery disease;
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.67	0.34	1.1e-10	Alzheimer's disease;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg01339444	chr6:118972232	C6orf204	0.54	6.15	0.32	2.25e-9	Diastolic blood pressure;
CRC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	9.78	0.47	5.41e-20	Platelet count;
CRC	cis	rs62432291	0.681	rs365045	chr6:159632250	A/G	cg14500486	chr6:159655392	FNDC1	0.81	10.71	0.51	3.53e-23	Joint mobility (Beighton score);
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg06699617	chr13:45491953	NA	-0.4	-5.99	-0.31	5.5e-9	Brain structure;
CRC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.02	10.07	0.49	5.84e-21	Opioid sensitivity;
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.65	-0.34	1.19e-10	Bipolar disorder;
CRC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.43	-6.66	-0.34	1.14e-10	Cardiovascular disease risk factors;
CRC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.88	-0.31	1.01e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.04	-0.32	4.21e-9	Axial length;
CRC	cis	rs1656402	0.953	rs10933398	chr2:233440544	G/A	cg03852847	chr2:233439513	NA	-0.41	-6.75	-0.35	6.81e-11	Non-small cell lung cancer (survival);
CRC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg14008862	chr17:28927542	LRRC37B2	0.56	5.8	0.3	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1973993	0.708	rs6593605	chr1:96956775	A/G	cg10631902	chr5:14652156	NA	-0.41	-6.82	-0.35	4.47e-11	Weight;
CRC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.52	6.96	0.36	1.84e-11	Obesity-related traits;
CRC	cis	rs6076065	0.723	rs7269627	chr20:23362727	A/T	cg11657817	chr20:23433608	CST11	0.45	6.79	0.35	5.39e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	6.08e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.56	-0.43	4.41e-16	Hemoglobin concentration;
CRC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.68	-8.53	-0.43	5.48e-16	Psoriasis;
CRC	cis	rs4766566	0.651	rs4766505	chr12:111758620	A/G	cg10833066	chr12:111807467	FAM109A	0.55	7.6	0.39	3.03e-13	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
CRC	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg27426351	chr10:43362370	NA	0.61	7.43	0.38	9.34e-13	Blood protein levels;
CRC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.72	10.0	0.48	1.02e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.36	-5.64	-0.3	3.66e-8	Crohn's disease;
CRC	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg14191688	chr11:70257035	CTTN	0.45	5.97	0.31	6.14e-9	Coronary artery disease;
CRC	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.7	7.71	0.39	1.48e-13	Blood protein levels;
CRC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.43	-8.31	-0.42	2.51e-15	Mean corpuscular volume;
CRC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.44	0.46	7.13e-19	Platelet count;
CRC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg20243544	chr17:37824526	PNMT	0.46	7.09	0.36	8.38e-12	Self-reported allergy;
CRC	cis	rs9649465	0.967	rs12534834	chr7:123307079	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-5.76	-0.3	1.91e-8	Migraine;
CRC	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg08071915	chr8:12219732	FAM66A	-0.32	-5.77	-0.3	1.85e-8	Retinal vascular caliber;
CRC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.18	10.78	0.51	2.11e-23	Alzheimer's disease (late onset);
CRC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg01849466	chr14:104193079	ZFYVE21	0.36	5.71	0.3	2.54e-8	Body mass index;
CRC	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	0.83	6.89	0.35	2.89e-11	Economic and political preferences (immigration/crime);
CRC	cis	rs12024301	0.557	rs10911397	chr1:183646757	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.64	5.73	0.3	2.32e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	1.04	7.73	0.39	1.32e-13	Type 2 diabetes nephropathy;
CRC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.45	-9.15	-0.45	6.27e-18	Renal cell carcinoma;
CRC	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg20885578	chr2:198174922	NA	-0.44	-7.08	-0.36	8.97e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg02569458	chr12:86230093	RASSF9	-0.42	-7.09	-0.36	8.05e-12	Major depressive disorder;
CRC	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg12458913	chr13:53173898	NA	0.46	6.77	0.35	5.99e-11	Lewy body disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05796909	chr17:7465070	SENP3	0.39	6.01	0.31	4.81e-9	Interleukin-6 levels;
CRC	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg05874882	chr4:1763078	NA	-0.37	-6.62	-0.34	1.42e-10	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg13565492	chr6:43139072	SRF	-0.72	-7.46	-0.38	7.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10827434	chr1:84944976	RPF1	0.45	7.5	0.38	6.05e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.63	7.44	0.38	8.87e-13	Menarche (age at onset);
CRC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.36	-5.93	-0.31	7.76e-9	Red cell distribution width;
CRC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg23625390	chr15:77176239	SCAPER	-0.48	-7.05	-0.36	1.04e-11	Blood metabolite levels;
CRC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	1.01	9.49	0.46	4.73e-19	Lymphocyte counts;
CRC	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.47	-9.05	-0.45	1.24e-17	Dupuytren's disease;
CRC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg25456477	chr12:86230367	RASSF9	0.33	5.62	0.3	4.16e-8	Major depressive disorder;
CRC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg03037974	chr15:76606532	NA	0.66	11.44	0.53	9.38e-26	Blood metabolite levels;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.95	-0.4	3.07e-14	Total body bone mineral density;
CRC	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg16540259	chr10:75572220	NDST2	0.38	5.91	0.31	8.72e-9	Inflammatory bowel disease;
CRC	cis	rs10878977	0.542	rs11177663	chr12:69818859	C/T	cg20891283	chr12:69753455	YEATS4	-0.58	-5.65	-0.3	3.4e-8	Colorectal cancer;
CRC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.41	6.0	0.31	5.34e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.12	-0.32	2.59e-9	Lung cancer;
CRC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.59	0.54	2.77e-26	Monocyte percentage of white cells;
CRC	cis	rs2108622	0.727	rs76984410	chr19:15982700	C/T	cg13772218	chr19:15982569	NA	0.49	7.01	0.36	1.39e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	cis	rs4290604	0.748	rs10929216	chr2:238080938	C/T	cg23555395	chr2:238036564	NA	-0.61	-6.18	-0.32	1.86e-9	Asthma;
CRC	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.58	6.47	0.34	3.47e-10	Bipolar disorder;
CRC	trans	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.92	0.44	3.29e-17	Hip circumference adjusted for BMI;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg23123621	chr4:1343375	KIAA1530	0.39	7.03	0.36	1.22e-11	Longevity;
CRC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.98	17.33	0.69	2.95e-48	Height;
CRC	cis	rs60871478	0.786	rs12536056	chr7:831351	T/A	cg05535760	chr7:792225	HEATR2	-0.99	-12.31	-0.56	6.71e-29	Cerebrospinal P-tau181p levels;
CRC	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg20885578	chr2:198174922	NA	-0.42	-6.69	-0.35	9.64e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg08075719	chr14:103021372	NA	-0.66	-7.69	-0.39	1.71e-13	Platelet count;
CRC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.42	7.06	0.36	1.02e-11	Body mass index;
CRC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.43	6.57	0.34	2.01e-10	Primary tooth development (time to first tooth eruption);
CRC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.72	0.43	1.44e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.98	-0.36	1.66e-11	Colorectal cancer;
CRC	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg25922239	chr6:33757077	LEMD2	0.44	6.13	0.32	2.53e-9	Crohn's disease;
CRC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-19.64	-0.73	2.23e-57	Ulcerative colitis;
CRC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.06	10.36	0.5	5.88e-22	Diabetic retinopathy;
CRC	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg25547332	chr5:131281432	NA	0.38	5.64	0.3	3.67e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg11887960	chr12:57824829	NA	0.64	7.08	0.36	8.89e-12	Obesity-related traits;
CRC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg24829409	chr8:58192753	C8orf71	-0.66	-7.16	-0.37	5.37e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg01843034	chr6:37503916	NA	-0.46	-8.71	-0.43	1.54e-16	Cognitive performance;
CRC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg00343986	chr7:65444356	GUSB	0.46	6.75	0.35	6.76e-11	Aortic root size;
CRC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.33	6.07e-10	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12796498	chr2:1276796	SNTG2	-0.37	-6.34	-0.33	7.64e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16642045	chr4:155471719	PLRG1	0.43	6.49	0.34	3.16e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-6.12	-0.32	2.61e-9	Ovarian reserve;
CRC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.16	-0.32	2.1e-9	Daytime sleep phenotypes;
CRC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.49	-7.77	-0.39	9.88e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg10578991	chr7:12443926	VWDE	-0.49	-5.62	-0.3	4.01e-8	Coronary artery disease;
CRC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.56	0.5	1.26e-22	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10591475	chr6:28109693	ZNF192	0.5	7.08	0.36	9.03e-12	Response to antipsychotic treatment;
CRC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.4	-0.38	1.11e-12	Height;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.58	10.96	0.52	4.77e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.39	0.33	5.52e-10	Depression;
CRC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.98	-0.44	2.07e-17	Aortic root size;
CRC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.56	6.13	0.32	2.48e-9	Menarche (age at onset);
CRC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.47	5.61	0.3	4.26e-8	Depression;
CRC	cis	rs4073416	0.542	rs1959145	chr14:65954740	A/G	cg03016385	chr14:66212404	NA	-0.41	-5.69	-0.3	2.76e-8	N-glycan levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	0.4	6.1	0.32	2.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.37	-6.72	-0.35	8.23e-11	Dilated cardiomyopathy;
CRC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.55	-8.3	-0.42	2.75e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg27499820	chr13:21296301	IL17D	-0.42	-5.98	-0.31	5.8e-9	Dental caries;
CRC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.44	7.24	0.37	3.22e-12	Lung cancer;
CRC	cis	rs7258465	0.931	rs11673604	chr19:18540988	T/C	cg10790698	chr19:18539756	SSBP4	-0.47	-8.78	-0.44	8.9e-17	Breast cancer;
CRC	cis	rs7932354	0.583	rs2306027	chr11:46907827	C/T	cg19486271	chr11:47235900	DDB2	-0.43	-6.42	-0.33	4.75e-10	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24960158	chr3:97690786	MINA	0.45	5.96	0.31	6.47e-9	Thyroid stimulating hormone;
CRC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.46	-7.18	-0.37	4.69e-12	Eye color traits;
CRC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.21	0.41	4.99e-15	Menopause (age at onset);
CRC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.34	-6.1	-0.32	3.05e-9	Rheumatoid arthritis;
CRC	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06307176	chr5:131281290	NA	0.42	5.96	0.31	6.48e-9	Life satisfaction;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg06470822	chr6:28175283	NA	0.95	13.59	0.6	1.08e-33	Parkinson's disease;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.41	-7.29	-0.37	2.3e-12	Hepatitis;
CRC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.57	-6.39	-0.33	5.73e-10	Red blood cell count;
CRC	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg23387468	chr7:139079360	LUC7L2	-0.4	-6.98	-0.36	1.64e-11	Diisocyanate-induced asthma;
CRC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg05207973	chr5:176823642	SLC34A1	0.41	5.89	0.31	9.77e-9	Urate levels in lean individuals;
CRC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.7	0.47	1.01e-19	Platelet count;
CRC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.46	-9.17	-0.45	5.24e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg19764421	chr1:228783274	DUSP5P	-0.4	-6.25	-0.33	1.31e-9	Brain structure;
CRC	cis	rs4728302	0.869	rs889825	chr7:133596227	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.79	0.3	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00251705	chr11:57434686	ZDHHC5	0.44	6.14	0.32	2.34e-9	Response to antipsychotic treatment;
CRC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg21132104	chr15:45694354	SPATA5L1	0.42	6.19	0.32	1.83e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.52	-5.97	-0.31	6.25e-9	Vitiligo;
CRC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.48	4.77e-20	Bladder cancer;
CRC	trans	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	6.83	0.35	4.18e-11	LDL cholesterol;
CRC	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg25110126	chr1:46999211	NA	-0.35	-5.83	-0.31	1.31e-8	Monobrow;
CRC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg19223190	chr17:80058835	NA	0.4	6.52	0.34	2.63e-10	Life satisfaction;
CRC	trans	rs693839	0.691	rs4884161	chr13:81089506	C/T	cg07052627	chr11:46401447	MDK;DGKZ	-0.38	-6.13	-0.32	2.46e-9	Body fat percentage;
CRC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.44	7.02	0.36	1.27e-11	High light scatter reticulocyte count;
CRC	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg15145174	chr5:6755386	POLS	-0.46	-6.4	-0.33	5.32e-10	Menopause (age at onset);
CRC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.43	-7.43	-0.38	9.66e-13	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg05313129	chr8:58192883	C8orf71	-0.5	-5.89	-0.31	9.49e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg12560992	chr17:57184187	TRIM37	0.47	5.75	0.3	2.08e-8	Vitamin D levels;
CRC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.51	7.29	0.37	2.34e-12	Height;
CRC	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.73	-0.35	7.56e-11	Vitamin D levels;
CRC	cis	rs10035650	0.510	rs6898585	chr5:93896128	A/G	cg21051031	chr5:93905482	C5orf36;MIR1974	0.41	6.71	0.35	8.28e-11	Cancer;
CRC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.15	0.32	2.27e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.29	0.33	1.02e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg23167259	chr10:102495509	NA	-0.49	-6.83	-0.35	4.22e-11	Alzheimer's disease;
CRC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	trans	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg01505111	chr6:125621795	HDDC2	0.4	6.02	0.31	4.57e-9	DNA methylation (variation);
CRC	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.51	-5.76	-0.3	1.93e-8	Lymphocyte percentage of white cells;
CRC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	16.08	0.66	2.35e-43	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18284523	chr14:24711562	TINF2	0.45	6.96	0.36	1.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.66	-10.49	-0.5	2.19e-22	Age at first birth;
CRC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.32e-29	Prostate cancer;
CRC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.79	12.78	0.58	1.18e-30	Breast cancer;
CRC	cis	rs889398	0.617	rs3790083	chr16:69895286	C/T	cg00738113	chr16:70207722	CLEC18C	0.35	6.18	0.32	1.89e-9	Body mass index;
CRC	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21643547	chr1:205240462	TMCC2	-0.42	-7.08	-0.36	8.74e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg10729496	chr3:10149963	C3orf24	0.48	5.63	0.3	3.81e-8	Alzheimer's disease;
CRC	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.37	-0.33	6.5e-10	Body mass index;
CRC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.8	14.04	0.61	1.97e-35	Breast cancer;
CRC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg03013999	chr17:37608204	MED1	-0.47	-7.4	-0.38	1.14e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs62229266	0.609	rs2835253	chr21:37419745	T/C	cg12218747	chr21:37451666	NA	-0.37	-6.24	-0.33	1.31e-9	Mitral valve prolapse;
CRC	cis	rs4662945	0.688	rs34713181	chr2:130212385	G/A	cg05962382	chr2:130345044	NA	-0.33	-5.61	-0.3	4.23e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.44	7.26	0.37	2.81e-12	Height;
CRC	cis	rs6700896	0.931	rs4655764	chr1:66126159	C/T	cg04111102	chr1:66153794	NA	0.34	6.06	0.32	3.74e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.68	-11.19	-0.53	7.65e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3018066	0.666	rs6829795	chr4:107065220	T/C	cg01869342	chr4:106983673	TBCK	0.48	6.15	0.32	2.25e-9	Cancer;
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-6.58	-0.34	1.88e-10	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14775296	chr2:66672841	MEIS1	0.26	6.82	0.35	4.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg12516270	chr8:143859308	LYNX1	-0.39	-6.15	-0.32	2.24e-9	Urinary tract infection frequency;
CRC	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg01420254	chr6:26195488	NA	0.67	6.0	0.31	5.2e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.6	-8.53	-0.43	5.48e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-8.03	-0.4	1.74e-14	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.87e-11	Bipolar disorder;
CRC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-11.18	-0.52	8.1e-25	Ulcerative colitis;
CRC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.77	13.65	0.6	6.57e-34	Oral cavity cancer;
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.58	9.28	0.46	2.38e-18	Glycated hemoglobin levels;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20887711	chr4:1340912	KIAA1530	0.41	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.48	-0.71	8.12e-53	Height;
CRC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-6.56	-0.34	2.15e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.67	-10.81	-0.51	1.71e-23	Motion sickness;
CRC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg12573674	chr2:1569213	NA	-0.67	-7.62	-0.39	2.77e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs972578	0.875	rs5751412	chr22:43408257	A/G	cg01576275	chr22:43409880	NA	-0.47	-7.51	-0.38	5.7e-13	Mean platelet volume;
CRC	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg20608306	chr11:116969690	SIK3	-0.31	-5.72	-0.3	2.4e-8	Subjective well-being;
CRC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.58	-7.94	-0.4	3.18e-14	Migraine;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25740925	chr13:95254690	GPR180	0.43	6.23	0.32	1.45e-9	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.62	9.73	0.47	7.59e-20	Corneal astigmatism;
CRC	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.75	13.37	0.59	7.39e-33	Lewy body disease;
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.54	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg24562669	chr7:97807699	LMTK2	-0.48	-7.71	-0.39	1.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10450586	0.863	rs7125719	chr11:27288359	G/C	cg10370305	chr11:27303972	NA	0.36	5.65	0.3	3.55e-8	Total body bone mineral density;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg13047869	chr3:10149882	C3orf24	0.48	6.09	0.32	3.17e-9	Alzheimer's disease;
CRC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.74	12.91	0.58	4.04e-31	Systemic lupus erythematosus;
CRC	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.73	-12.87	-0.58	5.73e-31	White blood cell count (basophil);
CRC	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg03469862	chr11:68924853	NA	0.46	5.89	0.31	9.37e-9	Blond vs. brown hair color;
CRC	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.46	-0.38	7.56e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg13206674	chr6:150067644	NUP43	0.47	6.7	0.35	8.81e-11	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03361557	chr19:19774500	ATP13A1	0.4	6.52	0.34	2.7e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs1265507	0.599	rs2076967	chr12:114869758	G/C	cg11700868	chr17:38521232	GJD3	0.42	5.99	0.31	5.5e-9	Percent mammographic density;
CRC	cis	rs17127169	0.536	rs74860172	chr1:65497547	T/A	cg13853591	chr1:65468921	NA	0.81	5.67	0.3	3.06e-8	Sitting height ratio;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.72	10.15	0.49	3.18e-21	Menarche (age at onset);
CRC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-9.5	-0.46	4.58e-19	Bronchopulmonary dysplasia;
CRC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.63	-7.54	-0.38	4.51e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-5.94	-0.31	7.41e-9	Menarche (age at onset);
CRC	cis	rs995000	0.783	rs993013	chr1:63111069	G/T	cg19896129	chr1:63156450	NA	-0.41	-6.31	-0.33	8.92e-10	Triglyceride levels;
CRC	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg19773385	chr1:10388646	KIF1B	-0.59	-8.26	-0.41	3.69e-15	Hepatocellular carcinoma;
CRC	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg16110827	chr15:48056943	SEMA6D	-0.55	-8.41	-0.42	1.26e-15	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.23	6.35	0.33	7.25e-10	Type 2 diabetes;
CRC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-7.24	-0.37	3.21e-12	Aortic root size;
CRC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.13	0.32	2.58e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.41	6.5	0.34	3e-10	Blood metabolite levels;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.48	8.79	0.44	8.41e-17	Acylcarnitine levels;
CRC	cis	rs12580194	0.556	rs61957898	chr12:55730423	T/C	cg19537932	chr12:55886519	OR6C68	-0.65	-8.32	-0.42	2.4e-15	Cancer;
CRC	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.18	0.41	6.13e-15	Type 2 diabetes;
CRC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21643547	chr1:205240462	TMCC2	-0.44	-7.06	-0.36	1.01e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.48	-9.03	-0.45	1.43e-17	Dupuytren's disease;
CRC	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg01339444	chr6:118972232	C6orf204	0.55	6.16	0.32	2.08e-9	Diastolic blood pressure;
CRC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.84	11.63	0.54	2.01e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.52	-6.25	-0.33	1.31e-9	Schizophrenia;
CRC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg08270630	chr22:50330655	NA	-0.52	-5.64	-0.3	3.63e-8	Schizophrenia;
CRC	cis	rs3736594	0.513	rs3811644	chr2:27802805	A/G	cg27432699	chr2:27873401	GPN1	0.65	7.88	0.4	4.95e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg21856205	chr7:94953877	PON1	-0.52	-6.57	-0.34	2.01e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9463078	0.617	rs9395063	chr6:45040793	T/G	cg25276700	chr6:44698697	NA	-0.24	-5.76	-0.3	1.88e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.47	-5.99	-0.31	5.53e-9	DNA methylation (variation);
CRC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.6	-10.05	-0.48	6.56e-21	Intelligence (multi-trait analysis);
CRC	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg18002602	chr11:66138449	SLC29A2	-0.28	-6.02	-0.31	4.78e-9	Educational attainment (years of education);
CRC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.76	13.05	0.58	1.2e-31	Colorectal cancer;
CRC	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.79	12.02	0.55	7.77e-28	Testicular germ cell tumor;
CRC	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.75	-0.43	1.1e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg06581033	chr10:766294	NA	-0.53	-5.79	-0.3	1.61e-8	Uric acid levels;
CRC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg09835421	chr16:68378352	PRMT7	-0.76	-8.1	-0.41	1.12e-14	Magnesium levels;
CRC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.67	8.43	0.42	1.1e-15	Coronary artery disease;
CRC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-5.97	-0.31	6.15e-9	Coronary artery disease;
CRC	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.57	8.97	0.44	2.37e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg24998770	chr7:37888106	TXNDC3	0.45	7.04	0.36	1.09e-11	Alzheimer's disease (late onset);
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.52	-9.01	-0.44	1.76e-17	Acylcarnitine levels;
CRC	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg13385794	chr1:248469461	NA	0.39	6.98	0.36	1.62e-11	Common traits (Other);
CRC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.66	0.34	1.14e-10	Menopause (age at onset);
CRC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.38	5.92	0.31	8.2e-9	HDL cholesterol levels;
CRC	trans	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.22	0.32	1.47e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg15832292	chr6:96025679	MANEA	-0.56	-6.21	-0.32	1.61e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.55	-9.14	-0.45	6.83e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.75	10.53	0.5	1.59e-22	Initial pursuit acceleration;
CRC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.93	18.76	0.72	6.63e-54	Bone mineral density;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10319399	chr8:145018285	PLEC1	-0.38	-6.04	-0.32	4.11e-9	Myopia (pathological);
CRC	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.69	-9.27	-0.46	2.54e-18	Blood pressure (smoking interaction);
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10819733	chr22:24237672	NA	0.35	6.05	0.32	4.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02232396	chr7:77428768	PHTF2;TMEM60	0.43	6.16	0.32	2.11e-9	Anxiety disorder;
CRC	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.6	-9.02	-0.45	1.59e-17	Dementia with Lewy bodies;
CRC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.52	8.53	0.43	5.56e-16	Calcium levels;
CRC	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg09597638	chr17:3907349	NA	0.7	12.84	0.58	7.5e-31	Type 2 diabetes;
CRC	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg13334819	chr7:99746414	C7orf59	-0.56	-7.02	-0.36	1.3e-11	Coronary artery disease;
CRC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.73	-10.65	-0.51	5.87e-23	Hemoglobin concentration;Hematocrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16267579	chr12:76953818	OSBPL8	0.44	6.05	0.32	3.89e-9	Response to antipsychotic treatment;
CRC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.5	-0.34	2.9e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg19678392	chr7:94953810	PON1	-0.53	-6.52	-0.34	2.58e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg11693508	chr17:37793320	STARD3	-0.49	-6.33	-0.33	8.19e-10	Bipolar disorder;
CRC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17554472	chr22:41940697	POLR3H	0.55	5.61	0.3	4.29e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.05	-0.32	3.85e-9	Schizophrenia;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg05569086	chr8:143859399	LYNX1	-0.43	-7.01	-0.36	1.34e-11	Urinary tract infection frequency;
CRC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.0	-0.31	5.16e-9	Axial length;
CRC	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg19486271	chr11:47235900	DDB2	-0.49	-7.53	-0.38	4.81e-13	Acne (severe);
CRC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.51	-8.2	-0.41	5.44e-15	Platelet count;
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.64	6.8	0.35	4.93e-11	Chronic lymphocytic leukemia;
CRC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.66	0.34	1.12e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.77	12.3	0.56	7.34e-29	Breast cancer;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.86	14.09	0.61	1.33e-35	Menarche (age at onset);
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-7.17	-0.37	4.95e-12	Total body bone mineral density;
CRC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.12	-0.45	7.75e-18	Migraine;Coronary artery disease;
CRC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.11	-0.32	2.81e-9	Total body bone mineral density;
CRC	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14119001	chr9:139324193	INPP5E	-0.45	-6.43	-0.33	4.55e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.4	6.25	0.33	1.31e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.32e-10	Alzheimer's disease;
CRC	cis	rs1656402	1.000	rs1190439	chr2:233422390	G/A	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg00564723	chr10:75632066	CAMK2G	-0.22	-5.61	-0.3	4.35e-8	Inflammatory bowel disease;
CRC	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.64	-9.06	-0.45	1.16e-17	Coronary artery disease;
CRC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.37	-0.42	1.64e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg17321639	chr7:2759063	NA	-0.37	-5.63	-0.3	3.94e-8	Height;
CRC	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg06223162	chr1:101003688	GPR88	-0.36	-6.62	-0.34	1.44e-10	Monocyte count;
CRC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	0.81	9.22	0.45	3.53e-18	Gout;Renal underexcretion gout;
CRC	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.99	-0.36	1.57e-11	Neuroticism;
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.51	-7.37	-0.38	1.39e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.98	-0.44	2.2e-17	Eye color traits;
CRC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg23625390	chr15:77176239	SCAPER	0.48	6.83	0.35	4.16e-11	Blood metabolite levels;
CRC	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg21452805	chr1:244014465	NA	-0.46	-6.27	-0.33	1.14e-9	RR interval (heart rate);
CRC	cis	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg27395922	chr11:50257633	LOC441601	-0.36	-5.77	-0.3	1.86e-8	Coronary artery disease;
CRC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.75	12.65	0.57	3.7e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.36	-0.33	6.56e-10	Neuroticism;
CRC	trans	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.34	-0.33	7.74e-10	Aortic root size;
CRC	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.78	-0.39	9.65e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs995000	0.931	rs638714	chr1:62906489	G/T	cg19896129	chr1:63156450	NA	0.4	6.17	0.32	2.03e-9	Triglyceride levels;
CRC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.9	15.94	0.66	8.83e-43	Prostate cancer;
CRC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.34	-6.99	-0.36	1.55e-11	Alzheimer's disease (late onset);
CRC	cis	rs7572644	0.699	rs10194283	chr2:28159079	G/A	cg27432699	chr2:27873401	GPN1	-0.4	-5.6	-0.3	4.45e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg07507251	chr3:52567010	NT5DC2	0.5	7.79	0.39	8.64e-14	Electroencephalogram traits;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22225685	chr22:38203998	GCAT	0.39	6.29	0.33	1.02e-9	Obesity-related traits;
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.76	11.03	0.52	2.84e-24	Longevity;
CRC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.58	-0.39	3.49e-13	Coronary artery disease;
CRC	cis	rs4692589	1.000	rs1871683	chr4:170937348	T/C	cg19918862	chr4:170955249	NA	0.38	6.26	0.33	1.18e-9	Anxiety disorder;
CRC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.13	0.52	1.28e-24	Prudent dietary pattern;
CRC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg12463550	chr7:65579703	CRCP	0.6	6.17	0.32	2.05e-9	Diabetic kidney disease;
CRC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	6.4	0.33	5.39e-10	Neuroticism;
CRC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.23	-0.56	1.32e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.4	5.63	0.3	3.94e-8	Emphysema distribution in smoking;
CRC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06481639	chr22:41940642	POLR3H	0.55	6.05	0.32	3.97e-9	Vitiligo;
CRC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg02135003	chr7:105160482	PUS7	-0.68	-10.13	-0.49	3.59e-21	Bipolar disorder (body mass index interaction);
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.69	9.16	0.45	5.63e-18	Alzheimer's disease;
CRC	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg12458913	chr13:53173898	NA	0.59	9.36	0.46	1.34e-18	Lewy body disease;
CRC	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.23	-0.53	5.33e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7113874	0.524	rs4244804	chr11:8617550	C/T	cg02811074	chr11:8615871	STK33	0.33	5.76	0.3	1.97e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06307176	chr5:131281290	NA	0.42	6.23	0.32	1.43e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17860381	chr5:142783569	NR3C1	0.29	6.27	0.33	1.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.64	9.5	0.46	4.57e-19	Blood protein levels;
CRC	trans	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg09045935	chr12:6379348	NA	1.13	9.12	0.45	7.59e-18	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7209700	0.662	rs8080254	chr17:45347892	C/G	cg17185639	chr17:45330862	ITGB3	-0.36	-5.95	-0.31	7.02e-9	IgG glycosylation;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.79	15.0	0.64	4.13e-39	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14813019	chr8:90996956	NBN	0.45	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.23	0.37	3.45e-12	Schizophrenia;
CRC	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg09835421	chr16:68378352	PRMT7	-0.8	-7.63	-0.39	2.55e-13	Magnesium levels;
CRC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.47	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.46	-7.57	-0.39	3.79e-13	IgG glycosylation;
CRC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.58	-0.39	3.59e-13	Coronary artery disease;
CRC	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg27661571	chr11:113659931	NA	-0.67	-7.64	-0.39	2.4e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.49	-6.61	-0.34	1.56e-10	Coronary artery disease;
CRC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.55	8.27	0.41	3.28e-15	High light scatter reticulocyte count;
CRC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg15147215	chr3:52552868	STAB1	-0.53	-9.09	-0.45	9.2e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.92	0.4	3.57e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.56	-6.76	-0.35	6.43e-11	Lymphocyte counts;
CRC	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.0	14.23	0.62	3.96e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs11264799	0.639	rs6677622	chr1:157751356	C/T	cg11810135	chr1:157771971	FCRL1	0.38	5.91	0.31	8.51e-9	IgA nephropathy;
CRC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.54	7.93	0.4	3.52e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs3750082	0.692	rs10248993	chr7:32927147	A/G	cg05721444	chr7:32995514	FKBP9	0.52	6.65	0.34	1.22e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.71	7.79	0.39	8.83e-14	Systolic blood pressure;
CRC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.25	-0.33	1.27e-9	Obesity-related traits;
CRC	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	cis	rs789852	0.867	rs6437391	chr3:194316826	C/T	cg21106136	chr3:194405973	FAM43A	-0.74	-6.17	-0.32	2.06e-9	QT interval;
CRC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.66	-0.3	3.3e-8	Aortic root size;
CRC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-11.57	-0.54	3.45e-26	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.48	7.24	0.37	3.13e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.582	rs2709826	chr4:152332120	G/T	cg09659197	chr4:152720779	NA	0.29	5.65	0.3	3.42e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.23	0.37	3.48e-12	Major depressive disorder;
CRC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs12760731	0.516	rs12403484	chr1:178129059	C/A	cg00404053	chr1:178313656	RASAL2	1.08	11.31	0.53	2.77e-25	Obesity-related traits;
CRC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.4	6.56	0.34	2.14e-10	Longevity;
CRC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.43	6.75	0.35	6.84e-11	Monocyte count;
CRC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.47	6.15	0.32	2.24e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs989128	0.642	rs7214956	chr17:48627148	G/C	cg16068336	chr17:48637367	CACNA1G	-0.54	-7.73	-0.39	1.36e-13	Type 2 diabetes;
CRC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.65	-10.67	-0.51	5.23e-23	Dental caries;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg12564285	chr5:131593104	PDLIM4	0.48	9.29	0.46	2.13e-18	Breast cancer;
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.43	6.29	0.33	1.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg07865391	chr16:88106882	BANP	0.46	6.05	0.32	3.86e-9	Menopause (age at onset);
CRC	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg19773385	chr1:10388646	KIF1B	-0.45	-6.07	-0.32	3.54e-9	Hepatocellular carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19905802	chr11:62554200	TMEM179B;TAF6L	0.39	6.47	0.34	3.62e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	16.63	0.68	1.69e-45	Platelet count;
CRC	cis	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg25886479	chr11:50257625	LOC441601	0.34	5.63	0.3	3.83e-8	Height;
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7680126	0.633	rs4697743	chr4:10294833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.46	-0.34	3.86e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.45	-5.98	-0.31	5.84e-9	Height;
CRC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.29	-0.46	2.22e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg24463073	chr6:118973353	C6orf204	0.48	6.3	0.33	9.45e-10	Diastolic blood pressure;
CRC	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	14.9	0.63	9.8e-39	Mean corpuscular hemoglobin;
CRC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.59	8.61	0.43	3e-16	Lymphocyte counts;
CRC	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.86	15.83	0.66	2.39e-42	Multiple myeloma;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-8.75	-0.43	1.13e-16	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23996948	chr1:61548526	NFIA	0.38	6.21	0.32	1.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg15205204	chr1:6545172	PLEKHG5	0.38	5.61	0.3	4.31e-8	Body mass index;
CRC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.75	0.54	7.43e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs73200209	0.701	rs61939684	chr12:116509365	G/A	cg01776926	chr12:116560359	MED13L	-0.64	-7.35	-0.38	1.57e-12	Total body bone mineral density;
CRC	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg16476235	chr8:21771668	DOK2	0.38	6.21	0.32	1.62e-9	Mean corpuscular volume;
CRC	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg10298567	chr3:47292165	KIF9	0.41	6.38	0.33	5.89e-10	Colorectal cancer;
CRC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.32	-6.03	-0.32	4.32e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01525244	chr22:39548611	CBX7	0.5	6.68	0.35	1e-10	Survival in pancreatic cancer;
CRC	cis	rs1223397	1.000	rs1223399	chr6:13271220	G/A	cg07912922	chr6:13274314	PHACTR1	0.49	6.09	0.32	3.08e-9	Blood pressure;
CRC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.59	-9.28	-0.46	2.37e-18	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.49	6.34	0.33	7.76e-10	Obesity-related traits;
CRC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.52	9.17	0.45	5.4e-18	Schizophrenia;
CRC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg00343986	chr7:65444356	GUSB	0.46	6.82	0.35	4.49e-11	Aortic root size;
CRC	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.14	8.76	0.43	1.03e-16	Economic and political preferences (immigration/crime);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17267720	chr15:34396248	PGBD4	-0.37	-6.26	-0.33	1.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg12564285	chr5:131593104	PDLIM4	0.31	5.64	0.3	3.69e-8	Blood metabolite levels;
CRC	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.7	8.29	0.42	2.98e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.72	0.39	1.45e-13	Motion sickness;
CRC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.54	0.54	4.41e-26	Hip circumference adjusted for BMI;
CRC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.6	-0.34	1.65e-10	HDL cholesterol;
CRC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.09	0.32	3.11e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-7.68	-0.39	1.79e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs12143943	0.966	rs3789047	chr1:204586184	A/G	cg17419461	chr1:204415978	PIK3C2B	0.4	6.18	0.32	1.91e-9	Cognitive performance;
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg07617317	chr6:118971624	C6orf204	0.52	6.47	0.34	3.53e-10	Renal cell carcinoma;
CRC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20623943	chr1:47799834	CMPK1	0.53	7.59	0.39	3.33e-13	Response to antipsychotic treatment;
CRC	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.99	-0.44	1.94e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.73	-9.87	-0.48	2.76e-20	Coronary artery disease;
CRC	cis	rs7781557	0.640	rs2228687	chr7:102616469	G/A	cg18108683	chr7:102477205	FBXL13	0.5	5.96	0.31	6.42e-9	Colorectal adenoma (advanced);
CRC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.06	0.32	3.73e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg20737812	chr15:86336631	KLHL25	-0.35	-5.67	-0.3	3.05e-8	Coronary artery disease;
CRC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-6.92	-0.36	2.3e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg23234261	chr14:55582407	NA	-0.29	-5.7	-0.3	2.69e-8	Protein biomarker;
CRC	cis	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg10928931	chr7:144051247	ARHGEF5	0.46	5.64	0.3	3.75e-8	Obesity-related traits;
CRC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.45	-6.68	-0.35	9.91e-11	Subjective well-being;
CRC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.68	-13.44	-0.6	3.92e-33	Educational attainment;
CRC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.5	-0.34	2.99e-10	Lung cancer;
CRC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.43	-6.44	-0.33	4.21e-10	Ulcerative colitis;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.1	-16.39	-0.67	1.49e-44	Platelet count;
CRC	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.34	-5.91	-0.31	8.51e-9	Mean corpuscular volume;
CRC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.8	-13.52	-0.6	1.97e-33	Menopause (age at onset);
CRC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.48	-7.18	-0.37	4.53e-12	Corneal astigmatism;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.75	12.51	0.57	1.26e-29	Longevity;Endometriosis;
CRC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.44	5.72	0.3	2.43e-8	Response to diuretic therapy;
CRC	cis	rs4731207	0.698	rs13228116	chr7:124480506	A/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.28e-9	Cutaneous malignant melanoma;
CRC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg25767906	chr1:53392781	SCP2	-0.41	-6.57	-0.34	1.92e-10	Monocyte count;
CRC	cis	rs7236492	0.505	rs11663549	chr18:77181989	A/G	cg15644404	chr18:77186268	NFATC1	0.73	7.01	0.36	1.36e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.4	-6.74	-0.35	7.29e-11	Blood metabolite levels;
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg16606324	chr3:10149918	C3orf24	0.57	6.91	0.36	2.47e-11	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22886643	chr4:159690732	FNIP2	0.42	6.05	0.32	4.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.46	6.31	0.33	9.22e-10	Parkinson's disease;
CRC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.48	-8.15	-0.41	7.84e-15	Breast cancer;
CRC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.61	-7.46	-0.38	7.7e-13	Bronchopulmonary dysplasia;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs3785888	0.548	rs11079744	chr17:45027119	A/T	cg16759221	chr17:45003025	GOSR2	-0.71	-10.52	-0.5	1.7e-22	Cleft lip with or without cleft palate;
CRC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.37	0.42	1.62e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.44	-6.7	-0.35	8.93e-11	Cardiovascular disease risk factors;
CRC	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg03909863	chr11:638404	DRD4	-0.51	-6.87	-0.35	3.24e-11	Systemic lupus erythematosus;
CRC	cis	rs9469578	0.792	rs73743331	chr6:33714036	G/T	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.59	0.47	2.24e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.1	0.32	2.91e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07701084	chr6:150067640	NUP43	0.52	7.03	0.36	1.2e-11	Testicular germ cell tumor;
CRC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.38	5.93	0.31	7.63e-9	Height;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.73	-0.35	7.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.54	8.36	0.42	1.84e-15	HDL cholesterol;
CRC	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg09659197	chr4:152720779	NA	0.52	11.15	0.52	1.01e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg05941027	chr17:61774174	LIMD2	0.35	6.02	0.31	4.7e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4700695	0.925	rs12653007	chr5:65396965	G/A	cg21114390	chr5:65439923	SFRS12	-0.49	-6.35	-0.33	7.17e-10	Facial morphology (factor 19);
CRC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.13	-0.61	9.4e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.63	-7.21	-0.37	3.91e-12	Ulcerative colitis;
CRC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.04	-0.48	7.17e-21	Height;
CRC	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.44	7.02	0.36	1.29e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9469913	0.542	rs3800461	chr6:34616322	G/C	cg17674042	chr6:34482479	PACSIN1	-0.74	-7.13	-0.37	6.47e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.17	-0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.49	7.61	0.39	2.9e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17767392	0.645	rs55737377	chr14:71671426	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.48	-5.77	-0.3	1.8e-8	Mitral valve prolapse;
CRC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.44	6.46	0.34	3.8e-10	Coronary artery disease;
CRC	cis	rs4589502	0.800	rs4776855	chr15:67202075	T/C	cg12317470	chr15:67143691	NA	-0.53	-6.63	-0.34	1.37e-10	Lung cancer (smoking interaction);
CRC	cis	rs9846480	0.598	rs3755751	chr3:138065567	A/G	cg25476813	chr3:138050155	TXNDC6	-0.4	-5.89	-0.31	9.56e-9	Whole-brain volume (Alzheimer's disease interaction);
CRC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.71	-0.3	2.59e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6662572	0.703	rs11580953	chr1:46387857	A/G	cg08644498	chr1:46502608	NA	0.44	7.0	0.36	1.45e-11	Blood protein levels;
CRC	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.69	10.77	0.51	2.33e-23	Bipolar disorder;
CRC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.56	8.31	0.42	2.54e-15	Morning vs. evening chronotype;
CRC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg20243544	chr17:37824526	PNMT	0.46	7.17	0.37	5.04e-12	Self-reported allergy;
CRC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.42e-16	Lymphocyte counts;
CRC	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.54	8.31	0.42	2.51e-15	Schizophrenia;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03923535	chr7:1197113	ZFAND2A	0.64	9.25	0.45	3.01e-18	Longevity;Endometriosis;
CRC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.76	-0.51	2.44e-23	Initial pursuit acceleration;
CRC	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.59	8.55	0.43	4.66e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.49	6.94	0.36	2.06e-11	Schizophrenia;
CRC	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.43	-6.94	-0.36	2.05e-11	Lung function (FVC);
CRC	cis	rs11153730	0.503	rs283049	chr6:118635122	G/C	cg15382696	chr6:118971807	C6orf204	-0.38	-5.81	-0.31	1.44e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
CRC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.56	9.06	0.45	1.15e-17	Coronary artery disease;
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	11.42	0.53	1.14e-25	Prudent dietary pattern;
CRC	cis	rs10986311	0.802	rs2416	chr9:127113660	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.42	6.35	0.33	7.03e-10	Vitiligo;
CRC	cis	rs449789	0.817	rs534519	chr6:159711929	A/C	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.46	6.62	0.34	1.46e-10	Response to temozolomide;
CRC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-7.16	-0.37	5.15e-12	Monocyte count;
CRC	cis	rs747650	0.504	rs2087215	chr11:47144542	A/C	cg19486271	chr11:47235900	DDB2	0.44	5.67	0.3	3.2e-8	Acne (severe);
CRC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg00086871	chr4:6988644	TBC1D14	0.9	7.74	0.39	1.2e-13	Granulocyte percentage of myeloid white cells;
CRC	trans	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.41	0.38	1.07e-12	Endometrial cancer;
CRC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.43	6.05	0.32	3.88e-9	Aortic root size;
CRC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg27661571	chr11:113659931	NA	-0.77	-9.65	-0.47	1.43e-19	Hip circumference adjusted for BMI;
CRC	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.62	8.58	0.43	3.82e-16	Menopause (age at onset);
CRC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.67	-0.3	3.2e-8	Gout;Renal underexcretion gout;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05902173	chr6:139013757	NA	0.44	6.24	0.33	1.37e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.15	0.69	1.5e-47	Platelet count;
CRC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.48	-6.9	-0.36	2.63e-11	Mean platelet volume;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg20284698	chr3:48956327	C3orf71;ARIH2	0.36	6.4	0.33	5.35e-10	Interleukin-6 levels;
CRC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.94	0.44	2.89e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs800160	0.777	rs2651781	chr11:2345677	G/A	cg09785033	chr11:2336066	TSPAN32	-0.48	-5.72	-0.3	2.45e-8	Bacteremia;
CRC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg13880726	chr7:1868755	MAD1L1	-0.42	-5.66	-0.3	3.31e-8	Bipolar disorder;
CRC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13198984	chr17:80129470	CCDC57	-0.4	-6.6	-0.34	1.66e-10	Life satisfaction;
CRC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.65	-10.9	-0.52	7.75e-24	Age at first birth;
CRC	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.77	-10.32	-0.49	8.16e-22	Smoking behavior;
CRC	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.16	-0.45	5.84e-18	Prevalent atrial fibrillation;
CRC	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.12	-0.32	2.7e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CRC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg01388757	chr2:102091195	RFX8	0.67	9.17	0.45	5.37e-18	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.1	-0.36	7.76e-12	Pulmonary function;
CRC	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.57	9.93	0.48	1.73e-20	Leprosy;
CRC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.34	-5.69	-0.3	2.83e-8	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22703791	chr19:1479558	C19orf25	-0.47	-7.14	-0.37	5.85e-12	Myopia (pathological);
CRC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.0	-0.36	1.46e-11	Height;
CRC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-7.93	-0.4	3.53e-14	Pancreatic cancer;
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14787946	chr3:138313112	CEP70	0.41	6.45	0.34	3.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.92	-0.4	3.72e-14	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg15845792	chr6:28175446	NA	0.53	7.18	0.37	4.65e-12	Parkinson's disease;
CRC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-8.76	-0.44	1.01e-16	Cognitive function;
CRC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.61	-0.43	2.98e-16	Hemoglobin concentration;
CRC	trans	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg07393940	chr7:158741817	NA	0.5	7.05	0.36	1.05e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg17724175	chr1:150552817	MCL1	0.49	7.28	0.37	2.43e-12	Melanoma;
CRC	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg23711669	chr6:146136114	FBXO30	0.59	9.57	0.47	2.76e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg13385794	chr1:248469461	NA	0.4	7.05	0.36	1.04e-11	Common traits (Other);
CRC	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg16482183	chr6:26056742	HIST1H1C	0.69	8.91	0.44	3.65e-17	Iron status biomarkers;
CRC	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg24130564	chr14:104152367	KLC1	-0.55	-8.42	-0.42	1.14e-15	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07760851	chr11:695000	TMEM80;DEAF1	0.46	5.96	0.31	6.32e-9	Anxiety disorder;
CRC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.53	6.86	0.35	3.41e-11	Longevity;
CRC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.75	-10.64	-0.51	6.61e-23	Blood metabolite levels;
CRC	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	7.22	0.37	3.7e-12	Blood protein levels;
CRC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg21770322	chr7:97807741	LMTK2	0.87	19.64	0.73	2.33e-57	Breast cancer;
CRC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.3	6.1	0.32	2.98e-9	Lung cancer;
CRC	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg01335087	chr22:19950166	COMT	0.23	6.68	0.35	1.01e-10	Blood metabolite levels;
CRC	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg11176159	chr1:28213800	NA	0.3	5.77	0.3	1.79e-8	Corneal astigmatism;
CRC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg11632617	chr15:75315747	PPCDC	-0.56	-7.96	-0.4	2.86e-14	Blood trace element (Zn levels);
CRC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07294406	chr7:64700536	NA	0.35	5.67	0.3	3.1e-8	Calcium levels;
CRC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg13206674	chr6:150067644	NUP43	0.55	7.77	0.39	1.02e-13	Lung cancer;
CRC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.57	8.32	0.42	2.4e-15	Alcohol dependence;
CRC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.27	14.96	0.64	5.61e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.65	-9.49	-0.46	4.7e-19	Longevity;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.71	10.85	0.51	1.17e-23	Longevity;Endometriosis;
CRC	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.41	0.46	8.79e-19	Fuchs's corneal dystrophy;
CRC	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.44	6.68	0.35	1.05e-10	HDL cholesterol;
CRC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.9	-0.36	2.73e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.62	-9.32	-0.46	1.77e-18	Menopause (age at onset);
CRC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-5.95	-0.31	6.79e-9	Major depressive disorder;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.539	rs72987442	chr11:103314023	A/G	cg01615333	chr12:127765195	NA	-0.63	-5.97	-0.31	6.2e-9	Diisocyanate-induced asthma;
CRC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.12	0.59	6.33e-32	Chronic sinus infection;
CRC	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg24304309	chr1:154577895	ADAR	-0.34	-5.74	-0.3	2.18e-8	Blood protein levels;
CRC	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg13401533	chr1:37979913	MEAF6	0.4	5.7	0.3	2.71e-8	Axial length;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17322444	chr19:33572249	GPATCH1	-0.51	-6.28	-0.33	1.05e-9	Diisocyanate-induced asthma;
CRC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs727505	0.754	rs55905546	chr7:124783064	A/C	cg23710748	chr7:124431027	NA	-0.67	-11.43	-0.53	1.04e-25	Lewy body disease;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.45	0.34	3.95e-10	Life satisfaction;
CRC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg03037974	chr15:76606532	NA	0.57	9.52	0.46	3.82e-19	Blood metabolite levels;
CRC	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg09324608	chr17:30823087	MYO1D	-0.35	-5.95	-0.31	6.72e-9	Schizophrenia;
CRC	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.19	-0.67	8.76e-44	Hip circumference;
CRC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg04498913	chr7:1135747	C7orf50	-0.5	-6.29	-0.33	9.95e-10	Bronchopulmonary dysplasia;
CRC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.61	10.39	0.5	4.7e-22	Resting heart rate;
CRC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg27432699	chr2:27873401	GPN1	-0.61	-9.26	-0.45	2.74e-18	Total body bone mineral density;
CRC	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg07513332	chr6:167530253	CCR6	-0.45	-8.24	-0.41	4.23e-15	Primary biliary cholangitis;
CRC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-10.6	-0.5	8.84e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg14631576	chr9:95140430	CENPP	-0.41	-7.24	-0.37	3.14e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg18335740	chr13:41363409	SLC25A15	-0.52	-7.39	-0.38	1.19e-12	Lewy body disease;
CRC	trans	rs783540	0.774	rs28415133	chr15:83264713	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.35	-6.1	-0.32	2.94e-9	Schizophrenia;
CRC	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.34	-5.69	-0.3	2.86e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02987984	chr7:101457447	NA	0.44	6.12	0.32	2.6e-9	Response to antipsychotic treatment;
CRC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-6.04	-0.32	4.23e-9	Alzheimer's disease (late onset);
CRC	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.57	9.78	0.47	5.32e-20	Breast cancer;
CRC	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg26211634	chr5:139558579	C5orf32	-0.37	-6.11	-0.32	2.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg02733842	chr7:1102375	C7orf50	-0.74	-8.64	-0.43	2.5e-16	Bronchopulmonary dysplasia;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg24531977	chr5:56204891	C5orf35	-0.46	-7.37	-0.38	1.4e-12	Coronary artery disease;
CRC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg20243544	chr17:37824526	PNMT	-0.37	-5.7	-0.3	2.72e-8	Self-reported allergy;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	trans	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg01134436	chr17:81009848	B3GNTL1	0.74	6.97	0.36	1.7e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs294883	0.858	rs2340803	chr6:159712800	A/G	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	8.87	0.44	4.74e-17	Schizophrenia;
CRC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg21153622	chr11:89784906	NA	-0.47	-7.55	-0.38	4.44e-13	HDL cholesterol;
CRC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.63	-10.52	-0.5	1.71e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg24046110	chr8:143859143	LYNX1	0.45	7.7	0.39	1.61e-13	Urinary tract infection frequency;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg23161317	chr6:28129485	ZNF389	0.45	6.32	0.33	8.63e-10	Parkinson's disease;
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg04731861	chr2:219085781	ARPC2	0.31	6.47	0.34	3.57e-10	Colorectal cancer;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg12273811	chr6:28175739	NA	0.4	5.91	0.31	8.72e-9	Parkinson's disease;
CRC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.15	-0.37	5.56e-12	Educational attainment;
CRC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.47	-9.32	-0.46	1.73e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22960635	chr16:1543151	TELO2	0.45	6.33	0.33	7.96e-10	Response to antipsychotic treatment;
CRC	cis	rs9292777	0.748	rs10512736	chr5:40395386	T/A	cg09067459	chr5:40385259	NA	-0.56	-9.27	-0.45	2.57e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.6	8.0	0.4	2.16e-14	Mammographic density (dense area);
CRC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.49	9.81	0.48	4.4e-20	Ulcerative colitis;
CRC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.75e-13	Hip circumference adjusted for BMI;
CRC	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg24759859	chr6:86352639	SYNCRIP	0.48	6.59	0.34	1.74e-10	Smooth-surface caries;
CRC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg22777020	chr22:31556080	RNF185	0.55	6.29	0.33	1.01e-9	Colorectal cancer;
CRC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg00343986	chr7:65444356	GUSB	-0.44	-6.17	-0.32	2.02e-9	Aortic root size;
CRC	cis	rs12580194	0.593	rs12296692	chr12:55756851	A/G	cg19537932	chr12:55886519	OR6C68	-0.67	-8.84	-0.44	6.06e-17	Cancer;
CRC	trans	rs11654801	0.812	rs11204327	chr17:20862566	C/T	cg23759823	chr7:139672531	TBXAS1	-0.42	-6.24	-0.33	1.37e-9	Mosquito bite size;
CRC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.68	-8.14	-0.41	8.53e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.81	10.71	0.51	3.7e-23	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.84	15.23	0.64	5.11e-40	Vitiligo;
CRC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.71	-10.35	-0.5	6.34e-22	Lung cancer (smoking interaction);
CRC	cis	rs889398	0.741	rs2362642	chr16:69931458	G/A	cg00738113	chr16:70207722	CLEC18C	-0.4	-6.63	-0.34	1.38e-10	Body mass index;
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg14329157	chr2:228736135	WDR69	-0.44	-6.1	-0.32	3e-9	Blood pressure;
CRC	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.6	-8.49	-0.42	7.44e-16	Waist circumference;Body mass index;
CRC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.51	7.86	0.4	5.66e-14	Aortic root size;
CRC	cis	rs10971721	0.822	rs72727335	chr9:33931718	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24847481	chr1:100435557	SLC35A3	0.39	6.71	0.35	8.55e-11	Obesity-related traits;
CRC	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.67	-0.3	3.1e-8	Electroencephalogram traits;
CRC	trans	rs2303319	0.504	rs56145818	chr2:162403778	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.58	0.47	2.41e-19	Lung cancer;
CRC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.77	-0.3	1.84e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.5	8.34	0.42	2.11e-15	Aortic root size;
CRC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.34	-5.86	-0.31	1.1e-8	Aortic root size;
CRC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.53	-7.61	-0.39	2.93e-13	Breast cancer;
CRC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.49	0.38	6.2800000000000005e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	8.78	0.44	8.81e-17	Schizophrenia;
CRC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.64	-9.25	-0.45	2.93e-18	Menarche (age at onset);
CRC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.47	-6.49	-0.34	3.22e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.68	0.47	1.12e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15687855	chr3:44754131	ZNF502	-0.34	-5.8	-0.3	1.59e-8	Depressive symptoms;
CRC	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.43	6.12	0.32	2.7e-9	Subjective well-being;
CRC	cis	rs7725052	0.609	rs4498294	chr5:40453522	T/C	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.18	-0.41	6.47e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.55	-8.49	-0.42	7.35e-16	Asthma (sex interaction);
CRC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg00343986	chr7:65444356	GUSB	-0.5	-7.43	-0.38	9.64e-13	Aortic root size;
CRC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.79	-10.4	-0.5	4.19e-22	Initial pursuit acceleration;
CRC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.71e-21	Aortic root size;
CRC	cis	rs9847710	1.000	rs13088455	chr3:53087482	C/G	cg04503182	chr3:53078218	SFMBT1	-0.45	-7.18	-0.37	4.53e-12	Ulcerative colitis;
CRC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg12927641	chr6:109611667	NA	-0.35	-6.23	-0.32	1.4e-9	Reticulocyte fraction of red cells;
CRC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-0.76	-9.17	-0.45	5.2e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg05673287	chr15:77411982	SGK269	0.56	8.23	0.41	4.45e-15	Type 2 diabetes;
CRC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg11212589	chr17:38028394	ZPBP2	0.36	6.71	0.35	8.34e-11	Self-reported allergy;
CRC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.61	0.39	2.9e-13	Axial length;
CRC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11645453	chr3:52864694	ITIH4	0.46	9.18	0.45	4.9e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.73	7.7	0.39	1.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.58	9.56	0.47	2.84e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.56	-9.04	-0.45	1.37e-17	Lung cancer in ever smokers;
CRC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-9.49	-0.46	5.01e-19	Alcohol dependence;
CRC	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.63	10.32	0.49	7.86e-22	Corneal structure;
CRC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.65	-9.74	-0.47	7.28e-20	Diastolic blood pressure;
CRC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.57	-6.0	-0.31	5.12e-9	White matter hyperintensity burden;
CRC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.17e-9	Menopause (age at onset);
CRC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.38	8.7	0.43	1.67e-16	Multiple system atrophy;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	10.12	0.49	3.89e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg23161317	chr6:28129485	ZNF389	0.47	6.64	0.34	1.28e-10	Parkinson's disease;
CRC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.28e-13	Heart rate;
CRC	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-0.96	-9.32	-0.46	1.78e-18	Post bronchodilator FEV1;
CRC	cis	rs71403859	0.803	rs34381861	chr16:71640230	T/C	cg08717414	chr16:71523259	ZNF19	-1.14	-10.91	-0.52	7.62e-24	Post bronchodilator FEV1;
CRC	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24718819	chr3:194033680	NA	0.38	6.19	0.32	1.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg06287003	chr12:125626642	AACS	-0.59	-7.68	-0.39	1.81e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg18721089	chr20:30220636	NA	-0.37	-5.85	-0.31	1.2e-8	Mean corpuscular hemoglobin;
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	6.99	0.36	1.54e-11	Bipolar disorder;
CRC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.34	-9.69	-0.47	1.08e-19	Mean corpuscular volume;
CRC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg16141378	chr3:129829833	LOC729375	0.46	6.83	0.35	4.18e-11	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25580254	chr12:8088937	SLC2A3	-0.58	-9.33	-0.46	1.64e-18	Liver disease severity in Alagille syndrome;
CRC	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg03316587	chr8:142245164	NA	0.43	6.8	0.35	4.91e-11	Birth weight;
CRC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.67	9.85	0.48	3.2e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg26248373	chr2:1572462	NA	-0.63	-7.15	-0.37	5.54e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.67	7.22	0.37	3.61e-12	Axial length;
CRC	cis	rs8170	0.859	rs11540855	chr19:17403361	A/G	cg04749549	chr19:17459798	NA	-0.46	-6.06	-0.32	3.74e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19628164	chr3:143689916	C3orf58	0.4	6.37	0.33	6.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.38	-6.94	-0.36	2.15e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg16898833	chr6:26189333	HIST1H4D	0.84	6.93	0.36	2.27e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg03469862	chr11:68924853	NA	0.46	5.91	0.31	8.56e-9	Blond vs. brown hair color;
CRC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	10.52	0.5	1.61e-22	Personality dimensions;
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.41	5.65	0.3	3.46e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.79	-0.44	8.4e-17	Personality dimensions;
CRC	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.55	5.7	0.3	2.62e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.0	0.4	2.19e-14	Platelet count;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.54	-7.6	-0.39	3.1e-13	Gut microbiome composition (summer);
CRC	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg08946332	chr17:6899888	ALOX12	0.34	5.78	0.3	1.76e-8	Tonsillectomy;
CRC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg02527881	chr3:46936655	PTH1R	0.38	6.9	0.36	2.65e-11	Colorectal cancer;
CRC	cis	rs2712184	0.687	rs62180470	chr2:217645451	A/G	cg05032264	chr2:217675019	NA	0.33	5.8	0.3	1.56e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-6.43	-0.33	4.62e-10	Height;
CRC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg15445000	chr17:37608096	MED1	0.27	5.95	0.31	6.8e-9	Asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25113610	chr2:74007324	DUSP11	0.44	6.09	0.32	3.13e-9	Response to antipsychotic treatment;
CRC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg11901034	chr3:128598214	ACAD9	-0.53	-6.34	-0.33	7.46e-10	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.74	0.35	7.01e-11	Axial length;
CRC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.57	-0.39	3.84e-13	Gut microbiome composition (summer);
CRC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.19	0.69	1.08e-47	Platelet count;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg15786705	chr6:28176104	NA	0.57	6.36	0.33	6.77e-10	Parkinson's disease;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Parkinson's disease;
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg15382696	chr6:118971807	C6orf204	0.61	7.88	0.4	4.86e-14	Diastolic blood pressure;
CRC	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.97	-13.73	-0.6	3.12e-34	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	0.91	8.76	0.43	1.03e-16	Diabetic retinopathy;
CRC	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.91	-0.4	4.07e-14	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg00343986	chr7:65444356	GUSB	0.45	6.27	0.33	1.12e-9	Aortic root size;
CRC	cis	rs6988985	0.530	rs57268571	chr8:143942602	A/G	cg10324643	chr8:143916377	GML	0.36	6.04	0.32	4.18e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.64	9.47	0.46	5.45e-19	Menopause (age at onset);
CRC	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.26	-0.37	2.9e-12	Systolic blood pressure;
CRC	cis	rs1656402	1.000	rs6749955	chr2:233437917	A/C	cg03852847	chr2:233439513	NA	0.45	7.64	0.39	2.44e-13	Non-small cell lung cancer (survival);
CRC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-7.38	-0.38	1.34e-12	Menarche (age at onset);
CRC	cis	rs972578	1.000	rs2010366	chr22:43381288	T/G	cg01576275	chr22:43409880	NA	-0.46	-6.96	-0.36	1.88e-11	Mean platelet volume;
CRC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-7.3	-0.37	2.12e-12	Hemoglobin concentration;
CRC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg09876464	chr15:85330779	ZNF592	0.45	7.66	0.39	2.05e-13	P wave terminal force;
CRC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg02725872	chr8:58115012	NA	-0.44	-6.61	-0.34	1.51e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17344085	chr7:100450162	SLC12A9	0.42	6.59	0.34	1.74e-10	Intelligence (multi-trait analysis);
CRC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.17	-0.37	5.07e-12	Mean corpuscular volume;
CRC	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.47	-0.38	7.35e-13	Psoriasis;
CRC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.28	-0.33	1.09e-9	QT interval;
CRC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.25	-16.79	-0.68	3.81e-46	Breast cancer;
CRC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.75	0.68	5.43e-46	Chronic sinus infection;
CRC	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg06484146	chr7:12443880	VWDE	-0.63	-6.52	-0.34	2.61e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01204964	chr21:35014044	ITSN1;CRYZL1	0.39	6.48	0.34	3.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-0.95	-11.98	-0.55	1.13e-27	Vitiligo;
CRC	cis	rs4594175	0.926	rs4131365	chr14:51622444	C/T	cg23942311	chr14:51606299	NA	0.64	10.31	0.49	8.54e-22	Cancer;
CRC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.38	7.31	0.37	2e-12	Iron status biomarkers;
CRC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-1.11	-13.32	-0.59	1.11e-32	Obesity-related traits;
CRC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.42e-9	Red blood cell count;
CRC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg05941027	chr17:61774174	LIMD2	0.35	6.31	0.33	8.87e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1552172	0.887	rs4970874	chr1:145709394	T/C	cg11743829	chr1:145714124	CD160	-0.41	-6.09	-0.32	3.19e-9	Breast cancer;
CRC	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg14530993	chr4:882597	GAK	0.79	7.2	0.37	4.22e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.35	5.7	0.3	2.64e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg20936604	chr3:58311152	NA	-0.76	-7.27	-0.37	2.69e-12	Cholesterol, total;
CRC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.55	0.34	2.22e-10	Lung cancer;
CRC	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.94	-0.31	7.15e-9	Alzheimer's disease (survival time);
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.21	-0.32	1.57e-9	Total body bone mineral density;
CRC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.29e-10	Childhood ear infection;
CRC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.16	0.52	9.94e-25	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23713156	chr17:80606235	WDR45L	0.42	6.72	0.35	7.93e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2380220	0.808	rs2380224	chr6:95895553	C/T	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg11645453	chr3:52864694	ITIH4	-0.42	-7.78	-0.39	9.3e-14	Body mass index;
CRC	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg01339444	chr6:118972232	C6orf204	0.55	6.14	0.32	2.35e-9	Diastolic blood pressure;
CRC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg05623727	chr3:50126028	RBM5	-0.44	-7.47	-0.38	7.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.79	11.6	0.54	2.58e-26	High light scatter reticulocyte count;
CRC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.97	-0.36	1.7e-11	Total cholesterol levels;
CRC	cis	rs9992667	0.910	rs28681431	chr4:38687928	G/A	cg19726192	chr4:38663646	FLJ13197	-0.7	-8.92	-0.44	3.35e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.53	7.5	0.38	6.03e-13	Response to temozolomide;
CRC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.47	9.06	0.45	1.17e-17	Alcohol dependence;
CRC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg09417038	chr21:47716443	C21orf57	-0.41	-6.35	-0.33	6.97e-10	Testicular germ cell tumor;
CRC	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.77	-15.48	-0.65	5.34e-41	Mean corpuscular hemoglobin;
CRC	cis	rs713477	0.678	rs4901566	chr14:55912663	C/A	cg13175173	chr14:55914753	NA	-0.43	-7.73	-0.39	1.29e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.53	7.81	0.4	7.65e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.62	9.08	0.45	1.04e-17	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg27398640	chr15:77910606	LINGO1	0.4	6.84	0.35	3.92e-11	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20304401	chr8:101733920	PABPC1	0.43	6.51	0.34	2.8e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.5	7.45	0.38	8.43e-13	Platelet distribution width;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.22	-0.56	1.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.52	7.8	0.4	8.25e-14	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05770837	chr13:45915717	LOC100190939;TPT1	0.46	5.99	0.31	5.59e-9	Thyroid stimulating hormone;
CRC	cis	rs11212617	0.967	rs605394	chr11:108243628	C/T	cg12106634	chr11:108092400	ATM;NPAT	-0.4	-5.74	-0.3	2.11e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2012796	0.719	rs12434434	chr14:81826129	C/A	cg02996355	chr14:81879375	NA	0.38	5.64	0.3	3.66e-8	Night sleep phenotypes;
CRC	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.58	8.37	0.42	1.68e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.77	-0.44	9.58e-17	Platelet count;
CRC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg25985355	chr7:65971099	NA	-0.47	-5.72	-0.3	2.39e-8	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.59	8.33	0.42	2.17e-15	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13789711	chr9:139743225	PHPT1	0.48	6.11	0.32	2.75e-9	Thyroid stimulating hormone;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06710349	chr5:139737425	NA	0.43	6.22	0.32	1.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg16576597	chr16:28551801	NUPR1	0.46	7.1	0.36	7.75e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.65	-11.08	-0.52	1.78e-24	Iron status biomarkers;
CRC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-15.88	-0.66	1.53e-42	Cognitive function;
CRC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.82	11.62	0.54	2.27e-26	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00333034	chr3:183948058	VWA5B2	0.43	5.98	0.31	5.83e-9	Anxiety disorder;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg24046110	chr8:143859143	LYNX1	0.49	8.57	0.43	4.14e-16	Urinary tract infection frequency;
CRC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-10.44	-0.5	3.18e-22	Multiple sclerosis;
CRC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.18e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Dilated cardiomyopathy;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg13491945	chr12:107078410	RFX4	-0.33	-5.62	-0.3	4.15e-8	Heart rate;
CRC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	1.02	18.52	0.71	5.84e-53	Parkinson's disease;
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg12516270	chr8:143859308	LYNX1	0.42	7.46	0.38	7.65e-13	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17955420	chr15:40987771	RAD51	0.45	6.38	0.33	6e-10	Response to antipsychotic treatment;
CRC	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.78	0.66	3.59e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.74	0.35	6.98e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9462027	0.585	rs1201873	chr6:34550657	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.01	-0.31	4.82e-9	Systemic lupus erythematosus;
CRC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg16235748	chr6:149772707	ZC3H12D	-0.39	-6.99	-0.36	1.5e-11	Dupuytren's disease;
CRC	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg19418318	chr19:17219073	MYO9B	0.41	6.61	0.34	1.51e-10	Reticulocyte fraction of red cells;
CRC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.27	-0.41	3.39e-15	Gut microbiome composition (summer);
CRC	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg14631576	chr9:95140430	CENPP	-0.3	-5.63	-0.3	3.78e-8	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08237663	chr3:130745839	NEK11;ASTE1	0.54	6.88	0.35	3.01e-11	Thyroid stimulating hormone;
CRC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg19554555	chr3:13937349	NA	0.43	6.25	0.33	1.28e-9	Ovarian reserve;
CRC	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-6.96	-0.36	1.88e-11	HDL cholesterol;
CRC	cis	rs6000550	0.954	rs13055107	chr22:37469821	G/A	cg07819160	chr22:37420328	MPST	0.5	5.61	0.3	4.25e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
CRC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.92	0.31	8.15e-9	Diabetic retinopathy;
CRC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.48	8.18	0.41	6.16e-15	Common traits (Other);
CRC	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.87	-0.31	1.05e-8	Pulmonary function;
CRC	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.74	13.52	0.6	2.06e-33	Lewy body disease;
CRC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.31e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.46	6.67	0.35	1.07e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.17e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs10046574	0.831	rs77819442	chr7:135072552	C/T	cg27474649	chr7:135195673	CNOT4	0.7	5.67	0.3	3.12e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.39	0.56	3.4e-29	Alzheimer's disease;
CRC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.76	-7.32	-0.37	1.87e-12	Diabetic retinopathy;
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.63	8.35	0.42	1.9e-15	Alzheimer's disease;
CRC	cis	rs4731207	0.536	rs7792731	chr7:124653436	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.52	-6.13	-0.32	2.48e-9	Gut microbiome composition (summer);
CRC	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-7.72	-0.39	1.39e-13	Homocysteine levels;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.64	10.21	0.49	1.91e-21	Height;
CRC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.41	6.35	0.33	7.32e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.94	-12.66	-0.57	3.25e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	0.74	9.33	0.46	1.63e-18	Prostate cancer;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.5	-7.22	-0.37	3.62e-12	Blood metabolite levels;
CRC	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.49	6.31	0.33	9.24e-10	Cholesterol, total;
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.27	0.33	1.11e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.56	9.01	0.44	1.78e-17	Type 2 diabetes;
CRC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.49	-6.88	-0.35	2.98e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg19318889	chr4:1322082	MAEA	0.44	6.5	0.34	2.89e-10	Obesity-related traits;
CRC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs9903692	0.865	rs7220520	chr17:46167942	A/G	cg21215337	chr17:46176117	CBX1	0.44	8.38	0.42	1.56e-15	Pulse pressure;
CRC	cis	rs17767392	0.958	rs61989377	chr14:71957362	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.23	-0.37	3.5e-12	Mitral valve prolapse;
CRC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09597638	chr17:3907349	NA	0.64	11.08	0.52	1.83e-24	Type 2 diabetes;
CRC	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg00603274	chr11:61596626	FADS2	-0.49	-6.92	-0.36	2.42e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.38	-5.74	-0.3	2.19e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg24644049	chr4:85504048	CDS1	0.87	7.08	0.36	8.68e-12	Skin colour saturation;
CRC	cis	rs427941	0.703	rs201454	chr7:101740056	A/G	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.37	-0.33	6.41e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg25876840	chr17:41920477	NA	0.62	8.55	0.43	4.6e-16	Triglycerides;
CRC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.83	-0.72	3.33e-54	Height;
CRC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg05043794	chr9:111880884	C9orf5	-0.33	-5.77	-0.3	1.82e-8	Menarche (age at onset);
CRC	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.46	8.34	0.42	2.06e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-0.96	-16.89	-0.68	1.61e-46	Height;
CRC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13198984	chr17:80129470	CCDC57	-0.46	-8.0	-0.4	2.13e-14	Life satisfaction;
CRC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg11766577	chr21:47581405	C21orf56	-0.4	-6.24	-0.33	1.33e-9	Testicular germ cell tumor;
CRC	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg11946769	chr3:48343235	NME6	-0.44	-5.88	-0.31	1.02e-8	Educational attainment (years of education);
CRC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg24140574	chr1:16342155	HSPB7	0.43	6.26	0.33	1.22e-9	Systolic blood pressure;
CRC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.47	0.53	7.29e-26	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.66e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.73	-0.3	2.29e-8	Electroencephalogram traits;
CRC	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.57	6.2	0.32	1.71e-9	Menarche (age at onset);
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.74	-0.51	2.95e-23	Bipolar disorder;
CRC	cis	rs7259376	0.902	rs8112041	chr19:22604565	C/T	cg02657401	chr19:22469223	NA	0.3	6.59	0.34	1.8e-10	Menopause (age at onset);
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg04969067	chr8:143858791	LYNX1	0.45	7.57	0.39	3.86e-13	Urinary tract infection frequency;
CRC	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13736514	chr6:26305472	NA	-0.46	-7.63	-0.39	2.53e-13	Educational attainment;
CRC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg15107132	chr11:63991130	FERMT3	-0.36	-5.91	-0.31	8.32e-9	Platelet count;
CRC	trans	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg17903999	chr18:56338584	MALT1	0.42	7.06	0.36	9.77e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.31e-10	Tonsillectomy;
CRC	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.28	-0.33	1.05e-9	Eye color traits;
CRC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.72	-7.11	-0.36	7.33e-12	Diabetic retinopathy;
CRC	cis	rs4073416	0.542	rs6573614	chr14:65958703	G/A	cg03016385	chr14:66212404	NA	-0.4	-5.66	-0.3	3.31e-8	N-glycan levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04804616	chr16:30622014	ZNF689	0.52	6.59	0.34	1.78e-10	Thyroid stimulating hormone;
CRC	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg27499820	chr13:21296301	IL17D	-0.4	-6.23	-0.32	1.46e-9	Dental caries;
CRC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.17	0.52	9.08e-25	Prudent dietary pattern;
CRC	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.4	5.91	0.31	8.78e-9	Pulmonary function;
CRC	trans	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg19862616	chr7:65841803	NCRNA00174	0.77	9.16	0.45	5.74e-18	Eotaxin levels;
CRC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.84	12.72	0.57	1.98e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg15845792	chr6:28175446	NA	0.77	11.38	0.53	1.54e-25	Parkinson's disease;
CRC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	8.87	0.44	4.6e-17	Platelet count;
CRC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.52	-9.21	-0.45	3.81e-18	Sense of smell;
CRC	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.39	5.75	0.3	2.07e-8	Growth-regulated protein alpha levels;
CRC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg03030879	chr14:75389066	RPS6KL1	0.42	6.4	0.33	5.21e-10	Height;
CRC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg24562669	chr7:97807699	LMTK2	0.41	6.85	0.35	3.6e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.68	-0.39	1.87e-13	Cholesterol, total;
CRC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg11070056	chr1:107600091	PRMT6	-0.42	-6.05	-0.32	3.95e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg16892393	chr17:41919603	NA	0.47	7.12	0.37	6.81e-12	Triglycerides;
CRC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.52	-8.02	-0.4	1.83e-14	Body mass index;
CRC	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-8.57	-0.43	3.95e-16	Ulcerative colitis;
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18402987	chr7:1209562	NA	0.44	6.53	0.34	2.49e-10	Longevity;Endometriosis;
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.73	-0.43	1.26e-16	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.84	14.84	0.63	1.73e-38	Blood protein levels;
CRC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg13072238	chr3:49761600	GMPPB	-0.54	-5.85	-0.31	1.19e-8	Menarche (age at onset);
CRC	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-14.55	-0.63	2.15e-37	Colorectal cancer;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.54e-18	Bladder cancer;
CRC	cis	rs12541635	0.677	rs6469032	chr8:107057509	A/T	cg10147462	chr8:107024639	NA	0.63	11.34	0.53	2.23e-25	Age of smoking initiation;
CRC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.91	15.22	0.64	5.41e-40	Parkinson's disease;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg00622528	chr6:41040237	C6orf130;NFYA	0.42	6.17	0.32	1.99e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.39	6.55	0.34	2.25e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09835421	chr16:68378352	PRMT7	-0.6	-5.76	-0.3	1.93e-8	Schizophrenia;
CRC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.56	-0.38	3.96e-13	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.82	0.44	6.92e-17	Morning vs. evening chronotype;
CRC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.28	-0.42	3.19e-15	Morning vs. evening chronotype;
CRC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.48	7.48	0.38	6.75e-13	Response to interferon beta in multiple sclerosis;
CRC	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg23254163	chr1:152506842	NA	0.49	9.78	0.47	5.49e-20	Hair morphology;
CRC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.34	5.78	0.3	1.75e-8	Mean corpuscular hemoglobin;
CRC	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.41	-6.2	-0.32	1.71e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.69	0.39	1.67e-13	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24265806	chr7:23053737	FAM126A	0.35	6.45	0.34	3.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.03	-0.36	1.17e-11	Putamen volume;
CRC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.39e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.66	-11.6	-0.54	2.63e-26	Educational attainment;
CRC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg21747405	chr11:67723411	NA	-0.49	-6.32	-0.33	8.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg03037974	chr15:76606532	NA	0.7	12.32	0.56	6.18e-29	Blood metabolite levels;
CRC	cis	rs524281	0.684	rs7946447	chr11:65864338	T/C	cg16950941	chr11:66035639	RAB1B	-0.58	-7.41	-0.38	1.06e-12	Electroencephalogram traits;
CRC	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-6.18	-0.32	1.92e-9	Metabolite levels;
CRC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg06970220	chr1:156163860	SLC25A44	0.52	7.51	0.38	5.47e-13	Testicular germ cell tumor;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.09	0.32	3.24e-9	Prudent dietary pattern;
CRC	cis	rs713477	0.505	rs8019080	chr14:55891372	C/T	cg13175173	chr14:55914753	NA	-0.44	-7.13	-0.37	6.42e-12	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg12682573	chr17:27188876	MIR451;MIR144	0.53	7.64	0.39	2.35e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.32	0.67	2.75e-44	Electrocardiographic conduction measures;
CRC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.5	-8.29	-0.42	2.87e-15	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01297674	chr2:122406765	CLASP1	0.48	6.7	0.35	9.22e-11	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.15	-0.32	2.21e-9	Cognitive function;
CRC	cis	rs6496667	0.779	rs7163560	chr15:91038620	A/T	cg04176472	chr15:90893244	GABARAPL3	0.53	7.72	0.39	1.37e-13	Rheumatoid arthritis;
CRC	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.62	-9.02	-0.45	1.64e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.04	-0.41	1.68e-14	Systolic blood pressure;
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02725872	chr8:58115012	NA	-0.59	-9.18	-0.45	4.97e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	8.16	0.41	7.3e-15	Cognitive test performance;
CRC	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.48	0.34	3.31e-10	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14455487	chr1:42800860	FOXJ3	0.44	6.18	0.32	1.89e-9	Anxiety disorder;
CRC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20887711	chr4:1340912	KIAA1530	-0.44	-6.38	-0.33	6.07e-10	Obesity-related traits;
CRC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.29	0.53	3.23e-25	Motion sickness;
CRC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	1.03	18.54	0.71	4.77e-53	Parkinson's disease;
CRC	trans	rs12517041	1.000	rs2099091	chr5:23295532	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs6076065	0.676	rs6076057	chr20:23335982	G/T	cg11657817	chr20:23433608	CST11	-0.5	-7.33	-0.37	1.79e-12	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.6	-8.59	-0.43	3.44e-16	Coronary artery disease;
CRC	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.34	5.71	0.3	2.58e-8	Major depressive disorder;
CRC	cis	rs3764400	0.567	rs12936369	chr17:46270696	C/T	cg10706073	chr17:46328419	SKAP1	-0.61	-6.7	-0.35	8.9e-11	Body mass index;
CRC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg03013999	chr17:37608204	MED1	0.45	6.97	0.36	1.77e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.51	0.34	2.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	8.09	0.41	1.19e-14	Platelet count;
CRC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.54	7.44	0.38	8.64e-13	Total body bone mineral density;
CRC	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.53	6.89	0.35	2.9100000000000002e-11	Blood protein levels;
CRC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-20.96	-0.76	1.47e-62	Primary sclerosing cholangitis;
CRC	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.4	-6.45	-0.33	4.04e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.04	-0.32	4.27e-9	Height;
CRC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.75	-8.75	-0.43	1.16e-16	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.67	0.47	1.25e-19	Alzheimer's disease;
CRC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.72	10.6	0.5	9.06e-23	Immature fraction of reticulocytes;
CRC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.3	0.53	3.14e-25	Tonsillectomy;
CRC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.68	-0.39	1.88e-13	Neuroticism;
CRC	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.45	7.33	0.37	1.74e-12	Total cholesterol levels;
CRC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.49	-9.22	-0.45	3.62e-18	Reticulocyte fraction of red cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10954261	chr6:11094075	LOC221710	0.46	6.14	0.32	2.35e-9	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.9	-0.31	8.81e-9	Life satisfaction;
CRC	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.03	0.68	4.35e-47	Electrocardiographic conduction measures;
CRC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg01721255	chr8:58191610	C8orf71	0.51	6.33	0.33	7.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.59	9.86	0.48	2.95e-20	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg06634786	chr22:41940651	POLR3H	-0.43	-5.81	-0.31	1.46e-8	Neuroticism;
CRC	cis	rs815815	0.583	rs878665	chr2:47403129	G/T	cg27223769	chr2:47403360	CALM2	-0.55	-7.35	-0.38	1.57e-12	Dialysis-related mortality;
CRC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	13.49	0.6	2.56e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.59	-0.47	2.33e-19	Migraine;Coronary artery disease;
CRC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg10431340	chr1:161279108	MPZ	-0.55	-7.39	-0.38	1.23e-12	Rheumatoid arthritis;
CRC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg10494257	chr1:16342123	HSPB7	0.44	5.7	0.3	2.67e-8	Dilated cardiomyopathy;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg16280098	chr14:23790882	PABPN1	0.46	6.43	0.33	4.6e-10	Hip circumference;
CRC	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.53	8.83	0.44	6.34e-17	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.59	5.88	0.31	1.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25595571	chr14:104029029	BAG5;C14orf153	0.43	7.01	0.36	1.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.66	-10.87	-0.51	1.01e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.57	-9.3	-0.46	2.01e-18	Myopia (pathological);
CRC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs4728302	0.838	rs2042453	chr7:133580730	G/A	cg03336402	chr7:133662267	EXOC4	-0.44	-6.37	-0.33	6.53e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg15654264	chr1:150340011	RPRD2	0.38	5.92	0.31	8.09e-9	Migraine;
CRC	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.49	7.77	0.39	9.9e-14	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00802000	chr16:706648	WDR90	-0.41	-5.84	-0.31	1.22e-8	Height;
CRC	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.89	10.92	0.52	6.84e-24	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.45e-11	Dilated cardiomyopathy;
CRC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.63	8.06	0.41	1.45e-14	Hip circumference adjusted for BMI;
CRC	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-5.89	-0.31	9.57e-9	Alzheimer's disease (survival time);
CRC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.68	9.77	0.47	5.75e-20	Vitamin D levels;
CRC	cis	rs8105895	0.877	rs28822164	chr19:22245108	C/A	cg02657401	chr19:22469223	NA	-0.34	-5.67	-0.3	3.15e-8	Body mass index (change over time);
CRC	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.28	-0.69	4.62e-48	Schizophrenia;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.43	7.46	0.38	7.78e-13	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14546197	chr17:38137043	PSMD3	0.41	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.48	7.41	0.38	1.09e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs501120	1.000	rs694425	chr10:44761804	C/G	cg09554077	chr10:44749378	NA	0.73	10.64	0.51	6.55e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.66	11.79	0.54	5.46e-27	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04480227	chr20:61904058	ARFGAP1	0.41	6.15	0.32	2.27e-9	Response to antipsychotic treatment;
CRC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.83	-9.96	-0.48	1.37e-20	Bronchopulmonary dysplasia;
CRC	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.41	6.2	0.32	1.66e-9	Endometrial cancer;
CRC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.8	-0.3	1.55e-8	Breast cancer;
CRC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.49	-7.74	-0.39	1.21e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg02336364	chr1:24764700	NIPAL3	0.37	6.22	0.32	1.53e-9	Response to interferon beta in multiple sclerosis;
CRC	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.56	8.4	0.42	1.33e-15	Blood protein levels;
CRC	cis	rs370915	0.963	rs59452206	chr4:187816484	G/T	cg12892747	chr4:187813459	NA	-0.41	-6.02	-0.32	4.62e-9	Gout;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20092199	chr4:1342459	KIAA1530	0.43	7.6	0.39	3.17e-13	Longevity;
CRC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.51	7.22	0.37	3.63e-12	Pancreatic cancer;
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.02	-0.4	1.91e-14	Electroencephalogram traits;
CRC	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	0.89	11.89	0.55	2.31e-27	Blood protein levels;
CRC	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.82	0.35	4.44e-11	Triglycerides;
CRC	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg00042356	chr1:8021962	PARK7	0.63	7.17	0.37	4.84e-12	Inflammatory bowel disease;
CRC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg07636037	chr3:49044803	WDR6	-0.82	-6.7	-0.35	9.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.68e-17	Bipolar disorder;
CRC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.74	-0.47	7.57e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.42	-8.07	-0.41	1.3e-14	Ulcerative colitis;
CRC	cis	rs7215564	0.908	rs2316059	chr17:78663732	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs4964805	1.000	rs4964805	chr12:104192824	C/G	cg02344784	chr12:104178138	NT5DC3	0.55	8.27	0.41	3.28e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.49	-6.82	-0.35	4.42e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-7.57	-0.39	3.7e-13	Hepatocellular carcinoma;
CRC	trans	rs2018683	0.700	rs13227954	chr7:29017188	A/C	cg19402173	chr7:128379420	CALU	0.47	6.83	0.35	4.18e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.49	6.63	0.34	1.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg14844989	chr11:31128820	NA	0.35	6.18	0.32	1.94e-9	Red blood cell count;
CRC	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.47	-7.52	-0.38	5.29e-13	Schizophrenia;
CRC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.49	6.39	0.33	5.8e-10	Alzheimer's disease (survival time);
CRC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.47	-6.51	-0.34	2.83e-10	Eosinophil percentage of white cells;
CRC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.51	-7.55	-0.38	4.4e-13	Sudden cardiac arrest;
CRC	trans	rs4714291	0.802	rs1923465	chr6:39971376	A/T	cg02267698	chr19:7991119	CTXN1	-0.51	-6.87	-0.35	3.15e-11	Strep throat;
CRC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.18	0.37	4.6e-12	Life satisfaction;
CRC	cis	rs11203032	0.831	rs11203019	chr10:90952774	A/T	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg15786705	chr6:28176104	NA	0.58	8.22	0.41	4.65e-15	Parkinson's disease;
CRC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.6	-0.43	3.21e-16	Hemoglobin concentration;
CRC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg16070123	chr10:51489643	NA	-0.34	-5.85	-0.31	1.2e-8	Prostate-specific antigen levels;
CRC	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.25	0.33	1.28e-9	Ovarian reserve;
CRC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.67	0.43	1.98e-16	Morning vs. evening chronotype;
CRC	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	6.51	0.34	2.85e-10	Coronary artery disease;
CRC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg10589385	chr1:150898437	SETDB1	0.27	5.87	0.31	1.07e-8	Melanoma;
CRC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg09654669	chr8:57350985	NA	-0.43	-5.81	-0.31	1.44e-8	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.96	-19.23	-0.73	9.03e-56	Height;
CRC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.82	13.67	0.6	5.17e-34	Menopause (age at onset);
CRC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25371950	chr2:242786524	NA	0.36	6.19	0.32	1.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.76	15.88	0.66	1.53e-42	Age-related hearing impairment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05815685	chr19:36036576	TMEM147	0.36	6.0	0.31	5.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.74	-0.3	2.12e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg24011408	chr12:48396354	COL2A1	0.4	5.71	0.3	2.47e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.24	-0.41	4.18e-15	Mean platelet volume;
CRC	cis	rs3849570	0.533	rs6809792	chr3:81990084	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-6.4	-0.33	5.35e-10	Waist circumference;Body mass index;
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg07414643	chr4:187882934	NA	-0.36	-6.12	-0.32	2.6e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.38	6.05	0.32	3.86e-9	Major depressive disorder;
CRC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.77	0.44	9.87e-17	Hip circumference adjusted for BMI;
CRC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg06740227	chr12:86229804	RASSF9	-0.38	-5.85	-0.31	1.17e-8	Major depressive disorder;
CRC	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.33	-6.76	-0.35	6.29e-11	Alzheimer's disease (late onset);
CRC	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.88	10.68	0.51	4.85e-23	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.57	-8.77	-0.44	1.01e-16	Bipolar disorder;
CRC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg03909863	chr11:638404	DRD4	-0.51	-6.6	-0.34	1.62e-10	Systemic lupus erythematosus;
CRC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.98	-0.44	2.17e-17	Alcohol dependence;
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.32	5.68	0.3	2.94e-8	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs4780401	0.933	rs4780396	chr16:11816671	G/A	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.61	-0.3	4.32e-8	Rheumatoid arthritis;
CRC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.33	0.53	2.35e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.82	-9.99	-0.48	1.04e-20	Blood pressure (smoking interaction);
CRC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	8.1	0.41	1.05e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.51e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.42	6.25	0.33	1.28e-9	Longevity;Endometriosis;
CRC	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg13385794	chr1:248469461	NA	0.35	6.39	0.33	5.79e-10	Common traits (Other);
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg22638593	chr5:131593259	PDLIM4	0.47	8.57	0.43	4.13e-16	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.54	-0.38	4.73e-13	Putamen volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19590290	chr4:104119639	CENPE	0.4	6.04	0.32	4.25e-9	Response to antipsychotic treatment;
CRC	cis	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg07460842	chr6:66804631	NA	-0.43	-5.78	-0.3	1.72e-8	Blood trace element (Cu levels);
CRC	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg15212455	chr7:39170539	POU6F2	0.45	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.46	7.72	0.39	1.41e-13	Major depressive disorder;
CRC	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg07884673	chr3:53033167	SFMBT1	0.76	6.04	0.32	4.25e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.46	-6.37	-0.33	6.41e-10	Fibrinogen levels;
CRC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg06917450	chr1:38156652	C1orf109	-0.48	-6.87	-0.35	3.13e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.6	-9.08	-0.45	1e-17	Pancreatic cancer;
CRC	cis	rs10486722	0.606	rs2190338	chr7:41787240	A/G	cg22138096	chr7:41772439	LOC285954	0.45	5.77	0.3	1.87e-8	Pit-and-Fissure caries;
CRC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.81	0.35	4.74e-11	Morning vs. evening chronotype;
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg26028573	chr6:26043587	HIST1H2BB	0.42	6.26	0.33	1.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.46	-6.95	-0.36	1.95e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.46	-9.48	-0.46	5.43e-19	Dupuytren's disease;
CRC	trans	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg17903999	chr18:56338584	MALT1	0.43	7.01	0.36	1.39e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23708337	chr7:1209742	NA	0.45	6.65	0.34	1.22e-10	Longevity;Endometriosis;
CRC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.51	-0.38	5.65e-13	Coronary artery disease;
CRC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.94	-0.4	3.16e-14	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg25173405	chr17:45401733	C17orf57	0.4	5.99	0.31	5.51e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.77	0.44	9.61e-17	Cognitive test performance;
CRC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.25	-0.33	1.3e-9	Colorectal cancer;
CRC	cis	rs17021463	0.555	rs7693950	chr4:95324901	A/T	cg11021082	chr4:95130006	SMARCAD1	0.39	5.64	0.3	3.6e-8	Testicular germ cell tumor;
CRC	trans	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.85	-0.35	3.75e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.61	-9.28	-0.46	2.37e-18	Body mass index;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.3	-0.46	2.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.29	6.15	0.32	2.27e-9	Homoarginine levels;
CRC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.6	8.13	0.41	8.81e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.26	-0.33	1.22e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.6	-8.66	-0.43	2.11e-16	Coronary artery disease;
CRC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg05044414	chr3:183734942	ABCC5	0.47	8.11	0.41	1.03e-14	Anterior chamber depth;
CRC	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg18753928	chr3:113234510	CCDC52	-0.57	-6.64	-0.34	1.26e-10	Dental caries;
CRC	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.44	6.7	0.35	8.94e-11	C-reactive protein levels;
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.27	0.75	7.25e-60	Prudent dietary pattern;
CRC	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.48	9.02	0.45	1.62e-17	Age-related hearing impairment;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg12273811	chr6:28175739	NA	0.75	10.54	0.5	1.48e-22	Depression;
CRC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.38	-6.95	-0.36	1.91e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9434723	0.841	rs12083129	chr1:9311323	G/A	cg04199779	chr1:9294473	H6PD	0.51	5.72	0.3	2.45e-8	Height;
CRC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.39	0.33	5.77e-10	Aortic root size;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.58	-8.57	-0.43	4.21e-16	Aortic root size;
CRC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-8.03	-0.4	1.71e-14	Total cholesterol levels;
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.65	7.42	0.38	1.03e-12	Body mass index;
CRC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10802521	chr3:52805072	NEK4	0.46	6.29	0.33	9.92e-10	Bipolar disorder;
CRC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg03929089	chr4:120376271	NA	-0.47	-6.62	-0.34	1.44e-10	HDL cholesterol;
CRC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg18016565	chr1:150552671	MCL1	-0.43	-6.3	-0.33	9.32e-10	Tonsillectomy;
CRC	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.52	7.34	0.37	1.72e-12	Body mass index (adult);
CRC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg05585544	chr11:47624801	NA	-0.62	-11.41	-0.53	1.22e-25	Subjective well-being;
CRC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg08314208	chr16:67682810	RLTPR	-0.58	-6.36	-0.33	6.74e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.3	0.53	3.07e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.54	-8.04	-0.41	1.62e-14	Obesity-related traits;
CRC	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.5	6.33	0.33	7.9e-10	Recombination rate (females);
CRC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.39	-6.79	-0.35	5.33e-11	Height;
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.71	-8.45	-0.42	9.58e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.27	-0.56	9.46e-29	Idiopathic membranous nephropathy;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1436351	0.683	rs7616848	chr3:104620951	G/T	cg09862801	chr2:45396991	NA	0.47	5.99	0.31	5.57e-9	Body mass index;
CRC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.23	0.32	1.41e-9	Menopause (age at onset);
CRC	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg21625330	chr8:9911636	MSRA	0.55	6.05	0.32	3.92e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.67	0.63	7.66e-38	Platelet count;
CRC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.6	8.51	0.42	6.3e-16	Longevity;
CRC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.43	8.68	0.43	1.82e-16	Vitiligo;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01591470	chr14:39736043	CTAGE5	0.37	6.05	0.32	3.86e-9	Obesity-related traits;
CRC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.54	8.03	0.4	1.73e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02387613	chr3:133380479	TOPBP1	0.45	6.52	0.34	2.6200000000000003e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.49	7.37	0.38	1.39e-12	Menarche (age at onset);
CRC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.61	9.9	0.48	2.08e-20	Coronary artery disease;
CRC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.66	12.54	0.57	9.25e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13082711	0.520	rs2724494	chr3:27563920	C/A	cg02860705	chr3:27208620	NA	0.42	6.17	0.32	2.05e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7703744	0.634	rs3797340	chr5:118691737	C/G	cg23985447	chr5:118691066	TNFAIP8	0.42	6.02	0.31	4.71e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.66	-9.77	-0.47	5.91e-20	Total body bone mineral density;
CRC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	9.22	0.45	3.56e-18	Personality dimensions;
CRC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.66	9.54	0.47	3.46e-19	Longevity;
CRC	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg09065629	chr16:1709722	CRAMP1L	0.9	9.15	0.45	5.99e-18	Snoring;
CRC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.53	7.11	0.37	7.11e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg15786705	chr6:28176104	NA	0.52	6.06	0.32	3.69e-9	Depression;
CRC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.44	6.82	0.35	4.4e-11	Corneal astigmatism;
CRC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.29	-0.49	1.06e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg08314208	chr16:67682810	RLTPR	-0.49	-5.97	-0.31	5.98e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.48	-7.88	-0.4	4.99e-14	Congenital heart disease (maternal effect);
CRC	trans	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.83	-0.35	4.14e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg08027265	chr7:2291960	NA	0.46	7.83	0.4	6.56e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.38	-6.69	-0.35	9.86e-11	Primary biliary cholangitis;
CRC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.41	6.1	0.32	2.98e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.47	5.92	0.31	8.03e-9	Metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04849129	chr2:191513396	NAB1	0.42	6.02	0.31	4.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.49	-0.42	7.39e-16	Monocyte count;
CRC	trans	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.14	-0.64	1.2e-39	Gut microbiome composition (summer);
CRC	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.31	0.37	2.01e-12	Eye color traits;
CRC	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.72	-0.72	9.47e-54	Schizophrenia;
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-6.64	-0.34	1.3100000000000001e-10	Total body bone mineral density;
CRC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.28	-0.33	1.05e-9	Life satisfaction;
CRC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.87	0.44	4.6e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.87	-0.4	5.21e-14	Gut microbiome composition (summer);
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg05569086	chr8:143859399	LYNX1	0.38	6.62	0.34	1.42e-10	Urinary tract infection frequency;
CRC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.85e-9	Aortic root size;
CRC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25517755	chr10:38738941	LOC399744	0.41	5.98	0.31	5.66e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs727505	0.754	rs56056794	chr7:124783027	C/T	cg23710748	chr7:124431027	NA	-0.67	-11.44	-0.53	9.61e-26	Lewy body disease;
CRC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.86	9.57	0.47	2.6e-19	Breast cancer;
CRC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.27	-0.71	5.69e-52	Height;
CRC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	11.98	0.55	1.1e-27	Height;
CRC	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.73	12.65	0.57	3.78e-30	Multiple myeloma;
CRC	cis	rs6479527	0.875	rs914295	chr9:96816843	C/A	cg14459158	chr9:96720562	NA	0.38	6.79	0.35	5.13e-11	Esophageal adenocarcinoma;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg16239906	chr20:35724590	RBL1	0.44	6.98	0.36	1.68e-11	Crohn's disease;
CRC	cis	rs9409565	0.586	rs58057339	chr9:97117788	T/C	cg04523069	chr9:97136363	HIATL1	-0.47	-6.35	-0.33	7.32e-10	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg16558208	chr1:156270281	VHLL	0.58	9.04	0.45	1.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.75	-0.35	6.59e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.54	8.2	0.41	5.59e-15	Testicular germ cell tumor;
CRC	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.49	-6.13	-0.32	2.58e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	8.99	0.44	1.96e-17	Cognitive test performance;
CRC	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg21839984	chr17:30846986	MYO1D	-0.33	-5.64	-0.3	3.68e-8	Schizophrenia;
CRC	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.63	-8.19	-0.41	5.99e-15	Migraine;Coronary artery disease;
CRC	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg20356878	chr3:121714668	ILDR1	0.51	7.9	0.4	4.1e-14	Cognitive performance;
CRC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg18709589	chr6:96969512	KIAA0776	-0.46	-5.93	-0.31	7.72e-9	Migraine;Coronary artery disease;
CRC	cis	rs7487075	0.823	rs34472481	chr12:46836348	C/G	cg22049899	chr12:47219821	SLC38A4	0.32	6.44	0.33	4.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.66	0.6	5.95e-34	Alzheimer's disease;
CRC	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.61	9.26	0.45	2.81e-18	Dementia with Lewy bodies;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg15786705	chr6:28176104	NA	0.79	10.68	0.51	4.77e-23	Depression;
CRC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg10820045	chr2:198174542	NA	0.55	9.19	0.45	4.68e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-15.23	-0.64	5.21e-40	Vitiligo;
CRC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24308560	chr3:49941425	MST1R	0.45	7.06	0.36	9.95e-12	Intelligence (multi-trait analysis);
CRC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.21	-26.44	-0.82	2.1e-83	Triglycerides;
CRC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.55	-7.91	-0.4	4e-14	Height;
CRC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.93	-16.57	-0.67	2.9e-45	Headache;
CRC	cis	rs58649573	0.509	rs10739635	chr9:126792086	A/G	cg14112217	chr9:126806003	NA	0.39	5.78	0.3	1.71e-8	Post-traumatic stress disorder;
CRC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18912574	chr7:65842487	NCRNA00174	0.33	5.66	0.3	3.37e-8	Aortic root size;
CRC	cis	rs4728302	0.807	rs10226267	chr7:133601862	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.78	0.3	1.76e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.45	-0.42	9.79e-16	Electroencephalogram traits;
CRC	cis	rs28489187	0.706	rs12124170	chr1:85811182	A/G	cg17737388	chr1:85724454	C1orf52	0.37	5.63	0.3	3.91e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-0.56	-7.62	-0.39	2.74e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg25164649	chr6:28176230	NA	0.57	7.55	0.38	4.3e-13	Parkinson's disease;
CRC	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06307176	chr5:131281290	NA	-0.4	-6.1	-0.32	2.9e-9	Life satisfaction;
CRC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.54	8.4	0.42	1.36e-15	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.22	-0.41	4.67e-15	Morning vs. evening chronotype;
CRC	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.14	-0.32	2.36e-9	Metabolite levels;
CRC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg12064134	chr16:90016061	DEF8	-0.69	-6.13	-0.32	2.54e-9	Skin colour saturation;
CRC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.49	9.75	0.47	6.84e-20	Iron status biomarkers (transferrin levels);
CRC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.89	-15.95	-0.66	7.68e-43	Height;
CRC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.6	0.3	4.52e-8	Lung cancer;
CRC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-9.31	-0.46	1.82e-18	Personality dimensions;
CRC	trans	rs4965598	0.958	rs4965593	chr15:100758385	C/G	cg05653646	chr5:139173162	NA	-0.44	-6.02	-0.31	4.66e-9	Height;
CRC	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.54	8.27	0.42	3.24e-15	Coronary artery disease;
CRC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.72	8.73	0.43	1.35e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	0.71	9.42	0.46	8.32e-19	Alzheimer's disease;
CRC	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg16898833	chr6:26189333	HIST1H4D	1.05	7.54	0.38	4.49e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.77	8.31	0.42	2.57e-15	Fat distribution (HIV);
CRC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg10589385	chr1:150898437	SETDB1	0.3	6.23	0.32	1.44e-9	Tonsillectomy;
CRC	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.04	-0.32	4.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.8	-0.63	2.42e-38	Exhaled nitric oxide output;
CRC	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.74	-12.1	-0.55	4.09e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.32	0.46	1.79e-18	Endometrial cancer;
CRC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.77	0.35	6.07e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg26061582	chr7:22766209	IL6	0.52	7.29	0.37	2.33e-12	Lung cancer;
CRC	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg26353448	chr1:248524236	OR2T4	-0.34	-6.93	-0.36	2.27e-11	Common traits (Other);
CRC	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.73	10.54	0.5	1.4e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.3	0.46	2.07e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04603834	chr13:50571387	TRIM13;DLEU2	0.45	6.25	0.33	1.28e-9	Response to antipsychotic treatment;
CRC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.25	15.13	0.64	1.26e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.96	15.65	0.65	1.23e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs216303	1.000	rs216298	chr12:6156477	C/T	cg19878637	chr12:6148451	VWF	-0.54	-6.14	-0.32	2.43e-9	Low vWF levels;
CRC	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.77	9.45	0.46	6.33e-19	Type 2 diabetes;
CRC	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.48	8.57	0.43	3.97e-16	Testicular germ cell tumor;
CRC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.6	7.56	0.38	4.03e-13	Dilated cardiomyopathy;
CRC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.8	14.31	0.62	1.96e-36	Breast cancer;
CRC	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.61	-8.69	-0.43	1.77e-16	Coronary artery disease;
CRC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17371350	chr17:655677	ELP2P;GEMIN4	0.42	7.08	0.36	8.54e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.16	12.98	0.58	2.18e-31	Mitochondrial DNA levels;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg08798685	chr6:27730294	NA	-0.44	-6.47	-0.34	3.6e-10	Parkinson's disease;
CRC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-7.65	-0.39	2.25e-13	Schizophrenia;
CRC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg06740227	chr12:86229804	RASSF9	0.38	5.62	0.3	4.06e-8	Major depressive disorder;
CRC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.65	-0.34	1.2e-10	Coronary artery disease;
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs783540	0.967	rs1269134	chr15:83282628	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.27	-0.33	1.13e-9	Schizophrenia;
CRC	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.44	-6.84	-0.35	3.81e-11	Asthma;
CRC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.31	-0.33	9.1e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11768411	chr8:144329279	ZFP41	0.37	6.14	0.32	2.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.05e-10	Life satisfaction;
CRC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.4	-6.14	-0.32	2.34e-9	HDL cholesterol;
CRC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg10546459	chr2:36825355	FEZ2	-0.52	-7.35	-0.38	1.55e-12	Height;
CRC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.34	-0.38	1.69e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.36	5.69	0.3	2.86e-8	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs17767392	0.918	rs17767410	chr14:71771967	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg26838691	chr2:24397539	C2orf84	0.41	5.72	0.3	2.46e-8	Asthma;
CRC	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg23750338	chr8:142222470	SLC45A4	0.4	6.12	0.32	2.62e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg04731861	chr2:219085781	ARPC2	0.34	6.99	0.36	1.57e-11	Colorectal cancer;
CRC	cis	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg17469321	chr7:55412551	NA	0.71	10.54	0.5	1.47e-22	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.76	-10.48	-0.5	2.24e-22	White matter hyperintensity burden;
CRC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.67	9.53	0.46	3.69e-19	Vitamin D levels;
CRC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.78	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs698833	0.852	rs698761	chr2:44547574	A/G	cg04920474	chr2:44395004	PPM1B	-0.41	-6.11	-0.32	2.79e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg21153622	chr11:89784906	NA	-0.44	-7.12	-0.37	6.86e-12	HDL cholesterol;
CRC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg00325661	chr8:49890786	NA	0.36	6.5	0.34	3.03e-10	Sudden cardiac arrest;
CRC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg05527609	chr1:210001259	C1orf107	0.57	6.42	0.33	4.72e-10	Red blood cell count;
CRC	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg15687855	chr3:44754131	ZNF502	-0.35	-5.87	-0.31	1.07e-8	Depressive symptoms;
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg12564285	chr5:131593104	PDLIM4	0.45	7.55	0.38	4.27e-13	Acylcarnitine levels;
CRC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-6.17	-0.32	1.99e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.59	8.92	0.44	3.42e-17	Bronchopulmonary dysplasia;
CRC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.85	15.68	0.65	8.75e-42	Menopause (age at onset);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09670790	chr13:76056027	TBC1D4	0.38	6.0	0.31	5.3e-9	Schizophrenia;
CRC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.43	5.7	0.3	2.69e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02018176	chr4:1364513	KIAA1530	0.37	6.17	0.32	2.03e-9	Longevity;
CRC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.68	11.5	0.54	6.01e-26	Alzheimer's disease (late onset);
CRC	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.83	0.44	6.36e-17	Corneal astigmatism;
CRC	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.91	-0.36	2.46e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs6076065	0.723	rs8183442	chr20:23415563	C/T	cg11657817	chr20:23433608	CST11	0.44	6.3	0.33	9.49e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4321325	0.733	rs4284778	chr2:127946326	A/G	cg11380483	chr2:127933992	NA	0.6	7.65	0.39	2.18e-13	Protein C levels;
CRC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.31	-5.89	-0.31	9.46e-9	Inflammatory skin disease;
CRC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	6.1	0.32	2.99e-9	Obesity-related traits;
CRC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-11.63	-0.54	2.05e-26	Chronic sinus infection;
CRC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.33	0.42	2.22e-15	Menarche (age at onset);
CRC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.09	0.36	8.45e-12	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16553574	chr7:64839175	ZNF92	0.44	6.73	0.35	7.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg09127314	chr1:152161683	NA	0.47	6.02	0.31	4.67e-9	Atopic dermatitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25266327	chr19:16435660	KLF2	-0.44	-6.75	-0.35	6.56e-11	Myopia (pathological);
CRC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg14004847	chr7:1930337	MAD1L1	0.41	5.85	0.31	1.2e-8	Schizophrenia;
CRC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.48	-5.63	-0.3	3.83e-8	Body mass index (adult);
CRC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.82	0.4	7.4e-14	Lung cancer;
CRC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs720844	0.684	rs7597133	chr2:149317833	G/A	cg09247360	chr2:149335327	NA	-0.56	-6.03	-0.32	4.49e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg09873164	chr1:152488093	CRCT1	0.37	6.29	0.33	1e-9	Hair morphology;
CRC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.73	-15.53	-0.65	3.42e-41	Refractive error;
CRC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg18512352	chr11:47633146	NA	-0.4	-7.77	-0.39	9.9e-14	Subjective well-being;
CRC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.2	0.32	1.7e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.44	-8.5	-0.42	6.94e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs76533333	0.646	rs12861423	chr13:113387084	C/A	cg04656015	chr13:113407548	ATP11A	0.75	5.75	0.3	2.09e-8	Red cell distribution width;
CRC	cis	rs1552172	0.887	rs12402867	chr1:145636226	G/A	cg11743829	chr1:145714124	CD160	-0.4	-6.09	-0.32	3.23e-9	Breast cancer;
CRC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-0.95	-9.42	-0.46	8.46e-19	Breast cancer;
CRC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.43	5.8	0.3	1.57e-8	Schizophrenia;
CRC	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg01858014	chr14:56050164	KTN1	-0.92	-7.32	-0.37	1.89e-12	Putamen volume;
CRC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.49	6.26	0.33	1.23e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4664293	0.605	rs2042774	chr2:160510007	G/T	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.67	-11.07	-0.52	2.03e-24	Mean platelet volume;
CRC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.16	0.37	5.38e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.57	0.57	7.41e-30	Coronary artery disease;
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg05569086	chr8:143859399	LYNX1	0.39	6.68	0.35	1.04e-10	Urinary tract infection frequency;
CRC	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg19635926	chr16:89946313	TCF25	0.69	5.82	0.31	1.37e-8	Skin colour saturation;
CRC	cis	rs1223397	0.938	rs34505804	chr6:13292514	G/A	cg00460589	chr6:13274354	PHACTR1	0.5	6.0	0.31	5.11e-9	Blood pressure;
CRC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-5.82	-0.31	1.39e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg05044414	chr3:183734942	ABCC5	0.49	8.34	0.42	2.09e-15	Anterior chamber depth;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg03623178	chr6:28175578	NA	0.77	11.27	0.53	4.05e-25	Parkinson's disease;
CRC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11777890	chr11:119205047	RNF26	-0.5	-6.19	-0.32	1.76e-9	Monocyte percentage of white cells;
CRC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.4	6.34	0.33	7.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.63	11.36	0.53	1.82e-25	Schizophrenia;
CRC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23378565	chr7:2036160	MAD1L1	-0.45	-6.37	-0.33	6.48e-10	Bipolar disorder;
CRC	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.47	-7.09	-0.36	8.29e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1555895	0.568	rs4097329	chr10:844839	T/C	cg10556349	chr10:835070	NA	-0.4	-7.68	-0.39	1.78e-13	Survival in rectal cancer;
CRC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.39	-0.33	5.65e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg11070056	chr1:107600091	PRMT6	0.4	5.7	0.3	2.66e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.61	-10.1	-0.49	4.42e-21	Dupuytren's disease;
CRC	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	11.92	0.55	1.78e-27	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23065101	chr7:100964734	RABL5	0.43	6.61	0.34	1.51e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7113874	0.569	rs4929942	chr11:8625096	A/G	cg17679104	chr11:8615758	STK33	0.37	6.33	0.33	8.02e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9462027	0.628	rs66506671	chr6:34777149	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.93	-0.31	7.48e-9	Systemic lupus erythematosus;
CRC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg26805224	chr10:79626177	DLG5	-0.54	-8.07	-0.41	1.29e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.88	13.06	0.58	1.07e-31	Diastolic blood pressure;
CRC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.84	-0.35	3.85e-11	Monocyte percentage of white cells;
CRC	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.6	8.42	0.42	1.21e-15	Uric acid levels;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.4	-5.64	-0.3	3.67e-8	Longevity;Endometriosis;
CRC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-21.02	-0.76	8.45e-63	Hemostatic factors and hematological phenotypes;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	8.72	0.43	1.36e-16	Ulcerative colitis;
CRC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg03030879	chr14:75389066	RPS6KL1	0.4	6.02	0.32	4.56e-9	Height;
CRC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.78	13.5	0.6	2.29e-33	Breast cancer;
CRC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.87	15.36	0.65	1.65e-40	Blood protein levels;
CRC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.55	-7.31	-0.37	2.06e-12	DNA methylation (variation);
CRC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.46	-6.35	-0.33	7.11e-10	Multiple myeloma;
CRC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.03	0.52	2.87e-24	Motion sickness;
CRC	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.31	5.82	0.31	1.41e-8	Pulse pressure;
CRC	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.51	-0.34	2.75e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6499129	0.867	rs11859352	chr16:67390448	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.36	-0.33	6.71e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.55	9.53	0.47	3.62e-19	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg27494647	chr7:150038898	RARRES2	0.35	5.8	0.3	1.56e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg05874882	chr4:1763078	NA	0.38	6.94	0.36	2.13e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg21770322	chr7:97807741	LMTK2	0.86	19.33	0.73	3.72e-56	Breast cancer;
CRC	cis	rs394563	0.601	rs432582	chr6:149794143	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.48	-7.52	-0.38	5.34e-13	Dupuytren's disease;
CRC	trans	rs9815354	0.857	rs12108064	chr3:42016217	C/T	cg04440885	chr16:51146856	NA	0.52	6.04	0.32	4.21e-9	Pulse pressure;Diastolic blood pressure;
CRC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.36	-6.51	-0.34	2.89e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.49	7.48	0.38	6.88e-13	Schizophrenia;
CRC	cis	rs4664293	0.867	rs12617546	chr2:160623590	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.99	-0.74	9.26e-59	Primary sclerosing cholangitis;
CRC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.65	-10.51	-0.5	1.83e-22	Dental caries;
CRC	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg09695851	chr17:3907499	NA	0.84	16.38	0.67	1.64e-44	Type 2 diabetes;
CRC	cis	rs6594499	0.872	rs7702774	chr5:110460851	G/T	cg04022379	chr5:110408740	TSLP	0.47	7.31	0.37	2.11e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.7	-12.16	-0.56	2.34e-28	Asthma;
CRC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.5	9.88	0.48	2.55e-20	Ulcerative colitis;
CRC	cis	rs9287719	0.624	rs10199831	chr2:10726863	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg21251018	chr6:28226885	NKAPL	0.51	5.95	0.31	6.9e-9	Depression;
CRC	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.23	6.54	0.34	2.39e-10	Type 2 diabetes;
CRC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.62	-9.89	-0.48	2.34e-20	Aortic root size;
CRC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.83	15.01	0.64	3.56e-39	Breast cancer;
CRC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.42e-13	Red blood cell count;
CRC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.5	9.58	0.47	2.47e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	7.91	0.4	4.03e-14	Bipolar disorder;
CRC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.65	-9.56	-0.47	2.96e-19	Total body bone mineral density;
CRC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg15107132	chr11:63991130	FERMT3	-0.39	-6.37	-0.33	6.23e-10	Platelet count;
CRC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg03623178	chr6:28175578	NA	0.81	7.83	0.4	6.91e-14	Depression;
CRC	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg03934865	chr2:198174659	NA	-0.45	-7.12	-0.37	6.84e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg24851651	chr11:66362959	CCS	-0.38	-6.56	-0.34	2.09e-10	Educational attainment (years of education);
CRC	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.66	-0.39	2.07e-13	Bipolar disorder;
CRC	cis	rs7703744	0.681	rs11957102	chr5:118701899	G/T	cg02283238	chr5:118691126	TNFAIP8	0.45	6.04	0.32	4.08e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg12458913	chr13:53173898	NA	-0.5	-7.49	-0.38	6.3e-13	Lewy body disease;
CRC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.51	8.36	0.42	1.77e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg12639453	chr1:2035780	PRKCZ	-0.42	-8.33	-0.42	2.2e-15	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27186011	chr3:49840712	C3orf54	0.42	6.09	0.32	3.09e-9	Anxiety disorder;
CRC	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg21496419	chr19:44306685	LYPD5	-0.32	-5.76	-0.3	1.98e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.43	6.83	0.35	4.07e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.31	-0.37	2.09e-12	Mean corpuscular volume;
CRC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.68	0.54	1.28e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.99	0.31	5.4e-9	Body mass index;
CRC	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.91	-11.47	-0.53	7.68e-26	Blood protein levels;
CRC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.64	-0.34	1.29e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.59	9.93	0.48	1.66e-20	Prudent dietary pattern;
CRC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg00717180	chr2:96193071	NA	-0.37	-5.97	-0.31	6.27e-9	HDL cholesterol;
CRC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.62	0.47	1.82e-19	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26980138	chr12:68726465	MDM1	0.43	6.12	0.32	2.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.07	0.45	1.1e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.45	6.76	0.35	6.23e-11	Type 2 diabetes;
CRC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.72	-11.01	-0.52	3.22e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2652834	1.000	rs4344684	chr15:63397318	C/T	cg05507819	chr15:63340323	TPM1	0.46	5.97	0.31	6.13e-9	HDL cholesterol;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05977900	chr3:182512126	ATP11B	0.5	6.37	0.33	6.24e-10	Thyroid stimulating hormone;
CRC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.43	0.38	9.44e-13	Motion sickness;
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	0.7	7.84	0.4	6.44e-14	Body mass index;
CRC	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg27398640	chr15:77910606	LINGO1	0.41	7.77	0.39	1.03e-13	Type 2 diabetes;
CRC	cis	rs9287719	0.649	rs10183359	chr2:10733044	G/A	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg08200770	chr17:80723486	TBCD	-0.41	-6.57	-0.34	1.98e-10	Glycated hemoglobin levels;
CRC	cis	rs755249	0.567	rs3754346	chr1:39814960	C/T	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.48	6.27	0.33	1.11e-9	Recombination rate (females);
CRC	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.73	-11.17	-0.52	8.96e-25	Waist circumference;Body mass index;
CRC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.8	-0.39	8.34e-14	Intelligence (multi-trait analysis);
CRC	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.73	-12.49	-0.57	1.4e-29	Brugada syndrome;
CRC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.43	-8.02	-0.4	1.84e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.75	0.39	1.14e-13	Menopause (age at onset);
CRC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.12e-10	Mean platelet volume;
CRC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.07	0.32	3.5e-9	Monocyte percentage of white cells;
CRC	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.81	-0.31	1.48e-8	Response to antipsychotic treatment;
CRC	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.57	9.78	0.47	5.51e-20	Menarche (age at onset);
CRC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.41	5.61	0.3	4.19e-8	Intelligence (multi-trait analysis);
CRC	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg15786705	chr6:28176104	NA	-0.55	-5.99	-0.31	5.54e-9	Depression;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg15845792	chr6:28175446	NA	0.77	11.41	0.53	1.22e-25	Parkinson's disease;
CRC	cis	rs526821	0.789	rs10896993	chr11:55303410	A/G	cg04317927	chr11:55418816	OR4S2	0.42	7.46	0.38	7.7e-13	Pediatric bone mineral density (spine);
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.25	0.41	3.98e-15	Alzheimer's disease;
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg08888203	chr3:10149979	C3orf24	-0.72	-8.81	-0.44	7.32e-17	Alzheimer's disease;
CRC	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg03929089	chr4:120376271	NA	0.63	6.01	0.31	4.92e-9	Axial length;
CRC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.29	0.33	1.02e-9	Lung cancer;
CRC	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.58	-10.09	-0.49	5.01e-21	Leprosy;
CRC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.5	8.31	0.42	2.54e-15	Coronary artery disease;
CRC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg15147215	chr3:52552868	STAB1	-0.65	-11.31	-0.53	2.75e-25	Electroencephalogram traits;
CRC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.5	6.95	0.36	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.83	0.55	3.7e-27	Longevity;
CRC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.58	-8.06	-0.41	1.4e-14	Response to antineoplastic agents;
CRC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.4	-0.38	1.16e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg23815491	chr16:72088622	HP	0.64	8.12	0.41	9.28e-15	Blood protein levels;
CRC	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg03315344	chr16:75512273	CHST6	0.49	5.9	0.31	8.99e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	8.68	0.43	1.93e-16	Cognitive test performance;
CRC	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-9.53	-0.47	3.46e-19	Blood protein levels;
CRC	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.37	-5.9	-0.31	8.89e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4924997	0.772	rs2018675	chr17:19441531	A/G	cg19949948	chr17:19361230	NA	0.36	6.2	0.32	1.64e-9	Lymphocyte counts;
CRC	cis	rs6764363	0.535	rs331897	chr3:279688	G/A	cg02057681	chr3:285234	CHL1	0.48	7.62	0.39	2.71e-13	Sudden cardiac arrest;
CRC	cis	rs9783347	1.000	rs4353250	chr11:18323517	T/C	cg15585147	chr11:18324498	HPS5	0.43	6.03	0.32	4.37e-9	Pancreatic cancer;
CRC	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.58	-9.55	-0.47	3.2e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs17234274	0.622	rs16910894	chr11:23238516	C/G	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.42	-8.27	-0.41	3.45e-15	Mean corpuscular volume;
CRC	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.71	-9.19	-0.45	4.51e-18	Blood protein levels;
CRC	trans	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg09045935	chr12:6379348	NA	1.14	9.25	0.45	2.99e-18	Blood metabolite levels;
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.56	-0.43	4.4e-16	Electroencephalogram traits;
CRC	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-7.15	-0.37	5.52e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.21	0.45	3.97e-18	Cognitive test performance;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18640608	chr19:13001970	GCDH	-0.51	-6.05	-0.32	4e-9	Diisocyanate-induced asthma;
CRC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00339695	chr16:24857497	SLC5A11	0.27	6.39	0.33	5.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg11204139	chr17:3907470	NA	0.75	14.23	0.62	3.77e-36	Type 2 diabetes;
CRC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.51	-8.43	-0.42	1.09e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.42	6.03	0.32	4.31e-9	Erythrocyte sedimentation rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20877313	chr12:56881753	GLS2	0.43	6.24	0.33	1.38e-9	Response to antipsychotic treatment;
CRC	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.74	-9.84	-0.48	3.28e-20	White matter hyperintensity burden;
CRC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg11189052	chr15:85197271	WDR73	0.59	8.36	0.42	1.75e-15	Schizophrenia;
CRC	cis	rs2486012	0.850	rs42962	chr1:44298564	A/C	cg12908607	chr1:44402522	ARTN	-0.41	-5.94	-0.31	7.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Bladder cancer;
CRC	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.75	9.77	0.47	5.9e-20	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	1.0	9.7	0.47	9.69e-20	Lymphocyte counts;
CRC	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.6	-9.24	-0.45	3.24e-18	Ulcerative colitis;
CRC	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.94	-12.64	-0.57	4.16e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.4	-8.0	-0.4	2.19e-14	Mean corpuscular volume;
CRC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.51	-8.98	-0.44	2.13e-17	Coronary artery disease;
CRC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.81	13.74	0.6	2.82e-34	Coronary artery disease;
CRC	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.53	6.95	0.36	1.99e-11	Hypertension (SNP x SNP interaction);
CRC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.46	6.61	0.34	1.51e-10	Lymphocyte counts;
CRC	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.62	9.32	0.46	1.78e-18	Dementia with Lewy bodies;
CRC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg24562669	chr7:97807699	LMTK2	-0.68	-12.88	-0.58	5.32e-31	Breast cancer;
CRC	cis	rs9361491	0.657	rs7382016	chr6:79455781	A/T	cg05283184	chr6:79620031	NA	0.38	5.82	0.31	1.38e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.31	-5.71	-0.3	2.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs61160187	0.582	rs10939879	chr5:60315823	T/C	cg16298547	chr5:60138761	ELOVL7	-0.26	-5.73	-0.3	2.3e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg19077165	chr18:44547161	KATNAL2	0.43	6.29	0.33	1.03e-9	Educational attainment;
CRC	cis	rs3849570	0.615	rs9817070	chr3:81982936	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-6.39	-0.33	5.64e-10	Waist circumference;Body mass index;
CRC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.52	9.08	0.45	1.05e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.33	6.07e-10	Vitiligo;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12273811	chr6:28175739	NA	0.62	8.29	0.42	2.87e-15	Parkinson's disease;
CRC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.41	-6.27	-0.33	1.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.91	-0.36	2.59e-11	Multiple sclerosis;
CRC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg22777020	chr22:31556080	RNF185	-0.53	-6.14	-0.32	2.34e-9	Colorectal cancer;
CRC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg27427491	chr17:78079615	GAA	0.44	5.98	0.31	5.67e-9	Yeast infection;
CRC	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.58	8.12	0.41	9.54e-15	Height;
CRC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.68	8.97	0.44	2.37e-17	Morning vs. evening chronotype;
CRC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.81	14.77	0.63	3.04e-38	Metabolic syndrome;
CRC	cis	rs59901009	0.863	rs56758314	chr11:10192648	C/T	cg23875677	chr11:10229755	SBF2	-0.48	-6.08	-0.32	3.37e-9	Hematocrit;Hemoglobin concentration;
CRC	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.59	8.55	0.43	4.66e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.3	-0.71	4.33e-52	Height;
CRC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg23533926	chr12:111358616	MYL2	-0.54	-8.02	-0.4	1.85e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg19875535	chr5:140030758	IK	-0.59	-9.67	-0.47	1.2e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg09658497	chr7:2847517	GNA12	-0.37	-5.86	-0.31	1.14e-8	Height;
CRC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.03	0.32	4.45e-9	Diabetic retinopathy;
CRC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.69	-0.3	2.75e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	10.72	0.51	3.49e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs731174	0.797	rs686083	chr1:38149193	C/T	cg06917450	chr1:38156652	C1orf109	-0.5	-7.16	-0.37	5.4e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17767392	0.958	rs9323561	chr14:72031563	A/C	cg13720639	chr14:72061746	SIPA1L1	0.56	6.98	0.36	1.68e-11	Mitral valve prolapse;
CRC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.05	-0.41	1.51e-14	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg21251018	chr6:28226885	NKAPL	0.47	6.16	0.32	2.07e-9	Depression;
CRC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.49	-7.47	-0.38	7.44e-13	Corneal astigmatism;
CRC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.05	20.97	0.76	1.32e-62	Primary sclerosing cholangitis;
CRC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.92	13.17	0.59	4.28e-32	Breast cancer;
CRC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.61	9.65	0.47	1.47e-19	Aortic root size;
CRC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.5	0.54	6.08e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12137294	0.866	rs1172151	chr1:205221659	A/C	cg24159697	chr1:205181237	DSTYK	-0.32	-5.88	-0.31	9.96e-9	Red cell distribution width;
CRC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg18764771	chr6:116381957	FRK	0.24	6.91	0.36	2.57e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.8e-13	Colorectal cancer;
CRC	trans	rs7176508	0.636	rs7179415	chr15:70045786	C/T	cg06571387	chr2:176964101	HOXD12	-0.32	-6.06	-0.32	3.73e-9	Chronic lymphocytic leukemia;
CRC	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.42	6.71	0.35	8.63e-11	Sitting height ratio;
CRC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg20399509	chr21:47717575	C21orf57	0.39	6.2	0.32	1.72e-9	Testicular germ cell tumor;
CRC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg16892393	chr17:41919603	NA	0.61	8.73	0.43	1.28e-16	Triglycerides;
CRC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.44	-7.33	-0.37	1.8e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	-0.51	-6.19	-0.32	1.82e-9	Diisocyanate-induced asthma;
CRC	cis	rs3760776	1.000	rs3760776	chr19:5839746	C/T	cg25387410	chr19:5844109	FUT3	-0.7	-9.45	-0.46	6.51e-19	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.86	0.35	3.42e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg07393940	chr7:158741817	NA	0.49	7.17	0.37	4.91e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.6	8.14	0.41	8.14e-15	Coronary artery disease;
CRC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg01444801	chr10:135216882	MTG1	-0.55	-7.89	-0.4	4.61e-14	Systemic lupus erythematosus;
CRC	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.49	7.04	0.36	1.16e-11	Primary sclerosing cholangitis;
CRC	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.65	8.01	0.4	1.95e-14	Cognitive test performance;
CRC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.42	-6.01	-0.31	4.85e-9	Daytime sleep phenotypes;
CRC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.58	7.18	0.37	4.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg24011408	chr12:48396354	COL2A1	0.44	6.13	0.32	2.5e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs17023223	0.537	rs2765542	chr1:119560326	T/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.02	-0.36	1.28e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg20607287	chr7:12443886	VWDE	-0.67	-6.78	-0.35	5.55e-11	Coronary artery disease;
CRC	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.42	-6.53	-0.34	2.51e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24047259	chr14:65347275	NA	0.4	6.42	0.33	4.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg04362960	chr10:104952993	NT5C2	0.47	6.94	0.36	2.13e-11	Waist circumference;Hip circumference;
CRC	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.51	-9.02	-0.45	1.61e-17	Proinsulin levels;
CRC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.42	-20.14	-0.74	2.38e-59	Hip circumference adjusted for BMI;
CRC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.63	0.34	1.34e-10	Schizophrenia;
CRC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.51	9.06	0.45	1.19e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19161053	chr7:99036702	CPSF4;PTCD1	-0.39	-6.06	-0.32	3.7e-9	Aortic root size;
CRC	cis	rs11605275	1.000	rs77993017	chr11:20031388	C/G	cg14835545	chr11:20032148	NAV2	-0.83	-5.64	-0.3	3.57e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.78	10.08	0.49	5.47e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg23758597	chr6:163146217	PARK2	-0.68	-6.73	-0.35	7.44e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18758796	chr5:131593413	PDLIM4	-0.45	-8.41	-0.42	1.29e-15	Breast cancer;
CRC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.62	-9.33	-0.46	1.56e-18	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.39	6.41	0.33	4.92e-10	Height;
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11645453	chr3:52864694	ITIH4	0.34	6.06	0.32	3.66e-9	Bipolar disorder;
CRC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg06781209	chr11:61594997	FADS2	-0.38	-5.74	-0.3	2.11e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.63	-0.63	1.07e-37	Height;
CRC	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06307176	chr5:131281290	NA	-0.43	-6.43	-0.33	4.55e-10	Life satisfaction;
CRC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.54	-8.06	-0.41	1.4e-14	Coronary artery disease;
CRC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.71	-10.85	-0.51	1.21e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg05623727	chr3:50126028	RBM5	0.45	7.34	0.37	1.73e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg18301423	chr5:131593218	PDLIM4	0.33	6.34	0.33	7.49e-10	Blood metabolite levels;
CRC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.54	6.85	0.35	3.62e-11	Morning vs. evening chronotype;
CRC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.33	6.55	0.34	2.17e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.58	-0.34	1.86e-10	Morning vs. evening chronotype;
CRC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.4	6.21	0.32	1.61e-9	Blood protein levels;
CRC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.71	0.35	8.75e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg12564285	chr5:131593104	PDLIM4	0.4	7.74	0.39	1.24e-13	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg25164649	chr6:28176230	NA	0.72	9.1	0.45	9.16e-18	Depression;
CRC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.37	0.33	6.3e-10	Diabetic kidney disease;
CRC	cis	rs10486722	0.583	rs10251553	chr7:41762017	C/T	cg22138096	chr7:41772439	LOC285954	0.4	5.95	0.31	6.84e-9	Pit-and-Fissure caries;
CRC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg13844804	chr7:814759	HEATR2	0.66	8.42	0.42	1.21e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.74	0.43	1.19e-16	Parkinson's disease;
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.91	-0.31	8.79e-9	Bipolar disorder;
CRC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.53	8.98	0.44	2.09e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-6.03	-0.32	4.3e-9	Mean corpuscular volume;
CRC	cis	rs4664293	0.867	rs3821299	chr2:160585740	C/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.88	-0.4	4.85e-14	Response to antipsychotic treatment;
CRC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	7.48	0.38	6.71e-13	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06028048	chr5:175815674	HIGD2A;NOP16	0.47	6.06	0.32	3.63e-9	Thyroid stimulating hormone;
CRC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.57	8.53	0.43	5.43e-16	Morning vs. evening chronotype;
CRC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-9.03	-0.45	1.45e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.39	-6.49	-0.34	3.1e-10	Longevity;Endometriosis;
CRC	cis	rs4731207	0.596	rs7788066	chr7:124630145	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.36	-0.33	6.87e-10	Cutaneous malignant melanoma;
CRC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.76	-10.06	-0.49	6.05e-21	Initial pursuit acceleration;
CRC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.18	0.32	1.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.41e-15	Lung cancer;
CRC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-7.82	-0.4	7.36e-14	Major depressive disorder;
CRC	cis	rs28655083	0.529	rs4550465	chr16:77104785	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.59	0.34	1.76e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg07713946	chr22:31675144	LIMK2	0.42	6.29	0.33	1.03e-9	Colorectal cancer;
CRC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.37	6.26	0.33	1.18e-9	Schizophrenia;
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.27	0.41	3.34e-15	Life satisfaction;
CRC	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg25304816	chr1:36627734	MAP7D1	-0.57	-9.57	-0.47	2.62e-19	Corneal structure;
CRC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg12365402	chr11:9010492	NRIP3	0.46	7.75	0.39	1.18e-13	Hemoglobin concentration;
CRC	cis	rs73206853	0.609	rs61582364	chr12:110967847	T/G	cg12870014	chr12:110450643	ANKRD13A	0.81	9.47	0.46	5.52e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.4	5.92	0.31	8.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg17321639	chr7:2759063	NA	-0.41	-6.18	-0.32	1.86e-9	Height;
CRC	cis	rs6545883	0.507	rs34668697	chr2:61568349	T/A	cg10580144	chr2:61372316	C2orf74	-0.35	-7.81	-0.4	7.95e-14	Tuberculosis;
CRC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.24	-0.33	1.37e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.41	1.5e-14	Cognitive performance;
CRC	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg02466173	chr16:30829666	NA	0.66	9.98	0.48	1.15e-20	Dementia with Lewy bodies;
CRC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.72	-7.86	-0.4	5.63e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs4731207	0.565	rs10954056	chr7:124600534	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg12218747	chr21:37451666	NA	-0.41	-7.0	-0.36	1.46e-11	Mitral valve prolapse;
CRC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.02	0.4	1.83e-14	Platelet count;
CRC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.48	-9.5	-0.46	4.65e-19	Prostate cancer;
CRC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-9.55	-0.47	3e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.37	5.61	0.3	4.26e-8	Breast cancer;
CRC	trans	rs701145	0.529	rs355759	chr3:154008078	G/C	cg22545385	chr10:131989303	NA	-0.43	-6.26	-0.33	1.19e-9	Coronary artery disease;
CRC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg12193833	chr17:30244370	NA	-0.75	-8.45	-0.42	9.86e-16	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03117819	chr17:48610072	EPN3	0.46	6.63	0.34	1.4e-10	Response to antipsychotic treatment;
CRC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.35	5.83	0.31	1.33e-8	Schizophrenia;
CRC	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg00105475	chr2:10696890	NA	0.44	7.14	0.37	6.13e-12	Prostate cancer;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	trans	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.48	-7.2	-0.37	4.09e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-9.24	-0.45	3.06e-18	Neuroticism;
CRC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.32	-0.37	1.88e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	5.94	0.31	7.13e-9	Prudent dietary pattern;
CRC	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.35	-6.79	-0.35	5.29e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-8.84	-0.44	5.92e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.58	7.31	0.37	2.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.38	5.69	0.3	2.76e-8	Essential tremor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08089031	chr6:139456240	HECA	0.39	6.21	0.32	1.57e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.7	11.14	0.52	1.15e-24	Hemoglobin concentration;
CRC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.3	3.18e-8	Diabetic retinopathy;
CRC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.25	-0.33	1.26e-9	Type 2 diabetes;
CRC	cis	rs883565	0.528	rs35946914	chr3:38992107	A/G	cg01426195	chr3:39028469	NA	-0.37	-6.05	-0.32	3.95e-9	Handedness;
CRC	cis	rs6076065	0.723	rs2236022	chr20:23373534	G/A	cg11657817	chr20:23433608	CST11	0.45	6.68	0.35	1.01e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.65	-7.61	-0.39	2.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.44	-6.26	-0.33	1.21e-9	Height;
CRC	trans	rs10911184	0.818	rs4652756	chr1:182954072	T/C	cg14803869	chr12:131237682	NA	0.53	6.21	0.32	1.56e-9	Diabetic kidney disease;
CRC	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.44	7.06	0.36	1.01e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg08847533	chr14:75593920	NEK9	-0.44	-6.65	-0.34	1.25e-10	Caffeine consumption;
CRC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.63	-9.01	-0.44	1.76e-17	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24531267	chr20:34043122	CEP250	0.41	6.79	0.35	5.16e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg02158880	chr13:53174818	NA	0.49	7.37	0.38	1.37e-12	Lewy body disease;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg12856521	chr11:46389249	DGKZ	0.73	10.56	0.5	1.21e-22	Crohn's disease;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11645453	chr3:52864694	ITIH4	0.38	6.67	0.35	1.05e-10	Bipolar disorder;
CRC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg23136738	chr11:925521	AP2A2	0.48	7.61	0.39	2.92e-13	Alzheimer's disease (late onset);
CRC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.62	-9.63	-0.47	1.75e-19	Coronary artery disease;
CRC	cis	rs6968419	0.747	rs56293030	chr7:115857170	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.48	-0.34	3.43e-10	Intraocular pressure;
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23708337	chr7:1209742	NA	0.38	5.69	0.3	2.84e-8	Longevity;Endometriosis;
CRC	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg21155852	chr7:2048760	MAD1L1	0.45	6.28	0.33	1.05e-9	Bipolar disorder;
CRC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg13798780	chr7:105162888	PUS7	0.54	6.91	0.36	2.46e-11	Bipolar disorder (body mass index interaction);
CRC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.79	-9.29	-0.46	2.23e-18	Breast cancer;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.94	16.29	0.67	3.81e-44	Menarche (age at onset);
CRC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg25452165	chr22:42524984	CYP2D6	0.39	5.63	0.3	3.79e-8	Cognitive function;
CRC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg11887960	chr12:57824829	NA	-0.64	-7.32	-0.37	1.87e-12	Obesity-related traits;
CRC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.66	12.11	0.56	3.56e-28	Calcium levels;
CRC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.07	-0.36	9.58e-12	Monocyte percentage of white cells;
CRC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.94	-13.06	-0.58	1.07e-31	Initial pursuit acceleration;
CRC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.36	-8.3	-0.42	2.73e-15	Mean corpuscular volume;
CRC	trans	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13892980	chr15:40545143	PAK6;C15orf56	0.46	6.34	0.33	7.76e-10	Anxiety disorder;
CRC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.98	-0.31	5.97e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.83	-13.82	-0.61	1.39e-34	Platelet count;
CRC	trans	rs1979967	0.524	rs1979966	chr15:79659028	A/G	cg14802097	chr12:42970349	PRICKLE1	0.52	6.06	0.32	3.66e-9	Interleukin-18 levels;
CRC	cis	rs6840360	0.642	rs7682837	chr4:152427686	C/T	cg09659197	chr4:152720779	NA	0.34	6.69	0.35	9.67e-11	Intelligence (multi-trait analysis);
CRC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.27e-20	Hip circumference adjusted for BMI;
CRC	cis	rs73200209	0.744	rs11615689	chr12:116699675	T/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.2	-0.37	4.1e-12	Total body bone mineral density;
CRC	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg05044414	chr3:183734942	ABCC5	0.35	5.96	0.31	6.56e-9	Anterior chamber depth;
CRC	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.37	5.76	0.3	1.89e-8	Blood metabolite levels;
CRC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.8	14.25	0.62	3.13e-36	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00137828	chr10:105881754	C10orf78	0.4	6.05	0.32	4.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg07125278	chr16:67683757	RLTPR	-0.62	-7.07	-0.36	9.54e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	10.8	0.51	1.74e-23	Coronary artery disease;
CRC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.37	6.32	0.33	8.33e-10	Total body bone mineral density;
CRC	cis	rs8032158	1.000	rs7162435	chr15:56121334	C/T	cg02198044	chr15:56286336	NEDD4	0.37	5.8	0.3	1.56e-8	Keloid;
CRC	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.53	-6.79	-0.35	5.19e-11	Body mass index;
CRC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.12	-0.32	2.73e-9	Aortic root size;
CRC	cis	rs1881396	0.531	rs72613829	chr2:27902987	C/T	cg27432699	chr2:27873401	GPN1	0.58	6.45	0.34	3.93e-10	Nonalcoholic fatty liver disease;
CRC	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg19637330	chr1:19110922	NA	-0.51	-6.99	-0.36	1.52e-11	Drug-induced liver injury (nitrofurantoin);
CRC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.63	-9.47	-0.46	5.56e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	8.19	0.41	5.93e-15	Axial length;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg15845792	chr6:28175446	NA	0.58	7.47	0.38	7.16e-13	Parkinson's disease;
CRC	cis	rs6738825	0.565	rs3792158	chr2:198407177	A/G	cg10820045	chr2:198174542	NA	0.34	6.08	0.32	3.32e-9	Crohn's disease;
CRC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.38	5.86	0.31	1.11e-8	Red blood cell count;
CRC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.58	6.69	0.35	9.64e-11	Plasma clusterin levels;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg05952120	chr17:61554416	ACE	0.41	6.16	0.32	2.14e-9	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25762580	chr7:108210082	THAP5;DNAJB9	0.49	6.27	0.33	1.14e-9	Thyroid stimulating hormone;
CRC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg01788221	chr16:89496183	ANKRD11	-0.44	-6.87	-0.35	3.21e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.51	8.25	0.41	3.98e-15	Testicular germ cell tumor;
CRC	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.08	0.36	8.84e-12	Diisocyanate-induced asthma;
CRC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.92	-8.25	-0.41	3.95e-15	Putamen volume;
CRC	cis	rs11688816	0.904	rs2539984	chr2:63133584	G/C	cg17519650	chr2:63277830	OTX1	0.42	5.8	0.3	1.57e-8	Body mass index;
CRC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.6	0.47	2.14e-19	Cognitive test performance;
CRC	trans	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg18187862	chr3:45730750	SACM1L	0.46	6.56	0.34	2.15e-10	Primary sclerosing cholangitis;
CRC	trans	rs150213942	1	rs150213942	chr3:135846911	T/G	cg17080335	chr12:131030206	NA	-0.4	-6.25	-0.33	1.24e-9	Fibrinogen levels;
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Parkinson's disease;
CRC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.43	8.86	0.44	5.25e-17	Renal cell carcinoma;
CRC	cis	rs1887596	0.705	rs11619978	chr13:27167841	A/G	cg01312412	chr13:27282625	NA	0.44	6.03	0.32	4.51e-9	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.72	8.95	0.44	2.64e-17	Diisocyanate-induced asthma;
CRC	trans	rs12517041	1.000	rs10066885	chr5:23296872	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.27	-0.33	1.16e-9	Bipolar disorder;
CRC	trans	rs10875746	0.859	rs4760695	chr12:48591848	A/G	cg16281234	chr15:35388805	NA	-0.51	-6.4	-0.33	5.23e-10	Longevity (90 years and older);
CRC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.37	6.51	0.34	2.85e-10	Systemic lupus erythematosus;
CRC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12516959	chr21:47718080	NA	0.33	5.87	0.31	1.06e-8	Testicular germ cell tumor;
CRC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg24416660	chr17:73865998	NA	-0.39	-5.95	-0.31	6.82e-9	Psoriasis;
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg19812747	chr11:111475976	SIK2	-0.59	-9.89	-0.48	2.37e-20	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22387939	chr2:71175719	ATP6V1B1	0.42	6.74	0.35	7.18e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.29	0.56	8.06e-29	Platelet count;
CRC	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg24140574	chr1:16342155	HSPB7	0.47	6.67	0.34	1.12e-10	Dilated cardiomyopathy;
CRC	trans	rs800082	0.516	rs1178895	chr3:144240563	G/T	cg24215973	chr2:240111563	HDAC4	0.46	6.49	0.34	3.14e-10	Smoking behavior;
CRC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.35	0.33	7.24e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.76	10.04	0.48	7.05e-21	Gestational age at birth (maternal effect);
CRC	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.41	-5.79	-0.3	1.68e-8	Strep throat;
CRC	cis	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.72	-0.3	2.44e-8	Blood trace element (Cu levels);
CRC	cis	rs4664293	0.625	rs4665102	chr2:160522587	A/C	cg08347373	chr2:160653686	CD302	0.37	6.44	0.33	4.15e-10	Monocyte percentage of white cells;
CRC	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg21934504	chr19:4445085	UBXN6	0.37	5.83	0.31	1.32e-8	Mean corpuscular volume;
CRC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg02527881	chr3:46936655	PTH1R	0.39	6.97	0.36	1.72e-11	Colorectal cancer;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.6	10.14	0.49	3.34e-21	Prudent dietary pattern;
CRC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.96	0.31	6.42e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg02683197	chr6:28174875	NA	0.62	6.52	0.34	2.67e-10	Depression;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg07713946	chr22:31675144	LIMK2	0.38	5.84	0.31	1.28e-8	Colorectal cancer;
CRC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	8.33	0.42	2.16e-15	Menarche (age at onset);
CRC	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.89	-11.49	-0.54	6.39e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17826168	chr19:6464103	CRB3	0.37	6.27	0.33	1.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17092148	1.000	rs60789653	chr20:33447162	G/A	cg08999081	chr20:33150536	PIGU	-0.46	-5.68	-0.3	2.91e-8	Neuroticism;
CRC	cis	rs370915	0.578	rs1431929	chr4:187775324	A/G	cg12892747	chr4:187813459	NA	-0.56	-8.16	-0.41	7.22e-15	Gout;
CRC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.61e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06925236	chr11:68039653	C11orf24	-0.5	-6.12	-0.32	2.6e-9	Diisocyanate-induced asthma;
CRC	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg16141378	chr3:129829833	LOC729375	-0.42	-6.19	-0.32	1.78e-9	Systolic blood pressure;
CRC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg15763984	chr4:1342303	KIAA1530	0.35	6.1	0.32	2.98e-9	Obesity-related traits;
CRC	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.56	6.36	0.33	6.77e-10	Osteoarthritis;
CRC	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg22134325	chr11:66188745	NPAS4	0.38	7.55	0.38	4.36e-13	Airway imaging phenotypes;
CRC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.64	-0.3	3.74e-8	Life satisfaction;
CRC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-5.66	-0.3	3.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs10411161	1.000	rs10414104	chr19:52368132	G/A	cg22319618	chr22:45562946	NUP50	-0.52	-6.02	-0.31	4.57e-9	Breast cancer;
CRC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg09127314	chr1:152161683	NA	-0.45	-5.89	-0.31	9.5e-9	Atopic dermatitis;
CRC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.84e-9	Schizophrenia;
CRC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg16060761	chr17:80687452	NA	-0.4	-5.81	-0.3	1.51e-8	Breast cancer;
CRC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg02569458	chr12:86230093	RASSF9	0.37	6.46	0.34	3.67e-10	Major depressive disorder;
CRC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.75	-0.35	6.68e-11	Height;
CRC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.75	0.39	1.18e-13	Red blood cell count;
CRC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg07828024	chr6:149772892	ZC3H12D	0.48	8.81	0.44	7.51e-17	Dupuytren's disease;
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.22	-0.45	3.66e-18	Bipolar disorder;
CRC	cis	rs6585424	1.000	rs10466226	chr10:81924055	C/T	cg11900509	chr10:81946545	ANXA11	0.72	8.55	0.43	4.75e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.87	0.31	1.04e-8	Refractive astigmatism;
CRC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	0.97	14.29	0.62	2.32e-36	Breast cancer;
CRC	cis	rs2188554	0.639	rs11978434	chr7:117231852	T/C	cg09181792	chr7:117119393	CFTR	0.35	6.15	0.32	2.22e-9	Esophageal adenocarcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02186127	chr17:33914245	AP2B1	0.49	6.26	0.33	1.2e-9	Thyroid stimulating hormone;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15042806	chr16:23652268	DCTN5;PALB2	0.49	6.33	0.33	8.25e-10	Thyroid stimulating hormone;
CRC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.83	0.44	6.23e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.47	-5.99	-0.31	5.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs185694	1.000	rs200505	chr13:30900868	G/T	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.32	-0.33	8.68e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs3790645	1.000	rs282176	chr1:26898956	T/C	cg17456097	chr1:26900765	RPS6KA1	0.44	6.7	0.35	8.78e-11	Glucose homeostasis traits;
CRC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.63	-9.89	-0.48	2.31e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-7.96	-0.4	2.84e-14	Gut microbiome composition (summer);
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg18758796	chr5:131593413	PDLIM4	-0.35	-6.27	-0.33	1.1e-9	Blood metabolite levels;
CRC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg09218773	chr11:619014	MUPCDH	-0.38	-5.91	-0.31	8.36e-9	Systemic lupus erythematosus;
CRC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.51	6.87	0.35	3.31e-11	Height;
CRC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.5	7.7	0.39	1.62e-13	Aortic root size;
CRC	cis	rs7605827	0.930	rs6431705	chr2:15599988	C/G	cg19274914	chr2:15703543	NA	-0.37	-5.69	-0.3	2.77e-8	Educational attainment (years of education);
CRC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg27661571	chr11:113659931	NA	0.65	7.59	0.39	3.3e-13	Hip circumference adjusted for BMI;
CRC	cis	rs35000415	0.873	rs13246321	chr7:128701331	T/C	cg19972273	chr7:128594194	NA	0.71	6.15	0.32	2.2e-9	Systemic lupus erythematosus;
CRC	cis	rs6499255	0.904	rs7190652	chr16:69616292	C/G	cg04110750	chr16:69646130	NFAT5	-0.56	-7.57	-0.39	3.75e-13	IgE levels;
CRC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-11.92	-0.55	1.86e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.58	8.14	0.41	8.33e-15	Perceived unattractiveness to mosquitoes;
CRC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg20203395	chr5:56204925	C5orf35	-0.57	-7.85	-0.4	5.76e-14	Initial pursuit acceleration;
CRC	trans	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-8.49	-0.42	6.97e-16	Extraversion;
CRC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg15465823	chr12:48382534	COL2A1	-0.36	-6.07	-0.32	3.59e-9	Glycated hemoglobin levels;
CRC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg08800497	chr19:1970008	CSNK1G2	-0.57	-9.07	-0.45	1.14e-17	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg26358599	chr1:24018029	RPL11	-0.74	-6.02	-0.31	4.71e-9	Cognitive function;
CRC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg25767906	chr1:53392781	SCP2	-0.46	-7.24	-0.37	3.15e-12	Monocyte count;
CRC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.64	9.34	0.46	1.51e-18	Menopause (age at onset);
CRC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21972741	chr5:435613	AHRR	0.53	7.37	0.38	1.41e-12	Cystic fibrosis severity;
CRC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.68	10.35	0.5	6.24e-22	Menopause (age at onset);
CRC	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg07478791	chr1:31886160	SERINC2	-0.41	-5.74	-0.3	2.21e-8	Alcohol dependence;
CRC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06028605	chr16:24865363	SLC5A11	0.41	6.42	0.33	4.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs501120	0.584	rs11238915	chr10:44696665	C/A	cg09554077	chr10:44749378	NA	0.69	7.91	0.4	4.04e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg13385521	chr17:29058706	SUZ12P	0.56	7.35	0.38	1.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg20933634	chr6:27740509	NA	0.59	8.74	0.43	1.19e-16	Parkinson's disease;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg12516270	chr8:143859308	LYNX1	0.45	7.3	0.37	2.21e-12	Urinary tract infection frequency;
CRC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg19912559	chr1:40204330	PPIE	0.51	7.39	0.38	1.2e-12	Blood protein levels;
CRC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg05342945	chr12:48394962	COL2A1	-0.39	-5.67	-0.3	3.06e-8	Lung cancer;
CRC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.43	8.95	0.44	2.66e-17	Renal cell carcinoma;
CRC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	8.3	0.42	2.67e-15	Height;
CRC	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg01420254	chr6:26195488	NA	0.72	6.03	0.32	4.42e-9	Iron status biomarkers (total iron binding capacity);
CRC	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg10130564	chr11:117069849	TAGLN	-0.37	-6.53	-0.34	2.49e-10	Blood protein levels;
CRC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.42	-7.51	-0.38	5.79e-13	Monocyte count;
CRC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.61	-10.54	-0.5	1.42e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.75	-9.26	-0.45	2.73e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg23503864	chr12:64616369	C12orf66	-0.45	-6.29	-0.33	1.01e-9	Protein C levels;
CRC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.6	8.88	0.44	4.43e-17	Corneal astigmatism;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg27350917	chr16:2021941	TBL3	-0.54	-6.52	-0.34	2.68e-10	Lung adenocarcinoma;
CRC	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg03316587	chr8:142245164	NA	-0.39	-5.84	-0.31	1.24e-8	Immature fraction of reticulocytes;
CRC	cis	rs1528435	1.000	rs1528446	chr2:181522955	A/C	cg23363182	chr2:181467187	NA	-0.35	-5.63	-0.3	3.92e-8	Body mass index;
CRC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.44	-6.6	-0.34	1.67e-10	Platelet distribution width;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24583131	chr6:18265189	DEK	0.49	6.44	0.33	4.18e-10	Thyroid stimulating hormone;
CRC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.92	-11.86	-0.55	2.95e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.5	-7.2	-0.37	4.05e-12	Pulse pressure;
CRC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.49	-9.83	-0.48	3.7799999999999997e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.5	-6.38	-0.33	6.04e-10	Resistin levels;
CRC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.83	-0.31	1.36e-8	Lung cancer;
CRC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg10498984	chr16:28874827	SH2B1	-0.73	-5.97	-0.31	6.13e-9	Cognitive function;
CRC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.32	0.42	2.37e-15	Homoarginine levels;
CRC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg03037974	chr15:76606532	NA	0.68	11.44	0.53	9.97e-26	Blood metabolite levels;
CRC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.76	-11.1	-0.52	1.59e-24	Blood metabolite levels;
CRC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16447950	chr5:562315	NA	-0.78	-10.22	-0.49	1.82e-21	Lung disease severity in cystic fibrosis;
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.62	7.67	0.39	1.94e-13	Alzheimer's disease;
CRC	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg04796162	chr7:45961102	IGFBP3	0.4	6.9	0.36	2.69e-11	Sitting height ratio;
CRC	cis	rs9925964	0.933	rs9923231	chr16:31107689	C/T	cg02466173	chr16:30829666	NA	0.41	5.65	0.3	3.43e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.07	0.69	3.06e-47	Blood protein levels;
CRC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.5	7.51	0.38	5.53e-13	Coronary artery disease;
CRC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.44	-6.55	-0.34	2.17e-10	Pancreatic cancer;
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.94	10.72	0.51	3.35e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06636001	chr8:8085503	FLJ10661	0.45	5.81	0.31	1.44e-8	Obesity-related traits;
CRC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.45	5.99	0.31	5.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06544989	chr22:39130855	UNC84B	0.45	7.26	0.37	2.85e-12	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.5	0.54	6.02e-26	Prudent dietary pattern;
CRC	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg25246084	chr19:4971487	KDM4B	-0.35	-5.96	-0.31	6.64e-9	Monocyte percentage of white cells;
CRC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.57	6.28	0.33	1.08e-9	Schizophrenia;
CRC	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.47	-6.06	-0.32	3.74e-9	Serum parathyroid hormone levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.5	7.3	0.37	2.25e-12	Response to antipsychotic treatment;
CRC	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.51	0.54	5.3e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9549328	0.700	rs4907568	chr13:113617574	A/T	cg25790453	chr13:113633590	MCF2L	-0.44	-7.77	-0.39	1.03e-13	Systolic blood pressure;
CRC	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg10556349	chr10:835070	NA	-0.32	-6.0	-0.31	5.09e-9	Survival in rectal cancer;
CRC	cis	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg18809830	chr7:99032528	PTCD1	-1.14	-8.33	-0.42	2.26e-15	Blood metabolite levels;
CRC	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg02206980	chr6:13574034	SIRT5	-0.49	-7.45	-0.38	8.27e-13	Breast cancer;
CRC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.53	0.6	1.83e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.46	-7.05	-0.36	1.06e-11	Cognitive test performance;
CRC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg23093090	chr10:104574429	C10orf26	-0.41	-5.74	-0.3	2.13e-8	Arsenic metabolism;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg06173978	chr16:50402162	BRD7	0.38	6.42	0.33	4.64e-10	Body mass index;
CRC	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg12856521	chr11:46389249	DGKZ	0.43	6.85	0.35	3.7e-11	Leprosy;
CRC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.4	0.38	1.11e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.11	0.37	7.13e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg15123519	chr2:136567270	LCT	-0.3	-5.75	-0.3	2.03e-8	Mosquito bite size;
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.7	-0.51	3.85e-23	Alzheimer's disease;
CRC	cis	rs3790844	0.955	rs3790848	chr1:200006111	C/A	cg13229857	chr1:200006247	NR5A2	0.59	8.34	0.42	2.13e-15	Pancreatic cancer;
CRC	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg04165759	chr1:150448943	RPRD2	0.34	5.61	0.3	4.2e-8	Migraine;
CRC	trans	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg21153622	chr11:89784906	NA	-0.44	-6.99	-0.36	1.5e-11	Height;
CRC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-0.81	-11.42	-0.53	1.13e-25	IgG glycosylation;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.17	-0.32	1.98e-9	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09580147	chr16:22431764	RRN3P3	-0.4	-6.31	-0.33	9.22e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg27661571	chr11:113659931	NA	-0.95	-11.14	-0.52	1.11e-24	Hip circumference adjusted for BMI;
CRC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.54	7.24	0.37	3.12e-12	Height;
CRC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.91	-0.31	8.44e-9	Lung cancer;
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04497992	chr16:616212	NHLRC4	0.44	7.16	0.37	5.31e-12	Height;
CRC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.38	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	9.99	0.48	1.1e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	9.12	0.45	7.51e-18	Bipolar disorder and schizophrenia;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg12273811	chr6:28175739	NA	0.5	6.83	0.35	4.15e-11	Parkinson's disease;
CRC	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.5	7.29	0.37	2.39e-12	Colorectal cancer;
CRC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.6	0.6	9.67e-34	Electrocardiographic conduction measures;
CRC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg09324608	chr17:30823087	MYO1D	0.36	6.31	0.33	8.91e-10	Schizophrenia;
CRC	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.66	0.39	2.07e-13	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.39	-0.5	4.76e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg03037974	chr15:76606532	NA	0.71	12.52	0.57	1.12e-29	Blood metabolite levels;
CRC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02450064	chr17:40260053	DHX58	-0.42	-6.12	-0.32	2.64e-9	Fibrinogen levels;
CRC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg03013999	chr17:37608204	MED1	-0.48	-7.51	-0.38	5.62e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.79	0.3	1.65e-8	Hemoglobin concentration;
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg03160526	chr17:80928410	B3GNTL1	0.57	7.63	0.39	2.63e-13	Glycated hemoglobin levels;
CRC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.46	0.42	8.82e-16	Lymphocyte counts;
CRC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg03030879	chr14:75389066	RPS6KL1	0.4	6.01	0.31	4.96e-9	Height;
CRC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.88	-0.31	9.95e-9	Cognitive function;
CRC	cis	rs7215564	0.908	rs115148337	chr17:78688545	G/T	cg09596252	chr17:78655493	RPTOR	0.59	6.33	0.33	8.02e-10	Myopia (pathological);
CRC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.13	-0.52	1.21e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs6973256	0.828	rs12707117	chr7:133429058	G/A	cg10665199	chr7:133106180	EXOC4	0.37	5.77	0.3	1.79e-8	Intelligence (multi-trait analysis);
CRC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-5.84	-0.31	1.28e-8	Sum eosinophil basophil counts;Eosinophil counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06310300	chr7:100076089	TSC22D4	0.46	6.68	0.35	1.03e-10	Response to antipsychotic treatment;
CRC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg09911534	chr15:67153556	NA	0.43	6.36	0.33	6.77e-10	Lung cancer (smoking interaction);
CRC	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg25547332	chr5:131281432	NA	0.38	5.64	0.3	3.67e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.85	0.4	5.93e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.48	-6.06	-0.32	3.69e-9	Crohn's disease;
CRC	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg09659197	chr4:152720779	NA	0.4	7.9	0.4	4.19e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg08222913	chr3:52553049	STAB1	0.36	6.56	0.34	2.03e-10	Bipolar disorder;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.67	13.72	0.6	3.43e-34	Tonsillectomy;
CRC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg16486109	chr11:613632	IRF7	0.73	12.28	0.56	8.42e-29	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg19223190	chr17:80058835	NA	0.4	6.32	0.33	8.74e-10	Life satisfaction;
CRC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.75	0.47	6.75e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg04362960	chr10:104952993	NT5C2	0.45	6.8	0.35	4.8e-11	Waist circumference;Hip circumference;
CRC	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.52	8.02	0.4	1.91e-14	Testicular germ cell tumor;
CRC	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.26	12.27	0.56	9.31e-29	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7781557	0.696	rs55849741	chr7:102584069	C/G	cg18108683	chr7:102477205	FBXL13	-0.49	-5.71	-0.3	2.48e-8	Colorectal adenoma (advanced);
CRC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg04204079	chr8:58130323	NA	-0.46	-5.72	-0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.78	-13.34	-0.59	9.2e-33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.69	-0.39	1.74e-13	Schizophrenia;
CRC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.31	5.74	0.3	2.13e-8	Huntington's disease progression;
CRC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.81	0.4	7.52e-14	Cognitive ability;
CRC	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.71	14.1	0.61	1.27e-35	Leprosy;
CRC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-8.92	-0.44	3.29e-17	Bone mineral density;
CRC	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg18240653	chr6:144019428	PHACTR2	-0.55	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.57	-7.69	-0.39	1.73e-13	Hip circumference adjusted for BMI;
CRC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.75	12.45	0.57	2e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.42	6.22	0.32	1.5e-9	Neutrophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27657525	chr19:30432971	C19orf2	0.46	7.28	0.37	2.42e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24512132	chr1:229478138	C1orf96	0.39	6.3	0.33	9.63e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg25985355	chr7:65971099	NA	-0.52	-6.1	-0.32	3.05e-9	Diabetic kidney disease;
CRC	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.41	6.28	0.33	1.05e-9	Red blood cell count;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.52	-0.5	1.72e-22	Bipolar disorder;
CRC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.51	-0.34	2.79e-10	Cystic fibrosis severity;
CRC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.79	13.41	0.59	4.99e-33	Menopause (age at onset);
CRC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.45	6.57	0.34	1.93e-10	Menopause (age at onset);
CRC	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.38	-6.08	-0.32	3.34e-9	Height;
CRC	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.72	-0.3	2.39e-8	Tuberculosis;
CRC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg09127314	chr1:152161683	NA	0.5	6.38	0.33	5.92e-10	Atopic dermatitis;
CRC	cis	rs932541	1.000	rs932541	chr20:16455774	G/T	cg17003395	chr20:16555519	KIF16B	0.41	5.73	0.3	2.25e-8	Intelligence;
CRC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19623624	chr10:135278901	LOC619207	-0.35	-5.75	-0.3	2.04e-8	Systemic lupus erythematosus;
CRC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-8.78	-0.44	8.99e-17	Uric acid levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06391300	chr11:119600292	PVRL1	0.46	6.21	0.32	1.64e-9	Survival in pancreatic cancer;
CRC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg00700412	chr12:58011837	NA	-0.37	-5.7	-0.3	2.62e-8	Multiple sclerosis;
CRC	cis	rs995000	0.931	rs1184547	chr1:63007228	G/A	cg19896129	chr1:63156450	NA	-0.44	-6.81	-0.35	4.6e-11	Triglyceride levels;
CRC	cis	rs11958404	1.000	rs72816538	chr5:157414303	A/G	cg05962755	chr5:157440814	NA	0.74	10.37	0.5	5.47e-22	IgG glycosylation;
CRC	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.67	-7.77	-0.39	9.88e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs970548	0.954	rs61854123	chr10:46065451	G/A	cg15590007	chr10:45870220	ALOX5	0.49	6.26	0.33	1.19e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs4478858	0.735	rs12404861	chr1:31861271	G/A	cg00250761	chr1:31883323	NA	-0.41	-7.51	-0.38	5.45e-13	Alcohol dependence;
CRC	trans	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg26805224	chr10:79626177	DLG5	-0.56	-8.34	-0.42	2.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.11	0.49	4.34e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	11.0	0.52	3.47e-24	Motion sickness;
CRC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.03	-0.36	1.22e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.47	-8.86	-0.44	5.06e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.46	-7.65	-0.39	2.29e-13	Lung cancer;
CRC	cis	rs2249694	1.000	rs2515644	chr10:135353079	A/C	cg20169779	chr10:135381914	SYCE1	0.54	8.67	0.43	1.93e-16	Obesity-related traits;
CRC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg22495460	chr2:25135724	ADCY3	-0.9	-18.29	-0.71	4.54e-52	Body mass index in non-asthmatics;
CRC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg16141378	chr3:129829833	LOC729375	0.46	6.97	0.36	1.72e-11	Neuroticism;
CRC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.41	-5.62	-0.3	4.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.54	9.97	0.48	1.27e-20	Lung cancer;
CRC	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.48	6.18	0.32	1.86e-9	Alopecia areata;
CRC	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.66	0.34	1.17e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.54	-7.47	-0.38	7.5e-13	Carotid intima media thickness;
CRC	cis	rs1124376	0.935	rs67660889	chr3:20170538	G/C	cg05072819	chr3:20081367	KAT2B	0.49	5.64	0.3	3.74e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg18904891	chr8:8559673	CLDN23	0.54	7.53	0.38	4.98e-13	Obesity-related traits;
CRC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.79	-10.82	-0.51	1.52e-23	Intelligence (multi-trait analysis);
CRC	cis	rs1322512	0.920	rs1744378	chr6:152943176	T/C	cg03415253	chr6:152958462	SYNE1	-0.43	-6.84	-0.35	3.88e-11	Tonometry;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg08222913	chr3:52553049	STAB1	0.38	7.34	0.38	1.66e-12	Electroencephalogram traits;
CRC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.38	6.15	0.32	2.2e-9	Major depressive disorder;
CRC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg26893134	chr6:116381904	FRK	0.27	7.98	0.4	2.46e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.55	6.4	0.33	5.3e-10	Childhood ear infection;
CRC	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	9.81e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg19338460	chr6:170058176	WDR27	-0.88	-8.89	-0.44	4.03e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6586163	1.000	rs1926196	chr10:90753748	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.5	7.26	0.37	2.83e-12	Chronic lymphocytic leukemia;
CRC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.42	-0.33	4.67e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9648428	0.515	rs11974488	chr7:36202112	G/T	cg14708893	chr7:36124863	NA	-0.41	-6.01	-0.31	4.8e-9	Obesity-related traits;
CRC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.87	8.87	0.44	4.77e-17	Major depressive disorder;
CRC	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.93	-11.65	-0.54	1.73e-26	Hair shape;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14301165	chr19:53324198	ZNF28	0.42	6.76	0.35	6.46e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4664293	0.867	rs6760485	chr2:160579690	T/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg20203395	chr5:56204925	C5orf35	-0.66	-7.94	-0.4	3.13e-14	Initial pursuit acceleration;
CRC	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg12870014	chr12:110450643	ANKRD13A	0.79	8.35	0.42	1.94e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg15786705	chr6:28176104	NA	0.53	6.92	0.36	2.32e-11	Parkinson's disease;
CRC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg15848620	chr12:58087721	OS9	-0.64	-8.86	-0.44	5.12e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg02683197	chr6:28174875	NA	0.66	6.56	0.34	2.06e-10	Lung cancer in ever smokers;
CRC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-9.93	-0.48	1.74e-20	Dental caries;
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.65	10.18	0.49	2.38e-21	Red cell distribution width;
CRC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	8.53	0.43	5.34e-16	Height;
CRC	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg06550200	chr5:1325588	CLPTM1L	0.63	9.56	0.47	2.96e-19	Lung cancer;
CRC	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg16540259	chr10:75572220	NDST2	0.38	6.0	0.31	5.25e-9	Inflammatory bowel disease;
CRC	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.47	6.01	0.31	4.85e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9549328	0.542	rs36172983	chr13:113616582	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.39	0.46	1e-18	Systolic blood pressure;
CRC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg06172871	chr16:72088244	HP	-0.39	-5.76	-0.3	1.95e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.46	6.91	0.36	2.59e-11	Menopause (age at onset);
CRC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.49	-0.34	3.13e-10	Fibrinogen levels;
CRC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs4938330	0.608	rs3882897	chr11:117091227	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-5.98	-0.31	5.71e-9	Blood protein levels;
CRC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg21724239	chr8:58056113	NA	0.57	7.34	0.38	1.66e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.28	-0.33	1.08e-9	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs12541635	0.966	rs12674846	chr8:107007178	A/G	cg10147462	chr8:107024639	NA	0.42	6.92	0.36	2.42e-11	Age of smoking initiation;
CRC	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.47	-6.94	-0.36	2.1e-11	Schizophrenia;
CRC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg14541582	chr5:601475	NA	-0.35	-7.25	-0.37	3.02e-12	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14988214	chr2:8977332	KIDINS220	0.47	6.66	0.34	1.17e-10	Response to antipsychotic treatment;
CRC	cis	rs77861329	1.000	rs9843852	chr3:52132029	C/G	cg08692210	chr3:52188851	WDR51A	0.88	8.41	0.42	1.29e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg04731861	chr2:219085781	ARPC2	-0.32	-6.72	-0.35	8.07e-11	Colorectal cancer;
CRC	trans	rs1367248	1.000	rs780039	chr2:125009650	A/G	cg07402188	chr19:40720005	MAP3K10	-0.45	-6.09	-0.32	3.16e-9	Tonometry;
CRC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.64	-10.48	-0.5	2.33e-22	Cystic fibrosis severity;
CRC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.52	0.38	5.35e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.72	-10.35	-0.5	6.44e-22	Lung cancer;
CRC	cis	rs6973256	0.865	rs2483509	chr7:133341162	G/A	cg10665199	chr7:133106180	EXOC4	-0.37	-5.65	-0.3	3.55e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15680518	chr12:132414800	PUS1	0.44	6.51	0.34	2.86e-10	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-6.04	-0.32	4.14e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.08	-0.32	3.33e-9	Height;
CRC	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg09659197	chr4:152720779	NA	-0.5	-10.37	-0.5	5.34e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.65	7.32	0.37	1.91e-12	Menarche (age at onset);
CRC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.69	-0.43	1.79e-16	Personality dimensions;
CRC	cis	rs6433857	0.594	rs11894486	chr2:181520678	C/T	cg23363182	chr2:181467187	NA	-0.47	-7.28	-0.37	2.5e-12	Body mass index;
CRC	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg00646200	chr1:148855367	NA	0.34	6.15	0.32	2.22e-9	Hip geometry;
CRC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.73	-13.35	-0.59	8.95e-33	Body mass index;
CRC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.68	10.91	0.52	7.16e-24	Colorectal cancer;
CRC	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg07606381	chr6:8435919	SLC35B3	-0.64	-9.92	-0.48	1.82e-20	Motion sickness;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02725872	chr8:58115012	NA	-0.59	-9.19	-0.45	4.62e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.59	7.88	0.4	4.77e-14	Bipolar disorder;
CRC	cis	rs10986311	0.802	rs1330811	chr9:127117346	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.4	6.03	0.32	4.44e-9	Vitiligo;
CRC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.44	-6.1	-0.32	3.04e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.14	0.32	2.31e-9	Bipolar disorder;
CRC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.75	-12.23	-0.56	1.3e-28	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.59	10.38	0.5	5.06e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg18761221	chr20:60518478	NA	0.53	8.59	0.43	3.47e-16	Body mass index;
CRC	cis	rs11264799	0.598	rs79853736	chr1:157732091	A/C	cg11810135	chr1:157771971	FCRL1	0.4	5.96	0.31	6.5e-9	IgA nephropathy;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.66	7.13	0.37	6.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.53	8.17	0.41	6.81e-15	Testicular germ cell tumor;
CRC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.51	-0.42	6.15e-16	Personality dimensions;
CRC	cis	rs7923609	0.902	rs7897379	chr10:65301725	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.9	-0.31	9.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.39	-6.25	-0.33	1.28e-9	Iron status biomarkers;
CRC	trans	rs2303319	0.504	rs12473497	chr2:162433766	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.77	-6.19	-0.32	1.79e-9	Cognitive function;
CRC	cis	rs6496667	0.779	rs7169787	chr15:91039929	C/T	cg04176472	chr15:90893244	GABARAPL3	0.57	7.64	0.39	2.44e-13	Rheumatoid arthritis;
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.73	0.54	8.92e-27	Prudent dietary pattern;
CRC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.13	-13.34	-0.59	9.36e-33	Diabetic kidney disease;
CRC	cis	rs2811415	0.597	rs9809497	chr3:127782514	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.98	-0.31	5.94e-9	Lung function (FEV1/FVC);
CRC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.17	11.65	0.54	1.69e-26	Skin colour saturation;
CRC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	10.37	0.5	5.63e-22	Lymphocyte counts;
CRC	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.43	6.63	0.34	1.38e-10	Red blood cell count;
CRC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.45	-0.46	6.39e-19	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17356280	chr15:56657632	TEX9	0.37	6.2	0.32	1.7e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs300489	0.887	rs1726005	chr12:78488999	A/C	cg24901662	chr10:34977342	PARD3	0.36	6.0	0.31	5.34e-9	Self-rated health;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22297934	chr17:76421671	DNAH17	-0.36	-6.21	-0.32	1.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg15511327	chr8:143859410	LYNX1	0.56	10.24	0.49	1.57e-21	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01732804	chr2:220118692	TUBA4A;TUBA4B	0.43	6.33	0.33	8.07e-10	Response to antipsychotic treatment;
CRC	cis	rs9323205	0.677	rs12589680	chr14:51723138	T/C	cg23942311	chr14:51606299	NA	-0.52	-6.19	-0.32	1.78e-9	Cancer;
CRC	cis	rs2735413	0.874	rs12917942	chr16:78064220	T/G	cg04733911	chr16:78082701	NA	-0.37	-6.0	-0.31	5.14e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs8141797	0.748	rs6004050	chr22:24461944	A/G	cg20894457	chr22:24584366	SUSD2	-0.61	-7.43	-0.38	9.27e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.36	0.38	1.5e-12	Blood metabolite levels;
CRC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	0.43	6.03	0.32	4.39e-9	Carotid intima media thickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16136840	chr5:95997740	CAST	0.41	7.04	0.36	1.15e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11693508	chr17:37793320	STARD3	-0.61	-7.56	-0.38	4.13e-13	Bipolar disorder;
CRC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.66	8.1	0.41	1.1e-14	Menarche (age at onset);
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg00246817	chr9:123691163	NA	-0.44	-5.7	-0.3	2.62e-8	Rheumatoid arthritis;
CRC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.21	-0.41	4.98e-15	Bipolar disorder;
CRC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	9.31	0.46	1.89e-18	Multiple sclerosis;
CRC	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.4	-0.33	5.34e-10	Coronary artery disease;
CRC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.22	0.45	3.68e-18	Iron status biomarkers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10554839	chr10:27529782	ACBD5	0.42	5.97	0.31	6.22e-9	Anxiety disorder;
CRC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-6.8	-0.35	5.01e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg23425280	chr12:56401806	NA	0.47	5.72	0.3	2.44e-8	Cancer;
CRC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.43	-7.05	-0.36	1.03e-11	Resting heart rate;
CRC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.49	6.33	0.33	7.83e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.55	9.03	0.45	1.48e-17	Colorectal cancer;
CRC	cis	rs12541635	0.966	rs114386112	chr8:107036340	G/A	cg10147462	chr8:107024639	NA	0.46	7.56	0.38	4.04e-13	Age of smoking initiation;
CRC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.8	-10.27	-0.49	1.24e-21	Initial pursuit acceleration;
CRC	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg25019722	chr6:37503610	NA	-0.37	-6.56	-0.34	2.06e-10	Cognitive performance;
CRC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.9	14.08	0.61	1.43e-35	Longevity;
CRC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.03	0.32	4.38e-9	Diabetic retinopathy;
CRC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.49	-7.39	-0.38	1.19e-12	Menarche (age at onset);
CRC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.71	6.79	0.35	5.34e-11	Diabetic retinopathy;
CRC	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.7	0.3	2.69e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg08992911	chr2:238395768	MLPH	0.47	5.75	0.3	2.04e-8	Prostate cancer;
CRC	cis	rs7429990	0.864	rs4858863	chr3:47855633	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.83	-0.31	1.29e-8	Educational attainment (years of education);
CRC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.61	8.72	0.43	1.45e-16	Multiple sclerosis;
CRC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.09e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.88	0.31	1.01e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.19	0.37	4.43e-12	Hemoglobin concentration;
CRC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg11833968	chr6:79620685	NA	-0.37	-6.48	-0.34	3.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg20203395	chr5:56204925	C5orf35	-0.65	-7.84	-0.4	6.36e-14	Initial pursuit acceleration;
CRC	cis	rs12431939	0.626	rs10138856	chr14:51712712	G/A	cg23942311	chr14:51606299	NA	0.5	6.55	0.34	2.16e-10	Cancer;
CRC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.44	-6.62	-0.34	1.43e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.83	0.35	4.1e-11	Diastolic blood pressure;
CRC	cis	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg20159608	chr7:32802032	NA	-0.59	-7.37	-0.38	1.36e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7213347	0.707	rs216182	chr17:2173063	A/G	cg15816464	chr17:2026533	SMG6	-0.37	-6.12	-0.32	2.62e-9	Total body bone mineral density;
CRC	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.5	7.68	0.39	1.89e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.08	-12.37	-0.56	4.09e-29	Diabetic kidney disease;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18297960	chr7:1142765	C7orf50	-0.46	-6.33	-0.33	8.18e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.76	-8.5	-0.42	6.66e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg21620606	chr4:1342894	KIAA1530	-0.45	-7.16	-0.37	5.26e-12	Obesity-related traits;
CRC	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.79	0.35	5.29e-11	Ovarian reserve;
CRC	cis	rs3087591	0.683	rs17826544	chr17:29640225	A/G	cg24425628	chr17:29625626	OMG;NF1	0.74	13.32	0.59	1.13e-32	Hip circumference;
CRC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-9.66	-0.47	1.35e-19	Body mass index;
CRC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg08648136	chr8:956695	NA	0.34	6.14	0.32	2.34e-9	Schizophrenia;
CRC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.45	6.66	0.34	1.13e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	6.38	0.33	5.87e-10	Blood metabolite levels;
CRC	trans	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.65	-0.34	1.22e-10	Depression;
CRC	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg23229984	chr5:148520753	ABLIM3	0.55	7.09	0.36	8.21e-12	Breast cancer;
CRC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.64	9.72	0.47	8.18e-20	Menopause (age at onset);
CRC	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg01475377	chr6:109611718	NA	-0.34	-5.98	-0.31	5.7e-9	Reticulocyte fraction of red cells;
CRC	cis	rs886126	0.650	rs4766566	chr12:111706877	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.09	0.32	3.22e-9	Coronary heart disease;
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg09491104	chr22:46646882	C22orf40	-0.41	-6.35	-0.33	7e-10	LDL cholesterol;Cholesterol, total;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02455064	chr1:233086327	C1orf57	0.47	6.47	0.34	3.59e-10	Anxiety disorder;
CRC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	8.74	0.43	1.21e-16	Schizophrenia;
CRC	cis	rs73200209	0.744	rs11614867	chr12:116658916	A/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.16	-0.37	5.42e-12	Total body bone mineral density;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg15786705	chr6:28176104	NA	0.7	9.41	0.46	9.04e-19	Parkinson's disease;
CRC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-0.86	-9.9	-0.48	2.13e-20	Breast cancer;
CRC	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg13385794	chr1:248469461	NA	0.34	6.36	0.33	6.59e-10	Common traits (Other);
CRC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.59	10.63	0.51	6.92e-23	Coronary artery disease;
CRC	trans	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.71	-0.35	8.62e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.76	-10.24	-0.49	1.58e-21	Coronary artery disease;
CRC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.46	-5.8	-0.3	1.56e-8	Diastolic blood pressure;
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.03	14.7	0.63	5.85e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00166722	chr3:10149974	C3orf24	0.66	7.71	0.39	1.49e-13	Alzheimer's disease;
CRC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-7.43	-0.38	9.71e-13	Coronary artery disease;
CRC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.49	6.33	0.33	8.1e-10	Menopause (age at onset);
CRC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg19812747	chr11:111475976	SIK2	-0.53	-8.33	-0.42	2.16e-15	Primary sclerosing cholangitis;
CRC	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg11579758	chr4:1086637	RNF212	0.4	6.61	0.34	1.58e-10	Recombination rate (males);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14489649	chr17:40021376	KLHL11	0.44	6.14	0.32	2.36e-9	Response to antipsychotic treatment;
CRC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.83	-0.51	1.42e-23	Total cholesterol levels;
CRC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-6.99	-0.36	1.49e-11	Hemoglobin concentration;
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg24505167	chr7:1915268	MAD1L1	-0.41	-5.63	-0.3	3.93e-8	Neuroticism;
CRC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.66	-11.52	-0.54	5.12e-26	Educational attainment;
CRC	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg12856521	chr11:46389249	DGKZ	0.42	6.53	0.34	2.57e-10	Leprosy;
CRC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg08222913	chr3:52553049	STAB1	-0.43	-8.72	-0.43	1.43e-16	Electroencephalogram traits;
CRC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.64	7.29	0.37	2.34e-12	Vitiligo;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.32	-0.46	1.75e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg21851534	chr17:3907994	ZZEF1	-0.36	-6.03	-0.32	4.37e-9	Type 2 diabetes;
CRC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.33	-6.08	-0.32	3.37e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.47	7.13	0.37	6.27e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.88	-0.31	1.01e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.83	14.44	0.62	5.96e-37	Breast cancer;
CRC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.48	-8.97	-0.44	2.23e-17	Longevity;
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg27532560	chr4:187881888	NA	-0.58	-10.93	-0.52	6.25e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6546324	0.625	rs2902007	chr2:67795462	A/T	cg15745817	chr2:67799979	NA	-0.55	-9.43	-0.46	7.6e-19	Endometriosis;
CRC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.62	-7.8	-0.39	8.46e-14	Body mass index;
CRC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.14	0.45	6.83e-18	Lymphocyte counts;
CRC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.53	-0.34	2.56e-10	Dupuytren's disease;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.45	0.38	8.46e-13	Breast cancer;
CRC	cis	rs11212617	1.000	rs227092	chr11:108236783	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.5	0.34	2.99e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6585424	1.000	rs34162901	chr10:81946856	A/C	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.64	-0.3	3.6e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg03934865	chr2:198174659	NA	-0.43	-7.02	-0.36	1.25e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-11.23	-0.53	5.27e-25	Systemic lupus erythematosus;
CRC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.69	0.35	9.55e-11	Menarche (age at onset);
CRC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.58	-0.34	1.82e-10	Systemic lupus erythematosus;
CRC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg16070123	chr10:51489643	NA	-0.34	-5.83	-0.31	1.36e-8	Prostate-specific antigen levels;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.18	-0.32	1.89e-9	Longevity;Endometriosis;
CRC	cis	rs35883536	0.935	rs12409832	chr1:101107725	A/G	cg14515779	chr1:101123966	NA	-0.43	-8.3	-0.42	2.75e-15	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09166705	chr1:151170883	PIP5K1A	0.38	6.02	0.31	4.57e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9969804	0.846	rs12683776	chr9:95434401	G/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.73	-0.3	2.3e-8	Height;
CRC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.54	8.84	0.44	5.76e-17	Parkinson's disease;
CRC	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	5.87e-36	Lewy body disease;
CRC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.1	-0.36	7.58e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03599547	chr12:56123102	CD63	0.41	6.2	0.32	1.68e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05792827	chr1:213224765	RPS6KC1	0.4	6.11	0.32	2.83e-9	Schizophrenia;
CRC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg24675056	chr1:15929824	NA	0.52	7.27	0.37	2.64e-12	Systolic blood pressure;
CRC	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg18551225	chr6:44695536	NA	0.39	5.69	0.3	2.87e-8	Total body bone mineral density;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.18	-0.32	1.89e-9	Total body bone mineral density;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg21747405	chr11:67723411	NA	-0.56	-8.76	-0.43	1.08e-16	Blood pressure (smoking interaction);
CRC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg12311346	chr5:56204834	C5orf35	-0.46	-6.92	-0.36	2.42e-11	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.71	0.6	3.81e-34	Breast cancer;
CRC	cis	rs1050631	0.592	rs1785903	chr18:33711642	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.38	5.85	0.31	1.18e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.67	-10.91	-0.52	7.63e-24	Blood protein levels;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.38	-6.61	-0.34	1.51e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	6.05	0.32	4.04e-9	Mean platelet volume;
CRC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.68	-9.07	-0.45	1.13e-17	Urate levels in lean individuals;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16595246	chr2:48009933	MSH6	0.37	6.22	0.32	1.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.5	-7.32	-0.37	1.88e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.62	6.51	0.34	2.76e-10	Initial pursuit acceleration;
CRC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.53	6.87	0.35	3.17e-11	Longevity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05468351	chr5:21459598	LOC728411	0.55	7.15	0.37	5.59e-12	Thyroid stimulating hormone;
CRC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg27661571	chr11:113659931	NA	-0.97	-11.28	-0.53	3.75e-25	Hip circumference adjusted for BMI;
CRC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-8.35	-0.42	1.89e-15	Blood metabolite levels;
CRC	cis	rs2882667	0.898	rs13163536	chr5:138377219	A/G	cg09476006	chr5:138032270	NA	0.44	7.31	0.37	2.05e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.49	7.9	0.4	4.26e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.75	-9.59	-0.47	2.26e-19	Initial pursuit acceleration;
CRC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	9.86	0.48	2.95e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs6600671	0.967	rs4844613	chr1:121173773	T/C	cg00646200	chr1:148855367	NA	0.33	5.98	0.31	5.77e-9	Hip geometry;
CRC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.78	0.35	5.42e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.52	-7.78	-0.39	9.39e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.83	11.21	0.53	6.62e-25	IgG glycosylation;
CRC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.84	-12.0	-0.55	9.19e-28	Gut microbiome composition (summer);
CRC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-11.11	-0.52	1.49e-24	Monocyte percentage of white cells;
CRC	cis	rs3751196	0.708	rs12423929	chr12:104146343	G/A	cg02344784	chr12:104178138	NT5DC3	0.66	6.31	0.33	9.18e-10	Sense of smell;
CRC	cis	rs3736594	0.513	rs76013440	chr2:27816315	G/A	cg27432699	chr2:27873401	GPN1	0.65	7.97	0.4	2.7e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.77	12.14	0.56	2.87e-28	Breast cancer;
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.04	-0.32	4.26e-9	Total body bone mineral density;
CRC	trans	rs7619427	0.544	rs9809968	chr3:44042297	A/T	cg09408571	chr1:101003634	GPR88	0.45	6.27	0.33	1.12e-9	Schizophrenia;
CRC	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.22	-0.37	3.72e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.4	-6.49	-0.34	3.16e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg00677455	chr12:58241039	CTDSP2	-0.44	-6.54	-0.34	2.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.51	8.27	0.41	3.29e-15	Coronary artery disease;
CRC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.72	-9.99	-0.48	1.09e-20	Cognitive function;
CRC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.7	11.81	0.55	4.42e-27	Alzheimer's disease (late onset);
CRC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.14	-0.45	6.84e-18	Platelet count;
CRC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.77	-0.3	1.88e-8	Aortic root size;
CRC	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.71	6.66	0.34	1.12e-10	Coronary artery disease;
CRC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-7.65	-0.39	2.18e-13	Type 2 diabetes;
CRC	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.55	9.5	0.46	4.51e-19	Schizophrenia;
CRC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17554472	chr22:41940697	POLR3H	-0.56	-6.11	-0.32	2.86e-9	Vitiligo;
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg12564285	chr5:131593104	PDLIM4	0.49	9.37	0.46	1.22e-18	Breast cancer;
CRC	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.62	-0.34	1.48e-10	Educational attainment;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.74	11.35	0.53	2.08e-25	Menarche (age at onset);
CRC	cis	rs4400599	0.618	rs1194582	chr1:154215973	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.71	-0.3	2.49e-8	Platelet distribution width;
CRC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24308560	chr3:49941425	MST1R	-0.45	-6.96	-0.36	1.84e-11	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16586002	chr3:196594898	SENP5	0.4	6.13	0.32	2.47e-9	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21659725	chr3:3221576	CRBN	-0.68	-9.33	-0.46	1.64e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.49	-0.62	3.8e-37	Body mass index;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16415856	chr7:99006352	BUD31;PDAP1	-0.42	-6.25	-0.33	1.3e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg24355006	chr19:1969744	CSNK1G2	0.5	8.07	0.41	1.31e-14	Coronary artery disease;
CRC	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg10724054	chr17:3904396	NA	-0.47	-7.8	-0.4	8.14e-14	Type 2 diabetes;
CRC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07513332	chr6:167530253	CCR6	0.37	6.28	0.33	1.1e-9	Primary biliary cholangitis;
CRC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.4	6.41	0.33	5.03e-10	Testicular germ cell tumor;
CRC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.82	11.15	0.52	1.05e-24	Cerebrospinal P-tau181p levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21796825	chr12:64173751	TMEM5	0.47	6.68	0.35	1.03e-10	Response to antipsychotic treatment;
CRC	cis	rs863345	0.604	rs6669271	chr1:158471999	A/G	cg12129480	chr1:158549410	OR10X1	-0.28	-5.92	-0.31	7.99e-9	Pneumococcal bacteremia;
CRC	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.34	0.37	1.74e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2530545	0.590	rs4313062	chr7:34647331	T/C	cg14401837	chr7:34697493	NPSR1	0.37	5.83	0.31	1.29e-8	IgG glycosylation;
CRC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.4	6.19	0.32	1.79e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	7.44	0.38	8.7e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg11707556	chr5:10655725	ANKRD33B	0.38	7.06	0.36	9.69e-12	Height;
CRC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.36	-0.33	6.83e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.46	-6.11	-0.32	2.77e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.63	-8.64	-0.43	2.44e-16	White matter hyperintensity burden;
CRC	cis	rs9463078	0.669	rs9381364	chr6:45069673	T/C	cg25276700	chr6:44698697	NA	-0.24	-5.76	-0.3	1.95e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg03934865	chr2:198174659	NA	-0.43	-7.4	-0.38	1.17e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs3924048	0.547	rs72642661	chr1:12612873	C/G	cg23650765	chr1:12612165	NA	0.38	7.34	0.38	1.65e-12	Optic cup area;
CRC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.25	0.33	1.28e-9	Self-reported allergy;
CRC	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg01339444	chr6:118972232	C6orf204	0.53	5.87	0.31	1.04e-8	Diastolic blood pressure;
CRC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.02	-10.08	-0.49	5.44e-21	Diabetic kidney disease;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg07869994	chr3:174095190	NA	-0.47	-6.37	-0.33	6.54e-10	Parkinson's disease;
CRC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.68	8.0	0.4	2.19e-14	IgG glycosylation;
CRC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.2	0.32	1.7e-9	Rheumatoid arthritis;
CRC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg15465823	chr12:48382534	COL2A1	-0.36	-5.9	-0.31	9.21e-9	Glycated hemoglobin levels;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.65	10.64	0.51	6.35e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	9.42	0.46	8.14e-19	Alzheimer's disease;
CRC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.06	0.32	3.83e-9	Rheumatoid arthritis;
CRC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.56	-8.73	-0.43	1.33e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.81	11.35	0.53	2.04e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	12.36	0.56	4.57e-29	Chronic sinus infection;
CRC	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.71	-7.62	-0.39	2.75e-13	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00400334	chr2:85981962	ATOH8	-0.49	-6.05	-0.32	3.93e-9	Diisocyanate-induced asthma;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg03774468	chr3:140950104	ACPL2	-0.66	-6.1	-0.32	3.01e-9	Cognitive function;
CRC	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-7.91	-0.4	3.98e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-8.1	-0.41	1.08e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.59	9.25	0.45	2.93e-18	Fibrinogen levels;
CRC	cis	rs10946940	0.965	rs10946935	chr6:27501345	T/C	cg15845792	chr6:28175446	NA	-0.45	-6.16	-0.32	2.14e-9	Systemic lupus erythematosus;
CRC	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.43	-0.38	9.4e-13	Schizophrenia;
CRC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg02766259	chr12:125626809	AACS	-0.45	-7.73	-0.39	1.33e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.34e-9	Major depressive disorder;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.53	6.58	0.34	1.85e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.78	-10.28	-0.49	1.11e-21	Initial pursuit acceleration;
CRC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.81	-12.8	-0.58	1.01e-30	Cognitive function;
CRC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.61	0.57	5.13e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg20312557	chr2:97357134	FER1L5	-0.61	-5.67	-0.3	3.19e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs6840360	0.642	rs4235219	chr4:152346103	T/G	cg09659197	chr4:152720779	NA	0.34	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27180880	chr18:74844787	MBP	0.42	6.87	0.35	3.3e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.38	0.5	5.24e-22	Corneal astigmatism;
CRC	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.27	0.33	1.16e-9	Axial length;
CRC	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.78	-0.3	1.74e-8	Neuroticism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07145255	chr5:59995354	DEPDC1B	0.5	6.49	0.34	3.24e-10	Thyroid stimulating hormone;
CRC	cis	rs1465370	0.720	rs1558917	chr7:130028723	C/T	cg03229158	chr7:130009420	NA	0.45	6.45	0.34	3.91e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15369054	chr17:80825471	TBCD	-0.34	-5.67	-0.3	3.09e-8	Breast cancer;
CRC	cis	rs929596	0.531	rs2741013	chr2:234509911	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-5.73	-0.3	2.26e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg05185784	chr16:90016020	DEF8	0.6	9.6	0.47	2.1e-19	Squamous cell carcinoma;
CRC	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.74	10.19	0.49	2.23e-21	Coronary artery disease;
CRC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg20295408	chr7:1910781	MAD1L1	-0.38	-5.68	-0.3	3.04e-8	Testicular germ cell tumor;
CRC	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.57	7.72	0.39	1.41e-13	Hepatocellular carcinoma;
CRC	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.43	-6.48	-0.34	3.3e-10	Asthma;
CRC	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg21452805	chr1:244014465	NA	0.51	6.74	0.35	7.29e-11	RR interval (heart rate);
CRC	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.46	7.18	0.37	4.78e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	trans	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg20935933	chr6:143382018	AIG1	0.55	7.05	0.36	1.04e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.59e-14	Bipolar disorder;
CRC	cis	rs10894147	0.756	rs1783917	chr11:129741274	T/A	cg27255275	chr11:129766154	NFRKB	0.41	5.75	0.3	2.07e-8	Obesity-related traits;
CRC	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.89e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg03013999	chr17:37608204	MED1	0.47	7.32	0.37	1.94e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	ch.11.29638519R	chr11:29681943	NA	-0.42	-6.7	-0.35	9.12e-11	Aortic root size;
CRC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.18	-0.32	1.9e-9	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07805240	chr7:8008383	GLCCI1	0.41	6.44	0.33	4.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg21251018	chr6:28226885	NKAPL	0.46	6.42	0.33	4.71e-10	Parkinson's disease;
CRC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	trans	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.47	0.34	3.57e-10	Axial length;
CRC	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14751398	chr6:20402153	E2F3	0.43	6.4	0.33	5.2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.57	-8.87	-0.44	4.81e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14769373	chr6:40998127	UNC5CL	0.46	5.97	0.31	6.14e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs10046574	1.000	rs10046574	chr7:135170470	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs96067	0.805	rs4653160	chr1:36599547	C/T	cg25304816	chr1:36627734	MAP7D1	0.43	6.13	0.32	2.46e-9	Corneal structure;
CRC	cis	rs4731207	0.596	rs1525614	chr7:124658600	C/G	cg23710748	chr7:124431027	NA	-0.4	-6.45	-0.34	4.01e-10	Cutaneous malignant melanoma;
CRC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.45	-8.06	-0.41	1.44e-14	Huntington's disease progression;
CRC	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.57	8.17	0.41	6.58e-15	Uric acid levels;
CRC	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg14668889	chr17:73230827	NUP85	-0.5	-7.42	-0.38	9.97e-13	Systemic lupus erythematosus;
CRC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.31e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.37	-5.97	-0.31	6.03e-9	Menopause (age at onset);
CRC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.75	-0.3	2.06e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.04e-9	Bladder cancer;
CRC	trans	rs41265665	0.661	rs1247636	chr4:74548474	T/A	cg09364089	chr1:92948788	GFI1	-0.67	-6.0	-0.31	5.13e-9	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23742887	chr15:34629998	SLC12A6	0.43	6.03	0.32	4.3e-9	Anxiety disorder;
CRC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.72	9.65	0.47	1.48e-19	Heart rate;
CRC	cis	rs12476592	0.602	rs1348803	chr2:63895617	C/T	cg10828910	chr2:63850056	LOC388955	0.52	6.44	0.33	4.3e-10	Childhood ear infection;
CRC	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.44	-5.98	-0.31	5.83e-9	Diastolic blood pressure;
CRC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.39	-5.88	-0.31	1e-8	Crohn's disease;
CRC	cis	rs972578	0.837	rs5759017	chr22:43296324	A/C	cg01576275	chr22:43409880	NA	-0.39	-6.19	-0.32	1.74e-9	Mean platelet volume;
CRC	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-0.66	-9.8	-0.48	4.69e-20	Acne (severe);
CRC	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg19025524	chr12:109796872	NA	-0.47	-6.76	-0.35	6.22e-11	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05564086	chr17:26926050	SPAG5	0.37	6.07	0.32	3.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg20356878	chr3:121714668	ILDR1	0.51	7.99	0.4	2.27e-14	Cognitive performance;
CRC	cis	rs3823572	0.586	rs2953625	chr7:133657789	A/G	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg25985355	chr7:65971099	NA	-0.52	-6.0	-0.31	5.22e-9	Diabetic kidney disease;
CRC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg17724175	chr1:150552817	MCL1	-0.5	-8.16	-0.41	7.11e-15	Tonsillectomy;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.96	16.69	0.68	9.46e-46	Menarche (age at onset);
CRC	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.82	-10.47	-0.5	2.4e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.67	-0.35	1.09e-10	Body mass index;
CRC	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.9	-0.31	8.89e-9	Subjective well-being;
CRC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	6.16	0.32	2.11e-9	Diabetic retinopathy;
CRC	cis	rs8040855	0.627	rs12909971	chr15:85588998	C/G	cg10818794	chr15:86012489	AKAP13	-0.42	-5.64	-0.3	3.76e-8	Bulimia nervosa;
CRC	cis	rs3736485	0.844	rs6493501	chr15:51815643	C/G	cg08986416	chr15:51914746	DMXL2	0.49	7.12	0.37	6.66e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.69	9.08	0.45	1.04e-17	Platelet count;
CRC	cis	rs6445967	0.966	rs35955376	chr3:58297779	G/A	cg23715586	chr3:58305044	RPP14	0.35	5.84	0.31	1.25e-8	Platelet count;
CRC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	8.82	0.44	6.95e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg23815491	chr16:72088622	HP	0.54	6.17	0.32	2.03e-9	Coronary artery disease;
CRC	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.54	7.05	0.36	1.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg16476235	chr8:21771668	DOK2	0.38	6.21	0.32	1.62e-9	Mean corpuscular volume;
CRC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-0.92	-15.9	-0.66	1.24e-42	Body mass index;
CRC	cis	rs6577655	0.517	rs11998030	chr8:135585325	C/T	cg17885191	chr8:135476712	NA	0.48	5.75	0.3	1.99e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.63	10.67	0.51	5.21e-23	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg06470822	chr6:28175283	NA	0.85	9.7	0.47	1.01e-19	Parkinson's disease;
CRC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	9.88	0.48	2.43e-20	Systolic blood pressure;
CRC	cis	rs1545257	0.505	rs7583687	chr2:24634003	C/G	cg06627628	chr2:24431161	ITSN2	-0.46	-6.74	-0.35	7.21e-11	Sjögren's syndrome;
CRC	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	6.78	0.35	5.64e-11	Eye color traits;
CRC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg11189052	chr15:85197271	WDR73	0.55	7.28	0.37	2.4e-12	Schizophrenia;
CRC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.48	-7.09	-0.36	8.14e-12	Menarche (age at onset);
CRC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg19913688	chr11:428466	ANO9	-0.73	-7.4	-0.38	1.18e-12	Body mass index;
CRC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg14711859	chr11:8959438	ASCL3	0.37	6.2	0.32	1.73e-9	Hemoglobin concentration;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.66	6.96	0.36	1.9e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.26	-0.33	1.18e-9	Lung cancer;
CRC	cis	rs6988985	0.765	rs4641039	chr8:143977819	T/C	cg10324643	chr8:143916377	GML	0.38	6.27	0.33	1.15e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.81	-0.35	4.6e-11	Body mass index;
CRC	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.8	0.3	1.55e-8	Educational attainment;
CRC	cis	rs12760731	0.565	rs11585236	chr1:178108441	G/A	cg00404053	chr1:178313656	RASAL2	1.08	11.32	0.53	2.69e-25	Obesity-related traits;
CRC	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.5	7.75	0.39	1.14e-13	Carotid intima media thickness;
CRC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg25456477	chr12:86230367	RASSF9	-0.36	-6.06	-0.32	3.68e-9	Major depressive disorder;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-10.7	-0.51	4.12e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.65	9.12	0.45	7.49e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9549328	0.700	rs34890317	chr13:113617245	G/C	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.32e-19	Systolic blood pressure;
CRC	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg02536541	chr18:77568900	NA	-0.38	-5.62	-0.3	4.03e-8	Schizophrenia;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg18301423	chr5:131593218	PDLIM4	0.31	5.93	0.31	7.79e-9	Blood metabolite levels;
CRC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.48	6.99	0.36	1.5e-11	Cognitive function;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg21251018	chr6:28226885	NKAPL	-0.47	-6.4	-0.33	5.49e-10	Parkinson's disease;
CRC	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg09040174	chr2:113837401	NA	0.65	10.3	0.49	9.83e-22	Protein quantitative trait loci;
CRC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg10272801	chr16:14013773	ERCC4	-0.69	-6.16	-0.32	2.15e-9	Cognitive function;
CRC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg01065977	chr19:18549689	ISYNA1	-0.39	-6.14	-0.32	2.44e-9	Breast cancer;
CRC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07157834	chr1:205819609	PM20D1	-0.43	-5.94	-0.31	7.15e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs524281	0.817	rs10791859	chr11:65978453	C/T	cg14541915	chr11:65894463	PACS1	0.34	5.65	0.3	3.39e-8	Electroencephalogram traits;
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.65	11.35	0.53	2.11e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.77	-12.21	-0.56	1.55e-28	Multiple myeloma;
CRC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-7.5	-0.38	5.95e-13	Bipolar disorder;
CRC	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.42	6.36	0.33	6.65e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.49	11.99	0.55	9.79e-28	Granulocyte percentage of myeloid white cells;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14331148	chr19:47551893	TMEM160	-0.39	-6.32	-0.33	8.69e-10	Obesity-related traits;
CRC	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.83	10.43	0.5	3.46e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-5.78	-0.3	1.71e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.52	7.94	0.4	3.29e-14	Crohn's disease;
CRC	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.44	-6.38	-0.33	5.89e-10	Magnesium levels;
CRC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.54	-0.34	2.38e-10	Blood metabolite levels;
CRC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.51	7.61	0.39	2.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg18232548	chr7:50535776	DDC	0.45	5.77	0.3	1.88e-8	Malaria;
CRC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.67	9.37	0.46	1.22e-18	Lung cancer;
CRC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-11.95	-0.55	1.38e-27	Prostate cancer;
CRC	cis	rs6496667	0.865	rs13329288	chr15:90897451	C/T	cg04176472	chr15:90893244	GABARAPL3	0.52	7.95	0.4	3.04e-14	Rheumatoid arthritis;
CRC	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.46	6.85	0.35	3.63e-11	Crohn's disease;
CRC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg17306686	chr7:157230923	NA	0.46	6.61	0.34	1.53e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.85	-20.84	-0.75	4.37e-62	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4908768	0.501	rs7518608	chr1:8557320	C/G	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.86	-0.48	2.81e-20	Blood protein levels;
CRC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.93	16.65	0.68	1.38e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg05570707	chr2:24270316	C2orf44	0.39	5.97	0.31	6.04e-9	Body mass index;
CRC	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.63	-10.77	-0.51	2.36e-23	Blood protein levels;
CRC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg07884673	chr3:53033167	SFMBT1	0.69	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg24011408	chr12:48396354	COL2A1	-0.44	-6.47	-0.34	3.47e-10	Glycated hemoglobin levels;
CRC	cis	rs739496	0.542	rs7300400	chr12:111792179	A/C	cg10833066	chr12:111807467	FAM109A	0.56	7.25	0.37	3.06e-12	Platelet count;
CRC	trans	rs7730934	1.000	rs7726239	chr5:55295306	C/A	cg10323188	chr3:28613979	NA	0.53	6.14	0.32	2.36e-9	Blood protein levels;
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg19041857	chr6:27730383	NA	-0.75	-7.18	-0.37	4.64e-12	Breast cancer;
CRC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.61	-9.06	-0.45	1.18e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.94	15.65	0.65	1.22e-41	Ewing sarcoma;
CRC	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.58	8.1	0.41	1.08e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.49	-7.5	-0.38	5.91e-13	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.09	0.36	7.99e-12	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00013441	chr12:123258908	CCDC62	0.41	6.42	0.33	4.88e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	16.51	0.67	4.85e-45	Platelet count;
CRC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.5	7.09	0.36	8.33e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24037166	chr10:75255724	PPP3CB	0.36	5.97	0.31	6.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg01788221	chr16:89496183	ANKRD11	-0.42	-6.27	-0.33	1.13e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-10.67	-0.51	5.14e-23	Cognitive function;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08858051	chr1:94313454	NA	0.45	6.6	0.34	1.65e-10	Schizophrenia;
CRC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg02776659	chr21:47717406	C21orf57	-0.34	-5.7	-0.3	2.61e-8	Testicular germ cell tumor;
CRC	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg25182066	chr10:30743637	MAP3K8	-0.41	-6.11	-0.32	2.86e-9	Inflammatory bowel disease;
CRC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.42	-7.96	-0.4	2.83e-14	Colorectal cancer;
CRC	cis	rs2179367	0.959	rs9285519	chr6:149692935	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.49	-0.34	3.17e-10	Dupuytren's disease;
CRC	cis	rs2834256	0.580	rs2040121	chr21:35146577	T/G	cg14850771	chr21:34775459	IFNGR2	0.42	6.03	0.32	4.38e-9	Red cell distribution width;
CRC	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.53	6.98	0.36	1.65e-11	Coronary artery disease;
CRC	cis	rs17067123	0.614	rs6813463	chr4:180068739	A/T	cg26610307	chr4:180072759	NA	-0.56	-6.72	-0.35	7.84e-11	Response to hepatitis C treatment;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-11.43	-0.53	1.04e-25	Ulcerative colitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27220681	chr17:685915	RNMTL1;GLOD4	0.41	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.42	6.41	0.33	4.95e-10	Red blood cell count;
CRC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg12064134	chr16:90016061	DEF8	0.61	10.5	0.5	1.89e-22	Squamous cell carcinoma;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg23254163	chr1:152506842	NA	0.46	9.02	0.45	1.6e-17	Hair morphology;
CRC	cis	rs10486722	0.606	rs6463040	chr7:41793377	A/G	cg22138096	chr7:41772439	LOC285954	0.62	7.28	0.37	2.51e-12	Pit-and-Fissure caries;
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	5.1e-12	Life satisfaction;
CRC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-1.02	-20.58	-0.75	4.48e-61	Headache;
CRC	cis	rs9292777	0.865	rs7711427	chr5:40414886	A/C	cg09067459	chr5:40385259	NA	0.51	8.86	0.44	4.94e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.86	-0.31	1.1e-8	Life satisfaction;
CRC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.5	-7.68	-0.39	1.89e-13	Monocyte count;
CRC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.5	7.04	0.36	1.09e-11	Pulse pressure;
CRC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.61	-10.74	-0.51	2.82e-23	Aortic root size;
CRC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	1.22	14.47	0.62	4.45e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.5	-0.54	5.96e-26	Psoriasis vulgaris;
CRC	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.34	12.9	0.58	4.23e-31	Granulocyte percentage of myeloid white cells;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg22950391	chr6:28109938	ZNF192	-0.4	-6.02	-0.31	4.6e-9	Daytime sleep phenotypes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01433114	chr10:88853758	GLUD1;FAM35A	0.46	6.65	0.34	1.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.6	-6.24	-0.33	1.32e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.72	-13.01	-0.58	1.61e-31	Iron status biomarkers;
CRC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.14	-0.45	6.5e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06505273	chr16:24850292	NA	0.53	6.28	0.33	1.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6700896	0.897	rs11208701	chr1:66134698	C/T	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	cis	rs7945718	0.870	rs10831903	chr11:12758660	C/T	cg25843174	chr11:12811716	TEAD1	0.51	9.22	0.45	3.64e-18	Educational attainment (years of education);
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg15147215	chr3:52552868	STAB1	-0.65	-10.97	-0.52	4.65e-24	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13487956	chr18:47340408	SCARNA17;ACAA2	0.37	6.03	0.32	4.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08821669	chr12:120875978	COX6A1	0.45	6.08	0.32	3.35e-9	Survival in pancreatic cancer;
CRC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.9	8.58	0.43	3.84e-16	Type 2 diabetes;
CRC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	trans	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13452718	chr1:23670887	HNRNPR	0.45	6.28	0.33	1.09e-9	Response to antipsychotic treatment;
CRC	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	6.01	0.31	4.92e-9	Monocyte count;
CRC	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg05049329	chr1:226924846	ITPKB	0.39	8.82	0.44	6.8e-17	Parkinson's disease;
CRC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.84	-11.97	-0.55	1.23e-27	Gut microbiome composition (summer);
CRC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26850624	chr5:429559	AHRR	0.52	8.87	0.44	4.87e-17	Cystic fibrosis severity;
CRC	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.78	-0.3	1.74e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.43	6.35	0.33	7.13e-10	Obesity-related traits;
CRC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.45	0.42	9.39e-16	Parkinson's disease;
CRC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.39	-5.68	-0.3	3.03e-8	Uric acid clearance;
CRC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.59	8.48	0.42	7.95e-16	Multiple sclerosis;
CRC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg24881330	chr22:46731750	TRMU	0.69	8.6	0.43	3.3e-16	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg10729496	chr3:10149963	C3orf24	0.51	5.9	0.31	8.81e-9	Alzheimer's disease;
CRC	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	1.1	12.9	0.58	4.37e-31	Obesity-related traits;
CRC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.69	11.96	0.55	1.32e-27	Resting heart rate;
CRC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg19678392	chr7:94953810	PON1	-0.61	-7.43	-0.38	9.49e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.18	0.32	1.89e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.0	11.32	0.53	2.52e-25	Vitiligo;
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg15845792	chr6:28175446	NA	0.75	7.86	0.4	5.59e-14	Depression;
CRC	cis	rs459193	0.917	rs40270	chr5:55804552	A/C	cg00049729	chr5:55776345	NA	0.4	5.77	0.3	1.82e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg08508325	chr11:3079039	CARS	-0.41	-7.19	-0.37	4.38e-12	Longevity;
CRC	cis	rs12024301	0.557	rs2231239	chr1:183602075	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg16141378	chr3:129829833	LOC729375	-0.43	-6.24	-0.33	1.37e-9	Mood instability;
CRC	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	cg04338863	chr8:33670619	NA	0.38	6.52	0.34	2.58e-10	Body mass index;
CRC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.49	-8.65	-0.43	2.35e-16	Longevity;
CRC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg25985355	chr7:65971099	NA	-0.51	-5.91	-0.31	8.44e-9	Gout;
CRC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.63	0.57	4.28e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.78	-0.3	1.74e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.38	0.38	1.27e-12	Total body bone mineral density;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	10.38	0.5	5.23e-22	Lymphocyte counts;
CRC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg05192639	chr6:26864778	GUSBL1	-0.31	-5.84	-0.31	1.25e-8	Schizophrenia;
CRC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-8.2	-0.41	5.64e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4700695	0.764	rs152993	chr5:65262968	A/T	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.48	5.9	0.31	9.01e-9	Platelet count;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.07	-0.36	9.29e-12	Longevity;Endometriosis;
CRC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.69	11.43	0.53	1.04e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02450064	chr17:40260053	DHX58	-0.42	-6.13	-0.32	2.54e-9	Fibrinogen levels;
CRC	cis	rs73206853	0.764	rs56179460	chr12:111125774	C/G	cg12870014	chr12:110450643	ANKRD13A	0.72	6.67	0.35	1.1e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6804368	0.553	rs9819139	chr3:30770421	G/A	cg06106510	chr3:30762233	NA	0.35	5.62	0.3	4.01e-8	Blood metabolite levels;
CRC	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	8.57	0.43	3.94e-16	Neuroticism;
CRC	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg05935833	chr10:81318306	SFTPA2	-0.75	-7.66	-0.39	2.06e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.48	7.67	0.39	1.95e-13	Prostate cancer;
CRC	trans	rs17361889	0.727	rs17458603	chr7:16279593	A/G	cg08271366	chr16:82816457	CDH13	0.24	6.23	0.32	1.39e-9	Pediatric bone mineral content (hip);
CRC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.76	-0.3	1.93e-8	Breast cancer;
CRC	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.78	9.24	0.45	3.17e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4708431	0.539	rs35108423	chr6:168491898	A/G	cg02770688	chr6:168491649	NA	0.4	5.97	0.31	6.13e-9	Attention deficit hyperactivity disorder (combined symptoms);
CRC	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.69	9.68	0.47	1.12e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg06470822	chr6:28175283	NA	0.87	8.85	0.44	5.4e-17	Lung cancer in ever smokers;
CRC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7605827	0.964	rs6748427	chr2:15564799	T/C	cg19274914	chr2:15703543	NA	0.38	5.84	0.31	1.23e-8	Educational attainment (years of education);
CRC	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.63	-10.46	-0.5	2.75e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs7254114	0.578	rs73506605	chr19:11307564	G/A	cg02815516	chr19:11306319	KANK2	-0.34	-6.51	-0.34	2.73e-10	Immature fraction of reticulocytes;
CRC	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.29	-0.37	2.27e-12	Crohn's disease;
CRC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.33	12.69	0.57	2.59e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.64	10.01	0.48	9.33e-21	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg03037974	chr15:76606532	NA	0.57	8.82	0.44	6.85e-17	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-8.89	-0.44	4.07e-17	Menarche (age at onset);
CRC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-5.93	-0.31	7.86e-9	Heart rate;
CRC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.95	0.52	5.22e-24	Motion sickness;
CRC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.84	11.5	0.54	5.87e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.7	0.35	8.8e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11212617	0.935	rs652541	chr11:108226025	C/T	cg12106634	chr11:108092400	ATM;NPAT	-0.4	-5.74	-0.3	2.12e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12282928	1.000	rs10838845	chr11:48280299	C/T	cg20307385	chr11:47447363	PSMC3	0.48	5.93	0.31	7.64e-9	Migraine - clinic-based;
CRC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.88	0.31	1.03e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.44	6.55	0.34	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.44	0.33	4.33e-10	Triglycerides;
CRC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.8	13.7	0.6	4.08e-34	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.57e-12	Life satisfaction;
CRC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.41	-7.26	-0.37	2.85e-12	Metabolite levels;
CRC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.45	9.25	0.45	2.89e-18	Renal cell carcinoma;
CRC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.37	5.64	0.3	3.61e-8	Brugada syndrome;
CRC	trans	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.3	-0.33	9.55e-10	Menarche (age at onset);
CRC	trans	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg20935933	chr6:143382018	AIG1	0.54	7.05	0.36	1.08e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02608231	chr3:47844363	DHX30	0.43	6.0	0.31	5.16e-9	Anxiety disorder;
CRC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.67	10.02	0.48	8.5e-21	Monocyte count;
CRC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg09264619	chr17:80180166	NA	0.39	6.5	0.34	3.03e-10	Life satisfaction;
CRC	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.75	-10.15	-0.49	3.06e-21	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.11	0.49	4.15e-21	Platelet count;
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.63	-9.87	-0.48	2.8e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.41	6.21	0.32	1.63e-9	Testicular germ cell tumor;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg00919237	chr7:87102261	ABCB4	-0.53	-6.7	-0.35	8.99e-11	Gallbladder cancer;
CRC	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.41	6.34	0.33	7.75e-10	Alcohol dependence (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01525597	chr12:1739061	WNT5B	0.46	6.47	0.34	3.6e-10	Response to antipsychotic treatment;
CRC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.72	-0.43	1.39e-16	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-6.98	-0.36	1.61e-11	HDL cholesterol;
CRC	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.64	7.03	0.36	1.21e-11	Prostate cancer;
CRC	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg10761708	chr20:43804764	PI3	0.48	5.64	0.3	3.58e-8	Blood protein levels;
CRC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.59	0.47	2.34e-19	Lung cancer;
CRC	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.77	-8.16	-0.41	7.07e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.43	6.36	0.33	6.77e-10	Menopause (age at onset);
CRC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg23262073	chr20:60523788	NA	-0.5	-7.3	-0.37	2.2e-12	Body mass index;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.62	11.28	0.53	3.48e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.7	-9.21	-0.45	3.93e-18	Bronchopulmonary dysplasia;
CRC	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.48	-8.37	-0.42	1.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9323205	0.723	rs55980461	chr14:51737434	G/A	cg23942311	chr14:51606299	NA	-0.5	-5.66	-0.3	3.23e-8	Cancer;
CRC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24308560	chr3:49941425	MST1R	-0.45	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.68	-11.21	-0.53	6.45e-25	Hepatocellular carcinoma;
CRC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg15105011	chr4:940614	TMEM175	0.57	8.86	0.44	5.27e-17	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	0.93	8.97	0.44	2.3e-17	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.69	0.3	2.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg13047869	chr3:10149882	C3orf24	0.39	5.95	0.31	6.9e-9	Alzheimer's disease;
CRC	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg27017172	chr16:57497170	POLR2C	0.66	5.88	0.31	1.01e-8	Blood protein levels;
CRC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.01	-0.48	9.04e-21	Menarche (age at onset);
CRC	cis	rs2160860	0.965	rs2543044	chr8:39819087	C/T	cg11363097	chr8:39792086	IDO2	-0.36	-5.78	-0.3	1.78e-8	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.98	-0.31	5.84e-9	Life satisfaction;
CRC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg24562669	chr7:97807699	LMTK2	0.45	7.66	0.39	2.06e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	12.31	0.56	6.96e-29	Platelet count;
CRC	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.56	-8.18	-0.41	6.16e-15	Autism;
CRC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.41	5.94	0.31	7.11e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg18357645	chr12:58087776	OS9	-0.5	-5.81	-0.3	1.51e-8	Multiple sclerosis;
CRC	trans	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.19	-0.32	1.82e-9	Aortic root size;
CRC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.51	7.35	0.38	1.62e-12	Height;
CRC	trans	rs4714291	0.802	rs1474870	chr6:39980359	C/T	cg02267698	chr19:7991119	CTXN1	0.49	6.82	0.35	4.29e-11	Strep throat;
CRC	cis	rs61332075	0.504	rs7596847	chr2:239321118	T/A	cg18131467	chr2:239335373	ASB1	-0.71	-8.87	-0.44	4.89e-17	Lung function (FEV1/FVC);
CRC	cis	rs10221833	0.602	rs355881	chr2:165633716	C/G	cg03182029	chr2:165697222	COBLL1	0.49	5.8	0.3	1.56e-8	Response to statin therapy;
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs3218092	1.000	rs3218092	chr6:41906661	A/G	cg17623882	chr6:41773611	USP49	0.48	5.65	0.3	3.52e-8	Red cell distribution width;
CRC	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.51	-7.31	-0.37	2.02e-12	Cocaine dependence;
CRC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	cis	rs2637266	0.519	rs11001805	chr10:78286474	C/T	cg18941641	chr10:78392320	NA	-0.36	-6.03	-0.32	4.41e-9	Pulmonary function;
CRC	cis	rs73206853	0.841	rs56184938	chr12:110817193	T/C	cg12870014	chr12:110450643	ANKRD13A	0.77	8.38	0.42	1.59e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg27489772	chr12:121021490	NA	-0.49	-6.57	-0.34	2e-10	Type 1 diabetes nephropathy;
CRC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.5	9.45	0.46	6.44e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg10298567	chr3:47292165	KIF9	-0.39	-6.02	-0.32	4.64e-9	Colorectal cancer;
CRC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.58	10.47	0.5	2.49e-22	Multiple system atrophy;
CRC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.62	-7.62	-0.39	2.78e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.47	-6.42	-0.33	4.79e-10	Height;
CRC	cis	rs17767392	0.794	rs61989259	chr14:71733506	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.42	-0.33	4.67e-10	Mitral valve prolapse;
CRC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.19	-0.37	4.26e-12	Schizophrenia;
CRC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.83	12.78	0.58	1.18e-30	Menarche (age at onset);
CRC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04731861	chr2:219085781	ARPC2	0.33	6.95	0.36	2.01e-11	Colorectal cancer;
CRC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.58	0.34	1.86e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg08075719	chr14:103021372	NA	0.65	7.6	0.39	3.13e-13	Platelet count;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg25164649	chr6:28176230	NA	0.6	8.51	0.42	6.28e-16	Parkinson's disease;
CRC	cis	rs995000	0.931	rs1629122	chr1:63046578	C/A	cg19896129	chr1:63156450	NA	-0.43	-6.7	-0.35	8.97e-11	Triglyceride levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11489389	chr3:63849240	ATXN7;THOC7	0.39	6.29	0.33	9.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg11657817	chr20:23433608	CST11	0.57	9.74	0.47	7.08e-20	Facial morphology (factor 15, philtrum width);
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.66	-10.07	-0.49	5.83e-21	Diastolic blood pressure;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-8.8	-0.44	7.71e-17	Mean corpuscular hemoglobin concentration;
CRC	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.01	0.45	1.67e-17	Fuchs's corneal dystrophy;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg17158414	chr2:27665306	KRTCAP3	0.28	6.0	0.31	5.27e-9	Total body bone mineral density;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02290350	chr8:58132656	NA	-0.51	-5.89	-0.31	9.42e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg27266060	chr8:22091797	NA	0.37	6.23	0.32	1.4e-9	Hypertriglyceridemia;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg26028573	chr6:26043587	HIST1H2BB	0.51	7.37	0.38	1.39e-12	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg17545662	chr6:170176663	C6orf70	0.53	5.82	0.31	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.4	-6.83	-0.35	4.13e-11	Hip circumference;Waist circumference;
CRC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04880052	chr2:219191631	PNKD	-0.44	-6.99	-0.36	1.5e-11	Colorectal cancer;
CRC	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.45	-6.02	-0.31	4.77e-9	Tuberculosis;
CRC	cis	rs10503871	0.625	rs13275869	chr8:30310335	T/C	cg26383811	chr8:30366931	RBPMS	0.48	7.61	0.39	2.97e-13	Metabolite levels  (X-11787);
CRC	cis	rs10992471	0.580	rs724102	chr9:95383290	T/C	cg14631576	chr9:95140430	CENPP	-0.34	-5.85	-0.31	1.21e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg01339444	chr6:118972232	C6orf204	0.54	6.01	0.31	5e-9	Diastolic blood pressure;
CRC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.8	-0.35	4.81e-11	Inflammatory skin disease;
CRC	cis	rs2075064	0.903	rs7034780	chr9:126788935	A/G	cg14112217	chr9:126806003	NA	0.39	5.67	0.3	3.12e-8	Waist circumference;
CRC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.97	0.31	6.3e-9	Personality dimensions;
CRC	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-18.76	-0.72	6.3e-54	Ulcerative colitis;
CRC	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.46	6.4	0.33	5.5e-10	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.63	9.19	0.45	4.6e-18	Schizophrenia;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12273811	chr6:28175739	NA	0.62	7.96	0.4	2.74e-14	Parkinson's disease;
CRC	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.47	7.18	0.37	4.62e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg13482628	chr17:19912719	NA	-0.4	-6.22	-0.32	1.47e-9	Obesity-related traits;
CRC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.56	10.99	0.52	3.97e-24	Schizophrenia;
CRC	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg24588162	chr13:113633484	MCF2L	-0.38	-6.67	-0.35	1.07e-10	Systolic blood pressure;
CRC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg02569458	chr12:86230093	RASSF9	0.46	7.8	0.39	8.41e-14	Major depressive disorder;
CRC	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.86e-40	Colorectal cancer;
CRC	cis	rs62408225	1.000	rs969577	chr6:90982387	T/C	cg06866423	chr6:90926672	BACH2	0.51	8.44	0.42	1.01e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.8	13.08	0.58	8.9e-32	Height;
CRC	cis	rs2637266	0.600	rs11591359	chr10:78339907	G/A	cg18941641	chr10:78392320	NA	-0.36	-6.05	-0.32	3.87e-9	Pulmonary function;
CRC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.83	-0.31	1.29e-8	Alzheimer's disease (late onset);
CRC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg20848291	chr7:100343083	ZAN	0.4	6.19	0.32	1.83e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs4481887	0.504	rs4576682	chr1:248358694	A/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg26608667	chr7:1196370	ZFAND2A	0.45	7.21	0.37	3.98e-12	Longevity;Endometriosis;
CRC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs1943345	0.556	rs588956	chr11:82926047	T/C	cg07047830	chr11:82868014	PCF11	0.45	6.42	0.33	4.74e-10	Obesity-related traits;
CRC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-5.66	-0.3	3.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.55	9.22	0.45	3.54e-18	Lung function (FVC);
CRC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.12	-0.32	2.64e-9	Alzheimer's disease (late onset);
CRC	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	0.96	7.0	0.36	1.48e-11	Fat distribution (HIV);
CRC	cis	rs990171	1.000	rs3860444	chr2:103007623	A/G	cg03938978	chr2:103052716	IL18RAP	0.47	5.89	0.31	9.5e-9	Lymphocyte counts;
CRC	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.51	-8.14	-0.41	8.15e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg14664628	chr15:75095509	CSK	0.46	6.83	0.35	4.21e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs911119	0.955	rs6048952	chr20:23607257	A/G	cg16589663	chr20:23618590	CST3	0.47	6.73	0.35	7.35e-11	Chronic kidney disease;
CRC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.48	6.14	0.32	2.42e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg19193384	chr17:30244184	NA	-0.51	-6.68	-0.35	9.99e-11	Hip circumference adjusted for BMI;
CRC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.37	0.46	1.23e-18	Lymphocyte counts;
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg24046110	chr8:143859143	LYNX1	0.47	8.17	0.41	6.57e-15	Urinary tract infection frequency;
CRC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.52	8.4	0.42	1.36e-15	Cystic fibrosis severity;
CRC	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg02733842	chr7:1102375	C7orf50	-0.68	-7.74	-0.39	1.2e-13	Bronchopulmonary dysplasia;
CRC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg25985355	chr7:65971099	NA	0.52	5.83	0.31	1.31e-8	Diabetic kidney disease;
CRC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.99	0.52	3.88e-24	Motion sickness;
CRC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.73	-9.23	-0.45	3.3e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.38	5.98	0.31	5.76e-9	Crohn's disease;
CRC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.85	-0.31	1.19e-8	Aortic root size;
CRC	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.42	6.35	0.33	7.1e-10	Alcohol dependence;
CRC	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg24881330	chr22:46731750	TRMU	0.68	8.07	0.41	1.34e-14	LDL cholesterol;Cholesterol, total;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17466598	chr12:98988242	SLC25A3	0.41	6.07	0.32	3.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.24e-10	Alzheimer's disease (late onset);
CRC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg15962314	chr1:44399869	ARTN	-0.31	-5.97	-0.31	6.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg08796741	chr22:46663681	TTC38	0.49	6.28	0.33	1.07e-9	Resistin levels;
CRC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.91	0.31	8.63e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg12193833	chr17:30244370	NA	-0.62	-7.94	-0.4	3.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.0	-11.59	-0.54	2.72e-26	Alzheimer's disease;
CRC	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg26727032	chr16:67993705	SLC12A4	-0.65	-10.01	-0.48	9.41e-21	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg11189052	chr15:85197271	WDR73	0.63	8.95	0.44	2.7e-17	Schizophrenia;
CRC	trans	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg05376469	chr2:102649931	NA	-0.38	-6.33	-0.33	7.97e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg24848437	chr7:2645542	IQCE	0.58	6.13	0.32	2.5e-9	Urate levels in lean individuals;
CRC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg15445000	chr17:37608096	MED1	-0.34	-6.78	-0.35	5.64e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg01251360	chr16:68772225	CDH1	-0.24	-5.89	-0.31	9.53e-9	Colorectal cancer;
CRC	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg14768367	chr16:72042858	DHODH	0.75	6.3	0.33	9.32e-10	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg26566898	chr11:117069891	TAGLN	0.32	6.83	0.35	4.1e-11	Blood protein levels;
CRC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.39	-6.04	-0.32	4.15e-9	Coronary artery disease or ischemic stroke;
CRC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.47	-0.53	7.28e-26	Platelet distribution width;
CRC	trans	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.21e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg26875233	chr11:93583750	C11orf90	-0.34	-6.66	-0.34	1.17e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg04969067	chr8:143858791	LYNX1	-0.43	-6.77	-0.35	5.89e-11	Urinary tract infection frequency;
CRC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.12	10.78	0.51	2.04e-23	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.43	-5.96	-0.31	6.64e-9	Schizophrenia;
CRC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.45	-7.75	-0.39	1.18e-13	Mitral valve prolapse;
CRC	trans	rs2303319	0.504	rs12465645	chr2:162437639	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.01	-0.31	5.03e-9	Cognitive function;
CRC	cis	rs2108622	0.668	rs62106153	chr19:15978507	C/T	cg13772218	chr19:15982569	NA	0.48	6.72	0.35	8.16e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.62	-8.7	-0.43	1.61e-16	Carotid intima media thickness;
CRC	cis	rs375066	0.599	rs10412955	chr19:44354868	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.72	-0.3	2.36e-8	Depression;
CRC	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.27	-0.33	1.12e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg08260959	chr6:26240920	HIST1H4F	0.39	5.97	0.31	6.1e-9	Gout;Renal underexcretion gout;
CRC	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg11271282	chr2:238384023	NA	0.46	5.97	0.31	6.3e-9	Prostate cancer;
CRC	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg15038512	chr6:170123185	PHF10	-0.39	-6.05	-0.32	3.91e-9	Obesity-related traits;
CRC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.6	0.39	3.13e-13	Lymphocyte percentage of white cells;
CRC	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	0.85	8.23	0.41	4.37e-15	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03001875	chr1:234614834	TARBP1	0.48	6.65	0.34	1.26e-10	Anxiety disorder;
CRC	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.01	-0.31	4.94e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12476592	0.636	rs262493	chr2:63845066	G/T	cg10828910	chr2:63850056	LOC388955	0.45	5.68	0.3	2.97e-8	Childhood ear infection;
CRC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.62	10.62	0.51	7.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	10.63	0.51	6.96e-23	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.4	-7.23	-0.37	3.44e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg23262073	chr20:60523788	NA	-0.42	-6.63	-0.34	1.38e-10	Body mass index;
CRC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs11212617	0.967	rs419716	chr11:108221099	G/T	cg14761454	chr11:108092087	ATM;NPAT	-0.4	-6.08	-0.32	3.42e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9292777	0.535	rs1031168	chr5:40381620	T/C	cg09067459	chr5:40385259	NA	0.45	6.97	0.36	1.73e-11	Crohn's disease;Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17436946	chr4:39699568	UBE2K	0.39	6.46	0.34	3.85e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.75	8.91	0.44	3.68e-17	Response to hepatitis C treatment;
CRC	cis	rs12936587	0.576	rs8073975	chr17:17555631	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.38	-5.7	-0.3	2.73e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.44	-7.93	-0.4	3.44e-14	Reticulocyte fraction of red cells;
CRC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	10.02	0.48	8.62e-21	HIV-1 control;
CRC	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg07423050	chr13:99094983	FARP1	0.45	6.41	0.33	5.15e-10	Neuroticism;
CRC	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.11	14.08	0.61	1.5e-35	Uric acid levels;
CRC	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	6.83	0.35	4.1e-11	Eye color traits;
CRC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.55	-7.51	-0.38	5.54e-13	Colorectal cancer;
CRC	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4664293	0.836	rs7567818	chr2:160602697	C/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg06713098	chr7:45960367	IGFBP3	0.44	6.85	0.35	3.65e-11	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17140673	chr4:111117400	ELOVL6	0.45	6.73	0.35	7.75e-11	Response to antipsychotic treatment;
CRC	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.49	-0.34	3.16e-10	Breast cancer;
CRC	cis	rs7215564	0.818	rs112155856	chr17:78594573	A/T	cg09596252	chr17:78655493	RPTOR	0.59	5.77	0.3	1.82e-8	Myopia (pathological);
CRC	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg27205649	chr11:78285834	NARS2	0.46	5.83	0.31	1.35e-8	Alzheimer's disease (survival time);
CRC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.25	5.82	0.31	1.42e-8	Psoriasis;
CRC	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg20354231	chr13:53171401	NA	-0.48	-7.75	-0.39	1.16e-13	Lewy body disease;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg23587288	chr2:27483067	SLC30A3	-0.33	-5.66	-0.3	3.31e-8	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19419581	chr17:79482410	NA	0.48	7.04	0.36	1.15e-11	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13198984	chr17:80129470	CCDC57	0.49	8.6	0.43	3.33e-16	Life satisfaction;
CRC	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg27398640	chr15:77910606	LINGO1	0.42	7.9	0.4	4.24e-14	Type 2 diabetes;
CRC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg14828511	chr1:107599125	PRMT6	0.47	6.45	0.34	3.91e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.3	-0.49	9.29e-22	Tonsillectomy;
CRC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg03037974	chr15:76606532	NA	0.68	11.13	0.52	1.22e-24	Blood metabolite levels;
CRC	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.72	-0.3	2.44e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19717773	chr7:2847554	GNA12	-0.45	-6.42	-0.33	4.72e-10	Height;
CRC	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-0.7	-7.84	-0.4	6.44e-14	Response to hepatitis C treatment;
CRC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15557168	chr22:42548783	NA	-0.34	-5.62	-0.3	4.08e-8	Cognitive function;
CRC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.46	-7.09	-0.36	8.22e-12	Psoriasis;
CRC	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.65	12.61	0.57	5.2e-30	Menarche (age at onset);
CRC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg10820045	chr2:198174542	NA	-0.55	-9.29	-0.46	2.12e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.58	7.53	0.38	4.94e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs73195822	0.614	rs1123852	chr12:111221408	C/G	cg12870014	chr12:110450643	ANKRD13A	0.66	7.0	0.36	1.41e-11	Itch intensity from mosquito bite;
CRC	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.11	0.36	7.28e-12	Diisocyanate-induced asthma;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.77	-0.35	6.02e-11	Bipolar disorder;
CRC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg03959625	chr15:84868606	LOC388152	0.41	6.08	0.32	3.27e-9	Schizophrenia;
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.71	-0.3	2.52e-8	Life satisfaction;
CRC	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg08992911	chr2:238395768	MLPH	0.61	6.09	0.32	3.07e-9	Prostate cancer;
CRC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.6e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-6.25	-0.33	1.28e-9	Height;
CRC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.49	5.83	0.31	1.35e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11601748	chr5:443197	C5orf55;EXOC3	0.42	6.16	0.32	2.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.69	-0.43	1.71e-16	Electroencephalogram traits;
CRC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.5	-0.34	3e-10	Aortic root size;
CRC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.67	12.19	0.56	1.9e-28	Aortic root size;
CRC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.44	6.91	0.36	2.55e-11	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.55	-6.99	-0.36	1.51e-11	Cerebrospinal fluid biomarker levels;
CRC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.9	-0.36	2.74e-11	Blood pressure (smoking interaction);
CRC	cis	rs360798	0.512	rs1906198	chr2:62946658	C/T	cg17519650	chr2:63277830	OTX1	0.43	5.93	0.31	7.52e-9	Coronary artery disease;
CRC	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma;
CRC	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg08271804	chr19:22816896	ZNF492	0.38	5.82	0.31	1.41e-8	Bronchopulmonary dysplasia;
CRC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg21620606	chr4:1342894	KIAA1530	0.51	8.03	0.4	1.77e-14	Obesity-related traits;
CRC	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-18.5	-0.71	6.73e-53	Ulcerative colitis;
CRC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.39	-6.64	-0.34	1.27e-10	Height;
CRC	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.75	-11.86	-0.55	3e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg03160526	chr17:80928410	B3GNTL1	0.59	8.18	0.41	6.07e-15	Glycated hemoglobin levels;
CRC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.48	10.31	0.49	8.81e-22	Bone mineral density;
CRC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg01941586	chr1:40203715	PPIE	-0.46	-6.37	-0.33	6.26e-10	Blood protein levels;
CRC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg09163369	chr1:210001066	C1orf107	0.41	5.76	0.3	1.97e-8	Orofacial clefts;
CRC	cis	rs75422866	0.867	rs73104138	chr12:48086085	C/T	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.42	6.76	0.35	6.3e-11	High light scatter reticulocyte count;
CRC	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.71	-9.93	-0.48	1.75e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.66	8.41	0.42	1.26e-15	Response to diuretic therapy;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20092199	chr4:1342459	KIAA1530	0.38	6.61	0.34	1.53e-10	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.63e-27	Alzheimer's disease;
CRC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.5	-6.67	-0.35	1.07e-10	Glioblastoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14751398	chr6:20402153	E2F3	0.48	6.35	0.33	7.17e-10	Thyroid stimulating hormone;
CRC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.96	-0.36	1.84e-11	Mood instability;
CRC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.14	-0.32	2.43e-9	Alzheimer's disease (late onset);
CRC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.19	0.41	5.97e-15	Height;
CRC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.57	7.1	0.36	7.84e-12	Neutrophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23237097	chr1:160278129	COPA	0.43	6.75	0.35	6.56e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7605827	0.930	rs10172344	chr2:15521591	A/G	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	3.99e-8	Educational attainment (years of education);
CRC	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11446398	chr5:77624930	NA	0.45	6.03	0.32	4.45e-9	Triglycerides;
CRC	cis	rs10106298	0.846	rs2436936	chr8:103677723	C/A	cg10187029	chr8:103597600	NA	0.44	6.14	0.32	2.37e-9	Schizophrenia;
CRC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.03e-12	Corneal astigmatism;
CRC	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.25	0.41	3.94e-15	Mean corpuscular volume;
CRC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg23298862	chr7:158159286	PTPRN2	-0.48	-7.32	-0.37	1.89e-12	Response to amphetamines;
CRC	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.44	-5.61	-0.3	4.22e-8	Height;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.61	8.99	0.44	1.97e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg08260959	chr6:26240920	HIST1H4F	0.36	5.95	0.31	6.92e-9	Gout;Renal underexcretion gout;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs6504622	0.557	rs197912	chr17:44989888	A/T	cg16759221	chr17:45003025	GOSR2	0.58	8.92	0.44	3.39e-17	Orofacial clefts;
CRC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.37	8.57	0.43	4.09e-16	Multiple system atrophy;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-8.29	-0.42	2.99e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9322817	0.617	rs9391242	chr6:105231257	G/A	cg02098413	chr6:105308735	HACE1	-0.43	-8.22	-0.41	4.66e-15	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg26587870	chr6:27730563	NA	-0.42	-6.22	-0.32	1.54e-9	Parkinson's disease;
CRC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.69	10.45	0.5	2.95e-22	Menopause (age at onset);
CRC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg03929089	chr4:120376271	NA	-0.48	-6.93	-0.36	2.24e-11	HDL cholesterol;
CRC	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.7	10.19	0.49	2.28e-21	Schizophrenia;
CRC	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.56	7.94	0.4	3.21e-14	Osteoporosis;
CRC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg00316803	chr15:76480434	C15orf27	-0.38	-6.41	-0.33	5.03e-10	Blood metabolite levels;
CRC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.44	5.62	0.3	4.14e-8	Mean corpuscular hemoglobin;
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg21784768	chr11:537496	LRRC56	-0.63	-5.99	-0.31	5.56e-9	Body mass index;
CRC	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg18200150	chr17:30822561	MYO1D	0.44	8.45	0.42	9.7e-16	Schizophrenia;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg04557695	chr7:92466167	CDK6	0.47	6.38	0.33	5.95e-10	Plasma plasminogen activator levels;
CRC	trans	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02772935	chr3:125709198	NA	-0.5	-6.54	-0.34	2.4e-10	Blood pressure (smoking interaction);
CRC	cis	rs4930561	0.714	rs11228151	chr11:67949371	C/G	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.98	-0.31	5.78e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg14844989	chr11:31128820	NA	0.34	6.09	0.32	3.19e-9	Red blood cell count;
CRC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.71	-0.39	1.46e-13	Colorectal cancer;
CRC	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-7.02	-0.36	1.29e-11	Subjective well-being;
CRC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.83	14.87	0.63	1.25e-38	Breast cancer;
CRC	cis	rs2346160	0.867	rs2989556	chr6:167704404	T/A	cg04673565	chr6:167680447	NA	-0.41	-6.83	-0.35	4.21e-11	Parental extreme longevity (95 years and older);
CRC	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg20356878	chr3:121714668	ILDR1	-0.43	-6.09	-0.32	3.08e-9	Multiple sclerosis;
CRC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.2	0.32	1.67e-9	Diabetic kidney disease;
CRC	trans	rs75246769	0.500	rs111234753	chr7:145673182	A/G	cg14916917	chr5:81574294	RPS23	0.92	6.34	0.33	7.48e-10	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs1322512	1.000	rs2758780	chr6:153008108	A/G	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16427967	chr20:30697241	TM9SF4	0.47	6.78	0.35	5.45e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.58	9.87	0.48	2.75e-20	Prudent dietary pattern;
CRC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.45	6.79	0.35	5.16e-11	Mood instability;
CRC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.94	0.36	2.08e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.69	-11.04	-0.52	2.5e-24	Hepatocellular carcinoma;
CRC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg19812747	chr11:111475976	SIK2	-0.58	-9.68	-0.47	1.18e-19	Primary sclerosing cholangitis;
CRC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.67	-10.89	-0.51	8.89e-24	Electrocardiographic conduction measures;
CRC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg03233332	chr7:66118400	NA	0.44	6.14	0.32	2.41e-9	Aortic root size;
CRC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.54	7.3	0.37	2.22e-12	RR interval (heart rate);
CRC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.54	-6.71	-0.35	8.41e-11	Body mass index;
CRC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.47	-8.64	-0.43	2.5e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs501120	0.584	rs1704218	chr10:44729599	C/T	cg09554077	chr10:44749378	NA	0.66	7.12	0.37	6.69e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg22561889	chr6:118971681	C6orf204	0.55	6.71	0.35	8.37e-11	Renal cell carcinoma;
CRC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg20487152	chr13:99095054	FARP1	-0.45	-6.48	-0.34	3.26e-10	Neuroticism;
CRC	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.37	6.54	0.34	2.42e-10	Crohn's disease;
CRC	cis	rs4728142	0.564	rs11767711	chr7:128651832	C/T	cg06630958	chr7:128577819	IRF5	-0.35	-5.78	-0.3	1.74e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.45	7.63	0.39	2.5e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.12	-0.52	1.33e-24	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08695707	chr1:197871847	C1orf53	0.49	6.88	0.35	2.94e-11	Response to antipsychotic treatment;
CRC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.38	6.61	0.34	1.54e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.68	-10.92	-0.52	6.84e-24	Hepatocellular carcinoma;
CRC	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.62	6.95	0.36	1.94e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23010568	chr17:568212	VPS53	-0.38	-6.07	-0.32	3.61e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg08999081	chr20:33150536	PIGU	0.4	6.18	0.32	1.93e-9	Skin pigmentation;
CRC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.67	-10.35	-0.5	6.34e-22	Hip circumference adjusted for BMI;
CRC	cis	rs1950626	0.699	rs12880855	chr14:101468382	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	15.7	0.65	7.45e-42	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg10820045	chr2:198174542	NA	-0.38	-6.51	-0.34	2.89e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs972578	1.000	rs5759075	chr22:43389090	G/C	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.96e-14	Mean platelet volume;
CRC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg19635926	chr16:89946313	TCF25	0.66	6.83	0.35	4.23e-11	Skin colour saturation;
CRC	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	cg04338863	chr8:33670619	NA	0.4	6.07	0.32	3.56e-9	Body mass index;
CRC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.08	19.11	0.73	2.82e-55	Cognitive function;
CRC	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg12870014	chr12:110450643	ANKRD13A	0.82	10.2	0.49	2.1e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg03030879	chr14:75389066	RPS6KL1	-0.44	-6.86	-0.35	3.42e-11	Caffeine consumption;
CRC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.32	-0.37	1.94e-12	Immature fraction of reticulocytes;
CRC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg22777020	chr22:31556080	RNF185	-0.52	-6.05	-0.32	3.91e-9	Colorectal cancer;
CRC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.35	6.62	0.34	1.47e-10	Mean corpuscular volume;
CRC	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg24438145	chr17:48624694	SPATA20	0.44	6.26	0.33	1.2e-9	Type 2 diabetes;
CRC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg11292332	chr7:45801988	SEPT13	-0.38	-6.83	-0.35	4.14e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs12692738	0.526	rs355835	chr2:165618530	G/A	cg03182029	chr2:165697222	COBLL1	0.48	5.66	0.3	3.32e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.95	-12.87	-0.58	5.82e-31	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.34	6.17	0.32	1.99e-9	Panic disorder;
CRC	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.55	-8.11	-0.41	1.01e-14	QRS duration;
CRC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.5	7.07	0.36	9.58e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.99	-0.36	1.56e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.18	-13.88	-0.61	8.21e-35	Diabetic kidney disease;
CRC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.54	-0.34	2.37e-10	Life satisfaction;
CRC	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg13385794	chr1:248469461	NA	0.39	6.63	0.34	1.35e-10	Common traits (Other);
CRC	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.52	5.97	0.31	6.19e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg13385794	chr1:248469461	NA	0.4	7.1	0.36	7.96e-12	Common traits (Other);
CRC	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg16589663	chr20:23618590	CST3	0.56	6.89	0.36	2.89e-11	Chronic kidney disease;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.7	10.89	0.51	8.31e-24	Vitiligo;
CRC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg16898833	chr6:26189333	HIST1H4D	0.94	7.65	0.39	2.25e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs904251	0.647	rs2776908	chr6:37434857	T/C	cg25019722	chr6:37503610	NA	-0.43	-6.2	-0.32	1.71e-9	Cognitive performance;
CRC	cis	rs55702914	0.628	rs3731570	chr2:198317783	C/T	cg10820045	chr2:198174542	NA	0.33	5.84	0.31	1.22e-8	Major depression and alcohol dependence;
CRC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg03233332	chr7:66118400	NA	0.45	6.18	0.32	1.92e-9	Aortic root size;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg21747405	chr11:67723411	NA	-0.58	-9.13	-0.45	6.88e-18	Blood pressure (smoking interaction);
CRC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.18	-0.37	4.7e-12	Gut microbiome composition (summer);
CRC	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05903289	chr2:130345205	NA	-0.42	-8.16	-0.41	7.21e-15	Response to cytidine analogues (gemcitabine);
CRC	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.62	-9.15	-0.45	6.06e-18	Type 2 diabetes;
CRC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.55	8.54	0.43	5.12e-16	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.22	-0.37	3.66e-12	Bipolar disorder;
CRC	cis	rs6586163	1.000	rs6586163	chr10:90752018	A/C	cg13456138	chr10:90753195	FAS	-0.44	-6.87	-0.35	3.31e-11	Chronic lymphocytic leukemia;
CRC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.2	-0.37	4.16e-12	Life satisfaction;
CRC	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg22495460	chr2:25135724	ADCY3	-0.88	-14.97	-0.64	5.2e-39	Body mass index;
CRC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.03	-0.48	7.84e-21	Bipolar disorder and schizophrenia;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg10473508	chr5:172068142	NEURL1B	-0.41	-6.03	-0.32	4.31e-9	HDL cholesterol;
CRC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.69	-12.23	-0.56	1.36e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.97	0.48	1.28e-20	Corneal astigmatism;
CRC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg04155289	chr7:94953770	PON1	-0.53	-7.28	-0.37	2.4e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24508409	chr1:112298175	DDX20;C1orf183	0.37	6.06	0.32	3.73e-9	Obesity-related traits;
CRC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.58	-8.18	-0.41	6.22e-15	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs12660387	1.000	rs62415786	chr6:65254384	G/A	cg13393512	chr9:135749454	C9orf98	0.53	6.1	0.32	2.91e-9	Schizophrenia;
CRC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.41	0.5	3.86e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg08975724	chr8:8085496	FLJ10661	0.39	5.63	0.3	3.94e-8	Neuroticism;
CRC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.66	7.64	0.39	2.36e-13	Body mass index;
CRC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.54	-7.88	-0.4	4.93e-14	Prostate cancer;
CRC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.29	0.33	9.83e-10	Lung cancer;
CRC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.44	-0.5	3.16e-22	Breast cancer;
CRC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.81	-0.35	4.57e-11	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11829371	chr17:981724	ABR	0.44	6.39	0.33	5.66e-10	Survival in pancreatic cancer;
CRC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.91	16.63	0.68	1.66e-45	Intelligence (multi-trait analysis);
CRC	cis	rs2882667	0.964	rs11958050	chr5:138301828	A/G	cg09476006	chr5:138032270	NA	0.54	9.38	0.46	1.13e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg05868516	chr6:26286170	HIST1H4H	0.39	5.68	0.3	3.02e-8	Educational attainment;
CRC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.14	-0.32	2.42e-9	Dupuytren's disease;
CRC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg18016565	chr1:150552671	MCL1	0.42	5.85	0.31	1.19e-8	Melanoma;
CRC	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.76	-10.7	-0.51	4.02e-23	Systemic lupus erythematosus;
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg07507251	chr3:52567010	NT5DC2	0.52	8.25	0.41	3.79e-15	Electroencephalogram traits;
CRC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02772935	chr3:125709198	NA	-0.49	-5.77	-0.3	1.81e-8	Blood pressure (smoking interaction);
CRC	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg20356878	chr3:121714668	ILDR1	0.52	8.21	0.41	5.11e-15	Cognitive performance;
CRC	trans	rs4692589	0.531	rs12650424	chr4:170975204	T/C	cg08679238	chr3:46449100	CCRL2	-0.49	-6.28	-0.33	1.1e-9	Anxiety disorder;
CRC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.69	9.41	0.46	8.7e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg27635394	chr6:26043820	HIST1H2BB	0.44	6.36	0.33	6.86e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.65	0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.26	-0.41	3.61e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.56	-9.02	-0.45	1.64e-17	Monocyte count;
CRC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.47	-6.54	-0.34	2.29e-10	Platelet distribution width;
CRC	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.46	8.23	0.41	4.37e-15	Blood metabolite ratios;
CRC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.56	-7.76	-0.39	1.07e-13	Pancreatic cancer;
CRC	cis	rs7487075	0.619	rs10880973	chr12:46853209	C/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.78	0.3	1.72e-8	Itch intensity from mosquito bite;
CRC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg23533926	chr12:111358616	MYL2	-0.44	-6.45	-0.34	3.95e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs3751196	0.710	rs17034639	chr12:104217799	C/T	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs1539053	0.932	rs12718425	chr1:58105213	G/A	cg20292791	chr1:58089357	DAB1	-0.32	-5.68	-0.3	3.04e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.11	0.32	2.84e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.12	-0.32	2.64e-9	Alzheimer's disease (late onset);
CRC	cis	rs3026101	0.671	rs56019636	chr17:5297551	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-6.11	-0.32	2.86e-9	Bipolar disorder;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Parkinson's disease;
CRC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.71	12.36	0.56	4.22e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08862778	chr1:11322643	MTOR	0.5	6.7	0.35	9.15e-11	Thyroid stimulating hormone;
CRC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.42	-6.49	-0.34	3.23e-10	Vitiligo;
CRC	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.48	6.9	0.36	2.67e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.61	-6.4	-0.33	5.25e-10	Schizophrenia;
CRC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.52	0.38	5.18e-13	Motion sickness;
CRC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.13	8.45	0.42	9.49e-16	Type 2 diabetes nephropathy;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.74	-0.43	1.21e-16	Bipolar disorder;
CRC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.43	8.72	0.43	1.36e-16	Renal cell carcinoma;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg15511327	chr8:143859410	LYNX1	-0.39	-6.52	-0.34	2.6e-10	Urinary tract infection frequency;
CRC	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg09695851	chr17:3907499	NA	0.78	14.47	0.62	4.59e-37	Type 2 diabetes;
CRC	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg11130432	chr3:121712080	ILDR1	-0.51	-6.72	-0.35	8.01e-11	Multiple sclerosis;
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg06713098	chr7:45960367	IGFBP3	0.49	7.5	0.38	6.07e-13	Sitting height ratio;
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.55	7.79	0.39	8.72e-14	Alzheimer's disease;
CRC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.4	-6.2	-0.32	1.69e-9	Blood metabolite levels;
CRC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.52	7.92	0.4	3.71e-14	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.22	-0.32	1.47e-9	Aortic root size;
CRC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.57	-9.84	-0.48	3.36e-20	Alzheimer's disease (late onset);
CRC	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.7	10.05	0.48	6.48e-21	Body mass index;
CRC	cis	rs9908102	0.740	rs8071615	chr17:12914535	G/T	cg26162695	chr17:12921313	ELAC2	0.4	5.63	0.3	3.82e-8	Schizophrenia;
CRC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg19980929	chr12:42632907	YAF2	0.44	6.56	0.34	2.14e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg25834613	chr7:1915315	MAD1L1	-0.41	-5.82	-0.31	1.38e-8	Bipolar disorder;
CRC	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.47	5.84	0.31	1.23e-8	Alzheimer's disease (survival time);
CRC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.43	6.14	0.32	2.38e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg23127183	chr11:57508653	C11orf31	-0.52	-7.12	-0.37	6.68e-12	Schizophrenia;
CRC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.52	-7.44	-0.38	9.1e-13	Blood trace element (Zn levels);
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.57	8.08	0.41	1.22e-14	Menarche (age at onset);
CRC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg00343986	chr7:65444356	GUSB	-0.5	-7.4	-0.38	1.18e-12	Aortic root size;
CRC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.68	11.5	0.54	5.71e-26	Mean platelet volume;
CRC	cis	rs8010344	0.685	rs11627032	chr14:93104072	T/C	cg26948596	chr14:93078627	RIN3	-0.45	-6.14	-0.32	2.42e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg14119001	chr9:139324193	INPP5E	-0.53	-7.53	-0.38	4.82e-13	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg21238619	chr17:78079768	GAA	-0.34	-5.72	-0.3	2.35e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg20203395	chr5:56204925	C5orf35	-0.59	-8.0	-0.4	2.16e-14	Initial pursuit acceleration;
CRC	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-8.18	-0.41	6.44e-15	Gut microbiome composition (summer);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13661497	chr9:5110940	JAK2	-0.37	-6.03	-0.32	4.44e-9	Obesity-related traits;
CRC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg03013999	chr17:37608204	MED1	-0.47	-7.39	-0.38	1.19e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05318427	chr2:85199320	KCMF1	-0.54	-6.63	-0.34	1.36e-10	Diisocyanate-induced asthma;
CRC	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg25110126	chr1:46999211	NA	0.56	8.31	0.42	2.55e-15	Monobrow;
CRC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.83	-0.4	6.79e-14	Height;
CRC	cis	rs9846480	0.598	rs6439807	chr3:138074001	G/C	cg25476813	chr3:138050155	TXNDC6	-0.38	-5.63	-0.3	3.95e-8	Whole-brain volume (Alzheimer's disease interaction);
CRC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.11	0.36	7.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.7	-11.48	-0.53	7.06e-26	Cognitive function;
CRC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg21153622	chr11:89784906	NA	-0.45	-7.39	-0.38	1.22e-12	Coronary artery disease;
CRC	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04733989	chr22:42467013	NAGA	0.4	5.63	0.3	3.78e-8	Cognitive function;
CRC	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.77	15.93	0.66	9.13e-43	Leprosy;
CRC	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.32	-6.14	-0.32	2.44e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21658946	chr16:69364455	COG8;PDF	0.43	6.01	0.31	4.89e-9	Anxiety disorder;
CRC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.03	-0.4	1.77e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.66	-0.3	3.23e-8	Breast cancer;Breast cancer (early onset);
CRC	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg26811252	chr16:29126840	RRN3P2	0.68	9.29	0.46	2.14e-18	Menopause (age at onset);
CRC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg10760299	chr15:45669010	GATM	0.36	5.63	0.3	3.95e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.67	-0.51	5.02e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.39	5.75	0.3	2.07e-8	Growth-regulated protein alpha levels;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg03623178	chr6:28175578	NA	1.03	15.75	0.66	4.97e-42	Depression;
CRC	cis	rs2108622	0.727	rs3093207	chr19:15988658	T/C	cg13772218	chr19:15982569	NA	0.48	6.75	0.35	6.72e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.51	-0.38	5.72e-13	Reticulocyte fraction of red cells;
CRC	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg23461800	chr14:103021989	NA	-0.75	-9.88	-0.48	2.49e-20	Platelet count;
CRC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.94	-16.88	-0.68	1.75e-46	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg21466736	chr12:48725269	NA	-0.5	-7.56	-0.38	3.95e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.49	-8.36	-0.42	1.8e-15	P wave terminal force;
CRC	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg11812906	chr14:75593930	NEK9	0.51	7.1	0.36	7.95e-12	Height;
CRC	cis	rs3751196	0.808	rs17034642	chr12:104218928	A/C	cg02344784	chr12:104178138	NT5DC3	0.71	7.55	0.38	4.35e-13	Sense of smell;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18342900	chr16:46865048	C16orf87	0.48	6.43	0.33	4.6e-10	Thyroid stimulating hormone;
CRC	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.81	10.27	0.49	1.22e-21	Prostate cancer;
CRC	cis	rs4700695	0.841	rs152935	chr5:65358593	A/G	cg21114390	chr5:65439923	SFRS12	-0.66	-7.1	-0.36	7.94e-12	Facial morphology (factor 19);
CRC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg14829360	chr17:73884958	NA	-0.47	-7.37	-0.38	1.39e-12	Psoriasis;
CRC	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg20608306	chr11:116969690	SIK3	-0.32	-6.12	-0.32	2.69e-9	Subjective well-being;
CRC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.07	-0.41	1.38e-14	Chronic sinus infection;
CRC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.38	6.84	0.35	3.85e-11	Cardiovascular disease risk factors;
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.65	10.16	0.49	2.92e-21	Huntington's disease progression;
CRC	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg21483461	chr5:81570383	RPS23	0.36	5.61	0.3	4.31e-8	Breast cancer;
CRC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.72	11.92	0.55	1.85e-27	Monocyte count;
CRC	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.85	0.31	1.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg08798685	chr6:27730294	NA	0.4	5.94	0.31	7.35e-9	Parkinson's disease;
CRC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg19500275	chr17:80737654	TBCD	0.47	6.54	0.34	2.35e-10	Glycated hemoglobin levels;
CRC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-8.16	-0.41	7.37e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg10064897	chr1:46598380	PIK3R3	0.61	6.8	0.35	4.96e-11	Lymphocyte counts;
CRC	cis	rs7209700	0.632	rs11657963	chr17:45347533	G/A	cg17185639	chr17:45330862	ITGB3	0.37	6.0	0.31	5.11e-9	IgG glycosylation;
CRC	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.7	-6.45	-0.34	3.94e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg00277334	chr10:82204260	NA	0.36	5.89	0.31	9.54e-9	Sarcoidosis;
CRC	cis	rs6504622	0.875	rs11652318	chr17:45041094	T/C	cg16759221	chr17:45003025	GOSR2	-0.55	-8.68	-0.43	1.85e-16	Orofacial clefts;
CRC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.65	-0.34	1.19e-10	Total cholesterol levels;
CRC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.49	-0.38	6.58e-13	Eye color traits;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg06805572	chr2:10444432	HPCAL1	0.45	6.24	0.33	1.37e-9	Depressive symptom measurement or major depressive disorder;
CRC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.19	0.37	4.52e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.62	-0.39	2.76e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg12870014	chr12:110450643	ANKRD13A	0.84	10.14	0.49	3.42e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg12273811	chr6:28175739	NA	0.39	5.77	0.3	1.79e-8	Pubertal anthropometrics;
CRC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.64	8.46	0.42	8.61e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.65	-9.83	-0.48	3.61e-20	Corneal astigmatism;
CRC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.79	10.85	0.51	1.23e-23	Cognitive function;
CRC	cis	rs6694672	0.850	rs10754213	chr1:197055925	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.65	0.39	2.3e-13	Asthma;
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.74	-0.43	1.22e-16	Bipolar disorder;
CRC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg27661571	chr11:113659931	NA	-0.94	-10.92	-0.52	7.04e-24	Hip circumference adjusted for BMI;
CRC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.5	-7.62	-0.39	2.72e-13	Monocyte count;
CRC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg14541582	chr5:601475	NA	0.32	6.52	0.34	2.67e-10	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	-0.54	-6.49	-0.34	3.22e-10	Diisocyanate-induced asthma;
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.96	-0.36	1.87e-11	Bipolar disorder;
CRC	cis	rs10911390	0.793	rs7552232	chr1:183582287	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.69	5.76	0.3	1.95e-8	Systemic lupus erythematosus;
CRC	cis	rs9925964	0.933	rs56314408	chr16:31117389	T/C	cg03418659	chr16:31128414	MYST1	-0.49	-7.23	-0.37	3.35e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	10.75	0.51	2.64e-23	Psoriasis;
CRC	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.62	9.87	0.48	2.71e-20	Corneal astigmatism;
CRC	trans	rs2303319	0.582	rs56315911	chr2:162560186	G/T	cg03757145	chr4:76555832	CDKL2	-0.65	-6.02	-0.31	4.58e-9	Cognitive function;
CRC	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	7.96	0.4	2.77e-14	Blood metabolite levels;
CRC	cis	rs2882667	0.931	rs10077896	chr5:138356756	G/A	cg09476006	chr5:138032270	NA	0.44	7.21	0.37	3.87e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs747650	0.504	rs11602250	chr11:46965730	G/A	cg19486271	chr11:47235900	DDB2	0.43	5.89	0.31	9.44e-9	Acne (severe);
CRC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.01	0.36	1.35e-11	Breast cancer;
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs2421770	0.530	rs6484784	chr11:35368347	A/C	cg13971030	chr11:35366721	SLC1A2	0.38	6.55	0.34	2.27e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.57	8.31	0.42	2.58e-15	Schizophrenia;
CRC	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.67	10.64	0.51	6.43e-23	Pulmonary function decline;
CRC	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.49	7.5	0.38	5.8e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.97	-0.31	6.14e-9	Blood protein levels;
CRC	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg27534772	chr1:16042836	PLEKHM2	0.42	6.97	0.36	1.78e-11	Systolic blood pressure;
CRC	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg17470449	chr10:769945	NA	0.41	6.03	0.32	4.5e-9	Uric acid levels;
CRC	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg14593290	chr7:50529359	DDC	0.58	8.0	0.4	2.13e-14	Malaria;
CRC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.5	-9.15	-0.45	6.25e-18	Longevity;
CRC	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg04586622	chr2:25135609	ADCY3	-0.57	-9.51	-0.46	4.22e-19	Body mass index;
CRC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.69	-11.35	-0.53	2.06e-25	Height;
CRC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.6	-7.82	-0.4	7.04e-14	Schizophrenia;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.13	-0.56	3.12e-28	Idiopathic membranous nephropathy;
CRC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg21918786	chr6:109611834	NA	-0.35	-5.99	-0.31	5.62e-9	Reticulocyte fraction of red cells;
CRC	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.71	7.39	0.38	1.26e-12	Pulse pressure;
CRC	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.41	6.44	0.33	4.34e-10	Corneal astigmatism;
CRC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.24e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.39	-5.86	-0.31	1.12e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06648271	chr10:126432949	FAM53B	0.47	6.33	0.33	8.16e-10	Anxiety disorder;
CRC	trans	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg11693508	chr17:37793320	STARD3	0.46	6.22	0.32	1.5e-9	Neuroticism;
CRC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg14631576	chr9:95140430	CENPP	0.4	7.11	0.36	7.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.38	6.29e-13	Ulcerative colitis;
CRC	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-0.82	-8.26	-0.41	3.54e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.42	7.11	0.36	7.29e-12	Body mass index;
CRC	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.19	-0.32	1.76e-9	Mean corpuscular hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs62187570	chr2:162373899	C/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.11	-0.32	2.75e-9	Cognitive function;
CRC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.13	0.32	2.58e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-9.74	-0.47	7.1e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.49	8.69	0.43	1.68e-16	Testicular germ cell tumor;
CRC	cis	rs3026101	0.671	rs739766	chr17:5290599	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.82	0.35	4.25e-11	Body mass index;
CRC	trans	rs4478147	0.636	rs4529013	chr4:87463813	G/A	cg01215037	chr19:50083917	PRRG2;NOSIP	0.45	5.97	0.31	6.1e-9	Migraine - clinic-based;
CRC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg08807101	chr21:30365312	RNF160	-0.48	-6.9	-0.36	2.69e-11	Pancreatic cancer;
CRC	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.46	-6.24	-0.33	1.35e-9	Extraversion;
CRC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.59	8.61	0.43	3e-16	Lymphocyte counts;
CRC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.69	-7.76	-0.39	1.08e-13	Body mass index;
CRC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.73	10.92	0.52	6.54e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.86	-10.88	-0.51	9.64e-24	Obesity-related traits;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.88	-0.4	4.72e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.64e-15	Menopause (age at onset);
CRC	cis	rs891088	0.622	rs10426094	chr19:7205240	C/T	cg00428638	chr19:7224713	INSR	-0.58	-7.32	-0.37	1.97e-12	Hip circumference adjusted for BMI;Height;
CRC	cis	rs459193	1.000	rs157843	chr5:55799184	G/T	cg26646659	chr5:55776364	NA	0.47	6.38	0.33	5.95e-10	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs490234	0.934	rs10119068	chr9:128424508	A/G	cg14078157	chr9:128172775	NA	-0.37	-6.22	-0.32	1.49e-9	Mean arterial pressure;
CRC	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.4	-7.07	-0.36	9.13e-12	Hepatitis;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg21251018	chr6:28226885	NKAPL	0.46	6.53	0.34	2.56e-10	Parkinson's disease;
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.94	0.31	7.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11192808	chr8:101170185	SPAG1	0.46	7.57	0.39	3.77e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.46	0.46	6.07e-19	Ileal carcinoids;
CRC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.56	8.69	0.43	1.78e-16	Obesity-related traits;
CRC	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.6	12.17	0.56	2.18e-28	Neuroticism;
CRC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17554472	chr22:41940697	POLR3H	-0.56	-5.83	-0.31	1.34e-8	Vitiligo;
CRC	cis	rs9398803	0.805	rs1591805	chr6:126717064	A/G	cg19875578	chr6:126661172	C6orf173	0.4	5.63	0.3	3.86e-8	Male-pattern baldness;
CRC	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.68	7.02	0.36	1.26e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.67	8.46	0.42	8.86e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs972578	1.000	rs4822248	chr22:43403379	G/A	cg01576275	chr22:43409880	NA	-0.51	-8.38	-0.42	1.53e-15	Mean platelet volume;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.88	0.55	2.55e-27	Prudent dietary pattern;
CRC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.72	11.07	0.52	2.07e-24	Corneal astigmatism;
CRC	cis	rs2882667	0.898	rs6882583	chr5:138385796	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.39e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg05805236	chr11:65401703	PCNXL3	-0.37	-5.75	-0.3	2.08e-8	Acne (severe);
CRC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg05627522	chr15:75251581	NA	0.38	5.82	0.31	1.36e-8	Breast cancer;
CRC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.7	-9.26	-0.45	2.62e-18	Initial pursuit acceleration;
CRC	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.42	6.17	0.32	2.05e-9	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs6684514	0.922	rs2075166	chr1:156215562	G/A	cg16558208	chr1:156270281	VHLL	0.62	9.42	0.46	8.08e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-7.87	-0.4	5.07e-14	Subjective well-being;
CRC	trans	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg17903999	chr18:56338584	MALT1	-0.43	-6.98	-0.36	1.61e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.59	-0.43	3.63e-16	Monocyte percentage of white cells;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.67	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.37	0.42	1.73e-15	Vitiligo;
CRC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg02887458	chr19:19495540	GATAD2A	-0.43	-5.78	-0.3	1.73e-8	Bipolar disorder;
CRC	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg16141378	chr3:129829833	LOC729375	-0.5	-7.55	-0.38	4.22e-13	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14213517	chr2:102972205	NA	0.41	6.95	0.36	1.93e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg17545662	chr6:170176663	C6orf70	0.56	6.45	0.34	3.94e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg00717180	chr2:96193071	NA	-0.37	-6.11	-0.32	2.77e-9	HDL cholesterol;
CRC	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg12315302	chr6:26189340	HIST1H4D	0.79	6.29	0.33	1.04e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.59	-8.21	-0.41	5.11e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8032158	1.000	rs2288344	chr15:56122347	T/G	cg02198044	chr15:56286336	NEDD4	-0.39	-6.03	-0.32	4.32e-9	Keloid;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04543156	chr10:89577850	ATAD1;CFLP1	0.47	6.58	0.34	1.83e-10	Response to antipsychotic treatment;
CRC	cis	rs1943345	0.556	rs606381	chr11:82907249	G/A	cg07047830	chr11:82868014	PCF11	0.47	6.64	0.34	1.32e-10	Obesity-related traits;
CRC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg27068330	chr11:65405492	SIPA1	-0.47	-6.47	-0.34	3.57e-10	Breast cancer;
CRC	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.82	-14.01	-0.61	2.7e-35	Lewy body disease;
CRC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.61	8.77	0.44	1e-16	Monobrow;
CRC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg19582491	chr16:67682965	RLTPR	0.61	7.45	0.38	8.51e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.91	0.52	7.51e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg12856521	chr11:46389249	DGKZ	-0.51	-8.57	-0.43	4.13e-16	Leprosy;
CRC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.44	-0.53	9.82e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.51	7.6	0.39	3.1400000000000003e-13	Emphysema distribution in smoking;
CRC	cis	rs863345	0.604	rs7512592	chr1:158489945	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.86	20.19	0.74	1.53e-59	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.35	-6.09	-0.32	3.19e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg14022721	chr22:25507536	KIAA1671	-0.49	-6.23	-0.32	1.45e-9	Diisocyanate-induced asthma;
CRC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg09876464	chr15:85330779	ZNF592	0.46	7.96	0.4	2.81e-14	P wave terminal force;
CRC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	7.61	0.39	3e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9783347	1.000	rs2061164	chr11:18329006	T/C	cg15585147	chr11:18324498	HPS5	0.42	5.9	0.31	8.87e-9	Pancreatic cancer;
CRC	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.67	-9.2	-0.45	4.1e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.93	0.44	3.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.58	-6.11	-0.32	2.87e-9	Vitiligo;
CRC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs365302	1.000	rs480052	chr6:159651869	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.47	6.86	0.35	3.43e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.48	-6.77	-0.35	6.05e-11	Height;
CRC	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.53	-7.52	-0.38	5.21e-13	Eye color traits;
CRC	cis	rs1403694	0.966	rs1648715	chr3:186439618	A/G	cg04611788	chr3:186434169	KNG1	-0.46	-7.13	-0.37	6.6e-12	Blood protein levels;
CRC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.48	6.14	0.32	2.33e-9	Lymphocyte counts;
CRC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12066438	chr12:98909292	TMPO;LOC100128191	0.45	6.17	0.32	2.01e-9	Anxiety disorder;
CRC	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.58	-8.49	-0.42	7.02e-16	Inhibitory control;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24866706	chr3:96338474	NA	0.51	6.72	0.35	7.9e-11	Hip circumference;
CRC	cis	rs501120	0.925	rs684521	chr10:44752523	G/A	cg09554077	chr10:44749378	NA	0.89	13.1	0.59	7.51e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg05941027	chr17:61774174	LIMD2	0.37	6.71	0.35	8.59e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg08798685	chr6:27730294	NA	-0.57	-6.48	-0.34	3.25e-10	Lung cancer in ever smokers;
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.72	9.91	0.48	1.93e-20	Alzheimer's disease;
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg08034379	chr2:228736324	WDR69	-0.53	-7.22	-0.37	3.59e-12	Blood pressure;
CRC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg08314208	chr16:67682810	RLTPR	-0.57	-6.09	-0.32	3.17e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg20356878	chr3:121714668	ILDR1	0.42	5.81	0.3	1.5e-8	Multiple sclerosis;
CRC	cis	rs9491140	0.539	rs2208814	chr6:124692555	G/A	cg05308643	chr6:124982296	NKAIN2	0.52	6.88	0.35	3.1e-11	Neuroticism;
CRC	cis	rs6840360	0.667	rs4266275	chr4:152348064	A/G	cg09659197	chr4:152720779	NA	0.34	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-8.32	-0.42	2.37e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	6.04	0.32	4.06e-9	Breast cancer;
CRC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	10.55	0.5	1.33e-22	Schizophrenia;
CRC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.54	-6.6	-0.34	1.62e-10	Diastolic blood pressure;
CRC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.79	7.64	0.39	2.41e-13	Body mass index;
CRC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.59	8.98	0.44	2.15e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.64	8.98	0.44	2.18e-17	Platelet count;
CRC	cis	rs7605827	0.930	rs722328	chr2:15657164	T/C	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.8e-9	Educational attainment (years of education);
CRC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-6.16	-0.32	2.09e-9	Vitiligo;
CRC	trans	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9494145	0.838	rs9483788	chr6:135435501	T/C	cg22676075	chr6:135203613	NA	0.52	6.25	0.33	1.27e-9	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	trans	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg24644049	chr4:85504048	CDS1	0.89	7.15	0.37	5.62e-12	Skin colour saturation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13348770	chr6:122720548	HSF2	0.47	6.97	0.36	1.75e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg16670446	chr17:27188758	MIR451;MIR144	-0.53	-8.35	-0.42	1.95e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.72	11.34	0.53	2.15e-25	Cognitive function;
CRC	cis	rs354033	1.000	rs354043	chr7:149297332	C/T	cg24335155	chr7:149193227	ZNF746	0.38	6.12	0.32	2.7e-9	Multiple sclerosis;
CRC	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.85	-14.97	-0.64	5.39e-39	Lewy body disease;
CRC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg13043300	chr11:71146211	DHCR7	-0.41	-5.82	-0.31	1.43e-8	Vitamin D levels;
CRC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg17191109	chr10:126851326	NA	-0.44	-6.39	-0.33	5.65e-10	Menarche (age at onset);
CRC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg26061582	chr7:22766209	IL6	-0.55	-8.42	-0.42	1.15e-15	Lung cancer;
CRC	trans	rs7517126	0.858	rs12726401	chr1:196660729	T/C	cg00574530	chr5:134872064	NEUROG1	0.46	6.01	0.31	5.06e-9	Blood protein levels;
CRC	cis	rs6700896	0.931	rs2154382	chr1:66131681	C/T	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.66	-7.84	-0.4	6.23e-14	Menarche (age at onset);
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.46	-0.34	3.7e-10	Breast cancer;
CRC	cis	rs12983728	0.505	rs12460050	chr19:58666109	G/A	cg08687515	chr19:58661962	ZNF329	0.48	6.04	0.32	4.19e-9	Cholesterol, total;
CRC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.5	-6.73	-0.35	7.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.22	-0.37	3.53e-12	Aortic root size;
CRC	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.51	8.61	0.43	3.09e-16	Dupuytren's disease;
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs7259376	0.623	rs3926992	chr19:22505876	A/G	cg02657401	chr19:22469223	NA	-0.31	-6.6	-0.34	1.69e-10	Menopause (age at onset);
CRC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.57	-8.19	-0.41	5.81e-15	Menarche (age at onset);
CRC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-6.37	-0.33	6.39e-10	Blood metabolite levels;
CRC	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg20885578	chr2:198174922	NA	-0.43	-6.83	-0.35	4.07e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9462027	0.628	rs9462030	chr6:34831280	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.13	-0.32	2.48e-9	Systemic lupus erythematosus;
CRC	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg08992911	chr2:238395768	MLPH	0.61	6.25	0.33	1.26e-9	Prostate cancer;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg03623178	chr6:28175578	NA	0.92	12.13	0.56	3.12e-28	Parkinson's disease;
CRC	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	0.68	7.08	0.36	8.91e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.17	-13.58	-0.6	1.22e-33	Diabetic kidney disease;
CRC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	9.19	0.45	4.72e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg15226275	chr6:116381976	FRK	0.31	8.97	0.44	2.3e-17	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.5	0.42	6.92e-16	Height;
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.27	-0.33	1.12e-9	Aortic root size;
CRC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.75	11.59	0.54	2.75e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17465063	chr10:111985564	MXI1	0.39	6.21	0.32	1.6e-9	Schizophrenia;
CRC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.45	0.34	3.99e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg01420254	chr6:26195488	NA	0.73	6.02	0.32	4.54e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs10512697	0.655	rs13162816	chr5:3497691	C/T	cg19473799	chr5:3511975	NA	-0.82	-6.32	-0.33	8.41e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.46	6.68	0.35	1.02e-10	Emphysema distribution in smoking;
CRC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.46	-0.38	7.91e-13	Reticulocyte fraction of red cells;
CRC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.46	0.38	7.65e-13	Lung cancer in ever smokers;
CRC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.56	8.32	0.42	2.45e-15	Morning vs. evening chronotype;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01497487	chr22:38141814	TRIOBP	-0.44	-6.59	-0.34	1.78e-10	Daytime sleep phenotypes;
CRC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18867708	chr6:26865862	GUSBL1	0.43	6.15	0.32	2.2e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.62	10.5	0.5	1.96e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-10.05	-0.48	6.52e-21	Personality dimensions;
CRC	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.81	-0.3	1.5e-8	Tuberculosis;
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs6840360	0.642	rs1596290	chr4:152410540	G/T	cg09659197	chr4:152720779	NA	0.33	6.54	0.34	2.29e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg10298567	chr3:47292165	KIF9	0.44	7.08	0.36	9.03e-12	Colorectal cancer;
CRC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg01879757	chr17:41196368	BRCA1	-0.42	-6.42	-0.33	4.89e-10	Menopause (age at onset);
CRC	trans	rs1864729	1.000	rs2053480	chr8:98278951	A/T	cg08679828	chr8:102218111	ZNF706	0.56	7.02	0.36	1.28e-11	Estradiol plasma levels (breast cancer);
CRC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.47e-10	Tonsillectomy;
CRC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.5	6.42	0.33	4.75e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg15786705	chr6:28176104	NA	0.78	10.83	0.51	1.38e-23	Depression;
CRC	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.54	10.33	0.49	7.42e-22	Urate levels in lean individuals;
CRC	cis	rs853679	0.567	rs9969098	chr6:28398748	G/T	cg21251018	chr6:28226885	NKAPL	0.42	6.11	0.32	2.78e-9	Depression;
CRC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg23018236	chr17:30244563	NA	0.51	6.78	0.35	5.7e-11	Hip circumference adjusted for BMI;
CRC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg06207120	chr15:45996521	NA	0.32	7.72	0.39	1.38e-13	Waist circumference;Weight;
CRC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.98	0.52	4.31e-24	Diabetic retinopathy;
CRC	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.54	9.33	0.46	1.62e-18	Body mass index;
CRC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.88	-0.31	9.88e-9	Type 2 diabetes;
CRC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.58	8.29	0.42	2.82e-15	Arsenic metabolism;
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-5.99	-0.31	5.63e-9	Electroencephalogram traits;
CRC	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.34	-0.46	1.45e-18	Capecitabine sensitivity;
CRC	cis	rs889398	0.802	rs12598642	chr16:69848772	A/G	cg00738113	chr16:70207722	CLEC18C	0.35	6.01	0.31	5.04e-9	Body mass index;
CRC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.35	0.38	1.59e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg17633681	chr16:88106987	BANP	0.87	16.24	0.67	5.81e-44	Menopause (age at onset);
CRC	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.27	-0.37	2.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg10820045	chr2:198174542	NA	-0.49	-7.93	-0.4	3.48e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg27053337	chr8:124217698	FAM83A	0.46	6.99	0.36	1.58e-11	Urinary uromodulin levels;
CRC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg08075719	chr14:103021372	NA	0.65	7.6	0.39	3.13e-13	Platelet count;
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.24e-34	Alzheimer's disease;
CRC	cis	rs6968419	0.674	rs57756655	chr7:115927168	C/T	cg02561103	chr7:115862891	TES	-0.43	-6.26	-0.33	1.19e-9	Intraocular pressure;
CRC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	8.94	0.44	2.91e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.95	0.4	2.99e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9462027	0.628	rs9469899	chr6:34793124	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.06	-0.32	3.69e-9	Systemic lupus erythematosus;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.6	10.06	0.49	6.13e-21	Electroencephalogram traits;
CRC	cis	rs236352	0.557	rs9368966	chr6:36825430	A/G	cg10099585	chr6:36853529	C6orf89	-0.44	-6.23	-0.32	1.42e-9	Heart rate;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg18123596	chr17:36956264	PIP4K2B	-0.41	-6.1	-0.32	2.94e-9	HDL cholesterol;
CRC	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg09760422	chr2:128146352	NA	-0.37	-7.27	-0.37	2.71e-12	Protein C levels;
CRC	cis	rs3736485	0.966	rs4774595	chr15:51893161	C/T	cg08986416	chr15:51914746	DMXL2	-0.48	-6.74	-0.35	7.06e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.27e-9	Red blood cell count;
CRC	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.02	-0.4	1.91e-14	Rheumatoid arthritis;
CRC	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg12963866	chr19:57752005	ZNF805	-0.41	-6.09	-0.32	3.15e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg18827107	chr12:86230957	RASSF9	-0.38	-6.25	-0.33	1.3e-9	Major depressive disorder;
CRC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.62	7.73	0.39	1.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.88	17.33	0.69	2.92e-48	Metabolic syndrome;
CRC	cis	rs11212617	0.875	rs228597	chr11:108107009	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.32	0.33	8.57e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg24562669	chr7:97807699	LMTK2	0.43	7.2	0.37	4.23e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg21106136	chr3:194405973	FAM43A	-0.45	-6.57	-0.34	1.92e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs77861329	0.748	rs4687607	chr3:52088651	G/A	cg08692210	chr3:52188851	WDR51A	0.55	6.4	0.33	5.5e-10	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg00738113	chr16:70207722	CLEC18C	-0.44	-6.59	-0.34	1.72e-10	IgE levels;
CRC	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.49	0.38	6.39e-13	Testicular germ cell tumor;
CRC	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg26248373	chr2:1572462	NA	-0.6	-7.4	-0.38	1.13e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.38	-6.54	-0.34	2.29e-10	Vitamin D levels;
CRC	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-6.42	-0.33	4.83e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.44	6.81	0.35	4.63e-11	Height;
CRC	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.21	0.45	4.02e-18	Parkinson's disease;
CRC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.61	7.66	0.39	2.03e-13	Height;
CRC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.46	6.21	0.32	1.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.58	7.74	0.39	1.27e-13	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17647863	chr3:127771317	SEC61A1	0.45	6.29	0.33	1.03e-9	Anxiety disorder;
CRC	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	4.89e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6973256	0.568	rs7783019	chr7:133347347	A/G	cg10665199	chr7:133106180	EXOC4	-0.47	-7.33	-0.37	1.74e-12	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.7	9.05	0.45	1.33e-17	Dementia with Lewy bodies;
CRC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.44	-0.42	1.02e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6834538	1.000	rs6533627	chr4:113479135	A/G	cg10021238	chr4:113569128	MIR367;LARP7	0.44	6.24	0.33	1.32e-9	Free thyroxine concentration;
CRC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.35	-5.73	-0.3	2.26e-8	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs17443541	0.507	rs6725254	chr2:200463248	A/C	cg03741458	chr2:200468445	NA	-0.36	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg08644498	chr1:46502608	NA	0.41	5.88	0.31	1.02e-8	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26784348	chr1:67520192	SLC35D1	0.39	6.25	0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg26893134	chr6:116381904	FRK	0.27	7.71	0.39	1.55e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.69	12.34	0.56	5.35e-29	Iron status biomarkers;
CRC	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	cis	rs6076065	0.676	rs6076059	chr20:23336261	C/T	cg11657817	chr20:23433608	CST11	0.49	7.33	0.37	1.8e-12	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6952808	0.724	rs7792631	chr7:1982779	C/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.95	-0.4	3.05e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02772935	chr3:125709198	NA	-0.47	-5.91	-0.31	8.34e-9	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04165910	chr11:208656	BET1L;RIC8A	0.37	6.13	0.32	2.49e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.22	0.32	1.48e-9	Diabetic retinopathy;
CRC	cis	rs73195822	0.614	rs56259130	chr12:111225650	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	6.92	0.36	2.3e-11	Itch intensity from mosquito bite;
CRC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.56	-8.47	-0.42	8.03e-16	Uric acid levels;
CRC	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.13	10.47	0.5	2.49e-22	Prostate cancer;
CRC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg26566898	chr11:117069891	TAGLN	0.32	6.7	0.35	8.93e-11	Blood protein levels;
CRC	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg14186256	chr22:23484241	RTDR1	0.46	5.87	0.31	1.07e-8	Serum parathyroid hormone levels;
CRC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg03037974	chr15:76606532	NA	-0.56	-8.6	-0.43	3.29e-16	Blood metabolite levels;
CRC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.51	-7.69	-0.39	1.72e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg14541582	chr5:601475	NA	-0.32	-6.61	-0.34	1.57e-10	Obesity-related traits;
CRC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.91	0.31	8.45e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.57	8.49	0.42	7.04e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04215179	chr7:23719682	C7orf46	0.39	6.48	0.34	3.4e-10	Obesity-related traits;
CRC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg00074818	chr8:8560427	CLDN23	0.35	6.38	0.33	5.93e-10	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.94e-12	Life satisfaction;
CRC	cis	rs185694	1.000	rs202099	chr13:30896874	C/T	cg07600127	chr13:30881527	KATNAL1	-0.57	-6.14	-0.32	2.38e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.1	-0.32	3e-9	Educational attainment (years of education);
CRC	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg04611788	chr3:186434169	KNG1	0.59	8.92	0.44	3.4e-17	Blood protein levels;
CRC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.71	0.43	1.54e-16	Height;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.82	-0.4	7.17e-14	Total body bone mineral density;
CRC	cis	rs6496667	0.779	rs62020693	chr15:90961504	A/G	cg04176472	chr15:90893244	GABARAPL3	0.63	8.43	0.42	1.09e-15	Rheumatoid arthritis;
CRC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.41	-0.5	4.13e-22	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26547359	chr10:16859530	RSU1	0.39	6.49	0.34	3.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg10494257	chr1:16342123	HSPB7	0.44	5.77	0.3	1.79e-8	Dilated cardiomyopathy;
CRC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.72	8.05	0.41	1.49e-14	Systolic blood pressure;
CRC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg15147215	chr3:52552868	STAB1	0.53	9.2	0.45	4.13e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg21153622	chr11:89784906	NA	-0.4	-6.25	-0.33	1.28e-9	Height;
CRC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.46	-6.45	-0.33	4.08e-10	DNA methylation (variation);
CRC	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg05562828	chr17:3906858	NA	-0.65	-11.36	-0.53	1.84e-25	Type 2 diabetes;
CRC	trans	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg24644049	chr4:85504048	CDS1	0.78	6.59	0.34	1.79e-10	Skin colour saturation;
CRC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	9.68	0.47	1.13e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs68151129	0.666	rs60277420	chr13:94996400	G/A	cg24755503	chr5:140706252	NA	0.77	6.06	0.32	3.81e-9	Lower facial height;
CRC	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.71	5.83	0.31	1.33e-8	Body mass index;
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg05569086	chr8:143859399	LYNX1	0.37	6.35	0.33	7.33e-10	Urinary tract infection frequency;
CRC	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg18323236	chr1:24743029	NIPAL3	0.38	5.68	0.3	2.9e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-9.58	-0.47	2.56e-19	Alzheimer's disease;
CRC	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.4	5.87	0.31	1.04e-8	Putamen volume;
CRC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg04498913	chr7:1135747	C7orf50	-0.49	-5.91	-0.31	8.58e-9	Bronchopulmonary dysplasia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12530254	chr20:17949265	C20orf72;SNX5	0.47	6.79	0.35	5.15e-11	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs7932354	0.583	rs2070851	chr11:46744528	T/C	cg19486271	chr11:47235900	DDB2	0.45	5.85	0.31	1.16e-8	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.39	-0.53	1.47e-25	Electrocardiographic conduction measures;
CRC	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.46	-6.99	-0.36	1.56e-11	Sudden cardiac arrest;
CRC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.9	16.37	0.67	1.7e-44	Intelligence (multi-trait analysis);
CRC	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg16558208	chr1:156270281	VHLL	0.58	9.04	0.45	1.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6076065	0.962	rs1003417	chr20:23348007	T/A	cg11657817	chr20:23433608	CST11	0.36	5.61	0.3	4.27e-8	Facial morphology (factor 15, philtrum width);
CRC	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.54	-8.54	-0.43	5.04e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.03	-0.36	1.17e-11	IgG glycosylation;
CRC	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	cis	rs7849270	1.000	rs6478867	chr9:131903923	A/C	cg13538475	chr9:131942899	NA	0.32	6.34	0.33	7.66e-10	Blood metabolite ratios;
CRC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs6662572	0.737	rs11584814	chr1:46504389	G/A	cg08644498	chr1:46502608	NA	0.47	7.6	0.39	3.08e-13	Blood protein levels;
CRC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.41	0.71	1.52e-52	Parkinson's disease;
CRC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	8.77	0.44	9.76e-17	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.56	0.47	2.92e-19	Lung cancer;
CRC	cis	rs6496667	0.632	rs6496658	chr15:90884105	A/G	cg22089800	chr15:90895588	ZNF774	0.43	6.41	0.33	5.03e-10	Rheumatoid arthritis;
CRC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.48	-0.34	3.42e-10	Systemic lupus erythematosus;
CRC	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg25809561	chr17:30822961	MYO1D	0.54	9.44	0.46	7.05e-19	Schizophrenia;
CRC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg06238570	chr21:40685208	BRWD1	-0.61	-8.95	-0.44	2.63e-17	Menarche (age at onset);
CRC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.53	7.98	0.4	2.39e-14	Red blood cell count;
CRC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.38	5.69	0.3	2.84e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg00666640	chr1:248458726	OR2T12	0.46	7.78	0.39	9.16e-14	Common traits (Other);
CRC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg08798685	chr6:27730294	NA	-0.54	-5.86	-0.31	1.13e-8	Lung cancer in ever smokers;
CRC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.49	7.13	0.37	6.28e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.62	-9.68	-0.47	1.12e-19	Systemic lupus erythematosus;
CRC	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.26	-0.37	2.77e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg13607699	chr17:42295918	UBTF	-0.45	-5.99	-0.31	5.51e-9	Total body bone mineral density;
CRC	cis	rs989128	0.614	rs8077587	chr17:48626575	C/T	cg24438145	chr17:48624694	SPATA20	0.52	7.41	0.38	1.04e-12	Type 2 diabetes;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg20041105	chr8:143859282	LYNX1	0.43	7.63	0.39	2.58e-13	Urinary tract infection frequency;
CRC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-11.34	-0.53	2.18e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg04202892	chr2:111875749	ACOXL	0.48	7.81	0.4	7.55e-14	Chronic lymphocytic leukemia;
CRC	cis	rs11212617	0.837	rs2070661	chr11:108043988	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.73	0.3	2.32e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.33	0.42	2.29e-15	Height;
CRC	cis	rs3750082	0.889	rs6962267	chr7:32939774	G/A	cg05721444	chr7:32995514	FKBP9	0.48	7.22	0.37	3.62e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.55	8.69	0.43	1.7e-16	Schizophrenia;
CRC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.51	8.25	0.41	3.86e-15	Aortic root size;
CRC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.75	-12.39	-0.56	3.52e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg04117972	chr1:227635322	NA	-0.51	-5.83	-0.31	1.32e-8	Major depressive disorder;
CRC	cis	rs7901135	0.924	rs1992658	chr10:60581358	G/A	cg23799393	chr10:60588674	BICC1	0.36	5.69	0.3	2.82e-8	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.84	-0.31	1.27e-8	Life satisfaction;
CRC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.36	-6.61	-0.34	1.51e-10	Menarche (age at onset);
CRC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.66	9.87	0.48	2.8e-20	Initial pursuit acceleration;
CRC	cis	rs501120	0.584	rs1704221	chr10:44710930	G/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.53	7.93	0.4	3.48e-14	Prostate cancer;
CRC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.65	-0.3	3.5e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1511802	0.501	rs7684025	chr4:187116227	C/T	cg24794857	chr4:187113578	CYP4V2	0.43	6.57	0.34	1.94e-10	Blood protein levels;
CRC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.56	9.16	0.45	5.9e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.31	5.82	0.31	1.4e-8	Abdominal aortic aneurysm;
CRC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg03037974	chr15:76606532	NA	0.73	13.27	0.59	1.76e-32	Blood metabolite levels;
CRC	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.62	-10.29	-0.49	1.05e-21	Obesity-related traits;
CRC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	7.48	0.38	6.84e-13	Caffeine consumption;
CRC	cis	rs17152411	1.000	rs7083298	chr10:126590691	T/C	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	trans	rs11581859	0.950	rs56240617	chr1:99373488	T/C	cg12183875	chr3:169587454	LRRC31	0.27	6.43	0.33	4.37e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg21784768	chr11:537496	LRRC56	-0.66	-6.13	-0.32	2.48e-9	Body mass index;
CRC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.14	0.41	8.41e-15	Menopause (age at onset);
CRC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.56	-8.15	-0.41	7.47e-15	IgG glycosylation;
CRC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.38	-6.97	-0.36	1.78e-11	Reticulocyte fraction of red cells;
CRC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.16	13.7	0.6	4.1e-34	Diabetic kidney disease;
CRC	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg18764771	chr6:116381957	FRK	0.26	6.35	0.33	7.26e-10	Total cholesterol levels;
CRC	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12476592	0.543	rs262512	chr2:63890260	T/C	cg10828910	chr2:63850056	LOC388955	0.5	6.24	0.33	1.37e-9	Childhood ear infection;
CRC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg07274523	chr3:49395745	GPX1	0.47	6.34	0.33	7.73e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg17903999	chr18:56338584	MALT1	0.42	7.23	0.37	3.41e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4132509	1.000	rs10927059	chr1:243852079	T/C	cg21452805	chr1:244014465	NA	0.49	6.63	0.34	1.4e-10	RR interval (heart rate);
CRC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.45	0.38	8.53e-13	Mean platelet volume;
CRC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.73	11.56	0.54	3.49e-26	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02232284	chr6:168120876	NA	-0.36	-6.3	-0.33	9.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-6.27	-0.33	1.12e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.698	rs10250911	chr7:124473034	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg15445000	chr17:37608096	MED1	0.34	5.85	0.31	1.16e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg19622623	chr12:86230825	RASSF9	-0.37	-5.64	-0.3	3.62e-8	Major depressive disorder;
CRC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg21399703	chr1:247681439	NA	0.45	7.38	0.38	1.33e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs335206	1.000	rs335205	chr5:122504682	A/C	cg16368670	chr5:122501738	PRDM6	-0.3	-5.82	-0.31	1.36e-8	QRS duration;
CRC	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-8.2	-0.41	5.3e-15	Bipolar disorder;
CRC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.34	-0.33	7.67e-10	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs12469302	chr2:162433831	G/T	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.24	-0.33	1.33e-9	Cognitive function;
CRC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg13319975	chr6:146136371	FBXO30	0.39	5.93	0.31	7.81e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.56	-7.36	-0.38	1.44e-12	Menopause (age at onset);
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.51	0.38	5.7e-13	Lymphocyte counts;
CRC	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.63	-8.31	-0.42	2.63e-15	Malaria;
CRC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.65	6.71	0.35	8.74e-11	Axial length;
CRC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.81	-0.31	1.48e-8	Life satisfaction;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg12273811	chr6:28175739	NA	0.46	6.93	0.36	2.18e-11	Pubertal anthropometrics;
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.59	-8.8	-0.44	7.79e-17	Body mass index;
CRC	cis	rs1223397	1.000	rs1223403	chr6:13271812	G/A	cg07912922	chr6:13274314	PHACTR1	0.53	6.52	0.34	2.66e-10	Blood pressure;
CRC	cis	rs7584330	0.504	rs6712927	chr2:238427808	G/A	cg14458575	chr2:238380390	NA	0.41	5.9	0.31	8.8e-9	Prostate cancer;
CRC	trans	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg18187862	chr3:45730750	SACM1L	0.47	6.78	0.35	5.68e-11	Primary sclerosing cholangitis;
CRC	trans	rs948562	0.947	rs78176302	chr11:58382649	A/T	cg26660744	chr1:1573181	CDK11B	0.54	6.1	0.32	2.94e-9	Lymphoma;
CRC	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.83	-14.11	-0.61	1.06e-35	Hypertriglyceridemia;
CRC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00933542	chr6:150070202	PCMT1	0.35	7.24	0.37	3.25e-12	Lung cancer;
CRC	cis	rs7215564	0.908	rs34710385	chr17:78676494	G/A	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.09e-9	Myopia (pathological);
CRC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.52	8.06	0.41	1.43e-14	Corneal astigmatism;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.42	8.47	0.42	8.02e-16	Bipolar disorder;
CRC	cis	rs3772130	0.603	rs35489993	chr3:121411876	A/C	cg20356878	chr3:121714668	ILDR1	0.37	6.03	0.32	4.3e-9	Cognitive performance;
CRC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg16342193	chr10:102329863	NA	-0.37	-6.1	-0.32	2.96e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4722166	0.532	rs1404008	chr7:22756000	A/T	cg05472934	chr7:22766657	IL6	0.68	10.66	0.51	5.67e-23	Lung cancer;
CRC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.95	-0.31	7.02e-9	Schizophrenia;
CRC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.66	9.52	0.46	3.97e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.81	0.35	4.72e-11	Axial length;
CRC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg02007433	chr3:129722099	NA	-0.44	-6.02	-0.31	4.6e-9	Blood pressure (smoking interaction);
CRC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg26727032	chr16:67993705	SLC12A4	0.6	9.68	0.47	1.18e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg04362960	chr10:104952993	NT5C2	-0.41	-5.94	-0.31	7.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.26	-0.33	1.23e-9	Gout;Renal underexcretion gout;
CRC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.53	7.13	0.37	6.5e-12	Homoarginine levels;
CRC	cis	rs3736485	0.966	rs7177471	chr15:51911232	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.38	-0.33	6.15e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.52	9.22	0.45	3.7e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg19875535	chr5:140030758	IK	-0.59	-9.64	-0.47	1.52e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.17	0.41	6.54e-15	Osteoporosis;
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.48	6.82	0.35	4.33e-11	Height;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg25164649	chr6:28176230	NA	0.79	11.08	0.52	1.9e-24	Depression;
CRC	cis	rs11955398	0.625	rs6449485	chr5:59995441	C/T	cg02684056	chr5:59996105	DEPDC1B	0.43	6.12	0.32	2.71e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9341808	0.667	rs1575541	chr6:80917485	T/A	cg08355045	chr6:80787529	NA	0.33	5.77	0.3	1.81e-8	Sitting height ratio;
CRC	trans	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg10756647	chr7:56101905	PSPH	0.74	7.77	0.39	9.91e-14	Diabetic kidney disease;
CRC	trans	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.69	0.35	9.46e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	11.01	0.52	3.26e-24	Neutrophil percentage of white cells;
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg07404485	chr7:94953653	PON1	-0.47	-6.12	-0.32	2.62e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.36	-5.93	-0.31	7.76e-9	Red cell distribution width;
CRC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg02825527	chr7:2087843	MAD1L1	-0.4	-5.62	-0.3	4.15e-8	Neuroticism;
CRC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	1.05	18.53	0.71	5.16e-53	Parkinson's disease;
CRC	trans	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg21153622	chr11:89784906	NA	-0.42	-6.54	-0.34	2.41e-10	Height;
CRC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.58	8.76	0.43	1.03e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg23758597	chr6:163146217	PARK2	-0.56	-6.18	-0.32	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg19318889	chr4:1322082	MAEA	0.41	5.95	0.31	6.97e-9	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg16358738	chr2:241808595	AGXT	-0.39	-5.93	-0.31	7.52e-9	Urinary metabolites;
CRC	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg12458913	chr13:53173898	NA	-0.49	-7.28	-0.37	2.49e-12	Lewy body disease;
CRC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.09	0.41	1.13e-14	Menarche (age at onset);
CRC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.74	-0.3	2.16e-8	Breast cancer;
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.42	-5.73	-0.3	2.3e-8	Corneal structure;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.51	-6.9	-0.36	2.64e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	7.42	0.38	1.03e-12	Aortic root size;
CRC	cis	rs7616330	0.836	rs73118214	chr3:71047396	A/C	cg01511742	chr3:71112437	FOXP1	-0.52	-6.22	-0.32	1.54e-9	QT interval;
CRC	cis	rs16975963	0.644	rs111694872	chr19:38046331	T/C	cg15135657	chr19:38346511	NA	-0.45	-6.25	-0.33	1.25e-9	Longevity;
CRC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg26695010	chr11:65641043	EFEMP2	-0.39	-6.08	-0.32	3.37e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg24154853	chr7:158122151	PTPRN2	-0.47	-7.11	-0.36	7.48e-12	Calcium levels;
CRC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.62	9.26	0.45	2.78e-18	Blood protein levels;
CRC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-7.91	-0.4	3.89e-14	Vitiligo;
CRC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.35	6.59	0.34	1.76e-10	Mean corpuscular volume;
CRC	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.52	7.37	0.38	1.43e-12	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.55	-9.03	-0.45	1.44e-17	Testicular germ cell tumor;
CRC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.47	-6.29	-0.33	1.03e-9	Multiple myeloma;
CRC	cis	rs4132509	0.947	rs10927041	chr1:243731890	T/C	cg21452805	chr1:244014465	NA	0.47	6.42	0.33	4.74e-10	RR interval (heart rate);
CRC	cis	rs4731207	0.569	rs75791754	chr7:124464917	C/T	cg23710748	chr7:124431027	NA	0.39	6.23	0.32	1.43e-9	Cutaneous malignant melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23601523	chr16:68119098	NFATC3	0.48	6.8	0.35	4.92e-11	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16266895	chr12:101674004	UTP20	0.43	6.35	0.33	7.08e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.44	7.55	0.38	4.39e-13	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	6.82	0.35	4.34e-11	Aortic root size;
CRC	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg19486271	chr11:47235900	DDB2	0.52	7.96	0.4	2.74e-14	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg21251018	chr6:28226885	NKAPL	0.45	7.7	0.39	1.65e-13	Pubertal anthropometrics;
CRC	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.43	6.73	0.35	7.72e-11	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19959005	chr18:19180920	ESCO1	0.44	5.98	0.31	5.87e-9	Anxiety disorder;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg17147758	chr8:6949321	NA	-0.52	-7.18	-0.37	4.82e-12	Blood pressure (smoking interaction);
CRC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg04586622	chr2:25135609	ADCY3	-0.61	-11.64	-0.54	1.92e-26	Body mass index in non-asthmatics;
CRC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.55	8.55	0.43	4.73e-16	Height;
CRC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.83	-0.44	6.31e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.9e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9463078	0.691	rs6938177	chr6:45271834	T/C	cg25276700	chr6:44698697	NA	-0.25	-6.0	-0.31	5.11e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.61	9.19	0.45	4.55e-18	Menopause (age at onset);
CRC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-7.01	-0.36	1.37e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.41	-6.1	-0.32	3.02e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg20936604	chr3:58311152	NA	-0.72	-7.15	-0.37	5.58e-12	Cholesterol, total;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02359409	chr6:42947317	PEX6	-0.69	-11.5	-0.54	5.82e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6694672	1.000	rs1888991	chr1:197110822	A/G	cg13682187	chr1:196946512	CFHR5	0.47	7.27	0.37	2.67e-12	Asthma;
CRC	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg00469287	chr7:23338798	C7orf30	-0.43	-5.76	-0.3	1.91e-8	Cerebrospinal fluid biomarker levels;
CRC	trans	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.44	0.46	6.87e-19	Common traits (Other);
CRC	cis	rs3731896	0.653	rs10932799	chr2:220200705	C/T	cg00436969	chr2:220197716	RESP18	-0.46	-5.82	-0.31	1.42e-8	Educational attainment;
CRC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.79	0.51	1.99e-23	Ileal carcinoids;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19069346	chr21:41239214	PCP4	0.44	6.79	0.35	5.29e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.6	-0.39	3.02e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.52	7.47	0.38	7.15e-13	Type 2 diabetes;
CRC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg10298567	chr3:47292165	KIF9	0.37	5.84	0.31	1.28e-8	Colorectal cancer;
CRC	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	trans	rs4378999	0.660	rs11928733	chr3:50833438	C/T	cg12383621	chr7:7735611	RPA3	-0.48	-6.1	-0.32	2.95e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.52	7.54	0.38	4.47e-13	Pulmonary function decline;
CRC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg21466736	chr12:48725269	NA	-0.49	-7.54	-0.38	4.68e-13	Glycated hemoglobin levels;
CRC	cis	rs73200209	0.744	rs56869346	chr12:116514538	T/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.25	-0.37	2.95e-12	Total body bone mineral density;
CRC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg15654264	chr1:150340011	RPRD2	0.41	6.05	0.32	3.93e-9	Migraine;
CRC	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg04989706	chr14:50066350	PPIL5	-0.49	-6.92	-0.36	2.32e-11	Carotid intima media thickness;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13628960	chr20:62258574	GMEB2	0.42	5.96	0.31	6.39e-9	Anxiety disorder;
CRC	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.5	8.91	0.44	3.47e-17	Testicular germ cell tumor;
CRC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.33	0.37	1.83e-12	Platelet count;
CRC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.93	0.4	3.43e-14	Lymphocyte percentage of white cells;
CRC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg02927042	chr1:21476669	EIF4G3	0.37	5.61	0.3	4.23e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.47	-7.09	-0.36	8.08e-12	Pancreatic cancer;
CRC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.45	-8.83	-0.44	6.35e-17	Subjective well-being;
CRC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.86	16.13	0.66	1.5e-43	Dental caries;
CRC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg27266060	chr8:22091797	NA	0.35	5.86	0.31	1.11e-8	Hypertriglyceridemia;
CRC	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg19875535	chr5:140030758	IK	0.42	6.42	0.33	4.88e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg09835421	chr16:68378352	PRMT7	-0.61	-7.55	-0.38	4.27e-13	Schizophrenia;
CRC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.46	-7.58	-0.39	3.66e-13	Type 2 diabetes;
CRC	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.06	-0.36	9.85e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg06606381	chr12:133084897	FBRSL1	-0.6	-5.98	-0.31	5.93e-9	Lung cancer in ever smokers;
CRC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.78	0.7	4.72e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.77	13.15	0.59	4.95e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg25985355	chr7:65971099	NA	0.53	6.05	0.32	3.9e-9	Diabetic kidney disease;
CRC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg06238570	chr21:40685208	BRWD1	0.74	10.35	0.5	6.5600000000000005e-22	Cognitive function;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12273811	chr6:28175739	NA	0.72	9.03	0.45	1.47e-17	Depression;
CRC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg25876840	chr17:41920477	NA	0.44	6.42	0.33	4.88e-10	Triglycerides;
CRC	trans	rs587242	1.000	rs12757257	chr1:96898302	G/A	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.56	-0.43	4.41e-16	Chronic sinus infection;
CRC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg02428538	chr16:24856791	SLC5A11	0.56	6.68	0.35	1.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.68	-11.18	-0.52	8.4e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.51	-0.57	1.18e-29	Idiopathic membranous nephropathy;
CRC	cis	rs7553864	1.000	rs7515367	chr1:87615798	A/T	cg02083836	chr1:87617350	LOC339524	0.36	6.34	0.33	7.65e-10	Smoking behavior;
CRC	trans	rs10403021	0.855	rs10500240	chr19:30068492	A/C	cg22044635	chr17:76557109	DNAH17	0.44	6.13	0.32	2.57e-9	Diabetic retinopathy;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.49	7.28	0.37	2.5e-12	Longevity;Endometriosis;
CRC	trans	rs9914544	0.545	rs7212905	chr17:18774271	A/G	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.15	-0.32	2.25e-9	Educational attainment (years of education);
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.56	-10.06	-0.49	6.05e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	9.16	0.45	5.79e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.95	-15.01	-0.64	3.79e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.61	7.3	0.37	2.12e-12	Neutrophil percentage of white cells;
CRC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.53	0.5	1.54e-22	Systolic blood pressure;
CRC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.55	8.36	0.42	1.85e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.57	-8.47	-0.42	8.14e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.56	-6.34	-0.33	7.62e-10	Vitiligo;
CRC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg04727924	chr7:799746	HEATR2	-0.39	-5.87	-0.31	1.04e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs7113874	0.589	rs10840060	chr11:8500045	A/C	cg02811074	chr11:8615871	STK33	0.38	6.43	0.33	4.54e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.38	6.43	0.33	4.54e-10	Schizophrenia;
CRC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.08	10.77	0.51	2.34e-23	Skin colour saturation;
CRC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg03037974	chr15:76606532	NA	-0.48	-6.98	-0.36	1.62e-11	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.59	-0.34	1.79e-10	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg16141378	chr3:129829833	LOC729375	0.48	6.89	0.36	2.78e-11	Systolic blood pressure;
CRC	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.42	-5.94	-0.31	7.23e-9	Blood pressure (smoking interaction);
CRC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.53e-12	Menopause (age at onset);
CRC	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22878388	chr2:105853796	NA	-0.32	-6.25	-0.33	1.27e-9	Type 2 diabetes;
CRC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.49	-7.11	-0.36	7.26e-12	DNA methylation (variation);
CRC	trans	rs11031096	0.702	rs2735691	chr11:4117709	C/G	cg22978087	chr8:24814126	NEFL	0.32	6.01	0.31	4.86e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.4	-6.83	-0.35	4.13e-11	Hip circumference;Waist circumference;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.67	-10.82	-0.51	1.46e-23	Asthma;
CRC	trans	rs10060123	1.000	rs10057227	chr5:125685374	A/G	ch.6.113866684R	chr6:113759991	NA	-0.38	-5.97	-0.31	6.31e-9	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue;
CRC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg02880119	chr16:3481970	NA	-0.41	-5.8	-0.3	1.55e-8	Body mass index (adult);
CRC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	13.85	0.61	1.09e-34	Platelet count;
CRC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.32e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg21466736	chr12:48725269	NA	-0.55	-8.25	-0.41	3.86e-15	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.78	10.15	0.49	3.14e-21	Cerebrospinal P-tau181p levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg16442050	chr2:27294098	LOC100128731	-0.43	-6.49	-0.34	3.19e-10	Daytime sleep phenotypes;
CRC	cis	rs2929278	0.589	rs7174732	chr15:44038463	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-5.82	-0.31	1.4e-8	Schizophrenia;
CRC	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg10494257	chr1:16342123	HSPB7	0.45	6.23	0.32	1.41e-9	Dilated cardiomyopathy;
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.83	8.43	0.42	1.11e-15	Fat distribution (HIV);
CRC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	3.04e-10	Fibrinogen levels;
CRC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.4	6.68	0.35	1.01e-10	Alcohol dependence;
CRC	cis	rs1383484	0.640	rs12101685	chr15:84643657	A/G	cg11189052	chr15:85197271	WDR73	-0.46	-5.82	-0.31	1.42e-8	Height;
CRC	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg22089800	chr15:90895588	ZNF774	0.49	7.79	0.39	9.01e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.76	14.12	0.61	1.01e-35	Prudent dietary pattern;
CRC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.72	0.68	7.16e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.06	10.38	0.5	5.21e-22	Diabetic retinopathy;
CRC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs883565	0.543	rs784496	chr3:39179536	A/G	cg01426195	chr3:39028469	NA	0.41	6.68	0.35	1.03e-10	Handedness;
CRC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13606994	chr1:44402422	ARTN	-0.34	-5.73	-0.3	2.23e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg01919652	chr6:150259930	NA	-0.69	-5.99	-0.31	5.48e-9	Cognitive function;
CRC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.85	-11.3	-0.53	3.17e-25	Initial pursuit acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20505218	chr17:80009845	GPS1;RFNG	0.47	6.63	0.34	1.4e-10	Response to antipsychotic treatment;
CRC	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg23815491	chr16:72088622	HP	0.52	6.35	0.33	7.24e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs519973	1.000	rs491087	chr3:187636166	G/A	cg10168494	chr3:187635183	NA	0.51	8.92	0.44	3.42e-17	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.45	-6.87	-0.35	3.15e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.24	-0.33	1.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.93	-18.3	-0.71	4.44e-52	Height;
CRC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.36	5.63	0.3	3.97e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.45	-6.26	-0.33	1.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.89e-9	Life satisfaction;
CRC	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.69	0.43	1.78e-16	Coffee consumption (cups per day);
CRC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.58	8.7	0.43	1.59e-16	Menopause (age at onset);
CRC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg06243084	chr11:63990629	FERMT3	0.4	6.19	0.32	1.79e-9	Platelet count;
CRC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.27	0.33	1.13e-9	Aortic root size;
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg00166722	chr3:10149974	C3orf24	0.65	8.51	0.42	6.38e-16	Alzheimer's disease;
CRC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.76	-10.48	-0.5	2.25e-22	Coronary artery disease;
CRC	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg10820045	chr2:198174542	NA	0.4	6.87	0.35	3.26e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-9.17	-0.45	5.24e-18	Longevity;Endometriosis;
CRC	cis	rs1223397	0.589	rs2439540	chr6:13309342	G/A	cg20827128	chr6:13274284	PHACTR1	0.4	6.08	0.32	3.34e-9	Blood pressure;
CRC	cis	rs4728302	0.869	rs7792492	chr7:133595316	C/T	cg03336402	chr7:133662267	EXOC4	-0.42	-6.36	-0.33	6.83e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.57	-8.81	-0.44	7.42e-17	Sudden cardiac arrest;
CRC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg18230493	chr5:56204884	C5orf35	0.59	8.59	0.43	3.5e-16	Initial pursuit acceleration;
CRC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg05072774	chr3:49840536	C3orf54	-0.43	-5.74	-0.3	2.15e-8	Resting heart rate;
CRC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg19582491	chr16:67682965	RLTPR	-0.58	-6.91	-0.36	2.5e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01622965	chr7:98476371	TRRAP	0.5	6.48	0.34	3.42e-10	Thyroid stimulating hormone;
CRC	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.49	7.66	0.39	2.08e-13	Red blood cell count;
CRC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	1.06	10.05	0.48	6.51e-21	Arsenic metabolism;
CRC	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.15e-10	Obesity-related traits;
CRC	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.8	10.05	0.48	6.61e-21	Prostate cancer;
CRC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.39e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs9928842	0.823	rs4888365	chr16:75282247	A/G	cg09066997	chr16:75300724	BCAR1	0.65	6.17	0.32	2e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.48	7.22	0.37	3.63e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.41	-0.33	5.19e-10	Life satisfaction;
CRC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.52	8.5	0.42	6.7e-16	Schizophrenia;
CRC	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.76	12.16	0.56	2.3e-28	Mean platelet volume;
CRC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.4	7.74	0.39	1.22e-13	Ulcerative colitis;
CRC	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.47	-7.72	-0.39	1.39e-13	Prevalent atrial fibrillation;
CRC	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg16797656	chr11:68205561	LRP5	0.48	6.82	0.35	4.36e-11	Total body bone mineral density (age 45-60);
CRC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.82	-12.41	-0.56	2.91e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.78	-0.3	1.76e-8	Electroencephalogram traits;
CRC	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs745570	1.000	rs745571	chr17:77781387	T/C	cg04986373	chr17:77768687	CBX8	0.44	6.58	0.34	1.83e-10	Breast cancer;
CRC	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.71	-9.4	-0.46	9.34e-19	Blood pressure (smoking interaction);
CRC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.83	-0.4	6.73e-14	Vitiligo;
CRC	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.73	10.13	0.49	3.49e-21	Systemic lupus erythematosus;
CRC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.76	0.39	1.09e-13	Lung cancer;
CRC	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.48	6.11	0.32	2.83e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	trans	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg26182253	chr13:112236782	NA	0.31	6.3	0.33	9.74e-10	Hepatitis;
CRC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04731861	chr2:219085781	ARPC2	0.33	6.93	0.36	2.21e-11	Colorectal cancer;
CRC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.22e-10	Lung cancer;
CRC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.36	5.9	0.31	8.97e-9	Blood metabolite levels;
CRC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.58	10.48	0.5	2.38e-22	Multiple system atrophy;
CRC	cis	rs12760731	0.720	rs12072124	chr1:178366990	G/A	cg00404053	chr1:178313656	RASAL2	0.9	10.11	0.49	4.33e-21	Obesity-related traits;
CRC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	11.07	0.52	2.09e-24	Neutrophil percentage of white cells;
CRC	cis	rs6499255	0.951	rs9788837	chr16:69688413	A/G	cg15192750	chr16:69999425	NA	0.59	7.96	0.4	2.79e-14	IgE levels;
CRC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.52	-7.88	-0.4	4.83e-14	Axial length;
CRC	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.66	9.18	0.45	4.89e-18	White matter hyperintensity burden;
CRC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg03037974	chr15:76606532	NA	0.72	12.72	0.57	1.97e-30	Blood metabolite levels;
CRC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.55	-8.6	-0.43	3.21e-16	Aortic root size;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20092199	chr4:1342459	KIAA1530	-0.41	-7.71	-0.39	1.48e-13	Obesity-related traits;
CRC	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.42	-0.38	1.03e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11645453	chr3:52864694	ITIH4	0.36	6.27	0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.57	-0.34	2.01e-10	Bipolar disorder;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg26587870	chr6:27730563	NA	-0.56	-6.44	-0.33	4.31e-10	Lung cancer in ever smokers;
CRC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.99	0.48	1.07e-20	Alzheimer's disease (late onset);
CRC	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-1.25	-11.45	-0.53	9.22e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10982256	0.935	rs1555700	chr9:117256375	T/C	cg13636371	chr9:117264095	DFNB31	0.39	7.5	0.38	5.88e-13	Bipolar disorder;
CRC	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.41	-5.85	-0.31	1.17e-8	Daytime sleep phenotypes;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Parkinson's disease;
CRC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.63	0.57	4.28e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg10862848	chr6:42927986	GNMT	-0.31	-5.84	-0.31	1.27e-8	Blood protein levels;
CRC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00166722	chr3:10149974	C3orf24	0.42	6.26	0.33	1.22e-9	Alzheimer's disease;
CRC	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.52	8.02	0.4	1.94e-14	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg05673287	chr15:77411982	SGK269	-0.54	-8.18	-0.41	6.41e-15	Type 2 diabetes;
CRC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.86	-0.35	3.48e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs16882447	0.607	rs10052279	chr5:53491197	A/G	cg06461071	chr5:53490839	ARL15	0.35	5.64	0.3	3.66e-8	Systolic blood pressure (dietary potassium intake interaction);
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.08	13.41	0.59	5.35e-33	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	6.19e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.62	9.93	0.48	1.74e-20	Anterior chamber depth;
CRC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg18230493	chr5:56204884	C5orf35	0.4	5.83	0.31	1.29e-8	Coronary artery disease;
CRC	cis	rs6838801	0.892	rs13108785	chr4:77576070	A/C	cg17476223	chr4:77663285	SHROOM3	0.42	5.9	0.31	9.22e-9	Cleft lip with or without cleft palate;
CRC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.67	0.63	7.94e-38	Chronic sinus infection;
CRC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg24905316	chr10:135186343	ECHS1	0.72	6.42	0.33	4.89e-10	Lifespan;
CRC	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg19688584	chr6:167529678	CCR6	-0.35	-6.39	-0.33	5.68e-10	Primary biliary cholangitis;
CRC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	12.24	0.56	1.2e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg01612440	chr4:3296283	NA	0.44	6.24	0.33	1.36e-9	Serum sulfate level;
CRC	cis	rs2108622	0.647	rs111427692	chr19:15977479	A/T	cg13772218	chr19:15982569	NA	0.47	6.59	0.34	1.74e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.71	9.34	0.46	1.55e-18	High light scatter reticulocyte count;
CRC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.97	13.91	0.61	6.76e-35	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.9	-15.53	-0.65	3.38e-41	Height;
CRC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.56	7.75	0.39	1.19e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.91	17.67	0.7	1.31e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.7	9.62	0.47	1.84e-19	Breast cancer;
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg12273811	chr6:28175739	NA	0.55	5.86	0.31	1.12e-8	Depression;
CRC	cis	rs3026101	0.671	rs748486	chr17:5290824	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg26762873	chr11:5879799	OR52E8	-0.4	-5.88	-0.31	1.01e-8	DNA methylation (variation);
CRC	trans	rs9409565	0.821	rs7858082	chr9:97063929	T/A	cg05679027	chr9:99775184	HIATL2	0.41	6.1	0.32	3.04e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7072216	0.770	rs942810	chr10:100167860	G/C	cg26618903	chr10:100175079	PYROXD2	-0.42	-7.08	-0.36	8.9e-12	Metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02888146	chr6:143267449	HIVEP2	0.43	6.03	0.32	4.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg16077055	chr2:106428750	NCK2	0.4	5.6	0.3	4.48e-8	Addiction;
CRC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg05623727	chr3:50126028	RBM5	-0.43	-7.32	-0.37	1.87e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.57	-8.46	-0.42	9.09e-16	Migraine;Coronary artery disease;
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg01216370	chr2:228736459	WDR69	-0.45	-5.72	-0.3	2.36e-8	Blood pressure;
CRC	trans	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.49	-7.59	-0.39	3.38e-13	Mortality in heart failure;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-7.15	-0.37	5.72e-12	Cystic fibrosis severity;
CRC	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.39	6.05	0.32	3.83e-9	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.44	0.38	8.78e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.57	7.6	0.39	3.05e-13	Cocaine dependence;
CRC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.6	-10.82	-0.51	1.5e-23	Multiple system atrophy;
CRC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.69	-10.64	-0.51	6.51e-23	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs12476592	0.602	rs262524	chr2:63892727	A/G	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs6586163	0.872	rs7910660	chr10:90743197	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.08	-0.36	8.67e-12	Chronic lymphocytic leukemia;
CRC	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	cg04338863	chr8:33670619	NA	0.39	6.73	0.35	7.52e-11	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22728371	chr5:32313149	MTMR12	0.4	6.18	0.32	1.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.81	-13.71	-0.6	3.61e-34	Height;
CRC	cis	rs3814231	0.531	rs12773054	chr10:115476042	C/T	cg24846397	chr10:115438155	CASP7	-0.34	-5.67	-0.3	3.17e-8	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00497091	chr1:145438415	TXNIP	0.44	6.05	0.32	3.87e-9	Response to antipsychotic treatment;
CRC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg12573674	chr2:1569213	NA	-0.75	-7.87	-0.4	5.22e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2242663	0.798	rs1791679	chr11:66337874	C/A	cg24851651	chr11:66362959	CCS	0.44	7.22	0.37	3.67e-12	Bipolar disorder;
CRC	cis	rs728616	0.867	rs79904324	chr10:81804688	A/G	cg11900509	chr10:81946545	ANXA11	-0.57	-6.19	-0.32	1.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.43	-6.51	-0.34	2.87e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs2949837	0.581	rs1542819	chr7:45978059	T/C	cg15898840	chr7:45960834	IGFBP3	0.45	7.4	0.38	1.12e-12	Sitting height ratio;
CRC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.86	0.31	1.15e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.2	-0.32	1.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg24172324	chr2:232258363	NA	-0.38	-5.97	-0.31	6.2e-9	Gut microbiome composition (winter);
CRC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg00919237	chr7:87102261	ABCB4	-0.52	-6.62	-0.34	1.42e-10	Gallbladder cancer;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-8.54	-0.43	5.17e-16	Alzheimer's disease;
CRC	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.74	7.55	0.38	4.46e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg12458913	chr13:53173898	NA	-0.51	-8.12	-0.41	9.43e-15	Lewy body disease;
CRC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.38	0.33	5.9e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.47	0.42	8.16e-16	Arsenic metabolism;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg12365402	chr11:9010492	NRIP3	-0.42	-6.71	-0.35	8.74e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg08717414	chr16:71523259	ZNF19	-0.45	-5.61	-0.3	4.36e-8	Post bronchodilator FEV1;
CRC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.84	0.51	1.3e-23	Motion sickness;
CRC	cis	rs12580194	0.556	rs12099811	chr12:55731200	T/A	cg19537932	chr12:55886519	OR6C68	-0.63	-8.03	-0.4	1.81e-14	Cancer;
CRC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.84	-13.43	-0.6	4.27e-33	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg10802521	chr3:52805072	NEK4	-0.47	-6.55	-0.34	2.28e-10	Schizophrenia;
CRC	cis	rs9487051	0.698	rs59502176	chr6:109644719	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.72	-0.3	2.39e-8	Reticulocyte fraction of red cells;
CRC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.98	-16.7	-0.68	8.97e-46	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs6496667	0.779	rs7169914	chr15:90952049	G/T	cg04176472	chr15:90893244	GABARAPL3	0.64	8.17	0.41	6.9e-15	Rheumatoid arthritis;
CRC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg04673462	chr1:38461896	NA	0.35	5.78	0.3	1.78e-8	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15273368	chr10:104221031	TMEM180	0.42	6.78	0.35	5.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.68	-9.47	-0.46	5.63e-19	Vitiligo;
CRC	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg23234261	chr14:55582407	NA	-0.29	-5.78	-0.3	1.73e-8	Protein biomarker;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg22907277	chr7:1156413	C7orf50	0.52	6.03	0.32	4.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	-0.66	-7.63	-0.39	2.59e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.51	0.46	4.14e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2346160	0.899	rs206980	chr6:167691798	A/G	cg27333441	chr6:167680455	NA	0.37	5.77	0.3	1.87e-8	Parental extreme longevity (95 years and older);
CRC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.63	12.18	0.56	1.97e-28	Coronary artery disease;
CRC	cis	rs732072	0.826	rs604615	chr11:65474813	G/T	cg21033440	chr11:65409861	SIPA1	-0.67	-5.7	-0.3	2.7e-8	Inflammatory bowel disease;
CRC	cis	rs4964805	0.913	rs12830701	chr12:104201682	A/C	cg02344784	chr12:104178138	NT5DC3	0.53	7.71	0.39	1.49e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-6.2	-0.32	1.72e-9	Mean corpuscular volume;
CRC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26614578	chr12:113623930	C12orf52;DDX54	0.5	6.73	0.35	7.36e-11	Thyroid stimulating hormone;
CRC	cis	rs7072216	0.881	rs10883084	chr10:100151189	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.25	-0.33	1.29e-9	Metabolite levels;
CRC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-12.14	-0.56	2.93e-28	Asthma;
CRC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.6	-9.13	-0.45	6.93e-18	Breast cancer;
CRC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-7.19	-0.37	4.25e-12	Coronary artery disease;
CRC	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg20045696	chr14:77926864	AHSA1	0.38	6.05	0.32	3.97e-9	Myeloid white cell count;
CRC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.46	-5.81	-0.3	1.5e-8	Aortic root size;
CRC	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg06553033	chr12:53270239	NA	0.43	5.88	0.31	1e-8	Cancer (pleiotropy);
CRC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg07125278	chr16:67683757	RLTPR	-0.63	-6.85	-0.35	3.56e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-0.98	-12.38	-0.56	3.82e-29	Uric acid levels;
CRC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg16141378	chr3:129829833	LOC729375	0.43	6.68	0.35	1.03e-10	Neuroticism;
CRC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg03013636	chr16:1946785	NA	0.54	6.79	0.35	5.4e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.7	-12.06	-0.55	5.72e-28	Longevity;
CRC	cis	rs1870323	0.689	rs10898483	chr11:86160313	C/T	cg01663953	chr11:86133777	CCDC81	-0.31	-5.71	-0.3	2.5e-8	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
CRC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.49	-8.2	-0.41	5.56e-15	Height;
CRC	cis	rs55702914	0.628	rs55658871	chr2:198278571	G/A	cg10820045	chr2:198174542	NA	0.32	5.7	0.3	2.72e-8	Major depression and alcohol dependence;
CRC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.31	-0.33	9.03e-10	Monocyte count;
CRC	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.75	-0.3	2.07e-8	Bladder cancer;
CRC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs9494145	0.680	rs35959442	chr6:135424179	C/G	cg22676075	chr6:135203613	NA	0.44	5.8	0.3	1.58e-8	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg08034379	chr2:228736324	WDR69	-0.51	-6.86	-0.35	3.47e-11	Blood pressure;
CRC	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-11.7	-0.54	1.14e-26	Urate levels in overweight individuals;
CRC	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.61	8.47	0.42	8.46e-16	Eosinophilic esophagitis;
CRC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg24562669	chr7:97807699	LMTK2	0.79	17.69	0.7	1.07e-49	Breast cancer;
CRC	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.3	-6.71	-0.35	8.67e-11	Migraine;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg11284414	chr2:232573146	PTMA	-0.42	-6.56	-0.34	2.15e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.51	-6.71	-0.35	8.33e-11	Lung cancer;
CRC	trans	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.41	-0.33	5.12e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg10790698	chr19:18539756	SSBP4	-0.45	-8.72	-0.43	1.41e-16	Breast cancer;
CRC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg14711859	chr11:8959438	ASCL3	0.44	7.5	0.38	5.82e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1109861	0.535	rs3243	chr10:11237928	A/G	cg24910943	chr10:11206320	CUGBP2	0.25	6.48	0.34	3.41e-10	Urinary albumin-to-creatinine ratio;
CRC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.49	7.48	0.38	6.88e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.84	-14.66	-0.63	8.68e-38	Longevity;
CRC	cis	rs741668	0.894	rs6561282	chr13:46596742	T/G	cg06018095	chr13:46550134	ZC3H13	0.43	5.95	0.31	7.04e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.49	-5.89	-0.31	9.56e-9	Diastolic blood pressure;
CRC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.3e-9	Prudent dietary pattern;
CRC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-7.01	-0.36	1.33e-11	Type 2 diabetes;
CRC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs2072510	0.593	rs2540493	chr12:96415842	A/C	cg15438951	chr12:96389694	HAL	-0.48	-5.83	-0.31	1.32e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7804356	0.906	rs12540388	chr7:26905731	A/T	cg03456212	chr7:26904342	SKAP2	-0.53	-5.93	-0.31	7.6e-9	Type 1 diabetes;
CRC	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.46	7.29	0.37	2.26e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.45	-8.01	-0.4	2.07e-14	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg12273811	chr6:28175739	NA	0.56	8.05	0.41	1.52e-14	Parkinson's disease;
CRC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.41	-7.85	-0.4	5.74e-14	Subjective well-being;
CRC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.78	0.35	5.54e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.39	-0.42	1.48e-15	Longevity;Endometriosis;
CRC	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.63	-7.76	-0.39	1.1e-13	Pursuit maintenance gain;
CRC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg13390004	chr1:15929781	NA	0.45	6.3	0.33	9.39e-10	Systolic blood pressure;
CRC	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg09695851	chr17:3907499	NA	0.73	13.38	0.59	6.69e-33	Type 2 diabetes;
CRC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.72	-12.78	-0.58	1.24e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs10919791	0.501	rs12029406	chr1:199905828	A/G	cg07208853	chr1:200005219	NR5A2	-0.24	-6.16	-0.32	2.16e-9	Pancreatic cancer;
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg03623178	chr6:28175578	NA	-0.42	-5.72	-0.3	2.44e-8	Systemic lupus erythematosus;
CRC	cis	rs6662572	0.737	rs10749859	chr1:46314170	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.85	0.31	1.2e-8	Blood protein levels;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	7.21	0.37	3.81e-12	Longevity;
CRC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.04	0.32	4.22e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg10589385	chr1:150898437	SETDB1	-0.27	-5.82	-0.31	1.41e-8	Tonsillectomy;
CRC	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.27	-0.33	1.12e-9	Blood pressure;
CRC	cis	rs4363385	0.765	rs1094409	chr1:153021040	T/A	cg25856811	chr1:152973957	SPRR3	-0.27	-7.48	-0.38	7.01e-13	Inflammatory skin disease;
CRC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-7.83	-0.4	6.83e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2257205	0.667	rs4453568	chr17:56934543	A/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.43e-8	Pancreatic cancer;
CRC	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.7	-0.39	1.59e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg08772003	chr10:104629869	AS3MT	-0.34	-5.9	-0.31	8.85e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg13491945	chr12:107078410	RFX4	0.34	5.74	0.3	2.18e-8	Heart rate;
CRC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14895029	chr7:2775587	GNA12	-0.4	-6.23	-0.32	1.42e-9	Height;
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg02033258	chr5:131593261	PDLIM4	0.39	7.51	0.38	5.48e-13	Breast cancer;
CRC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12463550	chr7:65579703	CRCP	0.68	6.14	0.32	2.32e-9	Diabetic kidney disease;
CRC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg22638593	chr5:131593259	PDLIM4	-0.31	-5.71	-0.3	2.51e-8	Blood metabolite levels;
CRC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.22	-0.37	3.59e-12	Aortic root size;
CRC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.5	7.79	0.39	8.91e-14	Red blood cell count;
CRC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.45	6.5	0.34	2.93e-10	Longevity;Endometriosis;
CRC	cis	rs1320333	0.772	rs111825088	chr2:695785	T/G	cg00500140	chr2:691012	NA	0.59	6.62	0.34	1.48e-10	Obesity-related traits;
CRC	trans	rs4586057	0.812	rs10881845	chr10:92648193	T/C	cg26894278	chr13:21016241	CRYL1	0.4	6.52	0.34	2.59e-10	Economic and political preferences (time);
CRC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg22532475	chr10:104410764	TRIM8	-0.37	-6.79	-0.35	5.28e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg24209194	chr3:40518798	ZNF619	0.42	6.5	0.34	3e-10	Renal cell carcinoma;
CRC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.79	14.08	0.61	1.43e-35	Metabolic syndrome;
CRC	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.53	8.1	0.41	1.08e-14	Testicular germ cell tumor;
CRC	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg18099408	chr3:52552593	STAB1	-0.49	-8.39	-0.42	1.5e-15	Electroencephalogram traits;
CRC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.69	-9.31	-0.46	1.85e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.39	-0.42	1.48e-15	Schizophrenia;
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.66	-0.34	1.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg26043149	chr18:55253948	FECH	-0.49	-7.52	-0.38	5.31e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.36	-5.74	-0.3	2.18e-8	Mood instability;
CRC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.51	6.87	0.35	3.3e-11	Height;
CRC	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.43	8.42	0.42	1.2e-15	Schizophrenia;
CRC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.43	5.94	0.31	7.22e-9	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13487185	chr1:29213677	EPB41	0.38	6.65	0.34	1.25e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-6.68	-0.35	1.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.5	-6.67	-0.35	1.07e-10	Glioblastoma;
CRC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.8	-0.44	7.75e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	9.09	0.45	9.3e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg21132104	chr15:45694354	SPATA5L1	0.41	5.92	0.31	8.14e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs2415984	0.579	rs12147933	chr14:46972443	G/A	cg14871534	chr14:47121158	RPL10L	-0.4	-5.96	-0.31	6.51e-9	Number of children ever born;
CRC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.64	-8.14	-0.41	8.51e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7487075	0.820	rs7314069	chr12:46708737	T/C	cg22049899	chr12:47219821	SLC38A4	0.32	6.1	0.32	3.02e-9	Itch intensity from mosquito bite;
CRC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg27535305	chr1:53392650	SCP2	0.34	6.36	0.33	6.57e-10	Monocyte count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09337511	chr12:112856520	PTPN11	0.41	6.48	0.34	3.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg14003231	chr6:33640908	ITPR3	-0.5	-8.26	-0.41	3.48e-15	Height;
CRC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	14.84	0.63	1.66e-38	Smoking behavior;
CRC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.6	-0.3	4.46e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.82	10.85	0.51	1.21e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs6691722	0.503	rs12086212	chr1:24708740	C/T	cg18323236	chr1:24743029	NIPAL3	0.4	5.89	0.31	9.66e-9	Response to interferon beta in multiple sclerosis;
CRC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.58	-10.35	-0.5	6.24e-22	Lung cancer;
CRC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04731861	chr2:219085781	ARPC2	0.37	7.9	0.4	4.12e-14	Colorectal cancer;
CRC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.46	0.34	3.84e-10	Aortic root size;
CRC	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.53	-0.34	2.5e-10	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20340149	chr2:122407145	CLASP1	0.41	6.36	0.33	6.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg20933634	chr6:27740509	NA	0.65	9.13	0.45	7.01e-18	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15985400	chr11:76091674	PRKRIR	0.46	7.35	0.38	1.55e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.91	-0.31	8.4e-9	Longevity;Endometriosis;
CRC	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.47	6.31	0.33	8.84e-10	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg14979609	chr8:8086686	FLJ10661	-0.36	-5.64	-0.3	3.62e-8	Neuroticism;
CRC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.84e-9	Schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21798447	chr4:85504053	CDS1	-0.43	-6.75	-0.35	6.74e-11	Myopia (pathological);
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg25164649	chr6:28176230	NA	0.7	8.93	0.44	3.12e-17	Parkinson's disease;
CRC	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.19	0.45	4.51e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg01483505	chr11:975446	AP2A2	0.43	6.92	0.36	2.41e-11	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.65	8.46	0.42	8.64e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.8	8.37	0.42	1.72e-15	Major depressive disorder;
CRC	cis	rs7553864	0.966	rs11161936	chr1:87614507	G/C	cg02083836	chr1:87617350	LOC339524	0.38	6.63	0.34	1.35e-10	Smoking behavior;
CRC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.07	13.65	0.6	6.58e-34	Vitiligo;
CRC	cis	rs12143943	0.866	rs4252745	chr1:204519187	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.39	-5.95	-0.31	6.76e-9	Cognitive performance;
CRC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.64	0.43	2.48e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.74	-10.42	-0.5	3.82e-22	Vitiligo;
CRC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.82	-10.35	-0.5	6.5600000000000005e-22	Glomerular filtration rate (creatinine);
CRC	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg09218773	chr11:619014	MUPCDH	-0.37	-5.8	-0.3	1.57e-8	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg08772003	chr10:104629869	AS3MT	-0.37	-6.35	-0.33	7.1e-10	Arsenic metabolism;
CRC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.62	-8.83	-0.44	6.4e-17	Menarche (age at onset);
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg23161317	chr6:28129485	ZNF389	-0.46	-6.0	-0.31	5.15e-9	Parkinson's disease;
CRC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg16447950	chr5:562315	NA	-0.81	-12.29	-0.56	8.11e-29	Obesity-related traits;
CRC	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg18830697	chr6:72922368	RIMS1	0.41	8.25	0.41	3.95e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg22687807	chr8:143858763	LYNX1	-0.63	-11.26	-0.53	4.2e-25	Urinary tract infection frequency;
CRC	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg12072164	chr19:44306565	LYPD5	0.38	5.93	0.31	7.71e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs253959	0.672	rs4920903	chr5:115421589	T/C	cg23108291	chr5:115420582	COMMD10	0.44	6.17	0.32	2.04e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg12935359	chr14:103987150	CKB	-0.37	-5.91	-0.31	8.63e-9	Body mass index;
CRC	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg23260525	chr10:116636907	FAM160B1	0.31	6.73	0.35	7.58e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg17724175	chr1:150552817	MCL1	-0.45	-6.55	-0.34	2.28e-10	Melanoma;
CRC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg24849736	chr1:201084428	NA	0.5	7.66	0.39	2.05e-13	Permanent tooth development;
CRC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.0	0.55	9.26e-28	Menopause (age at onset);
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg08888203	chr3:10149979	C3orf24	0.63	8.54	0.43	4.89e-16	Alzheimer's disease;
CRC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	7.0	0.36	1.47e-11	Rheumatoid arthritis;
CRC	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg24463073	chr6:118973353	C6orf204	0.52	6.67	0.35	1.08e-10	Diastolic blood pressure;
CRC	cis	rs3767633	0.925	rs6427633	chr1:161849569	C/T	cg09175582	chr1:161736000	ATF6	0.68	6.13	0.32	2.53e-9	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7246865	0.813	rs13346655	chr19:17176757	C/G	cg19418318	chr19:17219073	MYO9B	0.42	6.67	0.35	1.1e-10	Reticulocyte fraction of red cells;
CRC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.37	6.02	0.32	4.6e-9	Ulcerative colitis;
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg21238619	chr17:78079768	GAA	-0.34	-5.76	-0.3	1.95e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.78	-0.51	2.06e-23	Monocyte count;
CRC	trans	rs11225569	0.539	rs7946826	chr11:103340676	C/T	cg01615333	chr12:127765195	NA	-0.65	-6.17	-0.32	1.98e-9	Diisocyanate-induced asthma;
CRC	cis	rs9462027	0.606	rs2815001	chr6:34634353	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.73	-0.3	2.23e-8	Tonsillectomy;
CRC	cis	rs3106136	0.609	rs1876917	chr4:95099737	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-6.16	-0.32	2.15e-9	Capecitabine sensitivity;
CRC	cis	rs9491140	0.539	rs11751246	chr6:124692967	C/T	cg22366943	chr6:124882293	NKAIN2	0.57	8.07	0.41	1.3e-14	Neuroticism;
CRC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Bone mineral density;
CRC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.21e-15	Bladder cancer;
CRC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17507749	chr15:85114479	UBE2QP1	0.64	9.38	0.46	1.11e-18	Schizophrenia;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.37	-0.33	6.28e-10	Parkinson's disease;
CRC	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg04492858	chr10:133558786	NA	0.38	6.05	0.32	4e-9	Survival in rectal cancer;
CRC	cis	rs7680126	0.626	rs929575	chr4:10196886	C/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-6.6	-0.34	1.62e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.63	-0.3	3.94e-8	Colorectal cancer;
CRC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.36	6.93	0.36	2.23e-11	Renal cell carcinoma;
CRC	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.51	-9.54	-0.47	3.26e-19	HIV-1 susceptibility;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02902800	chr4:6784175	KIAA0232	0.42	6.78	0.35	5.74e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.4	6.48	0.34	3.31e-10	Height;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.52	7.47	0.38	7.28e-13	Testicular germ cell tumor;
CRC	cis	rs9296736	0.890	rs9382280	chr6:53912613	C/T	cg04374786	chr6:53939321	C6orf142	0.44	6.91	0.36	2.56e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg00692763	chr18:47088373	LIPG	0.56	6.03	0.32	4.39e-9	Airway imaging phenotypes;
CRC	trans	rs17661538	0.772	rs2497804	chr10:18354127	T/C	cg13235825	chr11:107574836	NA	0.5	6.06	0.32	3.75e-9	Response to antipsychotic treatment;
CRC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg24300038	chr13:113819356	PROZ	-0.46	-5.62	-0.3	4.15e-8	Platelet distribution width;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg04518342	chr5:131593106	PDLIM4	-0.42	-6.92	-0.36	2.39e-11	Breast cancer;
CRC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.64	0.3	3.58e-8	Total body bone mineral density;
CRC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.49	7.52	0.38	5.24e-13	Testicular germ cell tumor;
CRC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.86e-9	Axial length;
CRC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-8.78	-0.44	9.26e-17	Menarche (age at onset);
CRC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg12365402	chr11:9010492	NRIP3	0.47	7.56	0.38	4.06e-13	Hemoglobin concentration;
CRC	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg16898833	chr6:26189333	HIST1H4D	0.63	5.76	0.3	1.96e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.77	0.39	1.03e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7246760	1.000	rs73014068	chr19:9922783	T/C	cg16876255	chr19:9731953	ZNF561	0.69	5.69	0.3	2.79e-8	Pursuit maintenance gain;
CRC	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.55	9.38	0.46	1.1e-18	Common traits (Other);
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02357508	chr15:40331141	SRP14	0.42	6.11	0.32	2.76e-9	Response to antipsychotic treatment;
CRC	trans	rs6472235	0.837	rs2884235	chr8:66934767	T/C	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	0.64	9.59	0.47	2.2e-19	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Depression;
CRC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.39	7.48	0.38	6.96e-13	Mean corpuscular volume;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.82	-12.69	-0.57	2.56e-30	Menarche (age at onset);
CRC	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg14139581	chr11:64358342	SLC22A12	-0.39	-6.19	-0.32	1.81e-9	Urate levels in obese individuals;
CRC	cis	rs12760731	0.920	rs74226628	chr1:178484594	T/C	cg00404053	chr1:178313656	RASAL2	0.76	8.15	0.41	7.95e-15	Obesity-related traits;
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.66	5.76	0.3	1.93e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.42	-8.66	-0.43	2.08e-16	Bipolar disorder;
CRC	cis	rs2882667	0.690	rs3763016	chr5:138270732	C/G	cg09476006	chr5:138032270	NA	0.58	10.41	0.5	3.96e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4743820	0.590	rs7045796	chr9:93919427	G/C	cg14446406	chr9:93919335	NA	0.78	14.25	0.62	3.29e-36	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg02972257	chr16:68554789	NA	-0.64	-7.5	-0.38	5.91e-13	Ulcerative colitis;
CRC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg04719120	chr6:96025338	MANEA	0.55	6.47	0.34	3.51e-10	Behavioural disinhibition (generation interaction);
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg26394737	chr14:23067081	ABHD4	0.47	6.04	0.32	4.21e-9	Resistin levels;
CRC	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg14458575	chr2:238380390	NA	0.39	5.78	0.3	1.72e-8	Prostate cancer;
CRC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.81	0.51	1.71e-23	Motion sickness;
CRC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg19682013	chr15:45996608	NA	0.33	6.7	0.35	8.85e-11	Waist circumference;Weight;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.51	-10.56	-0.5	1.18e-22	Longevity;Endometriosis;
CRC	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg20512303	chr5:131592959	PDLIM4	0.37	7.2	0.37	4.02e-12	Breast cancer;
CRC	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg14515779	chr1:101123966	NA	-0.35	-6.36	-0.33	6.74e-10	Monocyte count;
CRC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.16	-0.32	2.1e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00626599	chr2:64068905	UGP2	0.4	6.0	0.31	5.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.04	-0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.12	-0.32	2.71e-9	Alzheimer's disease (late onset);
CRC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.58	-7.1	-0.36	7.97e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4692589	0.581	rs6817357	chr4:170962516	A/G	cg19918862	chr4:170955249	NA	0.53	6.98	0.36	1.66e-11	Anxiety disorder;
CRC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg23463467	chr20:60627584	TAF4	0.33	5.94	0.31	7.37e-9	Body mass index;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08448040	chr3:13521693	HDAC11	-0.51	-6.08	-0.32	3.36e-9	Diisocyanate-induced asthma;
CRC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg23071808	chr14:103021642	NA	-0.64	-7.21	-0.37	3.77e-12	Platelet count;
CRC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg05585544	chr11:47624801	NA	0.43	6.96	0.36	1.84e-11	Subjective well-being;
CRC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.9	-11.19	-0.53	7.31e-25	Vitiligo;
CRC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.96	0.36	1.84e-11	Mean platelet volume;
CRC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.64	-8.09	-0.41	1.17e-14	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11625451	chr16:81349061	GAN	0.38	5.96	0.31	6.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7605827	0.930	rs11685629	chr2:15662271	A/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs1322512	0.848	rs2695247	chr6:152948596	G/T	cg03415253	chr6:152958462	SYNE1	-0.42	-6.43	-0.33	4.53e-10	Tonometry;
CRC	cis	rs6496667	0.865	rs16944212	chr15:90888049	C/G	cg04176472	chr15:90893244	GABARAPL3	-0.55	-6.6	-0.34	1.64e-10	Rheumatoid arthritis;
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg05562828	chr17:3906858	NA	0.49	6.48	0.34	3.32e-10	Type 2 diabetes;
CRC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.74	12.94	0.58	3.06e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.44	5.7	0.3	2.73e-8	Response to diuretic therapy;
CRC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.44	0.53	9.32e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.81	0.3	1.5e-8	Parkinson's disease;
CRC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg12193833	chr17:30244370	NA	0.45	6.01	0.31	4.79e-9	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.77	-10.85	-0.51	1.17e-23	Height;
CRC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg19980929	chr12:42632907	YAF2	0.47	7.1	0.36	7.76e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg16434002	chr17:42200994	HDAC5	-0.43	-5.84	-0.31	1.26e-8	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06622468	chr19:10491460	TYK2	0.46	7.4	0.38	1.17e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.92e-31	White blood cell count (basophil);
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.92	-0.55	1.84e-27	Alzheimer's disease;
CRC	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg11900509	chr10:81946545	ANXA11	-0.66	-6.6	-0.34	1.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.41	5.86	0.31	1.13e-8	Erythrocyte sedimentation rate;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg15845792	chr6:28175446	NA	0.74	7.78	0.39	9.45e-14	Depression;
CRC	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg10437265	chr15:77819839	NA	0.69	12.75	0.57	1.6e-30	Type 2 diabetes;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg03623178	chr6:28175578	NA	0.67	9.54	0.47	3.41e-19	Parkinson's disease;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg27532560	chr4:187881888	NA	-0.56	-10.16	-0.49	2.83e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27146808	chr19:14200528	SAMD1	0.43	6.77	0.35	6.07e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg24560729	chr4:1342394	KIAA1530	0.39	6.27	0.33	1.15e-9	Obesity-related traits;
CRC	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg25664220	chr3:72788482	NA	-0.38	-5.83	-0.31	1.35e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.43	12.88	0.58	5.16e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.79	12.27	0.56	9.13e-29	Monocyte count;
CRC	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.37	0.42	1.7e-15	Platelet distribution width;
CRC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.64	12.03	0.55	6.98e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	9.11	0.45	8.42e-18	Schizophrenia;
CRC	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.54	-7.41	-0.38	1.07e-12	Hip circumference adjusted for BMI;
CRC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.75	-12.98	-0.58	2.18e-31	Body mass index;
CRC	cis	rs12023718	0.588	rs6659392	chr1:178598873	C/T	cg00404053	chr1:178313656	RASAL2	0.59	7.41	0.38	1.04e-12	Obesity-related traits;
CRC	trans	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg21153622	chr11:89784906	NA	-0.47	-7.26	-0.37	2.85e-12	HDL cholesterol;
CRC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg23136738	chr11:925521	AP2A2	0.43	7.25	0.37	3.05e-12	Alzheimer's disease (late onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01426831	chr19:12098817	NA	-0.51	-6.08	-0.32	3.41e-9	Diisocyanate-induced asthma;
CRC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.92	16.94	0.68	9.76e-47	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.95	0.36	2e-11	Cardiac Troponin-T levels;
CRC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.89e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg15568066	chr10:43904326	HNRNPF	-0.43	-6.32	-0.33	8.27e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.35	-5.69	-0.3	2.88e-8	Mean arterial pressure;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05922971	chr5:43121458	ZNF131	-0.44	-6.62	-0.34	1.47e-10	Myopia (pathological);
CRC	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.33	5.78	0.3	1.76e-8	Airway imaging phenotypes;
CRC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.5	7.78	0.39	9.4e-14	Prostate cancer;
CRC	cis	rs12760731	0.668	rs4573483	chr1:178268075	C/A	cg00404053	chr1:178313656	RASAL2	0.69	8.73	0.43	1.35e-16	Obesity-related traits;
CRC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	16.33	0.67	2.47e-44	Platelet count;
CRC	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.72	14.34	0.62	1.46e-36	Leprosy;
CRC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.48	6.7	0.35	8.9e-11	Lung cancer;
CRC	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg24300038	chr13:113819356	PROZ	0.45	5.98	0.31	5.73e-9	Platelet distribution width;
CRC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.24	-0.41	4.19e-15	Type 2 diabetes;
CRC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg16102536	chr7:156981717	UBE3C	-0.37	-6.27	-0.33	1.1e-9	Body mass index;
CRC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg04166393	chr7:2884313	GNA12	0.38	5.68	0.3	3.04e-8	Height;
CRC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.9	15.69	0.65	8.35e-42	Fuchs's corneal dystrophy;
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.79	9.65	0.47	1.4e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.8	14.25	0.62	3.19e-36	Breast cancer;
CRC	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg18232548	chr7:50535776	DDC	0.47	6.62	0.34	1.43e-10	Malaria;
CRC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg17948913	chr5:572064	NA	0.56	6.29	0.33	1e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg10298567	chr3:47292165	KIF9	0.39	5.95	0.31	6.69e-9	Colorectal cancer;
CRC	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg10483660	chr13:112241077	NA	0.36	5.82	0.31	1.39e-8	Menarche (age at onset);
CRC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.86e-17	Aortic root size;
CRC	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg06223162	chr1:101003688	GPR88	-0.34	-6.15	-0.32	2.21e-9	Monocyte count;
CRC	cis	rs3849570	0.565	rs1851926	chr3:81977231	A/C	cg07356753	chr3:81810745	GBE1	-0.47	-6.36	-0.33	6.72e-10	Waist circumference;Body mass index;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22716984	chr17:31203477	MYO1D	-0.52	-6.69	-0.35	9.66e-11	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	trans	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg05376469	chr2:102649931	NA	-0.37	-6.17	-0.32	1.95e-9	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg19223190	chr17:80058835	NA	-0.4	-6.24	-0.33	1.33e-9	Life satisfaction;
CRC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19623624	chr10:135278901	LOC619207	-0.35	-5.75	-0.3	2.07e-8	Systemic lupus erythematosus;
CRC	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.57	-10.83	-0.51	1.38e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs17767392	0.958	rs7144829	chr14:72066456	G/A	cg13720639	chr14:72061746	SIPA1L1	0.56	7.06	0.36	1.02e-11	Mitral valve prolapse;
CRC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.99	-0.74	9.26e-59	Primary sclerosing cholangitis;
CRC	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.55	-8.53	-0.43	5.38e-16	Corneal astigmatism;
CRC	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.42	5.88	0.31	9.95e-9	Blood protein levels;
CRC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04731861	chr2:219085781	ARPC2	0.34	6.94	0.36	2.12e-11	Colorectal cancer;
CRC	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg00564723	chr10:75632066	CAMK2G	-0.22	-5.61	-0.3	4.35e-8	Inflammatory bowel disease;
CRC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.47	7.42	0.38	1.03e-12	Hemoglobin concentration;
CRC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.58	10.21	0.49	1.96e-21	Aortic root size;
CRC	trans	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00938859	chr5:1591904	SDHAP3	0.65	5.97	0.31	6.02e-9	Breast cancer;
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	trans	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.46	6.34	0.33	7.53e-10	Cystic fibrosis severity;
CRC	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg25019722	chr6:37503610	NA	-0.46	-8.54	-0.43	5.12e-16	Cognitive performance;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs73195822	0.614	rs17683336	chr12:111212712	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	7.22	0.37	3.66e-12	Itch intensity from mosquito bite;
CRC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.45	6.11	0.32	2.74e-9	Red blood cell count;
CRC	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.84	-0.4	6.21e-14	Prevalent atrial fibrillation;
CRC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.46	-5.85	-0.31	1.18e-8	Resistin levels;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg02683197	chr6:28174875	NA	0.84	10.36	0.5	6.08e-22	Depression;
CRC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.39	5.86	0.31	1.1e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg20387954	chr3:183756860	HTR3D	0.38	6.5	0.34	2.95e-10	Anterior chamber depth;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13744070	chr11:61197882	SDHAF2;CPSF7	0.41	5.98	0.31	5.85e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2108622	0.683	rs112571591	chr19:15977445	G/A	cg13772218	chr19:15982569	NA	0.47	6.59	0.34	1.74e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg20291162	chr17:40259547	DHX58	-0.55	-7.98	-0.4	2.46e-14	Fibrinogen levels;
CRC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.45	5.76	0.3	1.94e-8	Response to diuretic therapy;
CRC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.6	6.76	0.35	6.25e-11	Bipolar disorder;
CRC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.45	6.48	0.34	3.36e-10	Emphysema distribution in smoking;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg03623178	chr6:28175578	NA	0.93	12.11	0.56	3.53e-28	Depression;
CRC	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.5	-8.44	-0.42	1.04e-15	Glycated hemoglobin levels;
CRC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.49	-8.76	-0.43	1.06e-16	Prostate cancer;
CRC	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.03	-0.45	1.43e-17	Brugada syndrome;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.67	5.72	0.3	2.33e-8	Depression;
CRC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.94	-11.33	-0.53	2.5e-25	IgG glycosylation;
CRC	trans	rs17106184	1.000	rs11205777	chr1:51286954	T/A	cg02869289	chr19:46177325	MIR642;GIPR	0.62	6.07	0.32	3.51e-9	Type 2 diabetes;
CRC	cis	rs8032158	0.702	rs12910830	chr15:56122664	T/C	cg02198044	chr15:56286336	NEDD4	-0.36	-5.73	-0.3	2.33e-8	Keloid;
CRC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.32	-0.33	8.49e-10	Blood metabolite levels;
CRC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg01065977	chr19:18549689	ISYNA1	0.39	6.04	0.32	4.05e-9	Breast cancer;
CRC	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg25811766	chr13:21894605	NA	-0.59	-6.07	-0.32	3.57e-9	White matter hyperintensity burden;
CRC	cis	rs12936587	0.601	rs11655881	chr17:17553133	G/A	cg04398451	chr17:18023971	MYO15A	0.35	5.79	0.3	1.62e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs10743315	0.557	rs17505005	chr12:19296294	C/T	cg02471346	chr12:19282374	PLEKHA5	0.75	6.29	0.33	1.02e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.35	7.51	0.38	5.48e-13	Total body bone mineral density;
CRC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-10.75	-0.51	2.75e-23	Platelet distribution width;
CRC	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.95	0.52	5.28e-24	Exhaled nitric oxide output;
CRC	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg19131313	chr8:1704013	NA	0.44	6.23	0.33	1.39e-9	Systolic blood pressure;
CRC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.34	-0.38	1.67e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg17147758	chr8:6949321	NA	-0.52	-7.2	-0.37	4.24e-12	Blood pressure (smoking interaction);
CRC	trans	rs10411161	1.000	rs8109345	chr19:52364933	T/C	cg22319618	chr22:45562946	NUP50	-0.52	-6.03	-0.32	4.4e-9	Breast cancer;
CRC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12588279	chr6:26043732	HIST1H2BB	0.45	6.68	0.35	1.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg15848620	chr12:58087721	OS9	-0.61	-8.3	-0.42	2.69e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.58	-0.34	1.83e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg07506560	chr2:240697449	NA	0.48	6.37	0.33	6.49e-10	Obesity-related traits;
CRC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.75	-11.08	-0.52	1.9e-24	Schizophrenia;
CRC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg16950941	chr11:66035639	RAB1B	-0.59	-7.95	-0.4	3.02e-14	Electroencephalogram traits;
CRC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.82	-14.44	-0.62	5.88e-37	Breast cancer;
CRC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.72	9.18	0.45	5.09e-18	Migraine;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12595647	chr1:54411915	LRRC42;HSPB11	0.42	6.74	0.35	7.17e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg12927641	chr6:109611667	NA	-0.35	-6.17	-0.32	2e-9	Reticulocyte fraction of red cells;
CRC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.78	-0.3	1.69e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.73	-0.3	2.32e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg19318889	chr4:1322082	MAEA	-0.4	-6.0	-0.31	5.09e-9	Obesity-related traits;
CRC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.72	9.91	0.48	1.98e-20	Heart rate;
CRC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.68	-11.47	-0.53	7.66e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs216303	1.000	rs216301	chr12:6157988	A/G	cg19878637	chr12:6148451	VWF	-0.54	-6.0	-0.31	5.32e-9	Low vWF levels;
CRC	cis	rs7916697	0.593	rs3740587	chr10:70020802	G/A	cg06988349	chr10:69991859	ATOH7	-0.37	-6.95	-0.36	1.96e-11	Optic disc area;
CRC	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.5	8.73	0.43	1.3e-16	Dietary macronutrient intake;
CRC	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.54	9.11	0.45	7.98e-18	Dupuytren's disease;
CRC	trans	rs2012709	0.837	rs72739259	chr5:32586387	T/C	cg03755955	chr8:6424269	MCPH1	0.47	7.03	0.36	1.18e-11	Breast cancer;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg19622623	chr12:86230825	RASSF9	-0.42	-6.88	-0.35	3.03e-11	Major depressive disorder;
CRC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.59	0.47	2.24e-19	Cognitive test performance;
CRC	cis	rs3823572	0.504	rs10255763	chr7:133632286	A/G	cg03336402	chr7:133662267	EXOC4	0.63	9.63	0.47	1.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.24	0.53	5.2e-25	Prudent dietary pattern;
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg10677697	chr7:45961126	IGFBP3	0.34	6.08	0.32	3.4e-9	Sitting height ratio;
CRC	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.96	-0.31	6.46e-9	Endometrial cancer;
CRC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.76	12.14	0.56	2.92e-28	Cognitive function;
CRC	cis	rs6896969	0.510	rs6874500	chr5:40427883	G/T	cg09067459	chr5:40385259	NA	-0.45	-7.83	-0.4	6.76e-14	Multiple sclerosis;
CRC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.58	9.01	0.44	1.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.37	-0.33	6.46e-10	Blood metabolite levels;
CRC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg20203395	chr5:56204925	C5orf35	-0.41	-5.64	-0.3	3.67e-8	Coronary artery disease;
CRC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg03037974	chr15:76606532	NA	0.72	13.12	0.59	6.35e-32	Blood metabolite levels;
CRC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.49	7.58	0.39	3.48e-13	Red blood cell count;
CRC	cis	rs10242455	0.702	rs73397447	chr7:99010949	G/T	cg18809830	chr7:99032528	PTCD1	-1.08	-8.03	-0.4	1.73e-14	Blood metabolite levels;
CRC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.92e-30	Blood trace element (Zn levels);
CRC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.65	9.52	0.46	3.76e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg05562828	chr17:3906858	NA	0.59	9.42	0.46	8.19e-19	Type 2 diabetes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg03352657	chr17:26684557	POLDIP2;TMEM199	0.36	6.13	0.32	2.48e-9	Interleukin-6 levels;
CRC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.32e-10	Alzheimer's disease;
CRC	trans	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg25214090	chr10:38739885	LOC399744	0.39	6.0	0.31	5.15e-9	Diastolic blood pressure;
CRC	cis	rs6088813	1.000	rs1406947	chr20:33969530	C/T	cg14752227	chr20:34000481	UQCC	-0.37	-5.6	-0.3	4.41e-8	Height;
CRC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.85	-11.02	-0.52	2.95e-24	Gut microbiome composition (summer);
CRC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.51	9.46	0.46	6.2800000000000005e-19	Lung cancer;
CRC	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.73	-11.59	-0.54	2.92e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.55	8.28	0.42	3.16e-15	Lymphocyte counts;
CRC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.08	10.68	0.51	4.63e-23	Skin colour saturation;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.51	6.14	0.32	2.39e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.64	8.05	0.41	1.53e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg15358701	chr1:161410459	NA	-0.67	-7.05	-0.36	1.03e-11	Rheumatoid arthritis;
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg15147215	chr3:52552868	STAB1	-0.57	-8.74	-0.43	1.22e-16	Bipolar disorder;
CRC	cis	rs2933343	0.716	rs9872706	chr3:128567105	A/G	cg11901034	chr3:128598214	ACAD9	0.51	6.1	0.32	3.03e-9	IgG glycosylation;
CRC	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02598441	chr17:62777298	LOC146880	-0.53	-7.08	-0.36	9.01e-12	QT interval;
CRC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.4	-6.02	-0.31	4.73e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.672	rs11983251	chr7:124459925	G/A	cg23710748	chr7:124431027	NA	0.38	6.1	0.32	2.96e-9	Cutaneous malignant melanoma;
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg04025307	chr7:1156635	C7orf50	0.67	7.4	0.38	1.17e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6496044	0.963	rs6496050	chr15:86069250	A/G	cg17133734	chr15:86042851	AKAP13	0.38	5.71	0.3	2.58e-8	Interstitial lung disease;
CRC	trans	rs10488031	1.000	rs10488031	chr7:37076854	A/G	cg03885431	chr1:3153144	PRDM16	-0.57	-6.11	-0.32	2.82e-9	QT interval;
CRC	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.71	0.39	1.46e-13	Red cell distribution width;
CRC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.71	-0.35	8.44e-11	Alzheimer's disease (late onset);
CRC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	11.25	0.53	4.82e-25	Schizophrenia;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-15.05	-0.64	2.59e-39	Lymphocyte percentage of white cells;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg18301423	chr5:131593218	PDLIM4	0.43	7.79	0.39	9.08e-14	Blood metabolite levels;
CRC	cis	rs6589219	0.954	rs4520624	chr11:111172210	A/G	cg25129781	chr11:111156908	C11orf53	-0.32	-5.7	-0.3	2.62e-8	Colorectal cancer;
CRC	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg23234261	chr14:55582407	NA	0.29	5.74	0.3	2.14e-8	Protein biomarker;
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg10396713	chr8:602097	NA	0.54	6.04	0.32	4.23e-9	IgG glycosylation;
CRC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.34	-5.85	-0.31	1.16e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18099408	chr3:52552593	STAB1	0.34	5.8	0.3	1.57e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg27615366	chr5:131592974	PDLIM4	0.32	5.67	0.3	3.19e-8	Breast cancer;
CRC	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.91	0.31	8.73e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.39	0.46	1.01e-18	Corneal astigmatism;
CRC	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.66	9.22	0.45	3.64e-18	White matter hyperintensity burden;
CRC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.16	-0.32	2.17e-9	Schizophrenia;
CRC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.74	7.56	0.38	4.17e-13	Diabetic retinopathy;
CRC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg23262073	chr20:60523788	NA	-0.38	-6.4	-0.33	5.41e-10	Body mass index;
CRC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.69	0.3	2.83e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg00383909	chr3:49044727	WDR6	0.61	6.44	0.33	4.23e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg24011408	chr12:48396354	COL2A1	0.45	6.23	0.32	1.41e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.51	-9.61	-0.47	1.92e-19	Hip circumference;Waist circumference;
CRC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06671706	chr8:8559999	CLDN23	0.54	8.22	0.41	4.76e-15	Obesity-related traits;
CRC	cis	rs7274811	0.652	rs291694	chr20:32000351	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	0.44	5.8	0.3	1.56e-8	Height;
CRC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg13798780	chr7:105162888	PUS7	0.67	7.93	0.4	3.42e-14	Bipolar disorder (body mass index interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22643867	chr2:131148877	NA	0.41	6.24	0.33	1.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg26102564	chr10:131424627	MGMT	0.38	5.67	0.3	3.05e-8	Response to temozolomide;
CRC	cis	rs12476592	0.602	rs262516	chr2:63891212	T/G	cg10828910	chr2:63850056	LOC388955	0.47	5.65	0.3	3.49e-8	Childhood ear infection;
CRC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg02725872	chr8:58115012	NA	-0.44	-6.51	-0.34	2.78e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.58	8.59	0.43	3.57e-16	Prostate cancer;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg15845792	chr6:28175446	NA	0.6	7.9	0.4	4.36e-14	Parkinson's disease;
CRC	trans	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.3	-0.37	2.13e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22194305	chr4:2264032	MXD4	-0.38	-5.98	-0.31	5.81e-9	Aortic root size;
CRC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.31	0.46	1.86e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.38	-5.86	-0.31	1.14e-8	Hip circumference adjusted for BMI;
CRC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.02	0.32	4.65e-9	Heart rate;
CRC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.53	7.89	0.4	4.65e-14	Corneal astigmatism;
CRC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.48	7.61	0.39	3e-13	Personality dimensions;
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg27432699	chr2:27873401	GPN1	-0.6	-8.85	-0.44	5.36e-17	Menopause (age at onset);
CRC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.56	-6.37	-0.33	6.29e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25754248	chr19:5123156	KDM4B	0.36	6.4	0.33	5.23e-10	Aortic root size;
CRC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg11212589	chr17:38028394	ZPBP2	0.43	7.71	0.39	1.55e-13	Self-reported allergy;
CRC	cis	rs73206853	0.534	rs73205062	chr12:110511136	G/C	cg12870014	chr12:110450643	ANKRD13A	0.86	8.87	0.44	4.74e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.7	-11.28	-0.53	3.54e-25	Mean platelet volume;
CRC	cis	rs73206853	0.609	rs55833146	chr12:110872335	A/G	cg12870014	chr12:110450643	ANKRD13A	0.82	9.8	0.48	4.76e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	0.98	15.21	0.64	6.1e-40	Cognitive function;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.2	0.32	1.73e-9	Bipolar disorder;
CRC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.38	6.87	0.35	3.26e-11	Reticulocyte fraction of red cells;
CRC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.81	-0.4	7.93e-14	Personality dimensions;
CRC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs73206853	0.686	rs56339227	chr12:111164963	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	8.89	0.44	4.07e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.79	10.76	0.51	2.39e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11317019	chr17:42219250	C17orf53	-0.49	-5.98	-0.31	5.84e-9	Diisocyanate-induced asthma;
CRC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg01879757	chr17:41196368	BRCA1	-0.42	-6.32	-0.33	8.39e-10	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg22677401	chr17:46026860	NA	-0.66	-6.04	-0.32	4.28e-9	Cognitive function;
CRC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.56	8.17	0.41	6.67e-15	Melanoma;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg23123621	chr4:1343375	KIAA1530	-0.34	-6.11	-0.32	2.77e-9	Obesity-related traits;
CRC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.15	11.19	0.53	7.45e-25	Type 2 diabetes;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg02683197	chr6:28174875	NA	0.88	12.35	0.56	4.59e-29	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07806421	chr2:139259153	SPOPL	0.44	6.46	0.34	3.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.91e-13	Colorectal cancer;
CRC	cis	rs3790645	0.831	rs873151	chr1:26880989	T/C	cg17456097	chr1:26900765	RPS6KA1	0.39	5.63	0.3	3.93e-8	Glucose homeostasis traits;
CRC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.5	7.7	0.39	1.58e-13	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14258675	chr14:75348443	DLST	0.43	6.16	0.32	2.15e-9	Response to antipsychotic treatment;
CRC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg06219103	chr11:63990595	FERMT3	-0.4	-6.14	-0.32	2.42e-9	Platelet count;
CRC	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.01	-0.31	4.84e-9	Metabolite levels (Pyroglutamine);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23261184	chr5:159866303	NA	-0.41	-6.42	-0.33	4.68e-10	Aortic root size;
CRC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.67	10.38	0.5	4.97e-22	Menopause (age at onset);
CRC	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg04415270	chr2:102091202	RFX8	0.56	7.78	0.39	9.25e-14	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg06243084	chr11:63990629	FERMT3	0.39	5.95	0.31	6.99e-9	Platelet count;
CRC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.48	7.55	0.38	4.24e-13	Eye color traits;
CRC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.73	-12.88	-0.58	5.02e-31	Hemoglobin concentration;
CRC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.62	10.62	0.51	7.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.91	-0.36	2.54e-11	Inflammatory skin disease;
CRC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg17321639	chr7:2759063	NA	-0.51	-6.77	-0.35	6.05e-11	Height;
CRC	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.64	-10.16	-0.49	2.86e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs4074961	0.544	rs11264067	chr1:37991458	C/T	cg13401533	chr1:37979913	MEAF6	0.43	6.08	0.32	3.29e-9	Axial length;
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.45	6.42	0.33	4.77e-10	Parkinson's disease;
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg08222913	chr3:52553049	STAB1	-0.36	-6.91	-0.36	2.44e-11	Electroencephalogram traits;
CRC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.52	-7.01	-0.36	1.32e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg15848620	chr12:58087721	OS9	-0.65	-8.94	-0.44	2.88e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.94	-0.31	7.38e-9	Cognitive function;
CRC	cis	rs720844	0.535	rs12997838	chr2:149284931	C/G	cg09247360	chr2:149335327	NA	-0.55	-5.78	-0.3	1.76e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2742417	1.000	rs1877932	chr3:45753539	A/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.59	-8.2	-0.41	5.52e-15	Cancer;
CRC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.63	-0.3	3.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6585424	1.000	rs61860024	chr10:81925363	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs947583	0.913	rs2027516	chr6:136131888	C/T	cg06563441	chr6:136217110	PDE7B	0.33	5.6	0.3	4.46e-8	Phosphorus levels;
CRC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.44	-6.47	-0.34	3.53e-10	Ulcerative colitis;
CRC	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.33	-6.73	-0.35	7.77e-11	Cutaneous nevi;
CRC	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.66	-7.8	-0.39	8.36e-14	Ulcerative colitis;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.16	0.32	2.07e-9	Depression;
CRC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.44	-0.38	8.91e-13	Morning vs. evening chronotype;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18758796	chr5:131593413	PDLIM4	0.46	8.57	0.43	4.01e-16	Breast cancer;
CRC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18912574	chr7:65842487	NCRNA00174	0.33	5.66	0.3	3.37e-8	Calcium levels;
CRC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-5.71	-0.3	2.52e-8	Total cholesterol levels;
CRC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.56	-7.67	-0.39	1.9e-13	Colorectal cancer;
CRC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.73	-12.27	-0.56	9.14e-29	Hemoglobin concentration;
CRC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.38	-0.33	5.94e-10	Monocyte percentage of white cells;
CRC	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.59	8.6	0.43	3.4e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg13010199	chr12:38710504	ALG10B	0.46	6.5	0.34	2.99e-10	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.42	-6.09	-0.32	3.17e-9	Platelet distribution width;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.54	10.42	0.5	3.71e-22	Acylcarnitine levels;
CRC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.67	0.34	1.11e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.58	9.1	0.45	9.19e-18	Prostate cancer;
CRC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg10760299	chr15:45669010	GATM	0.51	8.14	0.41	8.08e-15	Homoarginine levels;
CRC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg07636037	chr3:49044803	WDR6	0.72	5.7	0.3	2.61e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs17152411	1.000	rs11245423	chr10:126588435	C/A	cg07906193	chr10:126599966	NA	0.57	6.47	0.34	3.61e-10	Height;
CRC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.61	-0.34	1.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	5.04e-11	Prostate cancer;
CRC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.29	-0.46	2.23e-18	Dupuytren's disease;
CRC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.52	0.62	2.93e-37	Lymphocyte percentage of white cells;
CRC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-7.87	-0.4	5.32e-14	Lung cancer in ever smokers;
CRC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16447950	chr5:562315	NA	-0.73	-9.65	-0.47	1.41e-19	Lung disease severity in cystic fibrosis;
CRC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg18972013	chr17:78078605	GAA	-0.41	-6.03	-0.32	4.41e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg21620606	chr4:1342894	KIAA1530	0.33	5.6	0.3	4.47e-8	Obesity-related traits;
CRC	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.46	0.5	2.74e-22	Corneal astigmatism;
CRC	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.55	7.62	0.39	2.7e-13	Coronary artery disease;
CRC	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.77	-11.78	-0.54	5.83e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs7209700	0.547	rs11649785	chr17:45355720	G/A	cg08085267	chr17:45401833	C17orf57	0.54	6.4	0.33	5.22e-10	IgG glycosylation;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg10729496	chr3:10149963	C3orf24	0.54	6.97	0.36	1.71e-11	Alzheimer's disease;
CRC	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.8	-10.34	-0.5	6.98e-22	Initial pursuit acceleration;
CRC	trans	rs10139154	0.824	rs183467	chr14:31009261	A/T	cg18753625	chr19:36705707	ZNF565;ZNF146	-0.45	-6.51	-0.34	2.84e-10	Amyotrophic lateral sclerosis;
CRC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.59	9.2	0.45	4.27e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20623943	chr1:47799834	CMPK1	0.47	6.04	0.32	4.08e-9	Thyroid stimulating hormone;
CRC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg07817097	chr1:179851575	TOR1AIP1	0.47	5.97	0.31	6e-9	Plasma plasminogen activator levels;
CRC	cis	rs3790645	0.645	rs3790644	chr1:26884676	G/A	cg17456097	chr1:26900765	RPS6KA1	0.47	6.08	0.32	3.39e-9	Glucose homeostasis traits;
CRC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg09264619	chr17:80180166	NA	0.35	5.8	0.3	1.55e-8	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02956093	chr14:105261335	AKT1	0.49	6.34	0.33	7.5e-10	Thyroid stimulating hormone;
CRC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.9	0.52	7.71e-24	Diabetic retinopathy;
CRC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg15358701	chr1:161410459	NA	-0.58	-5.99	-0.31	5.55e-9	Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04294625	chr17:45727224	KPNB1	0.49	6.5	0.34	2.93e-10	Anxiety disorder;
CRC	cis	rs501120	0.925	rs1746050	chr10:44777188	C/A	cg09554077	chr10:44749378	NA	0.74	11.03	0.52	2.74e-24	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2274273	0.624	rs11158034	chr14:55753560	C/T	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.7	-0.3	2.65e-8	Protein biomarker;
CRC	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-12.7	-0.57	2.5e-30	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg18833306	chr6:118973337	C6orf204	-0.46	-6.22	-0.32	1.55e-9	Diastolic blood pressure;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.56	8.69	0.43	1.68e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.66e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6076065	0.723	rs6137949	chr20:23418217	T/G	cg11657817	chr20:23433608	CST11	0.44	6.34	0.33	7.68e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.46	-0.34	3.66e-10	Breast cancer;
CRC	trans	rs12744310	0.887	rs35464028	chr1:41800474	T/G	cg19175123	chr10:103411746	FBXW4	0.46	6.11	0.32	2.75e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00166722	chr3:10149974	C3orf24	0.67	9.26	0.45	2.71e-18	Alzheimer's disease;
CRC	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.39	0.5	4.71e-22	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15586420	chr15:90294517	MESP1	0.48	6.25	0.33	1.28e-9	Thyroid stimulating hormone;
CRC	cis	rs6976053	0.518	rs314357	chr7:100410069	A/G	cg20848291	chr7:100343083	ZAN	0.4	6.07	0.32	3.48e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19922493	chr2:176045768	ATP5G3	0.46	6.88	0.35	3.11e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05622764	chr5:72744675	FOXD1	0.48	6.51	0.34	2.86e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg13456138	chr10:90753195	FAS	0.42	5.94	0.31	7.22e-9	Chronic lymphocytic leukemia;
CRC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg13556452	chr1:2391241	NA	-0.35	-5.92	-0.31	7.97e-9	Schizophrenia;
CRC	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.47	6.13	0.32	2.52e-9	Exhaled nitric oxide output;
CRC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.48	-0.34	3.36e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg20356878	chr3:121714668	ILDR1	-0.42	-5.97	-0.31	6.25e-9	Multiple sclerosis;
CRC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.65	-10.18	-0.49	2.4e-21	Glaucoma (primary open-angle);
CRC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.92	0.52	6.75e-24	Prudent dietary pattern;
CRC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.42	-6.26	-0.33	1.23e-9	Breast cancer;
CRC	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.52	-6.34	-0.33	7.48e-10	Coronary artery calcification;
CRC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.55	-10.42	-0.5	3.73e-22	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg07507251	chr3:52567010	NT5DC2	0.45	6.37	0.33	6.43e-10	Bipolar disorder;
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg22110888	chr17:80059540	CCDC57	0.41	6.5	0.34	2.95e-10	Life satisfaction;
CRC	cis	rs995000	0.931	rs12037659	chr1:62923863	C/T	cg19896129	chr1:63156450	NA	0.4	5.78	0.3	1.76e-8	Triglyceride levels;
CRC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.82e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs13315871	0.929	rs11716580	chr3:58228695	G/C	cg20936604	chr3:58311152	NA	-0.72	-6.63	-0.34	1.41e-10	Cholesterol, total;
CRC	cis	rs11229555	0.645	rs11229459	chr11:58208025	G/A	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.47	8.28	0.42	3.18e-15	Hypertriglyceridemia;
CRC	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg15845792	chr6:28175446	NA	0.8	6.5	0.34	3.02e-10	Depression;
CRC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.26	0.37	2.78e-12	Motion sickness;
CRC	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.78	7.76	0.39	1.11e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.46	9.19	0.45	4.4e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05139649	chr11:108368923	KDELC2	-0.41	-6.17	-0.32	1.95e-9	Myopia (pathological);
CRC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.26	-0.41	3.58e-15	Morning vs. evening chronotype;
CRC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.05	-18.99	-0.72	8.42e-55	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.9	-0.31	9.08e-9	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg02560186	chr11:3602584	NA	-0.56	-6.98	-0.36	1.63e-11	Blood pressure (smoking interaction);
CRC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg14078730	chr11:63896557	MACROD1	0.35	5.73	0.3	2.21e-8	Platelet count;
CRC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.52	-8.29	-0.42	2.83e-15	Neurofibrillary tangles;
CRC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg03013636	chr16:1946785	NA	0.57	6.99	0.36	1.54e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2859741	0.608	rs532719	chr1:37477380	C/T	cg09363841	chr1:37513479	NA	0.53	8.94	0.44	2.86e-17	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.68	10.52	0.5	1.62e-22	Corneal astigmatism;
CRC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.34	-0.46	1.46e-18	Platelet count;
CRC	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-5.66	-0.3	3.35e-8	Schizophrenia;
CRC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg21839984	chr17:30846986	MYO1D	0.47	7.56	0.38	3.99e-13	Schizophrenia;
CRC	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.43	-8.47	-0.42	8.28e-16	Alcohol dependence;
CRC	cis	rs4380275	1.000	rs4450634	chr2:773257	G/A	cg27237671	chr2:676223	TMEM18	-0.43	-6.11	-0.32	2.76e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg06156847	chr2:113672199	IL1F7	-0.38	-5.67	-0.3	3.13e-8	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg05304507	chr6:116381966	FRK	0.31	8.56	0.43	4.29e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.58	9.16	0.45	5.58e-18	Tonsillectomy;
CRC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.88	17.33	0.69	2.92e-48	Metabolic syndrome;
CRC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.47	6.76	0.35	6.21e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Depression;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12612619	0.704	rs6754356	chr2:27315021	G/A	cg00617064	chr2:27272375	NA	-0.37	-6.03	-0.32	4.31e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.8	0.3	1.52e-8	Homoarginine levels;
CRC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg11632617	chr15:75315747	PPCDC	-0.56	-7.96	-0.4	2.86e-14	Blood trace element (Zn levels);
CRC	cis	rs6694672	1.000	rs1794003	chr1:197024643	G/A	cg13682187	chr1:196946512	CFHR5	0.43	6.92	0.36	2.35e-11	Asthma;
CRC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.47	7.17	0.37	4.89e-12	Corneal astigmatism;
CRC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.48	-9.5	-0.46	4.44e-19	Ulcerative colitis;
CRC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.5	-7.62	-0.39	2.69e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.56	-7.33	-0.37	1.8e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg12870014	chr12:110450643	ANKRD13A	0.82	10.56	0.5	1.21e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.44	-9.14	-0.45	6.68e-18	Renal cell carcinoma;
CRC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.12	-0.37	6.62e-12	Mean platelet volume;
CRC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.73	9.97	0.48	1.29e-20	Systemic lupus erythematosus;
CRC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.09	-18.8	-0.72	4.4e-54	Ulcerative colitis;
CRC	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg08717414	chr16:71523259	ZNF19	-1.01	-9.16	-0.45	5.49e-18	Post bronchodilator FEV1;
CRC	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.57	8.36	0.42	1.77e-15	Uric acid levels;
CRC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.69	-10.89	-0.51	8.74e-24	Dental caries;
CRC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.53	-7.67	-0.39	1.94e-13	Colorectal cancer;
CRC	cis	rs6604026	0.922	rs66525381	chr1:93296764	A/G	cg17283838	chr1:93427260	FAM69A	0.45	5.69	0.3	2.82e-8	Multiple sclerosis;
CRC	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.81	-0.31	1.45e-8	Pulmonary function;
CRC	cis	rs10849893	0.576	rs889970	chr12:121856217	G/A	cg01154721	chr12:121881891	KDM2B	-0.41	-5.88	-0.31	9.99e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.8	-0.3	1.54e-8	Type 2 diabetes;
CRC	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.57	9.24	0.45	3.08e-18	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs34172651	0.545	rs8056132	chr16:24716348	A/G	cg06028605	chr16:24865363	SLC5A11	0.32	6.19	0.32	1.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg27398640	chr15:77910606	LINGO1	-0.44	-7.9	-0.4	4.17e-14	Type 2 diabetes;
CRC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.45	0.34	3.89e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6681460	0.932	rs602513	chr1:67177270	G/A	cg02459107	chr1:67143332	SGIP1	0.37	6.54	0.34	2.35e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.46	-7.07	-0.36	9.56e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg13777783	chr17:79615861	NA	-0.3	-5.6	-0.3	4.47e-8	Eye color traits;
CRC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.49	6.86	0.35	3.45e-11	Height;
CRC	cis	rs3126085	0.515	rs7534951	chr1:152362972	C/T	cg09127314	chr1:152161683	NA	-0.44	-5.85	-0.31	1.2e-8	Atopic dermatitis;
CRC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.23	-0.37	3.41e-12	Reticulocyte fraction of red cells;
CRC	trans	rs12495832	0.778	rs16860195	chr3:147924457	A/G	cg10221266	chr7:153579447	NA	0.56	6.12	0.32	2.6e-9	Chin dimples;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15921587	chr2:73144353	EMX1	0.44	6.1	0.32	2.99e-9	Hip circumference;
CRC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.63	0.7	1.96e-49	Platelet count;
CRC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.31	12.49	0.57	1.46e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.85e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg15845792	chr6:28175446	NA	-0.62	-6.59	-0.34	1.73e-10	Depression;
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.94	-0.31	7.27e-9	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg11164639	chr15:91192950	NA	0.38	6.39	0.33	5.54e-10	Interleukin-6 levels;
CRC	cis	rs889398	0.715	rs13330951	chr16:69563842	C/T	cg00738113	chr16:70207722	CLEC18C	-0.32	-5.71	-0.3	2.51e-8	Body mass index;
CRC	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg24463073	chr6:118973353	C6orf204	0.49	6.37	0.33	6.29e-10	Diastolic blood pressure;
CRC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.85	0.51	1.18e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	13.17	0.59	4.11e-32	Platelet count;
CRC	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg05187965	chr10:45406764	TMEM72	-0.34	-7.01	-0.36	1.32e-11	Mean corpuscular volume;
CRC	cis	rs7605827	0.930	rs10201925	chr2:15528742	G/A	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.73e-9	Educational attainment (years of education);
CRC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg20673091	chr1:2541236	MMEL1	0.36	5.8	0.3	1.52e-8	Ulcerative colitis;
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.61	-0.3	4.19e-8	Lung cancer;
CRC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg15193198	chr20:60906057	LAMA5	0.42	6.88	0.35	3.11e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg04969067	chr8:143858791	LYNX1	0.44	7.49	0.38	6.29e-13	Urinary tract infection frequency;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg20062050	chr1:227730881	NA	0.37	6.09	0.32	3.09e-9	Menopause (age at onset);
CRC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.84e-24	Corneal astigmatism;
CRC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.32	-0.33	8.57e-10	Vitiligo;
CRC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.8	-0.4	8.05e-14	Vitiligo;
CRC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg09165964	chr15:75287851	SCAMP5	0.57	9.15	0.45	5.96e-18	Breast cancer;
CRC	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.98	0.4	2.47e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6743226	0.870	rs67652230	chr2:242235446	A/T	cg10021735	chr2:242295487	FARP2	0.48	6.96	0.36	1.9e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.53	8.02	0.4	1.91e-14	Methadone dose in opioid dependence;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg25985355	chr7:65971099	NA	-0.47	-5.65	-0.3	3.54e-8	Diabetic kidney disease;
CRC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.09	0.49	4.8e-21	Asthma;
CRC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.63	10.78	0.51	2.11e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.54	-0.63	2.39e-37	Exhaled nitric oxide output;
CRC	cis	rs35000415	0.938	rs34381587	chr7:128666825	A/G	cg19972273	chr7:128594194	NA	0.68	6.32	0.33	8.52e-10	Systemic lupus erythematosus;
CRC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2693676	0.920	rs1257483	chr14:99608934	A/C	cg11190754	chr5:64858552	CENPK;PPWD1	-0.52	-6.51	-0.34	2.84e-10	Corneal curvature;
CRC	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.55	8.88	0.44	4.57e-17	Mean corpuscular volume;
CRC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.9	-11.02	-0.52	3.11e-24	Gut microbiome composition (summer);
CRC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	9.54	0.47	3.4e-19	Cognitive test performance;
CRC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.34	-5.62	-0.3	4.08e-8	Aortic root size;
CRC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.55	-8.57	-0.43	4.07e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.52	-7.27	-0.37	2.63e-12	Response to antidepressants and depression;
CRC	cis	rs1519814	0.956	rs4871040	chr8:121131611	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-6.3	-0.33	9.33e-10	Breast cancer;
CRC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.69	-11.01	-0.52	3.32e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.43	6.39	0.33	5.8e-10	Neutrophil percentage of white cells;
CRC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.3e-13	Corneal astigmatism;
CRC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg18827107	chr12:86230957	RASSF9	-0.46	-7.53	-0.38	4.82e-13	Major depressive disorder;
CRC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg24920358	chr1:40204285	PPIE	0.56	8.31	0.42	2.47e-15	Blood protein levels;
CRC	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg21169611	chr9:106856078	SMC2	0.42	5.83	0.31	1.31e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg05625103	chr10:2543513	NA	0.4	6.31	0.33	9.24e-10	Age-related hearing impairment;
CRC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21643547	chr1:205240462	TMCC2	-0.37	-6.06	-0.32	3.67e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg17375396	chr11:67202808	RPS6KB2	0.33	5.65	0.3	3.4e-8	Mean corpuscular volume;
CRC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.34	5.82	0.31	1.37e-8	White matter hyperintensity burden;
CRC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg19318889	chr4:1322082	MAEA	0.41	5.93	0.31	7.58e-9	Obesity-related traits;
CRC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.33	-0.33	8.26e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg20908204	chr19:46285434	DMPK	-0.3	-5.62	-0.3	4.16e-8	Coronary artery disease;
CRC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.51	-6.99	-0.36	1.5e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg22345911	chr17:80231263	CSNK1D	0.34	6.71	0.35	8.76e-11	Interleukin-6 levels;
CRC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.57	9.39	0.46	1.03e-18	Schizophrenia;
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.2	0.56	1.77e-28	Alzheimer's disease;
CRC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg00383909	chr3:49044727	WDR6	0.47	5.89	0.31	9.55e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg00776166	chr8:613548	NA	-0.59	-5.87	-0.31	1.05e-8	IgG glycosylation;
CRC	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg12756093	chr1:115239321	AMPD1	-0.45	-5.66	-0.3	3.28e-8	Autism;
CRC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.88	-12.74	-0.57	1.69e-30	Platelet distribution width;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg04919811	chr17:78870302	RPTOR	-0.46	-7.2	-0.37	4.24e-12	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.64	10.52	0.5	1.73e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.32	-5.84	-0.31	1.23e-8	Rheumatoid arthritis;
CRC	cis	rs539514	0.637	rs2025354	chr13:76275577	T/C	cg04757411	chr13:76259545	LMO7	-0.36	-6.06	-0.32	3.71e-9	Type 1 diabetes;
CRC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-7.52	-0.38	5.1e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.13e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg15845792	chr6:28175446	NA	0.6	7.79	0.39	8.56e-14	Parkinson's disease;
CRC	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg01335087	chr22:19950166	COMT	0.23	6.31	0.33	9.22e-10	Blood metabolite levels;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg03623178	chr6:28175578	NA	0.78	6.94	0.36	2.07e-11	Depression;
CRC	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg09904177	chr6:26538194	HMGN4	-0.44	-6.18	-0.32	1.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2386661	0.826	rs10905519	chr10:5672483	C/A	cg26603656	chr10:5671107	NA	0.54	8.91	0.44	3.52e-17	Breast cancer;
CRC	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.69	-8.69	-0.43	1.68e-16	Blood protein levels;
CRC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg04880052	chr2:219191631	PNKD	0.41	6.73	0.35	7.38e-11	Colorectal cancer;
CRC	trans	rs1413885	1.000	rs6588134	chr1:65816050	G/T	cg26534493	chr8:28060551	NA	-0.38	-6.21	-0.32	1.58e-9	Anticoagulant levels;
CRC	cis	rs860295	0.702	rs475550	chr1:155652081	A/T	cg02153340	chr1:155202674	NA	-0.56	-7.11	-0.37	7.2e-12	Body mass index;
CRC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.42	8.25	0.41	3.95e-15	Mean corpuscular volume;
CRC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg12639453	chr1:2035780	PRKCZ	-0.32	-6.36	-0.33	6.75e-10	Height;
CRC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg18016565	chr1:150552671	MCL1	0.44	6.04	0.32	4.07e-9	Melanoma;
CRC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.13	-0.45	7.11e-18	Menarche (age at onset);
CRC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.98	-0.36	1.6e-11	Aortic root size;
CRC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.94	13.52	0.6	2.07e-33	Breast cancer;
CRC	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.62	6.91	0.36	2.58e-11	Red blood cell count;
CRC	cis	rs12580194	0.593	rs12579346	chr12:55786856	A/G	cg19537932	chr12:55886519	OR6C68	-0.72	-9.08	-0.45	9.94e-18	Cancer;
CRC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	0.79	8.66	0.43	2.1e-16	Gout;Renal underexcretion gout;
CRC	cis	rs17092148	0.887	rs6059915	chr20:33147737	C/G	cg08999081	chr20:33150536	PIGU	0.51	6.51	0.34	2.85e-10	Neuroticism;
CRC	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg00490450	chr3:139108681	COPB2	0.44	6.59	0.34	1.75e-10	Obesity-related traits;
CRC	cis	rs4731207	0.698	rs6977407	chr7:124499002	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.31e-9	Cutaneous malignant melanoma;
CRC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.9	0.58	4.48e-31	Chronic sinus infection;
CRC	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-7.21	-0.37	3.89e-12	Putamen volume;
CRC	trans	rs4576506	0.536	rs71512720	chr9:31499511	G/A	cg26940518	chr16:1593766	IFT140;TMEM204	-0.66	-6.02	-0.31	4.6e-9	Psychosis and Alzheimer's disease;
CRC	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.46	-7.05	-0.36	1.04e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.39	6.86	0.35	3.43e-11	Primary biliary cholangitis;
CRC	cis	rs41271951	0.512	rs16832976	chr1:151038135	T/C	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.74	-0.3	2.12e-8	Blood protein levels;
CRC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg02527881	chr3:46936655	PTH1R	-0.34	-5.95	-0.31	6.84e-9	Colorectal cancer;
CRC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg01721255	chr8:58191610	C8orf71	0.48	6.0	0.31	5.08e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.47	-6.56	-0.34	2.12e-10	Diastolic blood pressure;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09610735	chr10:22609918	BMI1	0.49	6.49	0.34	3.21e-10	Thyroid stimulating hormone;
CRC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg18512352	chr11:47633146	NA	-0.37	-7.33	-0.37	1.75e-12	Subjective well-being;
CRC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.54	-9.63	-0.47	1.66e-19	Age-related hearing impairment;
CRC	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg10761708	chr20:43804764	PI3	0.5	5.8	0.3	1.54e-8	Blood protein levels;
CRC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg21251018	chr6:28226885	NKAPL	0.49	7.8	0.4	8.17e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg06484146	chr7:12443880	VWDE	-0.61	-6.56	-0.34	2.05e-10	Coronary artery disease;
CRC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.85	10.35	0.5	6.22e-22	Menarche (age at onset);
CRC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.85	-14.81	-0.63	2.22e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.67	9.31	0.46	1.94e-18	White matter hyperintensity burden;
CRC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.82	-9.92	-0.48	1.82e-20	Initial pursuit acceleration;
CRC	cis	rs4780401	0.729	rs8045300	chr16:11769266	C/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.8	-0.3	1.52e-8	Rheumatoid arthritis;
CRC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.42	-8.15	-0.41	7.88e-15	Subjective well-being;
CRC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	6.99	0.36	1.58e-11	Eye color traits;
CRC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.2	-0.41	5.35e-15	Hemoglobin concentration;
CRC	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg26566898	chr11:117069891	TAGLN	0.39	6.99	0.36	1.51e-11	Blood protein levels;
CRC	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg21174375	chr14:64681225	SYNE2	0.4	6.47	0.34	3.45e-10	Atrial fibrillation;
CRC	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.34	0.5	6.98e-22	Corneal astigmatism;
CRC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.5	-6.79	-0.35	5.18e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg26762873	chr11:5879799	OR52E8	-0.49	-7.42	-0.38	1.01e-12	DNA methylation (variation);
CRC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.57	-0.38	3.88e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4731207	0.569	rs1600746	chr7:124585095	T/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg03623178	chr6:28175578	NA	0.7	9.33	0.46	1.61e-18	Parkinson's disease;
CRC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.59	-10.14	-0.49	3.28e-21	Type 2 diabetes;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	4.04e-9	Total body bone mineral density;
CRC	cis	rs3857067	1.000	rs3846291	chr4:95026735	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-6.41	-0.33	4.99e-10	QT interval;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00366722	chr15:37393576	MEIS2	0.43	6.38	0.33	5.95e-10	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.812	rs494349	chr5:131260452	C/A	cg25547332	chr5:131281432	NA	-0.36	-5.81	-0.31	1.47e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg13798780	chr7:105162888	PUS7	0.68	7.51	0.38	5.77e-13	Bipolar disorder (body mass index interaction);
CRC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.67	9.45	0.46	6.78e-19	Vitiligo;
CRC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.36	0.53	1.84e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg11262906	chr1:85462892	MCOLN2	-0.5	-6.96	-0.36	1.83e-11	Serum sulfate level;
CRC	cis	rs11608355	0.508	rs11066394	chr12:109799212	C/A	cg19025524	chr12:109796872	NA	-0.48	-7.15	-0.37	5.77e-12	Neuroticism;
CRC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.74	12.06	0.55	5.41e-28	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.67	9.13	0.45	7.3e-18	Breast cancer;
CRC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg20354231	chr13:53171401	NA	-0.5	-8.08	-0.41	1.22e-14	Lewy body disease;
CRC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.14	-0.37	5.9e-12	Total body bone mineral density;
CRC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	0.98	14.83	0.63	1.86e-38	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04335102	chr3:123680028	CCDC14	0.44	6.01	0.31	5.06e-9	Response to antipsychotic treatment;
CRC	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	0.57	8.89	0.44	4.08e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg02135003	chr7:105160482	PUS7	-0.92	-10.26	-0.49	1.32e-21	Bipolar disorder (body mass index interaction);
CRC	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.42	-5.69	-0.3	2.78e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.65e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg11915388	chr22:42470451	FAM109B	0.42	6.34	0.33	7.46e-10	Schizophrenia;
CRC	cis	rs10986311	0.862	rs11791290	chr9:127096347	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.41	6.18	0.32	1.85e-9	Vitiligo;
CRC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.65	8.17	0.41	6.53e-15	Diabetic retinopathy;
CRC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg22834771	chr12:69754056	YEATS4	-0.47	-6.91	-0.36	2.44e-11	Blood protein levels;
CRC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.94	-0.31	7.25e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4073416	0.542	rs10143206	chr14:66120675	A/G	cg03016385	chr14:66212404	NA	0.44	6.07	0.32	3.54e-9	N-glycan levels;
CRC	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg20578329	chr17:80767326	TBCD	-0.81	-10.11	-0.49	4.36e-21	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg06470822	chr6:28175283	NA	0.78	6.19	0.32	1.76e-9	Depression;
CRC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.51	-8.45	-0.42	9.25e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.59	-8.24	-0.41	4.15e-15	Personality dimensions;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04761648	chr13:26829199	CDK8	-0.43	-6.64	-0.34	1.3100000000000001e-10	Interleukin-6 levels;
CRC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02018176	chr4:1364513	KIAA1530	0.48	7.84	0.4	6.25e-14	Obesity-related traits;
CRC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg00343986	chr7:65444356	GUSB	0.5	7.38	0.38	1.34e-12	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27249304	chr10:71906591	TYSND1	0.42	6.79	0.35	5.17e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.19	-0.32	1.81e-9	Body mass index;
CRC	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg09829573	chr1:144692074	NBPF9	0.41	6.22	0.32	1.53e-9	Hip geometry;
CRC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.62	-0.34	1.43e-10	Menarche (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27106230	chr13:99229068	STK24	-0.39	-6.11	-0.32	2.88e-9	Myopia (pathological);
CRC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.6	8.64	0.43	2.47e-16	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.16	0.59	4.67e-32	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14704270	chr22:50639024	SELO	0.4	6.61	0.34	1.52e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.76	8.1	0.41	1.09e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.91	0.31	8.34e-9	Axial length;
CRC	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg23100626	chr2:96804247	ASTL	0.27	7.11	0.36	7.24e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.98	0.44	2.16e-17	Coffee consumption (cups per day);
CRC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.76	13.35	0.59	8.45e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs7572644	0.679	rs9679543	chr2:28050951	C/T	cg27432699	chr2:27873401	GPN1	0.47	6.24	0.33	1.33e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.52	0.34	2.71e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.7	-8.4	-0.42	1.39e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12922317	0.856	rs1641835	chr16:12136584	T/C	cg02368508	chr16:12060182	TNFRSF17	-0.39	-5.77	-0.3	1.87e-8	Schizophrenia;
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.41	-6.99	-0.36	1.56e-11	Height;
CRC	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg26875233	chr11:93583750	C11orf90	-0.31	-6.03	-0.32	4.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg18478394	chr8:109455254	TTC35	0.38	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg20936604	chr3:58311152	NA	-0.75	-7.03	-0.36	1.18e-11	Cholesterol, total;
CRC	cis	rs889398	0.835	rs62050037	chr16:69784670	T/C	cg00738113	chr16:70207722	CLEC18C	0.36	6.0	0.31	5.24e-9	Body mass index;
CRC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.44	5.87	0.31	1.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg00647820	chr17:40259828	DHX58	-0.46	-6.59	-0.34	1.78e-10	Fibrinogen levels;
CRC	cis	rs6534441	0.857	rs28733585	chr4:125455249	C/T	cg21609808	chr4:125404261	NA	0.39	5.83	0.31	1.3e-8	Major depressive disorder;
CRC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg06494592	chr3:125709126	NA	0.52	6.2	0.32	1.65e-9	Blood pressure (smoking interaction);
CRC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.45	0.38	8.03e-13	Major depressive disorder;
CRC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.61	10.36	0.5	5.88e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.51	7.3	0.37	2.22e-12	Melanoma;
CRC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.46e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.58	-8.22	-0.41	4.66e-15	Alcohol dependence;
CRC	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-6.02	-0.32	4.58e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9292777	0.863	rs10473187	chr5:40385134	C/T	cg09067459	chr5:40385259	NA	0.55	9.73	0.47	7.83e-20	Crohn's disease;Multiple sclerosis;
CRC	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.66	10.86	0.51	1.13e-23	Eosinophil percentage of white cells;
CRC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.73	-0.3	2.31e-8	Heart rate;
CRC	cis	rs867529	0.695	rs335115	chr2:89027647	C/T	cg26627705	chr2:89060884	NA	0.57	8.01	0.4	2.04e-14	Height;
CRC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.69	11.93	0.55	1.62e-27	Resting heart rate;
CRC	cis	rs2895526	0.521	rs6602606	chr10:12713901	C/T	cg00115178	chr10:12648176	CAMK1D	-0.36	-5.92	-0.31	8.11e-9	Headache;
CRC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.59	-0.34	1.72e-10	Blood metabolite levels;
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.29	-0.33	9.82e-10	Bipolar disorder;
CRC	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg25304816	chr1:36627734	MAP7D1	0.5	7.43	0.38	9.65e-13	Corneal structure;
CRC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.18	-0.37	4.74e-12	IgG glycosylation;
CRC	cis	rs2734839	0.929	rs7131627	chr11:113299829	G/A	cg14159747	chr11:113255604	NA	0.47	8.32	0.42	2.34e-15	Information processing speed;
CRC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	10.02	0.48	8.55e-21	Hip circumference adjusted for BMI;
CRC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.11	0.32	2.78e-9	Obesity-related traits;
CRC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.59	7.78	0.39	9.46e-14	Multiple sclerosis;
CRC	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg03418659	chr16:31128414	MYST1	-0.42	-6.23	-0.32	1.47e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg14036092	chr11:66035641	RAB1B	-0.46	-6.32	-0.33	8.27e-10	Electroencephalogram traits;
CRC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.79	-0.35	5.31e-11	Height;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.94	-0.55	1.51e-27	Alzheimer's disease;
CRC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.57	0.47	2.66e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg00502932	chr1:2160666	SKI	-0.52	-6.11	-0.32	2.78e-9	Airflow obstruction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00171983	chr16:9185448	C16orf72	0.51	7.19	0.37	4.32e-12	Response to antipsychotic treatment;
CRC	trans	rs12495832	0.778	rs76109782	chr3:147904411	T/C	cg10221266	chr7:153579447	NA	0.55	6.06	0.32	3.81e-9	Chin dimples;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10780647	chr20:3800838	C20orf29	0.37	5.99	0.31	5.57e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.44	-6.42	-0.33	4.8e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs7731657	0.575	rs12513465	chr5:130364503	A/G	cg08523029	chr5:130500466	HINT1	-0.45	-5.94	-0.31	7.42e-9	Fasting plasma glucose;
CRC	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.5	-9.51	-0.46	4.11e-19	Educational attainment (years of education);
CRC	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.5	-7.21	-0.37	3.94e-12	Barrett's esophagus;
CRC	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-8.72	-0.43	1.41e-16	Depression;
CRC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.74	-0.3	2.15e-8	Migraine;Coronary artery disease;
CRC	trans	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg24644049	chr4:85504048	CDS1	0.83	7.0	0.36	1.47e-11	Skin colour saturation;
CRC	cis	rs4478137	0.931	rs11100488	chr4:164237660	C/A	cg06758707	chr4:164254230	NPY1R	0.39	5.98	0.31	5.87e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.52	-7.23	-0.37	3.5e-12	Caudate activity during reward;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg02475695	chr16:616220	NHLRC4	0.45	7.32	0.37	1.95e-12	Height;
CRC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg24154853	chr7:158122151	PTPRN2	0.59	9.88	0.48	2.43e-20	Calcium levels;
CRC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg15205204	chr1:6545172	PLEKHG5	0.38	5.66	0.3	3.22e-8	Body mass index;
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg19678392	chr7:94953810	PON1	-0.56	-6.95	-0.36	1.99e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.64	11.62	0.54	2.13e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.7	12.08	0.55	4.69e-28	Gout;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01814186	chr16:69600788	NFAT5;MIR1538	0.49	6.34	0.33	7.51e-10	Thyroid stimulating hormone;
CRC	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.62	5.82	0.31	1.4e-8	IgG glycosylation;
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	19.35	0.73	2.98e-56	Prudent dietary pattern;
CRC	cis	rs12044355	0.927	rs12043433	chr1:231843591	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.95	0.31	6.93e-9	Alzheimer's disease;
CRC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg18099408	chr3:52552593	STAB1	0.35	6.1	0.32	2.91e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.86	-0.44	5.26e-17	IgG glycosylation;
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.47	-8.01	-0.4	2e-14	Lung cancer;
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.46	6.27	0.33	1.12e-9	Aortic root size;
CRC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg00990874	chr7:1149470	C7orf50	-0.47	-5.74	-0.3	2.14e-8	Bronchopulmonary dysplasia;
CRC	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.17	-0.32	2.01e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-12.81	-0.58	9.18e-31	Chronic sinus infection;
CRC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.72	-11.8	-0.55	4.76e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.46	-7.77	-0.39	1.04e-13	Height;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg15147215	chr3:52552868	STAB1	-0.66	-11.38	-0.53	1.56e-25	Electroencephalogram traits;
CRC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.47	-6.23	-0.32	1.45e-9	Gut microbiome composition (summer);
CRC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.48	-6.04	-0.32	4.22e-9	Bipolar disorder;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04139300	chr20:40247070	CHD6	0.44	6.02	0.31	4.55e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.37	6.7	0.35	9.13e-11	Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26155979	chr10:105110866	PCGF6	0.4	7.23	0.37	3.37e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.01	0.36	1.36e-11	Morning vs. evening chronotype;
CRC	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg14883916	chr11:6947541	ZNF215	0.63	6.87	0.35	3.29e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.49	-7.49	-0.38	6.57e-13	Longevity;
CRC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-11.42	-0.53	1.12e-25	Dental caries;
CRC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.63	0.57	4.27e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4728302	0.838	rs6954700	chr7:133588739	G/A	cg03336402	chr7:133662267	EXOC4	-0.44	-6.37	-0.33	6.27e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs972578	0.967	rs2267477	chr22:43334574	G/C	cg01576275	chr22:43409880	NA	-0.45	-7.24	-0.37	3.18e-12	Mean platelet volume;
CRC	cis	rs995000	0.931	rs641540	chr1:62908538	A/G	cg19896129	chr1:63156450	NA	0.44	6.84	0.35	3.76e-11	Triglyceride levels;
CRC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.71	0.39	1.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg15382696	chr6:118971807	C6orf204	-0.33	-5.61	-0.3	4.31e-8	Electrocardiographic conduction measures;
CRC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.74	-0.3	2.14e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.48	8.46	0.42	9.17e-16	Information processing speed;
CRC	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-11.91	-0.55	1.93e-27	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.44	6.52	0.34	2.6200000000000003e-10	Bone properties (heel);
CRC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg16342193	chr10:102329863	NA	-0.34	-5.79	-0.3	1.67e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.64	-8.88	-0.44	4.37e-17	DNA methylation (variation);
CRC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.22	-0.32	1.52e-9	Life satisfaction;
CRC	cis	rs2072510	0.569	rs7970524	chr12:96390152	A/G	cg09636302	chr12:96389483	HAL	-0.48	-6.36	-0.33	6.82e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs116248771	0.549	rs9849301	chr3:158444860	C/T	cg16708174	chr3:158430962	RARRES1	0.44	5.79	0.3	1.67e-8	diarrhoeal disease at age 2;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.38	6.64	0.34	1.33e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06958567	chr18:52495541	RAB27B	0.43	6.42	0.33	4.69e-10	Response to antipsychotic treatment;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24739457	chr1:205821442	NA	0.44	6.41	0.33	5.18e-10	Menarche (age at onset);
CRC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.49	-8.03	-0.4	1.7e-14	Coronary artery disease;
CRC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.56	0.72	4.06e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03741566	chr6:64346779	NA	0.41	6.3	0.33	9.58e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	7.01	0.36	1.38e-11	Mean corpuscular volume;
CRC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.44	0.38	8.57e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.89	-0.44	4.06e-17	Bipolar disorder;
CRC	trans	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg26040332	chr1:27960788	FGR	0.34	6.48	0.34	3.25e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.98	19.99	0.74	9.58e-59	Metabolite levels;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.57	7.36	0.38	1.46e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg09872104	chr7:134855509	C7orf49	-0.72	-6.84	-0.35	3.83e-11	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg21280719	chr6:42927975	GNMT	-0.32	-5.96	-0.31	6.49e-9	Blood protein levels;
CRC	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.71	-9.73	-0.47	7.84e-20	Blood pressure (smoking interaction);
CRC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.53	-0.34	2.52e-10	Triglycerides;
CRC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg10494257	chr1:16342123	HSPB7	-0.44	-5.9	-0.31	9.08e-9	Dilated cardiomyopathy;
CRC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg20684491	chr1:25596433	NA	0.42	7.29	0.37	2.32e-12	Erythrocyte sedimentation rate;
CRC	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg27223183	chr8:87520930	FAM82B	-0.44	-5.73	-0.3	2.22e-8	Caudate activity during reward;
CRC	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg26061582	chr7:22766209	IL6	0.86	6.91	0.36	2.57e-11	Tonsillectomy;
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.47	0.34	3.58e-10	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22466830	chr18:9475498	RALBP1	0.39	6.11	0.32	2.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.01	-0.31	5e-9	Monocyte percentage of white cells;
CRC	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.67	6.1	0.32	2.91e-9	IgG glycosylation;
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.88	-0.51	9.7e-24	Bipolar disorder;
CRC	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.74	8.62	0.43	2.94e-16	Diisocyanate-induced asthma;
CRC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg14008862	chr17:28927542	LRRC37B2	0.51	6.01	0.31	4.88e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1265507	0.666	rs1862908	chr12:114871981	A/C	cg11700868	chr17:38521232	GJD3	0.41	5.96	0.31	6.45e-9	Percent mammographic density;
CRC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg06470822	chr6:28175283	NA	0.52	7.7	0.39	1.63e-13	Pubertal anthropometrics;
CRC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.24	-0.33	1.32e-9	Aortic root size;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.89	-0.31	9.55e-9	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11178321	chr12:9601031	DDX12	0.42	6.0	0.31	5.13e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg04025307	chr7:1156635	C7orf50	0.61	6.74	0.35	7.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7705042	0.828	rs181826	chr5:141526057	C/A	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.5e-8	Asthma;
CRC	cis	rs727505	0.789	rs9641761	chr7:124735205	A/T	cg23710748	chr7:124431027	NA	-0.72	-12.35	-0.56	4.66e-29	Lewy body disease;
CRC	cis	rs400736	0.602	rs7553544	chr1:8165719	C/T	cg25007680	chr1:8021821	PARK7	-0.51	-6.12	-0.32	2.7e-9	Response to antidepressants and depression;
CRC	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.59	-10.1	-0.49	4.64e-21	Proinsulin levels;
CRC	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg02702477	chr5:179499311	RNF130	0.56	6.48	0.34	3.31e-10	LDL cholesterol;
CRC	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg23260525	chr10:116636907	FAM160B1	0.31	6.73	0.35	7.51e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg09417038	chr21:47716443	C21orf57	-0.42	-7.02	-0.36	1.29e-11	Testicular germ cell tumor;
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg20041105	chr8:143859282	LYNX1	0.45	8.04	0.41	1.67e-14	Urinary tract infection frequency;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.68e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.5	-9.49	-0.46	5.01e-19	Alcohol dependence;
CRC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6694672	0.867	rs5029273	chr1:197145382	C/G	cg13682187	chr1:196946512	CFHR5	0.46	7.25	0.37	3.09e-12	Asthma;
CRC	cis	rs12024301	0.557	rs74395504	chr1:183633411	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19379625	chr4:71859087	DCK	0.44	6.17	0.32	2.03e-9	Response to antipsychotic treatment;
CRC	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.09	-0.41	1.19e-14	Biliary atresia;
CRC	trans	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg26043149	chr18:55253948	FECH	-0.56	-8.07	-0.41	1.35e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg25459000	chr22:39777742	SYNGR1	-0.33	-5.99	-0.31	5.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-8.32	-0.42	2.33e-15	Asthma;
CRC	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.81	-0.4	7.94e-14	Homocysteine levels;
CRC	trans	rs11738223	0.678	rs17654445	chr5:171925864	C/T	cg27141267	chr11:66175971	NA	-0.53	-6.6	-0.34	1.61e-10	Menopause (age at onset);
CRC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.34	6.69	0.35	9.81e-11	Hip circumference adjusted for BMI;
CRC	cis	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.22e-9	Diastolic blood pressure;
CRC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg19812747	chr11:111475976	SIK2	0.43	6.29	0.33	1.03e-9	Primary sclerosing cholangitis;
CRC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02725872	chr8:58115012	NA	-0.44	-7.88	-0.4	4.69e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.75	15.25	0.64	4.43e-40	Leprosy;
CRC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.89	-15.93	-0.66	9.4e-43	Height;
CRC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	7.23	0.37	3.43e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.77	11.99	0.55	1.01e-27	Menarche (age at onset);
CRC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.69	0.39	1.75e-13	Mean platelet volume;
CRC	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	6.15	0.32	2.31e-9	Blood metabolite levels;
CRC	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-6.52	-0.34	2.63e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2735413	0.914	rs1922608	chr16:78065139	A/G	cg04733911	chr16:78082701	NA	-0.37	-6.0	-0.31	5.22e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.61	-9.21	-0.45	4.05e-18	Longevity;Endometriosis;
CRC	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.61	9.18	0.45	4.97e-18	Non-response to antidepressants and depression;
CRC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.7	-0.47	1.02e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg16898833	chr6:26189333	HIST1H4D	0.69	5.83	0.31	1.34e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00376283	chr12:123451042	ABCB9	-0.52	-6.14	-0.32	2.44e-9	Neutrophil percentage of white cells;
CRC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.75	-0.35	6.76e-11	Aortic root size;
CRC	cis	rs554111	0.891	rs609880	chr1:21055891	A/G	cg08890418	chr1:21044141	KIF17	0.32	6.0	0.31	5.28e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.39	0.33	5.65e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg25985355	chr7:65971099	NA	-0.5	-5.86	-0.31	1.11e-8	Diabetic kidney disease;
CRC	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.63	-8.01	-0.4	1.98e-14	Iron status biomarkers;
CRC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.26	0.41	3.66e-15	Lung cancer;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-10.1	-0.49	4.63e-21	Body mass index;
CRC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs4954585	0.683	rs13004902	chr2:137027680	A/G	cg05194412	chr2:137003533	NA	0.44	6.82	0.35	4.34e-11	Colorectal cancer;
CRC	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.65	-0.39	2.17e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.09	21.12	0.76	3.51e-63	Triglycerides;
CRC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.66	8.27	0.41	3.29e-15	Menarche (age at onset);
CRC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.82	12.31	0.56	6.59e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.65	-0.3	3.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	0.9	11.73	0.54	8.82e-27	Red blood cell traits;
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg02741985	chr17:80059408	CCDC57	0.42	6.97	0.36	1.76e-11	Life satisfaction;
CRC	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.1	-0.32	2.96e-9	Monocyte count;
CRC	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.07	-11.0	-0.52	3.46e-24	Post bronchodilator FEV1;
CRC	cis	rs7725052	0.609	rs67224409	chr5:40446876	T/C	cg09067459	chr5:40385259	NA	-0.4	-6.61	-0.34	1.53e-10	Pediatric autoimmune diseases;
CRC	cis	rs1712517	0.744	rs4293063	chr10:105052976	G/T	cg05636881	chr10:105038444	INA	0.47	8.08	0.41	1.23e-14	Migraine;
CRC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.65	-9.57	-0.47	2.68e-19	Acne (severe);
CRC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.52	0.43	5.79e-16	Menopause (age at onset);
CRC	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.67	10.18	0.49	2.46e-21	Corneal astigmatism;
CRC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.63	0.43	2.73e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09392819	chr2:26568944	SELI;GPR113	-0.4	-6.18	-0.32	1.9e-9	Myopia (pathological);
CRC	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.42	5.86	0.31	1.13e-8	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg23193639	chr7:45961078	IGFBP3	0.49	7.96	0.4	2.79e-14	Sitting height ratio;
CRC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-14.65	-0.63	8.89e-38	Gut microbiome composition (summer);
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg20512303	chr5:131592959	PDLIM4	0.33	6.22	0.32	1.51e-9	Breast cancer;
CRC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-5.71	-0.3	2.48e-8	Hemoglobin concentration;
CRC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.59	8.5	0.42	6.8e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.82	15.01	0.64	3.87e-39	Mean platelet volume;
CRC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.86	-0.63	1.38e-38	Gout;
CRC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.8	0.44	8.09e-17	Hip circumference adjusted for BMI;
CRC	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.33	-0.33	8.01e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.68	0.7	1.2e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg27615366	chr5:131592974	PDLIM4	0.33	5.68	0.3	2.95e-8	Blood metabolite levels;
CRC	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06307176	chr5:131281290	NA	-0.39	-5.91	-0.31	8.68e-9	Life satisfaction;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg16031283	chr22:20861701	MED15	-0.41	-6.0	-0.31	5.31e-9	Daytime sleep phenotypes;
CRC	cis	rs17253792	0.545	rs34136598	chr14:56013238	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.23	-0.32	1.41e-9	Putamen volume;
CRC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.49	-7.59	-0.39	3.37e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.6	0.39	3.07e-13	Menopause (age at onset);
CRC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg21620606	chr4:1342894	KIAA1530	0.35	5.75	0.3	2.04e-8	Obesity-related traits;
CRC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	2.97e-8	Skin colour saturation;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg20647610	chr2:228736258	WDR69	0.49	6.57	0.34	2.02e-10	Blood pressure;
CRC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.41	11.73	0.54	8.68e-27	Psoriasis vulgaris;
CRC	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.48	6.79	0.35	5.18e-11	Coronary artery disease;
CRC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg19682013	chr15:45996608	NA	0.29	5.88	0.31	9.88e-9	Waist circumference;Weight;
CRC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.84	17.16	0.69	1.41e-47	Ulcerative colitis;
CRC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.74	0.39	1.2e-13	Cognitive ability;
CRC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.97	-0.52	4.45e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.59	7.41	0.38	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.29	-0.56	7.62e-29	Idiopathic membranous nephropathy;
CRC	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg13491945	chr12:107078410	RFX4	0.36	6.07	0.32	3.61e-9	Heart rate;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg04969067	chr8:143858791	LYNX1	-0.42	-6.2	-0.32	1.7e-9	Urinary tract infection frequency;
CRC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.43	5.68	0.3	2.9e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.71	-8.96	-0.44	2.53e-17	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.88	-0.31	9.89e-9	Alzheimer's disease (late onset);
CRC	cis	rs4964805	0.581	rs7312825	chr12:104188388	G/C	cg02344784	chr12:104178138	NT5DC3	0.79	15.0	0.64	4.21e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21963583	chr11:68658836	MRPL21	0.6	10.28	0.49	1.15e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg15511327	chr8:143859410	LYNX1	0.39	6.87	0.35	3.13e-11	Urinary tract infection frequency;
CRC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg25382128	chr12:54346509	NA	0.39	5.71	0.3	2.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg13390004	chr1:15929781	NA	0.5	7.07	0.36	9.19e-12	Systolic blood pressure;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01719895	chr7:2443748	CHST12	0.44	6.05	0.32	3.94e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg15192750	chr16:69999425	NA	0.57	7.64	0.39	2.43e-13	IgE levels;
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13986249	chr9:37903631	MCART1	0.4	6.13	0.32	2.45e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.6	8.96	0.44	2.41e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.94	18.0	0.7	6.39e-51	Height;
CRC	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg11645453	chr3:52864694	ITIH4	-0.41	-7.71	-0.39	1.55e-13	Body mass index;
CRC	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg10790698	chr19:18539756	SSBP4	-0.45	-8.43	-0.42	1.1e-15	Breast cancer;
CRC	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.49	8.27	0.41	3.45e-15	Common traits (Other);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06087298	chr1:118149316	FAM46C	0.42	6.52	0.34	2.72e-10	Schizophrenia;
CRC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.36	6.81	0.35	4.57e-11	Renal cell carcinoma;
CRC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.23	-0.37	3.41e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg03315344	chr16:75512273	CHST6	-0.55	-6.28	-0.33	1.06e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg02880119	chr16:3481970	NA	-0.41	-5.8	-0.3	1.57e-8	Body mass index (adult);
CRC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.28	-6.52	-0.34	2.58e-10	Total body bone mineral density;
CRC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.52	7.3	0.37	2.22e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22949881	chr12:9601149	DDX12	0.48	6.85	0.35	3.67e-11	Response to antipsychotic treatment;
CRC	cis	rs4964805	0.594	rs3751204	chr12:104171455	C/T	cg02344784	chr12:104178138	NT5DC3	0.44	6.72	0.35	7.85e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg07828024	chr6:149772892	ZC3H12D	-0.49	-8.49	-0.42	7.11e-16	Dupuytren's disease;
CRC	cis	rs720844	0.684	rs16828836	chr2:149312728	A/G	cg09247360	chr2:149335327	NA	-0.58	-6.04	-0.32	4.12e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg19500275	chr17:80737654	TBCD	0.39	5.91	0.31	8.71e-9	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01973771	chr19:2740143	SLC39A3	0.48	6.75	0.35	6.83e-11	Response to antipsychotic treatment;
CRC	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.45	-7.23	-0.37	3.4e-12	Large artery stroke;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.53	9.97	0.48	1.25e-20	Blood metabolite levels;
CRC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.45	12.72	0.57	2.09e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.78	-0.3	1.75e-8	Carotid intima media thickness;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg15845792	chr6:28175446	NA	0.6	7.91	0.4	3.82e-14	Parkinson's disease;
CRC	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg14458575	chr2:238380390	NA	0.52	6.78	0.35	5.58e-11	Prostate cancer;
CRC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg12365402	chr11:9010492	NRIP3	-0.51	-9.1	-0.45	8.74e-18	Hemoglobin concentration;
CRC	cis	rs13253111	0.603	rs28605937	chr8:28099179	A/G	cg26534493	chr8:28060551	NA	0.41	7.17	0.37	4.87e-12	Childhood body mass index;
CRC	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.43	-8.47	-0.42	8.36e-16	Subjective well-being;
CRC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.72	-11.61	-0.54	2.33e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.54	-8.33	-0.42	2.28e-15	Height;
CRC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.24	-0.41	4.12e-15	Neuroticism;
CRC	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.4	0.33	5.42e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.62	9.1	0.45	8.93e-18	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05609751	chr17:4269695	UBE2G1	0.43	6.24	0.33	1.31e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.96	-0.36	1.84e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg13491945	chr12:107078410	RFX4	0.36	6.19	0.32	1.8e-9	Heart rate;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg02683197	chr6:28174875	NA	0.63	8.67	0.43	2.06e-16	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.42	6.93	0.36	2.24e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg15269541	chr15:43626905	ADAL	-0.55	-6.36	-0.33	6.56e-10	Lung cancer in ever smokers;
CRC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.36	-5.69	-0.3	2.88e-8	Red cell distribution width;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg03844506	chr4:4109441	NA	-0.51	-7.57	-0.39	3.88e-13	Blood pressure (smoking interaction);
CRC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg01304814	chr3:48885189	PRKAR2A	0.87	6.46	0.34	3.69e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7802263	0.876	rs4731204	chr7:124383834	G/A	cg23710748	chr7:124431027	NA	-0.39	-5.64	-0.3	3.63e-8	Reading and spelling;
CRC	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.44	-6.18	-0.32	1.87e-9	Eye color traits;
CRC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.49	6.58	0.34	1.83e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.59	0.34	1.79e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.66	-0.3	3.27e-8	Intelligence (multi-trait analysis);
CRC	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs891088	0.677	rs11670892	chr19:7185306	C/G	cg00428638	chr19:7224713	INSR	-0.59	-6.17	-0.32	1.99e-9	Hip circumference adjusted for BMI;Height;
CRC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.31	-0.42	2.54e-15	Type 2 diabetes;
CRC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.59	-9.9	-0.48	2.06e-20	Calcium levels;
CRC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg09264619	chr17:80180166	NA	0.37	6.16	0.32	2.08e-9	Life satisfaction;
CRC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.31	6.35	0.33	7.32e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-7.39	-0.38	1.21e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.85	10.95	0.52	5.53e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04731861	chr2:219085781	ARPC2	0.37	7.94	0.4	3.26e-14	Colorectal cancer;
CRC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.82	0.31	1.43e-8	Morning vs. evening chronotype;
CRC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.25	-0.33	1.27e-9	HDL cholesterol;
CRC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02290350	chr8:58132656	NA	-0.56	-7.77	-0.39	1.02e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs1656402	0.906	rs1190436	chr2:233424096	G/A	cg03852847	chr2:233439513	NA	0.46	7.87	0.4	5.19e-14	Non-small cell lung cancer (survival);
CRC	cis	rs728616	0.867	rs55835350	chr10:81801728	A/T	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.82	-0.35	4.41e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.46	-6.88	-0.35	2.99e-11	Body mass index;
CRC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.02	0.31	4.69e-9	Aortic root size;
CRC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.67	-10.27	-0.49	1.21e-21	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-11.67	-0.54	1.45e-26	Asthma;
CRC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12273811	chr6:28175739	NA	0.62	9.07	0.45	1.1e-17	Cardiac Troponin-T levels;
CRC	cis	rs7731657	0.537	rs10073487	chr5:130373397	G/A	cg08523029	chr5:130500466	HINT1	-0.45	-5.87	-0.31	1.06e-8	Fasting plasma glucose;
CRC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.71	8.94	0.44	2.88e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg21302420	chr1:112162376	RAP1A	0.83	7.41	0.38	1.07e-12	Skin colour saturation;
CRC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.38	6.34	0.33	7.54e-10	Cardiovascular disease risk factors;
CRC	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.72	-9.53	-0.47	3.66e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.64	10.23	0.49	1.6e-21	Hepatocellular carcinoma;
CRC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.53	7.72	0.39	1.38e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.72	-12.75	-0.57	1.6e-30	Hemoglobin concentration;
CRC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.68	0.51	4.55e-23	Platelet count;
CRC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.94	0.44	2.91e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17065868	0.764	rs60560319	chr13:45039622	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg12573674	chr2:1569213	NA	-0.76	-7.84	-0.4	6.48e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg14631576	chr9:95140430	CENPP	-0.39	-6.76	-0.35	6.18e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.86	0.4	5.55e-14	Morning vs. evening chronotype;
CRC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg25956985	chr22:39795188	MAP3K7IP1	-0.4	-5.79	-0.3	1.68e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.63	-9.23	-0.45	3.51e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg26043149	chr18:55253948	FECH	0.5	7.76	0.39	1.1e-13	Bone mineral density;
CRC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.56	9.04	0.45	1.34e-17	Blood protein levels;
CRC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg21153622	chr11:89784906	NA	-0.5	-8.34	-0.42	2.08e-15	HDL cholesterol;
CRC	cis	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg20159608	chr7:32802032	NA	-0.56	-7.35	-0.38	1.59e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.2	0.53	6.75e-25	Tonsillectomy;
CRC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.39	5.96	0.31	6.5e-9	Colorectal cancer;
CRC	cis	rs740160	0.558	rs73395508	chr7:98901894	A/C	cg24650262	chr7:98904301	NA	0.55	5.72	0.3	2.33e-8	Dehydroepiandrosterone sulphate levels;
CRC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg03929089	chr4:120376271	NA	-0.49	-7.08	-0.36	8.84e-12	Coronary artery disease;
CRC	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg17218026	chr1:154582156	ADAR	-0.39	-6.03	-0.32	4.5e-9	Blood protein levels;
CRC	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-0.76	-7.69	-0.39	1.7e-13	Blood protein levels;
CRC	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.58	-8.6	-0.43	3.36e-16	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.59	-0.34	1.75e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.8	-13.34	-0.59	9.22e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.52	-0.43	5.86e-16	Personality dimensions;
CRC	cis	rs1465370	0.720	rs7811463	chr7:130017488	G/A	cg03229158	chr7:130009420	NA	0.43	6.06	0.32	3.78e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.2	-0.37	4.13e-12	IgG glycosylation;
CRC	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.64	9.82	0.48	4e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.71	-11.55	-0.54	3.76e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.24	0.59	2.21e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.75	-0.35	6.85e-11	Total body bone mineral density;
CRC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-7.44	-0.38	9.14e-13	Self-reported allergy;
CRC	cis	rs2108622	0.727	rs62106158	chr19:15980492	T/G	cg13772218	chr19:15982569	NA	0.48	6.82	0.35	4.37e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.59	-7.97	-0.4	2.64e-14	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.61	9.04	0.45	1.41e-17	Lung cancer;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg12172441	chr6:28176163	NA	0.52	7.17	0.37	5.07e-12	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs56039028	chr2:162516363	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.48	6.95	0.36	1.98e-11	Bladder cancer;
CRC	cis	rs1005224	0.853	rs12898082	chr14:76306359	A/C	cg04684003	chr14:76127793	TTLL5;C14orf1	0.44	6.38	0.33	6.12e-10	Large artery stroke;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18579396	chr17:41623924	ETV4	0.43	6.01	0.31	4.91e-9	Survival in pancreatic cancer;
CRC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.54	6.81	0.35	4.56e-11	Methadone dose in opioid dependence;
CRC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg25456477	chr12:86230367	RASSF9	0.33	5.85	0.31	1.17e-8	Major depressive disorder;
CRC	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.68	7.47	0.38	7.25e-13	Eotaxin levels;
CRC	cis	rs6662572	0.737	rs4660330	chr1:46458298	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.69	-0.3	2.86e-8	Blood protein levels;
CRC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.74	0.63	4.11e-38	Intelligence (multi-trait analysis);
CRC	cis	rs6546324	1.000	rs6546324	chr2:67856490	A/C	cg15745817	chr2:67799979	NA	-0.29	-5.83	-0.31	1.35e-8	Endometriosis;
CRC	cis	rs7215564	0.908	rs35374347	chr17:78642244	C/T	cg09596252	chr17:78655493	RPTOR	0.63	5.78	0.3	1.69e-8	Myopia (pathological);
CRC	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.4	6.02	0.32	4.63e-9	Endometrial cancer;
CRC	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.52	7.54	0.38	4.47e-13	Pulmonary function decline;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.56	-0.34	2.14e-10	Breast cancer;
CRC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	7.23	0.37	3.47e-12	Motion sickness;
CRC	cis	rs2033908	0.620	rs7113256	chr11:12845849	T/C	cg25843174	chr11:12811716	TEAD1	-0.42	-7.38	-0.38	1.26e-12	Sitting height ratio;
CRC	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.52	7.36	0.38	1.45e-12	Caudate activity during reward;
CRC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.69	0.39	1.76e-13	Lung cancer;
CRC	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg21578987	chr21:40029669	ERG	0.42	6.0	0.31	5.3300000000000004e-09	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg11522145	chr4:3412961	RGS12	-0.41	-6.63	-0.34	1.37e-10	Serum sulfate level;
CRC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg15083037	chr5:83017644	HAPLN1	0.51	7.46	0.38	7.65e-13	Prostate cancer;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg15786705	chr6:28176104	NA	0.54	7.38	0.38	1.28e-12	Parkinson's disease;
CRC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg05501817	chr11:14380813	RRAS2	0.46	6.49	0.34	3.07e-10	Sense of smell;
CRC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.52	6.91	0.36	2.51e-11	Obesity-related traits;
CRC	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg23141183	chr17:80185318	SLC16A3	0.43	6.04	0.32	4.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2084637	1.000	rs2100246	chr11:122406638	G/C	cg21585512	chr11:122030076	LOC399959	-0.4	-7.29	-0.37	2.4e-12	Stroke;
CRC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg20354231	chr13:53171401	NA	-0.41	-6.48	-0.34	3.43e-10	Lewy body disease;
CRC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2303319	0.504	rs12473497	chr2:162433766	T/C	cg12500891	chr11:57225987	NA	-0.67	-5.98	-0.31	5.67e-9	Cognitive function;
CRC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.81e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00338735	chr4:53728038	RASL11B	0.46	6.17	0.32	1.95e-9	Optic nerve measurement (cup area);
CRC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.92	13.34	0.59	9.16e-33	Breast cancer;
CRC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg25767906	chr1:53392781	SCP2	0.47	7.48	0.38	6.61e-13	Monocyte count;
CRC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs11229555	0.645	rs12801475	chr11:58189034	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11645453	chr3:52864694	ITIH4	-0.38	-6.84	-0.35	3.95e-11	Body mass index;
CRC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.62	-14.1	-0.61	1.24e-35	Airflow obstruction;
CRC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	cis	rs9584850	0.834	rs3803253	chr13:99117149	G/A	cg20487152	chr13:99095054	FARP1	0.43	6.28	0.33	1.1e-9	Neuroticism;
CRC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.61	7.44	0.38	8.98e-13	Mean platelet volume;
CRC	cis	rs4654899	0.743	rs17409373	chr1:21188871	C/A	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.83	-0.4	6.62e-14	Superior frontal gyrus grey matter volume;
CRC	trans	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg09045935	chr12:6379348	NA	1.14	8.88	0.44	4.43e-17	Blood metabolite levels;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.57	-9.65	-0.47	1.46e-19	Breast cancer;
CRC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.46	6.91	0.36	2.53e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Depression;
CRC	trans	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.72e-15	Bone mineral density;
CRC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.5	7.52	0.38	5.15e-13	Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.49e-12	Life satisfaction;
CRC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.53	9.64	0.47	1.53e-19	Vitiligo;
CRC	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.71	-0.3	2.53e-8	Subjective well-being;
CRC	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.16	-0.32	2.13e-9	Diastolic blood pressure;
CRC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.3e-13	Corneal astigmatism;
CRC	cis	rs2160860	0.745	rs35995308	chr8:39800217	T/C	cg11363097	chr8:39792086	IDO2	-0.45	-7.65	-0.39	2.28e-13	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.6	9.45	0.46	6.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.72	-12.51	-0.57	1.24e-29	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.4	5.87	0.31	1.06e-8	Multiple myeloma (IgH translocation);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12075659	chr20:19738521	NA	-0.5	-6.47	-0.34	3.46e-10	Diisocyanate-induced asthma;
CRC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.53	0.5	1.6e-22	Menopause (age at onset);
CRC	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.05	19.85	0.74	3.26e-58	Schizophrenia;
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02018176	chr4:1364513	KIAA1530	0.39	6.4	0.33	5.28e-10	Obesity-related traits;
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.56	-0.5	1.19e-22	Alzheimer's disease;
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg04553112	chr3:125709451	NA	-0.49	-5.75	-0.3	2.04e-8	Blood pressure (smoking interaction);
CRC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.77	0.39	9.91e-14	Arsenic metabolism;
CRC	cis	rs4731207	0.596	rs2402757	chr7:124611713	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.93	0.44	3.08e-17	Menarche (age at onset);
CRC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.16	0.52	9.55e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs834811	0.602	rs834813	chr7:135886783	T/A	cg01726295	chr7:135938950	NA	0.41	7.16	0.37	5.28e-12	Post-traumatic stress disorder;
CRC	cis	rs10071761	0.513	rs62359405	chr5:40380858	A/C	cg09067459	chr5:40385259	NA	-0.51	-6.91	-0.36	2.46e-11	Selective IgA deficiency;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11645453	chr3:52864694	ITIH4	0.37	6.33	0.33	7.89e-10	Bipolar disorder;
CRC	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg20169779	chr10:135381914	SYCE1	0.61	9.93	0.48	1.67e-20	Obesity-related traits;
CRC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.63	0.34	1.37e-10	Bladder cancer;
CRC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-13.2	-0.59	3.3e-32	Vitiligo;
CRC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.37	-0.46	1.22e-18	Height;
CRC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	6.38	0.33	6.03e-10	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9341808	0.667	rs12209624	chr6:80919133	G/A	cg08355045	chr6:80787529	NA	0.34	5.83	0.31	1.3e-8	Sitting height ratio;
CRC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.8	-0.39	8.34e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.41	8.81	0.44	7.25e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg26182253	chr13:112236782	NA	0.32	6.36	0.33	6.93e-10	Hepatitis;
CRC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.97	-0.31	6.09e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg23205692	chr1:25664452	TMEM50A	-0.39	-5.67	-0.3	3.14e-8	Erythrocyte sedimentation rate;
CRC	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.49	8.92	0.44	3.21e-17	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg20737812	chr15:86336631	KLHL25	-0.48	-7.15	-0.37	5.64e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.84	-12.04	-0.55	6.38e-28	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.8	0.39	8.39e-14	Menopause (age at onset);
CRC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg22687807	chr8:143858763	LYNX1	-0.38	-6.67	-0.35	1.1e-10	Urinary tract infection frequency;
CRC	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg24060327	chr5:131705240	SLC22A5	0.4	5.73	0.3	2.29e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.72	7.36	0.38	1.52e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-7.15	-0.37	5.71e-12	Bladder cancer;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.51	8.45	0.42	9.63e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.33	-6.36	-0.33	6.88e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.63	-7.74	-0.39	1.2e-13	Vitamin D levels;
CRC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.53	6.65	0.34	1.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18656860	chr13:50018171	SETDB2;CAB39L	0.35	5.99	0.31	5.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.61	9.73	0.47	8.13e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg02683197	chr6:28174875	NA	0.62	8.4	0.42	1.32e-15	Parkinson's disease;
CRC	cis	rs2677744	0.626	rs11854429	chr15:91489685	C/T	cg23684204	chr15:91497937	RCCD1	-0.44	-6.66	-0.34	1.17e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.85	-14.1	-0.61	1.22e-35	Cognitive function;
CRC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-12.75	-0.58	1.54e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-8.64	-0.43	2.56e-16	Monocyte percentage of white cells;
CRC	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg20933634	chr6:27740509	NA	0.58	6.81	0.35	4.67e-11	Depression;
CRC	cis	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-5.88	-0.31	1.01e-8	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.2	-0.32	1.65e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.56	-0.38	3.92e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs2882667	0.964	rs11739351	chr5:138311742	A/G	cg09476006	chr5:138032270	NA	0.48	8.1	0.41	1.11e-14	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4728302	0.594	rs4596578	chr7:133697429	T/C	cg03336402	chr7:133662267	EXOC4	-0.53	-8.3	-0.42	2.76e-15	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-5.73	-0.3	2.22e-8	Vitiligo;
CRC	cis	rs2346160	1.000	rs4709159	chr6:167664918	C/T	cg04673565	chr6:167680447	NA	-0.38	-6.44	-0.33	4.33e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.59	-0.34	1.76e-10	Fibrinogen levels;
CRC	trans	rs7027930	0.524	rs16921144	chr9:614485	C/G	cg27061366	chr19:13044373	FARSA	0.5	6.15	0.32	2.24e-9	Pulmonary function decline;
CRC	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.44	7.06	0.36	9.65e-12	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.4	6.57	0.34	1.94e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.61	7.53	0.38	4.96e-13	Neutrophil percentage of white cells;
CRC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.53	7.81	0.4	7.92e-14	Response to temozolomide;
CRC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	15.19	0.64	7.26e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.11	-0.41	1.01e-14	Total body bone mineral density;
CRC	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.37e-19	Blood protein levels;
CRC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg17724175	chr1:150552817	MCL1	0.48	7.08	0.36	8.66e-12	Melanoma;
CRC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.64	-0.34	1.27e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.6	8.91	0.44	3.6e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.51	-7.96	-0.4	2.72e-14	Coronary artery disease;
CRC	cis	rs4964805	1.000	rs73192052	chr12:104190854	C/T	cg02344784	chr12:104178138	NT5DC3	0.51	7.17	0.37	4.91e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.42	6.39	0.33	5.63e-10	Red blood cell count;
CRC	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.57	-5.87	-0.31	1.07e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9549328	0.565	rs36145949	chr13:113616608	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.39	0.46	1e-18	Systolic blood pressure;
CRC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.5	7.01	0.36	1.37e-11	Schizophrenia;
CRC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	9.25	0.45	2.87e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg05535760	chr7:792225	HEATR2	0.44	5.7	0.3	2.67e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.62	-8.09	-0.41	1.19e-14	Immature fraction of reticulocytes;
CRC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.34	-0.38	1.67e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10486722	0.564	rs7811316	chr7:41788530	A/G	cg22138096	chr7:41772439	LOC285954	0.43	5.62	0.3	3.98e-8	Pit-and-Fissure caries;
CRC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg14844989	chr11:31128820	NA	-0.34	-5.93	-0.31	7.82e-9	Red blood cell count;
CRC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.1	0.32	2.98e-9	Diabetic kidney disease;
CRC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.77	-0.35	6.08e-11	Type 2 diabetes;
CRC	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-7.09	-0.36	8.21e-12	Educational attainment;
CRC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg09911534	chr15:67153556	NA	0.46	5.99	0.31	5.46e-9	Lung cancer (smoking interaction);
CRC	cis	rs2882667	0.898	rs3828600	chr5:138386859	G/T	cg09476006	chr5:138032270	NA	0.44	7.15	0.37	5.68e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.36	-13.12	-0.59	6.54e-32	Plateletcrit;
CRC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.59	8.32	0.42	2.29e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg07741184	chr6:167504864	NA	-0.32	-5.65	-0.3	3.55e-8	Primary biliary cholangitis;
CRC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.44	7.11	0.37	7.13e-12	Monocyte count;
CRC	cis	rs35883536	1.000	rs4243810	chr1:101139914	T/C	cg14515779	chr1:101123966	NA	-0.39	-7.56	-0.38	4.11e-13	Monocyte count;
CRC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6764363	0.587	rs455635	chr3:285316	G/T	cg02057681	chr3:285234	CHL1	-0.43	-7.23	-0.37	3.44e-12	Sudden cardiac arrest;
CRC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.47	7.91	0.4	3.89e-14	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.52	7.35	0.38	1.63e-12	Schizophrenia;
CRC	cis	rs12620999	0.941	rs58678188	chr2:237971036	C/A	cg23555395	chr2:238036564	NA	0.51	7.87	0.4	5.15e-14	Systemic lupus erythematosus;
CRC	trans	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg26043149	chr18:55253948	FECH	-0.53	-7.79	-0.39	8.74e-14	Bone mineral density;
CRC	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs747650	0.892	rs1976142	chr11:47225694	T/C	cg03339077	chr11:47165057	C11orf49	0.46	6.51	0.34	2.85e-10	Acne (severe);
CRC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.6	-0.34	1.67e-10	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01194336	chr12:66627997	IRAK3	0.37	6.16	0.32	2.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.06	-0.32	3.66e-9	Arsenic metabolism;
CRC	cis	rs7781266	0.739	rs1149551	chr7:133074763	C/T	cg03336402	chr7:133662267	EXOC4	-0.49	-5.92	-0.31	8.06e-9	Educational attainment (college completion);
CRC	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.46	-0.38	7.88e-13	Menarche (age at onset);
CRC	cis	rs8060686	0.858	rs7191129	chr16:67801391	A/G	cg07125278	chr16:67683757	RLTPR	-0.49	-6.46	-0.34	3.84e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg18288967	chr1:45987694	PRDX1	0.7	7.87	0.4	5.34e-14	Obesity-related traits;
CRC	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.46	-7.39	-0.38	1.24e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.76	-10.45	-0.5	3e-22	White matter hyperintensity burden;
CRC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.06	-0.32	3.71e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.49	0.34	3.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.66	-7.72	-0.39	1.4e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.95	-0.31	6.9e-9	Life satisfaction;
CRC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	17.03	0.68	4.53e-47	Body mass index (adult);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07927484	chr5:153826296	SAP30L	0.45	6.0	0.31	5.24e-9	Survival in pancreatic cancer;
CRC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg20607287	chr7:12443886	VWDE	-0.67	-6.75	-0.35	6.87e-11	Coronary artery disease;
CRC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.74	-0.3	2.21e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.85	13.31	0.59	1.28e-32	Ulcerative colitis;
CRC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-6.97	-0.36	1.7e-11	Intelligence (multi-trait analysis);
CRC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg19792802	chr11:65647270	CTSW	0.46	7.18	0.37	4.64e-12	Crohn's disease;
CRC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.68	10.55	0.5	1.36e-22	Monocyte count;
CRC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	8.2	0.41	5.52e-15	Cognitive test performance;
CRC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-8.68	-0.43	1.89e-16	Chronic sinus infection;
CRC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	9.92e-18	Bladder cancer;
CRC	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.5	7.96	0.4	2.79e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg02741985	chr17:80059408	CCDC57	-0.45	-7.21	-0.37	3.89e-12	Life satisfaction;
CRC	cis	rs7762018	0.505	rs79938197	chr6:170059932	A/T	cg19338460	chr6:170058176	WDR27	-1.26	-9.1	-0.45	9e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs2908835	0.521	rs1950111	chr12:11608877	C/T	cg03979024	chr10:419189	DIP2C	-0.39	-6.1	-0.32	3.05e-9	Information processing speed;
CRC	cis	rs6896969	0.560	rs7725523	chr5:40372223	A/G	cg09067459	chr5:40385259	NA	0.45	6.96	0.36	1.87e-11	Multiple sclerosis;
CRC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.49	8.47	0.42	8.25e-16	Primary biliary cholangitis;
CRC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg18827107	chr12:86230957	RASSF9	0.38	6.08	0.32	3.42e-9	Major depressive disorder;
CRC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.23	0.41	4.29e-15	Lung cancer;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	6.85	0.35	3.73e-11	Longevity;Endometriosis;
CRC	cis	rs2274273	0.588	rs7154831	chr14:55823965	A/C	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.02	-0.32	4.58e-9	Protein biomarker;
CRC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg16358738	chr2:241808595	AGXT	-0.41	-6.12	-0.32	2.73e-9	Urinary metabolites;
CRC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.72	10.42	0.5	3.71e-22	Cognitive function;
CRC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.72	12.46	0.57	1.95e-29	Longevity;
CRC	cis	rs8105895	0.935	rs2043317	chr19:22251096	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs73200209	0.744	rs11616043	chr12:116559922	T/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.16	-0.37	5.26e-12	Total body bone mineral density;
CRC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	3.99e-8	Bladder cancer;
CRC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.42e-12	Colorectal cancer;
CRC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-6.38	-0.33	5.89e-10	Schizophrenia;
CRC	cis	rs863345	0.625	rs4575081	chr1:158504837	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs7605827	0.930	rs7596951	chr2:15513473	G/C	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg13390004	chr1:15929781	NA	0.5	7.11	0.37	7.21e-12	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.55	-7.94	-0.4	3.16e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.74	10.37	0.5	5.52e-22	Testicular germ cell tumor;
CRC	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.4	-6.58	-0.34	1.82e-10	Mean arterial pressure;
CRC	cis	rs883565	0.569	rs2949565	chr3:39163425	G/A	cg01426195	chr3:39028469	NA	0.42	6.97	0.36	1.69e-11	Handedness;
CRC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2108622	0.727	rs8102532	chr19:15980060	G/A	cg13772218	chr19:15982569	NA	0.49	6.69	0.35	9.87e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14256136	chr10:74856824	P4HA1	0.45	6.75	0.35	6.83e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9906695	0.615	rs12453746	chr17:32635581	G/T	cg12698626	chr17:32581466	CCL2	0.43	5.89	0.31	9.51e-9	Monocyte percentage of white cells;
CRC	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg14515779	chr1:101123966	NA	-0.45	-8.46	-0.42	9.07e-16	Monocyte count;
CRC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.66	9.56	0.47	2.91e-19	Lung cancer;
CRC	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg05272587	chr13:111038400	COL4A2	-0.42	-6.8	-0.35	4.85e-11	White matter hyperintensity burden;
CRC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.6	8.94	0.44	2.84e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.46	7.22	0.37	3.72e-12	Coronary artery disease;
CRC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.62	9.56	0.47	2.9e-19	Corneal astigmatism;
CRC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.7	-0.39	1.65e-13	Psoriasis;
CRC	cis	rs10426930	0.607	rs877287	chr19:5041989	G/A	cg18473234	chr19:5097819	KDM4B	0.45	5.77	0.3	1.79e-8	Monocyte percentage of white cells;
CRC	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.41	0.33	4.92e-10	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01016553	chr1:51810627	TTC39A	0.4	6.81	0.35	4.68e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.69	-0.51	4.4e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.78	11.66	0.54	1.58e-26	Cognitive function;
CRC	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.33	-5.67	-0.3	3.16e-8	Menopause (age at onset);
CRC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	1.24	14.27	0.62	2.68e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg00425918	chr8:23563146	NKX2-6	-0.33	-6.25	-0.33	1.29e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.47	7.44	0.38	8.68e-13	Body mass index;
CRC	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.21	0.37	3.77e-12	Eye color traits;
CRC	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.61	-7.83	-0.4	6.91e-14	Hip circumference adjusted for BMI;
CRC	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.46	5.74	0.3	2.11e-8	Alzheimer's disease (survival time);
CRC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03676636	chr4:99064102	C4orf37	0.23	6.35	0.33	7.31e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg10760299	chr15:45669010	GATM	0.5	7.99	0.4	2.37e-14	Homoarginine levels;
CRC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg25036284	chr2:26402008	FAM59B	0.54	6.41	0.33	5.04e-10	Gut microbiome composition (summer);
CRC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.5e-8	Lung cancer;
CRC	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.62	-10.05	-0.48	6.58e-21	Myopia (pathological);
CRC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12292205	chr6:26970375	C6orf41	-0.47	-6.5	-0.34	3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs540254	0.578	rs4656933	chr1:160782561	T/A	cg20255094	chr1:160771763	LY9	0.48	6.4	0.33	5.44e-10	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17176228	chr8:145159019	SHARPIN;MAF1	0.46	6.61	0.34	1.51e-10	Anxiety disorder;
CRC	cis	rs2979489	0.945	rs11988541	chr8:30334273	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-9.84	-0.48	3.29e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	0.93	17.42	0.69	1.32e-48	Height;
CRC	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg21153622	chr11:89784906	NA	-0.5	-8.01	-0.4	1.95e-14	HDL cholesterol;
CRC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.7	9.02	0.45	1.55e-17	Psoriasis;
CRC	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg25797454	chr6:150327115	RAET1K	0.38	6.38	0.33	5.86e-10	Alopecia areata;
CRC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg10760299	chr15:45669010	GATM	0.52	7.87	0.4	5.07e-14	Homoarginine levels;
CRC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg13607699	chr17:42295918	UBTF	-0.45	-5.81	-0.3	1.51e-8	Total body bone mineral density;
CRC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.18	0.74	1.61e-59	Prudent dietary pattern;
CRC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.24	-16.67	-0.68	1.18e-45	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24458652	chr1:231377103	C1orf131;GNPAT	0.46	6.51	0.34	2.8e-10	Response to antipsychotic treatment;
CRC	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.1	0.45	8.81e-18	Blood protein levels;
CRC	trans	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	trans	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.18	-0.32	1.89e-9	Aortic root size;
CRC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.73	-12.58	-0.57	6.83e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg21238619	chr17:78079768	GAA	-0.4	-7.64	-0.39	2.42e-13	Yeast infection;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12273811	chr6:28175739	NA	0.57	8.23	0.41	4.52e-15	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.29	0.37	2.36e-12	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.74	6.66	0.34	1.14e-10	Diabetic kidney disease;
CRC	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.79	0.44	8.7e-17	Dupuytren's disease;
CRC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg02725872	chr8:58115012	NA	-0.41	-6.38	-0.33	6.05e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.33	0.33	7.9e-10	IgG glycosylation;
CRC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	11.6	0.54	2.68e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13794888	chr15:75917792	SNUPN	0.43	6.06	0.32	3.72e-9	Response to antipsychotic treatment;
CRC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg09417038	chr21:47716443	C21orf57	0.38	6.56	0.34	2.12e-10	Testicular germ cell tumor;
CRC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.42	9.22	0.45	3.56e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.57	-9.02	-0.45	1.58e-17	Neuroblastoma (high-risk);
CRC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.79	0.51	1.91e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.95	0.31	6.76e-9	Tonsillectomy;
CRC	cis	rs7945718	0.621	rs11022464	chr11:12685477	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg25834613	chr7:1915315	MAD1L1	-0.42	-5.93	-0.31	7.82e-9	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.24e-12	Coronary artery disease;
CRC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.56	-8.78	-0.44	9.43e-17	Height;
CRC	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg25190513	chr12:123201362	GPR109B	-0.48	-5.94	-0.31	7.24e-9	Adiponectin levels;
CRC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.48	-8.87	-0.44	4.67e-17	Total body bone mineral density;
CRC	trans	rs10242455	0.702	rs28668326	chr7:98998153	G/A	cg09045935	chr12:6379348	NA	1.0	7.62	0.39	2.79e-13	Blood metabolite levels;
CRC	cis	rs12550646	0.652	rs10090395	chr8:41666874	C/T	cg12180191	chr8:41686706	ANK1	0.44	6.38	0.33	6.04e-10	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg00603274	chr11:61596626	FADS2	-0.45	-6.6	-0.34	1.62e-10	Trans fatty acid levels;
CRC	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.41	-0.33	5.09e-10	Triglycerides;
CRC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg19052272	chr2:3704530	ALLC	0.52	7.51	0.38	5.72e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs731174	0.722	rs553888	chr1:38152509	C/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.3	-5.63	-0.3	3.95e-8	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg25214090	chr10:38739885	LOC399744	-0.41	-6.38	-0.33	6.13e-10	Diastolic blood pressure;
CRC	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg24848437	chr7:2645542	IQCE	0.58	6.13	0.32	2.45e-9	Urate levels in lean individuals;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19191357	chr22:42196520	CCDC134	0.43	7.13	0.37	6.33e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9491140	0.539	rs11154221	chr6:124675246	C/T	cg22366943	chr6:124882293	NKAIN2	0.56	8.53	0.43	5.42e-16	Neuroticism;
CRC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.59	0.34	1.76e-10	Lung cancer;
CRC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.75	-0.6	2.69e-34	Extrinsic epigenetic age acceleration;
CRC	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.57	8.08	0.41	1.26e-14	Smooth-surface caries;
CRC	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.85	-15.05	-0.64	2.7e-39	Lewy body disease;
CRC	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.66	-0.47	1.32e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.42	6.99	0.36	1.57e-11	P wave terminal force;
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02725872	chr8:58115012	NA	-0.6	-9.17	-0.45	5.2e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4713675	0.546	rs791903	chr6:33702645	G/C	cg14003231	chr6:33640908	ITPR3	-0.42	-6.94	-0.36	2.13e-11	Plateletcrit;
CRC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.45	6.65	0.34	1.24e-10	Menopause (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16682046	chr11:82612617	PRCP;C11orf82	-0.57	-7.13	-0.37	6.54e-12	Diisocyanate-induced asthma;
CRC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.99	-0.4	2.23e-14	Gut microbiome composition (summer);
CRC	cis	rs13098911	0.540	rs6791016	chr3:46074858	G/A	cg12691230	chr3:46064611	XCR1	-0.52	-5.62	-0.3	4.01e-8	Celiac disease;
CRC	cis	rs7692995	0.925	rs12513171	chr4:17997541	T/C	cg08925142	chr4:18023851	LCORL	-0.54	-6.03	-0.32	4.31e-9	Height;
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.67	7.18	0.37	4.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.77	-12.86	-0.58	6.04e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs2303319	0.504	rs2389549	chr2:162462209	C/T	cg18122310	chr12:50236657	BCDIN3D	0.72	6.11	0.32	2.8e-9	Cognitive function;
CRC	cis	rs2276314	0.512	rs7234973	chr18:33450336	A/G	cg19628046	chr18:33552617	C18orf21	0.4	5.89	0.31	9.37e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.31	5.88e-9	Heart rate;
CRC	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg25856811	chr1:152973957	SPRR3	-0.23	-6.01	-0.31	4.84e-9	Inflammatory skin disease;
CRC	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg14515779	chr1:101123966	NA	-0.33	-5.74	-0.3	2.19e-8	Monocyte count;
CRC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.4	5.89	0.31	9.44e-9	Renal cell carcinoma;
CRC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.5	-9.09	-0.45	9.32e-18	Longevity;
CRC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg12463550	chr7:65579703	CRCP	0.62	5.95	0.31	6.75e-9	Diabetic kidney disease;
CRC	cis	rs4926298	1.000	rs1077151	chr19:13151108	A/G	cg11738485	chr19:12877000	HOOK2	-0.45	-6.11	-0.32	2.84e-9	Bipolar disorder;
CRC	cis	rs501120	0.584	rs545025	chr10:44736544	C/T	cg09554077	chr10:44749378	NA	0.76	8.38	0.42	1.59e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.47	7.62	0.39	2.73e-13	Body mass index;
CRC	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.42	5.68	0.3	2.98e-8	Body mass index;
CRC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.45	-6.69	-0.35	9.81e-11	Cognitive test performance;
CRC	trans	rs12699921	0.632	rs2723494	chr7:17853983	C/T	cg02066331	chr6:17282778	RBM24	-0.35	-6.11	-0.32	2.89e-9	Fibrinogen levels;
CRC	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	10.22	0.49	1.73e-21	Itch intensity from mosquito bite;
CRC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.64	8.38	0.42	1.6e-15	Arsenic metabolism;
CRC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.69	-0.3	2.88e-8	Aortic root size;
CRC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	9.71	0.47	8.87e-20	Mean corpuscular hemoglobin;
CRC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.46	-0.34	3.7e-10	Electroencephalogram traits;
CRC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.57	7.48	0.38	6.85e-13	Breast cancer;
CRC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.42	6.03	0.32	4.3e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.49	7.52	0.38	5.16e-13	Testicular germ cell tumor;
CRC	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-8.02	-0.4	1.82e-14	Total cholesterol levels;
CRC	cis	rs72730918	0.590	rs8027162	chr15:51985147	T/C	cg14296394	chr15:51910925	DMXL2	-0.43	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg21194808	chr1:2205498	SKI	0.38	5.78	0.3	1.75e-8	Height;
CRC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	11.47	0.53	7.76e-26	Monocyte percentage of white cells;
CRC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.71	12.22	0.56	1.45e-28	Longevity;
CRC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.57	8.59	0.43	3.56e-16	High light scatter reticulocyte count;
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg20811857	chr17:78079795	GAA	-0.46	-6.77	-0.35	6.01e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2013441	0.965	rs1544421	chr17:20114217	T/C	cg13482628	chr17:19912719	NA	-0.42	-6.57	-0.34	1.95e-10	Obesity-related traits;
CRC	cis	rs9491140	0.539	rs11154231	chr6:124687586	T/C	cg19267163	chr6:125004984	NKAIN2	0.44	6.06	0.32	3.78e-9	Neuroticism;
CRC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-9.32	-0.46	1.79e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg12315302	chr6:26189340	HIST1H4D	0.86	6.63	0.34	1.34e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg09045935	chr12:6379348	NA	-1.07	-9.0	-0.44	1.91e-17	Blood metabolite levels;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.44	-7.34	-0.38	1.65e-12	Refractive error;
CRC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg13722127	chr7:150037890	RARRES2	0.47	7.1	0.36	7.74e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.59	7.95	0.4	2.94e-14	Alzheimer's disease;
CRC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg24253500	chr15:84953950	NA	0.38	6.48	0.34	3.43e-10	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02970861	chr11:62359288	TUT1	0.47	6.52	0.34	2.71e-10	Response to antipsychotic treatment;
CRC	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg15145174	chr5:6755386	POLS	-0.46	-6.44	-0.33	4.16e-10	Menopause (age at onset);
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.7	-13.11	-0.59	6.97e-32	Bipolar disorder;
CRC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.48	-7.65	-0.39	2.25e-13	Tonsillectomy;
CRC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.21	0.45	3.84e-18	Personality dimensions;
CRC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.08	-0.36	8.59e-12	Self-reported allergy;
CRC	trans	rs17374222	0.606	rs11854396	chr15:70036589	G/A	cg15808008	chr15:89764895	RLBP1	-0.29	-6.08	-0.32	3.31e-9	Rheumatoid arthritis;
CRC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.8	-0.35	4.81e-11	Total body bone mineral density;
CRC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.65	9.17	0.45	5.22e-18	Multiple sclerosis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg25010444	chr12:123717480	C12orf65	-0.41	-5.99	-0.31	5.65e-9	HDL cholesterol;
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg19223190	chr17:80058835	NA	0.4	6.4	0.33	5.26e-10	Life satisfaction;
CRC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg26395211	chr5:140044315	WDR55	0.38	5.68	0.3	2.99e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	trans	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg07817883	chr1:32538562	TMEM39B	1.46	13.16	0.59	4.47e-32	Granulocyte percentage of myeloid white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06465160	chr1:25071620	CLIC4	0.43	6.12	0.32	2.65e-9	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg12927641	chr6:109611667	NA	-0.34	-6.09	-0.32	3.09e-9	Reticulocyte fraction of red cells;
CRC	cis	rs728616	0.558	rs12767261	chr10:82162323	G/A	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.97	-0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg15845792	chr6:28175446	NA	0.72	6.18	0.32	1.9e-9	Breast cancer;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg20590175	chr12:132530165	EP400	-0.41	-6.01	-0.31	4.95e-9	Lung cancer;
CRC	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.19	0.45	4.51e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg19875578	chr6:126661172	C6orf173	0.42	5.76	0.3	1.91e-8	Male-pattern baldness;
CRC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.52	-8.58	-0.43	3.89e-16	Sense of smell;
CRC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.49	6.58	0.34	1.87e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg03623178	chr6:28175578	NA	0.66	10.08	0.49	5.38e-21	Pubertal anthropometrics;
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-6.04	-0.32	4.26e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs492478	0.892	rs11959334	chr5:3942641	C/T	cg09199442	chr11:28132951	METT5D1	-0.72	-6.42	-0.33	4.89e-10	Cognitive performance;
CRC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg13319975	chr6:146136371	FBXO30	0.38	5.79	0.3	1.62e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.53	-9.9	-0.48	2.14e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg13119609	chr19:45449297	APOC2	0.31	5.81	0.3	1.5e-8	Blood protein levels;
CRC	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.29	-5.68	-0.3	2.93e-8	Cutaneous nevi;
CRC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.53	7.94	0.4	3.21e-14	Body mass index;
CRC	cis	rs965469	1.000	rs1331215	chr20:3376565	T/C	cg25506879	chr20:3388711	C20orf194	-0.4	-5.84	-0.31	1.27e-8	IFN-related cytopenia;
CRC	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.14e-9	Hair morphology;
CRC	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.6	-7.28	-0.37	2.46e-12	Ulcerative colitis;
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs4664293	0.867	rs7582124	chr2:160572837	T/C	cg08347373	chr2:160653686	CD302	-0.47	-7.45	-0.38	8.04e-13	Monocyte percentage of white cells;
CRC	trans	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg21153622	chr11:89784906	NA	-0.48	-7.64	-0.39	2.36e-13	HDL cholesterol;
CRC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.87	0.44	4.91e-17	Schizophrenia;
CRC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	14.39	0.62	9.04e-37	Smoking behavior;
CRC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.49	-8.76	-0.43	1.06e-16	Prostate cancer;
CRC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.51	0.5	1.74e-22	Menopause (age at onset);
CRC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.6	-9.96	-0.48	1.31e-20	Colorectal cancer;
CRC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.74	10.47	0.5	2.54e-22	Blood metabolite levels;
CRC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.65	10.77	0.51	2.34e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.34	-0.33	7.6e-10	Menarche (age at onset);
CRC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.34	-5.62	-0.3	3.99e-8	Personality dimensions;
CRC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.37	-6.32	-0.33	8.46e-10	Mean corpuscular hemoglobin;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07145398	chr17:61523374	CYB561	0.39	6.01	0.31	4.94e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg11542086	chr8:79716756	IL7	-0.53	-5.97	-0.31	6.22e-9	Lung adenocarcinoma;
CRC	cis	rs7572644	0.699	rs13400398	chr2:28162109	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-5.69	-0.3	2.76e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg26248373	chr2:1572462	NA	-0.65	-7.02	-0.36	1.24e-11	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.92	14.18	0.62	5.85e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.31	5.7	0.3	2.73e-8	Pulse pressure;
CRC	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.83	10.95	0.52	5.27e-24	Prostate cancer;
CRC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.48	-6.85	-0.35	3.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg17321639	chr7:2759063	NA	-0.54	-7.52	-0.38	5.17e-13	Height;
CRC	cis	rs12044355	0.927	rs66909551	chr1:231834942	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.81	0.35	4.68e-11	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg19223190	chr17:80058835	NA	0.39	6.26	0.33	1.19e-9	Life satisfaction;
CRC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.37	-0.33	6.28e-10	Breast cancer;
CRC	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg05283184	chr6:79620031	NA	-0.44	-7.38	-0.38	1.31e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.08e-8	Bladder cancer;
CRC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.76	0.58	1.44e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00495681	chr13:53174319	NA	0.58	8.79	0.44	8.64e-17	Lewy body disease;
CRC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg09417038	chr21:47716443	C21orf57	-0.41	-6.75	-0.35	6.51e-11	Testicular germ cell tumor;
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.54	-9.78	-0.47	5.42e-20	Bipolar disorder;
CRC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	15.39	0.65	1.27e-40	Platelet count;
CRC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12667521	chr19:29218732	NA	0.43	5.75	0.3	2.05e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.36	0.46	1.32e-18	Blood protein levels;
CRC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.49	0.54	6.51e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.35	-5.65	-0.3	3.41e-8	Glycated hemoglobin levels;
CRC	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.1	-0.32	3.05e-9	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04742047	chr19:14544036	PKN1	-0.38	-5.96	-0.31	6.38e-9	Myopia (pathological);
CRC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.52	7.69e-24	Motion sickness;
CRC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg19622623	chr12:86230825	RASSF9	-0.42	-6.76	-0.35	6.21e-11	Major depressive disorder;
CRC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.62	-10.89	-0.51	8.94e-24	Body mass index;
CRC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg16892393	chr17:41919603	NA	-0.49	-7.13	-0.37	6.37e-12	Triglycerides;
CRC	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.67	6.06	0.32	3.71e-9	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.56	-8.4	-0.42	1.34e-15	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Corneal astigmatism;
CRC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24810637	chr10:64564243	ADO	0.45	6.35	0.33	7.34e-10	Response to antipsychotic treatment;
CRC	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.96	-0.31	6.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.13	0.32	2.47e-9	Vitiligo;
CRC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg20387954	chr3:183756860	HTR3D	0.43	7.37	0.38	1.35e-12	Anterior chamber depth;
CRC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.5	8.97	0.44	2.23e-17	Lung cancer;
CRC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.7	-11.12	-0.52	1.32e-24	Height;
CRC	cis	rs12760731	0.565	rs12403070	chr1:178094429	A/G	cg00404053	chr1:178313656	RASAL2	1.08	11.21	0.53	6.52e-25	Obesity-related traits;
CRC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.65	12.59	0.57	6.35e-30	HDL cholesterol;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16266895	chr12:101674004	UTP20	0.51	6.79	0.35	5.3e-11	Thyroid stimulating hormone;
CRC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	11.93	0.55	1.64e-27	Schizophrenia;
CRC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs2346160	0.899	rs384974	chr6:167688418	C/T	cg04673565	chr6:167680447	NA	-0.39	-6.58	-0.34	1.8e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.8	-0.3	1.57e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg12756093	chr1:115239321	AMPD1	0.48	6.96	0.36	1.84e-11	Autism;
CRC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.43	-20.42	-0.75	2e-60	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00119011	chr13:45694603	GTF2F2	0.43	6.11	0.32	2.78e-9	Anxiety disorder;
CRC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.76	0.43	1.04e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.43	-5.85	-0.31	1.19e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.79	-0.35	5.16e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.93	-0.36	2.19e-11	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg13919466	chr1:32135498	COL16A1	-0.32	-5.99	-0.31	5.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.44	6.65	0.34	1.23e-10	Calcium levels;
CRC	cis	rs972578	1.000	rs1569507	chr22:43356699	A/G	cg01576275	chr22:43409880	NA	0.44	6.73	0.35	7.7e-11	Mean platelet volume;
CRC	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.51	-7.03	-0.36	1.22e-11	Tuberculosis;
CRC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	9.25	0.45	2.85e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.69e-10	HDL cholesterol;
CRC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.42	-8.09	-0.41	1.2e-14	Subjective well-being;
CRC	trans	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.1	0.36	7.97e-12	Ulcerative colitis;
CRC	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg19554555	chr3:13937349	NA	0.44	6.34	0.33	7.58e-10	Ovarian reserve;
CRC	trans	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg17903999	chr18:56338584	MALT1	-0.38	-6.17	-0.32	1.96e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.78	-13.26	-0.59	1.9e-32	Obesity-related traits;
CRC	cis	rs9462027	0.628	rs9296131	chr6:34776361	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.97	-0.31	6.31e-9	Systemic lupus erythematosus;
CRC	cis	rs6504622	0.537	rs1662594	chr17:44992737	C/T	cg16759221	chr17:45003025	GOSR2	-0.63	-10.47	-0.5	2.45e-22	Orofacial clefts;
CRC	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.64	8.87	0.44	4.69e-17	Body mass index;
CRC	cis	rs9467160	1.000	rs9467161	chr6:24441963	C/T	cg20631270	chr6:24437470	GPLD1	0.48	6.34	0.33	7.61e-10	Liver enzyme levels;
CRC	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.41	-5.79	-0.3	1.63e-8	Daytime sleep phenotypes;
CRC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.35	-7.47	-0.38	7.51e-13	Urinary metabolites;
CRC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.85	-9.93	-0.48	1.71e-20	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14431266	chr11:67057003	ANKRD13D	0.44	6.36	0.33	6.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg14664628	chr15:75095509	CSK	-1.01	-19.19	-0.73	1.29e-55	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.84	0.31	1.25e-8	Tonsillectomy;
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.62	0.6	8.27e-34	Prudent dietary pattern;
CRC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg07701084	chr6:150067640	NUP43	0.54	7.44	0.38	8.71e-13	Lung cancer;
CRC	cis	rs889398	0.802	rs8051168	chr16:69887274	T/A	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.27	-0.33	1.12e-9	Body mass index;
CRC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg23136738	chr11:925521	AP2A2	0.42	7.14	0.37	5.96e-12	Alzheimer's disease (late onset);
CRC	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.31	0.33	9.07e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.45	-5.72	-0.3	2.43e-8	Gut microbiome composition (summer);
CRC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.6	-8.71	-0.43	1.51e-16	Menarche (age at onset);
CRC	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg26816564	chr1:7831052	VAMP3	0.61	6.52	0.34	2.65e-10	Inflammatory bowel disease;
CRC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.32	-0.42	2.45e-15	Chronic sinus infection;
CRC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.15	-0.32	2.26e-9	Bipolar disorder;
CRC	cis	rs12024301	0.557	rs115011681	chr1:183619683	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.12	0.37	6.85e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7605827	0.930	rs1990753	chr2:15612403	G/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.01	-0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	9.25	0.45	2.86e-18	Ileal carcinoids;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg25164649	chr6:28176230	NA	0.6	7.45	0.38	8.36e-13	Parkinson's disease;
CRC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.56	9.76	0.47	6.35e-20	Bipolar disorder;
CRC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg00677455	chr12:58241039	CTDSP2	0.54	8.13	0.41	8.79e-15	Multiple sclerosis;
CRC	cis	rs2380220	0.872	rs115871915	chr6:95934180	T/C	cg04719120	chr6:96025338	MANEA	-0.55	-6.0	-0.31	5.09e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.53	-8.77	-0.44	9.6e-17	Total body bone mineral density;
CRC	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.75	12.41	0.56	2.98e-29	Coronary artery disease;
CRC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg00901687	chr17:48585270	MYCBPAP	0.42	5.62	0.3	4.16e-8	Visceral fat;
CRC	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.65	11.2	0.53	7.2e-25	Phospholipid levels (plasma);
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.61	0.6	8.9e-34	Alzheimer's disease;
CRC	cis	rs4731207	0.596	rs6971179	chr7:124592351	G/A	cg23710748	chr7:124431027	NA	-0.43	-6.81	-0.35	4.56e-11	Cutaneous malignant melanoma;
CRC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-14.99	-0.64	4.54e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg22689833	chr10:102415991	NA	-0.32	-6.19	-0.32	1.82e-9	Body mass index;
CRC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg05313129	chr8:58192883	C8orf71	-0.46	-6.09	-0.32	3.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg22495460	chr2:25135724	ADCY3	0.67	11.12	0.52	1.38e-24	Body mass index in non-asthmatics;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg24851651	chr11:66362959	CCS	-0.37	-6.58	-0.34	1.91e-10	Educational attainment (years of education);
CRC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.6	-8.64	-0.43	2.48e-16	Menarche (age at onset);
CRC	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs11627756	0.918	rs2403070	chr14:103093432	T/C	cg12046867	chr14:103022105	NA	-0.41	-5.62	-0.3	4.02e-8	Mean platelet volume;
CRC	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.53	9.07	0.45	1.12e-17	Dupuytren's disease;
CRC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.61	-8.99	-0.44	1.95e-17	Menarche (age at onset);
CRC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.72	-7.92	-0.4	3.64e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.07	-27.76	-0.84	3.21e-88	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg08075719	chr14:103021372	NA	-0.66	-8.62	-0.43	2.83e-16	Platelet count;
CRC	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.51	-8.33	-0.42	2.14e-15	Menarche (age at onset);
CRC	cis	rs12928939	0.911	rs7202840	chr16:71824714	C/T	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.05	-0.32	4.04e-9	Post bronchodilator FEV1;
CRC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg16558177	chr4:4109446	NA	-0.49	-6.26	-0.33	1.22e-9	Blood pressure (smoking interaction);
CRC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.45	-6.99	-0.36	1.57e-11	Height;
CRC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.69	8.07	0.41	1.31e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.5	8.5	0.42	6.93e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09377915	chr6:56295593	NA	-0.37	-6.09	-0.32	3.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg00507830	chr2:103233733	NA	0.51	5.8	0.3	1.55e-8	Gut microbiota (bacterial taxa);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14893720	chr7:33149316	RP9	0.42	6.09	0.32	3.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg07514618	chr14:103979422	NA	-0.44	-6.77	-0.35	6.09e-11	Body mass index;
CRC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	0.67	7.75	0.39	1.15e-13	Lymphocyte counts;
CRC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.81	9.18	0.45	4.9e-18	Breast cancer;
CRC	cis	rs4731207	0.596	rs2017928	chr7:124672323	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.16	-0.32	2.07e-9	Cutaneous malignant melanoma;
CRC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	cis	rs17401966	0.597	rs11121555	chr1:10442856	C/T	cg19773385	chr1:10388646	KIF1B	-0.52	-8.15	-0.41	7.77e-15	Hepatocellular carcinoma;
CRC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg07936489	chr17:37558343	FBXL20	-0.44	-6.28	-0.33	1.06e-9	Asthma;
CRC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.63	-9.81	-0.48	4.19e-20	Obesity-related traits;
CRC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.38	7.3	0.37	2.23e-12	Mean corpuscular volume;
CRC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.9	-17.38	-0.69	1.92e-48	Obesity-related traits;
CRC	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.53	8.89	0.44	4.14e-17	Dupuytren's disease;
CRC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs9906695	0.656	rs3138034	chr17:32642725	C/T	cg12698626	chr17:32581466	CCL2	0.43	5.75	0.3	2.08e-8	Monocyte percentage of white cells;
CRC	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.78	0.35	5.68e-11	Rheumatoid arthritis;
CRC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg15786705	chr6:28176104	NA	0.67	6.48	0.34	3.27e-10	Depression;
CRC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg21856205	chr7:94953877	PON1	-0.45	-5.81	-0.31	1.47e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.68	9.63	0.47	1.72e-19	Body mass index;
CRC	cis	rs2249694	0.520	rs10776685	chr10:135327317	T/C	cg20169779	chr10:135381914	SYCE1	-0.53	-7.39	-0.38	1.23e-12	Obesity-related traits;
CRC	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.62	-8.56	-0.43	4.24e-16	Extraversion;
CRC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.29e-10	Childhood ear infection;
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.39	7.08	0.36	8.73e-12	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27556566	chr18:29671984	RNF138	0.46	6.64	0.34	1.29e-10	Response to antipsychotic treatment;
CRC	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg15704280	chr7:45808275	SEPT13	0.55	6.28	0.33	1.05e-9	Intraocular pressure;
CRC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.86	0.31	1.11e-8	Tonsillectomy;
CRC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.38	6.59	0.34	1.79e-10	Coronary artery disease;
CRC	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.57	-8.37	-0.42	1.62e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.47	-6.18	-0.32	1.91e-9	Blood metabolite levels;
CRC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.56	6.28	0.33	1.04e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.04	0.36	1.11e-11	Morning vs. evening chronotype;
CRC	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg09184832	chr6:79620586	NA	-0.34	-6.35	-0.33	6.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.29	0.33	9.93e-10	Depression;
CRC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg17796960	chr10:135278976	LOC619207	-0.37	-5.65	-0.3	3.53e-8	Systemic lupus erythematosus;
CRC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.63	7.34	0.38	1.73e-12	Bipolar disorder;
CRC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs12936587	0.811	rs12945496	chr17:17537197	G/C	cg09796270	chr17:17721594	SREBF1	-0.4	-5.68	-0.3	2.97e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.48	6.85	0.35	3.67e-11	Intelligence (multi-trait analysis);
CRC	cis	rs965469	0.779	rs6051830	chr20:3373397	T/C	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.96e-8	IFN-related cytopenia;
CRC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	0.99	12.71	0.57	2.26e-30	Triglycerides;
CRC	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.12e-18	Blood protein levels;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg12500891	chr11:57225987	NA	-0.69	-6.06	-0.32	3.82e-9	Cognitive function;
CRC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26240231	chr7:1148101	C7orf50	-0.44	-6.34	-0.33	7.6e-10	Bronchopulmonary dysplasia;
CRC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	7.49	0.38	6.27e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.57	-7.91	-0.4	3.86e-14	DNA methylation (variation);
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg19678392	chr7:94953810	PON1	-0.6	-7.49	-0.38	6.21e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	ch.11.42038R	chr11:967971	AP2A2	0.57	9.77	0.47	5.75e-20	Alzheimer's disease (late onset);
CRC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg24675056	chr1:15929824	NA	0.47	6.29	0.33	1.01e-9	Systolic blood pressure;
CRC	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg17691542	chr6:26056736	HIST1H1C	0.65	8.3	0.42	2.68e-15	Iron status biomarkers;
CRC	cis	rs9992667	0.955	rs7654470	chr4:38636229	C/T	cg19726192	chr4:38663646	FLJ13197	-0.67	-8.5	-0.42	6.48e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.6	-8.0	-0.4	2.09e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs524281	0.773	rs4393319	chr11:66001878	A/T	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.33	-6.82	-0.35	4.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-9.16	-0.45	5.88e-18	Bipolar disorder;
CRC	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg23229984	chr5:148520753	ABLIM3	-0.49	-6.74	-0.35	7.09e-11	Breast cancer;
CRC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.51	8.16	0.41	7.42e-15	Crohn's disease;
CRC	cis	rs17213078	0.647	rs17279736	chr2:106757365	C/G	cg16099169	chr2:106886729	NA	0.37	5.7	0.3	2.69e-8	Facial morphology (factor 23);
CRC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.6	-9.27	-0.46	2.53e-18	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.7	11.88	0.55	2.47e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.47	6.78	0.35	5.53e-11	Colorectal cancer;
CRC	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.43	-0.53	1.03e-25	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01397469	chr7:101458433	CUX1	0.5	6.84	0.35	3.97e-11	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.55	8.83	0.44	6.42e-17	Breast cancer;
CRC	cis	rs8067545	1.000	rs34291370	chr17:19942335	G/A	cg13482628	chr17:19912719	NA	0.52	8.09	0.41	1.15e-14	Schizophrenia;
CRC	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.58	8.22	0.41	4.63e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.98	12.08	0.55	4.57e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.08e-38	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-7.26	-0.37	2.79e-12	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11164639	chr15:91192950	NA	0.36	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17641971	0.708	rs2137013	chr8:49981091	C/T	cg00325661	chr8:49890786	NA	0.37	6.41	0.33	5.09e-10	Blood metabolite levels;
CRC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg23815491	chr16:72088622	HP	0.47	6.84	0.35	3.85e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg21858291	chr2:237994312	COPS8	0.52	6.11	0.32	2.89e-9	Kashin-Beck disease;
CRC	cis	rs4750440	0.585	rs4748069	chr10:14031188	A/G	cg00551146	chr10:14014579	FRMD4A	0.44	6.98	0.36	1.6e-11	Adiponectin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25374230	chr6:37225404	TMEM217;TBC1D22B	0.39	6.32	0.33	8.31e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.63	-8.26	-0.41	3.51e-15	Extraversion;
CRC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.67	11.48	0.53	7.08e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.54	0.54	4.15e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.65	-10.39	-0.5	4.64e-22	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.27	-0.33	1.11e-9	Lymphocyte counts;
CRC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.66	9.21	0.45	4.04e-18	Cognitive function;
CRC	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg11822372	chr1:151115635	SEMA6C	0.53	7.59	0.39	3.39e-13	Childhood ear infection;
CRC	cis	rs17234274	0.622	rs35342540	chr11:23238532	A/G	cg05245346	chr11:23248277	NA	0.36	5.88	0.31	1.03e-8	Cancer;
CRC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.79	7.93	0.4	3.39e-14	Diabetic retinopathy;
CRC	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.87	16.73	0.68	7.04e-46	Hip circumference;
CRC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.31	0.46	1.85e-18	High light scatter reticulocyte count;
CRC	trans	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.42e-8	Bladder cancer;
CRC	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.34	0.42	2e-15	Corneal astigmatism;
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.64	8.57	0.43	4.03e-16	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18513200	chr4:13629548	BOD1L	0.38	6.18	0.32	1.94e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg02551604	chr5:131831745	NA	-0.52	-6.55	-0.34	2.22e-10	Asthma (sex interaction);
CRC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.63	-9.85	-0.48	3.18e-20	Breast cancer;
CRC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.59	7.16	0.37	5.43e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3020333	0.875	rs3020334	chr6:152012956	A/G	cg22157087	chr6:152012887	ESR1	0.54	8.18	0.41	6.06e-15	Total body bone mineral density;
CRC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.68	-9.6	-0.47	2.05e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.85	-0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-5.7	-0.3	2.72e-8	Neuroticism;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg23807890	chr2:228736357	WDR69	-0.47	-6.54	-0.34	2.41e-10	Blood pressure;
CRC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.58	6.48	0.34	3.27e-10	Bipolar disorder;
CRC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.52	8.39	0.42	1.41e-15	Huntington's disease progression;
CRC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.48	-0.34	3.31e-10	Lung cancer;
CRC	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.99	-0.44	2.05e-17	Coffee consumption (cups per day);
CRC	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg01843034	chr6:37503916	NA	-0.43	-8.08	-0.41	1.21e-14	Cognitive performance;
CRC	trans	rs6678914	1.000	rs10920365	chr1:202189711	A/G	cg19977628	chr5:1262072	TERT	0.4	5.98	0.31	5.83e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg01176363	chr20:62369445	LIME1	-0.41	-5.63	-0.3	3.92e-8	Prostate cancer;
CRC	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.6	-0.34	1.66e-10	Depression;
CRC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.48	4.63e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	10.97	0.52	4.67e-24	Schizophrenia;
CRC	cis	rs294883	0.858	rs9457582	chr6:159722081	G/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.76	-0.3	1.95e-8	Coronary artery disease;
CRC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.47	-8.64	-0.43	2.51e-16	Total body bone mineral density;
CRC	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.41	-5.81	-0.3	1.48e-8	QT interval;
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg14092988	chr3:52407081	DNAH1	-0.3	-5.71	-0.3	2.55e-8	Electroencephalogram traits;
CRC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06544989	chr22:39130855	UNC84B	0.46	7.04	0.36	1.09e-11	Menopause (age at onset);
CRC	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.44	6.33	0.33	7.86e-10	Height;
CRC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.38e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.7	-0.39	1.6e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg08888203	chr3:10149979	C3orf24	0.7	9.84	0.48	3.31e-20	Alzheimer's disease;
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.42	-5.72	-0.3	2.34e-8	Prudent dietary pattern;
CRC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06544989	chr22:39130855	UNC84B	0.44	6.8	0.35	4.85e-11	Menopause (age at onset);
CRC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.41	-0.5	4.13e-22	Breast cancer;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04578738	chr17:34136331	TAF15	0.5	7.29	0.37	2.27e-12	Response to antipsychotic treatment;
CRC	cis	rs4664293	0.647	rs918969	chr2:160466656	C/T	cg08347373	chr2:160653686	CD302	0.39	6.6	0.34	1.67e-10	Monocyte percentage of white cells;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg06470822	chr6:28175283	NA	0.77	10.33	0.49	7.34e-22	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21629349	chr11:60691880	TMEM132A	0.39	6.54	0.34	2.4e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4233802	1.000	rs6761697	chr2:151141735	A/G	cg25300694	chr2:151184358	NA	0.91	7.25	0.37	2.96e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	trans	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg05376469	chr2:102649931	NA	0.38	6.11	0.32	2.86e-9	Coronary artery disease;
CRC	cis	rs4964805	0.802	rs934847	chr12:104185693	C/T	cg02344784	chr12:104178138	NT5DC3	0.57	8.92	0.44	3.3e-17	Attention deficit hyperactivity disorder;
CRC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg18972013	chr17:78078605	GAA	0.41	6.11	0.32	2.75e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.41	-7.06	-0.36	9.65e-12	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.17	25.32	0.81	3.06e-79	IgG glycosylation;
CRC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.33	1.01e-9	Bladder cancer;
CRC	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg23100626	chr2:96804247	ASTL	0.27	7.02	0.36	1.26e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09428623	chr2:68480128	PPP3R1	0.45	6.3	0.33	9.42e-10	Response to antipsychotic treatment;
CRC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.85	-15.99	-0.66	5.7e-43	Menopause (age at onset);
CRC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg16892393	chr17:41919603	NA	-0.48	-7.27	-0.37	2.64e-12	Triglycerides;
CRC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.82	14.76	0.63	3.5e-38	Vitiligo;
CRC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.9	-0.31	8.81e-9	Life satisfaction;
CRC	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.48	0.34	3.28e-10	Neuroticism;
CRC	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-6.6	-0.34	1.62e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.82	12.64	0.57	4.02e-30	Menarche (age at onset);
CRC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.85	-14.44	-0.62	5.75e-37	Ulcerative colitis;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Depression;
CRC	cis	rs11874712	0.527	rs7359798	chr18:43648999	A/C	cg26436583	chr18:43649176	PSTPIP2	0.36	5.79	0.3	1.68e-8	Migraine - clinic-based;
CRC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg11833968	chr6:79620685	NA	-0.35	-6.15	-0.32	2.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.867	rs7893241	chr10:81954338	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-7.66	-0.39	2.1e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4654899	0.897	rs611658	chr1:21089133	T/G	cg02927042	chr1:21476669	EIF4G3	-0.42	-6.63	-0.34	1.34e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.64	-9.51	-0.46	4.16e-19	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-12.09	-0.55	4.31e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs4728142	0.604	rs6467222	chr7:128674419	T/C	cg06630958	chr7:128577819	IRF5	-0.35	-5.74	-0.3	2.14e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.52	10.01	0.48	8.96e-21	Urate levels in lean individuals;
CRC	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.54	7.75	0.39	1.14e-13	White matter hyperintensity burden;
CRC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg16892393	chr17:41919603	NA	0.6	8.63	0.43	2.61e-16	Triglycerides;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg02683197	chr6:28174875	NA	0.61	8.31	0.42	2.52e-15	Parkinson's disease;
CRC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.42	6.55	0.34	2.19e-10	Neurofibrillary tangles;
CRC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-6.28	-0.33	1.06e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	10.43	0.5	3.35e-22	Lymphocyte counts;
CRC	cis	rs7172809	0.643	rs80347838	chr15:77841783	A/G	cg10437265	chr15:77819839	NA	-0.35	-5.86	-0.31	1.13e-8	Glucose homeostasis traits;
CRC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.52	8.01	0.4	2.07e-14	Sudden cardiac arrest;
CRC	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg13385794	chr1:248469461	NA	0.38	6.69	0.35	9.77e-11	Common traits (Other);
CRC	cis	rs6585424	1.000	rs12411386	chr10:81926231	T/A	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4750440	0.637	rs2447010	chr10:14032115	T/C	cg04819048	chr10:14014548	FRMD4A	0.37	6.11	0.32	2.89e-9	Adiponectin levels;
CRC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.7	7.84	0.4	6.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.47	6.82	0.35	4.38e-11	Primary sclerosing cholangitis;
CRC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg05562828	chr17:3906858	NA	-0.65	-11.66	-0.54	1.51e-26	Type 2 diabetes;
CRC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.96	-16.68	-0.68	1.1e-45	Headache;
CRC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg25767906	chr1:53392781	SCP2	0.37	5.86	0.31	1.13e-8	Monocyte count;
CRC	trans	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg24562669	chr7:97807699	LMTK2	0.44	7.28	0.37	2.53e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18912574	chr7:65842487	NCRNA00174	0.33	5.64	0.3	3.58e-8	Aortic root size;
CRC	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.68	-7.82	-0.4	7.11e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.61	-7.6	-0.39	3.07e-13	Body mass index;
CRC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs3736485	0.903	rs4545756	chr15:51877790	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.96	11.34	0.53	2.22e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17065868	1.000	rs9525985	chr13:45167390	C/G	cg10246903	chr13:45222710	NA	0.53	5.95	0.31	6.84e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	6.43	0.33	4.58e-10	Monocyte percentage of white cells;
CRC	cis	rs4728302	0.869	rs13228262	chr7:133598288	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.5	-0.34	2.97e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.6	10.68	0.51	4.65e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.52	-8.06	-0.41	1.46e-14	Coronary artery disease;
CRC	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg25482853	chr8:67687455	SGK3	0.76	9.32	0.46	1.7e-18	Obesity-related traits;
CRC	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.54	0.38	4.56e-13	Height;
CRC	cis	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg11143507	chr3:125485238	NA	-0.58	-7.46	-0.38	7.69e-13	Blood pressure (smoking interaction);
CRC	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.5	7.76	0.39	1.08e-13	Red blood cell count;
CRC	cis	rs12900413	0.959	rs28430604	chr15:90313782	C/T	cg24249390	chr15:90295951	MESP1	-0.6	-9.03	-0.45	1.51e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs6076065	0.723	rs2224074	chr20:23360171	G/C	cg11657817	chr20:23433608	CST11	0.47	6.85	0.35	3.74e-11	Facial morphology (factor 15, philtrum width);
CRC	trans	rs498079	0.544	rs509904	chr6:133517082	A/T	cg19727641	chr3:138067606	MRAS	-0.51	-6.27	-0.33	1.14e-9	Total body bone mineral density;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg26608667	chr7:1196370	ZFAND2A	0.39	6.11	0.32	2.76e-9	Longevity;Endometriosis;
CRC	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.71	-0.35	8.58e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg17321639	chr7:2759063	NA	-0.38	-5.74	-0.3	2.16e-8	Height;
CRC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.71	12.29	0.56	8.27e-29	Gout;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg18653534	chr16:772142	FAM173A	-0.37	-5.89	-0.31	9.6e-9	Height;
CRC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.11	-0.32	2.85e-9	Total body bone mineral density;
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg19223190	chr17:80058835	NA	0.38	6.17	0.32	2e-9	Life satisfaction;
CRC	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg04969067	chr8:143858791	LYNX1	-0.35	-5.92	-0.31	8.2e-9	Urinary tract infection frequency;
CRC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.72	12.59	0.57	6.15e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs3018066	0.666	rs10084928	chr4:107050979	T/C	cg01869342	chr4:106983673	TBCK	0.44	5.79	0.3	1.69e-8	Cancer;
CRC	cis	rs7605827	0.930	rs3805105	chr2:15535312	T/A	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg17633681	chr16:88106987	BANP	0.86	16.03	0.66	3.74e-43	Menopause (age at onset);
CRC	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	trans	rs72991	0.639	rs10750187	chr11:121230225	A/G	cg27192990	chr6:129479024	LAMA2	-0.42	-6.14	-0.32	2.44e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.28e-20	Ileal carcinoids;
CRC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg18806716	chr10:30721971	MAP3K8	-0.49	-6.98	-0.36	1.65e-11	Inflammatory bowel disease;
CRC	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.61	13.39	0.59	6.4e-33	Airflow obstruction;
CRC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.42	9.31	0.46	1.91e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg12273811	chr6:28175739	NA	0.58	6.06	0.32	3.72e-9	Lung cancer in ever smokers;
CRC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	6.65	0.34	1.19e-10	Systolic blood pressure;
CRC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.78	-11.39	-0.53	1.43e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.54	6.2	0.32	1.68e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	0.77	8.59	0.43	3.61e-16	Gout;Renal underexcretion gout;
CRC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-12.2	-0.56	1.72e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.29	-0.53	3.37e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.82	12.49	0.57	1.43e-29	Cognitive function;
CRC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-10.94	-0.52	5.99e-24	Hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08127348	chr19:17448311	GTPBP3	0.46	6.44	0.33	4.25e-10	Response to antipsychotic treatment;
CRC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.71	7.04	0.36	1.09e-11	Fat distribution (HIV);
CRC	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg09654669	chr8:57350985	NA	-0.4	-5.68	-0.3	2.99e-8	Obesity-related traits;
CRC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.65	8.93	0.44	3.15e-17	Alcohol dependence;
CRC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.82	-13.73	-0.6	3.09e-34	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.71	-0.3	2.56e-8	Life satisfaction;
CRC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg05044414	chr3:183734942	ABCC5	0.44	7.76	0.39	1.06e-13	Anterior chamber depth;
CRC	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.36	0.38	1.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.43	6.78	0.35	5.65e-11	High light scatter reticulocyte count;
CRC	cis	rs4845875	0.626	rs4845882	chr1:11843167	A/G	cg02448276	chr1:11845238	NA	0.36	5.65	0.3	3.47e-8	Midregional pro atrial natriuretic peptide levels;
CRC	cis	rs7113874	0.524	rs10769925	chr11:8623585	C/T	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2257205	0.667	rs28605629	chr17:56906157	C/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.85	-0.31	1.2e-8	Pancreatic cancer;
CRC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg04553112	chr3:125709451	NA	-0.53	-6.09	-0.32	3.2e-9	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.83	9.42	0.46	8.22e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.34	-0.42	2.05e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg06632207	chr12:54070931	ATP5G2	-0.38	-6.57	-0.34	1.96e-10	Height;
CRC	trans	rs1325598	0.935	rs1014719	chr1:176802766	G/T	cg03992096	chr13:114928177	NA	-0.38	-6.03	-0.32	4.51e-9	Height;
CRC	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.39	0.33	5.75e-10	Morning vs. evening chronotype;
CRC	cis	rs6545883	0.525	rs1621048	chr2:61364216	C/G	cg10580144	chr2:61372316	C2orf74	-0.28	-5.66	-0.3	3.36e-8	Tuberculosis;
CRC	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.68	11.33	0.53	2.39e-25	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg15192750	chr16:69999425	NA	-0.55	-7.27	-0.37	2.58e-12	IgE levels;
CRC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg25173405	chr17:45401733	C17orf57	0.48	7.61	0.39	2.96e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg00947319	chr17:47005597	UBE2Z	-0.35	-5.88	-0.31	9.86e-9	Type 2 diabetes;
CRC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14895029	chr7:2775587	GNA12	-0.45	-6.49	-0.34	3.09e-10	Height;
CRC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg15445000	chr17:37608096	MED1	-0.35	-6.12	-0.32	2.59e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6694672	0.867	rs571106	chr1:197256688	G/T	cg13682187	chr1:196946512	CFHR5	0.5	7.05	0.36	1.05e-11	Asthma;
CRC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg04731861	chr2:219085781	ARPC2	0.32	6.33	0.33	7.9e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg03013999	chr17:37608204	MED1	-0.45	-6.33	-0.33	8e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.82	0.58	8.55e-31	Prudent dietary pattern;
CRC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.48	6.44	0.33	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg11166453	chr1:247681781	NA	0.44	6.89	0.36	2.8e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.48	-0.34	3.32e-10	Daytime sleep phenotypes;
CRC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.74	0.43	1.22e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11098699	0.821	rs7665722	chr4:124201501	A/G	cg09941581	chr4:124220074	SPATA5	0.41	6.05	0.32	3.91e-9	Mosquito bite size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15008879	chr10:22292810	DNAJC1	-0.52	-6.45	-0.34	4.02e-10	Diisocyanate-induced asthma;
CRC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.48	8.02	0.4	1.82e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs863345	0.604	rs2873595	chr1:158508382	G/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	6.06	0.32	3.69e-9	Metabolite levels;
CRC	cis	rs526821	0.595	rs485555	chr11:55323570	A/G	cg04317927	chr11:55418816	OR4S2	-0.39	-6.67	-0.35	1.05e-10	Pediatric bone mineral density (spine);
CRC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.5	-8.15	-0.41	7.8e-15	Height;
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02290350	chr8:58132656	NA	-0.52	-5.68	-0.3	2.89e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.77	10.27	0.49	1.24e-21	Vitiligo;
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg08200770	chr17:80723486	TBCD	-0.41	-7.04	-0.36	1.09e-11	Glycated hemoglobin levels;
CRC	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg09184832	chr6:79620586	NA	-0.43	-7.27	-0.37	2.68e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.78	0.47	5.51e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24616553	chr3:113557638	GRAMD1C	0.38	6.17	0.32	2.06e-9	Obesity-related traits;
CRC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg14541582	chr5:601475	NA	-0.33	-6.59	-0.34	1.8e-10	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03705947	chr1:68152081	GADD45A	-0.54	-6.7	-0.35	9.2e-11	Diisocyanate-induced asthma;
CRC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg23758597	chr6:163146217	PARK2	-0.67	-6.96	-0.36	1.88e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg06238570	chr21:40685208	BRWD1	-0.46	-5.89	-0.31	9.5e-9	Menarche (age at onset);
CRC	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.74	-0.3	2.1e-8	Axial length;
CRC	cis	rs6445967	1.000	rs6445967	chr3:58282576	T/C	cg23715586	chr3:58305044	RPP14	0.36	5.94	0.31	7.17e-9	Platelet count;
CRC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.98	-0.44	2.17e-17	Alcohol dependence;
CRC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	14.57	0.63	1.94e-37	Smoking behavior;
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.63	10.64	0.51	6.32e-23	Prudent dietary pattern;
CRC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.83	0.68	2.65e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-7.39	-0.38	1.24e-12	Eye color traits;
CRC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-10.93	-0.52	6.14e-24	Colorectal cancer;
CRC	cis	rs12760731	0.920	rs12076608	chr1:178487861	C/G	cg00404053	chr1:178313656	RASAL2	0.69	7.72	0.39	1.45e-13	Obesity-related traits;
CRC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg19682013	chr15:45996608	NA	0.35	7.17	0.37	5.09e-12	Waist circumference;Weight;
CRC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13795627	chr1:157015873	ARHGEF11	-0.39	-6.14	-0.32	2.43e-9	Myopia (pathological);
CRC	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg12458913	chr13:53173898	NA	0.46	6.77	0.35	5.99e-11	Lewy body disease;
CRC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg10978503	chr1:24200527	CNR2	0.44	7.43	0.38	9.38e-13	Immature fraction of reticulocytes;
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.4	6.98	0.36	1.59e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg12311346	chr5:56204834	C5orf35	-0.45	-6.78	-0.35	5.5e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	11.88	0.55	2.53e-27	Schizophrenia;
CRC	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg01339444	chr6:118972232	C6orf204	0.54	6.01	0.31	4.89e-9	Diastolic blood pressure;
CRC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.64e-13	Diabetic retinopathy;
CRC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.6	8.7	0.43	1.67e-16	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25577272	chr5:54603267	SKIV2L2;DHX29	0.45	6.16	0.32	2.14e-9	Response to antipsychotic treatment;
CRC	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-6.52	-0.34	2.71e-10	Height;
CRC	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.36	-5.78	-0.3	1.75e-8	Mean corpuscular hemoglobin;
CRC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.52	-8.32	-0.42	2.4e-15	Type 2 diabetes;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg11843238	chr5:131593191	PDLIM4	0.43	7.34	0.37	1.73e-12	Blood metabolite levels;
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.22	0.53	6e-25	Prudent dietary pattern;
CRC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg03233332	chr7:66118400	NA	-0.44	-6.21	-0.32	1.62e-9	Aortic root size;
CRC	cis	rs524281	0.861	rs10896081	chr11:65880354	A/T	cg16950941	chr11:66035639	RAB1B	-0.59	-7.34	-0.37	1.72e-12	Electroencephalogram traits;
CRC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.01	0.45	1.66e-17	Lung cancer;
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.37	-0.33	6.41e-10	Breast cancer;
CRC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.63	8.48	0.42	7.48e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.38e-30	Bone mineral density;
CRC	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-6.61	-0.34	1.57e-10	Coronary artery disease;
CRC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	8.93	0.44	2.99e-17	Schizophrenia;
CRC	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg01312482	chr5:178451176	ZNF879	-0.37	-6.13	-0.32	2.55e-9	Pubertal anthropometrics;
CRC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.41	6.38	0.33	6e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg15711740	chr2:61764176	XPO1	-0.5	-6.84	-0.35	3.92e-11	Tuberculosis;
CRC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.8	-9.78	-0.47	5.44e-20	Initial pursuit acceleration;
CRC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.58	7.92	0.4	3.68e-14	Menopause (age at onset);
CRC	cis	rs12760731	0.720	rs7524556	chr1:178446659	C/T	cg00404053	chr1:178313656	RASAL2	0.87	9.66	0.47	1.31e-19	Obesity-related traits;
CRC	cis	rs501120	0.513	rs1680639	chr10:44701754	T/G	cg09554077	chr10:44749378	NA	0.67	7.47	0.38	7.27e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.55	8.85	0.44	5.5e-17	Prostate cancer;
CRC	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.62	9.26	0.45	2.68e-18	Lewy body disease;
CRC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.79	12.85	0.58	6.72e-31	Cognitive function;
CRC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.41	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	0.99	11.54	0.54	4.33e-26	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16410656	chr11:35965504	LDLRAD3	0.39	6.51	0.34	2.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.3	1.5e-8	Metabolite levels;
CRC	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.34	-0.38	1.66e-12	Retinal vascular caliber;
CRC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.4	-5.73	-0.3	2.28e-8	Daytime sleep phenotypes;
CRC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg04450456	chr4:17643702	FAM184B	0.41	6.7	0.35	8.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11343086	chr1:202113710	ARL8A	0.43	6.09	0.32	3.21e-9	Response to antipsychotic treatment;
CRC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg18099408	chr3:52552593	STAB1	0.35	6.04	0.32	4.21e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg12856521	chr11:46389249	DGKZ	-0.43	-6.87	-0.35	3.31e-11	Leprosy;
CRC	trans	rs2303319	0.504	rs16846026	chr2:162537691	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.16	-0.32	2.13e-9	Cognitive function;
CRC	cis	rs9287719	0.649	rs10929677	chr2:10717548	A/G	cg00105475	chr2:10696890	NA	0.45	7.07	0.36	9.39e-12	Prostate cancer;
CRC	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg09659197	chr4:152720779	NA	0.52	11.34	0.53	2.16e-25	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg27635394	chr6:26043820	HIST1H2BB	0.42	6.13	0.32	2.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.16	-0.37	5.39e-12	Body mass index;
CRC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.3	-0.33	9.71e-10	Mean corpuscular volume;
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.47	6.88	0.35	3.07e-11	Menarche (age at onset);
CRC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21643547	chr1:205240462	TMCC2	-0.43	-6.94	-0.36	2.08e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.56	8.04	0.41	1.63e-14	Resting heart rate;
CRC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.56	10.13	0.49	3.55e-21	HDL cholesterol levels;
CRC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg13047869	chr3:10149882	C3orf24	0.38	5.81	0.31	1.48e-8	Alzheimer's disease;
CRC	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.38	6.01	0.31	4.98e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg00933542	chr6:150070202	PCMT1	0.32	6.44	0.33	4.28e-10	Lung cancer;
CRC	trans	rs28643277	0.671	rs7070136	chr10:15555388	A/G	cg18315834	chr14:64909119	MTHFD1	0.42	6.06	0.32	3.67e-9	Periodontitis (CDC/AAP);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14885145	chr10:104262292	SUFU;ACTR1A	0.42	6.42	0.33	4.84e-10	Myopia (pathological);
CRC	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.53	-0.71	5.39e-53	Schizophrenia;
CRC	cis	rs2857891	0.695	rs2248438	chr11:6985062	G/C	cg04053776	chr11:6947353	ZNF215	0.4	6.24	0.33	1.33e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.86	-0.35	3.46e-11	IgG glycosylation;
CRC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.53	-0.34	2.45e-10	Renal cell carcinoma;
CRC	trans	rs2303319	0.504	rs72873624	chr2:162481453	G/A	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.43e-9	Cognitive function;
CRC	cis	rs6076065	0.723	rs2253925	chr20:23388021	C/G	cg11657817	chr20:23433608	CST11	0.44	6.38	0.33	5.85e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-1.13	-17.65	-0.7	1.58e-49	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg03938978	chr2:103052716	IL18RAP	0.42	6.67	0.35	1.06e-10	Blood protein levels;
CRC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.74	11.54	0.54	4.25e-26	Breast cancer;
CRC	cis	rs73206853	0.688	rs60971459	chr12:110702051	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	7.72	0.39	1.39e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.96	-0.48	1.35e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.75	-0.51	2.74e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg25985355	chr7:65971099	NA	0.51	5.79	0.3	1.6e-8	Diabetic kidney disease;
CRC	trans	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-9.62	-0.47	1.81e-19	Monocyte count;
CRC	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-5.94	-0.31	7.43e-9	Coronary artery disease;
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.83	13.16	0.59	4.52e-32	Menarche (age at onset);
CRC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.61	8.9	0.44	3.84e-17	Coronary artery disease;
CRC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg12273811	chr6:28175739	NA	0.57	5.75	0.3	2.08e-8	Depression;
CRC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.71	-0.3	2.51e-8	Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22684426	chr12:49351253	ARF3	-0.43	-6.75	-0.35	6.56e-11	Myopia (pathological);
CRC	cis	rs12760731	0.720	rs10913544	chr1:178350980	C/T	cg00404053	chr1:178313656	RASAL2	0.86	8.8	0.44	7.6e-17	Obesity-related traits;
CRC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-10.71	-0.51	3.62e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.82	-0.4	7.45e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg23161317	chr6:28129485	ZNF389	0.45	6.47	0.34	3.55e-10	Cardiac Troponin-T levels;
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg04871131	chr7:94954202	PON1	-0.46	-5.61	-0.3	4.36e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12143943	0.834	rs10900598	chr1:204525568	G/T	cg17419461	chr1:204415978	PIK3C2B	0.4	6.31	0.33	8.87e-10	Cognitive performance;
CRC	cis	rs2179367	0.959	rs514839	chr6:149648440	A/T	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.0	-0.31	5.26e-9	Dupuytren's disease;
CRC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.62	0.43	2.85e-16	Mean corpuscular volume;
CRC	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.9	-0.63	9.49e-39	Exhaled nitric oxide output;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26436829	chr16:86588937	MTHFSD;FLJ30679	0.41	6.06	0.32	3.81e-9	Response to antipsychotic treatment;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	ch.8.34907260F	chr8:34787718	NA	-0.43	-6.15	-0.32	2.26e-9	Underweight status;
CRC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.0	15.67	0.65	1.02e-41	Cognitive function;
CRC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.55	5.62	0.3	3.98e-8	Blood protein levels;
CRC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.25	0.45	2.95e-18	Personality dimensions;
CRC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg11204139	chr17:3907470	NA	0.53	6.77	0.35	5.76e-11	Type 2 diabetes;
CRC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.54	-8.68	-0.43	1.88e-16	Neurofibrillary tangles;
CRC	cis	rs4728302	0.869	rs889826	chr7:133595871	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.79	0.3	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.81	-12.46	-0.57	1.85e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	6.81	0.35	4.58e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.38	7.23	0.37	3.35e-12	Tonsillectomy;
CRC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-8.44	-0.42	1.02e-15	Self-reported allergy;
CRC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.6	6.72	0.35	8.11e-11	Lymphocyte counts;
CRC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.61	0.34	1.58e-10	Schizophrenia;
CRC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.95	-0.52	5.49e-24	Chronic sinus infection;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24341220	chr2:85581729	RETSAT;ELMOD3	0.42	6.0	0.31	5.17e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18047794	chr19:55770732	SAPS1	0.44	6.08	0.32	3.25e-9	Response to antipsychotic treatment;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg12172441	chr6:28176163	NA	0.44	6.39	0.33	5.72e-10	Cardiac Troponin-T levels;
CRC	trans	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.52	-0.34	2.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.86e-12	Prostate cancer;
CRC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.32	-6.12	-0.32	2.66e-9	Longevity;Endometriosis;
CRC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.66	-8.59	-0.43	3.56e-16	Gut microbiome composition (summer);
CRC	cis	rs2652834	1.000	rs7181141	chr15:63398552	A/G	cg05507819	chr15:63340323	TPM1	0.47	5.98	0.31	5.87e-9	HDL cholesterol;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.34	-0.33	7.73e-10	Cognitive function;
CRC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.62	-11.75	-0.54	7.66e-27	Educational attainment;
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-9.1	-0.45	8.97e-18	Bipolar disorder;
CRC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	0.65	7.07	0.36	9.51e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	10.0	0.48	9.56e-21	Ileal carcinoids;
CRC	cis	rs10971721	0.822	rs72727340	chr9:33936734	T/C	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	trans	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg25214090	chr10:38739885	LOC399744	0.4	6.28	0.33	1.08e-9	Diastolic blood pressure;
CRC	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg18753928	chr3:113234510	CCDC52	-0.49	-7.79	-0.39	8.81e-14	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.69	9.34	0.46	1.45e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg02033258	chr5:131593261	PDLIM4	-0.39	-6.58	-0.34	1.89e-10	Blood metabolite levels;
CRC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	0.87	9.32	0.46	1.8e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.37	5.88	0.31	9.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg05925327	chr15:68127851	NA	-0.3	-5.74	-0.3	2.14e-8	Restless legs syndrome;
CRC	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.75	-0.35	6.88e-11	Total body bone mineral density;
CRC	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg06632207	chr12:54070931	ATP5G2	0.5	8.73	0.43	1.33e-16	Height;
CRC	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.44	-7.15	-0.37	5.54e-12	Refractive error;
CRC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.81e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.55	10.41	0.5	3.84e-22	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg25251562	chr2:3704773	ALLC	-0.49	-6.16	-0.32	2.09e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.29	0.33	1.04e-9	Aortic root size;
CRC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.75	-0.51	2.71e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12889267	0.551	rs12432623	chr14:21588779	G/T	cg02988727	chr14:21567520	ZNF219;C14orf176	-0.46	-6.18	-0.32	1.94e-9	Hematocrit;Resting heart rate;
CRC	cis	rs7705042	0.865	rs6882226	chr5:141503870	T/A	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.83	-0.31	1.31e-8	Asthma;
CRC	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg16095767	chr12:122110467	NA	0.38	6.11	0.32	2.86e-9	Myopia;
CRC	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	0.69	11.08	0.52	1.91e-24	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs7605827	0.893	rs7572131	chr2:15691886	G/A	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg14036092	chr11:66035641	RAB1B	-0.47	-5.7	-0.3	2.6e-8	Electroencephalogram traits;
CRC	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg23425280	chr12:56401806	NA	0.48	5.87	0.31	1.07e-8	Contrast sensitivity;
CRC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.56	7.94	0.4	3.3e-14	Homoarginine levels;
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg17178900	chr1:205818956	PM20D1	0.45	6.49	0.34	3.08e-10	Menarche (age at onset);
CRC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.96	-0.4	2.78e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.62	9.6	0.47	2.15e-19	Longevity;Endometriosis;
CRC	cis	rs11212617	0.967	rs227053	chr11:108226855	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.11	0.32	2.8e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg00531865	chr16:30841666	NA	0.47	6.59	0.34	1.75e-10	Dementia with Lewy bodies;
CRC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.55	-8.15	-0.41	7.87e-15	Coronary artery disease;
CRC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg22563815	chr15:78856949	CHRNA5	0.31	5.7	0.3	2.63e-8	Sudden cardiac arrest;
CRC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.8	-12.76	-0.58	1.42e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26480543	chr19:55629279	PPP1R12C	0.46	6.73	0.35	7.56e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24308560	chr3:49941425	MST1R	-0.44	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg11843238	chr5:131593191	PDLIM4	0.32	5.79	0.3	1.63e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs6743376	0.556	rs1530548	chr2:113817402	G/A	cg24553058	chr2:113831203	IL1F10	0.43	6.97	0.36	1.69e-11	Inflammatory biomarkers;
CRC	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg04611788	chr3:186434169	KNG1	-0.58	-8.36	-0.42	1.79e-15	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08652404	chr7:99098009	ZNF394	0.44	6.41	0.33	5.12e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.57	-8.94	-0.44	2.92e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.6	-8.59	-0.43	3.44e-16	Coronary artery disease;
CRC	cis	rs7264396	0.943	rs11167267	chr20:34109273	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.66	-0.34	1.16e-10	Total cholesterol levels;
CRC	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.42	-6.3	-0.33	9.7e-10	IFN-related cytopenia;
CRC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.51	8.76	0.43	1.07e-16	Aortic root size;
CRC	trans	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg18404041	chr3:52824283	ITIH1	0.33	6.6	0.34	1.66e-10	Schizophrenia;
CRC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg01658259	chr14:24837143	NFATC4	0.5	6.73	0.35	7.66e-11	Height;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg19041857	chr6:27730383	NA	-0.44	-6.06	-0.32	3.81e-9	Parkinson's disease;
CRC	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs12580194	0.593	rs7959837	chr12:55734511	G/A	cg23425280	chr12:56401806	NA	0.52	6.36	0.33	6.8e-10	Cancer;
CRC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg20203395	chr5:56204925	C5orf35	-0.67	-7.99	-0.4	2.23e-14	Initial pursuit acceleration;
CRC	cis	rs3736594	0.546	rs6734059	chr2:27808154	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-8.15	-0.41	7.9e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg05639522	chr1:247681581	NA	0.46	6.98	0.36	1.68e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg02927042	chr1:21476669	EIF4G3	-0.46	-6.92	-0.36	2.41e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs357618	1.000	rs165351	chr5:150854881	C/T	cg03212797	chr5:150827313	SLC36A1	-0.37	-5.62	-0.3	4.01e-8	Basophil percentage of white cells;
CRC	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.92	-11.51	-0.54	5.56e-26	Exhaled nitric oxide output;
CRC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.65	6.79	0.35	5.15e-11	Axial length;
CRC	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg15131784	chr3:139108705	COPB2	0.41	6.07	0.32	3.43e-9	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs6968419	0.755	rs3823977	chr7:115893407	A/T	cg02561103	chr7:115862891	TES	-0.43	-6.53	-0.34	2.54e-10	Intraocular pressure;
CRC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg23107878	chr1:152161397	NA	0.42	6.2	0.32	1.7e-9	Inflammatory skin disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22713345	chr19:8070804	ELAVL1	0.46	6.14	0.32	2.35e-9	Anxiety disorder;
CRC	cis	rs3849570	0.643	rs9870954	chr3:81978850	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-6.57	-0.34	1.94e-10	Waist circumference;Body mass index;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg24634471	chr8:143751801	JRK	-0.45	-6.4	-0.33	5.28e-10	Urinary tract infection frequency;
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.69	0.51	4.34e-23	Alzheimer's disease;
CRC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.34e-40	Prostate cancer;
CRC	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg09873164	chr1:152488093	CRCT1	0.37	6.13	0.32	2.45e-9	Hair morphology;
CRC	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg23254163	chr1:152506842	NA	0.5	10.06	0.49	5.98e-21	Hair morphology;
CRC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.46	7.51	0.38	5.78e-13	Personality dimensions;
CRC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	12.02	0.55	7.68e-28	Chronic sinus infection;
CRC	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.74	11.73	0.54	8.89e-27	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.35	5.73	0.3	2.23e-8	Hemoglobin concentration;
CRC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.11	-0.41	9.98e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs13315871	0.929	rs9842917	chr3:58244800	C/T	cg20936604	chr3:58311152	NA	-0.67	-6.82	-0.35	4.3e-11	Cholesterol, total;
CRC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg14558114	chr2:88469736	THNSL2	0.58	5.79	0.3	1.64e-8	Plasma clusterin levels;
CRC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.38	5.93	0.31	7.85e-9	Height;
CRC	cis	rs3767633	0.925	rs2134696	chr1:161781200	A/T	cg09175582	chr1:161736000	ATF6	-0.62	-5.95	-0.31	6.76e-9	IgG glycosylation;
CRC	trans	rs701145	0.556	rs355758	chr3:154007682	C/G	cg22545385	chr10:131989303	NA	0.42	6.13	0.32	2.55e-9	Coronary artery disease;
CRC	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg19338460	chr6:170058176	WDR27	-0.76	-8.29	-0.42	2.95e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.39	-5.82	-0.31	1.38e-8	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg20041105	chr8:143859282	LYNX1	0.46	8.24	0.41	4.25e-15	Urinary tract infection frequency;
CRC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.68	-11.84	-0.55	3.49e-27	Resting heart rate;
CRC	cis	rs6496667	0.865	rs7163230	chr15:90884621	T/C	cg04176472	chr15:90893244	GABARAPL3	0.56	6.42	0.33	4.72e-10	Rheumatoid arthritis;
CRC	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.7	7.98	0.4	2.51e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10450586	0.863	rs7123838	chr11:27303826	C/T	cg10370305	chr11:27303972	NA	0.4	6.47	0.34	3.45e-10	Total body bone mineral density;
CRC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.69	10.83	0.51	1.36e-23	Intelligence (multi-trait analysis);
CRC	cis	rs9549328	0.589	rs34144481	chr13:113617322	T/G	cg08614441	chr13:113633676	MCF2L	0.4	7.06	0.36	1e-11	Systolic blood pressure;
CRC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.13e-13	Motion sickness;
CRC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.6	-8.72	-0.43	1.4e-16	Longevity;
CRC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.43	0.46	7.57e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.39	7.54	0.38	4.64e-13	Mean corpuscular volume;
CRC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00166722	chr3:10149974	C3orf24	0.45	6.83	0.35	4.21e-11	Alzheimer's disease;
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg04969067	chr8:143858791	LYNX1	0.44	7.49	0.38	6.29e-13	Urinary tract infection frequency;
CRC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	0.99	14.12	0.61	1.01e-35	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08245420	chr5:139726438	HBEGF	0.42	6.09	0.32	3.16e-9	Intelligence (multi-trait analysis);
CRC	trans	rs991639	0.697	rs13085229	chr3:94802	A/G	cg08213608	chr4:3748254	NA	0.51	6.25	0.33	1.26e-9	Problematic alcohol use in trauma-exposed individuals;
CRC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07701084	chr6:150067640	NUP43	0.42	6.08	0.32	3.3e-9	Testicular germ cell tumor;
CRC	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg08632701	chr21:37451849	NA	-0.45	-7.15	-0.37	5.77e-12	Mitral valve prolapse;
CRC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg00310523	chr12:86230176	RASSF9	0.44	7.48	0.38	7.04e-13	Major depressive disorder;
CRC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05834845	chr3:195489306	MUC4	0.67	7.37	0.38	1.43e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.45	5.85	0.31	1.19e-8	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	0.92	11.35	0.53	2.01e-25	Height;
CRC	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.51	-6.04	-0.32	4.26e-9	Obesity-related traits;
CRC	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg06042504	chr8:55087323	NA	-0.43	-6.75	-0.35	6.83e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06462663	chr19:18546047	ISYNA1	0.46	7.07	0.36	9.28e-12	Breast cancer;
CRC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.54	10.03	0.48	7.93e-21	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.45	10.63	0.51	6.99e-23	Temperament;
CRC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.61	-9.06	-0.45	1.18e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14831266	chr1:33283905	YARS;S100PBP	0.46	6.42	0.33	4.84e-10	Response to antipsychotic treatment;
CRC	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.37	5.94	0.31	7.21e-9	Height;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23784313	chr12:15942613	EPS8	-0.4	-6.48	-0.34	3.37e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	ch.1.64660926R	chr1:64888338	NA	0.47	7.42	0.38	1.01e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.8	-10.16	-0.49	2.83e-21	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07892339	chr1:156721493	HDGF	0.46	6.82	0.35	4.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.56	-0.34	2.05e-10	Type 2 diabetes;
CRC	cis	rs6662572	0.686	rs72690855	chr1:46266210	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.91	0.31	8.39e-9	Blood protein levels;
CRC	cis	rs11679072	1.000	rs6741183	chr2:240448959	A/G	cg03276489	chr2:240449683	NA	-0.84	-8.79	-0.44	8.4e-17	Blood pressure (smoking interaction);
CRC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.36	-5.88	-0.31	9.94e-9	Red cell distribution width;
CRC	trans	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.54	-0.34	2.39e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	6.04	0.32	4.25e-9	Tonsillectomy;
CRC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.57	9.03	0.45	1.44e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.48	-6.51	-0.34	2.82e-10	Metabolite levels;
CRC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.77	0.47	5.8e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	11.03	0.52	2.76e-24	Body mass index (adult);
CRC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.66	8.09	0.41	1.14e-14	Menarche (age at onset);
CRC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg02527881	chr3:46936655	PTH1R	0.37	6.75	0.35	6.76e-11	Colorectal cancer;
CRC	cis	rs4750440	0.702	rs7918501	chr10:14029895	C/T	cg00551146	chr10:14014579	FRMD4A	0.36	5.85	0.31	1.21e-8	Adiponectin levels;
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg24046110	chr8:143859143	LYNX1	0.46	8.11	0.41	9.8e-15	Urinary tract infection frequency;
CRC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg01721255	chr8:58191610	C8orf71	0.47	6.02	0.31	4.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	5.74	0.3	2.18e-8	Electroencephalogram traits;
CRC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.34	-5.66	-0.3	3.3e-8	Personality dimensions;
CRC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.73	-11.84	-0.55	3.64e-27	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8105895	0.935	rs10412953	chr19:22238482	C/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs4731207	0.698	rs10233306	chr7:124498417	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.67	0.3	3.16e-8	Putamen volume;
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2179367	0.959	rs562428	chr6:149647525	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.06	-0.32	3.65e-9	Dupuytren's disease;
CRC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg24675056	chr1:15929824	NA	0.52	7.27	0.37	2.64e-12	Systolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06893123	chr16:3185027	ZNF213	0.45	5.97	0.31	6.2e-9	Anxiety disorder;
CRC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.66	10.2	0.49	2.08e-21	Hemoglobin concentration;
CRC	trans	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06834434	chr14:75079333	LTBP2	0.55	6.62	0.34	1.47e-10	Obesity-related traits;
CRC	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg25834613	chr7:1915315	MAD1L1	-0.47	-7.38	-0.38	1.3e-12	Bipolar disorder;
CRC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06505273	chr16:24850292	NA	-0.5	-6.4	-0.33	5.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.57	-8.55	-0.43	4.86e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10046574	0.561	rs10226494	chr7:135214412	C/G	cg27474649	chr7:135195673	CNOT4	0.59	5.97	0.31	6.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7626444	0.625	rs843529	chr3:196480595	A/G	cg12930392	chr3:196481615	PAK2	-0.38	-6.88	-0.35	3.05e-11	Monocyte count;
CRC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.54	9.2	0.45	4.28e-18	Coronary artery disease;
CRC	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg03037974	chr15:76606532	NA	-0.5	-7.15	-0.37	5.67e-12	Blood metabolite levels;
CRC	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg24289452	chr6:170231220	NA	-0.6	-6.57	-0.34	2.01e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs28493229	0.708	rs10407650	chr19:41160970	T/C	cg21869046	chr19:41225005	ITPKC	0.41	6.15	0.32	2.26e-9	Kawasaki disease;
CRC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.37	3.53e-12	Blood metabolite levels;
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.63	11.52	0.54	4.85e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.27	-5.75	-0.3	2.09e-8	Educational attainment (years of education);
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.17	-0.32	2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.95	-0.36	2.01e-11	Bipolar disorder;
CRC	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg22013790	chr1:91990662	CDC7	0.42	6.11	0.32	2.79e-9	Eosinophil percentage of white cells;
CRC	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.67	10.24	0.49	1.58e-21	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23475963	chr7:128379258	CALU	0.46	6.46	0.34	3.85e-10	Response to antipsychotic treatment;
CRC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg00603274	chr11:61596626	FADS2	-0.44	-6.4	-0.33	5.33e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg15786705	chr6:28176104	NA	0.58	8.14	0.41	8.31e-15	Parkinson's disease;
CRC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.66	-12.03	-0.55	6.97e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg25838818	chr2:108905173	SULT1C2	-0.35	-5.85	-0.31	1.17e-8	Blood pressure;
CRC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.82	13.53	0.6	1.81e-33	Cognitive function;
CRC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.62	8.97	0.44	2.25e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg17133734	chr15:86042851	AKAP13	0.41	6.45	0.33	4.03e-10	Coronary artery disease;
CRC	cis	rs12826942	0.959	rs34507359	chr12:42736831	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.5	0.38	6.08e-13	Coronary artery disease;
CRC	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg24140574	chr1:16342155	HSPB7	0.47	6.67	0.34	1.12e-10	Dilated cardiomyopathy;
CRC	cis	rs1656402	1.000	rs1729251	chr2:233428518	G/A	cg03852847	chr2:233439513	NA	0.44	7.56	0.38	4.08e-13	Non-small cell lung cancer (survival);
CRC	cis	rs990171	1.000	rs2160232	chr2:103046880	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.41e-8	Lymphocyte counts;
CRC	cis	rs4664293	0.836	rs10190704	chr2:160594962	G/A	cg08347373	chr2:160653686	CD302	-0.46	-7.31	-0.37	2.02e-12	Monocyte percentage of white cells;
CRC	cis	rs3219474	0.614	rs114562368	chr1:45899178	G/A	cg06784218	chr1:46089804	CCDC17	0.64	6.41	0.33	5.15e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg12946690	chr17:2206740	SMG6;SRR	0.57	6.52	0.34	2.66e-10	Body mass index;
CRC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg15226275	chr6:116381976	FRK	0.29	8.35	0.42	1.9e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg10494973	chr17:80897199	TBCD	-0.36	-5.63	-0.3	3.87e-8	Breast cancer;
CRC	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.92	11.59	0.54	2.7e-26	Exhaled nitric oxide levels;
CRC	cis	rs847649	0.699	rs7794668	chr7:102510416	C/T	cg18108683	chr7:102477205	FBXL13	0.63	11.04	0.52	2.5e-24	Morning vs. evening chronotype;
CRC	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg17133734	chr15:86042851	AKAP13	-0.44	-7.13	-0.37	6.5e-12	Coronary artery disease;
CRC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.36	-5.73	-0.3	2.32e-8	Crohn's disease;
CRC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.29	0.33	9.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-7.58	-0.39	3.62e-13	Mean corpuscular volume;
CRC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg02683197	chr6:28174875	NA	0.7	9.74	0.47	7.45e-20	Cardiac Troponin-T levels;
CRC	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.26	-0.33	1.18e-9	Coronary artery disease;
CRC	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.42	6.02	0.31	4.71e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg12365402	chr11:9010492	NRIP3	0.5	8.04	0.41	1.62e-14	Hemoglobin concentration;
CRC	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07252851	chr5:74063056	GFM2;NSA2	0.41	6.53	0.34	2.55e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.28	14.93	0.64	7.56e-39	Diabetic kidney disease;
CRC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.51	8.5	0.42	6.57e-16	Colorectal cancer;
CRC	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.35	-0.38	1.55e-12	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07767672	chr17:1420129	INPP5K;LOC100306951	0.45	6.2	0.32	1.64e-9	Anxiety disorder;
CRC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.56	8.06	0.41	1.43e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg20487152	chr13:99095054	FARP1	-0.44	-6.47	-0.34	3.55e-10	Longevity;
CRC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.15	23.86	0.8	9.57e-74	IgG glycosylation;
CRC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg22331349	chr19:52391350	ZNF577	-0.45	-5.84	-0.31	1.26e-8	Breast cancer;
CRC	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.75	9.94	0.48	1.59e-20	Coronary artery disease;
CRC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-14.97	-0.64	5.28e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg21466736	chr12:48725269	NA	-0.53	-7.88	-0.4	4.71e-14	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg04269497	chr6:167369491	RNASET2	-0.75	-6.05	-0.32	3.91e-9	Cognitive function;
CRC	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.09	-0.32	3.11e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.64	0.3	3.59e-8	Tonsillectomy;
CRC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg24375607	chr4:120327624	NA	0.49	7.58	0.39	3.5e-13	Corneal astigmatism;
CRC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.2	-0.73	1.2e-55	Primary sclerosing cholangitis;
CRC	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg04837898	chr3:45731254	SACM1L	-0.36	-5.87	-0.31	1.09e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs2811415	0.597	rs11708842	chr3:127790625	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.25	6.83	0.35	4.13e-11	Type 2 diabetes;
CRC	cis	rs775227	1.000	rs13094203	chr3:112993367	G/A	cg18753928	chr3:113234510	CCDC52	-0.45	-5.63	-0.3	3.91e-8	Dental caries;
CRC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.77	-0.35	5.88e-11	Type 2 diabetes;
CRC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.71e-20	Eye color traits;
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg02825527	chr7:2087843	MAD1L1	-0.53	-6.02	-0.32	4.62e-9	Bipolar disorder;
CRC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.88	-15.51	-0.65	4.26e-41	Height;
CRC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.69	10.48	0.5	2.36e-22	Corneal astigmatism;
CRC	cis	rs4290604	0.748	rs4663241	chr2:238085960	T/C	cg23555395	chr2:238036564	NA	-0.6	-6.07	-0.32	3.57e-9	Asthma;
CRC	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.59	7.79	0.39	9.04e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	8.48	0.42	7.77e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.37	-6.91	-0.36	2.59e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.49	-7.35	-0.38	1.54e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.79	-0.39	8.84e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.54	6.9	0.36	2.76e-11	Morning vs. evening chronotype;
CRC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	13.32	0.59	1.16e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.5	-5.87	-0.31	1.08e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.68e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.35	0.46	1.41e-18	Vitamin D levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11595794	chr4:186317094	ANKRD37	0.41	6.23	0.32	1.4e-9	Intelligence (multi-trait analysis);
CRC	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg12856521	chr11:46389249	DGKZ	-0.42	-6.8	-0.35	5.03e-11	Leprosy;
CRC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg02527881	chr3:46936655	PTH1R	0.33	5.84	0.31	1.23e-8	Colorectal cancer;
CRC	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.58	0.5	1.03e-22	Coffee consumption (cups per day);
CRC	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.71	-0.47	8.86e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-8.54	-0.43	4.96e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg23102388	chr7:1867652	MAD1L1	-0.32	-5.98	-0.31	5.69e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.61	-11.76	-0.54	6.8e-27	Total body bone mineral density;
CRC	cis	rs2033908	0.620	rs1371753	chr11:12853703	G/A	cg25843174	chr11:12811716	TEAD1	-0.42	-7.49	-0.38	6.56e-13	Sitting height ratio;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.61	8.46	0.42	8.85e-16	Arsenic metabolism;
CRC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg25173405	chr17:45401733	C17orf57	0.47	7.15	0.37	5.6e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-10.29	-0.49	1.07e-21	Breast cancer;
CRC	cis	rs12541635	0.801	rs9642802	chr8:107101364	A/T	cg10147462	chr8:107024639	NA	-0.39	-5.93	-0.31	7.65e-9	Age of smoking initiation;
CRC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.01	9.44	0.46	7.17e-19	Alzheimer's disease (late onset);
CRC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18867708	chr6:26865862	GUSBL1	-0.41	-5.72	-0.3	2.34e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19774699	chr22:31688639	PIK3IP1	0.42	6.23	0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.94	-0.31	7.09e-9	Total body bone mineral density;
CRC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.45	-6.37	-0.33	6.54e-10	Platelet distribution width;
CRC	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.63	-11.81	-0.55	4.37e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.6	-9.34	-0.46	1.49e-18	Aortic root size;
CRC	cis	rs2249625	0.523	rs2496552	chr6:72853042	T/C	cg18830697	chr6:72922368	RIMS1	-0.31	-6.25	-0.33	1.3e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	trans	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg17903999	chr18:56338584	MALT1	0.41	6.64	0.34	1.26e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.8	14.05	0.61	1.92e-35	Breast cancer;
CRC	cis	rs4400599	0.572	rs7516809	chr1:154205501	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.71	-0.3	2.49e-8	Platelet distribution width;
CRC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.97	-0.52	4.45e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06634786	chr22:41940651	POLR3H	-0.47	-6.21	-0.32	1.56e-9	Vitiligo;
CRC	cis	rs2235544	0.579	rs1537323	chr1:54482523	G/T	cg25741118	chr1:54482237	LDLRAD1	0.22	6.29	0.33	1.03e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.19	-0.37	4.36e-12	QT interval;
CRC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-6.84	-0.35	3.84e-11	Schizophrenia;
CRC	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	8.1	0.41	1.11e-14	Adiposity;
CRC	trans	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.28	-0.33	1.05e-9	Mosquito bite size;
CRC	cis	rs2227564	0.729	rs2675674	chr10:75652682	G/A	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.58	-0.39	3.47e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.51	5.76	0.3	1.89e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.59	7.37	0.38	1.38e-12	Alzheimer's disease;
CRC	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg17470449	chr10:769945	NA	0.5	6.97	0.36	1.78e-11	Uric acid levels;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.45	6.31	0.33	9.06e-10	Bipolar disorder;
CRC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.6	8.41	0.42	1.23e-15	Arsenic metabolism;
CRC	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.61	-8.02	-0.4	1.82e-14	Malaria;
CRC	cis	rs995000	0.931	rs11207997	chr1:63061906	C/T	cg19896129	chr1:63156450	NA	0.41	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	0.9	7.84	0.4	6.14e-14	Left atrial antero-posterior diameter;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20573919	chr11:8710810	RPL27A	0.42	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.43	-6.35	-0.33	6.96e-10	Cognitive ability;
CRC	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.3	0.37	2.21e-12	Diisocyanate-induced asthma;
CRC	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg00507830	chr2:103233733	NA	0.52	5.78	0.3	1.7e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs1539053	0.932	rs7544337	chr1:58108645	T/C	cg23710611	chr1:58098908	DAB1	0.35	5.67	0.3	3.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.09	0.36	8.15e-12	Diisocyanate-induced asthma;
CRC	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg11693508	chr17:37793320	STARD3	0.57	6.61	0.34	1.58e-10	Neuroticism;
CRC	cis	rs7259376	1.000	rs11668269	chr19:22513960	G/A	cg02657401	chr19:22469223	NA	-0.39	-8.66	-0.43	2.18e-16	Menopause (age at onset);
CRC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.5	6.76	0.35	6.29e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg20041105	chr8:143859282	LYNX1	-0.71	-13.39	-0.59	6.18e-33	Urinary tract infection frequency;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20505218	chr17:80009845	GPS1;RFNG	0.45	6.55	0.34	2.2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg15786705	chr6:28176104	NA	0.63	6.06	0.32	3.78e-9	Depression;
CRC	cis	rs883565	0.606	rs7650682	chr3:39079418	C/A	cg01426195	chr3:39028469	NA	-0.47	-7.95	-0.4	3.02e-14	Handedness;
CRC	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.48	-7.59	-0.39	3.4e-13	Rheumatoid arthritis;
CRC	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.44	-5.74	-0.3	2.1e-8	Height;
CRC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.41	6.42	0.33	4.67e-10	Hemoglobin concentration;
CRC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg20243544	chr17:37824526	PNMT	0.47	5.6	0.3	4.45e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg09659197	chr4:152720779	NA	0.41	8.5	0.42	6.5e-16	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11928684	chr11:47291227	MADD	0.41	6.19	0.32	1.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.52	0.38	5.35e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.9	-0.36	2.67e-11	Prevalent atrial fibrillation;
CRC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg06470822	chr6:28175283	NA	0.88	9.76	0.47	6.43e-20	Parkinson's disease;
CRC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.6	8.64	0.43	2.54e-16	Response to temozolomide;
CRC	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg23815491	chr16:72088622	HP	0.47	6.83	0.35	4.09e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.39	6.81	0.35	4.54e-11	Lung cancer;
CRC	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.76	8.56	0.43	4.51e-16	Neuroticism;
CRC	cis	rs2982552	0.787	rs11155810	chr6:152056081	T/C	cg22157087	chr6:152012887	ESR1	0.37	5.66	0.3	3.31e-8	Bone properties (heel);
CRC	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.71	0.3	2.49e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11190155	chr3:9975447	CRELD1	0.51	7.31	0.37	2.03e-12	Response to antipsychotic treatment;
CRC	cis	rs73200209	0.703	rs57060349	chr12:116579304	T/C	cg01776926	chr12:116560359	MED13L	-0.63	-7.35	-0.38	1.6e-12	Total body bone mineral density;
CRC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.58	5.79	0.3	1.64e-8	Fat distribution (HIV);
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.56	0.34	2.14e-10	Alzheimer's disease;
CRC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg24308560	chr3:49941425	MST1R	-0.42	-5.99	-0.31	5.64e-9	Resting heart rate;
CRC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-9.67	-0.47	1.24e-19	Height;
CRC	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-8.06	-0.41	1.42e-14	Coronary artery disease;
CRC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg01472538	chr16:58549086	SETD6	1.1	7.19	0.37	4.4e-12	Schizophrenia;
CRC	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.53	8.09	0.41	1.15e-14	Testicular germ cell tumor;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.36	-5.9	-0.31	9.13e-9	Total body bone mineral density;
CRC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg08533674	chr1:46993347	NA	-0.81	-10.42	-0.5	3.8e-22	Monobrow;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.41	6.88	0.35	3.1e-11	Alcohol dependence;
CRC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg20203395	chr5:56204925	C5orf35	-0.41	-5.74	-0.3	2.19e-8	Coronary artery disease;
CRC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.63	-0.39	2.48e-13	Hematocrit;
CRC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.98	-0.4	2.5e-14	Height;
CRC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.57	-0.34	1.93e-10	Type 2 diabetes;
CRC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg13319975	chr6:146136371	FBXO30	0.42	6.28	0.33	1.06e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08925066	chr14:39572669	SEC23A	0.37	6.12	0.32	2.68e-9	Interleukin-6 levels;
CRC	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.92	11.4	0.53	1.31e-25	Exhaled nitric oxide output;
CRC	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.23	6.16	0.32	2.12e-9	Type 2 diabetes;
CRC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.89	-15.95	-0.66	7.68e-43	Height;
CRC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.27	-0.41	3.41e-15	Mean platelet volume;
CRC	trans	rs1569175	0.850	rs3106088	chr2:200907393	A/C	cg12143499	chr12:27615389	NA	0.68	6.15	0.32	2.25e-9	Response to treatment for acute lymphoblastic leukemia;
CRC	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg13334819	chr7:99746414	C7orf59	-0.44	-6.0	-0.31	5.32e-9	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.62	10.39	0.5	4.69e-22	Colorectal cancer;
CRC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.92	16.72	0.68	7.27e-46	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Alcohol dependence;
CRC	cis	rs16852403	0.619	rs2862317	chr1:178146278	A/T	cg00404053	chr1:178313656	RASAL2	0.6	7.63	0.39	2.6e-13	Childhood ear infection;
CRC	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.52	-6.28	-0.33	1.09e-9	Coronary artery calcification;
CRC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg23758597	chr6:163146217	PARK2	-0.66	-6.6	-0.34	1.69e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.59	8.93	0.44	3.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1532331	0.833	rs10058350	chr5:43141644	T/C	cg09164108	chr5:43007320	NA	0.38	5.8	0.3	1.58e-8	Menarche (age at onset);
CRC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.5	7.04	0.36	1.16e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	0.95	13.82	0.61	1.4e-34	Monocyte percentage of white cells;
CRC	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg14092571	chr14:90743983	NA	0.39	5.97	0.31	6.31e-9	Mortality in heart failure;
CRC	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg20608306	chr11:116969690	SIK3	-0.32	-5.94	-0.31	7.18e-9	Subjective well-being;
CRC	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.57	7.59	0.39	3.3e-13	Height;
CRC	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg01420254	chr6:26195488	NA	0.74	6.28	0.33	1.07e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg24024056	chr10:102415556	NA	-0.36	-7.16	-0.37	5.37e-12	Body mass index;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.51	-0.34	2.79e-10	Coronary artery calcification;
CRC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-15.14	-0.64	1.16e-39	Vitiligo;
CRC	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.44	-6.38	-0.33	6.05e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.49	-9.84	-0.48	3.46e-20	Prostate cancer;
CRC	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg14681854	chr1:93250590	EVI5	-0.42	-6.02	-0.31	4.68e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.79	7.64	0.39	2.36e-13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-9.27	-0.46	2.44e-18	Primary sclerosing cholangitis;
CRC	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.49	0.34	3.09e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs447	0.895	rs12707616	chr7:83745440	C/T	cg22846510	chr7:83753280	SEMA3A	-0.41	-5.7	-0.3	2.65e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.73	0.39	1.34e-13	Lymphocyte percentage of white cells;
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg25164649	chr6:28176230	NA	0.71	8.6	0.43	3.2e-16	Parkinson's disease;
CRC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.39	-6.64	-0.34	1.33e-10	Height;
CRC	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.59	6.47	0.34	3.56e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	-0.67	-7.35	-0.38	1.55e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg20684491	chr1:25596433	NA	0.42	7.37	0.38	1.41e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.58	-10.5	-0.5	1.94e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg10876282	chr6:28092338	ZSCAN16	0.5	6.73	0.35	7.44e-11	Cardiac Troponin-T levels;
CRC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.32	4.54e-9	Gut microbiome composition (summer);
CRC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	18.85	0.72	3e-54	Prudent dietary pattern;
CRC	trans	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg21302420	chr1:112162376	RAP1A	0.83	7.41	0.38	1.07e-12	Skin colour saturation;
CRC	cis	rs10512697	0.655	rs35747152	chr5:3459151	T/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25117062	chr2:10442836	HPCAL1	0.4	6.75	0.35	6.89e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg21784768	chr11:537496	LRRC56	-0.67	-6.21	-0.32	1.63e-9	Body mass index;
CRC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	0.97	11.59	0.54	2.78e-26	Iron status biomarkers;
CRC	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg12046867	chr14:103022105	NA	-0.43	-6.22	-0.32	1.53e-9	Platelet count;
CRC	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.59	7.76	0.39	1.06e-13	Mammographic density (dense area);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10922622	chr9:108210153	FSD1L	0.47	6.07	0.32	3.51e-9	Thyroid stimulating hormone;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg01339444	chr6:118972232	C6orf204	0.54	6.02	0.32	4.65e-9	Diastolic blood pressure;
CRC	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg02811702	chr13:24901961	NA	0.42	5.78	0.3	1.73e-8	Obesity-related traits;
CRC	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg16576597	chr16:28551801	NUPR1	0.44	6.75	0.35	6.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.47	6.23	0.32	1.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07254608	chr8:41997973	NA	0.48	6.27	0.33	1.1e-9	Thyroid stimulating hormone;
CRC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.71	8.01	0.4	2.03e-14	Major depressive disorder;
CRC	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.24e-37	Hypertriglyceridemia;
CRC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.36	0.38	1.44e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.59	8.58	0.43	3.7e-16	Schizophrenia;
CRC	cis	rs11649653	0.502	rs11864054	chr16:30846134	G/A	cg02466173	chr16:30829666	NA	-0.58	-8.1	-0.41	1.1e-14	Triglycerides;
CRC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.42	-7.98	-0.4	2.39e-14	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19250579	chr3:75487529	NA	-0.37	-6.06	-0.32	3.78e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg27472102	chr12:77459941	E2F7	-0.38	-6.08	-0.32	3.36e-9	Daytime sleep phenotypes;
CRC	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg08795948	chr3:128337044	NA	0.35	6.18	0.32	1.93e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.35	5.62	0.3	4.05e-8	Neuroticism;
CRC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg08314208	chr16:67682810	RLTPR	-0.64	-6.73	-0.35	7.38e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22133161	chr19:49891603	CCDC155	0.49	6.9	0.36	2.74e-11	Multiple sclerosis;
CRC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	13.92	0.61	5.73e-35	Smoking behavior;
CRC	cis	rs10760158	0.736	rs10760168	chr9:124048727	C/T	cg14417974	chr9:124058376	GSN	-0.33	-5.61	-0.3	4.38e-8	Pulse pressure;
CRC	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.57	5.78	0.3	1.73e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24022402	chr3:9834453	ARPC4;TADA3	0.44	6.04	0.32	4.23e-9	Response to antipsychotic treatment;
CRC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg03395651	chr16:88107091	BANP	0.56	7.43	0.38	9.52e-13	Menopause (age at onset);
CRC	cis	rs12692738	0.526	rs355827	chr2:165612448	C/A	cg03182029	chr2:165697222	COBLL1	0.49	5.68	0.3	2.91e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.11	0.37	7.09e-12	Lung cancer in ever smokers;
CRC	cis	rs7605827	0.964	rs10929367	chr2:15564718	T/C	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.69e-8	Educational attainment (years of education);
CRC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.46	0.5	2.59e-22	Platelet count;
CRC	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	0.93	17.69	0.7	1.09e-49	Eosinophil percentage of white cells;
CRC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.91e-22	Menopause (age at onset);
CRC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.57	-9.01	-0.44	1.75e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.6	10.26	0.49	1.3e-21	Body mass index;
CRC	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.47	7.62	0.39	2.75e-13	Schizophrenia;
CRC	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.13	0.49	3.68e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7546094	1.000	rs7524494	chr1:113197800	A/G	cg22162597	chr1:113214053	CAPZA1	-0.42	-5.75	-0.3	2.04e-8	Platelet distribution width;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.84	-0.31	1.26e-8	Subjective well-being;
CRC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.51	7.19	0.37	4.25e-12	Melanoma;
CRC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg03929089	chr4:120376271	NA	0.63	6.55	0.34	2.18e-10	Axial length;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg03804128	chr16:635623	NA	0.31	7.14	0.37	6.06e-12	Height;
CRC	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg06172871	chr16:72088244	HP	0.43	6.35	0.33	7.3e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg00246817	chr9:123691163	NA	-0.44	-5.65	-0.3	3.44e-8	Rheumatoid arthritis;
CRC	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.44	-6.84	-0.35	3.81e-11	Asthma;
CRC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	5.79	0.3	1.66e-8	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs4700695	0.764	rs251320	chr5:65237435	G/A	cg21114390	chr5:65439923	SFRS12	0.59	6.54	0.34	2.4e-10	Facial morphology (factor 19);
CRC	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg14664628	chr15:75095509	CSK	0.55	6.6	0.34	1.66e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.4	6.18	0.32	1.86e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg13385794	chr1:248469461	NA	-0.4	-7.02	-0.36	1.28e-11	Common traits (Other);
CRC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg02569458	chr12:86230093	RASSF9	0.48	7.98	0.4	2.39e-14	Major depressive disorder;
CRC	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg02023728	chr11:77925099	USP35	-0.35	-5.96	-0.31	6.32e-9	Alzheimer's disease (survival time);
CRC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.63	-9.33	-0.46	1.67e-18	Blood protein levels;
CRC	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.44	0.42	1.06e-15	Platelet distribution width;
CRC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.29	0.42	2.97e-15	Life satisfaction;
CRC	trans	rs7730934	1.000	rs11739016	chr5:55263373	C/T	cg10323188	chr3:28613979	NA	0.52	6.11	0.32	2.84e-9	Blood protein levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21517261	chr7:38217791	STARD3NL	-0.51	-6.27	-0.33	1.15e-9	Diisocyanate-induced asthma;
CRC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.62e-20	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05550371	chr3:49841167	C3orf54	0.5	6.34	0.33	7.62e-10	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg19338460	chr6:170058176	WDR27	-0.68	-7.49	-0.38	6.42e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.65	6.93	0.36	2.21e-11	Axial length;
CRC	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.41	-5.95	-0.31	6.74e-9	Body mass index;
CRC	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg01339444	chr6:118972232	C6orf204	0.53	5.87	0.31	1.04e-8	Diastolic blood pressure;
CRC	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.72	-11.45	-0.53	8.76e-26	Mean platelet volume;
CRC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.99	0.44	1.96e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.41	5.9	0.31	9.25e-9	Schizophrenia;
CRC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.03	-0.4	1.81e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.54	-8.54	-0.43	5e-16	Aortic root size;
CRC	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg19407955	chr1:165599744	MGST3	-0.52	-6.62	-0.34	1.49e-10	Total ventricular volume;
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.18e-22	Bipolar disorder;
CRC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg15786705	chr6:28176104	NA	0.57	5.99	0.31	5.57e-9	Depression;
CRC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.52	6.59	0.34	1.72e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.53	7.45	0.38	8.42e-13	Melanoma;
CRC	cis	rs6662572	0.737	rs6674105	chr1:46301379	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.09	-0.32	3.11e-9	Blood protein levels;
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg01339444	chr6:118972232	C6orf204	0.53	6.0	0.31	5.22e-9	Diastolic blood pressure;
CRC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	-0.51	-8.36	-0.42	1.83e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs11675805	chr2:15578274	C/T	cg19274914	chr2:15703543	NA	0.39	6.02	0.31	4.78e-9	Educational attainment (years of education);
CRC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.51	-7.8	-0.39	8.46e-14	Motion sickness;
CRC	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg15660573	chr17:549704	VPS53	-0.86	-15.83	-0.66	2.31e-42	Prostate cancer;
CRC	trans	rs172642	1.000	rs218696	chr17:6593922	A/G	cg26561570	chr1:161602002	FCGR3B	-0.28	-6.43	-0.33	4.43e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7539624	0.529	rs7412088	chr1:223899123	T/A	cg10100437	chr1:223903862	CAPN2	0.46	6.46	0.34	3.84e-10	Schizophrenia;
CRC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.44	-6.53	-0.34	2.56e-10	Menarche (age at onset);
CRC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.95	0.64	6.44e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg27579711	chr6:26172931	NA	0.45	6.4	0.33	5.2e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg03160526	chr17:80928410	B3GNTL1	-0.41	-5.93	-0.31	7.68e-9	Breast cancer;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg23807890	chr2:228736357	WDR69	0.49	6.65	0.34	1.2e-10	Blood pressure;
CRC	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg10483660	chr13:112241077	NA	0.36	5.82	0.31	1.39e-8	Menarche (age at onset);
CRC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.97	-18.5	-0.71	7.08e-53	Height;
CRC	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.6	9.51	0.46	4.26e-19	Anterior chamber depth;
CRC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.13	21.01	0.76	9.76e-63	Cognitive function;
CRC	trans	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg07393940	chr7:158741817	NA	-0.52	-7.43	-0.38	9.26e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.45	5.88	0.31	1.01e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg25427524	chr10:38739819	LOC399744	-0.56	-8.68	-0.43	1.91e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg19980929	chr12:42632907	YAF2	0.42	6.37	0.33	6.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.39	-5.77	-0.3	1.88e-8	Ovarian reserve;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08808811	chr3:184079573	CLCN2	0.4	6.37	0.33	6.22e-10	Obesity-related traits;
CRC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.11e-15	Lung cancer;
CRC	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.76	-10.27	-0.49	1.19e-21	Educational attainment;
CRC	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg08657710	chr16:75258780	CTRB1	-0.57	-6.81	-0.35	4.61e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.45	-8.03	-0.4	1.75e-14	Reticulocyte fraction of red cells;
CRC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18252515	chr7:66147081	NA	0.4	5.9	0.31	9.26e-9	Aortic root size;
CRC	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.79	-13.83	-0.61	1.33e-34	Lewy body disease;
CRC	cis	rs863345	0.604	rs10908654	chr1:158455790	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.03	-0.32	4.44e-9	Pneumococcal bacteremia;
CRC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-8.19	-0.41	5.66e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs2303319	0.582	rs56315911	chr2:162560186	G/T	cg12500891	chr11:57225987	NA	-0.66	-6.09	-0.32	3.19e-9	Cognitive function;
CRC	cis	rs911119	0.908	rs8121147	chr20:23601708	T/C	cg16589663	chr20:23618590	CST3	0.47	6.5	0.34	2.92e-10	Chronic kidney disease;
CRC	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.72	14.1	0.61	1.18e-35	Mean corpuscular hemoglobin;
CRC	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.67	10.49	0.5	2.12e-22	Corneal astigmatism;
CRC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.54	-7.96	-0.4	2.81e-14	Coronary artery disease;
CRC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21643547	chr1:205240462	TMCC2	-0.44	-7.06	-0.36	1.01e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.57	-9.51	-0.46	4.26e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.79	11.88	0.55	2.48e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs10506710	0.537	rs7964194	chr12:73563639	A/G	cg13063900	chr12:20810676	PDE3A	-0.39	-5.99	-0.31	5.42e-9	Systolic blood pressure;
CRC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg21724239	chr8:58056113	NA	0.52	7.04	0.36	1.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.4	0.33	5.42e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.46	-0.62	4.86e-37	Colorectal cancer;
CRC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.38	-6.93	-0.36	2.18e-11	Reticulocyte fraction of red cells;
CRC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg18827107	chr12:86230957	RASSF9	-0.41	-6.23	-0.32	1.42e-9	Major depressive disorder;
CRC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.45	-5.61	-0.3	4.38e-8	Gut microbiome composition (summer);
CRC	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.89e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs6429082	0.509	rs12027995	chr1:235517607	C/G	cg26050004	chr1:235667680	B3GALNT2	0.42	5.9	0.31	8.86e-9	Adiposity;
CRC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg04657146	chr19:12876947	HOOK2	0.39	5.61	0.3	4.32e-8	Bipolar disorder;
CRC	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-8.31	-0.42	2.53e-15	Hypospadias;
CRC	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg15654264	chr1:150340011	RPRD2	0.41	6.14	0.32	2.36e-9	Migraine;
CRC	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.98	-0.4	2.4e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg22687807	chr8:143858763	LYNX1	0.72	12.97	0.58	2.3e-31	Urinary tract infection frequency;
CRC	cis	rs62458065	0.850	rs6462362	chr7:32464733	C/T	cg20159608	chr7:32802032	NA	-0.53	-6.6	-0.34	1.62e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.66	-8.28	-0.42	3.19e-15	Blood protein levels;
CRC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg18171855	chr10:2543474	NA	0.41	6.67	0.34	1.1e-10	Age-related hearing impairment;
CRC	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg10437265	chr15:77819839	NA	0.56	9.34	0.46	1.5e-18	Type 2 diabetes;
CRC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.52	-7.01	-0.36	1.36e-11	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.54	8.21	0.41	5.07e-15	Longevity;Endometriosis;
CRC	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg20737812	chr15:86336631	KLHL25	-0.49	-7.23	-0.37	3.44e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.91	0.31	8.75e-9	Ulcerative colitis;
CRC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.63	0.65	1.46e-41	Primary sclerosing cholangitis;
CRC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02772935	chr3:125709198	NA	-0.49	-5.74	-0.3	2.11e-8	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg08461752	chr10:43522343	NA	-0.63	-5.87	-0.31	1.07e-8	Blood protein levels;
CRC	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg20356878	chr3:121714668	ILDR1	0.52	8.1	0.41	1.09e-14	Cognitive performance;
CRC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.98	0.31	5.88e-9	Lung cancer;
CRC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.41	5.65	0.3	3.48e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.66	9.49	0.46	4.72e-19	Menopause (age at onset);
CRC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg14008862	chr17:28927542	LRRC37B2	0.55	5.78	0.3	1.7e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10512697	0.655	rs13170915	chr5:3511974	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.41	6.27	0.33	1.15e-9	Testicular germ cell tumor;
CRC	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.52	-7.24	-0.37	3.15e-12	Triglycerides;
CRC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.1	0.32	3.01e-9	Tonsillectomy;
CRC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.36	0.33	6.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07544984	chr3:42845911	HIGD1A	0.38	6.04	0.32	4.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg06581033	chr10:766294	NA	-0.5	-5.62	-0.3	3.99e-8	Uric acid levels;
CRC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.62	-9.5	-0.46	4.49e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg16447950	chr5:562315	NA	-0.85	-12.52	-0.57	1.1e-29	Obesity-related traits;
CRC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg24881330	chr22:46731750	TRMU	0.7	8.79	0.44	8.56e-17	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.26	-0.37	2.76e-12	Morning vs. evening chronotype;
CRC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.0	-0.68	5.84e-47	Coronary artery disease;
CRC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg06462663	chr19:18546047	ISYNA1	0.5	7.39	0.38	1.26e-12	Breast cancer;
CRC	cis	rs863345	0.604	rs10908657	chr1:158465243	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.35	-0.33	7.19e-10	Pneumococcal bacteremia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04413696	chr16:17564591	XYLT1	0.45	6.3	0.33	9.7e-10	Anxiety disorder;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.74	-0.43	1.21e-16	Bipolar disorder;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg10989255	chr10:76970356	VDAC2	-0.37	-6.21	-0.32	1.63e-9	Aortic root size;
CRC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.1e-8	Bladder cancer;
CRC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.52	-0.34	2.68e-10	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26837270	chr19:42746884	GSK3A	0.4	5.98	0.31	5.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.36	-0.33	6.84e-10	Monocyte percentage of white cells;
CRC	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.4	5.91	0.31	8.7e-9	Platelet distribution width;
CRC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg21770322	chr7:97807741	LMTK2	0.85	19.35	0.73	3.14e-56	Breast cancer;
CRC	trans	rs473651	0.935	rs578510	chr2:239343140	C/T	cg13521940	chr21:36262239	RUNX1	-0.41	-6.06	-0.32	3.67e-9	Multiple system atrophy;
CRC	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.43	0.33	4.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.67	0.3	3.08e-8	Cardiac Troponin-T levels;
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.44	5.9	0.31	8.94e-9	Schizophrenia;
CRC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	ch.11.42038R	chr11:967971	AP2A2	0.57	9.86	0.48	2.86e-20	Alzheimer's disease (late onset);
CRC	cis	rs2692947	0.760	rs2438924	chr2:96645069	A/G	cg23100626	chr2:96804247	ASTL	0.25	6.92	0.36	2.31e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.64	-11.24	-0.53	5.05e-25	Brugada syndrome;
CRC	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.59	-8.64	-0.43	2.51e-16	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.52	0.46	3.79e-19	Bladder cancer;
CRC	cis	rs7567389	0.534	rs72845982	chr2:128098570	G/A	cg09760422	chr2:128146352	NA	0.34	5.61	0.3	4.2e-8	Self-rated health;
CRC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.65	13.12	0.59	6.34e-32	HDL cholesterol levels;
CRC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-8.74	-0.43	1.2e-16	Subjective well-being;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19864851	chr10:75503847	SEC24C	0.51	6.7	0.35	9.01e-11	Thyroid stimulating hormone;
CRC	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.62	8.79	0.44	8.32e-17	Schizophrenia;
CRC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.57	7.99	0.4	2.26e-14	Resting heart rate;
CRC	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	5.82	0.31	1.37e-8	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.48	7.63	0.39	2.61e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.69	9.6	0.47	2.11e-19	Alzheimer's disease;
CRC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg07074390	chr21:40555500	PSMG1	-0.45	-6.11	-0.32	2.78e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13009927	chr2:242254519	SEPT2;HDLBP	0.44	6.92	0.36	2.35e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-5.75	-0.3	2.02e-8	Breast cancer;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg15383120	chr6:291909	DUSP22	-0.51	-7.13	-0.37	6.35e-12	Menopause (age at onset);
CRC	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg06223162	chr1:101003688	GPR88	-0.36	-6.54	-0.34	2.34e-10	Monocyte count;
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs3823572	0.542	rs10269665	chr7:133630418	A/G	cg03336402	chr7:133662267	EXOC4	0.65	10.09	0.49	4.72e-21	Intelligence (multi-trait analysis);
CRC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.29e-11	Morning vs. evening chronotype;
CRC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg18230493	chr5:56204884	C5orf35	-0.4	-5.81	-0.3	1.51e-8	Coronary artery disease;
CRC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.55	8.26	0.41	3.49e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg15786705	chr6:28176104	NA	0.63	9.0	0.44	1.81e-17	Cardiac Troponin-T levels;
CRC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg08687515	chr19:58661962	ZNF329	0.8	8.74	0.43	1.23e-16	Cholesterol, total;
CRC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg25164649	chr6:28176230	NA	-0.41	-5.77	-0.3	1.82e-8	Systemic lupus erythematosus;
CRC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.55	8.82	0.44	6.6e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg14646075	chr2:228736089	WDR69	-0.42	-6.07	-0.32	3.43e-9	Blood pressure;
CRC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24308560	chr3:49941425	MST1R	-0.46	-7.23	-0.37	3.51e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.29	0.53	3.33e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg14711859	chr11:8959438	ASCL3	0.38	6.37	0.33	6.45e-10	Hemoglobin concentration;
CRC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg08213375	chr14:104286397	PPP1R13B	0.34	5.67	0.3	3.19e-8	Reticulocyte count;
CRC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.7	-10.58	-0.5	1.06e-22	Corneal astigmatism;
CRC	cis	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg05935833	chr10:81318306	SFTPA2	-0.49	-5.85	-0.31	1.21e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs10838798	0.563	rs4752902	chr11:48148779	G/A	cg21153622	chr11:89784906	NA	-0.43	-6.76	-0.35	6.4e-11	Height;
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg15786705	chr6:28176104	NA	0.48	7.18	0.37	4.74e-12	Cardiac Troponin-T levels;
CRC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.62	0.57	4.78e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg01251360	chr16:68772225	CDH1	-0.24	-5.85	-0.31	1.18e-8	Colorectal cancer;
CRC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg25985355	chr7:65971099	NA	0.47	5.98	0.31	5.87e-9	Diabetic kidney disease;
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg21724239	chr8:58056113	NA	0.39	5.83	0.31	1.29e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.84	-14.71	-0.63	5.62e-38	Hypertriglyceridemia;
CRC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.4	-0.46	9.54e-19	Platelet count;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg19041857	chr6:27730383	NA	-0.43	-6.11	-0.32	2.85e-9	Parkinson's disease;
CRC	cis	rs2811415	0.597	rs2304018	chr3:127779306	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg15448220	chr1:150897856	SETDB1	0.51	7.27	0.37	2.63e-12	Melanoma;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-9.19	-0.45	4.61e-18	Bipolar disorder;
CRC	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	6.66	0.34	1.13e-10	Neutrophil percentage of white cells;
CRC	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg14092571	chr14:90743983	NA	0.38	5.86	0.31	1.12e-8	Mortality in heart failure;
CRC	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg17545662	chr6:170176663	C6orf70	0.53	5.82	0.31	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg18187862	chr3:45730750	SACM1L	0.47	6.8	0.35	4.89e-11	Primary sclerosing cholangitis;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	9.37	0.46	1.16e-18	HIV-1 control;
CRC	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.73	10.49	0.5	2.15e-22	Menopause (age at onset);
CRC	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Dilated cardiomyopathy;
CRC	cis	rs595018	0.505	rs11230501	chr11:60598075	G/A	cg23904249	chr11:60608951	CCDC86	-0.51	-6.82	-0.35	4.3e-11	Wegener's granulomatosis;
CRC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.64	8.89	0.44	4.23e-17	Bronchopulmonary dysplasia;
CRC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.4	5.94	0.31	7.21e-9	Large artery stroke;
CRC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg17085576	chr10:5658249	NA	-0.42	-5.89	-0.31	9.39e-9	Breast cancer;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg03623178	chr6:28175578	NA	0.75	8.36	0.42	1.77e-15	Parkinson's disease;
CRC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.5	-6.67	-0.35	1.07e-10	Glioblastoma;
CRC	trans	rs1572438	0.619	rs36078286	chr6:866752	T/G	cg01563465	chr5:72512441	NA	0.31	6.02	0.31	4.58e-9	Aging;
CRC	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg19131313	chr8:1704013	NA	-0.45	-6.25	-0.33	1.28e-9	Systolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04371633	chr14:65381025	CHURC1	0.51	6.62	0.34	1.43e-10	Thyroid stimulating hormone;
CRC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.45	-6.3	-0.33	9.72e-10	Monocyte count;
CRC	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.47	6.23	0.32	1.45e-9	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	14.9	0.63	1.01e-38	Colorectal cancer;
CRC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.23	0.41	4.29e-15	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01485046	chr19:46498389	CCDC61	0.49	6.92	0.36	2.39e-11	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00629941	chr15:75287862	SCAMP5	0.43	6.54	0.34	2.38e-10	Schizophrenia;
CRC	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.52	-0.54	5e-26	Idiopathic membranous nephropathy;
CRC	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.67	0.63	7.57e-38	Colorectal cancer;
CRC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.5	6.45	0.34	3.89e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.08	-0.55	4.56e-28	Coffee consumption (cups per day);
CRC	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.72	11.59	0.54	2.83e-26	Dupuytren's disease;
CRC	cis	rs9584850	0.609	rs7983408	chr13:99155593	G/C	cg07423050	chr13:99094983	FARP1	0.46	5.67	0.3	3.09e-8	Neuroticism;
CRC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg26061582	chr7:22766209	IL6	0.54	8.15	0.41	7.51e-15	Lung cancer;
CRC	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.56	7.27	0.37	2.61e-12	Coronary artery disease;
CRC	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg16670446	chr17:27188758	MIR451;MIR144	-0.6	-10.42	-0.5	3.64e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.65	10.36	0.5	6.11e-22	Asthma (sex interaction);
CRC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.48	-0.34	3.32e-10	Menopause (age at onset);
CRC	cis	rs8105895	0.935	rs10406653	chr19:22238023	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.81	-0.3	1.51e-8	Gut microbiome composition (summer);
CRC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.18	-0.32	1.92e-9	Inflammatory bowel disease;
CRC	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.39	-0.38	1.18e-12	Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21054179	chr12:49412581	PRKAG1	0.39	6.16	0.32	2.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.5	6.89	0.35	2.92e-11	Obesity-related traits;
CRC	cis	rs7487075	0.820	rs7135897	chr12:46698902	C/T	cg22049899	chr12:47219821	SLC38A4	-0.31	-5.86	-0.31	1.14e-8	Itch intensity from mosquito bite;
CRC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.72	0.3	2.37e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg27535305	chr1:53392650	SCP2	-0.39	-6.9	-0.36	2.65e-11	Monocyte count;
CRC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg03623178	chr6:28175578	NA	0.78	6.64	0.34	1.27e-10	Breast cancer;
CRC	cis	rs13161895	0.646	rs75894617	chr5:179499854	G/C	cg02702477	chr5:179499311	RNF130	0.92	8.11	0.41	1e-14	LDL cholesterol;
CRC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg10589385	chr1:150898437	SETDB1	0.32	6.75	0.35	6.57e-11	Melanoma;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg07217954	chr7:1067459	C7orf50	0.5	5.87	0.31	1.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.05	-0.36	1.08e-11	Mean platelet volume;
CRC	cis	rs2386661	0.826	rs4749834	chr10:5671808	G/A	cg26603656	chr10:5671107	NA	0.54	8.92	0.44	3.41e-17	Breast cancer;
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02290350	chr8:58132656	NA	-0.41	-6.08	-0.32	3.25e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg04969067	chr8:143858791	LYNX1	-0.61	-10.59	-0.5	9.91e-23	Urinary tract infection frequency;
CRC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg07713946	chr22:31675144	LIMK2	0.4	5.82	0.31	1.37e-8	Colorectal cancer;
CRC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.84	0.35	3.76e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-6.02	-0.31	4.68e-9	Vitamin D levels;
CRC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.56	-8.42	-0.42	1.22e-15	Uric acid levels;
CRC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg13390004	chr1:15929781	NA	0.42	5.82	0.31	1.36e-8	Systolic blood pressure;
CRC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.47	8.97	0.44	2.3e-17	Renal cell carcinoma;
CRC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	cis	rs10986311	0.775	rs10986324	chr9:127121825	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.41	6.17	0.32	2.06e-9	Vitiligo;
CRC	trans	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg18288967	chr1:45987694	PRDX1	0.69	7.67	0.39	1.99e-13	Obesity-related traits;
CRC	cis	rs12476592	0.602	rs7570031	chr2:63792265	A/G	cg10828910	chr2:63850056	LOC388955	0.47	5.79	0.3	1.62e-8	Childhood ear infection;
CRC	trans	rs783540	0.934	rs803747	chr15:83258096	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.32	-0.33	8.45e-10	Schizophrenia;
CRC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.71	-0.43	1.53e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.56	7.69	0.39	1.77e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.65	-8.73	-0.43	1.31e-16	Alcohol dependence;
CRC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg15147215	chr3:52552868	STAB1	-0.59	-9.2	-0.45	4.14e-18	Bipolar disorder;
CRC	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.63	-7.88	-0.4	4.7e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg00666640	chr1:248458726	OR2T12	0.52	9.07	0.45	1.11e-17	Common traits (Other);
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg19041857	chr6:27730383	NA	-0.41	-5.99	-0.31	5.45e-9	Parkinson's disease;
CRC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg03013999	chr17:37608204	MED1	0.42	6.38	0.33	5.84e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	9.67	0.47	1.22e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.47	6.3	0.33	9.49e-10	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg07870213	chr5:140052090	DND1	0.64	8.11	0.41	9.98e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.42	-0.33	4.83e-10	Caffeine consumption;
CRC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.68	10.71	0.51	3.57e-23	Blood protein levels;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg03623178	chr6:28175578	NA	0.54	7.81	0.4	7.96e-14	Parkinson's disease;
CRC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg16342193	chr10:102329863	NA	-0.36	-5.86	-0.31	1.14e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14489649	chr17:40021376	KLHL11	0.42	5.98	0.31	5.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.97	-0.36	1.69e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2882667	0.858	rs4643949	chr5:138372345	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-5.98	-0.31	5.96e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.11	-22.53	-0.78	1.21e-68	Triglycerides;
CRC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg11070056	chr1:107600091	PRMT6	0.37	5.75	0.3	2.05e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.09	-0.32	3.2e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.31	-5.84	-0.31	1.27e-8	Inflammatory skin disease;
CRC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.42	0.5	3.68e-22	Menopause (age at onset);
CRC	trans	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg20064139	chr20:41823021	NA	-0.3	-6.26	-0.33	1.21e-9	Coronary artery disease;
CRC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.39	5.97	0.31	6.24e-9	Mean corpuscular volume;
CRC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.06	20.83	0.75	4.82e-62	Primary sclerosing cholangitis;
CRC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.78	-0.44	8.82e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg19486271	chr11:47235900	DDB2	-0.49	-7.37	-0.38	1.35e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg17346650	chr17:80929145	B3GNTL1	0.48	7.06	0.36	9.69e-12	Glycated hemoglobin levels;
CRC	trans	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.92	0.36	2.31e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12711979	0.513	rs11676551	chr2:3836782	A/G	cg17052675	chr2:3827356	NA	-0.35	-5.96	-0.31	6.6e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.48	6.86	0.35	3.36e-11	Breast cancer;
CRC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg05320533	chr16:89541815	ANKRD11	0.44	6.13	0.32	2.52e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs2013441	0.670	rs4924802	chr17:19955895	G/T	cg13482628	chr17:19912719	NA	0.41	5.71	0.3	2.5e-8	Obesity-related traits;
CRC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.91	-15.73	-0.66	5.53e-42	Headache;
CRC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.57	-9.13	-0.45	6.94e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg17330251	chr7:94953956	PON1	-0.59	-7.62	-0.39	2.69e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.56	-7.69	-0.39	1.68e-13	Caudate activity during reward;
CRC	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.75	-0.3	2.07e-8	Yeast infection;
CRC	cis	rs365302	0.904	rs392551	chr6:159650174	C/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	0.86	6.9	0.36	2.74e-11	Fat distribution (HIV);
CRC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.72	-8.15	-0.41	7.69e-15	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.14	-0.32	2.36e-9	Bipolar disorder;
CRC	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg26353448	chr1:248524236	OR2T4	-0.34	-6.87	-0.35	3.15e-11	Common traits (Other);
CRC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg11212589	chr17:38028394	ZPBP2	0.43	7.97	0.4	2.71e-14	Self-reported allergy;
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.15	-0.32	2.23e-9	Bipolar disorder;
CRC	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.57	-0.5	1.14e-22	Bipolar disorder;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg11843238	chr5:131593191	PDLIM4	0.43	7.3	0.37	2.22e-12	Acylcarnitine levels;
CRC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.56	8.46	0.42	8.77e-16	Mean corpuscular volume;
CRC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.74	-0.35	7.19e-11	Total body bone mineral density;
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg02683197	chr6:28174875	NA	0.42	5.92	0.31	8.18e-9	Pubertal anthropometrics;
CRC	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.33	-0.33	8.1e-10	Breast cancer;
CRC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg24562669	chr7:97807699	LMTK2	0.51	8.77	0.44	9.65e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.42	-8.14	-0.41	8.28e-15	Mean corpuscular volume;
CRC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.57	-5.84	-0.31	1.28e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.73	-12.12	-0.56	3.22e-28	Idiopathic membranous nephropathy;
CRC	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg00071950	chr4:10020882	SLC2A9	0.49	6.84	0.35	3.78e-11	Blood metabolite levels;
CRC	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg02927042	chr1:21476669	EIF4G3	0.45	7.22	0.37	3.56e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs55788414	0.932	rs9921666	chr16:81181669	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.45	7.93	0.4	3.52e-14	Childhood ear infection;
CRC	trans	rs7151302	0.749	rs243305	chr14:33738476	C/G	cg15822049	chr14:91338889	RPS6KA5	0.5	5.96	0.31	6.4e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs12024301	0.557	rs12028474	chr1:183643542	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4290604	0.748	rs62183336	chr2:237962784	C/G	cg23555395	chr2:238036564	NA	0.57	5.82	0.31	1.43e-8	Asthma;
CRC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.57	8.63	0.43	2.6e-16	High light scatter reticulocyte count;
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.09	-0.32	3.17e-9	Life satisfaction;
CRC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg16482183	chr6:26056742	HIST1H1C	-0.64	-8.61	-0.43	3.02e-16	Iron status biomarkers;
CRC	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.68	-11.62	-0.54	2.1e-26	Lewy body disease;
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg10298567	chr3:47292165	KIF9	0.43	7.08	0.36	8.79e-12	Colorectal cancer;
CRC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.36	-5.82	-0.31	1.39e-8	Ulcerative colitis;
CRC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.57	8.0	0.4	2.12e-14	IgG glycosylation;
CRC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.98	20.18	0.74	1.73e-59	Testicular germ cell tumor;
CRC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.34	-0.33	7.48e-10	Schizophrenia;
CRC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.7	6.45	0.34	3.98e-10	Diabetic kidney disease;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.45	-6.46	-0.34	3.87e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.93	-0.4	3.41e-14	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	13.85	0.61	1.14e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4664293	0.867	rs6432553	chr2:160577010	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.57e-13	Monocyte percentage of white cells;
CRC	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.49	7.7	0.39	1.66e-13	Resting heart rate;
CRC	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.67	-0.3	3.2e-8	Breast cancer;
CRC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.73	-8.33	-0.42	2.19e-15	Obesity-related traits;
CRC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	0.98	12.25	0.56	1.12e-28	Type 2 diabetes nephropathy;
CRC	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.83	-14.31	-0.62	1.94e-36	Lewy body disease;
CRC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.3	-0.33	9.71e-10	Aortic root size;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg06470822	chr6:28175283	NA	0.84	13.01	0.58	1.61e-31	Cardiac Troponin-T levels;
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg01339444	chr6:118972232	C6orf204	0.53	5.87	0.31	1.07e-8	Diastolic blood pressure;
CRC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.58	-9.24	-0.45	3.18e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.737	rs72692603	chr1:46378838	T/C	cg08644498	chr1:46502608	NA	0.43	6.65	0.34	1.2e-10	Blood protein levels;
CRC	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.46	9.44	0.46	7.13e-19	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.62	-8.4	-0.42	1.4e-15	Waist circumference;Body mass index;
CRC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg24046110	chr8:143859143	LYNX1	0.49	8.61	0.43	3.15e-16	Urinary tract infection frequency;
CRC	cis	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg05299278	chr17:33885742	SLFN14	-0.43	-6.5	-0.34	3.05e-10	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.71	0.51	3.67e-23	Alcohol dependence;
CRC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.24	0.41	4.17e-15	Parkinson's disease;
CRC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.6	8.48	0.42	7.85e-16	Breast cancer;
CRC	cis	rs992157	0.730	rs2382828	chr2:219184492	A/G	cg04880052	chr2:219191631	PNKD	0.4	6.08	0.32	3.32e-9	Colorectal cancer;
CRC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.52	0.5	1.72e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4865169	0.560	rs1277312	chr4:57902945	T/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.63	-0.3	3.89e-8	Breast cancer;
CRC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg06219103	chr11:63990595	FERMT3	-0.38	-5.73	-0.3	2.29e-8	Platelet count;
CRC	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.25	-0.37	3.01e-12	Putamen volume;
CRC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg15147215	chr3:52552868	STAB1	0.5	8.63	0.43	2.58e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg16892393	chr17:41919603	NA	0.59	8.51	0.42	6.2e-16	Triglycerides;
CRC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg02869306	chr7:64672164	INTS4L1	0.43	7.01	0.36	1.38e-11	Calcium levels;
CRC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.24	11.52	0.54	5.05e-26	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22108469	chr5:174158984	NA	0.27	6.31	0.33	9.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg04990556	chr1:26633338	UBXN11	0.55	5.91	0.31	8.35e-9	Obesity-related traits;
CRC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.85	-14.94	-0.64	7.01e-39	Height;
CRC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg20607287	chr7:12443886	VWDE	-0.54	-5.76	-0.3	1.89e-8	Coronary artery disease;
CRC	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg17133734	chr15:86042851	AKAP13	0.42	6.81	0.35	4.68e-11	Interstitial lung disease;
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.67	-12.49	-0.57	1.44e-29	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08377010	chr19:48673515	LIG1	0.44	6.06	0.32	3.64e-9	Anxiety disorder;
CRC	cis	rs6496667	0.779	rs8033512	chr15:90945307	A/T	cg04176472	chr15:90893244	GABARAPL3	0.59	7.69	0.39	1.72e-13	Rheumatoid arthritis;
CRC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.48	7.26	0.37	2.84e-12	Corneal astigmatism;
CRC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.51	-0.34	2.82e-10	Total body bone mineral density;
CRC	cis	rs282587	0.569	rs378491	chr13:113398408	C/A	cg04656015	chr13:113407548	ATP11A	0.62	7.97	0.4	2.63e-14	Glycated hemoglobin levels;
CRC	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.55	-6.67	-0.35	1.08e-10	Lymphocyte counts;
CRC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.64	8.72	0.43	1.36e-16	Methadone dose in opioid dependence;
CRC	trans	rs7027930	0.524	rs1962204	chr9:613315	A/G	cg27061366	chr19:13044373	FARSA	0.51	6.27	0.33	1.17e-9	Pulmonary function decline;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05312278	chr15:43803195	TP53BP1	-0.41	-6.21	-0.32	1.59e-9	Myopia (pathological);
CRC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	11.69	0.54	1.24e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.67	-0.43	1.96e-16	Aortic root size;
CRC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	0.77	6.44	0.33	4.35e-10	Type 2 diabetes nephropathy;
CRC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg21227347	chr9:117374170	C9orf91	-0.39	-6.03	-0.32	4.31e-9	Aortic root size;
CRC	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.57	10.18	0.49	2.44e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.74	10.42	0.5	3.73e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.5	8.68	0.43	1.9e-16	Hypertriglyceridemia;
CRC	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg00738113	chr16:70207722	CLEC18C	-0.41	-5.92	-0.31	7.99e-9	IgE levels;
CRC	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg12908607	chr1:44402522	ARTN	-0.47	-8.18	-0.41	6.32e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.73	-11.82	-0.55	4.15e-27	Height;
CRC	cis	rs2292864	0.764	rs36046953	chr17:45381791	A/G	cg18085866	chr17:45331354	ITGB3	-0.58	-5.63	-0.3	3.94e-8	Left atrial antero-posterior diameter;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg03623178	chr6:28175578	NA	0.75	8.28	0.42	3.23e-15	Parkinson's disease;
CRC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.76	12.32	0.56	6.15e-29	Selective IgA deficiency;
CRC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.37	-0.33	6.42e-10	Reticulocyte fraction of red cells;
CRC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.0	9.95	0.48	1.49e-20	Diabetic retinopathy;
CRC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg23625390	chr15:77176239	SCAPER	0.45	6.23	0.32	1.44e-9	Blood metabolite levels;
CRC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.53	9.8	0.48	4.52e-20	Eye color traits;
CRC	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg18200150	chr17:30822561	MYO1D	0.44	8.58	0.43	3.91e-16	Schizophrenia;
CRC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg16558177	chr4:4109446	NA	-0.56	-6.52	-0.34	2.73e-10	Blood pressure (smoking interaction);
CRC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.48	7.51	0.38	5.6e-13	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.32	-0.69	3.32e-48	Height;
CRC	cis	rs1624802	0.967	rs1696432	chr12:130496976	A/G	cg15444478	chr12:130494697	NA	-0.29	-6.05	-0.32	3.85e-9	Obesity-related traits;
CRC	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.68	7.36	0.38	1.47e-12	Childhood ear infection;
CRC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.01	0.36	1.33e-11	Life satisfaction;
CRC	cis	rs990171	1.000	rs1035127	chr2:103019919	C/T	cg03938978	chr2:103052716	IL18RAP	-0.46	-5.78	-0.3	1.7e-8	Lymphocyte counts;
CRC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg26762873	chr11:5879799	OR52E8	-0.49	-7.52	-0.38	5.17e-13	DNA methylation (variation);
CRC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg21851534	chr17:3907994	ZZEF1	0.37	6.29	0.33	9.89e-10	Type 2 diabetes;
CRC	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg14631576	chr9:95140430	CENPP	-0.32	-6.11	-0.32	2.88e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	trans	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg13844804	chr7:814759	HEATR2	0.6	7.93	0.4	3.45e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.07	-0.32	3.47e-9	Height;
CRC	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg14530993	chr4:882597	GAK	0.73	6.66	0.34	1.14e-10	Parkinson's disease;
CRC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.62	-0.39	2.82e-13	Neuroticism;
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg01339444	chr6:118972232	C6orf204	0.55	6.16	0.32	2.08e-9	Diastolic blood pressure;
CRC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg21770322	chr7:97807741	LMTK2	0.86	19.39	0.73	2.24e-56	Breast cancer;
CRC	cis	rs6867913	0.533	rs252152	chr5:141445774	A/G	cg08523384	chr5:141488047	NDFIP1	-0.35	-6.36	-0.33	6.75e-10	Asthma;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.79	0.51	1.94e-23	Motion sickness;
CRC	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg01993067	chr11:68851601	TPCN2	0.56	6.29	0.33	1.03e-9	Blond vs. brown hair color;
CRC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.38	5.86	0.31	1.11e-8	Red blood cell count;
CRC	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.5	-7.03	-0.36	1.22e-11	Educational attainment (college completion);
CRC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.69	10.51	0.5	1.78e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-5.67	-0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.02	0.4	1.87e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13198984	chr17:80129470	CCDC57	0.45	7.97	0.4	2.6e-14	Life satisfaction;
CRC	cis	rs12900413	0.687	rs72754547	chr15:90308166	A/C	cg24249390	chr15:90295951	MESP1	-0.57	-9.13	-0.45	7.11e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.59	-11.64	-0.54	1.91e-26	Asthma (sex interaction);
CRC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg17724175	chr1:150552817	MCL1	0.48	7.18	0.37	4.82e-12	Melanoma;
CRC	cis	rs754466	0.561	rs72806025	chr10:79707026	C/T	cg17075019	chr10:79541650	NA	-0.61	-6.85	-0.35	3.65e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.84	18.44	0.71	1.18e-52	Breast cancer;
CRC	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.7	-10.06	-0.48	6.32e-21	Lymphocyte percentage of white cells;
CRC	cis	rs995000	0.931	rs28641195	chr1:63128081	C/T	cg19896129	chr1:63156450	NA	-0.42	-6.45	-0.34	3.91e-10	Triglyceride levels;
CRC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06505273	chr16:24850292	NA	-0.39	-5.83	-0.31	1.32e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-5.95	-0.31	6.69e-9	Schizophrenia;
CRC	cis	rs3789045	0.774	rs12031912	chr1:204476113	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.89	-0.4	4.47e-14	Educational attainment (college completion);
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00166722	chr3:10149974	C3orf24	0.65	8.94	0.44	2.86e-17	Alzheimer's disease;
CRC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.25	-0.33	1.3e-9	Lung cancer;
CRC	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.73	-10.27	-0.49	1.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.73	9.99	0.48	1.03e-20	Alzheimer's disease;
CRC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.45	0.6	3.81e-33	Platelet count;
CRC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg24562669	chr7:97807699	LMTK2	0.78	17.5	0.69	6.1e-49	Breast cancer;
CRC	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.56	7.27	0.37	2.61e-12	Coronary artery disease;
CRC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.01	9.72	0.47	8.58e-20	Lymphocyte counts;
CRC	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.53	7.58	0.39	3.51e-13	Menopause (age at onset);
CRC	cis	rs16882447	0.607	rs2783	chr5:53489874	C/T	cg06461071	chr5:53490839	ARL15	-0.37	-6.08	-0.32	3.27e-9	Systolic blood pressure (dietary potassium intake interaction);
CRC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg03929089	chr4:120376271	NA	0.59	7.99	0.4	2.3e-14	Intraocular pressure;
CRC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg27432699	chr2:27873401	GPN1	-0.64	-9.82	-0.48	4e-20	Total body bone mineral density;
CRC	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg16141378	chr3:129829833	LOC729375	0.46	7.2	0.37	4.12e-12	Systolic blood pressure;
CRC	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-6.68	-0.35	1.04e-10	Caffeine consumption;
CRC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	7.27	0.37	2.63e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg03160526	chr17:80928410	B3GNTL1	0.49	8.0	0.4	2.11e-14	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13441983	chr11:10327014	ADM	0.47	6.94	0.36	2.06e-11	Response to antipsychotic treatment;
CRC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.75	0.39	1.12e-13	Breast cancer;
CRC	trans	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg21153622	chr11:89784906	NA	0.44	7.02	0.36	1.29e-11	HDL cholesterol;
CRC	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg02702477	chr5:179499311	RNF130	0.58	6.91	0.36	2.59e-11	LDL cholesterol;
CRC	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.41	6.27	0.33	1.15e-9	Testicular germ cell tumor;
CRC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.47	9.41	0.46	8.56e-19	Bone mineral density;
CRC	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.31	-0.37	2.11e-12	Coronary artery disease;
CRC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg26394196	chr10:1453818	ADARB2	-0.35	-6.21	-0.32	1.64e-9	Radiation response;
CRC	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.51	-6.59	-0.34	1.72e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs1178968	0.818	rs4717084	chr7:72764541	C/T	cg25889504	chr7:72793014	NA	0.52	5.96	0.31	6.55e-9	Triglyceride levels;
CRC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.37	-5.67	-0.3	3.18e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.44	7.13	0.37	6.59e-12	Anterior chamber depth;
CRC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.4	6.64	0.34	1.28e-10	Blood metabolite levels;
CRC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg24578937	chr1:2090814	PRKCZ	-0.39	-7.13	-0.37	6.23e-12	Height;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs8170	1.000	rs10418154	chr19:17386006	A/G	cg04749549	chr19:17459798	NA	-0.43	-5.88	-0.31	1.01e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.71	10.1	0.49	4.55e-21	Alzheimer's disease;
CRC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.47	7.35	0.38	1.54e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg10868875	chr11:61596307	FADS2	-0.55	-7.1	-0.36	7.97e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.88	0.35	3.07e-11	Axial length;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.4	-7.28	-0.37	2.43e-12	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	0.84	9.04	0.45	1.41e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.25	0.33	1.24e-9	Renal function-related traits (BUN);
CRC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8.07e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg21251018	chr6:28226885	NKAPL	0.5	8.2	0.41	5.34e-15	Depression;
CRC	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.63	6.91	0.36	2.54e-11	Childhood ear infection;
CRC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg20607287	chr7:12443886	VWDE	-0.68	-7.35	-0.38	1.59e-12	Coronary artery disease;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01881255	chr19:40950703	SERTAD3	0.45	6.14	0.32	2.39e-9	Anxiety disorder;
CRC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.1	27.56	0.84	1.78e-87	Primary sclerosing cholangitis;
CRC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.31	5.82	0.31	1.42e-8	QRS complex (12-leadsum);
CRC	cis	rs2274273	0.662	rs2147970	chr14:55660217	C/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.75	-0.3	2.08e-8	Protein biomarker;
CRC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06505273	chr16:24850292	NA	-0.39	-5.7	-0.3	2.7e-8	Intelligence (multi-trait analysis);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03506525	chr22:21213099	SNAP29;PI4KA	0.46	6.02	0.31	4.57e-9	Survival in pancreatic cancer;
CRC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.47	6.79	0.35	5.16e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.59	8.59	0.43	3.44e-16	Lymphocyte counts;
CRC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.06	-0.32	3.7e-9	Myopia (pathological);
CRC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.78	-0.35	5.63e-11	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17816893	chr10:118934735	NA	0.46	6.98	0.36	1.63e-11	Intelligence (multi-trait analysis);
CRC	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg25019722	chr6:37503610	NA	-0.37	-6.53	-0.34	2.57e-10	Cognitive performance;
CRC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.57	7.23	0.37	3.49e-12	Vitamin D levels;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg25193742	chr10:104614220	C10orf32	-0.72	-5.97	-0.31	6.32e-9	Cognitive function;
CRC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.85	-13.31	-0.59	1.28e-32	Blood metabolite levels;
CRC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.9	-17.41	-0.69	1.45e-48	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg02569458	chr12:86230093	RASSF9	0.4	6.69	0.35	9.82e-11	Major depressive disorder;
CRC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg24977027	chr2:88469347	THNSL2	0.63	7.75	0.39	1.14e-13	Plasma clusterin levels;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.43	-5.76	-0.3	1.91e-8	Breast cancer;
CRC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.57	-5.88	-0.31	9.94e-9	Hip circumference adjusted for BMI;
CRC	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.47	-0.38	7.11e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.52	8.11	0.41	1.03e-14	Colorectal cancer;
CRC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.92	0.52	6.82e-24	Systolic blood pressure;
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.52	6.99	0.36	1.49e-11	Height;
CRC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.62	-9.33	-0.46	1.56e-18	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs17095355	1.000	rs59804002	chr10:111692043	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.85	-0.35	3.55e-11	Biliary atresia;
CRC	cis	rs12760731	0.565	rs78577576	chr1:178141982	A/G	cg00404053	chr1:178313656	RASAL2	1.02	10.73	0.51	3.15e-23	Obesity-related traits;
CRC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.63	9.72	0.47	8.63e-20	Height;
CRC	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.48	6.93	0.36	2.22e-11	Type 2 diabetes;
CRC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4700695	1.000	rs3846481	chr5:65417803	T/C	cg21114390	chr5:65439923	SFRS12	-0.61	-6.88	-0.35	3.02e-11	Facial morphology (factor 19);
CRC	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.8	-0.4	8.33e-14	Prevalent atrial fibrillation;
CRC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.46	6.08	0.32	3.31e-9	Bladder cancer;
CRC	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.47	6.77	0.35	5.9e-11	Coronary heart disease;
CRC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-13.38	-0.59	6.74e-33	Vitiligo;
CRC	cis	rs12760731	0.920	rs3813637	chr1:178491680	C/G	cg00404053	chr1:178313656	RASAL2	0.72	7.88	0.4	4.93e-14	Obesity-related traits;
CRC	cis	rs6743376	0.556	rs2251876	chr2:113818727	A/G	cg09040174	chr2:113837401	NA	0.38	5.72	0.3	2.36e-8	Inflammatory biomarkers;
CRC	cis	rs6694672	0.867	rs1764629	chr1:197216632	A/G	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.36	2.31e-11	Asthma;
CRC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg11212589	chr17:38028394	ZPBP2	0.43	7.93	0.4	3.34e-14	Self-reported allergy;
CRC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.54	7.24	0.37	3.14e-12	IgG glycosylation;
CRC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.57	-9.05	-0.45	1.27e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.61	-0.34	1.58e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.58	7.74	0.39	1.25e-13	Alzheimer's disease;
CRC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	8.67	0.43	1.98e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg08614441	chr13:113633676	MCF2L	-0.44	-7.92	-0.4	3.63e-14	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06380449	chr17:73255012	GGA3	0.4	6.13	0.32	2.51e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	-0.6	-7.2	-0.37	4.21e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.47	7.86	0.4	5.36e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24308560	chr3:49941425	MST1R	0.45	7.01	0.36	1.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.68	-13.44	-0.6	3.92e-33	Educational attainment;
CRC	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.48	8.14	0.41	7.98e-15	Common traits (Other);
CRC	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg10820045	chr2:198174542	NA	0.39	6.37	0.33	6.39e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.53	7.5	0.38	5.91e-13	Testicular germ cell tumor;
CRC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.68	0.43	1.89e-16	Menopause (age at onset);
CRC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	7.08	0.36	8.58e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	5.9	0.31	9.17e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.21	-0.32	1.63e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6988985	0.728	rs4310186	chr8:143956247	C/G	cg10324643	chr8:143916377	GML	-0.36	-6.03	-0.32	4.44e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-7.69	-0.39	1.76e-13	Extraversion;
CRC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg23996704	chr18:44553084	KATNAL2	-0.31	-6.05	-0.32	4e-9	Personality dimensions;
CRC	cis	rs860295	0.812	rs7556519	chr1:155827546	T/C	cg02153340	chr1:155202674	NA	-0.5	-6.25	-0.33	1.27e-9	Body mass index;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06377929	chr1:1407001	ATAD3B	-0.41	-6.07	-0.32	3.6e-9	Myopia (pathological);
CRC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-6.9	-0.36	2.67e-11	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs10242455	0.702	rs28460612	chr7:98993205	C/G	cg09045935	chr12:6379348	NA	0.99	7.45	0.38	8.27e-13	Blood metabolite levels;
CRC	cis	rs4728142	0.593	rs7808907	chr7:128584084	C/T	cg06630958	chr7:128577819	IRF5	0.35	5.99	0.31	5.38e-9	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg15845792	chr6:28175446	NA	0.59	7.63	0.39	2.61e-13	Parkinson's disease;
CRC	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg01843034	chr6:37503916	NA	-0.48	-8.89	-0.44	4.24e-17	Cognitive performance;
CRC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg09779027	chr19:7224513	INSR	1.04	23.48	0.79	2.77e-72	Hypothyroidism;
CRC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg21138405	chr5:131827807	IRF1	0.37	6.23	0.32	1.42e-9	Breast cancer;Mosquito bite size;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01524359	chr1:46049306	NASP	-0.43	-6.24	-0.33	1.38e-9	Daytime sleep phenotypes;
CRC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.28	0.42	3.22e-15	Menopause (age at onset);
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg04969067	chr8:143858791	LYNX1	0.45	7.59	0.39	3.26e-13	Urinary tract infection frequency;
CRC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs3825932	0.961	rs10400877	chr15:79234378	A/T	cg25744700	chr15:79237217	CTSH	0.4	6.17	0.32	2.02e-9	Type 1 diabetes;
CRC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg20712883	chr12:51590929	POU6F1	0.46	6.29	0.33	1.02e-9	Cisplatin-induced ototoxicity;
CRC	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg25019722	chr6:37503610	NA	-0.41	-6.72	-0.35	8.03e-11	Cognitive performance;
CRC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9463078	0.764	rs976699	chr6:44952852	G/T	cg25276700	chr6:44698697	NA	-0.28	-6.91	-0.36	2.59e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg08314208	chr16:67682810	RLTPR	-0.58	-6.22	-0.32	1.53e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12315302	chr6:26189340	HIST1H4D	0.77	5.99	0.31	5.51e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.6	8.84	0.44	5.92e-17	Lung cancer;
CRC	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.08	-15.25	-0.64	4.51e-40	Exhaled nitric oxide output;
CRC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.34	0.42	2.06e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25517755	chr10:38738941	LOC399744	0.45	6.57	0.34	1.93e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.98	-0.31	5.87e-9	Rheumatoid arthritis;
CRC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.88	0.4	4.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.61	10.07	0.49	5.59e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg04731861	chr2:219085781	ARPC2	0.32	6.88	0.35	3.03e-11	Colorectal cancer;
CRC	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.77	-0.39	1.03e-13	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg24463073	chr6:118973353	C6orf204	0.5	6.69	0.35	9.8e-11	Diastolic blood pressure;
CRC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.56	-5.73	-0.3	2.25e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg18490616	chr2:88469792	THNSL2	0.58	5.85	0.31	1.22e-8	Plasma clusterin levels;
CRC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg00579200	chr11:133705235	NA	-0.41	-5.96	-0.31	6.32e-9	Childhood ear infection;
CRC	cis	rs12928939	0.911	rs11645704	chr16:71826611	G/T	cg08717414	chr16:71523259	ZNF19	-0.51	-6.35	-0.33	7.13e-10	Post bronchodilator FEV1;
CRC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.49	7.95	0.4	3.06e-14	Height;
CRC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg15110403	chr19:17392923	ANKLE1	-0.36	-5.75	-0.3	1.99e-8	Systemic lupus erythematosus;
CRC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.8	0.4	8.2e-14	Colorectal cancer;
CRC	cis	rs6496667	0.779	rs10083679	chr15:91022139	A/G	cg04176472	chr15:90893244	GABARAPL3	0.51	7.33	0.37	1.77e-12	Rheumatoid arthritis;
CRC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.4	7.61	0.39	2.9e-13	Mean corpuscular volume;
CRC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.4	-0.33	5.3e-10	Mean corpuscular volume;
CRC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	cis	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg08989290	chr16:615782	NHLRC4	0.48	9.2	0.45	4.14e-18	Height;
CRC	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-5.65	-0.3	3.4e-8	Osteoarthritis;
CRC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.69	0.39	1.71e-13	Lung cancer;
CRC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg04545296	chr12:48745243	ZNF641	0.33	5.68	0.3	3e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11229555	0.645	rs12269928	chr11:58184358	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg09473613	chr1:24152604	HMGCL	0.34	5.92	0.31	8.21e-9	Immature fraction of reticulocytes;
CRC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.52	8.89	0.44	4.15e-17	Iron status biomarkers;
CRC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg14979609	chr8:8086686	FLJ10661	0.36	5.77	0.3	1.81e-8	Joint mobility (Beighton score);
CRC	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.46	-6.98	-0.36	1.67e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.54	7.14	0.37	5.99e-12	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg24463073	chr6:118973353	C6orf204	0.52	6.9	0.36	2.6e-11	Diastolic blood pressure;
CRC	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg02353165	chr6:42928485	GNMT	0.54	6.91	0.36	2.57e-11	Blood protein levels;
CRC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg20607287	chr7:12443886	VWDE	-0.6	-6.22	-0.32	1.55e-9	Coronary artery disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10387458	chr1:93645817	TMED5;CCDC18	0.42	6.83	0.35	4.11e-11	Obesity-related traits;
CRC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg04731861	chr2:219085781	ARPC2	-0.32	-6.85	-0.35	3.73e-11	Colorectal cancer;
CRC	cis	rs1572438	0.868	rs1577625	chr6:860044	C/A	cg13447295	chr6:887704	NA	-0.44	-6.67	-0.35	1.06e-10	Aging;
CRC	cis	rs501120	0.640	rs10900001	chr10:44695585	C/G	cg09554077	chr10:44749378	NA	0.67	7.47	0.38	7.24e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg19257562	chr1:2043853	PRKCZ	0.39	6.53	0.34	2.5e-10	Height;
CRC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.82	-12.09	-0.55	4.28e-28	Blood metabolite levels;
CRC	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-1.05	-10.69	-0.51	4.34e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.14	-0.37	6.11e-12	IgG glycosylation;
CRC	cis	rs755249	0.567	rs2296172	chr1:39835817	A/G	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.79	-11.12	-0.52	1.39e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.71	10.94	0.52	5.75e-24	Diastolic blood pressure;
CRC	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.55	8.1	0.41	1.12e-14	Night sleep phenotypes;
CRC	trans	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.09	-0.32	3.19e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg12856521	chr11:46389249	DGKZ	0.6	8.78	0.44	9.08e-17	Crohn's disease;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg15786705	chr6:28176104	NA	0.66	8.93	0.44	3.1e-17	Parkinson's disease;
CRC	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg16989719	chr2:238392110	NA	-0.4	-8.25	-0.41	3.95e-15	Prostate cancer;
CRC	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.33	-5.62	-0.3	4.15e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.46	0.38	7.65e-13	Lung cancer in ever smokers;
CRC	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.35	-6.07	-0.32	3.62e-9	Pneumonia;
CRC	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg06522879	chr11:64358276	SLC22A12	0.57	8.85	0.44	5.42e-17	Urate levels in obese individuals;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12273811	chr6:28175739	NA	0.61	8.25	0.41	3.99e-15	Parkinson's disease;
CRC	trans	rs12432203	1.000	rs72622440	chr14:51737191	C/T	cg14592830	chr9:122318704	NA	0.58	6.0	0.31	5.07e-9	Cancer;
CRC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg08807101	chr21:30365312	RNF160	0.58	8.36	0.42	1.84e-15	Selective IgA deficiency;
CRC	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.53	9.43	0.46	7.58e-19	Common traits (Other);
CRC	cis	rs6142102	0.961	rs2268089	chr20:32667298	T/C	cg08999081	chr20:33150536	PIGU	0.38	5.92	0.31	8.21e-9	Skin pigmentation;
CRC	cis	rs9990333	0.622	rs57783901	chr3:195816357	G/A	cg12923728	chr3:195709715	SDHAP1	-0.44	-5.97	-0.31	6.3e-9	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12349875	chr7:32530336	LSM5	0.42	6.1	0.32	2.95e-9	Response to antipsychotic treatment;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25940730	chr4:16228647	TAPT1;FLJ39653	0.4	6.18	0.32	1.87e-9	Interleukin-6 levels;
CRC	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg25482853	chr8:67687455	SGK3	0.65	8.5	0.42	6.61e-16	Obesity-related traits;
CRC	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26714650	chr12:56694279	CS	-1.44	-11.18	-0.52	8.02e-25	Psoriasis vulgaris;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs76533333	0.646	rs71446625	chr13:113390285	G/T	cg04656015	chr13:113407548	ATP11A	0.75	5.75	0.3	2.09e-8	Red cell distribution width;
CRC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-7.41	-0.38	1.04e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.43	6.05	0.32	4.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.62	9.32	0.46	1.78e-18	Dementia with Lewy bodies;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg04816434	chr15:22945077	CYFIP1	-0.53	-6.1	-0.32	2.94e-9	Body mass index;
CRC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.3	-0.33	9.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.68	9.91	0.48	1.96e-20	Schizophrenia;
CRC	trans	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.65e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.04	14.41	0.62	7.52e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.4	-6.5	-0.34	2.93e-10	Hemoglobin concentration;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.45	5.81	0.31	1.46e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.49	-6.68	-0.35	1.05e-10	Height;
CRC	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg20354231	chr13:53171401	NA	-0.52	-8.71	-0.43	1.45e-16	Lewy body disease;
CRC	cis	rs524023	0.629	rs480617	chr11:64478320	C/T	cg06522879	chr11:64358276	SLC22A12	-0.43	-6.33	-0.33	8.07e-10	Urate levels in obese individuals;
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg15147215	chr3:52552868	STAB1	-0.61	-10.31	-0.49	8.95e-22	Bipolar disorder;
CRC	cis	rs3996993	0.597	rs62412888	chr6:52702026	G/A	cg20803780	chr6:52668592	GSTA1	0.4	6.85	0.35	3.63e-11	Hemoglobin concentration;
CRC	cis	rs4743820	0.651	rs73494920	chr9:93923153	G/C	cg14446406	chr9:93919335	NA	0.81	14.88	0.63	1.24e-38	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.45	0.34	3.91e-10	Intraocular pressure;
CRC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg01339444	chr6:118972232	C6orf204	0.53	5.93	0.31	7.73e-9	Diastolic blood pressure;
CRC	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.48	-0.34	3.25e-10	Height;
CRC	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg01620082	chr3:125678407	NA	-0.76	-7.0	-0.36	1.4e-11	Depression;
CRC	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg04837898	chr3:45731254	SACM1L	-0.35	-5.78	-0.3	1.69e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs6681460	1.000	rs7521123	chr1:67121663	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.38	0.42	1.54e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.23	0.53	5.25e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.68	11.48	0.53	7.22e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs587242	1.000	rs61786492	chr1:96904739	A/C	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.67	-11.61	-0.54	2.29e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.54	-8.37	-0.42	1.64e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.77	14.02	0.61	2.45e-35	Prostate cancer;
CRC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg01788221	chr16:89496183	ANKRD11	-0.44	-6.56	-0.34	2.12e-10	Multiple myeloma (IgH translocation);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17182302	chr1:116961525	C1orf203	0.36	6.04	0.32	4.16e-9	Obesity-related traits;
CRC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.81	-12.24	-0.56	1.19e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.6	-10.29	-0.49	9.89e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.72	8.49	0.42	7.22e-16	Bipolar disorder;
CRC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg03037974	chr15:76606532	NA	0.49	7.38	0.38	1.34e-12	Blood metabolite levels;
CRC	cis	rs35000415	0.938	rs10488631	chr7:128594183	T/C	cg19972273	chr7:128594194	NA	0.66	5.99	0.31	5.62e-9	Systemic lupus erythematosus;
CRC	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg02569458	chr12:86230093	RASSF9	-0.4	-6.82	-0.35	4.48e-11	Major depressive disorder;
CRC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-9.1	-0.45	8.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg26182253	chr13:112236782	NA	-0.3	-6.13	-0.32	2.46e-9	Hepatitis;
CRC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.49	6.58	0.34	1.85e-10	Cleft lip with or without cleft palate;
CRC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.46	-7.45	-0.38	8.25e-13	Obesity-related traits;
CRC	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg23417306	chr2:180868811	CWC22	0.49	6.78	0.35	5.51e-11	Schizophrenia;
CRC	cis	rs35520189	0.625	rs12614316	chr2:113705403	T/C	cg12858261	chr2:113808755	IL1F8	0.49	6.82	0.35	4.41e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg15654264	chr1:150340011	RPRD2	-0.4	-5.93	-0.31	7.47e-9	Migraine;
CRC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.76	-0.35	6.21e-11	Dupuytren's disease;
CRC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.49e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.79e-15	Bone mineral density;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.45	-6.7	-0.35	9.29e-11	Systemic lupus erythematosus;
CRC	trans	rs11673344	0.528	rs573294	chr19:37410162	C/T	cg18947437	chr10:1231002	ADARB2	-0.36	-6.39	-0.33	5.73e-10	Obesity-related traits;
CRC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.32	-6.87	-0.35	3.16e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.61	-10.89	-0.51	8.67e-24	Aortic root size;
CRC	cis	rs4073416	0.707	rs8003811	chr14:66211250	C/T	cg03016385	chr14:66212404	NA	-0.42	-5.77	-0.3	1.8e-8	N-glycan levels;
CRC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.51	8.51	0.42	6.32e-16	Aortic root size;
CRC	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.87	0.55	2.81e-27	Exhaled nitric oxide levels;
CRC	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.8	-0.4	8.23e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.3	0.46	2.04e-18	Bladder cancer;
CRC	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	trans	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg20935933	chr6:143382018	AIG1	0.52	6.73	0.35	7.57e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7487075	0.820	rs10880953	chr12:46725869	A/T	cg22049899	chr12:47219821	SLC38A4	0.33	6.35	0.33	7.05e-10	Itch intensity from mosquito bite;
CRC	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.27	0.46	2.51e-18	Blood protein levels;
CRC	cis	rs10924970	0.967	rs2382617	chr1:235402230	A/G	cg26050004	chr1:235667680	B3GALNT2	0.38	5.68	0.3	3.02e-8	Asthma;
CRC	cis	rs3020333	0.875	rs2982570	chr6:152013748	C/T	cg22157087	chr6:152012887	ESR1	0.53	7.87	0.4	5.16e-14	Total body bone mineral density;
CRC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg23018236	chr17:30244563	NA	-0.67	-8.08	-0.41	1.25e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-9.24	-0.45	3.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-8.93	-0.44	3.13e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-8.21	-0.41	4.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.49	7.29	0.37	2.32e-12	Corneal astigmatism;
CRC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg03609598	chr5:56110824	MAP3K1	0.58	8.02	0.4	1.82e-14	Initial pursuit acceleration;
CRC	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg14003231	chr6:33640908	ITPR3	-0.46	-7.68	-0.39	1.81e-13	Plateletcrit;
CRC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.83	-0.35	4.05e-11	Mean corpuscular volume;
CRC	cis	rs758324	0.853	rs10051653	chr5:131248894	G/A	cg25547332	chr5:131281432	NA	-0.36	-5.68	-0.3	2.9e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.64	-9.86	-0.48	2.95e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.66	9.6	0.47	2.07e-19	Menopause (age at onset);
CRC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.11	-0.32	2.83e-9	Eosinophil percentage of white cells;
CRC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.6	8.89	0.44	4.04e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.88	-10.63	-0.51	7.18e-23	Obesity-related traits;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg12172441	chr6:28176163	NA	-0.47	-6.43	-0.33	4.47e-10	Parkinson's disease;
CRC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.46	7.59	0.39	3.24e-13	Schizophrenia;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.5	7.65	0.39	2.3e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs948562	0.947	rs76985515	chr11:58371794	T/C	cg26660744	chr1:1573181	CDK11B	0.54	6.1	0.32	2.94e-9	Lymphoma;
CRC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.53	8.35	0.42	1.91e-15	Monocyte count;
CRC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.8	-14.59	-0.63	1.64e-37	Anterior chamber depth;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05588757	chr2:95825608	ZNF514	0.37	6.01	0.31	4.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.87	-13.75	-0.6	2.54e-34	Cognitive function;
CRC	cis	rs600626	0.636	rs11236517	chr11:75452721	T/C	cg24262691	chr11:75473276	NA	0.54	7.42	0.38	1.04e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.64	9.31	0.46	1.85e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg02733842	chr7:1102375	C7orf50	-0.79	-9.91	-0.48	1.94e-20	Bronchopulmonary dysplasia;
CRC	cis	rs1656402	0.953	rs1190441	chr2:233422237	C/T	cg03852847	chr2:233439513	NA	-0.44	-7.45	-0.38	8.11e-13	Non-small cell lung cancer (survival);
CRC	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	8.17	0.41	6.81e-15	Metabolite levels;
CRC	trans	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg18335740	chr13:41363409	SLC25A15	0.5	7.09	0.36	8.48e-12	Lewy body disease;
CRC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.54	7.21	0.37	3.77e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.53	9.57	0.47	2.67e-19	Lung cancer;
CRC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.56	6.25	0.33	1.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.26	-0.37	2.89e-12	Obesity-related traits;
CRC	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg21153622	chr11:89784906	NA	0.47	7.44	0.38	8.86e-13	HDL cholesterol;
CRC	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg09597638	chr17:3907349	NA	0.4	5.65	0.3	3.43e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.62	-0.3	4.16e-8	Pulmonary function;
CRC	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs11212617	0.967	rs2356802	chr11:108282169	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.45	6.89	0.36	2.79e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg02683197	chr6:28174875	NA	0.59	8.24	0.41	4.23e-15	Parkinson's disease;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg17147758	chr8:6949321	NA	-0.52	-7.35	-0.38	1.6e-12	Blood pressure (smoking interaction);
CRC	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.48	-6.09	-0.32	3.2e-9	Orofacial clefts;
CRC	cis	rs31872	0.597	rs31874	chr5:140369318	C/T	cg08985570	chr5:140589751	PCDHB12	-0.39	-5.73	-0.3	2.25e-8	Visceral adipose tissue adjusted for BMI;
CRC	cis	rs6681460	1.000	rs6656912	chr1:67083671	A/G	cg02459107	chr1:67143332	SGIP1	0.35	5.83	0.31	1.33e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg00105475	chr2:10696890	NA	0.44	7.03	0.36	1.16e-11	Prostate cancer;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg15845792	chr6:28175446	NA	0.8	11.85	0.55	3.22e-27	Parkinson's disease;
CRC	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs73200209	0.744	rs11615877	chr12:116709800	C/T	cg01776926	chr12:116560359	MED13L	-0.62	-7.31	-0.37	2.11e-12	Total body bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03276813	chr2:182757157	SSFA2	0.5	6.51	0.34	2.86e-10	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10169971	chr6:83902988	RWDD2A;PGM3	0.37	6.23	0.32	1.4e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.6	-9.43	-0.46	7.56e-19	Colorectal cancer;
CRC	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.52	-7.17	-0.37	4.84e-12	Blood metabolite levels;
CRC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.52	7.35	0.38	1.57e-12	Aortic root size;
CRC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	8.96	0.44	2.45e-17	Schizophrenia;
CRC	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg07699608	chr10:75541558	CHCHD1	0.67	6.65	0.34	1.19e-10	Incident atrial fibrillation;
CRC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.64	9.28	0.46	2.43e-18	Menopause (age at onset);
CRC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg16434002	chr17:42200994	HDAC5	-0.47	-6.39	-0.33	5.78e-10	Total body bone mineral density;
CRC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg07701084	chr6:150067640	NUP43	0.57	7.77	0.39	1.01e-13	Lung cancer;
CRC	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	8.32	0.42	2.44e-15	Iron status biomarkers;
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.2	0.59	3.17e-32	Alzheimer's disease;
CRC	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.34	-0.42	2.08e-15	Waist circumference adjusted for body mass index;
CRC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.71	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.28	-0.33	1.07e-9	Tonsillectomy;
CRC	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.43	-5.61	-0.3	4.38e-8	Height;
CRC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.83	0.44	6.16e-17	Schizophrenia;
CRC	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-6.09	-0.32	3.13e-9	Coronary artery disease;
CRC	cis	rs9292777	0.865	rs6888952	chr5:40412466	A/G	cg09067459	chr5:40385259	NA	0.51	8.86	0.44	4.94e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.4	5.91	0.31	8.7e-9	Platelet distribution width;
CRC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.06	-18.13	-0.71	2.03e-51	Blood pressure (smoking interaction);
CRC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-11.34	-0.53	2.23e-25	Electrocardiographic conduction measures;
CRC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.51	-6.57	-0.34	1.95e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	0.96	8.82	0.44	6.74e-17	Pulse pressure;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.08	-0.36	8.93e-12	Acylcarnitine levels;
CRC	cis	rs868943	0.582	rs12209747	chr6:116452561	A/G	cg15226275	chr6:116381976	FRK	0.26	6.14	0.32	2.37e-9	Total cholesterol levels;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg04518342	chr5:131593106	PDLIM4	0.51	9.12	0.45	7.89e-18	Blood metabolite levels;
CRC	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.81	8.55	0.43	4.61e-16	Gastritis;
CRC	cis	rs2730260	0.537	rs56023468	chr7:158875329	T/C	cg02254261	chr7:158964346	NA	-0.54	-6.07	-0.32	3.6e-9	Myopia (pathological);
CRC	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.97	-16.54	-0.67	3.64e-45	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg01505111	chr6:125621795	HDDC2	0.4	6.42	0.33	4.73e-10	DNA methylation (variation);
CRC	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.26e-9	Malaria;
CRC	cis	rs6743376	0.556	rs1374285	chr2:113818738	G/A	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.6	8.31	0.42	2.51e-15	Height;
CRC	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.68	10.47	0.5	2.54e-22	Intelligence (multi-trait analysis);
CRC	cis	rs858239	1.000	rs858239	chr7:23286315	G/A	cg00469287	chr7:23338798	C7orf30	0.42	5.63	0.3	3.89e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.15	0.32	2.31e-9	Hemoglobin concentration;
CRC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.58	8.14	0.41	8.04e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	5.76	0.3	1.92e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs35520189	0.796	rs1143627	chr2:113594387	C/T	cg12858261	chr2:113808755	IL1F8	-0.42	-6.61	-0.34	1.58e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg02228675	chr17:40259724	DHX58	-0.49	-6.92	-0.36	2.42e-11	Fibrinogen levels;
CRC	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.82	0.4	7.19e-14	Plateletcrit;
CRC	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg21153622	chr11:89784906	NA	0.45	7.24	0.37	3.21e-12	HDL cholesterol;
CRC	cis	rs11229555	0.598	rs12269888	chr11:58184336	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4964805	0.657	rs73192049	chr12:104187993	T/C	cg02344784	chr12:104178138	NT5DC3	0.79	15.0	0.64	4.21e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg17133734	chr15:86042851	AKAP13	0.39	6.31	0.33	9.23e-10	Interstitial lung disease;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg23161317	chr6:28129485	ZNF389	0.45	6.31	0.33	8.83e-10	Parkinson's disease;
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg22687807	chr8:143858763	LYNX1	0.49	8.85	0.44	5.36e-17	Urinary tract infection frequency;
CRC	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.64	10.07	0.49	5.61e-21	Corneal astigmatism;
CRC	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.48	7.16	0.37	5.44e-12	Red blood cell count;
CRC	cis	rs6534441	0.697	rs56194872	chr4:125418343	G/T	cg21609808	chr4:125404261	NA	0.45	6.38	0.33	6.04e-10	Major depressive disorder;
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg13206674	chr6:150067644	NUP43	0.68	9.64	0.47	1.52e-19	Lung cancer;
CRC	cis	rs4073416	0.542	rs2411815	chr14:66020071	A/T	cg03016385	chr14:66212404	NA	0.42	5.78	0.3	1.69e-8	N-glycan levels;
CRC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.57	-6.99	-0.36	1.55e-11	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg12273811	chr6:28175739	NA	0.54	7.7	0.39	1.59e-13	Parkinson's disease;
CRC	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.96	-0.44	2.56e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.66	-11.47	-0.53	7.41e-26	Depressive symptoms (multi-trait analysis);
CRC	trans	rs16846053	0.786	rs72877309	chr2:162587828	A/G	cg03774468	chr3:140950104	ACPL2	-0.66	-6.02	-0.31	4.63e-9	Blood osmolality (transformed sodium);
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.72	-12.28	-0.56	8.34e-29	Longevity;
CRC	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg11189052	chr15:85197271	WDR73	0.63	8.96	0.44	2.38e-17	Schizophrenia;
CRC	cis	rs9925964	0.967	rs1549293	chr16:31141993	C/T	cg03418659	chr16:31128414	MYST1	0.54	7.86	0.4	5.55e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9463078	0.683	rs1418433	chr6:44752568	C/T	cg25276700	chr6:44698697	NA	0.25	5.94	0.31	7.11e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg17788362	chr6:86352627	SYNCRIP	0.5	6.88	0.35	3e-11	Smooth-surface caries;
CRC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg27523141	chr10:43048294	ZNF37B	0.48	6.99	0.36	1.56e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.71	6.79	0.35	5.34e-11	Diabetic retinopathy;
CRC	cis	rs4481887	0.597	rs6587475	chr1:248578622	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.58	0.34	1.81e-10	Common traits (Other);
CRC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10819733	chr22:24237672	NA	0.36	6.17	0.32	2.06e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	trans	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg15845792	chr6:28175446	NA	0.66	6.42	0.33	4.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.59	-8.97	-0.44	2.32e-17	Dementia with Lewy bodies;
CRC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg03013999	chr17:37608204	MED1	-0.45	-6.87	-0.35	3.16e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg20512303	chr5:131592959	PDLIM4	0.4	7.55	0.38	4.36e-13	Acylcarnitine levels;
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg23807890	chr2:228736357	WDR69	-0.51	-6.99	-0.36	1.56e-11	Blood pressure;
CRC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg13451127	chr3:47050803	NBEAL2	0.21	5.64	0.3	3.61e-8	Colorectal cancer;
CRC	cis	rs6743376	0.556	rs1800930	chr2:113820530	A/G	cg24553058	chr2:113831203	IL1F10	0.44	7.18	0.37	4.61e-12	Inflammatory biomarkers;
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13047869	chr3:10149882	C3orf24	-0.53	-6.58	-0.34	1.82e-10	Alzheimer's disease;
CRC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.6	-6.96	-0.36	1.79e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs861318	0.838	rs855866	chr1:159052720	A/G	cg00508575	chr12:90050967	ATP2B1	-0.43	-6.01	-0.31	4.95e-9	Obesity-related traits;
CRC	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.39	6.6	0.34	1.64e-10	Sitting height ratio;
CRC	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg09760422	chr2:128146352	NA	-0.39	-7.44	-0.38	8.74e-13	Self-rated health;
CRC	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.44	6.39	0.33	5.52e-10	Height;
CRC	cis	rs3015497	0.648	rs10144512	chr14:51082271	A/C	cg09863266	chr14:51125203	SAV1	-0.31	-5.87	-0.31	1.08e-8	Mean platelet volume;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.37	6.68	0.35	1.04e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-12.51	-0.57	1.19e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.12	-0.41	9.51e-15	Mood instability;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg15845792	chr6:28175446	NA	-0.47	-6.51	-0.34	2.78e-10	Systemic lupus erythematosus;
CRC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.73	-12.86	-0.58	6.22e-31	Educational attainment;
CRC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.49	6.32	0.33	8.31e-10	Blood metabolite levels;
CRC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.69	-10.8	-0.51	1.83e-23	Blood protein levels;
CRC	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.46	-6.3	-0.33	9.71e-10	Longevity;Endometriosis;
CRC	trans	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg08566640	chr11:64091735	NA	-0.42	-6.68	-0.35	1.03e-10	Height;
CRC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.48	-7.1	-0.36	7.95e-12	Menarche (age at onset);
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	5.67	0.3	3.16e-8	Blood metabolite levels;
CRC	cis	rs939584	0.877	rs62105307	chr2:633661	A/G	cg03610516	chr2:642275	NA	0.42	5.65	0.3	3.49e-8	Body mass index;
CRC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.57	-7.59	-0.39	3.42e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.47	-6.03	-0.32	4.44e-9	Alopecia areata;
CRC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg11941060	chr3:133502564	NA	0.41	6.54	0.34	2.36e-10	Iron status biomarkers (transferrin levels);
CRC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-5.72	-0.3	2.44e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6076065	0.723	rs2424546	chr20:23391751	G/T	cg11657817	chr20:23433608	CST11	0.43	6.32	0.33	8.28e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs243505	1.000	rs243521	chr7:148421571	T/C	cg09806900	chr7:148480153	CUL1	-0.44	-6.24	-0.33	1.31e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2969070	0.831	rs10279360	chr7:2503998	T/C	cg03277898	chr7:2518824	NA	-0.42	-6.12	-0.32	2.64e-9	Diastolic blood pressure;
CRC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	5.81e-13	Motion sickness;
CRC	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.48	-6.23	-0.32	1.44e-9	Recombination rate (females);
CRC	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg27534772	chr1:16042836	PLEKHM2	0.43	7.23	0.37	3.45e-12	Systolic blood pressure;
CRC	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14019695	chr9:139328340	INPP5E	0.41	6.08	0.32	3.36e-9	Monocyte percentage of white cells;
CRC	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg09324608	chr17:30823087	MYO1D	0.36	6.31	0.33	9.25e-10	Schizophrenia;
CRC	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.46	7.12	0.37	6.81e-12	HDL cholesterol;
CRC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg16476235	chr8:21771668	DOK2	0.4	6.69	0.35	9.59e-11	Mean corpuscular volume;
CRC	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.69	11.55	0.54	3.91e-26	Eosinophil percentage of white cells;
CRC	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg04990556	chr1:26633338	UBXN11	-0.45	-5.76	-0.3	1.94e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.66	7.34	0.37	1.74e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.2	0.45	4.37e-18	Heart rate;
CRC	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg08501292	chr6:25962987	TRIM38	0.87	8.24	0.41	4.22e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Colorectal cancer;
CRC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.51	8.7	0.43	1.58e-16	Aortic root size;
CRC	cis	rs7572644	0.640	rs4564736	chr2:28069543	A/T	cg27432699	chr2:27873401	GPN1	0.45	6.1	0.32	3.03e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs459193	1.000	rs458741	chr5:55807837	T/C	cg26646659	chr5:55776364	NA	0.48	6.64	0.34	1.29e-10	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12172441	chr6:28176163	NA	0.49	6.64	0.34	1.28e-10	Parkinson's disease;
CRC	trans	rs963731	0.649	rs2305516	chr2:39198966	C/T	cg13401531	chr11:70333281	SHANK2	-0.72	-6.17	-0.32	2.05e-9	Corticobasal degeneration;
CRC	cis	rs3823572	0.564	rs2953618	chr7:133672476	G/C	cg03336402	chr7:133662267	EXOC4	-0.68	-10.11	-0.49	4.29e-21	Intelligence (multi-trait analysis);
CRC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.56	9.54	0.47	3.45e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs2257205	0.667	rs8076021	chr17:56694646	T/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.78	-0.3	1.72e-8	Pancreatic cancer;
CRC	cis	rs4716602	0.596	rs10458244	chr7:156164285	C/T	cg16983916	chr7:156159713	NA	-0.39	-6.78	-0.35	5.69e-11	Anti-saccade response;
CRC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.21	14.96	0.64	5.79e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.64	-0.47	1.51e-19	Hip circumference adjusted for BMI;
CRC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.42	-9.15	-0.45	5.94e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg04837898	chr3:45731254	SACM1L	-0.34	-5.68	-0.3	3.03e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.07	-0.32	3.55e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg15845792	chr6:28175446	NA	-0.58	-8.58	-0.43	3.76e-16	Cardiac Troponin-T levels;
CRC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs73206853	0.841	rs73191839	chr12:110967652	G/T	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.67e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17074213	chr1:92351695	TGFBR3	0.48	6.42	0.33	4.9e-10	Survival in pancreatic cancer;
CRC	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg10517650	chr3:113235015	CCDC52	-0.38	-5.91	-0.31	8.52e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.07	15.31	0.65	2.62e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4731207	0.596	rs10264766	chr7:124572916	T/A	cg23710748	chr7:124431027	NA	-0.44	-6.94	-0.36	2.09e-11	Cutaneous malignant melanoma;
CRC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.09	-0.69	2.69e-47	Primary sclerosing cholangitis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg24344011	chr20:39666465	PRO0628;TOP1	-0.37	-6.23	-0.32	1.46e-9	HDL cholesterol;
CRC	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg23254163	chr1:152506842	NA	-0.44	-8.5	-0.42	6.92e-16	Hair morphology;
CRC	cis	rs758324	0.773	rs4540167	chr5:131163022	G/A	cg25547332	chr5:131281432	NA	0.37	5.91	0.31	8.53e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	trans	rs724568	0.681	rs1978656	chr2:67920009	A/G	cg26386464	chr8:38033970	LSM1;BAG4	-0.41	-6.06	-0.32	3.71e-9	Major depressive disorder (broad);
CRC	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.87	-0.31	1.04e-8	Pulmonary function;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.65	9.98	0.48	1.12e-20	Longevity;Endometriosis;
CRC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg13798780	chr7:105162888	PUS7	0.63	7.16	0.37	5.16e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.42	6.35	0.33	6.97e-10	Mean platelet volume;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15726318	chr8:71315757	NCOA2	-0.36	-6.0	-0.31	5.24e-9	Myopia (pathological);
CRC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.35	-0.38	1.55e-12	Gut microbiome composition (summer);
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.88	-0.31	9.88e-9	Depression;
CRC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.5	7.7	0.39	1.5700000000000001e-13	Alzheimer's disease (late onset);
CRC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-8.87	-0.44	4.6e-17	HDL cholesterol;
CRC	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	10.96	0.52	4.72e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.4	-9.28	-0.46	2.4e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.5	-5.66	-0.3	3.31e-8	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24082730	chr3:126076366	KLF15	0.46	7.53	0.38	4.93e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs13128441	0.593	rs4370072	chr4:5149543	C/T	cg24266670	chr11:115630629	NA	-0.4	-6.1	-0.32	3.01e-9	Celiac disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05984320	chr8:144373269	ZNF696	0.46	6.33	0.33	7.96e-10	Anxiety disorder;
CRC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.6	-9.34	-0.46	1.49e-18	Aortic root size;
CRC	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22687382	chr19:2151882	AP3D1	-0.52	-6.36	-0.33	6.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg20356878	chr3:121714668	ILDR1	-0.49	-6.49	-0.34	3.23e-10	Multiple sclerosis;
CRC	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.53	5.93	0.31	7.74e-9	Pulse pressure;
CRC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg05673287	chr15:77411982	SGK269	-0.54	-8.33	-0.42	2.27e-15	Type 2 diabetes;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg15845792	chr6:28175446	NA	0.88	9.19	0.45	4.49e-18	Lung cancer in ever smokers;
CRC	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg18200150	chr17:30822561	MYO1D	0.45	8.6	0.43	3.21e-16	Schizophrenia;
CRC	cis	rs34293785	1.000	rs34293785	chr1:66137192	T/C	cg04111102	chr1:66153794	NA	0.35	6.02	0.31	4.67e-9	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
CRC	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg15786705	chr6:28176104	NA	0.64	5.9	0.31	9.03e-9	Depression;
CRC	trans	rs11581859	1.000	rs56027883	chr1:99311121	A/G	cg12183875	chr3:169587454	LRRC31	0.25	5.96	0.31	6.55e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.62	8.11	0.41	1e-14	Alzheimer's disease;
CRC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.52	7.54	0.38	4.53e-13	Colorectal cancer;
CRC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg18490616	chr2:88469792	THNSL2	-0.43	-6.17	-0.32	2.01e-9	Response to metformin (IC50);
CRC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	ch.7.38331565R	chr7:38365040	NA	0.42	6.32	0.33	8.7e-10	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.72	12.73	0.57	1.87e-30	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	7.14	0.37	5.88e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.79	-12.8	-0.58	1.0500000000000001e-30	Glaucoma (primary open-angle);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07769507	chr4:57844949	POLR2B;C4orf14	0.45	6.38	0.33	5.92e-10	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.53	-0.34	2.55e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.47	-0.34	3.57e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9826463	0.582	rs11708870	chr3:142070013	A/G	cg20824294	chr3:142316082	PLS1	0.35	5.67	0.3	3.1e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs10788264	0.716	rs7091348	chr10:124016160	C/T	cg09507567	chr10:124027408	NA	0.28	5.92	0.31	8.22e-9	Total body bone mineral density;
CRC	trans	rs13315871	0.585	rs12107189	chr3:58349022	C/T	cg25250853	chr2:85822726	RNF181	0.52	6.16	0.32	2.09e-9	Cholesterol, total;
CRC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg00105475	chr2:10696890	NA	-0.45	-7.26	-0.37	2.81e-12	Prostate cancer;
CRC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.52	8.23	0.41	4.52e-15	Red blood cell count;
CRC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-15.62	-0.65	1.57e-41	Prostate cancer;
CRC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.43	8.11	0.41	9.96e-15	Childhood ear infection;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg15763984	chr4:1342303	KIAA1530	0.34	5.67	0.3	3.2e-8	Obesity-related traits;
CRC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.73	-11.79	-0.54	5.53e-27	Breast cancer;
CRC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.7	9.06	0.45	1.15e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.65	8.63	0.43	2.69e-16	Interstitial lung disease;
CRC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg16102536	chr7:156981717	UBE3C	-0.4	-6.73	-0.35	7.4e-11	Body mass index;
CRC	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.92	11.19	0.53	7.51e-25	Exhaled nitric oxide output;
CRC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.43	7.53	0.38	4.78e-13	Major depressive disorder;
CRC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.42	6.96	0.36	1.89e-11	Major depressive disorder;
CRC	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.43	6.36	0.33	6.77e-10	Red blood cell count;
CRC	cis	rs6499255	0.951	rs57565297	chr16:69723122	G/T	cg04110750	chr16:69646130	NFAT5	-0.58	-7.91	-0.4	3.88e-14	IgE levels;
CRC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.66	10.33	0.49	7.58e-22	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	8.06	0.41	1.45e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg12179176	chr11:130786555	SNX19	0.58	8.48	0.42	7.99e-16	Schizophrenia;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.33e-18	Blood pressure (smoking interaction);
CRC	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-5.99	-0.31	5.51e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03992926	chr1:186344761	TPR;C1orf27;MIR548F1	0.39	6.37	0.33	6.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23226852	chr1:51425652	FAF1	-0.38	-6.21	-0.32	1.56e-9	Obesity-related traits;
CRC	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-6.52	-0.34	2.65e-10	Schizophrenia;
CRC	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.48	7.45	0.38	8.18e-13	Red blood cell count;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg18301423	chr5:131593218	PDLIM4	-0.31	-5.9	-0.31	8.8e-9	Breast cancer;
CRC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	7.38	0.38	1.29e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.59	11.09	0.52	1.65e-24	Hematocrit;
CRC	cis	rs56146971	0.763	rs28624795	chr14:91859055	C/T	cg16433844	chr14:91963127	SMEK1	-0.59	-6.09	-0.32	3.17e-9	Alzheimer disease and age of onset;
CRC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg26805224	chr10:79626177	DLG5	-0.49	-7.31	-0.37	2.02e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.88	-0.31	1.01e-8	Blood protein levels;
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg09218773	chr11:619014	MUPCDH	-0.4	-6.23	-0.32	1.42e-9	Systemic lupus erythematosus;
CRC	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.56	7.27	0.37	2.61e-12	Coronary artery disease;
CRC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg01788221	chr16:89496183	ANKRD11	-0.45	-6.83	-0.35	4.12e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs9786986	0.665	rs12402210	chr1:235701708	T/A	cg08848088	chr1:235714526	GNG4	0.57	6.71	0.35	8.3e-11	Body mass index;
CRC	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.93	-0.31	7.52e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4684776	0.676	rs3732941	chr3:11304575	A/G	cg00170343	chr3:11313890	ATG7	-0.49	-5.8	-0.3	1.52e-8	Small vessel stroke;
CRC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.04	18.48	0.71	8.19e-53	Parkinson's disease;
CRC	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02757696	chr20:33104113	DYNLRB1	-0.4	-5.98	-0.31	5.82e-9	Daytime sleep phenotypes;
CRC	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.44	6.45	0.34	4.01e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg07392085	chr5:141489673	NDFIP1	0.46	7.24	0.37	3.17e-12	Asthma;
CRC	cis	rs929596	0.564	rs2741042	chr2:234565917	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-5.85	-0.31	1.18e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg27388017	chr19:12273827	ZNF136	0.39	6.05	0.32	3.92e-9	Schizophrenia;
CRC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.29	-0.59	1.51e-32	Blood trace element (Zn levels);
CRC	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg23234261	chr14:55582407	NA	-0.29	-5.73	-0.3	2.32e-8	Protein biomarker;
CRC	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg24759859	chr6:86352639	SYNCRIP	0.48	6.68	0.35	1.05e-10	Smooth-surface caries;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg03623178	chr6:28175578	NA	0.76	8.16	0.41	7.12e-15	Parkinson's disease;
CRC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.44	6.71	0.35	8.71e-11	Coronary artery disease;
CRC	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.54	7.65	0.39	2.2e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7725052	0.609	rs10059585	chr5:40443644	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.6	-0.34	1.68e-10	Pediatric autoimmune diseases;
CRC	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.42	7.5	0.38	5.89e-13	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.56	9.0	0.44	1.9e-17	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09431544	chr19:14629187	DNAJB1	0.36	6.34	0.33	7.42e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs72687362	0.560	rs55878729	chr8:143373005	C/T	cg02224795	chr8:143363873	TSNARE1	0.34	5.68	0.3	2.93e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.93	-0.36	2.24e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs11203032	0.831	rs10887928	chr10:90945861	A/T	cg16672925	chr10:90967113	CH25H	0.45	5.73	0.3	2.31e-8	Heart failure;
CRC	cis	rs1572438	0.862	rs9378515	chr6:858212	A/G	cg13447295	chr6:887704	NA	-0.41	-5.9	-0.31	8.87e-9	Aging;
CRC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg03929089	chr4:120376271	NA	-0.46	-6.37	-0.33	6.23e-10	Height;
CRC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.29	5.84	0.31	1.27e-8	Methadone dose in opioid dependence;
CRC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.66	-12.33	-0.56	5.49e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg15511327	chr8:143859410	LYNX1	0.5	8.8	0.44	7.76e-17	Urinary tract infection frequency;
CRC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.66	-7.83	-0.4	6.8e-14	IgG glycosylation;
CRC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.47	7.59	0.39	3.3e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.28	-0.46	2.37e-18	Rheumatoid arthritis;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.77	-0.35	5.8200000000000003e-11	Longevity;Endometriosis;
CRC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.98	-0.31	5.69e-9	Daytime sleep phenotypes;
CRC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg24253500	chr15:84953950	NA	0.39	6.29	0.33	1.02e-9	Schizophrenia;
CRC	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg26805224	chr10:79626177	DLG5	-0.54	-8.02	-0.4	1.91e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg12172441	chr6:28176163	NA	0.46	6.45	0.34	3.93e-10	Parkinson's disease;
CRC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg24588162	chr13:113633484	MCF2L	-0.42	-7.46	-0.38	7.57e-13	Systolic blood pressure;
CRC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.66	7.5	0.38	6.14e-13	Cleft lip with or without cleft palate;
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg24675056	chr1:15929824	NA	0.51	7.04	0.36	1.15e-11	Systolic blood pressure;
CRC	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.58	7.38	0.38	1.28e-12	Diisocyanate-induced asthma;
CRC	cis	rs11212617	0.967	rs9667658	chr11:108276091	C/G	cg01991180	chr11:108092276	ATM;NPAT	-0.4	-5.66	-0.3	3.38e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10668512	chr15:42565522	GANC;TMEM87A	0.5	6.56	0.34	2.1e-10	Thyroid stimulating hormone;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg15845792	chr6:28175446	NA	0.96	12.86	0.58	6.21e-31	Depression;
CRC	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg06581033	chr10:766294	NA	-0.54	-5.74	-0.3	2.13e-8	Uric acid levels;
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.29	-0.37	2.38e-12	Lymphocyte counts;
CRC	trans	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg17903999	chr18:56338584	MALT1	0.4	6.52	0.34	2.71e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.08	-0.45	9.9e-18	Alzheimer's disease;
CRC	cis	rs7333181	1.000	rs1756091	chr13:112219853	A/C	cg27543320	chr13:112200689	NA	-0.4	-5.7	-0.3	2.68e-8	Menopause (age at onset);
CRC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg20885578	chr2:198174922	NA	-0.37	-6.45	-0.34	3.91e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4363385	0.693	rs368076	chr1:153046514	A/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.86e-10	Inflammatory skin disease;
CRC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.94e-15	Life satisfaction;
CRC	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg22878388	chr2:105853796	NA	-0.31	-5.99	-0.31	5.56e-9	Type 2 diabetes;
CRC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.39	6.5	0.34	3.01e-10	Height;
CRC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.67	-10.87	-0.51	1.01e-23	Sudden cardiac arrest;
CRC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.58	8.73	0.43	1.32e-16	Aortic root size;
CRC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.43	8.49	0.42	7.16e-16	Vitiligo;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16401214	chr16:15982478	C16orf63	0.44	6.08	0.32	3.41e-9	Anxiety disorder;
CRC	cis	rs540254	0.551	rs1961611	chr1:160773029	G/A	cg20255094	chr1:160771763	LY9	0.49	6.39	0.33	5.68e-10	Blood protein levels;
CRC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	7.75	0.39	1.19e-13	Personality dimensions;
CRC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg19223190	chr17:80058835	NA	-0.41	-6.54	-0.34	2.36e-10	Life satisfaction;
CRC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.93	-17.08	-0.69	2.88e-47	Height;
CRC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg07865391	chr16:88106882	BANP	0.46	6.04	0.32	4.23e-9	Menopause (age at onset);
CRC	trans	rs6964833	1.000	rs17515241	chr7:74132014	C/T	cg07504079	chr7:72649617	NCF1B	0.46	6.11	0.32	2.76e-9	Menarche (age at onset);
CRC	cis	rs459193	1.000	rs30000	chr5:55803533	G/A	cg26646659	chr5:55776364	NA	0.49	6.72	0.35	7.87e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg10483660	chr13:112241077	NA	0.38	5.98	0.31	5.94e-9	Menarche (age at onset);
CRC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg11292332	chr7:45801988	SEPT13	-0.36	-6.3	-0.33	9.74e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs13315871	1.000	rs9819072	chr3:58353647	A/C	cg20936604	chr3:58311152	NA	-0.75	-6.89	-0.35	2.89e-11	Cholesterol, total;
CRC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.51	-5.74	-0.3	2.13e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg15440763	chr7:158190612	PTPRN2	0.42	6.55	0.34	2.24e-10	Obesity-related traits;
CRC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.04e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.47	7.61	0.39	3e-13	Testicular germ cell tumor;
CRC	trans	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg17903999	chr18:56338584	MALT1	0.43	6.86	0.35	3.43e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7527798	0.592	rs11118281	chr1:207832102	C/T	cg09232269	chr1:207846808	CR1L	-0.51	-8.12	-0.41	9.14e-15	Erythrocyte sedimentation rate;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12963246	chr6:28129442	ZNF389	0.48	5.67	0.3	3.1e-8	Depression;
CRC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.29	-0.33	1e-9	Bipolar disorder;
CRC	trans	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg07817883	chr1:32538562	TMEM39B	-0.64	-8.22	-0.41	4.87e-15	Monocyte percentage of white cells;
CRC	trans	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.38	-0.33	5.9e-10	Aortic root size;
CRC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg20354231	chr13:53171401	NA	-0.52	-7.95	-0.4	2.95e-14	Lewy body disease;
CRC	cis	rs1572438	0.931	rs9406099	chr6:867030	A/G	cg21062780	chr6:887772	NA	-0.39	-6.2	-0.32	1.7e-9	Aging;
CRC	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.59	8.46	0.42	8.91e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs728616	0.558	rs2343302	chr10:82163186	A/G	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.97	-0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	16.79	0.68	3.83e-46	Chronic sinus infection;
CRC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.32	4.61e-9	Morning vs. evening chronotype;
CRC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.6	-7.1	-0.36	7.75e-12	Vitiligo;
CRC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.76	12.62	0.57	4.84e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.63	-7.67	-0.39	1.94e-13	Initial pursuit acceleration;
CRC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg00074818	chr8:8560427	CLDN23	0.41	7.36	0.38	1.45e-12	Obesity-related traits;
CRC	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-6.07	-0.32	3.59e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4728302	0.869	rs6954712	chr7:133618853	G/A	cg03336402	chr7:133662267	EXOC4	-0.44	-6.41	-0.33	4.96e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	6.77	0.35	5.85e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg07274523	chr3:49395745	GPX1	0.47	6.07	0.32	3.48e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg02683197	chr6:28174875	NA	0.65	6.84	0.35	3.95e-11	Parkinson's disease;
CRC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.98	0.58	2.23e-31	Bone mineral density;
CRC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg09582351	chr12:29534625	ERGIC2	0.34	7.47	0.38	7.38e-13	QT interval;
CRC	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg15192750	chr16:69999425	NA	0.56	7.44	0.38	9.02e-13	IgE levels;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.12	0.32	2.71e-9	Prudent dietary pattern;
CRC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	0.96	7.47	0.38	7.05e-13	Type 2 diabetes nephropathy;
CRC	cis	rs1760803	0.754	rs3762339	chr1:154208877	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-5.94	-0.31	7.2e-9	Nicotine dependence;
CRC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-6.95	-0.36	1.92e-11	Self-reported allergy;
CRC	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.48	-6.06	-0.32	3.69e-9	Crohn's disease;
CRC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.82	12.6	0.57	5.49e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg21285383	chr16:89894308	SPIRE2	0.36	6.12	0.32	2.73e-9	Vitiligo;
CRC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg12564285	chr5:131593104	PDLIM4	0.38	7.39	0.38	1.19e-12	Blood metabolite levels;
CRC	trans	rs2303319	0.582	rs72870248	chr2:162435849	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.03	-0.32	4.44e-9	Cognitive function;
CRC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg20243544	chr17:37824526	PNMT	0.57	9.04	0.45	1.33e-17	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08274380	chr1:109419600	GPSM2	0.38	6.11	0.32	2.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg03790207	chr6:42947109	PEX6	0.53	7.82	0.4	7.41e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.29	6.04	0.32	4.17e-9	Lung cancer;
CRC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg12365402	chr11:9010492	NRIP3	-0.57	-10.74	-0.51	2.88e-23	Hemoglobin concentration;
CRC	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg02574844	chr11:5959923	NA	0.4	5.72	0.3	2.4e-8	DNA methylation (variation);
CRC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg13844804	chr7:814759	HEATR2	0.68	7.94	0.4	3.3e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs10746514	0.931	rs11582890	chr1:232251218	C/T	cg09506761	chr1:232265262	NA	0.43	5.63	0.3	3.79e-8	Response to statin therapy;
CRC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	5.87	0.31	1.06e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7264396	0.573	rs58355182	chr20:34075687	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.53	-0.34	2.44e-10	Total cholesterol levels;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.29e-9	Depression;
CRC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.28	15.26	0.64	3.9e-40	Uric acid levels;
CRC	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.44	6.33	0.33	7.97e-10	Coronary artery disease;
CRC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg17401720	chr7:158221031	PTPRN2	0.39	6.05	0.32	3.9e-9	Obesity-related traits;
CRC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.42	0.42	1.16e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg11204139	chr17:3907470	NA	-0.76	-13.54	-0.6	1.71e-33	Type 2 diabetes;
CRC	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	trans	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.21	-0.37	3.81e-12	Endometrial cancer;
CRC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01338834	chr21:40720919	HMGN1	0.44	6.55	0.34	2.28e-10	Myopia (pathological);
CRC	cis	rs11608355	0.508	rs2075434	chr12:109797051	G/A	cg19025524	chr12:109796872	NA	-0.51	-7.63	-0.39	2.56e-13	Neuroticism;
CRC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	11.78	0.54	5.78e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.78	-0.35	5.58e-11	Dupuytren's disease;
CRC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.29	-5.72	-0.3	2.45e-8	Breast cancer;
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.06	-0.32	3.67e-9	Blood osmolality (transformed sodium);
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg07404485	chr7:94953653	PON1	-0.45	-6.14	-0.32	2.44e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12044355	0.927	rs16854809	chr1:231839247	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.94	0.31	7.06e-9	Alzheimer's disease;
CRC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg12311346	chr5:56204834	C5orf35	0.45	6.99	0.36	1.5e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6834538	0.539	rs10434013	chr4:113401356	T/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.39	-5.75	-0.3	2.02e-8	Free thyroxine concentration;
CRC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.71	9.64	0.47	1.6e-19	Cognitive function;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg07617317	chr6:118971624	C6orf204	0.52	6.48	0.34	3.43e-10	Diastolic blood pressure;
CRC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.41	5.88	0.31	9.96e-9	Plateletcrit;
CRC	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12560992	chr17:57184187	TRIM37	0.53	7.36	0.38	1.47e-12	Testicular germ cell tumor;
CRC	cis	rs12760731	0.668	rs72482621	chr1:178410442	C/T	cg00404053	chr1:178313656	RASAL2	0.96	9.87	0.48	2.62e-20	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.87	-0.35	3.13e-11	Lung cancer;
CRC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	6.35	0.33	7.15e-10	Personality dimensions;
CRC	trans	rs8005150	0.737	rs7156254	chr14:88481294	G/A	cg25527770	chr19:1444892	NA	-0.58	-6.24	-0.33	1.32e-9	Hepatitis B;
CRC	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-6.28	-0.33	1.06e-9	Immature fraction of reticulocytes;
CRC	cis	rs2274471	0.645	rs2031907	chr9:5087596	G/A	cg03390472	chr9:5043263	JAK2	-0.56	-6.01	-0.31	4.92e-9	Crohn's disease;
CRC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.57	9.65	0.47	1.48e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.4	6.05	0.32	3.83e-9	Endometrial cancer;
CRC	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.59	8.63	0.43	2.75e-16	Autism;
CRC	trans	rs9341835	0.679	rs9344137	chr6:64156964	A/T	cg13657004	chr13:50234944	EBPL	-0.38	-6.27	-0.33	1.15e-9	Schizophrenia;
CRC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	11.07	0.52	1.99e-24	Mean platelet volume;
CRC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25517755	chr10:38738941	LOC399744	-0.41	-6.09	-0.32	3.13e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg15845792	chr6:28175446	NA	0.71	6.22	0.32	1.51e-9	Depression;
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.46	6.48	0.34	3.27e-10	Lymphocyte counts;
CRC	cis	rs9549328	0.616	rs35086993	chr13:113617305	G/A	cg08614441	chr13:113633676	MCF2L	0.4	7.08	0.36	8.76e-12	Systolic blood pressure;
CRC	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg15147215	chr3:52552868	STAB1	0.38	5.77	0.3	1.81e-8	Schizophrenia;
CRC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.3	0.33	9.59e-10	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg17321639	chr7:2759063	NA	-0.42	-6.27	-0.33	1.11e-9	Height;
CRC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	6.03e-10	Red blood cell count;
CRC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.47	0.38	7.24e-13	Mean platelet volume;
CRC	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg09659197	chr4:152720779	NA	0.41	8.44	0.42	1.06e-15	Intelligence (multi-trait analysis);
CRC	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.57	8.27	0.41	3.44e-15	Inhibitory control;
CRC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.47	-6.99	-0.36	1.57e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs3889199	0.924	rs12569192	chr1:59676567	G/A	cg25881383	chr1:59680599	NA	-0.38	-6.05	-0.32	3.94e-9	Pulse pressure;
CRC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg00343986	chr7:65444356	GUSB	0.49	7.32	0.37	1.92e-12	Aortic root size;
CRC	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.67	11.63	0.54	2.04e-26	Blood protein levels;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg20512303	chr5:131592959	PDLIM4	0.4	7.58	0.39	3.67e-13	Acylcarnitine levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg00528793	chr22:19842837	GNB1L;C22orf29	0.44	5.98	0.31	5.92e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01363902	chr12:121022439	NA	0.43	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
CRC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.61	10.17	0.49	2.55e-21	Age at first birth;
CRC	trans	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.56	-0.38	3.97e-13	Bone mineral density;
CRC	trans	rs12940923	1.000	rs11658637	chr17:56376508	A/G	cg16900910	chr15:72789182	ARIH1	0.53	6.04	0.32	4.09e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.98	-0.31	5.87e-9	Orofacial clefts;
CRC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.36	0.33	6.57e-10	Rheumatoid arthritis;
CRC	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg13919466	chr1:32135498	COL16A1	-0.31	-5.82	-0.31	1.42e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.68	-10.46	-0.5	2.75e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11212617	0.967	rs4987982	chr11:108151269	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.24	0.33	1.38e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.94	0.31	7.06e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg02527881	chr3:46936655	PTH1R	0.38	6.98	0.36	1.63e-11	Colorectal cancer;
CRC	cis	rs7215564	0.908	rs34267318	chr17:78664619	G/A	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg07636037	chr3:49044803	WDR6	-0.68	-6.79	-0.35	5.19e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg27053337	chr8:124217698	FAM83A	0.45	6.81	0.35	4.55e-11	Urinary uromodulin levels;
CRC	cis	rs10208940	0.619	rs34187568	chr2:68863493	C/T	cg12452813	chr2:68675892	NA	0.52	6.34	0.33	7.55e-10	Urate levels in lean individuals;
CRC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.95	-13.52	-0.6	1.94e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4692589	0.581	rs62344678	chr4:170961308	G/A	cg19918862	chr4:170955249	NA	0.53	6.98	0.36	1.66e-11	Anxiety disorder;
CRC	cis	rs6496667	0.779	rs2283443	chr15:91001300	C/G	cg04176472	chr15:90893244	GABARAPL3	0.58	8.33	0.42	2.29e-15	Rheumatoid arthritis;
CRC	cis	rs459193	1.000	rs30000	chr5:55803533	G/A	cg18302225	chr5:55776401	NA	0.59	8.67	0.43	1.98e-16	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.65	12.02	0.55	7.5e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.82	0.31	1.36e-8	Heart rate;
CRC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg02135003	chr7:105160482	PUS7	-0.92	-12.45	-0.57	2.03e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.63	11.13	0.52	1.21e-24	Schizophrenia;
CRC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.03	-10.3	-0.49	9.36e-22	Body mass index;
CRC	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.64	6.72	0.35	7.95e-11	Chronic lymphocytic leukemia;
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg07617317	chr6:118971624	C6orf204	0.52	6.52	0.34	2.68e-10	Diastolic blood pressure;
CRC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.8	-0.44	7.65e-17	Aortic root size;
CRC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.85	0.44	5.63e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.48	-0.38	7.03e-13	Educational attainment;
CRC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.66	9.35	0.46	1.44e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.14	0.32	2.31e-9	Bipolar disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27109030	chr19:2702898	GNG7	-0.37	-6.06	-0.32	3.65e-9	Myopia (pathological);
CRC	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.26	-0.33	1.17e-9	Superior frontal gyrus grey matter volume;
CRC	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg21153622	chr11:89784906	NA	-0.44	-7.11	-0.36	7.07e-12	HDL cholesterol;
CRC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.93	-0.31	7.47e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.65	-8.26	-0.41	3.52e-15	Platelet count;
CRC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.13e-40	Gut microbiome composition (summer);
CRC	trans	rs9561329	0.800	rs9524036	chr13:94037300	T/A	cg23072629	chr2:239195537	PER2	0.33	6.26	0.33	1.2e-9	Neuroticism (age interaction);
CRC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg09324608	chr17:30823087	MYO1D	0.39	6.55	0.34	2.22e-10	Schizophrenia;
CRC	cis	rs7894407	0.760	rs1163085	chr10:105039241	G/A	cg05636881	chr10:105038444	INA	0.37	5.97	0.31	6.15e-9	White matter hyperintensity burden;
CRC	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	9.77	0.47	5.7e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6546324	0.625	rs2861640	chr2:67794589	G/C	cg15745817	chr2:67799979	NA	-0.54	-9.09	-0.45	9.4e-18	Endometriosis;
CRC	cis	rs7739232	0.920	rs77164467	chr6:53529687	G/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg24881330	chr22:46731750	TRMU	0.7	8.57	0.43	3.99e-16	LDL cholesterol;Cholesterol, total;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14546197	chr17:38137043	PSMD3	0.4	6.35	0.33	7.1e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	7.62	0.39	2.73e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.54	8.68	0.43	1.89e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.37	5.68	0.3	2.9e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs10050311	0.698	rs3775238	chr4:87633384	G/A	cg00004207	chr2:38977301	SFRS7	0.53	6.47	0.34	3.6e-10	Insulin-related traits;
CRC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg14711859	chr11:8959438	ASCL3	0.43	6.83	0.35	4.16e-11	Hemoglobin concentration;
CRC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.54	6.99	0.36	1.5e-11	Morning vs. evening chronotype;
CRC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.66	-7.88	-0.4	4.76e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg13615338	chr4:55094005	PDGFRA	0.4	5.8	0.3	1.57e-8	Corneal astigmatism;
CRC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.42	-9.02	-0.45	1.56e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.77	13.12	0.59	6.18e-32	Longevity;
CRC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.76	0.35	6.39e-11	Body mass index;
CRC	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg09218773	chr11:619014	MUPCDH	-0.36	-5.71	-0.3	2.56e-8	Systemic lupus erythematosus;
CRC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg14541582	chr5:601475	NA	-0.25	-5.65	-0.3	3.48e-8	Obesity-related traits;
CRC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	6.99	0.36	1.51e-11	Platelet count;
CRC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.93	17.33	0.69	2.93e-48	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15761814	chr2:109403565	CCDC138	0.49	7.02	0.36	1.3e-11	Response to antipsychotic treatment;
CRC	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.5	7.85	0.4	5.97e-14	Schizophrenia;
CRC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-13.42	-0.59	4.59e-33	Vitiligo;
CRC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.03	-22.9	-0.78	4.58e-70	Myeloid white cell count;
CRC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-8.24	-0.41	4.25e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg24675056	chr1:15929824	NA	0.49	6.66	0.34	1.12e-10	Systolic blood pressure;
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.04	0.36	1.11e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.32	0.33	8.68e-10	Lung cancer;
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg03188948	chr7:1209495	NA	0.41	5.87	0.31	1.08e-8	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15400169	chr12:120639619	RPLP0	0.39	6.11	0.32	2.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.48	-8.66	-0.43	2.15e-16	Birth weight;
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.62	7.61	0.39	2.98e-13	Alzheimer's disease;
CRC	cis	rs16867335	1.000	rs6739798	chr2:181465853	T/C	cg23363182	chr2:181467187	NA	-0.49	-6.62	-0.34	1.45e-10	Survival in rectal cancer;
CRC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs243505	0.691	rs243486	chr7:148448221	A/C	cg09806900	chr7:148480153	CUL1	-0.59	-7.5	-0.38	5.93e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19046167	chr17:80928561	B3GNTL1	0.51	7.07	0.36	9.59e-12	Glycated hemoglobin levels;
CRC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-7.78	-0.39	9.57e-14	Initial pursuit acceleration;
CRC	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.88	16.93	0.68	1.06e-46	Hip circumference;
CRC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.49	8.44	0.42	1e-15	Coronary artery disease;
CRC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.6	-0.43	3.21e-16	Aortic root size;
CRC	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.2	-0.45	4.3e-18	Migraine;Coronary artery disease;
CRC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg00343986	chr7:65444356	GUSB	0.42	5.93	0.31	7.86e-9	Aortic root size;
CRC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11645453	chr3:52864694	ITIH4	0.45	8.13	0.41	9.1e-15	Bipolar disorder;
CRC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg14122633	chr5:456516	EXOC3	-0.4	-7.11	-0.36	7.32e-12	Cystic fibrosis severity;
CRC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.55	0.34	2.17e-10	Mean platelet volume;
CRC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-7.59	-0.39	3.23e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg13837822	chr10:26931731	LOC731789	0.58	8.96	0.44	2.51e-17	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.55	-7.46	-0.38	7.91e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.17	-0.32	2.06e-9	Morning vs. evening chronotype;
CRC	trans	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.64	10.57	0.5	1.09e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.63	-0.39	2.48e-13	Heart rate;
CRC	cis	rs6764363	0.504	rs13077665	chr3:277878	C/G	cg02057681	chr3:285234	CHL1	0.42	7.14	0.37	5.94e-12	Sudden cardiac arrest;
CRC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.46	-0.38	7.59e-13	Morning vs. evening chronotype;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg12032191	chr1:46152434	TMEM69;GPBP1L1	-0.42	-6.02	-0.31	4.63e-9	Brain structure;
CRC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	12.97	0.58	2.27e-31	Hip circumference adjusted for BMI;
CRC	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.26e-10	Blood metabolite levels;
CRC	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.79	-0.39	8.84e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.54	-6.73	-0.35	7.59e-11	Platelet distribution width;
CRC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.79	14.08	0.61	1.43e-35	Metabolic syndrome;
CRC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20307385	chr11:47447363	PSMC3	0.44	5.67	0.3	3.1e-8	Subjective well-being;
CRC	cis	rs6700896	0.864	rs6588153	chr1:66092017	T/A	cg04111102	chr1:66153794	NA	0.33	5.8	0.3	1.55e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.47	-6.44	-0.33	4.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11669181	1	rs11669181	chr19:14445138	A/G	cg25450033	chr19:14444658	NA	-0.37	-6.75	-0.35	6.5e-11	Conotruncal heart defects (maternal effects);
CRC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.64	11.48	0.53	7.03e-26	Schizophrenia;
CRC	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.59	8.39	0.42	1.41e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.09	0.32	3.1e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.36	-6.95	-0.36	1.99e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.58	-8.16	-0.41	7.05e-15	Personality dimensions;
CRC	cis	rs6662572	0.703	rs7548617	chr1:46365489	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.85	-0.31	1.21e-8	Blood protein levels;
CRC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.51	-0.5	1.86e-22	Total cholesterol levels;
CRC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.54	6.37	0.33	6.45e-10	Vitiligo;
CRC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.32	-0.59	1.17e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg04733911	chr16:78082701	NA	-0.48	-7.89	-0.4	4.61e-14	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07600211	chr1:145516081	GNRHR2;PEX11B	0.45	7.75	0.39	1.14e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17181325	chr17:1613831	TLCD2	0.36	5.98	0.31	5.77e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg09655341	chr17:79618100	PDE6G	0.55	6.49	0.34	3.24e-10	Dental caries;
CRC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg00601486	chr12:48723148	H1FNT	-0.35	-6.78	-0.35	5.75e-11	Glycated hemoglobin levels;
CRC	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg25930673	chr12:123319894	HIP1R	0.52	5.79	0.3	1.69e-8	Schizophrenia;
CRC	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.93	15.7	0.65	7.26e-42	Dupuytren's disease;
CRC	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.43	6.59	0.34	1.73e-10	Red blood cell count;
CRC	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.04	-14.56	-0.63	2.1e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.43	5.98	0.31	5.73e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.49	6.34	0.33	7.53e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3018066	0.748	rs12512683	chr4:106999471	C/T	cg01869342	chr4:106983673	TBCK	0.44	6.62	0.34	1.48e-10	Cancer;
CRC	cis	rs370915	0.542	rs28440880	chr4:187793213	T/G	cg12892747	chr4:187813459	NA	-0.56	-8.07	-0.41	1.33e-14	Gout;
CRC	cis	rs524281	0.648	rs10896089	chr11:65936292	A/G	cg16950941	chr11:66035639	RAB1B	-0.57	-7.12	-0.37	6.65e-12	Electroencephalogram traits;
CRC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.46	-9.87	-0.48	2.66e-20	Blood protein levels;
CRC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs12618769	0.625	rs2278207	chr2:99163261	T/A	cg18455616	chr2:99124870	INPP4A	0.36	5.92	0.31	8.23e-9	Bipolar disorder;
CRC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg12564285	chr5:131593104	PDLIM4	0.32	5.82	0.31	1.36e-8	Blood metabolite levels;
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.67	7.73	0.39	1.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2457480	0.866	rs11238940	chr10:44721459	G/A	cg09554077	chr10:44749378	NA	0.65	7.32	0.37	1.9e-12	Coronary artery disease;
CRC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.44	6.5	0.34	3.06e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.37	0.38	1.35e-12	Motion sickness;
CRC	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg16540259	chr10:75572220	NDST2	0.38	6.0	0.31	5.31e-9	Inflammatory bowel disease;
CRC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.58	8.15	0.41	7.45e-15	Multiple sclerosis;
CRC	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.25	15.0	0.64	4.06e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.59	-6.54	-0.34	2.29e-10	Coronary artery disease;
CRC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.69	10.3	0.49	9.33e-22	Tonsillectomy;
CRC	cis	rs12024301	0.557	rs9633304	chr1:183636878	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg19318889	chr4:1322082	MAEA	0.39	5.67	0.3	3.14e-8	Obesity-related traits;
CRC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.34e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	7.73	0.39	1.34e-13	Body mass index;
CRC	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	7.03	0.36	1.23e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.48	-7.58	-0.39	3.57e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.68e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	1.13	8.44	0.42	9.96e-16	Type 2 diabetes nephropathy;
CRC	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg09141835	chr16:88988174	CBFA2T3	-0.28	-6.12	-0.32	2.69e-9	Social autistic-like traits;
CRC	cis	rs4728302	0.838	rs10224828	chr7:133591071	G/A	cg03336402	chr7:133662267	EXOC4	-0.44	-6.41	-0.33	4.91e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.5	0.38	5.85e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg03037974	chr15:76606532	NA	0.56	8.69	0.43	1.75e-16	Blood metabolite levels;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.58	-10.96	-0.52	4.9e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05002071	chr11:76510323	NA	0.49	6.28	0.33	1.06e-9	Thyroid stimulating hormone;
CRC	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.73	9.8	0.48	4.71e-20	Coronary artery disease;
CRC	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg01843034	chr6:37503916	NA	-0.45	-8.36	-0.42	1.77e-15	Cognitive performance;
CRC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.91	15.82	0.66	2.59e-42	Primary sclerosing cholangitis;
CRC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.48	7.36	0.38	1.48e-12	Corneal astigmatism;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg19764325	chr22:32340710	C22orf24;YWHAH	0.35	6.23	0.32	1.44e-9	Schizophrenia;
CRC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.94	-0.44	2.88e-17	Alcohol dependence;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg06470822	chr6:28175283	NA	1.03	13.63	0.6	7.33e-34	Depression;
CRC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.55	-8.65	-0.43	2.36e-16	Aortic root size;
CRC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.18	-0.37	4.59e-12	IgG glycosylation;
CRC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-18.54	-0.71	4.92e-53	Primary sclerosing cholangitis;
CRC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg23625390	chr15:77176239	SCAPER	0.46	6.79	0.35	5.27e-11	Blood metabolite levels;
CRC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.66	0.43	2.12e-16	Menopause (age at onset);
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.54	-0.38	4.48e-13	Total body bone mineral density;
CRC	trans	rs2822999	0.932	rs12483192	chr21:16371613	A/G	cg04886857	chr1:13914270	PDPN	0.39	6.0	0.31	5.18e-9	Breast cancer;
CRC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.49	-7.48	-0.38	6.82e-13	Bone properties (heel);
CRC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.31	0.56	6.64e-29	Exhaled nitric oxide levels;
CRC	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.45	-0.46	6.7e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.48	-0.34	3.29e-10	Menopause (age at onset);
CRC	cis	rs4073416	0.542	rs8010726	chr14:65932597	C/T	cg03016385	chr14:66212404	NA	-0.47	-6.44	-0.33	4.28e-10	N-glycan levels;
CRC	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.52	7.71	0.39	1.49e-13	Corneal astigmatism;
CRC	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.7	11.45	0.53	8.94e-26	Itch intensity from mosquito bite;
CRC	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg11822372	chr1:151115635	SEMA6C	-0.72	-5.81	-0.31	1.46e-8	Blood protein levels;
CRC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.21	0.53	6.63e-25	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.96e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg24692254	chr21:30365293	RNF160	0.38	5.69	0.3	2.78e-8	Pancreatic cancer;
CRC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.61	9.16	0.45	5.53e-18	Lung cancer;
CRC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.41	-6.5	-0.34	3.03e-10	Body mass index;
CRC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.33	-0.42	2.15e-15	Monocyte count;
CRC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.61	-9.36	-0.46	1.32e-18	Menopause (age at onset);
CRC	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.63	9.55	0.47	3.01e-19	Adiposity;
CRC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.48	-8.35	-0.42	1.93e-15	Birth weight;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.69	-10.75	-0.51	2.63e-23	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14035508	chr11:124543525	SIAE;SPA17	0.48	6.88	0.35	3.1e-11	Response to antipsychotic treatment;
CRC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg10724054	chr17:3904396	NA	0.46	7.56	0.38	4.16e-13	Type 2 diabetes;
CRC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.52	8.39	0.42	1.42e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs939584	1.000	rs7574359	chr2:652542	T/C	cg03610516	chr2:642275	NA	-0.43	-5.93	-0.31	7.78e-9	Body mass index;
CRC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg08200770	chr17:80723486	TBCD	0.48	9.11	0.45	8.23e-18	Glycated hemoglobin levels;
CRC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg18876405	chr7:65276391	NA	-0.45	-6.09	-0.32	3.12e-9	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06766273	chr11:62521983	ZBTB3	0.5	6.5	0.34	3.06e-10	Thyroid stimulating hormone;
CRC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.4	6.46	0.34	3.68e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08413565	chr3:129035733	H1FX;C3orf47	0.51	6.55	0.34	2.15e-10	Thyroid stimulating hormone;
CRC	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.96	16.52	0.67	4.66e-45	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg00745463	chr17:30367425	LRRC37B	0.43	5.87	0.31	1.07e-8	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.02	-0.36	1.3e-11	Height;
CRC	cis	rs9463078	0.565	rs10948183	chr6:44880881	T/C	cg25276700	chr6:44698697	NA	0.26	6.15	0.32	2.31e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.45	6.72	0.35	7.97e-11	N-glycan levels;
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg19223190	chr17:80058835	NA	0.4	6.4	0.33	5.44e-10	Life satisfaction;
CRC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs10411161	0.702	rs16983196	chr19:52384779	C/A	cg22319618	chr22:45562946	NUP50	-0.69	-7.57	-0.39	3.9e-13	Breast cancer;
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.46	-7.14	-0.37	6.08e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg00631329	chr6:26305371	NA	-0.53	-8.79	-0.44	8.19e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.89	0.44	4.18e-17	Schizophrenia;
CRC	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	0.65	6.38	0.33	6.11e-10	Pediatric areal bone mineral density (radius);
CRC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.49	-7.71	-0.39	1.46e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22269622	chr17:60501544	METTL2A	0.55	7.34	0.38	1.64e-12	Thyroid stimulating hormone;
CRC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.8	-0.39	8.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-11.11	-0.52	1.45e-24	Hepatocellular carcinoma;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08551857	chr8:82024104	PAG1	0.45	6.75	0.35	6.49e-11	Interleukin-6 levels;
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg09264619	chr17:80180166	NA	0.36	6.02	0.32	4.59e-9	Life satisfaction;
CRC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.62	7.4	0.38	1.14e-12	Blood protein levels;
CRC	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.2	-0.32	1.67e-9	Joint mobility (Beighton score);
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	5.99	0.31	5.59e-9	Prudent dietary pattern;
CRC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.31	-0.42	2.46e-15	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg01339444	chr6:118972232	C6orf204	0.52	5.9	0.31	8.98e-9	Diastolic blood pressure;
CRC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.42	-5.87	-0.31	1.09e-8	DNA methylation (variation);
CRC	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.46	-7.25	-0.37	2.92e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	9.18e-9	Lung cancer;
CRC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.46	-7.39	-0.38	1.26e-12	Monocyte count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14561881	chr17:62503076	CCDC45;DDX5	0.48	6.16	0.32	2.15e-9	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02459971	chr11:798364	NA	0.41	6.38	0.33	5.94e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12564526	chr7:66767603	PMS2L4;STAG3L4	0.41	6.48	0.34	3.4e-10	Interleukin-6 levels;
CRC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.95	18.84	0.72	3.13e-54	Height;
CRC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.47	-8.15	-0.41	7.79e-15	Facial morphology (factor 20);
CRC	trans	rs72991	0.686	rs903243	chr11:121259106	C/G	cg27192990	chr6:129479024	LAMA2	0.37	6.17	0.32	2.02e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.31e-17	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17548431	chr4:160024475	NA	0.41	6.82	0.35	4.33e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.58	-9.84	-0.48	3.46e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	5.65	0.3	3.49e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.62	8.91	0.44	3.65e-17	Coronary artery disease;
CRC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg13206674	chr6:150067644	NUP43	0.44	6.31	0.33	9.1e-10	Testicular germ cell tumor;
CRC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.51	0.34	2.84e-10	Height;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Depression;
CRC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-9.95	-0.48	1.42e-20	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.38	0.46	1.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.46	6.62	0.34	1.49e-10	Emphysema distribution in smoking;
CRC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-10.06	-0.48	6.41e-21	Breast cancer;
CRC	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg21064579	chr19:49206444	FUT2	0.47	8.26	0.41	3.51e-15	Dietary macronutrient intake;
CRC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.68	-10.58	-0.5	1.04e-22	Gestational age at birth (maternal effect);
CRC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg17633681	chr16:88106987	BANP	0.87	16.24	0.67	5.81e-44	Menopause (age at onset);
CRC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg07936489	chr17:37558343	FBXL20	-0.42	-5.97	-0.31	6.2e-9	Asthma;
CRC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg12193833	chr17:30244370	NA	-0.74	-8.72	-0.43	1.45e-16	Hip circumference adjusted for BMI;
CRC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.91	-17.84	-0.7	2.75e-50	Intelligence (multi-trait analysis);
CRC	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.54	-8.43	-0.42	1.09e-15	Ulcerative colitis;
CRC	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.84	9.52	0.46	3.83e-19	Iron status biomarkers;
CRC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg24531977	chr5:56204891	C5orf35	0.46	7.03	0.36	1.21e-11	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00597366	chr16:46917883	GPT2	0.43	6.15	0.32	2.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7705042	0.865	rs2043280	chr5:141513691	C/G	cg08523384	chr5:141488047	NDFIP1	0.32	5.68	0.3	2.98e-8	Asthma;
CRC	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.26	0.49	1.27e-21	Asthma;
CRC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg06636001	chr8:8085503	FLJ10661	0.49	7.33	0.37	1.82e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg13319975	chr6:146136371	FBXO30	0.43	6.4	0.33	5.37e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.48	-6.59	-0.34	1.72e-10	Longevity;Endometriosis;
CRC	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.79e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.54	0.47	3.33e-19	Intelligence (multi-trait analysis);
CRC	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.52	0.34	2.69e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.89	-20.13	-0.74	2.57e-59	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.92	12.74	0.57	1.68e-30	Initial pursuit acceleration;
CRC	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.8	-13.13	-0.59	5.8e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg07617317	chr6:118971624	C6orf204	0.5	6.21	0.32	1.56e-9	Diastolic blood pressure;
CRC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.45	6.34	0.33	7.57e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg13852791	chr20:30311386	BCL2L1	0.54	7.03	0.36	1.18e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.4	0.71	1.71e-52	Cognitive ability;
CRC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.62	9.4	0.46	9.51e-19	Birth weight;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21528620	chr1:110753221	KCNC4	0.37	5.98	0.31	5.84e-9	Obesity-related traits;
CRC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.17	24.99	0.81	5.35e-78	IgG glycosylation;
CRC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.67	10.08	0.49	5.26e-21	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01540024	chr16:19729665	C16orf88;IQCK	0.45	5.97	0.31	6.11e-9	Anxiety disorder;
CRC	cis	rs365302	1.000	rs375423	chr6:159648956	A/G	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs1838105	0.510	rs3851795	chr17:45061077	A/G	cg16759221	chr17:45003025	GOSR2	0.43	6.26	0.33	1.22e-9	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.41	8.05	0.41	1.55e-14	Mean corpuscular volume;
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.36	-0.53	1.9e-25	Alzheimer's disease;
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.52	-8.43	-0.42	1.13e-15	Blood pressure (smoking interaction);
CRC	trans	rs2012709	0.840	rs58390450	chr5:32575881	A/G	cg03755955	chr8:6424269	MCPH1	0.45	6.83	0.35	4.09e-11	Breast cancer;
CRC	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg20356878	chr3:121714668	ILDR1	0.51	7.94	0.4	3.22e-14	Cognitive performance;
CRC	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.48	6.0	0.31	5.07e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg16035780	chr5:759353	NA	0.43	5.79	0.3	1.67e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.52	8.54	0.43	5.1e-16	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg03146154	chr1:46216737	IPP	-0.39	-5.81	-0.31	1.46e-8	Red blood cell count;Reticulocyte count;
CRC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg16576597	chr16:28551801	NUPR1	0.49	7.07	0.36	9.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.53	-8.21	-0.41	4.93e-15	Aortic root size;
CRC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.39	-5.65	-0.3	3.43e-8	Aortic root size;
CRC	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.5	0.54	5.74e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11212617	0.901	rs4754301	chr11:108048541	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.3	0.33	9.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg03678062	chr6:149772716	ZC3H12D	0.36	6.58	0.34	1.86e-10	Dupuytren's disease;
CRC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.14	0.64	1.16e-39	Lymphocyte percentage of white cells;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07261734	chr13:49684383	FNDC3A	-0.42	-6.78	-0.35	5.43e-11	Aortic root size;
CRC	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg23254163	chr1:152506842	NA	-0.44	-7.58	-0.39	3.61e-13	Hair morphology;
CRC	cis	rs2745959	0.611	rs2466574	chr1:208053853	A/G	cg09788693	chr1:208063733	CD34	0.47	6.21	0.32	1.56e-9	Resting heart rate;
CRC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg15845792	chr6:28175446	NA	0.46	6.72	0.35	7.87e-11	Pubertal anthropometrics;
CRC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	6.53	0.34	2.55e-10	Platelet count;
CRC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.62	9.48	0.46	5.06e-19	Corneal astigmatism;
CRC	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.88	-0.31	1.02e-8	Daytime sleep phenotypes;
CRC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.45	0.34	4.08e-10	Axial length;
CRC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.48	-9.34	-0.46	1.52e-18	Prostate cancer;
CRC	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.46	-6.86	-0.35	3.41e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.68	0.3	2.96e-8	Cognitive ability;
CRC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.99	-0.31	5.46e-9	Monocyte percentage of white cells;
CRC	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg18830697	chr6:72922368	RIMS1	-0.39	-7.96	-0.4	2.85e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.32	-6.38	-0.33	6e-10	Cutaneous nevi;
CRC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg03623178	chr6:28175578	NA	0.94	12.29	0.56	7.67e-29	Depression;
CRC	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.52	9.24	0.45	3.06e-18	Hematocrit;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg15786705	chr6:28176104	NA	0.61	8.72	0.43	1.35e-16	Cardiac Troponin-T levels;
CRC	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg27398640	chr15:77910606	LINGO1	-0.44	-7.52	-0.38	5.19e-13	Type 2 diabetes;
CRC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.32	-6.87	-0.35	3.16e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.79	-12.14	-0.56	2.73e-28	Uric acid levels;
CRC	cis	rs7731657	0.537	rs10062336	chr5:130193668	T/A	cg08523029	chr5:130500466	HINT1	-0.46	-5.86	-0.31	1.11e-8	Fasting plasma glucose;
CRC	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.33	5.67	0.3	3.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-8.43	-0.42	1.08e-15	Idiopathic membranous nephropathy;
CRC	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg18830697	chr6:72922368	RIMS1	0.41	8.02	0.4	1.86e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg12172441	chr6:28176163	NA	0.58	7.9	0.4	4.21e-14	Parkinson's disease;
CRC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.34	-6.28	-0.33	1.08e-9	Menarche (age at onset);
CRC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.72	-0.35	7.82e-11	Type 2 diabetes;
CRC	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-0.69	-11.89	-0.55	2.34e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.46	-6.57	-0.34	2.01e-10	Mean platelet volume;
CRC	cis	rs9463078	0.715	rs1891411	chr6:44760903	G/C	cg25276700	chr6:44698697	NA	0.29	7.03	0.36	1.23e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg19193384	chr17:30244184	NA	-0.6	-6.01	-0.31	4.96e-9	Height;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.7	7.23	0.37	3.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.63	10.86	0.51	1.07e-23	Prostate cancer;
CRC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.29	-0.33	1e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.93	0.4	3.53e-14	Aortic root size;
CRC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.56	-8.4	-0.42	1.35e-15	Prostate cancer;
CRC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.82	13.74	0.6	2.79e-34	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10170637	chr12:49110646	CCNT1	0.38	6.06	0.32	3.74e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.61	10.47	0.5	2.56e-22	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg14844989	chr11:31128820	NA	-0.36	-6.33	-0.33	8.06e-10	Red blood cell count;
CRC	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.75	0.3	2.08e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.39	-6.14	-0.32	2.34e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9906695	0.950	rs11868941	chr17:32562941	C/T	cg12698626	chr17:32581466	CCL2	0.4	5.61	0.3	4.25e-8	Monocyte percentage of white cells;
CRC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-9.45	-0.46	6.64e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.41	11.82	0.55	4.19e-27	Psoriasis vulgaris;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22159483	chr17:1588198	PRPF8	-0.54	-6.65	-0.34	1.26e-10	Diisocyanate-induced asthma;
CRC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg22349387	chr12:9600060	DDX12	-0.4	-6.4	-0.33	5.47e-10	Breast size;
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.24	0.53	5.2e-25	Prudent dietary pattern;
CRC	cis	rs6908034	0.607	rs77791009	chr6:19812602	A/G	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.53	-8.89	-0.44	4.05e-17	Brugada syndrome;
CRC	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6764363	0.587	rs35762438	chr3:279853	G/C	cg02057681	chr3:285234	CHL1	0.44	7.4	0.38	1.14e-12	Sudden cardiac arrest;
CRC	cis	rs4750440	0.637	rs2457859	chr10:14032099	T/G	cg00551146	chr10:14014579	FRMD4A	0.45	8.06	0.41	1.42e-14	Adiponectin levels;
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg21155852	chr7:2048760	MAD1L1	-0.53	-6.96	-0.36	1.8e-11	Bipolar disorder;
CRC	trans	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.0	0.4	2.17e-14	Lewy body disease;
CRC	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.76	-10.46	-0.5	2.65e-22	White matter hyperintensity burden;
CRC	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.62	14.15	0.62	7.52e-36	Airflow obstruction;
CRC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-5.67	-0.3	3.07e-8	Neuroticism;
CRC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.52	-9.14	-0.45	6.82e-18	Schizophrenia;
CRC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.21	-0.32	1.64e-9	Arsenic metabolism;
CRC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg18721089	chr20:30220636	NA	-0.34	-5.64	-0.3	3.75e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9903692	0.909	rs2325885	chr17:46290375	C/T	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.56	9.13	0.45	7.33e-18	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.52	-8.91	-0.44	3.68e-17	Iron status biomarkers;
CRC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.81	8.58	0.43	3.87e-16	Plasma clusterin levels;
CRC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.24	14.87	0.63	1.34e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.67	12.76	0.58	1.47e-30	Coronary artery disease;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9311676	0.656	rs11721168	chr3:58408679	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	trans	rs820077	0.557	rs9366880	chr6:35144651	G/A	cg23173586	chr14:20945319	PNP	-0.29	-6.03	-0.32	4.43e-9	Systemic lupus erythematosus;
CRC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg17724175	chr1:150552817	MCL1	0.44	6.69	0.35	9.45e-11	Melanoma;
CRC	trans	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg07507251	chr3:52567010	NT5DC2	-0.42	-6.16	-0.32	2.11e-9	Bipolar disorder;
CRC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.85	14.57	0.63	1.85e-37	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03153608	chr11:64126457	RPS6KA4	0.4	6.0	0.31	5.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-12.75	-0.58	1.51e-30	Menarche (age at onset);
CRC	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.32	0.46	1.79e-18	Endometrial cancer;
CRC	cis	rs6433857	0.536	rs1971134	chr2:181351532	G/A	cg23363182	chr2:181467187	NA	-0.55	-8.11	-0.41	9.84e-15	Body mass index;
CRC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.61	-9.11	-0.45	8.53e-18	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg23229984	chr5:148520753	ABLIM3	-0.48	-6.49	-0.34	3.23e-10	Breast cancer;
CRC	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.53	-10.13	-0.49	3.74e-21	Pediatric bone mineral content (femoral neck);
CRC	cis	rs4692589	0.965	rs2291167	chr4:170950887	G/A	cg19918862	chr4:170955249	NA	0.4	6.35	0.33	6.99e-10	Anxiety disorder;
CRC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.43	6.24	0.33	1.31e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg15382696	chr6:118971807	C6orf204	0.58	6.99	0.36	1.58e-11	Diastolic blood pressure;
CRC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.83	-0.4	6.72e-14	Height;
CRC	cis	rs1971762	0.527	rs4019971	chr12:53978715	A/G	cg06632207	chr12:54070931	ATP5G2	0.39	6.47	0.34	3.47e-10	Height;
CRC	cis	rs6445967	1.000	rs1913715	chr3:58308214	G/A	cg23715586	chr3:58305044	RPP14	0.36	6.01	0.31	4.81e-9	Platelet count;
CRC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.32	0.33	8.33e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg23262073	chr20:60523788	NA	-0.42	-7.25	-0.37	2.99e-12	Body mass index;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.6	7.7	0.39	1.64e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.79e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14895029	chr7:2775587	GNA12	0.47	7.0	0.36	1.48e-11	Height;
CRC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.37	5.66	0.3	3.37e-8	Vitiligo;
CRC	cis	rs3736485	0.966	rs4144941	chr15:51796806	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.45	-0.34	3.88e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.75	12.54	0.57	9.07e-30	Adiposity;
CRC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.52	8.14	0.41	8.47e-15	Red blood cell count;
CRC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs965469	0.947	rs6051773	chr20:3330382	C/G	cg25506879	chr20:3388711	C20orf194	-0.39	-5.81	-0.31	1.44e-8	IFN-related cytopenia;
CRC	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg02560186	chr11:3602584	NA	-0.46	-6.18	-0.32	1.89e-9	Blood pressure (smoking interaction);
CRC	trans	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg26043149	chr18:55253948	FECH	-0.47	-7.32	-0.37	1.9e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.59	9.0	0.44	1.9e-17	Lewy body disease;
CRC	cis	rs10106298	0.846	rs1550005	chr8:103681662	C/G	cg10187029	chr8:103597600	NA	0.42	5.87	0.31	1.05e-8	Schizophrenia;
CRC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.23	-0.33	1.39e-9	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10694539	chr12:42538536	GXYLT1	0.41	6.22	0.32	1.5e-9	Response to antipsychotic treatment;
CRC	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.58	-10.82	-0.51	1.57e-23	Immature fraction of reticulocytes;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.38	-8.85	-0.44	5.34e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.73	0.3	2.21e-8	Diabetic retinopathy;
CRC	cis	rs7731657	0.537	rs1074840	chr5:130251717	A/G	cg08523029	chr5:130500466	HINT1	-0.43	-5.84	-0.31	1.27e-8	Fasting plasma glucose;
CRC	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.38	6.02	0.32	4.54e-9	Height;
CRC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.96	16.79	0.68	3.77e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.42	-6.27	-0.33	1.11e-9	Prostate cancer;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23465967	chr2:111435611	BUB1	0.41	6.26	0.33	1.21e-9	Schizophrenia;
CRC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.56	7.09	0.36	8.46e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.38	5.88	0.31	1.01e-8	Red blood cell count;
CRC	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.04	-0.36	1.15e-11	Prevalent atrial fibrillation;
CRC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	6.16	0.32	2.18e-9	Neuroticism;
CRC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	5.97e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg05569086	chr8:143859399	LYNX1	0.38	6.69	0.35	9.43e-11	Urinary tract infection frequency;
CRC	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.63	9.13	0.45	7.11e-18	Schizophrenia;
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.48	-6.58	-0.34	1.89e-10	Intelligence (multi-trait analysis);
CRC	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.3	-0.56	7.55e-29	Leprosy;
CRC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.0	0.44	1.88e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.66	9.21	0.45	3.9e-18	White matter hyperintensity burden;
CRC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg00343986	chr7:65444356	GUSB	-0.48	-7.11	-0.36	7.48e-12	Aortic root size;
CRC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.76	-0.35	6.21e-11	Morning vs. evening chronotype;
CRC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg15744005	chr10:104629667	AS3MT	0.47	5.8	0.3	1.54e-8	Arsenic metabolism;
CRC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.67	7.69	0.39	1.77e-13	Cleft lip with or without cleft palate;
CRC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg13662093	chr20:33865505	NA	0.51	6.61	0.34	1.59e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-7.29	-0.37	2.3e-12	Electroencephalogram traits;
CRC	cis	rs3996993	0.509	rs11752938	chr6:52675433	C/T	cg20803780	chr6:52668592	GSTA1	0.39	6.58	0.34	1.89e-10	Hemoglobin concentration;
CRC	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg08501292	chr6:25962987	TRIM38	1.15	9.94	0.48	1.63e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13047869	chr3:10149882	C3orf24	0.51	7.07	0.36	9.31e-12	Alzheimer's disease;
CRC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.74	-12.57	-0.57	7.4e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.43	6.86	0.35	3.38e-11	Menopause (age at onset);
CRC	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.95	0.44	2.66e-17	Coffee consumption (cups per day);
CRC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.53	6.57	0.34	1.98e-10	Vitiligo;
CRC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.55	7.71	0.39	1.47e-13	Melanoma;
CRC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg13844804	chr7:814759	HEATR2	0.68	8.0	0.4	2.15e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-7.36	-0.38	1.47e-12	Electroencephalogram traits;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4654899	0.796	rs61779135	chr1:21532625	G/A	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.96	-0.4	2.73e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.59	-8.54	-0.43	4.97e-16	Tuberculosis;
CRC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.52	-0.34	2.6e-10	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg25164649	chr6:28176230	NA	0.72	9.1	0.45	9.16e-18	Depression;
CRC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.61	-6.4	-0.33	5.25e-10	Schizophrenia;
CRC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.52	7.38	0.38	1.33e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	0.98	14.91	0.64	8.86e-39	Monocyte percentage of white cells;
CRC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.81	14.53	0.63	2.62e-37	Anterior chamber depth;
CRC	cis	rs7605827	0.930	rs12995776	chr2:15717131	T/A	cg19274914	chr2:15703543	NA	0.38	5.88	0.31	1.01e-8	Educational attainment (years of education);
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg12564285	chr5:131593104	PDLIM4	0.34	6.17	0.32	2.05e-9	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.28	-0.49	1.15e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.62	9.23	0.45	3.45e-18	Blood protein levels;
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.46	-8.68	-0.43	1.85e-16	Intraocular pressure;
CRC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.56	7.37	0.38	1.39e-12	Schizophrenia;
CRC	trans	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg07817883	chr1:32538562	TMEM39B	1.13	10.37	0.5	5.44e-22	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg18479299	chr3:125709523	NA	-0.52	-6.31	-0.33	9.06e-10	Blood pressure (smoking interaction);
CRC	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg00601450	chr5:74908170	NA	0.42	5.96	0.31	6.59e-9	Age-related disease endophenotypes;
CRC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg21951975	chr1:209979733	IRF6	0.5	6.76	0.35	6.12e-11	Cleft lip with or without cleft palate;
CRC	cis	rs9658691	1.000	rs9658691	chr10:90756163	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.94	-6.66	-0.34	1.16e-10	Mosquito bite size;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.64	-0.3	3.75e-8	Breast cancer;
CRC	cis	rs12541635	1.000	rs12541635	chr8:107090000	C/T	cg10147462	chr8:107024639	NA	-0.37	-6.22	-0.32	1.52e-9	Age of smoking initiation;
CRC	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg06781209	chr11:61594997	FADS2	-0.42	-5.99	-0.31	5.58e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.77	11.31	0.53	2.78e-25	High light scatter reticulocyte count;
CRC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.54	8.2	0.41	5.56e-15	Red blood cell count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05241839	chr16:53537463	AKTIP	0.39	6.21	0.32	1.57e-9	Obesity-related traits;
CRC	trans	rs1933755	0.541	rs61479838	chr6:130920921	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.92	-6.72	-0.35	7.93e-11	Colorectal cancer (calcium intake interaction);
CRC	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.5	6.74	0.35	7.22e-11	IgG glycosylation;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.64	-8.71	-0.43	1.46e-16	Alzheimer's disease;
CRC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg03714773	chr7:91764589	CYP51A1	0.35	5.81	0.31	1.45e-8	Breast cancer;
CRC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.51	-6.79	-0.35	5.24e-11	Colorectal cancer;
CRC	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg16898833	chr6:26189333	HIST1H4D	0.99	7.54	0.38	4.65e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg21251018	chr6:28226885	NKAPL	0.53	8.76	0.43	1.04e-16	Depression;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05994458	chr11:13484274	BTBD10	-0.53	-6.27	-0.33	1.15e-9	Diisocyanate-induced asthma;
CRC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg14541582	chr5:601475	NA	-0.32	-6.61	-0.34	1.57e-10	Obesity-related traits;
CRC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	-0.51	-8.26	-0.41	3.52e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg22437258	chr11:111473054	SIK2	0.36	5.63	0.3	3.93e-8	Primary sclerosing cholangitis;
CRC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg21620606	chr4:1342894	KIAA1530	-0.34	-5.81	-0.31	1.47e-8	Obesity-related traits;
CRC	cis	rs10486722	0.606	rs1990133	chr7:41800176	C/T	cg22138096	chr7:41772439	LOC285954	0.44	5.67	0.3	3.12e-8	Pit-and-Fissure caries;
CRC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.42	0.42	1.15e-15	Cognitive test performance;
CRC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.89	16.61	0.68	2.11e-45	Intelligence (multi-trait analysis);
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg17860133	chr12:117468345	FBXW8	-0.48	-6.21	-0.32	1.61e-9	Resistin levels;
CRC	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.5	7.73	0.39	1.29e-13	Corneal astigmatism;
CRC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg15511327	chr8:143859410	LYNX1	0.42	7.45	0.38	8.2e-13	Urinary tract infection frequency;
CRC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg16060761	chr17:80687452	NA	-0.44	-6.33	-0.33	8.21e-10	Breast cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25730138	chr19:5903868	NDUFA11;VMAC	0.45	6.09	0.32	3.08e-9	Survival in pancreatic cancer;
CRC	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.1	-0.32	2.9e-9	Diastolic blood pressure;
CRC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg03948781	chr1:205179583	DSTYK	0.43	6.13	0.32	2.56e-9	Red blood cell count;
CRC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg11212589	chr17:38028394	ZPBP2	0.34	5.77	0.3	1.81e-8	Asthma;
CRC	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg16141378	chr3:129829833	LOC729375	0.42	6.15	0.32	2.2e-9	Mood instability;
CRC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	24.43	0.8	6.45e-76	Testicular germ cell tumor;
CRC	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg23100626	chr2:96804247	ASTL	0.31	7.98	0.4	2.49e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.98	-0.48	1.12e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg00383167	chr18:77616694	NA	0.54	5.99	0.31	5.51e-9	Opioid sensitivity;
CRC	cis	rs11212617	1.000	rs228598	chr11:108107497	T/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.34	0.33	7.36e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg13565492	chr6:43139072	SRF	-0.7	-7.21	-0.37	3.78e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.82	-14.69	-0.63	6.5e-38	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24082730	chr3:126076366	KLF15	0.45	6.19	0.32	1.83e-9	Anxiety disorder;
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.43	-7.42	-0.38	9.91e-13	Height;
CRC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.76	0.35	6.45e-11	Obesity-related traits;
CRC	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.83	8.98	0.44	2.11e-17	Gastritis;
CRC	cis	rs77633900	0.772	rs2460161	chr15:76640430	C/T	cg21673338	chr15:77095150	SCAPER	-0.72	-6.32	-0.33	8.48e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.61	-9.36	-0.46	1.28e-18	Aortic root size;
CRC	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.52	8.1	0.41	1.05e-14	Corneal astigmatism;
CRC	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.71	14.1	0.61	1.25e-35	Leprosy;
CRC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.73	-8.86	-0.44	5.13e-17	Lung function (FEV1/FVC);
CRC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.55	-7.57	-0.39	3.67e-13	DNA methylation (variation);
CRC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.54	8.6	0.43	3.27e-16	Prostate cancer;
CRC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.67	-0.39	1.9e-13	Self-reported allergy;
CRC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg07701084	chr6:150067640	NUP43	0.56	7.75	0.39	1.14e-13	Lung cancer;
CRC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	12.26	0.56	1.02e-28	Schizophrenia;
CRC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg02428538	chr16:24856791	SLC5A11	0.57	6.8	0.35	4.96e-11	Intelligence (multi-trait analysis);
CRC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.88	-0.35	3.03e-11	Colorectal cancer;
CRC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.39e-11	Lung cancer;
CRC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.77	-11.67	-0.54	1.44e-26	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.63	0.57	4.41e-30	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.78	-0.35	5.72e-11	Type 2 diabetes;
CRC	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.74	0.43	1.21e-16	Coffee consumption (cups per day);
CRC	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.3	0.64	2.7e-40	Fuchs's corneal dystrophy;
CRC	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.95	-0.31	7.03e-9	Blood metabolite levels;
CRC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.41	-6.08	-0.32	3.26e-9	P wave terminal force;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19379625	chr4:71859087	DCK	0.49	6.25	0.33	1.31e-9	Thyroid stimulating hormone;
CRC	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.31	-6.52	-0.34	2.65e-10	Migraine;
CRC	cis	rs6662572	0.737	rs72677550	chr1:46589276	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.96	0.31	6.43e-9	Blood protein levels;
CRC	cis	rs2179367	0.959	rs544947	chr6:149723548	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.02	-0.31	4.68e-9	Dupuytren's disease;
CRC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.53	-11.11	-0.52	1.49e-24	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs3823572	0.564	rs2346273	chr7:133659764	A/T	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	ch.8.34907260F	chr8:34787718	NA	0.41	6.01	0.31	4.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.58	9.75	0.47	6.51e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.71	12.1	0.56	3.89e-28	Longevity;
CRC	trans	rs6544773	0.526	rs191468	chr2:45063290	G/A	cg10208897	chr5:178548229	ADAMTS2	0.35	6.18	0.32	1.86e-9	Mosquito bite size;
CRC	cis	rs6700896	0.931	rs59508186	chr1:66107881	C/A	cg04111102	chr1:66153794	NA	0.32	5.68	0.3	3e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.77	9.66	0.47	1.39e-19	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs59104589	0.617	rs56663202	chr2:242262311	A/G	cg19488206	chr2:242435732	STK25	0.46	6.53	0.34	2.44e-10	Fibrinogen levels;
CRC	cis	rs6773854	0.526	rs2253944	chr3:187643346	C/T	cg10168494	chr3:187635183	NA	-0.46	-7.5	-0.38	5.93e-13	B cell non-Hodgkin lymphoma;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13623690	chr16:84651800	COTL1	0.43	6.5	0.34	3.06e-10	Myopia (pathological);
CRC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09974566	chr22:32150118	DEPDC5	0.44	6.63	0.34	1.36e-10	Myopia (pathological);
CRC	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.76	-0.35	6.3e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg17775713	chr3:133465469	TF	0.34	6.04	0.32	4.07e-9	Iron status biomarkers;
CRC	cis	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.64	-0.3	3.75e-8	Neuroticism;
CRC	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.91	-0.31	8.54e-9	Schizophrenia;
CRC	cis	rs4664293	0.647	rs7575924	chr2:160429560	C/G	cg08347373	chr2:160653686	CD302	-0.38	-6.43	-0.33	4.52e-10	Monocyte percentage of white cells;
CRC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.59	8.43	0.42	1.12e-15	Multiple sclerosis;
CRC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04559178	chr12:29301719	NA	0.49	6.98	0.36	1.64e-11	Response to antipsychotic treatment;
CRC	cis	rs863345	0.604	rs7514968	chr1:158493852	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	7e-9	Pneumococcal bacteremia;
CRC	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.91	15.68	0.65	8.83e-42	Subjective well-being;
CRC	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.44	-7.02	-0.36	1.3e-11	Refractive error;
CRC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.45e-8	Educational attainment (college completion);
CRC	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.8	0.44	7.81e-17	Coffee consumption (cups per day);
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.8	-10.08	-0.49	5.35e-21	Cognitive test performance;
CRC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18357526	chr6:26021779	HIST1H4A	0.43	6.06	0.32	3.81e-9	Iron status biomarkers;
CRC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.08	-0.45	1.02e-17	Platelet count;
CRC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.59	-8.72	-0.43	1.4e-16	Longevity;
CRC	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.9	-0.31	8.95e-9	Alcohol dependence;
CRC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.38	0.59	6.83e-33	Chronic sinus infection;
CRC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.51	8.17	0.41	6.81e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.67	9.1	0.45	9.08e-18	Breast cancer;
CRC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg08614441	chr13:113633676	MCF2L	-0.47	-7.39	-0.38	1.24e-12	Systolic blood pressure;
CRC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.86	-0.44	5.27e-17	Myeloid white cell count;
CRC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.17	0.56	2.14e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.74	-8.45	-0.42	9.67e-16	Coronary artery disease;
CRC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg12639453	chr1:2035780	PRKCZ	0.32	5.87	0.31	1.07e-8	Height;
CRC	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg10862848	chr6:42927986	GNMT	-0.3	-5.64	-0.3	3.75e-8	Blood protein levels;
CRC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg05585544	chr11:47624801	NA	0.53	9.3	0.46	2.09e-18	Subjective well-being;
CRC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-5.86	-0.31	1.12e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.56	7.15	0.37	5.71e-12	Mammographic density (dense area);
CRC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg19046167	chr17:80928561	B3GNTL1	0.38	5.95	0.31	6.75e-9	Breast cancer;
CRC	cis	rs57590327	0.516	rs66665538	chr3:81796391	T/A	cg07356753	chr3:81810745	GBE1	-0.61	-6.18	-0.32	1.91e-9	Extraversion;
CRC	cis	rs8064454	0.764	rs11658063	chr17:36103872	C/G	cg04198914	chr17:36106025	HNF1B	0.37	8.4	0.42	1.37e-15	Prostate cancer;
CRC	cis	rs4074493	1.000	rs11122199	chr1:231172686	T/C	cg22172038	chr1:231176991	FAM89A	0.35	6.03	0.32	4.29e-9	Carotid plaque burden (smoking interaction);
CRC	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.57	-8.47	-0.42	8.54e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.36	5.75	0.3	2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs4478147	0.636	rs6847139	chr4:87465741	G/A	cg01215037	chr19:50083917	PRRG2;NOSIP	0.45	5.97	0.31	6.1e-9	Migraine - clinic-based;
CRC	cis	rs11212617	0.805	rs10890821	chr11:108022061	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.45	6.74	0.35	7.22e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg15832292	chr6:96025679	MANEA	0.56	6.29	0.33	1.03e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00414561	chr15:23034473	NIPA2	0.4	6.49	0.34	3.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.88	0.31	1.01e-8	Height;
CRC	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.48	7.41	0.38	1.1e-12	Red blood cell count;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg25243455	chr2:114033360	PAX8;LOC440839	-0.28	-6.66	-0.34	1.18e-10	Lymphocyte counts;
CRC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.64	10.01	0.48	9.44e-21	Breast cancer;
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.02	-0.4	1.82e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs1178968	0.901	rs4717752	chr7:72754237	A/T	cg25889504	chr7:72793014	NA	0.48	5.71	0.3	2.57e-8	Triglyceride levels;
CRC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg26805224	chr10:79626177	DLG5	-0.49	-7.25	-0.37	3.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.21	-0.37	3.89e-12	Monocyte percentage of white cells;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18110333	chr6:292329	DUSP22	-0.58	-8.29	-0.42	2.82e-15	Menopause (age at onset);
CRC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.67	-10.47	-0.5	2.39e-22	Blood protein levels;
CRC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.45	5.85	0.31	1.2e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.23	14.72	0.63	4.77e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.35	6.22	0.32	1.54e-9	Crohn's disease;
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.56	6.77	0.35	6e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg09659197	chr4:152720779	NA	0.43	8.4	0.42	1.37e-15	Intelligence (multi-trait analysis);
CRC	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.68	7.02	0.36	1.26e-11	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
CRC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg11833968	chr6:79620685	NA	-0.34	-5.82	-0.31	1.39e-8	Intelligence (multi-trait analysis);
CRC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg07713946	chr22:31675144	LIMK2	0.42	6.28	0.33	1.07e-9	Colorectal cancer;
CRC	cis	rs8141797	0.901	rs8140812	chr22:24553535	C/T	cg20894457	chr22:24584366	SUSD2	0.62	7.64	0.39	2.37e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.2	-0.37	4.21e-12	Retinal vascular caliber;
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.52	6.97	0.36	1.79e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.58	-7.43	-0.38	9.6e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.43	-5.91	-0.31	8.33e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg00129232	chr17:37814104	STARD3	0.58	7.15	0.37	5.6e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.5	6.74	0.35	7.17e-11	Diastolic blood pressure;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02290350	chr8:58132656	NA	-0.59	-6.85	-0.35	3.68e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.63	12.41	0.56	2.88e-29	Skin aging (microtopography measurement);
CRC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.48	5.62	0.3	4.16e-8	Vitiligo;
CRC	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Dilated cardiomyopathy;
CRC	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg25164649	chr6:28176230	NA	0.55	6.45	0.34	3.99e-10	Depression;
CRC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.72	12.22	0.56	1.39e-28	Mean platelet volume;
CRC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.53	-9.9	-0.48	2.13e-20	Dupuytren's disease;
CRC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.73	-11.46	-0.53	8.18e-26	Colorectal cancer;
CRC	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg19025524	chr12:109796872	NA	-0.45	-5.96	-0.31	6.61e-9	Neuroticism;
CRC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.86	-14.54	-0.63	2.36e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.13	-0.32	2.52e-9	IgG glycosylation;
CRC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg04731861	chr2:219085781	ARPC2	0.34	6.98	0.36	1.65e-11	Colorectal cancer;
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg09877947	chr5:131593287	PDLIM4	0.33	5.9	0.31	9.26e-9	Perceived unattractiveness to mosquitoes;
CRC	trans	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.42	-0.33	4.79e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.45	-7.16	-0.37	5.46e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-7.14	-0.37	6.05e-12	Cystic fibrosis severity;
CRC	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg10820045	chr2:198174542	NA	0.4	6.88	0.35	3.02e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04013166	chr16:89971882	TCF25	0.6	5.76	0.3	1.91e-8	Skin colour saturation;
CRC	trans	rs12432203	1.000	rs12432203	chr14:51710861	A/G	cg14592830	chr9:122318704	NA	0.61	6.23	0.32	1.4e-9	Cancer;
CRC	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg09695851	chr17:3907499	NA	0.78	14.7	0.63	6.01e-38	Type 2 diabetes;
CRC	cis	rs8070740	0.838	rs8072363	chr17:5335752	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.63	0.3	3.79e-8	Menopause (age at onset);
CRC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-10.48	-0.5	2.38e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	cis	rs787274	0.850	rs10759603	chr9:115639581	C/G	cg13803584	chr9:115635662	SNX30	-0.66	-5.97	-0.31	6.04e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.37	5.92	0.31	8.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.73	-8.22	-0.41	4.9e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.54	-0.34	2.38e-10	Blood metabolite levels;
CRC	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.6	8.56	0.43	4.31e-16	Body mass index;
CRC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.37	6.57	0.34	1.98e-10	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.11	-0.45	7.94e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg13385794	chr1:248469461	NA	0.37	6.25	0.33	1.26e-9	Common traits (Other);
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11446398	chr5:77624930	NA	0.43	6.33	0.33	8.01e-10	Triglycerides;
CRC	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-11.96	-0.55	1.28e-27	Plateletcrit;Platelet count;
CRC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.95	0.31	6.72e-9	Bladder cancer;
CRC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg15147215	chr3:52552868	STAB1	-0.42	-6.88	-0.35	3.03e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11353368	chr19:47363757	NA	0.43	6.51	0.34	2.85e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.41	6.05	0.32	3.93e-9	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.02	-0.32	4.55e-9	Menopause (age at onset);
CRC	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	15.86	0.66	1.76e-42	Mean corpuscular hemoglobin;
CRC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg11189052	chr15:85197271	WDR73	0.55	7.28	0.37	2.4e-12	Schizophrenia;
CRC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.67	-11.0	-0.52	3.54e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07308232	chr7:1071921	C7orf50	-0.44	-5.98	-0.31	5.88e-9	Longevity;Endometriosis;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12963246	chr6:28129442	ZNF389	0.49	5.71	0.3	2.53e-8	Depression;
CRC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.39	6.24	0.33	1.33e-9	Total body bone mineral density;
CRC	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.49	-7.52	-0.38	5.23e-13	Type 2 diabetes;
CRC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-7.26	-0.37	2.89e-12	Morning vs. evening chronotype;
CRC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.53	-7.85	-0.4	5.77e-14	Coronary artery disease;
CRC	cis	rs995000	0.839	rs12403207	chr1:62993620	T/C	cg19896129	chr1:63156450	NA	-0.45	-6.94	-0.36	2.07e-11	Triglyceride levels;
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg26566898	chr11:117069891	TAGLN	0.32	6.7	0.35	9.32e-11	Blood protein levels;
CRC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.7	-0.51	4.06e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.47	-0.42	8.34e-16	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25307556	chr1:246729459	CNST;TFB2M	0.4	5.96	0.31	6.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.58	-0.34	1.89e-10	Multiple sclerosis;
CRC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg10589385	chr1:150898437	SETDB1	0.32	6.54	0.34	2.4e-10	Melanoma;
CRC	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	6.4	0.33	5.29e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.27	-0.49	1.2e-21	Total cholesterol levels;
CRC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.55	-7.8	-0.4	8.13e-14	Monocyte count;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.73	11.42	0.53	1.16e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.4	6.16	0.32	2.12e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22466830	chr18:9475498	RALBP1	0.43	5.96	0.31	6.34e-9	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07437056	chr6:2765594	WRNIP1	0.46	6.36	0.33	6.66e-10	Anxiety disorder;
CRC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-6.23	-0.32	1.4e-9	Vitiligo;
CRC	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg00947319	chr17:47005597	UBE2Z	-0.35	-5.88	-0.31	9.86e-9	Coronary heart disease;
CRC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.67	-0.3	3.09e-8	Colorectal cancer;
CRC	cis	rs7916697	0.626	rs3858144	chr10:70011354	A/G	cg06988349	chr10:69991859	ATOH7	0.37	7.02	0.36	1.27e-11	Optic disc area;
CRC	cis	rs10971721	0.822	rs10971774	chr9:33900109	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.4	6.12	0.32	2.72e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03923535	chr7:1197113	ZFAND2A	0.63	8.9	0.44	3.96e-17	Longevity;Endometriosis;
CRC	cis	rs9463078	0.774	rs9369558	chr6:45274021	A/C	cg25276700	chr6:44698697	NA	-0.29	-6.94	-0.36	2.09e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs12410462	0.591	rs11802190	chr1:227635162	A/C	cg04117972	chr1:227635322	NA	0.45	5.95	0.31	6.98e-9	Major depressive disorder;
CRC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-5.92	-0.31	8.25e-9	Aortic root size;
CRC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.77	-0.3	1.81e-8	Breast cancer;
CRC	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.73	0.3	2.27e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.74e-11	Response to antipsychotic treatment;
CRC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.57	7.98	0.4	2.4e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.45	8.06	0.41	1.41e-14	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.07	-0.32	3.43e-9	Total body bone mineral density;
CRC	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.95	12.02	0.55	7.47e-28	Exhaled nitric oxide levels;
CRC	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg12855166	chr17:30846586	MYO1D	-0.37	-6.04	-0.32	4.26e-9	Schizophrenia;
CRC	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.4	0.46	9.88e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg04025307	chr7:1156635	C7orf50	0.67	7.66	0.39	2.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	8.26	0.41	3.57e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.61	-9.44	-0.46	6.9e-19	Aortic root size;
CRC	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.22	-5.91	-0.31	8.61e-9	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg22687807	chr8:143858763	LYNX1	-0.5	-8.92	-0.44	3.42e-17	Urinary tract infection frequency;
CRC	trans	rs61101201	1.000	rs1223079	chr11:31456846	T/A	cg11934170	chr4:155254326	DCHS2	-0.41	-5.96	-0.31	6.41e-9	Optic disc area;
CRC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg19678392	chr7:94953810	PON1	-0.55	-6.72	-0.35	8.11e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	7.16	0.37	5.16e-12	Eye color traits;
CRC	cis	rs3790844	0.501	rs12035139	chr1:199951850	G/A	cg13229857	chr1:200006247	NR5A2	0.51	7.62	0.39	2.68e-13	Pancreatic cancer;
CRC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg25008857	chr14:105974488	NA	0.43	6.13	0.32	2.54e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.51	-9.55	-0.47	3.06e-19	Educational attainment (years of education);
CRC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.85	14.77	0.63	3.2e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg21285383	chr16:89894308	SPIRE2	0.34	5.78	0.3	1.75e-8	Vitiligo;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07936541	chr2:98206095	ANKRD36B	0.49	6.58	0.34	1.89e-10	Thyroid stimulating hormone;
CRC	cis	rs7107770	0.629	rs7104313	chr11:125070197	A/C	cg27629782	chr11:125073726	PKNOX2	-0.47	-6.66	-0.34	1.15e-10	Photic sneeze reflex;
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.68	7.47	0.38	7.24e-13	Body mass index;
CRC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.97	0.44	2.23e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.69	-0.39	1.76e-13	Breast cancer;
CRC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.77	-10.29	-0.49	1.04e-21	Initial pursuit acceleration;
CRC	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg03934865	chr2:198174659	NA	-0.43	-6.81	-0.35	4.66e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-8.76	-0.44	1.02e-16	Alzheimer's disease;
CRC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.38	-0.42	1.52e-15	Schizophrenia;
CRC	cis	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg16898833	chr6:26189333	HIST1H4D	-0.7	-5.97	-0.31	6.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.24	-0.33	1.33e-9	Bipolar disorder;
CRC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-9.27	-0.46	2.46e-18	Monocyte count;
CRC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.57	-0.34	1.97e-10	Height;
CRC	cis	rs4363385	0.818	rs2339492	chr1:152985552	G/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.72	-0.35	8.13e-11	Inflammatory skin disease;
CRC	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-6.07	-0.32	3.45e-9	Coronary artery disease;
CRC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.83e-9	Depression;
CRC	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.5	7.85	0.4	5.97e-14	Schizophrenia;
CRC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.77	0.35	6.05e-11	Tonsillectomy;
CRC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	16.79	0.68	3.83e-46	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22476897	chr7:30518609	NOD1	0.43	6.12	0.32	2.66e-9	Response to antipsychotic treatment;
CRC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg20203395	chr5:56204925	C5orf35	-0.71	-8.56	-0.43	4.27e-16	Initial pursuit acceleration;
CRC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg09911534	chr15:67153556	NA	0.45	6.07	0.32	3.43e-9	Lung cancer (smoking interaction);
CRC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg11070056	chr1:107600091	PRMT6	-0.42	-6.01	-0.31	4.88e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.86	-0.31	1.1e-8	Response to antipsychotic treatment;
CRC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg11189052	chr15:85197271	WDR73	0.55	7.4	0.38	1.14e-12	Schizophrenia;
CRC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.63	-0.34	1.4e-10	Menopause (age at onset);
CRC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.91	-18.18	-0.71	1.23e-51	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg27532560	chr4:187881888	NA	-0.56	-10.25	-0.49	1.42e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.48e-17	Bladder cancer;
CRC	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-0.77	-7.84	-0.4	6.49e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.39	0.38	1.26e-12	Motion sickness;
CRC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg23298862	chr7:158159286	PTPRN2	0.4	6.23	0.33	1.39e-9	Calcium levels;
CRC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg02254261	chr7:158964346	NA	-0.53	-6.07	-0.32	3.6e-9	Myopia (pathological);
CRC	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg26353448	chr1:248524236	OR2T4	-0.32	-6.17	-0.32	2.02e-9	Common traits (Other);
CRC	cis	rs2242663	0.798	rs1945302	chr11:66337498	C/T	cg24851651	chr11:66362959	CCS	0.44	7.22	0.37	3.67e-12	Bipolar disorder;
CRC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.69	-0.43	1.69e-16	Breast cancer;
CRC	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.83	-0.51	1.4e-23	Bipolar disorder;
CRC	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.6	9.65	0.47	1.47e-19	Itch intensity from mosquito bite;
CRC	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.68	-7.63	-0.39	2.59e-13	Lung cancer (smoking interaction);
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	9.35	0.46	1.35e-18	Blood protein levels;
CRC	trans	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg26043149	chr18:55253948	FECH	0.54	8.27	0.41	3.27e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21939482	chr7:6388130	C7orf70	0.44	6.21	0.32	1.57e-9	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg15845792	chr6:28175446	NA	0.96	13.94	0.61	5.17e-35	Parkinson's disease;
CRC	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.63	-9.16	-0.45	5.53e-18	Intelligence (multi-trait analysis);
CRC	cis	rs427941	0.632	rs201492	chr7:101754138	C/T	cg06246474	chr7:101738831	CUX1	0.44	6.73	0.35	7.61e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.38	5.95	0.31	6.69e-9	Recombination rate (males);
CRC	cis	rs3018066	0.748	rs28391259	chr4:107014012	C/A	cg01869342	chr4:106983673	TBCK	0.44	6.4	0.33	5.49e-10	Cancer;
CRC	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg18876405	chr7:65276391	NA	0.46	6.44	0.33	4.29e-10	Aortic root size;
CRC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.61	8.52	0.43	5.91e-16	Arsenic metabolism;
CRC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.23	-0.56	1.32e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.65	-10.24	-0.49	1.48e-21	Total body bone mineral density;
CRC	cis	rs2276314	0.512	rs1789506	chr18:33625370	G/A	cg19628046	chr18:33552617	C18orf21	-0.4	-6.16	-0.32	2.13e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg24562669	chr7:97807699	LMTK2	0.42	7.04	0.36	1.1e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs35955747	0.778	rs9609263	chr22:31745274	G/T	cg02404636	chr22:31891804	SFI1	-0.38	-5.82	-0.31	1.39e-8	Neutrophil count;Sum basophil neutrophil counts;
CRC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	8.09e-9	Prudent dietary pattern;
CRC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.69	-12.24	-0.56	1.17e-28	Asthma;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg15845792	chr6:28175446	NA	1.01	13.47	0.6	3.16e-33	Depression;
CRC	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg16540259	chr10:75572220	NDST2	0.38	5.8	0.3	1.59e-8	Inflammatory bowel disease;
CRC	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.48	-7.29	-0.37	2.38e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.55	-6.38	-0.33	5.94e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1109861	0.783	rs625315	chr10:11225337	G/T	cg24910943	chr10:11206320	CUGBP2	0.33	9.01	0.44	1.68e-17	Urinary albumin-to-creatinine ratio;
CRC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.72	-10.86	-0.51	1.06e-23	Platelet distribution width;
CRC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.59	9.45	0.46	6.48e-19	Vitiligo;
CRC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.1	-0.32	2.91e-9	Obesity-related traits;
CRC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.82	-0.44	6.89e-17	Alcohol dependence;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Depression;
CRC	cis	rs4302906	0.964	rs10121856	chr9:95736264	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.74	-0.3	2.12e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.48	6.7	0.35	9.11e-11	Menarche (age at onset);
CRC	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg22495460	chr2:25135724	ADCY3	-0.84	-16.24	-0.67	5.86e-44	Body mass index in non-asthmatics;
CRC	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.42e-25	Intelligence (multi-trait analysis);
CRC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.1	13.39	0.59	6.08e-33	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.23	-0.41	4.33e-15	Intelligence (multi-trait analysis);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg02567788	chr10:71992279	PPA1	0.44	6.15	0.32	2.28e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg04969067	chr8:143858791	LYNX1	-0.42	-6.76	-0.35	6.24e-11	Urinary tract infection frequency;
CRC	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.64	10.73	0.51	3.05e-23	Cancer;
CRC	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	6.08	0.32	3.33e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.33	-0.33	7.89e-10	Parkinson's disease;
CRC	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-9.89	-0.48	2.31e-20	Blood protein levels;
CRC	cis	rs860295	0.702	rs11264397	chr1:155611485	G/C	cg02153340	chr1:155202674	NA	-0.55	-6.74	-0.35	7.03e-11	Body mass index;
CRC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-6.59	-0.34	1.8e-10	IgG glycosylation;
CRC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.5	-8.17	-0.41	6.71e-15	Aortic root size;
CRC	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.61	-8.51	-0.42	6.34e-16	White matter hyperintensity burden;
CRC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05472934	chr7:22766657	IL6	0.8	13.26	0.59	1.88e-32	Lung cancer;
CRC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.73	-11.25	-0.53	4.44e-25	Menopause (age at onset);
CRC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg25456477	chr12:86230367	RASSF9	0.34	5.92	0.31	8.19e-9	Major depressive disorder;
CRC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg15396367	chr9:139972779	UAP1L1	-0.49	-7.57	-0.39	3.86e-13	Cerebrospinal fluid biomarker levels;
CRC	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg21153622	chr11:89784906	NA	-0.47	-7.31	-0.37	2.02e-12	HDL cholesterol;
CRC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.5	9.59	0.47	2.32e-19	Iron status biomarkers;
CRC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.2	-0.37	4.07e-12	Gut microbiome composition (summer);
CRC	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.47	7.46	0.38	7.64e-13	Brain structure;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.39	-0.33	5.78e-10	Electroencephalogram traits;
CRC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.85	15.96	0.66	7.02e-43	Menopause (age at onset);
CRC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.54	8.66	0.43	2.13e-16	Prostate cancer;
CRC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-10.08	-0.49	5.23e-21	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.91	12.11	0.56	3.72e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.66	-10.72	-0.51	3.52e-23	Hepatocellular carcinoma;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03432716	chr1:6550858	PLEKHG5	0.48	6.64	0.34	1.3100000000000001e-10	Response to antipsychotic treatment;
CRC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg09491104	chr22:46646882	C22orf40	-0.47	-7.29	-0.37	2.36e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.73	11.01	0.52	3.2e-24	Testicular germ cell tumor;
CRC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	16.1	0.66	1.98e-43	Lymphocyte percentage of white cells;
CRC	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-7.46	-0.38	7.94e-13	HDL cholesterol;
CRC	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.38	-6.59	-0.34	1.73e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.58	-0.34	1.82e-10	Lung cancer;
CRC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.62	0.47	1.84e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-0.87	-13.4	-0.59	5.85e-33	Platelet distribution width;
CRC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Red blood cell count;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25220428	chr6:19144084	NA	-0.48	-6.4	-0.33	5.22e-10	Hip circumference;
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg16606324	chr3:10149918	C3orf24	0.68	9.18	0.45	5.04e-18	Alzheimer's disease;
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.01	-0.4	2.01e-14	Bipolar disorder;
CRC	cis	rs11098699	0.821	rs6830451	chr4:124230386	G/A	cg09941581	chr4:124220074	SPATA5	0.39	5.81	0.3	1.49e-8	Mosquito bite size;
CRC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg20933634	chr6:27740509	NA	-0.39	-5.67	-0.3	3.21e-8	Systemic lupus erythematosus;
CRC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-6.72	-0.35	7.92e-11	Psoriasis;
CRC	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.54	7.31	0.37	2.07e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.41	5.75	0.3	2.04e-8	Renal cell carcinoma;
CRC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.49	7.45	0.38	8.29e-13	Longevity;Endometriosis;
CRC	cis	rs11229555	0.645	rs12273638	chr11:58186335	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.33	-0.49	7.4e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.58	-8.85	-0.44	5.57e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.94	14.88	0.63	1.17e-38	Parkinson's disease;
CRC	cis	rs3823572	0.548	rs2971981	chr7:133651555	T/C	cg03336402	chr7:133662267	EXOC4	-0.69	-10.78	-0.51	2.15e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	0.91	10.8	0.51	1.77e-23	Type 2 diabetes nephropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06843030	chr22:41697630	ZC3H7B	0.38	6.12	0.32	2.6e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6504622	0.577	rs35707546	chr17:45001541	G/A	cg16759221	chr17:45003025	GOSR2	0.64	10.35	0.5	6.31e-22	Orofacial clefts;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg06470822	chr6:28175283	NA	0.67	9.07	0.45	1.1e-17	Parkinson's disease;
CRC	cis	rs7932354	0.528	rs7479189	chr11:47057009	T/A	cg03339077	chr11:47165057	C11orf49	0.44	6.24	0.33	1.35e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.17	0.59	4.16e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs12618769	0.597	rs17505326	chr2:99156807	T/A	cg18455616	chr2:99124870	INPP4A	0.36	5.9	0.31	8.84e-9	Bipolar disorder;
CRC	cis	rs728616	0.867	rs56235549	chr10:81834948	G/A	cg11900509	chr10:81946545	ANXA11	-0.55	-5.93	-0.31	7.73e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.45	0.38	8.11e-13	Body mass index;
CRC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.5	-6.77	-0.35	6.03e-11	Colorectal cancer;
CRC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.69	-10.8	-0.51	1.84e-23	Blood protein levels;
CRC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.89	0.31	9.61e-9	Lung cancer;
CRC	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.74	9.53	0.47	3.56e-19	Prostate cancer;
CRC	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.11	-0.32	2.84e-9	Height;
CRC	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg15711740	chr2:61764176	XPO1	0.45	6.19	0.32	1.81e-9	Tuberculosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24361086	chr7:123388661	WASL	0.54	7.71	0.39	1.51e-13	Response to antipsychotic treatment;
CRC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg19913688	chr11:428466	ANO9	-0.72	-6.9	-0.36	2.72e-11	Body mass index;
CRC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.86	10.44	0.5	3.27e-22	Glomerular filtration rate (creatinine);
CRC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg05585544	chr11:47624801	NA	0.46	8.16	0.41	7.15e-15	Subjective well-being;
CRC	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.52	8.73	0.43	1.35e-16	Dupuytren's disease;
CRC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg06470822	chr6:28175283	NA	0.48	6.43	0.33	4.59e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.37	-6.32	-0.33	8.49e-10	Schizophrenia;
CRC	cis	rs1712517	0.873	rs7894240	chr10:105000369	T/C	cg05636881	chr10:105038444	INA	-0.46	-8.11	-0.41	1.02e-14	Migraine;
CRC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.62	10.58	0.5	1.01e-22	Mean corpuscular volume;
CRC	cis	rs7215564	0.818	rs4889881	chr17:78664157	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.08	0.32	3.29e-9	Myopia (pathological);
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg02683197	chr6:28174875	NA	0.68	9.38	0.46	1.09e-18	Cardiac Troponin-T levels;
CRC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.29	0.42	2.94e-15	Lung cancer;
CRC	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-0.57	-5.77	-0.3	1.87e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	11.37	0.53	1.7e-25	Electrocardiographic conduction measures;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg17274400	chr12:8234945	NECAP1	-0.39	-6.05	-0.32	3.9e-9	Aortic root size;
CRC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.69	6.51	0.34	2.83e-10	Major depressive disorder;
CRC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	8.58	0.43	3.76e-16	Monocyte percentage of white cells;
CRC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg10765909	chr12:53715428	AAAS	0.52	6.81	0.35	4.55e-11	Platelet distribution width;
CRC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.43	0.5	3.46e-22	Systolic blood pressure;
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-6.53	-0.34	2.53e-10	Lymphocyte counts;
CRC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.24	-16.72	-0.68	7.21e-46	Breast cancer;
CRC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-9.14	-0.45	6.41e-18	Breast cancer;
CRC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.53	-7.06	-0.36	9.89e-12	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-5.99	-0.31	5.63e-9	Total body bone mineral density;
CRC	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.66	8.8	0.44	8.1e-17	Interstitial lung disease;
CRC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg15396367	chr9:139972779	UAP1L1	0.55	8.64	0.43	2.42e-16	Cerebrospinal fluid biomarker levels;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg13490827	chr1:46269305	MAST2	-0.72	-6.21	-0.32	1.6e-9	Cognitive function;
CRC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.75	0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.85	-12.39	-0.56	3.3e-29	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	5.8	0.3	1.56e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-8.03	-0.4	1.79e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs294883	0.739	rs905686	chr6:159733130	A/G	cg14500486	chr6:159655392	FNDC1	-0.36	-6.05	-0.32	3.83e-9	Coronary artery disease;
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg18972013	chr17:78078605	GAA	-0.39	-5.78	-0.3	1.77e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg05299278	chr17:33885742	SLFN14	0.38	5.68	0.3	2.95e-8	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.48	6.53	0.34	2.48e-10	Squamous cell carcinoma;
CRC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.57	-8.37	-0.42	1.64e-15	Dental caries;
CRC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.62	6.66	0.34	1.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg19223190	chr17:80058835	NA	0.39	6.32	0.33	8.75e-10	Life satisfaction;
CRC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.51	5.75	0.3	2.03e-8	Initial pursuit acceleration;
CRC	cis	rs9467160	1.000	rs9467158	chr6:24441215	G/A	cg20631270	chr6:24437470	GPLD1	0.49	6.32	0.33	8.75e-10	Liver enzyme levels;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.58	8.48	0.42	7.81e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12588279	chr6:26043732	HIST1H2BB	0.43	6.2	0.32	1.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.49	7.82	0.4	7.35e-14	Resting heart rate;
CRC	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg02158880	chr13:53174818	NA	0.55	8.85	0.44	5.54e-17	Lewy body disease;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Depression;
CRC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg20790798	chr5:1857306	NA	-0.41	-6.14	-0.32	2.44e-9	Cardiovascular disease risk factors;
CRC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.47	-7.47	-0.38	7.37e-13	Monocyte count;
CRC	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg00086871	chr4:6988644	TBC1D14	0.95	7.23	0.37	3.4e-12	Granulocyte percentage of myeloid white cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12951224	chr8:38126910	PPAPDC1B	0.47	6.02	0.31	4.7e-9	Thyroid stimulating hormone;
CRC	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.58	8.13	0.41	8.74e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.4	6.46	0.34	3.67e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.36	0.53	1.81e-25	Alzheimer's disease;
CRC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.46	7.33	0.37	1.8e-12	Testicular germ cell tumor;
CRC	cis	rs3736485	0.789	rs6493499	chr15:51812842	T/A	cg08986416	chr15:51914746	DMXL2	-0.49	-7.07	-0.36	9.19e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17767392	0.609	rs60526802	chr14:71680078	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.19	-0.32	1.75e-9	Mitral valve prolapse;
CRC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.56	-8.22	-0.41	4.64e-15	Prudent dietary pattern;
CRC	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.49	7.45	0.38	8.17e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg07274523	chr3:49395745	GPX1	0.45	5.73	0.3	2.32e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.61	-7.73	-0.39	1.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	10.92	0.52	6.53e-24	Neutrophil percentage of white cells;
CRC	cis	rs62229266	0.659	rs7275820	chr21:37409414	G/A	cg12218747	chr21:37451666	NA	-0.36	-6.2	-0.32	1.71e-9	Mitral valve prolapse;
CRC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.5	8.82	0.44	6.58e-17	Height;
CRC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.75	-11.07	-0.52	2.03e-24	Refractive error;
CRC	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-12.62	-0.57	4.89e-30	Idiopathic membranous nephropathy;
CRC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg16892393	chr17:41919603	NA	0.6	8.63	0.43	2.71e-16	Triglycerides;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21570168	chr14:102226945	PPP2R5C	0.39	6.55	0.34	2.24e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.92	-17.39	-0.69	1.63e-48	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08805160	chr11:8704501	RPL27A;SNORA3	-0.44	-6.99	-0.36	1.52e-11	Myopia (pathological);
CRC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.83	-0.4	6.57e-14	Putamen volume;
CRC	cis	rs939584	1.000	rs13397165	chr2:653354	G/A	cg03610516	chr2:642275	NA	-0.41	-5.65	-0.3	3.43e-8	Body mass index;
CRC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.42	-0.38	1.03e-12	Body mass index;
CRC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg09165964	chr15:75287851	SCAMP5	0.44	6.84	0.35	3.94e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.54	-7.93	-0.4	3.41e-14	Waist circumference;Hip circumference;
CRC	cis	rs863345	0.604	rs2051451	chr1:158464265	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.26	-0.33	1.17e-9	Pneumococcal bacteremia;
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg10217327	chr6:118973057	C6orf204	0.51	5.8	0.3	1.59e-8	Diastolic blood pressure;
CRC	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.48	-7.72	-0.39	1.45e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.57	-8.96	-0.44	2.49e-17	Height;
CRC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.33	-0.33	8.23e-10	Morning vs. evening chronotype;
CRC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	trans	rs12439619	1.000	rs35152457	chr15:82546548	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.69	-0.35	9.59e-11	Intelligence (multi-trait analysis);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg25533220	chr19:2328480	SPPL2B;LSM7	-0.43	-6.42	-0.33	4.67e-10	Daytime sleep phenotypes;
CRC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.01	0.4	2.07e-14	Resting heart rate;
CRC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.55	-0.38	4.36e-13	Gut microbiome composition (summer);
CRC	trans	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.19	-0.32	1.82e-9	Aortic root size;
CRC	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg11946769	chr3:48343235	NME6	-0.5	-6.6	-0.34	1.69e-10	Educational attainment (years of education);
CRC	cis	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg08799069	chr10:126477246	METTL10	0.43	6.52	0.34	2.57e-10	Asthma;
CRC	cis	rs10986311	0.802	rs7045589	chr9:127110354	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.39	5.97	0.31	6.04e-9	Vitiligo;
CRC	trans	rs9420907	0.748	rs9419958	chr10:105675946	T/C	ch.7.2986028F	chr7:141887997	LOC100124692	-0.54	-5.99	-0.31	5.49e-9	Telomere length;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg17105206	chr16:67211972	KIAA0895L	-0.4	-6.08	-0.32	3.32e-9	Protein C levels;
CRC	cis	rs9648716	0.935	rs1267647	chr7:140486288	C/T	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.14e-8	Type 2 diabetes;
CRC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.49	6.95	0.36	1.93e-11	Lymphocyte counts;
CRC	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg21466736	chr12:48725269	NA	-0.54	-8.55	-0.43	4.87e-16	Plateletcrit;
CRC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.69	-0.35	9.5e-11	Alcohol dependence;
CRC	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	1.14	10.04	0.48	7.37e-21	Mitochondrial DNA levels;
CRC	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg00373020	chr1:21041521	KIF17	0.41	6.33	0.33	8.04e-10	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.45	-7.74	-0.39	1.26e-13	Major depressive disorder;
CRC	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg19025524	chr12:109796872	NA	-0.47	-6.78	-0.35	5.7e-11	Neuroticism;
CRC	cis	rs938554	0.915	rs4697913	chr4:9941262	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.62	-0.3	4.15e-8	Blood metabolite levels;
CRC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06481639	chr22:41940642	POLR3H	0.52	5.63	0.3	3.81e-8	Vitiligo;
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg23161317	chr6:28129485	ZNF389	0.45	6.02	0.31	4.77e-9	Parkinson's disease;
CRC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.63	-9.97	-0.48	1.21e-20	Intelligence (multi-trait analysis);
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20916646	chr4:852691	GAK	0.47	6.95	0.36	1.93e-11	Sjögren's syndrome;
CRC	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.67	-10.28	-0.49	1.07e-21	Psoriasis;
CRC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.81	-0.31	1.45e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04470066	chr3:159943320	LOC401097	0.31	6.03	0.32	4.35e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00197636	chr8:57906363	IMPAD1	0.39	6.13	0.32	2.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.52	-8.51	-0.42	6.27e-16	Testicular germ cell tumor;
CRC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.99	17.96	0.7	9.34e-51	Parkinson's disease;
CRC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.52	7.32	0.37	1.89e-12	Lymphocyte counts;
CRC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.37	6.02	0.32	4.63e-9	Total body bone mineral density;
CRC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg17948913	chr5:572064	NA	0.53	6.12	0.32	2.72e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs812925	0.502	rs2084318	chr2:61652601	C/T	cg10580144	chr2:61372316	C2orf74	-0.31	-6.72	-0.35	8.16e-11	Immature fraction of reticulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04212729	chr14:65171037	PLEKHG3	0.46	6.52	0.34	2.63e-10	Response to antipsychotic treatment;
CRC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.87	-0.4	5.18e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs4714291	0.832	rs6917417	chr6:40104628	T/C	cg02267698	chr19:7991119	CTXN1	-0.52	-7.02	-0.36	1.26e-11	Strep throat;
CRC	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14119001	chr9:139324193	INPP5E	-0.44	-6.23	-0.32	1.46e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg21251018	chr6:28226885	NKAPL	0.48	7.52	0.38	5.21e-13	Parkinson's disease;
CRC	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.38	5.86	0.31	1.1e-8	Myeloid white cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24087235	chr1:54665621	CYB5RL;MRPL37	0.52	7.52	0.38	5.4e-13	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.87	0.4	5.09e-14	Lung cancer;
CRC	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg09659197	chr4:152720779	NA	0.52	11.43	0.53	1.07e-25	Intelligence (multi-trait analysis);
CRC	cis	rs4523957	0.547	rs11078856	chr17:2092064	G/A	cg16513277	chr17:2031491	SMG6	-0.58	-9.9	-0.48	2.08e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs12438356	0.571	rs6494785	chr15:69436267	C/T	cg25446197	chr4:25235616	PI4K2B	0.54	6.16	0.32	2.11e-9	CTACK levels;
CRC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.21	0.45	4.05e-18	Personality dimensions;
CRC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.14	0.45	6.42e-18	Smoking initiation;
CRC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.76	12.99	0.58	2e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18876494	chr12:69004196	RAP1B	-0.4	-5.99	-0.31	5.38e-9	Myopia (pathological);
CRC	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.76	8.36	0.42	1.74e-15	Systolic blood pressure;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg03623178	chr6:28175578	NA	0.8	11.88	0.55	2.41e-27	Cardiac Troponin-T levels;
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg10729496	chr3:10149963	C3orf24	0.51	5.9	0.31	8.81e-9	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.19e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.11	0.36	7.38e-12	Hemoglobin concentration;
CRC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg15465823	chr12:48382534	COL2A1	-0.38	-6.23	-0.32	1.46e-9	Glycated hemoglobin levels;
CRC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.79	9.55	0.47	3.09e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg21518248	chr2:162101506	NA	-0.43	-6.29	-0.33	9.89e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22255355	chr19:58838374	ZSCAN22	0.38	6.02	0.31	4.71e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.35	-0.46	1.43e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.61	0.54	2.3e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.59	5.84	0.31	1.23e-8	Fat distribution (HIV);
CRC	cis	rs11212617	1.000	rs227093	chr11:108233939	T/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.74	0.3	2.16e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs72615157	0.539	rs4729575	chr7:99686873	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.4	6.06	0.32	3.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg18479299	chr3:125709523	NA	-0.55	-6.53	-0.34	2.54e-10	Blood pressure (smoking interaction);
CRC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg14196790	chr5:131705035	SLC22A5	-0.35	-5.77	-0.3	1.87e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.1	14.29	0.62	2.3e-36	Uric acid levels;
CRC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.21	14.81	0.63	2.26e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg14191688	chr11:70257035	CTTN	0.57	7.86	0.4	5.55e-14	Coronary artery disease;
CRC	trans	rs7976838	0.908	rs34790713	chr12:60140993	G/A	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.31e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs12760731	0.623	rs1985761	chr1:178438645	A/G	cg00404053	chr1:178313656	RASAL2	0.69	8.61	0.43	3.05e-16	Obesity-related traits;
CRC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.72	10.09	0.49	4.78e-21	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17684478	chr11:118842230	FOXR1	0.4	6.49	0.34	3.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7113874	0.550	rs2044464	chr11:8559695	G/A	cg20771178	chr11:8615675	STK33	-0.35	-5.85	-0.31	1.18e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg12172441	chr6:28176163	NA	-0.45	-6.52	-0.34	2.72e-10	Cardiac Troponin-T levels;
CRC	cis	rs3750082	0.889	rs6462432	chr7:32935524	C/T	cg05721444	chr7:32995514	FKBP9	0.5	7.85	0.4	5.98e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6700896	0.931	rs12043644	chr1:66147348	A/G	cg04111102	chr1:66153794	NA	0.34	5.8	0.3	1.56e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9928842	0.882	rs11641896	chr16:75300179	T/C	cg08657710	chr16:75258780	CTRB1	-0.57	-6.48	-0.34	3.28e-10	Alcoholic chronic pancreatitis;
CRC	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.04	0.32	4.27e-9	Axial length;
CRC	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.75	-0.35	6.75e-11	Myopia (pathological);
CRC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.27	0.67	4.24e-44	Chronic sinus infection;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg22638593	chr5:131593259	PDLIM4	0.48	9.05	0.45	1.28e-17	Acylcarnitine levels;
CRC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.52	-8.31	-0.42	2.63e-15	Type 2 diabetes;
CRC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.64	8.5	0.42	6.82e-16	Menopause (age at onset);
CRC	trans	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg09045935	chr12:6379348	NA	1.13	9.24	0.45	3.24e-18	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23953233	chr12:53574539	ZNF740;CSAD	0.37	5.96	0.31	6.54e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.51	-7.63	-0.39	2.54e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	7.45	0.38	8.16e-13	Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs13007310	chr2:15710058	A/G	cg19274914	chr2:15703543	NA	-0.38	-5.79	-0.3	1.67e-8	Educational attainment (years of education);
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.4	5.99	0.31	5.47e-9	Hemoglobin concentration;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg02683197	chr6:28174875	NA	0.75	11.02	0.52	3.04e-24	Cardiac Troponin-T levels;
CRC	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.65	-0.68	1.37e-45	Hip circumference;
CRC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.03	-0.32	4.35e-9	Aortic root size;
CRC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.67	-11.6	-0.54	2.61e-26	Type 2 diabetes;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.55	9.57	0.47	2.62e-19	Acylcarnitine levels;
CRC	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg10761708	chr20:43804764	PI3	0.5	5.69	0.3	2.77e-8	Blood protein levels;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.7	10.66	0.51	5.29e-23	Longevity;Endometriosis;
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg19223190	chr17:80058835	NA	0.4	6.53	0.34	2.45e-10	Life satisfaction;
CRC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.25	-0.49	1.37e-21	Chronic sinus infection;
CRC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.21	-0.32	1.59e-9	Aortic root size;
CRC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.9	13.32	0.59	1.14e-32	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-17.1	-0.69	2.31e-47	Intelligence (multi-trait analysis);
CRC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg05192639	chr6:26864778	GUSBL1	0.34	6.37	0.33	6.34e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg07052231	chr12:7363540	PEX5	0.52	8.4	0.42	1.39e-15	IgG glycosylation;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12172441	chr6:28176163	NA	0.59	7.12	0.37	6.82e-12	Depression;
CRC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.5	-5.91	-0.31	8.45e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg08885800	chr1:201084119	NA	0.4	6.31	0.33	9.18e-10	Permanent tooth development;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.51	6.84	0.35	3.93e-11	Aortic root size;
CRC	cis	rs12692738	0.526	rs355833	chr2:165617089	G/T	cg03182029	chr2:165697222	COBLL1	0.48	5.66	0.3	3.32e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11742202	chr6:74364667	SLC17A5	0.29	5.96	0.31	6.32e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.54	7.14	0.37	5.92e-12	Obesity-related traits;
CRC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.37	-0.38	1.35e-12	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00166722	chr3:10149974	C3orf24	0.67	9.26	0.45	2.71e-18	Alzheimer's disease;
CRC	cis	rs673253	0.686	rs943513	chr1:44035472	G/A	cg10881128	chr1:44031826	PTPRF	0.2	5.66	0.3	3.26e-8	Intelligence (multi-trait analysis);
CRC	cis	rs972578	1.000	rs5759060	chr22:43361804	T/C	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs7202877	0.561	rs7202083	chr16:75383727	G/T	cg03315344	chr16:75512273	CHST6	0.58	5.94	0.31	7.28e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.59	9.89	0.48	2.31e-20	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06544989	chr22:39130855	UNC84B	0.46	7.37	0.38	1.43e-12	Menopause (age at onset);
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-7.15	-0.37	5.51e-12	Waist circumference;Body mass index;
CRC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7107770	0.739	rs12788937	chr11:125082221	G/A	cg27629782	chr11:125073726	PKNOX2	0.53	7.75	0.39	1.16e-13	Photic sneeze reflex;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25187254	chr7:100797533	AP1S1	0.4	6.56	0.34	2.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.74	12.49	0.57	1.41e-29	Systemic lupus erythematosus;
CRC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-7.57	-0.39	3.71e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg03623178	chr6:28175578	NA	0.96	12.59	0.57	6.03e-30	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08438989	chr1:181999219	NA	0.45	6.18	0.32	1.85e-9	Anxiety disorder;
CRC	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg21251018	chr6:28226885	NKAPL	0.46	6.16	0.32	2.12e-9	Parkinson's disease;
CRC	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.65	7.87	0.4	5.01e-14	Eotaxin levels;
CRC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.96	0.36	1.91e-11	Morning vs. evening chronotype;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg16721101	chr20:25176146	ENTPD6	-0.7	-6.09	-0.32	3.23e-9	Cognitive function;
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg22638593	chr5:131593259	PDLIM4	0.35	6.43	0.33	4.55e-10	Blood metabolite levels;
CRC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.15	-0.41	7.53e-15	Morning vs. evening chronotype;
CRC	cis	rs11212617	0.901	rs11212538	chr11:108045956	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.75	0.3	2e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-8.27	-0.42	3.25e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.14	0.69	1.69e-47	Blood protein levels;
CRC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.64	7.83	0.4	6.7e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12311644	chr22:31687046	PIK3IP1	0.5	7.33	0.37	1.75e-12	Response to antipsychotic treatment;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg06635371	chr11:62554837	TMEM179B	0.45	6.26	0.33	1.23e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs2413994	0.666	rs7173644	chr15:50232552	C/T	cg07095997	chr14:61188431	SIX4	0.36	6.26	0.33	1.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.41	-6.02	-0.32	4.64e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.64	0.34	1.33e-10	Schizophrenia;
CRC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.12e-10	Mean platelet volume;
CRC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.66	9.78	0.47	5.25e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.35	5.95	0.31	6.99e-9	Pelvic organ prolapse;
CRC	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	15.12	0.64	1.37e-39	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.74	9.33	0.46	1.62e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6968419	0.674	rs4730726	chr7:115913336	T/A	cg02561103	chr7:115862891	TES	-0.42	-6.32	-0.33	8.42e-10	Intraocular pressure;
CRC	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.47	7.69	0.39	1.71e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-8.82	-0.44	7e-17	Pancreatic cancer;
CRC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.54	5.8	0.3	1.58e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07508260	chr11:111742291	ALG9	0.49	6.88	0.35	2.99e-11	Response to antipsychotic treatment;
CRC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg21970626	chr13:21893289	NA	0.47	6.2	0.32	1.67e-9	White matter hyperintensity burden;
CRC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	6.77	0.35	6.01e-11	Schizophrenia;
CRC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg17178900	chr1:205818956	PM20D1	-0.4	-5.7	-0.3	2.73e-8	Menarche (age at onset);
CRC	trans	rs9341835	0.740	rs4710255	chr6:64156268	A/C	cg13657004	chr13:50234944	EBPL	-0.37	-6.18	-0.32	1.89e-9	Schizophrenia;
CRC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg10298567	chr3:47292165	KIF9	-0.35	-5.83	-0.31	1.33e-8	Colorectal cancer;
CRC	cis	rs7632954	0.567	rs6793940	chr3:8535006	C/A	cg03495237	chr3:8533978	NA	0.35	6.31	0.33	9.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.14	-0.41	8.26e-15	Breast cancer;
CRC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.08	-0.45	1.01e-17	Prostate cancer;
CRC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg11941060	chr3:133502564	NA	-0.44	-7.25	-0.37	3.09e-12	Iron status biomarkers;
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.47	-0.34	3.61e-10	Bipolar disorder;
CRC	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg26741380	chr15:41871084	TYRO3	0.49	6.89	0.36	2.9e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.37	6.77	0.35	5.84e-11	Panic disorder;
CRC	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg00012203	chr2:219082015	ARPC2	-0.38	-5.8	-0.3	1.52e-8	Ulcerative colitis;
CRC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs449789	0.857	rs1875816	chr6:159720314	A/G	cg14500486	chr6:159655392	FNDC1	-0.48	-7.39	-0.38	1.24e-12	Pulse pressure;
CRC	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.92	0.31	8.31e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.67	11.09	0.52	1.73e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	8.15	0.41	7.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08870933	chr16:71879943	ATXN1L	0.4	6.47	0.34	3.49e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.72	0.3	2.44e-8	Bipolar disorder;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg15845792	chr6:28175446	NA	0.75	6.47	0.34	3.6e-10	Breast cancer;
CRC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg11707556	chr5:10655725	ANKRD33B	0.38	6.61	0.34	1.57e-10	Coronary artery disease;
CRC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg14979609	chr8:8086686	FLJ10661	0.38	6.08	0.32	3.42e-9	Joint mobility (Beighton score);
CRC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.04	-0.32	4.14e-9	Obesity-related traits;
CRC	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg05714579	chr10:131428358	MGMT	-0.55	-7.61	-0.39	2.83e-13	Response to temozolomide;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Parkinson's disease;
CRC	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.65	9.07	0.45	1.09e-17	Coronary artery disease;
CRC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.24	0.37	3.19e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.56	5.68	0.3	2.94e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.49	-6.42	-0.33	4.85e-10	Platelet distribution width;
CRC	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg01843034	chr6:37503916	NA	-0.48	-9.06	-0.45	1.18e-17	Cognitive performance;
CRC	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.66	7.04	0.36	1.16e-11	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01622965	chr7:98476371	TRRAP	0.44	6.11	0.32	2.76e-9	Response to antipsychotic treatment;
CRC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.49	6.85	0.35	3.71e-11	Schizophrenia;
CRC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.62	9.01	0.44	1.68e-17	Multiple sclerosis;
CRC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.58	-8.9	-0.44	3.72e-17	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.06e-10	Depression;
CRC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.45	-6.82	-0.35	4.39e-11	Birth weight;
CRC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.55	8.16	0.41	7.26e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9323205	0.765	rs2999389	chr14:51654510	G/A	cg23942311	chr14:51606299	NA	0.62	9.88	0.48	2.46e-20	Cancer;
CRC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.1	0.59	7.65e-32	Chronic sinus infection;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23812325	chr4:56915719	NA	-0.41	-6.31	-0.33	9.22e-10	Aortic root size;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.55	-5.64	-0.3	3.64e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.48	8.09	0.41	1.12e-14	Common traits (Other);
CRC	cis	rs4237845	0.611	rs4760347	chr12:58346868	T/C	cg02175503	chr12:58329896	NA	0.76	11.97	0.55	1.2100000000000001e-27	Intelligence (multi-trait analysis);
CRC	trans	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.7	-0.35	8.99e-11	Depression;
CRC	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.55	0.47	3.03e-19	Type 2 diabetes;
CRC	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg13662093	chr20:33865505	NA	0.45	6.25	0.33	1.24e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.31	-0.42	2.53e-15	Schizophrenia;
CRC	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs1178968	0.901	rs9784947	chr7:72748888	C/G	cg25889504	chr7:72793014	NA	0.53	6.04	0.32	4.16e-9	Triglyceride levels;
CRC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.84	0.35	3.88e-11	Rheumatoid arthritis;
CRC	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg14664628	chr15:75095509	CSK	-0.49	-5.72	-0.3	2.34e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2227564	0.729	rs2688615	chr10:75651499	C/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.63	-0.39	2.58e-13	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-1.07	-18.03	-0.7	4.94e-51	Blood pressure (smoking interaction);
CRC	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.08	21.47	0.76	1.48e-64	Platelet distribution width;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg02683197	chr6:28174875	NA	0.61	8.54	0.43	5.01e-16	Parkinson's disease;
CRC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	15.07	0.64	2.12e-39	Electrocardiographic conduction measures;
CRC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.61	0.5	8.4e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11645453	chr3:52864694	ITIH4	-0.37	-7.03	-0.36	1.24e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Corneal astigmatism;
CRC	cis	rs6735179	0.837	rs6745451	chr2:1776761	C/T	cg19300414	chr2:1746591	PXDN	0.38	5.81	0.31	1.44e-8	Response to antipsychotic treatment;
CRC	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg08071915	chr8:12219732	FAM66A	0.36	6.38	0.33	5.96e-10	Retinal vascular caliber;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05148093	chr5:140027274	NDUFA2;IK	0.48	6.16	0.32	2.11e-9	Thyroid stimulating hormone;
CRC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.45	5.62	0.3	4.12e-8	Schizophrenia;
CRC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg19980929	chr12:42632907	YAF2	0.4	5.96	0.31	6.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-7.6	-0.39	3.18e-13	Hemoglobin concentration;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.51	0.34	2.8e-10	Bipolar disorder;
CRC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.47	-7.97	-0.4	2.65e-14	Prostate cancer;
CRC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg09163369	chr1:210001066	C1orf107	0.4	5.75	0.3	2.08e-8	Orofacial clefts;
CRC	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg25363559	chr8:143086065	NA	-0.33	-6.35	-0.33	7.25e-10	Amyotrophic lateral sclerosis;
CRC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	0.63	7.48	0.38	6.63e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg23136738	chr11:925521	AP2A2	0.4	6.23	0.32	1.42e-9	Alzheimer's disease (late onset);
CRC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.66	-0.39	2.09e-13	Colorectal cancer;
CRC	cis	rs4363385	0.693	rs402153	chr1:153054212	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.45	-0.34	3.95e-10	Inflammatory skin disease;
CRC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.54	6.74	0.35	7.23e-11	Diastolic blood pressure;
CRC	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg14711859	chr11:8959438	ASCL3	-0.49	-7.84	-0.4	6.46e-14	Hemoglobin concentration;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.54	-8.68	-0.43	1.86e-16	Endometriosis;
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02725872	chr8:58115012	NA	-0.39	-6.5	-0.34	3.01e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.64	-8.52	-0.43	5.66e-16	Platelet count;
CRC	cis	rs2857891	1.000	rs2638092	chr11:6961746	G/A	cg26870460	chr11:6947759	ZNF215	0.56	5.88	0.31	1.03e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.24	0.33	1.37e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	8.28	0.42	3.06e-15	Mean corpuscular volume;
CRC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.73	-8.37	-0.42	1.66e-15	Obesity-related traits;
CRC	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.53	8.84	0.44	5.77e-17	Dupuytren's disease;
CRC	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.87	-0.4	5.08e-14	Vitamin D levels;
CRC	cis	rs9463078	0.764	rs9367208	chr6:44830180	G/A	cg25276700	chr6:44698697	NA	-0.28	-6.73	-0.35	7.45e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs10411161	0.702	rs8100716	chr19:52384061	T/C	cg22319618	chr22:45562946	NUP50	-0.69	-7.66	-0.39	2.09e-13	Breast cancer;
CRC	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-11.75	-0.54	7.63e-27	Plateletcrit;Platelet count;
CRC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.47	7.38	0.38	1.32e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-6.31	-0.33	8.77e-10	Daytime sleep phenotypes;
CRC	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg19338460	chr6:170058176	WDR27	-0.73	-7.88	-0.4	4.76e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.9	-15.65	-0.65	1.22e-41	Height;
CRC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.54	-7.92	-0.4	3.81e-14	Platelet distribution width;
CRC	cis	rs7605827	0.893	rs35123590	chr2:15708639	T/C	cg19274914	chr2:15703543	NA	0.37	5.76	0.3	1.96e-8	Educational attainment (years of education);
CRC	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg10845886	chr2:3471009	TTC15	-0.58	-8.62	-0.43	2.95e-16	Neurofibrillary tangles;
CRC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.31	-0.33	9.25e-10	Arsenic metabolism;
CRC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg02094049	chr14:103021097	NA	-0.55	-7.22	-0.37	3.63e-12	Platelet count;
CRC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.71	12.12	0.56	3.47e-28	Gout;
CRC	cis	rs17601876	0.814	rs8042086	chr15:51561478	C/T	cg19946085	chr15:51559439	CYP19A1	-0.34	-6.99	-0.36	1.57e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.53	7.59	0.39	3.39e-13	Primary sclerosing cholangitis;
CRC	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.46	-6.9	-0.36	2.63e-11	Neutrophil percentage of white cells;
CRC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.88	11.77	0.54	6.18e-27	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg18876405	chr7:65276391	NA	0.46	6.31	0.33	9.12e-10	Aortic root size;
CRC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.54	-7.97	-0.4	2.7e-14	Monocyte count;
CRC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.49	-0.34	3.16e-10	Aortic root size;
CRC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.78	-0.35	5.43e-11	Breast cancer;
CRC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.58	-9.04	-0.45	1.38e-17	Height;
CRC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.49	0.46	4.69e-19	Cognitive test performance;
CRC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.43	-6.29	-0.33	1.01e-9	Schizophrenia;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.91	14.92	0.64	8.42e-39	Menarche (age at onset);
CRC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18912574	chr7:65842487	NCRNA00174	0.39	6.7	0.35	9.14e-11	Aortic root size;
CRC	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg08999081	chr20:33150536	PIGU	0.46	5.68	0.3	3.01e-8	Neuroticism;
CRC	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	cg04338863	chr8:33670619	NA	0.47	6.89	0.36	2.85e-11	Body mass index;
CRC	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg10820045	chr2:198174542	NA	0.41	6.91	0.36	2.5e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.64	8.47	0.42	8.16e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg01339444	chr6:118972232	C6orf204	0.58	6.44	0.33	4.28e-10	Diastolic blood pressure;
CRC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.41	-7.78	-0.39	9.14e-14	Ulcerative colitis;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.59	10.13	0.49	3.61e-21	Prudent dietary pattern;
CRC	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg26741380	chr15:41871084	TYRO3	-0.52	-7.14	-0.37	6.1e-12	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.86	-13.19	-0.59	3.58e-32	Gut microbiome composition (winter);
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.48	-0.34	3.31e-10	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-5.73	-0.3	2.22e-8	Vitiligo;
CRC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.49	-6.68	-0.35	1.05e-10	Rheumatoid arthritis;
CRC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.79	-0.3	1.65e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg02033258	chr5:131593261	PDLIM4	0.38	6.37	0.33	6.44e-10	Breast cancer;
CRC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.51	-8.25	-0.41	3.98e-15	Gout;
CRC	cis	rs1656402	1.000	rs1656398	chr2:233427852	C/T	cg03852847	chr2:233439513	NA	-0.45	-7.69	-0.39	1.76e-13	Non-small cell lung cancer (survival);
CRC	cis	rs3812762	0.783	rs34524863	chr11:8777408	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-6.59	-0.34	1.8e-10	Hypospadias;
CRC	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.25	-0.45	2.92e-18	Metabolite levels;
CRC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.42	-7.14	-0.37	5.96e-12	Huntington's disease progression;
CRC	cis	rs12476592	0.602	rs2305157	chr2:63822785	T/C	cg10828910	chr2:63850056	LOC388955	0.48	5.86	0.31	1.15e-8	Childhood ear infection;
CRC	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg01426195	chr3:39028469	NA	-0.53	-8.56	-0.43	4.39e-16	Handedness;
CRC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Melanoma;
CRC	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg12573674	chr2:1569213	NA	-0.74	-7.3	-0.37	2.21e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.36	-0.33	6.84e-10	Monocyte percentage of white cells;
CRC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg03037974	chr15:76606532	NA	-0.57	-8.7	-0.43	1.64e-16	Blood metabolite levels;
CRC	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.91	-16.03	-0.66	3.68e-43	Height;
CRC	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg04008429	chr3:160167646	TRIM59	-0.43	-6.31	-0.33	8.77e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg01339444	chr6:118972232	C6orf204	0.58	6.25	0.33	1.25e-9	Diastolic blood pressure;
CRC	cis	rs12612619	0.732	rs13021112	chr2:27259794	G/A	cg00617064	chr2:27272375	NA	-0.4	-6.57	-0.34	2.01e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.83	-0.31	1.36e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7264396	0.887	rs6120951	chr20:34045191	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.41	-0.33	5.12e-10	Total cholesterol levels;
CRC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02290350	chr8:58132656	NA	-0.44	-7.03	-0.36	1.23e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03352830	chr11:487213	PTDSS2	0.65	7.33	0.37	1.75e-12	Body mass index;
CRC	trans	rs2055729	1.000	rs2055729	chr8:9792662	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.45	-0.34	4.05e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2734839	0.964	rs1116313	chr11:113296107	A/G	cg14159747	chr11:113255604	NA	0.46	7.95	0.4	2.96e-14	Information processing speed;
CRC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.83	0.31	1.35e-8	Rheumatoid arthritis;
CRC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg17385448	chr1:15911702	AGMAT	0.28	5.61	0.3	4.22e-8	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17767392	0.681	rs1990035	chr14:71695958	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.56	-0.34	2.15e-10	Mitral valve prolapse;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.56	-8.37	-0.42	1.69e-15	Menopause (age at onset);
CRC	cis	rs16867321	0.853	rs73023563	chr2:181502830	C/T	cg23363182	chr2:181467187	NA	-0.51	-6.65	-0.34	1.21e-10	Obesity;
CRC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.18	-0.32	1.89e-9	Daytime sleep phenotypes;
CRC	cis	rs3101457	0.530	rs10754827	chr1:244528390	A/G	cg09033006	chr1:244517177	C1orf100	-0.41	-5.94	-0.31	7.16e-9	Smoking behavior;
CRC	cis	rs9595066	1.000	rs9595066	chr13:44706268	C/T	cg04068111	chr13:44716778	NA	-0.4	-5.91	-0.31	8.56e-9	Schizophrenia;
CRC	cis	rs10886558	0.674	rs10788015	chr10:121781396	C/T	cg02041677	chr10:121771263	NA	-0.32	-5.71	-0.3	2.59e-8	Shingles;
CRC	cis	rs7274811	0.652	rs291694	chr20:32000351	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.43	5.99	0.31	5.36e-9	Height;
CRC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg16342193	chr10:102329863	NA	-0.36	-5.87	-0.31	1.07e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04731861	chr2:219085781	ARPC2	0.34	6.97	0.36	1.74e-11	Colorectal cancer;
CRC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.64	10.38	0.5	5.13e-22	Height;
CRC	cis	rs11750568	0.967	rs10464079	chr5:178525779	G/A	cg10208897	chr5:178548229	ADAMTS2	0.35	5.69	0.3	2.81e-8	Height;
CRC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.63	7.55	0.38	4.44e-13	Lymphocyte counts;
CRC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg06781209	chr11:61594997	FADS2	0.38	5.72	0.3	2.42e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs7572644	0.640	rs11891769	chr2:28025580	G/C	cg27432699	chr2:27873401	GPN1	0.46	6.2	0.32	1.7e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	9.37	0.46	1.17e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs9549328	0.611	rs72661939	chr13:113617498	C/T	cg24588162	chr13:113633484	MCF2L	0.36	6.52	0.34	2.68e-10	Systolic blood pressure;
CRC	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg18198730	chr1:247681584	NA	0.63	6.91	0.36	2.52e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7932354	0.554	rs6485721	chr11:47040854	A/G	cg19486271	chr11:47235900	DDB2	-0.43	-6.34	-0.33	7.75e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.61	6.79	0.35	5.14e-11	Coronary artery disease;
CRC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Corneal astigmatism;
CRC	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg11993925	chr19:44307056	LYPD5	0.47	7.75	0.39	1.15e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg14646075	chr2:228736089	WDR69	-0.46	-6.2	-0.32	1.72e-9	Blood pressure;
CRC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.99	0.31	5.45e-9	Bladder cancer;
CRC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18912574	chr7:65842487	NCRNA00174	0.33	5.68	0.3	2.9e-8	Calcium levels;
CRC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.63	6.5	0.34	3.01e-10	Axial length;
CRC	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg05784532	chr1:230284198	GALNT2	0.45	6.28	0.33	1.1e-9	Coronary artery disease;
CRC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.32	-5.75	-0.3	1.99e-8	Menarche (age at onset);
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.3	-6.13	-0.32	2.58e-9	Bipolar disorder;
CRC	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg00086871	chr4:6988644	TBC1D14	1.05	7.01	0.36	1.33e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.6	0.43	3.24e-16	Homoarginine levels;
CRC	trans	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-8.05	-0.41	1.54e-14	Dilated cardiomyopathy;
CRC	cis	rs9361491	1.000	rs9443648	chr6:79853605	C/T	cg09184832	chr6:79620586	NA	-0.32	-5.77	-0.3	1.88e-8	Intelligence (multi-trait analysis);
CRC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg07507251	chr3:52567010	NT5DC2	0.4	6.31	0.33	9.06e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg06470822	chr6:28175283	NA	0.82	8.38	0.42	1.57e-15	Lung cancer in ever smokers;
CRC	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg14631576	chr9:95140430	CENPP	-0.39	-7.35	-0.38	1.53e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21551646	chr2:55921064	PNPT1	0.43	6.4	0.33	5.49e-10	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.76	11.52	0.54	4.84e-26	Menarche (age at onset);
CRC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg08314208	chr16:67682810	RLTPR	-0.64	-6.77	-0.35	5.77e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg14008862	chr17:28927542	LRRC37B2	0.56	5.8	0.3	1.6e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.99	0.31	5.47e-9	Metabolite levels;
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.4	6.05	0.32	3.99e-9	Longevity;Endometriosis;
CRC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.81	-0.3	1.52e-8	Migraine;Coronary artery disease;
CRC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13198984	chr17:80129470	CCDC57	0.46	7.98	0.4	2.45e-14	Life satisfaction;
CRC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	10.08	0.49	5.5e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg24253500	chr15:84953950	NA	0.38	6.48	0.34	3.43e-10	Schizophrenia;
CRC	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.38	5.86	0.31	1.11e-8	Myeloid white cell count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21583412	chr17:27621436	NUFIP2	0.43	6.41	0.33	4.96e-10	Intelligence (multi-trait analysis);
CRC	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	0.96	10.96	0.52	4.76e-24	Gut microbiota (bacterial taxa);
CRC	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.78	-7.57	-0.39	3.74e-13	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.52	7.41	0.38	1.09e-12	Testicular germ cell tumor;
CRC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	10.93	0.52	6.34e-24	Bone mineral density;
CRC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.63	9.32	0.46	1.79e-18	Schizophrenia;
CRC	cis	rs4789294	0.754	rs56280331	chr17:74403239	G/A	cg06840243	chr17:74442338	UBE2O	0.44	6.26	0.33	1.22e-9	Lymphocyte percentage of white cells;
CRC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.94	-0.4	3.16e-14	Intelligence (multi-trait analysis);
CRC	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Visceral adipose tissue adjusted for BMI;
CRC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.56	-6.71	-0.35	8.54e-11	Body mass index;
CRC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18934641	chr7:99869784	GATS	0.47	6.51	0.34	2.89e-10	Anxiety disorder;
CRC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.19	-0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg15193198	chr20:60906057	LAMA5	-0.45	-6.65	-0.34	1.24e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.46	7.53	0.38	4.8e-13	Refractive error;
CRC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg21251018	chr6:28226885	NKAPL	0.49	5.67	0.3	3.06e-8	Depression;
CRC	cis	rs365302	1.000	rs294917	chr6:159627077	C/T	cg14500486	chr6:159655392	FNDC1	0.51	7.75	0.39	1.16e-13	Coronary heart disease;
CRC	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.82	9.58	0.47	2.49e-19	Obesity-related traits;
CRC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	10.26	0.49	1.35e-21	Alzheimer's disease (late onset);
CRC	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.15	0.37	5.69e-12	Platelet count;
CRC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12501888	chr15:85177176	SCAND2	-0.36	-5.85	-0.31	1.22e-8	P wave terminal force;
CRC	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg24553058	chr2:113831203	IL1F10	-0.39	-6.35	-0.33	7.24e-10	Protein quantitative trait loci;
CRC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg04719120	chr6:96025338	MANEA	0.64	7.34	0.38	1.71e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg02569458	chr12:86230093	RASSF9	-0.42	-7.14	-0.37	6.06e-12	Major depressive disorder;
CRC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12463550	chr7:65579703	CRCP	0.67	6.08	0.32	3.4e-9	Diabetic kidney disease;
CRC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.53	0.47	3.56e-19	Bladder cancer;
CRC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.67	8.69	0.43	1.72e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.59	0.34	1.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.13	-0.32	2.51e-9	Daytime sleep phenotypes;
CRC	cis	rs17234274	0.644	rs1482710	chr11:23219073	G/A	cg05245346	chr11:23248277	NA	0.36	5.92	0.31	8.22e-9	Cancer;
CRC	cis	rs55702914	0.746	rs7588530	chr2:198146698	A/C	cg03934865	chr2:198174659	NA	-0.42	-7.16	-0.37	5.46e-12	Major depression and alcohol dependence;
CRC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-9.53	-0.46	3.69e-19	Mood instability;
CRC	cis	rs853679	1.000	rs853676	chr6:28299687	C/T	cg21251018	chr6:28226885	NKAPL	0.49	5.61	0.3	4.23e-8	Depression;
CRC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.59	-8.52	-0.43	5.76e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg12172441	chr6:28176163	NA	0.66	8.55	0.43	4.66e-16	Depression;
CRC	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg00318322	chr16:67708822	GFOD2	-0.33	-6.14	-0.32	2.4e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	7.32	0.37	1.91e-12	Bipolar disorder;
CRC	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04055981	chr11:115044050	NA	0.43	6.79	0.35	5.12e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.49	6.94	0.36	2.04e-11	Caffeine consumption;
CRC	cis	rs11679072	1.000	rs7573863	chr2:240448272	G/C	cg03276489	chr2:240449683	NA	-0.93	-9.41	-0.46	8.71e-19	Blood pressure (smoking interaction);
CRC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06550546	chr17:4166847	ANKFY1	0.42	6.01	0.31	4.91e-9	Response to antipsychotic treatment;
CRC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.48	6.16	0.32	2.13e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.66	8.45	0.42	9.26e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs2467099	1.000	rs2467099	chr17:73949045	C/T	cg08125733	chr17:73851984	WBP2	0.53	5.73	0.3	2.31e-8	Systolic blood pressure;
CRC	cis	rs28655083	0.529	rs285026	chr16:77100089	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.8	0.35	4.89e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.31	0.56	6.48e-29	Menopause (age at onset);
CRC	cis	rs12476592	0.571	rs2028883	chr2:63804531	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.18	0.32	1.84e-9	Childhood ear infection;
CRC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg20399509	chr21:47717575	C21orf57	0.33	5.62	0.3	4.01e-8	Testicular germ cell tumor;
CRC	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.49	8.36	0.42	1.75e-15	Dupuytren's disease;
CRC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.79	-12.75	-0.58	1.52e-30	Cognitive function;
CRC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.76	10.52	0.5	1.63e-22	Heart rate;
CRC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.49	7.42	0.38	1.01e-12	Corneal astigmatism;
CRC	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.46	9.44	0.46	7.13e-19	Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.18	-0.37	4.65e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg08755490	chr11:65554678	OVOL1	0.43	6.39	0.33	5.53e-10	Acne (severe);
CRC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-8.17	-0.41	6.79e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1322512	1.000	rs1322512	chr6:152947953	C/A	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.48	0.34	3.28e-10	Cognitive ability;
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg16060761	chr17:80687452	NA	-0.47	-6.06	-0.32	3.7e-9	Glycated hemoglobin levels;
CRC	trans	rs10242455	0.702	rs57832867	chr7:98966396	C/T	cg09045935	chr12:6379348	NA	0.9	7.09	0.36	8.37e-12	Blood metabolite levels;
CRC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg04450456	chr4:17643702	FAM184B	0.38	5.99	0.31	5.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.79	10.97	0.52	4.59e-24	Obesity;Body mass index;
CRC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.54	8.02	0.4	1.85e-14	Schizophrenia;
CRC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.77	-15.49	-0.65	5.1e-41	Prostate cancer;
CRC	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.51	7.27	0.37	2.72e-12	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09706180	chr15:50647709	GABPB1;FLJ10038;LOC100129387	0.41	7.22	0.37	3.64e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.47	6.5	0.34	2.97e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs1223397	0.938	rs3817742	chr6:13279552	T/C	cg00460589	chr6:13274354	PHACTR1	0.48	5.97	0.31	6.28e-9	Blood pressure;
CRC	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	16.02	0.66	4.19e-43	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7781266	0.690	rs1628880	chr7:133069285	A/T	cg03336402	chr7:133662267	EXOC4	0.5	6.11	0.32	2.81e-9	Educational attainment (college completion);
CRC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Reticulocyte count;High light scatter reticulocyte count;
CRC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.76	-12.83	-0.58	8.19e-31	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14729455	chr14:53019147	TXNDC16;GPR137C	0.42	6.16	0.32	2.09e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22479947	chr11:3078624	CARS	0.42	6.76	0.35	6.43e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.72	0.35	8.25e-11	HIV-1 control;
CRC	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-0.58	-6.26	-0.33	1.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-14.28	-0.62	2.52e-36	Blood metabolite levels;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23161317	chr6:28129485	ZNF389	0.44	5.85	0.31	1.17e-8	Depression;
CRC	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	0.49	6.12	0.32	2.7e-9	Neuroticism (multi-trait analysis);Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06474646	chr7:128864675	AHCYL2	-0.42	-6.05	-0.32	3.89e-9	Myopia (pathological);
CRC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.63	-11.13	-0.52	1.23e-24	Coronary artery disease;
CRC	trans	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02832646	chr16:81040020	CENPN;C16orf61	-0.41	-6.01	-0.31	5.04e-9	Daytime sleep phenotypes;
CRC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.75	-10.92	-0.52	6.56e-24	Longevity;
CRC	cis	rs4363385	0.791	rs3120744	chr1:153010330	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg02869306	chr7:64672164	INTS4L1	0.43	6.23	0.32	1.39e-9	Aortic root size;
CRC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.66	-9.81	-0.48	4.27e-20	Corneal astigmatism;
CRC	cis	rs10512697	0.764	rs35866886	chr5:3556681	A/G	cg19473799	chr5:3511975	NA	-0.72	-5.66	-0.3	3.22e-8	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16782848	chr15:83479213	WHAMM	0.36	6.17	0.32	2.04e-9	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12463550	chr7:65579703	CRCP	0.72	6.58	0.34	1.9e-10	Diabetic kidney disease;
CRC	cis	rs10046574	0.561	rs56014861	chr7:135203027	A/T	cg27474649	chr7:135195673	CNOT4	0.66	6.21	0.32	1.58e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.41	0.53	1.27e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	0.98	16.34	0.67	2.38e-44	Total cholesterol levels;
CRC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	14.87	0.63	1.28e-38	Primary sclerosing cholangitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22401940	chr2:169103153	STK39	0.46	6.96	0.36	1.85e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.6	10.15	0.49	3.09e-21	Mean corpuscular volume;
CRC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.6	-7.27	-0.37	2.65e-12	Type 2 diabetes nephropathy;
CRC	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.44	-6.62	-0.34	1.49e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14024788	chr5:1875611	NA	0.37	5.83	0.31	1.29e-8	Cardiovascular disease risk factors;
CRC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.31	0.42	2.53e-15	Vitiligo;
CRC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.84	0.4	6.26e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.74	-11.19	-0.52	7.75e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12620999	0.774	rs7584900	chr2:237957112	T/G	cg23555395	chr2:238036564	NA	0.5	7.8	0.4	8.01e-14	Systemic lupus erythematosus;
CRC	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.58	8.53	0.43	5.54e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	1.26	14.75	0.63	3.64e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.87	14.38	0.62	1e-36	Blood metabolite levels;
CRC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.86	0.48	2.86e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg02683197	chr6:28174875	NA	0.68	9.38	0.46	1.09e-18	Cardiac Troponin-T levels;
CRC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	8.99	0.44	1.94e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.65	0.57	3.55e-30	Menopause (age at onset);
CRC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.56	-6.62	-0.34	1.47e-10	Skin colour saturation;
CRC	cis	rs2882667	0.898	rs6882583	chr5:138385796	C/T	cg09476006	chr5:138032270	NA	0.44	7.37	0.38	1.35e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg01639898	chr1:32083012	HCRTR1	0.29	6.03	0.32	4.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.61	-7.86	-0.4	5.66e-14	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg15786705	chr6:28176104	NA	0.65	6.92	0.36	2.38e-11	Depression;
CRC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.21	-0.32	1.63e-9	Menopause (age at onset);
CRC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.93	-0.31	7.58e-9	Colorectal cancer;
CRC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg20542592	chr8:11973495	FAM66D	0.33	5.85	0.31	1.18e-8	Retinal vascular caliber;
CRC	cis	rs6604026	0.656	rs2774950	chr1:93353527	T/C	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	trans	rs2797369	0.882	rs2797368	chr6:101672809	T/C	cg26346621	chr12:6873348	NA	-0.4	-6.0	-0.31	5.15e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.68	11.4	0.53	1.39e-25	Height;
CRC	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.47	-6.05	-0.32	3.98e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.65	13.93	0.61	5.48e-35	Schizophrenia;
CRC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.52	6.89	0.35	2.9e-11	Obesity-related traits;
CRC	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg27395922	chr11:50257633	LOC441601	0.48	6.07	0.32	3.53e-9	Intraocular pressure;
CRC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.1	0.49	4.6e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg16898833	chr6:26189333	HIST1H4D	0.82	7.19	0.37	4.44e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.46	6.68	0.35	1.04e-10	Primary sclerosing cholangitis;
CRC	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg13385794	chr1:248469461	NA	0.39	6.85	0.35	3.57e-11	Common traits (Other);
CRC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.81	0.35	4.54e-11	Cognitive ability;
CRC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.71	12.12	0.56	3.48e-28	Gout;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg03623178	chr6:28175578	NA	-0.7	-9.32	-0.46	1.78e-18	Parkinson's disease;
CRC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.5	10.97	0.52	4.61e-24	Alcohol dependence;
CRC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg12458913	chr13:53173898	NA	0.8	14.88	0.63	1.15e-38	Lewy body disease;
CRC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.67	-0.3	3.07e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg10263370	chr3:44754102	ZNF502	-0.36	-5.96	-0.31	6.54e-9	Depressive symptoms;
CRC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.79	-13.8	-0.61	1.73e-34	Breast cancer;
CRC	cis	rs524281	0.731	rs78578425	chr11:65810239	G/A	cg16950941	chr11:66035639	RAB1B	-0.54	-5.81	-0.31	1.47e-8	Electroencephalogram traits;
CRC	cis	rs1572438	0.831	rs17139761	chr6:856766	A/G	cg13447295	chr6:887704	NA	-0.43	-6.55	-0.34	2.24e-10	Aging;
CRC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.95	-0.31	6.9e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg26043149	chr18:55253948	FECH	-0.53	-7.47	-0.38	7.23e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg20885578	chr2:198174922	NA	-0.42	-6.69	-0.35	9.64e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.44	-7.38	-0.38	1.33e-12	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04046427	chr10:75254985	PPP3CB	0.41	6.38	0.33	5.88e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg18653534	chr16:772142	FAM173A	-0.39	-6.16	-0.32	2.09e-9	Height;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.63	-0.3	3.78e-8	Blood metabolite levels;
CRC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.83	0.35	4.04e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg23517279	chr6:96025343	MANEA	0.57	6.49	0.34	3.24e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.51	8.4	0.42	1.38e-15	Cystic fibrosis severity;
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.68	12.6	0.57	5.55e-30	Systemic lupus erythematosus;
CRC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.51	0.6	2.16e-33	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05665937	chr4:1216051	CTBP1	0.41	5.93	0.31	7.85e-9	Obesity-related traits;
CRC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.77	11.87	0.55	2.83e-27	Schizophrenia;
CRC	trans	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg10756647	chr7:56101905	PSPH	0.74	7.77	0.39	9.82e-14	Diabetic kidney disease;
CRC	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.39	-0.38	1.24e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg01505111	chr6:125621795	HDDC2	0.38	6.04	0.32	4.06e-9	DNA methylation (variation);
CRC	cis	rs9938149	0.706	rs8059024	chr16:88314163	T/C	cg05435882	chr16:88311214	NA	-0.44	-5.82	-0.31	1.39e-8	Corneal structure;Central corneal thickness;
CRC	cis	rs703980	0.967	rs703967	chr10:80953451	A/C	cg20744163	chr10:80999841	ZMIZ1	0.32	5.88	0.31	1e-8	Type 2 diabetes;
CRC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.61	-0.3	4.25e-8	Tonsillectomy;
CRC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg23719950	chr11:63933701	MACROD1	-0.55	-5.88	-0.31	9.97e-9	Mean platelet volume;
CRC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg08999081	chr20:33150536	PIGU	0.44	5.72	0.3	2.39e-8	Protein C levels;
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg08200770	chr17:80723486	TBCD	-0.51	-7.69	-0.39	1.74e-13	Glycated hemoglobin levels;
CRC	cis	rs965469	0.817	rs6037582	chr20:3351696	C/T	cg25506879	chr20:3388711	C20orf194	-0.37	-5.73	-0.3	2.26e-8	IFN-related cytopenia;
CRC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.58	6.3	0.33	9.76e-10	Schizophrenia;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.36	5.87	0.31	1.04e-8	Lymphocyte counts;
CRC	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.96	15.65	0.65	1.23e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-10.41	-0.5	4.04e-22	Hypospadias;
CRC	cis	rs41271951	0.512	rs116666233	chr1:151056058	C/T	cg11822372	chr1:151115635	SEMA6C	-0.7	-5.62	-0.3	4.02e-8	Blood protein levels;
CRC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.89	-0.44	4.05e-17	Hemoglobin concentration;
CRC	cis	rs6662572	0.671	rs11211220	chr1:46365501	G/A	cg08644498	chr1:46502608	NA	-0.43	-6.67	-0.35	1.05e-10	Blood protein levels;
CRC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.88	0.35	2.98e-11	Bladder cancer;
CRC	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.62	8.64	0.43	2.56e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg20041105	chr8:143859282	LYNX1	-0.41	-6.61	-0.34	1.52e-10	Urinary tract infection frequency;
CRC	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.39	6.35	0.33	7.22e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.79	-0.3	1.69e-8	Daytime sleep phenotypes;
CRC	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	trans	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg01134436	chr17:81009848	B3GNTL1	0.7	6.42	0.33	4.8e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs12476592	0.602	rs262477	chr2:63870959	A/C	cg10828910	chr2:63850056	LOC388955	0.5	6.15	0.32	2.31e-9	Childhood ear infection;
CRC	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.03	0.52	2.83e-24	Bipolar disorder;
CRC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.1	26.81	0.83	9.1200000000000006e-85	Testicular germ cell tumor;
CRC	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg06204229	chr3:52865917	ITIH4	0.52	6.74	0.35	7.26e-11	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.34	-7.41	-0.38	1.07e-12	Inflammatory skin disease;
CRC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.77	10.4	0.5	4.3e-22	Monocyte percentage of white cells;
CRC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg03162506	chr22:38580953	NA	0.26	5.69	0.3	2.77e-8	Cutaneous nevi;
CRC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.62	9.87	0.48	2.72e-20	Height;
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg22561889	chr6:118971681	C6orf204	0.5	6.52	0.34	2.69e-10	Diastolic blood pressure;
CRC	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg09659197	chr4:152720779	NA	0.39	8.14	0.41	8.49e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	0.97	9.89	0.48	2.27e-20	Skin colour saturation;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg03790207	chr6:42947109	PEX6	-0.46	-6.6	-0.34	1.64e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.35	-7.47	-0.38	7.51e-13	Urinary metabolites;
CRC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.67	10.8	0.51	1.84e-23	Mean platelet volume;
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.81	-0.31	1.46e-8	Neuroticism;
CRC	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.82	-0.35	4.27e-11	Neuroticism;
CRC	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.69	-10.8	-0.51	1.8e-23	Type 2 diabetes;
CRC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.3	15.04	0.64	2.92e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.89	-15.36	-0.65	1.55e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06481639	chr22:41940642	POLR3H	0.56	6.21	0.32	1.57e-9	Vitiligo;
CRC	cis	rs6772849	0.931	rs60825080	chr3:128384834	G/T	cg08795948	chr3:128337044	NA	0.36	6.1	0.32	2.92e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.52	-7.2	-0.37	4.07e-12	Alzheimer's disease (late onset);
CRC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.93	13.36	0.59	8.14e-33	Breast cancer;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg22096450	chr11:6947773	ZNF215	0.59	6.1	0.32	3.03e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.66	10.58	0.5	1.07e-22	Corneal astigmatism;
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.75	0.3	2.05e-8	Life satisfaction;
CRC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.23	0.37	3.41e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg12223502	chr10:5658492	NA	-0.37	-5.93	-0.31	7.77e-9	Breast cancer;
CRC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg08213375	chr14:104286397	PPP1R13B	0.5	8.62	0.43	2.96e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.31	-0.37	2e-12	Longevity;Endometriosis;
CRC	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg09695851	chr17:3907499	NA	0.76	14.45	0.62	5.69e-37	Type 2 diabetes;
CRC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	0.86	8.28	0.42	3.15e-15	Granulocyte percentage of myeloid white cells;
CRC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg25985355	chr7:65971099	NA	0.32	5.67	0.3	3.12e-8	Aortic root size;
CRC	cis	rs2227564	0.649	rs2243610	chr10:75601653	A/T	cg16540259	chr10:75572220	NDST2	0.46	6.67	0.35	1.05e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23422044	chr7:1970798	MAD1L1	-0.4	-5.62	-0.3	4.18e-8	Neuroticism;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg12273811	chr6:28175739	NA	0.54	5.81	0.3	1.5e-8	Depression;
CRC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.7	-13.54	-0.6	1.68e-33	Educational attainment;
CRC	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.6	8.39	0.42	1.43e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.04	22.23	0.77	1.79e-67	Testicular germ cell tumor;
CRC	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.39	6.01	0.31	5.02e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg22192744	chr12:123187474	GPR109A	-0.4	-5.66	-0.3	3.25e-8	Adiponectin levels;
CRC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.57	-8.41	-0.42	1.29e-15	Mean platelet volume;
CRC	cis	rs9303542	0.559	rs2326012	chr17:46618581	C/T	cg04904318	chr17:46607828	HOXB1	-0.49	-6.02	-0.32	4.55e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.54	-8.25	-0.41	3.93e-15	HDL cholesterol;
CRC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg09264619	chr17:80180166	NA	-0.36	-6.1	-0.32	3e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11480627	chr11:70672876	SHANK2	0.37	7.85	0.4	5.83e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs6499255	0.951	rs10163235	chr16:69739867	G/T	cg15192750	chr16:69999425	NA	0.55	7.38	0.38	1.26e-12	IgE levels;
CRC	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg00603274	chr11:61596626	FADS2	-0.55	-7.59	-0.39	3.22e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-6.47	-0.34	3.49e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg23298862	chr7:158159286	PTPRN2	0.49	7.03	0.36	1.17e-11	Response to amphetamines;
CRC	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg27398640	chr15:77910606	LINGO1	0.4	7.65	0.39	2.21e-13	Type 2 diabetes;
CRC	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-7.08	-0.36	8.76e-12	Height;
CRC	cis	rs2735413	0.875	rs8053987	chr16:78084834	G/A	cg04733911	chr16:78082701	NA	0.44	7.37	0.38	1.4e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7692995	1.000	rs16896215	chr4:17995312	T/C	cg08925142	chr4:18023851	LCORL	-0.52	-5.65	-0.3	3.45e-8	Height;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg12273811	chr6:28175739	NA	0.45	6.51	0.34	2.86e-10	Hepatitis A;
CRC	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.51	0.46	4.3e-19	Corneal astigmatism;
CRC	trans	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg02674126	chr19:40336878	FBL	0.42	6.69	0.35	9.82e-11	Hyperactive-impulsive symptoms;
CRC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.05	-0.32	3.99e-9	Height;
CRC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-6.18	-0.32	1.92e-9	Heart rate;
CRC	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.77	-8.45	-0.42	9.35e-16	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.38	0.33	6.09e-10	Tonsillectomy;
CRC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.42	-8.07	-0.41	1.3e-14	Ulcerative colitis;
CRC	trans	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	6.41	0.33	5.03e-10	Mean corpuscular volume;
CRC	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	1.11	12.99	0.58	2.06e-31	Obesity-related traits;
CRC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.67	-11.39	-0.53	1.41e-25	Dental caries;
CRC	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg06287003	chr12:125626642	AACS	-0.62	-7.12	-0.37	6.71e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg23123621	chr4:1343375	KIAA1530	-0.37	-6.9	-0.36	2.68e-11	Obesity-related traits;
CRC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg22349387	chr12:9600060	DDX12	-0.37	-5.71	-0.3	2.57e-8	Breast size;
CRC	cis	rs6479527	0.875	rs2150625	chr9:96789831	C/T	cg14459158	chr9:96720562	NA	0.36	6.41	0.33	5.01e-10	Esophageal adenocarcinoma;
CRC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02850689	chr1:2391347	NA	-0.44	-6.83	-0.35	4.08e-11	Non-obstructive azoospermia;
CRC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.6	10.41	0.5	3.89e-22	Dental caries;
CRC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-10.51	-0.5	1.77e-22	Breast cancer;
CRC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.3	-15.32	-0.65	2.37e-40	Diabetic kidney disease;
CRC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.64	11.31	0.53	2.78e-25	Schizophrenia;
CRC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.74	-10.54	-0.5	1.38e-22	Platelet distribution width;
CRC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.54	-7.82	-0.4	7.38e-14	Headache;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	7.98	0.4	2.47e-14	Breast cancer;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg02683197	chr6:28174875	NA	0.64	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs2249694	0.537	rs9418988	chr10:135327632	C/T	cg20169779	chr10:135381914	SYCE1	0.64	10.1	0.49	4.69e-21	Obesity-related traits;
CRC	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.23	-0.33	1.39e-9	Aortic root size;
CRC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.64	10.77	0.51	2.33e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg01483505	chr11:975446	AP2A2	-0.41	-6.5	-0.34	2.99e-10	Alzheimer's disease (late onset);
CRC	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.4	-6.68	-0.35	1.03e-10	Vitamin D levels;
CRC	cis	rs9503598	0.644	rs7774747	chr6:3430996	A/G	cg00476032	chr6:3446245	SLC22A23	-0.34	-5.69	-0.3	2.83e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CRC	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg12756093	chr1:115239321	AMPD1	0.48	7.0	0.36	1.43e-11	Autism;
CRC	cis	rs9847710	0.933	rs1529544	chr3:53039455	A/G	cg04503182	chr3:53078218	SFMBT1	-0.41	-6.48	-0.34	3.41e-10	Ulcerative colitis;
CRC	cis	rs6741819	0.740	rs771265	chr2:7129744	A/G	cg27144453	chr2:7172511	RNF144A	-0.4	-5.89	-0.31	9.75e-9	Response to antipsychotic treatment;
CRC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15320075	chr8:145703422	NA	0.65	10.21	0.49	1.98e-21	Age at first birth;
CRC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.66	9.34	0.46	1.47e-18	Vitamin D levels;
CRC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.48	6.44	0.33	4.3e-10	Height;
CRC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.44	-5.91	-0.31	8.44e-9	Gut microbiome composition (summer);
CRC	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.68	7.88	0.4	4.77e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg14530993	chr4:882597	GAK	0.63	6.47	0.34	3.52e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.51	9.1	0.45	8.54e-18	Weight;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs863345	0.564	rs1418844	chr1:158457569	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.67	8.8	0.44	7.99e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.61	-8.13	-0.41	9e-15	Migraine;
CRC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg20885578	chr2:198174922	NA	-0.41	-7.35	-0.38	1.61e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg15110403	chr19:17392923	ANKLE1	-0.36	-5.73	-0.3	2.23e-8	Systemic lupus erythematosus;
CRC	cis	rs4731207	0.698	rs6949341	chr7:124564176	C/A	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs17767392	0.813	rs66645707	chr14:71985931	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.4	-0.33	5.28e-10	Mitral valve prolapse;
CRC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.37	-0.38	1.42e-12	Joint mobility (Beighton score);
CRC	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg03934865	chr2:198174659	NA	-0.45	-7.08	-0.36	8.71e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-10.3	-0.49	9.29e-22	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-5.94	-0.31	7.13e-9	Gut microbiome composition (summer);
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07685180	chr8:600429	NA	-0.73	-7.08	-0.36	8.74e-12	IgG glycosylation;
CRC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.6	-9.38	-0.46	1.15e-18	Body mass index;
CRC	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg01339444	chr6:118972232	C6orf204	0.54	5.96	0.31	6.41e-9	Diastolic blood pressure;
CRC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.49	7.0	0.36	1.42e-11	High light scatter reticulocyte count;
CRC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.74	-0.43	1.19e-16	Schizophrenia;
CRC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.65	0.63	9.4e-38	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg08546805	chr12:8549446	NA	-0.41	-6.27	-0.33	1.15e-9	Blood pressure (smoking interaction);
CRC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-6.86	-0.35	3.42e-11	Aortic root size;
CRC	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.85	0.48	3.23e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.38	8.81	0.44	7.54e-17	Multiple system atrophy;
CRC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.48	0.57	1.63e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg08222913	chr3:52553049	STAB1	-0.33	-5.99	-0.31	5.57e-9	Bipolar disorder;
CRC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.66	9.64	0.47	1.55e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg27615366	chr5:131592974	PDLIM4	0.35	6.67	0.35	1.1e-10	Blood metabolite levels;
CRC	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.66	-10.55	-0.5	1.28e-22	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg25985355	chr7:65971099	NA	-0.54	-6.14	-0.32	2.35e-9	Diabetic kidney disease;
CRC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.64	-0.34	1.3100000000000001e-10	Mean platelet volume;
CRC	cis	rs728616	0.681	rs3862518	chr10:81917957	A/G	cg11900509	chr10:81946545	ANXA11	-0.71	-8.58	-0.43	3.71e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.36	5.65	0.3	3.5e-8	Reticulocyte count;
CRC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26172385	chr10:120840446	EIF3A	0.47	6.51	0.34	2.87e-10	Anxiety disorder;
CRC	cis	rs6076065	0.723	rs2252824	chr20:23354748	C/T	cg11657817	chr20:23433608	CST11	0.44	6.37	0.33	6.43e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.72	0.35	7.96e-11	Aortic root size;
CRC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.58	-8.72	-0.43	1.38e-16	Aortic root size;
CRC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	9.19	0.45	4.49e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-0.89	-11.58	-0.54	3.16e-26	Blood protein levels;
CRC	cis	rs3751196	0.711	rs75479531	chr12:104226138	T/G	cg02344784	chr12:104178138	NT5DC3	0.7	7.16	0.37	5.32e-12	Sense of smell;
CRC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg05072774	chr3:49840536	C3orf54	-0.43	-5.68	-0.3	3e-8	Resting heart rate;
CRC	cis	rs3026101	0.671	rs56113612	chr17:5297761	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.79	0.35	5.16e-11	Body mass index;
CRC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg02158880	chr13:53174818	NA	0.39	5.64	0.3	3.76e-8	Lewy body disease;
CRC	cis	rs10486722	0.606	rs10951662	chr7:41811635	C/G	cg22138096	chr7:41772439	LOC285954	0.45	5.75	0.3	2.09e-8	Pit-and-Fissure caries;
CRC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.48	-0.5	2.21e-22	Breast cancer;
CRC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.47	7.28	0.37	2.45e-12	Longevity;
CRC	cis	rs6694672	0.510	rs1412638	chr1:196995638	T/C	cg13682187	chr1:196946512	CFHR5	0.49	7.59	0.39	3.32e-13	Asthma;
CRC	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	0.91	11.03	0.52	2.68e-24	Red blood cell traits;
CRC	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg05139728	chr16:28306816	SBK1	-0.34	-5.79	-0.3	1.6e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18357526	chr6:26021779	HIST1H4A	0.43	6.14	0.32	2.41e-9	Height;
CRC	cis	rs9818941	1.000	rs4507209	chr3:157710946	T/A	cg08654915	chr3:157813417	NA	-0.32	-5.94	-0.31	7.14e-9	Height;
CRC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.68	8.68	0.43	1.89e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.47	0.34	3.5e-10	Obesity-related traits;
CRC	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg17691542	chr6:26056736	HIST1H1C	0.74	9.27	0.45	2.6e-18	Iron status biomarkers;
CRC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.48	8.02	0.4	1.9e-14	Major depressive disorder;
CRC	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.53	-7.17	-0.37	4.9e-12	Triglycerides;
CRC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.44	-0.46	6.97e-19	Platelet count;
CRC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg25456477	chr12:86230367	RASSF9	0.37	6.16	0.32	2.13e-9	Major depressive disorder;
CRC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg26528668	chr16:1614120	IFT140	0.36	5.61	0.3	4.41e-8	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26365399	chr6:127587909	RNF146	0.35	6.06	0.32	3.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713675	0.565	rs4713671	chr6:33699899	A/G	cg14003231	chr6:33640908	ITPR3	0.44	7.17	0.37	4.85e-12	Plateletcrit;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.71	-0.3	2.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.44	9.05	0.45	1.27e-17	Vitiligo;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05665937	chr4:1216051	CTBP1	-0.37	-5.75	-0.3	1.99e-8	Obesity-related traits;
CRC	cis	rs2252521	0.583	rs317707	chr7:29098336	G/T	cg11728747	chr7:29037910	CPVL	-0.47	-6.85	-0.35	3.63e-11	Cognitive performance;
CRC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.67	9.79	0.48	4.92e-20	Lung cancer;
CRC	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.66	10.41	0.5	4.04e-22	Corneal astigmatism;
CRC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg25876840	chr17:41920477	NA	0.57	7.89	0.4	4.48e-14	Triglycerides;
CRC	cis	rs2882667	0.931	rs10075951	chr5:138355963	G/T	cg09476006	chr5:138032270	NA	0.43	7.13	0.37	6.58e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg02683197	chr6:28174875	NA	-0.54	-7.4	-0.38	1.15e-12	Systemic lupus erythematosus;
CRC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg24531977	chr5:56204891	C5orf35	-0.47	-7.17	-0.37	4.99e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.38	-0.42	1.58e-15	Personality dimensions;
CRC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.63	10.68	0.51	4.49e-23	Prostate cancer;
CRC	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg25190513	chr12:123201362	GPR109B	-0.5	-6.32	-0.33	8.41e-10	Adiponectin levels;
CRC	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.8	0.35	5.03e-11	Mean corpuscular volume;
CRC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.55	-7.22	-0.37	3.54e-12	Neutrophil percentage of white cells;
CRC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg17328964	chr8:145687451	CYHR1	-0.76	-13.63	-0.6	7.68e-34	Age at first birth;
CRC	cis	rs243505	0.660	rs3779037	chr7:148539323	T/C	cg09806900	chr7:148480153	CUL1	0.52	6.63	0.34	1.38e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.53	-7.61	-0.39	2.87e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.48	18.84	0.72	3.21e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg10298567	chr3:47292165	KIF9	-0.37	-6.01	-0.31	4.79e-9	Colorectal cancer;
CRC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.15	-0.32	2.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.41	5.98	0.31	5.89e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.84	-0.35	3.89e-11	Putamen volume;
CRC	cis	rs7113874	0.569	rs10769914	chr11:8576202	A/G	cg02811074	chr11:8615871	STK33	-0.34	-5.85	-0.31	1.21e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs863345	0.604	rs12123305	chr1:158498955	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs7725052	0.581	rs5022489	chr5:40457784	T/A	cg09067459	chr5:40385259	NA	-0.4	-6.58	-0.34	1.86e-10	Pediatric autoimmune diseases;
CRC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.69	10.56	0.5	1.2e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg15571903	chr15:79123663	NA	-0.32	-5.9	-0.31	9.06e-9	Coronary artery disease;
CRC	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.48	-8.12	-0.41	9.7e-15	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.27	-0.41	3.39e-15	Gut microbiome composition (summer);
CRC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.34	-0.42	2.08e-15	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.43	-7.4	-0.38	1.14e-12	Height;
CRC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.2	-0.37	4.09e-12	Alzheimer's disease (late onset);
CRC	cis	rs6908034	0.607	rs76525593	chr6:19809170	G/T	cg02682789	chr6:19804855	NA	0.79	6.58	0.34	1.81e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.95	0.4	3.02e-14	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg21251018	chr6:28226885	NKAPL	0.47	7.15	0.37	5.64e-12	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	11.11	0.52	1.51e-24	Personality dimensions;
CRC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.09	-14.69	-0.63	6.73e-38	Breast cancer;
CRC	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.51	-7.77	-0.39	1.02e-13	Diastolic blood pressure;
CRC	cis	rs995000	0.965	rs10789112	chr1:62957758	T/C	cg19896129	chr1:63156450	NA	0.4	5.83	0.31	1.33e-8	Triglyceride levels;
CRC	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.6	-0.39	3.12e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.42	6.65	0.34	1.19e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs863345	0.564	rs4614256	chr1:158464611	T/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	9.9e-10	Pneumococcal bacteremia;
CRC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.59	8.5	0.42	6.54e-16	Lung cancer;
CRC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.5	6.17	0.32	1.99e-9	Vitiligo;
CRC	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg27398640	chr15:77910606	LINGO1	0.41	7.79	0.39	9.13e-14	Type 2 diabetes;
CRC	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg06632207	chr12:54070931	ATP5G2	0.41	7.06	0.36	9.73e-12	Height;
CRC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.39	0.46	1.06e-18	Parkinson's disease;
CRC	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg04969067	chr8:143858791	LYNX1	0.36	6.16	0.32	2.15e-9	Urinary tract infection frequency;
CRC	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg21153622	chr11:89784906	NA	-0.44	-7.11	-0.36	7.07e-12	HDL cholesterol;
CRC	cis	rs2235544	0.579	rs1537321	chr1:54482236	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.21	-5.91	-0.31	8.48e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	trans	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg21153622	chr11:89784906	NA	-0.5	-8.01	-0.4	1.95e-14	HDL cholesterol;
CRC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	9.17	0.45	5.14e-18	Lymphocyte counts;
CRC	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.88	14.38	0.62	9.75e-37	Dupuytren's disease;
CRC	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg01858014	chr14:56050164	KTN1	-0.89	-6.84	-0.35	3.84e-11	Putamen volume;
CRC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.61	9.06	0.45	1.18e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.34	-0.38	1.63e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg15786705	chr6:28176104	NA	0.56	5.91	0.31	8.32e-9	Depression;
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg10760299	chr15:45669010	GATM	0.5	7.99	0.4	2.37e-14	Homoarginine levels;
CRC	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg17133734	chr15:86042851	AKAP13	0.45	7.08	0.36	8.55e-12	Coronary artery disease;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg25164649	chr6:28176230	NA	0.77	9.53	0.47	3.55e-19	Depression;
CRC	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.55	-9.08	-0.45	1.02e-17	Mosquito bite size;
CRC	cis	rs9463078	0.585	rs7757282	chr6:45302654	A/G	cg25276700	chr6:44698697	NA	0.24	5.61	0.3	4.21e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-6.29	-0.33	1.01e-9	Platelet distribution width;
CRC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.49	6.54	0.34	2.41e-10	Obesity-related traits;
CRC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.82	-11.24	-0.53	5.17e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.43	-7.15	-0.37	5.57e-12	Quantitative traits;
CRC	cis	rs2415984	0.622	rs61993305	chr14:46950955	C/T	cg14871534	chr14:47121158	RPL10L	-0.44	-6.31	-0.33	9.06e-10	Number of children ever born;
CRC	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg11887960	chr12:57824829	NA	0.7	7.46	0.38	7.78e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.36	8.25	0.41	3.79e-15	Multiple system atrophy;
CRC	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.71	0.35	8.3e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs972578	0.837	rs738387	chr22:43329819	A/G	cg01576275	chr22:43409880	NA	0.4	6.46	0.34	3.8e-10	Mean platelet volume;
CRC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12516959	chr21:47718080	NA	0.33	5.87	0.31	1.06e-8	Testicular germ cell tumor;
CRC	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.53	0.38	4.9e-13	Eye color traits;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02290350	chr8:58132656	NA	-0.54	-6.4	-0.33	5.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6969780	0.908	rs6461987	chr7:27166956	G/C	cg26364809	chr7:27145159	NA	-0.74	-6.6	-0.34	1.69e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.53	0.47	3.57e-19	Cognitive test performance;
CRC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24308560	chr3:49941425	MST1R	-0.44	-6.61	-0.34	1.59e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6028335	0.502	rs6028235	chr20:37608550	A/G	cg27552599	chr20:37590471	DHX35	0.37	5.81	0.3	1.49e-8	Alcohol and nicotine co-dependence;
CRC	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.53	8.89	0.44	4.14e-17	Dupuytren's disease;
CRC	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg15654264	chr1:150340011	RPRD2	0.43	6.52	0.34	2.68e-10	Migraine;
CRC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg05941027	chr17:61774174	LIMD2	-0.35	-6.16	-0.32	2.1e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg23262073	chr20:60523788	NA	-0.42	-7.3	-0.37	2.16e-12	Body mass index;
CRC	cis	rs6076065	0.723	rs2424550	chr20:23394669	C/T	cg11657817	chr20:23433608	CST11	0.43	6.33	0.33	8.11e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.51	-8.13	-0.41	8.9e-15	Monobrow;
CRC	cis	rs863345	0.625	rs11265006	chr1:158498485	C/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.28	-0.33	1.09e-9	Pneumococcal bacteremia;
CRC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.4	5.62	0.3	4.18e-8	Cognitive test performance;
CRC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	10.95	0.52	5.48e-24	Mean corpuscular hemoglobin;
CRC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-15.75	-0.66	4.89e-42	Prostate cancer;
CRC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.85	12.62	0.57	4.71e-30	Gut microbiome composition (summer);
CRC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.08	19.02	0.72	5.97e-55	Cognitive function;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09395034	chr5:137801102	EGR1	0.48	6.09	0.32	3.2e-9	Thyroid stimulating hormone;
CRC	cis	rs6940729	1	rs6940729	chr6:47552920	T/A	cg18841952	chr6:47652462	GPR111	0.33	5.82	0.31	1.43e-8	Plasma homocysteine levels;
CRC	trans	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg00953403	chr17:74099816	EXOC7	-0.45	-6.07	-0.32	3.56e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg05540913	chr6:167530185	CCR6	-0.35	-6.07	-0.32	3.58e-9	Primary biliary cholangitis;
CRC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg17346650	chr17:80929145	B3GNTL1	0.43	6.7	0.35	9.17e-11	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08830818	chr3:122514143	HSPBAP1;DIRC2	0.4	7.34	0.38	1.64e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg15786705	chr6:28176104	NA	0.64	9.23	0.45	3.27e-18	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.27	-0.37	2.67e-12	Breast cancer;
CRC	cis	rs7429990	0.866	rs3732529	chr3:47970109	C/T	cg11946769	chr3:48343235	NME6	0.45	5.92	0.31	8.17e-9	Educational attainment (years of education);
CRC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-7.59	-0.39	3.32e-13	Bipolar disorder;
CRC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.67	7.15	0.37	5.61e-12	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00295448	chr5:140044129	WDR55	0.47	6.93	0.36	2.27e-11	Intelligence (multi-trait analysis);
CRC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	12.0	0.55	9.1e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.73	0.3	2.22e-8	Breast cancer;
CRC	cis	rs7605827	0.780	rs2287278	chr2:15667771	C/G	cg19274914	chr2:15703543	NA	0.39	5.83	0.31	1.32e-8	Educational attainment (years of education);
CRC	cis	rs1223397	0.938	rs34505804	chr6:13292514	G/A	cg20827128	chr6:13274284	PHACTR1	0.56	6.56	0.34	2.05e-10	Blood pressure;
CRC	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.64	10.43	0.5	3.52e-22	Breast cancer;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg04497992	chr16:616212	NHLRC4	0.45	7.21	0.37	3.95e-12	Height;
CRC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.25	15.72	0.65	6.58e-42	Lung disease severity in cystic fibrosis;
CRC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.41	-9.02	-0.45	1.54e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.74	-10.23	-0.49	1.63e-21	Coronary artery disease;
CRC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.73	-9.07	-0.45	1.11e-17	Bone mineral density;
CRC	cis	rs6662572	1.000	rs7541935	chr1:46217493	C/T	cg08644498	chr1:46502608	NA	0.45	6.73	0.35	7.5e-11	Blood protein levels;
CRC	cis	rs7487075	0.797	rs10880959	chr12:46761127	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.99	0.31	5.43e-9	Itch intensity from mosquito bite;
CRC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.74	7.58	0.39	3.47e-13	Diabetic retinopathy;
CRC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.61	10.44	0.5	3.2e-22	Prudent dietary pattern;
CRC	cis	rs2257205	0.667	rs16943134	chr17:56681389	A/G	cg25885038	chr17:56607967	SEPT4	-0.55	-5.99	-0.31	5.54e-9	Pancreatic cancer;
CRC	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg20636351	chr8:55087400	NA	-0.32	-5.7	-0.3	2.69e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg21251018	chr6:28226885	NKAPL	0.39	5.81	0.31	1.48e-8	Depression;
CRC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	10.98	0.52	4.29e-24	Tonsillectomy;
CRC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.46	6.2	0.32	1.69e-9	Bladder cancer;
CRC	cis	rs2457480	0.778	rs11238933	chr10:44714250	C/G	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;
CRC	cis	rs12044355	0.964	rs12045144	chr1:231844248	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.93	0.31	7.85e-9	Alzheimer's disease;
CRC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg25171089	chr10:5708825	ASB13	0.42	5.87	0.31	1.07e-8	Menopause (age at onset);
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.14	-0.37	6.2e-12	Bipolar disorder;
CRC	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.75	-0.3	2.01e-8	Blood pressure;
CRC	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.43	6.51	0.34	2.85e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.32e-12	HDL cholesterol;
CRC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.35	-5.87	-0.31	1.07e-8	Diastolic blood pressure;
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg16606324	chr3:10149918	C3orf24	0.7	9.64	0.47	1.61e-19	Alzheimer's disease;
CRC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.6	-9.19	-0.45	4.59e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg10756647	chr7:56101905	PSPH	0.62	6.58	0.34	1.8e-10	Diabetic kidney disease;
CRC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg10356904	chr22:49881777	NA	-0.32	-5.99	-0.31	5.44e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.65	-0.3	3.4e-8	Bladder cancer;
CRC	cis	rs1178968	0.901	rs6949855	chr7:72728130	A/G	cg25889504	chr7:72793014	NA	0.53	6.04	0.32	4.16e-9	Triglyceride levels;
CRC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.82	-13.01	-0.58	1.66e-31	Blood trace element (Zn levels);
CRC	trans	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.76	-0.35	6.14e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-8.02	-0.4	1.9e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.49	7.54	0.38	4.55e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg15412446	chr2:106886593	NA	-0.53	-7.61	-0.39	2.89e-13	Facial morphology (factor 23);
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.39	0.56	3.4e-29	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11543725	chr11:10329292	NA	0.4	6.75	0.35	6.66e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6496667	0.779	rs28516870	chr15:91037754	G/A	cg04176472	chr15:90893244	GABARAPL3	0.53	7.77	0.39	9.86e-14	Rheumatoid arthritis;
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg20041105	chr8:143859282	LYNX1	0.42	7.34	0.38	1.65e-12	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27499259	chr13:28400924	NA	0.43	6.0	0.31	5.17e-9	Response to antipsychotic treatment;
CRC	cis	rs17592366	0.517	rs11845027	chr14:35315574	A/G	cg09327582	chr14:35236912	BAZ1A	0.49	6.89	0.36	2.82e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.4	-6.16	-0.32	2.15e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.5	7.31	0.37	2.06e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07362569	chr17:61921086	SMARCD2	0.38	5.84	0.31	1.25e-8	Prudent dietary pattern;
CRC	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.71	-0.3	2.56e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg18833306	chr6:118973337	C6orf204	0.44	5.82	0.31	1.42e-8	Diastolic blood pressure;
CRC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.54	8.66	0.43	2.12e-16	Mean corpuscular hemoglobin concentration;
CRC	trans	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.71	-0.35	8.62e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg18678763	chr11:4115507	RRM1	-0.36	-5.82	-0.31	1.43e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg17848003	chr1:3704513	LRRC47	0.41	6.04	0.32	4.27e-9	Red cell distribution width;
CRC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.56	7.75	0.39	1.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs41005	0.967	rs41002	chr2:8113921	C/T	cg03155496	chr2:8117019	LOC339788	0.41	7.25	0.37	2.96e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.69	11.74	0.54	8.24e-27	Alzheimer's disease (late onset);
CRC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg02527881	chr3:46936655	PTH1R	0.37	6.75	0.35	6.76e-11	Colorectal cancer;
CRC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-9.76	-0.47	6.13e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg13401533	chr1:37979913	MEAF6	0.42	6.04	0.32	4.28e-9	Axial length;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02290350	chr8:58132656	NA	-0.6	-6.94	-0.36	2.16e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1887596	0.639	rs581728	chr13:27202054	T/A	cg01312412	chr13:27282625	NA	0.45	5.9	0.31	9.11e-9	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.66	-0.34	1.18e-10	Mean corpuscular volume;
CRC	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg06470822	chr6:28175283	NA	0.64	8.49	0.42	6.99e-16	Parkinson's disease;
CRC	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	0.65	6.98	0.36	1.67e-11	Prostate cancer;
CRC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg24996280	chr8:143481281	TSNARE1	-0.33	-5.76	-0.3	1.95e-8	Schizophrenia;
CRC	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.4	-7.4	-0.38	1.13e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.46	0.34	3.82e-10	Axial length;
CRC	cis	rs4474465	0.573	rs7101478	chr11:78272517	C/A	cg27205649	chr11:78285834	NARS2	0.5	6.66	0.34	1.15e-10	Alzheimer's disease (survival time);
CRC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg08071915	chr8:12219732	FAM66A	0.33	5.96	0.31	6.39e-9	Retinal vascular caliber;
CRC	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.28	-0.37	2.45e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	-0.53	-8.77	-0.44	1.01e-16	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.96	18.43	0.71	1.32e-52	Height;
CRC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.2	-0.37	4.09e-12	Alzheimer's disease (late onset);
CRC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20026939	chr18:44788898	NA	-0.26	-6.25	-0.33	1.26e-9	Educational attainment;
CRC	cis	rs4660214	0.614	rs10888715	chr1:39699244	C/T	cg11070191	chr1:39582205	MACF1	0.36	5.81	0.3	1.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg06470822	chr6:28175283	NA	0.91	13.22	0.59	2.75e-32	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19286699	chr15:74667713	NA	0.42	6.05	0.32	4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg25809561	chr17:30822961	MYO1D	0.57	9.98	0.48	1.16e-20	Schizophrenia;
CRC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg24140574	chr1:16342155	HSPB7	0.42	5.63	0.3	3.95e-8	Dilated cardiomyopathy;
CRC	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg00042356	chr1:8021962	PARK7	-0.54	-6.46	-0.34	3.68e-10	Inflammatory bowel disease;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	7.42	0.38	9.76e-13	Breast cancer;
CRC	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.35	5.62	0.3	4.09e-8	Carotid intima media thickness;
CRC	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.44	-0.46	7.3e-19	Migraine;Coronary artery disease;
CRC	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.42	6.93	0.36	2.22e-11	Cleft lip with or without cleft palate;
CRC	cis	rs2062225	1.000	rs1384790	chr2:111757433	T/C	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.61e-8	Monocyte count;
CRC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg17545662	chr6:170176663	C6orf70	0.57	6.49	0.34	3.18e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs245880	0.765	rs245893	chr7:29191507	G/C	cg17163760	chr7:29186267	CPVL	-0.39	-6.79	-0.35	5.41e-11	Warfarin maintenance dose;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13014406	chr1:2323870	MORN1;RER1	0.46	6.07	0.32	3.47e-9	Anxiety disorder;
CRC	cis	rs6445967	0.832	rs1055973	chr3:58308960	T/C	cg23715586	chr3:58305044	RPP14	0.36	5.95	0.31	7.03e-9	Platelet count;
CRC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.86	-0.48	2.88e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.4	5.84	0.31	1.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs34381861	0.520	rs74382390	chr16:71458526	C/G	cg08717414	chr16:71523259	ZNF19	-0.72	-8.08	-0.41	1.21e-14	Post bronchodilator FEV1;
CRC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	7.12	0.37	6.86e-12	Mood instability;
CRC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.69e-18	Bladder cancer;
CRC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.51	8.97	0.44	2.23e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.48	7.5	0.38	6.11e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-6.45	-0.33	4.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs883565	0.569	rs7613766	chr3:39152248	C/G	cg01426195	chr3:39028469	NA	-0.42	-6.99	-0.36	1.56e-11	Handedness;
CRC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	10.06	0.49	6.17e-21	Total body bone mineral density;
CRC	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.96	-15.45	-0.65	7.15e-41	Gout;
CRC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.37	-6.35	-0.33	7.01e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13505011	chr12:133264131	POLE;PXMP2	0.45	6.22	0.32	1.53e-9	Anxiety disorder;
CRC	cis	rs938554	0.736	rs13125646	chr4:9982330	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.43	0.33	4.42e-10	Blood metabolite levels;
CRC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.38	6.64	0.34	1.29e-10	Systemic lupus erythematosus;
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.99	11.38	0.53	1.6e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.66	0.3	3.38e-8	Rheumatoid arthritis;
CRC	cis	rs6793245	0.801	rs62239356	chr3:38587093	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.66	-0.3	3.33e-8	QT interval;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg06156847	chr2:113672199	IL1F7	-0.4	-6.03	-0.32	4.38e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs6066835	0.572	rs12329434	chr20:47260191	T/C	cg18078177	chr20:47281410	PREX1	0.79	6.13	0.32	2.56e-9	Multiple myeloma;
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.4	7.22	0.37	3.6e-12	Lung cancer;
CRC	cis	rs6546324	0.625	rs2861687	chr2:67838184	C/G	cg15745817	chr2:67799979	NA	-0.56	-9.64	-0.47	1.62e-19	Endometriosis;
CRC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.46	-0.62	5.17e-37	Body mass index;
CRC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-7.7	-0.39	1.58e-13	Vitiligo;
CRC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.37	-0.38	1.35e-12	Reticulocyte fraction of red cells;
CRC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.85	16.11	0.66	1.88e-43	Dental caries;
CRC	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	16.2	0.67	8.32e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg24531977	chr5:56204891	C5orf35	-0.46	-7.0	-0.36	1.42e-11	Breast cancer;Breast cancer (early onset);
CRC	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg15704280	chr7:45808275	SEPT13	0.55	7.18	0.37	4.53e-12	Intraocular pressure;
CRC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg13798780	chr7:105162888	PUS7	0.65	7.53	0.38	4.96e-13	Bipolar disorder (body mass index interaction);
CRC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg22561889	chr6:118971681	C6orf204	0.53	6.53	0.34	2.43e-10	Diastolic blood pressure;
CRC	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.41	-5.81	-0.3	1.51e-8	Daytime sleep phenotypes;
CRC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.62	0.43	2.81e-16	Height;
CRC	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.49	5.65	0.3	3.55e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.98	-0.36	1.65e-11	Major depressive disorder;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.73	7.71	0.39	1.55e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.24	-0.37	3.15e-12	Inflammatory skin disease;
CRC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.71	-9.11	-0.45	8.07e-18	Initial pursuit acceleration;
CRC	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.35	6.02	0.31	4.7e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.35	5.69	0.3	2.76e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9826463	0.757	rs73238200	chr3:142204634	C/T	cg20824294	chr3:142316082	PLS1	0.38	6.41	0.33	5.14e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.41	6.74	0.35	7.11e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.6	9.38	0.46	1.09e-18	Intelligence (multi-trait analysis);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg27546118	chr12:3931453	PARP11	-0.42	-6.66	-0.34	1.18e-10	HDL cholesterol;
CRC	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg24851651	chr11:66362959	CCS	-0.4	-6.94	-0.36	2.08e-11	Educational attainment (years of education);
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg12273811	chr6:28175739	NA	0.52	7.39	0.38	1.2e-12	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19459784	chr19:5978416	RANBP3	0.48	6.72	0.35	8.11e-11	Anxiety disorder;
CRC	cis	rs755249	0.567	rs4660690	chr1:39819503	G/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.77	-0.3	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg19318889	chr4:1322082	MAEA	0.39	5.67	0.3	3.14e-8	Obesity-related traits;
CRC	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.69	-0.35	9.4e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg26353448	chr1:248524236	OR2T4	-0.35	-6.68	-0.35	1.02e-10	Common traits (Other);
CRC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.53	-7.91	-0.4	3.99e-14	Blood protein levels;
CRC	trans	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.19	-0.32	1.82e-9	Aortic root size;
CRC	cis	rs501120	0.636	rs920172	chr10:44782724	T/C	cg09554077	chr10:44749378	NA	0.79	8.36	0.42	1.78e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.61e-9	Arsenic metabolism;
CRC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.36	-0.46	1.3e-18	Dupuytren's disease;
CRC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg00603274	chr11:61596626	FADS2	-0.44	-6.4	-0.33	5.33e-10	Trans fatty acid levels;
CRC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.45	-8.31	-0.42	2.55e-15	Reticulocyte fraction of red cells;
CRC	cis	rs10274279	0.660	rs4716759	chr7:157374986	T/C	cg26886268	chr7:157387156	PTPRN2	-0.47	-6.57	-0.34	2.02e-10	Myopia (pathological);
CRC	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.57	-9.22	-0.45	3.79e-18	Intelligence (multi-trait analysis);
CRC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg08213375	chr14:104286397	PPP1R13B	0.37	5.81	0.31	1.46e-8	Reticulocyte count;
CRC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.76	12.73	0.57	1.82e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.66	6.75	0.35	6.57e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg21521518	chr4:53727714	RASL11B	0.41	6.07	0.32	3.59e-9	Optic nerve measurement (cup area);
CRC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg21238619	chr17:78079768	GAA	-0.49	-8.67	-0.43	1.99e-16	Yeast infection;
CRC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.59	7.21	0.37	3.98e-12	Body mass index;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg18758796	chr5:131593413	PDLIM4	0.4	6.4	0.33	5.26e-10	Acylcarnitine levels;
CRC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg06223162	chr1:101003688	GPR88	-0.36	-6.7	-0.35	8.92e-11	Monocyte count;
CRC	cis	rs6691722	0.503	rs2274167	chr1:24707296	C/T	cg18323236	chr1:24743029	NIPAL3	0.39	5.7	0.3	2.73e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.2	-0.41	5.63e-15	Schizophrenia;
CRC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.87	-0.78	5.86e-70	Myeloid white cell count;
CRC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.59	8.83	0.44	6.44e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.23	-0.71	8.29e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-7.47	-0.38	7.49e-13	Vitiligo;
CRC	cis	rs427941	0.610	rs201489	chr7:101749901	C/T	cg06246474	chr7:101738831	CUX1	0.44	6.72	0.35	8.09e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.67	-7.13	-0.37	6.49e-12	Diabetic retinopathy;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12172441	chr6:28176163	NA	-0.6	-7.48	-0.38	6.94e-13	Depression;
CRC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.59	7.13	0.37	6.5e-12	Menarche (age at onset);
CRC	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.36	0.46	1.32e-18	Common traits (Other);
CRC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.46	-8.71	-0.43	1.55e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9467160	0.734	rs10946702	chr6:24462672	A/G	cg20631270	chr6:24437470	GPLD1	-0.47	-6.91	-0.36	2.58e-11	Liver enzyme levels;
CRC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.5	-0.38	5.93e-13	Schizophrenia;
CRC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg14525755	chr12:132671672	NA	0.5	8.4	0.42	1.4e-15	Anti-saccade response;
CRC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.5	-6.64	-0.34	1.3e-10	Blood metabolite levels;
CRC	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.68	-0.43	1.82e-16	Coronary artery disease;
CRC	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.71	9.86	0.48	2.86e-20	Menopause (age at onset);
CRC	cis	rs7605827	0.893	rs741437	chr2:15626327	A/G	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	8.14e-9	Educational attainment (years of education);
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.63	8.34	0.42	2e-15	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05045343	chr2:219232747	C2orf62	0.37	6.32	0.33	8.63e-10	Interleukin-6 levels;
CRC	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg00490450	chr3:139108681	COPB2	0.44	6.5	0.34	3.05e-10	Obesity-related traits;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg23807890	chr2:228736357	WDR69	-0.51	-6.99	-0.36	1.56e-11	Blood pressure;
CRC	cis	rs78663649	0.708	rs79268770	chr19:16601411	A/T	cg10248733	chr19:16607483	C19orf44;CALR3	-0.87	-6.27	-0.33	1.1e-9	White blood cell count;
CRC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.54e-13	Mean platelet volume;
CRC	trans	rs12495832	0.778	rs78701509	chr3:147900925	T/C	cg10221266	chr7:153579447	NA	0.55	5.96	0.31	6.33e-9	Chin dimples;
CRC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.51	10.54	0.5	1.4e-22	Bone mineral density;
CRC	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg02158880	chr13:53174818	NA	-0.45	-6.77	-0.35	5.8e-11	Lewy body disease;
CRC	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg16950941	chr11:66035639	RAB1B	-0.56	-7.38	-0.38	1.33e-12	Electroencephalogram traits;
CRC	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.65	7.08	0.36	8.52e-12	Breast cancer;
CRC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.5	-7.31	-0.37	1.98e-12	Height;
CRC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.74	12.91	0.58	3.95e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.94	-14.89	-0.63	1.09e-38	Gout;
CRC	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.53	8.76	0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs3736485	0.899	rs6493505	chr15:51845172	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.51	-0.34	2.83e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.51	7.83	0.4	6.7e-14	Calcium levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12888358	chr2:86668281	KDM3A	-0.59	-9.21	-0.45	3.92e-18	Liver disease severity in Alagille syndrome;
CRC	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg03938978	chr2:103052716	IL18RAP	0.36	5.92	0.31	7.92e-9	Asthma;
CRC	cis	rs501916	0.634	rs1561479	chr15:48070157	C/G	cg16110827	chr15:48056943	SEMA6D	-0.46	-6.72	-0.35	8.26e-11	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21984481	chr17:79567631	NPLOC4	-0.42	-6.83	-0.35	4.09e-11	Myopia;
CRC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.54	-7.79	-0.39	8.84e-14	Birth weight;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg25164649	chr6:28176230	NA	0.62	8.82	0.44	6.67e-17	Parkinson's disease;
CRC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.42	0.42	1.17e-15	Menarche (age at onset);
CRC	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.05	-14.62	-0.63	1.19e-37	Exhaled nitric oxide output;
CRC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.79	0.3	1.63e-8	Prudent dietary pattern;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18324576	chr14:105452433	C14orf79	0.41	6.08	0.32	3.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.54	-8.3	-0.42	2.8e-15	Uric acid levels;
CRC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.51	-0.38	5.45e-13	Aortic root size;
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.53	-7.42	-0.38	1.01e-12	Intelligence (multi-trait analysis);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25858983	chr17:42295711	UBTF	0.45	6.55	0.34	2.25e-10	Survival in pancreatic cancer;
CRC	cis	rs12826942	0.765	rs118006794	chr12:42619524	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	6.64	0.34	1.26e-10	Coronary artery disease;
CRC	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.23	-0.37	3.46e-12	Cholesterol, total;
CRC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	7.91	0.4	4.04e-14	Aortic root size;
CRC	cis	rs7224610	0.931	rs7223342	chr17:53369594	A/G	cg02383154	chr17:53343283	HLF	-0.35	-5.88	-0.31	1.02e-8	Urate levels;
CRC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.38	7.38e-13	Lung cancer in ever smokers;
CRC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg17191109	chr10:126851326	NA	0.44	6.16	0.32	2.13e-9	Menarche (age at onset);
CRC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.43	0.42	1.08e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.44	6.44	0.33	4.33e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg08200582	chr11:442649	ANO9	-0.72	-7.44	-0.38	9e-13	Body mass index;
CRC	cis	rs3540	0.960	rs8025842	chr15:90995471	C/T	cg04176472	chr15:90893244	GABARAPL3	0.38	6.38	0.33	5.91e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.5	7.02	0.36	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-6.03	-0.32	4.32e-9	Alzheimer's disease (late onset);
CRC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12463550	chr7:65579703	CRCP	0.71	6.25	0.33	1.24e-9	Diabetic kidney disease;
CRC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.96	-18.65	-0.72	1.71e-53	Height;
CRC	cis	rs13315871	1.000	rs35542947	chr3:58323244	C/T	cg20936604	chr3:58311152	NA	-0.78	-7.38	-0.38	1.34e-12	Cholesterol, total;
CRC	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.52	-6.9	-0.36	2.72e-11	Caudate activity during reward;
CRC	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.69	-0.43	1.69e-16	Hemoglobin concentration;
CRC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg03037974	chr15:76606532	NA	-0.53	-7.76	-0.39	1.06e-13	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22555102	chr20:17949251	C20orf72;SNX5	0.48	6.89	0.36	2.86e-11	Anxiety disorder;
CRC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.67	9.77	0.47	5.65e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18634762	chr10:72968906	NA	0.44	6.11	0.32	2.89e-9	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	9.52	0.46	3.84e-19	Lymphocyte counts;
CRC	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Dilated cardiomyopathy;
CRC	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg24851651	chr11:66362959	CCS	-0.38	-6.71	-0.35	8.65e-11	Educational attainment (years of education);
CRC	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.52	-7.2	-0.37	4.18e-12	Schizophrenia;
CRC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg15465823	chr12:48382534	COL2A1	-0.38	-6.26	-0.33	1.19e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7626444	0.625	rs2669638	chr3:196477398	T/G	cg12930392	chr3:196481615	PAK2	0.41	7.3	0.37	2.23e-12	Monocyte count;
CRC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.6	9.42	0.46	8.33e-19	IgG glycosylation;
CRC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg16102536	chr7:156981717	UBE3C	-0.4	-6.81	-0.35	4.59e-11	Body mass index;
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-0.59	-8.3	-0.42	2.78e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.63	7.44	0.38	8.87e-13	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19370980	chr7:94537747	PPP1R9A	0.42	6.03	0.32	4.33e-9	Response to antipsychotic treatment;
CRC	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg17449086	chr7:139025432	C7orf55	-0.52	-5.71	-0.3	2.59e-8	Diisocyanate-induced asthma;
CRC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.86	15.97	0.66	6.57e-43	Metabolic syndrome;
CRC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.51	-6.25	-0.33	1.29e-9	Diastolic blood pressure;
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.66	8.3	0.42	2.68e-15	Body mass index;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	6.68	0.35	1.02e-10	Longevity;
CRC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	8.44	0.42	1.03e-15	Mean platelet volume;
CRC	cis	rs9786986	0.764	rs291374	chr1:235694600	T/C	cg08848088	chr1:235714526	GNG4	0.49	5.89	0.31	9.64e-9	Body mass index;
CRC	cis	rs11212617	0.901	rs11212538	chr11:108045956	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.11	0.32	2.78e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.49	7.16	0.37	5.31e-12	Menarche (age at onset);
CRC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.5	-8.25	-0.41	3.98e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.39	-6.85	-0.35	3.7e-11	Reticulocyte fraction of red cells;
CRC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.78	-12.19	-0.56	1.92e-28	Refractive error;
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11964345	chr12:110434092	GIT2	0.37	6.01	0.31	4.85e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05097221	chr19:11750825	NA	0.42	5.97	0.31	6.24e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg25164649	chr6:28176230	NA	0.6	8.01	0.4	1.95e-14	Parkinson's disease;
CRC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg00074818	chr8:8560427	CLDN23	0.4	7.27	0.37	2.69e-12	Obesity-related traits;
CRC	cis	rs17767392	0.958	rs17767446	chr14:71820963	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.84	-0.35	3.91e-11	Mitral valve prolapse;
CRC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Body mass index;
CRC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.48	-7.54	-0.38	4.52e-13	Height;
CRC	cis	rs741668	0.895	rs61953326	chr13:46568282	T/C	cg06018095	chr13:46550134	ZC3H13	0.41	5.73	0.3	2.21e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-1.03	-12.37	-0.56	4.17e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06544989	chr22:39130855	UNC84B	0.44	6.72	0.35	7.95e-11	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9905704	0.709	rs758378	chr17:56607746	G/C	cg12560992	chr17:57184187	TRIM37	-0.5	-5.96	-0.31	6.37e-9	Testicular germ cell tumor;
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg18833306	chr6:118973337	C6orf204	0.45	5.88	0.31	1.01e-8	Diastolic blood pressure;
CRC	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg09659197	chr4:152720779	NA	-0.51	-11.02	-0.52	3.03e-24	Intelligence (multi-trait analysis);
CRC	trans	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg05679027	chr9:99775184	HIATL2	-0.4	-6.12	-0.32	2.73e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.79e-9	Life satisfaction;
CRC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg06453172	chr10:134556979	INPP5A	-0.67	-9.38	-0.46	1.15e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.44	5.8	0.3	1.55e-8	Response to diuretic therapy;
CRC	cis	rs231513	0.954	rs231479	chr17:41983616	A/G	cg26893861	chr17:41843967	DUSP3	-0.64	-6.16	-0.32	2.12e-9	Cognitive function;
CRC	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	8.73	0.43	1.31e-16	Ulcerative colitis;
CRC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7605827	0.836	rs4396684	chr2:15634404	C/T	cg19274914	chr2:15703543	NA	0.38	5.9	0.31	9.25e-9	Educational attainment (years of education);
CRC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.65	11.3	0.53	3.18e-25	Prostate cancer;
CRC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.41	6.17	0.32	1.97e-9	Hemoglobin concentration;
CRC	cis	rs3736594	0.513	rs62138968	chr2:27824485	C/G	cg27432699	chr2:27873401	GPN1	0.65	8.29	0.42	2.95e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.68	0.51	4.76e-23	Prudent dietary pattern;
CRC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.84	11.13	0.52	1.27e-24	Cerebrospinal P-tau181p levels;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.95	12.02	0.55	7.69e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs2565722	0.622	rs2465873	chr6:161299972	A/G	cg03159191	chr6:161285451	NA	-0.46	-6.28	-0.33	1.07e-9	Blood protein levels;
CRC	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.98	0.44	2.17e-17	Coffee consumption (cups per day);
CRC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg15147215	chr3:52552868	STAB1	-0.65	-11.31	-0.53	2.75e-25	Electroencephalogram traits;
CRC	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.61	-6.77	-0.35	5.78e-11	Osteoarthritis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12427896	chr2:111880694	BCL2L11	-0.56	-6.93	-0.36	2.27e-11	Diisocyanate-induced asthma;
CRC	cis	rs7131987	0.630	rs1006409	chr12:29435675	A/G	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.43	-0.33	4.54e-10	QT interval;
CRC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.53	8.24	0.41	4.06e-15	Colorectal cancer;
CRC	trans	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg00953403	chr17:74099816	EXOC7	-0.48	-7.19	-0.37	4.33e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.5	-8.0	-0.4	2.2e-14	Monocyte percentage of white cells;
CRC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.45	5.4e-18	Bladder cancer;
CRC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.76	13.03	0.58	1.46e-31	Red cell distribution width;Reticulocyte count;
CRC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg15704280	chr7:45808275	SEPT13	-0.49	-6.9	-0.36	2.71e-11	HDL cholesterol;
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.44	0.33	4.14e-10	Alzheimer's disease;
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg17330251	chr7:94953956	PON1	-0.59	-7.66	-0.39	2.16e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs17767392	0.881	rs35620527	chr14:71915703	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.41	-0.33	5.19e-10	Mitral valve prolapse;
CRC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.26	-0.37	2.78e-12	QT interval;
CRC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-5.77	-0.3	1.87e-8	High light scatter reticulocyte count;
CRC	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.06	-0.32	3.8e-9	Coronary artery disease;
CRC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.42	-6.13	-0.32	2.58e-9	Non-obstructive azoospermia;
CRC	trans	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg07393940	chr7:158741817	NA	-0.51	-7.35	-0.38	1.61e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg12273811	chr6:28175739	NA	0.51	6.99	0.36	1.49e-11	Parkinson's disease;
CRC	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.16	-0.32	2.11e-9	Blood protein levels;
CRC	cis	rs9462027	0.628	rs2477507	chr6:34703599	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	trans	rs474558	0.569	rs506023	chr10:99696316	A/G	cg05303249	chr11:66036138	RAB1B	-0.54	-8.08	-0.41	1.24e-14	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	0.9	7.76	0.39	1.12e-13	Fat distribution (HIV);
CRC	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg21169611	chr9:106856078	SMC2	0.43	6.06	0.32	3.66e-9	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.33	-7.02	-0.36	1.25e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.51	7.1	0.36	7.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27138088	chr11:842605	TSPAN4;POLR2L	0.42	7.13	0.37	6.61e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs4838594	0.577	rs3888299	chr10:49687030	C/T	cg17291251	chr10:49678358	ARHGAP22	0.41	6.36	0.33	6.67e-10	Daytime sleep phenotypes;
CRC	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg09264619	chr17:80180166	NA	0.47	6.51	0.34	2.73e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23378565	chr7:2036160	MAD1L1	-0.43	-5.91	-0.31	8.53e-9	Neuroticism;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.74	-0.43	1.21e-16	Bipolar disorder;
CRC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.94	17.2	0.69	9.77e-48	Cognitive function;
CRC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.65	9.03	0.45	1.53e-17	Platelet count;
CRC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.49	7.88	0.4	4.73e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6504950	0.705	rs17745123	chr17:52988232	G/T	cg26251398	chr17:52985966	TOM1L1	0.47	6.62	0.34	1.42e-10	Breast cancer;
CRC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg24585782	chr17:78113791	EIF4A3	-0.53	-7.38	-0.38	1.3e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs8070740	1.000	rs8076900	chr17:5327927	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.98	0.36	1.65e-11	Menopause (age at onset);
CRC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.44	-0.53	9.35e-26	Ulcerative colitis;
CRC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.68	10.8	0.51	1.85e-23	Type 2 diabetes;
CRC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg20203395	chr5:56204925	C5orf35	-0.74	-8.72	-0.43	1.36e-16	Initial pursuit acceleration;
CRC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.73	11.19	0.53	7.34e-25	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2303319	0.504	rs55841284	chr2:162560011	A/G	cg03774468	chr3:140950104	ACPL2	-0.64	-5.99	-0.31	5.37e-9	Cognitive function;
CRC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	11.21	0.53	6.25e-25	Menopause (age at onset);
CRC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs9463078	0.809	rs6933553	chr6:45027770	T/C	cg25276700	chr6:44698697	NA	-0.28	-6.86	-0.35	3.35e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.5	8.49	0.42	7.32e-16	Coronary artery disease;
CRC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	7.35	0.38	1.6e-12	Breast cancer;
CRC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.4	5.92	0.31	7.95e-9	Obesity-related traits;
CRC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.54	9.34	0.46	1.49e-18	Loneliness (linear analysis);
CRC	cis	rs6908034	0.607	rs12529148	chr6:19806797	G/C	cg02682789	chr6:19804855	NA	0.79	6.75	0.35	6.62e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg12639453	chr1:2035780	PRKCZ	0.32	5.84	0.31	1.27e-8	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00323266	chr2:26256363	RAB10	0.43	6.14	0.32	2.33e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	9.08	0.45	1.01e-17	Ulcerative colitis;
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.47	0.6	3.1e-33	Alzheimer's disease;
CRC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.71	12.93	0.58	3.23e-31	Coronary artery disease;
CRC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.89	0.31	9.36e-9	Homoarginine levels;
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.63	-12.49	-0.57	1.49e-29	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.72	10.72	0.51	3.32e-23	Intelligence (multi-trait analysis);
CRC	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg12199221	chr5:83017078	HAPLN1	-0.36	-5.64	-0.3	3.64e-8	Prostate cancer;
CRC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.55	8.6	0.43	3.21e-16	Aortic root size;
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg09003973	chr2:102972529	NA	0.73	8.06	0.41	1.47e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06505273	chr16:24850292	NA	0.38	5.79	0.3	1.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.62	-0.3	4.17e-8	Life satisfaction;
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg04796162	chr7:45961102	IGFBP3	0.37	6.55	0.34	2.21e-10	Sitting height ratio;
CRC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg19338460	chr6:170058176	WDR27	0.83	8.51	0.42	6.39e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg03233332	chr7:66118400	NA	0.45	6.22	0.32	1.55e-9	Aortic root size;
CRC	cis	rs11212617	0.967	rs227074	chr11:108215095	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.23	0.32	1.42e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2252790	0.965	rs13209267	chr6:116635819	A/C	cg18764771	chr6:116381957	FRK	0.21	5.76	0.3	1.94e-8	Fast beta electroencephalogram;
CRC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-11.04	-0.52	2.49e-24	Hemoglobin concentration;
CRC	trans	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.07	-0.32	3.47e-9	Tuberculosis;
CRC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	8.62	0.43	2.79e-16	Sum eosinophil basophil counts;Eosinophil counts;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg17465063	chr10:111985564	MXI1	0.4	6.29	0.33	9.89e-10	Interleukin-6 levels;
CRC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.51	-0.42	6.43e-16	Gut microbiome composition (summer);
CRC	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.58	8.64	0.43	2.49e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.79	10.83	0.51	1.4e-23	Migraine;Coronary artery disease;
CRC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.45	7.03	0.36	1.22e-11	Hemoglobin concentration;
CRC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.45	-6.99	-0.36	1.56e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02725872	chr8:58115012	NA	-0.59	-9.08	-0.45	1.02e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.57	-10.08	-0.49	5.26e-21	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06656553	chr16:89960601	TCF25	-0.56	-5.7	-0.3	2.62e-8	Skin colour saturation;
CRC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg12573674	chr2:1569213	NA	-0.75	-7.98	-0.4	2.51e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs12476592	0.543	rs1446569	chr2:63818314	C/G	cg10828910	chr2:63850056	LOC388955	0.49	6.06	0.32	3.75e-9	Childhood ear infection;
CRC	cis	rs847649	0.731	rs1829957	chr7:102687010	T/A	cg18108683	chr7:102477205	FBXL13	0.51	7.98	0.4	2.44e-14	Morning vs. evening chronotype;
CRC	cis	rs812925	0.784	rs7588041	chr2:61461412	C/T	cg10580144	chr2:61372316	C2orf74	-0.32	-6.62	-0.34	1.44e-10	Immature fraction of reticulocytes;
CRC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.44	7.39	0.38	1.26e-12	Crohn's disease;
CRC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.26e-11	Alzheimer's disease (late onset);
CRC	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.5	-0.34	2.99e-10	Educational attainment;
CRC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.46	-5.77	-0.3	1.86e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg15147215	chr3:52552868	STAB1	-0.61	-9.97	-0.48	1.27e-20	Bipolar disorder;
CRC	cis	rs6076065	1.000	rs2424533	chr20:23375907	C/T	cg11657817	chr20:23433608	CST11	0.36	5.64	0.3	3.68e-8	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.48	6.81	0.35	4.55e-11	Corneal astigmatism;
CRC	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg09179987	chr1:167433047	CD247	0.48	7.62	0.39	2.77e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.66	9.69	0.47	1.07e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg00769240	chr8:12517080	NA	-0.58	-7.25	-0.37	3.05e-12	Blood pressure (smoking interaction);
CRC	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.1	11.91	0.55	1.96e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7487075	0.786	rs12302984	chr12:46684070	A/G	cg22049899	chr12:47219821	SLC38A4	0.32	6.11	0.32	2.84e-9	Itch intensity from mosquito bite;
CRC	cis	rs9405490	0.643	rs9328059	chr6:1523076	A/G	cg01806741	chr6:1527072	NA	0.66	5.91	0.31	8.57e-9	Inflammatory skin disease;
CRC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.79	0.44	8.66e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-6.48	-0.34	3.42e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg02683197	chr6:28174875	NA	0.6	8.31	0.42	2.55e-15	Parkinson's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22251877	chr8:125551349	TATDN1;NDUFB9	0.37	6.21	0.32	1.64e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09441736	chr7:101849549	CUX1	-0.4	-6.21	-0.32	1.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg22638593	chr5:131593259	PDLIM4	0.31	5.64	0.3	3.65e-8	Blood metabolite levels;
CRC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.73	11.41	0.53	1.28e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03676636	chr4:99064102	C4orf37	-0.2	-5.84	-0.31	1.26e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.06	-14.72	-0.63	5.16e-38	Exhaled nitric oxide output;
CRC	cis	rs9311676	0.609	rs62258080	chr3:58367493	G/A	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.5e-10	Systemic lupus erythematosus;
CRC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.38	6.28	0.33	1.08e-9	Major depressive disorder;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg06877462	chr1:205807181	PM20D1	0.37	5.85	0.31	1.17e-8	Menarche (age at onset);
CRC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.6	7.9	0.4	4.3e-14	Multiple sclerosis;
CRC	cis	rs117623576	0.887	rs211411	chr10:32394992	T/C	cg03047570	chr10:32398778	NA	0.78	9.01	0.44	1.7e-17	Anti-saccade response;
CRC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.55	-8.25	-0.41	3.87e-15	Non-alcoholic fatty liver disease histology (lobular);
CRC	cis	rs1223397	0.651	rs2439544	chr6:13312470	G/A	cg07912922	chr6:13274314	PHACTR1	0.37	5.73	0.3	2.26e-8	Blood pressure;
CRC	cis	rs8105895	0.935	rs7256462	chr19:22281993	T/C	cg02657401	chr19:22469223	NA	-0.35	-5.67	-0.3	3.06e-8	Body mass index (change over time);
CRC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.6	11.12	0.52	1.31e-24	Immature fraction of reticulocytes;
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg19913688	chr11:428466	ANO9	-0.69	-7.09	-0.36	8.4e-12	Body mass index;
CRC	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg14191688	chr11:70257035	CTTN	0.47	6.38	0.33	6.11e-10	Coronary artery disease;
CRC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.36	-0.38	1.52e-12	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09844983	chr1:28240714	RPA2	0.47	6.61	0.34	1.57e-10	Response to antipsychotic treatment;
CRC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg05627522	chr15:75251581	NA	0.5	7.6	0.39	3.04e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.53	-8.86	-0.44	5.18e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-7.3	-0.37	2.24e-12	Hematocrit;
CRC	cis	rs16867321	1.000	rs4289138	chr2:181364220	T/G	cg23363182	chr2:181467187	NA	-0.49	-6.09	-0.32	3.16e-9	Obesity;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.15	0.49	3.13e-21	Cognitive test performance;
CRC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.55	-9.89	-0.48	2.38e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.43	6.34	0.33	7.5e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg19318889	chr4:1322082	MAEA	0.4	5.71	0.3	2.57e-8	Obesity-related traits;
CRC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-9.56	-0.47	2.76e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4700695	0.686	rs251710	chr5:65347357	G/C	cg21114390	chr5:65439923	SFRS12	0.59	7.19	0.37	4.36e-12	Facial morphology (factor 19);
CRC	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06156847	chr2:113672199	IL1F7	0.5	7.7	0.39	1.6e-13	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs17767392	1.000	rs61991203	chr14:71767841	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.68	9.19	0.45	4.7e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg27053337	chr8:124217698	FAM83A	0.44	5.99	0.31	5.46e-9	Urinary uromodulin levels;
CRC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.45	6.68	0.35	1.03e-10	Asthma;
CRC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.81	-13.13	-0.59	5.97e-32	Tonsillectomy;
CRC	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.33	-0.37	1.84e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-7.88	-0.4	4.75e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.55	7.22	0.37	3.63e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg14139581	chr11:64358342	SLC22A12	0.38	6.04	0.32	4.15e-9	Urate levels in obese individuals;
CRC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-15.07	-0.64	2.18e-39	Schizophrenia;
CRC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg03161606	chr19:29218774	NA	0.49	5.72	0.3	2.37e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs61996546	0.622	rs17646626	chr15:26867286	A/G	cg15066197	chr15:26874202	GABRB3	0.39	5.98	0.31	5.87e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg16060761	chr17:80687452	NA	0.42	6.19	0.32	1.77e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08187779	chr8:102217898	ZNF706	0.49	8.59	0.43	3.47e-16	Liver disease severity in Alagille syndrome;
CRC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg24011408	chr12:48396354	COL2A1	0.46	6.35	0.33	7.23e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.98	-0.31	5.93e-9	Metabolite levels;
CRC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	7.27	0.37	2.56e-12	Menarche (age at onset);
CRC	trans	rs11654801	0.947	rs11658178	chr17:20923489	G/A	cg23759823	chr7:139672531	TBXAS1	-0.46	-6.75	-0.35	6.7e-11	Mosquito bite size;
CRC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.66	-0.75	2.16e-61	Myeloid white cell count;
CRC	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg01339444	chr6:118972232	C6orf204	0.49	6.02	0.31	4.73e-9	Renal cell carcinoma;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg21251018	chr6:28226885	NKAPL	0.47	7.25	0.37	2.99e-12	Cardiac Troponin-T levels;
CRC	cis	rs10426930	0.700	rs10407399	chr19:5009466	A/C	cg25246084	chr19:4971487	KDM4B	0.33	5.75	0.3	2.04e-8	Monocyte percentage of white cells;
CRC	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg24300038	chr13:113819356	PROZ	0.51	6.66	0.34	1.16e-10	Platelet distribution width;
CRC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.51	8.4	0.42	1.38e-15	Cystic fibrosis severity;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg25164649	chr6:28176230	NA	0.44	6.55	0.34	2.17e-10	Pubertal anthropometrics;
CRC	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.59	7.53	0.38	4.99e-13	Coronary artery disease;
CRC	cis	rs12936587	0.748	rs11871738	chr17:17525243	A/G	cg16928487	chr17:17741425	SREBF1	0.39	5.78	0.3	1.71e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.09	-0.59	8.67e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg06172871	chr16:72088244	HP	0.39	5.69	0.3	2.82e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7945718	0.591	rs7102432	chr11:12700132	T/C	cg25843174	chr11:12811716	TEAD1	0.41	7.44	0.38	9.02e-13	Educational attainment (years of education);
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg26587870	chr6:27730563	NA	-0.6	-5.91	-0.31	8.73e-9	Depression;
CRC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.97	0.44	2.26e-17	Bladder cancer;
CRC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.82	13.8	0.61	1.67e-34	Menopause (age at onset);
CRC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.51	8.4	0.42	1.36e-15	Aortic root size;
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg11235426	chr6:292522	DUSP22	-0.55	-7.67	-0.39	1.94e-13	Menopause (age at onset);
CRC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.39	0.33	5.56e-10	Dupuytren's disease;
CRC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg27523141	chr10:43048294	ZNF37B	0.45	6.53	0.34	2.47e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.51	-0.67	4.81e-45	Height;
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.64	8.31	0.42	2.59e-15	Alzheimer's disease;
CRC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.71	9.99	0.48	1.04e-20	Cleft lip with or without cleft palate;
CRC	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg13482628	chr17:19912719	NA	-0.41	-6.49	-0.34	3.18e-10	Obesity-related traits;
CRC	cis	rs7705042	0.865	rs6882226	chr5:141503870	T/A	cg07392085	chr5:141489673	NDFIP1	0.46	7.24	0.37	3.13e-12	Asthma;
CRC	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.82	-0.44	6.83e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.36	5.98	0.31	5.8e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03923535	chr7:1197113	ZFAND2A	0.52	7.69	0.39	1.77e-13	Longevity;Endometriosis;
CRC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.6	8.59	0.43	3.61e-16	Arsenic metabolism;
CRC	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg08533674	chr1:46993347	NA	0.47	6.58	0.34	1.86e-10	Monobrow;
CRC	cis	rs7849270	1.000	rs10988223	chr9:131903021	T/C	cg13538475	chr9:131942899	NA	-0.32	-6.23	-0.32	1.41e-9	Blood metabolite ratios;
CRC	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg13385794	chr1:248469461	NA	0.36	6.29	0.33	1.02e-9	Common traits (Other);
CRC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.59	6.42	0.33	4.85e-10	IgG glycosylation;
CRC	cis	rs7692995	1.000	rs7668417	chr4:18025029	G/A	cg08925142	chr4:18023851	LCORL	-0.53	-5.87	-0.31	1.06e-8	Height;
CRC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.72	11.32	0.53	2.52e-25	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.63	10.75	0.51	2.7e-23	Prudent dietary pattern;
CRC	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.78	9.49	0.46	4.69e-19	Inflammatory bowel disease;
CRC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.11	-0.32	2.75e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.56	7.94	0.4	3.33e-14	Blood metabolite levels;
CRC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.72	10.65	0.51	5.81e-23	Response to antineoplastic agents;
CRC	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg17145862	chr1:211918768	LPGAT1	0.49	6.4	0.33	5.47e-10	Crohn's disease;
CRC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.88	0.31	1.02e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg23533926	chr12:111358616	MYL2	-0.53	-8.19	-0.41	5.94e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-17.1	-0.69	2.27e-47	Schizophrenia;
CRC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.55	7.46	0.38	7.6e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.64	8.71	0.43	1.55e-16	Alzheimer's disease;
CRC	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.35	-6.0	-0.31	5.29e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.33e-9	Prudent dietary pattern;
CRC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg09417038	chr21:47716443	C21orf57	-0.4	-6.59	-0.34	1.72e-10	Testicular germ cell tumor;
CRC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-6.13	-0.32	2.53e-9	Lung cancer;
CRC	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.78	12.92	0.58	3.69e-31	Metabolic syndrome;
CRC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg27535305	chr1:53392650	SCP2	0.34	6.29	0.33	1.01e-9	Monocyte count;
CRC	cis	rs62432291	0.681	rs3003173	chr6:159665692	G/T	cg14500486	chr6:159655392	FNDC1	-0.75	-9.23	-0.45	3.37e-18	Joint mobility (Beighton score);
CRC	cis	rs2108622	0.727	rs9305069	chr19:15983386	A/G	cg13772218	chr19:15982569	NA	0.49	6.98	0.36	1.67e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg05527609	chr1:210001259	C1orf107	-0.43	-5.67	-0.3	3.05e-8	Monobrow;
CRC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.77	0.47	5.98e-20	Hip circumference adjusted for BMI;
CRC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg20684491	chr1:25596433	NA	0.42	7.34	0.37	1.73e-12	Erythrocyte sedimentation rate;
CRC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.75	12.17	0.56	2.24e-28	Blood protein levels;
CRC	trans	rs7979673	1.000	rs7953554	chr12:66200778	A/G	cg23076361	chr14:100622050	DEGS2	0.51	6.51	0.34	2.88e-10	Height;
CRC	trans	rs11581859	0.950	rs55936487	chr1:99359724	T/C	cg12183875	chr3:169587454	LRRC31	0.25	5.99	0.31	5.39e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs995000	0.931	rs4915840	chr1:62999595	C/G	cg19896129	chr1:63156450	NA	-0.45	-7.04	-0.36	1.15e-11	Triglyceride levels;
CRC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.55	-0.75	5.92e-61	Height;
CRC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.8	13.03	0.58	1.36e-31	IgG glycosylation;
CRC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.51	6.61	0.34	1.53e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7107174	0.748	rs4415799	chr11:77976475	C/T	cg02023728	chr11:77925099	USP35	-0.37	-6.35	-0.33	6.98e-10	Testicular germ cell tumor;
CRC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg18230493	chr5:56204884	C5orf35	-0.39	-5.77	-0.3	1.87e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.78	-0.47	5.21e-20	Hip circumference adjusted for BMI;
CRC	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg09179987	chr1:167433047	CD247	0.52	8.34	0.42	2.03e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.11	0.32	2.89e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2072510	0.569	rs7134975	chr12:96390420	C/A	cg15438951	chr12:96389694	HAL	-0.49	-5.92	-0.31	7.95e-9	Metabolite levels (small molecules and protein measures);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07237590	chr20:62526788	DNAJC5	0.38	6.32	0.33	8.32e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04880052	chr2:219191631	PNKD	-0.42	-6.66	-0.34	1.17e-10	Colorectal cancer;
CRC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.1	-0.36	7.85e-12	Testicular germ cell tumor;
CRC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.39	-6.46	-0.34	3.76e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.92	-0.36	2.36e-11	Inflammatory skin disease;
CRC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs7259376	0.936	rs12608491	chr19:22541627	A/G	cg02657401	chr19:22469223	NA	-0.34	-7.62	-0.39	2.73e-13	Menopause (age at onset);
CRC	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.39	-0.46	1.07e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-1.23	-11.16	-0.52	9.95e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.68	-10.39	-0.5	4.53e-22	Colorectal cancer;
CRC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.66	8.29	0.42	2.84e-15	Menarche (age at onset);
CRC	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg09659197	chr4:152720779	NA	-0.53	-11.57	-0.54	3.22e-26	Intelligence (multi-trait analysis);
CRC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.29e-9	Aortic root size;
CRC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.59	7.32	0.37	1.93e-12	Mean platelet volume;
CRC	trans	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg18335740	chr13:41363409	SLC25A15	0.53	8.07	0.41	1.29e-14	Lewy body disease;
CRC	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg20936604	chr3:58311152	NA	-0.72	-6.84	-0.35	3.78e-11	Cholesterol, total;
CRC	cis	rs753274	0.562	rs888876	chr19:14416793	T/C	cg19560656	chr19:14444267	NA	-0.39	-6.15	-0.32	2.23e-9	Tumor necrosis factor beta levels;
CRC	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.21	-0.56	1.56e-28	Migraine;Coronary artery disease;
CRC	cis	rs6743376	0.556	rs1374286	chr2:113819007	C/G	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02290350	chr8:58132656	NA	-0.5	-6.21	-0.32	1.6e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg09904177	chr6:26538194	HMGN4	-0.44	-6.04	-0.32	4.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.34	-5.62	-0.3	4.14e-8	Childhood ear infection;
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg01191114	chr3:48936118	SLC25A20	-0.67	-6.08	-0.32	3.35e-9	Cognitive function;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg02683197	chr6:28174875	NA	0.67	9.24	0.45	3.07e-18	Cardiac Troponin-T levels;
CRC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg09655341	chr17:79618100	PDE6G	0.36	6.21	0.32	1.55e-9	Eye color traits;
CRC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.29	-6.5	-0.34	3.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg26116260	chr4:7069785	GRPEL1	0.49	7.58	0.39	3.6e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.7	10.83	0.51	1.42e-23	Corneal astigmatism;
CRC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg18490616	chr2:88469792	THNSL2	0.57	5.64	0.3	3.73e-8	Plasma clusterin levels;
CRC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs4716602	0.596	rs10275400	chr7:156161550	A/G	cg16983916	chr7:156159713	NA	-0.4	-6.9	-0.36	2.62e-11	Anti-saccade response;
CRC	cis	rs7605827	0.930	rs1997304	chr2:15512073	G/T	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.73	-10.06	-0.48	6.29e-21	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg21620606	chr4:1342894	KIAA1530	0.4	7.0	0.36	1.49e-11	Obesity-related traits;
CRC	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg15234197	chr11:68924956	NA	0.44	6.12	0.32	2.72e-9	Blond vs. brown hair color;
CRC	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg20936604	chr3:58311152	NA	-0.76	-7.22	-0.37	3.53e-12	Cholesterol, total;
CRC	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.49	7.7	0.39	1.63e-13	Schizophrenia;
CRC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-11.63	-0.54	2.05e-26	Chronic sinus infection;
CRC	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.47	9.52	0.46	3.79e-19	Schizophrenia;
CRC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.56	6.19	0.32	1.75e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-6.27	-0.33	1.12e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg21724239	chr8:58056113	NA	0.43	6.07	0.32	3.43e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg00277334	chr10:82204260	NA	-0.56	-6.39	-0.33	5.55e-10	Post bronchodilator FEV1;
CRC	trans	rs2413583	0.536	rs17304621	chr22:39690791	C/T	cg09612413	chr10:12085555	UPF2	-0.57	-6.2	-0.32	1.71e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg00933542	chr6:150070202	PCMT1	0.32	6.35	0.33	7.3e-10	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19195327	chr1:6479725	HES2	0.46	6.37	0.33	6.4e-10	Thyroid stimulating hormone;
CRC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.99	-0.31	5.55e-9	Inflammatory bowel disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24642196	chr1:161136063	PPOX	0.47	6.45	0.34	3.89e-10	Anxiety disorder;
CRC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.3	-0.33	9.55e-10	Height;
CRC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg19980929	chr12:42632907	YAF2	0.44	6.57	0.34	2.01e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.71	-11.61	-0.54	2.44e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg24578937	chr1:2090814	PRKCZ	-0.39	-7.04	-0.36	1.09e-11	Height;
CRC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.42	6.79	0.35	5.39e-11	Mean corpuscular volume;
CRC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.18	0.32	1.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg02466173	chr16:30829666	NA	0.67	10.14	0.49	3.36e-21	Dementia with Lewy bodies;
CRC	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.56	-10.24	-0.49	1.54e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs11581859	0.950	rs72728602	chr1:99372148	C/A	cg12183875	chr3:169587454	LRRC31	0.27	6.36	0.33	6.74e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.83	-0.31	1.32e-8	Pulmonary function;
CRC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00801512	chr17:28996047	NA	-0.5	-5.97	-0.31	6.13e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.59	9.78	0.47	5.34e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg17133734	chr15:86042851	AKAP13	0.4	6.32	0.33	8.47e-10	Coronary artery disease;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg20512303	chr5:131592959	PDLIM4	0.41	6.96	0.36	1.89e-11	Breast cancer;
CRC	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg14593290	chr7:50529359	DDC	0.51	7.14	0.37	5.98e-12	Malaria;
CRC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	11.08	0.52	1.85e-24	Bipolar disorder lithium response (categorical) or schizophrenia;
CRC	cis	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg07480446	chr2:239069576	NA	0.37	6.86	0.35	3.46e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.73	-0.3	2.31e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.51	6.57	0.34	2.01e-10	Obesity-related traits;
CRC	cis	rs9303542	0.625	rs8064626	chr17:46567851	G/A	cg04904318	chr17:46607828	HOXB1	-0.51	-5.81	-0.31	1.44e-8	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg00277334	chr10:82204260	NA	0.37	5.97	0.31	6.06e-9	Sarcoidosis;
CRC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg01262667	chr19:19385393	TM6SF2	0.38	6.24	0.33	1.36e-9	Tonsillectomy;
CRC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.46	-7.13	-0.37	6.44e-12	Emphysema distribution in smoking;
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.86	-0.31	1.14e-8	Calcium levels;
CRC	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg09655341	chr17:79618100	PDE6G	0.62	7.1	0.36	7.87e-12	Dental caries;
CRC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.41	-7.52	-0.38	5.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2811415	0.597	rs35944498	chr3:127731662	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.96	-0.31	6.45e-9	Lung function (FEV1/FVC);
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	0.99	23.22	0.79	2.59e-71	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.7	9.23	0.45	3.28e-18	Alzheimer's disease;
CRC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg19683494	chr5:74908142	NA	0.49	6.21	0.32	1.57e-9	Age-related disease endophenotypes;
CRC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.87	-14.13	-0.61	9.55e-36	Multiple myeloma;
CRC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.59	10.73	0.51	3.12e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1007738	0.580	rs11039028	chr11:46944196	G/A	cg19486271	chr11:47235900	DDB2	0.47	6.3	0.33	9.81e-10	Bone mineral density (hip);
CRC	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.21	-0.45	3.84e-18	Coronary artery disease;
CRC	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg08501292	chr6:25962987	TRIM38	1.07	9.68	0.47	1.19e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.51	7.54	0.38	4.72e-13	Corneal astigmatism;
CRC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	0.99	13.07	0.58	9.68e-32	Vitiligo;
CRC	cis	rs10512697	0.803	rs11742420	chr5:3579874	A/C	cg19473799	chr5:3511975	NA	-0.72	-5.69	-0.3	2.81e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs780094	0.500	rs12467476	chr2:27825715	T/C	cg27432699	chr2:27873401	GPN1	0.48	6.11	0.32	2.82e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg21747405	chr11:67723411	NA	-0.49	-6.36	-0.33	6.71e-10	Blood pressure (smoking interaction);
CRC	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg08779649	chr13:50194554	NA	0.33	6.33	0.33	8.2e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.85	-0.4	6.1e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg11003573	chr3:44754125	ZNF502	-0.33	-5.64	-0.3	3.7e-8	Depressive symptoms;
CRC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.01	-9.66	-0.47	1.33e-19	Breast cancer;
CRC	cis	rs3015497	0.789	rs3015496	chr14:51114051	T/C	cg09863266	chr14:51125203	SAV1	-0.31	-5.77	-0.3	1.86e-8	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs62432291	0.681	rs420137	chr6:159652931	G/C	cg14500486	chr6:159655392	FNDC1	-0.75	-10.17	-0.49	2.55e-21	Joint mobility (Beighton score);
CRC	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg02158880	chr13:53174818	NA	0.43	6.62	0.34	1.46e-10	Lewy body disease;
CRC	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.62	-7.27	-0.37	2.57e-12	Ulcerative colitis;
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.43	-0.46	7.51e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg13456138	chr10:90753195	FAS	0.41	5.75	0.3	2.06e-8	Chronic lymphocytic leukemia;
CRC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.46	6.39	0.33	5.59e-10	Type 2 diabetes;
CRC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.6	9.38	0.46	1.09e-18	Intelligence (multi-trait analysis);
CRC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.51	-0.62	3.13e-37	Body mass index;
CRC	cis	rs9462846	0.919	rs34433785	chr6:42887693	A/C	cg02353165	chr6:42928485	GNMT	0.5	6.41	0.33	5.11e-10	Blood protein levels;
CRC	cis	rs11001819	0.562	rs10824419	chr10:78268635	C/T	cg18941641	chr10:78392320	NA	0.34	5.73	0.3	2.29e-8	Pulmonary function (smoking interaction);Pulmonary function;
CRC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg10802521	chr3:52805072	NEK4	-0.46	-6.24	-0.33	1.32e-9	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.23	-0.32	1.41e-9	Blood metabolite levels;
CRC	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.71	-9.4	-0.46	9.34e-19	Blood pressure (smoking interaction);
CRC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.99	0.31	5.36e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg17401720	chr7:158221031	PTPRN2	0.46	7.35	0.38	1.63e-12	Obesity-related traits;
CRC	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.43	6.87	0.35	3.17e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.96	0.48	1.4e-20	Platelet count;
CRC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Bladder cancer;
CRC	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg00042356	chr1:8021962	PARK7	-0.55	-6.08	-0.32	3.36e-9	Inflammatory bowel disease;
CRC	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.66	6.72	0.35	7.79e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg07889827	chr10:93443413	NA	-0.39	-6.48	-0.34	3.42e-10	Intelligence (multi-trait analysis);
CRC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-7.49	-0.38	6.19e-13	Schizophrenia;
CRC	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.45	6.86	0.35	3.4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.1	0.64	1.71e-39	Primary sclerosing cholangitis;
CRC	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg04586622	chr2:25135609	ADCY3	-0.56	-10.49	-0.5	2.11e-22	Body mass index in non-asthmatics;
CRC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.61	8.62	0.43	2.84e-16	Alcohol dependence;
CRC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg23018236	chr17:30244563	NA	-0.62	-7.78	-0.39	9.36e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-5.84	-0.31	1.26e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12898370	0.561	rs8028830	chr15:77508046	A/G	cg10437265	chr15:77819839	NA	0.53	6.24	0.33	1.39e-9	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs9303280	0.617	rs6503525	chr17:38095174	C/G	cg24910161	chr17:38119198	GSDMA	0.33	5.86	0.31	1.15e-8	Self-reported allergy;
CRC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.49	7.84	0.4	6.36e-14	Corneal astigmatism;
CRC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.28	-0.37	2.4e-12	Colorectal cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg13182412	chr17:73776098	H3F3B	-0.42	-6.45	-0.34	4.03e-10	Aortic root size;
CRC	trans	rs7923837	0.650	rs10882098	chr10:94444793	C/T	cg27121462	chr16:89883253	FANCA	-0.39	-6.06	-0.32	3.7e-9	Body mass index;Multiple sclerosis;
CRC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	0.93	12.6	0.57	5.76e-30	Red blood cell traits;
CRC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06634786	chr22:41940651	POLR3H	-0.4	-5.67	-0.3	3.19e-8	Vitiligo;
CRC	cis	rs62408225	0.925	rs6925032	chr6:91008027	C/A	cg06866423	chr6:90926672	BACH2	0.49	8.03	0.4	1.73e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg18187862	chr3:45730750	SACM1L	-0.5	-7.22	-0.37	3.74e-12	Primary sclerosing cholangitis;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg10876282	chr6:28092338	ZSCAN16	0.4	5.7	0.3	2.62e-8	Cardiac Troponin-T levels;
CRC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.58	8.58	0.43	3.7e-16	Aortic root size;
CRC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg21251018	chr6:28226885	NKAPL	-0.48	-8.3	-0.42	2.76e-15	Pubertal anthropometrics;
CRC	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.55	8.46	0.42	8.83e-16	Lewy body disease;
CRC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg21521518	chr4:53727714	RASL11B	0.4	5.93	0.31	7.81e-9	Optic nerve measurement (cup area);
CRC	cis	rs2882667	0.898	rs11950819	chr5:138397100	T/C	cg04439458	chr5:138467593	SIL1	-0.32	-5.93	-0.31	7.55e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.68	9.18	0.45	4.78e-18	Platelet count;
CRC	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-1.21	-10.07	-0.49	5.77e-21	Mitochondrial DNA levels;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.61	9.13	0.45	7.04e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12273811	chr6:28175739	NA	0.59	8.66	0.43	2.22e-16	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12760041	chr2:211036890	C2orf67	-0.46	-7.07	-0.36	9.28e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	6.98	0.36	1.61e-11	Response to antipsychotic treatment;
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.44	-6.22	-0.32	1.49e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.6	-8.32	-0.42	2.35e-15	Inflammatory bowel disease;
CRC	trans	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg18335740	chr13:41363409	SLC25A15	0.54	8.15	0.41	7.45e-15	Lewy body disease;
CRC	trans	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg07817883	chr1:32538562	TMEM39B	-0.63	-7.84	-0.4	6.13e-14	Monocyte percentage of white cells;
CRC	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg27382691	chr15:76552771	ETFA;TYRO3P	0.5	6.24	0.33	1.33e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.1	13.26	0.59	1.87e-32	Sexual dysfunction (female);
CRC	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.53	7.9	0.4	4.26e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.65e-10	Diabetic kidney disease;
CRC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.51	-8.29	-0.42	2.98e-15	Body mass index;
CRC	trans	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg18335740	chr13:41363409	SLC25A15	0.49	6.99	0.36	1.53e-11	Lewy body disease;
CRC	trans	rs4873772	0.834	rs7842068	chr8:48582964	A/G	cg05343739	chr1:154731938	KCNN3	0.36	6.58	0.34	1.83e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.3	-0.37	2.13e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.86	-16.8	-0.68	3.46e-46	Oral cavity cancer;
CRC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.5	5.95	0.31	6.83e-9	Coronary artery calcification;
CRC	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg04218760	chr10:45406644	TMEM72	-0.3	-7.35	-0.38	1.58e-12	Mean corpuscular volume;
CRC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.66	7.37	0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.11	-0.36	7.49e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg12870014	chr12:110450643	ANKRD13A	0.83	10.77	0.51	2.35e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.07	-13.81	-0.61	1.62e-34	Vitiligo;
CRC	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.55	7.36	0.38	1.51e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg26587870	chr6:27730563	NA	-0.45	-6.55	-0.34	2.18e-10	Parkinson's disease;
CRC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg01388757	chr2:102091195	RFX8	-0.62	-8.77	-0.44	9.74e-17	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.62	11.01	0.52	3.2e-24	Schizophrenia;
CRC	cis	rs4880487	0.505	rs883660	chr10:1206834	A/G	cg10055817	chr10:1229050	ADARB2	0.4	6.74	0.35	7.12e-11	Migraine;
CRC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.47	-9.09	-0.45	9.81e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.52e-18	Bladder cancer;
CRC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.53	0.38	4.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12311346	chr5:56204834	C5orf35	0.41	6.24	0.33	1.33e-9	Coronary artery disease;
CRC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	1.0	15.79	0.66	3.31e-42	Testicular germ cell tumor;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16322302	chr3:49157769	USP19	-0.41	-6.21	-0.32	1.59e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.59	0.63	1.55e-37	Hypertriglyceridemia;
CRC	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.66	-0.43	2.08e-16	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg05540913	chr6:167530185	CCR6	-0.42	-7.48	-0.38	6.66e-13	Primary biliary cholangitis;
CRC	cis	rs17767392	0.595	rs61174376	chr14:71654869	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.47	-6.04	-0.32	4.21e-9	Mitral valve prolapse;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04028315	chr7:21467710	SP4	0.42	6.33	0.33	8.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.86	-16.82	-0.68	2.95e-46	Oral cavity cancer;
CRC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.33	-5.93	-0.31	7.56e-9	Abdominal aortic aneurysm;
CRC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.63	10.77	0.51	2.32e-23	Gestational age at birth (maternal effect);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26596863	chr20:5108292	PCNA;CDS2	-0.4	-6.05	-0.32	3.84e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg12315302	chr6:26189340	HIST1H4D	0.7	5.65	0.3	3.42e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg17724175	chr1:150552817	MCL1	-0.45	-7.07	-0.36	9.09e-12	Tonsillectomy;
CRC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.41	-8.25	-0.41	3.92e-15	Renal cell carcinoma;
CRC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.46	-7.65	-0.39	2.19e-13	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.63	6.69	0.35	9.71e-11	Type 2 diabetes;
CRC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.36	5.93	0.31	7.78e-9	Major depressive disorder;
CRC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.94	-17.76	-0.7	5.67e-50	Height;
CRC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg23463467	chr20:60627584	TAF4	0.33	5.71	0.3	2.53e-8	Body mass index;
CRC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	7.97	0.4	2.6e-14	Menarche (age at onset);
CRC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.76	10.02	0.48	8.55e-21	Coronary artery disease;
CRC	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg01426195	chr3:39028469	NA	-0.52	-8.36	-0.42	1.79e-15	Handedness;
CRC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	7.01	0.36	1.34e-11	Educational attainment;
CRC	cis	rs7122539	0.646	rs9633985	chr11:66520608	A/T	cg24851651	chr11:66362959	CCS	0.43	7.6	0.39	3.16e-13	HIV-1 susceptibility;
CRC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.49	-0.42	7.39e-16	Monocyte count;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-11.23	-0.53	5.54e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-5.79	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs71403859	0.568	rs12149489	chr16:71813780	G/T	cg08717414	chr16:71523259	ZNF19	-0.92	-8.63	-0.43	2.66e-16	Post bronchodilator FEV1;
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg06470822	chr6:28175283	NA	-1.02	-15.73	-0.66	5.53e-42	Depression;
CRC	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg14458575	chr2:238380390	NA	-0.59	-7.86	-0.4	5.36e-14	Prostate cancer;
CRC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.48	-7.67	-0.39	1.94e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26240231	chr7:1148101	C7orf50	0.38	5.65	0.3	3.46e-8	Bronchopulmonary dysplasia;
CRC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.08	-0.32	3.29e-9	Renal cell carcinoma;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg25164649	chr6:28176230	NA	0.66	8.76	0.43	1.08e-16	Parkinson's disease;
CRC	trans	rs4768236	0.808	rs4768224	chr12:40661403	A/T	cg00973677	chr7:136553595	CHRM2	0.3	6.23	0.32	1.42e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.3	0.49	9.6e-22	Menopause (age at onset);
CRC	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.6	-5.7	-0.3	2.64e-8	White matter integrity;
CRC	cis	rs1656402	1.000	rs1190455	chr2:233435153	A/G	cg03852847	chr2:233439513	NA	-0.44	-7.5	-0.38	6.14e-13	Non-small cell lung cancer (survival);
CRC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg23815491	chr16:72088622	HP	0.51	7.65	0.39	2.17e-13	Fibrinogen levels;
CRC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.51	-0.79	2.15e-72	Myeloid white cell count;
CRC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	8.15	0.41	7.78e-15	Menarche (age at onset);
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg06470822	chr6:28175283	NA	0.95	13.58	0.6	1.14e-33	Parkinson's disease;
CRC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg17545662	chr6:170176663	C6orf70	0.57	6.4	0.33	5.21e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs4276421	0.837	rs7727890	chr5:45478771	G/A	cg04793272	chr11:119020941	ABCG4	-0.39	-6.53	-0.34	2.5e-10	P wave duration;
CRC	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.43	-0.33	4.52e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.65	-8.49	-0.42	7.09e-16	Immature fraction of reticulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06843320	chr6:27791727	HIST1H4J	0.45	6.33	0.33	8.18e-10	Response to antipsychotic treatment;
CRC	cis	rs4237845	0.562	rs7133278	chr12:58336066	C/A	cg02175503	chr12:58329896	NA	0.76	11.84	0.55	3.43e-27	Intelligence (multi-trait analysis);
CRC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg15465823	chr12:48382534	COL2A1	-0.38	-6.3	-0.33	9.29e-10	Glycated hemoglobin levels;
CRC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.99	-0.4	2.35e-14	Hemoglobin concentration;
CRC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg07274523	chr3:49395745	GPX1	0.46	5.93	0.31	7.68e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs10504390	0.656	rs76624481	chr8:66551779	C/T	cg26403416	chr21:43771339	TFF2	0.59	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg03938978	chr2:103052716	IL18RAP	0.41	6.53	0.34	2.51e-10	Blood protein levels;
CRC	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg14768367	chr16:72042858	DHODH	-0.49	-5.71	-0.3	2.56e-8	Blood protein levels;
CRC	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	5.75	0.3	2.01e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.74	11.13	0.52	1.27e-24	Testicular germ cell tumor;
CRC	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	1.08	12.7	0.57	2.48e-30	Blood pressure (smoking interaction);
CRC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.46	6.73	0.35	7.73e-11	Colorectal cancer;
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg12172441	chr6:28176163	NA	0.55	7.43	0.38	9.48e-13	Parkinson's disease;
CRC	cis	rs7739232	0.920	rs77374381	chr6:53530662	A/G	cg15658676	chr6:53530538	KLHL31	-0.76	-5.91	-0.31	8.68e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.46	6.34	0.33	7.42e-10	Type 2 diabetes;
CRC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg23136738	chr11:925521	AP2A2	-0.4	-6.56	-0.34	2.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg02683197	chr6:28174875	NA	0.68	6.72	0.35	8.24e-11	Lung cancer in ever smokers;
CRC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.61	9.59	0.47	2.36e-19	Vitiligo;
CRC	cis	rs995000	0.965	rs1168046	chr1:62983693	A/C	cg19896129	chr1:63156450	NA	-0.44	-6.91	-0.36	2.57e-11	Triglyceride levels;
CRC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg11189052	chr15:85197271	WDR73	0.57	8.22	0.41	4.83e-15	Schizophrenia;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.7	-11.23	-0.53	5.51e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg00631329	chr6:26305371	NA	-0.53	-8.79	-0.44	8.19e-17	Educational attainment;
CRC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg17294928	chr15:75287854	SCAMP5	-0.43	-6.36	-0.33	6.67e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.75	12.26	0.56	1.03e-28	Breast cancer;
CRC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.54	-7.55	-0.38	4.43e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.53	-11.4	-0.53	1.39e-25	Longevity;Endometriosis;
CRC	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg10279832	chr4:154682576	RNF175	0.38	5.79	0.3	1.65e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg13057898	chr1:3703894	LRRC47	0.57	7.69	0.39	1.69e-13	Red cell distribution width;
CRC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.27	0.41	3.31e-15	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00449941	chr17:26926011	SPAG5	0.42	6.22	0.32	1.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.69	0.3	2.79e-8	Axial length;
CRC	cis	rs1223397	0.651	rs488297	chr6:13300496	C/T	cg07912922	chr6:13274314	PHACTR1	0.36	5.61	0.3	4.19e-8	Blood pressure;
CRC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.62	-9.21	-0.45	3.85e-18	Menarche (age at onset);
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg09877947	chr5:131593287	PDLIM4	0.4	7.65	0.39	2.28e-13	Blood metabolite levels;
CRC	cis	rs3015497	0.789	rs8003372	chr14:51102351	G/A	cg09863266	chr14:51125203	SAV1	-0.33	-6.32	-0.33	8.75e-10	Mean platelet volume;
CRC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.15	-16.84	-0.68	2.44e-46	Hip circumference adjusted for BMI;
CRC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.31	-0.37	2.1e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg18512352	chr11:47633146	NA	-0.4	-7.75	-0.39	1.18e-13	Subjective well-being;
CRC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.53	7.92	0.4	3.58e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.55	8.08	0.41	1.25e-14	Cognitive ability;
CRC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.6	-11.03	-0.52	2.89e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-6.14	-0.32	2.34e-9	Colorectal cancer;
CRC	trans	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg21302420	chr1:112162376	RAP1A	0.81	7.43	0.38	9.4e-13	Skin colour saturation;
CRC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	trans	rs2303319	0.504	rs12473497	chr2:162433766	T/C	cg00039960	chr17:7142925	PHF23	-0.73	-6.0	-0.31	5.26e-9	Cognitive function;
CRC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.75	0.35	6.84e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-9.01	-0.44	1.69e-17	Hip circumference adjusted for BMI;
CRC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.54	-7.11	-0.36	7.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.85	-12.62	-0.57	4.71e-30	Gut microbiome composition (summer);
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg05192639	chr6:26864778	GUSBL1	-0.34	-5.93	-0.31	7.53e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02897623	chr16:89626761	RPL13;SNORD68	0.42	6.01	0.31	4.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.61	9.56	0.47	2.91e-19	Height;
CRC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.62e-9	Life satisfaction;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-6.97	-0.36	1.74e-11	Menarche (age at onset);
CRC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg06204229	chr3:52865917	ITIH4	0.5	5.7	0.3	2.67e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.35	6.09	0.32	3.22e-9	Schizophrenia;
CRC	cis	rs6968419	0.755	rs73452247	chr7:115893897	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.48e-10	Intraocular pressure;
CRC	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg23387468	chr7:139079360	LUC7L2	-0.4	-6.96	-0.36	1.79e-11	Diisocyanate-induced asthma;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg06700871	chr2:84686330	SUCLG1	-0.51	-6.02	-0.31	4.6e-9	Type 1 diabetes;
CRC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.53	-0.34	2.5e-10	Blood metabolite levels;
CRC	cis	rs972578	0.967	rs738391	chr22:43339878	A/G	cg01576275	chr22:43409880	NA	-0.45	-7.24	-0.37	3.23e-12	Mean platelet volume;
CRC	cis	rs4731207	0.596	rs7786384	chr7:124577270	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.61	9.12	0.45	7.81e-18	Lung cancer;
CRC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg00601486	chr12:48723148	H1FNT	0.33	5.98	0.31	5.8e-9	Glycated hemoglobin levels;
CRC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg25767906	chr1:53392781	SCP2	0.47	7.49	0.38	6.24e-13	Monocyte count;
CRC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.15	-0.41	7.66e-15	Morning vs. evening chronotype;
CRC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg10398005	chr11:117014888	PAFAH1B2	-0.4	-5.72	-0.3	2.41e-8	Blood protein levels;
CRC	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.43	6.12	0.32	2.67e-9	Body mass index;
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg24463073	chr6:118973353	C6orf204	0.52	6.83	0.35	4.1e-11	Diastolic blood pressure;
CRC	cis	rs2415984	0.622	rs61993303	chr14:46949716	G/C	cg14871534	chr14:47121158	RPL10L	-0.45	-6.42	-0.33	4.84e-10	Number of children ever born;
CRC	cis	rs3889199	1.000	rs12739770	chr1:59655744	A/G	cg25881383	chr1:59680599	NA	-0.36	-5.84	-0.31	1.23e-8	Pulse pressure;
CRC	cis	rs34638657	0.500	rs7405197	chr16:82169833	C/A	cg07918374	chr16:82182319	MPHOSPH6	0.4	5.64	0.3	3.65e-8	Lung adenocarcinoma;
CRC	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.81	-0.4	7.94e-14	Homocysteine levels;
CRC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11226613	0.547	rs1792762	chr11:104960976	C/T	cg04181079	chr11:104896587	CASP1	0.42	5.7	0.3	2.7e-8	Bronchopulmonary dysplasia;
CRC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.48	8.36	0.42	1.84e-15	Primary biliary cholangitis;
CRC	trans	rs194045	0.609	rs252344	chr16:29184882	G/A	cg17334114	chr3:133646504	NA	0.47	6.24	0.33	1.34e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7259376	0.936	rs1865075	chr19:22554854	T/C	cg02657401	chr19:22469223	NA	-0.33	-7.15	-0.37	5.7e-12	Menopause (age at onset);
CRC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.49	-7.99	-0.4	2.23e-14	Body mass index;
CRC	cis	rs911119	0.818	rs12625182	chr20:23604023	G/T	cg16589663	chr20:23618590	CST3	0.45	6.35	0.33	7.19e-10	Chronic kidney disease;
CRC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg21620606	chr4:1342894	KIAA1530	0.34	5.62	0.3	4.15e-8	Obesity-related traits;
CRC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.47	-6.86	-0.35	3.4e-11	Blood pressure (smoking interaction);
CRC	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.65	-7.76	-0.39	1.06e-13	Menarche (age at onset);
CRC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-8.59	-0.43	3.44e-16	Dental caries;
CRC	cis	rs11955398	0.625	rs10805370	chr5:59984244	A/T	cg02684056	chr5:59996105	DEPDC1B	0.4	5.85	0.31	1.21e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-6.81	-0.35	4.63e-11	Platelet distribution width;
CRC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg07130601	chr7:158766826	NA	-0.4	-5.83	-0.31	1.3e-8	Facial morphology (factor 20);
CRC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.98	-0.4	2.4e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.19	-0.37	4.47e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.64	11.84	0.55	3.53e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.74	-11.08	-0.52	1.87e-24	Waist circumference;Body mass index;
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg16606324	chr3:10149918	C3orf24	-0.58	-7.2	-0.37	4.02e-12	Alzheimer's disease;
CRC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-8.08	-0.41	1.25e-14	Breast cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24201716	chr10:115933917	C10orf118;MIR2110	0.45	6.24	0.33	1.37e-9	Survival in pancreatic cancer;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg27094323	chr7:1216898	NA	-0.4	-6.61	-0.34	1.52e-10	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04132851	chr1:85155548	SSX2IP	0.44	6.19	0.32	1.8e-9	Response to antipsychotic treatment;
CRC	cis	rs55675132	0.510	rs12120851	chr1:115262845	T/C	cg12756093	chr1:115239321	AMPD1	0.52	6.26	0.33	1.23e-9	Schizophrenia;
CRC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.5	-7.63	-0.39	2.49e-13	Aortic root size;
CRC	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg04176472	chr15:90893244	GABARAPL3	0.36	6.26	0.33	1.17e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg15786705	chr6:28176104	NA	0.73	9.31	0.46	1.85e-18	Depression;
CRC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.42	-6.41	-0.33	5.03e-10	Height;
CRC	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs12580194	0.593	rs11171435	chr12:55758053	T/C	cg19537932	chr12:55886519	OR6C68	-0.67	-8.84	-0.44	6.1e-17	Cancer;
CRC	cis	rs9549328	0.616	rs35086993	chr13:113617305	G/A	cg17524180	chr13:113633600	MCF2L	0.52	9.51	0.46	4.24e-19	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12172441	chr6:28176163	NA	0.6	7.19	0.37	4.46e-12	Depression;
CRC	cis	rs9900062	1.000	rs11871616	chr17:62737602	C/T	cg02598441	chr17:62777298	LOC146880	-0.57	-7.69	-0.39	1.69e-13	QT interval;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.67	-0.34	1.11e-10	Obesity-related traits;
CRC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg11189052	chr15:85197271	WDR73	0.53	7.58	0.39	3.57e-13	Schizophrenia;
CRC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.89	0.4	4.43e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.49	6.58	0.34	1.81e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.23	15.05	0.64	2.68e-39	Eosinophil percentage of granulocytes;
CRC	trans	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg21153622	chr11:89784906	NA	0.44	7.01	0.36	1.34e-11	HDL cholesterol;
CRC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg17321639	chr7:2759063	NA	-0.51	-6.79	-0.35	5.18e-11	Height;
CRC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.83	-16.58	-0.67	2.53e-45	Post bronchodilator FEV1;
CRC	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.95	-0.55	1.37e-27	Coffee consumption (cups per day);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23888375	chr2:203776317	ALS2CR8;WDR12	0.41	6.31	0.33	9.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.35	-5.95	-0.31	7.05e-9	Monocyte count;
CRC	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.55	7.1	0.36	7.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4964805	1.000	rs12228207	chr12:104196734	T/C	cg02344784	chr12:104178138	NT5DC3	0.5	7.0	0.36	1.41e-11	Attention deficit hyperactivity disorder;
CRC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.43	6.87	0.35	3.18e-11	Resting heart rate;
CRC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	0.76	6.1	0.32	2.92e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg13722127	chr7:150037890	RARRES2	0.39	5.69	0.3	2.86e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg04497992	chr16:616212	NHLRC4	0.42	6.57	0.34	2e-10	Height;
CRC	cis	rs2386661	0.826	rs4749922	chr10:5680689	A/G	cg26603656	chr10:5671107	NA	0.53	8.9	0.44	3.87e-17	Breast cancer;
CRC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.28e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.55	8.44	0.42	1e-15	Diastolic blood pressure;
CRC	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.49	-7.52	-0.38	5.23e-13	Type 2 diabetes;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18402987	chr7:1209562	NA	0.48	6.93	0.36	2.19e-11	Longevity;Endometriosis;
CRC	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.55	-5.72	-0.3	2.4e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14159672	chr1:205819179	PM20D1	0.42	5.7	0.3	2.65e-8	Parkinson's disease;
CRC	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.51	9.29	0.46	2.13e-18	Age-related hearing impairment;
CRC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.51	-5.76	-0.3	1.93e-8	Diabetic retinopathy;
CRC	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.54	-7.31	-0.37	2.04e-12	Triglycerides;
CRC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg02560186	chr11:3602584	NA	-0.56	-6.98	-0.36	1.63e-11	Blood pressure (smoking interaction);
CRC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-17.15	-0.69	1.51e-47	Electrocardiographic conduction measures;
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.31	-0.33	9.2e-10	Bipolar disorder;
CRC	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.51	-7.51	-0.38	5.79e-13	Uric acid levels;
CRC	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02902865	chr1:12679132	DHRS3	0.52	6.83	0.35	4.14e-11	Thyroid stimulating hormone;
CRC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.57	8.33	0.42	2.16e-15	Aortic root size;
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.05	0.36	1.04e-11	Life satisfaction;
CRC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.37	5.81	0.3	1.51e-8	Height;
CRC	cis	rs6504622	0.818	rs9303532	chr17:45034002	C/T	cg16759221	chr17:45003025	GOSR2	0.5	7.55	0.38	4.38e-13	Orofacial clefts;
CRC	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg26596964	chr10:102495354	NA	-0.41	-5.65	-0.3	3.4e-8	Alzheimer's disease;
CRC	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.51	-0.34	2.83e-10	Systemic lupus erythematosus;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04296434	chr20:48769996	TMEM189;TMEM189-UBE2V1	0.44	6.41	0.33	4.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17095355	0.786	rs61624875	chr10:111722489	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.36	-0.42	1.74e-15	Biliary atresia;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg27635394	chr6:26043820	HIST1H2BB	0.43	6.35	0.33	7.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.65	0.57	3.81e-30	Alzheimer's disease;
CRC	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.07	-15.14	-0.64	1.2e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.4	5.61	0.3	4.35e-8	Rheumatoid arthritis;
CRC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg09264619	chr17:80180166	NA	0.51	7.3	0.37	2.17e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.32e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg02376097	chr19:46275166	DMPK	0.36	5.79	0.3	1.66e-8	Coronary artery disease;
CRC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg11212589	chr17:38028394	ZPBP2	0.33	5.77	0.3	1.8e-8	Asthma;
CRC	cis	rs1223397	0.651	rs2496145	chr6:13312293	C/T	cg20827128	chr6:13274284	PHACTR1	-0.37	-5.7	-0.3	2.71e-8	Blood pressure;
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.82	-0.4	7.16e-14	Bipolar disorder;
CRC	cis	rs7113874	0.610	rs11041924	chr11:8463107	C/T	cg20771178	chr11:8615675	STK33	-0.35	-5.78	-0.3	1.71e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg11212589	chr17:38028394	ZPBP2	-0.44	-8.36	-0.42	1.76e-15	Self-reported allergy;
CRC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.47	8.19e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	6.17	0.32	1.96e-9	Axial length;
CRC	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg15848620	chr12:58087721	OS9	-0.6	-8.33	-0.42	2.17e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.28e-36	Colorectal cancer;
CRC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.72	-8.14	-0.41	8.04e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs1555895	0.656	rs61831439	chr10:840244	A/G	cg10556349	chr10:835070	NA	-0.38	-7.2	-0.37	4.23e-12	Survival in rectal cancer;
CRC	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.51	5.82	0.31	1.37e-8	Schizophrenia;
CRC	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg04362960	chr10:104952993	NT5C2	-0.49	-6.34	-0.33	7.39e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.39	7.04	0.36	1.15e-11	Obesity-related traits;
CRC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.45	-0.38	8.29e-13	Height;
CRC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	0.9	11.98	0.55	1.05e-27	Vitiligo;
CRC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.05	0.45	1.25e-17	Personality dimensions;
CRC	trans	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	0.99	12.3	0.56	7.43e-29	Iron status biomarkers;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06635431	chr1:33283895	YARS;S100PBP	0.42	6.11	0.32	2.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg24046110	chr8:143859143	LYNX1	0.73	12.98	0.58	2.09e-31	Urinary tract infection frequency;
CRC	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg11204139	chr17:3907470	NA	-0.49	-6.2	-0.32	1.68e-9	Type 2 diabetes;
CRC	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg06287003	chr12:125626642	AACS	-0.58	-7.05	-0.36	1.04e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.49	-0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02290350	chr8:58132656	NA	-0.61	-6.94	-0.36	2.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.79	0.3	1.68e-8	IgG glycosylation;
CRC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-7.81	-0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg16077055	chr2:106428750	NCK2	0.4	5.77	0.3	1.87e-8	Addiction;
CRC	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-7.03	-0.36	1.2e-11	Tuberculosis;
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.37	-0.33	6.46e-10	Total body bone mineral density;
CRC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.87	14.08	0.61	1.47e-35	Multiple system atrophy;
CRC	cis	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.59	5.88	0.31	1.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.94	0.31	7.16e-9	Total body bone mineral density;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.71	-11.35	-0.53	1.97e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.92	0.31	7.98e-9	Monocyte percentage of white cells;
CRC	trans	rs10021731	0.718	rs1870655	chr4:115412781	C/T	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.71	7.58	0.39	3.45e-13	Breast cancer;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg26587870	chr6:27730563	NA	-0.67	-6.29	-0.33	1.04e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs55788414	0.932	rs12102691	chr16:81181460	G/T	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.7	-0.35	9.27e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs501120	0.584	rs7097076	chr10:44701352	C/A	cg09554077	chr10:44749378	NA	0.69	7.87	0.4	5.01e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.65	-10.72	-0.51	3.29e-23	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.71	-11.37	-0.53	1.8e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.09	-0.49	4.87e-21	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.12	0.37	6.93e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.47	7.57	0.38	3.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.03	0.32	4.38e-9	Diabetic retinopathy;
CRC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27118876	chr15:92397541	SLCO3A1	0.39	6.1	0.32	3.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	7.02	0.36	1.27e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.43	7.11	0.37	7.14e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg26816564	chr1:7831052	VAMP3	0.49	5.67	0.3	3.12e-8	Inflammatory bowel disease;
CRC	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-10.66	-0.51	5.62e-23	Idiopathic membranous nephropathy;
CRC	cis	rs12024301	0.557	rs12033433	chr1:183594279	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.58	-9.17	-0.45	5.41e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-6.36	-0.33	6.79e-10	Lymphocyte counts;
CRC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.44	9.1	0.45	8.59e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.5	-0.46	4.5e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.04	0.32	4.08e-9	Bladder cancer;
CRC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.58	9.11	0.45	8.49e-18	Gestational age at birth (maternal effect);
CRC	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.07	-0.71	3.63e-51	Schizophrenia;
CRC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.41	7.1	0.36	7.63e-12	Height;
CRC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.33	-0.42	2.14e-15	Hemoglobin concentration;
CRC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.16	-13.46	-0.6	3.35e-33	Diabetic kidney disease;
CRC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.64	-0.34	1.29e-10	Response to antipsychotic treatment;
CRC	cis	rs2882667	0.838	rs11958529	chr5:138395068	C/T	cg09476006	chr5:138032270	NA	0.44	7.51	0.38	5.68e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg13206674	chr6:150067644	NUP43	0.67	9.62	0.47	1.84e-19	Lung cancer;
CRC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.42	8.63	0.43	2.58e-16	Intelligence (multi-trait analysis);
CRC	cis	rs10919791	0.501	rs4915189	chr1:199916450	C/A	cg13229857	chr1:200006247	NR5A2	0.43	6.51	0.34	2.89e-10	Pancreatic cancer;
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.73e-9	Life satisfaction;
CRC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs9462027	0.630	rs9469871	chr6:34745007	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs7692995	1.000	rs73098845	chr4:17940718	C/A	cg08925142	chr4:18023851	LCORL	-0.53	-5.84	-0.31	1.27e-8	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14967814	chr3:179041370	ZNF639	0.4	6.01	0.31	4.89e-9	Intelligence (multi-trait analysis);
CRC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-20.54	-0.75	6.41e-61	Hemostatic factors and hematological phenotypes;
CRC	cis	rs73206853	0.841	rs56130410	chr12:110824112	C/T	cg12870014	chr12:110450643	ANKRD13A	0.8	7.68	0.39	1.89e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg26061582	chr7:22766209	IL6	0.55	8.3	0.42	2.74e-15	Lung cancer;
CRC	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.89	-0.31	9.69e-9	Rheumatoid arthritis;
CRC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.84	0.31	1.27e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.17	-0.41	6.79e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00974835	chr14:74960278	NPC2;ISCA2	0.38	6.24	0.33	1.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-7.67	-0.39	2.01e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12476592	0.571	rs68183503	chr2:63802888	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-6.44	-0.33	4.2e-10	Menarche (age at onset);
CRC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.53	-7.9	-0.4	4.28e-14	Coronary artery disease;
CRC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.89	-0.31	9.64e-9	Aortic root size;
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs7605827	0.836	rs1549016	chr2:15616859	G/A	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-6.84	-0.35	3.77e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08102688	chr12:49463918	RHEBL1	0.47	6.56	0.34	2.06e-10	Anxiety disorder;
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.5	0.54	5.71e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17658546	chr4:90032747	TIGD2	0.46	6.47	0.34	3.64e-10	Response to antipsychotic treatment;
CRC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.53	-7.2	-0.37	4e-12	Monocyte percentage of white cells;
CRC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.41	0.33	4.95e-10	Diastolic blood pressure;
CRC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg18721089	chr20:30220636	NA	0.55	8.23	0.41	4.3e-15	Mean corpuscular hemoglobin;
CRC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.33	-5.62	-0.3	4.12e-8	Aortic root size;
CRC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.32e-13	Corneal astigmatism;
CRC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.45	-7.17	-0.37	4.89e-12	Neurofibrillary tangles;
CRC	cis	rs4547160	0.888	rs10877953	chr12:63488462	C/T	cg26727693	chr12:63544175	AVPR1A	0.46	9.28	0.46	2.32e-18	Morning vs. evening chronotype;
CRC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.52	-7.81	-0.4	7.86e-14	Body mass index;
CRC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg01320579	chr17:75405842	SEPT9	-0.36	-5.76	-0.3	1.88e-8	Airflow obstruction;
CRC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-7.05	-0.36	1.03e-11	Alzheimer's disease (late onset);
CRC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.79	0.3	1.64e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.9	0.31	8.93e-9	Hemoglobin concentration;
CRC	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg08999081	chr20:33150536	PIGU	0.46	5.68	0.3	3.01e-8	Neuroticism;
CRC	cis	rs9443645	0.611	rs10943616	chr6:79823541	G/A	cg09184832	chr6:79620586	NA	-0.39	-6.66	-0.34	1.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	8.48	0.42	7.52e-16	Rheumatoid arthritis;
CRC	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.93	0.36	2.23e-11	Cognitive test performance;
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.39	0.56	3.4e-29	Alzheimer's disease;
CRC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg15147215	chr3:52552868	STAB1	-0.56	-8.49	-0.42	7.14e-16	Bipolar disorder;
CRC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.32	-0.33	8.58e-10	Diabetic kidney disease;
CRC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.51e-34	Menopause (age at onset);
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.28	-0.33	1.09e-9	Lymphocyte counts;
CRC	cis	rs6496667	0.779	rs7169182	chr15:91024343	C/G	cg04176472	chr15:90893244	GABARAPL3	0.53	7.75	0.39	1.15e-13	Rheumatoid arthritis;
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg11843238	chr5:131593191	PDLIM4	0.33	5.78	0.3	1.72e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.78	-0.7	4.88e-50	Height;
CRC	cis	rs7705042	0.865	rs449454	chr5:141533062	A/G	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.72	-0.3	2.4e-8	Asthma;
CRC	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg13057898	chr1:3703894	LRRC47	0.54	7.06	0.36	9.71e-12	Red cell distribution width;
CRC	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg14593290	chr7:50529359	DDC	-0.44	-6.08	-0.32	3.34e-9	Systemic sclerosis;
CRC	trans	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg00953403	chr17:74099816	EXOC7	0.49	7.33	0.37	1.75e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.89	7.64	0.39	2.44e-13	Type 2 diabetes nephropathy;
CRC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.48	-6.15	-0.32	2.26e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.61	7.6	0.39	3.08e-13	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	1.02	12.44	0.57	2.13e-29	Iron status biomarkers;
CRC	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.48	6.86	0.35	3.32e-11	Primary sclerosing cholangitis;
CRC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.45	-7.6	-0.39	3.02e-13	Height;
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.53	-9.75	-0.47	6.88e-20	Bipolar disorder;
CRC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.57	8.31	0.42	2.53e-15	Prostate cancer;
CRC	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.14	0.56	2.78e-28	Coffee consumption (cups per day);
CRC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.53	8.41	0.42	1.22e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg17298326	chr8:142245477	NA	-0.38	-5.79	-0.3	1.61e-8	Immature fraction of reticulocytes;
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.52	-8.13	-0.41	9.09e-15	Blood pressure (smoking interaction);
CRC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.53	-9.04	-0.45	1.42e-17	Tonsillectomy;
CRC	cis	rs3736485	0.609	rs11638154	chr15:51969416	C/T	cg08986416	chr15:51914746	DMXL2	-0.39	-5.66	-0.3	3.3e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8106542	0.789	rs10420809	chr19:10727014	A/G	cg17710535	chr19:10819994	QTRT1	-0.42	-5.93	-0.31	7.51e-9	Platelet distribution width;
CRC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.65	9.59	0.47	2.27e-19	Menopause (age at onset);
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	5.1e-12	Life satisfaction;
CRC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.57	-9.75	-0.47	7.01e-20	Aortic root size;
CRC	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg06307176	chr5:131281290	NA	-0.42	-6.21	-0.32	1.57e-9	Life satisfaction;
CRC	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.74	10.59	0.5	9.48e-23	Type 2 diabetes;
CRC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.35	5.61	0.3	4.3e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.4	5.85	0.31	1.16e-8	Acne (severe);
CRC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg14074117	chr16:1909714	C16orf73	-0.35	-6.03	-0.32	4.35e-9	Insulin-like growth factors;
CRC	trans	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg02512902	chr17:25799447	KSR1	0.4	6.0	0.31	5.23e-9	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg02319466	chr17:76381040	PGS1	0.39	6.18	0.32	1.88e-9	HDL cholesterol levels;
CRC	cis	rs6691722	0.503	rs2274167	chr1:24707296	C/T	cg02336364	chr1:24764700	NIPAL3	0.38	6.34	0.33	7.67e-10	Response to interferon beta in multiple sclerosis;
CRC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.2	0.49	2.1e-21	Heart rate;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23057943	chr5:137877800	ETF1	0.42	6.27	0.33	1.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.54	-8.79	-0.44	8.53e-17	Neurofibrillary tangles;
CRC	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.11	-0.32	2.85e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.58	-9.57	-0.47	2.68e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.57	7.84	0.4	6.2e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18252515	chr7:66147081	NA	0.39	5.62	0.3	4.1e-8	Aortic root size;
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg14003231	chr6:33640908	ITPR3	0.49	7.97	0.4	2.64e-14	Plateletcrit;
CRC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	1.97e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs7725052	0.609	rs11954069	chr5:40452233	T/A	cg09067459	chr5:40385259	NA	-0.4	-6.56	-0.34	2.05e-10	Pediatric autoimmune diseases;
CRC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.59	-9.14	-0.45	6.67e-18	Vitiligo;
CRC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg20243544	chr17:37824526	PNMT	0.55	8.45	0.42	9.24e-16	Asthma;
CRC	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.3	0.64	2.7e-40	Fuchs's corneal dystrophy;
CRC	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	1.12	9.65	0.47	1.47e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.41	0.38	1.06e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg11204139	chr17:3907470	NA	-0.76	-13.81	-0.61	1.55e-34	Type 2 diabetes;
CRC	trans	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.94	0.36	2.07e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.38	-6.85	-0.35	3.69e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.39	0.33	5.56e-10	Diabetic kidney disease;
CRC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg27489772	chr12:121021490	NA	-0.46	-5.93	-0.31	7.77e-9	Type 1 diabetes nephropathy;
CRC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.72	10.69	0.51	4.31e-23	Immature fraction of reticulocytes;
CRC	cis	rs3849570	0.533	rs6785385	chr3:81989850	A/G	cg07356753	chr3:81810745	GBE1	-0.48	-6.4	-0.33	5.35e-10	Waist circumference;Body mass index;
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.97	0.52	4.47e-24	Prudent dietary pattern;
CRC	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-6.14	-0.32	2.4e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs17362650	0.960	rs12469362	chr2:9618957	T/C	cg12832956	chr2:9616023	IAH1	-0.5	-6.13	-0.32	2.55e-9	Alcohol dependence (age at onset);
CRC	cis	rs2971970	0.519	rs6467513	chr7:133687565	T/G	cg03336402	chr7:133662267	EXOC4	-0.63	-9.24	-0.45	3.04e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg00387323	chr7:6746715	ZNF12	0.58	5.61	0.3	4.4e-8	Hematocrit;Hemoglobin concentration;
CRC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-7.99	-0.4	2.32e-14	Platelet count;
CRC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.62	-9.35	-0.46	1.42e-18	Cognitive function;
CRC	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.57	10.3	0.49	9.35e-22	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.42	-8.35	-0.42	1.91e-15	Vitiligo;
CRC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg27121462	chr16:89883253	FANCA	0.39	5.71	0.3	2.46e-8	Hemoglobin concentration;
CRC	trans	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg05376469	chr2:102649931	NA	-0.39	-6.12	-0.32	2.59e-9	Coronary artery disease;
CRC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.51e-10	Schizophrenia;
CRC	cis	rs1322512	0.917	rs2758781	chr6:153008828	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.68	13.11	0.59	7.01e-32	Bone mineral density;
CRC	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	0.62	9.7	0.47	9.8e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.41	6.42	0.33	4.9e-10	Monocyte count;
CRC	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg14458575	chr2:238380390	NA	0.71	9.96	0.48	1.38e-20	Prostate cancer;
CRC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.4	-6.05	-0.32	3.87e-9	Monocyte count;
CRC	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg00531865	chr16:30841666	NA	0.47	6.59	0.34	1.75e-10	Dementia with Lewy bodies;
CRC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	10.11	0.49	4.35e-21	HIV-1 control;
CRC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.54	-8.07	-0.41	1.29e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.74	11.12	0.52	1.29e-24	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12439463	chr17:79848761	ANAPC11;THOC4	0.45	6.27	0.33	1.16e-9	Response to antipsychotic treatment;
CRC	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg05935833	chr10:81318306	SFTPA2	-0.73	-8.0	-0.4	2.14e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg11189052	chr15:85197271	WDR73	0.63	8.81	0.44	7.35e-17	Schizophrenia;
CRC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-9.31	-0.46	1.87e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.98	-0.31	5.95e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.48	5.87	0.31	1.08e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg02376097	chr19:46275166	DMPK	0.37	5.89	0.31	9.66e-9	Coronary artery disease;
CRC	cis	rs4731207	0.698	rs2040926	chr7:124457295	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.13	-0.32	2.58e-9	Cutaneous malignant melanoma;
CRC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.51	6.84	0.35	3.87e-11	Gut microbiome composition (summer);
CRC	cis	rs9311676	0.632	rs62258126	chr3:58396114	T/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.5	-7.99	-0.4	2.23e-14	Osteoporosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04865480	chr2:173421027	PDK1	0.38	6.68	0.35	1.01e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	0.86	8.77	0.44	9.94e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-8.25	-0.41	3.95e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.43	-0.79	4.22e-72	Myeloid white cell count;
CRC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg14593290	chr7:50529359	DDC	-0.51	-7.65	-0.39	2.28e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23661578	chr6:42981936	MEA1;KLHDC3	0.37	6.08	0.32	3.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.63	-0.3	3.78e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	9.93	0.48	1.74e-20	Myopia (pathological);
CRC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.66	-11.21	-0.53	6.44e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs7730934	1.000	rs11741953	chr5:55267814	T/C	cg10323188	chr3:28613979	NA	0.52	6.11	0.32	2.84e-9	Blood protein levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24815885	chr19:36486437	SDHAF1	0.43	6.06	0.32	3.73e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.68	-9.79	-0.47	5.05e-20	Longevity;
CRC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	11.09	0.52	1.76e-24	Bone mineral density;
CRC	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.55	9.3	0.46	1.99e-18	Dupuytren's disease;
CRC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.65	-17.72	-0.7	8.7e-50	Urate levels in overweight individuals;
CRC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg06484146	chr7:12443880	VWDE	-0.64	-6.83	-0.35	4.2e-11	Coronary artery disease;
CRC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg27489772	chr12:121021490	NA	0.42	5.87	0.31	1.05e-8	Type 1 diabetes nephropathy;
CRC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-1.04	-12.03	-0.55	7.25e-28	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg22134325	chr11:66188745	NPAS4	0.28	5.65	0.3	3.39e-8	Airway imaging phenotypes;
CRC	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.43	0.33	4.57e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg11189052	chr15:85197271	WDR73	0.6	8.83	0.44	6.13e-17	Schizophrenia;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg12273811	chr6:28175739	NA	0.61	8.81	0.44	7.35e-17	Parkinson's disease;
CRC	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.53	-8.29	-0.42	2.99e-15	Depressive symptoms (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08611093	chr12:57856004	GLI1	0.43	6.5	0.34	2.95e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.77e-9	Alzheimer's disease (late onset);
CRC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27652795	chr2:219265373	CTDSP1	0.45	6.21	0.32	1.6e-9	Response to antipsychotic treatment;
CRC	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.66	8.45	0.42	9.62e-16	Breast cancer;
CRC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.46	7.74	0.39	1.27e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs6681460	1.000	rs6680876	chr1:67129482	G/A	cg02459107	chr1:67143332	SGIP1	0.47	8.26	0.41	3.48e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	10.02	0.48	8.68e-21	Mood instability;
CRC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Melanoma;
CRC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.79	-11.73	-0.54	8.56e-27	Mean platelet volume;Platelet distribution width;
CRC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg21153622	chr11:89784906	NA	-0.42	-6.97	-0.36	1.72e-11	Height;
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg02033258	chr5:131593261	PDLIM4	0.35	6.69	0.35	9.47e-11	Blood metabolite levels;
CRC	cis	rs282587	0.569	rs1278658	chr13:113386832	G/C	cg04656015	chr13:113407548	ATP11A	0.63	7.9	0.4	4.11e-14	Glycated hemoglobin levels;
CRC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.44	-9.76	-0.47	6.22e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.7	11.16	0.52	9.62e-25	Dental caries;
CRC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.67	9.02	0.45	1.59e-17	Breast cancer;
CRC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg00999904	chr2:3704751	ALLC	-0.43	-6.16	-0.32	2.09e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.47	7.2	0.37	4.06e-12	Mean platelet volume;
CRC	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26306683	chr17:18585705	ZNF286B	0.5	6.98	0.36	1.62e-11	Educational attainment (years of education);
CRC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.49	-6.83	-0.35	4.12e-11	Gut microbiome composition (summer);
CRC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.38	0.46	1.15e-18	Smoking initiation;
CRC	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg09455208	chr3:40491958	NA	0.43	8.37	0.42	1.72e-15	Renal cell carcinoma;
CRC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg22532475	chr10:104410764	TRIM8	0.35	6.52	0.34	2.68e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-6.47	-0.34	3.5e-10	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12273811	chr6:28175739	NA	0.71	9.07	0.45	1.08e-17	Depression;
CRC	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.72	-9.74	-0.47	7.35e-20	Pubertal anthropometrics;
CRC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.21	-0.37	3.78e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.75e-9	Major depressive disorder;
CRC	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-6.89	-0.35	2.93e-11	Eye color traits;
CRC	cis	rs11229555	0.645	rs10896814	chr11:58430699	T/C	cg15696309	chr11:58395628	NA	-0.72	-7.67	-0.39	1.9e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.85	12.42	0.57	2.56e-29	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg00343986	chr7:65444356	GUSB	0.46	6.5	0.34	3.03e-10	Calcium levels;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg12172441	chr6:28176163	NA	0.53	7.33	0.37	1.85e-12	Parkinson's disease;
CRC	cis	rs10807026	1	rs10807026	chr6:27555519	A/C	cg02683197	chr6:28174875	NA	-0.43	-5.66	-0.3	3.24e-8	Lung adenocarcinoma;
CRC	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg00105475	chr2:10696890	NA	-0.45	-7.18	-0.37	4.77e-12	Prostate cancer;
CRC	cis	rs9409565	0.559	rs11788395	chr9:97251382	T/C	cg04523069	chr9:97136363	HIATL1	0.43	5.8	0.3	1.57e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg25856811	chr1:152973957	SPRR3	-0.22	-5.84	-0.31	1.28e-8	Inflammatory skin disease;
CRC	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.26	-0.37	2.88e-12	Testicular germ cell tumor;
CRC	cis	rs9311676	0.656	rs6799077	chr3:58404096	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg11693508	chr17:37793320	STARD3	0.6	6.85	0.35	3.57e-11	Neuroticism;
CRC	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.61	-0.34	1.6e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09377915	chr6:56295593	NA	0.4	6.11	0.32	2.79e-9	Myopia (pathological);
CRC	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg25246084	chr19:4971487	KDM4B	-0.35	-5.94	-0.31	7.17e-9	Monocyte percentage of white cells;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg11843238	chr5:131593191	PDLIM4	-0.45	-7.55	-0.38	4.43e-13	Breast cancer;
CRC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.54	-0.34	2.33e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.46	6.07	0.32	3.51e-9	Thyroid stimulating hormone;
CRC	cis	rs2637266	0.562	rs35305451	chr10:78408479	A/G	cg18941641	chr10:78392320	NA	-0.35	-5.83	-0.31	1.3e-8	Pulmonary function;
CRC	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.71	-0.3	2.56e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	6.57	0.34	1.93e-10	Mean platelet volume;
CRC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.41	-7.29	-0.37	2.3e-12	Alzheimer's disease (late onset);
CRC	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07165851	chr6:158734300	TULP4	0.61	7.72	0.39	1.37e-13	Height;
CRC	cis	rs995000	0.535	rs12239736	chr1:63085997	T/A	cg19896129	chr1:63156450	NA	0.42	6.33	0.33	8.1e-10	Triglyceride levels;
CRC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.43	5.82	0.31	1.43e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.44	7.9	0.4	4.11e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-21.47	-0.76	1.46e-64	Primary sclerosing cholangitis;
CRC	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg03013999	chr17:37608204	MED1	0.48	7.57	0.39	3.75e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.78	13.59	0.6	1.04e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.45	-0.38	8.42e-13	Gut microbiome composition (summer);
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.71	-11.09	-0.52	1.76e-24	Intelligence (multi-trait analysis);
CRC	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.5	9.23	0.45	3.35e-18	Weight;
CRC	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg25019722	chr6:37503610	NA	-0.42	-6.88	-0.35	3.06e-11	Cognitive performance;
CRC	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.44	-6.31	-0.33	9.05e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs860295	0.702	rs10908471	chr1:155542942	A/G	cg02153340	chr1:155202674	NA	-0.58	-6.75	-0.35	6.59e-11	Body mass index;
CRC	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.64	-8.72	-0.43	1.4e-16	Blood trace element (Cu levels);
CRC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg20243544	chr17:37824526	PNMT	0.56	8.53	0.43	5.39e-16	Asthma;
CRC	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	14.21	0.62	4.54e-36	Exhaled nitric oxide output;
CRC	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.39	6.02	0.32	4.54e-9	Endometrial cancer;
CRC	trans	rs867371	0.519	rs1566559	chr15:82524461	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.08	-0.32	3.32e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.51	-6.23	-0.32	1.41e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17767392	0.846	rs4899394	chr14:71773497	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.04	-0.32	4.09e-9	Mitral valve prolapse;
CRC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.47	-7.83	-0.4	6.67e-14	Breast cancer;
CRC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	9.94	0.48	1.54e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23439141	chr13:113951774	LAMP1	0.39	6.15	0.32	2.29e-9	Interleukin-6 levels;
CRC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg03037974	chr15:76606532	NA	0.69	11.95	0.55	1.36e-27	Blood metabolite levels;
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.39	6.82	0.35	4.47e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.95e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg11822372	chr1:151115635	SEMA6C	0.53	7.54	0.38	4.48e-13	Childhood ear infection;
CRC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.47	7.87	0.4	5.31e-14	Breast cancer;
CRC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.07	-0.36	9.19e-12	Response to antipsychotic treatment;
CRC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.4	0.42	1.34e-15	Height;
CRC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.55	8.78	0.44	9.33e-17	Mean corpuscular hemoglobin concentration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14657818	chr2:8822058	ID2	0.45	6.24	0.33	1.36e-9	Anxiety disorder;
CRC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.85	15.86	0.66	1.74e-42	Height;
CRC	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.52	9.14	0.45	6.57e-18	Common traits (Other);
CRC	cis	rs9491140	0.539	rs12210199	chr6:124684045	C/A	cg19267163	chr6:125004984	NKAIN2	0.49	6.59	0.34	1.73e-10	Neuroticism;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.97e-9	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12744310	0.887	rs12728217	chr1:41798269	C/T	cg19175123	chr10:103411746	FBXW4	0.44	5.99	0.31	5.61e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg24289452	chr6:170231220	NA	-0.56	-6.31	-0.33	9.03e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg18187862	chr3:45730750	SACM1L	0.45	6.38	0.33	6.06e-10	Primary sclerosing cholangitis;
CRC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.14	-0.41	8.01e-15	Type 2 diabetes;
CRC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.5	9.05	0.45	1.27e-17	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22350171	chr1:228675139	RNF187	0.41	6.86	0.35	3.5e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.57	-5.93	-0.31	7.57e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.49	-9.5	-0.46	4.51e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.64	-10.8	-0.51	1.78e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.88	-0.4	4.9e-14	Neuroticism;
CRC	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg04850286	chr10:81895943	PLAC9	-0.38	-6.83	-0.35	4.2e-11	Sarcoidosis;
CRC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.82	14.95	0.64	6.37e-39	Anterior chamber depth;
CRC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.6	-8.39	-0.42	1.44e-15	DNA methylation (variation);
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23161317	chr6:28129485	ZNF389	0.48	5.8	0.3	1.58e-8	Depression;
CRC	cis	rs4692589	0.531	rs12650424	chr4:170975204	T/C	cg19918862	chr4:170955249	NA	0.49	6.43	0.33	4.46e-10	Anxiety disorder;
CRC	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.57	9.01	0.44	1.73e-17	Corneal astigmatism;
CRC	cis	rs883565	0.569	rs1274972	chr3:39161456	G/A	cg01426195	chr3:39028469	NA	-0.42	-7.0	-0.36	1.4e-11	Handedness;
CRC	cis	rs2179367	0.959	rs9373592	chr6:149733255	A/T	cg16235748	chr6:149772707	ZC3H12D	-0.36	-5.76	-0.3	1.94e-8	Dupuytren's disease;
CRC	cis	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg11143507	chr3:125485238	NA	-0.57	-7.35	-0.38	1.56e-12	Blood pressure (smoking interaction);
CRC	cis	rs1832871	0.521	rs62437411	chr6:158823211	G/A	cg07165851	chr6:158734300	TULP4	0.45	5.91	0.31	8.63e-9	Height;
CRC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	1.01	17.76	0.7	5.64e-50	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.89e-9	Life satisfaction;
CRC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.47	-6.87	-0.35	3.2e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1048238	0.605	rs1889785	chr1:16348729	G/A	cg22431228	chr1:16359049	CLCNKA	-0.42	-8.62	-0.43	2.78e-16	Systolic blood pressure;
CRC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.01	0.72	6.89e-55	Prudent dietary pattern;
CRC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-15.85	-0.66	1.98e-42	Body mass index;
CRC	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.53	-7.55	-0.38	4.38e-13	Colorectal cancer;
CRC	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.69	9.73	0.47	7.59e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.4	-6.8	-0.35	5.07e-11	Mean arterial pressure;
CRC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.49	6.17	0.32	2.02e-9	Obesity-related traits;
CRC	cis	rs6743376	0.556	rs3820738	chr2:113819439	A/G	cg24553058	chr2:113831203	IL1F10	0.39	6.47	0.34	3.55e-10	Inflammatory biomarkers;
CRC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.63	7.74	0.39	1.24e-13	Type 2 diabetes nephropathy;
CRC	cis	rs6496667	1.000	rs6496666	chr15:90891662	T/C	cg04176472	chr15:90893244	GABARAPL3	0.57	8.81	0.44	7.13e-17	Rheumatoid arthritis;
CRC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg11070056	chr1:107600091	PRMT6	-0.4	-5.74	-0.3	2.1e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2252521	0.524	rs719675	chr7:29041931	C/G	cg11728747	chr7:29037910	CPVL	-0.49	-7.08	-0.36	8.94e-12	Cognitive performance;
CRC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.46	-0.34	3.85e-10	Tonsillectomy;
CRC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg12046867	chr14:103022105	NA	-0.77	-9.16	-0.45	5.82e-18	Platelet count;
CRC	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.19	0.67	9.15e-44	Electrocardiographic conduction measures;
CRC	cis	rs2882667	0.690	rs825677	chr5:138104770	T/C	cg09476006	chr5:138032270	NA	-0.56	-9.54	-0.47	3.28e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg09659197	chr4:152720779	NA	-0.51	-10.91	-0.52	7.18e-24	Intelligence (multi-trait analysis);
CRC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg08027265	chr7:2291960	NA	-0.36	-6.22	-0.32	1.51e-9	Schizophrenia;
CRC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg20243544	chr17:37824526	PNMT	0.54	8.25	0.41	3.87e-15	Asthma;
CRC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.93	18.98	0.72	9.12e-55	Menopause (age at onset);
CRC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.36	-5.61	-0.3	4.39e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs9584850	0.540	rs17574536	chr13:99171040	G/A	cg20487152	chr13:99095054	FARP1	0.45	5.84	0.31	1.23e-8	Neuroticism;
CRC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	6.4	0.33	5.41e-10	Breast cancer;
CRC	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg27398640	chr15:77910606	LINGO1	0.41	7.55	0.38	4.25e-13	Type 2 diabetes;
CRC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg20908204	chr19:46285434	DMPK	-0.35	-6.78	-0.35	5.64e-11	Coronary artery disease;
CRC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.68	7.52	0.38	5.14e-13	Vitiligo;
CRC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.1	26.74	0.83	1.69e-84	Testicular germ cell tumor;
CRC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.87	-0.35	3.16e-11	Blood metabolite levels;
CRC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg03395651	chr16:88107091	BANP	0.5	6.75	0.35	6.5500000000000006e-11	Menopause (age at onset);
CRC	cis	rs9648716	1.000	rs7776491	chr7:140605067	C/T	cg10747023	chr7:140774559	NA	0.45	5.89	0.31	9.29e-9	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg22134325	chr11:66188745	NPAS4	0.41	6.73	0.35	7.51e-11	Airway imaging phenotypes;
CRC	cis	rs3823572	0.542	rs61286514	chr7:133630693	G/A	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Intelligence (multi-trait analysis);
CRC	cis	rs12476592	0.602	rs262528	chr2:63903367	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.33	0.33	7.99e-10	Childhood ear infection;
CRC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.91	0.44	3.6e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg16898833	chr6:26189333	HIST1H4D	0.89	7.28	0.37	2.4e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.66	10.99	0.52	3.79e-24	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01141252	chr19:45251925	BCL3	0.47	6.56	0.34	2.13e-10	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg07125278	chr16:67683757	RLTPR	-0.46	-6.01	-0.31	4.91e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.5	0.38	6.17e-13	Height;
CRC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.15	-0.52	1.03e-24	Blood trace element (Zn levels);
CRC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.5	-0.38	6.16e-13	Coronary artery disease;
CRC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.61	-9.04	-0.45	1.34e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg18335740	chr13:41363409	SLC25A15	-0.55	-8.39	-0.42	1.48e-15	Lewy body disease;
CRC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.5	8.22	0.41	4.69e-15	Major depressive disorder;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.49	7.21	0.37	3.86e-12	Menopause (age at onset);
CRC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.52	-7.09	-0.36	8.45e-12	Iron status biomarkers;
CRC	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg23167259	chr10:102495509	NA	-0.49	-6.76	-0.35	6.28e-11	Alzheimer's disease;
CRC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.82	0.31	1.37e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10221833	0.602	rs355889	chr2:165634651	C/T	cg03182029	chr2:165697222	COBLL1	0.52	6.09	0.32	3.22e-9	Response to statin therapy;
CRC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.17	-13.23	-0.59	2.48e-32	Diabetic kidney disease;
CRC	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.66	0.43	2.14e-16	Coffee consumption (cups per day);
CRC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg10589385	chr1:150898437	SETDB1	0.3	6.08	0.32	3.34e-9	Melanoma;
CRC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.52	10.73	0.51	3.2e-23	Bipolar disorder;
CRC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.17	24.31	0.8	1.87e-75	IgG glycosylation;
CRC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.89	0.51	8.51e-24	Cognitive function;
CRC	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg23815491	chr16:72088622	HP	0.47	6.81	0.35	4.78e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.44	-6.89	-0.35	2.93e-11	Asthma;
CRC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.6	9.55	0.47	3.16e-19	Corneal astigmatism;
CRC	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.97	-0.31	6.08e-9	Diabetic kidney disease;
CRC	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.68	10.78	0.51	2.08e-23	Intelligence (multi-trait analysis);
CRC	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.26	11.71	0.54	1.03e-26	Prostate cancer;
CRC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.54	8.16	0.41	7.4e-15	Lymphocyte counts;
CRC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg08270630	chr22:50330655	NA	-0.41	-5.98	-0.31	5.85e-9	Schizophrenia;
CRC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg22110888	chr17:80059540	CCDC57	0.42	6.61	0.34	1.58e-10	Life satisfaction;
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.69	9.36	0.46	1.32e-18	Alzheimer's disease;
CRC	cis	rs7901135	0.962	rs9416746	chr10:60573753	G/T	cg23799393	chr10:60588674	BICC1	0.37	5.75	0.3	2.02e-8	Morning vs. evening chronotype;
CRC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.63	-0.34	1.38e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	7.2	0.37	4.11e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.61	6.56	0.34	2.05e-10	Vitiligo;
CRC	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4692589	0.556	rs2279267	chr4:170990053	A/G	cg19918862	chr4:170955249	NA	-0.47	-6.52	-0.34	2.64e-10	Anxiety disorder;
CRC	cis	rs7107770	1.000	rs34140247	chr11:125092360	G/A	cg27629782	chr11:125073726	PKNOX2	0.44	5.67	0.3	3.05e-8	Photic sneeze reflex;
CRC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.72	-8.15	-0.41	7.73e-15	Lung disease severity in cystic fibrosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08365438	chr10:21683093	NA	-0.38	-6.0	-0.31	5.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7487075	0.859	rs956910	chr12:46759788	A/G	cg22049899	chr12:47219821	SLC38A4	0.35	6.92	0.36	2.44e-11	Itch intensity from mosquito bite;
CRC	cis	rs75422866	0.717	rs73104143	chr12:48087232	C/A	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs2882667	0.654	rs700626	chr5:138117938	A/G	cg09476006	chr5:138032270	NA	-0.57	-9.77	-0.47	5.69e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.6	8.96	0.44	2.38e-17	Methadone dose in opioid dependence;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg08798685	chr6:27730294	NA	-0.4	-6.02	-0.32	4.56e-9	Parkinson's disease;
CRC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg05623727	chr3:50126028	RBM5	0.41	6.8	0.35	4.81e-11	Menarche (age at onset);
CRC	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg06632207	chr12:54070931	ATP5G2	0.41	7.03	0.36	1.18e-11	Height;
CRC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.65	-11.17	-0.52	8.86e-25	Brugada syndrome;
CRC	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg08992911	chr2:238395768	MLPH	0.61	6.13	0.32	2.53e-9	Prostate cancer;
CRC	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.19	-0.32	1.81e-9	Breast cancer;
CRC	cis	rs77861329	0.748	rs2334961	chr3:52173625	G/C	cg08692210	chr3:52188851	WDR51A	0.5	5.89	0.31	9.43e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.58	-10.81	-0.51	1.71e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.44	5.78	0.3	1.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.54	7.37	0.38	1.41e-12	Lung cancer;
CRC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.33	0.33	8.13e-10	Obesity-related traits;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg26587870	chr6:27730563	NA	-0.43	-6.69	-0.35	9.61e-11	Parkinson's disease;
CRC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.54	-8.38	-0.42	1.53e-15	Aortic root size;
CRC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.7	10.59	0.5	9.76e-23	Menopause (age at onset);
CRC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	10.89	0.51	8.71e-24	Total cholesterol levels;
CRC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.58	6.07	0.32	3.48e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg21851534	chr17:3907994	ZZEF1	0.36	6.01	0.31	4.8e-9	Type 2 diabetes;
CRC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.03	12.53	0.57	1.06e-29	Vitiligo;
CRC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg17724175	chr1:150552817	MCL1	-0.5	-8.07	-0.41	1.32e-14	Tonsillectomy;
CRC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.61	6.86	0.35	3.38e-11	Vitiligo;
CRC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg13628971	chr7:2884303	GNA12	0.43	6.5	0.34	2.99e-10	Height;
CRC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.74	-8.33	-0.42	2.15e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg08222913	chr3:52553049	STAB1	-0.41	-8.32	-0.42	2.38e-15	Electroencephalogram traits;
CRC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.48	8.0	0.4	2.1e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.5	7.12	0.37	6.72e-12	Caffeine consumption;
CRC	cis	rs2949837	0.581	rs1542819	chr7:45978059	T/C	cg21268650	chr7:45961089	IGFBP3	0.38	6.41	0.33	5.05e-10	Sitting height ratio;
CRC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.78	-0.47	5.21e-20	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.46	-0.34	3.75e-10	Aortic root size;
CRC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.16	25.92	0.82	1.73e-81	IgG glycosylation;
CRC	cis	rs6141769	0.542	rs28612490	chr20:31297568	G/A	cg13636640	chr20:31349939	DNMT3B	-0.38	-5.74	-0.3	2.12e-8	Subjective well-being;
CRC	cis	rs73200209	0.912	rs7969182	chr12:116612079	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.84	-0.31	1.27e-8	Total body bone mineral density;
CRC	cis	rs7553864	1.000	rs4551571	chr1:87614244	C/G	cg02083836	chr1:87617350	LOC339524	0.37	6.59	0.34	1.76e-10	Smoking behavior;
CRC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	9.66	0.47	1.33e-19	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07031794	chr2:26568949	SELI;GPR113	0.38	6.59	0.34	1.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.24	-0.41	4.2e-15	Hip circumference adjusted for BMI;
CRC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs7259376	0.714	rs4358065	chr19:22521132	A/G	cg02657401	chr19:22469223	NA	-0.38	-8.49	-0.42	7.42e-16	Menopause (age at onset);
CRC	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg08992911	chr2:238395768	MLPH	0.47	5.75	0.3	2.04e-8	Prostate cancer;
CRC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.79	14.22	0.62	4.1e-36	Breast cancer;
CRC	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.68	-11.02	-0.52	2.91e-24	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-8.58	-0.43	3.81e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.42	6.87	0.35	3.19e-11	Resting heart rate;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg17512474	chr5:149546335	CDX1	0.22	6.23	0.32	1.43e-9	Menarche (age at onset);
CRC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.95	0.44	2.65e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg15382696	chr6:118971807	C6orf204	0.6	7.67	0.39	1.9e-13	Renal cell carcinoma;
CRC	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.6	7.78	0.39	9.42e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.57	7.0	0.36	1.41e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.3	-0.33	9.28e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9549328	0.589	rs36164841	chr13:113616579	A/G	cg25790453	chr13:113633590	MCF2L	0.43	7.55	0.38	4.25e-13	Systolic blood pressure;
CRC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.53	8.3	0.42	2.69e-15	Height;
CRC	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	6.16	0.32	2.11e-9	Blood protein levels;
CRC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.37	5.6	0.3	4.48e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg17298326	chr8:142245477	NA	0.39	5.88	0.31	1.02e-8	Immature fraction of reticulocytes;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg03929089	chr4:120376271	NA	0.68	6.67	0.35	1.06e-10	Intraocular pressure;
CRC	cis	rs820218	0.926	rs820135	chr17:73674977	T/C	cg01973089	chr17:73647209	RECQL5	0.33	6.26	0.33	1.23e-9	Rotator cuff tears;
CRC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.48	-6.5	-0.34	3.02e-10	Colorectal cancer;
CRC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.75	11.99	0.55	9.62e-28	Blood protein levels;
CRC	cis	rs2257205	0.667	rs7342862	chr17:56816561	A/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs4664293	0.585	rs34385495	chr2:160512883	T/C	cg08347373	chr2:160653686	CD302	0.39	6.59	0.34	1.71e-10	Monocyte percentage of white cells;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg15664909	chr17:685709	GLOD4;RNMTL1	-0.7	-6.31	-0.33	8.85e-10	Cognitive function;
CRC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg14671364	chr1:107599128	PRMT6	0.6	8.07	0.41	1.33e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.57	9.7	0.47	9.94e-20	Dupuytren's disease;
CRC	trans	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.22	-0.32	1.48e-9	Aortic root size;
CRC	cis	rs9648716	1.000	rs1267616	chr7:140514131	A/G	cg10747023	chr7:140774559	NA	0.46	5.92	0.31	7.94e-9	Type 2 diabetes;
CRC	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.5	7.26	0.37	2.83e-12	Height;
CRC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg13319975	chr6:146136371	FBXO30	0.42	6.22	0.32	1.49e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg21465176	chr17:80358876	C17orf101	-0.51	-6.97	-0.36	1.72e-11	Temperament (bipolar disorder);
CRC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg16342193	chr10:102329863	NA	-0.33	-5.78	-0.3	1.72e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.7	0.35	9.12e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.66	-9.58	-0.47	2.47e-19	Type 2 diabetes;
CRC	cis	rs9322817	0.691	rs2499667	chr6:105319125	G/A	cg02098413	chr6:105308735	HACE1	0.43	8.49	0.42	7.27e-16	Thyroid stimulating hormone;
CRC	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg14003231	chr6:33640908	ITPR3	0.46	7.36	0.38	1.5e-12	Height;
CRC	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg12458913	chr13:53173898	NA	0.43	6.37	0.33	6.51e-10	Lewy body disease;
CRC	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg03929089	chr4:120376271	NA	0.63	6.01	0.31	4.92e-9	Axial length;
CRC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg15845792	chr6:28175446	NA	0.71	6.59	0.34	1.77e-10	Depression;
CRC	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.65	9.65	0.47	1.43e-19	Schizophrenia;
CRC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg23815491	chr16:72088622	HP	0.51	7.69	0.39	1.72e-13	Fibrinogen levels;
CRC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-6.17	-0.32	2.02e-9	IgG glycosylation;
CRC	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg27535305	chr1:53392650	SCP2	-0.44	-7.72	-0.39	1.44e-13	Monocyte count;
CRC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.08e-8	Aortic root size;
CRC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.53	7.69	0.39	1.76e-13	Uric acid levels;
CRC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg25251562	chr2:3704773	ALLC	-0.49	-6.14	-0.32	2.34e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17507749	chr15:85114479	UBE2QP1	0.62	8.8	0.44	7.98e-17	Schizophrenia;
CRC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg00717180	chr2:96193071	NA	-0.37	-6.1	-0.32	2.94e-9	HDL cholesterol;
CRC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16434002	chr17:42200994	HDAC5	-0.48	-6.61	-0.34	1.52e-10	Total body bone mineral density;
CRC	cis	rs941898	0.541	rs1951486	chr14:100607360	C/T	cg26002632	chr14:100625216	DEGS2	0.32	5.68	0.3	2.99e-8	White matter hyperintensity burden;
CRC	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.29	0.37	2.25e-12	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14751914	chr18:46477404	SMAD7	0.4	6.06	0.32	3.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.68	10.87	0.51	1.03e-23	Mean corpuscular hemoglobin;
CRC	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.7	-7.87	-0.4	5.18e-14	Response to hepatitis C treatment;
CRC	cis	rs6694672	1.000	rs1332669	chr1:197005883	C/T	cg13682187	chr1:196946512	CFHR5	0.43	6.89	0.36	2.85e-11	Asthma;
CRC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.61	8.97	0.44	2.29e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs9925964	0.869	rs749670	chr16:31088625	A/G	cg03418659	chr16:31128414	MYST1	0.47	6.74	0.35	7.01e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.75	-0.35	6.53e-11	Response to antipsychotic treatment;
CRC	cis	rs4930561	0.714	rs6591335	chr11:67976812	T/C	cg04465784	chr11:67976953	SUV420H1	-0.3	-6.01	-0.31	4.86e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs11212617	0.870	rs227078	chr11:108250381	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.62	0.34	1.5e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.42	6.82	0.35	4.42e-11	Alcohol dependence;
CRC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.81	14.06	0.61	1.72e-35	Breast cancer;
CRC	trans	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	1.0	18.91	0.72	1.68e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.43	5.86	0.31	1.13e-8	Diastolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16587794	chr15:69706675	KIF23	0.45	6.95	0.36	1.92e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.45	5.75	0.3	2.01e-8	Gut microbiome composition (summer);
CRC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.46	6.68	0.35	1.01e-10	Colorectal cancer;
CRC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.26	0.33	1.19e-9	Morning vs. evening chronotype;
CRC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs9549328	0.564	rs34556022	chr13:113617437	G/A	cg08614441	chr13:113633676	MCF2L	0.4	7.06	0.36	9.78e-12	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.93	-15.48	-0.65	5.67e-41	Longevity;
CRC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.68	13.27	0.59	1.78e-32	Coronary artery disease;
CRC	cis	rs812925	1.000	rs812925	chr2:61680993	C/G	cg10580144	chr2:61372316	C2orf74	-0.31	-6.5	-0.34	2.94e-10	Immature fraction of reticulocytes;
CRC	cis	rs672059	1.000	rs480132	chr1:183161779	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.16	0.37	5.19e-12	Hypertriglyceridemia;
CRC	cis	rs6479527	0.806	rs10761309	chr9:96753722	C/T	cg14459158	chr9:96720562	NA	-0.39	-7.08	-0.36	8.74e-12	Esophageal adenocarcinoma;
CRC	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg08314208	chr16:67682810	RLTPR	-0.52	-6.06	-0.32	3.73e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.61	8.23	0.41	4.42e-15	Schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03558408	chr5:134181967	C5orf24	-0.39	-6.21	-0.32	1.59e-9	Myopia (pathological);
CRC	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg21452805	chr1:244014465	NA	0.56	6.01	0.31	4.82e-9	RR interval (heart rate);
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg19041857	chr6:27730383	NA	0.41	5.97	0.31	6.27e-9	Parkinson's disease;
CRC	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.69	9.03	0.45	1.51e-17	Uric acid levels;
CRC	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg15192750	chr16:69999425	NA	0.56	7.27	0.37	2.67e-12	IgE levels;
CRC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg10978503	chr1:24200527	CNR2	0.62	11.34	0.53	2.2e-25	Immature fraction of reticulocytes;
CRC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.68	0.65	8.67e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg15309053	chr8:964076	NA	0.41	7.17	0.37	5.09e-12	Schizophrenia;
CRC	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.74	0.47	7.45e-20	Common traits (Other);
CRC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.46	7.08	0.36	8.82e-12	Schizophrenia;
CRC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg00603274	chr11:61596626	FADS2	0.45	6.67	0.35	1.08e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.61	-0.39	2.87e-13	Colorectal cancer;
CRC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.93	-0.48	1.71e-20	Chronic sinus infection;
CRC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.47	-6.43	-0.33	4.56e-10	Cognitive ability;
CRC	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg00531865	chr16:30841666	NA	0.47	6.77	0.35	5.97e-11	Dementia with Lewy bodies;
CRC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.42	0.33	4.85e-10	Tonsillectomy;
CRC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.61	-9.64	-0.47	1.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg21251018	chr6:28226885	NKAPL	0.45	6.51	0.34	2.73e-10	Parkinson's disease;
CRC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.15	0.45	6.27e-18	Hip circumference adjusted for BMI;
CRC	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.46	7.5	0.38	5.95e-13	Refractive error;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00553120	chr7:157129669	DNAJB6	0.46	6.45	0.34	4.1e-10	Anxiety disorder;
CRC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.06	-12.42	-0.56	2.67e-29	Diabetic kidney disease;
CRC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.52	7.6	0.39	3.03e-13	Coronary artery disease;
CRC	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.65	-10.44	-0.5	3.23e-22	Hepatocellular carcinoma;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg01305625	chr5:131593812	PDLIM4	0.32	5.74	0.3	2.15e-8	Blood metabolite levels;
CRC	cis	rs2933343	1.000	rs1683778	chr3:128644595	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-6.3	-0.33	9.3e-10	IgG glycosylation;
CRC	cis	rs867529	0.600	rs335120	chr2:89072731	A/G	cg26627705	chr2:89060884	NA	0.57	7.51	0.38	5.61e-13	Height;
CRC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.56	-9.14	-0.45	6.47e-18	Schizophrenia;
CRC	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.8	7.05	0.36	1.03e-11	Alzheimer's disease (late onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27431859	chr19:531042	CDC34	0.56	8.07	0.41	1.29e-14	Response to antipsychotic treatment;
CRC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg05139728	chr16:28306816	SBK1	-0.38	-6.23	-0.32	1.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07165851	chr6:158734300	TULP4	0.6	7.58	0.39	3.46e-13	Height;
CRC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.13	0.32	2.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06893537	chr18:47901419	SKA1	0.42	6.39	0.33	5.57e-10	Schizophrenia;
CRC	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg16898833	chr6:26189333	HIST1H4D	1.12	8.21	0.41	5.22e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg00071950	chr4:10020882	SLC2A9	0.39	5.66	0.3	3.22e-8	Psychosis and Alzheimer's disease;
CRC	cis	rs12980942	0.872	rs7248164	chr19:41807700	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.44	5.66	0.3	3.24e-8	Coronary artery disease;
CRC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg00647820	chr17:40259828	DHX58	-0.46	-6.48	-0.34	3.44e-10	Fibrinogen levels;
CRC	trans	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg24644049	chr4:85504048	CDS1	0.85	7.25	0.37	3.09e-12	Skin colour saturation;
CRC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg00601486	chr12:48723148	H1FNT	0.35	6.45	0.34	3.93e-10	Glycated hemoglobin levels;
CRC	cis	rs9463078	0.683	rs227847	chr6:44695493	A/G	cg25276700	chr6:44698697	NA	0.25	5.95	0.31	6.84e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg04110750	chr16:69646130	NFAT5	-0.52	-6.92	-0.36	2.3e-11	IgE levels;
CRC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.54	-7.45	-0.38	8.56e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.61	10.82	0.51	1.55e-23	Coronary artery disease;
CRC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg03909863	chr11:638404	DRD4	-0.53	-7.03	-0.36	1.17e-11	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23053741	chr5:72112459	TNPO1	0.37	6.16	0.32	2.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.77	-0.3	1.82e-8	Neuroticism;
CRC	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.44	-5.95	-0.31	6.77e-9	Superior crus of antihelix expression;
CRC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.52	8.56	0.43	4.37e-16	Uric acid clearance;
CRC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg12046867	chr14:103022105	NA	-0.78	-9.31	-0.46	1.88e-18	Platelet count;
CRC	cis	rs9635542	0.920	rs759194	chr16:5006249	C/G	cg06510647	chr16:5006106	NA	-0.63	-6.87	-0.35	3.14e-11	Lung cancer (asbestos exposure interaction);Cancer;
CRC	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg26597838	chr10:835615	NA	0.51	6.85	0.35	3.6e-11	Eosinophil percentage of granulocytes;
CRC	cis	rs4638749	0.501	rs6733637	chr2:108804564	A/G	cg25838818	chr2:108905173	SULT1C2	-0.31	-5.78	-0.3	1.7e-8	Blood pressure;
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17706896	chr19:46406599	MYPOP	0.39	6.04	0.32	4.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.3	0.33	9.48e-10	Lung cancer;
CRC	cis	rs995000	0.895	rs597076	chr1:62917865	T/A	cg19896129	chr1:63156450	NA	0.44	6.78	0.35	5.59e-11	Triglyceride levels;
CRC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg21854759	chr1:92012499	NA	-0.39	-6.03	-0.32	4.45e-9	Breast cancer;
CRC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.8e-8	Colorectal cancer;
CRC	trans	rs1899951	1.000	rs2881654	chr3:12396955	G/A	cg04083076	chr1:169452126	SLC19A2	-0.48	-6.13	-0.32	2.58e-9	Body mass index;
CRC	cis	rs9311676	0.632	rs62258075	chr3:58359851	G/A	cg06643156	chr3:58380774	PXK	0.43	6.73	0.35	7.6e-11	Systemic lupus erythematosus;
CRC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12172441	chr6:28176163	NA	0.51	7.07	0.36	9.54e-12	Parkinson's disease;
CRC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.49	6.84	0.35	3.81e-11	Monocyte percentage of white cells;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23235142	chr7:45066841	CCM2	0.3	6.68	0.35	9.98e-11	Interleukin-6 levels;
CRC	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.49	-5.94	-0.31	7.28e-9	Carotid intima media thickness;
CRC	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.41	6.32	0.33	8.44e-10	Endometrial cancer;
CRC	cis	rs8060686	0.925	rs13336189	chr16:67814152	C/A	cg00318322	chr16:67708822	GFOD2	-0.32	-5.81	-0.31	1.47e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.65	6.99	0.36	1.58e-11	Prostate cancer;
CRC	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.78	0.47	5.38e-20	Bipolar disorder;
CRC	cis	rs703980	0.565	rs703969	chr10:80953393	C/G	cg20744163	chr10:80999841	ZMIZ1	-0.32	-5.74	-0.3	2.11e-8	Type 2 diabetes;
CRC	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.55	-8.07	-0.41	1.32e-14	Response to antidepressants in depression;
CRC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.22	-0.53	6.09e-25	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12034229	chr7:48018855	HUS1	0.41	6.07	0.32	3.52e-9	Response to antipsychotic treatment;
CRC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg24046110	chr8:143859143	LYNX1	-0.4	-6.92	-0.36	2.39e-11	Urinary tract infection frequency;
CRC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	7.18	0.37	4.67e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.5	7.76	0.39	1.06e-13	Corneal astigmatism;
CRC	cis	rs990171	0.913	rs6543132	chr2:103029410	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.4e-8	Lymphocyte counts;
CRC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-11.01	-0.52	3.26e-24	Hemoglobin concentration;
CRC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-6.96	-0.36	1.86e-11	Coronary artery disease;
CRC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.43	6.68	0.35	1.04e-10	Colorectal cancer;
CRC	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg00490450	chr3:139108681	COPB2	0.43	6.43	0.33	4.53e-10	Obesity-related traits;
CRC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.62	9.41	0.46	8.91e-19	Testicular germ cell tumor;
CRC	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.76	-0.3	1.92e-8	Protein biomarker;
CRC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.8	11.23	0.53	5.39e-25	Height;
CRC	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg20045696	chr14:77926864	AHSA1	-0.65	-5.88	-0.31	1.03e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06656553	chr16:89960601	TCF25	-0.64	-5.82	-0.31	1.39e-8	Skin colour saturation;
CRC	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.2	-0.32	1.67e-9	Endometrial cancer;
CRC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.97	-0.31	6.26e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.65e-12	Inflammatory skin disease;
CRC	cis	rs11112613	0.648	rs11112635	chr12:106047112	A/G	cg03607813	chr12:105948248	NA	0.47	5.73	0.3	2.27e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs6429082	0.511	rs12748957	chr1:235426133	T/A	cg26050004	chr1:235667680	B3GALNT2	0.38	5.64	0.3	3.68e-8	Adiposity;
CRC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg10113582	chr4:905918	GAK	0.45	6.93	0.36	2.17e-11	Systemic sclerosis;
CRC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	8.6	0.43	3.27e-16	Cognitive test performance;
CRC	cis	rs78663649	0.540	rs7252709	chr19:16721183	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	-0.82	-6.13	-0.32	2.56e-9	White blood cell count;
CRC	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-9.62	-0.47	1.8e-19	Monocyte percentage of white cells;
CRC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-5.61	-0.3	4.4e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg15704280	chr7:45808275	SEPT13	0.55	7.34	0.38	1.7e-12	Intraocular pressure;
CRC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.24	-0.37	3.21e-12	Body mass index;
CRC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.52	-9.44	-0.46	7.16e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.47	0.34	3.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2179367	0.919	rs4897124	chr6:149763209	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.43	-6.88	-0.35	3e-11	Dupuytren's disease;
CRC	cis	rs17665859	0.669	rs56187424	chr8:447194	A/G	cg15469184	chr8:337539	NA	-0.5	-5.77	-0.3	1.79e-8	Bilirubin levels;
CRC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg03623178	chr6:28175578	NA	0.84	7.95	0.4	2.95e-14	Depression;
CRC	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.9	-0.31	9.24e-9	Height;
CRC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.66	8.85	0.44	5.65e-17	Bladder cancer;
CRC	cis	rs6496667	0.908	rs8040697	chr15:90853427	A/C	cg04176472	chr15:90893244	GABARAPL3	0.51	7.2	0.37	4.11e-12	Rheumatoid arthritis;
CRC	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg15145174	chr5:6755386	POLS	0.45	6.56	0.34	2.09e-10	Menopause (age at onset);
CRC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.4	6.13	0.32	2.5e-9	Mean corpuscular volume;
CRC	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.31	0.33	9.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.63	8.79	0.44	8.76e-17	Vitamin D levels;
CRC	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.59	-7.63	-0.39	2.48e-13	Body mass index;
CRC	trans	rs10411161	1.000	rs8106929	chr19:52368467	A/G	cg22319618	chr22:45562946	NUP50	-0.51	-6.04	-0.32	4.26e-9	Breast cancer;
CRC	cis	rs7572644	0.640	rs13027666	chr2:28058433	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.23	0.32	1.43e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20467896	chr19:6361623	CLPP	0.44	6.12	0.32	2.67e-9	Anxiety disorder;
CRC	trans	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-6.02	-0.32	4.65e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg20512303	chr5:131592959	PDLIM4	0.4	7.6	0.39	3.07e-13	Acylcarnitine levels;
CRC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7671266	0.611	rs10939833	chr4:10309537	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-5.88	-0.31	1.03e-8	Cardiovascular disease risk factors;
CRC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.98	-0.31	5.86e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.03	10.24	0.49	1.55e-21	Lymphocyte counts;
CRC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.9e-12	Aortic root size;
CRC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.43e-13	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24093429	chr19:12722027	ZNF791;ZNF490	0.42	6.86	0.35	3.47e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.49	-6.38	-0.33	6.12e-10	Neuroticism;
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.28	-0.33	1.06e-9	Total body bone mineral density;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10079107	chr15:31507907	NA	0.39	5.99	0.31	5.41e-9	Schizophrenia;
CRC	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.84e-10	Breast cancer;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.74	10.58	0.5	1.04e-22	Obesity-related traits;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.36	-0.38	1.52e-12	Bipolar disorder;
CRC	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs3018066	0.692	rs7698386	chr4:107038946	T/C	cg01869342	chr4:106983673	TBCK	0.44	5.82	0.31	1.36e-8	Cancer;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg23807890	chr2:228736357	WDR69	-0.48	-6.62	-0.34	1.43e-10	Blood pressure;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg27588902	chr6:42928151	GNMT	-0.42	-7.41	-0.38	1.05e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.5	7.04	0.36	1.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4731207	0.503	rs1481325	chr7:124625753	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg13844804	chr7:814759	HEATR2	0.67	8.61	0.43	3.1e-16	Cerebrospinal P-tau181p levels;
CRC	trans	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg18187862	chr3:45730750	SACM1L	-0.44	-6.23	-0.32	1.45e-9	Primary sclerosing cholangitis;
CRC	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.68	-0.35	1.02e-10	Depression;
CRC	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.17e-9	Coronary artery disease;
CRC	cis	rs55788414	0.932	rs2873367	chr16:81184380	T/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs16852403	0.517	rs316266	chr1:178102481	G/C	cg00404053	chr1:178313656	RASAL2	-0.49	-6.58	-0.34	1.87e-10	Childhood ear infection;
CRC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.53	8.85	0.44	5.56e-17	Aortic root size;
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.86	-0.31	1.1e-8	Life satisfaction;
CRC	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.51	-7.79	-0.39	8.79e-14	Diastolic blood pressure;
CRC	cis	rs6662572	0.737	rs10749859	chr1:46314170	C/T	cg08644498	chr1:46502608	NA	0.46	7.35	0.38	1.59e-12	Blood protein levels;
CRC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.88	-0.48	2.55e-20	Body mass index;
CRC	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.68	-0.3	2.91e-8	Metabolite levels;
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.1	0.36	7.93e-12	Alzheimer's disease;
CRC	cis	rs80130819	0.688	rs2054902	chr12:48724778	A/C	cg21466736	chr12:48725269	NA	-0.45	-5.65	-0.3	3.39e-8	Prostate cancer;
CRC	cis	rs7692995	1.000	rs6824748	chr4:17997066	G/A	cg08925142	chr4:18023851	LCORL	-0.54	-6.03	-0.32	4.31e-9	Height;
CRC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.5	-7.46	-0.38	7.81e-13	Height;
CRC	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg02927042	chr1:21476669	EIF4G3	-0.45	-7.39	-0.38	1.26e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg04117972	chr1:227635322	NA	-0.62	-7.0	-0.36	1.47e-11	Major depressive disorder;
CRC	cis	rs2857891	1.000	rs2857891	chr11:6962957	C/T	cg12728517	chr11:6947552	ZNF215	0.56	6.1	0.32	3.03e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05520353	chr13:113597554	NA	0.4	6.01	0.31	4.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.74	10.2	0.49	2.11e-21	Systemic lupus erythematosus;
CRC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.46	5.94	0.31	7.35e-9	Obesity-related traits;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg20237960	chr7:45926556	IGFBP1	-0.4	-6.3	-0.33	9.67e-10	HDL cholesterol;
CRC	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.54	-7.66	-0.39	2.1e-13	Response to temozolomide;
CRC	cis	rs1887596	0.672	rs1831466	chr13:27231212	C/G	cg01312412	chr13:27282625	NA	0.43	5.64	0.3	3.76e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-7.99	-0.4	2.33e-14	Menarche (age at onset);
CRC	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg21251018	chr6:28226885	NKAPL	0.4	6.12	0.32	2.7e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.71	11.6	0.54	2.68e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg02549819	chr16:58548995	SETD6	1.16	7.58	0.39	3.52e-13	Schizophrenia;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.13	-0.37	6.57e-12	Glycated hemoglobin levels;
CRC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg09003973	chr2:102972529	NA	0.73	8.0	0.4	2.09e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg07217954	chr7:1067459	C7orf50	0.48	5.67	0.3	3.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.66	7.15	0.37	5.59e-12	Childhood ear infection;
CRC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.45	0.53	8.93e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26917132	chr16:87425759	FBXO31;MAP1LC3B	0.48	6.58	0.34	1.82e-10	Survival in pancreatic cancer;
CRC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.43	6.91	0.36	2.5e-11	Resting heart rate;
CRC	cis	rs6968419	0.747	rs58595078	chr7:115881458	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.35	-0.33	7.09e-10	Intraocular pressure;
CRC	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.17	-0.37	4.91e-12	Multiple myeloma (hyperdiploidy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02667081	chr16:71880439	ATXN1L	0.48	6.28	0.33	1.08e-9	Thyroid stimulating hormone;
CRC	cis	rs66569888	0.583	rs66529457	chr2:106727010	G/A	cg16099169	chr2:106886729	NA	-0.37	-5.66	-0.3	3.35e-8	Facial morphology (factor 23);
CRC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.66	8.73	0.43	1.33e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.56	-10.56	-0.5	1.21e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.85	0.4	6.03e-14	Heart rate;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.76	8.5	0.42	6.61e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg25164649	chr6:28176230	NA	0.59	7.84	0.4	6.16e-14	Parkinson's disease;
CRC	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg04850286	chr10:81895943	PLAC9	0.38	6.74	0.35	7.04e-11	Sarcoidosis;
CRC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.58	8.97	0.44	2.34e-17	Vitiligo;
CRC	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.84	-11.09	-0.52	1.67e-24	Hair shape;
CRC	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.35	7.8	0.4	8.28e-14	Total body bone mineral density;
CRC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-0.91	-15.56	-0.65	2.7e-41	Body mass index;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg02683197	chr6:28174875	NA	0.63	8.19	0.41	5.64e-15	Parkinson's disease;
CRC	cis	rs889398	0.802	rs9940315	chr16:69876164	A/G	cg00738113	chr16:70207722	CLEC18C	-0.36	-6.21	-0.32	1.6e-9	Body mass index;
CRC	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg26597838	chr10:835615	NA	0.67	7.54	0.38	4.62e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs3825932	0.961	rs11855406	chr15:79234864	C/T	cg25744700	chr15:79237217	CTSH	-0.39	-6.08	-0.32	3.37e-9	Type 1 diabetes;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg25164649	chr6:28176230	NA	0.77	10.52	0.5	1.68e-22	Depression;
CRC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg03623178	chr6:28175578	NA	0.51	7.57	0.39	3.72e-13	Pubertal anthropometrics;
CRC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.58e-8	Aortic root size;
CRC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg03030879	chr14:75389066	RPS6KL1	0.55	8.76	0.44	1.03e-16	Caffeine consumption;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19315081	chr11:10326100	ADM	0.41	5.97	0.31	6.24e-9	Response to antipsychotic treatment;
CRC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg02993699	chr4:3415135	RGS12	-0.38	-6.11	-0.32	2.81e-9	Serum sulfate level;
CRC	cis	rs4731207	0.598	rs2301930	chr7:124465097	A/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.85	15.82	0.66	2.52e-42	Metabolic syndrome;
CRC	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg00105475	chr2:10696890	NA	0.46	7.45	0.38	8.43e-13	Prostate cancer;
CRC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.68	0.35	9.95e-11	Lung cancer;
CRC	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.56	-8.39	-0.42	1.46e-15	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.72	-13.13	-0.59	5.74e-32	Leprosy;
CRC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.66	-9.33	-0.46	1.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs16852403	0.619	rs6701497	chr1:178114644	G/C	cg00404053	chr1:178313656	RASAL2	0.6	7.56	0.38	4.18e-13	Childhood ear infection;
CRC	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg00277334	chr10:82204260	NA	0.38	6.25	0.33	1.26e-9	Sarcoidosis;
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.4	-5.83	-0.31	1.32e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2882667	0.690	rs700619	chr5:138088749	G/C	cg09476006	chr5:138032270	NA	-0.57	-9.69	-0.47	1.05e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.42	-0.33	4.72e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.06	-15.04	-0.64	2.94e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs863345	0.625	rs10908663	chr1:158492121	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.13e-9	Pneumococcal bacteremia;
CRC	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-7.34	-0.38	1.66e-12	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg25164649	chr6:28176230	NA	0.7	7.93	0.4	3.42e-14	Parkinson's disease;
CRC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.72	10.86	0.51	1.12e-23	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg09324608	chr17:30823087	MYO1D	0.33	5.63	0.3	3.89e-8	Schizophrenia;
CRC	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.56	7.49	0.38	6.52e-13	LDL cholesterol levels;LDL cholesterol;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25327839	chr11:73308997	FAM168A	-0.4	-6.61	-0.34	1.57e-10	Myopia (pathological);
CRC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.66	12.0	0.55	9.24e-28	Aortic root size;
CRC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.6	-0.47	2.04e-19	Migraine;Coronary artery disease;
CRC	cis	rs9292777	0.897	rs6451493	chr5:40410935	A/C	cg09067459	chr5:40385259	NA	-0.5	-8.49	-0.42	6.97e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.42	6.53	0.34	2.52e-10	High light scatter reticulocyte count;
CRC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg12386194	chr3:101231763	SENP7	0.48	6.89	0.35	2.92e-11	Colorectal cancer;
CRC	cis	rs6700896	0.966	rs4655557	chr1:66080787	T/C	cg04111102	chr1:66153794	NA	0.35	6.23	0.32	1.43e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs17065868	0.764	rs7996250	chr13:45029513	A/C	cg10246903	chr13:45222710	NA	0.54	5.66	0.3	3.29e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.53	-9.57	-0.47	2.66e-19	Intelligence (multi-trait analysis);
CRC	cis	rs910187	0.678	rs1046667	chr20:45817255	A/C	cg27589058	chr20:45804311	EYA2	-0.4	-7.66	-0.39	2.09e-13	Migraine;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05038804	chr3:119813689	GSK3B	0.44	6.19	0.32	1.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg14664628	chr15:75095509	CSK	0.55	6.32	0.33	8.68e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs8105895	0.867	rs8106762	chr19:22284736	C/T	cg02657401	chr19:22469223	NA	-0.35	-5.67	-0.3	3.06e-8	Body mass index (change over time);
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.98	16.78	0.68	4.33e-46	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01423147	chr1:89458345	RBMXL1;CCBL2	0.41	6.5	0.34	3.01e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg12193833	chr17:30244370	NA	0.45	6.01	0.31	4.79e-9	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.46	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs6123683	0.752	rs182784	chr20:55824533	A/G	cg13236649	chr20:55835020	BMP7	0.45	7.09	0.36	8.25e-12	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg20487152	chr13:99095054	FARP1	-0.48	-6.92	-0.36	2.34e-11	Neuroticism;
CRC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	1.0	14.41	0.62	7.76e-37	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg03938978	chr2:103052716	IL18RAP	0.4	6.25	0.33	1.27e-9	Blood protein levels;
CRC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.41	6.18	0.32	1.85e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.75	-8.71	-0.43	1.46e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18912574	chr7:65842487	NCRNA00174	0.35	5.91	0.31	8.66e-9	Aortic root size;
CRC	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg14664628	chr15:75095509	CSK	0.53	6.46	0.34	3.8e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.96	-0.31	6.58e-9	Educational attainment;
CRC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.37	-6.52	-0.34	2.58e-10	Schizophrenia;
CRC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg21770322	chr7:97807741	LMTK2	0.52	8.54	0.43	5.11e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg24154853	chr7:158122151	PTPRN2	0.51	7.07	0.36	9.19e-12	Response to amphetamines;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21877580	chr6:97731105	MIR548H3;C6orf167	0.41	6.0	0.31	5.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.37	5.61	0.3	4.23e-8	Mean corpuscular volume;
CRC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.95	-0.4	2.98e-14	Height;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.62	6.59	0.34	1.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.45	6.06	0.32	3.63e-9	Pulse pressure;
CRC	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.46	7.9	0.4	4.19e-14	Common traits (Other);
CRC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.67	-12.26	-0.56	1.03e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.59	11.66	0.54	1.52e-26	Asthma (sex interaction);
CRC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.44	-6.53	-0.34	2.44e-10	Tonsillectomy;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg26608667	chr7:1196370	ZFAND2A	0.36	5.63	0.3	3.78e-8	Longevity;Endometriosis;
CRC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg11247378	chr22:39784982	NA	0.35	6.65	0.34	1.21e-10	IgG glycosylation;
CRC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.56	-8.75	-0.43	1.13e-16	Aortic root size;
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.06	-28.15	-0.84	1.27e-89	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg04824913	chr4:887549	GAK	0.48	6.66	0.34	1.15e-10	Sjögren's syndrome;
CRC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.49	7.95	0.4	3.08e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3736485	0.903	rs8039835	chr15:51865864	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.58	-0.34	1.88e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3026101	0.671	rs72634032	chr17:5303437	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.49	6.23	0.32	1.4e-9	White matter hyperintensity burden;
CRC	cis	rs9903692	0.954	rs7224014	chr17:46150861	T/G	cg21215337	chr17:46176117	CBX1	0.42	7.79	0.39	8.7e-14	Pulse pressure;
CRC	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	7.35	0.38	1.6e-12	Total body bone mineral density;
CRC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	0.62	6.27	0.33	1.16e-9	Fat distribution (HIV);
CRC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-9.0	-0.44	1.82e-17	Schizophrenia;
CRC	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.49	-6.29	-0.33	1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg10437265	chr15:77819839	NA	-0.54	-8.97	-0.44	2.24e-17	Type 2 diabetes;
CRC	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.57	-9.14	-0.45	6.39e-18	Idiopathic membranous nephropathy;
CRC	cis	rs4889855	0.530	rs4477776	chr17:78581765	G/A	cg16591659	chr17:78472290	NA	-0.4	-6.0	-0.31	5.06e-9	Fractional excretion of uric acid;
CRC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.55	-8.45	-0.42	9.46e-16	Asthma (sex interaction);
CRC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.23	-0.33	1.39e-9	Breast cancer;
CRC	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg02158880	chr13:53174818	NA	0.49	7.37	0.38	1.37e-12	Lewy body disease;
CRC	cis	rs6076065	1.000	rs6083105	chr20:23368475	C/A	cg11657817	chr20:23433608	CST11	0.36	5.63	0.3	3.78e-8	Facial morphology (factor 15, philtrum width);
CRC	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg03929089	chr4:120376271	NA	-0.45	-6.37	-0.33	6.43e-10	HDL cholesterol;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.94	0.31	7.34e-9	Obesity-related traits;
CRC	cis	rs17767392	0.813	rs8013161	chr14:72021499	G/A	cg13720639	chr14:72061746	SIPA1L1	0.5	6.35	0.33	7e-10	Mitral valve prolapse;
CRC	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg01475377	chr6:109611718	NA	-0.34	-5.86	-0.31	1.12e-8	Reticulocyte fraction of red cells;
CRC	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.74	-0.3	2.11e-8	Pulmonary function;
CRC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.73	0.3	2.21e-8	Diabetic retinopathy;
CRC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.53	5.81	0.31	1.46e-8	Menarche (age at onset);
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg10217327	chr6:118973057	C6orf204	0.51	5.75	0.3	2e-8	Diastolic blood pressure;
CRC	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.81	12.32	0.56	6.13e-29	Testicular germ cell tumor;
CRC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.66	-11.64	-0.54	1.81e-26	Educational attainment;
CRC	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	8.21	0.41	5.1e-15	Iron status biomarkers;
CRC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.18	-0.32	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.59	-6.46	-0.34	3.79e-10	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.34	3.02e-10	Bipolar disorder;
CRC	cis	rs7112925	0.932	rs2282502	chr11:66834252	C/T	cg24851651	chr11:66362959	CCS	-0.39	-6.76	-0.35	6.16e-11	Height;
CRC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-8.21	-0.41	5.24e-15	Gut microbiome composition (summer);
CRC	cis	rs4743820	0.651	rs10991797	chr9:93930671	A/G	cg14446406	chr9:93919335	NA	-0.73	-12.98	-0.58	2.17e-31	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.41	-5.96	-0.31	6.4e-9	Asthma;
CRC	cis	rs13315871	0.929	rs71311849	chr3:58230809	G/A	cg20936604	chr3:58311152	NA	-0.64	-6.33	-0.33	8.21e-10	Cholesterol, total;
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.47	5.96	0.31	6.64e-9	Systemic lupus erythematosus;
CRC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7487075	0.893	rs12317787	chr12:46736729	T/C	cg22049899	chr12:47219821	SLC38A4	0.35	6.88	0.35	3.07e-11	Itch intensity from mosquito bite;
CRC	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg02466173	chr16:30829666	NA	-0.62	-9.41	-0.46	8.9e-19	Response to metformin (IC50);
CRC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.48	-0.67	6.65e-45	Height;
CRC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.66	0.57	3.43e-30	Menopause (age at onset);
CRC	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.67	-11.09	-0.52	1.66e-24	Hepatocellular carcinoma;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg21577049	chr2:228736449	WDR69	0.44	5.9	0.31	8.95e-9	Blood pressure;
CRC	cis	rs10242455	0.571	rs73713594	chr7:99326498	A/G	cg18809830	chr7:99032528	PTCD1	-0.96	-7.11	-0.36	7.45e-12	Blood metabolite levels;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20742182	chr15:101629240	NA	0.43	6.49	0.34	3.12e-10	Myopia (pathological);
CRC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg02725872	chr8:58115012	NA	-0.36	-6.18	-0.32	1.91e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg15145296	chr3:125709740	NA	-0.57	-6.64	-0.34	1.29e-10	Blood pressure (smoking interaction);
CRC	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.39	-6.16	-0.32	2.11e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19189012	chr12:56401370	NA	0.4	5.98	0.31	5.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs747650	0.532	rs7128650	chr11:47047059	A/G	cg19486271	chr11:47235900	DDB2	-0.43	-5.79	-0.3	1.64e-8	Acne (severe);
CRC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.49	6.54	0.34	2.3e-10	Height;
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg13047869	chr3:10149882	C3orf24	0.53	7.31	0.37	2.04e-12	Alzheimer's disease;
CRC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.45	-5.95	-0.31	6.92e-9	Gut microbiome composition (summer);
CRC	cis	rs834811	0.583	rs73168818	chr7:135878903	G/A	cg01726295	chr7:135938950	NA	0.34	5.77	0.3	1.82e-8	Post-traumatic stress disorder;
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.25	-0.33	1.28e-9	Total body bone mineral density;
CRC	cis	rs6604026	1.000	rs6657809	chr1:93293063	G/A	cg17283838	chr1:93427260	FAM69A	0.44	5.7	0.3	2.7e-8	Multiple sclerosis;
CRC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.12	10.91	0.52	7.06e-24	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg23758597	chr6:163146217	PARK2	-0.51	-5.9	-0.31	8.81e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-11.54	-0.54	4.29e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.63	-10.16	-0.49	2.82e-21	Obesity-related traits;
CRC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg22117107	chr15:45993392	NA	-0.44	-8.83	-0.44	6.22e-17	Waist circumference;Weight;
CRC	cis	rs600626	0.529	rs10899113	chr11:75468464	T/A	cg24262691	chr11:75473276	NA	0.52	7.2	0.37	4.03e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	0.59	5.99	0.31	5.45e-9	Left atrial antero-posterior diameter;
CRC	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.67	-0.35	1.07e-10	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25375453	chr3:14219857	LSM3;XPC	0.41	6.45	0.34	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.624	rs7151581	chr14:55788445	A/G	cg10130446	chr14:55658398	DLGAP5	0.4	5.65	0.3	3.42e-8	Protein biomarker;
CRC	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.87	-0.31	1.06e-8	Metabolite levels;
CRC	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg27499820	chr13:21296301	IL17D	0.41	5.82	0.31	1.39e-8	Dental caries;
CRC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.73	12.0	0.55	9.55e-28	Monocyte count;
CRC	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.64	-10.19	-0.49	2.22e-21	Smoking behavior;
CRC	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg20356878	chr3:121714668	ILDR1	-0.46	-6.78	-0.35	5.55e-11	Multiple sclerosis;
CRC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.88	0.4	4.73e-14	Neuroticism;
CRC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24308560	chr3:49941425	MST1R	-0.44	-6.98	-0.36	1.68e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.74	-0.54	8.41e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.99	0.31	5.65e-9	Tonsillectomy;
CRC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.21	-0.32	1.58e-9	Aortic root size;
CRC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.67	8.96	0.44	2.47e-17	Platelet distribution width;
CRC	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.04	14.63	0.63	1.08e-37	Exhaled nitric oxide output;
CRC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.58	-8.65	-0.43	2.27e-16	Aortic root size;
CRC	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.52	7.45	0.38	8.29e-13	Testicular germ cell tumor;
CRC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.42	6.03	0.32	4.34e-9	Renal cell carcinoma;
CRC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.75	-12.97	-0.58	2.37e-31	Body mass index;
CRC	cis	rs9462027	0.651	rs34493158	chr6:34753339	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.27e-9	Systemic lupus erythematosus;
CRC	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.51	-9.89	-0.48	2.32e-20	Alcoholic chronic pancreatitis;
CRC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.77	-12.95	-0.58	2.86e-31	Prostate cancer;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.49	-0.5	2.14e-22	Bipolar disorder;
CRC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.64	-0.43	2.57e-16	Platelet count;
CRC	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.9	-0.36	2.63e-11	Response to antipsychotic treatment;
CRC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.42	-0.33	4.69e-10	Dupuytren's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12672932	chr2:153575114	ARL6IP6;PRPF40A	0.39	6.08	0.32	3.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg07478791	chr1:31886160	SERINC2	-0.4	-5.64	-0.3	3.76e-8	Alcohol dependence;
CRC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.5	6.4	0.33	5.37e-10	Cholesterol, total;
CRC	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg24794228	chr19:52391166	ZNF577	0.48	5.76	0.3	1.96e-8	Breast cancer;
CRC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.61	11.13	0.52	1.27e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.36	6.39	0.33	5.76e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7707921	0.881	rs73134747	chr5:81378294	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.4	5.74	0.3	2.19e-8	Breast cancer;
CRC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06544989	chr22:39130855	UNC84B	-0.46	-7.23	-0.37	3.37e-12	Menopause (age at onset);
CRC	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.62	-5.69	-0.3	2.78e-8	White matter integrity;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg27635394	chr6:26043820	HIST1H2BB	0.41	5.95	0.31	7.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.72	-0.39	1.45e-13	Total body bone mineral density;
CRC	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14019695	chr9:139328340	INPP5E	0.44	6.43	0.33	4.48e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.68	-0.3	3.02e-8	Schizophrenia;
CRC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.57	8.71	0.43	1.48e-16	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.74	-12.25	-0.56	1.1e-28	Breast cancer;
CRC	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.94	16.26	0.67	5.01e-44	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs12956045	0.597	rs11662811	chr18:13855983	C/T	cg15534052	chr18:13871104	NA	-0.33	-5.98	-0.31	5.7e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
CRC	trans	rs72991	0.643	rs99673	chr11:121255108	C/T	cg27192990	chr6:129479024	LAMA2	-0.37	-5.99	-0.31	5.53e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs629535	0.821	rs660144	chr8:70035629	T/C	cg26132723	chr8:70041827	NA	0.35	5.68	0.3	3.03e-8	Dupuytren's disease;
CRC	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg25714306	chr4:1656736	FAM53A	-0.34	-6.0	-0.31	5.17e-9	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs11255291	1.000	rs2182652	chr10:7735876	C/T	cg00997801	chr10:7671259	ITIH5	-0.41	-5.92	-0.31	8.11e-9	Ovarian reserve;
CRC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg27068330	chr11:65405492	SIPA1	-0.48	-6.65	-0.34	1.23e-10	Breast cancer;
CRC	cis	rs11212617	0.967	rs228588	chr11:108113331	C/G	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.72	0.3	2.35e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.27	0.56	9.74e-29	Platelet count;
CRC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg12193833	chr17:30244370	NA	-0.75	-8.72	-0.43	1.4e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.43	0.38	9.15e-13	Hip circumference adjusted for BMI;
CRC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg09163369	chr1:210001066	C1orf107	-0.6	-7.84	-0.4	6.19e-14	Orofacial clefts;
CRC	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg02569458	chr12:86230093	RASSF9	0.39	6.52	0.34	2.7e-10	Major depressive disorder;
CRC	trans	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg14222797	chr10:16859974	RSU1	-0.67	-6.52	-0.34	2.66e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg22990158	chr14:24802150	ADCY4	-0.33	-5.61	-0.3	4.38e-8	Height;
CRC	cis	rs10450586	0.799	rs11029901	chr11:27287108	A/G	cg10370305	chr11:27303972	NA	0.37	5.79	0.3	1.68e-8	Total body bone mineral density;
CRC	cis	rs6504622	0.539	rs4968248	chr17:44993128	G/A	cg16759221	chr17:45003025	GOSR2	0.54	8.68	0.43	1.9e-16	Orofacial clefts;
CRC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.43	6.07	0.32	3.47e-9	Parkinson's disease;
CRC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg11833968	chr6:79620685	NA	-0.36	-6.09	-0.32	3.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	6.7	0.35	9.3e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.68	-12.45	-0.57	1.99e-29	Breast cancer;
CRC	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.03	-0.32	4.4e-9	Daytime sleep phenotypes;
CRC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.54	7.54	0.38	4.53e-13	Response to antidepressants and depression;
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.53	6.17	0.32	1.97e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg24140574	chr1:16342155	HSPB7	0.47	6.7	0.35	8.99e-11	Dilated cardiomyopathy;
CRC	cis	rs7705042	0.865	rs4912623	chr5:141505462	T/A	cg07392085	chr5:141489673	NDFIP1	0.46	7.27	0.37	2.59e-12	Asthma;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg22638593	chr5:131593259	PDLIM4	0.38	6.28	0.33	1.09e-9	Breast cancer;
CRC	cis	rs4743820	0.620	rs55934624	chr9:93917285	T/G	cg14446406	chr9:93919335	NA	0.77	13.47	0.6	2.94e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.78	-0.35	5.73e-11	Aortic root size;
CRC	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.83	9.5	0.46	4.66e-19	Lung function (FEV1/FVC);
CRC	cis	rs17331151	0.505	rs79979130	chr3:52551010	C/T	cg27565382	chr3:53032988	SFMBT1	0.79	5.8	0.3	1.59e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.51	-6.56	-0.34	2.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg02158880	chr13:53174818	NA	0.46	6.72	0.35	8.16e-11	Lewy body disease;
CRC	cis	rs1891275	0.515	rs1986941	chr10:93444343	C/T	cg07889827	chr10:93443413	NA	-0.39	-6.78	-0.35	5.48e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12463550	chr7:65579703	CRCP	0.76	6.72	0.35	8.14e-11	Diabetic kidney disease;
CRC	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg19401529	chr3:49056140	DALRD3	0.53	6.05	0.32	3.92e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CRC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.72	10.36	0.5	5.91e-22	Menarche (age at onset);
CRC	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.59	0.47	2.22e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	1.11	9.31	0.46	1.89e-18	Arsenic metabolism;
CRC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg19761014	chr17:28927070	LRRC37B2	0.58	5.85	0.31	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02725872	chr8:58115012	NA	-0.52	-7.24	-0.37	3.13e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07210462	chr1:39324918	RRAGC	0.44	6.42	0.33	4.82e-10	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	6.53	0.34	2.51e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.72	-0.35	8.27e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.73	13.07	0.58	1.02e-31	Oral cavity cancer;
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.53	0.34	2.57e-10	Bipolar disorder;
CRC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg16476235	chr8:21771668	DOK2	0.36	6.19	0.32	1.74e-9	Mean corpuscular volume;
CRC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.6	7.16	0.37	5.35e-12	Neutrophil percentage of white cells;
CRC	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.36	-5.8	-0.3	1.55e-8	Mean arterial pressure;
CRC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.08	18.38	0.71	1.99e-52	Cognitive function;
CRC	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.88	-0.35	3.05e-11	Response to antipsychotic treatment;
CRC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.42	-7.39	-0.38	1.25e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	8.99	0.44	1.94e-17	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.47	6.71	0.35	8.76e-11	Response to antipsychotic treatment;
CRC	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.76	-14.03	-0.61	2.19e-35	Hip circumference;
CRC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg10802521	chr3:52805072	NEK4	-0.38	-5.85	-0.31	1.21e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.77	-10.86	-0.51	1.07e-23	Blood metabolite levels;
CRC	cis	rs4838594	0.563	rs3853762	chr10:49678456	G/C	cg17291251	chr10:49678358	ARHGAP22	0.46	7.4	0.38	1.15e-12	Daytime sleep phenotypes;
CRC	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg15382696	chr6:118971807	C6orf204	0.57	7.06	0.36	1.02e-11	Diastolic blood pressure;
CRC	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.36	6.46	0.34	3.79e-10	Breast cancer;
CRC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	8.04	0.41	1.62e-14	Rheumatoid arthritis;
CRC	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24249390	chr15:90295951	MESP1	-0.58	-9.26	-0.45	2.81e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.62	-10.68	-0.51	4.55e-23	Body mass index;
CRC	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.43	-0.33	4.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6700896	0.931	rs1938497	chr1:66100450	G/A	cg04111102	chr1:66153794	NA	0.32	5.67	0.3	3.12e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg18827107	chr12:86230957	RASSF9	0.36	5.74	0.3	2.19e-8	Major depressive disorder;
CRC	trans	rs9409565	0.826	rs2769813	chr9:97151194	C/T	cg05679027	chr9:99775184	HIATL2	0.43	6.69	0.35	9.42e-11	Colorectal cancer (alcohol consumption interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13101865	chr20:3154899	NA	0.45	6.0	0.31	5.19e-9	Thyroid stimulating hormone;
CRC	cis	rs7632954	0.567	rs9813104	chr3:8534493	C/G	cg03495237	chr3:8533978	NA	0.34	6.13	0.32	2.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg02119693	chr2:192161142	MYO1B	-0.4	-6.18	-0.32	1.94e-9	HDL cholesterol;
CRC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.38	0.38	1.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg23463467	chr20:60627584	TAF4	0.36	6.33	0.33	7.98e-10	Body mass index;
CRC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.72	-0.35	8.26e-11	Reticulocyte fraction of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19000349	chr2:75061841	HK2	0.43	6.05	0.32	4.04e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00523012	chr19:13264324	IER2	0.36	5.99	0.31	5.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00255919	chr5:131827918	IRF1	-0.59	-11.53	-0.54	4.46e-26	Asthma (sex interaction);
CRC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.59	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.2	-0.32	1.67e-9	Alzheimer's disease (late onset);
CRC	cis	rs9463078	0.803	rs9463083	chr6:45272062	T/G	cg25276700	chr6:44698697	NA	-0.28	-6.73	-0.35	7.77e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.69	0.39	1.7e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.44	-0.42	1.02e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.75	-10.68	-0.51	4.7e-23	Platelet distribution width;
CRC	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg25930673	chr12:123319894	HIP1R	-0.57	-5.98	-0.31	5.97e-9	Schizophrenia;
CRC	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.69	-8.69	-0.43	1.68e-16	Blood protein levels;
CRC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.59	8.65	0.43	2.31e-16	Tuberculosis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14166846	chr1:220268091	IARS2	0.47	6.3	0.33	9.53e-10	Thyroid stimulating hormone;
CRC	cis	rs834811	0.602	rs17243535	chr7:135886453	T/C	cg01726295	chr7:135938950	NA	0.36	6.11	0.32	2.74e-9	Post-traumatic stress disorder;
CRC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.41	0.38	1.04e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.91	0.31	8.59e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.81	13.59	0.6	1.1e-33	Menopause (age at onset);
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg03623178	chr6:28175578	NA	0.64	8.29	0.42	2.88e-15	Parkinson's disease;
CRC	trans	rs1737890	0.623	rs6057570	chr20:30988098	A/T	cg05428433	chr16:3614067	NLRC3	-0.4	-5.96	-0.31	6.54e-9	Chronic obstructive pulmonary disease;
CRC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.49	7.95	0.4	3.08e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.6	-8.58	-0.43	3.82e-16	Body mass index;
CRC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.49	-5.85	-0.31	1.17e-8	Diastolic blood pressure;
CRC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg13390004	chr1:15929781	NA	0.52	7.28	0.37	2.49e-12	Systolic blood pressure;
CRC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.7	8.93	0.44	3.17e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.46	-0.34	3.8e-10	Aortic root size;
CRC	cis	rs10486722	0.606	rs1124538	chr7:41778055	C/T	cg22138096	chr7:41772439	LOC285954	0.43	5.76	0.3	1.96e-8	Pit-and-Fissure caries;
CRC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.6	-9.5	-0.46	4.46e-19	Aortic root size;
CRC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.79	-12.97	-0.58	2.43e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg06223162	chr1:101003688	GPR88	0.32	5.66	0.3	3.37e-8	Breast cancer;
CRC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg22495460	chr2:25135724	ADCY3	-0.9	-17.66	-0.7	1.51e-49	Body mass index in non-asthmatics;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18607491	chr14:51706792	TMX1	0.44	7.06	0.36	9.75e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg20041105	chr8:143859282	LYNX1	0.45	8.09	0.41	1.16e-14	Urinary tract infection frequency;
CRC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	16.26	0.67	4.86e-44	Smoking behavior;
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.26	-0.56	9.81e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	1.09	9.98	0.48	1.12e-20	Severe influenza A (H1N1) infection;
CRC	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg05585544	chr11:47624801	NA	-0.4	-6.36	-0.33	6.58e-10	Mean corpuscular hemoglobin;
CRC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg10298567	chr3:47292165	KIF9	0.39	6.34	0.33	7.54e-10	Colorectal cancer;
CRC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-10.44	-0.5	3.18e-22	Glomerular filtration rate (creatinine);
CRC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.54	8.3	0.42	2.72e-15	Aortic root size;
CRC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-10.33	-0.49	7.41e-22	Schizophrenia;
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02772935	chr3:125709198	NA	-0.49	-5.73	-0.3	2.27e-8	Blood pressure (smoking interaction);
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg01489032	chr8:143877656	NA	0.36	5.99	0.31	5.46e-9	Urinary tract infection frequency;
CRC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.64	-0.3	3.72e-8	Breast cancer;
CRC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.78	0.39	9.58e-14	Platelet count;
CRC	cis	rs4664293	0.642	rs6732598	chr2:160646881	G/A	cg08347373	chr2:160653686	CD302	0.51	8.76	0.43	1.08e-16	Monocyte percentage of white cells;
CRC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.62	9.66	0.47	1.37e-19	Corneal astigmatism;
CRC	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.41	6.42	0.33	4.72e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg18016565	chr1:150552671	MCL1	0.43	5.94	0.31	7.37e-9	Melanoma;
CRC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.13	11.0	0.52	3.68e-24	Intelligence (multi-trait analysis);
CRC	cis	rs791888	1.000	rs791882	chr10:89408258	C/T	cg13926569	chr10:89418898	PAPSS2	-0.46	-6.7	-0.35	9.12e-11	Magnesium levels;
CRC	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.03	-0.36	1.17e-11	Putamen volume;
CRC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.65	-7.65	-0.39	2.18e-13	Menarche (age at onset);
CRC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.53	-8.35	-0.42	1.86e-15	Monocyte count;
CRC	trans	rs531930	0.587	rs332611	chr6:124713527	C/T	cg10053779	chr10:121497344	INPP5F	-0.38	-6.24	-0.33	1.36e-9	Celiac disease;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg11235426	chr6:292522	DUSP22	-0.54	-7.62	-0.39	2.69e-13	Menopause (age at onset);
CRC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg18479299	chr3:125709523	NA	-0.55	-6.6	-0.34	1.66e-10	Blood pressure (smoking interaction);
CRC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.16	0.49	2.87e-21	Monocyte percentage of white cells;
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg04969067	chr8:143858791	LYNX1	-0.42	-6.64	-0.34	1.28e-10	Urinary tract infection frequency;
CRC	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg12310025	chr6:25882481	NA	-0.41	-5.74	-0.3	2.1e-8	Height;
CRC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04731861	chr2:219085781	ARPC2	0.33	6.94	0.36	2.07e-11	Colorectal cancer;
CRC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-8.05	-0.41	1.48e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09068198	chr2:65357064	RAB1A	0.56	7.31	0.37	2.07e-12	Thyroid stimulating hormone;
CRC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.15e-11	Morning vs. evening chronotype;
CRC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg10398005	chr11:117014888	PAFAH1B2	-0.37	-5.61	-0.3	4.35e-8	Blood protein levels;
CRC	trans	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg03060546	chr3:49711283	APEH	-0.52	-6.01	-0.31	4.84e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg24046110	chr8:143859143	LYNX1	-0.44	-6.72	-0.35	8.05e-11	Urinary tract infection frequency;
CRC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02825527	chr7:2087843	MAD1L1	-0.46	-5.62	-0.3	4.15e-8	Bipolar disorder;
CRC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20307385	chr11:47447363	PSMC3	0.62	9.22	0.45	3.6e-18	Subjective well-being;
CRC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.55	8.29	0.42	3.01e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg26816564	chr1:7831052	VAMP3	-0.46	-5.63	-0.3	3.89e-8	Inflammatory bowel disease;
CRC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.94	15.49	0.65	4.78e-41	Primary sclerosing cholangitis;
CRC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg25985355	chr7:65971099	NA	-0.54	-6.14	-0.32	2.35e-9	Diabetic kidney disease;
CRC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.94	-0.4	3.22e-14	Gut microbiome composition (summer);
CRC	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.81	15.27	0.64	3.62e-40	Hip circumference;
CRC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.42	-0.33	4.82e-10	Alzheimer's disease (late onset);
CRC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg10589385	chr1:150898437	SETDB1	0.32	6.52	0.34	2.59e-10	Melanoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09071838	chr13:25497213	CENPJ	0.42	6.65	0.34	1.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg22482690	chr17:47019901	SNF8	0.46	7.5	0.38	6.07e-13	Type 2 diabetes;
CRC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg22834771	chr12:69754056	YEATS4	0.45	6.51	0.34	2.86e-10	Blood protein levels;
CRC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.36	6.01	0.31	4.96e-9	Height;
CRC	cis	rs2072510	0.618	rs12302993	chr12:96393261	A/G	cg22491680	chr12:96389547	HAL	-0.47	-6.45	-0.34	3.88e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.57	-9.17	-0.45	5.23e-18	Intelligence (multi-trait analysis);
CRC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.62	9.12	0.45	7.57e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.46	-6.17	-0.32	1.97e-9	Red cell distribution width;
CRC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg03929089	chr4:120376271	NA	-0.49	-7.18	-0.37	4.75e-12	HDL cholesterol;
CRC	cis	rs11587400	0.593	rs2336365	chr1:115175415	G/T	cg12756093	chr1:115239321	AMPD1	-0.44	-6.12	-0.32	2.7e-9	Autism;
CRC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-5.95	-0.31	6.96e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3736485	0.844	rs76092251	chr15:51803193	A/G	cg08986416	chr15:51914746	DMXL2	-0.49	-7.13	-0.37	6.27e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.72	11.37	0.53	1.78e-25	Colorectal cancer;
CRC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg04518342	chr5:131593106	PDLIM4	0.45	8.39	0.42	1.5e-15	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13504215	chr3:30648325	TGFBR2	0.36	5.98	0.31	5.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.28	0.46	2.36e-18	Fuchs's corneal dystrophy;
CRC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.43	6.15	0.32	2.29e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00157855	chr7:35734423	HERPUD2	0.42	6.39	0.33	5.7e-10	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-9.36	-0.46	1.29e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg06238570	chr21:40685208	BRWD1	0.71	10.11	0.49	4.09e-21	Cognitive function;
CRC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg07713946	chr22:31675144	LIMK2	-0.39	-5.67	-0.3	3.09e-8	Colorectal cancer;
CRC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.47	-7.64	-0.39	2.35e-13	Iron status biomarkers;
CRC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg16797656	chr11:68205561	LRP5	0.36	5.75	0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.5	-6.81	-0.35	4.73e-11	Intelligence (multi-trait analysis);
CRC	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg10279832	chr4:154682576	RNF175	0.39	5.99	0.31	5.65e-9	Response to statins (LDL cholesterol change);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20376421	chr12:56546193	MYL6B	0.41	6.5	0.34	2.99e-10	Obesity-related traits;
CRC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.88	-17.12	-0.69	1.98e-47	Body mass index;
CRC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg10820045	chr2:198174542	NA	-0.55	-9.37	-0.46	1.24e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.45	0.62	5.37e-37	Platelet count;
CRC	cis	rs17155006	0.664	rs378962	chr7:107739538	A/C	cg05962710	chr7:107745446	LAMB4	-0.41	-7.25	-0.37	2.92e-12	Pneumococcal bacteremia;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg21251018	chr6:28226885	NKAPL	0.46	7.14	0.37	6.07e-12	Cardiac Troponin-T levels;
CRC	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.97	-0.44	2.32e-17	Coffee consumption (cups per day);
CRC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.67	10.01	0.48	9.3e-21	Menopause (age at onset);
CRC	trans	rs3118914	1.000	rs3116604	chr13:51114190	A/G	cg09222023	chr3:138669322	C3orf72	0.35	5.96	0.31	6.48e-9	Height;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg02732134	chr10:101732382	DNMBP	0.4	6.16	0.32	2.09e-9	Birth weight;Height;
CRC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.43	6.95	0.36	2.01e-11	High light scatter reticulocyte count;
CRC	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg00042356	chr1:8021962	PARK7	0.49	6.08	0.32	3.26e-9	Inflammatory bowel disease;
CRC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.39	-6.17	-0.32	2.02e-9	Monocyte count;
CRC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.79	13.08	0.58	9.09e-32	Height;
CRC	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.62	-8.62	-0.43	2.94e-16	Cocaine dependence;
CRC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg00745463	chr17:30367425	LRRC37B	0.54	6.6	0.34	1.67e-10	Hip circumference adjusted for BMI;
CRC	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg02766259	chr12:125626809	AACS	-0.46	-6.35	-0.33	7.1e-10	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg11204139	chr17:3907470	NA	-0.51	-6.42	-0.33	4.76e-10	Type 2 diabetes;
CRC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg24011408	chr12:48396354	COL2A1	-0.43	-6.31	-0.33	8.95e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs2290159	0.615	rs7610956	chr3:12677158	A/G	cg23032965	chr3:12705835	RAF1	0.49	6.12	0.32	2.59e-9	Cholesterol, total;
CRC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg24881330	chr22:46731750	TRMU	0.57	6.73	0.35	7.54e-11	LDL cholesterol;Cholesterol, total;
CRC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg07125278	chr16:67683757	RLTPR	-0.63	-6.85	-0.35	3.56e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.98	-0.36	1.65e-11	IgG glycosylation;
CRC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs2013441	0.866	rs10438824	chr17:20058510	C/T	cg13482628	chr17:19912719	NA	0.4	5.73	0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.98	-0.4	2.48e-14	Chronic sinus infection;
CRC	trans	rs16838233	0.925	rs9426354	chr1:29763684	C/T	cg12849791	chr3:38078307	NA	-0.5	-6.08	-0.32	3.42e-9	Paclitaxel disposition in epithelial ovarian cancer;
CRC	trans	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg24644049	chr4:85504048	CDS1	0.9	7.39	0.38	1.19e-12	Skin colour saturation;
CRC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.53	-8.45	-0.42	9.32e-16	Aortic root size;
CRC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.38	-7.27	-0.37	2.7e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.4	11.48	0.53	6.96e-26	Psoriasis vulgaris;
CRC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.85	-0.31	1.16e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7259376	0.936	rs7259586	chr19:22537862	C/T	cg02657401	chr19:22469223	NA	-0.33	-7.32	-0.37	1.91e-12	Menopause (age at onset);
CRC	cis	rs9491140	0.539	rs980656	chr6:124690303	A/G	cg19267163	chr6:125004984	NKAIN2	0.44	5.93	0.31	7.78e-9	Neuroticism;
CRC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.81	14.06	0.61	1.72e-35	Breast cancer;
CRC	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.34	0.38	1.64e-12	Eye color traits;
CRC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.74	-10.01	-0.48	9.27e-21	Coronary artery disease;
CRC	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.65	10.6	0.5	8.87e-23	Pulmonary function decline;
CRC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.71	-11.19	-0.52	7.81e-25	Lung cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25405238	chr17:79254455	SLC38A10	0.42	5.99	0.31	5.39e-9	Survival in pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02028540	chr16:67193883	TRADD;FBXL8	0.38	6.18	0.32	1.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	0.81	7.48	0.38	6.75e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg24560729	chr4:1342394	KIAA1530	-0.34	-6.23	-0.32	1.43e-9	Obesity-related traits;
CRC	cis	rs6772849	0.930	rs4467479	chr3:128369055	C/G	cg08795948	chr3:128337044	NA	0.35	6.2	0.32	1.73e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-9.01	-0.44	1.77e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg26587870	chr6:27730563	NA	-0.46	-6.69	-0.35	9.65e-11	Parkinson's disease;
CRC	cis	rs2398893	0.774	rs3909256	chr9:96889505	C/T	cg14459158	chr9:96720562	NA	-0.45	-6.38	-0.33	5.9e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.62	-0.57	4.76e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.58	8.3	0.42	2.68e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	11.28	0.53	3.53e-25	Schizophrenia;
CRC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg21251018	chr6:28226885	NKAPL	0.43	6.15	0.32	2.23e-9	Depression;
CRC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.77	12.78	0.58	1.2e-30	Breast cancer;
CRC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.56	8.53	0.43	5.37e-16	Blood protein levels;
CRC	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.59	6.3	0.33	9.68e-10	Schizophrenia;
CRC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.54	-7.59	-0.39	3.29e-13	Schizophrenia;
CRC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.45	-7.3	-0.37	2.13e-12	Post bronchodilator FEV1;
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13198984	chr17:80129470	CCDC57	0.46	8.24	0.41	4.11e-15	Life satisfaction;
CRC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.83	11.92	0.55	1.73e-27	Cognitive function;
CRC	trans	rs72862334	0.529	rs72863715	chr2:146656925	C/T	cg02985445	chr7:97908505	NA	0.39	6.23	0.32	1.45e-9	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.23	0.32	1.4e-9	Bladder cancer;
CRC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	7.09	0.36	8.45e-12	Iron status biomarkers;
CRC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.48	6.76	0.35	6.35e-11	Schizophrenia;
CRC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	7.83	0.4	6.73e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.47	-8.22	-0.41	4.66e-15	Red cell distribution width;
CRC	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.73	9.45	0.46	6.59e-19	Iron status biomarkers;
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs4731207	0.698	rs34618371	chr7:124496170	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.1	-0.32	2.96e-9	Cutaneous malignant melanoma;
CRC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02733842	chr7:1102375	C7orf50	-0.61	-8.02	-0.4	1.89e-14	Bronchopulmonary dysplasia;
CRC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg08975724	chr8:8085496	FLJ10661	0.41	6.16	0.32	2.18e-9	Neuroticism;
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-10.07	-0.49	5.54e-21	Menarche (age at onset);
CRC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.17	-0.32	2.04e-9	Height;
CRC	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.47	-7.02	-0.36	1.29e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg01831904	chr17:28903510	LRRC37B2	0.5	6.2	0.32	1.74e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	10.07	0.49	5.78e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.41	5.6	0.3	4.44e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg06634786	chr22:41940651	POLR3H	-0.44	-5.7	-0.3	2.66e-8	Neuroticism;
CRC	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg11176159	chr1:28213800	NA	0.3	5.86	0.31	1.13e-8	Corneal astigmatism;
CRC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg23283495	chr1:209979779	IRF6	0.48	6.8	0.35	4.82e-11	Cleft lip with or without cleft palate;
CRC	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg17133734	chr15:86042851	AKAP13	0.41	6.78	0.35	5.67e-11	Interstitial lung disease;
CRC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg18764771	chr6:116381957	FRK	0.26	7.46	0.38	7.62e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.76	10.0	0.48	9.56e-21	Bipolar disorder;
CRC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.27	-0.33	1.16e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.08	-12.43	-0.57	2.49e-29	Atopic dermatitis;
CRC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg07828024	chr6:149772892	ZC3H12D	0.49	9.24	0.45	3.25e-18	Dupuytren's disease;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Parkinson's disease;
CRC	cis	rs7192380	0.893	rs12924052	chr16:69777246	T/C	cg00738113	chr16:70207722	CLEC18C	0.34	5.99	0.31	5.61e-9	Sjögren's syndrome;
CRC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12741539	chr12:42719903	PPHLN1;ZCRB1	0.43	6.0	0.31	5.18e-9	Response to antipsychotic treatment;
CRC	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.71	-6.93	-0.36	2.28e-11	Non-glioblastoma glioma;Glioma;
CRC	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.5	9.2	0.45	4.34e-18	Weight;
CRC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg14541582	chr5:601475	NA	-0.33	-6.32	-0.33	8.55e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg15448220	chr1:150897856	SETDB1	0.45	6.4	0.33	5.25e-10	Urate levels;
CRC	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.6	-7.46	-0.38	7.96e-13	Fractional excretion of uric acid;
CRC	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.59	-8.02	-0.4	1.86e-14	Body mass index;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg11590700	chr3:169381241	MECOM	-0.41	-6.11	-0.32	2.75e-9	Protein C levels;
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.82e-9	Bipolar disorder;
CRC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.49	5.87	0.31	1.04e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.23	-0.32	1.45e-9	Menopause (age at onset);
CRC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.66	0.43	2.22e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg25420398	chr3:133968920	RYK	-0.41	-6.05	-0.32	3.97e-9	Underweight status;
CRC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.59	8.11	0.41	1.01e-14	Mean corpuscular hemoglobin;
CRC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.65	-8.08	-0.41	1.2e-14	Body mass index;
CRC	cis	rs7610312	0.681	rs6445972	chr3:58321707	C/T	cg06643156	chr3:58380774	PXK	-0.38	-5.65	-0.3	3.53e-8	Red blood cell count;
CRC	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.51	6.16	0.32	2.09e-9	Neuroticism;
CRC	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.45	6.09	0.32	3.14e-9	Recombination rate (females);
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.5e-9	Prudent dietary pattern;
CRC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04013166	chr16:89971882	TCF25	0.6	5.93	0.31	7.53e-9	Skin colour saturation;
CRC	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-10.4	-0.5	4.25e-22	Hepatocellular carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06272495	chr22:17652825	NA	0.42	6.34	0.33	7.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg10978503	chr1:24200527	CNR2	0.62	11.3	0.53	3.08e-25	Immature fraction of reticulocytes;
CRC	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.44	-6.39	-0.33	5.53e-10	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.99	-0.4	2.27e-14	Height;
CRC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.5	8.03	0.4	1.74e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg06462663	chr19:18546047	ISYNA1	0.5	7.63	0.39	2.48e-13	Breast cancer;
CRC	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.67	0.43	1.99e-16	Coffee consumption (cups per day);
CRC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.33	-0.49	7.67e-22	Tonsillectomy;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.57	-8.7	-0.43	1.57e-16	Pancreatic cancer;
CRC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.45	6.83	0.35	4.18e-11	Platelet count;
CRC	cis	rs4844614	1.000	rs6661764	chr1:207808385	C/G	cg17822947	chr1:207842917	CR1L	0.33	5.89	0.31	9.49e-9	LDL cholesterol;
CRC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.62	-10.38	-0.5	5.13e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4727963	0.765	rs1464877	chr7:122734266	G/A	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.19e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	6.66	0.34	1.12e-10	Platelet count;
CRC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.39	5.78	0.3	1.72e-8	Growth-regulated protein alpha levels;
CRC	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg26394196	chr10:1453818	ADARB2	-0.31	-5.65	-0.3	3.45e-8	Radiation response;
CRC	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg19897017	chr7:2163380	MAD1L1	0.41	6.23	0.32	1.45e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.63	0.34	1.34e-10	Dupuytren's disease;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-0.58	-8.18	-0.41	6.44e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.22	0.74	1.2e-59	Prudent dietary pattern;
CRC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg18479299	chr3:125709523	NA	-0.56	-6.64	-0.34	1.3e-10	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.4	-5.67	-0.3	3.08e-8	Longevity;Endometriosis;
CRC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg02158880	chr13:53174818	NA	0.59	9.46	0.46	6.12e-19	Lewy body disease;
CRC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.97	-18.53	-0.71	5.16e-53	Myeloid white cell count;
CRC	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.51	13.37	0.59	7.39e-33	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.52	7.72	0.39	1.37e-13	Intelligence (multi-trait analysis);
CRC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.22	0.32	1.51e-9	Rheumatoid arthritis;
CRC	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg01475377	chr6:109611718	NA	-0.33	-5.72	-0.3	2.4e-8	Reticulocyte fraction of red cells;
CRC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.68	11.87	0.55	2.69e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-6.97	-0.36	1.74e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.6	0.39	3.1400000000000003e-13	Major depressive disorder;
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.95	0.44	2.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg23100626	chr2:96804247	ASTL	0.27	7.32	0.37	1.93e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs16852403	0.904	rs6703721	chr1:178037791	C/T	cg00404053	chr1:178313656	RASAL2	0.49	6.18	0.32	1.91e-9	Childhood ear infection;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg03623178	chr6:28175578	NA	0.72	9.54	0.47	3.37e-19	Parkinson's disease;
CRC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.48	-6.85	-0.35	3.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10979	1.000	rs9403507	chr6:143887821	C/G	cg25407410	chr6:143891975	LOC285740	0.52	7.79	0.39	8.75e-14	Hypospadias;
CRC	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	15.32	0.65	2.24e-40	Mean corpuscular hemoglobin;
CRC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.65	8.76	0.43	1.07e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06837731	chr10:101945906	ERLIN1	0.46	6.74	0.35	7.09e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.64	-10.6	-0.5	8.95e-23	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12738864	chr3:40566248	ZNF621	0.42	6.01	0.31	4.8e-9	Response to antipsychotic treatment;
CRC	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.27e-25	White blood cell count (basophil);
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.77	14.57	0.63	1.9e-37	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11039072	chr15:35280907	ZNF770	0.45	6.29	0.33	9.98e-10	Response to antipsychotic treatment;
CRC	trans	rs57590327	0.503	rs2372906	chr3:81504673	G/A	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-5.97	-0.31	6.24e-9	Extraversion;
CRC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.83	-11.91	-0.55	1.9e-27	Gut microbiome composition (summer);
CRC	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.69	-11.69	-0.54	1.23e-26	White blood cell count (basophil);
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.65	9.07	0.45	1.1e-17	Menarche (age at onset);
CRC	cis	rs6735179	0.837	rs6548058	chr2:1775108	T/A	cg26137290	chr2:1776737	NA	-0.46	-6.1	-0.32	2.98e-9	Response to antipsychotic treatment;
CRC	trans	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.47	0.38	7.24e-13	Endometrial cancer;
CRC	trans	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.55	-6.05	-0.32	3.94e-9	Plateletcrit;
CRC	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg26816564	chr1:7831052	VAMP3	0.6	6.33	0.33	8.17e-10	Inflammatory bowel disease;
CRC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.54	8.16	0.41	7.02e-15	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-6.69	-0.35	9.33e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-6.5	-0.34	2.97e-10	Subjective well-being;
CRC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.73	-0.39	1.31e-13	Gut microbiome composition (summer);
CRC	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.55	-7.68	-0.39	1.87e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg22495460	chr2:25135724	ADCY3	-0.87	-16.52	-0.67	4.65e-45	Body mass index;
CRC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg14828511	chr1:107599125	PRMT6	0.45	6.21	0.32	1.58e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-9.2	-0.45	4.23e-18	Initial pursuit acceleration;
CRC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg03623178	chr6:28175578	NA	0.42	5.76	0.3	1.95e-8	Depression;
CRC	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.4	-6.28	-0.33	1.09e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg04719120	chr6:96025338	MANEA	0.52	6.44	0.33	4.13e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.55	-8.36	-0.42	1.85e-15	Height;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg22132876	chr20:62189343	NA	-0.37	-6.05	-0.32	3.94e-9	HDL cholesterol;
CRC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.53	7.92	0.4	3.58e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-6.92	-0.36	2.3e-11	Coronary artery disease;
CRC	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.59	-0.47	2.35e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.29e-11	Alzheimer's disease;
CRC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-8.61	-0.43	2.97e-16	Gut microbiome composition (summer);
CRC	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg03934865	chr2:198174659	NA	-0.46	-7.25	-0.37	2.93e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs8124695	0.764	rs61526616	chr20:39012631	G/A	cg15699267	chr20:61809557	MIR124-3	-0.54	-6.08	-0.32	3.33e-9	Dupuytren's disease;
CRC	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.36	5.61	0.3	4.39e-8	Height;
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-8.41	-0.42	1.24e-15	Total body bone mineral density;
CRC	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.12	17.14	0.69	1.66e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg02033258	chr5:131593261	PDLIM4	0.34	6.08	0.32	3.4e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg09723797	chr3:150481914	SIAH2	-0.65	-5.61	-0.3	4.36e-8	Breast cancer;
CRC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.46	-6.47	-0.34	3.56e-10	Platelet distribution width;
CRC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.06	10.61	0.5	8.48e-23	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20648385	chr11:72525603	ATG16L2	0.36	6.12	0.32	2.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.84	-10.45	-0.5	3.01e-22	Blood pressure (smoking interaction);
CRC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4523957	0.855	rs12601834	chr17:2112431	C/T	cg16513277	chr17:2031491	SMG6	-0.52	-8.62	-0.43	2.82e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	8.34	0.42	2.12e-15	Aortic root size;
CRC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.4	-0.46	9.84e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-8.78	-0.44	9e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.67	-0.57	3.13e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.84	15.56	0.65	2.72e-41	Lewy body disease;
CRC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg18833306	chr6:118973337	C6orf204	0.46	5.99	0.31	5.55e-9	Diastolic blood pressure;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg08798685	chr6:27730294	NA	0.62	5.95	0.31	7.04e-9	Depression;
CRC	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.42	-6.22	-0.32	1.54e-9	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.89	-15.95	-0.66	7.68e-43	Height;
CRC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	6.93	0.36	2.19e-11	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.85	-13.66	-0.6	5.96e-34	Hypospadias;
CRC	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-8.84	-0.44	5.73e-17	Systolic blood pressure;
CRC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.74	13.04	0.58	1.23e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	6.86	0.35	3.42e-11	Obesity-related traits;
CRC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.49	7.03	0.36	1.18e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-11.84	-0.55	3.61e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.99	-11.71	-0.54	1.01e-26	Blood protein levels;
CRC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.74e-21	Alzheimer's disease (late onset);
CRC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.47	6.73	0.35	7.62e-11	Lymphocyte counts;
CRC	cis	rs6679356	0.789	rs6662198	chr1:67806207	T/C	cg24364144	chr1:67875067	SERBP1	0.41	6.19	0.32	1.79e-9	Primary biliary cholangitis;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.84	0.31	1.27e-8	Bipolar disorder;
CRC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.39	-0.59	6.11e-33	Blood trace element (Zn levels);
CRC	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.46	6.92	0.36	2.3e-11	Red blood cell count;
CRC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.72	-0.47	8.68e-20	Total cholesterol levels;
CRC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.81	13.12	0.59	6.39e-32	Breast cancer;
CRC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg21285383	chr16:89894308	SPIRE2	0.38	6.66	0.34	1.18e-10	Vitiligo;
CRC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.93	-17.31	-0.69	3.63e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-8.55	-0.43	4.78e-16	Menarche (age at onset);
CRC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.64	-9.81	-0.48	4.14e-20	Cognitive function;
CRC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.49	7.88	0.4	4.8e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg03037974	chr15:76606532	NA	-0.54	-8.15	-0.41	7.44e-15	Blood metabolite levels;
CRC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.48	-7.22	-0.37	3.54e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.88	-0.31	9.82e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.62	-9.3	-0.46	2.08e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs720844	0.684	rs34324924	chr2:149307644	T/A	cg09247360	chr2:149335327	NA	-0.57	-5.98	-0.31	5.8e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.17	0.52	9.11e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.49	6.98	0.36	1.62e-11	Height;
CRC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.93	10.46	0.5	2.63e-22	Inflammatory bowel disease;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg19913688	chr11:428466	ANO9	-0.72	-7.58	-0.39	3.58e-13	Body mass index;
CRC	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg09455208	chr3:40491958	NA	0.32	6.35	0.33	7.07e-10	Renal cell carcinoma;
CRC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.95	-17.88	-0.7	1.91e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.56	0.5	1.18e-22	Corneal astigmatism;
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.55	-7.56	-0.38	4.16e-13	Colorectal cancer;
CRC	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg01858014	chr14:56050164	KTN1	-0.81	-6.11	-0.32	2.87e-9	Putamen volume;
CRC	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg09654669	chr8:57350985	NA	0.38	5.81	0.31	1.45e-8	Obesity-related traits;
CRC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.55	8.01	0.4	2.06e-14	Bladder cancer;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg10295955	chr4:187884368	NA	-0.99	-22.21	-0.77	2.03e-67	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11212617	0.905	rs172927	chr11:108124299	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.89	0.31	9.65e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg24324837	chr19:49891574	CCDC155	0.6	6.11	0.32	2.84e-9	Multiple sclerosis;
CRC	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg25482853	chr8:67687455	SGK3	1.06	12.12	0.56	3.22e-28	Obesity-related traits;
CRC	cis	rs1223397	0.651	rs202016	chr6:13301043	G/A	cg20827128	chr6:13274284	PHACTR1	0.37	5.69	0.3	2.8e-8	Blood pressure;
CRC	cis	rs9648716	0.554	rs10235900	chr7:140601438	G/T	cg17554604	chr7:140774522	NA	0.44	5.98	0.31	5.85e-9	Type 2 diabetes;
CRC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.5	9.54	0.47	3.24e-19	Alcohol dependence;
CRC	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.91	-0.4	3.84e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs12406019	0.548	rs11579434	chr1:78610022	T/C	cg20826526	chr3:156266748	SSR3	-0.41	-6.09	-0.32	3.14e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.94	-0.36	2.05e-11	Platelet distribution width;
CRC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs7605827	0.930	rs10179754	chr2:15541214	C/T	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.46	-0.46	6.05e-19	Capecitabine sensitivity;
CRC	cis	rs1950626	0.577	rs35097045	chr14:101454403	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.76	12.31	0.56	6.42e-29	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.36	-5.96	-0.31	6.34e-9	Personality dimensions;
CRC	cis	rs1532331	0.898	rs4498259	chr5:43165943	A/G	cg09164108	chr5:43007320	NA	-0.39	-6.09	-0.32	3.16e-9	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08083689	chr4:8442326	ACOX3	0.46	6.31	0.33	9.06e-10	Response to antipsychotic treatment;
CRC	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.61e-11	Inflammatory skin disease;
CRC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.74	0.57	1.73e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.11	0.41	9.95e-15	Rheumatoid arthritis;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6427782	0.542	rs11578938	chr1:199892279	C/T	cg07208853	chr1:200005219	NR5A2	0.24	6.08	0.32	3.31e-9	Menarche (age at onset);
CRC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg18230493	chr5:56204884	C5orf35	-0.4	-5.91	-0.31	8.61e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs12692738	0.526	rs355841	chr2:165622150	G/A	cg03182029	chr2:165697222	COBLL1	0.51	5.98	0.31	5.74e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg27398640	chr15:77910606	LINGO1	-0.37	-6.17	-0.32	2e-9	Type 2 diabetes;
CRC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.66	11.91	0.55	1.98e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7605827	0.930	rs2058866	chr2:15519992	G/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg20607287	chr7:12443886	VWDE	-0.47	-6.09	-0.32	3.07e-9	Coronary artery disease;
CRC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg09835421	chr16:68378352	PRMT7	-0.61	-5.64	-0.3	3.73e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.56	9.15	0.45	6.01e-18	Hemoglobin concentration;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.35	-6.58	-0.34	1.86e-10	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs7173389	0.530	rs6495064	chr15:73682867	C/T	cg01796676	chr15:73680284	NA	-0.53	-8.29	-0.42	2.87e-15	Resting heart rate;
CRC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg19223190	chr17:80058835	NA	0.38	5.96	0.31	6.45e-9	Life satisfaction;
CRC	cis	rs972578	1.000	rs738379	chr22:43400764	G/T	cg01576275	chr22:43409880	NA	0.52	8.55	0.43	4.64e-16	Mean platelet volume;
CRC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.58	-8.76	-0.43	1.04e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs783540	1.000	rs11637433	chr15:83321336	A/G	cg18393722	chr15:85113863	UBE2QP1	0.38	6.29	0.33	9.96e-10	Schizophrenia;
CRC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.67	-10.68	-0.51	4.82e-23	Sudden cardiac arrest;
CRC	cis	rs11030122	0.547	rs10835333	chr11:3957766	A/G	cg18678763	chr11:4115507	RRM1	-0.35	-6.01	-0.31	4.98e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg10589385	chr1:150898437	SETDB1	0.33	7.09	0.36	8.33e-12	Melanoma;
CRC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.73	-8.21	-0.41	5.01e-15	Psoriasis;
CRC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.43	-6.56	-0.34	2.05e-10	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.29	0.42	2.87e-15	Height;
CRC	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.6	-8.31	-0.42	2.58e-15	Body mass index;
CRC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg00166722	chr3:10149974	C3orf24	0.43	6.36	0.33	6.64e-10	Alzheimer's disease;
CRC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg15123519	chr2:136567270	LCT	0.34	6.51	0.34	2.85e-10	Mosquito bite size;
CRC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.52	8.24	0.41	4.11e-15	Hemoglobin concentration;Hematocrit;
CRC	cis	rs847649	1.000	rs847649	chr7:102556011	C/T	cg18108683	chr7:102477205	FBXL13	-0.57	-9.33	-0.46	1.61e-18	Morning vs. evening chronotype;
CRC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	15.18	0.64	8.04e-40	Smoking behavior;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03115081	chr17:74722049	C17orf95;JMJD6	0.44	6.05	0.32	3.87e-9	Response to antipsychotic treatment;
CRC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.64	-9.56	-0.47	2.92e-19	Menarche (age at onset);
CRC	trans	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	7.02	0.36	1.24e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg15445000	chr17:37608096	MED1	0.36	6.27	0.33	1.12e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.39	-9.21	-0.45	3.93e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01423368	chr11:76155379	C11orf30	0.44	6.17	0.32	2.05e-9	Response to antipsychotic treatment;
CRC	cis	rs1800978	0.925	rs12686004	chr9:107653426	C/T	cg14313833	chr9:107666037	ABCA1	-0.59	-5.97	-0.31	6.02e-9	Coronary artery disease;
CRC	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.72	13.07	0.58	9.7e-32	Inhibitory control;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg19041857	chr6:27730383	NA	-0.44	-6.06	-0.32	3.8e-9	Parkinson's disease;
CRC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.61	-8.02	-0.4	1.93e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6496667	0.642	rs62019394	chr15:91060730	C/T	cg04176472	chr15:90893244	GABARAPL3	0.55	7.88	0.4	4.85e-14	Rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.43	6.92	0.36	2.36e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.91	16.91	0.68	1.27e-46	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.83	8.71	0.43	1.51e-16	Gastritis;
CRC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg27432699	chr2:27873401	GPN1	-0.5	-7.6	-0.39	3.06e-13	Total body bone mineral density;
CRC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.85	15.96	0.66	7.32e-43	Dental caries;
CRC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.6	0.34	1.62e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.78	8.24	0.41	4.03e-15	Gut microbiome composition (summer);
CRC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.85	-14.55	-0.63	2.21e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.4	-5.83	-0.31	1.32e-8	Electroencephalogram traits;
CRC	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg10217327	chr6:118973057	C6orf204	0.52	5.62	0.3	3.98e-8	Diastolic blood pressure;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.59	8.99	0.44	1.99e-17	Longevity;Endometriosis;
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg12172441	chr6:28176163	NA	0.49	6.42	0.33	4.77e-10	Parkinson's disease;
CRC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.18	0.32	1.88e-9	Intraocular pressure;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg03188948	chr7:1209495	NA	0.42	6.12	0.32	2.65e-9	Longevity;Endometriosis;
CRC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.2	-0.45	4.22e-18	Platelet count;
CRC	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg15845792	chr6:28175446	NA	0.74	7.08	0.36	8.95e-12	Depression;
CRC	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.26e-10	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05176131	chr17:48624481	SPATA20	0.4	6.96	0.36	1.81e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.52	8.48	0.42	7.48e-16	Breast cancer;
CRC	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.36	6.57	0.34	1.91e-10	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.68	7.48	0.38	6.83e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.77	10.46	0.5	2.67e-22	Coronary artery disease;
CRC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.58	9.22	0.45	3.76e-18	Vitiligo;
CRC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.52	6.94	0.36	2.07e-11	Body mass index;
CRC	cis	rs9928842	0.712	rs8057843	chr16:75221555	T/G	cg09066997	chr16:75300724	BCAR1	0.65	6.12	0.32	2.67e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	10.55	0.5	1.36e-22	Motion sickness;
CRC	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.24	0.49	1.53e-21	Birth weight;
CRC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.75	-0.35	6.73e-11	Urate levels in overweight individuals;
CRC	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.74	-0.39	1.26e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	7.94	0.4	3.22e-14	Obesity-related traits;
CRC	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.48e-11	Inflammatory skin disease;
CRC	cis	rs2637266	0.538	rs11001852	chr10:78445987	G/C	cg18941641	chr10:78392320	NA	-0.35	-5.83	-0.31	1.31e-8	Pulmonary function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19941230	chr17:63051872	GNA13	0.38	6.14	0.32	2.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.76	-12.21	-0.56	1.6e-28	Breast cancer;
CRC	cis	rs490234	0.841	rs7856366	chr9:128442229	A/G	cg14078157	chr9:128172775	NA	-0.37	-6.17	-0.32	2e-9	Mean arterial pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02167865	chr10:99078850	FRAT1	0.46	6.46	0.34	3.77e-10	Response to antipsychotic treatment;
CRC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.63	-0.43	2.68e-16	Platelet count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12473036	chr20:62611207	SAMD10;PRPF6	0.49	6.73	0.35	7.42e-11	Thyroid stimulating hormone;
CRC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg23565292	chr14:50234668	KLHDC2	-0.39	-5.61	-0.3	4.36e-8	Carotid intima media thickness;
CRC	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.59	6.73	0.35	7.47e-11	Prostate cancer;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg26028573	chr6:26043587	HIST1H2BB	0.47	6.83	0.35	4.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg25164649	chr6:28176230	NA	0.6	7.91	0.4	3.87e-14	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3857067	1.000	rs1588381	chr4:95017558	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.06	-0.32	3.63e-9	QT interval;
CRC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.58	-0.75	4.64e-61	Myeloid white cell count;
CRC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.59	9.61	0.47	2.03e-19	Tonsillectomy;
CRC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.17	27.15	0.83	5.16e-86	IgG glycosylation;
CRC	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg17691542	chr6:26056736	HIST1H1C	0.49	6.38	0.33	6.04e-10	Height;
CRC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.32	-0.37	1.97e-12	Morning vs. evening chronotype;
CRC	cis	rs7527798	0.592	rs11118281	chr1:207832102	C/T	cg21110645	chr1:207815933	NA	-0.38	-5.79	-0.3	1.68e-8	Erythrocyte sedimentation rate;
CRC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.56	-8.96	-0.44	2.54e-17	Non-obstructive azoospermia;
CRC	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.4	-6.83	-0.35	4.13e-11	Hip circumference;Waist circumference;
CRC	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg23356831	chr14:105996513	TMEM121	0.41	6.98	0.36	1.59e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.07	0.41	1.33e-14	Cystic fibrosis severity;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.84	-18.62	-0.72	2.33e-53	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15871991	chr2:10829907	NOL10	0.43	5.99	0.31	5.47e-9	Response to antipsychotic treatment;
CRC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.92	-0.36	2.44e-11	Cutaneous nevi;
CRC	cis	rs10783615	0.719	rs1975471	chr12:54336981	A/G	cg25382128	chr12:54346509	NA	-0.51	-6.57	-0.34	2.01e-10	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06634786	chr22:41940651	POLR3H	0.44	5.62	0.3	4.06e-8	Vitiligo;
CRC	trans	rs17641971	0.862	rs341817	chr8:50023600	A/C	cg18784943	chr17:79371681	NA	0.39	5.96	0.31	6.47e-9	Blood metabolite levels;
CRC	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-0.98	-11.62	-0.54	2.16e-26	Height;
CRC	cis	rs2579500	0.807	rs11891926	chr2:97339781	A/G	cg23100626	chr2:96804247	ASTL	-0.23	-5.67	-0.3	3.09e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs2882667	1.000	rs10515505	chr5:138313146	A/G	cg09476006	chr5:138032270	NA	0.46	7.6	0.39	3.04e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.54	-0.7	4.43e-49	Height;
CRC	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.59	-9.31	-0.46	1.81e-18	HDL cholesterol;
CRC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.36	-6.15	-0.32	2.25e-9	Schizophrenia;
CRC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs524281	0.773	rs7951079	chr11:65980550	C/T	cg14036092	chr11:66035641	RAB1B	-0.54	-5.87	-0.31	1.04e-8	Electroencephalogram traits;
CRC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg13072238	chr3:49761600	GMPPB	-0.52	-5.86	-0.31	1.11e-8	Menarche (age at onset);
CRC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-12.79	-0.58	1.07e-30	Asthma;
CRC	cis	rs4234798	0.605	rs4689637	chr4:7211197	A/G	cg18431297	chr4:7219810	SORCS2	0.48	7.41	0.38	1.08e-12	Insulin-like growth factors;
CRC	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg02770688	chr6:168491649	NA	0.62	9.16	0.45	5.86e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21036854	chr14:77506705	NA	0.52	7.54	0.38	4.74e-13	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.51	7.79	0.39	9.12e-14	Motion sickness;
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.47	-0.42	8.31e-16	Bipolar disorder;
CRC	cis	rs1539053	0.934	rs1524708	chr1:58102590	T/A	cg20292791	chr1:58089357	DAB1	-0.33	-5.79	-0.3	1.69e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg21033440	chr11:65409861	SIPA1	-0.65	-8.27	-0.41	3.4e-15	Blood pressure (age interaction);
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg24675056	chr1:15929824	NA	0.51	7.06	0.36	9.73e-12	Systolic blood pressure;
CRC	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.52	-7.2	-0.37	4.21e-12	Coronary artery disease;
CRC	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg15147215	chr3:52552868	STAB1	0.44	7.4	0.38	1.18e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.53	-9.9	-0.48	2.14e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	8.4	0.42	1.35e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3741151	0.686	rs7123985	chr11:73260463	A/C	cg17517138	chr11:73019481	ARHGEF17	0.55	5.62	0.3	4.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg07217954	chr7:1067459	C7orf50	0.55	5.68	0.3	3.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11645453	chr3:52864694	ITIH4	0.33	6.22	0.32	1.49e-9	Electroencephalogram traits;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.66	-10.47	-0.5	2.5e-22	Motion sickness;
CRC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg13057898	chr1:3703894	LRRC47	0.57	7.69	0.39	1.69e-13	Red cell distribution width;
CRC	cis	rs10242455	0.702	rs58348977	chr7:99188014	G/A	cg18809830	chr7:99032528	PTCD1	-1.18	-8.08	-0.41	1.23e-14	Blood metabolite levels;
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.56	-7.21	-0.37	3.86e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-16.53	-0.67	4e-45	Coronary artery disease;
CRC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.71	12.16	0.56	2.36e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9302690	0.793	rs16956811	chr16:57444002	G/T	cg27017172	chr16:57497170	POLR2C	-0.55	-5.9	-0.31	9.25e-9	Blood protein levels;
CRC	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg15845792	chr6:28175446	NA	0.65	8.93	0.44	2.99e-17	Parkinson's disease;
CRC	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.42	-0.33	4.77e-10	Retinal vascular caliber;
CRC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.93	14.17	0.62	6.79e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.54	-9.01	-0.45	1.66e-17	Brugada syndrome;
CRC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.61	9.47	0.46	5.49e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7192750	0.527	rs30433	chr16:72145404	T/C	cg14768367	chr16:72042858	DHODH	0.76	6.02	0.32	4.6e-9	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs73206853	0.764	rs7953794	chr12:111081197	A/G	cg12870014	chr12:110450643	ANKRD13A	0.79	9.98	0.48	1.14e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.43	0.46	7.7e-19	Coffee consumption (cups per day);
CRC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg06654549	chr5:1875058	NA	0.4	5.92	0.31	7.98e-9	Cardiovascular disease risk factors;
CRC	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg06522879	chr11:64358276	SLC22A12	0.57	8.95	0.44	2.62e-17	Urate levels in obese individuals;
CRC	cis	rs981621	0.704	rs2867876	chr18:13316130	C/G	cg23768505	chr18:13262434	C18orf1	0.37	5.61	0.3	4.2e-8	Survival in pancreatic cancer;
CRC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.51	-7.73	-0.39	1.34e-13	Menarche (age at onset);
CRC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg02033258	chr5:131593261	PDLIM4	0.4	7.74	0.39	1.26e-13	Breast cancer;
CRC	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.97e-12	Diisocyanate-induced asthma;
CRC	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-0.81	-6.31	-0.33	8.98e-10	Depression;
CRC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg19622623	chr12:86230825	RASSF9	-0.35	-5.62	-0.3	4.12e-8	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10727759	chr12:50017361	PRPF40B	-0.39	-5.96	-0.31	6.43e-9	Myopia (pathological);
CRC	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.49	-0.38	6.29e-13	Metabolite levels;
CRC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.88	-0.35	2.99e-11	Breast cancer;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg11235426	chr6:292522	DUSP22	-0.54	-7.64	-0.39	2.38e-13	Menopause (age at onset);
CRC	cis	rs13082711	0.954	rs35523848	chr3:27552800	A/C	cg02860705	chr3:27208620	NA	0.58	7.43	0.38	9.49e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg19223190	chr17:80058835	NA	0.38	6.17	0.32	2e-9	Life satisfaction;
CRC	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.46	9.25	0.45	2.98e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs365302	1.000	rs481899	chr6:159651671	T/C	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.4	7.75	0.39	1.14e-13	Mean corpuscular volume;
CRC	cis	rs17767392	0.881	rs8006300	chr14:72050162	C/T	cg13720639	chr14:72061746	SIPA1L1	0.5	6.19	0.32	1.8e-9	Mitral valve prolapse;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18297960	chr7:1142765	C7orf50	-0.42	-5.72	-0.3	2.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs16924133	0.793	rs11032160	chr11:33162040	C/T	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02926368	chr1:202310824	UBE2T	0.52	6.61	0.34	1.53e-10	Thyroid stimulating hormone;
CRC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.66	0.34	1.13e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.42	6.68	0.35	1.03e-10	High light scatter reticulocyte count;
CRC	cis	rs11750568	0.935	rs10070609	chr5:178524969	T/C	cg10208897	chr5:178548229	ADAMTS2	0.35	5.69	0.3	2.81e-8	Height;
CRC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.68	0.35	1.03e-10	Lung cancer;
CRC	cis	rs4664293	1.000	rs11676412	chr2:160508071	G/T	cg08347373	chr2:160653686	CD302	-0.38	-6.24	-0.33	1.38e-9	Monocyte percentage of white cells;
CRC	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg15711740	chr2:61764176	XPO1	0.45	6.24	0.33	1.37e-9	Tuberculosis;
CRC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.77	14.38	0.62	9.97e-37	Prudent dietary pattern;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg14883916	chr11:6947541	ZNF215	0.61	6.45	0.34	3.93e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.88	-0.31	9.9e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.6	-7.29	-0.37	2.4e-12	Body mass index;
CRC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.73	6.61	0.34	1.55e-10	Diabetic kidney disease;
CRC	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.4	-0.38	1.13e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg22079747	chr2:228736145	WDR69	-0.44	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs4728142	0.604	rs7807018	chr7:128640188	A/G	cg06630958	chr7:128577819	IRF5	-0.35	-5.67	-0.3	3.11e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg17524180	chr13:113633600	MCF2L	-0.62	-11.32	-0.53	2.59e-25	Systolic blood pressure;
CRC	cis	rs11212617	0.967	rs1583598	chr11:108305989	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.7	0.3	2.71e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-9.83	-0.48	3.74e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.44	7.7	0.39	1.62e-13	HDL cholesterol;
CRC	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.65	-8.51	-0.42	6.07e-16	Extraversion;
CRC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.67	8.02	0.4	1.83e-14	Gut microbiome composition (summer);
CRC	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg02376178	chr19:1969988	CSNK1G2	0.59	9.35	0.46	1.4e-18	Coronary artery disease;
CRC	cis	rs4731207	0.596	rs10954051	chr7:124579236	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-10.86	-0.51	1.1e-23	Hepatocellular carcinoma;
CRC	cis	rs847649	0.599	rs13232194	chr7:102742554	T/A	cg18108683	chr7:102477205	FBXL13	0.54	8.66	0.43	2.08e-16	Morning vs. evening chronotype;
CRC	cis	rs9463078	0.715	rs7738526	chr6:45168417	C/A	cg25276700	chr6:44698697	NA	-0.24	-5.95	-0.31	7e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg01444801	chr10:135216882	MTG1	-0.41	-6.11	-0.32	2.8e-9	Systemic lupus erythematosus;
CRC	cis	rs9992667	1.000	rs10032639	chr4:38674728	A/T	cg19726192	chr4:38663646	FLJ13197	-0.71	-8.91	-0.44	3.47e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.47	6.59	0.34	1.76e-10	Blood metabolite levels;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.51	7.67	0.39	2.02e-13	Breast cancer;
CRC	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.38	-6.22	-0.32	1.48e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg08347473	chr17:78092826	GAA	-0.37	-6.02	-0.32	4.65e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.59	-11.23	-0.53	5.58e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.46	5.75	0.3	2.07e-8	Metabolite levels;
CRC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.43	-0.33	4.58e-10	Body mass index;
CRC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.41	0.33	5.06e-10	Rheumatoid arthritis;
CRC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.51	8.25	0.41	3.87e-15	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18892560	chr6:18264287	DEK	0.44	6.46	0.34	3.78e-10	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.33	1.4e-9	Bipolar disorder;
CRC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.64	9.5	0.46	4.57e-19	Blood protein levels;
CRC	trans	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg18187862	chr3:45730750	SACM1L	-0.55	-7.09	-0.36	8.19e-12	Primary sclerosing cholangitis;
CRC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.46	0.6	3.33e-33	Chronic sinus infection;
CRC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.66	10.75	0.51	2.61e-23	Height;
CRC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.77	-12.21	-0.56	1.51e-28	Tonsillectomy;
CRC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.33	0.33	8.26e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.5	8.16	0.41	7.17e-15	Endometrial cancer;
CRC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg17075019	chr10:79541650	NA	-0.87	-14.56	-0.63	2.09e-37	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.07	0.41	1.34e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg17410650	chr12:54324560	NA	-0.36	-6.69	-0.35	9.77e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.8	-11.78	-0.54	5.67e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.52	7.53	0.38	4.99e-13	Corneal astigmatism;
CRC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.52	1.55e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg25164649	chr6:28176230	NA	0.54	7.25	0.37	2.92e-12	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09732282	chr15:58474918	AQP9	0.46	6.49	0.34	3.08e-10	Thyroid stimulating hormone;
CRC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-11.27	-0.53	3.78e-25	Asthma;
CRC	cis	rs17155006	0.664	rs371024	chr7:107741055	A/G	cg05962710	chr7:107745446	LAMB4	-0.43	-7.57	-0.39	3.74e-13	Pneumococcal bacteremia;
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.5	-0.34	2.93e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.79	-0.44	8.53e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.24	6.06	0.32	3.65e-9	Lymphocyte counts;
CRC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.44	6.99	0.36	1.53e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.59	10.66	0.51	5.37e-23	Blood metabolite ratios;
CRC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.21	-16.5	-0.67	5.53e-45	Breast cancer;
CRC	cis	rs9649465	0.967	rs6944031	chr7:123299304	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-5.62	-0.3	3.99e-8	Migraine;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07220488	chr17:77006061	CANT1	0.4	6.14	0.32	2.34e-9	Schizophrenia;
CRC	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg24998770	chr7:37888106	TXNDC3	0.38	6.13	0.32	2.53e-9	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.5	0.65	4.55e-41	Fuchs's corneal dystrophy;
CRC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.53	7.13	0.37	6.34e-12	Obesity-related traits;
CRC	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.34	-5.84	-0.31	1.27e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.04	-0.32	4.2e-9	Neuroticism;
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg19041857	chr6:27730383	NA	-0.63	-6.79	-0.35	5.27e-11	Lung cancer in ever smokers;
CRC	cis	rs4750440	0.706	rs10906555	chr10:14016879	G/A	cg00551146	chr10:14014579	FRMD4A	0.35	5.71	0.3	2.57e-8	Adiponectin levels;
CRC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg25164649	chr6:28176230	NA	-0.8	-11.58	-0.54	2.96e-26	Depression;
CRC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.72	10.22	0.49	1.81e-21	Heart rate;
CRC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.44	7.41	0.38	1.11e-12	Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09351035	chr11:748060	TALDO1	0.47	6.54	0.34	2.35e-10	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.66	9.74	0.47	7.24e-20	Corneal astigmatism;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18591801	chr3:52553433	STAB1	-0.31	-6.06	-0.32	3.82e-9	Electroencephalogram traits;
CRC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg02659138	chr7:134003124	SLC35B4	0.35	5.7	0.3	2.68e-8	Mean platelet volume;
CRC	cis	rs7781266	0.790	rs17654334	chr7:133083234	C/T	cg03336402	chr7:133662267	EXOC4	0.51	5.99	0.31	5.39e-9	Educational attainment (college completion);
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.11	0.52	1.42e-24	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	11.42	0.53	1.18e-25	Mean corpuscular hemoglobin;
CRC	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.38e-26	Coffee consumption (cups per day);
CRC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.75	12.44	0.57	2.28e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.48	6.5	0.34	2.93e-10	Morning vs. evening chronotype;
CRC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg13606994	chr1:44402422	ARTN	-0.35	-5.93	-0.31	7.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg13385794	chr1:248469461	NA	0.38	6.73	0.35	7.57e-11	Common traits (Other);
CRC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.73	9.78	0.47	5.53e-20	Coronary artery disease;
CRC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg21854759	chr1:92012499	NA	-0.53	-8.79	-0.44	8.46e-17	Breast cancer;
CRC	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	0.86	9.21	0.45	3.82e-18	Gut microbiota (bacterial taxa);
CRC	cis	rs713477	0.654	rs11158040	chr14:55914607	T/C	cg21836586	chr14:55907198	TBPL2	0.35	6.44	0.33	4.32e-10	Pediatric bone mineral content (femoral neck);
CRC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.42	6.63	0.34	1.34e-10	Dupuytren's disease;
CRC	cis	rs7635838	0.859	rs9869423	chr3:11459156	G/T	cg00170343	chr3:11313890	ATG7	0.41	6.24	0.33	1.35e-9	HDL cholesterol;
CRC	cis	rs6564851	0.506	rs7186423	chr16:81257161	A/G	cg05274606	chr16:81253692	PKD1L2	-0.36	-5.93	-0.31	7.65e-9	Carotenoid and tocopherol levels;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.46	6.05	0.32	3.99e-9	IgG glycosylation;
CRC	cis	rs10924970	0.967	rs2185020	chr1:235440289	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.84e-9	Asthma;
CRC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.62	-7.82	-0.4	7.32e-14	Schizophrenia;
CRC	cis	rs11997175	0.600	rs6468188	chr8:33639478	T/C	ch.8.33884649F	chr8:33765107	NA	0.41	6.41	0.33	5e-10	Body mass index;
CRC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs501120	1.000	rs915083	chr10:44755406	T/G	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	trans	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg26043149	chr18:55253948	FECH	0.49	7.49	0.38	6.49e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.61	10.2	0.49	2.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg13319975	chr6:146136371	FBXO30	0.39	5.73	0.3	2.24e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.41	-7.44	-0.38	8.78e-13	Type 2 diabetes;
CRC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg24466277	chr1:23519622	HTR1D	0.42	5.81	0.31	1.47e-8	Height;
CRC	trans	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.89	9.04	0.45	1.4e-17	Lymphocyte counts;
CRC	trans	rs7027930	0.524	rs3812526	chr9:608703	A/G	cg27061366	chr19:13044373	FARSA	0.53	6.66	0.34	1.18e-10	Pulmonary function decline;
CRC	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	9.55	0.47	3.2e-19	Gastritis;
CRC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.53	6.9	0.36	2.71e-11	Morning vs. evening chronotype;
CRC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-0.96	-13.25	-0.59	2.05e-32	Hip circumference adjusted for BMI;
CRC	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.46	8.17	0.41	6.5e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.65	-11.74	-0.54	8.01e-27	Breast cancer;
CRC	cis	rs1975974	1.000	rs7224508	chr17:21722352	T/A	cg18423549	chr17:21743878	NA	-0.61	-8.63	-0.43	2.58e-16	Psoriasis;
CRC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.72	0.35	7.9e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.06	-0.36	9.85e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.55	-9.03	-0.45	1.5e-17	Congenital heart disease (maternal effect);
CRC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg15832292	chr6:96025679	MANEA	0.61	6.81	0.35	4.62e-11	Behavioural disinhibition (generation interaction);
CRC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.77	-13.36	-0.59	8.26e-33	Body mass index;
CRC	cis	rs11212617	0.967	rs662578	chr11:108194557	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.37	0.33	6.45e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17554472	chr22:41940697	POLR3H	0.56	5.71	0.3	2.55e-8	Vitiligo;
CRC	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg16964102	chr10:135390573	NA	0.48	6.33	0.33	7.95e-10	Gout;
CRC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.57	6.79	0.35	5.28e-11	Type 2 diabetes nephropathy;
CRC	cis	rs2882667	0.690	rs10515504	chr5:138222994	C/G	cg09476006	chr5:138032270	NA	-0.53	-9.05	-0.45	1.3e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg03929089	chr4:120376271	NA	-0.46	-6.62	-0.34	1.42e-10	HDL cholesterol;
CRC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.5	-6.47	-0.34	3.55e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.91	-0.55	1.94e-27	Type 2 diabetes;
CRC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.54	8.25	0.41	3.77e-15	Aortic root size;
CRC	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.64	8.22	0.41	4.62e-15	Iron status biomarkers;
CRC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg23463467	chr20:60627584	TAF4	0.44	8.31	0.42	2.47e-15	Body mass index;
CRC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg22495460	chr2:25135724	ADCY3	-0.87	-17.17	-0.69	1.23e-47	Body mass index;
CRC	cis	rs6694672	0.867	rs4915327	chr1:197079130	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.68	0.39	1.86e-13	Asthma;
CRC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.89e-8	Bladder cancer;
CRC	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	1.1	23.55	0.79	1.51e-72	Gut microbiome composition (winter);
CRC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.5	9.19	0.45	4.44e-18	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19056515	chr10:105361785	SH3PXD2A	-0.41	-6.67	-0.35	1.07e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.41	6.61	0.34	1.57e-10	Dupuytren's disease;
CRC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.53	7.39	0.38	1.2e-12	Lung cancer;
CRC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg23463467	chr20:60627584	TAF4	0.35	6.08	0.32	3.4e-9	Body mass index;
CRC	cis	rs9826463	0.757	rs73240318	chr3:142277427	A/G	cg20824294	chr3:142316082	PLS1	0.42	6.99	0.36	1.54e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.28	0.56	8.36e-29	Platelet count;
CRC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg25834613	chr7:1915315	MAD1L1	-0.37	-5.93	-0.31	7.48e-9	Neuroticism;
CRC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg09655341	chr17:79618100	PDE6G	-0.35	-6.07	-0.32	3.5e-9	Eye color traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19926395	chr7:150865207	GBX1	-0.36	-6.47	-0.34	3.47e-10	Myopia (pathological);
CRC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.38	-7.89	-0.4	4.4e-14	Cutaneous nevi;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.41	0.42	1.25e-15	Corneal astigmatism;
CRC	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs1223397	0.938	rs17700321	chr6:13280666	G/T	cg06879394	chr6:13274151	PHACTR1	0.51	6.24	0.33	1.33e-9	Blood pressure;
CRC	cis	rs4237845	0.611	rs4272820	chr12:58330541	G/A	cg02175503	chr12:58329896	NA	0.71	10.86	0.51	1.07e-23	Intelligence (multi-trait analysis);
CRC	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg02811702	chr13:24901961	NA	0.48	6.63	0.34	1.37e-10	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.68	10.29	0.49	1.05e-21	Platelet distribution width;
CRC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.66	8.29	0.42	3e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg24375607	chr4:120327624	NA	-0.41	-6.42	-0.33	4.87e-10	Corneal astigmatism;
CRC	cis	rs9937943	1.000	rs9937943	chr16:74499046	C/G	cg01733217	chr16:74700730	RFWD3	0.66	7.55	0.38	4.21e-13	Neutrophil percentage of white cells;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.16	-0.49	2.85e-21	Bipolar disorder;
CRC	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg09760422	chr2:128146352	NA	-0.36	-7.06	-0.36	1.01e-11	Protein C levels;
CRC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-7.5	-0.38	5.96e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.81	-13.6	-0.6	9.63e-34	Cystic fibrosis severity;
CRC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.65	10.8	0.51	1.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.36	-0.33	6.91e-10	Aortic root size;
CRC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.53	-0.43	5.29e-16	Aortic root size;
CRC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.63	-0.34	1.37e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	1.01	16.24	0.67	5.64e-44	Testicular germ cell tumor;
CRC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.81	-0.31	1.45e-8	Breast cancer;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.24e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	trans	rs11231420	1	rs11231420	chr11:55644734	T/C	cg25886479	chr11:50257625	LOC441601	0.38	6.31	0.33	8.8e-10	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.48e-10	Morning vs. evening chronotype;
CRC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	11.21	0.53	6.56e-25	Tonsillectomy;
CRC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.65	-6.95	-0.36	2e-11	Vitiligo;
CRC	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.74	-8.98	-0.44	2.08e-17	Bone mineral density;
CRC	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.54	7.56	0.38	4.07e-13	Eye color traits;
CRC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.29e-10	Childhood ear infection;
CRC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12516959	chr21:47718080	NA	0.33	5.87	0.31	1.06e-8	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13237906	chr5:149340052	SLC26A2	0.5	7.53	0.38	5.08e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.698	rs6973812	chr7:124506750	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg23815491	chr16:72088622	HP	0.64	8.21	0.41	5.02e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12745968	0.589	rs4484938	chr1:92955821	T/C	cg17283838	chr1:93427260	FAM69A	-0.43	-5.98	-0.31	5.73e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs10411161	0.702	rs7247017	chr19:52391769	T/C	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	trans	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.27	-0.37	2.72e-12	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs3018066	0.836	rs28784652	chr4:107025576	A/G	cg01869342	chr4:106983673	TBCK	0.36	5.67	0.3	3.17e-8	Cancer;
CRC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.66	-8.39	-0.42	1.5e-15	Mean platelet volume;
CRC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.55	-7.69	-0.39	1.74e-13	IgG glycosylation;
CRC	trans	rs12517041	1.000	rs10941982	chr5:23298902	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.82	-0.48	4.02e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	1.09	10.16	0.49	2.9e-21	Parkinson's disease;
CRC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.98	0.4	2.43e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.41	-5.73	-0.3	2.23e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.66	-8.15	-0.41	7.56e-15	Blood protein levels;
CRC	cis	rs73206853	0.688	rs73191809	chr12:110907639	T/A	cg12870014	chr12:110450643	ANKRD13A	0.77	7.34	0.38	1.69e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg11266682	chr4:10021025	SLC2A9	0.41	6.42	0.33	4.9e-10	Blood metabolite levels;
CRC	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.56	-7.55	-0.38	4.46e-13	Hepatocellular carcinoma;
CRC	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-6.94	-0.36	2.13e-11	Menarche (age at onset);
CRC	cis	rs6681460	1.000	rs1536115	chr1:67121001	A/T	cg02459107	chr1:67143332	SGIP1	0.48	8.19	0.41	5.83e-15	Presence of antiphospholipid antibodies;
CRC	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.56	-9.36	-0.46	1.3e-18	Aortic root size;
CRC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.68	10.55	0.5	1.36e-22	Monocyte count;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16746620	chr16:89178589	ACSF3	-0.39	-6.08	-0.32	3.31e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.71	-0.6	3.67e-34	Ulcerative colitis;
CRC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.42	-6.34	-0.33	7.66e-10	Obesity-related traits;
CRC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.77	13.46	0.6	3.42e-33	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	17.88	0.7	1.96e-50	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.75	12.49	0.57	1.48e-29	Selective IgA deficiency;
CRC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.45	-8.28	-0.42	3.16e-15	Huntington's disease progression;
CRC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg20092199	chr4:1342459	KIAA1530	0.47	7.65	0.39	2.24e-13	Obesity-related traits;
CRC	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00428944	chr8:101963525	YWHAZ	0.39	6.25	0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9462027	0.606	rs4513788	chr6:34694779	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02290350	chr8:58132656	NA	-0.5	-6.18	-0.32	1.95e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.34	0.38	1.66e-12	Eye color traits;
CRC	cis	rs12044355	0.929	rs11122322	chr1:231843962	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.43	-6.27	-0.33	1.16e-9	Alzheimer's disease;
CRC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.64	7.04	0.36	1.1e-11	Urinary 1,3-butadiene metabolite levels in smokers;
CRC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg24562669	chr7:97807699	LMTK2	0.48	8.04	0.41	1.69e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.79	-0.35	5.24e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.81	-10.15	-0.49	3.13e-21	Body mass index;
CRC	cis	rs6662572	1.000	rs1053941	chr1:46084383	G/T	cg08644498	chr1:46502608	NA	0.44	6.38	0.33	6.07e-10	Blood protein levels;
CRC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg00999904	chr2:3704751	ALLC	-0.53	-6.66	-0.34	1.15e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23391157	chr5:43313644	HMGCS1	0.43	6.02	0.31	4.73e-9	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg11707556	chr5:10655725	ANKRD33B	0.43	7.06	0.36	9.88e-12	Height;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.66	6.96	0.36	1.9e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.31	-0.59	1.24e-32	Systemic lupus erythematosus;
CRC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg13072238	chr3:49761600	GMPPB	-0.54	-5.85	-0.31	1.19e-8	Menarche (age at onset);
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg02033258	chr5:131593261	PDLIM4	-0.37	-6.21	-0.32	1.59e-9	Breast cancer;
CRC	cis	rs7725052	0.609	rs10052696	chr5:40450762	C/T	cg09067459	chr5:40385259	NA	-0.4	-6.61	-0.34	1.53e-10	Pediatric autoimmune diseases;
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.42	-5.89	-0.31	9.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.61	-12.04	-0.55	6.4e-28	Asthma (sex interaction);
CRC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.44	-0.38	9.14e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2814982	0.543	rs75776386	chr6:34465215	G/A	cg14254433	chr6:34482411	PACSIN1	-0.81	-8.65	-0.43	2.28e-16	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs9311676	0.632	rs11130630	chr3:58360800	A/G	cg06643156	chr3:58380774	PXK	0.43	6.73	0.35	7.6e-11	Systemic lupus erythematosus;
CRC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg16141378	chr3:129829833	LOC729375	0.42	6.15	0.32	2.28e-9	Triglycerides;
CRC	cis	rs9467160	1.000	rs9461012	chr6:24441844	A/G	cg20631270	chr6:24437470	GPLD1	-0.47	-6.24	-0.33	1.38e-9	Liver enzyme levels;
CRC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.24	-0.69	6.51e-48	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.96	-0.31	6.41e-9	Diabetic kidney disease;
CRC	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.47	0.46	5.62e-19	Blood protein levels;
CRC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.5	6.44	0.33	4.22e-10	Obesity-related traits;
CRC	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg18230493	chr5:56204884	C5orf35	0.4	6.07	0.32	3.55e-9	Coronary artery disease;
CRC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.98	-0.44	2.07e-17	Bipolar disorder;
CRC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	10.07	0.49	5.81e-21	Calcium levels;
CRC	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.51	8.78	0.44	9.02e-17	Coronary artery disease;
CRC	cis	rs6908034	0.607	rs114146042	chr6:19807229	G/A	cg02682789	chr6:19804855	NA	0.78	6.7	0.35	9.11e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	13.99	0.61	3.27e-35	Mean platelet volume;
CRC	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg16540259	chr10:75572220	NDST2	0.39	5.96	0.31	6.52e-9	Inflammatory bowel disease;
CRC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg16102536	chr7:156981717	UBE3C	0.39	6.51	0.34	2.81e-10	Body mass index;
CRC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.53	-8.58	-0.43	3.82e-16	Neurofibrillary tangles;
CRC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.91	0.36	2.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.52	8.84	0.44	6.07e-17	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00742472	chr14:31889912	NA	0.42	6.67	0.35	1.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg00343986	chr7:65444356	GUSB	-0.49	-7.42	-0.38	1e-12	Aortic root size;
CRC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.46	6.05	0.32	3.9e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.11	0.49	4.15e-21	Platelet count;
CRC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg19318889	chr4:1322082	MAEA	0.4	5.66	0.3	3.25e-8	Obesity-related traits;
CRC	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.57	-7.25	-0.37	3.01e-12	Type 2 diabetes;
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg15147215	chr3:52552868	STAB1	0.53	9.13	0.45	7.14e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	cis	rs59104589	0.617	rs16842449	chr2:242354979	C/T	cg19488206	chr2:242435732	STK25	0.46	6.31	0.33	8.92e-10	Fibrinogen levels;
CRC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.18	0.32	1.89e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7113874	0.589	rs10840051	chr11:8475180	G/C	cg17679104	chr11:8615758	STK33	-0.34	-5.67	-0.3	3.06e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg21620606	chr4:1342894	KIAA1530	-0.39	-6.01	-0.31	5.04e-9	Longevity;
CRC	cis	rs2062225	1.000	rs11685628	chr2:111769226	A/G	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.69	-6.38	-0.33	5.89e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg14004847	chr7:1930337	MAD1L1	-0.45	-5.8	-0.3	1.55e-8	Neuroticism;
CRC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg06713675	chr4:122721982	EXOSC9	-0.37	-6.14	-0.32	2.39e-9	Type 2 diabetes;
CRC	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.57	7.37	0.38	1.37e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.63	0.39	2.61e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg17321639	chr7:2759063	NA	-0.52	-7.04	-0.36	1.15e-11	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08109571	chr12:113573586	RASAL1	0.43	6.28	0.33	1.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7626444	0.625	rs1104375	chr3:196476043	C/G	cg12930392	chr3:196481615	PAK2	0.41	7.29	0.37	2.3e-12	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11936145	chr3:142297737	ATR	0.38	6.1	0.32	3.03e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.86	-0.44	5.2e-17	Joint mobility (Beighton score);
CRC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg27661571	chr11:113659931	NA	-0.78	-9.69	-0.47	1.08e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-15.04	-0.64	2.78e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.43	6.23	0.32	1.45e-9	Mean platelet volume;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.38	7.76	0.39	1.06e-13	Lung cancer;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03923535	chr7:1197113	ZFAND2A	0.71	10.63	0.51	7.07e-23	Longevity;Endometriosis;
CRC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.47	6.91	0.36	2.53e-11	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11126068	chr11:67195806	RPS6KB2	0.45	6.21	0.32	1.64e-9	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.62	0.43	2.89e-16	Bipolar disorder and schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22776125	chr6:167041314	RPS6KA2	-0.62	-7.81	-0.4	7.73e-14	Diisocyanate-induced asthma;
CRC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs7712401	0.755	rs10900759	chr5:122105080	T/A	cg18764291	chr5:122110994	SNX2	0.37	5.89	0.31	9.33e-9	Mean platelet volume;
CRC	cis	rs4728302	0.838	rs10225454	chr7:133591535	G/C	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.25e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.52	-7.03	-0.36	1.16e-11	Triglycerides;
CRC	cis	rs365302	1.000	rs411814	chr6:159644843	G/A	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.77e-10	Coronary heart disease;
CRC	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.65	-0.43	2.31e-16	Coffee consumption (cups per day);
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg15786705	chr6:28176104	NA	0.51	6.67	0.35	1.06e-10	Parkinson's disease;
CRC	trans	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg19894588	chr14:64061835	NA	-0.59	-7.72	-0.39	1.37e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.39	-5.73	-0.3	2.24e-8	Sleep quality;
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-10.09	-0.49	4.82e-21	Prudent dietary pattern;
CRC	cis	rs60871478	0.786	rs12532534	chr7:831891	G/A	cg13844804	chr7:814759	HEATR2	-0.65	-7.38	-0.38	1.28e-12	Cerebrospinal P-tau181p levels;
CRC	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.62e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg05132306	chr1:1846340	CALML6	-0.44	-6.78	-0.35	5.63e-11	Body mass index;
CRC	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg21836586	chr14:55907198	TBPL2	0.3	5.6	0.3	4.51e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg01312482	chr5:178451176	ZNF879	-0.36	-5.97	-0.31	6.04e-9	Pubertal anthropometrics;
CRC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs1532331	0.768	rs6884303	chr5:43152799	T/C	cg09164108	chr5:43007320	NA	0.38	5.82	0.31	1.43e-8	Menarche (age at onset);
CRC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg18612461	chr15:75251733	NA	0.38	5.86	0.31	1.1e-8	Breast cancer;
CRC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.43e-9	Coronary artery disease;
CRC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.46	-7.8	-0.4	8.18e-14	Longevity;
CRC	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg19875535	chr5:140030758	IK	0.44	6.76	0.35	6.44e-11	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.55	8.61	0.43	2.99e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.04	-0.36	1.13e-11	Body mass index;
CRC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.58	-8.83	-0.44	6.38e-17	Aortic root size;
CRC	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.91	0.4	3.97e-14	Corneal astigmatism;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	11.16	0.52	1.01e-24	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03664139	chr6:101329504	ASCC3	0.48	6.19	0.32	1.78e-9	Thyroid stimulating hormone;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg22638593	chr5:131593259	PDLIM4	0.42	6.78	0.35	5.43e-11	Breast cancer;
CRC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg23815491	chr16:72088622	HP	-0.46	-6.72	-0.35	8.08e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9549328	0.670	rs35992827	chr13:113616752	G/A	cg25790453	chr13:113633590	MCF2L	0.41	7.21	0.37	3.79e-12	Systolic blood pressure;
CRC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-7.38	-0.38	1.34e-12	Menarche (age at onset);
CRC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.47	7.58	0.39	3.45e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.48	-7.69	-0.39	1.71e-13	Coronary artery disease;
CRC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg13334819	chr7:99746414	C7orf59	-0.47	-6.34	-0.33	7.51e-10	Coronary artery disease;
CRC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg03690763	chr11:133734501	NA	-0.34	-5.73	-0.3	2.33e-8	Childhood ear infection;
CRC	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg14673194	chr17:80132900	CCDC57	-0.48	-6.13	-0.32	2.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	8.16	0.41	6.95e-15	Cognitive test performance;
CRC	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.82	-0.31	1.42e-8	Protein biomarker;
CRC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.1	-0.36	7.78e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6973256	0.897	rs7776986	chr7:133345635	A/G	cg10665199	chr7:133106180	EXOC4	-0.37	-5.89	-0.31	9.51e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2403907	0.758	rs7275695	chr21:16568524	C/T	cg00407105	chr4:90231041	NA	-0.39	-6.13	-0.32	2.56e-9	Breast cancer;
CRC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.99	0.31	5.52e-9	Morning vs. evening chronotype;
CRC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-5.99	-0.31	5.5e-9	Bipolar disorder;
CRC	trans	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.72e-15	Bone mineral density;
CRC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.69	-0.35	9.75e-11	Retinal vascular caliber;
CRC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.63	8.01	0.4	2.05e-14	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.85	11.58	0.54	2.93e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.55	0.43	4.83e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19855366	chr13:111267979	CARKD	0.4	6.44	0.33	4.21e-10	Obesity-related traits;
CRC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg19193384	chr17:30244184	NA	-0.49	-6.73	-0.35	7.42e-11	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-10.62	-0.51	7.84e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.51	7.62	0.39	2.65e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04880052	chr2:219191631	PNKD	0.41	6.72	0.35	8e-11	Colorectal cancer;
CRC	cis	rs728616	0.681	rs12412762	chr10:81907470	A/G	cg05935833	chr10:81318306	SFTPA2	0.51	5.86	0.31	1.1e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg11189052	chr15:85197271	WDR73	0.65	9.36	0.46	1.25e-18	Schizophrenia;
CRC	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs524281	0.861	rs9645684	chr11:65907964	G/A	cg14036092	chr11:66035641	RAB1B	-0.46	-5.65	-0.3	3.43e-8	Electroencephalogram traits;
CRC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg21452805	chr1:244014465	NA	0.54	7.23	0.37	3.35e-12	RR interval (heart rate);
CRC	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg21251018	chr6:28226885	NKAPL	0.38	5.69	0.3	2.87e-8	Depression;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg15786705	chr6:28176104	NA	0.64	8.45	0.42	9.45e-16	Depression;
CRC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg06238570	chr21:40685208	BRWD1	0.74	10.12	0.49	3.94e-21	Cognitive function;
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg05501817	chr11:14380813	RRAS2	-0.48	-6.61	-0.34	1.54e-10	Sense of smell;
CRC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4e-17	Electroencephalogram traits;
CRC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg22676075	chr6:135203613	NA	0.41	6.35	0.33	7.03e-10	Red blood cell count;
CRC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.77	-0.44	9.72e-17	Type 2 diabetes;
CRC	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.53	6.32	0.33	8.65e-10	QRS duration;
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.11	13.68	0.6	4.92e-34	Chin dimples;
CRC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.37	8.55	0.43	4.58e-16	Multiple system atrophy;
CRC	cis	rs12580194	0.593	rs12579408	chr12:55764348	G/A	cg19537932	chr12:55886519	OR6C68	-0.72	-9.12	-0.45	7.84e-18	Cancer;
CRC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg18230493	chr5:56204884	C5orf35	0.6	8.99	0.44	1.95e-17	Initial pursuit acceleration;
CRC	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.19	-0.64	7.33e-40	Exhaled nitric oxide output;
CRC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.58	11.04	0.52	2.47e-24	Glomerular filtration rate (creatinine);
CRC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg24881330	chr22:46731750	TRMU	0.57	5.7	0.3	2.61e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg23815491	chr16:72088622	HP	0.57	7.32	0.37	1.9e-12	Blood protein levels;
CRC	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.69	9.64	0.47	1.5700000000000001e-19	Vitiligo;
CRC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.45	6.44	0.33	4.32e-10	Bladder cancer;
CRC	trans	rs2797369	0.713	rs4240592	chr6:101550593	G/A	cg26346621	chr12:6873348	NA	-0.4	-6.01	-0.31	4.93e-9	Renal function-related traits (eGRFcrea);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21517261	chr7:38217791	STARD3NL	0.43	6.16	0.32	2.07e-9	Response to antipsychotic treatment;
CRC	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.46	-0.38	7.88e-13	Menarche (age at onset);
CRC	cis	rs7584330	0.554	rs74003110	chr2:238448188	C/T	cg14458575	chr2:238380390	NA	0.5	6.72	0.35	7.9e-11	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09855692	chr3:15643242	HACL1;BTD	0.45	6.28	0.33	1.04e-9	Response to antipsychotic treatment;
CRC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.62	8.06	0.41	1.4e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.53	-9.14	-0.45	6.65e-18	Aortic root size;
CRC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-9.28	-0.46	2.39e-18	Response to antipsychotic treatment;
CRC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	16.78	0.68	4.24e-46	Platelet count;
CRC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.03	0.32	4.47e-9	Life satisfaction;
CRC	cis	rs2346160	0.836	rs206991	chr6:167699378	A/G	cg04673565	chr6:167680447	NA	-0.4	-6.73	-0.35	7.34e-11	Parental extreme longevity (95 years and older);
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg06470822	chr6:28175283	NA	0.67	9.0	0.44	1.8e-17	Parkinson's disease;
CRC	cis	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg00086871	chr4:6988644	TBC1D14	0.92	6.5	0.34	2.99e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2617583	0.599	rs2975226	chr5:1445616	A/T	cg07151155	chr5:1473589	LPCAT1	-0.38	-5.83	-0.31	1.36e-8	Breast cancer;
CRC	cis	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.01	-0.31	4.9e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg11887960	chr12:57824829	NA	0.59	6.56	0.34	2.12e-10	Obesity-related traits;
CRC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg21546874	chr1:9294571	H6PD	-0.7	-6.03	-0.32	4.44e-9	Cognitive function;
CRC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16262614	chr3:133464971	TF	0.35	6.18	0.32	1.88e-9	Iron status biomarkers;
CRC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.44	7.44	0.38	8.61e-13	Schizophrenia;
CRC	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg02927042	chr1:21476669	EIF4G3	0.52	8.5	0.42	6.66e-16	Superior frontal gyrus grey matter volume;
CRC	trans	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg07393940	chr7:158741817	NA	-0.52	-7.45	-0.38	8.41e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.51	0.42	6.4e-16	Homoarginine levels;
CRC	cis	rs501916	0.605	rs11632156	chr15:48082099	A/G	cg16110827	chr15:48056943	SEMA6D	-0.48	-7.28	-0.37	2.53e-12	Inflammatory bowel disease;Ulcerative colitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03249710	chr13:48611439	NUDT15	0.45	5.99	0.31	5.47e-9	Thyroid stimulating hormone;
CRC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.55	-9.01	-0.44	1.71e-17	Total body bone mineral density;
CRC	cis	rs11077815	0.733	rs7219524	chr17:74442440	C/G	cg06840243	chr17:74442338	UBE2O	-0.42	-6.69	-0.35	9.54e-11	Lymphocyte counts;
CRC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.45	0.5	2.95e-22	Menopause (age at onset);
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02290350	chr8:58132656	NA	-0.61	-7.12	-0.37	6.7e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.42	-0.38	1.03e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs61160187	0.582	rs12652878	chr5:60164776	C/T	cg16298547	chr5:60138761	ELOVL7	-0.29	-6.02	-0.32	4.6e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg12185399	chr6:27640341	NA	0.83	6.03	0.32	4.38e-9	Depression;
CRC	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs2933343	0.859	rs789245	chr3:128583580	C/A	cg11901034	chr3:128598214	ACAD9	-0.52	-6.2	-0.32	1.65e-9	IgG glycosylation;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.65	6.84	0.35	3.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.49	-7.44	-0.38	9.05e-13	Systemic sclerosis;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg27532560	chr4:187881888	NA	-0.56	-10.38	-0.5	5e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.39	-5.78	-0.3	1.69e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.4	-6.75	-0.35	6.85e-11	Vitamin D levels;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg14196790	chr5:131705035	SLC22A5	0.32	5.72	0.3	2.37e-8	Blood metabolite levels;
CRC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg12365402	chr11:9010492	NRIP3	-0.48	-8.11	-0.41	9.99e-15	Hemoglobin concentration;
CRC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.51	7.52	0.38	5.12e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17554472	chr22:41940697	POLR3H	-0.6	-6.0	-0.31	5.13e-9	Vitiligo;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.47	-6.49	-0.34	3.24e-10	Longevity;Endometriosis;
CRC	trans	rs7011507	1.000	rs74451002	chr8:49191234	C/A	cg04544946	chr8:978226	NA	0.43	6.18	0.32	1.92e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.45	0.46	6.57e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg01987224	chr1:201084466	NA	0.53	9.84	0.48	3.42e-20	Permanent tooth development;
CRC	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.53	-9.39	-0.46	1.07e-18	Common traits (Other);
CRC	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11578532	chr1:161008127	TSTD1	0.28	5.83	0.31	1.33e-8	Granulocyte percentage of myeloid white cells;
CRC	trans	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg18335740	chr13:41363409	SLC25A15	0.56	8.91	0.44	3.59e-17	Lewy body disease;
CRC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg02659138	chr7:134003124	SLC35B4	0.37	6.4	0.33	5.45e-10	Mean platelet volume;
CRC	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.78	-0.63	3.02e-38	Exhaled nitric oxide output;
CRC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	6.04	0.32	4.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg07952391	chr2:88470173	THNSL2	0.66	6.74	0.35	6.94e-11	Plasma clusterin levels;
CRC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.61	-11.46	-0.53	8.56e-26	Educational attainment;
CRC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.44	8.62	0.43	2.9e-16	Iron status biomarkers (transferrin levels);
CRC	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.5	6.52	0.34	2.67e-10	Alzheimer's disease (survival time);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12896751	chr2:97536137	SEMA4C	0.45	6.09	0.32	3.23e-9	Thyroid stimulating hormone;
CRC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg09655341	chr17:79618100	PDE6G	0.36	6.22	0.32	1.5e-9	Eye color traits;
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.73	-0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs185694	1.000	rs846495	chr13:30894250	T/C	cg04551440	chr13:30881194	KATNAL1	-0.63	-6.5	-0.34	2.97e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11645453	chr3:52864694	ITIH4	0.35	6.3	0.33	9.46e-10	Electroencephalogram traits;
CRC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	9.48	0.46	5.21e-19	Monocyte count;
CRC	cis	rs12745968	0.589	rs7513775	chr1:93004497	T/C	cg17283838	chr1:93427260	FAM69A	-0.45	-6.21	-0.32	1.59e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07921184	chr16:71880281	ATXN1L	0.48	6.42	0.33	4.68e-10	Anxiety disorder;
CRC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.51	0.38	5.8e-13	Motion sickness;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14221825	chr19:46271408	SIX5	0.48	6.33	0.33	8.13e-10	Anxiety disorder;
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg17330251	chr7:94953956	PON1	-0.6	-7.49	-0.38	6.26e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg15763984	chr4:1342303	KIAA1530	0.48	8.41	0.42	1.3e-15	Longevity;
CRC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.44	-7.76	-0.39	1.07e-13	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11653107	chr12:6832969	COPS7A	0.5	7.1	0.36	7.98e-12	Response to antipsychotic treatment;
CRC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.62	-9.96	-0.48	1.3e-20	Dental caries;
CRC	cis	rs4499344	0.633	rs259239	chr19:33141090	C/T	cg08127369	chr19:33164662	ANKRD27	0.39	6.06	0.32	3.8e-9	Mean platelet volume;
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.94	-12.36	-0.56	4.37e-29	Breast cancer;
CRC	trans	rs6956675	1.000	rs1609527	chr7:62599257	C/T	cg01314568	chr7:57830625	NA	-0.68	-9.27	-0.46	2.56e-18	Obesity-related traits;
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg15511327	chr8:143859410	LYNX1	0.4	7.16	0.37	5.19e-12	Urinary tract infection frequency;
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00280220	chr17:61926910	NA	0.35	5.72	0.3	2.4e-8	Prudent dietary pattern;
CRC	cis	rs3956705	0.798	rs35443929	chr7:32935434	C/A	cg05721444	chr7:32995514	FKBP9	-0.44	-6.39	-0.33	5.58e-10	Red cell distribution width;
CRC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.44	8.84	0.44	5.82e-17	Renal cell carcinoma;
CRC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-12.62	-0.57	4.76e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.6	6.92	0.36	2.34e-11	Psoriasis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03273382	chr1:205782342	SLC41A1	0.47	6.64	0.34	1.3e-10	Response to antipsychotic treatment;
CRC	trans	rs891992	1.000	rs4705045	chr5:147220041	T/G	cg19319393	chr1:6321737	GPR153	0.47	5.96	0.31	6.46e-9	Obesity-related traits;
CRC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.13	-0.41	8.87e-15	Mood instability;
CRC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-20.07	-0.74	4.73e-59	Ulcerative colitis;
CRC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.85	-0.35	3.71e-11	Educational attainment (college completion);
CRC	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg14458575	chr2:238380390	NA	0.86	10.4	0.5	4.31e-22	Prostate cancer;
CRC	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg06606381	chr12:133084897	FBRSL1	0.59	5.99	0.31	5.48e-9	Depression;
CRC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.32e-10	Alzheimer's disease;
CRC	cis	rs4141404	0.781	rs4820945	chr22:31549155	T/C	cg22777020	chr22:31556080	RNF185	-0.47	-5.65	-0.3	3.54e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.73	9.31	0.46	1.83e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.13	0.32	2.45e-9	Hair morphology;
CRC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.42	6.61	0.34	1.51e-10	Dupuytren's disease;
CRC	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg03929089	chr4:120376271	NA	0.51	6.71	0.35	8.42e-11	Intraocular pressure;
CRC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg04969067	chr8:143858791	LYNX1	-0.35	-5.98	-0.31	5.67e-9	Urinary tract infection frequency;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.02	0.31	4.69e-9	Electroencephalogram traits;
CRC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.64	10.38	0.5	5.13e-22	Height;
CRC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12463550	chr7:65579703	CRCP	0.66	6.23	0.32	1.44e-9	Diabetic kidney disease;
CRC	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-8.49	-0.42	7.01e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.63	-10.51	-0.5	1.78e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.81	-9.73	-0.47	7.64e-20	Breast cancer;
CRC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12624087	chr22:32341561	C22orf24;YWHAH	0.52	6.74	0.35	6.92e-11	Thyroid stimulating hormone;
CRC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg21132104	chr15:45694354	SPATA5L1	0.42	6.15	0.32	2.29e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg01941586	chr1:40203715	PPIE	-0.42	-5.76	-0.3	1.97e-8	Blood protein levels;
CRC	cis	rs6662572	0.737	rs11211211	chr1:46340554	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg20417195	chr1:21767127	NBPF3	0.44	6.61	0.34	1.56e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg00717180	chr2:96193071	NA	-0.37	-5.99	-0.31	5.48e-9	HDL cholesterol;
CRC	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg16482183	chr6:26056742	HIST1H1C	-0.72	-9.17	-0.45	5.43e-18	Iron status biomarkers;
CRC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.22	-0.32	1.54e-9	Gout;Renal underexcretion gout;
CRC	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	0.9	11.11	0.52	1.48e-24	Red blood cell traits;
CRC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg09998033	chr7:158218633	PTPRN2	-0.64	-9.03	-0.45	1.47e-17	Obesity-related traits;
CRC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.57	5.67	0.3	3.21e-8	Plasma clusterin levels;
CRC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21643547	chr1:205240462	TMCC2	-0.45	-7.25	-0.37	2.98e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.66	-11.39	-0.53	1.42e-25	Personality dimensions;
CRC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.09	18.8	0.72	4.57e-54	Cognitive function;
CRC	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.41	-6.21	-0.32	1.62e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-6.78	-0.35	5.59e-11	Blood metabolite levels;
CRC	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-1.03	-9.0	-0.44	1.84e-17	Arsenic metabolism;
CRC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.44	-5.96	-0.31	6.43e-9	Prudent dietary pattern;
CRC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.66	-12.05	-0.55	5.86e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg15445000	chr17:37608096	MED1	0.32	5.7	0.3	2.69e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.54	0.34	2.29e-10	Menarche (age at onset);
CRC	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg09659197	chr4:152720779	NA	0.4	7.89	0.4	4.59e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.43	6.76	0.35	6.47e-11	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CRC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg16892393	chr17:41919603	NA	-0.37	-5.88	-0.31	9.96e-9	Triglycerides;
CRC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.33	-0.42	2.17e-15	Gut microbiome composition (summer);
CRC	cis	rs6840360	0.681	rs9968292	chr4:152297368	T/C	cg09659197	chr4:152720779	NA	0.32	6.2	0.32	1.71e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.61	6.99	0.36	1.52e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.51	6.96	0.36	1.82e-11	Morning vs. evening chronotype;
CRC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg16892393	chr17:41919603	NA	0.46	6.44	0.33	4.15e-10	Triglycerides;
CRC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.37	5.61	0.3	4.23e-8	Mean corpuscular volume;
CRC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg19683494	chr5:74908142	NA	0.51	6.36	0.33	6.81e-10	Age-related disease endophenotypes;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg02033258	chr5:131593261	PDLIM4	-0.37	-6.13	-0.32	2.5e-9	Breast cancer;
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.3	-0.33	9.34e-10	Bipolar disorder;
CRC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.76	8.73	0.43	1.29e-16	Lung disease severity in cystic fibrosis;
CRC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.48	6.53	0.34	2.46e-10	Pulse pressure;
CRC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-7.36	-0.38	1.44e-12	Menarche (age at onset);
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.64	10.08	0.49	5.24e-21	Longevity;Endometriosis;
CRC	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg13319975	chr6:146136371	FBXO30	0.42	6.22	0.32	1.48e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.4	-6.29	-0.33	1.01e-9	Neurofibrillary tangles;
CRC	cis	rs6563739	0.655	rs9594359	chr13:40223878	C/T	cg00026919	chr13:40226031	NA	0.5	6.41	0.33	5.18e-10	Menarche (age at onset);
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.54	-10.13	-0.49	3.48e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg09872104	chr7:134855509	C7orf49	-0.82	-7.2	-0.37	4e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02548780	chr16:22020026	C16orf52	0.42	6.52	0.34	2.65e-10	Myopia (pathological);
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.58	-8.21	-0.41	5.25e-15	Menopause (age at onset);
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg26587870	chr6:27730563	NA	-0.45	-6.68	-0.35	1e-10	Parkinson's disease;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.34	-6.38	-0.33	6e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.66	0.34	1.16e-10	Hip circumference adjusted for BMI;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.2	-0.32	1.71e-9	Longevity;
CRC	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg00105475	chr2:10696890	NA	0.44	7.14	0.37	6.13e-12	Prostate cancer;
CRC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.46	-0.42	9e-16	Monocyte percentage of white cells;
CRC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-0.43	-5.84	-0.31	1.28e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.79	-12.08	-0.55	4.76e-28	Multiple sclerosis;
CRC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	8.22	0.41	4.59e-15	Axial length;
CRC	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg13385794	chr1:248469461	NA	0.37	6.44	0.33	4.21e-10	Common traits (Other);
CRC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.93	-16.04	-0.66	3.49e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.29	6.54	0.34	2.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1223397	0.589	rs364493	chr6:13297020	C/T	cg00460589	chr6:13274354	PHACTR1	-0.41	-6.07	-0.32	3.54e-9	Blood pressure;
CRC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.67	-10.04	-0.48	7.14e-21	Menarche (age at onset);
CRC	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-10.86	-0.51	1.14e-23	Plateletcrit;Platelet count;
CRC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-9.75	-0.47	6.77e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.83e-21	Primary sclerosing cholangitis;
CRC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.59	6.66	0.34	1.17e-10	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Educational attainment;
CRC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg04362960	chr10:104952993	NT5C2	-0.48	-5.95	-0.31	6.91e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg19318889	chr4:1322082	MAEA	-0.42	-6.47	-0.34	3.53e-10	Obesity-related traits;
CRC	trans	rs4386084	1.000	rs7175764	chr15:50220398	C/T	cg02453146	chr1:53068587	GPX7	0.34	6.11	0.32	2.75e-9	Basophil percentage of white cells;Basophil percentage of granulocytes;
CRC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.97	13.58	0.6	1.17e-33	Breast cancer;
CRC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.61	-11.54	-0.54	4.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.97	-17.52	-0.69	5.33e-49	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg22495460	chr2:25135724	ADCY3	-0.85	-16.31	-0.67	3.12e-44	Body mass index;
CRC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.25e-10	Alzheimer's disease;
CRC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	6.9	0.36	2.65e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg19622623	chr12:86230825	RASSF9	-0.42	-6.76	-0.35	6.21e-11	Major depressive disorder;
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.57	-7.54	-0.38	4.65e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	6.51	0.34	2.88e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.23	0.37	3.48e-12	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16925090	chr11:101785516	KIAA1377;ANGPTL5	0.47	6.3	0.33	9.66e-10	Thyroid stimulating hormone;
CRC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.42	-6.14	-0.32	2.37e-9	Aortic root size;
CRC	cis	rs2062225	1.000	rs6733493	chr2:111773473	C/T	cg11729679	chr2:111877065	BCL2L11	0.57	5.67	0.3	3.06e-8	Monocyte count;
CRC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.39	9.15	0.45	6.36e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg10802521	chr3:52805072	NEK4	0.43	5.97	0.31	6.3e-9	Schizophrenia;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.93	-0.4	3.34e-14	Total body bone mineral density;
CRC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.24e-30	Bone mineral density;
CRC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg02659138	chr7:134003124	SLC35B4	0.4	6.94	0.36	2.09e-11	Mean platelet volume;
CRC	cis	rs2310173	0.575	rs4850993	chr2:102622466	G/C	cg20856504	chr2:102616538	IL1R2	0.37	5.94	0.31	7.4e-9	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19281693	chr22:42666674	NA	0.48	6.86	0.35	3.44e-11	Response to antipsychotic treatment;
CRC	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.45	5.85	0.31	1.19e-8	HDL cholesterol;
CRC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.12	13.67	0.6	5.31e-34	Vitiligo;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg20041105	chr8:143859282	LYNX1	-0.41	-6.48	-0.34	3.38e-10	Urinary tract infection frequency;
CRC	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.9	-0.44	3.84e-17	Coffee consumption (cups per day);
CRC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg13390004	chr1:15929781	NA	0.5	7.08	0.36	8.59e-12	Systolic blood pressure;
CRC	cis	rs539096	0.624	rs603542	chr1:44079411	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-6.68	-0.35	1.04e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552172	0.821	rs9286836	chr1:145588536	C/T	cg11743829	chr1:145714124	CD160	0.38	5.92	0.31	8.01e-9	Breast cancer;
CRC	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	0.87	10.17	0.49	2.62e-21	Height;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg02475695	chr16:616220	NHLRC4	0.46	7.46	0.38	8e-13	Height;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg26304593	chr6:42947056	PEX6	-0.45	-6.57	-0.34	1.96e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.07	-12.34	-0.56	5.05e-29	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04608317	chr7:117824414	NAA38	0.36	6.12	0.32	2.59e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.19	0.49	2.17e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.05	16.33	0.67	2.59e-44	Testicular germ cell tumor;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg19041857	chr6:27730383	NA	-0.45	-6.08	-0.32	3.26e-9	Parkinson's disease;
CRC	cis	rs6834538	0.500	rs17668047	chr4:113422830	T/A	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.8	-0.3	1.55e-8	Free thyroxine concentration;
CRC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.21	-0.41	4.95e-15	Biliary atresia;
CRC	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg05673287	chr15:77411982	SGK269	-0.54	-7.09	-0.36	8.02e-12	Risky sexual behaviors (alcohol dependence interaction);
CRC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg03929089	chr4:120376271	NA	-0.46	-6.53	-0.34	2.51e-10	HDL cholesterol;
CRC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg04545296	chr12:48745243	ZNF641	0.34	5.82	0.31	1.43e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.88	0.31	9.98e-9	Renal function-related traits (BUN);
CRC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.78	-0.3	1.76e-8	Tonsillectomy;
CRC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.45	-0.38	8.1e-13	Educational attainment;
CRC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.53	7.58	0.39	3.62e-13	Breast cancer;
CRC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg02725872	chr8:58115012	NA	-0.44	-6.61	-0.34	1.51e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg02007433	chr3:129722099	NA	-0.49	-6.22	-0.32	1.48e-9	Blood pressure (smoking interaction);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg25937148	chr3:43147320	C3orf39	-0.43	-6.51	-0.34	2.8e-10	Birth weight;Height;
CRC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.45	5.92	0.31	8.28e-9	Lymphocyte counts;
CRC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.86	8.96	0.44	2.39e-17	Major depressive disorder;
CRC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.37	-0.33	6.36e-10	Platelet distribution width;
CRC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	19.41	0.73	1.76e-56	Prudent dietary pattern;
CRC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg21839984	chr17:30846986	MYO1D	-0.34	-5.89	-0.31	9.69e-9	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25290657	chr19:17186505	HAUS8;MYO9B	0.45	6.24	0.33	1.33e-9	Anxiety disorder;
CRC	cis	rs73200209	0.912	rs61935844	chr12:116617887	A/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.82	-0.31	1.43e-8	Total body bone mineral density;
CRC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.68	10.42	0.5	3.68e-22	Menopause (age at onset);
CRC	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg26587870	chr6:27730563	NA	-0.5	-6.88	-0.35	2.96e-11	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.86	-0.31	1.15e-8	Lung cancer;
CRC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	1.03	18.4	0.71	1.66e-52	Parkinson's disease;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.79	11.98	0.55	1.1e-27	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg17948913	chr5:572064	NA	0.55	6.2	0.32	1.71e-9	Lung disease severity in cystic fibrosis;
CRC	trans	rs4873772	0.834	rs6986054	chr8:48574138	C/T	cg05343739	chr1:154731938	KCNN3	0.34	6.05	0.32	3.89e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg25214090	chr10:38739885	LOC399744	-0.42	-6.62	-0.34	1.5e-10	Diastolic blood pressure;
CRC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	12.45	0.57	2.06e-29	Menarche (age at onset);
CRC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg21747405	chr11:67723411	NA	-0.43	-6.07	-0.32	3.52e-9	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.32	6.55	0.34	2.23e-10	Lung cancer;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.73	-10.48	-0.5	2.3e-22	Menopause (age at onset);
CRC	cis	rs7804356	1.000	rs7791513	chr7:26893357	A/C	cg03456212	chr7:26904342	SKAP2	-0.49	-5.63	-0.3	3.96e-8	Type 1 diabetes;
CRC	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.56	-6.07	-0.32	3.45e-9	Coronary artery disease;
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg15511327	chr8:143859410	LYNX1	-0.42	-7.36	-0.38	1.45e-12	Urinary tract infection frequency;
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg13662093	chr20:33865505	NA	-0.48	-6.32	-0.33	8.31e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg14583973	chr4:3374767	RGS12	-0.27	-5.61	-0.3	4.36e-8	Serum sulfate level;
CRC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.93	0.52	6.15e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.06e-12	HDL cholesterol;
CRC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.39	-8.17	-0.41	6.76e-15	Schizophrenia;
CRC	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.09	-0.36	8.28e-12	Capecitabine sensitivity;
CRC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.61	9.82	0.48	3.81e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.49	7.75	0.39	1.18e-13	Red blood cell count;
CRC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.42	6.17	0.32	1.99e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg26762873	chr11:5879799	OR52E8	-0.47	-7.03	-0.36	1.21e-11	DNA methylation (variation);
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12273811	chr6:28175739	NA	0.6	8.55	0.43	4.66e-16	Parkinson's disease;
CRC	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.32	-5.76	-0.3	1.94e-8	Clozapine-induced cytotoxicity;
CRC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg02869306	chr7:64672164	INTS4L1	0.34	5.65	0.3	3.42e-8	Aortic root size;
CRC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg08075719	chr14:103021372	NA	-0.63	-7.52	-0.38	5.2e-13	Platelet count;
CRC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg08807892	chr2:162101083	NA	-0.43	-5.67	-0.3	3.16e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.38	6.4	0.33	5.43e-10	Blood metabolite levels;
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.01	-0.36	1.36e-11	Bipolar disorder;
CRC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.62	8.9	0.44	3.73e-17	Schizophrenia;
CRC	cis	rs2457480	0.516	rs11598966	chr10:44641416	C/T	cg09554077	chr10:44749378	NA	0.47	6.11	0.32	2.88e-9	Coronary artery disease;
CRC	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.46	9.32	0.46	1.78e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg03909863	chr11:638404	DRD4	-0.53	-7.14	-0.37	6.12e-12	Systemic lupus erythematosus;
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.78	12.17	0.56	2.2e-28	Menarche (age at onset);
CRC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg22777020	chr22:31556080	RNF185	0.49	5.91	0.31	8.42e-9	Colorectal cancer;
CRC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.11	-15.16	-0.64	9.65e-40	Vitiligo;
CRC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.39	7.21	0.37	3.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	0.86	8.28	0.42	3.15e-15	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7632954	0.967	rs6791290	chr3:8528727	C/G	cg03495237	chr3:8533978	NA	0.35	5.8	0.3	1.56e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg11292332	chr7:45801988	SEPT13	-0.35	-6.21	-0.32	1.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.48	7.95	0.4	3.03e-14	Crohn's disease;
CRC	trans	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg10756647	chr7:56101905	PSPH	0.74	7.79	0.39	8.68e-14	Diabetic kidney disease;
CRC	cis	rs4664293	1.000	rs6745766	chr2:160454795	G/A	cg08347373	chr2:160653686	CD302	-0.45	-7.31	-0.37	2.02e-12	Monocyte percentage of white cells;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-6.65	-0.34	1.25e-10	Electroencephalogram traits;
CRC	trans	rs10243593	0.673	rs10272641	chr7:40089932	C/G	cg13911576	chr9:84174038	NA	0.37	6.5	0.34	3.05e-10	Lymphocyte counts;
CRC	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.73e-21	Asthma;
CRC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.55	-0.34	2.16e-10	Height;
CRC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.68	10.63	0.51	6.98e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg04497992	chr16:616212	NHLRC4	0.42	6.63	0.34	1.36e-10	Height;
CRC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.43	-6.42	-0.33	4.89e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg22089800	chr15:90895588	ZNF774	0.48	7.72	0.39	1.39e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10723024	chr11:62494009	HNRNPUL2	0.45	6.3	0.33	9.66e-10	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg15845792	chr6:28175446	NA	0.8	11.85	0.55	3.12e-27	Parkinson's disease;
CRC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	13.86	0.61	1.03e-34	Smoking behavior;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17152658	chr8:132916406	EFR3A	-0.42	-6.83	-0.35	4.13e-11	Obesity-related traits;
CRC	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.77	8.63	0.43	2.72e-16	Neuroticism;
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.07	-0.55	5.3e-28	Alzheimer's disease;
CRC	cis	rs6496667	0.657	rs8026265	chr15:90885870	A/G	cg04176472	chr15:90893244	GABARAPL3	0.56	6.69	0.35	9.64e-11	Rheumatoid arthritis;
CRC	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.01	-0.31	5e-9	Height;
CRC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.49	-7.1	-0.36	7.96e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.63	9.98	0.48	1.12e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg15369054	chr17:80825471	TBCD	0.46	5.78	0.3	1.74e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.48	-0.34	3.31e-10	Lung cancer;
CRC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.44	-0.46	6.97e-19	Platelet count;
CRC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.34e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.62	9.5	0.46	4.61e-19	Testicular germ cell tumor;
CRC	cis	rs1712517	0.836	rs11191649	chr10:105067037	T/C	cg05636881	chr10:105038444	INA	0.43	7.39	0.38	1.19e-12	Migraine;
CRC	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.47	9.12	0.45	7.63e-18	Educational attainment (years of education);
CRC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg00857998	chr1:205179979	DSTYK	0.41	5.77	0.3	1.79e-8	Red blood cell count;
CRC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-7.49	-0.38	6.53e-13	Bipolar disorder;
CRC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg03030879	chr14:75389066	RPS6KL1	0.47	7.41	0.38	1.1e-12	Height;
CRC	cis	rs6743376	0.556	rs2515402	chr2:113820580	C/A	cg09040174	chr2:113837401	NA	0.4	5.84	0.31	1.22e-8	Inflammatory biomarkers;
CRC	cis	rs7849270	0.801	rs10819475	chr9:131930840	G/A	cg13538475	chr9:131942899	NA	0.31	5.85	0.31	1.19e-8	Blood metabolite ratios;
CRC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.48	6.82	0.35	4.34e-11	Pulse pressure;
CRC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.67	0.54	1.42e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.66	11.75	0.54	7.6e-27	Height;
CRC	trans	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg26043149	chr18:55253948	FECH	0.5	7.7	0.39	1.65e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg15786705	chr6:28176104	NA	0.56	5.65	0.3	3.39e-8	Lung cancer in ever smokers;
CRC	cis	rs9549328	0.564	rs34556022	chr13:113617437	G/A	cg17524180	chr13:113633600	MCF2L	0.52	9.5	0.46	4.44e-19	Systolic blood pressure;
CRC	cis	rs11585357	0.501	rs4262593	chr1:17594263	T/C	cg08277548	chr1:17600880	PADI3	-0.63	-7.3	-0.37	2.24e-12	Hair shape;
CRC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25517755	chr10:38738941	LOC399744	-0.42	-5.98	-0.31	5.66e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-9.01	-0.44	1.71e-17	Urate levels in overweight individuals;
CRC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg03013999	chr17:37608204	MED1	-0.44	-5.62	-0.3	4.12e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.61	10.94	0.52	5.58e-24	Bone mineral density;
CRC	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg04906043	chr13:21280425	IL17D	-0.4	-5.91	-0.31	8.75e-9	Dental caries;
CRC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.51	0.34	2.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.69	-11.41	-0.53	1.29e-25	Paraoxonase activity;
CRC	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg11900509	chr10:81946545	ANXA11	-0.71	-7.16	-0.37	5.2e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.95	-0.36	1.98e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	1.97e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg21724239	chr8:58056113	NA	0.4	5.79	0.3	1.66e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs534126	0.736	rs10239488	chr7:142949599	C/G	cg04039957	chr7:143013207	CLCN1	0.34	5.68	0.3	2.96e-8	Cancer;
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg08222913	chr3:52553049	STAB1	-0.33	-6.26	-0.33	1.2e-9	Bipolar disorder;
CRC	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.74	-0.3	2.14e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg04702396	chr17:15466718	FAM18B2	-0.47	-7.25	-0.37	3.07e-12	Educational attainment (years of education);
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg08222913	chr3:52553049	STAB1	-0.41	-8.22	-0.41	4.91e-15	Electroencephalogram traits;
CRC	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6546324	0.625	rs11900280	chr2:67840401	T/C	cg15745817	chr2:67799979	NA	-0.57	-9.66	-0.47	1.37e-19	Endometriosis;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg26870460	chr11:6947759	ZNF215	0.58	6.05	0.32	3.85e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.7	-11.88	-0.55	2.59e-27	Caffeine consumption;
CRC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg27205649	chr11:78285834	NARS2	0.49	6.1	0.32	2.93e-9	Alzheimer's disease (survival time);
CRC	cis	rs17270561	0.636	rs10946793	chr6:25699999	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	7.59	0.39	3.43e-13	Iron status biomarkers;
CRC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18099408	chr3:52552593	STAB1	-0.37	-5.7	-0.3	2.63e-8	Bipolar disorder;
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg21251018	chr6:28226885	NKAPL	0.52	8.87	0.44	4.61e-17	Pubertal anthropometrics;
CRC	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.45	5.68	0.3	3.02e-8	Systolic blood pressure;
CRC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.73	10.61	0.51	7.85e-23	Platelet distribution width;
CRC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.03	-23.09	-0.79	8.18e-71	Myeloid white cell count;
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg00325661	chr8:49890786	NA	0.4	7.03	0.36	1.19e-11	Sudden cardiac arrest;
CRC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.02	-23.18	-0.79	3.8e-71	Multiple system atrophy;
CRC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.86	-0.31	1.11e-8	Heart rate;
CRC	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg22732515	chr19:44031385	ETHE1	0.68	10.28	0.49	1.09e-21	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-16.4	-0.67	1.29e-44	Schizophrenia;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-8.34	-0.42	2.06e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs995000	0.899	rs11207974	chr1:62949960	T/C	cg19896129	chr1:63156450	NA	0.41	6.2	0.32	1.68e-9	Triglyceride levels;
CRC	cis	rs9908102	0.740	rs56131975	chr17:12912870	T/C	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.73	10.44	0.5	3.2800000000000002e-22	Menarche (age at onset);
CRC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.16	-0.32	2.1e-9	Gout;Renal underexcretion gout;
CRC	trans	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.91	0.36	2.5e-11	Platelet count;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs3790455	0.560	rs1171558	chr1:156452093	G/A	cg14087168	chr1:156450669	MEF2D	-0.37	-6.03	-0.32	4.45e-9	Migraine;
CRC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.24	-0.37	3.23e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.52	0.38	5.18e-13	Motion sickness;
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.92e-9	Life satisfaction;
CRC	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.4	5.91	0.31	8.7e-9	Mean platelet volume;
CRC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.49	7.97	0.4	2.72e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.37	6.27	0.33	1.14e-9	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21194723	chr11:60681294	TMEM109	0.43	6.2	0.32	1.65e-9	Response to antipsychotic treatment;
CRC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg22349387	chr12:9600060	DDX12	-0.36	-5.65	-0.3	3.41e-8	Breast size;
CRC	cis	rs6504622	0.875	rs3785888	chr17:45005703	C/T	cg16759221	chr17:45003025	GOSR2	0.46	6.88	0.35	3.08e-11	Orofacial clefts;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg07217954	chr7:1067459	C7orf50	0.51	6.04	0.32	4.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7572644	0.662	rs13402420	chr2:28271435	T/G	cg27432699	chr2:27873401	GPN1	-0.4	-5.61	-0.3	4.19e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg24011408	chr12:48396354	COL2A1	0.45	6.21	0.32	1.6e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16140913	chr4:8430389	ACOX3	0.46	6.48	0.34	3.28e-10	Response to antipsychotic treatment;
CRC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg02269571	chr22:50332266	NA	-0.55	-7.82	-0.4	7.41e-14	Schizophrenia;
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02290350	chr8:58132656	NA	-0.58	-8.21	-0.41	5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.57	10.85	0.51	1.23e-23	Cognitive performance;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg15593716	chr7:29845970	NA	0.4	6.07	0.32	3.5e-9	Resistin levels;
CRC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.79	-0.3	1.6e-8	Lung cancer;
CRC	cis	rs354033	1.000	rs58026905	chr7:149224358	G/A	cg24335155	chr7:149193227	ZNF746	0.38	5.86	0.31	1.13e-8	Multiple sclerosis;
CRC	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.61	-7.61	-0.39	2.89e-13	Ulcerative colitis;
CRC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.03e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg15786705	chr6:28176104	NA	0.48	7.16	0.37	5.19e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11226613	0.568	rs1785878	chr11:104963106	A/G	cg04181079	chr11:104896587	CASP1	0.41	5.72	0.3	2.33e-8	Bronchopulmonary dysplasia;
CRC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.54	8.86	0.44	4.93e-17	Breast cancer;
CRC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.43	-6.29	-0.33	1e-9	Hemoglobin concentration;
CRC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.58	-5.94	-0.31	7.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.69	-9.24	-0.45	3.1e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg26043149	chr18:55253948	FECH	0.49	7.42	0.38	1.02e-12	Bone mineral density;
CRC	cis	rs2949837	0.581	rs1542819	chr7:45978059	T/C	cg10677697	chr7:45961126	IGFBP3	0.36	6.3	0.33	9.38e-10	Sitting height ratio;
CRC	cis	rs6662572	0.737	rs4573476	chr1:46346721	T/A	cg08644498	chr1:46502608	NA	0.44	6.66	0.34	1.12e-10	Blood protein levels;
CRC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.86	0.4	5.63e-14	Morning vs. evening chronotype;
CRC	cis	rs7739232	0.920	rs41273882	chr6:53517228	A/C	cg15658676	chr6:53530538	KLHL31	-0.67	-5.66	-0.3	3.32e-8	Hip circumference adjusted for BMI;
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	1.05	11.42	0.53	1.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7091068	0.671	rs514120	chr10:95404400	G/A	cg20715218	chr10:95462985	C10orf4	-0.48	-5.66	-0.3	3.38e-8	Urinary tract infection frequency;
CRC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.44	6.94	0.36	2.1e-11	Response to radiotherapy in cancer (late toxicity);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08664617	chr1:155036082	EFNA4	0.39	5.98	0.31	5.75e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.53	7.27	0.37	2.59e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01220033	chr9:131419100	WDR34	0.47	6.47	0.34	3.56e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.55	7.06	0.36	1.02e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg27205649	chr11:78285834	NARS2	0.48	6.25	0.33	1.28e-9	Alzheimer's disease (survival time);
CRC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg08213375	chr14:104286397	PPP1R13B	0.47	7.57	0.39	3.71e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12000995	chr2:27665139	KRTCAP3	0.31	6.36	0.33	6.63e-10	Total body bone mineral density;
CRC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	8.66	0.43	2.19e-16	Eosinophil percentage of white cells;
CRC	cis	rs3106136	0.681	rs11097422	chr4:95302982	C/G	cg11021082	chr4:95130006	SMARCAD1	0.38	5.66	0.3	3.26e-8	Capecitabine sensitivity;
CRC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.83	0.31	1.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.65	0.63	8.94e-38	Breast cancer;
CRC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg02569458	chr12:86230093	RASSF9	0.47	7.98	0.4	2.42e-14	Major depressive disorder;
CRC	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg27205649	chr11:78285834	NARS2	0.49	6.23	0.32	1.41e-9	Alzheimer's disease (survival time);
CRC	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.5	0.46	4.4e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.51	-0.71	6.24e-53	Schizophrenia;
CRC	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.55	8.87	0.44	4.8e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	15.0	0.64	4.09e-39	Primary sclerosing cholangitis;
CRC	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	21.14	0.76	3.01e-63	Colorectal cancer;
CRC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-0.95	-9.31	-0.46	1.84e-18	Breast cancer;
CRC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg00769240	chr8:12517080	NA	-0.54	-6.41	-0.33	5.08e-10	Blood pressure (smoking interaction);
CRC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.92e-9	Aortic root size;
CRC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.7	-0.51	3.85e-23	Alzheimer's disease;
CRC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.73	9.18	0.45	4.77e-18	Behavioural disinhibition (generation interaction);
CRC	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg09582351	chr12:29534625	ERGIC2	0.32	6.93	0.36	2.23e-11	QT interval;
CRC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg02527881	chr3:46936655	PTH1R	0.38	7.06	0.36	9.69e-12	Colorectal cancer;
CRC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.74	10.83	0.51	1.37e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg04586622	chr2:25135609	ADCY3	-0.58	-9.9	-0.48	2.2e-20	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12513308	chr16:66586534	CKLF	0.47	6.73	0.35	7.34e-11	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.01	9.99	0.48	1.09e-20	Diabetic retinopathy;
CRC	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-6.46	-0.34	3.88e-10	Height;
CRC	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.62	-8.78	-0.44	9.07e-17	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.64	-12.72	-0.57	2.03e-30	Menarche (age at onset);
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.56	-10.2	-0.49	2.15e-21	Electroencephalogram traits;
CRC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	8.67	0.43	2e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23161317	chr6:28129485	ZNF389	0.52	6.4	0.33	5.21e-10	Depression;
CRC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.58	-8.72	-0.43	1.35e-16	Longevity;
CRC	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.48	-6.89	-0.36	2.76e-11	Coronary artery disease;
CRC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg24531977	chr5:56204891	C5orf35	-0.45	-6.89	-0.36	2.85e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	1.02	10.01	0.48	8.9e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg09779027	chr19:7224513	INSR	1.09	26.12	0.82	3.15e-82	Hypothyroidism;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg03124313	chr19:36036028	GAPDHS;TMEM147	-0.67	-6.0	-0.31	5.21e-9	Cognitive function;
CRC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.38	6.3	0.33	9.51e-10	Mean corpuscular volume;
CRC	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	1.12	10.46	0.5	2.65e-22	Arsenic metabolism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06458679	chr21:46974866	NA	0.38	6.12	0.32	2.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11212617	0.934	rs10890834	chr11:108286443	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.51	0.34	2.82e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-6.81	-0.35	4.67e-11	Coronary artery disease;
CRC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.85	-14.4	-0.62	8.2e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.46	-0.38	7.88e-13	Type 2 diabetes;
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg10130564	chr11:117069849	TAGLN	0.32	6.05	0.32	4.04e-9	Blood protein levels;
CRC	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.56	-8.24	-0.41	4.22e-15	Vitiligo;
CRC	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg20243544	chr17:37824526	PNMT	-0.43	-6.67	-0.35	1.09e-10	Self-reported allergy;
CRC	cis	rs9287719	0.649	rs10202370	chr2:10727043	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg13414629	chr9:132935646	FREQ	0.44	6.34	0.33	7.71e-10	Alzheimer's disease (cognitive decline);
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.95e-9	Body mass index;
CRC	cis	rs11948739	0.501	rs79115810	chr5:130374516	A/G	cg08523029	chr5:130500466	HINT1	-0.45	-5.96	-0.31	6.51e-9	Pediatric bone mineral content (hip);
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg20119798	chr7:94954144	PON1	-0.51	-6.48	-0.34	3.3e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.4	-8.56	-0.43	4.28e-16	Social autistic-like traits;
CRC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.5	0.46	4.39e-19	Bladder cancer;
CRC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg07870213	chr5:140052090	DND1	0.59	7.61	0.39	2.92e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs282587	0.569	rs9604421	chr13:113410493	C/G	cg04656015	chr13:113407548	ATP11A	0.61	7.43	0.38	9.63e-13	Glycated hemoglobin levels;
CRC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg12193833	chr17:30244370	NA	-0.76	-8.88	-0.44	4.43e-17	Hip circumference adjusted for BMI;
CRC	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.5	0.38	6e-13	Morning vs. evening chronotype;
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg10729496	chr3:10149963	C3orf24	0.51	6.57	0.34	1.92e-10	Alzheimer's disease;
CRC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.33	0.37	1.76e-12	Life satisfaction;
CRC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.5	0.5	1.94e-22	Personality dimensions;
CRC	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	7.16	0.37	5.23e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg15145296	chr3:125709740	NA	-0.56	-6.63	-0.34	1.35e-10	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg00976097	chr5:421733	AHRR	-0.45	-6.02	-0.31	4.76e-9	Cystic fibrosis severity;
CRC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.63	0.39	2.49e-13	Axial length;
CRC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.83	-12.83	-0.58	7.83e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.68	10.83	0.51	1.39e-23	Cognitive function;
CRC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.36e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg18016565	chr1:150552671	MCL1	-0.47	-7.07	-0.36	9.07e-12	Tonsillectomy;
CRC	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.02	0.31	4.78e-9	Diastolic blood pressure;
CRC	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.64	8.27	0.41	3.3e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.68	-0.35	1.04e-10	Body mass index;
CRC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-0.84	-7.78	-0.39	9.76e-14	Putamen volume;
CRC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.76	12.89	0.58	4.8e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14706950	chr10:93169801	HECTD2;LOC100188947	0.39	6.06	0.32	3.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17554472	chr22:41940697	POLR3H	-0.55	-5.93	-0.31	7.73e-9	Vitiligo;
CRC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.5	0.54	5.71e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.87e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.35	-0.38	1.6e-12	Inflammatory skin disease;
CRC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg05585544	chr11:47624801	NA	-0.6	-10.83	-0.51	1.37e-23	Subjective well-being;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16483426	chr12:110151678	C12orf34	0.42	5.99	0.31	5.39e-9	Anxiety disorder;
CRC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg16386425	chr10:429943	DIP2C	-0.38	-5.73	-0.3	2.3e-8	Psychosis in Alzheimer's disease;
CRC	trans	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg20935933	chr6:143382018	AIG1	0.5	6.42	0.33	4.64e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg11503833	chr11:492997	NA	0.54	6.06	0.32	3.66e-9	Body mass index;
CRC	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.74	9.8	0.48	4.62e-20	Prostate cancer;
CRC	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	0.89	11.01	0.52	3.36e-24	Blood protein levels;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg12273811	chr6:28175739	NA	0.55	6.74	0.35	6.97e-11	Parkinson's disease;
CRC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg23461800	chr14:103021989	NA	0.68	7.74	0.39	1.23e-13	Platelet count;
CRC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.4	6.2	0.32	1.68e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10905065	0.766	rs11598374	chr10:5826986	T/C	cg11519256	chr10:5708881	ASB13	-0.44	-6.34	-0.33	7.8e-10	Menopause (age at onset);
CRC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.48	6.51	0.34	2.81e-10	Schizophrenia;
CRC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.75	-0.35	6.62e-11	Alzheimer's disease (late onset);
CRC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg18761221	chr20:60518478	NA	0.39	6.84	0.35	3.81e-11	Body mass index;
CRC	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.86	0.4	5.61e-14	Corneal astigmatism;
CRC	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.66	-0.47	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg10876282	chr6:28092338	ZSCAN16	0.48	6.53	0.34	2.51e-10	Cardiac Troponin-T levels;
CRC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.43	0.38	9.58e-13	Obesity-related traits;
CRC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-9.05	-0.45	1.24e-17	Schizophrenia;
CRC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26240231	chr7:1148101	C7orf50	-0.41	-6.04	-0.32	4.24e-9	Bronchopulmonary dysplasia;
CRC	cis	rs2249694	1.000	rs1952467	chr10:135353499	T/G	cg20169779	chr10:135381914	SYCE1	0.54	8.67	0.43	1.93e-16	Obesity-related traits;
CRC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.79	14.79	0.63	2.66e-38	Prudent dietary pattern;
CRC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.58	-8.38	-0.42	1.61e-15	Initial pursuit acceleration;
CRC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.67	11.58	0.54	3.01e-26	Longevity;
CRC	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.18	0.32	1.87e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-7.0	-0.36	1.47e-11	Alzheimer's disease (late onset);
CRC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.53	7.84	0.4	6.46e-14	Lymphocyte counts;
CRC	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-7.72	-0.39	1.39e-13	Migraine;
CRC	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg00531865	chr16:30841666	NA	0.48	6.9	0.36	2.62e-11	Dementia with Lewy bodies;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11296937	chr11:64084966	PRDX5;TRMT112	-0.46	-6.63	-0.34	1.36e-10	Myopia (pathological);
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08501533	chr10:12084975	UPF2	0.46	6.24	0.33	1.32e-9	Anxiety disorder;
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-7.28	-0.37	2.46e-12	Renal function-related traits (BUN);
CRC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg07636037	chr3:49044803	WDR6	-0.8	-6.18	-0.32	1.88e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.64	-12.66	-0.57	3.39e-30	Electroencephalogram traits;
CRC	cis	rs45544231	0.544	rs9931232	chr16:52572832	A/G	cg09051775	chr16:52580266	TOX3	0.38	6.26	0.33	1.22e-9	Restless legs syndrome;
CRC	trans	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.42	0.42	1.14e-15	Lewy body disease;
CRC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.5	-0.46	4.4e-19	Heart rate;
CRC	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.8	9.92	0.48	1.77e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg17133734	chr15:86042851	AKAP13	0.4	6.51	0.34	2.8e-10	Interstitial lung disease;
CRC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.73	0.63	4.73e-38	Chronic sinus infection;
CRC	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.93	17.28	0.69	4.48e-48	Intelligence (multi-trait analysis);
CRC	cis	rs3790844	0.876	rs3790845	chr1:200006861	C/T	cg13229857	chr1:200006247	NR5A2	0.54	7.62	0.39	2.68e-13	Pancreatic cancer;
CRC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.89	-11.17	-0.52	8.84e-25	Vitiligo;
CRC	cis	rs3812762	0.618	rs11042072	chr11:8822032	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-7.25	-0.37	2.91e-12	Hypospadias;
CRC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.97	-0.31	6.27e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.22	-6.3	-0.33	9.33e-10	Urinary metabolites;
CRC	cis	rs7487075	0.578	rs10880967	chr12:46812023	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.74	-0.3	2.21e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13374225	chr1:10093824	UBE4B	0.42	6.02	0.31	4.65e-9	Response to antipsychotic treatment;
CRC	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg08501292	chr6:25962987	TRIM38	1.08	8.98	0.44	2.12e-17	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.47	5.78	0.3	1.74e-8	Vitiligo;
CRC	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs6499255	0.951	rs8052086	chr16:69692468	A/C	cg04110750	chr16:69646130	NFAT5	-0.57	-7.82	-0.4	7.23e-14	IgE levels;
CRC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.78	0.3	1.77e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg14458575	chr2:238380390	NA	0.46	6.51	0.34	2.8e-10	Prostate cancer;
CRC	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.68	9.46	0.46	6.05e-19	Vitiligo;
CRC	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.52	8.74	0.43	1.22e-16	Dupuytren's disease;
CRC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg18230493	chr5:56204884	C5orf35	-0.6	-8.76	-0.43	1.03e-16	Initial pursuit acceleration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09423085	chr2:68478351	PPP3R1	0.48	6.15	0.32	2.23e-9	Thyroid stimulating hormone;
CRC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.29	0.37	2.34e-12	Mean platelet volume;
CRC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.45	7.23	0.37	3.31e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs185694	0.947	rs202079	chr13:30879154	C/T	cg04551440	chr13:30881194	KATNAL1	-0.66	-6.52	-0.34	2.59e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.53	-0.38	4.85e-13	Coronary artery disease;
CRC	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg20356878	chr3:121714668	ILDR1	-0.47	-6.74	-0.35	7.17e-11	Multiple sclerosis;
CRC	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.62	8.88	0.44	4.31e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.53	-8.81	-0.44	7.13e-17	Menarche (age at onset);
CRC	cis	rs990171	0.955	rs10197881	chr2:103091715	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.85	0.31	1.19e-8	Lymphocyte counts;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg15331096	chr17:29861932	RAB11FIP4	-0.42	-6.16	-0.32	2.16e-9	Parkinson's disease;
CRC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-13.6	-0.6	1e-33	Blood metabolite levels;
CRC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg27535305	chr1:53392650	SCP2	0.38	7.2	0.37	4.06e-12	Monocyte count;
CRC	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.51	6.72	0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.47	-7.42	-0.38	1.02e-12	Bipolar disorder;
CRC	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg09659197	chr4:152720779	NA	0.51	11.12	0.52	1.29e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.49	0.46	4.96e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2398668	0.622	rs62442516	chr7:2306984	C/T	cg08027265	chr7:2291960	NA	0.44	7.93	0.4	3.35e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg06218622	chr17:8079772	TMEM107	-0.68	-5.99	-0.31	5.48e-9	Cognitive function;
CRC	cis	rs1322512	0.958	rs12195158	chr6:153006544	T/C	cg03415253	chr6:152958462	SYNE1	0.4	6.03	0.32	4.39e-9	Tonometry;
CRC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg03806693	chr22:41940476	POLR3H	-0.52	-6.01	-0.31	4.91e-9	Neuroticism;
CRC	cis	rs1740073	0.624	rs9472179	chr6:43938931	C/T	cg14777908	chr6:43939685	NA	-0.53	-8.94	-0.44	2.87e-17	Vascular endothelial growth factor levels;
CRC	cis	rs4965006	0.915	rs4965004	chr12:132424700	A/G	cg00588090	chr12:132412438	PUS1	0.53	6.58	0.34	1.81e-10	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg03623178	chr6:28175578	NA	0.81	6.68	0.35	1.04e-10	Depression;
CRC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg13206674	chr6:150067644	NUP43	0.66	9.68	0.47	1.12e-19	Lung cancer;
CRC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.34	5.95	0.31	6.72e-9	Dilated cardiomyopathy;
CRC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.61	-8.89	-0.44	4.14e-17	Total body bone mineral density;
CRC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.81	-13.83	-0.61	1.3e-34	Cystic fibrosis severity;
CRC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.0	-0.4	2.21e-14	Electroencephalogram traits;
CRC	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.62	-8.72	-0.43	1.41e-16	Coronary artery disease;
CRC	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.48	6.73	0.35	7.74e-11	Obesity-related traits;
CRC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-6.06	-0.32	3.71e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.68	-0.43	1.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11212617	1.000	rs7943165	chr11:108274890	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.39	0.33	5.72e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	0.67	7.22	0.37	3.66e-12	Body mass index;
CRC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.06	-0.49	6.04e-21	Aortic root size;
CRC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.98	-0.44	2.17e-17	Alcohol dependence;
CRC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.6	-9.11	-0.45	8.23e-18	Body mass index;
CRC	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg15309053	chr8:964076	NA	0.36	6.03	0.32	4.38e-9	Schizophrenia;
CRC	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg09915433	chr19:53449742	NA	-0.6	-8.96	-0.44	2.5e-17	Psoriasis;
CRC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg09455208	chr3:40491958	NA	0.32	6.68	0.35	9.99e-11	Renal cell carcinoma;
CRC	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg10589385	chr1:150898437	SETDB1	0.31	6.49	0.34	3.2e-10	Tonsillectomy;
CRC	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg16898833	chr6:26189333	HIST1H4D	0.69	6.06	0.32	3.64e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg10820045	chr2:198174542	NA	0.39	6.41	0.33	4.9e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg25930673	chr12:123319894	HIP1R	0.69	5.85	0.31	1.17e-8	Adiponectin levels;
CRC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.48	-6.73	-0.35	7.41e-11	Height;
CRC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs889398	0.641	rs9936589	chr16:69884817	C/T	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.46	-0.34	3.69e-10	Body mass index;
CRC	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.54	8.73	0.43	1.35e-16	Mean corpuscular volume;
CRC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg24675056	chr1:15929824	NA	0.53	7.22	0.37	3.68e-12	Systolic blood pressure;
CRC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg00814883	chr7:100076585	TSC22D4	-0.51	-6.11	-0.32	2.82e-9	Lung function (FEV1/FVC);
CRC	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.13	0.32	2.58e-9	Bipolar disorder;
CRC	cis	rs17065868	1.000	rs9533919	chr13:45156951	C/T	cg10246903	chr13:45222710	NA	0.53	5.7	0.3	2.64e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07671174	chr3:58224051	ABHD6	0.45	6.25	0.33	1.27e-9	Response to antipsychotic treatment;
CRC	cis	rs10982256	0.774	rs10759711	chr9:117253308	T/G	cg13636371	chr9:117264095	DFNB31	0.35	6.69	0.35	9.85e-11	Bipolar disorder;
CRC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	1.02	18.22	0.71	8.99e-52	Parkinson's disease;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg12273811	chr6:28175739	NA	0.58	7.55	0.38	4.33e-13	Parkinson's disease;
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg21856205	chr7:94953877	PON1	-0.48	-6.28	-0.33	1.1e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.93	-0.31	7.59e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4731207	0.596	rs34555990	chr7:124587844	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs281302	0.621	rs421853	chr15:47744331	C/T	cg13159054	chr15:47721715	NA	-0.46	-6.84	-0.35	3.95e-11	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs9903692	0.908	rs9807087	chr17:46204138	A/G	cg21215337	chr17:46176117	CBX1	-0.42	-7.83	-0.4	6.74e-14	Pulse pressure;
CRC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.75	-12.39	-0.56	3.44e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12912251	0.591	rs3104150	chr15:39003585	T/C	cg10631289	chr15:39006617	NA	-0.49	-5.64	-0.3	3.75e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CRC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.74	-0.39	1.27e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs8002861	0.515	rs9525846	chr13:44390857	A/G	cg17145862	chr1:211918768	LPGAT1	-0.6	-10.98	-0.52	4.17e-24	Leprosy;
CRC	cis	rs10411161	0.702	rs10423838	chr19:52387283	C/T	cg11269599	chr19:52391304	ZNF577	0.45	5.73	0.3	2.26e-8	Breast cancer;
CRC	cis	rs4711350	0.953	rs942496	chr6:33788055	A/G	cg07979401	chr6:33739406	LEMD2	-0.45	-5.61	-0.3	4.36e-8	Schizophrenia;
CRC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.33e-46	Breast cancer;
CRC	cis	rs6977940	0.558	rs11768054	chr7:2888015	T/G	cg19731401	chr7:2775893	GNA12	0.6	5.78	0.3	1.78e-8	White matter integrity;
CRC	cis	rs243505	0.632	rs887571	chr7:148505253	G/A	cg09806900	chr7:148480153	CUL1	0.49	7.1	0.36	7.9e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.52	-8.3	-0.42	2.79e-15	Menopause (age at onset);
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg19046167	chr17:80928561	B3GNTL1	0.42	6.51	0.34	2.87e-10	Glycated hemoglobin levels;
CRC	trans	rs9341835	0.584	rs2622286	chr6:64150067	A/T	cg13657004	chr13:50234944	EBPL	-0.37	-6.38	-0.33	6.03e-10	Schizophrenia;
CRC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	8.3	0.42	2.77e-15	Platelet count;
CRC	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg04969067	chr8:143858791	LYNX1	-0.36	-6.07	-0.32	3.58e-9	Urinary tract infection frequency;
CRC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg24675056	chr1:15929824	NA	0.47	6.21	0.32	1.56e-9	Systolic blood pressure;
CRC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.52	6.91	0.36	2.51e-11	Obesity-related traits;
CRC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg24209194	chr3:40518798	ZNF619	0.38	5.73	0.3	2.32e-8	Renal cell carcinoma;
CRC	cis	rs2179367	0.632	rs2143075	chr6:149746643	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.4	-5.62	-0.3	4.16e-8	Dupuytren's disease;
CRC	cis	rs2882667	0.898	rs12719519	chr5:138375687	G/A	cg09476006	chr5:138032270	NA	0.45	7.46	0.38	7.7e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.57	7.38	0.38	1.28e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9311676	0.656	rs56028017	chr3:58372508	C/T	cg06643156	chr3:58380774	PXK	0.42	6.37	0.33	6.33e-10	Systemic lupus erythematosus;
CRC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.85	12.68	0.57	2.93e-30	Gut microbiome composition (summer);
CRC	cis	rs4363385	0.658	rs426147	chr1:153045011	G/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.86e-10	Inflammatory skin disease;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	0.96	8.95	0.44	2.61e-17	Lymphocyte counts;
CRC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.53	-7.58	-0.39	3.44e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.5	-0.46	4.4e-19	Heart rate;
CRC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.74	0.35	7.06e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	5.99	0.31	5.54e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg19041857	chr6:27730383	NA	-0.67	-6.61	-0.34	1.51e-10	Breast cancer;
CRC	cis	rs1476670	0.710	rs751442	chr1:44509551	A/C	cg09470012	chr1:44509516	NA	0.42	6.94	0.36	2.1e-11	Eotaxin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11317343	chr5:177580912	NHP2	0.48	6.75	0.35	6.53e-11	Response to antipsychotic treatment;
CRC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg09127314	chr1:152161683	NA	0.54	6.92	0.36	2.32e-11	Atopic dermatitis;
CRC	cis	rs427941	0.632	rs201498	chr7:101756262	G/A	cg06246474	chr7:101738831	CUX1	0.44	6.73	0.35	7.61e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg22256960	chr15:77711686	NA	0.41	5.63	0.3	3.88e-8	Type 2 diabetes;
CRC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.48	9.05	0.45	1.24e-17	Alcohol dependence;
CRC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.77	13.51	0.6	2.17e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg08501292	chr6:25962987	TRIM38	0.72	7.22	0.37	3.66e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-6.85	-0.35	3.69e-11	Vitiligo;
CRC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.33	-0.42	2.16e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg23262073	chr20:60523788	NA	-0.49	-7.55	-0.38	4.2e-13	Body mass index;
CRC	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg17218026	chr1:154582156	ADAR	0.63	10.27	0.49	1.21e-21	Blood protein levels;
CRC	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-7.92	-0.4	3.6e-14	Schizophrenia;
CRC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg11212589	chr17:38028394	ZPBP2	0.35	6.17	0.32	2e-9	Asthma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27367768	chr5:171615456	STK10	-0.38	-5.98	-0.31	5.74e-9	Myopia (pathological);
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02290350	chr8:58132656	NA	-0.59	-8.03	-0.4	1.7e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.66	-8.18	-0.41	6.34e-15	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs3736485	0.934	rs11634999	chr15:51871461	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.63	-0.34	1.41e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg09455208	chr3:40491958	NA	0.31	6.19	0.32	1.8e-9	Renal cell carcinoma;
CRC	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	0.86	6.9	0.36	2.74e-11	Fat distribution (HIV);
CRC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.52	7.42	0.38	1.01e-12	Colorectal cancer;
CRC	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.52	9.09	0.45	9.69e-18	Common traits (Other);
CRC	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-7.91	-0.4	3.83e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10878977	0.542	rs58786840	chr12:69799163	C/T	cg20891283	chr12:69753455	YEATS4	-0.61	-6.13	-0.32	2.52e-9	Colorectal cancer;
CRC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	8.55e-15	Red blood cell count;
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.22	-0.41	4.71e-15	Total body bone mineral density;
CRC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.01	0.44	1.77e-17	Bladder cancer;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg21251018	chr6:28226885	NKAPL	0.39	5.82	0.31	1.42e-8	Parkinson's disease;
CRC	cis	rs4936891	0.577	rs4936885	chr11:123905876	C/A	cg22125253	chr11:123886957	OR10G4	-0.33	-5.79	-0.3	1.61e-8	Male fertility;
CRC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.28	-0.33	1.09e-9	Alzheimer's disease (late onset);
CRC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.81	10.14	0.49	3.29e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.81	11.89	0.55	2.36e-27	Cognitive function;
CRC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.61	0.73	2.85e-57	Prudent dietary pattern;
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.25	-0.41	3.81e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg10437265	chr15:77819839	NA	0.67	12.42	0.56	2.72e-29	Type 2 diabetes;
CRC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17848003	chr1:3704513	LRRC47	0.41	5.95	0.31	6.88e-9	Red cell distribution width;
CRC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg18612461	chr15:75251733	NA	0.37	5.85	0.31	1.21e-8	Breast cancer;
CRC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.06	-0.32	3.69e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.41	5.69	0.3	2.85e-8	Total body bone mineral density;
CRC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.3	0.33	9.74e-10	Morning vs. evening chronotype;
CRC	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.02	-0.36	1.31e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg00343986	chr7:65444356	GUSB	-0.51	-7.61	-0.39	2.83e-13	Aortic root size;
CRC	cis	rs4730250	0.711	rs117026964	chr7:107063656	C/A	cg02696742	chr7:106810147	HBP1	-0.62	-6.19	-0.32	1.79e-9	Osteoarthritis;
CRC	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.63	-7.76	-0.39	1.1e-13	Obesity (extreme);
CRC	cis	rs4664293	0.625	rs3821300	chr2:160567230	A/G	cg08347373	chr2:160653686	CD302	0.4	6.8	0.35	4.91e-11	Monocyte percentage of white cells;
CRC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.36e-9	Coronary artery disease;
CRC	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.5	7.58	0.39	3.46e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.93	17.28	0.69	4.48e-48	Intelligence (multi-trait analysis);
CRC	cis	rs4321325	0.733	rs79208542	chr2:127935686	G/C	cg11380483	chr2:127933992	NA	0.63	7.7	0.39	1.64e-13	Protein C levels;
CRC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.4	6.52	0.34	2.6200000000000003e-10	Major depressive disorder;
CRC	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.38	-5.9	-0.31	9.07e-9	Type 1 diabetes;
CRC	cis	rs362272	0.502	rs2798298	chr4:3036602	G/A	cg22930642	chr4:2936657	C4orf10;MFSD10	-0.4	-5.74	-0.3	2.13e-8	Serum sulfate level;
CRC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg13072238	chr3:49761600	GMPPB	-0.52	-5.75	-0.3	2.05e-8	Menarche (age at onset);
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg03623178	chr6:28175578	NA	0.92	13.12	0.59	6.4e-32	Parkinson's disease;
CRC	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.66	-0.3	3.34e-8	Gout;Renal underexcretion gout;
CRC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.44	5.9	0.31	9.21e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.08	-0.32	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg00691999	chr4:55094011	PDGFRA	0.44	6.27	0.33	1.15e-9	Corneal astigmatism;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.6	-13.71	-0.6	3.82e-34	Longevity;Endometriosis;
CRC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.51	-7.05	-0.36	1.06e-11	IgG glycosylation;
CRC	cis	rs7725052	0.609	rs4957297	chr5:40455074	A/G	cg09067459	chr5:40385259	NA	0.38	6.31	0.33	9.04e-10	Pediatric autoimmune diseases;
CRC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.26	0.41	3.65e-15	Height;
CRC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.83	14.92	0.64	7.97e-39	Breast cancer;
CRC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.92	-0.31	8.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.01	-0.31	5.04e-9	Neuroticism;
CRC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg12463550	chr7:65579703	CRCP	0.65	6.2	0.32	1.67e-9	Diabetic kidney disease;
CRC	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.81	0.68	3.37e-46	Electrocardiographic conduction measures;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01678049	chr5:149737331	TCOF1	0.49	6.77	0.35	6.06e-11	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg01879757	chr17:41196368	BRCA1	-0.39	-5.82	-0.31	1.38e-8	Menopause (age at onset);
CRC	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg23387468	chr7:139079360	LUC7L2	0.4	6.96	0.36	1.9e-11	Diisocyanate-induced asthma;
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.01	9.2	0.45	4.24e-18	Diabetic retinopathy;
CRC	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.53	9.64	0.47	1.56e-19	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs11574514	1.000	rs8061384	chr16:67911874	T/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.02	-0.31	4.73e-9	Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05910615	chr19:36248877	HSPB6;C19orf55	0.43	6.75	0.35	6.78e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7739232	0.920	rs112460412	chr6:53526863	T/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	7.01	0.36	1.32e-11	Breast cancer;
CRC	cis	rs7635838	1.000	rs7635838	chr3:11412604	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.42	0.33	4.75e-10	HDL cholesterol;
CRC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04607442	chr13:21872219	NA	0.49	7.91	0.4	3.85e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-10.48	-0.5	2.21e-22	Initial pursuit acceleration;
CRC	cis	rs812925	0.502	rs13028833	chr2:61644329	C/G	cg10580144	chr2:61372316	C2orf74	-0.32	-6.83	-0.35	4.18e-11	Immature fraction of reticulocytes;
CRC	cis	rs4594175	0.926	rs12434681	chr14:51595335	A/G	cg23942311	chr14:51606299	NA	0.67	10.66	0.51	5.51e-23	Cancer;
CRC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg19824325	chr16:58548873	SETD6	0.92	6.21	0.32	1.62e-9	Schizophrenia;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.54	7.4	0.38	1.14e-12	Longevity;Endometriosis;
CRC	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	1.1	9.78	0.47	5.37e-20	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.45	5.72	0.3	2.35e-8	Cholesterol, total;
CRC	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-9.66	-0.47	1.37e-19	Urate levels in overweight individuals;
CRC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.51e-8	Total body bone mineral density;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg26304593	chr6:42947056	PEX6	-0.41	-5.88	-0.31	1.02e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg22601191	chr20:60968625	CABLES2	-0.4	-6.56	-0.34	2.1e-10	Colorectal cancer;
CRC	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.65	-8.86	-0.44	5.02e-17	Extraversion;
CRC	cis	rs4731207	0.698	rs7811608	chr7:124447848	T/C	cg23710748	chr7:124431027	NA	0.38	6.03	0.32	4.49e-9	Cutaneous malignant melanoma;
CRC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	5.97e-10	Red blood cell count;
CRC	trans	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg24644049	chr4:85504048	CDS1	0.69	6.17	0.32	2.01e-9	Skin colour saturation;
CRC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.32	6.02	0.32	4.62e-9	Blood protein levels;
CRC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.38	6.14	0.32	2.35e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.31	-0.33	9.14e-10	Aortic root size;
CRC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.7	12.0	0.55	8.89e-28	Systemic lupus erythematosus;
CRC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.67	8.98	0.44	2.06e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02098413	chr6:105308735	HACE1	0.35	5.77	0.3	1.8e-8	Thyroid stimulating hormone;
CRC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-11.21	-0.53	6.17e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.51	7.24	0.37	3.2e-12	Aortic root size;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.68	-0.57	2.75e-30	Alzheimer's disease;
CRC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.81	-0.4	7.69e-14	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18355925	chr4:56212207	SRD5A3	0.44	6.8	0.35	5.03e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg11189052	chr15:85197271	WDR73	0.57	8.13	0.41	8.8e-15	Schizophrenia;
CRC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.67	7.26	0.37	2.84e-12	Body mass index;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01866215	chr16:3150293	NA	-0.47	-7.09	-0.36	8.32e-12	Interleukin-6 levels;
CRC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21028142	chr17:79581711	NPLOC4	0.33	6.96	0.36	1.81e-11	Eye color traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03634887	chr16:66730948	CMTM4	-0.52	-6.19	-0.32	1.83e-9	Diisocyanate-induced asthma;
CRC	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.72	-0.35	8.26e-11	Myopia (pathological);
CRC	cis	rs4731207	0.596	rs7810120	chr7:124644945	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg07404485	chr7:94953653	PON1	-0.47	-6.15	-0.32	2.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg02524346	chr8:600233	NA	-0.93	-8.26	-0.41	3.66e-15	IgG glycosylation;
CRC	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.62	-6.93	-0.36	2.21e-11	Breast cancer;
CRC	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.53	-6.77	-0.35	6.1e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.07	17.99	0.7	6.94e-51	Cognitive function;
CRC	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg17145862	chr1:211918768	LPGAT1	-0.47	-7.82	-0.4	7.28e-14	Leprosy;
CRC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.65	-11.78	-0.54	5.74e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs10411161	1.000	rs10412080	chr19:52373508	A/C	cg22319618	chr22:45562946	NUP50	-0.54	-6.24	-0.33	1.38e-9	Breast cancer;
CRC	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.38	6.16	0.32	2.15e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.9	-10.09	-0.49	5.02e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.75	12.57	0.57	7.04e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg03623178	chr6:28175578	NA	0.69	9.22	0.45	3.71e-18	Parkinson's disease;
CRC	cis	rs6460942	0.505	rs73290446	chr7:12358133	T/G	cg06484146	chr7:12443880	VWDE	-0.53	-5.7	-0.3	2.73e-8	Coronary artery disease;
CRC	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.53	-6.15	-0.32	2.31e-9	Obesity-related traits;
CRC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.54	-8.91	-0.44	3.67e-17	Schizophrenia;
CRC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg18721089	chr20:30220636	NA	-0.34	-5.72	-0.3	2.34e-8	Mean corpuscular hemoglobin;
CRC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.52	-8.55	-0.43	4.82e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg18827107	chr12:86230957	RASSF9	0.37	5.93	0.31	7.66e-9	Major depressive disorder;
CRC	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg08314208	chr16:67682810	RLTPR	-0.54	-5.83	-0.31	1.31e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.45	8.39	0.42	1.41e-15	Childhood ear infection;
CRC	cis	rs2565722	0.622	rs1937483	chr6:161295598	G/A	cg03159191	chr6:161285451	NA	-0.39	-6.0	-0.31	5.09e-9	Blood protein levels;
CRC	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg22732515	chr19:44031385	ETHE1	0.61	9.07	0.45	1.1e-17	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.01	-0.31	5.03e-9	Arsenic metabolism;
CRC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.74	-15.0	-0.64	4.06e-39	Prostate cancer;
CRC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs117623576	0.941	rs60146023	chr10:32411515	G/A	cg03047570	chr10:32398778	NA	-0.76	-8.78	-0.44	8.91e-17	Anti-saccade response;
CRC	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.03	7.49	0.38	6.51e-13	Economic and political preferences (immigration/crime);
CRC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.56	8.09	0.41	1.15e-14	Resting heart rate;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02018176	chr4:1364513	KIAA1530	0.42	6.96	0.36	1.88e-11	Obesity-related traits;
CRC	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.08	0.32	3.32e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs62189005	chr2:162562386	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs7849270	1.000	rs10988232	chr9:131915348	G/T	cg13538475	chr9:131942899	NA	-0.3	-5.88	-0.31	1.02e-8	Blood metabolite ratios;
CRC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-5.66	-0.3	3.29e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	0.91	10.99	0.52	3.76e-24	Red blood cell traits;
CRC	cis	rs6504622	0.537	rs1662576	chr17:44996245	C/T	cg16759221	chr17:45003025	GOSR2	-0.68	-11.04	-0.52	2.62e-24	Orofacial clefts;
CRC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg06634786	chr22:41940651	POLR3H	-0.45	-5.86	-0.31	1.12e-8	Neuroticism;
CRC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-5.94	-0.31	7.32e-9	Alzheimer's disease (late onset);
CRC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17554472	chr22:41940697	POLR3H	-0.52	-5.79	-0.3	1.65e-8	Vitiligo;
CRC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.51	7.86	0.4	5.44e-14	Aortic root size;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10372701	chr3:142546496	PCOLCE2	0.49	6.62	0.34	1.46e-10	Survival in pancreatic cancer;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg09877947	chr5:131593287	PDLIM4	0.36	6.79	0.35	5.24e-11	Blood metabolite levels;
CRC	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg09659197	chr4:152720779	NA	-0.44	-9.46	-0.46	5.89e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.89	11.8	0.55	4.91e-27	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.72	-0.35	8.02e-11	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg22110888	chr17:80059540	CCDC57	-0.44	-6.79	-0.35	5.37e-11	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22493673	chr1:156711108	MRPL24	0.46	6.8	0.35	4.86e-11	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg07870213	chr5:140052090	DND1	-0.58	-7.82	-0.4	7.25e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.44	6.21	0.32	1.58e-9	Schizophrenia;
CRC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg13206674	chr6:150067644	NUP43	0.49	7.04	0.36	1.13e-11	Testicular germ cell tumor;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg12273811	chr6:28175739	NA	-0.6	-8.43	-0.42	1.08e-15	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-7.91	-0.4	4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.06	-0.41	1.47e-14	Triglycerides;
CRC	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.67	-7.79	-0.39	8.84e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.37	6.36	0.33	6.89e-10	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25987185	chr17:18129087	LLGL1	0.38	6.01	0.31	5e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg13034943	chr12:132379564	ULK1	-0.68	-5.97	-0.31	6.02e-9	Cognitive function;
CRC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.03	0.58	1.44e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg15440763	chr7:158190612	PTPRN2	0.41	6.47	0.34	3.46e-10	Obesity-related traits;
CRC	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.78	-12.43	-0.57	2.47e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.21	-0.37	3.97e-12	Coronary artery disease;
CRC	trans	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg14318858	chr19:50204862	CPT1C	-0.37	-6.07	-0.32	3.47e-9	Schizophrenia;
CRC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg01444801	chr10:135216882	MTG1	-0.55	-7.84	-0.4	6.2e-14	Systemic lupus erythematosus;
CRC	cis	rs2982552	0.775	rs2982562	chr6:152052601	C/T	cg22157087	chr6:152012887	ESR1	0.38	5.87	0.31	1.07e-8	Bone properties (heel);
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02290350	chr8:58132656	NA	-0.59	-7.14	-0.37	6.05e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg27411982	chr8:10470053	RP1L1	-0.35	-5.72	-0.3	2.34e-8	Neuroticism;
CRC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg20203395	chr5:56204925	C5orf35	-0.51	-6.32	-0.33	8.62e-10	Type 2 diabetes;
CRC	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.36	6.0	0.31	5.16e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.49	7.21	0.37	3.85e-12	Cognitive test performance;
CRC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.66	-9.73	-0.47	7.94e-20	Inflammatory bowel disease;
CRC	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.57	9.69	0.47	1.04e-19	Dupuytren's disease;
CRC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.09	-0.66	2.29e-43	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.53	8.53	0.43	5.46e-16	Coronary artery disease;
CRC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.63	7.24	0.37	3.24e-12	Resting heart rate;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs7923609	0.902	rs10822182	chr10:65325478	G/A	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.81	-0.3	1.51e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9311676	0.632	rs6445978	chr3:58379586	T/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.92e-10	Systemic lupus erythematosus;
CRC	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.47	8.43	0.42	1.08e-15	Blood metabolite ratios;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02326931	chr13:37572901	ALG5	-0.52	-6.13	-0.32	2.46e-9	Diisocyanate-induced asthma;
CRC	cis	rs2882667	0.690	rs825672	chr5:138095643	A/G	cg09476006	chr5:138032270	NA	-0.53	-8.98	-0.44	2.14e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg27205649	chr11:78285834	NARS2	0.47	5.79	0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg22349126	chr12:25348261	LYRM5;CASC1	0.39	6.0	0.31	5.17e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14509581	chr15:68522181	CLN6	0.39	6.21	0.32	1.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.74e-9	Breast cancer;
CRC	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.1	-0.45	9.11e-18	Cancer;
CRC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.43	-6.83	-0.35	4.13e-11	High light scatter reticulocyte count;
CRC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.71	7.05	0.36	1.09e-11	Diabetic retinopathy;
CRC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg23996704	chr18:44553084	KATNAL2	-0.31	-5.83	-0.31	1.29e-8	Personality dimensions;
CRC	cis	rs6681460	1.000	rs964574	chr1:67062885	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.21	0.41	5.25e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.5	-0.34	2.99e-10	Total body bone mineral density;
CRC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8141797	1.000	rs115965884	chr22:24594662	C/T	cg20894457	chr22:24584366	SUSD2	0.66	6.75	0.35	6.71e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg04969067	chr8:143858791	LYNX1	-0.34	-5.82	-0.31	1.38e-8	Urinary tract infection frequency;
CRC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.74	12.81	0.58	9.59e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs365302	0.904	rs422232	chr6:159649745	A/G	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.65	-8.23	-0.41	4.29e-15	Coronary artery disease;
CRC	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.37	-6.05	-0.32	3.93e-9	Life satisfaction;
CRC	trans	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg24644049	chr4:85504048	CDS1	0.71	6.62	0.34	1.44e-10	Skin colour saturation;
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg12273811	chr6:28175739	NA	0.45	6.58	0.34	1.81e-10	Cardiac Troponin-T levels;
CRC	trans	rs7546	0.501	rs12102426	chr16:4922450	T/G	cg19252218	chr17:41477271	ARL4D	0.44	6.37	0.33	6.21e-10	Cancer;
CRC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.6e-9	Aortic root size;
CRC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.0	0.44	1.78e-17	Parkinson's disease;
CRC	cis	rs2637266	0.739	rs11001838	chr10:78376351	T/G	cg18941641	chr10:78392320	NA	-0.37	-6.37	-0.33	6.51e-10	Pulmonary function;
CRC	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.76	9.2	0.45	4.29e-18	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25964984	chr22:30783371	RNF215	-0.4	-6.09	-0.32	3.07e-9	Myopia (pathological);
CRC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.78	11.62	0.54	2.16e-26	Neutrophil percentage of white cells;
CRC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.82	13.85	0.61	1.07e-34	Coronary artery disease;
CRC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg05714579	chr10:131428358	MGMT	0.5	6.99	0.36	1.54e-11	Response to temozolomide;
CRC	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.15	0.49	3.02e-21	Corneal astigmatism;
CRC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg09998033	chr7:158218633	PTPRN2	0.5	7.05	0.36	1.04e-11	Obesity-related traits;
CRC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.55	-6.33	-0.33	7.89e-10	Vitiligo;
CRC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00074818	chr8:8560427	CLDN23	0.32	5.71	0.3	2.55e-8	Obesity-related traits;
CRC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07513332	chr6:167530253	CCR6	-0.37	-6.1	-0.32	3.03e-9	Primary biliary cholangitis;
CRC	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.73	-9.8	-0.48	4.73e-20	White matter hyperintensity burden;
CRC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-1.0	-12.82	-0.58	8.38e-31	Vitiligo;
CRC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.91	-17.02	-0.68	5.07e-47	IgG glycosylation;
CRC	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.75	13.98	0.61	3.62e-35	Cancer;
CRC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg26769984	chr7:1090371	C7orf50	0.47	6.05	0.32	3.87e-9	Bronchopulmonary dysplasia;
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.09	-27.79	-0.84	2.55e-88	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.46	6.28	0.33	1.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02097616	chr17:62675921	NA	0.51	7.19	0.37	4.39e-12	QT interval;
CRC	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.38	-0.46	1.11e-18	Urate levels in obese individuals;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg03938978	chr2:103052716	IL18RAP	0.36	5.92	0.31	7.92e-9	Asthma;
CRC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg03013999	chr17:37608204	MED1	0.47	7.26	0.37	2.88e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.56	8.97	0.44	2.3e-17	Type 2 diabetes;
CRC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg19622623	chr12:86230825	RASSF9	-0.36	-5.94	-0.31	7.17e-9	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17705056	chr18:77711560	PQLC1	0.43	7.18	0.37	4.53e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.77	8.03	0.4	1.73e-14	Major depressive disorder;
CRC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.6	9.2	0.45	4.34e-18	Corneal astigmatism;
CRC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.42	-6.13	-0.32	2.58e-9	Emphysema distribution in smoking;
CRC	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.51	0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.56	7.83	0.4	6.99e-14	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10518340	chr6:97731094	MIR548H3;C6orf167	0.52	7.28	0.37	2.44e-12	Anxiety disorder;
CRC	cis	rs4920343	0.645	rs851115	chr1:19070229	T/A	cg19637330	chr1:19110922	NA	0.4	6.12	0.32	2.65e-9	Knee osteoarthritis;
CRC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.58	7.85	0.4	5.85e-14	Alzheimer's disease;
CRC	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.37	-0.42	1.69e-15	Brugada syndrome;
CRC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.61	0.34	1.58e-10	Schizophrenia;
CRC	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg27398640	chr15:77910606	LINGO1	-0.44	-7.81	-0.4	7.8e-14	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg21251018	chr6:28226885	NKAPL	0.48	6.29	0.33	9.93e-10	Depression;
CRC	cis	rs3751196	0.901	rs79261387	chr12:104161484	T/C	cg02344784	chr12:104178138	NT5DC3	0.68	6.76	0.35	6.18e-11	Sense of smell;
CRC	cis	rs10924970	0.967	rs12035746	chr1:235405654	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05447486	chr1:112162367	RAP1A	0.42	6.53	0.34	2.42e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.41	-0.33	4.97e-10	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21909475	chr1:169764459	C1orf156;C1orf112	0.41	6.02	0.31	4.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.92	-0.48	1.83e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-14.19	-0.62	5.52e-36	Blood metabolite levels;
CRC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg22974920	chr21:40686053	BRWD1	0.42	5.98	0.31	5.79e-9	Cognitive function;
CRC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg15205204	chr1:6545172	PLEKHG5	0.38	5.66	0.3	3.22e-8	Body mass index;
CRC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg17294928	chr15:75287854	SCAMP5	-0.51	-7.63	-0.39	2.5e-13	Breast cancer;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.82	14.61	0.63	1.28e-37	Breast cancer;
CRC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.77	0.54	6.2e-27	Hip circumference adjusted for BMI;
CRC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.34e-40	Prostate cancer;
CRC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25517755	chr10:38738941	LOC399744	0.4	5.81	0.31	1.47e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-14.49	-0.62	3.75e-37	Ulcerative colitis;
CRC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.49	7.77	0.39	1e-13	Height;
CRC	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.26	11.71	0.54	1.03e-26	Prostate cancer;
CRC	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.44	6.58	0.34	1.83e-10	Neutrophil percentage of white cells;
CRC	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.77	-0.35	5.77e-11	Metabolite levels;
CRC	cis	rs954108	0.966	rs9508155	chr13:29372016	C/T	cg11788234	chr13:29393811	NA	0.43	7.26	0.37	2.78e-12	Obesity-related traits;
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg10729496	chr3:10149963	C3orf24	0.62	7.31	0.37	2.04e-12	Alzheimer's disease;
CRC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.61	-6.4	-0.33	5.25e-10	Schizophrenia;
CRC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.61	-9.68	-0.47	1.19e-19	Aortic root size;
CRC	cis	rs910187	0.624	rs6066219	chr20:45793967	A/T	cg27589058	chr20:45804311	EYA2	-0.36	-6.67	-0.35	1.07e-10	Migraine;
CRC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.76	10.57	0.5	1.16e-22	Neutrophil percentage of white cells;
CRC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg11212589	chr17:38028394	ZPBP2	0.43	7.93	0.4	3.36e-14	Self-reported allergy;
CRC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg03037974	chr15:76606532	NA	-0.55	-8.25	-0.41	3.89e-15	Blood metabolite levels;
CRC	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg10298567	chr3:47292165	KIF9	0.41	6.37	0.33	6.28e-10	Colorectal cancer;
CRC	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.25	15.0	0.64	4.06e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs6772849	0.708	rs12491942	chr3:128421469	C/G	cg08795948	chr3:128337044	NA	0.34	5.67	0.3	3.12e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.47	-0.57	1.66e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg18016565	chr1:150552671	MCL1	0.42	6.06	0.32	3.8e-9	Melanoma;
CRC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.89	0.51	8.98e-24	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05563107	chr19:50528575	VRK3;ZNF473	0.5	6.93	0.36	2.27e-11	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.57	8.16	0.41	7.21e-15	Lung cancer;
CRC	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	1.15	17.21	0.69	8.7e-48	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-13.32	-0.59	1.11e-32	Alzheimer's disease;
CRC	cis	rs12230513	0.732	rs61956331	chr12:55840856	G/A	cg19537932	chr12:55886519	OR6C68	-0.73	-9.5	-0.46	4.47e-19	Contrast sensitivity;
CRC	cis	rs9287719	0.649	rs11684537	chr2:10734832	C/T	cg00105475	chr2:10696890	NA	0.44	7.02	0.36	1.27e-11	Prostate cancer;
CRC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.71	0.57	2.19e-30	Menopause (age at onset);
CRC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.98	0.4	2.44e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg27615366	chr5:131592974	PDLIM4	0.32	5.73	0.3	2.22e-8	Breast cancer;
CRC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.63	-0.39	2.56e-13	Mean corpuscular volume;
CRC	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.49	7.52	0.38	5.23e-13	Type 2 diabetes;
CRC	trans	rs7178691	0.705	rs2899517	chr15:53892200	A/C	cg05337636	chr17:78720537	RPTOR	-0.48	-6.32	-0.33	8.48e-10	Fear of severe pain;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg03623178	chr6:28175578	NA	0.78	11.7	0.54	1.1e-26	Parkinson's disease;
CRC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.59	8.95	0.44	2.62e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.64	0.3	3.61e-8	Parkinson's disease;
CRC	cis	rs939584	1.000	rs7591067	chr2:642846	G/A	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12560992	chr17:57184187	TRIM37	0.53	7.37	0.38	1.41e-12	Testicular germ cell tumor;
CRC	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg26695010	chr11:65641043	EFEMP2	0.51	7.61	0.39	3.01e-13	Eosinophil percentage of white cells;
CRC	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	1.11	10.43	0.5	3.33e-22	Arsenic metabolism;
CRC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.55	8.56	0.43	4.49e-16	Aortic root size;
CRC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg12365402	chr11:9010492	NRIP3	0.47	8.08	0.41	1.26e-14	Hemoglobin concentration;
CRC	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.76	-10.28	-0.49	1.14e-21	Systemic lupus erythematosus;
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg22561889	chr6:118971681	C6orf204	0.53	6.87	0.35	3.16e-11	Diastolic blood pressure;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.79	-0.3	1.67e-8	Depression;
CRC	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg16606324	chr3:10149918	C3orf24	0.68	9.17	0.45	5.33e-18	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02537149	chr1:46769035	LRRC41;UQCRH	0.43	6.33	0.33	8.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00763555	chr13:30881437	KATNAL1	0.51	6.59	0.34	1.73e-10	Thyroid stimulating hormone;
CRC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg21475434	chr5:93447410	FAM172A	0.7	6.47	0.34	3.56e-10	Diabetic retinopathy;
CRC	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.27	0.37	2.59e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.09	-0.49	5.03e-21	Colorectal cancer;
CRC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	12.16	0.56	2.32e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg09417038	chr21:47716443	C21orf57	0.38	6.64	0.34	1.3100000000000001e-10	Testicular germ cell tumor;
CRC	cis	rs672059	0.812	rs61418038	chr1:183155717	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.51	7.33	0.37	1.79e-12	Hypertriglyceridemia;
CRC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.79	0.55	5.15e-27	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg23136738	chr11:925521	AP2A2	-0.5	-7.92	-0.4	3.57e-14	Alzheimer's disease (late onset);
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.68	10.33	0.49	7.34e-22	Initial pursuit acceleration;
CRC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.73	9.74	0.47	7.29e-20	Coronary artery disease;
CRC	cis	rs863345	0.604	rs1342947	chr1:158459714	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg09655341	chr17:79618100	PDE6G	0.64	7.68	0.39	1.79e-13	Dental caries;
CRC	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.42	7.25	0.37	3.09e-12	Body mass index;
CRC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	7.51	0.38	5.73e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7638909	0.512	rs6799868	chr3:38601556	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-7.08	-0.36	8.7e-12	Electrocardiographic conduction measures;
CRC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.17	-0.32	1.96e-9	Alzheimer's disease (late onset);
CRC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.48	-9.31	-0.46	1.94e-18	Subjective well-being;
CRC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.57	7.07	0.36	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg09659197	chr4:152720779	NA	0.51	11.13	0.52	1.27e-24	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.65	9.42	0.46	8.15e-19	Corneal astigmatism;
CRC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.58	-8.03	-0.4	1.75e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.59	-10.08	-0.49	5.24e-21	Recombination rate (males);
CRC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.97	-17.42	-0.69	1.34e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.07	-14.84	-0.63	1.64e-38	Exhaled nitric oxide output;
CRC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.86	-0.35	3.42e-11	Aortic root size;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Parkinson's disease;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg04155289	chr7:94953770	PON1	-0.6	-7.53	-0.38	4.89e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4692589	0.581	rs62344679	chr4:170963591	G/A	cg19918862	chr4:170955249	NA	0.53	7.01	0.36	1.35e-11	Anxiety disorder;
CRC	cis	rs3812111	0.524	rs12193094	chr6:116540395	C/T	cg15226275	chr6:116381976	FRK	0.26	6.1	0.32	3.06e-9	Age-related macular degeneration;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg16419706	chr3:141596184	ATP1B3	-0.42	-6.12	-0.32	2.59e-9	Daytime sleep phenotypes;
CRC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.6	8.07	0.41	1.34e-14	Coronary artery disease;
CRC	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg03433033	chr1:76189801	ACADM	-0.41	-5.77	-0.3	1.8e-8	Daytime sleep phenotypes;
CRC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.57	6.78	0.35	5.67e-11	Type 2 diabetes nephropathy;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg15845792	chr6:28175446	NA	0.68	10.11	0.49	4.05e-21	Cardiac Troponin-T levels;
CRC	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg19653624	chr11:20408972	PRMT3	0.61	7.26	0.37	2.75e-12	Pursuit maintenance gain;
CRC	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg13736514	chr6:26305472	NA	-0.45	-7.34	-0.38	1.67e-12	Educational attainment;
CRC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.53	-7.15	-0.37	5.7e-12	Gut microbiome composition (summer);
CRC	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg00277334	chr10:82204260	NA	-0.36	-5.91	-0.31	8.48e-9	Sarcoidosis;
CRC	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg14352298	chr13:112236639	NA	0.27	6.11	0.32	2.83e-9	Hepatitis;
CRC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg23417306	chr2:180868811	CWC22	-0.49	-6.72	-0.35	7.82e-11	Schizophrenia;
CRC	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg01714284	chr4:185714524	ACSL1	-0.55	-5.9	-0.31	9.11e-9	Type 2 diabetes;
CRC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.93	0.31	7.66e-9	Aortic root size;
CRC	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.48	7.16	0.37	5.44e-12	Red blood cell count;
CRC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.48	7.31	0.37	2.04e-12	Prostate cancer;
CRC	cis	rs6976053	0.935	rs4729620	chr7:100506528	C/A	cg10426581	chr7:100472382	SRRT	0.38	5.84	0.31	1.23e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.51	-8.69	-0.43	1.73e-16	Endometriosis;
CRC	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.45	0.33	4.04e-10	Lymphocyte counts;
CRC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.43	6.18	0.32	1.85e-9	Aortic root size;
CRC	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.77	-12.37	-0.56	4.04e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.38	1.23e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg15147215	chr3:52552868	STAB1	0.45	7.44	0.38	8.85e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.46	6.07	0.32	3.59e-9	Tuberculosis;
CRC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.9	-0.31	9.28e-9	Gout;Renal underexcretion gout;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg03790207	chr6:42947109	PEX6	-0.44	-6.14	-0.32	2.43e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.56	7.54	0.38	4.6e-13	Urinary tract infection frequency;
CRC	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg11204139	chr17:3907470	NA	0.74	14.02	0.61	2.4e-35	Type 2 diabetes;
CRC	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.14e-26	Coffee consumption (cups per day);
CRC	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.08	22.28	0.78	1.1e-67	Platelet distribution width;
CRC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.14	-13.85	-0.61	1.06e-34	Diabetic kidney disease;
CRC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg06484146	chr7:12443880	VWDE	-0.64	-6.83	-0.35	4.2e-11	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12012146	chr6:139094629	CCDC28A	0.44	6.17	0.32	2.03e-9	Response to antipsychotic treatment;
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg03909863	chr11:638404	DRD4	-0.53	-7.16	-0.37	5.39e-12	Systemic lupus erythematosus;
CRC	trans	rs9840812	0.953	rs34330586	chr3:135800409	A/T	cg17080335	chr12:131030206	NA	0.41	6.25	0.33	1.26e-9	Fibrinogen levels;
CRC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.52	8.22	0.41	4.86e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-7.23	-0.37	3.41e-12	Electroencephalogram traits;
CRC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.9	16.34	0.67	2.35e-44	Prostate cancer;
CRC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.6	-0.43	3.32e-16	IgG glycosylation;
CRC	cis	rs4722166	0.598	rs7804146	chr7:22800929	C/G	cg05472934	chr7:22766657	IL6	0.63	10.39	0.5	4.72e-22	Lung cancer;
CRC	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg20742385	chr13:113633654	MCF2L	-0.6	-10.46	-0.5	2.62e-22	Systolic blood pressure;
CRC	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.42	6.39	0.33	5.65e-10	Red blood cell count;
CRC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg24011408	chr12:48396354	COL2A1	0.45	6.24	0.33	1.34e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs524281	0.861	rs10750779	chr11:65974591	C/G	cg16950941	chr11:66035639	RAB1B	-0.62	-7.39	-0.38	1.23e-12	Electroencephalogram traits;
CRC	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg02466173	chr16:30829666	NA	-0.59	-9.09	-0.45	9.21e-18	Dementia with Lewy bodies;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.65	6.84	0.35	3.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-6.36	-0.33	6.71e-10	Coronary artery disease;
CRC	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg15192750	chr16:69999425	NA	0.56	7.51	0.38	5.69e-13	IgE levels;
CRC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg22495460	chr2:25135724	ADCY3	-0.87	-17.49	-0.69	6.67e-49	Body mass index;
CRC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.44	7.42	0.38	1.02e-12	Crohn's disease;
CRC	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg08717414	chr16:71523259	ZNF19	-0.46	-5.75	-0.3	2.08e-8	Post bronchodilator FEV1;
CRC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg05044414	chr3:183734942	ABCC5	0.36	5.94	0.31	7.44e-9	Anterior chamber depth;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06391894	chr10:72142531	LRRC20	0.41	6.06	0.32	3.79e-9	Interleukin-6 levels;
CRC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.61	7.41	0.38	1.09e-12	Mean platelet volume;
CRC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.5	8.87	0.44	4.62e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.53	7.59	0.39	3.26e-13	Platelet distribution width;
CRC	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.68	12.51	0.57	1.22e-29	Hip circumference;
CRC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.62	6.36	0.33	6.93e-10	Menarche (age at onset);
CRC	cis	rs2857891	0.817	rs2239730	chr11:6977175	G/C	cg04053776	chr11:6947353	ZNF215	0.39	5.71	0.3	2.54e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.08	-0.55	4.87e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg26248373	chr2:1572462	NA	-0.64	-8.09	-0.41	1.16e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs1712517	0.771	rs11191654	chr10:105077124	C/A	cg05636881	chr10:105038444	INA	0.44	7.78	0.39	9.32e-14	Migraine;
CRC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.81	0.35	4.6e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.66	-0.39	2.14e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg11632617	chr15:75315747	PPCDC	0.55	6.96	0.36	1.82e-11	Blood trace element (Zn levels);
CRC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg08772003	chr10:104629869	AS3MT	-0.41	-6.89	-0.36	2.86e-11	Arsenic metabolism;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg20512303	chr5:131592959	PDLIM4	0.4	7.55	0.38	4.36e-13	Acylcarnitine levels;
CRC	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg17133734	chr15:86042851	AKAP13	0.39	6.34	0.33	7.48e-10	Interstitial lung disease;
CRC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg02089348	chr4:1724449	TMEM129;TACC3	-0.4	-5.78	-0.3	1.77e-8	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	27.12	0.83	6.77e-86	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06404838	chr11:117015391	PAFAH1B2	0.46	6.35	0.33	7.33e-10	Response to antipsychotic treatment;
CRC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00745463	chr17:30367425	LRRC37B	0.6	6.92	0.36	2.42e-11	Hip circumference adjusted for BMI;
CRC	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.53	9.51	0.46	4.25e-19	Blood metabolite ratios;
CRC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.52	7.49	0.38	6.2800000000000005e-13	Longevity;
CRC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18252515	chr7:66147081	NA	0.4	5.9	0.31	9.26e-9	Aortic root size;
CRC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	15.28	0.64	3.22e-40	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18280492	chr10:124913593	BUB3	0.44	6.08	0.32	3.41e-9	Response to antipsychotic treatment;
CRC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.61	-8.85	-0.44	5.52e-17	Schizophrenia;
CRC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg19812747	chr11:111475976	SIK2	-0.6	-10.32	-0.49	8.4e-22	Primary sclerosing cholangitis;
CRC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.33	0.33	8.16e-10	Morning vs. evening chronotype;
CRC	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	0.56	6.8	0.35	4.93e-11	Prostate cancer;
CRC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.57	8.64	0.43	2.56e-16	Calcium levels;
CRC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.39	0.38	1.21e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.46	0.46	6.18e-19	Lymphocyte counts;
CRC	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.91	-0.44	3.47e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17050643	chr15:85144610	ZSCAN2	0.41	6.04	0.32	4.28e-9	Iron status biomarkers;
CRC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.16	-0.32	2.16e-9	Aortic root size;
CRC	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg22561889	chr6:118971681	C6orf204	0.48	6.03	0.32	4.35e-9	Diastolic blood pressure;
CRC	cis	rs7626444	0.625	rs2669637	chr3:196477369	G/A	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-6.65	-0.34	1.24e-10	Body mass index (adult);
CRC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.16e-13	Corneal astigmatism;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.52	7.93	0.4	3.49e-14	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.69	-0.3	2.74e-8	Neuroticism;
CRC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.4e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	6.62	0.34	1.45e-10	Body mass index;
CRC	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24249390	chr15:90295951	MESP1	-0.56	-8.74	-0.43	1.19e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg27398640	chr15:77910606	LINGO1	-0.44	-7.9	-0.4	4.22e-14	Type 2 diabetes;
CRC	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg07052231	chr12:7363540	PEX5	-0.56	-9.32	-0.46	1.71e-18	IgG glycosylation;
CRC	cis	rs16852403	0.619	rs10047059	chr1:178142196	A/C	cg00404053	chr1:178313656	RASAL2	-0.56	-6.88	-0.35	3.11e-11	Childhood ear infection;
CRC	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg14011486	chr1:26737247	LIN28	-0.43	-6.27	-0.33	1.13e-9	Atrial fibrillation;
CRC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg16576597	chr16:28551801	NUPR1	0.42	5.82	0.31	1.36e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg21620606	chr4:1342894	KIAA1530	0.5	8.56	0.43	4.35e-16	Longevity;
CRC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-6.21	-0.32	1.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs7142881	0.629	rs8018532	chr14:32296156	G/A	cg07250515	chr12:56618133	OBFC2B	0.39	5.97	0.31	6.15e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.64	10.19	0.49	2.27e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07147234	chr12:56522077	ESYT1	0.47	6.6	0.34	1.68e-10	Response to antipsychotic treatment;
CRC	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.58	-9.16	-0.45	5.76e-18	Breast cancer;
CRC	cis	rs7527798	0.592	rs12144801	chr1:207857773	A/G	cg09232269	chr1:207846808	CR1L	-0.45	-7.33	-0.37	1.84e-12	Erythrocyte sedimentation rate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23040205	chr20:23331342	NXT1	0.42	6.0	0.31	5.14e-9	Anxiety disorder;
CRC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.78	0.39	9.6e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg00919237	chr7:87102261	ABCB4	-0.53	-7.1	-0.36	7.54e-12	Gallbladder cancer;
CRC	cis	rs6743376	0.556	rs2472188	chr2:113820814	C/G	cg24553058	chr2:113831203	IL1F10	0.44	7.18	0.37	4.61e-12	Inflammatory biomarkers;
CRC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.93	0.44	3.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.57	7.76	0.39	1.06e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg04132472	chr17:19861366	AKAP10	0.43	6.72	0.35	7.87e-11	Schizophrenia;
CRC	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.48	8.92	0.44	3.38e-17	Age-related hearing impairment;
CRC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.59	9.31	0.46	1.9e-18	Height;
CRC	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.35	6.47	0.34	3.6e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg04880052	chr2:219191631	PNKD	0.4	6.1	0.32	3.01e-9	Colorectal cancer;
CRC	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.44	6.37	0.33	6.46e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg11204139	chr17:3907470	NA	0.46	5.75	0.3	2.05e-8	Type 2 diabetes;
CRC	cis	rs891088	0.677	rs17253937	chr19:7184801	C/T	cg00428638	chr19:7224713	INSR	-0.56	-6.07	-0.32	3.54e-9	Hip circumference adjusted for BMI;Height;
CRC	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.4	-6.83	-0.35	4.13e-11	Vitamin D levels;
CRC	cis	rs6499255	0.951	rs1437135	chr16:69757828	A/G	cg15192750	chr16:69999425	NA	0.54	7.1	0.36	7.55e-12	IgE levels;
CRC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.75	10.81	0.51	1.7e-23	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12651014	chr10:32735292	CCDC7	-0.45	-6.59	-0.34	1.72e-10	Myopia (pathological);
CRC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.66	8.75	0.43	1.14e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02755475	chr16:67927351	PSKH1	0.46	6.11	0.32	2.88e-9	Anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25403298	chr7:129251373	NRF1	0.46	6.85	0.35	3.53e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.88	0.55	2.43e-27	Alzheimer's disease;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg15845792	chr6:28175446	NA	0.66	9.05	0.45	1.3e-17	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00747290	chr2:42721154	KCNG3	0.35	6.54	0.34	2.31e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.47	-5.9	-0.31	9.03e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4716602	0.596	rs10949585	chr7:156165258	A/C	cg16983916	chr7:156159713	NA	-0.38	-6.65	-0.34	1.25e-10	Anti-saccade response;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02725872	chr8:58115012	NA	-0.58	-9.07	-0.45	1.07e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.51	-0.38	5.54e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.5	8.5	0.42	6.72e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.66	-0.54	1.59e-26	Idiopathic membranous nephropathy;
CRC	cis	rs597583	1.000	rs521609	chr11:117407301	C/T	cg27161313	chr11:117392002	DSCAML1	-0.38	-5.62	-0.3	4.05e-8	Putamen volume;
CRC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.6	-11.21	-0.53	6.38e-25	Glomerular filtration rate (creatinine);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14094063	chr7:140624470	BRAF	0.6	8.47	0.42	8.13e-16	Survival in pancreatic cancer;
CRC	cis	rs860295	0.702	rs11264375	chr1:155424065	C/T	cg02153340	chr1:155202674	NA	0.48	5.95	0.31	7e-9	Body mass index;
CRC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12463550	chr7:65579703	CRCP	0.55	5.64	0.3	3.62e-8	Diabetic kidney disease;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg02869364	chr7:1081709	C7orf50	-0.4	-6.05	-0.32	3.92e-9	Longevity;Endometriosis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21054179	chr12:49412581	PRKAG1	0.39	6.27	0.33	1.14e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24488506	chr11:65667952	FOSL1	0.4	6.13	0.32	2.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg22687807	chr8:143858763	LYNX1	0.61	10.84	0.51	1.34e-23	Urinary tract infection frequency;
CRC	cis	rs9891119	0.602	rs9895473	chr17:40515722	G/A	cg06270615	chr17:40516068	STAT3	-0.34	-7.17	-0.37	4.87e-12	Multiple sclerosis;Crohn's disease;
CRC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.42	6.14	0.32	2.38e-9	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs16975963	0.644	rs73033145	chr19:38097313	T/G	cg15135657	chr19:38346511	NA	-0.46	-6.32	-0.33	8.35e-10	Longevity;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg25164649	chr6:28176230	NA	0.54	7.8	0.4	8.18e-14	Parkinson's disease;
CRC	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.43	-6.17	-0.32	2.04e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.24	0.53	4.97e-25	Tonsillectomy;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.78	-7.07	-0.36	9.24e-12	IgG glycosylation;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09463466	chr15:77925892	LINGO1	-0.4	-6.09	-0.32	3.16e-9	Myopia (pathological);
CRC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.64	-9.15	-0.45	6.3e-18	Menopause (age at onset);
CRC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.41	7.97	0.4	2.55e-14	Mean corpuscular volume;
CRC	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.71	9.25	0.45	2.99e-18	Prostate cancer;
CRC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18375707	chr11:64034959	PLCB3	0.45	6.25	0.33	1.3e-9	Mean platelet volume;
CRC	cis	rs12044355	0.929	rs6693517	chr1:231852444	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.06	0.32	3.72e-9	Alzheimer's disease;
CRC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.61	8.58	0.43	3.82e-16	Alcohol dependence;
CRC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg04800585	chr6:26043546	HIST1H2BB	0.54	8.2	0.41	5.37e-15	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.25	-5.86	-0.31	1.15e-8	Total body bone mineral density;
CRC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.05	0.41	1.48e-14	Resting heart rate;
CRC	trans	rs1367248	0.943	rs780043	chr2:125007352	C/G	cg07402188	chr19:40720005	MAP3K10	-0.45	-6.16	-0.32	2.1e-9	Tonometry;
CRC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	14.65	0.63	8.89e-38	Gut microbiome composition (summer);
CRC	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg10437265	chr15:77819839	NA	0.52	8.81	0.44	7.34e-17	Type 2 diabetes;
CRC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.61	-8.99	-0.44	1.95e-17	Menarche (age at onset);
CRC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-7.3	-0.37	2.12e-12	Coronary artery disease;
CRC	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg06219103	chr11:63990595	FERMT3	-0.44	-6.92	-0.36	2.36e-11	Platelet count;
CRC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.6	8.15	0.41	7.58e-15	Neutrophil percentage of white cells;
CRC	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg16141378	chr3:129829833	LOC729375	0.43	6.14	0.32	2.43e-9	Triglycerides;
CRC	cis	rs10486722	0.606	rs10951661	chr7:41810755	A/G	cg22138096	chr7:41772439	LOC285954	0.45	6.01	0.31	4.95e-9	Pit-and-Fissure caries;
CRC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.59	-0.34	1.74e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.95	0.31	7.03e-9	Lung cancer;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg15763984	chr4:1342303	KIAA1530	0.33	5.67	0.3	3.15e-8	Obesity-related traits;
CRC	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg09141835	chr16:88988174	CBFA2T3	-0.27	-6.07	-0.32	3.52e-9	Social autistic-like traits;
CRC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.16	0.37	5.21e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.62	14.02	0.61	2.42e-35	Airflow obstruction;
CRC	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg20487152	chr13:99095054	FARP1	0.43	6.37	0.33	6.46e-10	Longevity;
CRC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.33	6.07e-10	Vitiligo;
CRC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.23	-0.56	1.31e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15350925	chr8:86132775	C8orf59	0.4	5.98	0.31	5.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.84	-0.31	1.25e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg10790698	chr19:18539756	SSBP4	-0.43	-8.4	-0.42	1.37e-15	Breast cancer;
CRC	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg20936604	chr3:58311152	NA	-0.76	-7.25	-0.37	2.99e-12	Cholesterol, total;
CRC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.48	-0.46	5.37e-19	Migraine;Coronary artery disease;
CRC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg04166393	chr7:2884313	GNA12	0.4	6.1	0.32	3.02e-9	Height;
CRC	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.72	-11.58	-0.54	2.94e-26	Breast cancer;
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg06470822	chr6:28175283	NA	0.89	13.43	0.59	4.47e-33	Parkinson's disease;
CRC	cis	rs1712517	0.771	rs10883858	chr10:105127708	G/A	cg05636881	chr10:105038444	INA	0.46	8.07	0.41	1.3e-14	Migraine;
CRC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.91	10.86	0.51	1.08e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg02527881	chr3:46936655	PTH1R	0.37	6.76	0.35	6.12e-11	Colorectal cancer;
CRC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.8	-11.63	-0.54	2.08e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.65	10.53	0.5	1.52e-22	Personality dimensions;
CRC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.78	-0.47	5.18e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg17321639	chr7:2759063	NA	-0.38	-5.63	-0.3	3.89e-8	Height;
CRC	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg21106136	chr3:194405973	FAM43A	-0.45	-6.53	-0.34	2.43e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02290350	chr8:58132656	NA	-0.5	-6.22	-0.32	1.5e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg04269497	chr6:167369491	RNASET2	-0.75	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.75	7.81	0.4	7.81e-14	Pulse pressure;
CRC	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.54	9.02	0.45	1.63e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg15440763	chr7:158190612	PTPRN2	0.53	8.64	0.43	2.49e-16	Obesity-related traits;
CRC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.62	-8.36	-0.42	1.76e-15	Obesity-related traits;
CRC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg17633681	chr16:88106987	BANP	0.81	13.72	0.6	3.35e-34	Menopause (age at onset);
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg04518342	chr5:131593106	PDLIM4	0.47	8.77	0.44	1.01e-16	Breast cancer;
CRC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14049382	chr22:50781530	SAPS2	0.5	7.07	0.36	9.48e-12	Response to antipsychotic treatment;
CRC	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.58	6.66	0.34	1.18e-10	Glioblastoma;
CRC	cis	rs10971721	0.818	rs10971708	chr9:33803271	T/A	cg13495928	chr9:33750294	PRSS3	0.6	5.76	0.3	1.91e-8	Body mass index;
CRC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.9	11.59	0.54	2.74e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7274811	0.625	rs293722	chr20:31927361	C/T	cg21523528	chr20:32077966	CBFA2T2	0.43	6.11	0.32	2.86e-9	Height;
CRC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	-0.62	-6.75	-0.35	6.77e-11	Tonsillectomy;
CRC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.37	-6.88	-0.35	3.03e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs773506	0.655	rs10991796	chr9:93930243	G/T	cg14446406	chr9:93919335	NA	-0.45	-7.75	-0.39	1.16e-13	Type 2 diabetes nephropathy;
CRC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg24881330	chr22:46731750	TRMU	-0.57	-6.87	-0.35	3.26e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.37e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24420395	chr8:29206910	DUSP4	0.48	6.95	0.36	1.91e-11	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08891424	chr2:190648631	ORMDL1;PMS1	0.47	6.04	0.32	4.14e-9	Thyroid stimulating hormone;
CRC	cis	rs6534441	0.857	rs9993116	chr4:125459632	G/A	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.33	7.83	0.4	6.58e-14	Corneal astigmatism;
CRC	cis	rs35520189	0.591	rs11696039	chr2:113698078	A/G	cg12858261	chr2:113808755	IL1F8	0.51	7.05	0.36	1.04e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.56	8.29	0.42	2.91e-15	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.45	-6.88	-0.35	3.12e-11	Blood metabolite levels;
CRC	cis	rs2307022	0.586	rs10852441	chr16:68385439	T/A	cg02226672	chr16:68398533	SMPD3	0.28	5.62	0.3	4.04e-8	Body mass index;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg09877947	chr5:131593287	PDLIM4	0.34	6.07	0.32	3.47e-9	Lung function (FEV1/FVC);
CRC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.5	-6.87	-0.35	3.12e-11	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	trans	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg19188899	chr13:112838565	NA	-0.41	-6.32	-0.33	8.27e-10	Systemic lupus erythematosus;
CRC	trans	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg17903999	chr18:56338584	MALT1	0.42	6.93	0.36	2.17e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg05304507	chr6:116381966	FRK	0.29	6.35	0.33	7.1e-10	Total cholesterol levels;
CRC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.15	0.37	5.68e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10863936	0.558	rs7522330	chr1:212234104	A/T	cg19386303	chr19:47104863	CALM3	-0.42	-6.19	-0.32	1.76e-9	Height;
CRC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg19223190	chr17:80058835	NA	0.4	6.33	0.33	7.89e-10	Life satisfaction;
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07308232	chr7:1071921	C7orf50	-0.49	-6.69	-0.35	9.86e-11	Longevity;Endometriosis;
CRC	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.53	7.27	0.37	2.56e-12	IgG glycosylation;
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg15382696	chr6:118971807	C6orf204	0.61	7.9	0.4	4.29e-14	Renal cell carcinoma;
CRC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13198984	chr17:80129470	CCDC57	0.44	7.63	0.39	2.51e-13	Life satisfaction;
CRC	cis	rs8105895	0.935	rs6511316	chr19:22237629	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.3	0.37	2.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.9	-0.31	8.99e-9	Life satisfaction;
CRC	cis	rs6976053	0.518	rs314353	chr7:100406144	A/G	cg20848291	chr7:100343083	ZAN	0.39	5.94	0.31	7.15e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs501916	0.634	rs1561482	chr15:48069663	G/A	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.46	-0.34	3.74e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.6	8.98	0.44	2.12e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg15145296	chr3:125709740	NA	-0.57	-6.77	-0.35	5.8200000000000003e-11	Blood pressure (smoking interaction);
CRC	trans	rs10507419	1.000	rs17753659	chr13:35187616	T/G	cg02971581	chr1:10895950	NA	0.42	5.98	0.31	5.82e-9	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);
CRC	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg08992911	chr2:238395768	MLPH	0.61	6.32	0.33	8.66e-10	Prostate cancer;
CRC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.46	-6.74	-0.35	7.09e-11	Subjective well-being;
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.26	0.41	3.64e-15	Alzheimer's disease;
CRC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05665937	chr4:1216051	CTBP1	0.39	5.64	0.3	3.6e-8	Obesity-related traits;
CRC	cis	rs2882667	0.627	rs1549203	chr5:138468344	A/G	cg09476006	chr5:138032270	NA	-0.41	-6.65	-0.34	1.23e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4594175	0.847	rs17252303	chr14:51632246	C/T	cg23942311	chr14:51606299	NA	0.61	9.58	0.47	2.45e-19	Cancer;
CRC	cis	rs73206853	0.841	rs55972509	chr12:110992755	T/C	cg12870014	chr12:110450643	ANKRD13A	0.72	7.58	0.39	3.64e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg21033440	chr11:65409861	SIPA1	-0.57	-7.87	-0.4	5.28e-14	Blood pressure (age interaction);
CRC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	5.65	0.3	3.48e-8	Multiple sclerosis;
CRC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.97	-18.83	-0.72	3.58e-54	Height;
CRC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.7	10.84	0.51	1.27e-23	Corneal astigmatism;
CRC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg11707556	chr5:10655725	ANKRD33B	0.35	6.29	0.33	1.04e-9	Coronary artery disease;
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.47	-5.82	-0.31	1.39e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.58	7.85	0.4	5.9e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg27635394	chr6:26043820	HIST1H2BB	0.43	6.28	0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.6	-8.78	-0.44	8.93e-17	Menarche (age at onset);
CRC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg19500275	chr17:80737654	TBCD	0.52	7.26	0.37	2.84e-12	Glycated hemoglobin levels;
CRC	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.43	-7.43	-0.38	9.26e-13	Type 1 diabetes;
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.64e-8	Prudent dietary pattern;
CRC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.47	6.51	0.34	2.73e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.54	-5.69	-0.3	2.83e-8	Systemic lupus erythematosus;
CRC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg20608306	chr11:116969690	SIK3	0.34	7.03	0.36	1.22e-11	Blood protein levels;
CRC	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg14003231	chr6:33640908	ITPR3	0.48	7.95	0.4	3.12e-14	Plateletcrit;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05432305	chr3:33840003	PDCD6IP	0.44	6.34	0.33	7.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg11212589	chr17:38028394	ZPBP2	0.34	5.68	0.3	2.94e-8	Asthma;
CRC	cis	rs12431939	0.571	rs7493931	chr14:51736401	T/C	cg23942311	chr14:51606299	NA	0.54	7.14	0.37	6.09e-12	Cancer;
CRC	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.36	-6.36	-0.33	6.8e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7487075	0.619	rs10748448	chr12:46803338	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.73	0.3	2.22e-8	Itch intensity from mosquito bite;
CRC	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.24	0.49	1.54e-21	Monocyte percentage of white cells;
CRC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.4	0.38	1.18e-12	Hemoglobin concentration;
CRC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg00852783	chr1:26633632	UBXN11	-0.39	-5.71	-0.3	2.51e-8	Obesity-related traits;
CRC	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.58	8.56	0.43	4.46e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.42	-0.46	8.4e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.43	-7.21	-0.37	3.76e-12	Breast cancer;
CRC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.83	13.11	0.59	6.83e-32	Height;
CRC	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg17885191	chr8:135476712	NA	0.52	7.03	0.36	1.18e-11	Hypertension (SNP x SNP interaction);
CRC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-8.54	-0.43	4.91e-16	Chronic sinus infection;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg18301423	chr5:131593218	PDLIM4	0.42	7.64	0.39	2.33e-13	Blood metabolite levels;
CRC	cis	rs7259376	0.623	rs59533346	chr19:22484182	C/T	cg02657401	chr19:22469223	NA	-0.3	-6.56	-0.34	2.07e-10	Menopause (age at onset);
CRC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	8.91	0.44	3.45e-17	Schizophrenia;
CRC	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	6.62	0.34	1.43e-10	Mean corpuscular volume;
CRC	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg04110750	chr16:69646130	NFAT5	-0.53	-7.43	-0.38	9.15e-13	IgE levels;
CRC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.55	-7.72	-0.39	1.36e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-7.74	-0.39	1.27e-13	Vitiligo;
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg10729496	chr3:10149963	C3orf24	0.48	5.63	0.3	3.81e-8	Alzheimer's disease;
CRC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg22676075	chr6:135203613	NA	-0.41	-6.4	-0.33	5.43e-10	Red blood cell count;
CRC	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg13919466	chr1:32135498	COL16A1	-0.32	-6.09	-0.32	3.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg10729496	chr3:10149963	C3orf24	0.56	7.51	0.38	5.64e-13	Alzheimer's disease;
CRC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg17724175	chr1:150552817	MCL1	0.44	6.66	0.34	1.15e-10	Melanoma;
CRC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.4	5.79	0.3	1.63e-8	Aortic root size;
CRC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg13334819	chr7:99746414	C7orf59	-0.46	-6.31	-0.33	9.18e-10	Coronary artery disease;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg11843238	chr5:131593191	PDLIM4	0.43	7.23	0.37	3.3e-12	Breast cancer;
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.32	5.68	0.3	2.94e-8	Erythrocyte sedimentation rate;
CRC	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg10820045	chr2:198174542	NA	0.45	7.79	0.39	8.73e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.68	10.11	0.49	4.11e-21	Breast cancer;
CRC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg02896835	chr1:92012615	NA	0.47	7.47	0.38	7.28e-13	Breast cancer;
CRC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.19	-0.32	1.79e-9	Tonsillectomy;
CRC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.55	-7.7	-0.39	1.63e-13	Obesity-related traits;
CRC	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.9	-0.31	8.95e-9	Alcohol dependence;
CRC	cis	rs10924970	0.904	rs10924500	chr1:235351436	T/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.77	0.3	1.88e-8	Asthma;
CRC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.52	-7.38	-0.38	1.34e-12	Menarche (age at onset);
CRC	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg23167259	chr10:102495509	NA	-0.49	-6.76	-0.35	6.28e-11	Alzheimer's disease;
CRC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.5	-0.34	2.95e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg03609598	chr5:56110824	MAP3K1	-0.45	-6.09	-0.32	3.22e-9	Coronary artery disease;
CRC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg15845792	chr6:28175446	NA	0.77	11.33	0.53	2.33e-25	Parkinson's disease;
CRC	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg07617317	chr6:118971624	C6orf204	0.47	5.69	0.3	2.79e-8	Diastolic blood pressure;
CRC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg04731861	chr2:219085781	ARPC2	0.33	6.54	0.34	2.37e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.83	13.85	0.61	1.09e-34	Cognitive function;
CRC	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg25363559	chr8:143086065	NA	-0.34	-6.49	-0.34	3.22e-10	Amyotrophic lateral sclerosis;
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.5	6.74	0.35	7.2e-11	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.77	-10.71	-0.51	3.74e-23	Blood metabolite levels;
CRC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.81	-0.31	1.48e-8	Schizophrenia;
CRC	trans	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg02778551	chr7:1045947	C7orf50	-0.45	-6.73	-0.35	7.76e-11	Systemic lupus erythematosus;
CRC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg13319975	chr6:146136371	FBXO30	0.39	5.72	0.3	2.33e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17065868	0.764	rs9533862	chr13:45034814	G/C	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.83	11.29	0.53	3.31e-25	Migraine;Coronary artery disease;
CRC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.39	0.53	1.52e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg15691649	chr6:25882328	NA	-0.45	-6.01	-0.31	5.04e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06953865	chr19:18549723	ISYNA1	-0.37	-5.65	-0.3	3.56e-8	Breast cancer;
CRC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.45	6.13	0.32	2.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13161895	1.000	rs34674199	chr5:179473900	G/A	cg02702477	chr5:179499311	RNF130	0.55	6.26	0.33	1.18e-9	LDL cholesterol;
CRC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.36	5.77	0.3	1.82e-8	Prostate cancer;
CRC	cis	rs2692947	0.666	rs7566050	chr2:96626030	T/C	cg23100626	chr2:96804247	ASTL	0.26	7.0	0.36	1.47e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-6.52	-0.34	2.61e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.62	8.57	0.43	4.22e-16	Height;
CRC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.61	10.15	0.49	3.18e-21	Ulcerative colitis;
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-9.75	-0.47	6.88e-20	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg04969067	chr8:143858791	LYNX1	0.59	10.09	0.49	4.97e-21	Urinary tract infection frequency;
CRC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.47	9.24	0.45	3.19e-18	Renal cell carcinoma;
CRC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg10723962	chr6:26240782	HIST1H4F	-0.37	-5.76	-0.3	1.94e-8	Gout;Renal underexcretion gout;
CRC	cis	rs780094	0.500	rs4665991	chr2:27766284	G/A	cg27432699	chr2:27873401	GPN1	0.46	5.82	0.31	1.43e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.94	13.69	0.6	4.45e-34	Glomerular filtration rate (creatinine);
CRC	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	8.74	0.43	1.2e-16	Lymphocyte counts;
CRC	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.8	-13.23	-0.59	2.41e-32	Hypospadias;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.53	8.19	0.41	5.77e-15	Bipolar disorder;
CRC	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg09659197	chr4:152720779	NA	0.3	5.62	0.3	4.07e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.52	6.33	0.33	8e-10	Menopause (age at onset);
CRC	cis	rs3744061	0.776	rs9916811	chr17:74749273	C/T	cg13533061	chr17:74712429	JMJD6	0.44	6.92	0.36	2.32e-11	Retinal arteriolar caliber;
CRC	trans	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg02674126	chr19:40336878	FBL	0.43	6.89	0.36	2.84e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.64	-9.24	-0.45	3.07e-18	Type 2 diabetes;
CRC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.61	7.3	0.37	2.14e-12	Type 2 diabetes nephropathy;
CRC	cis	rs9427116	1.000	rs9427117	chr1:154632231	C/G	cg24304309	chr1:154577895	ADAR	0.37	6.07	0.32	3.61e-9	Blood protein levels;
CRC	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.97	-0.36	1.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.63	-0.34	1.36e-10	Mean platelet volume;
CRC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg27535305	chr1:53392650	SCP2	0.36	6.39	0.33	5.78e-10	Monocyte count;
CRC	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg24553058	chr2:113831203	IL1F10	0.55	8.64	0.43	2.47e-16	Protein quantitative trait loci;
CRC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.32	-0.33	8.42e-10	Aortic root size;
CRC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.42	-5.94	-0.31	7.26e-9	Airflow obstruction;
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.56	7.66	0.39	2.11e-13	Alzheimer's disease;
CRC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg21153622	chr11:89784906	NA	-0.52	-8.68	-0.43	1.92e-16	HDL cholesterol;
CRC	cis	rs7072216	0.770	rs1739	chr10:100176339	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-7.45	-0.38	8.11e-13	Metabolite levels;
CRC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.33e-11	Menopause (age at onset);
CRC	cis	rs3764400	0.517	rs7224461	chr17:46203430	C/G	cg10706073	chr17:46328419	SKAP1	0.6	6.25	0.33	1.25e-9	Body mass index;
CRC	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.83	0.35	4.14e-11	Lymphocyte counts;
CRC	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	cis	rs4743820	0.651	rs16907199	chr9:93923617	A/G	cg14446406	chr9:93919335	NA	0.78	14.45	0.62	5.63e-37	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.64	-0.39	2.46e-13	Intelligence (multi-trait analysis);
CRC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-7.54	-0.38	4.58e-13	Calcium levels;
CRC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg08999081	chr20:33150536	PIGU	0.44	5.71	0.3	2.47e-8	Protein C levels;
CRC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg18512352	chr11:47633146	NA	0.34	6.56	0.34	2.04e-10	Subjective well-being;
CRC	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.5	7.51	0.38	5.45e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.51	8.12	0.41	9.53e-15	Red blood cell count;
CRC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.33	-0.79	9.69e-72	Myeloid white cell count;
CRC	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07165851	chr6:158734300	TULP4	0.61	7.72	0.39	1.37e-13	Height;
CRC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.29	-0.46	2.19e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.74	-12.41	-0.56	2.8e-29	Itch intensity from mosquito bite;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12172441	chr6:28176163	NA	0.65	7.64	0.39	2.39e-13	Depression;
CRC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.96	17.29	0.69	4.24e-48	IgG glycosylation;
CRC	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs7605827	0.930	rs2287260	chr2:15624810	T/C	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.64e-8	Educational attainment (years of education);
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.67	-9.65	-0.47	1.45e-19	Menopause (age at onset);
CRC	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.47	-7.3	-0.37	2.2e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19717773	chr7:2847554	GNA12	0.43	6.36	0.33	6.56e-10	Height;
CRC	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg09654669	chr8:57350985	NA	0.41	5.87	0.31	1.08e-8	Obesity-related traits;
CRC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg02527881	chr3:46936655	PTH1R	0.33	5.66	0.3	3.33e-8	Colorectal cancer;
CRC	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.98	-0.36	1.6e-11	Menopause (age at onset);
CRC	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.5	6.33	0.33	7.9e-10	Recombination rate (females);
CRC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg18490616	chr2:88469792	THNSL2	0.61	6.1	0.32	2.9e-9	Plasma clusterin levels;
CRC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.34	-6.72	-0.35	7.81e-11	Alzheimer's disease (late onset);
CRC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg21659725	chr3:3221576	CRBN	0.61	6.29	0.33	1.03e-9	Menarche (age at onset);
CRC	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.4	-0.38	1.15e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg24011408	chr12:48396354	COL2A1	0.47	6.36	0.33	6.59e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6662572	0.737	rs6659064	chr1:46346724	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg25344623	chr2:136566232	LCT	0.33	5.98	0.31	5.97e-9	Mosquito bite size;
CRC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.54	-6.17	-0.32	1.99e-9	Lymphocyte counts;
CRC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.43	-7.85	-0.4	5.81e-14	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg08888203	chr3:10149979	C3orf24	0.7	9.84	0.48	3.31e-20	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.26	0.45	2.71e-18	Height;
CRC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16447950	chr5:562315	NA	-0.77	-10.08	-0.49	5.3e-21	Obesity-related traits;
CRC	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg11861562	chr11:117069780	TAGLN	0.33	6.08	0.32	3.34e-9	Blood protein levels;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.53	-7.94	-0.4	3.23e-14	Breast cancer;
CRC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.67	-9.0	-0.44	1.87e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24060473	chr17:30228954	UTP6	0.43	6.0	0.31	5.06e-9	Anxiety disorder;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg06470822	chr6:28175283	NA	0.78	11.02	0.52	3.05e-24	Parkinson's disease;
CRC	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.62	9.42	0.46	8.43e-19	Type 2 diabetes;
CRC	trans	rs6897795	0.680	rs9329137	chr5:177616370	C/T	cg19598605	chr2:70056955	GMCL1	-0.7	-8.62	-0.43	2.92e-16	Plateletcrit;
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.3	-0.37	2.19e-12	Body mass index;
CRC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.77	-7.56	-0.38	4.16e-13	Coronary artery disease;
CRC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg22110888	chr17:80059540	CCDC57	-0.45	-7.02	-0.36	1.3e-11	Life satisfaction;
CRC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.43	6.21	0.32	1.62e-9	HIV-1 control;
CRC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.39	5.89	0.31	9.62e-9	Hemoglobin concentration;
CRC	cis	rs762407	0.925	rs4594536	chr21:45164854	C/T	cg24875593	chr21:45153009	PDXK	-0.42	-6.34	-0.33	7.48e-10	Systolic blood pressure change trajectories;
CRC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.53	-0.38	5.05e-13	Alzheimer's disease;
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.38	-8.69	-0.43	1.69e-16	Total body bone mineral density;
CRC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg16060761	chr17:80687452	NA	0.42	6.16	0.32	2.11e-9	Breast cancer;
CRC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.33e-9	Heart rate;
CRC	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg10437265	chr15:77819839	NA	0.66	11.6	0.54	2.63e-26	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.97	-0.31	6.27e-9	Lung cancer;
CRC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg04202892	chr2:111875749	ACOXL	0.43	6.97	0.36	1.74e-11	Chronic lymphocytic leukemia;
CRC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.52	8.09	0.41	1.17e-14	Body mass index;
CRC	cis	rs7705042	0.865	rs6580225	chr5:141489381	G/C	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.86	-0.31	1.14e-8	Asthma;
CRC	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.97	-0.36	1.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg16898833	chr6:26189333	HIST1H4D	0.94	7.7	0.39	1.64e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.52	10.02	0.48	8.14e-21	Urate levels in lean individuals;
CRC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg18099408	chr3:52552593	STAB1	0.35	6.15	0.32	2.28e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-0.88	-8.66	-0.43	2.09e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.51	8.53	0.43	5.27e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg10802521	chr3:52805072	NEK4	-0.48	-6.82	-0.35	4.5e-11	Bipolar disorder;
CRC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.5	8.02	0.4	1.93e-14	Height;
CRC	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.54	-8.65	-0.43	2.34e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg23387468	chr7:139079360	LUC7L2	0.4	6.72	0.35	7.93e-11	Diisocyanate-induced asthma;
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.29e-9	Bipolar disorder;
CRC	trans	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg24998770	chr7:37888106	TXNDC3	-0.36	-5.8	-0.3	1.58e-8	Alzheimer's disease (late onset);
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg21251018	chr6:28226885	NKAPL	0.46	6.93	0.36	2.19e-11	Parkinson's disease;
CRC	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg26811252	chr16:29126840	RRN3P2	0.65	8.73	0.43	1.31e-16	Menopause (age at onset);
CRC	cis	rs3213961	0.554	rs8256	chr2:33789068	C/G	cg04131969	chr2:33951647	MYADML	0.42	5.68	0.3	3.03e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.68	-0.35	1.02e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	5.75	0.3	2.03e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11645453	chr3:52864694	ITIH4	0.33	5.92	0.31	8.13e-9	Electroencephalogram traits;
CRC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02228675	chr17:40259724	DHX58	-0.5	-7.01	-0.36	1.38e-11	Fibrinogen levels;
CRC	cis	rs9649465	0.967	rs12537989	chr7:123308195	A/G	cg03229431	chr7:123269106	ASB15	-0.37	-5.76	-0.3	1.91e-8	Migraine;
CRC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.85	-0.35	3.74e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg03757805	chr13:111521981	C13orf29	-0.61	-7.59	-0.39	3.24e-13	Sitting height ratio;
CRC	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg01993067	chr11:68851601	TPCN2	0.56	6.3	0.33	9.54e-10	Blond vs. brown hair color;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17432135	chr20:43991688	SYS1;SYS1-DBNDD2	0.42	6.08	0.32	3.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg07979401	chr6:33739406	LEMD2	-0.46	-5.98	-0.31	5.7e-9	Schizophrenia;
CRC	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-7.92	-0.4	3.58e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.82	12.05	0.55	6.03e-28	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.81	-0.35	4.71e-11	Total body bone mineral density;
CRC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg21466736	chr12:48725269	NA	0.51	7.7	0.39	1.61e-13	Glycated hemoglobin levels;
CRC	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg13736514	chr6:26305472	NA	-0.36	-6.17	-0.32	1.99e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.71	-6.54	-0.34	2.35e-10	Inflammatory biomarkers;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	trans	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg18187862	chr3:45730750	SACM1L	0.45	6.39	0.33	5.58e-10	Primary sclerosing cholangitis;
CRC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.43	8.7	0.43	1.63e-16	Vitiligo;
CRC	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-6.95	-0.36	2.01e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19157971	chr1:202858393	RABIF	0.44	6.4	0.33	5.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg18404041	chr3:52824283	ITIH1	0.34	6.4	0.33	5.43e-10	Schizophrenia;
CRC	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24249390	chr15:90295951	MESP1	-0.58	-9.36	-0.46	1.28e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.49	-7.31	-0.37	1.98e-12	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22917237	chr19:18633401	ELL	0.4	5.98	0.31	5.85e-9	Response to antipsychotic treatment;
CRC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg00255919	chr5:131827918	IRF1	0.36	6.08	0.32	3.25e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.5	7.72	0.39	1.37e-13	Prostate cancer;
CRC	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg04165759	chr1:150448943	RPRD2	0.36	5.84	0.31	1.22e-8	Migraine;
CRC	cis	rs4728302	0.869	rs10255193	chr7:133608911	C/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.54	-0.34	2.33e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.26	-0.33	1.21e-9	Red cell distribution width;
CRC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12463550	chr7:65579703	CRCP	0.62	5.95	0.31	6.68e-9	Diabetic kidney disease;
CRC	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg03929089	chr4:120376271	NA	0.67	6.42	0.33	4.68e-10	Intraocular pressure;
CRC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.6	-8.77	-0.44	9.91e-17	Menarche (age at onset);
CRC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.63	13.98	0.61	3.61e-35	Airflow obstruction;
CRC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.73	13.3	0.59	1.32e-32	Prostate cancer;
CRC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-5.9	-0.31	9.03e-9	Blood metabolite levels;
CRC	cis	rs10512697	0.892	rs17636193	chr5:3540161	A/G	cg19473799	chr5:3511975	NA	0.76	6.03	0.32	4.47e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.11	-0.36	7.33e-12	Gut microbiome composition (summer);
CRC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg26721908	chr21:47610096	LSS	0.45	7.39	0.38	1.21e-12	Testicular germ cell tumor;
CRC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg13722127	chr7:150037890	RARRES2	0.49	7.59	0.39	3.25e-13	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg06606381	chr12:133084897	FBRSL1	-1.01	-7.32	-0.37	1.97e-12	Urinary tract infection frequency;
CRC	cis	rs62458065	0.850	rs62458099	chr7:32472395	C/T	cg20159608	chr7:32802032	NA	-0.55	-6.56	-0.34	2.11e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	6.02	0.32	4.62e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2457480	0.602	rs17155641	chr10:44708346	A/G	cg09554077	chr10:44749378	NA	0.51	6.64	0.34	1.27e-10	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11344692	chr8:61429175	RAB2A	0.44	6.51	0.34	2.73e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.15	-10.02	-0.48	8.37e-21	Diabetic kidney disease;
CRC	cis	rs6479527	0.904	rs10122334	chr9:96864227	A/G	cg14459158	chr9:96720562	NA	0.42	7.24	0.37	3.2e-12	Esophageal adenocarcinoma;
CRC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg06238570	chr21:40685208	BRWD1	0.75	10.33	0.49	7.45e-22	Cognitive function;
CRC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.96	18.28	0.71	4.95e-52	Lewy body disease;
CRC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-13.1	-0.59	7.4e-32	Blood metabolite levels;
CRC	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-1.05	-14.47	-0.62	4.53e-37	Exhaled nitric oxide output;
CRC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.52	-8.09	-0.41	1.15e-14	Menopause (age at onset);
CRC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	8.61	0.43	3.05e-16	Height;
CRC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.26	-0.49	1.26e-21	Body mass index;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg15571903	chr15:79123663	NA	-0.31	-6.06	-0.32	3.65e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.41	-7.67	-0.39	1.92e-13	Mean corpuscular volume;
CRC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.88	0.31	1e-8	Tonsillectomy;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04080724	chr4:140202327	C4orf49	0.39	6.23	0.32	1.45e-9	Interleukin-6 levels;
CRC	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.07	11.38	0.53	1.62e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.5	7.25	0.37	2.95e-12	Height;
CRC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg05585544	chr11:47624801	NA	-0.61	-10.75	-0.51	2.7e-23	Subjective well-being;
CRC	trans	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg17903999	chr18:56338584	MALT1	0.43	6.98	0.36	1.59e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs56399783	0.901	rs73051469	chr7:2877811	A/G	cg19731401	chr7:2775893	GNA12	0.6	6.32	0.33	8.44e-10	Childhood ear infection;
CRC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.51	-8.42	-0.42	1.15e-15	Coronary artery disease;
CRC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.58	-8.44	-0.42	1.01e-15	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg17633681	chr16:88106987	BANP	0.85	15.69	0.65	8.33e-42	Menopause (age at onset);
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	6.67	0.35	1.05e-10	Cardiac Troponin-T levels;
CRC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.45	0.6	3.81e-33	Platelet count;
CRC	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg23229016	chr1:26872525	RPS6KA1	0.3	7.02	0.36	1.24e-11	Glucose homeostasis traits;
CRC	cis	rs1570884	0.740	rs12146924	chr13:50134358	T/C	cg08779649	chr13:50194554	NA	0.31	5.99	0.31	5.41e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.45	0.34	3.93e-10	Tonsillectomy;
CRC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.77	7.8	0.4	8.13e-14	Diabetic retinopathy;
CRC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.83	0.55	3.96e-27	Monocyte percentage of white cells;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16655837	chr10:32636197	EPC1	-0.4	-6.28	-0.33	1.09e-9	Brain structure;
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.06	-0.41	1.42e-14	Electroencephalogram traits;
CRC	cis	rs11229555	0.645	rs4506677	chr11:58213852	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.59	8.6	0.43	3.36e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.6	-9.27	-0.45	2.56e-18	Colorectal cancer;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.28	0.33	1.06e-9	Depression;
CRC	cis	rs1223397	0.938	rs35511719	chr6:13282442	T/C	cg07912922	chr6:13274314	PHACTR1	0.53	6.47	0.34	3.49e-10	Blood pressure;
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg17330251	chr7:94953956	PON1	-0.58	-7.48	-0.38	7.01e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2462686	1.000	rs788765	chr7:45996985	C/G	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.96	-0.31	6.48e-9	Major depressive disorder;
CRC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.62	9.25	0.45	2.91e-18	Hemoglobin concentration;
CRC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.4	-7.37	-0.38	1.42e-12	Height;
CRC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.43	6.78	0.35	5.71e-11	Corneal astigmatism;
CRC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.56	6.2	0.32	1.69e-9	Initial pursuit acceleration;
CRC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg20387954	chr3:183756860	HTR3D	-0.44	-7.58	-0.39	3.59e-13	Anterior chamber depth;
CRC	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.59	-9.91	-0.48	2.03e-20	Calcium levels;
CRC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.76	0.3	1.94e-8	Height;
CRC	cis	rs35520189	0.591	rs6723197	chr2:113701598	T/G	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	0.56	8.76	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.57	8.94	0.44	2.81e-17	Smoking behavior;
CRC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg18876405	chr7:65276391	NA	0.44	6.19	0.32	1.82e-9	Aortic root size;
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.53	8.24	0.41	4.14e-15	Intelligence (multi-trait analysis);
CRC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00339695	chr16:24857497	SLC5A11	-0.28	-6.63	-0.34	1.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.39	0.38	1.18e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9925964	0.935	rs12597511	chr16:31145219	C/T	cg03418659	chr16:31128414	MYST1	0.55	7.97	0.4	2.7e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.03e-10	Bipolar disorder;
CRC	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.81	-0.4	7.94e-14	Homocysteine levels;
CRC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.66	0.47	1.39e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10484885	0.878	rs1328018	chr6:90297847	A/G	cg13799429	chr6:90582589	CASP8AP2	0.73	7.77	0.39	9.97e-14	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10911390	0.744	rs115862617	chr1:183652656	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Systemic lupus erythematosus;
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg02033258	chr5:131593261	PDLIM4	0.36	6.77	0.35	5.75e-11	Blood metabolite levels;
CRC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.18	0.37	4.81e-12	Rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.25	0.37	2.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6088813	1.000	rs6142376	chr20:33992761	T/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.74	-0.3	2.12e-8	Height;
CRC	cis	rs863345	0.564	rs11265014	chr1:158503221	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.28	-0.33	1.09e-9	Pneumococcal bacteremia;
CRC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.68	0.3	2.95e-8	Diabetic retinopathy;
CRC	trans	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg06791473	chr12:49259579	RND1	0.61	6.03	0.32	4.5e-9	Blood protein levels;
CRC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.95	-0.31	6.88e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.91	0.36	2.53e-11	Resting heart rate;
CRC	cis	rs11212617	0.967	rs4585	chr11:108239628	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.64	0.34	1.27e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21790971	chr4:54244117	FIP1L1	0.49	6.97	0.36	1.79e-11	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.27	0.33	1.14e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.53	0.75	6.95e-61	Prudent dietary pattern;
CRC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	5.99	0.31	5.64e-9	Life satisfaction;
CRC	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg09904177	chr6:26538194	HMGN4	0.56	7.77	0.39	1.04e-13	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
CRC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.78	-0.35	5.43e-11	Breast cancer;
CRC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.58	-9.19	-0.45	4.71e-18	Calcium levels;
CRC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.46	8.23	0.41	4.37e-15	Blood metabolite ratios;
CRC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.84	18.44	0.71	1.18e-52	Breast cancer;
CRC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg00343986	chr7:65444356	GUSB	-0.47	-6.94	-0.36	2.05e-11	Aortic root size;
CRC	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.48	8.34	0.42	2.03e-15	Testicular germ cell tumor;
CRC	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.72	8.92	0.44	3.26e-17	Type 2 diabetes;
CRC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.54	-6.86	-0.35	3.42e-11	Resistin levels;
CRC	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.45	-0.34	4.03e-10	Obesity-related traits;
CRC	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-5.72	-0.3	2.46e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.6	-7.12	-0.37	6.96e-12	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01353569	chr7:106810328	HBP1	0.53	7.67	0.39	1.94e-13	Response to antipsychotic treatment;
CRC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.1	-0.32	2.98e-9	Alzheimer's disease (late onset);
CRC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.04	0.48	7.27e-21	Systolic blood pressure;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12241367	chr10:13203349	MCM10	0.42	6.21	0.32	1.59e-9	Myopia (pathological);
CRC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg02896835	chr1:92012615	NA	0.48	6.31	0.33	9.19e-10	Eosinophil percentage of white cells;
CRC	cis	rs4757319	0.532	rs4456244	chr11:15439353	T/C	cg03245590	chr11:15329459	NA	0.42	7.27	0.37	2.62e-12	Breast cancer;
CRC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.12	0.66	1.72e-43	Platelet count;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg25164649	chr6:28176230	NA	0.57	7.98	0.4	2.44e-14	Parkinson's disease;
CRC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs4523957	0.890	rs6503324	chr17:2100512	C/T	cg16513277	chr17:2031491	SMG6	-0.52	-8.92	-0.44	3.24e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg12463550	chr7:65579703	CRCP	0.62	5.97	0.31	6.09e-9	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.71	-0.3	2.52e-8	Life satisfaction;
CRC	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg02766259	chr12:125626809	AACS	-0.42	-6.16	-0.32	2.13e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.55	9.35	0.46	1.39e-18	Dupuytren's disease;
CRC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.6	9.84	0.48	3.35e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg01843034	chr6:37503916	NA	-0.34	-6.0	-0.31	5.34e-9	Cognitive performance;
CRC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.81	-14.77	-0.63	3.3e-38	Body mass index;
CRC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.81	-14.08	-0.61	1.49e-35	Dental caries;
CRC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg24130564	chr14:104152367	KLC1	0.44	5.91	0.31	8.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4728302	0.869	rs12707129	chr7:133593177	A/G	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.25e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15644404	chr18:77186268	NFATC1	-0.8	-6.6	-0.34	1.62e-10	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs12517041	0.935	rs10062553	chr5:23294800	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg08501292	chr6:25962987	TRIM38	0.84	6.06	0.32	3.63e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7113874	0.589	rs2044463	chr11:8463951	G/A	cg17679104	chr11:8615758	STK33	-0.34	-5.63	-0.3	3.78e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.81	-0.4	7.97e-14	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.61	8.05	0.41	1.55e-14	Mean platelet volume;
CRC	trans	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg07817883	chr1:32538562	TMEM39B	1.51	13.3	0.59	1.33e-32	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg03690763	chr11:133734501	NA	-0.34	-5.78	-0.3	1.71e-8	Childhood ear infection;
CRC	cis	rs2108622	0.683	rs56228205	chr19:15981973	A/C	cg13772218	chr19:15982569	NA	0.48	6.81	0.35	4.52e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.5	-6.66	-0.34	1.13e-10	Total body bone mineral density;
CRC	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg10820045	chr2:198174542	NA	0.42	7.3	0.37	2.12e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg23533926	chr12:111358616	MYL2	-0.55	-8.38	-0.42	1.6e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.65	-10.65	-0.51	6.06e-23	Type 2 diabetes;
CRC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.88	0.31	1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07902188	chr19:30097207	POP4	0.46	6.48	0.34	3.37e-10	Anxiety disorder;
CRC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.83	14.42	0.62	7.25e-37	Intelligence (multi-trait analysis);
CRC	trans	rs885518	0.852	rs1440992	chr9:21778711	T/C	cg14925137	chr3:121554019	IQCB1;EAF2	0.55	6.08	0.32	3.31e-9	Lung adenocarcinoma;
CRC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.59	8.73	0.43	1.3e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.72	0.43	1.37e-16	Menopause (age at onset);
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg12516270	chr8:143859308	LYNX1	0.44	7.73	0.39	1.34e-13	Urinary tract infection frequency;
CRC	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.41	-0.59	5.06e-33	Hypospadias;
CRC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.17	0.49	2.6e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2179367	0.959	rs2262617	chr6:149759726	C/G	cg11245181	chr6:149772854	ZC3H12D	-0.42	-6.49	-0.34	3.14e-10	Dupuytren's disease;
CRC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15604682	chr7:102105781	ALKBH4;LRWD1	0.45	6.16	0.32	2.13e-9	Survival in pancreatic cancer;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00677455	chr12:58241039	CTDSP2	0.39	5.69	0.3	2.85e-8	Multiple sclerosis;
CRC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg23815491	chr16:72088622	HP	0.65	8.31	0.42	2.53e-15	Blood protein levels;
CRC	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.57	7.45	0.38	8.12e-13	Body mass index;
CRC	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg14829360	chr17:73884958	NA	-0.43	-6.67	-0.34	1.11e-10	Psoriasis;
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg15898840	chr7:45960834	IGFBP3	0.46	7.61	0.39	2.93e-13	Sitting height ratio;
CRC	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.58	7.9	0.4	4.31e-14	Adiposity;
CRC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.43	8.68	0.43	1.84e-16	Renal cell carcinoma;
CRC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.15	0.37	5.57e-12	Body mass index;
CRC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.56	8.67	0.43	2.04e-16	Psychosis in Alzheimer's disease;
CRC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.36	-0.46	1.31e-18	Platelet count;
CRC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg01879757	chr17:41196368	BRCA1	-0.42	-6.32	-0.33	8.39e-10	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.95	0.31	7.04e-9	Depression;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.66	6.86	0.35	3.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.58	-10.57	-0.5	1.11e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05834845	chr3:195489306	MUC4	0.67	7.24	0.37	3.14e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg24300038	chr13:113819356	PROZ	0.45	6.08	0.32	3.39e-9	Platelet distribution width;
CRC	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	10.45	0.5	2.91e-22	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09726240	chr11:70672878	SHANK2	0.27	6.26	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.53	8.6	0.43	3.29e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg24881330	chr22:46731750	TRMU	0.56	6.66	0.34	1.12e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24249390	chr15:90295951	MESP1	-0.56	-8.69	-0.43	1.71e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg03623178	chr6:28175578	NA	0.77	6.63	0.34	1.42e-10	Depression;
CRC	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg21064579	chr19:49206444	FUT2	0.43	6.93	0.36	2.19e-11	Dietary macronutrient intake;
CRC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.47	-7.05	-0.36	1.03e-11	Response to antineoplastic agents;
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg09877947	chr5:131593287	PDLIM4	0.36	6.51	0.34	2.82e-10	Blood metabolite levels;
CRC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25517755	chr10:38738941	LOC399744	-0.43	-6.12	-0.32	2.64e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2154427	0.511	rs7279487	chr21:34001824	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.6	7.1	0.36	7.91e-12	Bilirubin levels;
CRC	cis	rs6679356	0.789	rs3790566	chr1:67814440	T/C	cg24364144	chr1:67875067	SERBP1	0.43	6.55	0.34	2.17e-10	Primary biliary cholangitis;
CRC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.77	12.59	0.57	5.91e-30	Lung cancer;
CRC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.44	6.38	0.33	6.11e-10	Obesity-related traits;
CRC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg13844804	chr7:814759	HEATR2	0.68	8.0	0.4	2.15e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg07195577	chr17:27052828	TLCD1	0.42	6.07	0.32	3.45e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg23758597	chr6:163146217	PARK2	-0.68	-6.78	-0.35	5.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.43	-5.82	-0.31	1.43e-8	Platelet distribution width;
CRC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg10729496	chr3:10149963	C3orf24	0.49	6.81	0.35	4.72e-11	Alzheimer's disease;
CRC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.3	6.25	0.33	1.27e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.61	9.52	0.46	3.78e-19	Aortic root size;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.77	12.02	0.55	7.44e-28	Body mass index;
CRC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg22117107	chr15:45993392	NA	-0.43	-8.67	-0.43	2.02e-16	Waist circumference;Weight;
CRC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.7	0.39	1.56e-13	Obesity-related traits;
CRC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.55	7.47	0.38	7.52e-13	Height;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg03623178	chr6:28175578	NA	0.92	12.95	0.58	2.82e-31	Parkinson's disease;
CRC	trans	rs4621152	1.000	rs4621152	chr2:217908985	C/T	cg03559682	chr11:6439864	APBB1	0.31	6.06	0.32	3.76e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.01	-24.02	-0.8	2.33e-74	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	0.91	8.68	0.43	1.8e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg10820045	chr2:198174542	NA	-0.5	-8.23	-0.41	4.5e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg23247704	chr1:116518985	SLC22A15	-0.7	-6.04	-0.32	4.14e-9	Cognitive function;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22197824	chr11:65431114	RELA	0.4	6.09	0.32	3.16e-9	Myopia (pathological);
CRC	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	6.6	0.34	1.68e-10	Body mass index;
CRC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	11.45	0.53	8.87e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12588638	chr12:83080208	TMTC2	0.41	6.12	0.32	2.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.45	-0.42	9.48e-16	Electroencephalogram traits;
CRC	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.53	-0.34	2.53e-10	Height;
CRC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg09141835	chr16:88988174	CBFA2T3	-0.29	-6.17	-0.32	1.95e-9	Social autistic-like traits;
CRC	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg05714579	chr10:131428358	MGMT	0.54	7.72	0.39	1.43e-13	Response to temozolomide;
CRC	cis	rs7665939	0.860	rs61745583	chr4:190125993	A/G	cg09826759	chr4:190284978	NA	-0.65	-5.64	-0.3	3.58e-8	Amyotrophic lateral sclerosis;
CRC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg02527881	chr3:46936655	PTH1R	0.36	6.19	0.32	1.75e-9	Colorectal cancer;
CRC	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg06522879	chr11:64358276	SLC22A12	-0.54	-8.37	-0.42	1.66e-15	Urate levels in obese individuals;
CRC	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg01858014	chr14:56050164	KTN1	-0.81	-6.11	-0.32	2.87e-9	Putamen volume;
CRC	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.54	8.26	0.41	3.59e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.85	11.43	0.53	1.05e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs773506	0.628	rs10820836	chr9:93928329	A/G	cg14446406	chr9:93919335	NA	-0.44	-7.61	-0.39	2.91e-13	Type 2 diabetes nephropathy;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.53	-9.02	-0.45	1.64e-17	Type 2 diabetes;
CRC	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg21452805	chr1:244014465	NA	0.51	6.92	0.36	2.44e-11	RR interval (heart rate);
CRC	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.68	-0.43	1.88e-16	Coronary artery disease;
CRC	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.44	-6.43	-0.33	4.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.53	-8.82	-0.44	6.65e-17	Lung cancer;
CRC	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg06204229	chr3:52865917	ITIH4	0.58	7.97	0.4	2.71e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg06484146	chr7:12443880	VWDE	-0.67	-6.52	-0.34	2.7e-10	Coronary artery disease;
CRC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.47	-8.27	-0.41	3.37e-15	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02257712	chr5:150080478	RBM22	0.46	6.4	0.33	5.44e-10	Response to antipsychotic treatment;
CRC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.48	7.59	0.39	3.41e-13	Personality dimensions;
CRC	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-6.66	-0.34	1.13e-10	Coronary artery disease;
CRC	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.34	5.64	0.3	3.71e-8	Menopause (age at onset);
CRC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.45	6.6	0.34	1.67e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-12.04	-0.55	6.4e-28	Extrinsic epigenetic age acceleration;
CRC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.08	0.32	3.34e-9	Heart rate;
CRC	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.03	19.54	0.73	5.76e-57	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs10992471	0.651	rs7043984	chr9:95529408	C/T	cg14631576	chr9:95140430	CENPP	-0.4	-7.17	-0.37	5.13e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg12172441	chr6:28176163	NA	0.53	7.33	0.37	1.85e-12	Parkinson's disease;
CRC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-6.27	-0.33	1.16e-9	Menarche (age at onset);
CRC	cis	rs17767392	0.958	rs7148679	chr14:72160321	T/C	cg13720639	chr14:72061746	SIPA1L1	0.57	7.07	0.36	9.31e-12	Mitral valve prolapse;
CRC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.52	7.07	0.36	9.21e-12	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.67	9.34	0.46	1.55e-18	Cannabis dependence symptom count;
CRC	trans	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg17903999	chr18:56338584	MALT1	-0.43	-7.47	-0.38	7.29e-13	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg23250157	chr14:64679961	SYNE2	0.38	6.0	0.31	5.27e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg10298567	chr3:47292165	KIF9	-0.4	-6.63	-0.34	1.41e-10	Colorectal cancer;
CRC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg16342193	chr10:102329863	NA	-0.38	-5.83	-0.31	1.33e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs59104589	0.521	rs62190414	chr2:242424687	A/G	cg19488206	chr2:242435732	STK25	0.46	7.21	0.37	3.79e-12	Fibrinogen levels;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg14225146	chr17:72744664	SLC9A3R1	-0.68	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.45	5.73	0.3	2.21e-8	Aortic root size;
CRC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.76	-11.46	-0.53	7.99e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.59	-10.89	-0.51	8.55e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.75	-0.47	6.96e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	0.76	6.1	0.32	2.92e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg15147215	chr3:52552868	STAB1	-0.43	-6.09	-0.32	3.12e-9	Schizophrenia;
CRC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.71	-11.59	-0.54	2.83e-26	Idiopathic membranous nephropathy;
CRC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.62	8.01	0.4	2.05e-14	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg00343986	chr7:65444356	GUSB	-0.44	-6.15	-0.32	2.21e-9	Aortic root size;
CRC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg24154853	chr7:158122151	PTPRN2	-0.59	-9.85	-0.48	3.13e-20	Calcium levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg11502736	chr1:179923845	CEP350	0.46	6.54	0.34	2.42e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.27	0.49	1.17e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.54	8.73	0.43	1.29e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg13385794	chr1:248469461	NA	0.4	7.1	0.36	7.96e-12	Common traits (Other);
CRC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg03623178	chr6:28175578	NA	0.69	7.1	0.36	7.91e-12	Depression;
CRC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-9.35	-0.46	1.34e-18	Menarche (age at onset);
CRC	cis	rs4589502	0.800	rs4776855	chr15:67202075	T/C	cg09911534	chr15:67153556	NA	0.43	5.84	0.31	1.26e-8	Lung cancer (smoking interaction);
CRC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	6.59	0.34	1.74e-10	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs4478137	0.931	rs3967762	chr4:164244976	T/C	cg06758707	chr4:164254230	NPY1R	0.38	5.87	0.31	1.05e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs7274811	0.625	rs293723	chr20:31927706	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.49	-0.34	3.14e-10	Height;
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.36	-5.92	-0.31	7.96e-9	Total body bone mineral density;
CRC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.48	-7.88	-0.4	4.89e-14	Body mass index;
CRC	cis	rs6743376	0.642	rs4145014	chr2:113831185	A/G	cg24553058	chr2:113831203	IL1F10	0.7	9.61	0.47	1.89e-19	Inflammatory biomarkers;
CRC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.46	7.46	0.38	7.81e-13	Obesity-related traits;
CRC	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.51	-8.48	-0.42	7.73e-16	Crohn's disease;
CRC	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.98	-0.4	2.38e-14	Caffeine consumption;
CRC	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg05925327	chr15:68127851	NA	0.3	5.75	0.3	2.03e-8	Restless legs syndrome;
CRC	cis	rs6604026	0.656	rs949915	chr1:93369774	A/G	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs7739232	0.749	rs79359022	chr6:53527019	T/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs2333194	0.846	rs7159794	chr14:73804443	G/A	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.41	-6.25	-0.33	1.29e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.72	-11.43	-0.53	1.05e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.26	0.37	2.74e-12	Eye color traits;
CRC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-16.54	-0.67	3.83e-45	Schizophrenia;
CRC	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.47	6.49	0.34	3.22e-10	Obesity-related traits;
CRC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.65	-9.5	-0.46	4.38e-19	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg22110888	chr17:80059540	CCDC57	0.38	6.07	0.32	3.61e-9	Life satisfaction;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-9.02	-0.45	1.55e-17	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.65	0.34	1.19e-10	Anxiety disorder;
CRC	cis	rs7605827	0.930	rs12692267	chr2:15572834	A/G	cg19274914	chr2:15703543	NA	-0.38	-5.8	-0.3	1.54e-8	Educational attainment (years of education);
CRC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.65	8.55	0.43	4.66e-16	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.4	5.77	0.3	1.82e-8	Aortic root size;
CRC	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.61	10.43	0.5	3.31e-22	Leprosy;
CRC	cis	rs17095355	1.000	rs17126883	chr10:111694696	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.9	-0.36	2.69e-11	Biliary atresia;
CRC	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.49	0.5	2.16e-22	Corneal astigmatism;
CRC	cis	rs12134245	0.527	rs6681073	chr1:92022597	A/C	cg25838465	chr1:92012736	NA	-0.44	-6.51	-0.34	2.83e-10	Breast cancer;
CRC	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg23260525	chr10:116636907	FAM160B1	0.33	6.52	0.34	2.58e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11668638	chr6:42952412	PPP2R5D	-0.54	-6.58	-0.34	1.81e-10	Diisocyanate-induced asthma;
CRC	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg09127314	chr1:152161683	NA	0.45	5.86	0.31	1.14e-8	Atopic dermatitis;
CRC	trans	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg10756647	chr7:56101905	PSPH	0.76	7.81	0.4	7.54e-14	Diabetic kidney disease;
CRC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.06e-8	Bladder cancer;
CRC	cis	rs7113874	0.589	rs7101471	chr11:8463622	A/G	cg02811074	chr11:8615871	STK33	0.33	5.75	0.3	2.09e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs16973500	0.711	rs72801789	chr16:71959748	C/T	cg00732059	chr16:71740210	PHLPP2	-0.66	-6.76	-0.35	6.35e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg01831904	chr17:28903510	LRRC37B2	0.65	6.7	0.35	9.21e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.18	-0.32	1.86e-9	Aortic root size;
CRC	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.47	6.31	0.33	8.84e-10	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg10298567	chr3:47292165	KIF9	0.38	5.86	0.31	1.15e-8	Colorectal cancer;
CRC	cis	rs477692	0.637	rs7098627	chr10:131315866	C/T	cg05714579	chr10:131428358	MGMT	0.5	6.99	0.36	1.5e-11	Response to temozolomide;
CRC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.51	-7.76	-0.39	1.09e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg22638593	chr5:131593259	PDLIM4	0.4	7.33	0.37	1.75e-12	Breast cancer;
CRC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.8	8.11	0.41	9.83e-15	Diabetic retinopathy;
CRC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-12.71	-0.57	2.25e-30	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03647317	chr4:187891568	NA	-0.55	-10.24	-0.49	1.53e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.83	-13.92	-0.61	5.83e-35	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12295403	1.000	rs12295403	chr11:18689653	G/T	cg07538406	chr11:18686895	NA	-0.4	-6.09	-0.32	3.2e-9	Ovarian reserve;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg21620606	chr4:1342894	KIAA1530	0.38	6.82	0.35	4.26e-11	Obesity-related traits;
CRC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-15.43	-0.65	8.48e-41	Schizophrenia;
CRC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	8.79	0.44	8.52e-17	Cognitive test performance;
CRC	cis	rs7703744	0.681	rs11957102	chr5:118701899	G/T	cg23985447	chr5:118691066	TNFAIP8	0.4	5.64	0.3	3.66e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg12500891	chr11:57225987	NA	-0.69	-6.06	-0.32	3.82e-9	Cognitive function;
CRC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.63	0.34	1.34e-10	Schizophrenia;
CRC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg19318889	chr4:1322082	MAEA	0.4	5.74	0.3	2.13e-8	Obesity-related traits;
CRC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.58	-8.2	-0.41	5.61e-15	Itch intensity from mosquito bite;
CRC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.61	6.86	0.35	3.38e-11	Vitiligo;
CRC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.4	6.04	0.32	4.26e-9	Hemoglobin concentration;
CRC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg12590608	chr7:158785262	NA	-0.48	-9.05	-0.45	1.25e-17	Facial morphology (factor 20);
CRC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg12218747	chr21:37451666	NA	0.37	6.45	0.34	4.01e-10	Mitral valve prolapse;
CRC	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg15382696	chr6:118971807	C6orf204	0.56	6.77	0.35	5.81e-11	Diastolic blood pressure;
CRC	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.61	-7.61	-0.39	2.89e-13	Ulcerative colitis;
CRC	cis	rs4731207	0.596	rs1481328	chr7:124631026	C/T	cg23710748	chr7:124431027	NA	0.4	6.38	0.33	5.97e-10	Cutaneous malignant melanoma;
CRC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg12193833	chr17:30244370	NA	-0.62	-8.05	-0.41	1.51e-14	Hip circumference adjusted for BMI;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg22638593	chr5:131593259	PDLIM4	0.4	6.4	0.33	5.33e-10	Blood metabolite levels;
CRC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg10760299	chr15:45669010	GATM	0.53	8.27	0.41	3.35e-15	Homoarginine levels;
CRC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.68	9.26	0.45	2.69e-18	Breast cancer;
CRC	cis	rs17767392	0.958	rs35760654	chr14:71983757	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.26	-0.37	2.77e-12	Mitral valve prolapse;
CRC	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.57	-9.05	-0.45	1.27e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg10263370	chr3:44754102	ZNF502	-0.38	-6.25	-0.33	1.24e-9	Depressive symptoms;
CRC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.79	-0.35	5.19e-11	Bipolar disorder;
CRC	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-7.14	-0.37	6.11e-12	Menarche (age at onset);
CRC	cis	rs4654899	0.772	rs12404954	chr1:21074727	A/G	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.0	-0.36	1.45e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.41	-5.62	-0.3	4.02e-8	Diisocyanate-induced asthma;
CRC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg22561889	chr6:118971681	C6orf204	0.52	6.69	0.35	9.59e-11	Diastolic blood pressure;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg23123621	chr4:1343375	KIAA1530	0.35	6.14	0.32	2.4e-9	Longevity;
CRC	cis	rs3764400	0.508	rs74412170	chr17:46117509	C/G	cg10706073	chr17:46328419	SKAP1	-0.67	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.66	8.66	0.43	2.23e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	8.96	0.44	2.54e-17	Platelet distribution width;
CRC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.41	6.81	0.35	4.56e-11	Diastolic blood pressure;
CRC	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.86	16.15	0.66	1.31e-43	Hip circumference;
CRC	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.93	0.36	2.21e-11	Height;
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-7.95	-0.4	3.02e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.56	6.94	0.36	2.03e-11	Neutrophil percentage of white cells;
CRC	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.94	11.82	0.55	4.02e-27	Exhaled nitric oxide levels;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg03037974	chr15:76606532	NA	0.7	12.45	0.57	2.07e-29	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.74	9.83	0.48	3.64e-20	Alzheimer's disease;
CRC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.85	-0.35	3.67e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22658884	chr19:14192470	NA	0.49	6.3	0.33	9.48e-10	Thyroid stimulating hormone;
CRC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.68	-10.03	-0.48	7.91e-21	DNA methylation (variation);
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg05313129	chr8:58192883	C8orf71	-0.44	-6.15	-0.32	2.27e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg17724175	chr1:150552817	MCL1	0.49	7.26	0.37	2.88e-12	Melanoma;
CRC	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.5	6.38	0.33	5.92e-10	Cholesterol, total;
CRC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg02574844	chr11:5959923	NA	-0.43	-5.65	-0.3	3.48e-8	DNA methylation (variation);
CRC	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg10483660	chr13:112241077	NA	0.36	5.81	0.31	1.46e-8	Menarche (age at onset);
CRC	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg20019720	chr6:154832845	CNKSR3	0.5	8.26	0.41	3.58e-15	Lipoprotein (a) levels;
CRC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.42	8.56	0.43	4.32e-16	Renal cell carcinoma;
CRC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.47	6.55	0.34	2.26e-10	Lymphocyte counts;
CRC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.74	12.59	0.57	5.99e-30	Body mass index;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg25164649	chr6:28176230	NA	0.59	8.37	0.42	1.63e-15	Parkinson's disease;
CRC	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg11176159	chr1:28213800	NA	-0.32	-6.33	-0.33	7.82e-10	Corneal astigmatism;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg24560729	chr4:1342394	KIAA1530	0.34	6.26	0.33	1.24e-9	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15637605	chr3:148847786	HPS3	0.47	6.21	0.32	1.59e-9	Thyroid stimulating hormone;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg27629583	chr1:151431750	POGZ	-0.41	-5.96	-0.31	6.54e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	5.92	0.31	8.17e-9	Coronary artery disease;
CRC	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.75	-10.15	-0.49	2.97e-21	White matter hyperintensity burden;
CRC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.3	0.46	2.04e-18	Bladder cancer;
CRC	trans	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg17712092	chr4:129076599	LARP1B	-0.44	-6.27	-0.33	1.12e-9	Acne (severe);
CRC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	0.83	6.98	0.36	1.64e-11	LDL cholesterol;
CRC	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.57	-5.79	-0.3	1.64e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.57	-9.73	-0.47	7.6e-20	Iron status biomarkers;
CRC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.65	10.61	0.5	8.49e-23	Platelet count;
CRC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.39	-5.85	-0.31	1.18e-8	Total body bone mineral density;
CRC	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.47	-5.65	-0.3	3.52e-8	Carotid intima media thickness;
CRC	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-8.01	-0.4	2.01e-14	Bipolar disorder;
CRC	trans	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg01505111	chr6:125621795	HDDC2	0.38	6.0	0.31	5.25e-9	DNA methylation (variation);
CRC	cis	rs11212617	0.934	rs11212551	chr11:108078693	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.28	0.33	1.08e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.67	11.55	0.54	3.98e-26	Prostate cancer;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg25164649	chr6:28176230	NA	0.78	9.69	0.47	1.04e-19	Depression;
CRC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg02527881	chr3:46936655	PTH1R	-0.41	-7.83	-0.4	6.87e-14	Colorectal cancer;
CRC	cis	rs7605827	0.930	rs6737962	chr2:15526998	T/G	cg19274914	chr2:15703543	NA	0.38	5.63	0.3	3.81e-8	Educational attainment (years of education);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11733294	chr11:118123053	MPZL3	0.44	6.0	0.31	5.11e-9	Survival in pancreatic cancer;
CRC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-7.7	-0.39	1.65e-13	Aortic root size;
CRC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.74	11.17	0.52	8.95e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.68	0.3	3e-8	Life satisfaction;
CRC	cis	rs7703744	0.634	rs3797340	chr5:118691737	C/G	cg02283238	chr5:118691126	TNFAIP8	0.47	6.47	0.34	3.5e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.77	-0.35	5.83e-11	Inflammatory skin disease;
CRC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.78	-0.66	3.77e-42	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	cis	rs1033849	0.507	rs9507260	chr13:24723932	A/G	cg14860438	chr13:24731302	NA	0.36	5.94	0.31	7.16e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.49	0.42	7.38e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	-0.64	-6.98	-0.36	1.6e-11	Tonsillectomy;
CRC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.54e-30	Bone mineral density;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg21620606	chr4:1342894	KIAA1530	-0.4	-7.08	-0.36	8.97e-12	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13123156	chr7:105162878	PUS7	0.44	6.49	0.34	3.08e-10	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.25e-9	Prudent dietary pattern;
CRC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg24375607	chr4:120327624	NA	0.48	7.66	0.39	2.1e-13	Corneal astigmatism;
CRC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.44	-8.13	-0.41	8.67e-15	Reticulocyte fraction of red cells;
CRC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.72	-0.35	8.23e-11	Mean corpuscular volume;
CRC	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	5.96	0.31	6.47e-9	Diastolic blood pressure;
CRC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.75	10.9	0.52	7.74e-24	Longevity;
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg22562942	chr8:24772309	NEFM	-0.29	-6.0	-0.31	5.17e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7916697	0.898	rs1900005	chr10:69998055	A/C	cg06988349	chr10:69991859	ATOH7	-0.34	-6.29	-0.33	1.03e-9	Optic disc area;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.33	-0.33	8.13e-10	Breast cancer;
CRC	trans	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg14791747	chr16:20752902	THUMPD1	0.54	7.12	0.37	6.87e-12	Cognitive test performance;
CRC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg01951491	chr16:67709440	GFOD2	-0.44	-5.85	-0.31	1.17e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.52	7.45	0.38	8.13e-13	Lymphocyte counts;
CRC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.5	-7.33	-0.37	1.74e-12	Response to antineoplastic agents;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11087358	chr12:57940980	DCTN2	0.51	6.75	0.35	6.78e-11	Thyroid stimulating hormone;
CRC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg10790698	chr19:18539756	SSBP4	-0.45	-8.61	-0.43	3.07e-16	Breast cancer;
CRC	trans	rs6544773	0.668	rs341599	chr2:45066716	T/C	cg10208897	chr5:178548229	ADAMTS2	0.35	6.06	0.32	3.71e-9	Mosquito bite size;
CRC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg20243544	chr17:37824526	PNMT	0.55	8.95	0.44	2.66e-17	Asthma;
CRC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.64	0.34	1.27e-10	Axial length;
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg21724239	chr8:58056113	NA	0.39	5.83	0.31	1.29e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.5	9.46	0.46	6e-19	Alcohol dependence;
CRC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.4	-0.33	5.41e-10	Tonsillectomy;
CRC	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.72	-10.66	-0.51	5.48e-23	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-8.09	-0.41	1.13e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.31	0.33	9.13e-10	Life satisfaction;
CRC	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.43	-8.28	-0.42	3.22e-15	Alcohol dependence;
CRC	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.81	-0.4	7.61e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.92	-10.16	-0.49	2.86e-21	Hip circumference adjusted for BMI;
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg03188948	chr7:1209495	NA	0.44	6.29	0.33	1.04e-9	Longevity;Endometriosis;
CRC	cis	rs10924970	0.967	rs11585350	chr1:235482739	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	6.14	0.32	2.41e-9	Asthma;
CRC	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-9.95	-0.48	1.5e-20	Hepatocellular carcinoma;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg20615401	chr6:28092323	ZSCAN16	0.47	6.26	0.33	1.22e-9	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22897130	chr10:89419623	PAPSS2	0.39	6.38	0.33	5.98e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12474201	0.569	rs13411633	chr2:46932666	A/G	cg06386533	chr2:46925753	SOCS5	0.59	8.89	0.44	4.07e-17	Height;
CRC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg24977027	chr2:88469347	THNSL2	0.52	5.94	0.31	7.21e-9	Plasma clusterin levels;
CRC	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.13	11.95	0.55	1.43e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.77	15.06	0.64	2.42e-39	Prostate cancer;
CRC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.59	5.94	0.31	7.25e-9	Breast cancer;
CRC	cis	rs4973397	0.519	rs1669083	chr2:232196564	A/G	cg13347044	chr2:232276743	NA	-0.4	-6.18	-0.32	1.86e-9	Anti-saccade response;
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18758796	chr5:131593413	PDLIM4	0.45	8.14	0.41	8.41e-15	Breast cancer;
CRC	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.57	-8.09	-0.41	1.14e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.0	-0.31	5.27e-9	Aortic root size;
CRC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg06484146	chr7:12443880	VWDE	0.75	7.28	0.37	2.48e-12	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg20354231	chr13:53171401	NA	-0.44	-7.19	-0.37	4.48e-12	Lewy body disease;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.61	8.97	0.44	2.38e-17	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16385431	chr13:115079815	ZNF828	0.4	6.1	0.32	2.91e-9	Response to antipsychotic treatment;
CRC	cis	rs6060717	0.610	rs6058393	chr20:34608664	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-5.98	-0.31	5.81e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.91	17.31	0.69	3.38e-48	Blood protein levels;
CRC	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg12856521	chr11:46389249	DGKZ	-0.5	-8.2	-0.41	5.3e-15	Leprosy;
CRC	cis	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg01251360	chr16:68772225	CDH1	0.23	5.66	0.3	3.27e-8	Colorectal cancer;
CRC	cis	rs2013441	1.000	rs2243732	chr17:20088589	C/G	cg13482628	chr17:19912719	NA	-0.4	-6.07	-0.32	3.43e-9	Obesity-related traits;
CRC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-13.66	-0.6	6e-34	Chronic sinus infection;
CRC	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.39	-6.07	-0.32	3.58e-9	Breast cancer;
CRC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.9	-0.8	7.05e-74	Myeloid white cell count;
CRC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg23996704	chr18:44553084	KATNAL2	-0.4	-8.01	-0.4	2e-14	Personality dimensions;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.47	-0.34	3.47e-10	Bipolar disorder;
CRC	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.68	10.66	0.51	5.61e-23	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.61	-0.39	2.87e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.66	0.34	1.15e-10	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.59	7.22	0.37	3.7e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg11965913	chr1:205819406	PM20D1	0.44	6.25	0.33	1.24e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.18	-0.56	1.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12973672	0.904	rs10424619	chr19:35768237	A/T	cg12095397	chr19:35769544	USF2	0.47	6.04	0.32	4.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.0	0.31	5.08e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.62	-8.08	-0.41	1.21e-14	Coronary artery disease;
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg08200770	chr17:80723486	TBCD	-0.49	-7.55	-0.38	4.43e-13	Glycated hemoglobin levels;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.86	0.75	3.76e-62	Prudent dietary pattern;
CRC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	10.93	0.52	6.07e-24	Body mass index;
CRC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.71	0.39	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg09179987	chr1:167433047	CD247	-0.5	-7.4	-0.38	1.18e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.51	7.52	0.38	5.25e-13	Monocyte percentage of white cells;
CRC	cis	rs7333181	1.000	rs34631808	chr13:112236047	C/T	cg27543320	chr13:112200689	NA	0.5	6.45	0.33	4.03e-10	Menopause (age at onset);
CRC	cis	rs7737355	0.836	rs10900800	chr5:130914946	G/A	cg25547332	chr5:131281432	NA	0.38	5.92	0.31	8.09e-9	Life satisfaction;
CRC	trans	rs13221576	0.569	rs17166217	chr7:94011254	C/T	cg25582398	chr5:1217743	SLC6A19	-0.55	-6.19	-0.32	1.81e-9	Intelligence;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg22709453	chr3:122786502	PDIA5	-0.45	-5.97	-0.31	6.11e-9	Parkinson's disease;
CRC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-9.92	-0.48	1.87e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.61	9.85	0.48	3.12e-20	Hemostatic factors and hematological phenotypes;
CRC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.56	8.62	0.43	2.92e-16	Aortic root size;
CRC	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg07470512	chr20:32255052	NECAB3;C20orf134	0.44	6.0	0.31	5.27e-9	Height;
CRC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.6	8.11	0.41	9.79e-15	Multiple sclerosis;
CRC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	14.91	0.63	9.29e-39	Smoking behavior;
CRC	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.54	8.54	0.43	5e-16	Testicular germ cell tumor;
CRC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg11212589	chr17:38028394	ZPBP2	0.41	7.38	0.38	1.27e-12	Self-reported allergy;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg06470822	chr6:28175283	NA	0.82	12.25	0.56	1.14e-28	Cardiac Troponin-T levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08204369	chr17:73150733	HN1	-0.54	-6.53	-0.34	2.52e-10	Diisocyanate-induced asthma;
CRC	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg16342193	chr10:102329863	NA	-0.36	-5.86	-0.31	1.14e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.64	0.39	2.39e-13	Parkinson's disease;
CRC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.82	12.07	0.55	5.08e-28	Intelligence (multi-trait analysis);
CRC	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.36	-6.9	-0.36	2.65e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2857891	0.650	rs2857928	chr11:6989721	C/G	cg04053776	chr11:6947353	ZNF215	-0.41	-6.42	-0.33	4.82e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg03013999	chr17:37608204	MED1	0.44	6.63	0.34	1.35e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13887370	chr12:56224128	DNAJC14	0.44	6.25	0.33	1.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg10820045	chr2:198174542	NA	-0.53	-9.16	-0.45	5.52e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26859862	chr16:30389551	SEPT1	0.39	6.41	0.33	4.99e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg09491104	chr22:46646882	C22orf40	-0.37	-5.79	-0.3	1.62e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.22	-0.32	1.47e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.5	7.79	0.39	8.64e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.94	-0.31	7.09e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs77216612	0.877	rs72656645	chr12:12881055	A/G	cg04607235	chr12:12878440	APOLD1	-1.03	-14.06	-0.61	1.76e-35	Lymphocyte counts;
CRC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-5.61	-0.3	4.24e-8	Height;
CRC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-8.43	-0.42	1.08e-15	Hip circumference adjusted for BMI;
CRC	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21659725	chr3:3221576	CRBN	-0.41	-6.12	-0.32	2.67e-9	Menarche (age at onset);
CRC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.73	0.3	2.23e-8	Bladder cancer;
CRC	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.58	9.84	0.48	3.36e-20	Breast cancer;
CRC	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg14844989	chr11:31128820	NA	-0.34	-6.22	-0.32	1.54e-9	Red blood cell count;
CRC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.52	7.25	0.37	2.93e-12	Inflammatory bowel disease;
CRC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.79	-12.84	-0.58	7.27e-31	Cognitive function;
CRC	cis	rs995000	0.868	rs11208007	chr1:63176083	A/T	cg19896129	chr1:63156450	NA	0.4	5.78	0.3	1.72e-8	Triglyceride levels;
CRC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.86	0.31	1.13e-8	Life satisfaction;
CRC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg23815491	chr16:72088622	HP	0.51	7.65	0.39	2.3e-13	Fibrinogen levels;
CRC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.55	7.58	0.39	3.44e-13	Lymphocyte counts;
CRC	trans	rs1455244	0.665	rs9303735	chr18:11505086	C/T	cg06024642	chr17:4510776	SMTNL2	-0.32	-6.09	-0.32	3.11e-9	Schizophrenia;
CRC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.46	6.15	0.32	2.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-8.3	-0.42	2.65e-15	Type 2 diabetes;
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.42	-7.4	-0.38	1.11e-12	Height;
CRC	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.74	11.73	0.54	8.65e-27	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.5	7.13	0.37	6.55e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.56	-6.7	-0.35	9.25e-11	Carotid intima media thickness;
CRC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.49	9.7	0.47	9.74e-20	Iron status biomarkers;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.75	-0.35	6.85e-11	Total body bone mineral density;
CRC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	7.87	0.4	5.12e-14	Schizophrenia;
CRC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.57	7.07	0.36	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.84	14.57	0.63	1.88e-37	Height;
CRC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.6	7.84	0.4	6.24e-14	Gut microbiome composition (summer);
CRC	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.54	-7.12	-0.37	6.94e-12	Extraversion;
CRC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.48	-5.84	-0.31	1.25e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs501120	1.000	rs670056	chr10:44753375	C/T	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.6	8.4	0.42	1.4e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.85	-0.31	1.18e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg04553112	chr3:125709451	NA	-0.53	-6.1	-0.32	3.02e-9	Blood pressure (smoking interaction);
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg12172441	chr6:28176163	NA	-0.56	-7.48	-0.38	6.83e-13	Parkinson's disease;
CRC	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.47	6.85	0.35	3.65e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	trans	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg09045935	chr12:6379348	NA	1.14	8.99	0.44	1.99e-17	Blood metabolite levels;
CRC	trans	rs1992950	1.000	rs10497836	chr2:200288718	C/T	cg07934068	chr4:80883595	ANTXR2	0.43	6.61	0.34	1.58e-10	Ulcerative colitis;
CRC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.53	9.12	0.45	7.62e-18	Aortic root size;
CRC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg14008862	chr17:28927542	LRRC37B2	0.55	5.73	0.3	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08935602	chr16:2509817	C16orf59	0.51	6.53	0.34	2.44e-10	Thyroid stimulating hormone;
CRC	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.45	-7.04	-0.36	1.11e-11	HDL cholesterol;
CRC	cis	rs73206853	0.563	rs7301623	chr12:111170903	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	8.89	0.44	4.07e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs713477	1.000	rs713477	chr14:55904426	C/A	cg13175173	chr14:55914753	NA	-0.45	-8.23	-0.41	4.53e-15	Pediatric bone mineral content (femoral neck);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12680326	chr20:2821316	VPS16;FAM113A	-0.39	-6.34	-0.33	7.54e-10	Myopia (pathological);
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg14949292	chr17:78079608	GAA	-0.39	-6.12	-0.32	2.72e-9	Yeast infection;
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.59	7.23	0.37	3.38e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs12495832	0.778	rs79309301	chr3:147940024	T/A	cg10221266	chr7:153579447	NA	0.59	6.34	0.33	7.77e-10	Chin dimples;
CRC	cis	rs305851	0.875	rs9296304	chr6:39746879	A/G	cg02386599	chr6:39769542	DAAM2	0.39	6.15	0.32	2.2e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.77	-10.3	-0.49	9.5e-22	Initial pursuit acceleration;
CRC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.39	-0.33	5.56e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg03929089	chr4:120376271	NA	-0.46	-6.42	-0.33	4.85e-10	HDL cholesterol;
CRC	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.15	-0.37	5.64e-12	Capecitabine sensitivity;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00166722	chr3:10149974	C3orf24	0.66	7.71	0.39	1.49e-13	Alzheimer's disease;
CRC	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg00738113	chr16:70207722	CLEC18C	-0.37	-5.77	-0.3	1.79e-8	IgE levels;
CRC	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-1.06	-10.9	-0.52	7.66e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg04121214	chr22:50244548	NA	0.41	5.8	0.3	1.54e-8	Schizophrenia;
CRC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg12365402	chr11:9010492	NRIP3	0.54	9.11	0.45	7.96e-18	Hemoglobin concentration;
CRC	trans	rs11581859	0.950	rs7552573	chr1:99374181	A/C	cg12183875	chr3:169587454	LRRC31	0.28	6.46	0.34	3.78e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.41	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-10.74	-0.51	2.91e-23	Hemoglobin concentration;
CRC	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs9903692	0.954	rs9899461	chr17:46129353	A/G	cg21215337	chr17:46176117	CBX1	-0.44	-7.97	-0.4	2.61e-14	Pulse pressure;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.9e-11	Electroencephalogram traits;
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.26e-26	Prudent dietary pattern;
CRC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg08314208	chr16:67682810	RLTPR	-0.62	-6.61	-0.34	1.55e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg04111102	chr1:66153794	NA	-0.32	-5.73	-0.3	2.3e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg24296786	chr1:45957014	TESK2	0.52	7.66	0.39	2.05e-13	High light scatter reticulocyte count;
CRC	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.75	-7.64	-0.39	2.44e-13	Non-glioblastoma glioma;Glioma;
CRC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.53	9.33	0.46	1.55e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg14711859	chr11:8959438	ASCL3	0.45	7.52	0.38	5.34e-13	Hemoglobin concentration;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.39	-7.57	-0.39	3.71e-13	Longevity;Endometriosis;
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	1.01	11.55	0.54	3.95e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4750440	0.671	rs10796149	chr10:14025859	C/T	cg00551146	chr10:14014579	FRMD4A	0.37	5.98	0.31	5.68e-9	Adiponectin levels;
CRC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.69e-12	Obesity-related traits;
CRC	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.65	10.37	0.5	5.42e-22	Corneal astigmatism;
CRC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.88	12.53	0.57	1.04e-29	Initial pursuit acceleration;
CRC	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.52	-8.6	-0.43	3.42e-16	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg04545296	chr12:48745243	ZNF641	0.33	5.79	0.3	1.69e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.54	8.01	0.4	2e-14	Breast cancer;
CRC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg07701084	chr6:150067640	NUP43	0.54	7.44	0.38	8.71e-13	Lung cancer;
CRC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.84	-14.51	-0.62	3.33e-37	Intelligence (multi-trait analysis);
CRC	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg16964102	chr10:135390573	NA	-0.43	-5.73	-0.3	2.24e-8	Gout;
CRC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg20607287	chr7:12443886	VWDE	-0.6	-6.07	-0.32	3.59e-9	Coronary artery disease;
CRC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	8.08	0.41	1.21e-14	Colorectal cancer;
CRC	cis	rs9462846	0.887	rs2395938	chr6:42850659	C/A	cg21280719	chr6:42927975	GNMT	-0.3	-5.71	-0.3	2.52e-8	Blood protein levels;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.59	-0.34	1.75e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11948739	0.576	rs11242051	chr5:130261276	G/A	cg08523029	chr5:130500466	HINT1	0.49	6.25	0.33	1.25e-9	Pediatric bone mineral content (hip);
CRC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.49	6.64	0.34	1.33e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11212617	0.869	rs4754299	chr11:108025214	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.83	0.31	1.3e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg08501292	chr6:25962987	TRIM38	0.84	8.08	0.41	1.25e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.72	11.15	0.52	1.03e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg18479299	chr3:125709523	NA	-0.54	-6.28	-0.33	1.04e-9	Blood pressure (smoking interaction);
CRC	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.49	7.62	0.39	2.7e-13	Testicular germ cell tumor;
CRC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.54	-9.32	-0.46	1.71e-18	Migraine;
CRC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.57	9.44	0.46	7.1e-19	Schizophrenia;
CRC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.55	9.16	0.45	5.88e-18	Colorectal cancer;
CRC	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg23234261	chr14:55582407	NA	-0.3	-5.87	-0.31	1.07e-8	Protein biomarker;
CRC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.77	11.96	0.55	1.27e-27	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg10498984	chr16:28874827	SH2B1	-0.71	-6.11	-0.32	2.86e-9	Cognitive function;
CRC	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.57	7.58	0.39	3.45e-13	Macular telangiectasia type 2;
CRC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	1.17	10.78	0.51	2.08e-23	Arsenic metabolism;
CRC	cis	rs73206853	0.764	rs3026468	chr12:110758081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.8	7.76	0.39	1.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg02683197	chr6:28174875	NA	0.73	9.78	0.47	5.29e-20	Parkinson's disease;
CRC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.69	-8.95	-0.44	2.73e-17	Initial pursuit acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03367560	chr6:126307401	TRMT11	0.43	6.3	0.33	9.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8105895	0.935	rs28635943	chr19:22268712	G/T	cg02657401	chr19:22469223	NA	-0.34	-5.83	-0.31	1.33e-8	Body mass index (change over time);
CRC	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.52	7.8	0.4	8.25e-14	Testicular germ cell tumor;
CRC	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg09659197	chr4:152720779	NA	0.42	8.5	0.42	6.86e-16	Intelligence (multi-trait analysis);
CRC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.03	0.41	1.7e-14	Type 2 diabetes;
CRC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg05320533	chr16:89541815	ANKRD11	-0.43	-5.95	-0.31	6.98e-9	Multiple myeloma (IgH translocation);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05793409	chr1:35658810	SFPQ	0.53	7.74	0.39	1.21e-13	Response to antipsychotic treatment;
CRC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.89	16.16	0.67	1.17e-43	Blood protein levels;
CRC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2227564	0.649	rs2243610	chr10:75601653	A/T	cg00564723	chr10:75632066	CAMK2G	-0.37	-8.83	-0.44	6.36e-17	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.25	-0.45	2.97e-18	Intelligence (multi-trait analysis);
CRC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.38	-6.94	-0.36	2.14e-11	Height;
CRC	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-8.33	-0.42	2.2e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.61	7.46	0.38	7.81e-13	Body mass index;
CRC	cis	rs6586163	0.843	rs7069061	chr10:90754909	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.33	-0.37	1.74e-12	Chronic lymphocytic leukemia;
CRC	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg06462663	chr19:18546047	ISYNA1	0.47	6.9	0.36	2.67e-11	Breast cancer;
CRC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg20503657	chr10:835505	NA	0.62	8.4	0.42	1.34e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg02033258	chr5:131593261	PDLIM4	0.4	6.7	0.35	8.97e-11	Breast cancer;
CRC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	1.11	10.4	0.5	4.45e-22	Arsenic metabolism;
CRC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.41	-6.27	-0.33	1.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.55	7.69	0.39	1.73e-13	Gut microbiome composition (summer);
CRC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.47	6.82	0.35	4.33e-11	Tonsillectomy;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg02683197	chr6:28174875	NA	0.7	9.74	0.47	7.45e-20	Parkinson's disease;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.52	0.34	2.57e-10	Depression;
CRC	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.95	-12.39	-0.56	3.37e-29	Exhaled nitric oxide output;
CRC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.54	0.34	2.31e-10	Schizophrenia;
CRC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.6	8.93	0.44	2.99e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.51	-0.46	4.16e-19	Capecitabine sensitivity;
CRC	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06307176	chr5:131281290	NA	0.5	7.05	0.36	1.04e-11	Life satisfaction;
CRC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-9.3	-0.46	2.05e-18	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg10498984	chr16:28874827	SH2B1	-0.73	-5.97	-0.31	6.13e-9	Cognitive function;
CRC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.64e-15	Menopause (age at onset);
CRC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.72	-0.43	1.37e-16	Hemoglobin concentration;
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg06156847	chr2:113672199	IL1F7	-0.4	-6.03	-0.32	4.38e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.67	9.25	0.45	2.84e-18	Lung cancer;
CRC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.55	7.83	0.4	6.6e-14	Melanoma;
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg15790184	chr11:494944	RNH1	0.61	6.27	0.33	1.14e-9	Body mass index;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.72	-11.41	-0.53	1.24e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.19	14.94	0.64	6.8e-39	Uric acid levels;
CRC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.67	-9.9	-0.48	2.19e-20	Pancreatic cancer;
CRC	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.49	6.37	0.33	6.2e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.77	12.35	0.56	4.71e-29	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6662572	0.737	rs72677550	chr1:46589276	G/C	cg08644498	chr1:46502608	NA	0.42	6.56	0.34	2.15e-10	Blood protein levels;
CRC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg20933634	chr6:27740509	NA	0.62	8.21	0.41	5.17e-15	Parkinson's disease;
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.8	-0.35	5.02e-11	Bipolar disorder;
CRC	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.71	0.39	1.48e-13	Corneal astigmatism;
CRC	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.42	6.58	0.34	1.82e-10	Red blood cell count;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18301423	chr5:131593218	PDLIM4	-0.43	-7.44	-0.38	8.67e-13	Acylcarnitine levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11717700	chr4:154387421	KIAA0922	0.46	6.51	0.34	2.85e-10	Anxiety disorder;
CRC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.15	0.32	2.26e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.39	6.0	0.31	5.32e-9	Hemoglobin concentration;
CRC	trans	rs59888335	1.000	rs60381750	chr3:80752104	G/T	cg10129408	chr6:10421001	TFAP2A	0.38	6.02	0.31	4.57e-9	Schizophrenia;
CRC	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.7	-9.73	-0.47	8.09e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.19	0.67	9.15e-44	Electrocardiographic conduction measures;
CRC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.54	8.72	0.43	1.35e-16	Coronary artery disease;
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	7.27	0.37	2.68e-12	Electroencephalogram traits;
CRC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.69	9.48	0.46	5.35e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.55	-5.74	-0.3	2.15e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24589564	chr2:27357686	PREB	0.44	6.37	0.33	6.19e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.25	0.33	1.28e-9	Body mass index;
CRC	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.57	6.49	0.34	3.13e-10	Lymphocyte counts;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg03623178	chr6:28175578	NA	0.79	11.41	0.53	1.22e-25	Cardiac Troponin-T levels;
CRC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg06740227	chr12:86229804	RASSF9	-0.38	-5.78	-0.3	1.74e-8	Major depressive disorder;
CRC	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.48	7.34	0.38	1.68e-12	Carotid intima media thickness;
CRC	cis	rs10901296	0.660	rs2855197	chr9:133764406	A/G	cg01000188	chr9:133769184	QRFP	0.62	7.82	0.4	7.42e-14	Bilirubin levels;
CRC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	13.67	0.6	5.5e-34	Menopause (age at onset);
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.54	8.03	0.4	1.74e-14	Resting heart rate;
CRC	cis	rs2223471	0.967	rs3765306	chr6:50712784	C/T	cg03432817	chr6:50765336	NA	-0.41	-6.65	-0.34	1.26e-10	Subcutaneous adipose tissue;
CRC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.69	-10.76	-0.51	2.48e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs11203032	0.831	rs11203018	chr10:90948783	T/C	cg16672925	chr10:90967113	CH25H	0.46	5.79	0.3	1.66e-8	Heart failure;
CRC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.52	-6.12	-0.32	2.65e-9	Vitiligo;
CRC	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg24046110	chr8:143859143	LYNX1	-0.37	-6.43	-0.33	4.57e-10	Urinary tract infection frequency;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26433777	chr5:178157346	ZNF354A	0.38	6.06	0.32	3.66e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.5	-7.46	-0.38	7.74e-13	Response to antineoplastic agents;
CRC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.18	-0.37	4.69e-12	Coronary artery disease;
CRC	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg09003973	chr2:102972529	NA	0.42	5.84	0.31	1.23e-8	Blood protein levels;
CRC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.04	17.34	0.69	2.58e-48	Total cholesterol levels;
CRC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.87	15.24	0.64	4.63e-40	Breast cancer;
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.46	-6.55	-0.34	2.18e-10	Blood pressure (smoking interaction);
CRC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.37	5.94	0.31	7.25e-9	Prostate cancer;
CRC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg25456477	chr12:86230367	RASSF9	0.4	6.71	0.35	8.75e-11	Major depressive disorder;
CRC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.31e-12	Putamen volume;
CRC	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg14458575	chr2:238380390	NA	0.8	9.9	0.48	2.09e-20	Prostate cancer;
CRC	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.64	8.54	0.43	5.21e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.74	-12.39	-0.56	3.53e-29	Breast cancer;
CRC	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg15654264	chr1:150340011	RPRD2	0.37	5.81	0.31	1.46e-8	Migraine;
CRC	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	5.85	0.31	1.16e-8	Ovarian reserve;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-13.52	-0.6	1.94e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2882667	0.931	rs10038799	chr5:138362283	C/T	cg09476006	chr5:138032270	NA	0.44	7.42	0.38	1.01e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.48	0.53	7.22e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs449789	0.524	rs2879852	chr6:159748036	C/T	cg14500486	chr6:159655392	FNDC1	-0.46	-7.0	-0.36	1.41e-11	Pulse pressure;
CRC	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs3823572	0.542	rs62470438	chr7:133625504	A/G	cg03336402	chr7:133662267	EXOC4	0.67	10.05	0.48	6.82e-21	Intelligence (multi-trait analysis);
CRC	cis	rs216303	0.570	rs216321	chr12:6143984	T/C	cg19878637	chr12:6148451	VWF	-0.64	-6.96	-0.36	1.87e-11	Low vWF levels;
CRC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.72	-9.69	-0.47	1.09e-19	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.47	-0.46	5.55e-19	Migraine;Coronary artery disease;
CRC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.43	-6.04	-0.32	4.14e-9	Height;
CRC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.69	11.19	0.53	7.51e-25	Colorectal cancer;
CRC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg10589385	chr1:150898437	SETDB1	0.33	6.98	0.36	1.68e-11	Melanoma;
CRC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06505273	chr16:24850292	NA	-0.52	-6.73	-0.35	7.64e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.59	10.62	0.51	7.68e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.49	6.96	0.36	1.9e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.61	-0.43	3.09e-16	Aortic root size;
CRC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.56	8.45	0.42	9.58e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg15382696	chr6:118971807	C6orf204	-0.59	-7.77	-0.39	1.02e-13	Diastolic blood pressure;
CRC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.11	0.41	9.95e-15	Rheumatoid arthritis;
CRC	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg10437265	chr15:77819839	NA	0.55	7.55	0.38	4.35e-13	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.26	-0.45	2.8e-18	Mood instability;
CRC	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.5	-6.64	-0.34	1.3e-10	Metabolite levels;
CRC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	1.1	12.9	0.58	4.37e-31	Obesity-related traits;
CRC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.95	-16.37	-0.67	1.74e-44	Height;
CRC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg11189052	chr15:85197271	WDR73	0.62	8.86	0.44	5.29e-17	Schizophrenia;
CRC	cis	rs7605827	0.930	rs3792578	chr2:15534642	G/A	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.06e-8	Educational attainment (years of education);
CRC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg13390004	chr1:15929781	NA	0.5	7.08	0.36	8.51e-12	Systolic blood pressure;
CRC	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	1.05	20.5	0.75	9.74e-61	Platelet distribution width;
CRC	trans	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.43	7.61	0.39	2.84e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-6.75	-0.35	6.8e-11	Cognitive function;
CRC	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg15282417	chr9:129245246	FAM125B	0.44	7.86	0.4	5.69e-14	Intraocular pressure;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg16606324	chr3:10149918	C3orf24	0.61	6.83	0.35	4.15e-11	Alzheimer's disease;
CRC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.65	0.54	1.7e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg24130564	chr14:104152367	KLC1	0.42	5.67	0.3	3.08e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.47	7.06	0.36	1.02e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg09165964	chr15:75287851	SCAMP5	-0.5	-7.75	-0.39	1.16e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg18653534	chr16:772142	FAM173A	-0.37	-5.9	-0.31	9.18e-9	Height;
CRC	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.39	6.06	0.32	3.77e-9	Height;
CRC	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	15.88	0.66	1.56e-42	Electrocardiographic conduction measures;
CRC	cis	rs6694672	0.717	rs10801588	chr1:197062923	T/C	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.74e-11	Asthma;
CRC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.71	7.03	0.36	1.2e-11	Diabetic retinopathy;
CRC	cis	rs12692738	0.526	rs355869	chr2:165631397	C/T	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7635838	0.892	rs3942925	chr3:11442921	T/C	cg00170343	chr3:11313890	ATG7	0.42	6.4	0.33	5.47e-10	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06505121	chr5:1038489	NKD2	0.39	6.12	0.32	2.66e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.16	-0.32	2.08e-9	Cognitive function;
CRC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.57	8.51	0.42	6.03e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.57	8.87	0.44	4.72e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg00745463	chr17:30367425	LRRC37B	0.54	6.64	0.34	1.34e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2565722	0.665	rs9347466	chr6:161297926	A/T	cg03159191	chr6:161285451	NA	-0.46	-6.4	-0.33	5.47e-10	Blood protein levels;
CRC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.39	6.49	0.34	3.21e-10	Total body bone mineral density;
CRC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.33	6.81	0.35	4.71e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.37	-0.33	6.39e-10	Breast cancer;
CRC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.25	-0.45	2.94e-18	Platelet count;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.5	-6.97	-0.36	1.7e-11	Intelligence (multi-trait analysis);
CRC	trans	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.66e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11212617	1.000	rs10431060	chr11:108288228	A/C	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.8	0.3	1.59e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.56	8.36	0.42	1.85e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.79	-13.39	-0.59	6.41e-33	Ear protrusion;
CRC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.41	6.58	0.34	1.9e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6834538	0.520	rs34916940	chr4:113421609	C/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.8	-0.3	1.55e-8	Free thyroxine concentration;
CRC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.44	0.33	4.14e-10	Height;
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg26587870	chr6:27730563	NA	-0.36	-5.61	-0.3	4.28e-8	Parkinson's disease;
CRC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg14711859	chr11:8959438	ASCL3	0.44	7.28	0.37	2.42e-12	Hemoglobin concentration;
CRC	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-6.95	-0.36	1.97e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.44	5.79	0.3	1.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.49	5.91	0.31	8.45e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg02376097	chr19:46275166	DMPK	0.4	6.24	0.33	1.37e-9	Coronary artery disease;
CRC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.23	0.37	3.41e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg09695851	chr17:3907499	NA	0.5	6.36	0.33	6.84e-10	Type 2 diabetes;
CRC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.62	-9.08	-0.45	1.01e-17	Subjective well-being;
CRC	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.83	0.44	6.46e-17	Fuchs's corneal dystrophy;
CRC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.82	-0.48	3.98e-20	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.78	13.73	0.6	3.15e-34	Mean platelet volume;
CRC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.48	-9.03	-0.45	1.43e-17	Dupuytren's disease;
CRC	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg23293999	chr7:106826042	HBP1	-0.48	-5.72	-0.3	2.36e-8	Coronary artery disease;
CRC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.84	-0.44	6.02e-17	Aortic root size;
CRC	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.49	7.5	0.38	5.92e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-9.89	-0.48	2.26e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.08	-0.32	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg06092702	chr1:163392909	NA	-0.52	-8.18	-0.41	6.32e-15	Motion sickness;
CRC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.36	-5.92	-0.31	8.2e-9	Schizophrenia;
CRC	cis	rs727479	0.543	rs1143704	chr15:51510702	T/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-6.3	-0.33	9.53e-10	Estradiol levels;
CRC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg09179987	chr1:167433047	CD247	0.52	7.68	0.39	1.89e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs2274273	0.686	rs68083077	chr14:55574428	G/A	cg10130446	chr14:55658398	DLGAP5	-0.44	-5.8	-0.3	1.55e-8	Protein biomarker;
CRC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.81	-13.1	-0.59	7.6e-32	Coronary artery disease;
CRC	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-7.36	-0.38	1.44e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg21798802	chr22:38057573	PDXP	0.36	6.08	0.32	3.3e-9	Fat distribution (HIV);
CRC	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.84	-0.35	3.84e-11	Coronary artery disease;
CRC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.55	-9.22	-0.45	3.78e-18	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.55	-8.58	-0.43	3.85e-16	Uric acid levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02839273	chr15:85525387	PDE8A	0.43	6.25	0.33	1.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.11	14.57	0.63	1.81e-37	Vitiligo;
CRC	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.77	0.35	5.78e-11	Mean corpuscular volume;
CRC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.9e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09898070	chr2:48009866	MSH6	0.44	7.19	0.37	4.31e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	8.85	0.44	5.56e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg12573674	chr2:1569213	NA	-0.63	-7.44	-0.38	9.13e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.83	-14.62	-0.63	1.16e-37	Lewy body disease;
CRC	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-7.47	-0.38	7.2e-13	Coronary artery disease;
CRC	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg09029085	chr17:47094198	IGF2BP1	0.3	5.65	0.3	3.53e-8	Intelligence (multi-trait analysis);Body fat percentage;
CRC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	8.35	0.42	1.89e-15	Hemoglobin concentration;
CRC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	6.18	0.32	1.89e-9	Longevity;
CRC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg17633681	chr16:88106987	BANP	0.88	16.38	0.67	1.6e-44	Menopause (age at onset);
CRC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.66	10.92	0.52	6.78e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.18	-0.37	4.68e-12	Lymphocyte counts;
CRC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.66	-9.35	-0.46	1.44e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg16347377	chr7:143956670	OR2A7	-0.51	-5.93	-0.31	7.48e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07775675	chr17:74379922	SPHK1	0.44	6.33	0.33	8.19e-10	Response to antipsychotic treatment;
CRC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-5.89	-0.31	9.3e-9	Arsenic metabolism;
CRC	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-7.24	-0.37	3.13e-12	Subjective well-being;
CRC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.68	-0.39	1.78e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-7.21	-0.37	3.91e-12	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.61	-11.34	-0.53	2.15e-25	Leprosy;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg15786705	chr6:28176104	NA	0.72	9.34	0.46	1.52e-18	Parkinson's disease;
CRC	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-9.31	-0.46	1.83e-18	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.68	10.84	0.51	1.28e-23	Breast cancer;
CRC	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg14352298	chr13:112236639	NA	0.3	6.71	0.35	8.5e-11	Hepatitis;
CRC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	trans	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg21153622	chr11:89784906	NA	-0.48	-7.77	-0.39	1.03e-13	HDL cholesterol;
CRC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg25036284	chr2:26402008	FAM59B	0.53	6.16	0.32	2.1e-9	Gut microbiome composition (summer);
CRC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	6.39	0.33	5.61e-10	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.8	12.3	0.56	7.23e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.49	9.24	0.45	3.24e-18	Dupuytren's disease;
CRC	cis	rs3823572	0.542	rs28654576	chr7:133624445	A/G	cg03336402	chr7:133662267	EXOC4	0.67	10.27	0.49	1.25e-21	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.22	-0.37	3.66e-12	Bipolar disorder;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.47	-6.5	-0.34	2.97e-10	Menarche (age at onset);
CRC	cis	rs2257205	0.667	rs16943200	chr17:56829611	A/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.55	10.13	0.49	3.47e-21	Lung cancer;
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.44	-0.38	8.57e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7932354	0.583	rs6485692	chr11:46804583	G/C	cg19486271	chr11:47235900	DDB2	-0.43	-6.51	-0.34	2.78e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.42	5.79	0.3	1.64e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.63	0.34	1.41e-10	Dupuytren's disease;
CRC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.68	8.97	0.44	2.37e-17	Morning vs. evening chronotype;
CRC	cis	rs7680126	0.633	rs11729318	chr4:10336919	G/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.0	-0.31	5.27e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.43	6.54	0.34	2.4e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg06470822	chr6:28175283	NA	0.84	9.56	0.47	2.85e-19	Parkinson's disease;
CRC	cis	rs7731657	0.537	rs12332151	chr5:130344771	T/C	cg08523029	chr5:130500466	HINT1	-0.45	-5.77	-0.3	1.85e-8	Fasting plasma glucose;
CRC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.45	6.41	0.33	5.01e-10	Pulse pressure;
CRC	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.81	-13.21	-0.59	2.85e-32	Hypospadias;
CRC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.41	6.65	0.34	1.22e-10	Blood metabolite levels;
CRC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.18	-0.49	2.48e-21	Body mass index;
CRC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg00129232	chr17:37814104	STARD3	-0.44	-6.86	-0.35	3.37e-11	Self-reported allergy;
CRC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.21	-0.45	3.96e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg12560992	chr17:57184187	TRIM37	0.53	6.17	0.32	1.98e-9	Vitamin D levels;
CRC	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11783451	chr7:23637068	CCDC126	0.48	6.83	0.35	4.05e-11	Response to antipsychotic treatment;
CRC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.32	-5.64	-0.3	3.67e-8	Personality dimensions;
CRC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.31	-0.33	9.09e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.48	-0.38	6.75e-13	Retinal vascular caliber;
CRC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.52	-6.41	-0.33	4.98e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	7.33	0.37	1.75e-12	Mean corpuscular volume;
CRC	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.59	-8.01	-0.4	2e-14	Extraversion;
CRC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.54	-6.82	-0.35	4.25e-11	Diastolic blood pressure;
CRC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg04166393	chr7:2884313	GNA12	0.4	5.82	0.31	1.38e-8	Height;
CRC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.47	-7.25	-0.37	2.92e-12	Monocyte count;
CRC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.45	6.18	0.32	1.87e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.57	-0.5	1.14e-22	Bipolar disorder;
CRC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.53e-15	Height;
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.51	-7.23	-0.37	3.32e-12	Lymphocyte counts;
CRC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.02	0.32	4.65e-9	Heart rate;
CRC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.32	-0.33	8.44e-10	Aortic root size;
CRC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.66	-8.61	-0.43	3.04e-16	Bronchopulmonary dysplasia;
CRC	cis	rs3736485	0.966	rs7182977	chr15:51854130	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21643547	chr1:205240462	TMCC2	-0.42	-7.06	-0.36	1e-11	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs2211560	0.507	rs605320	chr1:61284339	A/G	cg21640187	chr6:4282172	NA	0.3	5.98	0.31	5.8e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CRC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.76	12.3	0.56	7.53e-29	Breast cancer;
CRC	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg16606324	chr3:10149918	C3orf24	0.63	8.19	0.41	5.81e-15	Alzheimer's disease;
CRC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg26805224	chr10:79626177	DLG5	-0.45	-6.89	-0.36	2.84e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg24375607	chr4:120327624	NA	0.5	7.49	0.38	6.34e-13	Corneal astigmatism;
CRC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-7.3	-0.37	2.2e-12	Morning vs. evening chronotype;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg15107132	chr11:63991130	FERMT3	0.45	7.51	0.38	5.7e-13	Platelet count;
CRC	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.53	8.11	0.41	1.04e-14	Fibrinogen levels;
CRC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.4	-6.04	-0.32	4.19e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs6662572	0.686	rs113117837	chr1:46278158	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.0	0.31	5.08e-9	Blood protein levels;
CRC	cis	rs7680126	0.633	rs4697743	chr4:10294833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.87	-0.31	1.05e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.85	-13.74	-0.6	2.97e-34	Gut microbiome composition (winter);
CRC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.79	-0.35	5.12e-11	Mean corpuscular volume;
CRC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg15145296	chr3:125709740	NA	-0.58	-6.91	-0.36	2.57e-11	Blood pressure (smoking interaction);
CRC	cis	rs7605827	0.930	rs11692624	chr2:15499127	C/T	cg19274914	chr2:15703543	NA	0.38	5.73	0.3	2.28e-8	Educational attainment (years of education);
CRC	trans	rs11581859	0.950	rs72730327	chr1:99392984	C/T	cg12183875	chr3:169587454	LRRC31	0.28	6.35	0.33	7.33e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.37	7.19e-12	Menopause (age at onset);
CRC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg14541582	chr5:601475	NA	-0.37	-7.17	-0.37	5.13e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg09877947	chr5:131593287	PDLIM4	0.47	8.69	0.43	1.75e-16	Breast cancer;
CRC	cis	rs12928939	0.723	rs28667298	chr16:71855134	T/G	cg03805757	chr16:71968109	PKD1L3	-0.53	-7.07	-0.36	9.19e-12	Post bronchodilator FEV1;
CRC	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.39	5.74	0.3	2.19e-8	Height;
CRC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.67	10.97	0.52	4.5e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.98	-0.31	5.7e-9	Height;
CRC	cis	rs4363385	0.667	rs73014331	chr1:152964533	A/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.37	-0.38	1.35e-12	Inflammatory skin disease;
CRC	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24249390	chr15:90295951	MESP1	-0.57	-8.8	-0.44	8.08e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12463550	chr7:65579703	CRCP	0.75	6.81	0.35	4.7e-11	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg02683197	chr6:28174875	NA	0.85	10.37	0.5	5.51e-22	Depression;
CRC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg04553112	chr3:125709451	NA	-0.54	-6.17	-0.32	1.97e-9	Blood pressure (smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00764560	chr22:42016991	XRCC6;PPPDE2	0.48	6.71	0.35	8.73e-11	Anxiety disorder;
CRC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.61	7.97	0.4	2.63e-14	Methadone dose in opioid dependence;
CRC	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.65	-10.05	-0.48	6.77e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2055729	0.710	rs112406488	chr8:9736362	T/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.23	0.32	1.46e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs79387448	0.808	rs77518775	chr2:103237642	T/C	cg00507830	chr2:103233733	NA	0.74	8.15	0.41	7.96e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.44	-5.93	-0.31	7.72e-9	Superior crus of antihelix expression;
CRC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.37	6.01	0.31	4.94e-9	Ulcerative colitis;
CRC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-6.87	-0.35	3.14e-11	Body mass index (adult);
CRC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	6.23	0.32	1.4e-9	Lung cancer;
CRC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg23298862	chr7:158159286	PTPRN2	0.38	5.98	0.31	5.8e-9	Calcium levels;
CRC	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.05e-14	Type 2 diabetes;
CRC	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.38	0.38	1.32e-12	Blood metabolite levels;
CRC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg02033258	chr5:131593261	PDLIM4	0.32	5.66	0.3	3.31e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11129343	chr17:27717641	TAOK1	0.46	6.47	0.34	3.6e-10	Response to antipsychotic treatment;
CRC	cis	rs8105895	0.935	rs4510150	chr19:22239669	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg14329157	chr2:228736135	WDR69	-0.47	-6.53	-0.34	2.48e-10	Blood pressure;
CRC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg19635926	chr16:89946313	TCF25	0.53	5.72	0.3	2.42e-8	Skin colour saturation;
CRC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg18612461	chr15:75251733	NA	0.38	5.82	0.31	1.38e-8	Breast cancer;
CRC	cis	rs747650	0.699	rs4237547	chr11:47236405	C/G	cg03339077	chr11:47165057	C11orf49	0.46	6.72	0.35	7.93e-11	Acne (severe);
CRC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.97	21.05	0.76	6.79e-63	Birth weight;
CRC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg02741985	chr17:80059408	CCDC57	0.44	7.28	0.37	2.55e-12	Life satisfaction;
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg21856205	chr7:94953877	PON1	0.44	6.55	0.34	2.2e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.44	-6.02	-0.31	4.71e-9	Type 2 diabetes;
CRC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.47	7.57	0.38	3.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.85	-0.44	5.38e-17	Coffee consumption (cups per day);
CRC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.27	-0.41	3.32e-15	Morning vs. evening chronotype;
CRC	trans	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg23262073	chr20:60523788	NA	-0.46	-7.24	-0.37	3.23e-12	Body mass index;
CRC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.72	-6.98	-0.36	1.68e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg11833968	chr6:79620685	NA	-0.35	-6.15	-0.32	2.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2882667	0.931	rs11955952	chr5:138329119	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-5.89	-0.31	9.6e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.48	7.18	0.37	4.78e-12	N-glycan levels;
CRC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.63	9.96	0.48	1.39e-20	Height;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.51	9.71	0.47	8.9e-20	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07156182	chr3:122513738	DIRC2;HSPBAP1	0.45	6.9	0.36	2.65e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg17133734	chr15:86042851	AKAP13	0.4	6.49	0.34	3.21e-10	Interstitial lung disease;
CRC	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.72	-0.3	2.44e-8	Height;
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.72	11.12	0.52	1.33e-24	Tonsillectomy;
CRC	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.39	5.8	0.3	1.55e-8	Growth-regulated protein alpha levels;
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.55	8.68	0.43	1.84e-16	Schizophrenia;
CRC	cis	rs1891275	0.515	rs1592051	chr10:93542186	A/G	cg07889827	chr10:93443413	NA	0.41	6.74	0.35	7.08e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg06462663	chr19:18546047	ISYNA1	0.5	7.39	0.38	1.26e-12	Breast cancer;
CRC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg16141378	chr3:129829833	LOC729375	0.47	6.99	0.36	1.57e-11	Neuroticism;
CRC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.82	11.24	0.53	4.86e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.67	-0.51	5.2e-23	Bipolar disorder;
CRC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg12193833	chr17:30244370	NA	-0.63	-7.96	-0.4	2.79e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.64	-0.34	1.29e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.5	-7.12	-0.37	6.71e-12	Aortic root size;
CRC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg04287289	chr16:89883240	FANCA	-0.39	-6.3	-0.33	9.57e-10	Vitiligo;
CRC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.68	-0.51	4.72e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.89	0.55	2.38e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.31	0.49	8.7e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg24644049	chr4:85504048	CDS1	0.82	6.87	0.35	3.16e-11	Skin colour saturation;
CRC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs41271951	0.512	rs114222784	chr1:151084781	C/T	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.72	-0.3	2.34e-8	Blood protein levels;
CRC	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.56	7.54	0.38	4.61e-13	Lung cancer;
CRC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.53	-8.78	-0.44	9e-17	Body mass index;
CRC	trans	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.23e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.53	-8.34	-0.42	2.04e-15	Corneal structure;
CRC	cis	rs2072510	0.569	rs7306086	chr12:96390502	T/C	cg15438951	chr12:96389694	HAL	-0.49	-5.92	-0.31	7.95e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs3540	0.960	rs8030390	chr15:90943471	C/T	cg22089800	chr15:90895588	ZNF774	0.5	7.69	0.39	1.74e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.48	4.84e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.53	9.48	0.46	5.15e-19	Blood metabolite ratios;
CRC	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg19338460	chr6:170058176	WDR27	-1.25	-10.26	-0.49	1.27e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs12699921	0.632	rs2723545	chr7:17859691	C/A	cg15753394	chr6:17282781	RBM24	-0.36	-6.01	-0.31	5.04e-9	Fibrinogen levels;
CRC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.19	-0.41	5.98e-15	Type 2 diabetes;
CRC	cis	rs4363385	0.747	rs3737867	chr1:152976474	A/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.14	-0.37	5.88e-12	Inflammatory skin disease;
CRC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.34	-5.94	-0.31	7.32e-9	Primary biliary cholangitis;
CRC	cis	rs10743315	0.778	rs9805106	chr12:19372357	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.63	-8.0	-0.4	2.18e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg18232548	chr7:50535776	DDC	0.45	5.97	0.31	6.32e-9	Malaria;
CRC	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg25190513	chr12:123201362	GPR109B	-0.49	-6.21	-0.32	1.57e-9	Adiponectin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11283154	chr5:55008216	SLC38A9	0.38	6.18	0.32	1.89e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.69	9.19	0.45	4.71e-18	Iron status biomarkers;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.75	11.11	0.52	1.49e-24	Menarche (age at onset);
CRC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg04539111	chr16:67997858	SLC12A4	-0.51	-5.91	-0.31	8.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.81	-13.95	-0.61	4.47e-35	Lewy body disease;
CRC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.2	-0.49	2.06e-21	Body mass index;
CRC	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg00042356	chr1:8021962	PARK7	0.63	7.23	0.37	3.39e-12	Inflammatory bowel disease;
CRC	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.65	-10.19	-0.49	2.24e-21	Cognitive test performance;
CRC	cis	rs78077440	0.866	rs78412068	chr5:40332809	T/G	cg09067459	chr5:40385259	NA	-0.54	-5.83	-0.31	1.3e-8	Multiple sclerosis;
CRC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg22777020	chr22:31556080	RNF185	-0.52	-6.04	-0.32	4.23e-9	Colorectal cancer;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg18479299	chr3:125709523	NA	-0.55	-6.53	-0.34	2.54e-10	Blood pressure (smoking interaction);
CRC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-11.71	-0.54	1.06e-26	Cognitive function;
CRC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg18678763	chr11:4115507	RRM1	-0.35	-5.67	-0.3	3.05e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg18876405	chr7:65276391	NA	0.44	6.12	0.32	2.67e-9	Aortic root size;
CRC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.37	-5.78	-0.3	1.73e-8	Mean corpuscular volume;
CRC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.3	6.01	0.31	4.83e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.89	20.76	0.75	9.08e-62	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.95	-15.0	-0.64	4.17e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.44	6.5	0.34	2.91e-10	Obesity-related traits;
CRC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.52	5.82	0.31	1.4e-8	Vitiligo;
CRC	cis	rs12024301	0.557	rs74720994	chr1:183607214	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.51	7.34	0.38	1.67e-12	Pancreatic cancer;
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg08200582	chr11:442649	ANO9	0.7	7.4	0.38	1.16e-12	Body mass index;
CRC	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg08729031	chr10:102416179	NA	-0.41	-7.16	-0.37	5.21e-12	Body mass index;
CRC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Educational attainment;
CRC	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg09873164	chr1:152488093	CRCT1	0.34	5.67	0.3	3.17e-8	Hair morphology;
CRC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg06987292	chr12:125626746	AACS	-0.36	-6.23	-0.33	1.4e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.89	-0.36	2.88e-11	IgG glycosylation;
CRC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg08222913	chr3:52553049	STAB1	0.36	6.82	0.35	4.36e-11	Bipolar disorder;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg24046110	chr8:143859143	LYNX1	-0.43	-6.67	-0.35	1.06e-10	Urinary tract infection frequency;
CRC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg05941027	chr17:61774174	LIMD2	0.36	6.57	0.34	2e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.49	6.58	0.34	1.87e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.56	-8.52	-0.43	5.7e-16	Colorectal cancer;
CRC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg03233332	chr7:66118400	NA	-0.45	-6.3	-0.33	9.52e-10	Aortic root size;
CRC	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.77	10.11	0.49	4.05e-21	Iron status biomarkers;
CRC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.57	9.23	0.45	3.48e-18	Blood metabolite levels;
CRC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	6.72	0.35	7.84e-11	HIV-1 control;
CRC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.3	0.69	3.94e-48	Platelet count;
CRC	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.7	7.63	0.39	2.58e-13	Breast cancer;
CRC	cis	rs3823572	0.564	rs2953619	chr7:133669649	C/G	cg03336402	chr7:133662267	EXOC4	-0.69	-10.56	-0.5	1.19e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.57	9.3	0.46	1.99e-18	Mean corpuscular volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02914497	chr6:37787052	ZFAND3	0.48	6.34	0.33	7.66e-10	Anxiety disorder;
CRC	cis	rs11212617	0.934	rs609557	chr11:108084513	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.27	0.33	1.11e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs11874381	1.000	rs35337492	chr18:47210824	G/A	cg03239335	chr2:3418641	TTC15	-0.41	-5.97	-0.31	6.24e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
CRC	cis	rs9513593	1.000	rs7325957	chr13:99965155	C/T	cg21788972	chr13:99853209	UBAC2	-0.42	-5.61	-0.3	4.38e-8	Psoriasis;
CRC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.95	-0.31	7e-9	Type 2 diabetes;
CRC	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.63e-17	Dupuytren's disease;
CRC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg03160526	chr17:80928410	B3GNTL1	0.5	8.3	0.42	2.64e-15	Breast cancer;
CRC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.65	-8.03	-0.4	1.74e-14	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.54	-7.38	-0.38	1.3e-12	DNA methylation (variation);
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-8.98	-0.44	2.07e-17	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs524281	0.731	rs3814744	chr11:65809763	C/T	cg16950941	chr11:66035639	RAB1B	-0.52	-5.77	-0.3	1.81e-8	Electroencephalogram traits;
CRC	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.84	0.51	1.24e-23	Coffee consumption (cups per day);
CRC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.55	5.95	0.31	6.71e-9	Schizophrenia;
CRC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-7.54	-0.38	4.73e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.46	6.1	0.32	3.03e-9	Thyroid stimulating hormone;
CRC	cis	rs7605827	0.930	rs7605077	chr2:15546240	C/A	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	8.58	0.43	3.88e-16	Lymphocyte counts;
CRC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.23	-0.32	1.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg22677401	chr17:46026860	NA	-0.68	-6.15	-0.32	2.24e-9	Cognitive function;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02290350	chr8:58132656	NA	-0.51	-6.39	-0.33	5.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.06	0.32	3.82e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.91	15.44	0.65	7.91e-41	IgG glycosylation;
CRC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.47	5.9	0.31	9.21e-9	Aortic root size;
CRC	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.89e-8	Prostate cancer;
CRC	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg14844989	chr11:31128820	NA	0.33	5.86	0.31	1.14e-8	Red blood cell count;
CRC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.58	-0.63	1.79e-37	Gout;
CRC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg18827107	chr12:86230957	RASSF9	0.39	5.98	0.31	5.76e-9	Major depressive disorder;
CRC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.47	-7.37	-0.38	1.41e-12	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03490839	chr16:73082051	ZFHX3	0.4	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg02421172	chr7:1938701	MAD1L1	0.48	6.46	0.34	3.82e-10	Bipolar disorder;
CRC	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.48	0.46	5.18e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2294693	0.891	rs9381024	chr6:40984262	A/C	cg14769373	chr6:40998127	UNC5CL	0.47	5.87	0.31	1.07e-8	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.16e-9	Pneumonia;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg02416716	chr11:6948024	ZNF215	0.58	5.93	0.31	7.58e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.77	10.83	0.51	1.37e-23	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.39	0.46	1.02e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7224610	0.932	rs10852974	chr17:53372566	G/C	cg02383154	chr17:53343283	HLF	-0.34	-5.62	-0.3	4.04e-8	Urate levels;
CRC	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.75	-10.04	-0.48	7.14e-21	Coronary artery disease;
CRC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.58	-6.2	-0.32	1.65e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.4	-7.77	-0.39	1.03e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.52	5.6	0.3	4.46e-8	Vitiligo;
CRC	cis	rs6838801	1.000	rs7694630	chr4:77556983	C/T	cg17476223	chr4:77663285	SHROOM3	0.42	5.74	0.3	2.19e-8	Cleft lip with or without cleft palate;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg22638593	chr5:131593259	PDLIM4	0.39	6.36	0.33	6.76e-10	Breast cancer;
CRC	cis	rs728616	0.867	rs61859763	chr10:81671615	A/T	cg11900509	chr10:81946545	ANXA11	-0.64	-6.52	-0.34	2.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.81	9.85	0.48	3.21e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg02683197	chr6:28174875	NA	0.81	9.98	0.48	1.15e-20	Depression;
CRC	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.44	-6.41	-0.33	5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12172441	chr6:28176163	NA	0.55	6.96	0.36	1.83e-11	Parkinson's disease;
CRC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg18230493	chr5:56204884	C5orf35	0.59	8.82	0.44	7.05e-17	Initial pursuit acceleration;
CRC	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.83	-13.64	-0.6	7.14e-34	Hypospadias;
CRC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.36	-7.55	-0.38	4.45e-13	Cutaneous nevi;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13789711	chr9:139743225	PHPT1	0.44	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05966498	chr5:10761293	DAP	-0.45	-6.71	-0.35	8.57e-11	Myopia (pathological);
CRC	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.55	8.01	0.4	1.98e-14	Alzheimer's disease biomarkers;
CRC	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg12856521	chr11:46389249	DGKZ	0.63	9.38	0.46	1.1e-18	Crohn's disease;
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg03160526	chr17:80928410	B3GNTL1	0.57	7.68	0.39	1.79e-13	Glycated hemoglobin levels;
CRC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.46	8.06	0.41	1.44e-14	Bipolar disorder;
CRC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.51	-0.38	5.61e-13	Blood metabolite levels;
CRC	cis	rs6604026	0.630	rs56193705	chr1:93455887	C/G	cg17283838	chr1:93427260	FAM69A	0.46	5.97	0.31	6.21e-9	Multiple sclerosis;
CRC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg11271282	chr2:238384023	NA	-0.46	-5.79	-0.3	1.63e-8	Prostate cancer;
CRC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.64	10.21	0.49	1.95e-21	Height;
CRC	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg05784532	chr1:230284198	GALNT2	0.45	6.21	0.32	1.57e-9	Coronary artery disease;
CRC	cis	rs7899719	1.000	rs10458641	chr10:77406954	C/T	cg24369728	chr10:77472158	NA	0.4	6.65	0.34	1.2e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
CRC	cis	rs7113874	0.531	rs7934396	chr11:8615632	C/G	cg20771178	chr11:8615675	STK33	0.35	5.79	0.3	1.67e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.49	7.55	0.38	4.23e-13	Red blood cell count;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg05722611	chr22:51001334	C22orf41	-0.65	-6.01	-0.31	4.97e-9	Cognitive function;
CRC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg09491104	chr22:46646882	C22orf40	-0.42	-6.21	-0.32	1.62e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.42	0.33	4.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.27	-0.37	2.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	12.04	0.55	6.53e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.51	7.74	0.39	1.24e-13	Pulmonary function decline;
CRC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	1.0	15.15	0.64	1.09e-39	Monocyte percentage of white cells;
CRC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.13	0.49	3.68e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.65	-0.3	3.47e-8	Major depressive disorder;
CRC	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.73	0.35	7.64e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.48	7.29	0.37	2.35e-12	Testicular germ cell tumor;
CRC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	1.17	10.93	0.52	6.24e-24	Arsenic metabolism;
CRC	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg14139581	chr11:64358342	SLC22A12	0.38	6.08	0.32	3.35e-9	Urate levels in obese individuals;
CRC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.11	-0.32	2.8e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg23463467	chr20:60627584	TAF4	0.39	7.87	0.4	5.19e-14	Body mass index;
CRC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.55	6.2	0.32	1.69e-9	Bipolar disorder;
CRC	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.6	8.47	0.42	8.01e-16	DNA methylation (variation);
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.52	7.13	0.37	6.58e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4604732	0.685	rs4925673	chr1:247636800	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.77	0.35	5.75e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6496667	0.779	rs8033897	chr15:90947842	T/G	cg04176472	chr15:90893244	GABARAPL3	0.61	7.96	0.4	2.9e-14	Rheumatoid arthritis;
CRC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.6	9.53	0.47	3.52e-19	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.5	6.42	0.33	4.71e-10	Thyroid stimulating hormone;
CRC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs6694672	0.867	rs2786114	chr1:197302717	T/C	cg13682187	chr1:196946512	CFHR5	0.45	5.96	0.31	6.61e-9	Asthma;
CRC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.38	5.68	0.3	2.99e-8	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.59	-8.26	-0.41	3.7e-15	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.32	0.37	1.92e-12	Breast cancer;
CRC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg15147215	chr3:52552868	STAB1	0.5	8.75	0.43	1.14e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	6.99	0.36	1.58e-11	Obesity-related traits;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg12172441	chr6:28176163	NA	0.54	7.32	0.37	1.87e-12	Parkinson's disease;
CRC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.85	-0.4	5.95e-14	Morning vs. evening chronotype;
CRC	trans	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg17712092	chr4:129076599	LARP1B	0.51	6.77	0.35	5.8200000000000003e-11	DNA methylation (variation);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16782848	chr15:83479213	WHAMM	0.41	7.09	0.36	8.34e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311676	0.632	rs11705721	chr3:58400414	T/C	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.59	7.89	0.4	4.67e-14	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18440893	chr6:16760537	ATXN1	-0.4	-6.13	-0.32	2.47e-9	Myopia (pathological);
CRC	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.18e-18	Blood protein levels;
CRC	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.84	-0.35	3.84e-11	Height;
CRC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.4	6.29	0.33	1.04e-9	Dupuytren's disease;
CRC	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.66	8.67	0.43	2.01e-16	Hypospadias;
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.68	9.86	0.48	2.89e-20	Menarche (age at onset);
CRC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.45	-0.62	5.56e-37	Body mass index;
CRC	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs7617773	1.000	rs6771889	chr3:48194326	C/T	cg11946769	chr3:48343235	NME6	-0.51	-6.85	-0.35	3.73e-11	Coronary artery disease;
CRC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-10.23	-0.49	1.7e-21	Height;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.37	6.44	0.33	4.15e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.48	-8.26	-0.41	3.66e-15	Hypertriglyceridemia;
CRC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg20811857	chr17:78079795	GAA	-0.46	-6.69	-0.35	9.75e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.6	7.59	0.39	3.33e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg10820045	chr2:198174542	NA	0.4	6.81	0.35	4.64e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.09	-15.06	-0.64	2.3e-39	Exhaled nitric oxide output;
CRC	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.48	-0.38	6.93e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13198984	chr17:80129470	CCDC57	0.47	8.46	0.42	8.84e-16	Life satisfaction;
CRC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13606994	chr1:44402422	ARTN	-0.34	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4737010	0.959	rs4737009	chr8:41630405	A/G	cg17182837	chr8:41585554	ANK1	-0.48	-6.58	-0.34	1.87e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.33	1.26e-9	Heart rate;
CRC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.35e-14	Colorectal cancer;
CRC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg24977027	chr2:88469347	THNSL2	0.63	7.75	0.39	1.14e-13	Plasma clusterin levels;
CRC	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	16.19	0.67	8.83e-44	Colorectal cancer;
CRC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg17321639	chr7:2759063	NA	-0.51	-6.79	-0.35	5.35e-11	Height;
CRC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.52	8.08	0.41	1.27e-14	Colorectal cancer;
CRC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.53	-6.92	-0.36	2.35e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.81	-11.04	-0.52	2.48e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.07e-11	Common traits (Other);
CRC	cis	rs1256061	0.669	rs1256065	chr14:64698932	G/T	cg23250157	chr14:64679961	SYNE2	0.44	6.76	0.35	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.3	-0.49	9.61e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.72	11.55	0.54	3.87e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.52	8.1	0.41	1.05e-14	Corneal astigmatism;
CRC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg18478394	chr8:109455254	TTC35	0.38	5.8	0.3	1.55e-8	Dupuytren's disease;
CRC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg15448220	chr1:150897856	SETDB1	0.48	6.87	0.35	3.21e-11	Tonsillectomy;
CRC	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg18404041	chr3:52824283	ITIH1	-0.34	-6.05	-0.32	3.95e-9	Schizophrenia;
CRC	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	7.23	0.37	3.44e-12	Response to antipsychotic treatment;
CRC	cis	rs1887596	0.705	rs1087258	chr13:27200006	T/C	cg01312412	chr13:27282625	NA	0.43	5.81	0.31	1.44e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-6.42	-0.33	4.8e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs972578	0.837	rs2073199	chr22:43275250	G/A	cg01576275	chr22:43409880	NA	-0.41	-6.48	-0.34	3.44e-10	Mean platelet volume;
CRC	cis	rs12144094	0.766	rs74984954	chr1:120234068	G/A	cg20995928	chr1:120229863	NA	0.49	6.98	0.36	1.59e-11	Height;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-8.97	-0.44	2.31e-17	Bipolar disorder;
CRC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.51	8.22	0.41	4.66e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.65	-9.72	-0.47	8.32e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11226613	0.547	rs3913640	chr11:104988630	T/A	cg04181079	chr11:104896587	CASP1	0.41	5.62	0.3	4.17e-8	Bronchopulmonary dysplasia;
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.41	-0.33	5.16e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.24	11.54	0.54	4.15e-26	Alzheimer's disease (late onset);
CRC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07701084	chr6:150067640	NUP43	0.49	7.17	0.37	4.95e-12	Testicular germ cell tumor;
CRC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg02549819	chr16:58548995	SETD6	1.13	7.37	0.38	1.43e-12	Schizophrenia;
CRC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	13.66	0.6	5.74e-34	Chronic sinus infection;
CRC	cis	rs1519814	1.000	rs12678023	chr8:121123494	G/A	cg22335954	chr8:121166405	COL14A1	-0.49	-6.1	-0.32	3.06e-9	Breast cancer;
CRC	cis	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg06988349	chr10:69991859	ATOH7	-0.36	-6.31	-0.33	8.93e-10	Optic disc area;
CRC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.65	-10.01	-0.48	9.17e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.72	8.27	0.41	3.42e-15	Educational attainment;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23708337	chr7:1209742	NA	0.51	7.97	0.4	2.57e-14	Longevity;Endometriosis;
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg23627948	chr7:2760692	NA	0.47	5.64	0.3	3.75e-8	Childhood ear infection;
CRC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg20203395	chr5:56204925	C5orf35	-0.69	-8.24	-0.41	4.08e-15	Initial pursuit acceleration;
CRC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-5.72	-0.3	2.37e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.63	9.72	0.47	8.33e-20	Corneal astigmatism;
CRC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.61	8.15	0.41	7.69e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg01788221	chr16:89496183	ANKRD11	-0.4	-6.02	-0.31	4.66e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg25834613	chr7:1915315	MAD1L1	0.41	6.03	0.32	4.38e-9	Bipolar disorder;
CRC	cis	rs2745967	0.755	rs2724368	chr1:208072697	G/A	cg09788693	chr1:208063733	CD34	0.42	6.43	0.33	4.41e-10	Resting heart rate;
CRC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.37	-0.33	6.41e-10	Lung cancer;
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02807482	chr3:125708958	NA	-0.46	-5.76	-0.3	1.95e-8	Blood pressure (smoking interaction);
CRC	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.59	-8.81	-0.44	7.5e-17	Primary sclerosing cholangitis;
CRC	cis	rs11212617	1.000	rs600931	chr11:108117335	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.34	0.33	7.78e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	8.16	0.41	6.94e-15	Monocyte count;
CRC	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.53	7.7	0.39	1.63e-13	Menopause (age at onset);
CRC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-9.64	-0.47	1.61e-19	Personality dimensions;
CRC	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg16964102	chr10:135390573	NA	-0.48	-6.54	-0.34	2.41e-10	Gout;
CRC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg03469862	chr11:68924853	NA	-0.37	-5.71	-0.3	2.51e-8	Blond vs. brown hair color;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg07617317	chr6:118971624	C6orf204	0.5	6.25	0.33	1.25e-9	Diastolic blood pressure;
CRC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg23205692	chr1:25664452	TMEM50A	0.41	5.79	0.3	1.68e-8	Erythrocyte sedimentation rate;
CRC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.74	-0.35	6.94e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.61	0.47	1.92e-19	Cognitive test performance;
CRC	trans	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg16355469	chr20:37678765	NA	0.46	5.62	0.3	4.01e-8	Alcohol and nicotine co-dependence;
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg22687807	chr8:143858763	LYNX1	-0.39	-6.8	-0.35	5e-11	Urinary tract infection frequency;
CRC	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg02158880	chr13:53174818	NA	0.39	5.6	0.3	4.51e-8	Lewy body disease;
CRC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.47	6.79	0.35	5.13e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.75	-0.43	1.1e-16	Hemoglobin concentration;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16669491	chr19:19314215	NR2C2AP	0.45	6.36	0.33	6.74e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg23234261	chr14:55582407	NA	-0.29	-5.65	-0.3	3.54e-8	Protein biomarker;
CRC	cis	rs970548	1.000	rs10900224	chr10:46024534	C/T	cg15590007	chr10:45870220	ALOX5	0.5	6.43	0.33	4.5e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-6.47	-0.34	3.56e-10	Platelet distribution width;
CRC	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg16898833	chr6:26189333	HIST1H4D	0.67	5.91	0.31	8.41e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.77	13.18	0.59	3.72e-32	Colorectal cancer;
CRC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.57	-9.15	-0.45	6.22e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.8	14.23	0.62	3.95e-36	Breast cancer;
CRC	cis	rs2398893	0.889	rs7872984	chr9:96782447	T/C	cg14459158	chr9:96720562	NA	0.41	6.81	0.35	4.57e-11	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.6	9.62	0.47	1.81e-19	Blood protein levels;
CRC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg05044414	chr3:183734942	ABCC5	0.4	7.02	0.36	1.3e-11	Anterior chamber depth;
CRC	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.49	-7.17	-0.37	4.98e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg16060761	chr17:80687452	NA	-0.47	-6.8	-0.35	4.99e-11	Breast cancer;
CRC	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.54	8.47	0.42	8.49e-16	HDL cholesterol;
CRC	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.58	-0.39	3.67e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.97	0.55	1.17e-27	Alzheimer's disease;
CRC	cis	rs2735413	0.875	rs12924402	chr16:78083477	C/G	cg04733911	chr16:78082701	NA	-0.46	-7.58	-0.39	3.54e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg04545296	chr12:48745243	ZNF641	-0.36	-6.16	-0.32	2.15e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.44	-5.94	-0.31	7.2e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg17724175	chr1:150552817	MCL1	0.49	7.25	0.37	2.95e-12	Melanoma;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03923535	chr7:1197113	ZFAND2A	0.71	10.63	0.51	7.07e-23	Longevity;Endometriosis;
CRC	cis	rs243505	0.898	rs243535	chr7:148410123	A/C	cg09806900	chr7:148480153	CUL1	-0.43	-6.01	-0.31	4.84e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.39	-6.51	-0.34	2.74e-10	Breast cancer;
CRC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.42	5.96	0.31	6.5e-9	Aortic root size;
CRC	cis	rs12745968	0.532	rs4970704	chr1:92971702	T/A	cg17283838	chr1:93427260	FAM69A	-0.48	-6.52	-0.34	2.72e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.86	-12.44	-0.57	2.22e-29	Platelet distribution width;
CRC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.55	7.4	0.38	1.18e-12	Menopause (age at onset);
CRC	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.54	-8.62	-0.43	2.86e-16	Corneal astigmatism;
CRC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.55	7.27	0.37	2.63e-12	Monocyte percentage of white cells;
CRC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg14324370	chr2:177042789	NA	-0.69	-9.35	-0.46	1.34e-18	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.89	0.36	2.92e-11	Neuroticism;
CRC	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	9.03e-40	Colorectal cancer;
CRC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg17294928	chr15:75287854	SCAMP5	0.52	8.06	0.41	1.43e-14	Breast cancer;
CRC	cis	rs4731207	0.698	rs12154816	chr7:124478299	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14036097	chr4:190862158	FRG1	0.36	6.02	0.31	4.63e-9	Obesity-related traits;
CRC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.15	0.45	6.28e-18	Alzheimer's disease (late onset);
CRC	cis	rs6694672	1.000	rs9427660	chr1:196946420	T/A	cg13682187	chr1:196946512	CFHR5	-0.5	-7.97	-0.4	2.59e-14	Asthma;
CRC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg16476235	chr8:21771668	DOK2	0.38	6.53	0.34	2.48e-10	Mean corpuscular volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg09071838	chr13:25497213	CENPJ	0.42	6.72	0.35	8.1e-11	Obesity-related traits;
CRC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.74	10.36	0.5	5.72e-22	Chronic sinus infection;
CRC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.77	-11.43	-0.53	1.1e-25	Mean platelet volume;Platelet distribution width;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19195327	chr1:6479725	HES2	-0.41	-6.81	-0.35	4.62e-11	Aortic root size;
CRC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.78	11.11	0.52	1.48e-24	Neutrophil percentage of white cells;
CRC	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-6.11	-0.32	2.77e-9	Educational attainment;
CRC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-5.63	-0.3	3.83e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.53	0.47	3.61e-19	Menopause (age at onset);
CRC	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.43	0.38	9.57e-13	Eye color traits;
CRC	cis	rs12541635	1.000	rs4734897	chr8:107075518	G/A	cg10147462	chr8:107024639	NA	-0.38	-6.41	-0.33	5.1e-10	Age of smoking initiation;
CRC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.81	0.44	7.43e-17	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs10242455	0.702	rs28460612	chr7:98993205	C/G	cg18809830	chr7:99032528	PTCD1	-1.11	-7.93	-0.4	3.46e-14	Blood metabolite levels;
CRC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.76	-0.35	6.25e-11	Alzheimer's disease (late onset);
CRC	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.73	-11.65	-0.54	1.69e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.38	-5.94	-0.31	7.19e-9	High light scatter reticulocyte count;
CRC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.16	-0.32	2.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg26176469	chr17:28951361	LRRC37B2	0.56	6.11	0.32	2.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7605827	0.866	rs9710889	chr2:15533779	G/A	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.09e-8	Educational attainment (years of education);
CRC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.51	7.93	0.4	3.37e-14	Tonsillectomy;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.1	-0.32	2.98e-9	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22416137	chr6:52930106	FBXO9	0.46	6.03	0.32	4.46e-9	Anxiety disorder;
CRC	cis	rs2882667	0.898	rs11952020	chr5:138395156	A/T	cg09476006	chr5:138032270	NA	0.45	7.67	0.39	1.99e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs11229555	0.574	rs11603800	chr11:58202085	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00370926	chr17:7835519	TRAPPC1;CNTROB	0.41	7.02	0.36	1.3e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.03	-14.7	-0.63	6.17e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.25	0.45	2.97e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.59	-7.34	-0.38	1.71e-12	Ulcerative colitis;
CRC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.83	0.44	6.16e-17	Schizophrenia;
CRC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.48	7.64	0.39	2.38e-13	Prostate cancer;
CRC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.16	-0.37	5.17e-12	Gut microbiome composition (summer);
CRC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.75	-11.91	-0.55	1.91e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs12760731	0.623	rs12045201	chr1:178399218	A/G	cg00404053	chr1:178313656	RASAL2	0.69	8.27	0.41	3.3e-15	Obesity-related traits;
CRC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.48	-9.49	-0.46	4.92e-19	Renal cell carcinoma;
CRC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg13777783	chr17:79615861	NA	-0.31	-5.73	-0.3	2.27e-8	Eye color traits;
CRC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.62	0.39	2.72e-13	Motion sickness;
CRC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg18827107	chr12:86230957	RASSF9	-0.39	-5.99	-0.31	5.37e-9	Major depressive disorder;
CRC	cis	rs3741151	0.686	rs7935948	chr11:73219118	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.55	-6.18	-0.32	1.86e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14196303	chr9:6757347	KDM4C	0.45	6.27	0.33	1.12e-9	Response to antipsychotic treatment;
CRC	cis	rs12580194	0.593	rs56677471	chr12:55749967	T/A	cg19537932	chr12:55886519	OR6C68	-0.69	-8.95	-0.44	2.63e-17	Cancer;
CRC	trans	rs75246769	0.706	rs76040643	chr7:145679110	A/C	cg14916917	chr5:81574294	RPS23	0.91	6.28	0.33	1.09e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-7.2	-0.37	4.19e-12	Coronary artery disease;
CRC	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.51	-8.1	-0.41	1.11e-14	Corneal astigmatism;
CRC	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.68	9.94	0.48	1.57e-20	Inflammatory bowel disease;
CRC	trans	rs10411161	0.810	rs77458785	chr19:52384295	T/G	cg22319618	chr22:45562946	NUP50	-0.69	-6.01	-0.31	4.9e-9	Breast cancer;
CRC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.54	7.81	0.4	7.96e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.85	-0.51	1.16e-23	Alzheimer's disease;
CRC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.39	5.89	0.31	9.49e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	13.12	0.59	6.59e-32	Bone mineral density;
CRC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.49	7.63	0.39	2.5e-13	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15790941	chr4:39640517	C4orf34	0.37	6.08	0.32	3.34e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.61	9.36	0.46	1.3e-18	Corneal astigmatism;
CRC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.4	0.53	1.38e-25	Prudent dietary pattern;
CRC	cis	rs524281	0.773	rs2155198	chr11:66014300	C/T	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.01	-0.55	8.3e-28	Bipolar disorder and schizophrenia;
CRC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.66	-0.43	2.18e-16	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3751196	0.901	rs12422418	chr12:104202160	C/T	cg02344784	chr12:104178138	NT5DC3	0.69	7.05	0.36	1.06e-11	Sense of smell;
CRC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-12.17	-0.56	2.17e-28	Cognitive function;
CRC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.83	-14.01	-0.61	2.7900000000000003e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg13390004	chr1:15929781	NA	0.49	6.79	0.35	5.28e-11	Systolic blood pressure;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg15845792	chr6:28175446	NA	1.02	14.65	0.63	8.95e-38	Depression;
CRC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24308560	chr3:49941425	MST1R	-0.47	-7.44	-0.38	9e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3018066	0.867	rs13121614	chr4:107166246	G/A	cg01869342	chr4:106983673	TBCK	-0.36	-5.66	-0.3	3.37e-8	Cancer;
CRC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.58	0.5	1.02e-22	Platelet count;
CRC	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg16606324	chr3:10149918	C3orf24	0.49	7.24	0.37	3.24e-12	Alzheimer's disease;
CRC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.88	0.44	4.54e-17	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.3	-0.37	2.17e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.53	-8.27	-0.41	3.39e-15	Corneal astigmatism;
CRC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.41	5.74	0.3	2.15e-8	Cognitive function;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg06470822	chr6:28175283	NA	0.59	6.9	0.36	2.61e-11	Breast cancer;
CRC	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs6840360	0.642	rs1443088	chr4:152450126	G/A	cg09659197	chr4:152720779	NA	0.33	6.49	0.34	3.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg24046110	chr8:143859143	LYNX1	-0.37	-6.32	-0.33	8.7e-10	Urinary tract infection frequency;
CRC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.35	5.63	0.3	3.86e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.19	0.59	3.46e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs185694	1.000	rs846498	chr13:30900541	A/G	cg07600127	chr13:30881527	KATNAL1	-0.57	-6.05	-0.32	4.01e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg25985355	chr7:65971099	NA	0.32	5.71	0.3	2.54e-8	Aortic root size;
CRC	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.53	7.06	0.36	9.78e-12	Anxiety disorder;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg20744362	chr22:50050164	C22orf34	0.35	6.4	0.33	5.29e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.63	-10.34	-0.5	6.76e-22	Motion sickness;
CRC	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.51	9.63	0.47	1.66e-19	Total body bone mineral density;
CRC	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.5	7.96	0.4	2.75e-14	Migraine;
CRC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.68	8.97	0.44	2.32e-17	Bronchopulmonary dysplasia;
CRC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.8	-0.55	5e-27	Type 2 diabetes;
CRC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.02	-0.36	1.27e-11	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2303319	0.504	rs55841284	chr2:162560011	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.45	-0.34	4.07e-10	Cognitive function;
CRC	cis	rs4936891	0.557	rs470242	chr11:123909342	G/A	cg22125253	chr11:123886957	OR10G4	-0.34	-6.03	-0.32	4.33e-9	Male fertility;
CRC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.82	-14.76	-0.63	3.49e-38	Breast cancer;
CRC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.09	0.49	4.78e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12172441	chr6:28176163	NA	0.57	7.0	0.36	1.49e-11	Parkinson's disease;
CRC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs7626444	0.625	rs843540	chr3:196475313	C/A	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.74e-12	Monocyte count;
CRC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.55	-8.9	-0.44	3.96e-17	Pulse pressure;
CRC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.62	-8.86	-0.44	5.28e-17	Obesity-related traits;
CRC	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.41	8.84	0.44	5.95e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.59	-9.45	-0.46	6.41e-19	Aortic root size;
CRC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.59	-8.97	-0.44	2.36e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-6.13	-0.32	2.56e-9	Diabetic retinopathy;
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.31	0.46	1.89e-18	Fuchs's corneal dystrophy;
CRC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.67	-12.22	-0.56	1.45e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.43	6.86	0.35	3.48e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.54	8.78	0.44	9.02e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.55	9.84	0.48	3.27e-20	Lung cancer;
CRC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-6.73	-0.35	7.56e-11	Schizophrenia;
CRC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.64	-9.98	-0.48	1.12e-20	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.97	-21.04	-0.76	7.01e-63	Birth weight;
CRC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.56	10.33	0.5	7.26e-22	HDL cholesterol levels;
CRC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.81	-13.4	-0.59	5.66e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.8	13.49	0.6	2.61e-33	Menopause (age at onset);
CRC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.43	-0.38	9.59e-13	Reticulocyte fraction of red cells;
CRC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.32	0.46	1.79e-18	Bladder cancer;
CRC	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	1.24	10.84	0.51	1.26e-23	Arsenic metabolism;
CRC	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-7.57	-0.39	3.74e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg03315344	chr16:75512273	CHST6	-0.51	-5.9	-0.31	9.27e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.53	8.02	0.4	1.81e-14	Lymphocyte counts;
CRC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg08260959	chr6:26240920	HIST1H4F	-0.37	-6.03	-0.32	4.35e-9	Gout;Renal underexcretion gout;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.09	0.32	3.24e-9	Cardiac Troponin-T levels;
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.45	0.53	8.88e-26	Alzheimer's disease;
CRC	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.42	-6.3	-0.33	9.8e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs3812762	0.871	rs3862352	chr11:8818020	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.4	-6.38	-0.33	6.03e-10	Hypospadias;
CRC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg09179987	chr1:167433047	CD247	0.47	7.45	0.38	8.41e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14014525	chr17:42148052	G6PC3	0.49	6.28	0.33	1.05e-9	Thyroid stimulating hormone;
CRC	cis	rs501120	0.636	rs3123689	chr10:44773121	G/A	cg09554077	chr10:44749378	NA	0.78	11.91	0.55	1.96e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.44	6.7	0.35	9.02e-11	Intelligence (multi-trait analysis);
CRC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	0.97	8.98	0.44	2.1e-17	Lymphocyte counts;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg09344028	chr17:70110421	NA	0.49	7.33	0.37	1.75e-12	Thyroid hormone levels;
CRC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.93	0.52	6.22e-24	Systolic blood pressure;
CRC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	8.39	0.42	1.45e-15	Height;
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.43	6.48	0.34	3.28e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.65	-10.66	-0.51	5.47e-23	Type 2 diabetes;
CRC	cis	rs9283706	0.594	rs7735834	chr5:66337444	A/G	cg11590213	chr5:66331682	MAST4	-0.41	-5.84	-0.31	1.28e-8	Coronary artery disease;
CRC	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12560992	chr17:57184187	TRIM37	0.53	7.27	0.37	2.57e-12	Testicular germ cell tumor;
CRC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.38	-7.78	-0.39	9.62e-14	Arsenic metabolism;
CRC	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.81	8.55	0.43	4.61e-16	Gastritis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07788451	chr12:58146524	CDK4	0.48	6.27	0.33	1.13e-9	Thyroid stimulating hormone;
CRC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.52	11.47	0.53	7.56e-26	Alcohol dependence;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.83e-9	Life satisfaction;
CRC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs524281	0.861	rs9645684	chr11:65907964	G/A	cg16950941	chr11:66035639	RAB1B	-0.61	-7.5	-0.38	5.99e-13	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01410469	chr8:82692895	NA	0.5	6.37	0.33	6.4e-10	Thyroid stimulating hormone;
CRC	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.5	7.08	0.36	9.03e-12	AIDS;
CRC	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.43	-6.05	-0.32	3.9e-9	Colorectal cancer;
CRC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.05	-0.71	4.24e-51	Height;
CRC	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg05784532	chr1:230284198	GALNT2	0.42	5.86	0.31	1.15e-8	Coronary artery disease;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg03534058	chr9:99381359	CDC14B	-0.46	-6.1	-0.32	2.95e-9	Parkinson's disease;
CRC	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.19	0.67	9.15e-44	Electrocardiographic conduction measures;
CRC	trans	rs62295889	0.602	rs62295919	chr4:12537080	G/A	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	0.93	10.03	0.48	7.54e-21	Atopic dermatitis;
CRC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg03929089	chr4:120376271	NA	-0.56	-7.15	-0.37	5.78e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.69	13.77	0.6	2.19e-34	Coronary artery disease;
CRC	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.64	8.17	0.41	6.93e-15	Iron status biomarkers;
CRC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg22903471	chr2:27725779	GCKR	-0.34	-5.63	-0.3	3.91e-8	Oral cavity cancer;
CRC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.96e-18	Lymphocyte counts;
CRC	cis	rs185694	1.000	rs202098	chr13:30896774	G/T	cg07600127	chr13:30881527	KATNAL1	-0.57	-6.14	-0.32	2.38e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.58	-8.22	-0.41	4.71e-15	Platelet distribution width;
CRC	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.66e-9	Corneal astigmatism;
CRC	cis	rs9463078	0.739	rs1041333	chr6:44945206	A/T	cg25276700	chr6:44698697	NA	-0.29	-7.14	-0.37	6.17e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4074493	1.000	rs4074493	chr1:231172281	C/T	cg22172038	chr1:231176991	FAM89A	0.35	6.11	0.32	2.88e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20135002	chr11:47629003	NA	0.34	5.72	0.3	2.37e-8	Subjective well-being;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg25483003	chr9:139948856	ENTPD2	0.31	6.07	0.32	3.61e-9	Menarche (age at onset);
CRC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.25	-5.88	-0.31	1e-8	Psoriasis;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Depression;
CRC	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg24910161	chr17:38119198	GSDMA	0.35	5.72	0.3	2.44e-8	Myeloid white cell count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00287370	chr1:234736092	NA	0.41	6.45	0.34	3.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg10862848	chr6:42927986	GNMT	-0.29	-6.05	-0.32	3.92e-9	Blood protein levels;
CRC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.65	-10.1	-0.49	4.44e-21	Coronary artery disease;
CRC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.92	-0.31	8.25e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.47	5.77	0.3	1.84e-8	Parkinson's disease;
CRC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg21782813	chr7:2030301	MAD1L1	0.4	7.39	0.38	1.23e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg12831148	chr6:146136093	FBXO30	-0.39	-6.01	-0.31	5.04e-9	Aortic root size;
CRC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg11212589	chr17:38028394	ZPBP2	0.35	5.89	0.31	9.44e-9	Asthma;
CRC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.39	-0.5	4.67e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg15445000	chr17:37608096	MED1	0.39	8.36	0.42	1.74e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg04553112	chr3:125709451	NA	-0.53	-6.1	-0.32	3.02e-9	Blood pressure (smoking interaction);
CRC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-14.26	-0.62	2.98e-36	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26187342	chr17:65713858	NOL11	0.41	6.52	0.34	2.66e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg18478394	chr8:109455254	TTC35	0.38	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg02466173	chr16:30829666	NA	-0.66	-9.77	-0.47	5.83e-20	Multiple myeloma;
CRC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-10.67	-0.51	5.11e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.56	-0.34	2.04e-10	Lymphocyte counts;
CRC	cis	rs6743376	0.556	rs1530553	chr2:113818171	G/A	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs629535	0.911	rs490165	chr8:70014976	A/G	cg26132723	chr8:70041827	NA	-0.35	-5.95	-0.31	6.99e-9	Dupuytren's disease;
CRC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.66	0.47	1.32e-19	Lung cancer;
CRC	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg20307385	chr11:47447363	PSMC3	0.48	5.9	0.31	9.15e-9	Migraine - clinic-based;
CRC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.62	7.8	0.4	8.04e-14	Dilated cardiomyopathy;
CRC	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg19338460	chr6:170058176	WDR27	-1.22	-10.16	-0.49	2.95e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10097731	0.901	rs10464890	chr8:82042727	A/G	cg25230327	chr8:82042993	NA	-0.92	-13.67	-0.6	5.31e-34	Serum total protein level;
CRC	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg05756136	chr1:119680316	WARS2	0.52	6.95	0.36	1.98e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6076065	0.692	rs6083111	chr20:23374667	A/G	cg11657817	chr20:23433608	CST11	0.44	6.63	0.34	1.41e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	6.8	0.35	5.03e-11	Neutrophil percentage of white cells;
CRC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.7	-11.31	-0.53	2.85e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.68	-8.97	-0.44	2.29e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.59	9.66	0.47	1.32e-19	Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06586915	chr7:65958596	NA	0.49	6.17	0.32	1.97e-9	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg03623178	chr6:28175578	NA	0.83	12.42	0.56	2.64e-29	Parkinson's disease;
CRC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	10.26	0.49	1.35e-21	Alzheimer's disease (late onset);
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg05569086	chr8:143859399	LYNX1	-0.4	-6.51	-0.34	2.81e-10	Urinary tract infection frequency;
CRC	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg25856811	chr1:152973957	SPRR3	-0.21	-5.69	-0.3	2.74e-8	Inflammatory skin disease;
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg09264619	chr17:80180166	NA	0.36	6.07	0.32	3.45e-9	Life satisfaction;
CRC	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.48	7.51	0.38	5.64e-13	Testicular germ cell tumor;
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.91	16.74	0.68	5.96e-46	Intelligence (multi-trait analysis);
CRC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.82	-9.05	-0.45	1.31e-17	Breast cancer;
CRC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.95	12.47	0.57	1.67e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg08890418	chr1:21044141	KIF17	0.33	5.98	0.31	5.89e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg07332563	chr6:291687	DUSP22	-0.48	-6.86	-0.35	3.46e-11	Menopause (age at onset);
CRC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-11.6	-0.54	2.54e-26	Vitiligo;
CRC	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	7.14	0.37	5.87e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.17e-23	Motion sickness;
CRC	cis	rs12476592	0.571	rs166384	chr2:63863630	G/T	cg10828910	chr2:63850056	LOC388955	0.49	6.04	0.32	4.23e-9	Childhood ear infection;
CRC	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.74	9.37	0.46	1.23e-18	Iron status biomarkers;
CRC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg02007433	chr3:129722099	NA	-0.52	-6.53	-0.34	2.44e-10	Blood pressure (smoking interaction);
CRC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg11212589	chr17:38028394	ZPBP2	0.34	6.1	0.32	2.96e-9	Asthma;
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.52	-0.5	1.72e-22	Bipolar disorder;
CRC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg03623178	chr6:28175578	NA	-0.61	-9.17	-0.45	5.2e-18	Cardiac Troponin-T levels;
CRC	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg11161846	chr1:160990452	F11R	-0.4	-6.01	-0.31	5.04e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.55	0.34	2.19e-10	Alzheimer's disease (late onset);
CRC	cis	rs9469578	0.901	rs16869459	chr6:33714908	G/A	cg18708504	chr6:33715942	IP6K3	0.65	7.39	0.38	1.25e-12	Phosphorus levels;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg25164649	chr6:28176230	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.74	-9.84	-0.48	3.35e-20	Prostate cancer;
CRC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.47	6.48	0.34	3.41e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2949837	0.581	rs2965074	chr7:45983129	G/T	cg15898840	chr7:45960834	IGFBP3	0.46	7.68	0.39	1.8e-13	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14080001	chr15:75940555	SNX33	0.41	6.09	0.32	3.13e-9	Response to antipsychotic treatment;
CRC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.58	8.64	0.43	2.5e-16	Lewy body disease;
CRC	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg00105475	chr2:10696890	NA	0.43	6.83	0.35	4.05e-11	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00331096	chr20:22564947	FOXA2	0.48	6.97	0.36	1.75e-11	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.88	-0.35	3.08e-11	Obesity-related traits;
CRC	cis	rs7113874	0.524	rs10769921	chr11:8621143	G/A	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg05175333	chr18:18692284	ROCK1	0.47	6.06	0.32	3.77e-9	Obesity (extreme);
CRC	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg21918786	chr6:109611834	NA	-0.33	-5.61	-0.3	4.38e-8	Reticulocyte fraction of red cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22152050	chr18:60987904	BCL2	0.41	6.97	0.36	1.76e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.49	7.69	0.39	1.67e-13	Red blood cell count;
CRC	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.4	-7.12	-0.37	6.85e-12	Rheumatoid arthritis;
CRC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.53	-8.22	-0.41	4.75e-15	Body mass index;
CRC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.08e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs116248771	0.549	rs9825140	chr3:158435374	C/T	cg16708174	chr3:158430962	RARRES1	0.45	6.05	0.32	4.04e-9	diarrhoeal disease at age 2;
CRC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-14.99	-0.64	4.38e-39	Vitiligo;
CRC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.44	-7.01	-0.36	1.36e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg03623178	chr6:28175578	NA	0.87	12.9	0.58	4.23e-31	Parkinson's disease;
CRC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.18	-0.32	1.88e-9	Morning vs. evening chronotype;
CRC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.62	9.11	0.45	8.27e-18	Morning vs. evening chronotype;
CRC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.44	-6.24	-0.33	1.35e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-13.39	-0.59	6.18e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg20512303	chr5:131592959	PDLIM4	0.38	6.71	0.35	8.6e-11	Blood metabolite levels;
CRC	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.6	-0.39	3.06e-13	HDL cholesterol;
CRC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.54	7.25	0.37	3.03e-12	Tourette syndrome;
CRC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.71	-0.3	2.55e-8	Tonsillectomy;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.35	0.33	7.2e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg27534772	chr1:16042836	PLEKHM2	0.5	9.67	0.47	1.21e-19	Systolic blood pressure;
CRC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg04545296	chr12:48745243	ZNF641	0.32	5.61	0.3	4.4e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.44	-6.85	-0.35	3.63e-11	Endometrial cancer;
CRC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.51	8.98	0.44	2.07e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.57	7.66	0.39	2.11e-13	Adiposity;
CRC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06544989	chr22:39130855	UNC84B	0.42	6.15	0.32	2.24e-9	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15044954	chr7:89874365	C7orf63	0.5	7.45	0.38	8.1e-13	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-8.23	-0.41	4.32e-15	Mean platelet volume;
CRC	cis	rs9469578	1.000	rs9469581	chr6:33715904	C/A	cg18708504	chr6:33715942	IP6K3	0.65	7.5	0.38	5.93e-13	Phosphorus levels;
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.55	6.71	0.35	8.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12273811	chr6:28175739	NA	0.61	8.97	0.44	2.27e-17	Cardiac Troponin-T levels;
CRC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.48	-8.2	-0.41	5.43e-15	Schizophrenia;
CRC	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.59	7.18	0.37	4.59e-12	Vitiligo;
CRC	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.87	-0.31	1.05e-8	Neuroticism;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.95	-0.4	3.01e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.43	8.1	0.41	1.06e-14	Childhood ear infection;
CRC	cis	rs1838105	0.640	rs12603447	chr17:45146237	A/G	cg16759221	chr17:45003025	GOSR2	-0.6	-9.23	-0.45	3.32e-18	Nonsyndromic cleft lip with cleft palate;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05808815	chr1:54666250	CYB5RL;MRPL37	0.39	6.3	0.33	9.52e-10	Obesity-related traits;
CRC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.55	8.0	0.4	2.15e-14	Obesity;
CRC	cis	rs7300001	0.667	rs7302441	chr12:110506468	T/C	cg12870014	chr12:110450643	ANKRD13A	0.94	9.82	0.48	3.97e-20	Headache;
CRC	cis	rs7534824	0.625	rs61780281	chr1:101324152	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	5.61	0.3	4.38e-8	Refractive astigmatism;
CRC	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg01475377	chr6:109611718	NA	-0.34	-5.98	-0.31	5.7e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg06970220	chr1:156163860	SLC25A44	0.52	7.56	0.38	4.01e-13	Testicular germ cell tumor;
CRC	cis	rs2885135	1.000	rs12066711	chr1:13906820	C/T	cg04886857	chr1:13914270	PDPN	-0.36	-6.36	-0.33	6.72e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11229555	0.574	rs12272310	chr11:58186462	A/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.86	-0.31	1.13e-8	Longevity;
CRC	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.18	-0.37	4.6e-12	Capecitabine sensitivity;
CRC	trans	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg15371732	chr17:78194151	SLC26A11;SGSH	0.45	6.28	0.33	1.09e-9	Cystic fibrosis severity;
CRC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	11.39	0.53	1.42e-25	Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00736819	chr19:3871003	NA	0.37	6.13	0.32	2.51e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.63	7.14	0.37	5.9e-12	Gut microbiome composition (summer);
CRC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.57	-8.94	-0.44	2.92e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs12024301	0.557	rs114460405	chr1:183653703	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg14671364	chr1:107599128	PRMT6	0.6	8.05	0.41	1.49e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.11	-0.32	2.89e-9	Total body bone mineral density;
CRC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg19193384	chr17:30244184	NA	0.53	5.95	0.31	6.73e-9	Hip circumference adjusted for BMI;
CRC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-9.36	-0.46	1.25e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-6.67	-0.35	1.09e-10	Self-reported allergy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24861683	chr3:37284451	GOLGA4	0.37	5.99	0.31	5.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-6.84	-0.35	3.92e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.66	-9.84	-0.48	3.35e-20	Initial pursuit acceleration;
CRC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.82	11.69	0.54	1.24e-26	Cognitive function;
CRC	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg09659197	chr4:152720779	NA	0.52	11.23	0.53	5.49e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.68	-10.16	-0.49	2.83e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.58	8.85	0.44	5.32e-17	Vitiligo;
CRC	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.62	0.34	1.45e-10	Menarche (age at onset);
CRC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.37	-6.38	-0.33	6.13e-10	Erythrocyte sedimentation rate;
CRC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.42	-7.65	-0.39	2.27e-13	Prostate cancer;
CRC	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.41	0.5	3.84e-22	Corneal astigmatism;
CRC	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg05585544	chr11:47624801	NA	-0.4	-6.36	-0.33	6.58e-10	Intraocular pressure;
CRC	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg15445000	chr17:37608096	MED1	0.32	5.68	0.3	2.96e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10954261	chr6:11094075	LOC221710	0.47	6.35	0.33	7.02e-10	Anxiety disorder;
CRC	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg00042356	chr1:8021962	PARK7	-0.56	-6.3	-0.33	9.64e-10	Inflammatory bowel disease;
CRC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21582582	chr3:182698605	DCUN1D1	0.42	6.12	0.32	2.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4141404	0.818	rs6518737	chr22:31582662	A/G	cg22777020	chr22:31556080	RNF185	-0.45	-5.9	-0.31	8.94e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.68	-0.47	1.13e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.22e-17	Mean platelet volume;
CRC	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.26	0.33	1.18e-9	Hair morphology;
CRC	cis	rs6911131	0.554	rs11155304	chr6:143903156	A/G	cg25407410	chr6:143891975	LOC285740	0.7	5.77	0.3	1.82e-8	Response to paliperidone in schizophrenia (positive Marder score);
CRC	cis	rs889398	0.641	rs9936723	chr16:69884854	G/A	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.46	-0.34	3.69e-10	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21201435	chr9:108210605	FSD1L	0.4	6.18	0.32	1.86e-9	Response to antipsychotic treatment;
CRC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00040446	chr1:40367965	MYCL1	0.39	6.22	0.32	1.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.43	6.55	0.34	2.18e-10	Prostate cancer;
CRC	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.69	12.32	0.56	5.96e-29	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	0.75	6.76	0.35	6.32e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.87	0.44	4.8e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11645453	chr3:52864694	ITIH4	0.33	5.9	0.31	9.04e-9	Electroencephalogram traits;
CRC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.24	14.83	0.63	1.93e-38	Lung disease severity in cystic fibrosis;
CRC	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg18833306	chr6:118973337	C6orf204	-0.44	-5.89	-0.31	9.35e-9	Diastolic blood pressure;
CRC	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.65	-9.91	-0.48	1.91e-20	Dementia with Lewy bodies;
CRC	cis	rs10155981	0.510	rs75613086	chr7:22584526	A/C	cg05062323	chr7:22590069	NA	-0.61	-5.72	-0.3	2.42e-8	Bilirubin levels;
CRC	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.51	8.76	0.44	1.02e-16	Dupuytren's disease;
CRC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.07	11.48	0.53	7.25e-26	Skin colour saturation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22249281	chr19:41082756	SHKBP1	0.41	5.99	0.31	5.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4499344	0.730	rs259285	chr19:33164697	T/C	cg08127369	chr19:33164662	ANKRD27	0.39	6.01	0.31	5.02e-9	Mean platelet volume;
CRC	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg15131784	chr3:139108705	COPB2	-0.42	-6.04	-0.32	4.28e-9	Obesity-related traits;
CRC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18252515	chr7:66147081	NA	0.39	5.74	0.3	2.14e-8	Aortic root size;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.58	-11.58	-0.54	3.13e-26	Asthma (sex interaction);
CRC	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.36e-11	Prostate cancer;
CRC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3812049	0.532	rs251390	chr5:127538346	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	8.02	0.4	1.92e-14	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.53	8.47	0.42	8.56e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.86	-14.97	-0.64	5.18e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.44	-7.1	-0.36	7.68e-12	Refractive error;
CRC	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	20.51	0.75	8.58e-61	Colorectal cancer;
CRC	cis	rs28655083	0.529	rs682081	chr16:77103050	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.89	0.36	2.84e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6694672	0.867	rs6679189	chr1:197100556	C/A	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.69e-11	Asthma;
CRC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.7	10.43	0.5	3.53e-22	Longevity;
CRC	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.55	9.72	0.47	8.52e-20	Optic cup area;
CRC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.73	9.51	0.46	4.07e-19	Platelet count;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg01583514	chr19:3730768	TJP3	-0.42	-6.03	-0.32	4.39e-9	Lung cancer;
CRC	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg06042504	chr8:55087323	NA	-0.37	-5.78	-0.3	1.71e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-6.89	-0.36	2.77e-11	Schizophrenia;
CRC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	6.27	0.33	1.14e-9	Personality dimensions;
CRC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.11	-0.32	2.75e-9	Height;
CRC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.72	-9.69	-0.47	1.09e-19	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.4	5.92	0.31	8.21e-9	Life satisfaction;
CRC	trans	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg18288967	chr1:45987694	PRDX1	0.66	6.83	0.35	4.21e-11	Obesity-related traits;
CRC	cis	rs2637266	0.519	rs7072009	chr10:78301652	G/A	cg18941641	chr10:78392320	NA	-0.36	-6.01	-0.31	4.86e-9	Pulmonary function;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg01664833	chr10:134351118	INPP5A	0.5	6.22	0.32	1.54e-9	Intelligence (multi-trait analysis);
CRC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg02254774	chr11:50257496	LOC441601	0.57	6.03	0.32	4.33e-9	Intraocular pressure;
CRC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg21155852	chr7:2048760	MAD1L1	-0.53	-7.19	-0.37	4.38e-12	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.82	13.92	0.61	5.82e-35	Menopause (age at onset);
CRC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.46	-7.92	-0.4	3.72e-14	Vitamin D levels;
CRC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.29	-0.59	1.46e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs6840360	0.642	rs28666858	chr4:152416382	T/C	cg09659197	chr4:152720779	NA	0.33	6.52	0.34	2.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.44	-6.61	-0.34	1.56e-10	Systemic lupus erythematosus;
CRC	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.42	6.42	0.33	4.85e-10	Recombination rate (males);
CRC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12524338	chr4:183729343	NA	0.52	5.82	0.31	1.37e-8	Pediatric autoimmune diseases;
CRC	trans	rs10077885	0.869	rs2974516	chr5:114448597	A/G	cg05316309	chr22:43011028	POLDIP3;RNU12	0.37	6.03	0.32	4.4e-9	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.9	16.62	0.68	1.87e-45	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.32	-0.33	8.67e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.01	-0.31	4.81e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	0.94	18.11	0.71	2.52e-51	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14634336	chr6:111804804	REV3L	0.57	7.7	0.39	1.5700000000000001e-13	Thyroid stimulating hormone;
CRC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.6	9.68	0.47	1.17e-19	Vitiligo;
CRC	cis	rs6604026	0.922	rs12750269	chr1:93311661	T/C	cg22128645	chr1:93425802	FAM69A	-0.39	-5.72	-0.3	2.36e-8	Multiple sclerosis;
CRC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.45	6.1	0.32	2.99e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.4	6.82	0.35	4.41e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CRC	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.48	-6.07	-0.32	3.48e-9	Body mass index;
CRC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.79	-11.47	-0.53	7.55e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.47	-7.72	-0.39	1.41e-13	Congenital heart disease (maternal effect);
CRC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-8.79	-0.44	8.46e-17	Coronary artery disease;
CRC	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.65	-8.89	-0.44	4.25e-17	Extraversion;
CRC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-9.51	-0.46	4.29e-19	Monocyte percentage of white cells;
CRC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.48	7.04	0.36	1.12e-11	Colorectal cancer;
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.57	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.58	-0.34	1.91e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg00677455	chr12:58241039	CTDSP2	0.56	6.77	0.35	5.8200000000000003e-11	Multiple sclerosis;
CRC	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs9532580	0.710	rs9577090	chr13:41225228	G/T	cg21288729	chr13:41239152	FOXO1	0.48	7.48	0.38	6.95e-13	Mean corpuscular hemoglobin;
CRC	cis	rs7605827	0.930	rs10929372	chr2:15662434	A/G	cg19274914	chr2:15703543	NA	0.38	5.89	0.31	9.64e-9	Educational attainment (years of education);
CRC	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.59	-9.73	-0.47	7.77e-20	Brugada syndrome;
CRC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Melanoma;
CRC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg21280719	chr6:42927975	GNMT	-0.32	-6.23	-0.32	1.41e-9	Blood protein levels;
CRC	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.53	-8.26	-0.41	3.72e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg18230493	chr5:56204884	C5orf35	-0.4	-5.67	-0.3	3.14e-8	Coronary artery disease;
CRC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg04545296	chr12:48745243	ZNF641	0.36	6.15	0.32	2.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.49	7.65	0.39	2.31e-13	Age-related hearing impairment;
CRC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.09	-0.45	9.53e-18	Bipolar disorder;
CRC	cis	rs4853036	0.904	rs2278934	chr2:70121197	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.57	-0.34	1.92e-10	Colorectal or endometrial cancer;
CRC	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg12573674	chr2:1569213	NA	-0.65	-7.6	-0.39	3.13e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.49	9.16	0.45	5.61e-18	Smoking initiation;
CRC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg08213375	chr14:104286397	PPP1R13B	0.57	11.88	0.55	2.46e-27	Schizophrenia;
CRC	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.47	6.67	0.35	1.06e-10	Body mass index;
CRC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.39	-5.98	-0.31	5.89e-9	Testicular germ cell tumor;
CRC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.35	7.07	0.36	9.24e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	trans	rs57590327	0.503	rs6776737	chr3:81513729	T/C	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-6.0	-0.31	5.25e-9	Extraversion;
CRC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.29	-0.53	3.39e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7259376	0.936	rs17391718	chr19:22554154	A/G	cg02657401	chr19:22469223	NA	-0.32	-7.02	-0.36	1.3e-11	Menopause (age at onset);
CRC	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.59	7.94	0.4	3.23e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.21	-25.8	-0.82	5.04e-81	Triglycerides;
CRC	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.56	9.78	0.47	5.29e-20	Common traits (Other);
CRC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.87	-11.85	-0.55	3.24e-27	Gut microbiome composition (summer);
CRC	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs1223397	0.938	rs35549743	chr6:13294354	C/T	cg00460589	chr6:13274354	PHACTR1	0.5	5.98	0.31	5.93e-9	Blood pressure;
CRC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg22732515	chr19:44031385	ETHE1	0.61	9.07	0.45	1.1e-17	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg10298567	chr3:47292165	KIF9	-0.41	-6.85	-0.35	3.66e-11	Colorectal cancer;
CRC	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.72	-0.35	8.25e-11	Schizophrenia;
CRC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.44	6.72	0.35	8.13e-11	Mean platelet volume;
CRC	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23422044	chr7:1970798	MAD1L1	-0.51	-6.04	-0.32	4.23e-9	Neuroticism;
CRC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.12	0.45	7.78e-18	Mean platelet volume;
CRC	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.49	7.17	0.37	5.06e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2302190	0.882	rs8073754	chr17:56618030	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-7.88	-0.4	4.84e-14	Vitamin D levels;
CRC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.65	-9.81	-0.48	4.18e-20	Cognitive function;
CRC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg03623178	chr6:28175578	NA	0.59	8.64	0.43	2.4e-16	Pubertal anthropometrics;
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg19875535	chr5:140030758	IK	0.43	6.61	0.34	1.54e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12315302	chr6:26189340	HIST1H4D	0.74	5.82	0.31	1.38e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.89	0.36	2.88e-11	Aortic root size;
CRC	trans	rs10227393	0.614	rs10239379	chr7:144970348	C/T	cg00620628	chr2:238165917	NA	0.48	6.05	0.32	3.93e-9	Coffee consumption;
CRC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs7074356	0.831	rs12764048	chr10:82148963	A/G	cg11900509	chr10:81946545	ANXA11	-0.56	-6.26	-0.33	1.23e-9	Borderline personality disorder;
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg24505167	chr7:1915268	MAD1L1	-0.44	-5.98	-0.31	5.89e-9	Neuroticism;
CRC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg09491104	chr22:46646882	C22orf40	-0.4	-6.27	-0.33	1.12e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.05	0.68	3.64e-47	Platelet count;
CRC	cis	rs9491140	0.539	rs12529386	chr6:124678200	A/G	cg19267163	chr6:125004984	NKAIN2	0.47	6.39	0.33	5.71e-10	Neuroticism;
CRC	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.64	-10.19	-0.49	2.22e-21	Smoking behavior;
CRC	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.44	6.68	0.35	1.04e-10	Coronary heart disease;
CRC	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.8	9.58	0.47	2.49e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.41	-6.19	-0.32	1.76e-9	Menarche (age at onset);
CRC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.87	-0.31	1.05e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.64	6.55	0.34	2.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.58	-9.03	-0.45	1.48e-17	Breast cancer;
CRC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.98	0.64	4.65e-39	Mean platelet volume;
CRC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.58	0.34	1.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.77	14.73	0.63	4.64e-38	Ulcerative colitis;
CRC	trans	rs7142881	0.715	rs34977423	chr14:32127868	G/A	cg07250515	chr12:56618133	OBFC2B	0.39	6.19	0.32	1.84e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.43	6.27	0.33	1.16e-9	Mean platelet volume;
CRC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14895029	chr7:2775587	GNA12	-0.48	-7.03	-0.36	1.17e-11	Height;
CRC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.9	0.44	3.91e-17	Homoarginine levels;
CRC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.67	-7.84	-0.4	6.27e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg05756136	chr1:119680316	WARS2	-0.54	-7.27	-0.37	2.68e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.93	18.45	0.71	1.11e-52	Menopause (age at onset);
CRC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.72	11.56	0.54	3.73e-26	Dental caries;
CRC	cis	rs12745968	0.589	rs7530780	chr1:93130268	C/T	cg17283838	chr1:93427260	FAM69A	-0.46	-6.17	-0.32	1.96e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25101061	chr5:176739547	MXD3	0.41	6.41	0.33	5.1e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg19622623	chr12:86230825	RASSF9	-0.35	-5.68	-0.3	3.01e-8	Major depressive disorder;
CRC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs394563	0.601	rs367133	chr6:149797720	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.43	-6.87	-0.35	3.24e-11	Dupuytren's disease;
CRC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.48	7.45	0.38	8.51e-13	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08313788	chr9:115095520	ROD1	0.52	7.22	0.37	3.56e-12	Response to antipsychotic treatment;
CRC	cis	rs8099014	0.861	rs4940705	chr18:56120155	G/A	cg12907477	chr18:56117327	MIR122	0.44	5.68	0.3	2.92e-8	Platelet count;
CRC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.37	-6.62	-0.34	1.43e-10	Menarche (age at onset);
CRC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.38	5.95	0.31	6.73e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00385063	chr21:34852302	TMEM50B	0.41	6.55	0.34	2.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg20684491	chr1:25596433	NA	-0.43	-7.34	-0.38	1.69e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg14847009	chr1:175162515	KIAA0040	0.3	6.66	0.34	1.18e-10	Alcohol dependence;
CRC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg03030879	chr14:75389066	RPS6KL1	0.43	6.46	0.34	3.71e-10	Height;
CRC	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.14	0.41	8.37e-15	Rheumatoid arthritis;
CRC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.51	-0.34	2.84e-10	Dupuytren's disease;
CRC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg11204139	chr17:3907470	NA	0.49	6.24	0.33	1.33e-9	Type 2 diabetes;
CRC	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg18404041	chr3:52824283	ITIH1	-0.33	-5.77	-0.3	1.83e-8	Schizophrenia;
CRC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.71	0.51	3.81e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15225105	chr11:64808343	SAC3D1	0.44	6.17	0.32	1.96e-9	Response to antipsychotic treatment;
CRC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.45	-6.08	-0.32	3.29e-9	Diastolic blood pressure;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg15786705	chr6:28176104	NA	0.74	9.47	0.46	5.74e-19	Depression;
CRC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.6	8.45	0.42	9.72e-16	Homoarginine levels;
CRC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.13	0.32	2.52e-9	Renal function-related traits (BUN);
CRC	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.51	8.0	0.4	2.21e-14	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.68	10.3	0.49	9.71e-22	Lung cancer;
CRC	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.07	0.52	2.07e-24	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23187205	chr6:109416245	SESN1;C6orf182	0.49	7.03	0.36	1.18e-11	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg19622623	chr12:86230825	RASSF9	-0.42	-6.78	-0.35	5.42e-11	Major depressive disorder;
CRC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.58	11.62	0.54	2.11e-26	Schizophrenia;
CRC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.57	-7.92	-0.4	3.73e-14	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.22	0.53	5.79e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27649522	chr12:12877729	APOLD1	0.48	6.91	0.36	2.51e-11	Response to antipsychotic treatment;
CRC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.57	-6.83	-0.35	4.15e-11	Menarche (age at onset);
CRC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-6.72	-0.35	7.87e-11	Psoriasis;
CRC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.13	-0.32	2.48e-9	Tonsillectomy;
CRC	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.14	-0.37	5.85e-12	Menarche (age at onset);
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg15845792	chr6:28175446	NA	-0.6	-8.43	-0.42	1.06e-15	Parkinson's disease;
CRC	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.65	-6.91	-0.36	2.45e-11	Osteoarthritis;
CRC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.51	0.34	2.88e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23615959	chr11:3818253	NUP98;PGAP2	-0.52	-6.24	-0.33	1.31e-9	Diisocyanate-induced asthma;
CRC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg02527881	chr3:46936655	PTH1R	-0.34	-5.98	-0.31	5.85e-9	Colorectal cancer;
CRC	cis	rs6066835	0.867	rs11698214	chr20:47359603	G/A	cg18078177	chr20:47281410	PREX1	0.6	5.73	0.3	2.25e-8	Multiple myeloma;
CRC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg18230493	chr5:56204884	C5orf35	-0.46	-6.67	-0.34	1.1e-10	Coronary artery disease;
CRC	cis	rs1983891	0.826	rs4714476	chr6:41513740	T/C	cg20194872	chr6:41519635	FOXP4	0.39	5.65	0.3	3.42e-8	Prostate cancer;
CRC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.44e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.62	0.39	2.68e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs58106596	0.848	rs2241742	chr2:232574807	C/G	cg01370599	chr3:116745421	NA	0.72	8.67	0.43	1.94e-16	White blood cell count;Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.77	0.3	1.84e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.39	-6.22	-0.32	1.55e-9	Neurofibrillary tangles;
CRC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.6	8.82	0.44	6.68e-17	Corneal astigmatism;
CRC	cis	rs7113874	0.569	rs10769916	chr11:8598214	G/A	cg02811074	chr11:8615871	STK33	-0.35	-6.05	-0.32	3.97e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.57	6.19	0.32	1.83e-9	Type 2 diabetes;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg20647610	chr2:228736258	WDR69	-0.5	-6.76	-0.35	6.37e-11	Blood pressure;
CRC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg25876840	chr17:41920477	NA	0.62	8.55	0.43	4.6e-16	Triglycerides;
CRC	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.73	-11.33	-0.53	2.34e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.67	9.36	0.46	1.29e-18	Prostate cancer;
CRC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.59	9.29	0.46	2.2e-18	Schizophrenia;
CRC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.45	6.92	0.36	2.35e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	7.12	0.37	6.73e-12	Lymphocyte counts;
CRC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.65	10.41	0.5	4.08e-22	Colorectal cancer;
CRC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.45	-7.93	-0.4	3.38e-14	Longevity;
CRC	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.79e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.04	-0.45	1.36e-17	Prostate cancer;
CRC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.45	6.67	0.34	1.11e-10	Menopause (age at onset);
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg21784768	chr11:537496	LRRC56	-0.7	-6.64	-0.34	1.32e-10	Body mass index;
CRC	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.78	-11.51	-0.54	5.62e-26	Pubertal anthropometrics;
CRC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg07828024	chr6:149772892	ZC3H12D	-0.48	-9.05	-0.45	1.26e-17	Dupuytren's disease;
CRC	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.52	-0.34	2.6200000000000003e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg00631329	chr6:26305371	NA	-0.52	-8.72	-0.43	1.42e-16	Educational attainment;
CRC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.46	-8.55	-0.43	4.61e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-6.44	-0.33	4.24e-10	Heart rate;
CRC	trans	rs2890652	0.702	rs17777246	chr2:142967890	G/A	cg00809969	chr7:27181067	HOXA5	-0.67	-6.08	-0.32	3.24e-9	Body mass index;
CRC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg19223190	chr17:80058835	NA	-0.48	-7.72	-0.39	1.39e-13	Life satisfaction;
CRC	cis	rs6662572	0.737	rs4660333	chr1:46462059	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.69	-0.3	2.86e-8	Blood protein levels;
CRC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.43	-6.76	-0.35	6.42e-11	Body mass index;
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg11503833	chr11:492997	NA	0.55	5.74	0.3	2.12e-8	Body mass index;
CRC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.41	6.69	0.35	9.37e-11	Diastolic blood pressure;
CRC	cis	rs1760803	0.754	rs6657214	chr1:154206538	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.35	-0.33	7.04e-10	Nicotine dependence;
CRC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.4	0.71	1.71e-52	Cognitive ability;
CRC	cis	rs6743376	0.556	rs2441375	chr2:113817268	T/C	cg24553058	chr2:113831203	IL1F10	0.43	6.97	0.36	1.78e-11	Inflammatory biomarkers;
CRC	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.54	-9.08	-0.45	1.01e-17	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15239874	chr12:121148841	UNC119B	0.43	6.24	0.33	1.37e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01830644	chr10:12110754	DHTKD1	0.43	6.08	0.32	3.42e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18071532	chr12:48357234	TMEM106C	0.4	6.75	0.35	6.66e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.95	10.6	0.5	8.78e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23708337	chr7:1209742	NA	0.51	7.75	0.39	1.14e-13	Longevity;Endometriosis;
CRC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.74	0.63	4.05e-38	Lymphocyte percentage of white cells;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg26353448	chr1:248524236	OR2T4	-0.3	-5.81	-0.31	1.45e-8	Common traits (Other);
CRC	cis	rs6546324	0.625	rs2861698	chr2:67854808	A/G	cg15745817	chr2:67799979	NA	-0.57	-9.66	-0.47	1.37e-19	Endometriosis;
CRC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.94	18.4	0.71	1.68e-52	Height;
CRC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.37	5.62	0.3	4.14e-8	Neuroticism;
CRC	cis	rs524281	0.773	rs10896105	chr11:66002260	A/G	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-8.5	-0.42	6.51e-16	Gut microbiome composition (summer);
CRC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	7.45	0.38	8.07e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.64	11.5	0.54	6.02e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.45	6.4	0.33	5.38e-10	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07151637	chr22:32149913	DEPDC5	0.37	6.47	0.34	3.6e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.57	7.54	0.38	4.59e-13	Mean platelet volume;
CRC	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-6.45	-0.34	4.02e-10	Lymphocyte counts;
CRC	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg04990556	chr1:26633338	UBXN11	0.57	6.2	0.32	1.69e-9	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6976053	1.000	rs6976053	chr7:100512119	C/T	cg10426581	chr7:100472382	SRRT	0.37	5.69	0.3	2.78e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs3018066	0.666	rs77934361	chr4:106980535	T/C	cg01869342	chr4:106983673	TBCK	0.48	6.26	0.33	1.21e-9	Cancer;
CRC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg10431340	chr1:161279108	MPZ	-0.52	-6.96	-0.36	1.84e-11	Rheumatoid arthritis;
CRC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.66	-7.89	-0.4	4.4e-14	Cognitive test performance;
CRC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.46	6.84	0.35	3.98e-11	Tonsillectomy;
CRC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24308560	chr3:49941425	MST1R	-0.45	-6.86	-0.35	3.4e-11	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25019564	chr18:9475492	RALBP1	0.45	6.78	0.35	5.58e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.63	-9.84	-0.48	3.47e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.19	0.32	1.8e-9	Hemoglobin concentration;
CRC	cis	rs1882538	0.504	rs6951416	chr7:133092278	A/G	cg10665199	chr7:133106180	EXOC4	0.55	8.28	0.42	3.21e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.9	-13.46	-0.6	3.44e-33	Longevity;
CRC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.62	9.63	0.47	1.65e-19	Blood pressure (smoking interaction);
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.46	0.57	1.84e-29	Alzheimer's disease;
CRC	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg23254163	chr1:152506842	NA	0.44	8.89	0.44	4.08e-17	Hair morphology;
CRC	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg14631576	chr9:95140430	CENPP	-0.32	-6.01	-0.31	4.9e-9	Height;
CRC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg21512124	chr14:70655805	SLC8A3	-0.31	-6.0	-0.31	5.31e-9	Prostate cancer;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg02683197	chr6:28174875	NA	-0.68	-8.7	-0.43	1.63e-16	Parkinson's disease;
CRC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg24578937	chr1:2090814	PRKCZ	0.38	7.0	0.36	1.49e-11	Coronary artery disease;
CRC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg22676075	chr6:135203613	NA	0.41	6.18	0.32	1.91e-9	Red blood cell count;
CRC	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.91	-0.31	8.42e-9	Pulmonary function;
CRC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.08	0.55	4.6e-28	Chronic sinus infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27109030	chr19:2702898	GNG7	0.4	7.08	0.36	8.88e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg08501292	chr6:25962987	TRIM38	-0.87	-8.19	-0.41	6e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg14593290	chr7:50529359	DDC	-0.63	-8.67	-0.43	2.05e-16	Malaria;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg02683197	chr6:28174875	NA	0.57	7.53	0.38	5.05e-13	Parkinson's disease;
CRC	cis	rs1322512	0.959	rs2623954	chr6:152966001	G/A	cg03415253	chr6:152958462	SYNE1	-0.44	-6.77	-0.35	5.99e-11	Tonometry;
CRC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.57	-0.34	1.96e-10	Response to antipsychotic treatment;
CRC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.17	0.62	6.37e-36	Chronic sinus infection;
CRC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg12273811	chr6:28175739	NA	0.47	5.73	0.3	2.25e-8	Breast cancer;
CRC	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.36	5.65	0.3	3.54e-8	Myeloid white cell count;
CRC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.6	10.49	0.5	2.19e-22	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19704520	chr7:100291891	NA	0.4	6.09	0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2415984	0.622	rs1761025	chr14:46930439	T/C	cg14871534	chr14:47121158	RPL10L	0.42	6.0	0.31	5.14e-9	Number of children ever born;
CRC	cis	rs4731207	0.596	rs1871775	chr7:124674652	G/T	cg23710748	chr7:124431027	NA	-0.4	-6.23	-0.33	1.39e-9	Cutaneous malignant melanoma;
CRC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.54	-8.17	-0.41	6.54e-15	Cancer;
CRC	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.45	-5.82	-0.31	1.38e-8	Red blood cell traits;
CRC	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg08610935	chr16:1836813	NUBP2	0.62	9.54	0.47	3.35e-19	Insulin-like growth factors;
CRC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.12	-0.32	2.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.02	0.32	4.54e-9	Prudent dietary pattern;
CRC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg03037974	chr15:76606532	NA	-0.5	-7.28	-0.37	2.45e-12	Blood metabolite levels;
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg04969067	chr8:143858791	LYNX1	0.46	7.64	0.39	2.35e-13	Urinary tract infection frequency;
CRC	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.61	-7.64	-0.39	2.46e-13	Ulcerative colitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12435494	chr20:61493322	TCFL5	0.42	5.97	0.31	6.06e-9	Anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05147077	chr5:36606601	SLC1A3	0.43	6.28	0.33	1.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.07	-0.36	9.26e-12	IgG glycosylation;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.96	-0.44	2.47e-17	Bipolar disorder;
CRC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18252515	chr7:66147081	NA	0.4	5.9	0.31	9.26e-9	Aortic root size;
CRC	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg04110750	chr16:69646130	NFAT5	-0.53	-7.27	-0.37	2.62e-12	IgE levels;
CRC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.62	-10.33	-0.49	7.34e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.61	10.1	0.49	4.69e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.68e-17	Bipolar disorder;
CRC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.44	6.84	0.35	3.89e-11	Colorectal cancer;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.06	-28.15	-0.84	1.27e-89	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.91	19.03	0.72	5.59e-55	Birth weight;
CRC	cis	rs7924005	0.787	rs10905876	chr10:6174601	C/T	cg17191567	chr10:6178319	NA	0.39	5.95	0.31	6.93e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	8.74	0.43	1.19e-16	Personality dimensions;
CRC	cis	rs4737010	0.644	rs506763	chr8:41612487	C/T	cg17182837	chr8:41585554	ANK1	0.52	7.49	0.38	6.57e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg15465823	chr12:48382534	COL2A1	-0.37	-6.14	-0.32	2.41e-9	Glycated hemoglobin levels;
CRC	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.36	6.6	0.34	1.68e-10	Neuroticism;
CRC	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg27083787	chr2:113543245	IL1A	0.44	6.35	0.33	7.26e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.62	-9.74	-0.47	7.35e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.67	-10.91	-0.52	7.09e-24	Mean corpuscular hemoglobin;
CRC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	0.92	15.29	0.64	2.9e-40	Dupuytren's disease;
CRC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.17	11.46	0.53	8.2e-26	Intelligence (multi-trait analysis);
CRC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.73	-0.3	2.23e-8	Tonsillectomy;
CRC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.44	-0.5	3.21e-22	Initial pursuit acceleration;
CRC	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.53	-5.92	-0.31	8.31e-9	Prostate cancer;
CRC	cis	rs7091068	0.802	rs10786121	chr10:95419796	G/A	cg20715218	chr10:95462985	C10orf4	0.5	5.95	0.31	6.85e-9	Urinary tract infection frequency;
CRC	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.3	6.4	0.33	5.2400000000000005e-10	Migraine;
CRC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.61	10.87	0.51	1e-23	Schizophrenia;
CRC	cis	rs7254114	0.578	rs6511727	chr19:11315817	G/T	cg02815516	chr19:11306319	KANK2	-0.36	-6.42	-0.33	4.79e-10	Immature fraction of reticulocytes;
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.59	7.3	0.37	2.17e-12	Alzheimer's disease;
CRC	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg23609528	chr2:113191194	RGPD5;RGPD8	0.65	5.65	0.3	3.53e-8	Yeast infection;
CRC	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.71	-10.01	-0.48	8.94e-21	Body mass index;
CRC	cis	rs8070740	0.838	rs35491297	chr17:5327481	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	6.86	0.35	3.46e-11	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12273811	chr6:28175739	NA	0.71	9.07	0.45	1.08e-17	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26666886	chr16:89558024	ANKRD11	0.44	6.22	0.32	1.5e-9	Thyroid stimulating hormone;
CRC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-9.07	-0.45	1.07e-17	Body mass index;
CRC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.57	8.76	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.94	0.48	1.54e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg00383909	chr3:49044727	WDR6	0.47	5.89	0.31	9.58e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg16950941	chr11:66035639	RAB1B	0.54	7.51	0.38	5.57e-13	Electroencephalogram traits;
CRC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.67	-11.06	-0.52	2.19e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.89e-22	Menopause (age at onset);
CRC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	13.88	0.61	8.5e-35	Platelet count;
CRC	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg19683494	chr5:74908142	NA	0.5	6.28	0.33	1.06e-9	Age-related disease endophenotypes;
CRC	cis	rs6662572	0.737	rs6665193	chr1:46347910	G/A	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs3736485	0.844	rs7181470	chr15:51800882	T/C	cg08986416	chr15:51914746	DMXL2	-0.47	-6.82	-0.35	4.28e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6840360	0.539	rs1443087	chr4:152450095	C/A	cg09659197	chr4:152720779	NA	0.33	6.49	0.34	3.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.49	-7.2	-0.37	4.24e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.66	10.57	0.5	1.15e-22	Monocyte percentage of white cells;
CRC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.91e-9	Hemoglobin concentration;
CRC	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.43	6.51	0.34	2.74e-10	Birth weight;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg12172441	chr6:28176163	NA	0.5	6.73	0.35	7.42e-11	Parkinson's disease;
CRC	cis	rs3764400	0.567	rs9890691	chr17:46192936	G/T	cg10706073	chr17:46328419	SKAP1	0.58	6.57	0.34	1.99e-10	Body mass index;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg16558177	chr4:4109446	NA	-0.62	-8.74	-0.43	1.23e-16	Blood pressure (smoking interaction);
CRC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg18678763	chr11:4115507	RRM1	-0.36	-5.84	-0.31	1.23e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs61160187	0.582	rs4647150	chr5:60170605	T/C	cg16298547	chr5:60138761	ELOVL7	-0.29	-6.02	-0.32	4.6e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.94	0.31	7.06e-9	IgG glycosylation;
CRC	cis	rs2637266	0.521	rs4587671	chr10:78398879	A/G	cg18941641	chr10:78392320	NA	-0.35	-6.05	-0.32	4.03e-9	Pulmonary function;
CRC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.71	11.16	0.52	9.64e-25	Monocyte count;
CRC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.61	-0.43	3.11e-16	Uric acid levels;
CRC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.63	10.09	0.49	4.8e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.87	-0.35	3.13e-11	Dilated cardiomyopathy;
CRC	cis	rs294883	0.739	rs4144224	chr6:159732620	G/A	cg14500486	chr6:159655392	FNDC1	-0.36	-6.16	-0.32	2.11e-9	Coronary artery disease;
CRC	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg25011176	chr20:3776985	CDC25B	-0.45	-5.99	-0.31	5.43e-9	Bipolar disorder;
CRC	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.59	9.05	0.45	1.27e-17	Crohn's disease;
CRC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.78	13.64	0.6	7.23e-34	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05657792	chr17:6899758	ALOX12	0.48	8.91	0.44	3.59e-17	Tonsillectomy;
CRC	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.98	16.95	0.68	9.33e-47	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.79e-9	Life satisfaction;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06367102	chr7:1192688	ZFAND2A	0.36	5.97	0.31	6.11e-9	Aortic root size;
CRC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	1.1	10.48	0.5	2.33e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9584850	0.718	rs6491427	chr13:99113166	A/G	cg20487152	chr13:99095054	FARP1	0.43	6.23	0.32	1.41e-9	Neuroticism;
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.76	-12.11	-0.56	3.64e-28	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.67	10.7	0.51	3.86e-23	Sudden cardiac arrest;
CRC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg13206674	chr6:150067644	NUP43	0.51	7.3	0.37	2.16e-12	Lung cancer;
CRC	cis	rs55675132	0.510	rs72687890	chr1:115296524	A/G	cg12756093	chr1:115239321	AMPD1	0.52	6.24	0.33	1.34e-9	Schizophrenia;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10819733	chr22:24237672	NA	0.35	6.16	0.32	2.13e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.38	6.31	0.33	9.14e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.72	-11.11	-0.52	1.41e-24	Platelet distribution width;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg22687807	chr8:143858763	LYNX1	-0.46	-7.58	-0.39	3.57e-13	Urinary tract infection frequency;
CRC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg16606324	chr3:10149918	C3orf24	0.47	7.01	0.36	1.38e-11	Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg02033258	chr5:131593261	PDLIM4	-0.39	-6.58	-0.34	1.81e-10	Breast cancer;
CRC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.49	-7.18	-0.37	4.6e-12	Blood metabolite levels;
CRC	trans	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg09872104	chr7:134855509	C7orf49	-0.72	-7.04	-0.36	1.1e-11	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg09491104	chr22:46646882	C22orf40	-0.4	-6.4	-0.33	5.3e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-11.87	-0.55	2.69e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.1	-0.32	2.98e-9	Height;
CRC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14671364	chr1:107599128	PRMT6	-0.58	-7.9	-0.4	4.18e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg23260525	chr10:116636907	FAM160B1	0.32	6.78	0.35	5.43e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg09659197	chr4:152720779	NA	-0.42	-8.5	-0.42	6.53e-16	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	10.67	0.51	5.07e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.76	-10.02	-0.48	8.16e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24308560	chr3:49941425	MST1R	0.41	6.19	0.32	1.75e-9	Body mass index;
CRC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.27	-0.41	3.36e-15	Menarche (age at onset);
CRC	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg20744362	chr22:50050164	C22orf34	0.32	5.82	0.31	1.38e-8	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs6141769	0.518	rs28565102	chr20:31285458	T/G	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.87	-0.31	1.06e-8	Subjective well-being;
CRC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg24879335	chr3:133465180	TF	0.31	5.88	0.31	9.95e-9	Iron status biomarkers;
CRC	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	6.05	0.32	3.98e-9	Response to antipsychotic treatment;
CRC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.56	9.29	0.46	2.24e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs5751901	0.929	rs2330805	chr22:24998619	A/G	cg08808123	chr22:24999002	GGT1	-0.4	-5.99	-0.31	5.47e-9	Protein quantitative trait loci;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.47	6.37	0.33	6.34e-10	Resistin levels;
CRC	cis	rs2108622	0.727	rs7253873	chr19:15980900	A/G	cg13772218	chr19:15982569	NA	0.48	6.73	0.35	7.45e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20721121	chr10:64565336	ADO	0.45	6.3	0.33	9.5e-10	Anxiety disorder;
CRC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.09	-18.8	-0.72	4.4e-54	Ulcerative colitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22567473	chr15:63902661	HERC1	0.44	5.96	0.31	6.49e-9	Thyroid stimulating hormone;
CRC	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.47	8.39	0.42	1.46e-15	Weight;
CRC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.78	-0.47	5.54e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.1	0.52	1.55e-24	Coffee consumption (cups per day);
CRC	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg08017634	chr8:144659831	NAPRT1	0.66	5.81	0.3	1.5e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg08795948	chr3:128337044	NA	0.35	5.97	0.31	6.23e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg02421172	chr7:1938701	MAD1L1	-0.47	-6.68	-0.35	9.93e-11	Bipolar disorder;
CRC	cis	rs742115	0.563	rs2281063	chr6:11298263	T/C	cg25250968	chr6:11318770	NEDD9	-0.39	-7.61	-0.39	2.83e-13	Coronary artery disease;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.79	-9.35	-0.46	1.4e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg18833306	chr6:118973337	C6orf204	0.44	5.71	0.3	2.59e-8	Diastolic blood pressure;
CRC	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.52	-8.14	-0.41	8.01e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.16e-13	Educational attainment;
CRC	cis	rs6604026	0.630	rs2263247	chr1:93364067	T/C	cg17283838	chr1:93427260	FAM69A	-0.45	-5.87	-0.31	1.07e-8	Multiple sclerosis;
CRC	cis	rs7487075	0.619	rs7311504	chr12:46830776	G/A	cg22049899	chr12:47219821	SLC38A4	0.32	5.89	0.31	9.68e-9	Itch intensity from mosquito bite;
CRC	cis	rs11212617	0.905	rs672964	chr11:108125471	C/G	cg01991180	chr11:108092276	ATM;NPAT	0.39	5.65	0.3	3.46e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.54	7.98	0.4	2.52e-14	Lung cancer;
CRC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.84	-0.48	3.38e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.41	-6.09	-0.32	3.17e-9	Male sexual orientation;
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg18833306	chr6:118973337	C6orf204	0.44	5.71	0.3	2.59e-8	Diastolic blood pressure;
CRC	cis	rs4731207	0.565	rs1904972	chr7:124669687	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.15	-0.32	2.22e-9	Cutaneous malignant melanoma;
CRC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.53	0.43	5.25e-16	Height;
CRC	cis	rs12541635	1.000	rs1366965	chr8:107085224	T/A	cg10147462	chr8:107024639	NA	-0.39	-6.48	-0.34	3.36e-10	Age of smoking initiation;
CRC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg11189052	chr15:85197271	WDR73	0.64	9.31	0.46	1.88e-18	Schizophrenia;
CRC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.53	-7.92	-0.4	3.76e-14	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10905065	0.931	rs6602240	chr10:5816751	C/A	cg11519256	chr10:5708881	ASB13	-0.42	-5.89	-0.31	9.37e-9	Menopause (age at onset);
CRC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg07713946	chr22:31675144	LIMK2	0.42	6.24	0.33	1.35e-9	Colorectal cancer;
CRC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.56	9.2	0.45	4.12e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.41	5.84	0.31	1.29e-8	Blood metabolite levels;
CRC	cis	rs6968419	0.674	rs1918912	chr7:115906373	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.32	-0.33	8.33e-10	Intraocular pressure;
CRC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	10.69	0.51	4.37e-23	Prudent dietary pattern;
CRC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.63	0.57	4.28e-30	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06491456	chr7:7606812	MIOS	-0.34	-5.96	-0.31	6.34e-9	Myopia (pathological);
CRC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.49	-9.09	-0.45	9.28e-18	Dupuytren's disease;
CRC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.53	-5.94	-0.31	7.38e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.03	0.68	4.35e-47	Electrocardiographic conduction measures;
CRC	cis	rs1322512	1.000	rs2800632	chr6:153008632	C/A	cg03415253	chr6:152958462	SYNE1	0.39	6.01	0.31	4.94e-9	Tonometry;
CRC	cis	rs911119	0.913	rs6048922	chr20:23578116	G/C	cg16589663	chr20:23618590	CST3	0.41	5.71	0.3	2.51e-8	Chronic kidney disease;
CRC	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.73	-0.35	7.73e-11	Putamen volume;
CRC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.68	-0.57	2.79e-30	Ulcerative colitis;
CRC	cis	rs910187	0.596	rs12329631	chr20:45794427	C/T	cg27589058	chr20:45804311	EYA2	-0.37	-6.6	-0.34	1.6e-10	Migraine;
CRC	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.75	-10.32	-0.49	8.13e-22	White matter hyperintensity burden;
CRC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.58	9.06	0.45	1.22e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.44	6.26	0.33	1.23e-9	Body mass index;
CRC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg03037974	chr15:76606532	NA	-0.51	-7.66	-0.39	2.13e-13	Blood metabolite levels;
CRC	cis	rs10155981	0.510	rs78815495	chr7:22584529	C/T	cg05062323	chr7:22590069	NA	-0.63	-6.73	-0.35	7.7e-11	Bilirubin levels;
CRC	cis	rs2637266	0.538	rs11001803	chr10:78269701	A/G	cg18941641	chr10:78392320	NA	-0.35	-5.82	-0.31	1.43e-8	Pulmonary function;
CRC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.52	6.17	0.32	1.98e-9	Bipolar disorder;
CRC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.61	-7.48	-0.38	6.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2710642	0.927	rs6705798	chr2:63259881	C/T	cg17519650	chr2:63277830	OTX1	0.5	6.78	0.35	5.42e-11	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.65	-0.43	2.39e-16	Uric acid levels;
CRC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.67	8.74	0.43	1.21e-16	Morning vs. evening chronotype;
CRC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg01943577	chr7:158741284	NA	-0.4	-5.82	-0.31	1.42e-8	Height;
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg17346650	chr17:80929145	B3GNTL1	-0.48	-7.27	-0.37	2.62e-12	Glycated hemoglobin levels;
CRC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg21770322	chr7:97807741	LMTK2	0.87	19.51	0.73	6.95e-57	Breast cancer;
CRC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.39	5.8	0.3	1.52e-8	Mean corpuscular volume;
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	4.04e-9	Total body bone mineral density;
CRC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.78	10.95	0.52	5.45e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg12193833	chr17:30244370	NA	-0.74	-8.72	-0.43	1.45e-16	Hip circumference adjusted for BMI;
CRC	cis	rs4663969	0.839	rs7572563	chr2:234617236	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.57	-0.34	1.98e-10	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.39	6.43	0.33	4.56e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.05	-0.36	1.03e-11	Alzheimer's disease (late onset);
CRC	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.34	-0.33	7.79e-10	Breast cancer;
CRC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.66	8.87	0.44	4.62e-17	Morning vs. evening chronotype;
CRC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.17	0.41	6.62e-15	Arsenic metabolism;
CRC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg23018236	chr17:30244563	NA	-0.66	-7.89	-0.4	4.54e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6908034	0.607	rs34109983	chr6:19808042	G/A	cg02682789	chr6:19804855	NA	0.78	6.83	0.35	4.16e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.46	8.04	0.41	1.68e-14	Coronary artery disease;
CRC	cis	rs10924970	0.967	rs12739707	chr1:235466564	C/G	cg26050004	chr1:235667680	B3GALNT2	0.42	6.23	0.32	1.45e-9	Asthma;
CRC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.65	-0.3	3.56e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg18016565	chr1:150552671	MCL1	0.44	6.17	0.32	2.03e-9	Melanoma;
CRC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg11189052	chr15:85197271	WDR73	0.63	9.07	0.45	1.07e-17	Schizophrenia;
CRC	trans	rs9914544	0.545	rs2892015	chr17:18786849	C/T	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.18	-0.32	1.93e-9	Educational attainment (years of education);
CRC	cis	rs4880487	0.888	rs67456501	chr10:1252400	G/A	cg03183215	chr10:1252341	ADARB2	-0.3	-6.37	-0.33	6.38e-10	Migraine;
CRC	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	9.33	0.46	1.56e-18	Blood protein levels;
CRC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-6.29	-0.33	1.03e-9	Major depressive disorder;
CRC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.68	10.07	0.49	5.66e-21	Platelet distribution width;
CRC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.94	0.74	1.46e-58	Prudent dietary pattern;
CRC	cis	rs41005	1.000	rs12692349	chr2:8114312	G/A	cg03155496	chr2:8117019	LOC339788	-0.39	-6.88	-0.35	3.12e-11	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg21466736	chr12:48725269	NA	0.47	7.3	0.37	2.11e-12	Plateletcrit;
CRC	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.62	8.16	0.41	7.21e-15	Coronary artery disease;
CRC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.37	-6.06	-0.32	3.63e-9	Platelet distribution width;
CRC	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg27398640	chr15:77910606	LINGO1	0.46	8.61	0.43	3.14e-16	Type 2 diabetes;
CRC	trans	rs2055729	0.710	rs114038384	chr8:9737519	T/A	cg08975724	chr8:8085496	FLJ10661	0.5	6.23	0.32	1.46e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.68	0.35	1e-10	Resistin levels;
CRC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	15.42	0.65	9.52e-41	Lymphocyte percentage of white cells;
CRC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21028142	chr17:79581711	NPLOC4	0.34	7.02	0.36	1.25e-11	Eye color traits;
CRC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.36	-0.56	4.32e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.18	-0.32	1.88e-9	Menopause (age at onset);
CRC	trans	rs7730934	1.000	rs6450357	chr5:55269996	T/C	cg10323188	chr3:28613979	NA	0.51	5.97	0.31	6.05e-9	Blood protein levels;
CRC	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg02158880	chr13:53174818	NA	0.55	8.78	0.44	9e-17	Lewy body disease;
CRC	cis	rs7487075	0.786	rs4768694	chr12:46677658	T/A	cg22049899	chr12:47219821	SLC38A4	0.32	6.11	0.32	2.84e-9	Itch intensity from mosquito bite;
CRC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.14	-16.86	-0.68	2.12e-46	Hip circumference adjusted for BMI;
CRC	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.72	11.04	0.52	2.6e-24	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg18288967	chr1:45987694	PRDX1	0.68	7.26	0.37	2.87e-12	Obesity-related traits;
CRC	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.61	8.87	0.44	4.6e-17	Corneal astigmatism;
CRC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.91	-0.52	7.25e-24	Blood trace element (Zn levels);
CRC	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06307176	chr5:131281290	NA	-0.42	-6.24	-0.33	1.32e-9	Life satisfaction;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs11203032	0.831	rs4511206	chr10:90968759	C/T	cg16672925	chr10:90967113	CH25H	0.47	6.0	0.31	5.19e-9	Heart failure;
CRC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-6.19	-0.32	1.76e-9	Lung cancer;
CRC	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.55	8.31	0.42	2.48e-15	Testicular germ cell tumor;
CRC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.87	12.74	0.57	1.71e-30	Diastolic blood pressure;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03856714	chr2:96658020	NA	-0.43	-6.4	-0.33	5.32e-10	HDL cholesterol;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg07754938	chr3:48885314	PRKAR2A	0.42	5.97	0.31	6.01e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg01216370	chr2:228736459	WDR69	-0.45	-5.72	-0.3	2.36e-8	Blood pressure;
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg10729496	chr3:10149963	C3orf24	0.48	6.31	0.33	9.01e-10	Alzheimer's disease;
CRC	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.62	6.61	0.34	1.55e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg07828024	chr6:149772892	ZC3H12D	0.48	9.03	0.45	1.5e-17	Dupuytren's disease;
CRC	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg22495460	chr2:25135724	ADCY3	-0.81	-13.57	-0.6	1.24e-33	Body mass index;
CRC	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.84	14.03	0.61	2.31e-35	Phospholipid levels (plasma);
CRC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg15687855	chr3:44754131	ZNF502	-0.36	-6.09	-0.32	3.16e-9	Depressive symptoms;
CRC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg01629716	chr15:45996671	NA	0.4	8.25	0.41	3.97e-15	Waist circumference;Weight;
CRC	cis	rs2084637	0.931	rs1450796	chr11:122395018	T/A	cg21585512	chr11:122030076	LOC399959	-0.41	-7.49	-0.38	6.44e-13	Stroke;
CRC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.6	9.12	0.45	7.8e-18	Body mass index;
CRC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.37	-0.33	6.29e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6545883	0.501	rs935860	chr2:61406561	G/C	cg10580144	chr2:61372316	C2orf74	0.33	7.5	0.38	6.18e-13	Tuberculosis;
CRC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg19635926	chr16:89946313	TCF25	0.67	6.1	0.32	2.97e-9	Skin colour saturation;
CRC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.46	-6.68	-0.35	1.01e-10	Type 2 diabetes;
CRC	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.57	8.39	0.42	1.48e-15	Autism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13415434	chr3:49044522	P4HTM;WDR6	0.52	6.88	0.35	3.11e-11	Thyroid stimulating hormone;
CRC	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg19875578	chr6:126661172	C6orf173	0.41	5.63	0.3	3.95e-8	Male-pattern baldness;
CRC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-8.28	-0.42	3.03e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg26248373	chr2:1572462	NA	-0.67	-7.24	-0.37	3.16e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.03	21.64	0.77	3.44e-65	Myeloid white cell count;
CRC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.4	-5.94	-0.31	7.19e-9	Response to metformin (IC50);
CRC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.53	8.71	0.43	1.54e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg05679027	chr9:99775184	HIATL2	-0.41	-6.15	-0.32	2.24e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.61	-0.3	4.22e-8	Migraine;
CRC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.66	-10.29	-0.49	1.01e-21	Height;
CRC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.66	11.81	0.55	4.44e-27	Height;
CRC	cis	rs6976053	0.868	rs10953305	chr7:100492568	G/A	cg10426581	chr7:100472382	SRRT	0.38	5.8	0.3	1.57e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg01941586	chr1:40203715	PPIE	-0.44	-6.11	-0.32	2.75e-9	Blood protein levels;
CRC	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg16898833	chr6:26189333	HIST1H4D	0.97	7.93	0.4	3.43e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg21251018	chr6:28226885	NKAPL	0.55	9.34	0.46	1.51e-18	Pulmonary function;
CRC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.72	-0.3	2.43e-8	Intelligence (multi-trait analysis);
CRC	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-6.01	-0.31	4.82e-9	Vitamin D levels;
CRC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg26248373	chr2:1572462	NA	-0.67	-7.24	-0.37	3.16e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14094681	chr14:78174204	C14orf156;ALKBH1	0.46	6.37	0.33	6.26e-10	Anxiety disorder;
CRC	cis	rs990171	1.000	rs2270297	chr2:102992675	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.37e-8	Lymphocyte counts;
CRC	cis	rs9462027	0.628	rs7742652	chr6:34667075	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.28	0.33	1.1e-9	Systemic lupus erythematosus;
CRC	cis	rs73206853	0.614	rs12322130	chr12:110512408	C/T	cg12870014	chr12:110450643	ANKRD13A	0.79	7.17	0.37	5.14e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.65	10.18	0.49	2.49e-21	Personality dimensions;
CRC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg16141378	chr3:129829833	LOC729375	0.42	6.26	0.33	1.19e-9	Neuroticism;
CRC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.56	-8.69	-0.43	1.68e-16	Aortic root size;
CRC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-6.17	-0.32	2.02e-9	Schizophrenia;
CRC	trans	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.39	-6.11	-0.32	2.81e-9	Mean corpuscular volume;
CRC	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.53	-8.35	-0.42	1.94e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18099408	chr3:52552593	STAB1	-0.52	-9.02	-0.45	1.57e-17	Electroencephalogram traits;
CRC	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-9.52	-0.46	3.94e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.61	-9.5	-0.46	4.62e-19	Body mass index;
CRC	cis	rs1891275	0.515	rs6583784	chr10:93491576	A/G	cg07889827	chr10:93443413	NA	0.4	6.77	0.35	6.03e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18357526	chr6:26021779	HIST1H4A	0.43	6.08	0.32	3.27e-9	Iron status biomarkers;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs6604026	0.656	rs2811598	chr1:93336933	A/G	cg17283838	chr1:93427260	FAM69A	-0.43	-5.6	-0.3	4.52e-8	Multiple sclerosis;
CRC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg03198203	chr11:17034484	PLEKHA7	-0.27	-6.59	-0.34	1.76e-10	Coronary artery disease;
CRC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.16	-0.32	2.1e-9	Daytime sleep phenotypes;
CRC	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg09873164	chr1:152488093	CRCT1	0.38	6.33	0.33	7.97e-10	Hair morphology;
CRC	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.06	0.45	1.18e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.85	-15.05	-0.64	2.48e-39	Lewy body disease;
CRC	cis	rs73206853	0.841	rs73191825	chr12:110942205	T/C	cg12870014	chr12:110450643	ANKRD13A	0.77	7.44	0.38	8.61e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.82e-8	Major depressive disorder;
CRC	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.52	8.05	0.41	1.51e-14	Corneal astigmatism;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.69	7.77	0.39	9.92e-14	Body mass index;
CRC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-9.3	-0.46	2.08e-18	Type 2 diabetes;
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.52	7.03	0.36	1.19e-11	Alzheimer's disease;
CRC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.54	-9.41	-0.46	8.76e-19	Dupuytren's disease;
CRC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg00409905	chr10:38381863	ZNF37A	0.52	8.0	0.4	2.16e-14	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.92	0.58	3.72e-31	Alzheimer's disease;
CRC	cis	rs6840360	0.642	rs7676493	chr4:152426765	C/T	cg09659197	chr4:152720779	NA	0.33	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12504957	chr12:69202060	MDM2	0.43	6.12	0.32	2.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.42	-5.67	-0.3	3.1e-8	Schizophrenia;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg23715435	chr6:26027513	HIST1H4B	0.57	6.36	0.33	6.94e-10	Lymphocyte counts;
CRC	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.78	-0.3	1.73e-8	Daytime sleep phenotypes;
CRC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.08	0.32	3.35e-9	Monocyte percentage of white cells;
CRC	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.38	-0.42	1.55e-15	Idiopathic membranous nephropathy;
CRC	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg00490450	chr3:139108681	COPB2	0.45	6.69	0.35	9.56e-11	Obesity-related traits;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01575614	chr17:40169693	DNAJC7;NKIRAS2	-0.42	-6.13	-0.32	2.58e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-5.84	-0.31	1.27e-8	Morning vs. evening chronotype;
CRC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.09	0.55	4.38e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-5.93	-0.31	7.5e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.38	-6.87	-0.35	3.25e-11	Reticulocyte fraction of red cells;
CRC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.67	-8.14	-0.41	8.07e-15	Rheumatoid arthritis;
CRC	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.43	-5.75	-0.3	2e-8	Height;
CRC	cis	rs6584202	0.589	rs10883094	chr10:100188106	C/T	cg26618903	chr10:100175079	PYROXD2	-0.43	-6.54	-0.34	2.34e-10	Obesity-related traits;
CRC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.58	9.64	0.47	1.51e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.13	0.32	2.46e-9	Aortic root size;
CRC	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-6.56	-0.34	2.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg03959625	chr15:84868606	LOC388152	0.41	6.07	0.32	3.55e-9	Schizophrenia;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg10876282	chr6:28092338	ZSCAN16	0.49	6.62	0.34	1.5e-10	Parkinson's disease;
CRC	trans	rs1126478	0.650	rs11130091	chr3:46504531	G/C	cg23913400	chr17:73717552	ITGB4	0.47	6.05	0.32	3.89e-9	Blood protein levels;
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.37	-0.33	6.19e-10	Bipolar disorder;
CRC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.35	5.81	0.31	1.46e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs12534701	1.000	rs12534701	chr7:154680910	A/C	cg24255201	chr7:154684926	DPP6	-0.58	-8.46	-0.42	8.97e-16	Colorectal cancer (diet interaction);
CRC	cis	rs3996993	0.809	rs2894802	chr6:52656169	T/G	cg20803780	chr6:52668592	GSTA1	-0.38	-7.17	-0.37	5.05e-12	Hemoglobin concentration;
CRC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg19980929	chr12:42632907	YAF2	0.42	6.24	0.33	1.37e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.2	0.67	8.61e-44	Chronic sinus infection;
CRC	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.41	-5.79	-0.3	1.68e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.52	8.15	0.41	7.88e-15	Red blood cell count;
CRC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg20684491	chr1:25596433	NA	0.43	7.79	0.39	8.55e-14	Erythrocyte sedimentation rate;
CRC	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg27398640	chr15:77910606	LINGO1	-0.42	-7.14	-0.37	5.93e-12	Type 2 diabetes;
CRC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg05043794	chr9:111880884	C9orf5	-0.33	-5.77	-0.3	1.82e-8	Menarche (age at onset);
CRC	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.6	-7.28	-0.37	2.46e-12	Ulcerative colitis;
CRC	cis	rs2735413	0.914	rs2707604	chr16:78054853	A/G	cg04733911	chr16:78082701	NA	-0.35	-5.69	-0.3	2.76e-8	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.64	-0.3	3.72e-8	Breast cancer;
CRC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.48e-17	Bladder cancer;
CRC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.02	0.45	1.55e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6496667	1.000	rs6496665	chr15:90891615	G/A	cg04176472	chr15:90893244	GABARAPL3	0.55	8.43	0.42	1.09e-15	Rheumatoid arthritis;
CRC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.02	-0.52	2.97e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg24675056	chr1:15929824	NA	0.49	6.78	0.35	5.69e-11	Systolic blood pressure;
CRC	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.55	8.85	0.44	5.51e-17	Mean corpuscular volume;
CRC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.75	0.39	1.15e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7192380	0.893	rs1469908	chr16:69764412	C/T	cg00738113	chr16:70207722	CLEC18C	0.33	5.77	0.3	1.79e-8	Sjögren's syndrome;
CRC	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg27124370	chr19:33622961	WDR88	0.41	5.68	0.3	2.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.16	0.37	5.47e-12	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18097281	chr15:40545145	PAK6;C15orf56	0.44	5.99	0.31	5.55e-9	Anxiety disorder;
CRC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	6.25	0.33	1.24e-9	Asthma;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg06470822	chr6:28175283	NA	0.94	12.8	0.58	1.0500000000000001e-30	Parkinson's disease;
CRC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.74	-11.12	-0.52	1.33e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg26260408	chr4:53727979	RASL11B	0.41	5.92	0.31	8.2e-9	Optic nerve measurement (cup area);
CRC	trans	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19862616	chr7:65841803	NCRNA00174	0.48	6.79	0.35	5.11e-11	Eotaxin levels;
CRC	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.49	-8.72	-0.43	1.36e-16	Intelligence (multi-trait analysis);
CRC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.81	0.44	7.07e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	10.1	0.49	4.65e-21	HIV-1 control;
CRC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	0.91	10.87	0.51	9.82e-24	Red blood cell traits;
CRC	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg00531865	chr16:30841666	NA	-0.42	-6.09	-0.32	3.15e-9	Dementia with Lewy bodies;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02073511	chr16:3550924	CLUAP1	-0.4	-6.21	-0.32	1.64e-9	Myopia (pathological);
CRC	trans	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg05376469	chr2:102649931	NA	0.39	6.3	0.33	9.63e-10	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg06784218	chr1:46089804	CCDC17	-0.35	-6.47	-0.34	3.5e-10	Red blood cell count;Reticulocyte count;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg05679836	chr12:57472765	TMEM194A	0.58	6.01	0.31	5.05e-9	Airway imaging phenotypes;
CRC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.63	-0.34	1.39e-10	Menopause (age at onset);
CRC	cis	rs6585424	1.000	rs61860045	chr10:81947397	C/T	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.64	-0.3	3.6e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.68	-9.72	-0.47	8.49e-20	Menopause (age at onset);
CRC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg10494257	chr1:16342123	HSPB7	0.41	5.74	0.3	2.16e-8	Systolic blood pressure;
CRC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg15832292	chr6:96025679	MANEA	-0.6	-6.35	-0.33	7.11e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.47e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	8.9	0.44	3.81e-17	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.56	7.29	0.37	2.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17092148	0.887	rs2378199	chr20:33186480	T/C	cg08999081	chr20:33150536	PIGU	0.51	6.41	0.33	5.13e-10	Neuroticism;
CRC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.34	-0.33	7.54e-10	Obesity-related traits;
CRC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.53	7.72	0.39	1.43e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.45	0.42	9.82e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	12.14	0.56	2.76e-28	Menopause (age at onset);
CRC	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.09	0.52	1.78e-24	Coffee consumption (cups per day);
CRC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.08	0.41	1.23e-14	Height;
CRC	cis	rs1256061	0.646	rs1152588	chr14:64688175	G/C	cg23250157	chr14:64679961	SYNE2	0.44	6.93	0.36	2.28e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-17.97	-0.7	9.06e-51	Coronary artery disease;
CRC	cis	rs9462027	0.675	rs9296132	chr6:34777531	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.93	-0.31	7.48e-9	Systemic lupus erythematosus;
CRC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.48	-6.36	-0.33	6.9e-10	Cognitive ability;
CRC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.97	-14.57	-0.63	1.9e-37	Monocyte percentage of white cells;
CRC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	10.8	0.51	1.79e-23	Motion sickness;
CRC	cis	rs6968419	0.755	rs4730719	chr7:115895010	A/C	cg02561103	chr7:115862891	TES	0.44	6.66	0.34	1.18e-10	Intraocular pressure;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg11843238	chr5:131593191	PDLIM4	0.52	9.21	0.45	4.05e-18	Acylcarnitine levels;
CRC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.44	7.4	0.38	1.12e-12	Diastolic blood pressure;
CRC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg23136738	chr11:925521	AP2A2	-0.42	-6.92	-0.36	2.4e-11	Alzheimer's disease (late onset);
CRC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.21	0.64	6.34e-40	Platelet count;
CRC	cis	rs847649	0.767	rs11972261	chr7:102641244	T/G	cg18108683	chr7:102477205	FBXL13	0.56	8.97	0.44	2.3e-17	Morning vs. evening chronotype;
CRC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.68	-11.01	-0.52	3.15e-24	Personality dimensions;
CRC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.27e-46	Breast cancer;
CRC	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg12682573	chr17:27188876	MIR451;MIR144	-0.6	-8.79	-0.44	8.51e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg18232548	chr7:50535776	DDC	0.47	6.15	0.32	2.2e-9	Malaria;
CRC	cis	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.7	-0.35	9.21e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.64	6.27	0.33	1.16e-9	Axial length;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23943013	chr5:79551904	SERINC5	0.38	5.99	0.31	5.61e-9	Interleukin-6 levels;
CRC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-12.44	-0.57	2.29e-29	Electrocardiographic conduction measures;
CRC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.69	10.25	0.49	1.36e-21	Other erythrocyte phenotypes;
CRC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.78	-9.37	-0.46	1.15e-18	Platelet count;
CRC	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg16898833	chr6:26189333	HIST1H4D	0.77	6.45	0.33	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg16060761	chr17:80687452	NA	0.54	8.34	0.42	2.06e-15	Glycated hemoglobin levels;
CRC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.22	-0.53	5.99e-25	Blood trace element (Zn levels);
CRC	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg01312482	chr5:178451176	ZNF879	0.36	6.27	0.33	1.16e-9	Pubertal anthropometrics;
CRC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.65	-0.3	3.48e-8	Obesity-related traits;
CRC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg10305451	chr2:177043427	NA	0.72	11.31	0.53	2.76e-25	IgG glycosylation;
CRC	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.53	9.0	0.44	1.82e-17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg21665744	chr7:39171113	POU6F2	0.45	6.13	0.32	2.54e-9	IgG glycosylation;
CRC	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg12458913	chr13:53173898	NA	0.55	8.69	0.43	1.69e-16	Lewy body disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15344021	chr17:2240169	TSR1;SGSM2	0.51	6.71	0.35	8.43e-11	Thyroid stimulating hormone;
CRC	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.45	-6.29	-0.33	9.93e-10	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.09	0.32	3.17e-9	Bipolar disorder;
CRC	cis	rs720844	0.748	rs10928407	chr2:149329961	C/G	cg09247360	chr2:149335327	NA	-0.56	-5.86	-0.31	1.09e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11229555	0.645	rs4347409	chr11:58176252	C/T	cg15696309	chr11:58395628	NA	0.8	10.3	0.49	9.25e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20566420	chr12:122327043	PSMD9	0.51	6.62	0.34	1.42e-10	Thyroid stimulating hormone;
CRC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg18478394	chr8:109455254	TTC35	0.41	6.18	0.32	1.88e-9	Dupuytren's disease;
CRC	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.16	0.32	2.09e-9	Neuroticism;
CRC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.96	0.36	1.85e-11	HDL cholesterol;
CRC	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.64	-9.26	-0.45	2.65e-18	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04361527	chr1:154909836	PMVK	0.43	6.1	0.32	3.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	trans	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg19188899	chr13:112838565	NA	-0.43	-6.75	-0.35	6.79e-11	Systemic lupus erythematosus;
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11645453	chr3:52864694	ITIH4	0.34	5.9	0.31	9.11e-9	Bipolar disorder;
CRC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.44	-6.15	-0.32	2.28e-9	Fibrinogen levels;
CRC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.9	18.72	0.72	9.17e-54	Urate levels in lean individuals;
CRC	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.41	7.22	0.37	3.55e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.56	0.34	2.03e-10	Diastolic blood pressure;
CRC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.48	-0.42	7.49e-16	Hip circumference adjusted for BMI;
CRC	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg09537434	chr19:41945824	ATP5SL	-0.49	-6.33	-0.33	8.03e-10	Colorectal cancer;
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg19678392	chr7:94953810	PON1	-0.56	-7.06	-0.36	9.89e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs67981189	0.529	rs2810097	chr14:71434114	C/T	cg15910301	chr14:71632612	NA	-0.29	-5.68	-0.3	2.89e-8	Schizophrenia;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.22e-22	Bipolar disorder;
CRC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	8.45	0.42	9.38e-16	Total body bone mineral density;
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.65	8.74	0.43	1.2e-16	Alzheimer's disease;
CRC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg25456477	chr12:86230367	RASSF9	0.35	5.97	0.31	6.11e-9	Major depressive disorder;
CRC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.77	-0.35	6.04e-11	Mood instability;
CRC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.55	6.73	0.35	7.57e-11	Birth weight;
CRC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg25834613	chr7:1915315	MAD1L1	-0.41	-5.89	-0.31	9.69e-9	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00597366	chr16:46917883	GPT2	0.48	6.71	0.35	8.74e-11	Response to antipsychotic treatment;
CRC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg06028605	chr16:24865363	SLC5A11	-0.42	-6.53	-0.34	2.43e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7859245	1.000	rs7859245	chr9:138490597	A/G	cg05843800	chr3:4508875	SUMF1	-0.39	-6.13	-0.32	2.56e-9	Response to paliperidone in schizophrenia (negative Marder score);
CRC	trans	rs6956675	0.534	rs7780975	chr7:62652443	G/A	cg01314568	chr7:57830625	NA	-0.43	-6.31	-0.33	9.04e-10	Obesity-related traits;
CRC	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg24851651	chr11:66362959	CCS	0.38	6.43	0.33	4.56e-10	Educational attainment (years of education);
CRC	cis	rs4665630	0.522	rs114382704	chr2:23951810	G/T	cg07265300	chr2:24346000	PFN4;LOC375190	0.78	5.91	0.31	8.42e-9	Hypertension;
CRC	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg10820045	chr2:198174542	NA	0.46	7.83	0.4	6.65e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs245880	0.740	rs245902	chr7:29194919	T/A	cg17163760	chr7:29186267	CPVL	-0.39	-6.88	-0.35	3.05e-11	Warfarin maintenance dose;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.74	-12.79	-0.58	1.07e-30	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.14	-0.37	6.14e-12	Height;
CRC	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	5.04e-11	Prostate cancer;
CRC	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg00490450	chr3:139108681	COPB2	0.44	6.52	0.34	2.64e-10	Obesity-related traits;
CRC	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg14844989	chr11:31128820	NA	0.35	6.07	0.32	3.58e-9	Red blood cell count;
CRC	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.88	13.01	0.58	1.73e-31	Diastolic blood pressure;Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07251136	chr5:95158433	GLRX	0.45	6.29	0.33	1.03e-9	Response to antipsychotic treatment;
CRC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.76	13.35	0.59	9.06e-33	Oral cavity cancer;
CRC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg24011408	chr12:48396354	COL2A1	0.45	6.1	0.32	3.01e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.59	-10.97	-0.52	4.48e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.28	-0.42	3.05e-15	Brugada syndrome;
CRC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.33	-12.9	-0.58	4.5e-31	Plateletcrit;
CRC	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg09659197	chr4:152720779	NA	0.35	6.18	0.32	1.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-5.92	-0.31	7.92e-9	Tonsillectomy;
CRC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	0.98	14.41	0.62	7.96e-37	Breast cancer;
CRC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.38	5.93	0.31	7.85e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19940975	chr18:32820997	ZNF397	0.41	6.88	0.35	3.05e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg19223190	chr17:80058835	NA	0.41	6.52	0.34	2.58e-10	Life satisfaction;
CRC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg03609598	chr5:56110824	MAP3K1	0.74	8.84	0.44	5.96e-17	Initial pursuit acceleration;
CRC	cis	rs12936587	0.748	rs11871738	chr17:17525243	A/G	cg09796270	chr17:17721594	SREBF1	-0.41	-5.96	-0.31	6.44e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.11	19.13	0.73	2.31e-55	Cognitive function;
CRC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	7.98	0.4	2.49e-14	Height;
CRC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.47	5.82	0.31	1.42e-8	Vitiligo;
CRC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg11189052	chr15:85197271	WDR73	-0.57	-7.77	-0.39	9.98e-14	Schizophrenia;
CRC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	0.59	6.4	0.33	5.3e-10	LDL cholesterol;Cholesterol, total;
CRC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.42	-20.26	-0.75	8.39e-60	Hip circumference adjusted for BMI;
CRC	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg13491945	chr12:107078410	RFX4	0.36	6.11	0.32	2.77e-9	Heart rate;
CRC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.81	11.14	0.52	1.09e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.05	-0.66	3.08e-43	Intelligence (multi-trait analysis);
CRC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.67	-11.39	-0.53	1.41e-25	Dental caries;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.37	-0.33	6.43e-10	Breast cancer;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg03623178	chr6:28175578	NA	0.59	8.47	0.42	8.46e-16	Parkinson's disease;
CRC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg01639898	chr1:32083012	HCRTR1	0.3	6.13	0.32	2.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.57	9.16	0.45	5.83e-18	Schizophrenia;
CRC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.85	-0.35	3.63e-11	Lung cancer;
CRC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.86	15.4	0.65	1.17e-40	Breast cancer;
CRC	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg18809830	chr7:99032528	PTCD1	-1.18	-8.59	-0.43	3.66e-16	Blood metabolite levels;
CRC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.44	7.46	0.38	7.96e-13	Crohn's disease;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg12273811	chr6:28175739	NA	0.5	6.72	0.35	8.08e-11	Parkinson's disease;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00802000	chr16:706648	WDR90	-0.44	-6.34	-0.33	7.61e-10	Height;
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg12564285	chr5:131593104	PDLIM4	0.4	7.52	0.38	5.2e-13	Blood metabolite levels;
CRC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.34	7.04	0.36	1.12e-11	Lung cancer;
CRC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.5	13.63	0.6	7.37e-34	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-12.88	-0.58	5.23e-31	Obesity-related traits;
CRC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.04e-12	Testicular germ cell tumor;
CRC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg11887960	chr12:57824829	NA	0.58	6.44	0.33	4.17e-10	Lung disease severity in cystic fibrosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03811519	chr9:134001305	NUP214	0.48	6.83	0.35	4.19e-11	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.51	-0.34	2.75e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.91	0.31	8.39e-9	Tonsillectomy;
CRC	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.38	6.1	0.32	3.02e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.83	-0.31	1.3e-8	Daytime sleep phenotypes;
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg16721101	chr20:25176146	ENTPD6	-0.7	-6.09	-0.32	3.23e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12172441	chr6:28176163	NA	0.62	7.38	0.38	1.28e-12	Depression;
CRC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-8.33	-0.42	2.22e-15	Hemoglobin concentration;
CRC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.85	0.31	1.19e-8	Homoarginine levels;
CRC	cis	rs4253311	0.520	rs10000459	chr4:187124459	A/C	cg24794857	chr4:187113578	CYP4V2	0.4	5.95	0.31	6.98e-9	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
CRC	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.3	-0.33	9.75e-10	Depressive episodes in bipolar disorder;
CRC	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg21496419	chr19:44306685	LYPD5	0.35	6.5	0.34	3.02e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg06522879	chr11:64358276	SLC22A12	0.41	5.89	0.31	9.6e-9	Body mass index;Urate levels;
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-6.48	-0.34	3.43e-10	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.66	0.57	3.43e-30	Alzheimer's disease;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg26304593	chr6:42947056	PEX6	-0.45	-6.56	-0.34	2.09e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg09252805	chr1:22778600	ZBTB40	-0.4	-6.03	-0.32	4.29e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11446398	chr5:77624930	NA	0.41	5.93	0.31	7.48e-9	Triglycerides;
CRC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg21153622	chr11:89784906	NA	-0.37	-5.98	-0.31	5.8e-9	Height;
CRC	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg00750074	chr16:89608354	SPG7	-0.47	-7.11	-0.36	7.4e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13844804	chr7:814759	HEATR2	-0.53	-5.61	-0.3	4.37e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg13880726	chr7:1868755	MAD1L1	-0.43	-5.71	-0.3	2.52e-8	Bipolar disorder;
CRC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-0.85	-12.51	-0.57	1.18e-29	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15576692	chr20:18548019	LOC388789	0.36	6.15	0.32	2.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-9.07	-0.45	1.08e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.76	-13.15	-0.59	4.88e-32	Body mass index;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg00167275	chr10:88854588	FAM35A;GLUD1	-0.41	-6.0	-0.31	5.22e-9	Protein C levels;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.07	-0.32	3.49e-9	Parkinson's disease;
CRC	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.84	9.59	0.47	2.33e-19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg15845792	chr6:28175446	NA	0.67	8.78	0.44	8.82e-17	Parkinson's disease;
CRC	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg01422370	chr2:73384389	NA	0.37	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.79	14.69	0.63	6.18e-38	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18252515	chr7:66147081	NA	0.39	5.6	0.3	4.46e-8	Aortic root size;
CRC	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.47	-6.7	-0.35	9.13e-11	Breast cancer;
CRC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.27	0.49	1.21e-21	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.45	-7.05	-0.36	1.06e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg15147215	chr3:52552868	STAB1	-0.53	-9.27	-0.46	2.51e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.65	-11.93	-0.55	1.7e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg18016565	chr1:150552671	MCL1	0.45	6.16	0.32	2.07e-9	Melanoma;
CRC	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.76	9.45	0.46	6.58e-19	Type 2 diabetes;
CRC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.81	0.58	9.33e-31	Mean platelet volume;
CRC	cis	rs28829049	0.597	rs2066002	chr1:19504300	G/A	cg13387374	chr1:19411106	UBR4	0.39	5.67	0.3	3.19e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.36	-5.98	-0.31	5.84e-9	Glycated hemoglobin levels;
CRC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.29	-6.31	-0.33	8.78e-10	IgG glycosylation;
CRC	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.44	-6.2	-0.32	1.71e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.6	10.58	0.5	1.07e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1867631	0.585	rs11208940	chr1:67127242	A/G	cg02459107	chr1:67143332	SGIP1	-0.37	-6.54	-0.34	2.34e-10	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03705947	chr1:68152081	GADD45A	0.48	6.96	0.36	1.84e-11	Response to antipsychotic treatment;
CRC	trans	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.03	-0.32	4.46e-9	Tuberculosis;
CRC	cis	rs8105895	0.935	rs1560717	chr19:22292247	A/G	cg02657401	chr19:22469223	NA	-0.39	-5.82	-0.31	1.37e-8	Body mass index (change over time);
CRC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg11168104	chr5:1857477	NA	-0.36	-6.15	-0.32	2.23e-9	Cardiovascular disease risk factors;
CRC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.33	-6.04	-0.32	4.21e-9	Rheumatoid arthritis;
CRC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg21153622	chr11:89784906	NA	-0.44	-7.13	-0.37	6.61e-12	Coronary artery disease;
CRC	cis	rs7215564	0.818	rs7214465	chr17:78566792	G/A	cg09596252	chr17:78655493	RPTOR	0.67	6.21	0.32	1.58e-9	Myopia (pathological);
CRC	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.48	-6.06	-0.32	3.83e-9	Body mass index;
CRC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-5.97	-0.31	6.09e-9	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.93	17.28	0.69	4.48e-48	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	5.87	0.31	1.05e-8	Prudent dietary pattern;
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.2	-0.37	4.22e-12	Lymphocyte counts;
CRC	cis	rs7429990	0.965	rs35199727	chr3:47946708	T/C	cg11946769	chr3:48343235	NME6	0.49	6.19	0.32	1.8e-9	Educational attainment (years of education);
CRC	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-8.96	-0.44	2.38e-17	Blood protein levels;
CRC	trans	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3736485	0.816	rs882386	chr15:51882273	C/T	cg08986416	chr15:51914746	DMXL2	-0.49	-6.8	-0.35	4.88e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.61	10.68	0.51	4.53e-23	Body mass index;
CRC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	16.88	0.68	1.7e-46	Platelet count;
CRC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-0.86	-10.22	-0.49	1.74e-21	Breast cancer;
CRC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.42e-12	Colorectal cancer;
CRC	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.26	0.37	2.78e-12	Eye color traits;
CRC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.51	-6.75	-0.35	6.74e-11	Glioblastoma;
CRC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.73	0.3	2.22e-8	Bladder cancer;
CRC	cis	rs4074493	0.963	rs4074492	chr1:231172439	G/A	cg22172038	chr1:231176991	FAM89A	0.34	5.89	0.31	9.48e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.38	0.53	1.58e-25	Bone mineral density;
CRC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.5	-0.46	4.4e-19	Heart rate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14925012	chr15:60771315	NARG2	0.46	6.19	0.32	1.74e-9	Anxiety disorder;
CRC	cis	rs6594535	0.663	rs10062378	chr5:111040064	A/G	cg06838283	chr5:111090142	C5orf13	0.41	5.65	0.3	3.43e-8	Chickenpox;
CRC	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.49	-7.67	-0.39	1.9e-13	Type 2 diabetes;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg15786705	chr6:28176104	NA	-0.47	-6.96	-0.36	1.88e-11	Cardiac Troponin-T levels;
CRC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.51	8.35	0.42	1.94e-15	Testicular germ cell tumor;
CRC	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.78	-0.35	5.45e-11	Ulcerative colitis;
CRC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg23815491	chr16:72088622	HP	0.58	7.21	0.37	3.95e-12	Blood protein levels;
CRC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05585630	chr7:157510462	PTPRN2	-0.41	-6.38	-0.33	6.04e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.08	-0.41	1.22e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11252926	0.563	rs58840923	chr10:578484	T/TGA	cg09445902	chr10:555545	DIP2C	0.82	6.5	0.34	2.91e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.16e-10	Body mass index;
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.39	0.33	5.65e-10	Bipolar disorder;
CRC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.59	8.82	0.44	6.74e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.6	10.69	0.51	4.26e-23	Aortic root size;
CRC	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.47	-6.73	-0.35	7.39e-11	IgG glycosylation;
CRC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.05	-0.55	5.8e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg25809561	chr17:30822961	MYO1D	-0.52	-9.35	-0.46	1.39e-18	Schizophrenia;
CRC	cis	rs77633900	0.772	rs16968196	chr15:76682238	C/T	cg21673338	chr15:77095150	SCAPER	-0.67	-5.62	-0.3	4.15e-8	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg09998033	chr7:158218633	PTPRN2	-0.54	-7.25	-0.37	3e-12	Obesity-related traits;
CRC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-5.92	-0.31	8.21e-9	Response to bleomycin (chromatid breaks);
CRC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg12639453	chr1:2035780	PRKCZ	-0.38	-7.39	-0.38	1.21e-12	Height;
CRC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.48	7.2	0.37	4.15e-12	Pancreatic cancer;
CRC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.45	-6.79	-0.35	5.27e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.65	-8.5	-0.42	6.68e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs8105895	0.935	rs7259971	chr19:22237319	C/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.64	-0.34	1.3100000000000001e-10	Joint mobility (Beighton score);
CRC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9648716	1.000	rs6950946	chr7:140572545	T/C	cg10747023	chr7:140774559	NA	0.45	5.82	0.31	1.36e-8	Type 2 diabetes;
CRC	cis	rs2982552	0.901	rs2982561	chr6:152052652	C/T	cg22157087	chr6:152012887	ESR1	0.41	6.31	0.33	9e-10	Bone properties (heel);
CRC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.6	9.08	0.45	1.05e-17	Corneal astigmatism;
CRC	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.53	-5.63	-0.3	3.88e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.47	6.77	0.35	6.1e-11	Primary sclerosing cholangitis;
CRC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.76	0.35	6.2e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.65	8.61	0.43	3.07e-16	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.25	14.62	0.63	1.19e-37	Diabetic kidney disease;
CRC	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.43	-8.18	-0.41	6.25e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CRC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-11.85	-0.55	3.29e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs7246760	1.000	rs67844335	chr19:9898039	G/A	cg16876255	chr19:9731953	ZNF561	0.69	5.69	0.3	2.79e-8	Pursuit maintenance gain;
CRC	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg11901034	chr3:128598214	ACAD9	-0.53	-6.38	-0.33	5.95e-10	IgG glycosylation;
CRC	cis	rs11098699	0.821	rs4833890	chr4:124217864	G/C	cg09941581	chr4:124220074	SPATA5	0.43	6.37	0.33	6.51e-10	Mosquito bite size;
CRC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.46	-8.96	-0.44	2.43e-17	Ulcerative colitis;
CRC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg23018236	chr17:30244563	NA	-0.47	-6.57	-0.34	1.92e-10	Hip circumference adjusted for BMI;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg23161317	chr6:28129485	ZNF389	0.47	6.84	0.35	3.86e-11	Cardiac Troponin-T levels;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.57	-10.23	-0.49	1.61e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10924970	0.687	rs12737933	chr1:235363908	C/T	cg09010748	chr1:235293032	TOMM20	0.43	6.08	0.32	3.31e-9	Asthma;
CRC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.25	-14.78	-0.63	2.8e-38	Diabetic kidney disease;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg25164649	chr6:28176230	NA	0.64	8.67	0.43	1.95e-16	Parkinson's disease;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.33e-18	Blood pressure (smoking interaction);
CRC	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.41e-18	Platelet count;
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-7.85	-0.4	6.06e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg16898833	chr6:26189333	HIST1H4D	0.92	7.53	0.38	4.85e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg20159608	chr7:32802032	NA	-0.59	-6.96	-0.36	1.87e-11	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.45	6.31	0.33	8.85e-10	Breast cancer;
CRC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.65	10.58	0.5	1.01e-22	Personality dimensions;
CRC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.44	6.07	0.32	3.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.73	9.63	0.47	1.7e-19	Alzheimer's disease;
CRC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.77	-0.39	9.89e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7899719	1.000	rs11001458	chr10:77431050	G/T	cg24369728	chr10:77472158	NA	0.42	5.63	0.3	3.81e-8	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
CRC	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg07166546	chr14:35805898	NA	-0.3	-5.97	-0.31	6.25e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7249698	1	rs7249698	chr19:17210615	G/A	cg19418318	chr19:17219073	MYO9B	0.42	7.53	0.38	4.93e-13	Breast cancer;
CRC	trans	rs2303319	0.504	rs62187658	chr2:162488095	A/C	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.09	-0.32	3.1e-9	Cognitive function;
CRC	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.37	-5.88	-0.31	1.01e-8	Beta-trace protein levels;
CRC	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.44	-0.38	8.78e-13	Bipolar disorder;
CRC	cis	rs1186222	0.967	rs1018945	chr7:75255748	C/G	cg05145297	chr7:75264568	HIP1	0.52	9.1	0.45	9.05e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.84	12.69	0.57	2.67e-30	Multiple sclerosis;
CRC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.45	-5.94	-0.31	7.16e-9	Gut microbiome composition (summer);
CRC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.53	8.27	0.41	3.38e-15	Height;
CRC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.59	6.67	0.34	1.12e-10	Bipolar disorder;
CRC	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg04202892	chr2:111875749	ACOXL	0.43	6.96	0.36	1.8e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-8.07	-0.41	1.29e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.53	-6.81	-0.35	4.59e-11	Coronary artery disease;
CRC	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.55	8.28	0.42	3.12e-15	Blood protein levels;
CRC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.62	10.7	0.51	3.84e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.5	7.33	0.37	1.78e-12	Type 2 diabetes;
CRC	cis	rs62408225	0.894	rs17585295	chr6:90944831	C/T	cg06866423	chr6:90926672	BACH2	0.45	7.32	0.37	1.88e-12	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12760731	0.565	rs34676994	chr1:178054513	A/T	cg00404053	chr1:178313656	RASAL2	1.09	10.85	0.51	1.24e-23	Obesity-related traits;
CRC	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-0.65	-5.89	-0.31	9.49e-9	Pediatric areal bone mineral density (radius);
CRC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.82	-0.55	4.03e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs1790761	0.967	rs1638588	chr11:67199706	C/A	cg17375396	chr11:67202808	RPS6KB2	0.33	5.65	0.3	3.48e-8	Mean corpuscular volume;
CRC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.9	-0.31	8.82e-9	Heart rate;
CRC	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs11212617	0.967	rs228592	chr11:108123189	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.46	0.34	3.76e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.76	13.05	0.58	1.23e-31	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19824362	chr12:95467522	NR2C1	0.41	6.13	0.32	2.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.07	0.36	9.36e-12	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.06	-0.41	1.43e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	7.04	0.36	1.14e-11	Blood protein levels;
CRC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg06238570	chr21:40685208	BRWD1	0.78	10.69	0.51	4.36e-23	Cognitive function;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg24296761	chr19:42408458	ARHGEF1	-0.27	-6.03	-0.32	4.49e-9	Schizophrenia;
CRC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg02880119	chr16:3481970	NA	0.42	5.93	0.31	7.49e-9	Body mass index (adult);
CRC	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.47	6.09	0.32	3.23e-9	Tuberculosis;
CRC	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.47	6.89	0.36	2.86e-11	Lymphocyte counts;
CRC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-12.76	-0.58	1.49e-30	Menarche (age at onset);
CRC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.68	-0.3	2.99e-8	Colorectal cancer;
CRC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26587870	chr6:27730563	NA	-0.59	-5.91	-0.31	8.72e-9	Depression;
CRC	cis	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg02972257	chr16:68554789	NA	0.44	5.67	0.3	3.13e-8	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	6.12	0.32	2.72e-9	Life satisfaction;
CRC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.37	0.33	6.55e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.29	6.05	0.32	3.94e-9	Lung cancer;
CRC	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.53	-7.27	-0.37	2.66e-12	Triglycerides;
CRC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15369054	chr17:80825471	TBCD	0.34	5.63	0.3	3.8e-8	Breast cancer;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.58	9.82	0.48	4.07e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg26805224	chr10:79626177	DLG5	-0.43	-6.41	-0.33	5.12e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg21951975	chr1:209979733	IRF6	0.35	5.94	0.31	7.11e-9	Monobrow;
CRC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.85	9.76	0.47	6.29e-20	Cerebrospinal P-tau181p levels;
CRC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg00334542	chr7:100209784	MOSPD3	-0.52	-6.63	-0.34	1.38e-10	Other erythrocyte phenotypes;
CRC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.88	-16.18	-0.67	9.76e-44	Body mass index;
CRC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg06470822	chr6:28175283	NA	-0.66	-7.29	-0.37	2.33e-12	Depression;
CRC	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-7.42	-0.38	9.77e-13	Primary sclerosing cholangitis;
CRC	cis	rs995000	0.931	rs1748200	chr1:63046039	T/C	cg19896129	chr1:63156450	NA	-0.43	-6.71	-0.35	8.47e-11	Triglyceride levels;
CRC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	8.87	0.44	4.87e-17	Neuroticism;
CRC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg17321639	chr7:2759063	NA	-0.44	-6.13	-0.32	2.56e-9	Height;
CRC	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg05304507	chr6:116381966	FRK	0.28	6.3	0.33	9.64e-10	Total cholesterol levels;
CRC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.49	-0.34	3.1e-10	Breast cancer;
CRC	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg23684204	chr15:91497937	RCCD1	-0.47	-7.37	-0.38	1.41e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.79	13.44	0.6	3.95e-33	Menopause (age at onset);
CRC	trans	rs6472235	0.837	rs12114319	chr8:66930916	C/G	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.94	10.71	0.51	3.53e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02725872	chr8:58115012	NA	-0.59	-9.18	-0.45	4.97e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-8.02	-0.4	1.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg27661571	chr11:113659931	NA	-0.96	-11.16	-0.52	1e-24	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15876000	chr3:49067026	IMPDH2	0.45	6.27	0.33	1.15e-9	Response to antipsychotic treatment;
CRC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.49	-7.59	-0.39	3.29e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.44	-6.06	-0.32	3.74e-9	Longevity;Endometriosis;
CRC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.65	13.2	0.59	3.14e-32	HDL cholesterol levels;
CRC	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.12e-18	Blood protein levels;
CRC	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg26875233	chr11:93583750	C11orf90	0.34	6.67	0.34	1.11e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.69	8.18	0.41	6.39e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.78	-13.21	-0.59	3e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.55	8.02	0.4	1.81e-14	Type 1 diabetes;
CRC	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg00507830	chr2:103233733	NA	0.57	6.25	0.33	1.31e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.41	-0.59	5.15e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg05585544	chr11:47624801	NA	-0.46	-8.25	-0.41	3.79e-15	Subjective well-being;
CRC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.74	-0.3	2.21e-8	Vitiligo;
CRC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.34	-5.69	-0.3	2.87e-8	Diastolic blood pressure;
CRC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.45	6.55	0.34	2.16e-10	Menopause (age at onset);
CRC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.65	-11.14	-0.52	1.1e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.83e-13	HDL cholesterol;
CRC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.43	6.19	0.32	1.83e-9	Heart rate;
CRC	cis	rs6748734	0.625	rs4563218	chr2:241820035	G/A	cg16358738	chr2:241808595	AGXT	-0.41	-7.26	-0.37	2.8e-12	Urinary metabolites;
CRC	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-15.78	-0.66	3.69e-42	Intelligence (multi-trait analysis);
CRC	trans	rs7011507	0.945	rs13282865	chr8:49206289	T/G	cg04544946	chr8:978226	NA	0.46	6.09	0.32	3.1e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7086803	1.000	rs7090269	chr10:114504533	A/G	cg03281572	chr10:114502318	VTI1A	-0.72	-6.04	-0.32	4.09e-9	Lung cancer;
CRC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.72	9.1	0.45	8.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.22e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg14664628	chr15:75095509	CSK	0.44	6.13	0.32	2.5e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.18	24.24	0.8	3.36e-75	Schizophrenia;
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.33e-18	Blood pressure (smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05481085	chr12:109549869	NA	0.43	6.56	0.34	2.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg23071808	chr14:103021642	NA	0.63	6.95	0.36	1.97e-11	Platelet count;
CRC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.45	-0.46	6.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg09218773	chr11:619014	MUPCDH	-0.42	-5.87	-0.31	1.05e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg00769240	chr8:12517080	NA	-0.74	-10.23	-0.49	1.64e-21	Blood pressure (smoking interaction);
CRC	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.38	6.5	0.34	3.04e-10	IFN-related cytopenia;
CRC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.41	5.72	0.3	2.37e-8	Parkinson's disease;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.66	-0.3	3.29e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12517041	1.000	rs7720974	chr5:23300191	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.56	-6.2	-0.32	1.74e-9	Calcium levels;
CRC	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.35	0.5	6.49e-22	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18099408	chr3:52552593	STAB1	0.46	7.67	0.39	2.01e-13	Bipolar disorder;
CRC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg20203395	chr5:56204925	C5orf35	0.58	7.88	0.4	4.87e-14	Initial pursuit acceleration;
CRC	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.68	-12.21	-0.56	1.59e-28	Lewy body disease;
CRC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.52	0.34	2.64e-10	Menopause (age at onset);
CRC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg11070056	chr1:107600091	PRMT6	-0.39	-5.62	-0.3	4.03e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg24375607	chr4:120327624	NA	-0.44	-7.06	-0.36	9.73e-12	Corneal astigmatism;
CRC	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg04611788	chr3:186434169	KNG1	-0.61	-9.1	-0.45	8.64e-18	Blood protein levels;
CRC	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.38	-7.3	-0.37	2.12e-12	Migraine;
CRC	cis	rs1223397	0.651	rs3001966	chr6:13312684	C/T	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg22687807	chr8:143858763	LYNX1	-0.75	-13.97	-0.61	3.8e-35	Urinary tract infection frequency;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05565475	chr9:136223383	SURF2;SURF1	0.43	5.98	0.31	5.81e-9	Anxiety disorder;
CRC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.59	-8.18	-0.41	6.07e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.53	7.3	0.37	2.25e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.2e-9	Menopause (age at onset);
CRC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.59	9.04	0.45	1.36e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg06470822	chr6:28175283	NA	0.48	6.58	0.34	1.84e-10	Depression;
CRC	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg16989719	chr2:238392110	NA	-0.43	-6.38	-0.33	6.02e-10	Prostate cancer;
CRC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg11707556	chr5:10655725	ANKRD33B	0.34	6.28	0.33	1.08e-9	Coronary artery disease;
CRC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg10790698	chr19:18539756	SSBP4	-0.41	-7.76	-0.39	1.06e-13	Breast cancer;
CRC	cis	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.39	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7072216	0.881	rs1079179	chr10:100149346	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.2	-0.32	1.72e-9	Metabolite levels;
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg12516270	chr8:143859308	LYNX1	0.41	7.31	0.37	2.04e-12	Urinary tract infection frequency;
CRC	trans	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg05376469	chr2:102649931	NA	-0.4	-6.44	-0.33	4.22e-10	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11645453	chr3:52864694	ITIH4	0.36	6.39	0.33	5.61e-10	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.84	-12.98	-0.58	2.2e-31	Blood metabolite levels;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.6	-8.05	-0.41	1.53e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg16691251	chr5:66510806	NA	-0.42	-7.59	-0.39	3.3e-13	Breast cancer;
CRC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.39	0.42	1.43e-15	Body mass index;
CRC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.91	-18.84	-0.72	3.08e-54	Urate levels in lean individuals;
CRC	cis	rs3849570	0.643	rs6548779	chr3:81968512	A/G	cg07356753	chr3:81810745	GBE1	-0.46	-6.16	-0.32	2.16e-9	Waist circumference;Body mass index;
CRC	cis	rs524281	0.773	rs2155031	chr11:66030927	C/T	cg14036092	chr11:66035641	RAB1B	-0.55	-6.04	-0.32	4.16e-9	Electroencephalogram traits;
CRC	cis	rs9908102	0.740	rs2286336	chr17:12915941	C/T	cg26162695	chr17:12921313	ELAC2	-0.44	-5.95	-0.31	7.04e-9	Schizophrenia;
CRC	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg00531865	chr16:30841666	NA	-0.43	-5.85	-0.31	1.16e-8	Dementia with Lewy bodies;
CRC	cis	rs8141797	0.818	rs762271	chr22:24448082	T/C	cg20894457	chr22:24584366	SUSD2	-0.65	-6.71	-0.35	8.4e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.71	12.52	0.57	1.15e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9309413	0.679	rs13393517	chr2:68556100	G/A	cg21581504	chr2:68545960	CNRIP1	0.32	6.18	0.32	1.86e-9	Metabolite levels;
CRC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.3	-0.49	9.29e-22	Tonsillectomy;
CRC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.69	-10.24	-0.49	1.49e-21	Intelligence (multi-trait analysis);
CRC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.63	10.46	0.5	2.78e-22	Hemoglobin concentration;Hematocrit;
CRC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-5.75	-0.3	2.03e-8	Lung cancer;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.54	6.2	0.32	1.68e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.47	-5.82	-0.31	1.42e-8	Response to bleomycin (chromatid breaks);
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	15.36	0.65	1.54e-40	Lymphocyte percentage of white cells;
CRC	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	cis	rs9462027	0.561	rs2814972	chr6:34566975	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.9	-0.31	9.03e-9	Systemic lupus erythematosus;
CRC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.76	-0.43	1.08e-16	Uric acid levels;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg23760165	chr11:61595485	FADS2	-0.47	-6.25	-0.33	1.25e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.63	-0.51	6.98e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14997559	chr19:40950494	SERTAD3	0.43	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2179367	0.959	rs652807	chr6:149737495	A/G	cg07828024	chr6:149772892	ZC3H12D	0.36	6.02	0.32	4.6e-9	Dupuytren's disease;
CRC	cis	rs2462686	1.000	rs2462686	chr7:45982460	A/G	cg15898840	chr7:45960834	IGFBP3	-0.38	-5.72	-0.3	2.34e-8	Major depressive disorder;
CRC	cis	rs2179367	0.959	rs9322178	chr6:149693267	G/C	cg11245181	chr6:149772854	ZC3H12D	-0.42	-6.47	-0.34	3.48e-10	Dupuytren's disease;
CRC	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg14352298	chr13:112236639	NA	0.3	6.71	0.35	8.5e-11	Hepatitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03228222	chr19:18747721	KLHL26	0.38	6.07	0.32	3.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.49	-6.36	-0.33	6.68e-10	Neutrophil percentage of white cells;
CRC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.82	-10.78	-0.51	2.12e-23	Obesity-related traits;
CRC	cis	rs11229555	0.645	rs12272911	chr11:58183839	G/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.0	0.31	5.15e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	0.59	6.65	0.34	1.24e-10	Prostate cancer;
CRC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg02569458	chr12:86230093	RASSF9	0.35	5.9	0.31	9.26e-9	Major depressive disorder;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg12273811	chr6:28175739	NA	-0.44	-6.53	-0.34	2.46e-10	Cardiac Troponin-T levels;
CRC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.11	-0.41	1.01e-14	Schizophrenia;
CRC	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg21399703	chr1:247681439	NA	0.49	5.7	0.3	2.61e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.37	-6.09	-0.32	3.17e-9	Bone mineral density (spine);
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg24046110	chr8:143859143	LYNX1	-0.46	-7.51	-0.38	5.72e-13	Urinary tract infection frequency;
CRC	cis	rs447	1.000	rs6978184	chr7:83778360	C/T	cg22846510	chr7:83753280	SEMA3A	-0.56	-7.01	-0.36	1.34e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.62	-7.55	-0.38	4.19e-13	Vitamin D levels;
CRC	cis	rs3857067	1.000	rs6532463	chr4:95027048	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.22	-0.32	1.55e-9	QT interval;
CRC	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.4	-0.38	1.15e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg03934865	chr2:198174659	NA	-0.43	-6.81	-0.35	4.66e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg15845792	chr6:28175446	NA	1.0	13.06	0.58	1.11e-31	Parkinson's disease;
CRC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24308560	chr3:49941425	MST1R	0.5	8.2	0.41	5.41e-15	Intelligence (multi-trait analysis);
CRC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.6	-10.65	-0.51	5.75e-23	Aortic root size;
CRC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.32	-0.33	8.58e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.55	-0.34	2.28e-10	Lung cancer;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.4	0.42	1.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.15	-0.32	2.19e-9	Alzheimer's disease (late onset);
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg10729496	chr3:10149963	C3orf24	0.48	6.22	0.32	1.54e-9	Alzheimer's disease;
CRC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.69	-0.3	2.75e-8	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17169982	chr17:80787973	TBCD;ZNF750	0.42	6.58	0.34	1.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.49	6.86	0.35	3.38e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.61	-8.66	-0.43	2.22e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.53	7.32	0.37	1.9e-12	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11651961	chr2:54197711	PSME4	0.41	6.12	0.32	2.65e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg22907277	chr7:1156413	C7orf50	0.76	8.42	0.42	1.17e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg02569458	chr12:86230093	RASSF9	0.46	7.78	0.39	9.25e-14	Major depressive disorder;
CRC	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.59	-6.69	-0.35	9.7e-11	Blood protein levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19310740	chr8:103424477	UBR5	-0.41	-6.4	-0.33	5.31e-10	Aortic root size;
CRC	cis	rs73200209	0.744	rs17498872	chr12:116669888	A/T	cg01776926	chr12:116560359	MED13L	-0.58	-6.5	-0.34	3.06e-10	Total body bone mineral density;
CRC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg20744362	chr22:50050164	C22orf34	0.31	5.74	0.3	2.12e-8	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.39	-19.56	-0.73	4.54e-57	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.46	6.91	0.36	2.52e-11	Menopause (age at onset);
CRC	trans	rs11031096	0.666	rs1662173	chr11:4127649	C/G	cg22978087	chr8:24814126	NEFL	0.32	5.98	0.31	5.73e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg20487152	chr13:99095054	FARP1	-0.43	-6.3	-0.33	9.37e-10	Longevity;
CRC	cis	rs883565	0.502	rs7427462	chr3:38963275	G/A	cg01426195	chr3:39028469	NA	0.42	7.07	0.36	9.39e-12	Handedness;
CRC	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.56	-9.17	-0.45	5.13e-18	P wave terminal force;
CRC	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.6	-8.19	-0.41	5.95e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg16141378	chr3:129829833	LOC729375	-0.46	-6.94	-0.36	2.15e-11	Neuroticism;
CRC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg08975724	chr8:8085496	FLJ10661	0.42	6.08	0.32	3.25e-9	Retinal vascular caliber;
CRC	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg20487152	chr13:99095054	FARP1	0.37	6.14	0.32	2.33e-9	Longevity;
CRC	cis	rs62209	0.530	rs17444979	chr10:10994159	C/T	cg26901096	chr10:10994189	LOC254312	0.43	5.89	0.31	9.79e-9	Alzheimer's disease (late onset);
CRC	trans	rs10207628	1.000	rs1530047	chr2:127848936	A/C	cg22628694	chr19:58663362	ZNF329	0.57	6.02	0.31	4.78e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.51	8.76	0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs747650	0.504	rs10769225	chr11:46982481	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.84	-0.31	1.24e-8	Acne (severe);
CRC	trans	rs11800820	0.595	rs35558093	chr1:246711077	A/G	cg26885821	chr6:124125002	NKAIN2	0.37	6.04	0.32	4.26e-9	Obesity-related traits;
CRC	cis	rs501120	1.000	rs503859	chr10:44753560	G/C	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg10700019	chr8:145984882	NA	0.33	6.53	0.34	2.52e-10	Age at first birth;
CRC	cis	rs9292777	0.901	rs6896969	chr5:40424426	A/C	cg09067459	chr5:40385259	NA	0.53	9.25	0.45	3.02e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg10589385	chr1:150898437	SETDB1	0.33	6.95	0.36	1.92e-11	Melanoma;
CRC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.61	7.34	0.38	1.65e-12	Menarche (age at onset);
CRC	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.8	6.21	0.32	1.62e-9	LDL cholesterol;
CRC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.57	-0.43	4.21e-16	Mean corpuscular volume;
CRC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg18099408	chr3:52552593	STAB1	0.36	6.14	0.32	2.43e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4728302	0.869	rs10155909	chr7:133593036	A/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.56	-0.34	2.04e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.63	9.58	0.47	2.4e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg20356878	chr3:121714668	ILDR1	0.53	8.28	0.42	3.06e-15	Cognitive performance;
CRC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-8.39	-0.42	1.41e-15	Gut microbiome composition (summer);
CRC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.45	0.42	9.84e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg10279832	chr4:154682576	RNF175	0.38	5.81	0.3	1.51e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs2882667	0.964	rs12719517	chr5:138305502	C/T	cg09476006	chr5:138032270	NA	0.47	7.44	0.38	9.02e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.05	-0.32	4.03e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg13385521	chr17:29058706	SUZ12P	0.52	6.99	0.36	1.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.44	-8.6	-0.43	3.19e-16	Body mass index;
CRC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg20203395	chr5:56204925	C5orf35	-0.7	-8.28	-0.42	3.23e-15	Initial pursuit acceleration;
CRC	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg19131313	chr8:1704013	NA	-0.48	-5.74	-0.3	2.17e-8	Systolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07876271	chr5:5422799	KIAA0947	0.46	6.21	0.32	1.63e-9	Anxiety disorder;
CRC	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg25627403	chr19:41769009	HNRNPUL1	-0.54	-6.12	-0.32	2.59e-9	Coronary artery disease;
CRC	cis	rs294883	0.821	rs9365035	chr6:159703722	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.73	-0.3	2.23e-8	Coronary artery disease;
CRC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs6756513	0.501	rs7581977	chr2:70174054	C/T	cg02498382	chr2:70120550	SNRNP27	0.49	8.14	0.41	8.52e-15	Breast cancer;Platelet count;
CRC	trans	rs9545047	0.716	rs9530920	chr13:79997389	C/T	cg07061582	chr15:90234082	PEX11A;WDR93	0.41	5.98	0.31	5.82e-9	Schizophrenia;
CRC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.63	-0.47	1.7e-19	Hip circumference adjusted for BMI;
CRC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.74	-0.51	2.89e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg09127314	chr1:152161683	NA	0.47	6.04	0.32	4.25e-9	Atopic dermatitis;
CRC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.44	-5.96	-0.31	6.39e-9	Prudent dietary pattern;
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.92	-19.57	-0.73	4.36e-57	Urate levels in lean individuals;
CRC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.73	-8.23	-0.41	4.37e-15	Obesity-related traits;
CRC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.07	0.32	3.58e-9	Bladder cancer;
CRC	cis	rs11650494	0.710	rs61427980	chr17:47473580	A/G	cg08112188	chr17:47440006	ZNF652	0.69	6.28	0.33	1.05e-9	Prostate cancer;
CRC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.44	-0.33	4.15e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.38	0.33	6.15e-10	Parkinson's disease;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg24046110	chr8:143859143	LYNX1	-0.43	-6.99	-0.36	1.51e-11	Urinary tract infection frequency;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg20647610	chr2:228736258	WDR69	-0.47	-6.46	-0.34	3.72e-10	Blood pressure;
CRC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.36	6.2	0.32	1.74e-9	Reticulocyte fraction of red cells;
CRC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.8	14.24	0.62	3.57e-36	Breast cancer;
CRC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.73	8.75	0.43	1.11e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.54	-8.76	-0.43	1.04e-16	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.27e-20	Hip circumference adjusted for BMI;
CRC	trans	rs4965598	0.957	rs12901204	chr15:100756407	A/G	cg05653646	chr5:139173162	NA	-0.47	-6.17	-0.32	2e-9	Height;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg04269497	chr6:167369491	RNASET2	-0.71	-5.99	-0.31	5.49e-9	Cognitive function;
CRC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.79	-11.78	-0.54	5.82e-27	Cognitive function;
CRC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.62	8.97	0.44	2.37e-17	Longevity;
CRC	cis	rs459193	1.000	rs458741	chr5:55807837	T/C	cg00049729	chr5:55776345	NA	0.39	5.83	0.31	1.31e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.49	7.12	0.37	6.64e-12	Type 2 diabetes;
CRC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg09324608	chr17:30823087	MYO1D	0.34	5.86	0.31	1.14e-8	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20272604	chr1:231004631	C1orf198	0.39	6.28	0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.61	8.71	0.43	1.48e-16	Alcohol dependence;
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.83	0.31	1.3e-8	Prudent dietary pattern;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg25797454	chr6:150327115	RAET1K	0.35	6.09	0.32	3.22e-9	Alopecia areata;
CRC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg17321639	chr7:2759063	NA	-0.42	-5.85	-0.31	1.17e-8	Height;
CRC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg19223190	chr17:80058835	NA	-0.4	-6.41	-0.33	5.14e-10	Life satisfaction;
CRC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.48	-7.43	-0.38	9.71e-13	Coronary artery disease;
CRC	cis	rs4073416	0.508	rs2898818	chr14:65972584	G/C	cg03016385	chr14:66212404	NA	-0.42	-5.93	-0.31	7.71e-9	N-glycan levels;
CRC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.21	0.53	6.19e-25	Prudent dietary pattern;
CRC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.6	-8.64	-0.43	2.47e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.33	5.77	0.3	1.85e-8	Sitting height ratio;
CRC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-10.55	-0.5	1.32e-22	Coronary artery disease;
CRC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.08	0.52	1.9e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg23123621	chr4:1343375	KIAA1530	0.32	5.64	0.3	3.65e-8	Obesity-related traits;
CRC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.57	-8.89	-0.44	3.97e-17	Motion sickness;
CRC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.32	-0.33	8.54e-10	Monocyte percentage of white cells;
CRC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg10978503	chr1:24200527	CNR2	0.62	11.26	0.53	4.43e-25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
CRC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-10.33	-0.49	7.46e-22	Initial pursuit acceleration;
CRC	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.57	-10.83	-0.51	1.38e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg20503657	chr10:835505	NA	0.7	8.24	0.41	4.05e-15	Eosinophil percentage of granulocytes;
CRC	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4481887	0.502	rs4916108	chr1:248360633	G/A	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.69	-0.35	9.85e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01117833	chr14:94547303	DDX24;IFI27L1	0.39	6.1	0.32	2.92e-9	Obesity-related traits;
CRC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.9	14.34	0.62	1.46e-36	Ewing sarcoma;
CRC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.56	-10.47	-0.5	2.58e-22	Schizophrenia;
CRC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.48	-8.85	-0.44	5.64e-17	Alcohol dependence;
CRC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.74	-0.35	7.23e-11	Major depressive disorder;
CRC	trans	rs2797369	0.882	rs2764271	chr6:101651617	A/T	cg26346621	chr12:6873348	NA	-0.4	-6.26	-0.33	1.2e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.01	-0.31	4.85e-9	Lung cancer;
CRC	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.6	0.34	1.63e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.63	-10.58	-0.5	1e-22	Coronary artery disease;
CRC	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg19875535	chr5:140030758	IK	-0.59	-9.67	-0.47	1.2e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg03037974	chr15:76606532	NA	0.7	12.57	0.57	7.07e-30	Blood metabolite levels;
CRC	cis	rs7605827	0.897	rs10432400	chr2:15667324	T/C	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.62e-8	Educational attainment (years of education);
CRC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	7.08	0.36	8.77e-12	Lung cancer in ever smokers;
CRC	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg08632701	chr21:37451849	NA	-0.45	-7.07	-0.36	9.09e-12	Mitral valve prolapse;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25199208	chr2:109402912	CCDC138	-0.4	-6.46	-0.34	3.79e-10	Aortic root size;
CRC	cis	rs713477	0.967	rs10483642	chr14:55920460	A/G	cg13175173	chr14:55914753	NA	0.45	8.5	0.42	6.71e-16	Pediatric bone mineral content (femoral neck);
CRC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg21153622	chr11:89784906	NA	-0.41	-6.83	-0.35	4.16e-11	Coronary artery disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23120805	chr2:43453872	LOC100129726;ZFP36L2	0.42	6.72	0.35	8.04e-11	Schizophrenia;
CRC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11645453	chr3:52864694	ITIH4	0.39	6.64	0.34	1.26e-10	Bipolar disorder;
CRC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg13072238	chr3:49761600	GMPPB	-0.57	-5.81	-0.31	1.46e-8	Menarche (age at onset);
CRC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg11212589	chr17:38028394	ZPBP2	0.34	6.05	0.32	3.94e-9	Asthma;
CRC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.67	-11.75	-0.54	7.55e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.01	0.36	1.36e-11	Morning vs. evening chronotype;
CRC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.55	7.15	0.37	5.71e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg09659197	chr4:152720779	NA	0.31	5.69	0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.21e-15	Bladder cancer;
CRC	cis	rs7703744	0.681	rs11957102	chr5:118701899	G/T	cg23917399	chr5:118691751	TNFAIP8	0.42	5.72	0.3	2.46e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.81	13.52	0.6	2.04e-33	Menopause (age at onset);
CRC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	8.08	0.41	1.28e-14	Vitiligo;
CRC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.61	9.54	0.47	3.35e-19	Corneal astigmatism;
CRC	cis	rs12143943	0.966	rs11240762	chr1:204566999	C/T	cg17419461	chr1:204415978	PIK3C2B	0.37	5.75	0.3	2e-8	Cognitive performance;
CRC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.57	10.79	0.51	2.01e-23	Eye color traits;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-8.05	-0.41	1.56e-14	Breast cancer;
CRC	cis	rs6479527	0.840	rs2094927	chr9:96765386	C/A	cg14459158	chr9:96720562	NA	0.41	7.4	0.38	1.16e-12	Esophageal adenocarcinoma;
CRC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.38	0.53	1.56e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg04586622	chr2:25135609	ADCY3	-0.56	-10.45	-0.5	2.87e-22	Body mass index;
CRC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.56	-7.88	-0.4	4.97e-14	Pancreatic cancer;
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg27615366	chr5:131592974	PDLIM4	0.34	5.88	0.31	1e-8	Acylcarnitine levels;
CRC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.58	9.13	0.45	6.99e-18	Body mass index;
CRC	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.33e-15	Type 2 diabetes;
CRC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.33	1.26e-9	Heart rate;
CRC	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.64	-9.86	-0.48	2.84e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3812762	0.826	rs2292045	chr11:8806709	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.01	-0.31	4.84e-9	Hypospadias;
CRC	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.61	8.72	0.43	1.42e-16	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23437166	chr4:13486582	RAB28	0.49	6.36	0.33	6.74e-10	Thyroid stimulating hormone;
CRC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.33	6.84e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg02290350	chr8:58132656	NA	-0.46	-5.84	-0.31	1.24e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.54	-7.25	-0.37	2.92e-12	Tonsillectomy;
CRC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.52	-8.11	-0.41	1.03e-14	Total body bone mineral density;
CRC	cis	rs9783347	0.961	rs4150526	chr11:18343209	G/A	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.74	0.3	2.17e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07369507	chr6:28304287	ZNF323	0.45	6.96	0.36	1.85e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg14664628	chr15:75095509	CSK	0.55	6.5	0.34	3.05e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.77	10.37	0.5	5.34e-22	Coronary artery disease;
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-7.52	-0.38	5.11e-13	Renal function-related traits (BUN);
CRC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.58	-7.36	-0.38	1.49e-12	Neuroticism;
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg24140574	chr1:16342155	HSPB7	0.47	6.62	0.34	1.44e-10	Dilated cardiomyopathy;
CRC	cis	rs11212617	0.935	rs11212543	chr11:108054922	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.01	0.31	4.79e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg18830697	chr6:72922368	RIMS1	-0.39	-7.87	-0.4	5.03e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.49	-8.33	-0.42	2.22e-15	Common traits (Other);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04200765	chr15:73925532	NPTN	0.44	6.33	0.33	8.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.11	19.23	0.73	9.17e-56	Cognitive function;
CRC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.37	6.55	0.34	2.18e-10	Schizophrenia;
CRC	cis	rs62458065	1.000	rs6462363	chr7:32464759	T/G	cg20159608	chr7:32802032	NA	-0.49	-6.2	-0.32	1.68e-9	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.7	11.18	0.52	8.35e-25	Osteoporosis;
CRC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.27	0.67	4.32e-44	Chronic sinus infection;
CRC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-19.47	-0.73	1.07e-56	Ulcerative colitis;
CRC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.47	6.3	0.33	9.61e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.55	8.32	0.42	2.45e-15	Body mass index;
CRC	cis	rs6066835	0.764	rs6066843	chr20:47372817	C/G	cg18078177	chr20:47281410	PREX1	0.69	5.92	0.31	8.29e-9	Multiple myeloma;
CRC	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.67	11.32	0.53	2.64e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.38	-7.3	-0.37	2.12e-12	Migraine;
CRC	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.53	6.62	0.34	1.42e-10	Exhaled nitric oxide output;
CRC	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.6	-8.81	-0.44	7.21e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg20203395	chr5:56204925	C5orf35	0.42	5.86	0.31	1.11e-8	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg25164649	chr6:28176230	NA	0.57	7.84	0.4	6.42e-14	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02340915	chr12:121904480	KDM2B	0.43	6.88	0.35	3.05e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.32	6.39	0.33	5.73e-10	Ewing sarcoma;
CRC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.91	11.42	0.53	1.15e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs7680126	0.633	rs11728093	chr4:10296407	A/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.68	-0.35	1.01e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg02820901	chr13:113351484	ATP11A	0.61	6.65	0.34	1.2e-10	Glycated hemoglobin levels;
CRC	cis	rs35520189	0.556	rs11893071	chr2:113708790	T/A	cg12858261	chr2:113808755	IL1F8	0.47	6.3	0.33	9.67e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs1190596	0.567	rs36060205	chr14:102719697	G/C	cg04767283	chr14:102695768	RAGE	-0.44	-5.64	-0.3	3.75e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg13390004	chr1:15929781	NA	0.45	5.95	0.31	6.93e-9	Systolic blood pressure;
CRC	cis	rs9903692	0.954	rs1860866	chr17:46201031	C/T	cg21215337	chr17:46176117	CBX1	-0.43	-7.94	-0.4	3.33e-14	Pulse pressure;
CRC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.59	8.92	0.44	3.38e-17	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02807482	chr3:125708958	NA	-0.46	-5.9	-0.31	9.13e-9	Blood pressure (smoking interaction);
CRC	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.63	-9.75	-0.47	6.74e-20	Testicular germ cell tumor;
CRC	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.44	7.04	0.36	1.1e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg18016565	chr1:150552671	MCL1	0.43	6.42	0.33	4.9e-10	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26203883	chr20:36156320	BLCAP	0.37	6.25	0.33	1.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg10298567	chr3:47292165	KIF9	0.37	6.03	0.32	4.37e-9	Colorectal cancer;
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg05569086	chr8:143859399	LYNX1	-0.39	-6.43	-0.33	4.54e-10	Urinary tract infection frequency;
CRC	trans	rs9650657	0.615	rs11996727	chr8:10691489	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-5.97	-0.31	6.23e-9	Neuroticism;
CRC	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.38	6.08	0.32	3.29e-9	Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18756060	chr2:27294719	LOC100128731	0.41	6.11	0.32	2.87e-9	Response to antipsychotic treatment;
CRC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg16342193	chr10:102329863	NA	-0.36	-6.05	-0.32	3.85e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs2625529	0.526	rs7179942	chr15:72563074	C/G	cg16672083	chr15:72433130	SENP8	0.45	6.87	0.35	3.25e-11	Red blood cell count;
CRC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg02376097	chr19:46275166	DMPK	0.38	5.98	0.31	5.66e-9	Coronary artery disease;
CRC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg00343986	chr7:65444356	GUSB	0.4	5.66	0.3	3.31e-8	Aortic root size;
CRC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	6.54	0.34	2.31e-10	Total body bone mineral density;
CRC	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg04586622	chr2:25135609	ADCY3	-0.56	-9.47	-0.46	5.84e-19	Body mass index;
CRC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.71	10.97	0.52	4.39e-24	Tonsillectomy;
CRC	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.58	-8.11	-0.41	1.03e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.69	10.96	0.52	4.89e-24	Response to diuretic therapy;
CRC	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.9	0.52	8.03e-24	Exhaled nitric oxide output;
CRC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.25	-0.33	1.3e-9	Coronary artery calcification;
CRC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.76	0.47	6.14e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg20041105	chr8:143859282	LYNX1	-0.32	-5.71	-0.3	2.59e-8	Urinary tract infection frequency;
CRC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.69	11.95	0.55	1.36e-27	Resting heart rate;
CRC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.68	0.39	1.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs34638657	0.500	rs1056675	chr16:82181934	T/C	cg07918374	chr16:82182319	MPHOSPH6	0.41	5.66	0.3	3.29e-8	Lung adenocarcinoma;
CRC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.07	0.32	3.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12612619	0.732	rs11681562	chr2:27250603	A/G	cg00617064	chr2:27272375	NA	-0.35	-5.9	-0.31	9.04e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.24	0.53	5.23e-25	Prudent dietary pattern;
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.6	8.39	0.42	1.49e-15	Longevity;
CRC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg09676794	chr13:100310162	CLYBL	0.44	6.03	0.32	4.42e-9	Obesity-related traits;
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.7	-0.3	2.68e-8	Neuroticism;
CRC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-8.08	-0.41	1.27e-14	Response to antipsychotic treatment;
CRC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.53	8.53	0.43	5.59e-16	Prostate cancer;
CRC	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg07299736	chr8:135490787	ZFAT	-0.38	-6.42	-0.33	4.65e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg17949981	chr6:28129498	ZNF389	0.4	5.6	0.3	4.43e-8	Cardiac Troponin-T levels;
CRC	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-9.8	-0.48	4.54e-20	Blood protein levels;
CRC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.46	-6.22	-0.32	1.51e-9	Gut microbiome composition (summer);
CRC	trans	rs1590305	0.786	rs73180681	chr13:38059979	C/T	cg03965764	chr11:45248109	NA	-0.59	-6.08	-0.32	3.35e-9	Hip geometry;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03822858	chr10:4066499	NA	-0.4	-6.12	-0.32	2.68e-9	HDL cholesterol;
CRC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.25	-0.53	4.62e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.47	7.2	0.37	4.04e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg06632207	chr12:54070931	ATP5G2	-0.49	-8.55	-0.43	4.55e-16	Height;
CRC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.67	0.3	3.13e-8	Heart rate;
CRC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.59	-0.34	1.8e-10	IgG glycosylation;
CRC	cis	rs7605827	0.893	rs6734024	chr2:15718180	A/G	cg19274914	chr2:15703543	NA	0.39	5.85	0.31	1.2e-8	Educational attainment (years of education);
CRC	cis	rs2160860	0.773	rs7003411	chr8:39800461	A/G	cg11363097	chr8:39792086	IDO2	-0.45	-7.66	-0.39	2.12e-13	Blood metabolite levels;
CRC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.59	10.46	0.5	2.73e-22	Aortic root size;
CRC	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.73	-10.27	-0.49	1.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg09127314	chr1:152161683	NA	0.53	6.87	0.35	3.25e-11	Atopic dermatitis;
CRC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.68	9.63	0.47	1.65e-19	Cognitive function;
CRC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.25	-0.33	1.25e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs73200209	0.912	rs57703342	chr12:116677337	C/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.91	-0.31	8.58e-9	Total body bone mineral density;
CRC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg23996704	chr18:44553084	KATNAL2	-0.31	-6.17	-0.32	2.05e-9	Personality dimensions;
CRC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	7.71	0.39	1.54e-13	Height;
CRC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.91	-0.31	8.41e-9	Gout;
CRC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg15147215	chr3:52552868	STAB1	0.5	8.61	0.43	3.13e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4789693	0.938	rs12952655	chr17:80421139	C/T	cg04308225	chr17:80449738	NA	-0.54	-7.39	-0.38	1.25e-12	Glucocorticoid-induced osteonecrosis;
CRC	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.93	10.45	0.5	2.97e-22	Iron status biomarkers;
CRC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.2	-0.32	1.67e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg24505167	chr7:1915268	MAD1L1	-0.48	-7.31	-0.37	2.08e-12	Bipolar disorder;
CRC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.67	10.01	0.48	8.89e-21	Prudent dietary pattern;
CRC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg18404041	chr3:52824283	ITIH1	0.35	6.48	0.34	3.37e-10	Schizophrenia;
CRC	cis	rs990171	1.000	rs7603250	chr2:103068834	T/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.7e-9	Lymphocyte counts;
CRC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.42	5.9	0.31	9.18e-9	Renal cell carcinoma;
CRC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg18876405	chr7:65276391	NA	0.45	6.39	0.33	5.64e-10	Aortic root size;
CRC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.94	-15.72	-0.65	6.47e-42	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.41	6.63	0.34	1.36e-10	Monocyte count;
CRC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.59	8.2	0.41	5.42e-15	Chronic sinus infection;
CRC	cis	rs747650	0.504	rs7938169	chr11:46971539	T/C	cg19486271	chr11:47235900	DDB2	-0.43	-6.52	-0.34	2.72e-10	Acne (severe);
CRC	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg02820901	chr13:113351484	ATP11A	-0.58	-6.35	-0.33	7.24e-10	Glycated hemoglobin levels;
CRC	trans	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.37	-0.33	6.44e-10	Aortic root size;
CRC	cis	rs847649	0.732	rs56269620	chr7:102489456	A/G	cg18108683	chr7:102477205	FBXL13	-0.65	-11.31	-0.53	2.76e-25	Morning vs. evening chronotype;
CRC	trans	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.23e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7605827	0.893	rs7589238	chr2:15606409	C/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg21880720	chr19:2163652	DOT1L	0.48	6.03	0.32	4.51e-9	Myocardial infarction;
CRC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.61	-8.14	-0.41	8.48e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg13639937	chr1:92012655	NA	-0.36	-6.11	-0.32	2.84e-9	Breast cancer;
CRC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.55	6.75	0.35	6.89e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-7.67	-0.39	1.93e-13	Extraversion;
CRC	trans	rs1360141	0.964	rs4745112	chr9:74292618	T/C	cg07994661	chr4:153856847	NA	0.32	6.02	0.31	4.72e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg10760299	chr15:45669010	GATM	0.49	7.79	0.39	8.71e-14	Homoarginine levels;
CRC	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.61	-0.3	4.19e-8	Neuroticism;
CRC	cis	rs10924970	0.967	rs12027832	chr1:235385934	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.81	0.3	1.49e-8	Asthma;
CRC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.71	11.53	0.54	4.48e-26	Dental caries;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg10876282	chr6:28092338	ZSCAN16	0.47	6.44	0.33	4.36e-10	Parkinson's disease;
CRC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg03037974	chr15:76606532	NA	0.69	11.51	0.54	5.25e-26	Blood metabolite levels;
CRC	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.23e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.34	-6.17	-0.32	2.02e-9	Dilated cardiomyopathy;
CRC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg17524180	chr13:113633600	MCF2L	-0.68	-12.77	-0.58	1.32e-30	Systolic blood pressure;
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-7.13	-0.37	6.48e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14159672	chr1:205819179	PM20D1	0.42	5.68	0.3	2.89e-8	Parkinson's disease;
CRC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg24011408	chr12:48396354	COL2A1	0.45	6.18	0.32	1.92e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg27205649	chr11:78285834	NARS2	-0.51	-6.68	-0.35	9.93e-11	Alzheimer's disease (survival time);
CRC	cis	rs699	0.698	rs1326888	chr1:230863160	A/G	cg07502417	chr1:230849801	AGT	0.28	5.7	0.3	2.71e-8	Coronary artery disease;
CRC	trans	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.7	-0.35	8.99e-11	Depression;
CRC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg12311346	chr5:56204834	C5orf35	-0.46	-6.98	-0.36	1.61e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg15845792	chr6:28175446	NA	0.8	8.27	0.41	3.3e-15	Parkinson's disease;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg06470822	chr6:28175283	NA	0.95	13.56	0.6	1.43e-33	Parkinson's disease;
CRC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.62	-9.57	-0.47	2.57e-19	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13198984	chr17:80129470	CCDC57	0.45	7.82	0.4	7.07e-14	Life satisfaction;
CRC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg07195577	chr17:27052828	TLCD1	-0.42	-6.02	-0.31	4.78e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.18	-16.33	-0.67	2.61e-44	Breast cancer;
CRC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.09	0.41	1.19e-14	Platelet count;
CRC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-0.65	-10.98	-0.52	4.23e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg01028140	chr2:1542097	TPO	-0.6	-6.03	-0.32	4.39e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg22687807	chr8:143858763	LYNX1	-0.45	-6.95	-0.36	1.95e-11	Urinary tract infection frequency;
CRC	cis	rs9786986	0.665	rs10925942	chr1:235699585	C/T	cg08848088	chr1:235714526	GNG4	0.56	6.51	0.34	2.84e-10	Body mass index;
CRC	cis	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg04733911	chr16:78082701	NA	-0.44	-7.14	-0.37	5.83e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg14844989	chr11:31128820	NA	0.33	5.83	0.31	1.33e-8	Red blood cell count;
CRC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.44	0.53	9.47e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23350446	chr6:170893182	PDCD2	-0.52	-6.06	-0.32	3.67e-9	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-7.13	-0.37	6.48e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.61	-9.2	-0.45	4.25e-18	Blood pressure (smoking interaction);
CRC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	0.95	17.72	0.7	8.59e-50	Primary sclerosing cholangitis;
CRC	cis	rs2637266	0.549	rs10824433	chr10:78412843	T/C	cg18941641	chr10:78392320	NA	-0.36	-5.95	-0.31	6.96e-9	Pulmonary function;
CRC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.26	-0.41	3.59e-15	Intelligence (multi-trait analysis);
CRC	trans	rs4130344	0.935	rs11100197	chr4:159685743	C/T	cg01113538	chr6:53658866	LRRC1	-0.4	-5.99	-0.31	5.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg02023728	chr11:77925099	USP35	0.36	6.01	0.31	4.89e-9	Testicular germ cell tumor;
CRC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg00343986	chr7:65444356	GUSB	0.49	7.34	0.38	1.64e-12	Aortic root size;
CRC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.67	-9.64	-0.47	1.6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder;
CRC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.45	-6.45	-0.34	3.96e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.07	-0.41	1.31e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.77	-10.29	-0.49	1.02e-21	Initial pursuit acceleration;
CRC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.48	0.34	3.34e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs77633900	0.772	rs2957607	chr15:76686527	A/G	cg21673338	chr15:77095150	SCAPER	0.69	6.23	0.32	1.41e-9	Non-glioblastoma glioma;Glioma;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg02579316	chr6:126278500	HINT3	0.45	6.33	0.33	8.19e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11068520	chr14:50234443	KLHDC2	0.45	6.26	0.33	1.2e-9	Response to antipsychotic treatment;
CRC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.38	6.42	0.33	4.87e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.92	-11.97	-0.55	1.18e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.19	11.18	0.52	8.1e-25	Prostate cancer;
CRC	trans	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg18232548	chr7:50535776	DDC	0.43	6.14	0.32	2.44e-9	Malaria;
CRC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9287719	0.601	rs10178751	chr2:10734203	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.42	8.64	0.43	2.56e-16	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.57	7.6	0.39	3.06e-13	Height;
CRC	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.47	8.03	0.4	1.78e-14	Common traits (Other);
CRC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.47	-6.95	-0.36	1.97e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg24505167	chr7:1915268	MAD1L1	-0.4	-5.66	-0.3	3.3e-8	Bipolar disorder;
CRC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.41	6.99	0.36	1.58e-11	Breast cancer;
CRC	cis	rs863345	0.967	rs10908683	chr1:158522770	C/G	cg12129480	chr1:158549410	OR10X1	-0.26	-5.68	-0.3	2.93e-8	Pneumococcal bacteremia;
CRC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.7	10.65	0.51	6.12e-23	Metabolic syndrome;
CRC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.57	8.34	0.42	2.09e-15	Menopause (age at onset);
CRC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.81	11.93	0.55	1.61e-27	Cognitive function;
CRC	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg12682573	chr17:27188876	MIR451;MIR144	-0.6	-8.81	-0.44	7.1e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.69	7.85	0.4	5.88e-14	Vitiligo;
CRC	cis	rs4294134	1.000	rs10234309	chr7:135311167	G/A	cg20392616	chr7:135392013	SLC13A4	-0.5	-5.87	-0.31	1.08e-8	Paget's disease;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg21251018	chr6:28226885	NKAPL	0.53	8.11	0.41	1.03e-14	Parkinson's disease;
CRC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.64	8.31	0.42	2.59e-15	Alzheimer's disease;
CRC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.16	-0.49	2.95e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.66	7.23	0.37	3.32e-12	Axial length;
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg05552183	chr6:42928497	GNMT	0.52	7.84	0.4	6.21e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.74	-13.0	-0.58	1.76e-31	Body mass index;
CRC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.81	15.0	0.64	4.08e-39	Metabolic syndrome;
CRC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Urate levels;
CRC	cis	rs2033908	0.619	rs10765994	chr11:12850819	A/G	cg25843174	chr11:12811716	TEAD1	0.43	7.61	0.39	2.97e-13	Sitting height ratio;
CRC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.62	0.43	2.88e-16	Cognitive test performance;
CRC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.36	0.42	1.86e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.26	-6.48	-0.34	3.4e-10	Lymphocyte counts;
CRC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.61	-9.85	-0.48	3.19e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.51	7.53	0.38	5.05e-13	Pancreatic cancer;
CRC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.14	-12.55	-0.57	8.91e-30	Diabetic kidney disease;
CRC	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.63	-9.81	-0.48	4.18e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.46	-5.78	-0.3	1.72e-8	Gut microbiome composition (summer);
CRC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.12	-0.32	2.69e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.95	-11.87	-0.55	2.67e-27	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.33	-0.37	1.81e-12	Caudate activity during reward;
CRC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.62	12.96	0.58	2.67e-31	Schizophrenia;
CRC	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg03623178	chr6:28175578	NA	0.58	6.37	0.33	6.5e-10	Parkinson's disease;
CRC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg06494592	chr3:125709126	NA	-0.56	-6.74	-0.35	7.2e-11	Blood pressure (smoking interaction);
CRC	cis	rs12143943	0.866	rs4252726	chr1:204513402	G/A	cg17419461	chr1:204415978	PIK3C2B	0.4	6.18	0.32	1.87e-9	Cognitive performance;
CRC	cis	rs216303	1.000	rs216302	chr12:6158022	G/A	cg19878637	chr12:6148451	VWF	-0.54	-6.0	-0.31	5.32e-9	Low vWF levels;
CRC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.53	8.14	0.41	8.21e-15	Lung cancer;
CRC	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.49	-6.3	-0.33	9.34e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.81	12.46	0.57	1.95e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg12183467	chr14:104352244	NA	-0.5	-6.96	-0.36	1.83e-11	Bipolar disorder;
CRC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.34	-0.33	7.67e-10	Bipolar disorder;
CRC	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg00338735	chr4:53728038	RASL11B	-0.44	-6.78	-0.35	5.45e-11	Optic nerve measurement (cup area);
CRC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg08999081	chr20:33150536	PIGU	0.46	5.68	0.3	3.01e-8	Neuroticism;
CRC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.54	8.02	0.4	1.9e-14	Body mass index;
CRC	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.49	7.69	0.39	1.73e-13	Resting heart rate;
CRC	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg16141378	chr3:129829833	LOC729375	0.4	6.12	0.32	2.63e-9	Joint mobility (Beighton score);
CRC	cis	rs10512697	0.655	rs34560950	chr5:3512343	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.61	9.81	0.48	4.13e-20	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08219700	chr8:58056026	NA	0.53	6.09	0.32	3.21e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg09915433	chr19:53449742	NA	-0.6	-8.96	-0.44	2.5e-17	Psoriasis;
CRC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.27	14.66	0.63	8.59e-38	Diabetic kidney disease;
CRC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg07713946	chr22:31675144	LIMK2	-0.39	-5.6	-0.3	4.42e-8	Colorectal cancer;
CRC	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.59	8.61	0.43	3.06e-16	Schizophrenia;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg19041857	chr6:27730383	NA	-0.45	-6.13	-0.32	2.58e-9	Parkinson's disease;
CRC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg00769240	chr8:12517080	NA	-0.61	-6.99	-0.36	1.55e-11	Blood pressure (smoking interaction);
CRC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg23625390	chr15:77176239	SCAPER	0.48	6.92	0.36	2.34e-11	Blood metabolite levels;
CRC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.75	13.52	0.6	1.98e-33	Anterior chamber depth;
CRC	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-14.45	-0.62	5.67e-37	Colorectal cancer;
CRC	cis	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg26958806	chr6:27640298	NA	-0.84	-6.15	-0.32	2.3e-9	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02258066	chr2:65357768	RAB1A	0.4	6.06	0.32	3.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-7.97	-0.4	2.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.98	-19.31	-0.73	4.27e-56	Height;
CRC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.83	11.36	0.53	1.87e-25	Cisplatin-induced ototoxicity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19969113	chr12:118810441	TAOK3	0.41	6.27	0.33	1.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.86	0.31	1.12e-8	Tonsillectomy;
CRC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	9.08	0.45	1.03e-17	Total body bone mineral density;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.54	-9.47	-0.46	5.62e-19	Sense of smell;
CRC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.59	-0.34	1.75e-10	Aortic root size;
CRC	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	0.74	9.33	0.46	1.63e-18	Prostate cancer;
CRC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.83	-12.67	-0.57	3.01e-30	Response to antineoplastic agents;
CRC	cis	rs17152411	0.895	rs61872118	chr10:126583450	C/T	cg07906193	chr10:126599966	NA	0.54	6.0	0.31	5.1e-9	Height;
CRC	cis	rs3026445	0.887	rs4766497	chr12:110950376	T/C	cg12870014	chr12:110450643	ANKRD13A	-0.39	-6.04	-0.32	4.18e-9	QT interval;
CRC	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.47	-5.78	-0.3	1.73e-8	Adiposity;
CRC	trans	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg21153622	chr11:89784906	NA	-0.49	-7.78	-0.39	9.36e-14	HDL cholesterol;
CRC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.35	6.32	0.33	8.58e-10	Crohn's disease;
CRC	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.42	5.74	0.3	2.15e-8	Height;
CRC	cis	rs531930	0.959	rs506292	chr6:124735082	T/C	cg05308643	chr6:124982296	NKAIN2	-0.43	-5.7	-0.3	2.62e-8	Celiac disease;
CRC	cis	rs2565722	0.665	rs2465854	chr6:161310910	A/G	cg03159191	chr6:161285451	NA	0.45	6.36	0.33	6.92e-10	Blood protein levels;
CRC	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg23167259	chr10:102495509	NA	-0.49	-6.76	-0.35	6.28e-11	Alzheimer's disease;
CRC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.75	-9.22	-0.45	3.69e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23838375	chr17:72732946	RAB37	0.4	6.66	0.34	1.13e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.55	-0.43	4.76e-16	Life satisfaction;
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.39	-0.38	1.22e-12	Total body bone mineral density;
CRC	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-6.52	-0.34	2.61e-10	Coronary artery disease;
CRC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.68	0.54	1.28e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.6	-9.24	-0.45	3.1e-18	Aortic root size;
CRC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.51	-8.37	-0.42	1.69e-15	Breast cancer;
CRC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg03609598	chr5:56110824	MAP3K1	-0.44	-6.23	-0.32	1.42e-9	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg23161317	chr6:28129485	ZNF389	0.44	6.47	0.34	3.48e-10	Parkinson's disease;
CRC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.69	0.35	9.84e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg02560186	chr11:3602584	NA	-0.63	-9.54	-0.47	3.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg21827317	chr3:136751795	NA	0.36	5.87	0.31	1.05e-8	Neuroticism;
CRC	cis	rs728616	0.867	rs1983776	chr10:81663695	C/T	cg11900509	chr10:81946545	ANXA11	-0.62	-6.31	-0.33	8.96e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03605463	chr16:89740564	NA	-0.4	-6.04	-0.32	4.09e-9	Vitiligo;
CRC	cis	rs4664293	0.647	rs7580816	chr2:160475881	G/A	cg08347373	chr2:160653686	CD302	-0.39	-6.63	-0.34	1.4e-10	Monocyte percentage of white cells;
CRC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.58	8.77	0.44	1e-16	Aortic root size;
CRC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg16102536	chr7:156981717	UBE3C	0.42	7.14	0.37	5.87e-12	Body mass index;
CRC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.3	0.37	2.22e-12	Aortic root size;
CRC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg06046430	chr4:77819534	ANKRD56	0.41	5.71	0.3	2.5e-8	Emphysema distribution in smoking;
CRC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.67	-11.79	-0.55	5.29e-27	Height;
CRC	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg13086574	chr8:135490821	ZFAT	-0.36	-6.27	-0.33	1.16e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg05673287	chr15:77411982	SGK269	-0.37	-6.22	-0.32	1.48e-9	Type 2 diabetes;
CRC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.7	0.39	1.62e-13	Platelet count;
CRC	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.86	-14.6	-0.63	1.44e-37	Longevity;
CRC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.36	5.9	0.31	8.92e-9	Ulcerative colitis;
CRC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.31	0.46	1.88e-18	Bladder cancer;
CRC	cis	rs10512697	0.772	rs34227872	chr5:3523512	G/T	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg00225070	chr15:80189496	MTHFS	0.41	6.22	0.32	1.54e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.1	-0.41	1.06e-14	Bipolar disorder;
CRC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.9	17.3	0.69	3.92e-48	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.74	12.94	0.58	2.97e-31	Breast cancer;
CRC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.52	6.58	0.34	1.9e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.46	6.09	0.32	3.1e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg04110750	chr16:69646130	NFAT5	-0.57	-7.72	-0.39	1.45e-13	IgE levels;
CRC	cis	rs9491140	0.514	rs11154227	chr6:124681816	G/A	cg19267163	chr6:125004984	NKAIN2	0.46	5.97	0.31	6.31e-9	Neuroticism;
CRC	cis	rs3736485	0.966	rs11634039	chr15:51895575	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.7	-0.35	9e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.77	0.3	1.85e-8	Tonsillectomy;
CRC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-12.83	-0.58	8.13e-31	Menarche (age at onset);
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg15845792	chr6:28175446	NA	0.6	8.68	0.43	1.8e-16	Parkinson's disease;
CRC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14451452	chr21:33104301	SFRS15	0.46	6.25	0.33	1.29e-9	Anxiety disorder;
CRC	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.58	6.16	0.32	2.11e-9	Childhood ear infection;
CRC	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.76	0.35	6.22e-11	Coronary artery disease;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.59	6.91	0.36	2.55e-11	Parkinson's disease;
CRC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.33	-0.42	2.29e-15	Monocyte percentage of white cells;
CRC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg15845792	chr6:28175446	NA	-0.58	-6.29	-0.33	9.99e-10	Depression;
CRC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.76	0.35	6.2e-11	Aortic root size;
CRC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-7.85	-0.4	5.73e-14	Monocyte percentage of white cells;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg02033258	chr5:131593261	PDLIM4	0.41	7.89	0.4	4.37e-14	Breast cancer;
CRC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.98	-0.31	5.95e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.57	0.34	1.99e-10	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg15786705	chr6:28176104	NA	0.73	9.43	0.46	7.63e-19	Parkinson's disease;
CRC	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg10437265	chr15:77819839	NA	0.59	9.99	0.48	1.03e-20	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.12	0.45	7.61e-18	Fuchs's corneal dystrophy;
CRC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.45	5.97	0.31	6.11e-9	Response to diuretic therapy;
CRC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg06654549	chr5:1875058	NA	0.43	6.32	0.33	8.74e-10	Cardiovascular disease risk factors;
CRC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.5	-7.23	-0.37	3.39e-12	White blood cell count (basophil);White blood cell count;
CRC	cis	rs2062225	1.000	rs6731964	chr2:111762043	T/C	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.73	0.35	7.59e-11	Myopia (pathological);
CRC	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.78	0.3	1.75e-8	Height;
CRC	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.18	-0.32	1.93e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.93	-0.31	7.47e-9	Heart rate;
CRC	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg02569458	chr12:86230093	RASSF9	0.39	6.51	0.34	2.8e-10	Major depressive disorder;
CRC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg11941060	chr3:133502564	NA	-0.47	-7.65	-0.39	2.28e-13	Iron status biomarkers;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.64	6.59	0.34	1.72e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.63	9.58	0.47	2.53e-19	Cleft lip with or without cleft palate;
CRC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.63	10.21	0.49	1.91e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.43	8.1	0.41	1.06e-14	Childhood ear infection;
CRC	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg16950941	chr11:66035639	RAB1B	0.7	10.39	0.5	4.59e-22	Gout;
CRC	cis	rs8105895	0.935	rs62110993	chr19:22268260	G/A	cg02657401	chr19:22469223	NA	-0.37	-5.73	-0.3	2.32e-8	Body mass index (change over time);
CRC	trans	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg21167628	chr1:45308625	PTCH2	-0.38	-6.46	-0.34	3.86e-10	Facial morphology (factor 20);
CRC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.56	-7.76	-0.39	1.07e-13	Pancreatic cancer;
CRC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	3.95e-13	Motion sickness;
CRC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg19913688	chr11:428466	ANO9	-0.73	-7.41	-0.38	1.08e-12	Body mass index;
CRC	cis	rs58141407	1	rs58141407	chr8:21791772	C/T	cg25597362	chr8:21767310	DOK2	-0.58	-6.48	-0.34	3.32e-10	Red blood cell count;Mean corpuscular volume;
CRC	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg24463073	chr6:118973353	C6orf204	0.54	7.01	0.36	1.36e-11	Diastolic blood pressure;
CRC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.95	-19.14	-0.73	2.04e-55	Height;
CRC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg24910161	chr17:38119198	GSDMA	-0.36	-5.95	-0.31	6.8e-9	Myeloid white cell count;
CRC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.59	-7.98	-0.4	2.47e-14	Schizophrenia;
CRC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.71	-11.0	-0.52	3.53e-24	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.03	10.1	0.49	4.66e-21	Immature fraction of reticulocytes;
CRC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.46	-6.49	-0.34	3.17e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.72	8.71	0.43	1.53e-16	Gut microbiome composition (summer);
CRC	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-8.12	-0.41	9.14e-15	Blood pressure (smoking interaction);
CRC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	0.94	8.96	0.44	2.43e-17	IgG glycosylation;
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	5.99	0.31	5.59e-9	Prudent dietary pattern;
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.6	10.2	0.49	2.13e-21	Prudent dietary pattern;
CRC	cis	rs11212617	1.000	rs227094	chr11:108233800	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.45	6.72	0.35	8.02e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.49	8.27	0.41	3.45e-15	Common traits (Other);
CRC	cis	rs4664293	0.833	rs10170336	chr2:160589343	T/C	cg08347373	chr2:160653686	CD302	-0.35	-5.61	-0.3	4.36e-8	Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17308151	chr11:8703888	RPL27A	0.47	6.75	0.35	6.68e-11	Response to antipsychotic treatment;
CRC	cis	rs4664293	0.967	rs12611922	chr2:160462749	T/G	cg08347373	chr2:160653686	CD302	-0.45	-7.31	-0.37	2.02e-12	Monocyte percentage of white cells;
CRC	trans	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg15845792	chr6:28175446	NA	0.65	7.33	0.37	1.85e-12	Intelligence (multi-trait analysis);
CRC	cis	rs73206853	0.563	rs4073472	chr12:111176494	A/G	cg12870014	chr12:110450643	ANKRD13A	0.78	8.38	0.42	1.51e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.44	7.08	0.36	8.6e-12	Resting heart rate;
CRC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg11212589	chr17:38028394	ZPBP2	0.43	7.95	0.4	2.96e-14	Self-reported allergy;
CRC	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg07423050	chr13:99094983	FARP1	-0.42	-6.77	-0.35	5.77e-11	Longevity;
CRC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.49	-6.94	-0.36	2.09e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.83	-11.07	-0.52	2.05e-24	Hair shape;
CRC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg03013999	chr17:37608204	MED1	0.45	6.82	0.35	4.26e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.93	15.32	0.65	2.37e-40	Dupuytren's disease;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg20062050	chr1:227730881	NA	0.36	6.01	0.31	4.79e-9	Menopause (age at onset);
CRC	cis	rs2233152	0.572	rs10403040	chr19:41296046	A/T	cg21869046	chr19:41225005	ITPKC	-0.34	-5.63	-0.3	3.94e-8	Kawasaki disease;
CRC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-5.69	-0.3	2.81e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg05941027	chr17:61774174	LIMD2	0.37	6.71	0.35	8.59e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6496667	0.779	rs16944509	chr15:91032003	G/A	cg04176472	chr15:90893244	GABARAPL3	0.63	8.25	0.41	3.84e-15	Rheumatoid arthritis;
CRC	trans	rs10269006	0.634	rs6465431	chr7:94374906	T/C	cg05903386	chr2:217555456	IGFBP5	-0.38	-6.34	-0.33	7.38e-10	Breast cancer;
CRC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg02449762	chr10:5661741	NA	-0.33	-5.68	-0.3	2.96e-8	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25789201	chr7:72395803	POM121	0.44	6.18	0.32	1.87e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	ch.2.148072779R	chr2:148356309	NA	0.43	6.28	0.33	1.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.84e-24	Corneal astigmatism;
CRC	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-5.92	-0.31	8.27e-9	Schizophrenia;
CRC	cis	rs3996993	0.809	rs4715332	chr6:52669185	C/A	cg20803780	chr6:52668592	GSTA1	-0.38	-7.11	-0.36	7.41e-12	Hemoglobin concentration;
CRC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.57	-8.07	-0.41	1.33e-14	Systemic lupus erythematosus;
CRC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs2302190	0.769	rs7215531	chr17:56493374	A/T	cg12560992	chr17:57184187	TRIM37	0.49	5.8	0.3	1.54e-8	Vitamin D levels;
CRC	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg09184832	chr6:79620586	NA	-0.33	-6.37	-0.33	6.29e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.45	-0.34	3.98e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.75	-10.44	-0.5	3.03e-22	Cognitive function;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg15786705	chr6:28176104	NA	0.64	9.21	0.45	3.94e-18	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-8.65	-0.43	2.34e-16	Inflammatory bowel disease;
CRC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.68	10.0	0.48	9.99e-21	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-7.08	-0.36	8.65e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.59	-7.02	-0.36	1.25e-11	Lymphocyte counts;
CRC	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg09659197	chr4:152720779	NA	0.42	8.57	0.43	4.15e-16	Intelligence (multi-trait analysis);
CRC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.74	-0.3	2.13e-8	Response to bleomycin (chromatid breaks);
CRC	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg00919237	chr7:87102261	ABCB4	-0.5	-6.53	-0.34	2.57e-10	Gallbladder cancer;
CRC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.83	-0.4	6.67e-14	Mean corpuscular volume;
CRC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.19	0.69	1.08e-47	Platelet count;
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	0.7	7.81	0.4	7.99e-14	Body mass index;
CRC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg15511327	chr8:143859410	LYNX1	0.4	7.3	0.37	2.13e-12	Urinary tract infection frequency;
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.19	-0.32	1.77e-9	Total body bone mineral density;
CRC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.74	12.91	0.58	4.03e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27078813	chr10:43633258	CSGALNACT2	0.46	6.57	0.34	2.01e-10	Response to antipsychotic treatment;
CRC	cis	rs3814231	0.531	rs17090904	chr10:115476138	C/T	cg24846397	chr10:115438155	CASP7	-0.34	-5.67	-0.3	3.17e-8	Vitiligo;
CRC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.85	-14.71	-0.63	5.4e-38	Coronary artery disease;
CRC	cis	rs812925	0.519	rs2463099	chr2:61618311	T/C	cg10580144	chr2:61372316	C2orf74	-0.32	-6.99	-0.36	1.57e-11	Immature fraction of reticulocytes;
CRC	trans	rs6011368	0.630	rs1570520	chr20:62910954	A/G	cg13869341	chr1:15865	WASH5P	0.41	6.3	0.33	9.65e-10	Clozapine-induced cytotoxicity;
CRC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.45	-0.34	3.92e-10	Tonsillectomy;
CRC	trans	rs10099002	0.643	rs12679657	chr8:5157061	A/G	cg04650094	chr6:41006974	UNC5CL	0.36	6.06	0.32	3.81e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.11	0.32	2.86e-9	Rheumatoid arthritis;
CRC	trans	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06834434	chr14:75079333	LTBP2	0.56	7.1	0.36	7.83e-12	Obesity-related traits;
CRC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg18512352	chr11:47633146	NA	0.35	6.8	0.35	4.95e-11	Subjective well-being;
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.41	-7.19	-0.37	4.29e-12	Height;
CRC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.69	11.94	0.55	1.55e-27	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03160445	chr3:100120349	LNP1;TOMM70A	0.53	6.82	0.35	4.36e-11	Thyroid stimulating hormone;
CRC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.19	-0.37	4.37e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.89	-0.31	9.58e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6908034	0.607	rs75060331	chr6:19812956	C/T	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2213920	0.749	rs10121366	chr9:118244022	T/C	cg13918206	chr9:118159781	DEC1	0.56	5.7	0.3	2.67e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs7692995	1.000	rs6811842	chr4:18009798	T/A	cg08925142	chr4:18023851	LCORL	-0.53	-5.89	-0.31	9.52e-9	Height;
CRC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg03623178	chr6:28175578	NA	0.41	5.63	0.3	3.91e-8	Pulmonary function;
CRC	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.46	5.69	0.3	2.79e-8	Metabolite levels;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg16721101	chr20:25176146	ENTPD6	-0.7	-6.08	-0.32	3.35e-9	Cognitive function;
CRC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.66	-9.54	-0.47	3.28e-19	Vitamin D levels;
CRC	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg19077165	chr18:44547161	KATNAL2	0.42	6.32	0.33	8.61e-10	Educational attainment;
CRC	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg23920097	chr1:209922102	NA	-0.52	-6.59	-0.34	1.72e-10	Red blood cell count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03738979	chr19:11145704	SMARCA4	-0.39	-6.12	-0.32	2.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.61	6.64	0.34	1.28e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.81	-14.77	-0.63	3.3e-38	Body mass index;
CRC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13844804	chr7:814759	HEATR2	-0.53	-5.61	-0.3	4.37e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	5.83	0.31	1.29e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg09597638	chr17:3907349	NA	-0.66	-11.6	-0.54	2.65e-26	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08052428	chr9:135996421	RALGDS	0.49	7.05	0.36	1.06e-11	Response to antipsychotic treatment;
CRC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.6	6.77	0.35	5.87e-11	Bipolar disorder;
CRC	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg09127314	chr1:152161683	NA	-0.45	-5.75	-0.3	2.05e-8	Atopic dermatitis;
CRC	trans	rs1642645	0.831	rs7529102	chr1:42493322	T/C	cg16926213	chr1:1841314	NA	-0.43	-6.17	-0.32	1.96e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	1.07	10.44	0.5	3.1e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg22535103	chr8:58192502	C8orf71	-0.44	-5.8	-0.3	1.55e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.27	5.78	0.3	1.78e-8	Migraine;
CRC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	trans	rs12940923	1.000	rs11079343	chr17:56369007	T/C	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.15e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.52	-8.57	-0.43	3.95e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.68	0.43	1.89e-16	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00166722	chr3:10149974	C3orf24	0.62	8.7	0.43	1.66e-16	Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.08	0.32	3.35e-9	Renal function-related traits (BUN);
CRC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.52	-0.34	2.64e-10	Subjective well-being;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs59964204	1.000	rs59964204	chr7:36939322	G/A	cg10440835	chr17:78484142	NA	0.52	6.03	0.32	4.49e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.42	7.01	0.36	1.32e-11	Diastolic blood pressure;
CRC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.42	-6.08	-0.32	3.29e-9	Renal cell carcinoma;
CRC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.96	14.11	0.61	1.11e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg05562828	chr17:3906858	NA	0.49	6.48	0.34	3.32e-10	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg00105475	chr2:10696890	NA	0.46	7.12	0.37	6.69e-12	Prostate cancer;
CRC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.37	-5.9	-0.31	9.25e-9	Ulcerative colitis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13093793	chr14:35099518	SNX6	0.46	6.57	0.34	2.01e-10	Survival in pancreatic cancer;
CRC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24308560	chr3:49941425	MST1R	-0.47	-7.44	-0.38	8.95e-13	Intelligence (multi-trait analysis);
CRC	trans	rs12432203	1.000	rs78769565	chr14:51726384	A/T	cg14592830	chr9:122318704	NA	0.61	6.28	0.33	1.08e-9	Cancer;
CRC	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.87	-0.35	3.26e-11	Schizophrenia;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.79	-0.44	8.53e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.47	-7.27	-0.37	2.71e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg02033258	chr5:131593261	PDLIM4	0.38	6.51	0.34	2.79e-10	Acylcarnitine levels;
CRC	cis	rs4237845	0.611	rs7136981	chr12:58342677	A/G	cg02175503	chr12:58329896	NA	0.77	12.22	0.56	1.39e-28	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.53e-10	Response to antipsychotic treatment;
CRC	cis	rs73206853	0.841	rs11829321	chr12:110864593	C/G	cg12870014	chr12:110450643	ANKRD13A	0.76	8.18	0.41	6.33e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26496372	chr5:37379396	WDR70	0.49	6.21	0.32	1.59e-9	Thyroid stimulating hormone;
CRC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.67	-11.16	-0.52	9.58e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.55	9.3	0.46	1.99e-18	Dupuytren's disease;
CRC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.34	-0.5	6.78e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.94	-0.31	7.33e-9	Menopause (age at onset);
CRC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.56	8.61	0.43	3.02e-16	Breast cancer;
CRC	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg07125278	chr16:67683757	RLTPR	-0.47	-6.53	-0.34	2.42e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.83	-7.24	-0.37	3.25e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7731657	0.537	rs973901	chr5:130362623	G/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.96	-0.31	6.37e-9	Fasting plasma glucose;
CRC	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg16540259	chr10:75572220	NDST2	0.51	7.86	0.4	5.61e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.13	-0.32	2.47e-9	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.95	-0.31	6.87e-9	Height;
CRC	cis	rs17162190	0.698	rs2290588	chr1:26797508	C/T	cg17456097	chr1:26900765	RPS6KA1	0.47	6.62	0.34	1.5e-10	Mean corpuscular volume;
CRC	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.52	9.02	0.45	1.56e-17	Body mass index;
CRC	cis	rs7737355	0.755	rs1151481	chr5:130926374	A/C	cg25547332	chr5:131281432	NA	0.39	5.93	0.31	7.53e-9	Life satisfaction;
CRC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.94	0.44	2.95e-17	Coffee consumption (cups per day);
CRC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg09218773	chr11:619014	MUPCDH	-0.4	-5.72	-0.3	2.41e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12528394	chr19:59056208	TRIM28	0.44	6.01	0.31	5.05e-9	Anxiety disorder;
CRC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs35520189	0.523	rs66591921	chr2:113707577	G/A	cg12858261	chr2:113808755	IL1F8	0.46	5.89	0.31	9.77e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.33	4.06e-10	Electroencephalogram traits;
CRC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.78	0.63	2.99e-38	Lymphocyte percentage of white cells;
CRC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.36	0.46	1.27e-18	IgG glycosylation;
CRC	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.49	-7.56	-0.38	4.04e-13	Atrial fibrillation;
CRC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.67	6.71	0.35	8.51e-11	Diabetic retinopathy;
CRC	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg16591659	chr17:78472290	NA	-0.43	-6.23	-0.33	1.39e-9	Fractional excretion of uric acid;
CRC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.79	0.39	8.84e-14	Major depressive disorder;
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg21192091	chr7:2758800	NA	-0.35	-5.76	-0.3	1.97e-8	Height;
CRC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.59e-10	Blood metabolite levels;
CRC	cis	rs10771511	1	rs10771511	chr12:29437217	T/C	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.26	-0.33	1.21e-9	Platelet distribution width;
CRC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg14530993	chr4:882597	GAK	0.82	7.8	0.4	8.21e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg20243544	chr17:37824526	PNMT	0.37	5.68	0.3	2.9e-8	Self-reported allergy;
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.92	-0.44	3.29e-17	Alzheimer's disease;
CRC	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-7.29	-0.37	2.38e-12	Coronary artery disease;
CRC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.58	7.94	0.4	3.29e-14	Lung cancer;
CRC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.62	8.45	0.42	9.86e-16	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg18490616	chr2:88469792	THNSL2	0.61	6.1	0.32	2.9e-9	Plasma clusterin levels;
CRC	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg00105475	chr2:10696890	NA	0.46	7.42	0.38	1.02e-12	Prostate cancer;
CRC	cis	rs1950626	0.833	rs35151884	chr14:101394196	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.88	0.66	1.56e-42	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06604058	chr11:63448992	RTN3	0.44	7.28	0.37	2.55e-12	Obesity-related traits;
CRC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.92	11.73	0.54	9.09e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.97	-17.63	-0.7	1.84e-49	Headache;
CRC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg05044414	chr3:183734942	ABCC5	0.48	8.18	0.41	6.13e-15	Anterior chamber depth;
CRC	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg03929089	chr4:120376271	NA	0.58	6.1	0.32	2.91e-9	Intraocular pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22024508	chr19:16771032	TMEM38A;C19orf42	0.48	6.13	0.32	2.56e-9	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.44	-7.44	-0.38	8.65e-13	Metabolite levels;
CRC	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.5	0.38	6.05e-13	Coronary artery disease;
CRC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg17321639	chr7:2759063	NA	-0.51	-6.68	-0.35	1.02e-10	Height;
CRC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.42	-7.04	-0.36	1.1e-11	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21959036	chr4:129733057	PHF17	0.44	7.73	0.39	1.31e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg00531865	chr16:30841666	NA	-0.45	-6.13	-0.32	2.58e-9	Multiple myeloma;
CRC	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.73	-11.52	-0.54	5.11e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.71	-12.37	-0.56	4.08e-29	Inhibitory control;
CRC	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg02702477	chr5:179499311	RNF130	0.54	6.22	0.32	1.5e-9	LDL cholesterol;
CRC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg03037974	chr15:76606532	NA	0.66	11.44	0.53	9.38e-26	Blood metabolite levels;
CRC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.87	-11.75	-0.54	7.38e-27	Initial pursuit acceleration;
CRC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.64	-10.99	-0.52	3.89e-24	Dental caries;
CRC	cis	rs860295	0.812	rs3820594	chr1:155829511	C/T	cg02153340	chr1:155202674	NA	-0.5	-5.98	-0.31	5.7e-9	Body mass index;
CRC	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg26816564	chr1:7831052	VAMP3	0.54	6.07	0.32	3.6e-9	Inflammatory bowel disease;
CRC	cis	rs9649465	1.000	rs1006764	chr7:123337873	C/T	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg16964102	chr10:135390573	NA	0.53	7.44	0.38	8.95e-13	Gout;
CRC	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-5.81	-0.31	1.45e-8	Type 2 diabetes;
CRC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.39	6.42	0.33	4.66e-10	Cardiovascular disease risk factors;
CRC	cis	rs1165668	0.785	rs1165681	chr12:104325111	A/G	cg21863207	chr12:104234989	NT5DC3	-0.43	-6.5	-0.34	2.97e-10	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	trans	rs6472235	0.837	rs10104877	chr8:66932244	C/T	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	trans	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.94	0.36	2.03e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs6686842	0.864	rs6662279	chr1:41553561	T/C	cg19787969	chr8:9763211	NA	0.29	6.13	0.32	2.57e-9	Height;
CRC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg00129232	chr17:37814104	STARD3	-0.43	-6.91	-0.36	2.47e-11	Self-reported allergy;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg15845792	chr6:28175446	NA	0.79	11.71	0.54	1.05e-26	Cardiac Troponin-T levels;
CRC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg04880052	chr2:219191631	PNKD	-0.44	-6.93	-0.36	2.27e-11	Colorectal cancer;
CRC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.59	8.85	0.44	5.43e-17	Aortic root size;
CRC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.79	12.27	0.56	9.13e-29	Monocyte count;
CRC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.37	6.58	0.34	1.86e-10	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg15269541	chr15:43626905	ADAL	0.45	5.72	0.3	2.35e-8	Lung cancer in ever smokers;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.41	6.6	0.34	1.61e-10	Lung cancer;
CRC	trans	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.97	15.64	0.65	1.34e-41	Parkinson's disease;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.77	-13.1	-0.59	7.42e-32	Paraoxonase activity;
CRC	cis	rs965469	0.779	rs6051785	chr20:3339199	C/T	cg25506879	chr20:3388711	C20orf194	-0.37	-5.68	-0.3	2.92e-8	IFN-related cytopenia;
CRC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.56	8.91	0.44	3.55e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.6	8.9	0.44	3.88e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg21251018	chr6:28226885	NKAPL	0.57	10.16	0.49	2.8e-21	Pubertal anthropometrics;
CRC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.47e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg16540259	chr10:75572220	NDST2	0.38	5.98	0.31	5.91e-9	Inflammatory bowel disease;
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00166722	chr3:10149974	C3orf24	0.69	8.15	0.41	7.57e-15	Alzheimer's disease;
CRC	cis	rs897984	0.647	rs7203999	chr16:31017554	T/C	cg00531865	chr16:30841666	NA	0.44	6.21	0.32	1.59e-9	Dementia with Lewy bodies;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs7546094	1.000	rs6669096	chr1:113132361	T/C	cg22162597	chr1:113214053	CAPZA1	0.43	6.08	0.32	3.3e-9	Platelet distribution width;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26383936	chr5:39075183	RICTOR	-0.4	-5.98	-0.31	5.8e-9	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20891225	chr3:57994481	FLNB	0.36	6.26	0.33	1.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.77	11.53	0.54	4.59e-26	Menarche (age at onset);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg12474759	chr6:26027625	HIST1H4B	0.42	6.04	0.32	4.23e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2249694	1.000	rs4363513	chr10:135355534	A/G	cg20169779	chr10:135381914	SYCE1	0.59	9.5	0.46	4.48e-19	Obesity-related traits;
CRC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-6.18	-0.32	1.95e-9	Fibrinogen levels;
CRC	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg13119609	chr19:45449297	APOC2	0.31	5.9	0.31	9.2e-9	Blood protein levels;
CRC	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.31	-0.37	1.99e-12	Venous thromboembolism;
CRC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.21	0.37	3.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg03923535	chr7:1197113	ZFAND2A	0.46	6.41	0.33	4.93e-10	Longevity;Endometriosis;
CRC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.61	9.75	0.47	6.69e-20	Tonsillectomy;
CRC	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg14593290	chr7:50529359	DDC	0.52	7.25	0.37	2.92e-12	Malaria;
CRC	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg00531865	chr16:30841666	NA	0.49	6.83	0.35	4.03e-11	Dementia with Lewy bodies;
CRC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.91	-17.91	-0.7	1.52e-50	Intelligence (multi-trait analysis);
CRC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.54	9.37	0.46	1.16e-18	Migraine;
CRC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.92	12.02	0.55	7.64e-28	Triglycerides;
CRC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.78	-8.36	-0.42	1.76e-15	Tuberculosis;
CRC	cis	rs3790844	1.000	rs3790844	chr1:200007432	A/G	cg07208853	chr1:200005219	NR5A2	0.34	8.12	0.41	9.78e-15	Pancreatic cancer;
CRC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.51	-0.34	2.8e-10	Dupuytren's disease;
CRC	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg10724054	chr17:3904396	NA	0.47	7.5	0.38	5.95e-13	Type 2 diabetes;
CRC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.7	10.62	0.51	7.68e-23	Corneal astigmatism;
CRC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-6.6	-0.34	1.68e-10	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14230166	chr19:1020974	C19orf6	0.49	6.8	0.35	5.02e-11	Anxiety disorder;
CRC	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.56	-6.7	-0.35	9.25e-11	Carotid intima media thickness;
CRC	cis	rs10208940	0.920	rs7571506	chr2:68836317	C/A	cg12452813	chr2:68675892	NA	0.48	6.02	0.31	4.69e-9	Urate levels in lean individuals;
CRC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	5.81e-13	Motion sickness;
CRC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.79	-14.37	-0.62	1.16e-36	Body mass index;
CRC	cis	rs77861329	0.925	rs72964042	chr3:52088485	A/C	cg08692210	chr3:52188851	WDR51A	0.87	8.39	0.42	1.5e-15	Macrophage inflammatory protein 1b levels;
CRC	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.82	0.35	4.3e-11	Primary sclerosing cholangitis;
CRC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.67	9.02	0.45	1.65e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.16	-0.45	5.88e-18	Bipolar disorder;
CRC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.37	6.1	0.32	2.98e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.75	0.3	2.05e-8	Systemic lupus erythematosus;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg21620606	chr4:1342894	KIAA1530	0.33	5.74	0.3	2.14e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14799209	chr7:106809543	HBP1	0.39	6.72	0.35	7.96e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.58	9.74	0.47	7.16e-20	Platelet count;
CRC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.55	7.44	0.38	8.91e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs282587	0.502	rs416018	chr13:113396488	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.8	0.4	8.04e-14	Glycated hemoglobin levels;
CRC	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg03929089	chr4:120376271	NA	-0.48	-6.76	-0.35	6.44e-11	Height;
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg08888203	chr3:10149979	C3orf24	0.68	9.55	0.47	3.06e-19	Alzheimer's disease;
CRC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.37	-0.46	1.17e-18	Platelet count;
CRC	cis	rs2971970	0.519	rs28566817	chr7:133628668	A/G	cg03336402	chr7:133662267	EXOC4	0.63	9.64	0.47	1.5700000000000001e-19	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.86	15.04	0.64	2.85e-39	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg20399509	chr21:47717575	C21orf57	-0.39	-6.5	-0.34	2.93e-10	Testicular germ cell tumor;
CRC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg13385794	chr1:248469461	NA	0.38	6.67	0.35	1.09e-10	Common traits (Other);
CRC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.45	6.19	0.32	1.74e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.9	-0.31	8.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.66	-7.89	-0.4	4.55e-14	Ulcerative colitis;
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg21268650	chr7:45961089	IGFBP3	0.36	6.12	0.32	2.66e-9	Sitting height ratio;
CRC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.97	15.36	0.65	1.65e-40	Primary sclerosing cholangitis;
CRC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.36	6.72	0.35	8.1e-11	Ulcerative colitis;
CRC	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.49	6.82	0.35	4.33e-11	IgG glycosylation;
CRC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.7	0.57	2.49e-30	Menopause (age at onset);
CRC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.58	-7.44	-0.38	8.95e-13	Aortic root size;
CRC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg13206674	chr6:150067644	NUP43	0.58	8.37	0.42	1.7e-15	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24835014	chr4:76911891	SDAD1	0.45	6.21	0.32	1.62e-9	Anxiety disorder;
CRC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24308560	chr3:49941425	MST1R	0.51	8.25	0.41	3.73e-15	Intelligence (multi-trait analysis);
CRC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.77	-9.37	-0.46	1.2e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.41	6.04	0.32	4.05e-9	Hemoglobin concentration;
CRC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.53	-8.07	-0.41	1.3e-14	Urate levels in obese individuals;
CRC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.57	8.55	0.43	4.87e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.2	18.64	0.72	2.04e-53	Atopic dermatitis;
CRC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.6e-10	Morning vs. evening chronotype;
CRC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.99	0.55	9.92e-28	Hip circumference adjusted for BMI;
CRC	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.26	-0.37	2.82e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-9.1	-0.45	8.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.18e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.63	-5.93	-0.31	7.51e-9	Yeast infection;
CRC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg20573242	chr4:122745356	CCNA2	0.42	6.24	0.33	1.33e-9	Type 2 diabetes;
CRC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02725872	chr8:58115012	NA	-0.59	-9.12	-0.45	7.51e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.22	0.32	1.51e-9	Prudent dietary pattern;
CRC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg21578987	chr21:40029669	ERG	0.39	5.67	0.3	3.18e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.12	-0.32	2.59e-9	Aortic root size;
CRC	trans	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg14520829	chr3:18390388	SATB1	0.42	5.98	0.31	5.76e-9	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs642858	0.956	rs646747	chr6:140280368	T/C	cg27524944	chr6:140295369	NA	0.34	5.63	0.3	3.83e-8	Type 2 diabetes;
CRC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08550205	chr17:45786854	TBKBP1	-0.35	-5.62	-0.3	3.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg13043300	chr11:71146211	DHCR7	-0.46	-6.35	-0.33	7.16e-10	Vitamin D levels;
CRC	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg25019722	chr6:37503610	NA	-0.38	-6.59	-0.34	1.75e-10	Cognitive performance;
CRC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.48	7.3	0.37	2.17e-12	Corneal astigmatism;
CRC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.76	-0.66	4.38e-42	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.72	-12.86	-0.58	6.04e-31	Educational attainment;
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.11	0.59	7.1e-32	Alzheimer's disease;
CRC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.53	-8.73	-0.43	1.29e-16	Mean platelet volume;Platelet distribution width;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg15097968	chr15:63449935	RPS27L	-0.46	-7.0	-0.36	1.44e-11	Daytime sleep phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07208322	chr5:177027175	B4GALT7	0.39	6.32	0.33	8.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg03948781	chr1:205179583	DSTYK	0.41	5.91	0.31	8.43e-9	Red blood cell count;
CRC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	6.89	0.35	2.9100000000000002e-11	Headache;
CRC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.85	-14.29	-0.62	2.21e-36	Ulcerative colitis;
CRC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.13	-0.37	6.42e-12	Joint mobility (Beighton score);
CRC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.89e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.53	-0.34	2.56e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2342406	0.825	rs6704663	chr2:45140616	A/G	cg23424933	chr2:45157613	NA	0.44	6.06	0.32	3.77e-9	Myopia;
CRC	trans	rs1864729	1.000	rs2635161	chr8:98282907	A/C	cg08679828	chr8:102218111	ZNF706	0.63	8.05	0.41	1.51e-14	Estradiol plasma levels (breast cancer);
CRC	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	8.86	0.44	4.97e-17	Gastritis;
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.27	-5.68	-0.3	2.9e-8	Alcohol dependence;
CRC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg23109721	chr2:106886537	NA	-0.46	-7.18	-0.37	4.82e-12	Facial morphology (factor 23);
CRC	cis	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg18131467	chr2:239335373	ASB1	0.68	6.18	0.32	1.95e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs4731207	0.698	rs1468377	chr7:124458599	A/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.42	6.69	0.35	9.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.06	-0.32	3.77e-9	Gut microbiome composition (summer);
CRC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.41	-6.13	-0.32	2.52e-9	P wave terminal force;
CRC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg17903999	chr18:56338584	MALT1	0.43	6.92	0.36	2.38e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1186222	0.501	rs4731227	chr7:75263700	C/T	cg05145297	chr7:75264568	HIP1	0.68	12.21	0.56	1.63e-28	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.63	-0.47	1.69e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.41	6.54	0.34	2.38e-10	Dupuytren's disease;
CRC	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg16342193	chr10:102329863	NA	-0.34	-5.67	-0.3	3.16e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg03316587	chr8:142245164	NA	0.42	6.28	0.33	1.09e-9	Immature fraction of reticulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23330034	chr19:41770021	HNRNPUL1	0.48	6.87	0.35	3.18e-11	Response to antipsychotic treatment;
CRC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05422897	chr2:113403145	SLC20A1	0.51	6.52	0.34	2.7e-10	Thyroid stimulating hormone;
CRC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.26e-11	Alzheimer's disease (late onset);
CRC	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg23100626	chr2:96804247	ASTL	0.27	7.2	0.37	4.21e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg05585544	chr11:47624801	NA	0.41	6.32	0.33	8.5e-10	Mean corpuscular hemoglobin;
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg08377800	chr16:31885014	ZNF267	0.62	6.6	0.34	1.65e-10	Lymphocyte counts;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.55	-7.86	-0.4	5.56e-14	Menopause (age at onset);
CRC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.41	7.97	0.4	2.71e-14	Mean corpuscular volume;
CRC	cis	rs364477	0.811	rs279882	chr9:984779	G/T	cg13952963	chr9:998547	NA	0.47	5.63	0.3	3.96e-8	Major depressive disorder;
CRC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	7.87	0.4	5.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs6563739	0.655	rs1028671	chr13:40220011	A/G	cg00026919	chr13:40226031	NA	-0.44	-5.61	-0.3	4.36e-8	Menarche (age at onset);
CRC	cis	rs644148	0.676	rs2571114	chr19:44997579	A/G	cg15540054	chr19:45004280	ZNF180	-0.42	-5.77	-0.3	1.79e-8	Personality dimensions;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07681156	chr19:56154921	ZNF581	0.46	7.39	0.38	1.24e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg20487152	chr13:99095054	FARP1	0.35	5.82	0.31	1.42e-8	Longevity;
CRC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.23	-0.32	1.41e-9	Arsenic metabolism;
CRC	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.62	9.8	0.48	4.56e-20	Crohn's disease;
CRC	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.51	8.22	0.41	4.9e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.43	6.66	0.34	1.16e-10	Type 2 diabetes;
CRC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.76	8.63	0.43	2.74e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs10242455	0.850	rs57367781	chr7:99116819	G/A	cg09045935	chr12:6379348	NA	1.14	8.78	0.44	9.15e-17	Blood metabolite levels;
CRC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg27661571	chr11:113659931	NA	-0.7	-8.75	-0.43	1.15e-16	Hip circumference adjusted for BMI;
CRC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	13.52	0.6	2.07e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.41	-7.27	-0.37	2.71e-12	Height;
CRC	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.09	0.41	1.2e-14	Type 2 diabetes;
CRC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	6.6	0.34	1.61e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.69	10.01	0.48	9.07e-21	Multiple sclerosis;
CRC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.91	-15.76	-0.66	4.29e-42	Height;
CRC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg03037974	chr15:76606532	NA	-0.64	-11.0	-0.52	3.65e-24	Blood metabolite levels;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.31	5.8	0.3	1.52e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.37	1.72e-12	Alzheimer's disease;
CRC	cis	rs7173389	0.530	rs6495063	chr15:73682708	G/T	cg01796676	chr15:73680284	NA	0.55	8.56	0.43	4.48e-16	Resting heart rate;
CRC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.53	-6.89	-0.35	2.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.62	-0.39	2.82e-13	Cystic fibrosis severity;
CRC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.69	-11.93	-0.55	1.61e-27	Schizophrenia;
CRC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg05623727	chr3:50126028	RBM5	0.53	6.92	0.36	2.37e-11	Intelligence (multi-trait analysis);
CRC	trans	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg26043149	chr18:55253948	FECH	0.51	8.03	0.4	1.75e-14	Bone mineral density;
CRC	cis	rs6662572	0.737	rs6429590	chr1:46457250	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.63	0.3	3.8e-8	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06424594	chr17:37824825	PNMT	0.45	6.07	0.32	3.56e-9	Anxiety disorder;
CRC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg09184832	chr6:79620586	NA	-0.43	-7.3	-0.37	2.2e-12	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.53	8.07	0.41	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.44	0.62	5.96e-37	Chronic sinus infection;
CRC	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.75	-0.3	2.06e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.42	6.74	0.35	7.19e-11	High light scatter reticulocyte count;
CRC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg19318889	chr4:1322082	MAEA	0.4	5.74	0.3	2.13e-8	Obesity-related traits;
CRC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.55	-8.34	-0.42	2.11e-15	Calcium levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01430082	chr1:26438394	PDIK1L	0.46	6.05	0.32	4.01e-9	Anxiety disorder;
CRC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.56	-6.65	-0.34	1.21e-10	Blood pressure (smoking interaction);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg14094063	chr7:140624470	BRAF	-0.44	-6.68	-0.35	1.04e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	16.63	0.68	1.7e-45	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.6	7.95	0.4	2.97e-14	Uric acid levels;
CRC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.64	9.13	0.45	7.07e-18	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs2637266	0.561	rs7090852	chr10:78499053	A/G	cg18941641	chr10:78392320	NA	-0.35	-5.99	-0.31	5.4e-9	Pulmonary function;
CRC	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.61	9.66	0.47	1.36e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2415984	0.558	rs10220566	chr14:46965511	A/T	cg14871534	chr14:47121158	RPL10L	-0.43	-6.23	-0.32	1.44e-9	Number of children ever born;
CRC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg06935464	chr4:38784597	TLR10	0.57	5.66	0.3	3.25e-8	Breast cancer;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.59	-0.34	1.77e-10	Breast cancer;
CRC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-6.6	-0.34	1.6e-10	Total body bone mineral density;
CRC	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.49	-6.74	-0.35	6.9e-11	Tuberculosis;
CRC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06481639	chr22:41940642	POLR3H	-0.44	-5.66	-0.3	3.22e-8	Vitiligo;
CRC	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.27	-0.37	2.69e-12	Cholesterol, total;
CRC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg21854759	chr1:92012499	NA	-0.39	-6.03	-0.32	4.45e-9	Breast cancer;
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02421172	chr7:1938701	MAD1L1	0.42	5.66	0.3	3.27e-8	Neuroticism;
CRC	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg19131313	chr8:1704013	NA	-0.44	-5.77	-0.3	1.81e-8	Systolic blood pressure;
CRC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-6.93	-0.36	2.24e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg09040174	chr2:113837401	NA	-0.64	-10.51	-0.5	1.78e-22	Protein quantitative trait loci;
CRC	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg15382696	chr6:118971807	C6orf204	0.56	6.96	0.36	1.84e-11	Diastolic blood pressure;
CRC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.59	0.47	2.24e-19	Cognitive test performance;
CRC	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.64	10.13	0.49	3.61e-21	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs56274002	chr2:162536715	A/T	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs1178968	0.591	rs10440929	chr7:72786770	A/C	cg25889504	chr7:72793014	NA	0.52	5.9	0.31	9.14e-9	Triglyceride levels;
CRC	cis	rs737337	0.623	rs3810308	chr19:11333596	T/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.79	8.85	0.44	5.52e-17	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg20742385	chr13:113633654	MCF2L	-0.72	-12.59	-0.57	6.32e-30	Systolic blood pressure;
CRC	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg09040174	chr2:113837401	NA	0.65	10.31	0.49	9.07e-22	Protein quantitative trait loci;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07237882	chr5:137090689	HNRNPA0	0.4	6.41	0.33	5.07e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.58	0.54	3.17e-26	Bipolar disorder;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03923535	chr7:1197113	ZFAND2A	0.58	8.19	0.41	5.69e-15	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15012766	chr1:41832369	NA	0.41	6.07	0.32	3.62e-9	Anxiety disorder;
CRC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.82	-0.48	4.04e-20	Coronary artery disease;
CRC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.74	-0.43	1.26e-16	Body mass index;
CRC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	0.58	9.0	0.44	1.9e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg08648136	chr8:956695	NA	-0.33	-6.27	-0.33	1.13e-9	Schizophrenia;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.12e-10	Bipolar disorder;
CRC	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.46	6.1	0.32	3.03e-9	Tuberculosis;
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg01546243	chr14:61748019	TMEM30B	-0.41	-6.03	-0.32	4.35e-9	Total body bone mineral density;
CRC	trans	rs11165623	0.602	rs6677110	chr1:97018734	A/C	cg10631902	chr5:14652156	NA	-0.36	-6.21	-0.32	1.57e-9	Hip circumference;Waist circumference;
CRC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.53	7.33	0.37	1.83e-12	Total cholesterol levels;
CRC	trans	rs9369640	0.674	rs1332845	chr6:12892456	C/T	cg05562828	chr17:3906858	NA	0.41	5.99	0.31	5.57e-9	Coronary artery disease;
CRC	cis	rs11212617	0.935	rs609655	chr11:108204253	A/G	cg01991180	chr11:108092276	ATM;NPAT	-0.4	-5.65	-0.3	3.47e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.92	-0.36	2.37e-11	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17774305	chr12:50505649	C12orf62	0.49	6.89	0.36	2.79e-11	Response to antipsychotic treatment;
CRC	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	7.13	0.37	6.6e-12	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg25164649	chr6:28176230	NA	0.73	9.16	0.45	5.49e-18	Depression;
CRC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg25811766	chr13:21894605	NA	0.57	6.77	0.35	5.88e-11	White matter hyperintensity burden;
CRC	cis	rs501120	0.925	rs1632484	chr10:44773984	C/T	cg09554077	chr10:44749378	NA	0.74	10.86	0.51	1.12e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.62	-0.3	4.07e-8	Aortic root size;
CRC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.65	-9.73	-0.47	8.11e-20	QT interval;
CRC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.74	-10.93	-0.52	6.33e-24	Cognitive function;
CRC	cis	rs2735413	0.918	rs7197254	chr16:78063353	C/G	cg04733911	chr16:78082701	NA	-0.36	-5.94	-0.31	7.41e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	14.21	0.62	4.58e-36	Platelet count;
CRC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-20.27	-0.75	7.32e-60	Exhaled nitric oxide output;
CRC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.53	6.75	0.35	6.88e-11	Morning vs. evening chronotype;
CRC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.46	-7.96	-0.4	2.79e-14	Major depressive disorder;
CRC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg04362960	chr10:104952993	NT5C2	-0.4	-5.7	-0.3	2.6e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg17145862	chr1:211918768	LPGAT1	0.49	7.04	0.36	1.15e-11	Crohn's disease;
CRC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg24130564	chr14:104152367	KLC1	0.45	5.9	0.31	8.88e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23868848	chr8:128806661	PVT1	0.4	6.97	0.36	1.69e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9491140	0.539	rs10872285	chr6:124689145	C/T	cg05308643	chr6:124982296	NKAIN2	0.54	7.19	0.37	4.46e-12	Neuroticism;
CRC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.36	-6.36	-0.33	6.85e-10	Erythrocyte sedimentation rate;
CRC	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.53	6.77	0.35	5.94e-11	Exhaled nitric oxide output;
CRC	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.64	-0.34	1.29e-10	Hematocrit;
CRC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.7	9.93	0.48	1.69e-20	Multiple sclerosis;
CRC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.42	5.62	0.3	4.06e-8	Parkinson's disease;
CRC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.46	-0.67	7.62e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00605358	chr12:89747739	DUSP6	-0.55	-6.67	-0.35	1.07e-10	Diisocyanate-induced asthma;
CRC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.38	0.42	1.53e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.84	-0.7	2.9e-50	Height;
CRC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg13160058	chr8:26243215	BNIP3L	-0.47	-8.2	-0.41	5.49e-15	Red cell distribution width;
CRC	cis	rs992157	0.764	rs2891076	chr2:219184398	C/T	cg04880052	chr2:219191631	PNKD	0.4	6.08	0.32	3.32e-9	Colorectal cancer;
CRC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-7.64	-0.39	2.4e-13	Major depressive disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08642325	chr8:26149300	PPP2R2A	0.4	5.99	0.31	5.58e-9	Schizophrenia;
CRC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.51	8.04	0.41	1.64e-14	Graves' disease;
CRC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.75	-9.3	-0.46	1.96e-18	Blood protein levels;
CRC	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg08461752	chr10:43522343	NA	-0.78	-6.03	-0.32	4.48e-9	Pediatric bone mineral content (radius);
CRC	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.1	-0.32	2.96e-9	Metabolite levels (Pyroglutamine);
CRC	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.8	-9.53	-0.47	3.51e-19	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.37e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17767392	1.000	rs7156460	chr14:71855334	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.89	-0.35	2.93e-11	Mitral valve prolapse;
CRC	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.65	8.4	0.42	1.31e-15	Uric acid levels;
CRC	cis	rs7487075	0.619	rs6582658	chr12:46856095	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.73	0.3	2.22e-8	Itch intensity from mosquito bite;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.73	8.87	0.44	4.88e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Primary biliary cholangitis;
CRC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.91	0.44	3.58e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.41	0.42	1.24e-15	Corneal astigmatism;
CRC	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg14825688	chr5:132208181	LEAP2	-0.41	-6.5	-0.34	3.02e-10	Apolipoprotein A-IV levels;
CRC	cis	rs3812762	0.912	rs10769954	chr11:8783713	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.2	0.32	1.74e-9	Hypospadias;
CRC	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.77	9.7	0.47	1.02e-19	Height;
CRC	cis	rs3812762	0.833	rs35670750	chr11:8782444	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-6.52	-0.34	2.68e-10	Hypospadias;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.72	-0.39	1.41e-13	Blood metabolite levels;
CRC	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg06643013	chr6:134217242	NA	-0.43	-7.79	-0.39	8.55e-14	Coronary artery disease;
CRC	cis	rs972578	1.000	rs2038062	chr22:43397966	A/G	cg01576275	chr22:43409880	NA	-0.49	-7.46	-0.38	7.9e-13	Mean platelet volume;
CRC	cis	rs7113874	0.589	rs10769908	chr11:8484089	A/G	cg17679104	chr11:8615758	STK33	0.35	5.83	0.31	1.36e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.43	5.8	0.3	1.56e-8	Colorectal cancer;
CRC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	7.14	0.37	6.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-7.44	-0.38	9.08e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20135002	chr11:47629003	NA	0.35	5.75	0.3	2.06e-8	Subjective well-being;
CRC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.84	14.85	0.63	1.52e-38	Breast cancer;
CRC	cis	rs8032158	0.927	rs7179116	chr15:56174827	A/G	cg02198044	chr15:56286336	NEDD4	-0.4	-6.32	-0.33	8.27e-10	Keloid;
CRC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.52	-5.98	-0.31	5.88e-9	Lymphocyte counts;
CRC	cis	rs863345	0.548	rs1032352	chr1:158493154	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	7e-9	Pneumococcal bacteremia;
CRC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.31	0.33	9.14e-10	Tonsillectomy;
CRC	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.85	7.93	0.4	3.35e-14	Arsenic metabolism;
CRC	cis	rs12630931	1.000	rs11712388	chr3:31975160	C/A	cg21375017	chr3:31988082	OSBPL10	0.44	6.14	0.32	2.44e-9	Periodontal disease-related phenotypes;
CRC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.01	0.44	1.77e-17	Bladder cancer;
CRC	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27054308	chr14:20922865	APEX1;OSGEP	0.54	7.23	0.37	3.34e-12	Thyroid stimulating hormone;
CRC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	6.79	0.35	5.17e-11	Coronary artery disease;
CRC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.65	-10.45	-0.5	2.87e-22	Breast cancer;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.4	-5.75	-0.3	2.01e-8	Longevity;Endometriosis;
CRC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.4	-5.94	-0.31	7.33e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	6.49	0.34	3.15e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg17321639	chr7:2759063	NA	-0.51	-6.77	-0.35	6.01e-11	Height;
CRC	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg14515779	chr1:101123966	NA	-0.36	-6.37	-0.33	6.26e-10	Monocyte count;
CRC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.82	9.11	0.45	8.01e-18	Breast cancer;
CRC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.91	0.72	1.7e-54	Cognitive ability;
CRC	cis	rs12760731	0.623	rs10913551	chr1:178410131	T/G	cg00404053	chr1:178313656	RASAL2	0.75	9.35	0.46	1.4e-18	Obesity-related traits;
CRC	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg11693508	chr17:37793320	STARD3	0.61	7.54	0.38	4.51e-13	Bipolar disorder;
CRC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.52	8.94	0.44	2.93e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.5	0.38	6.02e-13	Morning vs. evening chronotype;
CRC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-9.08	-0.45	1.02e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.59	9.04	0.45	1.33e-17	Diastolic blood pressure;
CRC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.94	15.75	0.66	4.87e-42	Primary sclerosing cholangitis;
CRC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.15	-0.37	5.67e-12	Total body bone mineral density;
CRC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.6	7.91	0.4	4.01e-14	Methadone dose in opioid dependence;
CRC	trans	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg24644049	chr4:85504048	CDS1	0.93	7.58	0.39	3.6e-13	Skin colour saturation;
CRC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.87	-13.89	-0.61	7.95e-35	Cognitive function;
CRC	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs12406019	0.510	rs12126464	chr1:78608215	T/C	cg20826526	chr3:156266748	SSR3	-0.4	-6.05	-0.32	3.87e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.49	6.3	0.33	9.54e-10	Obesity-related traits;
CRC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.39	6.21	0.32	1.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.05	0.61	1.92e-35	Hypertriglyceridemia;
CRC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.44	-6.45	-0.33	4.11e-10	Ulcerative colitis;
CRC	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.91e-9	Arsenic metabolism;
CRC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.18	-0.49	2.4e-21	Chronic sinus infection;
CRC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.43	-8.32	-0.42	2.44e-15	Subjective well-being;
CRC	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.55	8.63	0.43	2.67e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs17095355	1.000	rs3862006	chr10:111750764	A/G	cg00817464	chr10:111662876	XPNPEP1	0.6	7.89	0.4	4.52e-14	Biliary atresia;
CRC	cis	rs12612619	0.690	rs6754371	chr2:27315064	G/A	cg00617064	chr2:27272375	NA	-0.37	-5.98	-0.31	5.88e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04586407	chr16:31008574	STX1B	0.43	6.15	0.32	2.21e-9	Response to antipsychotic treatment;
CRC	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.12	-0.32	2.62e-9	IgE levels;
CRC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.02	0.31	4.7e-9	Heart rate;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg09877947	chr5:131593287	PDLIM4	0.44	6.9	0.36	2.74e-11	Blood metabolite levels;
CRC	cis	rs12230513	0.732	rs60450959	chr12:55861373	A/T	cg19537932	chr12:55886519	OR6C68	-0.73	-9.4	-0.46	9.2e-19	Contrast sensitivity;
CRC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.57	8.88	0.44	4.4e-17	Colorectal cancer;
CRC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.92	-19.3	-0.73	4.73e-56	Urate levels in lean individuals;
CRC	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.92	0.31	7.94e-9	Cognitive test performance;
CRC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	15.92	0.66	9.96e-43	Platelet count;
CRC	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg11176159	chr1:28213800	NA	0.29	5.6	0.3	4.44e-8	Corneal astigmatism;
CRC	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24249390	chr15:90295951	MESP1	-0.58	-9.3	-0.46	1.95e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.99	-0.31	5.54e-9	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12849807	chr6:90348187	LYRM2	0.43	6.89	0.36	2.93e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.85	0.51	1.23e-23	Coffee consumption (cups per day);
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03934478	chr11:495069	RNH1	0.67	7.36	0.38	1.45e-12	Body mass index;
CRC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg24881330	chr22:46731750	TRMU	0.67	6.12	0.32	2.64e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg03162506	chr22:38580953	NA	0.27	5.76	0.3	1.93e-8	Cutaneous nevi;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09646206	chr20:17949260	C20orf72;SNX5	0.47	6.55	0.34	2.17e-10	Anxiety disorder;
CRC	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11161846	chr1:160990452	F11R	-0.49	-7.36	-0.38	1.48e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-0.83	-12.33	-0.56	5.69e-29	IgG glycosylation;
CRC	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg14631576	chr9:95140430	CENPP	-0.41	-7.35	-0.38	1.61e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6496667	1.000	rs8026533	chr15:90893228	A/C	cg04176472	chr15:90893244	GABARAPL3	0.53	8.12	0.41	9.57e-15	Rheumatoid arthritis;
CRC	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg06287003	chr12:125626642	AACS	-0.6	-6.77	-0.35	5.79e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.67	-0.3	3.18e-8	Parkinson's disease;
CRC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg19193384	chr17:30244184	NA	-0.64	-7.44	-0.38	8.6e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4804416	1.000	rs4804414	chr19:7223785	C/T	cg00428638	chr19:7224713	INSR	0.59	9.71	0.47	8.9e-20	Thyroid hormone levels;Hypothyroidism;
CRC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.73	8.73	0.43	1.3e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6504622	0.557	rs7213526	chr17:45011157	T/C	cg16759221	chr17:45003025	GOSR2	0.58	9.41	0.46	9.07e-19	Orofacial clefts;
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg12273811	chr6:28175739	NA	0.64	6.54	0.34	2.41e-10	Depression;
CRC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.51	8.13	0.41	8.54e-15	Height;
CRC	cis	rs713477	0.654	rs4901569	chr14:55912880	C/T	cg13175173	chr14:55914753	NA	-0.44	-7.75	-0.39	1.13e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg13615338	chr4:55094005	PDGFRA	0.4	5.8	0.3	1.57e-8	Corneal astigmatism;
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.5	-7.92	-0.4	3.77e-14	Prostate cancer;
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01516881	chr6:292596	DUSP22	-0.55	-7.88	-0.4	4.8e-14	Menopause (age at onset);
CRC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.83	-10.44	-0.5	3.04e-22	Initial pursuit acceleration;
CRC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.47	6.92	0.36	2.34e-11	Subjective well-being;
CRC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.76	-9.14	-0.45	6.71e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.67	10.82	0.51	1.5e-23	DNA methylation (variation);
CRC	cis	rs2882667	0.690	rs10043478	chr5:138188711	C/G	cg09476006	chr5:138032270	NA	0.54	9.36	0.46	1.28e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg00631329	chr6:26305371	NA	-0.53	-8.8	-0.44	8.16e-17	Educational attainment;
CRC	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg09654669	chr8:57350985	NA	-0.45	-6.01	-0.31	5.02e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06442790	chr1:89458396	RBMXL1;CCBL2	0.41	6.43	0.33	4.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs501120	0.657	rs114070077	chr10:44742911	A/G	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.63	-9.71	-0.47	8.91e-20	Hepatocellular carcinoma;
CRC	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg22815214	chr1:201083145	CACNA1S	0.54	6.74	0.35	6.9e-11	Permanent tooth development;
CRC	cis	rs4363385	0.782	rs394859	chr1:153025704	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.5	-0.38	5.87e-13	Inflammatory skin disease;
CRC	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.94	-0.31	7.15e-9	Alzheimer's disease (survival time);
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg06470822	chr6:28175283	NA	0.98	13.08	0.59	8.77e-32	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15428304	chr15:63481580	RAB8B	0.42	6.4	0.33	5.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs10929374	chr2:15676884	T/A	cg19274914	chr2:15703543	NA	0.37	5.61	0.3	4.2e-8	Educational attainment (years of education);
CRC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18912574	chr7:65842487	NCRNA00174	-0.38	-6.5	-0.34	3e-10	Aortic root size;
CRC	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.53	11.8	0.55	4.99e-27	Cutaneous nevi;
CRC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg18230493	chr5:56204884	C5orf35	-0.59	-8.66	-0.43	2.09e-16	Initial pursuit acceleration;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.68	11.18	0.52	8.4e-25	Height;
CRC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.16	0.37	5.22e-12	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14509921	chr1:184357113	C1orf21	0.46	6.01	0.31	4.93e-9	Thyroid stimulating hormone;
CRC	trans	rs4785204	1.000	rs8064107	chr16:50094323	T/C	cg07960154	chr17:37760198	NEUROD2	-0.66	-6.13	-0.32	2.52e-9	Esophageal cancer (squamous cell);
CRC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg05585544	chr11:47624801	NA	-0.55	-9.73	-0.47	8.12e-20	Subjective well-being;
CRC	cis	rs225245	0.531	rs321609	chr17:33880676	G/T	cg05299278	chr17:33885742	SLFN14	0.41	5.76	0.3	1.91e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs4073416	0.542	rs7144345	chr14:66111841	G/C	cg03016385	chr14:66212404	NA	-0.45	-6.2	-0.32	1.67e-9	N-glycan levels;
CRC	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.85	12.67	0.57	3.16e-30	Migraine;Coronary artery disease;
CRC	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg04415270	chr2:102091202	RFX8	-0.35	-5.95	-0.31	6.79e-9	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs3743266	0.507	rs34092508	chr15:60722979	C/T	cg21667061	chr15:60772094	NARG2	0.37	5.64	0.3	3.68e-8	Menarche (age at onset);
CRC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg20488157	chr14:104394430	TDRD9	0.64	9.54	0.47	3.44e-19	Bipolar disorder;
CRC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg21523564	chr15:75251491	NA	0.37	5.66	0.3	3.22e-8	Breast cancer;
CRC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg27535305	chr1:53392650	SCP2	0.36	6.42	0.33	4.77e-10	Monocyte count;
CRC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06544989	chr22:39130855	UNC84B	0.49	7.78	0.39	9.51e-14	Menopause (age at onset);
CRC	cis	rs501120	0.584	rs11511598	chr10:44716036	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs2282802	0.635	rs270162	chr5:139539090	A/G	cg26211634	chr5:139558579	C5orf32	-0.37	-6.38	-0.33	6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs972578	1.000	rs738378	chr22:43398962	A/G	cg01576275	chr22:43409880	NA	0.47	7.32	0.37	1.9e-12	Mean platelet volume;
CRC	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.61	-10.23	-0.49	1.66e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.54	9.39	0.46	1.01e-18	Schizophrenia;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg10596483	chr8:143751796	JRK	-0.49	-6.68	-0.35	9.98e-11	Urinary tract infection frequency;
CRC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.3	-0.59	1.39e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.42	5.78	0.3	1.7e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.81	-0.55	4.59e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.6	-8.86	-0.44	4.97e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg24011408	chr12:48396354	COL2A1	0.46	6.28	0.33	1.1e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg24375607	chr4:120327624	NA	0.46	6.99	0.36	1.52e-11	Corneal astigmatism;
CRC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg21724239	chr8:58056113	NA	0.79	8.62	0.43	2.91e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs58106596	0.950	rs11695646	chr2:232584807	C/T	cg01370599	chr3:116745421	NA	-0.46	-6.33	-0.33	8.15e-10	White blood cell count;Lymphocyte counts;
CRC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-9.23	-0.45	3.41e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-8.46	-0.42	8.63e-16	Uric acid levels;
CRC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.22	-0.56	1.48e-28	Alzheimer's disease;
CRC	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.48	-7.37	-0.38	1.4e-12	Schizophrenia;
CRC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	16.47	0.67	6.96e-45	Platelet count;
CRC	cis	rs853679	0.567	rs6905380	chr6:28374902	A/G	cg21251018	chr6:28226885	NKAPL	0.42	6.08	0.32	3.25e-9	Depression;
CRC	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.93	-14.86	-0.63	1.48e-38	Dupuytren's disease;
CRC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.52	-8.96	-0.44	2.5e-17	Sense of smell;
CRC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.62e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	5.99	0.31	5.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-7.37	-0.38	1.43e-12	Menarche (age at onset);
CRC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.93	-17.8	-0.7	4.12e-50	Height;
CRC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-11.03	-0.52	2.81e-24	Asthma;
CRC	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.51	-7.15	-0.37	5.61e-12	Schizophrenia;
CRC	cis	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg17519650	chr2:63277830	OTX1	-0.42	-5.98	-0.31	5.91e-9	Coronary artery disease;
CRC	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg09264619	chr17:80180166	NA	-0.5	-7.08	-0.36	8.53e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00910907	chr19:4124188	MAP2K2	0.44	5.97	0.31	6.09e-9	Anxiety disorder;
CRC	cis	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg17519650	chr2:63277830	OTX1	0.45	6.21	0.32	1.59e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-6.05	-0.32	3.83e-9	Monocyte count;
CRC	cis	rs3996993	0.809	rs12529579	chr6:52686079	T/C	cg20803780	chr6:52668592	GSTA1	0.35	6.32	0.33	8.38e-10	Hemoglobin concentration;
CRC	cis	rs775227	1.000	rs41271355	chr3:113004155	G/A	cg18753928	chr3:113234510	CCDC52	-0.49	-6.16	-0.32	2.09e-9	Dental caries;
CRC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.65	-8.41	-0.42	1.24e-15	Mean platelet volume;
CRC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg06470822	chr6:28175283	NA	0.69	5.82	0.31	1.37e-8	Depression;
CRC	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg08533674	chr1:46993347	NA	0.43	6.13	0.32	2.53e-9	Monobrow;
CRC	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.35e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4665630	0.522	rs114880940	chr2:23930352	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	0.95	7.28	0.37	2.44e-12	Hypertension;
CRC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	trans	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.72	0.35	7.9e-11	Neuroticism;
CRC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.46	0.46	6.3e-19	Platelet count;
CRC	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg01420254	chr6:26195488	NA	0.69	6.13	0.32	2.45e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.91	-0.31	8.45e-9	Neuroticism;
CRC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.47	7.35	0.38	1.59e-12	Eye color traits;
CRC	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.53	9.53	0.47	3.57e-19	Optic cup area;
CRC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08826281	chr19:49655176	HRC	0.44	7.14	0.37	6.05e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs6469488	1.000	rs2063497	chr8:114900979	A/G	cg16821992	chr8:116679935	TRPS1	-0.48	-6.01	-0.31	4.96e-9	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.06	0.52	2.21e-24	Prudent dietary pattern;
CRC	cis	rs883565	0.569	rs784515	chr3:39163848	C/T	cg01426195	chr3:39028469	NA	0.42	6.97	0.36	1.69e-11	Handedness;
CRC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs12913538	0.862	rs4774441	chr15:62887791	C/T	cg09983546	chr15:62884068	NA	0.55	8.67	0.43	2.03e-16	Sleep depth;
CRC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.57	9.11	0.45	8.45e-18	Monobrow;
CRC	cis	rs939584	1.000	rs1320338	chr2:649347	T/G	cg03610516	chr2:642275	NA	-0.42	-5.85	-0.31	1.2e-8	Body mass index;
CRC	cis	rs36093844	0.851	rs10898417	chr11:85547503	C/T	cg25872744	chr11:85566296	CCDC83	0.38	5.8	0.3	1.55e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
CRC	cis	rs995000	0.868	rs10889360	chr1:63173918	C/T	cg19896129	chr1:63156450	NA	0.38	5.62	0.3	4.17e-8	Triglyceride levels;
CRC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.63	10.07	0.49	5.81e-21	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7671266	0.559	rs7681212	chr4:10358964	C/G	cg00071950	chr4:10020882	SLC2A9	0.46	6.19	0.32	1.84e-9	Cardiovascular disease risk factors;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.32	0.46	1.72e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg13491731	chr14:76594783	NA	-0.43	-6.51	-0.34	2.87e-10	White matter integrity;
CRC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg10494973	chr17:80897199	TBCD	-0.38	-5.99	-0.31	5.45e-9	Breast cancer;
CRC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.45	-5.94	-0.31	7.38e-9	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12334424	chr7:100034074	C7orf47	0.38	6.17	0.32	2.01e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6494488	0.500	rs16948170	chr15:64967654	C/T	cg07470598	chr14:107239068	NA	0.52	6.21	0.32	1.56e-9	Coronary artery disease;
CRC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg20203395	chr5:56204925	C5orf35	-0.43	-6.1	-0.32	2.91e-9	Coronary artery disease;
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.17	-0.32	2.02e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.68	-0.35	1.03e-10	Mean corpuscular volume;
CRC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.17	10.88	0.51	9.5e-24	Alzheimer's disease (late onset);
CRC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.47	9.53	0.47	3.67e-19	Alcohol dependence;
CRC	cis	rs11212617	1.000	rs186595	chr11:108251211	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.77	0.35	5.98e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.05	-0.36	1.07e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.79	9.65	0.47	1.4e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-11.87	-0.55	2.79e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs524281	0.773	rs2298468	chr11:66042962	G/A	cg14036092	chr11:66035641	RAB1B	-0.55	-6.04	-0.32	4.16e-9	Electroencephalogram traits;
CRC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg23093090	chr10:104574429	C10orf26	0.4	6.65	0.34	1.25e-10	Immature fraction of reticulocytes;Schizophrenia;
CRC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.84	-11.54	-0.54	4.39e-26	Platelet distribution width;
CRC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.45	0.42	9.44e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.48	0.34	3.27e-10	Monocyte count;
CRC	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.76	10.93	0.52	6.24e-24	Systemic lupus erythematosus;
CRC	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg06935464	chr4:38784597	TLR10	0.59	7.08	0.36	8.58e-12	Breast cancer;
CRC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg08213375	chr14:104286397	PPP1R13B	0.54	8.28	0.42	3.24e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.86	0.35	3.42e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg27534772	chr1:16042836	PLEKHM2	0.42	6.93	0.36	2.27e-11	Systolic blood pressure;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg13884470	chr9:86595151	HNRNPK;RMI1	0.36	6.04	0.32	4.22e-9	Interleukin-6 levels;
CRC	cis	rs365302	1.000	rs444708	chr6:159644830	C/T	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.77e-10	Coronary heart disease;
CRC	cis	rs449789	0.681	rs12529478	chr6:159704722	T/C	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.62	0.34	1.45e-10	Tonsillectomy;
CRC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.52	8.8	0.44	7.74e-17	Migraine;
CRC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg10589385	chr1:150898437	SETDB1	0.29	6.2	0.32	1.7e-9	Tonsillectomy;
CRC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.61	-9.56	-0.47	2.83e-19	Motion sickness;
CRC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-8.29	-0.42	2.83e-15	Sense of smell;
CRC	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg16141378	chr3:129829833	LOC729375	0.42	6.11	0.32	2.81e-9	Triglycerides;
CRC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.51	7.47	0.38	7.42e-13	Blood metabolite levels;
CRC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.45	-0.34	3.9e-10	Aortic root size;
CRC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg20203395	chr5:56204925	C5orf35	-0.72	-8.56	-0.43	4.54e-16	Initial pursuit acceleration;
CRC	trans	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03605463	chr16:89740564	NA	-0.4	-5.69	-0.3	2.85e-8	Hemoglobin concentration;
CRC	cis	rs2742417	1.000	rs2742368	chr3:45752293	C/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.67	-10.06	-0.48	6.42e-21	Corneal astigmatism;
CRC	trans	rs73162807	0.793	rs6802762	chr3:146443921	T/C	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg15445000	chr17:37608096	MED1	0.36	6.28	0.33	1.08e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.01	0.52	3.17e-24	Prudent dietary pattern;
CRC	trans	rs7690467	0.720	rs13111735	chr4:133395764	C/A	cg19296258	chr17:78878799	RPTOR	-0.47	-6.3	-0.33	9.32e-10	Eating disorders;
CRC	cis	rs4713675	0.505	rs753890	chr6:33652880	G/A	cg14003231	chr6:33640908	ITPR3	0.53	8.52	0.43	5.81e-16	Plateletcrit;
CRC	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.6	10.17	0.49	2.69e-21	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.47	0.34	3.66e-10	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22029345	chr4:6711623	MRFAP1L1	0.44	6.37	0.33	6.22e-10	Anxiety disorder;
CRC	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg22153745	chr1:153894579	GATAD2B	-0.56	-7.33	-0.37	1.77e-12	Total cholesterol levels;
CRC	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg14768367	chr16:72042858	DHODH	-0.6	-6.7	-0.35	8.97e-11	Blood protein levels;
CRC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg07212818	chr11:638076	DRD4	-0.46	-5.93	-0.31	7.71e-9	Systemic lupus erythematosus;
CRC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.9	-0.36	2.71e-11	HDL cholesterol;
CRC	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.57	8.9	0.44	3.76e-17	HDL cholesterol;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg26608667	chr7:1196370	ZFAND2A	0.42	6.85	0.35	3.54e-11	Longevity;Endometriosis;
CRC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.63	-0.39	2.62e-13	Psoriasis;
CRC	trans	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg17903999	chr18:56338584	MALT1	0.43	6.86	0.35	3.43e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg06634786	chr22:41940651	POLR3H	-0.45	-6.11	-0.32	2.84e-9	Neuroticism;
CRC	cis	rs977987	0.836	rs11646044	chr16:75312548	G/T	cg03315344	chr16:75512273	CHST6	0.53	8.81	0.44	7.31e-17	Dupuytren's disease;
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.42	-5.99	-0.31	5.37e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10924970	0.967	rs10754588	chr1:235438205	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.84e-9	Asthma;
CRC	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg10761708	chr20:43804764	PI3	0.5	5.65	0.3	3.49e-8	Blood protein levels;
CRC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	0.99	10.35	0.5	6.39e-22	Diabetic retinopathy;
CRC	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg00601450	chr5:74908170	NA	-0.41	-6.03	-0.32	4.31e-9	Age-related disease endophenotypes;
CRC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.17	0.59	4.28e-32	Breast cancer;
CRC	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-9.36	-0.46	1.27e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.16	0.37	5.47e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.596	rs10270055	chr7:124649406	T/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.27e-9	Cutaneous malignant melanoma;
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.42	6.25	0.33	1.31e-9	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14858152	chr1:109289596	STXBP3	0.42	6.06	0.32	3.75e-9	Response to antipsychotic treatment;
CRC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg15123519	chr2:136567270	LCT	0.33	6.42	0.33	4.79e-10	Mosquito bite size;
CRC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.81	13.38	0.59	6.69e-33	Menopause (age at onset);
CRC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.36	-6.91	-0.36	2.59e-11	Iron status biomarkers;
CRC	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-8.51	-0.42	6.25e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg17321639	chr7:2759063	NA	-0.51	-6.83	-0.35	4.2e-11	Height;
CRC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.56	10.01	0.48	9.4e-21	HDL cholesterol levels;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-8.37	-0.42	1.65e-15	Putamen volume;
CRC	cis	rs7584330	0.504	rs61213635	chr2:238428132	A/G	cg14458575	chr2:238380390	NA	0.44	6.1	0.32	2.96e-9	Prostate cancer;
CRC	cis	rs7804356	0.954	rs3801815	chr7:26881292	T/C	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.1e-8	Type 1 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13917004	chr19:42462874	RABAC1	0.47	6.8	0.35	5.05e-11	Response to antipsychotic treatment;
CRC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.72	-0.35	7.92e-11	HDL cholesterol;
CRC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-7.46	-0.38	7.91e-13	Aortic root size;
CRC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.96	13.38	0.59	6.9e-33	Breast cancer;
CRC	cis	rs2398893	0.960	rs11788176	chr9:96829243	C/T	cg14459158	chr9:96720562	NA	0.49	7.96	0.4	2.81e-14	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.93	-11.84	-0.55	3.62e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.64	-7.05	-0.36	1.09e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.74	-0.3	2.19e-8	Tonsillectomy;
CRC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.7	12.36	0.56	4.27e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs1567420	chr2:162475601	C/T	cg14875682	chr5:52083620	ITGA1;PELO	0.73	5.98	0.31	5.89e-9	Cognitive function;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg25164649	chr6:28176230	NA	-0.4	-5.69	-0.3	2.78e-8	Systemic lupus erythematosus;
CRC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.91	16.63	0.68	1.66e-45	Intelligence (multi-trait analysis);
CRC	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.46	-7.35	-0.38	1.55e-12	Schizophrenia;
CRC	cis	rs6763159	0.566	rs2121794	chr3:59644233	A/G	cg07069742	chr3:59644285	NA	0.48	9.61	0.47	1.99e-19	Conotruncal heart defects;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg25164649	chr6:28176230	NA	0.6	8.01	0.4	1.95e-14	Parkinson's disease;
CRC	cis	rs12144044	0.701	rs2999159	chr1:113230758	A/G	cg22162597	chr1:113214053	CAPZA1	-0.63	-7.56	-0.38	3.97e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7113874	0.569	rs7104646	chr11:8558841	G/T	cg20771178	chr11:8615675	STK33	-0.35	-5.81	-0.3	1.5e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6956675	0.831	rs10268923	chr7:62652624	C/G	cg01314568	chr7:57830625	NA	-0.63	-8.98	-0.44	2.13e-17	Obesity-related traits;
CRC	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	16.19	0.67	8.83e-44	Colorectal cancer;
CRC	cis	rs972578	0.967	rs2038059	chr22:43334398	T/G	cg01576275	chr22:43409880	NA	-0.41	-6.36	-0.33	6.77e-10	Mean platelet volume;
CRC	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg23071808	chr14:103021642	NA	0.63	7.04	0.36	1.14e-11	Platelet count;
CRC	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.37	-0.46	1.23e-18	Prevalent atrial fibrillation;
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.8	15.3	0.64	2.82e-40	Prudent dietary pattern;
CRC	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg18551225	chr6:44695536	NA	-0.41	-5.96	-0.31	6.36e-9	Total body bone mineral density;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10819733	chr22:24237672	NA	0.34	5.8	0.3	1.53e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs243505	0.762	rs1019218	chr7:148488964	C/T	cg09806900	chr7:148480153	CUL1	0.52	7.56	0.38	3.94e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2072510	0.593	rs2247304	chr12:96424665	T/C	cg15438951	chr12:96389694	HAL	-0.5	-6.25	-0.33	1.29e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.77	-0.35	5.77e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.76	11.75	0.54	7.34e-27	Schizophrenia;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg03844506	chr4:4109441	NA	-0.51	-7.53	-0.38	5.02e-13	Blood pressure (smoking interaction);
CRC	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.43	-6.05	-0.32	3.95e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg15786705	chr6:28176104	NA	0.64	9.31	0.46	1.89e-18	Parkinson's disease;
CRC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.56	8.33	0.42	2.26e-15	Resting heart rate;
CRC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.6	-9.5	-0.46	4.46e-19	Aortic root size;
CRC	cis	rs11212617	0.967	rs396552	chr11:108221483	G/C	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.67	0.3	3.21e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-5.84	-0.31	1.25e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.6	10.14	0.49	3.34e-21	Mean corpuscular volume;
CRC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.53	6.7	0.35	8.96e-11	Methadone dose in opioid dependence;
CRC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.6	9.1	0.45	9.16e-18	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24351916	chr3:39452635	SNORA62;RPSA	-0.41	-6.39	-0.33	5.53e-10	Obesity-related traits;
CRC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.44	5.7	0.3	2.66e-8	Platelet distribution width;
CRC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.5	-8.08	-0.41	1.26e-14	Body mass index;
CRC	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg04239558	chr2:103089729	SLC9A4	0.36	6.07	0.32	3.47e-9	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06097357	chr14:35591625	PPP2R3C;KIAA0391	0.44	6.13	0.32	2.47e-9	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.04	-0.36	1.1e-11	Obesity-related traits;
CRC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.38	6.1	0.32	2.93e-9	Testicular germ cell tumor;
CRC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg18876405	chr7:65276391	NA	0.45	6.39	0.33	5.75e-10	Aortic root size;
CRC	cis	rs1971762	0.527	rs9737721	chr12:54074696	A/T	cg06632207	chr12:54070931	ATP5G2	0.44	7.45	0.38	8.3e-13	Height;
CRC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.58	-7.21	-0.37	3.95e-12	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17470637	chr19:8478017	MARCH2	0.38	6.14	0.32	2.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg16358738	chr2:241808595	AGXT	-0.4	-6.25	-0.33	1.24e-9	Urinary metabolites;
CRC	cis	rs7215564	0.908	rs34969384	chr17:78678716	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.26e-9	Myopia (pathological);
CRC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg12064134	chr16:90016061	DEF8	-0.62	-5.62	-0.3	4.11e-8	Skin colour saturation;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.59	-8.96	-0.44	2.54e-17	Bipolar disorder;
CRC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg24881330	chr22:46731750	TRMU	0.57	5.65	0.3	3.51e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.34	-6.4	-0.33	5.45e-10	Colorectal cancer;
CRC	trans	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg26043149	chr18:55253948	FECH	-0.49	-7.42	-0.38	1.02e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.48	-7.62	-0.39	2.73e-13	Schizophrenia;
CRC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-1.12	-17.62	-0.7	2.02e-49	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25508545	chr19:49467065	FTL	0.45	6.85	0.35	3.65e-11	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.48	7.36	0.38	1.5e-12	Corneal astigmatism;
CRC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-10.3	-0.49	9.51e-22	Personality dimensions;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13797228	chr3:126076243	KLF15	0.47	6.68	0.35	9.96e-11	Anxiety disorder;
CRC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.52	-6.81	-0.35	4.78e-11	DNA methylation (variation);
CRC	cis	rs6066835	0.867	rs6090900	chr20:47364120	C/A	cg18078177	chr20:47281410	PREX1	0.62	5.72	0.3	2.35e-8	Multiple myeloma;
CRC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23903597	chr17:61704154	MAP3K3	-0.44	-6.05	-0.32	3.99e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	0.82	7.93	0.4	3.37e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.59	8.71	0.43	1.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	0.67	6.33	0.33	8.04e-10	Fat distribution (HIV);
CRC	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-0.83	-8.17	-0.41	6.61e-15	Post bronchodilator FEV1;
CRC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.38	-5.78	-0.3	1.72e-8	Height;
CRC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.33	-6.16	-0.32	2.12e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.16	-0.41	7.42e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4803480	0.766	rs115449590	chr19:42088883	T/C	cg08478046	chr19:42093086	CEACAM21	-0.31	-6.08	-0.32	3.27e-9	Schizophrenia;
CRC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-5.96	-0.31	6.32e-9	Menarche (age at onset);
CRC	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg12560992	chr17:57184187	TRIM37	-0.52	-6.59	-0.34	1.74e-10	Vitamin D levels;
CRC	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.51	-0.34	2.86e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.73	7.5	0.38	5.96e-13	Plasma clusterin levels;
CRC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	1.26	14.05	0.61	1.96e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.77	-9.94	-0.48	1.53e-20	Pancreatic cancer;
CRC	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg18196295	chr10:418757	DIP2C	-0.57	-7.91	-0.4	3.83e-14	Psychosis in Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7632954	0.596	rs9837823	chr3:8514282	C/G	cg03495237	chr3:8533978	NA	0.34	6.32	0.33	8.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.29	-0.33	1.01e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg11189052	chr15:85197271	WDR73	0.58	8.43	0.42	1.1e-15	Schizophrenia;
CRC	cis	rs863345	0.604	rs1578762	chr1:158497440	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs4929949	0.902	rs61875898	chr11:8627224	C/A	cg17679104	chr11:8615758	STK33	0.35	5.69	0.3	2.82e-8	Body mass index;
CRC	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg21535247	chr6:8435926	SLC35B3	-0.41	-6.0	-0.31	5.22e-9	Motion sickness;
CRC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg25767906	chr1:53392781	SCP2	-0.43	-6.73	-0.35	7.35e-11	Monocyte count;
CRC	cis	rs11585357	0.501	rs72646775	chr1:17592121	T/C	cg08277548	chr1:17600880	PADI3	-0.67	-7.66	-0.39	2.12e-13	Hair shape;
CRC	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg09324608	chr17:30823087	MYO1D	0.33	5.71	0.3	2.52e-8	Schizophrenia;
CRC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.8	-0.55	5.04e-27	Type 2 diabetes;
CRC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.74	0.3	2.13e-8	Protein C levels;
CRC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg05341575	chr12:125625032	AACS	-0.38	-5.88	-0.31	1.01e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.37	-0.33	6.39e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.4	6.29	0.33	1.02e-9	Electroencephalogram traits;
CRC	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg17810781	chr1:201082982	CACNA1S	-0.42	-7.02	-0.36	1.28e-11	Permanent tooth development;
CRC	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg23254163	chr1:152506842	NA	0.44	8.48	0.42	7.52e-16	Hair morphology;
CRC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg06970220	chr1:156163860	SLC25A44	0.48	6.86	0.35	3.39e-11	Testicular germ cell tumor;
CRC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs9491140	0.539	rs10457447	chr6:124698568	A/C	cg05308643	chr6:124982296	NKAIN2	-0.58	-6.94	-0.36	2.06e-11	Neuroticism;
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg10217327	chr6:118973057	C6orf204	0.52	5.89	0.31	9.38e-9	Diastolic blood pressure;
CRC	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg26893134	chr6:116381904	FRK	0.27	6.46	0.34	3.67e-10	Total cholesterol levels;
CRC	cis	rs1971762	0.527	rs1247957	chr12:53961493	G/T	cg06632207	chr12:54070931	ATP5G2	-0.49	-8.35	-0.42	1.95e-15	Height;
CRC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-5.85	-0.31	1.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7781266	0.895	rs17167170	chr7:133302345	A/G	cg03336402	chr7:133662267	EXOC4	0.49	5.98	0.31	5.75e-9	Educational attainment (college completion);
CRC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-8.89	-0.44	3.98e-17	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05075067	chr2:28113413	BRE;RBKS;LOC100302650	0.4	6.45	0.34	4.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-6.45	-0.33	4.05e-10	Subjective well-being;
CRC	cis	rs7605827	0.930	rs12995845	chr2:15520539	C/T	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.08e-9	Educational attainment (years of education);
CRC	cis	rs524281	0.861	rs9736673	chr11:65924024	T/A	cg14036092	chr11:66035641	RAB1B	-0.46	-5.87	-0.31	1.09e-8	Electroencephalogram traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00400334	chr2:85981962	ATOH8	0.46	6.62	0.34	1.48e-10	Response to antipsychotic treatment;
CRC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg01420254	chr6:26195488	NA	0.84	8.64	0.43	2.44e-16	Gout;Renal underexcretion gout;
CRC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.86	10.95	0.52	5.46e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.34	5.63	0.3	3.78e-8	Major depressive disorder;
CRC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs117623576	0.680	rs72777120	chr10:32367608	A/G	cg03047570	chr10:32398778	NA	-0.62	-6.92	-0.36	2.39e-11	Anti-saccade response;
CRC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.39	-5.89	-0.31	9.33e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg05304507	chr6:116381966	FRK	0.3	8.15	0.41	7.84e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.69	9.69	0.47	1.11e-19	Heart rate;
CRC	cis	rs9659323	0.730	rs10923720	chr1:119541879	T/C	cg26570165	chr1:119541833	NA	-0.43	-7.17	-0.37	4.93e-12	Body mass index;
CRC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.57	-11.62	-0.54	2.2e-26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4964805	0.954	rs11111786	chr12:104189057	T/C	cg02344784	chr12:104178138	NT5DC3	0.56	8.51	0.42	6.45e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.55	-6.68	-0.35	1.01e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs10128264	0.934	rs1250589	chr10:80980304	C/G	cg18737081	chr10:80999807	ZMIZ1	-0.37	-6.52	-0.34	2.67e-10	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.53	7.85	0.4	5.9e-14	Testicular germ cell tumor;
CRC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.75	-0.35	6.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.9	-0.31	8.99e-9	Subjective well-being;
CRC	cis	rs12024301	0.557	rs74832909	chr1:183646077	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.73	6.43	0.33	4.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg14711859	chr11:8959438	ASCL3	-0.45	-7.16	-0.37	5.31e-12	Hemoglobin concentration;
CRC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.64	0.47	1.52e-19	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs17532515	0.628	rs1494808	chr4:141483735	A/C	cg09181644	chr4:141490428	UCP1	0.32	5.78	0.3	1.71e-8	Select biomarker traits;
CRC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	7.95	0.4	2.93e-14	Height;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg03623178	chr6:28175578	NA	0.75	5.99	0.31	5.52e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg08501292	chr6:25962987	TRIM38	0.98	9.07	0.45	1.09e-17	Autism spectrum disorder or schizophrenia;
CRC	trans	rs587242	1.000	rs12757248	chr1:96898294	G/A	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg03929089	chr4:120376271	NA	-0.62	-6.65	-0.34	1.19e-10	Axial length;
CRC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg06287003	chr12:125626642	AACS	-0.58	-7.66	-0.39	2.09e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	1.02	18.23	0.71	8.01e-52	Parkinson's disease;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg19678392	chr7:94953810	PON1	-0.57	-7.19	-0.37	4.31e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.53	7.38	0.38	1.33e-12	Triglycerides;
CRC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.23	0.32	1.4e-9	Bladder cancer;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.43	6.24	0.33	1.33e-9	Obesity-related traits;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.95	12.22	0.56	1.43e-28	Triglycerides;
CRC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.49	-6.83	-0.35	4.12e-11	Gut microbiome composition (summer);
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg04871131	chr7:94954202	PON1	-0.46	-5.61	-0.3	4.23e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg25019722	chr6:37503610	NA	-0.5	-9.29	-0.46	2.17e-18	Cognitive performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10668512	chr15:42565522	GANC;TMEM87A	0.47	6.74	0.35	7.14e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.43	-6.21	-0.32	1.61e-9	Aortic root size;
CRC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.48	-0.57	1.53e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg09873164	chr1:152488093	CRCT1	0.35	5.9	0.31	9e-9	Hair morphology;
CRC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	cis	rs1881396	0.947	rs77350364	chr2:27866139	A/G	cg27432699	chr2:27873401	GPN1	0.63	8.08	0.41	1.28e-14	Nonalcoholic fatty liver disease;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.63e-9	Bipolar disorder;
CRC	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.73	9.2	0.45	4.12e-18	Exhaled nitric oxide levels;
CRC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.4	6.17	0.32	2.06e-9	HDL cholesterol levels;
CRC	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg02158880	chr13:53174818	NA	0.42	6.41	0.33	5.11e-10	Lewy body disease;
CRC	cis	rs459193	0.912	rs27984	chr5:55802419	C/T	cg00049729	chr5:55776345	NA	0.39	5.8	0.3	1.58e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07930192	chr7:1003750	NA	0.4	6.15	0.32	2.21e-9	Longevity;Endometriosis;
CRC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.96	0.52	5.09e-24	Motion sickness;
CRC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.77	0.47	5.76e-20	Alzheimer's disease (late onset);
CRC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-0.91	-10.93	-0.52	6.17e-24	Type 2 diabetes nephropathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01497487	chr22:38141814	TRIOBP	0.51	7.37	0.38	1.39e-12	Response to antipsychotic treatment;
CRC	cis	rs4938330	0.552	rs3882895	chr11:117090545	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.06	-0.32	3.66e-9	Blood protein levels;
CRC	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-5.95	-0.31	6.95e-9	Alzheimer's disease (survival time);
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-10.87	-0.51	1.01e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg02927042	chr1:21476669	EIF4G3	-0.53	-8.22	-0.41	4.73e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-5.95	-0.31	6.98e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.47	-6.05	-0.32	3.87e-9	Alopecia areata;
CRC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg03030879	chr14:75389066	RPS6KL1	0.47	7.21	0.37	3.97e-12	Height;
CRC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.41	5.84	0.31	1.22e-8	Tonsillectomy;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.92	15.75	0.66	4.68e-42	Menarche (age at onset);
CRC	trans	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.05e-13	Diabetic kidney disease;
CRC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	8.0	0.4	2.12e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.59	8.37	0.42	1.63e-15	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26464524	chr7:99699573	MCM7;AP4M1	0.36	5.96	0.31	6.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg04497992	chr16:616212	NHLRC4	0.41	6.38	0.33	5.92e-10	Height;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.1	-0.32	2.91e-9	Obesity-related traits;
CRC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.5	-9.23	-0.45	3.38e-18	Longevity;
CRC	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.45	6.06	0.32	3.63e-9	Pulse pressure;
CRC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.58	10.42	0.5	3.71e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.37	-7.59	-0.39	3.24e-13	Arsenic metabolism;
CRC	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.23	0.41	4.48e-15	Mean corpuscular volume;
CRC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.54	6.97	0.36	1.69e-11	Obesity-related traits;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg02092906	chr6:83903419	PGM3;RWDD2A	-0.45	-6.54	-0.34	2.4e-10	Schizophrenia;
CRC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.95	-13.06	-0.58	1.12e-31	Initial pursuit acceleration;
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg03623178	chr6:28175578	NA	0.92	12.95	0.58	2.82e-31	Parkinson's disease;
CRC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg17321639	chr7:2759063	NA	-0.5	-6.43	-0.33	4.53e-10	Height;
CRC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg00310523	chr12:86230176	RASSF9	0.44	7.36	0.38	1.5e-12	Major depressive disorder;
CRC	cis	rs7113874	0.569	rs10769924	chr11:8623193	C/A	cg20771178	chr11:8615675	STK33	0.35	5.76	0.3	1.92e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.5	-6.99	-0.36	1.5e-11	Gut microbiome composition (summer);
CRC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.6	0.47	2.11e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg12458913	chr13:53173898	NA	0.59	9.19	0.45	4.7e-18	Lewy body disease;
CRC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.9e-14	Gut microbiome composition (summer);
CRC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25517755	chr10:38738941	LOC399744	-0.43	-6.25	-0.33	1.27e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg01422129	chr2:677375	TMEM18	-0.74	-6.01	-0.31	4.85e-9	Cognitive function;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.52	9.68	0.47	1.19e-19	Acylcarnitine levels;
CRC	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	1.27	11.19	0.53	7.38e-25	Arsenic metabolism;
CRC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.53	-7.49	-0.38	6.34e-13	Aortic root size;
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.42	-0.33	4.82e-10	Lymphocyte counts;
CRC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.7	-10.78	-0.51	2.1e-23	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15114107	chr1:228328228	GUK1	0.38	6.14	0.32	2.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.53	7.68	0.39	1.82e-13	Corneal astigmatism;
CRC	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.48	0.5	2.24e-22	Corneal astigmatism;
CRC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.55	-0.38	4.25e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.81	17.1	0.69	2.47e-47	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.88	11.79	0.55	5.15e-27	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg16576597	chr16:28551801	NUPR1	0.42	5.72	0.3	2.45e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11637544	chr11:66886765	KDM2A	0.42	6.03	0.32	4.51e-9	Response to antipsychotic treatment;
CRC	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.34	6.14	0.32	2.44e-9	Monocyte count;
CRC	trans	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg11693508	chr17:37793320	STARD3	0.57	7.08	0.36	8.78e-12	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs6741819	1.000	rs10495549	chr2:7142367	C/T	cg27144453	chr2:7172511	RNF144A	-0.42	-6.15	-0.32	2.26e-9	Response to antipsychotic treatment;
CRC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.95	-0.31	6.86e-9	Crohn's disease;
CRC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.64	7.84	0.4	6.18e-14	Obesity (extreme);
CRC	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.34	0.5	6.8e-22	Corneal astigmatism;
CRC	cis	rs13064447	0.845	rs11128610	chr3:12761123	G/T	cg07775309	chr3:12595852	NA	0.36	5.78	0.3	1.74e-8	Major depression and alcohol dependence;
CRC	cis	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg18809830	chr7:99032528	PTCD1	-1.05	-7.42	-0.38	1.01e-12	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-0.65	-11.62	-0.54	2.2e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg21167628	chr1:45308625	PTCH2	-0.38	-6.46	-0.34	3.71e-10	Facial morphology (factor 20);
CRC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.51	-8.2	-0.41	5.32e-15	Body mass index;
CRC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.88	15.75	0.66	4.75e-42	Coronary artery disease;
CRC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.54	0.38	4.61e-13	Neuroticism;
CRC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.24	0.45	3.2e-18	Cognitive test performance;
CRC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-7.34	-0.38	1.71e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.84	-0.31	1.27e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.32e-9	Prudent dietary pattern;
CRC	cis	rs4731207	0.562	rs6975534	chr7:124686461	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.54e-9	Cutaneous malignant melanoma;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg03623178	chr6:28175578	NA	0.88	13.28	0.59	1.66e-32	Parkinson's disease;
CRC	cis	rs3015497	0.653	rs2356456	chr14:51093216	A/T	cg09863266	chr14:51125203	SAV1	-0.29	-5.63	-0.3	3.9e-8	Mean platelet volume;
CRC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.56	-8.11	-0.41	1.01e-14	IgG glycosylation;
CRC	cis	rs12484776	0.786	rs6001794	chr22:40529415	A/C	cg21771250	chr22:40406049	FAM83F	-0.32	-5.83	-0.31	1.35e-8	Uterine fibroids;
CRC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.86	-12.81	-0.58	9.07e-31	Platelet distribution width;
CRC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.72	-6.67	-0.35	1.09e-10	Lung cancer in ever smokers;
CRC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg15193198	chr20:60906057	LAMA5	-0.42	-6.37	-0.33	6.49e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs9323205	0.765	rs2999387	chr14:51652986	C/G	cg23942311	chr14:51606299	NA	-0.63	-9.94	-0.48	1.55e-20	Cancer;
CRC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.75	-0.3	2.07e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg24848437	chr7:2645542	IQCE	0.55	5.88	0.31	1.01e-8	Urate levels in lean individuals;
CRC	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg19875535	chr5:140030758	IK	-0.58	-9.51	-0.46	4.12e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.64	-7.9	-0.4	4.09e-14	Gut microbiome composition (summer);
CRC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.71	9.45	0.46	6.4e-19	Bronchopulmonary dysplasia;
CRC	cis	rs970548	0.954	rs11239536	chr10:45978598	T/A	cg15590007	chr10:45870220	ALOX5	0.47	5.92	0.31	8.09e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	trans	rs7976838	0.614	rs12578499	chr12:60257018	G/A	cg16974014	chr22:22007515	MIR130B	0.51	6.06	0.32	3.67e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs4494114	1.000	rs4491033	chr1:39352083	A/C	cg25970120	chr1:39325951	RRAGC	-0.45	-6.28	-0.33	1.08e-9	Blood protein levels;
CRC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.62	9.66	0.47	1.37e-19	Corneal astigmatism;
CRC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-10.94	-0.52	5.91e-24	Platelet distribution width;
CRC	cis	rs2227564	0.794	rs2688607	chr10:75663736	C/T	cg00564723	chr10:75632066	CAMK2G	0.3	7.01	0.36	1.35e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg23161317	chr6:28129485	ZNF389	0.43	5.71	0.3	2.46e-8	Parkinson's disease;
CRC	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg13456138	chr10:90753195	FAS	0.4	5.64	0.3	3.71e-8	Chronic lymphocytic leukemia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21676273	chr3:45635931	LIMD1	0.42	6.0	0.31	5.24e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16143176	chr8:61591199	CHD7	0.37	6.29	0.33	1e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-6.34	-0.33	7.41e-10	Plateletcrit;
CRC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg20243544	chr17:37824526	PNMT	0.44	6.82	0.35	4.33e-11	Self-reported allergy;
CRC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.67	-11.39	-0.53	1.41e-25	Dental caries;
CRC	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-7.29	-0.37	2.3e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg25356066	chr3:128598488	ACAD9	0.39	5.66	0.3	3.22e-8	IgG glycosylation;
CRC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg03037974	chr15:76606532	NA	0.55	8.73	0.43	1.3e-16	Blood metabolite levels;
CRC	cis	rs294883	0.858	rs9364509	chr6:159703212	G/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.72	-0.43	1.38e-16	Aortic root size;
CRC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.79	0.39	8.87e-14	Lymphocyte percentage of white cells;
CRC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg23758597	chr6:163146217	PARK2	-0.66	-6.79	-0.35	5.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.55	6.09	0.32	3.23e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	13.84	0.61	1.21e-34	Platelet count;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Depression;
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.56	-10.14	-0.49	3.23e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-12.77	-0.58	1.37e-30	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.3	-0.37	2.13e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.38	6.17	0.32	1.98e-9	Height;
CRC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.58	9.04	0.45	1.38e-17	Blood metabolite levels;
CRC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg19812747	chr11:111475976	SIK2	0.44	6.33	0.33	7.9e-10	Primary sclerosing cholangitis;
CRC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.34e-40	Prostate cancer;
CRC	cis	rs243505	1.000	rs243510	chr7:148432534	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-6.05	-0.32	3.92e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.67	-10.24	-0.49	1.54e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7638909	0.901	rs9845438	chr3:38600456	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.66	-0.3	3.26e-8	Electrocardiographic conduction measures;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25653011	chr17:38296442	CASC3	0.43	6.38	0.33	6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg00677455	chr12:58241039	CTDSP2	-0.43	-6.17	-0.32	2.02e-9	Multiple sclerosis;
CRC	cis	rs7539542	0.556	rs2275734	chr1:202887295	C/T	cg19681188	chr1:202830198	LOC148709	0.43	6.35	0.33	6.97e-10	Mean platelet volume;
CRC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg02993699	chr4:3415135	RGS12	-0.38	-6.21	-0.32	1.59e-9	Serum sulfate level;
CRC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.16	0.37	5.25e-12	Rheumatoid arthritis;
CRC	trans	rs11635191	0.636	rs4887125	chr15:74559478	C/G	cg06477056	chr5:175110609	HRH2	0.34	6.2	0.32	1.68e-9	Diisocyanate-induced asthma;
CRC	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.49	-0.34	3.14e-10	Obesity-related traits;
CRC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg16892393	chr17:41919603	NA	-0.4	-5.72	-0.3	2.42e-8	Triglycerides;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.82	14.42	0.62	7.03e-37	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg10217327	chr6:118973057	C6orf204	0.51	5.87	0.31	1.04e-8	Diastolic blood pressure;
CRC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.51	7.34	0.38	1.71e-12	Colorectal cancer;
CRC	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.66	-9.82	-0.48	4.02e-20	Acne (severe);
CRC	trans	rs800082	0.501	rs9878902	chr3:144220319	A/T	cg24215973	chr2:240111563	HDAC4	0.49	7.51	0.38	5.45e-13	Smoking behavior;
CRC	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg14825688	chr5:132208181	LEAP2	0.4	6.62	0.34	1.48e-10	Apolipoprotein A-IV levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05692643	chr21:43223990	PRDM15	-0.39	-6.14	-0.32	2.35e-9	HDL cholesterol;
CRC	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg15234197	chr11:68924956	NA	0.44	6.1	0.32	2.9e-9	Blond vs. brown hair color;
CRC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.53	0.5	1.51e-22	Skin colour saturation;
CRC	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.96	0.4	2.79e-14	Coffee consumption (cups per day);
CRC	cis	rs501120	0.584	rs58129751	chr10:44706720	G/A	cg09554077	chr10:44749378	NA	0.67	7.44	0.38	8.88e-13	Coronary artery disease;Coronary heart disease;
CRC	trans	rs2413583	0.591	rs79605405	chr22:39696638	C/A	cg09612413	chr10:12085555	UPF2	-0.56	-6.21	-0.32	1.58e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-0.66	-9.8	-0.48	4.69e-20	Acne (severe);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16109953	chr14:24701739	GMPR2;NEDD8	0.45	6.36	0.33	6.61e-10	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.76	0.35	6.37e-11	Lymphocyte counts;
CRC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.5	-6.61	-0.34	1.56e-10	Gut microbiome composition (summer);
CRC	cis	rs7932354	0.528	rs11039112	chr11:47174296	C/T	cg19486271	chr11:47235900	DDB2	0.45	6.66	0.34	1.13e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.84	0.35	3.84e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.08	0.32	3.26e-9	Rheumatoid arthritis;
CRC	trans	rs4714291	0.832	rs761798	chr6:40087514	C/T	cg02267698	chr19:7991119	CTXN1	0.49	6.63	0.34	1.41e-10	Strep throat;
CRC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.7	-10.45	-0.5	2.96e-22	Corneal astigmatism;
CRC	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.63e-9	Arsenic metabolism;
CRC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	7.3	0.37	2.23e-12	Parkinson's disease;
CRC	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	6.53	0.34	2.51e-10	Blood protein levels;
CRC	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.58	8.22	0.41	4.63e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.5	8.19	0.41	5.74e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.73	-12.44	-0.57	2.19e-29	Body mass index;
CRC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.5	-8.74	-0.43	1.25e-16	Height;
CRC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg15445000	chr17:37608096	MED1	0.33	5.67	0.3	3.09e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs9532580	0.778	rs61963319	chr13:41244220	A/T	cg21288729	chr13:41239152	FOXO1	0.5	7.6	0.39	3.04e-13	Mean corpuscular hemoglobin;
CRC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.25	14.86	0.63	1.38e-38	Gout;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.73	0.3	2.23e-8	Parkinson's disease;
CRC	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.97	-0.31	6.02e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10983056	chr13:113344077	ATP11A	0.4	5.96	0.31	6.44e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22538323	chr7:27702700	HIBADH	0.49	6.89	0.36	2.8e-11	Response to antipsychotic treatment;
CRC	trans	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.66	-0.34	1.17e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg11130432	chr3:121712080	ILDR1	-0.49	-5.68	-0.3	3.01e-8	Multiple sclerosis;
CRC	trans	rs75804782	0.935	rs61332075	chr2:239316560	G/C	cg01134436	chr17:81009848	B3GNTL1	0.73	6.56	0.34	2.03e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6909279	0.933	rs9479072	chr6:151890789	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.37	-5.62	-0.3	3.98e-8	Bone mineral density;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02567788	chr10:71992279	PPA1	0.58	6.26	0.33	1.2e-9	Interleukin-4 levels;
CRC	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg17788362	chr6:86352627	SYNCRIP	0.56	7.89	0.4	4.52e-14	Smooth-surface caries;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16956456	chr5:172483378	C5orf41	0.53	7.07	0.36	9.3e-12	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.5	6.79	0.35	5.25e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg08516792	chr17:33866067	SLFN12L	-0.36	-5.96	-0.31	6.52e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.31	0.46	1.86e-18	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg17724175	chr1:150552817	MCL1	0.44	6.71	0.35	8.35e-11	Melanoma;
CRC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.73	-0.35	7.76e-11	Mean corpuscular volume;
CRC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg05110241	chr16:68378359	PRMT7	-0.62	-7.62	-0.39	2.65e-13	Schizophrenia;
CRC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	1.03	16.29	0.67	3.78e-44	Testicular germ cell tumor;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00767560	chr19:19887256	LOC284440	0.47	6.1	0.32	3.04e-9	Thyroid stimulating hormone;
CRC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.35	-9.76	-0.47	6.27e-20	Mean corpuscular volume;
CRC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.4	6.62	0.34	1.43e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs11466653	1.000	rs10029775	chr4:38777875	C/T	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg10298567	chr3:47292165	KIF9	0.38	6.11	0.32	2.74e-9	Colorectal cancer;
CRC	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.89	-0.36	2.92e-11	Depression;
CRC	cis	rs11606709	1	rs11606709	chr11:46730522	A/G	cg19486271	chr11:47235900	DDB2	-0.48	-7.48	-0.38	6.72e-13	Total body bone mineral density;
CRC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06481639	chr22:41940642	POLR3H	0.52	5.63	0.3	3.81e-8	Cannabis dependence symptom count;
CRC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.61	10.3	0.49	9.23e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6976053	0.765	rs12705099	chr7:100518458	C/T	cg10426581	chr7:100472382	SRRT	0.37	5.74	0.3	2.1e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg15654264	chr1:150340011	RPRD2	0.4	5.8	0.3	1.54e-8	Migraine;
CRC	cis	rs909002	0.720	rs4949459	chr1:32142354	G/T	cg13919466	chr1:32135498	COL16A1	-0.33	-6.3	-0.33	9.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg09695851	chr17:3907499	NA	0.48	6.04	0.32	4.12e-9	Type 2 diabetes;
CRC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.53	8.96	0.44	2.45e-17	Mosquito bite size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24859228	chr10:12391835	CAMK1D	0.49	6.36	0.33	6.65e-10	Thyroid stimulating hormone;
CRC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	10.74	0.51	3e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.27e-46	Breast cancer;
CRC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.82	15.47	0.65	5.89e-41	Metabolic syndrome;
CRC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg13126279	chr21:47581558	C21orf56	0.4	6.02	0.31	4.7e-9	Testicular germ cell tumor;
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.57	8.37	0.42	1.65e-15	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.76	-0.43	1.08e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg03623178	chr6:28175578	NA	0.99	14.94	0.64	6.72e-39	Depression;
CRC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21643547	chr1:205240462	TMCC2	-0.35	-5.63	-0.3	3.94e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.55	7.92	0.4	3.76e-14	Homocysteine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22382455	chr15:42787814	SNAP23	0.39	6.26	0.33	1.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.45	-7.13	-0.37	6.27e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.35	-5.82	-0.31	1.4e-8	Gout;Renal underexcretion gout;
CRC	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.8	-0.3	1.6e-8	Tuberculosis;
CRC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.03	0.45	1.51e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.91	-16.26	-0.67	4.89e-44	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg12463550	chr7:65579703	CRCP	0.71	6.53	0.34	2.52e-10	Diabetic kidney disease;
CRC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.44	-7.22	-0.37	3.63e-12	Iron status biomarkers;
CRC	cis	rs11585357	0.501	rs17458002	chr1:17591524	A/G	cg08277548	chr1:17600880	PADI3	-0.63	-7.3	-0.37	2.16e-12	Hair shape;
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg21856205	chr7:94953877	PON1	-0.52	-6.67	-0.35	1.06e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.38	-6.28	-0.33	1.1e-9	Childhood ear infection;
CRC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg17775713	chr3:133465469	TF	0.37	6.78	0.35	5.61e-11	Iron status biomarkers;
CRC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.58	11.19	0.53	7.42e-25	Eye color traits;
CRC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.47	-0.53	7.28e-26	Platelet distribution width;
CRC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg21138405	chr5:131827807	IRF1	-0.35	-6.01	-0.31	5.06e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs939584	1.000	rs13401686	chr2:650519	A/G	cg03610516	chr2:642275	NA	-0.42	-5.84	-0.31	1.24e-8	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18880390	chr1:175162128	KIAA0040	0.46	6.0	0.31	5.28e-9	Thyroid stimulating hormone;
CRC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg06287003	chr12:125626642	AACS	-0.51	-7.05	-0.36	1.05e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg16898833	chr6:26189333	HIST1H4D	0.69	6.42	0.33	4.82e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2303319	0.504	rs16845945	chr2:162480684	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.11	-0.32	2.89e-9	Cognitive function;
CRC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25517755	chr10:38738941	LOC399744	0.45	6.59	0.34	1.77e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7487075	0.820	rs7958774	chr12:46724668	A/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.18	0.32	1.91e-9	Itch intensity from mosquito bite;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.57	-9.37	-0.46	1.21e-18	Paraoxonase activity;
CRC	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg25885038	chr17:56607967	SEPT4	-0.51	-7.72	-0.39	1.44e-13	Vitamin D levels;
CRC	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg07507251	chr3:52567010	NT5DC2	-0.37	-5.62	-0.3	4.09e-8	Body mass index;
CRC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg03623178	chr6:28175578	NA	0.7	5.94	0.31	7.06e-9	Depression;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04246357	chr6:158589294	SERAC1;GTF2H5	-0.41	-6.44	-0.33	4.31e-10	Myopia (pathological);
CRC	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.48	7.82	0.4	7.05e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.65	-12.01	-0.55	8.26e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.32	-0.56	5.95e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2398893	0.924	rs7047684	chr9:96792790	C/T	cg14459158	chr9:96720562	NA	0.39	6.49	0.34	3.18e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg17401720	chr7:158221031	PTPRN2	-0.38	-6.41	-0.33	5.06e-10	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg15382696	chr6:118971807	C6orf204	0.6	7.89	0.4	4.57e-14	Diastolic blood pressure;
CRC	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.28e-36	Hypertriglyceridemia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06434972	chr7:44122219	POLM	0.45	6.33	0.33	7.87e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.17	-0.32	2.05e-9	Aortic root size;
CRC	cis	rs9296736	0.890	rs9637973	chr6:53903152	C/T	cg04374786	chr6:53939321	C6orf142	0.47	7.43	0.38	9.5e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.84	-14.86	-0.63	1.41e-38	Birth weight;
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg16606324	chr3:10149918	C3orf24	0.69	9.58	0.47	2.45e-19	Alzheimer's disease;
CRC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.14	14.82	0.63	2.06e-38	Uric acid levels;
CRC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	11.17	0.52	9.04e-25	Motion sickness;
CRC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.14	-12.55	-0.57	8.83e-30	Diabetic kidney disease;
CRC	trans	rs3213758	0.588	rs78389273	chr16:53563813	G/C	cg18584265	chr19:15219983	SYDE1	0.65	6.47	0.34	3.59e-10	Vitiligo (non-segmental);
CRC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg05501817	chr11:14380813	RRAS2	-0.47	-6.5	-0.34	2.97e-10	Sense of smell;
CRC	cis	rs6504950	0.720	rs9914836	chr17:52997875	C/G	cg26251398	chr17:52985966	TOM1L1	0.4	5.77	0.3	1.87e-8	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25608973	chr2:21022431	C2orf43	0.44	6.32	0.33	8.46e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-6.03	-0.32	4.34e-9	Vitiligo;
CRC	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.42	-11.61	-0.54	2.3e-26	Psoriasis vulgaris;
CRC	cis	rs4731207	0.662	rs6466950	chr7:124453074	G/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg11130432	chr3:121712080	ILDR1	-0.51	-6.06	-0.32	3.75e-9	Multiple sclerosis;
CRC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.53	8.15	0.41	7.69e-15	Colorectal cancer;
CRC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.57	-8.6	-0.43	3.23e-16	Height;
CRC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	1.99e-11	Morning vs. evening chronotype;
CRC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.98	-0.4	2.39e-14	Reticulocyte fraction of red cells;
CRC	trans	rs9630182	0.561	rs10832038	chr11:13472254	G/C	cg13741668	chr9:85679694	NA	0.38	6.19	0.32	1.79e-9	Bone mineral density;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg06314568	chr15:52043507	LYSMD2;TMOD2	-0.45	-6.97	-0.36	1.73e-11	Parkinson's disease;
CRC	cis	rs2070997	0.702	rs2227985	chr9:133755528	A/G	cg01000188	chr9:133769184	QRFP	0.56	5.65	0.3	3.5e-8	Response to amphetamines;
CRC	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.67	-0.3	3.13e-8	Erythrocyte sedimentation rate;
CRC	trans	rs7800418	0.723	rs56156003	chr7:26590737	G/T	cg14387656	chr2:233470847	EFHD1	0.47	6.43	0.33	4.6e-10	Cognitive function;
CRC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.79	-12.49	-0.57	1.48e-29	Cognitive function;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg07404363	chr5:112197029	SRP19	-0.58	-6.36	-0.33	6.92e-10	Lung adenocarcinoma;
CRC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.08	-0.41	1.22e-14	Intelligence (multi-trait analysis);
CRC	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg18200150	chr17:30822561	MYO1D	0.45	8.74	0.43	1.24e-16	Schizophrenia;
CRC	cis	rs7527798	0.592	rs11118359	chr1:207858546	T/C	cg09232269	chr1:207846808	CR1L	-0.45	-7.32	-0.37	1.88e-12	Erythrocyte sedimentation rate;
CRC	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg15571903	chr15:79123663	NA	0.34	6.92	0.36	2.4e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.57	6.97	0.36	1.79e-11	Insulin-like growth factors;
CRC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.64	8.53	0.43	5.5e-16	Gut microbiome composition (summer);
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.58	-10.91	-0.52	7.21e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs1124376	1.000	rs11712709	chr3:20139777	G/C	cg05072819	chr3:20081367	KAT2B	0.54	6.27	0.33	1.15e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.07	-0.32	3.43e-9	Diabetic kidney disease;
CRC	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-7.22	-0.37	3.69e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07931783	chr6:49431133	CENPQ;MUT	-0.4	-6.32	-0.33	8.58e-10	Aortic root size;
CRC	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg20356878	chr3:121714668	ILDR1	0.51	8.03	0.4	1.74e-14	Cognitive performance;
CRC	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg12365402	chr11:9010492	NRIP3	0.46	7.21	0.37	3.79e-12	Hemoglobin concentration;
CRC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.49	7.22	0.37	3.65e-12	Melanoma;
CRC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.45	-7.04	-0.36	1.16e-11	HDL cholesterol;
CRC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg05623727	chr3:50126028	RBM5	0.46	7.69	0.39	1.76e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-7.91	-0.4	3.83e-14	Renal function-related traits (BUN);
CRC	cis	rs6545883	0.525	rs1729662	chr2:61391305	G/A	cg10580144	chr2:61372316	C2orf74	0.28	5.75	0.3	2.07e-8	Tuberculosis;
CRC	trans	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.7	-0.39	1.5700000000000001e-13	HDL cholesterol;
CRC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.35	0.38	1.63e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg10437265	chr15:77819839	NA	0.69	12.51	0.57	1.24e-29	Type 2 diabetes;
CRC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.33	16.72	0.68	7.48e-46	Uric acid levels;
CRC	cis	rs6662572	0.906	rs11582058	chr1:46245423	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-6.02	-0.32	4.61e-9	Blood protein levels;
CRC	cis	rs7793239	0.550	rs10246191	chr7:130029811	G/A	cg03229158	chr7:130009420	NA	0.4	5.65	0.3	3.39e-8	Antipsychotic drug-induced QTc interval change in schizophrenia;
CRC	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.61	-9.38	-0.46	1.15e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.56	8.8	0.44	7.83e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs10411161	0.702	rs7251689	chr19:52389117	A/T	cg22319618	chr22:45562946	NUP50	-0.65	-7.24	-0.37	3.26e-12	Breast cancer;
CRC	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.98	-17.76	-0.7	5.6e-50	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg23234261	chr14:55582407	NA	-0.29	-5.74	-0.3	2.19e-8	Protein biomarker;
CRC	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.62	-7.08	-0.36	8.68e-12	Ulcerative colitis;
CRC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-0.77	-7.99	-0.4	2.25e-14	Coronary artery disease;
CRC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.42	6.09	0.32	3.21e-9	HIV-1 control;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12909559	chr1:100435310	SLC35A3	0.37	6.12	0.32	2.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.4	-7.19	-0.37	4.38e-12	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16326998	chr7:5553266	FBXL18	0.45	7.42	0.38	1.03e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.47	7.13	0.37	6.55e-12	Corneal astigmatism;
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg04155289	chr7:94953770	PON1	-0.6	-7.44	-0.38	8.8e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg11212589	chr17:38028394	ZPBP2	0.37	6.42	0.33	4.74e-10	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18500192	chr3:19189930	KCNH8	0.4	6.64	0.34	1.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg18301423	chr5:131593218	PDLIM4	-0.38	-6.27	-0.33	1.14e-9	Breast cancer;
CRC	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.99	0.44	2.03e-17	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.7	9.41	0.46	8.92e-19	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.83e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2462686	1.000	rs2462686	chr7:45982460	A/G	cg23193639	chr7:45961078	IGFBP3	-0.37	-5.72	-0.3	2.38e-8	Major depressive disorder;
CRC	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg00490450	chr3:139108681	COPB2	-0.43	-6.49	-0.34	3.11e-10	Obesity-related traits;
CRC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg16558177	chr4:4109446	NA	-0.49	-5.99	-0.31	5.37e-9	Blood pressure (smoking interaction);
CRC	cis	rs7113874	0.524	rs9734055	chr11:8577236	C/A	cg17679104	chr11:8615758	STK33	-0.35	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.3	0.64	2.69e-40	Bipolar disorder;
CRC	cis	rs79387448	0.745	rs57942521	chr2:103139849	A/G	cg09003973	chr2:102972529	NA	0.73	7.79	0.39	8.69e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg08501292	chr6:25962987	TRIM38	0.61	6.75	0.35	6.68e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16262614	chr3:133464971	TF	0.32	5.78	0.3	1.76e-8	Iron status biomarkers;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg27615366	chr5:131592974	PDLIM4	0.33	5.81	0.31	1.48e-8	Breast cancer;
CRC	cis	rs6546324	0.514	rs2861639	chr2:67779919	G/C	cg15745817	chr2:67799979	NA	-0.5	-8.12	-0.41	9.7e-15	Endometriosis;
CRC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.1e-8	Bladder cancer;
CRC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.29	0.53	3.35e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg19897017	chr7:2163380	MAD1L1	0.39	6.19	0.32	1.78e-9	Schizophrenia;
CRC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg03623178	chr6:28175578	NA	0.77	6.63	0.34	1.42e-10	Breast cancer;
CRC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-12.42	-0.57	2.6e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09476286	chr2:26101366	ASXL2	0.47	6.45	0.34	4e-10	Anxiety disorder;
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.47	-6.48	-0.34	3.31e-10	Height;
CRC	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.24	6.5	0.34	2.91e-10	Type 2 diabetes;
CRC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.17	10.76	0.51	2.43e-23	Alzheimer's disease (late onset);
CRC	cis	rs860295	0.702	rs11264383	chr1:155545346	C/T	cg02153340	chr1:155202674	NA	-0.58	-6.75	-0.35	6.59e-11	Body mass index;
CRC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.33	0.53	2.47e-25	Bone mineral density;
CRC	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg00691999	chr4:55094011	PDGFRA	0.41	5.82	0.31	1.4e-8	Corneal astigmatism;
CRC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.79	11.6	0.54	2.58e-26	High light scatter reticulocyte count;
CRC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg23920097	chr1:209922102	NA	0.51	5.84	0.31	1.22e-8	Red blood cell count;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg02683197	chr6:28174875	NA	0.68	9.57	0.47	2.73e-19	Cardiac Troponin-T levels;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12172441	chr6:28176163	NA	0.61	7.18	0.37	4.72e-12	Depression;
CRC	cis	rs12745968	0.620	rs6666831	chr1:93222797	C/A	cg17283838	chr1:93427260	FAM69A	-0.47	-6.43	-0.33	4.48e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.32	-6.05	-0.32	3.87e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.81	14.19	0.62	5.71e-36	Breast cancer;
CRC	trans	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg18288967	chr1:45987694	PRDX1	0.68	7.43	0.38	9.51e-13	Obesity-related traits;
CRC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.54	-8.77	-0.44	9.92e-17	Coronary artery disease;
CRC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.49	10.27	0.49	1.19e-21	Alcohol dependence;
CRC	cis	rs3825932	0.961	rs10400881	chr15:79234384	G/C	cg25744700	chr15:79237217	CTSH	0.4	6.09	0.32	3.08e-9	Type 1 diabetes;
CRC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.56	6.35	0.33	7.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.42	6.3	0.33	9.56e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14433847	chr20:34329491	RBM39	0.42	6.28	0.33	1.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.51	9.63	0.47	1.66e-19	Total body bone mineral density;
CRC	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.41	5.82	0.31	1.39e-8	Osteoporosis;
CRC	trans	rs75246769	0.929	rs2030631	chr7:145504942	C/T	cg14916917	chr5:81574294	RPS23	-0.82	-6.09	-0.32	3.24e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.46	0.34	3.7e-10	Cognitive ability;
CRC	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-6.81	-0.35	4.57e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg02023728	chr11:77925099	USP35	-0.37	-6.28	-0.33	1.09e-9	Alzheimer's disease (survival time);
CRC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg12199221	chr5:83017078	HAPLN1	-0.38	-5.85	-0.31	1.2e-8	Prostate cancer;
CRC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.46	0.34	3.87e-10	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02725872	chr8:58115012	NA	-0.52	-7.31	-0.37	2.06e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.7	8.49	0.42	7.45e-16	Phospholipid levels (plasma);
CRC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.56	6.44	0.33	4.14e-10	IgG glycosylation;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg06764565	chr10:75910434	ADK;AP3M1	-0.44	-6.29	-0.33	9.98e-10	HDL cholesterol;
CRC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.68	9.91	0.48	1.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	6.87	0.35	3.16e-11	Mean platelet volume;
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.79	14.22	0.62	4.1e-36	Breast cancer;
CRC	trans	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.68	0.39	1.79e-13	Diabetic kidney disease;
CRC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.38	-6.09	-0.32	3.19e-9	Major depressive disorder;
CRC	cis	rs3996993	0.780	rs2290758	chr6:52662153	G/A	cg20803780	chr6:52668592	GSTA1	-0.39	-7.21	-0.37	3.86e-12	Hemoglobin concentration;
CRC	trans	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg01339444	chr6:118972232	C6orf204	0.53	6.03	0.32	4.29e-9	Diastolic blood pressure;
CRC	trans	rs2303319	0.504	rs57464189	chr2:162419312	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Cognitive function;
CRC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.87	-13.31	-0.59	1.27e-32	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17287814	chr8:26149013	PPP2R2A	0.44	6.41	0.33	5.17e-10	Response to antipsychotic treatment;
CRC	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	7.88	0.4	4.82e-14	Motion sickness;
CRC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.77e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12760731	0.720	rs10753178	chr1:178401000	A/T	cg00404053	chr1:178313656	RASAL2	0.87	10.32	0.49	7.87e-22	Obesity-related traits;
CRC	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.58	7.18	0.37	4.54e-12	Coronary artery disease;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg03623178	chr6:28175578	NA	0.88	12.63	0.57	4.53e-30	Parkinson's disease;
CRC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.33	-0.42	2.24e-15	Personality dimensions;
CRC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg10298567	chr3:47292165	KIF9	0.38	6.06	0.32	3.71e-9	Colorectal cancer;
CRC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.71	10.91	0.52	7.13e-24	Tonsillectomy;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.7	10.75	0.51	2.57e-23	Longevity;Endometriosis;
CRC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg23506944	chr17:28257236	EFCAB5;SSH2	0.62	6.99	0.36	1.49e-11	Body mass index;
CRC	cis	rs727479	0.502	rs4775932	chr15:51498539	A/G	cg19946085	chr15:51559439	CYP19A1	-0.29	-5.86	-0.31	1.15e-8	Estradiol levels;
CRC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.68	10.44	0.5	3.19e-22	Diastolic blood pressure;
CRC	cis	rs7259376	0.645	rs7245650	chr19:22483695	A/G	cg02657401	chr19:22469223	NA	-0.3	-6.88	-0.35	3.09e-11	Menopause (age at onset);
CRC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.52	6.31	0.33	8.81e-10	Neutrophil percentage of white cells;
CRC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg23018236	chr17:30244563	NA	-0.58	-7.79	-0.39	9.07e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.39	-6.6	-0.34	1.65e-10	Longevity;Endometriosis;
CRC	cis	rs9908102	0.740	rs8078394	chr17:12910602	C/T	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg20444381	chr8:109456000	TTC35	0.61	6.64	0.34	1.3100000000000001e-10	Body mass index;
CRC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.69	-8.6	-0.43	3.24e-16	Coronary artery disease;
CRC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg16576597	chr16:28551801	NUPR1	0.48	6.89	0.35	2.93e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15356674	chr10:79471309	NA	0.42	6.2	0.32	1.69e-9	Response to antipsychotic treatment;
CRC	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg25547332	chr5:131281432	NA	0.37	5.8	0.3	1.53e-8	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25259117	chr17:49337500	MBTD1;UTP18	0.39	6.21	0.32	1.58e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg18187862	chr3:45730750	SACM1L	-0.51	-6.93	-0.36	2.18e-11	Primary sclerosing cholangitis;
CRC	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.4	-6.2	-0.32	1.69e-9	IFN-related cytopenia;
CRC	cis	rs317865	0.737	rs55949632	chr4:16207072	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.64	5.77	0.3	1.88e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-7.24	-0.37	3.22e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07513332	chr6:167530253	CCR6	0.39	6.89	0.35	2.92e-11	Primary biliary cholangitis;
CRC	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-7.01	-0.36	1.33e-11	Blood pressure (smoking interaction);
CRC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.18	0.32	1.85e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-6.57	-0.34	2e-10	Menarche (age at onset);
CRC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg02659138	chr7:134003124	SLC35B4	0.36	6.24	0.33	1.33e-9	Mean platelet volume;
CRC	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg01426195	chr3:39028469	NA	-0.37	-6.23	-0.32	1.42e-9	Handedness;
CRC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.32	0.53	2.6e-25	Intelligence (multi-trait analysis);
CRC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg08896387	chr1:24191740	FUCA1	0.52	6.93	0.36	2.17e-11	Immature fraction of reticulocytes;
CRC	cis	rs1223397	1.000	rs1223402	chr6:13271640	G/A	cg07912922	chr6:13274314	PHACTR1	0.5	6.12	0.32	2.68e-9	Blood pressure;
CRC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg03013999	chr17:37608204	MED1	-0.43	-5.78	-0.3	1.71e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.12	10.91	0.52	7.06e-24	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	8.52	0.43	5.79e-16	Schizophrenia;
CRC	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.39	5.79	0.3	1.65e-8	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg00063174	chr2:228736253	WDR69	-0.51	-6.86	-0.35	3.49e-11	Blood pressure;
CRC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-7.22	-0.37	3.54e-12	Neutrophil percentage of white cells;
CRC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.41	-5.64	-0.3	3.64e-8	Cognitive function;
CRC	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg00469287	chr7:23338798	C7orf30	0.48	6.1	0.32	2.98e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.86	14.87	0.63	1.27e-38	Intelligence (multi-trait analysis);
CRC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.45	-6.77	-0.35	6e-11	Cerebrospinal P-tau181p levels;
CRC	trans	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg14711859	chr11:8959438	ASCL3	-0.5	-7.97	-0.4	2.58e-14	Hemoglobin concentration;
CRC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.21	-0.32	1.57e-9	Heart rate;
CRC	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg25019722	chr6:37503610	NA	0.46	8.34	0.42	2.09e-15	Cognitive performance;
CRC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.56	-6.13	-0.32	2.56e-9	White matter hyperintensity burden;
CRC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.5	8.13	0.41	8.85e-15	Height;
CRC	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg23254163	chr1:152506842	NA	0.45	9.15	0.45	6.31e-18	Hair morphology;
CRC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.31	0.37	2.08e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg24562669	chr7:97807699	LMTK2	-0.42	-7.32	-0.37	1.9e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.91	12.29	0.56	8.03e-29	Migraine;
CRC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg11189052	chr15:85197271	WDR73	0.64	9.04	0.45	1.39e-17	Schizophrenia;
CRC	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.46	6.74	0.35	7.28e-11	Primary sclerosing cholangitis;
CRC	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.45	-0.38	8.41e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.15	0.32	2.28e-9	Diabetic kidney disease;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.48	-6.59	-0.34	1.72e-10	Longevity;Endometriosis;
CRC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.63	-9.18	-0.45	4.94e-18	Menarche (age at onset);
CRC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg19041857	chr6:27730383	NA	-0.76	-7.08	-0.36	8.75e-12	Depression;
CRC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg17788362	chr6:86352627	SYNCRIP	0.54	7.53	0.38	5.06e-13	Smooth-surface caries;
CRC	cis	rs6961069	0.777	rs2366855	chr7:80253455	A/T	cg04458919	chr7:80252533	CD36	-0.33	-5.82	-0.31	1.37e-8	Platelet count;
CRC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07395648	chr5:131743802	NA	-0.4	-5.96	-0.31	6.33e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.47	0.69	8.01e-49	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05307908	chr4:37687729	RELL1	0.43	6.0	0.31	5.16e-9	Response to antipsychotic treatment;
CRC	trans	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg17903999	chr18:56338584	MALT1	-0.43	-7.18	-0.37	4.65e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.6	-8.72	-0.43	1.42e-16	Menarche (age at onset);
CRC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg06363034	chr20:62225388	GMEB2	-0.44	-6.56	-0.34	2.15e-10	Glioblastoma;
CRC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg03013999	chr17:37608204	MED1	0.48	7.57	0.39	3.75e-13	Glomerular filtration rate (creatinine);
CRC	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.45	-0.34	4.03e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.57	5.67	0.3	3.21e-8	Plasma clusterin levels;
CRC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.33	0.53	2.35e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs12580194	1.000	rs12582022	chr12:55694360	A/G	cg19537932	chr12:55886519	OR6C68	-0.53	-6.69	-0.35	9.76e-11	Cancer;
CRC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg19622623	chr12:86230825	RASSF9	0.38	5.81	0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.72	11.08	0.52	1.91e-24	Corneal astigmatism;
CRC	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg02811702	chr13:24901961	NA	0.41	5.74	0.3	2.13e-8	Obesity-related traits;
CRC	cis	rs6908034	0.505	rs77880623	chr6:19819454	T/C	cg02682789	chr6:19804855	NA	0.83	6.67	0.35	1.08e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	1.04	10.12	0.49	3.79e-21	Lymphocyte counts;
CRC	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg13919466	chr1:32135498	COL16A1	0.31	5.88	0.31	1e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-11.68	-0.54	1.29e-26	Colorectal cancer;
CRC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02018176	chr4:1364513	KIAA1530	-0.49	-8.32	-0.42	2.42e-15	Obesity-related traits;
CRC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8105895	0.935	rs1560717	chr19:22292247	A/G	cg02912127	chr19:22235281	ZNF257	-0.43	-5.86	-0.31	1.15e-8	Body mass index (change over time);
CRC	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.63	10.99	0.52	3.71e-24	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg00601450	chr5:74908170	NA	0.42	5.81	0.31	1.46e-8	Age-related disease endophenotypes;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg04497992	chr16:616212	NHLRC4	0.4	6.54	0.34	2.29e-10	Height;
CRC	cis	rs2882667	0.690	rs288022	chr5:138224275	A/C	cg09476006	chr5:138032270	NA	0.57	10.13	0.49	3.47e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.57	-9.38	-0.46	1.09e-18	Neuroticism;
CRC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.62	-8.8	-0.44	8.02e-17	Carotid intima media thickness;
CRC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.09	-0.32	3.16e-9	Bipolar disorder;
CRC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg00343986	chr7:65444356	GUSB	-0.44	-6.3	-0.33	9.42e-10	Aortic root size;
CRC	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.43	6.37	0.33	6.42e-10	Neutrophil percentage of white cells;
CRC	cis	rs11212617	0.875	rs10789659	chr11:108255828	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.37	0.33	6.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.4	-0.33	5.39e-10	Multiple sclerosis;
CRC	cis	rs6496667	0.817	rs74528922	chr15:90921009	T/C	cg04176472	chr15:90893244	GABARAPL3	0.6	7.88	0.4	4.77e-14	Rheumatoid arthritis;
CRC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.68	11.28	0.53	3.51e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg23254163	chr1:152506842	NA	-0.5	-10.05	-0.48	6.73e-21	Hair morphology;
CRC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg17298326	chr8:142245477	NA	-0.38	-5.7	-0.3	2.63e-8	Immature fraction of reticulocytes;
CRC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.66	9.34	0.46	1.55e-18	Multiple sclerosis;
CRC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.51	0.46	4.07e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14895029	chr7:2775587	GNA12	-0.39	-5.97	-0.31	6.27e-9	Height;
CRC	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.49	-9.2	-0.45	4.28e-18	Educational attainment (years of education);
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg23590916	chr17:43697445	MGC57346	0.7	7.16	0.37	5.21e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.25	0.33	1.29e-9	Morning vs. evening chronotype;
CRC	cis	rs12913538	0.552	rs8037466	chr15:62910862	C/T	cg09983546	chr15:62884068	NA	-0.48	-7.5	-0.38	6.17e-13	Sleep depth;
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-6.93	-0.36	2.23e-11	Renal function-related traits (BUN);
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.55	9.3	0.46	2.01e-18	Age of smoking initiation;
CRC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.86	11.72	0.54	9.64e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg20885578	chr2:198174922	NA	-0.36	-6.44	-0.33	4.3e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg02869306	chr7:64672164	INTS4L1	-0.36	-5.92	-0.31	8.28e-9	Aortic root size;
CRC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.67	9.94	0.48	1.6e-20	Corneal astigmatism;
CRC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4664293	0.669	rs357021	chr2:160489083	G/C	cg08347373	chr2:160653686	CD302	-0.39	-6.74	-0.35	7.15e-11	Monocyte percentage of white cells;
CRC	trans	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.42	-0.38	9.82e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.85	16.04	0.66	3.66e-43	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg06470822	chr6:28175283	NA	0.64	9.21	0.45	3.97e-18	Parkinson's disease;
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg18301423	chr5:131593218	PDLIM4	0.3	5.64	0.3	3.66e-8	Blood metabolite levels;
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.82	-12.6	-0.57	5.62e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg24304309	chr1:154577895	ADAR	0.36	6.0	0.31	5.3e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.51	8.81	0.44	7.27e-17	Aortic root size;
CRC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.46	-6.08	-0.32	3.29e-9	Red cell distribution width;
CRC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.8	13.43	0.59	4.46e-33	Menopause (age at onset);
CRC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg10978503	chr1:24200527	CNR2	-0.5	-8.86	-0.44	5.28e-17	Immature fraction of reticulocytes;
CRC	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.02	12.56	0.57	8.29e-30	Uric acid levels;
CRC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg06145435	chr7:1022769	CYP2W1	0.35	5.78	0.3	1.78e-8	Bronchopulmonary dysplasia;
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.23	-0.45	3.45e-18	Electroencephalogram traits;
CRC	cis	rs427941	0.703	rs201449	chr7:101739054	A/G	cg06246474	chr7:101738831	CUX1	0.44	6.88	0.35	3.02e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.17	-0.32	1.99e-9	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08247611	chr16:71928811	KIAA0174	0.53	6.83	0.35	4.11e-11	Thyroid stimulating hormone;
CRC	trans	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg21153622	chr11:89784906	NA	-0.49	-7.73	-0.39	1.31e-13	HDL cholesterol;
CRC	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg20742385	chr13:113633654	MCF2L	0.55	9.32	0.46	1.7e-18	Systolic blood pressure;
CRC	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg07299736	chr8:135490787	ZFAT	-0.37	-6.31	-0.33	8.98e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.74e-9	Depression;
CRC	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.78	12.79	0.58	1.07e-30	Colorectal cancer;
CRC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.55	0.63	2.29e-37	Mean platelet volume;
CRC	cis	rs13144136	0.687	rs13143538	chr4:10656897	T/C	cg10242279	chr4:10666415	CLNK	-0.37	-6.38	-0.33	6.04e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.21	0.32	1.63e-9	Aortic root size;
CRC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.98	14.73	0.63	4.43e-38	Diastolic blood pressure;
CRC	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg15192750	chr16:69999425	NA	0.6	7.74	0.39	1.24e-13	IgE levels;
CRC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.1	-0.49	4.38e-21	Primary sclerosing cholangitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21611187	chr4:38321009	NA	0.39	6.11	0.32	2.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.57	-9.21	-0.45	3.98e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg01657329	chr11:68192670	LRP5	-0.45	-6.32	-0.33	8.46e-10	Total body bone mineral density;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.79	-0.44	8.68e-17	Bipolar disorder;
CRC	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.56	6.58	0.34	1.87e-10	Lymphocyte counts;
CRC	cis	rs12900413	0.687	rs12911196	chr15:90310734	G/C	cg24249390	chr15:90295951	MESP1	-0.59	-9.32	-0.46	1.75e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.81	-0.3	1.51e-8	Blood protein levels;
CRC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00166722	chr3:10149974	C3orf24	0.42	6.26	0.33	1.22e-9	Alzheimer's disease;
CRC	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.07	-14.34	-0.62	1.5e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.96	-0.36	1.87e-11	Schizophrenia;
CRC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg03160526	chr17:80928410	B3GNTL1	0.58	7.61	0.39	3.01e-13	Glycated hemoglobin levels;
CRC	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg11887960	chr12:57824829	NA	0.66	7.1	0.36	7.76e-12	Obesity-related traits;
CRC	cis	rs698833	0.892	rs1067363	chr2:44658401	G/T	cg04920474	chr2:44395004	PPM1B	0.39	5.75	0.3	2.05e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.68	7.81	0.4	7.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12999616	0.817	rs35530168	chr2:98328477	C/G	cg26665480	chr2:98280029	ACTR1B	0.52	6.43	0.33	4.6e-10	Colorectal cancer;
CRC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-6.99	-0.36	1.51e-11	Response to antipsychotic treatment;
CRC	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.51	-7.79	-0.39	8.79e-14	Diastolic blood pressure;
CRC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.3	-0.37	2.14e-12	Personality dimensions;
CRC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	9.23e-17	Morning vs. evening chronotype;
CRC	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.49	-7.72	-0.39	1.44e-13	Coronary artery disease;
CRC	cis	rs12760731	0.720	rs10913542	chr1:178348568	A/G	cg00404053	chr1:178313656	RASAL2	0.71	9.0	0.44	1.79e-17	Obesity-related traits;
CRC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg05941027	chr17:61774174	LIMD2	0.37	6.56	0.34	2.11e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4601821	0.895	rs2282511	chr11:113244177	A/C	cg14159747	chr11:113255604	NA	0.49	8.92	0.44	3.41e-17	Alcoholic chronic pancreatitis;
CRC	cis	rs12431939	1.000	rs55851845	chr14:51645583	A/T	cg23942311	chr14:51606299	NA	-0.54	-6.1	-0.32	3.02e-9	Cancer;
CRC	cis	rs9908102	0.740	rs7216235	chr17:12900383	C/T	cg26162695	chr17:12921313	ELAC2	-0.43	-5.8	-0.3	1.55e-8	Schizophrenia;
CRC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.45	-6.0	-0.31	5.12e-9	Cognitive ability;
CRC	cis	rs7707921	0.767	rs226202	chr5:81571669	C/T	cg07807695	chr5:81608485	ATP6AP1L	-0.49	-7.79	-0.39	8.67e-14	Breast cancer;
CRC	cis	rs2992756	0.663	rs3007733	chr1:18800911	C/T	cg14356550	chr1:18808102	KLHDC7A	-0.41	-5.83	-0.31	1.3e-8	Breast cancer;
CRC	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	0.74	6.78	0.35	5.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10764405	chr11:67888285	CHKA	0.41	6.21	0.32	1.56e-9	Interleukin-6 levels;
CRC	cis	rs12476592	0.602	rs262483	chr2:63877246	G/C	cg10828910	chr2:63850056	LOC388955	0.49	6.15	0.32	2.31e-9	Childhood ear infection;
CRC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg02527881	chr3:46936655	PTH1R	-0.37	-6.94	-0.36	2.05e-11	Colorectal cancer;
CRC	cis	rs7129556	0.954	rs10899387	chr11:77276188	C/T	cg12586386	chr11:77299805	AQP11	0.41	5.74	0.3	2.19e-8	Weight loss (gastric bypass surgery);
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07685180	chr8:600429	NA	0.74	7.12	0.37	6.78e-12	IgG glycosylation;
CRC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.24	-0.33	1.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg14593290	chr7:50529359	DDC	0.63	8.33	0.42	2.24e-15	Malaria;
CRC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.08	-0.45	1.05e-17	Chronic sinus infection;
CRC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg03934865	chr2:198174659	NA	-0.45	-8.05	-0.41	1.54e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.15	0.41	7.56e-15	Arsenic metabolism;
CRC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg18301423	chr5:131593218	PDLIM4	-0.36	-6.18	-0.32	1.91e-9	Breast cancer;
CRC	cis	rs2735413	0.875	rs8045975	chr16:78090187	C/G	cg04733911	chr16:78082701	NA	0.43	7.1	0.36	7.71e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs2303319	0.504	rs2175142	chr2:162450124	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.72	-5.97	-0.31	6.06e-9	Cognitive function;
CRC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.73	7.37	0.38	1.39e-12	Type 2 diabetes;
CRC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.49	-6.77	-0.35	5.96e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.92	-0.31	8.14e-9	Calcium levels;
CRC	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg12856521	chr11:46389249	DGKZ	0.73	10.56	0.5	1.21e-22	Crohn's disease;
CRC	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.53	0.47	3.47e-19	Coffee consumption (cups per day);
CRC	cis	rs1223397	0.651	rs3001966	chr6:13312684	C/T	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-8.17	-0.41	6.63e-15	Type 2 diabetes;
CRC	cis	rs12692738	0.526	rs355870	chr2:165631433	C/T	cg03182029	chr2:165697222	COBLL1	0.5	5.87	0.31	1.09e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.54	-8.86	-0.44	5.29e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-17.08	-0.69	2.88e-47	Height;
CRC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.48	6.58	0.34	1.86e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg04545296	chr12:48745243	ZNF641	0.33	5.68	0.3	2.94e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg16989719	chr2:238392110	NA	-0.46	-8.56	-0.43	4.27e-16	Prostate cancer;
CRC	cis	rs6496667	0.865	rs62019275	chr15:90874834	C/T	cg04176472	chr15:90893244	GABARAPL3	0.67	7.76	0.39	1.09e-13	Rheumatoid arthritis;
CRC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.44	6.11	0.32	2.85e-9	Aortic root size;
CRC	cis	rs9903692	0.954	rs1010228	chr17:46200348	A/C	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	3.09e-14	Pulse pressure;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22947959	chr10:75670903	PLAU;C10orf55	0.43	6.02	0.31	4.73e-9	Anxiety disorder;
CRC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.83	12.55	0.57	8.97e-30	Cognitive ability;
CRC	cis	rs11212617	0.875	rs10789659	chr11:108255828	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.41	5.96	0.31	6.59e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.42	-0.59	4.71e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.39	6.25	0.33	1.24e-9	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.75	-10.09	-0.49	4.8e-21	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.83	17.41	0.69	1.4e-48	Cancer;
CRC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.77	9.79	0.48	4.92e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg10820045	chr2:198174542	NA	-0.53	-9.12	-0.45	7.78e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.69	10.4	0.5	4.2e-22	Lymphocyte counts;
CRC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg23136738	chr11:925521	AP2A2	-0.5	-7.92	-0.4	3.57e-14	Alzheimer's disease (late onset);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06559547	chr6:86387318	SNHG5;SNORD50B;SNORD50A	-0.43	-6.89	-0.36	2.88e-11	Aortic root size;
CRC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg02659138	chr7:134003124	SLC35B4	0.35	6.12	0.32	2.7e-9	Mean platelet volume;
CRC	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.88	-15.14	-0.64	1.2e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.62	-10.25	-0.49	1.38e-21	Colorectal cancer;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg25164649	chr6:28176230	NA	0.78	9.81	0.48	4.4e-20	Depression;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.48	6.9	0.36	2.76e-11	Intelligence (multi-trait analysis);
CRC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg10820045	chr2:198174542	NA	-0.52	-8.79	-0.44	8.27e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.52	-7.18	-0.37	4.73e-12	Corneal structure;
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	7.29	0.37	2.34e-12	Electroencephalogram traits;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg12172441	chr6:28176163	NA	0.54	7.35	0.38	1.62e-12	Cardiac Troponin-T levels;
CRC	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.6	-8.71	-0.43	1.52e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.87	14.74	0.63	4.22e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg02135003	chr7:105160482	PUS7	-0.9	-12.16	-0.56	2.37e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs3751196	0.908	rs7295408	chr12:104212599	T/C	cg02344784	chr12:104178138	NT5DC3	0.69	8.05	0.41	1.53e-14	Sense of smell;
CRC	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.32	0.49	7.82e-22	Corneal astigmatism;
CRC	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.47	-9.44	-0.46	7.04e-19	Schizophrenia;
CRC	cis	rs989128	0.642	rs8077316	chr17:48626389	C/T	cg24438145	chr17:48624694	SPATA20	0.52	7.41	0.38	1.04e-12	Type 2 diabetes;
CRC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	8.04	0.41	1.61e-14	Height;
CRC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.53	6.68	0.35	1.04e-10	Methadone dose in opioid dependence;
CRC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.36	7.57	0.38	3.89e-13	Ewing sarcoma;
CRC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.62	-10.01	-0.48	9.08e-21	Aortic root size;
CRC	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-8.2	-0.41	5.3e-15	Bipolar disorder;
CRC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-6.08	-0.32	3.25e-9	Eosinophil percentage of white cells;
CRC	cis	rs7264396	0.887	rs2236165	chr20:34096725	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-6.22	-0.32	1.47e-9	Total cholesterol levels;
CRC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-6.14	-0.32	2.36e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg22561889	chr6:118971681	C6orf204	0.51	6.55	0.34	2.19e-10	Diastolic blood pressure;
CRC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg13722127	chr7:150037890	RARRES2	0.39	5.73	0.3	2.21e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.68	8.22	0.41	4.71e-15	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg03609598	chr5:56110824	MAP3K1	-0.57	-7.83	-0.4	6.6e-14	Coronary artery disease;
CRC	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.47	5.9	0.31	9.09e-9	Metabolite levels;
CRC	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg08614441	chr13:113633676	MCF2L	0.4	7.0	0.36	1.45e-11	Systolic blood pressure;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.64e-18	Parkinson's disease;
CRC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.5	-6.88	-0.35	3.01e-11	Menarche (age at onset);
CRC	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg27398640	chr15:77910606	LINGO1	-0.4	-7.01	-0.36	1.37e-11	Type 2 diabetes;
CRC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.72	8.73	0.43	1.35e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9443645	0.611	rs10943616	chr6:79823541	G/A	cg05283184	chr6:79620031	NA	-0.4	-5.78	-0.3	1.76e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.94	-0.55	1.5e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	9.87	0.48	2.65e-20	Total body bone mineral density;
CRC	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.38	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.79	0.63	2.57e-38	Chronic sinus infection;
CRC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.62	-9.08	-0.45	1.05e-17	Menarche (age at onset);
CRC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.61	-11.46	-0.53	8.56e-26	Educational attainment;
CRC	cis	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg18131467	chr2:239335373	ASB1	-0.71	-6.28	-0.33	1.06e-9	Chronotype;
CRC	cis	rs356992	0.874	rs168565	chr2:60744331	A/G	cg08426369	chr2:60753602	BCL11A	0.53	7.31	0.37	2.09e-12	Educational attainment (years of education);
CRC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-0.98	-9.75	-0.47	6.54e-20	Breast cancer;
CRC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.93	-0.48	1.71e-20	Chronic sinus infection;
CRC	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-1.04	-10.96	-0.52	4.87e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12024301	0.557	rs12044922	chr1:183613088	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg01339444	chr6:118972232	C6orf204	0.53	5.98	0.31	5.71e-9	Diastolic blood pressure;
CRC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-12.59	-0.57	6.27e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs1524976	1.000	rs2037670	chr3:65488142	C/A	cg16238336	chr3:65465873	MAGI1	-0.53	-6.81	-0.35	4.72e-11	PR interval;
CRC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg18833306	chr6:118973337	C6orf204	0.44	5.73	0.3	2.26e-8	Diastolic blood pressure;
CRC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg15226275	chr6:116381976	FRK	0.29	8.23	0.41	4.46e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs4660214	0.694	rs16866216	chr1:39674588	A/G	cg11070191	chr1:39582205	MACF1	0.37	5.89	0.31	9.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04880052	chr2:219191631	PNKD	-0.44	-6.98	-0.36	1.66e-11	Colorectal cancer;
CRC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.97	0.44	2.25e-17	Morning vs. evening chronotype;
CRC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg22495460	chr2:25135724	ADCY3	0.84	16.12	0.66	1.65e-43	Body mass index;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg09436375	chr6:42928200	GNMT	-0.34	-6.25	-0.33	1.29e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25593040	chr2:118572325	DDX18	0.47	6.21	0.32	1.56e-9	Thyroid stimulating hormone;
CRC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.59	-6.84	-0.35	3.76e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.77	-12.7	-0.57	2.37e-30	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.9	0.55	2.04e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.55	6.91	0.36	2.49e-11	Psoriasis;
CRC	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.44	6.19	0.32	1.77e-9	Height;
CRC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.77	-9.72	-0.47	8.65e-20	Initial pursuit acceleration;
CRC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.44	-6.65	-0.34	1.23e-10	Height;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.63	-8.69	-0.43	1.79e-16	Obesity-related traits;
CRC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.53	5.75	0.3	2.01e-8	Schizophrenia;
CRC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.24e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-12.8	-0.58	1.04e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg08075719	chr14:103021372	NA	-0.68	-7.94	-0.4	3.23e-14	Platelet count;
CRC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.84	-0.31	1.24e-8	Neuroticism;
CRC	cis	rs9649465	0.934	rs718781	chr7:123313573	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-5.71	-0.3	2.54e-8	Migraine;
CRC	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg27083787	chr2:113543245	IL1A	0.44	6.07	0.32	3.43e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.76	-0.39	1.08e-13	Total body bone mineral density;
CRC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.55	-7.11	-0.37	7.05e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg15845792	chr6:28175446	NA	-0.85	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
CRC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22029157	chr1:209979665	IRF6	0.61	6.76	0.35	6.47e-11	Coronary artery disease;
CRC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.31	9.81e-9	Bladder cancer;
CRC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	cis	rs12431939	0.598	rs12437085	chr14:51728941	G/T	cg23942311	chr14:51606299	NA	0.51	6.77	0.35	6.02e-11	Cancer;
CRC	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.46	-7.6	-0.39	3.21e-13	Educational attainment;
CRC	cis	rs10426930	0.607	rs2613768	chr19:5074637	G/A	cg18473234	chr19:5097819	KDM4B	-0.54	-6.77	-0.35	6.02e-11	Monocyte percentage of white cells;
CRC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.72	-8.72	-0.43	1.4e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg12855166	chr17:30846586	MYO1D	0.34	5.65	0.3	3.41e-8	Schizophrenia;
CRC	cis	rs11229555	0.609	rs11229451	chr11:58201687	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg14004847	chr7:1930337	MAD1L1	0.46	6.67	0.35	1.05e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.45	6.5	0.34	2.96e-10	Parkinson's disease;
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg21155852	chr7:2048760	MAD1L1	-0.53	-7.08	-0.36	8.98e-12	Bipolar disorder;
CRC	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.76	9.94	0.48	1.56e-20	Bipolar disorder;
CRC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.75	-0.35	6.67e-11	Platelet distribution width;
CRC	trans	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg17903999	chr18:56338584	MALT1	-0.4	-6.82	-0.35	4.4e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	1.18	13.33	0.59	1.03e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6141769	0.518	rs2377665	chr20:31309054	T/C	cg13636640	chr20:31349939	DNMT3B	-0.38	-5.84	-0.31	1.22e-8	Subjective well-being;
CRC	cis	rs28655083	0.828	rs7190227	chr16:77119568	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.58	8.31	0.42	2.63e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17162190	0.698	rs4970514	chr1:26846195	C/T	cg17456097	chr1:26900765	RPS6KA1	0.42	6.13	0.32	2.54e-9	Mean corpuscular volume;
CRC	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.42	7.51	0.38	5.6e-13	Blood metabolite ratios;
CRC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg26695010	chr11:65641043	EFEMP2	-0.39	-5.97	-0.31	6.06e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.45	6.01	0.31	4.87e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg23387468	chr7:139079360	LUC7L2	0.4	7.13	0.37	6.58e-12	Diisocyanate-induced asthma;
CRC	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.49	8.0	0.4	2.12e-14	Schizophrenia;
CRC	cis	rs9341808	0.622	rs684283	chr6:80967317	T/G	cg08355045	chr6:80787529	NA	-0.36	-5.93	-0.31	7.8e-9	Sitting height ratio;
CRC	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.45	13.05	0.58	1.22e-31	Granulocyte percentage of myeloid white cells;
CRC	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.37	-5.99	-0.31	5.43e-9	Mean arterial pressure;
CRC	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg15382696	chr6:118971807	C6orf204	0.58	7.38	0.38	1.29e-12	Diastolic blood pressure;
CRC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg13390004	chr1:15929781	NA	0.53	7.41	0.38	1.07e-12	Systolic blood pressure;
CRC	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.6	-9.29	-0.46	2.12e-18	Colorectal cancer;
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg14646075	chr2:228736089	WDR69	-0.42	-5.8	-0.3	1.52e-8	Blood pressure;
CRC	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg00935504	chr16:1863053	HAGH	0.31	5.62	0.3	4.07e-8	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08366132	chr1:27191899	NA	0.46	6.46	0.34	3.88e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	trans	rs12517041	1.000	rs10057246	chr5:23294721	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.45	-0.34	4e-10	Bipolar disorder;
CRC	cis	rs1223397	0.651	rs2458312	chr6:13309989	G/A	cg07912922	chr6:13274314	PHACTR1	0.39	6.08	0.32	3.39e-9	Blood pressure;
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.49	6.86	0.35	3.39e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7527798	0.544	rs11118354	chr1:207856868	A/G	cg09232269	chr1:207846808	CR1L	-0.45	-7.33	-0.37	1.84e-12	Erythrocyte sedimentation rate;
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg21620606	chr4:1342894	KIAA1530	0.4	6.94	0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.53e-18	Parkinson's disease;
CRC	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.44	7.24	0.37	3.14e-12	Refractive error;
CRC	trans	rs7579899	0.927	rs2121266	chr2:46535924	A/C	cg02204578	chr7:132766399	CHCHD3	0.42	5.99	0.31	5.37e-9	Renal cell carcinoma;
CRC	cis	rs17767392	0.958	rs1981588	chr14:72039689	G/A	cg13720639	chr14:72061746	SIPA1L1	0.56	6.88	0.35	2.96e-11	Mitral valve prolapse;
CRC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.8	-0.44	7.65e-17	Aortic root size;
CRC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.49	6.19	0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.41	6.6	0.34	1.65e-10	High light scatter reticulocyte count;
CRC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.55	-8.43	-0.42	1.11e-15	Height;
CRC	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg06581033	chr10:766294	NA	-0.5	-5.76	-0.3	1.93e-8	Uric acid levels;
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.63	-7.66	-0.39	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-10.62	-0.51	7.37e-23	Colorectal cancer;
CRC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg15147215	chr3:52552868	STAB1	0.48	8.21	0.41	5.2e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.72	-11.27	-0.53	3.81e-25	Tonsillectomy;
CRC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.62	-8.81	-0.44	7.22e-17	Inflammatory bowel disease;
CRC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg14671364	chr1:107599128	PRMT6	-0.62	-8.45	-0.42	9.23e-16	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.82	-8.74	-0.43	1.18e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-1.4	-14.49	-0.62	3.87e-37	Plateletcrit;
CRC	trans	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13047869	chr3:10149882	C3orf24	0.51	7.07	0.36	9.31e-12	Alzheimer's disease;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.01	24.82	0.81	2.18e-77	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.54	-8.1	-0.41	1.07e-14	Blood protein levels;
CRC	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	6.9	0.36	2.64e-11	Airway imaging phenotypes;
CRC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.83	-0.68	2.82e-46	Height;
CRC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	6.22	0.32	1.48e-9	Protein C levels;
CRC	cis	rs995000	0.839	rs1168026	chr1:62970996	T/C	cg19896129	chr1:63156450	NA	-0.39	-6.08	-0.32	3.29e-9	Triglyceride levels;
CRC	cis	rs9584850	0.708	rs4411372	chr13:99130423	T/C	cg07423050	chr13:99094983	FARP1	0.45	6.17	0.32	2.04e-9	Neuroticism;
CRC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.52	-0.43	5.76e-16	Coronary artery disease;
CRC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.76	9.18	0.45	5.09e-18	Body mass index;
CRC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.52	-7.38	-0.38	1.34e-12	Menarche (age at onset);
CRC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg17321639	chr7:2759063	NA	-0.5	-6.42	-0.33	4.71e-10	Height;
CRC	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.37	6.17	0.32	1.95e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01893439	chr7:148581376	EZH2	0.42	6.38	0.33	6.16e-10	Schizophrenia;
CRC	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg06781209	chr11:61594997	FADS2	-0.42	-5.99	-0.31	5.58e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.03	16.5	0.67	5.26e-45	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15342139	chr6:170124938	PHF10	0.42	7.13	0.37	6.47e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.7	-0.39	1.63e-13	Gut microbiome composition (summer);
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18591801	chr3:52553433	STAB1	-0.32	-6.17	-0.32	1.98e-9	Electroencephalogram traits;
CRC	cis	rs28493229	0.708	rs10408065	chr19:41161096	T/C	cg21869046	chr19:41225005	ITPKC	0.41	6.15	0.32	2.26e-9	Kawasaki disease;
CRC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg19223190	chr17:80058835	NA	0.41	6.62	0.34	1.49e-10	Life satisfaction;
CRC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07564175	chr17:8024546	HES7	-0.41	-5.99	-0.31	5.47e-9	Brain structure;
CRC	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.45	6.71	0.35	8.43e-11	HDL cholesterol;
CRC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06656553	chr16:89960601	TCF25	-0.68	-5.66	-0.3	3.31e-8	Skin colour saturation;
CRC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.44	5.91	0.31	8.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02073511	chr16:3550924	CLUAP1	0.42	7.02	0.36	1.24e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.69	-9.84	-0.48	3.3e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg25182066	chr10:30743637	MAP3K8	0.45	6.01	0.31	4.96e-9	Inflammatory bowel disease;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-8.17	-0.41	6.67e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.34	0.38	1.73e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.9	13.39	0.59	6.2e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg05585544	chr11:47624801	NA	-0.52	-9.41	-0.46	8.6e-19	Subjective well-being;
CRC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg11212589	chr17:38028394	ZPBP2	0.48	9.02	0.45	1.62e-17	Self-reported allergy;
CRC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	12.99	0.58	1.92e-31	Multiple sclerosis;
CRC	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg14003231	chr6:33640908	ITPR3	0.43	7.08	0.36	8.96e-12	Plateletcrit;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg23123621	chr4:1343375	KIAA1530	-0.34	-6.2	-0.32	1.68e-9	Obesity-related traits;
CRC	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.34	5.67	0.3	3.19e-8	Menopause (age at onset);
CRC	cis	rs4803480	0.507	rs10420992	chr19:42064462	T/A	cg08478046	chr19:42093086	CEACAM21	-0.29	-6.17	-0.32	2.06e-9	Schizophrenia;
CRC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.77	11.6	0.54	2.55e-26	Menarche (age at onset);
CRC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.03e-12	Corneal astigmatism;
CRC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg09127314	chr1:152161683	NA	-0.45	-5.61	-0.3	4.29e-8	Atopic dermatitis;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-8.57	-0.43	4.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.75	-0.39	1.19e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg23071808	chr14:103021642	NA	-0.7	-9.22	-0.45	3.53e-18	Platelet count;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg15786705	chr6:28176104	NA	-0.75	-9.6	-0.47	2.16e-19	Depression;
CRC	cis	rs1032355	0.722	rs13139650	chr4:100513580	G/C	cg05468953	chr4:100565104	NA	0.41	5.72	0.3	2.44e-8	Celiac disease;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4561483	0.583	rs9925010	chr16:11956668	A/G	cg08843971	chr16:11963173	GSPT1	0.52	7.76	0.39	1.1e-13	Testicular germ cell tumor;
CRC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.65	11.91	0.55	1.97e-27	Calcium levels;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.46	-6.59	-0.34	1.8e-10	Menarche (age at onset);
CRC	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg09659197	chr4:152720779	NA	0.41	8.5	0.42	6.5e-16	Intelligence (multi-trait analysis);
CRC	cis	rs8141797	0.818	rs1985047	chr22:24580381	G/C	cg20894457	chr22:24584366	SUSD2	0.65	7.8	0.4	8.27e-14	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs1867631	0.585	rs11208922	chr1:67080226	T/C	cg02459107	chr1:67143332	SGIP1	0.34	6.18	0.32	1.95e-9	Menopause (age at onset);
CRC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg14844989	chr11:31128820	NA	-0.34	-5.97	-0.31	5.99e-9	Red blood cell count;
CRC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.51	7.38	0.38	1.34e-12	Birth weight;
CRC	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.65	10.48	0.5	2.33e-22	Cancer;
CRC	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.67	-9.28	-0.46	2.26e-18	Vitiligo;
CRC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg07919128	chr17:18022025	MYO15A	-0.41	-6.81	-0.35	4.6e-11	Total body bone mineral density;
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg00815214	chr21:47717953	NA	-0.35	-6.04	-0.32	4.19e-9	Testicular germ cell tumor;
CRC	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg04662943	chr10:102668895	NA	0.61	7.13	0.37	6.44e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg06243084	chr11:63990629	FERMT3	-0.39	-5.95	-0.31	6.76e-9	Platelet count;
CRC	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.56	0.34	2.06e-10	Lymphocyte counts;
CRC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.36	-0.33	6.81e-10	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02551244	chr2:23608357	KLHL29	0.44	6.2	0.32	1.72e-9	Response to antipsychotic treatment;
CRC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg05585544	chr11:47624801	NA	-0.54	-9.69	-0.47	1.08e-19	Subjective well-being;
CRC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg19077165	chr18:44547161	KATNAL2	0.43	6.71	0.35	8.7e-11	Personality dimensions;
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07362569	chr17:61921086	SMARCD2	0.36	5.61	0.3	4.36e-8	Prudent dietary pattern;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Depression;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg00063174	chr2:228736253	WDR69	-0.51	-6.9	-0.36	2.6e-11	Blood pressure;
CRC	cis	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg03281426	chr2:240109471	HDAC4	0.63	6.86	0.35	3.4e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.22e-37	Hypertriglyceridemia;
CRC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-6.28	-0.33	1.06e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg01843034	chr6:37503916	NA	-0.35	-5.67	-0.3	3.2e-8	Cognitive performance;
CRC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.34	-5.8	-0.3	1.52e-8	Blood metabolite levels;
CRC	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.14	-0.37	5.97e-12	Capecitabine sensitivity;
CRC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg00750074	chr16:89608354	SPG7	-0.49	-7.44	-0.38	9.09e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.23e-8	Protein C levels;
CRC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.67	0.63	7.94e-38	Chronic sinus infection;
CRC	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg19486271	chr11:47235900	DDB2	-0.47	-7.12	-0.37	6.91e-12	Acne (severe);
CRC	cis	rs9976767	1.000	rs34544259	chr21:43834854	A/G	cg23042151	chr21:43824109	UBASH3A	-0.33	-5.66	-0.3	3.3e-8	Type 1 diabetes;
CRC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.24	0.45	3.14e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.5	9.77	0.47	5.89e-20	Hepatitis;
CRC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.5	7.54	0.38	4.49e-13	Methadone dose in opioid dependence;
CRC	cis	rs73206853	0.841	rs55951950	chr12:110800254	A/T	cg12870014	chr12:110450643	ANKRD13A	0.8	7.68	0.39	1.89e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.64	-0.3	3.69e-8	Longevity;Endometriosis;
CRC	cis	rs3750082	0.815	rs6964458	chr7:32935224	G/T	cg05721444	chr7:32995514	FKBP9	0.49	7.45	0.38	8.12e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7113874	0.569	rs10769924	chr11:8623193	C/A	cg17679104	chr11:8615758	STK33	0.38	6.4	0.33	5.35e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1178968	1.000	rs1178968	chr7:72767451	T/C	cg25889504	chr7:72793014	NA	0.55	6.21	0.32	1.64e-9	Triglyceride levels;
CRC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.7	0.35	8.9e-11	Lung cancer;
CRC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00815214	chr21:47717953	NA	0.38	6.26	0.33	1.22e-9	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	ch.7.38331565R	chr7:38365040	NA	0.38	6.04	0.32	4.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg26248373	chr2:1572462	NA	-0.66	-7.2	-0.37	4.09e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg24046110	chr8:143859143	LYNX1	-0.38	-6.63	-0.34	1.36e-10	Urinary tract infection frequency;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg03623178	chr6:28175578	NA	0.73	10.52	0.5	1.7e-22	Parkinson's disease;
CRC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg15147215	chr3:52552868	STAB1	-0.51	-7.49	-0.38	6.37e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg03030879	chr14:75389066	RPS6KL1	0.44	6.77	0.35	6.05e-11	Height;
CRC	cis	rs1223397	1.000	rs1232392	chr6:13272671	C/G	cg00460589	chr6:13274354	PHACTR1	0.48	5.92	0.31	8.21e-9	Blood pressure;
CRC	cis	rs8105895	0.935	rs28857211	chr19:22243104	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.5	-7.78	-0.39	9.28e-14	Type 2 diabetes;
CRC	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-0.85	-12.51	-0.57	1.18e-29	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.58	-0.43	3.74e-16	Bipolar disorder;
CRC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.05	10.88	0.51	9.17e-24	Diabetic retinopathy;
CRC	cis	rs11958404	0.860	rs72818136	chr5:157462866	C/T	cg05962755	chr5:157440814	NA	0.99	12.74	0.57	1.74e-30	IgG glycosylation;
CRC	cis	rs10746514	0.833	rs10864720	chr1:232271232	C/T	cg09506761	chr1:232265262	NA	-0.46	-6.54	-0.34	2.33e-10	Response to statin therapy;
CRC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg02659138	chr7:134003124	SLC35B4	0.37	6.31	0.33	9.06e-10	Mean platelet volume;
CRC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.29	6.14	0.32	2.41e-9	Homoarginine levels;
CRC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.82	0.35	4.27e-11	Testicular germ cell tumor;
CRC	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.81	-0.31	1.48e-8	Height;
CRC	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.65	-9.98	-0.48	1.11e-20	Itch intensity from mosquito bite;
CRC	cis	rs972578	1.000	rs1546861	chr22:43355167	G/A	cg01576275	chr22:43409880	NA	-0.45	-7.31	-0.37	1.99e-12	Mean platelet volume;
CRC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg09655341	chr17:79618100	PDE6G	0.56	6.72	0.35	8.17e-11	Dental caries;
CRC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.48	-7.2	-0.37	4.15e-12	Coronary artery disease;
CRC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.66	8.73	0.43	1.33e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg19041857	chr6:27730383	NA	-0.72	-6.75	-0.35	6.7e-11	Breast cancer;
CRC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.54	-0.5	1.4e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg15309053	chr8:964076	NA	0.34	6.01	0.31	4.95e-9	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15470672	chr1:24104458	C1orf128	0.4	5.96	0.31	6.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg14541582	chr5:601475	NA	-0.32	-6.65	-0.34	1.22e-10	Obesity-related traits;
CRC	cis	rs9292777	0.897	rs6865484	chr5:40391104	C/T	cg09067459	chr5:40385259	NA	0.55	9.76	0.47	6.15e-20	Crohn's disease;Multiple sclerosis;
CRC	cis	rs2882667	0.898	rs6890272	chr5:138371116	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.58e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.67	8.51	0.42	6.11e-16	Gastritis;
CRC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.79	13.38	0.59	6.65e-33	Menopause (age at onset);
CRC	trans	rs11105468	0.922	rs11105443	chr12:90260446	A/T	cg23572944	chr11:60720130	SLC15A3	0.45	6.39	0.33	5.79e-10	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg05623727	chr3:50126028	RBM5	0.45	6.85	0.35	3.68e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.53	6.08	0.32	3.31e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.88	-13.8	-0.61	1.63e-34	Bipolar disorder and schizophrenia;
CRC	cis	rs447	0.806	rs929335	chr7:83744488	C/G	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.76	-0.3	1.95e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7705042	0.828	rs10875596	chr5:141495715	T/C	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.9	-0.31	9e-9	Asthma;
CRC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.95	0.58	2.85e-31	Chronic sinus infection;
CRC	cis	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg03623178	chr6:28175578	NA	0.73	7.35	0.38	1.57e-12	Depression;
CRC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg03013636	chr16:1946785	NA	0.58	7.09	0.36	8.32e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg13615338	chr4:55094005	PDGFRA	0.42	6.14	0.32	2.32e-9	Corneal astigmatism;
CRC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg12193833	chr17:30244370	NA	0.44	6.13	0.32	2.59e-9	Hip circumference adjusted for BMI;
CRC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.5	7.67	0.39	1.96e-13	Red blood cell count;
CRC	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg00531865	chr16:30841666	NA	0.48	6.91	0.36	2.6e-11	Dementia with Lewy bodies;
CRC	cis	rs364477	0.811	rs279895	chr9:967981	C/G	cg13952963	chr9:998547	NA	-0.57	-6.14	-0.32	2.44e-9	Major depressive disorder;
CRC	trans	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.22	0.41	4.72e-15	Diabetic kidney disease;
CRC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-9.68	-0.47	1.16e-19	Dental caries;
CRC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.76	10.6	0.5	8.75e-23	Heart rate;
CRC	trans	rs2321882	0.834	rs17682907	chr13:59460631	T/G	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.93	-11.89	-0.55	2.38e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs7703744	0.681	rs17145294	chr5:118701433	G/T	cg23985447	chr5:118691066	TNFAIP8	0.44	6.27	0.33	1.15e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.55	-8.65	-0.43	2.25e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.43	0.38	9.6e-13	Menopause (age at onset);
CRC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.46	5.86	0.31	1.14e-8	Systemic lupus erythematosus;
CRC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.91	11.67	0.54	1.4e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07991241	chr10:33269695	NA	-0.51	-6.11	-0.32	2.76e-9	Diisocyanate-induced asthma;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.76	-11.59	-0.54	2.74e-26	Menarche (age at onset);
CRC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.62	9.15	0.45	6.16e-18	Obesity-related traits;
CRC	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.43	7.79	0.39	8.58e-14	Quantitative traits;
CRC	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-5.67	-0.3	3.08e-8	Alzheimer's disease (survival time);
CRC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	trans	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg26043149	chr18:55253948	FECH	-0.57	-8.83	-0.44	6.35e-17	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01442104	chr4:159690352	FNIP2	0.44	6.36	0.33	6.93e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.18	-0.32	1.91e-9	Longevity;Endometriosis;
CRC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.4	5.63	0.3	3.84e-8	Aortic root size;
CRC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.8	11.68	0.54	1.28e-26	Platelet distribution width;
CRC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.59	9.2	0.45	4.15e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg21951975	chr1:209979733	IRF6	0.36	6.13	0.32	2.51e-9	Monobrow;
CRC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-7.64	-0.39	2.44e-13	Aortic root size;
CRC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg21709803	chr11:61594965	FADS2	-0.41	-5.67	-0.3	3.15e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg15786705	chr6:28176104	NA	0.63	6.13	0.32	2.5e-9	Depression;
CRC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg13385521	chr17:29058706	SUZ12P	0.55	7.36	0.38	1.53e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-7.2	-0.37	4.04e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07754938	chr3:48885314	PRKAR2A	-0.42	-6.27	-0.33	1.13e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg11867950	chr14:31890052	NA	0.52	6.04	0.32	4.19e-9	Kashin-Beck disease;
CRC	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg13385794	chr1:248469461	NA	0.34	6.37	0.33	6.32e-10	Common traits (Other);
CRC	cis	rs12024301	0.557	rs75223998	chr1:183690598	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.72	5.63	0.3	3.8e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.67	7.25	0.37	2.97e-12	Pediatric areal bone mineral density (radius);
CRC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	9.55	0.47	3.07e-19	Lymphocyte counts;
CRC	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg21280719	chr6:42927975	GNMT	-0.31	-5.86	-0.31	1.11e-8	Blood protein levels;
CRC	cis	rs860295	0.702	rs11264387	chr1:155563152	G/T	cg02153340	chr1:155202674	NA	-0.52	-6.37	-0.33	6.36e-10	Body mass index;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02359409	chr6:42947317	PEX6	-0.67	-11.09	-0.52	1.72e-24	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg23141183	chr17:80185318	SLC16A3	0.4	5.62	0.3	4.11e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16504641	chr6:137143711	PEX7	0.39	6.45	0.34	3.94e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.31	0.37	2.01e-12	Major depressive disorder;
CRC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.63	-7.23	-0.37	3.43e-12	Body mass index;
CRC	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.1	0.32	2.96e-9	IgG glycosylation;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg20933634	chr6:27740509	NA	0.43	5.94	0.31	7.3e-9	Parkinson's disease;
CRC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg12639453	chr1:2035780	PRKCZ	-0.38	-7.04	-0.36	1.12e-11	Height;
CRC	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.55	8.31	0.42	2.51e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg25452165	chr22:42524984	CYP2D6	0.39	5.92	0.31	7.9e-9	Schizophrenia;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.99	0.61	3.18e-35	Alzheimer's disease;
CRC	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg12573674	chr2:1569213	NA	-0.72	-7.28	-0.37	2.42e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.66	6.87	0.35	3.25e-11	Fat distribution (HIV);
CRC	cis	rs1656402	1.000	rs2077930	chr2:233425867	G/A	cg03852847	chr2:233439513	NA	0.45	7.66	0.39	2.12e-13	Non-small cell lung cancer (survival);
CRC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.69	-12.11	-0.56	3.58e-28	Urate levels in obese individuals;
CRC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.64	-0.63	1.01e-37	Lymphocyte percentage of white cells;
CRC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg07507251	chr3:52567010	NT5DC2	0.4	6.22	0.32	1.53e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg26875233	chr11:93583750	C11orf90	-0.31	-6.03	-0.32	4.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg05047319	chr11:86748661	TMEM135	-0.43	-6.14	-0.32	2.37e-9	Birth weight;Height;
CRC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.98	0.48	1.15e-20	Cognitive test performance;
CRC	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs910187	0.597	rs2073172	chr20:45809176	A/G	cg27589058	chr20:45804311	EYA2	-0.39	-7.52	-0.38	5.3e-13	Migraine;
CRC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg10760299	chr15:45669010	GATM	0.36	5.65	0.3	3.52e-8	Glomerular filtration rate;
CRC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg15845792	chr6:28175446	NA	0.72	6.15	0.32	2.24e-9	Breast cancer;
CRC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.49	-7.2	-0.37	4.24e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.2	0.32	1.7e-9	Aortic root size;
CRC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg03037974	chr15:76606532	NA	0.69	11.52	0.54	5.16e-26	Blood metabolite levels;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg25164649	chr6:28176230	NA	0.66	9.28	0.46	2.36e-18	Parkinson's disease;
CRC	cis	rs11948739	0.537	rs12518203	chr5:130233745	G/A	cg08523029	chr5:130500466	HINT1	-0.47	-6.05	-0.32	3.95e-9	Pediatric bone mineral content (hip);
CRC	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg06172871	chr16:72088244	HP	0.44	6.45	0.33	4.08e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg05036130	chr6:150231994	NA	0.28	5.8	0.3	1.53e-8	Testicular germ cell tumor;
CRC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.15	0.32	2.27e-9	Rheumatoid arthritis;
CRC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.33	5.97	0.31	6.29e-9	Monobrow;
CRC	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg14074117	chr16:1909714	C16orf73	0.36	6.17	0.32	1.98e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg09344028	chr17:70110421	NA	0.49	7.19	0.37	4.28e-12	Thyroid hormone levels;
CRC	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.62	-12.38	-0.56	3.76e-29	Menarche (age at onset);
CRC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg01483505	chr11:975446	AP2A2	0.4	6.1	0.32	2.93e-9	Alzheimer's disease (late onset);
CRC	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.55	7.92	0.4	3.73e-14	Coronary artery disease;
CRC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg00129232	chr17:37814104	STARD3	-0.43	-6.91	-0.36	2.47e-11	Self-reported allergy;
CRC	cis	rs720844	0.684	rs35154707	chr2:149310951	C/T	cg09247360	chr2:149335327	NA	-0.56	-5.75	-0.3	2.04e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.64	-10.1	-0.49	4.7e-21	Menarche (age at onset);
CRC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg25985355	chr7:65971099	NA	-0.49	-5.65	-0.3	3.51e-8	Diabetic kidney disease;
CRC	cis	rs1322512	0.959	rs1744375	chr6:152944464	C/T	cg03415253	chr6:152958462	SYNE1	-0.41	-6.38	-0.33	6.06e-10	Tonometry;
CRC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg10298567	chr3:47292165	KIF9	-0.38	-6.04	-0.32	4.24e-9	Colorectal cancer;
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg15382696	chr6:118971807	C6orf204	0.61	7.88	0.4	4.86e-14	Diastolic blood pressure;
CRC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	4.92e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2882667	0.652	rs700622	chr5:138098551	T/C	cg09476006	chr5:138032270	NA	-0.56	-9.6	-0.47	2.19e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.17	-0.49	2.65e-21	Body mass index;
CRC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.73	9.51	0.46	4.32e-19	Cleft lip with or without cleft palate;
CRC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.43	18.91	0.72	1.66e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.61	-9.32	-0.46	1.8e-18	Blood pressure (smoking interaction);
CRC	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg20307385	chr11:47447363	PSMC3	0.48	5.91	0.31	8.43e-9	Migraine - clinic-based;
CRC	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg09695851	chr17:3907499	NA	0.54	8.69	0.43	1.8e-16	Type 2 diabetes;
CRC	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.4	-7.61	-0.39	2.94e-13	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18715716	chr3:52489445	TNNC1;NISCH	0.42	6.0	0.31	5.17e-9	Anxiety disorder;
CRC	cis	rs12900413	0.687	rs10152954	chr15:90307442	T/C	cg24249390	chr15:90295951	MESP1	-0.58	-9.15	-0.45	6.26e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs73206853	0.764	rs56273026	chr12:110901691	A/C	cg12870014	chr12:110450643	ANKRD13A	0.84	9.77	0.47	5.83e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.83	13.36	0.59	8.29e-33	Menarche (age at onset);
CRC	trans	rs474558	0.597	rs577834	chr10:99699045	C/T	cg05303249	chr11:66036138	RAB1B	-0.58	-8.6	-0.43	3.2e-16	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg09877947	chr5:131593287	PDLIM4	-0.36	-6.38	-0.33	6.11e-10	Blood metabolite levels;
CRC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg18099408	chr3:52552593	STAB1	0.44	6.83	0.35	4.17e-11	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg13490827	chr1:46269305	MAST2	-0.69	-6.05	-0.32	4.03e-9	Cognitive function;
CRC	cis	rs11212617	0.837	rs10890822	chr11:108027060	C/A	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.56	0.34	2.13e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.53	7.33	0.37	1.78e-12	Testicular germ cell tumor;
CRC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.71	0.39	1.54e-13	Motion sickness;
CRC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.64	0.3	3.68e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.27	0.33	1.14e-9	Cognitive ability;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs965469	1.000	rs6051753	chr20:3315513	G/A	cg25506879	chr20:3388711	C20orf194	-0.39	-5.64	-0.3	3.62e-8	IFN-related cytopenia;
CRC	trans	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.0	-0.36	1.43e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.67	-0.34	1.12e-10	Monocyte percentage of white cells;
CRC	cis	rs2033908	0.588	rs1899068	chr11:12872156	A/T	cg25843174	chr11:12811716	TEAD1	0.37	6.5	0.34	2.99e-10	Sitting height ratio;
CRC	cis	rs7107770	0.739	rs4936995	chr11:125081694	G/T	cg27629782	chr11:125073726	PKNOX2	0.53	7.91	0.4	4.07e-14	Photic sneeze reflex;
CRC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs3751196	0.808	rs59716163	chr12:104207414	C/T	cg02344784	chr12:104178138	NT5DC3	0.71	7.21	0.37	3.94e-12	Sense of smell;
CRC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg24130564	chr14:104152367	KLC1	0.44	5.81	0.31	1.44e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.07	-0.32	3.48e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg08741688	chr4:3415352	RGS12	-0.35	-5.67	-0.3	3.14e-8	Parental longevity (mother's age at death);
CRC	cis	rs1681630	0.545	rs1228001	chr11:47986994	A/T	cg05585544	chr11:47624801	NA	-0.42	-7.24	-0.37	3.13e-12	Height;
CRC	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg02770688	chr6:168491649	NA	0.61	8.97	0.44	2.24e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.39	-6.01	-0.31	4.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.45	7.28	0.37	2.51e-12	Hemoglobin concentration;
CRC	cis	rs9039	1.000	rs11862745	chr16:9218887	C/T	cg08831531	chr16:9218945	NA	0.63	8.88	0.44	4.4e-17	Menopause (age at onset);
CRC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21028142	chr17:79581711	NPLOC4	0.34	7.1	0.36	7.88e-12	Eye color traits;
CRC	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg23293999	chr7:106826042	HBP1	-0.54	-5.71	-0.3	2.52e-8	Osteoarthritis;
CRC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.79	7.91	0.4	4.03e-14	Diabetic retinopathy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07631383	chr7:131012765	MKLN1	0.45	6.52	0.34	2.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	16.03	0.66	3.87e-43	Platelet count;
CRC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-6.94	-0.36	2.15e-11	Axial length;
CRC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg10790698	chr19:18539756	SSBP4	-0.46	-8.72	-0.43	1.44e-16	Breast cancer;
CRC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.96	0.31	6.56e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19935506	chr2:242626874	DTYMK	0.43	6.05	0.32	3.94e-9	Response to antipsychotic treatment;
CRC	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.47	6.17	0.32	2.02e-9	Fractional excretion of uric acid;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04582424	chr1:203764710	ZC3H11A	-0.47	-6.68	-0.35	1.03e-10	Myopia (pathological);
CRC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg13798780	chr7:105162888	PUS7	0.67	7.93	0.4	3.42e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.65	-8.55	-0.43	4.85e-16	Extraversion;
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.73	0.3	2.27e-8	Prudent dietary pattern;
CRC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.67	10.34	0.5	6.89e-22	Corneal astigmatism;
CRC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.41	-8.0	-0.4	2.2e-14	Renal cell carcinoma;
CRC	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg13160058	chr8:26243215	BNIP3L	-0.46	-7.82	-0.4	7.06e-14	Red cell distribution width;
CRC	cis	rs55788414	1.000	rs34242559	chr16:81180138	T/C	cg06400318	chr16:81190750	PKD1L2	-0.68	-6.38	-0.33	5.87e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs7113874	0.589	rs10840056	chr11:8498064	A/C	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.64	10.38	0.5	4.88e-22	Height;
CRC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.73	-11.4	-0.53	1.34e-25	Monocyte count;
CRC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.09	-0.32	3.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.51	7.61	0.39	2.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.87	-0.31	1.07e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.4	-5.97	-0.31	6.26e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg13798780	chr7:105162888	PUS7	0.64	7.39	0.38	1.2e-12	Bipolar disorder (body mass index interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12698737	chr15:69110455	ANP32A	0.46	6.93	0.36	2.28e-11	Schizophrenia;
CRC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.4	5.74	0.3	2.19e-8	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08245420	chr5:139726438	HBEGF	0.5	7.3	0.37	2.23e-12	Response to antipsychotic treatment;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg25164649	chr6:28176230	NA	0.59	8.31	0.42	2.63e-15	Cardiac Troponin-T levels;
CRC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg15763984	chr4:1342303	KIAA1530	0.35	5.99	0.31	5.49e-9	Longevity;
CRC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.89	0.44	4.13e-17	Morning vs. evening chronotype;
CRC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.4	-0.38	1.12e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg09344028	chr17:70110421	NA	-0.49	-7.47	-0.38	7.23e-13	Thyroid hormone levels;
CRC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.6	9.53	0.47	3.52e-19	Educational attainment;
CRC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.39	-6.33	-0.33	8.02e-10	HDL cholesterol;
CRC	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.67	11.03	0.52	2.84e-24	Itch intensity from mosquito bite;
CRC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg01788221	chr16:89496183	ANKRD11	-0.41	-6.26	-0.33	1.17e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.39	-6.79	-0.35	5.31e-11	Height;
CRC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg04202892	chr2:111875749	ACOXL	0.47	7.76	0.39	1.05e-13	Chronic lymphocytic leukemia;
CRC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.06e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg21153622	chr11:89784906	NA	-0.46	-7.31	-0.37	2.06e-12	HDL cholesterol;
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs7461897	0.511	rs1383916	chr8:26825245	A/G	cg06816054	chr8:27695695	PBK	-0.57	-5.8	-0.3	1.58e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
CRC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.63	-0.51	6.86e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg24851651	chr11:66362959	CCS	-0.38	-6.71	-0.35	8.65e-11	Educational attainment (years of education);
CRC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.67	-0.3	3.2e-8	Breast cancer;
CRC	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.55	-7.9	-0.4	4.17e-14	Rheumatoid arthritis;
CRC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg20243544	chr17:37824526	PNMT	0.57	8.88	0.44	4.54e-17	Asthma;
CRC	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.49	7.29	0.37	2.39e-12	Coronary heart disease;
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg15511327	chr8:143859410	LYNX1	0.41	7.21	0.37	3.96e-12	Urinary tract infection frequency;
CRC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.8	-13.46	-0.6	3.46e-33	Dilated cardiomyopathy;
CRC	cis	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg26958806	chr6:27640298	NA	0.93	6.09	0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.72	-12.09	-0.55	4.33e-28	Idiopathic membranous nephropathy;
CRC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.74	7.9	0.4	4.3e-14	Diabetic retinopathy;
CRC	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.48	7.94	0.4	3.13e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg03623178	chr6:28175578	NA	0.93	12.26	0.56	9.88e-29	Depression;
CRC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.63	7.25	0.37	2.97e-12	IgG glycosylation;
CRC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.93	-0.36	2.26e-11	Mean corpuscular volume;
CRC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.09	-0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.65	8.48	0.42	7.95e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	13.18	0.59	3.93e-32	Schizophrenia;
CRC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.65	7.08	0.36	8.93e-12	Vitiligo;
CRC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	5.92	0.31	8.08e-9	Height;
CRC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.1	12.91	0.58	3.82e-31	Sexual dysfunction (female);
CRC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.65	11.08	0.52	1.83e-24	Vitiligo;
CRC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7487075	0.820	rs7134855	chr12:46711310	A/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.54	0.34	2.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.38	0.5	4.9e-22	Diabetic retinopathy;
CRC	trans	rs6544773	0.668	rs2673280	chr2:45065353	G/A	cg10208897	chr5:178548229	ADAMTS2	0.35	6.12	0.32	2.59e-9	Mosquito bite size;
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg15147215	chr3:52552868	STAB1	-0.61	-10.13	-0.49	3.53e-21	Bipolar disorder;
CRC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.54	-8.21	-0.41	5.22e-15	Monocyte count;
CRC	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.51	-8.21	-0.41	5.26e-15	Tourette's syndrome or obsessive-compulsive disorder;
CRC	trans	rs2303319	0.504	rs62188147	chr2:162286552	G/T	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.46	-0.34	3.79e-10	Cognitive function;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26515694	chr19:21949968	ZNF100	0.34	6.43	0.33	4.6e-10	Obesity-related traits;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg06470822	chr6:28175283	NA	1.01	15.38	0.65	1.29e-40	Depression;
CRC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Alcohol dependence;
CRC	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-7.68	-0.39	1.8e-13	Mood instability;
CRC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.61	-11.48	-0.53	7.05e-26	Hemoglobin concentration;
CRC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg09796270	chr17:17721594	SREBF1	0.46	7.97	0.4	2.58e-14	Total body bone mineral density;
CRC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.71	-8.16	-0.41	7.27e-15	Vitiligo;
CRC	cis	rs17067123	0.614	rs7340789	chr4:180052417	C/T	cg26610307	chr4:180072759	NA	-0.54	-6.5	-0.34	3.01e-10	Response to hepatitis C treatment;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg16471585	chr12:118199103	KSR2	-0.59	-6.86	-0.35	3.34e-11	Body mass index;
CRC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg22110888	chr17:80059540	CCDC57	-0.45	-6.96	-0.36	1.9e-11	Life satisfaction;
CRC	cis	rs10760158	0.832	rs3810942	chr9:124044995	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.83	-0.31	1.32e-8	Pulse pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23831110	chr14:102785987	ZNF839	0.39	6.14	0.32	2.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.47	6.26	0.33	1.23e-9	Schizophrenia;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.49	7.19	0.37	4.26e-12	Carotid intima media thickness;
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.61	7.53	0.38	4.98e-13	Alzheimer's disease;
CRC	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg06204229	chr3:52865917	ITIH4	0.52	5.86	0.31	1.13e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2386661	0.826	rs7092383	chr10:5671101	A/C	cg26603656	chr10:5671107	NA	0.55	9.1	0.45	8.84e-18	Breast cancer;
CRC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-7.37	-0.38	1.43e-12	Hemoglobin concentration;
CRC	cis	rs6764363	0.527	rs12496555	chr3:278154	A/G	cg02057681	chr3:285234	CHL1	0.42	7.11	0.37	7.08e-12	Sudden cardiac arrest;
CRC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.54	-5.65	-0.3	3.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03372779	chr16:2069785	NPW	0.34	6.37	0.33	6.25e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19429466	chr4:87515395	PTPN13	0.44	6.4	0.33	5.23e-10	Hip circumference;
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.32	-0.33	8.34e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-1.25	-10.18	-0.49	2.44e-21	Mitochondrial DNA levels;
CRC	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.32	12.64	0.57	3.95e-30	Granulocyte percentage of myeloid white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13674574	chr14:64971270	ZBTB25;ZBTB1	0.38	5.97	0.31	6.21e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11581859	0.950	rs72730322	chr1:99384244	T/C	cg12183875	chr3:169587454	LRRC31	0.28	6.36	0.33	6.89e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg19193384	chr17:30244184	NA	-0.65	-7.54	-0.38	4.67e-13	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15441325	chr3:106959341	LOC344595;LOC100302640	0.42	6.0	0.31	5.2e-9	Response to antipsychotic treatment;
CRC	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.89	-11.28	-0.53	3.61e-25	Hair shape;
CRC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.04	-0.48	7.11e-21	Initial pursuit acceleration;
CRC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.85	-0.44	5.49e-17	Platelet count;
CRC	cis	rs2398893	0.924	rs7855830	chr9:96798659	A/G	cg14459158	chr9:96720562	NA	0.4	6.62	0.34	1.42e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.82	-17.2	-0.69	9.78e-48	Ulcerative colitis;
CRC	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.13	-9.56	-0.47	2.83e-19	Mitochondrial DNA levels;
CRC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	7.42	0.38	1.01e-12	Obesity-related traits;
CRC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.43	0.33	4.48e-10	Obesity-related traits;
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg21784768	chr11:537496	LRRC56	-0.7	-6.64	-0.34	1.32e-10	Body mass index;
CRC	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg25019722	chr6:37503610	NA	-0.48	-8.87	-0.44	4.78e-17	Cognitive performance;
CRC	cis	rs10924970	0.687	rs61836127	chr1:235363740	T/G	cg09010748	chr1:235293032	TOMM20	-0.43	-5.91	-0.31	8.38e-9	Asthma;
CRC	cis	rs728616	0.867	rs17606361	chr10:81845411	G/C	cg05935833	chr10:81318306	SFTPA2	-0.61	-6.95	-0.36	1.97e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.42	-6.0	-0.31	5.21e-9	Aortic root size;
CRC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.98	-18.29	-0.71	4.52e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg06223162	chr1:101003688	GPR88	-0.34	-6.1	-0.32	2.96e-9	Monocyte count;
CRC	cis	rs9847710	0.683	rs2581818	chr3:53071652	C/A	cg18099408	chr3:52552593	STAB1	0.39	5.83	0.31	1.3e-8	Ulcerative colitis;
CRC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.21	-0.41	5.12e-15	Mean corpuscular volume;
CRC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg02741985	chr17:80059408	CCDC57	-0.44	-7.2	-0.37	4.13e-12	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11471666	chr12:53400335	EIF4B	0.45	6.48	0.34	3.39e-10	Response to antipsychotic treatment;
CRC	trans	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg20935933	chr6:143382018	AIG1	0.55	7.05	0.36	1.04e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg07617317	chr6:118971624	C6orf204	0.49	6.16	0.32	2.17e-9	Diastolic blood pressure;
CRC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.88	16.0	0.66	5e-43	Blood protein levels;
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.65	-7.06	-0.36	1.01e-11	IgG glycosylation;
CRC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.88	-15.57	-0.65	2.54e-41	Body mass index;
CRC	cis	rs12023718	0.588	rs16853133	chr1:178602237	C/G	cg00404053	chr1:178313656	RASAL2	-0.63	-7.84	-0.4	6.21e-14	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08125682	chr16:11038455	CLEC16A	0.46	7.78	0.39	9.76e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg14515779	chr1:101123966	NA	-0.43	-8.31	-0.42	2.46e-15	Monocyte count;
CRC	cis	rs4363385	0.693	rs1933384	chr1:152959488	A/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.29	-0.37	2.3e-12	Inflammatory skin disease;
CRC	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg20936604	chr3:58311152	NA	-0.64	-5.97	-0.31	6.1e-9	Cholesterol, total;
CRC	cis	rs995000	0.965	rs11207982	chr1:63007182	C/T	cg19896129	chr1:63156450	NA	0.4	5.83	0.31	1.29e-8	Triglyceride levels;
CRC	cis	rs6961069	0.806	rs10499859	chr7:80258810	A/G	cg04458919	chr7:80252533	CD36	0.35	6.05	0.32	3.95e-9	Platelet count;
CRC	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.4	-5.75	-0.3	2e-8	QT interval;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg03909902	chr12:108154529	PRDM4	-0.44	-6.56	-0.34	2.1e-10	Birth weight;Height;
CRC	cis	rs6880778	0.505	rs6891041	chr5:40406238	G/A	cg09067459	chr5:40385259	NA	0.46	7.69	0.39	1.71e-13	Inflammatory bowel disease;
CRC	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.22	-5.75	-0.3	2.03e-8	Type 2 diabetes;
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.72	0.39	1.45e-13	Alzheimer's disease;
CRC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg26102564	chr10:131424627	MGMT	0.39	5.68	0.3	2.91e-8	Response to temozolomide;
CRC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.38	-7.08	-0.36	9.03e-12	Lymphocyte counts;
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-6.69	-0.35	9.51e-11	Lymphocyte counts;
CRC	cis	rs758324	0.812	rs667437	chr5:131275509	C/T	cg25547332	chr5:131281432	NA	-0.36	-5.72	-0.3	2.46e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.04	16.07	0.66	2.57e-43	Lymphocyte percentage of white cells;
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.91	-17.23	-0.69	7.38e-48	Height;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg20503117	chr3:5164013	ARL8B	-0.46	-6.21	-0.32	1.56e-9	Protein C levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27306034	chr1:155224863	FAM189B	0.4	6.53	0.34	2.49e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg25834613	chr7:1915315	MAD1L1	-0.45	-6.29	-0.33	1.02e-9	Bipolar disorder;
CRC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.56	8.98	0.44	2.11e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.25	-0.62	3.16e-36	Height;
CRC	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg23555395	chr2:238036564	NA	0.52	8.12	0.41	9.17e-15	Systemic lupus erythematosus;
CRC	cis	rs17532515	0.628	rs3113196	chr4:141477273	T/C	cg09181644	chr4:141490428	UCP1	0.33	5.98	0.31	5.91e-9	Select biomarker traits;
CRC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg21770322	chr7:97807741	LMTK2	0.52	8.58	0.43	3.88e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.51	7.11	0.36	7.46e-12	Dental caries;
CRC	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg26893861	chr17:41843967	DUSP3	0.68	6.81	0.35	4.57e-11	Cognitive function;
CRC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.72	0.35	8.19e-11	Lung cancer;
CRC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	5.78	0.3	1.78e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.59	-8.29	-0.42	2.99e-15	Inflammatory bowel disease;
CRC	trans	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg21153622	chr11:89784906	NA	-0.47	-7.58	-0.39	3.59e-13	HDL cholesterol;
CRC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.8	13.35	0.59	8.92e-33	Menopause (age at onset);
CRC	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.62	-9.94	-0.48	1.59e-20	Breast cancer;
CRC	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg09873164	chr1:152488093	CRCT1	0.4	6.73	0.35	7.52e-11	Hair morphology;
CRC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.69	8.87	0.44	4.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg12501888	chr15:85177176	SCAND2	-0.35	-5.8	-0.3	1.57e-8	P wave terminal force;
CRC	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg25834613	chr7:1915315	MAD1L1	-0.41	-5.82	-0.31	1.38e-8	Bipolar disorder;
CRC	cis	rs9463078	0.605	rs3799984	chr6:44893640	C/G	cg25276700	chr6:44698697	NA	0.24	5.88	0.31	1.03e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.57	7.65	0.39	2.26e-13	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg07195197	chr16:1662150	IFT140	-0.7	-5.98	-0.31	5.91e-9	Cognitive function;
CRC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-19.1	-0.73	2.9e-55	Height;
CRC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	cis	rs449789	0.857	rs4708817	chr6:159720640	A/G	cg14500486	chr6:159655392	FNDC1	-0.48	-7.42	-0.38	1.03e-12	Pulse pressure;
CRC	cis	rs9462027	0.606	rs2744941	chr6:34646917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg04165759	chr1:150448943	RPRD2	0.34	5.62	0.3	4.11e-8	Migraine;
CRC	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg13611204	chr9:139324423	INPP5E	-0.45	-6.3	-0.33	9.48e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg09476006	chr5:138032270	NA	0.48	7.59	0.39	3.22e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-5.99	-0.31	5.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9969804	0.875	rs10992395	chr9:95433844	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.73	-0.3	2.3e-8	Height;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg19959974	chr12:75905392	KRR1	0.49	6.25	0.33	1.28e-9	Plasma plasminogen activator levels;
CRC	cis	rs75422866	0.867	rs73104152	chr12:48092874	A/C	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.46	5.64	0.3	3.66e-8	Bladder cancer;
CRC	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.49	-7.67	-0.39	1.9e-13	Type 2 diabetes;
CRC	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.06	12.98	0.58	2.17e-31	Type 2 diabetes nephropathy;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.6	-0.43	3.21e-16	Hemoglobin concentration;
CRC	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.53	7.33	0.37	1.82e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.52	-7.23	-0.37	3.43e-12	LDL cholesterol to HDL cholesterol ratio;
CRC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.62	6.67	0.35	1.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.76	-13.38	-0.59	6.95e-33	Body mass index;
CRC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.57	8.88	0.44	4.4e-17	Colorectal cancer;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.39	-0.33	5.55e-10	Blood metabolite levels;
CRC	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.76	7.99	0.4	2.31e-14	Type 2 diabetes;
CRC	cis	rs2530545	0.512	rs10265324	chr7:34611746	C/T	cg14401837	chr7:34697493	NPSR1	0.37	5.75	0.3	2.04e-8	IgG glycosylation;
CRC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.56	8.23	0.41	4.4e-15	Melanoma;
CRC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.64	0.3	3.67e-8	Bladder cancer;
CRC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg26248373	chr2:1572462	NA	-0.65	-7.02	-0.36	1.24e-11	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4728302	0.869	rs7792905	chr7:133595602	G/T	cg10665199	chr7:133106180	EXOC4	0.38	5.79	0.3	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.77	-0.3	1.8e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs11874712	0.965	rs11661945	chr18:43672194	T/A	cg05477517	chr6:164531576	NA	0.41	6.1	0.32	2.9e-9	Migraine - clinic-based;
CRC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg18478394	chr8:109455254	TTC35	0.37	5.65	0.3	3.42e-8	Dupuytren's disease;
CRC	cis	rs10463316	0.817	rs7708940	chr5:150789051	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.74	-0.35	7.27e-11	Metabolite levels (Pyroglutamine);
CRC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.6	-9.73	-0.47	7.88e-20	Aortic root size;
CRC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Reticulocyte count;High light scatter reticulocyte count;
CRC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20739912	chr4:3294241	NA	0.43	6.52	0.34	2.6200000000000003e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4731207	0.596	rs1026839	chr7:124672599	C/T	cg23710748	chr7:124431027	NA	0.37	5.85	0.31	1.19e-8	Cutaneous malignant melanoma;
CRC	cis	rs6662572	0.671	rs12047120	chr1:46478496	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.96	-0.31	6.45e-9	Blood protein levels;
CRC	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.85	7.76	0.39	1.08e-13	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.66	-10.92	-0.52	6.98e-24	Personality dimensions;
CRC	trans	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.21e-12	Ulcerative colitis;
CRC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.59	9.7	0.47	1.02e-19	Vitiligo;
CRC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-6.12	-0.32	2.73e-9	Aortic root size;
CRC	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg20203395	chr5:56204925	C5orf35	0.4	5.77	0.3	1.87e-8	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23036426	chr1:10093530	UBE4B	0.46	6.74	0.35	7.31e-11	Response to antipsychotic treatment;
CRC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.34	-0.46	1.5e-18	Heart rate;
CRC	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	7.48	0.38	6.62e-13	Diisocyanate-induced asthma;
CRC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg11915388	chr22:42470451	FAM109B	-0.43	-6.51	-0.34	2.85e-10	Schizophrenia;
CRC	trans	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg15845792	chr6:28175446	NA	0.68	6.59	0.34	1.7e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7584330	0.740	rs13426236	chr2:238447940	A/G	cg16989719	chr2:238392110	NA	-0.38	-6.98	-0.36	1.59e-11	Prostate cancer;
CRC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.41	-7.03	-0.36	1.23e-11	Height;
CRC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.45	-6.69	-0.35	9.48e-11	Breast size;
CRC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg20203395	chr5:56204925	C5orf35	-0.69	-8.36	-0.42	1.79e-15	Initial pursuit acceleration;
CRC	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.79	-9.67	-0.47	1.22e-19	Multiple sclerosis;
CRC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.22	-14.06	-0.61	1.66e-35	Diabetic kidney disease;
CRC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.17	-0.37	5.01e-12	Bladder cancer;
CRC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.68	0.35	1.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10089	0.552	rs59430737	chr5:127557568	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	7.65	0.39	2.31e-13	Ileal carcinoids;
CRC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.64	8.86	0.44	5.07e-17	Bladder cancer;
CRC	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg21452805	chr1:244014465	NA	0.5	6.9	0.36	2.66e-11	RR interval (heart rate);
CRC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.63	-9.98	-0.48	1.12e-20	Height;
CRC	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.98	-13.66	-0.6	5.72e-34	Exhaled nitric oxide output;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01490821	chr2:170684022	UBR3	0.44	6.09	0.32	3.19e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg13482628	chr17:19912719	NA	-0.41	-6.28	-0.33	1.07e-9	Obesity-related traits;
CRC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.92	-19.27	-0.73	6.24e-56	Urate levels in lean individuals;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.91	17.12	0.69	2e-47	Height;
CRC	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.94	0.36	2.05e-11	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs8032158	0.702	rs1042477	chr15:56121886	C/A	cg02198044	chr15:56286336	NEDD4	-0.36	-5.73	-0.3	2.33e-8	Keloid;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22541143	chr4:84377292	HELQ;MRPS18C	0.39	6.27	0.33	1.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.44	-8.42	-0.42	1.16e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24341800	chr11:107992076	ACAT1	0.49	6.31	0.33	8.81e-10	Thyroid stimulating hormone;
CRC	cis	rs2274471	0.634	rs913594	chr9:5063199	C/T	cg03390472	chr9:5043263	JAK2	-0.55	-6.82	-0.35	4.42e-11	Crohn's disease;
CRC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg18761221	chr20:60518478	NA	0.44	7.46	0.38	7.77e-13	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16245844	chr12:1800488	ADIPOR2	0.33	6.2	0.32	1.7e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg25204440	chr1:209979598	IRF6	0.47	5.71	0.3	2.49e-8	Cleft lip with or without cleft palate;
CRC	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg06223162	chr1:101003688	GPR88	0.34	6.31	0.33	8.82e-10	Monocyte count;
CRC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.42	8.09	0.41	1.15e-14	Mean corpuscular volume;
CRC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.57	9.31	0.46	1.83e-18	Menopause (age at onset);
CRC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.62	-0.39	2.82e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.13e-9	Prudent dietary pattern;
CRC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg06238570	chr21:40685208	BRWD1	0.7	10.07	0.49	5.84e-21	Cognitive function;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.39	6.59	0.34	1.71e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35520189	0.591	rs12464758	chr2:113703281	T/C	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.75	-0.3	2.07e-8	Yeast infection;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.47	6.43	0.33	4.37e-10	Menarche (age at onset);
CRC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg27432699	chr2:27873401	GPN1	-0.48	-7.35	-0.38	1.61e-12	Total body bone mineral density;
CRC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.38	5.72	0.3	2.37e-8	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01497487	chr22:38141814	TRIOBP	0.43	6.34	0.33	7.48e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	8.63	0.43	2.6e-16	Ileal carcinoids;
CRC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.49	-6.83	-0.35	4.07e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.37	-0.42	1.66e-15	Electroencephalogram traits;
CRC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg21951975	chr1:209979733	IRF6	0.46	5.6	0.3	4.48e-8	Cleft lip with or without cleft palate;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05397609	chr1:67896184	SERBP1	0.44	6.36	0.33	6.92e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg23260525	chr10:116636907	FAM160B1	-0.32	-6.05	-0.32	3.86e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23155395	chr7:128045684	IMPDH1	0.38	6.45	0.34	4.02e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.91	-0.48	1.94e-20	Height;
CRC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.1	0.61	1.17e-35	Prudent dietary pattern;
CRC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.77	0.3	1.82e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.5	-6.55	-0.34	2.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.96	0.48	1.4e-20	Platelet count;
CRC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg10589385	chr1:150898437	SETDB1	0.28	6.07	0.32	3.43e-9	Melanoma;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg12516270	chr8:143859308	LYNX1	0.4	7.08	0.36	9.03e-12	Urinary tract infection frequency;
CRC	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg26248373	chr2:1572462	NA	-0.8	-10.96	-0.52	4.81e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.92	11.19	0.53	7.51e-25	Exhaled nitric oxide output;
CRC	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	17.89	0.7	1.85e-50	Smoking behavior;
CRC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.73	-0.35	7.69e-11	Major depressive disorder;
CRC	cis	rs3026445	0.672	rs10774603	chr12:111155947	C/T	cg12870014	chr12:110450643	ANKRD13A	0.39	5.93	0.31	7.76e-9	QT interval;
CRC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-5.88	-0.31	1.01e-8	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25955816	chr1:228612876	HIST3H3	-0.38	-5.98	-0.31	5.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg08798685	chr6:27730294	NA	0.46	6.22	0.32	1.55e-9	Parkinson's disease;
CRC	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg15382696	chr6:118971807	C6orf204	0.6	7.53	0.38	5.03e-13	Diastolic blood pressure;
CRC	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg03037974	chr15:76606532	NA	-0.51	-7.2	-0.37	4.17e-12	Blood metabolite levels;
CRC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.67	9.74	0.47	7.45e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	0.88	9.66	0.47	1.31e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09820084	chr6:18387507	RNF144B	-0.52	-6.37	-0.33	6.26e-10	Diisocyanate-induced asthma;
CRC	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.69	9.88	0.48	2.49e-20	Obesity-related traits;
CRC	cis	rs11677416	1.000	rs1516789	chr2:113531024	C/T	cg27083787	chr2:113543245	IL1A	0.47	6.74	0.35	6.99e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.68	9.91	0.48	2.04e-20	Cognitive function;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-7.93	-0.4	3.51e-14	Longevity;Endometriosis;
CRC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	11.71	0.54	1.02e-26	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25146111	chr4:40059615	N4BP2;LOC344967	0.45	6.23	0.32	1.43e-9	Response to antipsychotic treatment;
CRC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg03160526	chr17:80928410	B3GNTL1	0.49	8.01	0.4	1.99e-14	Breast cancer;
CRC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg12193833	chr17:30244370	NA	-0.63	-8.19	-0.41	5.67e-15	Hip circumference adjusted for BMI;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg18758796	chr5:131593413	PDLIM4	-0.37	-6.1	-0.32	2.92e-9	Breast cancer;
CRC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.76	0.35	6.19e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg23018236	chr17:30244563	NA	-0.49	-6.4	-0.33	5.22e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.63	-9.69	-0.47	1.11e-19	Cognitive function;
CRC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg12193833	chr17:30244370	NA	-0.75	-8.74	-0.43	1.23e-16	Hip circumference adjusted for BMI;
CRC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-17.68	-0.7	1.22e-49	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19219560	chr2:88926950	EIF2AK3	0.5	6.96	0.36	1.83e-11	Response to antipsychotic treatment;
CRC	cis	rs3736485	0.808	rs28813458	chr15:51947023	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-6.24	-0.33	1.36e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.73	10.56	0.5	1.23e-22	Menarche (age at onset);
CRC	cis	rs11625487	0.609	rs74063377	chr14:77951431	C/G	cg20045696	chr14:77926864	AHSA1	-0.71	-6.78	-0.35	5.51e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs4731207	0.698	rs6966415	chr7:124531469	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.67	-9.0	-0.44	1.87e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.5	8.12	0.41	9.57e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2814982	0.605	rs80254589	chr6:34478514	C/T	cg14254433	chr6:34482411	PACSIN1	-0.84	-8.54	-0.43	5.1e-16	Cholesterol, total;Total cholesterol levels;
CRC	trans	rs6956675	1.000	rs10280052	chr7:62600311	C/T	cg01314568	chr7:57830625	NA	-0.69	-9.4	-0.46	9.55e-19	Obesity-related traits;
CRC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg11279151	chr3:101281821	RG9MTD1	0.71	8.98	0.44	2.2e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.47	-6.01	-0.31	4.95e-9	Aortic root size;
CRC	cis	rs995000	0.895	rs1472257	chr1:63042126	A/G	cg19896129	chr1:63156450	NA	-0.43	-6.7	-0.35	8.85e-11	Triglyceride levels;
CRC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.66	-0.43	2.23e-16	Bipolar disorder;
CRC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.68	-12.57	-0.57	7.32e-30	Breast cancer;
CRC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg14530993	chr4:882597	GAK	0.82	7.83	0.4	6.7e-14	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.78	13.37	0.59	7.09e-33	Adiposity;
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg26354017	chr1:205819088	PM20D1	0.43	5.98	0.31	5.93e-9	Parkinson's disease;
CRC	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs554111	0.891	rs531044	chr1:21057011	T/C	cg08890418	chr1:21044141	KIF17	0.32	6.05	0.32	3.88e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg03233332	chr7:66118400	NA	0.43	5.78	0.3	1.71e-8	Aortic root size;
CRC	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.37	-5.76	-0.3	1.9e-8	Obesity-related traits;
CRC	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.6	-7.48	-0.38	6.93e-13	Hypospadias;
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02421172	chr7:1938701	MAD1L1	-0.42	-5.82	-0.31	1.38e-8	Bipolar disorder;
CRC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.73	0.35	7.36e-11	Body mass index;
CRC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.96	-0.31	6.65e-9	Gut microbiome composition (summer);
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg19913688	chr11:428466	ANO9	-0.69	-7.15	-0.37	5.67e-12	Body mass index;
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	0.7	9.4	0.46	9.47e-19	Alzheimer's disease;
CRC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.7	10.28	0.49	1.1e-21	Corneal astigmatism;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.72	12.11	0.56	3.75e-28	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.2	0.64	6.75e-40	Colorectal cancer;
CRC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.51	-7.93	-0.4	3.55e-14	Neurofibrillary tangles;
CRC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.3	0.42	2.78e-15	Coffee consumption (cups per day);
CRC	cis	rs3889199	0.887	rs7522429	chr1:59661437	G/T	cg25881383	chr1:59680599	NA	-0.39	-6.23	-0.32	1.41e-9	Pulse pressure;
CRC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.96	0.66	7.52e-43	Platelet count;
CRC	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.67	7.42	0.38	9.91e-13	Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg20811857	chr17:78079795	GAA	0.45	6.69	0.35	9.42e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg26061582	chr7:22766209	IL6	0.38	5.83	0.31	1.35e-8	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11614195	chr16:2265446	PGP	0.43	6.14	0.32	2.41e-9	Response to antipsychotic treatment;
CRC	cis	rs77861329	1.000	rs352151	chr3:52210272	C/G	cg08692210	chr3:52188851	WDR51A	0.84	7.86	0.4	5.6e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2745967	0.765	rs2785647	chr1:208079715	G/A	cg09788693	chr1:208063733	CD34	0.42	6.42	0.33	4.67e-10	Resting heart rate;
CRC	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.51	-8.51	-0.42	6.14e-16	Congenital heart disease (maternal effect);
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.39	5.78	0.3	1.7e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11608447	chr9:38620746	ANKRD18A;C9orf122	0.38	6.3	0.33	9.48e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.36	5.7	0.3	2.73e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg18099408	chr3:52552593	STAB1	0.33	5.67	0.3	3.2e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.62	9.92	0.48	1.87e-20	Aortic root size;
CRC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.47	-7.94	-0.4	3.28e-14	Type 2 diabetes;
CRC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg00579200	chr11:133705235	NA	-0.4	-5.75	-0.3	2e-8	Childhood ear infection;
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.8	-13.35	-0.59	8.38e-33	Menarche (age at onset);
CRC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.85	-12.36	-0.56	4.43e-29	Platelet distribution width;
CRC	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg09904177	chr6:26538194	HMGN4	-0.45	-6.28	-0.33	1.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.37	6.61	0.34	1.56e-10	Lung cancer;
CRC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg26566898	chr11:117069891	TAGLN	0.29	6.09	0.32	3.1e-9	Blood protein levels;
CRC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.44	6.9	0.36	2.61e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12273811	chr6:28175739	NA	0.63	8.07	0.41	1.35e-14	Parkinson's disease;
CRC	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.71	-0.3	2.56e-8	Male-pattern baldness;
CRC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.54	-7.63	-0.39	2.58e-13	Corneal structure;
CRC	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.08	-0.36	8.77e-12	Putamen volume;
CRC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.53	7.93	0.4	3.51e-14	Body mass index;
CRC	cis	rs7635838	0.892	rs9814907	chr3:11438645	G/A	cg00170343	chr3:11313890	ATG7	0.41	6.28	0.33	1.08e-9	HDL cholesterol;
CRC	cis	rs3812762	0.912	rs11042058	chr11:8763815	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.02	-0.32	4.62e-9	Hypospadias;
CRC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.46	6.41	0.33	5.06e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.75	0.35	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.94	0.52	5.62e-24	Prudent dietary pattern;
CRC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-8.11	-0.41	1.01e-14	IgG glycosylation;
CRC	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.45	-7.61	-0.39	2.87e-13	Schizophrenia;
CRC	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.75	-10.31	-0.49	9.05e-22	Systemic lupus erythematosus;
CRC	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg12072164	chr19:44306565	LYPD5	-0.45	-7.15	-0.37	5.71e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.82	0.35	4.3e-11	Melanoma;
CRC	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6735179	0.565	rs733376	chr2:1751958	C/A	cg19300414	chr2:1746591	PXDN	0.46	7.85	0.4	6.01e-14	Response to antipsychotic treatment;
CRC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.57	-9.96	-0.48	1.37e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.79	11.38	0.53	1.57e-25	Neutrophil percentage of white cells;
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.23	-0.32	1.45e-9	Total body bone mineral density;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.4	-0.33	5.35e-10	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00578828	chr5:131826934	IRF1	0.48	6.61	0.34	1.52e-10	Response to antipsychotic treatment;
CRC	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.62	9.95	0.48	1.44e-20	Corneal astigmatism;
CRC	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.74	-12.54	-0.57	9.67e-30	Eosinophil percentage of white cells;
CRC	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.59	7.88	0.4	4.77e-14	Bipolar disorder;
CRC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.47	7.28	0.37	2.51e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg10876282	chr6:28092338	ZSCAN16	0.5	6.6	0.34	1.61e-10	Cardiac Troponin-T levels;
CRC	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg11130432	chr3:121712080	ILDR1	-0.5	-6.18	-0.32	1.89e-9	Multiple sclerosis;
CRC	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.89	-16.85	-0.68	2.31e-46	Hip circumference;
CRC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.54	7.79	0.39	9.09e-14	Resting heart rate;
CRC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg21770322	chr7:97807741	LMTK2	-0.53	-8.67	-0.43	2.07e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.61	8.94	0.44	2.96e-17	Lymphocyte counts;
CRC	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg19812747	chr11:111475976	SIK2	-0.46	-7.39	-0.38	1.25e-12	Primary sclerosing cholangitis;
CRC	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg06632207	chr12:54070931	ATP5G2	0.39	6.71	0.35	8.61e-11	Height;
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg15382696	chr6:118971807	C6orf204	0.59	7.18	0.37	4.64e-12	Diastolic blood pressure;
CRC	cis	rs7572733	0.592	rs4389332	chr2:198477620	G/T	cg10820045	chr2:198174542	NA	0.35	6.38	0.33	6.12e-10	Dermatomyositis;
CRC	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg15903213	chr10:43522190	NA	0.72	5.77	0.3	1.85e-8	Pediatric bone mineral content (radius);
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg16606324	chr3:10149918	C3orf24	-0.71	-9.72	-0.47	8.6e-20	Alzheimer's disease;
CRC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.51	-0.57	1.2e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.47	7.02	0.36	1.3e-11	Birth weight;
CRC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.85	0.44	5.32e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg03060546	chr3:49711283	APEH	0.4	5.61	0.3	4.38e-8	Parkinson's disease;
CRC	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg23100626	chr2:96804247	ASTL	0.27	7.1	0.36	7.79e-12	Diastolic blood pressure;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg25369027	chr8:103666178	KLF10	-0.43	-6.29	-0.33	1.03e-9	Daytime sleep phenotypes;
CRC	cis	rs10450586	0.932	rs10450562	chr11:27310006	A/G	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.38	5.81	0.31	1.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg09127314	chr1:152161683	NA	-0.49	-6.35	-0.33	7.27e-10	Atopic dermatitis;
CRC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.23	14.38	0.62	9.77e-37	Diabetic kidney disease;
CRC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.48	-0.34	3.43e-10	Renal cell carcinoma;
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23378565	chr7:2036160	MAD1L1	-0.4	-5.67	-0.3	3.18e-8	Neuroticism;
CRC	cis	rs1524976	1.000	rs11719771	chr3:65481987	G/T	cg16238336	chr3:65465873	MAGI1	-0.52	-7.16	-0.37	5.43e-12	PR interval;
CRC	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-0.98	-10.19	-0.49	2.32e-21	Prostate cancer;
CRC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02725872	chr8:58115012	NA	-0.38	-6.48	-0.34	3.41e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.6	9.12	0.45	7.86e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25858261	chr10:12085058	UPF2	0.49	7.45	0.38	8.56e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.49	6.34	0.33	7.65e-10	Lymphocyte counts;
CRC	cis	rs7932354	0.502	rs10769244	chr11:47182368	A/G	cg03339077	chr11:47165057	C11orf49	-0.48	-6.56	-0.34	2.09e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg04004882	chr2:215674386	BARD1	-0.56	-6.84	-0.35	3.91e-11	Neuroblastoma;
CRC	cis	rs4594175	0.962	rs72688734	chr14:51634618	T/C	cg23942311	chr14:51606299	NA	0.6	9.29	0.46	2.24e-18	Cancer;
CRC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.5	-9.85	-0.48	3.03e-20	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02371369	chr7:102074135	ORAI2	0.44	6.81	0.35	4.52e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.74	-0.39	1.27e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6546324	0.625	rs2861644	chr2:67799964	A/G	cg15745817	chr2:67799979	NA	-0.55	-9.71	-0.47	9.4e-20	Endometriosis;
CRC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.63	10.26	0.49	1.34e-21	Aortic root size;
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-7.42	-0.38	9.96e-13	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10120645	chr8:125486635	RNF139	0.42	6.78	0.35	5.69e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.99	-0.31	5.37e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	8.93	0.44	3.18e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.55	8.54	0.43	5.13e-16	Methadone dose in opioid dependence;
CRC	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.47	6.99	0.36	1.58e-11	Crohn's disease;
CRC	cis	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg26958806	chr6:27640298	NA	0.78	5.91	0.31	8.63e-9	Depression;
CRC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.52	-7.32	-0.37	1.89e-12	Fibrinogen levels;
CRC	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.65	9.41	0.46	9.1e-19	Blood protein levels;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.96	-0.31	6.52e-9	Lung cancer;
CRC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg02269571	chr22:50332266	NA	0.47	6.52	0.34	2.63e-10	Schizophrenia;
CRC	cis	rs375066	0.623	rs7259647	chr19:44353383	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.9	-0.31	9.28e-9	Gout;Renal underexcretion gout;
CRC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	11.97	0.55	1.2100000000000001e-27	Schizophrenia;
CRC	trans	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	6.05	0.32	4.01e-9	Aortic root size;
CRC	cis	rs9322817	0.691	rs2499663	chr6:105300570	A/G	cg02098413	chr6:105308735	HACE1	-0.41	-7.96	-0.4	2.88e-14	Thyroid stimulating hormone;
CRC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.48	-0.34	3.31e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.42	-5.93	-0.31	7.55e-9	Subjective well-being;
CRC	cis	rs8105895	0.935	rs7252023	chr19:22245646	C/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12292205	chr6:26970375	C6orf41	-0.48	-6.7	-0.35	9.22e-11	Intelligence (multi-trait analysis);
CRC	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.64	12.88	0.58	5.26e-31	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-6.12	-0.32	2.63e-9	Cognitive function;
CRC	trans	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg26043149	chr18:55253948	FECH	-0.51	-7.78	-0.39	9.59e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.62	14.39	0.62	9.05e-37	Airflow obstruction;
CRC	cis	rs9847710	1.000	rs4687697	chr3:53090490	C/T	cg04503182	chr3:53078218	SFMBT1	-0.45	-7.18	-0.37	4.53e-12	Ulcerative colitis;
CRC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg00343986	chr7:65444356	GUSB	0.49	7.01	0.36	1.32e-11	Calcium levels;
CRC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.21	-0.32	1.56e-9	Bipolar disorder;
CRC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.58	-7.32	-0.37	1.91e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.14	-0.32	2.4e-9	Aortic root size;
CRC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg07134254	chr20:33865797	NA	-0.44	-5.7	-0.3	2.71e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs9287719	0.601	rs759401	chr2:10709922	G/A	cg00105475	chr2:10696890	NA	0.48	7.39	0.38	1.23e-12	Prostate cancer;
CRC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.53	7.75	0.39	1.15e-13	Colorectal cancer;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14577476	chr17:49337432	MBTD1;UTP18	-0.36	-6.06	-0.32	3.75e-9	Obesity-related traits;
CRC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.43	-0.42	1.12e-15	Monocyte percentage of white cells;
CRC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.14	-0.52	1.17e-24	Platelet distribution width;
CRC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.63	7.17	0.37	4.99e-12	Vitiligo;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.79	-13.0	-0.58	1.84e-31	Obesity-related traits;
CRC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	0.92	17.18	0.69	1.15e-47	Height;
CRC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.46	-5.89	-0.31	9.71e-9	Gut microbiome composition (summer);
CRC	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.61	-6.78	-0.35	5.75e-11	Coronary artery disease;
CRC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.42	-7.18	-0.37	4.71e-12	Breast cancer;
CRC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.42	6.79	0.35	5.35e-11	Resting heart rate;
CRC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.89	-0.31	9.37e-9	Schizophrenia;
CRC	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.46	-0.34	3.79e-10	Vitamin D levels;
CRC	cis	rs2637266	0.514	rs11001862	chr10:78474147	A/G	cg18941641	chr10:78392320	NA	0.34	6.0	0.31	5.3300000000000004e-09	Pulmonary function;
CRC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.8	14.26	0.62	3.07e-36	Breast cancer;
CRC	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.04	-0.32	4.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg19540316	chr13:113622750	MCF2L	0.47	6.12	0.32	2.7e-9	Breast cancer;
CRC	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.43	6.52	0.34	2.59e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.64	10.15	0.49	2.99e-21	Mood instability;
CRC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.67	9.63	0.47	1.65e-19	Lung cancer;
CRC	cis	rs4731207	0.596	rs10276834	chr7:124607549	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.66	10.99	0.52	4e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.24	6.67	0.35	1.06e-10	Type 2 diabetes;
CRC	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.56	10.13	0.49	3.61e-21	Menarche (age at onset);
CRC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.66	-10.52	-0.5	1.67e-22	Obesity-related traits;
CRC	cis	rs7605827	0.897	rs7564514	chr2:15654808	G/A	cg19274914	chr2:15703543	NA	0.4	6.0	0.31	5.16e-9	Educational attainment (years of education);
CRC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.81	13.32	0.59	1.11e-32	Menopause (age at onset);
CRC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-7.17	-0.37	5.11e-12	HDL cholesterol;
CRC	cis	rs847649	0.621	rs2222539	chr7:102674786	G/A	cg18108683	chr7:102477205	FBXL13	0.54	8.48	0.42	7.88e-16	Morning vs. evening chronotype;
CRC	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.49	8.56	0.43	4.3e-16	Testicular germ cell tumor;
CRC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.48	6.52	0.34	2.63e-10	Schizophrenia;
CRC	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg02811702	chr13:24901961	NA	0.48	6.6	0.34	1.68e-10	Obesity-related traits;
CRC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.6	-8.4	-0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	7.3	0.37	2.18e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.47	-7.61	-0.39	2.87e-13	Platelet count;
CRC	trans	rs77926410	0.929	rs12826560	chr12:10532965	T/C	cg23926866	chr1:1058658	NA	0.52	6.11	0.32	2.78e-9	Mean corpuscular volume;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.68e-19	Corneal astigmatism;
CRC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.59	-9.11	-0.45	8.37e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.27	-0.33	1.14e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg04077850	chr5:125800366	GRAMD3	0.38	6.44	0.33	4.14e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg20203395	chr5:56204925	C5orf35	0.69	8.31	0.42	2.5e-15	Initial pursuit acceleration;
CRC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	0.93	17.79	0.7	4.27e-50	Height;
CRC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17507749	chr15:85114479	UBE2QP1	0.64	9.16	0.45	5.61e-18	Schizophrenia;
CRC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22433210	chr17:43662623	NA	-0.58	-7.08	-0.36	8.55e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg21856205	chr7:94953877	PON1	-0.51	-6.66	-0.34	1.16e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.65	0.3	3.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	8.15	0.41	7.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.21	-0.37	3.86e-12	Bipolar disorder;
CRC	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.59	-7.24	-0.37	3.15e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.7	0.51	3.88e-23	Cognitive function;
CRC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.91	0.72	1.7e-54	Cognitive ability;
CRC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.44	-0.38	9.1e-13	Joint mobility (Beighton score);
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.57	-0.34	1.94e-10	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01855760	chr4:68567075	LOC550112;UBA6	0.51	7.3	0.37	2.23e-12	Response to antipsychotic treatment;
CRC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.63	-9.24	-0.45	3.08e-18	Height;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	6.53	0.34	2.51e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.98	-0.55	1.12e-27	Coffee consumption (cups per day);
CRC	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg16591659	chr17:78472290	NA	0.41	5.97	0.31	6.24e-9	Fractional excretion of uric acid;
CRC	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-11.07	-0.52	1.96e-24	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.63	9.23	0.45	3.27e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.17	0.32	1.96e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.67	10.24	0.49	1.52e-21	Corneal astigmatism;
CRC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.05	-0.32	3.87e-9	Tonsillectomy;
CRC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.85	-0.44	5.58e-17	HDL cholesterol;
CRC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.6	-0.39	3.03e-13	Height;
CRC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.48	8.23	0.41	4.5e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1256061	0.624	rs944047	chr14:64700292	C/T	cg23250157	chr14:64679961	SYNE2	0.46	7.13	0.37	6.4e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	15.05	0.64	2.65e-39	Intelligence (multi-trait analysis);
CRC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg19980929	chr12:42632907	YAF2	-0.41	-6.25	-0.33	1.27e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg21251018	chr6:28226885	NKAPL	0.47	7.07	0.36	9.43e-12	Cardiac Troponin-T levels;
CRC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg08200770	chr17:80723486	TBCD	-0.5	-7.65	-0.39	2.3e-13	Glycated hemoglobin levels;
CRC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.4	-5.77	-0.3	1.79e-8	Response to metformin (IC50);
CRC	trans	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg01505111	chr6:125621795	HDDC2	0.4	6.42	0.33	4.73e-10	DNA methylation (variation);
CRC	cis	rs877282	0.741	rs35865720	chr10:753022	G/A	cg17470449	chr10:769945	NA	0.6	7.76	0.39	1.06e-13	Uric acid levels;
CRC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.57	-0.39	3.77e-13	Eye color traits;
CRC	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg05527609	chr1:210001259	C1orf107	-0.57	-6.21	-0.32	1.59e-9	Red blood cell count;
CRC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.37	-0.33	6.44e-10	Monocyte percentage of white cells;
CRC	cis	rs1223397	0.651	rs2439535	chr6:13305822	C/T	cg20827128	chr6:13274284	PHACTR1	0.4	6.01	0.31	4.87e-9	Blood pressure;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg12564285	chr5:131593104	PDLIM4	0.47	9.02	0.45	1.65e-17	Breast cancer;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg09877947	chr5:131593287	PDLIM4	0.43	7.06	0.36	9.99e-12	Acylcarnitine levels;
CRC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.84	-8.92	-0.44	3.35e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9341808	0.667	rs7745301	chr6:80922561	G/T	cg08355045	chr6:80787529	NA	0.33	5.69	0.3	2.83e-8	Sitting height ratio;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22783262	chr22:45098346	PRR5-ARHGAP8;PRR5	-0.4	-6.31	-0.33	8.96e-10	Aortic root size;
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg04969067	chr8:143858791	LYNX1	0.36	6.01	0.31	4.85e-9	Urinary tract infection frequency;
CRC	trans	rs9813712	0.597	rs10934931	chr3:129980208	C/T	cg23942268	chr17:6347992	FAM64A	-0.42	-6.13	-0.32	2.5e-9	Response to amphetamines;
CRC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.51	7.69	0.39	1.76e-13	Prostate cancer;
CRC	cis	rs7487075	0.786	rs7316127	chr12:46674249	A/C	cg22049899	chr12:47219821	SLC38A4	0.32	5.83	0.31	1.33e-8	Itch intensity from mosquito bite;
CRC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.82	-13.01	-0.58	1.66e-31	Blood trace element (Zn levels);
CRC	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.74	9.84	0.48	3.35e-20	Prostate cancer;
CRC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.8	11.88	0.55	2.56e-27	Mean platelet volume;
CRC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.79	-12.78	-0.58	1.23e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs990171	0.954	rs6543137	chr2:103065908	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.32e-9	Lymphocyte counts;
CRC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.16	0.41	7.39e-15	Lung cancer;
CRC	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.02	-0.4	1.86e-14	Body mass index;
CRC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.01	-0.31	4.8e-9	Bipolar disorder;
CRC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.6	-7.51	-0.38	5.76e-13	Vitiligo;
CRC	cis	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg02972257	chr16:68554789	NA	0.44	5.61	0.3	4.28e-8	Colorectal cancer;
CRC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg16797656	chr11:68205561	LRP5	-0.39	-6.23	-0.32	1.46e-9	Bone mineral density (spine);
CRC	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.51	6.71	0.35	8.58e-11	Personality dimensions;
CRC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.64	9.82	0.48	3.9e-20	Response to diuretic therapy;
CRC	cis	rs1261795	1.000	rs1261795	chr14:21505628	C/T	cg04957377	chr14:21507259	NA	-0.31	-5.73	-0.3	2.23e-8	Pediatric bone mineral content (radius);
CRC	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.59	7.8	0.4	8.21e-14	Mammographic density (dense area);
CRC	cis	rs7212590	1.000	rs7212590	chr17:57885709	C/T	cg10252138	chr17:58120427	NA	-0.54	-5.73	-0.3	2.32e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg11843238	chr5:131593191	PDLIM4	0.33	6.31	0.33	9.26e-10	Blood metabolite levels;
CRC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.91	-15.92	-0.66	1.01e-42	Cognitive function;
CRC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-7.81	-0.4	7.69e-14	Vitiligo;
CRC	cis	rs2630709	0.562	rs3102959	chr2:8461625	C/G	cg12167548	chr2:8464763	NA	0.33	6.25	0.33	1.26e-9	Monocyte percentage of white cells;
CRC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.66	-0.39	2.09e-13	Colorectal cancer;
CRC	cis	rs6662572	0.737	rs74523130	chr1:46599619	C/T	cg08644498	chr1:46502608	NA	0.44	6.99	0.36	1.57e-11	Blood protein levels;
CRC	trans	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg22110888	chr17:80059540	CCDC57	0.38	6.01	0.31	5.06e-9	Life satisfaction;
CRC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	trans	rs17150703	0.630	rs12545481	chr8:9747377	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	6.49	0.34	3.2e-10	Obesity (early onset extreme);
CRC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg06219103	chr11:63990595	FERMT3	-0.44	-6.88	-0.35	3.12e-11	Platelet count;
CRC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13606994	chr1:44402422	ARTN	-0.34	-5.76	-0.3	1.94e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg23461800	chr14:103021989	NA	0.69	7.84	0.4	6.5e-14	Platelet count;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.55	-7.83	-0.4	6.84e-14	Menopause (age at onset);
CRC	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg00603274	chr11:61596626	FADS2	-0.45	-6.49	-0.34	3.21e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.47	-0.46	5.55e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg25344623	chr2:136566232	LCT	0.33	5.98	0.31	5.97e-9	Mosquito bite size;
CRC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.7	-8.17	-0.41	6.68e-15	Obesity-related traits;
CRC	cis	rs1364705	1.000	rs13262685	chr8:120226145	A/G	cg27215916	chr8:120218354	NA	-0.39	-5.9	-0.31	8.85e-9	Hippocampal atrophy;
CRC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg00677455	chr12:58241039	CTDSP2	0.55	8.08	0.41	1.24e-14	Intelligence (multi-trait analysis);
CRC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04731861	chr2:219085781	ARPC2	0.33	6.95	0.36	2.01e-11	Colorectal cancer;
CRC	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg23167259	chr10:102495509	NA	-0.47	-6.35	-0.33	6.97e-10	Alzheimer's disease;
CRC	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.63	-0.3	3.86e-8	Daytime sleep phenotypes;
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg09264619	chr17:80180166	NA	-0.35	-5.98	-0.31	5.97e-9	Life satisfaction;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08767708	chr16:73082503	ZFHX3	0.39	6.0	0.31	5.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.62	-12.06	-0.55	5.36e-28	Intelligence (multi-trait analysis);
CRC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.29	-5.9	-0.31	9.03e-9	Schizophrenia;
CRC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.21	0.32	1.63e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg01444801	chr10:135216882	MTG1	-0.55	-7.82	-0.4	7.4e-14	Systemic lupus erythematosus;
CRC	cis	rs9549328	0.589	rs34144481	chr13:113617322	T/G	cg25790453	chr13:113633590	MCF2L	0.44	7.56	0.38	3.94e-13	Systolic blood pressure;
CRC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.48	0.34	3.44e-10	Axial length;
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.63	-7.29	-0.37	2.29e-12	Parkinson's disease;
CRC	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.55	8.12	0.41	9.36e-15	Night sleep phenotypes;
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg22638593	chr5:131593259	PDLIM4	0.38	6.24	0.33	1.33e-9	Breast cancer;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg23161317	chr6:28129485	ZNF389	0.45	6.51	0.34	2.82e-10	Parkinson's disease;
CRC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.47	-7.01	-0.36	1.35e-11	Tonsillectomy;
CRC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.8	-8.59	-0.43	3.55e-16	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05592363	chr5:78908495	PAPD4	0.39	6.06	0.32	3.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs9462027	0.628	rs2744957	chr6:34618516	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.31	-0.33	9.16e-10	Systemic lupus erythematosus;
CRC	cis	rs174601	0.721	rs174530	chr11:61546592	A/G	cg00603274	chr11:61596626	FADS2	-0.41	-6.14	-0.32	2.43e-9	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.51	7.96	0.4	2.89e-14	Colorectal cancer;
CRC	cis	rs10795061	0.576	rs10904074	chr10:3710962	G/A	cg22632523	chr10:3711048	NA	0.6	7.53	0.38	5.03e-13	Subjective well-being;
CRC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.65	8.7	0.43	1.65e-16	Alcohol dependence;
CRC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06634786	chr22:41940651	POLR3H	-0.41	-5.61	-0.3	4.25e-8	Vitiligo;
CRC	trans	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg16606324	chr3:10149918	C3orf24	0.56	6.82	0.35	4.44e-11	Alzheimer's disease;
CRC	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.95	-12.37	-0.56	4.11e-29	Exhaled nitric oxide output;
CRC	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.84	-10.53	-0.5	1.61e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.67	9.15	0.45	6.18e-18	Alcohol dependence;
CRC	cis	rs727505	0.866	rs66852389	chr7:124724348	T/A	cg23710748	chr7:124431027	NA	-0.72	-12.33	-0.56	5.81e-29	Lewy body disease;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.34	0.38	1.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.36	5.94	0.31	7.16e-9	Prostate-specific antigen levels;
CRC	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg25019722	chr6:37503610	NA	-0.38	-6.73	-0.35	7.65e-11	Cognitive performance;
CRC	cis	rs10991814	0.920	rs7852934	chr9:94112399	T/C	cg14446406	chr9:93919335	NA	0.59	6.66	0.34	1.13e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.82	-10.69	-0.51	4.23e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.55	-5.7	-0.3	2.72e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.27e-46	Breast cancer;
CRC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.04	-0.52	2.56e-24	Extrinsic epigenetic age acceleration;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg26851410	chr19:2785307	THOP1	0.43	6.05	0.32	4.04e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.58	7.18	0.37	4.57e-12	Mean platelet volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12593303	chr2:54785406	SPTBN1	0.46	6.53	0.34	2.42e-10	Response to antipsychotic treatment;
CRC	cis	rs2745967	0.715	rs2796254	chr1:208069137	G/A	cg09788693	chr1:208063733	CD34	0.45	6.78	0.35	5.44e-11	Resting heart rate;
CRC	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.62	12.35	0.56	4.76e-29	Weight;
CRC	cis	rs970548	1.000	rs12257549	chr10:46029631	C/T	cg15590007	chr10:45870220	ALOX5	0.47	5.91	0.31	8.38e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.63	9.23	0.45	3.31e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4766646	0.619	rs7304559	chr12:110289501	T/G	cg01252219	chr12:110302105	GLTP	0.4	6.08	0.32	3.38e-9	Metabolite levels (MHPG);
CRC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg15147215	chr3:52552868	STAB1	-0.42	-5.94	-0.31	7.43e-9	Bipolar disorder;
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg02683197	chr6:28174875	NA	-0.62	-7.45	-0.38	8.28e-13	Parkinson's disease;
CRC	cis	rs12024301	0.557	rs12048127	chr1:183610804	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.97	-0.52	4.45e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03114442	chr13:52378179	DHRS12	0.45	6.15	0.32	2.19e-9	Anxiety disorder;
CRC	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.6	8.44	0.42	1.02e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.7	10.9	0.52	8.12e-24	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	1.06	12.52	0.57	1.15e-29	Obesity-related traits;
CRC	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg24848339	chr3:12840334	CAND2	0.31	5.8	0.3	1.6e-8	QRS complex (12-leadsum);
CRC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-7.16	-0.37	5.15e-12	Colorectal cancer;
CRC	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg23100626	chr2:96804247	ASTL	0.27	7.07	0.36	9.2e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg26162295	chr17:38119207	GSDMA	-0.35	-5.91	-0.31	8.71e-9	Myeloid white cell count;
CRC	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.47	-8.92	-0.44	3.28e-17	Hepatitis;
CRC	cis	rs62432291	0.681	rs431205	chr6:159662499	A/G	cg14500486	chr6:159655392	FNDC1	-0.76	-10.24	-0.49	1.53e-21	Joint mobility (Beighton score);
CRC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg04289385	chr6:36355825	ETV7	0.45	5.65	0.3	3.56e-8	Platelet distribution width;
CRC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.66	10.45	0.5	2.82e-22	Systolic blood pressure;
CRC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11645453	chr3:52864694	ITIH4	-0.42	-8.07	-0.41	1.32e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg03469862	chr11:68924853	NA	0.46	6.14	0.32	2.33e-9	Blond vs. brown hair color;
CRC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.6	-0.3	4.44e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.64	-9.4	-0.46	9.62e-19	Type 2 diabetes;
CRC	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-24.6	-0.8	1.51e-76	Exhaled nitric oxide output;
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.91	-0.36	2.47e-11	Electroencephalogram traits;
CRC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg13606994	chr1:44402422	ARTN	-0.33	-5.61	-0.3	4.2e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6545883	0.524	rs7561697	chr2:61519165	G/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.69	-0.39	1.73e-13	Tuberculosis;
CRC	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.45	-7.09	-0.36	8.13e-12	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.43	6.76	0.35	6.23e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.71	9.72	0.47	8.73e-20	Alzheimer's disease;
CRC	trans	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.92	-0.36	2.32e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.37	-0.42	1.72e-15	Height;
CRC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.67	9.74	0.47	7.45e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.79	-0.35	5.09e-11	Coronary artery disease;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.51	-7.58	-0.39	3.52e-13	Intelligence (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.52	-9.81	-0.48	4.19e-20	Renal cell carcinoma;
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg02570054	chr12:49717017	TROAP	-0.54	-6.19	-0.32	1.77e-9	Hirschsprung disease;
CRC	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg19773385	chr1:10388646	KIF1B	-0.58	-8.04	-0.41	1.58e-14	Hepatocellular carcinoma;
CRC	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.66	-8.87	-0.44	4.61e-17	Blood pressure (smoking interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14272175	chr3:58318960	PXK	-0.42	-6.22	-0.32	1.53e-9	Myopia (pathological);
CRC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	6.2	0.32	1.74e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.64	-9.23	-0.45	3.5e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322817	0.691	rs9391249	chr6:105343433	T/A	cg02098413	chr6:105308735	HACE1	0.46	9.14	0.45	6.64e-18	Thyroid stimulating hormone;
CRC	cis	rs62408225	1.000	rs62408233	chr6:90976609	G/A	cg06866423	chr6:90926672	BACH2	0.5	8.15	0.41	7.56e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.62	-7.08	-0.36	8.68e-12	Ulcerative colitis;
CRC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-5.97	-0.31	6.01e-9	Height;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg20011051	chr10:105881722	C10orf78	0.61	6.42	0.33	4.67e-10	Body mass index;
CRC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg14541582	chr5:601475	NA	-0.36	-7.3	-0.37	2.21e-12	Obesity-related traits;
CRC	cis	rs17152411	0.895	rs7080475	chr10:126585767	A/G	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.23	6.32	0.33	8.37e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.57	9.29	0.46	2.21e-18	Migraine;
CRC	cis	rs995000	0.899	rs10889356	chr1:63155349	G/A	cg19896129	chr1:63156450	NA	0.41	5.96	0.31	6.67e-9	Triglyceride levels;
CRC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.04	17.05	0.68	3.79e-47	IgG glycosylation;
CRC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg10589385	chr1:150898437	SETDB1	0.32	6.51	0.34	2.73e-10	Melanoma;
CRC	cis	rs4731207	0.596	rs12113770	chr7:124589740	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21790971	chr4:54244117	FIP1L1	0.56	7.38	0.38	1.34e-12	Thyroid stimulating hormone;
CRC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-9.86	-0.48	2.87e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.71	12.29	0.56	8.27e-29	Gout;
CRC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg24562669	chr7:97807699	LMTK2	-0.77	-16.88	-0.68	1.72e-46	Breast cancer;
CRC	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.94	15.83	0.66	2.25e-42	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.7	0.3	2.72e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg15845792	chr6:28175446	NA	0.63	9.35	0.46	1.43e-18	Cardiac Troponin-T levels;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00706505	chr3:49142215	QARS	0.41	5.91	0.31	8.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg23127183	chr11:57508653	C11orf31	-0.52	-6.83	-0.35	4.17e-11	Schizophrenia;
CRC	cis	rs4509693	0.722	rs10883536	chr10:102489331	A/C	cg23167259	chr10:102495509	NA	-0.43	-5.68	-0.3	3.02e-8	Alzheimer's disease;
CRC	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg25190513	chr12:123201362	GPR109B	-0.49	-6.27	-0.33	1.11e-9	Adiponectin levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25937854	chr12:120150414	CIT	0.35	5.96	0.31	6.53e-9	Aortic root size;
CRC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg19582491	chr16:67682965	RLTPR	-0.56	-6.8	-0.35	4.8e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg09654669	chr8:57350985	NA	-0.44	-5.86	-0.31	1.12e-8	Obesity-related traits;
CRC	cis	rs9908102	0.740	rs4792311	chr17:12915009	A/G	cg26162695	chr17:12921313	ELAC2	-0.45	-6.04	-0.32	4.25e-9	Schizophrenia;
CRC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.44	6.31	0.33	8.89e-10	Morning vs. evening chronotype;
CRC	cis	rs10986311	0.775	rs1984001	chr9:127137801	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.45	0.33	4.07e-10	Vitiligo;
CRC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11617147	chr7:105517689	ATXN7L1	0.38	6.01	0.31	4.87e-9	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.78e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg10729496	chr3:10149963	C3orf24	-0.51	-6.74	-0.35	7.29e-11	Alzheimer's disease;
CRC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg24849736	chr1:201084428	NA	0.65	12.36	0.56	4.37e-29	Permanent tooth development;
CRC	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.58	8.3	0.42	2.8e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.89	-0.36	2.79e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs12692738	0.526	rs355857	chr2:165629214	A/G	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.58	0.34	1.91e-10	Subjective well-being;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.48	-0.34	3.31e-10	Total body bone mineral density;
CRC	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg16989719	chr2:238392110	NA	-0.38	-7.57	-0.38	3.88e-13	Prostate cancer;
CRC	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.3	0.49	9.79e-22	Corneal astigmatism;
CRC	cis	rs12760731	0.920	rs61109337	chr1:178484674	A/G	cg00404053	chr1:178313656	RASAL2	0.72	8.02	0.4	1.89e-14	Obesity-related traits;
CRC	cis	rs1519814	1.000	rs7000609	chr8:121106264	C/T	cg22335954	chr8:121166405	COL14A1	0.57	7.19	0.37	4.26e-12	Breast cancer;
CRC	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg14515779	chr1:101123966	NA	0.38	7.03	0.36	1.21e-11	Monocyte count;
CRC	cis	rs9969804	0.747	rs7021624	chr9:95531220	C/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.73	-0.3	2.23e-8	Height;
CRC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.69	11.08	0.52	1.79e-24	Mean corpuscular hemoglobin;
CRC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.34	6.97	0.36	1.74e-11	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00415263	chr7:26331488	SNX10	0.43	5.97	0.31	6.27e-9	Anxiety disorder;
CRC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.07	9.87	0.48	2.78e-20	Diabetic retinopathy;
CRC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.26e-13	Schizophrenia;
CRC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.59	9.45	0.46	6.64e-19	Gestational age at birth (maternal effect);
CRC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg15845792	chr6:28175446	NA	-0.47	-6.39	-0.33	5.73e-10	Systemic lupus erythematosus;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00323100	chr4:40059856	N4BP2;LOC344967	-0.43	-6.74	-0.35	7.3e-11	Aortic root size;
CRC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.06	0.36	9.75e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.73	12.0	0.55	9.38e-28	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
CRC	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.4	-5.64	-0.3	3.72e-8	Blood metabolite levels;
CRC	cis	rs6747952	0.899	rs2121404	chr2:239083826	A/G	cg07480446	chr2:239069576	NA	-0.37	-6.98	-0.36	1.68e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.78	10.04	0.48	7.01e-21	Iron status biomarkers;
CRC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.45	-6.26	-0.33	1.18e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.5	8.55	0.43	4.83e-16	Dupuytren's disease;
CRC	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.93	-0.4	3.52e-14	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.75	14.04	0.61	2.11e-35	Prudent dietary pattern;
CRC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg18404041	chr3:52824283	ITIH1	-0.41	-7.65	-0.39	2.25e-13	Schizophrenia;
CRC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.64	0.6	6.82e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg05207973	chr5:176823642	SLC34A1	-0.49	-7.48	-0.38	6.86e-13	Hemoglobin concentration;Hematocrit;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06102777	chr11:63382095	PLA2G16	-0.41	-6.39	-0.33	5.55e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.39	5.95	0.31	6.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg15845792	chr6:28175446	NA	0.77	6.27	0.33	1.12e-9	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17362109	chr3:194981274	C3orf21	0.46	6.16	0.32	2.11e-9	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05526438	chr5:174350112	NA	-0.39	-6.48	-0.34	3.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	cis	rs6088813	1.000	rs2248393	chr20:33926103	C/G	cg14752227	chr20:34000481	UQCC	0.37	5.82	0.31	1.42e-8	Height;
CRC	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	12.62	0.57	4.88e-30	Hip circumference;
CRC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.66	9.53	0.47	3.49e-19	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07639963	chr12:77157760	ZDHHC17	0.39	5.99	0.31	5.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.99	0.44	1.98e-17	Coffee consumption (cups per day);
CRC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.64	-0.47	1.56e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.54	-7.48	-0.38	6.94e-13	Corneal structure;
CRC	cis	rs6662572	0.737	rs4434876	chr1:46270129	T/C	cg08644498	chr1:46502608	NA	-0.44	-7.0	-0.36	1.44e-11	Blood protein levels;
CRC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg21194808	chr1:2205498	SKI	-0.39	-5.66	-0.3	3.3e-8	Height;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.42	-5.78	-0.3	1.72e-8	Breast cancer;
CRC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg27523141	chr10:43048294	ZNF37B	0.45	6.47	0.34	3.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg19193384	chr17:30244184	NA	0.46	5.7	0.3	2.62e-8	Hip circumference adjusted for BMI;
CRC	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg15786705	chr6:28176104	NA	0.7	9.41	0.46	9.04e-19	Parkinson's disease;
CRC	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.87	7.47	0.38	7.52e-13	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08219700	chr8:58056026	NA	0.55	6.5	0.34	2.99e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7107770	1.000	rs4935912	chr11:125090279	T/G	cg27629782	chr11:125073726	PKNOX2	0.47	5.86	0.31	1.11e-8	Photic sneeze reflex;
CRC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg15845792	chr6:28175446	NA	0.72	6.15	0.32	2.24e-9	Breast cancer;
CRC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.53	-6.46	-0.34	3.74e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.61	-11.48	-0.53	6.9e-26	Intelligence (multi-trait analysis);
CRC	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.06e-11	Primary sclerosing cholangitis;
CRC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	0.95	18.41	0.71	1.56e-52	Height;
CRC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.47	7.2	0.37	4e-12	Red blood cell count;
CRC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg11861562	chr11:117069780	TAGLN	0.39	8.99	0.44	2e-17	Blood protein levels;
CRC	cis	rs7904985	1.000	rs7904985	chr10:88116479	A/G	cg07322936	chr10:88137208	NA	0.46	6.11	0.32	2.84e-9	Barrett's esophagus;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25750404	chr12:6579648	VAMP1	-0.58	-7.15	-0.37	5.5e-12	Diisocyanate-induced asthma;
CRC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	7.01	0.36	1.39e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4664293	1.000	rs13014418	chr2:160483685	T/G	cg08347373	chr2:160653686	CD302	-0.44	-7.25	-0.37	2.97e-12	Monocyte percentage of white cells;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg12069248	chr11:65628378	MUS81	0.5	5.96	0.31	6.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.43	-0.42	1.06e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg16434002	chr17:42200994	HDAC5	-0.43	-6.25	-0.33	1.28e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs12745968	0.653	rs4847301	chr1:93200924	A/G	cg17283838	chr1:93427260	FAM69A	-0.44	-5.99	-0.31	5.4e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	7.13	0.37	6.58e-12	Diisocyanate-induced asthma;
CRC	cis	rs863345	0.604	rs6664542	chr1:158462431	G/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg11833968	chr6:79620685	NA	-0.37	-6.47	-0.34	3.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.61	-6.48	-0.34	3.38e-10	Left atrial antero-posterior diameter;
CRC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.75	7.65	0.39	2.18e-13	Diabetic retinopathy;
CRC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.6	10.36	0.5	6.12e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.26	0.45	2.62e-18	Parkinson's disease;
CRC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg00933542	chr6:150070202	PCMT1	0.33	6.65	0.34	1.21e-10	Lung cancer;
CRC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.22	0.32	1.5e-9	Mean platelet volume;
CRC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	0.93	17.81	0.7	3.75e-50	Height;
CRC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.84	15.48	0.65	5.52e-41	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.18	13.92	0.61	5.82e-35	Diabetic kidney disease;
CRC	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.45	-7.43	-0.38	9.29e-13	Beta-trace protein levels;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.58	-0.34	1.91e-10	Recombination measurement;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg27615366	chr5:131592974	PDLIM4	0.34	6.46	0.34	3.73e-10	Acylcarnitine levels;
CRC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg25204440	chr1:209979598	IRF6	0.49	5.92	0.31	8.1e-9	Cleft lip with or without cleft palate;
CRC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.45	0.53	8.7e-26	Bone mineral density;
CRC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.46	6.38	0.33	6.11e-10	Schizophrenia;
CRC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26879891	chr1:152191343	HRNR	-0.31	-5.89	-0.31	9.8e-9	Inflammatory skin disease;
CRC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.64	10.52	0.5	1.65e-22	Colorectal cancer;
CRC	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg17133734	chr15:86042851	AKAP13	0.42	6.76	0.35	6.22e-11	Coronary artery disease;
CRC	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.72	9.17	0.45	5.35e-18	Blood protein levels;
CRC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.4	-5.61	-0.3	4.38e-8	DNA methylation (variation);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg13789711	chr9:139743225	PHPT1	-0.52	-6.24	-0.33	1.33e-9	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.25	0.45	2.97e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg24209194	chr3:40518798	ZNF619	0.42	6.35	0.33	7.22e-10	Renal cell carcinoma;
CRC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	9.12	0.45	7.72e-18	Platelet count;
CRC	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.47	7.49	0.38	6.5e-13	Sitting height ratio;
CRC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.68	-12.01	-0.55	8.36e-28	Asthma;
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.596	rs12535807	chr7:124591433	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.12	-0.32	2.61e-9	Cutaneous malignant melanoma;
CRC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg17948913	chr5:572064	NA	-0.54	-6.28	-0.33	1.06e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.7	-10.35	-0.5	6.42e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	trans	rs12495832	0.778	rs80192600	chr3:147910628	G/T	cg10221266	chr7:153579447	NA	0.56	6.13	0.32	2.54e-9	Chin dimples;
CRC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg18404041	chr3:52824283	ITIH1	0.33	6.51	0.34	2.86e-10	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15926737	chr12:57853737	GLI1	0.5	6.58	0.34	1.88e-10	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg12172441	chr6:28176163	NA	0.6	6.59	0.34	1.71e-10	Parkinson's disease;
CRC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg00343986	chr7:65444356	GUSB	-0.47	-6.99	-0.36	1.52e-11	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23606286	chr1:145470592	ANKRD34A;POLR3GL	-0.41	-5.99	-0.31	5.39e-9	Myopia (pathological);
CRC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-20.11	-0.74	3.17e-59	Primary sclerosing cholangitis;
CRC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg21620606	chr4:1342894	KIAA1530	0.4	6.97	0.36	1.74e-11	Longevity;
CRC	cis	rs2530545	0.619	rs6975964	chr7:34662452	T/G	cg14401837	chr7:34697493	NPSR1	0.42	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.66	8.14	0.41	8.02e-15	Childhood ear infection;
CRC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.85	15.11	0.64	1.46e-39	Breast cancer;
CRC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.69	0.39	1.76e-13	Resting heart rate;
CRC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-19.95	-0.74	1.32e-58	Height;
CRC	cis	rs11229555	0.609	rs12273635	chr11:58186327	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.42	-6.31	-0.33	8.79e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.87	15.21	0.64	6.01e-40	Height;
CRC	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg23100626	chr2:96804247	ASTL	0.28	7.62	0.39	2.78e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs4731207	0.596	rs2170351	chr7:124642197	A/G	cg23710748	chr7:124431027	NA	-0.43	-6.86	-0.35	3.42e-11	Cutaneous malignant melanoma;
CRC	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg14345882	chr6:26364793	BTN3A2	0.43	6.65	0.34	1.19e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14778235	chr10:102589102	PAX2	-0.37	-6.33	-0.33	8.12e-10	Myopia (pathological);
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-10.0	-0.48	9.97e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.49	0.38	6.42e-13	Lung function (FEV1/FVC);
CRC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-14.97	-0.64	5.54e-39	Height;
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15985338	chr7:6048868	PMS2;AIMP2	0.49	8.14	0.41	8.24e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.27	-0.33	1.13e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg22561889	chr6:118971681	C6orf204	0.51	6.65	0.34	1.26e-10	Diastolic blood pressure;
CRC	cis	rs10743315	0.778	rs1586843	chr12:19354550	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.62	-7.89	-0.4	4.41e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.58	-6.77	-0.35	5.81e-11	Bronchopulmonary dysplasia;
CRC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.22	-0.53	6.01e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.42	-0.42	1.18e-15	Gut microbiome composition (summer);
CRC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg05585544	chr11:47624801	NA	-0.44	-7.8	-0.39	8.54e-14	Subjective well-being;
CRC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.79	-0.47	5.05e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.42	0.62	7.21e-37	Hypertriglyceridemia;
CRC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg19193384	chr17:30244184	NA	0.47	5.72	0.3	2.36e-8	Hip circumference adjusted for BMI;
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg04497992	chr16:616212	NHLRC4	0.45	7.32	0.37	1.95e-12	Height;
CRC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.08	0.32	3.26e-9	Rheumatoid arthritis;
CRC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.49	9.2	0.45	4.13e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	9.9	0.48	2.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs17767392	0.781	rs8015644	chr14:71842729	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.81	-0.31	1.47e-8	Mitral valve prolapse;
CRC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.71	12.11	0.56	3.52e-28	Gout;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15011721	chr7:56032604	GBAS	0.45	6.55	0.34	2.26e-10	Anxiety disorder;
CRC	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11578532	chr1:161008127	TSTD1	0.32	6.65	0.34	1.25e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.52	-7.01	-0.36	1.32e-11	Triglycerides;
CRC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.81	-17.34	-0.69	2.64e-48	Prostate cancer;
CRC	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg19407955	chr1:165599744	MGST3	-0.43	-5.63	-0.3	3.94e-8	Total ventricular volume;
CRC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	6.31	0.33	9.25e-10	Myopia (pathological);
CRC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.41	6.73	0.35	7.45e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-7.45	-0.38	8.28e-13	Neuroticism;
CRC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg21839984	chr17:30846986	MYO1D	-0.33	-5.61	-0.3	4.33e-8	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11255154	chr2:191879104	STAT1	0.38	6.1	0.32	3.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.24	-16.52	-0.67	4.4e-45	Breast cancer;
CRC	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.57	-7.36	-0.38	1.46e-12	Body mass index;
CRC	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	6.6	0.34	1.69e-10	Myopia (pathological);
CRC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.49	7.65	0.39	2.17e-13	Corneal astigmatism;
CRC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-5.91	-0.31	8.34e-9	Gout;
CRC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	0.96	8.28	0.42	3.22e-15	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20150887	chr17:43210745	PLCD3;ACBD4	0.44	6.62	0.34	1.42e-10	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	6.3	0.33	9.3e-10	Obesity-related traits;
CRC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg09127314	chr1:152161683	NA	-0.46	-5.66	-0.3	3.27e-8	Atopic dermatitis;
CRC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.47	8.45	0.42	9.75e-16	Lung cancer;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg02475695	chr16:616220	NHLRC4	0.48	8.0	0.4	2.18e-14	Height;
CRC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.77	10.47	0.5	2.55e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.75	9.38	0.46	1.07e-18	Type 2 diabetes;
CRC	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-0.92	-7.3	-0.37	2.14e-12	Putamen volume;
CRC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.2	-0.41	5.62e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg07884673	chr3:53033167	SFMBT1	0.7	6.15	0.32	2.23e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.42	0.33	4.87e-10	Depressive episodes in bipolar disorder;
CRC	trans	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg01134436	chr17:81009848	B3GNTL1	0.7	6.42	0.33	4.8e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.5	9.88	0.48	2.55e-20	Ulcerative colitis;
CRC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.65	-10.39	-0.5	4.53e-22	Breast cancer;
CRC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg22495460	chr2:25135724	ADCY3	-0.85	-16.31	-0.67	3.12e-44	Body mass index;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs9837602	0.592	rs1606481	chr3:99427552	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-5.76	-0.3	1.96e-8	Breast cancer;
CRC	cis	rs7605827	0.930	rs1015835	chr2:15625768	T/C	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-9.95	-0.48	1.45e-20	Coronary artery disease;
CRC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg00601486	chr12:48723148	H1FNT	-0.33	-6.25	-0.33	1.26e-9	Glycated hemoglobin levels;
CRC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02290350	chr8:58132656	NA	-0.44	-6.96	-0.36	1.82e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.18	0.37	4.82e-12	Mean corpuscular volume;
CRC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg08741688	chr4:3415352	RGS12	-0.41	-5.82	-0.31	1.41e-8	Serum sulfate level;
CRC	trans	rs2055729	0.677	rs6990268	chr8:9741171	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.77	-0.35	5.78e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Depression;
CRC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.64	9.34	0.46	1.51e-18	Menopause (age at onset);
CRC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.44	7.1	0.36	7.52e-12	Obesity-related traits;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13731338	chr3:128145454	NA	0.44	5.98	0.31	5.71e-9	Hip circumference;
CRC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.25	0.45	2.97e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg21922841	chr17:72744131	SLC9A3R1	0.28	5.84	0.31	1.28e-8	Monocyte count;
CRC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.89e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	0.64	6.07	0.32	3.49e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg10298567	chr3:47292165	KIF9	-0.37	-6.04	-0.32	4.2e-9	Colorectal cancer;
CRC	cis	rs751837	0.591	rs10138056	chr14:103424854	A/G	cg10087771	chr14:103399429	CDC42BPB	0.67	6.58	0.34	1.83e-10	Large B-cell lymphoma;
CRC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.7e-9	Rheumatoid arthritis;
CRC	cis	rs4664293	0.625	rs13006088	chr2:160509426	A/G	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg11189052	chr15:85197271	WDR73	0.66	9.6	0.47	2.09e-19	Schizophrenia;
CRC	cis	rs9491140	0.539	rs11154228	chr6:124686042	A/G	cg19267163	chr6:125004984	NKAIN2	0.45	6.1	0.32	2.95e-9	Neuroticism;
CRC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg10183150	chr4:120222239	C4orf3	-0.33	-5.99	-0.31	5.44e-9	Educational attainment;
CRC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.44	0.42	1.06e-15	Height;
CRC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.53	-0.54	4.56e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs12432203	1.000	rs3507	chr14:51730548	G/C	cg14592830	chr9:122318704	NA	0.59	6.12	0.32	2.62e-9	Cancer;
CRC	cis	rs4727963	0.755	rs1525471	chr7:122733962	C/T	cg03640110	chr7:122635026	TAS2R16	0.35	6.36	0.33	6.9e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.58	-7.29	-0.37	2.28e-12	Gut microbiome composition (summer);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16139199	chr18:19180362	ESCO1	-0.48	-5.97	-0.31	5.99e-9	Diisocyanate-induced asthma;
CRC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.41	0.33	4.93e-10	Schizophrenia;
CRC	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg26248373	chr2:1572462	NA	-0.8	-11.74	-0.54	8.41e-27	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg20933634	chr6:27740509	NA	0.42	5.85	0.31	1.21e-8	Parkinson's disease;
CRC	cis	rs11212617	0.967	rs4585	chr11:108239628	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.62	0.34	1.5e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.7	9.54	0.47	3.31e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.92	-0.44	3.34e-17	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.73	0.51	3.03e-23	Exhaled nitric oxide output;
CRC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg03030879	chr14:75389066	RPS6KL1	0.51	8.19	0.41	5.79e-15	Caffeine consumption;
CRC	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.25	14.99	0.64	4.45e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.43	6.8	0.35	4.95e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.63	9.08	0.45	9.95e-18	Schizophrenia;
CRC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	1.02	17.98	0.7	7.89e-51	Parkinson's disease;
CRC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.51	8.95	0.44	2.57e-17	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.62	9.71	0.47	9.26e-20	Corneal astigmatism;
CRC	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg09127314	chr1:152161683	NA	0.5	6.41	0.33	5.03e-10	Atopic dermatitis;
CRC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.24	-0.41	4.11e-15	Neuroticism;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg02683197	chr6:28174875	NA	0.64	8.9	0.44	3.89e-17	Cardiac Troponin-T levels;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26611836	chr5:126112609	LMNB1	-0.55	-6.48	-0.34	3.43e-10	Monocyte percentage of white cells;
CRC	cis	rs10982256	0.766	rs1535959	chr9:117248479	G/A	cg13636371	chr9:117264095	DFNB31	0.42	7.97	0.4	2.55e-14	Bipolar disorder;
CRC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.43	7.66	0.39	2.05e-13	Perceived unattractiveness to mosquitoes;
CRC	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.57	-9.05	-0.45	1.25e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg02659138	chr7:134003124	SLC35B4	0.42	7.24	0.37	3.1e-12	Mean platelet volume;
CRC	cis	rs2811415	0.597	rs9824536	chr3:127763956	C/A	cg13719885	chr3:127795394	NA	-0.37	-5.72	-0.3	2.37e-8	Lung function (FEV1/FVC);
CRC	cis	rs7301826	0.651	rs7971046	chr12:131286807	G/A	cg11011512	chr12:131303247	STX2	0.38	5.7	0.3	2.73e-8	Plasma plasminogen activator levels;
CRC	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.72	-10.81	-0.51	1.71e-23	Breast cancer;
CRC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.59	-6.6	-0.34	1.6e-10	Blood protein levels;
CRC	cis	rs11255291	1.000	rs10905218	chr10:7733898	C/T	cg00997801	chr10:7671259	ITIH5	0.42	6.13	0.32	2.51e-9	Ovarian reserve;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25846339	chr11:85359022	TMEM126A	0.5	7.17	0.37	4.97e-12	Response to antipsychotic treatment;
CRC	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg16691251	chr5:66510806	NA	0.58	11.56	0.54	3.73e-26	Breast cancer;
CRC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.76	10.78	0.51	2.12e-23	Blood metabolite levels;
CRC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.87	-15.95	-0.66	8.1e-43	Coronary artery disease;
CRC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.69	-12.07	-0.55	5.12e-28	Urate levels in obese individuals;
CRC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.43	-9.02	-0.45	1.62e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.47	8.09	0.41	1.17e-14	Primary biliary cholangitis;
CRC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.8	12.28	0.56	8.31e-29	Height;
CRC	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.45	6.15	0.32	2.27e-9	Ovarian reserve;
CRC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	trans	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-7.0	-0.36	1.48e-11	Colorectal cancer;
CRC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.65	-6.45	-0.34	4.01e-10	Tuberculosis;
CRC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.46	7.46	0.38	7.83e-13	Major depressive disorder;
CRC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.71e-20	Eye color traits;
CRC	cis	rs2944755	0.919	rs2944754	chr8:141574350	A/G	cg07466463	chr8:141574207	EIF2C2	-0.4	-5.82	-0.31	1.38e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7429990	0.864	rs7629850	chr3:47857082	T/C	cg11946769	chr3:48343235	NME6	-0.46	-5.83	-0.31	1.29e-8	Educational attainment (years of education);
CRC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.81	11.93	0.55	1.61e-27	Cognitive function;
CRC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg25876840	chr17:41920477	NA	-0.46	-7.27	-0.37	2.63e-12	Triglycerides;
CRC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-6.24	-0.33	1.33e-9	Lung cancer;
CRC	cis	rs905456	0.716	rs6804368	chr3:30753573	A/G	cg06106510	chr3:30762233	NA	0.33	6.05	0.32	3.87e-9	Positive affect;
CRC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg25985355	chr7:65971099	NA	-0.49	-5.73	-0.3	2.27e-8	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.92	-0.31	7.94e-9	Life satisfaction;
CRC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.97	-0.44	2.27e-17	Platelet count;
CRC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg06096015	chr1:231504339	EGLN1	0.4	6.04	0.32	4.19e-9	Hemoglobin concentration;
CRC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.8	-13.38	-0.59	6.77e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13028789	chr6:34856920	ANKS1A;TAF11	0.37	6.16	0.32	2.07e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.27	0.33	1.16e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.96	-13.93	-0.61	5.22e-35	Breast cancer;
CRC	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.48e-17	Dupuytren's disease;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.87	10.61	0.5	8.32e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg15382696	chr6:118971807	C6orf204	0.59	7.53	0.38	4.79e-13	Diastolic blood pressure;
CRC	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.56	10.13	0.49	3.62e-21	Cognitive performance;
CRC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg06634786	chr22:41940651	POLR3H	-0.44	-5.69	-0.3	2.81e-8	Neuroticism;
CRC	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	cg04338863	chr8:33670619	NA	-0.36	-5.79	-0.3	1.63e-8	Body mass index;
CRC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg25985355	chr7:65971099	NA	-0.47	-5.65	-0.3	3.54e-8	Diabetic kidney disease;
CRC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg00343986	chr7:65444356	GUSB	-0.49	-7.23	-0.37	3.38e-12	Aortic root size;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02970425	chr20:48552805	RNF114	0.45	6.07	0.32	3.45e-9	Thyroid stimulating hormone;
CRC	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.53	8.44	0.42	9.98e-16	Sum neutrophil eosinophil counts;
CRC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.6	11.05	0.52	2.37e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.53	-0.43	5.39e-16	Breast cancer;
CRC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg26116260	chr4:7069785	GRPEL1	-0.59	-5.65	-0.3	3.54e-8	Granulocyte percentage of myeloid white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22943607	chr19:4400723	SH3GL1	0.42	6.37	0.33	6.51e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.06	-0.48	6.41e-21	Monocyte count;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.41	-5.86	-0.31	1.15e-8	Longevity;Endometriosis;
CRC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.08	0.32	3.34e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.39	7.52	0.38	5.28e-13	Mean corpuscular volume;
CRC	cis	rs17767392	0.846	rs61991200	chr14:71762569	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.06	-0.32	3.68e-9	Mitral valve prolapse;
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg15786705	chr6:28176104	NA	0.75	7.4	0.38	1.13e-12	Depression;
CRC	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	9.69	0.47	1.1e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg20041105	chr8:143859282	LYNX1	-0.5	-9.12	-0.45	7.8e-18	Urinary tract infection frequency;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg15763984	chr4:1342303	KIAA1530	0.48	8.41	0.42	1.3e-15	Longevity;
CRC	cis	rs2882667	0.690	rs274118	chr5:138064887	A/G	cg09476006	chr5:138032270	NA	0.58	10.42	0.5	3.74e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg25164649	chr6:28176230	NA	0.7	7.91	0.4	3.86e-14	Parkinson's disease;
CRC	cis	rs932541	1.000	rs6105612	chr20:16458404	T/G	cg17003395	chr20:16555519	KIF16B	0.42	5.8	0.3	1.58e-8	Intelligence;
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.7	9.26	0.45	2.78e-18	Alzheimer's disease;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.92	-11.98	-0.55	1.09e-27	Alzheimer's disease;
CRC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.55	-8.18	-0.41	6.37e-15	IgG glycosylation;
CRC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg20203395	chr5:56204925	C5orf35	-0.41	-5.77	-0.3	1.84e-8	Coronary artery disease;
CRC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg07718321	chr6:96025334	MANEA	0.58	7.42	0.38	9.96e-13	Behavioural disinhibition (generation interaction);
CRC	cis	rs972578	0.967	rs6002985	chr22:43333427	C/T	cg01576275	chr22:43409880	NA	-0.42	-6.77	-0.35	6.07e-11	Mean platelet volume;
CRC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.67	10.3	0.49	9.15e-22	Corneal astigmatism;
CRC	cis	rs294883	0.789	rs397344	chr6:159694590	C/T	cg14500486	chr6:159655392	FNDC1	-0.36	-5.85	-0.31	1.16e-8	Coronary artery disease;
CRC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.43	6.14	0.32	2.35e-9	Aortic root size;
CRC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.72	-10.98	-0.52	4.02e-24	Hip circumference adjusted for BMI;
CRC	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg12516270	chr8:143859308	LYNX1	-0.58	-10.34	-0.5	7.1e-22	Urinary tract infection frequency;
CRC	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08989290	chr16:615782	NHLRC4	0.48	9.51	0.46	4.15e-19	Height;
CRC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.93	-17.34	-0.69	2.58e-48	Coronary artery disease;
CRC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.46	6.74	0.35	7.3e-11	Menarche (age at onset);
CRC	cis	rs13315871	1.000	rs71311864	chr3:58372324	C/T	cg20936604	chr3:58311152	NA	-0.73	-6.69	-0.35	9.48e-11	Cholesterol, total;
CRC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.63	8.58	0.43	3.93e-16	Bladder cancer;
CRC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.39e-11	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10367214	chr6:139094545	CCDC28A	0.39	6.25	0.33	1.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg26805224	chr10:79626177	DLG5	-0.49	-7.26	-0.37	2.86e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.08	-12.32	-0.56	5.94e-29	Diabetic kidney disease;
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-1.05	-12.2	-0.56	1.69e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg25164649	chr6:28176230	NA	0.61	8.67	0.43	1.95e-16	Cardiac Troponin-T levels;
CRC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg25876840	chr17:41920477	NA	0.48	7.37	0.38	1.41e-12	Triglycerides;
CRC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.64	0.34	1.33e-10	Schizophrenia;
CRC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.35	-6.91	-0.36	2.51e-11	Alzheimer's disease (late onset);
CRC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1403694	0.966	rs1656910	chr3:186438993	A/C	cg04611788	chr3:186434169	KNG1	-0.45	-6.95	-0.36	1.93e-11	Blood protein levels;
CRC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg20684491	chr1:25596433	NA	0.41	7.24	0.37	3.23e-12	Erythrocyte sedimentation rate;
CRC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.94	11.01	0.52	3.17e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	trans	rs10090774	0.965	rs10106750	chr8:142004909	A/G	cg14360659	chr9:137029702	RNU6ATAC	0.45	5.96	0.31	6.33e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg25164649	chr6:28176230	NA	0.56	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.1e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.5	8.05	0.41	1.58e-14	Red blood cell count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01939414	chr2:103353548	MFSD9	0.49	6.39	0.33	5.54e-10	Thyroid stimulating hormone;
CRC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15289517	chr15:65809633	DPP8	0.42	6.42	0.33	4.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.65	-9.88	-0.48	2.44e-20	Acne (severe);
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.66	9.05	0.45	1.26e-17	Menarche (age at onset);
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg22482690	chr17:47019901	SNF8	0.48	8.18	0.41	6.13e-15	Type 2 diabetes;
CRC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08144172	chr1:41849203	NA	0.36	5.9	0.31	9.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.32	0.46	1.72e-18	Hip circumference adjusted for BMI;
CRC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg05627522	chr15:75251581	NA	0.38	5.93	0.31	7.87e-9	Breast cancer;
CRC	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg17848003	chr1:3704513	LRRC47	0.41	6.06	0.32	3.79e-9	Red cell distribution width;
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-0.88	-19.34	-0.73	3.42e-56	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21767207	chr19:36236454	PSENEN;U2AF1L4	0.45	7.42	0.38	9.83e-13	Obesity-related traits;
CRC	cis	rs17681684	0.565	rs12150182	chr17:9764757	C/T	cg26853458	chr17:9805074	RCVRN	0.53	9.35	0.46	1.41e-18	GIP levels in response to oral glucose tolerance test (fasting);
CRC	cis	rs727479	0.502	rs1065779	chr15:51504811	A/C	cg19946085	chr15:51559439	CYP19A1	-0.29	-5.92	-0.31	8.01e-9	Estradiol levels;
CRC	cis	rs10986311	0.775	rs7857897	chr9:127118550	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.4	6.01	0.31	4.97e-9	Vitiligo;
CRC	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg24209194	chr3:40518798	ZNF619	-0.45	-7.02	-0.36	1.3e-11	Renal cell carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26529371	chr19:12911983	PRDX2	0.35	6.16	0.32	2.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18867708	chr6:26865862	GUSBL1	-0.42	-5.89	-0.31	9.8e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.81	-0.35	4.63e-11	Platelet distribution width;
CRC	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	0.73	7.66	0.39	2.12e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg16482183	chr6:26056742	HIST1H1C	0.72	9.14	0.45	6.37e-18	Iron status biomarkers;
CRC	cis	rs2882667	0.690	rs288016	chr5:138194988	C/T	cg09476006	chr5:138032270	NA	-0.53	-9.41	-0.46	9.2e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	3.08e-24	Corneal astigmatism;
CRC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.66	-0.3	3.28e-8	Depression;
CRC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg27661571	chr11:113659931	NA	-0.71	-8.85	-0.44	5.32e-17	Hip circumference adjusted for BMI;
CRC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.87	-14.59	-0.63	1.61e-37	Prudent dietary pattern;
CRC	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	1.08	10.08	0.49	5.16e-21	Parkinson's disease;
CRC	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg06632207	chr12:54070931	ATP5G2	0.46	7.87	0.4	5.09e-14	Height;
CRC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.9	16.34	0.67	2.4e-44	Prostate cancer;
CRC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-8.19	-0.41	5.93e-15	Response to bleomycin (chromatid breaks);
CRC	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.33	0.37	1.78e-12	Testicular germ cell tumor;
CRC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.69	9.3	0.46	2.03e-18	High light scatter reticulocyte count;
CRC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.14	0.32	2.42e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13072153	0.793	rs9841477	chr3:123157477	A/C	cg04138502	chr3:123167522	ADCY5	0.33	5.91	0.31	8.76e-9	Chronic kidney disease;
CRC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg06634786	chr22:41940651	POLR3H	-0.46	-5.89	-0.31	9.41e-9	Neuroticism;
CRC	cis	rs17539620	0.628	rs62432730	chr6:154830717	G/A	cg20019720	chr6:154832845	CNKSR3	0.49	7.78	0.39	9.31e-14	Lipoprotein (a) levels;
CRC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg15192750	chr16:69999425	NA	0.52	7.16	0.37	5.32e-12	IgE levels;
CRC	cis	rs3101457	0.515	rs4658629	chr1:244516754	G/T	cg09033006	chr1:244517177	C1orf100	-0.46	-6.56	-0.34	2.07e-10	Smoking behavior;
CRC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.59	8.81	0.44	7.57e-17	Aortic root size;
CRC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.97	12.03	0.55	7.14e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	cis	rs6988985	0.728	rs5299	chr8:143955471	T/C	cg10324643	chr8:143916377	GML	0.35	5.8	0.3	1.53e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs2270875	0.736	rs79099489	chr8:132886358	T/G	cg24184792	chr8:132919238	EFR3A	-0.75	-6.9	-0.36	2.69e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.79	14.28	0.62	2.55e-36	Anterior chamber depth;
CRC	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21155796	chr2:242212141	HDLBP	0.64	7.02	0.36	1.25e-11	Prostate cancer;
CRC	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	0.58	6.66	0.34	1.18e-10	Prostate cancer;
CRC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-7.05	-0.36	1.06e-11	Total body bone mineral density;
CRC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.62	-0.34	1.49e-10	Coronary artery disease;
CRC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.08	0.32	3.26e-9	Height;
CRC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-7.8	-0.39	8.4e-14	Bipolar disorder;
CRC	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.76	0.3	1.93e-8	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16221875	chr6:21588597	NA	0.45	6.02	0.31	4.73e-9	Thyroid stimulating hormone;
CRC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-7.28	-0.37	2.42e-12	Pulmonary function;
CRC	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg04110750	chr16:69646130	NFAT5	-0.52	-6.79	-0.35	5.3e-11	IgE levels;
CRC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.78	0.54	5.85e-27	Hip circumference adjusted for BMI;
CRC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.61	10.91	0.52	7.19e-24	Schizophrenia;
CRC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02725872	chr8:58115012	NA	-0.59	-9.17	-0.45	5.24e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9467160	0.834	rs17247566	chr6:24450404	A/C	cg20631270	chr6:24437470	GPLD1	-0.48	-6.51	-0.34	2.76e-10	Liver enzyme levels;
CRC	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg10756647	chr7:56101905	PSPH	0.78	8.17	0.41	6.58e-15	Gout;
CRC	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.64	11.52	0.54	5.1e-26	Blood metabolite ratios;
CRC	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.51	7.92	0.4	3.71e-14	Malaria;
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg20119798	chr7:94954144	PON1	-0.51	-6.46	-0.34	3.7e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62188990	chr2:162540635	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.72	-6.0	-0.31	5.31e-9	Cognitive function;
CRC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.59	-7.4	-0.38	1.15e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2737618	0.651	rs2816976	chr1:200081021	A/T	cg21825944	chr1:200113062	NR5A2	-0.49	-7.18	-0.37	4.67e-12	Uric acid levels;
CRC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.17	-13.07	-0.58	9.77e-32	Diabetic kidney disease;
CRC	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.49	7.41	0.38	1.09e-12	Testicular germ cell tumor;
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg18230493	chr5:56204884	C5orf35	-0.4	-5.91	-0.31	8.54e-9	Coronary artery disease;
CRC	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg08071915	chr8:12219732	FAM66A	0.32	5.81	0.31	1.45e-8	Retinal vascular caliber;
CRC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.68	-8.5	-0.42	6.71e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12725198	0.507	rs41393951	chr1:16053493	C/T	cg27534772	chr1:16042836	PLEKHM2	0.33	6.12	0.32	2.62e-9	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26514337	chr18:57026503	LMAN1	0.37	6.01	0.31	4.83e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.46	-0.38	7.53e-13	Glycated hemoglobin levels;
CRC	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	15.35	0.65	1.81e-40	Ulcerative colitis;
CRC	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg05925327	chr15:68127851	NA	-0.31	-6.01	-0.31	4.84e-9	Restless legs syndrome;
CRC	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22878388	chr2:105853796	NA	-0.34	-6.57	-0.34	1.94e-10	Type 2 diabetes;
CRC	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.52	9.16	0.45	5.86e-18	Common traits (Other);
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.5	-6.44	-0.33	4.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.33	0.33	8.01e-10	Aortic root size;
CRC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg19635926	chr16:89946313	TCF25	0.53	5.72	0.3	2.42e-8	Skin colour saturation;
CRC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg24675056	chr1:15929824	NA	0.51	7.04	0.36	1.15e-11	Systolic blood pressure;
CRC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.16	0.59	4.67e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	20.05	0.74	5.27e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg14558114	chr2:88469736	THNSL2	-0.43	-6.25	-0.33	1.28e-9	Response to metformin (IC50);
CRC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.45	-6.64	-0.34	1.27e-10	Menarche (age at onset);
CRC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.45	-6.63	-0.34	1.37e-10	Platelet distribution width;
CRC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.53	6.06	0.32	3.66e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg18016565	chr1:150552671	MCL1	0.41	5.75	0.3	2.01e-8	Melanoma;
CRC	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.6	10.18	0.49	2.41e-21	Dupuytren's disease;
CRC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg13722127	chr7:150037890	RARRES2	0.47	7.23	0.37	3.44e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.4	6.02	0.31	4.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7165102	1.000	rs7163482	chr15:65739683	C/T	cg22383888	chr3:27764816	EOMES	-0.28	-5.99	-0.31	5.61e-9	Mean corpuscular hemoglobin;
CRC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.56	-11.65	-0.54	1.74e-26	Alcohol dependence;
CRC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.48	6.45	0.33	4.09e-10	Obesity-related traits;
CRC	cis	rs526821	0.595	rs551665	chr11:55343268	G/A	cg04317927	chr11:55418816	OR4S2	0.39	6.66	0.34	1.15e-10	Pediatric bone mineral density (spine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05707844	chr2:37383994	EIF2AK2	0.43	7.06	0.36	9.77e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.49	7.24	0.37	3.23e-12	Glioblastoma;Glioma;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	8.53	0.43	5.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg06207120	chr15:45996521	NA	0.32	7.66	0.39	2.09e-13	Waist circumference;Weight;
CRC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.41	-6.58	-0.34	1.89e-10	Testicular germ cell tumor;
CRC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.41	-0.38	1.06e-12	Joint mobility (Beighton score);
CRC	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.76	10.24	0.49	1.55e-21	Coronary artery disease;
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19500275	chr17:80737654	TBCD	0.53	7.19	0.37	4.32e-12	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01539630	chr17:20946013	USP22	0.47	6.6	0.34	1.62e-10	Response to antipsychotic treatment;
CRC	cis	rs501120	0.810	rs622472	chr10:44749211	A/C	cg09554077	chr10:44749378	NA	0.91	13.53	0.6	1.87e-33	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg22907277	chr7:1156413	C7orf50	0.7	7.72	0.39	1.41e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.66	8.08	0.41	1.24e-14	Gut microbiome composition (summer);
CRC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg09127314	chr1:152161683	NA	-0.48	-5.91	-0.31	8.37e-9	Atopic dermatitis;
CRC	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.76	8.3	0.42	2.71e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.52	-7.98	-0.4	2.51e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	7.21	0.37	3.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2274273	0.588	rs58296156	chr14:55828327	C/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.03	-0.32	4.3e-9	Protein biomarker;
CRC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.52	-0.38	5.28e-13	Major depressive disorder;
CRC	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg21153622	chr11:89784906	NA	-0.45	-7.11	-0.36	7.19e-12	HDL cholesterol;
CRC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.08	-0.52	1.78e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs17253792	0.545	rs71412688	chr14:56021539	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-6.65	-0.34	1.24e-10	Putamen volume;
CRC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-7.7	-0.39	1.63e-13	Major depressive disorder;
CRC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.46	-8.95	-0.44	2.57e-17	Intelligence (multi-trait analysis);
CRC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	7.21	0.37	3.91e-12	Parkinson's disease;
CRC	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.58	-7.32	-0.37	1.87e-12	Platelet distribution width;
CRC	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg08210727	chr20:33865349	NA	-0.43	-5.96	-0.31	6.57e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg03623178	chr6:28175578	NA	0.79	11.75	0.54	7.49e-27	Parkinson's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg24515799	chr6:149867235	PPIL4	0.38	6.06	0.32	3.67e-9	Interleukin-6 levels;
CRC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg15147215	chr3:52552868	STAB1	-0.46	-7.03	-0.36	1.21e-11	Schizophrenia;
CRC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg15440763	chr7:158190612	PTPRN2	-0.4	-6.51	-0.34	2.76e-10	Obesity-related traits;
CRC	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.52	-7.84	-0.4	6.45e-14	Diastolic blood pressure;
CRC	cis	rs11166629	1.000	rs4909332	chr8:135646340	T/C	cg27224718	chr8:135614730	ZFAT	0.52	7.65	0.39	2.3e-13	Smoking quantity;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.72	0.39	1.44e-13	Lymphocyte counts;
CRC	cis	rs17767392	0.836	rs35415083	chr14:72009196	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.3	-0.37	2.25e-12	Mitral valve prolapse;
CRC	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg18806716	chr10:30721971	MAP3K8	-0.46	-6.78	-0.35	5.5e-11	Inflammatory bowel disease;
CRC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.21	0.32	1.58e-9	Prudent dietary pattern;
CRC	cis	rs6479527	0.840	rs1360429	chr9:96762314	C/T	cg14459158	chr9:96720562	NA	0.41	7.57	0.39	3.86e-13	Esophageal adenocarcinoma;
CRC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.73	-8.21	-0.41	5.2e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.81	13.6	0.6	9.97e-34	Menopause (age at onset);
CRC	cis	rs10760158	0.769	rs7870797	chr9:124060422	G/A	cg14417974	chr9:124058376	GSN	-0.34	-5.72	-0.3	2.41e-8	Pulse pressure;
CRC	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.58	0.34	1.8e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.57	8.15	0.41	7.63e-15	Melanoma;
CRC	cis	rs7215564	0.908	rs35363308	chr17:78687190	A/T	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.22e-9	Myopia (pathological);
CRC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-0.81	-9.24	-0.45	3.18e-18	Type 2 diabetes nephropathy;
CRC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.23	0.32	1.44e-9	Diastolic blood pressure;
CRC	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.49	8.29	0.42	3.01e-15	Common traits (Other);
CRC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.31	-0.37	2.06e-12	Schizophrenia;
CRC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg10298567	chr3:47292165	KIF9	-0.35	-5.83	-0.31	1.33e-8	Colorectal cancer;
CRC	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.56	8.25	0.41	3.76e-15	Schizophrenia;
CRC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg16102536	chr7:156981717	UBE3C	0.4	6.79	0.35	5.41e-11	Body mass index;
CRC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.82	11.36	0.53	1.91e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.76	11.93	0.55	1.71e-27	Hemoglobin concentration;Hematocrit;
CRC	cis	rs8099014	0.906	rs4940693	chr18:56101171	T/G	cg12907477	chr18:56117327	MIR122	0.47	5.88	0.31	1.01e-8	Platelet count;
CRC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg19980929	chr12:42632907	YAF2	-0.38	-5.66	-0.3	3.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7215564	0.908	rs35434628	chr17:78714760	C/T	cg09596252	chr17:78655493	RPTOR	0.53	5.62	0.3	3.98e-8	Myopia (pathological);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01496648	chr16:67880937	CENPT;NUTF2	0.39	6.25	0.33	1.3e-9	Schizophrenia;
CRC	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.67	-0.35	1.07e-10	Response to antipsychotic treatment;
CRC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.39	-0.56	3.32e-29	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg13047869	chr3:10149882	C3orf24	0.5	6.88	0.35	3.1e-11	Alzheimer's disease;
CRC	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	8.5	0.42	6.78e-16	Eotaxin levels;
CRC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.34	0.46	1.52e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg07713946	chr22:31675144	LIMK2	0.39	5.69	0.3	2.75e-8	Colorectal cancer;
CRC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.69	8.61	0.43	3.04e-16	Prostate cancer;
CRC	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg12072164	chr19:44306565	LYPD5	0.41	6.47	0.34	3.58e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.08e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.63	6.64	0.34	1.3100000000000001e-10	Childhood ear infection;
CRC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	13.59	0.6	1.05e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.03e-10	Bipolar disorder;
CRC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.52	8.85	0.44	5.57e-17	Coronary artery disease;
CRC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg13072238	chr3:49761600	GMPPB	0.48	5.63	0.3	3.86e-8	Menarche (age at onset);
CRC	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.64	-8.69	-0.43	1.68e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.49	6.41	0.33	5.05e-10	Blood metabolite levels;
CRC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.48	5.99	0.31	5.51e-9	Bipolar disorder;
CRC	cis	rs62432291	0.764	rs436743	chr6:159655102	A/G	cg14500486	chr6:159655392	FNDC1	-0.76	-10.4	-0.5	4.17e-22	Joint mobility (Beighton score);
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.54	-7.44	-0.38	8.91e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.71	9.83	0.48	3.72e-20	Platelet count;
CRC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-7.17	-0.37	5.01e-12	Chronic sinus infection;
CRC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.56	7.91	0.4	3.98e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	7.85	0.4	5.96e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18002896	chr8:144465845	RHPN1	0.44	7.31	0.37	2.1e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg11645453	chr3:52864694	ITIH4	-0.4	-7.44	-0.38	8.7e-13	Body mass index;
CRC	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.88	-0.35	3.05e-11	Height;
CRC	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.98	8.49	0.42	7.39e-16	Blood protein levels;
CRC	cis	rs737337	0.623	rs17699089	chr19:11343795	A/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.82	9.38	0.46	1.13e-18	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.5	7.04	0.36	1.14e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.29	-5.61	-0.3	4.23e-8	Personality dimensions;
CRC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.59	0.65	2.1e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg23920097	chr1:209922102	NA	-0.52	-6.48	-0.34	3.27e-10	Red blood cell count;
CRC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg12193833	chr17:30244370	NA	-0.75	-8.72	-0.43	1.4e-16	Hip circumference adjusted for BMI;
CRC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.42	7.06	0.36	1.02e-11	Schizophrenia;
CRC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg00750074	chr16:89608354	SPG7	-0.44	-6.62	-0.34	1.47e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-7.02	-0.36	1.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.79	14.13	0.61	9.31e-36	Mean platelet volume;
CRC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg21970626	chr13:21893289	NA	-0.44	-6.59	-0.34	1.8e-10	White matter hyperintensity burden;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.59	-8.46	-0.42	9.2e-16	Gut microbiome composition (summer);
CRC	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg09904177	chr6:26538194	HMGN4	0.42	5.88	0.31	9.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.41	5.87	0.31	1.09e-8	Tonsillectomy;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg12172441	chr6:28176163	NA	0.45	6.55	0.34	2.16e-10	Cardiac Troponin-T levels;
CRC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-9.0	-0.44	1.84e-17	Schizophrenia;
CRC	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.44	0.38	9e-13	Blood metabolite levels;
CRC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg12193833	chr17:30244370	NA	-0.72	-8.54	-0.43	5.04e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-8.05	-0.41	1.55e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.39	-0.33	5.62e-10	Blood metabolite levels;
CRC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	1.02	20.45	0.75	1.42e-60	Headache;
CRC	cis	rs4666002	0.956	rs10169065	chr2:27778560	A/G	cg27432699	chr2:27873401	GPN1	0.45	5.87	0.31	1.05e-8	Phospholipid levels (plasma);
CRC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.86	11.82	0.55	3.99e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	4.97e-15	Red blood cell count;
CRC	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg20363699	chr7:23626180	CLK2P	0.35	6.26	0.33	1.17e-9	Schizophrenia;
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16471084	chr6:11537861	TMEM170B	-0.4	-6.46	-0.34	3.77e-10	Myopia (pathological);
CRC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg18827107	chr12:86230957	RASSF9	-0.37	-5.73	-0.3	2.23e-8	Major depressive disorder;
CRC	cis	rs2249625	0.523	rs1969530	chr6:72861276	A/C	cg18830697	chr6:72922368	RIMS1	-0.31	-6.19	-0.32	1.8e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs365302	0.767	rs413952	chr6:159612661	A/G	cg14500486	chr6:159655392	FNDC1	0.59	8.57	0.43	4.21e-16	Coronary heart disease;
CRC	cis	rs4804416	1.000	rs4804416	chr19:7223848	G/T	cg00428638	chr19:7224713	INSR	-0.6	-9.89	-0.48	2.35e-20	Thyroid hormone levels;Hypothyroidism;
CRC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg22110888	chr17:80059540	CCDC57	-0.42	-6.43	-0.33	4.51e-10	Life satisfaction;
CRC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg15744005	chr10:104629667	AS3MT	-0.32	-6.21	-0.32	1.56e-9	Arsenic metabolism;
CRC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.73	-11.35	-0.53	1.97e-25	Tonsillectomy;
CRC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg18198730	chr1:247681584	NA	0.57	8.44	0.42	1.03e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs12541635	0.966	rs55729609	chr8:107056034	A/C	cg10147462	chr8:107024639	NA	0.47	7.82	0.4	7.24e-14	Age of smoking initiation;
CRC	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.4	-0.38	1.16e-12	Schizophrenia;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Depression;
CRC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.55	-9.85	-0.48	3.24e-20	Dupuytren's disease;
CRC	cis	rs501120	0.810	rs683297	chr10:44746140	A/G	cg09554077	chr10:44749378	NA	0.9	13.3	0.59	1.4e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg13047869	chr3:10149882	C3orf24	0.52	6.13	0.32	2.48e-9	Alzheimer's disease;
CRC	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.6	-7.01	-0.36	1.35e-11	Major depressive disorder;
CRC	cis	rs1528435	1.000	rs11690655	chr2:181519434	C/T	cg23363182	chr2:181467187	NA	-0.35	-5.69	-0.3	2.82e-8	Body mass index;
CRC	cis	rs9462027	0.628	rs2814945	chr6:34647978	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.51	-6.9	-0.36	2.62e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	7.33	0.37	1.83e-12	Motion sickness;
CRC	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.6	9.3	0.46	1.99e-18	Crohn's disease;
CRC	cis	rs9891119	0.576	rs8069645	chr17:40494902	C/T	cg06270615	chr17:40516068	STAT3	0.34	7.03	0.36	1.24e-11	Multiple sclerosis;Crohn's disease;
CRC	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg04562611	chr16:615315	C16orf11	0.36	6.0	0.31	5.3300000000000004e-09	Height;
CRC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.73	-11.4	-0.53	1.4e-25	Immature fraction of reticulocytes;
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg10729496	chr3:10149963	C3orf24	0.54	6.98	0.36	1.65e-11	Alzheimer's disease;
CRC	cis	rs4654899	0.643	rs651538	chr1:21097866	A/G	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.84	-0.31	1.29e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg27326032	chr3:127006922	NA	-0.55	-7.28	-0.37	2.48e-12	Interleukin-10 levels;Interleukin-13 levels;
CRC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.54	-5.73	-0.3	2.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3736485	0.966	rs11070854	chr15:51808365	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.3	-0.33	9.47e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg15534755	chr11:117069859	TAGLN	0.35	6.65	0.34	1.22e-10	Blood protein levels;
CRC	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.48	6.94	0.36	2.06e-11	Pulmonary function decline;
CRC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	7.16	0.37	5.44e-12	Lung cancer in ever smokers;
CRC	cis	rs6880778	0.505	rs10473189	chr5:40402692	G/C	cg09067459	chr5:40385259	NA	0.46	7.9	0.4	4.18e-14	Inflammatory bowel disease;
CRC	cis	rs1223397	1.000	rs1232392	chr6:13272671	C/G	cg21538684	chr6:13274180	PHACTR1	0.47	5.82	0.31	1.41e-8	Blood pressure;
CRC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg00507830	chr2:103233733	NA	0.67	6.35	0.33	7.17e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	0.57	6.74	0.35	6.92e-11	Prostate cancer;
CRC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.49	7.51	0.38	5.68e-13	Corneal astigmatism;
CRC	cis	rs1528435	1.000	rs2887185	chr2:181528597	C/A	cg23363182	chr2:181467187	NA	-0.35	-5.67	-0.3	3.14e-8	Body mass index;
CRC	cis	rs6504622	0.818	rs9912794	chr17:45034441	C/T	cg16759221	chr17:45003025	GOSR2	-0.49	-7.4	-0.38	1.13e-12	Orofacial clefts;
CRC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.31	-0.42	2.52e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-9.08	-0.45	1.06e-17	Prostate cancer;
CRC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg03030879	chr14:75389066	RPS6KL1	0.43	6.45	0.34	4e-10	Height;
CRC	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.59	8.59	0.43	3.42e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg04315214	chr1:2043799	PRKCZ	0.38	6.7	0.35	9.25e-11	Height;
CRC	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg16141378	chr3:129829833	LOC729375	0.39	6.11	0.32	2.89e-9	Mood instability;
CRC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.38	6.08	0.32	3.4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.51	-7.02	-0.36	1.29e-11	Colorectal cancer;
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg15242686	chr22:24348715	GSTTP1	0.45	6.73	0.35	7.47e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	0.98	13.85	0.61	1.08e-34	Breast cancer;
CRC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.64	8.63	0.43	2.58e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.55	-8.07	-0.41	1.34e-14	Headache;
CRC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.39	6.7	0.35	8.79e-11	Schizophrenia;
CRC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.92	-0.52	6.78e-24	Aortic root size;
CRC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.82	-14.56	-0.63	2e-37	Coronary artery disease;
CRC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.58	-11.35	-0.53	2.12e-25	Asthma (sex interaction);
CRC	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-6.16	-0.32	2.07e-9	Coronary artery disease;
CRC	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-6.01	-0.31	4.84e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.82	-13.66	-0.6	6.03e-34	Height;
CRC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.59	9.14	0.45	6.67e-18	Schizophrenia;
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg13880726	chr7:1868755	MAD1L1	0.45	5.76	0.3	1.89e-8	Bipolar disorder;
CRC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.63	8.76	0.43	1.05e-16	Coronary artery disease;
CRC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	cis	rs427941	0.655	rs201472	chr7:101744428	C/T	cg06246474	chr7:101738831	CUX1	0.44	6.7	0.35	8.96e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.68	6.34	0.33	7.74e-10	Diabetic kidney disease;
CRC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.95	-0.36	1.99e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.01e-12	Alzheimer's disease (late onset);
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg25204440	chr1:209979598	IRF6	0.48	6.32	0.33	8.69e-10	Cleft lip with or without cleft palate;
CRC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.68	9.66	0.47	1.36e-19	Lung cancer;
CRC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12463550	chr7:65579703	CRCP	-0.73	-6.56	-0.34	2.1e-10	Diabetic kidney disease;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg12516270	chr8:143859308	LYNX1	-0.4	-6.23	-0.32	1.46e-9	Urinary tract infection frequency;
CRC	cis	rs4824093	0.610	rs9627798	chr22:50317857	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-8.7	-0.43	1.57e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7605827	0.930	rs6749063	chr2:15565278	T/G	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.62e-9	Educational attainment (years of education);
CRC	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.51	8.68	0.43	1.88e-16	Facial morphology (factor 15, philtrum width);
CRC	trans	rs2303319	0.504	rs66761688	chr2:162578911	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.5e-9	Cognitive function;
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg12500891	chr11:57225987	NA	-0.67	-5.99	-0.31	5.59e-9	Cognitive function;
CRC	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg07701084	chr6:150067640	NUP43	0.47	5.78	0.3	1.73e-8	Lung cancer;
CRC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg09417038	chr21:47716443	C21orf57	0.38	6.26	0.33	1.17e-9	Testicular germ cell tumor;
CRC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.38	-6.72	-0.35	8.08e-11	Crohn's disease;
CRC	cis	rs6479527	0.840	rs1331218	chr9:96766421	T/C	cg14459158	chr9:96720562	NA	0.38	6.99	0.36	1.51e-11	Esophageal adenocarcinoma;
CRC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg16892393	chr17:41919603	NA	0.39	5.9	0.31	8.88e-9	Triglycerides;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00043095	chr2:223289277	SGPP2	0.39	6.35	0.33	7.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg21625146	chr5:486483	SLC9A3	-0.47	-5.72	-0.3	2.35e-8	Cystic fibrosis severity;
CRC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.53	-7.31	-0.37	2.02e-12	Dental caries;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg05569086	chr8:143859399	LYNX1	0.37	6.59	0.34	1.76e-10	Urinary tract infection frequency;
CRC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-7.87	-0.4	5.35e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.28	-0.37	2.52e-12	Thrombosis;
CRC	trans	rs10202249	0.716	rs75322913	chr2:154081080	G/A	cg25823578	chr14:52781312	PTGER2	-0.56	-6.0	-0.31	5.2e-9	Conotruncal heart defects (inherited effects);
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg12564526	chr7:66767603	PMS2L4;STAG3L4	-0.55	-6.03	-0.32	4.29e-9	Lung adenocarcinoma;
CRC	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg11812906	chr14:75593930	NEK9	0.51	6.96	0.36	1.84e-11	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05881034	chr3:42623675	SEC22C	-0.42	-6.22	-0.32	1.48e-9	Myopia (pathological);
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg15145296	chr3:125709740	NA	-0.56	-6.79	-0.35	5.37e-11	Blood pressure (smoking interaction);
CRC	cis	rs2836754	1.000	rs11701117	chr21:40292512	C/T	cg16734191	chr21:40194848	ETS2	-0.32	-5.65	-0.3	3.53e-8	Crohn's disease;Body mass index;
CRC	trans	rs587242	1.000	rs661573	chr1:96891371	G/A	cg10631902	chr5:14652156	NA	0.45	7.06	0.36	1.02e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg18827107	chr12:86230957	RASSF9	-0.49	-8.01	-0.4	1.98e-14	Major depressive disorder;
CRC	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.83	0.44	6.44e-17	Coffee consumption (cups per day);
CRC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.05	-12.05	-0.55	6.18e-28	Diabetic kidney disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24166786	chr3:124775112	HEG1	0.43	6.26	0.33	1.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.89	0.44	3.96e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.73	8.69	0.43	1.8e-16	Arsenic metabolism;
CRC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.8	-12.02	-0.55	7.5e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.05	-0.32	3.89e-9	Coronary artery disease;
CRC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.32	-0.33	8.42e-10	Aortic root size;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.41	7.48	0.38	7.04e-13	Lung cancer;
CRC	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	cg22592108	chr5:53304441	ARL15	0.53	6.24	0.33	1.32e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11056435	chr2:69969221	ANXA4	0.45	6.12	0.32	2.59e-9	Response to antipsychotic treatment;
CRC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg10760299	chr15:45669010	GATM	0.5	7.82	0.4	7.18e-14	Homoarginine levels;
CRC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.68	-0.3	2.92e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11446398	chr5:77624930	NA	-0.48	-6.72	-0.35	7.94e-11	Triglycerides;
CRC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.33	0.37	1.83e-12	Motion sickness;
CRC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-10.23	-0.49	1.67e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Parkinson's disease;
CRC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg03037974	chr15:76606532	NA	-0.66	-11.16	-0.52	9.99e-25	Blood metabolite levels;
CRC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.59	-9.88	-0.48	2.53e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg05139728	chr16:28306816	SBK1	-0.37	-5.99	-0.31	5.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg20647610	chr2:228736258	WDR69	-0.5	-6.8	-0.35	4.83e-11	Blood pressure;
CRC	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.55	9.02	0.45	1.61e-17	Corneal astigmatism;
CRC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.38	6.64	0.34	1.29e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.68	0.51	4.61e-23	Motion sickness;
CRC	cis	rs9311676	0.632	rs11130631	chr3:58366128	G/C	cg06643156	chr3:58380774	PXK	0.42	6.55	0.34	2.17e-10	Systemic lupus erythematosus;
CRC	trans	rs11581859	0.950	rs10489918	chr1:99389462	A/T	cg12183875	chr3:169587454	LRRC31	0.28	6.33	0.33	7.89e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg08200770	chr17:80723486	TBCD	0.42	7.15	0.37	5.63e-12	Glycated hemoglobin levels;
CRC	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.46	6.78	0.35	5.55e-11	Carotid intima media thickness;
CRC	cis	rs4880487	0.853	rs883490	chr10:1249567	G/C	cg03183215	chr10:1252341	ADARB2	-0.3	-6.35	-0.33	7.02e-10	Migraine;
CRC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.43	9.48	0.46	5.3e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-6.16	-0.32	2.13e-9	Obesity (extreme);
CRC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.5	-9.54	-0.47	3.37e-19	Subjective well-being;
CRC	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg12458913	chr13:53173898	NA	0.56	8.7	0.43	1.66e-16	Lewy body disease;
CRC	cis	rs2637266	0.538	rs11001860	chr10:78473388	G/T	cg18941641	chr10:78392320	NA	-0.35	-5.88	-0.31	9.86e-9	Pulmonary function;
CRC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.33	5.94	0.31	7.08e-9	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14559409	chr10:65930703	NA	-0.43	-6.92	-0.36	2.32e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg19338460	chr6:170058176	WDR27	-0.76	-8.3	-0.42	2.78e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	0.57	8.6	0.43	3.25e-16	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.59	-0.34	1.72e-10	Total body bone mineral density;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg03623178	chr6:28175578	NA	0.92	9.6	0.47	2.07e-19	Lung cancer in ever smokers;
CRC	trans	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.52	8.79	0.44	8.22e-17	Aortic root size;
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23120805	chr2:43453872	LOC100129726;ZFP36L2	0.39	6.0	0.31	5.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.52	7.24	0.37	3.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.55	-7.94	-0.4	3.2e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05903289	chr2:130345205	NA	-0.36	-6.97	-0.36	1.79e-11	Response to cytidine analogues (gemcitabine);
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05935360	chr19:11639865	ECSIT	-0.41	-6.59	-0.34	1.79e-10	Obesity-related traits;
CRC	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.58	-8.51	-0.42	6.34e-16	Autism;
CRC	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-0.98	-23.09	-0.79	8.68e-71	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg23461800	chr14:103021989	NA	0.68	7.74	0.39	1.23e-13	Platelet count;
CRC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.19e-17	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12356431	chr5:177591266	NA	0.48	6.79	0.35	5.22e-11	Response to antipsychotic treatment;
CRC	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.68	8.62	0.43	2.96e-16	Gastritis;
CRC	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg15711740	chr2:61764176	XPO1	-0.53	-7.24	-0.37	3.26e-12	Tuberculosis;
CRC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.34e-9	Major depressive disorder;
CRC	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.64	-8.73	-0.43	1.3e-16	Blood trace element (Cu levels);
CRC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.58	8.5	0.42	6.71e-16	Resting heart rate;
CRC	cis	rs8099014	0.731	rs4261624	chr18:56101290	T/A	cg19312305	chr18:56117016	MIR122	-0.43	-5.96	-0.31	6.55e-9	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27544288	chr4:103940923	NHEDC1	0.37	6.18	0.32	1.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-14.36	-0.62	1.19e-36	Longevity;
CRC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg18612461	chr15:75251733	NA	0.36	5.61	0.3	4.31e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs317865	0.737	rs73234642	chr4:16186730	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	5.72	0.3	2.4e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg15571903	chr15:79123663	NA	0.31	6.14	0.32	2.31e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.47	8.53	0.43	5.33e-16	Monocyte count;
CRC	cis	rs911119	0.908	rs6048949	chr20:23603199	C/T	cg16589663	chr20:23618590	CST3	0.45	6.32	0.33	8.44e-10	Chronic kidney disease;
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg25164649	chr6:28176230	NA	0.55	5.75	0.3	2e-8	Depression;
CRC	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg07424746	chr4:185654737	MLF1IP	-0.63	-5.98	-0.31	5.66e-9	Blood protein levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21803754	chr20:60718392	PSMA7;SS18L1	0.43	6.01	0.31	4.97e-9	Survival in pancreatic cancer;
CRC	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-5.99	-0.31	5.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02359409	chr6:42947317	PEX6	-0.69	-11.35	-0.53	2.01e-25	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg26721908	chr21:47610096	LSS	-0.4	-6.04	-0.32	4.26e-9	Testicular germ cell tumor;
CRC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg05623727	chr3:50126028	RBM5	0.46	7.58	0.39	3.49e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.593	rs1944121	chr11:111347223	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	5.85	0.31	1.22e-8	Primary sclerosing cholangitis;
CRC	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14019695	chr9:139328340	INPP5E	0.44	6.39	0.33	5.62e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs524281	0.684	rs7946447	chr11:65864338	T/C	cg14036092	chr11:66035641	RAB1B	-0.45	-5.74	-0.3	2.14e-8	Electroencephalogram traits;
CRC	cis	rs11191205	0.686	rs11191070	chr10:103396862	C/T	cg15320455	chr10:103880129	LDB1	0.56	6.19	0.32	1.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.4	-6.74	-0.35	7.28e-11	Mean arterial pressure;
CRC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.58	-0.47	2.55e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs995000	0.931	rs10789117	chr1:63072265	A/C	cg19896129	chr1:63156450	NA	0.43	6.75	0.35	6.54e-11	Triglyceride levels;
CRC	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.81	5.9	0.31	8.83e-9	LDL cholesterol;
CRC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg00343986	chr7:65444356	GUSB	0.41	5.67	0.3	3.15e-8	Aortic root size;
CRC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.59	10.05	0.48	6.89e-21	Menarche (age at onset);
CRC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg19223190	chr17:80058835	NA	0.42	6.52	0.34	2.69e-10	Life satisfaction;
CRC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-6.93	-0.36	2.22e-11	Alzheimer's disease (late onset);
CRC	trans	rs12643440	0.585	rs601517	chr4:17167630	T/C	cg16738984	chr19:14519121	CD97	0.2	5.98	0.31	5.8e-9	Metabolite levels (Pyroglutamine);
CRC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.77	11.99	0.55	1.01e-27	Monocyte count;
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.46	-10.37	-0.5	5.51e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2811415	0.597	rs3733158	chr3:127787157	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg16447950	chr5:562315	NA	-0.85	-13.07	-0.58	1.01e-31	Ulcerative colitis;
CRC	cis	rs10450586	0.932	rs10767630	chr11:27314069	A/T	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg18845289	chr12:121124611	MLEC	-0.41	-6.22	-0.32	1.53e-9	Daytime sleep phenotypes;
CRC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg23018236	chr17:30244563	NA	-0.47	-6.65	-0.34	1.23e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.9	12.69	0.57	2.51e-30	Initial pursuit acceleration;
CRC	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg10820045	chr2:198174542	NA	-0.56	-9.94	-0.48	1.61e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.48	7.66	0.39	2.08e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg21115391	chr11:93143810	CCDC67	0.39	5.81	0.3	1.5e-8	Pulmonary function decline;
CRC	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg12573674	chr2:1569213	NA	-0.64	-6.89	-0.36	2.81e-11	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2979489	0.891	rs17627965	chr8:30354376	C/T	cg26383811	chr8:30366931	RBPMS	0.64	9.15	0.45	6.21e-18	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.51	-7.87	-0.4	5.06e-14	Diastolic blood pressure;
CRC	cis	rs12753569	0.934	rs6676370	chr1:76490185	G/T	cg00791851	chr1:76518896	NA	-0.4	-7.14	-0.37	5.94e-12	Personality dimensions;
CRC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-12.18	-0.56	1.96e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.17	0.41	6.79e-15	Lung cancer;
CRC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.61	11.44	0.53	9.47e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.42	8.19	0.41	5.67e-15	Mean corpuscular volume;
CRC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.43	10.05	0.48	6.76e-21	Coronary artery disease;
CRC	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.63e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.53	-9.23	-0.45	3.49e-18	Aortic root size;
CRC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg12927641	chr6:109611667	NA	-0.39	-6.88	-0.35	3.11e-11	Reticulocyte fraction of red cells;
CRC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.44	5.62	0.3	4.14e-8	Mean corpuscular hemoglobin;
CRC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.58	6.47	0.34	3.47e-10	Bipolar disorder;
CRC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.1	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.52	8.44	0.42	9.99e-16	Breast cancer;
CRC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	7.22	0.37	3.72e-12	Schizophrenia;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg04518342	chr5:131593106	PDLIM4	0.48	8.81	0.44	7.59e-17	Breast cancer;
CRC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.46	-6.45	-0.33	4.02e-10	DNA methylation (variation);
CRC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06544989	chr22:39130855	UNC84B	0.43	6.43	0.33	4.49e-10	Menopause (age at onset);
CRC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.31	0.37	2.04e-12	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs7027930	0.524	rs6477035	chr9:618490	G/T	cg27061366	chr19:13044373	FARSA	0.53	6.48	0.34	3.25e-10	Pulmonary function decline;
CRC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.67	-0.35	1.06e-10	Response to antipsychotic treatment;
CRC	cis	rs4787491	0.729	rs3814878	chr16:30041966	A/G	cg08188419	chr16:30022634	DOC2A	0.38	5.66	0.3	3.34e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.55	7.42	0.38	1.03e-12	Height;
CRC	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.43	7.62	0.39	2.82e-13	Prostate cancer;
CRC	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg21496419	chr19:44306685	LYPD5	-0.34	-6.38	-0.33	6.09e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.61	10.76	0.51	2.53e-23	Aortic root size;
CRC	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.96	-13.63	-0.6	7.41e-34	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.12	0.32	2.73e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg21956150	chr19:1438388	RPS15	0.41	6.27	0.33	1.1e-9	Interleukin-6 levels;
CRC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.45	0.38	8.13e-13	Motion sickness;
CRC	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg25547332	chr5:131281432	NA	0.39	5.73	0.3	2.25e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.68	-7.97	-0.4	2.55e-14	Pursuit maintenance gain;
CRC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.47	8.19e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4664293	0.867	rs6432558	chr2:160601908	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.41	0.5	4.04e-22	Corneal astigmatism;
CRC	cis	rs9491140	0.539	rs11154230	chr6:124686156	A/G	cg05308643	chr6:124982296	NKAIN2	0.47	6.59	0.34	1.7e-10	Neuroticism;
CRC	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg21851534	chr17:3907994	ZZEF1	-0.37	-6.72	-0.35	7.78e-11	Type 2 diabetes;
CRC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.66	-0.3	3.38e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.68	0.3	2.98e-8	Lung cancer;
CRC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.39	-0.33	5.55e-10	Aortic root size;
CRC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-12.2	-0.56	1.72e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22029157	chr1:209979665	IRF6	0.66	7.25	0.37	2.97e-12	Cleft lip with or without cleft palate;
CRC	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.73	-0.3	2.24e-8	Protein biomarker;
CRC	cis	rs6662572	1.000	rs72688469	chr1:46118393	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.74	0.3	2.18e-8	Blood protein levels;
CRC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.29	5.94	0.31	7.29e-9	Homoarginine levels;
CRC	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	12.14	0.56	2.94e-28	Coffee consumption (cups per day);
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.95	-0.36	1.91e-11	Breast cancer;
CRC	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg00507830	chr2:103233733	NA	0.67	6.48	0.34	3.4e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.77	0.44	9.61e-17	Cognitive test performance;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12598163	chr13:111806585	ARHGEF7	0.43	6.46	0.34	3.66e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.45	-0.34	4e-10	Lymphocyte counts;
CRC	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	cg04338863	chr8:33670619	NA	0.46	7.29	0.37	2.31e-12	Body mass index;
CRC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.62	9.5	0.46	4.49e-19	Corneal astigmatism;
CRC	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-8.72	-0.43	1.42e-16	Educational attainment;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.83	-7.76	-0.39	1.11e-13	IgG glycosylation;
CRC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.75	12.83	0.58	7.79e-31	Colorectal cancer;
CRC	cis	rs12044355	0.927	rs11585959	chr1:231833718	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.55	-0.34	2.28e-10	Alzheimer's disease;
CRC	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.53	8.92	0.44	3.24e-17	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg15145296	chr3:125709740	NA	-0.58	-6.83	-0.35	4.22e-11	Blood pressure (smoking interaction);
CRC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-7.06	-0.36	9.89e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.98	-19.27	-0.73	6.62e-56	Height;
CRC	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.6	-8.08	-0.41	1.22e-14	Waist circumference;Body mass index;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg05756136	chr1:119680316	WARS2	-0.53	-7.15	-0.37	5.56e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.52	7.65	0.39	2.24e-13	DNA methylation (variation);
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.65	6.1	0.32	2.93e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs16867321	0.951	rs1901749	chr2:181350633	G/A	cg23363182	chr2:181467187	NA	-0.53	-6.26	-0.33	1.18e-9	Obesity;
CRC	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg12856521	chr11:46389249	DGKZ	0.43	6.67	0.35	1.11e-10	Leprosy;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14653225	chr1:228003938	PRSS38	-0.42	-6.03	-0.32	4.41e-9	Hip circumference;
CRC	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.34	6.26	0.33	1.22e-9	Panic disorder;
CRC	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg00631329	chr6:26305371	NA	-0.41	-6.93	-0.36	2.19e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.23	-0.45	3.34e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.39	5.65	0.3	3.52e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg14352298	chr13:112236639	NA	0.29	6.59	0.34	1.74e-10	Hepatitis;
CRC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.51	8.11	0.41	1.01e-14	Red blood cell count;
CRC	cis	rs12431939	1.000	rs4567626	chr14:51647640	A/T	cg23942311	chr14:51606299	NA	0.48	5.67	0.3	3.16e-8	Cancer;
CRC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.53	7.72	0.39	1.43e-13	Tuberculosis;
CRC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.46	7.46	0.38	7.95e-13	Educational attainment;
CRC	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg06632207	chr12:54070931	ATP5G2	0.4	6.91	0.36	2.6e-11	Height;
CRC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.54	9.2	0.45	4.28e-18	Eye color traits;
CRC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.74	-0.35	7.05e-11	Aortic root size;
CRC	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.11	0.41	1e-14	Cognitive performance;
CRC	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg26248373	chr2:1572462	NA	-0.74	-10.3	-0.49	9.68e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10046574	0.519	rs10250947	chr7:135211017	T/G	cg27474649	chr7:135195673	CNOT4	0.6	5.88	0.31	1.01e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.79	-13.59	-0.6	1.03e-33	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7632954	1.000	rs9312021	chr3:8526809	T/A	cg03495237	chr3:8533978	NA	0.33	5.86	0.31	1.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.3	-0.49	9.26e-22	Bone mineral density;
CRC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.76	-12.32	-0.56	6.4e-29	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21638108	chr19:19431283	KIAA0892;SF4	0.43	7.2	0.37	4.01e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	7.09	0.36	8.19e-12	Breast cancer;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg12172441	chr6:28176163	NA	0.54	6.97	0.36	1.74e-11	Parkinson's disease;
CRC	cis	rs11382616	1	rs11382616	chr14:103081465	G/GC	cg12046867	chr14:103022105	NA	-0.41	-5.61	-0.3	4.27e-8	Plateletcrit;Platelet count;
CRC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.38	5.7	0.3	2.61e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.47	6.31	0.33	8.99e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.81	-10.01	-0.48	8.99e-21	Initial pursuit acceleration;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg06470822	chr6:28175283	NA	0.87	9.01	0.44	1.74e-17	Lung cancer in ever smokers;
CRC	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00495681	chr13:53174319	NA	0.51	7.7	0.39	1.5700000000000001e-13	Lewy body disease;
CRC	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.65	11.06	0.52	2.14e-24	Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14415379	chr5:118324374	DTWD2	0.45	6.73	0.35	7.48e-11	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01370623	chr17:35849806	DUSP14	0.49	6.3	0.33	9.52e-10	Anxiety disorder;
CRC	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg00601450	chr5:74908170	NA	0.4	5.64	0.3	3.71e-8	Age-related disease endophenotypes;
CRC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.65	9.54	0.47	3.3e-19	Menopause (age at onset);
CRC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	9.71	0.47	9.3e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.75	11.24	0.53	5.11e-25	High light scatter reticulocyte count;
CRC	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg14191688	chr11:70257035	CTTN	0.45	5.84	0.31	1.26e-8	Coronary artery disease;
CRC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.82	-0.44	6.69e-17	Chronic sinus infection;
CRC	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg15654264	chr1:150340011	RPRD2	0.4	5.73	0.3	2.3e-8	Migraine;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22985182	chr3:156273085	SSR3	0.45	6.21	0.32	1.64e-9	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.56	6.58	0.34	1.9e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.6	9.47	0.46	5.48e-19	Anterior chamber depth;
CRC	trans	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg19694781	chr19:47549865	TMEM160	-0.44	-7.0	-0.36	1.44e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.57	8.95	0.44	2.68e-17	HDL cholesterol;
CRC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	8.57	0.43	4.09e-16	Schizophrenia;
CRC	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	7.94	0.4	3.32e-14	Menarche (age at onset);
CRC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg17294928	chr15:75287854	SCAMP5	0.5	7.69	0.39	1.75e-13	Breast cancer;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.74	7.49	0.38	6.31e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg20608306	chr11:116969690	SIK3	0.29	5.84	0.31	1.24e-8	Blood protein levels;
CRC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.64	7.41	0.38	1.05e-12	Gut microbiome composition (summer);
CRC	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.36	-7.02	-0.36	1.27e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs6504950	0.705	rs9899545	chr17:52986845	T/C	cg26251398	chr17:52985966	TOM1L1	0.41	6.06	0.32	3.66e-9	Breast cancer;
CRC	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg08999081	chr20:33150536	PIGU	0.46	5.66	0.3	3.22e-8	Neuroticism;
CRC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.92	-17.71	-0.7	9.15e-50	Myeloid white cell count;
CRC	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg04132472	chr17:19861366	AKAP10	0.42	6.47	0.34	3.56e-10	Schizophrenia;
CRC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg13072238	chr3:49761600	GMPPB	-0.52	-5.92	-0.31	8.06e-9	Menarche (age at onset);
CRC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-0.84	-12.74	-0.57	1.68e-30	Blood trace element (Zn levels);
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.35	-0.42	1.91e-15	Aortic root size;
CRC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.56	6.26	0.33	1.2e-9	Bipolar disorder;
CRC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.67	5.7	0.3	2.61e-8	Putamen volume;
CRC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07513332	chr6:167530253	CCR6	-0.41	-7.13	-0.37	6.45e-12	Primary biliary cholangitis;
CRC	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.38	5.81	0.31	1.46e-8	HDL cholesterol;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg02007433	chr3:129722099	NA	-0.61	-9.27	-0.46	2.51e-18	Blood pressure (smoking interaction);
CRC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.27	14.66	0.63	8.59e-38	Diabetic kidney disease;
CRC	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.51	6.26	0.33	1.2e-9	Late-onset Alzheimer's disease;
CRC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.38	6.05	0.32	4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18099408	chr3:52552593	STAB1	0.46	7.64	0.39	2.44e-13	Bipolar disorder;
CRC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	11.41	0.53	1.2e-25	High light scatter reticulocyte count;
CRC	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.57	9.06	0.45	1.16e-17	Vitiligo;
CRC	cis	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.72	-0.35	8e-11	Daytime sleep phenotypes;
CRC	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.97	0.52	4.4e-24	Bipolar disorder;
CRC	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.42	-6.49	-0.34	3.19e-10	Breast cancer;
CRC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg15147215	chr3:52552868	STAB1	0.46	6.56	0.34	2.11e-10	Schizophrenia;
CRC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg09163369	chr1:210001066	C1orf107	0.41	5.75	0.3	2.01e-8	Orofacial clefts;
CRC	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.7	10.16	0.49	2.78e-21	White matter hyperintensity burden;
CRC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.12	-0.32	2.7e-9	Morning vs. evening chronotype;
CRC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg11189052	chr15:85197271	WDR73	0.58	7.58	0.39	3.65e-13	Schizophrenia;
CRC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.92	-0.44	3.24e-17	Multiple myeloma (hyperdiploidy);
CRC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-7.34	-0.38	1.64e-12	Coronary artery disease;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02359409	chr6:42947317	PEX6	-0.57	-8.83	-0.44	6.16e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.6	-9.7	-0.47	9.91e-20	Vitiligo;
CRC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg20203395	chr5:56204925	C5orf35	0.7	8.17	0.41	6.8e-15	Initial pursuit acceleration;
CRC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.38	-0.46	1.1e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.74	10.49	0.5	2.2e-22	Cognitive function;
CRC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.25	-0.33	1.28e-9	Monocyte percentage of white cells;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg27532560	chr4:187881888	NA	0.53	9.47	0.46	5.86e-19	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9693857	0.520	rs7830572	chr8:9356802	T/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.3	0.33	9.52e-10	Systolic blood pressure;
CRC	cis	rs12620999	0.941	rs62183344	chr2:237979165	T/C	cg23555395	chr2:238036564	NA	0.54	8.34	0.42	2.03e-15	Systemic lupus erythematosus;
CRC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg21523564	chr15:75251491	NA	0.4	5.83	0.31	1.34e-8	Breast cancer;
CRC	cis	rs9658691	0.646	rs7079111	chr10:90750982	T/G	cg03111039	chr10:90751583	FAS;ACTA2	0.77	5.87	0.31	1.04e-8	Mosquito bite size;
CRC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.62	7.22	0.37	3.55e-12	Menarche (age at onset);
CRC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg23298862	chr7:158159286	PTPRN2	-0.48	-7.9	-0.4	4.22e-14	Calcium levels;
CRC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.54	6.82	0.35	4.35e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4803480	0.529	rs4803481	chr19:42066556	A/G	cg08478046	chr19:42093086	CEACAM21	-0.28	-5.92	-0.31	7.88e-9	Schizophrenia;
CRC	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg24851651	chr11:66362959	CCS	-0.39	-6.77	-0.35	5.93e-11	Educational attainment (years of education);
CRC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.72	-10.35	-0.5	6.44e-22	Lung cancer;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.27e-9	Life satisfaction;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg09597638	chr17:3907349	NA	0.63	11.22	0.53	5.9e-25	Type 2 diabetes;
CRC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.37	5.86	0.31	1.1e-8	Life satisfaction;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.69	-0.35	9.4e-11	Electroencephalogram traits;
CRC	cis	rs10924970	0.967	rs10495362	chr1:235390396	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.79	0.3	1.64e-8	Asthma;
CRC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.75	-0.47	6.69e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.47	-8.56	-0.43	4.51e-16	Total body bone mineral density;
CRC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	10.73	0.51	3.25e-23	Hip circumference adjusted for BMI;
CRC	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.66	13.03	0.58	1.46e-31	Schizophrenia;
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg04553112	chr3:125709451	NA	-0.52	-5.97	-0.31	6.27e-9	Blood pressure (smoking interaction);
CRC	cis	rs216303	1.000	rs216304	chr12:6159537	A/G	cg19878637	chr12:6148451	VWF	-0.55	-6.06	-0.32	3.73e-9	Low vWF levels;
CRC	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.69	7.17	0.37	4.83e-12	Recalcitrant atopic dermatitis;
CRC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	trans	rs9840812	0.953	rs61791721	chr3:135804550	T/A	cg17080335	chr12:131030206	NA	0.41	6.25	0.33	1.27e-9	Fibrinogen levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg27434351	chr11:14521491	COPB1	0.4	6.32	0.33	8.52e-10	Interleukin-6 levels;
CRC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.46	6.52	0.34	2.6e-10	Cognitive ability;
CRC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.08	16.91	0.68	1.36e-46	Testicular germ cell tumor;
CRC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.73	9.52	0.46	4e-19	Cleft lip with or without cleft palate;
CRC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.82	12.6	0.57	5.59e-30	Cognitive function;
CRC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg13047869	chr3:10149882	C3orf24	0.4	6.05	0.32	3.83e-9	Alzheimer's disease;
CRC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.71	-0.43	1.48e-16	Platelet count;
CRC	cis	rs3996993	0.809	rs6458879	chr6:52688783	G/C	cg20803780	chr6:52668592	GSTA1	-0.39	-7.27	-0.37	2.62e-12	Hemoglobin concentration;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01750847	chr16:30007184	HIRIP3;INO80E	0.42	7.13	0.37	6.57e-12	Obesity-related traits;
CRC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg03160526	chr17:80928410	B3GNTL1	-0.52	-8.68	-0.43	1.9e-16	Breast cancer;
CRC	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.6	8.78	0.44	9.43e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21871583	chr3:15374148	SH3BP5	0.3	6.25	0.33	1.31e-9	Obesity-related traits;
CRC	cis	rs6499129	1.000	rs8047159	chr16:67453634	T/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.73	-0.35	7.7e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg08942682	chr3:197409980	KIAA0226	-0.47	-6.12	-0.32	2.71e-9	Parkinson's disease;
CRC	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg23229984	chr5:148520753	ABLIM3	0.48	6.81	0.35	4.71e-11	Breast cancer;
CRC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.07	-18.29	-0.71	4.77e-52	Blood pressure (smoking interaction);
CRC	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs72634258	0.945	rs7517357	chr1:8025275	C/T	cg26816564	chr1:7831052	VAMP3	0.56	6.04	0.32	4.12e-9	Inflammatory bowel disease;
CRC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg19812747	chr11:111475976	SIK2	0.52	7.58	0.39	3.46e-13	Primary sclerosing cholangitis;
CRC	cis	rs6076065	0.723	rs2275787	chr20:23338486	A/G	cg11657817	chr20:23433608	CST11	0.46	6.81	0.35	4.7e-11	Facial morphology (factor 15, philtrum width);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17133724	chr18:22932450	ZNF521	0.38	6.12	0.32	2.63e-9	Schizophrenia;
CRC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-0.65	-6.18	-0.32	1.88e-9	Lung cancer;
CRC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.38e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.47	7.33	0.37	1.85e-12	Prostate cancer;
CRC	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.5	7.12	0.37	6.81e-12	Caudate activity during reward;
CRC	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-5.97	-0.31	6.19e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Parkinson's disease;
CRC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.76	-12.23	-0.56	1.32e-28	Cystic fibrosis severity;
CRC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.43	-7.9	-0.4	4.32e-14	Iron status biomarkers;
CRC	cis	rs2882667	0.690	rs167009	chr5:138200457	G/C	cg09476006	chr5:138032270	NA	-0.54	-8.92	-0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7487075	0.820	rs12816413	chr12:46723289	T/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.34	0.33	7.36e-10	Itch intensity from mosquito bite;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02842104	chr19:12251201	ZNF20	0.36	6.27	0.33	1.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.61	-0.34	1.59e-10	Acne (severe);
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02725872	chr8:58115012	NA	-0.51	-7.09	-0.36	8.18e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.2e-25	Prostate cancer;
CRC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.16	0.41	7.42e-15	Platelet count;
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg24503407	chr1:205819492	PM20D1	0.46	6.35	0.33	7.26e-10	Parkinson's disease;
CRC	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	7.62	0.39	2.79e-13	Homocysteine levels;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.98	-0.44	2.11e-17	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13265914	chr8:21999630	REEP4	0.41	6.17	0.32	1.97e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.62	7.96	0.4	2.73e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11229555	0.645	rs35735990	chr11:58187371	G/A	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.9	-15.42	-0.65	9.69e-41	Height;
CRC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.38	0.42	1.56e-15	Platelet count;
CRC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.43	6.87	0.35	3.16e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.64	-6.87	-0.35	3.27e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.61	8.92	0.44	3.38e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg24881330	chr22:46731750	TRMU	-0.6	-7.0	-0.36	1.43e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg26816564	chr1:7831052	VAMP3	-0.51	-6.15	-0.32	2.29e-9	Inflammatory bowel disease;
CRC	cis	rs2274273	0.588	rs9919932	chr14:55814080	A/G	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.82	-0.31	1.4e-8	Protein biomarker;
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.66	0.3	3.23e-8	Prudent dietary pattern;
CRC	cis	rs8105895	0.935	rs4257328	chr19:22240090	G/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-8.14	-0.41	8.04e-15	Gut microbiome composition (summer);
CRC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.0	0.31	5.22e-9	Diabetic kidney disease;
CRC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.64	-8.34	-0.42	2.01e-15	DNA methylation (variation);
CRC	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg20356878	chr3:121714668	ILDR1	-0.48	-7.04	-0.36	1.12e-11	Multiple sclerosis;
CRC	cis	rs2070677	0.736	rs12261564	chr10:135354594	C/T	cg20169779	chr10:135381914	SYCE1	-0.69	-8.46	-0.42	9.21e-16	Gout;
CRC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs4917300	0.626	rs1388796	chr8:143096437	A/G	cg25363559	chr8:143086065	NA	-0.34	-6.35	-0.33	6.98e-10	Amyotrophic lateral sclerosis;
CRC	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-5.93	-0.31	7.68e-9	Blood pressure;
CRC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24308560	chr3:49941425	MST1R	-0.45	-7.06	-0.36	9.94e-12	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs354225	0.584	rs7591231	chr2:54829596	C/G	cg26097391	chr2:54893211	SPTBN1	0.41	6.11	0.32	2.8e-9	Schizophrenia;
CRC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-8.06	-0.41	1.42e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.83	0.66	2.4e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.72	0.54	9.63e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.75	-0.35	6.77e-11	Monocyte count;
CRC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.51	0.46	4.25e-19	Hip circumference adjusted for BMI;
CRC	cis	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg11143507	chr3:125485238	NA	-0.51	-5.61	-0.3	4.4e-8	Blood pressure (smoking interaction);
CRC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg09876464	chr15:85330779	ZNF592	0.45	7.61	0.39	2.9e-13	P wave terminal force;
CRC	cis	rs12024301	0.557	rs7542316	chr1:183595222	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.48	-9.49	-0.46	4.73e-19	Prostate cancer;
CRC	cis	rs4750440	0.585	rs7072791	chr10:14028195	A/C	cg00551146	chr10:14014579	FRMD4A	0.46	7.4	0.38	1.15e-12	Adiponectin levels;
CRC	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg21153622	chr11:89784906	NA	0.46	7.18	0.37	4.56e-12	HDL cholesterol;
CRC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.62	-9.27	-0.46	2.52e-18	Blood protein levels;
CRC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.75	7.1	0.36	7.91e-12	Body mass index;
CRC	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	7.48	0.38	6.71e-13	Height;
CRC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	9.31	0.46	1.89e-18	Psoriasis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09144709	chr1:116915824	ATP1A1	0.45	6.23	0.32	1.47e-9	Survival in pancreatic cancer;
CRC	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.63	-7.77	-0.39	1.01e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.79	9.53	0.47	3.55e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs2735413	0.918	rs12918959	chr16:78081719	T/C	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg08501292	chr6:25962987	TRIM38	0.91	8.23	0.41	4.35e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg21251018	chr6:28226885	NKAPL	0.46	6.93	0.36	2.19e-11	Cardiac Troponin-T levels;
CRC	cis	rs12144094	0.882	rs11577560	chr1:120229865	A/G	cg20995928	chr1:120229863	NA	0.45	6.48	0.34	3.34e-10	Height;
CRC	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg04586622	chr2:25135609	ADCY3	-0.55	-9.32	-0.46	1.68e-18	Body mass index;
CRC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.72	9.5	0.46	4.34e-19	Cleft lip with or without cleft palate;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg04553112	chr3:125709451	NA	-0.49	-5.74	-0.3	2.2e-8	Blood pressure (smoking interaction);
CRC	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.77	15.46	0.65	6.37e-41	Mean corpuscular hemoglobin;
CRC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.57	8.46	0.42	8.9e-16	Homoarginine levels;
CRC	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.9	7.84	0.4	6.13e-14	Pediatric areal bone mineral density (radius);
CRC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.04	16.67	0.68	1.18e-45	Testicular germ cell tumor;
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg16989086	chr20:62203971	PRIC285	0.47	6.03	0.32	4.52e-9	Glioblastoma;
CRC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.02	-0.45	1.64e-17	Chronic sinus infection;
CRC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-6.76	-0.35	6.45e-11	Bone mineral density (hip);Bone mineral density (spine);
CRC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.81	-0.35	4.53e-11	Total body bone mineral density;
CRC	cis	rs4880487	0.888	rs7074199	chr10:1251022	C/T	cg03183215	chr10:1252341	ADARB2	-0.3	-6.31	-0.33	8.86e-10	Migraine;
CRC	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.52	-8.31	-0.42	2.49e-15	Corneal astigmatism;
CRC	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.95	-0.55	1.42e-27	Colorectal cancer;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg15786705	chr6:28176104	NA	0.55	7.73	0.39	1.28e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.61	7.43	0.38	9.64e-13	Lymphocyte counts;
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg15145296	chr3:125709740	NA	-0.57	-6.5	-0.34	2.98e-10	Blood pressure (smoking interaction);
CRC	cis	rs17152411	1.000	rs12573033	chr10:126607803	T/G	cg07906193	chr10:126599966	NA	0.57	6.43	0.33	4.38e-10	Height;
CRC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.71	9.54	0.47	3.27e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10486722	0.607	rs1003291	chr7:41750087	G/A	cg22138096	chr7:41772439	LOC285954	0.69	8.18	0.41	6.32e-15	Pit-and-Fissure caries;
CRC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.39	-5.71	-0.3	2.53e-8	Neurofibrillary tangles;
CRC	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-7.81	-0.4	7.82e-14	Post bronchodilator FEV1;
CRC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.53	6.83	0.35	4.04e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg13798780	chr7:105162888	PUS7	0.64	7.32	0.37	1.91e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.4	0.33	5.42e-10	Diabetic kidney disease;
CRC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.4	-6.74	-0.35	7.29e-11	Blood metabolite levels;
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg07404485	chr7:94953653	PON1	-0.44	-5.83	-0.31	1.3e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.01	0.48	9.43e-21	Platelet count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01705458	chr11:27384997	CCDC34	0.46	5.98	0.31	5.83e-9	Anxiety disorder;
CRC	cis	rs400736	0.894	rs226253	chr1:8027706	T/C	cg25007680	chr1:8021821	PARK7	0.56	7.6	0.39	3.13e-13	Response to antidepressants and depression;
CRC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	13.34	0.59	9.15e-33	Bone mineral density;
CRC	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.61	-9.39	-0.46	1.06e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7707921	0.881	rs2629744	chr5:81381997	A/T	cg07807695	chr5:81608485	ATP6AP1L	0.41	6.06	0.32	3.75e-9	Breast cancer;
CRC	cis	rs2070997	0.702	rs11792273	chr9:133754032	A/G	cg01000188	chr9:133769184	QRFP	0.56	5.9	0.31	9.07e-9	Response to amphetamines;
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.62	0.54	2.25e-26	Prudent dietary pattern;
CRC	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg11900509	chr10:81946545	ANXA11	-0.63	-6.43	-0.33	4.58e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg26576206	chr19:1064938	ABCA7	0.42	5.96	0.31	6.6e-9	Alzheimer's disease (late onset);
CRC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.85	0.4	6.07e-14	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.54	8.43	0.42	1.08e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg06243866	chr13:111019493	COL4A2	-0.39	-5.99	-0.31	5.6e-9	White matter hyperintensity burden;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.59	-10.15	-0.49	3.12e-21	Prudent dietary pattern;
CRC	cis	rs12541635	0.677	rs13439705	chr8:106967268	T/C	cg10147462	chr8:107024639	NA	0.57	9.42	0.46	8e-19	Age of smoking initiation;
CRC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-5.95	-0.31	6.96e-9	Arsenic metabolism;
CRC	cis	rs6743226	0.870	rs4675966	chr2:242244342	T/C	cg10021735	chr2:242295487	FARP2	0.46	6.57	0.34	1.94e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.45	-21.36	-0.76	3.94e-64	Hemostatic factors and hematological phenotypes;
CRC	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.54	7.98	0.4	2.43e-14	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.931	rs1168044	chr1:62977558	A/C	cg19896129	chr1:63156450	NA	-0.44	-6.86	-0.35	3.42e-11	Triglyceride levels;
CRC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.8	-12.19	-0.56	1.91e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg23123621	chr4:1343375	KIAA1530	0.38	6.07	0.32	3.46e-9	Obesity-related traits;
CRC	trans	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.53	-8.5	-0.42	6.79e-16	Aortic root size;
CRC	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg00318322	chr16:67708822	GFOD2	-0.32	-5.96	-0.31	6.51e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02056921	chr1:901892	PLEKHN1	-0.51	-6.46	-0.34	3.82e-10	Diisocyanate-induced asthma;
CRC	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.45	-5.82	-0.31	1.38e-8	Red blood cell traits;
CRC	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	17.88	0.7	1.95e-50	Colorectal cancer;
CRC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.07	-12.34	-0.56	5.05e-29	Diabetic kidney disease;
CRC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	1.03	20.96	0.76	1.52e-62	Headache;
CRC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.44	-0.33	4.25e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.46	7.07	0.36	9.57e-12	HDL cholesterol;
CRC	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg15571903	chr15:79123663	NA	-0.31	-6.08	-0.32	3.34e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.75	12.28	0.56	8.63e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg20265528	chr2:105853269	NA	-0.34	-5.74	-0.3	2.1e-8	Type 2 diabetes;
CRC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	8.88	0.44	4.29e-17	Bipolar disorder and schizophrenia;
CRC	trans	rs9561329	0.800	rs12865188	chr13:94034234	G/A	cg23072629	chr2:239195537	PER2	0.32	6.01	0.31	5.03e-9	Neuroticism (age interaction);
CRC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.15	0.41	7.9e-15	Lung cancer;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.37	-5.73	-0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg01849466	chr14:104193079	ZFYVE21	0.41	6.44	0.33	4.16e-10	Body mass index;
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02725872	chr8:58115012	NA	-0.52	-7.24	-0.37	3.13e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg09915433	chr19:53449742	NA	-0.51	-7.33	-0.37	1.76e-12	Psoriasis;
CRC	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	5.78	0.3	1.72e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg17467752	chr17:38218738	THRA	-0.38	-5.63	-0.3	3.87e-8	Self-reported allergy;
CRC	trans	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04565464	chr8:145669602	NFKBIL2	0.41	6.38	0.33	6.08e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs72956618	0.715	rs72933222	chr2:207319653	C/T	cg13699355	chr2:468179	NA	-0.63	-6.07	-0.32	3.43e-9	Tonsillectomy;
CRC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.57	11.37	0.53	1.67e-25	Asthma (sex interaction);
CRC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.82	9.46	0.46	6.06e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.8e-13	Colorectal cancer;
CRC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg08761264	chr16:28874980	SH2B1	-0.42	-5.63	-0.3	3.83e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.66	-9.39	-0.46	1.07e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.89	8.73	0.43	1.32e-16	Lymphocyte counts;
CRC	cis	rs1223397	0.651	rs449727	chr6:13296310	A/G	cg07912922	chr6:13274314	PHACTR1	0.37	5.72	0.3	2.4e-8	Blood pressure;
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.25e-36	Prudent dietary pattern;
CRC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg21155852	chr7:2048760	MAD1L1	-0.51	-6.9	-0.36	2.76e-11	Bipolar disorder;
CRC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.49	0.5	2.13e-22	Systolic blood pressure;
CRC	cis	rs6681460	0.966	rs4655506	chr1:67150811	C/T	cg02459107	chr1:67143332	SGIP1	0.41	7.19	0.37	4.5e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.64	8.56	0.43	4.5e-16	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16196087	chr6:146135442	FBXO30	0.38	5.97	0.31	6.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4908768	0.501	rs1922983	chr1:8531326	A/G	cg20416874	chr1:8611966	RERE	-0.42	-5.84	-0.31	1.22e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.52	-0.34	2.59e-10	Bipolar disorder;
CRC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg00334542	chr7:100209784	MOSPD3	-0.69	-7.91	-0.4	4e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.76	9.03	0.45	1.49e-17	Lung function (FEV1/FVC);
CRC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.71	0.35	8.75e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs7027930	0.520	rs10975385	chr9:607178	C/G	cg01026373	chr5:141071769	NA	0.5	5.97	0.31	6.2e-9	Pulmonary function decline;
CRC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	12.13	0.56	3.08e-28	Mean platelet volume;
CRC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17554472	chr22:41940697	POLR3H	-0.57	-5.82	-0.31	1.37e-8	Vitiligo;
CRC	trans	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg10756647	chr7:56101905	PSPH	0.74	7.74	0.39	1.23e-13	Diabetic kidney disease;
CRC	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg11130432	chr3:121712080	ILDR1	-0.54	-6.31	-0.33	9.1e-10	Multiple sclerosis;
CRC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg02659138	chr7:134003124	SLC35B4	0.4	6.96	0.36	1.84e-11	Mean platelet volume;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04577441	chr4:100870687	LOC256880;H2AFZ	-0.41	-6.13	-0.32	2.55e-9	Interleukin-6 levels;
CRC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.48	-7.85	-0.4	5.87e-14	Body mass index;
CRC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.64	-13.25	-0.59	2.01e-32	Schizophrenia;
CRC	cis	rs2179367	0.959	rs4895788	chr6:149748091	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.38	-5.79	-0.3	1.68e-8	Dupuytren's disease;
CRC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.35e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.82	-0.35	4.48e-11	QT interval;
CRC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.54	-8.79	-0.44	8.63e-17	Coronary artery disease;
CRC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.72	-9.64	-0.47	1.55e-19	Coronary artery disease;
CRC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-6.68	-0.35	9.91e-11	Schizophrenia;
CRC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.53	-7.87	-0.4	5.12e-14	Coronary artery disease;
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg04155289	chr7:94953770	PON1	0.52	7.54	0.38	4.49e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16473141	chr14:24641501	REC8	0.2	6.01	0.31	5.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2302190	0.882	rs11650105	chr17:56588072	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.14	0.32	2.37e-9	Vitamin D levels;
CRC	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg08501292	chr6:25962987	TRIM38	0.99	9.48	0.46	5.43e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg25956985	chr22:39795188	MAP3K7IP1	-0.41	-5.86	-0.31	1.12e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.72	-11.42	-0.53	1.12e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg21153622	chr11:89784906	NA	-0.51	-8.55	-0.43	4.71e-16	HDL cholesterol;
CRC	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	6.68	0.35	1.01e-10	Body mass index;
CRC	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.66	10.41	0.5	4.04e-22	Corneal astigmatism;
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.14	0.37	6.2e-12	Alzheimer's disease;
CRC	cis	rs9341808	0.539	rs2490253	chr6:80895870	T/C	cg08355045	chr6:80787529	NA	0.34	5.79	0.3	1.6e-8	Sitting height ratio;
CRC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.8	-0.4	8.23e-14	Gut microbiome composition (summer);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24806503	chr7:135194850	CNOT4	0.45	6.13	0.32	2.49e-9	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg14695609	chr3:45430048	LARS2	0.56	6.07	0.32	3.51e-9	Body mass index;
CRC	cis	rs73200209	0.912	rs11612304	chr12:116517704	C/T	cg01776926	chr12:116560359	MED13L	0.49	6.1	0.32	2.95e-9	Total body bone mineral density;
CRC	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.19	-0.32	1.84e-9	Breast cancer;
CRC	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.45	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.32	0.65	2.39e-40	Fuchs's corneal dystrophy;
CRC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	11.82	0.55	4.03e-27	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg24644049	chr4:85504048	CDS1	0.75	7.48	0.38	6.78e-13	Skin colour saturation;
CRC	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg09232269	chr1:207846808	CR1L	-0.5	-7.76	-0.39	1.05e-13	Erythrocyte sedimentation rate;
CRC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.45	8.34	0.42	2.09e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.94e-10	Lung cancer;
CRC	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.6	9.22	0.45	3.63e-18	Obesity;
CRC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg15147215	chr3:52552868	STAB1	-0.45	-7.39	-0.38	1.22e-12	Body mass index;
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg03030879	chr14:75389066	RPS6KL1	0.45	7.16	0.37	5.36e-12	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06833562	chr1:86174060	ZNHIT6	0.49	6.89	0.36	2.76e-11	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg17885191	chr8:135476712	NA	0.52	7.03	0.36	1.18e-11	Hypertension (SNP x SNP interaction);
CRC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.5	-0.34	3e-10	Aortic root size;
CRC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-5.82	-0.31	1.43e-8	Height;
CRC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.8	0.55	4.74e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11645453	chr3:52864694	ITIH4	0.42	7.05	0.36	1.06e-11	Bipolar disorder;
CRC	cis	rs4964805	0.626	rs4964827	chr12:104177081	G/T	cg02344784	chr12:104178138	NT5DC3	0.54	7.99	0.4	2.36e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	6.71	0.35	8.37e-11	Breast cancer;
CRC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.7	-0.3	2.64e-8	Blood trace element (Cu levels);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14576681	chr2:42588304	COX7A2L	0.45	6.38	0.33	6.17e-10	Response to antipsychotic treatment;
CRC	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	0.88	7.19	0.37	4.35e-12	Severe influenza A (H1N1) infection;
CRC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21028142	chr17:79581711	NPLOC4	-0.33	-6.96	-0.36	1.81e-11	Eye color traits;
CRC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.5	-0.46	4.61e-19	Aortic root size;
CRC	trans	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg26043149	chr18:55253948	FECH	0.51	7.92	0.4	3.73e-14	Bone mineral density;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.53	0.38	4.9e-13	Eye color traits;
CRC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.51	6.89	0.35	2.92e-11	Height;
CRC	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.55	8.48	0.42	7.78e-16	Diastolic blood pressure;
CRC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.58	-0.47	2.55e-19	Platelet count;
CRC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.4	6.25	0.33	1.27e-9	Red blood cell count;
CRC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg03233332	chr7:66118400	NA	-0.45	-6.3	-0.33	9.52e-10	Aortic root size;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg25858983	chr17:42295711	UBTF	-0.41	-6.31	-0.33	8.87e-10	Birth weight;Height;
CRC	cis	rs3026445	0.742	rs2339524	chr12:111116655	T/C	cg12870014	chr12:110450643	ANKRD13A	0.39	5.91	0.31	8.74e-9	QT interval;
CRC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.42	9.24	0.45	3.16e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.3	-0.37	2.14e-12	Personality dimensions;
CRC	trans	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.92	0.36	2.41e-11	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16136385	chr11:46848389	CKAP5	0.41	6.79	0.35	5.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.38	-5.8	-0.3	1.56e-8	Large artery stroke;
CRC	trans	rs771998	0.820	rs61914027	chr12:52343231	C/A	cg04286455	chr5:77803462	LHFPL2	-0.44	-6.13	-0.32	2.52e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.63	9.03	0.45	1.44e-17	Body mass index;
CRC	cis	rs7527798	0.592	rs2025372	chr1:207829653	T/G	cg09232269	chr1:207846808	CR1L	-0.45	-7.31	-0.37	2.02e-12	Erythrocyte sedimentation rate;
CRC	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05962382	chr2:130345044	NA	-0.44	-7.73	-0.39	1.28e-13	Response to cytidine analogues (gemcitabine);
CRC	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg13615338	chr4:55094005	PDGFRA	0.41	5.9	0.31	8.93e-9	Corneal astigmatism;
CRC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.65	9.95	0.48	1.4e-20	Testicular germ cell tumor;
CRC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.39	-7.47	-0.38	7.51e-13	Intelligence (multi-trait analysis);
CRC	cis	rs216303	0.642	rs216324	chr12:6145225	A/G	cg19878637	chr12:6148451	VWF	-0.64	-6.83	-0.35	4.23e-11	Low vWF levels;
CRC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.57	0.43	4.07e-16	Schizophrenia;
CRC	cis	rs883565	0.771	rs1053516	chr3:39137883	G/A	cg01426195	chr3:39028469	NA	-0.52	-7.98	-0.4	2.52e-14	Handedness;
CRC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg09127314	chr1:152161683	NA	0.48	6.02	0.31	4.66e-9	Atopic dermatitis;
CRC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg08213375	chr14:104286397	PPP1R13B	0.59	12.05	0.55	5.96e-28	Schizophrenia;
CRC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.92	12.7	0.57	2.35e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.3	1.83e-8	Bladder cancer;
CRC	cis	rs73058052	0.569	rs10417980	chr19:50101713	T/C	cg15963326	chr19:50037085	RCN3	-0.37	-5.96	-0.31	6.58e-9	Fibrinogen levels;
CRC	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.65	9.1	0.45	8.73e-18	Bipolar disorder;
CRC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.2	-0.32	1.74e-9	Height;
CRC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.59	0.39	3.34e-13	Coronary artery disease;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.72	10.33	0.49	7.45e-22	Menarche (age at onset);
CRC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.99	0.31	5.44e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs863345	0.526	rs857723	chr1:158604000	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.33	-0.33	7.99e-10	Pneumococcal bacteremia;
CRC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.63	-9.23	-0.45	3.51e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.88	0.44	4.51e-17	Fuchs's corneal dystrophy;
CRC	cis	rs909002	0.849	rs6425777	chr1:32105447	G/C	cg13919466	chr1:32135498	COL16A1	-0.31	-6.09	-0.32	3.2e-9	Intelligence (multi-trait analysis);
CRC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.0	0.36	1.44e-11	Morning vs. evening chronotype;
CRC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.77	0.44	9.58e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg23625390	chr15:77176239	SCAPER	0.49	7.22	0.37	3.68e-12	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg13047869	chr3:10149882	C3orf24	0.54	7.5	0.38	6.09e-13	Alzheimer's disease;
CRC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-8.5	-0.42	6.55e-16	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7849270	0.959	rs10739742	chr9:131921668	A/G	cg13538475	chr9:131942899	NA	-0.34	-6.7	-0.35	9.2e-11	Blood metabolite ratios;
CRC	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.71	-7.07	-0.36	9.48e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg21251018	chr6:28226885	NKAPL	0.46	7.07	0.36	9.6e-12	Cardiac Troponin-T levels;
CRC	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.55	9.46	0.46	6.06e-19	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.53	-6.4	-0.33	5.48e-10	Coronary artery calcification;
CRC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg18721089	chr20:30220636	NA	-0.36	-5.86	-0.31	1.12e-8	Mean corpuscular hemoglobin;
CRC	trans	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg26043149	chr18:55253948	FECH	-0.47	-7.02	-0.36	1.26e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.13	0.45	7.15e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.51	0.6	2.23e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.65	-10.98	-0.52	4.2e-24	Paraoxonase activity;
CRC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.33	0.42	2.17e-15	Height;
CRC	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.75	-10.2	-0.49	2.08e-21	Coronary artery disease;
CRC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00166722	chr3:10149974	C3orf24	0.64	7.57	0.39	3.79e-13	Alzheimer's disease;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg05569086	chr8:143859399	LYNX1	-0.4	-6.3	-0.33	9.28e-10	Urinary tract infection frequency;
CRC	trans	rs2270927	0.510	rs6453214	chr5:75584423	A/G	cg13563193	chr19:33072644	PDCD5	0.7	6.2	0.32	1.66e-9	Mean corpuscular volume;
CRC	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.45	5.91	0.31	8.47e-9	Recombination rate (females);
CRC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.67	-0.3	3.14e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs73206853	0.841	rs7961345	chr12:111081598	C/T	cg12870014	chr12:110450643	ANKRD13A	0.76	7.16	0.37	5.14e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	6.22	0.32	1.48e-9	Blood metabolite levels;
CRC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.67	8.27	0.41	3.3e-15	Menarche (age at onset);
CRC	cis	rs9868809	0.649	rs17256786	chr3:48604016	C/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.9	0.31	9.14e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.82	-0.31	1.4e-8	Life satisfaction;
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg02018176	chr4:1364513	KIAA1530	0.45	7.56	0.38	4.03e-13	Obesity-related traits;
CRC	cis	rs6066835	0.572	rs6066804	chr20:47262322	G/A	cg18078177	chr20:47281410	PREX1	0.79	6.15	0.32	2.26e-9	Multiple myeloma;
CRC	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.76	8.5	0.42	6.78e-16	Neuroticism;
CRC	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.49	-7.79	-0.39	8.79e-14	Schizophrenia;
CRC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.35	0.53	2.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs802075	0.967	rs360562	chr6:49658441	G/T	cg20364632	chr6:49636226	NA	-0.37	-5.97	-0.31	6.3e-9	Bone mineral density (hip) and age at menarche;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14094063	chr7:140624470	BRAF	0.43	6.23	0.32	1.46e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs17152411	0.895	rs11245419	chr10:126586392	A/T	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17507749	chr15:85114479	UBE2QP1	0.62	8.58	0.43	3.89e-16	Schizophrenia;
CRC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.58	0.34	1.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2386661	0.522	rs11258033	chr10:5644372	C/T	cg26603656	chr10:5671107	NA	-0.36	-6.25	-0.33	1.25e-9	Breast cancer;
CRC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.24	0.41	4.06e-15	Life satisfaction;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22090150	chr17:4098227	ANKFY1	0.4	6.46	0.34	3.84e-10	Aortic root size;
CRC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-5.83	-0.31	1.31e-8	Longevity;
CRC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.55	-0.34	2.18e-10	Reticulocyte fraction of red cells;
CRC	trans	rs684232	0.644	rs2543781	chr17:602469	C/G	cg22807402	chr17:73269154	SLC25A19	-0.34	-6.0	-0.31	5.23e-9	Prostate cancer;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.52	-8.94	-0.44	2.87e-17	Acylcarnitine levels;
CRC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.28	-0.42	3.06e-15	Monocyte count;
CRC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	0.95	7.78	0.39	9.74e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	26.14	0.82	2.79e-82	Colorectal cancer;
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg24463073	chr6:118973353	C6orf204	0.52	6.97	0.36	1.69e-11	Diastolic blood pressure;
CRC	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.36	5.69	0.3	2.86e-8	Mean arterial pressure;
CRC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.97	-17.82	-0.7	3.28e-50	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg03030879	chr14:75389066	RPS6KL1	0.44	6.67	0.35	1.08e-10	Height;
CRC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-18.2	-0.71	1.05e-51	Ulcerative colitis;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.78	12.84	0.58	7.15e-31	Height;
CRC	trans	rs4853036	0.672	rs34764641	chr2:70024823	G/T	cg14633329	chr9:139640053	LCN6	-0.34	-6.02	-0.31	4.72e-9	Colorectal or endometrial cancer;
CRC	cis	rs1165668	0.785	rs2070908	chr12:104324182	C/G	cg21863207	chr12:104234989	NT5DC3	-0.5	-7.58	-0.39	3.53e-13	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg25164649	chr6:28176230	NA	0.69	10.25	0.49	1.39e-21	Cardiac Troponin-T levels;
CRC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg22676075	chr6:135203613	NA	0.43	6.73	0.35	7.43e-11	Red blood cell count;
CRC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.56	-9.44	-0.46	7.34e-19	Personality dimensions;
CRC	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.41	-5.69	-0.3	2.78e-8	Tonsillectomy;
CRC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.64	7.35	0.38	1.6e-12	Gut microbiome composition (summer);
CRC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.5	7.7	0.39	1.5700000000000001e-13	Response to antineoplastic agents;
CRC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.38	-6.6	-0.34	1.67e-10	Crohn's disease;
CRC	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg11693508	chr17:37793320	STARD3	-0.64	-8.43	-0.42	1.08e-15	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05877740	chr15:64673601	KIAA0101	0.43	6.15	0.32	2.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg16606324	chr3:10149918	C3orf24	0.7	9.72	0.47	8.71e-20	Alzheimer's disease;
CRC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.56	6.63	0.34	1.38e-10	Body mass index;
CRC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg10760299	chr15:45669010	GATM	0.5	7.99	0.4	2.28e-14	Homoarginine levels;
CRC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.43	6.56	0.34	2.12e-10	Calcium levels;
CRC	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.84	-0.31	1.23e-8	Total body bone mineral density;
CRC	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.45	0.42	9.23e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.99	-0.48	1.04e-20	Aortic root size;
CRC	trans	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg26043149	chr18:55253948	FECH	0.49	7.37	0.38	1.35e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-5.73	-0.3	2.22e-8	Axial length;
CRC	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.52	7.1	0.36	7.53e-12	Alzheimer's disease;
CRC	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.73	16.05	0.66	3.26e-43	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.69	-10.86	-0.51	1.08e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.79	-6.09	-0.32	3.09e-9	Putamen volume;
CRC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.55	-8.68	-0.43	1.81e-16	Mean corpuscular hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08226295	chr22:31892562	SFI1	0.39	6.47	0.34	3.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.96	14.96	0.64	5.92e-39	Testicular germ cell tumor;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.34	0.53	2.15e-25	Prudent dietary pattern;
CRC	cis	rs73200209	0.744	rs61937387	chr12:116707971	A/T	cg01776926	chr12:116560359	MED13L	-0.62	-7.31	-0.37	2.11e-12	Total body bone mineral density;
CRC	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.27	6.28	0.33	1.1e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.72e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg16606324	chr3:10149918	C3orf24	0.69	8.08	0.41	1.2e-14	Alzheimer's disease;
CRC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Body mass index;
CRC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg10790698	chr19:18539756	SSBP4	-0.47	-8.7	-0.43	1.6e-16	Breast cancer;
CRC	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.54	6.71	0.35	8.48e-11	Dental caries;
CRC	trans	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg11704114	chr12:21509398	SLCO1A2	-0.33	-6.22	-0.32	1.52e-9	Tuberculosis;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg26761047	chr1:15944228	DDI2	0.6	6.38	0.33	5.91e-10	Airway imaging phenotypes;
CRC	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg07617317	chr6:118971624	C6orf204	-0.49	-6.16	-0.32	2.08e-9	Diastolic blood pressure;
CRC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19717773	chr7:2847554	GNA12	0.42	5.91	0.31	8.67e-9	Height;
CRC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6840360	0.617	rs2724563	chr4:152349959	G/C	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.59	-8.87	-0.44	4.75e-17	Longevity;
CRC	trans	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg18187862	chr3:45730750	SACM1L	0.47	6.78	0.35	5.68e-11	Primary sclerosing cholangitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15974272	chr11:2466598	KCNQ1	0.44	6.03	0.32	4.35e-9	Anxiety disorder;
CRC	cis	rs4728302	1.000	rs4728302	chr7:133630463	C/T	cg10665199	chr7:133106180	EXOC4	-0.39	-6.1	-0.32	2.9e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.57	7.82	0.4	7.12e-14	Coronary artery disease;
CRC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.54	-8.31	-0.42	2.53e-15	Height;
CRC	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.62	8.76	0.43	1.04e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-0.58	-8.11	-0.41	1.03e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	6.74	0.35	7.06e-11	Multiple sclerosis;
CRC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-7.93	-0.4	3.37e-14	Intelligence (multi-trait analysis);
CRC	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg09179987	chr1:167433047	CD247	0.44	6.94	0.36	2.07e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.2	-25.61	-0.82	2.42e-80	Exhaled nitric oxide output;
CRC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.72	11.32	0.53	2.68e-25	Intelligence (multi-trait analysis);
CRC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg10760299	chr15:45669010	GATM	0.5	7.73	0.39	1.29e-13	Homoarginine levels;
CRC	cis	rs4731207	0.564	rs7794565	chr7:124648968	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs375066	0.623	rs7247863	chr19:44354518	A/G	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs364477	0.904	rs382037	chr9:957521	G/C	cg13952963	chr9:998547	NA	0.54	5.85	0.31	1.21e-8	Major depressive disorder;
CRC	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	1.1	24.03	0.8	2.18e-74	Gut microbiome composition (winter);
CRC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.37	5.85	0.31	1.2e-8	Blood metabolite levels;
CRC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.16	-0.49	2.85e-21	Monocyte count;
CRC	cis	rs7534824	0.625	rs7545402	chr1:101321076	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.61	0.3	4.27e-8	Refractive astigmatism;
CRC	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.57	8.62	0.43	2.87e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.91	-0.58	3.94e-31	Alzheimer's disease;
CRC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.54	8.45	0.42	9.28e-16	Intelligence (multi-trait analysis);
CRC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg07952391	chr2:88470173	THNSL2	-0.41	-6.03	-0.32	4.44e-9	Response to metformin (IC50);
CRC	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg00691999	chr4:55094011	PDGFRA	0.41	5.73	0.3	2.31e-8	Corneal astigmatism;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg02033258	chr5:131593261	PDLIM4	0.36	5.88	0.31	1.03e-8	Breast cancer;
CRC	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-6.08	-0.32	3.35e-9	Axial length;
CRC	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-7.47	-0.38	7.07e-13	Hepatocellular carcinoma;
CRC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg01612440	chr4:3296283	NA	0.41	5.93	0.31	7.57e-9	Serum sulfate level;
CRC	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-8.28	-0.42	3.12e-15	Blood protein levels;
CRC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg15845792	chr6:28175446	NA	0.48	6.99	0.36	1.56e-11	Pubertal anthropometrics;
CRC	cis	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg24596788	chr1:163392923	NA	0.62	9.93	0.48	1.66e-20	Motion sickness;
CRC	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg14828511	chr1:107599125	PRMT6	-0.54	-7.45	-0.38	8.11e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.84	-10.25	-0.49	1.39e-21	Bronchopulmonary dysplasia;
CRC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.91	-10.45	-0.5	2.88e-22	Breast cancer;
CRC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.26	0.45	2.71e-18	Height;
CRC	cis	rs2274273	0.624	rs8014477	chr14:55841477	A/G	cg10130446	chr14:55658398	DLGAP5	0.42	6.09	0.32	3.14e-9	Protein biomarker;
CRC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.76	-15.86	-0.66	1.84e-42	Age-related hearing impairment;
CRC	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.54	6.94	0.36	2.06e-11	Multiple sclerosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20623943	chr1:47799834	CMPK1	0.42	6.01	0.31	4.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg00531865	chr16:30841666	NA	-0.5	-7.15	-0.37	5.68e-12	Dementia with Lewy bodies;
CRC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.67	11.1	0.52	1.53e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12230513	0.732	rs61956327	chr12:55828708	C/T	cg19537932	chr12:55886519	OR6C68	-0.75	-9.64	-0.47	1.53e-19	Contrast sensitivity;
CRC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg26721908	chr21:47610096	LSS	0.4	6.03	0.32	4.3e-9	Testicular germ cell tumor;
CRC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	0.33	6.31	0.33	8.82e-10	Colorectal cancer;
CRC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.41	6.15	0.32	2.25e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg11003573	chr3:44754125	ZNF502	-0.37	-6.39	-0.33	5.6e-10	Depressive symptoms;
CRC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.46	0.46	6.3e-19	Platelet count;
CRC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg00745463	chr17:30367425	LRRC37B	-0.55	-6.57	-0.34	1.98e-10	Hip circumference adjusted for BMI;
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg22561889	chr6:118971681	C6orf204	0.53	6.92	0.36	2.43e-11	Diastolic blood pressure;
CRC	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.47e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg02683197	chr6:28174875	NA	0.73	9.71	0.47	9.11e-20	Parkinson's disease;
CRC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.32	0.33	8.34e-10	Diabetic retinopathy;
CRC	cis	rs4547160	0.821	rs7955356	chr12:63485687	A/G	cg26727693	chr12:63544175	AVPR1A	-0.41	-7.69	-0.39	1.73e-13	Morning vs. evening chronotype;
CRC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	10.62	0.51	7.3e-23	Motion sickness;
CRC	cis	rs6662572	0.737	rs4557909	chr1:46316949	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01074347	chr1:93427451	FAM69A	0.44	6.03	0.32	4.51e-9	Survival in pancreatic cancer;
CRC	trans	rs2303319	0.504	rs12474470	chr2:162535336	T/C	cg03757145	chr4:76555832	CDKL2	-0.66	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.71	10.25	0.49	1.43e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.46	7.23	0.37	3.49e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg08222913	chr3:52553049	STAB1	-0.31	-5.93	-0.31	7.54e-9	Electroencephalogram traits;
CRC	cis	rs11212617	0.840	rs172894	chr11:108262090	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.31e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.4	-0.33	5.43e-10	Bipolar disorder;
CRC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.61	7.52	0.38	5.28e-13	Menarche (age at onset);
CRC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.1	-0.32	2.91e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.54	7.19	0.37	4.4e-12	Gallbladder cancer;
CRC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg21475434	chr5:93447410	FAM172A	0.49	5.9	0.31	8.91e-9	Diabetic retinopathy;
CRC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.73	-8.35	-0.42	1.94e-15	Obesity-related traits;
CRC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.52	-8.63	-0.43	2.67e-16	Menarche (age at onset);
CRC	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	1.05	12.63	0.57	4.57e-30	Diisocyanate-induced asthma;
CRC	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg14844989	chr11:31128820	NA	0.33	5.77	0.3	1.87e-8	Red blood cell count;
CRC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.49	-8.13	-0.41	8.67e-15	Huntington's disease progression;
CRC	cis	rs6741819	0.911	rs11898648	chr2:7136926	C/A	cg27144453	chr2:7172511	RNF144A	-0.41	-5.99	-0.31	5.49e-9	Response to antipsychotic treatment;
CRC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg18709589	chr6:96969512	KIAA0776	-0.49	-6.13	-0.32	2.55e-9	Migraine;Coronary artery disease;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.55	-0.38	4.4e-13	Endometrial cancer;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg12516270	chr8:143859308	LYNX1	-0.4	-6.22	-0.32	1.54e-9	Urinary tract infection frequency;
CRC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.62	-0.51	7.64e-23	Bipolar disorder;
CRC	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg16141378	chr3:129829833	LOC729375	0.42	6.04	0.32	4.25e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.41	-0.53	1.24e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg15962314	chr1:44399869	ARTN	0.31	6.11	0.32	2.83e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg15816464	chr17:2026533	SMG6	0.37	6.16	0.32	2.12e-9	Total body bone mineral density;
CRC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.5	-8.67	-0.43	1.99e-16	Aortic root size;
CRC	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg20936604	chr3:58311152	NA	-0.74	-6.94	-0.36	2.05e-11	Cholesterol, total;
CRC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg20684491	chr1:25596433	NA	0.43	7.48	0.38	6.65e-13	Erythrocyte sedimentation rate;
CRC	trans	rs12495832	0.749	rs79597840	chr3:147926901	C/T	cg10221266	chr7:153579447	NA	0.57	6.37	0.33	6.44e-10	Chin dimples;
CRC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-1.03	-12.4	-0.56	3.16e-29	Hip circumference adjusted for BMI;
CRC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.14	0.61	8.77e-36	Mean platelet volume;
CRC	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg01475377	chr6:109611718	NA	-0.38	-5.79	-0.3	1.61e-8	Reticulocyte fraction of red cells;
CRC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.27	0.45	2.57e-18	Mean platelet volume;
CRC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg19223106	chr19:58898630	RPS5	-0.45	-6.32	-0.33	8.56e-10	Select biomarker traits;
CRC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.38	5.7	0.3	2.62e-8	Longevity;Endometriosis;
CRC	cis	rs883565	0.569	rs784514	chr3:39164622	A/G	cg01426195	chr3:39028469	NA	0.42	6.99	0.36	1.56e-11	Handedness;
CRC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg02428538	chr16:24856791	SLC5A11	0.62	7.16	0.37	5.24e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	11.38	0.53	1.62e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs314253	1.000	rs314253	chr17:7091650	A/G	cg23681664	chr3:9746637	CPNE9	-0.31	-5.99	-0.31	5.61e-9	LDL cholesterol levels;Cholesterol, total;LDL cholesterol;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06382698	chr2:54015232	LOC100302652;ERLEC1;ASB3	0.43	6.06	0.32	3.81e-9	Response to antipsychotic treatment;
CRC	cis	rs9463078	0.587	rs1150806	chr6:44897787	C/T	cg25276700	chr6:44698697	NA	-0.25	-6.06	-0.32	3.75e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07754938	chr3:48885314	PRKAR2A	0.45	6.18	0.32	1.92e-9	Survival in pancreatic cancer;
CRC	cis	rs6088813	1.000	rs6142370	chr20:33973378	G/A	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12172441	chr6:28176163	NA	0.55	6.96	0.36	1.83e-11	Parkinson's disease;
CRC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.89e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.75	-0.35	6.65e-11	Aortic root size;
CRC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.23	-0.37	3.38e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2457480	0.543	rs1905150	chr10:44713311	G/A	cg09554077	chr10:44749378	NA	0.51	6.75	0.35	6.54e-11	Coronary artery disease;
CRC	cis	rs9326248	0.727	rs4938347	chr11:117021759	T/A	cg26566898	chr11:117069891	TAGLN	0.38	6.88	0.35	2.96e-11	Blood protein levels;
CRC	cis	rs6764363	0.527	rs7648248	chr3:275692	A/G	cg02057681	chr3:285234	CHL1	0.4	6.68	0.35	1.01e-10	Sudden cardiac arrest;
CRC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.85	-15.03	-0.64	3.12e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.52	0.34	2.6200000000000003e-10	Morning vs. evening chronotype;
CRC	trans	rs587242	1.000	rs12744194	chr1:96898486	T/G	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.9	0.4	4.14e-14	Resting heart rate;
CRC	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.6	-9.43	-0.46	7.76e-19	Ulcerative colitis;
CRC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.38	-0.5	4.99e-22	Bipolar disorder;
CRC	cis	rs10971721	1.000	rs10971721	chr9:33827694	C/T	cg13495928	chr9:33750294	PRSS3	0.55	5.86	0.31	1.14e-8	Body mass index;
CRC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24308560	chr3:49941425	MST1R	0.45	7.07	0.36	9.39e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg20243544	chr17:37824526	PNMT	-0.38	-5.92	-0.31	8.24e-9	Self-reported allergy;
CRC	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs6546324	0.625	rs6730286	chr2:67848054	C/T	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.26	-0.33	1.21e-9	Endometriosis;
CRC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.68	-0.3	2.94e-8	Total body bone mineral density;
CRC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.66	11.79	0.54	5.46e-27	Height;
CRC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg26176469	chr17:28951361	LRRC37B2	0.53	5.85	0.31	1.2e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg04202892	chr2:111875749	ACOXL	0.43	6.91	0.36	2.51e-11	Chronic lymphocytic leukemia;
CRC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg21132104	chr15:45694354	SPATA5L1	0.4	5.63	0.3	3.9e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg12573674	chr2:1569213	NA	-0.65	-7.36	-0.38	1.5e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.58	8.73	0.43	1.3e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs2882667	0.964	rs12055237	chr5:138307306	A/G	cg09476006	chr5:138032270	NA	0.49	8.18	0.41	6.47e-15	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-11.03	-0.52	2.81e-24	Platelet distribution width;
CRC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.22e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-5.91	-0.31	8.39e-9	Joint mobility (Beighton score);
CRC	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14119001	chr9:139324193	INPP5E	-0.47	-6.71	-0.35	8.56e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.51	8.95	0.44	2.6e-17	Body mass index;
CRC	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.56	-7.56	-0.38	4.06e-13	IgG glycosylation;
CRC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.65	10.15	0.49	3.18e-21	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.52	0.34	2.6200000000000003e-10	Morning vs. evening chronotype;
CRC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg06740227	chr12:86229804	RASSF9	-0.38	-5.78	-0.3	1.74e-8	Major depressive disorder;
CRC	cis	rs7605827	0.930	rs11694458	chr2:15530469	C/G	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.04	0.48	7.2e-21	Platelet count;
CRC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg10356904	chr22:49881777	NA	-0.32	-6.0	-0.31	5.27e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.42	9.34	0.46	1.53e-18	Blood protein levels;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg03623178	chr6:28175578	NA	-0.6	-8.34	-0.42	2.12e-15	Parkinson's disease;
CRC	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.01	0.45	1.67e-17	Fuchs's corneal dystrophy;
CRC	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.34	6.0	0.31	5.29e-9	Inattentive symptoms;
CRC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.97	0.31	6.28e-9	Rheumatoid arthritis;
CRC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.08	-0.61	1.46e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.55	6.05	0.32	3.94e-9	Initial pursuit acceleration;
CRC	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg15147215	chr3:52552868	STAB1	-0.54	-8.01	-0.4	2.07e-14	Bipolar disorder;
CRC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-7.76	-0.39	1.06e-13	Educational attainment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06988368	chr1:147142773	ACP6	0.4	6.86	0.35	3.39e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg23417306	chr2:180868811	CWC22	-0.45	-6.09	-0.32	3.1e-9	Schizophrenia;
CRC	cis	rs12044355	0.927	rs61835384	chr1:231833422	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	6.74	0.35	7.06e-11	Alzheimer's disease;
CRC	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg17545662	chr6:170176663	C6orf70	0.52	5.79	0.3	1.63e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26259546	chr3:57113458	ARHGEF3	0.44	6.57	0.34	1.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	5.8	0.3	1.57e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-11.45	-0.53	9.17e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.35	-5.99	-0.31	5.49e-9	Erythrocyte sedimentation rate;
CRC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.49	7.77	0.39	1e-13	Height;
CRC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg05320533	chr16:89541815	ANKRD11	-0.44	-6.24	-0.33	1.32e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.65	-8.57	-0.43	4.22e-16	Gut microbiome composition (summer);
CRC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.44	8.9	0.44	3.72e-17	Renal cell carcinoma;
CRC	cis	rs4664293	0.647	rs6711049	chr2:160441145	G/C	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.02	0.4	1.82e-14	Platelet count;
CRC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.43	-7.78	-0.39	9.32e-14	Reticulocyte fraction of red cells;
CRC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02228675	chr17:40259724	DHX58	-0.48	-6.8	-0.35	5.05e-11	Fibrinogen levels;
CRC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7572644	0.723	rs7578052	chr2:28318879	G/A	cg27432699	chr2:27873401	GPN1	0.41	5.67	0.3	3.07e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.37	6.21	0.32	1.58e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.44	-7.63	-0.39	2.52e-13	Major depressive disorder;
CRC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg13206674	chr6:150067644	NUP43	0.66	9.38	0.46	1.12e-18	Lung cancer;
CRC	cis	rs62408225	1.000	rs55881869	chr6:90968025	C/A	cg06866423	chr6:90926672	BACH2	0.47	7.8	0.4	8.11e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.0	-0.4	2.14e-14	Mean platelet volume;
CRC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.68	7.79	0.39	8.9e-14	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg21251018	chr6:28226885	NKAPL	0.48	7.52	0.38	5.31e-13	Parkinson's disease;
CRC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.43e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04567173	chr4:25379221	ANAPC4	-0.43	-6.57	-0.34	1.97e-10	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04575144	chr19:4067379	ZBTB7A	0.49	8.17	0.41	6.76e-15	Liver disease severity in Alagille syndrome;
CRC	trans	rs6601327	0.898	rs1458942	chr8:9406602	C/T	cg16141378	chr3:129829833	LOC729375	0.44	6.21	0.32	1.62e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs9903692	0.505	rs208009	chr17:46229691	C/T	cg10706073	chr17:46328419	SKAP1	0.59	6.36	0.33	6.7e-10	Pulse pressure;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg09877947	chr5:131593287	PDLIM4	0.47	8.93	0.44	3.07e-17	Breast cancer;
CRC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.68	-0.39	1.84e-13	Axial length;
CRC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.67	7.76	0.39	1.06e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg12590608	chr7:158785262	NA	0.32	5.61	0.3	4.22e-8	Facial morphology (factor 20);
CRC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	0.901	rs10789656	chr11:108024336	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.07	0.32	3.58e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.63	8.89	0.44	4.23e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg12463550	chr7:65579703	CRCP	0.67	6.15	0.32	2.2e-9	Diabetic kidney disease;
CRC	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg10820045	chr2:198174542	NA	0.39	6.51	0.34	2.74e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg06470822	chr6:28175283	NA	0.82	12.25	0.56	1.14e-28	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.29	0.33	1.03e-9	Life satisfaction;
CRC	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.71	0.35	8.38e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.52	8.39	0.42	1.46e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.36	6.37	0.33	6.36e-10	Primary biliary cholangitis;
CRC	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.39	-6.62	-0.34	1.42e-10	Hip circumference;Waist circumference;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09133562	chr1:20126395	TMCO4	0.37	6.13	0.32	2.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.4	-6.18	-0.32	1.89e-9	Height;
CRC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.98	0.52	4.2e-24	Motion sickness;
CRC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.83	14.87	0.63	1.25e-38	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.76	-11.62	-0.54	2.12e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.62	0.3	4.06e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.72	-0.3	2.36e-8	Life satisfaction;
CRC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.43	-6.53	-0.34	2.52e-10	N-glycan levels;
CRC	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.66	-9.82	-0.48	4.02e-20	Acne (severe);
CRC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.44	7.82	0.4	7.35e-14	Eye color traits;
CRC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10905065	0.931	rs10795510	chr10:5758827	G/A	cg11519256	chr10:5708881	ASB13	0.43	6.12	0.32	2.67e-9	Menopause (age at onset);
CRC	cis	rs16975963	0.644	rs73031322	chr19:38040879	C/A	cg15135657	chr19:38346511	NA	-0.45	-6.25	-0.33	1.25e-9	Longevity;
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	0.91	11.12	0.52	1.3e-24	Red blood cell traits;
CRC	cis	rs7605827	0.930	rs4668911	chr2:15610650	A/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.9	0.63	1.01e-38	Hypertriglyceridemia;
CRC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.06	-0.32	3.64e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.25	14.99	0.64	4.45e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs6700896	0.932	rs6678033	chr1:66077624	G/A	cg04111102	chr1:66153794	NA	0.35	6.26	0.33	1.22e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg26043149	chr18:55253948	FECH	0.46	6.92	0.36	2.34e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7091068	0.721	rs618951	chr10:95404967	A/G	cg20715218	chr10:95462985	C10orf4	-0.47	-5.66	-0.3	3.29e-8	Urinary tract infection frequency;
CRC	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.76	6.6	0.34	1.62e-10	Alzheimer's disease (late onset);
CRC	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg06606381	chr12:133084897	FBRSL1	-0.92	-7.56	-0.38	4e-13	Depression;
CRC	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg08501292	chr6:25962987	TRIM38	-1.11	-9.86	-0.48	2.84e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.03e-11	Diisocyanate-induced asthma;
CRC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-9.44	-0.46	7.2e-19	Mood instability;
CRC	cis	rs282587	0.569	rs409896	chr13:113400338	G/T	cg04656015	chr13:113407548	ATP11A	0.62	7.65	0.39	2.27e-13	Glycated hemoglobin levels;
CRC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	0.68	6.06	0.32	3.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg10876282	chr6:28092338	ZSCAN16	0.47	6.43	0.33	4.62e-10	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.56	8.42	0.42	1.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.37	6.15	0.32	2.21e-9	Sitting height ratio;
CRC	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.42	-6.45	-0.33	4.03e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02269272	chr17:17991219	DRG2	0.43	6.03	0.32	4.33e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.34	2.16e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.61	10.64	0.51	6.26e-23	Body mass index;
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.48	-0.42	7.92e-16	Bipolar disorder;
CRC	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.37	-0.38	1.43e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.61	11.23	0.53	5.62e-25	Immature fraction of reticulocytes;
CRC	cis	rs10097731	0.901	rs10464932	chr8:82042901	T/G	cg25230327	chr8:82042993	NA	-0.93	-13.69	-0.6	4.32e-34	Serum total protein level;
CRC	trans	rs12744310	0.887	rs35690915	chr1:41797999	T/C	cg19175123	chr10:103411746	FBXW4	0.44	6.01	0.31	4.87e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg08027265	chr7:2291960	NA	-0.36	-5.78	-0.3	1.77e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07509094	chr11:60674167	PRPF19	0.48	6.75	0.35	6.66e-11	Response to antipsychotic treatment;
CRC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.67	0.47	1.25e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.43	6.6	0.34	1.65e-10	Recombination rate (males);
CRC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.64	-10.55	-0.5	1.31e-22	Colorectal cancer;
CRC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg04166393	chr7:2884313	GNA12	0.45	6.13	0.32	2.56e-9	Height;
CRC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	9.3	0.46	1.96e-18	Cognitive test performance;
CRC	cis	rs7703744	0.597	rs73237297	chr5:118691121	G/T	cg17471836	chr5:118691007	TNFAIP8	0.42	6.02	0.32	4.61e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg02319466	chr17:76381040	PGS1	0.36	5.63	0.3	3.82e-8	HDL cholesterol;
CRC	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.72	10.02	0.48	8.66e-21	Orofacial clefts;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg18301423	chr5:131593218	PDLIM4	0.38	6.24	0.33	1.32e-9	Blood metabolite levels;
CRC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg12193833	chr17:30244370	NA	-0.57	-7.67	-0.39	1.94e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.53	-8.78	-0.44	9.08e-17	Metabolite levels;
CRC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.56	0.47	2.93e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.57	0.57	7.46e-30	Body mass index;
CRC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.97	14.88	0.63	1.16e-38	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.42	5.81	0.31	1.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg01422129	chr2:677375	TMEM18	-0.7	-6.09	-0.32	3.21e-9	Cognitive function;
CRC	cis	rs294883	0.827	rs1875815	chr6:159720280	C/T	cg14500486	chr6:159655392	FNDC1	-0.34	-5.65	-0.3	3.54e-8	Coronary artery disease;
CRC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.89	-0.44	4.01e-17	Bipolar disorder;
CRC	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.49	7.68	0.39	1.82e-13	Red blood cell count;
CRC	cis	rs2898681	0.581	rs731073	chr4:53680090	A/G	cg00338735	chr4:53728038	RASL11B	0.39	5.92	0.31	8.08e-9	Optic nerve measurement (cup area);
CRC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03539474	chr2:172751088	SLC25A12	0.44	6.36	0.33	6.86e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	-0.69	-5.85	-0.31	1.21e-8	Depression;
CRC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg02376178	chr19:1969988	CSNK1G2	-0.59	-9.48	-0.46	5.38e-19	Coronary artery disease;
CRC	cis	rs9311676	0.609	rs55845662	chr3:58424899	A/C	cg06643156	chr3:58380774	PXK	0.43	6.53	0.34	2.5e-10	Systemic lupus erythematosus;
CRC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.54e-16	Homoarginine levels;
CRC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-11.01	-0.52	3.14e-24	Platelet distribution width;
CRC	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.09	0.41	1.15e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.81	10.61	0.51	7.87e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20045888	chr4:151000084	DCLK2	-0.35	-6.01	-0.31	4.87e-9	Obesity-related traits;
CRC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg01200585	chr1:228362443	C1orf69	0.46	5.92	0.31	7.99e-9	Diastolic blood pressure;
CRC	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.69	9.39	0.46	1.02e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg02560186	chr11:3602584	NA	-0.63	-9.54	-0.47	3.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.41	0.38	1.08e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.39	-6.3	-0.33	9.32e-10	IgG glycosylation;
CRC	cis	rs7616330	0.836	rs17008114	chr3:71045000	A/C	cg01511742	chr3:71112437	FOXP1	-0.51	-6.19	-0.32	1.79e-9	QT interval;
CRC	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.7	-0.35	9.21e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs9549328	0.589	rs36164841	chr13:113616579	A/G	cg08614441	chr13:113633676	MCF2L	0.4	6.97	0.36	1.69e-11	Systolic blood pressure;
CRC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.67	9.53	0.47	3.52e-19	Bladder cancer;
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.73	-0.3	2.25e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs939584	0.935	rs12993295	chr2:632808	G/T	cg03610516	chr2:642275	NA	0.42	5.65	0.3	3.49e-8	Body mass index;
CRC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.0	15.36	0.65	1.61e-40	IgG glycosylation;
CRC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg11292332	chr7:45801988	SEPT13	-0.36	-6.29	-0.33	9.88e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.31	-6.37	-0.33	6.24e-10	Longevity;Endometriosis;
CRC	cis	rs939584	1.000	rs2867115	chr2:651382	T/C	cg03610516	chr2:642275	NA	-0.43	-5.94	-0.31	7.33e-9	Body mass index;
CRC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.38	5.97	0.31	6.29e-9	Total body bone mineral density;
CRC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.82	11.35	0.53	2.12e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14385122	chr9:71320671	PIP5K1B	-0.41	-6.2	-0.32	1.72e-9	Myopia (pathological);
CRC	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-7.89	-0.4	4.65e-14	Mean platelet volume;Platelet distribution width;
CRC	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.52	-0.38	5.2e-13	Depression;
CRC	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Colorectal cancer;
CRC	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.78	12.32	0.56	6.28e-29	Multiple system atrophy;
CRC	cis	rs2274471	0.645	rs10974955	chr9:5090641	G/A	cg03390472	chr9:5043263	JAK2	-0.6	-7.05	-0.36	1.07e-11	Crohn's disease;
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.15	-0.56	2.53e-28	Alzheimer's disease;
CRC	trans	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg26043149	chr18:55253948	FECH	0.49	7.45	0.38	8.21e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.92	-11.51	-0.54	5.56e-26	Exhaled nitric oxide output;
CRC	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.73	-7.17	-0.37	5.04e-12	Recalcitrant atopic dermatitis;
CRC	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.51	8.69	0.43	1.76e-16	Aortic root size;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg20512303	chr5:131592959	PDLIM4	0.34	6.63	0.34	1.41e-10	Breast cancer;
CRC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.74	12.62	0.57	4.92e-30	Body mass index;
CRC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg25459000	chr22:39777742	SYNGR1	-0.32	-5.67	-0.3	3.14e-8	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12172441	chr6:28176163	NA	0.59	7.01	0.36	1.36e-11	Depression;
CRC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.69	9.77	0.47	5.67e-20	Cognitive function;
CRC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.49	9.63	0.47	1.66e-19	Renal cell carcinoma;
CRC	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	0.98	8.0	0.4	2.12e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.68	-0.3	2.96e-8	Metabolite levels;
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg21724239	chr8:58056113	NA	0.59	7.25	0.37	2.94e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.61	-8.82	-0.44	6.77e-17	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.91	-0.36	2.52e-11	Monocyte count;
CRC	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg03804128	chr16:635623	NA	0.3	6.86	0.35	3.45e-11	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02208506	chr17:4634804	MED11	0.46	6.52	0.34	2.6200000000000003e-10	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05573837	chr3:42696434	ZBTB47	0.36	6.17	0.32	2.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.6	7.95	0.4	3.06e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.39	-6.26	-0.33	1.2e-9	Iron status biomarkers;
CRC	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg12458913	chr13:53173898	NA	0.49	7.71	0.39	1.5e-13	Lewy body disease;
CRC	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.65	6.74	0.35	6.94e-11	Inflammatory bowel disease;
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg21155852	chr7:2048760	MAD1L1	-0.52	-6.87	-0.35	3.24e-11	Neuroticism;
CRC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.44	5.88	0.31	9.91e-9	Schizophrenia;
CRC	cis	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg07356753	chr3:81810745	GBE1	-0.53	-6.97	-0.36	1.76e-11	Extraversion;
CRC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.55	7.42	0.38	9.97e-13	Obesity-related traits;
CRC	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.9	-0.36	2.65e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.44	-7.08	-0.36	8.5e-12	Refractive error;
CRC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.55	7.15	0.37	5.81e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs185694	0.947	rs169331	chr13:30878695	G/T	cg04551440	chr13:30881194	KATNAL1	-0.64	-6.31	-0.33	9.21e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	0.34	5.86	0.31	1.14e-8	Mean platelet volume;Platelet distribution width;
CRC	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.24	14.62	0.63	1.19e-37	Uric acid levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18149653	chr12:53267995	NA	0.43	6.23	0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01839850	chr22:38240395	ANKRD54;MIR658	0.47	6.01	0.31	4.82e-9	Thyroid stimulating hormone;
CRC	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.15	-0.37	5.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs11203032	0.831	rs11203027	chr10:90956290	T/A	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.6	8.55	0.43	4.76e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.61	-0.34	1.51e-10	Total body bone mineral density;
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg10217327	chr6:118973057	C6orf204	0.53	5.94	0.31	7.14e-9	Diastolic blood pressure;
CRC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.47	-6.24	-0.33	1.38e-9	Body mass index;
CRC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.91	-0.36	2.56e-11	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03112782	chr1:37979729	MEAF6	0.47	6.31	0.33	9.14e-10	Thyroid stimulating hormone;
CRC	cis	rs9463078	0.547	rs116177834	chr6:44738548	C/A	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.81e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.61	9.69	0.47	1.03e-19	Longevity;Endometriosis;
CRC	cis	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg06470822	chr6:28175283	NA	0.86	6.93	0.36	2.27e-11	Depression;
CRC	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.23	14.38	0.62	9.77e-37	Diabetic kidney disease;
CRC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.92	-0.64	8.28e-39	Lymphocyte percentage of white cells;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg26028573	chr6:26043587	HIST1H2BB	0.5	7.26	0.37	2.83e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg02683197	chr6:28174875	NA	0.8	10.0	0.48	9.7e-21	Parkinson's disease;
CRC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25517755	chr10:38738941	LOC399744	-0.43	-6.32	-0.33	8.7e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.48	7.84	0.4	6.19e-14	Cystic fibrosis severity;
CRC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.35e-14	Colorectal cancer;
CRC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.52	8.32	0.42	2.41e-15	Aortic root size;
CRC	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg18755752	chr8:142205143	DENND3	-0.41	-5.79	-0.3	1.62e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-7.28	-0.37	2.55e-12	Asthma;
CRC	cis	rs62229266	0.682	rs2835224	chr21:37370030	A/T	cg08632701	chr21:37451849	NA	-0.37	-5.61	-0.3	4.39e-8	Mitral valve prolapse;
CRC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.58	8.55	0.43	4.67e-16	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.46	-0.34	3.77e-10	Educational attainment;
CRC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.68e-10	HDL cholesterol;
CRC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.23	-0.53	5.45e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.53	8.05	0.41	1.56e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9400239	0.584	rs1268177	chr6:109017322	A/G	cg11073813	chr6:109029018	NA	-0.38	-5.84	-0.31	1.23e-8	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg23609571	chr14:70655845	SLC8A3	-0.31	-6.24	-0.33	1.35e-9	Prostate cancer;
CRC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.83	-11.2	-0.53	6.87e-25	Asthma;
CRC	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.64	10.38	0.5	5e-22	Breast cancer;
CRC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.62	10.4	0.5	4.35e-22	Colorectal cancer;
CRC	trans	rs16846053	0.792	rs72875528	chr2:162533523	C/T	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Blood osmolality (transformed sodium);
CRC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.45	7.92	0.4	3.65e-14	Lung cancer;
CRC	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.59	8.63	0.43	2.64e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.5	-0.34	2.96e-10	Coronary artery disease;
CRC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg00579200	chr11:133705235	NA	-0.39	-5.65	-0.3	3.48e-8	Childhood ear infection;
CRC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.86	-10.04	-0.48	7.52e-21	Breast cancer;
CRC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-8.38	-0.42	1.55e-15	Bipolar disorder;
CRC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg03929089	chr4:120376271	NA	-0.48	-7.03	-0.36	1.19e-11	HDL cholesterol;
CRC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.58	-9.22	-0.45	3.52e-18	Motion sickness;
CRC	cis	rs6969780	1.000	rs739734	chr7:27159405	C/T	cg26364809	chr7:27145159	NA	-0.74	-6.62	-0.34	1.49e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-19.52	-0.73	6.34e-57	Height;
CRC	cis	rs2860975	0.936	rs7904000	chr10:96767858	A/T	cg09036531	chr10:96991505	NA	-0.47	-6.33	-0.33	7.93e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg02869306	chr7:64672164	INTS4L1	0.44	6.33	0.33	7.85e-10	Aortic root size;
CRC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-10.89	-0.51	8.39e-24	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9549328	0.643	rs4907567	chr13:113617533	C/T	cg24588162	chr13:113633484	MCF2L	0.36	6.52	0.34	2.68e-10	Systolic blood pressure;
CRC	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.47	6.05	0.32	3.85e-9	Neuroticism;
CRC	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg26182253	chr13:112236782	NA	0.31	6.29	0.33	9.96e-10	Hepatitis;
CRC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.33e-16	Response to antipsychotic treatment;
CRC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	15.11	0.64	1.57e-39	Mean platelet volume;
CRC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.59	-9.13	-0.45	7.21e-18	Corneal astigmatism;
CRC	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.97	-0.36	1.79e-11	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	0.62	9.72	0.47	8.72e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	11.2	0.53	6.93e-25	Tonsillectomy;
CRC	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg10631289	chr15:39006617	NA	-0.46	-5.78	-0.3	1.72e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CRC	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.71	12.22	0.56	1.39e-28	White blood cell count (basophil);
CRC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.46	-6.21	-0.32	1.61e-9	Diastolic blood pressure;
CRC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	3.99e-16	Life satisfaction;
CRC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg05044414	chr3:183734942	ABCC5	0.47	8.0	0.4	2.11e-14	Anterior chamber depth;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01074628	chr11:74204917	LIPT2	0.55	7.85	0.4	5.96e-14	Response to antipsychotic treatment;
CRC	cis	rs2814982	0.514	rs73405691	chr6:34468767	A/G	cg17674042	chr6:34482479	PACSIN1	-0.74	-8.65	-0.43	2.35e-16	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.58	8.15	0.41	7.87e-15	Longevity;Endometriosis;
CRC	cis	rs11212617	0.967	rs227061	chr11:108205329	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.34	0.33	7.77e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.61	-9.2	-0.45	4.2e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-8.7	-0.43	1.63e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs6681460	0.932	rs2483705	chr1:67191180	C/G	cg02459107	chr1:67143332	SGIP1	-0.36	-6.31	-0.33	8.91e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.42	-8.87	-0.44	4.8e-17	Renal cell carcinoma;
CRC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.4	6.67	0.35	1.09e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg16928487	chr17:17741425	SREBF1	-0.54	-9.52	-0.46	3.93e-19	Total body bone mineral density;
CRC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.46e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.59	8.67	0.43	1.94e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.39	-11.42	-0.53	1.14e-25	Psoriasis vulgaris;
CRC	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg22753661	chr15:79092743	ADAMTS7	-0.46	-5.64	-0.3	3.64e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs6088813	1.000	rs4911492	chr20:33951799	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.71	-0.3	2.49e-8	Height;
CRC	cis	rs727479	0.502	rs28757202	chr15:51503881	T/A	cg19946085	chr15:51559439	CYP19A1	-0.29	-5.83	-0.31	1.35e-8	Estradiol levels;
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder;
CRC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.83	0.31	1.3e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg07718321	chr6:96025334	MANEA	0.43	5.65	0.3	3.4e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	0.96	9.87	0.48	2.62e-20	Gut microbiota (bacterial taxa);
CRC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg15440763	chr7:158190612	PTPRN2	-0.41	-6.71	-0.35	8.4e-11	Obesity-related traits;
CRC	cis	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg02972257	chr16:68554789	NA	0.45	5.62	0.3	4.03e-8	Colorectal cancer;
CRC	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.65	9.36	0.46	1.26e-18	Schizophrenia;
CRC	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg14458575	chr2:238380390	NA	0.57	7.47	0.38	7.48e-13	Prostate cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04314247	chr1:95286125	SLC44A3	0.37	6.24	0.33	1.37e-9	Interleukin-6 levels;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg03623178	chr6:28175578	NA	-1.01	-15.66	-0.65	1.09e-41	Depression;
CRC	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg06484146	chr7:12443880	VWDE	-0.6	-8.03	-0.4	1.76e-14	Coronary artery disease;
CRC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.71	0.3	2.51e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05013783	chr12:56652058	ANKRD52	0.52	6.78	0.35	5.58e-11	Thyroid stimulating hormone;
CRC	cis	rs3736485	0.966	rs12440990	chr15:51902259	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.44	-0.33	4.36e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	trans	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg18288967	chr1:45987694	PRDX1	0.68	7.43	0.38	9.51e-13	Obesity-related traits;
CRC	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.58	-10.43	-0.5	3.2800000000000002e-22	Waist-hip ratio;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.86e-16	Life satisfaction;
CRC	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg26893134	chr6:116381904	FRK	0.27	6.49	0.34	3.09e-10	Total cholesterol levels;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg04362960	chr10:104952993	NT5C2	0.46	6.18	0.32	1.85e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-6.03	-0.32	4.45e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg12172441	chr6:28176163	NA	0.52	7.34	0.38	1.64e-12	Parkinson's disease;
CRC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg04166393	chr7:2884313	GNA12	0.45	6.06	0.32	3.65e-9	Height;
CRC	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.19	-0.32	1.74e-9	Breast cancer;
CRC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg21620606	chr4:1342894	KIAA1530	0.36	5.89	0.31	9.62e-9	Obesity-related traits;
CRC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.53	6.76	0.35	6.43e-11	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16933224	chr11:63604740	NA	0.41	6.01	0.31	5.06e-9	Response to antipsychotic treatment;
CRC	cis	rs6694672	0.681	rs7554995	chr1:197148761	T/C	cg13682187	chr1:196946512	CFHR5	0.5	7.53	0.38	4.98e-13	Asthma;
CRC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.62	-9.11	-0.45	7.99e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-9.47	-0.46	5.45e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg19731401	chr7:2775893	GNA12	0.48	5.91	0.31	8.52e-9	White matter integrity;
CRC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.76	-0.58	1.38e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.34	0.53	2.15e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12760731	0.920	rs12096233	chr1:178482882	A/G	cg00404053	chr1:178313656	RASAL2	0.54	6.43	0.33	4.37e-10	Obesity-related traits;
CRC	cis	rs9491140	0.539	rs10457447	chr6:124698568	A/C	cg19267163	chr6:125004984	NKAIN2	-0.58	-6.91	-0.36	2.56e-11	Neuroticism;
CRC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.76	-0.3	1.95e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-10.84	-0.51	1.27e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs4664293	0.647	rs357030	chr2:160493026	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.68	-0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs6534441	0.727	rs6534444	chr4:125425867	A/G	cg21609808	chr4:125404261	NA	-0.41	-5.99	-0.31	5.44e-9	Major depressive disorder;
CRC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.57	-9.1	-0.45	8.86e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs720844	0.535	rs12997473	chr2:149284887	A/G	cg09247360	chr2:149335327	NA	-0.57	-5.85	-0.31	1.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4728302	0.869	rs6954712	chr7:133618853	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.24e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7635838	0.892	rs9310383	chr3:11491305	A/G	cg00170343	chr3:11313890	ATG7	-0.4	-6.1	-0.32	3.04e-9	HDL cholesterol;
CRC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.47	9.44	0.46	7.24e-19	Renal cell carcinoma;
CRC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-6.58	-0.34	1.88e-10	Total body bone mineral density;
CRC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg24675056	chr1:15929824	NA	0.52	6.93	0.36	2.16e-11	Systolic blood pressure;
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11645453	chr3:52864694	ITIH4	-0.38	-6.49	-0.34	3.24e-10	Bipolar disorder;
CRC	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg09654669	chr8:57350985	NA	-0.41	-6.0	-0.31	5.28e-9	Obesity-related traits;
CRC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg15465823	chr12:48382534	COL2A1	-0.38	-6.14	-0.32	2.39e-9	Glycated hemoglobin levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01213128	chr5:138629571	MATR3	-0.39	-6.18	-0.32	1.86e-9	Myopia (pathological);
CRC	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-8.69	-0.43	1.69e-16	Blood protein levels;
CRC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.27	-0.37	2.69e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg10217327	chr6:118973057	C6orf204	-0.49	-5.62	-0.3	4.07e-8	Diastolic blood pressure;
CRC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg18230493	chr5:56204884	C5orf35	0.58	8.63	0.43	2.72e-16	Initial pursuit acceleration;
CRC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.59	8.73	0.43	1.29e-16	Menopause (age at onset);
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9847710	0.967	rs2581824	chr3:53022408	A/C	cg04503182	chr3:53078218	SFMBT1	-0.42	-6.35	-0.33	7.11e-10	Ulcerative colitis;
CRC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	6.48	0.34	3.31e-10	Platelet count;
CRC	cis	rs7259376	0.902	rs11669179	chr19:22604729	C/G	cg02657401	chr19:22469223	NA	0.3	6.54	0.34	2.3e-10	Menopause (age at onset);
CRC	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.72	11.1	0.52	1.6e-24	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg07393940	chr7:158741817	NA	-0.52	-7.46	-0.38	7.77e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.64	-8.53	-0.43	5.25e-16	Facial morphology (factor 19);
CRC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-7.54	-0.38	4.75e-13	Vitamin D levels;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg12172441	chr6:28176163	NA	0.47	6.19	0.32	1.75e-9	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg03929089	chr4:120376271	NA	0.63	6.04	0.32	4.15e-9	Axial length;
CRC	cis	rs4664293	0.867	rs7606046	chr2:160576158	A/G	cg08347373	chr2:160653686	CD302	-0.46	-7.32	-0.37	1.95e-12	Monocyte percentage of white cells;
CRC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18912574	chr7:65842487	NCRNA00174	0.33	5.66	0.3	3.37e-8	Calcium levels;
CRC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.22	0.56	1.4e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	8.25	0.41	3.8e-15	Cognitive test performance;
CRC	cis	rs4938330	0.608	rs2238006	chr11:117087792	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.14	-0.32	2.33e-9	Blood protein levels;
CRC	trans	rs16984718	1.000	rs16984718	chr2:18509254	C/T	cg08952239	chr16:85952285	IRF8	0.59	6.69	0.35	9.9e-11	Urate levels in obese individuals;
CRC	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg12072164	chr19:44306565	LYPD5	0.36	5.68	0.3	3.04e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.81	-0.35	4.66e-11	Colorectal cancer;
CRC	cis	rs1062746	0.520	rs17770965	chr16:87328597	G/A	cg02258303	chr16:87377426	FBXO31	-0.51	-7.32	-0.37	1.93e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.3	-6.25	-0.33	1.24e-9	Melanoma;
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg03623178	chr6:28175578	NA	0.92	9.49	0.46	4.91e-19	Depression;
CRC	cis	rs73206853	0.764	rs67828368	chr12:110546298	C/T	cg12870014	chr12:110450643	ANKRD13A	0.79	9.26	0.45	2.68e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22822919	chr1:10270658	KIF1B	0.45	6.38	0.33	5.85e-10	Anxiety disorder;
CRC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.54	8.35	0.42	1.86e-15	Aortic root size;
CRC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg11292332	chr7:45801988	SEPT13	-0.38	-6.83	-0.35	4.14e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.08	0.55	4.6e-28	Chronic sinus infection;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg02683197	chr6:28174875	NA	0.72	8.8	0.44	7.84e-17	Parkinson's disease;
CRC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	9.76	0.47	6.12e-20	Cognitive test performance;
CRC	cis	rs279910	0.862	rs279899	chr9:965006	A/T	cg13952963	chr9:998547	NA	-0.37	-5.7	-0.3	2.68e-8	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
CRC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.71	-9.1	-0.45	8.93e-18	Initial pursuit acceleration;
CRC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	11.41	0.53	1.27e-25	Body mass index;
CRC	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.46	6.82	0.35	4.48e-11	Neutrophil percentage of white cells;
CRC	trans	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.72	-0.35	7.96e-11	Endometrial cancer;
CRC	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.55	-8.5	-0.42	6.61e-16	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg09659197	chr4:152720779	NA	0.52	11.32	0.53	2.59e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.44	5.76	0.3	1.94e-8	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-10.76	-0.51	2.51e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21643547	chr1:205240462	TMCC2	-0.47	-8.03	-0.4	1.79e-14	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7113874	0.589	rs10769908	chr11:8484089	A/G	cg20771178	chr11:8615675	STK33	0.35	5.7	0.3	2.71e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg05139728	chr16:28306816	SBK1	-0.37	-5.99	-0.31	5.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.55	-8.65	-0.43	2.34e-16	Aortic root size;
CRC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12273811	chr6:28175739	NA	0.73	9.13	0.45	7.14e-18	Depression;
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg25834613	chr7:1915315	MAD1L1	-0.37	-6.34	-0.33	7.44e-10	Bipolar disorder;
CRC	cis	rs1552172	0.881	rs1471634	chr1:145702115	A/G	cg11743829	chr1:145714124	CD160	0.41	6.29	0.33	1.04e-9	Breast cancer;
CRC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.95	-0.36	1.96e-11	Type 2 diabetes;
CRC	cis	rs56307353	0.513	rs2041120	chr19:1961474	C/T	cg02376178	chr19:1969988	CSNK1G2	0.73	12.21	0.56	1.53e-28	Coronary artery disease;
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.36	0.46	1.3e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.71	-0.57	2.2e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs4664293	0.647	rs1425042	chr2:160440515	G/A	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23069444	chr2:85839322	C2orf68	-0.42	-6.5	-0.34	3.06e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.41	-0.33	5.13e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg16850897	chr7:100343110	ZAN	-0.54	-6.62	-0.34	1.44e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.47	-0.34	3.52e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg01721255	chr8:58191610	C8orf71	0.5	6.06	0.32	3.65e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.44	6.56	0.34	2.03e-10	Calcium levels;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg11900509	chr10:81946545	ANXA11	-0.67	-6.83	-0.35	4.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.18	-0.32	1.86e-9	Aortic root size;
CRC	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.37	-0.38	1.38e-12	Caudate activity during reward;
CRC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.45	-0.57	2.04e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.41	6.23	0.32	1.4e-9	Mean corpuscular volume;
CRC	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg08501292	chr6:25962987	TRIM38	0.95	9.32	0.46	1.72e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg17724175	chr1:150552817	MCL1	-0.51	-8.08	-0.41	1.27e-14	Tonsillectomy;
CRC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.73	-11.04	-0.52	2.67e-24	Menopause (age at onset);
CRC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.47	7.17	0.37	5.06e-12	Corneal astigmatism;
CRC	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.85	16.17	0.67	1.04e-43	Hip circumference;
CRC	cis	rs9556958	0.588	rs9556964	chr13:99159306	T/C	cg15168958	chr13:99100528	FARP1	0.37	5.64	0.3	3.73e-8	Educational attainment (years of education);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.35	5.7	0.3	2.66e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.86e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg10724054	chr17:3904396	NA	0.47	7.6	0.39	3.05e-13	Type 2 diabetes;
CRC	cis	rs6922632	1.000	rs6922632	chr6:24107093	C/A	cg26194775	chr6:24126114	NRSN1	-0.62	-7.07	-0.36	9.42e-12	Information processing speed;
CRC	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.47	5.9	0.31	9.09e-9	Metabolite levels;
CRC	cis	rs7635838	0.859	rs6784883	chr3:11444453	G/A	cg00170343	chr3:11313890	ATG7	0.42	6.35	0.33	7.36e-10	HDL cholesterol;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.18	0.74	1.67e-59	Prudent dietary pattern;
CRC	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg22495460	chr2:25135724	ADCY3	-0.8	-14.66	-0.63	8.74e-38	Body mass index in non-asthmatics;
CRC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.5	6.35	0.33	7.17e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11166629	1.000	rs894349	chr8:135638055	T/C	cg27224718	chr8:135614730	ZFAT	0.51	7.6	0.39	3.18e-13	Smoking quantity;
CRC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.59	-0.47	2.24e-19	Migraine;Coronary artery disease;
CRC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg09324608	chr17:30823087	MYO1D	0.34	5.93	0.31	7.52e-9	Schizophrenia;
CRC	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.37	0.42	1.7e-15	Coffee consumption (cups per day);
CRC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24308560	chr3:49941425	MST1R	0.45	7.01	0.36	1.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2617583	0.530	rs1478435	chr5:1454612	T/C	cg07148919	chr5:1466943	LPCAT1	-0.46	-5.93	-0.31	7.79e-9	Breast cancer;
CRC	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.45	6.59	0.34	1.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.49	5.85	0.31	1.2e-8	Diabetic retinopathy;
CRC	cis	rs12024301	0.557	rs79534455	chr1:183623626	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.91	0.36	2.49e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.79	0.63	2.66e-38	Prudent dietary pattern;
CRC	trans	rs1864585	0.520	rs73208782	chr8:10677555	G/A	cg26278703	chr11:58910052	FAM111A	0.56	6.47	0.34	3.51e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.48	7.49	0.38	6.38e-13	Corneal astigmatism;
CRC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.85	10.44	0.5	3.2e-22	Obesity-related traits;
CRC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13198984	chr17:80129470	CCDC57	-0.47	-7.99	-0.4	2.37e-14	Life satisfaction;
CRC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-13.1	-0.59	7.34e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.95	0.4	3e-14	Testicular germ cell tumor;
CRC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.25	-0.41	3.82e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9925964	0.900	rs9934438	chr16:31104878	G/A	cg03418659	chr16:31128414	MYST1	0.47	6.75	0.35	6.72e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.71	-12.42	-0.57	2.59e-29	Inhibitory control;
CRC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.1	0.32	2.93e-9	Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02709261	chr1:179051893	TOR3A	0.45	6.13	0.32	2.5e-9	Response to antipsychotic treatment;
CRC	cis	rs747650	0.504	rs10838652	chr11:47077837	C/T	cg19486271	chr11:47235900	DDB2	-0.44	-5.86	-0.31	1.11e-8	Acne (severe);
CRC	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg07125278	chr16:67683757	RLTPR	-0.46	-6.22	-0.32	1.51e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.42	-6.3	-0.33	9.7e-10	IFN-related cytopenia;
CRC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.52	-7.34	-0.38	1.65e-12	Melanoma;
CRC	cis	rs7731657	0.537	rs10073388	chr5:130188080	C/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.92	-0.31	8.17e-9	Fasting plasma glucose;
CRC	trans	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.54	-0.34	2.3e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs4400599	0.618	rs10908751	chr1:154187305	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.65	-0.3	3.48e-8	Platelet distribution width;
CRC	cis	rs6586163	0.934	rs7897395	chr10:90754607	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.33	-0.37	1.74e-12	Chronic lymphocytic leukemia;
CRC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.28	-0.42	3.19e-15	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15604425	chr10:103825102	HPS6	0.42	6.16	0.32	2.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Primary biliary cholangitis;
CRC	cis	rs12024301	0.557	rs16861254	chr1:183592275	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07165851	chr6:158734300	TULP4	0.61	7.67	0.39	1.92e-13	Height;
CRC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.71	-9.2	-0.45	4.39e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6496667	0.865	rs62019305	chr15:90887765	A/T	cg04176472	chr15:90893244	GABARAPL3	0.58	6.84	0.35	3.94e-11	Rheumatoid arthritis;
CRC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg02175503	chr12:58329896	NA	0.46	5.67	0.3	3.09e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.53	-8.58	-0.43	3.92e-16	Neurofibrillary tangles;
CRC	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg22256960	chr15:77711686	NA	-0.54	-8.24	-0.41	4.17e-15	Type 2 diabetes;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg19626500	chr19:17445531	ANO8	0.37	5.99	0.31	5.47e-9	Schizophrenia;
CRC	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg24463073	chr6:118973353	C6orf204	0.51	6.81	0.35	4.71e-11	Diastolic blood pressure;
CRC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg06204229	chr3:52865917	ITIH4	0.5	5.7	0.3	2.67e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.59	-11.26	-0.53	4.41e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs427941	0.703	rs201453	chr7:101739788	T/C	cg06246474	chr7:101738831	CUX1	0.46	7.23	0.37	3.35e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.42	-0.67	1.09e-44	Height;
CRC	cis	rs10971721	0.731	rs10971750	chr9:33869781	T/C	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.71	-9.21	-0.45	3.82e-18	Coronary artery disease;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg03790207	chr6:42947109	PEX6	-0.44	-6.18	-0.32	1.92e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg11887960	chr12:57824829	NA	0.58	6.44	0.33	4.17e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.59	-0.39	3.38e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs67981189	0.529	rs17093738	chr14:71586648	C/T	cg15910301	chr14:71632612	NA	0.3	6.0	0.31	5.24e-9	Schizophrenia;
CRC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg22815214	chr1:201083145	CACNA1S	0.58	9.36	0.46	1.28e-18	Permanent tooth development;
CRC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg15848620	chr12:58087721	OS9	0.6	8.14	0.41	8.12e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3823572	0.564	rs2953624	chr7:133659125	C/G	cg03336402	chr7:133662267	EXOC4	-0.69	-10.79	-0.51	1.99e-23	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg25876840	chr17:41920477	NA	0.6	8.38	0.42	1.56e-15	Triglycerides;
CRC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.02	-0.4	1.85e-14	Height;
CRC	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.68	0.35	1.03e-10	Lymphocyte counts;
CRC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg05585544	chr11:47624801	NA	0.47	8.48	0.42	7.86e-16	Subjective well-being;
CRC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.47	-0.34	3.52e-10	Reticulocyte fraction of red cells;
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.71	0.54	1.01e-26	Prudent dietary pattern;
CRC	cis	rs7487075	0.786	rs4768696	chr12:46726376	G/A	cg22049899	chr12:47219821	SLC38A4	0.33	6.19	0.32	1.83e-9	Itch intensity from mosquito bite;
CRC	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-7.31	-0.37	2e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-5.85	-0.31	1.19e-8	Mood instability;
CRC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.54	6.88	0.35	2.99e-11	Morning vs. evening chronotype;
CRC	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg15212455	chr7:39170539	POU6F2	0.45	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg16589663	chr20:23618590	CST3	0.42	6.17	0.32	1.95e-9	Chronic kidney disease;
CRC	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg24588162	chr13:113633484	MCF2L	0.36	6.36	0.33	6.63e-10	Systolic blood pressure;
CRC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.4	5.94	0.31	7.25e-9	Pulse pressure;
CRC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.45	-5.69	-0.3	2.75e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg03030879	chr14:75389066	RPS6KL1	0.41	6.18	0.32	1.84e-9	Height;
CRC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.43	-6.52	-0.34	2.65e-10	Vitiligo;
CRC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06544989	chr22:39130855	UNC84B	0.46	7.04	0.36	1.09e-11	Menopause (age at onset);
CRC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.12	0.52	1.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg18301423	chr5:131593218	PDLIM4	0.42	7.63	0.39	2.62e-13	Blood metabolite levels;
CRC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.67	0.39	1.97e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.58	-9.1	-0.45	8.74e-18	Corneal astigmatism;
CRC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.67	8.91	0.44	3.47e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.39	-5.66	-0.3	3.39e-8	Erythrocyte sedimentation rate;
CRC	cis	rs427941	0.632	rs201509	chr7:101765002	C/T	cg06246474	chr7:101738831	CUX1	0.45	6.86	0.35	3.36e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg07699608	chr10:75541558	CHCHD1	0.61	6.37	0.33	6.53e-10	Incident atrial fibrillation;
CRC	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg16329197	chr12:53359506	NA	-1.05	-10.08	-0.49	5.41e-21	Prostate cancer;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	6.46	0.34	3.68e-10	Obesity-related traits;
CRC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg05623727	chr3:50126028	RBM5	-0.45	-7.57	-0.39	3.74e-13	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-7.34	-0.38	1.7e-12	Total body bone mineral density;
CRC	cis	rs6662572	0.737	rs10890357	chr1:46318054	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg25876840	chr17:41920477	NA	0.53	7.65	0.39	2.23e-13	Triglycerides;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.33	-0.33	8.21e-10	Total body bone mineral density;
CRC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg03030879	chr14:75389066	RPS6KL1	0.43	6.8	0.35	4.94e-11	Height;
CRC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.74	10.15	0.49	3.2e-21	Cognitive function;
CRC	cis	rs6893807	1.000	rs2304608	chr5:87962298	C/A	cg09002922	chr5:87956389	LOC645323	-0.44	-6.2	-0.32	1.72e-9	Body mass index;
CRC	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.72	0.65	6.5e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7605827	0.930	rs6431704	chr2:15592061	G/T	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg02683197	chr6:28174875	NA	0.72	9.05	0.45	1.31e-17	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.14	0.74	2.41e-59	Prudent dietary pattern;
CRC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.73	-8.35	-0.42	1.94e-15	Obesity-related traits;
CRC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.17	-0.37	4.9e-12	Monocyte count;
CRC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg05585544	chr11:47624801	NA	-0.53	-9.38	-0.46	1.15e-18	Subjective well-being;
CRC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg13835894	chr2:219148914	PNKD;TMBIM1	0.32	6.17	0.32	1.98e-9	Colorectal cancer;
CRC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg02033258	chr5:131593261	PDLIM4	-0.34	-6.12	-0.32	2.59e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs1712517	0.844	rs4918003	chr10:105044157	C/T	cg05636881	chr10:105038444	INA	0.47	8.09	0.41	1.16e-14	Migraine;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg06896663	chr8:82754093	SNX16	-0.68	-6.1	-0.32	3.01e-9	Blood osmolality (transformed sodium);
CRC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.82	0.4	7.23e-14	Schizophrenia;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg01086389	chr3:150321178	SELT	-0.42	-6.09	-0.32	3.24e-9	Schizophrenia;
CRC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg23127183	chr11:57508653	C11orf31	0.47	6.41	0.33	5.04e-10	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21989094	chr19:39421295	MRPS12;SARS2	0.43	6.25	0.33	1.27e-9	Response to antipsychotic treatment;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg15845792	chr6:28175446	NA	0.79	11.65	0.54	1.66e-26	Cardiac Troponin-T levels;
CRC	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg09264619	chr17:80180166	NA	0.52	7.54	0.38	4.48e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.97	-0.36	1.7e-11	Total cholesterol levels;
CRC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.39	-0.33	5.79e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.64	10.34	0.5	7.07e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.78	-0.72	5.61e-54	Height;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg18512352	chr11:47633146	NA	0.34	6.55	0.34	2.28e-10	Subjective well-being;
CRC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-6.1	-0.32	2.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg20935933	chr6:143382018	AIG1	0.45	6.12	0.32	2.65e-9	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03244796	chr16:84163961	HSDL1	-0.38	-6.17	-0.32	1.96e-9	HDL cholesterol;
CRC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.64	11.67	0.54	1.42e-26	Total body bone mineral density;
CRC	cis	rs644148	0.738	rs2686767	chr19:44995037	G/C	cg15540054	chr19:45004280	ZNF180	-0.41	-5.74	-0.3	2.14e-8	Personality dimensions;
CRC	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg21062780	chr6:887772	NA	-0.49	-7.19	-0.37	4.52e-12	Aging;
CRC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07513332	chr6:167530253	CCR6	-0.41	-7.35	-0.38	1.62e-12	Primary biliary cholangitis;
CRC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg25019722	chr6:37503610	NA	-0.43	-7.8	-0.39	8.48e-14	Cognitive performance;
CRC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.44	7.08	0.36	8.92e-12	Uric acid clearance;
CRC	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg26182253	chr13:112236782	NA	0.31	6.24	0.33	1.33e-9	Hepatitis;
CRC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.73	9.59	0.47	2.2e-19	Cleft lip with or without cleft palate;
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02290350	chr8:58132656	NA	-0.51	-6.4	-0.33	5.49e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	10.34	0.5	6.91e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.43	6.59	0.34	1.71e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg17133734	chr15:86042851	AKAP13	0.41	6.47	0.34	3.54e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13393204	chr11:86748738	TMEM135	0.41	6.7	0.35	9.3e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.8	-0.3	1.55e-8	Breast cancer;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg26587870	chr6:27730563	NA	-0.39	-5.86	-0.31	1.13e-8	Cardiac Troponin-T levels;
CRC	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.44	6.67	0.35	1.07e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg06287003	chr12:125626642	AACS	-0.52	-8.0	-0.4	2.15e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.65	9.87	0.48	2.78e-20	Testicular germ cell tumor;
CRC	cis	rs12023718	0.545	rs12024886	chr1:178547662	T/G	cg00404053	chr1:178313656	RASAL2	0.63	7.1	0.36	7.76e-12	Obesity-related traits;
CRC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg25164649	chr6:28176230	NA	0.66	6.78	0.35	5.46e-11	Parkinson's disease;
CRC	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.45	6.38	0.33	5.87e-10	Height;
CRC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg04362960	chr10:104952993	NT5C2	-0.43	-6.02	-0.32	4.58e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg20684491	chr1:25596433	NA	0.42	7.35	0.38	1.53e-12	Erythrocyte sedimentation rate;
CRC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.31	-0.53	2.83e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.55	7.41	0.38	1.08e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg19980929	chr12:42632907	YAF2	0.43	6.35	0.33	7.26e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21099776	chr17:17739742	SREBF1	0.42	6.39	0.33	5.55e-10	Myopia (pathological);
CRC	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.73	-11.6	-0.54	2.55e-26	Plateletcrit;Platelet count;
CRC	cis	rs1980080	1.000	rs1980080	chr3:124911841	C/T	cg01464473	chr3:124912499	SLC12A8	0.36	5.84	0.31	1.25e-8	Tonsillectomy;
CRC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.27	-0.41	3.42e-15	Mean corpuscular volume;
CRC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-8.5	-0.42	6.93e-16	Body mass index;
CRC	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.9	-0.31	8.94e-9	Coronary artery disease;
CRC	trans	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg20251008	chr1:161136045	PPOX	0.41	5.98	0.31	5.71e-9	Height;
CRC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.54e-13	Mean platelet volume;
CRC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	11.94	0.55	1.5e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg22815214	chr1:201083145	CACNA1S	0.57	9.52	0.46	3.97e-19	Permanent tooth development;
CRC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.36	6.48	0.34	3.37e-10	Reticulocyte fraction of red cells;
CRC	trans	rs6015450	1.000	rs77506764	chr20:57751948	A/G	cg22122715	chr13:96086023	CLDN10	-0.55	-6.07	-0.32	3.48e-9	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg20512303	chr5:131592959	PDLIM4	0.41	7.11	0.37	7.12e-12	Breast cancer;
CRC	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.66	8.5	0.42	6.56e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg10517650	chr3:113235015	CCDC52	-0.42	-7.31	-0.37	2.02e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13714271	chr9:33076774	SMU1	0.44	6.44	0.33	4.24e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg02674126	chr19:40336878	FBL	0.42	6.67	0.35	1.09e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg18479299	chr3:125709523	NA	-0.56	-6.6	-0.34	1.6e-10	Blood pressure (smoking interaction);
CRC	cis	rs4692589	0.965	rs733672	chr4:170950243	C/A	cg19918862	chr4:170955249	NA	0.4	6.36	0.33	6.94e-10	Anxiety disorder;
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.61	-0.5	8.31e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs12594515	0.600	rs12903858	chr15:45972166	A/G	cg06207120	chr15:45996521	NA	0.25	5.82	0.31	1.43e-8	Waist circumference;Weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27022615	chr11:70049105	FADD	0.45	6.57	0.34	1.99e-10	Response to antipsychotic treatment;
CRC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.75	0.39	1.14e-13	Mean corpuscular volume;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04370476	chr3:49761188	GMPPB	-0.39	-5.96	-0.31	6.51e-9	Myopia (pathological);
CRC	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg18232548	chr7:50535776	DDC	-0.43	-5.67	-0.3	3.11e-8	Malaria;
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.6	-0.57	5.62e-30	Alzheimer's disease;
CRC	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	1.06	20.05	0.74	5.59e-59	Platelet distribution width;
CRC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.36	5.86	0.31	1.11e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg00343986	chr7:65444356	GUSB	0.45	6.23	0.32	1.42e-9	Aortic root size;
CRC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.25	0.41	3.99e-15	Height;
CRC	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg19676328	chr12:49525230	TUBA1B	-0.47	-6.28	-0.33	1.08e-9	Total cholesterol levels;
CRC	trans	rs7976838	0.908	rs12811364	chr12:60128317	A/G	cg16974014	chr22:22007515	MIR130B	0.49	6.03	0.32	4.41e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.2	0.64	6.75e-40	Colorectal cancer;
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.38	6.59	0.34	1.7e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.05	10.24	0.49	1.55e-21	Opioid sensitivity;
CRC	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg19773385	chr1:10388646	KIF1B	-0.56	-7.86	-0.4	5.59e-14	Hepatocellular carcinoma;
CRC	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.79	-13.36	-0.59	8.1e-33	Hip circumference;
CRC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.17	-0.45	5.48e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.67	11.43	0.53	1.07e-25	Subjective well-being (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.4	0.33	5.31e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20483112	chr1:11954174	NA	0.46	6.07	0.32	3.58e-9	Thyroid stimulating hormone;
CRC	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.7	8.78	0.44	9.05e-17	Type 2 diabetes;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.07	-0.49	5.69e-21	Bipolar disorder;
CRC	cis	rs600806	0.888	rs3768497	chr1:109866230	T/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.8	-0.3	1.59e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg03258749	chr1:151040405	MLLT11	-0.48	-7.37	-0.38	1.43e-12	Childhood ear infection;
CRC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.96	-0.31	6.4e-9	Cognitive function;
CRC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	7.67	0.39	2.01e-13	Lung cancer in ever smokers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02841941	chr3:152552615	P2RY1	0.44	6.28	0.33	1.05e-9	Response to antipsychotic treatment;
CRC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.61	6.9	0.36	2.67e-11	Resting heart rate;
CRC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.47	7.21	0.37	3.83e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.53	8.23	0.41	4.47e-15	Coronary artery disease;
CRC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.64	-7.05	-0.36	1.09e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg14646075	chr2:228736089	WDR69	-0.46	-6.17	-0.32	1.99e-9	Blood pressure;
CRC	cis	rs17767392	0.718	rs61989206	chr14:71686049	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.72	-0.35	7.83e-11	Mitral valve prolapse;
CRC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg25214090	chr10:38739885	LOC399744	-0.43	-6.58	-0.34	1.82e-10	Diastolic blood pressure;
CRC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.52	7.28	0.37	2.54e-12	Melanoma;
CRC	cis	rs931127	0.658	rs12787843	chr11:65477306	A/C	cg27068330	chr11:65405492	SIPA1	-0.44	-5.97	-0.31	6.06e-9	Systemic lupus erythematosus;
CRC	cis	rs7605827	0.930	rs11900088	chr2:15613994	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.64	9.7	0.47	1e-19	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18570997	chr7:129710291	KLHDC10	0.48	6.97	0.36	1.73e-11	Response to antipsychotic treatment;
CRC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.69	-9.35	-0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.38	6.52	0.34	2.64e-10	Systemic lupus erythematosus;
CRC	cis	rs911119	0.913	rs4815222	chr20:23576964	A/G	cg16589663	chr20:23618590	CST3	-0.44	-6.19	-0.32	1.77e-9	Chronic kidney disease;
CRC	cis	rs995000	0.783	rs6686331	chr1:63182135	C/T	cg19896129	chr1:63156450	NA	-0.42	-6.47	-0.34	3.55e-10	Triglyceride levels;
CRC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.05	-0.66	3.08e-43	Intelligence (multi-trait analysis);
CRC	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.44	6.62	0.34	1.43e-10	Neutrophil percentage of white cells;
CRC	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg21869046	chr19:41225005	ITPKC	0.41	6.22	0.32	1.51e-9	Kawasaki disease;
CRC	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.57	0.63	1.8e-37	Hypertriglyceridemia;
CRC	cis	rs62408225	0.962	rs6899623	chr6:90986559	A/G	cg06866423	chr6:90926672	BACH2	0.48	7.94	0.4	3.28e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs185694	0.947	rs595451	chr13:30896848	T/C	cg04551440	chr13:30881194	KATNAL1	-0.6	-6.22	-0.32	1.54e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	11.56	0.54	3.5e-26	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.71e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4692589	1.000	rs12643956	chr4:170932819	A/C	cg19918862	chr4:170955249	NA	0.38	6.23	0.32	1.43e-9	Anxiety disorder;
CRC	cis	rs4664293	0.647	rs1425040	chr2:160428423	G/A	cg08347373	chr2:160653686	CD302	-0.38	-6.41	-0.33	4.95e-10	Monocyte percentage of white cells;
CRC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.59	-10.04	-0.48	7.21e-21	Breast cancer;
CRC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.38	5.87	0.31	1.08e-8	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25447549	chr5:150603693	CCDC69	0.47	6.07	0.32	3.62e-9	Thyroid stimulating hormone;
CRC	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.51	-7.3	-0.37	2.16e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.49	-7.14	-0.37	5.88e-12	White blood cell count (basophil);White blood cell count;
CRC	cis	rs57466243	1	rs57466243	chr17:27059666	T/A	cg16670446	chr17:27188758	MIR451;MIR144	-0.39	-7.06	-0.36	1.02e-11	Reticulocyte count;
CRC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg24140574	chr1:16342155	HSPB7	0.44	6.53	0.34	2.47e-10	Dilated cardiomyopathy;
CRC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg11522145	chr4:3412961	RGS12	-0.41	-6.27	-0.33	1.16e-9	Serum sulfate level;
CRC	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.4	-6.8	-0.35	4.94e-11	Mean arterial pressure;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Parkinson's disease;
CRC	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	cg04338863	chr8:33670619	NA	0.46	7.02	0.36	1.3e-11	Body mass index;
CRC	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.59	-9.41	-0.46	8.85e-19	Waist circumference adjusted for body mass index;
CRC	cis	rs7487075	0.859	rs2307061	chr12:46758494	A/G	cg22049899	chr12:47219821	SLC38A4	0.31	5.72	0.3	2.37e-8	Itch intensity from mosquito bite;
CRC	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-7.6	-0.39	3.03e-13	Self-reported allergy;
CRC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.42	-6.61	-0.34	1.58e-10	Testicular germ cell tumor;
CRC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.01	-0.31	4.86e-9	Alzheimer's disease (late onset);
CRC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.0	0.31	5.29e-9	Diabetic retinopathy;
CRC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.56	6.4	0.33	5.2e-10	Bipolar disorder;
CRC	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.51	8.72	0.43	1.35e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.5	0.34	2.92e-10	Morning vs. evening chronotype;
CRC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.65	-8.02	-0.4	1.93e-14	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg19812747	chr11:111475976	SIK2	-0.58	-9.76	-0.47	6.21e-20	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg19041857	chr6:27730383	NA	-0.43	-6.25	-0.33	1.27e-9	Parkinson's disease;
CRC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg03013636	chr16:1946785	NA	0.59	7.18	0.37	4.64e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	1.02	9.74	0.47	7.31e-20	Lymphocyte counts;
CRC	cis	rs10128264	0.902	rs1250582	chr10:80973447	G/T	cg20744163	chr10:80999841	ZMIZ1	-0.39	-6.73	-0.35	7.78e-11	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.14e-24	Corneal astigmatism;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg01216370	chr2:228736459	WDR69	-0.45	-5.7	-0.3	2.68e-8	Blood pressure;
CRC	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-0.95	-9.26	-0.45	2.72e-18	Post bronchodilator FEV1;
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg13957321	chr17:43675089	NA	0.49	6.14	0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10888329	0.744	rs7533755	chr1:248359891	A/G	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Autism spectrum disorder;
CRC	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.1	-15.01	-0.64	3.68e-39	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs3736594	0.513	rs6704596	chr2:27796927	A/G	cg27432699	chr2:27873401	GPN1	0.64	8.52	0.43	5.74e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16035638	chr15:66797798	RPL4;ZWILCH	0.41	6.05	0.32	3.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg19077165	chr18:44547161	KATNAL2	0.43	6.35	0.33	7.24e-10	Educational attainment;
CRC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.53	7.92	0.4	3.8e-14	Tuberculosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04946603	chr15:41221376	DLL4	0.43	6.95	0.36	2.02e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	10.35	0.5	6.5600000000000005e-22	Blood protein levels;
CRC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.43	-6.29	-0.33	1.01e-9	Platelet distribution width;
CRC	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg05272587	chr13:111038400	COL4A2	-0.39	-6.15	-0.32	2.26e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2270875	1.000	rs75457232	chr8:132926435	A/G	cg24184792	chr8:132919238	EFR3A	-0.69	-6.74	-0.35	7.27e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.65	8.4	0.42	1.38e-15	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.4	-5.94	-0.31	7.06e-9	Blood metabolite levels;
CRC	cis	rs2108622	0.727	rs12609900	chr19:15982414	G/A	cg13772218	chr19:15982569	NA	0.49	6.97	0.36	1.75e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7945718	0.621	rs7931934	chr11:12679245	T/G	cg25843174	chr11:12811716	TEAD1	0.41	7.71	0.39	1.49e-13	Educational attainment (years of education);
CRC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.86	-0.44	5.21e-17	Alcohol dependence;
CRC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.62	6.99	0.36	1.58e-11	Menarche (age at onset);
CRC	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.57	-7.19	-0.37	4.43e-12	Cancer;
CRC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.87	0.48	2.71e-20	Platelet count;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.85	-0.4	6.05e-14	Menopause (age at onset);
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg02033258	chr5:131593261	PDLIM4	-0.35	-6.03	-0.32	4.29e-9	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10894806	chr6:6724955	NA	0.43	5.97	0.31	6.11e-9	Response to antipsychotic treatment;
CRC	cis	rs3785888	0.569	rs11655668	chr17:45007632	A/G	cg16759221	chr17:45003025	GOSR2	0.61	9.08	0.45	1.02e-17	Cleft lip with or without cleft palate;
CRC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.55	9.46	0.46	6.31e-19	Iron status biomarkers;
CRC	cis	rs6445967	1.000	rs35495842	chr3:58310250	T/C	cg23715586	chr3:58305044	RPP14	0.37	6.01	0.31	4.82e-9	Platelet count;
CRC	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.48	6.79	0.35	5.35e-11	Malaria;
CRC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.63	-10.37	-0.5	5.57e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg00601486	chr12:48723148	H1FNT	-0.35	-6.82	-0.35	4.3e-11	Glycated hemoglobin levels;
CRC	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg00042356	chr1:8021962	PARK7	0.54	6.87	0.35	3.13e-11	Inflammatory bowel disease;
CRC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg13256891	chr4:100009986	ADH5	0.42	6.09	0.32	3.07e-9	Alcohol dependence;
CRC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-9.08	-0.45	1.06e-17	Prostate cancer;
CRC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.38	5.93	0.31	7.85e-9	Height;
CRC	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.3	-0.37	2.23e-12	Inflammatory skin disease;
CRC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.57	8.95	0.44	2.73e-17	Aortic root size;
CRC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18357526	chr6:26021779	HIST1H4A	0.41	5.82	0.31	1.43e-8	Height;
CRC	cis	rs9296736	1.000	rs7450517	chr6:53902843	G/A	cg04374786	chr6:53939321	C6orf142	0.46	7.41	0.38	1.04e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.9	11.33	0.53	2.42e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.92	12.37	0.56	4.2e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.4	6.18	0.32	1.86e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.79	14.23	0.62	3.74e-36	Oral cavity cancer;
CRC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-1.03	-12.7	-0.57	2.48e-30	Hip circumference adjusted for BMI;
CRC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.57	-7.68	-0.39	1.87e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.22	-5.97	-0.31	6.17e-9	Type 2 diabetes;
CRC	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.14	-0.32	2.4e-9	Height;
CRC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.49	7.68	0.39	1.85e-13	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07698384	chr15:25684465	UBE3A	0.49	6.23	0.32	1.41e-9	Thyroid stimulating hormone;
CRC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg09218773	chr11:619014	MUPCDH	-0.36	-5.64	-0.3	3.62e-8	Systemic lupus erythematosus;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13655938	chr17:40540819	STAT3	0.46	6.48	0.34	3.4e-10	Response to antipsychotic treatment;
CRC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.75	0.3	2.08e-8	IgG glycosylation;
CRC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.93	0.72	1.44e-54	Cognitive ability;
CRC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.4	7.32	0.37	1.89e-12	Colorectal cancer;
CRC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.67	11.73	0.54	8.47e-27	Height;
CRC	cis	rs8067545	1.000	rs56142708	chr17:19934963	A/C	cg13482628	chr17:19912719	NA	0.52	8.11	0.41	9.88e-15	Schizophrenia;
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.7	9.76	0.47	6.23e-20	Alzheimer's disease;
CRC	cis	rs6662572	0.737	rs56047133	chr1:46517228	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.98	0.31	5.76e-9	Blood protein levels;
CRC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.29e-24	Motion sickness;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15923342	chr7:130353794	COPG2;TSGA13	0.42	6.53	0.34	2.56e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg21466736	chr12:48725269	NA	-0.52	-8.02	-0.4	1.9e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.4	-5.67	-0.3	3.1e-8	Longevity;
CRC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.56	-0.43	4.45e-16	Aortic root size;
CRC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.74	11.83	0.55	3.79e-27	Blood protein levels;
CRC	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg12185399	chr6:27640341	NA	0.83	6.03	0.32	4.38e-9	Depression;
CRC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	ch.11.42038R	chr11:967971	AP2A2	0.61	10.35	0.5	6.31e-22	Alzheimer's disease (late onset);
CRC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.84	-0.31	1.29e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.7	0.43	1.6e-16	Rheumatoid arthritis;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.43	6.44	0.33	4.34e-10	Obesity-related traits;
CRC	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.01	0.31	5.04e-9	Ovarian reserve;
CRC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.62	-7.82	-0.4	7.32e-14	Schizophrenia;
CRC	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	5.74	0.3	2.13e-8	Breast cancer;
CRC	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.18	-0.56	1.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2415984	0.579	rs1389608	chr14:46957777	C/A	cg14871534	chr14:47121158	RPL10L	-0.42	-5.92	-0.31	8.18e-9	Number of children ever born;
CRC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.95	0.64	6.44e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg11211951	chr8:145729740	GPT	-0.37	-6.45	-0.33	4.05e-10	Age at first birth;
CRC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg09165964	chr15:75287851	SCAMP5	0.43	6.81	0.35	4.58e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs73206853	0.841	rs73191836	chr12:110966177	G/T	cg12870014	chr12:110450643	ANKRD13A	0.77	7.44	0.38	8.61e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1832871	0.672	rs62437399	chr6:158784251	C/A	cg07165851	chr6:158734300	TULP4	0.62	7.8	0.39	8.5e-14	Height;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg15786705	chr6:28176104	NA	-0.73	-9.56	-0.47	2.89e-19	Depression;
CRC	cis	rs7901135	0.962	rs7067550	chr10:60562236	C/T	cg23799393	chr10:60588674	BICC1	-0.37	-5.76	-0.3	1.97e-8	Morning vs. evening chronotype;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.13	-0.37	6.6e-12	Bipolar disorder;
CRC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg04586622	chr2:25135609	ADCY3	-0.57	-10.75	-0.51	2.75e-23	Body mass index in non-asthmatics;
CRC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg23625390	chr15:77176239	SCAPER	0.39	5.81	0.31	1.47e-8	Blood metabolite levels;
CRC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	trans	rs79464052	0.677	rs77605361	chr5:140954026	A/G	cg05255351	chr5:1503979	LPCAT1	-0.55	-6.91	-0.36	2.58e-11	Diffuse large B cell lymphoma;
CRC	cis	rs4499344	0.576	rs259280	chr19:33161452	C/T	cg08127369	chr19:33164662	ANKRD27	0.39	5.95	0.31	6.81e-9	Mean platelet volume;
CRC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.57	8.76	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26306683	chr17:18585705	ZNF286B	-0.4	-5.94	-0.31	7.32e-9	Educational attainment (years of education);
CRC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.58	8.54	0.43	4.96e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-5.84	-0.31	1.25e-8	Schizophrenia;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.12	-0.32	2.68e-9	Aortic root size;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg13615338	chr4:55094005	PDGFRA	0.42	6.19	0.32	1.81e-9	Corneal astigmatism;
CRC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.61	0.3	4.41e-8	Coronary artery disease;
CRC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.19	-0.37	4.52e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.59	-0.43	3.47e-16	Bipolar disorder;
CRC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.98	-0.31	5.74e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg19193384	chr17:30244184	NA	-0.58	-7.01	-0.36	1.33e-11	Hip circumference adjusted for BMI;
CRC	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg09127314	chr1:152161683	NA	-0.45	-5.94	-0.31	7.08e-9	Atopic dermatitis;
CRC	cis	rs7626444	0.625	rs7648479	chr3:196477213	G/C	cg12930392	chr3:196481615	PAK2	0.39	7.06	0.36	9.86e-12	Monocyte count;
CRC	cis	rs6546324	0.625	rs2861686	chr2:67838051	A/T	cg15745817	chr2:67799979	NA	-0.55	-9.6	-0.47	2.17e-19	Endometriosis;
CRC	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg11693508	chr17:37793320	STARD3	0.64	8.22	0.41	4.72e-15	Bipolar disorder;
CRC	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.85	-13.99	-0.61	3.18e-35	Hypospadias;
CRC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg23461800	chr14:103021989	NA	-0.75	-9.93	-0.48	1.71e-20	Platelet count;
CRC	cis	rs11212617	1.000	rs227092	chr11:108236783	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.48	0.34	3.33e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.5	0.54	6.02e-26	Prudent dietary pattern;
CRC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.39	5.91	0.31	8.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs17767392	0.957	rs36057816	chr14:71760546	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	trans	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg10756647	chr7:56101905	PSPH	0.74	7.52	0.38	5.22e-13	Diabetic kidney disease;
CRC	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.69	11.58	0.54	3e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12431939	0.779	rs3007081	chr14:51645492	G/A	cg23942311	chr14:51606299	NA	0.49	6.81	0.35	4.68e-11	Cancer;
CRC	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg10761708	chr20:43804764	PI3	0.5	5.8	0.3	1.54e-8	Blood protein levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg05951993	chr19:49496864	GYS1;RUVBL2	-0.41	-6.18	-0.32	1.85e-9	Daytime sleep phenotypes;
CRC	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg10724054	chr17:3904396	NA	0.47	7.57	0.39	3.75e-13	Type 2 diabetes;
CRC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-9.86	-0.48	2.93e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25517755	chr10:38738941	LOC399744	-0.42	-6.06	-0.32	3.79e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.87	19.45	0.73	1.29e-56	Breast cancer;
CRC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg04989706	chr14:50066350	PPIL5	-0.6	-8.25	-0.41	3.95e-15	Carotid intima media thickness;
CRC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.47	-5.86	-0.31	1.15e-8	Gut microbiome composition (summer);
CRC	cis	rs4237845	0.611	rs4760347	chr12:58346868	T/C	cg00677455	chr12:58241039	CTDSP2	0.4	5.67	0.3	3.08e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7539542	0.556	rs6692075	chr1:202881302	C/T	cg19681188	chr1:202830198	LOC148709	0.45	6.54	0.34	2.37e-10	Mean platelet volume;
CRC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg17724175	chr1:150552817	MCL1	0.5	7.46	0.38	7.75e-13	Melanoma;
CRC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.4	-0.46	9.54e-19	Platelet count;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-10.53	-0.5	1.59e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.19	-0.37	4.47e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.57	-9.59	-0.47	2.24e-19	Huntington's disease progression;
CRC	cis	rs888194	0.677	rs10850139	chr12:109875934	A/C	cg19025524	chr12:109796872	NA	-0.4	-5.81	-0.3	1.5e-8	Neuroticism;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.57	6.99	0.36	1.57e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9326248	0.574	rs1263173	chr11:116681008	C/T	cg11861562	chr11:117069780	TAGLN	0.27	6.16	0.32	2.08e-9	Blood protein levels;
CRC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg00717180	chr2:96193071	NA	-0.39	-6.4	-0.33	5.23e-10	HDL cholesterol;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.81	-12.54	-0.57	9.37e-30	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg10589385	chr1:150898437	SETDB1	-0.29	-6.05	-0.32	3.84e-9	Tonsillectomy;
CRC	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs6088813	1.000	rs6088816	chr20:33982435	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.74	-0.3	2.12e-8	Height;
CRC	cis	rs11605275	1.000	rs74809393	chr11:20031520	C/A	cg14835545	chr11:20032148	NAV2	-0.83	-5.64	-0.3	3.57e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg02072170	chr3:194406190	FAM43A	-0.44	-7.61	-0.39	2.85e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02598441	chr17:62777298	LOC146880	-0.52	-6.71	-0.35	8.51e-11	Joint mobility (Beighton score);
CRC	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.47	-5.93	-0.31	7.81e-9	IgG glycosylation;
CRC	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg14631576	chr9:95140430	CENPP	-0.41	-7.35	-0.38	1.61e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg16141378	chr3:129829833	LOC729375	-0.42	-6.38	-0.33	6.18e-10	Neuroticism;
CRC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.81	-14.37	-0.62	1.09e-36	Breast cancer;
CRC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.35	-0.38	1.59e-12	Life satisfaction;
CRC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.77	14.38	0.62	9.97e-37	Prudent dietary pattern;
CRC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.32	-0.33	8.5e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.27e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-6.32	-0.33	8.74e-10	Arsenic metabolism;
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.26e-10	Bipolar disorder;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg02683197	chr6:28174875	NA	0.71	9.08	0.45	1.06e-17	Depression;
CRC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.57	7.08	0.36	8.83e-12	Body mass index (adult);
CRC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.83	12.88	0.58	5.05e-31	Cognitive function;
CRC	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg15147215	chr3:52552868	STAB1	-0.42	-5.84	-0.31	1.25e-8	Schizophrenia;
CRC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.66	-10.75	-0.51	2.65e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg01721255	chr8:58191610	C8orf71	0.46	5.92	0.31	8.21e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg10729496	chr3:10149963	C3orf24	0.5	6.13	0.32	2.53e-9	Alzheimer's disease;
CRC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg07636037	chr3:49044803	WDR6	-0.83	-6.8	-0.35	4.84e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03695666	chr19:38210224	ZNF607	0.36	5.98	0.31	5.71e-9	Obesity-related traits;
CRC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.88	-16.15	-0.66	1.27e-43	Coronary artery disease;
CRC	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.52	-7.2	-0.37	4.18e-12	Schizophrenia;
CRC	trans	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg21302420	chr1:112162376	RAP1A	0.78	6.95	0.36	2.02e-11	Skin colour saturation;
CRC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.63	0.51	7.1e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.18	0.52	8.01e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24308560	chr3:49941425	MST1R	-0.42	-6.51	-0.34	2.78e-10	Body mass index;
CRC	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg00495681	chr13:53174319	NA	0.56	8.08	0.41	1.22e-14	Lewy body disease;
CRC	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg02158880	chr13:53174818	NA	0.39	5.62	0.3	4.11e-8	Lewy body disease;
CRC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.4	6.29	0.33	9.87e-10	Dupuytren's disease;
CRC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.55	-7.73	-0.39	1.35e-13	Pancreatic cancer;
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.13	0.52	1.23e-24	Prudent dietary pattern;
CRC	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg04132472	chr17:19861366	AKAP10	0.45	7.15	0.37	5.54e-12	Schizophrenia;
CRC	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg11812906	chr14:75593930	NEK9	0.5	7.04	0.36	1.1e-11	Height;
CRC	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.87	11.27	0.53	3.91e-25	Orofacial clefts;
CRC	cis	rs7216064	0.861	rs12449312	chr17:65829358	A/C	cg12091567	chr17:66097778	LOC651250	-0.66	-7.97	-0.4	2.6e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.58	-8.78	-0.44	8.85e-17	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06742493	chr19:13056745	RAD23A	-0.4	-6.04	-0.32	4.13e-9	Myopia (pathological);
CRC	cis	rs73206853	0.841	rs17619763	chr12:110645829	C/T	cg12870014	chr12:110450643	ANKRD13A	0.79	7.76	0.39	1.06e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.56	6.19	0.32	1.75e-9	Vitiligo;
CRC	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.91	-11.62	-0.54	2.12e-26	Hair shape;
CRC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.74	0.39	1.22e-13	Height;
CRC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.78	-0.47	5.21e-20	Hip circumference adjusted for BMI;
CRC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg17178900	chr1:205818956	PM20D1	-0.39	-5.62	-0.3	4.1e-8	Menarche (age at onset);
CRC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.65	5.74	0.3	2.15e-8	Yeast infection;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Depression;
CRC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.57	-8.21	-0.41	4.99e-15	Malaria;
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00166722	chr3:10149974	C3orf24	0.67	7.94	0.4	3.17e-14	Alzheimer's disease;
CRC	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg08600765	chr20:34638493	LOC647979	-0.58	-6.58	-0.34	1.86e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.81	14.76	0.63	3.54e-38	Anterior chamber depth;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10353612	chr8:33330866	FUT10	0.39	5.98	0.31	5.9e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs12469302	chr2:162433831	G/T	cg12500891	chr11:57225987	NA	-0.67	-5.98	-0.31	5.67e-9	Cognitive function;
CRC	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.5	-6.69	-0.35	9.35e-11	Response to antidepressants and depression;
CRC	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg26741380	chr15:41871084	TYRO3	0.41	6.07	0.32	3.51e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.09	18.58	0.72	3.25e-53	Cognitive function;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg03623178	chr6:28175578	NA	0.73	9.19	0.45	4.45e-18	Parkinson's disease;
CRC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.17	0.52	8.58e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.43	5.92	0.31	7.92e-9	Male-pattern baldness;
CRC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.36	6.21	0.32	1.61e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06544989	chr22:39130855	UNC84B	0.48	7.6	0.39	3.18e-13	Menopause (age at onset);
CRC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.76	10.12	0.49	3.8e-21	Platelet count;
CRC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.06	0.41	1.47e-14	Menopause (age at onset);
CRC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg19980929	chr12:42632907	YAF2	0.4	6.11	0.32	2.82e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-9.02	-0.45	1.62e-17	Bipolar disorder;
CRC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg25956985	chr22:39795188	MAP3K7IP1	-0.42	-6.2	-0.32	1.69e-9	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.76	-8.44	-0.42	1.01e-15	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03674076	chr20:524243	CSNK2A1	0.38	5.96	0.31	6.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs972578	0.967	rs5759082	chr22:43401079	C/T	cg01576275	chr22:43409880	NA	-0.48	-7.85	-0.4	5.83e-14	Mean platelet volume;
CRC	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg27083787	chr2:113543245	IL1A	0.42	5.86	0.31	1.12e-8	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23249942	chr5:109027037	MAN2A1	0.42	6.02	0.31	4.78e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26646878	chr17:900222	TIMM22	0.47	7.18	0.37	4.64e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.59	9.76	0.47	6.44e-20	Mean corpuscular volume;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg15845792	chr6:28175446	NA	0.86	13.56	0.6	1.46e-33	Cardiac Troponin-T levels;
CRC	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	6.44	0.33	4.13e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Depression;
CRC	cis	rs6997458	0.742	rs13269441	chr8:86330635	G/C	cg21346043	chr8:86351067	CA3	-0.27	-5.89	-0.31	9.69e-9	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg14345882	chr6:26364793	BTN3A2	-0.68	-5.89	-0.31	9.3e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg25790453	chr13:113633590	MCF2L	0.44	7.51	0.38	5.45e-13	Systolic blood pressure;
CRC	cis	rs4731207	0.564	rs10954057	chr7:124613938	T/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg20742385	chr13:113633654	MCF2L	-0.66	-11.58	-0.54	3.06e-26	Systolic blood pressure;
CRC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.5	-7.64	-0.39	2.46e-13	Menarche (age at onset);
CRC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.08	12.39	0.56	3.42e-29	Sexual dysfunction (female);
CRC	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.1	-0.32	2.96e-9	Menopause (age at onset);
CRC	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.45	7.5	0.38	6.1e-13	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.76	13.44	0.6	3.97e-33	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19545348	chr1:211434133	RCOR3	0.47	6.6	0.34	1.62e-10	Response to antipsychotic treatment;
CRC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.8	14.56	0.63	2.12e-37	Metabolic syndrome;
CRC	cis	rs9400239	0.622	rs1159806	chr6:109006838	A/T	cg11073813	chr6:109029018	NA	-0.39	-6.11	-0.32	2.75e-9	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.44	0.6	3.86e-33	Lymphocyte percentage of white cells;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06836181	chr2:64995545	NA	-0.56	-6.91	-0.36	2.54e-11	Diisocyanate-induced asthma;
CRC	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.6e-14	Height;
CRC	cis	rs62432291	0.681	rs2932987	chr6:159655673	C/G	cg14500486	chr6:159655392	FNDC1	0.79	10.65	0.51	5.77e-23	Joint mobility (Beighton score);
CRC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg23996704	chr18:44553084	KATNAL2	0.28	5.85	0.31	1.21e-8	Educational attainment;
CRC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.2	0.49	2.05e-21	Platelet count;
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg04204079	chr8:58130323	NA	-0.45	-5.75	-0.3	2.06e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg06784218	chr1:46089804	CCDC17	-0.5	-8.04	-0.41	1.63e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18158177	chr1:39492193	NDUFS5	0.44	6.28	0.33	1.05e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.67	-12.17	-0.56	2.24e-28	Aortic root size;
CRC	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg21153622	chr11:89784906	NA	-0.5	-8.3	-0.42	2.65e-15	Height;
CRC	cis	rs3889199	1.000	rs34370185	chr1:59656909	G/T	cg25881383	chr1:59680599	NA	-0.37	-5.9	-0.31	9e-9	Pulse pressure;
CRC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.45	7.28	0.37	2.48e-12	Type 2 diabetes;
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg18833306	chr6:118973337	C6orf204	0.44	5.74	0.3	2.12e-8	Diastolic blood pressure;
CRC	cis	rs9818941	1.000	rs9845687	chr3:157682536	T/C	cg08654915	chr3:157813417	NA	-0.32	-5.92	-0.31	8.11e-9	Height;
CRC	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.49	7.27	0.37	2.6e-12	Night sleep phenotypes;
CRC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.76	14.31	0.62	1.87e-36	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23233605	chr9:130548199	CDK9	0.45	6.95	0.36	2e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04215179	chr7:23719682	C7orf46	-0.4	-5.97	-0.31	6.11e-9	Myopia (pathological);
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.22e-9	Life satisfaction;
CRC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.01	-0.31	4.96e-9	Aortic root size;
CRC	cis	rs10905065	0.930	rs10795485	chr10:5755047	T/C	cg11519256	chr10:5708881	ASB13	0.43	6.13	0.32	2.53e-9	Menopause (age at onset);
CRC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.15	0.32	2.26e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.34	3.35e-10	Lung cancer;
CRC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg21770322	chr7:97807741	LMTK2	0.52	8.58	0.43	3.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg11003573	chr3:44754125	ZNF502	-0.33	-5.64	-0.3	3.7e-8	Depressive symptoms;
CRC	cis	rs7215564	0.908	rs59254087	chr17:78665278	A/C	cg09596252	chr17:78655493	RPTOR	0.55	6.13	0.32	2.57e-9	Myopia (pathological);
CRC	cis	rs1545257	0.537	rs2702089	chr2:24643291	A/G	cg06627628	chr2:24431161	ITSN2	0.45	6.55	0.34	2.2e-10	Sjögren's syndrome;
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg20512303	chr5:131592959	PDLIM4	0.3	5.79	0.3	1.68e-8	Blood metabolite levels;
CRC	cis	rs12476592	0.571	rs1446565	chr2:63731575	T/C	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.56	-9.52	-0.46	3.75e-19	Congenital heart disease (maternal effect);
CRC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.63	0.39	2.63e-13	Aortic root size;
CRC	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	trans	rs1864585	0.520	rs9650659	chr8:10667765	G/T	cg26278703	chr11:58910052	FAM111A	0.51	6.07	0.32	3.55e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	trans	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.39	-0.33	5.79e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.43	-0.33	4.49e-10	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.4	-0.53	1.31e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2811415	0.597	rs2033445	chr3:127730507	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.93	-0.31	7.85e-9	Lung function (FEV1/FVC);
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.02	-0.45	1.55e-17	Bipolar disorder;
CRC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.63	-10.46	-0.5	2.67e-22	Sudden cardiac arrest;
CRC	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg09873164	chr1:152488093	CRCT1	0.36	6.13	0.32	2.48e-9	Hair morphology;
CRC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.45	6.61	0.34	1.53e-10	Menopause (age at onset);
CRC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.06	24.4	0.8	8.27e-76	Testicular germ cell tumor;
CRC	cis	rs2257205	0.667	rs9889631	chr17:56630359	G/T	cg25885038	chr17:56607967	SEPT4	-0.56	-6.21	-0.32	1.55e-9	Pancreatic cancer;
CRC	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.65	-7.67	-0.39	1.91e-13	Ulcerative colitis;
CRC	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg05802477	chr12:132629385	DDX51;NOC4L	-0.41	-6.03	-0.32	4.34e-9	Schizophrenia;
CRC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-5.62	-0.3	4.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.31	6.16	0.32	2.09e-9	Abdominal aortic aneurysm;
CRC	cis	rs776905	0.598	rs6042	chr13:113770068	C/T	cg09069900	chr13:113776964	F10	-0.44	-6.98	-0.36	1.63e-11	Blood protein levels;
CRC	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg09127314	chr1:152161683	NA	0.45	5.86	0.31	1.14e-8	Atopic dermatitis;
CRC	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.5	7.94	0.4	3.33e-14	Anxiety disorder;
CRC	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.57	8.66	0.43	2.13e-16	Corneal astigmatism;
CRC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.51	0.34	2.82e-10	HIV-1 control;
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.59	-0.34	1.76e-10	Bipolar disorder;
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg25834613	chr7:1915315	MAD1L1	-0.46	-6.46	-0.34	3.67e-10	Neuroticism;
CRC	cis	rs3823572	0.564	rs2953626	chr7:133657458	A/G	cg03336402	chr7:133662267	EXOC4	-0.67	-10.31	-0.49	8.51e-22	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11636699	chr19:13044490	FARSA	0.39	6.24	0.33	1.34e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	6.47	0.34	3.54e-10	Mean corpuscular volume;
CRC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.43	-20.51	-0.75	8.67e-61	Hip circumference adjusted for BMI;
CRC	cis	rs282587	0.502	rs375741	chr13:113397794	G/C	cg04656015	chr13:113407548	ATP11A	0.64	8.02	0.4	1.83e-14	Glycated hemoglobin levels;
CRC	cis	rs9650315	0.778	rs36063247	chr8:57154653	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.13	0.32	2.57e-9	Height;
CRC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.69	11.01	0.52	3.31e-24	Colorectal cancer;
CRC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg12927641	chr6:109611667	NA	-0.38	-6.75	-0.35	6.72e-11	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.71	9.52	0.46	3.86e-19	Alzheimer's disease;
CRC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.05	0.52	2.31e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.68	10.27	0.49	1.24e-21	Cognitive function;
CRC	cis	rs703980	1.000	rs703976	chr10:80945964	C/G	cg20744163	chr10:80999841	ZMIZ1	0.31	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.46	7.18	0.37	4.8e-12	Lung cancer;
CRC	cis	rs728616	0.764	rs61859016	chr10:81852500	C/A	cg05935833	chr10:81318306	SFTPA2	-0.61	-6.95	-0.36	1.97e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg00601450	chr5:74908170	NA	0.36	5.66	0.3	3.33e-8	Age-related disease endophenotypes;
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.47	-6.08	-0.32	3.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.19	-0.32	1.74e-9	Vitiligo;
CRC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg16416165	chr4:3325029	RGS12	0.4	5.76	0.3	1.89e-8	Serum sulfate level;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.46	6.0	0.31	5.18e-9	Thyroid stimulating hormone;
CRC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17554472	chr22:41940697	POLR3H	0.55	5.66	0.3	3.31e-8	Vitiligo;
CRC	cis	rs12760731	0.720	rs10913545	chr1:178360201	G/A	cg00404053	chr1:178313656	RASAL2	0.96	10.0	0.48	9.77e-21	Obesity-related traits;
CRC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs73200209	0.744	rs73200226	chr12:116637861	G/A	cg01776926	chr12:116560359	MED13L	-0.61	-7.0	-0.36	1.41e-11	Total body bone mineral density;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.59	-11.16	-0.52	9.97e-25	Tonsillectomy;
CRC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg02158880	chr13:53174818	NA	0.59	9.4	0.46	9.33e-19	Lewy body disease;
CRC	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18834200	chr2:172017416	TLK1	-0.44	-5.96	-0.31	6.35e-9	Energy expenditure (24h);
CRC	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.48	-8.11	-0.41	1.01e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs73206853	0.764	rs61117387	chr12:110867725	C/A	cg12870014	chr12:110450643	ANKRD13A	0.82	9.83	0.48	3.73e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.39	0.33	5.69e-10	Blood protein levels;
CRC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-0.71	-7.27	-0.37	2.64e-12	Magnesium levels;
CRC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.71	-0.63	5.39e-38	Exhaled nitric oxide output;
CRC	cis	rs1524976	0.843	rs11711704	chr3:65444814	T/C	cg16238336	chr3:65465873	MAGI1	-0.48	-6.92	-0.36	2.42e-11	PR interval;
CRC	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg15382696	chr6:118971807	C6orf204	0.6	7.57	0.39	3.76e-13	Diastolic blood pressure;
CRC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	1.0	12.85	0.58	6.4e-31	Vitiligo;
CRC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.76	9.94	0.48	1.61e-20	Platelet count;
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.76	11.29	0.53	3.22e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.41	-0.33	5.03e-10	Monocyte count;
CRC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg02321871	chr13:50159138	RCBTB1	-0.43	-6.16	-0.32	2.18e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.42	-0.33	4.72e-10	Bipolar disorder;
CRC	trans	rs9395066	0.545	rs10456119	chr6:44889045	C/T	cg04786201	chr1:17185605	NA	0.28	6.06	0.32	3.78e-9	Height;
CRC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.69	10.0	0.48	9.69e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.6	10.54	0.5	1.43e-22	Iron status biomarkers;
CRC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg08493051	chr2:3487164	NA	-0.43	-6.19	-0.32	1.75e-9	Neurofibrillary tangles;
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg16060761	chr17:80687452	NA	-0.45	-5.85	-0.31	1.17e-8	Glycated hemoglobin levels;
CRC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg11833968	chr6:79620685	NA	-0.36	-6.36	-0.33	6.62e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg07074390	chr21:40555500	PSMG1	-0.43	-5.63	-0.3	3.95e-8	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17434043	chr11:2907123	CDKN1C	0.53	7.5	0.38	5.84e-13	Response to antipsychotic treatment;
CRC	cis	rs6988985	0.703	rs7016594	chr8:143950352	G/A	cg10324643	chr8:143916377	GML	0.35	5.7	0.3	2.69e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs939574	0.512	rs55908154	chr2:220145960	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.54	6.2	0.32	1.67e-9	Platelet distribution width;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg02033258	chr5:131593261	PDLIM4	0.39	6.37	0.33	6.32e-10	Blood metabolite levels;
CRC	cis	rs910187	0.631	rs2228	chr20:45809941	G/A	cg27589058	chr20:45804311	EYA2	-0.41	-7.74	-0.39	1.24e-13	Migraine;
CRC	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg08501292	chr6:25962987	TRIM38	0.85	7.53	0.38	4.89e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs501120	0.564	rs1509931	chr10:44682080	C/T	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg09455208	chr3:40491958	NA	0.32	6.43	0.33	4.38e-10	Renal cell carcinoma;
CRC	cis	rs2811415	0.597	rs9813812	chr3:127791936	G/T	cg13719885	chr3:127795394	NA	-0.39	-5.96	-0.31	6.34e-9	Lung function (FEV1/FVC);
CRC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.43	10.1	0.49	4.56e-21	Coronary artery disease;
CRC	cis	rs4731207	0.596	rs11767737	chr7:124637905	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.27	-0.33	1.15e-9	Cutaneous malignant melanoma;
CRC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg23533926	chr12:111358616	MYL2	0.44	6.43	0.33	4.44e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-9.56	-0.47	2.78e-19	HDL cholesterol;
CRC	cis	rs910187	0.641	rs3186647	chr20:45817067	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-7.51	-0.38	5.45e-13	Migraine;
CRC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg16476235	chr8:21771668	DOK2	0.4	6.85	0.35	3.55e-11	Mean corpuscular volume;
CRC	cis	rs4336470	0.547	rs9499924	chr6:105142638	C/G	cg02098413	chr6:105308735	HACE1	-0.43	-8.38	-0.42	1.53e-15	Neuroblastoma;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg22407090	chr2:61765448	XPO1	-0.67	-6.02	-0.31	4.75e-9	Cognitive function;
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.91	0.36	2.52e-11	Diastolic blood pressure;
CRC	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	9.25	0.45	2.88e-18	Menopause (age at onset);
CRC	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg11441379	chr12:63026424	NA	0.53	5.76	0.3	1.97e-8	IgG glycosylation;
CRC	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	7.96	0.4	2.82e-14	Total cholesterol levels;
CRC	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.41	1.5e-14	Cognitive performance;
CRC	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.58	0.54	3.17e-26	Bipolar disorder;
CRC	cis	rs4728302	0.869	rs2042455	chr7:133580545	A/G	cg10665199	chr7:133106180	EXOC4	0.42	6.32	0.33	8.64e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg11887960	chr12:57824829	NA	0.58	6.42	0.33	4.87e-10	Lung disease severity in cystic fibrosis;
CRC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.82	11.59	0.54	2.78e-26	Platelet distribution width;
CRC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.44	6.22	0.32	1.5e-9	Lung cancer;
CRC	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.57	9.73	0.47	8.02e-20	Leprosy;
CRC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg20737812	chr15:86336631	KLHL25	-0.47	-7.19	-0.37	4.5e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg10437265	chr15:77819839	NA	-0.44	-7.82	-0.4	7.44e-14	Type 2 diabetes;
CRC	cis	rs7131987	0.675	rs1436322	chr12:29554805	A/G	cg09582351	chr12:29534625	ERGIC2	0.31	6.6	0.34	1.67e-10	QT interval;
CRC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.93	17.52	0.69	5.2e-49	Height;
CRC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.96	-9.67	-0.47	1.23e-19	Breast cancer;
CRC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.51	0.38	5.8e-13	Motion sickness;
CRC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.57	-0.34	1.95e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg05585544	chr11:47624801	NA	-0.61	-10.84	-0.51	1.25e-23	Subjective well-being;
CRC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg17948913	chr5:572064	NA	0.56	6.36	0.33	6.88e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg15226275	chr6:116381976	FRK	0.29	8.35	0.42	1.87e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg10760299	chr15:45669010	GATM	0.5	7.97	0.4	2.72e-14	Homoarginine levels;
CRC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	14.81	0.63	2.14e-38	Smoking behavior;
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.62	-5.95	-0.31	7.02e-9	Lung cancer;
CRC	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.8	-12.92	-0.58	3.63e-31	Hypospadias;
CRC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.33	0.37	1.83e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.66	10.65	0.51	5.86e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.6	-9.27	-0.45	2.59e-18	Colorectal cancer;
CRC	cis	rs747650	0.926	rs11039119	chr11:47201924	G/A	cg03339077	chr11:47165057	C11orf49	-0.45	-6.16	-0.32	2.18e-9	Acne (severe);
CRC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg15465823	chr12:48382534	COL2A1	0.38	6.14	0.32	2.4e-9	Glycated hemoglobin levels;
CRC	cis	rs73206853	0.841	rs3759382	chr12:110889483	G/A	cg12870014	chr12:110450643	ANKRD13A	0.75	8.21	0.41	5.25e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.95	0.31	6.72e-9	Bladder cancer;
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.72e-9	Bipolar disorder;
CRC	cis	rs2280630	0.529	rs4342048	chr3:39012943	A/G	cg01426195	chr3:39028469	NA	-0.42	-6.99	-0.36	1.57e-11	Verbal declarative memory;
CRC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg24562669	chr7:97807699	LMTK2	0.79	17.53	0.69	4.71e-49	Breast cancer;
CRC	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.48e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.49	-8.77	-0.44	1.01e-16	Childhood ear infection;
CRC	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.33	0.42	2.26e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.33	5.89	0.31	9.53e-9	Pulse pressure;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs7487075	0.619	rs9669404	chr12:46798963	A/G	cg22049899	chr12:47219821	SLC38A4	-0.31	-5.77	-0.3	1.85e-8	Itch intensity from mosquito bite;
CRC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg12501888	chr15:85177176	SCAND2	-0.35	-5.64	-0.3	3.67e-8	P wave terminal force;
CRC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.77	10.39	0.5	4.63e-22	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg09491104	chr22:46646882	C22orf40	-0.49	-7.63	-0.39	2.51e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.56	-0.38	3.98e-13	Type 2 diabetes;
CRC	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg21153622	chr11:89784906	NA	-0.46	-7.33	-0.37	1.85e-12	HDL cholesterol;
CRC	cis	rs12594515	0.600	rs12903858	chr15:45972166	A/G	cg01629716	chr15:45996671	NA	0.34	6.75	0.35	6.68e-11	Waist circumference;Weight;
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	13.74	0.6	3e-34	Alzheimer's disease;
CRC	cis	rs863345	0.604	rs10797011	chr1:158465371	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	9.9e-10	Pneumococcal bacteremia;
CRC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.65	7.52	0.38	5.13e-13	Lymphocyte counts;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg13139730	chr1:161576322	HSPA7	-0.38	-6.17	-0.32	1.99e-9	HDL cholesterol;
CRC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.41	6.41	0.33	5.01e-10	Methadone dose in opioid dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14417830	chr9:137977929	OLFM1	0.41	6.17	0.32	2.02e-9	Response to antipsychotic treatment;
CRC	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.85	0.48	3.1e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.56	7.49	0.38	6.51e-13	Height;
CRC	cis	rs1465370	0.692	rs2402996	chr7:130017003	C/T	cg03229158	chr7:130009420	NA	0.44	6.26	0.33	1.23e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15174977	chr3:52931857	TMEM110	0.4	6.52	0.34	2.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.46	-0.34	3.85e-10	Monocyte count;
CRC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg13628971	chr7:2884303	GNA12	0.41	6.25	0.33	1.28e-9	Height;
CRC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg00316803	chr15:76480434	C15orf27	-0.36	-5.83	-0.31	1.3e-8	Blood metabolite levels;
CRC	cis	rs995000	0.895	rs11208001	chr1:63130431	C/T	cg19896129	chr1:63156450	NA	0.4	6.03	0.32	4.52e-9	Triglyceride levels;
CRC	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg22732515	chr19:44031385	ETHE1	0.69	10.35	0.5	6.57e-22	Fractional exhaled nitric oxide (childhood);
CRC	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg15704280	chr7:45808275	SEPT13	-0.57	-7.12	-0.37	6.66e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg21565078	chr2:241069202	MYEOV2	-0.36	-6.09	-0.32	3.09e-9	HDL cholesterol;
CRC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.6	-8.98	-0.44	2.11e-17	Height;
CRC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.5	6.31	0.33	8.84e-10	Recombination rate (females);
CRC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.23	-13.49	-0.6	2.59e-33	Diabetic kidney disease;
CRC	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.95	-14.96	-0.64	5.93e-39	Gout;
CRC	cis	rs4664293	0.613	rs9784044	chr2:160622365	C/T	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.47	-6.23	-0.32	1.45e-9	Gut microbiome composition (summer);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17938371	chr2:85555240	TGOLN2	0.39	5.96	0.31	6.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.75	12.55	0.57	8.33e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.36	5.63	0.3	3.88e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg16433844	chr14:91963127	SMEK1	-0.56	-5.84	-0.31	1.28e-8	Alzheimer disease and age of onset;
CRC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.11	-0.32	2.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.63	7.72	0.39	1.45e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20149998	chr11:73587608	CHCHD8;PAAF1	0.44	6.35	0.33	7.3e-10	Response to antipsychotic treatment;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09377915	chr6:56295593	NA	-0.44	-6.19	-0.32	1.81e-9	Hip circumference;
CRC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	5.91	0.31	8.62e-9	Diabetic retinopathy;
CRC	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg13491945	chr12:107078410	RFX4	0.37	6.29	0.33	9.86e-10	Heart rate;
CRC	cis	rs12024301	0.557	rs12041570	chr1:183612890	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.11	-0.64	1.5e-39	Gut microbiome composition (summer);
CRC	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg15382696	chr6:118971807	C6orf204	0.57	7.49	0.38	6.32e-13	Diastolic blood pressure;
CRC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.14	0.32	2.41e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.51	7.67	0.39	2.02e-13	Height;
CRC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.18	-0.37	4.75e-12	Life satisfaction;
CRC	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.55	8.22	0.41	4.68e-15	HDL cholesterol;
CRC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg17724175	chr1:150552817	MCL1	-0.4	-6.15	-0.32	2.26e-9	Melanoma;
CRC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg23920097	chr1:209922102	NA	-0.52	-6.59	-0.34	1.72e-10	Red blood cell count;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg22079747	chr2:228736145	WDR69	-0.42	-5.76	-0.3	1.9e-8	Blood pressure;
CRC	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.73	14.1	0.61	1.22e-35	Mean corpuscular hemoglobin;
CRC	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg04733911	chr16:78082701	NA	0.43	6.86	0.35	3.46e-11	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.49	6.55	0.34	2.17e-10	Coronary artery disease;
CRC	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg01851573	chr8:8652454	MFHAS1	0.54	6.75	0.35	6.71e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01745510	chr12:12870119	CDKN1B	0.45	6.2	0.32	1.74e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg19773385	chr1:10388646	KIF1B	-0.49	-7.71	-0.39	1.54e-13	Hepatocellular carcinoma;
CRC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.14	-0.56	2.73e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.52	-0.34	2.66e-10	Colorectal cancer;
CRC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.71	10.97	0.52	4.39e-24	Tonsillectomy;
CRC	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg26875233	chr11:93583750	C11orf90	-0.33	-6.5	-0.34	2.96e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18934136	chr17:55927456	MRPS23	0.38	5.97	0.31	6.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg02033258	chr5:131593261	PDLIM4	0.35	6.61	0.34	1.54e-10	Blood metabolite levels;
CRC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	8.16	0.41	6.95e-15	Cognitive test performance;
CRC	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.76	12.31	0.56	6.57e-29	Height;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.71	11.07	0.52	2.09e-24	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.58	8.39	0.42	1.42e-15	Parkinson's disease;
CRC	cis	rs7605827	0.930	rs13029846	chr2:15674686	T/C	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.62e-8	Educational attainment (years of education);
CRC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19346786	chr7:2764209	NA	-0.34	-5.7	-0.3	2.61e-8	Height;
CRC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.73	-9.2	-0.45	4.31e-18	Body mass index;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg19678392	chr7:94953810	PON1	-0.59	-7.3	-0.37	2.22e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg10298567	chr3:47292165	KIF9	0.4	6.28	0.33	1.08e-9	Colorectal cancer;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.39	-0.33	5.62e-10	Total body bone mineral density;
CRC	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.42	5.63	0.3	3.78e-8	IgE levels in asthmatics (D.p. specific);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06624832	chr17:72772340	TMEM104;NAT9	0.47	6.64	0.34	1.29e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.59	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-9.22	-0.45	3.64e-18	Initial pursuit acceleration;
CRC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg25456477	chr12:86230367	RASSF9	-0.39	-6.54	-0.34	2.36e-10	Major depressive disorder;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg12273811	chr6:28175739	NA	0.46	6.94	0.36	2.04e-11	Cardiac Troponin-T levels;
CRC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.84	10.25	0.49	1.42e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.89	15.79	0.66	3.4e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.76e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-14.35	-0.62	1.39e-36	Blood metabolite levels;
CRC	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.75	10.37	0.5	5.35e-22	Systemic lupus erythematosus;
CRC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.53	-8.45	-0.42	9.32e-16	Aortic root size;
CRC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-9.58	-0.47	2.52e-19	Body mass index;
CRC	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.81	-14.48	-0.62	4.19e-37	Lewy body disease;
CRC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.38	6.93	0.36	2.2e-11	Obesity-related traits;
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg06470822	chr6:28175283	NA	0.76	8.05	0.41	1.49e-14	Depression;
CRC	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg16558208	chr1:156270281	VHLL	0.58	9.04	0.45	1.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs3789045	0.866	rs11584700	chr1:204576983	C/T	cg17419461	chr1:204415978	PIK3C2B	0.53	7.59	0.39	3.29e-13	Educational attainment (college completion);
CRC	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.69	-8.59	-0.43	3.43e-16	Multiple sclerosis;
CRC	cis	rs2242663	0.705	rs551708	chr11:66486143	T/C	cg24851651	chr11:66362959	CCS	-0.44	-7.38	-0.38	1.31e-12	Bipolar disorder;
CRC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg09876464	chr15:85330779	ZNF592	-0.38	-6.27	-0.33	1.14e-9	P wave terminal force;
CRC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.89	10.49	0.5	2.13e-22	Psoriasis;
CRC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg03959625	chr15:84868606	LOC388152	0.4	5.78	0.3	1.74e-8	Schizophrenia;
CRC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg26116260	chr4:7069785	GRPEL1	-0.69	-5.93	-0.31	7.61e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9398803	0.835	rs9321065	chr6:126744087	G/A	cg19875578	chr6:126661172	C6orf173	0.42	5.94	0.31	7.42e-9	Male-pattern baldness;
CRC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.58	9.01	0.44	1.78e-17	Breast cancer;
CRC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.47	-0.46	5.59e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg16558177	chr4:4109446	NA	-0.62	-8.74	-0.43	1.23e-16	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg03623178	chr6:28175578	NA	0.78	6.8	0.35	4.91e-11	Depression;
CRC	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.4	8.61	0.43	3.14e-16	Alcohol dependence;
CRC	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.44	-0.46	7.3e-19	Migraine;Coronary artery disease;
CRC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.42	8.19	0.41	5.86e-15	Mean corpuscular volume;
CRC	trans	rs11673344	0.528	rs579452	chr19:37410838	C/T	cg18947437	chr10:1231002	ADARB2	-0.36	-6.39	-0.33	5.73e-10	Obesity-related traits;
CRC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.41	6.29	0.33	1.01e-9	High light scatter reticulocyte count;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg10876282	chr6:28092338	ZSCAN16	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
CRC	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03037974	chr15:76606532	NA	-0.51	-8.31	-0.42	2.59e-15	Blood metabolite levels;
CRC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.69	9.12	0.45	7.92e-18	High light scatter reticulocyte count;
CRC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.5	7.53	0.38	5e-13	Emphysema distribution in smoking;
CRC	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg00277334	chr10:82204260	NA	0.37	5.93	0.31	7.57e-9	Sarcoidosis;
CRC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.06	9.97	0.48	1.21e-20	Opioid sensitivity;
CRC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.62	-0.34	1.44e-10	Alzheimer's disease (late onset);
CRC	cis	rs28829049	0.597	rs72651403	chr1:19519887	G/C	cg13387374	chr1:19411106	UBR4	0.41	5.96	0.31	6.53e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.54	0.34	2.31e-10	Schizophrenia;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg15845792	chr6:28175446	NA	0.95	13.88	0.61	8.57e-35	Depression;
CRC	cis	rs10450586	0.899	rs11029916	chr11:27311695	T/C	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.62	9.64	0.47	1.58e-19	Mood instability;
CRC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.79	-11.37	-0.53	1.68e-25	Blood trace element (Zn levels);
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg20399509	chr21:47717575	C21orf57	-0.38	-6.38	-0.33	5.93e-10	Testicular germ cell tumor;
CRC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg18867708	chr6:26865862	GUSBL1	0.37	5.75	0.3	2.09e-8	Schizophrenia;
CRC	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.8	-13.52	-0.6	1.95e-33	Hip circumference;
CRC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.49	-8.17	-0.41	6.49e-15	Neuroticism;
CRC	cis	rs9494145	0.680	rs4895441	chr6:135426573	C/T	cg22676075	chr6:135203613	NA	-0.55	-7.0	-0.36	1.46e-11	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.83	15.37	0.65	1.41e-40	Hip circumference;
CRC	cis	rs62458065	0.850	rs62458066	chr7:32464484	C/T	cg20159608	chr7:32802032	NA	-0.54	-6.51	-0.34	2.8e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg16476235	chr8:21771668	DOK2	-0.37	-6.11	-0.32	2.87e-9	Mean corpuscular volume;
CRC	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.13	0.37	6.31e-12	Blood metabolite levels;
CRC	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.7	-9.76	-0.47	6.09e-20	Waist circumference;Body mass index;
CRC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	10.79	0.51	1.93e-23	Nonalcoholic fatty liver disease;
CRC	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.77	-0.35	5.97e-11	Inflammatory skin disease;
CRC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg03233332	chr7:66118400	NA	0.45	6.21	0.32	1.64e-9	Aortic root size;
CRC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.78	-10.48	-0.5	2.37e-22	IgG glycosylation;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.59	10.84	0.51	1.3e-23	Educational attainment;
CRC	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	1.06	14.74	0.63	4.07e-38	Exhaled nitric oxide output;
CRC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.7	-10.42	-0.5	3.8e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02132458	chr4:57333267	SRP72	0.5	6.38	0.33	5.88e-10	Thyroid stimulating hormone;
CRC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.43	8.56	0.43	4.25e-16	Vitiligo;
CRC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.18	-17.22	-0.69	7.98e-48	Hip circumference adjusted for BMI;
CRC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.58	6.62	0.34	1.48e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.67	9.37	0.46	1.21e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6681460	0.576	rs7355221	chr1:66986301	G/C	cg02459107	chr1:67143332	SGIP1	0.38	5.87	0.31	1.09e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg20194872	chr6:41519635	FOXP4	0.4	5.86	0.31	1.14e-8	Prostate cancer;
CRC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	trans	rs6472235	0.837	rs28605672	chr8:66929194	A/G	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg25164649	chr6:28176230	NA	0.71	9.0	0.44	1.9e-17	Parkinson's disease;
CRC	cis	rs10242455	0.571	rs73713595	chr7:99326659	G/A	cg18809830	chr7:99032528	PTCD1	-0.96	-7.11	-0.36	7.45e-12	Blood metabolite levels;
CRC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg14008862	chr17:28927542	LRRC37B2	0.5	6.1	0.32	3.05e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg05527609	chr1:210001259	C1orf107	0.42	5.79	0.3	1.68e-8	Orofacial clefts;
CRC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.58	0.39	3.51e-13	Mean corpuscular volume;
CRC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.61e-9	Arsenic metabolism;
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg22561889	chr6:118971681	C6orf204	0.53	6.87	0.35	3.16e-11	Diastolic blood pressure;
CRC	cis	rs2457480	0.778	rs1704217	chr10:44729307	T/C	cg09554077	chr10:44749378	NA	0.65	7.32	0.37	1.9e-12	Coronary artery disease;
CRC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.67	11.09	0.52	1.7e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg03623178	chr6:28175578	NA	0.73	6.88	0.35	3.12e-11	Depression;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg18758796	chr5:131593413	PDLIM4	0.39	6.32	0.33	8.39e-10	Breast cancer;
CRC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.6	9.18	0.45	4.8e-18	Mean platelet volume;
CRC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.35	5.61	0.3	4.38e-8	Reticulocyte count;
CRC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg00343986	chr7:65444356	GUSB	-0.46	-6.49	-0.34	3.14e-10	Aortic root size;
CRC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.14	-0.32	2.35e-9	Diabetic kidney disease;
CRC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.43	6.32	0.33	8.56e-10	Diastolic blood pressure;
CRC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.61	8.77	0.44	9.49e-17	Response to temozolomide;
CRC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.57	9.32	0.46	1.68e-18	Gestational age at birth (maternal effect);
CRC	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.54	6.68	0.35	1.04e-10	Mammographic density (dense area);
CRC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.71	10.55	0.5	1.32e-22	Body mass index;
CRC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg18827107	chr12:86230957	RASSF9	-0.37	-5.73	-0.3	2.23e-8	Major depressive disorder;
CRC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg18099408	chr3:52552593	STAB1	0.35	5.85	0.31	1.17e-8	Electroencephalogram traits;
CRC	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.77	-0.35	5.85e-11	Inflammatory skin disease;
CRC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg03623178	chr6:28175578	NA	0.78	6.64	0.34	1.27e-10	Breast cancer;
CRC	cis	rs2795502	0.506	rs11819501	chr10:43465544	C/T	cg20628663	chr10:43360327	NA	0.6	7.25	0.37	2.95e-12	Blood protein levels;
CRC	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg09218773	chr11:619014	MUPCDH	-0.4	-5.8	-0.3	1.53e-8	Systemic lupus erythematosus;
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg06494592	chr3:125709126	NA	-0.52	-6.86	-0.35	3.36e-11	Blood pressure (smoking interaction);
CRC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.1	0.32	3e-9	Rheumatoid arthritis;
CRC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg06470822	chr6:28175283	NA	0.54	8.0	0.4	2.1e-14	Pubertal anthropometrics;
CRC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg03959625	chr15:84868606	LOC388152	0.42	6.33	0.33	8.21e-10	Schizophrenia;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.53	-9.39	-0.46	1.06e-18	Cognitive function;
CRC	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.4	6.13	0.32	2.47e-9	Endometrial cancer;
CRC	cis	rs6460942	0.908	rs6978367	chr7:12232347	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.05	-0.32	4.03e-9	Coronary artery disease;
CRC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.16	-0.32	2.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.58	0.34	1.85e-10	Blood protein levels;
CRC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.28	0.37	2.51e-12	Mean platelet volume;
CRC	cis	rs7605827	0.930	rs10929376	chr2:15692856	A/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs911119	0.955	rs61035931	chr20:23595714	A/G	cg16589663	chr20:23618590	CST3	0.44	6.16	0.32	2.12e-9	Chronic kidney disease;
CRC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.28	0.53	3.77e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.62	9.39	0.46	1.02e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	10.23	0.49	1.71e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-1.02	-19.9	-0.74	2.09e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07364046	chr12:93861583	MRPL42	0.45	6.78	0.35	5.55e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg27534772	chr1:16042836	PLEKHM2	0.51	9.3	0.46	1.96e-18	Systolic blood pressure;
CRC	cis	rs12024301	0.557	rs12036825	chr1:183594432	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.93	16.41	0.67	1.29e-44	Obesity (extreme);
CRC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.4	6.2	0.32	1.68e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.79	14.94	0.64	6.66e-39	Prudent dietary pattern;
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.56	-7.22	-0.37	3.52e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.32	0.33	8.49e-10	LDL cholesterol;
CRC	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.09	0.36	7.99e-12	Diisocyanate-induced asthma;
CRC	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg18827107	chr12:86230957	RASSF9	0.36	5.61	0.3	4.25e-8	Major depressive disorder;
CRC	cis	rs1223397	0.651	rs453877	chr6:13297463	G/T	cg20827128	chr6:13274284	PHACTR1	0.37	5.61	0.3	4.39e-8	Blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14511745	chr11:47573874	CUGBP1	0.47	6.68	0.35	9.92e-11	Response to antipsychotic treatment;
CRC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.77	-0.44	1.01e-16	IgG glycosylation;
CRC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.43	5.69	0.3	2.82e-8	IgG glycosylation;
CRC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.91	-0.44	3.55e-17	Electroencephalogram traits;
CRC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg18230493	chr5:56204884	C5orf35	0.42	6.31	0.33	8.96e-10	Coronary artery disease;
CRC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.75	0.47	6.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	0.93	18.06	0.71	3.89e-51	Height;
CRC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg22815214	chr1:201083145	CACNA1S	0.51	6.39	0.33	5.64e-10	Permanent tooth development;
CRC	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.77	-8.37	-0.42	1.63e-15	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09003876	chr18:33552519	C18orf21	0.41	6.04	0.32	4.27e-9	Response to antipsychotic treatment;
CRC	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.13	0.32	2.46e-9	Ovarian reserve;
CRC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg21665744	chr7:39171113	POU6F2	0.45	5.89	0.31	9.32e-9	IgG glycosylation;
CRC	cis	rs7605827	0.930	rs6431695	chr2:15539816	T/C	cg19274914	chr2:15703543	NA	0.4	5.97	0.31	6.2e-9	Educational attainment (years of education);
CRC	cis	rs6554196	0.895	rs7665611	chr4:55518878	C/A	cg18836493	chr4:55524333	KIT	-0.34	-5.65	-0.3	3.56e-8	Monocyte count;
CRC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-7.23	-0.37	3.38e-12	Aortic root size;
CRC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.71	-8.61	-0.43	3.04e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-7.96	-0.4	2.79e-14	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17915139	chr4:74904765	CXCL3	0.43	6.09	0.32	3.22e-9	Response to antipsychotic treatment;
CRC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg25767906	chr1:53392781	SCP2	-0.38	-5.86	-0.31	1.13e-8	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14511273	chr3:128746334	CCDC48	0.43	6.75	0.35	6.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg00647820	chr17:40259828	DHX58	-0.46	-6.49	-0.34	3.15e-10	Fibrinogen levels;
CRC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.41	6.84	0.35	3.96e-11	Childhood ear infection;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.38	5.82	0.31	1.39e-8	Obesity-related traits;
CRC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.02	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs4731207	0.596	rs6945951	chr7:124667200	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.73e-9	Cutaneous malignant melanoma;
CRC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg06219103	chr11:63990595	FERMT3	-0.38	-5.73	-0.3	2.29e-8	Platelet count;
CRC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg17724175	chr1:150552817	MCL1	0.46	6.86	0.35	3.43e-11	Melanoma;
CRC	cis	rs883565	0.543	rs784488	chr3:39173135	C/G	cg01426195	chr3:39028469	NA	0.42	7.0	0.36	1.48e-11	Handedness;
CRC	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.42	6.7	0.35	8.91e-11	Pancreatic cancer;
CRC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.62	10.43	0.5	3.41e-22	Resting heart rate;
CRC	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.73	-9.89	-0.48	2.3e-20	Blood metabolite levels;
CRC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.61	-9.85	-0.48	3.17e-20	P wave terminal force;
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg09032863	chr1:44412568	IPO13	-0.45	-6.03	-0.32	4.36e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg22532475	chr10:104410764	TRIM8	0.33	5.71	0.3	2.53e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.05	-13.43	-0.6	4.21e-33	Vitiligo;
CRC	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.76	-0.3	1.97e-8	Morning vs. evening chronotype;
CRC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.83	0.35	4.22e-11	Rheumatoid arthritis;
CRC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.65	10.31	0.49	8.72e-22	Blood metabolite levels;
CRC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.48	-0.34	3.32e-10	Mean corpuscular volume;
CRC	cis	rs11212617	0.870	rs227078	chr11:108250381	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.64	0.34	1.27e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.7	0.6	4.05e-34	Prudent dietary pattern;
CRC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	14.99	0.64	4.43e-39	Chronic sinus infection;
CRC	trans	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg18187862	chr3:45730750	SACM1L	0.46	6.74	0.35	7.28e-11	Primary sclerosing cholangitis;
CRC	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.58	-8.49	-0.42	7.15e-16	Autism;
CRC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.61	9.12	0.45	7.57e-18	Methadone dose in opioid dependence;
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18099408	chr3:52552593	STAB1	0.45	7.57	0.38	3.89e-13	Bipolar disorder;
CRC	cis	rs4908768	0.539	rs6670508	chr1:8647917	G/C	cg20416874	chr1:8611966	RERE	-0.41	-5.65	-0.3	3.44e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23646337	chr19:42817556	TMEM145	0.41	6.86	0.35	3.46e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.51	7.82	0.4	7.07e-14	Body mass index;
CRC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg03013999	chr17:37608204	MED1	0.48	7.5	0.38	5.93e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs2227564	0.620	rs11000787	chr10:75584383	T/C	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.86	-0.4	5.42e-14	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs6956675	0.915	rs7780762	chr7:62654263	T/C	cg01314568	chr7:57830625	NA	-0.62	-8.88	-0.44	4.41e-17	Obesity-related traits;
CRC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.46	7.43	0.38	9.38e-13	Lung cancer;
CRC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg18709589	chr6:96969512	KIAA0776	0.49	5.66	0.3	3.3e-8	Migraine;Coronary artery disease;
CRC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.1	-0.56	3.88e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.46	-6.87	-0.35	3.28e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.94	-0.4	3.18e-14	Bipolar disorder;
CRC	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg15845792	chr6:28175446	NA	0.72	6.15	0.32	2.24e-9	Breast cancer;
CRC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.84	-15.47	-0.65	6.1e-41	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.74	9.13	0.45	7.35e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.39	-0.56	3.32e-29	Type 2 diabetes;
CRC	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.58	9.15	0.45	6e-18	Bone mineral density;
CRC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.49	7.64	0.39	2.37e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.82	15.09	0.64	1.86e-39	Anterior chamber depth;
CRC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.58	9.14	0.45	6.67e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-7.75	-0.39	1.16e-13	Menarche (age at onset);
CRC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.42e-10	Mean platelet volume;
CRC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg13385521	chr17:29058706	SUZ12P	0.55	7.36	0.38	1.53e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.62	7.39	0.38	1.26e-12	Lymphocyte counts;
CRC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	27.34	0.83	1.06e-86	Testicular germ cell tumor;
CRC	cis	rs35883536	1.000	rs1855798	chr1:101114191	T/C	cg14515779	chr1:101123966	NA	-0.41	-7.87	-0.4	5.11e-14	Monocyte count;
CRC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.86	-11.71	-0.54	1.02e-26	Asthma;
CRC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.66	0.68	1.34e-45	Platelet count;
CRC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17554472	chr22:41940697	POLR3H	0.56	5.74	0.3	2.21e-8	Vitiligo;
CRC	cis	rs7705042	0.865	rs6863411	chr5:141513204	A/T	cg07392085	chr5:141489673	NDFIP1	0.44	7.12	0.37	6.83e-12	Asthma;
CRC	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg06606381	chr12:133084897	FBRSL1	-1.11	-7.58	-0.39	3.5e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9311676	0.656	rs11130638	chr3:58405947	A/G	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.42	6.43	0.33	4.55e-10	Methadone dose in opioid dependence;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg27615366	chr5:131592974	PDLIM4	0.35	6.19	0.32	1.81e-9	Acylcarnitine levels;
CRC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg27205649	chr11:78285834	NARS2	0.51	6.52	0.34	2.65e-10	Alzheimer's disease (survival time);
CRC	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-10.76	-0.51	2.38e-23	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.65	-10.0	-0.48	9.64e-21	Height;
CRC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.56	-8.16	-0.41	7.26e-15	Prudent dietary pattern;
CRC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.74	10.54	0.5	1.46e-22	High light scatter reticulocyte count;
CRC	trans	rs7142881	0.604	rs12887004	chr14:32286490	C/T	cg07250515	chr12:56618133	OBFC2B	-0.39	-5.98	-0.31	5.67e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.75	9.66	0.47	1.37e-19	Monocyte percentage of white cells;
CRC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.92	-0.36	2.43e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.1	-17.5	-0.69	5.96e-49	Blood pressure (smoking interaction);
CRC	cis	rs10760158	0.832	rs10513365	chr9:124020925	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.68	-0.3	2.96e-8	Pulse pressure;
CRC	trans	rs17641971	0.899	rs341804	chr8:49991553	G/C	cg18784943	chr17:79371681	NA	0.41	6.18	0.32	1.87e-9	Blood metabolite levels;
CRC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.94	14.24	0.62	3.57e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4780401	0.967	rs11075012	chr16:11831030	T/C	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.75	-0.3	2.05e-8	Rheumatoid arthritis;
CRC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.63	12.05	0.55	5.97e-28	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.22	0.32	1.48e-9	Hemoglobin concentration;
CRC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.55	7.74	0.39	1.22e-13	Melanoma;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.22	0.37	3.66e-12	Lymphocyte counts;
CRC	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	5.65	0.3	3.44e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-7.71	-0.39	1.49e-13	Menopause (age at onset);
CRC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.4	-0.5	4.29e-22	Total cholesterol levels;
CRC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.71	11.07	0.52	1.97e-24	Coronary artery disease;
CRC	cis	rs1555895	0.680	rs11253448	chr10:841115	T/C	cg10556349	chr10:835070	NA	-0.37	-6.97	-0.36	1.75e-11	Survival in rectal cancer;
CRC	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg19025524	chr12:109796872	NA	-0.45	-5.96	-0.31	6.61e-9	Neuroticism;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.29	-0.33	1.02e-9	Cognitive function;
CRC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.79	13.19	0.59	3.55e-32	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12638871	chr3:127842906	RUVBL1	0.44	6.56	0.34	2.11e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.06	0.41	1.45e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.94	0.36	2.13e-11	Platelet count;
CRC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg12046867	chr14:103022105	NA	0.76	8.98	0.44	2.2e-17	Platelet count;
CRC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg21466736	chr12:48725269	NA	0.48	7.34	0.38	1.64e-12	Glycated hemoglobin levels;
CRC	trans	rs887912	0.722	rs980183	chr2:59311536	A/G	cg11150664	chr10:94351507	KIF11	-0.5	-6.07	-0.32	3.62e-9	Hip circumference;Body mass index;Obesity;
CRC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.56	-6.95	-0.36	1.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10128264	0.902	rs942797	chr10:80986432	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.42	-7.24	-0.37	3.27e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs6743376	0.642	rs4145014	chr2:113831185	A/G	cg12858261	chr2:113808755	IL1F8	0.47	5.84	0.31	1.22e-8	Inflammatory biomarkers;
CRC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg26248373	chr2:1572462	NA	-0.83	-12.38	-0.56	3.62e-29	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.62	7.06	0.36	9.92e-12	Resting heart rate;
CRC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg13777783	chr17:79615861	NA	-0.3	-5.61	-0.3	4.26e-8	Eye color traits;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg07217954	chr7:1067459	C7orf50	0.55	5.61	0.3	4.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28493229	0.708	rs10408310	chr19:41161190	T/C	cg21869046	chr19:41225005	ITPKC	0.41	6.15	0.32	2.26e-9	Kawasaki disease;
CRC	trans	rs6472235	0.837	rs11995702	chr8:66926423	A/G	cg07884673	chr3:53033167	SFMBT1	-0.46	-6.25	-0.33	1.27e-9	Myopia (pathological);Plateletcrit;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05046026	chr11:61559981	C11orf10;FEN1;MIR611	0.39	6.45	0.34	3.95e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.28	-0.33	1.07e-9	Longevity;Endometriosis;
CRC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg03013999	chr17:37608204	MED1	-0.48	-7.44	-0.38	8.74e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg19041857	chr6:27730383	NA	-0.43	-6.24	-0.33	1.33e-9	Parkinson's disease;
CRC	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.7	-0.39	1.63e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2895526	0.540	rs12412190	chr10:12714721	A/G	cg00115178	chr10:12648176	CAMK1D	-0.39	-6.27	-0.33	1.16e-9	Headache;
CRC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	1.07	10.52	0.5	1.69e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg20512303	chr5:131592959	PDLIM4	-0.37	-6.29	-0.33	1.02e-9	Breast cancer;
CRC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.54	-8.33	-0.42	2.16e-15	Uric acid levels;
CRC	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.26	11.71	0.54	1.03e-26	Prostate cancer;
CRC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.11	0.41	9.97e-15	Parkinson's disease;
CRC	trans	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.83	0.4	6.82e-14	Diabetic kidney disease;
CRC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.04	0.55	6.41e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-9.83	-0.48	3.74e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.68	9.86	0.48	2.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.0	0.44	1.88e-17	Bladder cancer;
CRC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg01304814	chr3:48885189	PRKAR2A	0.82	6.18	0.32	1.94e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.82	-12.56	-0.57	7.9e-30	IgG glycosylation;
CRC	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	5.72	0.3	2.4e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6838801	0.857	rs903044	chr4:77578750	A/G	cg17476223	chr4:77663285	SHROOM3	0.42	5.67	0.3	3.14e-8	Cleft lip with or without cleft palate;
CRC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.91	-11.53	-0.54	4.78e-26	Bronchopulmonary dysplasia;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg06009330	chr2:70485380	PCYOX1	-0.42	-6.34	-0.33	7.76e-10	Birth weight;Height;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg12172441	chr6:28176163	NA	0.56	7.24	0.37	3.11e-12	Parkinson's disease;
CRC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.83	0.55	3.79e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg02683197	chr6:28174875	NA	0.66	8.59	0.43	3.46e-16	Parkinson's disease;
CRC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.2	0.45	4.38e-18	Hip circumference adjusted for BMI;
CRC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg05941027	chr17:61774174	LIMD2	0.37	6.56	0.34	2.11e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.34	5.71	0.3	2.54e-8	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27284088	chr4:84031130	PLAC8	0.47	6.23	0.32	1.4e-9	Thyroid stimulating hormone;
CRC	cis	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg12046867	chr14:103022105	NA	-0.73	-8.78	-0.44	9.15e-17	Platelet count;
CRC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	5.91	0.31	8.4e-9	Alzheimer's disease (late onset);
CRC	cis	rs3849570	0.533	rs6809793	chr3:81990089	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-6.4	-0.33	5.35e-10	Waist circumference;Body mass index;
CRC	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.2	0.32	1.68e-9	Morning vs. evening chronotype;
CRC	cis	rs863345	0.604	rs4313395	chr1:158505135	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.51	-6.51	-0.34	2.82e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.18	-0.41	6.23e-15	Hemoglobin concentration;
CRC	cis	rs9311676	0.656	rs6775710	chr3:58336201	A/G	cg06643156	chr3:58380774	PXK	-0.44	-6.66	-0.34	1.15e-10	Systemic lupus erythematosus;
CRC	cis	rs10484885	0.818	rs117562849	chr6:90249804	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.98	-0.36	1.62e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.54	-8.98	-0.44	2.2e-17	Prudent dietary pattern;
CRC	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.83	-13.72	-0.6	3.57e-34	Hypospadias;
CRC	cis	rs7605827	0.930	rs6716384	chr2:15608210	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg12172441	chr6:28176163	NA	0.54	7.07	0.36	9.53e-12	Parkinson's disease;
CRC	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg14979609	chr8:8086686	FLJ10661	0.37	6.05	0.32	4.03e-9	Neuroticism;
CRC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.48	6.67	0.34	1.12e-10	Tonsillectomy;
CRC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg01483505	chr11:975446	AP2A2	0.42	6.88	0.35	3.01e-11	Alzheimer's disease (late onset);
CRC	cis	rs9976767	0.792	rs883869	chr21:43844840	T/C	cg23042151	chr21:43824109	UBASH3A	-0.36	-6.33	-0.33	7.88e-10	Type 1 diabetes;
CRC	cis	rs7901135	1.000	rs7902062	chr10:60586473	C/T	cg23799393	chr10:60588674	BICC1	0.36	5.66	0.3	3.33e-8	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.47	5.77	0.3	1.81e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg18490616	chr2:88469792	THNSL2	0.58	5.84	0.31	1.28e-8	Plasma clusterin levels;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.79	11.82	0.55	4.23e-27	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.65	-9.97	-0.48	1.23e-20	Corneal astigmatism;
CRC	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.53	9.1	0.45	9.11e-18	Migraine;
CRC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg15147215	chr3:52552868	STAB1	0.45	7.5	0.38	6.06e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.7	6.61	0.34	1.59e-10	Diabetic kidney disease;
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg24046110	chr8:143859143	LYNX1	-0.43	-6.91	-0.36	2.48e-11	Urinary tract infection frequency;
CRC	cis	rs12523822	0.957	rs1402572	chr6:154965837	A/G	cg20019720	chr6:154832845	CNKSR3	0.27	5.77	0.3	1.85e-8	Diabetic kidney disease;
CRC	cis	rs9491140	0.539	rs12529386	chr6:124678200	A/G	cg05308643	chr6:124982296	NKAIN2	0.49	6.91	0.36	2.54e-11	Neuroticism;
CRC	cis	rs7692995	1.000	rs7671110	chr4:17874089	C/T	cg08925142	chr4:18023851	LCORL	-0.53	-5.85	-0.31	1.16e-8	Height;
CRC	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.7	-10.84	-0.51	1.34e-23	Type 2 diabetes;
CRC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.27	5.77	0.3	1.8e-8	Homoarginine levels;
CRC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.99	0.4	2.27e-14	Height;
CRC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.45	-8.77	-0.44	9.88e-17	Prostate cancer;
CRC	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg02158880	chr13:53174818	NA	-0.44	-6.41	-0.33	5.12e-10	Lewy body disease;
CRC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg23590916	chr17:43697445	MGC57346	0.59	6.2	0.32	1.73e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	trans	rs11661542	0.967	rs11082043	chr18:20222985	C/G	cg21945992	chr3:48956913	ARIH2;C3orf71	-0.44	-6.45	-0.34	4.11e-10	Intracranial aneurysm;
CRC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.42	-6.17	-0.32	1.98e-9	Intelligence (multi-trait analysis);
CRC	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-10.73	-0.51	3.09e-23	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7538876	1.000	rs2526829	chr1:17728231	A/G	cg07965774	chr1:17746286	RCC2	0.3	5.74	0.3	2.14e-8	Basal cell carcinoma;
CRC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.01	0.31	4.94e-9	Tonsillectomy;
CRC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.4	5.75	0.3	1.99e-8	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg07195197	chr16:1662150	IFT140	-0.71	-6.29	-0.33	9.86e-10	Cognitive function;
CRC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	9.4	0.46	9.31e-19	Schizophrenia;
CRC	trans	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.55	-0.38	4.4e-13	Endometrial cancer;
CRC	cis	rs17234274	0.644	rs10833972	chr11:23219904	C/A	cg05245346	chr11:23248277	NA	0.35	5.75	0.3	2.03e-8	Cancer;
CRC	cis	rs7712401	0.791	rs10063253	chr5:122128711	T/C	cg18764291	chr5:122110994	SNX2	0.41	6.63	0.34	1.37e-10	Mean platelet volume;
CRC	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.61	8.67	0.43	2e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6662572	1.000	rs56251392	chr1:46210829	C/T	cg08644498	chr1:46502608	NA	0.45	6.31	0.33	8.91e-10	Blood protein levels;
CRC	cis	rs370915	1.000	rs370915	chr4:187818256	C/G	cg19519643	chr4:187840862	NA	-0.44	-6.62	-0.34	1.42e-10	Gout;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg24046110	chr8:143859143	LYNX1	-0.43	-6.91	-0.36	2.48e-11	Urinary tract infection frequency;
CRC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.94	15.63	0.65	1.48e-41	Menarche (age at onset);
CRC	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg07299736	chr8:135490787	ZFAT	-0.38	-6.42	-0.33	4.65e-10	Hypertension (SNP x SNP interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05370860	chr19:10514434	MIR1181;CDC37	0.45	6.11	0.32	2.87e-9	Anxiety disorder;
CRC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	8.59	0.43	3.52e-16	Colorectal cancer;
CRC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg18016565	chr1:150552671	MCL1	0.45	6.28	0.33	1.06e-9	Melanoma;
CRC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.82	12.67	0.57	3.15e-30	Cognitive function;
CRC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.44	-0.46	7.26e-19	Height;
CRC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.71	0.54	1e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.91	-0.4	3.85e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg03623178	chr6:28175578	NA	0.86	13.64	0.6	7.14e-34	Cardiac Troponin-T levels;
CRC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg10589385	chr1:150898437	SETDB1	0.3	6.24	0.33	1.34e-9	Tonsillectomy;
CRC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.69	0.51	4.32e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07701084	chr6:150067640	NUP43	0.54	7.65	0.39	2.24e-13	Testicular germ cell tumor;
CRC	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.65	10.42	0.5	3.58e-22	Corneal astigmatism;
CRC	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	1.06	11.6	0.54	2.58e-26	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.4	-6.74	-0.35	7.29e-11	Blood metabolite levels;
CRC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg25985355	chr7:65971099	NA	-0.51	-5.8	-0.3	1.54e-8	Gout;
CRC	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.59	-6.2	-0.32	1.69e-9	Coronary artery disease;
CRC	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.88	0.44	4.51e-17	Fuchs's corneal dystrophy;
CRC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	8.54	0.43	5.13e-16	Cognitive test performance;
CRC	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.74	9.49	0.46	5.01e-19	Iron status biomarkers;
CRC	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.54	7.6	0.39	3.13e-13	Corneal astigmatism;
CRC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	5.71	0.3	2.49e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs73200209	0.744	rs61939700	chr12:116570921	T/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.35	-0.33	7.32e-10	Total body bone mineral density;
CRC	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.32	-0.37	1.92e-12	Type 2 diabetes;
CRC	cis	rs447	0.806	rs2527037	chr7:83716429	C/T	cg22846510	chr7:83753280	SEMA3A	-0.54	-6.59	-0.34	1.76e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.77	8.61	0.43	3.16e-16	Neuroticism;
CRC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-1.08	-12.8	-0.58	1.02e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg11707556	chr5:10655725	ANKRD33B	0.35	6.41	0.33	5.17e-10	Coronary artery disease;
CRC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.23e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	5.97e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6496667	0.865	rs7163130	chr15:90883937	C/G	cg04176472	chr15:90893244	GABARAPL3	0.56	6.49	0.34	3.13e-10	Rheumatoid arthritis;
CRC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.63	15.69	0.65	8.52e-42	Alcohol dependence;
CRC	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.51	6.78	0.35	5.59e-11	Coronary artery disease;
CRC	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.55	8.19	0.41	6.03e-15	Multiple sclerosis;
CRC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.56	7.55	0.38	4.32e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.8	-8.59	-0.43	3.55e-16	Coronary artery disease;
CRC	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.71	-10.11	-0.49	4.23e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.88	11.31	0.53	2.93e-25	Iron status biomarkers;
CRC	cis	rs728616	0.558	rs2880599	chr10:82164435	A/G	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.97	-0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.17	0.41	6.94e-15	Menopause (age at onset);
CRC	cis	rs7630877	0.719	rs73057366	chr3:179672470	C/G	cg18765712	chr3:179670323	PEX5L	0.5	7.18	0.37	4.82e-12	Type 2 diabetes;
CRC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.44	-9.91	-0.48	1.93e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	1.0	9.03	0.45	1.47e-17	Pulse pressure;
CRC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.72	-8.17	-0.41	6.5e-15	Lung disease severity in cystic fibrosis;
CRC	trans	rs12699921	0.632	rs2723572	chr7:17888587	T/C	cg02066331	chr6:17282778	RBM24	-0.35	-6.12	-0.32	2.65e-9	Fibrinogen levels;
CRC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.37	5.71	0.3	2.47e-8	Height;
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.36	-7.33	-0.37	1.77e-12	Electroencephalogram traits;
CRC	cis	rs6854137	0.967	rs10033898	chr4:169734457	A/G	cg20607169	chr4:169750834	PALLD	-0.44	-7.02	-0.36	1.28e-11	Vein graft stenosis in coronary artery bypass grafting;
CRC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.14	-0.45	6.63e-18	Birth weight;
CRC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.35	-7.25	-0.37	2.95e-12	Schizophrenia;
CRC	cis	rs365302	1.000	rs509648	chr6:159650978	A/G	cg14500486	chr6:159655392	FNDC1	0.43	6.61	0.34	1.55e-10	Coronary heart disease;
CRC	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg15654264	chr1:150340011	RPRD2	0.43	6.49	0.34	3.17e-10	Migraine;
CRC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.74	-0.3	2.17e-8	Obesity-related traits;
CRC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.81	-12.75	-0.58	1.54e-30	Multiple myeloma;
CRC	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.59	-6.5	-0.34	2.89e-10	Coronary artery disease;
CRC	cis	rs6662572	0.737	rs6674105	chr1:46301379	G/T	cg08644498	chr1:46502608	NA	-0.44	-6.97	-0.36	1.74e-11	Blood protein levels;
CRC	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg12756093	chr1:115239321	AMPD1	0.52	6.8	0.35	5.06e-11	Autism;
CRC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.66	0.43	2.12e-16	Menopause (age at onset);
CRC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg14671364	chr1:107599128	PRMT6	0.51	6.78	0.35	5.5e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22199361	chr20:5081567	C20orf30	0.41	6.27	0.33	1.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7926971	0.598	rs4288736	chr11:12652968	A/G	cg25843174	chr11:12811716	TEAD1	0.32	5.62	0.3	4e-8	Height;
CRC	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-1.02	-18.1	-0.71	2.59e-51	Gut microbiome composition (winter);
CRC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.37	5.88	0.31	9.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.71	-12.61	-0.57	5.17e-30	Prostate cancer;
CRC	cis	rs6534441	0.824	rs6856045	chr4:125457662	T/C	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs6496667	0.779	rs6496670	chr15:90949480	A/G	cg04176472	chr15:90893244	GABARAPL3	0.61	7.82	0.4	7.34e-14	Rheumatoid arthritis;
CRC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.51	-7.04	-0.36	1.09e-11	Lymphocyte percentage of white cells;
CRC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.82	-10.94	-0.52	5.91e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.32	4.57e-9	Gut microbiome composition (summer);
CRC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20307385	chr11:47447363	PSMC3	-0.46	-6.33	-0.33	8.18e-10	Subjective well-being;
CRC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	9.22	0.45	3.61e-18	Response to antipsychotic treatment;
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg06243084	chr11:63990629	FERMT3	0.45	7.14	0.37	5.98e-12	Platelet count;
CRC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.71	12.45	0.57	2.02e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.75	-10.98	-0.52	4.09e-24	Platelet distribution width;
CRC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.4	0.53	1.37e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.7	-10.47	-0.5	2.41e-22	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.58	-8.61	-0.43	3.1e-16	Coronary artery disease;
CRC	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.51	-8.79	-0.44	8.17e-17	Airway imaging phenotypes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00300090	chr3:4345167	SETMAR	0.38	6.06	0.32	3.64e-9	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.45	0.5	2.95e-22	Menopause (age at onset);
CRC	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg00732059	chr16:71740210	PHLPP2	-0.67	-6.89	-0.36	2.86e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.43	-0.33	4.41e-10	Coronary artery disease;
CRC	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.39	5.75	0.3	2e-8	Growth-regulated protein alpha levels;
CRC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	8.91	0.44	3.67e-17	Height;
CRC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15369054	chr17:80825471	TBCD	-0.36	-6.02	-0.31	4.68e-9	Breast cancer;
CRC	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.64	-0.39	2.4e-13	Bipolar disorder;
CRC	cis	rs6834538	0.558	rs13120366	chr4:113394085	T/C	cg10021238	chr4:113569128	MIR367;LARP7	-0.38	-5.79	-0.3	1.67e-8	Free thyroxine concentration;
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg15790184	chr11:494944	RNH1	0.62	6.26	0.33	1.22e-9	Body mass index;
CRC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg15786705	chr6:28176104	NA	0.48	5.72	0.3	2.44e-8	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.62	-8.79	-0.44	8.72e-17	Coronary artery disease;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg25164649	chr6:28176230	NA	0.52	7.41	0.38	1.07e-12	Parkinson's disease;
CRC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.71	13.94	0.61	4.92e-35	Mean corpuscular hemoglobin;
CRC	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.48	7.29	0.37	2.35e-12	Testicular germ cell tumor;
CRC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.79	13.57	0.6	1.3e-33	Menopause (age at onset);
CRC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.25	-0.33	1.24e-9	Type 2 diabetes;
CRC	cis	rs7202877	0.610	rs3784936	chr16:75337583	C/G	cg03315344	chr16:75512273	CHST6	0.51	5.85	0.31	1.18e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.46	0.46	6.23e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg13047869	chr3:10149882	C3orf24	0.52	6.27	0.33	1.15e-9	Alzheimer's disease;
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg04727332	chr7:45960243	IGFBP3	0.36	5.63	0.3	3.77e-8	Sitting height ratio;
CRC	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs6968419	0.755	rs6967695	chr7:115896049	G/A	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.48e-10	Intraocular pressure;
CRC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.57	8.56	0.43	4.33e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.73	-0.43	1.27e-16	Uric acid levels;
CRC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.86	10.95	0.52	5.46e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg10398005	chr11:117014888	PAFAH1B2	-0.39	-5.65	-0.3	3.49e-8	Blood protein levels;
CRC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg20811857	chr17:78079795	GAA	-0.45	-6.52	-0.34	2.58e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	cis	rs72634501	0.716	rs67637163	chr1:39576621	T/G	cg18385671	chr1:39797026	MACF1	-0.42	-5.82	-0.31	1.41e-8	HDL cholesterol;
CRC	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg10978503	chr1:24200527	CNR2	-0.42	-6.13	-0.32	2.45e-9	Immature fraction of reticulocytes;
CRC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg27535305	chr1:53392650	SCP2	0.39	7.01	0.36	1.34e-11	Monocyte count;
CRC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.12	-16.79	-0.68	3.95e-46	Platelet count;
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.79	-12.09	-0.55	4.31e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.28	-0.49	1.13e-21	Bipolar disorder;
CRC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.34	3.94e-10	Electroencephalogram traits;
CRC	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg06470822	chr6:28175283	NA	0.62	6.93	0.36	2.28e-11	Parkinson's disease;
CRC	cis	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg00086871	chr4:6988644	TBC1D14	0.9	7.36	0.38	1.46e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	12.61	0.57	5.3e-30	Electrocardiographic conduction measures;
CRC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.94	9.94	0.48	1.61e-20	Inflammatory bowel disease;
CRC	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg27398640	chr15:77910606	LINGO1	-0.45	-7.78	-0.39	9.51e-14	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18013306	chr15:68521911	CLN6	0.45	6.11	0.32	2.77e-9	Anxiety disorder;
CRC	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.38	-0.38	1.29e-12	Diisocyanate-induced asthma;
CRC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg01483505	chr11:975446	AP2A2	0.45	7.58	0.39	3.59e-13	Alzheimer's disease (late onset);
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.54	7.43	0.38	9.22e-13	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02630704	chr19:13260775	IER2;STX10	0.43	5.97	0.31	5.99e-9	Response to antipsychotic treatment;
CRC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.43	-0.5	3.29e-22	Initial pursuit acceleration;
CRC	cis	rs747650	0.504	rs6485726	chr11:47082122	C/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.86	-0.31	1.11e-8	Acne (severe);
CRC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.55	6.17	0.32	1.96e-9	Bipolar disorder;
CRC	cis	rs6545883	0.894	rs12615783	chr2:61440947	T/C	cg15711740	chr2:61764176	XPO1	0.43	5.74	0.3	2.2e-8	Tuberculosis;
CRC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg17321639	chr7:2759063	NA	-0.4	-5.79	-0.3	1.62e-8	Height;
CRC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg14024328	chr4:719362	PCGF3	-0.55	-7.73	-0.39	1.32e-13	White blood cell count;
CRC	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.65	-7.95	-0.4	2.98e-14	Obesity (extreme);
CRC	cis	rs972578	1.000	rs1071961	chr22:43349699	C/A	cg01576275	chr22:43409880	NA	-0.45	-7.24	-0.37	3.23e-12	Mean platelet volume;
CRC	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.54	-7.61	-0.39	2.88e-13	Primary sclerosing cholangitis;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg23123621	chr4:1343375	KIAA1530	-0.36	-5.69	-0.3	2.86e-8	Obesity-related traits;
CRC	cis	rs3020333	0.875	rs2941742	chr6:152012988	A/G	cg22157087	chr6:152012887	ESR1	0.54	8.18	0.41	6.06e-15	Total body bone mineral density;
CRC	cis	rs7487075	0.578	rs11183486	chr12:46837704	A/C	cg22049899	chr12:47219821	SLC38A4	0.32	5.83	0.31	1.34e-8	Itch intensity from mosquito bite;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg17084751	chr11:6953558	ZNF215	-0.51	-5.81	-0.31	1.47e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.6	-0.39	3.05e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.41	8.1	0.41	1.08e-14	Hypertriglyceridemia;
CRC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.51	7.08	0.36	8.52e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.64	9.84	0.48	3.37e-20	Itch intensity from mosquito bite;
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.47e-8	Prudent dietary pattern;
CRC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg24675056	chr1:15929824	NA	0.48	6.52	0.34	2.66e-10	Systolic blood pressure;
CRC	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.59	8.44	0.42	1.04e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-0.59	-7.96	-0.4	2.85e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9783347	0.961	rs12293544	chr11:18348581	T/C	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg10298567	chr3:47292165	KIF9	0.38	5.79	0.3	1.61e-8	Colorectal cancer;
CRC	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.26	-0.37	2.81e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg08514558	chr10:81106712	PPIF	0.36	5.79	0.3	1.65e-8	Height;
CRC	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	cg04338863	chr8:33670619	NA	0.44	7.06	0.36	9.65e-12	Body mass index;
CRC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.67	9.8	0.48	4.77e-20	Menopause (age at onset);
CRC	cis	rs1519814	0.876	rs10955954	chr8:121108052	A/G	cg22335954	chr8:121166405	COL14A1	-0.49	-6.07	-0.32	3.59e-9	Breast cancer;
CRC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg15448220	chr1:150897856	SETDB1	0.41	5.97	0.31	6.2e-9	Tonsillectomy;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs1979967	0.524	rs1979965	chr15:79658995	G/A	cg14802097	chr12:42970349	PRICKLE1	0.52	6.06	0.32	3.66e-9	Interleukin-18 levels;
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11645453	chr3:52864694	ITIH4	0.36	6.24	0.33	1.31e-9	Bipolar disorder;
CRC	cis	rs12137294	0.866	rs1172153	chr1:205220661	T/C	cg24159697	chr1:205181237	DSTYK	-0.34	-6.08	-0.32	3.39e-9	Red cell distribution width;
CRC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.47	-7.98	-0.4	2.49e-14	Major depressive disorder;
CRC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.5	0.38	6.17e-13	Height;
CRC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-7.0	-0.36	1.42e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.29e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4964805	0.865	rs35371470	chr12:104203720	C/G	cg02344784	chr12:104178138	NT5DC3	0.47	6.46	0.34	3.68e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg21425842	chr6:26240939	HIST1H4F	-0.34	-5.68	-0.3	2.98e-8	Gout;Renal underexcretion gout;
CRC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-10.9	-0.51	8.17e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.51	7.77	0.39	1.04e-13	Pulmonary function decline;
CRC	cis	rs17767392	0.881	rs12881957	chr14:71909854	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.55	-7.08	-0.36	9.04e-12	Mitral valve prolapse;
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg21856205	chr7:94953877	PON1	-0.49	-6.44	-0.33	4.12e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg10437265	chr15:77819839	NA	-0.47	-8.34	-0.42	2.01e-15	Type 2 diabetes;
CRC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.13	10.9	0.52	7.71e-24	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-11.86	-0.55	2.96e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13939156	chr17:80058883	NA	-0.4	-6.49	-0.34	3.1e-10	Life satisfaction;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg03623178	chr6:28175578	NA	0.74	10.55	0.5	1.28e-22	Parkinson's disease;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.67	-10.41	-0.5	3.88e-22	Platelet count;
CRC	cis	rs8141797	0.901	rs4820581	chr22:24480503	G/A	cg20894457	chr22:24584366	SUSD2	-0.61	-7.56	-0.38	4.14e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	trans	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.59e-14	HDL cholesterol;
CRC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.65	10.86	0.51	1.07e-23	Prudent dietary pattern;
CRC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	12.04	0.55	6.36e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.61	6.44	0.33	4.22e-10	Mean platelet volume;
CRC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.61	8.45	0.42	9.8e-16	Platelet count;
CRC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.5	7.78	0.39	9.69e-14	Menopause (age at onset);
CRC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.01	-0.31	4.85e-9	Lung cancer;
CRC	cis	rs4654899	0.627	rs667071	chr1:21045726	T/C	cg02927042	chr1:21476669	EIF4G3	-0.45	-6.78	-0.35	5.71e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg02869306	chr7:64672164	INTS4L1	-0.46	-7.87	-0.4	5.22e-14	Calcium levels;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24714709	chr7:95064397	PON2	0.39	6.77	0.35	5.78e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-0.84	-13.16	-0.59	4.39e-32	Blood trace element (Zn levels);
CRC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	8.62	0.43	2.92e-16	Homoarginine levels;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg09877947	chr5:131593287	PDLIM4	-0.36	-6.6	-0.34	1.66e-10	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02951021	chr12:120934296	DYNLL1	0.41	6.45	0.34	3.9e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg18099408	chr3:52552593	STAB1	0.33	5.68	0.3	2.99e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.73	-9.4	-0.46	9.52e-19	Blood protein levels;
CRC	trans	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg02927042	chr1:21476669	EIF4G3	-0.42	-6.52	-0.34	2.6e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.37	-6.98	-0.36	1.64e-11	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01636747	chr16:28957148	NA	0.46	6.74	0.35	6.92e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.99	-18.89	-0.72	2.08e-54	Headache;
CRC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.45	7.03	0.36	1.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.71	0.47	9.27e-20	Monocyte percentage of white cells;
CRC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg05192639	chr6:26864778	GUSBL1	0.33	6.08	0.32	3.28e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg08888203	chr3:10149979	C3orf24	-0.5	-7.69	-0.39	1.69e-13	Alzheimer's disease;
CRC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.29	0.46	2.16e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg10298567	chr3:47292165	KIF9	0.41	6.53	0.34	2.53e-10	Colorectal cancer;
CRC	cis	rs3804749	0.966	rs3792366	chr3:122839876	G/A	cg26084141	chr3:122786895	PDIA5	0.23	6.04	0.32	4.11e-9	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	trans	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	7.07	0.36	9.16e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-14.83	-0.63	1.91e-38	Vitiligo;
CRC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.36	0.33	6.77e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg24675056	chr1:15929824	NA	0.5	6.96	0.36	1.83e-11	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05323904	chr16:691677	FAM195A	0.42	6.05	0.32	3.98e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg06470822	chr6:28175283	NA	0.99	12.76	0.58	1.4e-30	Depression;
CRC	cis	rs7215564	0.908	rs2316062	chr17:78663558	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.66	0.47	1.39e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.67	8.52	0.43	5.67e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.85	-0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.04	0.32	4.22e-9	Personality dimensions;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg06470822	chr6:28175283	NA	1.0	13.03	0.58	1.36e-31	Parkinson's disease;
CRC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-7.01	-0.36	1.36e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21097640	chr13:28195548	POLR1D;LNX2	0.48	6.12	0.32	2.61e-9	Thyroid stimulating hormone;
CRC	trans	rs6006893	0.935	rs8139558	chr22:45251169	C/T	cg18016826	chr5:176560001	NSD1	-0.44	-5.96	-0.31	6.45e-9	Binge eating behaviour in bipolar disorder;
CRC	cis	rs4731207	0.596	rs1871773	chr7:124674939	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.23	-0.32	1.44e-9	Cutaneous malignant melanoma;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.37	6.45	0.34	3.89e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.43	-6.42	-0.33	4.89e-10	Renal cell carcinoma;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg03623178	chr6:28175578	NA	0.79	11.53	0.54	4.47e-26	Cardiac Troponin-T levels;
CRC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.61	-7.89	-0.4	4.52e-14	Cocaine dependence;
CRC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.23	-0.33	1.39e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	5.65	0.3	3.52e-8	Bipolar disorder;
CRC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.58	-8.52	-0.43	5.71e-16	Monobrow;
CRC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg11204139	chr17:3907470	NA	0.64	11.14	0.52	1.11e-24	Type 2 diabetes;
CRC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg08533674	chr1:46993347	NA	-0.8	-10.42	-0.5	3.71e-22	Monobrow;
CRC	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg12700464	chr11:78128424	GAB2	-0.51	-6.16	-0.32	2.1e-9	Testicular germ cell tumor;
CRC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs7429990	0.965	rs5016900	chr3:47822877	G/C	cg11946769	chr3:48343235	NME6	0.56	6.34	0.33	7.8e-10	Educational attainment (years of education);
CRC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.6	7.78	0.39	9.56e-14	Prostate cancer;
CRC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.83	-0.48	3.72e-20	Height;
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-16.5	-0.67	5.24e-45	Height;
CRC	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg12856521	chr11:46389249	DGKZ	-0.5	-8.27	-0.41	3.37e-15	Leprosy;
CRC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.62	-9.05	-0.45	1.32e-17	Cognitive function;
CRC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.23	0.45	3.35e-18	Schizophrenia;
CRC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.47	6.4	0.33	5.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-6.97	-0.36	1.73e-11	IgG glycosylation;
CRC	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg07322936	chr10:88137208	NA	-0.62	-8.55	-0.43	4.57e-16	Schizophrenia;
CRC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg09473613	chr1:24152604	HMGCL	0.34	5.76	0.3	1.92e-8	Immature fraction of reticulocytes;
CRC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.94	11.85	0.55	3.1e-27	Exhaled nitric oxide levels;
CRC	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg13491945	chr12:107078410	RFX4	0.35	6.14	0.32	2.36e-9	Heart rate;
CRC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg19812747	chr11:111475976	SIK2	0.43	6.29	0.33	1.03e-9	Primary sclerosing cholangitis;
CRC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.8	-0.48	4.49e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg14711859	chr11:8959438	ASCL3	0.35	6.01	0.31	4.93e-9	Hemoglobin concentration;
CRC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.68	12.23	0.56	1.36e-28	Body mass index;
CRC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.51	7.88	0.4	4.76e-14	Corneal astigmatism;
CRC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.33	-6.98	-0.36	1.64e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg02049041	chr17:27085579	C17orf63	0.44	5.61	0.3	4.31e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	1.01	19.93	0.74	1.64e-58	Headache;
CRC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.42e-9	Height;
CRC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.55	9.13	0.45	7.21e-18	Total body bone mineral density;
CRC	cis	rs17767392	1.000	rs61991250	chr14:71869684	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs972578	0.967	rs8138930	chr22:43336728	C/T	cg01576275	chr22:43409880	NA	-0.46	-7.47	-0.38	7.46e-13	Mean platelet volume;
CRC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.59	-6.59	-0.34	1.73e-10	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22335246	chr12:120763591	PLA2G1B	0.48	7.22	0.37	3.62e-12	Response to antipsychotic treatment;
CRC	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02598441	chr17:62777298	LOC146880	-0.53	-6.82	-0.35	4.45e-11	QT interval;
CRC	cis	rs863345	0.604	rs10908660	chr1:158466189	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.35	-0.33	7.19e-10	Pneumococcal bacteremia;
CRC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	0.35	5.84	0.31	1.22e-8	Personality dimensions;
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-7.08	-0.36	9.03e-12	Lymphocyte counts;
CRC	cis	rs863345	0.564	rs7540999	chr1:158504570	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.13	-0.32	2.45e-9	Schizophrenia;
CRC	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg11212589	chr17:38028394	ZPBP2	0.42	7.79	0.39	8.57e-14	Self-reported allergy;
CRC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.53	8.11	0.41	1.04e-14	Fibrinogen levels;
CRC	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.69	-12.72	-0.57	2.07e-30	Educational attainment;
CRC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.45	0.33	4.03e-10	Aortic root size;
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg24046110	chr8:143859143	LYNX1	0.48	8.34	0.42	2.11e-15	Urinary tract infection frequency;
CRC	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg15654264	chr1:150340011	RPRD2	0.43	6.46	0.34	3.76e-10	Migraine;
CRC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg04545296	chr12:48745243	ZNF641	0.33	5.86	0.31	1.1e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.6	9.54	0.47	3.41e-19	Gestational age at birth (maternal effect);
CRC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.49	-6.97	-0.36	1.7e-11	DNA methylation (variation);
CRC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg12927641	chr6:109611667	NA	-0.38	-6.66	-0.34	1.18e-10	Reticulocyte fraction of red cells;
CRC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.46	6.7	0.35	9.16e-11	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08677755	chr19:7604888	PNPLA6	-0.45	-6.96	-0.36	1.81e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.62	10.16	0.49	2.9e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.45	-6.32	-0.33	8.47e-10	DNA methylation (variation);
CRC	cis	rs9361491	0.657	rs9341742	chr6:79440229	C/T	cg05283184	chr6:79620031	NA	-0.37	-5.69	-0.3	2.84e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2882667	0.690	rs185956	chr5:138230263	A/G	cg09476006	chr5:138032270	NA	0.55	9.14	0.45	6.76e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.14e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.64	-11.56	-0.54	3.64e-26	Hematocrit;
CRC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.46	-6.28	-0.33	1.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9891119	0.965	rs3816769	chr17:40498273	C/T	cg06270615	chr17:40516068	STAT3	0.28	6.04	0.32	4.24e-9	Multiple sclerosis;Crohn's disease;
CRC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg03623178	chr6:28175578	NA	-0.43	-5.86	-0.31	1.14e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg20814179	chr4:940893	TMEM175	-0.42	-6.88	-0.35	3.05e-11	Parkinson's disease;
CRC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24110177	chr3:50126178	RBM5	0.46	6.98	0.36	1.63e-11	Menarche (age at onset);
CRC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg11292332	chr7:45801988	SEPT13	-0.38	-6.83	-0.35	4.14e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.88	0.4	4.67e-14	Lung cancer;
CRC	trans	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg11693508	chr17:37793320	STARD3	0.53	6.81	0.35	4.74e-11	Bipolar disorder;
CRC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.52	9.15	0.45	5.92e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.15	-24.54	-0.8	2.57e-76	Exhaled nitric oxide output;
CRC	cis	rs812925	0.859	rs778138	chr2:61687214	A/C	cg10580144	chr2:61372316	C2orf74	0.3	6.07	0.32	3.49e-9	Immature fraction of reticulocytes;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08275802	chr7:155137875	NA	0.45	6.06	0.32	3.78e-9	Survival in pancreatic cancer;
CRC	cis	rs7259376	0.902	rs10408428	chr19:22578023	G/T	cg02657401	chr19:22469223	NA	0.31	6.79	0.35	5.21e-11	Menopause (age at onset);
CRC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.65	-0.47	1.4e-19	Hip circumference adjusted for BMI;
CRC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.18	-17.22	-0.69	7.98e-48	Hip circumference adjusted for BMI;
CRC	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg25797454	chr6:150327115	RAET1K	0.38	6.51	0.34	2.8e-10	Alopecia areata;
CRC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	8.27	0.41	3.46e-15	Breast cancer;
CRC	cis	rs17227506	0.704	rs6530649	chr8:13448112	A/G	cg03566418	chr8:13424080	C8orf48	-0.34	-5.86	-0.31	1.14e-8	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs7605827	0.930	rs11679632	chr2:15605659	G/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.59	7.82	0.4	7.02e-14	Mean platelet volume;
CRC	cis	rs4929949	0.809	rs1900273	chr11:8483335	G/A	cg20771178	chr11:8615675	STK33	-0.34	-5.67	-0.3	3.07e-8	Body mass index;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg16141378	chr3:129829833	LOC729375	0.42	6.21	0.32	1.62e-9	Neuroticism;
CRC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg05941027	chr17:61774174	LIMD2	0.37	6.56	0.34	2.06e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg21856205	chr7:94953877	PON1	-0.46	-6.11	-0.32	2.75e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg03929089	chr4:120376271	NA	0.58	7.49	0.38	6.27e-13	Intraocular pressure;
CRC	trans	rs4785204	1.000	rs9932240	chr16:50094227	T/C	cg07960154	chr17:37760198	NEUROD2	-0.66	-6.13	-0.32	2.52e-9	Esophageal cancer (squamous cell);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26657230	chr5:94891026	TTC37;ARSK	0.39	6.18	0.32	1.87e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.9	-17.34	-0.69	2.66e-48	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.56	8.27	0.41	3.41e-15	Melanoma;
CRC	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.66	-7.95	-0.4	3.11e-14	Rheumatoid arthritis;
CRC	trans	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09920427	chr19:12777674	MORG1;MAN2B1	0.53	6.94	0.36	2.07e-11	Thyroid stimulating hormone;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg00603274	chr11:61596626	FADS2	-0.8	-9.26	-0.45	2.76e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg18335740	chr13:41363409	SLC25A15	0.53	8.27	0.41	3.33e-15	Lewy body disease;
CRC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.43	-5.9	-0.31	9.27e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg17524180	chr13:113633600	MCF2L	-0.56	-10.22	-0.49	1.72e-21	Systolic blood pressure;
CRC	cis	rs12541635	0.966	rs11786829	chr8:107023752	C/G	cg10147462	chr8:107024639	NA	0.46	7.78	0.39	9.16e-14	Age of smoking initiation;
CRC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.63	10.29	0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.2	-25.61	-0.82	2.42e-80	Exhaled nitric oxide output;
CRC	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-5.86	-0.31	1.11e-8	Blood protein levels;
CRC	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg22561889	chr6:118971681	C6orf204	0.48	5.92	0.31	8.1e-9	Diastolic blood pressure;
CRC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-12.73	-0.57	1.87e-30	Ulcerative colitis;
CRC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg12386194	chr3:101231763	SENP7	0.48	6.75	0.35	6.6e-11	Colorectal cancer;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-8.09	-0.41	1.13e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.42	6.81	0.35	4.66e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg14191688	chr11:70257035	CTTN	0.47	6.03	0.32	4.39e-9	Coronary artery disease;
CRC	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.66	7.46	0.38	7.83e-13	Breast cancer;
CRC	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.49	7.78	0.39	9.2e-14	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.52	-5.93	-0.31	7.72e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg03929089	chr4:120376271	NA	0.69	6.76	0.35	6.37e-11	Intraocular pressure;
CRC	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg17133734	chr15:86042851	AKAP13	0.42	6.68	0.35	1.05e-10	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12744310	0.830	rs12045184	chr1:41799611	G/A	cg19175123	chr10:103411746	FBXW4	0.47	6.23	0.32	1.45e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.47	6.97	0.36	1.71e-11	Birth weight;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04579211	chr15:41221939	DLL4	0.46	6.06	0.32	3.71e-9	Thyroid stimulating hormone;
CRC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.56	0.43	4.49e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2462686	1.000	rs1525828	chr7:46002078	T/A	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.86	-0.31	1.11e-8	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25883402	chr1:173837173	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.47	6.69	0.35	9.7e-11	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.6	10.28	0.49	1.13e-21	Prudent dietary pattern;
CRC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-5.61	-0.3	4.22e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs6011002	0.745	rs6011068	chr20:62364885	T/A	cg01176363	chr20:62369445	LIME1	-0.72	-5.67	-0.3	3.14e-8	Dental caries;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg23161317	chr6:28129485	ZNF389	0.44	6.35	0.33	7.18e-10	Parkinson's disease;
CRC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.84	-11.08	-0.52	1.83e-24	Ankle injury;
CRC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg18721089	chr20:30220636	NA	-0.42	-6.79	-0.35	5.27e-11	Mean corpuscular hemoglobin;
CRC	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg26566898	chr11:117069891	TAGLN	0.39	6.89	0.36	2.85e-11	Blood protein levels;
CRC	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg13160058	chr8:26243215	BNIP3L	-0.48	-7.56	-0.38	4.13e-13	Red cell distribution width;
CRC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-5.96	-0.31	6.32e-9	Menarche (age at onset);
CRC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.77	-0.39	1e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs7113874	0.524	rs10840092	chr11:8624915	A/G	cg17679104	chr11:8615758	STK33	0.33	5.65	0.3	3.44e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.41	6.71	0.35	8.73e-11	Height;
CRC	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg20356878	chr3:121714668	ILDR1	-0.42	-6.01	-0.31	5.02e-9	Multiple sclerosis;
CRC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-8.33	-0.42	2.26e-15	Chronic sinus infection;
CRC	cis	rs365302	1.000	rs294920	chr6:159622802	C/T	cg14500486	chr6:159655392	FNDC1	0.46	7.14	0.37	5.84e-12	Coronary heart disease;
CRC	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg25834613	chr7:1915315	MAD1L1	-0.37	-6.37	-0.33	6.19e-10	Bipolar disorder;
CRC	cis	rs11212617	0.875	rs10789659	chr11:108255828	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.01	0.31	4.91e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.71	0.51	3.81e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4728142	0.625	rs4731533	chr7:128602142	A/G	cg06630958	chr7:128577819	IRF5	-0.34	-5.63	-0.3	3.93e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-7.9	-0.4	4.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.58	9.17	0.45	5.36e-18	Schizophrenia;
CRC	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.58	-0.39	3.52e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.67	-0.3	3.06e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-9.86	-0.48	2.93e-20	Menarche (age at onset);
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.59e-12	Life satisfaction;
CRC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	0.97	8.98	0.44	2.1e-17	Lymphocyte counts;
CRC	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.44	6.87	0.35	3.17e-11	Red blood cell count;
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.41	8.56	0.43	4.3e-16	Electroencephalogram traits;
CRC	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.58	-0.34	1.86e-10	Intelligence (multi-trait analysis);
CRC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg24531977	chr5:56204891	C5orf35	-0.45	-6.7	-0.35	9.2e-11	Coronary artery disease;
CRC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg17724175	chr1:150552817	MCL1	0.49	7.28	0.37	2.54e-12	Melanoma;
CRC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.66	0.43	2.22e-16	Coffee consumption (cups per day);
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.49e-17	Bladder cancer;
CRC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.49	-0.38	6.37e-13	Self-reported allergy;
CRC	cis	rs10888329	0.744	rs6587431	chr1:248354978	T/C	cg00666640	chr1:248458726	OR2T12	0.43	7.05	0.36	1.05e-11	Autism spectrum disorder;
CRC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.82	-0.4	7.43e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg14139581	chr11:64358342	SLC22A12	-0.39	-6.19	-0.32	1.81e-9	Urate levels in obese individuals;
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.23e-12	Bipolar disorder;
CRC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.46	8.4	0.42	1.36e-15	Childhood ear infection;
CRC	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg14345882	chr6:26364793	BTN3A2	0.66	5.77	0.3	1.8e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.54	8.06	0.41	1.45e-14	Morning vs. evening chronotype;
CRC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.08	-0.32	3.39e-9	Daytime sleep phenotypes;
CRC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.6	0.47	2.18e-19	Lung cancer;
CRC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg03037974	chr15:76606532	NA	-0.48	-6.89	-0.36	2.8e-11	Blood metabolite levels;
CRC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	7.18	0.37	4.65e-12	Calcium levels;
CRC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs73206853	0.563	rs7960761	chr12:111164415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.76	7.9	0.4	4.34e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7567389	0.600	rs72845979	chr2:128095754	C/A	cg09760422	chr2:128146352	NA	0.34	5.61	0.3	4.2e-8	Self-rated health;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	trans	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg02509730	chr13:100310205	CLYBL	0.6	6.07	0.32	3.46e-9	Breast cancer;
CRC	cis	rs1347297	0.666	rs4019558	chr2:179270883	A/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.41	-5.81	-0.31	1.44e-8	Alzheimer disease and age of onset;
CRC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.31	-0.33	9.14e-10	Aortic root size;
CRC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.61	-0.75	3.5e-61	Height;
CRC	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg12856521	chr11:46389249	DGKZ	-0.49	-8.23	-0.41	4.46e-15	Leprosy;
CRC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.44	-8.12	-0.41	9.42e-15	Intelligence (multi-trait analysis);
CRC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.69	0.39	1.67e-13	Schizophrenia;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11012683	chr17:4402158	SPNS2	-0.38	-6.0	-0.31	5.32e-9	Obesity-related traits;
CRC	cis	rs2256039	1.000	rs2245879	chr9:86789653	A/C	cg14555996	chr9:86785905	NA	-0.39	-5.68	-0.3	2.96e-8	Multiple system atrophy;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg11326919	chr17:43324904	LOC100133991	-0.65	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg08847533	chr14:75593920	NEK9	-0.43	-5.75	-0.3	2.09e-8	IgG glycosylation;
CRC	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg12856521	chr11:46389249	DGKZ	-0.4	-6.57	-0.34	1.94e-10	Leprosy;
CRC	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg02135003	chr7:105160482	PUS7	-0.53	-8.34	-0.42	2.05e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs16975963	0.644	rs73033139	chr19:38091685	A/C	cg15135657	chr19:38346511	NA	-0.46	-6.3	-0.33	9.32e-10	Longevity;
CRC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg20302533	chr7:39170763	POU6F2	0.41	5.66	0.3	3.38e-8	IgG glycosylation;
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg20512303	chr5:131592959	PDLIM4	0.29	5.61	0.3	4.2e-8	Blood metabolite levels;
CRC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg25956985	chr22:39795188	MAP3K7IP1	-0.43	-6.44	-0.33	4.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.4	-6.84	-0.35	3.91e-11	Height;
CRC	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg00507830	chr2:103233733	NA	0.53	5.83	0.31	1.33e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-9.89	-0.48	2.25e-20	Personality dimensions;
CRC	cis	rs6460942	0.643	rs80264734	chr7:12233800	T/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	cis	rs7429990	0.965	rs4599334	chr3:48066400	A/C	cg11946769	chr3:48343235	NME6	-0.47	-6.03	-0.32	4.4e-9	Educational attainment (years of education);
CRC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg21466736	chr12:48725269	NA	-0.45	-6.98	-0.36	1.67e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg18131467	chr2:239335373	ASB1	-0.72	-6.21	-0.32	1.62e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.49	6.82	0.35	4.49e-11	Response to temozolomide;
CRC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg12193833	chr17:30244370	NA	-0.62	-7.94	-0.4	3.33e-14	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04320405	chr7:131012679	MKLN1	0.5	7.06	0.36	1.01e-11	Anxiety disorder;
CRC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg04719120	chr6:96025338	MANEA	0.55	6.61	0.34	1.52e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg19678392	chr7:94953810	PON1	-0.57	-7.07	-0.36	9.34e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.66	10.45	0.5	2.97e-22	Pulmonary function decline;
CRC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.47	0.42	8.18e-16	Height;
CRC	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg10756647	chr7:56101905	PSPH	0.76	7.93	0.4	3.53e-14	Gout;
CRC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-10.06	-0.48	6.41e-21	Breast cancer;
CRC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg02880119	chr16:3481970	NA	0.43	5.98	0.31	5.8e-9	Body mass index (adult);
CRC	cis	rs3026101	0.671	rs57085931	chr17:5305370	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.52	8.03	0.4	1.75e-14	Aortic root size;
CRC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.78	-9.6	-0.47	2.1e-19	Platelet count;
CRC	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.61	9.25	0.45	2.86e-18	Corneal astigmatism;
CRC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg00901687	chr17:48585270	MYCBPAP	-0.49	-7.09	-0.36	8.3e-12	Visceral fat;
CRC	trans	rs10242455	0.571	rs117370443	chr7:98975258	T/C	cg09045935	chr12:6379348	NA	0.88	6.87	0.35	3.29e-11	Blood metabolite levels;
CRC	trans	rs16846053	0.786	rs62187647	chr2:162446018	C/T	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Blood osmolality (transformed sodium);
CRC	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.14	-0.32	2.38e-9	Daytime sleep phenotypes;
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.38	0.5	5.13e-22	Hemoglobin concentration;
CRC	trans	rs867371	0.502	rs2047679	chr15:82531881	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.14	-0.32	2.34e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.33	-6.36	-0.33	6.73e-10	Breast cancer;
CRC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.22	-0.32	1.48e-9	Menarche (age at onset);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.05	-0.32	4.02e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27520502	chr17:26684562	POLDIP2;TMEM199	0.41	6.32	0.33	8.52e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.11	-0.32	2.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.56	7.97	0.4	2.71e-14	Lung cancer;
CRC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg05207973	chr5:176823642	SLC34A1	-0.36	-5.95	-0.31	6.74e-9	Urinary electrolytes (magnesium/calcium ratio);
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs4766646	0.600	rs3782893	chr12:110293678	G/C	cg01252219	chr12:110302105	GLTP	0.42	6.44	0.33	4.21e-10	Metabolite levels (MHPG);
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg03623178	chr6:28175578	NA	0.88	12.21	0.56	1.5e-28	Parkinson's disease;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg23196781	chr12:27117782	FGFR1OP2	0.42	6.21	0.32	1.64e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.39	6.67	0.35	1.06e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg15382696	chr6:118971807	C6orf204	0.59	7.46	0.38	7.96e-13	Diastolic blood pressure;
CRC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.65	8.92	0.44	3.37e-17	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg03395511	chr6:291903	DUSP22	-0.51	-6.92	-0.36	2.41e-11	Menopause (age at onset);
CRC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg00246817	chr9:123691163	NA	-0.43	-5.61	-0.3	4.37e-8	Rheumatoid arthritis;
CRC	trans	rs2055729	0.677	rs592420	chr8:9760420	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.96	0.36	1.87e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg20041105	chr8:143859282	LYNX1	-0.35	-6.05	-0.32	4.01e-9	Urinary tract infection frequency;
CRC	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg20356878	chr3:121714668	ILDR1	-0.51	-7.17	-0.37	4.83e-12	Multiple sclerosis;
CRC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg19913688	chr11:428466	ANO9	-0.73	-6.95	-0.36	2e-11	Body mass index;
CRC	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.49	-8.21	-0.41	5.06e-15	Congenital heart disease (maternal effect);
CRC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.38	-0.33	6.06e-10	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.83	-13.54	-0.6	1.73e-33	Hypospadias;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02096396	chr2:26395556	FAM59B	0.37	6.05	0.32	3.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg06581033	chr10:766294	NA	-0.51	-5.78	-0.3	1.7e-8	Uric acid levels;
CRC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.37	-0.5	5.45e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg10298567	chr3:47292165	KIF9	-0.41	-6.67	-0.35	1.06e-10	Colorectal cancer;
CRC	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15541040	chr2:3486749	NA	-0.51	-8.15	-0.41	7.77e-15	Neurofibrillary tangles;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg09730361	chr9:20622599	MLLT3	-0.44	-5.97	-0.31	6.3e-9	Protein C levels;
CRC	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.74	-0.3	2.21e-8	Tuberculosis;
CRC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.25	-0.62	3.35e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.38	6.13	0.32	2.5e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13985271	chr9:97140681	HIATL1	-0.44	-7.3	-0.37	2.12e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.38	6.56	0.34	2.07e-10	Mean corpuscular volume;
CRC	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg14829360	chr17:73884958	NA	-0.44	-7.05	-0.36	1.03e-11	Psoriasis;
CRC	cis	rs4804416	1.000	rs4804416	chr19:7223848	G/T	cg09779027	chr19:7224513	INSR	-0.65	-10.97	-0.52	4.48e-24	Thyroid hormone levels;Hypothyroidism;
CRC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.34	-5.72	-0.3	2.34e-8	Childhood ear infection;
CRC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.65	11.79	0.54	5.42e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11212617	0.840	rs172894	chr11:108262090	C/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.69	0.3	2.88e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg06606381	chr12:133084897	FBRSL1	-1.19	-8.02	-0.4	1.94e-14	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.55	-0.47	3.01e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg23758597	chr6:163146217	PARK2	-0.54	-6.02	-0.31	4.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg20936604	chr3:58311152	NA	-0.73	-7.56	-0.38	4.03e-13	Cholesterol, total;
CRC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.49	7.35	0.38	1.56e-12	Longevity;
CRC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg23298862	chr7:158159286	PTPRN2	0.41	6.39	0.33	5.71e-10	Calcium levels;
CRC	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.82	-0.4	7.24e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.84	9.89	0.48	2.27e-20	Obesity-related traits;
CRC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.01e-12	Rheumatoid arthritis;
CRC	cis	rs4728142	0.604	rs12155080	chr7:128658739	C/G	cg06630958	chr7:128577819	IRF5	-0.36	-5.86	-0.31	1.1e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.16	0.37	5.47e-12	Life satisfaction;
CRC	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.01	-0.31	4.93e-9	Height;
CRC	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.75	-0.3	2.02e-8	Axial length;
CRC	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs6433857	0.594	rs11680811	chr2:181519898	A/G	cg23363182	chr2:181467187	NA	-0.47	-7.31	-0.37	2.03e-12	Body mass index;
CRC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.85	-14.36	-0.62	1.21e-36	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12737363	chr1:183604674	ARPC5;RGL1	0.5	6.44	0.33	4.14e-10	Thyroid stimulating hormone;
CRC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.6	-7.87	-0.4	5.32e-14	Gut microbiome composition (summer);
CRC	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.42	6.81	0.35	4.67e-11	Sitting height ratio;
CRC	trans	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg13565492	chr6:43139072	SRF	-0.85	-6.23	-0.32	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25517755	chr10:38738941	LOC399744	-0.45	-6.62	-0.34	1.47e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.61	-7.47	-0.38	7.19e-13	Fractional excretion of uric acid;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.67	-0.35	1.08e-10	Lymphocyte counts;
CRC	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg21174375	chr14:64681225	SYNE2	0.39	6.3	0.33	9.65e-10	Atrial fibrillation;
CRC	trans	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.83	-11.62	-0.54	2.25e-26	Asthma;
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg00531865	chr16:30841666	NA	-0.42	-6.09	-0.32	3.15e-9	Dementia with Lewy bodies;
CRC	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.36	-7.43	-0.38	9.66e-13	Cutaneous nevi;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.54	-7.39	-0.38	1.19e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.0	-0.31	5.13e-9	Blood metabolite levels;
CRC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.5	-9.85	-0.48	3.03e-20	Ulcerative colitis;
CRC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.54	5.67	0.3	3.12e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.43	-6.1	-0.32	3.04e-9	Lung cancer;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.79	-13.19	-0.59	3.47e-32	Height;
CRC	cis	rs2457480	0.850	rs61855743	chr10:44681729	A/G	cg09554077	chr10:44749378	NA	0.68	7.34	0.38	1.65e-12	Coronary artery disease;
CRC	cis	rs972578	1.000	rs4822242	chr22:43375439	G/A	cg01576275	chr22:43409880	NA	-0.48	-7.65	-0.39	2.25e-13	Mean platelet volume;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg08222913	chr3:52553049	STAB1	-0.42	-8.62	-0.43	2.95e-16	Electroencephalogram traits;
CRC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.74e-12	Obesity-related traits;
CRC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.39	6.45	0.34	3.91e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs7209700	0.574	rs3851806	chr17:45350919	G/C	cg18085866	chr17:45331354	ITGB3	-0.52	-6.47	-0.34	3.49e-10	IgG glycosylation;
CRC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.43	-6.09	-0.32	3.19e-9	Menarche (age at onset);
CRC	cis	rs12760731	0.582	rs74967269	chr1:178571703	T/C	cg00404053	chr1:178313656	RASAL2	0.65	7.01	0.36	1.36e-11	Obesity-related traits;
CRC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.55	-8.94	-0.44	2.85e-17	Prostate cancer;
CRC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg23262073	chr20:60523788	NA	-0.41	-6.84	-0.35	3.92e-11	Body mass index;
CRC	cis	rs72772090	0.539	rs11748795	chr5:96168056	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.88	-0.31	1.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.59	0.63	1.55e-37	Hypertriglyceridemia;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.03	-0.32	4.47e-9	Acylcarnitine levels;
CRC	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg21918786	chr6:109611834	NA	-0.35	-5.92	-0.31	8e-9	Reticulocyte fraction of red cells;
CRC	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.8	-0.4	8.18e-14	QT interval;
CRC	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.9	15.97	0.66	6.5e-43	Fuchs's corneal dystrophy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19741500	chr1:27930843	AHDC1	0.4	5.99	0.31	5.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26803216	chr1:193029757	TROVE2;UCHL5	-0.4	-6.43	-0.33	4.45e-10	Aortic root size;
CRC	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg05784532	chr1:230284198	GALNT2	0.44	6.19	0.32	1.75e-9	Coronary artery disease;
CRC	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg06042504	chr8:55087323	NA	-0.42	-6.72	-0.35	8.23e-11	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs10242455	0.702	rs75156180	chr7:98964100	G/A	cg09045935	chr12:6379348	NA	0.89	6.64	0.34	1.32e-10	Blood metabolite levels;
CRC	cis	rs4929949	0.809	rs1900273	chr11:8483335	G/A	cg02811074	chr11:8615871	STK33	-0.36	-6.15	-0.32	2.24e-9	Body mass index;
CRC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg19193384	chr17:30244184	NA	-0.53	-6.67	-0.35	1.06e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg04155289	chr7:94953770	PON1	-0.58	-7.18	-0.37	4.59e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20713816	chr5:89705801	CETN3	0.41	6.99	0.36	1.51e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7605827	0.930	rs59135666	chr2:15592448	G/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.14e-9	Educational attainment (years of education);
CRC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.47	7.57	0.38	3.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.62	-11.56	-0.54	3.75e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.94	-17.71	-0.7	8.92e-50	Height;
CRC	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.56	8.79	0.44	8.47e-17	Male sexual orientation;
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg04824913	chr4:887549	GAK	0.42	6.03	0.32	4.37e-9	Sjögren's syndrome;
CRC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.73	-9.38	-0.46	1.15e-18	Initial pursuit acceleration;
CRC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.5	8.18	0.41	6.38e-15	Total body bone mineral density;
CRC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.48	6.81	0.35	4.64e-11	Type 1 diabetes nephropathy;
CRC	cis	rs904251	0.647	rs2776908	chr6:37434857	T/C	cg01843034	chr6:37503916	NA	-0.4	-5.84	-0.31	1.27e-8	Cognitive performance;
CRC	cis	rs7091068	0.566	rs7909925	chr10:95507170	A/G	cg20715218	chr10:95462985	C10orf4	0.53	5.65	0.3	3.53e-8	Urinary tract infection frequency;
CRC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg24699146	chr1:24152579	HMGCL	-0.32	-5.69	-0.3	2.83e-8	Immature fraction of reticulocytes;
CRC	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg06632207	chr12:54070931	ATP5G2	0.42	7.08	0.36	8.82e-12	Height;
CRC	cis	rs73206853	0.841	rs28480627	chr12:110834659	T/C	cg12870014	chr12:110450643	ANKRD13A	0.85	10.16	0.49	2.87e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg14178696	chr11:47291038	MADD	0.42	6.15	0.32	2.31e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg23625390	chr15:77176239	SCAPER	0.49	7.22	0.37	3.68e-12	Blood metabolite levels;
CRC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg25456477	chr12:86230367	RASSF9	0.35	6.13	0.32	2.47e-9	Major depressive disorder;
CRC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg00343986	chr7:65444356	GUSB	0.4	5.62	0.3	4.16e-8	Aortic root size;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.65	7.59	0.39	3.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12582905	chr11:310771	NA	0.4	6.41	0.33	5.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.25	0.33	1.28e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs73206853	0.841	rs16940885	chr12:110971666	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.7	-7.91	-0.4	3.93e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg09218773	chr11:619014	MUPCDH	-0.36	-5.79	-0.3	1.64e-8	Systemic lupus erythematosus;
CRC	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.89	-0.36	2.87e-11	Putamen volume;
CRC	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	9.07e-12	Putamen volume;
CRC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-8.07	-0.41	1.37e-14	Colorectal cancer;
CRC	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg06386533	chr2:46925753	SOCS5	0.41	5.62	0.3	4.13e-8	Height;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15313956	chr14:91744445	CCDC88C	0.45	6.09	0.32	3.13e-9	Survival in pancreatic cancer;
CRC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.05	-24.32	-0.8	1.66e-75	Myeloid white cell count;
CRC	cis	rs883565	0.569	rs6599273	chr3:38998552	T/G	cg01426195	chr3:39028469	NA	-0.42	-6.97	-0.36	1.74e-11	Handedness;
CRC	cis	rs10924970	0.649	rs11590729	chr1:235422177	T/G	cg09010748	chr1:235293032	TOMM20	-0.41	-5.66	-0.3	3.37e-8	Asthma;
CRC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.7	-11.02	-0.52	3.12e-24	Lung cancer;
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-6.25	-0.33	1.25e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	trans	rs17607347	0.697	rs7204260	chr16:72384689	A/G	cg27230510	chr3:50404023	CACNA2D2	-0.54	-6.09	-0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.57	-8.4	-0.42	1.38e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.17	-0.37	5.12e-12	Response to antipsychotic treatment;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg12595990	chr12:49351331	ARF3	0.4	6.23	0.32	1.4e-9	Interleukin-6 levels;
CRC	cis	rs3018066	0.748	rs7678847	chr4:106987426	A/G	cg01869342	chr4:106983673	TBCK	0.44	6.71	0.35	8.61e-11	Cancer;
CRC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg04553112	chr3:125709451	NA	-0.51	-5.89	-0.31	9.55e-9	Blood pressure (smoking interaction);
CRC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg23093090	chr10:104574429	C10orf26	-0.43	-6.82	-0.35	4.43e-11	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.2	-0.32	1.74e-9	Menopause (age at onset);
CRC	cis	rs7605827	0.930	rs2287264	chr2:15637592	C/G	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg24560729	chr4:1342394	KIAA1530	0.32	5.76	0.3	1.88e-8	Obesity-related traits;
CRC	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg09597638	chr17:3907349	NA	0.64	11.73	0.54	8.96e-27	Type 2 diabetes;
CRC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.66	8.75	0.43	1.14e-16	Interstitial lung disease;
CRC	cis	rs11958404	0.929	rs72816533	chr5:157413352	G/T	cg05962755	chr5:157440814	NA	0.89	11.91	0.55	1.94e-27	IgG glycosylation;
CRC	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.74	9.92	0.48	1.8899999999999998e-20	Diastolic blood pressure;
CRC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	8.63	0.43	2.71e-16	Bone mineral density;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg03361557	chr19:19774500	ATP13A1	-0.41	-6.02	-0.31	4.68e-9	Protein C levels;
CRC	cis	rs9467160	1.000	rs9461011	chr6:24440351	C/T	cg20631270	chr6:24437470	GPLD1	-0.45	-5.98	-0.31	5.85e-9	Liver enzyme levels;
CRC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.48	0.42	7.87e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.87	11.85	0.55	3.24e-27	Gut microbiome composition (summer);
CRC	cis	rs4664293	0.867	rs16822556	chr2:160600903	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg20936604	chr3:58311152	NA	-0.72	-6.94	-0.36	2.09e-11	Cholesterol, total;
CRC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.97	0.44	2.37e-17	Intelligence (multi-trait analysis);
CRC	trans	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.32	-0.37	1.91e-12	Endometrial cancer;
CRC	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.47	-6.94	-0.36	2.06e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg08774802	chr16:691652	FAM195A	0.48	6.0	0.31	5.27e-9	Kashin-Beck disease;
CRC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.56	-7.81	-0.4	7.72e-14	IgG glycosylation;
CRC	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.72	-13.22	-0.59	2.74e-32	Leprosy;
CRC	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.47	7.01	0.36	1.39e-11	Red blood cell count;
CRC	trans	rs11825064	0.520	rs2226891	chr11:134486796	T/G	cg00033773	chr19:12779366	MORG1;C19orf56	0.45	6.2	0.32	1.69e-9	Seasonality;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg24560729	chr4:1342394	KIAA1530	0.32	5.62	0.3	4.15e-8	Obesity-related traits;
CRC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.59	0.7	2.82e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg24675056	chr1:15929824	NA	0.53	7.22	0.37	3.68e-12	Systolic blood pressure;
CRC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.32	16.33	0.67	2.65e-44	Uric acid levels;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.08	-0.41	1.22e-14	Electroencephalogram traits;
CRC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.51	8.32	0.42	2.31e-15	Coronary artery disease;
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08219700	chr8:58056026	NA	0.54	5.89	0.31	9.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg05623727	chr3:50126028	RBM5	0.47	7.63	0.39	2.51e-13	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.55	-8.66	-0.43	2.21e-16	Aortic root size;
CRC	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.4	5.76	0.3	1.91e-8	Platelet distribution width;
CRC	cis	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg11619707	chr19:22235551	ZNF257	-0.29	-5.86	-0.31	1.13e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CRC	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.51	7.31	0.37	2.03e-12	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg25164649	chr6:28176230	NA	0.75	9.29	0.46	2.13e-18	Depression;
CRC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.66	11.73	0.54	8.84e-27	Height;
CRC	cis	rs889398	0.617	rs11648348	chr16:69890722	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.21	-0.32	1.58e-9	Body mass index;
CRC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs524281	0.861	rs10791858	chr11:65978396	A/G	cg14541915	chr11:65894463	PACS1	0.34	5.65	0.3	3.39e-8	Electroencephalogram traits;
CRC	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg22495460	chr2:25135724	ADCY3	-0.88	-15.31	-0.64	2.55e-40	Body mass index;
CRC	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg27398640	chr15:77910606	LINGO1	-0.46	-8.02	-0.4	1.85e-14	Type 2 diabetes;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg20744362	chr22:50050164	C22orf34	0.35	6.38	0.33	5.86e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg08501292	chr6:25962987	TRIM38	0.79	7.3	0.37	2.19e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2882667	0.931	rs1433009	chr5:138333784	G/A	cg09476006	chr5:138032270	NA	0.42	6.8	0.35	4.96e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg27432699	chr2:27873401	GPN1	-0.61	-9.14	-0.45	6.74e-18	Total body bone mineral density;
CRC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.61	-11.09	-0.52	1.75e-24	Aortic root size;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg17949981	chr6:28129498	ZNF389	0.41	5.63	0.3	3.84e-8	Cardiac Troponin-T levels;
CRC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	10.3	0.49	9.27e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.55	-0.43	4.79e-16	Platelet count;
CRC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg12365402	chr11:9010492	NRIP3	-0.37	-6.08	-0.32	3.33e-9	Hematocrit;
CRC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.25	-0.74	8.67e-60	Height;
CRC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg21138405	chr5:131827807	IRF1	0.35	6.04	0.32	4.13e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.47	7.15	0.37	5.7e-12	Cleft lip with or without cleft palate;
CRC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.25	0.33	1.29e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.16	25.88	0.82	2.46e-81	IgG glycosylation;
CRC	cis	rs282587	0.569	rs7987086	chr13:113409889	G/A	cg04656015	chr13:113407548	ATP11A	0.63	8.09	0.41	1.12e-14	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12859234	chr8:38089495	DDHD2	0.43	6.11	0.32	2.8e-9	Response to antipsychotic treatment;
CRC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg17470449	chr10:769945	NA	-0.59	-8.16	-0.41	7.24e-15	Uric acid levels;
CRC	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.68	-11.13	-0.52	1.19e-24	Breast cancer;
CRC	trans	rs444386	1.000	rs444386	chr10:90528178	A/G	cg05650238	chr5:55215955	NA	-0.32	-6.14	-0.32	2.33e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.88	0.4	4.92e-14	Morning vs. evening chronotype;
CRC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.31	-0.49	9.12e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.7	10.86	0.51	1.08e-23	Corneal astigmatism;
CRC	cis	rs17065868	0.764	rs61949801	chr13:45040176	T/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.29	0.33	1.02e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.93	16.28	0.67	3.89e-44	Menarche (age at onset);
CRC	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.49	-7.9	-0.4	4.31e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg09877947	chr5:131593287	PDLIM4	0.43	7.14	0.37	5.93e-12	Breast cancer;
CRC	cis	rs9311676	0.632	rs4228	chr3:58413669	G/T	cg06643156	chr3:58380774	PXK	0.42	6.45	0.33	4.08e-10	Systemic lupus erythematosus;
CRC	cis	rs990171	1.000	rs11123931	chr2:103085660	A/G	cg03938978	chr2:103052716	IL18RAP	0.47	5.93	0.31	7.82e-9	Lymphocyte counts;
CRC	cis	rs16975963	0.639	rs112997435	chr19:38204631	C/T	cg15135657	chr19:38346511	NA	-0.46	-6.33	-0.33	7.91e-10	Longevity;
CRC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.62	9.14	0.45	6.73e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	0.88	10.36	0.5	6.12e-22	Type 2 diabetes nephropathy;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.15	-0.49	2.99e-21	Bipolar disorder;
CRC	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-6.51	-0.34	2.88e-10	Response to bleomycin (chromatid breaks);
CRC	cis	rs2811415	0.597	rs2276867	chr3:127786675	T/G	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12504415	chr17:74722752	JMJD6;C17orf95	0.41	7.07	0.36	9.06e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10746514	0.833	rs2026302	chr1:232264047	A/G	cg09506761	chr1:232265262	NA	-0.47	-6.82	-0.35	4.48e-11	Response to statin therapy;
CRC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.45	-7.04	-0.36	1.16e-11	Monocyte count;
CRC	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg14191688	chr11:70257035	CTTN	0.67	8.71	0.43	1.49e-16	Coronary artery disease;
CRC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.51	8.53	0.43	5.36e-16	Primary biliary cholangitis;
CRC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.77	-0.39	1e-13	Schizophrenia;
CRC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.36	0.46	1.25e-18	Personality dimensions;
CRC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.74	-0.35	7.27e-11	Alzheimer's disease (late onset);
CRC	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg24438145	chr17:48624694	SPATA20	0.43	6.22	0.32	1.53e-9	Type 2 diabetes;
CRC	cis	rs2070632	0.708	rs2248690	chr3:186330088	A/T	cg25162301	chr3:186330055	AHSG	-0.4	-5.75	-0.3	2.05e-8	Blood protein levels;
CRC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg03030879	chr14:75389066	RPS6KL1	0.44	6.79	0.35	5.22e-11	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06254406	chr13:103450982	BIVM;KDELC1	0.46	6.39	0.33	5.65e-10	Response to antipsychotic treatment;
CRC	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	1.06	12.52	0.57	1.15e-29	Obesity-related traits;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg15790184	chr11:494944	RNH1	0.59	6.1	0.32	2.95e-9	Body mass index;
CRC	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.68	0.3	2.97e-8	Coronary artery disease;
CRC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg12046867	chr14:103022105	NA	0.76	8.9	0.44	3.85e-17	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09592155	chr17:8029700	NA	0.39	6.35	0.33	6.96e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.53	-8.93	-0.44	3.08e-17	Coronary artery disease;
CRC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.6	0.3	4.42e-8	Major depressive disorder;
CRC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.77	8.71	0.43	1.47e-16	Tuberculosis;
CRC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg22333259	chr1:19394757	NA	0.36	5.66	0.3	3.34e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.56	-6.77	-0.35	5.95e-11	Breast cancer;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg20512303	chr5:131592959	PDLIM4	0.42	7.22	0.37	3.69e-12	Breast cancer;
CRC	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.79e-13	HDL cholesterol;
CRC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg23229984	chr5:148520753	ABLIM3	0.56	7.48	0.38	6.91e-13	Breast cancer;
CRC	cis	rs728616	0.764	rs12413678	chr10:81687099	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-8.86	-0.44	5.1e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.4	5.71	0.3	2.52e-8	Aortic root size;
CRC	cis	rs7264396	0.667	rs224368	chr20:34070380	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.09	-0.32	3.2e-9	Total cholesterol levels;
CRC	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg15382696	chr6:118971807	C6orf204	0.56	6.86	0.35	3.34e-11	Diastolic blood pressure;
CRC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg26762873	chr11:5879799	OR52E8	-0.5	-7.52	-0.38	5.2e-13	DNA methylation (variation);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22800477	chr1:10853793	CASZ1	0.44	6.66	0.34	1.13e-10	Schizophrenia;
CRC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.63	-0.3	3.78e-8	Gout;Renal underexcretion gout;
CRC	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.46	6.75	0.35	6.5500000000000006e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs539514	0.612	rs1830760	chr13:76296625	G/A	cg04757411	chr13:76259545	LMO7	-0.37	-6.29	-0.33	1.01e-9	Type 1 diabetes;
CRC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1124376	0.935	rs9855900	chr3:20147172	C/T	cg05072819	chr3:20081367	KAT2B	0.49	5.92	0.31	8.07e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg11635098	chr7:100497156	NA	-0.54	-6.81	-0.35	4.58e-11	Resting heart rate;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg01339444	chr6:118972232	C6orf204	0.52	5.92	0.31	8.31e-9	Diastolic blood pressure;
CRC	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.69	0.39	1.77e-13	Height;
CRC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.52	7.08	0.36	8.61e-12	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs7725052	0.609	rs4495224	chr5:40477515	C/A	cg09067459	chr5:40385259	NA	0.4	6.68	0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.31	-0.37	2.08e-12	Coronary artery disease;
CRC	cis	rs2398893	0.883	rs34169833	chr9:96840611	G/A	cg14459158	chr9:96720562	NA	0.44	7.25	0.37	2.93e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.73	10.0	0.48	9.76e-21	Alzheimer's disease;
CRC	trans	rs7591064	0.505	rs6545089	chr2:49198934	C/A	cg05049280	chr1:110155535	GNAT2	0.41	6.02	0.31	4.78e-9	Radiation response;
CRC	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.66	8.59	0.43	3.44e-16	Uric acid levels;
CRC	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.46	5.68	0.3	3e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.41	5.72	0.3	2.34e-8	Aortic root size;
CRC	trans	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg20935933	chr6:143382018	AIG1	0.53	6.76	0.35	6.45e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.69	12.31	0.56	6.55e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg23758597	chr6:163146217	PARK2	-0.69	-7.08	-0.36	8.87e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-7.01	-0.36	1.37e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.25	14.52	0.63	2.87e-37	Diabetic kidney disease;
CRC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12463550	chr7:65579703	CRCP	0.7	6.48	0.34	3.32e-10	Diabetic kidney disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09909671	chr11:13689641	FAR1	-0.38	-6.01	-0.31	5.05e-9	Myopia (pathological);
CRC	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.59	-0.47	2.35e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07425090	chr6:86353447	SYNCRIP	0.46	6.32	0.33	8.41e-10	Anxiety disorder;
CRC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.05	-0.32	3.92e-9	Obesity-related traits;
CRC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.72	-9.39	-0.46	1.07e-18	Vitiligo;
CRC	cis	rs802075	1.000	rs802072	chr6:49656000	G/A	cg20364632	chr6:49636226	NA	-0.36	-5.88	-0.31	9.95e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs910187	0.678	rs6122563	chr20:45813885	C/T	cg27589058	chr20:45804311	EYA2	-0.39	-7.39	-0.38	1.21e-12	Migraine;
CRC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.06	0.41	1.42e-14	Menarche (age at onset);
CRC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg19041857	chr6:27730383	NA	-0.76	-7.29	-0.37	2.34e-12	Depression;
CRC	cis	rs2565722	0.825	rs1247537	chr6:161251788	T/C	cg03159191	chr6:161285451	NA	-0.48	-5.83	-0.31	1.35e-8	Blood protein levels;
CRC	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg00105475	chr2:10696890	NA	0.46	7.17	0.37	5.09e-12	Prostate cancer;
CRC	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.74	0.39	1.27e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3823572	0.564	rs10272270	chr7:133636174	A/T	cg03336402	chr7:133662267	EXOC4	0.68	10.53	0.5	1.5e-22	Intelligence (multi-trait analysis);
CRC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.5	-5.69	-0.3	2.83e-8	Body mass index;
CRC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.06e-15	Menopause (age at onset);
CRC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.66	-11.52	-0.54	4.89e-26	Brugada syndrome;
CRC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.69	11.17	0.52	8.91e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18115022	chr15:65822705	PTPLAD1	0.4	6.14	0.32	2.44e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.55	8.19	0.41	5.68e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs427941	0.659	rs2529373	chr7:101739618	A/G	cg06246474	chr7:101738831	CUX1	0.46	7.23	0.37	3.35e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11191270	0.554	rs11191274	chr10:104140350	G/A	cg15320455	chr10:103880129	LDB1	0.87	7.27	0.37	2.7e-12	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.92	0.48	1.81e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg11693508	chr17:37793320	STARD3	-0.6	-7.42	-0.38	1.03e-12	Bipolar disorder;
CRC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-6.07	-0.32	3.58e-9	Personality dimensions;
CRC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.62	0.57	4.78e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3741151	0.892	rs2027763	chr11:73035799	A/G	cg17517138	chr11:73019481	ARHGEF17	0.64	6.64	0.34	1.26e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg13206674	chr6:150067644	NUP43	0.52	7.12	0.37	6.64e-12	Lung cancer;
CRC	cis	rs12024301	0.557	rs16861400	chr1:183619781	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.52	-8.03	-0.4	1.8e-14	Immature fraction of reticulocytes;
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.31e-36	Prudent dietary pattern;
CRC	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-13.26	-0.59	1.86e-32	Blood metabolite levels;
CRC	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.48	8.08	0.41	1.24e-14	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	ch.2.1420302F	chr2:62093097	NA	-0.39	-6.0	-0.31	5.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.69	10.89	0.51	8.69e-24	Height;
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.66	-8.08	-0.41	1.25e-14	Initial pursuit acceleration;
CRC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.03	0.45	1.53e-17	Migraine;Coronary artery disease;
CRC	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.77	0.3	1.79e-8	Corneal astigmatism;
CRC	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.44	-6.21	-0.32	1.61e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs59104589	0.617	rs3771561	chr2:242353704	A/G	cg19488206	chr2:242435732	STK25	-0.44	-6.48	-0.34	3.36e-10	Fibrinogen levels;
CRC	cis	rs4132509	1.000	rs10927043	chr1:243762208	C/T	cg21452805	chr1:244014465	NA	0.46	6.09	0.32	3.14e-9	RR interval (heart rate);
CRC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.67	-0.39	1.91e-13	Coronary artery disease;
CRC	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.95	-12.38	-0.56	3.81e-29	Exhaled nitric oxide output;
CRC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.61	-0.39	2.98e-13	Waist circumference;Hip circumference;
CRC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	7.88	0.4	4.9e-14	Colorectal cancer;
CRC	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg23032129	chr1:109941072	SORT1	-0.29	-6.01	-0.31	4.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.46	7.1	0.36	7.91e-12	Height;
CRC	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.44	5.76	0.3	1.91e-8	Platelet distribution width;
CRC	cis	rs720844	0.608	rs7564206	chr2:149333686	G/A	cg09247360	chr2:149335327	NA	0.47	6.28	0.33	1.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs13402330	0.730	rs72828098	chr2:103394261	A/C	cg02746748	chr4:906741	GAK	-0.28	-6.1	-0.32	2.93e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg00769240	chr8:12517080	NA	-0.74	-10.37	-0.5	5.27e-22	Blood pressure (smoking interaction);
CRC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.41	-0.42	1.27e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg12856521	chr11:46389249	DGKZ	0.75	10.39	0.5	4.5e-22	Crohn's disease;
CRC	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg06632207	chr12:54070931	ATP5G2	0.39	6.72	0.35	8.1e-11	Height;
CRC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg03233332	chr7:66118400	NA	-0.42	-5.83	-0.31	1.3e-8	Aortic root size;
CRC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-10.82	-0.51	1.56e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.56	8.26	0.41	3.52e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00922727	chr6:109415123	C6orf182;SESN1	-0.39	-6.08	-0.32	3.34e-9	Aortic root size;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.99	-0.31	5.44e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-6.06	-0.32	3.76e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg14078730	chr11:63896557	MACROD1	0.34	5.63	0.3	3.87e-8	Platelet count;
CRC	cis	rs6694672	0.764	rs672928	chr1:197198558	T/C	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.36	2.31e-11	Asthma;
CRC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.51	-8.36	-0.42	1.77e-15	Huntington's disease progression;
CRC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	10.06	0.49	6.09e-21	Lung cancer;
CRC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.46	-0.34	3.86e-10	Aortic root size;
CRC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-6.16	-0.32	2.09e-9	Mean corpuscular volume;
CRC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg08896387	chr1:24191740	FUCA1	0.47	5.98	0.31	5.91e-9	Immature fraction of reticulocytes;
CRC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.67	-10.22	-0.49	1.81e-21	Acne (severe);
CRC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.61	8.82	0.44	6.62e-17	Response to temozolomide;
CRC	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg04906043	chr13:21280425	IL17D	0.43	6.4	0.33	5.33e-10	Dental caries;
CRC	cis	rs2179367	0.959	rs9390677	chr6:149710497	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.01	-0.31	5.01e-9	Dupuytren's disease;
CRC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02725872	chr8:58115012	NA	-0.59	-9.18	-0.45	4.97e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7107770	1.000	rs1025812	chr11:125088182	C/G	cg27629782	chr11:125073726	PKNOX2	0.49	6.01	0.31	4.83e-9	Photic sneeze reflex;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26894311	chr10:104153930	NFKB2	0.38	6.39	0.33	5.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg03623178	chr6:28175578	NA	0.58	6.39	0.33	5.64e-10	Depression;
CRC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.59	10.42	0.5	3.82e-22	Schizophrenia;
CRC	cis	rs17443541	0.507	rs7594660	chr2:200468594	A/G	cg03741458	chr2:200468445	NA	-0.36	-5.77	-0.3	1.82e-8	Intelligence (multi-trait analysis);
CRC	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg06553033	chr12:53270239	NA	0.41	5.61	0.3	4.23e-8	Cancer (pleiotropy);
CRC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.29	-0.46	2.22e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.38	6.68	0.35	9.92e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.97e-20	Coronary artery disease;
CRC	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-7.41	-0.38	1.04e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg19980929	chr12:42632907	YAF2	-0.41	-6.26	-0.33	1.22e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-7.48	-0.38	7.04e-13	Longevity;Endometriosis;
CRC	cis	rs2530545	0.531	rs59560152	chr7:34613107	C/T	cg14401837	chr7:34697493	NPSR1	0.43	6.26	0.33	1.19e-9	IgG glycosylation;
CRC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.68	0.39	1.85e-13	Mean corpuscular volume;
CRC	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg04239558	chr2:103089729	SLC9A4	0.37	6.59	0.34	1.72e-10	Blood protein levels;
CRC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.53	-0.46	3.71e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.46	-0.34	3.66e-10	Blood metabolite levels;
CRC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.67	11.92	0.55	1.86e-27	Eye color traits;
CRC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	9.34	0.46	1.5e-18	Platelet count;
CRC	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg20607287	chr7:12443886	VWDE	-0.44	-5.85	-0.31	1.2e-8	Coronary artery disease;
CRC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.41	7.02	0.36	1.27e-11	Major depressive disorder;
CRC	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg00738113	chr16:70207722	CLEC18C	-0.39	-5.66	-0.3	3.28e-8	IgE levels;
CRC	cis	rs10274279	0.660	rs2021743	chr7:157381899	T/C	cg26886268	chr7:157387156	PTPRN2	-0.44	-5.99	-0.31	5.6e-9	Myopia (pathological);
CRC	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.26e-9	Red blood cell count;
CRC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg12855166	chr17:30846586	MYO1D	-0.39	-6.57	-0.34	1.92e-10	Schizophrenia;
CRC	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg21452805	chr1:244014465	NA	0.48	6.54	0.34	2.3e-10	RR interval (heart rate);
CRC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.52	-8.67	-0.43	2.01e-16	Menarche (age at onset);
CRC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.75	-0.35	6.5500000000000006e-11	Monocyte count;
CRC	cis	rs2834256	0.625	rs2834248	chr21:35056766	G/A	cg14850771	chr21:34775459	IFNGR2	-0.42	-6.17	-0.32	1.96e-9	Red cell distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01029575	chr19:54641418	CNOT3	0.52	7.36	0.38	1.5e-12	Response to antipsychotic treatment;
CRC	cis	rs12295403	0.964	rs34364314	chr11:18691674	G/A	cg07538406	chr11:18686895	NA	-0.42	-6.3	-0.33	9.66e-10	Ovarian reserve;
CRC	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg14458575	chr2:238380390	NA	0.52	7.25	0.37	2.95e-12	Prostate cancer;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.36	-5.83	-0.31	1.32e-8	Lymphocyte counts;
CRC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.73	0.51	3.22e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.68	0.39	1.81e-13	Height;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg06470822	chr6:28175283	NA	0.95	13.56	0.6	1.43e-33	Parkinson's disease;
CRC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg16358738	chr2:241808595	AGXT	-0.39	-5.82	-0.31	1.38e-8	Urinary metabolites;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg20512303	chr5:131592959	PDLIM4	0.29	5.72	0.3	2.43e-8	Blood metabolite levels;
CRC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.91	-0.36	2.53e-11	Lung cancer;
CRC	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	0.79	8.2	0.41	5.6e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg22532475	chr10:104410764	TRIM8	0.33	5.62	0.3	4e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-0.82	-8.9	-0.44	3.83e-17	Post bronchodilator FEV1;
CRC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.64	9.5	0.46	4.57e-19	Blood protein levels;
CRC	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	1.0	18.51	0.71	6.11e-53	Gut microbiome composition (winter);
CRC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.26	-0.75	8.32e-60	Primary sclerosing cholangitis;
CRC	cis	rs59104589	0.617	rs3771550	chr2:242302811	A/G	cg19488206	chr2:242435732	STK25	0.43	6.38	0.33	5.86e-10	Fibrinogen levels;
CRC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6076065	0.723	rs4815199	chr20:23347169	G/A	cg11657817	chr20:23433608	CST11	0.43	6.34	0.33	7.66e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.55	8.48	0.42	7.81e-16	Diastolic blood pressure;
CRC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg27101125	chr19:17392770	ANKLE1	-0.32	-5.69	-0.3	2.81e-8	Systemic lupus erythematosus;
CRC	cis	rs7916697	0.520	rs12246624	chr10:70036562	C/T	cg06988349	chr10:69991859	ATOH7	0.39	6.79	0.35	5.21e-11	Optic disc area;
CRC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	1.09	10.21	0.49	1.97e-21	Arsenic metabolism;
CRC	cis	rs2179367	0.887	rs2789488	chr6:149725290	A/G	cg11245181	chr6:149772854	ZC3H12D	0.37	5.95	0.31	7.03e-9	Dupuytren's disease;
CRC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.76	-10.0	-0.48	9.92e-21	Initial pursuit acceleration;
CRC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg06470822	chr6:28175283	NA	0.99	14.14	0.61	8.85e-36	Depression;
CRC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.82	13.79	0.61	1.91e-34	Coronary artery disease;
CRC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.32	16.93	0.68	1.11e-46	Hip circumference adjusted for BMI;
CRC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg25767906	chr1:53392781	SCP2	0.42	6.67	0.35	1.09e-10	Monocyte count;
CRC	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg01339444	chr6:118972232	C6orf204	0.54	6.01	0.31	4.89e-9	Diastolic blood pressure;
CRC	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg25019722	chr6:37503610	NA	-0.49	-8.91	-0.44	3.44e-17	Cognitive performance;
CRC	cis	rs7827545	1.000	rs6578235	chr8:135568022	C/T	cg13086574	chr8:135490821	ZFAT	-0.37	-6.32	-0.33	8.52e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.47	7.7	0.39	1.63e-13	Fat distribution (HIV);
CRC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.46	7.09	0.36	8.09e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs6000550	0.954	rs13055107	chr22:37469821	G/A	cg12253469	chr22:37420454	MPST	0.51	5.76	0.3	1.88e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
CRC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg00343986	chr7:65444356	GUSB	-0.46	-6.27	-0.33	1.16e-9	Aortic root size;
CRC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.48	-0.38	7.02e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs11681344	chr2:15711885	C/A	cg19274914	chr2:15703543	NA	0.37	5.78	0.3	1.73e-8	Educational attainment (years of education);
CRC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.71	-0.39	1.46e-13	Blood metabolite levels;
CRC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.66	10.56	0.5	1.21e-22	Breast cancer;
CRC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg09417038	chr21:47716443	C21orf57	-0.35	-6.0	-0.31	5.17e-9	Testicular germ cell tumor;
CRC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.69	-0.35	9.34e-11	Bipolar disorder;
CRC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.72	0.39	1.41e-13	Mean platelet volume;
CRC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg20243544	chr17:37824526	PNMT	0.43	6.63	0.34	1.41e-10	Self-reported allergy;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14881459	chr19:797693	PTBP1	0.44	6.13	0.32	2.54e-9	Anxiety disorder;
CRC	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg25797454	chr6:150327115	RAET1K	0.38	6.42	0.33	4.77e-10	Alopecia areata;
CRC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.27	0.33	1.14e-9	Tonsillectomy;
CRC	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg15744005	chr10:104629667	AS3MT	-0.32	-6.32	-0.33	8.34e-10	Arsenic metabolism;
CRC	cis	rs6534441	0.824	rs6856467	chr4:125457781	T/C	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs4363385	0.668	rs1933386	chr1:152959265	T/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.23	-0.37	3.47e-12	Inflammatory skin disease;
CRC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.64e-39	Lymphocyte percentage of white cells;
CRC	cis	rs6496667	0.821	rs7182338	chr15:90879810	C/T	cg04176472	chr15:90893244	GABARAPL3	0.58	6.66	0.34	1.15e-10	Rheumatoid arthritis;
CRC	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.73	9.71	0.47	9.45e-20	Coronary artery disease;
CRC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.59	8.27	0.41	3.44e-15	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13929263	chr20:36156140	BLCAP	0.43	6.21	0.32	1.62e-9	Anxiety disorder;
CRC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.77	-12.56	-0.57	7.86e-30	Prostate cancer;
CRC	cis	rs9925964	0.900	rs56813533	chr16:31070481	A/T	cg02466173	chr16:30829666	NA	0.43	5.91	0.31	8.74e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg00490450	chr3:139108681	COPB2	0.44	6.61	0.34	1.51e-10	Obesity-related traits;
CRC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg17848003	chr1:3704513	LRRC47	0.39	5.72	0.3	2.45e-8	Red cell distribution width;
CRC	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg06042504	chr8:55087323	NA	-0.43	-6.86	-0.35	3.43e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg11861562	chr11:117069780	TAGLN	0.34	6.41	0.33	4.94e-10	Blood protein levels;
CRC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.6	-8.68	-0.43	1.8e-16	Menarche (age at onset);
CRC	cis	rs600626	0.578	rs10793126	chr11:75453982	C/T	cg24262691	chr11:75473276	NA	-0.49	-6.65	-0.34	1.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg19338460	chr6:170058176	WDR27	-0.71	-7.8	-0.4	8.04e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	7.75	0.39	1.12e-13	Motion sickness;
CRC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg23625390	chr15:77176239	SCAPER	0.47	6.86	0.35	3.43e-11	Blood metabolite levels;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.77	-9.3	-0.46	1.98e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.84	9.71	0.47	8.84e-20	Psoriasis;
CRC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.2	0.37	4.21e-12	Lung cancer;
CRC	cis	rs73206853	0.764	rs28580853	chr12:110826209	C/G	cg12870014	chr12:110450643	ANKRD13A	0.63	8.1	0.41	1.06e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	0.66	7.69	0.39	1.68e-13	Lymphocyte counts;
CRC	cis	rs17209837	0.667	rs45605032	chr7:87090301	C/T	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.69	11.57	0.54	3.26e-26	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.84e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13700589	chr9:15511220	PSIP1	0.38	6.48	0.34	3.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	0.71	6.7	0.35	9.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.48	-8.96	-0.44	2.53e-17	Intelligence (multi-trait analysis);
CRC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg13798912	chr7:905769	UNC84A	0.56	6.28	0.33	1.1e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.18	0.37	4.57e-12	Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg03623178	chr6:28175578	NA	0.97	12.38	0.56	3.55e-29	Depression;
CRC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg02135003	chr7:105160482	PUS7	-0.94	-12.71	-0.57	2.14e-30	Bipolar disorder (body mass index interaction);
CRC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.35	-0.42	1.87e-15	Chronic sinus infection;
CRC	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	8.24	0.41	4.16e-15	Iron status biomarkers;
CRC	cis	rs6499129	0.764	rs16957291	chr16:67326102	T/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.33	-0.33	7.81e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.71	0.51	3.81e-23	Prudent dietary pattern;
CRC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.51	7.5	0.38	5.9e-13	Multiple sclerosis;
CRC	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-7.65	-0.39	2.21e-13	Vitamin D levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10999867	chr6:114292751	HDAC2	0.45	6.47	0.34	3.61e-10	Response to antipsychotic treatment;
CRC	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.64	-10.26	-0.49	1.34e-21	Lewy body disease;
CRC	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.49	-0.46	4.98e-19	Prevalent atrial fibrillation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14497348	chr9:6757781	KDM4C	0.41	6.05	0.32	4.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.08	0.32	3.37e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.19	-0.53	7.43e-25	Colorectal cancer;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg04518342	chr5:131593106	PDLIM4	0.43	7.03	0.36	1.17e-11	Acylcarnitine levels;
CRC	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.42	6.58	0.34	1.82e-10	Red blood cell count;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg22638593	chr5:131593259	PDLIM4	-0.38	-6.16	-0.32	2.13e-9	Breast cancer;
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.75	14.17	0.62	6.74e-36	Prudent dietary pattern;
CRC	trans	rs13418717	0.793	rs3795874	chr2:127656383	A/G	cg05987030	chr3:137834655	DZIP1L	-0.74	-6.21	-0.32	1.58e-9	Heart failure;
CRC	cis	rs75422866	0.510	rs73104197	chr12:48111056	T/G	cg14736327	chr12:48174669	SLC48A1	-0.73	-5.76	-0.3	1.94e-8	Pneumonia;
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg02033258	chr5:131593261	PDLIM4	0.32	5.65	0.3	3.47e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg22676075	chr6:135203613	NA	-0.65	-10.08	-0.49	5.16e-21	Red blood cell count;
CRC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.79	8.61	0.43	3.12e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs7580658	0.963	rs9789510	chr2:128137012	G/A	cg09760422	chr2:128146352	NA	-0.36	-7.02	-0.36	1.25e-11	Protein C levels;
CRC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.82	-12.74	-0.57	1.68e-30	Cognitive function;
CRC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-5.97	-0.31	6.09e-9	Gut microbiome composition (summer);
CRC	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.55	8.37	0.42	1.72e-15	Testicular germ cell tumor;
CRC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg23996704	chr18:44553084	KATNAL2	0.39	7.67	0.39	1.93e-13	Personality dimensions;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg12516270	chr8:143859308	LYNX1	-0.4	-6.69	-0.35	9.56e-11	Urinary tract infection frequency;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12273811	chr6:28175739	NA	0.72	9.03	0.45	1.47e-17	Depression;
CRC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.52	-8.35	-0.42	1.97e-15	Pancreatic cancer;
CRC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.0	-0.44	1.87e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-8.26	-0.41	3.49e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.7	12.46	0.57	1.81e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg24881330	chr22:46731750	TRMU	0.64	5.87	0.31	1.06e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.72	-0.3	2.33e-8	Height;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg06470822	chr6:28175283	NA	0.74	10.0	0.48	9.56e-21	Parkinson's disease;
CRC	cis	rs2735413	0.875	rs4888736	chr16:78083784	T/C	cg04733911	chr16:78082701	NA	-0.45	-7.54	-0.38	4.5e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg25164649	chr6:28176230	NA	0.62	8.82	0.44	6.67e-17	Parkinson's disease;
CRC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.53	8.57	0.43	4.22e-16	Breast cancer;
CRC	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.27	-0.33	1.11e-9	Metabolite levels;
CRC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg25452165	chr22:42524984	CYP2D6	0.42	6.42	0.33	4.89e-10	Schizophrenia;
CRC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg10130564	chr11:117069849	TAGLN	0.37	7.0	0.36	1.46e-11	Blood protein levels;
CRC	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-6.09	-0.32	3.09e-9	Putamen volume;
CRC	cis	rs12630931	1.000	rs11719084	chr3:31972165	T/G	cg21375017	chr3:31988082	OSBPL10	0.43	5.9	0.31	8.82e-9	Periodontal disease-related phenotypes;
CRC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.63	9.11	0.45	8.18e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg12365402	chr11:9010492	NRIP3	0.45	6.83	0.35	4.23e-11	Hemoglobin concentration;
CRC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.85	-11.58	-0.54	3.01e-26	Asthma;
CRC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.66	-10.65	-0.51	5.88e-23	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg15845792	chr6:28175446	NA	0.73	6.16	0.32	2.08e-9	Depression;
CRC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.62	-0.72	2.27e-53	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06620269	chr17:2952258	NA	0.44	6.85	0.35	3.67e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg05044414	chr3:183734942	ABCC5	0.45	7.9	0.4	4.33e-14	Anterior chamber depth;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg07217954	chr7:1067459	C7orf50	0.52	5.61	0.3	4.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14938410	chr1:150521562	ADAMTSL4	0.47	6.13	0.32	2.47e-9	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.49	7.24	0.37	3.12e-12	Blood metabolite levels;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.43	-5.79	-0.3	1.61e-8	Parkinson's disease;
CRC	cis	rs9847710	0.566	rs2564951	chr3:53060449	C/T	cg15147215	chr3:52552868	STAB1	0.45	5.88	0.31	1.03e-8	Ulcerative colitis;
CRC	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg20750642	chr13:99100586	FARP1	0.4	6.03	0.32	4.44e-9	Educational attainment (years of education);
CRC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.59	-9.14	-0.45	6.43e-18	Height;
CRC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.48	0.57	1.63e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.45	7.07	0.36	9.36e-12	Platelet count;
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.64e-9	Electroencephalogram traits;
CRC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.59	-10.17	-0.49	2.56e-21	Calcium levels;
CRC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg25347419	chr2:177043501	NA	-0.48	-6.39	-0.33	5.66e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.85	-0.31	1.21e-8	Metabolite levels;
CRC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	0.99	12.34	0.56	5.14e-29	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.57	-9.85	-0.48	3.07e-20	Body mass index;
CRC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.16	-0.56	2.37e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15506890	chr2:3487001	NA	-0.52	-8.27	-0.41	3.35e-15	Neurofibrillary tangles;
CRC	cis	rs3026101	0.671	rs1806239	chr17:5295528	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs1656402	1.000	rs1729246	chr2:233426816	T/G	cg03852847	chr2:233439513	NA	0.45	7.73	0.39	1.34e-13	Non-small cell lung cancer (survival);
CRC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.36	5.79	0.3	1.64e-8	Blood metabolite levels;
CRC	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.65	-0.68	1.37e-45	Hip circumference;
CRC	cis	rs2811415	0.597	rs9821500	chr3:127734929	T/C	cg13719885	chr3:127795394	NA	-0.41	-6.14	-0.32	2.36e-9	Lung function (FEV1/FVC);
CRC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg00255919	chr5:131827918	IRF1	0.53	8.28	0.42	3.06e-15	Asthma (sex interaction);
CRC	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg03162506	chr22:38580953	NA	0.28	6.05	0.32	4.02e-9	Cutaneous nevi;
CRC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	10.72	0.51	3.49e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg15147215	chr3:52552868	STAB1	-0.65	-11.31	-0.53	2.75e-25	Electroencephalogram traits;
CRC	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.6	-9.16	-0.45	5.58e-18	QRS duration;
CRC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.6	9.46	0.46	6.09e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.57	0.57	7.49e-30	Height;
CRC	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.56	6.89	0.35	2.9100000000000002e-11	Coronary artery disease;
CRC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.4	-7.37	-0.38	1.4e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg12218747	chr21:37451666	NA	-0.41	-6.51	-0.34	2.78e-10	Mitral valve prolapse;
CRC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg04450456	chr4:17643702	FAM184B	-0.38	-5.77	-0.3	1.79e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.49	-6.3	-0.33	9.3e-10	Serum thyroid-stimulating hormone levels;
CRC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg14671364	chr1:107599128	PRMT6	0.52	7.12	0.37	6.62e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.47	7.15	0.37	5.57e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.47	-6.16	-0.32	2.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs55726902	1.000	rs55726902	chr12:48196982	G/A	cg14736327	chr12:48174669	SLC48A1	-0.58	-7.29	-0.37	2.39e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-7.06	-0.36	1.02e-11	Lung cancer;
CRC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.75	0.39	1.12e-13	Breast cancer;
CRC	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg03637622	chr5:179334771	TBC1D9B	-0.43	-6.08	-0.32	3.39e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	cg04338863	chr8:33670619	NA	0.42	6.34	0.33	7.39e-10	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11589374	chr3:126398357	NA	0.53	6.93	0.36	2.26e-11	Thyroid stimulating hormone;
CRC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.36	0.38	1.47e-12	Breast cancer;
CRC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg19622623	chr12:86230825	RASSF9	-0.4	-6.43	-0.33	4.53e-10	Major depressive disorder;
CRC	cis	rs911119	0.955	rs6048930	chr20:23592492	T/C	cg16589663	chr20:23618590	CST3	0.45	6.3	0.33	9.76e-10	Chronic kidney disease;
CRC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.64	5.75	0.3	2e-8	Gout;
CRC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	1.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg05309505	chr11:612837	IRF7	0.37	5.73	0.3	2.22e-8	Systemic lupus erythematosus;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12963246	chr6:28129442	ZNF389	0.44	5.64	0.3	3.66e-8	Depression;
CRC	cis	rs10128264	0.902	rs1250582	chr10:80973447	G/T	cg18737081	chr10:80999807	ZMIZ1	-0.33	-5.76	-0.3	1.94e-8	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs501120	0.584	rs11238923	chr10:44701232	A/T	cg09554077	chr10:44749378	NA	0.69	7.87	0.4	5.01e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9826463	0.582	rs11714528	chr3:142133218	C/T	cg20824294	chr3:142316082	PLS1	0.38	6.03	0.32	4.36e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.59	-0.34	1.78e-10	Fibrinogen levels;
CRC	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	10.07	0.49	5.54e-21	Myopia (pathological);
CRC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg22532475	chr10:104410764	TRIM8	-0.38	-6.26	-0.33	1.22e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg08336687	chr16:907744	LMF1	0.47	6.45	0.34	4.09e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg24644049	chr4:85504048	CDS1	0.87	7.12	0.37	7.01e-12	Skin colour saturation;
CRC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26734620	chr12:56694298	CS	-0.61	-5.71	-0.3	2.52e-8	Psoriasis vulgaris;
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.66	6.33	0.33	8.06e-10	Initial pursuit acceleration;
CRC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs863345	0.604	rs60104403	chr1:158500847	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.21	-0.32	1.61e-9	Pneumococcal bacteremia;
CRC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg07274523	chr3:49395745	GPX1	0.47	6.07	0.32	3.48e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.51	5.95	0.31	7e-9	Diastolic blood pressure;
CRC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.21	-0.45	3.96e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg08222913	chr3:52553049	STAB1	0.36	6.6	0.34	1.64e-10	Bipolar disorder;
CRC	trans	rs1147246	0.714	rs323852	chr12:125877998	A/G	cg23470196	chr14:102695671	RAGE	0.41	5.98	0.31	5.73e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs11212617	0.967	rs6589017	chr11:108308504	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.66	0.3	3.24e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.49	7.32	0.37	1.86e-12	Corneal astigmatism;
CRC	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.98	17.05	0.68	3.66e-47	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg10517650	chr3:113235015	CCDC52	-0.4	-6.95	-0.36	1.94e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.77e-10	Bladder cancer;
CRC	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	0.68	6.06	0.32	3.71e-9	Mean corpuscular volume;
CRC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.45	-6.66	-0.34	1.15e-10	Height;
CRC	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg11887960	chr12:57824829	NA	0.62	6.76	0.35	6.26e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.75	11.29	0.53	3.42e-25	Testicular germ cell tumor;
CRC	cis	rs375066	0.623	rs1909	chr19:44355517	C/T	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-6.89	-0.36	2.81e-11	Colorectal cancer;
CRC	cis	rs9491140	0.539	rs11154230	chr6:124686156	A/G	cg19267163	chr6:125004984	NKAIN2	0.44	6.01	0.31	4.88e-9	Neuroticism;
CRC	cis	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs929596	0.564	rs2602364	chr2:234524229	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.1	-0.32	3.04e-9	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.51	-6.87	-0.35	3.27e-11	Obesity-related traits;
CRC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	7.62	0.39	2.73e-13	Breast cancer;
CRC	cis	rs7680126	0.596	rs10489070	chr4:10276352	C/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.5	-0.34	2.91e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.58	7.53	0.38	4.97e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.6	9.3	0.46	2.06e-18	Itch intensity from mosquito bite;
CRC	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg10820045	chr2:198174542	NA	0.45	7.78	0.39	9.61e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg09264619	chr17:80180166	NA	-0.36	-6.04	-0.32	4.23e-9	Life satisfaction;
CRC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.56	7.99	0.4	2.33e-14	Lung cancer;
CRC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg00700412	chr12:58011837	NA	0.4	6.29	0.33	9.87e-10	Multiple sclerosis;
CRC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg08885800	chr1:201084119	NA	-0.47	-8.94	-0.44	2.87e-17	Permanent tooth development;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23753457	chr11:69455870	CCND1	0.47	6.71	0.35	8.38e-11	Response to antipsychotic treatment;
CRC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.18	0.37	4.61e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg06223162	chr1:101003688	GPR88	0.34	6.32	0.33	8.46e-10	Monocyte count;
CRC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-7.48	-0.38	6.87e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25356086	chr21:33764900	C21orf119;URB1	0.5	7.24	0.37	3.29e-12	Response to antipsychotic treatment;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.67	7.18	0.37	4.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.28	-0.56	8.4e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.92	13.23	0.59	2.5e-32	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23161317	chr6:28129485	ZNF389	0.46	6.02	0.31	4.79e-9	Depression;
CRC	trans	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.31	0.37	1.99e-12	Endometrial cancer;
CRC	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg27523141	chr10:43048294	ZNF37B	0.43	5.98	0.31	5.71e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg17903999	chr18:56338584	MALT1	0.42	6.79	0.35	5.11e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg18490616	chr2:88469792	THNSL2	0.61	6.1	0.32	2.9e-9	Plasma clusterin levels;
CRC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.75	-0.47	6.56e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06467769	chr19:37808668	NA	-0.4	-6.11	-0.32	2.78e-9	Myopia (pathological);
CRC	cis	rs315934	0.739	rs315920	chr2:113873018	A/G	cg24553058	chr2:113831203	IL1F10	0.49	6.06	0.32	3.72e-9	Dysmenorrheic pain;
CRC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-6.94	-0.36	2.04e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.74	-0.39	1.25e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg02007433	chr3:129722099	NA	-0.61	-9.15	-0.45	6.13e-18	Blood pressure (smoking interaction);
CRC	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.47	7.01	0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9292777	0.933	rs9292771	chr5:40434652	A/T	cg09067459	chr5:40385259	NA	0.51	8.87	0.44	4.77e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg12564285	chr5:131593104	PDLIM4	0.53	10.05	0.48	6.61e-21	Blood metabolite levels;
CRC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.81	-0.35	4.6e-11	Body mass index;
CRC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.56	-0.67	3.26e-45	Height;
CRC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.07	-17.38	-0.69	1.88e-48	Dilated cardiomyopathy;
CRC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-5.91	-0.31	8.76e-9	Bronchopulmonary dysplasia;
CRC	cis	rs72627123	0.749	rs10149956	chr14:74649106	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.71	-5.61	-0.3	4.32e-8	Morning vs. evening chronotype;
CRC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg12463550	chr7:65579703	CRCP	0.67	6.13	0.32	2.58e-9	Diabetic kidney disease;
CRC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.29	0.33	1e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.73	-12.39	-0.56	3.43e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.596	rs3903522	chr7:124668142	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.82e-9	Cutaneous malignant melanoma;
CRC	cis	rs13038095	1	rs13038095	chr20:46425576	A/C	cg21798815	chr20:46414765	SULF2	-0.62	-6.23	-0.32	1.45e-9	Atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22617550	chr15:89974231	NA	0.44	6.12	0.32	2.72e-9	Response to antipsychotic treatment;
CRC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg25173405	chr17:45401733	C17orf57	-0.59	-9.79	-0.47	4.97e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.56	6.25	0.33	1.25e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.48	6.38	0.33	6.04e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.68	-7.26	-0.37	2.85e-12	Type 2 diabetes;
CRC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.5	-0.34	3.03e-10	Daytime sleep phenotypes;
CRC	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07282944	chr12:48499338	SENP1;PFKM	0.46	6.36	0.33	6.56e-10	Response to antipsychotic treatment;
CRC	cis	rs4363385	0.818	rs532743	chr1:153011758	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-7.0	-0.36	1.49e-11	Inflammatory skin disease;
CRC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg17885791	chr6:149771845	ZC3H12D	0.32	5.77	0.3	1.88e-8	Dupuytren's disease;
CRC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	6.08e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg26028573	chr6:26043587	HIST1H2BB	0.47	7.22	0.37	3.59e-12	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg18876405	chr7:65276391	NA	-0.46	-6.27	-0.33	1.13e-9	Aortic root size;
CRC	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07513332	chr6:167530253	CCR6	-0.32	-5.6	-0.3	4.41e-8	Rheumatoid arthritis;
CRC	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg15654264	chr1:150340011	RPRD2	0.39	5.98	0.31	5.74e-9	Migraine;
CRC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.43	-0.46	7.61e-19	HDL cholesterol;
CRC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.68	9.48	0.46	5.09e-19	Gestational age at birth (maternal effect);
CRC	cis	rs3118233	1	rs3118233	chr16:68733646	G/C	cg02972257	chr16:68554789	NA	0.45	5.68	0.3	2.95e-8	Red cell distribution width;
CRC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.59	8.63	0.43	2.6e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg10756647	chr7:56101905	PSPH	0.69	7.49	0.38	6.37e-13	Diabetic kidney disease;
CRC	trans	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	6.06	0.32	3.69e-9	Metabolite levels;
CRC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.69	-10.31	-0.49	8.63e-22	Initial pursuit acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13659026	chr2:85788631	GGCX	0.39	6.3	0.33	9.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg21620606	chr4:1342894	KIAA1530	0.37	6.4	0.33	5.42e-10	Obesity-related traits;
CRC	trans	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg11693508	chr17:37793320	STARD3	0.62	8.39	0.42	1.48e-15	Bipolar disorder;
CRC	trans	rs12940923	1.000	rs34770605	chr17:56376206	C/T	cg16900910	chr15:72789182	ARIH1	0.53	6.04	0.32	4.19e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.85	-9.74	-0.47	7.39e-20	Breast cancer;
CRC	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-6.25	-0.33	1.25e-9	Cardiovascular disease risk factors;
CRC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	10.99	0.52	3.91e-24	Platelet count;
CRC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg17724175	chr1:150552817	MCL1	0.49	7.14	0.37	5.93e-12	Melanoma;
CRC	cis	rs9648716	1.000	rs986050	chr7:140490928	C/A	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.1e-8	Type 2 diabetes;
CRC	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.57	-0.34	1.93e-10	Acne (severe);
CRC	cis	rs6764363	0.587	rs7646675	chr3:276273	C/T	cg02057681	chr3:285234	CHL1	0.43	7.19	0.37	4.31e-12	Sudden cardiac arrest;
CRC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg11292332	chr7:45801988	SEPT13	-0.38	-6.86	-0.35	3.49e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg00042356	chr1:8021962	PARK7	0.52	5.94	0.31	7.41e-9	Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg09659197	chr4:152720779	NA	0.4	7.97	0.4	2.62e-14	Intelligence (multi-trait analysis);
CRC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-6.01	-0.31	4.95e-9	Eosinophil percentage of white cells;
CRC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg24289452	chr6:170231220	NA	-0.59	-6.6	-0.34	1.63e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.91	16.64	0.68	1.56e-45	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.59	10.59	0.5	9.48e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg09127314	chr1:152161683	NA	-0.45	-5.61	-0.3	4.29e-8	Atopic dermatitis;
CRC	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg04110750	chr16:69646130	NFAT5	-0.52	-7.11	-0.36	7.26e-12	IgE levels;
CRC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.49	-8.47	-0.42	8.44e-16	Facial morphology (factor 20);
CRC	trans	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg20935933	chr6:143382018	AIG1	0.53	6.78	0.35	5.42e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg04455712	chr21:45112962	RRP1B	0.38	7.35	0.38	1.57e-12	Mean corpuscular volume;
CRC	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.37	0.42	1.7e-15	Coffee consumption (cups per day);
CRC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg19193384	chr17:30244184	NA	-0.53	-6.65	-0.34	1.19e-10	Hip circumference adjusted for BMI;
CRC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.54	9.37	0.46	1.16e-18	Height;
CRC	cis	rs13315871	1.000	rs71311865	chr3:58372423	G/A	cg20936604	chr3:58311152	NA	-0.73	-6.69	-0.35	9.48e-11	Cholesterol, total;
CRC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.88	0.35	3.09e-11	Melanoma;
CRC	cis	rs1519814	0.740	rs4348544	chr8:121044090	T/C	cg22335954	chr8:121166405	COL14A1	-0.51	-5.78	-0.3	1.72e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26957012	chr11:65305575	SCYL1	-0.35	-5.96	-0.31	6.52e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06110578	chr6:43597079	MAD2L1BP;GTPBP2	-0.55	-6.46	-0.34	3.82e-10	Diisocyanate-induced asthma;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.79	-12.9	-0.58	4.41e-31	Height;
CRC	cis	rs758324	0.812	rs13174462	chr5:131217988	A/G	cg25547332	chr5:131281432	NA	0.35	5.61	0.3	4.4e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.43	6.85	0.35	3.59e-11	Blood metabolite levels;
CRC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.46	9.28	0.46	2.4e-18	Prostate cancer;
CRC	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg09760422	chr2:128146352	NA	-0.36	-6.9	-0.36	2.6e-11	Protein C levels;
CRC	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg07166546	chr14:35805898	NA	-0.3	-5.89	-0.31	9.79e-9	Hip circumference adjusted for BMI;
CRC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.36	5.92	0.31	8.06e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.05	-0.32	3.99e-9	Height;
CRC	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.7	9.16	0.45	5.53e-18	Dementia with Lewy bodies;
CRC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg11212589	chr17:38028394	ZPBP2	0.33	5.63	0.3	3.8e-8	Asthma;
CRC	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.9	-0.4	4.33e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.8	-0.3	1.59e-8	Life satisfaction;
CRC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.7	-9.11	-0.45	8.53e-18	Initial pursuit acceleration;
CRC	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-7.53	-0.38	4.94e-13	Metabolite levels;
CRC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg10978503	chr1:24200527	CNR2	0.51	8.82	0.44	6.58e-17	Immature fraction of reticulocytes;
CRC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07970400	chr15:40650285	DISP2	0.37	6.02	0.31	4.65e-9	Obesity-related traits;
CRC	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.6	-8.01	-0.4	2.03e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.48	0.42	7.52e-16	Coffee consumption (cups per day);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09284707	chr11:107799080	RAB39	-0.33	-6.17	-0.32	1.96e-9	Myopia (pathological);
CRC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.62	9.28	0.46	2.37e-18	Obesity-related traits;
CRC	cis	rs4700695	1.000	rs4700695	chr5:65411710	G/T	cg21114390	chr5:65439923	SFRS12	-0.62	-6.67	-0.35	1.05e-10	Facial morphology (factor 19);
CRC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.52	7.15	0.37	5.58e-12	Migraine;
CRC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.56	-5.79	-0.3	1.65e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.43	-5.63	-0.3	3.85e-8	Heschl's gyrus morphology;
CRC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.58	8.13	0.41	8.73e-15	Height;
CRC	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg21535247	chr6:8435926	SLC35B3	-0.41	-6.0	-0.31	5.22e-9	Motion sickness;
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg09877947	chr5:131593287	PDLIM4	-0.47	-8.88	-0.44	4.27e-17	Breast cancer;
CRC	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.43	-6.67	-0.35	1.07e-10	C-reactive protein levels;
CRC	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.63	9.91	0.48	2.03e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2457480	0.866	rs10160170	chr10:44692843	A/G	cg09554077	chr10:44749378	NA	0.48	5.8	0.3	1.54e-8	Coronary artery disease;
CRC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.59	7.08	0.36	8.54e-12	Menarche (age at onset);
CRC	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.78	-0.39	9.48e-14	Coronary artery disease;
CRC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.8	13.98	0.61	3.38e-35	Breast cancer;
CRC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.15	0.32	2.26e-9	Asthma;
CRC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.2e-12	Corneal astigmatism;
CRC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.21e-15	Bladder cancer;
CRC	trans	rs9693857	0.520	rs13267391	chr8:9356714	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.25	0.33	1.27e-9	Systolic blood pressure;
CRC	trans	rs4653663	0.599	rs4653665	chr1:225941904	T/G	cg08367804	chr16:3639160	BTBD12	-0.34	-5.97	-0.31	6.02e-9	Neuroticism;
CRC	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-6.01	-0.31	4.97e-9	Daytime sleep phenotypes;
CRC	cis	rs3789045	1.000	rs11588857	chr1:204587047	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.49	-6.94	-0.36	2.05e-11	Educational attainment (college completion);
CRC	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.37	-6.64	-0.34	1.29e-10	Dilated cardiomyopathy;
CRC	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.24	-0.45	3.14e-18	Type 2 diabetes;
CRC	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg07423050	chr13:99094983	FARP1	0.38	6.04	0.32	4.19e-9	Longevity;
CRC	cis	rs995000	0.965	rs12116574	chr1:63037837	C/T	cg19896129	chr1:63156450	NA	0.39	5.72	0.3	2.39e-8	Triglyceride levels;
CRC	cis	rs6479527	0.773	rs10739967	chr9:96757117	A/G	cg14459158	chr9:96720562	NA	0.41	7.41	0.38	1.09e-12	Esophageal adenocarcinoma;
CRC	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg03929089	chr4:120376271	NA	0.63	6.33	0.33	8.23e-10	Axial length;
CRC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.56	-9.86	-0.48	2.86e-20	Huntington's disease progression;
CRC	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs427941	0.703	rs201446	chr7:101738323	C/G	cg06246474	chr7:101738831	CUX1	0.46	7.16	0.37	5.46e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.84	-12.73	-0.57	1.79e-30	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.55	0.5	1.28e-22	Fuchs's corneal dystrophy;
CRC	trans	rs10242455	0.702	rs73713580	chr7:99241610	C/T	cg09045935	chr12:6379348	NA	0.92	6.84	0.35	3.8e-11	Blood metabolite levels;
CRC	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg04110750	chr16:69646130	NFAT5	-0.56	-7.62	-0.39	2.73e-13	IgE levels;
CRC	cis	rs2230307	0.656	rs644835	chr1:100543962	A/G	cg24955406	chr1:100503596	HIAT1	0.59	6.09	0.32	3.11e-9	Carotid intima media thickness;
CRC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.4	0.33	5.43e-10	Bladder cancer;
CRC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg15358701	chr1:161410459	NA	-0.6	-6.44	-0.33	4.35e-10	Rheumatoid arthritis;
CRC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.35	-0.46	1.35e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	trans	rs10411161	0.702	rs7251929	chr19:52389258	C/T	cg22319618	chr22:45562946	NUP50	-0.62	-6.51	-0.34	2.78e-10	Breast cancer;
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.02	0.31	4.75e-9	Prudent dietary pattern;
CRC	cis	rs7172809	0.643	rs61483316	chr15:77834147	C/T	cg10437265	chr15:77819839	NA	-0.37	-5.99	-0.31	5.45e-9	Glucose homeostasis traits;
CRC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg13047869	chr3:10149882	C3orf24	0.53	6.47	0.34	3.57e-10	Alzheimer's disease;
CRC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.56	-6.93	-0.36	2.21e-11	Body mass index;
CRC	trans	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.55	-0.34	2.22e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.57	-0.34	1.91e-10	Depression;
CRC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg17724175	chr1:150552817	MCL1	-0.46	-7.28	-0.37	2.55e-12	Tonsillectomy;
CRC	cis	rs2108622	0.727	rs62107764	chr19:15982658	A/G	cg13772218	chr19:15982569	NA	0.49	7.01	0.36	1.39e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.21	0.32	1.55e-9	Blood metabolite levels;
CRC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.61	8.92	0.44	3.25e-17	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.56	-8.23	-0.41	4.54e-15	Lewy body disease;
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.7	0.43	1.63e-16	Height;
CRC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.29	-0.49	1.03e-21	Tonsillectomy;
CRC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21643547	chr1:205240462	TMCC2	-0.44	-7.06	-0.36	1.01e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs6662572	0.703	rs6689417	chr1:46388008	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.76	-0.3	1.98e-8	Blood protein levels;
CRC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.52	8.59	0.43	3.45e-16	Type 2 diabetes;
CRC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	10.18	0.49	2.4e-21	Total body bone mineral density;
CRC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.63	0.47	1.71e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.51	-9.67	-0.47	1.21e-19	Schizophrenia;
CRC	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs9549328	0.614	rs35872678	chr13:113617231	A/T	cg20742385	chr13:113633654	MCF2L	0.56	9.52	0.46	3.92e-19	Systolic blood pressure;
CRC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg03923535	chr7:1197113	ZFAND2A	0.41	5.65	0.3	3.53e-8	Longevity;Endometriosis;
CRC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg16141378	chr3:129829833	LOC729375	0.42	6.24	0.33	1.35e-9	Neuroticism;
CRC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.68e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.0	0.52	3.6e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg02135003	chr7:105160482	PUS7	-0.67	-10.2	-0.49	2.07e-21	Bipolar disorder (body mass index interaction);
CRC	cis	rs3018066	0.867	rs6852388	chr4:107011960	G/T	cg01869342	chr4:106983673	TBCK	0.37	5.69	0.3	2.79e-8	Cancer;
CRC	cis	rs2882667	0.690	rs288014	chr5:138195793	A/G	cg09476006	chr5:138032270	NA	-0.55	-9.83	-0.48	3.65e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg03623178	chr6:28175578	NA	0.83	6.72	0.35	7.91e-11	Depression;
CRC	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.36	0.62	1.26e-36	Hypertriglyceridemia;
CRC	trans	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg07817883	chr1:32538562	TMEM39B	1.56	13.2	0.59	3.14e-32	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7503807	0.515	rs869190	chr17:78668593	G/T	cg00549398	chr17:78725201	RPTOR	0.43	5.7	0.3	2.62e-8	Obesity;
CRC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.42	6.35	0.33	6.97e-10	Mean platelet volume;
CRC	cis	rs7705042	0.828	rs249677	chr5:141539339	C/A	cg07392085	chr5:141489673	NDFIP1	0.43	6.75	0.35	6.75e-11	Asthma;
CRC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.19	0.32	1.79e-9	Monocyte percentage of white cells;
CRC	cis	rs7712401	0.755	rs6595407	chr5:122100398	C/T	cg18764291	chr5:122110994	SNX2	0.41	6.46	0.34	3.7e-10	Mean platelet volume;
CRC	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg13491945	chr12:107078410	RFX4	0.34	5.92	0.31	7.9e-9	Heart rate;
CRC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg20243544	chr17:37824526	PNMT	0.37	5.69	0.3	2.82e-8	Self-reported allergy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06056004	chr5:44809616	MRPS30	0.43	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.81	-0.35	4.68e-11	Height;
CRC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg22495460	chr2:25135724	ADCY3	-0.78	-14.01	-0.61	2.67e-35	Body mass index in non-asthmatics;
CRC	cis	rs10242455	0.571	rs41279866	chr7:99315276	C/T	cg18809830	chr7:99032528	PTCD1	-1.05	-7.59	-0.39	3.23e-13	Blood metabolite levels;
CRC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.81	-0.35	4.65e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00004979	chr12:111885466	SH2B3	-0.38	-6.17	-0.32	2.01e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6479527	0.840	rs987511	chr9:96757868	C/T	cg14459158	chr9:96720562	NA	0.42	7.62	0.39	2.69e-13	Esophageal adenocarcinoma;
CRC	cis	rs11212617	0.967	rs11605442	chr11:108077857	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.62	0.34	1.44e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.46	-6.96	-0.36	1.89e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.33	1.01e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.61	-8.29	-0.42	2.95e-15	White matter hyperintensity burden;
CRC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.49	-7.07	-0.36	9.19e-12	Pulse pressure;
CRC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-18.4	-0.71	1.8e-52	Height;
CRC	cis	rs1178968	0.901	rs1178958	chr7:72777384	G/A	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg00255919	chr5:131827918	IRF1	-0.35	-6.04	-0.32	4.22e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg15226275	chr6:116381976	FRK	0.3	7.25	0.37	3e-12	Total cholesterol levels;
CRC	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg01388757	chr2:102091195	RFX8	-0.35	-5.81	-0.3	1.5e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-1.21	-11.41	-0.53	1.29e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg16141378	chr3:129829833	LOC729375	-0.42	-6.17	-0.32	2.04e-9	Mood instability;
CRC	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg12573674	chr2:1569213	NA	-0.65	-7.65	-0.39	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	6.45	0.34	3.98e-10	Blood metabolite levels;
CRC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg12439463	chr17:79848761	ANAPC11;THOC4	-0.41	-6.05	-0.32	4.05e-9	Daytime sleep phenotypes;
CRC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.79	-10.49	-0.5	2.05e-22	Initial pursuit acceleration;
CRC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.91	-0.31	8.75e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.04	-0.32	4.06e-9	Menopause (age at onset);
CRC	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.6	-9.02	-0.45	1.57e-17	Inhibitory control;
CRC	cis	rs7605827	0.930	rs4668903	chr2:15530051	C/G	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg26605046	chr4:2439731	NA	-0.42	-6.49	-0.34	3.18e-10	Cognitive function;
CRC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.76	8.49	0.42	7.17e-16	Tuberculosis;
CRC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg06494592	chr3:125709126	NA	-0.57	-6.78	-0.35	5.71e-11	Blood pressure (smoking interaction);
CRC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.57	7.0	0.36	1.43e-11	Response to diuretic therapy;
CRC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg17401720	chr7:158221031	PTPRN2	-0.41	-6.7	-0.35	9.01e-11	Obesity-related traits;
CRC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.46	-6.93	-0.36	2.18e-11	Colorectal cancer;
CRC	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg06204229	chr3:52865917	ITIH4	0.49	5.68	0.3	2.95e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg21854759	chr1:92012499	NA	-0.53	-8.76	-0.43	1.05e-16	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17270843	chr10:99079074	FRAT1	-0.33	-6.48	-0.34	3.28e-10	Myopia (pathological);
CRC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.14	0.32	2.31e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.27	-5.9	-0.31	9.13e-9	Educational attainment (years of education);
CRC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03676636	chr4:99064102	C4orf37	0.22	6.19	0.32	1.83e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4237845	0.611	rs9971722	chr12:58308383	G/T	cg02175503	chr12:58329896	NA	0.78	12.36	0.56	4.24e-29	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.43	6.36	0.33	6.77e-10	Menopause (age at onset);
CRC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg19980929	chr12:42632907	YAF2	0.45	6.87	0.35	3.17e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.45	-6.02	-0.31	4.77e-9	Tuberculosis;
CRC	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-7.9	-0.4	4.16e-14	Menarche (age at onset);
CRC	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.57	-0.43	3.99e-16	Biliary atresia;
CRC	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg04990556	chr1:26633338	UBXN11	0.52	5.68	0.3	3.04e-8	Obesity-related traits;
CRC	cis	rs2521295	1.000	rs2521295	chr11:2348860	T/A	cg09785033	chr11:2336066	TSPAN32	-0.53	-6.24	-0.33	1.36e-9	Monocyte count;
CRC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.65	10.29	0.49	1.04e-21	Colorectal cancer;
CRC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.69	-11.58	-0.54	3.12e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.12	-0.32	2.59e-9	Aortic root size;
CRC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.43	-0.38	9.74e-13	Coronary artery disease;
CRC	trans	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs427941	0.632	rs201507	chr7:101764141	T/C	cg06246474	chr7:101738831	CUX1	0.44	6.81	0.35	4.77e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18069125	chr20:45439836	NA	-0.3	-5.98	-0.31	5.74e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.63	-0.34	1.37e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6123683	0.752	rs6070035	chr20:55825693	A/G	cg13236649	chr20:55835020	BMP7	0.43	6.78	0.35	5.64e-11	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08635118	chr7:6144369	USP42	0.45	6.14	0.32	2.39e-9	Anxiety disorder;
CRC	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-7.17	-0.37	4.91e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.55	9.13	0.45	7.17e-18	Menarche (age at onset);
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03923535	chr7:1197113	ZFAND2A	0.68	9.98	0.48	1.2e-20	Longevity;Endometriosis;
CRC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.82	11.35	0.53	2.12e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.18	-0.56	1.98e-28	Coffee consumption (cups per day);
CRC	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.55	-6.71	-0.35	8.75e-11	Dental caries;
CRC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.77	12.28	0.56	8.8e-29	Breast cancer;
CRC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg08755490	chr11:65554678	OVOL1	0.4	5.79	0.3	1.66e-8	Acne (severe);
CRC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg05044414	chr3:183734942	ABCC5	0.48	8.34	0.42	2.1e-15	Anterior chamber depth;
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg15763984	chr4:1342303	KIAA1530	0.44	6.9	0.36	2.74e-11	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00067102	chr1:241803367	OPN3	0.44	6.39	0.33	5.6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.56	-8.96	-0.44	2.44e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4663866	1.000	rs6734408	chr2:239137481	A/C	cg16914508	chr2:239161102	PER2	0.73	7.85	0.4	5.82e-14	Irritable bowel syndrome;
CRC	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg23260525	chr10:116636907	FAM160B1	0.32	6.85	0.35	3.73e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg00919237	chr7:87102261	ABCB4	-0.54	-7.18	-0.37	4.66e-12	Gallbladder cancer;
CRC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-18.41	-0.71	1.64e-52	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.83	-0.31	1.36e-8	Life satisfaction;
CRC	cis	rs6694672	1.000	rs1759009	chr1:197026672	C/T	cg13682187	chr1:196946512	CFHR5	-0.46	-7.78	-0.39	9.67e-14	Asthma;
CRC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg15832292	chr6:96025679	MANEA	0.59	6.08	0.32	3.41e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.23	-9.95	-0.48	1.45e-20	Mitochondrial DNA levels;
CRC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.64	7.3	0.37	2.2e-12	IgG glycosylation;
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.82	12.47	0.57	1.73e-29	Menarche (age at onset);
CRC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.26	-0.37	2.76e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.53	6.88	0.35	3.02e-11	Alzheimer's disease (survival time);
CRC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.33	-0.33	8.01e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3751196	0.901	rs12422615	chr12:104184884	A/G	cg02344784	chr12:104178138	NT5DC3	0.68	7.26	0.37	2.79e-12	Sense of smell;
CRC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg18876405	chr7:65276391	NA	0.44	6.18	0.32	1.89e-9	Aortic root size;
CRC	cis	rs16975963	0.843	rs73041045	chr19:38296026	C/T	cg15135657	chr19:38346511	NA	-0.44	-5.94	-0.31	7.12e-9	Longevity;
CRC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.83	-0.4	6.87e-14	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06510711	chr12:123849672	NA	0.48	6.05	0.32	3.96e-9	Thyroid stimulating hormone;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg06930513	chr13:20623578	ZMYM2	0.47	6.22	0.32	1.52e-9	Hip circumference;
CRC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.48	7.02	0.36	1.3e-11	Melanoma;
CRC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.54e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.92	-0.4	3.7e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs3106136	0.814	rs6839224	chr4:95279214	A/C	cg11021082	chr4:95130006	SMARCAD1	0.36	5.63	0.3	3.84e-8	Capecitabine sensitivity;
CRC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg25767906	chr1:53392781	SCP2	0.47	7.49	0.38	6.24e-13	Monocyte count;
CRC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.82	-0.31	1.43e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.48	-0.34	3.36e-10	Blood metabolite levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11381792	chr21:45432451	TRAPPC10	0.49	6.94	0.36	2.08e-11	Survival in pancreatic cancer;
CRC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg26566898	chr11:117069891	TAGLN	0.42	8.1	0.41	1.05e-14	Blood protein levels;
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07167872	chr1:205819463	PM20D1	0.41	5.78	0.3	1.74e-8	Parkinson's disease;
CRC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg08314208	chr16:67682810	RLTPR	-0.58	-6.23	-0.32	1.47e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg20933634	chr6:27740509	NA	0.57	8.5	0.42	6.56e-16	Parkinson's disease;
CRC	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg02135003	chr7:105160482	PUS7	-0.52	-8.07	-0.41	1.32e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.55e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg07168214	chr17:7380112	ZBTB4	0.39	5.91	0.31	8.66e-9	Androgen levels;
CRC	cis	rs9969804	1.000	rs9969804	chr9:95429120	A/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.74	-0.3	2.18e-8	Height;
CRC	cis	rs17767392	0.813	rs11848785	chr14:72057355	G/A	cg13720639	chr14:72061746	SIPA1L1	0.5	6.34	0.33	7.64e-10	Mitral valve prolapse;
CRC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.55	-0.38	4.32e-13	Aortic root size;
CRC	cis	rs863345	0.604	rs1873511	chr1:158461366	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	7.07	0.36	9.38e-12	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.72	-8.29	-0.42	2.99e-15	Obesity-related traits;
CRC	trans	rs9630182	0.540	rs11022834	chr11:13479364	T/C	cg13741668	chr9:85679694	NA	0.37	5.97	0.31	6.12e-9	Bone mineral density;
CRC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg08222913	chr3:52553049	STAB1	-0.38	-7.12	-0.37	6.74e-12	Electroencephalogram traits;
CRC	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.53	7.34	0.38	1.68e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15604425	chr10:103825102	HPS6	0.49	6.98	0.36	1.62e-11	Response to antipsychotic treatment;
CRC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.86	0.31	1.1e-8	Hip circumference adjusted for BMI;
CRC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.32	2.93e-9	Arsenic metabolism;
CRC	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.04	0.36	1.15e-11	Menarche (age at onset);
CRC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.36	-13.12	-0.59	6.59e-32	Plateletcrit;
CRC	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg15485101	chr11:133734466	NA	0.39	7.16	0.37	5.37e-12	Childhood ear infection;
CRC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18912574	chr7:65842487	NCRNA00174	0.38	6.49	0.34	3.1e-10	Aortic root size;
CRC	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.53	7.27	0.37	2.59e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs3804749	0.966	rs920900	chr3:122845671	C/G	cg26084141	chr3:122786895	PDIA5	-0.22	-5.77	-0.3	1.81e-8	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-7.94	-0.4	3.3e-14	HDL cholesterol;
CRC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.38	0.33	6.16e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs3020333	0.755	rs851996	chr6:152016803	C/T	cg22157087	chr6:152012887	ESR1	0.5	7.58	0.39	3.54e-13	Total body bone mineral density;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg18301423	chr5:131593218	PDLIM4	0.39	6.42	0.33	4.87e-10	Breast cancer;
CRC	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.57	8.23	0.41	4.44e-15	Carotid intima media thickness;
CRC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg24289452	chr6:170231220	NA	-0.57	-6.21	-0.32	1.6e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.09	18.67	0.72	1.44e-53	Cognitive function;
CRC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg06713675	chr4:122721982	EXOSC9	0.4	6.48	0.34	3.27e-10	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16076804	chr14:45366412	C14orf28	0.44	6.23	0.32	1.42e-9	Response to antipsychotic treatment;
CRC	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg15705551	chr2:10952987	PDIA6	0.43	5.9	0.31	9.09e-9	Cardiac Troponin-T levels;
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg10729496	chr3:10149963	C3orf24	0.54	6.87	0.35	3.26e-11	Alzheimer's disease;
CRC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-9.53	-0.47	3.62e-19	Alcohol dependence;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08187779	chr8:102217898	ZNF706	-0.41	-6.39	-0.33	5.62e-10	Myopia (pathological);
CRC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.66	-0.34	1.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg24879335	chr3:133465180	TF	0.37	6.92	0.36	2.42e-11	Iron status biomarkers;
CRC	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.43	-0.38	9.2e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.16	-12.06	-0.55	5.57e-28	Breast cancer;
CRC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.75	12.45	0.57	2e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	13.22	0.59	2.82e-32	Schizophrenia;
CRC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.18	-0.37	4.65e-12	Mean corpuscular volume;
CRC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.55	8.26	0.41	3.49e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.58	-5.86	-0.31	1.11e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.76	-0.35	6.37e-11	Multiple sclerosis;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg03623178	chr6:28175578	NA	0.65	8.93	0.44	3.16e-17	Parkinson's disease;
CRC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg05673287	chr15:77411982	SGK269	-0.56	-8.61	-0.43	3.13e-16	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15635336	chr19:4182521	SIRT6;ANKRD24	0.4	6.18	0.32	1.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.36	-13.12	-0.59	6.59e-32	Plateletcrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01083650	chr1:202858430	RABIF	0.5	6.88	0.35	3.05e-11	Response to antipsychotic treatment;
CRC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	7.22	0.37	3.57e-12	Myopia (pathological);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02442412	chr4:83720054	SCD5	-0.4	-6.46	-0.34	3.88e-10	Aortic root size;
CRC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.9	-0.36	2.63e-11	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10729317	chr20:2821390	FAM113A;VPS16	0.4	6.49	0.34	3.11e-10	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03031933	chr8:145598519	ADCK5	0.42	7.38	0.38	1.33e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.65	9.92	0.48	1.82e-20	Tuberculosis;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg15786705	chr6:28176104	NA	0.68	9.73	0.47	8.1e-20	Parkinson's disease;
CRC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg05139728	chr16:28306816	SBK1	-0.37	-5.93	-0.31	7.65e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18402987	chr7:1209562	NA	0.42	6.25	0.33	1.29e-9	Longevity;Endometriosis;
CRC	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.52	-6.1	-0.32	3.03e-9	Blood protein levels;
CRC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.63e-9	Rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg10760299	chr15:45669010	GATM	0.5	7.82	0.4	7.18e-14	Homoarginine levels;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg12172441	chr6:28176163	NA	0.48	5.69	0.3	2.81e-8	Breast cancer;
CRC	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.75	8.52	0.43	5.81e-16	Neuroticism;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg25164649	chr6:28176230	NA	0.55	5.75	0.3	2e-8	Depression;
CRC	cis	rs7215564	0.908	rs7501497	chr17:78660738	T/C	cg09596252	chr17:78655493	RPTOR	0.54	5.73	0.3	2.25e-8	Myopia (pathological);
CRC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.21	-0.32	1.58e-9	Alzheimer's disease (late onset);
CRC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.49	9.55	0.47	3.16e-19	Iron status biomarkers (transferrin levels);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23288521	chr20:37075451	SNORA39;SNHG11	0.45	6.56	0.34	2.06e-10	Response to antipsychotic treatment;
CRC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.48	-5.81	-0.31	1.47e-8	Diastolic blood pressure;
CRC	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg25856811	chr1:152973957	SPRR3	-0.22	-6.01	-0.31	4.96e-9	Inflammatory skin disease;
CRC	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg02683197	chr6:28174875	NA	0.86	8.08	0.41	1.22e-14	Parkinson's disease;
CRC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.51	-5.92	-0.31	8.16e-9	Vitiligo;
CRC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.14e-9	Hair morphology;
CRC	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.42	-8.13	-0.41	8.87e-15	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.84	-11.06	-0.52	2.14e-24	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs11654801	0.812	rs9972887	chr17:20876472	A/G	cg23759823	chr7:139672531	TBXAS1	-0.42	-6.35	-0.33	7.07e-10	Mosquito bite size;
CRC	cis	rs35520189	0.591	rs34027384	chr2:113698094	G/A	cg12858261	chr2:113808755	IL1F8	0.46	6.1	0.32	3.05e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.81	-0.55	4.47e-27	Type 2 diabetes;
CRC	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg27398640	chr15:77910606	LINGO1	-0.44	-7.53	-0.38	4.81e-13	Type 2 diabetes;
CRC	cis	rs11120822	0.787	rs11120829	chr1:7123793	A/C	cg20434152	chr1:7120926	CAMTA1	-0.4	-7.15	-0.37	5.79e-12	Stearic acid (18:0) levels;
CRC	cis	rs9287719	0.601	rs10177062	chr2:10713698	C/T	cg00105475	chr2:10696890	NA	0.48	7.3	0.37	2.23e-12	Prostate cancer;
CRC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.57	0.34	1.93e-10	Lung cancer;
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4237845	0.637	rs7299249	chr12:58343710	C/T	cg00677455	chr12:58241039	CTDSP2	0.4	5.67	0.3	3.08e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg20387954	chr3:183756860	HTR3D	0.44	7.37	0.38	1.43e-12	Anterior chamber depth;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg12273811	chr6:28175739	NA	0.45	6.71	0.35	8.28e-11	Cardiac Troponin-T levels;
CRC	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.93	11.47	0.53	7.55e-26	Diisocyanate-induced asthma;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.51	7.44	0.38	8.99e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-5.95	-0.31	6.95e-9	Alzheimer's disease (survival time);
CRC	cis	rs9925964	0.933	rs9923231	chr16:31107689	C/T	cg03418659	chr16:31128414	MYST1	0.47	6.75	0.35	6.72e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.79	9.53	0.47	3.55e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg25456477	chr12:86230367	RASSF9	0.32	5.61	0.3	4.38e-8	Major depressive disorder;
CRC	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.56	6.26	0.33	1.22e-9	RR interval (heart rate);
CRC	cis	rs2249694	1.000	rs2480258	chr10:135352100	T/C	cg20169779	chr10:135381914	SYCE1	0.54	8.67	0.43	1.93e-16	Obesity-related traits;
CRC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.41	0.46	8.86e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	1.0	12.65	0.57	3.79e-30	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.3	0.37	2.15e-12	Life satisfaction;
CRC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.4	6.01	0.31	4.81e-9	Hemoglobin concentration;
CRC	cis	rs1018836	0.923	rs12545726	chr8:91532087	T/A	cg16814680	chr8:91681699	NA	-0.7	-11.14	-0.52	1.15e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1656402	1.000	rs1656399	chr2:233427803	C/T	cg03852847	chr2:233439513	NA	0.43	7.47	0.38	7.25e-13	Non-small cell lung cancer (survival);
CRC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg13607699	chr17:42295918	UBTF	-0.46	-6.07	-0.32	3.57e-9	Total body bone mineral density;
CRC	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.62	-7.66	-0.39	2.12e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02290350	chr8:58132656	NA	-0.42	-6.06	-0.32	3.67e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg18187862	chr3:45730750	SACM1L	-0.43	-5.99	-0.31	5.56e-9	Primary sclerosing cholangitis;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg06896663	chr8:82754093	SNX16	-0.69	-5.98	-0.31	5.75e-9	Cognitive function;
CRC	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.46	-7.29	-0.37	2.28e-12	Schizophrenia;
CRC	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.61	11.02	0.52	2.99e-24	Blood metabolite ratios;
CRC	trans	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg10756647	chr7:56101905	PSPH	0.73	7.85	0.4	5.73e-14	Diabetic kidney disease;
CRC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.55	8.11	0.41	1.01e-14	Lung cancer;
CRC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.78	0.35	5.74e-11	Obesity-related traits;
CRC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-10.68	-0.51	4.75e-23	Asthma;
CRC	cis	rs11212617	0.967	rs227040	chr11:108223391	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.41	0.33	5.07e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2880765	0.546	rs11637726	chr15:86059271	C/T	cg10818794	chr15:86012489	AKAP13	0.42	6.11	0.32	2.88e-9	Coronary artery disease;
CRC	cis	rs9462027	0.606	rs9462024	chr6:34772793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.04	-0.32	4.26e-9	Systemic lupus erythematosus;
CRC	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.46	6.96	0.36	1.91e-11	Menopause (age at onset);
CRC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.08	0.45	1.02e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.36	6.03	0.32	4.48e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.63	-11.27	-0.53	3.95e-25	Aortic root size;
CRC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.82	11.69	0.54	1.24e-26	Cognitive function;
CRC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	17.24	0.69	6.55e-48	Electrocardiographic conduction measures;
CRC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg00343986	chr7:65444356	GUSB	-0.47	-6.89	-0.36	2.79e-11	Calcium levels;
CRC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-11.4	-0.53	1.3e-25	Height;
CRC	trans	rs885518	0.852	rs7040432	chr9:21776159	T/C	cg14925137	chr3:121554019	IQCB1;EAF2	0.54	5.99	0.31	5.37e-9	Lung adenocarcinoma;
CRC	cis	rs10924970	1.000	rs4660145	chr1:235350207	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.76	0.3	1.92e-8	Asthma;
CRC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.63	0.34	1.35e-10	Hip circumference adjusted for BMI;
CRC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	9.93	0.48	1.74e-20	Hemoglobin concentration;
CRC	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.36	-6.05	-0.32	4.01e-9	Sitting height ratio;
CRC	cis	rs6496667	0.865	rs7178854	chr15:90884634	G/A	cg04176472	chr15:90893244	GABARAPL3	0.59	6.6	0.34	1.6e-10	Rheumatoid arthritis;
CRC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.85	-0.44	5.66e-17	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17411103	chr17:65241599	HELZ	0.4	6.52	0.34	2.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.45	-6.23	-0.32	1.46e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.55	-7.74	-0.39	1.2e-13	IgG glycosylation;
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-6.67	-0.35	1.07e-10	Lymphocyte counts;
CRC	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26850624	chr5:429559	AHRR	-0.77	-12.45	-0.57	1.99e-29	Cystic fibrosis severity;
CRC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.29	-5.87	-0.31	1.05e-8	Homoarginine levels;
CRC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.86	9.51	0.46	4.18e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg25363559	chr8:143086065	NA	-0.32	-6.14	-0.32	2.42e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg19635926	chr16:89946313	TCF25	0.67	7.06	0.36	9.96e-12	Skin colour saturation;
CRC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.84	15.41	0.65	1.01e-40	Lewy body disease;
CRC	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg08265495	chr8:11212668	TDH	-0.34	-5.78	-0.3	1.77e-8	Neuroticism;
CRC	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg24289452	chr6:170231220	NA	-0.57	-6.21	-0.32	1.6e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.6	-10.23	-0.49	1.61e-21	Prudent dietary pattern;
CRC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.56	-6.87	-0.35	3.24e-11	Bronchopulmonary dysplasia;
CRC	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.76	9.95	0.48	1.4e-20	Bipolar disorder;
CRC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	9.3	0.46	2.01e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	trans	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg18288967	chr1:45987694	PRDX1	0.68	7.43	0.38	9.51e-13	Obesity-related traits;
CRC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.91	13.53	0.6	1.84e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs11212617	0.967	rs172895	chr11:108265876	C/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.4	0.33	5.26e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.65	-0.34	1.26e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg24375607	chr4:120327624	NA	-0.47	-7.51	-0.38	5.45e-13	Corneal astigmatism;
CRC	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg12315302	chr6:26189340	HIST1H4D	0.71	6.06	0.32	3.81e-9	Depression;
CRC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg27661571	chr11:113659931	NA	-0.95	-11.14	-0.52	1.11e-24	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06798479	chr14:102553207	HSP90AA1	0.44	6.04	0.32	4.21e-9	Anxiety disorder;
CRC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.44	6.47	0.34	3.64e-10	HIV-1 control;
CRC	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg25547332	chr5:131281432	NA	0.38	5.64	0.3	3.67e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.81	12.46	0.57	1.95e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.49	7.31	0.37	2.11e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.698	rs11979724	chr7:124451045	G/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.28e-9	Cutaneous malignant melanoma;
CRC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.81	-0.55	4.41e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-9.04	-0.45	1.36e-17	Prostate cancer;
CRC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	5.78	0.3	1.76e-8	Diabetic retinopathy;
CRC	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.75	-8.9	-0.44	3.82e-17	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	16.82	0.68	3.07e-46	Platelet count;
CRC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg02007433	chr3:129722099	NA	-0.45	-6.14	-0.32	2.35e-9	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02848331	chr11:134094369	NCAPD3;VPS26B	0.46	6.41	0.33	5.05e-10	Response to antipsychotic treatment;
CRC	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.31	6.04	0.32	4.13e-9	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs17095355	1.000	rs56273398	chr10:111708183	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.28	-0.37	2.53e-12	Biliary atresia;
CRC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.23	-0.37	3.45e-12	Eye color traits;
CRC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.84	0.44	5.75e-17	Morning vs. evening chronotype;
CRC	cis	rs995000	0.868	rs10889357	chr1:63160282	C/T	cg19896129	chr1:63156450	NA	0.4	5.92	0.31	8.23e-9	Triglyceride levels;
CRC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-10.44	-0.5	3.04e-22	Platelet distribution width;
CRC	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg17401720	chr7:158221031	PTPRN2	0.5	8.99	0.44	1.99e-17	Obesity-related traits;
CRC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.49	-8.02	-0.4	1.91e-14	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12208283	chr19:19303500	LOC729991-MEF2B;RFXANK;LOC729991	0.45	6.52	0.34	2.68e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg14768367	chr16:72042858	DHODH	-0.59	-6.58	-0.34	1.84e-10	Blood protein levels;
CRC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.69	10.31	0.49	8.56e-22	Lung cancer;
CRC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.39	-6.39	-0.33	5.8e-10	Red cell distribution width;
CRC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	15.71	0.65	6.77e-42	Platelet count;
CRC	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.06e-10	Hepatitis;
CRC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.75	0.39	1.18e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.7	0.39	1.63e-13	Neuroticism;
CRC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-8.19	-0.41	5.94e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.53	8.06	0.41	1.4e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00166722	chr3:10149974	C3orf24	0.58	7.87	0.4	5.06e-14	Alzheimer's disease;
CRC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg23141183	chr17:80185318	SLC16A3	0.41	5.67	0.3	3.1e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg08772003	chr10:104629869	AS3MT	-0.35	-6.12	-0.32	2.71e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg02135003	chr7:105160482	PUS7	0.68	10.23	0.49	1.59e-21	Bipolar disorder (body mass index interaction);
CRC	trans	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg21659725	chr3:3221576	CRBN	0.63	7.15	0.37	5.68e-12	Menarche (age at onset);
CRC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.86	-0.31	1.1e-8	Calcium levels;
CRC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg23625390	chr15:77176239	SCAPER	0.48	7.04	0.36	1.14e-11	Blood metabolite levels;
CRC	cis	rs1062746	0.544	rs17770933	chr16:87325729	C/T	cg02258303	chr16:87377426	FBXO31	-0.51	-7.32	-0.37	1.95e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.59	-0.39	3.32e-13	Thrombosis;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18301423	chr5:131593218	PDLIM4	0.38	7.21	0.37	3.98e-12	Breast cancer;
CRC	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg23920097	chr1:209922102	NA	-0.51	-6.39	-0.33	5.54e-10	Red blood cell count;
CRC	cis	rs78077440	1.000	rs75239587	chr5:40330302	G/A	cg09067459	chr5:40385259	NA	-0.54	-5.69	-0.3	2.87e-8	Multiple sclerosis;
CRC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg18132624	chr14:105716052	BTBD6;BRF1	0.45	7.35	0.38	1.56e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.44	5.86	0.31	1.1e-8	Mean platelet volume;
CRC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	13.76	0.6	2.47e-34	Schizophrenia;
CRC	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.73	-0.43	1.28e-16	Metabolite levels;
CRC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.8	0.48	4.77e-20	Common traits (Other);
CRC	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.48	7.47	0.38	7.15e-13	HDL cholesterol;
CRC	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.72	-0.39	1.37e-13	Homocysteine levels;
CRC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.44	-0.42	9.92e-16	Morning vs. evening chronotype;
CRC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.15	0.52	1.02e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7605827	0.930	rs2111455	chr2:15549882	C/T	cg19274914	chr2:15703543	NA	0.38	5.66	0.3	3.31e-8	Educational attainment (years of education);
CRC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.37	-6.72	-0.35	8.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.77	0.39	1.02e-13	Coronary heart disease;
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.02	-0.45	1.55e-17	Bipolar disorder;
CRC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.44	-7.98	-0.4	2.45e-14	Height;
CRC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.48	7.02	0.36	1.27e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg03790207	chr6:42947109	PEX6	-0.45	-6.34	-0.33	7.6e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18104674	chr18:60190218	ZCCHC2	0.49	6.58	0.34	1.88e-10	Anxiety disorder;
CRC	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.03	0.32	4.46e-9	Educational attainment (years of education);
CRC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.83	-0.44	6.38e-17	Aortic root size;
CRC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg04976154	chr16:1532411	NA	0.43	8.26	0.41	3.52e-15	Bone mineral density;
CRC	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg00012203	chr2:219082015	ARPC2	-0.38	-5.77	-0.3	1.84e-8	Ulcerative colitis;
CRC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.89	0.4	4.53e-14	Lung cancer;
CRC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg26816564	chr1:7831052	VAMP3	0.72	8.4	0.42	1.38e-15	Inflammatory bowel disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15564972	chr6:79787561	PHIP	0.47	6.37	0.33	6.5e-10	Anxiety disorder;
CRC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.15e-10	Mean platelet volume;
CRC	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs4481887	0.504	rs11204611	chr1:248364697	T/C	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-1.26	-10.23	-0.49	1.62e-21	Mitochondrial DNA levels;
CRC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.81	-0.48	4.27e-20	Neuroticism;
CRC	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.57	-5.85	-0.31	1.21e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.39	0.56	3.52e-29	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09655822	chr6:146136083	FBXO30	0.39	6.41	0.33	4.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.45	5.75	0.3	1.99e-8	Aortic root size;
CRC	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	13.69	0.6	4.38e-34	Platelet count;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg23641560	chr2:182755044	SSFA2	-0.37	-6.21	-0.32	1.62e-9	HDL cholesterol;
CRC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.38	-5.81	-0.3	1.51e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg25885038	chr17:56607967	SEPT4	-0.41	-6.54	-0.34	2.3e-10	Vitamin D levels;
CRC	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.67	-0.35	1.1e-10	Multiple sclerosis;
CRC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.08	0.36	8.96e-12	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.64	-9.99	-0.48	1.11e-20	Breast cancer;
CRC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.8	14.15	0.62	7.64e-36	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20630943	chr20:44563219	PCIF1	0.45	6.14	0.32	2.4e-9	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg12458913	chr13:53173898	NA	0.5	7.38	0.38	1.29e-12	Lewy body disease;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg21620606	chr4:1342894	KIAA1530	0.4	7.19	0.37	4.37e-12	Obesity-related traits;
CRC	cis	rs2929278	0.638	rs2016840	chr15:44211868	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.44	-6.15	-0.32	2.21e-9	Schizophrenia;
CRC	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg18809830	chr7:99032528	PTCD1	-1.18	-8.59	-0.43	3.66e-16	Blood metabolite levels;
CRC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.34	0.38	1.64e-12	Obesity-related traits;
CRC	cis	rs4561483	0.583	rs17236573	chr16:11994655	G/C	cg08843971	chr16:11963173	GSPT1	0.5	7.45	0.38	8.14e-13	Testicular germ cell tumor;
CRC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-6.68	-0.35	1.02e-10	Body mass index (adult);
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.03e-10	Bipolar disorder;
CRC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.5	8.29	0.42	2.85e-15	Aortic root size;
CRC	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.88	8.83	0.44	6.14e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2336384	1.000	rs6672267	chr1:12054911	A/G	cg13216073	chr1:12042593	MFN2	0.5	7.24	0.37	3.29e-12	Platelet count;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-8.32	-0.42	2.37e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.11	9.94	0.48	1.58e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.18	-0.32	1.9e-9	Menarche (age at onset);
CRC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.63	-9.2	-0.45	4.32e-18	Menarche (age at onset);
CRC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-9.21	-0.45	3.99e-18	Chronic sinus infection;
CRC	cis	rs6700896	0.966	rs4655729	chr1:66082471	A/G	cg04111102	chr1:66153794	NA	0.35	6.21	0.32	1.56e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.72	-0.3	2.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg27532560	chr4:187881888	NA	-0.55	-10.08	-0.49	5.4e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg14003231	chr6:33640908	ITPR3	0.55	8.75	0.43	1.16e-16	Plateletcrit;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14059817	chr7:64466808	NA	0.38	6.02	0.31	4.54e-9	Obesity-related traits;
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.75	-0.47	7e-20	Primary sclerosing cholangitis;
CRC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.46e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg04110750	chr16:69646130	NFAT5	-0.52	-7.0	-0.36	1.46e-11	IgE levels;
CRC	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg02927042	chr1:21476669	EIF4G3	0.37	5.96	0.31	6.48e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.94e-9	Schizophrenia;
CRC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.53	-0.43	5.31e-16	Chronic sinus infection;
CRC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.11	0.32	2.75e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4481887	0.535	rs7512756	chr1:248362179	T/C	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs3823572	0.542	rs62470445	chr7:133630961	T/C	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Intelligence (multi-trait analysis);
CRC	trans	rs3001167	0.609	rs10921619	chr1:194561967	C/T	cg22004422	chr13:113740730	MCF2L	-0.61	-6.19	-0.32	1.78e-9	Obesity-related traits;
CRC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	10.12	0.49	3.87e-21	HIV-1 control;
CRC	cis	rs16975963	0.793	rs73034946	chr19:38460493	T/C	cg15135657	chr19:38346511	NA	-0.44	-5.8	-0.3	1.52e-8	Longevity;
CRC	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.61	0.34	1.59e-10	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.38	-0.33	5.91e-10	Parkinson's disease;
CRC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.58e-24	Corneal astigmatism;
CRC	cis	rs7605827	0.897	rs6753675	chr2:15539706	C/T	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.63	-0.3	3.78e-8	Gout;Renal underexcretion gout;
CRC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.28	16.09	0.66	2.14e-43	Uric acid levels;
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg15147215	chr3:52552868	STAB1	-0.65	-11.13	-0.52	1.19e-24	Bipolar disorder;
CRC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.43	-7.67	-0.39	2.02e-13	Monocyte count;
CRC	cis	rs6973256	0.862	rs11762935	chr7:133327950	G/T	cg10665199	chr7:133106180	EXOC4	-0.37	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.47	-0.38	7.07e-13	Caudate activity during reward;
CRC	cis	rs61996546	0.622	rs11637029	chr15:26836107	T/A	cg15066197	chr15:26874202	GABRB3	-0.4	-5.83	-0.31	1.32e-8	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs9467603	0.547	rs4632883	chr6:25424191	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.76	-5.81	-0.3	1.5e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.63	-8.06	-0.41	1.42e-14	Body mass index;
CRC	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg27398640	chr15:77910606	LINGO1	-0.41	-6.83	-0.35	4.04e-11	Type 2 diabetes;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.76	13.06	0.58	1.11e-31	Adiposity;
CRC	cis	rs4727963	0.792	rs10953968	chr7:122716333	G/A	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.22e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.05	9.72	0.47	8.7e-20	Diabetic retinopathy;
CRC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.47	6.26	0.33	1.23e-9	Protein C levels;
CRC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.05	-0.32	3.86e-9	Axial length;
CRC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.36	5.61	0.3	4.32e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.56	9.04	0.45	1.42e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.76	0.3	1.94e-8	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00009970	chr18:48723811	MEX3C	0.41	6.55	0.34	2.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.4	8.52	0.43	5.87e-16	Bipolar disorder;
CRC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.38	6.05	0.32	4.02e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12986726	chr20:48806920	CEBPB	0.42	5.99	0.31	5.63e-9	Response to antipsychotic treatment;
CRC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg06287003	chr12:125626642	AACS	0.49	7.52	0.38	5.28e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg03938978	chr2:103052716	IL18RAP	0.42	6.7	0.35	8.81e-11	Blood protein levels;
CRC	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg25164649	chr6:28176230	NA	0.62	8.16	0.41	7.1e-15	Parkinson's disease;
CRC	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.71	-9.99	-0.48	1.07e-20	Hair shape;
CRC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg04990556	chr1:26633338	UBXN11	-0.47	-5.78	-0.3	1.75e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg09473613	chr1:24152604	HMGCL	0.34	5.94	0.31	7.35e-9	Immature fraction of reticulocytes;
CRC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06544989	chr22:39130855	UNC84B	-0.41	-6.48	-0.34	3.42e-10	Menopause (age at onset);
CRC	cis	rs4664293	0.867	rs13389662	chr2:160586437	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.65	-10.44	-0.5	3.11e-22	Motion sickness;
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg23807890	chr2:228736357	WDR69	-0.51	-6.99	-0.36	1.56e-11	Blood pressure;
CRC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.97	11.71	0.54	1.05e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.53	0.43	5.37e-16	Menopause (age at onset);
CRC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.68	-0.39	1.79e-13	Cystic fibrosis severity;
CRC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.53	5.94	0.31	7.35e-9	Initial pursuit acceleration;
CRC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.54	11.93	0.55	1.64e-27	Alcohol dependence;
CRC	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.24	11.59	0.54	2.8e-26	Granulocyte percentage of myeloid white cells;
CRC	cis	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg20159608	chr7:32802032	NA	-0.6	-7.29	-0.37	2.3e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.45	-5.9	-0.31	8.92e-9	Urinary tract infection frequency;
CRC	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.67	11.22	0.53	5.87e-25	Cancer;
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg15786705	chr6:28176104	NA	0.49	7.01	0.36	1.36e-11	Parkinson's disease;
CRC	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg25164649	chr6:28176230	NA	0.67	6.36	0.33	6.84e-10	Parkinson's disease;
CRC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg02560186	chr11:3602584	NA	-0.58	-7.36	-0.38	1.52e-12	Blood pressure (smoking interaction);
CRC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs6774721	1.000	rs6774721	chr3:49381898	G/A	cg19401529	chr3:49056140	DALRD3	0.51	5.72	0.3	2.36e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.3e-13	Corneal astigmatism;
CRC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.53	6.68	0.35	9.98e-11	Morning vs. evening chronotype;
CRC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.91	-0.36	2.49e-11	IgG glycosylation;
CRC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.54	7.73	0.39	1.32e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg22834172	chr17:37774349	NA	0.43	5.99	0.31	5.61e-9	Depressive symptom measurement or major depressive disorder;
CRC	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.65	-10.25	-0.49	1.46e-21	Smoking behavior;
CRC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg16102536	chr7:156981717	UBE3C	0.39	6.62	0.34	1.45e-10	Body mass index;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22007326	chr12:124069649	TMED2	-0.42	-6.6	-0.34	1.62e-10	Aortic root size;
CRC	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.51	-7.69	-0.39	1.75e-13	Response to antidepressants in depression;
CRC	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg16540259	chr10:75572220	NDST2	0.38	5.78	0.3	1.73e-8	Inflammatory bowel disease;
CRC	cis	rs12760731	0.720	rs12048834	chr1:178353998	A/G	cg00404053	chr1:178313656	RASAL2	1.13	11.35	0.53	2.06e-25	Obesity-related traits;
CRC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.56	8.17	0.41	6.67e-15	Melanoma;
CRC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg21153622	chr11:89784906	NA	-0.37	-5.98	-0.31	5.8e-9	Height;
CRC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.01e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1519814	1.000	rs1519814	chr8:121115024	T/G	cg22335954	chr8:121166405	COL14A1	-0.55	-6.23	-0.32	1.45e-9	Breast cancer;
CRC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg14664628	chr15:75095509	CSK	0.45	6.51	0.34	2.89e-10	Caffeine consumption;
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg07404485	chr7:94953653	PON1	-0.47	-6.15	-0.32	2.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg19223190	chr17:80058835	NA	-0.45	-7.07	-0.36	9.57e-12	Life satisfaction;
CRC	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.99	-0.74	9.26e-59	Primary sclerosing cholangitis;
CRC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.69	9.31	0.46	1.87e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.83	7.15	0.37	5.59e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24375607	chr4:120327624	NA	0.44	6.86	0.35	3.46e-11	Corneal astigmatism;
CRC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.6	10.8	0.51	1.77e-23	Aortic root size;
CRC	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	ch.8.33884649F	chr8:33765107	NA	0.39	5.76	0.3	1.9e-8	Body mass index;
CRC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg09491104	chr22:46646882	C22orf40	-0.4	-6.1	-0.32	3.04e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3996993	0.809	rs2894805	chr6:52680600	C/T	cg20803780	chr6:52668592	GSTA1	-0.36	-6.82	-0.35	4.3e-11	Hemoglobin concentration;
CRC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-7.01	-0.36	1.37e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.35	5.66	0.3	3.25e-8	Total body bone mineral density;
CRC	cis	rs73206853	0.841	rs4131852	chr12:110812657	C/G	cg12870014	chr12:110450643	ANKRD13A	0.75	8.17	0.41	6.62e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.77	10.0	0.48	1.01e-20	Bipolar disorder;
CRC	trans	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06834434	chr14:75079333	LTBP2	0.55	7.19	0.37	4.5e-12	Obesity-related traits;
CRC	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.65	0.51	6.15e-23	Corneal astigmatism;
CRC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg07274523	chr3:49395745	GPX1	0.48	6.21	0.32	1.57e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12913538	1.000	rs11071676	chr15:62889661	C/T	cg09983546	chr15:62884068	NA	-0.6	-9.72	-0.47	8.82e-20	Sleep depth;
CRC	trans	rs9650657	0.615	rs11986935	chr8:10691549	T/A	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.18	-0.32	1.9e-9	Neuroticism;
CRC	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12311346	chr5:56204834	C5orf35	-0.52	-8.02	-0.4	1.82e-14	Coronary artery disease;
CRC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.87	-14.13	-0.61	9.49e-36	Cognitive function;
CRC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	14.87	0.63	1.3e-38	Platelet count;
CRC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.45	6.87	0.35	3.13e-11	Menopause (age at onset);
CRC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg05729581	chr11:3078854	CARS	0.42	6.09	0.32	3.08e-9	Longevity;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg02683197	chr6:28174875	NA	0.66	8.59	0.43	3.46e-16	Parkinson's disease;
CRC	cis	rs6700896	0.931	rs2211651	chr1:66156021	G/T	cg04111102	chr1:66153794	NA	0.34	5.87	0.31	1.04e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.48	6.43	0.33	4.45e-10	Migraine;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18036873	chr19:10362545	MRPL4	0.43	6.18	0.32	1.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.63	-12.59	-0.57	6.21e-30	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.66	-11.83	-0.55	3.91e-27	Eye color traits;
CRC	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-9.38	-0.46	1.12e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs10071761	0.513	rs4957278	chr5:40361820	T/G	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs2274273	0.624	rs72717738	chr14:55842761	C/G	cg10130446	chr14:55658398	DLGAP5	-0.44	-6.15	-0.32	2.25e-9	Protein biomarker;
CRC	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.42	6.18	0.32	1.92e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10450586	0.897	rs28416407	chr11:27308244	G/T	cg10370305	chr11:27303972	NA	0.36	5.8	0.3	1.53e-8	Total body bone mineral density;
CRC	cis	rs1223397	0.651	rs2458311	chr6:13310012	T/C	cg20827128	chr6:13274284	PHACTR1	0.38	5.8	0.3	1.52e-8	Blood pressure;
CRC	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg02569458	chr12:86230093	RASSF9	0.39	6.58	0.34	1.81e-10	Major depressive disorder;
CRC	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg15123519	chr2:136567270	LCT	-0.29	-5.63	-0.3	3.96e-8	Mosquito bite size;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	cis	rs6908034	0.505	rs76391302	chr6:19819116	G/A	cg02682789	chr6:19804855	NA	0.83	6.67	0.35	1.08e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.66	-8.89	-0.44	4.24e-17	Prostate cancer;
CRC	cis	rs459193	1.000	rs256904	chr5:55810305	A/T	cg26646659	chr5:55776364	NA	0.45	5.81	0.3	1.5e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06887260	chr4:48271826	TEC	0.39	5.96	0.31	6.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg03013999	chr17:37608204	MED1	0.47	7.28	0.37	2.48e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg02896835	chr1:92012615	NA	0.54	6.65	0.34	1.25e-10	Eosinophil percentage of white cells;
CRC	cis	rs4731207	0.689	rs2054585	chr7:124552447	T/C	cg23710748	chr7:124431027	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Cutaneous malignant melanoma;
CRC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.5	-0.46	4.35e-19	Migraine;Coronary artery disease;
CRC	trans	rs7088591	0.558	rs57392412	chr10:59818661	T/C	cg21239940	chr8:68870412	PREX2	0.54	6.01	0.31	4.93e-9	Blood pressure;
CRC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.37	-5.76	-0.3	1.95e-8	Crohn's disease;
CRC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.55	5.76	0.3	1.95e-8	Lung cancer;
CRC	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg21452805	chr1:244014465	NA	0.54	7.3	0.37	2.12e-12	RR interval (heart rate);
CRC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg00734567	chr1:86172782	ZNHIT6	-0.49	-7.41	-0.38	1.08e-12	Urate levels in overweight individuals;
CRC	cis	rs539514	0.690	rs585233	chr13:76317973	A/G	cg04757411	chr13:76259545	LMO7	0.35	5.9	0.31	9.19e-9	Type 1 diabetes;
CRC	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg22495460	chr2:25135724	ADCY3	0.88	15.28	0.64	3.27e-40	Body mass index;
CRC	trans	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg21153622	chr11:89784906	NA	-0.51	-8.08	-0.41	1.22e-14	HDL cholesterol;
CRC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.55	-8.15	-0.41	7.81e-15	Mean platelet volume;
CRC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg05627522	chr15:75251581	NA	0.41	6.27	0.33	1.16e-9	Breast cancer;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.66	-0.39	2.15e-13	Acylcarnitine levels;
CRC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.05	0.32	3.9e-9	Menopause (age at onset);
CRC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.53	5.78	0.3	1.72e-8	Vitiligo;
CRC	cis	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg18809830	chr7:99032528	PTCD1	-1.06	-7.83	-0.4	6.73e-14	Blood metabolite levels;
CRC	cis	rs7173389	1.000	rs8039168	chr15:73664723	A/T	cg01796676	chr15:73680284	NA	0.51	6.76	0.35	6.43e-11	Resting heart rate;
CRC	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.46	-6.06	-0.32	3.72e-9	Heschl's gyrus morphology;
CRC	cis	rs10924970	1.000	rs7339935	chr1:235337761	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.83	0.31	1.35e-8	Asthma;
CRC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.4	8.69	0.43	1.71e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	1.36	11.12	0.52	1.35e-24	Cognitive function;
CRC	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg23100626	chr2:96804247	ASTL	0.3	7.97	0.4	2.62e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.37	6.22	0.32	1.51e-9	Blood metabolite levels;
CRC	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03713592	chr11:72463424	ARAP1	1.05	10.38	0.5	5.07e-22	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11087747	chr19:41107377	LTBP4	0.43	6.06	0.32	3.67e-9	Response to antipsychotic treatment;
CRC	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.57	7.35	0.38	1.58e-12	Body mass index;
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.26	-0.56	9.81e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.6	10.84	0.51	1.3e-23	Blood metabolite ratios;
CRC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg18827107	chr12:86230957	RASSF9	-0.42	-6.64	-0.34	1.28e-10	Major depressive disorder;
CRC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.72	10.57	0.5	1.09e-22	Immature fraction of reticulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11487532	chr11:44586968	CD82	0.42	6.64	0.34	1.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.25	18.05	0.71	4.12e-51	IgG glycosylation;
CRC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.61	-9.72	-0.47	8.32e-20	Mean corpuscular hemoglobin concentration;
CRC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg26805224	chr10:79626177	DLG5	-0.49	-7.21	-0.37	3.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.34e-12	Bipolar disorder;
CRC	cis	rs1178968	1.000	rs2237285	chr7:72760213	C/T	cg25889504	chr7:72793014	NA	0.53	5.93	0.31	7.73e-9	Triglyceride levels;
CRC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8.1e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg26587870	chr6:27730563	NA	-0.63	-6.39	-0.33	5.69e-10	Depression;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs2249694	0.520	rs7096203	chr10:135324505	A/C	cg20169779	chr10:135381914	SYCE1	-0.54	-7.33	-0.37	1.76e-12	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.55	-0.6	1.52e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26072759	chr17:75277365	SEPT9	0.44	6.39	0.33	5.6e-10	Anxiety disorder;
CRC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.39	-7.53	-0.38	4.97e-13	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg17133734	chr15:86042851	AKAP13	0.4	6.51	0.34	2.8e-10	Interstitial lung disease;
CRC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg00074818	chr8:8560427	CLDN23	0.34	6.43	0.33	4.44e-10	Obesity-related traits;
CRC	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14119001	chr9:139324193	INPP5E	-0.48	-6.73	-0.35	7.46e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.56	10.03	0.48	7.75e-21	HDL cholesterol levels;
CRC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg04450456	chr4:17643702	FAM184B	-0.37	-6.0	-0.31	5.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg05623727	chr3:50126028	RBM5	-0.43	-7.3	-0.37	2.18e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg10760299	chr15:45669010	GATM	0.51	7.78	0.39	9.59e-14	Homoarginine levels;
CRC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg22777020	chr22:31556080	RNF185	0.5	5.99	0.31	5.4e-9	Colorectal cancer;
CRC	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.45	7.73	0.39	1.29e-13	Common traits (Other);
CRC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-9.96	-0.48	1.32e-20	Menarche (age at onset);
CRC	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	0.46	6.52	0.34	2.72e-10	Blood protein levels;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg15845792	chr6:28175446	NA	0.95	13.85	0.61	1.07e-34	Parkinson's disease;
CRC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4780401	0.703	rs12921129	chr16:11769176	C/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-6.1	-0.32	2.95e-9	Rheumatoid arthritis;
CRC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.69	-10.39	-0.5	4.75e-22	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27343303	chr11:34380546	NA	0.42	6.15	0.32	2.28e-9	Response to antipsychotic treatment;
CRC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.47	7.25	0.37	3.08e-12	Colorectal cancer;
CRC	trans	rs16846053	0.792	rs55893794	chr2:162418751	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Blood osmolality (transformed sodium);
CRC	cis	rs4253311	0.520	rs7687818	chr4:187122060	A/G	cg24794857	chr4:187113578	CYP4V2	0.4	5.99	0.31	5.5e-9	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
CRC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	trans	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg20935933	chr6:143382018	AIG1	0.51	6.64	0.34	1.3e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg11301795	chr4:187892539	NA	-0.83	-17.83	-0.7	3.17e-50	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.79	-0.44	8.24e-17	Coffee consumption (cups per day);
CRC	cis	rs77633900	0.772	rs2957612	chr15:76703688	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-5.62	-0.3	4.15e-8	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.62	-0.34	1.44e-10	Bipolar disorder;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg12564285	chr5:131593104	PDLIM4	-0.45	-7.6	-0.39	3.07e-13	Acylcarnitine levels;
CRC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg13047869	chr3:10149882	C3orf24	0.36	5.63	0.3	3.86e-8	Alzheimer's disease;
CRC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg21466736	chr12:48725269	NA	-0.53	-7.99	-0.4	2.23e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs427943	0.750	rs6518214	chr21:46601699	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	5.97	0.31	6.28e-9	Body mass index;
CRC	cis	rs12999616	0.696	rs56035334	chr2:98329047	T/G	cg26665480	chr2:98280029	ACTR1B	0.52	6.43	0.33	4.6e-10	Colorectal cancer;
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.64	-8.79	-0.44	8.75e-17	Coronary artery disease;
CRC	cis	rs7251806	1	rs7251806	chr19:16499569	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.54	6.28	0.33	1.06e-9	Lymphocyte counts;
CRC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg24140574	chr1:16342155	HSPB7	0.43	6.29	0.33	9.87e-10	Systolic blood pressure;
CRC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.52	-0.5	1.61e-22	Monocyte count;
CRC	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.54	-8.16	-0.41	7.04e-15	Vitiligo;
CRC	cis	rs8105895	0.935	rs7253053	chr19:22245685	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs7215564	0.908	rs34143200	chr17:78673008	G/A	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.09e-9	Myopia (pathological);
CRC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg25344623	chr2:136566232	LCT	0.31	5.67	0.3	3.05e-8	Mosquito bite size;
CRC	cis	rs55637647	0.515	rs7206699	chr16:88523815	A/G	cg26899496	chr16:88551223	ZFPM1	-0.37	-5.84	-0.31	1.28e-8	Testicular germ cell tumor;
CRC	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.01	0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6772849	0.805	rs13325747	chr3:128336023	G/A	cg08795948	chr3:128337044	NA	0.34	6.03	0.32	4.38e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg24955955	chr5:415729	AHRR	0.62	6.37	0.33	6.46e-10	Fat distribution (HIV);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09740319	chr1:231004641	C1orf198	0.48	6.72	0.35	7.81e-11	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.78	10.77	0.51	2.25e-23	Cognitive function;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg10295955	chr4:187884368	NA	-1.0	-21.78	-0.77	9.59e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg27615366	chr5:131592974	PDLIM4	-0.29	-5.61	-0.3	4.21e-8	Breast cancer;
CRC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.78	-0.72	5.61e-54	Height;
CRC	cis	rs9292777	0.720	rs60823023	chr5:40425810	T/C	cg09067459	chr5:40385259	NA	-0.55	-8.93	-0.44	3.12e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06544989	chr22:39130855	UNC84B	0.45	7.04	0.36	1.12e-11	Menopause (age at onset);
CRC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.51	0.34	2.82e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg07299736	chr8:135490787	ZFAT	-0.37	-6.48	-0.34	3.41e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg06632207	chr12:54070931	ATP5G2	0.42	7.27	0.37	2.64e-12	Height;
CRC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	6.19e-10	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg22988483	chr14:93581567	ITPK1	-0.67	-6.04	-0.32	4.16e-9	Cognitive function;
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.46	6.4	0.33	5.27e-10	Height;
CRC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.19e-12	Testicular germ cell tumor;
CRC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg16989086	chr20:62203971	PRIC285	0.47	5.99	0.31	5.44e-9	Glioblastoma;
CRC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.61	0.57	5.06e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg16892393	chr17:41919603	NA	0.5	7.23	0.37	3.48e-12	Triglycerides;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25762580	chr7:108210082	THAP5;DNAJB9	0.48	6.63	0.34	1.36e-10	Response to antipsychotic treatment;
CRC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.61	-0.34	1.58e-10	Coronary artery disease;
CRC	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg14186256	chr22:23484241	RTDR1	0.46	5.87	0.31	1.07e-8	Serum parathyroid hormone levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg04467838	chr17:27071119	TRAF4	0.49	6.88	0.35	3.03e-11	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.01	-0.31	5.03e-9	Height;
CRC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.93e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6141769	0.542	rs28730896	chr20:31295844	A/G	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.83	-0.31	1.34e-8	Subjective well-being;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12588279	chr6:26043732	HIST1H2BB	0.43	6.23	0.32	1.42e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.67	0.35	1.1e-10	Menarche (age at onset);
CRC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg13777783	chr17:79615861	NA	-0.3	-5.71	-0.3	2.57e-8	Eye color traits;
CRC	cis	rs1223397	0.938	rs3817742	chr6:13279552	T/C	cg20827128	chr6:13274284	PHACTR1	0.53	6.41	0.33	4.94e-10	Blood pressure;
CRC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg13722127	chr7:150037890	RARRES2	0.47	7.07	0.36	9.06e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg11800794	chr20:31407338	MAPRE1	-0.35	-6.05	-0.32	3.93e-9	Ulcerative colitis;
CRC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-8.47	-0.42	8.06e-16	Homoarginine levels;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg20647610	chr2:228736258	WDR69	-0.5	-6.8	-0.35	4.83e-11	Blood pressure;
CRC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.65	-0.3	3.5e-8	Mean platelet volume;
CRC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.45	-0.34	4.02e-10	Triglycerides;
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.74	-0.3	2.18e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs747650	0.504	rs10838644	chr11:47035761	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.88	-0.31	1.03e-8	Acne (severe);
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.82	12.19	0.56	1.86e-28	Menarche (age at onset);
CRC	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.52	7.08	0.36	8.8e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg04166393	chr7:2884313	GNA12	-0.38	-5.72	-0.3	2.36e-8	Height;
CRC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.05	0.68	3.64e-47	Platelet count;
CRC	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg06781209	chr11:61594997	FADS2	0.47	5.95	0.31	6.75e-9	Neutrophil count;Sum basophil neutrophil counts;
CRC	cis	rs9311676	0.656	rs11130632	chr3:58369324	C/T	cg06643156	chr3:58380774	PXK	0.41	6.26	0.33	1.18e-9	Systemic lupus erythematosus;
CRC	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.75	-11.86	-0.55	3e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.0	0.31	5.16e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16196758	chr18:47901430	SKA1	0.45	6.16	0.32	2.11e-9	Anxiety disorder;
CRC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.68	0.3	3.04e-8	Coronary artery disease;
CRC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg02007433	chr3:129722099	NA	-0.5	-6.22	-0.32	1.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs6834538	0.538	rs13145085	chr4:113414871	A/C	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.76	-0.3	1.92e-8	Free thyroxine concentration;
CRC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.86	-0.35	3.37e-11	Lung cancer;
CRC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.59	10.38	0.5	4.93e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg11632617	chr15:75315747	PPCDC	-0.56	-7.74	-0.39	1.23e-13	Blood trace element (Zn levels);
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.47	5.77	0.3	1.83e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg02927042	chr1:21476669	EIF4G3	-0.52	-8.32	-0.42	2.33e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.46	-7.7	-0.39	1.65e-13	P wave terminal force;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs11212617	0.967	rs227086	chr11:108244251	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.4e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.78	12.03	0.55	6.93e-28	Schizophrenia;
CRC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.51	7.85	0.4	6e-14	Aortic root size;
CRC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg12590608	chr7:158785262	NA	0.5	9.24	0.45	3.12e-18	Facial morphology (factor 20);
CRC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg09491104	chr22:46646882	C22orf40	-0.4	-6.27	-0.33	1.12e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-12.06	-0.55	5.47e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs4804416	1.000	rs4804414	chr19:7223785	C/T	cg09779027	chr19:7224513	INSR	0.65	10.9	0.52	7.79e-24	Thyroid hormone levels;Hypothyroidism;
CRC	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg24289452	chr6:170231220	NA	-0.67	-6.64	-0.34	1.32e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13063040	chr8:145669623	NFKBIL2	-0.43	-6.35	-0.33	7.3e-10	Myopia (pathological);
CRC	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg09127314	chr1:152161683	NA	0.46	5.63	0.3	3.79e-8	Atopic dermatitis;
CRC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.75	-0.39	1.12e-13	Colorectal cancer;
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.47	-0.38	7.46e-13	Lymphocyte counts;
CRC	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.58	9.91	0.48	1.95e-20	Asthma;
CRC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.8	16.6	0.68	2.13e-45	Height;
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.53	-9.9	-0.48	2.14e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.51	8.39	0.42	1.44e-15	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27281285	chr12:120315368	CIT	0.52	6.7	0.35	8.84e-11	Thyroid stimulating hormone;
CRC	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg18827107	chr12:86230957	RASSF9	0.36	5.7	0.3	2.65e-8	Major depressive disorder;
CRC	trans	rs662064	0.852	rs617728	chr1:10566522	C/T	cg20645065	chr1:21836138	ALPL	-0.42	-6.27	-0.33	1.15e-9	Asthma;
CRC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.25e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.81	10.59	0.5	9.87e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.85	0.61	1.08e-34	Prudent dietary pattern;
CRC	cis	rs4853036	0.904	rs62152020	chr2:70147664	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-5.84	-0.31	1.27e-8	Colorectal or endometrial cancer;
CRC	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.7	0.3	2.72e-8	Blood metabolite levels;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg20512303	chr5:131592959	PDLIM4	0.37	7.22	0.37	3.61e-12	Breast cancer;
CRC	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.45	-7.44	-0.38	8.84e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02002494	chr3:119013045	CDGAP	0.52	6.82	0.35	4.47e-11	Thyroid stimulating hormone;
CRC	cis	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg03623178	chr6:28175578	NA	0.83	5.76	0.3	1.93e-8	Depression;
CRC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.45	3.2e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.5	8.09	0.41	1.2e-14	Plateletcrit;Platelet count;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22924838	chr2:200715629	NA	-0.41	-6.23	-0.32	1.45e-9	Brain structure;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg26587870	chr6:27730563	NA	-0.37	-5.69	-0.3	2.87e-8	Cardiac Troponin-T levels;
CRC	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10802521	chr3:52805072	NEK4	-0.48	-6.63	-0.34	1.37e-10	Bipolar disorder;
CRC	cis	rs2227564	0.620	rs11000787	chr10:75584383	T/C	cg16540259	chr10:75572220	NDST2	0.5	7.6	0.39	3.15e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-7.99	-0.4	2.23e-14	Monocyte count;
CRC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	14.45	0.62	5.43e-37	Platelet count;
CRC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.58	-9.37	-0.46	1.21e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-1.06	-10.96	-0.52	4.88e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg27083787	chr2:113543245	IL1A	-0.44	-6.31	-0.33	9.06e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.6	0.43	3.24e-16	Homoarginine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08322149	chr10:46222875	FAM21C	0.5	7.11	0.36	7.07e-12	Response to antipsychotic treatment;
CRC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs3736485	0.868	rs60060794	chr15:51937181	A/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.55	-0.34	2.16e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg05585544	chr11:47624801	NA	-0.62	-10.84	-0.51	1.26e-23	Subjective well-being;
CRC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	7.29	0.37	2.32e-12	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13198984	chr17:80129470	CCDC57	0.48	8.31	0.42	2.62e-15	Life satisfaction;
CRC	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.62	0.51	7.43e-23	Iron status biomarkers;
CRC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.89	0.44	4.26e-17	Menopause (age at onset);
CRC	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.44	6.44	0.33	4.33e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.47	-5.98	-0.31	5.94e-9	Recombination rate (females);
CRC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.42	6.71	0.35	8.28e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg05299278	chr17:33885742	SLFN14	-0.39	-5.96	-0.31	6.64e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.4	0.33	5.27e-10	Blood protein levels;
CRC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.52	-8.37	-0.42	1.68e-15	Neurofibrillary tangles;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg20933634	chr6:27740509	NA	0.57	8.08	0.41	1.24e-14	Parkinson's disease;
CRC	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg20356878	chr3:121714668	ILDR1	0.51	7.9	0.4	4.1e-14	Cognitive performance;
CRC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs11212617	0.967	rs3781868	chr11:108059569	T/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.54	0.34	2.31e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.47	7.69	0.39	1.71e-13	Fat distribution (HIV);
CRC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg21153622	chr11:89784906	NA	-0.37	-5.97	-0.31	6.05e-9	Height;
CRC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg02725872	chr8:58115012	NA	-0.43	-6.63	-0.34	1.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.86	-19.72	-0.74	1.09e-57	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.95	12.4	0.56	3.15e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13083004	chr1:23809994	ASAP3	0.35	6.11	0.32	2.81e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.24	14.62	0.63	1.19e-37	Uric acid levels;
CRC	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	6.23	0.32	1.41e-9	Blood metabolite levels;
CRC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.47	-5.65	-0.3	3.4e-8	Urinary tract infection frequency;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17695382	chr2:61697821	USP34	-0.38	-5.98	-0.31	5.68e-9	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg05569086	chr8:143859399	LYNX1	0.38	6.54	0.34	2.4e-10	Urinary tract infection frequency;
CRC	cis	rs77861329	0.748	rs6786592	chr3:52196241	T/C	cg08692210	chr3:52188851	WDR51A	0.5	5.92	0.31	7.91e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg14829360	chr17:73884958	NA	-0.34	-5.75	-0.3	2.09e-8	White matter hyperintensity burden;
CRC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.46	-6.79	-0.35	5.33e-11	Menarche (age at onset);
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.78	-12.96	-0.58	2.68e-31	Cystic fibrosis severity;
CRC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.51	-7.48	-0.38	7.02e-13	White blood cell count;
CRC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg12935359	chr14:103987150	CKB	-0.38	-5.97	-0.31	6.15e-9	Body mass index;
CRC	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.62	9.76	0.47	6.12e-20	Testicular germ cell tumor;
CRC	trans	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg09545894	chr13:24008532	SACS	0.45	6.15	0.32	2.2e-9	Lung cancer;
CRC	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg08222913	chr3:52553049	STAB1	-0.37	-7.02	-0.36	1.28e-11	Electroencephalogram traits;
CRC	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-5.61	-0.3	4.41e-8	Schizophrenia;
CRC	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.78	9.58	0.47	2.56e-19	Height;
CRC	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg08600765	chr20:34638493	LOC647979	-0.64	-8.52	-0.43	6.02e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.73	-10.87	-0.51	1.05e-23	Platelet distribution width;
CRC	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs17162190	0.590	rs10902748	chr1:26817825	G/A	cg17456097	chr1:26900765	RPS6KA1	0.44	6.08	0.32	3.39e-9	Mean corpuscular volume;
CRC	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg16329197	chr12:53359506	NA	-1.05	-10.12	-0.49	3.94e-21	Prostate cancer;
CRC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.5	-6.65	-0.34	1.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg19610905	chr11:61596333	FADS2	-0.59	-7.12	-0.37	6.65e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs3743266	0.507	rs56261931	chr15:60731618	C/T	cg21667061	chr15:60772094	NARG2	0.38	6.11	0.32	2.78e-9	Menarche (age at onset);
CRC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.9	0.55	2.04e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg11168104	chr5:1857477	NA	-0.36	-6.2	-0.32	1.66e-9	Cardiovascular disease risk factors;
CRC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.61	9.4	0.46	9.66e-19	Neuroticism;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03934478	chr11:495069	RNH1	0.66	7.41	0.38	1.1e-12	Body mass index;
CRC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg16342193	chr10:102329863	NA	-0.33	-5.63	-0.3	3.84e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.62	9.59	0.47	2.2e-19	Corneal astigmatism;
CRC	cis	rs6694672	0.717	rs2151135	chr1:197106604	C/T	cg13682187	chr1:196946512	CFHR5	0.43	6.87	0.35	3.26e-11	Asthma;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.37	-6.16	-0.32	2.08e-9	Lymphocyte counts;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26770385	chr8:125486821	RNF139	0.38	6.07	0.32	3.44e-9	Obesity-related traits;
CRC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.68	-0.3	2.91e-8	Monocyte percentage of white cells;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg06470822	chr6:28175283	NA	-0.98	-14.46	-0.62	5.05e-37	Depression;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.59	-10.85	-0.51	1.2e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	8.86	0.44	5.07e-17	Personality dimensions;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg06470822	chr6:28175283	NA	0.76	10.98	0.52	4.06e-24	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg18187862	chr3:45730750	SACM1L	0.45	6.4	0.33	5.43e-10	Primary sclerosing cholangitis;
CRC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.5	7.51	0.38	5.77e-13	Coronary artery disease;
CRC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.72	8.53	0.43	5.61e-16	Inflammatory bowel disease;
CRC	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg11143507	chr3:125485238	NA	-0.57	-7.37	-0.38	1.37e-12	Blood pressure (smoking interaction);
CRC	cis	rs2836754	1.000	rs2836753	chr21:40291187	A/G	cg02119577	chr21:40195074	ETS2	-0.36	-6.19	-0.32	1.82e-9	Crohn's disease;Body mass index;
CRC	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg26695010	chr11:65641043	EFEMP2	0.45	6.88	0.35	3.07e-11	Eosinophil percentage of white cells;
CRC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.67	11.1	0.52	1.53e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs73206853	0.563	rs1107652	chr12:111176213	A/G	cg12870014	chr12:110450643	ANKRD13A	0.78	9.7	0.47	9.64e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg10724054	chr17:3904396	NA	0.45	7.88	0.4	4.76e-14	Type 2 diabetes;
CRC	cis	rs7091068	0.518	rs4144097	chr10:95432480	A/C	cg20715218	chr10:95462985	C10orf4	0.53	7.22	0.37	3.56e-12	Urinary tract infection frequency;
CRC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg02741985	chr17:80059408	CCDC57	0.44	7.18	0.37	4.6e-12	Life satisfaction;
CRC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg06238570	chr21:40685208	BRWD1	0.71	10.11	0.49	4.09e-21	Cognitive function;
CRC	cis	rs8105895	0.935	rs10407250	chr19:22238151	G/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23822915	chr6:84569161	CYB5R4	0.45	6.43	0.33	4.42e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.9	16.62	0.68	1.89e-45	Intelligence (multi-trait analysis);
CRC	trans	rs204595	0.965	rs10281881	chr7:20897865	A/C	cg02372745	chr13:50365574	KPNA3	-0.47	-6.19	-0.32	1.75e-9	Depressive symptoms (stressful life events interaction);
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg19041857	chr6:27730383	NA	0.43	5.65	0.3	3.43e-8	Parkinson's disease;
CRC	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21659725	chr3:3221576	CRBN	-0.52	-7.99	-0.4	2.28e-14	Body mass index;
CRC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	cis	rs7178572	0.633	rs11854328	chr15:77840129	A/G	cg22256960	chr15:77711686	NA	-0.64	-9.26	-0.45	2.71e-18	Type 2 diabetes;
CRC	cis	rs62432291	0.681	rs417719	chr6:159658042	C/T	cg14500486	chr6:159655392	FNDC1	-0.75	-10.12	-0.49	3.83e-21	Joint mobility (Beighton score);
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-7.9	-0.4	4.21e-14	Bipolar disorder;
CRC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.49	7.19	0.37	4.41e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg15786705	chr6:28176104	NA	0.64	7.06	0.36	9.77e-12	Parkinson's disease;
CRC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg14711859	chr11:8959438	ASCL3	0.38	6.66	0.34	1.18e-10	Hemoglobin concentration;
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.73	11.16	0.52	9.56e-25	Intelligence (multi-trait analysis);
CRC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.8	11.87	0.55	2.76e-27	Diastolic blood pressure;
CRC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.56	6.52	0.34	2.67e-10	Bipolar disorder;
CRC	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.51	-6.72	-0.35	7.97e-11	White matter hyperintensity burden;
CRC	cis	rs4654899	0.931	rs10753506	chr1:21141022	A/G	cg02927042	chr1:21476669	EIF4G3	0.47	7.53	0.38	5.02e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg14003231	chr6:33640908	ITPR3	0.51	8.28	0.42	3.03e-15	Plateletcrit;
CRC	cis	rs3751196	0.808	rs78823917	chr12:104219073	T/C	cg02344784	chr12:104178138	NT5DC3	0.71	7.27	0.37	2.63e-12	Sense of smell;
CRC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.52	8.87	0.44	4.61e-17	Systemic lupus erythematosus;
CRC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-7.16	-0.37	5.15e-12	Colorectal cancer;
CRC	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg11003573	chr3:44754125	ZNF502	0.34	6.09	0.32	3.15e-9	Depressive symptoms;
CRC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.4	-0.38	1.12e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg13047869	chr3:10149882	C3orf24	0.37	5.82	0.31	1.39e-8	Alzheimer's disease;
CRC	cis	rs16852403	0.501	rs2862318	chr1:178180127	C/T	cg00404053	chr1:178313656	RASAL2	0.5	6.59	0.34	1.74e-10	Childhood ear infection;
CRC	cis	rs501120	0.657	rs589655	chr10:44745315	C/G	cg09554077	chr10:44749378	NA	0.73	8.0	0.4	2.15e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg04043695	chr12:129287642	SLC15A4	0.37	5.64	0.3	3.66e-8	Systemic lupus erythematosus;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22195704	chr2:25016199	CENPO;C2orf79	0.39	6.02	0.31	4.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.63	10.69	0.51	4.21e-23	Prudent dietary pattern;
CRC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.63	9.58	0.47	2.53e-19	Cleft lip with or without cleft palate;
CRC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.44	6.85	0.35	3.57e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10053473	chr17:62856997	LRRC37A3	0.72	8.47	0.42	8.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg14646075	chr2:228736089	WDR69	-0.45	-6.14	-0.32	2.43e-9	Blood pressure;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs9292777	0.897	rs11742570	chr5:40410584	C/T	cg09067459	chr5:40385259	NA	-0.52	-9.06	-0.45	1.23e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.63	9.44	0.46	7.31e-19	Hemoglobin concentration;
CRC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.57	-7.09	-0.36	8.22e-12	Body mass index (adult);
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.52	-7.19	-0.37	4.5e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.62	12.79	0.58	1.15e-30	Neuroticism;
CRC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.54	-10.03	-0.48	7.66e-21	Prostate cancer;
CRC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.18	0.37	4.76e-12	Hemoglobin concentration;
CRC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13198984	chr17:80129470	CCDC57	-0.39	-6.63	-0.34	1.41e-10	Life satisfaction;
CRC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.62	-7.38	-0.38	1.26e-12	Hip circumference adjusted for BMI;
CRC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	6.13	0.32	2.58e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.51	6.53	0.34	2.44e-10	Alzheimer's disease (survival time);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27221266	chr10:96122679	NOC3L	0.45	6.3	0.33	9.6e-10	Response to antipsychotic treatment;
CRC	cis	rs2275731	0.506	rs11254015	chr10:16522078	A/G	cg04254609	chr10:16479192	PTER	0.43	5.82	0.31	1.37e-8	Bone fracture in osteoporosis;
CRC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.09	-0.32	3.11e-9	Gout;Renal underexcretion gout;
CRC	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	6.67	0.35	1.06e-10	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.42	5.96	0.31	6.5e-9	Aortic root size;
CRC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.39	-6.66	-0.34	1.18e-10	Mean arterial pressure;
CRC	cis	rs10971721	0.822	rs10971758	chr9:33876069	T/G	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg22638593	chr5:131593259	PDLIM4	0.41	6.6	0.34	1.67e-10	Breast cancer;
CRC	cis	rs8192917	0.573	rs66505306	chr14:25078610	G/C	cg01932691	chr14:25045625	CTSG	-0.58	-5.72	-0.3	2.36e-8	Vitiligo;
CRC	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.53	-9.98	-0.48	1.17e-20	Schizophrenia;
CRC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.35	-0.46	1.35e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs12699921	0.632	rs2691613	chr7:17883981	G/A	cg02066331	chr6:17282778	RBM24	-0.35	-6.08	-0.32	3.38e-9	Fibrinogen levels;
CRC	trans	rs6956675	0.874	rs10266439	chr7:62647022	G/T	cg01314568	chr7:57830625	NA	-0.61	-8.84	-0.44	6.05e-17	Obesity-related traits;
CRC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-7.25	-0.37	3.05e-12	Colorectal cancer;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg11843238	chr5:131593191	PDLIM4	0.53	9.55	0.47	3e-19	Acylcarnitine levels;
CRC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.81	13.33	0.59	1.05e-32	Menopause (age at onset);
CRC	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg05342945	chr12:48394962	COL2A1	-0.43	-5.62	-0.3	4.14e-8	Lung cancer;
CRC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.7	12.08	0.55	4.69e-28	Gout;
CRC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.06	-0.32	3.65e-9	Reticulocyte count;
CRC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	0.66	6.47	0.34	3.6e-10	Fat distribution (HIV);
CRC	cis	rs10944	0.598	rs650304	chr5:78275892	G/A	cg13121490	chr5:78280331	ARSB	-0.46	-6.75	-0.35	6.56e-11	Blood and toenail selenium levels;
CRC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg23590916	chr17:43697445	MGC57346	0.71	7.23	0.37	3.48e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.38	-0.53	1.63e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.81	12.57	0.57	7.2e-30	Testicular germ cell tumor;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.79	12.62	0.57	4.62e-30	Height;
CRC	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.62	5.77	0.3	1.84e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-10.56	-0.5	1.25e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs600626	0.588	rs10899112	chr11:75458518	T/C	cg24262691	chr11:75473276	NA	0.5	7.27	0.37	2.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg13753209	chr17:57696993	CLTC	0.45	5.79	0.3	1.61e-8	Hemoglobin concentration;
CRC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg14673194	chr17:80132900	CCDC57	-0.47	-5.9	-0.31	9.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3751196	0.901	rs1550207	chr12:104210068	A/T	cg02344784	chr12:104178138	NT5DC3	0.7	7.21	0.37	3.92e-12	Sense of smell;
CRC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg03388025	chr16:89894329	SPIRE2	0.3	5.8	0.3	1.55e-8	Vitiligo;
CRC	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.7	-0.3	2.61e-8	Blood protein levels;
CRC	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.58	8.03	0.4	1.72e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.83	-12.43	-0.57	2.4e-29	Blood metabolite levels;
CRC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg24977027	chr2:88469347	THNSL2	0.58	6.54	0.34	2.29e-10	Plasma clusterin levels;
CRC	cis	rs7113874	0.589	rs2044463	chr11:8463951	G/A	cg02811074	chr11:8615871	STK33	-0.35	-5.87	-0.31	1.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05210937	chr4:185655043	MLF1IP	0.44	5.99	0.31	5.41e-9	Anxiety disorder;
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.03	-0.4	1.7e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25992645	chr11:65244888	NA	0.47	6.4	0.33	5.22e-10	Anxiety disorder;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.02	-0.4	1.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10717722	chr10:124134020	PLEKHA1	0.42	6.69	0.35	9.67e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	0.89	12.48	0.57	1.64e-29	Red blood cell traits;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-8.34	-0.42	2.09e-15	Bipolar disorder;
CRC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.53	7.55	0.38	4.18e-13	Cystic fibrosis severity;
CRC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg16606324	chr3:10149918	C3orf24	0.48	7.03	0.36	1.19e-11	Alzheimer's disease;
CRC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-9.53	-0.47	3.48e-19	Alcohol dependence;
CRC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00791764	chr4:53727839	RASL11B	0.5	6.68	0.35	1.03e-10	Optic nerve measurement (cup area);
CRC	trans	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg17903999	chr18:56338584	MALT1	-0.43	-7.01	-0.36	1.39e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.62	8.71	0.43	1.5e-16	Longevity;Endometriosis;
CRC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg04796162	chr7:45961102	IGFBP3	0.39	6.76	0.35	6.38e-11	Sitting height ratio;
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.64	-0.3	3.61e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	6.29	0.33	1.03e-9	Schizophrenia;
CRC	cis	rs11212617	0.967	rs227058	chr11:108265213	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.46	0.34	3.73e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.5	-7.38	-0.38	1.28e-12	Menarche (age at onset);
CRC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.65	-9.83	-0.48	3.69e-20	Pancreatic cancer;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.22e-12	Bipolar disorder;
CRC	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg10298567	chr3:47292165	KIF9	-0.38	-5.96	-0.31	6.55e-9	Colorectal cancer;
CRC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.56	8.4	0.42	1.38e-15	Morning vs. evening chronotype;
CRC	trans	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg16606324	chr3:10149918	C3orf24	0.48	7.03	0.36	1.19e-11	Alzheimer's disease;
CRC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.35	5.77	0.3	1.84e-8	Blood metabolite levels;
CRC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg24289452	chr6:170231220	NA	-0.83	-7.15	-0.37	5.79e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.96	-12.08	-0.55	4.82e-28	Orofacial clefts;
CRC	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.49	-6.86	-0.35	3.51e-11	Tuberculosis;
CRC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg19193384	chr17:30244184	NA	-0.53	-6.66	-0.34	1.15e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	8.21	0.41	5.02e-15	HIV-1 control;
CRC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.89	0.36	2.83e-11	Common traits (Other);
CRC	cis	rs17767392	1.000	rs34528013	chr14:71767848	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg12756093	chr1:115239321	AMPD1	0.47	6.77	0.35	5.81e-11	Autism;
CRC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg12193833	chr17:30244370	NA	-0.62	-7.49	-0.38	6.39e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg17724175	chr1:150552817	MCL1	-0.38	-5.77	-0.3	1.8e-8	Tonsillectomy;
CRC	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21155796	chr2:242212141	HDLBP	0.62	6.65	0.34	1.25e-10	Prostate cancer;
CRC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.56	-6.72	-0.35	7.81e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg24375607	chr4:120327624	NA	0.49	7.71	0.39	1.49e-13	Corneal astigmatism;
CRC	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg14664628	chr15:75095509	CSK	0.48	5.69	0.3	2.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.73	-10.45	-0.5	2.88e-22	Blood metabolite levels;
CRC	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg16892393	chr17:41919603	NA	0.55	7.73	0.39	1.36e-13	Triglycerides;
CRC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg09417038	chr21:47716443	C21orf57	-0.43	-7.05	-0.36	1.03e-11	Testicular germ cell tumor;
CRC	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.18	-0.45	4.75e-18	Capecitabine sensitivity;
CRC	cis	rs672059	0.966	rs492228	chr1:183156476	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.13	0.37	6.54e-12	Hypertriglyceridemia;
CRC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.33e-29	Prostate cancer;
CRC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-13.75	-0.6	2.69e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg00129232	chr17:37814104	STARD3	-0.43	-6.91	-0.36	2.47e-11	Self-reported allergy;
CRC	cis	rs4908760	0.931	rs1463049	chr1:8597108	A/T	cg20416874	chr1:8611966	RERE	-0.45	-6.43	-0.33	4.39e-10	Vitiligo;
CRC	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.37	5.72	0.3	2.39e-8	Reticulocyte fraction of red cells;
CRC	cis	rs4757319	0.553	rs10766252	chr11:15443714	A/C	cg03245590	chr11:15329459	NA	0.51	8.91	0.44	3.61e-17	Breast cancer;
CRC	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg19537932	chr12:55886519	OR6C68	-0.69	-8.71	-0.43	1.49e-16	Cancer;
CRC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg05192639	chr6:26864778	GUSBL1	-0.37	-6.5	-0.34	3.05e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8008758	1.000	rs8008758	chr14:101690045	A/C	cg26224664	chr14:101693935	NA	0.37	5.84	0.31	1.28e-8	Body mass index (alcohol intake interaction);
CRC	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.68	10.81	0.51	1.67e-23	Pulmonary function decline;
CRC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg23743428	chr13:21893420	NA	-0.42	-6.49	-0.34	3.08e-10	White matter hyperintensity burden;
CRC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg15123519	chr2:136567270	LCT	-0.35	-6.88	-0.35	3.01e-11	Mosquito bite size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26084319	chr14:21905280	CHD8	0.52	7.57	0.39	3.76e-13	Response to antipsychotic treatment;
CRC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.02	0.32	4.65e-9	Heart rate;
CRC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg08213375	chr14:104286397	PPP1R13B	0.35	5.82	0.31	1.4e-8	Reticulocyte count;
CRC	cis	rs12612619	0.732	rs1078809	chr2:27288915	C/T	cg00617064	chr2:27272375	NA	-0.38	-6.29	-0.33	9.83e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9992667	0.911	rs12332031	chr4:38653502	C/T	cg19726192	chr4:38663646	FLJ13197	-0.71	-8.93	-0.44	3.18e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg25459000	chr22:39777742	SYNGR1	-0.33	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg01788221	chr16:89496183	ANKRD11	-0.45	-6.95	-0.36	1.99e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg04611788	chr3:186434169	KNG1	-0.57	-8.32	-0.42	2.41e-15	Blood protein levels;
CRC	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg27534772	chr1:16042836	PLEKHM2	-0.44	-7.53	-0.38	4.8e-13	Systolic blood pressure;
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg12516270	chr8:143859308	LYNX1	0.44	7.7	0.39	1.5700000000000001e-13	Urinary tract infection frequency;
CRC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.19	0.64	7.34e-40	Primary sclerosing cholangitis;
CRC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.48	8.02	0.4	1.9e-14	Major depressive disorder;
CRC	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.83	0.63	1.82e-38	Exhaled nitric oxide output;
CRC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg21475434	chr5:93447410	FAM172A	-0.48	-5.79	-0.3	1.66e-8	Diabetic retinopathy;
CRC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17507749	chr15:85114479	UBE2QP1	0.64	9.03	0.45	1.49e-17	Schizophrenia;
CRC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg05304507	chr6:116381966	FRK	0.3	8.08	0.41	1.23e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.67	-9.32	-0.46	1.78e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg04166393	chr7:2884313	GNA12	0.37	5.69	0.3	2.77e-8	Height;
CRC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.58	0.43	3.88e-16	Lymphocyte counts;
CRC	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.51	7.89	0.4	4.51e-14	Coronary artery disease;
CRC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.65	-9.72	-0.47	8.36e-20	Menarche (age at onset);
CRC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-11.37	-0.53	1.68e-25	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.49	7.21	0.37	3.81e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.35	-5.93	-0.31	7.59e-9	Schizophrenia;
CRC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg03909863	chr11:638404	DRD4	-0.51	-6.73	-0.35	7.46e-11	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.54	6.82	0.35	4.35e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.83	15.06	0.64	2.31e-39	Vitiligo;
CRC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-13.7	-0.6	4.19e-34	Gut microbiome composition (summer);
CRC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.83	13.12	0.59	6.25e-32	Alcohol dependence;
CRC	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.8e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg07274523	chr3:49395745	GPX1	0.48	6.17	0.32	2.05e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10760158	0.800	rs3747850	chr9:124064928	G/T	cg14417974	chr9:124058376	GSN	-0.35	-5.74	-0.3	2.18e-8	Pulse pressure;
CRC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.42	6.31	0.33	9.18e-10	Alzheimer's disease (late onset);
CRC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.55	8.69	0.43	1.7e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.6	-8.58	-0.43	3.77e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.86	-19.72	-0.74	1.08e-57	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6840360	0.681	rs4519779	chr4:152301185	G/A	cg09659197	chr4:152720779	NA	0.32	6.24	0.33	1.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3804749	1.000	rs3804749	chr3:122833003	A/G	cg26084141	chr3:122786895	PDIA5	-0.25	-6.88	-0.35	3.1e-11	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.53	-6.59	-0.34	1.76e-10	Cholesterol, total;
CRC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.68	10.64	0.51	6.64e-23	Dental caries;
CRC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs2227564	0.700	rs2688613	chr10:75653045	C/T	cg00564723	chr10:75632066	CAMK2G	-0.29	-6.68	-0.35	1e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9322817	0.691	rs2499658	chr6:105291412	A/G	cg02098413	chr6:105308735	HACE1	0.44	8.72	0.43	1.42e-16	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg15845792	chr6:28175446	NA	0.63	8.61	0.43	3.13e-16	Parkinson's disease;
CRC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.36	5.81	0.31	1.48e-8	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg12273811	chr6:28175739	NA	0.45	6.81	0.35	4.63e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg00063174	chr2:228736253	WDR69	-0.52	-7.04	-0.36	1.12e-11	Blood pressure;
CRC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.52	0.46	3.8e-19	Parkinson's disease;
CRC	cis	rs2179367	0.959	rs480034	chr6:149735430	C/T	cg11245181	chr6:149772854	ZC3H12D	0.42	6.24	0.33	1.38e-9	Dupuytren's disease;
CRC	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	2.97e-10	Fibrinogen levels;
CRC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.49	0.67	6.2e-45	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-9.61	-0.47	2.03e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	5.98e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs62408225	0.963	rs55885254	chr6:90976234	T/C	cg06866423	chr6:90926672	BACH2	0.5	8.15	0.41	7.56e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	5.79	0.3	1.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10901841	chr8:145149865	CYC1	0.41	6.02	0.31	4.62e-9	Anxiety disorder;
CRC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg20203395	chr5:56204925	C5orf35	0.47	6.57	0.34	1.97e-10	Coronary artery disease;
CRC	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.39	0.56	3.52e-29	Height;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg01721255	chr8:58191610	C8orf71	0.47	6.02	0.31	4.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10486722	0.575	rs7777373	chr7:41804661	T/C	cg22138096	chr7:41772439	LOC285954	0.54	6.53	0.34	2.54e-10	Pit-and-Fissure caries;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18789337	chr6:114180353	MARCKS	0.52	7.0	0.36	1.41e-11	Thyroid stimulating hormone;
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg05569086	chr8:143859399	LYNX1	0.37	6.58	0.34	1.81e-10	Urinary tract infection frequency;
CRC	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	0.83	6.89	0.35	2.89e-11	Economic and political preferences (immigration/crime);
CRC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.96	-0.48	1.31e-20	Chronic sinus infection;
CRC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.3	0.33	9.77e-10	Aortic root size;
CRC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-18.33	-0.71	3.41e-52	Height;
CRC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.76	-0.39	1.1e-13	Schizophrenia;
CRC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.69	9.63	0.47	1.62e-19	Lung cancer;
CRC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.52	7.99	0.4	2.34e-14	Calcium levels;
CRC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.66	-9.62	-0.47	1.75e-19	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20591167	chr15:99602178	NA	0.42	6.0	0.31	5.13e-9	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.53	8.18	0.41	6.27e-15	Corneal astigmatism;
CRC	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.77	-9.18	-0.45	4.96e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg13334819	chr7:99746414	C7orf59	-0.44	-6.0	-0.31	5.32e-9	Coronary artery disease;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg02683314	chr19:4182606	SIRT6;ANKRD24	0.53	6.36	0.33	6.59e-10	Body mass index;
CRC	cis	rs6756513	0.520	rs7569566	chr2:70174030	T/C	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.9	-0.4	4.32e-14	Breast cancer;Platelet count;
CRC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg24375607	chr4:120327624	NA	0.47	7.72	0.39	1.42e-13	Corneal astigmatism;
CRC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.45	5.8	0.3	1.58e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.65	9.89	0.48	2.29e-20	Corneal astigmatism;
CRC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg00343986	chr7:65444356	GUSB	-0.41	-5.85	-0.31	1.2e-8	Aortic root size;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg22687807	chr8:143858763	LYNX1	0.49	8.93	0.44	3.15e-17	Urinary tract infection frequency;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19970200	chr7:47621223	NA	-0.48	-6.19	-0.32	1.82e-9	Diisocyanate-induced asthma;
CRC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg21770322	chr7:97807741	LMTK2	0.57	9.43	0.46	7.59e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	12.54	0.57	9.57e-30	Lymphocyte percentage of white cells;
CRC	cis	rs2882667	0.931	rs13153618	chr5:138352776	C/A	cg09476006	chr5:138032270	NA	0.42	6.91	0.36	2.54e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	trans	rs2797369	0.583	rs7740295	chr6:101549059	T/G	cg26346621	chr12:6873348	NA	-0.4	-6.01	-0.31	4.93e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg05527609	chr1:210001259	C1orf107	-0.43	-5.64	-0.3	3.64e-8	Monobrow;
CRC	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg07979401	chr6:33739406	LEMD2	-0.46	-5.99	-0.31	5.37e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26733140	chr11:63993641	NUDT22;TRPT1	0.37	6.91	0.36	2.44e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.44	6.63	0.34	1.39e-10	Colorectal cancer;
CRC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.64	-0.34	1.27e-10	Coronary artery disease;
CRC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.5	-8.03	-0.4	1.8e-14	Huntington's disease progression;
CRC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg03948781	chr1:205179583	DSTYK	0.41	5.62	0.3	4.02e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.61	-0.3	4.38e-8	Breast cancer;
CRC	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.48	-7.12	-0.37	6.74e-12	Coronary heart disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19016253	chr10:101945959	ERLIN1	0.46	6.01	0.31	4.8e-9	Thyroid stimulating hormone;
CRC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.2	-0.32	1.65e-9	Height;
CRC	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg16540259	chr10:75572220	NDST2	0.39	5.88	0.31	9.93e-9	Inflammatory bowel disease;
CRC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs7572644	0.640	rs11127125	chr2:28023120	T/C	cg27432699	chr2:27873401	GPN1	0.45	5.66	0.3	3.27e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08190410	chr16:67217759	KIAA0895L	0.46	6.44	0.33	4.32e-10	Anxiety disorder;
CRC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-8.36	-0.42	1.78e-15	Uric acid levels;
CRC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.6	9.33	0.46	1.67e-18	Diastolic blood pressure;
CRC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10905065	0.895	rs1567706	chr10:5853767	T/C	cg11519256	chr10:5708881	ASB13	-0.44	-6.29	-0.33	9.83e-10	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs12467279	chr2:162544744	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.58e-9	Cognitive function;
CRC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.24	0.33	1.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24583646	chr2:75937918	C2orf3	0.39	6.07	0.32	3.54e-9	Schizophrenia;
CRC	trans	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg26043149	chr18:55253948	FECH	0.51	7.79	0.39	8.57e-14	Bone mineral density;
CRC	cis	rs9359856	0.956	rs6933010	chr6:90299879	G/C	cg13799429	chr6:90582589	CASP8AP2	0.47	6.61	0.34	1.55e-10	Bipolar disorder;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.63	8.37	0.42	1.67e-15	Alzheimer's disease;
CRC	trans	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.97	0.36	1.72e-11	Ulcerative colitis;
CRC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.5	6.79	0.35	5.11e-11	Total body bone mineral density;
CRC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg02741985	chr17:80059408	CCDC57	0.42	6.66	0.34	1.12e-10	Life satisfaction;
CRC	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg02353165	chr6:42928485	GNMT	0.55	7.0	0.36	1.44e-11	Blood protein levels;
CRC	cis	rs7487075	0.786	rs2242355	chr12:46662485	C/G	cg22049899	chr12:47219821	SLC38A4	0.29	5.63	0.3	3.88e-8	Itch intensity from mosquito bite;
CRC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.46	-6.75	-0.35	6.5e-11	Melanoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07811750	chr17:4890503	CAMTA2	0.41	6.56	0.34	2.05e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9409565	0.826	rs4744338	chr9:97158965	C/T	cg05679027	chr9:99775184	HIATL2	0.43	6.65	0.34	1.24e-10	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg09163369	chr1:210001066	C1orf107	0.4	5.75	0.3	2.08e-8	Orofacial clefts;
CRC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-7.15	-0.37	5.68e-12	Personality dimensions;
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.33	-5.72	-0.3	2.38e-8	Blood metabolite levels;
CRC	cis	rs995000	0.868	rs9787156	chr1:63179212	G/A	cg19896129	chr1:63156450	NA	-0.43	-6.51	-0.34	2.88e-10	Triglyceride levels;
CRC	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.55	-8.05	-0.41	1.55e-14	Response to temozolomide;
CRC	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg13385794	chr1:248469461	NA	0.38	6.57	0.34	1.94e-10	Common traits (Other);
CRC	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg01951491	chr16:67709440	GFOD2	-0.43	-5.76	-0.3	1.92e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	17.67	0.7	1.31e-49	Platelet count;
CRC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.53	8.95	0.44	2.57e-17	Systemic lupus erythematosus;
CRC	cis	rs2019216	1.000	rs2019216	chr17:21909650	C/T	cg05591447	chr17:21909280	FLJ36000	-0.36	-7.23	-0.37	3.32e-12	Pelvic organ prolapse;
CRC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.65	10.17	0.49	2.53e-21	Mood instability;
CRC	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.37	6.33	0.33	8.12e-10	Sitting height ratio;
CRC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.63	-0.34	1.36e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.57	-8.52	-0.43	5.82e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg00953403	chr17:74099816	EXOC7	-0.44	-6.0	-0.31	5.28e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.47	8.09	0.41	1.14e-14	Schizophrenia;
CRC	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06307176	chr5:131281290	NA	0.45	6.51	0.34	2.74e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.6	10.27	0.49	1.18e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.49	0.34	3.12e-10	Coronary artery disease;
CRC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg05043794	chr9:111880884	C9orf5	-0.32	-5.67	-0.3	3.14e-8	Menarche (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05127367	chr3:113234065	CCDC52	0.46	6.31	0.33	8.97e-10	Anxiety disorder;
CRC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.64	5.75	0.3	2.08e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.6	8.93	0.44	3.13e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.28	-0.49	1.15e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.37	5.77	0.3	1.8e-8	Height;
CRC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg12365402	chr11:9010492	NRIP3	0.52	8.48	0.42	7.59e-16	Hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12676444	chr3:25825192	NGLY1	0.38	6.12	0.32	2.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.06	-0.32	3.74e-9	Life satisfaction;
CRC	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg12458913	chr13:53173898	NA	-0.54	-8.51	-0.42	6.3e-16	Lewy body disease;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.16	-0.32	2.14e-9	Bipolar disorder;
CRC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg10589385	chr1:150898437	SETDB1	0.28	5.82	0.31	1.38e-8	Urate levels;
CRC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-6.8	-0.35	5.03e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg15465823	chr12:48382534	COL2A1	-0.37	-6.14	-0.32	2.41e-9	Glycated hemoglobin levels;
CRC	cis	rs10971721	0.822	rs12377078	chr9:33934821	A/C	cg13495928	chr9:33750294	PRSS3	-0.55	-5.67	-0.3	3.05e-8	Body mass index;
CRC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.08e-13	Alzheimer's disease (late onset);
CRC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg23517279	chr6:96025343	MANEA	-0.56	-6.2	-0.32	1.64e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs4853036	0.951	rs10496175	chr2:70153848	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.95	-0.31	6.82e-9	Colorectal or endometrial cancer;
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg04553112	chr3:125709451	NA	-0.47	-6.02	-0.32	4.63e-9	Blood pressure (smoking interaction);
CRC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.57	-6.51	-0.34	2.83e-10	Red cell distribution width;
CRC	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.61	-9.09	-0.45	9.79e-18	Schizophrenia;
CRC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg05341575	chr12:125625032	AACS	0.37	5.78	0.3	1.7e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1788820	0.717	rs1788823	chr18:21114917	A/G	cg14672496	chr18:21087552	C18orf8	0.44	7.46	0.38	8e-13	Body mass index;
CRC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg05585544	chr11:47624801	NA	-0.39	-6.06	-0.32	3.69e-9	Mean corpuscular hemoglobin;
CRC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg23815491	chr16:72088622	HP	0.57	7.32	0.37	1.9e-12	Blood protein levels;
CRC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.59	9.39	0.46	1.04e-18	Type 2 diabetes;
CRC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.56	-0.34	2.04e-10	Subjective well-being;
CRC	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg18404041	chr3:52824283	ITIH1	0.33	6.6	0.34	1.66e-10	Schizophrenia;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg10729496	chr3:10149963	C3orf24	0.5	6.64	0.34	1.28e-10	Alzheimer's disease;
CRC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg20243544	chr17:37824526	PNMT	0.42	6.6	0.34	1.69e-10	Asthma;
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.23	-0.32	1.44e-9	Total body bone mineral density;
CRC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	8.88	0.44	4.37e-17	Platelet count;
CRC	cis	rs9491140	0.539	rs11154224	chr6:124678535	G/A	cg22366943	chr6:124882293	NKAIN2	0.56	8.52	0.43	5.69e-16	Neuroticism;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg12172441	chr6:28176163	NA	0.54	7.07	0.36	9.53e-12	Parkinson's disease;
CRC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.44	0.46	6.98e-19	Cognitive test performance;
CRC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg27661571	chr11:113659931	NA	-0.76	-9.53	-0.47	3.57e-19	Hip circumference adjusted for BMI;
CRC	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.55	7.92	0.4	3.81e-14	Uric acid levels;
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	6.66	0.34	1.13e-10	Blood metabolite levels;
CRC	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg08508325	chr11:3079039	CARS	-0.41	-7.15	-0.37	5.52e-12	Longevity;
CRC	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.45	7.3	0.37	2.2e-12	Sitting height ratio;
CRC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.58	-9.0	-0.44	1.87e-17	Aortic root size;
CRC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg20203395	chr5:56204925	C5orf35	-0.42	-5.73	-0.3	2.27e-8	Coronary artery disease;
CRC	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg00277334	chr10:82204260	NA	-0.52	-5.68	-0.3	2.98e-8	Post bronchodilator FEV1;
CRC	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.45	0.34	4.04e-10	Body mass index;
CRC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.56	8.12	0.41	9.72e-15	Morning vs. evening chronotype;
CRC	cis	rs7113874	0.531	rs7934396	chr11:8615632	C/G	cg02811074	chr11:8615871	STK33	0.35	6.05	0.32	3.93e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-11.01	-0.52	3.19e-24	Personality dimensions;
CRC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25517755	chr10:38738941	LOC399744	-0.43	-6.3	-0.33	9.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.89	0.55	2.24e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs727505	0.866	rs3214004	chr7:124720929	T/C	cg23710748	chr7:124431027	NA	-0.72	-12.33	-0.56	5.81e-29	Lewy body disease;
CRC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.49	-0.34	3.19e-10	Aortic root size;
CRC	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.4	7.69	0.39	1.72e-13	Ulcerative colitis;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02698600	chr1:201450009	NA	-0.39	-6.0	-0.31	5.1e-9	Myopia (pathological);
CRC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.25	-0.33	1.31e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27479418	chr10:126107594	OAT	0.37	6.1	0.32	3.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.81e-8	Major depressive disorder;
CRC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.52	-8.51	-0.42	6.27e-16	Testicular germ cell tumor;
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.45	-0.38	8.06e-13	Type 2 diabetes;
CRC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.96	13.99	0.61	3.33e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg22676075	chr6:135203613	NA	0.41	6.35	0.33	7.3e-10	Red blood cell count;
CRC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.58	-8.61	-0.43	3.09e-16	Longevity;
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg07404485	chr7:94953653	PON1	-0.45	-6.04	-0.32	4.16e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.58	0.5	1.07e-22	Alzheimer's disease;
CRC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.34	5.79	0.3	1.67e-8	Major depressive disorder;
CRC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg16745616	chr19:8428856	ANGPTL4	-0.45	-7.04	-0.36	1.16e-11	HDL cholesterol;
CRC	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg10820045	chr2:198174542	NA	0.39	6.41	0.33	4.94e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	5.98	0.31	5.97e-9	Neuroticism;
CRC	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.5	7.76	0.39	1.08e-13	Red blood cell count;
CRC	cis	rs4684776	0.676	rs1809049	chr3:11302884	C/T	cg00170343	chr3:11313890	ATG7	-0.47	-5.62	-0.3	4.08e-8	Small vessel stroke;
CRC	cis	rs9462846	0.853	rs7741547	chr6:42873813	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-6.43	-0.33	4.47e-10	Blood protein levels;
CRC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg25767906	chr1:53392781	SCP2	-0.38	-5.93	-0.31	7.8e-9	Monocyte count;
CRC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.75	10.35	0.5	6.58e-22	Initial pursuit acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27252137	chr12:124155579	TCTN2	0.42	6.01	0.31	4.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg01475377	chr6:109611718	NA	-0.35	-6.09	-0.32	3.18e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.09	0.32	3.16e-9	Bladder cancer;
CRC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-8.12	-0.41	9.51e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.45	-0.33	4.04e-10	DNA methylation (variation);
CRC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.13	0.64	1.23e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.03	0.45	1.46e-17	Coffee consumption (cups per day);
CRC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.35	-6.43	-0.33	4.4e-10	Menarche (age at onset);
CRC	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.49	-6.09	-0.32	3.18e-9	Coronary artery calcification;
CRC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.14	-0.45	6.38e-18	Migraine;Coronary artery disease;
CRC	cis	rs7274811	0.711	rs657040	chr20:32001292	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.89	0.31	9.59e-9	Height;
CRC	cis	rs12024301	0.557	rs9286849	chr1:183655210	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.62	5.61	0.3	4.28e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.35	-5.75	-0.3	1.99e-8	Body mass index;
CRC	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.88	0.4	4.94e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.14	0.37	5.87e-12	Corneal astigmatism;
CRC	cis	rs3736485	0.934	rs12442803	chr15:51898754	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.5	-0.34	3.02e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24516711	chr2:242576858	ATG4B;THAP4	0.47	6.63	0.34	1.4e-10	Anxiety disorder;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20310071	chr8:77912528	PXMP3	0.45	5.99	0.31	5.43e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg11861562	chr11:117069780	TAGLN	0.34	6.26	0.33	1.19e-9	Blood protein levels;
CRC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Tonsillectomy;
CRC	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.33	5.75	0.3	2.03e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.2	-0.32	1.68e-9	Coronary artery disease;
CRC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg04450456	chr4:17643702	FAM184B	0.41	6.69	0.35	9.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.55	8.76	0.43	1.08e-16	Breast cancer;
CRC	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.11	0.36	7.11e-12	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.48e-9	Depression;
CRC	cis	rs2811415	0.597	rs9861755	chr3:127739721	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.72	-0.3	2.37e-8	Lung function (FEV1/FVC);
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.84	-0.31	1.25e-8	Longevity;Endometriosis;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg14646075	chr2:228736089	WDR69	-0.47	-6.42	-0.33	4.82e-10	Blood pressure;
CRC	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02664216	chr12:19592651	AEBP2	0.52	6.91	0.36	2.53e-11	Thyroid stimulating hormone;
CRC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg21466736	chr12:48725269	NA	-0.53	-7.95	-0.4	3.09e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24796471	chr19:6737389	GPR108	0.46	6.96	0.36	1.8e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.73	-8.33	-0.42	2.18e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.58	-6.75	-0.35	6.74e-11	Bronchopulmonary dysplasia;
CRC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.54	8.73	0.43	1.29e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.48	-7.81	-0.4	7.54e-14	Huntington's disease progression;
CRC	cis	rs6076065	0.723	rs2281429	chr20:23399544	A/T	cg11657817	chr20:23433608	CST11	0.4	6.21	0.32	1.6e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	9.3	0.46	1.95e-18	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.52	-7.97	-0.4	2.67e-14	Menarche (age at onset);
CRC	cis	rs12144094	0.882	rs1853048	chr1:120240114	C/A	cg20995928	chr1:120229863	NA	0.48	6.9	0.36	2.74e-11	Height;
CRC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.68	10.14	0.49	3.26e-21	Menopause (age at onset);
CRC	cis	rs4731207	0.698	rs10272583	chr7:124509451	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.24	-0.41	4.22e-15	Metabolite levels;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg22677401	chr17:46026860	NA	-0.7	-6.05	-0.32	3.89e-9	Cognitive function;
CRC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.44	6.64	0.34	1.29e-10	Calcium levels;
CRC	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg12756093	chr1:115239321	AMPD1	0.57	8.69	0.43	1.74e-16	Autism;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg20505218	chr17:80009845	GPS1;RFNG	-0.41	-6.24	-0.33	1.34e-9	Aortic root size;
CRC	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg27205649	chr11:78285834	NARS2	0.48	5.85	0.31	1.2e-8	Alzheimer's disease (survival time);
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.8	13.61	0.6	9.07e-34	Menopause (age at onset);
CRC	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.56	-7.9	-0.4	4.36e-14	Osteoporosis;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg17684478	chr11:118842230	FOXR1	0.43	6.82	0.35	4.26e-11	Interleukin-6 levels;
CRC	cis	rs6691722	0.503	rs2274168	chr1:24707211	G/T	cg02336364	chr1:24764700	NIPAL3	0.38	6.34	0.33	7.53e-10	Response to interferon beta in multiple sclerosis;
CRC	cis	rs6479527	0.875	rs7033898	chr9:96804235	T/C	cg14459158	chr9:96720562	NA	0.39	6.95	0.36	1.96e-11	Esophageal adenocarcinoma;
CRC	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	6.21	0.32	1.63e-9	Axial length;
CRC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.97	-0.31	6.12e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.39	-5.74	-0.3	2.17e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-8.92	-0.44	3.31e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-10.71	-0.51	3.75e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11229555	0.609	rs7928676	chr11:58188022	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	10.25	0.49	1.45e-21	Intelligence (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.43	-8.69	-0.43	1.74e-16	Renal cell carcinoma;
CRC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.55	6.62	0.34	1.49e-10	Diastolic blood pressure;
CRC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg16102536	chr7:156981717	UBE3C	-0.41	-6.85	-0.35	3.58e-11	Body mass index;
CRC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.14e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02933969	chr8:12612811	LONRF1	0.47	6.46	0.34	3.83e-10	Anxiety disorder;
CRC	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.78	-0.35	5.43e-11	Neuroticism;
CRC	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.54	-6.77	-0.35	6e-11	Personality dimensions;
CRC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.94	0.44	2.93e-17	Morning vs. evening chronotype;
CRC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg23758597	chr6:163146217	PARK2	-0.52	-6.08	-0.32	3.36e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6662572	0.703	rs56278140	chr1:46357544	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.71	0.3	2.46e-8	Blood protein levels;
CRC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.57	-8.08	-0.41	1.23e-14	Inflammatory bowel disease;
CRC	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg14673194	chr17:80132900	CCDC57	0.48	6.27	0.33	1.13e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-1.03	-9.73	-0.47	8.1e-20	Post bronchodilator FEV1;
CRC	cis	rs4731207	0.596	rs6954614	chr7:124629794	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.33	-0.33	7.94e-10	Cutaneous malignant melanoma;
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.59e-12	Life satisfaction;
CRC	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg24300038	chr13:113819356	PROZ	-0.47	-6.03	-0.32	4.5e-9	Platelet distribution width;
CRC	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.64	11.52	0.54	5.1e-26	Blood metabolite ratios;
CRC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg26816564	chr1:7831052	VAMP3	0.51	5.78	0.3	1.74e-8	Inflammatory bowel disease;
CRC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	15.14	0.64	1.16e-39	Smoking behavior;
CRC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.73	-11.56	-0.54	3.63e-26	Colorectal cancer;
CRC	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg04733911	chr16:78082701	NA	-0.41	-6.55	-0.34	2.19e-10	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.09e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.42	-6.45	-0.34	3.97e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9992667	0.955	rs66709517	chr4:38649393	A/G	cg19726192	chr4:38663646	FLJ13197	-0.69	-8.69	-0.43	1.72e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.46	0.42	9.08e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.06	0.32	3.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7923609	0.967	rs10740134	chr10:65315433	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.72	-0.3	2.42e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg06092702	chr1:163392909	NA	0.39	6.02	0.31	4.66e-9	Motion sickness;
CRC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.55	0.5	1.3e-22	Ileal carcinoids;
CRC	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg23229984	chr5:148520753	ABLIM3	0.49	6.8	0.35	4.85e-11	Breast cancer;
CRC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg21620606	chr4:1342894	KIAA1530	0.4	7.19	0.37	4.39e-12	Longevity;
CRC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.3	0.33	9.81e-10	Rheumatoid arthritis;
CRC	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg09659197	chr4:152720779	NA	0.52	11.25	0.53	4.71e-25	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg13206674	chr6:150067644	NUP43	0.5	6.93	0.36	2.24e-11	Testicular germ cell tumor;
CRC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08047338	chr2:75873982	MRPL19	0.48	6.72	0.35	8.06e-11	Response to antipsychotic treatment;
CRC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.37	0.56	4.15e-29	Menopause (age at onset);
CRC	cis	rs7635838	0.892	rs9310381	chr3:11458466	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.26	0.33	1.22e-9	HDL cholesterol;
CRC	cis	rs9783347	0.857	rs2124374	chr11:18313911	A/C	cg15585147	chr11:18324498	HPS5	0.43	5.98	0.31	5.75e-9	Pancreatic cancer;
CRC	cis	rs9409565	0.821	rs7858082	chr9:97063929	T/A	cg04523069	chr9:97136363	HIATL1	-0.41	-6.22	-0.32	1.53e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.76	-12.53	-0.57	1.07e-29	Menopause (age at onset);
CRC	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.52	-8.88	-0.44	4.34e-17	Mean corpuscular volume;
CRC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.64e-17	Prostate cancer;
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.15	-0.32	2.25e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs6066835	0.702	rs6066807	chr20:47267144	C/T	cg21109867	chr19:55897418	RPL28	-0.74	-6.05	-0.32	3.88e-9	Multiple myeloma;
CRC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.06	0.69	3.31e-47	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.41	9.08	0.45	1.06e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	17.09	0.69	2.6e-47	Testicular germ cell tumor;
CRC	cis	rs4664293	0.647	rs4665082	chr2:160429966	T/G	cg08347373	chr2:160653686	CD302	-0.38	-6.43	-0.33	4.52e-10	Monocyte percentage of white cells;
CRC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	0.59	6.09	0.32	3.08e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.46	-7.45	-0.38	8.25e-13	Obesity-related traits;
CRC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.09	-0.49	4.8e-21	Body mass index;
CRC	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.51	7.77	0.39	1e-13	Red cell distribution width;
CRC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.41	5.71	0.3	2.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.35	-0.38	1.61e-12	Eye color traits;
CRC	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.48	-6.84	-0.35	3.79e-11	Schizophrenia;
CRC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.64	-10.55	-0.5	1.3e-22	Systemic lupus erythematosus;
CRC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.76	13.64	0.6	7.09e-34	Age at first birth;
CRC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	6.76	0.35	6.45e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-7.69	-0.39	1.71e-13	Body mass index;
CRC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg21951975	chr1:209979733	IRF6	0.46	5.87	0.31	1.08e-8	Cleft lip with or without cleft palate;
CRC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.38	7.81	0.4	7.75e-14	Cutaneous nevi;
CRC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	9.32	0.46	1.74e-18	Multiple sclerosis;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10757027	chr7:150783788	AGAP3	0.33	6.01	0.31	4.91e-9	Obesity-related traits;
CRC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg13798912	chr7:905769	UNC84A	0.52	5.92	0.31	8.23e-9	Cerebrospinal P-tau181p levels;
CRC	trans	rs1642645	0.831	rs6698877	chr1:42500436	T/C	cg16926213	chr1:1841314	NA	-0.44	-6.15	-0.32	2.22e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs501120	0.657	rs649192	chr10:44741179	G/C	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg00343986	chr7:65444356	GUSB	-0.49	-7.23	-0.37	3.38e-12	Aortic root size;
CRC	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg21174375	chr14:64681225	SYNE2	0.39	6.41	0.33	5.04e-10	Atrial fibrillation;
CRC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg14186256	chr22:23484241	RTDR1	0.47	5.76	0.3	1.97e-8	Serum parathyroid hormone levels;
CRC	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.54	0.47	3.31e-19	Type 2 diabetes;
CRC	trans	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg17903999	chr18:56338584	MALT1	0.39	6.5	0.34	2.96e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.7	-13.84	-0.61	1.22e-34	Educational attainment;
CRC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-9.23	-0.45	3.5e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23335946	chr1:185125966	C1orf25;C1orf26	0.47	6.11	0.32	2.85e-9	Thyroid stimulating hormone;
CRC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.74	10.83	0.51	1.37e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7976838	0.908	rs17122978	chr12:60167835	A/C	cg16974014	chr22:22007515	MIR130B	-0.48	-5.99	-0.31	5.38e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.47	6.05	0.32	3.89e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg04110750	chr16:69646130	NFAT5	-0.49	-6.79	-0.35	5.34e-11	IgE levels;
CRC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg02869306	chr7:64672164	INTS4L1	-0.41	-6.11	-0.32	2.78e-9	Aortic root size;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg21620606	chr4:1342894	KIAA1530	-0.41	-7.3	-0.37	2.25e-12	Obesity-related traits;
CRC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.39	-6.3	-0.33	9.56e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.47	-7.35	-0.38	1.62e-12	Diastolic blood pressure;
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.63	0.34	1.39e-10	Alzheimer's disease;
CRC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.57	0.34	1.95e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg03037974	chr15:76606532	NA	0.51	7.55	0.38	4.39e-13	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg16606324	chr3:10149918	C3orf24	0.7	9.79	0.48	4.82e-20	Alzheimer's disease;
CRC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.45	6.06	0.32	3.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-7.19	-0.37	4.36e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.1	-0.36	7.9e-12	Bipolar disorder;
CRC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.12	0.52	1.29e-24	Monocyte percentage of white cells;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg17949981	chr6:28129498	ZNF389	0.41	5.62	0.3	4.15e-8	Cardiac Troponin-T levels;
CRC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg03030879	chr14:75389066	RPS6KL1	0.44	6.75	0.35	6.78e-11	Height;
CRC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.95	18.15	0.71	1.66e-51	Height;
CRC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs524281	0.861	rs12226649	chr11:65842047	T/C	cg16950941	chr11:66035639	RAB1B	-0.58	-7.13	-0.37	6.39e-12	Electroencephalogram traits;
CRC	cis	rs9311676	0.609	rs6770113	chr3:58379297	C/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.34	-0.38	1.67e-12	Schizophrenia;
CRC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg21153622	chr11:89784906	NA	-0.43	-7.01	-0.36	1.39e-11	Height;
CRC	cis	rs3996993	0.646	rs1051775	chr6:52658962	T/C	cg20803780	chr6:52668592	GSTA1	0.36	6.48	0.34	3.43e-10	Hemoglobin concentration;
CRC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.52	8.15	0.41	7.64e-15	Colorectal cancer;
CRC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-6.93	-0.36	2.2e-11	Rheumatoid arthritis;
CRC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg01262667	chr19:19385393	TM6SF2	-0.37	-5.96	-0.31	6.34e-9	Tonsillectomy;
CRC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-7.08	-0.36	8.59e-12	Self-reported allergy;
CRC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.58	0.34	1.86e-10	Vitiligo;
CRC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg03160526	chr17:80928410	B3GNTL1	-0.42	-6.09	-0.32	3.08e-9	Breast cancer;
CRC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.46	6.11	0.32	2.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.35	5.98	0.31	5.93e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.49	0.54	6.58e-26	Prudent dietary pattern;
CRC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.9	16.39	0.67	1.5e-44	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.77	10.47	0.5	2.56e-22	Vitiligo;
CRC	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg15711740	chr2:61764176	XPO1	0.43	5.69	0.3	2.8e-8	Tuberculosis;
CRC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.68e-12	Obesity-related traits;
CRC	cis	rs9649465	0.935	rs3815458	chr7:123304323	A/T	cg03229431	chr7:123269106	ASB15	-0.37	-5.71	-0.3	2.56e-8	Migraine;
CRC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.37	0.38	1.41e-12	Calcium levels;
CRC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg13722127	chr7:150037890	RARRES2	0.37	5.96	0.31	6.41e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.55	-8.56	-0.43	4.38e-16	Huntington's disease progression;
CRC	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.5	-6.89	-0.36	2.85e-11	Tuberculosis;
CRC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.42	5.69	0.3	2.83e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11078198	chr14:21572134	ZNF219	0.52	6.89	0.36	2.85e-11	Thyroid stimulating hormone;
CRC	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.47	0.65	6.02e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7625357	0.964	rs10513679	chr3:169353184	C/T	cg04414509	chr3:169351419	MECOM	0.61	8.27	0.41	3.29e-15	Childhood and early adolescence aggressive behavior;
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02290350	chr8:58132656	NA	-0.61	-6.94	-0.36	2.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.55	6.79	0.35	5.32e-11	Exhaled nitric oxide output;
CRC	cis	rs2953174	0.529	rs3997219	chr2:241541619	T/C	cg07929629	chr2:241523174	NA	0.64	8.52	0.43	5.72e-16	Bipolar disorder;
CRC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.51	7.87	0.4	5.31e-14	Emphysema distribution in smoking;
CRC	cis	rs2333194	0.869	rs177368	chr14:73761247	T/C	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.43	-6.46	-0.34	3.74e-10	Bipolar disorder with mood-incongruent psychosis;
CRC	trans	rs1412337	1.000	rs1412337	chr1:168618641	C/T	cg03540912	chr16:71792711	SNORD71;AP1G1	0.5	6.11	0.32	2.86e-9	Morbidity-free survival;
CRC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg02659138	chr7:134003124	SLC35B4	0.39	6.67	0.35	1.09e-10	Mean platelet volume;
CRC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.54	7.59	0.39	3.39e-13	Melanoma;
CRC	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg11693508	chr17:37793320	STARD3	0.64	7.33	0.37	1.75e-12	Bipolar disorder;
CRC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.07	0.49	5.87e-21	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.83	-0.31	1.31e-8	Depression;
CRC	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.45	8.92	0.44	3.35e-17	Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.4	0.53	1.3e-25	Exhaled nitric oxide levels;
CRC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.58	6.48	0.34	3.27e-10	Bipolar disorder;
CRC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26850624	chr5:429559	AHRR	0.52	8.8	0.44	7.95e-17	Cystic fibrosis severity;
CRC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-5.67	-0.3	3.07e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-6.87	-0.35	3.29e-11	Morning vs. evening chronotype;
CRC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg05304507	chr6:116381966	FRK	0.29	7.97	0.4	2.57e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.36	6.17	0.32	2.06e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.75	12.39	0.56	3.37e-29	Neuroticism;
CRC	cis	rs11212617	1.000	rs228590	chr11:108096141	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.26	0.33	1.19e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.59	9.01	0.45	1.66e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.69	-0.43	1.73e-16	Bone mineral density;
CRC	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.12	0.32	2.64e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.76	16.79	0.68	4e-46	Breast cancer;
CRC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-8.77	-0.44	9.84e-17	Mean corpuscular hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03217408	chr17:72919480	OTOP2;USH1G	0.5	7.01	0.36	1.38e-11	Response to antipsychotic treatment;
CRC	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09022552	chr16:28962119	NFATC2IP	0.43	6.17	0.32	2.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.35e-8	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08855568	chr3:61547104	PTPRG	0.38	5.97	0.31	5.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg18612461	chr15:75251733	NA	0.4	6.12	0.32	2.68e-9	Breast cancer;
CRC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.66	8.81	0.44	7.3e-17	Morning vs. evening chronotype;
CRC	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.85	16.25	0.67	5.09e-44	Hip circumference;
CRC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.56	-7.3	-0.37	2.14e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.38	-0.33	6.14e-10	Mood instability;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01737828	chr15:75230659	COX5A	0.46	6.37	0.33	6.45e-10	Response to antipsychotic treatment;
CRC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.39	6.72	0.35	7.78e-11	Crohn's disease;
CRC	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.79	11.39	0.53	1.42e-25	Gout;
CRC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.86	12.26	0.56	9.86e-29	Initial pursuit acceleration;
CRC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.36	-5.66	-0.3	3.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.57e-10	HDL cholesterol;
CRC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	8.15	0.41	7.78e-15	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg01874867	chr7:94954059	PON1	-0.48	-6.02	-0.32	4.57e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.29	-0.42	2.99e-15	Schizophrenia;
CRC	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.8	9.78	0.47	5.36e-20	Exhaled nitric oxide output;
CRC	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-5.88	-0.31	1.02e-8	Eosinophil percentage of white cells;
CRC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.7	-11.86	-0.55	3.01e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.83	-12.88	-0.58	4.96e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.36	5.74	0.3	2.1e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.48	6.09	0.32	3.21e-9	Response to diuretic therapy;
CRC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.41	-0.33	5.06e-10	Monocyte percentage of white cells;
CRC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.88	-10.64	-0.51	6.45e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs3889199	0.924	rs7543389	chr1:59680536	A/G	cg25881383	chr1:59680599	NA	-0.38	-6.35	-0.33	7.07e-10	Pulse pressure;
CRC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.6	-10.66	-0.51	5.65e-23	Dupuytren's disease;
CRC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.5	7.02	0.36	1.3e-11	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.52e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.53	9.08	0.45	1e-17	Dupuytren's disease;
CRC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.46	5.89	0.31	9.33e-9	Lung function (FEV1/FVC);
CRC	cis	rs6700896	0.931	rs4655582	chr1:66153363	C/G	cg04111102	chr1:66153794	NA	0.35	6.07	0.32	3.47e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.5	6.99	0.36	1.53e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.48e-12	Eye color traits;
CRC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg22117107	chr15:45993392	NA	-0.45	-9.33	-0.46	1.67e-18	Waist circumference;Weight;
CRC	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.87	16.79	0.68	3.95e-46	Bone mineral density;
CRC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.62	-0.39	2.71e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs972578	0.967	rs2038058	chr22:43334295	C/G	cg01576275	chr22:43409880	NA	-0.43	-6.78	-0.35	5.59e-11	Mean platelet volume;
CRC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.95	0.66	8.21e-43	Primary sclerosing cholangitis;
CRC	cis	rs12024301	0.557	rs12036830	chr1:183601471	G/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.21	-0.41	4.98e-15	Chronic sinus infection;
CRC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg13206674	chr6:150067644	NUP43	0.56	8.05	0.41	1.51e-14	Lung cancer;
CRC	cis	rs4728302	0.838	rs10264922	chr7:133598975	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.77	0.3	1.8e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.42	-6.85	-0.35	3.6e-11	Height;
CRC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.66	7.21	0.37	3.85e-12	Axial length;
CRC	cis	rs294883	0.858	rs9355709	chr6:159700754	G/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs3015497	0.646	rs871643	chr14:51107452	T/C	cg26011998	chr14:51135199	SAV1	-0.44	-5.67	-0.3	3.08e-8	Mean platelet volume;
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.52	-9.56	-0.47	2.93e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	trans	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg18288967	chr1:45987694	PRDX1	0.68	7.73	0.39	1.3e-13	Obesity-related traits;
CRC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.8	11.86	0.55	3.02e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg10517650	chr3:113235015	CCDC52	-0.37	-5.89	-0.31	9.37e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15664640	chr17:80829946	TBCD	0.59	6.16	0.32	2.1e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs6681460	0.966	rs10749763	chr1:67062126	G/A	cg02459107	chr1:67143332	SGIP1	0.47	7.87	0.4	5.24e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.35	-0.33	7.09e-10	Bipolar disorder;
CRC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.58	8.03	0.4	1.74e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg15845792	chr6:28175446	NA	1.04	13.81	0.61	1.6e-34	Depression;
CRC	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.55	9.62	0.47	1.79e-19	Common traits (Other);
CRC	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg00469287	chr7:23338798	C7orf30	0.48	6.1	0.32	2.97e-9	Cerebrospinal fluid biomarker levels;
CRC	trans	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg10756647	chr7:56101905	PSPH	0.69	7.25	0.37	3e-12	Diabetic kidney disease;
CRC	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.72	-12.62	-0.57	4.76e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	8.73	0.43	1.31e-16	Menarche (age at onset);
CRC	cis	rs9658691	0.920	rs55803311	chr10:90753135	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.92	-6.67	-0.34	1.12e-10	Mosquito bite size;
CRC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg15845792	chr6:28175446	NA	0.52	7.77	0.39	1.02e-13	Pubertal anthropometrics;
CRC	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg21115391	chr11:93143810	CCDC67	-0.4	-5.91	-0.31	8.77e-9	Pulmonary function decline;
CRC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.39	7.27	0.37	2.62e-12	Mean corpuscular volume;
CRC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	13.71	0.6	3.61e-34	Menopause (age at onset);
CRC	trans	rs72991	0.561	rs75755602	chr11:121231729	T/C	cg27192990	chr6:129479024	LAMA2	-0.43	-6.14	-0.32	2.42e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.91	-15.9	-0.66	1.19e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.8	-13.42	-0.59	4.56e-33	Glaucoma (primary open-angle);
CRC	trans	rs8073060	0.586	rs72829933	chr17:34056406	C/T	cg19694781	chr19:47549865	TMEM160	1.08	13.25	0.59	2.06e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.55	-7.7	-0.39	1.58e-13	Corneal structure;
CRC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.47	6.29	0.33	9.96e-10	Obesity-related traits;
CRC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg12855166	chr17:30846586	MYO1D	0.58	9.4	0.46	9.74e-19	Schizophrenia;
CRC	cis	rs2860975	0.875	rs2211272	chr10:96765905	G/A	cg09036531	chr10:96991505	NA	-0.42	-5.79	-0.3	1.65e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.17	-13.55	-0.6	1.59e-33	Diabetic kidney disease;
CRC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg14061069	chr19:46274453	DMPK	0.68	12.53	0.57	1.02e-29	Coronary artery disease;
CRC	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.45	0.46	6.58e-19	Fuchs's corneal dystrophy;
CRC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.8	-10.85	-0.51	1.17e-23	Initial pursuit acceleration;
CRC	cis	rs909341	0.649	rs4809320	chr20:62282439	G/A	cg16989086	chr20:62203971	PRIC285	-0.53	-6.7	-0.35	8.79e-11	Atopic dermatitis;
CRC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg24289452	chr6:170231220	NA	-0.54	-6.01	-0.31	5.05e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9826463	0.527	rs112722008	chr3:142053561	A/G	cg20824294	chr3:142316082	PLS1	0.35	5.67	0.3	3.1e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.68	-11.05	-0.52	2.44e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.32	-5.97	-0.31	6.14e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.6	0.43	3.24e-16	Homoarginine levels;
CRC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.41	8.48	0.42	7.97e-16	Cutaneous nevi;
CRC	cis	rs9403521	1.000	rs12528456	chr6:144003706	A/G	cg18240653	chr6:144019428	PHACTR2	-0.55	-6.21	-0.32	1.62e-9	Obesity-related traits;
CRC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.57	-0.34	1.97e-10	Renal cell carcinoma;
CRC	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.86	9.52	0.46	3.92e-19	Diisocyanate-induced asthma;
CRC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.43	-7.91	-0.4	3.93e-14	Colorectal cancer;
CRC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.65	10.16	0.49	2.75e-21	Type 2 diabetes;
CRC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.64	9.47	0.46	5.67e-19	Primary sclerosing cholangitis;
CRC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.43	7.07	0.36	9.24e-12	Obesity-related traits;
CRC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.6	9.66	0.47	1.39e-19	Tonsillectomy;
CRC	trans	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg10756647	chr7:56101905	PSPH	-0.65	-6.84	-0.35	3.76e-11	Diabetic kidney disease;
CRC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.47	5.82	0.31	1.4e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.58	9.13	0.45	6.85e-18	Mean platelet volume;Platelet distribution width;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25026715	chr17:26989248	SUPT6H;SDF2	-0.4	-6.48	-0.34	3.29e-10	Myopia (pathological);
CRC	trans	rs800082	0.516	rs2889043	chr3:144231238	C/T	cg24215973	chr2:240111563	HDAC4	0.46	6.44	0.33	4.18e-10	Smoking behavior;
CRC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.37	6.38	0.33	5.86e-10	Crohn's disease;
CRC	cis	rs10924970	0.934	rs56681442	chr1:235466800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.4	6.0	0.31	5.32e-9	Asthma;
CRC	trans	rs11847697	1.000	rs28591603	chr14:30477520	G/A	cg01202639	chr12:100898608	NR1H4	0.51	6.64	0.34	1.29e-10	Body mass index;
CRC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.4	-5.61	-0.3	4.34e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg03160526	chr17:80928410	B3GNTL1	0.5	8.17	0.41	6.73e-15	Breast cancer;
CRC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.77	-0.3	1.78e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-7.4	-0.38	1.15e-12	Lung cancer;
CRC	cis	rs9549328	0.643	rs4907567	chr13:113617533	C/T	cg08614441	chr13:113633676	MCF2L	0.4	7.06	0.36	9.78e-12	Systolic blood pressure;
CRC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg21153622	chr11:89784906	NA	-0.42	-7.1	-0.36	7.57e-12	Coronary artery disease;
CRC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12292205	chr6:26970375	C6orf41	-0.47	-6.56	-0.34	2.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.59	-0.34	1.75e-10	Height;
CRC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.01	-0.31	5.06e-9	Alzheimer's disease (late onset);
CRC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.09	-12.55	-0.57	8.52e-30	Diabetic kidney disease;
CRC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	7.8	0.4	8.12e-14	Platelet count;
CRC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg02741985	chr17:80059408	CCDC57	0.42	6.99	0.36	1.51e-11	Life satisfaction;
CRC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg21856205	chr7:94953877	PON1	-0.47	-5.99	-0.31	5.45e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-9.21	-0.45	4.05e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.61	-8.53	-0.43	5.4e-16	Coronary artery disease;
CRC	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg23387468	chr7:139079360	LUC7L2	-0.4	-6.98	-0.36	1.63e-11	Diisocyanate-induced asthma;
CRC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.9	11.59	0.54	2.74e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs9906695	0.950	rs17652343	chr17:32572855	A/G	cg12698626	chr17:32581466	CCL2	0.42	5.89	0.31	9.46e-9	Monocyte percentage of white cells;
CRC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.3	5.6	0.3	4.51e-8	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	9.52	0.46	3.87e-19	Type 2 diabetes;
CRC	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-6.06	-0.32	3.83e-9	Osteoarthritis;
CRC	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.55	7.88	0.4	4.9e-14	Coronary artery disease;
CRC	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg23100626	chr2:96804247	ASTL	0.27	7.13	0.37	6.6e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.53	9.1	0.45	9.1e-18	Dupuytren's disease;
CRC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.45	0.53	9.19e-26	Menarche (age at onset);
CRC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.91	-17.91	-0.7	1.52e-50	Intelligence (multi-trait analysis);
CRC	cis	rs7113874	0.569	rs10160805	chr11:8600393	C/T	cg02811074	chr11:8615871	STK33	0.35	6.06	0.32	3.76e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.75	8.29	0.42	2.94e-15	Iron status biomarkers;
CRC	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.76	-0.43	1.06e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.52	0.34	2.63e-10	Electroencephalogram traits;
CRC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4400599	0.642	rs4364874	chr1:154167788	C/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.82	-0.31	1.37e-8	Platelet distribution width;
CRC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.52	8.22	0.41	4.72e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.65	-10.5	-0.5	1.91e-22	Post bronchodilator FEV1;
CRC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.67	-11.14	-0.52	1.18e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs806215	0.813	rs806175	chr7:127289435	A/G	cg25922125	chr7:127225783	GCC1	0.53	6.26	0.33	1.17e-9	Type 2 diabetes;
CRC	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg20936604	chr3:58311152	NA	-0.73	-7.25	-0.37	3.06e-12	Cholesterol, total;
CRC	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-5.92	-0.31	8.27e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.52	9.31	0.46	1.85e-18	Common traits (Other);
CRC	trans	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.83	-0.31	1.35e-8	Coronary artery disease;
CRC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.27e-13	Hip circumference adjusted for BMI;
CRC	trans	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg17712092	chr4:129076599	LARP1B	-0.61	-9.29	-0.46	2.25e-18	Eosinophil percentage of white cells;
CRC	trans	rs79464052	0.571	rs76945386	chr5:140969091	T/C	cg05255351	chr5:1503979	LPCAT1	-0.45	-6.07	-0.32	3.6e-9	Diffuse large B cell lymphoma;
CRC	cis	rs12580194	0.957	rs73118932	chr12:55706631	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-5.97	-0.31	5.99e-9	Cancer;
CRC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.73	12.0	0.55	9.38e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg04500099	chr12:95610991	FGD6;VEZT	-0.43	-6.2	-0.32	1.67e-9	Daytime sleep phenotypes;
CRC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-1.01	-19.14	-0.73	2.1e-55	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.03	-14.37	-0.62	1.16e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs75828804	1.000	rs76558985	chr16:77577513	A/G	cg19423196	chr10:82049429	MAT1A	0.54	6.26	0.33	1.17e-9	Intraocular pressure;
CRC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg27427491	chr17:78079615	GAA	0.4	6.56	0.34	2.11e-10	Yeast infection;
CRC	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.35	-0.33	7.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-8.19	-0.41	5.83e-15	Coronary artery disease;
CRC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.47	6.91	0.36	2.53e-11	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.75	-0.3	2.06e-8	Parkinson's disease;
CRC	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-8.61	-0.43	3.14e-16	Facial morphology (factor 19);
CRC	cis	rs3026101	0.671	rs3026136	chr17:5310308	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-6.0	-0.31	5.07e-9	Morning vs. evening chronotype;
CRC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.82	14.51	0.62	3.19e-37	Breast cancer;
CRC	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.59	-8.29	-0.42	2.94e-15	Arsenic metabolism;
CRC	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg16964102	chr10:135390573	NA	-0.42	-6.88	-0.35	3.08e-11	Obesity-related traits;
CRC	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.59	7.01	0.36	1.34e-11	Carotid intima media thickness;
CRC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.7	0.3	2.72e-8	Heart rate;
CRC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07685180	chr8:600429	NA	0.87	8.68	0.43	1.92e-16	IgG glycosylation;
CRC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.44	0.46	7.29e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg17948913	chr5:572064	NA	0.55	6.33	0.33	7.93e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs61160187	0.556	rs62367862	chr5:60268961	C/A	cg16298547	chr5:60138761	ELOVL7	-0.26	-5.61	-0.3	4.39e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg24438145	chr17:48624694	SPATA20	0.44	6.26	0.33	1.2e-9	Type 2 diabetes;
CRC	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.03	-0.32	4.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.55	8.98	0.44	2.16e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.38	5.94	0.31	7.44e-9	Height;
CRC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-8.32	-0.42	2.4e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg26554054	chr8:600488	NA	0.61	5.82	0.31	1.37e-8	IgG glycosylation;
CRC	cis	rs3768716	0.500	rs777329	chr2:215742595	A/G	cg04004882	chr2:215674386	BARD1	-0.61	-8.31	-0.42	2.62e-15	Neuroblastoma;
CRC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.66	-9.97	-0.48	1.29e-20	Cognitive function;
CRC	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.43	6.35	0.33	7.21e-10	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05989625	chr8:145661381	NFKBIL2	-0.45	-6.11	-0.32	2.81e-9	Hip circumference;
CRC	cis	rs11212617	1.000	rs228594	chr11:108104525	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.4	5.82	0.31	1.43e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.7	8.41	0.42	1.22e-15	Menarche (age at onset);
CRC	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg00071950	chr4:10020882	SLC2A9	0.44	6.83	0.35	4.16e-11	Blood metabolite levels;
CRC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.11	0.45	8.1e-18	Height;
CRC	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.68	7.37	0.38	1.36e-12	Childhood ear infection;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Blood metabolite levels;
CRC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg07701084	chr6:150067640	NUP43	0.57	7.74	0.39	1.2e-13	Lung cancer;
CRC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.54	-0.38	4.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg06470822	chr6:28175283	NA	0.9	13.45	0.6	3.52e-33	Parkinson's disease;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg00106211	chr6:36514552	STK38	0.43	6.11	0.32	2.78e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs1320333	0.772	rs17786120	chr2:700580	A/T	cg00500140	chr2:691012	NA	0.56	6.22	0.32	1.54e-9	Obesity-related traits;
CRC	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.75	-10.32	-0.49	8.04e-22	White matter hyperintensity burden;
CRC	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.4	6.1	0.32	3.02e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.52	-7.37	-0.38	1.38e-12	Lymphocyte counts;
CRC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg23071808	chr14:103021642	NA	-0.67	-8.63	-0.43	2.64e-16	Platelet count;
CRC	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.43	6.49	0.34	3.24e-10	HDL cholesterol;
CRC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.08	-0.32	3.26e-9	Gut microbiome composition (summer);
CRC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg09264619	chr17:80180166	NA	0.38	6.44	0.33	4.28e-10	Life satisfaction;
CRC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.61	-0.43	3.15e-16	Chronic sinus infection;
CRC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.57	9.01	0.44	1.75e-17	Aortic root size;
CRC	cis	rs1656402	0.954	rs1190454	chr2:233435325	G/T	cg03852847	chr2:233439513	NA	-0.44	-7.5	-0.38	6.14e-13	Non-small cell lung cancer (survival);
CRC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.59	-0.34	1.75e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg03233332	chr7:66118400	NA	-0.42	-5.83	-0.31	1.3e-8	Aortic root size;
CRC	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg15816464	chr17:2026533	SMG6	-0.38	-6.31	-0.33	9.21e-10	Total body bone mineral density;
CRC	trans	rs1973993	0.745	rs6593606	chr1:96968005	C/T	cg10631902	chr5:14652156	NA	-0.4	-6.76	-0.35	6.18e-11	Weight;
CRC	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	8.78	0.44	9.1e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.7	-11.4	-0.53	1.31e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12463550	chr7:65579703	CRCP	0.63	6.03	0.32	4.46e-9	Diabetic kidney disease;
CRC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	7.1	0.36	7.66e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.98	-0.31	5.86e-9	Total body bone mineral density;
CRC	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg12700464	chr11:78128424	GAB2	-0.51	-6.39	-0.33	5.66e-10	Testicular germ cell tumor;
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.44	-0.38	9.02e-13	Lymphocyte counts;
CRC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.53	8.43	0.42	1.13e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.12	10.45	0.5	2.84e-22	Skin colour saturation;
CRC	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	6.22	0.32	1.53e-9	IgG glycosylation;
CRC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg04121214	chr22:50244548	NA	-0.39	-5.7	-0.3	2.74e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25971440	chr7:108166545	PNPLA8	0.49	6.89	0.36	2.92e-11	Response to antipsychotic treatment;
CRC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-7.14	-0.37	5.92e-12	Intelligence (multi-trait analysis);
CRC	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.9	11.42	0.53	1.18e-25	Exhaled nitric oxide levels;
CRC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.65e-9	Aortic root size;
CRC	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.24	-0.33	1.37e-9	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05298461	chr20:33999889	UQCC	0.44	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.79	-9.46	-0.46	5.91e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg02269571	chr22:50332266	NA	-0.87	-8.96	-0.44	2.39e-17	Mean platelet volume;
CRC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.52	-7.69	-0.39	1.74e-13	Obesity-related traits;
CRC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.46	-7.2	-0.37	4.07e-12	Monocyte count;
CRC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.6	9.25	0.45	2.85e-18	Vitiligo;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Parkinson's disease;
CRC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.45	-9.98	-0.48	1.15e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg15845792	chr6:28175446	NA	0.58	8.62	0.43	2.79e-16	Pubertal anthropometrics;
CRC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg03929089	chr4:120376271	NA	-0.46	-6.53	-0.34	2.51e-10	HDL cholesterol;
CRC	trans	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg21153622	chr11:89784906	NA	-0.48	-7.62	-0.39	2.78e-13	HDL cholesterol;
CRC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.35	-0.33	6.97e-10	Monocyte percentage of white cells;
CRC	cis	rs9303280	0.901	rs7216558	chr17:38070071	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-6.67	-0.34	1.12e-10	Self-reported allergy;
CRC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg26893134	chr6:116381904	FRK	0.26	7.6	0.39	3.03e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg08755490	chr11:65554678	OVOL1	-0.4	-5.98	-0.31	5.95e-9	Acne (severe);
CRC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.57	-6.0	-0.31	5.12e-9	White matter hyperintensity burden;
CRC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.09	-0.32	3.2e-9	Morning vs. evening chronotype;
CRC	cis	rs2882667	0.894	rs1433008	chr5:138333664	T/C	cg09476006	chr5:138032270	NA	0.44	7.39	0.38	1.19e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.8	-0.3	1.57e-8	Monobrow;
CRC	cis	rs449789	0.524	rs6912475	chr6:159747473	C/G	cg14500486	chr6:159655392	FNDC1	0.48	7.19	0.37	4.4e-12	Pulse pressure;
CRC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	5.93	0.31	7.87e-9	Mood instability;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg06470822	chr6:28175283	NA	0.66	10.11	0.49	4.13e-21	Cardiac Troponin-T levels;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg04025307	chr7:1156635	C7orf50	0.68	7.22	0.37	3.65e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.46	-7.45	-0.38	8.42e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg06470822	chr6:28175283	NA	0.78	9.64	0.47	1.54e-19	Parkinson's disease;
CRC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.69	-0.3	2.77e-8	Aortic root size;
CRC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.69	-9.31	-0.46	1.85e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08858051	chr1:94313454	NA	0.46	6.4	0.33	5.38e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.64	-0.43	2.54e-16	Aortic root size;
CRC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.95	0.52	5.22e-24	Motion sickness;
CRC	cis	rs789852	0.764	rs2794668	chr3:194316895	C/T	cg21106136	chr3:194405973	FAM43A	-0.74	-6.17	-0.32	2.06e-9	QT interval;
CRC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg14829360	chr17:73884958	NA	0.43	6.87	0.35	3.15e-11	Psoriasis;
CRC	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg20312557	chr2:97357134	FER1L5	-0.61	-5.64	-0.3	3.57e-8	Erectile dysfunction and prostate cancer treatment;
CRC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.67	-0.47	1.2e-19	Height;
CRC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.11	20.54	0.75	6.6e-61	Cognitive function;
CRC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg24977027	chr2:88469347	THNSL2	0.54	6.41	0.33	5e-10	Plasma clusterin levels;
CRC	cis	rs10128264	0.902	rs1250583	chr10:80975004	A/G	cg18737081	chr10:80999807	ZMIZ1	0.37	6.72	0.35	8.05e-11	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	6.26	0.33	1.17e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.69	0.39	1.74e-13	Height;
CRC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.03	0.32	4.38e-9	Diabetic retinopathy;
CRC	cis	rs3736485	0.934	rs4775953	chr15:51873173	G/T	cg08986416	chr15:51914746	DMXL2	-0.47	-6.74	-0.35	7.23e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg05569086	chr8:143859399	LYNX1	0.4	6.81	0.35	4.69e-11	Urinary tract infection frequency;
CRC	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.35	-0.38	1.62e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs10986311	0.802	rs3780201	chr9:127104775	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.4	-6.01	-0.31	5.03e-9	Vitiligo;
CRC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.71	0.39	1.5e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg06028605	chr16:24865363	SLC5A11	-0.44	-7.04	-0.36	1.16e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.56	-8.5	-0.42	6.87e-16	Asthma;
CRC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg18225595	chr11:63971243	STIP1	0.43	5.61	0.3	4.31e-8	Mean platelet volume;
CRC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.5	-9.48	-0.46	5.09e-19	Reticulocyte fraction of red cells;
CRC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.34	-0.33	7.54e-10	Obesity-related traits;
CRC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.56	-0.47	2.89e-19	Bladder cancer;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10373780	chr19:8455179	RAB11B	0.4	6.04	0.32	4.12e-9	Schizophrenia;
CRC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.58	-7.43	-0.38	9.6e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.1	18.82	0.72	3.71e-54	Schizophrenia;
CRC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.7	-9.35	-0.46	1.39e-18	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.35	6.68	0.35	1.04e-10	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21866596	chr11:93474724	C11orf54;TAF1D	0.45	7.32	0.37	1.97e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.78	-0.3	1.72e-8	Educational attainment;
CRC	cis	rs6662572	0.723	rs72677543	chr1:46565329	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.24	0.33	1.33e-9	Blood protein levels;
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.7	0.39	1.5700000000000001e-13	Alzheimer's disease;
CRC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.71	10.95	0.52	5.47e-24	Corneal astigmatism;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05913197	chr6:166796386	BRP44L	0.42	6.13	0.32	2.51e-9	Myopia (pathological);
CRC	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.46	7.6	0.39	3.06e-13	Refractive error;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23238458	chr12:89919833	GALNT4;WDR51B	0.45	6.3	0.33	9.6e-10	Response to antipsychotic treatment;
CRC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.55	10.75	0.51	2.58e-23	Asthma (sex interaction);
CRC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-16.52	-0.67	4.54e-45	Height;
CRC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.74	-0.43	1.22e-16	Aortic root size;
CRC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg21770322	chr7:97807741	LMTK2	0.51	8.23	0.41	4.31e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.49	-0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.66	0.57	3.42e-30	Platelet count;
CRC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25072359	chr17:41440525	NA	0.43	6.35	0.33	7.14e-10	Menopause (age at onset);
CRC	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.77	-13.11	-0.59	6.81e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.72	12.53	0.57	1.05e-29	Body mass index;
CRC	cis	rs629535	0.783	rs510632	chr8:70034570	A/G	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs7487075	0.820	rs12310125	chr12:46693154	A/G	cg22049899	chr12:47219821	SLC38A4	0.31	6.01	0.31	4.98e-9	Itch intensity from mosquito bite;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.29e-9	Bipolar disorder;
CRC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.02	-21.82	-0.77	6.64e-66	Myeloid white cell count;
CRC	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.64	-0.3	3.71e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7429990	0.965	rs1060407	chr3:47958037	G/T	cg11946769	chr3:48343235	NME6	0.48	6.09	0.32	3.16e-9	Educational attainment (years of education);
CRC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	13.03	0.58	1.44e-31	Mean platelet volume;
CRC	trans	rs35094601	1.000	rs13031641	chr2:139228769	G/C	cg25299176	chr17:1303341	YWHAE	-0.46	-6.63	-0.34	1.42e-10	Schizophrenia;
CRC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.18	0.59	3.97e-32	Bone mineral density;
CRC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.53	-8.13	-0.41	8.68e-15	Schizophrenia;
CRC	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.92e-10	Subjective well-being;
CRC	cis	rs71403859	0.614	rs12935422	chr16:71664225	T/A	cg08717414	chr16:71523259	ZNF19	-0.99	-9.6	-0.47	2.08e-19	Post bronchodilator FEV1;
CRC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.48	6.1	0.32	2.98e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg25985355	chr7:65971099	NA	-0.51	-5.87	-0.31	1.05e-8	Diabetic kidney disease;
CRC	cis	rs1178968	1.000	rs4717756	chr7:72765458	C/G	cg25889504	chr7:72793014	NA	-0.55	-6.21	-0.32	1.62e-9	Triglyceride levels;
CRC	cis	rs2415984	0.579	rs4485263	chr14:46967552	A/G	cg14871534	chr14:47121158	RPL10L	-0.4	-5.99	-0.31	5.53e-9	Number of children ever born;
CRC	cis	rs4809627	1	rs4809627	chr20:45757655	C/T	cg27589058	chr20:45804311	EYA2	-0.32	-5.66	-0.3	3.34e-8	Type 2 diabetes;
CRC	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.91	-13.23	-0.59	2.44e-32	Blood pressure (smoking interaction);
CRC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.54	0.34	2.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	7.03	0.36	1.17e-11	Cognitive test performance;
CRC	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.58	7.83	0.4	6.94e-14	Breast cancer;
CRC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.59	-6.95	-0.36	1.97e-11	Red cell distribution width;
CRC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.66	7.37	0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.56	7.49	0.38	6.44e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.25	0.33	1.27e-9	Renal cell carcinoma;
CRC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.08	-0.45	1.01e-17	Prostate cancer;
CRC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.8	13.01	0.58	1.7e-31	Breast cancer;
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.05	-0.32	3.99e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2882667	0.964	rs12108892	chr5:138299630	G/A	cg09476006	chr5:138032270	NA	0.53	9.11	0.45	8.19e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.8	-8.55	-0.43	4.58e-16	Coronary artery disease;
CRC	trans	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg18335740	chr13:41363409	SLC25A15	0.48	7.08	0.36	8.93e-12	Lewy body disease;
CRC	cis	rs12143943	0.934	rs17335392	chr1:204595899	C/T	cg17419461	chr1:204415978	PIK3C2B	0.43	6.92	0.36	2.35e-11	Cognitive performance;
CRC	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg10517650	chr3:113235015	CCDC52	-0.39	-6.92	-0.36	2.31e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.86	-10.02	-0.48	8.73e-21	Breast cancer;
CRC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-6.41	-0.33	5.19e-10	Lung cancer;
CRC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.49	6.69	0.35	9.48e-11	Gut microbiome composition (summer);
CRC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg05110241	chr16:68378359	PRMT7	-0.75	-7.86	-0.4	5.71e-14	Schizophrenia;
CRC	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg20045696	chr14:77926864	AHSA1	0.36	5.61	0.3	4.4e-8	Myeloid white cell count;
CRC	cis	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs4979906	1.000	rs11002247	chr10:79446901	T/C	cg07817648	chr10:79422355	NA	-0.43	-5.64	-0.3	3.57e-8	Mortality in heart failure;
CRC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.71	-10.99	-0.52	3.81e-24	Pancreatic cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11135003	chr1:225998164	EPHX1	0.39	6.36	0.33	6.8e-10	Obesity-related traits;
CRC	cis	rs672059	1.000	rs674343	chr1:183162052	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.16	0.37	5.23e-12	Hypertriglyceridemia;
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.64	11.17	0.52	8.66e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.92	0.4	3.58e-14	Joint mobility (Beighton score);
CRC	cis	rs501120	1.000	rs622956	chr10:44755183	A/G	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg00255919	chr5:131827918	IRF1	0.36	6.1	0.32	2.99e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg10820045	chr2:198174542	NA	0.33	5.67	0.3	3.06e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.67	-9.87	-0.48	2.79e-20	Multiple myeloma;
CRC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.6	7.41	0.38	1.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.49	8.82	0.44	6.79e-17	Age-related hearing impairment;
CRC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg26721908	chr21:47610096	LSS	0.47	6.81	0.35	4.55e-11	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19531713	chr17:41277059	BRCA1;NBR2	0.47	6.84	0.35	3.88e-11	Response to antipsychotic treatment;
CRC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24308560	chr3:49941425	MST1R	0.44	6.94	0.36	2.05e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.25e-8	Protein C levels;
CRC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.89	-0.31	9.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.9	-0.36	2.63e-11	Response to antipsychotic treatment;
CRC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.58	-8.87	-0.44	4.85e-17	Height;
CRC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.5	7.28	0.37	2.44e-12	Resting heart rate;
CRC	cis	rs28655083	0.673	rs1872509	chr16:77058990	G/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.63	-7.41	-0.38	1.09e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg20356878	chr3:121714668	ILDR1	0.53	8.22	0.41	4.69e-15	Cognitive performance;
CRC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.55	-5.74	-0.3	2.15e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-18.1	-0.71	2.58e-51	Schizophrenia;
CRC	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.56	0.5	1.18e-22	Corneal astigmatism;
CRC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.84	0.63	1.67e-38	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24350360	chr1:225997662	EPHX1	0.37	6.13	0.32	2.51e-9	Response to antipsychotic treatment;
CRC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.61	9.37	0.46	1.21e-18	Blood protein levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18986451	chr3:100428869	TFG	-0.52	-6.26	-0.33	1.19e-9	Diisocyanate-induced asthma;
CRC	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg09659197	chr4:152720779	NA	-0.41	-8.6	-0.43	3.19e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.54	7.86	0.4	5.55e-14	Mean platelet volume;
CRC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.22	0.32	1.47e-9	Lung cancer;
CRC	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.53	8.46	0.42	8.78e-16	Corneal astigmatism;
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.07	-0.49	5.69e-21	Bipolar disorder;
CRC	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.4	-6.86	-0.35	3.48e-11	Hip circumference;Waist circumference;
CRC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg26528668	chr16:1614120	IFT140	0.38	5.9	0.31	9.26e-9	Coronary artery disease;
CRC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg05639522	chr1:247681581	NA	0.46	6.98	0.36	1.68e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05628496	chr17:17991167	DRG2	0.49	6.35	0.33	7.29e-10	Thyroid stimulating hormone;
CRC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.44	-6.73	-0.35	7.56e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg20512303	chr5:131592959	PDLIM4	0.3	5.79	0.3	1.68e-8	Blood metabolite levels;
CRC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.71	-12.7	-0.57	2.32e-30	Dental caries;
CRC	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.51	-7.77	-0.39	1.04e-13	Diastolic blood pressure;
CRC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg24375607	chr4:120327624	NA	0.48	7.66	0.39	2.1e-13	Corneal astigmatism;
CRC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-12.36	-0.56	4.36e-29	Blood metabolite levels;
CRC	trans	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg21153622	chr11:89784906	NA	0.45	7.1	0.36	7.58e-12	HDL cholesterol;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.4	-0.42	1.36e-15	Bipolar disorder;
CRC	cis	rs231513	0.911	rs231525	chr17:41951283	C/T	cg26893861	chr17:41843967	DUSP3	-0.73	-7.36	-0.38	1.52e-12	Cognitive function;
CRC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.36e-9	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs975369	1.000	rs1553399	chr7:25620866	A/C	cg08255105	chr15:81489160	IL16	0.6	6.04	0.32	4.16e-9	Preeclampsia;
CRC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.14	0.32	2.33e-9	Height;
CRC	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.51	-5.94	-0.31	7.4e-9	Lymphocyte percentage of white cells;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg27444651	chr4:13486108	RAB28	0.5	6.18	0.32	1.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg13722127	chr7:150037890	RARRES2	0.48	7.81	0.4	7.99e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.45	-0.33	4.07e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-23.04	-0.79	1.32e-70	Exhaled nitric oxide output;
CRC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23378565	chr7:2036160	MAD1L1	-0.48	-6.87	-0.35	3.13e-11	Bipolar disorder;
CRC	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.73	9.52	0.46	3.77e-19	Iron status biomarkers;
CRC	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.66	7.63	0.39	2.54e-13	Eotaxin levels;
CRC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.61	10.22	0.49	1.79e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.59	9.43	0.46	7.65e-19	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	trans	rs12478296	1.000	rs6717667	chr2:242997530	C/T	cg18288967	chr1:45987694	PRDX1	0.64	7.32	0.37	1.94e-12	Obesity-related traits;
CRC	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.89	-19.5	-0.73	7.75e-57	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg26028573	chr6:26043587	HIST1H2BB	-0.42	-6.08	-0.32	3.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg22535103	chr8:58192502	C8orf71	-0.53	-6.32	-0.33	8.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.55e-18	Parkinson's disease;
CRC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.77	13.9	0.61	7e-35	Anterior chamber depth;
CRC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg19337854	chr7:99768885	GPC2	-0.49	-6.51	-0.34	2.84e-10	Lung function (FEV1/FVC);
CRC	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.44	7.03	0.36	1.19e-11	Red blood cell count;
CRC	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.62	7.55	0.38	4.46e-13	Extraversion;
CRC	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.38	0.33	5.97e-10	Cognitive ability;
CRC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.47	0.71	9.49e-53	Parkinson's disease;
CRC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.38	0.33	6.12e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09283396	chr2:62423333	B3GNT2	0.45	6.45	0.34	4.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.73	-8.21	-0.41	5.01e-15	Psoriasis;
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg24139520	chr8:28573832	EXTL3	-0.49	-6.73	-0.35	7.47e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7072216	0.621	rs11189595	chr10:100167322	C/T	cg26618903	chr10:100175079	PYROXD2	-0.49	-7.34	-0.38	1.68e-12	Metabolite levels;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg20488697	chr17:79885644	LOC92659;MAFG	0.42	6.04	0.32	4.23e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.51	8.17	0.41	6.92e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.39	5.87	0.31	1.04e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs4780401	0.728	rs7198518	chr16:11771094	C/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.8	-0.3	1.53e-8	Rheumatoid arthritis;
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03934478	chr11:495069	RNH1	0.7	7.36	0.38	1.45e-12	Body mass index;
CRC	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.55	0.34	2.21e-10	Blood protein levels;
CRC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.53	7.81	0.4	7.74e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.04	0.32	4.07e-9	Axial length;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.64	9.5	0.46	4.58e-19	Blood protein levels;
CRC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.79	-11.72	-0.54	9.42e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.83	-9.19	-0.45	4.47e-18	Anti-saccade response;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg23123621	chr4:1343375	KIAA1530	0.36	6.68	0.35	1.03e-10	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08330919	chr4:40058921	LOC344967;N4BP2	0.44	6.96	0.36	1.85e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1223397	0.651	rs2458312	chr6:13309989	G/A	cg20827128	chr6:13274284	PHACTR1	0.39	5.95	0.31	6.85e-9	Blood pressure;
CRC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	8.87	0.44	4.67e-17	Lymphocyte counts;
CRC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg18016565	chr1:150552671	MCL1	0.51	7.23	0.37	3.46e-12	Urate levels;
CRC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.45	7.44	0.38	8.91e-13	Facial morphology (factor 20);
CRC	trans	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.6	10.08	0.49	5.29e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.76	0.54	6.69e-27	Hip circumference adjusted for BMI;
CRC	cis	rs185694	1.000	rs202098	chr13:30896774	G/T	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.33	-0.33	7.8e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11751927	chr11:117857137	IL10RA	0.44	6.11	0.32	2.87e-9	Anxiety disorder;
CRC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.77	-0.3	1.86e-8	Neuroticism;
CRC	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.57e-27	Cognitive function;
CRC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.7	0.43	1.58e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.47	-6.74	-0.35	7.23e-11	Platelet distribution width;
CRC	cis	rs7113874	0.569	rs10769915	chr11:8597449	C/G	cg17679104	chr11:8615758	STK33	-0.36	-6.05	-0.32	4.05e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9292777	0.720	rs1025969	chr5:40402913	C/T	cg09067459	chr5:40385259	NA	-0.55	-8.97	-0.44	2.31e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.64	6.59	0.34	1.72e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.46	0.42	9.08e-16	Schizophrenia;
CRC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.38	-0.33	6.05e-10	Breast cancer;
CRC	trans	rs9395066	0.545	rs4711805	chr6:44870102	T/C	cg04786201	chr1:17185605	NA	0.29	6.09	0.32	3.17e-9	Height;
CRC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.99	-0.31	5.4e-9	Gut microbiome composition (summer);
CRC	cis	rs12760731	0.565	rs12036491	chr1:178163651	C/A	cg00404053	chr1:178313656	RASAL2	1.05	10.93	0.52	6.36e-24	Obesity-related traits;
CRC	cis	rs1552172	0.881	rs1471634	chr1:145702115	A/G	cg25221984	chr1:145714143	CD160	0.38	5.75	0.3	2.05e-8	Breast cancer;
CRC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	13.4	0.59	5.63e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.5	9.58	0.47	2.47e-19	Iron status biomarkers (transferrin levels);
CRC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-19.82	-0.74	4.3e-58	Height;
CRC	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-6.42	-0.33	4.83e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2882667	0.652	rs6596463	chr5:138444926	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-5.76	-0.3	1.89e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg11900509	chr10:81946545	ANXA11	-0.66	-6.66	-0.34	1.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.55	9.01	0.44	1.68e-17	Gout;
CRC	cis	rs460214	0.564	rs458465	chr21:40024644	A/T	cg05519781	chr21:40033154	ERG	-0.38	-5.88	-0.31	1e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs2055729	0.813	rs55999429	chr8:9741185	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.21	-0.32	1.64e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.59	-7.96	-0.4	2.86e-14	Height;
CRC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg19622623	chr12:86230825	RASSF9	-0.42	-6.75	-0.35	6.68e-11	Major depressive disorder;
CRC	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg09760422	chr2:128146352	NA	-0.34	-5.68	-0.3	2.99e-8	Self-rated health;
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.56	0.75	5.27e-61	Prudent dietary pattern;
CRC	trans	rs9693857	0.520	rs6601320	chr8:9355888	G/C	cg08975724	chr8:8085496	FLJ10661	0.43	6.02	0.31	4.61e-9	Systolic blood pressure;
CRC	cis	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-9.39	-0.46	9.99e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.37	-5.89	-0.31	9.32e-9	Psoriasis vulgaris;Psoriasis;
CRC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	ch.11.42038R	chr11:967971	AP2A2	0.61	10.34	0.5	6.76e-22	Alzheimer's disease (late onset);
CRC	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.72	-8.11	-0.41	9.89e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7692995	1.000	rs16896210	chr4:17992332	A/G	cg08925142	chr4:18023851	LCORL	-0.53	-5.84	-0.31	1.22e-8	Height;
CRC	trans	rs264943	0.600	rs11677232	chr2:104096271	G/A	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.8e-9	HIV-1 viral setpoint;
CRC	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.49	7.62	0.39	2.75e-13	Red blood cell count;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg15845792	chr6:28175446	NA	0.65	9.78	0.47	5.56e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg08314208	chr16:67682810	RLTPR	-0.65	-7.04	-0.36	1.12e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4731207	0.671	rs12706626	chr7:124531370	G/A	cg23710748	chr7:124431027	NA	0.37	5.68	0.3	2.95e-8	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.54	7.23	0.37	3.34e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs2637266	0.600	rs11001833	chr10:78356913	T/G	cg18941641	chr10:78392320	NA	-0.37	-6.22	-0.32	1.49e-9	Pulmonary function;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.54	-9.99	-0.48	1.07e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.11	-9.13	-0.45	7.11e-18	Mitochondrial DNA levels;
CRC	cis	rs7215564	0.818	rs756076	chr17:78662918	A/G	cg09596252	chr17:78655493	RPTOR	0.54	6.08	0.32	3.26e-9	Myopia (pathological);
CRC	cis	rs8010715	0.816	rs11574503	chr14:24601318	C/G	cg23112188	chr14:24563095	PCK2	0.36	7.0	0.36	1.42e-11	IgG glycosylation;
CRC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.48	7.18	0.37	4.73e-12	Total body bone mineral density;
CRC	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.0	-0.31	5.09e-9	Pubertal anthropometrics;
CRC	cis	rs870825	0.655	rs6845058	chr4:185653696	G/A	cg04058563	chr4:185651563	MLF1IP	-0.77	-9.24	-0.45	3.06e-18	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08664652	chr17:28804287	GOSR1	0.43	6.15	0.32	2.26e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.49	0.34	3.18e-10	Alzheimer's disease;
CRC	cis	rs9992667	0.955	rs1491199	chr4:38643014	G/A	cg19726192	chr4:38663646	FLJ13197	-0.66	-8.66	-0.43	2.21e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs11212617	1.000	rs573890	chr11:108251363	C/G	cg12106634	chr11:108092400	ATM;NPAT	-0.39	-5.79	-0.3	1.6e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.54	-0.34	2.37e-10	Life satisfaction;
CRC	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	21.42	0.76	2.32e-64	Exhaled nitric oxide output;
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.18	0.74	1.67e-59	Prudent dietary pattern;
CRC	cis	rs12550646	0.625	rs1549064	chr8:41684488	A/C	cg12180191	chr8:41686706	ANK1	-0.46	-6.62	-0.34	1.44e-10	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg23254163	chr1:152506842	NA	0.45	9.14	0.45	6.46e-18	Hair morphology;
CRC	cis	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg21782813	chr7:2030301	MAD1L1	-0.44	-8.03	-0.4	1.77e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs55702914	0.809	rs2376407	chr2:198183465	A/G	cg20885578	chr2:198174922	NA	-0.33	-5.72	-0.3	2.36e-8	Major depression and alcohol dependence;
CRC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg10494257	chr1:16342123	HSPB7	-0.43	-5.79	-0.3	1.67e-8	Dilated cardiomyopathy;
CRC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg14671364	chr1:107599128	PRMT6	0.55	7.41	0.38	1.1e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg15192750	chr16:69999425	NA	0.56	7.27	0.37	2.67e-12	IgE levels;
CRC	cis	rs501120	0.584	rs661697	chr10:44740698	G/T	cg09554077	chr10:44749378	NA	0.75	8.3	0.42	2.76e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg14711859	chr11:8959438	ASCL3	-0.43	-7.19	-0.37	4.35e-12	Hemoglobin concentration;
CRC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	0.99	10.33	0.49	7.55e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg00086871	chr4:6988644	TBC1D14	1.01	7.58	0.39	3.49e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.55	-9.17	-0.45	5.26e-18	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg03623178	chr6:28175578	NA	0.74	7.82	0.4	7.43e-14	Depression;
CRC	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	1.1	11.79	0.54	5.31e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg19622623	chr12:86230825	RASSF9	-0.39	-5.98	-0.31	5.91e-9	Major depressive disorder;
CRC	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg27124370	chr19:33622961	WDR88	0.41	5.68	0.3	2.96e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.48	-6.55	-0.34	2.24e-10	Tonsillectomy;
CRC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.8	12.62	0.57	4.88e-30	Cognitive function;
CRC	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.26	5.84	0.31	1.26e-8	Parkinson's disease;
CRC	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg22189786	chr22:42395067	WBP2NL	0.42	6.32	0.33	8.47e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg13043300	chr11:71146211	DHCR7	-0.43	-5.75	-0.3	2.09e-8	Vitamin D levels;
CRC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05377417	chr17:59940892	BRIP1	0.41	6.16	0.32	2.08e-9	Smoking initiation;
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.45	6.78	0.35	5.55e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.92	-21.62	-0.77	3.92e-65	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.72	-0.35	7.92e-11	HDL cholesterol;
CRC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.15	0.32	2.26e-9	Renal function-related traits (BUN);
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg02683197	chr6:28174875	NA	0.88	10.83	0.51	1.42e-23	Depression;
CRC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7945718	0.621	rs6485992	chr11:12697359	C/T	cg25843174	chr11:12811716	TEAD1	0.42	7.75	0.39	1.13e-13	Educational attainment (years of education);
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg03623178	chr6:28175578	NA	0.92	12.19	0.56	1.91e-28	Parkinson's disease;
CRC	cis	rs12760731	0.623	rs3791026	chr1:178343890	G/A	cg00404053	chr1:178313656	RASAL2	0.73	9.34	0.46	1.48e-18	Obesity-related traits;
CRC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.48	9.58	0.47	2.46e-19	Renal cell carcinoma;
CRC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg13798780	chr7:105162888	PUS7	-0.42	-5.69	-0.3	2.78e-8	Bipolar disorder (body mass index interaction);
CRC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.78	-13.35	-0.59	9.09e-33	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12760731	0.720	rs1510266	chr1:178346771	A/T	cg00404053	chr1:178313656	RASAL2	-0.81	-9.81	-0.48	4.31e-20	Obesity-related traits;
CRC	cis	rs4700695	1.000	rs4700696	chr5:65412634	G/C	cg21114390	chr5:65439923	SFRS12	-0.61	-6.93	-0.36	2.27e-11	Facial morphology (factor 19);
CRC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.6	8.66	0.43	2.15e-16	Homoarginine levels;
CRC	cis	rs2415984	0.579	rs12185007	chr14:46976217	G/A	cg14871534	chr14:47121158	RPL10L	-0.39	-5.81	-0.31	1.46e-8	Number of children ever born;
CRC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.58	6.77	0.35	5.92e-11	Mean platelet volume;
CRC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	12.24	0.56	1.24e-28	Mean platelet volume;
CRC	cis	rs990171	0.913	rs6729638	chr2:102996022	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.37e-8	Lymphocyte counts;
CRC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.69	-10.62	-0.51	7.57e-23	Mean platelet volume;Platelet distribution width;
CRC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-7.78	-0.39	9.51e-14	Aortic root size;
CRC	cis	rs3804749	0.966	rs2278668	chr3:122835232	T/C	cg26084141	chr3:122786895	PDIA5	0.24	6.51	0.34	2.88e-10	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.82	-10.1	-0.49	4.65e-21	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg05941027	chr17:61774174	LIMD2	0.33	5.88	0.31	1.02e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.06	0.32	3.76e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.41	-8.69	-0.43	1.71e-16	Electroencephalogram traits;
CRC	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.69	-6.49	-0.34	3.08e-10	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.4	6.12	0.32	2.71e-9	Endometrial cancer;
CRC	trans	rs800082	1.000	rs7613909	chr3:144308606	A/G	cg24215973	chr2:240111563	HDAC4	0.54	7.66	0.39	2.16e-13	Smoking behavior;
CRC	cis	rs7705042	0.833	rs12653848	chr5:141489853	A/G	cg07392085	chr5:141489673	NDFIP1	-0.43	-5.9	-0.31	9.2e-9	Asthma;
CRC	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg12855166	chr17:30846586	MYO1D	-0.4	-6.64	-0.34	1.28e-10	Schizophrenia;
CRC	cis	rs4964805	0.594	rs9132	chr12:104166243	C/T	cg02344784	chr12:104178138	NT5DC3	0.47	7.23	0.37	3.35e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.18	-0.37	4.55e-12	Schizophrenia;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-5.8	-0.3	1.59e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-0.68	-7.96	-0.4	2.78e-14	Post bronchodilator FEV1;
CRC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg08314208	chr16:67682810	RLTPR	-0.47	-5.69	-0.3	2.75e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.52	0.38	5.39e-13	Lung cancer in ever smokers;
CRC	cis	rs9287719	0.649	rs12473957	chr2:10717714	C/G	cg00105475	chr2:10696890	NA	-0.45	-7.08	-0.36	8.89e-12	Prostate cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04245373	chr16:71392615	CALB2	0.39	6.0	0.31	5.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.71	11.06	0.52	2.18e-24	Corneal astigmatism;
CRC	cis	rs6662572	0.737	rs56368769	chr1:46451739	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.64	0.3	3.59e-8	Blood protein levels;
CRC	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.52	7.91	0.4	4.05e-14	Corneal astigmatism;
CRC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg13628971	chr7:2884303	GNA12	-0.37	-5.91	-0.31	8.55e-9	Height;
CRC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg24588162	chr13:113633484	MCF2L	-0.41	-7.39	-0.38	1.23e-12	Systolic blood pressure;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg17147758	chr8:6949321	NA	-0.5	-6.95	-0.36	1.94e-11	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00946381	chr16:2205241	TRAF7;SNORD60	0.46	6.31	0.33	8.82e-10	Response to antipsychotic treatment;
CRC	cis	rs13315871	0.929	rs4560319	chr3:58386274	C/T	cg20936604	chr3:58311152	NA	-0.72	-6.7	-0.35	9.26e-11	Cholesterol, total;
CRC	cis	rs73206853	0.764	rs7312139	chr12:110985442	C/A	cg12870014	chr12:110450643	ANKRD13A	0.8	9.2	0.45	4.16e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs4684776	0.606	rs12632336	chr3:11663307	G/A	cg20302342	chr1:156215951	PAQR6	-0.45	-6.02	-0.31	4.6e-9	Small vessel stroke;
CRC	cis	rs3741151	0.656	rs112699563	chr11:73015243	C/T	cg17517138	chr11:73019481	ARHGEF17	0.68	7.23	0.37	3.39e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg18016565	chr1:150552671	MCL1	0.43	6.16	0.32	2.15e-9	Melanoma;
CRC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg22777020	chr22:31556080	RNF185	-0.52	-6.12	-0.32	2.6e-9	Colorectal cancer;
CRC	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.75	10.37	0.5	5.35e-22	Systemic lupus erythematosus;
CRC	cis	rs2241584	0.507	rs2913897	chr5:175921783	A/G	cg24735937	chr5:175843923	CLTB	-0.4	-6.36	-0.33	6.74e-10	Menopause (age at onset);
CRC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.72	11.35	0.53	1.96e-25	Monocyte count;
CRC	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs4692589	1.000	rs4519759	chr4:170933919	T/C	cg19918862	chr4:170955249	NA	0.38	6.22	0.32	1.48e-9	Anxiety disorder;
CRC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.76	12.9	0.58	4.36e-31	Body mass index;
CRC	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06307176	chr5:131281290	NA	0.42	6.16	0.32	2.11e-9	Life satisfaction;
CRC	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.48	-9.13	-0.45	7.34e-18	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.22	-0.32	1.53e-9	Monocyte percentage of white cells;
CRC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg10589385	chr1:150898437	SETDB1	0.29	6.21	0.32	1.6e-9	Melanoma;
CRC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.54	7.84	0.4	6.25e-14	Resting heart rate;
CRC	cis	rs524281	1.000	rs524281	chr11:65886662	C/A	cg16950941	chr11:66035639	RAB1B	0.63	8.95	0.44	2.65e-17	Electroencephalogram traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07917886	chr7:156793362	NA	0.4	6.56	0.34	2.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12476592	0.602	rs166385	chr2:63888023	T/A	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.47	-6.64	-0.34	1.32e-10	Blood pressure (smoking interaction);
CRC	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg20200711	chr11:2211776	NA	-0.47	-6.5	-0.34	3.05e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CRC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.28	0.49	1.13e-21	Alzheimer's disease (late onset);
CRC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-14.88	-0.63	1.22e-38	Schizophrenia;
CRC	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg15147215	chr3:52552868	STAB1	-0.66	-11.52	-0.54	5.16e-26	Electroencephalogram traits;
CRC	cis	rs12230513	0.732	rs61956300	chr12:55812640	T/G	cg19537932	chr12:55886519	OR6C68	-0.75	-9.64	-0.47	1.53e-19	Contrast sensitivity;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg21251018	chr6:28226885	NKAPL	0.47	6.38	0.33	6.15e-10	Parkinson's disease;
CRC	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg18646521	chr2:111875858	NA	0.39	6.12	0.32	2.7e-9	Chronic lymphocytic leukemia;
CRC	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg12560992	chr17:57184187	TRIM37	0.53	6.17	0.32	1.98e-9	Vitamin D levels;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03404566	chr17:6899310	ALOX12	0.62	11.2	0.53	6.91e-25	Tonsillectomy;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.3	-6.01	-0.31	4.88e-9	Total body bone mineral density;
CRC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.46	7.0	0.36	1.42e-11	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.62	-0.34	1.51e-10	Menopause (age at onset);
CRC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.77	11.7	0.54	1.16e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg18479299	chr3:125709523	NA	-0.51	-6.25	-0.33	1.29e-9	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.43	5.98	0.31	5.87e-9	Longevity;Endometriosis;
CRC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.45	-6.25	-0.33	1.29e-9	Multiple sclerosis;
CRC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-5.85	-0.31	1.22e-8	Tonsillectomy;
CRC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg22723502	chr6:26240528	HIST1H4F	-0.38	-6.35	-0.33	7.27e-10	Gout;Renal underexcretion gout;
CRC	cis	rs7178572	0.633	rs4886877	chr15:77838535	C/G	cg22256960	chr15:77711686	NA	-0.63	-8.72	-0.43	1.38e-16	Type 2 diabetes;
CRC	cis	rs4731207	0.596	rs6466979	chr7:124648029	T/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs2070997	0.938	rs6597644	chr9:133744911	C/T	cg01000188	chr9:133769184	QRFP	0.53	6.87	0.35	3.22e-11	Response to amphetamines;
CRC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.59	-10.62	-0.51	7.43e-23	Aortic root size;
CRC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.61	-11.3	-0.53	3e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	1.05	21.14	0.76	2.96e-63	Platelet distribution width;
CRC	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.81	-13.19	-0.59	3.42e-32	Hypospadias;
CRC	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.6	8.4	0.42	1.32e-15	Osteoporosis;
CRC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.58	8.94	0.44	2.79e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7289126	1.000	rs5750571	chr22:38640312	A/G	cg25457927	chr22:38595422	NA	-0.32	-6.16	-0.32	2.07e-9	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.68	11.14	0.52	1.13e-24	Colorectal cancer;
CRC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg03030879	chr14:75389066	RPS6KL1	0.46	7.3	0.37	2.14e-12	Height;
CRC	trans	rs800082	0.516	rs9852425	chr3:144215405	A/C	cg24215973	chr2:240111563	HDAC4	0.44	6.01	0.31	4.96e-9	Smoking behavior;
CRC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.77	0.39	9.8e-14	Motion sickness;
CRC	cis	rs7394190	0.935	rs12570126	chr10:75416789	C/T	cg07699608	chr10:75541558	CHCHD1	-0.52	-6.05	-0.32	3.99e-9	Incident atrial fibrillation;
CRC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.62	-9.23	-0.45	3.37e-18	Cognitive function;
CRC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg00343986	chr7:65444356	GUSB	-0.48	-7.11	-0.36	7.48e-12	Aortic root size;
CRC	cis	rs3736485	0.966	rs12441167	chr15:51850652	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.52	-0.34	2.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.58	-7.9	-0.4	4.34e-14	Alzheimer's disease;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg15763984	chr4:1342303	KIAA1530	0.36	6.25	0.33	1.29e-9	Obesity-related traits;
CRC	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg01493522	chr13:37497338	NA	-0.53	-7.2	-0.37	4.01e-12	Coronary artery disease;
CRC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg14530993	chr4:882597	GAK	-0.81	-7.52	-0.38	5.42e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.71	0.47	9.43e-20	Bladder cancer;
CRC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.78	-12.58	-0.57	6.48e-30	Height;
CRC	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg14581129	chr12:53358946	NA	-0.91	-8.8	-0.44	7.98e-17	Prostate cancer;
CRC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.68	9.04	0.45	1.43e-17	Bronchopulmonary dysplasia;
CRC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.76	7.71	0.39	1.55e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg09760422	chr2:128146352	NA	-0.36	-6.89	-0.36	2.84e-11	Protein C levels;
CRC	cis	rs3812762	1.000	rs3812762	chr11:8751640	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-5.63	-0.3	3.89e-8	Hypospadias;
CRC	cis	rs1519814	0.736	rs7822384	chr8:121071789	A/G	cg22335954	chr8:121166405	COL14A1	-0.59	-6.18	-0.32	1.91e-9	Breast cancer;
CRC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.45	6.9	0.36	2.72e-11	Hemoglobin concentration;
CRC	cis	rs4363385	0.747	rs4255332	chr1:152958745	G/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.07e-13	Inflammatory skin disease;
CRC	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-6.09	-0.32	3.13e-9	Coronary artery disease;
CRC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs13098911	0.540	rs61650989	chr3:46054156	G/T	cg12691230	chr3:46064611	XCR1	-0.52	-5.81	-0.3	1.51e-8	Celiac disease;
CRC	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg19582491	chr16:67682965	RLTPR	-0.58	-6.54	-0.34	2.29e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.65	11.13	0.52	1.27e-24	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.5	6.71	0.35	8.37e-11	Thyroid stimulating hormone;
CRC	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.54	-6.96	-0.36	1.87e-11	Testicular germ cell tumor;Testicular germ cell cancer;
CRC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.94	11.58	0.54	3.16e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.83	0.31	1.29e-8	Diabetic retinopathy;
CRC	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg23254163	chr1:152506842	NA	-0.45	-8.84	-0.44	5.88e-17	Hair morphology;
CRC	cis	rs7680126	0.596	rs10489070	chr4:10276352	C/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.1	-0.32	2.99e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.03	0.45	1.45e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg16898833	chr6:26189333	HIST1H4D	0.95	6.45	0.34	3.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg16950941	chr11:66035639	RAB1B	-0.61	-7.66	-0.39	2.1e-13	Electroencephalogram traits;
CRC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg19193384	chr17:30244184	NA	-0.54	-6.84	-0.35	3.89e-11	Hip circumference adjusted for BMI;
CRC	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg26703956	chr19:39260304	NA	-0.35	-5.72	-0.3	2.4e-8	Heart rate;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06700871	chr2:84686330	SUCLG1	0.45	7.01	0.36	1.32e-11	Obesity-related traits;
CRC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg02869306	chr7:64672164	INTS4L1	0.43	6.29	0.33	1.04e-9	Aortic root size;
CRC	cis	rs9786986	0.764	rs75753504	chr1:235697380	C/T	cg08848088	chr1:235714526	GNG4	0.56	6.57	0.34	1.99e-10	Body mass index;
CRC	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.33	-0.42	2.18e-15	Biliary atresia;
CRC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	cis	rs77688320	0.535	rs6435084	chr2:202325997	T/G	cg00712779	chr2:202317602	STRADB;TRAK2	0.38	5.61	0.3	4.23e-8	Breast cancer;
CRC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.66	-11.48	-0.53	7.01e-26	Brugada syndrome;
CRC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.91	-16.99	-0.68	6.51e-47	Coronary artery disease;
CRC	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.65	8.11	0.41	1.03e-14	Arsenic metabolism;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg24879335	chr3:133465180	TF	0.31	5.88	0.31	9.95e-9	Iron status biomarkers;
CRC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.54	7.29	0.37	2.33e-12	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24487027	chr10:92923837	NA	0.44	6.04	0.32	4.06e-9	Anxiety disorder;
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	7.25	0.37	2.91e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg18827107	chr12:86230957	RASSF9	0.39	5.98	0.31	5.76e-9	Major depressive disorder;
CRC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.18	-15.77	-0.66	3.86e-42	Breast cancer;
CRC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg10645314	chr2:3704589	ALLC	-0.41	-5.62	-0.3	4.13e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00924484	chr1:110753232	KCNC4	0.41	6.66	0.34	1.14e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.57	-10.15	-0.49	3.15e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.65	10.05	0.48	6.59e-21	Lymphocyte counts;
CRC	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg14581129	chr12:53358946	NA	-0.91	-8.8	-0.44	7.76e-17	Prostate cancer;
CRC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.63	0.65	1.44e-41	Fuchs's corneal dystrophy;
CRC	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.53	-0.38	4.95e-13	Morning vs. evening chronotype;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg21546874	chr1:9294571	H6PD	-0.7	-6.03	-0.32	4.44e-9	Cognitive function;
CRC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.84	-0.4	6.53e-14	Chronic sinus infection;
CRC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.15	-0.49	3.03e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.72	-9.21	-0.45	4.06e-18	Initial pursuit acceleration;
CRC	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.42	7.09	0.36	8.13e-12	Childhood ear infection;
CRC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.44	0.5	3.06e-22	Heart rate;
CRC	trans	rs1569175	0.655	rs3115414	chr2:200913244	A/C	cg19477977	chr2:235599692	NA	0.68	6.12	0.32	2.72e-9	Response to treatment for acute lymphoblastic leukemia;
CRC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.44	5.98	0.31	5.66e-9	Parkinson's disease;
CRC	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg15654264	chr1:150340011	RPRD2	0.44	6.59	0.34	1.7e-10	Migraine;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg04153890	chr17:47633892	NA	-0.5	-6.26	-0.33	1.18e-9	Parkinson's disease;
CRC	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.68	10.13	0.49	3.74e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21159473	chr9:15510228	PSIP1	-0.42	-6.73	-0.35	7.6e-11	Myopia (pathological);
CRC	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	-0.42	-6.5	-0.34	2.96e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.66	10.49	0.5	2.16e-22	Sudden cardiac arrest;
CRC	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.48	7.72	0.39	1.37e-13	Endometrial cancer;
CRC	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg07130601	chr7:158766826	NA	0.4	5.83	0.31	1.32e-8	Facial morphology (factor 20);
CRC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg19041857	chr6:27730383	NA	-0.72	-6.75	-0.35	6.7e-11	Breast cancer;
CRC	trans	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg14791747	chr16:20752902	THUMPD1	0.54	6.94	0.36	2.11e-11	Cognitive test performance;
CRC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.93	-12.0	-0.55	9.31e-28	IgG glycosylation;
CRC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.5	-7.91	-0.4	4.05e-14	Prostate cancer;
CRC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.41	6.01	0.31	4.99e-9	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs9311676	0.632	rs11130643	chr3:58423288	G/A	cg06643156	chr3:58380774	PXK	0.43	6.53	0.34	2.5e-10	Systemic lupus erythematosus;
CRC	cis	rs11212617	1.000	rs637064	chr11:108140909	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.15	0.32	2.31e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.47	8.93	0.44	3.11e-17	Renal cell carcinoma;
CRC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg21475434	chr5:93447410	FAM172A	0.46	5.82	0.31	1.36e-8	Diabetic retinopathy;
CRC	cis	rs7605827	0.930	rs7587257	chr2:15513256	A/G	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.34e-9	Educational attainment (years of education);
CRC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg07865391	chr16:88106882	BANP	0.46	5.91	0.31	8.39e-9	Menopause (age at onset);
CRC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.57	8.83	0.44	6.39e-17	Night sleep phenotypes;
CRC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.93	17.78	0.7	4.82e-50	Height;
CRC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.63	9.59	0.47	2.35e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3736485	0.966	rs8028017	chr15:51912708	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.38	-0.33	5.86e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg21251018	chr6:28226885	NKAPL	0.41	6.24	0.33	1.35e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs540254	0.619	rs1556517	chr1:160771761	C/A	cg20255094	chr1:160771763	LY9	0.5	6.36	0.33	6.58e-10	Blood protein levels;
CRC	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-7.03	-0.36	1.17e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.53	8.71	0.43	1.55e-16	Dupuytren's disease;
CRC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.44	-6.47	-0.34	3.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18912574	chr7:65842487	NCRNA00174	0.33	5.68	0.3	2.9e-8	Calcium levels;
CRC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.71	6.62	0.34	1.46e-10	Diabetic kidney disease;
CRC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-8.95	-0.44	2.57e-17	Morning vs. evening chronotype;
CRC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg20487152	chr13:99095054	FARP1	-0.46	-6.71	-0.35	8.74e-11	Neuroticism;
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62187653	chr2:162469128	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs4979906	1.000	rs7923587	chr10:79453218	C/T	cg07817648	chr10:79422355	NA	0.43	5.69	0.3	2.75e-8	Mortality in heart failure;
CRC	cis	rs6534441	0.579	rs10029005	chr4:125451364	A/G	cg21609808	chr4:125404261	NA	-0.36	-5.79	-0.3	1.69e-8	Major depressive disorder;
CRC	cis	rs7945718	0.591	rs4515952	chr11:12690200	G/A	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	5.06e-12	Educational attainment (years of education);
CRC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	10.24	0.49	1.49e-21	Cognitive test performance;
CRC	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.39	5.98	0.31	5.66e-9	Red blood cell count;
CRC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg22535103	chr8:58192502	C8orf71	-0.53	-6.32	-0.33	8.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.52	6.68	0.35	9.92e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.61	-8.71	-0.43	1.56e-16	Coronary artery disease;
CRC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.62	0.34	1.48e-10	Morning vs. evening chronotype;
CRC	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-7.65	-0.39	2.21e-13	Depression;
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.04	-0.55	6.36e-28	Alzheimer's disease;
CRC	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.71	-12.97	-0.58	2.37e-31	Leprosy;
CRC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.5	-0.54	6.03e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.59	0.39	3.29e-13	Lung cancer;
CRC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-14.99	-0.64	4.59e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg10589385	chr1:150898437	SETDB1	0.29	6.17	0.32	2.04e-9	Tonsillectomy;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg09876464	chr15:85330779	ZNF592	-0.37	-6.13	-0.32	2.46e-9	P wave terminal force;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21767207	chr19:36236454	PSENEN;U2AF1L4	0.44	7.18	0.37	4.65e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Depression;
CRC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.76	-0.39	1.07e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20307385	chr11:47447363	PSMC3	-0.57	-8.04	-0.41	1.65e-14	Subjective well-being;
CRC	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	8.52	0.43	5.72e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.7	-0.3	2.69e-8	Electroencephalogram traits;
CRC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.94	-12.33	-0.56	5.59e-29	Breast cancer;
CRC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.61	-9.45	-0.46	6.78e-19	Height;
CRC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.5	7.04	0.36	1.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg13957321	chr17:43675089	NA	0.49	6.15	0.32	2.19e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.48	-8.99	-0.44	2.01e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg04545296	chr12:48745243	ZNF641	-0.34	-5.84	-0.31	1.28e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg16434002	chr17:42200994	HDAC5	0.45	6.09	0.32	3.19e-9	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23048660	chr19:45004795	ZNF180	0.35	6.42	0.33	4.63e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12667079	chr6:166796700	BRP44L	0.43	6.35	0.33	7.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-11.6	-0.54	2.55e-26	Ulcerative colitis;
CRC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.53	7.46	0.38	7.74e-13	Melanoma;
CRC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.59	-7.59	-0.39	3.22e-13	Neuroticism;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg06470822	chr6:28175283	NA	1.01	13.28	0.59	1.55e-32	Depression;
CRC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg03037974	chr15:76606532	NA	0.58	9.85	0.48	3.12e-20	Blood metabolite levels;
CRC	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	7.23	0.37	3.41e-12	Personality dimensions;
CRC	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	8.39	0.42	1.49e-15	Response to antipsychotic treatment;
CRC	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg12082025	chr19:1064218	ABCA7	-0.36	-6.01	-0.31	4.83e-9	Alzheimer's disease (late onset);
CRC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	1.17	10.93	0.52	6.24e-24	Arsenic metabolism;
CRC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2882667	0.931	rs7706391	chr5:138349164	G/A	cg09476006	chr5:138032270	NA	0.41	6.59	0.34	1.73e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg15654264	chr1:150340011	RPRD2	-0.39	-5.76	-0.3	1.95e-8	Migraine;
CRC	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.54	-7.89	-0.4	4.4e-14	Cocaine dependence;
CRC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.04	-0.32	4.2e-9	Eosinophil percentage of white cells;
CRC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.66	12.24	0.56	1.21e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6700896	0.931	rs11208716	chr1:66158825	C/T	cg04111102	chr1:66153794	NA	0.34	5.87	0.31	1.09e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg20119798	chr7:94954144	PON1	0.48	6.14	0.32	2.41e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.47	0.46	5.56e-19	IgG glycosylation;
CRC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.52	5.91	0.31	8.37e-9	Vitiligo;
CRC	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg25809561	chr17:30822961	MYO1D	-0.53	-9.48	-0.46	5.34e-19	Schizophrenia;
CRC	cis	rs113296370	0.808	rs6717198	chr2:43874398	C/A	cg24650394	chr2:43863435	PLEKHH2	0.47	5.9	0.31	9.19e-9	Diabetes in response to antihypertensive drug treatment (treatment strategy interaction);
CRC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.82e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	trans	rs2303319	0.582	rs56094729	chr2:162464835	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.16	-0.32	2.13e-9	Cognitive function;
CRC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.73	-10.68	-0.51	4.59e-23	Platelet distribution width;
CRC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.36	5.93	0.31	7.72e-9	Cardiovascular disease risk factors;
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13198984	chr17:80129470	CCDC57	0.45	8.12	0.41	9.48e-15	Life satisfaction;
CRC	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg09597638	chr17:3907349	NA	0.65	11.53	0.54	4.64e-26	Type 2 diabetes;
CRC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.42	-7.21	-0.37	3.96e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2282802	0.685	rs6870103	chr5:139692515	G/T	cg26211634	chr5:139558579	C5orf32	-0.44	-7.47	-0.38	7.11e-13	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21488398	chr2:70369791	NA	0.46	6.52	0.34	2.6e-10	Anxiety disorder;
CRC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.72	10.3	0.49	9.79e-22	Cognitive function;
CRC	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg05283184	chr6:79620031	NA	-0.45	-6.5	-0.34	2.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.35	-0.38	1.61e-12	Bipolar disorder;
CRC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg07713946	chr22:31675144	LIMK2	0.4	6.08	0.32	3.37e-9	Colorectal cancer;
CRC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-12.79	-0.58	1.13e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg00277334	chr10:82204260	NA	0.37	5.91	0.31	8.4e-9	Sarcoidosis;
CRC	cis	rs3849570	0.643	rs1969433	chr3:81968869	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-6.42	-0.33	4.79e-10	Waist circumference;Body mass index;
CRC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.5	8.29	0.42	2.84e-15	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22432269	chr15:22892697	CYFIP1	0.42	6.1	0.32	3.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.81	14.19	0.62	5.71e-36	Breast cancer;
CRC	trans	rs12702919	0.580	rs2350853	chr7:9553215	G/T	cg15597424	chr4:24472487	NA	-0.38	-6.06	-0.32	3.67e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.29	0.37	2.31e-12	Hip circumference adjusted for BMI;
CRC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg15147215	chr3:52552868	STAB1	-0.64	-11.08	-0.52	1.88e-24	Electroencephalogram traits;
CRC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.38	-6.61	-0.34	1.56e-10	Monobrow;
CRC	cis	rs2179367	0.959	rs521845	chr6:149671698	A/C	cg11245181	chr6:149772854	ZC3H12D	0.39	6.04	0.32	4.27e-9	Dupuytren's disease;
CRC	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.6	10.38	0.5	5.22e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg23260525	chr10:116636907	FAM160B1	0.32	6.87	0.35	3.2e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9625935	0.536	rs9608819	chr22:30260809	A/C	cg01021169	chr22:30184971	ASCC2	0.38	5.8	0.3	1.55e-8	Tonsillectomy;
CRC	trans	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg18288967	chr1:45987694	PRDX1	0.65	6.92	0.36	2.34e-11	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.71	5.04e-53	Height;
CRC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.4	-5.79	-0.3	1.66e-8	Aortic root size;
CRC	cis	rs3741151	0.686	rs2298469	chr11:73133030	T/C	cg17517138	chr11:73019481	ARHGEF17	0.53	5.67	0.3	3.07e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg25193742	chr10:104614220	C10orf32	-0.71	-6.0	-0.31	5.12e-9	Cognitive function;
CRC	cis	rs7538876	0.787	rs57142672	chr1:17744536	A/G	cg07965774	chr1:17746286	RCC2	0.32	5.95	0.31	7.05e-9	Basal cell carcinoma;
CRC	cis	rs62432291	0.681	rs429339	chr6:159660148	C/T	cg14500486	chr6:159655392	FNDC1	-0.75	-10.23	-0.49	1.6e-21	Joint mobility (Beighton score);
CRC	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg07512295	chr2:234599026	UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.38	5.85	0.31	1.2e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-8.24	-0.41	4.1e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-6.15	-0.32	2.24e-9	Schizophrenia;
CRC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg15845792	chr6:28175446	NA	0.76	6.25	0.33	1.3e-9	Depression;
CRC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg23463467	chr20:60627584	TAF4	-0.38	-7.84	-0.4	6.34e-14	Body mass index;
CRC	cis	rs6815814	0.768	rs6851685	chr4:38893843	G/T	cg06935464	chr4:38784597	TLR10	0.51	6.04	0.32	4.22e-9	Breast cancer;
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg09264619	chr17:80180166	NA	0.36	6.07	0.32	3.45e-9	Life satisfaction;
CRC	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.77	9.45	0.46	6.33e-19	Type 2 diabetes;
CRC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.48	0.38	6.79e-13	Calcium levels;
CRC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.39	0.42	1.45e-15	Height;
CRC	cis	rs3736485	0.966	rs7177720	chr15:51890282	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.43	-0.33	4.59e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.66	-6.1	-0.32	2.95e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-8.66	-0.43	2.18e-16	Lymphocyte counts;
CRC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-7.42	-0.38	9.97e-13	Testicular germ cell tumor;
CRC	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.46	8.21	0.41	5.01e-15	Blood metabolite ratios;
CRC	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg11901034	chr3:128598214	ACAD9	-0.5	-6.12	-0.32	2.64e-9	IgG glycosylation;
CRC	cis	rs17095355	1.000	rs975442	chr10:111705895	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.77	-0.39	1.02e-13	Biliary atresia;
CRC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.58	7.9	0.4	4.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg00628130	chr8:95908808	CCNE2	0.46	6.62	0.34	1.42e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6496667	0.821	rs77731392	chr15:90897450	G/C	cg04176472	chr15:90893244	GABARAPL3	0.6	8.04	0.41	1.69e-14	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20731533	chr19:36631058	CAPNS1	0.43	6.33	0.33	7.81e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.17	-0.32	1.96e-9	Aortic root size;
CRC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg22532475	chr10:104410764	TRIM8	-0.39	-6.42	-0.33	4.9e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg27661571	chr11:113659931	NA	-0.68	-8.76	-0.43	1.07e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg11833968	chr6:79620685	NA	-0.36	-6.18	-0.32	1.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.42	-5.85	-0.31	1.17e-8	Blood pressure (smoking interaction);
CRC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg04719120	chr6:96025338	MANEA	0.61	6.99	0.36	1.58e-11	Behavioural disinhibition (generation interaction);
CRC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg25956985	chr22:39795188	MAP3K7IP1	-0.45	-6.66	-0.34	1.13e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07172597	chr19:42817659	TMEM145	0.52	7.29	0.37	2.29e-12	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04364726	chr19:21512166	ZNF708	0.38	6.2	0.32	1.66e-9	Obesity-related traits;
CRC	cis	rs12900463	0.813	rs187316	chr15:85405995	T/C	cg11189052	chr15:85197271	WDR73	0.45	6.07	0.32	3.44e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg06028605	chr16:24865363	SLC5A11	-0.35	-6.56	-0.34	2.11e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.52	-9.08	-0.45	1.02e-17	Aortic root size;
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.75	-12.3	-0.56	7.55e-29	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.67	-0.3	3.12e-8	Aortic root size;
CRC	cis	rs501916	0.605	rs17332642	chr15:48080805	G/A	cg16110827	chr15:48056943	SEMA6D	-0.5	-7.54	-0.38	4.6e-13	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg27205649	chr11:78285834	NARS2	0.49	6.12	0.32	2.61e-9	Alzheimer's disease (survival time);
CRC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.52	7.54	0.38	4.61e-13	Uric acid levels;
CRC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg25344623	chr2:136566232	LCT	0.33	6.06	0.32	3.8e-9	Mosquito bite size;
CRC	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.53	7.2	0.37	4.05e-12	Caudate activity during reward;
CRC	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg12046867	chr14:103022105	NA	0.42	6.26	0.33	1.23e-9	Platelet count;
CRC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg15448220	chr1:150897856	SETDB1	0.49	7.03	0.36	1.2e-11	Tonsillectomy;
CRC	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.48	-7.16	-0.37	5.42e-12	Caudate activity during reward;
CRC	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.43	-0.46	7.78e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.79	-0.47	5.04e-20	Blood protein levels;
CRC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.0	11.99	0.55	1.01e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.91	-18.72	-0.72	9.45e-54	Urate levels in lean individuals;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.61	-0.34	1.51e-10	Breast cancer;
CRC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg16558177	chr4:4109446	NA	-0.56	-6.48	-0.34	3.35e-10	Blood pressure (smoking interaction);
CRC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.08	-0.32	3.35e-9	Bipolar disorder;
CRC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg23018236	chr17:30244563	NA	-0.58	-7.85	-0.4	6.09e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.49	-10.83	-0.51	1.41e-23	Rheumatoid arthritis;
CRC	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg20608306	chr11:116969690	SIK3	-0.32	-5.94	-0.31	7.18e-9	Subjective well-being;
CRC	cis	rs3824347	0.839	rs10869471	chr9:77629472	C/A	cg01251476	chr9:77566080	C9orf40	0.36	5.63	0.3	3.8e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs2882667	0.659	rs700621	chr5:138098430	C/T	cg09476006	chr5:138032270	NA	-0.59	-10.52	-0.5	1.7e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.47	6.01	0.31	4.95e-9	Aortic root size;
CRC	cis	rs1943345	0.556	rs553484	chr11:82921538	C/T	cg07047830	chr11:82868014	PCF11	0.46	6.44	0.33	4.24e-10	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05902997	chr5:65440515	SFRS12	0.41	6.49	0.34	3.17e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.45	5.91	0.31	8.75e-9	Menarche (age at onset);
CRC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg03037974	chr15:76606532	NA	0.57	9.55	0.47	3.07e-19	Blood metabolite levels;
CRC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.66	8.51	0.42	6.16e-16	Response to diuretic therapy;
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11645453	chr3:52864694	ITIH4	0.37	6.53	0.34	2.57e-10	Bipolar disorder;
CRC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg04880052	chr2:219191631	PNKD	-0.39	-5.93	-0.31	7.68e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg09455208	chr3:40491958	NA	0.31	6.06	0.32	3.74e-9	Renal cell carcinoma;
CRC	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4964805	0.580	rs10861097	chr12:104170474	C/T	cg02344784	chr12:104178138	NT5DC3	0.45	6.86	0.35	3.4e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg07930552	chr6:133119739	C6orf192	0.63	5.6	0.3	4.48e-8	Type 2 diabetes nephropathy;
CRC	cis	rs2257205	0.667	rs6503872	chr17:56696008	C/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.79	-0.3	1.62e-8	Pancreatic cancer;
CRC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg05623727	chr3:50126028	RBM5	0.44	7.07	0.36	9.24e-12	Intelligence (multi-trait analysis);
CRC	trans	rs6600671	0.967	rs11249347	chr1:121188347	G/T	cg09829573	chr1:144692074	NBPF9	-0.4	-5.99	-0.31	5.47e-9	Hip geometry;
CRC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg10263370	chr3:44754102	ZNF502	-0.41	-6.81	-0.35	4.57e-11	Depressive symptoms;
CRC	trans	rs9650657	0.615	rs1549796	chr8:10692359	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.17	-0.32	2.04e-9	Neuroticism;
CRC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24308560	chr3:49941425	MST1R	0.46	7.23	0.37	3.51e-12	Intelligence (multi-trait analysis);
CRC	cis	rs834811	0.602	rs7784422	chr7:135883502	G/T	cg01726295	chr7:135938950	NA	0.35	5.95	0.31	7.01e-9	Post-traumatic stress disorder;
CRC	trans	rs6686842	1.000	rs6663565	chr1:41563688	C/T	cg19787969	chr8:9763211	NA	0.28	5.97	0.31	6.25e-9	Height;
CRC	cis	rs9467160	1.000	rs9467162	chr6:24442047	T/C	cg20631270	chr6:24437470	GPLD1	0.48	6.34	0.33	7.61e-10	Liver enzyme levels;
CRC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.4	6.15	0.32	2.31e-9	Red blood cell count;
CRC	cis	rs9847710	0.901	rs2564937	chr3:53025859	C/T	cg04503182	chr3:53078218	SFMBT1	0.41	6.19	0.32	1.75e-9	Ulcerative colitis;
CRC	cis	rs3849570	0.555	rs6548783	chr3:81993621	G/A	cg07356753	chr3:81810745	GBE1	-0.51	-7.11	-0.37	7.08e-12	Waist circumference;Body mass index;
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.75	10.48	0.5	2.38e-22	Longevity;
CRC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	10.12	0.49	4.01e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.54	8.06	0.41	1.44e-14	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17358899	chr7:148580458	EZH2	0.46	6.7	0.35	9.26e-11	Response to antipsychotic treatment;
CRC	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg16989719	chr2:238392110	NA	0.41	7.45	0.38	8.26e-13	Prostate cancer;
CRC	cis	rs672059	1.000	rs551569	chr1:183158293	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.28	0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs9648716	1.000	rs6966197	chr7:140597229	C/A	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.57	8.63	0.43	2.63e-16	Longevity;Endometriosis;
CRC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg20194872	chr6:41519635	FOXP4	0.39	5.64	0.3	3.61e-8	Prostate cancer;
CRC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.49	-8.12	-0.41	9.31e-15	Bipolar disorder;
CRC	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.28e-11	Body mass index;
CRC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.46	6.55	0.34	2.27e-10	Alcohol dependence;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.92	-0.31	7.88e-9	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.86	0.51	1.13e-23	Motion sickness;
CRC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.77	6.87	0.35	3.14e-11	Diabetic retinopathy;
CRC	cis	rs731174	0.759	rs12133523	chr1:38153110	T/A	cg06917450	chr1:38156652	C1orf109	-0.51	-7.18	-0.37	4.74e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg14092571	chr14:90743983	NA	0.39	5.94	0.31	7.29e-9	Mortality in heart failure;
CRC	cis	rs7129556	0.906	rs72945508	chr11:77267537	G/C	cg12586386	chr11:77299805	AQP11	0.41	5.67	0.3	3.16e-8	Weight loss (gastric bypass surgery);
CRC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.54	-7.88	-0.4	4.75e-14	Carotid intima media thickness;
CRC	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg14515779	chr1:101123966	NA	-0.35	-6.26	-0.33	1.19e-9	Monocyte count;
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.57	-10.21	-0.49	1.98e-21	Multiple system atrophy;
CRC	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg07166546	chr14:35805898	NA	-0.3	-6.0	-0.31	5.31e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg11189052	chr15:85197271	WDR73	0.64	8.98	0.44	2.1e-17	Schizophrenia;
CRC	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg18646521	chr2:111875858	NA	0.37	5.78	0.3	1.78e-8	Chronic lymphocytic leukemia;
CRC	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.52	-8.46	-0.42	9.13e-16	Crohn's disease;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Parkinson's disease;
CRC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg10298567	chr3:47292165	KIF9	0.45	7.18	0.37	4.55e-12	Colorectal cancer;
CRC	cis	rs422249	0.896	rs174449	chr11:61640379	A/G	cg01500311	chr11:61656094	FADS3	-0.43	-7.53	-0.38	4.99e-13	Trans fatty acid levels;
CRC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	6.08	0.32	3.36e-9	Protein C levels;
CRC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.48	6.94	0.36	2.16e-11	Melanoma;
CRC	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg15621731	chr19:5074616	KDM4B	0.31	5.96	0.31	6.54e-9	Monocyte percentage of white cells;
CRC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.56	6.09	0.32	3.18e-9	Schizophrenia;
CRC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.72	0.68	7.3e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2223471	1.000	rs2223471	chr6:50733648	A/T	cg03432817	chr6:50765336	NA	0.38	6.18	0.32	1.89e-9	Subcutaneous adipose tissue;
CRC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg21194808	chr1:2205498	SKI	0.43	6.23	0.33	1.4e-9	Coronary artery disease;
CRC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg27565382	chr3:53032988	SFMBT1	0.7	6.16	0.32	2.07e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-6.58	-0.34	1.85e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg23127183	chr11:57508653	C11orf31	-0.53	-7.08	-0.36	8.9e-12	Schizophrenia;
CRC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.49	-9.49	-0.46	4.8e-19	Intelligence (multi-trait analysis);
CRC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg02094049	chr14:103021097	NA	-0.54	-6.97	-0.36	1.7e-11	Platelet count;
CRC	cis	rs6545883	0.630	rs12998475	chr2:61437487	T/C	cg15711740	chr2:61764176	XPO1	0.41	5.62	0.3	4.01e-8	Tuberculosis;
CRC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg09659197	chr4:152720779	NA	0.5	10.71	0.51	3.59e-23	Intelligence (multi-trait analysis);
CRC	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg21951975	chr1:209979733	IRF6	0.48	6.46	0.34	3.87e-10	Cleft lip with or without cleft palate;
CRC	trans	rs4745661	0.703	rs1328530	chr9:80409138	C/G	cg02160872	chr5:212506	CCDC127	0.37	6.1	0.32	3.06e-9	IgG glycosylation;
CRC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	1.03	13.47	0.6	2.98e-33	Cerebrospinal P-tau181p levels;
CRC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.67	10.93	0.52	6.15e-24	Monocyte percentage of white cells;
CRC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg11518657	chr1:67396239	MIER1	0.55	5.93	0.31	7.58e-9	Lymphocyte percentage of white cells;
CRC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.36	-6.1	-0.32	2.92e-9	Childhood ear infection;
CRC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.61	9.81	0.48	4.35e-20	Intelligence (multi-trait analysis);
CRC	cis	rs2257205	0.667	rs9909635	chr17:56752159	G/A	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.87e-8	Pancreatic cancer;
CRC	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.95	-0.31	6.94e-9	Arsenic metabolism;
CRC	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.81	9.96	0.48	1.31e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg23161317	chr6:28129485	ZNF389	0.45	6.39	0.33	5.77e-10	Parkinson's disease;
CRC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.82	8.7	0.43	1.59e-16	Plasma clusterin levels;
CRC	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.53	-7.96	-0.4	2.82e-14	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13788301	chr22:35695944	TOM1	0.42	6.22	0.32	1.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.66	7.79	0.39	8.63e-14	Vitiligo;
CRC	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg11993925	chr19:44307056	LYPD5	-0.47	-7.68	-0.39	1.86e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6445525	1.000	rs9860098	chr3:65992808	A/G	cg06109867	chr3:66002991	MAGI1	-0.39	-6.46	-0.34	3.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.91	-0.31	8.75e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.65	7.42	0.38	1.02e-12	Body mass index;
CRC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.57	-0.43	4.03e-16	Body mass index;
CRC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.6	8.96	0.44	2.38e-17	Methadone dose in opioid dependence;
CRC	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.39	0.33	5.56e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.7	-0.35	8.99e-11	Depression;
CRC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.76	-0.47	6.15e-20	Hemoglobin concentration;
CRC	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.51	-0.34	2.86e-10	Height;
CRC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg15468180	chr1:107600409	PRMT6	-0.41	-6.07	-0.32	3.51e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.87	8.85	0.44	5.4e-17	Major depressive disorder;
CRC	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg02254261	chr7:158964346	NA	-0.51	-5.98	-0.31	5.87e-9	Myopia (pathological);
CRC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg16898833	chr6:26189333	HIST1H4D	0.94	7.7	0.39	1.64e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg17456266	chr11:43964085	LOC387763	-0.55	-5.98	-0.31	5.95e-9	Cognitive function;
CRC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18876405	chr7:65276391	NA	0.5	8.14	0.41	8.53e-15	Aortic root size;
CRC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-7.7	-0.39	1.64e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.31	-7.23	-0.37	3.41e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.14	-0.32	2.42e-9	Alzheimer's disease (late onset);
CRC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg16606324	chr3:10149918	C3orf24	0.48	7.03	0.36	1.23e-11	Alzheimer's disease;
CRC	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg00935504	chr16:1863053	HAGH	0.38	5.99	0.31	5.57e-9	Blood metabolite levels;
CRC	cis	rs12599426	0.852	rs3853178	chr16:34597543	C/T	cg08331635	chr16:34430078	NA	-0.47	-5.76	-0.3	1.94e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24308560	chr3:49941425	MST1R	0.5	8.23	0.41	4.39e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.31	-5.62	-0.3	4.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.26	-0.41	3.58e-15	Monocyte percentage of white cells;
CRC	cis	rs9648716	0.808	rs6953658	chr7:140467095	T/C	cg10747023	chr7:140774559	NA	0.44	5.64	0.3	3.71e-8	Type 2 diabetes;
CRC	cis	rs7517126	1.000	rs2336504	chr1:196843654	C/T	cg13682187	chr1:196946512	CFHR5	-0.38	-6.16	-0.32	2.09e-9	Blood protein levels;
CRC	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.92	11.19	0.53	7.51e-25	Exhaled nitric oxide output;
CRC	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.64	-0.34	1.3e-10	Plateletcrit;
CRC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.51	7.61	0.39	2.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.6	-9.02	-0.45	1.61e-17	Bipolar disorder;
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg04155289	chr7:94953770	PON1	-0.59	-7.53	-0.38	5.06e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.11	-0.61	1.1e-35	Colorectal cancer;
CRC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg18282456	chr14:51561492	TRIM9	0.3	5.71	0.3	2.5e-8	Cancer;
CRC	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.74	9.74	0.47	7.13e-20	Prostate cancer;
CRC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.57	8.43	0.42	1.1e-15	Homoarginine levels;
CRC	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.88	16.85	0.68	2.35e-46	Hip circumference;
CRC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.43	5.62	0.3	4e-8	Aortic root size;
CRC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.43	7.32	0.37	1.89e-12	Cardiovascular disease risk factors;
CRC	cis	rs6604026	0.656	rs11164843	chr1:93416142	A/C	cg17283838	chr1:93427260	FAM69A	0.42	5.65	0.3	3.43e-8	Multiple sclerosis;
CRC	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-7.97	-0.4	2.6e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.81	14.74	0.63	4.18e-38	Anterior chamber depth;
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.66	-0.43	2.17e-16	Bipolar disorder;
CRC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.82	0.31	1.43e-8	Homoarginine levels;
CRC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg13160058	chr8:26243215	BNIP3L	-0.49	-8.17	-0.41	6.84e-15	Red cell distribution width;
CRC	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.58	7.87	0.4	5.02e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.15e-10	Mean platelet volume;
CRC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	8.05	0.41	1.55e-14	Height;
CRC	cis	rs3785888	0.548	rs197922	chr17:45008570	G/A	cg16759221	chr17:45003025	GOSR2	-0.63	-9.54	-0.47	3.23e-19	Cleft lip with or without cleft palate;
CRC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.71	0.35	8.75e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs910187	0.678	rs8115769	chr20:45813704	A/C	cg27589058	chr20:45804311	EYA2	-0.39	-7.55	-0.38	4.27e-13	Migraine;
CRC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11645453	chr3:52864694	ITIH4	0.4	6.81	0.35	4.65e-11	Bipolar disorder;
CRC	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.65	9.1	0.45	9.13e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg21856205	chr7:94953877	PON1	-0.49	-6.31	-0.33	8.83e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg22349387	chr12:9600060	DDX12	-0.36	-5.65	-0.3	3.41e-8	Breast size;
CRC	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.88	10.91	0.52	7.35e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.64	7.02	0.36	1.28e-11	Gut microbiome composition (summer);
CRC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.62	-0.3	4.18e-8	Schizophrenia;
CRC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg00383909	chr3:49044727	WDR6	0.45	5.63	0.3	3.93e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg05501817	chr11:14380813	RRAS2	-0.46	-6.11	-0.32	2.87e-9	Sense of smell;
CRC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.17	0.32	2.02e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	1.03	18.33	0.71	3.39e-52	Parkinson's disease;
CRC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.9	-14.88	-0.63	1.14e-38	Headache;
CRC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.37	-8.69	-0.43	1.71e-16	Mean corpuscular volume;
CRC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.91	0.52	7.29e-24	Motion sickness;
CRC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.29	-6.1	-0.32	3.03e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.53	-7.11	-0.37	7.16e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg17724175	chr1:150552817	MCL1	-0.5	-8.16	-0.41	7.11e-15	Tonsillectomy;
CRC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.67	10.34	0.5	6.89e-22	Corneal astigmatism;
CRC	cis	rs17713451	0.593	rs78219774	chr7:151279032	T/A	cg18404559	chr7:151322523	PRKAG2	-0.55	-6.3	-0.33	9.43e-10	Interleukin-4 levels;
CRC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.44	6.68	0.35	1.04e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs427941	0.550	rs201515	chr7:101769164	G/A	cg06246474	chr7:101738831	CUX1	0.37	5.66	0.3	3.27e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.56	-0.47	2.93e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.38	0.53	1.6e-25	Bone mineral density;
CRC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.42	7.05	0.36	1.08e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs800082	1.000	rs1961653	chr3:144286098	C/T	cg24215973	chr2:240111563	HDAC4	-0.51	-7.14	-0.37	5.94e-12	Smoking behavior;
CRC	cis	rs7705042	0.865	rs9324866	chr5:141497650	A/G	cg07392085	chr5:141489673	NDFIP1	0.47	7.43	0.38	9.4e-13	Asthma;
CRC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	trans	rs9395066	0.545	rs12209076	chr6:44833423	G/A	cg04786201	chr1:17185605	NA	0.28	6.04	0.32	4.21e-9	Height;
CRC	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.81	-0.4	7.49e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.64	-0.39	2.34e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.53	-6.59	-0.34	1.8e-10	Ankle injury;
CRC	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.57	0.5	1.14e-22	Coffee consumption (cups per day);
CRC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	9.58	0.47	2.38e-19	Migraine;Coronary artery disease;
CRC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg11212589	chr17:38028394	ZPBP2	0.37	6.75	0.35	6.63e-11	Lymphocyte counts;
CRC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.53	6.77	0.35	5.86e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.48	-7.45	-0.38	8.27e-13	Red blood cell count;
CRC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.69	11.2	0.53	6.71e-25	Motion sickness;
CRC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	14.08	0.61	1.51e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.23	0.32	1.47e-9	Parkinson's disease;
CRC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	trans	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	7.05	0.36	1.08e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg01422370	chr2:73384389	NA	0.37	5.83	0.31	1.35e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Depression;
CRC	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.2	-0.32	1.68e-9	Breast cancer;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg22638593	chr5:131593259	PDLIM4	0.5	8.7	0.43	1.57e-16	Acylcarnitine levels;
CRC	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.5	6.41	0.33	4.99e-10	Recombination rate (females);
CRC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg11166453	chr1:247681781	NA	-0.47	-8.22	-0.41	4.81e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs61160187	0.582	rs1382917	chr5:60252495	A/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.88	-0.31	9.95e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.62	-0.3	4e-8	Body mass index;
CRC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.84	12.5	0.57	1.28e-29	Body mass index;
CRC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.8	14.27	0.62	2.79e-36	Breast cancer;
CRC	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.47	-6.15	-0.32	2.29e-9	Migraine;
CRC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.43	5.7	0.3	2.72e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.66	-10.07	-0.49	5.83e-21	Diastolic blood pressure;
CRC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11997175	0.626	rs6468189	chr8:33648189	C/A	ch.8.33884649F	chr8:33765107	NA	0.4	6.23	0.32	1.45e-9	Body mass index;
CRC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.8	10.19	0.49	2.26e-21	Gut microbiome composition (summer);
CRC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg07718321	chr6:96025334	MANEA	0.59	7.49	0.38	6.54e-13	Behavioural disinhibition (generation interaction);
CRC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.45	-8.7	-0.43	1.65e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-9.95	-0.48	1.42e-20	IgG glycosylation;
CRC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.43	0.38	9.44e-13	Motion sickness;
CRC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs758324	0.504	rs55764014	chr5:131170905	G/T	cg25547332	chr5:131281432	NA	0.35	5.68	0.3	3.03e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg17182837	chr8:41585554	ANK1	-0.52	-6.89	-0.36	2.81e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.03	18.47	0.71	9.49e-53	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16314058	chr1:43312353	ZNF691	0.45	6.14	0.32	2.42e-9	Anxiety disorder;
CRC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.07	-0.36	9.19e-12	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26459430	chr19:680063	FSTL3	0.44	6.28	0.33	1.08e-9	Anxiety disorder;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01844098	chr20:5987246	CRLS1	0.49	6.42	0.33	4.75e-10	Survival in pancreatic cancer;
CRC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	10.84	0.51	1.26e-23	Multiple sclerosis;
CRC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.7	11.59	0.54	2.91e-26	Breast cancer;
CRC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.43	6.36	0.33	6.77e-10	Menopause (age at onset);
CRC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg05707623	chr12:122985044	ZCCHC8	0.75	8.4	0.42	1.35e-15	Body mass index;
CRC	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.42	5.9	0.31	9.09e-9	Subjective well-being;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21354621	chr12:46384284	SFRS2IP	0.49	6.5	0.34	3.01e-10	Thyroid stimulating hormone;
CRC	cis	rs858239	0.698	rs4265084	chr7:23407240	G/C	cg00469287	chr7:23338798	C7orf30	0.46	6.11	0.32	2.85e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13606994	chr1:44402422	ARTN	-0.37	-6.28	-0.33	1.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs531930	0.959	rs506292	chr6:124735082	T/C	cg22366943	chr6:124882293	NKAIN2	-0.43	-5.86	-0.31	1.1e-8	Celiac disease;
CRC	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.45	-6.97	-0.36	1.78e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-5.96	-0.31	6.43e-9	Coronary artery disease;
CRC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg05585544	chr11:47624801	NA	-0.55	-9.78	-0.47	5.26e-20	Subjective well-being;
CRC	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.85	12.67	0.57	3.16e-30	Migraine;Coronary artery disease;
CRC	cis	rs698833	0.926	rs786626	chr2:44604066	C/G	cg04920474	chr2:44395004	PPM1B	0.42	6.2	0.32	1.67e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg15358743	chr18:56807035	SEC11C	-0.39	-6.03	-0.32	4.35e-9	Daytime sleep phenotypes;
CRC	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg22482690	chr17:47019901	SNF8	0.48	8.08	0.41	1.21e-14	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00436663	chr22:38793933	LOC400927	0.46	6.93	0.36	2.27e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6893807	1.000	rs1422192	chr5:87959023	G/A	cg09002922	chr5:87956389	LOC645323	-0.45	-6.55	-0.34	2.19e-10	Body mass index;
CRC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg22495460	chr2:25135724	ADCY3	-0.88	-17.44	-0.69	1.05e-48	Body mass index;
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.65	-9.03	-0.45	1.51e-17	Alzheimer's disease;
CRC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.76	10.21	0.49	1.96e-21	Platelet count;
CRC	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.74	-10.45	-0.5	2.97e-22	Smoking behavior;
CRC	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07741184	chr6:167504864	NA	-0.34	-6.0	-0.31	5.07e-9	Rheumatoid arthritis;
CRC	trans	rs58688157	0.705	rs936469	chr11:606749	G/A	cg19188899	chr13:112838565	NA	-0.43	-6.76	-0.35	6.41e-11	Systemic lupus erythematosus;
CRC	cis	rs28830936	1.000	rs4924570	chr15:41974660	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.38	-0.33	6.09e-10	Diastolic blood pressure;
CRC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg04518342	chr5:131593106	PDLIM4	0.33	5.82	0.31	1.41e-8	Blood metabolite levels;
CRC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.01	-0.68	5.43e-47	Body mass index;
CRC	cis	rs7894051	0.717	rs35297981	chr10:135150600	T/G	cg24905316	chr10:135186343	ECHS1	-0.72	-5.9	-0.31	8.92e-9	Lifespan;
CRC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg19622623	chr12:86230825	RASSF9	-0.35	-5.63	-0.3	3.79e-8	Major depressive disorder;
CRC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.81	11.48	0.53	7.1e-26	Migraine;Coronary artery disease;
CRC	cis	rs7173389	1.000	rs7174098	chr15:73664041	G/A	cg01796676	chr15:73680284	NA	0.55	7.12	0.37	6.96e-12	Resting heart rate;
CRC	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.72	10.34	0.5	6.97e-22	Obesity-related traits;
CRC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg19193384	chr17:30244184	NA	-0.54	-6.95	-0.36	2.02e-11	Hip circumference adjusted for BMI;
CRC	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg13611204	chr9:139324423	INPP5E	-0.42	-5.9	-0.31	8.84e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.72	-0.43	1.43e-16	Coffee consumption (cups per day);
CRC	cis	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs282587	0.597	rs12876520	chr13:113393566	C/G	cg04656015	chr13:113407548	ATP11A	0.61	7.39	0.38	1.23e-12	Glycated hemoglobin levels;
CRC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.14	-0.32	2.34e-9	Height;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	1.0	17.77	0.7	5.15e-50	Menarche (age at onset);
CRC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.16	10.93	0.52	6.45e-24	Skin colour saturation;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.55	-0.43	4.57e-16	Life satisfaction;
CRC	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.84	8.99	0.44	1.96e-17	Gastritis;
CRC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg00490450	chr3:139108681	COPB2	-0.48	-7.21	-0.37	3.94e-12	Obesity-related traits;
CRC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.33	-0.33	7.93e-10	Aortic root size;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.72	9.5	0.46	4.68e-19	Alzheimer's disease;
CRC	cis	rs7112925	0.932	rs12287978	chr11:66833327	G/A	cg24851651	chr11:66362959	CCS	-0.38	-6.56	-0.34	2.14e-10	Height;
CRC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg27523141	chr10:43048294	ZNF37B	0.45	6.53	0.34	2.47e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.59	-10.35	-0.5	6.63e-22	Body mass index;
CRC	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg21827317	chr3:136751795	NA	0.35	5.76	0.3	1.89e-8	Neuroticism;
CRC	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg25876840	chr17:41920477	NA	0.36	5.67	0.3	3.11e-8	Triglycerides;
CRC	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.38	-0.46	1.11e-18	Urate levels in obese individuals;
CRC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-6.94	-0.36	2.15e-11	IgG glycosylation;
CRC	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-10.12	-0.49	3.87e-21	Breast cancer;
CRC	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg09873164	chr1:152488093	CRCT1	0.38	6.35	0.33	7.21e-10	Hair morphology;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02125727	chr4:47916636	NFXL1	0.41	6.1	0.32	2.98e-9	Schizophrenia;
CRC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-6.74	-0.35	7.05e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4654899	0.714	rs12123093	chr1:21114416	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.62	-0.39	2.78e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	16.11	0.66	1.94e-43	Electrocardiographic conduction measures;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24037629	chr17:48226544	PPP1R9B	0.48	7.07	0.36	9.61e-12	Response to antipsychotic treatment;
CRC	cis	rs802075	0.967	rs187233	chr6:49659703	C/T	cg20364632	chr6:49636226	NA	-0.36	-5.88	-0.31	9.95e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.78	-9.14	-0.45	6.41e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.14	0.41	8.16e-15	Menopause (age at onset);
CRC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.55	0.47	3.12e-19	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04175895	chr11:64851783	CDCA5;ZFPL1	0.48	6.43	0.33	4.55e-10	Anxiety disorder;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20092199	chr4:1342459	KIAA1530	0.37	6.54	0.34	2.42e-10	Obesity-related traits;
CRC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg03037974	chr15:76606532	NA	-0.53	-8.21	-0.41	5.15e-15	Blood metabolite levels;
CRC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.6	-10.0	-0.48	9.84e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.9	0.48	2.14e-20	Corneal astigmatism;
CRC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-15.98	-0.66	5.79e-43	Electrocardiographic conduction measures;
CRC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	9.18	0.45	4.83e-18	Mean platelet volume;
CRC	cis	rs1009181	0.585	rs72834696	chr6:26161399	G/A	cg13736514	chr6:26305472	NA	-0.4	-5.89	-0.31	9.36e-9	Childhood ear infection;
CRC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.58	7.56	0.38	4.06e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05712126	chr22:29601860	EMID1	0.42	6.98	0.36	1.64e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.63	11.29	0.53	3.27e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg16898833	chr6:26189333	HIST1H4D	0.77	6.45	0.33	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg12855166	chr17:30846586	MYO1D	-0.38	-6.44	-0.33	4.27e-10	Schizophrenia;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.48	-0.34	3.3e-10	Total body bone mineral density;
CRC	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.49	7.68	0.39	1.89e-13	Red blood cell count;
CRC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.85	-13.1	-0.59	7.41e-32	Diastolic blood pressure;
CRC	trans	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg01505111	chr6:125621795	HDDC2	0.39	6.13	0.32	2.51e-9	DNA methylation (variation);
CRC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.06	9.98	0.48	1.12e-20	Opioid sensitivity;
CRC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-6.67	-0.35	1.1e-10	Glycated hemoglobin levels;
CRC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.01e-12	Rheumatoid arthritis;
CRC	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-0.78	-10.26	-0.49	1.3e-21	IgG glycosylation;
CRC	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.51	5.76	0.3	1.89e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-10.21	-0.49	1.99e-21	Coronary artery disease;
CRC	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.91	-0.31	8.38e-9	Type 2 diabetes;
CRC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.37	-0.33	6.36e-10	Alzheimer's disease (late onset);
CRC	cis	rs1465370	0.750	rs3807136	chr7:130019481	C/T	cg03229158	chr7:130009420	NA	0.43	6.09	0.32	3.22e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.36	-0.38	1.48e-12	Gut microbiome composition (summer);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05253283	chr3:195717344	SDHAP1	0.43	6.26	0.33	1.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg25547332	chr5:131281432	NA	-0.38	-5.62	-0.3	4.18e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg23123621	chr4:1343375	KIAA1530	0.35	5.65	0.3	3.47e-8	Obesity-related traits;
CRC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.94	16.01	0.66	4.61e-43	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26056348	chr7:75932317	HSPB1	0.43	6.15	0.32	2.31e-9	Anxiety disorder;
CRC	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg06204229	chr3:52865917	ITIH4	0.57	7.88	0.4	4.95e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-6.08	-0.32	3.38e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg19773385	chr1:10388646	KIF1B	-0.66	-10.76	-0.51	2.38e-23	Hepatocellular carcinoma;
CRC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.67	-13.81	-0.61	1.54e-34	Schizophrenia;
CRC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg13722127	chr7:150037890	RARRES2	0.48	7.78	0.39	9.7e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs61160187	0.610	rs4700399	chr5:60136454	C/T	cg16298547	chr5:60138761	ELOVL7	-0.29	-6.14	-0.32	2.32e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs747650	0.892	rs2029298	chr11:47234718	C/T	cg19486271	chr11:47235900	DDB2	-0.51	-7.76	-0.39	1.1e-13	Acne (severe);
CRC	cis	rs12541635	0.966	rs1603363	chr8:107031319	A/G	cg10147462	chr8:107024639	NA	0.45	7.51	0.38	5.57e-13	Age of smoking initiation;
CRC	cis	rs7113874	0.569	rs10840072	chr11:8569360	T/C	cg20771178	chr11:8615675	STK33	-0.34	-5.6	-0.3	4.41e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg13628971	chr7:2884303	GNA12	0.38	5.84	0.31	1.24e-8	Height;
CRC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg21620606	chr4:1342894	KIAA1530	0.36	5.91	0.31	8.57e-9	Obesity-related traits;
CRC	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	6.13	0.32	2.52e-9	Depressive episodes in bipolar disorder;
CRC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.48	6.9	0.36	2.73e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg15962314	chr1:44399869	ARTN	0.3	5.86	0.31	1.15e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.61e-9	Height;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27186011	chr3:49840712	C3orf54	0.37	5.85	0.31	1.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.59	7.22	0.37	3.7e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17554472	chr22:41940697	POLR3H	-0.56	-5.94	-0.31	7.15e-9	Vitiligo;
CRC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.35	0.38	1.62e-12	Aortic root size;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg26132723	chr8:70041827	NA	0.36	5.8	0.3	1.6e-8	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.6	-9.1	-0.45	8.63e-18	Psoriasis;
CRC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg03013999	chr17:37608204	MED1	-0.47	-7.4	-0.38	1.14e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.86	-16.17	-0.67	1.12e-43	Dental caries;
CRC	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.3	-0.33	9.71e-10	Neuroticism;
CRC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.79	-0.3	1.68e-8	Mean corpuscular volume;
CRC	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.49	7.67	0.39	1.97e-13	Schizophrenia;
CRC	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg15711740	chr2:61764176	XPO1	0.43	5.73	0.3	2.26e-8	Tuberculosis;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg03376565	chr6:26104165	HIST1H4C	0.49	6.53	0.34	2.45e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.44	0.33	4.3e-10	Blood protein levels;
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11645453	chr3:52864694	ITIH4	0.36	6.45	0.34	3.93e-10	Electroencephalogram traits;
CRC	cis	rs11628318	0.515	rs60573537	chr14:103150407	A/G	cg12046867	chr14:103022105	NA	0.4	5.69	0.3	2.87e-8	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04567173	chr4:25379221	ANAPC4	0.4	6.6	0.34	1.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-7.88	-0.4	4.69e-14	Coronary artery disease;
CRC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg23996704	chr18:44553084	KATNAL2	0.32	6.22	0.32	1.55e-9	Personality dimensions;
CRC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.26	-0.33	1.23e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs5753037	0.639	rs5997534	chr22:30220190	G/A	cg01021169	chr22:30184971	ASCC2	-0.43	-6.62	-0.34	1.43e-10	Type 1 diabetes;
CRC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.46	6.54	0.34	2.39e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11138902	0.649	rs13286400	chr9:72148579	C/G	cg14123607	chr9:72164709	APBA1	0.41	6.0	0.31	5.27e-9	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg23161317	chr6:28129485	ZNF389	0.39	5.85	0.31	1.17e-8	Cardiac Troponin-T levels;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.8	-0.4	8.13e-14	Breast cancer;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	0.71	7.87	0.4	5.25e-14	Body mass index;
CRC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.76	-12.83	-0.58	8.19e-31	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00666446	chr1:247242273	ZNF670	0.46	6.51	0.34	2.87e-10	Response to antipsychotic treatment;
CRC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.0	-0.31	5.15e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7932354	0.528	rs7108902	chr11:47091571	C/T	cg19486271	chr11:47235900	DDB2	-0.45	-6.46	-0.34	3.8e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7605827	0.930	rs10929366	chr2:15531754	C/T	cg19274914	chr2:15703543	NA	0.39	5.76	0.3	1.98e-8	Educational attainment (years of education);
CRC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg26762873	chr11:5879799	OR52E8	-0.45	-6.55	-0.34	2.23e-10	DNA methylation (variation);
CRC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.46	6.44	0.33	4.12e-10	Alcohol dependence;
CRC	cis	rs629535	0.773	rs655299	chr8:70074534	C/T	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.51e-8	Dupuytren's disease;
CRC	cis	rs7274811	0.711	rs373618	chr20:31992639	C/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.83	0.31	1.29e-8	Height;
CRC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.34	-0.42	2.08e-15	Initial pursuit acceleration;
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg18758796	chr5:131593413	PDLIM4	0.33	5.83	0.31	1.3e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs7551222	0.749	rs6594019	chr1:204568610	T/C	cg07972458	chr1:204535000	NA	0.37	5.7	0.3	2.65e-8	Schizophrenia;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg15786705	chr6:28176104	NA	0.56	5.65	0.3	3.39e-8	Lung cancer in ever smokers;
CRC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.51	0.57	1.22e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg20302533	chr7:39170763	POU6F2	0.4	5.66	0.3	3.33e-8	IgG glycosylation;
CRC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.39	6.37	0.33	6.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.54	9.1	0.45	8.85e-18	Eye color traits;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02756545	chr1:94884060	ABCD3	-0.4	-5.98	-0.31	5.7e-9	Aortic root size;
CRC	cis	rs6565681	0.883	rs4523980	chr17:78347664	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.55	-6.32	-0.33	8.6e-10	Moyamoya disease;
CRC	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.66	-9.16	-0.45	5.73e-18	Menopause (age at onset);
CRC	cis	rs17443541	0.507	rs7576031	chr2:200470616	G/A	cg03741458	chr2:200468445	NA	-0.36	-5.77	-0.3	1.87e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.36	0.5	5.74e-22	Ileal carcinoids;
CRC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.55	-7.58	-0.39	3.56e-13	Longevity;
CRC	cis	rs6011002	0.614	rs1291208	chr20:62330417	T/C	cg01176363	chr20:62369445	LIME1	-0.74	-5.68	-0.3	3.04e-8	Dental caries;
CRC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg26554054	chr8:600488	NA	-0.66	-6.11	-0.32	2.85e-9	IgG glycosylation;
CRC	cis	rs972578	1.000	rs5759070	chr22:43375701	G/A	cg01576275	chr22:43409880	NA	-0.49	-7.84	-0.4	6.52e-14	Mean platelet volume;
CRC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-8.63	-0.43	2.65e-16	Menarche (age at onset);
CRC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-15.89	-0.66	1.39e-42	Cognitive function;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg22638593	chr5:131593259	PDLIM4	0.48	9.05	0.45	1.28e-17	Acylcarnitine levels;
CRC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.66	9.52	0.46	3.79e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.72	-0.3	2.42e-8	Coronary artery disease;
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.39	5.97	0.31	6.29e-9	Bipolar disorder;
CRC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg04121214	chr22:50244548	NA	0.43	6.02	0.31	4.74e-9	Schizophrenia;
CRC	cis	rs9322817	0.691	rs9391244	chr6:105257690	G/A	cg02098413	chr6:105308735	HACE1	-0.44	-8.6	-0.43	3.29e-16	Thyroid stimulating hormone;
CRC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.56	0.34	2.12e-10	Renal cell carcinoma;
CRC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg11189052	chr15:85197271	WDR73	0.62	8.86	0.44	4.93e-17	Schizophrenia;
CRC	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg02820901	chr13:113351484	ATP11A	0.58	6.17	0.32	1.95e-9	Glycated hemoglobin levels;
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.02	0.58	1.59e-31	Alzheimer's disease;
CRC	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	0.87	13.56	0.6	1.39e-33	Platelet distribution width;
CRC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.63	-0.39	2.52e-13	Alzheimer's disease;
CRC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-21.06	-0.76	5.95e-63	Myeloid white cell count;
CRC	cis	rs9914988	0.887	rs7213285	chr17:27206029	G/A	cg20469991	chr17:27169893	C17orf63	-0.6	-5.83	-0.31	1.32e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.87	16.05	0.66	3.26e-43	Lewy body disease;
CRC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.82	14.65	0.63	8.85e-38	Vitiligo;
CRC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg05341575	chr12:125625032	AACS	-0.38	-5.95	-0.31	6.79e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	0.99	9.37	0.46	1.21e-18	Lymphocyte counts;
CRC	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.28	-0.42	3.03e-15	Biliary atresia;
CRC	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg13491945	chr12:107078410	RFX4	0.34	5.73	0.3	2.3e-8	Heart rate;
CRC	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg04586622	chr2:25135609	ADCY3	0.35	5.96	0.31	6.35e-9	Body mass index in non-asthmatics;
CRC	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	5.75	0.3	2.02e-8	Schizophrenia;
CRC	cis	rs55702914	0.625	rs59757315	chr2:198250213	T/C	cg10820045	chr2:198174542	NA	0.4	7.04	0.36	1.15e-11	Major depression and alcohol dependence;
CRC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.57	6.78	0.35	5.68e-11	Blood trace element (Zn levels);
CRC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg10437265	chr15:77819839	NA	-0.54	-8.97	-0.44	2.24e-17	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08265418	chr11:134123803	THYN1;ACAD8	0.41	6.68	0.35	1.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs41005	0.967	rs41006	chr2:8109348	A/G	cg03155496	chr2:8117019	LOC339788	0.4	7.15	0.37	5.73e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.2	0.41	5.41e-15	Alzheimer's disease;
CRC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.47	7.86	0.4	5.36e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg05139728	chr16:28306816	SBK1	-0.37	-6.05	-0.32	4.05e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg11189052	chr15:85197271	WDR73	0.61	9.04	0.45	1.35e-17	Schizophrenia;
CRC	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg02927042	chr1:21476669	EIF4G3	-0.52	-8.18	-0.41	6.12e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg07125278	chr16:67683757	RLTPR	-0.63	-6.85	-0.35	3.56e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.59	-7.05	-0.36	1.04e-11	Blood protein levels;
CRC	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	0.89	7.75	0.39	1.18e-13	Fat distribution (HIV);
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.53	-7.32	-0.37	1.86e-12	Tuberculosis;
CRC	cis	rs7259376	0.936	rs1865074	chr19:22554949	G/C	cg02657401	chr19:22469223	NA	-0.31	-6.77	-0.35	5.96e-11	Menopause (age at onset);
CRC	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.88	16.42	0.67	1.1e-44	Hip circumference;
CRC	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.89	0.44	4.22e-17	Coffee consumption (cups per day);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04980793	chr14:35451984	SRP54	0.42	6.4	0.33	5.42e-10	Myopia (pathological);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg09455096	chr2:61765470	XPO1	-0.4	-6.01	-0.31	4.86e-9	Aortic root size;
CRC	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg20607287	chr7:12443886	VWDE	-0.53	-5.69	-0.3	2.86e-8	Coronary artery disease;
CRC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.59	8.42	0.42	1.18e-15	Arsenic metabolism;
CRC	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-5.9	-0.31	8.9e-9	Coronary artery disease;
CRC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03641858	chr19:12777774	MORG1;MAN2B1	-0.4	-6.03	-0.32	4.42e-9	Myopia (pathological);
CRC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.56	-0.5	1.2e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3857067	0.509	rs61069704	chr4:95091856	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-6.15	-0.32	2.29e-9	QT interval;
CRC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg13482628	chr17:19912719	NA	-0.4	-6.17	-0.32	2e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21244846	chr9:27529339	MOBKL2B	0.39	6.53	0.34	2.51e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs728616	0.681	rs55899456	chr10:82050646	G/A	cg11900509	chr10:81946545	ANXA11	-0.56	-6.12	-0.32	2.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	8.13	0.41	8.87e-15	Hip circumference adjusted for BMI;
CRC	cis	rs375066	0.623	rs1036246	chr19:44355264	C/T	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg06581033	chr10:766294	NA	-0.52	-5.78	-0.3	1.71e-8	Uric acid levels;
CRC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg20243544	chr17:37824526	PNMT	0.53	8.49	0.42	7.38e-16	Asthma;
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.5	-10.11	-0.49	4.35e-21	Lung cancer;
CRC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.69	-9.12	-0.45	7.49e-18	Initial pursuit acceleration;
CRC	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.23	-0.32	1.41e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg03757145	chr4:76555832	CDKL2	-0.65	-6.0	-0.31	5.07e-9	Cognitive function;
CRC	cis	rs10760158	0.865	rs2239696	chr9:124029155	T/C	cg14417974	chr9:124058376	GSN	-0.34	-5.68	-0.3	3.01e-8	Pulse pressure;
CRC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.42	8.7	0.43	1.61e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs73206853	0.841	rs57299791	chr12:110954021	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	7.86	0.4	5.56e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg17133734	chr15:86042851	AKAP13	0.43	6.79	0.35	5.14e-11	Coronary artery disease;
CRC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.52	-8.37	-0.42	1.68e-15	Neurofibrillary tangles;
CRC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg24011408	chr12:48396354	COL2A1	0.47	6.36	0.33	6.59e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.5	-6.29	-0.33	9.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.62	9.97	0.48	1.26e-20	Alzheimer's disease (late onset);
CRC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg10298567	chr3:47292165	KIF9	-0.36	-5.92	-0.31	7.91e-9	Colorectal cancer;
CRC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.75	0.3	2.07e-8	Diabetic retinopathy;
CRC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.62	8.87	0.44	4.65e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg03037974	chr15:76606532	NA	-0.49	-7.43	-0.38	9.25e-13	Blood metabolite levels;
CRC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.42	6.66	0.34	1.12e-10	Monocyte count;
CRC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07513332	chr6:167530253	CCR6	-0.36	-6.05	-0.32	4.05e-9	Primary biliary cholangitis;
CRC	cis	rs2836754	1.000	rs2836754	chr21:40291740	C/T	cg16734191	chr21:40194848	ETS2	0.32	5.8	0.3	1.56e-8	Crohn's disease;Body mass index;
CRC	cis	rs79387448	0.745	rs9677607	chr2:103149520	A/T	cg09003973	chr2:102972529	NA	0.73	8.14	0.41	8.53e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg02683197	chr6:28174875	NA	0.47	6.68	0.35	1.04e-10	Cardiac Troponin-T levels;
CRC	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.49	-7.87	-0.4	5.02e-14	Endometrial cancer;
CRC	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg25885038	chr17:56607967	SEPT4	-0.5	-7.59	-0.39	3.36e-13	Vitamin D levels;
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg20041105	chr8:143859282	LYNX1	-0.58	-10.49	-0.5	2.07e-22	Urinary tract infection frequency;
CRC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.62	0.34	1.48e-10	Neuroticism;
CRC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.49	6.27	0.33	1.11e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3018066	0.738	rs76654812	chr4:106944699	C/T	cg01869342	chr4:106983673	TBCK	0.45	6.06	0.32	3.66e-9	Cancer;
CRC	cis	rs9463078	0.585	rs10456552	chr6:45313952	G/A	cg25276700	chr6:44698697	NA	0.25	5.98	0.31	5.75e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.77	-0.35	6.08e-11	Monocyte count;
CRC	cis	rs6911131	0.504	rs79489282	chr6:143906265	G/A	cg25407410	chr6:143891975	LOC285740	0.71	5.74	0.3	2.21e-8	Response to paliperidone in schizophrenia (positive Marder score);
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-7.71	-0.39	1.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24971181	chr8:25316395	CDCA2;KCTD9	0.44	6.51	0.34	2.81e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.14	0.32	2.41e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.7	0.39	1.64e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.49	-0.38	6.33e-13	Blood metabolite levels;
CRC	cis	rs4728302	0.869	rs6978170	chr7:133603838	C/T	cg03336402	chr7:133662267	EXOC4	-0.45	-6.52	-0.34	2.61e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg00066750	chr6:126080132	HEY2	0.58	6.16	0.32	2.11e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.62	-7.39	-0.38	1.24e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg01505111	chr6:125621795	HDDC2	0.38	5.98	0.31	5.69e-9	DNA methylation (variation);
CRC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg22834771	chr12:69754056	YEATS4	-0.41	-5.81	-0.31	1.48e-8	Blood protein levels;
CRC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg04166393	chr7:2884313	GNA12	0.58	7.72	0.39	1.44e-13	Height;
CRC	cis	rs9463078	0.727	rs9463054	chr6:44917197	T/C	cg25276700	chr6:44698697	NA	-0.27	-6.69	-0.35	9.48e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg14003231	chr6:33640908	ITPR3	0.51	8.22	0.41	4.71e-15	Height;
CRC	trans	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg18187862	chr3:45730750	SACM1L	-0.43	-5.99	-0.31	5.56e-9	Primary sclerosing cholangitis;
CRC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.69	-8.7	-0.43	1.65e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11446398	chr5:77624930	NA	0.45	5.99	0.31	5.64e-9	Triglycerides;
CRC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg24011408	chr12:48396354	COL2A1	0.45	6.19	0.32	1.84e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.34	-6.19	-0.32	1.83e-9	Dupuytren's disease;
CRC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.6	10.31	0.49	9.09e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00857557	chr6:42982050	MEA1;KLHDC3	-0.41	-6.26	-0.33	1.2e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07380405	chr12:7126460	LPCAT3	0.45	6.35	0.33	7.03e-10	Response to antipsychotic treatment;
CRC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg18099408	chr3:52552593	STAB1	0.34	5.91	0.31	8.56e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.7	9.13	0.45	6.88e-18	Bladder cancer;
CRC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.89	-0.63	1.04e-38	Height;
CRC	cis	rs995000	0.965	rs1168023	chr1:63006595	A/T	cg19896129	chr1:63156450	NA	-0.45	-7.04	-0.36	1.15e-11	Triglyceride levels;
CRC	cis	rs12612619	0.732	rs4665366	chr2:27212596	G/A	cg00617064	chr2:27272375	NA	0.34	5.61	0.3	4.23e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg26727032	chr16:67993705	SLC12A4	0.6	6.55	0.34	2.2e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg01483505	chr11:975446	AP2A2	-0.44	-7.29	-0.37	2.37e-12	Alzheimer's disease (late onset);
CRC	cis	rs9361491	0.657	rs13198615	chr6:79430552	A/G	cg05283184	chr6:79620031	NA	-0.37	-5.73	-0.3	2.31e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12692738	0.526	rs355837	chr2:165619091	A/G	cg03182029	chr2:165697222	COBLL1	0.5	6.02	0.31	4.71e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.6	8.36	0.42	1.74e-15	Arsenic metabolism;
CRC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg16342193	chr10:102329863	NA	-0.36	-5.91	-0.31	8.64e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg03923535	chr7:1197113	ZFAND2A	0.55	8.03	0.4	1.74e-14	Longevity;Endometriosis;
CRC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg25876840	chr17:41920477	NA	0.41	6.54	0.34	2.3e-10	Triglycerides;
CRC	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.84	14.47	0.62	4.76e-37	Phospholipid levels (plasma);
CRC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg12463550	chr7:65579703	CRCP	0.71	6.53	0.34	2.52e-10	Diabetic kidney disease;
CRC	cis	rs11212617	0.901	rs594153	chr11:108131646	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.77	0.3	1.79e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.99	0.58	2.05e-31	Platelet count;
CRC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg04362960	chr10:104952993	NT5C2	-0.46	-5.68	-0.3	3e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.53	0.38	4.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.49	5.8	0.3	1.59e-8	QRS duration;
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg10729496	chr3:10149963	C3orf24	0.52	6.38	0.33	6.14e-10	Alzheimer's disease;
CRC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg03013636	chr16:1946785	NA	0.55	6.55	0.34	2.25e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.33	0.53	2.39e-25	Asthma (sex interaction);
CRC	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-0.42	-6.8	-0.35	4.99e-11	Mean arterial pressure;
CRC	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.74	-0.3	2.16e-8	Coronary artery disease;
CRC	cis	rs1656402	0.953	rs1550099	chr2:233428147	A/G	cg03852847	chr2:233439513	NA	0.42	7.27	0.37	2.71e-12	Non-small cell lung cancer (survival);
CRC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	0.98	14.42	0.62	6.85e-37	Breast cancer;
CRC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg05623727	chr3:50126028	RBM5	0.46	7.32	0.37	1.95e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.53	-7.45	-0.38	8.18e-13	Menarche (age at onset);
CRC	cis	rs7781266	1.000	rs7781266	chr7:133505101	G/T	cg03336402	chr7:133662267	EXOC4	0.58	7.86	0.4	5.6e-14	Educational attainment (college completion);
CRC	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	7.66	0.39	2.09e-13	QT interval;
CRC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.84	0.31	1.25e-8	Life satisfaction;
CRC	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg03339077	chr11:47165057	C11orf49	0.5	7.3	0.37	2.22e-12	Acne (severe);
CRC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.58	-0.34	1.91e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg00383909	chr3:49044727	WDR6	0.69	7.15	0.37	5.49e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg10756647	chr7:56101905	PSPH	0.73	8.1	0.41	1.11e-14	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06159435	chr11:118966351	H2AFX	0.43	7.09	0.36	8.33e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.5	-7.5	-0.38	6.16e-13	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26994227	chr5:130971071	RAPGEF6	0.39	6.19	0.32	1.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg16342193	chr10:102329863	NA	-0.36	-5.93	-0.31	7.49e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.07	0.32	3.43e-9	Bipolar disorder;
CRC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.52	8.38	0.42	1.6e-15	Aortic root size;
CRC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg07636037	chr3:49044803	WDR6	-0.68	-6.65	-0.34	1.19e-10	Cognitive function;
CRC	cis	rs815815	0.608	rs815809	chr2:47380203	T/C	cg27223769	chr2:47403360	CALM2	-0.58	-7.55	-0.38	4.41e-13	Dialysis-related mortality;
CRC	cis	rs6066835	1.000	rs6066837	chr20:47357337	A/C	cg18078177	chr20:47281410	PREX1	0.65	6.05	0.32	4.01e-9	Multiple myeloma;
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11645453	chr3:52864694	ITIH4	0.37	6.68	0.35	9.97e-11	Bipolar disorder;
CRC	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg20356878	chr3:121714668	ILDR1	0.5	6.9	0.36	2.69e-11	Multiple sclerosis;
CRC	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.42	0.33	4.76e-10	Lymphocyte counts;
CRC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.51	-0.34	2.88e-10	Alzheimer's disease (late onset);
CRC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.83	15.23	0.64	5.35e-40	Mean platelet volume;
CRC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.38	6.66	0.34	1.12e-10	Cardiovascular disease risk factors;
CRC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.79	13.19	0.59	3.55e-32	Blood protein levels;
CRC	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.43	-6.87	-0.35	3.18e-11	Refractive error;
CRC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.6	9.45	0.46	6.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9322817	0.691	rs4142531	chr6:105324811	G/A	cg02098413	chr6:105308735	HACE1	0.43	8.49	0.42	7.27e-16	Thyroid stimulating hormone;
CRC	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	7.96	0.4	2.87e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9469913	0.542	rs75398113	chr6:34728071	G/C	cg14254433	chr6:34482411	PACSIN1	-0.68	-5.93	-0.31	7.51e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.3	0.33	9.55e-10	IgG glycosylation;
CRC	cis	rs9322817	0.691	rs7769270	chr6:105230729	C/A	cg02098413	chr6:105308735	HACE1	-0.44	-8.55	-0.43	4.67e-16	Thyroid stimulating hormone;
CRC	trans	rs67981189	0.679	rs221901	chr14:71602226	C/T	cg06081482	chr11:108093084	ATM;NPAT	-0.44	-6.01	-0.31	4.83e-9	Schizophrenia;
CRC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.47	-6.5	-0.34	2.9e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18357526	chr6:26021779	HIST1H4A	0.41	5.8	0.3	1.54e-8	Height;
CRC	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg07701084	chr6:150067640	NUP43	0.44	6.31	0.33	8.79e-10	Testicular germ cell tumor;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg05064044	chr6:292385	DUSP22	-0.57	-8.01	-0.4	2.01e-14	Menopause (age at onset);
CRC	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.53	-8.76	-0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.1	0.32	3.04e-9	Bladder cancer;
CRC	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.71	-8.18	-0.41	6.37e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.63	8.98	0.44	2.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17554472	chr22:41940697	POLR3H	-0.57	-5.83	-0.31	1.36e-8	Vitiligo;
CRC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.34	-5.75	-0.3	1.99e-8	Metabolite levels;
CRC	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg01639898	chr1:32083012	HCRTR1	0.29	5.93	0.31	7.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg01483505	chr11:975446	AP2A2	0.41	6.23	0.33	1.39e-9	Alzheimer's disease (late onset);
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg19913688	chr11:428466	ANO9	-0.72	-7.58	-0.39	3.58e-13	Body mass index;
CRC	cis	rs7605827	0.930	rs2287276	chr2:15660254	A/G	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.8e-9	Educational attainment (years of education);
CRC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-7.21	-0.37	3.76e-12	Menarche (age at onset);
CRC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.47	9.46	0.46	5.91e-19	Alcohol dependence;
CRC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.61	9.58	0.47	2.37e-19	Corneal astigmatism;
CRC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.51	9.66	0.47	1.36e-19	Intelligence (multi-trait analysis);
CRC	cis	rs62367758	0.683	rs316413	chr5:43094029	A/G	cg09164108	chr5:43007320	NA	-0.47	-5.76	-0.3	1.96e-8	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
CRC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.77	-13.87	-0.61	9.19e-35	Body mass index;
CRC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.54	-10.03	-0.48	7.8e-21	HDL cholesterol levels;
CRC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.64	9.2	0.45	4.26e-18	Menopause (age at onset);
CRC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.43	7.04	0.36	1.1e-11	Obesity-related traits;
CRC	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.68	-9.98	-0.48	1.14e-20	Non-response to antidepressants and depression;
CRC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg27101125	chr19:17392770	ANKLE1	-0.33	-5.75	-0.3	1.99e-8	Systemic lupus erythematosus;
CRC	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.85	-0.31	1.19e-8	Daytime sleep phenotypes;
CRC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-0.87	-10.59	-0.5	9.4e-23	Vitiligo;
CRC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg26162295	chr17:38119207	GSDMA	0.39	6.95	0.36	1.99e-11	Asthma and hay fever;
CRC	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.83	0.31	1.36e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.49	-8.39	-0.42	1.45e-15	Schizophrenia;
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg12564285	chr5:131593104	PDLIM4	0.5	9.45	0.46	6.35e-19	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12081917	chr17:39804985	NA	0.51	7.32	0.37	1.9e-12	Response to antipsychotic treatment;
CRC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.46	-7.45	-0.38	8.25e-13	Obesity-related traits;
CRC	trans	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.58	10.52	0.5	1.69e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg14213021	chr10:71930531	SAR1A	-0.43	-6.39	-0.33	5.72e-10	Underweight status;
CRC	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.43	0.5	3.37e-22	Corneal astigmatism;
CRC	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.73	0.43	1.3e-16	Coffee consumption (cups per day);
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg15511327	chr8:143859410	LYNX1	0.41	7.24	0.37	3.28e-12	Urinary tract infection frequency;
CRC	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg09760422	chr2:128146352	NA	-0.36	-7.1	-0.36	7.91e-12	Protein C levels;
CRC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg06470822	chr6:28175283	NA	0.48	6.52	0.34	2.66e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg03037974	chr15:76606532	NA	0.69	12.13	0.56	3.19e-28	Blood metabolite levels;
CRC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg24881330	chr22:46731750	TRMU	0.68	8.73	0.43	1.29e-16	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg18099408	chr3:52552593	STAB1	0.35	6.04	0.32	4.15e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00052422	chr3:41240987	CTNNB1	0.39	6.0	0.31	5.17e-9	Interleukin-6 levels;
CRC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.69	10.65	0.51	6.17e-23	Corneal astigmatism;
CRC	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.71	7.9	0.4	4.14e-14	Eotaxin levels;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.53	7.53	0.38	5e-13	Alzheimer's disease;
CRC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg00769240	chr8:12517080	NA	-0.57	-6.69	-0.35	9.48e-11	Blood pressure (smoking interaction);
CRC	cis	rs4780401	0.755	rs8191297	chr16:11766986	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.73	-0.3	2.28e-8	Rheumatoid arthritis;
CRC	cis	rs12913538	0.962	rs4774442	chr15:62897853	G/A	cg09983546	chr15:62884068	NA	0.57	9.09	0.45	9.56e-18	Sleep depth;
CRC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.71	-11.94	-0.55	1.47e-27	Breast cancer;
CRC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg05343316	chr1:45956843	TESK2	-0.42	-6.11	-0.32	2.88e-9	Platelet count;
CRC	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.31	-5.87	-0.31	1.05e-8	Cutaneous nevi;
CRC	cis	rs1357245	0.692	rs34978733	chr3:27204567	T/C	cg02860705	chr3:27208620	NA	-0.39	-5.84	-0.31	1.25e-8	Breast cancer;
CRC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	8.94	0.44	2.82e-17	Schizophrenia;
CRC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.3	-6.28	-0.33	1.1e-9	Homoarginine levels;
CRC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-5.85	-0.31	1.17e-8	Lung cancer;
CRC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg11707556	chr5:10655725	ANKRD33B	0.34	6.31	0.33	9.24e-10	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg12172441	chr6:28176163	NA	0.49	6.66	0.34	1.16e-10	Parkinson's disease;
CRC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-6.07	-0.32	3.53e-9	Monocyte percentage of white cells;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg02033258	chr5:131593261	PDLIM4	0.38	7.19	0.37	4.3e-12	Breast cancer;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg13047869	chr3:10149882	C3orf24	0.56	6.66	0.34	1.15e-10	Alzheimer's disease;
CRC	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	7.67	0.39	1.92e-13	Aortic root size;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg21251018	chr6:28226885	NKAPL	0.44	6.32	0.33	8.51e-10	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07949612	chr2:69664562	NFU1	0.41	6.02	0.31	4.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.59	-8.31	-0.42	2.55e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg03340356	chr1:67600835	NA	0.3	6.77	0.35	5.77e-11	Psoriasis;
CRC	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg01392867	chr16:30410429	ZNF48	0.38	6.09	0.32	3.21e-9	Tonsillectomy;
CRC	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.13	0.64	1.23e-39	Bipolar disorder;
CRC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.45	7.42	0.38	9.94e-13	Colorectal cancer;
CRC	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-1.07	-9.57	-0.47	2.57e-19	Post bronchodilator FEV1;
CRC	cis	rs995000	0.931	rs11207970	chr1:62915473	C/T	cg19896129	chr1:63156450	NA	0.39	5.7	0.3	2.62e-8	Triglyceride levels;
CRC	cis	rs16867321	0.950	rs9677293	chr2:181499459	C/G	cg23363182	chr2:181467187	NA	-0.51	-6.65	-0.34	1.21e-10	Obesity;
CRC	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	8.39	0.42	1.45e-15	Obesity-related traits;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12273811	chr6:28175739	NA	0.69	8.83	0.44	6.17e-17	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20470467	chr16:30886130	NA	0.47	5.96	0.31	6.55e-9	Thyroid stimulating hormone;
CRC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.05	13.07	0.58	1.02e-31	Vitiligo;
CRC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg21280719	chr6:42927975	GNMT	-0.34	-6.26	-0.33	1.22e-9	Blood protein levels;
CRC	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.48	-7.64	-0.39	2.43e-13	Schizophrenia;
CRC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	16.12	0.66	1.64e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg25456477	chr12:86230367	RASSF9	0.34	5.77	0.3	1.82e-8	Major depressive disorder;
CRC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.76	13.05	0.58	1.17e-31	Blood protein levels;
CRC	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.18	-0.37	4.6e-12	Capecitabine sensitivity;
CRC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.66	-8.34	-0.42	2.08e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-15.12	-0.64	1.37e-39	Gut microbiome composition (summer);
CRC	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-7.37	-0.38	1.43e-12	Menarche (age at onset);
CRC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.3	4.23e-8	Hemoglobin concentration;
CRC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.28e-13	Heart rate;
CRC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.07	0.32	3.45e-9	Lung cancer;
CRC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.37	0.65	1.54e-40	Platelet count;
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.31	-0.53	2.81e-25	Blood trace element (Zn levels);
CRC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg00745463	chr17:30367425	LRRC37B	0.54	6.64	0.34	1.34e-10	Hip circumference adjusted for BMI;
CRC	trans	rs2303319	0.504	rs12470830	chr2:162429996	C/T	cg04269497	chr6:167369491	RNASET2	-0.75	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs11229555	0.645	rs12283414	chr11:58176920	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.47	-9.3	-0.46	1.95e-18	Prostate cancer;
CRC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	18.11	0.71	2.42e-51	Platelet count;
CRC	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg01500311	chr11:61656094	FADS3	-0.49	-8.87	-0.44	4.67e-17	Trans fatty acid levels;
CRC	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21659725	chr3:3221576	CRBN	-0.43	-6.62	-0.34	1.5e-10	Menarche (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06057576	chr1:27719045	GPR3	0.46	6.18	0.32	1.87e-9	Anxiety disorder;
CRC	cis	rs73200209	0.912	rs17498914	chr12:116675689	C/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.91	-0.31	8.58e-9	Total body bone mineral density;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23084309	chr19:6280164	MLLT1	-0.4	-6.03	-0.32	4.29e-9	Myopia (pathological);
CRC	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.66	9.72	0.47	8.69e-20	Autism;
CRC	cis	rs4930561	0.690	rs6591334	chr11:67924559	A/G	cg04465784	chr11:67976953	SUV420H1	-0.3	-6.06	-0.32	3.8e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg27395922	chr11:50257633	LOC441601	0.49	6.2	0.32	1.71e-9	Axial length;
CRC	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs11679072	1.000	rs73110504	chr2:240449770	G/A	cg03276489	chr2:240449683	NA	-0.92	-9.23	-0.45	3.45e-18	Blood pressure (smoking interaction);
CRC	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg17410650	chr12:54324560	NA	-0.37	-6.69	-0.35	9.45e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.47	6.46	0.34	3.77e-10	Schizophrenia;
CRC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.57	-7.66	-0.39	2.04e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.72	-12.45	-0.57	1.97e-29	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg10298567	chr3:47292165	KIF9	0.37	5.98	0.31	5.79e-9	Colorectal cancer;
CRC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.57	8.22	0.41	4.71e-15	Platelet distribution width;
CRC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.81	-0.3	1.51e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.71	-9.92	-0.48	1.9e-20	Coronary artery disease;
CRC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.66	9.2	0.45	4.22e-18	Vitamin D levels;
CRC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	6.32	0.33	8.6e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg18478394	chr8:109455254	TTC35	0.4	6.0	0.31	5.24e-9	Dupuytren's disease;
CRC	cis	rs673253	0.686	rs2819334	chr1:44014735	C/T	cg10881128	chr1:44031826	PTPRF	-0.22	-6.23	-0.32	1.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9311676	0.656	rs11917591	chr3:58368449	C/T	cg06643156	chr3:58380774	PXK	-0.42	-6.41	-0.33	5.04e-10	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg00129232	chr17:37814104	STARD3	-0.6	-7.21	-0.37	3.94e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg17133734	chr15:86042851	AKAP13	0.39	6.34	0.33	7.39e-10	Interstitial lung disease;
CRC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.9	-0.31	9.06e-9	Type 2 diabetes;
CRC	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.81	14.07	0.61	1.53e-35	Hip circumference;
CRC	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	9.81e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs889398	0.617	rs11075742	chr16:69898934	A/G	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.22	-0.32	1.49e-9	Body mass index;
CRC	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.45	6.97	0.36	1.78e-11	Red blood cell count;
CRC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.64	11.76	0.54	7.05e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.21e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg25182066	chr10:30743637	MAP3K8	0.38	5.72	0.3	2.35e-8	Inflammatory bowel disease;
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.6	10.28	0.49	1.13e-21	Prudent dietary pattern;
CRC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.56	-7.24	-0.37	3.26e-12	Mean platelet volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11589374	chr3:126398357	NA	0.49	6.89	0.36	2.78e-11	Response to antipsychotic treatment;
CRC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.41	-6.1	-0.32	2.93e-9	Breast cancer;
CRC	cis	rs863345	0.604	rs12044288	chr1:158463863	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.26	-0.33	1.17e-9	Pneumococcal bacteremia;
CRC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.1	-0.32	2.93e-9	Menopause (age at onset);
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg02683197	chr6:28174875	NA	0.57	7.29	0.37	2.33e-12	Parkinson's disease;
CRC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Primary biliary cholangitis;
CRC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.74	-12.31	-0.56	6.62e-29	Breast cancer;
CRC	cis	rs939584	1.000	rs6756518	chr2:651483	G/A	cg03610516	chr2:642275	NA	-0.43	-5.94	-0.31	7.19e-9	Body mass index;
CRC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg04362960	chr10:104952993	NT5C2	-0.42	-6.02	-0.31	4.7e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg12935359	chr14:103987150	CKB	-0.52	-7.27	-0.37	2.7e-12	Monocyte count;
CRC	trans	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg09045935	chr12:6379348	NA	1.14	8.88	0.44	4.43e-17	Blood metabolite levels;
CRC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.39	-7.34	-0.38	1.64e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-9.1	-0.45	8.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.36	-5.79	-0.3	1.61e-8	Iron status biomarkers;
CRC	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg06204229	chr3:52865917	ITIH4	0.6	8.31	0.42	2.63e-15	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg24308560	chr3:49941425	MST1R	-0.44	-6.27	-0.33	1.15e-9	Resting heart rate;
CRC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.84	-12.46	-0.57	1.94e-29	Gut microbiome composition (summer);
CRC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg05874882	chr4:1763078	NA	-0.36	-6.62	-0.34	1.5e-10	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.62	-11.06	-0.52	2.22e-24	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	8.27	0.41	3.31e-15	HIV-1 control;
CRC	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg10437265	chr15:77819839	NA	0.67	12.16	0.56	2.31e-28	Type 2 diabetes;
CRC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.56	-8.81	-0.44	7.51e-17	Motion sickness;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05226292	chr8:71520850	TRAM1	0.38	6.14	0.32	2.44e-9	Obesity-related traits;
CRC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	5.79	0.3	1.69e-8	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2811415	0.597	rs13097739	chr3:127739076	T/C	cg13719885	chr3:127795394	NA	-0.37	-5.72	-0.3	2.37e-8	Lung function (FEV1/FVC);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23562514	chr4:18022479	LCORL	0.45	6.66	0.34	1.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.23	14.35	0.62	1.34e-36	Diabetic kidney disease;
CRC	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.64	-10.26	-0.49	1.34e-21	Lewy body disease;
CRC	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-0.95	-8.04	-0.41	1.59e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.62	0.57	4.92e-30	Body mass index;
CRC	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.13	0.32	2.46e-9	Ovarian reserve;
CRC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg13319975	chr6:146136371	FBXO30	0.42	6.25	0.33	1.26e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg27523141	chr10:43048294	ZNF37B	0.5	7.23	0.37	3.41e-12	Extrinsic epigenetic age acceleration;
CRC	trans	rs11800820	0.567	rs3124119	chr1:246707816	T/C	cg26885821	chr6:124125002	NKAIN2	0.38	6.09	0.32	3.11e-9	Obesity-related traits;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg01109287	chr10:65281299	REEP3	0.52	6.16	0.32	2.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg17321639	chr7:2759063	NA	-0.52	-7.02	-0.36	1.3e-11	Height;
CRC	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.16	-24.69	-0.81	7.19e-77	Exhaled nitric oxide output;
CRC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.45	0.38	8.53e-13	Mean platelet volume;
CRC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.61	-11.92	-0.55	1.77e-27	Intelligence (multi-trait analysis);
CRC	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.75	9.36	0.46	1.31e-18	Type 2 diabetes;
CRC	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-1.11	-12.92	-0.58	3.75e-31	Blood pressure (smoking interaction);
CRC	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	1.01	13.9	0.61	7.03e-35	Exhaled nitric oxide output;
CRC	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg06581033	chr10:766294	NA	-0.47	-5.65	-0.3	3.41e-8	Uric acid levels;
CRC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.05	0.36	1.04e-11	Rheumatoid arthritis;
CRC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.74	-0.35	6.94e-11	Total cholesterol levels;
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.5	9.88	0.48	2.55e-20	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08498597	chr11:67163067	RAD9A	-0.37	-6.75	-0.35	6.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9039	0.959	rs12148920	chr16:9183900	C/G	cg08831531	chr16:9218945	NA	0.54	7.53	0.38	4.84e-13	Menopause (age at onset);
CRC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.03	-0.32	4.4e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.52	7.83	0.4	6.95e-14	Corneal astigmatism;
CRC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.62	-7.41	-0.38	1.08e-12	Cleft lip with or without cleft palate;
CRC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg12064134	chr16:90016061	DEF8	-0.65	-5.98	-0.31	5.89e-9	Skin colour saturation;
CRC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06028605	chr16:24865363	SLC5A11	0.44	7.92	0.4	3.75e-14	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.91	0.31	8.7e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg05585544	chr11:47624801	NA	-0.59	-10.64	-0.51	6.55e-23	Subjective well-being;
CRC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.22e-38	Intelligence (multi-trait analysis);
CRC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-7.65	-0.39	2.25e-13	Schizophrenia;
CRC	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.41	-5.83	-0.31	1.35e-8	DNA methylation (variation);
CRC	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21659725	chr3:3221576	CRBN	0.46	6.61	0.34	1.59e-10	Body mass index;
CRC	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg21251018	chr6:28226885	NKAPL	0.4	6.08	0.32	3.25e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.5e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg02527881	chr3:46936655	PTH1R	0.42	7.54	0.38	4.75e-13	Colorectal cancer;
CRC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg13072238	chr3:49761600	GMPPB	-0.48	-5.68	-0.3	2.89e-8	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.83e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.56	-7.4	-0.38	1.17e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg14345882	chr6:26364793	BTN3A2	0.66	5.76	0.3	1.92e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.87	-12.36	-0.56	4.43e-29	Gut microbiome composition (summer);
CRC	cis	rs11250464	0.517	rs2387667	chr10:1430761	T/C	cg02408697	chr10:1416920	ADARB2	0.39	5.62	0.3	3.98e-8	Radiation response;
CRC	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg06917450	chr1:38156652	C1orf109	-0.52	-7.0	-0.36	1.47e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.56	-9.75	-0.47	6.58e-20	Menarche (age at onset);
CRC	trans	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg21784768	chr11:537496	LRRC56	-0.69	-6.45	-0.33	4.06e-10	Body mass index;
CRC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg12935359	chr14:103987150	CKB	-0.39	-6.1	-0.32	2.9e-9	Body mass index;
CRC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.77	-13.0	-0.58	1.76e-31	Breast cancer;
CRC	cis	rs7680126	0.626	rs929575	chr4:10196886	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.61	-0.34	1.52e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg02458384	chr16:2021763	TBL3	0.38	6.12	0.32	2.61e-9	Obesity-related traits;
CRC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg13010199	chr12:38710504	ALG10B	0.39	5.7	0.3	2.62e-8	Morning vs. evening chronotype;
CRC	trans	rs8177876	0.822	rs56119129	chr16:81118266	C/T	cg09779152	chr17:73205364	NUP85	0.61	5.99	0.31	5.49e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.55	7.69	0.39	1.71e-13	Melanoma;
CRC	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg00507830	chr2:103233733	NA	0.64	6.46	0.34	3.73e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg03030879	chr14:75389066	RPS6KL1	0.39	5.8	0.3	1.59e-8	Height;
CRC	cis	rs10512697	1.000	rs13189312	chr5:3545313	T/C	cg19473799	chr5:3511975	NA	-0.76	-5.94	-0.31	7.41e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.49	9.66	0.47	1.3e-19	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23029100	chr15:76603787	ETFA	0.44	6.19	0.32	1.79e-9	Anxiety disorder;
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg03804128	chr16:635623	NA	0.31	7.42	0.38	1.03e-12	Height;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-6.29	-0.33	9.98e-10	Schizophrenia;
CRC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg09876464	chr15:85330779	ZNF592	0.47	8.23	0.41	4.38e-15	P wave terminal force;
CRC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg18764771	chr6:116381957	FRK	0.25	7.29	0.37	2.3e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.76	-0.39	1.05e-13	Breast cancer;
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg23758597	chr6:163146217	PARK2	-0.59	-5.91	-0.31	8.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs2882667	0.898	rs2351465	chr5:138363851	A/C	cg09476006	chr5:138032270	NA	0.45	7.47	0.38	7.24e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg27661571	chr11:113659931	NA	-0.77	-9.59	-0.47	2.24e-19	Hip circumference adjusted for BMI;
CRC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.47	0.46	5.73e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.56	0.43	4.52e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	6.1	0.32	3.04e-9	Axial length;
CRC	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg22495460	chr2:25135724	ADCY3	0.76	12.79	0.58	1.14e-30	Body mass index;
CRC	trans	rs11168936	0.637	rs10875942	chr12:49670854	A/G	cg23665973	chr2:219757534	WNT10A	-0.45	-6.46	-0.34	3.75e-10	Cancer (pleiotropy);
CRC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.61	-11.27	-0.53	3.94e-25	Immature fraction of reticulocytes;
CRC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.87	-11.78	-0.54	5.83e-27	Gut microbiome composition (summer);
CRC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.49	8.35	0.42	1.94e-15	Platelet count;
CRC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.82	-0.31	1.37e-8	Skin colour saturation;
CRC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.4	0.46	9.22e-19	Lung cancer;
CRC	cis	rs243505	0.660	rs243487	chr7:148448211	G/A	cg09806900	chr7:148480153	CUL1	-0.59	-7.5	-0.38	5.93e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.1	26.74	0.83	1.69e-84	Testicular germ cell tumor;
CRC	cis	rs2882667	0.659	rs288037	chr5:138208441	A/G	cg09476006	chr5:138032270	NA	0.54	8.92	0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg21770322	chr7:97807741	LMTK2	0.55	9.29	0.46	2.16e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.6	-8.64	-0.43	2.47e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.64	0.47	1.51e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.57	-7.37	-0.38	1.42e-12	Gut microbiome composition (summer);
CRC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.66	10.96	0.52	4.98e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8105895	0.935	rs62111032	chr19:22281349	C/G	cg02912127	chr19:22235281	ZNF257	-0.41	-5.71	-0.3	2.54e-8	Body mass index (change over time);
CRC	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.37	6.23	0.32	1.4e-9	Blood metabolite levels;
CRC	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.71	-9.38	-0.46	1.1e-18	Ileal carcinoids;
CRC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.52	-0.46	3.76e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs6076065	0.723	rs2424537	chr20:23382026	T/C	cg11657817	chr20:23433608	CST11	0.44	6.46	0.34	3.68e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.86	-0.31	1.11e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CRC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.65	11.19	0.53	7.37e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs995000	0.931	rs10889344	chr1:63033941	T/C	cg19896129	chr1:63156450	NA	-0.43	-6.7	-0.35	8.85e-11	Triglyceride levels;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg22638593	chr5:131593259	PDLIM4	-0.31	-5.66	-0.3	3.24e-8	Breast cancer;
CRC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.38	0.46	1.1e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23708337	chr7:1209742	NA	0.51	7.9	0.4	4.34e-14	Longevity;Endometriosis;
CRC	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg02158880	chr13:53174818	NA	0.42	6.02	0.31	4.78e-9	Lewy body disease;
CRC	cis	rs11723261	0.582	rs11733927	chr4:166828	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	6.47	0.34	3.61e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03361557	chr19:19774500	ATP13A1	0.42	6.88	0.35	3.05e-11	Obesity-related traits;
CRC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.35	0.53	2.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08330117	chr8:90770456	RIPK2	0.49	6.32	0.33	8.27e-10	Thyroid stimulating hormone;
CRC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.42	7.59	0.39	3.42e-13	Height;
CRC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg14711859	chr11:8959438	ASCL3	0.45	7.52	0.38	5.21e-13	Hemoglobin concentration;
CRC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.77	-13.36	-0.59	7.73e-33	Body mass index;
CRC	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	5.7	0.3	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552172	0.887	rs12405132	chr1:145644984	A/G	cg11743829	chr1:145714124	CD160	0.37	5.65	0.3	3.4e-8	Breast cancer;
CRC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.62	6.36	0.33	6.93e-10	Menarche (age at onset);
CRC	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg07979401	chr6:33739406	LEMD2	-0.48	-6.18	-0.32	1.94e-9	Schizophrenia;
CRC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.59	8.38	0.42	1.58e-15	Longevity;
CRC	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg03160526	chr17:80928410	B3GNTL1	0.45	6.44	0.33	4.15e-10	Breast cancer;
CRC	trans	rs16846053	0.584	rs57840078	chr2:162402459	T/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.01	-0.31	4.88e-9	Blood osmolality (transformed sodium);
CRC	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg17133734	chr15:86042851	AKAP13	0.42	6.86	0.35	3.44e-11	Coronary artery disease;
CRC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.66	-0.47	1.38e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg02880119	chr16:3481970	NA	-0.41	-5.8	-0.3	1.55e-8	Body mass index (adult);
CRC	cis	rs2415984	0.644	rs1669808	chr14:46930473	A/G	cg14871534	chr14:47121158	RPL10L	0.43	6.16	0.32	2.15e-9	Number of children ever born;
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg21665744	chr7:39171113	POU6F2	-0.42	-5.68	-0.3	3.01e-8	IgG glycosylation;
CRC	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg18240653	chr6:144019428	PHACTR2	-0.56	-6.15	-0.32	2.23e-9	Obesity-related traits;
CRC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.73	-0.3	2.27e-8	Mean corpuscular volume;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.72	10.48	0.5	2.26e-22	Menarche (age at onset);
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.77	11.22	0.53	5.89e-25	Menarche (age at onset);
CRC	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.34	0.42	2.06e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.77	11.55	0.54	4.07e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.73	6.77	0.35	5.79e-11	Major depressive disorder;
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg16606324	chr3:10149918	C3orf24	0.69	9.61	0.47	2.01e-19	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.21	-0.41	5e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2179367	0.959	rs9373592	chr6:149733255	A/T	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.1	-0.32	2.98e-9	Dupuytren's disease;
CRC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.43	-5.89	-0.31	9.6e-9	IgG glycosylation;
CRC	cis	rs2336384	1.000	rs2336384	chr1:12046063	A/C	cg13216073	chr1:12042593	MFN2	-0.48	-7.01	-0.36	1.39e-11	Platelet count;
CRC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.41	-7.25	-0.37	2.96e-12	Height;
CRC	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.06	-0.36	9.98e-12	Body mass index;
CRC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.53	-6.56	-0.34	2.1e-10	Diastolic blood pressure;
CRC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg24881330	chr22:46731750	TRMU	0.56	6.63	0.34	1.35e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg01339444	chr6:118972232	C6orf204	0.51	5.86	0.31	1.11e-8	Diastolic blood pressure;
CRC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	0.74	8.02	0.4	1.84e-14	Gout;Renal underexcretion gout;
CRC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.09	-0.41	1.13e-14	IgG glycosylation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08066755	chr14:58765184	FLJ31306;ARID4A	0.48	6.85	0.35	3.73e-11	Intelligence (multi-trait analysis);
CRC	trans	rs6687430	0.512	rs11121587	chr1:10618109	A/G	cg20645065	chr1:21836138	ALPL	-0.4	-6.02	-0.31	4.71e-9	Hand grip strength;
CRC	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.0	-0.4	2.08e-14	Chronic sinus infection;
CRC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.66e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.4	-6.69	-0.35	9.83e-11	Prostate cancer;
CRC	cis	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12148714	chr16:69345699	VPS4A	0.45	6.29	0.33	1e-9	Response to antipsychotic treatment;
CRC	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.68	8.67	0.43	1.96e-16	Gastritis;
CRC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.57	8.5	0.42	6.7e-16	Type 2 diabetes;
CRC	cis	rs1524976	0.760	rs11706564	chr3:65443720	G/C	cg16238336	chr3:65465873	MAGI1	-0.47	-6.9	-0.36	2.72e-11	PR interval;
CRC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.48	4.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-8.02	-0.4	1.92e-14	Body mass index;
CRC	cis	rs995000	0.929	rs12038768	chr1:63040728	G/T	cg19896129	chr1:63156450	NA	0.39	5.72	0.3	2.39e-8	Triglyceride levels;
CRC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.19	-0.37	4.5e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.6	-11.37	-0.53	1.73e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg25856811	chr1:152973957	SPRR3	0.25	6.88	0.35	3.02e-11	Inflammatory skin disease;
CRC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	9.81	0.48	4.31e-20	Mean corpuscular hemoglobin;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg03623178	chr6:28175578	NA	0.94	12.33	0.56	5.52e-29	Depression;
CRC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18876405	chr7:65276391	NA	0.51	8.24	0.41	4.17e-15	Aortic root size;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02909592	chr3:149181944	NA	-0.45	-6.0	-0.31	5.14e-9	Hip circumference;
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg01874867	chr7:94954059	PON1	-0.48	-6.19	-0.32	1.81e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg22110888	chr17:80059540	CCDC57	0.41	6.51	0.34	2.86e-10	Life satisfaction;
CRC	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.37	-0.38	1.38e-12	Caudate activity during reward;
CRC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.78	-13.78	-0.61	1.99e-34	Prostate cancer;
CRC	trans	rs1569175	1.000	rs1509830	chr2:200908143	G/A	cg19477977	chr2:235599692	NA	0.68	6.16	0.32	2.09e-9	Response to treatment for acute lymphoblastic leukemia;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.46	-0.34	3.78e-10	Blood metabolite levels;
CRC	trans	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.63	9.79	0.47	4.8e-20	Corneal astigmatism;
CRC	trans	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg24644049	chr4:85504048	CDS1	0.74	7.25	0.37	2.95e-12	Skin colour saturation;
CRC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.76	16.52	0.67	4.67e-45	Breast cancer;
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.0	-23.48	-0.79	2.81e-72	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.46	-0.34	3.85e-10	Alzheimer's disease (late onset);
CRC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg05861140	chr6:150128134	PCMT1	0.37	5.74	0.3	2.17e-8	Lung cancer;
CRC	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.49	-0.46	4.98e-19	Prevalent atrial fibrillation;
CRC	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21395782	chr19:19626814	NDUFA13;TSSK6	0.51	6.9	0.36	2.62e-11	Thyroid stimulating hormone;
CRC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.93	11.28	0.53	3.59e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs7517126	1.000	rs57426012	chr1:196837456	T/A	cg13682187	chr1:196946512	CFHR5	-0.43	-6.26	-0.33	1.2e-9	Blood protein levels;
CRC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg15511327	chr8:143859410	LYNX1	0.39	6.97	0.36	1.79e-11	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03839322	chr16:57816956	KIFC3	-0.39	-6.08	-0.32	3.37e-9	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.96	-19.27	-0.73	6.37e-56	Height;
CRC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg25985355	chr7:65971099	NA	0.51	5.8	0.3	1.58e-8	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03152577	chr1:54411898	LRRC42;HSPB11	0.45	7.37	0.38	1.39e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03051979	chr16:58283909	CCDC113	0.37	6.01	0.31	4.88e-9	Obesity-related traits;
CRC	cis	rs7926971	0.729	rs5016300	chr11:12659464	G/A	cg25843174	chr11:12811716	TEAD1	0.35	6.08	0.32	3.28e-9	Height;
CRC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg13043300	chr11:71146211	DHCR7	0.44	6.16	0.32	2.16e-9	Vitamin D levels;
CRC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.5	-8.2	-0.41	5.35e-15	Body mass index;
CRC	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	0.91	11.13	0.52	1.26e-24	Height;
CRC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.43	6.21	0.32	1.62e-9	Aortic root size;
CRC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.52	8.23	0.41	4.32e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg22495460	chr2:25135724	ADCY3	-0.88	-14.62	-0.63	1.23e-37	Body mass index;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07581031	chr16:89898288	SPIRE2	0.39	6.39	0.33	5.6e-10	Aortic root size;
CRC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg02428538	chr16:24856791	SLC5A11	-0.57	-6.74	-0.35	6.91e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.6	9.38	0.46	1.14e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.61	9.44	0.46	7.29e-19	Aortic root size;
CRC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.86	14.4	0.62	8.63e-37	Coronary artery disease;
CRC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.64	0.34	1.3e-10	Mean platelet volume;
CRC	cis	rs4731207	0.662	rs2219954	chr7:124555855	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.02	-0.32	4.57e-9	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.25	-0.41	3.77e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.58	-8.66	-0.43	2.16e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.72	11.59	0.54	2.85e-26	Obesity-related traits;
CRC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg11632617	chr15:75315747	PPCDC	-0.57	-8.05	-0.41	1.49e-14	Blood trace element (Zn levels);
CRC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.29	15.72	0.65	6.19e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.8	0.39	8.39e-14	Menopause (age at onset);
CRC	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg18646521	chr2:111875858	NA	0.39	6.12	0.32	2.65e-9	Chronic lymphocytic leukemia;
CRC	trans	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg17903999	chr18:56338584	MALT1	0.43	6.85	0.35	3.73e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.58	8.1	0.41	1.08e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg13390004	chr1:15929781	NA	0.53	7.44	0.38	9.04e-13	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05663655	chr7:107532014	DLD	0.44	6.11	0.32	2.74e-9	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg15445000	chr17:37608096	MED1	0.36	6.27	0.33	1.14e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg09476006	chr5:138032270	NA	0.44	6.78	0.35	5.62e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.37	6.12	0.32	2.69e-9	Neuroticism;
CRC	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.57	-9.01	-0.44	1.69e-17	Brain structure;
CRC	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg26205652	chr12:48591994	NA	0.46	5.61	0.3	4.33e-8	Longevity (90 years and older);
CRC	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg12573674	chr2:1569213	NA	-0.65	-7.58	-0.39	3.56e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.15	-0.52	1.03e-24	Blood trace element (Zn levels);
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs10208940	0.920	rs35878577	chr2:68737456	C/T	cg12452813	chr2:68675892	NA	0.49	6.01	0.31	5.03e-9	Urate levels in lean individuals;
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.68	0.35	1e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00568128	chr10:115934100	MIR2110;C10orf118	0.45	6.1	0.32	2.91e-9	Response to antipsychotic treatment;
CRC	cis	rs13098911	0.540	rs6790866	chr3:46074711	G/A	cg12691230	chr3:46064611	XCR1	-0.52	-5.62	-0.3	4.01e-8	Celiac disease;
CRC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg21153622	chr11:89784906	NA	-0.51	-8.48	-0.42	7.88e-16	HDL cholesterol;
CRC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.58e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.71	12.23	0.56	1.34e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.6	-0.34	1.61e-10	Vitiligo;
CRC	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	0.68	6.19	0.32	1.76e-9	Inflammatory biomarkers;
CRC	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.48	-6.31	-0.33	9.24e-10	Exhaled nitric oxide output;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.55	7.45	0.38	8.54e-13	Longevity;Endometriosis;
CRC	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.22	11.44	0.53	9.63e-26	Prostate cancer;
CRC	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg26776924	chr19:1969666	CSNK1G2	0.45	7.22	0.37	3.69e-12	Coronary artery disease;
CRC	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.49	-8.37	-0.42	1.66e-15	Pursuit maintenance gain;
CRC	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.67	7.14	0.37	6.18e-12	Axial length;
CRC	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg14581129	chr12:53358946	NA	-0.36	-5.62	-0.3	4.14e-8	Cancer (pleiotropy);
CRC	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.16	9.51	0.46	4.23e-19	Economic and political preferences (immigration/crime);
CRC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	1.15	13.53	0.6	1.84e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg18827107	chr12:86230957	RASSF9	-0.39	-6.38	-0.33	5.99e-10	Major depressive disorder;
CRC	cis	rs728616	1.000	rs12768613	chr10:81916566	C/T	cg11900509	chr10:81946545	ANXA11	-0.63	-7.58	-0.39	3.49e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10208940	0.843	rs7608248	chr2:68851403	C/T	cg12452813	chr2:68675892	NA	0.49	6.1	0.32	2.97e-9	Urate levels in lean individuals;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13482925	chr10:64028750	RTKN2	0.44	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.16	-0.32	2.14e-9	Breast cancer;
CRC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.33	0.49	7.43e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.61	-0.43	2.98e-16	Hemoglobin concentration;
CRC	trans	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg10756647	chr7:56101905	PSPH	-0.76	-7.89	-0.4	4.47e-14	Diabetic kidney disease;
CRC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.71	11.06	0.52	2.23e-24	Tonsillectomy;
CRC	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	cg04338863	chr8:33670619	NA	0.42	6.76	0.35	6.19e-11	Body mass index;
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg21153622	chr11:89784906	NA	-0.37	-5.98	-0.31	5.84e-9	Height;
CRC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg12792011	chr19:58661915	ZNF329	0.71	7.72	0.39	1.37e-13	Cholesterol, total;
CRC	cis	rs883565	0.569	rs1298712	chr3:39169693	A/G	cg01426195	chr3:39028469	NA	0.39	6.39	0.33	5.57e-10	Handedness;
CRC	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.22	0.53	5.75e-25	Prudent dietary pattern;
CRC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.49	8.87	0.44	4.69e-17	Birth weight;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12273811	chr6:28175739	NA	0.62	8.22	0.41	4.78e-15	Parkinson's disease;
CRC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg18016565	chr1:150552671	MCL1	0.43	5.92	0.31	8.07e-9	Melanoma;
CRC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.93	-0.31	7.83e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.5	-8.08	-0.41	1.27e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6662572	0.703	rs6689417	chr1:46388008	C/T	cg08644498	chr1:46502608	NA	-0.45	-7.08	-0.36	8.76e-12	Blood protein levels;
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	1.03	10.37	0.5	5.3e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2.04e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg03948781	chr1:205179583	DSTYK	0.43	6.02	0.31	4.77e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	14.08	0.61	1.51e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.05	-14.84	-0.63	1.67e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.08	0.41	1.26e-14	Height;
CRC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg16416165	chr4:3325029	RGS12	0.39	5.9	0.31	9.06e-9	Serum sulfate level;
CRC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.44	7.06	0.36	9.87e-12	Resting heart rate;
CRC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.03	10.1	0.49	4.66e-21	Lymphocyte counts;
CRC	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg02428538	chr16:24856791	SLC5A11	0.56	6.66	0.34	1.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs216303	0.642	rs216315	chr12:6136914	A/G	cg19878637	chr12:6148451	VWF	-0.61	-6.82	-0.35	4.34e-11	Low vWF levels;
CRC	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.63	-8.86	-0.44	5.11e-17	Arsenic metabolism;
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg17330251	chr7:94953956	PON1	-0.6	-7.49	-0.38	6.26e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.65	0.63	9.36e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg11070056	chr1:107600091	PRMT6	-0.4	-5.74	-0.3	2.19e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.61	9.99	0.48	1.09e-20	Calcium levels;
CRC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	6.33	0.33	8.23e-10	Breast cancer;
CRC	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-5.68	-0.3	3.03e-8	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.38	-6.4	-0.33	5.28e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs62432291	0.681	rs378339	chr6:159658852	C/T	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs1178968	0.818	rs2528709	chr7:72788457	C/A	cg25889504	chr7:72793014	NA	0.49	5.63	0.3	3.81e-8	Triglyceride levels;
CRC	cis	rs539514	0.550	rs2328956	chr13:76294595	G/A	cg04757411	chr13:76259545	LMO7	-0.35	-5.96	-0.31	6.55e-9	Type 1 diabetes;
CRC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.9	10.5	0.5	1.98e-22	Psoriasis;
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.13	0.52	1.23e-24	Prudent dietary pattern;
CRC	cis	rs1472147	1.000	rs3736609	chr7:128509319	G/A	cg00260937	chr7:128520193	KCP	0.47	7.11	0.36	7.43e-12	Calcium levels;
CRC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg03934865	chr2:198174659	NA	0.36	5.81	0.31	1.44e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg14541582	chr5:601475	NA	-0.32	-6.61	-0.34	1.57e-10	Obesity-related traits;
CRC	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg05562828	chr17:3906858	NA	-0.67	-11.81	-0.55	4.59e-27	Type 2 diabetes;
CRC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.75	-10.65	-0.51	5.74e-23	Platelet distribution width;
CRC	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.61	-7.18	-0.37	4.74e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg26322434	chr3:61237156	FHIT	-0.46	-6.31	-0.33	9.27e-10	Protein C levels;
CRC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs1899951	1.000	rs4684848	chr3:12395645	G/A	cg04083076	chr1:169452126	SLC19A2	-0.47	-6.09	-0.32	3.17e-9	Body mass index;
CRC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.57	8.6	0.43	3.4e-16	Schizophrenia;
CRC	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg13385794	chr1:248469461	NA	0.38	6.66	0.34	1.14e-10	Common traits (Other);
CRC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.68	-8.14	-0.41	8.53e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.56	10.13	0.49	3.7e-21	HDL cholesterol levels;
CRC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.5	0.38	6.03e-13	Mean platelet volume;
CRC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.68e-14	Schizophrenia;
CRC	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.39	5.92	0.31	8.14e-9	Obesity;
CRC	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.67	-10.86	-0.51	1.13e-23	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.54	-0.34	2.39e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07192240	chr11:3829780	PGAP2	0.35	6.02	0.31	4.63e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg17903999	chr18:56338584	MALT1	-0.43	-7.07	-0.36	9.06e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs863345	0.604	rs10908661	chr1:158466990	T/A	cg12129480	chr1:158549410	OR10X1	-0.29	-6.21	-0.32	1.61e-9	Pneumococcal bacteremia;
CRC	cis	rs4363385	0.693	rs6668311	chr1:152964586	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.32	-0.37	1.97e-12	Inflammatory skin disease;
CRC	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.65	-8.89	-0.44	4.18e-17	Psoriasis;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20149956	chr1:249132233	ZNF672	0.39	6.13	0.32	2.5e-9	Obesity-related traits;
CRC	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg15571903	chr15:79123663	NA	0.31	6.1	0.32	3.05e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03923535	chr7:1197113	ZFAND2A	0.71	10.73	0.51	3.25e-23	Longevity;Endometriosis;
CRC	cis	rs11212617	0.967	rs6589019	chr11:108324961	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.9	0.31	9.28e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.7	9.21	0.45	3.89e-18	Alzheimer's disease;
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.52	8.05	0.41	1.58e-14	Colorectal cancer;
CRC	cis	rs997295	0.535	rs11630854	chr15:67858116	A/T	cg24247231	chr15:67904302	MAP2K5	-0.35	-6.14	-0.32	2.4e-9	Motion sickness;
CRC	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.34	6.21	0.32	1.61e-9	Neuroticism;
CRC	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.57	9.36	0.46	1.25e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.82	-13.96	-0.61	4.04e-35	Urate levels in obese individuals;
CRC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.04	-0.32	4.2e-9	Vitiligo;
CRC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.03e-8	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.64	-8.54	-0.43	5.02e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.37	-5.75	-0.3	2.01e-8	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.72	0.35	7.88e-11	Alzheimer's disease;
CRC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.66	9.71	0.47	8.86e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.74	-0.3	2.16e-8	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12753518	chr1:28414763	EYA3	0.49	6.55	0.34	2.15e-10	Thyroid stimulating hormone;
CRC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg01721255	chr8:58191610	C8orf71	0.45	5.76	0.3	1.96e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg12046867	chr14:103022105	NA	-0.79	-9.13	-0.45	7.13e-18	Platelet count;
CRC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.55	0.43	4.63e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.46	-6.38	-0.33	6.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.07	-0.52	2.08e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.38	-0.38	1.31e-12	Personality dimensions;
CRC	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg07617317	chr6:118971624	C6orf204	0.49	5.86	0.31	1.11e-8	Diastolic blood pressure;
CRC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg14541582	chr5:601475	NA	-0.36	-7.37	-0.38	1.42e-12	Obesity-related traits;
CRC	cis	rs8040855	0.627	rs2304418	chr15:85640983	T/C	cg10818794	chr15:86012489	AKAP13	-0.42	-5.65	-0.3	3.4e-8	Bulimia nervosa;
CRC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.58	-6.04	-0.32	4.28e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs10982256	0.870	rs10982247	chr9:117250792	C/T	cg13636371	chr9:117264095	DFNB31	-0.34	-6.57	-0.34	1.92e-10	Bipolar disorder;
CRC	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.76	-0.3	1.91e-8	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24276841	chr17:4125562	ANKFY1	0.41	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.41	-0.33	5.06e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.72	0.51	3.51e-23	Motion sickness;
CRC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.57	-9.6	-0.47	2.15e-19	Menopause (age at onset);
CRC	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.01	0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.42	-6.13	-0.32	2.56e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.52	-7.05	-0.36	1.07e-11	Colorectal cancer;
CRC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-5.61	-0.3	4.24e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg21747405	chr11:67723411	NA	-0.49	-6.25	-0.33	1.26e-9	Blood pressure (smoking interaction);
CRC	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.56	10.75	0.51	2.57e-23	Cognitive performance;
CRC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.62	-8.35	-0.42	1.86e-15	Obesity-related traits;
CRC	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg00383909	chr3:49044727	WDR6	1.37	10.99	0.52	3.88e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-8.13	-0.41	8.97e-15	Vitiligo;
CRC	cis	rs7584330	0.554	rs6740834	chr2:238423442	T/C	cg16989719	chr2:238392110	NA	-0.35	-5.64	-0.3	3.6e-8	Prostate cancer;
CRC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.62	9.03	0.45	1.52e-17	Morning vs. evening chronotype;
CRC	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-8.64	-0.43	2.49e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs800082	0.675	rs2117004	chr3:144180576	G/A	cg24215973	chr2:240111563	HDAC4	0.45	6.46	0.34	3.86e-10	Smoking behavior;
CRC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg16342193	chr10:102329863	NA	-0.37	-5.96	-0.31	6.42e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.06	0.64	2.3e-39	Primary sclerosing cholangitis;
CRC	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.63	10.39	0.5	4.86e-22	Cancer;
CRC	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.63	-9.84	-0.48	3.47e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.51	-9.81	-0.48	4.18e-20	HIV-1 susceptibility;
CRC	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg17145862	chr1:211918768	LPGAT1	0.49	6.31	0.33	8.95e-10	Crohn's disease;
CRC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.63	9.69	0.47	1.09e-19	Hemoglobin concentration;
CRC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg19438565	chr8:143695827	ARC	-0.48	-6.63	-0.34	1.41e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg27565382	chr3:53032988	SFMBT1	0.65	5.68	0.3	2.94e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.46	6.98	0.36	1.67e-11	Menopause (age at onset);
CRC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.63	-0.34	1.38e-10	Aortic root size;
CRC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg22192744	chr12:123187474	GPR109A	-0.4	-5.66	-0.3	3.25e-8	Adiponectin levels;
CRC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	19.8	0.74	5.09e-58	Prudent dietary pattern;
CRC	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.69	11.63	0.54	2.09e-26	Subjective well-being (multi-trait analysis);
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg12516270	chr8:143859308	LYNX1	0.44	7.65	0.39	2.28e-13	Urinary tract infection frequency;
CRC	cis	rs17065868	0.764	rs9533863	chr13:45036780	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.39	-0.38	1.25e-12	Breast cancer;
CRC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.83	11.32	0.53	2.68e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs8014671	0.567	rs6573971	chr14:71011469	C/T	cg25576086	chr14:70833871	SYNJ2BP	0.36	6.1	0.32	2.97e-9	Prostate cancer;
CRC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.06	0.36	1.01e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.77	10.83	0.51	1.37e-23	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg26893134	chr6:116381904	FRK	0.26	6.43	0.33	4.61e-10	Total cholesterol levels;
CRC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg02549819	chr16:58548995	SETD6	1.11	7.23	0.37	3.5e-12	Schizophrenia;
CRC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.42	9.14	0.45	6.65e-18	Glomerular filtration rate (creatinine);
CRC	trans	rs9341835	0.740	rs10755410	chr6:64150689	G/A	cg13657004	chr13:50234944	EBPL	-0.36	-6.08	-0.32	3.38e-9	Schizophrenia;
CRC	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg05639522	chr1:247681581	NA	0.56	6.05	0.32	3.95e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.37	-5.78	-0.3	1.74e-8	Crohn's disease;
CRC	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg21827317	chr3:136751795	NA	0.36	5.87	0.31	1.05e-8	Neuroticism;
CRC	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.45	-6.28	-0.33	1.07e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.44	6.81	0.35	4.61e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CRC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.6	10.88	0.51	9.33e-24	Multiple system atrophy;
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-6.77	-0.35	5.81e-11	Lymphocyte counts;
CRC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.81	-11.5	-0.54	6.09e-26	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs12038024	chr1:183603907	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.27	14.75	0.63	3.81e-38	Diabetic kidney disease;
CRC	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.76	0.43	1.06e-16	Mean corpuscular volume;
CRC	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg07807695	chr5:81608485	ATP6AP1L	-0.47	-7.4	-0.38	1.14e-12	Breast cancer;
CRC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg01420254	chr6:26195488	NA	0.75	8.48	0.42	7.58e-16	Gout;Renal underexcretion gout;
CRC	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.56	6.33	0.33	7.8e-10	Type 2 diabetes;
CRC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg02527881	chr3:46936655	PTH1R	-0.34	-5.96	-0.31	6.66e-9	Colorectal cancer;
CRC	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.39	-5.67	-0.3	3.16e-8	IFN-related cytopenia;
CRC	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg00531865	chr16:30841666	NA	-0.43	-6.32	-0.33	8.3e-10	Dementia with Lewy bodies;
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg09264619	chr17:80180166	NA	-0.36	-6.09	-0.32	3.09e-9	Life satisfaction;
CRC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg15445000	chr17:37608096	MED1	0.35	6.24	0.33	1.34e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg12223502	chr10:5658492	NA	0.41	6.49	0.34	3.1e-10	Breast cancer;
CRC	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.25	0.37	3.04e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.79	0.47	5.02e-20	Ileal carcinoids;
CRC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg24977027	chr2:88469347	THNSL2	0.56	6.62	0.34	1.47e-10	Plasma clusterin levels;
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03923535	chr7:1197113	ZFAND2A	0.51	7.51	0.38	5.77e-13	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08023020	chr16:2059559	ZNF598	0.47	6.52	0.34	2.66e-10	Anxiety disorder;
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg05569086	chr8:143859399	LYNX1	0.4	6.85	0.35	3.6e-11	Urinary tract infection frequency;
CRC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg20487152	chr13:99095054	FARP1	-0.48	-7.25	-0.37	2.92e-12	Longevity;
CRC	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg16576597	chr16:28551801	NUPR1	0.48	6.61	0.34	1.56e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01956147	chr2:17935879	GEN1;SMC6	-0.39	-6.04	-0.32	4.23e-9	Myopia (pathological);
CRC	cis	rs10208940	0.764	rs6741037	chr2:68787042	C/T	cg12452813	chr2:68675892	NA	0.47	5.93	0.31	7.57e-9	Urate levels in lean individuals;
CRC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg13628971	chr7:2884303	GNA12	0.37	5.72	0.3	2.35e-8	Plateletcrit;
CRC	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00495681	chr13:53174319	NA	-0.53	-8.13	-0.41	9e-15	Lewy body disease;
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.43e-10	Bipolar disorder;
CRC	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.58	-10.01	-0.48	9.4499999999999992e-21	Asthma;
CRC	cis	rs11958404	0.932	rs60504573	chr5:157436786	T/A	cg05962755	chr5:157440814	NA	0.95	12.34	0.56	5.17e-29	IgG glycosylation;
CRC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-10.74	-0.51	2.87e-23	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-6.88	-0.35	3.02e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg15382696	chr6:118971807	C6orf204	0.6	7.57	0.39	3.76e-13	Diastolic blood pressure;
CRC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg11843238	chr5:131593191	PDLIM4	0.48	8.88	0.44	4.47e-17	Blood metabolite levels;
CRC	cis	rs699	0.556	rs2478517	chr1:230867887	A/G	cg07502417	chr1:230849801	AGT	0.29	5.76	0.3	1.93e-8	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.67	0.51	4.87e-23	Prudent dietary pattern;
CRC	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.43	6.43	0.33	4.44e-10	Neutrophil percentage of white cells;
CRC	trans	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg11693508	chr17:37793320	STARD3	0.45	6.1	0.32	2.92e-9	Neuroticism;
CRC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.07	-0.32	3.55e-9	Bladder cancer;
CRC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.76	-13.38	-0.59	6.59e-33	Systemic lupus erythematosus;
CRC	cis	rs3812762	0.701	rs4929915	chr11:8824418	A/C	cg14711859	chr11:8959438	ASCL3	0.45	6.64	0.34	1.34e-10	Hypospadias;
CRC	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg01639898	chr1:32083012	HCRTR1	0.31	6.41	0.33	4.95e-10	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.7	-9.88	-0.48	2.51e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.72	10.03	0.48	7.74e-21	Breast cancer;
CRC	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg19338460	chr6:170058176	WDR27	-0.96	-9.69	-0.47	1.04e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.5	-7.14	-0.37	6.08e-12	Educational attainment (college completion);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02034563	chr2:179060011	OSBPL6	-0.5	-6.36	-0.33	6.76e-10	Diisocyanate-induced asthma;
CRC	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	cg04338863	chr8:33670619	NA	0.44	6.55	0.34	2.28e-10	Body mass index;
CRC	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg07884673	chr3:53033167	SFMBT1	0.75	5.99	0.31	5.41e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg09488452	chr16:14723959	PARN	0.4	5.97	0.31	6.18e-9	Crohn's disease;
CRC	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.64	7.8	0.4	8.03e-14	Eotaxin levels;
CRC	cis	rs12630931	1.000	rs11714698	chr3:31971524	G/T	cg21375017	chr3:31988082	OSBPL10	0.43	5.89	0.31	9.53e-9	Periodontal disease-related phenotypes;
CRC	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.76	8.5	0.42	6.78e-16	Neuroticism;
CRC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-11.91	-0.55	2.01e-27	Coronary artery disease;
CRC	cis	rs427941	0.669	rs417013	chr7:101820155	G/A	cg06246474	chr7:101738831	CUX1	0.41	6.03	0.32	4.29e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	9.64	0.47	1.54e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.72	-6.07	-0.32	3.58e-9	Cognitive function;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16728516	chr1:1342558	MRPL20	0.47	6.59	0.34	1.73e-10	Anxiety disorder;
CRC	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg07513332	chr6:167530253	CCR6	-0.47	-8.65	-0.43	2.28e-16	Primary biliary cholangitis;
CRC	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg04289385	chr6:36355825	ETV7	-0.38	-5.6	-0.3	4.47e-8	Platelet distribution width;
CRC	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.56	-8.45	-0.42	9.43e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.59	-8.56	-0.43	4.54e-16	Menarche (age at onset);
CRC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.05	-0.66	3.08e-43	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.9	-17.34	-0.69	2.66e-48	Intelligence (multi-trait analysis);
CRC	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3750082	0.889	rs1817050	chr7:32931906	T/G	cg05721444	chr7:32995514	FKBP9	0.5	7.71	0.39	1.54e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.73	-0.54	8.45e-27	Alzheimer's disease;
CRC	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.69	9.56	0.47	2.94e-19	Coronary artery disease;
CRC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	10.86	0.51	1.11e-23	Schizophrenia;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-7.81	-0.4	7.54e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.69	11.25	0.53	4.66e-25	Bone mineral density;
CRC	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.67	-7.7	-0.39	1.61e-13	Opioid sensitivity;
CRC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.58	-11.3	-0.53	3.09e-25	Asthma (sex interaction);
CRC	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.35	16.39	0.67	1.43e-44	Uric acid levels;
CRC	trans	rs1200821	0.671	rs2226276	chr10:37673052	A/T	cg25427524	chr10:38739819	LOC399744	0.42	6.26	0.33	1.21e-9	Hemostatic factors and hematological phenotypes;
CRC	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.59	7.32	0.37	1.92e-12	Obesity (extreme);
CRC	cis	rs62408225	1.000	rs1604831	chr6:90967197	G/A	cg06866423	chr6:90926672	BACH2	0.49	8.16	0.41	7.32e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7632954	0.967	rs7638980	chr3:8529618	C/G	cg03495237	chr3:8533978	NA	0.35	5.76	0.3	1.94e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg16606324	chr3:10149918	C3orf24	0.61	8.26	0.41	3.48e-15	Alzheimer's disease;
CRC	cis	rs9311676	0.656	rs62258127	chr3:58397102	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.43	-6.21	-0.32	1.61e-9	Aortic root size;
CRC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg18721089	chr20:30220636	NA	-0.34	-5.64	-0.3	3.61e-8	Mean corpuscular hemoglobin;
CRC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.69	-9.17	-0.45	5.35e-18	Initial pursuit acceleration;
CRC	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	0.44	6.29	0.33	1.04e-9	Atrial fibrillation;
CRC	cis	rs61160187	0.582	rs4700402	chr5:60262047	A/G	cg16298547	chr5:60138761	ELOVL7	-0.26	-5.6	-0.3	4.47e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.6	7.29	0.37	2.36e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.46	-6.71	-0.35	8.58e-11	Diastolic blood pressure;
CRC	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.36	-6.9	-0.36	2.67e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg18683604	chr14:51561293	TRIM9	0.3	6.05	0.32	4.03e-9	Cancer;
CRC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21767207	chr19:36236454	PSENEN;U2AF1L4	0.45	5.96	0.31	6.33e-9	Hip circumference;
CRC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.69	7.61	0.39	2.91e-13	Body mass index;
CRC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg06172871	chr16:72088244	HP	0.39	5.69	0.3	2.81e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.73	0.35	7.74e-11	Body mass index;
CRC	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.76	15.33	0.65	2.19e-40	Mean corpuscular hemoglobin;
CRC	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	0.88	8.49	0.42	6.96e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20092199	chr4:1342459	KIAA1530	0.34	5.96	0.31	6.56e-9	Obesity-related traits;
CRC	cis	rs1555895	0.543	rs749297	chr10:861837	A/G	cg10556349	chr10:835070	NA	-0.36	-7.08	-0.36	8.85e-12	Survival in rectal cancer;
CRC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.3	-0.42	2.7e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.81	-0.4	7.58e-14	HDL cholesterol;
CRC	cis	rs9434723	0.841	rs9435152	chr1:9308249	C/T	cg04199779	chr1:9294473	H6PD	0.55	6.17	0.32	2.04e-9	Height;
CRC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.09	-0.32	3.14e-9	Inflammatory bowel disease;
CRC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg04880052	chr2:219191631	PNKD	-0.44	-6.59	-0.34	1.79e-10	Colorectal cancer;
CRC	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	10.04	0.48	7.19e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.49	8.05	0.41	1.51e-14	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs62229266	0.625	rs2051395	chr21:37431265	A/C	cg08632701	chr21:37451849	NA	0.41	6.5	0.34	3.04e-10	Mitral valve prolapse;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.01	0.36	1.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02290350	chr8:58132656	NA	-0.44	-6.41	-0.33	5.13e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs73058052	0.597	rs2288921	chr19:50092002	G/T	cg15963326	chr19:50037085	RCN3	0.36	5.76	0.3	1.98e-8	Fibrinogen levels;
CRC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.73	-11.73	-0.54	8.7e-27	Dental caries;
CRC	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.98	-0.48	1.13e-20	Colorectal cancer;
CRC	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.51	-7.97	-0.4	2.66e-14	Systemic lupus erythematosus;
CRC	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.68	11.45	0.53	8.78e-26	Prostate cancer;
CRC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	7.91	0.4	3.82e-14	Aortic root size;
CRC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-14.5	-0.62	3.42e-37	Height;
CRC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.39e-13	Methadone dose in opioid dependence;
CRC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.81	-0.35	4.64e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	0.91	12.52	0.57	1.16e-29	Red blood cell traits;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg19041857	chr6:27730383	NA	-0.62	-6.8	-0.35	5.04e-11	Lung cancer in ever smokers;
CRC	cis	rs2949837	0.581	rs1542819	chr7:45978059	T/C	cg06713098	chr7:45960367	IGFBP3	0.42	6.71	0.35	8.43e-11	Sitting height ratio;
CRC	cis	rs72802342	0.541	rs185052	chr16:75467063	C/T	cg03315344	chr16:75512273	CHST6	-0.51	-5.94	-0.31	7.05e-9	Advanced age-related macular degeneration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07650554	chr16:30457408	SEPHS2	0.43	6.08	0.32	3.31e-9	Response to antipsychotic treatment;
CRC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.33	6.77	0.35	5.99e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.15	-0.45	6.28e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.84	-0.58	7.52e-31	Alzheimer's disease;
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg10729496	chr3:10149963	C3orf24	0.5	6.53	0.34	2.55e-10	Alzheimer's disease;
CRC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.22e-17	Mean platelet volume;
CRC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.49	-10.82	-0.51	1.55e-23	Rheumatoid arthritis;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.97	16.82	0.68	2.99e-46	Menarche (age at onset);
CRC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg27535305	chr1:53392650	SCP2	0.39	7.07	0.36	9.17e-12	Monocyte count;
CRC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg05941027	chr17:61774174	LIMD2	0.33	5.63	0.3	3.8e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.51	-8.0	-0.4	2.2e-14	Monocyte count;
CRC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.55	8.7	0.43	1.59e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.46	6.65	0.34	1.19e-10	Height;
CRC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.86	-16.82	-0.68	2.95e-46	Oral cavity cancer;
CRC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	8.95	0.44	2.6e-17	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.29	0.37	2.34e-12	Diisocyanate-induced asthma;
CRC	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.54	-7.78	-0.39	9.48e-14	Prostate cancer;
CRC	cis	rs17209837	1.000	rs2302387	chr7:87092185	G/A	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs6692729	0.901	rs4653470	chr1:227082726	T/A	cg18027831	chr1:227083489	PSEN2	0.36	5.92	0.31	7.88e-9	Electrodermal activity;
CRC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.67	0.34	1.11e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.57	0.34	2.02e-10	Morning vs. evening chronotype;
CRC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.54	0.54	4.2e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg04362960	chr10:104952993	NT5C2	-0.45	-6.32	-0.33	8.39e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.67	8.26	0.41	3.57e-15	Menarche (age at onset);
CRC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.72	0.35	7.98e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg09264619	chr17:80180166	NA	-0.36	-6.08	-0.32	3.42e-9	Life satisfaction;
CRC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	6.26	0.33	1.22e-9	Diabetic retinopathy;
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg10729496	chr3:10149963	C3orf24	0.51	6.68	0.35	1.04e-10	Alzheimer's disease;
CRC	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-6.39	-0.33	5.73e-10	Subjective well-being;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg24209194	chr3:40518798	ZNF619	0.41	6.01	0.31	4.82e-9	Renal cell carcinoma;
CRC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.42	5.74	0.3	2.11e-8	Schizophrenia;
CRC	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.63	8.91	0.44	3.46e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs11212617	1.000	rs641605	chr11:108101919	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.3	0.33	9.5e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg24489972	chr7:105817320	NA	0.5	6.36	0.33	6.93e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg05044414	chr3:183734942	ABCC5	0.45	7.66	0.39	2.13e-13	Anterior chamber depth;
CRC	cis	rs3741151	0.686	rs17132115	chr11:73264656	C/T	cg17517138	chr11:73019481	ARHGEF17	0.55	5.62	0.3	4.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg14593290	chr7:50529359	DDC	-0.44	-6.12	-0.32	2.72e-9	Systemic sclerosis;
CRC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.73	12.82	0.58	8.29e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs394563	0.601	rs391875	chr6:149795136	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.45	-7.16	-0.37	5.33e-12	Dupuytren's disease;
CRC	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-8.76	-0.44	1.02e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15216925	chr5:179921655	CNOT6	-0.4	-6.17	-0.32	1.99e-9	Myopia (pathological);
CRC	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.32	1.43e-9	Systemic lupus erythematosus;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10318443	chr17:685449	GLOD4;RNMTL1	0.43	6.46	0.34	3.66e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.45	-8.62	-0.43	2.91e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.55	9.38	0.46	1.1e-18	Common traits (Other);
CRC	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.6	6.93	0.36	2.16e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.58	7.81	0.4	7.95e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs17177486	0.661	rs2050931	chr1:203304679	C/T	cg09587487	chr1:178993784	FAM20B	-0.89	-6.1	-0.32	2.9e-9	Mumps;
CRC	trans	rs7705042	0.659	rs11743029	chr5:141509282	G/A	cg03701575	chr16:83960119	NA	-0.37	-5.98	-0.31	5.76e-9	Asthma;
CRC	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.85	16.19	0.67	9.08e-44	Hip circumference;
CRC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.65	-10.98	-0.52	4.29e-24	Breast cancer;
CRC	trans	rs800082	1.000	rs1405596	chr3:144314033	C/G	cg24215973	chr2:240111563	HDAC4	-0.53	-7.52	-0.38	5.16e-13	Smoking behavior;
CRC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.46	7.67	0.39	1.97e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.52	8.21	0.41	5.05e-15	Red blood cell count;
CRC	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.46	-7.89	-0.4	4.48e-14	Mitral valve prolapse;
CRC	cis	rs1519814	0.740	rs2326433	chr8:121043723	T/A	cg22335954	chr8:121166405	COL14A1	-0.51	-5.78	-0.3	1.72e-8	Breast cancer;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.67	-11.9	-0.55	2.21e-27	Paraoxonase activity;
CRC	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.87	-16.9	-0.68	1.51e-46	Hip circumference;
CRC	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.85	-13.67	-0.6	5.47e-34	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	7.56	0.38	4.1e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs863345	0.604	rs1578761	chr1:158497572	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs4908760	0.965	rs7542312	chr1:8573471	G/C	cg20416874	chr1:8611966	RERE	-0.44	-6.26	-0.33	1.19e-9	Vitiligo;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06028048	chr5:175815674	HIGD2A;NOP16	-0.51	-6.21	-0.32	1.63e-9	Diisocyanate-induced asthma;
CRC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.15	-0.32	2.3e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg21557407	chr3:178865550	PIK3CA	-0.4	-6.05	-0.32	4.01e-9	HDL cholesterol;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg26587870	chr6:27730563	NA	-0.46	-6.82	-0.35	4.26e-11	Parkinson's disease;
CRC	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.69	0.43	1.78e-16	Coffee consumption (cups per day);
CRC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.63	10.57	0.5	1.12e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.57	9.61	0.47	1.97e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs2072510	0.593	rs2660892	chr12:96420978	T/C	cg22491680	chr12:96389547	HAL	-0.47	-5.75	-0.3	2e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.59	6.44	0.33	4.34e-10	Bipolar disorder;
CRC	cis	rs9462027	0.606	rs6906129	chr6:34801160	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.15	-0.32	2.24e-9	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19320564	chr1:40157253	HPCAL4	0.37	6.23	0.32	1.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.3	6.23	0.32	1.47e-9	Homoarginine levels;
CRC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.67	11.71	0.54	1.03e-26	Height;
CRC	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg05562828	chr17:3906858	NA	0.73	14.0	0.61	2.86e-35	Type 2 diabetes;
CRC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-12.03	-0.55	7.12e-28	Exhaled nitric oxide output;
CRC	cis	rs7587476	0.861	rs17488049	chr2:215651750	G/A	cg04004882	chr2:215674386	BARD1	0.63	7.08	0.36	8.86e-12	Neuroblastoma;
CRC	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.63	-8.83	-0.44	6.51e-17	Coronary artery disease;
CRC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.63	-0.39	2.52e-13	Alzheimer's disease;
CRC	cis	rs9826463	0.757	rs73240305	chr3:142222770	A/G	cg20824294	chr3:142316082	PLS1	0.41	6.89	0.36	2.77e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.29	-0.37	2.35e-12	Life satisfaction;
CRC	cis	rs1887596	0.705	rs1590954	chr13:27200239	A/G	cg01312412	chr13:27282625	NA	0.45	5.75	0.3	2.01e-8	Facial morphology (factor 3, length of philtrum);
CRC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-1.06	-17.68	-0.7	1.19e-49	Blood pressure (smoking interaction);
CRC	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg25790453	chr13:113633590	MCF2L	-0.44	-7.82	-0.4	7.3e-14	Systolic blood pressure;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08322149	chr10:46222875	FAM21C	0.57	6.11	0.32	2.76e-9	Interleukin-4 levels;
CRC	cis	rs2979489	0.773	rs2915617	chr8:30272310	C/G	cg26383811	chr8:30366931	RBPMS	0.48	6.87	0.35	3.27e-11	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.44	0.57	2.13e-29	Alzheimer's disease;
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg15511327	chr8:143859410	LYNX1	-0.62	-11.11	-0.52	1.46e-24	Urinary tract infection frequency;
CRC	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19995117	chr12:2880862	NA	0.37	6.55	0.34	2.19e-10	Quantitative traits;
CRC	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12560992	chr17:57184187	TRIM37	0.53	7.22	0.37	3.69e-12	Testicular germ cell tumor;
CRC	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs524281	0.773	rs2155030	chr11:66030687	A/G	cg14036092	chr11:66035641	RAB1B	-0.55	-6.04	-0.32	4.16e-9	Electroencephalogram traits;
CRC	cis	rs7113874	0.589	rs10840060	chr11:8500045	A/C	cg20771178	chr11:8615675	STK33	0.36	5.85	0.31	1.21e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9992667	0.955	rs6855993	chr4:38608912	A/T	cg19726192	chr4:38663646	FLJ13197	-0.54	-7.14	-0.37	5.98e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.81	-0.4	7.69e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.28	0.33	1.07e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	0.99	14.98	0.64	4.76e-39	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01133099	chr17:1933418	DPH1	0.43	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.8	9.67	0.47	1.21e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg10437265	chr15:77819839	NA	0.7	12.76	0.58	1.44e-30	Type 2 diabetes;
CRC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13198984	chr17:80129470	CCDC57	-0.43	-7.3	-0.37	2.19e-12	Life satisfaction;
CRC	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.74	0.39	1.26e-13	Gout;
CRC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.38	-0.53	1.57e-25	Migraine;Coronary artery disease;
CRC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs4908768	0.501	rs4351668	chr1:8535818	C/T	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.59	-8.61	-0.43	3e-16	Homoarginine levels;
CRC	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.44	8.99	0.44	1.92e-17	Migraine;
CRC	cis	rs6908034	0.607	rs79162793	chr6:19813065	A/G	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.96	-15.36	-0.65	1.56e-40	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.63	-8.76	-0.43	1.03e-16	Blood pressure (smoking interaction);
CRC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.89	-0.78	4.88e-70	Myeloid white cell count;
CRC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.58	-8.87	-0.44	4.75e-17	Height;
CRC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.52	10.02	0.48	8.44e-21	Neuroticism;
CRC	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-0.95	-10.52	-0.5	1.71e-22	Atopic dermatitis;
CRC	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg14191688	chr11:70257035	CTTN	0.48	6.17	0.32	2.02e-9	Coronary artery disease;
CRC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.92	-0.52	6.61e-24	Blood trace element (Zn levels);
CRC	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg24759859	chr6:86352639	SYNCRIP	0.44	6.04	0.32	4.21e-9	Smooth-surface caries;
CRC	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg26816564	chr1:7831052	VAMP3	0.65	8.09	0.41	1.13e-14	Inflammatory bowel disease;
CRC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.21	-0.53	6.58e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.78	9.38	0.46	1.08e-18	Psoriasis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21271961	chr1:95285780	SLC44A3	0.45	6.63	0.34	1.35e-10	Response to antipsychotic treatment;
CRC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg25767906	chr1:53392781	SCP2	-0.4	-6.18	-0.32	1.9e-9	Monocyte count;
CRC	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.28	-0.42	3.07e-15	Electroencephalogram traits;
CRC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg01849466	chr14:104193079	ZFYVE21	0.42	6.5	0.34	3.01e-10	Body mass index;
CRC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg09264619	chr17:80180166	NA	-0.38	-6.46	-0.34	3.76e-10	Life satisfaction;
CRC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.55e-18	Parkinson's disease;
CRC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.8	14.02	0.61	2.36e-35	Breast cancer;
CRC	trans	rs9914544	0.545	rs2892016	chr17:18786776	C/T	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.11	-0.32	2.84e-9	Educational attainment (years of education);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16303686	chr3:132136102	DNAJC13	0.47	6.64	0.34	1.3e-10	Anxiety disorder;
CRC	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg20312557	chr2:97357134	FER1L5	-0.61	-5.64	-0.3	3.63e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.71	-0.3	2.56e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.53	-6.8	-0.35	4.85e-11	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.5	8.31	0.42	2.59e-15	Aortic root size;
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg24463073	chr6:118973353	C6orf204	0.49	6.14	0.32	2.34e-9	Diastolic blood pressure;
CRC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg14711859	chr11:8959438	ASCL3	0.39	6.67	0.34	1.11e-10	Hemoglobin concentration;
CRC	cis	rs7703744	0.597	rs73237297	chr5:118691121	G/T	cg23985447	chr5:118691066	TNFAIP8	0.41	5.97	0.31	6.04e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs728616	0.867	rs28365998	chr10:81965436	C/A	cg05935833	chr10:81318306	SFTPA2	-0.76	-7.53	-0.38	5.02e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-6.48	-0.34	3.39e-10	Systemic lupus erythematosus;
CRC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.21	0.64	6.34e-40	Platelet count;
CRC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.44	0.46	6.92e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg11204139	chr17:3907470	NA	0.77	14.69	0.63	6.34e-38	Type 2 diabetes;
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.46	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg19193384	chr17:30244184	NA	-0.52	-6.69	-0.35	9.9e-11	Hip circumference adjusted for BMI;
CRC	trans	rs75246769	0.570	rs80127121	chr7:145690896	G/A	cg14916917	chr5:81574294	RPS23	0.88	6.04	0.32	4.05e-9	Facial morphology (factor 10, width of nasal floor);
CRC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.69	-0.43	1.68e-16	IgG glycosylation;
CRC	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg24110177	chr3:50126178	RBM5	-0.44	-6.61	-0.34	1.54e-10	Menarche (age at onset);
CRC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg12365402	chr11:9010492	NRIP3	0.47	7.62	0.39	2.67e-13	Hemoglobin concentration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06335251	chr10:31320888	ZNF438	0.46	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs146817970	1	rs146817970	chr5:81512947	TA/T	cg17942617	chr5:81327376	ATG10	0.39	5.82	0.31	1.39e-8	Breast cancer;
CRC	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg00277334	chr10:82204260	NA	-0.55	-6.37	-0.33	6.38e-10	Post bronchodilator FEV1;
CRC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.63	-7.78	-0.39	9.52e-14	Blood trace element (Cu levels);
CRC	cis	rs2882667	0.518	rs10041986	chr5:138424437	A/G	cg09476006	chr5:138032270	NA	0.36	6.03	0.32	4.37e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg27366882	chr3:133540807	NA	-0.58	-8.65	-0.43	2.33e-16	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.56	8.27	0.41	3.29e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.5	-7.57	-0.39	3.84e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.49	7.2	0.37	4.01e-12	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14842398	chr16:85645310	KIAA0182	0.53	7.53	0.38	4.82e-13	Response to antipsychotic treatment;
CRC	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg27398640	chr15:77910606	LINGO1	-0.44	-7.33	-0.37	1.85e-12	Type 2 diabetes;
CRC	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.71	8.28	0.42	3.1e-15	Educational attainment;
CRC	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.46	-5.92	-0.31	8.06e-9	Coronary artery disease;
CRC	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.95	8.57	0.43	4.01e-16	Pediatric bone mineral content (radius);
CRC	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg10556349	chr10:835070	NA	0.37	7.21	0.37	3.84e-12	Survival in rectal cancer;
CRC	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.47	-7.38	-0.38	1.29e-12	Schizophrenia;
CRC	cis	rs73206853	0.764	rs61227741	chr12:110598319	G/T	cg12870014	chr12:110450643	ANKRD13A	0.79	8.0	0.4	2.21e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.95	-0.52	5.36e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	0.89	8.3	0.42	2.68e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.52	7.43	0.38	9.62e-13	Schizophrenia;
CRC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg23205692	chr1:25664452	TMEM50A	0.4	5.66	0.3	3.28e-8	Erythrocyte sedimentation rate;
CRC	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Intelligence (multi-trait analysis);
CRC	trans	rs200113	0.947	rs200075	chr5:8667441	C/T	cg26233084	chr5:15510258	FBXL7	-0.48	-5.98	-0.31	5.94e-9	Uric acid levels;
CRC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-17.25	-0.69	6.17e-48	Height;
CRC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.54	-0.34	2.33e-10	Menopause (age at onset);
CRC	cis	rs4716602	0.550	rs12672151	chr7:156159053	A/G	cg16983916	chr7:156159713	NA	-0.39	-6.97	-0.36	1.72e-11	Anti-saccade response;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg15845792	chr6:28175446	NA	0.97	13.15	0.59	4.96e-32	Parkinson's disease;
CRC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg14103574	chr5:162932455	MAT2B	-0.5	-5.98	-0.31	5.85e-9	Diisocyanate-induced asthma;
CRC	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-7.5	-0.38	5.95e-13	Hepatocellular carcinoma;
CRC	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-10.88	-0.51	9.3e-24	Hemoglobin concentration;
CRC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.53	-0.34	2.5e-10	Bladder cancer;
CRC	trans	rs10784762	1.000	rs10784762	chr12:69523923	C/T	cg27455578	chr7:86850357	C7orf23	-0.3	-6.26	-0.33	1.17e-9	QRS duration;
CRC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg03623178	chr6:28175578	NA	0.78	6.65	0.34	1.22e-10	Depression;
CRC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.64	9.63	0.47	1.67e-19	Birth weight;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg10298567	chr3:47292165	KIF9	0.39	6.33	0.33	8.13e-10	Colorectal cancer;
CRC	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.5	6.39	0.33	5.55e-10	Cholesterol, total;
CRC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.39	0.33	5.65e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22489740	chr19:13991002	NANOS3	0.5	7.08	0.36	8.78e-12	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.12	-0.32	2.59e-9	Cognitive function;
CRC	cis	rs10208940	0.920	rs7580719	chr2:68833572	A/G	cg12452813	chr2:68675892	NA	-0.48	-6.07	-0.32	3.48e-9	Urate levels in lean individuals;
CRC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.62	0.39	2.73e-13	Motion sickness;
CRC	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.15	-0.32	2.21e-9	Monocyte count;
CRC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.62	10.45	0.5	3.01e-22	Mean corpuscular volume;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.45	-6.39	-0.33	5.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3857067	1.000	rs7682116	chr4:95002704	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.04	-0.32	4.06e-9	QT interval;
CRC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	16.76	0.68	5.02e-46	Smoking behavior;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.16	-0.32	2.15e-9	Longevity;Endometriosis;
CRC	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.83	-0.44	6.17e-17	Coffee consumption (cups per day);
CRC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.25	-0.41	3.82e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.48	6.77	0.35	5.86e-11	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.51	5.81	0.31	1.45e-8	Vitiligo;
CRC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.72	11.24	0.53	4.9e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg21665744	chr7:39171113	POU6F2	0.45	5.96	0.31	6.67e-9	IgG glycosylation;
CRC	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.94	0.36	2.14e-11	Neuranatomic and neurocognitive phenotypes;
CRC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.93	-17.05	-0.68	3.89e-47	Height;
CRC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.5	0.34	2.91e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.61	9.53	0.46	3.7e-19	Schizophrenia;
CRC	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.59	8.51	0.42	6.14e-16	Platelet distribution width;
CRC	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.5	9.39	0.46	1.03e-18	Alcoholic chronic pancreatitis;
CRC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.55	-8.35	-0.42	1.87e-15	Vitiligo;
CRC	trans	rs4130344	0.595	rs7675394	chr4:159863649	T/C	cg04008429	chr3:160167646	TRIM59	0.4	5.98	0.31	5.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.5	-8.02	-0.4	1.85e-14	Huntington's disease progression;
CRC	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg23032129	chr1:109941072	SORT1	-0.28	-6.04	-0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10221833	0.636	rs355891	chr2:165634983	T/C	cg03182029	chr2:165697222	COBLL1	0.52	6.09	0.32	3.22e-9	Response to statin therapy;
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.46	6.91	0.36	2.46e-11	Longevity;Endometriosis;
CRC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.88	16.69	0.68	9.63e-46	Hip circumference;
CRC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-7.65	-0.39	2.21e-13	Subjective well-being;
CRC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-9.4	-0.46	9.34e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.76	10.03	0.48	7.73e-21	Monocyte percentage of white cells;
CRC	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.32	12.64	0.57	3.95e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4073416	0.508	rs10152007	chr14:66047434	A/T	cg03016385	chr14:66212404	NA	-0.46	-6.25	-0.33	1.31e-9	N-glycan levels;
CRC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg09695851	chr17:3907499	NA	0.52	6.45	0.33	4.05e-10	Type 2 diabetes;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg06494592	chr3:125709126	NA	-0.55	-6.57	-0.34	2e-10	Blood pressure (smoking interaction);
CRC	cis	rs1511802	0.666	rs3817184	chr4:187122304	C/T	cg24794857	chr4:187113578	CYP4V2	0.39	5.74	0.3	2.15e-8	Blood protein levels;
CRC	cis	rs7201929	0.801	rs9933198	chr16:28888409	C/T	cg10436792	chr16:28889110	ATP2A1	0.42	5.94	0.31	7.1e-9	QT interval;
CRC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.59	6.77	0.35	5.92e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26306683	chr17:18585705	ZNF286B	0.49	6.92	0.36	2.32e-11	Educational attainment (years of education);
CRC	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs2249694	0.960	rs2515642	chr10:135352013	C/T	cg20169779	chr10:135381914	SYCE1	0.54	8.67	0.43	1.93e-16	Obesity-related traits;
CRC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.65	10.27	0.49	1.21e-21	Colorectal cancer;
CRC	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg22495460	chr2:25135724	ADCY3	-0.75	-13.67	-0.6	5.51e-34	Body mass index in non-asthmatics;
CRC	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg09659197	chr4:152720779	NA	0.54	11.79	0.55	5.22e-27	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10353859	chr19:39109696	MAP4K1;EIF3K	0.45	6.36	0.33	6.81e-10	Anxiety disorder;
CRC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg00129232	chr17:37814104	STARD3	-0.43	-6.9	-0.36	2.67e-11	Self-reported allergy;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.58	10.31	0.49	8.45e-22	Acylcarnitine levels;
CRC	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.07	0.32	3.43e-9	Systemic lupus erythematosus;
CRC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	0.91	10.97	0.52	4.52e-24	Iron status biomarkers;
CRC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.61	-0.3	4.32e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.92	-0.31	8.27e-9	Neuroticism;
CRC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.54	-0.34	2.31e-10	Retinal vascular caliber;
CRC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.91	11.89	0.55	2.22e-27	Triglycerides;
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.25	-0.53	4.63e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg10729496	chr3:10149963	C3orf24	0.54	7.0	0.36	1.41e-11	Alzheimer's disease;
CRC	cis	rs1109861	0.557	rs2399664	chr10:11244173	G/A	cg24910943	chr10:11206320	CUGBP2	-0.27	-6.83	-0.35	4.18e-11	Urinary albumin-to-creatinine ratio;
CRC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.43	-5.98	-0.31	5.95e-9	Calcium levels;
CRC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.8	14.67	0.63	8.01e-38	Metabolic syndrome;
CRC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.68	0.47	1.13e-19	Birth weight;
CRC	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.57	6.87	0.35	3.23e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg20512303	chr5:131592959	PDLIM4	0.4	6.62	0.34	1.43e-10	Blood metabolite levels;
CRC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.2	-0.49	2.06e-21	Body mass index;
CRC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg00769240	chr8:12517080	NA	-0.68	-7.78	-0.39	9.14e-14	Blood pressure (smoking interaction);
CRC	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg00603274	chr11:61596626	FADS2	-0.44	-6.44	-0.33	4.2e-10	Trans fatty acid levels;
CRC	cis	rs12024301	0.557	rs6671085	chr1:183602532	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.75	13.33	0.59	1.05e-32	Oral cavity cancer;
CRC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Primary biliary cholangitis;
CRC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg10130564	chr11:117069849	TAGLN	-0.38	-6.92	-0.36	2.36e-11	Blood protein levels;
CRC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.19	0.37	4.46e-12	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05218490	chr2:148778969	ORC4L	0.45	6.18	0.32	1.91e-9	Response to antipsychotic treatment;
CRC	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg08999081	chr20:33150536	PIGU	0.46	5.88	0.31	9.91e-9	Protein C levels;
CRC	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.55e-12	Diisocyanate-induced asthma;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.62	6.63	0.34	1.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12699921	0.598	rs2723504	chr7:17854833	T/A	cg02066331	chr6:17282778	RBM24	-0.35	-6.1	-0.32	2.9e-9	Fibrinogen levels;
CRC	cis	rs4731207	0.570	rs7784616	chr7:124677194	C/G	cg23710748	chr7:124431027	NA	-0.39	-6.18	-0.32	1.94e-9	Cutaneous malignant melanoma;
CRC	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.45	6.73	0.35	7.64e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.78	-0.3	1.76e-8	Neuroticism;
CRC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg21681030	chr2:46777652	RHOQ	0.44	5.81	0.3	1.51e-8	Height;
CRC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18912574	chr7:65842487	NCRNA00174	0.35	6.07	0.32	3.6e-9	Aortic root size;
CRC	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-14.55	-0.63	2.15e-37	Colorectal cancer;
CRC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg18230493	chr5:56204884	C5orf35	0.6	8.95	0.44	2.64e-17	Initial pursuit acceleration;
CRC	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	15.85	0.66	1.97e-42	Colorectal cancer;
CRC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.25	-0.67	5.44e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg05941027	chr17:61774174	LIMD2	0.36	6.46	0.34	3.76e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg14530993	chr4:882597	GAK	0.84	7.94	0.4	3.18e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.68e-12	Life satisfaction;
CRC	cis	rs501916	0.634	rs1045688	chr15:48065487	A/G	cg16110827	chr15:48056943	SEMA6D	0.45	6.63	0.34	1.4e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	8.08	0.41	1.21e-14	Colorectal cancer;
CRC	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07165851	chr6:158734300	TULP4	0.6	7.59	0.39	3.38e-13	Height;
CRC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.44	7.42	0.38	1.02e-12	Crohn's disease;
CRC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.5	-8.06	-0.41	1.42e-14	Testicular germ cell tumor;
CRC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.4	0.46	9.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg23920097	chr1:209922102	NA	-0.49	-6.07	-0.32	3.61e-9	Red blood cell count;
CRC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.55	-8.3	-0.42	2.75e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.57	6.3	0.33	9.37e-10	Childhood ear infection;
CRC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg03013999	chr17:37608204	MED1	0.45	7.04	0.36	1.1e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05298461	chr20:33999889	UQCC	0.45	5.97	0.31	6.21e-9	Anxiety disorder;
CRC	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.42	5.72	0.3	2.37e-8	Eye color traits;
CRC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04241444	chr20:43594850	STK4	0.47	6.78	0.35	5.6e-11	Response to antipsychotic treatment;
CRC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	0.91	8.39	0.42	1.43e-15	Plateletcrit;
CRC	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13937449	chr12:56320970	WIBG	0.43	6.07	0.32	3.51e-9	Response to antipsychotic treatment;
CRC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg05393297	chr12:53359155	NA	-1.06	-10.26	-0.49	1.26e-21	Prostate cancer;
CRC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	6.51	0.34	2.78e-10	Platelet count;
CRC	trans	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.12	-0.37	7.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11761441	0.602	rs6979396	chr7:93116	G/A	cg12845006	chr7:82380	NA	-0.23	-5.79	-0.3	1.69e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.97	15.9	0.66	1.27e-42	Parkinson's disease;
CRC	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg19338460	chr6:170058176	WDR27	-0.74	-8.01	-0.4	1.97e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.69	11.74	0.54	8.24e-27	Alzheimer's disease (late onset);
CRC	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg06042504	chr8:55087323	NA	-0.43	-6.58	-0.34	1.88e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.66	-6.63	-0.34	1.35e-10	Response to haloperidol in psychosis;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-8.12	-0.41	9.42e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.45	-6.59	-0.34	1.75e-10	Magnesium levels;
CRC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.31	-0.49	8.84e-22	Initial pursuit acceleration;
CRC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	cis	rs2227564	0.729	rs2227551	chr10:75669190	G/T	cg00564723	chr10:75632066	CAMK2G	-0.28	-6.52	-0.34	2.6200000000000003e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	8.51	0.42	6.42e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.77	8.89	0.44	4.09e-17	Lung function (FEV1/FVC);
CRC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.48	-0.34	3.28e-10	Total body bone mineral density;
CRC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.37	0.38	1.41e-12	Height;
CRC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19623624	chr10:135278901	LOC619207	-0.4	-6.41	-0.33	4.91e-10	Systemic lupus erythematosus;
CRC	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.46	-6.52	-0.34	2.57e-10	Malaria;
CRC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg22777020	chr22:31556080	RNF185	-0.53	-6.14	-0.32	2.34e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.13	0.32	2.48e-9	Height;
CRC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg24562669	chr7:97807699	LMTK2	0.79	17.64	0.7	1.72e-49	Breast cancer;
CRC	cis	rs7849270	1.000	rs10819471	chr9:131896325	A/C	cg13538475	chr9:131942899	NA	-0.31	-6.28	-0.33	1.05e-9	Blood metabolite ratios;
CRC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg08213375	chr14:104286397	PPP1R13B	0.37	5.65	0.3	3.39e-8	Reticulocyte count;
CRC	trans	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.2	-0.37	4.21e-12	Endometrial cancer;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.16	-0.37	5.34e-12	Obesity-related traits;
CRC	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-6.46	-0.34	3.88e-10	Height;
CRC	trans	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg16141378	chr3:129829833	LOC729375	-0.42	-6.26	-0.33	1.2e-9	Mood instability;
CRC	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg15192750	chr16:69999425	NA	0.55	7.42	0.38	9.78e-13	IgE levels;
CRC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.67	7.6	0.39	3.08e-13	Major depressive disorder;
CRC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg20243544	chr17:37824526	PNMT	0.47	5.6	0.3	4.45e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07962812	chr1:183441443	SMG7	0.46	6.2	0.32	1.67e-9	Anxiety disorder;
CRC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.66	0.39	2.06e-13	Intelligence (multi-trait analysis);
CRC	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg25811766	chr13:21894605	NA	-0.53	-5.76	-0.3	1.92e-8	White matter hyperintensity burden;
CRC	trans	rs7976838	0.908	rs35889150	chr12:60143798	G/T	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	0.33	6.31	0.33	8.82e-10	Colorectal cancer;
CRC	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.69	-0.39	1.76e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.1	0.61	1.27e-35	Prudent dietary pattern;
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.77	11.27	0.53	3.9e-25	Menarche (age at onset);
CRC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.89	0.44	4.26e-17	Menopause (age at onset);
CRC	cis	rs12024301	0.557	rs7556582	chr1:183645446	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.82	6.81	0.35	4.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.46	6.98	0.36	1.64e-11	Corneal astigmatism;
CRC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.41	7.49	0.38	6.25e-13	Schizophrenia;
CRC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg05887092	chr17:76393375	PGS1	0.52	9.41	0.46	8.65e-19	HDL cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06254406	chr13:103450982	BIVM;KDELC1	0.47	6.91	0.36	2.54e-11	Intelligence (multi-trait analysis);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg20929922	chr5:43484725	C5orf28	-0.4	-6.01	-0.31	4.92e-9	Birth weight;Height;
CRC	cis	rs365302	1.000	rs823903	chr6:159652445	G/A	cg14500486	chr6:159655392	FNDC1	-0.44	-6.82	-0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.15	0.32	2.21e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg12273811	chr6:28175739	NA	0.54	5.62	0.3	4.04e-8	Depression;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.26	-0.33	1.17e-9	Bipolar disorder;
CRC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.73	12.0	0.55	9.38e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CRC	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.56	-0.43	4.5e-16	Biliary atresia;
CRC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.51	-9.2	-0.45	4.29e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg02033258	chr5:131593261	PDLIM4	0.36	6.66	0.34	1.13e-10	Blood metabolite levels;
CRC	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg16589663	chr20:23618590	CST3	0.42	6.09	0.32	3.19e-9	Chronic kidney disease;
CRC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-9.88	-0.48	2.56e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.49	7.03	0.36	1.2e-11	Pancreatic cancer;
CRC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.58	6.18	0.32	1.92e-9	Initial pursuit acceleration;
CRC	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.07e-8	Type 2 diabetes;
CRC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.07	13.48	0.6	2.85e-33	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg05623727	chr3:50126028	RBM5	-0.43	-7.33	-0.37	1.84e-12	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.42	0.62	6.95e-37	Chronic sinus infection;
CRC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.84	12.69	0.57	2.67e-30	Multiple sclerosis;
CRC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.46	-7.24	-0.37	3.19e-12	Response to antineoplastic agents;
CRC	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.48	6.82	0.35	4.43e-11	Malaria;
CRC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.42	7.04	0.36	1.15e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2072510	0.569	rs7134975	chr12:96390420	C/A	cg09636302	chr12:96389483	HAL	-0.52	-6.5	-0.34	3.02e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.43	5.69	0.3	2.76e-8	Tuberculosis;
CRC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06544989	chr22:39130855	UNC84B	0.48	7.65	0.39	2.27e-13	Menopause (age at onset);
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg12564285	chr5:131593104	PDLIM4	0.39	7.46	0.38	7.65e-13	Blood metabolite levels;
CRC	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-5.61	-0.3	4.22e-8	Schizophrenia;
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg24046110	chr8:143859143	LYNX1	-0.64	-11.29	-0.53	3.22e-25	Urinary tract infection frequency;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12273811	chr6:28175739	NA	0.69	8.75	0.43	1.13e-16	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10477754	chr10:103892376	PPRC1	0.49	7.03	0.36	1.18e-11	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.78	11.03	0.52	2.86e-24	Vitiligo;
CRC	trans	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg20935933	chr6:143382018	AIG1	0.51	6.68	0.35	1.03e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.58	0.43	3.83e-16	Arsenic metabolism;
CRC	cis	rs3764400	0.508	rs2240119	chr17:46111172	C/T	cg10706073	chr17:46328419	SKAP1	0.66	6.94	0.36	2.16e-11	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21684385	chr6:143772210	ADAT2;PEX3	0.42	6.0	0.31	5.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg12458913	chr13:53173898	NA	0.54	8.49	0.42	7.44e-16	Lewy body disease;
CRC	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.57	7.19	0.37	4.34e-12	Pursuit maintenance gain;
CRC	cis	rs9908102	0.770	rs73300518	chr17:12914795	G/C	cg26162695	chr17:12921313	ELAC2	0.42	5.71	0.3	2.54e-8	Schizophrenia;
CRC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.48	-9.2	-0.45	4.37e-18	Prostate cancer;
CRC	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-7.46	-0.38	8e-13	Migraine;
CRC	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg19773385	chr1:10388646	KIF1B	-0.64	-10.56	-0.5	1.21e-22	Hepatocellular carcinoma;
CRC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg02527881	chr3:46936655	PTH1R	-0.39	-7.33	-0.37	1.84e-12	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12107637	chr18:3248148	MYL12A	0.49	6.88	0.35	3.02e-11	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg09877947	chr5:131593287	PDLIM4	0.45	8.41	0.42	1.25e-15	Breast cancer;
CRC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.87	-19.83	-0.74	4.13e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7705042	0.865	rs249641	chr5:141525305	A/G	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.5e-8	Asthma;
CRC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.39	8.48	0.42	7.93e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs7943203	0.925	rs12223381	chr11:108354102	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.82	0.31	1.37e-8	Red blood cell count;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26679024	chr12:57400033	ZBTB39	0.45	6.63	0.34	1.39e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.44	-9.71	-0.47	9.25e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs12760731	0.623	rs12691480	chr1:178328790	T/A	cg00404053	chr1:178313656	RASAL2	0.74	9.32	0.46	1.73e-18	Obesity-related traits;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.82	10.55	0.5	1.28e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg27395922	chr11:50257633	LOC441601	0.49	6.2	0.32	1.68e-9	Intraocular pressure;
CRC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.93	0.31	7.49e-9	Diabetic retinopathy;
CRC	trans	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.42	-0.38	9.82e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg10756647	chr7:56101905	PSPH	-0.75	-8.03	-0.4	1.73e-14	Diabetic kidney disease;
CRC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.75	0.39	1.19e-13	Mean platelet volume;
CRC	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.04	-0.32	4.16e-9	Systolic blood pressure;
CRC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.62	-0.39	2.82e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.75	0.63	3.76e-38	Platelet count;
CRC	cis	rs7781266	0.793	rs4731968	chr7:133292697	A/G	cg03336402	chr7:133662267	EXOC4	0.48	5.61	0.3	4.18e-8	Educational attainment (college completion);
CRC	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.9	-0.31	8.82e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg20512303	chr5:131592959	PDLIM4	0.4	7.41	0.38	1.09e-12	Blood metabolite levels;
CRC	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.56	-0.65	2.74e-41	Schizophrenia;
CRC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.44	-6.78	-0.35	5.66e-11	Menarche (age at onset);
CRC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.61	9.3	0.46	2.01e-18	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22476893	chr17:7210162	EIF5A	0.47	6.97	0.36	1.7e-11	Response to antipsychotic treatment;
CRC	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.8	-8.43	-0.42	1.07e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9616064	0.638	rs738244	chr22:46946127	C/T	cg05621596	chr22:47072043	GRAMD4	-0.54	-8.08	-0.41	1.24e-14	Urate levels in obese individuals;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg08798685	chr6:27730294	NA	-0.41	-5.87	-0.31	1.06e-8	Parkinson's disease;
CRC	cis	rs449789	0.524	rs1875819	chr6:159747743	A/G	cg14500486	chr6:159655392	FNDC1	-0.49	-7.39	-0.38	1.21e-12	Pulse pressure;
CRC	cis	rs6681460	0.576	rs1338194	chr1:66986476	T/A	cg02459107	chr1:67143332	SGIP1	0.36	5.62	0.3	4.16e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.52	8.01	0.4	1.95e-14	Emphysema distribution in smoking;
CRC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg04586622	chr2:25135609	ADCY3	-0.54	-10.17	-0.49	2.64e-21	Body mass index;
CRC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg10589385	chr1:150898437	SETDB1	0.3	6.13	0.32	2.57e-9	Melanoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21422400	chr1:1747243	GNB1	-0.45	-6.96	-0.36	1.81e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg22495460	chr2:25135724	ADCY3	0.87	16.91	0.68	1.34e-46	Body mass index;
CRC	trans	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg26043149	chr18:55253948	FECH	0.51	7.61	0.39	2.93e-13	Bone mineral density;
CRC	cis	rs11212617	0.934	rs172896	chr11:108217049	T/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.47	0.34	3.64e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.61	9.58	0.47	2.5e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.34	-0.33	7.72e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.51	-0.71	6.56e-53	Schizophrenia;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.36	-5.88	-0.31	9.87e-9	Glycated hemoglobin levels;
CRC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.5	7.69	0.39	1.73e-13	Corneal astigmatism;
CRC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.55	7.75	0.39	1.13e-13	Melanoma;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.43	-0.38	9.63e-13	Blood metabolite levels;
CRC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.54	-8.3	-0.42	2.71e-15	Aortic root size;
CRC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.37e-10	Breast cancer;
CRC	cis	rs7692995	1.000	rs1472852	chr4:17910236	C/A	cg08925142	chr4:18023851	LCORL	-0.52	-5.7	-0.3	2.73e-8	Height;
CRC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.07	0.32	3.47e-9	Dupuytren's disease;
CRC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.43	8.11	0.41	9.96e-15	Childhood ear infection;
CRC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.86	-13.84	-0.61	1.22e-34	Blood metabolite levels;
CRC	cis	rs540254	0.619	rs4656270	chr1:160779412	A/G	cg20255094	chr1:160771763	LY9	0.49	6.42	0.33	4.64e-10	Blood protein levels;
CRC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.39	5.73	0.3	2.23e-8	Breast cancer;
CRC	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg03433033	chr1:76189801	ACADM	0.4	5.68	0.3	2.96e-8	Daytime sleep phenotypes;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs629535	0.814	rs506931	chr8:70068129	T/G	cg26132723	chr8:70041827	NA	0.35	5.77	0.3	1.8e-8	Dupuytren's disease;
CRC	cis	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg15845792	chr6:28175446	NA	0.85	5.82	0.31	1.36e-8	Depression;
CRC	cis	rs6594499	1.000	rs1438673	chr5:110467499	C/T	cg04022379	chr5:110408740	TSLP	0.43	6.54	0.34	2.41e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-7.42	-0.38	9.96e-13	Glycated hemoglobin levels;
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg25164649	chr6:28176230	NA	0.54	7.91	0.4	3.99e-14	Parkinson's disease;
CRC	cis	rs2302190	0.769	rs7211294	chr17:56462783	G/A	cg25885038	chr17:56607967	SEPT4	-0.45	-6.48	-0.34	3.32e-10	Vitamin D levels;
CRC	trans	rs35094601	1.000	rs12621131	chr2:139225736	C/T	cg25299176	chr17:1303341	YWHAE	-0.47	-6.67	-0.35	1.1e-10	Schizophrenia;
CRC	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg15704280	chr7:45808275	SEPT13	-0.58	-7.09	-0.36	8.03e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs728616	0.717	rs17098169	chr10:81816134	C/T	cg05935833	chr10:81318306	SFTPA2	0.53	6.28	0.33	1.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg22687807	chr8:143858763	LYNX1	-0.45	-6.95	-0.36	1.95e-11	Urinary tract infection frequency;
CRC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.42	7.84	0.4	6.46e-14	Ulcerative colitis;
CRC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.51	7.64	0.39	2.47e-13	Corneal astigmatism;
CRC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.83	-10.99	-0.52	3.94e-24	Initial pursuit acceleration;
CRC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.91	-16.88	-0.68	1.77e-46	Height;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.79	-12.5	-0.57	1.36e-29	Blood trace element (Zn levels);
CRC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.66	11.73	0.54	8.54e-27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.55	7.41	0.38	1.08e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4731207	0.591	rs9691875	chr7:124675705	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.1	-0.32	2.98e-9	Cutaneous malignant melanoma;
CRC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.58	5.99	0.31	5.52e-9	Fat distribution (HIV);
CRC	cis	rs3018066	0.692	rs6824682	chr4:107007919	G/A	cg01869342	chr4:106983673	TBCK	0.44	6.47	0.34	3.56e-10	Cancer;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.59e-12	Life satisfaction;
CRC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg24011408	chr12:48396354	COL2A1	-0.44	-6.47	-0.34	3.47e-10	Glycated hemoglobin levels;
CRC	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg14550559	chr2:240039617	HDAC4	-0.52	-7.81	-0.4	7.89e-14	Skin aging (microtopography measurement);
CRC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	6.76	0.35	6.48e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.6	9.27	0.46	2.44e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03041700	chr1:1407645	ATAD3B	0.46	6.56	0.34	2.13e-10	Response to antipsychotic treatment;
CRC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs4356975	0.563	rs7657423	chr4:69955914	G/T	cg25583503	chr4:69962676	UGT2B7	0.31	5.71	0.3	2.53e-8	Obesity-related traits;
CRC	cis	rs16924133	0.793	rs12289960	chr11:33171742	C/G	cg05567920	chr11:33183001	CSTF3	-0.75	-5.66	-0.3	3.31e-8	Anger;
CRC	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.58	10.44	0.5	3.1e-22	Blood metabolite ratios;
CRC	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.98	18.12	0.71	2.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.13	-0.49	3.53e-21	Bipolar disorder;
CRC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.37	6.08	0.32	3.37e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.51	-0.46	4.32e-19	Aortic root size;
CRC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	15.3	0.64	2.66e-40	Primary sclerosing cholangitis;
CRC	cis	rs12044355	0.927	rs11122321	chr1:231835610	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.01	0.31	4.97e-9	Alzheimer's disease;
CRC	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.6	-9.75	-0.47	6.79e-20	Systemic lupus erythematosus;
CRC	trans	rs7142881	0.508	rs8013530	chr14:32142930	C/T	cg07244268	chr3:164924675	NA	-0.44	-6.05	-0.32	4.05e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs524281	0.773	rs79770412	chr11:66045344	G/C	cg14036092	chr11:66035641	RAB1B	-0.54	-6.0	-0.31	5.25e-9	Electroencephalogram traits;
CRC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.91	-0.4	3.95e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	8.6	0.43	3.24e-16	IgG glycosylation;
CRC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.8	-13.06	-0.58	1.13e-31	Glaucoma (primary open-angle);
CRC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.56	7.18	0.37	4.77e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg25456477	chr12:86230367	RASSF9	0.4	6.73	0.35	7.75e-11	Major depressive disorder;
CRC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg02290350	chr8:58132656	NA	-0.46	-5.84	-0.31	1.24e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.681	rs55838345	chr10:82085120	G/C	cg11900509	chr10:81946545	ANXA11	-0.54	-6.11	-0.32	2.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.69	10.34	0.5	7e-22	Intelligence (multi-trait analysis);
CRC	cis	rs939584	1.000	rs7558910	chr2:645122	C/G	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.07	-0.32	3.48e-9	Eosinophil percentage of white cells;
CRC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.49	6.99	0.36	1.54e-11	Schizophrenia;
CRC	trans	rs7800418	0.723	rs4461797	chr7:26588044	C/T	cg14387656	chr2:233470847	EFHD1	0.45	6.17	0.32	2.05e-9	Cognitive function;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.98	-0.44	2.07e-17	Bipolar disorder;
CRC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.87	11.64	0.54	1.87e-26	Triglycerides;
CRC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.2	-0.49	2.06e-21	Body mass index;
CRC	cis	rs892085	0.654	rs8106691	chr19:10889469	C/A	cg17710535	chr19:10819994	QTRT1	0.38	5.7	0.3	2.71e-8	Psoriasis vulgaris;Psoriasis;
CRC	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06307176	chr5:131281290	NA	0.41	6.02	0.31	4.78e-9	Life satisfaction;
CRC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.24	-16.72	-0.68	7.21e-46	Breast cancer;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.4	0.33	5.21e-10	Depression;
CRC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg17294928	chr15:75287854	SCAMP5	-0.58	-9.16	-0.45	5.58e-18	Breast cancer;
CRC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	8.66	0.43	2.15e-16	Height;
CRC	cis	rs2415984	0.562	rs1494092	chr14:46970304	T/C	cg14871534	chr14:47121158	RPL10L	0.41	5.73	0.3	2.29e-8	Number of children ever born;
CRC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg07211511	chr3:129823064	LOC729375	-0.62	-7.25	-0.37	3.03e-12	Blood pressure (smoking interaction);
CRC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	1.08	10.7	0.51	4.09e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.47	-8.94	-0.44	2.86e-17	Reticulocyte fraction of red cells;
CRC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.26	-0.37	2.84e-12	Coronary artery disease;
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.52	6.14	0.32	2.44e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg14459158	chr9:96720562	NA	0.47	7.43	0.38	9.16e-13	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg25767906	chr1:53392781	SCP2	0.43	6.72	0.35	7.95e-11	Monocyte count;
CRC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.47	7.78	0.39	9.77e-14	Major depressive disorder;
CRC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.79	13.38	0.59	6.66e-33	Menopause (age at onset);
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg06470822	chr6:28175283	NA	-0.9	-12.14	-0.56	2.77e-28	Parkinson's disease;
CRC	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.47	-7.48	-0.38	6.68e-13	Carotid intima media thickness;
CRC	cis	rs847649	0.804	rs4729866	chr7:102685561	A/C	cg18108683	chr7:102477205	FBXL13	0.54	8.86	0.44	5.18e-17	Morning vs. evening chronotype;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg06470822	chr6:28175283	NA	0.98	13.08	0.59	8.77e-32	Depression;
CRC	cis	rs6445967	1.000	rs11712758	chr3:58306579	T/C	cg23715586	chr3:58305044	RPP14	0.34	5.71	0.3	2.55e-8	Platelet count;
CRC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.52	0.63	2.87e-37	Colorectal cancer;
CRC	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg04202892	chr2:111875749	ACOXL	0.46	7.59	0.39	3.23e-13	Chronic lymphocytic leukemia;
CRC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14479329	chr6:167370587	RNASET2	0.4	6.06	0.32	3.62e-9	Interleukin-6 levels;
CRC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.54	6.4	0.33	5.49e-10	Vitiligo;
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.62	-0.34	1.44e-10	Bipolar disorder;
CRC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg07701084	chr6:150067640	NUP43	0.57	8.23	0.41	4.51e-15	Lung cancer;
CRC	cis	rs7849270	1.000	rs10819466	chr9:131881492	G/C	cg13538475	chr9:131942899	NA	-0.29	-5.89	-0.31	9.75e-9	Blood metabolite ratios;
CRC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	7.42	0.38	1.01e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.97	-20.58	-0.75	4.69e-61	Cerebrospinal fluid biomarker levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06258179	chr7:92463261	CDK6	0.38	6.08	0.32	3.42e-9	Schizophrenia;
CRC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.63	-7.17	-0.37	5.02e-12	Hip circumference adjusted for BMI;
CRC	cis	rs4731207	0.698	rs4377885	chr7:124533680	A/G	cg23710748	chr7:124431027	NA	0.37	5.9	0.31	9.15e-9	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg12273811	chr6:28175739	NA	0.5	6.91	0.36	2.57e-11	Parkinson's disease;
CRC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	7.04	0.36	1.13e-11	Body mass index;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12172441	chr6:28176163	NA	0.67	8.63	0.43	2.64e-16	Depression;
CRC	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.41	-6.21	-0.32	1.61e-9	Endometrial cancer;
CRC	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.5	6.33	0.33	7.9e-10	Recombination rate (females);
CRC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg06363034	chr20:62225388	GMEB2	-0.45	-6.88	-0.35	2.94e-11	Glioblastoma;
CRC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg08923669	chr16:420230	MRPL28	0.49	7.05	0.36	1.05e-11	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs2227564	0.700	rs12413039	chr10:75524759	C/G	cg16540259	chr10:75572220	NDST2	-0.43	-6.02	-0.31	4.72e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg01483505	chr11:975446	AP2A2	0.4	6.14	0.32	2.31e-9	Alzheimer's disease (late onset);
CRC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.55	7.23	0.37	3.41e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.76	15.09	0.64	1.83e-39	Leprosy;
CRC	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.67	11.49	0.54	6.22e-26	Prostate cancer;
CRC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.93	0.31	7.68e-9	Self-reported allergy;
CRC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05385059	chr20:60718641	SS18L1;PSMA7	0.43	6.06	0.32	3.75e-9	Anxiety disorder;
CRC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.67	-7.59	-0.39	3.25e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs9287719	0.649	rs10803724	chr2:10732323	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.39	5.9	0.31	8.93e-9	Red blood cell count;
CRC	cis	rs2982552	0.844	rs2982560	chr6:152055606	A/T	cg22157087	chr6:152012887	ESR1	0.38	5.82	0.31	1.38e-8	Bone properties (heel);
CRC	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg20703242	chr1:230279135	GALNT2	0.53	8.06	0.41	1.4e-14	Coronary artery disease;
CRC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg07507251	chr3:52567010	NT5DC2	0.39	5.84	0.31	1.26e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.87	0.48	2.74e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.2	-0.32	1.7e-9	Height;
CRC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.63	-10.88	-0.51	9.62e-24	Coronary artery disease;
CRC	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.64	-0.3	3.73e-8	Blood protein levels;
CRC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.96	-0.31	6.46e-9	Life satisfaction;
CRC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs11191205	0.644	rs11191069	chr10:103388129	A/C	cg15320455	chr10:103880129	LDB1	-0.58	-6.36	-0.33	6.77e-10	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	13.7	0.6	4.13e-34	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11176924	chr14:24740855	RABGGTA	0.46	6.25	0.33	1.25e-9	Anxiety disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27005246	chr16:31044731	STX4	0.43	5.97	0.31	6.18e-9	Response to antipsychotic treatment;
CRC	cis	rs2565722	0.622	rs2489947	chr6:161301113	A/G	cg03159191	chr6:161285451	NA	-0.46	-6.28	-0.33	1.07e-9	Blood protein levels;
CRC	cis	rs2252521	0.524	rs2214973	chr7:29059891	A/G	cg11728747	chr7:29037910	CPVL	-0.48	-7.01	-0.36	1.37e-11	Cognitive performance;
CRC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.93	-16.96	-0.68	8.53e-47	Height;
CRC	cis	rs2108622	0.711	rs113059233	chr19:15977368	G/A	cg13772218	chr19:15982569	NA	0.46	6.43	0.33	4.44e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.66	11.73	0.54	8.84e-27	Height;
CRC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25809561	chr17:30822961	MYO1D	0.71	12.23	0.56	1.29e-28	Schizophrenia;
CRC	cis	rs1465370	0.682	rs2239604	chr7:130021331	C/T	cg03229158	chr7:130009420	NA	0.43	6.19	0.32	1.8e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.66	0.51	5.52e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.98	11.72	0.54	9.41e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.7e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg00786952	chr1:21763130	NA	0.52	9.18	0.45	5.09e-18	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.51	6.78	0.35	5.51e-11	Height;
CRC	cis	rs62458065	0.850	rs28677012	chr7:32469811	C/A	cg20159608	chr7:32802032	NA	-0.56	-6.75	-0.35	6.67e-11	Metabolite levels (HVA/MHPG ratio);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22802068	chr17:900285	TIMM22	0.36	6.08	0.32	3.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg04043695	chr12:129287642	SLC15A4	0.38	5.68	0.3	3e-8	Systemic lupus erythematosus;
CRC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.34	1.25e-10	Renal cell carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04436474	chr3:49977685	RBM6	0.53	7.33	0.37	1.85e-12	Response to antipsychotic treatment;
CRC	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.7	-12.07	-0.55	5.14e-28	Coronary artery disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg14430738	chr6:26596151	ABT1	-0.38	-6.25	-0.33	1.3e-9	Aortic root size;
CRC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.43	0.33	4.6e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8070740	0.898	rs4442872	chr17:5324236	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	7.46	0.38	7.92e-13	Menopause (age at onset);
CRC	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg02811702	chr13:24901961	NA	0.48	6.63	0.34	1.4e-10	Obesity-related traits;
CRC	cis	rs11212617	0.967	rs371406	chr11:108221482	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.61	0.3	4.3e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.57	-5.95	-0.31	6.9e-9	Coronary artery disease;
CRC	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg03030879	chr14:75389066	RPS6KL1	0.41	6.38	0.33	6.08e-10	Caffeine consumption;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg24560729	chr4:1342394	KIAA1530	0.38	6.13	0.32	2.53e-9	Obesity-related traits;
CRC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	6.35	0.33	6.97e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.21	-0.32	1.59e-9	Arsenic metabolism;
CRC	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.75	-11.7	-0.54	1.09e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.04	16.07	0.66	2.57e-43	Lymphocyte percentage of white cells;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.63	-9.03	-0.45	1.48e-17	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24496317	chr7:24613120	MPP6	0.46	6.79	0.35	5.27e-11	Intelligence (multi-trait analysis);
CRC	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.19	0.45	4.45e-18	Mean corpuscular volume;
CRC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg00343986	chr7:65444356	GUSB	-0.5	-7.44	-0.38	8.98e-13	Aortic root size;
CRC	cis	rs938554	0.784	rs7682751	chr4:9976294	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.65	0.34	1.21e-10	Blood metabolite levels;
CRC	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.81	13.48	0.6	2.83e-33	Hypertriglyceridemia;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08125682	chr16:11038455	CLEC16A	0.4	6.46	0.34	3.81e-10	Interleukin-6 levels;
CRC	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.48	-7.07	-0.36	9.27e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs904251	0.714	rs2776910	chr6:37436284	A/G	cg25019722	chr6:37503610	NA	-0.4	-6.02	-0.32	4.53e-9	Cognitive performance;
CRC	cis	rs4664293	0.647	rs4665099	chr2:160495538	G/A	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs365302	1.000	rs485626	chr6:159651279	A/G	cg14500486	chr6:159655392	FNDC1	0.44	6.78	0.35	5.7e-11	Coronary heart disease;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.49	-0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.58	8.43	0.42	1.11e-15	Lung cancer;
CRC	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.43	7.61	0.39	2.95e-13	Prostate cancer;
CRC	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg04025307	chr7:1156635	C7orf50	0.64	6.76	0.35	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.86	-0.35	3.35e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.79	13.35	0.59	9.09e-33	Menopause (age at onset);
CRC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.65	9.25	0.45	2.82e-18	Lung cancer;
CRC	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg10437265	chr15:77819839	NA	0.58	10.38	0.5	5.07e-22	Type 2 diabetes;
CRC	cis	rs2479724	0.870	rs6913232	chr6:41915143	C/T	cg17623882	chr6:41773611	USP49	0.51	8.21	0.41	4.97e-15	Menarche (age at onset);
CRC	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg01692110	chr13:113365389	ATP11A	-0.5	-5.98	-0.31	5.89e-9	Glycated hemoglobin levels;
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.61	-0.34	1.58e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	0.967	rs227062	chr11:108205383	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.26	0.33	1.2e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.66	-10.25	-0.49	1.46e-21	Neuroticism;
CRC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.38	-5.9	-0.31	8.95e-9	Breast cancer;
CRC	cis	rs6586163	0.872	rs1926200	chr10:90746533	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.21	-0.37	3.77e-12	Chronic lymphocytic leukemia;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg10596483	chr8:143751796	JRK	-0.49	-6.69	-0.35	9.65e-11	Urinary tract infection frequency;
CRC	cis	rs57561814	0.510	rs1800796	chr7:22766246	G/C	cg26061582	chr7:22766209	IL6	0.95	7.14	0.37	6.13e-12	Tonsillectomy;
CRC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00166722	chr3:10149974	C3orf24	0.46	6.7	0.35	9.05e-11	Alzheimer's disease;
CRC	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg12564285	chr5:131593104	PDLIM4	0.32	5.71	0.3	2.49e-8	Blood metabolite levels;
CRC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg22561889	chr6:118971681	C6orf204	0.51	6.47	0.34	3.45e-10	Diastolic blood pressure;
CRC	cis	rs2745967	0.791	rs2724379	chr1:208076856	A/C	cg09788693	chr1:208063733	CD34	0.41	6.37	0.33	6.36e-10	Resting heart rate;
CRC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.46	6.98	0.36	1.63e-11	Corneal astigmatism;
CRC	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.66	-9.67	-0.47	1.23e-19	Blood protein levels;
CRC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.52	-6.3	-0.33	9.27e-10	Body mass index;
CRC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg08314208	chr16:67682810	RLTPR	-0.59	-6.37	-0.33	6.28e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.91	-0.4	4.02e-14	Caffeine consumption;
CRC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg22676075	chr6:135203613	NA	0.41	6.35	0.33	7.16e-10	Red blood cell count;
CRC	cis	rs8005677	0.770	rs56180741	chr14:23377246	T/C	cg25600027	chr14:23388339	RBM23	-0.46	-6.99	-0.36	1.54e-11	Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.45	5.76	0.3	1.89e-8	Obesity-related traits;
CRC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.72	-7.86	-0.4	5.63e-14	Lung disease severity in cystic fibrosis;
CRC	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.55	0.5	1.36e-22	Corneal astigmatism;
CRC	cis	rs8170	1.000	rs10416654	chr19:17385176	T/C	cg04749549	chr19:17459798	NA	-0.43	-5.88	-0.31	1.01e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.58	8.81	0.44	7.22e-17	Endometrial cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07830110	chr22:38794284	LOC400927	0.51	7.65	0.39	2.24e-13	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg03030879	chr14:75389066	RPS6KL1	0.43	6.63	0.34	1.39e-10	Height;
CRC	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg05579598	chr16:88989069	CBFA2T3	0.33	6.84	0.35	3.83e-11	Social autistic-like traits;
CRC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg10589385	chr1:150898437	SETDB1	0.32	6.53	0.34	2.52e-10	Melanoma;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg02683197	chr6:28174875	NA	-0.82	-10.15	-0.49	3.13e-21	Depression;
CRC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg13206674	chr6:150067644	NUP43	0.56	8.0	0.4	2.14e-14	Lung cancer;
CRC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.78	-11.58	-0.54	2.98e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.89	-0.4	4.46e-14	Bone mineral density;
CRC	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg00691999	chr4:55094011	PDGFRA	0.44	6.34	0.33	7.43e-10	Corneal astigmatism;
CRC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.68	-8.16	-0.41	7.16e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.68	0.35	1.04e-10	Mean platelet volume;
CRC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.57	-8.58	-0.43	3.74e-16	Schizophrenia;
CRC	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.17	-0.32	1.97e-9	Blood protein levels;
CRC	trans	rs7942260	1.000	rs56352228	chr11:94346099	A/G	cg10632000	chr19:42806201	PRR19;PAFAH1B3	-0.55	-6.04	-0.32	4.19e-9	Colorectal cancer;
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg22687807	chr8:143858763	LYNX1	0.49	8.92	0.44	3.32e-17	Urinary tract infection frequency;
CRC	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.74	9.84	0.48	3.35e-20	Prostate cancer;
CRC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.67e-18	Parkinson's disease;
CRC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-12.69	-0.57	2.72e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.63	10.37	0.5	5.37e-22	Schizophrenia;
CRC	trans	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg13521940	chr21:36262239	RUNX1	-0.4	-5.97	-0.31	6.12e-9	Multiple system atrophy;
CRC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg07125278	chr16:67683757	RLTPR	0.61	6.75	0.35	6.86e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.55	-7.62	-0.39	2.79e-13	Schizophrenia;
CRC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.55	7.23	0.37	3.41e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg00225070	chr15:80189496	MTHFS	0.4	6.06	0.32	3.73e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.32	0.46	1.79e-18	Tonsillectomy;
CRC	cis	rs9311676	0.656	rs6445973	chr3:58336595	G/T	cg06643156	chr3:58380774	PXK	-0.43	-6.43	-0.33	4.49e-10	Systemic lupus erythematosus;
CRC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	7.52	0.38	5.32e-13	Mood instability;
CRC	trans	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg18288967	chr1:45987694	PRDX1	0.61	7.08	0.36	8.96e-12	Obesity-related traits;
CRC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg24011408	chr12:48396354	COL2A1	0.43	6.18	0.32	1.87e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-6.67	-0.35	1.09e-10	Metabolite levels;
CRC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg00579200	chr11:133705235	NA	-0.39	-5.6	-0.3	4.51e-8	Childhood ear infection;
CRC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.79	-0.48	4.8e-20	Hip circumference adjusted for BMI;
CRC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.43	6.97	0.36	1.75e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3857067	1.000	rs6532454	chr4:95019067	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.67	-0.3	3.06e-8	QT interval;
CRC	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	8.29	0.42	3.02e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.44	6.15	0.32	2.28e-9	Lymphocyte counts;
CRC	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.77	15.89	0.66	1.3e-42	Leprosy;
CRC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	14.47	0.62	4.68e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7814319	0.700	rs7838479	chr8:97268077	G/A	cg20787634	chr8:97240163	UQCRB	-0.45	-7.19	-0.37	4.34e-12	Lung function (FVC);
CRC	cis	rs11212617	0.967	rs12272183	chr11:108077181	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.38	5.61	0.3	4.36e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.01	11.92	0.55	1.85e-27	Nonalcoholic fatty liver disease;
CRC	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-7.93	-0.4	3.4e-14	Body mass index;
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.52	-10.49	-0.5	2.07e-22	Urate levels in overweight individuals;
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7725052	0.609	rs4331943	chr5:40450245	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.61	-0.34	1.53e-10	Pediatric autoimmune diseases;
CRC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg02659138	chr7:134003124	SLC35B4	0.36	5.71	0.3	2.54e-8	Mean platelet volume;
CRC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg23533926	chr12:111358616	MYL2	-0.45	-6.57	-0.34	1.94e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.68	9.92	0.48	1.88e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.19	-0.32	1.8e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs10411161	0.702	rs8110546	chr19:52383556	C/A	cg22319618	chr22:45562946	NUP50	-0.68	-7.53	-0.38	4.85e-13	Breast cancer;
CRC	trans	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg18755114	chr2:209119030	IDH1	-0.41	-6.18	-0.32	1.9e-9	Blood protein levels;
CRC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	13.87	0.61	8.95e-35	Total body bone mineral density;
CRC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg04880052	chr2:219191631	PNKD	-0.44	-6.93	-0.36	2.24e-11	Colorectal cancer;
CRC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.42	-6.25	-0.33	1.26e-9	Obesity-related traits;
CRC	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.75	13.63	0.6	7.34e-34	Anterior chamber depth;
CRC	cis	rs12580194	0.556	rs7955088	chr12:55732963	G/T	cg23425280	chr12:56401806	NA	0.47	5.88	0.31	9.99e-9	Cancer;
CRC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.33	-0.33	8e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.76	-0.35	6.3e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9549328	0.670	rs61963562	chr13:113616523	T/G	cg20742385	chr13:113633654	MCF2L	0.55	9.39	0.46	1.01e-18	Systolic blood pressure;
CRC	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg09659197	chr4:152720779	NA	0.52	11.2	0.53	7.17e-25	Intelligence (multi-trait analysis);
CRC	cis	rs3789045	0.685	rs12036042	chr1:204469314	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.95	-0.4	3.06e-14	Educational attainment (college completion);
CRC	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg19077165	chr18:44547161	KATNAL2	0.4	6.08	0.32	3.26e-9	Educational attainment;
CRC	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg22674798	chr1:3096360	PRDM16	0.35	7.41	0.38	1.04e-12	Migraine;
CRC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.37	6.27	0.33	1.13e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.61	-8.86	-0.44	5.28e-17	Schizophrenia;
CRC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg08888203	chr3:10149979	C3orf24	0.46	7.21	0.37	3.9e-12	Alzheimer's disease;
CRC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg08071915	chr8:12219732	FAM66A	0.33	6.08	0.32	3.33e-9	Neuroticism;
CRC	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.71	5.89	0.31	9.63e-9	Alzheimer's disease (late onset);
CRC	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.26	0.33	1.18e-9	Hair morphology;
CRC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.68	9.04	0.45	1.41e-17	Platelet count;
CRC	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.52	7.03	0.36	1.21e-11	Metabolite levels;
CRC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg00383909	chr3:49044727	WDR6	0.47	5.82	0.31	1.43e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17507749	chr15:85114479	UBE2QP1	-0.62	-8.67	-0.43	1.95e-16	Schizophrenia;
CRC	cis	rs12079745	0.793	rs12073439	chr1:169284482	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.91	-5.88	-0.31	1.03e-8	QT interval;
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs3020333	1.000	rs3020332	chr6:152008924	C/T	cg22157087	chr6:152012887	ESR1	0.53	7.98	0.4	2.49e-14	Total body bone mineral density;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.51	7.19	0.37	4.31e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.27	-6.42	-0.33	4.66e-10	Urate levels in overweight individuals;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19711724	chr3:19188166	NA	0.45	6.36	0.33	6.9e-10	Thyroid stimulating hormone;
CRC	cis	rs501120	0.810	rs541483	chr10:44746395	A/G	cg09554077	chr10:44749378	NA	0.87	11.81	0.55	4.44e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.58	-9.09	-0.45	9.72e-18	Asthma;
CRC	cis	rs2811415	0.597	rs13094572	chr3:127772785	G/A	cg13719885	chr3:127795394	NA	-0.4	-6.05	-0.32	3.83e-9	Lung function (FEV1/FVC);
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg04633409	chr12:44195947	TWF1	0.41	6.16	0.32	2.13e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs698833	0.819	rs698772	chr2:44580634	G/A	cg04920474	chr2:44395004	PPM1B	0.42	6.27	0.33	1.15e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg02527881	chr3:46936655	PTH1R	0.38	7.08	0.36	8.93e-12	Colorectal cancer;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg15845792	chr6:28175446	NA	0.59	8.4	0.42	1.31e-15	Parkinson's disease;
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.98	0.44	2.15e-17	Attention deficit hyperactivity disorder;
CRC	cis	rs294883	0.739	rs1504256	chr6:159731036	A/C	cg14500486	chr6:159655392	FNDC1	-0.34	-5.93	-0.31	7.85e-9	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.45	0.38	8.28e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg03013999	chr17:37608204	MED1	0.45	6.86	0.35	3.45e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg12927641	chr6:109611667	NA	-0.37	-6.71	-0.35	8.55e-11	Reticulocyte fraction of red cells;
CRC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg01483505	chr11:975446	AP2A2	0.43	6.94	0.36	2.05e-11	Alzheimer's disease (late onset);
CRC	cis	rs6433857	0.594	rs1406257	chr2:181521345	A/G	cg23363182	chr2:181467187	NA	-0.48	-7.38	-0.38	1.29e-12	Body mass index;
CRC	cis	rs524281	0.506	rs560393	chr11:66005477	A/G	cg16950941	chr11:66035639	RAB1B	-0.5	-6.12	-0.32	2.62e-9	Electroencephalogram traits;
CRC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.82	-10.96	-0.52	5.02e-24	IgG glycosylation;
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.44	-5.98	-0.31	5.66e-9	Large artery stroke;
CRC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	0.79	6.22	0.32	1.51e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg26958806	chr6:27640298	NA	0.85	5.63	0.3	3.79e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7487075	0.780	rs1873793	chr12:46761324	A/G	cg07601320	chr12:47219841	SLC38A4	-0.27	-5.68	-0.3	3.04e-8	Itch intensity from mosquito bite;
CRC	cis	rs12541635	0.966	rs7839239	chr8:107020406	C/T	cg10147462	chr8:107024639	NA	0.42	7.05	0.36	1.07e-11	Age of smoking initiation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26072759	chr17:75277365	SEPT9	0.39	6.22	0.32	1.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg25985355	chr7:65971099	NA	0.51	5.75	0.3	2.08e-8	Diabetic kidney disease;
CRC	cis	rs17767392	0.958	rs4902942	chr14:72140659	A/T	cg13720639	chr14:72061746	SIPA1L1	0.56	7.01	0.36	1.38e-11	Mitral valve prolapse;
CRC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg20636351	chr8:55087400	NA	-0.34	-6.07	-0.32	3.5e-9	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22190833	chr7:150929518	CHPF2	-0.33	-6.02	-0.31	4.58e-9	Myopia (pathological);
CRC	cis	rs9311676	0.632	rs62258078	chr3:58363432	G/A	cg06643156	chr3:58380774	PXK	0.44	6.8	0.35	4.98e-11	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	trans	rs926326	0.789	rs35033684	chr6:25507639	T/G	cg25354657	chr11:129991445	APLP2	-0.43	-6.34	-0.33	7.39e-10	Platelet count;
CRC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05830473	chr16:58718573	SLC38A7	0.42	6.12	0.32	2.71e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg10130564	chr11:117069849	TAGLN	0.3	5.81	0.31	1.47e-8	Blood protein levels;
CRC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-13.31	-0.59	1.25e-32	Vitiligo;
CRC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-9.75	-0.47	6.58e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg25985355	chr7:65971099	NA	-0.5	-5.8	-0.3	1.57e-8	Diabetic kidney disease;
CRC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.25	0.37	2.97e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.79	11.64	0.54	1.79e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs365302	0.767	rs364581	chr6:159613190	G/A	cg14500486	chr6:159655392	FNDC1	0.55	8.35	0.42	1.98e-15	Coronary heart disease;
CRC	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg24463073	chr6:118973353	C6orf204	0.48	6.21	0.32	1.61e-9	Diastolic blood pressure;
CRC	cis	rs4516970	0.655	rs73781666	chr6:160206106	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	-0.73	-5.68	-0.3	3.03e-8	Iron status biomarkers;
CRC	cis	rs7527798	0.592	rs6667238	chr1:207822856	G/A	cg09232269	chr1:207846808	CR1L	-0.47	-7.66	-0.39	2.16e-13	Erythrocyte sedimentation rate;
CRC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.79	-0.39	8.55e-14	Psoriasis;
CRC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.51	7.71	0.39	1.48e-13	Coronary artery disease;
CRC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.33	4.06e-10	Electroencephalogram traits;
CRC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.8	-11.09	-0.52	1.72e-24	Platelet distribution width;
CRC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg26061582	chr7:22766209	IL6	0.39	6.19	0.32	1.79e-9	Lung cancer;
CRC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.79	0.35	5.14e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg16898833	chr6:26189333	HIST1H4D	0.74	6.18	0.32	1.94e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.56	-8.4	-0.42	1.35e-15	Prostate cancer;
CRC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	7.99	0.4	2.27e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.62	12.42	0.56	2.59e-29	Weight;
CRC	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg27499820	chr13:21296301	IL17D	-0.38	-6.16	-0.32	2.16e-9	Dental caries;
CRC	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.65	-7.11	-0.36	7.38e-12	Breast cancer;
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg15790184	chr11:494944	RNH1	0.57	5.71	0.3	2.59e-8	Body mass index;
CRC	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.53	5.81	0.31	1.46e-8	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12989020	chr6:157098657	ARID1B	0.44	6.17	0.32	1.99e-9	Response to antipsychotic treatment;
CRC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg13334819	chr7:99746414	C7orf59	-0.45	-6.16	-0.32	2.11e-9	Coronary artery disease;
CRC	cis	rs6968419	0.714	rs1048508	chr7:115892650	G/T	cg02561103	chr7:115862891	TES	0.42	6.36	0.33	6.81e-10	Intraocular pressure;
CRC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.62	9.12	0.45	7.86e-18	Obesity-related traits;
CRC	cis	rs17428704	0.649	rs6883134	chr5:14415590	A/G	cg05138787	chr5:14405925	TRIO	-0.6	-5.99	-0.31	5.59e-9	Electroencephalogram traits;
CRC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.48	0.65	5.58e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg14003231	chr6:33640908	ITPR3	0.49	7.95	0.4	2.97e-14	Plateletcrit;
CRC	cis	rs9937943	0.615	rs35495670	chr16:74610422	T/C	cg01733217	chr16:74700730	RFWD3	0.74	8.33	0.42	2.27e-15	Neutrophil percentage of white cells;
CRC	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07741184	chr6:167504864	NA	0.35	6.01	0.31	4.88e-9	Primary biliary cholangitis;
CRC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.22	-0.45	3.61e-18	Prevalent atrial fibrillation;
CRC	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.89	-0.31	9.31e-9	Height;
CRC	cis	rs1983891	0.955	rs4714480	chr6:41520891	T/C	cg20194872	chr6:41519635	FOXP4	0.42	6.02	0.31	4.74e-9	Prostate cancer;
CRC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg00129232	chr17:37814104	STARD3	0.54	7.1	0.36	7.51e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg04132472	chr17:19861366	AKAP10	-0.37	-5.81	-0.31	1.47e-8	Schizophrenia;
CRC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.56	8.62	0.43	2.86e-16	Motion sickness;
CRC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.55	8.3	0.42	2.76e-15	Type 2 diabetes;
CRC	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.55	-0.34	2.26e-10	Hemoglobin concentration;
CRC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.5	7.63	0.39	2.5e-13	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg12273811	chr6:28175739	NA	0.62	9.03	0.45	1.52e-17	Parkinson's disease;
CRC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.71	-0.35	8.42e-11	Alcohol dependence;
CRC	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.69	-0.3	2.83e-8	Type 2 diabetes;
CRC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg21251018	chr6:28226885	NKAPL	0.4	6.09	0.32	3.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg18490616	chr2:88469792	THNSL2	0.59	5.99	0.31	5.51e-9	Plasma clusterin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04297258	chr16:88772664	RNF166;CTU2	0.45	6.33	0.33	8.16e-10	Response to antipsychotic treatment;
CRC	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg20935368	chr5:178288625	ZNF354B	0.43	7.01	0.36	1.32e-11	Sleep duration;
CRC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.6	9.16	0.45	5.79e-18	Schizophrenia;
CRC	cis	rs9463078	0.585	rs1521355	chr6:44932755	T/C	cg25276700	chr6:44698697	NA	-0.23	-5.63	-0.3	3.94e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	7.98	0.4	2.52e-14	Breast cancer;
CRC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-7.81	-0.4	7.83e-14	Mean corpuscular volume;
CRC	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.78	-0.3	1.76e-8	Height;
CRC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.46	6.55	0.34	2.15e-10	Diastolic blood pressure;
CRC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg26762873	chr11:5879799	OR52E8	-0.48	-7.2	-0.37	4.19e-12	DNA methylation (variation);
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.79	-0.39	8.88e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.61	-0.34	1.56e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12681287	0.888	rs13042	chr8:87484913	G/A	cg27223183	chr8:87520930	FAM82B	-0.45	-6.52	-0.34	2.65e-10	Caudate activity during reward;
CRC	cis	rs4774899	0.866	rs2431023	chr15:57553832	A/T	cg08128148	chr15:57256372	TCF12	-0.4	-5.66	-0.3	3.33e-8	Urinary tract infection frequency;
CRC	trans	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.68	0.35	1.02e-10	Mean corpuscular volume;
CRC	cis	rs11212617	0.935	rs186591	chr11:108200142	T/G	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.3	0.33	9.78e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.51	8.74	0.43	1.23e-16	Crohn's disease;
CRC	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs8050755	0.649	rs2516737	chr16:2101749	A/G	cg04515572	chr16:2107413	TSC2	0.67	7.13	0.37	6.49e-12	Major depressive disorder;
CRC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.36	-0.42	1.75e-15	Schizophrenia;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.67	-11.37	-0.53	1.66e-25	Lewy body disease;
CRC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	11.95	0.55	1.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.8	-11.81	-0.55	4.54e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-9.08	-0.45	1.01e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.2	-0.41	5.62e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.6	-0.39	3.19e-13	Body mass index;
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.54e-14	Bipolar disorder;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg24453429	chr1:161136002	PPOX	-0.44	-6.05	-0.32	4e-9	Protein C levels;
CRC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.55	6.09	0.32	3.2e-9	Vitiligo;
CRC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg20291162	chr17:40259547	DHX58	-0.55	-8.01	-0.4	2.06e-14	Fibrinogen levels;
CRC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	18.82	0.72	3.84e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg08798685	chr6:27730294	NA	-0.48	-6.66	-0.34	1.12e-10	Parkinson's disease;
CRC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.56	7.88	0.4	4.96e-14	Resting heart rate;
CRC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.92	17.18	0.69	1.12e-47	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.6	-8.64	-0.43	2.48e-16	Menarche (age at onset);
CRC	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.39	-6.49	-0.34	3.2e-10	Sitting height ratio;
CRC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.75	-0.43	1.11e-16	Alcohol dependence;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.64	6.65	0.34	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3736485	0.844	rs7174495	chr15:51895291	A/G	cg08986416	chr15:51914746	DMXL2	-0.49	-6.94	-0.36	2.11e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.71	9.38	0.46	1.1e-18	Alzheimer's disease;
CRC	cis	rs3026101	0.671	rs12602074	chr17:5302778	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.51	8.91	0.44	3.51e-17	Bone mineral density;
CRC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.51	-8.11	-0.41	9.9e-15	Attention deficit hyperactivity disorder;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14993530	chr1:245027115	HNRNPU	-0.39	-6.0	-0.31	5.11e-9	Brain structure;
CRC	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg26816564	chr1:7831052	VAMP3	0.8	9.0	0.44	1.82e-17	Inflammatory bowel disease;
CRC	cis	rs3736485	0.932	rs4774592	chr15:51778879	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.51	-0.34	2.74e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.74	10.8	0.51	1.72e-23	Menopause (age at onset);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13253660	chr19:53837494	ZNF845	0.38	5.97	0.31	6.09e-9	Schizophrenia;
CRC	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg06470822	chr6:28175283	NA	0.62	6.81	0.35	4.6e-11	Depression;
CRC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.45	6.18	0.32	1.9e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	9.05	0.45	1.26e-17	Bone mineral density;
CRC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-5.69	-0.3	2.77e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg27661571	chr11:113659931	NA	-0.93	-9.31	-0.46	1.85e-18	Height;
CRC	cis	rs11229555	0.645	rs61889554	chr11:58424081	C/A	cg15696309	chr11:58395628	NA	-0.74	-8.03	-0.4	1.81e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg02683197	chr6:28174875	NA	0.88	10.9	0.52	7.78e-24	Depression;
CRC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.8	0.63	2.35e-38	Chronic sinus infection;
CRC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.22	-0.32	1.5e-9	Blood pressure;
CRC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.52e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs10865541	0.869	rs6548162	chr2:3434332	C/T	cg22182287	chr2:3452347	TTC15	0.37	5.67	0.3	3.12e-8	Obesity-related traits;
CRC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.07	12.57	0.57	7.19e-30	Sexual dysfunction (female);
CRC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.6	7.98	0.4	2.52e-14	Methadone dose in opioid dependence;
CRC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.74	10.48	0.5	2.24e-22	Blood metabolite levels;
CRC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg03037974	chr15:76606532	NA	0.6	9.93	0.48	1.7e-20	Blood metabolite levels;
CRC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg21770322	chr7:97807741	LMTK2	-0.47	-7.54	-0.38	4.66e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.49	-6.07	-0.32	3.55e-9	Alopecia areata;
CRC	cis	rs10484885	0.553	rs72911820	chr6:90281934	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.58	-6.42	-0.33	4.79e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.84	0.31	1.26e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg07153921	chr17:41440717	NA	-0.38	-5.74	-0.3	2.13e-8	Menopause (age at onset);
CRC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg06470822	chr6:28175283	NA	0.5	7.28	0.37	2.45e-12	Pubertal anthropometrics;
CRC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-1.12	-10.15	-0.49	3e-21	Arsenic metabolism;
CRC	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.67	6.96	0.36	1.82e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.44	6.82	0.35	4.4e-11	Corneal astigmatism;
CRC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg03233332	chr7:66118400	NA	-0.41	-5.63	-0.3	3.93e-8	Aortic root size;
CRC	trans	rs587242	1.000	rs12740202	chr1:96905594	G/A	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.81	-0.35	4.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg17169982	chr17:80787973	TBCD;ZNF750	-0.44	-6.72	-0.35	7.98e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg15147215	chr3:52552868	STAB1	0.63	10.95	0.52	5.15e-24	Bipolar disorder;
CRC	cis	rs2160860	0.773	rs11773975	chr8:39797690	A/T	cg11363097	chr8:39792086	IDO2	-0.42	-7.25	-0.37	2.94e-12	Blood metabolite levels;
CRC	cis	rs11997175	0.713	rs4733454	chr8:33651253	C/A	ch.8.33884649F	chr8:33765107	NA	0.41	6.32	0.33	8.61e-10	Body mass index;
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.96	0.31	6.48e-9	Bipolar disorder;
CRC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.15	0.32	2.24e-9	Aortic root size;
CRC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24308560	chr3:49941425	MST1R	-0.47	-7.44	-0.38	9e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.51	8.79	0.44	8.69e-17	Testicular germ cell tumor;
CRC	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.44	7.4	0.38	1.12e-12	Diastolic blood pressure;
CRC	cis	rs4731207	0.564	rs7776821	chr7:124657504	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.43	-6.48	-0.34	3.26e-10	Height;
CRC	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Parkinson's disease;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18301423	chr5:131593218	PDLIM4	0.46	7.95	0.4	3.01e-14	Acylcarnitine levels;
CRC	trans	rs2303319	0.504	rs62187597	chr2:162398263	A/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Cognitive function;
CRC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.63	10.18	0.49	2.51e-21	Height;
CRC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.93	-11.84	-0.55	3.62e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.47	7.15	0.37	5.83e-12	Red blood cell count;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg16606324	chr3:10149918	C3orf24	0.66	7.77	0.39	9.99e-14	Alzheimer's disease;
CRC	cis	rs834811	0.523	rs4732180	chr7:135881462	T/C	cg01726295	chr7:135938950	NA	0.34	5.75	0.3	2.07e-8	Post-traumatic stress disorder;
CRC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg23283495	chr1:209979779	IRF6	0.48	6.82	0.35	4.49e-11	Cleft lip with or without cleft palate;
CRC	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.48	6.6	0.34	1.69e-10	Tuberculosis;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23721301	chr10:112064230	SMNDC1	0.4	6.37	0.33	6.27e-10	Interleukin-6 levels;
CRC	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.4	-0.33	5.34e-10	Neuroticism;
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.66	7.09	0.36	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19623624	chr10:135278901	LOC619207	-0.35	-5.75	-0.3	2.04e-8	Systemic lupus erythematosus;
CRC	cis	rs7264396	0.887	rs58458373	chr20:34045611	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.41	-0.33	5.12e-10	Total cholesterol levels;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg25164649	chr6:28176230	NA	0.66	9.43	0.46	7.69e-19	Parkinson's disease;
CRC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg04362960	chr10:104952993	NT5C2	-0.43	-6.04	-0.32	4.13e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg21770322	chr7:97807741	LMTK2	-0.51	-8.39	-0.42	1.5e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7605827	0.930	rs1318980	chr2:15549890	G/T	cg19274914	chr2:15703543	NA	0.38	5.68	0.3	2.91e-8	Educational attainment (years of education);
CRC	cis	rs17767392	0.756	rs11626445	chr14:71739134	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.58	-0.34	1.8e-10	Mitral valve prolapse;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00902873	chr3:127771089	SEC61A1	0.4	6.05	0.32	3.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.6	-9.42	-0.46	8.32e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.36	-6.03	-0.32	4.37e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg04999148	chr11:65188955	NEAT1	-0.52	-6.08	-0.32	3.3e-9	Type 1 diabetes;
CRC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00255919	chr5:131827918	IRF1	0.58	11.29	0.53	3.32e-25	Asthma (sex interaction);
CRC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.67	-9.06	-0.45	1.17e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-7.45	-0.38	8.38e-13	Menarche (age at onset);
CRC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.51	7.1	0.36	7.67e-12	Lymphocyte counts;
CRC	cis	rs7692995	1.000	rs6821168	chr4:18005019	A/C	cg08925142	chr4:18023851	LCORL	-0.55	-6.06	-0.32	3.73e-9	Height;
CRC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.82	0.4	7.47e-14	Colorectal cancer;
CRC	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.89	18.21	0.71	9.62e-52	Ulcerative colitis;
CRC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16395712	chr17:8339139	NDEL1	0.38	6.08	0.32	3.33e-9	Interleukin-6 levels;
CRC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.67	9.24	0.45	3.23e-18	Response to diuretic therapy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04193309	chr9:139980676	LOC100289341;MAN1B1	0.4	6.18	0.32	1.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.37	5.66	0.3	3.34e-8	Height;
CRC	cis	rs8020095	0.571	rs7156655	chr14:67356061	T/C	cg00791868	chr14:66963628	C14orf53	0.5	6.73	0.35	7.73e-11	Depression (quantitative trait);
CRC	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.86	11.37	0.53	1.77e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2882667	0.690	rs288012	chr5:138196273	C/T	cg09476006	chr5:138032270	NA	-0.56	-10.04	-0.48	7.36e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg05192639	chr6:26864778	GUSBL1	-0.35	-6.05	-0.32	3.97e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6076065	0.723	rs6137924	chr20:23366171	C/G	cg11657817	chr20:23433608	CST11	0.45	6.69	0.35	9.76e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7776786	0.934	rs13243526	chr7:18812917	C/T	cg13420273	chr7:18810212	HDAC9	-0.33	-6.42	-0.33	4.65e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1883415	0.591	rs10456305	chr6:24491341	C/T	cg20631270	chr6:24437470	GPLD1	-0.41	-6.4	-0.33	5.49e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.66	-11.21	-0.53	6.23e-25	Calcium levels;
CRC	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.65	9.4	0.46	9.64e-19	Platelet distribution width;
CRC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.51	8.12	0.41	9.59e-15	Red blood cell count;
CRC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg21854759	chr1:92012499	NA	-0.53	-8.76	-0.43	1.05e-16	Breast cancer;
CRC	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.58	-8.46	-0.42	8.83e-16	Vitiligo;
CRC	trans	rs2018683	0.649	rs221193	chr7:29015784	G/T	cg19402173	chr7:128379420	CALU	-0.45	-6.21	-0.32	1.59e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs2415984	0.519	rs2642102	chr14:46965502	A/G	cg14871534	chr14:47121158	RPL10L	0.4	5.96	0.31	6.64e-9	Number of children ever born;
CRC	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.38	6.58	0.34	1.85e-10	Systemic lupus erythematosus;
CRC	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.51	7.22	0.37	3.67e-12	Testicular germ cell tumor;
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg15790184	chr11:494944	RNH1	0.61	6.25	0.33	1.26e-9	Body mass index;
CRC	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14119001	chr9:139324193	INPP5E	-0.39	-5.85	-0.31	1.21e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.33	-7.19	-0.37	4.36e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.48	6.57	0.34	1.92e-10	Morning vs. evening chronotype;
CRC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg27535305	chr1:53392650	SCP2	0.34	6.36	0.33	6.57e-10	Monocyte count;
CRC	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.9	-11.63	-0.54	1.95e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.52	8.17	0.41	6.67e-15	Multiple system atrophy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03395546	chr19:41222599	ADCK4;ITPKC	0.45	7.0	0.36	1.45e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3026101	0.671	rs14231	chr17:5294976	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs7705042	0.865	rs6874308	chr5:141506911	C/T	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.84	-0.31	1.23e-8	Asthma;
CRC	cis	rs6908034	0.607	rs73376650	chr6:19805506	T/G	cg02682789	chr6:19804855	NA	0.8	6.74	0.35	6.9e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18247638	chr13:103451366	KDELC1;BIVM	0.5	7.39	0.38	1.21e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.08	26.22	0.82	1.39e-82	Testicular germ cell tumor;
CRC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.59	-10.45	-0.5	2.9e-22	Iron status biomarkers;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20092199	chr4:1342459	KIAA1530	0.46	8.28	0.42	3.11e-15	Longevity;
CRC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.95	18.2	0.71	1.07e-51	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.75e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs7209700	0.889	rs11079769	chr17:45349731	A/T	cg08085267	chr17:45401833	C17orf57	0.46	6.67	0.35	1.1e-10	IgG glycosylation;
CRC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.35	-6.7	-0.35	8.83e-11	Menarche (age at onset);
CRC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.29	0.53	3.35e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.36	-5.71	-0.3	2.48e-8	Blood metabolite levels;
CRC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.14e-24	Corneal astigmatism;
CRC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.82	-0.4	7.26e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.9	-16.61	-0.68	2.07e-45	Dementia with Lewy bodies;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04248937	chr5:1222847	SLC6A19	0.43	6.31	0.33	9.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.38	-6.85	-0.35	3.7e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4664293	0.867	rs13415100	chr2:160586227	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07139811	chr2:176033051	ATF2;MIR933	0.4	6.33	0.33	8e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.23	-0.37	3.42e-12	Inflammatory skin disease;
CRC	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.63	8.27	0.41	3.43e-15	Breast cancer;
CRC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.46	-7.18	-0.37	4.7e-12	Obesity-related traits;
CRC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.39	6.59	0.34	1.73e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7429990	0.965	rs4392441	chr3:48077701	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.82	-0.31	1.42e-8	Educational attainment (years of education);
CRC	cis	rs2070997	0.756	rs7872328	chr9:133727453	T/A	cg01000188	chr9:133769184	QRFP	0.5	5.92	0.31	8.28e-9	Response to amphetamines;
CRC	cis	rs7932354	0.528	rs10769234	chr11:47084061	G/C	cg19486271	chr11:47235900	DDB2	-0.45	-6.46	-0.34	3.8e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.88	14.32	0.62	1.81e-36	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.51	0.5	1.88e-22	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22727364	chr8:126443014	TRIB1	0.39	6.13	0.32	2.57e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1178968	0.901	rs2353066	chr7:72755791	T/G	cg25889504	chr7:72793014	NA	0.51	5.82	0.31	1.37e-8	Triglyceride levels;
CRC	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.06e-12	HDL cholesterol;
CRC	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.63	-8.86	-0.44	5.27e-17	White matter hyperintensity burden;
CRC	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.73	9.76	0.47	6.14e-20	Prostate cancer;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03188948	chr7:1209495	NA	-0.45	-6.48	-0.34	3.25e-10	Longevity;Endometriosis;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg02683197	chr6:28174875	NA	0.62	8.36	0.42	1.78e-15	Parkinson's disease;
CRC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg19046167	chr17:80928561	B3GNTL1	0.48	8.11	0.41	1.01e-14	Breast cancer;
CRC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg21724239	chr8:58056113	NA	0.56	7.26	0.37	2.79e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.73	-8.37	-0.42	1.66e-15	Obesity-related traits;
CRC	cis	rs7605827	0.930	rs765432	chr2:15561440	C/T	cg19274914	chr2:15703543	NA	-0.42	-6.33	-0.33	7.8e-10	Educational attainment (years of education);
CRC	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg11130432	chr3:121712080	ILDR1	-0.5	-6.14	-0.32	2.33e-9	Multiple sclerosis;
CRC	cis	rs72772090	0.539	rs72773981	chr5:96156059	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-5.68	-0.3	2.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.42	-6.1	-0.32	2.99e-9	Aortic root size;
CRC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.48	7.43	0.38	9.4e-13	Corneal astigmatism;
CRC	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-7.66	-0.39	2.11e-13	Schizophrenia;
CRC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg03037974	chr15:76606532	NA	0.7	12.45	0.57	2.07e-29	Blood metabolite levels;
CRC	cis	rs9905704	0.627	rs1267544	chr17:56643398	T/G	cg12560992	chr17:57184187	TRIM37	-0.51	-6.03	-0.32	4.46e-9	Testicular germ cell tumor;
CRC	cis	rs11958404	0.932	rs72816598	chr5:157436017	G/A	cg05962755	chr5:157440814	NA	0.95	12.36	0.56	4.48e-29	IgG glycosylation;
CRC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.99	-19.73	-0.74	9.59e-58	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	9.72	0.47	8.35e-20	Breast cancer;
CRC	cis	rs356992	0.915	rs356977	chr2:60748758	A/G	cg08426369	chr2:60753602	BCL11A	0.52	7.09	0.36	8.1e-12	Educational attainment (years of education);
CRC	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg26182253	chr13:112236782	NA	0.31	6.23	0.32	1.4e-9	Hepatitis;
CRC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.43	6.69	0.35	9.9e-11	Red blood cell count;
CRC	cis	rs12692738	0.526	rs355831	chr2:165616757	C/A	cg03182029	chr2:165697222	COBLL1	0.48	5.66	0.3	3.32e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.65	8.58	0.43	3.84e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05518842	chr16:1823291	MRPS34;EME2	0.42	7.75	0.39	1.12e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.5	7.75	0.39	1.13e-13	Red blood cell count;
CRC	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg06307176	chr5:131281290	NA	0.42	6.37	0.33	6.44e-10	Life satisfaction;
CRC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.59	9.2	0.45	4.36e-18	Height;
CRC	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07513332	chr6:167530253	CCR6	0.34	6.0	0.31	5.15e-9	Crohn's disease;
CRC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.88	-12.77	-0.58	1.29e-30	Blood pressure (smoking interaction);
CRC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.81	10.86	0.51	1.08e-23	Cerebrospinal P-tau181p levels;
CRC	cis	rs7429990	0.931	rs62262084	chr3:47653822	C/T	cg11946769	chr3:48343235	NME6	0.5	5.7	0.3	2.67e-8	Educational attainment (years of education);
CRC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	7.08	0.36	8.68e-12	Hip circumference adjusted for BMI;
CRC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg08648136	chr8:956695	NA	0.3	5.77	0.3	1.85e-8	Schizophrenia;
CRC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	8.03	0.4	1.72e-14	Total body bone mineral density;
CRC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.42	-5.71	-0.3	2.54e-8	Vitiligo;
CRC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Primary biliary cholangitis;
CRC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.44	0.38	8.69e-13	Menopause (age at onset);
CRC	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.5	8.93	0.44	2.97e-17	Body mass index (alcohol intake interaction);
CRC	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.64	10.43	0.5	3.48e-22	Breast cancer;
CRC	cis	rs4700695	0.841	rs251608	chr5:65247893	C/T	cg21114390	chr5:65439923	SFRS12	0.5	6.21	0.32	1.57e-9	Facial morphology (factor 19);
CRC	cis	rs3764400	0.567	rs8079616	chr17:46213488	C/T	cg10706073	chr17:46328419	SKAP1	0.62	6.52	0.34	2.7e-10	Body mass index;
CRC	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.71	-0.43	1.54e-16	Coronary artery disease;
CRC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.74	12.1	0.55	3.95e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04579211	chr15:41221939	DLL4	0.49	7.08	0.36	8.81e-12	Response to antipsychotic treatment;
CRC	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.74	-10.26	-0.49	1.32e-21	Blood protein levels;
CRC	cis	rs7259376	0.875	rs4932755	chr19:22494816	A/G	cg02657401	chr19:22469223	NA	-0.36	-7.96	-0.4	2.85e-14	Menopause (age at onset);
CRC	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.97	-0.36	1.78e-11	QT interval;
CRC	cis	rs12760731	0.565	rs12406779	chr1:178088936	C/G	cg00404053	chr1:178313656	RASAL2	1.06	11.28	0.53	3.63e-25	Obesity-related traits;
CRC	cis	rs2786111	0.965	rs1764622	chr1:197282079	T/C	cg13682187	chr1:196946512	CFHR5	0.29	5.71	0.3	2.47e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23868848	chr8:128806661	PVT1	-0.39	-6.17	-0.32	1.98e-9	Myopia (pathological);
CRC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg03013999	chr17:37608204	MED1	-0.47	-7.35	-0.38	1.61e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.47	6.38	0.33	6.16e-10	Cholesterol, total;
CRC	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.95	-0.31	6.9e-9	Educational attainment;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg15786705	chr6:28176104	NA	0.68	10.18	0.49	2.51e-21	Cardiac Troponin-T levels;
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg06470822	chr6:28175283	NA	0.65	9.68	0.47	1.16e-19	Cardiac Troponin-T levels;
CRC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.94	11.01	0.52	3.17e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.97	-0.44	2.23e-17	Bipolar disorder;
CRC	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg03938978	chr2:103052716	IL18RAP	0.36	5.92	0.31	7.92e-9	Asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24350612	chr8:73921026	TERF1	0.42	5.97	0.31	6.08e-9	Anxiety disorder;
CRC	cis	rs294883	0.701	rs2007263	chr6:159735074	G/A	cg14500486	chr6:159655392	FNDC1	-0.36	-5.87	-0.31	1.08e-8	Coronary artery disease;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg02683197	chr6:28174875	NA	0.52	6.04	0.32	4.06e-9	Breast cancer;
CRC	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.62	-0.3	3.98e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.78	7.82	0.4	7.47e-14	Diabetic retinopathy;
CRC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.7	-0.43	1.57e-16	Alcohol dependence;
CRC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.84	-0.51	1.32e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg23262073	chr20:60523788	NA	-0.37	-5.83	-0.31	1.31e-8	Body mass index;
CRC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg11189052	chr15:85197271	WDR73	0.62	8.86	0.44	4.93e-17	Schizophrenia;
CRC	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg27398640	chr15:77910606	LINGO1	-0.43	-7.44	-0.38	9.03e-13	Type 2 diabetes;
CRC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.94	-15.49	-0.65	4.94e-41	Longevity;
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg03948781	chr1:205179583	DSTYK	0.41	5.62	0.3	4.02e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg02428538	chr16:24856791	SLC5A11	-0.54	-6.4	-0.33	5.49e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06656553	chr16:89960601	TCF25	-0.69	-5.73	-0.3	2.33e-8	Skin colour saturation;
CRC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.67	-11.11	-0.52	1.46e-24	Hepatocellular carcinoma;
CRC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.72	-8.15	-0.41	7.73e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-8.39	-0.42	1.41e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	11.1	0.52	1.62e-24	Motion sickness;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.2	-0.41	5.49e-15	Mean platelet volume;Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00448143	chr16:56703788	MT1H	0.36	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg16447950	chr5:562315	NA	-0.84	-12.37	-0.56	4.19e-29	Obesity-related traits;
CRC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.9	16.37	0.67	1.74e-44	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.51	-0.57	1.25e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg08924777	chr16:48278166	LONP2	0.52	5.99	0.31	5.58e-9	Kashin-Beck disease;
CRC	cis	rs3751196	0.803	rs12422701	chr12:104185661	A/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.25	0.37	2.92e-12	Sense of smell;
CRC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.53	8.82	0.44	6.94e-17	Schizophrenia;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.64	0.34	1.29e-10	Depression;
CRC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.88	0.44	4.28e-17	Morning vs. evening chronotype;
CRC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.6	9.24	0.45	3.17e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg06238570	chr21:40685208	BRWD1	-0.7	-9.95	-0.48	1.42e-20	Cognitive function;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg13047869	chr3:10149882	C3orf24	0.48	6.78	0.35	5.47e-11	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.48	-0.46	5.06e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.51	7.12	0.37	6.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04385144	chr22:27053419	MIAT	0.34	6.0	0.31	5.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg21285383	chr16:89894308	SPIRE2	0.37	6.21	0.32	1.62e-9	Vitiligo;
CRC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-0.86	-12.69	-0.57	2.63e-30	IgG glycosylation;
CRC	cis	rs800160	0.668	rs10734191	chr11:2341002	C/T	cg09785033	chr11:2336066	TSPAN32	-0.48	-5.61	-0.3	4.3e-8	Bacteremia;
CRC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.98	0.4	2.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg20159608	chr7:32802032	NA	0.56	7.42	0.38	1e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.95	10.93	0.52	6.22e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.58	-0.47	2.56e-19	Heart rate;
CRC	cis	rs6681460	1.000	rs1445575	chr1:67052164	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.17	0.41	6.69e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.41	0.53	1.27e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-8.95	-0.44	2.61e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.34	0.42	2.09e-15	Rheumatoid arthritis;
CRC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.53	5.7	0.3	2.69e-8	Lung cancer (smoking interaction);
CRC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.07	-0.36	9.17e-12	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24580635	chr7:76178542	LOC100133091	0.4	6.32	0.33	8.56e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg00666640	chr1:248458726	OR2T12	0.35	6.62	0.34	1.49e-10	Common traits (Other);
CRC	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.85	-0.55	3.21e-27	Colorectal cancer;
CRC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg25834613	chr7:1915315	MAD1L1	-0.42	-6.04	-0.32	4.24e-9	Bipolar disorder;
CRC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.2	0.37	4.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg06470822	chr6:28175283	NA	0.99	13.01	0.58	1.7e-31	Depression;
CRC	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.51	6.71	0.35	8.67e-11	Coronary artery disease;
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg04800585	chr6:26043546	HIST1H2BB	0.54	8.29	0.42	2.96e-15	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18099408	chr3:52552593	STAB1	-0.39	-5.72	-0.3	2.44e-8	Bipolar disorder;
CRC	cis	rs2737618	0.722	rs2821330	chr1:200082464	C/T	cg21825944	chr1:200113062	NR5A2	0.47	6.48	0.34	3.26e-10	Uric acid levels;
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.66	-0.39	2.03e-13	Total body bone mineral density;
CRC	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg12856521	chr11:46389249	DGKZ	0.81	9.93	0.48	1.73e-20	Crohn's disease;
CRC	cis	rs911555	0.547	rs8006994	chr14:103841296	C/T	cg12935359	chr14:103987150	CKB	-0.51	-8.02	-0.4	1.84e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-8.04	-0.41	1.58e-14	Menarche (age at onset);
CRC	cis	rs1712517	0.525	rs11191642	chr10:105055912	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-6.15	-0.32	2.29e-9	Migraine;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg21251018	chr6:28226885	NKAPL	0.46	6.46	0.34	3.67e-10	Parkinson's disease;
CRC	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg12072164	chr19:44306565	LYPD5	0.39	6.14	0.32	2.36e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg08936952	chr14:74026160	HEATR4	-0.38	-5.6	-0.3	4.49e-8	Blood metabolite ratios;
CRC	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.51	9.18	0.45	4.87e-18	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg20487152	chr13:99095054	FARP1	0.35	5.63	0.3	3.95e-8	Longevity;
CRC	cis	rs16975963	0.843	rs75802547	chr19:38393321	C/T	cg15135657	chr19:38346511	NA	-0.44	-5.88	-0.31	9.82e-9	Longevity;
CRC	trans	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg07211511	chr3:129823064	LOC729375	-0.44	-6.06	-0.32	3.68e-9	Blood pressure (smoking interaction);
CRC	cis	rs2625529	0.590	rs8023703	chr15:72504059	G/A	cg16672083	chr15:72433130	SENP8	0.39	5.65	0.3	3.46e-8	Red blood cell count;
CRC	trans	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-7.42	-0.38	1.03e-12	Menarche (age at onset);
CRC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg00343986	chr7:65444356	GUSB	0.44	6.46	0.34	3.84e-10	Aortic root size;
CRC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.53	7.72	0.39	1.38e-13	Mean platelet volume;
CRC	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.46	6.35	0.33	7.26e-10	Uric acid levels;
CRC	cis	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg03623178	chr6:28175578	NA	0.83	6.72	0.35	7.91e-11	Depression;
CRC	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.96	13.36	0.59	7.92e-33	Breast cancer;
CRC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.26	0.71	6.46e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12024301	0.557	rs6668853	chr1:183608040	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg01305625	chr5:131593812	PDLIM4	0.32	5.65	0.3	3.47e-8	Blood metabolite levels;
CRC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.62	10.4	0.5	4.48e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.58	-5.84	-0.31	1.27e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-0.91	-12.41	-0.56	2.95e-29	Vitiligo;
CRC	cis	rs13144136	0.748	rs4697774	chr4:10670461	A/G	cg10242279	chr4:10666415	CLNK	-0.33	-5.64	-0.3	3.74e-8	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	17.67	0.7	1.31e-49	Platelet count;
CRC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.05	12.34	0.56	5.22e-29	Vitiligo;
CRC	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.65e-9	Life satisfaction;
CRC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.67	-7.86	-0.4	5.54e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.61	10.11	0.49	4.34e-21	Monocyte count;
CRC	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.61	8.8	0.44	7.61e-17	Schizophrenia;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.52	9.68	0.47	1.19e-19	Acylcarnitine levels;
CRC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	9.13	0.45	7.28e-18	Eosinophil percentage of white cells;
CRC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg05709478	chr1:6581295	PLEKHG5	0.58	7.71	0.39	1.52e-13	Body mass index;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.39	-6.98	-0.36	1.66e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.5	-7.63	-0.39	2.51e-13	Aortic root size;
CRC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.76	-15.66	-0.65	1.1e-41	Refractive error;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03397750	chr1:51810503	TTC39A	0.41	6.77	0.35	6e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.31	6.61	0.34	1.57e-10	Educational attainment (years of education);
CRC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.44	6.71	0.35	8.71e-11	Coronary artery disease;
CRC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.69	-8.23	-0.41	4.32e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg10523679	chr1:76189770	ACADM	-0.41	-5.81	-0.31	1.46e-8	Daytime sleep phenotypes;
CRC	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg14092571	chr14:90743983	NA	0.38	5.92	0.31	8.07e-9	Mortality in heart failure;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg02683197	chr6:28174875	NA	0.51	7.08	0.36	8.59e-12	Cardiac Troponin-T levels;
CRC	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.18	-0.37	4.6e-12	Capecitabine sensitivity;
CRC	trans	rs13434995	0.842	rs73236149	chr4:56373474	C/T	cg05873268	chr16:1290058	TPSAB1	-0.43	-6.24	-0.33	1.35e-9	Adiponectin levels;
CRC	cis	rs939584	1.000	rs2903489	chr2:649638	C/T	cg03610516	chr2:642275	NA	-0.41	-5.7	-0.3	2.65e-8	Body mass index;
CRC	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg27398640	chr15:77910606	LINGO1	0.37	6.43	0.33	4.39e-10	Type 2 diabetes;
CRC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg03060546	chr3:49711283	APEH	0.44	6.37	0.33	6.21e-10	Menarche (age at onset);
CRC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg05203877	chr14:70655686	SLC8A3	-0.35	-6.7	-0.35	9.2e-11	Prostate cancer;
CRC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.65	0.39	2.21e-13	Schizophrenia;
CRC	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg24344662	chr13:114018021	GRTP1	-0.42	-6.46	-0.34	3.78e-10	Mean platelet volume;
CRC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg25811766	chr13:21894605	NA	-0.56	-6.01	-0.31	4.93e-9	White matter hyperintensity burden;
CRC	trans	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg17903999	chr18:56338584	MALT1	0.4	6.69	0.35	9.66e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	6.98	0.36	1.59e-11	Ulcerative colitis;
CRC	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-0.66	-7.78	-0.39	9.25e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.43	5.82	0.31	1.43e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.49	-7.32	-0.37	1.91e-12	DNA methylation (variation);
CRC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.61	-8.56	-0.43	4.52e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg19980929	chr12:42632907	YAF2	0.48	7.47	0.38	7.34e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.77	-0.47	5.69e-20	Height;
CRC	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.61	-8.44	-0.42	1e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg11189052	chr15:85197271	WDR73	0.57	8.22	0.41	4.83e-15	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20418281	chr17:27717751	TAOK1	0.45	6.22	0.32	1.53e-9	Anxiety disorder;
CRC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg15382696	chr6:118971807	C6orf204	0.56	6.86	0.35	3.34e-11	Diastolic blood pressure;
CRC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.4	-0.71	1.66e-52	Schizophrenia;
CRC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg16141378	chr3:129829833	LOC729375	0.44	6.91	0.36	2.59e-11	Systolic blood pressure;
CRC	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.14	-23.94	-0.8	4.92e-74	Exhaled nitric oxide output;
CRC	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.38	6.2	0.32	1.7e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CRC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg14784868	chr12:69753453	YEATS4	0.46	5.84	0.31	1.27e-8	Response to diuretic therapy;
CRC	cis	rs11212617	0.967	rs227054	chr11:108257943	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.01	0.31	4.91e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs995000	0.931	rs1168097	chr1:63120371	C/T	cg19896129	chr1:63156450	NA	-0.41	-6.23	-0.33	1.39e-9	Triglyceride levels;
CRC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.18	0.37	4.6e-12	Life satisfaction;
CRC	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.55	0.47	3.15e-19	Common traits (Other);
CRC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.58	9.19	0.45	4.54e-18	Blood metabolite levels;
CRC	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.44	-6.95	-0.36	1.99e-11	Asthma;
CRC	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg16141378	chr3:129829833	LOC729375	-0.41	-6.02	-0.31	4.57e-9	Retinal vascular caliber;
CRC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.65	-0.3	3.44e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	13.66	0.6	6.07e-34	Hypertriglyceridemia;
CRC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.55	7.93	0.4	3.44e-14	Obesity-related traits;
CRC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg11130432	chr3:121712080	ILDR1	0.47	5.93	0.31	7.58e-9	Multiple sclerosis;
CRC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.56	9.33	0.46	1.6e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg25456477	chr12:86230367	RASSF9	-0.34	-5.83	-0.31	1.31e-8	Major depressive disorder;
CRC	cis	rs4731207	0.698	rs16871295	chr7:124461288	C/G	cg23710748	chr7:124431027	NA	0.37	6.05	0.32	4e-9	Cutaneous malignant melanoma;
CRC	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.99	-18.63	-0.72	2.21e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	0.94	11.83	0.55	3.85e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg12365402	chr11:9010492	NRIP3	0.48	7.84	0.4	6.53e-14	Hemoglobin concentration;
CRC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	14.71	0.63	5.4e-38	Mean corpuscular hemoglobin;
CRC	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg04176472	chr15:90893244	GABARAPL3	0.34	6.01	0.31	4.91e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.54	-0.34	2.41e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg04586622	chr2:25135609	ADCY3	-0.57	-9.57	-0.47	2.57e-19	Body mass index;
CRC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.69	-11.87	-0.55	2.62e-27	P wave terminal force;
CRC	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.45	-7.26	-0.37	2.77e-12	Refractive error;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04475877	chr11:2951676	PHLDA2	0.39	6.01	0.31	4.83e-9	Myopia (pathological);
CRC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.66	-8.08	-0.41	1.25e-14	Initial pursuit acceleration;
CRC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.71	12.25	0.56	1.07e-28	Longevity;
CRC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg26695010	chr11:65641043	EFEMP2	-0.4	-5.79	-0.3	1.67e-8	Eosinophil percentage of white cells;
CRC	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.51	6.42	0.33	4.86e-10	Late-onset Alzheimer's disease;
CRC	cis	rs728616	0.681	rs36023925	chr10:81906846	T/C	cg05935833	chr10:81318306	SFTPA2	-0.57	-6.61	-0.34	1.59e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.55	8.52	0.43	5.79e-16	Aortic root size;
CRC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg07701084	chr6:150067640	NUP43	0.5	6.89	0.36	2.86e-11	Lung cancer;
CRC	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.46	-7.16	-0.37	5.14e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg07090678	chr1:91966139	CDC7	0.42	6.92	0.36	2.35e-11	Breast cancer;
CRC	cis	rs10971721	0.822	rs72725387	chr9:33863671	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg18876405	chr7:65276391	NA	0.44	6.21	0.32	1.58e-9	Aortic root size;
CRC	trans	rs1413885	1.000	rs10789181	chr1:65816567	A/G	cg26534493	chr8:28060551	NA	-0.38	-6.14	-0.32	2.32e-9	Anticoagulant levels;
CRC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.41	6.55	0.34	2.26e-10	Dupuytren's disease;
CRC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.53	8.89	0.44	4.06e-17	Systemic lupus erythematosus;
CRC	cis	rs6973256	0.897	rs2911495	chr7:133331405	T/C	cg10665199	chr7:133106180	EXOC4	-0.37	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6693567	0.874	rs698915	chr1:150388318	C/T	cg17724175	chr1:150552817	MCL1	0.48	7.16	0.37	5.41e-12	Migraine;
CRC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.91e-9	Arsenic metabolism;
CRC	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.75	-9.96	-0.48	1.36e-20	White matter hyperintensity burden;
CRC	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.57	8.95	0.44	2.74e-17	HDL cholesterol;
CRC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	9.37	0.46	1.16e-18	Schizophrenia;
CRC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs9648716	1.000	rs10244133	chr7:140603329	G/T	cg10747023	chr7:140774559	NA	0.44	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg11886554	chr3:170076028	SKIL	0.72	8.13	0.41	8.58e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.57	8.9	0.44	3.96e-17	Type 2 diabetes;
CRC	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg05049329	chr1:226924846	ITPKB	0.41	9.05	0.45	1.29e-17	Parkinson's disease;
CRC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.65	11.95	0.55	1.41e-27	Aortic root size;
CRC	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.89e-8	Prostate cancer;
CRC	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.27	-0.33	1.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.74	-0.35	7.11e-11	Monocyte percentage of white cells;
CRC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.26	0.41	3.49e-15	Menopause (age at onset);
CRC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.54	-0.38	4.51e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.97	-20.74	-0.75	1.06e-61	Metabolite levels;
CRC	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.64	-10.85	-0.51	1.19e-23	Mosquito bite size;
CRC	cis	rs7074356	0.704	rs1417220	chr10:82168154	G/A	cg27171509	chr10:82033454	MAT1A	-0.45	-7.78	-0.39	9.46e-14	Borderline personality disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06041595	chr7:140714854	MRPS33	0.41	6.59	0.34	1.77e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00949670	chr12:120967105	COQ5	0.43	6.22	0.32	1.5e-9	Response to antipsychotic treatment;
CRC	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.1	-0.32	2.95e-9	Triglycerides;
CRC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.41	6.49	0.34	3.15e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg00691999	chr4:55094011	PDGFRA	0.42	6.02	0.31	4.75e-9	Corneal astigmatism;
CRC	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.63	0.65	1.44e-41	Fuchs's corneal dystrophy;
CRC	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.77	-12.25	-0.56	1.16e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg02290350	chr8:58132656	NA	-0.45	-5.75	-0.3	2.02e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.83e-9	Depression;
CRC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.51	-0.42	6.33e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg04497992	chr16:616212	NHLRC4	0.43	6.84	0.35	3.8e-11	Height;
CRC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.55	9.25	0.45	2.82e-18	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26228351	chr1:200992656	KIF21B	0.44	6.14	0.32	2.37e-9	Anxiety disorder;
CRC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg11212589	chr17:38028394	ZPBP2	0.37	6.14	0.32	2.33e-9	Asthma;
CRC	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.98	8.06	0.41	1.41e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.47	6.92	0.36	2.32e-11	Blood metabolite levels;
CRC	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.75	-12.14	-0.56	2.74e-28	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.34	2.93e-10	Bipolar disorder;
CRC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.38	0.42	1.6e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg03013999	chr17:37608204	MED1	-0.46	-6.85	-0.35	3.7e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.76	14.31	0.62	1.87e-36	Prudent dietary pattern;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.36	-6.07	-0.32	3.54e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	trans	rs8064024	0.508	rs2037912	chr16:4933939	G/C	cg19252218	chr17:41477271	ARL4D	-0.41	-5.99	-0.31	5.44e-9	Cancer;
CRC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.9	-10.05	-0.48	6.51e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg03013999	chr17:37608204	MED1	-0.48	-7.43	-0.38	9.53e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg09323728	chr8:95962352	TP53INP1	0.43	6.94	0.36	2.15e-11	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22708233	chr11:47198576	ARFGAP2	0.41	7.16	0.37	5.22e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg23807890	chr2:228736357	WDR69	-0.47	-6.54	-0.34	2.36e-10	Blood pressure;
CRC	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.26	0.33	1.22e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg06972903	chr1:6580525	PLEKHG5	0.43	5.64	0.3	3.6e-8	Body mass index;
CRC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	7.91	0.4	4e-14	Schizophrenia;
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.36	0.33	6.76e-10	Life satisfaction;
CRC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.77	-10.47	-0.5	2.5e-22	Height;
CRC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg03032677	chr6:36648794	CDKN1A	0.41	6.16	0.32	2.17e-9	QRS duration;
CRC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.76	-12.47	-0.57	1.69e-29	Red cell distribution width;Reticulocyte count;
CRC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	15.05	0.64	2.59e-39	Multiple sclerosis;
CRC	cis	rs12143943	0.966	rs3795567	chr1:204585738	A/G	cg17419461	chr1:204415978	PIK3C2B	0.38	6.0	0.31	5.26e-9	Cognitive performance;
CRC	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.05	-0.41	1.52e-14	Neuroticism;
CRC	trans	rs9885413	0.502	rs13362072	chr5:110280203	C/G	cg13894719	chr4:56534223	NA	-0.56	-6.01	-0.31	4.8e-9	Mortality in heart failure;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.61	9.69	0.47	1.03e-19	Longevity;Endometriosis;
CRC	cis	rs7215564	0.908	rs2316061	chr17:78663660	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.17	0.32	1.97e-9	Myopia (pathological);
CRC	cis	rs6504622	0.935	rs17608961	chr17:45029668	G/T	cg16759221	chr17:45003025	GOSR2	0.46	7.25	0.37	3.09e-12	Orofacial clefts;
CRC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.37	5.74	0.3	2.14e-8	Hemoglobin concentration;
CRC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.5	8.33	0.42	2.18e-15	Systemic lupus erythematosus;
CRC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.81	-12.15	-0.56	2.69e-28	Multiple myeloma;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg27532560	chr4:187881888	NA	-0.56	-10.26	-0.49	1.31e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.79	10.13	0.49	3.74e-21	Migraine;
CRC	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.48	-8.78	-0.44	8.85e-17	Educational attainment (years of education);
CRC	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.26	15.74	0.66	5.34e-42	Uric acid levels;
CRC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.47	-6.6	-0.34	1.66e-10	Multiple myeloma;
CRC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.07	-0.32	3.56e-9	Bipolar disorder;
CRC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.55	8.3	0.42	2.77e-15	Resting heart rate;
CRC	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.23	0.41	4.32e-15	Neuroticism;
CRC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-11.45	-0.53	8.76e-26	Monocyte percentage of white cells;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.78	13.08	0.58	8.95e-32	Longevity;Endometriosis;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12172441	chr6:28176163	NA	0.69	9.19	0.45	4.69e-18	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00381330	chr20:25228575	PYGB	0.46	6.31	0.33	8.81e-10	Response to antipsychotic treatment;
CRC	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-5.89	-0.31	9.34e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.75	0.3	2e-8	HDL cholesterol;
CRC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	9.11	0.45	8.42e-18	Schizophrenia;
CRC	trans	rs800082	0.934	rs6788831	chr3:144290498	G/T	cg24215973	chr2:240111563	HDAC4	-0.54	-7.68	-0.39	1.85e-13	Smoking behavior;
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg15790184	chr11:494944	RNH1	0.59	6.1	0.32	2.95e-9	Body mass index;
CRC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.62	0.39	2.74e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.42	-0.53	1.17e-25	Ulcerative colitis;
CRC	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.84e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	0.73	8.07	0.41	1.31e-14	Gout;Renal underexcretion gout;
CRC	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.29	-6.33	-0.33	8.24e-10	Total body bone mineral density;
CRC	cis	rs10229583	0.527	rs1440971	chr7:127272400	C/T	cg01233922	chr7:127693937	SND1	0.47	6.91	0.36	2.57e-11	Type 2 diabetes;
CRC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.72	-7.47	-0.38	7.09e-13	Inflammatory biomarkers;
CRC	cis	rs7301826	0.651	rs7132657	chr12:131285187	T/C	cg11011512	chr12:131303247	STX2	0.39	5.75	0.3	2.04e-8	Plasma plasminogen activator levels;
CRC	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.61	9.89	0.48	2.34e-20	Itch intensity from mosquito bite;
CRC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.95	13.75	0.6	2.59e-34	Breast cancer;
CRC	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.46	6.66	0.34	1.16e-10	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03934443	chr10:134639821	NA	-0.37	-6.0	-0.31	5.21e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06307176	chr5:131281290	NA	0.42	6.23	0.32	1.45e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg00531865	chr16:30841666	NA	-0.41	-5.91	-0.31	8.45e-9	Dementia with Lewy bodies;
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.52	9.43	0.46	7.81e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.83	14.21	0.62	4.78e-36	Monocyte count;
CRC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.88	0.55	2.61e-27	Bone mineral density;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17470723	chr8:74884337	TCEB1	-0.4	-5.99	-0.31	5.39e-9	Myopia (pathological);
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-7.17	-0.37	4.95e-12	Total body bone mineral density;
CRC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.79	-8.93	-0.44	2.98e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg16691251	chr5:66510806	NA	0.42	7.32	0.37	1.94e-12	Breast cancer;
CRC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.56	-15.11	-0.64	1.48e-39	Urate levels in overweight individuals;
CRC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.51	7.67	0.39	1.93e-13	Intelligence (multi-trait analysis);
CRC	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.46	7.55	0.38	4.27e-13	Alcohol dependence (age at onset);
CRC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.51	-7.61	-0.39	2.89e-13	DNA methylation (variation);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08267591	chr2:165693745	COBLL1	0.39	6.27	0.33	1.11e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08990198	chr1:202318195	PPP1R12B	0.56	7.24	0.37	3.16e-12	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg02741985	chr17:80059408	CCDC57	0.42	6.99	0.36	1.51e-11	Life satisfaction;
CRC	cis	rs2274273	0.905	rs4652	chr14:55605036	A/C	cg23234261	chr14:55582407	NA	-0.3	-5.91	-0.31	8.46e-9	Protein biomarker;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14458654	chr3:174095293	NA	-0.38	-6.32	-0.33	8.46e-10	Obesity-related traits;
CRC	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.43	6.4	0.33	5.27e-10	Neutrophil percentage of white cells;
CRC	cis	rs2249694	1.000	rs4240522	chr10:135355557	C/T	cg20169779	chr10:135381914	SYCE1	0.59	9.5	0.46	4.48e-19	Obesity-related traits;
CRC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg14541582	chr5:601475	NA	-0.36	-7.37	-0.38	1.42e-12	Obesity-related traits;
CRC	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.46	6.59	0.34	1.71e-10	Macular telangiectasia type 2;
CRC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.47	7.94	0.4	3.16e-14	Childhood ear infection;
CRC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.08	-0.41	1.29e-14	Height;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg21204522	chr6:27730016	NA	-0.41	-5.63	-0.3	3.86e-8	Parkinson's disease;
CRC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07701084	chr6:150067640	NUP43	0.49	6.79	0.35	5.19e-11	Lung cancer;
CRC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.52	10.02	0.48	8.14e-21	Urate levels in lean individuals;
CRC	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.74	7.38	0.38	1.29e-12	Severe influenza A (H1N1) infection;
CRC	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.94	-17.85	-0.7	2.56e-50	Height;
CRC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.91	-16.65	-0.68	1.46e-45	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21813546	chr1:182808991	DHX9	0.52	7.4	0.38	1.12e-12	Response to antipsychotic treatment;
CRC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg01941586	chr1:40203715	PPIE	-0.42	-5.84	-0.31	1.24e-8	Blood protein levels;
CRC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.08	0.32	3.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.74	-9.02	-0.45	1.64e-17	Blood protein levels;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg21251018	chr6:28226885	NKAPL	0.38	5.62	0.3	3.99e-8	Parkinson's disease;
CRC	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.79	-0.35	5.1e-11	Coronary artery disease;
CRC	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.73	11.89	0.55	2.4e-27	Birth weight;
CRC	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.76	9.3	0.46	2.08e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.6	9.12	0.45	7.81e-18	Menopause (age at onset);
CRC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25517755	chr10:38738941	LOC399744	-0.45	-6.47	-0.34	3.64e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.02	23.29	0.79	1.49e-71	Multiple system atrophy;
CRC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg07636037	chr3:49044803	WDR6	-0.74	-6.14	-0.32	2.39e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg05585544	chr11:47624801	NA	-0.52	-9.17	-0.45	5.19e-18	Subjective well-being;
CRC	cis	rs2062225	1.000	rs1483533	chr2:111757918	T/C	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.36	6.38	0.33	5.87e-10	Dilated cardiomyopathy;
CRC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg03037974	chr15:76606532	NA	0.75	13.59	0.6	1.11e-33	Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs6431708	chr2:15638175	C/T	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.5	-9.49	-0.46	4.89e-19	Alcohol dependence;
CRC	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.4	-7.4	-0.38	1.14e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg25985355	chr7:65971099	NA	0.52	5.95	0.31	6.88e-9	Gout;
CRC	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg16540259	chr10:75572220	NDST2	0.39	5.96	0.31	6.52e-9	Inflammatory bowel disease;
CRC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.73	12.62	0.57	4.89e-30	Longevity;
CRC	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg15192750	chr16:69999425	NA	0.57	7.53	0.38	4.78e-13	IgE levels;
CRC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.43	0.38	9.47e-13	Motion sickness;
CRC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.81	0.44	7.32e-17	Rheumatoid arthritis;
CRC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.68	0.39	1.84e-13	Axial length;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02685901	chr6:43597772	MAD2L1BP;GTPBP2	0.49	6.42	0.33	4.71e-10	Thyroid stimulating hormone;
CRC	cis	rs12476592	0.602	rs262508	chr2:63885280	G/C	cg10828910	chr2:63850056	LOC388955	0.51	6.44	0.33	4.22e-10	Childhood ear infection;
CRC	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg10279832	chr4:154682576	RNF175	0.37	5.66	0.3	3.37e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs1545257	0.505	rs2584950	chr2:24632762	A/G	cg06627628	chr2:24431161	ITSN2	-0.45	-6.63	-0.34	1.34e-10	Sjögren's syndrome;
CRC	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.47	9.52	0.46	3.79e-19	Schizophrenia;
CRC	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.69	11.75	0.54	7.67e-27	Coronary artery disease;
CRC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.75	11.02	0.52	3.07e-24	High light scatter reticulocyte count;
CRC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg24550644	chr17:30846204	MYO1D	-0.4	-7.1	-0.36	7.91e-12	Schizophrenia;
CRC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	7.74	0.39	1.22e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.63	-7.24	-0.37	3.19e-12	Vitiligo;
CRC	cis	rs9311676	0.632	rs62259779	chr3:58425692	C/G	cg06643156	chr3:58380774	PXK	0.43	6.53	0.34	2.5e-10	Systemic lupus erythematosus;
CRC	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.42	-0.33	4.78e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg21972741	chr5:435613	AHRR	0.45	6.13	0.32	2.51e-9	Cystic fibrosis severity;
CRC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.77	13.56	0.6	1.37e-33	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.46	-0.34	3.66e-10	Body mass index;
CRC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.67	-11.39	-0.53	1.42e-25	Dental caries;
CRC	cis	rs10760158	0.832	rs4836848	chr9:124063352	G/A	cg14417974	chr9:124058376	GSN	-0.33	-5.68	-0.3	3e-8	Pulse pressure;
CRC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.9	-11.19	-0.53	7.31e-25	Vitiligo;
CRC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg11189052	chr15:85197271	WDR73	0.61	8.77	0.44	9.49e-17	Schizophrenia;
CRC	trans	rs771998	0.909	rs2252518	chr12:52381026	C/A	cg04286455	chr5:77803462	LHFPL2	-0.38	-6.04	-0.32	4.18e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.42	6.79	0.35	5.2e-11	Sitting height ratio;
CRC	trans	rs4073221	0.520	rs1108439	chr3:18201319	A/G	cg19396872	chr19:8495671	MARCH2	0.64	6.2	0.32	1.74e-9	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs9648716	1.000	rs1267632	chr7:140487202	C/T	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.14e-8	Type 2 diabetes;
CRC	cis	rs6432018	1.000	rs6432024	chr2:9743134	A/G	cg12832956	chr2:9616023	IAH1	-0.37	-5.66	-0.3	3.39e-8	Heart rate variability traits;
CRC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg12386194	chr3:101231763	SENP7	0.5	7.11	0.37	7.2e-12	Colorectal cancer;
CRC	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg00579200	chr11:133705235	NA	-0.41	-5.91	-0.31	8.52e-9	Childhood ear infection;
CRC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg00074818	chr8:8560427	CLDN23	0.37	6.85	0.35	3.67e-11	Obesity-related traits;
CRC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-5.86	-0.31	1.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.44	7.26	0.37	2.85e-12	Cystic fibrosis severity;
CRC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.66	-0.3	3.33e-8	Lung cancer;
CRC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.85	-0.44	5.59e-17	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.52	-8.46	-0.42	8.81e-16	Aortic root size;
CRC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.52	-9.6	-0.47	2.17e-19	Eye color traits;
CRC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.56	-9.67	-0.47	1.28e-19	Body mass index;
CRC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.57	-5.9	-0.31	8.82e-9	Schizophrenia;
CRC	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.51	6.58	0.34	1.82e-10	Red blood cell count;
CRC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg21153622	chr11:89784906	NA	-0.38	-6.04	-0.32	4.27e-9	Height;
CRC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.61	-9.12	-0.45	7.57e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.49	-7.8	-0.4	8.13e-14	Eye color traits;
CRC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.57	8.35	0.42	1.96e-15	Height;
CRC	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.74	-0.39	1.26e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.57	-9.23	-0.45	3.44e-18	Congenital heart disease (maternal effect);
CRC	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.66	8.54	0.43	4.99e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.3	-0.46	2.05e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.49	7.23	0.37	3.35e-12	Blood metabolite levels;
CRC	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.9	-0.63	9.49e-39	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.57e-10	Life satisfaction;
CRC	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg09654669	chr8:57350985	NA	-0.43	-5.87	-0.31	1.05e-8	Obesity-related traits;
CRC	cis	rs2479724	0.870	rs7766817	chr6:41918104	T/A	cg17623882	chr6:41773611	USP49	-0.52	-8.31	-0.42	2.49e-15	Menarche (age at onset);
CRC	cis	rs12143943	0.902	rs7541449	chr1:204578308	G/T	cg17419461	chr1:204415978	PIK3C2B	0.38	5.96	0.31	6.59e-9	Cognitive performance;
CRC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.35	-0.42	1.91e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7538876	0.935	rs6586542	chr1:17763566	C/G	cg07965774	chr1:17746286	RCC2	-0.31	-5.8	-0.3	1.55e-8	Basal cell carcinoma;
CRC	cis	rs6564851	0.506	rs11641342	chr16:81257588	G/A	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.65	-0.3	3.53e-8	Carotenoid and tocopherol levels;
CRC	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg14673194	chr17:80132900	CCDC57	0.49	6.12	0.32	2.59e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.46	6.32	0.33	8.5e-10	Morning vs. evening chronotype;
CRC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.52	-0.34	2.7e-10	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19767562	chr7:100224437	TFR2	0.42	6.71	0.35	8.74e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg24955406	chr1:100503596	HIAT1	-0.52	-6.31	-0.33	8.83e-10	Carotid intima media thickness;
CRC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.43	6.81	0.35	4.74e-11	Fat distribution (HIV);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01258499	chr20:30540016	PDRG1	0.44	6.25	0.33	1.25e-9	Response to antipsychotic treatment;
CRC	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg25588852	chr2:216877276	MREG	-0.31	-5.85	-0.31	1.22e-8	Alcohol dependence;
CRC	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.95	-0.36	1.97e-11	Capecitabine sensitivity;
CRC	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.64	-0.57	3.92e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	15.91	0.66	1.15e-42	Mean corpuscular hemoglobin;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24361620	chr11:45868787	CRY2	0.46	6.83	0.35	4.17e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.55	9.04	0.45	1.37e-17	Congenital heart disease (maternal effect);
CRC	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg09127314	chr1:152161683	NA	0.46	5.93	0.31	7.69e-9	Atopic dermatitis;
CRC	trans	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg26043149	chr18:55253948	FECH	-0.54	-7.7	-0.39	1.63e-13	Bone mineral density;
CRC	cis	rs2257205	0.667	rs9916423	chr17:56773834	T/C	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-7.16	-0.37	5.16e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.43	7.41	0.38	1.06e-12	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15312298	chr8:127570908	FAM84B	0.44	6.45	0.34	4.01e-10	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	trans	rs1642645	0.831	rs6600396	chr1:42489534	G/A	cg16926213	chr1:1841314	NA	-0.43	-6.09	-0.32	3.07e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg09184832	chr6:79620586	NA	-0.44	-7.7	-0.39	1.5700000000000001e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9378357	0.702	rs4383859	chr6:3280241	C/G	cg08754725	chr6:3293098	SLC22A23	0.71	5.66	0.3	3.32e-8	Obesity-related traits;
CRC	cis	rs9400239	0.622	rs2207731	chr6:109013664	C/T	cg11073813	chr6:109029018	NA	0.4	6.41	0.33	4.93e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.8	10.09	0.49	5.06e-21	Prostate cancer;
CRC	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.83e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.73	10.44	0.5	3.2e-22	Response to antineoplastic agents;
CRC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.61	9.09	0.45	9.33e-18	Morning vs. evening chronotype;
CRC	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.06	20.35	0.75	3.63e-60	Triglycerides;
CRC	cis	rs889398	0.741	rs4146819	chr16:69923563	C/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.81	-0.3	1.49e-8	Body mass index;
CRC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.57	-0.39	3.78e-13	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.96e-8	Bladder cancer;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Parkinson's disease;
CRC	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.22	-5.83	-0.31	1.33e-8	Type 2 diabetes;
CRC	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.61	9.1	0.45	8.58e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.79	-9.64	-0.47	1.59e-19	Initial pursuit acceleration;
CRC	cis	rs6743376	0.556	rs1530551	chr2:113817566	C/T	cg24553058	chr2:113831203	IL1F10	-0.41	-6.62	-0.34	1.5e-10	Inflammatory biomarkers;
CRC	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.6	7.59	0.39	3.39e-13	Height;
CRC	trans	rs6546043	0.756	rs6705192	chr2:64137828	C/G	cg20306022	chr2:7947960	NA	-0.51	-6.02	-0.31	4.6e-9	Clozapine-induced agranulocytosis;
CRC	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg23100626	chr2:96804247	ASTL	-0.28	-7.89	-0.4	4.43e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg10756647	chr7:56101905	PSPH	-0.76	-7.89	-0.4	4.47e-14	Diabetic kidney disease;
CRC	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.57	-9.01	-0.44	1.76e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.42	6.69	0.35	9.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg04731861	chr2:219085781	ARPC2	0.29	5.83	0.31	1.33e-8	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.21	-5.81	-0.3	1.49e-8	Urinary metabolites;
CRC	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg14003231	chr6:33640908	ITPR3	0.51	8.26	0.41	3.71e-15	Plateletcrit;
CRC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.56	9.45	0.46	6.32e-19	Schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26385523	chr19:51611757	CTU1	0.4	6.01	0.31	4.92e-9	Schizophrenia;
CRC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.18	0.49	2.44e-21	Alzheimer's disease (late onset);
CRC	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.76	13.78	0.61	1.96e-34	Insulin-like growth factors;
CRC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.77	8.18	0.41	6.4e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7605827	0.930	rs6431711	chr2:15683930	G/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.62	-10.41	-0.5	4.14e-22	Depressive symptoms (multi-trait analysis);
CRC	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.84	-0.35	3.76e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.66	-9.92	-0.48	1.78e-20	Total body bone mineral density;
CRC	cis	rs9522267	0.511	rs4773397	chr13:112245044	T/C	cg14352298	chr13:112236639	NA	0.28	6.3	0.33	9.57e-10	Hepatitis;
CRC	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg01788221	chr16:89496183	ANKRD11	-0.41	-6.07	-0.32	3.44e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg12273811	chr6:28175739	NA	0.45	6.52	0.34	2.59e-10	Parkinson's disease;
CRC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg27661571	chr11:113659931	NA	0.68	7.53	0.38	5.08e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg05562828	chr17:3906858	NA	0.44	5.64	0.3	3.57e-8	Type 2 diabetes;
CRC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg13206674	chr6:150067644	NUP43	0.48	6.86	0.35	3.33e-11	Lung cancer;
CRC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg02869306	chr7:64672164	INTS4L1	0.44	6.17	0.32	2.02e-9	Aortic root size;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg25164649	chr6:28176230	NA	0.66	8.75	0.43	1.12e-16	Parkinson's disease;
CRC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00166722	chr3:10149974	C3orf24	0.42	6.3	0.33	9.75e-10	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12463550	chr7:65579703	CRCP	0.67	6.31	0.33	8.99e-10	Diabetic kidney disease;
CRC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.23	-16.46	-0.67	8.13e-45	Breast cancer;
CRC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.4	6.13	0.32	2.52e-9	Red blood cell count;
CRC	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg18827107	chr12:86230957	RASSF9	-0.37	-5.89	-0.31	9.39e-9	Major depressive disorder;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.74	-11.68	-0.54	1.29e-26	Prudent dietary pattern;
CRC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg11168104	chr5:1857477	NA	-0.39	-6.78	-0.35	5.53e-11	Cardiovascular disease risk factors;
CRC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.87	0.44	4.89e-17	Hip circumference adjusted for BMI;
CRC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.37	5.88	0.31	1.02e-8	Huntington's disease progression;
CRC	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg00852783	chr1:26633632	UBXN11	-0.49	-5.81	-0.31	1.45e-8	Obesity-related traits;
CRC	cis	rs2062225	1.000	rs6722913	chr2:111762160	C/T	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.62	-0.3	4.08e-8	Monocyte count;
CRC	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.09	-0.32	3.09e-9	Menopause (age at onset);
CRC	cis	rs7605827	0.930	rs7605730	chr2:15598696	A/G	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.58e-9	Educational attainment (years of education);
CRC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.45	6.87	0.35	3.2e-11	Menarche (age at onset);
CRC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	0.64	6.18	0.32	1.86e-9	Fat distribution (HIV);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03157738	chr19:11308118	KANK2	0.47	6.04	0.32	4.08e-9	Thyroid stimulating hormone;
CRC	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg21096502	chr7:56174374	CHCHD2	-0.65	-6.84	-0.35	3.98e-11	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg23387468	chr7:139079360	LUC7L2	-0.41	-7.28	-0.37	2.56e-12	Diisocyanate-induced asthma;
CRC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.68	0.3	2.95e-8	Diabetic retinopathy;
CRC	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.45	7.84	0.4	6.43e-14	Migraine;
CRC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.14	-13.85	-0.61	1.06e-34	Diabetic kidney disease;
CRC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.44	-6.79	-0.35	5.21e-11	Height;
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.64	-9.67	-0.47	1.24e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg17321639	chr7:2759063	NA	-0.42	-6.45	-0.34	3.94e-10	Height;
CRC	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg04176472	chr15:90893244	GABARAPL3	0.35	6.05	0.32	4.02e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg16892393	chr17:41919603	NA	0.39	5.9	0.31	8.88e-9	Triglycerides;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14684917	chr11:62380363	EML3;ROM1	0.4	7.15	0.37	5.73e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.86	12.56	0.57	8.21e-30	Gut microbiome composition (summer);
CRC	cis	rs6076065	0.723	rs2424544	chr20:23390314	C/T	cg11657817	chr20:23433608	CST11	0.43	6.34	0.33	7.77e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.6	8.54	0.43	4.93e-16	Homoarginine levels;
CRC	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg00666640	chr1:248458726	OR2T12	0.5	7.4	0.38	1.14e-12	Common traits (Other);
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02359409	chr6:42947317	PEX6	-0.57	-8.86	-0.44	5.05e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg15691649	chr6:25882328	NA	-0.44	-5.9	-0.31	8.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.4	5.83	0.31	1.35e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.74	-0.51	2.85e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.83	-0.4	6.57e-14	Putamen volume;
CRC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg11292332	chr7:45801988	SEPT13	-0.35	-6.22	-0.32	1.51e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.66	-0.3	3.31e-8	Coronary artery disease;
CRC	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg24140574	chr1:16342155	HSPB7	-0.47	-6.73	-0.35	7.61e-11	Dilated cardiomyopathy;
CRC	trans	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg07817883	chr1:32538562	TMEM39B	-0.62	-8.06	-0.41	1.46e-14	Monocyte percentage of white cells;
CRC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.03	-0.32	4.5e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-25.99	-0.82	9.95e-82	Exhaled nitric oxide output;
CRC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.46	-6.98	-0.36	1.67e-11	Height;
CRC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.68	10.5	0.5	1.88e-22	Monocyte count;
CRC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.56	6.78	0.35	5.54e-11	Heart rate;
CRC	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg22482690	chr17:47019901	SNF8	0.48	8.18	0.41	6.13e-15	Type 2 diabetes;
CRC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.52	-9.62	-0.47	1.88e-19	Eye color traits;
CRC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.43	5.77	0.3	1.8e-8	Schizophrenia;
CRC	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.44	-7.08	-0.36	8.8e-12	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-6.0	-0.31	5.2e-9	Coronary artery disease;
CRC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg11189052	chr15:85197271	WDR73	0.56	7.45	0.38	8.13e-13	Schizophrenia;
CRC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg03037974	chr15:76606532	NA	-0.54	-7.78	-0.39	9.15e-14	Blood metabolite levels;
CRC	cis	rs7923609	0.846	rs10740115	chr10:65094990	G/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.77	-0.3	1.81e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.81	-12.91	-0.58	4.11e-31	Cognitive function;
CRC	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-5.98	-0.31	5.87e-9	Response to antipsychotic treatment;
CRC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.47	6.17	0.32	2.05e-9	Lymphocyte counts;
CRC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg04586622	chr2:25135609	ADCY3	-0.54	-10.01	-0.48	8.89e-21	Body mass index;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.56	8.61	0.43	3.11e-16	Longevity;Endometriosis;
CRC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg24879335	chr3:133465180	TF	-0.35	-6.78	-0.35	5.45e-11	Iron status biomarkers;
CRC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg10790698	chr19:18539756	SSBP4	-0.45	-8.69	-0.43	1.69e-16	Breast cancer;
CRC	cis	rs12476592	0.602	rs7576316	chr2:63741122	G/A	cg10828910	chr2:63850056	LOC388955	0.48	5.99	0.31	5.45e-9	Childhood ear infection;
CRC	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.7	-0.39	1.6e-13	Metabolite levels (Pyroglutamine);
CRC	trans	rs8124695	0.504	rs980356	chr20:38992538	G/A	cg12409982	chr3:137489312	NA	-0.47	-6.08	-0.32	3.31e-9	Dupuytren's disease;
CRC	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.56	7.64	0.39	2.46e-13	Height;
CRC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.59	9.92	0.48	1.82e-20	Prudent dietary pattern;
CRC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.93	0.52	6.22e-24	Systolic blood pressure;
CRC	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg04110750	chr16:69646130	NFAT5	-0.57	-7.72	-0.39	1.4e-13	IgE levels;
CRC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.72	-12.09	-0.55	4.16e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg15786705	chr6:28176104	NA	0.58	8.22	0.41	4.65e-15	Parkinson's disease;
CRC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00700412	chr12:58011837	NA	0.48	7.75	0.39	1.14e-13	Multiple sclerosis;
CRC	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg23136738	chr11:925521	AP2A2	-0.41	-6.61	-0.34	1.59e-10	Alzheimer's disease (late onset);
CRC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.27	0.64	3.58e-40	Platelet count;
CRC	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg27205649	chr11:78285834	NARS2	0.48	5.87	0.31	1.05e-8	Alzheimer's disease (survival time);
CRC	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg26182253	chr13:112236782	NA	0.31	6.29	0.33	9.96e-10	Hepatitis;
CRC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.08	0.45	1.05e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.48	9.02	0.45	1.63e-17	Reticulocyte fraction of red cells;
CRC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg04166393	chr7:2884313	GNA12	0.54	7.1	0.36	7.65e-12	Height;
CRC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.49	-8.58	-0.43	3.93e-16	Blood metabolite levels;
CRC	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg12458913	chr13:53173898	NA	0.51	7.96	0.4	2.82e-14	Lewy body disease;
CRC	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.75	-12.09	-0.55	4.23e-28	Plateletcrit;Platelet count;
CRC	cis	rs2315504	0.509	rs3760335	chr17:39026061	T/A	cg05063374	chr17:38953512	KRT28	-0.37	-5.64	-0.3	3.71e-8	Height;
CRC	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg00601450	chr5:74908170	NA	0.42	5.83	0.31	1.34e-8	Age-related disease endophenotypes;
CRC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg00074818	chr8:8560427	CLDN23	0.34	6.23	0.32	1.42e-9	Obesity-related traits;
CRC	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.2e-12	Prostate cancer;
CRC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.65	-0.3	3.39e-8	Type 2 diabetes;
CRC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.82	0.35	4.28e-11	Obesity-related traits;
CRC	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.65	-0.34	1.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16447950	chr5:562315	NA	0.74	9.71	0.47	9.02e-20	Obesity-related traits;
CRC	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.59	-6.54	-0.34	2.29e-10	Coronary artery disease;
CRC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.6	-10.53	-0.5	1.56e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.9	-0.31	8.95e-9	Alcohol dependence;
CRC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.35	0.42	1.86e-15	Lymphocyte counts;
CRC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg19622623	chr12:86230825	RASSF9	0.38	5.81	0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.79	14.39	0.62	8.91e-37	Anterior chamber depth;
CRC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.46	-0.46	5.93e-19	Body mass index;
CRC	cis	rs883565	0.528	rs9311200	chr3:38953896	C/T	cg01426195	chr3:39028469	NA	-0.37	-6.18	-0.32	1.92e-9	Handedness;
CRC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.72	11.95	0.55	1.38e-27	Mean platelet volume;
CRC	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg19052272	chr2:3704530	ALLC	-0.41	-5.64	-0.3	3.62e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.56	-9.89	-0.48	2.39e-20	Common traits (Other);
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.67	9.85	0.48	3.24e-20	Menarche (age at onset);
CRC	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.71	-12.05	-0.55	5.91e-28	Itch intensity from mosquito bite;
CRC	trans	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.45	6.88	0.35	2.99e-11	Colorectal cancer;
CRC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.48	-6.25	-0.33	1.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg12172441	chr6:28176163	NA	0.57	6.25	0.33	1.25e-9	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.94	0.31	7.24e-9	Tonsillectomy;
CRC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs73200209	0.626	rs55984419	chr12:116578042	G/A	cg01776926	chr12:116560359	MED13L	-0.57	-6.28	-0.33	1.06e-9	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01151424	chr11:17411006	KCNJ11	0.42	6.32	0.33	8.44e-10	Intelligence (multi-trait analysis);
CRC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg26776924	chr19:1969666	CSNK1G2	-0.44	-7.05	-0.36	1.09e-11	Coronary artery disease;
CRC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.36	6.25	0.33	1.24e-9	Erythrocyte sedimentation rate;
CRC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.34	0.38	1.65e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.09	13.45	0.6	3.5e-33	Cannabis dependence symptom count;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.4	-0.5	4.44e-22	Bipolar disorder;
CRC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.53	-8.43	-0.42	1.13e-15	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.82	13.78	0.6	2.04e-34	Menopause (age at onset);
CRC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg05627522	chr15:75251581	NA	0.38	5.87	0.31	1.08e-8	Breast cancer;
CRC	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-1.05	-10.86	-0.51	1.12e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6504622	0.905	rs736603	chr17:45024745	G/T	cg16759221	chr17:45003025	GOSR2	-0.54	-8.46	-0.42	8.86e-16	Orofacial clefts;
CRC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.22	0.32	1.47e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.48	5.93	0.31	7.86e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.25	-0.41	3.74e-15	Hemoglobin concentration;
CRC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg25456477	chr12:86230367	RASSF9	0.34	5.86	0.31	1.1e-8	Major depressive disorder;
CRC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.97	11.95	0.55	1.36e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg15382696	chr6:118971807	C6orf204	0.59	7.5	0.38	6.18e-13	Diastolic blood pressure;
CRC	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg23372001	chr6:27791640	HIST1H4J	0.83	5.61	0.3	4.28e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs728616	1.000	rs56317427	chr10:81861934	T/C	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.54	-0.34	2.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.37	-8.36	-0.42	1.8e-15	Mean corpuscular volume;
CRC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.61	-9.58	-0.47	2.49e-19	Heart rate;
CRC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.71	-0.47	9.1e-20	Personality dimensions;
CRC	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.84	9.91	0.48	1.91e-20	Exhaled nitric oxide output;
CRC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.54	-0.38	4.7e-13	Bladder cancer;
CRC	cis	rs35123781	1.000	rs601728	chr5:139057076	T/C	cg10513866	chr5:139070639	NA	0.48	7.45	0.38	8.42e-13	Schizophrenia;
CRC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.71	7.02	0.36	1.29e-11	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.7	10.97	0.52	4.62e-24	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06307176	chr5:131281290	NA	0.43	6.29	0.33	1e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg03623178	chr6:28175578	NA	-0.86	-11.39	-0.53	1.49e-25	Parkinson's disease;
CRC	cis	rs2415984	0.562	rs12895104	chr14:46972736	G/A	cg14871534	chr14:47121158	RPL10L	0.41	5.75	0.3	2.03e-8	Number of children ever born;
CRC	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.83	-0.35	4.2e-11	Height;
CRC	cis	rs11587400	0.679	rs6537836	chr1:115108923	T/C	cg12756093	chr1:115239321	AMPD1	0.43	5.9	0.31	9.27e-9	Autism;
CRC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg13607699	chr17:42295918	UBTF	-0.53	-6.93	-0.36	2.29e-11	Total body bone mineral density;
CRC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.7	10.82	0.51	1.47e-23	Corneal astigmatism;
CRC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg22110888	chr17:80059540	CCDC57	-0.41	-6.44	-0.33	4.12e-10	Life satisfaction;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.34e-9	Parkinson's disease;
CRC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.63	9.67	0.47	1.21e-19	Corneal astigmatism;
CRC	cis	rs910873	0.505	rs6087607	chr20:33197489	A/G	cg08999081	chr20:33150536	PIGU	0.5	6.19	0.32	1.75e-9	Melanoma;
CRC	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.37	-0.33	6.34e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.53	7.2	0.37	4.23e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.79	-0.3	1.67e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.06	0.32	3.71e-9	Ovarian reserve;
CRC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg19812747	chr11:111475976	SIK2	-0.56	-9.45	-0.46	6.39e-19	Primary sclerosing cholangitis;
CRC	trans	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.06	-0.32	3.77e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.89	0.36	2.81e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13773948	chr10:43277913	BMS1	0.38	6.22	0.32	1.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs4920343	0.698	rs578988	chr1:19077291	T/C	cg19637330	chr1:19110922	NA	0.39	5.87	0.31	1.09e-8	Knee osteoarthritis;
CRC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.44	-6.49	-0.34	3.07e-10	Menarche (age at onset);
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg15511327	chr8:143859410	LYNX1	-0.4	-6.68	-0.35	9.91e-11	Urinary tract infection frequency;
CRC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.96	0.48	1.32e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg14593290	chr7:50529359	DDC	0.57	7.89	0.4	4.57e-14	Malaria;
CRC	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.66	-0.43	2.1e-16	Coffee consumption (cups per day);
CRC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	0.77	8.59	0.43	3.61e-16	Gout;Renal underexcretion gout;
CRC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.71	7.67	0.39	2.01e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.82	-9.93	-0.48	1.72e-20	Dilated cardiomyopathy;
CRC	cis	rs4731207	0.596	rs6967707	chr7:124609355	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.23	-0.32	1.46e-9	Cutaneous malignant melanoma;
CRC	trans	rs2303319	0.504	rs12469052	chr2:162319353	T/C	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.27	-0.33	1.13e-9	Cognitive function;
CRC	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.4	-0.59	5.88e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs3823572	0.525	rs7785128	chr7:133684991	T/C	cg03336402	chr7:133662267	EXOC4	-0.63	-9.22	-0.45	3.74e-18	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg00280220	chr17:61926910	NA	0.33	5.64	0.3	3.66e-8	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01080592	chr19:36248739	HSPB6;C19orf55	0.45	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg22105103	chr4:187893119	NA	0.63	11.4	0.53	1.32e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.76	-13.3	-0.59	1.38e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg19731401	chr7:2775893	GNA12	-0.62	-6.51	-0.34	2.86e-10	Childhood ear infection;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.17	-0.32	1.98e-9	Bipolar disorder;
CRC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.92	12.26	0.56	1.06e-28	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.0	14.15	0.62	7.94e-36	Breast cancer;
CRC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.44e-13	Motion sickness;
CRC	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.6	0.5	9.01e-23	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.84e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.18	0.32	1.94e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.62	-6.99	-0.36	1.53e-11	Body mass index (adult);
CRC	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.43	6.17	0.32	1.95e-9	Body mass index;
CRC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg27572855	chr1:25598939	RHD	0.36	6.36	0.33	6.65e-10	Erythrocyte sedimentation rate;
CRC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.76	9.07	0.45	1.11e-17	Eosinophilic esophagitis;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24267428	chr3:50649269	CISH	0.37	5.64	0.3	3.75e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.93	-0.36	2.22e-11	Response to antipsychotic treatment;
CRC	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg27053337	chr8:124217698	FAM83A	0.46	6.99	0.36	1.58e-11	Urinary uromodulin levels;
CRC	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg13491945	chr12:107078410	RFX4	0.35	5.97	0.31	6.1e-9	Total body bone mineral density;
CRC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.48	8.51	0.42	6.09e-16	Blood metabolite levels;
CRC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.54	-7.88	-0.4	4.75e-14	Total body bone mineral density;
CRC	cis	rs7131987	0.675	rs3847678	chr12:29551560	A/C	cg09582351	chr12:29534625	ERGIC2	0.31	6.76	0.35	6.4e-11	QT interval;
CRC	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg10217327	chr6:118973057	C6orf204	0.51	5.78	0.3	1.73e-8	Diastolic blood pressure;
CRC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.5	7.89	0.4	4.51e-14	Aortic root size;
CRC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.63	-10.03	-0.48	7.75e-21	Motion sickness;
CRC	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.42	-0.33	4.88e-10	Caffeine consumption;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10620100	chr15:40714174	NA	0.48	7.09	0.36	8.16e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2735413	0.914	rs11150035	chr16:78066449	G/C	cg04733911	chr16:78082701	NA	-0.37	-6.03	-0.32	4.33e-9	Systolic blood pressure (alcohol consumption interaction);
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.81	-9.06	-0.45	1.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.45	-5.76	-0.3	1.89e-8	Aortic root size;
CRC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.8	-10.1	-0.49	4.68e-21	Cognitive test performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22753376	chr8:117768031	EIF3H	0.43	6.26	0.33	1.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1572438	0.899	rs9392198	chr6:860561	T/G	cg21062780	chr6:887772	NA	-0.38	-5.97	-0.31	6.21e-9	Aging;
CRC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.09	-0.32	3.13e-9	Vitiligo;
CRC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.69	-0.35	9.58e-11	Aortic root size;
CRC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-6.34	-0.33	7.7e-10	Type 2 diabetes;
CRC	cis	rs3026101	0.671	rs3026125	chr17:5293627	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg00343986	chr7:65444356	GUSB	-0.57	-8.59	-0.43	3.53e-16	Calcium levels;
CRC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.42	0.33	4.74e-10	Renal cell carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20762182	chr15:69727293	KIF23	-0.39	-6.25	-0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg08888203	chr3:10149979	C3orf24	0.47	7.23	0.37	3.47e-12	Alzheimer's disease;
CRC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.83	-0.58	7.64e-31	Alzheimer's disease;
CRC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16447950	chr5:562315	NA	-0.83	-10.81	-0.51	1.71e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.48	6.03	0.32	4.43e-9	Alzheimer's disease (survival time);
CRC	cis	rs6815814	0.861	rs6531663	chr4:38792340	T/C	cg06935464	chr4:38784597	TLR10	0.61	7.9	0.4	4.31e-14	Breast cancer;
CRC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.45	3.13e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.98	-0.31	5.91e-9	Pulmonary function;
CRC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.54	7.19	0.37	4.4e-12	Neutrophil percentage of white cells;
CRC	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.38	-5.92	-0.31	7.99e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.48	7.0	0.36	1.44e-11	Pulmonary function decline;
CRC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg21153622	chr11:89784906	NA	0.42	6.14	0.32	2.37e-9	Coronary artery disease;
CRC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-7.84	-0.4	6.39e-14	Bipolar disorder;
CRC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.75	8.87	0.44	4.69e-17	Body mass index;
CRC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06505273	chr16:24850292	NA	0.49	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.27	0.33	1.12e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.8	12.31	0.56	6.7200000000000006e-29	Testicular germ cell tumor;
CRC	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.34	-5.94	-0.31	7.22e-9	Pneumonia;
CRC	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.68	0.3	2.97e-8	Coronary artery disease;
CRC	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.62	-8.13	-0.41	8.68e-15	Body mass index;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.87	0.35	3.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg26762873	chr11:5879799	OR52E8	-0.43	-6.13	-0.32	2.54e-9	DNA methylation (variation);
CRC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.71	10.14	0.49	3.35e-21	Cognitive function;
CRC	cis	rs3218092	0.701	rs11970772	chr6:41925290	A/T	cg17623882	chr6:41773611	USP49	0.43	5.7	0.3	2.73e-8	Red cell distribution width;
CRC	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.71	12.7	0.57	2.34e-30	Hip circumference;
CRC	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.8	-0.35	5.08e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22636278	chr5:167913346	RARS	0.38	6.05	0.32	4.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.45	6.82	0.35	4.26e-11	Menopause (age at onset);
CRC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg20129853	chr10:51489980	NA	-0.36	-5.89	-0.31	9.73e-9	Prostate-specific antigen levels;
CRC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.21	0.41	5.15e-15	Body mass index;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs2530545	0.512	rs17169877	chr7:34626472	T/C	cg14401837	chr7:34697493	NPSR1	0.37	5.81	0.31	1.45e-8	IgG glycosylation;
CRC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.44	0.38	9.07e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.7	8.5	0.42	6.75e-16	Bipolar disorder;
CRC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.54	8.49	0.42	7.11e-16	Intelligence (multi-trait analysis);
CRC	cis	rs73200209	0.744	rs57085207	chr12:116579289	T/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.12	-0.37	6.94e-12	Total body bone mineral density;
CRC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.6	-0.43	3.27e-16	Mean platelet volume;
CRC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	8.11	0.41	1.04e-14	Monocyte count;
CRC	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	6.44	0.33	4.13e-10	Breast cancer;
CRC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.72	-13.03	-0.58	1.42e-31	Lung cancer;
CRC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.57	9.1	0.45	8.71e-18	Vitiligo;
CRC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg06970220	chr1:156163860	SLC25A44	0.5	7.2	0.37	4.15e-12	Testicular germ cell tumor;
CRC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg27535305	chr1:53392650	SCP2	-0.36	-6.47	-0.34	3.63e-10	Monocyte count;
CRC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.57	9.02	0.45	1.59e-17	Eosinophil percentage of white cells;
CRC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.5	6.22	0.32	1.51e-9	Recombination rate (females);
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18301423	chr5:131593218	PDLIM4	0.37	6.81	0.35	4.75e-11	Breast cancer;
CRC	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24249390	chr15:90295951	MESP1	-0.56	-8.69	-0.43	1.71e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.46	6.54	0.34	2.39e-10	Pulmonary function decline;
CRC	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg07930552	chr6:133119739	C6orf192	0.58	6.61	0.34	1.52e-10	Type 2 diabetes nephropathy;
CRC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.84	-0.48	3.47e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.6	-8.96	-0.44	2.45e-17	Other erythrocyte phenotypes;
CRC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.49	6.67	0.35	1.08e-10	Pulse pressure;
CRC	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.64	9.35	0.46	1.39e-18	Waist circumference;Body mass index;
CRC	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.33	-6.36	-0.33	6.64e-10	Breast cancer;
CRC	trans	rs4785204	1.000	rs8056208	chr16:50097104	A/G	cg07960154	chr17:37760198	NEUROD2	-0.64	-6.03	-0.32	4.47e-9	Esophageal cancer (squamous cell);
CRC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs4844614	0.904	rs4844388	chr1:207842900	G/A	cg17822947	chr1:207842917	CR1L	-0.38	-6.3	-0.33	9.45e-10	LDL cholesterol;
CRC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.4	-7.0	-0.36	1.46e-11	Lung cancer;
CRC	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-5.62	-0.3	3.99e-8	Alzheimer's disease (survival time);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg12488586	chr5:178220967	NA	-0.39	-6.01	-0.31	4.83e-9	HDL cholesterol;
CRC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.52	6.8	0.35	5.08e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25338623	chr11:67250427	AIP	0.4	5.96	0.31	6.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg02094049	chr14:103021097	NA	-0.55	-7.05	-0.36	1.08e-11	Platelet count;
CRC	cis	rs4731207	0.596	rs13224820	chr7:124655399	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs1434579	0.865	rs1434573	chr19:44923277	A/G	cg15540054	chr19:45004280	ZNF180	0.5	6.32	0.33	8.64e-10	Tuberculosis;
CRC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-6.04	-0.32	4.23e-9	Longevity;Endometriosis;
CRC	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg11887960	chr12:57824829	NA	0.63	6.89	0.36	2.93e-11	Lung disease severity in cystic fibrosis;
CRC	trans	rs2055729	0.645	rs12543685	chr8:9747056	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.57	0.34	1.95e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg13837822	chr10:26931731	LOC731789	0.56	8.75	0.43	1.11e-16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.96	-0.36	1.8e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08219700	chr8:58056026	NA	0.52	6.75	0.35	6.78e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4664293	0.605	rs12474082	chr2:160513914	A/G	cg08347373	chr2:160653686	CD302	0.39	6.57	0.34	1.95e-10	Monocyte percentage of white cells;
CRC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.95	-0.4	2.97e-14	Intelligence (multi-trait analysis);
CRC	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	0.88	8.98	0.44	2.2e-17	Post bronchodilator FEV1;
CRC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg03623178	chr6:28175578	NA	0.78	6.64	0.34	1.27e-10	Breast cancer;
CRC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.32	0.37	1.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	0.84	7.67	0.39	2.03e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9311676	0.656	rs11918201	chr3:58387777	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.07e-8	Type 2 diabetes;
CRC	cis	rs12580194	0.593	rs66902680	chr12:55724080	A/C	cg23425280	chr12:56401806	NA	0.48	5.82	0.31	1.39e-8	Cancer;
CRC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.74	12.05	0.55	6.24e-28	Selective IgA deficiency;
CRC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.49	9.23	0.45	3.4e-18	Renal cell carcinoma;
CRC	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg20387954	chr3:183756860	HTR3D	0.46	7.82	0.4	7.01e-14	Anterior chamber depth;
CRC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.6	-9.39	-0.46	1.07e-18	Corneal astigmatism;
CRC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.42	9.24	0.45	3.08e-18	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07157834	chr1:205819609	PM20D1	0.42	5.88	0.31	1.01e-8	Parkinson's disease;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg06470822	chr6:28175283	NA	0.72	10.34	0.5	6.75e-22	Parkinson's disease;
CRC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.6	7.91	0.4	3.93e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.43	-7.14	-0.37	5.85e-12	Height;
CRC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.77	11.26	0.53	4.18e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10046574	0.831	rs56285116	chr7:135164950	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg26587870	chr6:27730563	NA	-0.43	-6.01	-0.31	4.93e-9	Parkinson's disease;
CRC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.44	-7.72	-0.39	1.44e-13	Monocyte count;
CRC	cis	rs7508679	0.692	rs10413734	chr19:7227871	T/G	cg00428638	chr19:7224713	INSR	-0.89	-14.31	-0.62	1.84e-36	Hypothyroidism;
CRC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg03233332	chr7:66118400	NA	-0.43	-5.9	-0.31	9.26e-9	Aortic root size;
CRC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-0.85	-8.42	-0.42	1.16e-15	Schizophrenia;
CRC	trans	rs12432203	1.000	rs72622431	chr14:51732854	G/T	cg14592830	chr9:122318704	NA	0.57	6.01	0.31	4.88e-9	Cancer;
CRC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.47	7.46	0.38	8.02e-13	Calcium levels;
CRC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.42	-0.33	4.69e-10	Dupuytren's disease;
CRC	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.44	-0.33	4.18e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.39	5.72	0.3	2.45e-8	Aortic root size;
CRC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg17133734	chr15:86042851	AKAP13	0.43	6.89	0.35	2.92e-11	Coronary artery disease;
CRC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.95	0.44	2.61e-17	Morning vs. evening chronotype;
CRC	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.13	-0.37	6.38e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.52	7.37	0.38	1.4e-12	Testicular germ cell tumor;
CRC	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.43	7.08	0.36	8.69e-12	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01168649	chr22:31892074	SFI1	0.45	6.36	0.33	6.58e-10	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.36	0.46	1.32e-18	Blood protein levels;
CRC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-6.82	-0.35	4.38e-11	Height;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12172441	chr6:28176163	NA	-0.63	-7.57	-0.39	3.83e-13	Depression;
CRC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Parkinson's disease;
CRC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-5.98	-0.31	5.72e-9	Aortic root size;
CRC	cis	rs12580194	0.593	rs67015069	chr12:55759968	T/A	cg23425280	chr12:56401806	NA	0.48	5.8	0.3	1.55e-8	Cancer;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-8.67	-0.43	2.06e-16	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22437020	chr17:41623744	ETV4	0.45	6.3	0.33	9.36e-10	Response to antipsychotic treatment;
CRC	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-9.9	-0.48	2.1e-20	Blood protein levels;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12963246	chr6:28129442	ZNF389	0.5	5.75	0.3	2e-8	Depression;
CRC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.37	-7.99	-0.4	2.24e-14	Schizophrenia;
CRC	cis	rs4664293	0.669	rs10174515	chr2:160462035	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07292445	chr17:27055725	NEK8	0.49	6.59	0.34	1.71e-10	Anxiety disorder;
CRC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg11632617	chr15:75315747	PPCDC	-0.56	-7.96	-0.4	2.86e-14	Blood trace element (Zn levels);
CRC	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.01	0.64	3.66e-39	Colorectal cancer;
CRC	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.66	7.41	0.38	1.07e-12	Eotaxin levels;
CRC	cis	rs4731207	0.596	rs1904973	chr7:124669547	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.44e-9	Cutaneous malignant melanoma;
CRC	cis	rs747650	0.961	rs7945315	chr11:47110652	A/C	cg19486271	chr11:47235900	DDB2	-0.45	-6.73	-0.35	7.77e-11	Acne (severe);
CRC	cis	rs2530545	0.762	rs28605015	chr7:34666834	C/A	cg14401837	chr7:34697493	NPSR1	0.43	6.34	0.33	7.68e-10	IgG glycosylation;
CRC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.07	13.47	0.6	3.02e-33	Vitiligo;
CRC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.61	0.34	1.54e-10	Diabetic kidney disease;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.46	6.62	0.34	1.43e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.76	-0.39	1.08e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg09491104	chr22:46646882	C22orf40	-0.47	-7.29	-0.37	2.36e-12	LDL cholesterol;Cholesterol, total;
CRC	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.47	-0.34	3.6e-10	Retinal vascular caliber;
CRC	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg03929089	chr4:120376271	NA	-0.48	-6.68	-0.35	1.02e-10	Height;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg02683197	chr6:28174875	NA	0.57	7.52	0.38	5.18e-13	Parkinson's disease;
CRC	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.43	-6.53	-0.34	2.55e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	0.93	13.48	0.6	2.71e-33	Breast cancer;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg12564285	chr5:131593104	PDLIM4	0.45	7.32	0.37	1.9e-12	Blood metabolite levels;
CRC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg10790698	chr19:18539756	SSBP4	-0.46	-8.79	-0.44	8.55e-17	Breast cancer;
CRC	cis	rs1656402	1.000	rs2950878	chr2:233424954	C/T	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.27	10.45	0.5	2.98e-22	Cognitive function;
CRC	cis	rs17767392	0.846	rs61991213	chr14:71796441	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.88	-0.31	1.02e-8	Mitral valve prolapse;
CRC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.92	-0.4	3.72e-14	Gut microbiome composition (summer);
CRC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg00343986	chr7:65444356	GUSB	0.45	6.41	0.33	5.12e-10	Aortic root size;
CRC	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00638210	chr3:126732518	PLXNA1	0.29	6.01	0.31	4.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg24977027	chr2:88469347	THNSL2	0.56	6.66	0.34	1.15e-10	Plasma clusterin levels;
CRC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg23758597	chr6:163146217	PARK2	-0.7	-7.12	-0.37	6.76e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg22096450	chr11:6947773	ZNF215	0.61	6.38	0.33	6.15e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs16846053	0.786	rs116099394	chr2:162600082	G/T	cg06075789	chr19:39894767	NA	-0.67	-5.97	-0.31	6.06e-9	Blood osmolality (transformed sodium);
CRC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Red blood cell count;
CRC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.14	-0.32	2.41e-9	Menopause (age at onset);
CRC	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg07507251	chr3:52567010	NT5DC2	0.4	6.01	0.31	4.92e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.89	-16.04	-0.66	3.41e-43	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25327839	chr11:73308997	FAM168A	0.39	7.06	0.36	1.01e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.71	-7.95	-0.4	2.98e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs236352	0.521	rs58214515	chr6:36827416	T/C	cg10099585	chr6:36853529	C6orf89	-0.42	-5.79	-0.3	1.66e-8	Heart rate;
CRC	cis	rs7705042	0.828	rs181826	chr5:141526057	C/A	cg07392085	chr5:141489673	NDFIP1	0.45	7.25	0.37	2.94e-12	Asthma;
CRC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.92	-11.89	-0.55	2.39e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg08533674	chr1:46993347	NA	-0.59	-7.77	-0.39	1.03e-13	Monobrow;
CRC	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-5.9	-0.31	9.05e-9	Inflammatory bowel disease;
CRC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12315302	chr6:26189340	HIST1H4D	0.82	6.33	0.33	8.12e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3757247	0.729	rs4707605	chr6:90915601	C/T	cg06866423	chr6:90926672	BACH2	0.4	7.01	0.36	1.33e-11	Vitiligo;Type 1 diabetes;
CRC	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.25e-12	HDL cholesterol;
CRC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.37	-5.65	-0.3	3.52e-8	Blood metabolite levels;
CRC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.67	12.26	0.56	1.01e-28	Body mass index;
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03934478	chr11:495069	RNH1	0.66	7.41	0.38	1.1e-12	Body mass index;
CRC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg23378565	chr7:2036160	MAD1L1	-0.43	-6.09	-0.32	3.16e-9	Bipolar disorder;
CRC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.54	-8.1	-0.41	1.07e-14	Blood protein levels;
CRC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.02	0.4	1.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.47	7.65	0.39	2.27e-13	Vitiligo;
CRC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.61	-10.06	-0.49	6.07e-21	P wave terminal force;
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	1.07	18.9	0.72	1.84e-54	Parkinson's disease;
CRC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.43	-7.32	-0.37	1.89e-12	Height;
CRC	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.61	0.34	1.53e-10	Subjective well-being;
CRC	cis	rs16975963	0.594	rs73039018	chr19:38217894	C/A	cg15135657	chr19:38346511	NA	-0.47	-6.39	-0.33	5.69e-10	Longevity;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.05	-26.61	-0.83	5.09e-84	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9928842	0.664	rs8053265	chr16:75221851	C/T	cg03088958	chr16:75232330	NA	-0.32	-5.72	-0.3	2.34e-8	Alcoholic chronic pancreatitis;
CRC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg15445000	chr17:37608096	MED1	0.35	6.21	0.32	1.63e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs6676180	0.555	rs947430	chr1:119778734	G/A	cg05756136	chr1:119680316	WARS2	-0.44	-6.54	-0.34	2.41e-10	Monobrow;
CRC	cis	rs117623576	0.941	rs67225815	chr10:32408946	C/T	cg03047570	chr10:32398778	NA	-0.81	-9.08	-0.45	1.05e-17	Anti-saccade response;
CRC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.47	0.42	8.18e-16	Height;
CRC	cis	rs2457480	0.516	rs7901877	chr10:44633766	G/C	cg09554077	chr10:44749378	NA	0.47	6.01	0.31	5.01e-9	Coronary artery disease;
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.6	10.2	0.49	2.03e-21	Prudent dietary pattern;
CRC	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	0.8	6.53	0.34	2.47e-10	Economic and political preferences (immigration/crime);
CRC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	9.55	0.47	3e-19	Lymphocyte percentage of white cells;
CRC	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.46	6.96	0.36	1.83e-11	Red blood cell count;
CRC	cis	rs7703744	0.634	rs112352373	chr5:118687625	C/G	cg02283238	chr5:118691126	TNFAIP8	0.47	6.27	0.33	1.14e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	13.13	0.59	5.98e-32	Electrocardiographic conduction measures;
CRC	cis	rs2811415	0.531	rs13081382	chr3:127740304	C/G	cg13719885	chr3:127795394	NA	-0.37	-5.61	-0.3	4.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.28	0.49	1.15e-21	Alzheimer's disease (late onset);
CRC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.74e-9	Breast cancer;
CRC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.62e-17	Prostate cancer;
CRC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.43	-8.33	-0.42	2.27e-15	Huntington's disease progression;
CRC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.81	-0.51	1.71e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg01843034	chr6:37503916	NA	-0.4	-7.24	-0.37	3.1e-12	Cognitive performance;
CRC	cis	rs3750082	0.889	rs13244998	chr7:32912910	T/C	cg05721444	chr7:32995514	FKBP9	0.51	7.87	0.4	5.33e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs12432203	1.000	rs72622423	chr14:51726108	A/T	cg14592830	chr9:122318704	NA	0.61	6.28	0.33	1.08e-9	Cancer;
CRC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg18479299	chr3:125709523	NA	-0.56	-6.6	-0.34	1.6e-10	Blood pressure (smoking interaction);
CRC	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.47	-6.66	-0.34	1.16e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.6	9.13	0.45	7.26e-18	Longevity;Endometriosis;
CRC	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.47	8.15	0.41	7.75e-15	Testicular germ cell tumor;
CRC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.46	6.87	0.35	3.22e-11	Testicular germ cell tumor;
CRC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg01181863	chr3:195395398	SDHAP2	0.57	8.55	0.43	4.85e-16	Pancreatic cancer;
CRC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.67	10.85	0.51	1.24e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.56	8.21	0.41	5.11e-15	Autism;
CRC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	9.13	0.45	7.28e-18	Schizophrenia;
CRC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.67	11.16	0.52	1e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.41	0.33	4.91e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg18758796	chr5:131593413	PDLIM4	0.39	6.35	0.33	7.24e-10	Breast cancer;
CRC	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.46	-0.34	3.84e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg15192750	chr16:69999425	NA	0.56	7.47	0.38	7.35e-13	IgE levels;
CRC	cis	rs9292777	0.901	rs957100	chr5:40426420	G/T	cg09067459	chr5:40385259	NA	0.53	9.32	0.46	1.7e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs9463078	0.774	rs7451423	chr6:45241343	C/T	cg25276700	chr6:44698697	NA	-0.27	-6.35	-0.33	7.14e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs12476592	0.543	rs262513	chr2:63890766	T/A	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14761318	chr5:68788469	OCLN	0.39	6.52	0.34	2.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg03316587	chr8:142245164	NA	0.37	5.63	0.3	3.81e-8	Immature fraction of reticulocytes;
CRC	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg09760422	chr2:128146352	NA	-0.36	-6.9	-0.36	2.6e-11	Protein C levels;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-6.68	-0.35	1.02e-10	Blood pressure (smoking interaction);
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg15845792	chr6:28175446	NA	0.76	10.74	0.51	2.89e-23	Parkinson's disease;
CRC	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg06781209	chr11:61594997	FADS2	-0.4	-6.01	-0.31	4.91e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
CRC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.94	-16.83	-0.68	2.79e-46	Height;
CRC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.67	-0.39	2.03e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.88	16.34	0.67	2.37e-44	Intelligence (multi-trait analysis);
CRC	cis	rs1124376	1.000	rs9857135	chr3:20147790	G/A	cg05072819	chr3:20081367	KAT2B	0.49	5.92	0.31	8.07e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.72	-8.29	-0.42	2.99e-15	Obesity-related traits;
CRC	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg23032129	chr1:109941072	SORT1	0.28	5.89	0.31	9.37e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.24	0.41	4.11e-15	Life satisfaction;
CRC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.98	-19.27	-0.73	6.62e-56	Height;
CRC	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.92	-16.83	-0.68	2.69e-46	Longevity;
CRC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg05501817	chr11:14380813	RRAS2	0.41	5.67	0.3	3.19e-8	Sense of smell;
CRC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.73	-8.31	-0.42	2.51e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.72	-7.89	-0.4	4.61e-14	Psoriasis;
CRC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg19582491	chr16:67682965	RLTPR	-0.58	-6.95	-0.36	1.99e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	6.39	0.33	5.66e-10	Menopause (age at onset);
CRC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.73	0.3	2.31e-8	Coronary artery disease;
CRC	trans	rs10242455	0.867	rs45624139	chr7:99319495	T/C	cg09045935	chr12:6379348	NA	0.61	6.06	0.32	3.65e-9	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04318602	chr14:53162623	ERO1L	0.44	7.34	0.38	1.7e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg14593290	chr7:50529359	DDC	-0.49	-7.0	-0.36	1.42e-11	Systemic sclerosis;
CRC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg26805224	chr10:79626177	DLG5	-0.48	-6.96	-0.36	1.81e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.39	-6.48	-0.34	3.27e-10	IgG glycosylation;
CRC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.62	-11.47	-0.53	7.71e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	1.23	15.4	0.65	1.15e-40	Lung disease severity in cystic fibrosis;
CRC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg14768367	chr16:72042858	DHODH	0.77	6.05	0.32	3.84e-9	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg06470822	chr6:28175283	NA	-0.61	-6.14	-0.32	2.42e-9	Depression;
CRC	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg25838818	chr2:108905173	SULT1C2	-0.35	-5.93	-0.31	7.49e-9	Blood pressure;
CRC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.5	5.82	0.31	1.41e-8	Vitiligo;
CRC	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg00319359	chr11:70116639	PPFIA1	0.65	6.89	0.36	2.78e-11	Coronary artery disease;
CRC	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00376283	chr12:123451042	ABCB9	0.54	7.13	0.37	6.4e-12	Neutrophil percentage of white cells;
CRC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.58	8.44	0.42	1.04e-15	Lymphocyte counts;
CRC	trans	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg07817883	chr1:32538562	TMEM39B	0.69	7.62	0.39	2.75e-13	Monocyte percentage of white cells;
CRC	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg10517650	chr3:113235015	CCDC52	-0.41	-7.05	-0.36	1.04e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.52e-18	Depression;
CRC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.6	9.96	0.48	1.31e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.64	8.64	0.43	2.5e-16	Alcohol dependence;
CRC	cis	rs8010715	0.636	rs3825584	chr14:24587639	C/T	cg23112188	chr14:24563095	PCK2	-0.37	-6.91	-0.36	2.57e-11	IgG glycosylation;
CRC	cis	rs6496667	1.000	rs1971898	chr15:90890836	C/G	cg04176472	chr15:90893244	GABARAPL3	0.53	8.15	0.41	7.58e-15	Rheumatoid arthritis;
CRC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.79e-15	Bone mineral density;
CRC	cis	rs6662572	0.737	rs77017199	chr1:46532407	G/A	cg08644498	chr1:46502608	NA	0.42	6.48	0.34	3.29e-10	Blood protein levels;
CRC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.62	-8.09	-0.41	1.2e-14	Immature fraction of reticulocytes;
CRC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg00717180	chr2:96193071	NA	-0.37	-6.11	-0.32	2.77e-9	HDL cholesterol;
CRC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.53	-7.87	-0.4	5.15e-14	Blood protein levels;
CRC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.62	-15.03	-0.64	3.08e-39	Alcohol dependence;
CRC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.52	6.74	0.35	7.13e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg04132472	chr17:19861366	AKAP10	0.44	6.86	0.35	3.48e-11	Schizophrenia;
CRC	trans	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg22319618	chr22:45562946	NUP50	0.6	6.95	0.36	1.91e-11	Breast cancer;
CRC	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.67	9.25	0.45	2.84e-18	Hair shape;
CRC	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg06042504	chr8:55087323	NA	-0.36	-5.72	-0.3	2.45e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg03934865	chr2:198174659	NA	-0.4	-6.09	-0.32	3.09e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-5.81	-0.31	1.47e-8	Schizophrenia;
CRC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	8.58	0.43	3.91e-16	Chronic sinus infection;
CRC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.12	0.37	6.76e-12	Morning vs. evening chronotype;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg02683197	chr6:28174875	NA	0.67	9.18	0.45	4.91e-18	Cardiac Troponin-T levels;
CRC	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg21918786	chr6:109611834	NA	-0.35	-5.93	-0.31	7.65e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.56	8.66	0.43	2.16e-16	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs573890	chr11:108251363	C/G	cg14761454	chr11:108092087	ATM;NPAT	-0.4	-6.05	-0.32	3.99e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg23229984	chr5:148520753	ABLIM3	-0.44	-5.89	-0.31	9.41e-9	Breast cancer;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.07	-28.55	-0.84	4.63e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.86	-15.97	-0.66	6.87e-43	Menopause (age at onset);
CRC	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg13385794	chr1:248469461	NA	0.33	5.7	0.3	2.67e-8	Common traits (Other);
CRC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.83e-8	Major depressive disorder;
CRC	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg15687855	chr3:44754131	ZNF502	-0.34	-5.69	-0.3	2.84e-8	Depressive symptoms;
CRC	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg06632207	chr12:54070931	ATP5G2	0.37	6.24	0.33	1.32e-9	Height;
CRC	cis	rs282587	0.569	rs395246	chr13:113415392	C/A	cg04656015	chr13:113407548	ATP11A	0.59	7.56	0.38	3.96e-13	Glycated hemoglobin levels;
CRC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.3	6.03	0.32	4.51e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.39	-6.03	-0.32	4.52e-9	Breast cancer;
CRC	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.66	6.47	0.34	3.49e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.19	0.32	1.76e-9	Mean platelet volume;
CRC	trans	rs6716963	0.597	rs34518729	chr2:194452807	A/T	cg00362665	chr19:19370064	HAPLN4	-0.35	-5.97	-0.31	6.03e-9	Schizophrenia;
CRC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.54	-5.91	-0.31	8.5e-9	Schizophrenia;
CRC	cis	rs9326248	0.574	rs1263173	chr11:116681008	C/T	cg26566898	chr11:117069891	TAGLN	0.27	5.85	0.31	1.18e-8	Blood protein levels;
CRC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.46	-7.1	-0.36	7.94e-12	Cardiovascular disease risk factors;
CRC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.83	0.35	4.22e-11	Mean platelet volume;
CRC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.36	-7.46	-0.38	7.99e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.59	7.23	0.37	3.38e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.88	-0.35	3.04e-11	Retinal vascular caliber;
CRC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg19812747	chr11:111475976	SIK2	-0.58	-10.08	-0.49	5.38e-21	Primary sclerosing cholangitis;
CRC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.44	-7.27	-0.37	2.58e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg05250797	chr16:70222502	NA	0.42	5.65	0.3	3.45e-8	IgE levels;
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.46	-0.38	7.85e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs17155006	0.651	rs416811	chr7:107724047	G/C	cg05962710	chr7:107745446	LAMB4	-0.36	-5.85	-0.31	1.17e-8	Pneumococcal bacteremia;
CRC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.5	8.04	0.41	1.68e-14	Height;
CRC	cis	rs12024301	0.557	rs10911392	chr1:183617311	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.12	0.37	6.85e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.27	11.15	0.52	1.07e-24	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9659323	1.000	rs56897173	chr1:119515732	G/A	cg26570165	chr1:119541833	NA	-0.38	-6.42	-0.33	4.63e-10	Body mass index;
CRC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.51	8.11	0.41	1.01e-14	Red blood cell count;
CRC	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.49	7.89	0.4	4.49e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.4	-6.75	-0.35	6.61e-11	Blood metabolite levels;
CRC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	13.54	0.6	1.74e-33	Electrocardiographic conduction measures;
CRC	cis	rs4731207	0.672	rs2896360	chr7:124448516	T/C	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.86	-0.31	1.1e-8	Aortic root size;
CRC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg27266060	chr8:22091797	NA	-0.36	-6.04	-0.32	4.12e-9	Hypertriglyceridemia;
CRC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg08888203	chr3:10149979	C3orf24	0.48	7.29	0.37	2.31e-12	Alzheimer's disease;
CRC	cis	rs7605827	0.930	rs12692266	chr2:15572380	T/C	cg19274914	chr2:15703543	NA	0.39	5.86	0.31	1.15e-8	Educational attainment (years of education);
CRC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.31	5.76	0.3	1.95e-8	Huntington's disease progression;
CRC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg20399509	chr21:47717575	C21orf57	-0.34	-5.71	-0.3	2.56e-8	Testicular germ cell tumor;
CRC	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.1	0.52	1.55e-24	Coffee consumption (cups per day);
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.5	7.0	0.36	1.42e-11	Lung cancer;
CRC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.62	9.16	0.45	5.49e-18	Blood protein levels;
CRC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.81	11.25	0.53	4.61e-25	Orofacial clefts;
CRC	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.4	-0.33	5.49e-10	Body mass index;
CRC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.73	-11.79	-0.54	5.35e-27	Monocyte count;
CRC	cis	rs1144713	0.531	rs2683491	chr12:32250865	A/T	cg01321189	chr12:32259338	BICD1	0.5	7.04	0.36	1.1e-11	Obesity-related traits;
CRC	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	0.95	12.54	0.57	9.76e-30	IgG glycosylation;
CRC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg15845792	chr6:28175446	NA	0.76	7.42	0.38	9.81e-13	Depression;
CRC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.37	-0.38	1.43e-12	Neuroticism;
CRC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.62	-8.72	-0.43	1.4e-16	Subjective well-being;
CRC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg27068330	chr11:65405492	SIPA1	0.43	6.35	0.33	7.22e-10	Acne (severe);
CRC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg19812747	chr11:111475976	SIK2	0.42	6.26	0.33	1.22e-9	Primary sclerosing cholangitis;
CRC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-7.01	-0.36	1.37e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg05304507	chr6:116381966	FRK	0.28	6.44	0.33	4.3e-10	Total cholesterol levels;
CRC	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.51	7.52	0.38	5.31e-13	Asthma;
CRC	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg12856521	chr11:46389249	DGKZ	-0.43	-6.86	-0.35	3.47e-11	Leprosy;
CRC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg06634786	chr22:41940651	POLR3H	-0.44	-5.7	-0.3	2.66e-8	Neuroticism;
CRC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-13.61	-0.6	9.01e-34	Blood metabolite levels;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg26587870	chr6:27730563	NA	-0.44	-6.78	-0.35	5.42e-11	Parkinson's disease;
CRC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4073416	0.542	rs11158604	chr14:66094450	G/A	cg03016385	chr14:66212404	NA	-0.45	-6.2	-0.32	1.67e-9	N-glycan levels;
CRC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.68	-8.41	-0.42	1.26e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.55	8.67	0.43	2.02e-16	Type 2 diabetes;
CRC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.36	-0.33	6.81e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.75	-0.3	2.06e-8	Crohn's disease;
CRC	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.64	-9.36	-0.46	1.32e-18	Waist circumference;Body mass index;
CRC	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg09344028	chr17:70110421	NA	0.5	7.38	0.38	1.32e-12	Thyroid hormone levels;
CRC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.48	6.5	0.34	2.89e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg16606324	chr3:10149918	C3orf24	0.6	8.18	0.41	6.05e-15	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.48	7.56	0.38	4.07e-13	Red blood cell count;
CRC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.59	6.52	0.34	2.68e-10	Skin colour saturation;
CRC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.24e-16	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.71	9.38	0.46	1.1e-18	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.71	0.35	8.69e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs780094	0.500	rs6760250	chr2:27812252	G/A	cg27432699	chr2:27873401	GPN1	0.48	6.33	0.33	8.08e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.78	-13.48	-0.6	2.8e-33	Breast cancer;
CRC	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg09659197	chr4:152720779	NA	0.33	5.76	0.3	1.92e-8	Intelligence (multi-trait analysis);
CRC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.63	13.98	0.61	3.61e-35	Airflow obstruction;
CRC	cis	rs10944	0.598	rs559088	chr5:78275931	G/C	cg13121490	chr5:78280331	ARSB	-0.46	-6.75	-0.35	6.56e-11	Blood and toenail selenium levels;
CRC	trans	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg01448155	chr10:3564782	NA	-0.5	-6.09	-0.32	3.23e-9	Lymphocyte percentage of white cells;
CRC	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.7	-7.34	-0.38	1.68e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.5	6.97	0.36	1.7e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg26585868	chr7:149322723	ZNF767	0.4	6.03	0.32	4.48e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.73	-8.21	-0.41	5.01e-15	Psoriasis;
CRC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.75	12.42	0.56	2.62e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.85	0.7	2.61e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg04165759	chr1:150448943	RPRD2	0.35	5.62	0.3	4.04e-8	Migraine;
CRC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.72	10.6	0.5	9.06e-23	Immature fraction of reticulocytes;
CRC	trans	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12172441	chr6:28176163	NA	0.6	7.27	0.37	2.64e-12	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11830880	chr17:34136324	TAF15	0.49	6.34	0.33	7.51e-10	Thyroid stimulating hormone;
CRC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg05673287	chr15:77411982	SGK269	0.52	7.93	0.4	3.47e-14	Type 2 diabetes;
CRC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.05	0.45	1.31e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07926482	chr16:84651521	COTL1	0.38	6.16	0.32	2.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.62	11.31	0.53	2.82e-25	Immature fraction of reticulocytes;
CRC	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg09695851	chr17:3907499	NA	0.76	14.41	0.62	8.08e-37	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.71	0.35	8.37e-11	Lung cancer;
CRC	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.4	-0.33	5.25e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.58	-7.74	-0.39	1.26e-13	Renal function-related traits (BUN);
CRC	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.57	-7.79	-0.39	8.85e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-1.1	-17.93	-0.7	1.29e-50	Blood pressure (smoking interaction);
CRC	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.52	6.78	0.35	5.7e-11	Exhaled nitric oxide output;
CRC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.27	0.33	1.15e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6681460	1.000	rs6680944	chr1:67122565	A/T	cg02459107	chr1:67143332	SGIP1	0.48	8.35	0.42	1.92e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs970548	0.954	rs7076198	chr10:45996309	C/T	cg15590007	chr10:45870220	ALOX5	0.48	6.04	0.32	4.24e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.53	-7.36	-0.38	1.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6840360	0.642	rs6851814	chr4:152346437	G/A	cg09659197	chr4:152720779	NA	0.34	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.53	8.88	0.44	4.46e-17	Calcium levels;
CRC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.2	0.37	4.23e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.68	8.53	0.43	5.4e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18758796	chr5:131593413	PDLIM4	0.42	7.67	0.39	2.02e-13	Breast cancer;
CRC	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg20159608	chr7:32802032	NA	-0.62	-7.79	-0.39	8.77e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12560992	chr17:57184187	TRIM37	0.52	7.27	0.37	2.56e-12	Testicular germ cell tumor;
CRC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.8	-0.48	4.78e-20	Body mass index;
CRC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.56	-7.81	-0.4	7.96e-14	Pancreatic cancer;
CRC	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/A	cg12701268	chr15:85882886	NA	-0.46	-7.42	-0.38	9.86e-13	Central corneal thickness;Corneal structure;
CRC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.48	-9.49	-0.46	4.92e-19	Renal cell carcinoma;
CRC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg22777020	chr22:31556080	RNF185	0.46	5.61	0.3	4.21e-8	Colorectal cancer;
CRC	cis	rs9287719	0.649	rs10929683	chr2:10732208	C/T	cg00105475	chr2:10696890	NA	-0.45	-7.07	-0.36	9.3e-12	Prostate cancer;
CRC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.6	-9.52	-0.46	3.88e-19	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg11900509	chr10:81946545	ANXA11	-0.68	-6.77	-0.35	5.99e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg26695010	chr11:65641043	EFEMP2	0.48	7.43	0.38	9.26e-13	Eosinophil percentage of white cells;
CRC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.61	-9.46	-0.46	5.98e-19	Body mass index;
CRC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg21747405	chr11:67723411	NA	-0.5	-6.24	-0.33	1.34e-9	Blood pressure (smoking interaction);
CRC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg13073564	chr4:8508604	NA	0.4	6.06	0.32	3.66e-9	Response to antineoplastic agents;
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.91	-16.51	-0.67	5.17e-45	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.71	-10.34	-0.5	7.19e-22	Platelet distribution width;
CRC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg09658497	chr7:2847517	GNA12	-0.38	-6.32	-0.33	8.56e-10	Height;
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg25838818	chr2:108905173	SULT1C2	-0.35	-5.91	-0.31	8.58e-9	Blood pressure;
CRC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-16.54	-0.67	3.73e-45	Schizophrenia;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.64	-8.91	-0.44	3.59e-17	Menopause (age at onset);
CRC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg22676075	chr6:135203613	NA	0.41	6.35	0.33	7.28e-10	Red blood cell count;
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.9	-0.44	3.76e-17	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg05579598	chr16:88989069	CBFA2T3	0.35	6.99	0.36	1.5e-11	Social autistic-like traits;
CRC	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12560992	chr17:57184187	TRIM37	0.54	7.62	0.39	2.77e-13	Testicular germ cell tumor;
CRC	cis	rs12760731	0.582	rs12046110	chr1:178531117	C/T	cg00404053	chr1:178313656	RASAL2	-0.61	-6.89	-0.36	2.86e-11	Obesity-related traits;
CRC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.65	-0.68	1.36e-45	Height;
CRC	cis	rs7113874	0.589	rs6578969	chr11:8488991	G/A	cg02811074	chr11:8615871	STK33	-0.36	-6.17	-0.32	2.04e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12745968	0.623	rs6604007	chr1:93170564	G/A	cg17283838	chr1:93427260	FAM69A	-0.44	-5.99	-0.31	5.41e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.84	0.48	3.41e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.49	6.21	0.32	1.62e-9	Red blood cell count;
CRC	cis	rs4731207	0.596	rs12533918	chr7:124647263	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.24	-0.33	1.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.55	8.93	0.44	3.13e-17	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17159837	chr22:38864121	KDELR3	0.46	6.27	0.33	1.11e-9	Anxiety disorder;
CRC	trans	rs2303319	0.504	rs56407015	chr2:162455625	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.17	-0.32	2.06e-9	Cognitive function;
CRC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.78	-8.56	-0.43	4.25e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7605827	0.860	rs13425097	chr2:15528920	C/G	cg19274914	chr2:15703543	NA	0.4	5.97	0.31	6.31e-9	Educational attainment (years of education);
CRC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg05044414	chr3:183734942	ABCC5	-0.38	-6.56	-0.34	2.14e-10	Anterior chamber depth;
CRC	cis	rs12024301	0.557	rs75462421	chr1:183623105	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-7.09	-0.36	8.44e-12	Blood protein levels;
CRC	cis	rs713477	0.618	rs6573033	chr14:55919060	C/G	cg13175173	chr14:55914753	NA	-0.43	-7.48	-0.38	6.98e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.22	-0.32	1.53e-9	Bipolar disorder;
CRC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.82	0.35	4.43e-11	Obesity-related traits;
CRC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.81	-0.3	1.52e-8	Migraine;Coronary artery disease;
CRC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.48	7.39	0.38	1.19e-12	Corneal astigmatism;
CRC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.56	9.01	0.44	1.77e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg03623178	chr6:28175578	NA	0.87	12.49	0.57	1.51e-29	Parkinson's disease;
CRC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.03	-0.36	1.22e-11	Psoriasis;
CRC	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.17	-0.32	1.97e-9	Blood protein levels;
CRC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.44	-8.56	-0.43	4.34e-16	Prostate cancer;
CRC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.34	5.83	0.31	1.3e-8	Major depressive disorder;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20092199	chr4:1342459	KIAA1530	0.34	5.9	0.31	8.88e-9	Obesity-related traits;
CRC	cis	rs62408225	0.748	rs7744528	chr6:90916931	C/G	cg06866423	chr6:90926672	BACH2	0.65	12.2	0.56	1.65e-28	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.61	-8.87	-0.44	4.81e-17	Schizophrenia;
CRC	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.84	-0.4	6.52e-14	Bladder cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06911519	chr2:28615662	FOSL2	0.53	6.87	0.35	3.29e-11	Thyroid stimulating hormone;
CRC	trans	rs9409565	0.826	rs9409564	chr9:97248166	C/T	cg05679027	chr9:99775184	HIATL2	-0.41	-6.22	-0.32	1.52e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg17346650	chr17:80929145	B3GNTL1	0.46	6.7	0.35	8.82e-11	Glycated hemoglobin levels;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg09877947	chr5:131593287	PDLIM4	0.45	8.43	0.42	1.13e-15	Breast cancer;
CRC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.9	0.36	2.61e-11	Height;
CRC	cis	rs6088813	1.000	rs6141549	chr20:33974051	T/C	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs2933343	1.000	rs1683776	chr3:128622760	G/T	cg11901034	chr3:128598214	ACAD9	-0.51	-6.2	-0.32	1.71e-9	IgG glycosylation;
CRC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-8.83	-0.44	6.46e-17	Monocyte percentage of white cells;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.67	0.3	3.09e-8	Cardiac Troponin-T levels;
CRC	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg19041857	chr6:27730383	NA	-0.46	-5.96	-0.31	6.49e-9	Parkinson's disease;
CRC	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.47	0.34	3.65e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8005677	0.828	rs4981451	chr14:23410281	T/C	cg25600027	chr14:23388339	RBM23	-0.43	-6.44	-0.33	4.13e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.49	6.4	0.33	5.23e-10	Longevity;
CRC	trans	rs1569175	0.655	rs3115414	chr2:200913244	A/C	cg12143499	chr12:27615389	NA	0.68	6.02	0.31	4.75e-9	Response to treatment for acute lymphoblastic leukemia;
CRC	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg01312482	chr5:178451176	ZNF879	-0.36	-6.02	-0.32	4.59e-9	Pubertal anthropometrics;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10317628	chr1:117113342	CD58	0.54	6.93	0.36	2.18e-11	Thyroid stimulating hormone;
CRC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg04121214	chr22:50244548	NA	0.41	5.86	0.31	1.14e-8	Schizophrenia;
CRC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.57	9.63	0.47	1.65e-19	Menopause (age at onset);
CRC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.56	-9.15	-0.45	6.29e-18	Vitiligo;
CRC	cis	rs3996993	0.809	rs59119896	chr6:52688467	G/A	cg20803780	chr6:52668592	GSTA1	0.35	6.19	0.32	1.74e-9	Hemoglobin concentration;
CRC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.49	7.66	0.39	2.06e-13	Mean platelet volume;
CRC	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg12046867	chr14:103022105	NA	0.42	6.21	0.32	1.56e-9	Platelet count;
CRC	cis	rs12936587	0.692	rs12943416	chr17:17535535	A/C	cg09796270	chr17:17721594	SREBF1	-0.42	-5.92	-0.31	8.01e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.42	9.11	0.45	7.94e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg16476235	chr8:21771668	DOK2	0.37	6.44	0.33	4.13e-10	Mean corpuscular volume;
CRC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg02659138	chr7:134003124	SLC35B4	-0.39	-6.68	-0.35	1.02e-10	Mean platelet volume;
CRC	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg01639898	chr1:32083012	HCRTR1	0.3	6.27	0.33	1.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg22638593	chr5:131593259	PDLIM4	0.39	6.39	0.33	5.55e-10	Acylcarnitine levels;
CRC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg24881330	chr22:46731750	TRMU	0.64	5.9	0.31	9.08e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19451435	chr6:158402916	SYNJ2	-0.4	-6.45	-0.34	4.1e-10	Aortic root size;
CRC	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.56	-7.25	-0.37	2.96e-12	Vitiligo;
CRC	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.49	-5.99	-0.31	5.65e-9	Coronary artery calcification;
CRC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.67	9.29	0.46	2.13e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.99	-0.4	2.29e-14	Height;
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg04562611	chr16:615315	C16orf11	0.39	6.72	0.35	7.88e-11	Height;
CRC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.16	-0.79	4.32e-71	Myeloid white cell count;
CRC	trans	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7605827	0.930	rs7598068	chr2:15596535	A/T	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	8.31e-9	Educational attainment (years of education);
CRC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg00255919	chr5:131827918	IRF1	0.36	6.21	0.32	1.57e-9	Breast cancer;Mosquito bite size;
CRC	trans	rs7179994	0.579	rs55802438	chr15:28300339	G/A	cg05237436	chr5:138533428	SIL1	0.7	6.28	0.33	1.1e-9	Shingles;
CRC	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.6	9.36	0.46	1.28e-18	Lewy body disease;
CRC	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg25809561	chr17:30822961	MYO1D	0.52	9.19	0.45	4.5e-18	Schizophrenia;
CRC	cis	rs3823572	0.542	rs11767663	chr7:133630596	T/C	cg03336402	chr7:133662267	EXOC4	0.68	10.44	0.5	3.23e-22	Intelligence (multi-trait analysis);
CRC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.77	-9.05	-0.45	1.31e-17	Hemostatic factors and hematological phenotypes;
CRC	cis	rs360798	0.532	rs2421816	chr2:63075033	C/A	cg17519650	chr2:63277830	OTX1	0.47	6.49	0.34	3.19e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07464025	chr10:13482639	BEND7	0.44	7.39	0.38	1.21e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7680126	0.633	rs4698040	chr4:10352550	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-6.47	-0.34	3.65e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.51	8.07	0.41	1.34e-14	Red blood cell count;
CRC	trans	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg06840491	chr10:48416966	GDF2	-0.36	-6.13	-0.32	2.56e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Blood metabolite levels;
CRC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.67	9.26	0.45	2.74e-18	Multiple sclerosis;
CRC	trans	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg17154259	chr5:32444035	ZFR	0.53	6.29	0.33	1.02e-9	Breast cancer;
CRC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.5	0.34	2.94e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg10596483	chr8:143751796	JRK	-0.46	-6.44	-0.33	4.22e-10	Urinary tract infection frequency;
CRC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.56	-7.84	-0.4	6.21e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.72	10.65	0.51	5.79e-23	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18395393	chr17:8339079	NDEL1	0.42	7.03	0.36	1.23e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649465	0.846	rs13044	chr7:123322716	T/A	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.43	8.25	0.41	3.9e-15	Alcohol dependence;
CRC	cis	rs4363385	0.667	rs399550	chr1:153049917	T/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.86e-10	Inflammatory skin disease;
CRC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.9	16.4	0.67	1.32e-44	Prostate cancer;
CRC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.38	-6.52	-0.34	2.59e-10	Aortic root size;
CRC	cis	rs9463078	0.702	rs9369530	chr6:45024911	G/A	cg25276700	chr6:44698697	NA	-0.23	-5.62	-0.3	3.99e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs858239	0.676	rs3807459	chr7:23389751	T/C	cg00469287	chr7:23338798	C7orf30	0.42	5.79	0.3	1.63e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.71	-10.4	-0.5	4.34e-22	Menarche (age at onset);
CRC	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.64	10.17	0.49	2.62e-21	Lewy body disease;
CRC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg22535103	chr8:58192502	C8orf71	-0.48	-5.71	-0.3	2.57e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.56	8.23	0.41	4.34e-15	Longevity;Endometriosis;
CRC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.6	-9.07	-0.45	1.07e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.57	8.49	0.42	7.19e-16	Type 2 diabetes;
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.81	-11.56	-0.54	3.67e-26	Bipolar disorder and schizophrenia;
CRC	trans	rs7027930	0.524	rs4585791	chr9:614530	T/A	cg27061366	chr19:13044373	FARSA	0.47	6.02	0.31	4.62e-9	Pulmonary function decline;
CRC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11800820	0.567	rs3129568	chr1:246707858	A/G	cg26885821	chr6:124125002	NKAIN2	0.38	6.09	0.32	3.11e-9	Obesity-related traits;
CRC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.11	0.52	1.46e-24	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg05283184	chr6:79620031	NA	-0.45	-6.46	-0.34	3.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9549328	0.670	rs61963562	chr13:113616523	T/G	cg25790453	chr13:113633590	MCF2L	0.43	7.55	0.38	4.25e-13	Systolic blood pressure;
CRC	cis	rs6076065	0.723	rs7988	chr20:23352685	C/A	cg11657817	chr20:23433608	CST11	0.43	6.46	0.34	3.77e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg06470822	chr6:28175283	NA	0.72	10.35	0.5	6.55e-22	Parkinson's disease;
CRC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg00745463	chr17:30367425	LRRC37B	-0.45	-6.03	-0.32	4.35e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.58	6.71	0.35	8.55e-11	Vitiligo;
CRC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.59	7.9	0.4	4.3e-14	Mean platelet volume;
CRC	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.42	-8.37	-0.42	1.67e-15	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg04800585	chr6:26043546	HIST1H2BB	0.57	8.36	0.42	1.76e-15	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.13	0.32	2.57e-9	Tonsillectomy;
CRC	cis	rs10905065	0.827	rs7089100	chr10:5849877	C/G	cg25171089	chr10:5708825	ASB13	0.42	5.86	0.31	1.13e-8	Menopause (age at onset);
CRC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.83	15.4	0.65	1.1e-40	Dental caries;
CRC	trans	rs9826463	0.941	rs73238201	chr3:142204728	C/T	cg13928417	chr9:124498782	DAB2IP	-0.54	-6.47	-0.34	3.48e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.81	-0.3	1.51e-8	Lung cancer;
CRC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.46	6.75	0.35	6.76e-11	Bone mineral density (spine);
CRC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.87	-0.48	2.63e-20	Neuroticism;
CRC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.55	8.67	0.43	2.03e-16	Colorectal cancer;
CRC	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg07501729	chr16:846077	CHTF18	0.56	8.39	0.42	1.44e-15	Mean corpuscular volume;
CRC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.97	15.81	0.66	2.91e-42	Testicular germ cell tumor;
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg12516270	chr8:143859308	LYNX1	0.41	7.23	0.37	3.32e-12	Urinary tract infection frequency;
CRC	trans	rs586533	0.634	rs676649	chr11:99533358	C/T	cg14135551	chr6:39760416	DAAM2	0.36	6.0	0.31	5.31e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.3	0.46	2.07e-18	Cognitive test performance;
CRC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg02659138	chr7:134003124	SLC35B4	0.43	7.58	0.39	3.52e-13	Mean platelet volume;
CRC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg12751644	chr20:60527061	NA	-0.38	-5.84	-0.31	1.25e-8	Body mass index;
CRC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.61	-0.43	3.14e-16	Monocyte percentage of white cells;
CRC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg18827107	chr12:86230957	RASSF9	-0.39	-6.32	-0.33	8.28e-10	Major depressive disorder;
CRC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg23996704	chr18:44553084	KATNAL2	-0.3	-6.25	-0.33	1.3e-9	Personality dimensions;
CRC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.63	-10.38	-0.5	5.12e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg24463073	chr6:118973353	C6orf204	0.54	7.24	0.37	3.26e-12	Diastolic blood pressure;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg21251018	chr6:28226885	NKAPL	0.51	5.95	0.31	6.9e-9	Depression;
CRC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.44	6.86	0.35	3.48e-11	Blood metabolite levels;
CRC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg20607287	chr7:12443886	VWDE	-0.69	-7.29	-0.37	2.4e-12	Coronary artery disease;
CRC	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.83	15.59	0.65	2e-41	Lewy body disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00668182	chr20:30795591	POFUT1;PLAGL2	0.48	6.74	0.35	7.13e-11	Anxiety disorder;
CRC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	0.88	10.85	0.51	1.17e-23	Left atrial antero-posterior diameter;
CRC	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.29	-0.33	1.01e-9	Depression;
CRC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.22	0.32	1.52e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11645453	chr3:52864694	ITIH4	0.36	6.27	0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg16670446	chr17:27188758	MIR451;MIR144	0.57	8.94	0.44	2.76e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2055729	0.614	rs17150693	chr8:9741652	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.77	0.35	5.77e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.83	-0.44	6.49e-17	Chronic sinus infection;
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.75	-11.85	-0.55	3.3e-27	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg15511327	chr8:143859410	LYNX1	0.41	7.15	0.37	5.68e-12	Urinary tract infection frequency;
CRC	trans	rs6075982	0.749	rs6082952	chr20:22947253	C/T	cg03184243	chr8:28347962	FBXO16	0.48	6.08	0.32	3.27e-9	Obesity-related traits;
CRC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg10729496	chr3:10149963	C3orf24	0.51	5.9	0.31	8.81e-9	Alzheimer's disease;
CRC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.44	-0.33	4.12e-10	Life satisfaction;
CRC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.92	0.4	3.63e-14	Resting heart rate;
CRC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-7.99	-0.4	2.33e-14	Vitiligo;
CRC	cis	rs2637266	0.600	rs11001822	chr10:78325833	T/C	cg18941641	chr10:78392320	NA	-0.35	-5.85	-0.31	1.21e-8	Pulmonary function;
CRC	cis	rs9534288	0.619	rs6561290	chr13:46682460	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-7.83	-0.4	6.95e-14	Blood protein levels;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.37	-6.66	-0.34	1.15e-10	Lymphocyte counts;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg25164649	chr6:28176230	NA	0.55	5.75	0.3	2e-8	Depression;
CRC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.69	-0.47	1.08e-19	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03249710	chr13:48611439	NUDT15	0.42	6.36	0.33	6.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.51	7.2	0.37	4.04e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg16797656	chr11:68205561	LRP5	0.46	6.46	0.34	3.87e-10	Total body bone mineral density (age 45-60);
CRC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg19046167	chr17:80928561	B3GNTL1	0.44	7.47	0.38	7.18e-13	Breast cancer;
CRC	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs6694672	0.681	rs476390	chr1:197253267	T/C	cg13682187	chr1:196946512	CFHR5	0.5	7.05	0.36	1.05e-11	Asthma;
CRC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.74	8.78	0.44	9.19e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.8	-10.38	-0.5	4.95e-22	Initial pursuit acceleration;
CRC	cis	rs519973	1.000	rs763342	chr3:187639375	G/T	cg10168494	chr3:187635183	NA	-0.5	-8.7	-0.43	1.66e-16	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-7.07	-0.36	9.32e-12	Colorectal cancer;
CRC	trans	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.6	-0.34	1.6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg15898840	chr7:45960834	IGFBP3	0.44	7.19	0.37	4.47e-12	Sitting height ratio;
CRC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg07274523	chr3:49395745	GPX1	0.45	6.05	0.32	4.03e-9	Educational attainment (college completion);
CRC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.29	5.87	0.31	1.07e-8	Homoarginine levels;
CRC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	7.16	0.37	5.3e-12	Breast cancer;
CRC	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.25	-0.33	1.31e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.85	-0.31	1.2e-8	Alcohol dependence;
CRC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549328	0.614	rs35872678	chr13:113617231	A/T	cg24588162	chr13:113633484	MCF2L	0.36	6.49	0.34	3.22e-10	Systolic blood pressure;
CRC	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg06606381	chr12:133084897	FBRSL1	-0.9	-7.56	-0.38	4.17e-13	Depression;
CRC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.53	-6.05	-0.32	3.84e-9	Schizophrenia;
CRC	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	7.09	0.36	8.04e-12	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4936891	0.577	rs11219422	chr11:123920178	C/T	cg22125253	chr11:123886957	OR10G4	-0.34	-6.13	-0.32	2.46e-9	Male fertility;
CRC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.07	0.45	1.07e-17	Lung cancer;
CRC	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.39	-6.91	-0.36	2.46e-11	Survival in sporadic amyotrophic lateral sclerosis;
CRC	cis	rs10221833	0.530	rs355888	chr2:165634551	A/G	cg03182029	chr2:165697222	COBLL1	0.52	6.09	0.32	3.22e-9	Response to statin therapy;
CRC	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg23032129	chr1:109941072	SORT1	-0.28	-5.81	-0.31	1.47e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs12024301	0.557	rs10911415	chr1:183664889	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00745463	chr17:30367425	LRRC37B	0.7	7.21	0.37	3.77e-12	Hip circumference adjusted for BMI;
CRC	cis	rs9914988	0.576	rs11080075	chr17:27322441	A/C	cg16670446	chr17:27188758	MIR451;MIR144	-0.45	-6.22	-0.32	1.51e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.69	-0.35	9.62e-11	Prevalent atrial fibrillation;
CRC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.43	-9.48	-0.46	5.3e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.65	8.78	0.44	9.01e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.59	-9.43	-0.46	7.91e-19	Tonsillectomy;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.68	11.28	0.53	3.69e-25	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg24209194	chr3:40518798	ZNF619	0.42	6.33	0.33	8.25e-10	Renal cell carcinoma;
CRC	cis	rs755249	0.567	rs16825939	chr1:39662508	G/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.93	-0.31	7.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.65	7.78	0.39	9.55e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7215564	0.908	rs35844609	chr17:78664850	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.39	6.13	0.32	2.55e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-6.77	-0.35	5.89e-11	Platelet distribution width;
CRC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg18230493	chr5:56204884	C5orf35	-0.43	-5.66	-0.3	3.31e-8	Type 2 diabetes;
CRC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.6	7.34	0.37	1.73e-12	Obesity (extreme);
CRC	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-5.6	-0.3	4.43e-8	Putamen volume;
CRC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.45	9.19	0.45	4.67e-18	Renal cell carcinoma;
CRC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.83	15.2	0.64	6.7e-40	Breast cancer;
CRC	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.56	9.03	0.45	1.43e-17	Mean corpuscular volume;
CRC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.85	14.08	0.61	1.42e-35	Blood metabolite levels;
CRC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.53	-8.42	-0.42	1.16e-15	Coronary artery disease;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg26587870	chr6:27730563	NA	-0.45	-7.08	-0.36	8.96e-12	Parkinson's disease;
CRC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.55	-7.98	-0.4	2.46e-14	Mean platelet volume;
CRC	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.47	6.96	0.36	1.9e-11	Red blood cell count;
CRC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg20684491	chr1:25596433	NA	0.42	7.37	0.38	1.37e-12	Erythrocyte sedimentation rate;
CRC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.49	7.71	0.39	1.48e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.59	8.81	0.44	7.57e-17	Aortic root size;
CRC	cis	rs3736485	0.578	rs1456300	chr15:51982016	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.86	-0.31	1.14e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21554109	chr19:18747733	KLHL26	0.56	9.05	0.45	1.31e-17	Liver disease severity in Alagille syndrome;
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	0.8	7.35	0.38	1.58e-12	IgG glycosylation;
CRC	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.85	-12.21	-0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.43e-13	Type 2 diabetes;
CRC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	6.09	0.32	3.11e-9	Myopia (pathological);
CRC	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg14036092	chr11:66035641	RAB1B	0.56	7.89	0.4	4.54e-14	Gout;
CRC	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg02072170	chr3:194406190	FAM43A	0.42	7.23	0.37	3.44e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.79	-10.19	-0.49	2.21e-21	Initial pursuit acceleration;
CRC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.65	9.96	0.48	1.39e-20	Corneal astigmatism;
CRC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.48e-17	Morning vs. evening chronotype;
CRC	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.16	-0.32	2.11e-9	IgE levels;
CRC	trans	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg19894588	chr14:64061835	NA	-0.58	-7.69	-0.39	1.71e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.51	6.47	0.34	3.5e-10	Neuroticism;
CRC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-12.23	-0.56	1.3e-28	Coronary artery disease;
CRC	cis	rs6908034	0.607	rs73376681	chr6:19808175	A/G	cg02682789	chr6:19804855	NA	0.78	6.83	0.35	4.16e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg23229984	chr5:148520753	ABLIM3	0.51	7.04	0.36	1.13e-11	Breast cancer;
CRC	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.33	-6.91	-0.36	2.47e-11	Educational attainment (years of education);
CRC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.82e-16	Prostate cancer;
CRC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.53	-6.61	-0.34	1.57e-10	Colorectal cancer;
CRC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.56	-8.23	-0.41	4.5e-15	Lung cancer;
CRC	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.34	7.88	0.4	4.8e-14	Corneal astigmatism;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg15145296	chr3:125709740	NA	-0.57	-6.5	-0.34	2.98e-10	Blood pressure (smoking interaction);
CRC	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.53	-6.37	-0.33	6.37e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-9.09	-0.45	9.63e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.63	-0.39	2.5e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg09436375	chr6:42928200	GNMT	-0.34	-6.24	-0.33	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg13662093	chr20:33865505	NA	0.51	6.58	0.34	1.88e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.71	12.57	0.57	7.49e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg14092571	chr14:90743983	NA	0.38	5.92	0.31	8.07e-9	Mortality in heart failure;
CRC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.86	9.21	0.45	3.99e-18	Hip circumference adjusted for BMI;
CRC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.34	-0.33	7.68e-10	Bladder cancer;
CRC	cis	rs863345	0.604	rs7533071	chr1:158504479	T/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.25	-0.33	1.28e-9	Total body bone mineral density;
CRC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.05	-0.41	1.53e-14	Height;
CRC	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.63	5.99	0.31	5.37e-9	IgG glycosylation;
CRC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.48	-0.38	6.71e-13	Aortic root size;
CRC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	7.13	0.37	6.37e-12	Rheumatoid arthritis;
CRC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.41	-6.12	-0.32	2.72e-9	P wave terminal force;
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg19678392	chr7:94953810	PON1	0.49	7.16	0.37	5.36e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7731657	0.537	rs10053245	chr5:130353033	G/A	cg08523029	chr5:130500466	HINT1	-0.45	-5.8	-0.3	1.57e-8	Fasting plasma glucose;
CRC	cis	rs12900413	1.000	rs12900413	chr15:90321039	C/T	cg24249390	chr15:90295951	MESP1	0.62	9.41	0.46	8.57e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.66	-0.34	1.15e-10	Total body bone mineral density;
CRC	trans	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg17903999	chr18:56338584	MALT1	0.43	6.84	0.35	3.85e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.71	6.8	0.35	4.84e-11	Diabetic retinopathy;
CRC	cis	rs449789	0.779	rs553197	chr6:159714625	G/T	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.88e-9	Hemoglobin concentration;
CRC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.42	6.33	0.33	7.89e-10	Menopause (age at onset);
CRC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg01483505	chr11:975446	AP2A2	0.41	6.15	0.32	2.27e-9	Alzheimer's disease (late onset);
CRC	cis	rs77861329	0.748	rs4687810	chr3:52169095	T/C	cg08692210	chr3:52188851	WDR51A	0.51	5.72	0.3	2.36e-8	Macrophage inflammatory protein 1b levels;
CRC	cis	rs10512697	0.803	rs36036519	chr5:3579493	G/A	cg19473799	chr5:3511975	NA	-0.72	-5.67	-0.3	3.1e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4737010	0.644	rs777870	chr8:41610234	G/A	cg17182837	chr8:41585554	ANK1	0.52	7.49	0.38	6.35e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg09659197	chr4:152720779	NA	0.5	10.59	0.5	9.76e-23	Intelligence (multi-trait analysis);
CRC	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.61	7.95	0.4	2.99e-14	Uric acid levels;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-0.99	-11.02	-0.52	2.92e-24	Height;
CRC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg04731861	chr2:219085781	ARPC2	-0.3	-6.22	-0.32	1.47e-9	Colorectal cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25833238	chr6:153304325	FBXO5	0.39	6.37	0.33	6.21e-10	Obesity-related traits;
CRC	cis	rs4074493	1.000	rs4074494	chr1:231172249	G/A	cg22172038	chr1:231176991	FAM89A	0.35	6.03	0.32	4.29e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg00129232	chr17:37814104	STARD3	-0.55	-6.97	-0.36	1.73e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.43	5.71	0.3	2.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.96	-13.7	-0.6	4.13e-34	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.8	14.76	0.63	3.44e-38	Oral cavity cancer;
CRC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.38	0.56	3.79e-29	Height;
CRC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.33	-0.53	2.36e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.83	11.88	0.55	2.57e-27	Cognitive function;
CRC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.69	0.47	1.03e-19	Lung cancer;
CRC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.36	-0.56	4.47e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.49	-6.99	-0.36	1.53e-11	Smooth-surface caries;
CRC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.56	-8.15	-0.41	7.47e-15	IgG glycosylation;
CRC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.59	8.05	0.41	1.57e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.01	0.31	4.95e-9	Intelligence (multi-trait analysis);
CRC	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	17.19	0.69	9.99e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.23	0.67	6.36e-44	Chronic sinus infection;
CRC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-6.08	-0.32	3.36e-9	Schizophrenia;
CRC	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg13385794	chr1:248469461	NA	0.34	6.32	0.33	8.74e-10	Common traits (Other);
CRC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.07	19.02	0.72	6.4e-55	Cognitive function;
CRC	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.12	11.88	0.55	2.49e-27	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-6.75	-0.35	6.69e-11	Type 2 diabetes;
CRC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.8	-0.35	5.03e-11	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.49	0.5	2.13e-22	Systolic blood pressure;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05555928	chr11:63887634	MACROD1	0.38	6.23	0.32	1.43e-9	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07865790	chr12:99038290	IKBIP;APAF1	0.43	6.08	0.32	3.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg27615366	chr5:131592974	PDLIM4	0.35	6.79	0.35	5.34e-11	Acylcarnitine levels;
CRC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.52	7.6	0.39	3.04e-13	Monocyte percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24550865	chr3:190040375	CLDN1	0.4	6.27	0.33	1.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07513332	chr6:167530253	CCR6	0.33	5.78	0.3	1.75e-8	Rheumatoid arthritis;
CRC	cis	rs9463078	0.764	rs7754698	chr6:44782717	A/G	cg25276700	chr6:44698697	NA	-0.27	-6.43	-0.33	4.61e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.14	-9.47	-0.46	5.64e-19	Mitochondrial DNA levels;
CRC	cis	rs12580194	0.593	rs7485991	chr12:55789129	T/C	cg23425280	chr12:56401806	NA	0.46	5.62	0.3	4.07e-8	Cancer;
CRC	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg00603274	chr11:61596626	FADS2	-0.44	-6.41	-0.33	4.9e-10	Trans fatty acid levels;
CRC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.63	13.15	0.59	4.91e-32	Schizophrenia;
CRC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg05585544	chr11:47624801	NA	0.48	8.57	0.43	4e-16	Subjective well-being;
CRC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg13047869	chr3:10149882	C3orf24	0.38	5.93	0.31	7.73e-9	Alzheimer's disease;
CRC	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg21918786	chr6:109611834	NA	0.35	6.12	0.32	2.68e-9	Reticulocyte fraction of red cells;
CRC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg25456477	chr12:86230367	RASSF9	0.42	7.03	0.36	1.22e-11	Major depressive disorder;
CRC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.05	-0.32	4.01e-9	Lung cancer;
CRC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.92	-16.19	-0.67	9.24e-44	Height;
CRC	cis	rs597583	0.951	rs636530	chr11:117421858	C/T	cg27161313	chr11:117392002	DSCAML1	0.39	5.67	0.3	3.05e-8	Putamen volume;
CRC	trans	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6840360	0.557	rs1143036	chr4:152329404	A/G	cg09659197	chr4:152720779	NA	0.34	6.58	0.34	1.87e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12431939	1.000	rs12432466	chr14:51638873	T/C	cg23942311	chr14:51606299	NA	-0.54	-5.98	-0.31	5.95e-9	Cancer;
CRC	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.75	-0.35	6.64e-11	Retinal vascular caliber;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.69	-11.3	-0.53	2.96e-25	Monocyte percentage of white cells;
CRC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.54	-6.79	-0.35	5.16e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg06470822	chr6:28175283	NA	0.99	13.83	0.61	1.26e-34	Depression;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg12172441	chr6:28176163	NA	0.52	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg25204440	chr1:209979598	IRF6	0.48	5.76	0.3	1.9e-8	Cleft lip with or without cleft palate;
CRC	cis	rs7429990	0.965	rs34750113	chr3:47986392	C/T	cg11946769	chr3:48343235	NME6	0.5	6.34	0.33	7.68e-10	Educational attainment (years of education);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09015484	chr9:96929106	NA	-0.56	-6.89	-0.36	2.81e-11	Diisocyanate-induced asthma;
CRC	cis	rs4731207	0.596	rs1525618	chr7:124654706	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg08501292	chr6:25962987	TRIM38	0.85	5.77	0.3	1.79e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.64	-6.85	-0.35	3.56e-11	Axial length;
CRC	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.58	-0.34	1.89e-10	Breast cancer;
CRC	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg18830697	chr6:72922368	RIMS1	-0.39	-7.9	-0.4	4.11e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.92	0.31	8.24e-9	Diabetic retinopathy;
CRC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.4	-6.37	-0.33	6.4e-10	Blood metabolite levels;
CRC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.88	-9.91	-0.48	2.02e-20	Breast cancer;
CRC	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.4	6.07	0.32	3.52e-9	Testicular germ cell tumor;
CRC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.81	-13.77	-0.6	2.29e-34	Hip circumference adjusted for BMI;
CRC	cis	rs57590327	0.503	rs6800295	chr3:81593011	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-7.15	-0.37	5.66e-12	Extraversion;
CRC	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg00105475	chr2:10696890	NA	0.46	7.05	0.36	1.09e-11	Prostate cancer;
CRC	cis	rs7289126	0.966	rs2267380	chr22:38631768	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.92	-0.31	7.99e-9	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs8105895	0.935	rs10411943	chr19:22259782	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg13491945	chr12:107078410	RFX4	0.33	5.66	0.3	3.27e-8	Heart rate;
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.48	-8.52	-0.42	6.03e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-1.03	-14.2	-0.62	4.96e-36	Exhaled nitric oxide output;
CRC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.56	10.02	0.48	8.14e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.53	-6.96	-0.36	1.91e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.0	-0.36	1.47e-11	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg22561889	chr6:118971681	C6orf204	0.5	6.43	0.33	4.49e-10	Diastolic blood pressure;
CRC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg21194808	chr1:2205498	SKI	0.4	5.97	0.31	6.1e-9	Height;
CRC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg12458913	chr13:53173898	NA	0.76	13.84	0.61	1.24e-34	Lewy body disease;
CRC	cis	rs9648716	1.000	rs9648716	chr7:140612163	A/T	cg10747023	chr7:140774559	NA	0.47	6.11	0.32	2.74e-9	Type 2 diabetes;
CRC	cis	rs4664293	0.867	rs73967903	chr2:160574125	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.45	-0.38	8.04e-13	Monocyte percentage of white cells;
CRC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.73	10.48	0.5	2.32e-22	High light scatter reticulocyte count;
CRC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg02807482	chr3:125708958	NA	0.46	5.9	0.31	9.06e-9	Blood pressure (smoking interaction);
CRC	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg04053776	chr11:6947353	ZNF215	0.52	7.08	0.36	8.52e-12	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.77	9.86	0.48	2.89e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg16591659	chr17:78472290	NA	0.38	5.64	0.3	3.66e-8	Fractional excretion of uric acid;
CRC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.38	-6.97	-0.36	1.75e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08436942	chr4:4249992	TMEM128	0.41	6.3	0.33	9.41e-10	Myopia (pathological);
CRC	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.33	0.37	1.74e-12	Blood metabolite levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08326301	chr2:232329264	NCL	0.42	6.26	0.33	1.18e-9	Schizophrenia;
CRC	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.49	-7.36	-0.38	1.47e-12	Neuroticism;
CRC	cis	rs2257205	0.667	rs8077548	chr17:56690848	T/C	cg25885038	chr17:56607967	SEPT4	-0.53	-5.79	-0.3	1.62e-8	Pancreatic cancer;
CRC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-17.39	-0.69	1.75e-48	Height;
CRC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg22815214	chr1:201083145	CACNA1S	0.5	6.28	0.33	1.08e-9	Permanent tooth development;
CRC	cis	rs9322817	0.540	rs2034823	chr6:105219573	A/T	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.33e-16	Thyroid stimulating hormone;
CRC	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.22	-0.41	4.68e-15	Mean corpuscular volume;
CRC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.39	-0.46	1.03e-18	Gut microbiome composition (summer);
CRC	cis	rs972578	1.000	rs2267480	chr22:43362976	T/C	cg01576275	chr22:43409880	NA	-0.43	-6.62	-0.34	1.45e-10	Mean platelet volume;
CRC	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg09127314	chr1:152161683	NA	0.46	5.88	0.31	9.97e-9	Atopic dermatitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15256944	chr17:79651359	ARL16;HGS	0.49	6.78	0.35	5.49e-11	Anxiety disorder;
CRC	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.93	16.41	0.67	1.25e-44	Obesity (extreme);
CRC	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.53	8.87	0.44	4.72e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7572644	0.723	rs13019037	chr2:28024642	C/T	cg27432699	chr2:27873401	GPN1	0.45	5.63	0.3	3.85e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	trans	rs6472827	0.645	rs2936683	chr8:75113239	G/C	cg16732884	chr16:2569654	AMDHD2;ATP6V0C	0.38	5.97	0.31	6.16e-9	Uterine fibroids;
CRC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg08270630	chr22:50330655	NA	-0.51	-5.8	-0.3	1.56e-8	Mean platelet volume;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12463550	chr7:65579703	CRCP	0.73	6.55	0.34	2.24e-10	Diabetic kidney disease;
CRC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24308560	chr3:49941425	MST1R	-0.44	-6.89	-0.36	2.83e-11	Body mass index;
CRC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg03013999	chr17:37608204	MED1	-0.47	-7.3	-0.37	2.2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg07865391	chr16:88106882	BANP	0.45	5.61	0.3	4.2e-8	Menopause (age at onset);
CRC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.48	0.34	3.3e-10	Schizophrenia;
CRC	cis	rs2276314	0.553	rs12964535	chr18:33611691	A/C	cg19628046	chr18:33552617	C18orf21	-0.38	-6.02	-0.31	4.67e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.95	-0.36	2e-11	Response to antipsychotic treatment;
CRC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg17031739	chr1:67600172	NA	0.43	6.67	0.35	1.06e-10	Psoriasis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03558408	chr5:134181967	C5orf24	0.4	6.85	0.35	3.6e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-6.4	-0.33	5.2400000000000005e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg24531977	chr5:56204891	C5orf35	-0.43	-6.48	-0.34	3.36e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.03	-0.32	4.39e-9	Blood osmolality (transformed sodium);
CRC	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg14631576	chr9:95140430	CENPP	-0.3	-5.63	-0.3	3.78e-8	Height;
CRC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.0	0.68	6.03e-47	Intelligence (multi-trait analysis);
CRC	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg23555395	chr2:238036564	NA	-0.44	-6.88	-0.35	3.11e-11	Systemic lupus erythematosus;
CRC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.87	12.74	0.57	1.71e-30	Diastolic blood pressure;
CRC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.47	9.56	0.47	2.81e-19	Schizophrenia;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg02546941	chr17:73030677	NA	0.51	6.17	0.32	2.02e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04915463	chr1:162039957	NOS1AP	0.44	6.09	0.32	3.16e-9	Response to antipsychotic treatment;
CRC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18490616	chr2:88469792	THNSL2	-0.39	-5.72	-0.3	2.42e-8	Response to metformin (IC50);
CRC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg01788221	chr16:89496183	ANKRD11	-0.47	-7.15	-0.37	5.54e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs2386661	0.704	rs2386650	chr10:5678058	G/A	cg26603656	chr10:5671107	NA	0.56	9.21	0.45	3.89e-18	Breast cancer;
CRC	trans	rs11031096	0.702	rs1015998	chr11:4150869	G/A	cg22978087	chr8:24814126	NEFL	0.33	6.08	0.32	3.37e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.53	6.94	0.36	2.09e-11	Homoarginine levels;
CRC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.65	11.41	0.53	1.22e-25	Prostate cancer;
CRC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.42	-20.26	-0.75	8.39e-60	Hip circumference adjusted for BMI;
CRC	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.64e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs72730918	0.564	rs11070861	chr15:51894270	A/T	cg14296394	chr15:51910925	DMXL2	-0.44	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.53	7.91	0.4	3.83e-14	Red blood cell count;
CRC	cis	rs2415984	0.579	rs2817548	chr14:46969149	A/T	cg14871534	chr14:47121158	RPL10L	0.4	5.98	0.31	5.66e-9	Number of children ever born;
CRC	trans	rs6011368	0.840	rs6062361	chr20:62904542	C/T	cg13869341	chr1:15865	WASH5P	-0.51	-7.85	-0.4	5.84e-14	Clozapine-induced cytotoxicity;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.06	-0.36	9.74e-12	Breast cancer;
CRC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg02725872	chr8:58115012	NA	-0.45	-6.65	-0.34	1.22e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg24562669	chr7:97807699	LMTK2	0.5	8.52	0.43	5.92e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.41	6.83	0.35	4.08e-11	Childhood ear infection;
CRC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	0.92	7.33	0.37	1.84e-12	Type 2 diabetes nephropathy;
CRC	cis	rs12422267	1.000	rs12422267	chr12:132601596	A/G	cg09764611	chr12:132620959	NA	-0.68	-5.76	-0.3	1.96e-8	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07167872	chr1:205819463	PM20D1	0.41	5.65	0.3	3.56e-8	Parkinson's disease;
CRC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs534126	0.961	rs7810486	chr7:143007111	G/A	cg04039957	chr7:143013207	CLCN1	0.35	6.19	0.32	1.79e-9	Cancer;
CRC	cis	rs12760731	0.720	rs1994233	chr1:178269823	C/T	cg00404053	chr1:178313656	RASAL2	-0.99	-10.6	-0.5	9.15e-23	Obesity-related traits;
CRC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.22	-0.49	1.78e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	8.44	0.42	1.02e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.24	-0.33	1.38e-9	Bipolar disorder;
CRC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.62	8.07	0.41	1.35e-14	Bronchopulmonary dysplasia;
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs35883536	1.000	rs11547648	chr1:101106268	G/T	cg14515779	chr1:101123966	NA	-0.43	-8.3	-0.42	2.75e-15	Monocyte count;
CRC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.99	12.12	0.56	3.21e-28	Cerebrospinal P-tau181p levels;
CRC	trans	rs2860975	0.542	rs1579029	chr10:96811010	T/C	cg16459667	chr5:161124759	GABRA6	-0.38	-6.01	-0.31	5.03e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.14	-0.41	8.48e-15	Type 2 diabetes;
CRC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.36	-0.33	6.62e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.72	8.75	0.43	1.12e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg06470822	chr6:28175283	NA	-0.66	-9.87	-0.48	2.69e-20	Cardiac Troponin-T levels;
CRC	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg14325436	chr19:17404977	ABHD8	-0.35	-5.65	-0.3	3.43e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.69	0.47	1.04e-19	Lung cancer;
CRC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.48	-7.85	-0.4	5.83e-14	Facial morphology (factor 20);
CRC	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.43	-7.52	-0.38	5.29e-13	Type 1 diabetes;
CRC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.52	-7.81	-0.4	7.66e-14	Body mass index;
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-6.95	-0.36	2e-11	Longevity;Endometriosis;
CRC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.9	0.44	3.88e-17	Menopause (age at onset);
CRC	cis	rs12541635	0.934	rs60482457	chr8:106970504	A/G	cg10147462	chr8:107024639	NA	0.4	6.41	0.33	5.16e-10	Age of smoking initiation;
CRC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg06505273	chr16:24850292	NA	0.4	6.03	0.32	4.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs61160187	0.582	rs4647132	chr5:60182720	C/T	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg23018236	chr17:30244563	NA	-0.6	-8.08	-0.41	1.21e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.53	7.63	0.39	2.55e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-7.73	-0.39	1.33e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.58	6.97	0.36	1.72e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-6.3	-0.33	9.41e-10	Electroencephalogram traits;
CRC	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg16540259	chr10:75572220	NDST2	0.52	7.91	0.4	3.98e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg10790698	chr19:18539756	SSBP4	-0.46	-8.72	-0.43	1.44e-16	Breast cancer;
CRC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.07	-0.41	1.31e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs11212617	0.967	rs227041	chr11:108222801	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.62	0.34	1.47e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.8	12.25	0.56	1.15e-28	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.68	0.3	2.93e-8	Lung cancer;
CRC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.66	8.75	0.43	1.14e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.13	11.0	0.52	3.68e-24	Intelligence (multi-trait analysis);
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg11503833	chr11:492997	NA	0.44	5.64	0.3	3.63e-8	Systemic lupus erythematosus;
CRC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.41	6.76	0.35	6.39e-11	Resting heart rate;
CRC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.62	8.84	0.44	6.08e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18357526	chr6:26021779	HIST1H4A	0.39	5.6	0.3	4.47e-8	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07921731	chr18:47013764	C18orf32;MIR1539	0.5	6.8	0.35	5.04e-11	Anxiety disorder;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg19041857	chr6:27730383	NA	-0.62	-6.8	-0.35	5.04e-11	Lung cancer in ever smokers;
CRC	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.48	-7.59	-0.39	3.31e-13	Schizophrenia;
CRC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.54	-7.95	-0.4	3.04e-14	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.42	1.07e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00747360	chr7:127228685	ARF5	0.41	6.35	0.33	7.29e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.92	15.32	0.65	2.38e-40	Dupuytren's disease;
CRC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg24289452	chr6:170231220	NA	-0.67	-6.78	-0.35	5.59e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.79	12.29	0.56	7.87e-29	Breast cancer;
CRC	trans	rs36069016	1	rs36069016	chr8:25058491	C/T	cg05951425	chr10:75457629	AGAP5	0.41	6.01	0.31	4.88e-9	Coronary artery disease;
CRC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg07424746	chr4:185654737	MLF1IP	-0.57	-5.64	-0.3	3.76e-8	Blood protein levels;
CRC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg00343986	chr7:65444356	GUSB	0.42	5.85	0.31	1.22e-8	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05451842	chr14:93581139	ITPK1	0.41	6.28	0.33	1.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg16576597	chr16:28551801	NUPR1	0.47	7.34	0.37	1.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	ch.11.42038R	chr11:967971	AP2A2	0.57	9.99	0.48	1.07e-20	Alzheimer's disease (late onset);
CRC	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.75	-0.63	3.82e-38	Exhaled nitric oxide output;
CRC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.81	12.3	0.56	7.53e-29	Cognitive function;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg13484946	chr2:61293354	KIAA1841	0.52	6.0	0.31	5.19e-9	Body mass index;
CRC	trans	rs482700	0.842	rs4376166	chr4:116162730	T/A	cg00976532	chr16:2636476	PDPK1	0.35	6.06	0.32	3.62e-9	Stromal-cell-derived factor 1 alpha levels;
CRC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.63	7.54	0.38	4.62e-13	Blood protein levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15186648	chr13:103452789	BIVM;KDELC1	-0.41	-6.05	-0.32	4e-9	Myopia (pathological);
CRC	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg12183467	chr14:104352244	NA	0.45	6.19	0.32	1.83e-9	Bipolar disorder;
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.31e-10	Bipolar disorder;
CRC	cis	rs3823572	0.542	rs11764961	chr7:133631142	C/A	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg10756647	chr7:56101905	PSPH	0.71	7.84	0.4	6.35e-14	Diabetic kidney disease;
CRC	trans	rs12200782	0.578	rs2237233	chr6:26387535	A/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs9323205	0.677	rs4264315	chr14:51728356	G/A	cg23942311	chr14:51606299	NA	-0.52	-6.18	-0.32	1.9e-9	Cancer;
CRC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg18478394	chr8:109455254	TTC35	0.39	6.06	0.32	3.81e-9	Dupuytren's disease;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.63	-9.34	-0.46	1.46e-18	Menarche (age at onset);
CRC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.34	-0.42	2.06e-15	Aortic root size;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01171360	chr6:293285	DUSP22	-0.46	-6.49	-0.34	3.12e-10	Menopause (age at onset);
CRC	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg24848437	chr7:2645542	IQCE	0.56	5.88	0.31	9.82e-9	Urate levels in lean individuals;
CRC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.09	-0.36	8.15e-12	Response to antipsychotic treatment;
CRC	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.45	6.3	0.33	9.4e-10	Systolic blood pressure;
CRC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.38	-0.33	6.09e-10	Aortic root size;
CRC	trans	rs6600671	1.000	rs10794671	chr1:121168242	A/C	cg09829573	chr1:144692074	NBPF9	-0.4	-6.07	-0.32	3.49e-9	Hip geometry;
CRC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.51	-9.14	-0.45	6.48e-18	Longevity;
CRC	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg10483660	chr13:112241077	NA	0.36	5.77	0.3	1.87e-8	Menarche (age at onset);
CRC	cis	rs9478638	0.507	rs9371882	chr6:155638741	G/A	cg06694381	chr6:155569200	TIAM2	-0.48	-6.2	-0.32	1.66e-9	Electroencephalogram traits;
CRC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.51	-0.38	5.77e-13	Gut microbiome composition (summer);
CRC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.46	-0.71	9.73e-53	Schizophrenia;
CRC	cis	rs11622475	1.000	rs10136440	chr14:104397367	C/A	cg20488157	chr14:104394430	TDRD9	-0.67	-9.79	-0.47	5.06e-20	Bipolar disorder;
CRC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.53	-6.94	-0.36	2.15e-11	Body mass index;
CRC	trans	rs11581859	0.950	rs55962014	chr1:99373428	T/C	cg12183875	chr3:169587454	LRRC31	0.27	6.43	0.33	4.37e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.78	11.92	0.55	1.85e-27	Testicular germ cell tumor;
CRC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-15.87	-0.66	1.62e-42	Electrocardiographic conduction measures;
CRC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.94	10.71	0.51	3.53e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	1.02	9.16	0.45	5.8e-18	Lymphocyte counts;
CRC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-11.05	-0.52	2.44e-24	Hemoglobin concentration;
CRC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18912574	chr7:65842487	NCRNA00174	0.38	6.52	0.34	2.6e-10	Aortic root size;
CRC	cis	rs11166629	1.000	rs1545240	chr8:135642632	A/C	cg27224718	chr8:135614730	ZFAT	0.5	7.44	0.38	8.72e-13	Smoking quantity;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg03623178	chr6:28175578	NA	0.77	11.49	0.54	6.21e-26	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05485520	chr3:45883628	LZTFL1	0.44	6.23	0.32	1.41e-9	Response to antipsychotic treatment;
CRC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	8.94	0.44	2.91e-17	Height;
CRC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.47	6.23	0.32	1.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg18099408	chr3:52552593	STAB1	-0.35	-6.13	-0.32	2.46e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.49	7.91	0.4	3.85e-14	Height;
CRC	cis	rs2333194	0.739	rs61987083	chr14:73915861	T/C	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.42	-6.23	-0.32	1.47e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.54	9.77	0.47	6e-20	Intelligence (multi-trait analysis);
CRC	cis	rs67981189	0.529	rs2158996	chr14:71529599	G/A	cg15910301	chr14:71632612	NA	0.31	6.14	0.32	2.41e-9	Schizophrenia;
CRC	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.39	7.84	0.4	6.4e-14	Migraine;
CRC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-15.17	-0.64	8.66e-40	Height;
CRC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.61	9.32	0.46	1.79e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22438603	chr5:127418940	SLC12A2;FLJ33630	0.41	6.57	0.34	1.99e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.16	-12.06	-0.55	5.57e-28	Breast cancer;
CRC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg20573242	chr4:122745356	CCNA2	0.4	6.01	0.31	4.92e-9	Type 2 diabetes;
CRC	cis	rs17065868	0.764	rs61949762	chr13:45005842	T/C	cg10246903	chr13:45222710	NA	0.56	5.63	0.3	3.82e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg06632207	chr12:54070931	ATP5G2	0.39	6.71	0.35	8.4e-11	Height;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg04867738	chr17:42298359	UBTF	0.47	6.42	0.33	4.72e-10	Hip circumference;
CRC	trans	rs17106184	1.000	rs12062764	chr1:51296907	G/A	cg02869289	chr19:46177325	MIR642;GIPR	0.62	6.07	0.32	3.51e-9	Type 2 diabetes;
CRC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.77	-0.3	1.8e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.73	9.71	0.47	9.09e-20	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg22110888	chr17:80059540	CCDC57	0.41	6.54	0.34	2.39e-10	Life satisfaction;
CRC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	12.76	0.58	1.48e-30	Platelet count;
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-5.75	-0.3	2.02e-8	Height;
CRC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.44	7.52	0.38	5.23e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2811415	0.597	rs10934845	chr3:127763859	C/T	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.1e-8	Lung function (FEV1/FVC);
CRC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	10.8	0.51	1.85e-23	Type 2 diabetes;
CRC	cis	rs7932354	0.583	rs3829940	chr11:46879973	A/G	cg19486271	chr11:47235900	DDB2	-0.42	-6.34	-0.33	7.49e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.68	-10.93	-0.52	6.07e-24	Neurofibrillary tangles;
CRC	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.46	-0.34	3.73e-10	Metabolite levels;
CRC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.46	-6.49	-0.34	3.17e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg20355731	chr12:37942439	NA	0.41	6.28	0.33	1.1e-9	Interleukin-6 levels;
CRC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg03609598	chr5:56110824	MAP3K1	0.66	7.87	0.4	5.29e-14	Initial pursuit acceleration;
CRC	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	0.95	16.15	0.66	1.35e-43	Dupuytren's disease;
CRC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.83	14.7	0.63	6.08e-38	Intelligence (multi-trait analysis);
CRC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg04880052	chr2:219191631	PNKD	-0.41	-6.17	-0.32	2.01e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.37e-40	Prostate cancer;
CRC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06505273	chr16:24850292	NA	0.39	6.01	0.31	5.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.55	7.45	0.38	8.13e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6141769	0.542	rs6058821	chr20:31304713	C/T	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.92	-0.31	8.02e-9	Subjective well-being;
CRC	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg06484146	chr7:12443880	VWDE	-0.63	-6.47	-0.34	3.48e-10	Coronary artery disease;
CRC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.49	0.42	7.13e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.61	-9.1	-0.45	8.77e-18	Other erythrocyte phenotypes;
CRC	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg20542592	chr8:11973495	FAM66D	-0.35	-6.31	-0.33	9.06e-10	Retinal vascular caliber;
CRC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23978390	chr7:1156363	C7orf50	0.62	7.67	0.39	2.02e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg02896835	chr1:92012615	NA	0.48	6.5	0.34	2.97e-10	Eosinophil percentage of white cells;
CRC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-0.92	-13.1	-0.59	7.4e-32	Hip circumference adjusted for BMI;
CRC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg20607287	chr7:12443886	VWDE	-0.67	-6.78	-0.35	5.55e-11	Coronary artery disease;
CRC	trans	rs10411161	1.000	rs3848562	chr19:52379835	C/T	cg22319618	chr22:45562946	NUP50	0.54	5.98	0.31	5.78e-9	Breast cancer;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg12273811	chr6:28175739	NA	-0.45	-6.68	-0.35	1.05e-10	Cardiac Troponin-T levels;
CRC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg02659138	chr7:134003124	SLC35B4	0.36	6.24	0.33	1.33e-9	Mean platelet volume;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.31	-0.33	8.81e-10	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.55	8.16	0.41	7.34e-15	Longevity;Endometriosis;
CRC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-5.97	-0.31	6.15e-9	Coronary artery disease;
CRC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.7	10.97	0.52	4.52e-24	Body mass index;
CRC	cis	rs501120	0.810	rs474281	chr10:44749120	T/C	cg09554077	chr10:44749378	NA	0.91	13.08	0.58	9.13e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.24e-10	Dupuytren's disease;
CRC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg02290350	chr8:58132656	NA	-0.39	-5.63	-0.3	3.77e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg07856975	chr6:36356162	ETV7	-0.47	-6.09	-0.32	3.21e-9	Platelet distribution width;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg09877947	chr5:131593287	PDLIM4	0.45	7.23	0.37	3.51e-12	Breast cancer;
CRC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg18404041	chr3:52824283	ITIH1	0.31	5.74	0.3	2.21e-8	Bipolar disorder;
CRC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.73	13.65	0.6	6.56e-34	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02008025	chr2:102314465	MAP4K4	0.43	6.0	0.31	5.26e-9	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.1	19.01	0.72	6.7e-55	Cognitive function;
CRC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg25767906	chr1:53392781	SCP2	0.45	7.22	0.37	3.55e-12	Monocyte count;
CRC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg19913688	chr11:428466	ANO9	-0.73	-7.41	-0.38	1.08e-12	Body mass index;
CRC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg22496339	chr2:162101262	NA	-0.58	-8.28	-0.42	3.05e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-10.18	-0.49	2.34e-21	Hepatocellular carcinoma;
CRC	cis	rs59104589	0.535	rs73002160	chr2:242321707	A/C	cg19488206	chr2:242435732	STK25	0.47	6.69	0.35	9.9e-11	Fibrinogen levels;
CRC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.4e-11	Lung cancer;
CRC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.54	8.51	0.42	6.33e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg10978503	chr1:24200527	CNR2	0.62	11.34	0.53	2.16e-25	Immature fraction of reticulocytes;
CRC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.63	-8.87	-0.44	4.67e-17	Coronary artery disease;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11645453	chr3:52864694	ITIH4	0.36	6.43	0.33	4.42e-10	Bipolar disorder;
CRC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.8	10.52	0.5	1.68e-22	Cerebrospinal P-tau181p levels;
CRC	trans	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.37	6.7	0.35	9.13e-11	Crohn's disease;
CRC	trans	rs6472235	0.837	rs6992002	chr8:66927237	G/A	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-0.79	-7.91	-0.4	4e-14	Schizophrenia;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg12172441	chr6:28176163	NA	0.55	6.96	0.36	1.9e-11	Depression;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg27094323	chr7:1216898	NA	-0.39	-6.18	-0.32	1.93e-9	Longevity;Endometriosis;
CRC	cis	rs2882667	0.690	rs6877187	chr5:138159344	T/C	cg09476006	chr5:138032270	NA	-0.58	-10.51	-0.5	1.8e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4e-17	Electroencephalogram traits;
CRC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg06238570	chr21:40685208	BRWD1	-0.44	-5.62	-0.3	4.17e-8	Menarche (age at onset);
CRC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.33	0.42	2.19e-15	Height;
CRC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.49	6.97	0.36	1.75e-11	High light scatter reticulocyte count;
CRC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.5	-7.73	-0.39	1.32e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.07	0.32	3.48e-9	Rheumatoid arthritis;
CRC	cis	rs4713675	0.649	rs568901	chr6:33710038	A/G	cg07979401	chr6:33739406	LEMD2	0.38	5.65	0.3	3.51e-8	Plateletcrit;
CRC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.34	-0.37	1.73e-12	Morning vs. evening chronotype;
CRC	cis	rs7739232	0.920	rs79279936	chr6:53529471	C/T	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.56	-0.43	4.51e-16	Monocyte count;
CRC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.77	0.51	2.32e-23	Platelet count;
CRC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.55	8.13	0.41	8.74e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2573652	1.000	rs2727195	chr15:100513117	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.14	-0.32	2.33e-9	Height;
CRC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.53	-7.06	-0.36	9.76e-12	DNA methylation (variation);
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.87	19.41	0.73	1.78e-56	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg04025307	chr7:1156635	C7orf50	0.67	7.14	0.37	5.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.37	-0.33	6.45e-10	Lung cancer in ever smokers;
CRC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.47	-7.16	-0.37	5.17e-12	Body mass index;
CRC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg03013999	chr17:37608204	MED1	0.46	7.14	0.37	5.87e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.55	-7.96	-0.4	2.84e-14	Multiple sclerosis;
CRC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.33e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	15.39	0.65	1.27e-40	Platelet count;
CRC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.47	-5.82	-0.31	1.38e-8	Gut microbiome composition (summer);
CRC	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.7	9.85	0.48	3.22e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.87e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.34	6.38	0.33	6.16e-10	Mean corpuscular volume;
CRC	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-7.29	-0.37	2.32e-12	Schizophrenia;
CRC	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg16989719	chr2:238392110	NA	-0.46	-8.72	-0.43	1.43e-16	Prostate cancer;
CRC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg25456477	chr12:86230367	RASSF9	-0.34	-6.07	-0.32	3.54e-9	Major depressive disorder;
CRC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	6.29	0.33	9.84e-10	Breast cancer;
CRC	cis	rs1030268	0.651	rs12707121	chr7:133496379	A/G	cg10665199	chr7:133106180	EXOC4	0.55	6.22	0.32	1.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07165851	chr6:158734300	TULP4	0.6	7.58	0.39	3.46e-13	Height;
CRC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.68	-0.43	1.93e-16	Aortic root size;
CRC	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg03929089	chr4:120376271	NA	-0.55	-6.39	-0.33	5.6e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg16540259	chr10:75572220	NDST2	-0.38	-6.03	-0.32	4.36e-9	Inflammatory bowel disease;
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.98	-0.31	5.78e-9	Menopause (age at onset);
CRC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg20673091	chr1:2541236	MMEL1	-0.36	-5.91	-0.31	8.39e-9	Ulcerative colitis;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg15511327	chr8:143859410	LYNX1	-0.39	-6.56	-0.34	2.13e-10	Urinary tract infection frequency;
CRC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg02659138	chr7:134003124	SLC35B4	0.42	7.06	0.36	9.8e-12	Mean platelet volume;
CRC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.44	6.49	0.34	3.07e-10	Mean platelet volume;
CRC	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.01	0.52	3.15e-24	Bipolar disorder;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg15786705	chr6:28176104	NA	0.6	8.65	0.43	2.29e-16	Parkinson's disease;
CRC	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg02023728	chr11:77925099	USP35	-0.36	-6.15	-0.32	2.29e-9	Alzheimer's disease (survival time);
CRC	cis	rs2252521	0.524	rs317744	chr7:29067293	T/G	cg11728747	chr7:29037910	CPVL	-0.5	-7.21	-0.37	3.86e-12	Cognitive performance;
CRC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-7.25	-0.37	2.96e-12	Renal function-related traits (BUN);
CRC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.73	10.47	0.5	2.51e-22	Cognitive function;
CRC	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg20356878	chr3:121714668	ILDR1	-0.43	-5.92	-0.31	7.9e-9	Multiple sclerosis;
CRC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.35	0.62	1.29e-36	Chronic sinus infection;
CRC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg00620190	chr6:26240307	HIST1H4F	-0.48	-5.89	-0.31	9.69e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg12564285	chr5:131593104	PDLIM4	0.46	7.69	0.39	1.75e-13	Breast cancer;
CRC	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.95	-12.45	-0.57	2.06e-29	Hair shape;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09376352	chr11:119076657	CBL	-0.41	-6.0	-0.31	5.14e-9	Myopia (pathological);
CRC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.61	10.28	0.49	1.08e-21	Prudent dietary pattern;
CRC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg06028605	chr16:24865363	SLC5A11	0.39	7.55	0.38	4.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.624	rs12050123	chr14:55840386	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.13	-0.32	2.46e-9	Protein biomarker;
CRC	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.77	8.61	0.43	3.16e-16	Neuroticism;
CRC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.56	-6.1	-0.32	2.96e-9	Schizophrenia;
CRC	cis	rs3740540	0.530	rs2362503	chr10:126290538	T/C	cg04949429	chr10:126290192	LHPP	0.43	6.36	0.33	6.86e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg14825688	chr5:132208181	LEAP2	-0.41	-6.64	-0.34	1.32e-10	Apolipoprotein A-IV levels;
CRC	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg06239285	chr11:62104954	ASRGL1	0.58	7.02	0.36	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg10437265	chr15:77819839	NA	-0.47	-7.67	-0.39	2.02e-13	Type 2 diabetes;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.51	7.58	0.39	3.63e-13	Longevity;
CRC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg16342193	chr10:102329863	NA	-0.37	-5.96	-0.31	6.66e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs669446	0.528	rs7538463	chr1:44196416	T/A	cg12908607	chr1:44402522	ARTN	-0.34	-5.85	-0.31	1.17e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.47	-5.92	-0.31	8.1e-9	Orofacial clefts;
CRC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg27661571	chr11:113659931	NA	0.62	7.53	0.38	4.94e-13	Hip circumference adjusted for BMI;
CRC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg08270630	chr22:50330655	NA	-0.66	-6.38	-0.33	6.04e-10	Acne (severe);
CRC	cis	rs4728302	0.838	rs7798804	chr7:133584085	C/T	cg03336402	chr7:133662267	EXOC4	-0.44	-6.37	-0.33	6.27e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.34	-0.38	1.67e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg01388757	chr2:102091195	RFX8	-0.61	-8.22	-0.41	4.67e-15	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.61	0.3	4.4e-8	Protein C levels;
CRC	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg16898833	chr6:26189333	HIST1H4D	0.77	6.45	0.33	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7781266	0.739	rs62469985	chr7:133218084	C/T	cg03336402	chr7:133662267	EXOC4	0.47	5.61	0.3	4.3e-8	Educational attainment (college completion);
CRC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.51e-24	Motion sickness;
CRC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	12.12	0.56	3.32e-28	Monocyte percentage of white cells;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg06896663	chr8:82754093	SNX16	-0.69	-5.96	-0.31	6.54e-9	Cognitive function;
CRC	cis	rs9463078	0.739	rs6458425	chr6:45173857	C/G	cg25276700	chr6:44698697	NA	-0.24	-5.77	-0.3	1.79e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06544989	chr22:39130855	UNC84B	0.5	7.84	0.4	6.37e-14	Menopause (age at onset);
CRC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.51	-6.92	-0.36	2.32e-11	Height;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg27615366	chr5:131592974	PDLIM4	0.32	5.65	0.3	3.42e-8	Acylcarnitine levels;
CRC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.28	-0.37	2.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg12064134	chr16:90016061	DEF8	-0.69	-6.14	-0.32	2.38e-9	Skin colour saturation;
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	trans	rs4586057	0.812	rs7085559	chr10:92650119	T/C	cg26894278	chr13:21016241	CRYL1	0.39	6.47	0.34	3.52e-10	Economic and political preferences (time);
CRC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.26	-14.74	-0.63	4.13e-38	Gout;
CRC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.66	9.22	0.45	3.72e-18	Neuroblastoma;
CRC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg20615401	chr6:28092323	ZSCAN16	0.45	6.06	0.32	3.66e-9	Parkinson's disease;
CRC	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg00469287	chr7:23338798	C7orf30	0.44	5.87	0.31	1.06e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg10790698	chr19:18539756	SSBP4	-0.44	-8.43	-0.42	1.08e-15	Breast cancer;
CRC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.43	5.77	0.3	1.83e-8	Platelet distribution width;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02895995	chr19:7554069	PEX11G	-0.49	-5.96	-0.31	6.34e-9	Diisocyanate-induced asthma;
CRC	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.76	8.56	0.43	4.51e-16	Neuroticism;
CRC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05917416	chr14:70826434	COX16	-0.43	-6.03	-0.32	4.3e-9	Asthma;
CRC	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00938859	chr5:1591904	SDHAP3	0.67	7.32	0.37	1.95e-12	Breast cancer;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg15786705	chr6:28176104	NA	0.57	8.1	0.41	1.11e-14	Parkinson's disease;
CRC	cis	rs6564851	0.506	rs56291739	chr16:81258372	C/T	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.66	-0.3	3.32e-8	Carotenoid and tocopherol levels;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.52	0.38	5.12e-13	Blood metabolite levels;
CRC	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.36e-12	Putamen volume;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg02869364	chr7:1081709	C7orf50	-0.37	-5.61	-0.3	4.32e-8	Longevity;Endometriosis;
CRC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.86e-17	Aortic root size;
CRC	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg16898833	chr6:26189333	HIST1H4D	0.77	6.45	0.33	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7725052	0.609	rs11955354	chr5:40457459	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.58	-0.34	1.86e-10	Pediatric autoimmune diseases;
CRC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.38	-7.98	-0.4	2.46e-14	Cutaneous nevi;
CRC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.1e-8	Bladder cancer;
CRC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg00255919	chr5:131827918	IRF1	-0.37	-6.28	-0.33	1.07e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs642858	1.000	rs646695	chr6:140280398	C/T	cg27524944	chr6:140295369	NA	-0.34	-5.72	-0.3	2.37e-8	Type 2 diabetes;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg17987601	chr16:30389834	SEPT1	-0.41	-6.07	-0.32	3.51e-9	HDL cholesterol;
CRC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.43	6.69	0.35	9.9e-11	Red blood cell count;
CRC	cis	rs3736594	0.513	rs2384627	chr2:27774449	G/A	cg27432699	chr2:27873401	GPN1	0.66	8.49	0.42	7.24e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-6.36	-0.33	6.84e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg11579758	chr4:1086637	RNF212	0.41	6.84	0.35	3.85e-11	Recombination rate (males);
CRC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.13	-0.32	2.58e-9	Diabetic kidney disease;
CRC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.04	-10.38	-0.5	5.25e-22	Diabetic retinopathy;
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg09564133	chr5:176738847	MXD3	-0.41	-6.12	-0.32	2.68e-9	Daytime sleep phenotypes;
CRC	trans	rs800082	1.000	rs9817588	chr3:144288302	A/T	cg24215973	chr2:240111563	HDAC4	-0.52	-6.94	-0.36	2.04e-11	Smoking behavior;
CRC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.08	-9.46	-0.46	5.95e-19	Diabetic kidney disease;
CRC	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.1	0.32	2.94e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.48	-8.99	-0.44	2.04e-17	Hepatitis;
CRC	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.53	8.34	0.42	2.05e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg18721089	chr20:30220636	NA	-0.42	-6.82	-0.35	4.31e-11	Mean corpuscular hemoglobin;
CRC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.55	7.06	0.36	1.02e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4664293	0.867	rs12692563	chr2:160602811	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	9.23	0.45	3.32e-18	Monocyte count;
CRC	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	0.91	10.15	0.49	3.04e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-7.1	-0.36	7.51e-12	Mean platelet volume;
CRC	cis	rs2415984	0.562	rs1389604	chr14:46972218	C/A	cg14871534	chr14:47121158	RPL10L	0.41	5.73	0.3	2.29e-8	Number of children ever born;
CRC	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.18	0.41	6.23e-15	Cognitive performance;
CRC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.22e-22	Bipolar disorder;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.69	0.35	9.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08120389	chr17:19881268	AKAP10	-0.41	-5.99	-0.31	5.64e-9	Myopia (pathological);
CRC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg21620606	chr4:1342894	KIAA1530	0.34	5.67	0.3	3.06e-8	Obesity-related traits;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.7	11.98	0.55	1.1e-27	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg22753661	chr15:79092743	ADAMTS7	0.43	5.9	0.31	9.02e-9	Coronary artery disease or large artery stroke;
CRC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.46	7.9	0.4	4.29e-14	Childhood ear infection;
CRC	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg17757837	chr7:157058334	UBE3C	-0.49	-6.38	-0.33	6.07e-10	Type 2 diabetes;
CRC	cis	rs11212617	1.000	rs652311	chr11:108240069	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.62	0.34	1.5e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.79	-10.48	-0.5	2.21e-22	Initial pursuit acceleration;
CRC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg24011408	chr12:48396354	COL2A1	0.44	6.17	0.32	2.04e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg06204229	chr3:52865917	ITIH4	0.52	5.86	0.31	1.14e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.24	0.33	1.31e-9	Obesity-related traits;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00166722	chr3:10149974	C3orf24	0.7	7.36	0.38	1.47e-12	Alzheimer's disease;
CRC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs2013441	0.866	rs62067558	chr17:20025706	G/T	cg13482628	chr17:19912719	NA	0.4	5.77	0.3	1.82e-8	Obesity-related traits;
CRC	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg13385794	chr1:248469461	NA	0.38	6.76	0.35	6.25e-11	Common traits (Other);
CRC	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.6	7.02	0.36	1.27e-11	Prostate cancer;
CRC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.47	7.58	0.39	3.53e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.77	-12.18	-0.56	1.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg21765224	chr20:34359771	PHF20	-0.34	-5.96	-0.31	6.53e-9	Aortic root size;
CRC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.83	-11.35	-0.53	1.99e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.48	7.16	0.37	5.23e-12	Intelligence (multi-trait analysis);
CRC	trans	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg04077850	chr5:125800366	GRAMD3	0.36	6.13	0.32	2.47e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.84	14.79	0.63	2.58e-38	Blood protein levels;
CRC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.4	6.11	0.32	2.82e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7901135	0.962	rs3740451	chr10:60566137	G/A	cg23799393	chr10:60588674	BICC1	0.37	5.67	0.3	3.2e-8	Morning vs. evening chronotype;
CRC	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.58	-8.92	-0.44	3.3e-17	Ulcerative colitis;
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.05	0.64	2.66e-39	Primary sclerosing cholangitis;
CRC	cis	rs2398893	0.960	rs2153791	chr9:96744928	G/A	cg14459158	chr9:96720562	NA	0.47	7.09	0.36	8.25e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17097992	chr2:10443818	HPCAL1	0.44	6.07	0.32	3.45e-9	Anxiety disorder;
CRC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.7	8.45	0.42	9.26e-16	Bipolar disorder;
CRC	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.63	-9.42	-0.46	7.97e-19	Acne (severe);
CRC	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.46	7.77	0.39	9.97e-14	Testicular germ cell tumor;
CRC	trans	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.65	0.34	1.24e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg16558177	chr4:4109446	NA	-0.56	-6.52	-0.34	2.73e-10	Blood pressure (smoking interaction);
CRC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.08	-15.25	-0.64	4.51e-40	Exhaled nitric oxide output;
CRC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.33e-17	Reticulocyte count;
CRC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	6.21	0.32	1.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.41	0.38	1.08e-12	Lung cancer in ever smokers;
CRC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.26	-0.45	2.76e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1507153	0.651	rs9350781	chr6:79481815	A/T	cg05283184	chr6:79620031	NA	-0.41	-5.72	-0.3	2.35e-8	Sjögren's syndrome;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.42	7.56	0.38	3.93e-13	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14089728	chr14:24563796	PCK2	0.44	5.97	0.31	6.07e-9	Anxiety disorder;
CRC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.51	-0.42	6.05e-16	Hemoglobin concentration;
CRC	cis	rs17065868	0.649	rs9533853	chr13:45020119	G/C	cg10246903	chr13:45222710	NA	0.59	5.83	0.31	1.33e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.93e-18	Lymphocyte counts;
CRC	cis	rs12476592	0.571	rs2176415	chr2:63636568	A/C	cg10828910	chr2:63850056	LOC388955	0.55	6.54	0.34	2.39e-10	Childhood ear infection;
CRC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg26043149	chr18:55253948	FECH	-0.47	-7.02	-0.36	1.26e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg14847009	chr1:175162515	KIAA0040	0.27	6.06	0.32	3.73e-9	Alcohol dependence;
CRC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.69	9.1	0.45	8.88e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.41	8.9	0.44	3.82e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.47	-8.36	-0.42	1.75e-15	Lung function (FVC);
CRC	cis	rs6840360	0.642	rs1899550	chr4:152407236	T/C	cg09659197	chr4:152720779	NA	0.34	6.65	0.34	1.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg01879757	chr17:41196368	BRCA1	0.43	6.45	0.33	4.11e-10	Menopause (age at onset);
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg10729496	chr3:10149963	C3orf24	0.51	6.57	0.34	1.92e-10	Alzheimer's disease;
CRC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.71	9.5	0.46	4.39e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.51	-6.67	-0.35	1.07e-10	Alzheimer's disease;
CRC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg23262073	chr20:60523788	NA	-0.45	-7.08	-0.36	8.95e-12	Body mass index;
CRC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.5	-8.01	-0.4	2.05e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.75	9.93	0.48	1.69e-20	Platelet count;
CRC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	0.95	18.79	0.72	5e-54	Height;
CRC	trans	rs6463739	1.000	rs6463731	chr7:7902895	G/T	cg09417038	chr21:47716443	C21orf57	-0.43	-6.59	-0.34	1.75e-10	Small cell lung carcinoma;
CRC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.87	-0.35	3.13e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.66	9.87	0.48	2.6e-20	Inflammatory bowel disease;
CRC	cis	rs6534441	0.727	rs312492	chr4:125448257	A/G	cg21609808	chr4:125404261	NA	-0.41	-5.96	-0.31	6.36e-9	Major depressive disorder;
CRC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.43	6.19	0.32	1.81e-9	Red blood cell count;
CRC	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg04731861	chr2:219085781	ARPC2	0.29	6.0	0.31	5.34e-9	Ulcerative colitis;
CRC	cis	rs9826463	0.582	rs73238187	chr3:142143674	T/C	cg20824294	chr3:142316082	PLS1	0.38	6.05	0.32	3.87e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.68	-0.39	1.9e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10208940	0.920	rs72903979	chr2:68813938	C/T	cg12452813	chr2:68675892	NA	0.48	6.0	0.31	5.28e-9	Urate levels in lean individuals;
CRC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.79	8.68	0.43	1.93e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	cg04338863	chr8:33670619	NA	-0.44	-6.43	-0.33	4.55e-10	Body mass index;
CRC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.35	0.33	7.33e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg09324608	chr17:30823087	MYO1D	-0.34	-6.01	-0.31	4.83e-9	Schizophrenia;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08980237	chr3:156534860	NA	0.38	6.3	0.33	9.79e-10	Interleukin-6 levels;
CRC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.61	-10.09	-0.49	5.01e-21	Extrinsic epigenetic age acceleration;
CRC	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.6	-8.21	-0.41	5.25e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.44	6.88	0.35	3.1e-11	Longevity;
CRC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.43	-0.38	9.45e-13	Joint mobility (Beighton score);
CRC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg16892393	chr17:41919603	NA	0.59	8.52	0.43	5.92e-16	Triglycerides;
CRC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.57	-8.65	-0.43	2.24e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg18551225	chr6:44695536	NA	-0.41	-5.92	-0.31	8.07e-9	Total body bone mineral density;
CRC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-6.38	-0.33	6.17e-10	Monocyte count;
CRC	cis	rs7517126	1.000	rs57809726	chr1:196841377	A/G	cg13682187	chr1:196946512	CFHR5	-0.37	-5.97	-0.31	6.03e-9	Blood protein levels;
CRC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg03929089	chr4:120376271	NA	0.56	7.53	0.38	5.02e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs17532515	0.628	rs3113195	chr4:141475837	A/G	cg09181644	chr4:141490428	UCP1	-0.33	-5.98	-0.31	5.75e-9	Select biomarker traits;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg01422129	chr2:677375	TMEM18	-0.74	-6.01	-0.31	4.85e-9	Cognitive function;
CRC	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg01843034	chr6:37503916	NA	-0.43	-8.11	-0.41	1.02e-14	Cognitive performance;
CRC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.49	-6.73	-0.35	7.58e-11	Total body bone mineral density;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg19318889	chr4:1322082	MAEA	0.41	5.87	0.31	1.05e-8	Obesity-related traits;
CRC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.52	7.14	0.37	6.09e-12	Height;
CRC	cis	rs72634501	0.716	rs72660086	chr1:39571992	T/G	cg18385671	chr1:39797026	MACF1	-0.44	-6.02	-0.32	4.57e-9	HDL cholesterol;
CRC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg20607287	chr7:12443886	VWDE	-0.62	-6.91	-0.36	2.48e-11	Coronary artery disease;
CRC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.97	-15.21	-0.64	6.35e-40	Cognitive function;
CRC	trans	rs12136737	0.826	rs6699949	chr1:184346908	C/T	cg01883195	chr6:117802401	DCBLD1	0.56	6.2	0.32	1.65e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs17665859	0.669	rs55838337	chr8:447314	G/A	cg18996590	chr8:30890583	WRN;PURG	-0.45	-6.24	-0.33	1.33e-9	Bilirubin levels;
CRC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.92	0.64	8.25e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09332974	chr1:113616366	LRIG2	0.49	6.92	0.36	2.38e-11	Response to antipsychotic treatment;
CRC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7619833	0.512	rs9858306	chr3:27222542	T/G	cg02860705	chr3:27208620	NA	0.38	5.91	0.31	8.51e-9	Breast cancer;
CRC	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg06470822	chr6:28175283	NA	0.51	6.04	0.32	4.06e-9	Parkinson's disease;
CRC	trans	rs783540	0.967	rs2870966	chr15:83295244	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.24	-0.33	1.34e-9	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09517077	chr6:108880982	FOXO3	0.47	6.39	0.33	5.81e-10	Anxiety disorder;
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.74e-12	Urinary tract infection frequency;
CRC	cis	rs12024301	0.557	rs12024089	chr1:183608107	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg24209194	chr3:40518798	ZNF619	0.38	5.66	0.3	3.28e-8	Renal cell carcinoma;
CRC	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.63	-0.3	3.8e-8	Tuberculosis;
CRC	cis	rs6840360	1.000	rs10007167	chr4:152603655	C/T	cg09659197	chr4:152720779	NA	0.49	9.56	0.47	2.83e-19	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.77	-10.89	-0.51	8.48e-24	Blood pressure (smoking interaction);
CRC	trans	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg05376469	chr2:102649931	NA	-0.38	-6.31	-0.33	9.25e-10	Coronary artery disease;
CRC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.74	10.2	0.49	2.13e-21	Cognitive function;
CRC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.62	13.95	0.61	4.63e-35	Airflow obstruction;
CRC	cis	rs12983728	0.536	rs34380569	chr19:58648528	A/G	cg24884572	chr19:58661833	ZNF329	0.47	5.87	0.31	1.05e-8	Cholesterol, total;
CRC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.1	-0.32	2.98e-9	Mean corpuscular volume;
CRC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-15.16	-0.64	9.95e-40	Primary sclerosing cholangitis;
CRC	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.61	7.45	0.38	8.1e-13	Post bronchodilator FEV1;
CRC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.45	-6.8	-0.35	4.82e-11	Ulcerative colitis;
CRC	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg26741380	chr15:41871084	TYRO3	-0.49	-6.75	-0.35	6.74e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg13072238	chr3:49761600	GMPPB	0.5	5.73	0.3	2.25e-8	Menarche (age at onset);
CRC	cis	rs7781557	1.000	rs17474893	chr7:102480757	C/T	cg18108683	chr7:102477205	FBXL13	-0.49	-6.18	-0.32	1.92e-9	Colorectal adenoma (advanced);
CRC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.73	0.3	2.21e-8	Renal function-related traits (BUN);
CRC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg26695010	chr11:65641043	EFEMP2	-0.39	-5.99	-0.31	5.64e-9	Eosinophil percentage of white cells;
CRC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.37	-6.68	-0.35	1.04e-10	Crohn's disease;
CRC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg20203395	chr5:56204925	C5orf35	-0.41	-5.79	-0.3	1.68e-8	Breast cancer;Breast cancer (early onset);
CRC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg11707556	chr5:10655725	ANKRD33B	0.44	6.78	0.35	5.47e-11	Coronary artery disease;
CRC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.5	8.15	0.41	7.81e-15	Monocyte count;
CRC	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg20363699	chr7:23626180	CLK2P	-0.34	-6.06	-0.32	3.75e-9	Schizophrenia;
CRC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.9	-0.44	3.75e-17	Type 2 diabetes;
CRC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.51	8.19	0.41	5.69e-15	Aortic root size;
CRC	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.68	-10.59	-0.5	9.85e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9292777	0.720	rs56131636	chr5:40397378	C/T	cg09067459	chr5:40385259	NA	-0.55	-8.97	-0.44	2.31e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg18016565	chr1:150552671	MCL1	0.48	6.98	0.36	1.63e-11	Tonsillectomy;
CRC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.53	7.02	0.36	1.29e-11	Obesity-related traits;
CRC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg20790798	chr5:1857306	NA	-0.42	-6.27	-0.33	1.16e-9	Cardiovascular disease risk factors;
CRC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg19980929	chr12:42632907	YAF2	0.44	6.55	0.34	2.22e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg12179176	chr11:130786555	SNX19	0.6	8.83	0.44	6.37e-17	Schizophrenia;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06790019	chr1:44435457	DPH2	0.39	6.03	0.32	4.35e-9	Myopia (pathological);
CRC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg02007433	chr3:129722099	NA	-0.46	-6.28	-0.33	1.08e-9	Blood pressure (smoking interaction);
CRC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.88	-14.1	-0.61	1.26e-35	Body mass index (adult);
CRC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg23018236	chr17:30244563	NA	-0.62	-7.78	-0.39	9.36e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg20512303	chr5:131592959	PDLIM4	-0.3	-5.74	-0.3	2.2e-8	Breast cancer;
CRC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.09e-12	Headache;
CRC	cis	rs12431939	0.948	rs12436364	chr14:51671320	T/C	cg23942311	chr14:51606299	NA	-0.53	-6.66	-0.34	1.18e-10	Cancer;
CRC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.34	0.38	1.66e-12	Platelet count;
CRC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	10.77	0.51	2.2e-23	Mean corpuscular hemoglobin;
CRC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02772935	chr3:125709198	NA	-0.49	-5.74	-0.3	2.11e-8	Blood pressure (smoking interaction);
CRC	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg26741380	chr15:41871084	TYRO3	-0.49	-6.87	-0.35	3.18e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1950626	0.699	rs12896504	chr14:101467948	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.92	-15.19	-0.64	7.57e-40	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg16589663	chr20:23618590	CST3	0.59	7.24	0.37	3.1e-12	Chronic kidney disease;
CRC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg03013999	chr17:37608204	MED1	0.48	7.39	0.38	1.25e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg14003231	chr6:33640908	ITPR3	0.43	6.92	0.36	2.39e-11	Height;
CRC	cis	rs6076065	0.723	rs6083088	chr20:23343793	G/T	cg11657817	chr20:23433608	CST11	0.41	6.05	0.32	3.98e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg10130564	chr11:117069849	TAGLN	0.33	5.97	0.31	5.99e-9	Blood protein levels;
CRC	cis	rs8018808	0.935	rs963283	chr14:77901456	C/A	cg20045696	chr14:77926864	AHSA1	0.36	5.61	0.3	4.24e-8	Myeloid white cell count;
CRC	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.57	9.22	0.45	3.63e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.68	-13.3	-0.59	1.33e-32	Educational attainment;
CRC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.5	-7.39	-0.38	1.19e-12	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-6.97	-0.36	1.79e-11	Chickenpox;
CRC	cis	rs4692589	0.540	rs1904823	chr4:170956772	C/T	cg19918862	chr4:170955249	NA	0.54	6.93	0.36	2.29e-11	Anxiety disorder;
CRC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.53	9.8	0.48	4.52e-20	Eye color traits;
CRC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.52	0.34	2.64e-10	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00435006	chr16:1877199	HAGH;FAHD1	0.43	6.03	0.32	4.37e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg13798780	chr7:105162888	PUS7	0.56	7.36	0.38	1.45e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.88	-0.48	2.42e-20	Primary sclerosing cholangitis;
CRC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg23517279	chr6:96025343	MANEA	0.47	5.65	0.3	3.57e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.01	-0.36	1.39e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.79	0.7	4.54e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs79464052	0.571	rs75065885	chr5:140935085	T/C	cg05255351	chr5:1503979	LPCAT1	-0.45	-6.07	-0.32	3.6e-9	Diffuse large B cell lymphoma;
CRC	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg00647820	chr17:40259828	DHX58	-0.43	-5.71	-0.3	2.53e-8	Fibrinogen levels;
CRC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg03609598	chr5:56110824	MAP3K1	-0.63	-6.01	-0.31	4.91e-9	Type 2 diabetes;
CRC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.86	-0.58	5.94e-31	Hemoglobin concentration;
CRC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.61	10.26	0.49	1.3e-21	Prudent dietary pattern;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.6	-11.05	-0.52	2.44e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.88	-16.78	-0.68	4.13e-46	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.59	9.4	0.46	9.75e-19	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.44	5.83	0.31	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.22	0.32	1.49e-9	Aortic root size;
CRC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.72	8.98	0.44	2.16e-17	Iron status biomarkers;
CRC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.85	13.49	0.6	2.52e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.82	17.08	0.69	2.73e-47	Prostate cancer;
CRC	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.55	-5.93	-0.31	7.6e-9	Coronary artery disease;
CRC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.4	-0.42	1.32e-15	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15921587	chr2:73144353	EMX1	0.4	6.7	0.35	9.21e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg22110888	chr17:80059540	CCDC57	0.42	6.58	0.34	1.88e-10	Life satisfaction;
CRC	cis	rs990171	1.000	rs4851575	chr2:103025203	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	5.81	0.3	1.49e-8	Lymphocyte counts;
CRC	cis	rs7394190	0.630	rs78845904	chr10:75517249	C/A	cg07699608	chr10:75541558	CHCHD1	0.6	6.34	0.33	7.42e-10	Incident atrial fibrillation;
CRC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	11.06	0.52	2.15e-24	Menopause (age at onset);
CRC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.47	-7.07	-0.36	9.21e-12	Colorectal cancer;
CRC	cis	rs6961069	0.745	rs13233631	chr7:80270822	A/G	cg04458919	chr7:80252533	CD36	0.35	6.19	0.32	1.76e-9	Platelet count;
CRC	cis	rs9463078	0.683	rs227850	chr6:44699068	C/T	cg25276700	chr6:44698697	NA	0.26	6.2	0.32	1.71e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.49	6.94	0.36	2.03e-11	Bone mineral density (spine);
CRC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg22676075	chr6:135203613	NA	-0.38	-5.76	-0.3	1.91e-8	Red blood cell count;
CRC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.63	-11.22	-0.53	6.04e-25	Coronary artery disease;
CRC	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg00531865	chr16:30841666	NA	0.49	6.96	0.36	1.84e-11	Dementia with Lewy bodies;
CRC	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.63	7.52	0.38	5.2e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3764400	0.567	rs1979897	chr17:46309546	C/T	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10040922	chr8:124778506	NA	0.39	6.13	0.32	2.49e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10071761	0.513	rs10462011	chr5:40372062	T/A	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg15511327	chr8:143859410	LYNX1	-0.39	-6.32	-0.33	8.3e-10	Urinary tract infection frequency;
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08146621	chr2:158453928	ACVR1C	0.31	6.01	0.31	4.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.36	5.63	0.3	3.83e-8	HDL cholesterol levels;
CRC	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg23032129	chr1:109941072	SORT1	-0.28	-6.04	-0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2411233	1.000	rs11070162	chr15:39270290	C/T	cg23129342	chr15:39283510	NA	0.31	5.69	0.3	2.8e-8	Platelet count;
CRC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.66	10.99	0.52	3.83e-24	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.4	-8.17	-0.41	6.54e-15	Renal cell carcinoma;
CRC	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg04850286	chr10:81895943	PLAC9	0.37	6.68	0.35	1.01e-10	Sarcoidosis;
CRC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.79	0.51	1.94e-23	Motion sickness;
CRC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.55	-7.41	-0.38	1.08e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.79	11.14	0.52	1.12e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17155006	0.702	rs399290	chr7:107725977	T/C	cg05962710	chr7:107745446	LAMB4	-0.36	-5.82	-0.31	1.39e-8	Pneumococcal bacteremia;
CRC	cis	rs990171	1.000	rs6753717	chr2:102993161	A/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.37e-8	Lymphocyte counts;
CRC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg18761221	chr20:60518478	NA	0.45	7.21	0.37	3.74e-12	Body mass index;
CRC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.55	-0.38	4.32e-13	Aortic root size;
CRC	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg20356878	chr3:121714668	ILDR1	0.5	7.56	0.38	4.08e-13	Cognitive performance;
CRC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg14784868	chr12:69753453	YEATS4	0.46	5.81	0.31	1.44e-8	Response to diuretic therapy;
CRC	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.46	-7.04	-0.36	1.12e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	7.85	0.4	5.96e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.52	1.55e-24	Nonalcoholic fatty liver disease;
CRC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.55	8.06	0.41	1.47e-14	Melanoma;
CRC	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.8	-11.67	-0.54	1.42e-26	Pubertal anthropometrics;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg25433682	chr16:30407049	ZNF48	0.6	6.37	0.33	6.55e-10	Airway imaging phenotypes;
CRC	cis	rs7680126	0.500	rs4697933	chr4:10146493	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.12	-0.32	2.67e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.6	-7.46	-0.38	7.85e-13	Ulcerative colitis;
CRC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.68	-10.3	-0.49	9.16e-22	Initial pursuit acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03333267	chr4:6577084	MAN2B2	0.48	7.22	0.37	3.6e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9323205	0.773	rs4334206	chr14:51702414	G/C	cg23942311	chr14:51606299	NA	-0.52	-6.19	-0.32	1.82e-9	Cancer;
CRC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg02428538	chr16:24856791	SLC5A11	-0.57	-6.94	-0.36	2.12e-11	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25880573	chr1:24073129	TCEB3	0.43	6.96	0.36	1.8e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.83	-13.58	-0.6	1.21e-33	Hypospadias;
CRC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.84	-0.44	5.97e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg16576597	chr16:28551801	NUPR1	0.48	6.89	0.35	2.93e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20444381	chr8:109456000	TTC35	0.41	6.17	0.32	2.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg02725872	chr8:58115012	NA	-0.56	-6.81	-0.35	4.53e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg15786705	chr6:28176104	NA	0.54	7.17	0.37	4.95e-12	Parkinson's disease;
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg03623178	chr6:28175578	NA	0.95	12.14	0.56	2.76e-28	Depression;
CRC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.96	-0.36	1.89e-11	Colorectal cancer;
CRC	cis	rs9786986	0.516	rs12401892	chr1:235701393	A/G	cg08848088	chr1:235714526	GNG4	0.51	6.19	0.32	1.84e-9	Body mass index;
CRC	cis	rs7113874	0.569	rs10769916	chr11:8598214	G/A	cg20771178	chr11:8615675	STK33	-0.35	-5.73	-0.3	2.29e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2072510	0.966	rs2660896	chr12:96423782	A/G	cg09636302	chr12:96389483	HAL	-0.37	-5.89	-0.31	9.58e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.47	7.32	0.37	1.86e-12	HDL cholesterol;
CRC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg17321639	chr7:2759063	NA	-0.54	-7.28	-0.37	2.52e-12	Height;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg20684491	chr1:25596433	NA	0.45	7.96	0.4	2.75e-14	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg20607287	chr7:12443886	VWDE	-0.62	-7.08	-0.36	8.95e-12	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26595336	chr15:82338380	MEX3B	0.35	6.06	0.32	3.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg21770322	chr7:97807741	LMTK2	0.87	19.48	0.73	9.87e-57	Breast cancer;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg03623178	chr6:28175578	NA	0.77	11.47	0.53	7.75e-26	Parkinson's disease;
CRC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg13777783	chr17:79615861	NA	-0.3	-5.61	-0.3	4.38e-8	Eye color traits;
CRC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.2	0.49	2.12e-21	Type 2 diabetes;
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg02033258	chr5:131593261	PDLIM4	0.34	6.62	0.34	1.48e-10	Blood metabolite levels;
CRC	cis	rs6834538	0.538	rs4833412	chr4:113410427	C/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.36	-5.64	-0.3	3.76e-8	Free thyroxine concentration;
CRC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg03339717	chr7:157503488	PTPRN2	0.32	5.69	0.3	2.83e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20706316	chr1:8398600	SLC45A1	-0.4	-6.44	-0.33	4.33e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.85	-0.44	5.46e-17	Hemoglobin concentration;
CRC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg11189052	chr15:85197271	WDR73	0.59	8.23	0.41	4.55e-15	Schizophrenia;
CRC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.69	9.18	0.45	4.98e-18	High light scatter reticulocyte count;
CRC	trans	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.74	-0.39	1.26e-13	HDL cholesterol;
CRC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.88	-13.56	-0.6	1.38e-33	Blood trace element (Zn levels);
CRC	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-9.66	-0.47	1.37e-19	Urate levels in overweight individuals;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg20933634	chr6:27740509	NA	0.57	8.06	0.41	1.42e-14	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	cis	rs2346160	1.000	rs7753298	chr6:167664193	G/A	cg04673565	chr6:167680447	NA	0.39	6.55	0.34	2.28e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs7703744	0.681	rs17145294	chr5:118701433	G/T	cg17471836	chr5:118691007	TNFAIP8	0.44	6.08	0.32	3.4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02725872	chr8:58115012	NA	-0.37	-6.24	-0.33	1.33e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs449789	0.857	rs591953	chr6:159716746	G/A	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	1.01	12.18	0.56	1.97e-28	Iron status biomarkers;
CRC	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.66	-10.48	-0.5	2.21e-22	Corneal astigmatism;
CRC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg03013999	chr17:37608204	MED1	0.45	6.92	0.36	2.36e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.42	6.69	0.35	9.55e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9992667	0.955	rs6858772	chr4:38651003	T/C	cg19726192	chr4:38663646	FLJ13197	-0.69	-8.97	-0.44	2.31e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.55	-0.63	2.24e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg14191688	chr11:70257035	CTTN	0.48	6.17	0.32	2.02e-9	Coronary artery disease;
CRC	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.03	8.96	0.44	2.43e-17	Prostate cancer;
CRC	trans	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.23e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.92	0.36	2.41e-11	Neuroticism;
CRC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg10398005	chr11:117014888	PAFAH1B2	-0.4	-5.7	-0.3	2.66e-8	Blood protein levels;
CRC	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg14191688	chr11:70257035	CTTN	0.4	5.66	0.3	3.29e-8	Coronary artery disease;
CRC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.86	0.35	3.49e-11	Dupuytren's disease;
CRC	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.54	9.02	0.45	1.64e-17	Dupuytren's disease;
CRC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-7.58	-0.39	3.44e-13	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.47	-0.53	7.42e-26	Alzheimer's disease;
CRC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg13072238	chr3:49761600	GMPPB	0.51	5.82	0.31	1.41e-8	Menarche (age at onset);
CRC	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.68	-10.25	-0.49	1.39e-21	Pubertal anthropometrics;
CRC	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.82	-14.2	-0.62	4.84e-36	Colorectal cancer;
CRC	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.76	0.44	1.01e-16	Dupuytren's disease;
CRC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.45	6.31	0.33	9.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg08772003	chr10:104629869	AS3MT	-0.35	-5.8	-0.3	1.53e-8	Arsenic metabolism;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg06470822	chr6:28175283	NA	-1.0	-14.15	-0.62	7.84e-36	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08080475	chr2:110962626	NPHP1	0.46	6.45	0.34	3.99e-10	Thyroid stimulating hormone;
CRC	trans	rs2172802	0.659	rs2343251	chr4:62492671	C/A	cg01233948	chr15:31318495	TRPM1	0.43	6.01	0.31	4.87e-9	Partial epilepsies;
CRC	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg27398640	chr15:77910606	LINGO1	-0.38	-6.22	-0.32	1.53e-9	Type 2 diabetes;
CRC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg14541582	chr5:601475	NA	-0.28	-5.87	-0.31	1.05e-8	Ulcerative colitis;
CRC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.16	0.71	1.53e-51	Cognitive ability;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02316091	chr9:5628906	KIAA1432	0.43	6.15	0.32	2.25e-9	Response to antipsychotic treatment;
CRC	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg04439458	chr5:138467593	SIL1	-0.35	-6.05	-0.32	3.85e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.56	6.3	0.33	9.81e-10	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg10659575	chr11:102188233	BIRC3	-0.51	-6.28	-0.33	1.05e-9	Diisocyanate-induced asthma;
CRC	cis	rs7429990	0.932	rs6442101	chr3:48130893	C/T	cg11946769	chr3:48343235	NME6	-0.47	-5.98	-0.31	5.78e-9	Educational attainment (years of education);
CRC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.56	-6.57	-0.34	1.96e-10	Lung cancer in ever smokers;
CRC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.59	6.95	0.36	1.92e-11	Menarche (age at onset);
CRC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.93	-0.36	2.18e-11	Total body bone mineral density;
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg22079747	chr2:228736145	WDR69	-0.44	-5.94	-0.31	7.4e-9	Blood pressure;
CRC	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-12.6	-0.57	5.74e-30	Body mass index;
CRC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.34	0.33	7.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.11	19.14	0.73	2.01e-55	Cognitive function;
CRC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.66	6.99	0.36	1.58e-11	Axial length;
CRC	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.44	8.75	0.43	1.14e-16	Dupuytren's disease;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg20512303	chr5:131592959	PDLIM4	0.42	7.16	0.37	5.31e-12	Acylcarnitine levels;
CRC	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.95	-16.91	-0.68	1.3e-46	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.53	7.04	0.36	1.16e-11	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.65	8.91	0.44	3.5e-17	Morning vs. evening chronotype;
CRC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg19622623	chr12:86230825	RASSF9	-0.36	-5.94	-0.31	7.17e-9	Major depressive disorder;
CRC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.67	-12.22	-0.56	1.45e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.34	-0.56	5.38e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	1.11	10.44	0.5	3.09e-22	Arsenic metabolism;
CRC	cis	rs4731207	0.591	rs28634794	chr7:124614430	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs2625529	0.617	rs2306576	chr15:72170686	C/T	cg16672083	chr15:72433130	SENP8	0.45	7.02	0.36	1.26e-11	Red blood cell count;
CRC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.69	-10.35	-0.5	6.19e-22	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.63	-7.97	-0.4	2.6e-14	Body mass index;
CRC	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.5	-6.97	-0.36	1.74e-11	Schizophrenia;
CRC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg25767906	chr1:53392781	SCP2	0.43	6.8	0.35	4.85e-11	Monocyte count;
CRC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg01788221	chr16:89496183	ANKRD11	-0.4	-5.97	-0.31	6.07e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.19	-0.53	7.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	trans	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.2	0.37	4.18e-12	Endometrial cancer;
CRC	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.48	5.84	0.31	1.24e-8	Blood protein levels;
CRC	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs9311676	0.656	rs6800514	chr3:58358717	C/T	cg06643156	chr3:58380774	PXK	0.45	6.88	0.35	3.09e-11	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09906747	chr21:34914446	SON;GART	0.4	6.23	0.32	1.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-7.96	-0.4	2.89e-14	HDL cholesterol;
CRC	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.71	7.4	0.38	1.15e-12	Pulse pressure;
CRC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-9.26	-0.45	2.76e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.51	7.2	0.37	4.11e-12	High light scatter reticulocyte count;
CRC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.87	0.51	1.01e-23	Motion sickness;
CRC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg00343986	chr7:65444356	GUSB	0.49	7.26	0.37	2.87e-12	Aortic root size;
CRC	cis	rs6545883	0.524	rs811871	chr2:61577949	C/T	cg10580144	chr2:61372316	C2orf74	-0.35	-7.72	-0.39	1.46e-13	Tuberculosis;
CRC	cis	rs3750082	0.926	rs11762628	chr7:32926571	T/C	cg05721444	chr7:32995514	FKBP9	0.42	5.98	0.31	5.97e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09938965	chr16:89557187	ANKRD11	0.36	6.08	0.32	3.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	0.79	8.09	0.41	1.18e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-10.11	-0.49	4.17e-21	Total cholesterol levels;
CRC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.87	-0.44	4.73e-17	Hemoglobin concentration;
CRC	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.58	-8.54	-0.43	4.9e-16	Height;
CRC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg02683197	chr6:28174875	NA	0.68	8.89	0.44	4.12e-17	Parkinson's disease;
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.74	0.35	7.11e-11	Blood metabolite levels;
CRC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.9	0.52	8.07e-24	Motion sickness;
CRC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.44	6.49	0.34	3.25e-10	Menopause (age at onset);
CRC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg18806716	chr10:30721971	MAP3K8	0.46	6.65	0.34	1.25e-10	Inflammatory bowel disease;
CRC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.48	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs73206853	0.609	rs7966169	chr12:111045898	T/C	cg12870014	chr12:110450643	ANKRD13A	0.8	9.13	0.45	7.15e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg18833306	chr6:118973337	C6orf204	0.47	6.78	0.35	5.67e-11	Renal cell carcinoma;
CRC	cis	rs9462027	1.000	rs6457792	chr6:34764443	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	5.6	0.3	4.49e-8	Systemic lupus erythematosus;
CRC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.67	9.89	0.48	2.25e-20	Corneal astigmatism;
CRC	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.78	10.66	0.51	5.66e-23	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.39	-5.73	-0.3	2.27e-8	Obesity-related traits;
CRC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg17911788	chr17:44343683	NA	-0.52	-6.59	-0.34	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg03013999	chr17:37608204	MED1	0.45	6.63	0.34	1.35e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7546094	0.967	rs1006298	chr1:113061959	G/C	cg22162597	chr1:113214053	CAPZA1	0.41	5.66	0.3	3.23e-8	Platelet distribution width;
CRC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.99	21.36	0.76	4.12e-64	Cerebrospinal fluid biomarker levels;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg07807695	chr5:81608485	ATP6AP1L	-0.49	-7.76	-0.39	1.07e-13	Breast cancer;
CRC	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-8.94	-0.44	2.86e-17	Neuroticism;
CRC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.59	-10.76	-0.51	2.43e-23	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg20203395	chr5:56204925	C5orf35	0.55	7.5	0.38	5.94e-13	Initial pursuit acceleration;
CRC	cis	rs6743376	0.556	rs12475161	chr2:113823626	T/C	cg09040174	chr2:113837401	NA	0.4	5.86	0.31	1.13e-8	Inflammatory biomarkers;
CRC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg18827107	chr12:86230957	RASSF9	-0.42	-6.7	-0.35	9.21e-11	Major depressive disorder;
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	10.96	0.52	5.09e-24	Alzheimer's disease;
CRC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.76	-12.94	-0.58	3.02e-31	DNA methylation (variation);
CRC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	17.23	0.69	7.26e-48	Body mass index (adult);
CRC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.5	8.83	0.44	6.56e-17	Testicular germ cell tumor;
CRC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg24562669	chr7:97807699	LMTK2	0.78	17.5	0.69	6.1e-49	Breast cancer;
CRC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg20908204	chr19:46285434	DMPK	-0.39	-7.76	-0.39	1.11e-13	Coronary artery disease;
CRC	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.61	0.54	2.45e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg23996704	chr18:44553084	KATNAL2	-0.31	-6.05	-0.32	3.94e-9	Personality dimensions;
CRC	trans	rs2303319	0.504	rs1567420	chr2:162475601	C/T	cg18122310	chr12:50236657	BCDIN3D	0.71	6.0	0.31	5.07e-9	Cognitive function;
CRC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.46	7.3	0.37	2.22e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.47	6.4	0.33	5.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2944591	0.505	rs2592127	chr2:233791648	G/T	cg11972305	chr2:233791962	NGEF	-0.43	-6.83	-0.35	4.2e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.67	-11.08	-0.52	1.79e-24	Mean platelet volume;
CRC	cis	rs3018066	0.867	rs6819081	chr4:107132629	G/A	cg01869342	chr4:106983673	TBCK	-0.36	-5.61	-0.3	4.26e-8	Cancer;
CRC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.24	0.53	5.09e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01202751	chr6:143248085	HIVEP2	0.47	6.68	0.35	1e-10	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04205485	chr20:32399084	CHMP4B	0.4	6.74	0.35	7.12e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.5	6.95	0.36	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg05714579	chr10:131428358	MGMT	0.55	8.07	0.41	1.35e-14	Response to temozolomide;
CRC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg00601486	chr12:48723148	H1FNT	-0.35	-6.51	-0.34	2.89e-10	Glycated hemoglobin levels;
CRC	cis	rs12630931	0.964	rs11710895	chr3:31980246	A/T	cg21375017	chr3:31988082	OSBPL10	0.42	5.82	0.31	1.38e-8	Periodontal disease-related phenotypes;
CRC	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.41e-13	Electroencephalogram traits;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.54	-10.22	-0.49	1.83e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.49	-0.34	3.23e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.03	-0.55	7.13e-28	Coffee consumption (cups per day);
CRC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.41	6.47	0.34	3.58e-10	Cystic fibrosis severity;
CRC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.38	6.1	0.32	3.01e-9	Major depressive disorder;
CRC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.35	-0.38	1.53e-12	QT interval;
CRC	cis	rs7264396	0.832	rs224378	chr20:34088764	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.11	-0.36	7.49e-12	Total cholesterol levels;
CRC	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.31	-0.33	8.91e-10	Breast cancer;
CRC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.79	10.0	0.48	9.8e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.58	8.1	0.41	1.07e-14	Arsenic metabolism;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg02683197	chr6:28174875	NA	0.9	11.93	0.55	1.69e-27	Depression;
CRC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	trans	rs6693295	0.605	rs4396095	chr1:246213270	A/G	cg08881680	chr11:94965469	SESN3	0.49	6.02	0.31	4.7e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs7849270	0.885	rs10760588	chr9:131877474	C/T	cg13538475	chr9:131942899	NA	-0.3	-6.04	-0.32	4.14e-9	Blood metabolite ratios;
CRC	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg00666640	chr1:248458726	OR2T12	0.43	7.64	0.39	2.34e-13	Common traits (Other);
CRC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.64	0.39	2.33e-13	Schizophrenia;
CRC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.73	-11.12	-0.52	1.29e-24	Breast cancer;
CRC	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.41	6.31	0.33	9.08e-10	Longevity;
CRC	cis	rs2257205	0.667	rs6503879	chr17:56888183	T/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg14352298	chr13:112236639	NA	0.3	6.71	0.35	8.5e-11	Hepatitis;
CRC	trans	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg26043149	chr18:55253948	FECH	0.52	8.06	0.41	1.46e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.83	8.23	0.41	4.37e-15	Diabetic retinopathy;
CRC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.85	0.68	2.34e-46	Platelet count;
CRC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg15445000	chr17:37608096	MED1	-0.33	-5.79	-0.3	1.62e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.58	-8.64	-0.43	2.51e-16	Testicular germ cell tumor;
CRC	cis	rs7605827	0.930	rs1024870	chr2:15625846	T/C	cg19274914	chr2:15703543	NA	0.39	6.05	0.32	3.96e-9	Educational attainment (years of education);
CRC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg06505273	chr16:24850292	NA	0.37	5.68	0.3	3.02e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1161463	0.834	rs1161458	chr13:29433372	A/G	cg16311697	chr3:124249497	KALRN	-0.45	-6.16	-0.32	2.11e-9	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
CRC	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.71	0.3	2.49e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.71	10.48	0.5	2.25e-22	Longevity;
CRC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.5	10.96	0.52	4.83e-24	Alcohol dependence;
CRC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25517755	chr10:38738941	LOC399744	-0.43	-6.22	-0.32	1.51e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.53	8.21	0.41	5.16e-15	Lung cancer;
CRC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.85	-0.31	1.17e-8	Gout;Renal underexcretion gout;
CRC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg24375607	chr4:120327624	NA	0.49	7.84	0.4	6.14e-14	Educational attainment;
CRC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg10298567	chr3:47292165	KIF9	-0.39	-6.59	-0.34	1.74e-10	Colorectal cancer;
CRC	cis	rs12024301	0.557	rs16861259	chr1:183593328	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.69	-6.61	-0.34	1.56e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.37	6.9	0.36	2.75e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs4803480	1.000	rs3745937	chr19:42071289	T/C	cg08478046	chr19:42093086	CEACAM21	-0.34	-5.99	-0.31	5.44e-9	Schizophrenia;
CRC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.72	11.22	0.53	5.84e-25	Corneal astigmatism;
CRC	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg09597638	chr17:3907349	NA	0.64	11.59	0.54	2.84e-26	Type 2 diabetes;
CRC	trans	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.32	-0.33	8.38e-10	Aortic root size;
CRC	cis	rs9992667	0.829	rs337628	chr4:38635144	A/T	cg19726192	chr4:38663646	FLJ13197	-0.43	-6.58	-0.34	1.83e-10	Eosinophil percentage of granulocytes;
CRC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg02319466	chr17:76381040	PGS1	0.39	6.09	0.32	3.12e-9	HDL cholesterol levels;
CRC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.78	0.39	9.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg02741985	chr17:80059408	CCDC57	0.41	6.66	0.34	1.17e-10	Life satisfaction;
CRC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.51	-9.15	-0.45	6.35e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	1.12	9.9	0.48	2.22e-20	Arsenic metabolism;
CRC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.69	11.36	0.53	1.87e-25	Mean corpuscular hemoglobin;
CRC	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.69	-6.38	-0.33	5.89e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6694672	1.000	rs7542397	chr1:197096720	G/A	cg13682187	chr1:196946512	CFHR5	0.47	7.53	0.38	4.89e-13	Asthma;
CRC	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.89	-0.4	4.61e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.8	17.97	0.7	8.5e-51	Breast cancer;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.68	0.43	1.91e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg21115391	chr11:93143810	CCDC67	-0.39	-5.74	-0.3	2.17e-8	Pulmonary function decline;
CRC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.88	-12.74	-0.57	1.69e-30	Platelet distribution width;
CRC	trans	rs12714668	0.502	rs9833343	chr3:86822457	A/C	cg13618939	chr10:46090486	MARCH8	-0.46	-6.07	-0.32	3.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.07	-10.22	-0.49	1.71e-21	Diabetic retinopathy;
CRC	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.67	0.35	1.09e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg04969067	chr8:143858791	LYNX1	0.45	7.71	0.39	1.5e-13	Urinary tract infection frequency;
CRC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg01529538	chr14:23388837	RBM23	0.41	6.43	0.33	4.6e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg12317470	chr15:67143691	NA	-0.52	-6.32	-0.33	8.32e-10	Lung cancer (smoking interaction);
CRC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.83	-0.48	3.75e-20	Total cholesterol levels;
CRC	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-7.23	-0.37	3.35e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.71	11.72	0.54	9.78e-27	Body mass index;
CRC	cis	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg08501292	chr6:25962987	TRIM38	-0.98	-8.48	-0.42	7.8e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.36	-6.34	-0.33	7.43e-10	Erythrocyte sedimentation rate;
CRC	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.68	0.39	1.79e-13	Testicular germ cell tumor;
CRC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.84	-0.31	1.25e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22841110	chr11:64053472	BAD;GPR137	0.38	6.01	0.31	4.8e-9	Obesity-related traits;
CRC	cis	rs17023223	0.537	rs2794313	chr1:119587440	T/C	cg05756136	chr1:119680316	WARS2	-0.47	-6.29	-0.33	1.01e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-11.16	-0.52	9.29e-25	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09735905	chr1:70820197	HHLA3;ANKRD13C	0.47	6.51	0.34	2.75e-10	Response to antipsychotic treatment;
CRC	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.43	-6.17	-0.32	2.04e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg19678392	chr7:94953810	PON1	-0.59	-7.34	-0.38	1.65e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.82	-0.4	7.24e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	5.88	0.31	1.02e-8	Obesity-related traits;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg02033258	chr5:131593261	PDLIM4	0.37	6.32	0.33	8.71e-10	Breast cancer;
CRC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.75	11.51	0.54	5.31e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2303319	0.504	rs62187657	chr2:162488091	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.09	-0.32	3.1e-9	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14878357	chr5:32174468	GOLPH3	0.43	6.01	0.31	4.84e-9	Anxiety disorder;
CRC	cis	rs17213078	0.602	rs4851926	chr2:106742660	A/G	cg15412446	chr2:106886593	NA	0.38	6.16	0.32	2.11e-9	Facial morphology (factor 23);
CRC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.92	14.89	0.63	1.13e-38	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.23	-0.32	1.42e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg15786705	chr6:28176104	NA	-0.77	-9.8	-0.48	4.72e-20	Depression;
CRC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16262614	chr3:133464971	TF	-0.38	-6.99	-0.36	1.51e-11	Iron status biomarkers;
CRC	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg16670446	chr17:27188758	MIR451;MIR144	-0.61	-10.26	-0.49	1.34e-21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.91	-15.53	-0.65	3.58e-41	Dupuytren's disease;
CRC	trans	rs2303319	0.504	rs12469302	chr2:162433831	G/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.14	-0.32	2.36e-9	Cognitive function;
CRC	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24249390	chr15:90295951	MESP1	-0.59	-9.23	-0.45	3.35e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.62	7.39	0.38	1.26e-12	Lymphocyte counts;
CRC	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	7.69	0.39	1.73e-13	Mean corpuscular volume;
CRC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.49	-7.27	-0.37	2.6e-12	Cognitive test performance;
CRC	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.28	16.63	0.68	1.75e-45	Uric acid levels;
CRC	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.52	0.38	5.41e-13	Lung cancer;
CRC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.54	7.95	0.4	3.05e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg02569458	chr12:86230093	RASSF9	0.39	6.7	0.35	9.15e-11	Major depressive disorder;
CRC	cis	rs8060686	0.858	rs8051587	chr16:67796315	A/C	cg00318322	chr16:67708822	GFOD2	-0.31	-5.68	-0.3	3.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs17713451	0.593	rs17715595	chr7:151272490	C/T	cg18404559	chr7:151322523	PRKAG2	-0.54	-6.33	-0.33	7.94e-10	Interleukin-4 levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22640452	chr17:38256967	NR1D1	0.45	6.28	0.33	1.09e-9	Response to antipsychotic treatment;
CRC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.81	-0.31	1.47e-8	Daytime sleep phenotypes;
CRC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg18972013	chr17:78078605	GAA	-0.4	-5.8	-0.3	1.58e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-12.04	-0.55	6.58e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg24304309	chr1:154577895	ADAR	0.34	5.69	0.3	2.87e-8	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06824134	chr2:45878977	PRKCE	0.44	6.06	0.32	3.81e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg03934865	chr2:198174659	NA	-0.4	-6.26	-0.33	1.2e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.69	-0.3	2.75e-8	Lung cancer;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.32	-0.33	8.55e-10	Total body bone mineral density;
CRC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.86	-15.13	-0.64	1.24e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.45	-6.79	-0.35	5.27e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.85	14.38	0.62	1.05e-36	Intelligence (multi-trait analysis);
CRC	cis	rs1355223	0.902	rs34751755	chr11:34694243	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.67	-0.3	3.17e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06834434	chr14:75079333	LTBP2	0.56	6.98	0.36	1.64e-11	Obesity-related traits;
CRC	cis	rs4766646	0.619	rs4766638	chr12:110298858	T/C	cg01252219	chr12:110302105	GLTP	0.41	6.26	0.33	1.17e-9	Metabolite levels (MHPG);
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg21251018	chr6:28226885	NKAPL	0.44	5.64	0.3	3.75e-8	Depression;
CRC	cis	rs10905065	0.965	rs2797488	chr10:5784509	C/T	cg11519256	chr10:5708881	ASB13	0.43	6.16	0.32	2.15e-9	Menopause (age at onset);
CRC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.67	-7.85	-0.4	6.07e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.86	14.87	0.63	1.27e-38	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.78	-12.91	-0.58	3.86e-31	Blood metabolite levels;
CRC	cis	rs11628318	0.515	rs12884619	chr14:103095724	C/A	cg12046867	chr14:103022105	NA	-0.44	-5.89	-0.31	9.38e-9	Platelet count;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg10729496	chr3:10149963	C3orf24	0.49	6.45	0.34	3.88e-10	Alzheimer's disease;
CRC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.48	6.51	0.34	2.81e-10	Schizophrenia;
CRC	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.17	-0.32	1.97e-9	Blood protein levels;
CRC	cis	rs1552172	0.887	rs2040086	chr1:145651876	C/A	cg11743829	chr1:145714124	CD160	-0.42	-6.29	-0.33	1.04e-9	Breast cancer;
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.16	0.41	7.42e-15	Platelet count;
CRC	cis	rs755249	0.508	rs12023553	chr1:39671492	C/A	cg11070191	chr1:39582205	MACF1	0.36	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg25344623	chr2:136566232	LCT	0.33	6.03	0.32	4.33e-9	Mosquito bite size;
CRC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.23	0.56	1.36e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs79387448	0.810	rs75218113	chr2:103239356	C/G	cg09003973	chr2:102972529	NA	0.74	7.27	0.37	2.71e-12	Gut microbiota (bacterial taxa);
CRC	cis	rs910187	0.678	rs3818012	chr20:45816594	G/A	cg27589058	chr20:45804311	EYA2	-0.36	-6.99	-0.36	1.54e-11	Migraine;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23237097	chr1:160278129	COPA	0.41	6.22	0.32	1.47e-9	Interleukin-6 levels;
CRC	cis	rs7901135	0.924	rs4948547	chr10:60568514	C/A	cg23799393	chr10:60588674	BICC1	0.36	5.62	0.3	4.12e-8	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7308116	0.546	rs17307888	chr12:108212639	A/G	cg10318744	chr14:69282256	NA	-0.41	-6.01	-0.31	4.89e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.7	-9.21	-0.45	4e-18	Bronchopulmonary dysplasia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01159149	chr11:10830970	EIF4G2	0.44	6.09	0.32	3.23e-9	Response to antipsychotic treatment;
CRC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.95e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.6	9.93	0.48	1.76e-20	Vitiligo;
CRC	trans	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg13565492	chr6:43139072	SRF	-0.86	-6.19	-0.32	1.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg22922770	chr7:98923339	ARPC1A	-0.69	-6.19	-0.32	1.77e-9	Cognitive function;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg08322149	chr10:46222875	FAM21C	0.47	6.68	0.35	1.02e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	8.06	0.41	1.4e-14	Body mass index;
CRC	cis	rs747650	0.504	rs7935346	chr11:47008379	A/G	cg19486271	chr11:47235900	DDB2	-0.4	-5.97	-0.31	6.08e-9	Acne (severe);
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.65	0.3	3.4e-8	Bipolar disorder;
CRC	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg03929089	chr4:120376271	NA	0.56	6.49	0.34	3.14e-10	Intraocular pressure;
CRC	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.46	8.23	0.41	4.37e-15	Blood metabolite ratios;
CRC	cis	rs11009175	0.725	rs4934646	chr10:33296609	C/T	cg00146027	chr10:33299147	NA	-0.28	-5.76	-0.3	1.95e-8	Depression (quantitative trait);
CRC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	0.67	7.26	0.37	2.84e-12	Body mass index;
CRC	cis	rs7605827	0.930	rs4668446	chr2:15516020	C/T	cg19274914	chr2:15703543	NA	0.4	6.03	0.32	4.33e-9	Educational attainment (years of education);
CRC	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.78	-12.39	-0.56	3.49e-29	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg23071808	chr14:103021642	NA	-0.68	-8.76	-0.44	1.02e-16	Platelet count;
CRC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.84	0.31	1.28e-8	Nonalcoholic fatty liver disease;
CRC	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg01843034	chr6:37503916	NA	-0.48	-8.8	-0.44	7.73e-17	Cognitive performance;
CRC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.01	0.4	2.07e-14	Resting heart rate;
CRC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.11	0.32	2.86e-9	Rheumatoid arthritis;
CRC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.79	14.13	0.61	9.31e-36	Mean platelet volume;
CRC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.63	10.6	0.5	8.74e-23	Breast cancer;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7209700	0.708	rs2292865	chr17:45364722	C/T	cg08085267	chr17:45401833	C17orf57	0.48	7.1	0.36	7.5e-12	IgG glycosylation;
CRC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.52	-7.29	-0.37	2.35e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg03233332	chr7:66118400	NA	-0.44	-6.23	-0.32	1.46e-9	Aortic root size;
CRC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.28	0.33	1.09e-9	Bladder cancer;
CRC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg15848620	chr12:58087721	OS9	-0.61	-8.31	-0.42	2.52e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.84e-24	Corneal astigmatism;
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.95	-0.31	6.92e-9	Total body bone mineral density;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.52	8.43	0.42	1.1e-15	Electroencephalogram traits;
CRC	cis	rs863345	0.967	rs12133354	chr1:158526537	T/C	cg12129480	chr1:158549410	OR10X1	-0.26	-5.73	-0.3	2.21e-8	Pneumococcal bacteremia;
CRC	trans	rs948562	0.895	rs11229537	chr11:58352865	T/C	cg26660744	chr1:1573181	CDK11B	0.53	6.19	0.32	1.83e-9	Lymphoma;
CRC	cis	rs9584850	0.574	rs17471079	chr13:99168721	C/T	cg20487152	chr13:99095054	FARP1	0.48	6.12	0.32	2.67e-9	Neuroticism;
CRC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.45	-6.62	-0.34	1.43e-10	Breast size;
CRC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.46	0.69	8.98e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.99	18.05	0.71	4.29e-51	Menarche (age at onset);
CRC	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs6546324	0.625	rs2902025	chr2:67842424	A/G	cg15745817	chr2:67799979	NA	-0.56	-9.54	-0.47	3.44e-19	Endometriosis;
CRC	cis	rs16975963	0.644	rs73031309	chr19:38031984	C/T	cg15135657	chr19:38346511	NA	-0.46	-6.32	-0.33	8.53e-10	Longevity;
CRC	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg00684032	chr4:1343700	KIAA1530	-0.58	-5.61	-0.3	4.35e-8	Systolic blood pressure;
CRC	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.16	0.64	9.43e-40	Bipolar disorder;
CRC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-12.15	-0.56	2.59e-28	Extrinsic epigenetic age acceleration;
CRC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg02527881	chr3:46936655	PTH1R	-0.41	-7.83	-0.4	6.74e-14	Colorectal cancer;
CRC	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg01993067	chr11:68851601	TPCN2	0.58	6.66	0.34	1.13e-10	Blond vs. brown hair color;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.92	17.18	0.69	1.12e-47	Height;
CRC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.14	-13.85	-0.61	1.06e-34	Diabetic kidney disease;
CRC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg23136738	chr11:925521	AP2A2	-0.38	-5.95	-0.31	6.73e-9	Alzheimer's disease (late onset);
CRC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.01	-0.31	4.81e-9	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15344021	chr17:2240169	TSR1;SGSM2	0.45	6.31	0.33	9.14e-10	Response to antipsychotic treatment;
CRC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.49	-7.64	-0.39	2.36e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.69	9.24	0.45	3.2e-18	High light scatter reticulocyte count;
CRC	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.56	8.28	0.42	3.12e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.34	0.42	2e-15	Corneal astigmatism;
CRC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg23298862	chr7:158159286	PTPRN2	0.38	5.98	0.31	5.8e-9	Calcium levels;
CRC	cis	rs2398893	0.924	rs11789837	chr9:96817369	T/G	cg14459158	chr9:96720562	NA	0.42	6.92	0.36	2.39e-11	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg10494257	chr1:16342123	HSPB7	0.45	6.33	0.33	7.97e-10	Dilated cardiomyopathy;
CRC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.48	0.42	7.73e-16	Rheumatoid arthritis;
CRC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg25124228	chr12:125621409	AACS	-0.52	-6.67	-0.35	1.05e-10	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg06972903	chr1:6580525	PLEKHG5	-0.62	-5.78	-0.3	1.71e-8	Body mass index;
CRC	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-6.58	-0.34	1.85e-10	Alzheimer's disease (survival time);
CRC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.08e-8	Morning vs. evening chronotype;
CRC	cis	rs10982256	0.875	rs10759710	chr9:117252598	C/T	cg13636371	chr9:117264095	DFNB31	0.4	7.6	0.39	3.18e-13	Bipolar disorder;
CRC	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.43	-5.75	-0.3	2.02e-8	Daytime sleep phenotypes;
CRC	cis	rs7173389	1.000	rs8035896	chr15:73664310	T/G	cg01796676	chr15:73680284	NA	0.5	6.72	0.35	7.88e-11	Resting heart rate;
CRC	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.61	8.3	0.42	2.79e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.15	-0.32	2.2e-9	Intelligence (multi-trait analysis);Body fat percentage;
CRC	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.95	-17.74	-0.7	7.08e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs28643277	0.633	rs3178793	chr10:15556102	T/C	cg18315834	chr14:64909119	MTHFD1	0.42	6.07	0.32	3.59e-9	Periodontitis (CDC/AAP);
CRC	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg12858261	chr2:113808755	IL1F8	-0.44	-6.55	-0.34	2.18e-10	Protein quantitative trait loci;
CRC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.48	-7.28	-0.37	2.5e-12	Testicular germ cell tumor;
CRC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg13319975	chr6:146136371	FBXO30	0.42	6.61	0.34	1.58e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs501916	0.634	rs3803349	chr15:48064867	T/A	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.62	-0.34	1.43e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.95	-0.44	2.62e-17	Prostate cancer;
CRC	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg27411982	chr8:10470053	RP1L1	0.39	5.68	0.3	2.94e-8	Neuroticism;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.93	-22.01	-0.77	1.17e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-6.43	-0.33	4.61e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.41	-0.42	1.28e-15	Coronary artery disease;
CRC	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.59	0.47	2.32e-19	Type 2 diabetes;
CRC	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg25767906	chr1:53392781	SCP2	0.46	7.53	0.38	4.87e-13	Monocyte count;
CRC	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg26805224	chr10:79626177	DLG5	-0.56	-8.26	-0.41	3.57e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-8.25	-0.41	3.78e-15	Bipolar disorder;
CRC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg14828511	chr1:107599125	PRMT6	-0.53	-7.31	-0.37	2.1e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.53	8.56	0.43	4.24e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.55	0.47	3.2e-19	Ileal carcinoids;
CRC	cis	rs73206853	0.925	rs12297709	chr12:110901758	A/G	cg12870014	chr12:110450643	ANKRD13A	0.7	8.68	0.43	1.82e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg23161317	chr6:28129485	ZNF389	0.45	6.52	0.34	2.72e-10	Parkinson's disease;
CRC	cis	rs372883	0.901	rs407463	chr21:30722440	G/A	cg24692254	chr21:30365293	RNF160	-0.39	-5.96	-0.31	6.44e-9	Pancreatic cancer;
CRC	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg15845792	chr6:28175446	NA	-0.45	-6.12	-0.32	2.65e-9	Systemic lupus erythematosus;
CRC	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.6	-8.68	-0.43	1.81e-16	Coronary artery disease;
CRC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.79	-0.39	9.04e-14	Height;
CRC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.18	0.32	1.91e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg09040174	chr2:113837401	NA	0.65	10.3	0.49	9.83e-22	Protein quantitative trait loci;
CRC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg03037974	chr15:76606532	NA	0.74	13.26	0.59	1.96e-32	Blood metabolite levels;
CRC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	5.76	0.3	1.89e-8	Hip circumference adjusted for BMI;
CRC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.69	0.3	2.8e-8	Hemoglobin concentration;
CRC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.59	10.35	0.5	6.37e-22	Schizophrenia;
CRC	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg21153622	chr11:89784906	NA	-0.42	-6.8	-0.35	4.94e-11	Coronary artery disease;
CRC	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg09873164	chr1:152488093	CRCT1	-0.39	-6.58	-0.34	1.87e-10	Hair morphology;
CRC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.6	-8.74	-0.43	1.19e-16	Aortic root size;
CRC	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.58	9.33	0.46	1.55e-18	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.08	-0.32	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg26043149	chr18:55253948	FECH	0.46	7.41	0.38	1.1e-12	Bone mineral density;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17286491	chr1:179923514	CEP350	-0.53	-6.43	-0.33	4.47e-10	Diisocyanate-induced asthma;
CRC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.64	-9.24	-0.45	3.12e-18	Menarche (age at onset);
CRC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.55	-7.35	-0.38	1.54e-12	IgG glycosylation;
CRC	trans	rs7027930	0.560	rs10758737	chr9:610960	G/C	cg27061366	chr19:13044373	FARSA	0.52	6.38	0.33	6.13e-10	Pulmonary function decline;
CRC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.74	-0.51	2.95e-23	Bipolar disorder;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg16132339	chr22:24313637	DDTL;DDT	0.67	11.12	0.52	1.29e-24	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.41	-7.44	-0.38	8.78e-13	Type 2 diabetes;
CRC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9816226	0.591	rs1516725	chr3:185824004	T/C	cg00760338	chr3:185826511	ETV5	0.65	5.78	0.3	1.72e-8	Obesity;Body mass index;
CRC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-16.77	-0.68	4.65e-46	Primary sclerosing cholangitis;
CRC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25517755	chr10:38738941	LOC399744	-0.43	-6.29	-0.33	9.92e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.73	-0.35	7.54e-11	Breast cancer;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg02416716	chr11:6948024	ZNF215	0.57	5.86	0.31	1.14e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.41	6.66	0.34	1.13e-10	Huntington's disease progression;
CRC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.39	6.63	0.34	1.36e-10	Coronary artery disease;
CRC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg14196790	chr5:131705035	SLC22A5	-0.35	-5.67	-0.3	3.18e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs9969804	0.818	rs6479429	chr9:95501785	A/T	cg14631576	chr9:95140430	CENPP	-0.32	-5.97	-0.31	6.03e-9	Height;
CRC	cis	rs6662572	0.737	rs4660315	chr1:46270942	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.22	-0.32	1.52e-9	Blood protein levels;
CRC	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.07	-0.41	1.34e-14	Coronary artery disease;
CRC	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg02702477	chr5:179499311	RNF130	0.54	6.21	0.32	1.61e-9	LDL cholesterol;
CRC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.63	0.3	3.9e-8	Cystic fibrosis severity;
CRC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-15.86	-0.66	1.71e-42	Prostate cancer;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Parkinson's disease;
CRC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.46	6.79	0.35	5.16e-11	Plateletcrit;
CRC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.63	-10.27	-0.49	1.2e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2179367	0.887	rs506268	chr6:149685617	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.36	-6.01	-0.31	4.94e-9	Dupuytren's disease;
CRC	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.59	7.01	0.36	1.34e-11	Carotid intima media thickness;
CRC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.44	0.62	5.96e-37	Chronic sinus infection;
CRC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.72	-11.21	-0.53	6.29e-25	Cognitive function;
CRC	trans	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg17903999	chr18:56338584	MALT1	0.41	6.71	0.35	8.45e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.85	8.18	0.41	6.31e-15	Pulse pressure;
CRC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg13607699	chr17:42295918	UBTF	-0.5	-6.55	-0.34	2.26e-10	Total body bone mineral density;
CRC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.57	8.28	0.42	3.14e-15	Alcohol dependence;
CRC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.85	-12.66	-0.57	3.37e-30	Response to antineoplastic agents;
CRC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.33	-5.75	-0.3	2.01e-8	Menarche (age at onset);
CRC	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.71	-11.52	-0.54	4.82e-26	Mean platelet volume;
CRC	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.6	6.65	0.34	1.22e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18058077	chr11:319009	NA	0.42	6.63	0.34	1.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3823572	0.542	rs2346267	chr7:133639554	T/C	cg03336402	chr7:133662267	EXOC4	0.66	10.02	0.48	8.55e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01519350	chr3:137906342	ARMC8	0.48	6.91	0.36	2.59e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16590012	chr1:1265354	TAS1R3	-0.37	-6.49	-0.34	3.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.46	-10.44	-0.5	3.2e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.6	-11.21	-0.53	6.38e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Parkinson's disease;
CRC	trans	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.27	-0.37	2.72e-12	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.83	12.7	0.57	2.44e-30	Glomerular filtration rate (creatinine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08408563	chr2:120980996	TMEM185B	0.42	6.22	0.32	1.52e-9	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg23590916	chr17:43697445	MGC57346	0.69	7.23	0.37	3.41e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-5.79	-0.3	1.62e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	14.7	0.63	5.68e-38	Lymphocyte percentage of white cells;
CRC	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.55	8.7	0.43	1.64e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg08992911	chr2:238395768	MLPH	0.57	5.85	0.31	1.2e-8	Prostate cancer;
CRC	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.71	0.3	2.46e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.72	-11.22	-0.53	5.71e-25	Tonsillectomy;
CRC	cis	rs17155006	0.746	rs366690	chr7:107749880	T/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.33	-0.37	1.77e-12	Pneumococcal bacteremia;
CRC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	8.32	0.42	2.35e-15	Rheumatoid arthritis;
CRC	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.5	7.95	0.4	2.98e-14	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg09835421	chr16:68378352	PRMT7	-0.75	-7.79	-0.39	8.77e-14	Schizophrenia;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12172441	chr6:28176163	NA	0.53	7.32	0.37	1.96e-12	Cardiac Troponin-T levels;
CRC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg21153622	chr11:89784906	NA	0.43	7.15	0.37	5.77e-12	Coronary artery disease;
CRC	cis	rs16975963	0.843	rs60731897	chr19:38269259	C/A	cg15135657	chr19:38346511	NA	-0.44	-5.89	-0.31	9.55e-9	Longevity;
CRC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-12.69	-0.57	2.64e-30	Refractive error;
CRC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg16558177	chr4:4109446	NA	-0.52	-6.24	-0.33	1.32e-9	Blood pressure (smoking interaction);
CRC	cis	rs9783347	1.000	rs7947378	chr11:18381327	T/C	cg15585147	chr11:18324498	HPS5	0.46	6.5	0.34	3.03e-10	Pancreatic cancer;
CRC	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.23	-9.95	-0.48	1.45e-20	Mitochondrial DNA levels;
CRC	cis	rs10971721	0.822	rs10971735	chr9:33851799	T/C	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.49	7.13	0.37	6.42e-12	Height;
CRC	cis	rs427941	0.550	rs201523	chr7:101771851	C/T	cg06246474	chr7:101738831	CUX1	0.37	5.67	0.3	3.17e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg09473613	chr1:24152604	HMGCL	0.35	5.66	0.3	3.35e-8	Immature fraction of reticulocytes;
CRC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.65	-9.24	-0.45	3.12e-18	DNA methylation (variation);
CRC	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	1.15	18.72	0.72	9.24e-54	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg03806693	chr22:41940476	POLR3H	-0.52	-6.01	-0.31	4.91e-9	Neuroticism;
CRC	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg13385794	chr1:248469461	NA	0.39	6.98	0.36	1.62e-11	Common traits (Other);
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.51	6.07	0.32	3.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2692947	0.727	rs2692950	chr2:96673524	T/C	cg23100626	chr2:96804247	ASTL	0.25	6.78	0.35	5.61e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2072510	0.593	rs2540497	chr12:96404275	A/T	cg22491680	chr12:96389547	HAL	-0.47	-5.84	-0.31	1.25e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg23018236	chr17:30244563	NA	0.52	6.64	0.34	1.3100000000000001e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.83	-15.95	-0.66	7.62e-43	Prostate cancer;
CRC	cis	rs73206853	0.688	rs56691704	chr12:110568623	A/G	cg12870014	chr12:110450643	ANKRD13A	0.82	9.4	0.46	9.47e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9462027	0.628	rs2814961	chr6:34706951	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg10589385	chr1:150898437	SETDB1	0.31	6.48	0.34	3.43e-10	Blood protein levels;
CRC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.54	-6.42	-0.33	4.63e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	1.95e-33	Vitiligo;
CRC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.63	7.3	0.37	2.24e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg14003231	chr6:33640908	ITPR3	0.51	8.25	0.41	3.77e-15	Plateletcrit;
CRC	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg17470449	chr10:769945	NA	0.53	7.97	0.4	2.58e-14	Uric acid levels;
CRC	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg01951491	chr16:67709440	GFOD2	-0.45	-5.9	-0.31	9.23e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-6.01	-0.31	4.95e-9	Eosinophil percentage of white cells;
CRC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg11887960	chr12:57824829	NA	0.58	6.44	0.33	4.17e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7605827	0.930	rs1015837	chr2:15665847	C/T	cg19274914	chr2:15703543	NA	0.37	5.7	0.3	2.62e-8	Educational attainment (years of education);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17344085	chr7:100450162	SLC12A9	0.49	6.97	0.36	1.75e-11	Anxiety disorder;
CRC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06656553	chr16:89960601	TCF25	-0.68	-5.99	-0.31	5.35e-9	Skin colour saturation;
CRC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg10298567	chr3:47292165	KIF9	0.37	5.8	0.3	1.58e-8	Colorectal cancer;
CRC	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.57	-8.52	-0.42	6.02e-16	Lung cancer;
CRC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg25456477	chr12:86230367	RASSF9	0.32	5.63	0.3	3.83e-8	Major depressive disorder;
CRC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.58	-6.13	-0.32	2.54e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg05540913	chr6:167530185	CCR6	-0.34	-6.0	-0.31	5.1e-9	Primary biliary cholangitis;
CRC	cis	rs7487075	0.859	rs7968173	chr12:46759017	A/T	cg22049899	chr12:47219821	SLC38A4	-0.32	-6.01	-0.31	4.99e-9	Itch intensity from mosquito bite;
CRC	trans	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg05376469	chr2:102649931	NA	-0.36	-6.03	-0.32	4.51e-9	Coronary artery disease;
CRC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.78	14.05	0.61	1.88e-35	Mean platelet volume;
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.07	-0.32	3.43e-9	Total body bone mineral density;
CRC	cis	rs9891119	0.550	rs11079043	chr17:40545770	T/C	cg06270615	chr17:40516068	STAT3	0.31	6.34	0.33	7.58e-10	Multiple sclerosis;Crohn's disease;
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.72	-0.51	3.38e-23	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.12	0.32	2.66e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17023223	0.537	rs17023174	chr1:119593301	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-6.24	-0.33	1.33e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-7.52	-0.38	5.27e-13	Homocysteine levels;
CRC	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	trans	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg05376469	chr2:102649931	NA	-0.38	-6.07	-0.32	3.5e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.54	-7.25	-0.37	3.03e-12	Triglycerides;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg10729496	chr3:10149963	C3orf24	0.61	7.18	0.37	4.55e-12	Alzheimer's disease;
CRC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.76	0.39	1.09e-13	Lung cancer;
CRC	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs45544231	0.569	rs11642645	chr16:52558907	C/A	cg09051775	chr16:52580266	TOX3	-0.38	-6.09	-0.32	3.13e-9	Restless legs syndrome;
CRC	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg15654264	chr1:150340011	RPRD2	0.4	5.72	0.3	2.36e-8	Migraine;
CRC	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06307176	chr5:131281290	NA	-0.42	-6.15	-0.32	2.2e-9	Life satisfaction;
CRC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-7.82	-0.4	7.1e-14	Colorectal cancer;
CRC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.52	7.66	0.39	2.12e-13	Colorectal cancer;
CRC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.45	-7.46	-0.38	7.62e-13	Type 2 diabetes;
CRC	cis	rs6564851	0.506	rs56389940	chr16:81259152	C/A	cg05274606	chr16:81253692	PKD1L2	-0.38	-6.28	-0.33	1.05e-9	Carotenoid and tocopherol levels;
CRC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg11189052	chr15:85197271	WDR73	0.58	8.28	0.42	3.08e-15	Schizophrenia;
CRC	cis	rs55788414	0.932	rs8043592	chr16:81182537	A/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.95	0.36	2.02e-11	Response to antipsychotic treatment;
CRC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-6.45	-0.33	4.06e-10	Platelet distribution width;
CRC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.68	0.35	1.03e-10	Lung cancer;
CRC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg13047869	chr3:10149882	C3orf24	-0.38	-5.89	-0.31	9.31e-9	Alzheimer's disease;
CRC	cis	rs7113874	0.589	rs10840051	chr11:8475180	G/C	cg20771178	chr11:8615675	STK33	-0.34	-5.6	-0.3	4.46e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10624784	chr7:77427913	PHTF2;TMEM60	0.38	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs635808	0.520	rs656938	chr6:167172048	C/T	cg27626620	chr6:167171727	RPS6KA2	0.37	6.31	0.33	9.18e-10	Dental caries;
CRC	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	cg04338863	chr8:33670619	NA	0.44	6.94	0.36	2.07e-11	Body mass index;
CRC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18252515	chr7:66147081	NA	0.4	5.9	0.31	9.26e-9	Aortic root size;
CRC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	11.08	0.52	1.85e-24	Bone mineral density;
CRC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg25456477	chr12:86230367	RASSF9	0.32	5.63	0.3	3.86e-8	Major depressive disorder;
CRC	trans	rs1864585	0.520	rs73208793	chr8:10680785	T/C	cg26278703	chr11:58910052	FAM111A	0.56	6.55	0.34	2.24e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg04969067	chr8:143858791	LYNX1	0.44	7.34	0.37	1.72e-12	Urinary tract infection frequency;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10287303	chr10:74855401	P4HA1	-0.51	-6.15	-0.32	2.22e-9	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.86e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-25.28	-0.81	4.14e-79	Exhaled nitric oxide output;
CRC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg23625390	chr15:77176239	SCAPER	-0.48	-6.73	-0.35	7.42e-11	Blood metabolite levels;
CRC	cis	rs3857067	1.000	rs899133	chr4:95019609	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.06	-0.32	3.63e-9	QT interval;
CRC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg13319975	chr6:146136371	FBXO30	0.62	8.23	0.41	4.36e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.43	0.42	1.11e-15	Schizophrenia;
CRC	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg15660573	chr17:549704	VPS53	-0.69	-11.83	-0.55	3.68e-27	Prostate cancer;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.59	9.97	0.48	1.2e-20	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14151426	chr13:113864409	CUL4A;PCID2	0.45	6.37	0.33	6.31e-10	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.51	-6.99	-0.36	1.51e-11	Alzheimer's disease;
CRC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.38	6.09	0.32	3.22e-9	Testicular germ cell tumor;
CRC	cis	rs11673344	0.583	rs10425719	chr19:37950798	C/G	cg11720556	chr19:37764088	NA	-0.41	-5.86	-0.31	1.14e-8	Obesity-related traits;
CRC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg02776659	chr21:47717406	C21orf57	-0.34	-5.66	-0.3	3.27e-8	Testicular germ cell tumor;
CRC	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg26248373	chr2:1572462	NA	-0.69	-7.61	-0.39	2.97e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.46	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.58	11.86	0.55	2.87e-27	Schizophrenia;
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.12	10.45	0.5	2.84e-22	Skin colour saturation;
CRC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg22110888	chr17:80059540	CCDC57	0.41	6.53	0.34	2.56e-10	Life satisfaction;
CRC	trans	rs9813712	0.597	rs1453255	chr3:129977658	A/G	cg23942268	chr17:6347992	FAM64A	-0.41	-6.0	-0.31	5.22e-9	Response to amphetamines;
CRC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.04e-16	Schizophrenia;
CRC	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21659725	chr3:3221576	CRBN	-0.45	-6.81	-0.35	4.79e-11	Menarche (age at onset);
CRC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.26	-0.33	1.18e-9	Coronary artery disease;
CRC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.51	-7.24	-0.37	3.28e-12	Lymphocyte counts;
CRC	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg20744362	chr22:50050164	C22orf34	0.32	5.82	0.31	1.38e-8	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg25214090	chr10:38739885	LOC399744	-0.42	-6.54	-0.34	2.37e-10	Diastolic blood pressure;
CRC	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg11663144	chr21:46675770	NA	-0.41	-5.7	-0.3	2.67e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg09659197	chr4:152720779	NA	0.52	11.13	0.52	1.23e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.81	8.82	0.44	6.79e-17	Breast cancer;
CRC	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	1.19	14.24	0.62	3.37e-36	Lung disease severity in cystic fibrosis;
CRC	cis	rs10924970	0.805	rs12030234	chr1:235517557	T/G	cg26050004	chr1:235667680	B3GALNT2	0.42	5.89	0.31	9.36e-9	Asthma;
CRC	cis	rs10991814	0.925	rs10991808	chr9:93946379	C/T	cg14446406	chr9:93919335	NA	-0.47	-6.31	-0.33	8.84e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg25885038	chr17:56607967	SEPT4	0.43	6.93	0.36	2.27e-11	Vitamin D levels;
CRC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.52	7.56	0.38	4.08e-13	Uric acid levels;
CRC	cis	rs6840360	0.642	rs7680013	chr4:152409477	A/C	cg09659197	chr4:152720779	NA	0.33	6.52	0.34	2.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg17031739	chr1:67600172	NA	0.41	6.33	0.33	8.2e-10	Psoriasis;
CRC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.04	-0.41	1.63e-14	Hemoglobin concentration;
CRC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg10589385	chr1:150898437	SETDB1	-0.28	-6.06	-0.32	3.65e-9	Tonsillectomy;
CRC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg05941027	chr17:61774174	LIMD2	0.34	5.81	0.3	1.51e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.31	5.84	0.31	1.23e-8	Lung cancer;
CRC	cis	rs661713	0.734	rs656214	chr6:90991488	T/C	cg06866423	chr6:90926672	BACH2	0.38	5.63	0.3	3.97e-8	Hypothyroidism;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg10876282	chr6:28092338	ZSCAN16	0.43	5.78	0.3	1.77e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.55	7.11	0.36	7.26e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.84	15.92	0.66	1.08e-42	Hip circumference;
CRC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg06713675	chr4:122721982	EXOSC9	-0.37	-6.05	-0.32	4e-9	Type 2 diabetes;
CRC	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.57	-6.77	-0.35	6e-11	Dental caries;
CRC	cis	rs17713451	0.593	rs17643028	chr7:151280487	C/A	cg18404559	chr7:151322523	PRKAG2	-0.56	-6.42	-0.33	4.65e-10	Interleukin-4 levels;
CRC	cis	rs3736485	0.934	rs4775956	chr15:51882638	G/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.73	11.58	0.54	3.15e-26	Plateletcrit;Platelet count;
CRC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.43	-7.15	-0.37	5.75e-12	Height;
CRC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-10.06	-0.49	6.26e-21	Coronary artery disease;
CRC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg00129232	chr17:37814104	STARD3	0.46	7.28	0.37	2.45e-12	Self-reported allergy;
CRC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg15445000	chr17:37608096	MED1	0.34	5.82	0.31	1.41e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	9.91	0.48	2.02e-20	Bipolar disorder;
CRC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.19	0.41	5.68e-15	Vitiligo;
CRC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	0.9	8.17	0.41	6.82e-15	Plateletcrit;
CRC	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.58	9.68	0.47	1.17e-19	Prostate cancer;
CRC	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg16329197	chr12:53359506	NA	-0.39	-5.85	-0.31	1.18e-8	Cancer (pleiotropy);
CRC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.73	13.07	0.58	1.02e-31	Oral cavity cancer;
CRC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.67	9.71	0.47	8.93e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.5	-6.17	-0.32	2.02e-9	Longevity;
CRC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.56	-9.02	-0.45	1.61e-17	Intelligence (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05592363	chr5:78908495	PAPD4	0.39	6.24	0.33	1.32e-9	Obesity-related traits;
CRC	trans	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.25	-0.33	1.24e-9	Aortic root size;
CRC	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.73	-12.68	-0.57	2.97e-30	White blood cell count (basophil);
CRC	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.43	8.11	0.41	9.96e-15	Childhood ear infection;
CRC	cis	rs6496667	0.779	rs3213649	chr15:90999128	A/C	cg04176472	chr15:90893244	GABARAPL3	0.59	8.32	0.42	2.4e-15	Rheumatoid arthritis;
CRC	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg03929089	chr4:120376271	NA	0.6	6.12	0.32	2.7e-9	Intraocular pressure;
CRC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg23565292	chr14:50234668	KLHDC2	-0.43	-5.98	-0.31	5.95e-9	Carotid intima media thickness;
CRC	cis	rs4363385	0.553	rs11580383	chr1:152942192	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.59	-0.34	1.73e-10	Inflammatory skin disease;
CRC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.65	9.59	0.47	2.27e-19	Menopause (age at onset);
CRC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.56	-7.78	-0.39	9.54e-14	Pancreatic cancer;
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg03623178	chr6:28175578	NA	0.75	7.82	0.4	7.2e-14	Depression;
CRC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.56	8.44	0.42	1.01e-15	Schizophrenia;
CRC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-8.58	-0.43	3.89e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.7	0.39	1.56e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg09659197	chr4:152720779	NA	0.41	8.4	0.42	1.32e-15	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.36e-24	Prudent dietary pattern;
CRC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.5	-8.01	-0.4	1.97e-14	Height;
CRC	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.47	6.13	0.32	2.52e-9	Exhaled nitric oxide output;
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6662572	0.737	rs72677518	chr1:46511118	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.12	0.32	2.7e-9	Blood protein levels;
CRC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.99	11.89	0.55	2.31e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.43	-9.7	-0.47	9.71e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.0	-11.72	-0.54	9.77e-27	Alzheimer's disease;
CRC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg07090678	chr1:91966139	CDC7	0.41	6.71	0.35	8.27e-11	Breast cancer;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.85	0.31	1.2e-8	Prudent dietary pattern;
CRC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	7.56	0.38	4.04e-13	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg26176469	chr17:28951361	LRRC37B2	-0.51	-6.04	-0.32	4.22e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg18512352	chr11:47633146	NA	0.34	6.46	0.34	3.73e-10	Subjective well-being;
CRC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.38	5.68	0.3	2.95e-8	HDL cholesterol levels;
CRC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg21770322	chr7:97807741	LMTK2	0.59	9.81	0.48	4.17e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.77	13.18	0.59	3.88e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9648716	1.000	rs6962239	chr7:140613919	C/T	cg10747023	chr7:140774559	NA	0.47	6.1	0.32	2.98e-9	Type 2 diabetes;
CRC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg13072238	chr3:49761600	GMPPB	0.49	5.69	0.3	2.83e-8	Menarche (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05942152	chr11:64902077	SYVN1	0.47	6.35	0.33	7e-10	Anxiety disorder;
CRC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.45	-6.46	-0.34	3.67e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3020333	0.653	rs851983	chr6:152024415	A/G	cg22157087	chr6:152012887	ESR1	0.48	7.22	0.37	3.57e-12	Total body bone mineral density;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.55	9.71	0.47	9.47e-20	Acylcarnitine levels;
CRC	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.57	-5.91	-0.31	8.42e-9	Coronary artery disease;
CRC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	0.94	13.54	0.6	1.62e-33	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21767656	chr15:63674112	CA12	-0.5	-6.3	-0.33	9.28e-10	Diisocyanate-induced asthma;
CRC	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg21153622	chr11:89784906	NA	-0.45	-7.11	-0.36	7.19e-12	HDL cholesterol;
CRC	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.6	-0.39	3.09e-13	Depression;
CRC	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.42	-6.24	-0.33	1.39e-9	High light scatter reticulocyte count;
CRC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg24562669	chr7:97807699	LMTK2	0.43	7.19	0.37	4.41e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg03623178	chr6:28175578	NA	0.8	10.53	0.5	1.5e-22	Parkinson's disease;
CRC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg03623178	chr6:28175578	NA	0.43	5.75	0.3	2.01e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2315504	0.692	rs12602410	chr17:39017343	A/G	cg06456531	chr17:38929184	KRT26	0.32	5.67	0.3	3.07e-8	Height;
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	cis	rs758324	0.812	rs2133706	chr5:131165216	T/G	cg25547332	chr5:131281432	NA	0.37	5.89	0.31	9.62e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	9.78	0.47	5.4e-20	Metabolite levels;
CRC	cis	rs6681460	1.000	rs10889641	chr1:67138367	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.26	0.41	3.5e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.61	-10.95	-0.52	5.42e-24	Aortic root size;
CRC	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.36	-6.9	-0.36	2.65e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg08071915	chr8:12219732	FAM66A	0.34	6.09	0.32	3.15e-9	Morning vs. evening chronotype;
CRC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg11941060	chr3:133502564	NA	-0.42	-6.97	-0.36	1.71e-11	Iron status biomarkers;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.12	-0.32	2.72e-9	Longevity;
CRC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg14541582	chr5:601475	NA	-0.37	-7.17	-0.37	5.13e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.5	-7.98	-0.4	2.47e-14	Aortic root size;
CRC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.6	8.77	0.44	9.67e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.19	-0.41	5.99e-15	QT interval;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24105797	chr17:74553636	SNORD1C	0.46	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.41	5.92	0.31	7.9e-9	Body mass index;
CRC	trans	rs9341835	0.608	rs2076874	chr6:64153691	G/A	cg13657004	chr13:50234944	EBPL	-0.37	-6.42	-0.33	4.86e-10	Schizophrenia;
CRC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.88	11.79	0.55	5.3e-27	Triglycerides;
CRC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.19	-0.41	5.81e-15	Calcium levels;
CRC	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg24375607	chr4:120327624	NA	0.47	7.18	0.37	4.76e-12	Corneal astigmatism;
CRC	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07165851	chr6:158734300	TULP4	0.59	7.37	0.38	1.41e-12	Height;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg22110888	chr17:80059540	CCDC57	-0.44	-6.83	-0.35	4.06e-11	Life satisfaction;
CRC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.67	9.92	0.48	1.8899999999999998e-20	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.43	-6.78	-0.35	5.71e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg21153622	chr11:89784906	NA	-0.45	-7.24	-0.37	3.25e-12	HDL cholesterol;
CRC	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.31	6.7	0.35	8.88e-11	Mean corpuscular volume;
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11645453	chr3:52864694	ITIH4	0.32	5.74	0.3	2.15e-8	Electroencephalogram traits;
CRC	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.85	-0.31	1.19e-8	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00495681	chr13:53174319	NA	0.64	9.57	0.47	2.72e-19	Lewy body disease;
CRC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg20129853	chr10:51489980	NA	-0.36	-5.92	-0.31	8.09e-9	Prostate-specific antigen levels;
CRC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg18876405	chr7:65276391	NA	0.44	6.12	0.32	2.67e-9	Aortic root size;
CRC	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg19812747	chr11:111475976	SIK2	0.43	6.42	0.33	4.79e-10	Primary sclerosing cholangitis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27304813	chr3:120068385	LRRC58	-0.49	-6.01	-0.31	5.03e-9	Diisocyanate-induced asthma;
CRC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.36	-0.33	6.88e-10	Cotinine glucuronidation;
CRC	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.76	14.72	0.63	4.76e-38	Mean corpuscular hemoglobin;
CRC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.34	-9.67	-0.47	1.2e-19	Mean corpuscular volume;
CRC	cis	rs4363385	0.818	rs11205167	chr1:152989727	T/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.13	-0.37	6.43e-12	Inflammatory skin disease;
CRC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.55	-6.67	-0.35	1.1e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.56	-9.6	-0.47	2.17e-19	Iron status biomarkers;
CRC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.12	-0.32	2.69e-9	Tonsillectomy;
CRC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	6.53	0.34	2.5e-10	Platelet count;
CRC	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03264960	chr2:187350743	ZC3H15	0.44	6.07	0.32	3.46e-9	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13559478	chr7:148959298	ZNF783	0.45	6.16	0.32	2.08e-9	Anxiety disorder;
CRC	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.6	-9.16	-0.45	5.81e-18	Schizophrenia;
CRC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.43	-5.91	-0.31	8.39e-9	Schizophrenia;
CRC	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg09040174	chr2:113837401	NA	0.64	10.17	0.49	2.58e-21	Protein quantitative trait loci;
CRC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg25456477	chr12:86230367	RASSF9	0.34	5.93	0.31	7.72e-9	Major depressive disorder;
CRC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg10760299	chr15:45669010	GATM	0.5	7.97	0.4	2.72e-14	Homoarginine levels;
CRC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.07	17.99	0.7	6.94e-51	Cognitive function;
CRC	cis	rs2179367	0.600	rs11155654	chr6:149763137	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.41	-5.77	-0.3	1.85e-8	Dupuytren's disease;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-6.25	-0.33	1.3e-9	Longevity;Endometriosis;
CRC	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg18764771	chr6:116381957	FRK	0.25	6.11	0.32	2.81e-9	Total cholesterol levels;
CRC	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg05095123	chr13:29393749	NA	-0.33	-6.05	-0.32	3.97e-9	Obesity-related traits;
CRC	cis	rs629535	0.862	rs638412	chr8:70047690	C/T	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.98	-10.21	-0.49	1.99e-21	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01008834	chr1:150207620	ANP32E	-0.43	-6.39	-0.33	5.73e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2811415	0.597	rs9814296	chr3:127732028	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.96	-0.31	6.45e-9	Lung function (FEV1/FVC);
CRC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg16342193	chr10:102329863	NA	0.37	5.95	0.31	6.84e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.93	14.38	0.62	1.01e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.51	8.03	0.4	1.79e-14	Methadone dose in opioid dependence;
CRC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-8.1	-0.41	1.06e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.52	-7.28	-0.37	2.45e-12	Coronary artery disease;
CRC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.67	9.89	0.48	2.28e-20	Corneal astigmatism;
CRC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.46	-6.73	-0.35	7.38e-11	Daytime sleep phenotypes;
CRC	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg01475377	chr6:109611718	NA	-0.35	-6.07	-0.32	3.59e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs3750082	0.817	rs4723221	chr7:32954207	C/T	cg05721444	chr7:32995514	FKBP9	-0.52	-7.88	-0.4	4.91e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.49	6.97	0.36	1.79e-11	Neuroticism;
CRC	cis	rs4363385	0.782	rs310105	chr1:153022253	A/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.49	-0.38	6.4e-13	Inflammatory skin disease;
CRC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.33	-5.91	-0.31	8.4e-9	Monocyte percentage of white cells;
CRC	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.18	13.47	0.6	3.17e-33	Uric acid levels;
CRC	cis	rs7932354	0.528	rs10466478	chr11:47162604	A/C	cg19486271	chr11:47235900	DDB2	-0.47	-7.27	-0.37	2.72e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.4	-5.84	-0.31	1.26e-8	Platelet distribution width;
CRC	cis	rs7849270	0.959	rs913276	chr9:131917164	C/T	cg13538475	chr9:131942899	NA	-0.3	-5.78	-0.3	1.73e-8	Blood metabolite ratios;
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.57	0.75	5.01e-61	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23187101	chr19:1812290	ATP8B3	0.37	6.27	0.33	1.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg05569086	chr8:143859399	LYNX1	0.39	6.64	0.34	1.3100000000000001e-10	Urinary tract infection frequency;
CRC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg07701084	chr6:150067640	NUP43	0.45	6.41	0.33	4.9e-10	Lung cancer;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.27	-5.85	-0.31	1.18e-8	Depression;
CRC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.59	-10.3	-0.49	9.49e-22	Schizophrenia;
CRC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07157834	chr1:205819609	PM20D1	-0.44	-6.15	-0.32	2.21e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg12500891	chr11:57225987	NA	-0.66	-6.1	-0.32	2.98e-9	Cognitive function;
CRC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg03037974	chr15:76606532	NA	-0.5	-7.36	-0.38	1.46e-12	Blood metabolite levels;
CRC	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg14003231	chr6:33640908	ITPR3	0.51	8.22	0.41	4.71e-15	Height;
CRC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.41	0.71	1.56e-52	Cognitive ability;
CRC	cis	rs4073416	0.542	rs2300864	chr14:66119800	A/G	cg03016385	chr14:66212404	NA	-0.45	-6.14	-0.32	2.37e-9	N-glycan levels;
CRC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.41	5.73	0.3	2.26e-8	Aortic root size;
CRC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.28	0.33	1.07e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg22110888	chr17:80059540	CCDC57	0.41	6.46	0.34	3.71e-10	Life satisfaction;
CRC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.48	0.34	3.39e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.74	10.39	0.5	4.59e-22	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.77	-0.44	1.01e-16	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs56152608	chr2:162283469	G/A	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.86	-6.37	-0.33	6.37e-10	Cognitive function;
CRC	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.49	7.66	0.39	2.05e-13	Red blood cell count;
CRC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.3	0.71	4.39e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg18288967	chr1:45987694	PRDX1	0.63	7.37	0.38	1.42e-12	Obesity-related traits;
CRC	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg11693508	chr17:37793320	STARD3	0.6	7.04	0.36	1.15e-11	Bipolar disorder;
CRC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.21	-0.41	5.2e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-0.74	-9.56	-0.47	2.93e-19	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6940116	1	rs6940116	chr6:27708732	A/G	cg06470822	chr6:28175283	NA	0.59	5.98	0.31	5.97e-9	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02772935	chr3:125709198	NA	-0.49	-5.73	-0.3	2.27e-8	Blood pressure (smoking interaction);
CRC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.03	0.41	1.7e-14	Type 2 diabetes;
CRC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.14	-0.41	8.44e-15	Hip circumference adjusted for BMI;
CRC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg03609598	chr5:56110824	MAP3K1	0.54	7.39	0.38	1.22e-12	Initial pursuit acceleration;
CRC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg16447950	chr5:562315	NA	-0.85	-13.05	-0.58	1.17e-31	Obesity-related traits;
CRC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.5	6.85	0.35	3.68e-11	Height;
CRC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.45	0.42	9.68e-16	Rheumatoid arthritis;
CRC	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs9513593	1.000	rs7323390	chr13:99997968	A/G	cg21788972	chr13:99853209	UBAC2	0.46	5.98	0.31	5.9e-9	Psoriasis;
CRC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.27	-0.33	1.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12900413	0.959	rs12902793	chr15:90304402	G/A	cg24249390	chr15:90295951	MESP1	-0.63	-9.13	-0.45	6.91e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12273811	chr6:28175739	NA	0.63	8.52	0.43	5.94e-16	Parkinson's disease;
CRC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg13319975	chr6:146136371	FBXO30	0.4	5.89	0.31	9.62e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg15832292	chr6:96025679	MANEA	0.61	6.66	0.34	1.17e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.42	0.42	1.22e-15	Iron status biomarkers;
CRC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg19980929	chr12:42632907	YAF2	0.44	6.53	0.34	2.47e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.49	0.57	1.39e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.52	-6.72	-0.35	8.21e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.43	-6.13	-0.32	2.55e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg17848003	chr1:3704513	LRRC47	0.39	5.72	0.3	2.38e-8	Red cell distribution width;
CRC	trans	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.8e-15	Bone mineral density;
CRC	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg23193639	chr7:45961078	IGFBP3	0.4	6.59	0.34	1.76e-10	Sitting height ratio;
CRC	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg03623178	chr6:28175578	NA	0.7	9.33	0.46	1.61e-18	Parkinson's disease;
CRC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.42	6.41	0.33	4.96e-10	Mean platelet volume;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg19445734	chr2:55566679	CCDC88A	0.44	6.31	0.33	9.27e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	12.42	0.57	2.56e-29	Alzheimer's disease;
CRC	cis	rs9469890	0.604	rs77186075	chr6:34504478	C/T	cg17674042	chr6:34482479	PACSIN1	-0.66	-7.76	-0.39	1.1e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg27661571	chr11:113659931	NA	-0.71	-8.73	-0.43	1.33e-16	Hip circumference adjusted for BMI;
CRC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.42	6.13	0.32	2.54e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.46	8.66	0.43	2.2e-16	Renal cell carcinoma;
CRC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.29	0.33	9.89e-10	Hip circumference adjusted for BMI;
CRC	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg20737812	chr15:86336631	KLHL25	-0.48	-7.15	-0.37	5.63e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.87	-0.48	2.65e-20	Hip circumference adjusted for BMI;
CRC	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	6.39	0.33	5.69e-10	Axial length;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg20933634	chr6:27740509	NA	0.61	7.88	0.4	4.77e-14	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg10756647	chr7:56101905	PSPH	-0.78	-8.17	-0.41	6.58e-15	Gout;
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18099408	chr3:52552593	STAB1	-0.46	-7.76	-0.39	1.07e-13	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25018357	chr1:26490989	NA	0.41	7.06	0.36	9.67e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	0.93	9.52	0.46	4.01e-19	Skin colour saturation;
CRC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.57	-0.34	1.94e-10	Major depressive disorder;
CRC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.56	6.82	0.35	4.5e-11	Vitiligo;
CRC	cis	rs3857067	0.901	rs965807	chr4:95045567	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.8	-0.3	1.54e-8	QT interval;
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg02741985	chr17:80059408	CCDC57	-0.43	-7.14	-0.37	5.98e-12	Life satisfaction;
CRC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg02869306	chr7:64672164	INTS4L1	-0.36	-5.89	-0.31	9.51e-9	Aortic root size;
CRC	cis	rs12760731	0.582	rs34016755	chr1:178517005	G/C	cg00404053	chr1:178313656	RASAL2	0.7	7.82	0.4	7.33e-14	Obesity-related traits;
CRC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg00316803	chr15:76480434	C15orf27	-0.35	-5.74	-0.3	2.21e-8	Blood metabolite levels;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.53e-18	Parkinson's disease;
CRC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg23283495	chr1:209979779	IRF6	-0.43	-6.3	-0.33	9.38e-10	Cleft lip with or without cleft palate;
CRC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.46	-6.13	-0.32	2.58e-9	Gut microbiome composition (summer);
CRC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	-0.51	-8.21	-0.41	5.03e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24308560	chr3:49941425	MST1R	0.41	6.13	0.32	2.56e-9	Body mass index;
CRC	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.79	0.44	8.58e-17	Electrocardiographic conduction measures;
CRC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.7	-0.3	2.63e-8	Crohn's disease;
CRC	cis	rs7539624	0.588	rs7414311	chr1:223901497	A/G	cg10100437	chr1:223903862	CAPN2	0.45	6.33	0.33	8.07e-10	Schizophrenia;
CRC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.8	8.37	0.42	1.72e-15	Major depressive disorder;
CRC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.63	10.94	0.52	5.56e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.25	-0.33	1.28e-9	Total body bone mineral density;
CRC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.62	12.41	0.56	2.91e-29	Schizophrenia;
CRC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.56	-9.02	-0.45	1.61e-17	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg21153622	chr11:89784906	NA	0.48	7.57	0.39	3.84e-13	HDL cholesterol;
CRC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.34	3.79e-10	Diabetic kidney disease;
CRC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg09796270	chr17:17721594	SREBF1	0.49	8.33	0.42	2.15e-15	Total body bone mineral density;
CRC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.37	5.66	0.3	3.34e-8	Height;
CRC	cis	rs17155006	0.664	rs401487	chr7:107743409	A/G	cg05962710	chr7:107745446	LAMB4	-0.4	-7.19	-0.37	4.29e-12	Pneumococcal bacteremia;
CRC	trans	rs58106596	0.747	rs10166046	chr2:232560984	C/T	cg01370599	chr3:116745421	NA	-0.46	-6.43	-0.33	4.48e-10	White blood cell count;Lymphocyte counts;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg25164649	chr6:28176230	NA	0.58	7.72	0.39	1.39e-13	Parkinson's disease;
CRC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg21970626	chr13:21893289	NA	-0.44	-6.68	-0.35	1.02e-10	White matter hyperintensity burden;
CRC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.44	-0.53	9.35e-26	Ulcerative colitis;
CRC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.58	9.47	0.46	5.85e-19	Calcium levels;
CRC	trans	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.86	-0.35	3.39e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.42	-7.82	-0.4	7.38e-14	Colorectal cancer;
CRC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.38	6.03	0.32	4.4e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.97	0.4	2.65e-14	Breast cancer;
CRC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.65	0.34	1.21e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.57	-0.43	4.07e-16	Gut microbiome composition (summer);
CRC	cis	rs4731207	0.698	rs4279518	chr7:124528086	G/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs728616	1.000	rs12768613	chr10:81916566	C/T	cg05935833	chr10:81318306	SFTPA2	-0.48	-5.89	-0.31	9.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg26727032	chr16:67993705	SLC12A4	0.53	6.72	0.35	7.81e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg02321871	chr13:50159138	RCBTB1	0.43	6.11	0.32	2.76e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs12928939	0.774	rs7205340	chr16:71645670	A/T	cg08717414	chr16:71523259	ZNF19	0.47	6.0	0.31	5.11e-9	Post bronchodilator FEV1;
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg01339444	chr6:118972232	C6orf204	0.52	5.97	0.31	6.11e-9	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15670579	chr15:102264312	TARSL2	0.41	6.59	0.34	1.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.95	15.6	0.65	1.9e-41	Primary sclerosing cholangitis;
CRC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.71	-0.35	8.3e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.35	6.1	0.32	2.92e-9	Erythrocyte sedimentation rate;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.61	8.51	0.42	6.45e-16	Arsenic metabolism;
CRC	cis	rs6580110	0.714	rs9324791	chr5:154078556	T/C	cg11923914	chr5:154071666	NA	-0.48	-7.34	-0.38	1.68e-12	Facial morphology (factor 9, facial height related to vertical position of nasion);
CRC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-5.98	-0.31	5.68e-9	Schizophrenia;
CRC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.38	-6.01	-0.31	4.82e-9	Red cell distribution width;
CRC	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.51	-6.57	-0.34	2e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.99	-14.53	-0.63	2.73e-37	Hip circumference adjusted for BMI;
CRC	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg00631329	chr6:26305371	NA	-0.4	-6.89	-0.36	2.86e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs4481887	0.504	rs7529953	chr1:248357645	T/A	cg00666640	chr1:248458726	OR2T12	0.44	7.11	0.37	7.14e-12	Common traits (Other);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.5	7.2	0.37	4.2e-12	Response to antipsychotic treatment;
CRC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg03233332	chr7:66118400	NA	-0.43	-6.02	-0.31	4.74e-9	Aortic root size;
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-6.77	-0.35	6.02e-11	Renal function-related traits (BUN);
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10819733	chr22:24237672	NA	0.34	5.7	0.3	2.7e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.51	7.91	0.4	3.87e-14	Emphysema distribution in smoking;
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.71	-0.39	1.48e-13	Bipolar disorder;
CRC	trans	rs12495832	0.778	rs76365698	chr3:147883980	A/G	cg10221266	chr7:153579447	NA	0.55	6.02	0.31	4.67e-9	Chin dimples;
CRC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg13798780	chr7:105162888	PUS7	0.67	7.78	0.39	9.18e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.14	0.82	2.8e-82	Schizophrenia;
CRC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.6	-10.83	-0.51	1.37e-23	Aortic root size;
CRC	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.45	6.84	0.35	3.83e-11	Menopause (age at onset);
CRC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.39	5.71	0.3	2.5e-8	Aortic root size;
CRC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg20387954	chr3:183756860	HTR3D	0.44	7.53	0.38	4.82e-13	Anterior chamber depth;
CRC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.6	8.43	0.42	1.11e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.56	-7.99	-0.4	2.26e-14	Melanoma;
CRC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.56	7.65	0.39	2.2e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1950626	0.623	rs66722144	chr14:101457434	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.76	12.31	0.56	6.42e-29	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg23417306	chr2:180868811	CWC22	0.48	6.63	0.34	1.39e-10	Schizophrenia;
CRC	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg25190513	chr12:123201362	GPR109B	-0.48	-5.94	-0.31	7.24e-9	Adiponectin levels;
CRC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.59	8.97	0.44	2.22e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs800160	0.777	rs962902	chr11:2352225	T/C	cg09785033	chr11:2336066	TSPAN32	-0.52	-5.92	-0.31	8.21e-9	Bacteremia;
CRC	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg00373020	chr1:21041521	KIF17	0.42	6.48	0.34	3.41e-10	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23378565	chr7:2036160	MAD1L1	-0.44	-6.32	-0.33	8.4e-10	Bipolar disorder;
CRC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.83	17.41	0.69	1.4e-48	Cancer;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg26608667	chr7:1196370	ZFAND2A	0.37	5.83	0.31	1.35e-8	Longevity;Endometriosis;
CRC	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.46	7.25	0.37	3.04e-12	Dental caries;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg00769240	chr8:12517080	NA	-0.74	-10.46	-0.5	2.63e-22	Blood pressure (smoking interaction);
CRC	cis	rs6921919	0.848	rs9468350	chr6:28319107	A/G	cg15845792	chr6:28175446	NA	0.48	6.17	0.32	2.04e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.29	0.33	1.01e-9	Lung cancer;
CRC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg11130432	chr3:121712080	ILDR1	-0.5	-6.61	-0.34	1.56e-10	Multiple sclerosis;
CRC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.94	-0.44	2.85e-17	Urinary metabolites;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg12564285	chr5:131593104	PDLIM4	0.49	9.33	0.46	1.59e-18	Breast cancer;
CRC	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	5.94	0.31	7.39e-9	Ovarian reserve;
CRC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19623624	chr10:135278901	LOC619207	-0.38	-6.15	-0.32	2.29e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7086803	0.793	rs6585182	chr10:114500402	A/G	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg21839984	chr17:30846986	MYO1D	-0.33	-5.61	-0.3	4.34e-8	Schizophrenia;
CRC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.6	10.64	0.51	6.3e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01931797	chr11:77899910	KCTD21;USP35	0.47	6.78	0.35	5.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.58	6.1	0.32	2.9e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-6.04	-0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg26304593	chr6:42947056	PEX6	-0.46	-6.68	-0.35	1.03e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg26248373	chr2:1572462	NA	-0.68	-7.51	-0.38	5.75e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg14515779	chr1:101123966	NA	-0.4	-7.24	-0.37	3.27e-12	Monocyte count;
CRC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.55	-6.86	-0.35	3.34e-11	Body mass index;
CRC	cis	rs7113874	0.589	rs725502	chr11:8503743	A/G	cg17679104	chr11:8615758	STK33	0.35	5.78	0.3	1.77e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05065690	chr12:49246007	DDX23	-0.56	-6.76	-0.35	6.29e-11	Diisocyanate-induced asthma;
CRC	cis	rs17767392	1.000	rs723966	chr14:71765910	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.04	11.08	0.52	1.92e-24	Skin colour saturation;
CRC	cis	rs938554	0.779	rs6449173	chr4:9966105	A/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.95	-0.31	7e-9	Blood metabolite levels;
CRC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.49	7.89	0.4	4.67e-14	Endometrial cancer;
CRC	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.19	-0.32	1.74e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg18081818	chr7:23246105	NA	-0.33	-5.62	-0.3	4.07e-8	Blood protein levels;
CRC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.98	-0.31	5.7e-9	Height;
CRC	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.59	8.65	0.43	2.3e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.45	-6.09	-0.32	3.2e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.15	-0.37	5.76e-12	Major depressive disorder;
CRC	cis	rs1881492	0.518	rs940666	chr2:233458679	A/C	cg03852847	chr2:233439513	NA	-0.39	-6.22	-0.32	1.53e-9	Refractive error;
CRC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.59	0.34	1.74e-10	Lung cancer;
CRC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.48	0.46	5.31e-19	Schizophrenia;
CRC	cis	rs16975963	0.644	rs73033117	chr19:38073146	C/T	cg15135657	chr19:38346511	NA	-0.46	-6.24	-0.33	1.38e-9	Longevity;
CRC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg00786952	chr1:21763130	NA	0.5	8.33	0.42	2.21e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	9.97	0.48	1.21e-20	HIV-1 control;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg02683197	chr6:28174875	NA	0.66	8.59	0.43	3.46e-16	Parkinson's disease;
CRC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	10.52	0.5	1.67e-22	Menopause (age at onset);
CRC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-9.09	-0.45	9.5e-18	Initial pursuit acceleration;
CRC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg10820045	chr2:198174542	NA	0.47	8.22	0.41	4.73e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg07870213	chr5:140052090	DND1	-0.59	-7.91	-0.4	4.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.4	5.71	0.3	2.55e-8	Morning vs. evening chronotype;
CRC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.39	-8.65	-0.43	2.27e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.87	12.21	0.56	1.52e-28	Triglycerides;
CRC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.89	0.51	8.53e-24	Prudent dietary pattern;
CRC	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	10.38	0.5	4.9e-22	Exhaled nitric oxide output;
CRC	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.78	-0.63	3.02e-38	Exhaled nitric oxide output;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02720131	chr3:9851598	TTLL3	-0.42	-6.29	-0.33	9.91e-10	Myopia (pathological);
CRC	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.49	6.21	0.32	1.64e-9	Systolic blood pressure;
CRC	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-0.74	-7.66	-0.39	2.14e-13	Blood protein levels;
CRC	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg12855166	chr17:30846586	MYO1D	-0.35	-5.63	-0.3	3.85e-8	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20155988	chr1:1590632	CDK11B	0.45	6.34	0.33	7.44e-10	Anxiety disorder;
CRC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg23127183	chr11:57508653	C11orf31	-0.53	-7.44	-0.38	8.82e-13	Schizophrenia;
CRC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.16	0.37	5.44e-12	Life satisfaction;
CRC	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.81	-11.07	-0.52	2.08e-24	Orofacial clefts;
CRC	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.54	-8.9	-0.44	3.9e-17	Mean corpuscular volume;
CRC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.67	10.82	0.51	1.52e-23	Lung cancer;
CRC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg00316803	chr15:76480434	C15orf27	-0.35	-5.7	-0.3	2.64e-8	Blood metabolite levels;
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.37	6.19	0.32	1.78e-9	Cardiovascular disease risk factors;
CRC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.76	0.3	1.89e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg00530740	chr6:53409368	GCLC	-0.46	-6.25	-0.33	1.27e-9	Protein C levels;
CRC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.78	-0.3	1.7e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg19622623	chr12:86230825	RASSF9	0.38	6.02	0.32	4.62e-9	Major depressive disorder;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.99	-0.44	2.05e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6694672	1.000	rs928439	chr1:196950482	G/A	cg13682187	chr1:196946512	CFHR5	-0.48	-7.61	-0.39	2.83e-13	Asthma;
CRC	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs12980942	0.591	rs11879429	chr19:41757444	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.6	0.34	1.67e-10	Coronary artery disease;
CRC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg21770322	chr7:97807741	LMTK2	0.59	9.85	0.48	3.04e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg00603274	chr11:61596626	FADS2	-0.42	-6.03	-0.32	4.39e-9	Trans fatty acid levels;
CRC	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg27144592	chr16:783916	NARFL	0.69	9.91	0.48	1.97e-20	Height;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.67	7.86	0.4	5.71e-14	Body mass index;
CRC	cis	rs5498	0.869	rs892188	chr19:10409793	A/G	cg10604476	chr19:10403908	ICAM5	-0.3	-5.76	-0.3	1.95e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CRC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06505273	chr16:24850292	NA	0.52	6.82	0.35	4.42e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs3026101	0.671	rs3944127	chr17:5297766	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.79	0.35	5.16e-11	Body mass index;
CRC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.75	13.85	0.61	1.12e-34	Oral cavity cancer;
CRC	trans	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg26043149	chr18:55253948	FECH	0.49	7.84	0.4	6.4e-14	Bone mineral density;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg19223190	chr17:80058835	NA	-0.39	-6.25	-0.33	1.27e-9	Life satisfaction;
CRC	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg00170343	chr3:11313890	ATG7	0.53	6.09	0.32	3.07e-9	Circulating chemerin levels;
CRC	cis	rs4803480	0.554	rs12462194	chr19:42072289	G/A	cg08478046	chr19:42093086	CEACAM21	-0.3	-6.19	-0.32	1.81e-9	Schizophrenia;
CRC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.52	7.82	0.4	7.17e-14	Monocyte count;
CRC	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.6	-0.43	3.27e-16	Coffee consumption (cups per day);
CRC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.08	-0.55	4.67e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01830644	chr10:12110754	DHTKD1	0.41	5.98	0.31	5.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg06470822	chr6:28175283	NA	0.98	13.17	0.59	4.07e-32	Depression;
CRC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.35	-5.75	-0.3	2.04e-8	Childhood ear infection;
CRC	cis	rs7926971	0.756	rs6485968	chr11:12660201	G/A	cg25843174	chr11:12811716	TEAD1	0.35	6.08	0.32	3.33e-9	Height;
CRC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16262614	chr3:133464971	TF	0.4	7.13	0.37	6.4e-12	Iron status biomarkers;
CRC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02850689	chr1:2391347	NA	-0.4	-6.39	-0.33	5.83e-10	Non-obstructive azoospermia;
CRC	cis	rs2857891	1.000	rs2638092	chr11:6961746	G/A	cg04053776	chr11:6947353	ZNF215	0.52	7.01	0.36	1.35e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg18830697	chr6:72922368	RIMS1	-0.39	-7.9	-0.4	4.11e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04657831	chr21:46707951	POFUT2;LOC642852	0.43	6.06	0.32	3.8e-9	Anxiety disorder;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.74e-9	Depression;
CRC	cis	rs540254	0.551	rs12143580	chr1:160790918	G/C	cg20255094	chr1:160771763	LY9	0.49	6.41	0.33	5.13e-10	Blood protein levels;
CRC	cis	rs6662572	0.737	rs72692632	chr1:46437192	A/C	cg08644498	chr1:46502608	NA	0.44	6.82	0.35	4.28e-11	Blood protein levels;
CRC	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg14664628	chr15:75095509	CSK	0.51	5.94	0.31	7.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs1973993	0.745	rs6686016	chr1:96948002	G/A	cg10631902	chr5:14652156	NA	-0.43	-7.24	-0.37	3.24e-12	Weight;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20803232	chr8:42995089	HGSNAT	0.43	6.37	0.33	6.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6700896	0.931	rs12034502	chr1:66099831	C/T	cg04111102	chr1:66153794	NA	0.32	5.67	0.3	3.12e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg15147215	chr3:52552868	STAB1	-0.61	-9.99	-0.48	1.06e-20	Bipolar disorder;
CRC	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.94	-0.31	7.29e-9	Educational attainment;
CRC	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.04	-0.32	4.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg23463467	chr20:60627584	TAF4	0.33	5.75	0.3	2.03e-8	Body mass index;
CRC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.45	7.58	0.39	3.6e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg15147215	chr3:52552868	STAB1	-0.65	-11.29	-0.53	3.36e-25	Electroencephalogram traits;
CRC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.11	9.19	0.45	4.5e-18	Plateletcrit;
CRC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.68	0.7	1.16e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.38	-6.09	-0.32	3.19e-9	Major depressive disorder;
CRC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.4	5.78	0.3	1.74e-8	Obesity-related traits;
CRC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.65	-0.34	1.24e-10	Tonsillectomy;
CRC	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.84	-0.31	1.25e-8	Alzheimer's disease (survival time);
CRC	cis	rs7274811	0.688	rs56234419	chr20:32086447	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.46	-6.48	-0.34	3.25e-10	Height;
CRC	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.6	-8.31	-0.42	2.52e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.77	13.12	0.59	6.18e-32	Breast cancer;
CRC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.58	10.54	0.5	1.4e-22	Multiple system atrophy;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.1	0.32	3.04e-9	Bipolar disorder;
CRC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg13628971	chr7:2884303	GNA12	0.4	6.19	0.32	1.74e-9	Height;
CRC	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg00666640	chr1:248458726	OR2T12	0.35	6.52	0.34	2.63e-10	Common traits (Other);
CRC	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg10437265	chr15:77819839	NA	0.59	10.74	0.51	2.95e-23	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14803350	chr5:159545855	PWWP2A	0.38	6.02	0.31	4.56e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg12935359	chr14:103987150	CKB	-0.4	-6.73	-0.35	7.55e-11	Body mass index;
CRC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.76	10.28	0.49	1.07e-21	Initial pursuit acceleration;
CRC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg11471262	chr4:3318911	RGS12	-0.37	-5.74	-0.3	2.11e-8	Serum sulfate level;
CRC	cis	rs17253792	0.545	rs35536987	chr14:56024021	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-6.61	-0.34	1.56e-10	Putamen volume;
CRC	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	7.44	0.38	8.7e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.73	10.92	0.52	6.54e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs12928939	0.768	rs11861296	chr16:71850632	T/C	cg03805757	chr16:71968109	PKD1L3	-0.48	-6.04	-0.32	4.18e-9	Post bronchodilator FEV1;
CRC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg14122633	chr5:456516	EXOC3	-0.4	-7.13	-0.37	6.3e-12	Cystic fibrosis severity;
CRC	cis	rs6694672	1.000	rs4915315	chr1:197059878	G/A	cg13682187	chr1:196946512	CFHR5	0.44	7.2	0.37	4.07e-12	Asthma;
CRC	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg01312482	chr5:178451176	ZNF879	-0.37	-6.15	-0.32	2.26e-9	Pubertal anthropometrics;
CRC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27383215	chr2:201729287	CLK1	0.46	6.25	0.33	1.24e-9	Response to antipsychotic treatment;
CRC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-10.35	-0.5	6.2e-22	Coronary artery disease;
CRC	cis	rs12024301	0.557	rs12034427	chr1:183660238	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg15511327	chr8:143859410	LYNX1	0.5	8.74	0.43	1.24e-16	Urinary tract infection frequency;
CRC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.59	-10.05	-0.48	6.6e-21	Calcium levels;
CRC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.8	-13.29	-0.59	1.42e-32	Obesity-related traits;
CRC	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.78	-8.66	-0.43	2.16e-16	Type 2 diabetes;
CRC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.56	-7.3	-0.37	2.22e-12	Gut microbiome composition (summer);
CRC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.49	8.17	0.41	6.65e-15	Coronary artery disease;
CRC	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.67	0.51	5.22e-23	Corneal astigmatism;
CRC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-6.86	-0.35	3.43e-11	Vitiligo;
CRC	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.6	9.72	0.47	8.36e-20	Itch intensity from mosquito bite;
CRC	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.34	7.88	0.4	4.91e-14	Corneal astigmatism;
CRC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg15848620	chr12:58087721	OS9	-0.61	-8.35	-0.42	1.97e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.35	-0.33	7.25e-10	Breast cancer;
CRC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.98	-19.07	-0.72	4.11e-55	Height;
CRC	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg21153622	chr11:89784906	NA	-0.46	-7.26	-0.37	2.9e-12	HDL cholesterol;
CRC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	10.79	0.51	1.86e-23	Motion sickness;
CRC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.35	-0.38	1.54e-12	Personality dimensions;
CRC	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.49	8.34	0.42	2.08e-15	Common traits (Other);
CRC	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.4	5.83	0.31	1.36e-8	Daytime sleep phenotypes;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg03623178	chr6:28175578	NA	0.63	8.4	0.42	1.36e-15	Parkinson's disease;
CRC	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.83	0.44	6.16e-17	Fuchs's corneal dystrophy;
CRC	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-0.54	-7.73	-0.39	1.35e-13	Prostate cancer;
CRC	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	cg04338863	chr8:33670619	NA	0.44	7.06	0.36	9.65e-12	Body mass index;
CRC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg23018236	chr17:30244563	NA	-0.65	-7.74	-0.39	1.21e-13	Hip circumference adjusted for BMI;
CRC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.5	9.79	0.48	4.89e-20	Renal cell carcinoma;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg25164649	chr6:28176230	NA	0.61	8.86	0.44	4.96e-17	Parkinson's disease;
CRC	trans	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg25985355	chr7:65971099	NA	0.51	5.77	0.3	1.85e-8	Diabetic kidney disease;
CRC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.59	-8.33	-0.42	2.16e-15	Inflammatory bowel disease;
CRC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.39	9.53e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-7.01	-0.36	1.33e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg22117107	chr15:45993392	NA	-0.44	-9.07	-0.45	1.08e-17	Waist circumference;Weight;
CRC	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg10589385	chr1:150898437	SETDB1	0.27	5.93	0.31	7.65e-9	Melanoma;
CRC	trans	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg18187862	chr3:45730750	SACM1L	-0.52	-6.85	-0.35	3.69e-11	Primary sclerosing cholangitis;
CRC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.47	6.22	0.32	1.48e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.81	8.55	0.43	4.61e-16	Gastritis;
CRC	trans	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg26043149	chr18:55253948	FECH	0.53	8.1	0.41	1.08e-14	Bone mineral density;
CRC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg10589385	chr1:150898437	SETDB1	0.28	6.0	0.31	5.31e-9	Tonsillectomy;
CRC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg14433983	chr11:636460	DRD4	-0.45	-5.86	-0.31	1.1e-8	Systemic lupus erythematosus;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg05838956	chr11:6704805	MRPL17	0.47	6.19	0.32	1.83e-9	Plasma plasminogen activator levels;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.16e-10	Obesity-related traits;
CRC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-8.82	-0.44	6.83e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.48	-6.25	-0.33	1.29e-9	DNA methylation (variation);
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg14092988	chr3:52407081	DNAH1	0.29	5.61	0.3	4.24e-8	Bipolar disorder;
CRC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.6	7.9	0.4	4.3e-14	Multiple sclerosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22973319	chr3:50310839	SEMA3B	0.44	6.03	0.32	4.35e-9	Anxiety disorder;
CRC	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.11	0.45	8.52e-18	Blood protein levels;
CRC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg19812747	chr11:111475976	SIK2	-0.56	-9.45	-0.46	6.39e-19	Primary sclerosing cholangitis;
CRC	cis	rs1209950	0.536	rs464366	chr21:40225071	C/T	cg02119577	chr21:40195074	ETS2	-0.36	-5.7	-0.3	2.71e-8	Non-small cell lung cancer (survival);
CRC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg15123519	chr2:136567270	LCT	0.33	6.39	0.33	5.65e-10	Mosquito bite size;
CRC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg09473613	chr1:24152604	HMGCL	0.35	6.0	0.31	5.34e-9	Immature fraction of reticulocytes;
CRC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.59	8.05	0.41	1.54e-14	Lung cancer;
CRC	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.93	17.28	0.69	4.48e-48	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.01	-0.31	4.83e-9	Gut microbiome composition (summer);
CRC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.53	6.72	0.35	8.12e-11	Morning vs. evening chronotype;
CRC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.7	11.03	0.52	2.83e-24	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.52	7.8	0.4	8e-14	Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.46	6.53	0.34	2.55e-10	Response to temozolomide;
CRC	trans	rs11673344	0.528	rs563786	chr19:37412914	A/G	cg18947437	chr10:1231002	ADARB2	-0.36	-6.39	-0.33	5.73e-10	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.82e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.34	0.33	7.69e-10	Depression;
CRC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg19193384	chr17:30244184	NA	-0.52	-6.28	-0.33	1.1e-9	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26335527	chr1:155100185	EFNA1	0.41	6.28	0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.73	13.06	0.58	1.06e-31	Cancer;
CRC	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg11130432	chr3:121712080	ILDR1	-0.5	-6.62	-0.34	1.45e-10	Multiple sclerosis;
CRC	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg12756093	chr1:115239321	AMPD1	0.47	6.79	0.35	5.26e-11	Autism;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.63	-9.6	-0.47	2.09e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	7.73	0.39	1.35e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.9	16.04	0.66	3.36e-43	Prostate cancer;
CRC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg21854759	chr1:92012499	NA	-0.53	-8.79	-0.44	8.36e-17	Breast cancer;
CRC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.21	-0.41	5.19e-15	Body mass index;
CRC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-18.44	-0.71	1.16e-52	Height;
CRC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.47	0.5	2.52e-22	Heart rate;
CRC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-12.65	-0.57	3.57e-30	Menopause (age at onset);
CRC	cis	rs911119	0.955	rs1555355	chr20:23594580	T/C	cg16589663	chr20:23618590	CST3	0.44	6.18	0.32	1.94e-9	Chronic kidney disease;
CRC	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.42	-6.97	-0.36	1.76e-11	Eotaxin levels;
CRC	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.0	0.36	1.49e-11	Red blood cell count;
CRC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13844804	chr7:814759	HEATR2	-0.54	-5.76	-0.3	1.94e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.62	8.92	0.44	3.38e-17	Height;
CRC	trans	rs1864729	1.000	rs2439700	chr8:98277168	G/A	cg08679828	chr8:102218111	ZNF706	-0.61	-7.34	-0.38	1.67e-12	Estradiol plasma levels (breast cancer);
CRC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg06462663	chr19:18546047	ISYNA1	0.48	7.37	0.38	1.39e-12	Breast cancer;
CRC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.52	-7.57	-0.39	3.77e-13	White blood cell count;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.76	0.43	1.05e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg10862848	chr6:42927986	GNMT	-0.37	-8.56	-0.43	4.36e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg19318889	chr4:1322082	MAEA	0.41	5.84	0.31	1.23e-8	Obesity-related traits;
CRC	cis	rs6679356	0.789	rs3790567	chr1:67822377	A/G	cg24364144	chr1:67875067	SERBP1	0.44	6.68	0.35	9.93e-11	Primary biliary cholangitis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09920427	chr19:12777674	MORG1;MAN2B1	-0.53	-6.43	-0.33	4.54e-10	Diisocyanate-induced asthma;
CRC	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.68	-11.01	-0.52	3.19e-24	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs1165668	0.816	rs1866072	chr12:104310706	C/G	cg21863207	chr12:104234989	NT5DC3	0.44	6.44	0.33	4.23e-10	Coronary heart disease (SNP X SNP interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07633598	chr16:84179194	LRRC50;HSDL1	0.42	6.06	0.32	3.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.88	-14.83	-0.63	1.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.24	0.33	1.35e-9	Monocyte percentage of white cells;
CRC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17554472	chr22:41940697	POLR3H	-0.55	-5.98	-0.31	5.91e-9	Vitiligo;
CRC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.58	8.65	0.43	2.3e-16	Schizophrenia;
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20092199	chr4:1342459	KIAA1530	0.48	8.67	0.43	2e-16	Longevity;
CRC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg11887960	chr12:57824829	NA	0.58	6.44	0.33	4.17e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-7.14	-0.37	5.92e-12	Subjective well-being;
CRC	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg25617285	chr1:211431773	RCOR3	-0.39	-5.8	-0.3	1.52e-8	Educational attainment (years of education);
CRC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.97	-18.55	-0.72	4.41e-53	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	trans	rs887912	0.722	rs980183	chr2:59311536	A/G	cg21870469	chr6:16238691	GMPR	-0.53	-6.33	-0.33	8.22e-10	Hip circumference;Body mass index;Obesity;
CRC	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg18232548	chr7:50535776	DDC	-0.4	-6.03	-0.32	4.33e-9	Body mass index;
CRC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.48	7.02	0.36	1.31e-11	Methadone dose in opioid dependence;
CRC	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	7.07	0.36	9.23e-12	Neuroticism;
CRC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.65	10.21	0.49	1.85e-21	Dental caries;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04360780	chr4:2010701	WHSC2	0.45	6.17	0.32	2.03e-9	Anxiety disorder;
CRC	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	0.96	7.44	0.38	8.7e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.46	9.05	0.45	1.31e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.96	12.73	0.57	1.87e-30	Triglycerides;
CRC	cis	rs6908034	0.607	rs74559916	chr6:19818717	G/T	cg02682789	chr6:19804855	NA	0.83	6.67	0.35	1.08e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.57	-6.94	-0.36	2.11e-11	Ulcerative colitis;
CRC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.14e-20	Depressive symptoms (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15066777	chr18:66382427	CCDC102B;TMX3	0.4	6.22	0.32	1.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.14	13.65	0.6	6.42e-34	Sexual dysfunction (female);
CRC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.17e-12	Motion sickness;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg13435101	chr6:74171350	MTO1	-0.42	-6.27	-0.33	1.15e-9	Interleukin-6 levels;
CRC	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.67	-8.48	-0.42	7.94e-16	Dementia with Lewy bodies;
CRC	cis	rs4523957	0.579	rs2307143	chr17:2089754	G/A	cg16513277	chr17:2031491	SMG6	-0.59	-9.87	-0.48	2.66e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	0.63	7.12	0.37	6.99e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.64	8.61	0.43	3.16e-16	Multiple sclerosis;
CRC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.03	10.1	0.49	4.66e-21	Lymphocyte counts;
CRC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	8.41	0.42	1.26e-15	Neuroticism;
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg16606324	chr3:10149918	C3orf24	0.64	8.41	0.42	1.23e-15	Alzheimer's disease;
CRC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.7	-11.31	-0.53	2.76e-25	Hepatocellular carcinoma;
CRC	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4731207	0.698	rs7793441	chr7:124536238	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26240231	chr7:1148101	C7orf50	-0.42	-5.67	-0.3	3.15e-8	Bronchopulmonary dysplasia;
CRC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.61	9.66	0.47	1.32e-19	Vitiligo;
CRC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.79	0.44	8.51e-17	Cognitive test performance;
CRC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg05941027	chr17:61774174	LIMD2	0.36	6.43	0.33	4.56e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.73	-0.35	7.78e-11	Urate levels in overweight individuals;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10139443	chr6:99963249	USP45	0.43	6.59	0.34	1.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.45	0.42	9.68e-16	Height;
CRC	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.34	6.43	0.33	4.36e-10	Ulcerative colitis;
CRC	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	9.83	0.48	3.66e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.42	6.68	0.35	1.03e-10	Multiple sclerosis;
CRC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.45	0.42	9.68e-16	Height;
CRC	cis	rs13088645	0.652	rs13074557	chr3:134153526	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	7.7	0.39	1.63e-13	Coronary artery disease;
CRC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.69	13.77	0.6	2.26e-34	Coronary artery disease;
CRC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.53	-7.34	-0.38	1.66e-12	Longevity;
CRC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.73	9.39	0.46	1.04e-18	Psoriasis;
CRC	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.54	-9.33	-0.46	1.6e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.42	6.09	0.32	3.08e-9	Diastolic blood pressure;
CRC	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	1.14	17.42	0.69	1.34e-48	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06815754	chr16:30905741	BCL7C	0.46	6.58	0.34	1.9e-10	Anxiety disorder;
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02825527	chr7:2087843	MAD1L1	-0.5	-6.06	-0.32	3.71e-9	Neuroticism;
CRC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.61	8.75	0.43	1.11e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.99	9.66	0.47	1.39e-19	Parkinson's disease;
CRC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.66	-11.67	-0.54	1.4e-26	Prudent dietary pattern;
CRC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.56	8.44	0.42	1.04e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs12495832	0.778	rs76104977	chr3:147930352	A/C	cg10221266	chr7:153579447	NA	0.56	6.12	0.32	2.6e-9	Chin dimples;
CRC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15369054	chr17:80825471	TBCD	0.34	5.72	0.3	2.4e-8	Breast cancer;
CRC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.53	0.34	2.53e-10	Tonsillectomy;
CRC	cis	rs7113874	0.589	rs7120065	chr11:8484896	C/T	cg17679104	chr11:8615758	STK33	-0.35	-5.74	-0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg07322936	chr10:88137208	NA	-0.63	-8.66	-0.43	2.12e-16	Schizophrenia;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.97	-0.44	2.26e-17	Bipolar disorder;
CRC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg03160526	chr17:80928410	B3GNTL1	-0.39	-5.72	-0.3	2.46e-8	Breast cancer;
CRC	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	6.94	0.36	2.05e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.32	6.05	0.32	3.84e-9	Ulcerative colitis;
CRC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.62	10.33	0.49	7.46e-22	Colorectal cancer;
CRC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	11.44	0.53	9.34e-26	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.56	9.08	0.45	9.96e-18	Mean corpuscular volume;
CRC	cis	rs6076065	0.723	rs4815203	chr20:23395633	C/G	cg11657817	chr20:23433608	CST11	0.43	6.33	0.33	8.11e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.51	-0.38	5.61e-13	Blood metabolite levels;
CRC	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.63	-9.65	-0.47	1.47e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.57	-7.73	-0.39	1.3e-13	Response to antineoplastic agents;
CRC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.51	8.03	0.4	1.79e-14	Methadone dose in opioid dependence;
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.68	8.08	0.41	1.26e-14	Body mass index;
CRC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.43	-6.31	-0.33	9.23e-10	Cerebrospinal P-tau181p levels;
CRC	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.6	-9.68	-0.47	1.18e-19	Corneal astigmatism;
CRC	trans	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg01472538	chr16:58549086	SETD6	1.06	6.94	0.36	2.05e-11	Schizophrenia;
CRC	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.52	-0.54	5e-26	Idiopathic membranous nephropathy;
CRC	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.66	-8.36	-0.42	1.79e-15	Immature fraction of reticulocytes;
CRC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.29	5.65	0.3	3.49e-8	Longevity;Endometriosis;
CRC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07167872	chr1:205819463	PM20D1	-0.43	-5.99	-0.31	5.37e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.6	8.56	0.43	4.29e-16	Coronary artery disease;
CRC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.8	10.93	0.52	6.41e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.93	-0.31	7.58e-9	Lung cancer;
CRC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.52	8.21	0.41	5.22e-15	Multiple system atrophy;
CRC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	11.57	0.54	3.37e-26	Mean corpuscular hemoglobin;
CRC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.51	8.5	0.42	6.91e-16	Coronary artery disease;
CRC	cis	rs3764400	0.567	rs16951519	chr17:46152291	G/A	cg10706073	chr17:46328419	SKAP1	-0.62	-6.71	-0.35	8.77e-11	Body mass index;
CRC	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.29	-0.37	2.34e-12	Multiple myeloma (hyperdiploidy);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg19193384	chr17:30244184	NA	-0.53	-6.67	-0.35	1.06e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.43	-6.4	-0.33	5.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.46	6.75	0.35	6.69e-11	Menopause (age at onset);
CRC	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.2	0.45	4.18e-18	Coffee consumption (cups per day);
CRC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg17724175	chr1:150552817	MCL1	0.39	6.0	0.31	5.11e-9	Melanoma;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg27367768	chr5:171615456	STK10	0.38	6.53	0.34	2.53e-10	Interleukin-6 levels;
CRC	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.64	9.11	0.45	8.22e-18	Body mass index;
CRC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18099408	chr3:52552593	STAB1	-0.48	-7.95	-0.4	2.93e-14	Electroencephalogram traits;
CRC	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.45e-11	Prostate cancer;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.95	-0.31	6.7e-9	Longevity;Endometriosis;
CRC	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.61	8.94	0.44	2.77e-17	Testicular germ cell tumor;
CRC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.38	6.28	0.33	1.04e-9	Major depressive disorder;
CRC	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg25164649	chr6:28176230	NA	0.63	8.21	0.41	5.03e-15	Depression;
CRC	cis	rs7605827	0.930	rs6761904	chr2:15599658	A/G	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.45	-5.94	-0.31	7.28e-9	Aortic root size;
CRC	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.73	11.68	0.54	1.34e-26	Plateletcrit;Platelet count;
CRC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg06470822	chr6:28175283	NA	0.47	6.55	0.34	2.17e-10	Depression;
CRC	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26306683	chr17:18585705	ZNF286B	0.49	7.04	0.36	1.11e-11	Educational attainment (years of education);
CRC	trans	rs12495832	0.778	rs74980258	chr3:147921660	G/A	cg10221266	chr7:153579447	NA	0.56	6.13	0.32	2.54e-9	Chin dimples;
CRC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-6.02	-0.31	4.73e-9	Schizophrenia;
CRC	cis	rs2637266	0.549	rs11516640	chr10:78414532	A/G	cg18941641	chr10:78392320	NA	-0.34	-5.73	-0.3	2.32e-8	Pulmonary function;
CRC	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg14550559	chr2:240039617	HDAC4	0.5	7.61	0.39	2.98e-13	Skin aging (microtopography measurement);
CRC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.69	10.42	0.5	3.66e-22	Gestational age at birth (maternal effect);
CRC	cis	rs4731207	0.597	rs12536017	chr7:124562301	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.0	-0.31	5.32e-9	Cutaneous malignant melanoma;
CRC	trans	rs2303319	0.504	rs16845945	chr2:162480684	C/T	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02359409	chr6:42947317	PEX6	-0.57	-8.92	-0.44	3.24e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.76	-0.51	2.55e-23	Bipolar disorder and schizophrenia;
CRC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-8.4	-0.42	1.38e-15	Intelligence (multi-trait analysis);
CRC	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg06172871	chr16:72088244	HP	0.44	6.44	0.33	4.35e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg06522879	chr11:64358276	SLC22A12	0.57	8.89	0.44	4.04e-17	Urate levels in obese individuals;
CRC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.82	-9.19	-0.45	4.62e-18	Breast cancer;
CRC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg12172441	chr6:28176163	NA	0.53	7.28	0.37	2.5e-12	Parkinson's disease;
CRC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.5	-9.25	-0.45	3e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.56	-8.48	-0.42	7.57e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.59	8.61	0.43	3.05e-16	Lymphocyte counts;
CRC	cis	rs8170	1.000	rs10406920	chr19:17389648	C/T	cg04749549	chr19:17459798	NA	-0.45	-6.11	-0.32	2.76e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg03037974	chr15:76606532	NA	0.54	8.04	0.41	1.65e-14	Blood metabolite levels;
CRC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-8.01	-0.4	1.99e-14	Major depressive disorder;
CRC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.8	0.44	7.95e-17	Rheumatoid arthritis;
CRC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg02869306	chr7:64672164	INTS4L1	-0.49	-8.38	-0.42	1.59e-15	Calcium levels;
CRC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.74	6.87	0.35	3.28e-11	Diabetic retinopathy;
CRC	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.41	-0.33	5.08e-10	Subjective well-being;
CRC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg05585544	chr11:47624801	NA	-0.4	-6.34	-0.33	7.63e-10	Mean corpuscular hemoglobin;
CRC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.73	0.47	7.96e-20	Hip circumference adjusted for BMI;
CRC	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.71	-8.08	-0.41	1.24e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.4	-5.84	-0.31	1.26e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg01843034	chr6:37503916	NA	-0.44	-8.2	-0.41	5.61e-15	Cognitive performance;
CRC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg08501292	chr6:25962987	TRIM38	0.78	6.07	0.32	3.44e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.26	0.49	1.35e-21	Alzheimer's disease (late onset);
CRC	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.24	0.67	5.59e-44	Chronic sinus infection;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12172441	chr6:28176163	NA	0.58	7.01	0.36	1.37e-11	Depression;
CRC	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.82	10.82	0.51	1.5e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.42	0.38	9.99e-13	Hip circumference adjusted for BMI;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03819338	chr20:39942766	NA	-0.35	-6.1	-0.32	3.01e-9	HDL cholesterol;
CRC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.44	5.66	0.3	3.3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg17283838	chr1:93427260	FAM69A	0.47	6.5	0.34	2.97e-10	Multiple sclerosis;
CRC	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg16358738	chr2:241808595	AGXT	-0.41	-7.26	-0.37	2.76e-12	Urinary metabolites;
CRC	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.46	6.7	0.35	8.98e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs4750440	0.706	rs12358733	chr10:14016290	A/G	cg00551146	chr10:14014579	FRMD4A	-0.36	-5.95	-0.31	6.76e-9	Adiponectin levels;
CRC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg21770322	chr7:97807741	LMTK2	-0.66	-12.04	-0.55	6.29e-28	Breast cancer;
CRC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.2	-0.32	1.71e-9	Post bronchodilator FEV1;
CRC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.32	-0.33	8.29e-10	Aortic root size;
CRC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.68	-9.94	-0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg05044414	chr3:183734942	ABCC5	0.42	7.45	0.38	8.42e-13	Anterior chamber depth;
CRC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.8	0.3	1.58e-8	Schizophrenia;
CRC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-6.96	-0.36	1.81e-11	Neuroticism;
CRC	trans	rs2303319	0.504	rs62188984	chr2:162514518	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.8	-13.38	-0.59	6.77e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3015497	0.608	rs3015499	chr14:51112460	T/C	cg26011998	chr14:51135199	SAV1	-0.44	-5.67	-0.3	3.08e-8	Mean platelet volume;
CRC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-7.61	-0.39	2.86e-13	Menarche (age at onset);
CRC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.62	0.6	8.2e-34	Chronic sinus infection;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.95	0.4	3.07e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.61	7.51	0.38	5.72e-13	Post bronchodilator FEV1;
CRC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.65	-0.3	3.44e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.44	-5.97	-0.31	6.24e-9	Colorectal cancer;
CRC	cis	rs7264396	0.832	rs224381	chr20:34097136	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.13	-0.37	6.49e-12	Total cholesterol levels;
CRC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.19	0.53	7.47e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.47	0.34	3.54e-10	Bipolar disorder;
CRC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.01	0.31	5.02e-9	Renal cell carcinoma;
CRC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-19.17	-0.73	1.63e-55	Ulcerative colitis;
CRC	cis	rs7894407	0.892	rs10883859	chr10:105128134	T/G	cg05636881	chr10:105038444	INA	-0.37	-5.83	-0.31	1.33e-8	White matter hyperintensity burden;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12346351	chr4:152330392	FAM160A1	0.49	7.18	0.37	4.61e-12	Response to antipsychotic treatment;
CRC	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.25	0.41	3.9e-15	Arsenic metabolism;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20887711	chr4:1340912	KIAA1530	0.43	6.06	0.32	3.78e-9	Obesity-related traits;
CRC	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.21	0.45	3.89e-18	Blood protein levels;
CRC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.77	-0.39	9.87e-14	Hemoglobin concentration;
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg12564285	chr5:131593104	PDLIM4	-0.5	-9.72	-0.47	8.34e-20	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17482927	chr17:63133259	RGS9	0.48	7.21	0.37	3.78e-12	Response to antipsychotic treatment;
CRC	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-5.74	-0.3	2.11e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.45	5.97	0.31	6.11e-9	Response to diuretic therapy;
CRC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.82e-15	Mean platelet volume;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg08034379	chr2:228736324	WDR69	0.52	6.94	0.36	2.09e-11	Blood pressure;
CRC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.93	0.36	2.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg20356878	chr3:121714668	ILDR1	-0.47	-6.91	-0.36	2.59e-11	Multiple sclerosis;
CRC	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09695851	chr17:3907499	NA	0.43	6.07	0.32	3.46e-9	Type 2 diabetes;
CRC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.39	6.75	0.35	6.7e-11	Crohn's disease;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg15786705	chr6:28176104	NA	-0.77	-9.53	-0.46	3.68e-19	Depression;
CRC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16262614	chr3:133464971	TF	0.34	6.04	0.32	4.15e-9	Iron status biomarkers;
CRC	trans	rs2303319	0.504	rs1567420	chr2:162475601	C/T	cg12500891	chr11:57225987	NA	0.66	6.0	0.31	5.3e-9	Cognitive function;
CRC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.53	0.34	2.52e-10	Morning vs. evening chronotype;
CRC	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.79	-0.35	5.18e-11	Mood instability;
CRC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.39e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.25e-36	Prudent dietary pattern;
CRC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.66	0.39	2.1e-13	Schizophrenia;
CRC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.52	8.62	0.43	2.87e-16	Menarche (age at onset);
CRC	cis	rs12541635	0.677	rs7460291	chr8:107057861	A/G	cg10147462	chr8:107024639	NA	0.6	10.5	0.5	2.01e-22	Age of smoking initiation;
CRC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg18016565	chr1:150552671	MCL1	0.41	5.78	0.3	1.73e-8	Melanoma;
CRC	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.85	10.92	0.52	6.59e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg19682013	chr15:45996608	NA	0.32	6.62	0.34	1.48e-10	Waist circumference;Weight;
CRC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.62	10.57	0.5	1.11e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2857891	0.695	rs2346002	chr11:6987741	T/C	cg22096450	chr11:6947773	ZNF215	0.48	5.72	0.3	2.35e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs10242455	0.702	rs73711294	chr7:99088714	G/A	cg09045935	chr12:6379348	NA	1.08	7.75	0.39	1.14e-13	Blood metabolite levels;
CRC	cis	rs9891119	1.000	rs9891119	chr17:40507980	A/C	cg06270615	chr17:40516068	STAT3	-0.26	-5.64	-0.3	3.7e-8	Multiple sclerosis;Crohn's disease;
CRC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg06238570	chr21:40685208	BRWD1	0.75	10.22	0.49	1.75e-21	Cognitive function;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.71	-0.35	8.61e-11	Total body bone mineral density;
CRC	cis	rs7932354	0.528	rs4752967	chr11:47169376	T/C	cg19486271	chr11:47235900	DDB2	0.43	6.42	0.33	4.89e-10	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03771185	chr4:775700	NA	0.53	7.01	0.36	1.33e-11	Thyroid stimulating hormone;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21512275	chr2:157198069	NA	0.51	6.73	0.35	7.47e-11	Thyroid stimulating hormone;
CRC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19941686	chr7:23221979	NUPL2	0.42	5.99	0.31	5.61e-9	Response to antipsychotic treatment;
CRC	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg06223162	chr1:101003688	GPR88	-0.36	-6.66	-0.34	1.12e-10	Monocyte count;
CRC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.67	-9.0	-0.44	1.87e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg13628971	chr7:2884303	GNA12	0.44	6.79	0.35	5.26e-11	Height;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg07870213	chr5:140052090	DND1	-0.63	-8.2	-0.41	5.64e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.66e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-13.31	-0.59	1.26e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.29	0.33	1.03e-9	Primary sclerosing cholangitis;
CRC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg25767906	chr1:53392781	SCP2	0.45	7.22	0.37	3.54e-12	Monocyte count;
CRC	cis	rs11625487	0.505	rs10145609	chr14:77957377	G/A	cg20045696	chr14:77926864	AHSA1	-0.42	-5.9	-0.31	8.92e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CRC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.82	0.51	1.58e-23	Coronary artery disease;
CRC	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13385794	chr1:248469461	NA	0.39	6.91	0.36	2.51e-11	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12996417	chr4:152198109	PRSS48	0.42	6.9	0.36	2.65e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg19052272	chr2:3704530	ALLC	-0.47	-6.7	-0.35	9.01e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.54	7.86	0.4	5.51e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23031969	chr7:5014415	RNF216L	0.44	7.07	0.36	9.17e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.33e-29	Prostate cancer;
CRC	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.73	8.61	0.43	3.13e-16	Eotaxin levels;
CRC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-9.17	-0.45	5.12e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs62408225	0.722	rs3734660	chr6:90916345	A/G	cg06866423	chr6:90926672	BACH2	0.65	12.04	0.55	6.69e-28	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg02158880	chr13:53174818	NA	0.47	7.1	0.36	7.9e-12	Lewy body disease;
CRC	cis	rs10971721	0.731	rs10971782	chr9:33909464	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg03929089	chr4:120376271	NA	0.64	6.05	0.32	3.97e-9	Axial length;
CRC	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.62	-8.74	-0.43	1.18e-16	Coronary artery disease;
CRC	cis	rs939584	0.877	rs13027828	chr2:632379	T/G	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.58e-8	Body mass index;
CRC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg24562669	chr7:97807699	LMTK2	0.44	7.32	0.37	1.97e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.71	0.51	3.54e-23	Ileal carcinoids;
CRC	cis	rs12580194	0.593	rs67934812	chr12:55785591	T/G	cg23425280	chr12:56401806	NA	0.47	5.71	0.3	2.53e-8	Cancer;
CRC	cis	rs2227564	0.678	rs2242257	chr10:75597605	A/G	cg16540259	chr10:75572220	NDST2	-0.47	-6.66	-0.34	1.12e-10	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg06028048	chr5:175815674	HIGD2A;NOP16	-0.52	-6.02	-0.31	4.71e-9	Hirschsprung disease;
CRC	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.43	-6.97	-0.36	1.73e-11	Refractive error;
CRC	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-6.11	-0.32	2.83e-9	Schizophrenia;
CRC	cis	rs17023223	0.537	rs2645292	chr1:119573194	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-6.38	-0.33	5.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg04450456	chr4:17643702	FAM184B	0.41	6.65	0.34	1.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	19.41	0.73	1.76e-56	Prudent dietary pattern;
CRC	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.59	-0.47	2.36e-19	Prevalent atrial fibrillation;
CRC	cis	rs3750082	1.000	rs3750082	chr7:32919927	T/A	cg05721444	chr7:32995514	FKBP9	0.42	5.98	0.31	5.97e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-7.95	-0.4	3.08e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-8.1	-0.41	1.06e-14	Fibrinogen levels;
CRC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24308560	chr3:49941425	MST1R	0.43	6.78	0.35	5.65e-11	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20617676	chr7:123389167	WASL	0.45	7.78	0.39	9.23e-14	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06433995	chr6:13615570	NOL7	0.47	6.73	0.35	7.6e-11	Response to antipsychotic treatment;
CRC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.49	-8.51	-0.42	6.37e-16	Longevity;
CRC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17219203	chr10:38645113	HSD17B7P2	0.41	5.69	0.3	2.85e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.48	-0.34	3.42e-10	Coronary artery calcification;
CRC	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.59	-7.22	-0.37	3.67e-12	Carotid intima media thickness;
CRC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg05304507	chr6:116381966	FRK	0.31	8.57	0.43	4.03e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7692995	1.000	rs7694806	chr4:18029100	C/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.75	-0.3	2.04e-8	Height;
CRC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.74	-12.16	-0.56	2.3e-28	Prostate cancer;
CRC	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg11861562	chr11:117069780	TAGLN	0.33	6.2	0.32	1.71e-9	Blood protein levels;
CRC	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.41	-0.38	1.07e-12	Inflammatory bowel disease;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg01758942	chr3:52551074	STAB1	0.31	6.15	0.32	2.28e-9	Electroencephalogram traits;
CRC	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.42	-0.65	9.04e-41	Exhaled nitric oxide output;
CRC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.54	0.47	3.33e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.05	-0.45	1.33e-17	Bipolar disorder;
CRC	cis	rs17227506	0.730	rs35380952	chr8:13457292	G/A	cg03566418	chr8:13424080	C8orf48	0.39	6.36	0.33	6.56e-10	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs501120	0.850	rs642222	chr10:44770473	A/G	cg09554077	chr10:44749378	NA	0.78	11.91	0.55	1.96e-27	Coronary artery disease;Coronary heart disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27054308	chr14:20922865	APEX1;OSGEP	0.44	6.56	0.34	2.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.58	-6.86	-0.35	3.45e-11	Bronchopulmonary dysplasia;
CRC	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg09592903	chr2:55203963	RTN4	0.63	10.43	0.5	3.34e-22	Mean platelet volume;
CRC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg10589385	chr1:150898437	SETDB1	-0.31	-6.46	-0.34	3.76e-10	Blood protein levels;
CRC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.45	6.58	0.34	1.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.49	-9.0	-0.44	1.83e-17	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20393609	chr7:102105195	ALKBH4;LRWD1	0.45	6.45	0.34	4.05e-10	Anxiety disorder;
CRC	cis	rs939584	1.000	rs10172769	chr2:646345	G/A	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16140449	chr1:178511703	C1orf220	0.48	6.62	0.34	1.46e-10	Response to antipsychotic treatment;
CRC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.41	6.88	0.35	2.98e-11	Primary biliary cholangitis;
CRC	cis	rs4664293	0.903	rs10185155	chr2:160553228	G/A	cg08347373	chr2:160653686	CD302	-0.46	-7.41	-0.38	1.09e-12	Monocyte percentage of white cells;
CRC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.65	-0.43	2.32e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.55	8.79	0.44	8.59e-17	Hemoglobin concentration;
CRC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg18016565	chr1:150552671	MCL1	0.42	6.06	0.32	3.8e-9	Melanoma;
CRC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-9.67	-0.47	1.24e-19	Pancreatic cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25515063	chr12:121019412	POP5	0.44	6.2	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13219625	chr3:49823913	IP6K1	-0.39	-6.09	-0.32	3.07e-9	Myopia (pathological);
CRC	cis	rs6681460	0.966	rs10889642	chr1:67143334	T/G	cg02459107	chr1:67143332	SGIP1	0.49	8.8	0.44	7.89e-17	Presence of antiphospholipid antibodies;
CRC	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	6.77	0.35	6.05e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.46	-7.47	-0.38	7.49e-13	Height;
CRC	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.82	12.4	0.56	3.13e-29	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.64	-9.31	-0.46	1.85e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg20041105	chr8:143859282	LYNX1	0.58	10.6	0.5	9.17e-23	Urinary tract infection frequency;
CRC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg17330251	chr7:94953956	PON1	-0.54	-6.78	-0.35	5.59e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.49	-7.82	-0.4	7.14e-14	Asthma;
CRC	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.25	5.91	0.31	8.7e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.24	-9.92	-0.48	1.84e-20	Mitochondrial DNA levels;
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11645453	chr3:52864694	ITIH4	0.35	6.02	0.32	4.62e-9	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg25576086	chr14:70833871	SYNJ2BP	-0.41	-7.45	-0.38	8.28e-13	Prostate cancer;
CRC	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.67	10.46	0.5	2.59e-22	Corneal astigmatism;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.6	-0.43	3.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16262614	chr3:133464971	TF	0.36	6.15	0.32	2.22e-9	Iron status biomarkers;
CRC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.47	7.38	0.38	1.27e-12	Corneal astigmatism;
CRC	cis	rs2882667	0.690	rs288017	chr5:138193515	A/T	cg09476006	chr5:138032270	NA	-0.54	-8.92	-0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg06470822	chr6:28175283	NA	-0.69	-10.51	-0.5	1.88e-22	Cardiac Troponin-T levels;
CRC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.44	0.62	5.96e-37	Chronic sinus infection;
CRC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.46	6.27	0.33	1.14e-9	Red blood cell count;
CRC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.49	-8.04	-0.41	1.61e-14	Crohn's disease;
CRC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.08	-0.36	8.75e-12	Gut microbiome composition (summer);
CRC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.94	0.48	1.59e-20	Cognitive test performance;
CRC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	0.9	11.01	0.52	3.3e-24	Hip circumference adjusted for BMI;
CRC	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg12700464	chr11:78128424	GAB2	-0.49	-5.82	-0.31	1.38e-8	Testicular germ cell tumor;
CRC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.59	10.63	0.51	7.18e-23	Blood metabolite ratios;
CRC	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.53	7.94	0.4	3.33e-14	Coronary artery disease;
CRC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.79	0.39	9.11e-14	Total body bone mineral density;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11196904	chr1:10491304	APITD1	0.36	5.97	0.31	6.14e-9	Obesity-related traits;
CRC	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	7.74	0.39	1.26e-13	Menarche (age at onset);
CRC	cis	rs11212617	0.967	rs227058	chr11:108265213	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.68	0.35	1.03e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.81	-13.87	-0.61	9.2e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.85	12.58	0.57	7e-30	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs245880	0.740	rs245886	chr7:29189336	G/T	cg17163760	chr7:29186267	CPVL	-0.39	-6.73	-0.35	7.63e-11	Warfarin maintenance dose;
CRC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.69	10.35	0.5	6.36e-22	Breast cancer;
CRC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.98	12.27	0.56	9.8e-29	Vitiligo;
CRC	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-0.6	-6.62	-0.34	1.5e-10	Blood protein levels;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg12172441	chr6:28176163	NA	0.5	6.73	0.35	7.38e-11	Parkinson's disease;
CRC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.0	0.48	9.85e-21	Systolic blood pressure;
CRC	cis	rs6580110	0.793	rs6868098	chr5:154080958	G/A	cg11923914	chr5:154071666	NA	-0.48	-7.23	-0.37	3.38e-12	Facial morphology (factor 9, facial height related to vertical position of nasion);
CRC	cis	rs6504950	0.800	rs7209926	chr17:53006324	C/T	cg26251398	chr17:52985966	TOM1L1	-0.38	-5.81	-0.31	1.45e-8	Breast cancer;
CRC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.49	9.43	0.46	7.5e-19	Bone mineral density;
CRC	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.53	6.11	0.32	2.83e-9	Carotid intima media thickness;
CRC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-7.87	-0.4	5.2e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Colorectal cancer;
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.69	11.05	0.52	2.38e-24	Cognitive function;
CRC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.49	7.07	0.36	9.48e-12	Methadone dose in opioid dependence;
CRC	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.77	11.66	0.54	1.6e-26	Type 2 diabetes;
CRC	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.86	14.77	0.63	3.26e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.55	-0.6	1.57e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06685340	chr10:82213598	TSPAN14	0.41	5.99	0.31	5.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg02683197	chr6:28174875	NA	0.47	6.65	0.34	1.24e-10	Cardiac Troponin-T levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg19320564	chr1:40157253	HPCAL4	0.36	6.01	0.31	4.85e-9	Interleukin-6 levels;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg07870213	chr5:140052090	DND1	-0.62	-8.13	-0.41	8.96e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-17.6	-0.7	2.53e-49	Intelligence (multi-trait analysis);
CRC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.5	6.93	0.36	2.21e-11	Lymphocyte counts;
CRC	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.53	-6.4	-0.33	5.31e-10	Opioid sensitivity;
CRC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg08314208	chr16:67682810	RLTPR	-0.63	-6.75	-0.35	6.58e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.56	-8.12	-0.41	9.6e-15	Platelet distribution width;
CRC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-8.29	-0.42	3.01e-15	Uric acid levels;
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg20119798	chr7:94954144	PON1	-0.52	-6.48	-0.34	3.39e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg16236679	chr11:96123321	JRKL;CCDC82	-0.48	-6.07	-0.32	3.46e-9	Parkinson's disease;
CRC	cis	rs2386661	0.523	rs7896088	chr10:5652286	C/T	cg26603656	chr10:5671107	NA	0.39	7.25	0.37	2.94e-12	Breast cancer;
CRC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.26	-0.41	3.59e-15	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs10905065	0.965	rs12571639	chr10:5748052	G/A	cg11519256	chr10:5708881	ASB13	0.44	6.31	0.33	8.92e-10	Menopause (age at onset);
CRC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.45	6.54	0.34	2.38e-10	Blood metabolite levels;
CRC	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg02549819	chr16:58548995	SETD6	1.2	7.97	0.4	2.72e-14	Schizophrenia;
CRC	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-6.32	-0.33	8.69e-10	Schizophrenia;
CRC	cis	rs77633900	0.772	rs2957560	chr15:76700310	A/T	cg21673338	chr15:77095150	SCAPER	-0.66	-5.61	-0.3	4.23e-8	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.58	-0.34	1.89e-10	Subjective well-being;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg24634471	chr8:143751801	JRK	-0.47	-6.55	-0.34	2.26e-10	Urinary tract infection frequency;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg27342122	chr8:133787442	PHF20L1	-0.71	-6.02	-0.31	4.6e-9	Cognitive function;
CRC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg11003573	chr3:44754125	ZNF502	-0.33	-5.68	-0.3	2.98e-8	Depressive symptoms;
CRC	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-0.67	-9.56	-0.47	2.93e-19	Type 2 diabetes;
CRC	cis	rs863345	0.604	rs11265009	chr1:158498772	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.08	-0.32	3.42e-9	Pneumococcal bacteremia;
CRC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.58	-0.34	1.85e-10	Aortic root size;
CRC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-6.42	-0.33	4.63e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.37	-5.93	-0.31	7.86e-9	Alcohol dependence;
CRC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.48	6.52	0.34	2.63e-10	Schizophrenia;
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg12908607	chr1:44402522	ARTN	-0.47	-8.18	-0.41	6.32e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.77	10.6	0.5	8.75e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11212617	1.000	rs599558	chr11:108177538	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.52	0.34	2.68e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6840360	0.642	rs1443090	chr4:152451819	T/C	cg09659197	chr4:152720779	NA	0.33	6.47	0.34	3.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.67	-0.3	3.11e-8	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg17949981	chr6:28129498	ZNF389	0.41	5.67	0.3	3.12e-8	Cardiac Troponin-T levels;
CRC	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.36	0.65	1.62e-40	Bipolar disorder;
CRC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.17	0.52	9e-25	Bone mineral density;
CRC	cis	rs9463078	0.585	rs7754378	chr6:44863106	A/G	cg25276700	chr6:44698697	NA	0.25	6.07	0.32	3.45e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.04	-0.45	1.34e-17	Schizophrenia;
CRC	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg26182253	chr13:112236782	NA	0.31	6.29	0.33	9.96e-10	Hepatitis;
CRC	cis	rs9322817	0.902	rs9322812	chr6:105194651	A/G	cg02098413	chr6:105308735	HACE1	-0.36	-6.58	-0.34	1.9e-10	Thyroid stimulating hormone;
CRC	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	4.92e-11	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05860723	chr12:81102486	MYF6	0.18	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.66	0.34	1.18e-10	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03856714	chr2:96658020	NA	0.43	6.25	0.33	1.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.48	-5.66	-0.3	3.34e-8	Menarche (age at onset);
CRC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.31	0.46	1.92e-18	Bladder cancer;
CRC	trans	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.67	9.31	0.46	1.93e-18	Response to diuretic therapy;
CRC	cis	rs12024301	0.557	rs7530186	chr1:183610283	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs9395066	0.545	rs3799976	chr6:44835622	T/G	cg04786201	chr1:17185605	NA	0.28	6.04	0.32	4.21e-9	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26354228	chr1:29213635	EPB41	0.4	6.15	0.32	2.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.83	-0.31	1.36e-8	Breast cancer;
CRC	trans	rs2890652	0.646	rs72853432	chr2:142973655	T/G	cg00809969	chr7:27181067	HOXA5	-0.68	-6.11	-0.32	2.76e-9	Body mass index;
CRC	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.65	10.04	0.48	7.12e-21	Corneal astigmatism;
CRC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.9	-17.3	-0.69	3.92e-48	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.69	-11.13	-0.52	1.24e-24	Cognitive function;
CRC	cis	rs57561814	1.000	rs6949149	chr7:22749157	G/T	cg26061582	chr7:22766209	IL6	0.74	6.27	0.33	1.13e-9	Tonsillectomy;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.43	-6.36	-0.33	6.64e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07701084	chr6:150067640	NUP43	0.49	6.8	0.35	4.98e-11	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01076405	chr8:99057832	RPL30	0.36	6.09	0.32	3.09e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.43	6.7	0.35	9.06e-11	Red blood cell count;
CRC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.59	9.38	0.46	1.08e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.72	-13.49	-0.6	2.56e-33	Educational attainment;
CRC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	6.98	0.36	1.6e-11	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs4964805	0.632	rs11111782	chr12:104188476	A/G	cg02344784	chr12:104178138	NT5DC3	-0.77	-14.48	-0.62	4.34e-37	Attention deficit hyperactivity disorder;
CRC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.58	0.57	6.77e-30	Menopause (age at onset);
CRC	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.62	-8.47	-0.42	8.32e-16	White matter hyperintensity burden;
CRC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.65	-12.21	-0.56	1.5e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.53	-9.34	-0.46	1.44e-18	Dupuytren's disease;
CRC	trans	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg00383909	chr3:49044727	WDR6	0.48	5.96	0.31	6.48e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.37	-0.38	1.43e-12	Vitiligo;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04677061	chr11:32112634	RCN1	0.39	6.06	0.32	3.67e-9	Obesity-related traits;
CRC	cis	rs9847710	0.967	rs2564938	chr3:53026384	C/T	cg04503182	chr3:53078218	SFMBT1	0.43	6.36	0.33	6.77e-10	Ulcerative colitis;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg21620606	chr4:1342894	KIAA1530	-0.44	-7.07	-0.36	9.14e-12	Obesity-related traits;
CRC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.69	0.47	1.04e-19	Lung cancer;
CRC	cis	rs863345	0.604	rs1873509	chr1:158461563	A/G	cg12129480	chr1:158549410	OR10X1	0.28	5.76	0.3	1.94e-8	Pneumococcal bacteremia;
CRC	cis	rs9648716	0.554	rs1092351	chr7:140657027	A/G	cg10747023	chr7:140774559	NA	0.43	5.84	0.31	1.24e-8	Type 2 diabetes;
CRC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.4	-6.19	-0.32	1.75e-9	Menopause (age at onset);
CRC	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.54	-6.12	-0.32	2.71e-9	Moyamoya disease;
CRC	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.42	6.82	0.35	4.25e-11	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.78	0.35	5.64e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.85	0.51	1.15e-23	Coffee consumption (cups per day);
CRC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg04121214	chr22:50244548	NA	0.39	5.78	0.3	1.75e-8	Schizophrenia;
CRC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.66	-9.27	-0.46	2.45e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.75	-12.45	-0.57	2.02e-29	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg27661571	chr11:113659931	NA	-0.93	-9.31	-0.46	1.85e-18	Height;
CRC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	8.59	0.43	3.65e-16	Colorectal cancer;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg05313129	chr8:58192883	C8orf71	0.47	6.15	0.32	2.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.58	-6.85	-0.35	3.68e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg10756647	chr7:56101905	PSPH	0.72	7.98	0.4	2.39e-14	Diabetic kidney disease;
CRC	cis	rs972578	1.000	rs5759086	chr22:43404929	C/G	cg01576275	chr22:43409880	NA	-0.51	-8.38	-0.42	1.53e-15	Mean platelet volume;
CRC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg26805224	chr10:79626177	DLG5	-0.51	-7.45	-0.38	8.07e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18938469	chr14:23564120	C14orf119;ACIN1	0.5	6.96	0.36	1.91e-11	Anxiety disorder;
CRC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.19e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-8.82	-0.44	7.04e-17	Bladder cancer;
CRC	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	trans	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg13565492	chr6:43139072	SRF	-0.67	-7.23	-0.37	3.36e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10905065	0.610	rs55913768	chr10:5749449	G/A	cg11519256	chr10:5708881	ASB13	-0.44	-6.05	-0.32	4.02e-9	Menopause (age at onset);
CRC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg15832292	chr6:96025679	MANEA	0.61	6.71	0.35	8.38e-11	Behavioural disinhibition (generation interaction);
CRC	trans	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.51	-0.38	5.78e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.72	-0.3	2.38e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	7.93	0.4	3.5e-14	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.73	0.47	7.79e-20	Corneal astigmatism;
CRC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.45	-6.1	-0.32	3e-9	Aortic root size;
CRC	cis	rs6968419	0.641	rs17138519	chr7:115906178	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.32	-0.33	8.33e-10	Intraocular pressure;
CRC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.67	-8.18	-0.41	6.4e-15	Cognitive test performance;
CRC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02018176	chr4:1364513	KIAA1530	0.48	7.88	0.4	4.67e-14	Obesity-related traits;
CRC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.02	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-12.93	-0.58	3.38e-31	Ulcerative colitis;
CRC	cis	rs812925	0.892	rs4672440	chr2:61616653	T/G	cg10580144	chr2:61372316	C2orf74	-0.31	-6.39	-0.33	5.68e-10	Immature fraction of reticulocytes;
CRC	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.48	7.59	0.39	3.42e-13	Systemic lupus erythematosus;
CRC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.32	-0.33	8.34e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.5	6.23	0.32	1.41e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2303319	0.504	rs72870226	chr2:162420429	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.04	-0.32	4.15e-9	Cognitive function;
CRC	cis	rs2982552	0.873	rs2152751	chr6:152069999	A/G	cg22157087	chr6:152012887	ESR1	0.38	5.87	0.31	1.05e-8	Bone properties (heel);
CRC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.57	0.57	7.46e-30	Body mass index;
CRC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.46	6.53	0.34	2.53e-10	Tonsillectomy;
CRC	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.45	9.15	0.45	5.95e-18	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg12573674	chr2:1569213	NA	-0.77	-8.03	-0.4	1.78e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	trans	rs1642645	0.831	rs7535305	chr1:42489602	C/A	cg16926213	chr1:1841314	NA	-0.43	-6.08	-0.32	3.37e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg19592336	chr6:28129416	ZNF389	0.48	5.86	0.31	1.14e-8	Depression;
CRC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg07211511	chr3:129823064	LOC729375	-0.61	-6.97	-0.36	1.73e-11	Blood pressure (smoking interaction);
CRC	cis	rs7849270	1.000	rs7849160	chr9:131874552	A/T	cg13538475	chr9:131942899	NA	-0.3	-5.98	-0.31	5.76e-9	Blood metabolite ratios;
CRC	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.78	10.91	0.52	7.6e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs4733770	0.581	rs12550366	chr8:131136047	A/T	cg21674704	chr8:131455249	NA	-0.37	-5.99	-0.31	5.46e-9	Schizophrenia;
CRC	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.8	-15.38	-0.65	1.29e-40	Ulcerative colitis;
CRC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	ch.8.34907260F	chr8:34787718	NA	-0.53	-6.29	-0.33	9.93e-10	Type 1 diabetes;
CRC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.42	6.93	0.36	2.22e-11	Cleft lip with or without cleft palate;
CRC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.74	-0.39	1.25e-13	Hemoglobin concentration;
CRC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.49	7.01	0.36	1.33e-11	Height;
CRC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.03e-20	Lung cancer;
CRC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.59	9.02	0.45	1.59e-17	Height;
CRC	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg20636351	chr8:55087400	NA	-0.34	-6.06	-0.32	3.65e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.07e-10	Life satisfaction;
CRC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.81	13.52	0.6	1.92e-33	Menopause (age at onset);
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg20119798	chr7:94954144	PON1	-0.51	-6.46	-0.34	3.7e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs9409565	0.762	rs55877910	chr9:97234213	G/C	cg05679027	chr9:99775184	HIATL2	-0.4	-6.04	-0.32	4.2e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.53	-0.34	2.47e-10	Menopause (age at onset);
CRC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg13880726	chr7:1868755	MAD1L1	-0.46	-5.68	-0.3	2.95e-8	Bipolar disorder;
CRC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.51	6.89	0.35	2.9100000000000002e-11	Obesity-related traits;
CRC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.81	13.61	0.6	9.13e-34	Menopause (age at onset);
CRC	cis	rs12612619	0.704	rs3769139	chr2:27315714	C/T	cg00617064	chr2:27272375	NA	-0.37	-6.01	-0.31	4.9e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg07125278	chr16:67683757	RLTPR	-0.62	-7.05	-0.36	1.08e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6681460	1.000	rs6697088	chr1:67044724	C/G	cg02459107	chr1:67143332	SGIP1	-0.45	-7.43	-0.38	9.17e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-8.06	-0.41	1.4e-14	Blood protein levels;
CRC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.53	7.42	0.38	1.03e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.43	0.69	1.17e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9346649	0.591	rs1873338	chr6:168492087	T/C	cg02770688	chr6:168491649	NA	0.61	8.97	0.44	2.24e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	5.99	0.31	5.39e-9	Diabetic retinopathy;
CRC	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg24046110	chr8:143859143	LYNX1	-0.38	-6.6	-0.34	1.65e-10	Urinary tract infection frequency;
CRC	cis	rs8010715	0.816	rs6573572	chr14:24599230	C/A	cg23112188	chr14:24563095	PCK2	-0.36	-7.22	-0.37	3.59e-12	IgG glycosylation;
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg24046110	chr8:143859143	LYNX1	0.47	8.18	0.41	6.22e-15	Urinary tract infection frequency;
CRC	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.2	-18.39	-0.71	1.85e-52	Blood pressure (smoking interaction);
CRC	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.58	7.59	0.39	3.32e-13	DNA methylation (variation);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18950002	chr17:79673969	MRPL12	0.48	6.64	0.34	1.29e-10	Survival in pancreatic cancer;
CRC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg11887960	chr12:57824829	NA	0.64	7.2	0.37	4.1e-12	Obesity-related traits;
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg15786705	chr6:28176104	NA	0.51	7.25	0.37	3.05e-12	Parkinson's disease;
CRC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.54	-7.12	-0.37	7.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.59	13.66	0.6	5.61e-34	Breast size;
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg19046167	chr17:80928561	B3GNTL1	0.49	6.83	0.35	4.14e-11	Glycated hemoglobin levels;
CRC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.65	-0.3	3.42e-8	Tonsillectomy;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg25164649	chr6:28176230	NA	0.66	8.12	0.41	9.72e-15	Parkinson's disease;
CRC	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-0.88	-8.1	-0.41	1.12e-14	Blood protein levels;
CRC	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.64	8.2	0.41	5.35e-15	Alzheimer's disease;
CRC	cis	rs11229555	0.609	rs12286421	chr11:58174898	A/G	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02825527	chr7:2087843	MAD1L1	-0.47	-5.71	-0.3	2.51e-8	Bipolar disorder;
CRC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg08027265	chr7:2291960	NA	-0.33	-5.74	-0.3	2.19e-8	Schizophrenia;
CRC	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.23	-0.56	1.28e-28	Coffee consumption (cups per day);
CRC	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg09654669	chr8:57350985	NA	-0.41	-5.71	-0.3	2.51e-8	Obesity-related traits;
CRC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-17.3	-0.69	3.68e-48	Coronary artery disease;
CRC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg06207120	chr15:45996521	NA	0.31	7.48	0.38	6.71e-13	Waist circumference;Weight;
CRC	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.79	-0.35	5.4e-11	Total cholesterol levels;
CRC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.85	-0.44	5.55e-17	Electroencephalogram traits;
CRC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg00383909	chr3:49044727	WDR6	0.47	5.89	0.31	9.55e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.65	8.51	0.42	6.25e-16	Uric acid levels;
CRC	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.58	-0.34	1.83e-10	Coronary artery disease;
CRC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.94	18.5	0.71	7.07e-53	Multiple system atrophy;
CRC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg04362960	chr10:104952993	NT5C2	-0.47	-6.22	-0.32	1.53e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.05	0.32	3.91e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs2013441	1.000	rs2526484	chr17:20103760	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.28	-0.33	1.05e-9	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.46	0.42	8.91e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.4	6.11	0.32	2.83e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	6.59	0.34	1.75e-10	Blood protein levels;
CRC	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.82	-0.35	4.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-7.92	-0.4	3.65e-14	Coronary artery disease;
CRC	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg24505687	chr6:33548425	BAK1	0.31	5.88	0.31	9.87e-9	Platelet count;
CRC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	16.63	0.68	1.69e-45	Platelet count;
CRC	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.66	10.67	0.51	5.22e-23	Corneal astigmatism;
CRC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02290350	chr8:58132656	NA	-0.42	-6.17	-0.32	2.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.37	-6.64	-0.34	1.33e-10	Reticulocyte fraction of red cells;
CRC	cis	rs1178968	0.818	rs2108235	chr7:72783383	A/G	cg25889504	chr7:72793014	NA	0.51	5.72	0.3	2.45e-8	Triglyceride levels;
CRC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.62	-9.75	-0.47	6.81e-20	Height;
CRC	trans	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg26043149	chr18:55253948	FECH	0.54	8.27	0.41	3.27e-15	Bone mineral density;
CRC	cis	rs597583	0.775	rs11216440	chr11:117406111	G/A	cg27161313	chr11:117392002	DSCAML1	-0.38	-5.75	-0.3	2.03e-8	Putamen volume;
CRC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.52	-9.52	-0.46	3.81e-19	Eye color traits;
CRC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.45	6.75	0.35	6.77e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.68	8.24	0.41	4.22e-15	Menarche (age at onset);
CRC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-9.39	-0.46	1.06e-18	Pancreatic cancer;
CRC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.11e-16	Alcohol dependence;
CRC	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.6	9.64	0.47	1.5700000000000001e-19	Anterior chamber depth;
CRC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06544989	chr22:39130855	UNC84B	0.45	7.28	0.37	2.46e-12	Menopause (age at onset);
CRC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	9.51	0.46	4.31e-19	Total body bone mineral density;
CRC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.7	-9.37	-0.46	1.18e-18	Bladder cancer;
CRC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.77	11.26	0.53	4.18e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg13628971	chr7:2884303	GNA12	0.4	5.93	0.31	7.59e-9	Height;
CRC	cis	rs4666002	0.957	rs1919128	chr2:27801759	A/G	cg27432699	chr2:27873401	GPN1	0.46	5.77	0.3	1.83e-8	Phospholipid levels (plasma);
CRC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.38	6.28	0.33	1.08e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg05874882	chr4:1763078	NA	-0.35	-6.36	-0.33	6.75e-10	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg09760422	chr2:128146352	NA	-0.36	-6.9	-0.36	2.6e-11	Protein C levels;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg07138452	chr17:17141020	FLCN	-0.43	-6.41	-0.33	4.92e-10	Birth weight;Height;
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg19223190	chr17:80058835	NA	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.82	0.31	1.44e-8	Eosinophil percentage of white cells;
CRC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg17321639	chr7:2759063	NA	-0.5	-6.39	-0.33	5.73e-10	Height;
CRC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg11212589	chr17:38028394	ZPBP2	0.35	6.25	0.33	1.24e-9	Asthma;
CRC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.47	0.42	8.2e-16	Homoarginine levels;
CRC	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.13	0.49	3.7e-21	Corneal astigmatism;
CRC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-5.71	-0.3	2.49e-8	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs8032158	1.000	rs28770330	chr15:56248743	T/G	cg02198044	chr15:56286336	NEDD4	-0.43	-6.26	-0.33	1.22e-9	Keloid;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.44	7.77	0.39	1.01e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.44	6.39	0.33	5.59e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	trans	rs4591358	0.689	rs2173773	chr2:196414425	T/G	cg12742475	chr15:75233485	NA	0.3	5.96	0.31	6.4e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
CRC	trans	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.48	6.26	0.33	1.23e-9	Blood metabolite levels;
CRC	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.41	6.2	0.32	1.69e-9	Red blood cell count;
CRC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.53	-7.49	-0.38	6.3e-13	Breast cancer;
CRC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.28	-0.46	2.28e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.44	5.92	0.31	7.96e-9	Aortic root size;
CRC	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.41	6.32	0.33	8.64e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.75	9.05	0.45	1.3e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg06470822	chr6:28175283	NA	0.85	11.24	0.53	5.08e-25	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00677986	chr12:80084523	PAWR	0.39	6.39	0.33	5.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg16476235	chr8:21771668	DOK2	0.33	5.65	0.3	3.49e-8	Lung cancer in ever smokers;
CRC	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.56	8.22	0.41	4.75e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs6564851	0.506	rs7204019	chr16:81253015	G/A	cg05274606	chr16:81253692	PKD1L2	-0.36	-5.94	-0.31	7.09e-9	Carotenoid and tocopherol levels;
CRC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.61	-9.82	-0.48	4.04e-20	Aortic root size;
CRC	trans	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg20935933	chr6:143382018	AIG1	-0.52	-6.89	-0.36	2.9100000000000002e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12030002	chr3:61237226	FHIT	0.43	6.43	0.33	4.54e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.53	6.65	0.34	1.25e-10	Bipolar disorder (body mass index interaction);
CRC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg16060761	chr17:80687452	NA	0.46	6.52	0.34	2.68e-10	Breast cancer;
CRC	trans	rs12699921	0.632	rs2691609	chr7:17881162	C/T	cg15753394	chr6:17282781	RBM24	-0.36	-6.09	-0.32	3.19e-9	Fibrinogen levels;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.67	7.14	0.37	5.91e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11212617	0.869	rs12801988	chr11:108357747	C/T	cg14761454	chr11:108092087	ATM;NPAT	-0.4	-5.81	-0.31	1.48e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.83	-0.35	4.04e-11	HDL cholesterol;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14089512	chr10:102106757	SCD	0.4	6.46	0.34	3.68e-10	Obesity-related traits;
CRC	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.82	10.66	0.51	5.69e-23	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg13198984	chr17:80129470	CCDC57	0.43	7.56	0.38	3.92e-13	Life satisfaction;
CRC	cis	rs7551222	0.749	rs11240761	chr1:204566700	C/A	cg07972458	chr1:204535000	NA	0.37	5.67	0.3	3.07e-8	Schizophrenia;
CRC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.56	-0.6	1.36e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20024234	chr21:43431083	ZNF295	0.46	6.73	0.35	7.41e-11	Anxiety disorder;
CRC	cis	rs4964805	0.594	rs10861096	chr12:104169356	C/T	cg02344784	chr12:104178138	NT5DC3	0.47	7.2	0.37	4.14e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg14711859	chr11:8959438	ASCL3	0.37	5.8	0.3	1.52e-8	Hemoglobin concentration;
CRC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg24300038	chr13:113819356	PROZ	-0.44	-5.68	-0.3	3.02e-8	Platelet distribution width;
CRC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18912574	chr7:65842487	NCRNA00174	-0.38	-6.46	-0.34	3.71e-10	Aortic root size;
CRC	trans	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg16950941	chr11:66035639	RAB1B	-0.61	-7.47	-0.38	7.24e-13	Electroencephalogram traits;
CRC	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg08632701	chr21:37451849	NA	-0.42	-6.53	-0.34	2.48e-10	Mitral valve prolapse;
CRC	trans	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.52	0.38	5.13e-13	Endometrial cancer;
CRC	cis	rs76993477	0.666	rs76487956	chr1:169717555	C/A	cg03211132	chr1:169703751	SELE	0.61	5.83	0.31	1.32e-8	Tonsillectomy;
CRC	cis	rs11212617	0.935	rs664143	chr11:108225661	C/T	cg01991180	chr11:108092276	ATM;NPAT	-0.43	-6.18	-0.32	1.89e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.89	0.51	8.54e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22433210	chr17:43662623	NA	-0.58	-7.05	-0.36	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10691036	chr19:49622443	C19orf73;PPFIA3	0.41	6.19	0.32	1.77e-9	Schizophrenia;
CRC	cis	rs1797885	0.714	rs299661	chr3:12554069	A/G	cg07775309	chr3:12595852	NA	0.32	5.78	0.3	1.75e-8	Immature fraction of reticulocytes;
CRC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg08265495	chr8:11212668	TDH	0.34	6.06	0.32	3.67e-9	Retinal vascular caliber;
CRC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.49	7.28	0.37	2.5e-12	Menarche (age at onset);
CRC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg24977027	chr2:88469347	THNSL2	0.64	7.72	0.39	1.37e-13	Plasma clusterin levels;
CRC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.9	0.4	4.23e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.46	6.26	0.33	1.22e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs6973256	0.568	rs7800126	chr7:133521356	A/C	cg03336402	chr7:133662267	EXOC4	-0.41	-5.84	-0.31	1.27e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.53	7.97	0.4	2.61e-14	Corneal astigmatism;
CRC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.46	6.52	0.34	2.6e-10	Cognitive ability;
CRC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg19257562	chr1:2043853	PRKCZ	0.4	6.56	0.34	2.09e-10	Height;
CRC	trans	rs4276421	0.806	rs6860200	chr5:45440343	G/T	cg04793272	chr11:119020941	ABCG4	-0.37	-6.11	-0.32	2.82e-9	P wave duration;
CRC	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.61	-9.2	-0.45	4.32e-18	Dementia with Lewy bodies;
CRC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg12458913	chr13:53173898	NA	0.76	13.84	0.61	1.2e-34	Lewy body disease;
CRC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.6	-8.6	-0.43	3.31e-16	Breast cancer;
CRC	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg23996704	chr18:44553084	KATNAL2	-0.29	-5.66	-0.3	3.29e-8	Educational attainment;
CRC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.67	10.5	0.5	2.03e-22	Mean corpuscular hemoglobin;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.1	-0.32	3.06e-9	Obesity-related traits;
CRC	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.63	8.19	0.41	5.88e-15	Hip circumference adjusted for BMI;
CRC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs7632954	0.596	rs9858072	chr3:8508515	T/C	cg03495237	chr3:8533978	NA	0.33	6.2	0.32	1.74e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.69	0.35	9.65e-11	Subjective well-being;
CRC	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.71	8.03	0.4	1.71e-14	Major depressive disorder;
CRC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.55	-8.3	-0.42	2.75e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.61	10.06	0.48	6.42e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	5.81	0.3	1.49e-8	Renal function-related traits (BUN);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24371536	chr6:79943342	HMGN3	0.5	7.18	0.37	4.7e-12	Response to antipsychotic treatment;
CRC	cis	rs10484885	0.514	rs10944450	chr6:90228498	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.26	-0.33	1.17e-9	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.47	7.17	0.37	5.06e-12	Corneal astigmatism;
CRC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg23996704	chr18:44553084	KATNAL2	0.37	7.42	0.38	1.03e-12	Personality dimensions;
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg14646075	chr2:228736089	WDR69	-0.45	-6.14	-0.32	2.43e-9	Blood pressure;
CRC	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.51	13.4	0.59	5.67e-33	Granulocyte percentage of myeloid white cells;
CRC	cis	rs995000	0.931	rs11207984	chr1:63013396	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.82	-0.35	4.3e-11	Triglyceride levels;
CRC	cis	rs2811415	0.597	rs6808774	chr3:127759090	G/A	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs539096	0.624	rs499257	chr1:44078384	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-6.62	-0.34	1.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.62	-11.53	-0.54	4.55e-26	Educational attainment;
CRC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	7.77	0.39	1.03e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.62	8.35	0.42	1.98e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	9.77	0.47	5.81e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg00343986	chr7:65444356	GUSB	0.58	8.79	0.44	8.29e-17	Aortic root size;
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.44	-0.33	4.13e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.5	-6.65	-0.34	1.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-7.08	-0.36	8.8e-12	Longevity;Endometriosis;
CRC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg10589385	chr1:150898437	SETDB1	-0.27	-5.8	-0.3	1.56e-8	Melanoma;
CRC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.85	13.38	0.59	6.93e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.38	-11.56	-0.54	3.59e-26	Psoriasis vulgaris;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00000769	chr12:124086477	DDX55	0.39	6.1	0.32	2.92e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.3	0.42	2.64e-15	Intraocular pressure;
CRC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg17948913	chr5:572064	NA	0.56	6.25	0.33	1.28e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.38	6.05	0.32	3.86e-9	Major depressive disorder;
CRC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg21770322	chr7:97807741	LMTK2	0.52	8.5	0.42	6.78e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.39	-7.0	-0.36	1.45e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9463078	0.691	rs1852986	chr6:45329489	C/G	cg25276700	chr6:44698697	NA	-0.23	-5.66	-0.3	3.26e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg02569458	chr12:86230093	RASSF9	0.4	6.72	0.35	8.2e-11	Major depressive disorder;
CRC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg25459000	chr22:39777742	SYNGR1	-0.34	-5.96	-0.31	6.32e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05300939	chr11:44587523	CD82	0.44	6.41	0.33	5.1e-10	Response to antipsychotic treatment;
CRC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.37	-0.5	5.4e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-14.47	-0.62	4.42e-37	Height;
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.39	-0.53	1.41e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	0.54	9.1	0.45	8.91e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg20387954	chr3:183756860	HTR3D	0.45	7.69	0.39	1.72e-13	Anterior chamber depth;
CRC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.98	14.11	0.61	1.13e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.59	-7.5	-0.38	5.91e-13	Dilated cardiomyopathy;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.48	5.92	0.31	7.97e-9	Vitiligo;
CRC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.55	7.87	0.4	5.09e-14	Tuberculosis;
CRC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs12144309	0.554	rs2476599	chr1:114363459	G/A	cg03325407	chr1:114423726	BCL2L15	0.35	6.47	0.34	3.48e-10	Coronary artery disease;
CRC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg06970220	chr1:156163860	SLC25A44	0.47	6.73	0.35	7.73e-11	Testicular germ cell tumor;
CRC	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.49	8.3	0.42	2.7e-15	Testicular germ cell tumor;
CRC	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.63	10.61	0.5	8.04e-23	Metabolite levels;
CRC	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.52	6.32	0.33	8.39e-10	QRS duration;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg02683197	chr6:28174875	NA	0.64	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs4838594	0.590	rs1867579	chr10:49671394	A/G	cg17291251	chr10:49678358	ARHGAP22	-0.38	-5.89	-0.31	9.33e-9	Daytime sleep phenotypes;
CRC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg22333259	chr1:19394757	NA	0.37	6.03	0.32	4.31e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs427941	0.585	rs201511	chr7:101767653	A/G	cg06246474	chr7:101738831	CUX1	0.45	6.92	0.36	2.41e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.33	0.46	1.61e-18	Heart rate;
CRC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg25972092	chr12:117363249	FBXW8	0.51	6.03	0.32	4.39e-9	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg15534755	chr11:117069859	TAGLN	-0.34	-6.19	-0.32	1.75e-9	Blood protein levels;
CRC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.66	11.25	0.53	4.47e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.66	11.42	0.53	1.1e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17818399	0.788	rs13013245	chr2:46806086	T/C	cg21681030	chr2:46777652	RHOQ	0.42	5.97	0.31	6.07e-9	Height;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg26304593	chr6:42947056	PEX6	-0.46	-6.76	-0.35	6.47e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.54	-8.53	-0.43	5.29e-16	Aortic root size;
CRC	trans	rs12699921	0.632	rs2723545	chr7:17859691	C/A	cg02066331	chr6:17282778	RBM24	-0.35	-6.03	-0.32	4.3e-9	Fibrinogen levels;
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.94	-0.58	2.96e-31	Alzheimer's disease;
CRC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.1	-0.36	7.74e-12	Self-reported allergy;
CRC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.53	8.55	0.43	4.78e-16	Hemoglobin concentration;Hematocrit;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg09127314	chr1:152161683	NA	0.52	6.53	0.34	2.53e-10	Atopic dermatitis;
CRC	cis	rs12249377	0.519	rs11599902	chr10:92598823	A/G	cg14313238	chr10:92632228	RPP30	0.46	6.44	0.33	4.28e-10	White matter microstructure (global fractional anisotropy);
CRC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.63	-10.53	-0.5	1.49e-22	Anterior chamber depth;
CRC	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.85	-12.32	-0.56	6.07e-29	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02010524	chr4:57333365	SRP72	0.55	7.81	0.4	7.58e-14	Response to antipsychotic treatment;
CRC	trans	rs7144011	0.654	rs4903847	chr14:79854832	A/G	cg27114086	chr1:155658701	YY1AP1;DAP3	-0.45	-6.64	-0.34	1.28e-10	Waist circumference;Hip circumference;
CRC	cis	rs6076065	0.723	rs2424541	chr20:23386776	T/C	cg11657817	chr20:23433608	CST11	0.44	6.51	0.34	2.89e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs1223397	0.651	rs2496142	chr6:13311794	C/T	cg07912922	chr6:13274314	PHACTR1	-0.39	-6.05	-0.32	3.96e-9	Blood pressure;
CRC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	7.14	0.37	5.88e-12	Eye color traits;
CRC	trans	rs1864585	0.520	rs17776946	chr8:10682674	A/C	cg26278703	chr11:58910052	FAM111A	0.56	7.05	0.36	1.07e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg14458575	chr2:238380390	NA	0.51	9.03	0.45	1.46e-17	Prostate cancer;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs888194	0.649	rs10774697	chr12:109875981	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.71	-0.3	2.52e-8	Neuroticism;
CRC	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg25686905	chr3:183603175	PARL	-0.44	-6.23	-0.32	1.44e-9	Menopause (age at onset);
CRC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-8.31	-0.42	2.48e-15	Electroencephalogram traits;
CRC	cis	rs10128264	1.000	rs2802364	chr10:80960486	G/C	cg18737081	chr10:80999807	ZMIZ1	-0.33	-5.86	-0.31	1.12e-8	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.55	-8.09	-0.41	1.14e-14	Dental caries;
CRC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.46	0.38	7.83e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	10.22	0.49	1.81e-21	Coronary artery disease;
CRC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.5	7.5	0.38	5.94e-13	Corneal astigmatism;
CRC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg13385521	chr17:29058706	SUZ12P	0.63	7.45	0.38	8.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.73	12.15	0.56	2.67e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.75	0.47	6.97e-20	Alzheimer's disease;
CRC	cis	rs863345	0.967	rs7534319	chr1:158532295	G/C	cg12129480	chr1:158549410	OR10X1	-0.26	-5.66	-0.3	3.32e-8	Pneumococcal bacteremia;
CRC	trans	rs564309	0.681	rs2230656	chr1:228612838	G/T	cg24066601	chr6:26271455	HIST1H3G	-0.57	-6.47	-0.34	3.47e-10	Hip circumference (psychosocial stress interaction);
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.34	0.38	1.66e-12	Aortic root size;
CRC	trans	rs17126268	0.502	rs1856774	chr1:102876232	T/C	cg18468354	chr14:36993517	NA	0.39	6.14	0.32	2.37e-9	Glomerular filtration rate;
CRC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.83	12.25	0.56	1.11e-28	Body mass index;
CRC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.45	-5.86	-0.31	1.12e-8	Diabetic retinopathy;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg03623178	chr6:28175578	NA	0.67	10.21	0.49	1.89e-21	Cardiac Troponin-T levels;
CRC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg15654264	chr1:150340011	RPRD2	0.42	6.29	0.33	1.04e-9	Migraine;
CRC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.09	-0.32	3.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg12365402	chr11:9010492	NRIP3	-0.57	-10.29	-0.49	1.01e-21	Hemoglobin concentration;
CRC	cis	rs9462027	0.606	rs1201874	chr6:34549810	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.94	-0.31	7.44e-9	Systemic lupus erythematosus;
CRC	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.99	18.25	0.71	7e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.72	0.39	1.44e-13	Motion sickness;
CRC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.78	11.45	0.53	9.28e-26	Neutrophil percentage of white cells;
CRC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.31	0.33	8.84e-10	Diabetic retinopathy;
CRC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.36	-6.02	-0.31	4.7e-9	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.17	-12.86	-0.58	5.92e-31	Diabetic kidney disease;
CRC	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg10724054	chr17:3904396	NA	-0.45	-7.27	-0.37	2.7e-12	Type 2 diabetes;
CRC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-7.1	-0.36	7.51e-12	Schizophrenia;
CRC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.52	7.4	0.38	1.17e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.66	9.62	0.47	1.76e-19	Menopause (age at onset);
CRC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg19824325	chr16:58548873	SETD6	0.9	6.09	0.32	3.09e-9	Schizophrenia;
CRC	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.63	9.01	0.44	1.68e-17	Body mass index;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.47	0.38	7.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1044826	0.692	rs188421	chr3:139234066	A/C	cg00490450	chr3:139108681	COPB2	-0.43	-6.49	-0.34	3.11e-10	Obesity-related traits;
CRC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.25	0.59	2.02e-32	Platelet count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17027945	chr15:74284732	STOML1	0.53	6.92	0.36	2.35e-11	Thyroid stimulating hormone;
CRC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg03929089	chr4:120376271	NA	0.68	6.7	0.35	8.92e-11	Intraocular pressure;
CRC	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg27205649	chr11:78285834	NARS2	0.47	5.79	0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs2882667	0.931	rs10075893	chr5:138355871	A/G	cg04439458	chr5:138467593	SIL1	0.32	5.75	0.3	1.99e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.63	5.67	0.3	3.2e-8	Diabetic kidney disease;
CRC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-7.87	-0.4	5.02e-14	Subjective well-being;
CRC	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.5	-8.31	-0.42	2.61e-15	Bipolar disorder;
CRC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.33	0.53	2.35e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-13.83	-0.61	1.35e-34	Colorectal cancer;
CRC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.84	16.62	0.68	1.87e-45	White blood cell count;
CRC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.67	5.7	0.3	2.61e-8	Putamen volume;
CRC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg12463550	chr7:65579703	CRCP	0.71	6.53	0.34	2.52e-10	Diabetic kidney disease;
CRC	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	5.78	0.3	1.72e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs1031925	0.687	rs6778196	chr3:51770429	C/T	cg21573611	chr7:89975649	GTPBP10	0.65	6.24	0.33	1.32e-9	Melanoma;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg22638593	chr5:131593259	PDLIM4	0.52	9.08	0.45	1e-17	Acylcarnitine levels;
CRC	trans	rs1549309	0.767	rs9313387	chr5:167173269	C/T	cg24963307	chr14:21979594	METTL3	0.51	6.01	0.31	4.82e-9	Dietary macronutrient intake;
CRC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.7	-11.14	-0.52	1.18e-24	Height;
CRC	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.29	-0.37	2.39e-12	Metabolite levels (Pyroglutamine);
CRC	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg16898833	chr6:26189333	HIST1H4D	0.72	6.45	0.34	4.08e-10	Depression;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.72	11.62	0.54	2.11e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.75	11.44	0.53	9.61e-26	Immature fraction of reticulocytes;
CRC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.43	6.2	0.32	1.66e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg26893134	chr6:116381904	FRK	0.27	6.46	0.34	3.67e-10	Total cholesterol levels;
CRC	trans	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg10756647	chr7:56101905	PSPH	0.73	7.98	0.4	2.44e-14	Diabetic kidney disease;
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.55	0.54	3.91e-26	Prudent dietary pattern;
CRC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg03013999	chr17:37608204	MED1	0.43	6.36	0.33	6.78e-10	Urinary metabolites;
CRC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.19	-16.12	-0.66	1.68e-43	Breast cancer;
CRC	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg04110750	chr16:69646130	NFAT5	-0.52	-7.23	-0.37	3.48e-12	IgE levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03270376	chr2:219536588	RNF25;STK36	-0.57	-6.94	-0.36	2.1e-11	Diisocyanate-induced asthma;
CRC	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg09363841	chr1:37513479	NA	-0.48	-8.06	-0.41	1.42e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-0.9	-9.15	-0.45	5.93e-18	Schizophrenia;
CRC	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.7	7.63	0.39	2.58e-13	Breast cancer;
CRC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.44	-0.42	1e-15	Biliary atresia;
CRC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg20573242	chr4:122745356	CCNA2	0.42	6.31	0.33	8.84e-10	Type 2 diabetes;
CRC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.43	-6.8	-0.35	4.81e-11	Urate levels in obese individuals;
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	19.51	0.73	7.46e-57	Prudent dietary pattern;
CRC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.35	-0.5	6.5e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.6	9.76	0.47	6.11e-20	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.67	-8.24	-0.41	4.18e-15	Coronary artery disease;
CRC	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.52	9.73	0.47	8.05e-20	Educational attainment (years of education);
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.47	5.61	0.3	4.26e-8	Depression;
CRC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.23	11.33	0.53	2.5e-25	Alzheimer's disease (late onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06496078	chr12:107350075	C12orf23	0.48	6.31	0.33	9.11e-10	Thyroid stimulating hormone;
CRC	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.31	-5.69	-0.3	2.86e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08429159	chr1:6663269	KLHL21	0.47	6.58	0.34	1.88e-10	Response to antipsychotic treatment;
CRC	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs1223397	0.651	rs202016	chr6:13301043	G/A	cg07912922	chr6:13274314	PHACTR1	0.37	5.71	0.3	2.53e-8	Blood pressure;
CRC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.11	-0.41	1.01e-14	Schizophrenia;
CRC	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.68	8.9	0.44	3.88e-17	Breast cancer;
CRC	trans	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg26043149	chr18:55253948	FECH	-0.56	-8.7	-0.43	1.57e-16	Bone mineral density;
CRC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.96	0.36	1.84e-11	Mean platelet volume;
CRC	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07165851	chr6:158734300	TULP4	0.64	7.73	0.39	1.32e-13	Height;
CRC	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg16482183	chr6:26056742	HIST1H1C	0.78	9.76	0.47	6.31e-20	Height;
CRC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg11245181	chr6:149772854	ZC3H12D	-0.53	-8.77	-0.44	9.48e-17	Dupuytren's disease;
CRC	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg07424746	chr4:185654737	MLF1IP	-0.58	-5.71	-0.3	2.56e-8	Blood protein levels;
CRC	cis	rs2108622	0.727	rs12611308	chr19:15978586	C/T	cg13772218	chr19:15982569	NA	0.48	6.72	0.35	8.16e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.03	-10.3	-0.49	9.36e-22	Body mass index;
CRC	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.42	5.83	0.31	1.31e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs57590327	0.527	rs11917558	chr3:81610805	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-6.78	-0.35	5.42e-11	Extraversion;
CRC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.91	0.48	1.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.98	-0.31	5.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.65	-11.11	-0.52	1.43e-24	Brugada syndrome;
CRC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	8.81	0.44	7.28e-17	Menarche (age at onset);
CRC	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg08645402	chr16:4508243	NA	0.59	9.74	0.47	7.57e-20	Schizophrenia;
CRC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.02	-0.32	4.57e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	0.77	7.83	0.4	6.98e-14	Pediatric areal bone mineral density (radius);
CRC	cis	rs3018066	0.640	rs4337798	chr4:107029008	G/A	cg01869342	chr4:106983673	TBCK	0.46	6.01	0.31	4.84e-9	Cancer;
CRC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg24250549	chr1:154909240	PMVK	0.61	10.08	0.49	5.25e-21	Prostate cancer;
CRC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg08999081	chr20:33150536	PIGU	0.44	5.74	0.3	2.18e-8	Protein C levels;
CRC	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg16512390	chr1:228756714	NA	0.63	6.59	0.34	1.71e-10	Chronic lymphocytic leukemia;
CRC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.09	-0.32	3.07e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.94	-0.44	2.94e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg00343986	chr7:65444356	GUSB	0.45	6.26	0.33	1.19e-9	Aortic root size;
CRC	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.49	9.34	0.46	1.49e-18	Educational attainment (years of education);
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg12273811	chr6:28175739	NA	0.54	7.72	0.39	1.43e-13	Parkinson's disease;
CRC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.57	-6.99	-0.36	1.58e-11	Platelet distribution width;
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18758796	chr5:131593413	PDLIM4	0.44	8.06	0.41	1.39e-14	Breast cancer;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg10272801	chr16:14013773	ERCC4	-0.69	-6.06	-0.32	3.8e-9	Cognitive function;
CRC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.3	3.66e-8	Hemoglobin concentration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26671183	chr1:207226604	PFKFB2	0.39	6.44	0.33	4.33e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg10729496	chr3:10149963	C3orf24	0.45	6.13	0.32	2.57e-9	Alzheimer's disease;
CRC	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.44	6.37	0.33	6.21e-10	Height;
CRC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg03160526	chr17:80928410	B3GNTL1	0.5	8.3	0.42	2.64e-15	Breast cancer;
CRC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Bladder cancer;
CRC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-9.74	-0.47	7.04e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-0.5	-6.23	-0.33	1.39e-9	Diastolic blood pressure;
CRC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg00677455	chr12:58241039	CTDSP2	-0.59	-8.88	-0.44	4.48e-17	Multiple sclerosis;
CRC	cis	rs7539542	0.556	rs6662413	chr1:202888496	C/T	cg19681188	chr1:202830198	LOC148709	-0.43	-6.17	-0.32	2.03e-9	Mean platelet volume;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.35	6.11	0.32	2.76e-9	Erythrocyte sedimentation rate;
CRC	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.82	-0.4	7.41e-14	QT interval;
CRC	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.45	5.78	0.3	1.7e-8	DNA methylation (variation);
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg15511327	chr8:143859410	LYNX1	-0.44	-7.93	-0.4	3.45e-14	Urinary tract infection frequency;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.64	-9.85	-0.48	3.1e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg06219103	chr11:63990595	FERMT3	-0.44	-7.01	-0.36	1.39e-11	Platelet count;
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.29	0.42	2.83e-15	Life satisfaction;
CRC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg04414720	chr1:150670196	GOLPH3L	0.4	5.71	0.3	2.46e-8	Melanoma;
CRC	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-16.46	-0.67	7.51e-45	Electrocardiographic conduction measures;
CRC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.54	8.54	0.43	5.04e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.52	-6.97	-0.36	1.74e-11	Colorectal cancer;
CRC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg20243544	chr17:37824526	PNMT	0.41	5.63	0.3	3.83e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.51	-6.7	-0.35	8.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs59104589	0.617	rs56390510	chr2:242274489	G/C	cg19488206	chr2:242435732	STK25	0.47	6.75	0.35	6.67e-11	Fibrinogen levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19472759	chr11:69456837	CCND1	0.37	6.02	0.31	4.56e-9	Obesity-related traits;
CRC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg11189052	chr15:85197271	WDR73	0.65	9.36	0.46	1.25e-18	Schizophrenia;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg20933634	chr6:27740509	NA	0.57	7.33	0.37	1.76e-12	Parkinson's disease;
CRC	cis	rs2252790	0.764	rs2027851	chr6:116681682	C/G	cg18764771	chr6:116381957	FRK	-0.22	-6.03	-0.32	4.34e-9	Fast beta electroencephalogram;
CRC	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg15654264	chr1:150340011	RPRD2	0.39	5.61	0.3	4.35e-8	Migraine;
CRC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg16482183	chr6:26056742	HIST1H1C	0.82	10.12	0.49	3.96e-21	Iron status biomarkers;
CRC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.81	-12.91	-0.58	4.11e-31	Cognitive function;
CRC	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg13456138	chr10:90753195	FAS	0.41	5.73	0.3	2.29e-8	Chronic lymphocytic leukemia;
CRC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg14593290	chr7:50529359	DDC	-0.48	-6.82	-0.35	4.39e-11	Systemic sclerosis;
CRC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg16102536	chr7:156981717	UBE3C	-0.38	-6.49	-0.34	3.1e-10	Body mass index;
CRC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.0	-0.31	5.15e-9	Menopause (age at onset);
CRC	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg20636351	chr8:55087400	NA	-0.34	-6.07	-0.32	3.51e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs972578	0.806	rs4822212	chr22:43267873	G/T	cg01576275	chr22:43409880	NA	-0.41	-6.42	-0.33	4.73e-10	Mean platelet volume;
CRC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg06238570	chr21:40685208	BRWD1	0.76	10.62	0.51	7.3e-23	Cognitive function;
CRC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.42	6.63	0.34	1.36e-10	Blood metabolite levels;
CRC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.57e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.53	7.37	0.38	1.35e-12	Testicular germ cell tumor;
CRC	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg12315302	chr6:26189340	HIST1H4D	0.99	6.94	0.36	2.04e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.93	17.35	0.69	2.49e-48	Height;
CRC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.85	-0.4	5.97e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg14541582	chr5:601475	NA	-0.34	-6.4	-0.33	5.46e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.94e-9	Schizophrenia;
CRC	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg13385794	chr1:248469461	NA	0.4	7.1	0.36	7.54e-12	Common traits (Other);
CRC	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.69	10.35	0.5	6.61e-22	Schizophrenia;
CRC	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg13491945	chr12:107078410	RFX4	0.33	5.7	0.3	2.73e-8	Heart rate;
CRC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.38	5.75	0.3	2e-8	Mean corpuscular volume;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg01470323	chr11:66139715	SLC29A2	0.49	6.45	0.34	3.93e-10	Hip circumference;
CRC	trans	rs11581859	0.950	rs7529505	chr1:99362556	C/T	cg12183875	chr3:169587454	LRRC31	0.25	5.99	0.31	5.39e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.51	0.34	2.88e-10	Tonsillectomy;
CRC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.56	-7.19	-0.37	4.3e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.66	-9.47	-0.46	5.59e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg18016565	chr1:150552671	MCL1	-0.46	-7.06	-0.36	1.01e-11	Tonsillectomy;
CRC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-10.75	-0.51	2.65e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.49	7.09	0.36	8.44e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7558233	0.614	rs6544858	chr2:23676071	C/T	cg00747342	chr2:23700632	KLHL29	-0.55	-5.7	-0.3	2.67e-8	Cannabis use (initiation);
CRC	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.68	10.37	0.5	5.68e-22	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.66	10.35	0.5	6.18e-22	Personality dimensions;
CRC	cis	rs2227564	0.672	rs10824042	chr10:75645628	C/T	cg00564723	chr10:75632066	CAMK2G	-0.34	-7.77	-0.39	9.98e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.21	0.32	1.64e-9	Hemoglobin concentration;
CRC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.11	-0.32	2.75e-9	Aortic root size;
CRC	trans	rs9341835	0.681	rs9352960	chr6:64150426	C/G	cg13657004	chr13:50234944	EBPL	-0.36	-6.08	-0.32	3.38e-9	Schizophrenia;
CRC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.59	9.88	0.48	2.43e-20	Calcium levels;
CRC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.19	0.49	2.27e-21	Platelet count;
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.53	6.64	0.34	1.27e-10	Longevity;
CRC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg18867708	chr6:26865862	GUSBL1	0.37	5.67	0.3	3.09e-8	Schizophrenia;
CRC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-12.64	-0.57	4.01e-30	Gut microbiome composition (summer);
CRC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg22676075	chr6:135203613	NA	0.41	6.39	0.33	5.63e-10	Red blood cell count;
CRC	cis	rs9783347	1.000	rs10734259	chr11:18314865	A/G	cg15585147	chr11:18324498	HPS5	0.43	5.98	0.31	5.75e-9	Pancreatic cancer;
CRC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg14673194	chr17:80132900	CCDC57	-0.5	-6.48	-0.34	3.44e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12580194	0.593	rs7489047	chr12:55759851	A/G	cg23425280	chr12:56401806	NA	0.48	5.8	0.3	1.55e-8	Cancer;
CRC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.63	-10.38	-0.5	5e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.6	9.62	0.47	1.8e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg18135206	chr14:102964638	TECPR2	0.49	6.06	0.32	3.77e-9	Plateletcrit;
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg08888203	chr3:10149979	C3orf24	0.67	9.36	0.46	1.25e-18	Alzheimer's disease;
CRC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.26	-0.33	1.24e-9	Menopause (age at onset);
CRC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg19438565	chr8:143695827	ARC	-0.45	-6.63	-0.34	1.35e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11212617	0.967	rs227072	chr11:108212093	A/C	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.55	0.34	2.19e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg02390115	chr1:21767211	NBPF3	0.55	8.49	0.42	7.28e-16	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs62408225	1.000	rs2021716	chr6:90941289	C/T	cg06866423	chr6:90926672	BACH2	0.53	8.6	0.43	3.3e-16	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21153962	chr11:57102758	SSRP1	0.4	6.13	0.32	2.55e-9	Myopia (pathological);
CRC	cis	rs847649	0.692	rs10257317	chr7:102447056	T/C	cg18108683	chr7:102477205	FBXL13	-0.67	-11.29	-0.53	3.37e-25	Morning vs. evening chronotype;
CRC	trans	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.53	-8.19	-0.41	5.93e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg02033258	chr5:131593261	PDLIM4	0.46	8.64	0.43	2.54e-16	Acylcarnitine levels;
CRC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.13	-0.52	1.21e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.76	10.45	0.5	3.02e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs6504622	0.537	rs2920397	chr17:44997329	G/A	cg16759221	chr17:45003025	GOSR2	-0.65	-10.51	-0.5	1.84e-22	Orofacial clefts;
CRC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg09876464	chr15:85330779	ZNF592	0.45	7.61	0.39	2.88e-13	P wave terminal force;
CRC	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg07972458	chr1:204535000	NA	-0.36	-5.7	-0.3	2.73e-8	Schizophrenia;
CRC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	12.05	0.55	6.14e-28	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.38	5.81	0.3	1.51e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9649465	0.807	rs11770249	chr7:123286412	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-6.15	-0.32	2.21e-9	Migraine;
CRC	cis	rs6893807	0.778	rs13162708	chr5:87943345	C/T	cg09002922	chr5:87956389	LOC645323	-0.44	-5.89	-0.31	9.53e-9	Body mass index;
CRC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.71	0.39	1.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs995000	0.931	rs1167996	chr1:62927797	T/G	cg19896129	chr1:63156450	NA	-0.44	-6.73	-0.35	7.48e-11	Triglyceride levels;
CRC	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg08501292	chr6:25962987	TRIM38	0.98	9.39	0.46	1.06e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24308560	chr3:49941425	MST1R	0.46	7.27	0.37	2.6e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.35e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11645453	chr3:52864694	ITIH4	0.33	6.05	0.32	4.01e-9	Bipolar disorder;
CRC	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.37	-0.38	1.39e-12	Type 2 diabetes;
CRC	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg01426195	chr3:39028469	NA	-0.53	-8.58	-0.43	3.86e-16	Handedness;
CRC	cis	rs6662572	0.737	rs7532388	chr1:46472734	G/A	cg08644498	chr1:46502608	NA	0.46	7.38	0.38	1.29e-12	Blood protein levels;
CRC	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.44	7.49	0.38	6.24e-13	Common traits (Other);
CRC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.68	-13.44	-0.6	3.92e-33	Educational attainment;
CRC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.25	0.53	4.68e-25	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg00490450	chr3:139108681	COPB2	-0.48	-7.21	-0.37	3.84e-12	Obesity-related traits;
CRC	trans	rs10243593	0.673	rs10246466	chr7:40073341	C/T	cg13911576	chr9:84174038	NA	0.34	6.0	0.31	5.32e-9	Lymphocyte counts;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19209385	chr6:53659379	LRRC1	0.46	6.18	0.32	1.86e-9	Thyroid stimulating hormone;
CRC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15686437	chr5:130500979	HINT1	0.44	6.44	0.33	4.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	13.76	0.6	2.47e-34	Schizophrenia;
CRC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.54	-6.51	-0.34	2.88e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs3750082	0.889	rs12536400	chr7:32936390	C/G	cg05721444	chr7:32995514	FKBP9	0.49	7.45	0.38	8.12e-13	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.64	-0.7	1.77e-49	Height;
CRC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-5.66	-0.3	3.29e-8	Obesity-related traits;
CRC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.66	9.17	0.45	5.16e-18	Neuroblastoma;
CRC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-5.81	-0.3	1.51e-8	Height;
CRC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg03013999	chr17:37608204	MED1	-0.45	-6.74	-0.35	7.08e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.18	-0.41	6.14e-15	Bipolar disorder;
CRC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-0.91	-10.41	-0.5	4.13e-22	Breast cancer;
CRC	cis	rs10450586	0.863	rs7481148	chr11:27298139	A/T	cg10370305	chr11:27303972	NA	0.38	6.11	0.32	2.86e-9	Total body bone mineral density;
CRC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.49	-10.09	-0.49	4.83e-21	Prostate cancer;
CRC	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-5.9	-0.31	8.9e-9	Osteoarthritis;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg15786705	chr6:28176104	NA	0.64	8.69	0.43	1.7e-16	Parkinson's disease;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg02657892	chr1:62190594	TM2D1	0.52	6.14	0.32	2.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	7.13	0.37	6.53e-12	Schizophrenia;
CRC	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg15654264	chr1:150340011	RPRD2	0.37	5.81	0.31	1.46e-8	Migraine;
CRC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-7.71	-0.39	1.51e-13	Menarche (age at onset);
CRC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.93	-0.48	1.73e-20	Chronic sinus infection;
CRC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.57	-7.88	-0.4	4.98e-14	DNA methylation (variation);
CRC	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.39	6.43	0.33	4.52e-10	Sitting height ratio;
CRC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.67	0.63	7.94e-38	Chronic sinus infection;
CRC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg02569458	chr12:86230093	RASSF9	0.49	8.24	0.41	4.05e-15	Major depressive disorder;
CRC	cis	rs3751196	0.901	rs1057892	chr12:104157234	G/C	cg02344784	chr12:104178138	NT5DC3	0.69	6.79	0.35	5.37e-11	Sense of smell;
CRC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.57	-0.34	2.02e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.72	8.28	0.42	3.07e-15	Type 2 diabetes;
CRC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg09835421	chr16:68378352	PRMT7	0.78	8.02	0.4	1.83e-14	Schizophrenia;
CRC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	7.84	0.4	6.42e-14	Height;
CRC	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg18758796	chr5:131593413	PDLIM4	-0.33	-5.63	-0.3	3.93e-8	Blood metabolite levels;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg25243455	chr2:114033360	PAX8;LOC440839	-0.29	-6.9	-0.36	2.62e-11	Lymphocyte counts;
CRC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.49	-9.4	-0.46	9.41e-19	Subjective well-being;
CRC	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-0.81	-6.31	-0.33	8.98e-10	Depression;
CRC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.58	10.47	0.5	2.42e-22	Multiple system atrophy;
CRC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-8.92	-0.44	3.21e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.75	16.64	0.68	1.47e-45	Breast cancer;
CRC	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg07856975	chr6:36356162	ETV7	0.48	5.9	0.31	9.26e-9	Platelet distribution width;
CRC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	11.94	0.55	1.55e-27	Menarche (age at onset);
CRC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.79	12.82	0.58	8.47e-31	Cognitive function;
CRC	cis	rs6700896	0.931	rs10443261	chr1:66129121	T/C	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-7.5	-0.38	6.05e-13	Longevity;Endometriosis;
CRC	cis	rs12044355	0.858	rs12040259	chr1:231826253	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.26	0.33	1.23e-9	Alzheimer's disease;
CRC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.89e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.59	-7.41	-0.38	1.1e-12	Body mass index;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-5.81	-0.31	1.47e-8	Breast cancer;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg12193833	chr17:30244370	NA	-0.76	-8.95	-0.44	2.68e-17	Hip circumference adjusted for BMI;
CRC	cis	rs10221833	0.602	rs355885	chr2:165633939	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.83	0.31	1.35e-8	Response to statin therapy;
CRC	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.1	-0.32	2.91e-9	Blood pressure;
CRC	trans	rs12702919	0.677	rs12702918	chr7:9550525	C/A	cg15597424	chr4:24472487	NA	-0.39	-5.97	-0.31	6.29e-9	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs11212617	0.967	rs113995	chr11:108256837	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.47	0.34	3.47e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg01656853	chr19:49199172	FUT2	0.24	5.87	0.31	1.09e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	trans	rs12495832	0.778	rs6782620	chr3:147938355	T/G	cg10221266	chr7:153579447	NA	0.58	6.22	0.32	1.48e-9	Chin dimples;
CRC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-5.69	-0.3	2.84e-8	Reticulocyte count;
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.6	-0.39	3.15e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.56	-5.87	-0.31	1.07e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs59104589	0.617	rs12233133	chr2:242256812	G/C	cg19488206	chr2:242435732	STK25	0.45	6.26	0.33	1.22e-9	Fibrinogen levels;
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.34	-0.33	7.58e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.75	13.33	0.59	1.03e-32	Mean platelet volume;
CRC	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.77	12.05	0.55	6.12e-28	Body mass index;
CRC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.6	8.31	0.42	2.6e-15	Arsenic metabolism;
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.13	-0.49	3.7e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.9	17.42	0.69	1.29e-48	Bone mineral density;
CRC	cis	rs16867321	0.950	rs4667228	chr2:181498824	T/A	cg23363182	chr2:181467187	NA	-0.51	-6.65	-0.34	1.21e-10	Obesity;
CRC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.7	-0.39	1.65e-13	Psoriasis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07479707	chr1:11396967	NA	0.42	6.56	0.34	2.09e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg24046110	chr8:143859143	LYNX1	0.45	7.22	0.37	3.72e-12	Urinary tract infection frequency;
CRC	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.6	-8.61	-0.43	3.06e-16	Coronary artery disease;
CRC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.62	-8.41	-0.42	1.25e-15	Obesity-related traits;
CRC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-5.6	-0.3	4.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02421172	chr7:1938701	MAD1L1	0.42	5.63	0.3	3.92e-8	Bipolar disorder;
CRC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.67	10.95	0.52	5.51e-24	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06124975	chr6:107810578	SOBP	-0.56	-6.9	-0.36	2.74e-11	Diisocyanate-induced asthma;
CRC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg19318889	chr4:1322082	MAEA	0.4	5.71	0.3	2.57e-8	Obesity-related traits;
CRC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	-0.51	-8.29	-0.42	2.86e-15	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11825064	0.666	rs4245140	chr11:134484487	A/G	cg00033773	chr19:12779366	MORG1;C19orf56	0.43	6.05	0.32	3.88e-9	Seasonality;
CRC	cis	rs6585424	0.850	rs61860036	chr10:81934859	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-9.31	-0.46	1.92e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10982256	0.811	rs10759713	chr9:117254214	G/A	cg13636371	chr9:117264095	DFNB31	0.41	7.83	0.4	6.88e-14	Bipolar disorder;
CRC	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21659725	chr3:3221576	CRBN	0.63	7.06	0.36	1.01e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6076065	0.676	rs6083084	chr20:23335582	A/G	cg11657817	chr20:23433608	CST11	-0.42	-6.3	-0.33	9.62e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.52	0.34	2.6200000000000003e-10	Parkinson's disease;
CRC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg08200582	chr11:442649	ANO9	-0.71	-7.44	-0.38	8.72e-13	Body mass index;
CRC	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.51	-7.97	-0.4	2.6e-14	Coronary artery disease;
CRC	cis	rs7731657	0.537	rs72801791	chr5:130374799	T/C	cg08523029	chr5:130500466	HINT1	-0.45	-5.96	-0.31	6.51e-9	Fasting plasma glucose;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24490039	chr12:120967180	COQ5	0.43	5.97	0.31	6.02e-9	Response to antipsychotic treatment;
CRC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.72	11.05	0.52	2.45e-24	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.5	-0.42	6.75e-16	Endometrial cancer;
CRC	trans	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.64	10.65	0.51	5.82e-23	Brugada syndrome;
CRC	cis	rs6973256	0.897	rs9656422	chr7:133324665	C/T	cg10665199	chr7:133106180	EXOC4	-0.37	-5.78	-0.3	1.7e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.37	-6.01	-0.31	4.79e-9	Diastolic blood pressure;
CRC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg21770322	chr7:97807741	LMTK2	0.87	19.47	0.73	1.03e-56	Breast cancer;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg15786705	chr6:28176104	NA	0.76	9.63	0.47	1.68e-19	Depression;
CRC	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg14458575	chr2:238380390	NA	0.41	5.8	0.3	1.53e-8	Prostate cancer;
CRC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.53	8.75	0.43	1.1e-16	Menarche (age at onset);
CRC	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.56	9.67	0.47	1.25e-19	Common traits (Other);
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.58	-0.34	1.81e-10	Bipolar disorder;
CRC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Corneal astigmatism;
CRC	cis	rs9584850	0.834	rs3803253	chr13:99117149	G/A	cg07423050	chr13:99094983	FARP1	0.43	6.0	0.31	5.22e-9	Neuroticism;
CRC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.52	0.46	3.91e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.68	10.3	0.49	9.17e-22	Corneal astigmatism;
CRC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	17.33	0.69	2.96e-48	Platelet count;
CRC	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.51	-7.31	-0.37	1.98e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.53	-0.71	5.39e-53	Schizophrenia;
CRC	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.66	-8.99	-0.44	1.99e-17	Blood trace element (Cu levels);
CRC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.98	15.66	0.65	1.12e-41	Primary sclerosing cholangitis;
CRC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.76	-13.09	-0.59	8.7e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.07	0.45	1.11e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.32	5.94	0.31	7.28e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg04969067	chr8:143858791	LYNX1	0.44	7.54	0.38	4.73e-13	Urinary tract infection frequency;
CRC	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg02158880	chr13:53174818	NA	0.39	5.6	0.3	4.53e-8	Lewy body disease;
CRC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs1712517	0.838	rs1891293	chr10:105001797	C/T	cg05636881	chr10:105038444	INA	-0.48	-8.32	-0.42	2.29e-15	Migraine;
CRC	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg12870014	chr12:110450643	ANKRD13A	0.81	9.1	0.45	8.98e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7781557	1.000	rs10487281	chr7:102477581	G/C	cg18108683	chr7:102477205	FBXL13	-0.55	-7.01	-0.36	1.39e-11	Colorectal adenoma (advanced);
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.74	-0.51	2.95e-23	Bipolar disorder;
CRC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.03	12.95	0.58	2.89e-31	Vitiligo;
CRC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.32	5.6	0.3	4.5e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.94	0.61	4.9e-35	Alzheimer's disease;
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg16606324	chr3:10149918	C3orf24	0.61	7.95	0.4	2.97e-14	Alzheimer's disease;
CRC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-8.01	-0.4	2.04e-14	Dilated cardiomyopathy;
CRC	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg12183467	chr14:104352244	NA	-0.5	-6.04	-0.32	4.28e-9	Bipolar disorder;
CRC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg18478394	chr8:109455254	TTC35	0.38	5.82	0.31	1.43e-8	Dupuytren's disease;
CRC	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.58e-15	Type 2 diabetes;
CRC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.6	-8.31	-0.42	2.59e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg00074818	chr8:8560427	CLDN23	0.4	7.24	0.37	3.13e-12	Obesity-related traits;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17737141	chr1:173793901	CENPL;DARS2	0.47	6.16	0.32	2.14e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.5	8.19	0.41	5.92e-15	Coronary artery disease;
CRC	cis	rs8141797	0.901	rs6004051	chr22:24462072	A/C	cg20894457	chr22:24584366	SUSD2	-0.6	-5.85	-0.31	1.18e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00012762	chr17:72744649	SLC9A3R1	0.46	7.64	0.39	2.35e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.44e-9	Homoarginine levels;
CRC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.84	13.09	0.59	8.21e-32	Glomerular filtration rate (creatinine);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15254786	chr2:207630414	MDH1B;FASTKD2	-0.51	-6.23	-0.32	1.4e-9	Diisocyanate-induced asthma;
CRC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.54	7.99	0.4	2.24e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.61	-7.71	-0.39	1.53e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg10760299	chr15:45669010	GATM	0.35	5.62	0.3	4.02e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs6460942	0.908	rs6979046	chr7:12232744	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.05	-0.32	4.03e-9	Coronary artery disease;
CRC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.55	0.43	4.8e-16	Homoarginine levels;
CRC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.39	5.75	0.3	2.08e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6735179	0.798	rs6737190	chr2:1779036	C/A	cg19300414	chr2:1746591	PXDN	0.39	5.69	0.3	2.81e-8	Response to antipsychotic treatment;
CRC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.36	7.3	0.37	2.15e-12	Ewing sarcoma;
CRC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.47	7.16	0.37	5.18e-12	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23313650	chr7:123389169	WASL	0.4	6.45	0.34	3.89e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9311676	0.656	rs55913214	chr3:58388026	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.55	-8.26	-0.41	3.69e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-6.34	-0.33	7.41e-10	Systemic lupus erythematosus;
CRC	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg02569458	chr12:86230093	RASSF9	-0.42	-7.14	-0.37	6.06e-12	Major depressive disorder;
CRC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.51e-10	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.65	10.66	0.51	5.31e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg03037974	chr15:76606532	NA	0.73	13.13	0.59	5.83e-32	Blood metabolite levels;
CRC	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.69	-10.17	-0.49	2.56e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg21251018	chr6:28226885	NKAPL	0.48	7.42	0.38	9.78e-13	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg23533926	chr12:111358616	MYL2	-0.51	-7.67	-0.39	1.95e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26850624	chr5:429559	AHRR	-0.68	-10.74	-0.51	2.97e-23	Cystic fibrosis severity;
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.59	7.3	0.37	2.17e-12	Alzheimer's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16189954	chr22:29138267	HSCB;CHEK2	-0.48	-5.99	-0.31	5.5e-9	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.72	-0.3	2.36e-8	Life satisfaction;
CRC	trans	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg05376469	chr2:102649931	NA	-0.36	-6.08	-0.32	3.25e-9	Prostate cancer;
CRC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.61	11.55	0.54	3.94e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg05527609	chr1:210001259	C1orf107	-0.62	-5.98	-0.31	5.89e-9	Red blood cell count;
CRC	cis	rs7209700	0.547	rs61131650	chr17:45344327	G/A	cg17185639	chr17:45330862	ITGB3	0.39	6.11	0.32	2.76e-9	IgG glycosylation;
CRC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.83	-10.84	-0.51	1.27e-23	Migraine;Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00251250	chr1:234746546	IRF2BP2	0.37	5.96	0.31	6.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg00071950	chr4:10020882	SLC2A9	0.55	8.06	0.41	1.43e-14	Blood metabolite levels;
CRC	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.35	0.53	2e-25	Height;
CRC	cis	rs282587	0.569	rs403530	chr13:113396380	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.8	0.4	8.04e-14	Glycated hemoglobin levels;
CRC	cis	rs12282928	0.959	rs2170663	chr11:48319806	A/T	cg20307385	chr11:47447363	PSMC3	-0.46	-5.64	-0.3	3.66e-8	Migraine - clinic-based;
CRC	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg14593290	chr7:50529359	DDC	0.64	7.8	0.4	8.1e-14	Malaria;
CRC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.46	8.99	0.44	1.95e-17	Ulcerative colitis;
CRC	cis	rs2084637	0.931	rs35916509	chr11:122397509	T/A	cg21585512	chr11:122030076	LOC399959	-0.4	-7.39	-0.38	1.22e-12	Stroke;
CRC	trans	rs800082	0.516	rs12486830	chr3:144228339	A/T	cg24215973	chr2:240111563	HDAC4	0.46	6.38	0.33	5.92e-10	Smoking behavior;
CRC	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg03929089	chr4:120376271	NA	0.62	5.98	0.31	5.79e-9	Axial length;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.24	-0.37	3.11e-12	Bipolar disorder;
CRC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.89	15.86	0.66	1.84e-42	Prostate cancer;
CRC	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.34e-11	Response to antipsychotic treatment;
CRC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg04880052	chr2:219191631	PNKD	0.42	6.77	0.35	6.09e-11	Colorectal cancer;
CRC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg08210727	chr20:33865349	NA	0.49	6.17	0.32	1.96e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg15147215	chr3:52552868	STAB1	-0.66	-11.52	-0.54	4.85e-26	Electroencephalogram traits;
CRC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	9.3	0.46	2.03e-18	Cognitive test performance;
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.95e-9	Body mass index;
CRC	trans	rs2303319	0.504	rs16846050	chr2:162563553	A/G	cg18122310	chr12:50236657	BCDIN3D	0.75	6.17	0.32	2.03e-9	Cognitive function;
CRC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg10760299	chr15:45669010	GATM	0.49	7.72	0.39	1.43e-13	Homoarginine levels;
CRC	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg02683197	chr6:28174875	NA	0.55	7.84	0.4	6.25e-14	Parkinson's disease;
CRC	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.47	-8.22	-0.41	4.88e-15	Testicular germ cell tumor;
CRC	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	0.92	11.35	0.53	2.01e-25	Height;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.56	8.65	0.43	2.28e-16	Bipolar disorder;
CRC	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.6	7.58	0.39	3.47e-13	RR interval (heart rate);
CRC	cis	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.72	-0.3	2.44e-8	Blood trace element (Cu levels);
CRC	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.04	-0.32	4.26e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.5	6.38	0.33	5.92e-10	Cholesterol, total;
CRC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.14	0.37	5.92e-12	Joint mobility (Beighton score);
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25994096	chr11:61348278	SYT7	-0.41	-6.33	-0.33	8.08e-10	Myopia (pathological);
CRC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.94	-0.31	7.41e-9	Daytime sleep phenotypes;
CRC	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg08657710	chr16:75258780	CTRB1	0.46	5.68	0.3	3.01e-8	Alcoholic chronic pancreatitis;
CRC	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	1.09	12.84	0.58	7.36e-31	Obesity-related traits;
CRC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.58	-8.46	-0.42	8.75e-16	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12230010	chr10:72163718	EIF4EBP2	0.52	6.91	0.36	2.56e-11	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg25164649	chr6:28176230	NA	0.56	7.66	0.39	2.12e-13	Parkinson's disease;
CRC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.76e-10	Bladder cancer;
CRC	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.62	10.22	0.49	1.77e-21	Calcium levels;
CRC	cis	rs9682041	0.561	rs7643214	chr3:170144281	C/T	cg11886554	chr3:170076028	SKIL	0.68	7.57	0.39	3.81e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg11212589	chr17:38028394	ZPBP2	0.33	5.67	0.3	3.19e-8	Asthma;
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	trans	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg09872104	chr7:134855509	C7orf49	-0.87	-8.4	-0.42	1.33e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg15845792	chr6:28175446	NA	0.71	5.88	0.31	1e-8	Depression;
CRC	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-7.07	-0.36	9.07e-12	Height;
CRC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.86	-0.35	3.41e-11	Cutaneous nevi;
CRC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.86	-12.54	-0.57	9.81e-30	Blood metabolite levels;
CRC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.04	0.36	1.12e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.74	12.02	0.55	7.59e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs673253	0.686	rs2819333	chr1:44014573	A/T	cg10881128	chr1:44031826	PTPRF	0.21	6.43	0.33	4.6e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg00976097	chr5:421733	AHRR	-0.42	-5.66	-0.3	3.32e-8	Cystic fibrosis severity;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg04026000	chr5:79628372	NA	-0.48	-6.07	-0.32	3.43e-9	Plasma plasminogen activator levels;
CRC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.81	-0.35	4.62e-11	Major depressive disorder;
CRC	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.59	8.64	0.43	2.43e-16	Coronary artery disease;
CRC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00476814	chr22:19974536	ARVCF	0.38	6.33	0.33	7.84e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg21153622	chr11:89784906	NA	-0.47	-7.58	-0.39	3.59e-13	HDL cholesterol;
CRC	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.75	13.65	0.6	6.45e-34	Ulcerative colitis;
CRC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg21138405	chr5:131827807	IRF1	0.35	6.03	0.32	4.33e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.45	-7.31	-0.37	2.08e-12	Refractive error;
CRC	cis	rs910187	0.605	rs6018324	chr20:45810181	G/C	cg27589058	chr20:45804311	EYA2	-0.41	-7.74	-0.39	1.24e-13	Migraine;
CRC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.78	-0.66	3.79e-42	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.14	0.37	5.83e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.49	-8.82	-0.44	6.68e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.67	7.49	0.38	6.22e-13	Vitiligo;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg21251018	chr6:28226885	NKAPL	0.47	7.31	0.37	2.08e-12	Parkinson's disease;
CRC	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.6	0.63	1.48e-37	Fuchs's corneal dystrophy;
CRC	cis	rs995000	0.931	rs7539035	chr1:63106767	G/T	cg19896129	chr1:63156450	NA	0.41	6.47	0.34	3.52e-10	Triglyceride levels;
CRC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg02741985	chr17:80059408	CCDC57	-0.45	-7.11	-0.36	7.45e-12	Life satisfaction;
CRC	cis	rs713477	0.654	rs998871	chr14:55918302	G/A	cg13175173	chr14:55914753	NA	-0.44	-7.61	-0.39	2.96e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.61	-8.42	-0.42	1.21e-15	Coronary artery disease;
CRC	cis	rs55675132	0.510	rs55953277	chr1:115270907	T/A	cg12756093	chr1:115239321	AMPD1	0.52	6.14	0.32	2.33e-9	Schizophrenia;
CRC	trans	rs11581859	0.950	rs72730324	chr1:99388561	A/C	cg12183875	chr3:169587454	LRRC31	0.29	6.42	0.33	4.74e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs4586057	0.812	rs4282910	chr10:92631244	C/T	cg26894278	chr13:21016241	CRYL1	0.39	6.57	0.34	1.93e-10	Economic and political preferences (time);
CRC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.48	0.42	7.52e-16	Parkinson's disease;
CRC	cis	rs3936840	0.686	rs2896439	chr14:102806291	A/G	cg18135206	chr14:102964638	TECPR2	0.41	5.66	0.3	3.22e-8	Plateletcrit;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg19318889	chr4:1322082	MAEA	-0.42	-6.35	-0.33	7.29e-10	Obesity-related traits;
CRC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.7	-10.67	-0.51	4.99e-23	Tonsillectomy;
CRC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg01843034	chr6:37503916	NA	0.46	8.6	0.43	3.21e-16	Cognitive performance;
CRC	cis	rs672059	1.000	rs672059	chr1:183162539	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.1	0.36	7.63e-12	Hypertriglyceridemia;
CRC	cis	rs3736485	0.966	rs4775965	chr15:51908251	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.53	-0.34	2.57e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg11766577	chr21:47581405	C21orf56	-0.37	-5.69	-0.3	2.85e-8	Testicular germ cell tumor;
CRC	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg26816564	chr1:7831052	VAMP3	0.56	6.08	0.32	3.26e-9	Inflammatory bowel disease;
CRC	cis	rs2580764	0.566	rs2920900	chr2:55280083	T/C	cg09592903	chr2:55203963	RTN4	0.65	10.49	0.5	2.14e-22	Mean platelet volume;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02208506	chr17:4634804	MED11	-0.42	-6.13	-0.32	2.53e-9	Daytime sleep phenotypes;
CRC	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.48	7.59	0.39	3.25e-13	Red blood cell count;
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02772935	chr3:125709198	NA	-0.51	-5.99	-0.31	5.46e-9	Blood pressure (smoking interaction);
CRC	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.47	-6.52	-0.34	2.67e-10	Hair color;
CRC	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.57	8.47	0.42	8.23e-16	Multiple myeloma (IgH translocation);
CRC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.54	-9.53	-0.47	3.48e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs755249	0.567	rs72661965	chr1:39846590	A/C	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12760731	0.920	rs4132869	chr1:178476501	A/T	cg00404053	chr1:178313656	RASAL2	0.86	8.35	0.42	1.88e-15	Obesity-related traits;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.37	-7.95	-0.4	2.99e-14	Total body bone mineral density;
CRC	cis	rs12505749	0.542	rs17086794	chr4:57334752	C/T	cg06922635	chr4:57371607	ARL9	-0.52	-5.63	-0.3	3.83e-8	Airflow obstruction;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg27615366	chr5:131592974	PDLIM4	0.33	5.75	0.3	2e-8	Acylcarnitine levels;
CRC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.78	0.51	2.09e-23	Coronary artery disease;
CRC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.55	8.89	0.44	4.03e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg15845792	chr6:28175446	NA	0.77	11.47	0.53	7.32e-26	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg10729496	chr3:10149963	C3orf24	-0.54	-7.21	-0.37	3.96e-12	Alzheimer's disease;
CRC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-10.07	-0.49	5.72e-21	Developmental language disorder (linguistic errors);
CRC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg18230493	chr5:56204884	C5orf35	-0.4	-5.9	-0.31	9.16e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg02527881	chr3:46936655	PTH1R	0.35	6.09	0.32	3.07e-9	Colorectal cancer;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23161317	chr6:28129485	ZNF389	0.44	5.71	0.3	2.49e-8	Parkinson's disease;
CRC	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg15704280	chr7:45808275	SEPT13	-0.47	-6.73	-0.35	7.35e-11	HDL cholesterol;
CRC	cis	rs531930	0.959	rs483052	chr6:124728270	A/C	cg05308643	chr6:124982296	NKAIN2	-0.45	-5.9	-0.31	8.91e-9	Celiac disease;
CRC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.73	12.13	0.56	3.09e-28	DNA methylation (variation);
CRC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg10589385	chr1:150898437	SETDB1	0.27	5.74	0.3	2.13e-8	Tonsillectomy;
CRC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg09659197	chr4:152720779	NA	0.4	7.88	0.4	4.97e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg09760422	chr2:128146352	NA	-0.37	-7.22	-0.37	3.74e-12	Protein C levels;
CRC	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.76	10.42	0.5	3.71e-22	Systemic lupus erythematosus;
CRC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.48	-6.73	-0.35	7.75e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg13844804	chr7:814759	HEATR2	0.63	8.15	0.41	7.48e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.45	-0.34	4.01e-10	Metabolite levels;
CRC	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.52	-7.82	-0.4	7.14e-14	Dupuytren's disease;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.53	9.12	0.45	7.61e-18	Acylcarnitine levels;
CRC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg25767906	chr1:53392781	SCP2	0.47	7.48	0.38	6.61e-13	Monocyte count;
CRC	cis	rs1545257	0.505	rs67786999	chr2:24637160	T/G	cg06627628	chr2:24431161	ITSN2	-0.48	-7.09	-0.36	8.44e-12	Sjögren's syndrome;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.83	13.04	0.58	1.3e-31	Menarche (age at onset);
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg21251018	chr6:28226885	NKAPL	0.42	6.73	0.35	7.45e-11	Parkinson's disease;
CRC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.63	-0.47	1.69e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.16	-0.37	5.34e-12	IgG glycosylation;
CRC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.33e-11	Menopause (age at onset);
CRC	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.47	6.69	0.35	9.58e-11	Primary sclerosing cholangitis;
CRC	cis	rs1223397	0.651	rs202018	chr6:13301502	G/A	cg07912922	chr6:13274314	PHACTR1	0.37	5.71	0.3	2.53e-8	Blood pressure;
CRC	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.85	16.13	0.66	1.55e-43	Hip circumference;
CRC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.85	10.82	0.51	1.51e-23	Eosinophil percentage of granulocytes;
CRC	trans	rs4276421	0.806	rs6451801	chr5:45439433	G/A	cg04793272	chr11:119020941	ABCG4	-0.39	-6.42	-0.33	4.83e-10	P wave duration;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.29	-0.46	2.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg08798685	chr6:27730294	NA	-0.63	-6.14	-0.32	2.38e-9	Depression;
CRC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-7.24	-0.37	3.1e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg19847866	chr10:1019161	NA	-0.41	-5.88	-0.31	1.01e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs73206853	0.541	rs11837455	chr12:110505621	C/A	cg12870014	chr12:110450643	ANKRD13A	0.87	7.64	0.39	2.42e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04067598	chr5:70751409	BDP1	0.46	6.37	0.33	6.19e-10	Response to antipsychotic treatment;
CRC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.89	-16.54	-0.67	3.68e-45	Chronic sinus infection;
CRC	trans	rs529967	1.000	rs529967	chr3:124166503	A/G	cg01377916	chr16:46654868	SHCBP1	0.45	6.04	0.32	4.24e-9	Acute graft versus host disease in bone marrow transplantation (donor effect);
CRC	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.45	8.04	0.41	1.67e-14	Blood metabolite ratios;
CRC	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.5	-9.74	-0.47	7.21e-20	Urate levels in overweight individuals;
CRC	cis	rs77861329	1.000	rs13314125	chr3:52115398	C/T	cg08692210	chr3:52188851	WDR51A	0.83	6.95	0.36	1.95e-11	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1656402	0.569	rs80234614	chr2:233424159	A/T	cg03852847	chr2:233439513	NA	0.45	7.52	0.38	5.2e-13	Non-small cell lung cancer (survival);
CRC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.33e-12	Motion sickness;
CRC	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg19875578	chr6:126661172	C6orf173	0.42	5.77	0.3	1.88e-8	Male-pattern baldness;
CRC	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg23071808	chr14:103021642	NA	-0.52	-6.89	-0.36	2.79e-11	Platelet count;
CRC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.63	0.47	1.63e-19	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg12856521	chr11:46389249	DGKZ	0.76	9.53	0.47	3.68e-19	Crohn's disease;
CRC	cis	rs6445967	0.722	rs6445961	chr3:58232659	C/T	cg23715586	chr3:58305044	RPP14	0.4	5.98	0.31	5.85e-9	Platelet count;
CRC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	13.71	0.6	3.61e-34	Menopause (age at onset);
CRC	cis	rs7932354	0.528	rs7931260	chr11:47088303	T/C	cg19486271	chr11:47235900	DDB2	-0.45	-6.46	-0.34	3.8e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg21251018	chr6:28226885	NKAPL	0.47	7.29	0.37	2.36e-12	Parkinson's disease;
CRC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.55	7.91	0.4	4.08e-14	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.74	-7.76	-0.39	1.06e-13	Type 2 diabetes;
CRC	cis	rs501120	0.925	rs535949	chr10:44752330	A/C	cg09554077	chr10:44749378	NA	-0.89	-13.36	-0.59	8.15e-33	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.57	0.34	2e-10	Electroencephalogram traits;
CRC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.4	0.38	1.15e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg08450636	chr7:93717240	NA	-0.41	-6.43	-0.33	4.45e-10	Aortic root size;
CRC	cis	rs362272	0.525	rs2798286	chr4:3046173	A/G	cg22930642	chr4:2936657	C4orf10;MFSD10	-0.4	-5.72	-0.3	2.42e-8	Serum sulfate level;
CRC	cis	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg18809830	chr7:99032528	PTCD1	-0.93	-7.32	-0.37	1.89e-12	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03132089	chr20:55926498	RAE1	0.43	6.24	0.33	1.33e-9	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07400628	chr1:6761934	DNAJC11	0.46	6.17	0.32	1.96e-9	Anxiety disorder;
CRC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.61	-11.39	-0.53	1.47e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg21251018	chr6:28226885	NKAPL	0.51	5.95	0.31	6.9e-9	Depression;
CRC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.64	10.59	0.5	9.21e-23	Calcium levels;
CRC	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.93	-0.36	2.25e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.49	-5.85	-0.31	1.17e-8	Diastolic blood pressure;
CRC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.49	6.85	0.35	3.62e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.27	0.37	2.62e-12	Mean corpuscular volume;
CRC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg08755490	chr11:65554678	OVOL1	-0.43	-6.33	-0.33	7.93e-10	Acne (severe);
CRC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg23298862	chr7:158159286	PTPRN2	-0.48	-7.88	-0.4	4.73e-14	Calcium levels;
CRC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.45	6.2	0.32	1.7e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg02269571	chr22:50332266	NA	-0.61	-7.6	-0.39	3.1e-13	Schizophrenia;
CRC	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-0.57	-6.61	-0.34	1.54e-10	Prostate cancer;
CRC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.85	15.97	0.66	6.78e-43	Menopause (age at onset);
CRC	cis	rs11212617	1.000	rs227077	chr11:108253252	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.14	0.32	2.39e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.48	7.41	0.38	1.09e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg13607699	chr17:42295918	UBTF	-0.54	-7.28	-0.37	2.54e-12	Total body bone mineral density;
CRC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.92	18.19	0.71	1.2e-51	Menopause (age at onset);
CRC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg02033258	chr5:131593261	PDLIM4	0.33	5.8	0.3	1.55e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.84	14.85	0.63	1.52e-38	Breast cancer;
CRC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg24562669	chr7:97807699	LMTK2	0.42	7.02	0.36	1.3e-11	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23698501	chr2:220042748	FAM134A;C2orf24	0.46	6.49	0.34	3.14e-10	Response to antipsychotic treatment;
CRC	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg18551225	chr6:44695536	NA	0.42	5.8	0.3	1.57e-8	Total body bone mineral density;
CRC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.6	-8.44	-0.42	1.05e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.41	6.93	0.36	2.3e-11	Lung cancer;
CRC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg15083037	chr5:83017644	HAPLN1	-0.52	-7.0	-0.36	1.46e-11	Prostate cancer;
CRC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.55	8.96	0.44	2.51e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.61	11.4	0.53	1.4e-25	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg20936604	chr3:58311152	NA	-0.72	-6.84	-0.35	3.78e-11	Cholesterol, total;
CRC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.52	-8.53	-0.43	5.27e-16	Schizophrenia;
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg27266060	chr8:22091797	NA	0.36	6.06	0.32	3.79e-9	Hypertriglyceridemia;
CRC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.08	0.36	8.85e-12	Rheumatoid arthritis;
CRC	cis	rs9463078	0.625	rs12190513	chr6:44920679	A/T	cg25276700	chr6:44698697	NA	0.24	5.85	0.31	1.22e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-7.1	-0.36	7.68e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21851282	chr13:106751175	NA	0.43	6.94	0.36	2.15e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.13	0.64	1.32e-39	Bipolar disorder;
CRC	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.78	-0.3	1.73e-8	Axial length;
CRC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.27	14.66	0.63	8.59e-38	Diabetic kidney disease;
CRC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.36	-5.61	-0.3	4.24e-8	Gout;Renal underexcretion gout;
CRC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.83	0.31	1.33e-8	Electroencephalogram traits;
CRC	cis	rs2871473	0.951	rs1030025	chr2:103105611	A/T	cg09003973	chr2:102972529	NA	0.48	6.3	0.33	9.76e-10	Blood protein levels;
CRC	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg23032129	chr1:109941072	SORT1	-0.27	-5.84	-0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.5	-5.95	-0.31	6.76e-9	Blood trace element (Cu levels);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19764421	chr1:228783274	DUSP5P	0.41	6.73	0.35	7.48e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	0.47	6.72	0.35	8.19e-11	Blood protein levels;
CRC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	8.1	0.41	1.1e-14	Aortic root size;
CRC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg15205204	chr1:6545172	PLEKHG5	0.4	5.73	0.3	2.26e-8	Body mass index;
CRC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.5	8.15	0.41	7.51e-15	Lipoprotein (a) levels;
CRC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.6	7.28	0.37	2.53e-12	Mean platelet volume;
CRC	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.58	9.13	0.45	6.99e-18	Body mass index;
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02772935	chr3:125709198	NA	-0.5	-5.71	-0.3	2.53e-8	Blood pressure (smoking interaction);
CRC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.55	9.3	0.46	2.08e-18	Systemic lupus erythematosus;
CRC	cis	rs6908034	0.607	rs73376657	chr6:19805960	C/T	cg02682789	chr6:19804855	NA	0.79	6.75	0.35	6.62e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	trans	rs2303319	0.504	rs55650699	chr2:162388931	T/C	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Cognitive function;
CRC	cis	rs990171	1.000	rs1468791	chr2:103092021	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	5.78	0.3	1.77e-8	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17170942	chr3:124452405	UMPS	-0.38	-6.28	-0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	11.96	0.55	1.33e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.36	-5.73	-0.3	2.32e-8	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15877295	chr7:138915876	UBN2	0.47	6.75	0.35	6.73e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12049485	chr15:78858219	CHRNA5	0.41	6.62	0.34	1.49e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.62	9.11	0.45	8.27e-18	Morning vs. evening chronotype;
CRC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg11632617	chr15:75315747	PPCDC	-0.57	-8.05	-0.41	1.49e-14	Blood trace element (Zn levels);
CRC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	6.31	0.33	8.96e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18886436	chr12:54785171	ZNF385A	0.37	6.36	0.33	6.88e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6681460	0.800	rs485543	chr1:67194372	C/T	cg02459107	chr1:67143332	SGIP1	-0.35	-5.82	-0.31	1.42e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.7	11.26	0.53	4.27e-25	Mean platelet volume;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.59	-8.79	-0.44	8.46e-17	Menopause (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08237663	chr3:130745839	NEK11;ASTE1	-0.51	-6.0	-0.31	5.08e-9	Diisocyanate-induced asthma;
CRC	cis	rs807029	0.533	rs2295716	chr10:102744214	T/C	cg04662943	chr10:102668895	NA	0.61	7.3	0.37	2.2e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg04267008	chr7:1944627	MAD1L1	-0.45	-5.62	-0.3	4.18e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.45	-0.46	6.72e-19	HDL cholesterol;
CRC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.51	7.32	0.37	1.92e-12	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg25985355	chr7:65971099	NA	0.51	5.72	0.3	2.46e-8	Diabetic kidney disease;
CRC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.47	6.37	0.33	6.37e-10	Schizophrenia;
CRC	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg10167463	chr7:75959203	YWHAG	-0.53	-7.59	-0.39	3.25e-13	Multiple sclerosis;
CRC	cis	rs868943	0.512	rs72953957	chr6:116546543	A/G	cg15226275	chr6:116381976	FRK	0.26	6.13	0.32	2.58e-9	Total cholesterol levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15605853	chr6:47755961	OPN5	0.43	6.21	0.32	1.64e-9	Response to antipsychotic treatment;
CRC	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg26552321	chr15:43477455	CCNDBP1	-0.45	-6.01	-0.31	4.95e-9	Kawasaki disease;
CRC	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.07	16.1	0.66	1.96e-43	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.14	9.86	0.48	2.84e-20	Skin colour saturation;
CRC	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.54	8.59	0.43	3.49e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.25	6.96	0.36	1.89e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.44	-6.47	-0.34	3.61e-10	Ulcerative colitis;
CRC	cis	rs6460942	0.731	rs7799372	chr7:12233784	T/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-6.11	-0.32	2.79e-9	Schizophrenia;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.85	15.05	0.64	2.54e-39	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg16606324	chr3:10149918	C3orf24	0.47	6.98	0.36	1.59e-11	Alzheimer's disease;
CRC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.45	0.57	2.02e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-12.37	-0.56	4.18e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.81	8.51	0.42	6.37e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6908034	0.607	rs76413455	chr6:19808964	T/G	cg02682789	chr6:19804855	NA	0.79	6.58	0.34	1.81e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.42	-20.73	-0.75	1.2e-61	Hemostatic factors and hematological phenotypes;
CRC	cis	rs1570989	0.571	rs6916066	chr6:12016009	G/C	cg17804551	chr6:12015979	HIVEP1	0.4	6.44	0.33	4.22e-10	Alcohol and nicotine co-dependence;
CRC	cis	rs17155006	0.628	rs397941	chr7:107727709	C/T	cg05962710	chr7:107745446	LAMB4	-0.35	-5.85	-0.31	1.16e-8	Pneumococcal bacteremia;
CRC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg03152288	chr2:177042942	NA	0.67	9.5	0.46	4.67e-19	IgG glycosylation;
CRC	cis	rs6479527	0.840	rs1576640	chr9:96770131	A/G	cg14459158	chr9:96720562	NA	0.37	6.62	0.34	1.46e-10	Esophageal adenocarcinoma;
CRC	cis	rs427943	0.639	rs2838820	chr21:46646005	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.42	5.73	0.3	2.26e-8	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09936566	chr1:163292020	NUF2	0.45	6.54	0.34	2.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.45	-6.17	-0.32	2.06e-9	Gut microbiome composition (summer);
CRC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg11189052	chr15:85197271	WDR73	0.62	8.91	0.44	3.47e-17	Schizophrenia;
CRC	cis	rs11212617	1.000	rs654005	chr11:108155397	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.17	0.32	1.95e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.88	16.69	0.68	9.63e-46	Hip circumference;
CRC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg19980929	chr12:42632907	YAF2	-0.4	-6.18	-0.32	1.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg08660285	chr1:67390436	MIER1;WDR78	0.93	10.99	0.52	3.81e-24	Neutrophil percentage of white cells;
CRC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.33	-0.33	8.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.93	-0.55	1.67e-27	Alzheimer's disease;
CRC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs4973397	0.643	rs2369271	chr2:232289244	C/T	cg13347044	chr2:232276743	NA	-0.39	-5.63	-0.3	3.84e-8	Anti-saccade response;
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.28e-9	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07364046	chr12:93861583	MRPL42	0.43	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg07507251	chr3:52567010	NT5DC2	0.43	6.15	0.32	2.19e-9	Bipolar disorder;
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg04497992	chr16:616212	NHLRC4	0.44	7.16	0.37	5.17e-12	Height;
CRC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.68	0.39	1.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.86	12.62	0.57	4.91e-30	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7113874	0.589	rs10840056	chr11:8498064	A/C	cg20771178	chr11:8615675	STK33	0.34	5.67	0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9549328	0.700	rs3011473	chr13:113618096	A/G	cg17524180	chr13:113633600	MCF2L	0.53	9.57	0.47	2.68e-19	Systolic blood pressure;
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg05569086	chr8:143859399	LYNX1	0.4	6.96	0.36	1.91e-11	Urinary tract infection frequency;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg24046110	chr8:143859143	LYNX1	-0.46	-7.44	-0.38	8.99e-13	Urinary tract infection frequency;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg25164649	chr6:28176230	NA	0.58	7.24	0.37	3.2e-12	Parkinson's disease;
CRC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	7.26	0.37	2.89e-12	Lung cancer in ever smokers;
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.56	8.95	0.44	2.74e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg00745463	chr17:30367425	LRRC37B	0.51	6.26	0.33	1.22e-9	Hip circumference adjusted for BMI;
CRC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.98e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02021460	chr16:19729639	C16orf88;IQCK	0.44	6.08	0.32	3.32e-9	Response to antipsychotic treatment;
CRC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.62	-0.34	1.51e-10	Menopause (age at onset);
CRC	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.27e-25	White blood cell count (basophil);
CRC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.51	9.88	0.48	2.58e-20	Renal cell carcinoma;
CRC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg03959625	chr15:84868606	LOC388152	0.42	6.39	0.33	5.74e-10	Schizophrenia;
CRC	cis	rs13315871	1.000	rs13327709	chr3:58408767	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg18827107	chr12:86230957	RASSF9	-0.38	-5.81	-0.3	1.5e-8	Major depressive disorder;
CRC	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	10.89	0.51	8.89e-24	Height;
CRC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	5.89e-13	Motion sickness;
CRC	cis	rs4664293	0.967	rs13000070	chr2:160525774	C/G	cg08347373	chr2:160653686	CD302	-0.47	-7.58	-0.39	3.51e-13	Monocyte percentage of white cells;
CRC	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.82	0.35	4.31e-11	Prostate cancer;
CRC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.71	-0.3	2.51e-8	Mean platelet volume;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.44	0.46	7.24e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.5	7.98	0.4	2.39e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.46	-6.58	-0.34	1.84e-10	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05755010	chr1:147142917	ACP6	0.4	6.06	0.32	3.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.3	3.66e-8	Hemoglobin concentration;
CRC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06998765	chr14:75389618	RPS6KL1	-0.25	-5.99	-0.31	5.44e-9	Caffeine consumption;
CRC	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02896705	chr19:18112042	ARRDC2	0.38	6.44	0.33	4.15e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	0.97	18.25	0.71	6.72e-52	Height;
CRC	cis	rs17021463	0.676	rs12512832	chr4:95310216	G/T	cg11021082	chr4:95130006	SMARCAD1	0.43	6.17	0.32	2.02e-9	Testicular germ cell tumor;
CRC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg20354231	chr13:53171401	NA	-0.46	-7.3	-0.37	2.15e-12	Lewy body disease;
CRC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg26554054	chr8:600488	NA	0.7	6.84	0.35	3.84e-11	IgG glycosylation;
CRC	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg10494257	chr1:16342123	HSPB7	0.45	6.31	0.33	8.91e-10	Dilated cardiomyopathy;
CRC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.42	0.33	4.87e-10	Cognitive ability;
CRC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.5	-7.75	-0.39	1.14e-13	Aortic root size;
CRC	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.36	-6.25	-0.33	1.28e-9	Sitting height ratio;
CRC	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.59	8.11	0.41	1.01e-14	Extraversion;
CRC	cis	rs3956705	0.866	rs71532543	chr7:32998910	G/A	cg05721444	chr7:32995514	FKBP9	-0.51	-7.22	-0.37	3.63e-12	Red cell distribution width;
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.83	-0.44	6.26e-17	Bipolar disorder;
CRC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg15744005	chr10:104629667	AS3MT	0.3	5.92	0.31	8.06e-9	Arsenic metabolism;
CRC	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg05639522	chr1:247681581	NA	0.56	6.05	0.32	3.95e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.54	8.35	0.42	1.86e-15	Aortic root size;
CRC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.66	7.27	0.37	2.62e-12	Vitiligo;
CRC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.32	-0.37	1.91e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.59	9.22	0.45	3.77e-18	HDL cholesterol;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.51	7.45	0.38	8.07e-13	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.45	0.5	3.01e-22	Corneal astigmatism;
CRC	cis	rs6662572	0.901	rs28484896	chr1:46184200	C/G	cg08644498	chr1:46502608	NA	0.43	6.48	0.34	3.35e-10	Blood protein levels;
CRC	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.82	-0.44	6.77e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.52	-9.41	-0.46	8.67e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg19223190	chr17:80058835	NA	0.39	6.32	0.33	8.71e-10	Life satisfaction;
CRC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.53	7.15	0.37	5.8e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-6.38	-0.33	6.12e-10	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.48	-0.38	6.81e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg18827107	chr12:86230957	RASSF9	-0.38	-6.29	-0.33	1.03e-9	Major depressive disorder;
CRC	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.51	8.21	0.41	5.12e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.36e-12	Putamen volume;
CRC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.09	-0.32	3.17e-9	Bipolar disorder;
CRC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.17	-0.41	6.79e-15	Type 2 diabetes;
CRC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.19	-0.32	1.79e-9	Breast cancer;
CRC	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.88	11.19	0.53	7.32e-25	Orofacial clefts;
CRC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.09	12.78	0.58	1.25e-30	Sexual dysfunction (female);
CRC	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.44	-6.17	-0.32	1.98e-9	Eye color traits;
CRC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.17	0.41	6.87e-15	Lung cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04703844	chr8:74207197	RPL7;RDH10	0.47	6.04	0.32	4.22e-9	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02951150	chr4:185654545	MLF1IP	0.37	5.97	0.31	6.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs4731207	0.505	rs7795233	chr7:124578468	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.44	6.64	0.34	1.27e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10573403	chr14:36003118	INSM2	0.4	6.52	0.34	2.6e-10	Response to antipsychotic treatment;
CRC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	6.14	0.32	2.39e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-5.96	-0.31	6.53e-9	Type 1 diabetes;
CRC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg19318889	chr4:1322082	MAEA	0.42	6.43	0.33	4.55e-10	Obesity-related traits;
CRC	cis	rs12476592	0.516	rs1922421	chr2:63592792	G/A	cg10828910	chr2:63850056	LOC388955	0.47	5.87	0.31	1.07e-8	Childhood ear infection;
CRC	cis	rs55788414	0.860	rs28697180	chr16:81185079	C/T	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg15654264	chr1:150340011	RPRD2	0.42	6.06	0.32	3.72e-9	Migraine;
CRC	cis	rs230203	0.506	rs230193	chr20:55774246	C/T	cg13236649	chr20:55835020	BMP7	0.38	5.66	0.3	3.29e-8	Monobrow;
CRC	cis	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg16898833	chr6:26189333	HIST1H4D	-0.72	-6.04	-0.32	4.25e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.55	11.27	0.53	3.93e-25	Gait variability;
CRC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg11632617	chr15:75315747	PPCDC	-0.57	-8.25	-0.41	3.96e-15	Blood trace element (Zn levels);
CRC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-6.42	-0.33	4.82e-10	Total body bone mineral density;
CRC	cis	rs972578	0.905	rs9623736	chr22:43406673	A/G	cg01576275	chr22:43409880	NA	-0.51	-8.44	-0.42	1e-15	Mean platelet volume;
CRC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.62	0.34	1.43e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2565722	0.714	rs2489935	chr6:161280245	T/C	cg03159191	chr6:161285451	NA	-0.5	-6.02	-0.31	4.67e-9	Blood protein levels;
CRC	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg20628663	chr10:43360327	NA	0.57	6.85	0.35	3.55e-11	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01524359	chr1:46049306	NASP	0.51	6.56	0.34	2.15e-10	Thyroid stimulating hormone;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.4	-6.29	-0.33	9.98e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19894588	chr14:64061835	NA	0.43	6.09	0.32	3.1e-9	Glioblastoma;Glioma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15884411	chr2:96932403	CIAO1;TMEM127	0.44	6.12	0.32	2.63e-9	Response to antipsychotic treatment;
CRC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.7	9.06	0.45	1.23e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	10.21	0.49	1.87e-21	Menarche (age at onset);
CRC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.41	-6.49	-0.34	3.09e-10	Body mass index;
CRC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg16576597	chr16:28551801	NUPR1	0.49	7.07	0.36	9.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.51	-9.18	-0.45	4.84e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-7.26	-0.37	2.8e-12	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25937148	chr3:43147320	C3orf39	0.47	6.71	0.35	8.51e-11	Survival in pancreatic cancer;
CRC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.66	-0.3	3.23e-8	Migraine;Coronary artery disease;
CRC	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg14515779	chr1:101123966	NA	0.36	6.65	0.34	1.22e-10	Monocyte count;
CRC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.59	8.71	0.43	1.53e-16	Lung cancer;
CRC	cis	rs812925	0.893	rs1186705	chr2:61673278	A/C	cg10580144	chr2:61372316	C2orf74	0.3	6.13	0.32	2.47e-9	Immature fraction of reticulocytes;
CRC	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg18404041	chr3:52824283	ITIH1	-0.35	-6.55	-0.34	2.21e-10	Schizophrenia;
CRC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.57	6.82	0.35	4.48e-11	Diastolic blood pressure;
CRC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg05192639	chr6:26864778	GUSBL1	-0.37	-6.5	-0.34	3.05e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg27535305	chr1:53392650	SCP2	0.39	7.01	0.36	1.34e-11	Monocyte count;
CRC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.6	0.34	1.68e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg13206674	chr6:150067644	NUP43	0.47	5.75	0.3	2.03e-8	Lung cancer;
CRC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.38	-6.13	-0.32	2.48e-9	Menarche (age at onset);
CRC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.44	0.38	8.57e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.59	9.66	0.47	1.38e-19	Anterior chamber depth;
CRC	cis	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.82	0.55	4.16e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7809950	0.817	rs2204833	chr7:107283069	T/C	cg23024343	chr7:107201750	COG5	0.66	8.86	0.44	5.28e-17	Coronary artery disease;
CRC	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.67	11.1	0.52	1.59e-24	Eosinophil percentage of white cells;
CRC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg15845792	chr6:28175446	NA	0.7	6.44	0.33	4.26e-10	Depression;
CRC	trans	rs11654801	0.891	rs1045215	chr17:20902959	G/C	cg23759823	chr7:139672531	TBXAS1	-0.46	-6.49	-0.34	3.09e-10	Mosquito bite size;
CRC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-8.67	-0.43	1.94e-16	Gut microbiome composition (summer);
CRC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.43	0.69	1.17e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	11.91	0.55	1.92e-27	Platelet count;
CRC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg23996704	chr18:44553084	KATNAL2	-0.3	-5.78	-0.3	1.71e-8	Personality dimensions;
CRC	cis	rs3764563	1.000	rs4239612	chr19:15727442	A/G	cg20725493	chr19:15740067	CYP4F8	-0.68	-6.43	-0.33	4.46e-10	Inflammatory biomarkers;
CRC	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06307176	chr5:131281290	NA	0.45	6.5	0.34	2.93e-10	Life satisfaction;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg02683197	chr6:28174875	NA	0.61	8.23	0.41	4.46e-15	Parkinson's disease;
CRC	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg11887960	chr12:57824829	NA	0.63	7.0	0.36	1.42e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg03948781	chr1:205179583	DSTYK	0.42	5.85	0.31	1.18e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg03395651	chr16:88107091	BANP	0.6	7.72	0.39	1.37e-13	Menopause (age at onset);
CRC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.66	-11.94	-0.55	1.47e-27	Refractive error;
CRC	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg09127314	chr1:152161683	NA	0.49	6.38	0.33	5.91e-10	Atopic dermatitis;
CRC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.12	-17.56	-0.7	3.5e-49	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19791253	chr1:203595809	ATP2B4	0.44	6.23	0.32	1.39e-9	Response to antipsychotic treatment;
CRC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.62	-0.43	2.91e-16	Platelet count;
CRC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.65	-10.43	-0.5	3.34e-22	Breast cancer;
CRC	cis	rs10982256	0.875	rs11789406	chr9:117246188	G/A	cg13636371	chr9:117264095	DFNB31	0.4	7.56	0.38	4.09e-13	Bipolar disorder;
CRC	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg15654264	chr1:150340011	RPRD2	0.4	5.91	0.31	8.38e-9	Migraine;
CRC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.67	0.3	3.06e-8	Hemoglobin concentration;
CRC	cis	rs7107174	0.901	rs7937277	chr11:78114977	C/G	cg02023728	chr11:77925099	USP35	0.39	6.2	0.32	1.71e-9	Testicular germ cell tumor;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25312474	chr6:142468512	VTA1	0.4	6.03	0.32	4.36e-9	Interleukin-6 levels;
CRC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.59	0.39	3.29e-13	Hemoglobin concentration;
CRC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.51	-7.1	-0.36	7.86e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.71	-8.77	-0.44	1.01e-16	Educational attainment;
CRC	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg09163369	chr1:210001066	C1orf107	0.54	7.13	0.37	6.27e-12	Orofacial clefts;
CRC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg11070056	chr1:107600091	PRMT6	-0.4	-5.62	-0.3	4e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg26043149	chr18:55253948	FECH	0.52	7.99	0.4	2.25e-14	Bone mineral density;
CRC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	10.07	0.49	5.54e-21	Mean corpuscular hemoglobin;
CRC	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.63	-9.79	-0.47	5e-20	Testicular germ cell tumor;
CRC	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg23939001	chr4:940644	TMEM175	0.7	12.7	0.57	2.42e-30	Sjögren's syndrome;
CRC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02772935	chr3:125709198	NA	-0.5	-5.83	-0.31	1.3e-8	Blood pressure (smoking interaction);
CRC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.58	7.4	0.38	1.14e-12	Neutrophil percentage of white cells;
CRC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	7.92	0.4	3.58e-14	Aortic root size;
CRC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.43	6.62	0.34	1.48e-10	High light scatter reticulocyte count;
CRC	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg08501292	chr6:25962987	TRIM38	0.83	7.89	0.4	4.46e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.58	8.91	0.44	3.66e-17	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.36	-5.89	-0.31	9.77e-9	Total body bone mineral density;
CRC	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.63	0.43	2.65e-16	Coffee consumption (cups per day);
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.72	-11.92	-0.55	1.8e-27	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2836754	1.000	rs11701117	chr21:40292512	C/T	cg02119577	chr21:40195074	ETS2	-0.36	-6.13	-0.32	2.54e-9	Crohn's disease;Body mass index;
CRC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.08	12.0	0.55	9.48e-28	Skin colour saturation;
CRC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	1.16	10.88	0.51	9.66e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs11581859	0.950	rs59785571	chr1:99368627	C/A	cg12183875	chr3:169587454	LRRC31	0.26	6.07	0.32	3.54e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.4	-6.18	-0.32	1.93e-9	Endometrial cancer;
CRC	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	cis	rs6142102	0.961	rs2284387	chr20:32644588	C/T	cg08999081	chr20:33150536	PIGU	0.4	5.6	0.3	4.44e-8	Skin pigmentation;
CRC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.02	-0.68	5.01e-47	Height;
CRC	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.42	6.15	0.32	2.2e-9	Life satisfaction;
CRC	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.56	-0.34	2.05e-10	Prevalent atrial fibrillation;
CRC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.75	12.06	0.55	5.55e-28	Selective IgA deficiency;
CRC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.47	6.61	0.34	1.52e-10	Tuberculosis;
CRC	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.67	-9.92	-0.48	1.81e-20	Acne (severe);
CRC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.5	7.01	0.36	1.37e-11	Schizophrenia;
CRC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.73	-9.18	-0.45	4.87e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg07809909	chr20:30433512	FOXS1	0.35	5.8	0.3	1.53e-8	Monocyte count;
CRC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.72	-0.35	8e-11	Response to antipsychotic treatment;
CRC	cis	rs17767392	0.918	rs35094946	chr14:71752790	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.34	-0.33	7.62e-10	Mitral valve prolapse;
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.62	9.08	0.45	9.98e-18	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26731897	chr17:79633822	C17orf90;CCDC137	0.39	6.35	0.33	7.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.27	-0.37	2.61e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg03152288	chr2:177042942	NA	0.8	12.97	0.58	2.38e-31	IgG glycosylation;
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1274963	0.601	rs811970	chr3:39196552	A/G	cg02254461	chr3:39195904	CSRNP1	-0.5	-7.43	-0.38	9.45e-13	Chronic lymphocytic leukemia;
CRC	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	cg04338863	chr8:33670619	NA	0.4	6.77	0.35	5.92e-11	Body mass index;
CRC	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg13491945	chr12:107078410	RFX4	0.36	6.09	0.32	3.1e-9	Heart rate;
CRC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg17401720	chr7:158221031	PTPRN2	0.41	6.45	0.33	4.09e-10	Obesity-related traits;
CRC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-6.92	-0.36	2.41e-11	Response to bleomycin (chromatid breaks);
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.84	-13.07	-0.58	9.91e-32	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg03623178	chr6:28175578	NA	0.83	12.47	0.57	1.76e-29	Parkinson's disease;
CRC	cis	rs4664293	0.632	rs7588230	chr2:160653720	C/T	cg08347373	chr2:160653686	CD302	0.51	8.62	0.43	2.92e-16	Monocyte percentage of white cells;
CRC	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg21238619	chr17:78079768	GAA	-0.42	-6.87	-0.35	3.27e-11	Yeast infection;
CRC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.71	12.3	0.56	7.37e-29	Gout;
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg20119798	chr7:94954144	PON1	-0.51	-6.48	-0.34	3.3e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg05683857	chr10:124030795	BTBD16	0.32	5.83	0.31	1.34e-8	Total body bone mineral density;
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.86	-0.55	3.02e-27	Alzheimer's disease;
CRC	cis	rs4664293	1.000	rs6432542	chr2:160480536	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.28	-0.33	1.06e-9	Monocyte percentage of white cells;
CRC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg12317470	chr15:67143691	NA	-0.54	-6.93	-0.36	2.25e-11	Lung cancer (smoking interaction);
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg04551154	chr10:95462393	C10orf4	-0.73	-5.98	-0.31	5.86e-9	Blood osmolality (transformed sodium);
CRC	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.73	8.38	0.42	1.52e-15	Systolic blood pressure;
CRC	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg17470449	chr10:769945	NA	0.57	7.86	0.4	5.4e-14	Uric acid levels;
CRC	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg12315302	chr6:26189340	HIST1H4D	0.8	6.44	0.33	4.14e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.69	10.74	0.51	2.99e-23	Diastolic blood pressure;
CRC	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.52	5.63	0.3	3.82e-8	Vitamin D levels;
CRC	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg26816564	chr1:7831052	VAMP3	-0.46	-5.63	-0.3	3.86e-8	Inflammatory bowel disease;
CRC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg27534772	chr1:16042836	PLEKHM2	-0.54	-10.56	-0.5	1.21e-22	Systolic blood pressure;
CRC	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg02811702	chr13:24901961	NA	0.48	6.63	0.34	1.4e-10	Obesity-related traits;
CRC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.35	0.56	4.64e-29	Menopause (age at onset);
CRC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg08270630	chr22:50330655	NA	-0.4	-5.61	-0.3	4.4e-8	Schizophrenia;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg15786705	chr6:28176104	NA	0.59	6.99	0.36	1.58e-11	Depression;
CRC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.49	7.19	0.37	4.43e-12	Breast cancer;
CRC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.54	0.43	5.11e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17804987	chr3:50654788	MAPKAPK3	0.44	6.1	0.32	2.95e-9	Anxiety disorder;
CRC	cis	rs995000	0.931	rs630144	chr1:62918864	A/G	cg19896129	chr1:63156450	NA	0.44	6.78	0.35	5.59e-11	Triglyceride levels;
CRC	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg09659197	chr4:152720779	NA	0.52	11.39	0.53	1.51e-25	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.38	-6.29	-0.33	1.01e-9	Childhood ear infection;
CRC	trans	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg19894588	chr14:64061835	NA	0.61	8.65	0.43	2.32e-16	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.69	-0.43	1.76e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.45	7.65	0.39	2.26e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4561483	0.583	rs11647580	chr16:11957609	G/C	cg08843971	chr16:11963173	GSPT1	0.52	7.76	0.39	1.1e-13	Testicular germ cell tumor;
CRC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg03609598	chr5:56110824	MAP3K1	0.58	7.95	0.4	2.98e-14	Initial pursuit acceleration;
CRC	cis	rs4728302	0.934	rs2971963	chr7:133641505	A/G	cg03336402	chr7:133662267	EXOC4	0.47	7.16	0.37	5.19e-12	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs1030268	0.505	rs80305547	chr7:133259400	A/G	cg10665199	chr7:133106180	EXOC4	0.66	7.88	0.4	4.73e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06307176	chr5:131281290	NA	0.42	6.13	0.32	2.54e-9	Life satisfaction;
CRC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg07636037	chr3:49044803	WDR6	-0.66	-5.7	-0.3	2.69e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg21153622	chr11:89784906	NA	0.47	7.46	0.38	7.87e-13	HDL cholesterol;
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.35	0.33	7.32e-10	Life satisfaction;
CRC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.35	5.67	0.3	3.12e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12302829	chr15:63341214	TPM1	0.42	6.41	0.33	5.1e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.08	-0.36	8.67e-12	Body mass index;
CRC	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg16892393	chr17:41919603	NA	-0.53	-5.78	-0.3	1.77e-8	Cognitive function;
CRC	cis	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg21251018	chr6:28226885	NKAPL	0.42	6.11	0.32	2.75e-9	Depression;
CRC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.62	0.43	2.79e-16	Height;
CRC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg16606324	chr3:10149918	C3orf24	0.45	6.8	0.35	4.87e-11	Alzheimer's disease;
CRC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.5	-7.85	-0.4	5.75e-14	Red blood cell count;
CRC	cis	rs6988985	0.560	rs7826809	chr8:143925609	C/T	cg10324643	chr8:143916377	GML	0.38	6.3	0.33	9.63e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Systemic lupus erythematosus;
CRC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.59	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.41	6.73	0.35	7.45e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.03	-0.32	4.47e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.61	0.34	1.55e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg03929089	chr4:120376271	NA	0.62	6.01	0.31	4.91e-9	Axial length;
CRC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg13206674	chr6:150067644	NUP43	0.5	6.97	0.36	1.73e-11	Testicular germ cell tumor;
CRC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-19.38	-0.73	2.35e-56	Ulcerative colitis;
CRC	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	1.04	7.73	0.39	1.32e-13	Type 2 diabetes nephropathy;
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.22	-0.49	1.76e-21	Bipolar disorder and schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24677732	chr10:6019526	IL15RA	0.44	6.02	0.31	4.74e-9	Anxiety disorder;
CRC	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg16794390	chr17:18148240	FLII	0.31	5.88	0.31	9.84e-9	Parental longevity (combined parental age at death);
CRC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg08888203	chr3:10149979	C3orf24	0.45	7.19	0.37	4.45e-12	Alzheimer's disease;
CRC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.79	0.66	3.5e-42	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Alcohol dependence;
CRC	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.67	-9.72	-0.47	8.78e-20	Type 2 diabetes;
CRC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-7.08	-0.36	8.71e-12	Morning vs. evening chronotype;
CRC	trans	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.82	-16.45	-0.67	8.68e-45	Post bronchodilator FEV1;
CRC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.38	6.14	0.32	2.34e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02835499	chr17:46178918	CBX1	0.4	6.59	0.34	1.75e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.48	-5.83	-0.31	1.36e-8	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.12	-0.56	3.46e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.5	6.66	0.34	1.12e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.25	-0.33	1.24e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs370915	0.578	rs28627789	chr4:187788774	T/C	cg12892747	chr4:187813459	NA	-0.55	-7.89	-0.4	4.63e-14	Gout;
CRC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.42	-7.07	-0.36	9.18e-12	Height;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg26587870	chr6:27730563	NA	-0.43	-6.36	-0.33	6.83e-10	Parkinson's disease;
CRC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg20684491	chr1:25596433	NA	-0.43	-7.43	-0.38	9.68e-13	Erythrocyte sedimentation rate;
CRC	trans	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg16141378	chr3:129829833	LOC729375	0.42	6.3	0.33	9.66e-10	Joint mobility (Beighton score);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22713327	chr12:120703336	PXN	0.36	6.15	0.32	2.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7215564	0.908	rs35584560	chr17:78668256	G/A	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.19e-9	Myopia (pathological);
CRC	cis	rs938554	0.779	rs11735831	chr4:9951591	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.91	-0.31	8.72e-9	Blood metabolite levels;
CRC	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.4	-5.83	-0.31	1.31e-8	Ovarian reserve;
CRC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.37	-7.66	-0.39	2.04e-13	Cutaneous nevi;
CRC	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.74	11.38	0.53	1.54e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg18016565	chr1:150552671	MCL1	-0.41	-6.15	-0.32	2.25e-9	Tonsillectomy;
CRC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.48	-9.35	-0.46	1.37e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg23234261	chr14:55582407	NA	-0.3	-5.94	-0.31	7.18e-9	Protein biomarker;
CRC	cis	rs10512697	0.655	rs35209468	chr5:3473582	C/T	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.86e-10	Inflammatory skin disease;
CRC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.41	7.94	0.4	3.17e-14	Mean corpuscular volume;
CRC	cis	rs524281	0.682	rs4483592	chr11:65990439	C/T	cg16950941	chr11:66035639	RAB1B	-0.7	-8.05	-0.41	1.53e-14	Electroencephalogram traits;
CRC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.7	-0.3	2.72e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg27432699	chr2:27873401	GPN1	-0.62	-9.48	-0.46	5.39e-19	Total body bone mineral density;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13357455	chr5:134240501	PCBD2	0.38	6.1	0.32	3.05e-9	Schizophrenia;
CRC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.87	14.17	0.62	6.71e-36	Ewing sarcoma;
CRC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.66	9.66	0.47	1.35e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg15445000	chr17:37608096	MED1	-0.35	-6.23	-0.32	1.43e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg13491945	chr12:107078410	RFX4	0.34	5.85	0.31	1.2e-8	Heart rate;
CRC	cis	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg27395922	chr11:50257633	LOC441601	0.39	6.6	0.34	1.61e-10	Coronary artery disease;
CRC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.63	-0.43	2.59e-16	Aortic root size;
CRC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.56	9.13	0.45	7.33e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.05	12.84	0.58	7.03e-31	Type 2 diabetes nephropathy;
CRC	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.76	9.5	0.46	4.61e-19	Iron status biomarkers;
CRC	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.45	6.97	0.36	1.78e-11	Red blood cell count;
CRC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	8.82e-17	Morning vs. evening chronotype;
CRC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14008862	chr17:28927542	LRRC37B2	0.49	6.17	0.32	1.96e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg12458913	chr13:53173898	NA	-0.55	-8.87	-0.44	4.78e-17	Lewy body disease;
CRC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.49	9.67	0.47	1.26e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	7.56	0.38	4.15e-13	Body mass index;
CRC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.5	-7.39	-0.38	1.2e-12	Uric acid clearance;
CRC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.61e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.51	-8.46	-0.42	9.08e-16	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20430124	chr2:9954241	NA	0.4	6.05	0.32	3.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.72	11.48	0.53	6.74e-26	Immature fraction of reticulocytes;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.54	-7.32	-0.37	1.9e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-0.63	-11.21	-0.53	6.31e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	0.74	6.06	0.32	3.68e-9	Type 2 diabetes nephropathy;
CRC	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.47	-6.74	-0.35	6.9e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05903289	chr2:130345205	NA	-0.36	-6.82	-0.35	4.49e-11	Response to cytidine analogues (gemcitabine);
CRC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.19	0.59	3.44e-32	Breast cancer;
CRC	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg00603274	chr11:61596626	FADS2	-0.49	-6.8	-0.35	5.04e-11	Trans fatty acid levels;
CRC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.57	-0.34	1.91e-10	Vitiligo;
CRC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg03037974	chr15:76606532	NA	0.82	16.48	0.67	6.46e-45	Blood metabolite levels;
CRC	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg10523679	chr1:76189770	ACADM	-0.39	-5.65	-0.3	3.43e-8	Daytime sleep phenotypes;
CRC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg00999904	chr2:3704751	ALLC	-0.96	-11.37	-0.53	1.75e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.46	-6.59	-0.34	1.74e-10	Bladder cancer;
CRC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-14.06	-0.61	1.68e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.88	11.59	0.54	2.78e-26	Triglycerides;
CRC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.14	-0.32	2.42e-9	Morning vs. evening chronotype;
CRC	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.37	6.22	0.32	1.51e-9	Blood metabolite levels;
CRC	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg07423050	chr13:99094983	FARP1	-0.45	-6.54	-0.34	2.37e-10	Neuroticism;
CRC	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-7.01	-0.36	1.39e-11	Colorectal cancer;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg05569086	chr8:143859399	LYNX1	0.65	11.32	0.53	2.55e-25	Urinary tract infection frequency;
CRC	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg18758796	chr5:131593413	PDLIM4	0.33	5.65	0.3	3.44e-8	Blood metabolite levels;
CRC	trans	rs61101201	1.000	rs1223120	chr11:31465050	T/G	cg11934170	chr4:155254326	DCHS2	-0.41	-5.96	-0.31	6.41e-9	Optic disc area;
CRC	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.51	9.61	0.47	1.92e-19	Alcoholic chronic pancreatitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02741808	chr17:73780792	UNK	0.44	6.05	0.32	3.95e-9	Response to antipsychotic treatment;
CRC	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg14593290	chr7:50529359	DDC	-0.64	-8.52	-0.42	6e-16	Malaria;
CRC	cis	rs3823572	0.525	rs6946805	chr7:133714482	T/C	cg03336402	chr7:133662267	EXOC4	-0.64	-9.18	-0.45	4.92e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.48	7.36	0.38	1.52e-12	HDL cholesterol;
CRC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.61	-0.57	5.23e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.22	-0.32	1.49e-9	Aortic root size;
CRC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.59	8.81	0.44	7.45e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg26666090	chr16:58549219	SETD6	0.97	6.47	0.34	3.54e-10	Schizophrenia;
CRC	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.74	-0.43	1.2e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg13490827	chr1:46269305	MAST2	-0.72	-6.21	-0.32	1.6e-9	Cognitive function;
CRC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.32	0.33	8.69e-10	Morning vs. evening chronotype;
CRC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.54	7.34	0.38	1.65e-12	Resting heart rate;
CRC	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.53	7.48	0.38	7.02e-13	Glioblastoma;Glioma;
CRC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg22110888	chr17:80059540	CCDC57	-0.44	-7.01	-0.36	1.36e-11	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03501777	chr10:45869613	ALOX5	0.38	5.99	0.31	5.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4908768	0.539	rs1061039	chr1:8642588	T/C	cg20416874	chr1:8611966	RERE	-0.4	-5.68	-0.3	3e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.37	-0.33	6.41e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs243505	0.691	rs243484	chr7:148448655	G/T	cg09806900	chr7:148480153	CUL1	-0.57	-7.15	-0.37	5.56e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg20936604	chr3:58311152	NA	-0.59	-5.66	-0.3	3.23e-8	Cholesterol, total;
CRC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.76	12.24	0.56	1.25e-28	Breast cancer;
CRC	cis	rs9287719	0.649	rs2884232	chr2:10719679	C/A	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs6681460	0.898	rs1032634	chr1:67195192	C/G	cg02459107	chr1:67143332	SGIP1	-0.36	-6.05	-0.32	3.9e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg01483505	chr11:975446	AP2A2	0.43	6.82	0.35	4.37e-11	Alzheimer's disease (late onset);
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.4	5.84	0.31	1.24e-8	Obesity-related traits;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-12.46	-0.57	1.89e-29	Height;
CRC	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.44	6.5	0.34	2.95e-10	Malaria;
CRC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.67	-0.35	1.06e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs963731	0.649	rs3765058	chr2:39189636	A/G	cg13401531	chr11:70333281	SHANK2	-0.74	-6.35	-0.33	7.11e-10	Corticobasal degeneration;
CRC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg25452165	chr22:42524984	CYP2D6	0.4	6.04	0.32	4.11e-9	Schizophrenia;
CRC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.89	-0.48	2.27e-20	Extrinsic epigenetic age acceleration;
CRC	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.52	-8.2	-0.41	5.31e-15	Corneal astigmatism;
CRC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg26721908	chr21:47610096	LSS	-0.46	-6.67	-0.34	1.11e-10	Testicular germ cell tumor;
CRC	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.74	9.66	0.47	1.34e-19	Blood protein levels;
CRC	cis	rs4662945	0.762	rs2406822	chr2:130218178	C/T	cg05962382	chr2:130345044	NA	-0.34	-5.77	-0.3	1.86e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.98	15.46	0.65	6.74e-41	Parkinson's disease;
CRC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.43	6.4	0.33	5.45e-10	Psychosis in Alzheimer's disease;
CRC	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.89	-0.31	9.7e-9	Height;
CRC	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.41	-0.33	5.04e-10	Caffeine consumption;
CRC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg15445000	chr17:37608096	MED1	0.4	8.65	0.43	2.37e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg24519413	chr1:26490540	NA	0.37	6.28	0.33	1.05e-9	Height;
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.59	8.92	0.44	3.28e-17	Bipolar disorder;
CRC	trans	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg26043149	chr18:55253948	FECH	0.51	7.85	0.4	5.94e-14	Bone mineral density;
CRC	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.55	6.16	0.32	2.15e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.59	-6.55	-0.34	2.2e-10	Blood protein levels;
CRC	cis	rs10838708	1.000	rs10838708	chr11:47441513	G/A	cg05585544	chr11:47624801	NA	-0.43	-7.36	-0.38	1.44e-12	Height;
CRC	trans	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.97	-0.36	1.79e-11	Endometrial cancer;
CRC	cis	rs35000415	0.938	rs12706861	chr7:128616582	C/T	cg19972273	chr7:128594194	NA	0.68	6.31	0.33	8.75e-10	Systemic lupus erythematosus;
CRC	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.61	-0.34	1.56e-10	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19069963	chr22:29663643	EWSR1;RHBDD3	0.37	6.11	0.32	2.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.08	-13.76	-0.6	2.34e-34	Vitiligo;
CRC	trans	rs9815354	0.857	rs73073252	chr3:42016891	C/T	cg04440885	chr16:51146856	NA	0.52	6.04	0.32	4.21e-9	Pulse pressure;Diastolic blood pressure;
CRC	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.09	0.49	4.82e-21	Asthma (childhood onset);
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg08888203	chr3:10149979	C3orf24	0.66	9.67	0.47	1.21e-19	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05596267	chr15:34331198	CHRM5;AVEN	0.38	6.0	0.31	5.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1223397	0.938	rs13205692	chr6:13291560	C/T	cg06879394	chr6:13274151	PHACTR1	0.53	6.21	0.32	1.57e-9	Blood pressure;
CRC	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg04110750	chr16:69646130	NFAT5	-0.55	-7.63	-0.39	2.53e-13	IgE levels;
CRC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.83	-14.06	-0.61	1.78e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9908102	0.740	rs7211778	chr17:12901227	A/C	cg26162695	chr17:12921313	ELAC2	0.46	6.43	0.33	4.39e-10	Schizophrenia;
CRC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.47	-0.34	3.6e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.74	9.72	0.47	8.79e-20	Coronary artery disease;
CRC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	14.61	0.63	1.33e-37	Gut microbiome composition (summer);
CRC	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg15083037	chr5:83017644	HAPLN1	-0.46	-5.97	-0.31	6.03e-9	Prostate cancer;
CRC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	1.01	19.62	0.73	2.77e-57	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg20885578	chr2:198174922	NA	-0.43	-6.93	-0.36	2.16e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.5	-5.74	-0.3	2.21e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.6	8.55	0.43	4.62e-16	Multiple sclerosis;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg02033258	chr5:131593261	PDLIM4	0.46	8.66	0.43	2.08e-16	Acylcarnitine levels;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg26618056	chr16:25043323	NA	0.48	6.38	0.33	5.99e-10	Plasma plasminogen activator levels;
CRC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.41	7.33	0.37	1.8e-12	Schizophrenia;
CRC	cis	rs2953174	0.507	rs4234123	chr2:241541640	C/T	cg07929629	chr2:241523174	NA	0.66	9.43	0.46	7.8e-19	Bipolar disorder;
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.22	-0.41	4.71e-15	Total body bone mineral density;
CRC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg16892393	chr17:41919603	NA	0.46	7.12	0.37	6.77e-12	Triglycerides;
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.61	-9.56	-0.47	2.97e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2072510	0.569	rs2540488	chr12:96426745	G/A	cg15438951	chr12:96389694	HAL	-0.51	-6.23	-0.32	1.46e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg23202291	chr11:1979235	NA	0.47	6.41	0.33	5.08e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg22561889	chr6:118971681	C6orf204	0.5	6.25	0.33	1.24e-9	Diastolic blood pressure;
CRC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-11.11	-0.52	1.4e-24	Blood trace element (Zn levels);
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg00597713	chr6:42947103	PEX6	-0.4	-5.69	-0.3	2.88e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12172441	chr6:28176163	NA	0.49	6.64	0.34	1.28e-10	Parkinson's disease;
CRC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg19678392	chr7:94953810	PON1	0.51	6.48	0.34	3.3e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.24	0.33	1.37e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.93	-0.36	2.22e-11	Response to antipsychotic treatment;
CRC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg04880052	chr2:219191631	PNKD	-0.42	-6.66	-0.34	1.14e-10	Colorectal cancer;
CRC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	7.72	0.39	1.42e-13	Mean corpuscular volume;
CRC	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.49	9.9	0.48	2.21e-20	Hand grip strength;
CRC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg27535305	chr1:53392650	SCP2	0.38	7.08	0.36	8.86e-12	Monocyte count;
CRC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.56	-0.5	1.23e-22	Chronic sinus infection;
CRC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.61e-9	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15600987	chr1:151483609	CGN	0.46	6.38	0.33	6.02e-10	Anxiety disorder;
CRC	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg00250761	chr1:31883323	NA	-0.43	-8.25	-0.41	3.92e-15	Alcohol dependence;
CRC	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg11579758	chr4:1086637	RNF212	0.41	6.68	0.35	1.01e-10	Recombination rate (males);
CRC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.38	-5.7	-0.3	2.7e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs597583	0.950	rs473343	chr11:117408156	G/C	cg27161313	chr11:117392002	DSCAML1	-0.4	-5.9	-0.31	9.03e-9	Putamen volume;
CRC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	5.91	0.31	8.69e-9	Height;
CRC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg08314208	chr16:67682810	RLTPR	-0.65	-7.04	-0.36	1.12e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs394563	0.601	rs432582	chr6:149794143	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.41	-6.77	-0.35	5.83e-11	Dupuytren's disease;
CRC	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg15382696	chr6:118971807	C6orf204	-0.36	-5.71	-0.3	2.58e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
CRC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg24209194	chr3:40518798	ZNF619	0.45	6.89	0.36	2.81e-11	Renal cell carcinoma;
CRC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-16.18	-0.67	1.03e-43	Prostate cancer;
CRC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg05623727	chr3:50126028	RBM5	-0.44	-7.51	-0.38	5.58e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.39	6.87	0.35	3.15e-11	Cardiovascular disease risk factors;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg20615401	chr6:28092323	ZSCAN16	0.46	6.21	0.32	1.62e-9	Parkinson's disease;
CRC	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.3	-0.37	2.17e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02825527	chr7:2087843	MAD1L1	-0.46	-5.65	-0.3	3.39e-8	Neuroticism;
CRC	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.67	10.48	0.5	2.25e-22	Corneal astigmatism;
CRC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	6.8	0.35	4.95e-11	Schizophrenia;
CRC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.55	8.33	0.42	2.15e-15	Morning vs. evening chronotype;
CRC	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg20356878	chr3:121714668	ILDR1	-0.46	-6.13	-0.32	2.47e-9	Multiple sclerosis;
CRC	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.96	-0.31	6.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-6.19	-0.32	1.83e-9	Menarche (age at onset);
CRC	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg02811702	chr13:24901961	NA	0.42	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.75	9.02	0.45	1.59e-17	Response to hepatitis C treatment;
CRC	cis	rs4728302	0.869	rs10224683	chr7:133590937	A/G	cg03336402	chr7:133662267	EXOC4	0.43	6.36	0.33	6.87e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.41	-5.64	-0.3	3.73e-8	Menarche (age at onset);
CRC	trans	rs12699921	0.632	rs2691597	chr7:17870340	C/T	cg02066331	chr6:17282778	RBM24	-0.36	-6.19	-0.32	1.8e-9	Fibrinogen levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20803232	chr8:42995089	HGSNAT	0.5	7.29	0.37	2.27e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.42	-0.38	9.76e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6840360	0.541	rs4696251	chr4:152266326	T/C	cg09659197	chr4:152720779	NA	0.34	6.63	0.34	1.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.66	-0.3	3.25e-8	Tuberculosis;
CRC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.37	-6.16	-0.32	2.1e-9	Childhood ear infection;
CRC	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.57	8.54	0.43	4.9e-16	Lewy body disease;
CRC	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.72	-0.51	3.41e-23	Alzheimer's disease;
CRC	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg20578329	chr17:80767326	TBCD	-0.81	-9.79	-0.48	4.92e-20	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.54	-8.22	-0.41	4.86e-15	Lewy body disease;
CRC	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.6	-9.03	-0.45	1.49e-17	Type 2 diabetes;
CRC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.77	7.8	0.4	8.13e-14	Diabetic retinopathy;
CRC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg11843238	chr5:131593191	PDLIM4	-0.5	-8.71	-0.43	1.55e-16	Acylcarnitine levels;
CRC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg16434002	chr17:42200994	HDAC5	-0.45	-6.17	-0.32	2.02e-9	Total body bone mineral density;
CRC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.43	5.77e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.57	8.22	0.41	4.88e-15	Resting heart rate;
CRC	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.49	8.93	0.44	3.17e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.42	-9.08	-0.45	1.04e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg15845792	chr6:28175446	NA	0.5	6.79	0.35	5.21e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg18016565	chr1:150552671	MCL1	-0.42	-6.22	-0.32	1.5e-9	Tonsillectomy;
CRC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg17321639	chr7:2759063	NA	-0.38	-5.8	-0.3	1.58e-8	Height;
CRC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.7	-8.61	-0.43	3.04e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04966789	chr14:35591779	PPP2R3C;KIAA0391	0.49	6.16	0.32	2.12e-9	Thyroid stimulating hormone;
CRC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.53	11.51	0.54	5.44e-26	Alcohol dependence;
CRC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.54	-7.13	-0.37	6.25e-12	Height;
CRC	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg09324608	chr17:30823087	MYO1D	0.36	6.19	0.32	1.79e-9	Schizophrenia;
CRC	cis	rs3996993	0.597	rs62412901	chr6:52724949	G/A	cg20803780	chr6:52668592	GSTA1	0.39	6.6	0.34	1.62e-10	Hemoglobin concentration;
CRC	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.46	-6.62	-0.34	1.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs3736485	0.934	rs1902593	chr15:51882080	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.56	-0.34	2.11e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.7	-0.3	2.64e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg10876282	chr6:28092338	ZSCAN16	0.4	5.76	0.3	1.93e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-20.7	-0.75	1.52e-61	Primary sclerosing cholangitis;
CRC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg26727032	chr16:67993705	SLC12A4	0.6	7.36	0.38	1.44e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.82	13.86	0.61	1e-34	Menopause (age at onset);
CRC	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.76	9.43	0.46	7.35e-19	Type 2 diabetes;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Parkinson's disease;
CRC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg13722127	chr7:150037890	RARRES2	0.4	5.75	0.3	2.05e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.26	-0.56	1.03e-28	Alzheimer's disease;
CRC	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-6.64	-0.34	1.26e-10	Breast cancer;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.34	-0.33	7.62e-10	Longevity;
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	10.01	0.48	8.96e-21	Calcium levels;
CRC	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.8e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.4	5.69	0.3	2.77e-8	Parkinson's disease;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.36	-5.62	-0.3	4.15e-8	Acylcarnitine levels;
CRC	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg20169779	chr10:135381914	SYCE1	-0.67	-11.46	-0.53	8.33e-26	Obesity-related traits;
CRC	cis	rs501916	0.575	rs56345741	chr15:48065010	A/C	cg16110827	chr15:48056943	SEMA6D	-0.44	-6.49	-0.34	3.08e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-11.46	-0.53	8.12e-26	Personality dimensions;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg21251018	chr6:28226885	NKAPL	0.52	8.02	0.4	1.86e-14	Parkinson's disease;
CRC	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg12856521	chr11:46389249	DGKZ	0.41	6.56	0.34	2.1e-10	Leprosy;
CRC	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.58	-0.34	1.86e-10	Subjective well-being;
CRC	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.21e-13	QT interval;
CRC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-18.26	-0.71	6.14e-52	Height;
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.9	-0.36	2.7e-11	Bipolar disorder;
CRC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	6.63	0.34	1.4e-10	Cognitive test performance;
CRC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.37	6.34	0.33	7.77e-10	Major depressive disorder;
CRC	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.19	0.45	4.44e-18	Blood protein levels;
CRC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg14137381	chr5:502291	SLC9A3	-0.33	-5.65	-0.3	3.43e-8	Cystic fibrosis severity;
CRC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-8.03	-0.4	1.76e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg25456477	chr12:86230367	RASSF9	-0.39	-6.54	-0.34	2.36e-10	Major depressive disorder;
CRC	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.13	12.71	0.57	2.16e-30	Mitochondrial DNA levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06112779	chr12:54982626	PPP1R1A	0.39	6.62	0.34	1.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg15382696	chr6:118971807	C6orf204	0.59	7.46	0.38	7.96e-13	Diastolic blood pressure;
CRC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg10645314	chr2:3704589	ALLC	-0.55	-6.45	-0.34	4.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs17152411	1.000	rs17152374	chr10:126592644	T/C	cg07906193	chr10:126599966	NA	0.54	5.64	0.3	3.67e-8	Height;
CRC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	8.01	0.4	2.04e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10274279	1.000	rs73163816	chr7:157388126	C/G	cg26886268	chr7:157387156	PTPRN2	-0.48	-5.81	-0.31	1.45e-8	Myopia (pathological);
CRC	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg23254163	chr1:152506842	NA	0.44	8.62	0.43	2.8e-16	Hair morphology;
CRC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	6.5	0.34	2.92e-10	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12273811	chr6:28175739	NA	0.61	8.39	0.42	1.45e-15	Parkinson's disease;
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg06470822	chr6:28175283	NA	0.66	10.08	0.49	5.48e-21	Cardiac Troponin-T levels;
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg07617317	chr6:118971624	C6orf204	0.52	6.47	0.34	3.53e-10	Diastolic blood pressure;
CRC	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.61	-9.17	-0.45	5.41e-18	Blood pressure (smoking interaction);
CRC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.43	7.64	0.39	2.37e-13	Longevity;
CRC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg16476235	chr8:21771668	DOK2	0.37	6.18	0.32	1.89e-9	Mean corpuscular volume;
CRC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14479329	chr6:167370587	RNASET2	0.52	8.36	0.42	1.8e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.4	5.8	0.3	1.54e-8	Obesity-related traits;
CRC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-8.99	-0.44	2.02e-17	Chronic sinus infection;
CRC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.53	8.62	0.43	2.89e-16	Coronary artery disease;
CRC	cis	rs9549260	0.632	rs7323267	chr13:41204015	A/G	cg21288729	chr13:41239152	FOXO1	0.48	5.91	0.31	8.66e-9	Red blood cell count;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00282216	chr8:145823653	KIAA1688	-0.43	-6.67	-0.35	1.1e-10	Interleukin-6 levels;
CRC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.46	-6.49	-0.34	3.17e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.81	0.35	4.68e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg02033258	chr5:131593261	PDLIM4	0.49	8.75	0.43	1.13e-16	Acylcarnitine levels;
CRC	cis	rs863345	0.604	rs10797022	chr1:158494193	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-5.93	-0.31	7.72e-9	Pneumococcal bacteremia;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.74	10.58	0.5	1.06e-22	Menarche (age at onset);
CRC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.84	-16.97	-0.68	7.46e-47	Post bronchodilator FEV1;
CRC	cis	rs939584	1.000	rs13386627	chr2:650560	G/C	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.5	0.46	4.53e-19	Height;
CRC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-12.66	-0.57	3.28e-30	Vitiligo;
CRC	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.86	-17.02	-0.68	4.83e-47	Oral cavity cancer;
CRC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.35	-0.5	6.51e-22	Chronic sinus infection;
CRC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg13047869	chr3:10149882	C3orf24	0.38	5.81	0.31	1.48e-8	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg19223190	chr17:80058835	NA	0.41	6.7	0.35	8.79e-11	Life satisfaction;
CRC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg09127314	chr1:152161683	NA	0.51	6.46	0.34	3.81e-10	Atopic dermatitis;
CRC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.39	6.46	0.34	3.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.27	-0.37	2.69e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.77	11.55	0.54	4.07e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.49	6.32	0.33	8.51e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg26893134	chr6:116381904	FRK	0.26	7.6	0.39	3.02e-13	Cholesterol, total;LDL cholesterol;
CRC	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.64	8.4	0.42	1.37e-15	Bipolar disorder;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg27532560	chr4:187881888	NA	-0.56	-10.16	-0.49	2.83e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.55	8.2	0.41	5.28e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg00334542	chr7:100209784	MOSPD3	-0.52	-6.63	-0.34	1.38e-10	Other erythrocyte phenotypes;
CRC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.21	-16.66	-0.68	1.3e-45	Breast cancer;
CRC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg22482690	chr17:47019901	SNF8	0.48	7.96	0.4	2.83e-14	Type 2 diabetes;
CRC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.45	-8.19	-0.41	5.98e-15	Reticulocyte fraction of red cells;
CRC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.53	9.68	0.47	1.17e-19	Vitiligo;
CRC	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg15654264	chr1:150340011	RPRD2	0.42	6.2	0.32	1.68e-9	Migraine;
CRC	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.8	-14.31	-0.62	1.91e-36	Colorectal cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08187779	chr8:102217898	ZNF706	0.41	6.8	0.35	4.99e-11	Interleukin-6 levels;
CRC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.17e-23	Motion sickness;
CRC	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.81	-0.31	1.46e-8	Response to antipsychotic treatment;
CRC	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg06915193	chr4:185205329	NA	-0.38	-5.93	-0.31	7.46e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
CRC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.84	15.36	0.65	1.54e-40	Menopause (age at onset);
CRC	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.27	-0.37	2.66e-12	Capecitabine sensitivity;
CRC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg25344623	chr2:136566232	LCT	-0.32	-5.87	-0.31	1.06e-8	Mosquito bite size;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg14010720	chr20:62168878	PTK6	0.29	6.38	0.33	5.99e-10	Myopia;
CRC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg00343986	chr7:65444356	GUSB	0.49	7.22	0.37	3.53e-12	Aortic root size;
CRC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.41	-6.49	-0.34	3.21e-10	Menopause (age at onset);
CRC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-7.32	-0.37	1.96e-12	Blood pressure (smoking interaction);
CRC	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg23229984	chr5:148520753	ABLIM3	-0.52	-7.19	-0.37	4.5e-12	Breast cancer;
CRC	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.73	-11.89	-0.55	2.25e-27	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05521474	chr5:135082196	NA	-0.41	-6.73	-0.35	7.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06319359	chr1:22109595	USP48	0.45	6.33	0.33	8.16e-10	Anxiety disorder;
CRC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg08314208	chr16:67682810	RLTPR	-0.57	-6.09	-0.32	3.17e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.5	6.71	0.35	8.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg24046110	chr8:143859143	LYNX1	-0.37	-6.43	-0.33	4.57e-10	Urinary tract infection frequency;
CRC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.17	0.64	8.68e-40	Smoking behavior;
CRC	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg09003973	chr2:102972529	NA	0.41	5.86	0.31	1.12e-8	Blood protein levels;
CRC	cis	rs67981189	0.558	rs56043821	chr14:71570552	T/C	cg15910301	chr14:71632612	NA	0.31	6.15	0.32	2.24e-9	Schizophrenia;
CRC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.33	-0.67	2.51e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.77	-9.29	-0.46	2.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs55675132	0.548	rs12120506	chr1:115377777	C/T	cg25493687	chr8:27288214	PTK2B	0.49	6.0	0.31	5.23e-9	Schizophrenia;
CRC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.65	-7.55	-0.38	4.35e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.45	8.69	0.43	1.77e-16	Alcohol dependence;
CRC	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.67	0.39	2e-13	Neuroticism;
CRC	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg08461752	chr10:43522343	NA	-0.63	-5.93	-0.31	7.78e-9	Blood protein levels;
CRC	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg00919237	chr7:87102261	ABCB4	-0.54	-7.18	-0.37	4.66e-12	Gallbladder cancer;
CRC	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.9	-0.31	9e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	9.97	0.48	1.21e-20	Platelet count;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-7.23	-0.37	3.38e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.52	-6.78	-0.35	5.42e-11	Menarche (age at onset);
CRC	cis	rs713477	1.000	rs8014526	chr14:55885054	C/G	cg13175173	chr14:55914753	NA	-0.47	-8.57	-0.43	4e-16	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.35	-7.18	-0.37	4.7e-12	Electroencephalogram traits;
CRC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	11.85	0.55	3.35e-27	Menarche (age at onset);
CRC	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg23254163	chr1:152506842	NA	0.43	7.36	0.38	1.48e-12	Hair morphology;
CRC	cis	rs10743315	0.778	rs7397459	chr12:19377578	C/G	cg02471346	chr12:19282374	PLEKHA5	0.61	7.9	0.4	4.32e-14	Gut microbiota (bacterial taxa);
CRC	trans	rs1973993	0.745	rs56119386	chr1:96962215	C/T	cg10631902	chr5:14652156	NA	-0.4	-6.72	-0.35	7.89e-11	Weight;
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.95	0.55	1.39e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.3e-9	Prudent dietary pattern;
CRC	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.74	9.91	0.48	2.05e-20	White matter hyperintensity burden;
CRC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.55	-8.01	-0.4	2.06e-14	Fibrinogen levels;
CRC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-7.76	-0.39	1.1e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.09	0.32	3.18e-9	Heart rate;
CRC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06138931	chr13:21896616	NA	0.54	6.87	0.35	3.16e-11	White matter hyperintensity burden;
CRC	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	9.58	0.47	2.49e-19	Type 2 diabetes;
CRC	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg21839984	chr17:30846986	MYO1D	-0.35	-5.89	-0.31	9.55e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26976744	chr8:120845108	TAF2	0.38	6.14	0.32	2.35e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg04204079	chr8:58130323	NA	-0.46	-5.8	-0.3	1.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg18830697	chr6:72922368	RIMS1	-0.4	-7.93	-0.4	3.37e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs713477	0.654	rs6573030	chr14:55913720	T/G	cg21836586	chr14:55907198	TBPL2	0.35	6.43	0.33	4.54e-10	Pediatric bone mineral content (femoral neck);
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg20512303	chr5:131592959	PDLIM4	0.4	7.55	0.38	4.36e-13	Acylcarnitine levels;
CRC	trans	rs11088226	0.581	rs2833860	chr21:33882309	G/A	cg09050820	chr6:167586206	TCP10L2	0.52	7.14	0.37	5.97e-12	Gastritis;
CRC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.38	7.38e-13	Lung cancer in ever smokers;
CRC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.14	-0.32	2.43e-9	Alzheimer's disease (late onset);
CRC	trans	rs2814331	0.825	rs2814342	chr10:88003609	T/C	cg23982858	chr12:95941869	USP44	-0.51	-6.05	-0.32	3.9e-9	Balding;
CRC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-7.03	-0.36	1.23e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-6.33	-0.33	8.22e-10	Blood metabolite levels;
CRC	cis	rs7572644	0.679	rs4447576	chr2:28076248	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.1	0.32	3.03e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs4666002	0.789	rs12998770	chr2:27913188	T/C	cg27432699	chr2:27873401	GPN1	0.55	7.02	0.36	1.27e-11	Phospholipid levels (plasma);
CRC	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	7.79	0.39	8.75e-14	Body mass index;
CRC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg16681516	chr19:46297285	DMWD	0.38	6.1	0.32	2.97e-9	Coronary artery disease;
CRC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.51	7.14	0.37	6.09e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg21659725	chr3:3221576	CRBN	0.61	6.32	0.33	8.72e-10	Menarche (age at onset);
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-8.75	-0.43	1.14e-16	Bipolar disorder;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg23161317	chr6:28129485	ZNF389	0.38	5.8	0.3	1.55e-8	Cardiac Troponin-T levels;
CRC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	8.19	0.41	5.85e-15	Platelet count;
CRC	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.45	5.61	0.3	4.3e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs12143943	0.966	rs3789046	chr1:204586805	G/A	cg17419461	chr1:204415978	PIK3C2B	0.41	6.22	0.32	1.47e-9	Cognitive performance;
CRC	cis	rs9467160	1.000	rs9295624	chr6:24439600	A/G	cg20631270	chr6:24437470	GPLD1	-0.51	-6.46	-0.34	3.81e-10	Liver enzyme levels;
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg15786705	chr6:28176104	NA	0.54	7.17	0.37	4.95e-12	Parkinson's disease;
CRC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.53	7.92	0.4	3.59e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg11861562	chr11:117069780	TAGLN	0.34	6.33	0.33	8.16e-10	Blood protein levels;
CRC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.68	9.55	0.47	3.05e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.37	5.8	0.3	1.59e-8	Height;
CRC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg12935359	chr14:103987150	CKB	-0.37	-6.14	-0.32	2.44e-9	Body mass index;
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-7.22	-0.37	3.55e-12	Lymphocyte counts;
CRC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.51	0.34	2.88e-10	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05634287	chr5:148931071	CSNK1A1	0.4	6.13	0.32	2.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.73	0.43	1.3e-16	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-7.64	-0.39	2.35e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs73206853	0.543	rs7972256	chr12:110575444	G/A	cg12870014	chr12:110450643	ANKRD13A	0.81	9.45	0.46	6.46e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4321325	0.733	rs13421996	chr2:127934812	G/T	cg11380483	chr2:127933992	NA	0.63	7.74	0.39	1.28e-13	Protein C levels;
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14159672	chr1:205819179	PM20D1	0.41	5.62	0.3	4.13e-8	Parkinson's disease;
CRC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.48	6.5	0.34	3.02e-10	Height;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-0.85	-12.07	-0.55	5e-28	Intelligence (multi-trait analysis);
CRC	trans	rs492478	0.892	rs76693729	chr5:3933574	A/G	cg09199442	chr11:28132951	METT5D1	-0.71	-6.34	-0.33	7.54e-10	Cognitive performance;
CRC	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-7.48	-0.38	7e-13	Coronary artery disease;
CRC	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.56	-9.44	-0.46	7.1e-19	Graves' disease;
CRC	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.66e-9	Corneal astigmatism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14756197	chr21:45196586	CSTB	0.44	6.16	0.32	2.15e-9	Anxiety disorder;
CRC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.32	-5.86	-0.31	1.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11229555	0.645	rs7931394	chr11:58212617	T/A	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.34	0.46	1.52e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg12365402	chr11:9010492	NRIP3	-0.49	-8.26	-0.41	3.66e-15	Hemoglobin concentration;
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg20041105	chr8:143859282	LYNX1	-0.41	-6.78	-0.35	5.42e-11	Urinary tract infection frequency;
CRC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.56	-7.64	-0.39	2.42e-13	Colorectal cancer;
CRC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.18e-35	Mean platelet volume;
CRC	trans	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg18288967	chr1:45987694	PRDX1	0.66	6.41	0.33	4.93e-10	Obesity-related traits;
CRC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.37	-0.42	1.7e-15	Personality dimensions;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10326891	chr4:88343821	NUDT9	0.39	6.06	0.32	3.76e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.09	18.64	0.72	1.93e-53	Cognitive function;
CRC	cis	rs727505	0.607	rs66478705	chr7:124789211	C/G	cg23710748	chr7:124431027	NA	-0.64	-10.24	-0.49	1.56e-21	Lewy body disease;
CRC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	16.07	0.66	2.72e-43	Electrocardiographic conduction measures;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05926280	chr4:77997196	CCNI	0.41	6.0	0.31	5.11e-9	Response to antipsychotic treatment;
CRC	cis	rs17443541	0.507	rs6742907	chr2:200455180	C/A	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-6.4	-0.33	5.38e-10	Mean corpuscular hemoglobin concentration;
CRC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.05	-0.68	3.89e-47	Height;
CRC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.43	5.65	0.3	3.5e-8	Total body bone mineral density;
CRC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.56	8.88	0.44	4.37e-17	Eosinophil percentage of white cells;
CRC	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg05044414	chr3:183734942	ABCC5	0.42	7.49	0.38	6.38e-13	Anterior chamber depth;
CRC	cis	rs2982552	0.903	rs2982555	chr6:152057656	A/C	cg22157087	chr6:152012887	ESR1	0.39	5.94	0.31	7.16e-9	Bone properties (heel);
CRC	cis	rs720844	1.000	rs13004738	chr2:149343644	C/T	cg09247360	chr2:149335327	NA	-0.62	-7.8	-0.39	8.45e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg25804541	chr17:80189381	SLC16A3	0.31	6.02	0.32	4.61e-9	Life satisfaction;
CRC	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	10.11	0.49	4.12e-21	Monocyte count;
CRC	trans	rs12408261	0.843	rs1342552	chr1:189311683	C/G	cg20050113	chr2:103236861	SLC9A2	0.25	6.04	0.32	4.08e-9	Number of pregnancies;
CRC	cis	rs6429082	0.509	rs2803845	chr1:235520228	C/G	cg26050004	chr1:235667680	B3GALNT2	0.46	6.72	0.35	8.12e-11	Adiposity;
CRC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.89	0.44	4.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7259376	0.905	rs8112246	chr19:22567447	C/T	cg02657401	chr19:22469223	NA	-0.33	-7.23	-0.37	3.4e-12	Menopause (age at onset);
CRC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.52	7.43	0.38	9.67e-13	Schizophrenia;
CRC	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.59	8.71	0.43	1.53e-16	Lung cancer;
CRC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	11.86	0.55	2.92e-27	Menopause (age at onset);
CRC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg15845792	chr6:28175446	NA	0.47	6.5	0.34	3.06e-10	Pulmonary function;
CRC	trans	rs2303319	0.504	rs60824222	chr2:162368719	A/C	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.54e-9	Cognitive function;
CRC	cis	rs1223397	0.938	rs3817738	chr6:13279388	G/T	cg00460589	chr6:13274354	PHACTR1	0.51	5.97	0.31	6.03e-9	Blood pressure;
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.5	-0.42	6.63e-16	Life satisfaction;
CRC	cis	rs2070997	0.702	rs2229070	chr9:133760029	C/G	cg01000188	chr9:133769184	QRFP	0.58	5.88	0.31	9.98e-9	Response to amphetamines;
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.6	9.12	0.45	7.5e-18	Birth weight;
CRC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.56	8.38	0.42	1.6e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg01339444	chr6:118972232	C6orf204	0.52	5.9	0.31	8.98e-9	Diastolic blood pressure;
CRC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.19	0.32	1.8e-9	Prudent dietary pattern;
CRC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.29	-0.42	2.99e-15	Hemoglobin concentration;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	19.34	0.73	3.27e-56	Prudent dietary pattern;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg25840210	chr13:45152287	NA	-0.4	-5.96	-0.31	6.45e-9	HDL cholesterol;
CRC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	trans	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg23260799	chr11:451101	PTDSS2	0.5	6.05	0.32	3.96e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.44	-6.36	-0.33	6.92e-10	Male sexual orientation;
CRC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg25876840	chr17:41920477	NA	0.61	8.53	0.43	5.25e-16	Triglycerides;
CRC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.87	0.48	2.71e-20	Platelet count;
CRC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7973719	0.966	rs7310539	chr12:7329996	C/G	cg07052231	chr12:7363540	PEX5	0.5	8.16	0.41	7.34e-15	IgG glycosylation;
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg24503407	chr1:205819492	PM20D1	0.46	6.34	0.33	7.63e-10	Parkinson's disease;
CRC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg20243544	chr17:37824526	PNMT	0.37	5.69	0.3	2.79e-8	Self-reported allergy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10796467	chr19:11546103	CCDC151;PRKCSH	0.45	6.38	0.33	6.05e-10	Response to antipsychotic treatment;
CRC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	7.53	0.38	4.91e-13	Lung cancer in ever smokers;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24094675	chr7:1015382	COX19	0.45	6.85	0.35	3.64e-11	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.59	10.17	0.49	2.63e-21	Bone mineral density;
CRC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.74	-12.06	-0.55	5.72e-28	Total body bone mineral density;
CRC	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg04969067	chr8:143858791	LYNX1	-0.36	-6.07	-0.32	3.58e-9	Urinary tract infection frequency;
CRC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	7.23	0.37	3.36e-12	Menarche (age at onset);
CRC	trans	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg10756647	chr7:56101905	PSPH	0.69	7.54	0.38	4.72e-13	Diabetic kidney disease;
CRC	cis	rs9392556	0.600	rs611500	chr6:4126763	C/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.23	5.86	0.31	1.11e-8	Blood metabolite levels;
CRC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg20295408	chr7:1910781	MAD1L1	0.46	6.3	0.33	9.4e-10	Bipolar disorder and schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02322140	chr16:9057781	USP7	0.45	6.08	0.32	3.34e-9	Anxiety disorder;
CRC	cis	rs4363385	0.776	rs1890284	chr1:152942190	G/A	cg25856811	chr1:152973957	SPRR3	-0.21	-5.82	-0.31	1.4e-8	Inflammatory skin disease;
CRC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.85	15.02	0.64	3.54e-39	Breast cancer;
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg22718636	chr4:961658	DGKQ	0.28	5.99	0.31	5.52e-9	Sjögren's syndrome;
CRC	cis	rs911119	0.954	rs2254635	chr20:23622758	G/T	cg16589663	chr20:23618590	CST3	0.59	8.57	0.43	4.05e-16	Chronic kidney disease;
CRC	cis	rs939584	1.000	rs7601028	chr2:642499	C/G	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg23815491	chr16:72088622	HP	0.5	7.6	0.39	3.09e-13	Fibrinogen levels;
CRC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.43	6.91	0.36	2.57e-11	Resting heart rate;
CRC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg05313129	chr8:58192883	C8orf71	0.45	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.68	9.48	0.46	5.11e-19	Vitiligo;
CRC	cis	rs1355223	0.867	rs7925421	chr11:34681677	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.92	-0.31	8.2e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg09873164	chr1:152488093	CRCT1	0.36	6.13	0.32	2.48e-9	Hair morphology;
CRC	trans	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.58	-7.61	-0.39	2.94e-13	Platelet count;
CRC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.63	10.23	0.49	1.61e-21	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.44	-6.5	-0.34	2.92e-10	Body mass index;
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg11266682	chr4:10021025	SLC2A9	0.39	6.19	0.32	1.76e-9	Blood metabolite levels;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg20647610	chr2:228736258	WDR69	-0.48	-6.52	-0.34	2.58e-10	Blood pressure;
CRC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-11.5	-0.54	6.09e-26	Coronary artery disease;
CRC	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.62	-8.49	-0.42	7.24e-16	Coronary artery disease;
CRC	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.48	6.79	0.35	5.31e-11	Corneal astigmatism;
CRC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg05709478	chr1:6581295	PLEKHG5	0.64	6.3	0.33	9.37e-10	Body mass index;
CRC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.39	6.09	0.32	3.22e-9	Crohn's disease;
CRC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg19500275	chr17:80737654	TBCD	-0.39	-5.94	-0.31	7.44e-9	Glycated hemoglobin levels;
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg12172441	chr6:28176163	NA	-0.6	-6.65	-0.34	1.22e-10	Parkinson's disease;
CRC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.77	12.93	0.58	3.28e-31	Menopause (age at onset);
CRC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.6	0.47	2.12e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs16975963	0.843	rs11083442	chr19:38427528	C/A	cg15135657	chr19:38346511	NA	-0.43	-5.75	-0.3	2.01e-8	Longevity;
CRC	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.64	-6.88	-0.35	2.95e-11	Verbal memory performance (residualized delayed recall change);
CRC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.53	8.0	0.4	2.08e-14	Corneal astigmatism;
CRC	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-5.98	-0.31	5.66e-9	Coronary artery disease;
CRC	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg01475377	chr6:109611718	NA	-0.34	-5.91	-0.31	8.78e-9	Reticulocyte fraction of red cells;
CRC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.5	8.43	0.42	1.12e-15	Systemic lupus erythematosus;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	11.17	0.52	8.95e-25	Alzheimer's disease;
CRC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-8.31	-0.42	2.54e-15	Metabolite levels;
CRC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.25	-0.56	1.1e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.53	-8.01	-0.4	1.99e-14	HDL cholesterol;
CRC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.6	8.45	0.42	9.39e-16	Homoarginine levels;
CRC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.41	-6.41	-0.33	5e-10	Type 2 diabetes;
CRC	cis	rs4965869	0.866	rs2412012	chr15:101974653	C/T	cg12371147	chr15:101978424	PCSK6	-0.41	-5.78	-0.3	1.75e-8	Platelet-derived growth factor BB levels;
CRC	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.74	-13.04	-0.58	1.25e-31	White blood cell count (basophil);
CRC	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg05304507	chr6:116381966	FRK	0.29	6.45	0.34	3.96e-10	Total cholesterol levels;
CRC	cis	rs12760731	0.720	rs35215865	chr1:178313756	G/A	cg00404053	chr1:178313656	RASAL2	1.2	10.39	0.5	4.61e-22	Obesity-related traits;
CRC	cis	rs10426930	0.607	rs2613762	chr19:5064948	T/G	cg18473234	chr19:5097819	KDM4B	-0.54	-6.73	-0.35	7.68e-11	Monocyte percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21545977	chr1:11741439	MAD2L2	0.48	6.53	0.34	2.46e-10	Anxiety disorder;
CRC	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.5	-0.34	3.05e-10	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-6.45	-0.34	4.01e-10	Schizophrenia;
CRC	cis	rs990171	0.506	rs9284725	chr2:102744854	C/A	cg22835712	chr2:102737379	NA	0.46	6.29	0.33	9.9e-10	Lymphocyte counts;
CRC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.51	6.49	0.34	3.07e-10	Longevity;
CRC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg13319975	chr6:146136371	FBXO30	0.4	5.89	0.31	9.62e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.66	-11.4	-0.53	1.4e-25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4728142	1.000	rs4728142	chr7:128573967	C/T	cg06630958	chr7:128577819	IRF5	-0.46	-7.88	-0.4	4.79e-14	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.81	-0.35	4.6e-11	Response to antipsychotic treatment;
CRC	cis	rs55702914	0.712	rs12619296	chr2:198148767	A/G	cg20885578	chr2:198174922	NA	-0.34	-5.99	-0.31	5.45e-9	Major depression and alcohol dependence;
CRC	cis	rs853679	0.760	rs9393909	chr6:28207200	A/G	cg15845792	chr6:28175446	NA	-0.57	-5.61	-0.3	4.21e-8	Depression;
CRC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.54	-7.99	-0.4	2.33e-14	Schizophrenia;
CRC	cis	rs7605827	0.930	rs10168299	chr2:15615063	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.95	0.31	6.81e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.86	0.4	5.59e-14	Cognitive ability;
CRC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.92	-0.48	1.78e-20	Monocyte count;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.63	-0.3	3.93e-8	Acylcarnitine levels;
CRC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	0.84	8.08	0.41	1.22e-14	Granulocyte percentage of myeloid white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02008025	chr2:102314465	MAP4K4	0.45	6.57	0.34	2.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg16576597	chr16:28551801	NUPR1	0.48	6.8	0.35	4.9e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.49	7.35	0.38	1.54e-12	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21739009	chr19:1591627	MBD3	0.42	5.97	0.31	6.23e-9	Response to antipsychotic treatment;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg14911132	chr11:61596755	FADS2	-0.52	-5.72	-0.3	2.43e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs938554	0.784	rs11722229	chr4:9980697	C/A	cg11266682	chr4:10021025	SLC2A9	0.35	5.62	0.3	4.06e-8	Blood metabolite levels;
CRC	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.54	-8.28	-0.42	3.05e-15	Primary sclerosing cholangitis;
CRC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-5.94	-0.31	7.11e-9	Eosinophil percentage of white cells;
CRC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.63	11.52	0.54	5.02e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12745968	0.590	rs1337107	chr1:93218776	A/G	cg17283838	chr1:93427260	FAM69A	-0.44	-6.05	-0.32	3.98e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.61	-9.53	-0.47	3.59e-19	Aortic root size;
CRC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg18230493	chr5:56204884	C5orf35	-0.51	-7.41	-0.38	1.08e-12	Coronary artery disease;
CRC	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.93	-12.48	-0.57	1.55e-29	Exhaled nitric oxide output;
CRC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.23	-0.32	1.4e-9	Menopause (age at onset);
CRC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg03037974	chr15:76606532	NA	-0.53	-8.33	-0.42	2.18e-15	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23975375	chr4:103997221	NHEDC2	0.37	6.05	0.32	3.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg22482690	chr17:47019901	SNF8	0.47	7.94	0.4	3.2e-14	Type 2 diabetes;
CRC	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-5.75	-0.3	2.01e-8	Alzheimer's disease (survival time);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26755928	chr19:10363173	MRPL4	0.51	6.6	0.34	1.67e-10	Thyroid stimulating hormone;
CRC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg18230493	chr5:56204884	C5orf35	-0.4	-5.98	-0.31	5.9e-9	Breast cancer;Breast cancer (early onset);
CRC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.16	-16.97	-0.68	7.37e-47	Hip circumference adjusted for BMI;
CRC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08550205	chr17:45786854	TBKBP1	-0.35	-5.75	-0.3	2.08e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	0.81	8.53	0.43	5.51e-16	Pediatric areal bone mineral density (radius);
CRC	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.52	9.95	0.48	1.47e-20	HIV-1 susceptibility;
CRC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.6	0.63	1.45e-37	Chronic sinus infection;
CRC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.73	-13.55	-0.6	1.48e-33	Prudent dietary pattern;
CRC	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg24046110	chr8:143859143	LYNX1	-0.44	-7.07	-0.36	9.18e-12	Urinary tract infection frequency;
CRC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.71	-9.53	-0.47	3.51e-19	Initial pursuit acceleration;
CRC	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.63	-7.32	-0.37	1.9e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.02	-0.48	8.18e-21	Bipolar disorder;
CRC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.59	-9.36	-0.46	1.29e-18	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11152033	chr20:61542496	DIDO1	-0.38	-6.14	-0.32	2.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.49	7.61	0.39	3.01e-13	Corneal astigmatism;
CRC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.38	-0.38	1.31e-12	Monocyte percentage of white cells;
CRC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.79	-0.39	8.93e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg09873164	chr1:152488093	CRCT1	0.38	6.28	0.33	1.04e-9	Hair morphology;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04152460	chr6:28109974	ZNF192	0.47	6.57	0.34	1.93e-10	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg22079747	chr2:228736145	WDR69	-0.45	-6.23	-0.32	1.43e-9	Blood pressure;
CRC	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg14458575	chr2:238380390	NA	0.83	10.4	0.5	4.44e-22	Prostate cancer;
CRC	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.44	6.26	0.33	1.23e-9	Body mass index;
CRC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25517755	chr10:38738941	LOC399744	0.42	5.98	0.31	5.86e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.58	-0.47	2.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg06470822	chr6:28175283	NA	0.67	6.62	0.34	1.48e-10	Depression;
CRC	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.46	7.97	0.4	2.59e-14	Common traits (Other);
CRC	cis	rs75804782	0.522	rs11889150	chr2:239324542	A/G	cg18131467	chr2:239335373	ASB1	-0.71	-8.88	-0.44	4.57e-17	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.44	-0.46	7.3e-19	Migraine;Coronary artery disease;
CRC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.91	-16.07	-0.66	2.64e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg20512303	chr5:131592959	PDLIM4	0.34	6.46	0.34	3.75e-10	Breast cancer;
CRC	cis	rs1178968	1.000	rs2353062	chr7:72740048	C/T	cg25889504	chr7:72793014	NA	0.52	6.0	0.31	5.19e-9	Triglyceride levels;
CRC	trans	rs2303319	0.504	rs66761688	chr2:162578911	T/C	cg12500891	chr11:57225987	NA	-0.67	-5.97	-0.31	6.24e-9	Cognitive function;
CRC	cis	rs4276421	0.577	rs10054424	chr5:45748871	A/T	cg07796823	chr5:45696928	HCN1	0.7	6.28	0.33	1.07e-9	P wave duration;
CRC	trans	rs9545047	0.716	rs9545061	chr13:79884830	G/A	cg07061582	chr15:90234082	PEX11A;WDR93	0.42	6.07	0.32	3.47e-9	Schizophrenia;
CRC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg15123519	chr2:136567270	LCT	0.33	6.39	0.33	5.65e-10	Mosquito bite size;
CRC	trans	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.91	0.36	2.48e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.71	9.35	0.46	1.44e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9409565	0.821	rs9299419	chr9:97066584	C/T	cg04523069	chr9:97136363	HIATL1	-0.39	-6.03	-0.32	4.33e-9	Colorectal cancer (alcohol consumption interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02499576	chr20:44601037	ZNF335	0.51	7.15	0.37	5.66e-12	Response to antipsychotic treatment;
CRC	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.69	8.26	0.41	3.53e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.42	-9.22	-0.45	3.61e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.89	0.51	8.98e-24	Platelet count;
CRC	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.54	-6.53	-0.34	2.49e-10	Coronary artery calcification;
CRC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.51	-6.68	-0.35	1.03e-10	Corneal structure;
CRC	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg05784532	chr1:230284198	GALNT2	0.44	6.19	0.32	1.75e-9	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01105557	chr1:15931098	NA	-0.38	-6.17	-0.32	2.03e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg07393940	chr7:158741817	NA	0.51	7.4	0.38	1.15e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.61	-9.64	-0.47	1.6e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-6.74	-0.35	6.95e-11	Monocyte count;
CRC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.47	6.21	0.32	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.37	0.33	6.35e-10	Menarche (age at onset);
CRC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg04731861	chr2:219085781	ARPC2	-0.33	-7.07	-0.36	9.07e-12	Colorectal cancer;
CRC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.45	0.71	1.13e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.1	-0.55	3.99e-28	Alzheimer's disease;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.64	-9.66	-0.47	1.34e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.6	-10.34	-0.5	7.11e-22	Body mass index;
CRC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg17031739	chr1:67600172	NA	0.51	7.98	0.4	2.45e-14	Psoriasis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22476295	chr7:559000	PDGFA	0.43	6.28	0.33	1.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg12193833	chr17:30244370	NA	-0.62	-8.01	-0.4	2e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg13072238	chr3:49761600	GMPPB	-0.51	-5.86	-0.31	1.15e-8	Menarche (age at onset);
CRC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.51	7.6	0.39	3.1400000000000003e-13	Emphysema distribution in smoking;
CRC	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.55	-8.85	-0.44	5.44e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.63	-9.7	-0.47	9.57e-20	Testicular germ cell tumor;
CRC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.76	10.48	0.5	2.31e-22	Heart rate;
CRC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.78	0.51	2.15e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.68	-10.13	-0.49	3.52e-21	Monocyte count;
CRC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.82	12.49	0.57	1.43e-29	Cognitive function;
CRC	cis	rs4604732	0.642	rs6426252	chr1:247639887	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.39	6.38	0.33	6.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.53	7.21	0.37	3.92e-12	Height;
CRC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg06138931	chr13:21896616	NA	0.56	7.14	0.37	6.03e-12	White matter hyperintensity burden;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11192808	chr8:101170185	SPAG1	-0.41	-6.1	-0.32	2.97e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24594819	chr4:105416480	NA	0.41	6.03	0.32	4.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.45	7.75	0.39	1.19e-13	Post-traumatic stress disorder;
CRC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.37	5.88	0.31	1.02e-8	Testicular germ cell tumor;
CRC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6662572	0.855	rs7517418	chr1:46252418	G/A	cg08644498	chr1:46502608	NA	-0.46	-7.38	-0.38	1.29e-12	Blood protein levels;
CRC	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg10845886	chr2:3471009	TTC15	-0.39	-6.02	-0.32	4.59e-9	Neurofibrillary tangles;
CRC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.31	-0.37	2.08e-12	Height;
CRC	cis	rs3762318	0.951	rs12095536	chr1:67600142	T/C	cg17031739	chr1:67600172	NA	0.49	5.98	0.31	5.84e-9	Leprosy;
CRC	cis	rs524281	0.861	rs7931544	chr11:65917034	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00556514	chr3:38066524	PLCD1	0.46	7.22	0.37	3.65e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.92	13.95	0.61	4.4e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg19025524	chr12:109796872	NA	-0.47	-6.72	-0.35	8e-11	Neuroticism;
CRC	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg23815491	chr16:72088622	HP	0.5	7.23	0.37	3.35e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg16928487	chr17:17741425	SREBF1	-0.44	-7.37	-0.38	1.39e-12	Total body bone mineral density;
CRC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg02725872	chr8:58115012	NA	-0.56	-6.76	-0.35	6.26e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs2292864	1.000	rs2292864	chr17:45367681	C/T	cg03564338	chr16:50585384	NKD1	0.62	6.01	0.31	4.88e-9	Left atrial antero-posterior diameter;
CRC	cis	rs9635542	0.833	rs60006336	chr16:5007563	C/T	cg06510647	chr16:5006106	NA	-0.61	-6.67	-0.34	1.1e-10	Lung cancer (asbestos exposure interaction);Cancer;
CRC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg23018236	chr17:30244563	NA	0.52	6.69	0.35	9.75e-11	Hip circumference adjusted for BMI;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00026974	chr17:42298151	UBTF	-0.42	-6.07	-0.32	3.54e-9	Myopia (pathological);
CRC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	16.72	0.68	7.41e-46	Platelet count;
CRC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.43	9.59	0.47	2.25e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05889321	chr10:97416837	ALDH18A1	0.45	6.68	0.35	1.02e-10	Response to antipsychotic treatment;
CRC	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg21153622	chr11:89784906	NA	-0.49	-7.98	-0.4	2.5e-14	Height;
CRC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg24140574	chr1:16342155	HSPB7	-0.42	-5.83	-0.31	1.35e-8	Dilated cardiomyopathy;
CRC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg22676075	chr6:135203613	NA	0.42	6.39	0.33	5.6e-10	Red blood cell count;
CRC	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.44	5.86	0.31	1.11e-8	Blood trace element (Cu levels);
CRC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8.07e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7680126	0.596	rs4698030	chr4:10315850	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.04	-0.32	4.17e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6747952	0.899	rs1374387	chr2:239085687	A/C	cg17459225	chr2:239074497	NA	0.46	7.96	0.4	2.91e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs652260	0.646	rs693941	chr19:7903851	C/T	cg26014689	chr19:7917955	EVI5L	-0.64	-10.53	-0.5	1.5e-22	Menarche (age at onset);
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.26	-0.37	2.79e-12	Total body bone mineral density;
CRC	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg15382696	chr6:118971807	C6orf204	0.6	7.57	0.39	3.76e-13	Diastolic blood pressure;
CRC	cis	rs4731207	0.596	rs115520589	chr7:124635877	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.18	-0.32	1.86e-9	Cutaneous malignant melanoma;
CRC	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	cg04338863	chr8:33670619	NA	0.44	6.95	0.36	1.93e-11	Body mass index;
CRC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.62	-0.34	1.43e-10	Alzheimer's disease (late onset);
CRC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12483801	chr4:183727862	NA	0.63	8.45	0.42	9.55e-16	Pediatric autoimmune diseases;
CRC	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.47	-0.38	7.25e-13	Inflammatory bowel disease;
CRC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.3	-0.46	1.96e-18	Mood instability;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.6	-8.53	-0.43	5.31e-16	Intelligence (multi-trait analysis);
CRC	cis	rs4903604	0.560	rs4903605	chr14:78035619	C/T	cg18872420	chr14:78023429	SPTLC2	0.37	6.18	0.32	1.91e-9	Gut microbiome composition (winter);
CRC	trans	rs7800418	0.723	rs1029556	chr7:26588186	G/A	cg14387656	chr2:233470847	EFHD1	0.46	6.37	0.33	6.36e-10	Cognitive function;
CRC	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg04586622	chr2:25135609	ADCY3	-0.56	-10.5	-0.5	1.94e-22	Body mass index in non-asthmatics;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	9.24	0.45	3.16e-18	Lymphocyte counts;
CRC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.56	10.41	0.5	4.15e-22	HDL cholesterol levels;
CRC	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.75	9.19	0.45	4.46e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.71e-10	Diabetic kidney disease;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	9.82	0.48	3.89e-20	Lymphocyte counts;
CRC	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg10437265	chr15:77819839	NA	-0.48	-7.9	-0.4	4.28e-14	Type 2 diabetes;
CRC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.75e-12	Menopause (age at onset);
CRC	cis	rs713477	1.000	rs28604440	chr14:55911324	C/T	cg13175173	chr14:55914753	NA	-0.47	-8.89	-0.44	4.09e-17	Pediatric bone mineral content (femoral neck);
CRC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.51	9.33	0.46	1.66e-18	Vitiligo;
CRC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.64	9.83	0.48	3.66e-20	Initial pursuit acceleration;
CRC	cis	rs1223397	0.651	rs2439542	chr6:13311823	G/A	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.5	7.55	0.38	4.25e-13	Methadone dose in opioid dependence;
CRC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-9.46	-0.46	6.1e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.79	-13.76	-0.6	2.47e-34	Breast cancer;
CRC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.68	11.12	0.52	1.36e-24	Colorectal cancer;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.17	-0.49	2.64e-21	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10982358	chr1:51435615	CDKN2C	0.44	6.71	0.35	8.58e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.52	-8.49	-0.42	7.14e-16	Crohn's disease;
CRC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.48	-6.42	-0.33	4.88e-10	Total body bone mineral density;
CRC	cis	rs720844	0.748	rs16829034	chr2:149349581	C/T	cg09247360	chr2:149335327	NA	-0.59	-6.01	-0.31	4.95e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg25452165	chr22:42524984	CYP2D6	0.44	6.51	0.34	2.8e-10	Cognitive function;
CRC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	9.45	0.46	6.5e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.35	0.56	4.96e-29	Coronary artery disease;
CRC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.37	0.53	1.78e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs16975963	0.843	rs241935	chr19:38293963	A/C	cg15135657	chr19:38346511	NA	0.43	5.83	0.31	1.35e-8	Longevity;
CRC	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-6.06	-0.32	3.64e-9	Lymphocyte counts;
CRC	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.34	-7.43	-0.38	9.36e-13	Total body bone mineral density;
CRC	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	7.84	0.4	6.12e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg04989706	chr14:50066350	PPIL5	-0.6	-8.19	-0.41	5.67e-15	Carotid intima media thickness;
CRC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.68	8.87	0.44	4.71e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.45	7.12	0.37	6.67e-12	Height;
CRC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.54	0.57	9.5e-30	Menopause (age at onset);
CRC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.07	-0.36	9.19e-12	Response to antipsychotic treatment;
CRC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.32	0.42	2.31e-15	Height;
CRC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.75	7.34	0.37	1.73e-12	Diabetic retinopathy;
CRC	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.99	18.25	0.71	6.79e-52	Gut microbiome composition (winter);
CRC	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.49	5.68	0.3	2.94e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg02683197	chr6:28174875	NA	0.7	7.39	0.38	1.24e-12	Parkinson's disease;
CRC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.37	0.33	6.35e-10	Height;
CRC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg23590916	chr17:43697445	MGC57346	0.71	7.24	0.37	3.1e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.34	-7.11	-0.36	7.29e-12	Renal cell carcinoma;
CRC	trans	rs948562	1.000	rs12365551	chr11:58358368	T/C	cg26660744	chr1:1573181	CDK11B	0.53	6.19	0.32	1.83e-9	Lymphoma;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg24463073	chr6:118973353	C6orf204	0.52	6.84	0.35	3.84e-11	Diastolic blood pressure;
CRC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.51	-0.38	5.75e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg11693508	chr17:37793320	STARD3	0.61	7.58	0.39	3.44e-13	Neuroticism;
CRC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.61	9.31	0.46	1.87e-18	Night sleep phenotypes;
CRC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.1	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg17724175	chr1:150552817	MCL1	0.4	6.1	0.32	2.98e-9	Melanoma;
CRC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.36	5.65	0.3	3.57e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.6	11.68	0.54	1.32e-26	Schizophrenia;
CRC	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg14458575	chr2:238380390	NA	0.52	6.86	0.35	3.51e-11	Prostate cancer;
CRC	cis	rs77861329	1.000	rs164638	chr3:52207886	T/G	cg08692210	chr3:52188851	WDR51A	0.85	7.95	0.4	2.99e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg14673194	chr17:80132900	CCDC57	-0.48	-6.02	-0.32	4.56e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.31	-0.33	9.16e-10	Aortic root size;
CRC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	9.72	0.47	8.72e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2811415	0.597	rs3774796	chr3:127780473	C/T	cg13719885	chr3:127795394	NA	0.4	6.08	0.32	3.33e-9	Lung function (FEV1/FVC);
CRC	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.72	9.79	0.47	4.95e-20	Coronary artery disease;
CRC	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg12963866	chr19:57752005	ZNF805	-0.41	-6.09	-0.32	3.15e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.91	13.76	0.6	2.34e-34	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg08888203	chr3:10149979	C3orf24	0.48	7.33	0.37	1.74e-12	Alzheimer's disease;
CRC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.56	-7.25	-0.37	2.95e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.78	-12.49	-0.57	1.51e-29	Diastolic blood pressure;
CRC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg25985355	chr7:65971099	NA	0.32	5.62	0.3	4.16e-8	Aortic root size;
CRC	cis	rs728616	0.681	rs36023925	chr10:81906846	T/C	cg11900509	chr10:81946545	ANXA11	-0.71	-8.0	-0.4	2.21e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.5	7.74	0.39	1.26e-13	Corneal astigmatism;
CRC	cis	rs4965869	0.806	rs34257513	chr15:101993017	G/A	cg12371147	chr15:101978424	PCSK6	-0.43	-5.99	-0.31	5.43e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg06028605	chr16:24865363	SLC5A11	0.39	7.26	0.37	2.9e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	10.75	0.51	2.74e-23	Platelet count;
CRC	cis	rs9462027	0.628	rs9462020	chr6:34751265	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.43	0.46	7.7e-19	Coffee consumption (cups per day);
CRC	cis	rs501120	1.000	rs479596	chr10:44760473	C/T	cg09554077	chr10:44749378	NA	0.78	11.84	0.55	3.45e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg22495460	chr2:25135724	ADCY3	0.87	14.76	0.63	3.34e-38	Body mass index;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg08546805	chr12:8549446	NA	-0.43	-6.52	-0.34	2.65e-10	Blood pressure (smoking interaction);
CRC	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.44	6.43	0.33	4.45e-10	Body mass index;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs711830	0.931	rs6755766	chr2:177043205	T/C	cg13092806	chr2:177043255	NA	0.75	9.53	0.47	3.51e-19	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.39	6.06	0.32	3.78e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03128421	chr2:55647401	CCDC88A	0.39	6.06	0.32	3.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.64	6.8	0.35	4.93e-11	Chronic lymphocytic leukemia;
CRC	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg09040174	chr2:113837401	NA	-0.64	-10.19	-0.49	2.26e-21	Protein quantitative trait loci;
CRC	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg07274523	chr3:49395745	GPX1	0.45	5.99	0.31	5.5e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);
CRC	cis	rs11031096	0.505	rs10835743	chr11:4226692	C/T	cg18678763	chr11:4115507	RRM1	-0.37	-5.61	-0.3	4.26e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.8	14.55	0.63	2.29e-37	Mean platelet volume;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg00959118	chr1:169455055	SLC19A2	0.49	5.98	0.31	5.79e-9	Plasma plasminogen activator levels;
CRC	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21659725	chr3:3221576	CRBN	0.66	7.31	0.37	2e-12	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16004202	chr4:159689901	FNIP2	0.4	6.54	0.34	2.32e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.24	0.45	3.17e-18	Cognitive test performance;
CRC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	trans	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.44	-6.53	-0.34	2.42e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.5	-0.34	2.95e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg15382696	chr6:118971807	C6orf204	0.56	6.89	0.36	2.84e-11	Diastolic blood pressure;
CRC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.33	-0.53	2.33e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs747650	0.859	rs4567413	chr11:47232184	A/G	cg19486271	chr11:47235900	DDB2	-0.52	-7.78	-0.39	9.22e-14	Acne (severe);
CRC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12292205	chr6:26970375	C6orf41	0.61	6.72	0.35	8.1e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg23193639	chr7:45961078	IGFBP3	0.39	6.54	0.34	2.42e-10	Sitting height ratio;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg24560729	chr4:1342394	KIAA1530	0.38	6.22	0.32	1.5e-9	Obesity-related traits;
CRC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg03286735	chr4:906491	GAK	0.27	5.92	0.31	7.93e-9	Systemic sclerosis;
CRC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg18016565	chr1:150552671	MCL1	0.42	6.06	0.32	3.8e-9	Melanoma;
CRC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg27661571	chr11:113659931	NA	-0.58	-7.29	-0.37	2.38e-12	Hip circumference adjusted for BMI;
CRC	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.16	-9.44	-0.46	7.24e-19	Mitochondrial DNA levels;
CRC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg11707556	chr5:10655725	ANKRD33B	0.47	7.61	0.39	2.89e-13	Height;
CRC	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg13385794	chr1:248469461	NA	0.34	5.98	0.31	5.81e-9	Common traits (Other);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23839113	chr7:30634781	GARS	0.45	6.38	0.33	5.87e-10	Anxiety disorder;
CRC	cis	rs9341808	0.519	rs684251	chr6:80967337	G/A	cg08355045	chr6:80787529	NA	-0.35	-5.71	-0.3	2.58e-8	Sitting height ratio;
CRC	cis	rs7259376	0.807	rs7254434	chr19:22500033	G/A	cg02657401	chr19:22469223	NA	-0.36	-7.97	-0.4	2.69e-14	Menopause (age at onset);
CRC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.62	-11.4	-0.53	1.32e-25	Educational attainment;
CRC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.13	-0.37	6.58e-12	Total body bone mineral density;
CRC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg18016565	chr1:150552671	MCL1	-0.44	-6.02	-0.32	4.58e-9	Melanoma;
CRC	cis	rs7429990	0.813	rs7627568	chr3:48093052	A/T	cg11946769	chr3:48343235	NME6	-0.44	-5.65	-0.3	3.49e-8	Educational attainment (years of education);
CRC	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.57	-5.93	-0.31	7.49e-9	Vitamin D levels;
CRC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.44	0.33	4.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.27	0.33	1.13e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4838594	0.715	rs11101340	chr10:49682402	C/T	cg17291251	chr10:49678358	ARHGAP22	0.37	5.71	0.3	2.51e-8	Daytime sleep phenotypes;
CRC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.65	-9.51	-0.46	4.3e-19	Vitiligo;
CRC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg03013999	chr17:37608204	MED1	0.46	7.14	0.37	5.87e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.66	-0.54	1.59e-26	Idiopathic membranous nephropathy;
CRC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg18478394	chr8:109455254	TTC35	0.46	6.97	0.36	1.76e-11	Dupuytren's disease;
CRC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.72	10.66	0.51	5.48e-23	Blood metabolite levels;
CRC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.63	-0.34	1.4e-10	IgG glycosylation;
CRC	trans	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg10756647	chr7:56101905	PSPH	0.77	7.97	0.4	2.7e-14	Diabetic kidney disease;
CRC	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.67	-0.3	3.16e-8	Tuberculosis;
CRC	cis	rs3751196	0.808	rs1550208	chr12:104210240	A/G	cg02344784	chr12:104178138	NT5DC3	0.68	6.91	0.36	2.49e-11	Sense of smell;
CRC	cis	rs7580658	0.895	rs9636237	chr2:128076022	T/C	cg09760422	chr2:128146352	NA	-0.3	-5.81	-0.3	1.49e-8	Protein C levels;
CRC	cis	rs9346649	0.606	rs7750135	chr6:168490841	C/A	cg02770688	chr6:168491649	NA	0.6	8.69	0.43	1.74e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs587242	1.000	rs12744063	chr1:96898431	T/C	cg10631902	chr5:14652156	NA	0.44	6.74	0.35	7.14e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg03111951	chr1:180123704	QSOX1	0.42	6.45	0.34	4.11e-10	Schizophrenia;
CRC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.59	6.84	0.35	3.84e-11	Post bronchodilator FEV1;
CRC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.89	0.51	8.51e-24	Cognitive function;
CRC	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.49	-7.88	-0.4	4.7e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-5.69	-0.3	2.75e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10971721	0.822	rs56253239	chr9:33860066	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs17767392	0.881	rs7140501	chr14:72023175	C/G	cg13720639	chr14:72061746	SIPA1L1	0.56	7.11	0.37	7.05e-12	Mitral valve prolapse;
CRC	cis	rs965469	0.779	rs6051772	chr20:3328654	C/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg19193384	chr17:30244184	NA	-0.53	-6.61	-0.34	1.52e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7517126	1.000	rs13375236	chr1:196842271	A/G	cg13682187	chr1:196946512	CFHR5	0.37	6.31	0.33	8.81e-10	Blood protein levels;
CRC	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.48	-7.43	-0.38	9.29e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.07	21.46	0.76	1.67e-64	Schizophrenia;
CRC	cis	rs519973	0.687	rs542887	chr3:187650907	C/T	cg10168494	chr3:187635183	NA	0.32	5.61	0.3	4.23e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7605827	0.897	rs4668899	chr2:15511575	C/A	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.39	6.07	0.32	3.59e-9	Hemoglobin concentration;
CRC	cis	rs17065868	0.764	rs9533856	chr13:45029865	C/T	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg22561889	chr6:118971681	C6orf204	0.52	6.58	0.34	1.91e-10	Diastolic blood pressure;
CRC	cis	rs3800461	0.509	rs73407707	chr6:34476644	T/G	cg14254433	chr6:34482411	PACSIN1	-0.79	-8.42	-0.42	1.15e-15	Chronic lymphocytic leukemia;
CRC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.53	7.39	0.38	1.22e-12	Melanoma;
CRC	cis	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.41	-0.33	4.97e-10	Ulcerative colitis;
CRC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.3e-9	Heart rate;
CRC	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.47	7.2	0.37	4.24e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.5	-0.42	6.6e-16	Electroencephalogram traits;
CRC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04731861	chr2:219085781	ARPC2	0.33	6.94	0.36	2.06e-11	Colorectal cancer;
CRC	cis	rs9341808	0.667	rs2505944	chr6:80888410	T/C	cg08355045	chr6:80787529	NA	0.35	6.01	0.31	4.88e-9	Sitting height ratio;
CRC	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.93	-0.36	2.19e-11	Inflammatory skin disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18342900	chr16:46865048	C16orf87	-0.56	-7.12	-0.37	6.67e-12	Diisocyanate-induced asthma;
CRC	cis	rs6662572	1.000	rs55951835	chr1:46132442	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.86	0.31	1.12e-8	Blood protein levels;
CRC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.68	-10.51	-0.5	1.87e-22	Colorectal cancer;
CRC	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-8.32	-0.42	2.31e-15	Type 2 diabetes;
CRC	cis	rs653465	0.583	rs7652855	chr3:27257026	G/A	cg02860705	chr3:27208620	NA	0.4	6.17	0.32	2.05e-9	Breast cancer (early onset);
CRC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.97	-17.69	-0.7	1.11e-49	Headache;
CRC	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.72	-8.14	-0.41	8.43e-15	Response to hepatitis C treatment;
CRC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.7e-8	Lung cancer;
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg21784768	chr11:537496	LRRC56	0.65	6.32	0.33	8.36e-10	Body mass index;
CRC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg19847866	chr10:1019161	NA	0.43	6.4	0.33	5.29e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs185694	1.000	rs613291	chr13:30894404	T/C	cg07600127	chr13:30881527	KATNAL1	-0.56	-5.87	-0.31	1.09e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	6.64	0.34	1.33e-10	Schizophrenia;
CRC	cis	rs9463078	0.605	rs17422760	chr6:44885288	C/T	cg25276700	chr6:44698697	NA	0.23	5.66	0.3	3.37e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg02466173	chr16:30829666	NA	0.61	9.0	0.44	1.87e-17	Dementia with Lewy bodies;
CRC	cis	rs62458065	0.850	rs62458098	chr7:32471129	G/A	cg20159608	chr7:32802032	NA	-0.55	-6.56	-0.34	2.11e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg15786705	chr6:28176104	NA	0.68	7.39	0.38	1.23e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.46	6.96	0.36	1.9e-11	Red blood cell count;
CRC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.79	-12.18	-0.56	2.06e-28	Platelet distribution width;
CRC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	8.04e-20	Intelligence (multi-trait analysis);
CRC	cis	rs4743820	0.651	rs4744036	chr9:93932466	G/A	cg14446406	chr9:93919335	NA	-0.69	-12.14	-0.56	2.75e-28	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg27068330	chr11:65405492	SIPA1	-0.67	-9.87	-0.48	2.75e-20	Acne (severe);
CRC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg25767906	chr1:53392781	SCP2	-0.39	-6.11	-0.32	2.86e-9	Monocyte count;
CRC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg10437265	chr15:77819839	NA	0.69	12.51	0.57	1.24e-29	Type 2 diabetes;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05792022	chr13:41239732	FOXO1	0.41	6.01	0.31	4.86e-9	Myopia (pathological);
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02421172	chr7:1938701	MAD1L1	0.47	6.21	0.32	1.6e-9	Neuroticism;
CRC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.05	-0.32	3.86e-9	Menopause (age at onset);
CRC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16447950	chr5:562315	NA	-0.83	-10.78	-0.51	2.14e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.54	-7.4	-0.38	1.12e-12	Colorectal cancer;
CRC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs9287719	0.601	rs12996735	chr2:10716716	C/A	cg00105475	chr2:10696890	NA	0.49	7.38	0.38	1.33e-12	Prostate cancer;
CRC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.64	-9.0	-0.44	1.81e-17	DNA methylation (variation);
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.67	10.02	0.48	8.74e-21	Intelligence (multi-trait analysis);
CRC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg00343986	chr7:65444356	GUSB	-0.48	-7.25	-0.37	2.98e-12	Aortic root size;
CRC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.99	-0.4	2.25e-14	Life satisfaction;
CRC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg11292332	chr7:45801988	SEPT13	-0.39	-7.1	-0.36	7.55e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs73206853	0.688	rs7314248	chr12:110559173	G/A	cg12870014	chr12:110450643	ANKRD13A	0.82	9.4	0.46	9.47e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.77	10.66	0.51	5.37e-23	Orofacial clefts;
CRC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg19193384	chr17:30244184	NA	0.52	6.0	0.31	5.13e-9	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	7.43	0.38	9.36e-13	Obesity-related traits;
CRC	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.36	11.13	0.52	1.22e-24	Psoriasis vulgaris;
CRC	trans	rs7148069	0.553	rs17123829	chr14:51824498	G/A	cg24818418	chr4:110834590	EGF	0.44	6.03	0.32	4.47e-9	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.36	-0.33	6.84e-10	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg10876282	chr6:28092338	ZSCAN16	0.46	6.37	0.33	6.25e-10	Parkinson's disease;
CRC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg18827107	chr12:86230957	RASSF9	-0.41	-6.57	-0.34	2.03e-10	Major depressive disorder;
CRC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.84	-0.48	3.27e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.66	-9.8	-0.48	4.77e-20	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22303846	chr2:152145870	NMI	0.42	6.31	0.33	8.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg20811857	chr17:78079795	GAA	-0.46	-6.77	-0.35	6.01e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.51	-0.46	4.33e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.11	9.98	0.48	1.13e-20	Skin colour saturation;
CRC	trans	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs55702914	0.742	rs6744206	chr2:198148522	A/G	cg10820045	chr2:198174542	NA	-0.44	-7.97	-0.4	2.6e-14	Major depression and alcohol dependence;
CRC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg12292205	chr6:26970375	C6orf41	0.63	9.89	0.48	2.26e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.61	8.56	0.43	4.54e-16	Arsenic metabolism;
CRC	cis	rs12630931	1.000	rs73061493	chr3:31984329	T/A	cg21375017	chr3:31988082	OSBPL10	0.43	5.89	0.31	9.55e-9	Periodontal disease-related phenotypes;
CRC	cis	rs7605827	0.930	rs918157	chr2:15657729	G/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	9.11e-9	Educational attainment (years of education);
CRC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	7.49	0.38	6.56e-13	Personality dimensions;
CRC	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-7.72	-0.39	1.44e-13	Vitamin D levels;
CRC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.21	-16.46	-0.67	7.6e-45	Breast cancer;
CRC	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05553502	chr5:92924091	NR2F1	-0.27	-6.01	-0.31	4.84e-9	HDL cholesterol;
CRC	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.05	0.58	1.15e-31	Hip circumference;
CRC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.66	10.68	0.51	4.65e-23	Coronary artery disease;
CRC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.64	10.27	0.49	1.21e-21	Alzheimer's disease (late onset);
CRC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg03609598	chr5:56110824	MAP3K1	0.66	7.51	0.38	5.62e-13	Initial pursuit acceleration;
CRC	cis	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg15845792	chr6:28175446	NA	0.8	6.4	0.33	5.31e-10	Depression;
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg03160526	chr17:80928410	B3GNTL1	0.58	7.66	0.39	2.05e-13	Glycated hemoglobin levels;
CRC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg16342193	chr10:102329863	NA	-0.36	-5.95	-0.31	6.71e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27665925	chr19:12098906	NA	0.39	6.1	0.32	3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs863345	0.604	rs1873510	chr1:158461418	G/A	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.71	-14.06	-0.61	1.66e-35	Leprosy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17848531	chr2:182756352	SSFA2	0.53	7.98	0.4	2.41e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.49	-7.06	-0.36	1e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.4	6.7	0.35	9.18e-11	Total body bone mineral density;
CRC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg08885800	chr1:201084119	NA	0.41	5.7	0.3	2.62e-8	Permanent tooth development;
CRC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg27661571	chr11:113659931	NA	-0.95	-10.95	-0.52	5.51e-24	Hip circumference adjusted for BMI;
CRC	cis	rs17092148	0.836	rs4564863	chr20:33179367	T/C	cg08999081	chr20:33150536	PIGU	0.49	6.3	0.33	9.31e-10	Neuroticism;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg03623178	chr6:28175578	NA	0.95	13.37	0.59	7.53e-33	Depression;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg23807890	chr2:228736357	WDR69	-0.51	-6.99	-0.36	1.56e-11	Blood pressure;
CRC	trans	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg20935933	chr6:143382018	AIG1	-0.47	-6.22	-0.32	1.5e-9	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.76	14.37	0.62	1.12e-36	Cancer;
CRC	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg09127314	chr1:152161683	NA	0.47	6.02	0.31	4.67e-9	Atopic dermatitis;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg05569086	chr8:143859399	LYNX1	0.38	6.59	0.34	1.79e-10	Urinary tract infection frequency;
CRC	cis	rs863345	0.565	rs7549123	chr1:158444920	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.08	-0.32	3.27e-9	Pneumococcal bacteremia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16139199	chr18:19180362	ESCO1	0.51	6.83	0.35	4.22e-11	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.43	-6.21	-0.32	1.56e-9	Aortic root size;
CRC	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg04202892	chr2:111875749	ACOXL	0.47	7.76	0.39	1.06e-13	Chronic lymphocytic leukemia;
CRC	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	trans	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg24644049	chr4:85504048	CDS1	0.83	7.0	0.36	1.47e-11	Skin colour saturation;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.42	6.86	0.35	3.33e-11	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12450255	chr15:34659304	LPCAT4	0.48	6.9	0.36	2.66e-11	Response to antipsychotic treatment;
CRC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.07	-0.41	1.33e-14	Hemoglobin concentration;
CRC	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg19688584	chr6:167529678	CCR6	0.33	6.04	0.32	4.06e-9	Primary biliary cholangitis;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs6496667	0.779	rs7175440	chr15:90949403	C/T	cg04176472	chr15:90893244	GABARAPL3	0.6	7.77	0.39	1.02e-13	Rheumatoid arthritis;
CRC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.31	0.33	8.87e-10	Life satisfaction;
CRC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg03160526	chr17:80928410	B3GNTL1	-0.4	-5.64	-0.3	3.7e-8	Breast cancer;
CRC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.46	1.19e-18	Bladder cancer;
CRC	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06634786	chr22:41940651	POLR3H	-0.44	-6.02	-0.32	4.55e-9	Vitiligo;
CRC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg00999904	chr2:3704751	ALLC	-0.53	-6.7	-0.35	9.16e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs4714291	0.832	rs9471247	chr6:40105318	A/G	cg02267698	chr19:7991119	CTXN1	-0.52	-6.96	-0.36	1.8e-11	Strep throat;
CRC	cis	rs9650315	0.706	rs36112366	chr8:57138676	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	5.98	0.31	5.77e-9	Height;
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.5	-0.34	3.06e-10	Neuroticism;
CRC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.84	0.31	1.24e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.07	0.41	1.34e-14	Red blood cell count;
CRC	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.72	-11.87	-0.55	2.66e-27	Ear protrusion;
CRC	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.28	0.46	2.31e-18	Fuchs's corneal dystrophy;
CRC	cis	rs10971721	0.908	rs55684780	chr9:33833208	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg06042504	chr8:55087323	NA	-0.44	-6.86	-0.35	3.42e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.85	-0.31	1.17e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.64	0.57	3.97e-30	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs672059	1.000	rs510642	chr1:183162776	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.48	6.88	0.35	3.1e-11	Hypertriglyceridemia;
CRC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.49	6.8	0.35	4.87e-11	Aortic root size;
CRC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-18.12	-0.71	2.17e-51	Schizophrenia;
CRC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.45	5.98	0.31	5.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9992667	0.955	rs11096953	chr4:38643792	A/G	cg19726192	chr4:38663646	FLJ13197	0.66	8.66	0.43	2.21e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.67	-7.84	-0.4	6.19e-14	Rheumatoid arthritis;
CRC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.81	-15.39	-0.65	1.28e-40	Prostate cancer;
CRC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.84	-9.89	-0.48	2.37e-20	Initial pursuit acceleration;
CRC	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg15571903	chr15:79123663	NA	0.31	6.21	0.32	1.61e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs11031096	0.542	rs7924984	chr11:3974588	C/T	cg18678763	chr11:4115507	RRM1	-0.41	-6.84	-0.35	3.91e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.49	-0.46	4.9e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.61	-7.43	-0.38	9.74e-13	Bronchopulmonary dysplasia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	0.4	5.98	0.31	5.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.49	0.54	6.54e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg25456477	chr12:86230367	RASSF9	-0.39	-6.54	-0.34	2.36e-10	Major depressive disorder;
CRC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.86	11.56	0.54	3.73e-26	Gut microbiome composition (summer);
CRC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.45	-6.59	-0.34	1.72e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.79	-12.51	-0.57	1.27e-29	Blood pressure (smoking interaction);
CRC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.43e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs12476592	0.714	rs262494	chr2:63845484	C/T	cg10828910	chr2:63850056	LOC388955	0.53	6.58	0.34	1.83e-10	Childhood ear infection;
CRC	cis	rs1712517	0.566	rs7076274	chr10:105046007	G/A	cg04362960	chr10:104952993	NT5C2	-0.47	-6.15	-0.32	2.29e-9	Migraine;
CRC	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-5.82	-0.31	1.37e-8	Daytime sleep phenotypes;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-11.12	-0.52	1.3e-24	Electroencephalogram traits;
CRC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.16	27.12	0.83	6.77e-86	IgG glycosylation;
CRC	cis	rs2249694	0.520	rs6537609	chr10:135323084	A/G	cg20169779	chr10:135381914	SYCE1	-0.53	-7.24	-0.37	3.18e-12	Obesity-related traits;
CRC	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.19	-0.37	4.39e-12	Tuberculosis;
CRC	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.47	8.15	0.41	7.73e-15	Common traits (Other);
CRC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg21466736	chr12:48725269	NA	-0.55	-8.1	-0.41	1.11e-14	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21972741	chr5:435613	AHRR	0.54	7.37	0.38	1.39e-12	Cystic fibrosis severity;
CRC	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg25174290	chr11:3078921	CARS	0.39	5.74	0.3	2.12e-8	Longevity;
CRC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.72	8.62	0.43	2.8e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.48	-0.42	7.76e-16	Metabolite levels;
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.2	-0.32	1.68e-9	Cognitive function;
CRC	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.37	5.82	0.31	1.39e-8	Reticulocyte fraction of red cells;
CRC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-9.46	-0.46	6.32e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.5	-9.45	-0.46	6.36e-19	Educational attainment (years of education);
CRC	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-17.08	-0.69	2.77e-47	Schizophrenia;
CRC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.45	5.82	0.31	1.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.57	-7.7	-0.39	1.58e-13	Coronary artery disease;
CRC	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-5.74	-0.3	2.13e-8	Breast cancer;
CRC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg03030879	chr14:75389066	RPS6KL1	0.4	6.06	0.32	3.66e-9	Height;
CRC	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg26741380	chr15:41871084	TYRO3	0.45	6.2	0.32	1.73e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11645453	chr3:52864694	ITIH4	0.36	6.18	0.32	1.91e-9	Bipolar disorder;
CRC	cis	rs6840360	0.667	rs2709829	chr4:152355390	C/T	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.82	-0.55	3.98e-27	Exhaled nitric oxide output;
CRC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-12.01	-0.55	8.36e-28	Asthma;
CRC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.81	7.08	0.36	8.92e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.44	-6.08	-0.32	3.24e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.27	-5.68	-0.3	3.04e-8	Renal function-related traits (BUN);
CRC	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.1	0.32	3.01e-9	Asthma;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04847795	chr1:70820736	HHLA3;ANKRD13C	0.4	6.44	0.33	4.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.58	-9.22	-0.45	3.52e-18	Breast cancer;
CRC	cis	rs9372498	0.764	rs4599686	chr6:118722118	T/A	cg18833306	chr6:118973337	C6orf204	0.49	6.19	0.32	1.83e-9	Diastolic blood pressure;
CRC	trans	rs9341835	0.583	rs2753062	chr6:64131810	G/T	cg13657004	chr13:50234944	EBPL	-0.37	-6.29	-0.33	1.01e-9	Schizophrenia;
CRC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.99	0.48	1.07e-20	Platelet count;
CRC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.39	-0.5	4.76e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg25164649	chr6:28176230	NA	0.7	8.93	0.44	3.12e-17	Parkinson's disease;
CRC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.71	-8.55	-0.43	4.75e-16	Hemostatic factors and hematological phenotypes;
CRC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-9.33	-0.46	1.66e-18	Breast cancer;
CRC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg20607287	chr7:12443886	VWDE	-0.65	-6.92	-0.36	2.33e-11	Coronary artery disease;
CRC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.44	6.0	0.31	5.28e-9	Reticulocyte count;
CRC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.56	7.9	0.4	4.08e-14	Schizophrenia;
CRC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.6	7.36	0.38	1.45e-12	Mean platelet volume;
CRC	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.5	-0.34	2.93e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.42	6.76	0.35	6.28e-11	High light scatter reticulocyte count;
CRC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	0.99	13.96	0.61	4.32e-35	Breast cancer;
CRC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg11271282	chr2:238384023	NA	0.48	6.14	0.32	2.39e-9	Prostate cancer;
CRC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.21e-15	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.79	13.46	0.6	3.47e-33	Menopause (age at onset);
CRC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.26	-0.33	1.24e-9	Bipolar disorder;
CRC	cis	rs755249	0.567	rs76111861	chr1:39842690	G/T	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9847710	0.818	rs6445558	chr3:53097660	G/T	cg04503182	chr3:53078218	SFMBT1	-0.41	-6.4	-0.33	5.25e-10	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09601704	chr17:8027427	HES7	0.39	6.64	0.34	1.28e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg16486109	chr11:613632	IRF7	0.67	10.01	0.48	8.86e-21	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.56	-8.38	-0.42	1.56e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg18480310	chr19:39421315	MRPS12;SARS2	-0.41	-6.0	-0.31	5.2e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20092199	chr4:1342459	KIAA1530	-0.44	-8.08	-0.41	1.21e-14	Obesity-related traits;
CRC	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.46	-7.31	-0.37	1.99e-12	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs6977955	1.000	rs67250450	chr7:28174986	T/C	cg23620719	chr7:28220237	JAZF1	0.42	5.62	0.3	4.13e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.69e-11	Prostate cancer;
CRC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.69	10.33	0.5	7.26e-22	Corneal astigmatism;
CRC	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.6	-8.72	-0.43	1.43e-16	Inhibitory control;
CRC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.75	0.54	7.23e-27	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg03637622	chr5:179334771	TBC1D9B	-0.53	-6.82	-0.35	4.29e-11	Parkinson's disease;
CRC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg24300038	chr13:113819356	PROZ	-0.47	-6.05	-0.32	3.88e-9	Platelet distribution width;
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00166722	chr3:10149974	C3orf24	-0.67	-7.97	-0.4	2.69e-14	Alzheimer's disease;
CRC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-11.09	-0.52	1.74e-24	Bipolar disorder;
CRC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg10298567	chr3:47292165	KIF9	0.39	6.15	0.32	2.19e-9	Colorectal cancer;
CRC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.54	9.69	0.47	1.03e-19	Multiple system atrophy;
CRC	cis	rs1524976	0.941	rs9854638	chr3:65477793	C/T	cg16238336	chr3:65465873	MAGI1	-0.51	-7.07	-0.36	9.59e-12	PR interval;
CRC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.35	-9.76	-0.47	6.33e-20	Mean corpuscular volume;
CRC	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.46	7.31	0.37	1.98e-12	Platelet count;
CRC	cis	rs11203032	0.831	rs11203024	chr10:90955239	G/T	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg20512303	chr5:131592959	PDLIM4	-0.4	-6.91	-0.36	2.5e-11	Breast cancer;
CRC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-8.2	-0.41	5.3e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.38	-8.87	-0.44	4.65e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg13491945	chr12:107078410	RFX4	0.34	5.77	0.3	1.79e-8	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08642325	chr8:26149300	PPP2R2A	0.46	6.82	0.35	4.45e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg02353165	chr6:42928485	GNMT	0.52	6.68	0.35	9.95e-11	Blood protein levels;
CRC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.59	-0.34	1.72e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.91	-15.31	-0.65	2.44e-40	Blood metabolite levels;
CRC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.75	12.44	0.57	2.28e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs889398	0.738	rs7196842	chr16:69923333	T/C	cg00738113	chr16:70207722	CLEC18C	-0.35	-5.65	-0.3	3.49e-8	Body mass index;
CRC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg04586622	chr2:25135609	ADCY3	-0.54	-10.13	-0.49	3.64e-21	Body mass index;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg21251018	chr6:28226885	NKAPL	0.44	5.95	0.31	6.99e-9	Parkinson's disease;
CRC	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	15.83	0.66	2.3e-42	Colorectal cancer;
CRC	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg21155852	chr7:2048760	MAD1L1	-0.44	-5.78	-0.3	1.69e-8	Neuroticism;
CRC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg09655341	chr17:79618100	PDE6G	-0.35	-6.01	-0.31	4.97e-9	Eye color traits;
CRC	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.47	5.63	0.3	3.88e-8	Lung function (FEV1/FVC);
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg15845792	chr6:28175446	NA	-1.02	-15.98	-0.66	6.21e-43	Depression;
CRC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.47	-6.62	-0.34	1.48e-10	Corneal structure;
CRC	trans	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg10756647	chr7:56101905	PSPH	0.78	8.03	0.4	1.79e-14	Diabetic kidney disease;
CRC	trans	rs2898857	0.504	rs35822701	chr17:47422317	C/T	cg11430096	chr6:110968061	CDK19	-0.49	-7.46	-0.38	8.01e-13	Cancer;
CRC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19211149	chr12:3982353	PARP11	0.37	6.26	0.33	1.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3731896	0.607	rs7600417	chr2:220169492	C/T	cg00436969	chr2:220197716	RESP18	0.47	6.04	0.32	4.09e-9	Educational attainment;
CRC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	1.0	14.46	0.62	4.91e-37	Initial pursuit acceleration;
CRC	cis	rs427943	0.750	rs2838803	chr21:46600126	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.45	-5.9	-0.31	9.19e-9	Body mass index;
CRC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg12193833	chr17:30244370	NA	0.43	5.95	0.31	6.85e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7581030	0.874	rs4852772	chr2:71443645	A/G	cg07678644	chr2:71558969	ZNF638	0.55	6.02	0.32	4.62e-9	Testicular germ cell tumor;
CRC	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.47	-8.82	-0.44	6.62e-17	Hepatitis;
CRC	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg15571903	chr15:79123663	NA	-0.3	-5.77	-0.3	1.79e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs728616	0.764	rs56122289	chr10:81746027	G/A	cg11900509	chr10:81946545	ANXA11	-0.68	-6.74	-0.35	6.97e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24308560	chr3:49941425	MST1R	0.41	6.29	0.33	9.92e-10	Body mass index;
CRC	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.99	-0.4	2.22e-14	Testicular germ cell tumor;
CRC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.51	7.1	0.36	7.57e-12	Lymphocyte counts;
CRC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.43	6.44	0.33	4.32e-10	Menopause (age at onset);
CRC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.42	7.85	0.4	6.1e-14	Iron status biomarkers (transferrin levels);
CRC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg15468180	chr1:107600409	PRMT6	-0.39	-5.86	-0.31	1.15e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.81	-0.44	7.22e-17	Bipolar disorder;
CRC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13126279	chr21:47581558	C21orf56	-0.38	-5.81	-0.31	1.48e-8	Testicular germ cell tumor;
CRC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	cis	rs77861329	0.702	rs7644325	chr3:52081136	A/G	cg08692210	chr3:52188851	WDR51A	0.49	5.82	0.31	1.36e-8	Macrophage inflammatory protein 1b levels;
CRC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg02007433	chr3:129722099	NA	-0.45	-6.08	-0.32	3.24e-9	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02725872	chr8:58115012	NA	-0.4	-6.85	-0.35	3.63e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg25797454	chr6:150327115	RAET1K	0.38	6.47	0.34	3.48e-10	Alopecia areata;
CRC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg03037974	chr15:76606532	NA	-0.49	-7.32	-0.37	1.96e-12	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26221423	chr11:118800852	NA	0.42	6.04	0.32	4.26e-9	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22975147	chr17:8021903	ALOXE3	0.53	6.83	0.35	4.2e-11	Thyroid stimulating hormone;
CRC	trans	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg16141378	chr3:129829833	LOC729375	-0.53	-7.37	-0.38	1.37e-12	Parkinson's disease;
CRC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.6	10.57	0.5	1.16e-22	Schizophrenia;
CRC	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.21	0.45	3.85e-18	Hip circumference adjusted for BMI;
CRC	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg10761708	chr20:43804764	PI3	0.49	5.6	0.3	4.41e-8	Blood protein levels;
CRC	cis	rs10486722	0.575	rs11770999	chr7:41812252	C/T	cg22138096	chr7:41772439	LOC285954	0.54	6.53	0.34	2.5e-10	Pit-and-Fissure caries;
CRC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14895029	chr7:2775587	GNA12	-0.42	-6.38	-0.33	6.15e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05299703	chr18:43678513	ATP5A1	0.45	6.64	0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg01426195	chr3:39028469	NA	-0.53	-8.56	-0.43	4.35e-16	Handedness;
CRC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-11.54	-0.54	4.11e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg26384229	chr12:38710491	ALG10B	0.43	5.97	0.31	5.98e-9	Morning vs. evening chronotype;
CRC	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.08	-0.32	3.3e-9	Schizophrenia;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6662572	0.641	rs4660891	chr1:46319447	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.39	6.72	0.35	7.79e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	11.0	0.52	3.53e-24	Personality dimensions;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01189917	chr3:71633604	FOXP1	0.46	6.0	0.31	5.3e-9	Thyroid stimulating hormone;
CRC	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.49	7.35	0.38	1.61e-12	Asthma;
CRC	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg21064579	chr19:49206444	FUT2	0.49	8.53	0.43	5.31e-16	Dietary macronutrient intake;
CRC	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.63	9.77	0.47	5.84e-20	Corneal astigmatism;
CRC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg02094049	chr14:103021097	NA	-0.55	-7.32	-0.37	1.88e-12	Platelet count;
CRC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.61	-9.69	-0.47	1.09e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.9	0.4	4.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20848291	chr7:100343083	ZAN	0.48	7.35	0.38	1.56e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.75	0.3	2.07e-8	Rheumatoid arthritis;
CRC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.11	-0.36	7.28e-12	Height;
CRC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg23123621	chr4:1343375	KIAA1530	0.38	6.35	0.33	7.17e-10	Obesity-related traits;
CRC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.51e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12476592	0.571	rs2604617	chr2:63898663	A/G	cg10828910	chr2:63850056	LOC388955	0.52	6.44	0.33	4.3e-10	Childhood ear infection;
CRC	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.53	7.73	0.39	1.36e-13	White matter hyperintensity burden;
CRC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23708337	chr7:1209742	NA	0.42	6.15	0.32	2.25e-9	Longevity;Endometriosis;
CRC	trans	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.47	7.39	0.38	1.22e-12	Schizophrenia;
CRC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.53	8.26	0.41	3.49e-15	Intelligence (multi-trait analysis);
CRC	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.94	-0.64	7.14e-39	Exhaled nitric oxide output;
CRC	cis	rs2223471	0.719	rs2744489	chr6:50766781	G/A	cg03432817	chr6:50765336	NA	0.39	6.26	0.33	1.21e-9	Subcutaneous adipose tissue;
CRC	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.73	11.05	0.52	2.33e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21467203	chr3:49911342	NA	-0.25	-6.05	-0.32	4.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.58	8.6	0.43	3.29e-16	Autism;
CRC	cis	rs2735413	0.875	rs11649082	chr16:78082256	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.83	-0.4	6.74e-14	Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg02659138	chr7:134003124	SLC35B4	0.39	6.76	0.35	6.49e-11	Mean platelet volume;
CRC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg00129232	chr17:37814104	STARD3	0.57	7.04	0.36	1.14e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg08798685	chr6:27730294	NA	-0.38	-5.65	-0.3	3.46e-8	Parkinson's disease;
CRC	cis	rs12024301	0.557	rs7542136	chr1:183595057	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg15017411	chr7:106301767	FLJ36031	0.5	6.01	0.31	4.89e-9	Kashin-Beck disease;
CRC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg03579179	chr7:12444095	VWDE	-0.4	-5.62	-0.3	4.06e-8	Coronary artery disease;
CRC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.08	24.93	0.81	8.84e-78	Testicular germ cell tumor;
CRC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-0.65	-6.18	-0.32	1.88e-9	Lung cancer;
CRC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg03037974	chr15:76606532	NA	0.54	7.71	0.39	1.49e-13	Blood metabolite levels;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.84	-15.08	-0.64	1.92e-39	Paraoxonase activity;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg21251018	chr6:28226885	NKAPL	0.47	6.04	0.32	4.16e-9	Depression;
CRC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.39	-7.41	-0.38	1.05e-12	Ulcerative colitis;
CRC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.4	5.7	0.3	2.6e-8	Axial length;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04769218	chr7:99098020	ZNF394	0.4	6.36	0.33	6.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7259376	0.936	rs2195964	chr19:22538338	C/T	cg02657401	chr19:22469223	NA	-0.33	-7.44	-0.38	8.61e-13	Menopause (age at onset);
CRC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.69	10.26	0.49	1.29e-21	Menopause (age at onset);
CRC	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg25019722	chr6:37503610	NA	0.45	8.51	0.42	6.09e-16	Cognitive performance;
CRC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.77	11.21	0.53	6.49e-25	Menopause (age at onset);
CRC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg25204440	chr1:209979598	IRF6	0.48	5.83	0.31	1.35e-8	Cleft lip with or without cleft palate;
CRC	cis	rs77633900	0.772	rs157761	chr15:76796078	C/A	cg21673338	chr15:77095150	SCAPER	-0.74	-6.77	-0.35	5.96e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.67	9.46	0.46	6.19e-19	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	trans	rs8085804	1.000	rs658728	chr18:40222856	C/T	cg09434832	chr19:52642515	ZNF616	-0.42	-6.0	-0.31	5.1e-9	Cognitive performance;
CRC	cis	rs9292777	0.777	rs2197428	chr5:40392200	T/C	cg09067459	chr5:40385259	NA	-0.57	-9.39	-0.46	1.05e-18	Crohn's disease;Multiple sclerosis;
CRC	trans	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg26043149	chr18:55253948	FECH	-0.49	-7.5	-0.38	6.14e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg24011408	chr12:48396354	COL2A1	0.45	6.65	0.34	1.19e-10	Glycated hemoglobin levels;
CRC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.29	0.33	9.93e-10	Primary sclerosing cholangitis;
CRC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg08999081	chr20:33150536	PIGU	-0.36	-5.72	-0.3	2.44e-8	Height;
CRC	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.65	9.1	0.45	9.03e-18	White matter hyperintensity burden;
CRC	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.59	-8.6	-0.43	3.28e-16	Coronary artery disease;
CRC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.47	-6.63	-0.34	1.39e-10	Height;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg03804128	chr16:635623	NA	0.31	7.13	0.37	6.61e-12	Height;
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.1	-0.32	2.91e-9	Obesity-related traits;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00166722	chr3:10149974	C3orf24	0.63	8.79	0.44	8.71e-17	Alzheimer's disease;
CRC	cis	rs6960043	0.905	rs11514706	chr7:15059272	A/C	cg19272540	chr7:15055459	NA	-0.22	-6.02	-0.31	4.78e-9	Type 2 diabetes;
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg24505167	chr7:1915268	MAD1L1	-0.42	-5.8	-0.3	1.56e-8	Neuroticism;
CRC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.36	6.12	0.32	2.61e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09328466	chr7:64023458	ZNF680	0.47	7.32	0.37	1.9e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.41	-7.06	-0.36	9.83e-12	Height;
CRC	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.43	5.9	0.31	9.03e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.8	11.12	0.52	1.36e-24	Orofacial clefts;
CRC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.65	-0.34	1.22e-10	Total body bone mineral density;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg18758796	chr5:131593413	PDLIM4	0.33	6.18	0.32	1.88e-9	Blood metabolite levels;
CRC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.44	-6.57	-0.34	1.94e-10	Cognitive test performance;
CRC	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11547950	chr5:77652471	NA	-0.5	-7.43	-0.38	9.69e-13	Triglycerides;
CRC	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg21918786	chr6:109611834	NA	-0.35	-6.01	-0.31	4.88e-9	Reticulocyte fraction of red cells;
CRC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg21854759	chr1:92012499	NA	0.49	6.31	0.33	9.08e-10	Eosinophil percentage of white cells;
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.78	0.44	9.09e-17	Alzheimer's disease;
CRC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg23018236	chr17:30244563	NA	-0.67	-8.01	-0.4	1.96e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9549328	0.611	rs72661939	chr13:113617498	C/T	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.7e-13	Systolic blood pressure;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg02018176	chr4:1364513	KIAA1530	0.39	5.73	0.3	2.22e-8	Obesity-related traits;
CRC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.66	9.42	0.46	8.42e-19	Vitamin D levels;
CRC	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.47	7.1	0.36	7.52e-12	Red blood cell count;
CRC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.62	7.3	0.37	2.2e-12	Gut microbiome composition (summer);
CRC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg06632207	chr12:54070931	ATP5G2	0.49	8.48	0.42	7.63e-16	Height;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg15845792	chr6:28175446	NA	0.74	7.78	0.39	9.45e-14	Depression;
CRC	trans	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg20064139	chr20:41823021	NA	-0.29	-6.07	-0.32	3.54e-9	Coronary artery disease;
CRC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.84	14.28	0.62	2.46e-36	Platelet distribution width;
CRC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	10.34	0.5	7.15e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg09218773	chr11:619014	MUPCDH	-0.46	-6.89	-0.36	2.82e-11	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg06470822	chr6:28175283	NA	0.98	13.22	0.59	2.69e-32	Depression;
CRC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.39	-0.38	1.25e-12	Bladder cancer;
CRC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.75	-0.39	1.16e-13	Personality dimensions;
CRC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-9.47	-0.46	5.76e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs7705042	0.897	rs7718955	chr5:141521459	A/G	cg07392085	chr5:141489673	NDFIP1	0.45	7.25	0.37	2.94e-12	Asthma;
CRC	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.59	7.86	0.4	5.49e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.67	-9.72	-0.47	8.52e-20	Type 2 diabetes;
CRC	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	cg04338863	chr8:33670619	NA	0.38	6.17	0.32	2.01e-9	Body mass index;
CRC	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.7	0.3	2.61e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.1	0.32	2.93e-9	Electroencephalogram traits;
CRC	cis	rs3020333	0.875	rs2941741	chr6:152008982	G/A	cg22157087	chr6:152012887	ESR1	0.52	7.64	0.39	2.37e-13	Total body bone mineral density;
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg00145849	chr4:39699494	UBE2K	-0.46	-6.38	-0.33	6.09e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.46	-9.14	-0.45	6.83e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.44	-6.67	-0.35	1.07e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.61	10.94	0.52	5.61e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg23250157	chr14:64679961	SYNE2	0.35	5.72	0.3	2.36e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg25985355	chr7:65971099	NA	-0.51	-5.91	-0.31	8.44e-9	Gout;
CRC	cis	rs10924970	0.935	rs12731746	chr1:235392546	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg24585782	chr17:78113791	EIF4A3	-0.37	-5.71	-0.3	2.56e-8	Yeast infection;
CRC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.34	0.38	1.71e-12	Iron status biomarkers;
CRC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg00343986	chr7:65444356	GUSB	-0.49	-7.42	-0.38	1e-12	Aortic root size;
CRC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.45	-8.97	-0.44	2.32e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg00343986	chr7:65444356	GUSB	-0.57	-8.59	-0.43	3.53e-16	Calcium levels;
CRC	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg18683604	chr14:51561293	TRIM9	0.3	6.11	0.32	2.84e-9	Cancer;
CRC	trans	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg11764359	chr7:65958608	NA	-0.45	-6.49	-0.34	3.17e-10	Aortic root size;
CRC	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg14664628	chr15:75095509	CSK	-0.47	-5.68	-0.3	2.93e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20887711	chr4:1340912	KIAA1530	0.41	5.77	0.3	1.81e-8	Obesity-related traits;
CRC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.56	7.56	0.38	3.96e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.74	7.49	0.38	6.31e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg13043300	chr11:71146211	DHCR7	-0.47	-6.39	-0.33	5.76e-10	Vitamin D levels;
CRC	trans	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg11704114	chr12:21509398	SLCO1A2	-0.33	-6.14	-0.32	2.37e-9	Tuberculosis;
CRC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.88	-14.04	-0.61	1.99e-35	Blood metabolite levels;
CRC	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.62	-10.1	-0.49	4.72e-21	Neuroticism;
CRC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg24130564	chr14:104152367	KLC1	0.42	5.76	0.3	1.93e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	7.62	0.39	2.79e-13	Height;
CRC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.5	9.54	0.47	3.24e-19	Alcohol dependence;
CRC	cis	rs9937943	0.673	rs12922972	chr16:74494522	T/A	cg01733217	chr16:74700730	RFWD3	0.71	7.9	0.4	4.16e-14	Neutrophil percentage of white cells;
CRC	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg00105475	chr2:10696890	NA	0.45	6.93	0.36	2.3e-11	Prostate cancer;
CRC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.74	-9.51	-0.46	4.03e-19	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04474326	chr20:57556688	TH1L	0.44	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.56	-9.56	-0.47	2.82e-19	Temporomandibular joint disorder;
CRC	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.62	8.28	0.42	3.12e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.79	-11.37	-0.53	1.7e-25	Multiple sclerosis;
CRC	cis	rs7703744	0.681	rs73239278	chr5:118695051	G/A	cg23917399	chr5:118691751	TNFAIP8	0.41	5.69	0.3	2.8e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg22687807	chr8:143858763	LYNX1	-0.39	-6.8	-0.35	4.8e-11	Urinary tract infection frequency;
CRC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.57	7.54	0.38	4.59e-13	Mean platelet volume;
CRC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.14	-0.32	2.43e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.06	0.41	1.48e-14	Type 2 diabetes;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.37	-5.93	-0.31	7.66e-9	Lymphocyte counts;
CRC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg10820045	chr2:198174542	NA	-0.52	-8.93	-0.44	3.1e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.57	6.62	0.34	1.48e-10	Bipolar disorder;
CRC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg07884673	chr3:53033167	SFMBT1	0.7	6.15	0.32	2.23e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.8	13.44	0.6	3.93e-33	Menopause (age at onset);
CRC	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg06632207	chr12:54070931	ATP5G2	0.41	6.98	0.36	1.63e-11	Height;
CRC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.44	-6.81	-0.35	4.64e-11	Menarche (age at onset);
CRC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-9.07	-0.45	1.09e-17	Hemoglobin concentration;
CRC	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-9.43	-0.46	7.75e-19	Body mass index;
CRC	trans	rs10050311	0.698	rs17454154	chr4:87636160	A/G	cg00004207	chr2:38977301	SFRS7	0.5	6.07	0.32	3.56e-9	Insulin-related traits;
CRC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg00647820	chr17:40259828	DHX58	-0.45	-6.51	-0.34	2.74e-10	Fibrinogen levels;
CRC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.43	6.69	0.35	9.9e-11	Red blood cell count;
CRC	cis	rs2302729	0.545	rs10161181	chr12:2770730	A/C	cg19945202	chr12:2788847	CACNA1C	-0.44	-7.28	-0.37	2.49e-12	Sleep quality;
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.49	6.25	0.33	1.24e-9	Alzheimer's disease;
CRC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.89	0.68	1.61e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4964805	0.913	rs3812803	chr12:104200460	T/C	cg02344784	chr12:104178138	NT5DC3	0.53	7.71	0.39	1.49e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.49	8.34	0.42	2.08e-15	Common traits (Other);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11316784	chr5:176560594	NSD1	0.4	6.01	0.31	4.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg00343986	chr7:65444356	GUSB	-0.46	-6.27	-0.33	1.16e-9	Aortic root size;
CRC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.51	-6.6	-0.34	1.61e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.83	12.58	0.57	6.53e-30	Menarche (age at onset);
CRC	cis	rs10208940	0.764	rs6737186	chr2:68782763	A/C	cg12452813	chr2:68675892	NA	0.46	5.71	0.3	2.48e-8	Urate levels in lean individuals;
CRC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.46	7.29	0.37	2.3e-12	Dental caries;
CRC	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.47	6.11	0.32	2.78e-9	Putamen volume;
CRC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.51	7.25	0.37	2.92e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.66	-9.78	-0.47	5.53e-20	Initial pursuit acceleration;
CRC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg10760299	chr15:45669010	GATM	0.5	7.99	0.4	2.37e-14	Homoarginine levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06153298	chr16:88851960	FAM38A	0.44	5.96	0.31	6.38e-9	Anxiety disorder;
CRC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.61	7.36	0.38	1.48e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.86	-0.48	2.97e-20	Intelligence (multi-trait analysis);
CRC	cis	rs10971721	0.822	rs117733169	chr9:33938099	A/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15459742	chr9:111775564	CTNNAL1	0.47	6.1	0.32	3.05e-9	Thyroid stimulating hormone;
CRC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.49	-7.47	-0.38	7.44e-13	Total body bone mineral density;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg12273811	chr6:28175739	NA	0.54	7.72	0.39	1.43e-13	Parkinson's disease;
CRC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg03037974	chr15:76606532	NA	0.72	12.65	0.57	3.7e-30	Blood metabolite levels;
CRC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.45	-6.7	-0.35	9e-11	Height;
CRC	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.47	5.76	0.3	1.94e-8	Alzheimer's disease (survival time);
CRC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.09	-0.66	2.29e-43	Intelligence (multi-trait analysis);
CRC	cis	rs4853036	0.951	rs35344582	chr2:70148093	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-5.84	-0.31	1.27e-8	Colorectal or endometrial cancer;
CRC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.61	8.97	0.44	2.34e-17	Lung cancer;
CRC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.51	8.54	0.43	5.01e-16	Coronary artery disease;
CRC	cis	rs6735179	0.607	rs10188708	chr2:1746032	G/C	cg19300414	chr2:1746591	PXDN	0.47	7.92	0.4	3.71e-14	Response to antipsychotic treatment;
CRC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.76	13.13	0.59	6.08e-32	Colorectal cancer;
CRC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg05623727	chr3:50126028	RBM5	0.47	7.72	0.39	1.43e-13	Intelligence (multi-trait analysis);
CRC	trans	rs559356	0.519	rs475330	chr3:34841244	A/G	cg18960307	chr17:4699574	PSMB6	-0.4	-5.96	-0.31	6.47e-9	Cognitive function;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg02683197	chr6:28174875	NA	0.63	8.77	0.44	1e-16	Parkinson's disease;
CRC	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg27382691	chr15:76552771	ETFA;TYRO3P	0.47	6.03	0.32	4.47e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6681460	0.898	rs1032635	chr1:67195184	C/G	cg02459107	chr1:67143332	SGIP1	-0.4	-6.83	-0.35	4.2e-11	Presence of antiphospholipid antibodies;
CRC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.94	11.17	0.52	8.94e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg27661571	chr11:113659931	NA	-0.94	-10.92	-0.52	7.04e-24	Hip circumference adjusted for BMI;
CRC	cis	rs6499255	0.951	rs1437135	chr16:69757828	A/G	cg04110750	chr16:69646130	NFAT5	-0.54	-7.34	-0.38	1.66e-12	IgE levels;
CRC	cis	rs12431939	0.817	rs7153408	chr14:51671492	G/A	cg23942311	chr14:51606299	NA	0.49	6.74	0.35	7.02e-11	Cancer;
CRC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.49	-7.5	-0.38	5.96e-13	Menarche (age at onset);
CRC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.67	5.7	0.3	2.61e-8	Putamen volume;
CRC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.16	-0.41	7.4e-15	Neuroticism;
CRC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.78	11.12	0.52	1.3e-24	High light scatter reticulocyte count;
CRC	cis	rs7209700	0.662	rs11656865	chr17:45346489	A/G	cg08085267	chr17:45401833	C17orf57	0.44	5.96	0.31	6.44e-9	IgG glycosylation;
CRC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.19	0.32	1.78e-9	Tonsillectomy;
CRC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-8.11	-0.41	1.03e-14	Hemoglobin concentration;
CRC	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg11900509	chr10:81946545	ANXA11	-0.72	-7.26	-0.37	2.88e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7703744	0.634	rs73237292	chr5:118688520	A/T	cg23985447	chr5:118691066	TNFAIP8	0.41	6.04	0.32	4.2e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07518035	chr19:54693944	MBOAT7;TSEN34	0.46	6.16	0.32	2.13e-9	Anxiety disorder;
CRC	cis	rs3751196	0.808	rs55736751	chr12:104217303	T/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg02527881	chr3:46936655	PTH1R	0.36	6.19	0.32	1.75e-9	Colorectal cancer;
CRC	cis	rs524281	0.861	rs10896095	chr11:65962560	A/G	cg16950941	chr11:66035639	RAB1B	-0.58	-7.17	-0.37	5.08e-12	Electroencephalogram traits;
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-8.73	-0.43	1.31e-16	Bipolar disorder;
CRC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.73	11.02	0.52	3.13e-24	Corneal astigmatism;
CRC	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.58	6.75	0.35	6.67e-11	Glioblastoma;
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.54	-7.66	-0.39	2.09e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.59	0.47	2.24e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg15845792	chr6:28175446	NA	0.66	9.23	0.45	3.49e-18	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13857382	chr1:175162153	KIAA0040	0.47	6.4	0.33	5.44e-10	Anxiety disorder;
CRC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	cis	rs6604026	0.656	rs2774956	chr1:93364726	A/G	cg17283838	chr1:93427260	FAM69A	-0.43	-5.8	-0.3	1.52e-8	Multiple sclerosis;
CRC	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.52	-6.1	-0.32	2.91e-9	Body mass index;
CRC	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg13385794	chr1:248469461	NA	0.39	6.73	0.35	7.54e-11	Common traits (Other);
CRC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.52	8.06	0.41	1.41e-14	Corneal astigmatism;
CRC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg18478394	chr8:109455254	TTC35	0.4	6.23	0.32	1.4e-9	Dupuytren's disease;
CRC	trans	rs4853036	0.586	rs35066995	chr2:70005544	T/C	cg14633329	chr9:139640053	LCN6	-0.39	-6.44	-0.33	4.13e-10	Colorectal or endometrial cancer;
CRC	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg23127183	chr11:57508653	C11orf31	-0.53	-7.22	-0.37	3.69e-12	Schizophrenia;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.47	6.96	0.36	1.81e-11	Obesity-related traits;
CRC	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs4664293	0.546	rs7564399	chr2:160632119	C/T	cg08347373	chr2:160653686	CD302	0.43	7.42	0.38	1.03e-12	Monocyte percentage of white cells;
CRC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg03929089	chr4:120376271	NA	0.58	7.47	0.38	7.18e-13	Intraocular pressure;
CRC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	8.95	0.44	2.57e-17	Height;
CRC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg14728415	chr7:32535168	LSM5;AVL9	0.49	7.15	0.37	5.54e-12	Cognitive ability;
CRC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg18809830	chr7:99032528	PTCD1	-1.21	-8.72	-0.43	1.36e-16	Blood metabolite levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg22583711	chr7:154795321	PAXIP1;LOC202781	0.41	6.49	0.34	3.12e-10	Interleukin-6 levels;
CRC	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.81	10.19	0.49	2.33e-21	Prostate cancer;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.83	-0.31	1.3e-8	Total body bone mineral density;
CRC	cis	rs863345	0.565	rs7551497	chr1:158444925	T/G	cg12129480	chr1:158549410	OR10X1	-0.29	-5.94	-0.31	7.45e-9	Pneumococcal bacteremia;
CRC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.06	-0.32	3.72e-9	Obesity-related traits;
CRC	cis	rs6741819	1.000	rs3755509	chr2:7144838	A/G	cg27144453	chr2:7172511	RNF144A	-0.42	-6.24	-0.33	1.38e-9	Response to antipsychotic treatment;
CRC	cis	rs1223397	0.651	rs2496142	chr6:13311794	C/T	cg20827128	chr6:13274284	PHACTR1	-0.38	-5.77	-0.3	1.83e-8	Blood pressure;
CRC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-8.41	-0.42	1.24e-15	Total body bone mineral density;
CRC	trans	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg10756647	chr7:56101905	PSPH	0.7	7.47	0.38	7.51e-13	Diabetic kidney disease;
CRC	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.39	5.86	0.31	1.14e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg15147215	chr3:52552868	STAB1	0.43	7.25	0.37	2.93e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.05e-12	HDL cholesterol;
CRC	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.82	-0.44	6.83e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-6.31	-0.33	8.76e-10	Menarche (age at onset);
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg03623178	chr6:28175578	NA	0.88	9.03	0.45	1.48e-17	Lung cancer in ever smokers;
CRC	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg25834613	chr7:1915315	MAD1L1	-0.51	-7.94	-0.4	3.14e-14	Bipolar disorder;
CRC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.39	-6.89	-0.36	2.77e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.44	6.65	0.34	1.21e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21490793	chr19:38827205	CATSPERG	0.43	5.99	0.31	5.4e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17367356	chr11:45907078	MAPK8IP1	0.34	6.06	0.32	3.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-13.0	-0.58	1.88e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg02702477	chr5:179499311	RNF130	0.7	7.65	0.39	2.3e-13	LDL cholesterol;
CRC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.63	-11.69	-0.54	1.23e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg23071808	chr14:103021642	NA	-0.68	-8.97	-0.44	2.38e-17	Platelet count;
CRC	cis	rs6662572	1.000	rs41310432	chr1:46083706	C/G	cg08644498	chr1:46502608	NA	0.45	6.51	0.34	2.81e-10	Blood protein levels;
CRC	cis	rs7692995	1.000	rs7668933	chr4:17988141	A/G	cg08925142	chr4:18023851	LCORL	-0.53	-5.9	-0.31	8.82e-9	Height;
CRC	cis	rs17092148	0.652	rs4911154	chr20:32996101	A/G	cg08999081	chr20:33150536	PIGU	0.48	6.0	0.31	5.31e-9	Neuroticism;
CRC	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg16964102	chr10:135390573	NA	0.43	7.22	0.37	3.72e-12	Obesity-related traits;
CRC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.69	10.55	0.5	1.27e-22	Corneal astigmatism;
CRC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.69	9.02	0.45	1.56e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12159259	chr13:113642515	MCF2L	-0.43	-7.02	-0.36	1.26e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.66	-10.13	-0.49	3.56e-21	Height;
CRC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.29	0.33	9.92e-10	Height;
CRC	cis	rs3864277	0.510	rs31478	chr5:131423475	T/C	cg12564285	chr5:131593104	PDLIM4	0.33	5.82	0.31	1.4e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.61	-11.06	-0.52	2.12e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg09695851	chr17:3907499	NA	0.83	16.4	0.67	1.33e-44	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26859392	chr3:10143019	FANCD2;C3orf24	0.43	6.92	0.36	2.34e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.91	-0.31	8.42e-9	Pulmonary function;
CRC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.78	-12.33	-0.56	5.47e-29	Cognitive function;
CRC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.3	0.46	2.03e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.64	7.35	0.38	1.6e-12	Gut microbiome composition (summer);
CRC	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.49	-0.38	6.29e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.44	6.35	0.33	7.07e-10	Headache;
CRC	trans	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg07817883	chr1:32538562	TMEM39B	-0.6	-7.53	-0.38	4.96e-13	Monocyte percentage of white cells;
CRC	cis	rs7289126	1.000	rs7289126	chr22:38628306	A/C	cg25457927	chr22:38595422	NA	0.3	6.1	0.32	3.03e-9	Mammographic density (dense area);Percent mammographic density;
CRC	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.99	18.51	0.71	6.2e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.48	6.44	0.33	4.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.89e-11	Obesity-related traits;
CRC	cis	rs9303542	0.625	rs8066613	chr17:46583520	T/A	cg04904318	chr17:46607828	HOXB1	-0.52	-6.27	-0.33	1.16e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.02	0.7	5.41e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.39	0.33	5.61e-10	Alzheimer's disease;
CRC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg22110888	chr17:80059540	CCDC57	0.38	6.01	0.31	5.06e-9	Life satisfaction;
CRC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs12541635	0.677	rs11781331	chr8:107066936	G/A	cg10147462	chr8:107024639	NA	-0.59	-10.3	-0.49	9.32e-22	Age of smoking initiation;
CRC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.68	-0.3	3.02e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16447950	chr5:562315	NA	-0.74	-9.73	-0.47	7.89e-20	Obesity-related traits;
CRC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.47	-8.62	-0.43	2.86e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg20203395	chr5:56204925	C5orf35	0.52	7.02	0.36	1.28e-11	Initial pursuit acceleration;
CRC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.76	11.1	0.52	1.61e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.84	-0.63	1.75e-38	Exhaled nitric oxide output;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg26587870	chr6:27730563	NA	-0.43	-6.69	-0.35	9.61e-11	Parkinson's disease;
CRC	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg01951491	chr16:67709440	GFOD2	-0.44	-5.85	-0.31	1.17e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.59	0.34	1.71e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.46	0.42	9e-16	Schizophrenia;
CRC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.75	-11.75	-0.54	7.27e-27	Immature fraction of reticulocytes;
CRC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.96	0.4	2.75e-14	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12871507	chr1:110163427	AMPD2	0.48	7.15	0.37	5.68e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.8	-0.3	1.55e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.83	12.71	0.57	2.19e-30	Menarche (age at onset);
CRC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06544989	chr22:39130855	UNC84B	0.45	6.95	0.36	1.96e-11	Menopause (age at onset);
CRC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.66	9.22	0.45	3.72e-18	Neuroblastoma;
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg07217954	chr7:1067459	C7orf50	0.55	5.75	0.3	2.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.32	0.42	2.33e-15	Corneal astigmatism;
CRC	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg08071915	chr8:12219732	FAM66A	0.36	6.32	0.33	8.47e-10	Retinal vascular caliber;
CRC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.46	-0.42	8.86e-16	Monocyte count;
CRC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.48	6.72	0.35	8.08e-11	Total body bone mineral density;
CRC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg09218773	chr11:619014	MUPCDH	-0.43	-6.28	-0.33	1.09e-9	Systemic lupus erythematosus;
CRC	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg07972458	chr1:204535000	NA	0.36	5.61	0.3	4.21e-8	Schizophrenia;
CRC	cis	rs853679	0.567	rs16894091	chr6:28390137	A/T	cg21251018	chr6:28226885	NKAPL	-0.39	-5.64	-0.3	3.7e-8	Depression;
CRC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg12317470	chr15:67143691	NA	-0.72	-7.31	-0.37	2.05e-12	Lung cancer (smoking interaction);
CRC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg21153622	chr11:89784906	NA	-0.49	-8.07	-0.41	1.32e-14	HDL cholesterol;
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.661	rs6466956	chr7:124520366	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.53	0.47	3.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.44	6.59	0.34	1.7e-10	N-glycan levels;
CRC	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.64	11.03	0.52	2.86e-24	Cancer;
CRC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.21	-0.56	1.56e-28	Migraine;Coronary artery disease;
CRC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg21770322	chr7:97807741	LMTK2	0.52	8.52	0.43	5.7e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.48	6.24	0.33	1.35e-9	Exhaled nitric oxide output;
CRC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.73	11.98	0.55	1.12e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-10.6	-0.5	8.82e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.8	10.66	0.51	5.65e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.35	-0.33	7.06e-10	Neuroticism;
CRC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.48	7.36	0.38	1.5e-12	Corneal astigmatism;
CRC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg15382696	chr6:118971807	C6orf204	0.59	7.4	0.38	1.16e-12	Diastolic blood pressure;
CRC	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg12560992	chr17:57184187	TRIM37	0.53	6.19	0.32	1.79e-9	Vitamin D levels;
CRC	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.2	0.41	5.3e-15	Cognitive performance;
CRC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.63	8.94	0.44	2.92e-17	Homoarginine levels;
CRC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.53	0.34	2.47e-10	Bladder cancer;
CRC	trans	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg02869306	chr7:64672164	INTS4L1	-0.45	-6.42	-0.33	4.84e-10	Aortic root size;
CRC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.53	-6.89	-0.35	2.9e-11	Blood pressure (smoking interaction);
CRC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg20129853	chr10:51489980	NA	-0.36	-5.92	-0.31	8.09e-9	Prostate-specific antigen levels;
CRC	trans	rs9545047	0.716	rs9545053	chr13:79870214	T/G	cg07061582	chr15:90234082	PEX11A;WDR93	0.42	5.98	0.31	5.82e-9	Schizophrenia;
CRC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg07274523	chr3:49395745	GPX1	0.45	6.06	0.32	3.67e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	0.47	6.06	0.32	3.8e-9	Thyroid stimulating hormone;
CRC	trans	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.83e-14	HDL cholesterol;
CRC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.58	-7.78	-0.39	9.14e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11105468	1.000	rs11105462	chr12:90311971	G/A	cg23572944	chr11:60720130	SLC15A3	-0.43	-5.99	-0.31	5.37e-9	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.66	0.7	1.49e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg25164649	chr6:28176230	NA	0.59	6.14	0.32	2.33e-9	Depression;
CRC	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg26566898	chr11:117069891	TAGLN	0.39	6.97	0.36	1.76e-11	Blood protein levels;
CRC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg05625103	chr10:2543513	NA	0.39	6.22	0.32	1.54e-9	Age-related hearing impairment;
CRC	cis	rs6496667	0.865	rs7183944	chr15:90889111	C/T	cg04176472	chr15:90893244	GABARAPL3	0.63	7.14	0.37	5.9e-12	Rheumatoid arthritis;
CRC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.33	-6.23	-0.32	1.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg01993067	chr11:68851601	TPCN2	0.51	6.5	0.34	3.03e-10	Blond vs. brown hair color;
CRC	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.28	-0.33	1.09e-9	Arsenic metabolism;
CRC	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.76	0.43	1.04e-16	Mean corpuscular volume;
CRC	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.01	-0.31	4.99e-9	Subjective well-being;
CRC	trans	rs800082	0.516	rs7611932	chr3:144200593	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.23	0.32	1.43e-9	Smoking behavior;
CRC	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.45	-6.37	-0.33	6.3e-10	Blood protein levels;
CRC	cis	rs1223397	0.651	rs202019	chr6:13301790	A/C	cg07912922	chr6:13274314	PHACTR1	0.37	5.72	0.3	2.36e-8	Blood pressure;
CRC	cis	rs13217239	0.511	rs3800314	chr6:27236048	T/G	cg11262757	chr6:27280423	POM121L2	0.28	5.68	0.3	2.97e-8	Schizophrenia;
CRC	cis	rs974417	0.530	rs11751305	chr6:97296833	G/A	cg14723344	chr6:97285662	GPR63	0.42	6.02	0.32	4.6e-9	Body mass index;
CRC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.69	12.05	0.55	6.21e-28	Body mass index;
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.19	-0.32	1.84e-9	Obesity-related traits;
CRC	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.06	14.72	0.63	5.16e-38	Exhaled nitric oxide output;
CRC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.8	13.69	0.6	4.46e-34	Menopause (age at onset);
CRC	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.43	-6.33	-0.33	8.11e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs10411161	1.000	rs8111316	chr19:52369069	A/C	cg22319618	chr22:45562946	NUP50	-0.5	-5.97	-0.31	6.2e-9	Breast cancer;
CRC	trans	rs6413860	0.637	rs12035469	chr1:246858531	A/G	cg25623271	chr1:240656217	GREM2	-0.43	-6.2	-0.32	1.67e-9	Gut microbiome composition (summer);
CRC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.5	10.04	0.48	7.51e-21	Bone mineral density;
CRC	cis	rs243505	0.668	rs2072406	chr7:148483760	G/A	cg09806900	chr7:148480153	CUL1	0.55	7.91	0.4	4.06e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.52	-8.13	-0.41	9.06e-15	Corneal astigmatism;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg06476606	chr10:91061728	IFIT2	-0.43	-5.98	-0.31	5.92e-9	Protein C levels;
CRC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.62	9.42	0.46	8.4e-19	Testicular germ cell tumor;
CRC	cis	rs7605827	0.897	rs7590198	chr2:15536314	C/T	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs7849270	0.921	rs7019373	chr9:131897221	C/T	cg13538475	chr9:131942899	NA	-0.32	-6.4	-0.33	5.3e-10	Blood metabolite ratios;
CRC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.37	6.81	0.35	4.61e-11	Reticulocyte fraction of red cells;
CRC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.37	-15.11	-0.64	1.47e-39	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07991241	chr10:33269695	NA	0.48	6.79	0.35	5.14e-11	Response to antipsychotic treatment;
CRC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.48	6.9	0.36	2.61e-11	Lymphocyte counts;
CRC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22133161	chr19:49891603	CCDC155	0.52	7.29	0.37	2.36e-12	Multiple sclerosis;
CRC	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.58	-5.87	-0.31	1.09e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg11833968	chr6:79620685	NA	-0.36	-6.26	-0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg09127314	chr1:152161683	NA	0.47	6.08	0.32	3.36e-9	Atopic dermatitis;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg15786705	chr6:28176104	NA	0.71	9.12	0.45	7.73e-18	Depression;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.84	-0.44	5.81e-17	Bipolar disorder;
CRC	trans	rs9650657	0.675	rs2409658	chr8:10668965	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.22	-0.32	1.54e-9	Neuroticism;
CRC	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-8.49	-0.42	7.01e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.67	9.3	0.46	2.04e-18	Bladder cancer;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg09877947	chr5:131593287	PDLIM4	0.35	6.57	0.34	1.96e-10	Blood metabolite levels;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg03623178	chr6:28175578	NA	0.8	11.74	0.54	8.21e-27	Parkinson's disease;
CRC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.86	-15.13	-0.64	1.24e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9311676	0.656	rs11714807	chr3:58405431	A/G	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.49	7.68	0.39	1.83e-13	Eye color traits;
CRC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg20399509	chr21:47717575	C21orf57	-0.39	-6.48	-0.34	3.43e-10	Testicular germ cell tumor;
CRC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.18	-0.32	1.9e-9	Menarche (age at onset);
CRC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.52	7.88	0.4	4.8e-14	Body mass index;
CRC	cis	rs4731207	0.698	rs10954045	chr7:124498155	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg12923728	chr3:195709715	SDHAP1	-0.59	-6.16	-0.32	2.1e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg25767906	chr1:53392781	SCP2	0.45	7.16	0.37	5.34e-12	Monocyte count;
CRC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.68	-0.35	1.01e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11212617	0.870	rs227063	chr11:108207304	T/G	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.59	0.34	1.77e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.91	17.27	0.69	4.82e-48	Intelligence (multi-trait analysis);
CRC	cis	rs17065868	0.764	rs73188730	chr13:45031377	C/T	cg10246903	chr13:45222710	NA	0.56	5.92	0.31	8.25e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg18230493	chr5:56204884	C5orf35	-0.41	-6.21	-0.32	1.58e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.67	6.98	0.36	1.65e-11	Axial length;
CRC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.88	-0.35	3.01e-11	Coronary artery disease;
CRC	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg26875233	chr11:93583750	C11orf90	-0.33	-6.44	-0.33	4.28e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	1.11	10.44	0.5	3.09e-22	Arsenic metabolism;
CRC	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.7	9.09	0.45	9.48e-18	Breast cancer;
CRC	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg01993067	chr11:68851601	TPCN2	0.53	5.93	0.31	7.58e-9	Blond vs. brown hair color;
CRC	cis	rs2421770	0.504	rs4756213	chr11:35363566	T/C	cg13971030	chr11:35366721	SLC1A2	-0.4	-6.83	-0.35	4.1e-11	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.49	-6.1	-0.32	2.9e-9	Coronary artery calcification;
CRC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.83	0.35	4.05e-11	Melanoma;
CRC	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.95	-13.36	-0.59	7.99e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03480535	chr4:87856849	AFF1	-0.53	-6.65	-0.34	1.23e-10	Diisocyanate-induced asthma;
CRC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.34	5.72	0.3	2.34e-8	Lung cancer;
CRC	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.35	-0.42	1.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.58	-0.34	1.91e-10	Menopause (age at onset);
CRC	trans	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg10756647	chr7:56101905	PSPH	0.69	7.2	0.37	4.24e-12	Diabetic kidney disease;
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg09218773	chr11:619014	MUPCDH	-0.44	-6.38	-0.33	5.9e-10	Systemic lupus erythematosus;
CRC	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg06470822	chr6:28175283	NA	-0.67	-7.23	-0.37	3.46e-12	Depression;
CRC	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg06581033	chr10:766294	NA	-0.47	-5.71	-0.3	2.58e-8	Uric acid levels;
CRC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg24505167	chr7:1915268	MAD1L1	0.49	8.0	0.4	2.22e-14	Bipolar disorder;
CRC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.93	16.72	0.68	7.64e-46	Cognitive function;
CRC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg15269541	chr15:43626905	ADAL	-0.48	-5.88	-0.31	9.87e-9	Lung cancer in ever smokers;
CRC	cis	rs6445525	0.905	rs7636143	chr3:65992411	C/T	cg06109867	chr3:66002991	MAGI1	0.35	5.79	0.3	1.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.76	-0.35	6.29e-11	Alzheimer's disease (late onset);
CRC	cis	rs2712184	0.652	rs13000985	chr2:217644361	T/G	cg05032264	chr2:217675019	NA	0.33	5.73	0.3	2.29e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14611757	chr11:1012211	AP2A2	-0.39	-6.53	-0.34	2.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.46	6.2	0.32	1.69e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3790645	0.958	rs2290589	chr1:26880288	C/T	cg23229016	chr1:26872525	RPS6KA1	0.28	6.29	0.33	1e-9	Glucose homeostasis traits;
CRC	trans	rs2303319	0.504	rs62188961	chr2:162495399	A/G	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-14.1	-0.61	1.2e-35	Blood metabolite levels;
CRC	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	0.65	6.98	0.36	1.67e-11	Prostate cancer;
CRC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-7.29	-0.37	2.28e-12	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26537410	chr10:74451932	CCDC109A	0.45	6.51	0.34	2.81e-10	Anxiety disorder;
CRC	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg10263370	chr3:44754102	ZNF502	-0.39	-6.51	-0.34	2.87e-10	Depressive symptoms;
CRC	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.53	-8.79	-0.44	8.32e-17	Congenital heart disease (maternal effect);
CRC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.67	0.35	1.1e-10	Morning vs. evening chronotype;
CRC	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11446398	chr5:77624930	NA	0.43	6.39	0.33	5.54e-10	Triglycerides;
CRC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg24849736	chr1:201084428	NA	0.46	6.05	0.32	3.87e-9	Permanent tooth development;
CRC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	9.39	0.46	9.95e-19	Cognitive test performance;
CRC	cis	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg11143507	chr3:125485238	NA	-0.58	-7.46	-0.38	7.69e-13	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg06896663	chr8:82754093	SNX16	-0.68	-6.1	-0.32	3.01e-9	Cognitive function;
CRC	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.51	7.8	0.4	8.07e-14	Alzheimer's disease (cognitive decline);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27301331	chr6:20401917	E2F3	0.48	6.08	0.32	3.27e-9	Thyroid stimulating hormone;
CRC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg12193833	chr17:30244370	NA	-0.39	-5.85	-0.31	1.17e-8	Hip circumference adjusted for BMI;
CRC	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.58	-0.39	3.62e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.56	8.51	0.42	6.23e-16	Longevity;Endometriosis;
CRC	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.59	7.13	0.37	6.35e-12	Carotid intima media thickness;
CRC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.22e-9	Life satisfaction;
CRC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg16447950	chr5:562315	NA	-0.84	-10.48	-0.5	2.32e-22	Lung disease severity in cystic fibrosis;
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.09	0.52	1.72e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18301423	chr5:131593218	PDLIM4	0.38	7.03	0.36	1.2e-11	Breast cancer;
CRC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.51	6.97	0.36	1.77e-11	Morning vs. evening chronotype;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg23123621	chr4:1343375	KIAA1530	0.37	6.4	0.33	5.28e-10	Longevity;
CRC	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.71	-14.79	-0.63	2.64e-38	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.86	-0.44	4.98e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.64	9.67	0.47	1.25e-19	Initial pursuit acceleration;
CRC	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.49	-6.35	-0.33	7.19e-10	Height;
CRC	cis	rs995000	0.931	rs12074528	chr1:63010871	T/C	cg19896129	chr1:63156450	NA	-0.44	-6.82	-0.35	4.3e-11	Triglyceride levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27006547	chr11:62606509	WDR74	-0.5	-6.49	-0.34	3.12e-10	Diisocyanate-induced asthma;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.11	-0.37	7.08e-12	Blood metabolite levels;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.47	-6.15	-0.32	2.21e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.5	-6.78	-0.35	5.54e-11	Intelligence (multi-trait analysis);
CRC	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.39	-0.33	5.55e-10	Schizophrenia;
CRC	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.59	-8.94	-0.44	2.89e-17	Dementia with Lewy bodies;
CRC	cis	rs4664293	0.605	rs6741498	chr2:160554622	G/A	cg08347373	chr2:160653686	CD302	0.39	6.53	0.34	2.44e-10	Monocyte percentage of white cells;
CRC	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.44	6.02	0.31	4.66e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg14541582	chr5:601475	NA	-0.36	-7.32	-0.37	1.97e-12	Obesity-related traits;
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.86	0.44	4.99e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.62	9.11	0.45	8.27e-18	Morning vs. evening chronotype;
CRC	cis	rs7212590	0.655	rs8072050	chr17:58010972	G/A	cg10252138	chr17:58120427	NA	-0.58	-6.28	-0.33	1.1e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg00691999	chr4:55094011	PDGFRA	0.43	6.28	0.33	1.06e-9	Corneal astigmatism;
CRC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.36	-0.53	1.9e-25	Alzheimer's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08167047	chr11:72463418	ARAP1	0.44	6.15	0.32	2.25e-9	Anxiety disorder;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.03	0.55	6.96e-28	Alzheimer's disease;
CRC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.53	-8.24	-0.41	4.02e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.01	0.31	5.04e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06916729	chr5:90676249	LOC100129716;ARRDC3	0.48	6.64	0.34	1.3100000000000001e-10	Response to antipsychotic treatment;
CRC	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	10.56	0.5	1.21e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.77	10.62	0.51	7.79e-23	IgG glycosylation;
CRC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.53	7.73	0.39	1.36e-13	Mean platelet volume;
CRC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg07952391	chr2:88470173	THNSL2	-0.41	-6.11	-0.32	2.75e-9	Response to metformin (IC50);
CRC	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg05925327	chr15:68127851	NA	-0.3	-5.79	-0.3	1.65e-8	Restless legs syndrome;
CRC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.71	10.79	0.51	1.87e-23	Coronary artery disease;
CRC	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06156847	chr2:113672199	IL1F7	0.46	7.06	0.36	1e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg14345882	chr6:26364793	BTN3A2	0.4	6.25	0.33	1.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.63	-8.54	-0.43	5.14e-16	Extraversion;
CRC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-7.16	-0.37	5.2e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.68	-7.15	-0.37	5.55e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs3540	0.960	rs6496675	chr15:90982756	C/T	cg22089800	chr15:90895588	ZNF774	0.51	8.12	0.41	9.6e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg09659197	chr4:152720779	NA	0.53	11.67	0.54	1.47e-26	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.41	-0.33	4.92e-10	Bipolar disorder;
CRC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.4	6.19	0.32	1.78e-9	HDL cholesterol levels;
CRC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg18512352	chr11:47633146	NA	-0.4	-7.77	-0.39	9.9e-14	Subjective well-being;
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.74	-0.35	7.24e-11	Metabolite levels;
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.41	-5.74	-0.3	2.15e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.38	-6.85	-0.35	3.61e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg26061582	chr7:22766209	IL6	-0.48	-7.46	-0.38	7.67e-13	Lung cancer;
CRC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.44	0.33	4.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.39	-6.27	-0.33	1.11e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg07507251	chr3:52567010	NT5DC2	0.4	6.2	0.32	1.71e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1881396	0.947	rs10173720	chr2:27855397	A/T	cg27432699	chr2:27873401	GPN1	-0.62	-8.09	-0.41	1.2e-14	Nonalcoholic fatty liver disease;
CRC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.54	8.38	0.42	1.52e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-7.64	-0.39	2.45e-13	Headache;
CRC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-10.51	-0.5	1.82e-22	Menarche (age at onset);
CRC	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.47	6.95	0.36	1.92e-11	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg08222618	chr4:941054	TMEM175	0.74	12.83	0.58	7.98e-31	Sjögren's syndrome;
CRC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.71e-21	Aortic root size;
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-0.73	-6.95	-0.36	1.93e-11	IgG glycosylation;
CRC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.6	-10.53	-0.5	1.54e-22	Aortic root size;
CRC	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg19554555	chr3:13937349	NA	0.44	6.39	0.33	5.7e-10	Ovarian reserve;
CRC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.4	0.42	1.36e-15	Height;
CRC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.51	-0.38	5.45e-13	Aortic root size;
CRC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-15.58	-0.65	2.29e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9467160	0.871	rs9461015	chr6:24449020	C/G	cg20631270	chr6:24437470	GPLD1	-0.5	-7.01	-0.36	1.35e-11	Liver enzyme levels;
CRC	cis	rs12580194	1.000	rs61539173	chr12:55703206	C/T	cg19537932	chr12:55886519	OR6C68	-0.58	-8.07	-0.41	1.33e-14	Cancer;
CRC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.46	-0.34	3.86e-10	Tonsillectomy;
CRC	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.13	17.17	0.69	1.3e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg05095123	chr13:29393749	NA	0.34	6.11	0.32	2.82e-9	Obesity-related traits;
CRC	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-9.3	-0.46	2.01e-18	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.33	0.33	8.17e-10	Heart rate;
CRC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.29	6.1	0.32	2.99e-9	Homoarginine levels;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.58	6.78	0.35	5.52e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1712517	0.904	rs4918007	chr10:105107470	G/A	cg05636881	chr10:105038444	INA	-0.44	-7.55	-0.38	4.25e-13	Migraine;
CRC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg26979339	chr12:107168153	RIC8B	-0.41	-6.39	-0.33	5.76e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.04	0.45	1.42e-17	Bladder cancer;
CRC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.79	0.35	5.21e-11	Axial length;
CRC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.4	-0.69	1.57e-48	Primary sclerosing cholangitis;
CRC	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.38	0.33	6.18e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2084637	1.000	rs2084637	chr11:122391187	T/C	cg21585512	chr11:122030076	LOC399959	-0.38	-6.65	-0.34	1.21e-10	Stroke;
CRC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.7	9.25	0.45	3.03e-18	Vitiligo;
CRC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.6	-9.5	-0.46	4.46e-19	Aortic root size;
CRC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg13628971	chr7:2884303	GNA12	0.41	6.08	0.32	3.35e-9	Height;
CRC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg24112000	chr20:60950667	NA	-0.47	-6.15	-0.32	2.29e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-12.38	-0.56	3.69e-29	Breast cancer;
CRC	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg15571903	chr15:79123663	NA	0.34	6.92	0.36	2.4e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.61	10.95	0.52	5.42e-24	Aortic root size;
CRC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	9.92e-18	Bladder cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14347670	chr6:41908995	CCND3	0.49	6.39	0.33	5.83e-10	Thyroid stimulating hormone;
CRC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg14979609	chr8:8086686	FLJ10661	0.38	6.23	0.32	1.42e-9	Joint mobility (Beighton score);
CRC	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.01e-12	Headache;
CRC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg06238570	chr21:40685208	BRWD1	0.7	9.28	0.46	2.28e-18	Cognitive function;
CRC	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg19773385	chr1:10388646	KIF1B	-0.58	-7.95	-0.4	2.92e-14	Hepatocellular carcinoma;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.27e-9	Blood osmolality (transformed sodium);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23023044	chr1:110765955	KCNC4	-0.4	-6.44	-0.33	4.13e-10	Interleukin-6 levels;
CRC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.45	-6.73	-0.35	7.4e-11	Menarche (age at onset);
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.64	-9.87	-0.48	2.76e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg08888203	chr3:10149979	C3orf24	0.7	7.55	0.38	4.22e-13	Alzheimer's disease;
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-11.62	-0.54	2.13e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.55	8.23	0.41	4.36e-15	Multiple myeloma (IgH translocation);
CRC	trans	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.38	-0.38	1.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.35	-5.87	-0.31	1.06e-8	Childhood ear infection;
CRC	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg22495460	chr2:25135724	ADCY3	-0.73	-12.05	-0.55	6.08e-28	Body mass index;
CRC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.71	8.44	0.42	1.03e-15	Eotaxin levels;
CRC	cis	rs67981189	0.529	rs61990379	chr14:71467070	A/G	cg15910301	chr14:71632612	NA	0.31	6.11	0.32	2.89e-9	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11301416	chr6:37225561	TMEM217;TBC1D22B	0.45	6.49	0.34	3.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.55	-7.85	-0.4	6.02e-14	Prostate cancer;
CRC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg04880052	chr2:219191631	PNKD	0.41	6.61	0.34	1.53e-10	Colorectal cancer;
CRC	trans	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.63	8.77	0.44	1e-16	Coronary artery disease;
CRC	trans	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg01505111	chr6:125621795	HDDC2	0.38	6.04	0.32	4.06e-9	DNA methylation (variation);
CRC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.16	0.41	7.25e-15	Colorectal cancer;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg26608667	chr7:1196370	ZFAND2A	0.43	6.89	0.36	2.78e-11	Longevity;Endometriosis;
CRC	cis	rs6456156	0.904	rs2021033	chr6:167524239	C/T	cg19688584	chr6:167529678	CCR6	-0.33	-5.74	-0.3	2.14e-8	Primary biliary cholangitis;
CRC	cis	rs728616	0.614	rs1538818	chr10:82122793	G/A	cg11900509	chr10:81946545	ANXA11	-0.56	-6.3	-0.33	9.41e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg03519263	chr14:21152327	RNASE4;ANG	-0.42	-6.07	-0.32	3.61e-9	Birth weight;Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18168982	chr10:70661333	DDX50	0.41	6.06	0.32	3.72e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13237843	chr11:6640720	TPP1	0.44	6.45	0.34	3.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg05562828	chr17:3906858	NA	0.66	12.35	0.56	4.58e-29	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04623168	chr12:112546260	NAA25	0.45	6.12	0.32	2.6e-9	Response to antipsychotic treatment;
CRC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.57	-10.11	-0.49	4.16e-21	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.19	-0.32	1.78e-9	Axial length;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17103702	chr17:73901075	MRPL38	0.43	6.16	0.32	2.13e-9	Anxiety disorder;
CRC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18912574	chr7:65842487	NCRNA00174	0.33	5.66	0.3	3.22e-8	Calcium levels;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg26587870	chr6:27730563	NA	-0.36	-5.62	-0.3	4.14e-8	Cardiac Troponin-T levels;
CRC	trans	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg18288967	chr1:45987694	PRDX1	0.65	6.92	0.36	2.34e-11	Obesity-related traits;
CRC	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg15192750	chr16:69999425	NA	0.62	8.26	0.41	3.63e-15	IgE levels;
CRC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.02	0.36	1.29e-11	Rheumatoid arthritis;
CRC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.76	16.49	0.67	5.94e-45	Breast cancer;
CRC	cis	rs10484885	0.553	rs12661697	chr6:90284329	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.58	-6.49	-0.34	3.07e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg16068336	chr17:48637367	CACNA1G	-0.48	-6.94	-0.36	2.11e-11	Type 2 diabetes;
CRC	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.59	-6.77	-0.35	6.01e-11	Red cell distribution width;
CRC	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg20936604	chr3:58311152	NA	-0.74	-6.94	-0.36	2.05e-11	Cholesterol, total;
CRC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.97	-0.36	1.77e-11	IgG glycosylation;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg15786705	chr6:28176104	NA	0.54	7.43	0.38	9.41e-13	Parkinson's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02825653	chr17:7383046	ZBTB4	0.44	6.95	0.36	1.97e-11	Interleukin-6 levels;
CRC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-6.63	-0.34	1.36e-10	Tonsillectomy;
CRC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.89	-11.17	-0.52	8.84e-25	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07080049	chr9:96214194	FAM120A;FAM120AOS	0.54	7.71	0.39	1.52e-13	Response to antipsychotic treatment;
CRC	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg16141378	chr3:129829833	LOC729375	0.43	6.27	0.33	1.13e-9	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11944815	chr12:125473709	DHX37	0.38	6.03	0.32	4.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.79	-13.81	-0.61	1.52e-34	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20859470	chr1:153963593	RPS27	0.43	6.02	0.31	4.66e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.25	-0.33	1.27e-9	Aortic root size;
CRC	trans	rs10242455	1.000	rs6948775	chr7:98945480	A/G	cg09045935	chr12:6379348	NA	0.73	6.83	0.35	4e-11	Blood metabolite levels;
CRC	cis	rs2882667	0.690	rs11749163	chr5:138262670	A/G	cg09476006	chr5:138032270	NA	0.58	10.08	0.49	5.28e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg11292332	chr7:45801988	SEPT13	0.34	6.27	0.33	1.15e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg12172441	chr6:28176163	NA	0.53	6.13	0.32	2.53e-9	Depression;
CRC	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-5.75	-0.3	2.07e-8	Total body bone mineral density (age 45-60);
CRC	cis	rs4660306	0.677	rs11211110	chr1:45904815	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.52	-6.53	-0.34	2.47e-10	Homocysteine levels;
CRC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17507749	chr15:85114479	UBE2QP1	0.57	8.06	0.41	1.41e-14	Schizophrenia;
CRC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.21	-0.41	4.95e-15	Morning vs. evening chronotype;
CRC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.22	6.31	0.33	9.23e-10	Urinary metabolites;
CRC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.81	14.83	0.63	1.79e-38	Body mass index;
CRC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.05	0.36	1.04e-11	Diabetic retinopathy;
CRC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12745968	0.589	rs6697491	chr1:93032714	A/G	cg17283838	chr1:93427260	FAM69A	-0.47	-6.29	-0.33	1e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-6.75	-0.35	6.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.52	9.29	0.46	2.23e-18	Common traits (Other);
CRC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.23	0.32	1.44e-9	Tonsillectomy;
CRC	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs6694672	1.000	rs10754215	chr1:197086669	C/T	cg13682187	chr1:196946512	CFHR5	0.44	7.19	0.37	4.38e-12	Asthma;
CRC	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg24848437	chr7:2645542	IQCE	0.58	6.03	0.32	4.3e-9	Urate levels in lean individuals;
CRC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.59	0.43	3.5e-16	Height;
CRC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.91	16.61	0.68	1.98e-45	Intelligence (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25350635	chr12:49182847	ADCY6	0.36	6.01	0.31	5.02e-9	Obesity-related traits;
CRC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg23957660	chr17:17878224	LRRC48	0.35	5.93	0.31	7.6e-9	Total body bone mineral density;
CRC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg23533926	chr12:111358616	MYL2	0.45	6.6	0.34	1.69e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.23	-0.74	1.07e-59	Height;
CRC	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.57	9.28	0.46	2.36e-18	Mean corpuscular volume;
CRC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.45	7.15	0.37	5.54e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.5	6.65	0.34	1.2e-10	White matter hyperintensity burden;
CRC	cis	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs11958404	0.932	rs72816547	chr5:157417820	G/T	cg05962755	chr5:157440814	NA	1.01	12.45	0.57	1.96e-29	IgG glycosylation;
CRC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.62	9.62	0.47	1.88e-19	Corneal astigmatism;
CRC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.86	-0.44	5.09e-17	Joint mobility (Beighton score);
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.68	10.18	0.49	2.4e-21	Menarche (age at onset);
CRC	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.41	6.06	0.32	3.67e-9	Height;
CRC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.36e-9	Coronary artery disease;
CRC	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg11204139	chr17:3907470	NA	0.41	5.69	0.3	2.82e-8	Type 2 diabetes;
CRC	cis	rs9292777	0.681	rs2197426	chr5:40418273	C/G	cg09067459	chr5:40385259	NA	-0.55	-8.93	-0.44	3.12e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs11212617	0.967	rs227090	chr11:108241349	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.03	0.32	4.31e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg04155289	chr7:94953770	PON1	-0.59	-7.48	-0.38	6.83e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg09003973	chr2:102972529	NA	0.41	5.68	0.3	2.96e-8	Blood protein levels;
CRC	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.36	5.97	0.31	6.19e-9	Carotid intima media thickness;
CRC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.29	0.46	2.1e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.55	8.21	0.41	5.08e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg02811702	chr13:24901961	NA	0.41	5.73	0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-0.6	-10.9	-0.52	7.91e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.54	7.25	0.37	2.95e-12	Response to antidepressants and depression;
CRC	cis	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg07460842	chr6:66804631	NA	-0.42	-5.71	-0.3	2.5e-8	Blood trace element (Cu levels);
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.41	5.95	0.31	6.88e-9	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23471890	chr12:111051874	TCTN1	0.39	6.41	0.33	4.9e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.69	-0.35	9.51e-11	Total body bone mineral density;
CRC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg10790698	chr19:18539756	SSBP4	-0.44	-8.44	-0.42	1e-15	Breast cancer;
CRC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg20684491	chr1:25596433	NA	0.43	7.39	0.38	1.23e-12	Erythrocyte sedimentation rate;
CRC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg05941027	chr17:61774174	LIMD2	0.35	6.23	0.32	1.45e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg25251562	chr2:3704773	ALLC	-0.43	-6.42	-0.33	4.67e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.13e-13	Motion sickness;
CRC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-10.24	-0.49	1.51e-21	Personality dimensions;
CRC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12463550	chr7:65579703	CRCP	0.62	5.95	0.31	6.68e-9	Diabetic kidney disease;
CRC	cis	rs11696501	0.688	rs1013562	chr20:44310744	A/G	cg11783356	chr20:44313418	WFDC10B	-0.41	-6.23	-0.32	1.42e-9	Brain structure;
CRC	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg18002602	chr11:66138449	SLC29A2	-0.29	-6.12	-0.32	2.63e-9	Educational attainment (years of education);
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.81	12.47	0.57	1.66e-29	Menarche (age at onset);
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg02018176	chr4:1364513	KIAA1530	0.4	5.92	0.31	8.31e-9	Obesity-related traits;
CRC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.51e-12	Motion sickness;
CRC	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.75	-11.9	-0.55	2.12e-27	Body mass index;
CRC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg03037974	chr15:76606532	NA	0.71	12.4	0.56	3.06e-29	Blood metabolite levels;
CRC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg03037974	chr15:76606532	NA	0.61	10.31	0.49	8.67e-22	Blood metabolite levels;
CRC	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg12700464	chr11:78128424	GAB2	-0.46	-5.66	-0.3	3.37e-8	Testicular germ cell tumor;
CRC	cis	rs4728302	0.608	rs6950383	chr7:133727497	C/T	cg03336402	chr7:133662267	EXOC4	0.42	6.47	0.34	3.46e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.53	9.12	0.45	7.62e-18	Aortic root size;
CRC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.83	-0.48	3.72e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.23e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.81	-14.33	-0.62	1.54e-36	Tonsillectomy;
CRC	trans	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg04295733	chr1:166845736	TADA1	-0.41	-5.98	-0.31	5.73e-9	Dental caries;
CRC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.54	8.12	0.41	9.26e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.46	7.15	0.37	5.8e-12	Corneal astigmatism;
CRC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.6	8.31	0.42	2.53e-15	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg14593290	chr7:50529359	DDC	-0.42	-6.06	-0.32	3.76e-9	Body mass index;
CRC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.7	9.38	0.46	1.14e-18	Alzheimer's disease;
CRC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg17545662	chr6:170176663	C6orf70	0.57	6.43	0.33	4.53e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.5	0.42	6.88e-16	Homoarginine levels;
CRC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.72	-0.39	1.41e-13	Psoriasis;
CRC	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.57	0.63	1.8e-37	Hypertriglyceridemia;
CRC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.76	11.25	0.53	4.77e-25	Breast cancer;
CRC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg16342193	chr10:102329863	NA	-0.36	-6.09	-0.32	3.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.03	-0.32	4.41e-9	Educational attainment;
CRC	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.65	9.75	0.47	6.76e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6694672	1.000	rs9427942	chr1:196946448	G/A	cg13682187	chr1:196946512	CFHR5	-0.5	-7.97	-0.4	2.59e-14	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24487361	chr1:231473529	EXOC8;C1orf124	0.37	6.16	0.32	2.11e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.81	-0.4	7.76e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg13047869	chr3:10149882	C3orf24	0.39	5.95	0.31	6.8e-9	Alzheimer's disease;
CRC	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.66	-9.82	-0.48	4.09e-20	Acne (severe);
CRC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.23e-9	Obesity-related traits;
CRC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.77	-0.35	5.98e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.48	-6.48	-0.34	3.29e-10	Serum thyroid-stimulating hormone levels;
CRC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.73	-11.17	-0.52	9.27e-25	Tonsillectomy;
CRC	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.67	0.39	1.97e-13	Height;
CRC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg00428638	chr19:7224713	INSR	1.01	21.75	0.77	1.2e-65	Hypothyroidism;
CRC	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.23	-0.32	1.4e-9	Tonsillectomy;
CRC	cis	rs10486722	0.651	rs12537065	chr7:41781911	A/G	cg22138096	chr7:41772439	LOC285954	0.49	6.37	0.33	6.33e-10	Pit-and-Fissure caries;
CRC	cis	rs62432291	0.681	rs445957	chr6:159662064	C/T	cg14500486	chr6:159655392	FNDC1	-0.79	-10.63	-0.51	6.84e-23	Joint mobility (Beighton score);
CRC	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.15e-10	Obesity-related traits;
CRC	cis	rs17401966	0.538	rs7418410	chr1:10236402	A/G	cg19773385	chr1:10388646	KIF1B	0.47	7.13	0.37	6.22e-12	Hepatocellular carcinoma;
CRC	cis	rs2274471	0.645	rs73395330	chr9:5082839	C/T	cg03390472	chr9:5043263	JAK2	-0.6	-7.05	-0.36	1.03e-11	Crohn's disease;
CRC	cis	rs10464366	0.597	rs10951590	chr7:39091043	C/T	cg18850127	chr7:39170497	POU6F2	0.44	5.82	0.31	1.36e-8	IgG glycosylation;
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg07506560	chr2:240697449	NA	0.48	6.37	0.33	6.49e-10	Obesity-related traits;
CRC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.25	-0.33	1.29e-9	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.57e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg27535305	chr1:53392650	SCP2	-0.36	-6.32	-0.33	8.45e-10	Monocyte count;
CRC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.41	6.74	0.35	7.13e-11	Resting heart rate;
CRC	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg04586622	chr2:25135609	ADCY3	-0.55	-10.21	-0.49	1.95e-21	Body mass index;
CRC	cis	rs8105895	0.935	rs62112364	chr19:22294903	C/A	cg02912127	chr19:22235281	ZNF257	-0.41	-5.6	-0.3	4.52e-8	Body mass index (change over time);
CRC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.78	13.6	0.6	9.81e-34	Breast cancer;
CRC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg22496339	chr2:162101262	NA	-0.54	-7.29	-0.37	2.26e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.27	0.37	2.65e-12	Motion sickness;
CRC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg27535305	chr1:53392650	SCP2	0.33	5.74	0.3	2.1e-8	Monocyte count;
CRC	cis	rs858239	1.000	rs156425	chr7:23309119	C/T	cg00469287	chr7:23338798	C7orf30	-0.5	-6.74	-0.35	7.05e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.71	-0.47	9.47e-20	Heart rate;
CRC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.58	0.47	2.54e-19	Lung cancer;
CRC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	9.4	0.46	9.32e-19	Mean platelet volume;
CRC	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	9.15	0.45	6.3e-18	Blood protein levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00814883	chr7:100076585	TSC22D4	0.39	6.11	0.32	2.76e-9	Obesity-related traits;
CRC	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg16691251	chr5:66510806	NA	0.41	7.18	0.37	4.7e-12	Breast cancer;
CRC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16447950	chr5:562315	NA	-0.83	-10.81	-0.51	1.71e-23	Lung disease severity in cystic fibrosis;
CRC	trans	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg19188899	chr13:112838565	NA	-0.42	-6.28	-0.33	1.05e-9	Systemic lupus erythematosus;
CRC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.41	-6.0	-0.31	5.3e-9	Alzheimer's disease (late onset);
CRC	cis	rs8105895	0.935	rs6511321	chr19:22270068	A/G	cg02657401	chr19:22469223	NA	-0.35	-5.78	-0.3	1.75e-8	Body mass index (change over time);
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs939584	1.000	rs7560127	chr2:643315	T/C	cg03610516	chr2:642275	NA	0.41	5.74	0.3	2.18e-8	Body mass index;
CRC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.67	7.42	0.38	1.01e-12	Vitiligo;
CRC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.72	11.15	0.52	1.02e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg05861140	chr6:150128134	PCMT1	-0.34	-5.7	-0.3	2.71e-8	Testicular germ cell tumor;
CRC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg20203395	chr5:56204925	C5orf35	0.58	8.0	0.4	2.11e-14	Initial pursuit acceleration;
CRC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.81	-0.48	4.26e-20	Height;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.54	-8.19	-0.41	5.78e-15	Longevity;Endometriosis;
CRC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.59	-8.68	-0.43	1.87e-16	Diastolic blood pressure;
CRC	cis	rs7527798	0.592	rs6671969	chr1:207839667	C/T	cg21110645	chr1:207815933	NA	-0.43	-6.69	-0.35	9.56e-11	Erythrocyte sedimentation rate;
CRC	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg16898833	chr6:26189333	HIST1H4D	0.85	7.14	0.37	5.87e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	8.99	0.44	1.92e-17	Platelet count;
CRC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-10.31	-0.49	8.7e-22	Venous thromboembolism (SNP x SNP interaction);
CRC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.13	-0.41	9.13e-15	Height;
CRC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.86	0.48	2.94e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.79	6.38	0.33	5.89e-10	Alzheimer's disease (late onset);
CRC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.3e-9	Prudent dietary pattern;
CRC	cis	rs6908034	0.556	rs113071446	chr6:19810835	A/C	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg02683197	chr6:28174875	NA	0.68	6.72	0.35	8.24e-11	Lung cancer in ever smokers;
CRC	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.44	-7.15	-0.37	5.54e-12	Refractive error;
CRC	trans	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.05e-13	Diabetic kidney disease;
CRC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.35	0.38	1.58e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13009927	chr2:242254519	SEPT2;HDLBP	-0.44	-6.37	-0.33	6.44e-10	Myopia (pathological);
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg08487696	chr7:150945928	SMARCD3	-0.45	-6.41	-0.33	5.14e-10	Total body bone mineral density;
CRC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.12	0.32	2.72e-9	Aortic root size;
CRC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.6	8.15	0.41	7.75e-15	Height;
CRC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	8.32	0.42	2.35e-15	Rheumatoid arthritis;
CRC	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.61	0.5	8.09e-23	Bipolar disorder;
CRC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg14541582	chr5:601475	NA	-0.36	-7.3	-0.37	2.21e-12	Obesity-related traits;
CRC	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg04662567	chr6:169592167	NA	-0.41	-5.76	-0.3	1.98e-8	Pulse pressure;
CRC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.98	0.7	7.57e-51	Platelet count;
CRC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.6	-7.85	-0.4	6.05e-14	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08762750	chr15:91497995	RCCD1	0.45	6.14	0.32	2.43e-9	Anxiety disorder;
CRC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs7605827	0.930	rs722327	chr2:15657263	T/A	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.8e-9	Educational attainment (years of education);
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.35	0.5	6.28e-22	Hemoglobin concentration;
CRC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.4	-6.0	-0.31	5.17e-9	P wave terminal force;
CRC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.54	-7.97	-0.4	2.67e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.54	7.86	0.4	5.58e-14	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg25985355	chr7:65971099	NA	-0.53	-6.02	-0.32	4.65e-9	Diabetic kidney disease;
CRC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg11070056	chr1:107600091	PRMT6	0.4	5.68	0.3	3.01e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.62	-10.61	-0.5	8.23e-23	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg23018236	chr17:30244563	NA	0.49	5.78	0.3	1.77e-8	Hip circumference adjusted for BMI;
CRC	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	0.98	12.17	0.56	2.19e-28	Obesity-related traits;
CRC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.52e-10	Menopause (age at onset);
CRC	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg23254163	chr1:152506842	NA	0.5	10.14	0.49	3.42e-21	Hair morphology;
CRC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.71	0.3	2.51e-8	Lung cancer;
CRC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.61	9.11	0.45	8.24e-18	Lung cancer;
CRC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.75	-12.63	-0.57	4.47e-30	Breast cancer;
CRC	trans	rs7800418	0.784	rs882540	chr7:26589889	G/A	cg14387656	chr2:233470847	EFHD1	0.47	6.51	0.34	2.79e-10	Cognitive function;
CRC	cis	rs9487051	0.724	rs13196219	chr6:109635787	A/T	cg01475377	chr6:109611718	NA	-0.38	-5.89	-0.31	9.3e-9	Reticulocyte fraction of red cells;
CRC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.62	-7.91	-0.4	3.97e-14	Gut microbiome composition (summer);
CRC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg17724175	chr1:150552817	MCL1	0.46	7.02	0.36	1.28e-11	Melanoma;
CRC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.65	11.29	0.53	3.37e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.6	-11.01	-0.52	3.33e-24	Type 2 diabetes;
CRC	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02097616	chr17:62675921	NA	0.5	6.91	0.36	2.46e-11	QT interval;
CRC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	15.53	0.65	3.63e-41	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg08501292	chr6:25962987	TRIM38	0.84	7.74	0.39	1.24e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.6	9.31	0.46	1.84e-18	Longevity;Endometriosis;
CRC	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.53	7.83	0.4	6.85e-14	Corneal astigmatism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16092956	chr4:185747098	ACSL1	-0.55	-6.75	-0.35	6.59e-11	Diisocyanate-induced asthma;
CRC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg25985355	chr7:65971099	NA	-0.5	-5.86	-0.31	1.11e-8	Diabetic kidney disease;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg20647610	chr2:228736258	WDR69	-0.5	-6.71	-0.35	8.29e-11	Blood pressure;
CRC	cis	rs10743315	0.643	rs75009806	chr12:19466457	A/G	cg02471346	chr12:19282374	PLEKHA5	0.81	6.16	0.32	2.18e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg24463073	chr6:118973353	C6orf204	0.49	6.07	0.32	3.48e-9	Diastolic blood pressure;
CRC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.46	7.72	0.39	1.4e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	11.58	0.54	2.96e-26	Bone mineral density;
CRC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.7	-0.39	1.62e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.6	-10.55	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-5.85	-0.31	1.17e-8	High light scatter reticulocyte count;
CRC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06636001	chr8:8085503	FLJ10661	0.45	5.79	0.3	1.65e-8	Obesity-related traits;
CRC	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	2.02e-8	Intelligence (multi-trait analysis);
CRC	cis	rs939584	1.000	rs4452188	chr2:648810	A/G	cg03610516	chr2:642275	NA	-0.42	-5.85	-0.31	1.2e-8	Body mass index;
CRC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	16.45	0.67	8.44e-45	Smoking behavior;
CRC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.58	-0.39	3.59e-13	Body mass index;
CRC	cis	rs7739232	0.920	rs75332545	chr6:53527070	A/G	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	trans	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg05376469	chr2:102649931	NA	-0.38	-6.26	-0.33	1.23e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.54	8.62	0.43	2.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg03934865	chr2:198174659	NA	-0.46	-8.31	-0.42	2.5e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.82	10.44	0.5	3.11e-22	Diisocyanate-induced asthma;
CRC	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.3	-0.64	2.65e-40	Exhaled nitric oxide output;
CRC	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg06581033	chr10:766294	NA	-0.51	-5.74	-0.3	2.14e-8	Uric acid levels;
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg21620606	chr4:1342894	KIAA1530	0.37	6.45	0.34	3.9e-10	Obesity-related traits;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.13	-0.37	6.43e-12	Obesity-related traits;
CRC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg13072238	chr3:49761600	GMPPB	-0.51	-5.86	-0.31	1.15e-8	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12086046	chr17:5389958	MIS12;DERL2	0.46	6.68	0.35	1.04e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.44	7.01	0.36	1.36e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs2457480	0.657	rs2624683	chr10:44679140	A/G	cg09554077	chr10:44749378	NA	0.51	7.02	0.36	1.31e-11	Coronary artery disease;
CRC	cis	rs17067123	0.614	rs72712852	chr4:180066270	T/C	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	7.28e-11	Response to hepatitis C treatment;
CRC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	0.98	14.42	0.62	6.85e-37	Breast cancer;
CRC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.76	13.14	0.59	5.49e-32	Body mass index;
CRC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg04121214	chr22:50244548	NA	0.42	5.97	0.31	6.05e-9	Schizophrenia;
CRC	cis	rs501120	0.564	rs7917089	chr10:44688587	G/A	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.53	-6.57	-0.34	1.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.59	-0.43	3.63e-16	Monocyte percentage of white cells;
CRC	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.66	-0.34	1.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs56775891	0.537	rs7236339	chr18:77579773	C/T	cg24058013	chr18:77568902	NA	-0.41	-6.08	-0.32	3.31e-9	Schizophrenia;
CRC	cis	rs863345	0.604	rs12133794	chr1:158506697	C/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.16	-0.32	2.18e-9	Pneumococcal bacteremia;
CRC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg24463073	chr6:118973353	C6orf204	-0.51	-6.88	-0.35	3.02e-11	Diastolic blood pressure;
CRC	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg10298567	chr3:47292165	KIF9	-0.41	-6.78	-0.35	5.51e-11	Colorectal cancer;
CRC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.65	7.85	0.4	5.96e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01865113	chr17:70117105	SOX9	0.41	5.96	0.31	6.46e-9	Response to antipsychotic treatment;
CRC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.67	8.24	0.41	4.06e-15	Menarche (age at onset);
CRC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg04793015	chr2:86790474	VPS24	-0.45	-6.53	-0.34	2.51e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg01420254	chr6:26195488	NA	0.69	6.13	0.32	2.45e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.5	7.86	0.4	5.58e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	13.35	0.59	8.6e-33	Electrocardiographic conduction measures;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg15786705	chr6:28176104	NA	0.73	9.31	0.46	1.85e-18	Depression;
CRC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.49	9.63	0.47	1.66e-19	Renal cell carcinoma;
CRC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.18e-20	Bladder cancer;
CRC	trans	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg18335740	chr13:41363409	SLC25A15	-0.47	-6.95	-0.36	1.97e-11	Lewy body disease;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg16558177	chr4:4109446	NA	-0.62	-8.7	-0.43	1.58e-16	Blood pressure (smoking interaction);
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg25164649	chr6:28176230	NA	0.63	6.3	0.33	9.8e-10	Lung cancer in ever smokers;
CRC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.54	-6.71	-0.35	8.41e-11	Body mass index;
CRC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg21856205	chr7:94953877	PON1	-0.51	-6.51	-0.34	2.73e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg12172441	chr6:28176163	NA	0.49	6.52	0.34	2.68e-10	Parkinson's disease;
CRC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.55	7.23	0.37	3.32e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.49	6.33	0.33	7.85e-10	Longevity;
CRC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg05585544	chr11:47624801	NA	-0.59	-10.68	-0.51	4.72e-23	Subjective well-being;
CRC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.44	6.94	0.36	2.04e-11	Testicular germ cell tumor;
CRC	cis	rs728616	0.867	rs77376252	chr10:81809382	C/T	cg05935833	chr10:81318306	SFTPA2	-0.57	-6.65	-0.34	1.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.88	-0.51	9.23e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-11.4	-0.53	1.32e-25	Colorectal cancer;
CRC	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	7.02	0.36	1.27e-11	Blood protein levels;
CRC	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.71	-0.39	1.51e-13	Bipolar disorder;
CRC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.59	7.14	0.37	5.85e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.89	0.4	4.53e-14	Lung cancer;
CRC	cis	rs77633900	0.502	rs116917406	chr15:76922940	T/C	cg21673338	chr15:77095150	SCAPER	-0.76	-6.3	-0.33	9.7e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7209700	0.644	rs7214468	chr17:45370766	G/A	cg08085267	chr17:45401833	C17orf57	0.5	7.37	0.38	1.36e-12	IgG glycosylation;
CRC	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.74	9.28	0.46	2.32e-18	Iron status biomarkers;
CRC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.75	-13.04	-0.58	1.25e-31	Body mass index;
CRC	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	0.91	11.36	0.53	1.9e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-11.06	-0.52	2.23e-24	Platelet distribution width;
CRC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.37	-0.46	1.18e-18	Height;
CRC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs12580194	1.000	rs12579915	chr12:55696789	C/T	cg19537932	chr12:55886519	OR6C68	0.56	7.91	0.4	3.9e-14	Cancer;
CRC	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg06935464	chr4:38784597	TLR10	0.58	5.89	0.31	9.66e-9	Breast cancer;
CRC	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg04165759	chr1:150448943	RPRD2	0.36	5.79	0.3	1.63e-8	Migraine;
CRC	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg23229984	chr5:148520753	ABLIM3	-0.49	-6.79	-0.35	5.16e-11	Breast cancer;
CRC	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.81	9.93	0.48	1.71e-20	Iron status biomarkers;
CRC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg25173405	chr17:45401733	C17orf57	0.4	6.02	0.31	4.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.33	7.72	0.39	1.37e-13	Corneal astigmatism;
CRC	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.73	9.78	0.47	5.46e-20	Coronary artery disease;
CRC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.67	-11.29	-0.53	3.47e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13047869	chr3:10149882	C3orf24	0.57	7.69	0.39	1.76e-13	Alzheimer's disease;
CRC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20307385	chr11:47447363	PSMC3	-0.51	-6.63	-0.34	1.39e-10	Neuroticism;
CRC	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg07162820	chr14:24837146	NFATC4	-0.41	-6.5	-0.34	3.02e-10	Parent of origin effect on language impairment (paternal);
CRC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.58	-6.74	-0.35	7.23e-11	Red cell distribution width;
CRC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.47	-6.6	-0.34	1.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.53	10.92	0.52	6.76e-24	Alcohol dependence;
CRC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.58	-8.77	-0.44	9.8e-17	Aortic root size;
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg08200582	chr11:442649	ANO9	-0.71	-7.39	-0.38	1.2e-12	Body mass index;
CRC	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg15744005	chr10:104629667	AS3MT	0.31	6.14	0.32	2.41e-9	Arsenic metabolism;
CRC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.2	0.41	5.46e-15	Platelet count;
CRC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.57	9.18	0.45	5.02e-18	DNA methylation (variation);
CRC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.43	7.35	0.38	1.61e-12	Rheumatoid arthritis;
CRC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.67e-18	Bladder cancer;
CRC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.74	9.82	0.48	3.84e-20	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.67	-0.35	1.09e-10	Monocyte count;
CRC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg02527881	chr3:46936655	PTH1R	0.33	5.64	0.3	3.65e-8	Colorectal cancer;
CRC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12463550	chr7:65579703	CRCP	0.69	6.54	0.34	2.39e-10	Diabetic kidney disease;
CRC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.46	6.09	0.32	3.1e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg16797656	chr11:68205561	LRP5	0.5	6.89	0.35	2.93e-11	Bone mineral density (spine);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01668174	chr2:106810661	UXS1	0.49	6.2	0.32	1.71e-9	Thyroid stimulating hormone;
CRC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg20243544	chr17:37824526	PNMT	0.55	8.95	0.44	2.66e-17	Asthma;
CRC	cis	rs4676482	1.000	rs4676482	chr3:39237190	A/T	cg02254461	chr3:39195904	CSRNP1	0.55	6.73	0.35	7.75e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-10.88	-0.51	9.23e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10021731	0.645	rs7698524	chr4:115413573	C/T	cg25927708	chr2:119603813	EN1	-0.33	-6.1	-0.32	2.96e-9	Optic disc area;
CRC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.71	-0.39	1.54e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4731207	0.596	rs7795199	chr7:124578345	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.79e-9	Cutaneous malignant melanoma;
CRC	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg16964102	chr10:135390573	NA	0.43	7.25	0.37	3.06e-12	Obesity-related traits;
CRC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg16558177	chr4:4109446	NA	-0.56	-6.7	-0.35	8.94e-11	Blood pressure (smoking interaction);
CRC	cis	rs10242455	0.571	rs55830753	chr7:99292222	A/G	cg18809830	chr7:99032528	PTCD1	-0.97	-7.55	-0.38	4.31e-13	Blood metabolite levels;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg15786705	chr6:28176104	NA	0.48	6.34	0.33	7.69e-10	Parkinson's disease;
CRC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.4	6.17	0.32	2.06e-9	HDL cholesterol levels;
CRC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.75	-0.35	6.77e-11	Monocyte count;
CRC	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.46	7.93	0.4	3.55e-14	Common traits (Other);
CRC	cis	rs12431939	0.948	rs12436158	chr14:51669891	G/A	cg23942311	chr14:51606299	NA	-0.55	-6.29	-0.33	1e-9	Cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19987288	chr12:56122958	CD63	0.36	6.17	0.32	1.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.93	-0.44	2.97e-17	Bipolar disorder;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02970861	chr11:62359288	TUT1	-0.44	-6.48	-0.34	3.26e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-6.46	-0.34	3.76e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.24	-0.56	1.22e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.27	0.49	1.19e-21	Menopause (age at onset);
CRC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.46	8.42	0.42	1.15e-15	Schizophrenia;
CRC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg06671706	chr8:8559999	CLDN23	0.52	7.63	0.39	2.56e-13	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02664664	chr10:72163983	EIF4EBP2	0.43	6.77	0.35	5.95e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs938554	0.784	rs13102218	chr4:9976113	G/T	cg11266682	chr4:10021025	SLC2A9	0.35	5.64	0.3	3.62e-8	Blood metabolite levels;
CRC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17507749	chr15:85114479	UBE2QP1	0.62	8.97	0.44	2.36e-17	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03509671	chr3:101497876	FAM55C	0.39	6.51	0.34	2.87e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg19678392	chr7:94953810	PON1	-0.56	-7.07	-0.36	9.28e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.69	-8.23	-0.41	4.32e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-0.82	-8.53	-0.43	5.26e-16	Pediatric areal bone mineral density (radius);
CRC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.77	9.23	0.45	3.32e-18	Lung function (FEV1/FVC);
CRC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.62	-8.75	-0.43	1.1e-16	Inflammatory bowel disease;
CRC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Body mass index;
CRC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.16	-0.32	2.12e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.48	6.25	0.33	1.26e-9	Schizophrenia;
CRC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02290350	chr8:58132656	NA	-0.45	-6.57	-0.34	1.99e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.03	23.5	0.79	2.21e-72	Multiple system atrophy;
CRC	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.34	-0.67	2.32e-44	Hip circumference;
CRC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg08888203	chr3:10149979	C3orf24	0.71	8.58	0.43	3.91e-16	Alzheimer's disease;
CRC	trans	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg00953403	chr17:74099816	EXOC7	-0.49	-6.67	-0.35	1.08e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.46	6.79	0.35	5.3e-11	Asthma;
CRC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.43	-0.38	9.16e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24543526	chr10:75911479	ADK;AP3M1	0.41	5.98	0.31	5.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.49	-7.1	-0.36	7.72e-12	Longevity;Endometriosis;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.2	-0.37	4.22e-12	Bipolar disorder;
CRC	cis	rs6694672	1.000	rs6680497	chr1:197083329	G/A	cg13682187	chr1:196946512	CFHR5	0.47	7.63	0.39	2.49e-13	Asthma;
CRC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.64	0.34	1.29e-10	Bipolar disorder;
CRC	trans	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg06840491	chr10:48416966	GDF2	-0.35	-6.07	-0.32	3.45e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.31	5.13e-9	Hemoglobin concentration;
CRC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg01483505	chr11:975446	AP2A2	0.42	6.83	0.35	4.1e-11	Alzheimer's disease (late onset);
CRC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg16670446	chr17:27188758	MIR451;MIR144	0.6	9.71	0.47	9.02e-20	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04152460	chr6:28109974	ZNF192	0.42	6.04	0.32	4.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.63	10.38	0.5	4.96e-22	Height;
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.56	6.92	0.36	2.37e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-14.75	-0.63	3.79e-38	Lymphocyte percentage of white cells;
CRC	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-8.1	-0.41	1.11e-14	Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18123596	chr17:36956264	PIP4K2B	0.43	6.06	0.32	3.73e-9	Response to antipsychotic treatment;
CRC	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg27422857	chr2:105853526	NA	0.3	5.68	0.3	2.94e-8	Type 2 diabetes;
CRC	cis	rs4716602	0.596	rs1996994	chr7:156159694	A/G	cg16983916	chr7:156159713	NA	0.39	6.81	0.35	4.59e-11	Anti-saccade response;
CRC	cis	rs11622475	1.000	rs10136440	chr14:104397367	C/A	cg12183467	chr14:104352244	NA	0.49	6.8	0.35	4.86e-11	Bipolar disorder;
CRC	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg04880052	chr2:219191631	PNKD	0.4	6.03	0.32	4.48e-9	Colorectal cancer;
CRC	cis	rs7072216	0.666	rs2274248	chr10:100148542	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.73	-0.3	2.22e-8	Metabolite levels;
CRC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.12	-0.32	2.7e-9	Morning vs. evening chronotype;
CRC	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.49	8.46	0.42	9.01e-16	Schizophrenia;
CRC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg26587870	chr6:27730563	NA	0.44	6.25	0.33	1.27e-9	Parkinson's disease;
CRC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	9.96	0.48	1.31e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg18230493	chr5:56204884	C5orf35	-0.4	-5.87	-0.31	1.05e-8	Coronary artery disease;
CRC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.39	-7.68	-0.39	1.84e-13	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	14.61	0.63	1.33e-37	Gut microbiome composition (summer);
CRC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.48	6.53	0.34	2.43e-10	Height;
CRC	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.34	-5.67	-0.3	3.17e-8	Resting heart rate;
CRC	cis	rs4664293	0.867	rs6432560	chr2:160607269	G/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.24	-0.33	1.34e-9	Arsenic metabolism;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.34	-6.34	-0.33	7.71e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.7	-11.34	-0.53	2.2e-25	DNA methylation (variation);
CRC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.43	-7.66	-0.39	2.07e-13	Longevity;
CRC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.36	-5.92	-0.31	8.2e-9	Schizophrenia;
CRC	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.7	9.2	0.45	4.31e-18	Blood protein levels;
CRC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.67	-0.43	2e-16	Subjective well-being;
CRC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.69	0.35	9.85e-11	Tonsillectomy;
CRC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.46	5.85	0.31	1.19e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.67	9.45	0.46	6.78e-19	Vitiligo;
CRC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.7	-11.72	-0.54	9.48e-27	Alzheimer's disease (late onset);
CRC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.55	8.77	0.44	9.72e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.31e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.12	0.32	2.63e-9	Aortic root size;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg20243544	chr17:37824526	PNMT	0.55	8.87	0.44	4.67e-17	Asthma;
CRC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.44	7.45	0.38	8.38e-13	Alcohol dependence;
CRC	cis	rs2179367	0.959	rs2262617	chr6:149759726	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.31	-0.33	9.19e-10	Dupuytren's disease;
CRC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.96	0.55	1.34e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10620530	chr9:139922595	C9orf139;ABCA2	0.45	6.33	0.33	8.18e-10	Response to antipsychotic treatment;
CRC	cis	rs16867321	0.950	rs12477283	chr2:181501355	G/T	cg23363182	chr2:181467187	NA	-0.51	-6.59	-0.34	1.72e-10	Obesity;
CRC	cis	rs9491140	0.539	rs10457447	chr6:124698568	A/C	cg22366943	chr6:124882293	NKAIN2	-0.55	-6.87	-0.35	3.15e-11	Neuroticism;
CRC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.72	0.39	1.41e-13	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01117833	chr14:94547303	DDX24;IFI27L1	0.41	6.46	0.34	3.77e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.52	7.36	0.38	1.45e-12	Caudate activity during reward;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg20041105	chr8:143859282	LYNX1	-0.42	-6.55	-0.34	2.28e-10	Urinary tract infection frequency;
CRC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23240857	chr4:140005776	ELF2	0.48	6.99	0.36	1.52e-11	Response to antipsychotic treatment;
CRC	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg00646200	chr1:148855367	NA	-0.34	-6.07	-0.32	3.45e-9	Hip geometry;
CRC	trans	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12066864	chr14:32672656	NA	0.41	6.1	0.32	3.01e-9	Barrett's esophagus  or Esophageal adenocarcinoma;
CRC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg04586622	chr2:25135609	ADCY3	-0.57	-10.46	-0.5	2.65e-22	Body mass index in non-asthmatics;
CRC	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-8.4	-0.42	1.36e-15	HDL cholesterol;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25261059	chr19:44031185	ETHE1	-0.42	-6.18	-0.32	1.87e-9	Myopia (pathological);
CRC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.83	-0.55	3.83e-27	Alzheimer's disease;
CRC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg13628971	chr7:2884303	GNA12	0.43	6.62	0.34	1.43e-10	Height;
CRC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg10589385	chr1:150898437	SETDB1	-0.28	-5.7	-0.3	2.65e-8	Melanoma;
CRC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.55	9.26	0.45	2.68e-18	Systemic lupus erythematosus;
CRC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	10.55	0.5	1.32e-22	Schizophrenia;
CRC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.47	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.93	0.44	3.1e-17	Bladder cancer;
CRC	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg16898833	chr6:26189333	HIST1H4D	0.78	6.28	0.33	1.04e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9903692	0.954	rs8076380	chr17:46190390	G/A	cg21215337	chr17:46176117	CBX1	-0.42	-7.91	-0.4	4e-14	Pulse pressure;
CRC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.61	7.68	0.39	1.85e-13	Dilated cardiomyopathy;
CRC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.75	0.35	6.49e-11	Aortic root size;
CRC	cis	rs12760731	0.720	rs16852801	chr1:178403134	A/T	cg00404053	chr1:178313656	RASAL2	-0.88	-9.38	-0.46	1.14e-18	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13928594	chr12:110562699	IFT81	0.49	6.43	0.33	4.55e-10	Thyroid stimulating hormone;
CRC	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.81	-0.3	1.5e-8	Metabolite levels;
CRC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg15083037	chr5:83017644	HAPLN1	-0.42	-6.46	-0.34	3.69e-10	Prostate cancer;
CRC	trans	rs2814331	0.607	rs1902678	chr10:88006634	C/G	cg16062483	chr14:98444417	C14orf64	0.66	6.07	0.32	3.5e-9	Balding;
CRC	cis	rs2992756	0.663	rs2992755	chr1:18807897	C/G	cg14356550	chr1:18808102	KLHDC7A	-0.38	-5.69	-0.3	2.83e-8	Breast cancer;
CRC	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.29	0.33	9.94e-10	Hair morphology;
CRC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.69	-11.7	-0.54	1.14e-26	P wave terminal force;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.67	-10.45	-0.5	2.8e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs492478	0.892	rs11952713	chr5:3942942	G/T	cg09199442	chr11:28132951	METT5D1	-0.71	-6.24	-0.33	1.36e-9	Cognitive performance;
CRC	cis	rs12541635	0.934	rs2029882	chr8:107022894	G/A	cg10147462	chr8:107024639	NA	0.44	7.29	0.37	2.38e-12	Age of smoking initiation;
CRC	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.4	-7.68	-0.39	1.79e-13	Self-rated health;
CRC	cis	rs4711336	0.633	rs9469583	chr6:33717770	T/C	cg14003231	chr6:33640908	ITPR3	0.37	5.87	0.31	1.04e-8	Height;
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.69	9.16	0.45	5.63e-18	Alzheimer's disease;
CRC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.79	0.3	1.61e-8	Bladder cancer;
CRC	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.84	14.48	0.62	4.09e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1907989	1.000	rs2172443	chr4:4819565	A/G	cg24061105	chr18:77125858	ATP9B	-0.39	-5.98	-0.31	5.66e-9	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-8.11	-0.41	9.9e-15	Monocyte percentage of white cells;
CRC	cis	rs938554	0.784	rs16868246	chr4:9978305	C/G	cg11266682	chr4:10021025	SLC2A9	0.35	5.62	0.3	4.17e-8	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.42	-0.33	4.79e-10	Alzheimer's disease (late onset);
CRC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.79	0.35	5.29e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.42	-6.32	-0.33	8.63e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg05250797	chr16:70222502	NA	-0.4	-5.63	-0.3	3.94e-8	IgE levels;
CRC	cis	rs7680126	0.626	rs11721501	chr4:10189135	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-6.67	-0.35	1.09e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07116851	chr12:58146173	CDK4	0.38	6.08	0.32	3.3e-9	Interleukin-6 levels;
CRC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.43	-0.33	4.56e-10	Mean corpuscular volume;
CRC	cis	rs12024301	0.557	rs12045762	chr1:183617413	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg21659725	chr3:3221576	CRBN	-0.61	-6.29	-0.33	1.01e-9	Menarche (age at onset);
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg03623178	chr6:28175578	NA	0.67	9.51	0.46	4.27e-19	Parkinson's disease;
CRC	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.42	-8.44	-0.42	9.92e-16	Migraine;
CRC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	8.5	0.42	6.83e-16	Schizophrenia;
CRC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg17724175	chr1:150552817	MCL1	0.48	7.09	0.36	7.99e-12	Melanoma;
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.35e-12	Life satisfaction;
CRC	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.33	-0.33	8.23e-10	Monocyte count;
CRC	trans	rs875033	0.690	rs856835	chr6:68293485	C/T	cg00112309	chr8:106787982	ZFPM2	-0.41	-6.0	-0.31	5.17e-9	Response to amphetamines;
CRC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg02018176	chr4:1364513	KIAA1530	0.44	7.1	0.36	7.52e-12	Obesity-related traits;
CRC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.69	-8.82	-0.44	6.97e-17	Psoriasis;
CRC	cis	rs1524976	1.000	rs62255276	chr3:65457776	C/A	cg16238336	chr3:65465873	MAGI1	-0.53	-7.56	-0.38	4.08e-13	PR interval;
CRC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.47	7.58	0.39	3.53e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.54	-8.49	-0.42	7.45e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.47	0.42	8.41e-16	Menarche (age at onset);
CRC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.22	0.41	4.85e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23901904	chr1:10855062	CASZ1	0.46	6.54	0.34	2.3e-10	Response to antipsychotic treatment;
CRC	cis	rs9648716	0.554	rs10235900	chr7:140601438	G/T	cg10747023	chr7:140774559	NA	0.46	6.32	0.33	8.29e-10	Type 2 diabetes;
CRC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg02290350	chr8:58132656	NA	-0.43	-5.64	-0.3	3.68e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13632070	chr5:79552065	SERINC5	0.46	6.27	0.33	1.15e-9	Anxiety disorder;
CRC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg00734567	chr1:86172782	ZNHIT6	-0.48	-7.38	-0.38	1.33e-12	Urate levels in overweight individuals;
CRC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.29	0.42	3.01e-15	Rheumatoid arthritis;
CRC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.47e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg01483505	chr11:975446	AP2A2	0.45	7.44	0.38	9.1e-13	Alzheimer's disease (late onset);
CRC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-7.91	-0.4	4.03e-14	IgG glycosylation;
CRC	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.02	-0.4	1.89e-14	Blood metabolite levels;
CRC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg17346650	chr17:80929145	B3GNTL1	0.49	7.46	0.38	7.71e-13	Glycated hemoglobin levels;
CRC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.5	7.58	0.39	3.58e-13	Emphysema distribution in smoking;
CRC	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.39	-6.97	-0.36	1.72e-11	Blood metabolite ratios;
CRC	cis	rs6460942	0.544	rs73287153	chr7:12139272	A/G	cg06484146	chr7:12443880	VWDE	-0.51	-6.1	-0.32	3.04e-9	Coronary artery disease;
CRC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg15358701	chr1:161410459	NA	-0.61	-6.57	-0.34	2.02e-10	Rheumatoid arthritis;
CRC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg12193833	chr17:30244370	NA	0.57	7.29	0.37	2.26e-12	Hip circumference adjusted for BMI;
CRC	cis	rs243505	0.898	rs243524	chr7:148418181	A/C	cg09806900	chr7:148480153	CUL1	-0.4	-5.79	-0.3	1.68e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg20487152	chr13:99095054	FARP1	-0.43	-6.25	-0.33	1.28e-9	Longevity;
CRC	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.61	9.97	0.48	1.26e-20	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg16416165	chr4:3325029	RGS12	0.38	5.71	0.3	2.47e-8	Serum sulfate level;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg15190599	chr6:26156487	HIST1H1E	0.49	6.03	0.32	4.3e-9	Kashin-Beck disease;
CRC	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg13491945	chr12:107078410	RFX4	0.34	5.86	0.31	1.09e-8	Heart rate;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg18758796	chr5:131593413	PDLIM4	0.47	8.4	0.42	1.37e-15	Blood metabolite levels;
CRC	cis	rs9969804	0.782	rs10761170	chr9:95529203	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.91	-0.31	8.56e-9	Height;
CRC	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg00319359	chr11:70116639	PPFIA1	0.62	6.6	0.34	1.61e-10	Coronary artery disease;
CRC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg11663144	chr21:46675770	NA	-0.64	-8.7	-0.43	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.85	-11.37	-0.53	1.74e-25	Initial pursuit acceleration;
CRC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg02428538	chr16:24856791	SLC5A11	-0.57	-6.74	-0.35	7.08e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg05425664	chr17:57184151	TRIM37	-0.41	-6.24	-0.33	1.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.43	-6.2	-0.32	1.67e-9	Airflow obstruction;
CRC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs2882667	0.898	rs2043272	chr5:138390631	A/C	cg04439458	chr5:138467593	SIL1	-0.36	-6.47	-0.34	3.61e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.64	-7.38	-0.38	1.26e-12	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg14844989	chr11:31128820	NA	0.34	5.98	0.31	5.66e-9	Red blood cell count;
CRC	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.4	5.88	0.31	1.03e-8	Body mass index;
CRC	trans	rs10242455	1.000	rs73395557	chr7:98934424	C/A	cg09045935	chr12:6379348	NA	0.73	6.83	0.35	4e-11	Blood metabolite levels;
CRC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.54	8.79	0.44	8.54e-17	Schizophrenia;
CRC	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.49	7.98	0.4	2.48e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs3026101	0.671	rs1806242	chr17:5304763	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg00409905	chr10:38381863	ZNF37A	0.47	7.29	0.37	2.38e-12	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg24553058	chr2:113831203	IL1F10	0.39	6.3	0.33	9.43e-10	Protein quantitative trait loci;
CRC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.94	-0.4	3.22e-14	Gut microbiome composition (summer);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06545189	chr10:75936595	ADK	0.47	6.49	0.34	3.22e-10	Anxiety disorder;
CRC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05438183	chr7:149582572	NA	-0.43	-7.12	-0.37	6.85e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg00999904	chr2:3704751	ALLC	-0.44	-6.61	-0.34	1.53e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.38	0.53	1.56e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.83	-0.55	3.66e-27	Idiopathic membranous nephropathy;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.33	5.69	0.3	2.88e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg00631329	chr6:26305371	NA	-0.53	-8.86	-0.44	5.06e-17	Educational attainment;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12583927	chr10:61469753	SLC16A9	-0.4	-6.2	-0.32	1.69e-9	Myopia (pathological);
CRC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	ch.11.42038R	chr11:967971	AP2A2	0.71	11.93	0.55	1.64e-27	Alzheimer's disease (late onset);
CRC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.38	6.09	0.32	3.11e-9	Major depressive disorder;
CRC	trans	rs11581859	0.950	rs56012015	chr1:99362046	T/A	cg12183875	chr3:169587454	LRRC31	0.25	5.99	0.31	5.39e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.63	-0.68	1.74e-45	Hip circumference;
CRC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.73	11.48	0.53	6.77e-26	Tonsillectomy;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.62	-8.79	-0.44	8.52e-17	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.8	-9.46	-0.46	6.2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.7	-9.55	-0.47	3.18e-19	Hypospadias;
CRC	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.78	-11.32	-0.53	2.53e-25	Multiple sclerosis;
CRC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg06970220	chr1:156163860	SLC25A44	0.49	6.92	0.36	2.31e-11	Testicular germ cell tumor;
CRC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.41	6.89	0.36	2.82e-11	Testicular germ cell tumor;
CRC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg15205204	chr1:6545172	PLEKHG5	0.4	5.73	0.3	2.26e-8	Body mass index;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-8.48	-0.42	7.67e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg01420254	chr6:26195488	NA	0.63	6.21	0.32	1.58e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs34375054	1.000	rs3751178	chr12:125664357	C/T	cg06287003	chr12:125626642	AACS	0.5	7.22	0.37	3.53e-12	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.32	-0.37	1.91e-12	Endometrial cancer;
CRC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg09264619	chr17:80180166	NA	0.51	7.31	0.37	1.99e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg03623178	chr6:28175578	NA	0.8	12.08	0.55	4.79e-28	Parkinson's disease;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg25164649	chr6:28176230	NA	0.71	8.96	0.44	2.42e-17	Depression;
CRC	cis	rs8141797	0.901	rs176161	chr22:24516291	C/T	cg20894457	chr22:24584366	SUSD2	0.65	6.81	0.35	4.69e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs28498503	0.867	rs1841765	chr18:76644636	A/T	cg00806245	chr18:76673096	NA	-0.59	-5.87	-0.31	1.05e-8	Attention function in attention deficit hyperactive disorder;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.73	0.3	2.27e-8	Prudent dietary pattern;
CRC	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.87	16.06	0.66	2.96e-43	Hip circumference;
CRC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.96	-0.4	2.89e-14	Body mass index;
CRC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.47	7.5	0.38	6.13e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs524281	0.773	rs2155201	chr11:65992344	T/C	cg14036092	chr11:66035641	RAB1B	-0.56	-6.36	-0.33	6.73e-10	Electroencephalogram traits;
CRC	trans	rs12519859	1	rs12519859	chr5:32581186	G/A	cg03755955	chr8:6424269	MCPH1	0.42	6.29	0.33	9.86e-10	Breast cancer;
CRC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	7.21	0.37	3.77e-12	Mean platelet volume;
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.76	11.55	0.54	3.89e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg08514558	chr10:81106712	PPIF	0.36	5.79	0.3	1.65e-8	Height;
CRC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.71	9.34	0.46	1.55e-18	High light scatter reticulocyte count;
CRC	trans	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.26	0.67	4.63e-44	Chronic sinus infection;
CRC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg22676075	chr6:135203613	NA	0.41	6.19	0.32	1.74e-9	Red blood cell count;
CRC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg03934865	chr2:198174659	NA	-0.45	-8.11	-0.41	9.84e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.86	-0.31	1.14e-8	Height;
CRC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.75	0.39	1.18e-13	Lung cancer;
CRC	cis	rs4700695	0.841	rs251308	chr5:65284279	C/T	cg21114390	chr5:65439923	SFRS12	-0.54	-6.12	-0.32	2.73e-9	Facial morphology (factor 19);
CRC	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.06	0.52	2.21e-24	Exhaled nitric oxide output;
CRC	cis	rs7113874	0.569	rs4620720	chr11:8615939	G/A	cg02811074	chr11:8615871	STK33	0.34	6.03	0.32	4.3e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.66	9.07	0.45	1.08e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.6	9.09	0.45	9.84e-18	Schizophrenia;
CRC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg23590916	chr17:43697445	MGC57346	-0.55	-6.17	-0.32	1.98e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg07809909	chr20:30433512	FOXS1	0.35	5.7	0.3	2.65e-8	Mean corpuscular hemoglobin;
CRC	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg11130432	chr3:121712080	ILDR1	-0.52	-6.75	-0.35	6.81e-11	Multiple sclerosis;
CRC	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg02466173	chr16:30829666	NA	0.66	10.0	0.48	9.53e-21	Dementia with Lewy bodies;
CRC	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg13385794	chr1:248469461	NA	0.39	6.63	0.34	1.35e-10	Common traits (Other);
CRC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.67	9.86	0.48	2.83e-20	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7605827	0.930	rs13035937	chr2:15698050	C/T	cg19274914	chr2:15703543	NA	-0.4	-6.06	-0.32	3.71e-9	Educational attainment (years of education);
CRC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg07870213	chr5:140052090	DND1	0.63	8.06	0.41	1.41e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg15845792	chr6:28175446	NA	-0.96	-13.44	-0.6	3.84e-33	Depression;
CRC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg14847009	chr1:175162515	KIAA0040	-0.26	-5.75	-0.3	2.06e-8	Alcohol dependence;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19566272	chr6:139695824	CITED2	0.43	6.16	0.32	2.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.21	-0.37	3.76e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.59	-6.87	-0.35	3.2e-11	Red cell distribution width;
CRC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.59	0.47	2.24e-19	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.87	0.35	3.28e-11	Neuroticism;
CRC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.92	-0.31	8e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg27326032	chr3:127006922	NA	-0.52	-7.53	-0.38	4.86e-13	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CRC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.01	-0.48	9.28e-21	Height;
CRC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.51	0.38	5.74e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.43	-6.52	-0.34	2.59e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.22	-0.32	1.52e-9	Osteoarthritis;
CRC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.51	8.52	0.43	5.71e-16	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05602987	chr16:28834702	ATXN2L	-0.44	-6.67	-0.35	1.1e-10	Myopia (pathological);
CRC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.22	-0.37	3.74e-12	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg02725872	chr8:58115012	NA	0.35	6.17	0.32	1.97e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg15511327	chr8:143859410	LYNX1	0.41	7.41	0.38	1.06e-12	Urinary tract infection frequency;
CRC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-5.9	-0.31	8.97e-9	Mean corpuscular volume;
CRC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.03	0.32	4.51e-9	Dupuytren's disease;
CRC	cis	rs6694672	1.000	rs1170881	chr1:196949271	G/A	cg13682187	chr1:196946512	CFHR5	-0.58	-8.5	-0.42	6.6e-16	Asthma;
CRC	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.84	-10.12	-0.49	3.98e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.97	-0.52	4.56e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg26576206	chr19:1064938	ABCA7	0.42	5.96	0.31	6.6e-9	Alzheimer's disease (late onset);
CRC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.9	0.36	2.7e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.67	11.61	0.54	2.38e-26	Longevity;
CRC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.49	-0.6	2.67e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg21251018	chr6:28226885	NKAPL	0.47	6.06	0.32	3.79e-9	Depression;
CRC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.14e-8	Major depressive disorder;
CRC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-8.7	-0.43	1.64e-16	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg00343986	chr7:65444356	GUSB	-0.43	-5.89	-0.31	9.46e-9	Aortic root size;
CRC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.44	5.79	0.3	1.67e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18099408	chr3:52552593	STAB1	-0.49	-8.44	-0.42	1e-15	Electroencephalogram traits;
CRC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg23533926	chr12:111358616	MYL2	-0.53	-8.19	-0.41	5.94e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.67	0.43	2.06e-16	Schizophrenia;
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.65	-11.75	-0.54	7.23e-27	Educational attainment;
CRC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.64	-0.3	3.75e-8	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08039701	chr5:74063125	NSA2;GFM2	0.45	6.98	0.36	1.67e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg23254163	chr1:152506842	NA	0.46	9.36	0.46	1.28e-18	Hair morphology;
CRC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.95	0.36	2e-11	Menopause (age at onset);
CRC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.21	0.53	6.56e-25	Tonsillectomy;
CRC	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg00507830	chr2:103233733	NA	0.74	7.98	0.4	2.38e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.31	-0.33	9.08e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.82	-10.96	-0.52	5.02e-24	IgG glycosylation;
CRC	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg08034379	chr2:228736324	WDR69	-0.51	-6.9	-0.36	2.63e-11	Blood pressure;
CRC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg09218773	chr11:619014	MUPCDH	-0.43	-6.34	-0.33	7.78e-10	Systemic lupus erythematosus;
CRC	cis	rs2860975	0.967	rs11188134	chr10:96774255	G/C	cg09036531	chr10:96991505	NA	-0.42	-5.64	-0.3	3.73e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.34	-6.12	-0.32	2.61e-9	Lung cancer;
CRC	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-11.25	-0.53	4.82e-25	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4664293	0.539	rs7580661	chr2:160445837	C/G	cg08347373	chr2:160653686	CD302	-0.38	-6.44	-0.33	4.12e-10	Monocyte percentage of white cells;
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.17e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg21399703	chr1:247681439	NA	0.51	5.75	0.3	2e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.93	-0.31	7.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.15e-9	Lung cancer;
CRC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.4	-0.38	1.17e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.43	8.7	0.43	1.65e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.84	-0.58	7.52e-31	Alzheimer's disease;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.38	-8.93	-0.44	3.17e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg24562669	chr7:97807699	LMTK2	0.4	6.41	0.33	4.98e-10	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.47	-6.67	-0.35	1.08e-10	Diastolic blood pressure;
CRC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	0.47	6.4	0.33	5.36e-10	Resistin levels;
CRC	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.58	10.58	0.5	1.07e-22	Blood metabolite ratios;
CRC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.45	-0.46	6.6e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg12193833	chr17:30244370	NA	0.56	6.92	0.36	2.32e-11	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.64	0.39	2.37e-13	Height;
CRC	cis	rs73206853	0.698	rs73191806	chr12:110899913	A/G	cg12870014	chr12:110450643	ANKRD13A	0.84	9.88	0.48	2.53e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18252515	chr7:66147081	NA	0.39	5.6	0.3	4.46e-8	Aortic root size;
CRC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs365302	1.000	rs375512	chr6:159646450	T/A	cg14500486	chr6:159655392	FNDC1	0.43	6.68	0.35	1e-10	Coronary heart disease;
CRC	cis	rs245880	0.740	rs245897	chr7:29193940	C/T	cg17163760	chr7:29186267	CPVL	0.38	6.72	0.35	8.12e-11	Warfarin maintenance dose;
CRC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.3	0.46	2.03e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.45	6.5	0.34	2.91e-10	HIV-1 control;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg27615366	chr5:131592974	PDLIM4	0.34	5.87	0.31	1.09e-8	Breast cancer;
CRC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg04450456	chr4:17643702	FAM184B	0.38	6.23	0.32	1.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.68	8.63	0.43	2.7e-16	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg18683604	chr14:51561293	TRIM9	-0.34	-6.46	-0.34	3.67e-10	Cancer;
CRC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg22777020	chr22:31556080	RNF185	-0.52	-5.9	-0.31	8.86e-9	Colorectal cancer;
CRC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg11518657	chr1:67396239	MIER1	0.57	6.21	0.32	1.59e-9	Lymphocyte percentage of white cells;
CRC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.6	7.02	0.36	1.24e-11	Vitiligo;
CRC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.4	-0.38	1.11e-12	Height;
CRC	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.21	-0.32	1.62e-9	Bladder cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11050527	chr8:54755511	ATP6V1H	0.49	6.31	0.33	9.24e-10	Thyroid stimulating hormone;
CRC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg14671364	chr1:107599128	PRMT6	-0.53	-7.53	-0.38	4.8e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.5	7.26	0.37	2.81e-12	Subjective well-being;
CRC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.48	-7.74	-0.39	1.26e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.48	-7.92	-0.4	3.61e-14	Major depressive disorder;
CRC	cis	rs4663866	0.901	rs35713061	chr2:239183774	C/T	cg16914508	chr2:239161102	PER2	0.77	7.88	0.4	4.92e-14	Irritable bowel syndrome;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-12.14	-0.56	2.79e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00377757	chr17:76921538	TIMP2	0.39	6.28	0.33	1.08e-9	Obesity-related traits;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.62	8.31	0.42	2.62e-15	Gut microbiome composition (summer);
CRC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.94	-0.44	2.93e-17	Hip circumference adjusted for BMI;
CRC	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs3026101	0.624	rs11869800	chr17:5307781	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.56	8.06	0.41	1.38e-14	Coronary artery disease;
CRC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03605463	chr16:89740564	NA	-0.4	-5.68	-0.3	2.97e-8	Vitiligo;
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.07	-0.41	1.32e-14	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs2274471	0.716	rs10974911	chr9:5010471	C/A	cg03390472	chr9:5043263	JAK2	-0.59	-6.66	-0.34	1.17e-10	Crohn's disease;
CRC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.29	6.12	0.32	2.69e-9	Lung cancer;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs2625529	0.730	rs2957725	chr15:72248205	C/A	cg16672083	chr15:72433130	SENP8	0.45	6.48	0.34	3.27e-10	Red blood cell count;
CRC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.95	-23.72	-0.79	3.41e-73	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg01788221	chr16:89496183	ANKRD11	-0.45	-6.92	-0.36	2.44e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.51	6.04	0.32	4.24e-9	Recombination rate (females);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25760412	chr20:36793747	TGM2	0.42	6.13	0.32	2.58e-9	Anxiety disorder;
CRC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.59	-9.13	-0.45	6.86e-18	Height;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	1.03	19.53	0.73	6.18e-57	Menarche (age at onset);
CRC	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.57	7.36	0.38	1.46e-12	Body mass index;
CRC	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg00603274	chr11:61596626	FADS2	-0.49	-7.0	-0.36	1.41e-11	Trans fatty acid levels;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.41	0.38	1.06e-12	Lymphocyte counts;
CRC	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.73	-7.04	-0.36	1.11e-11	Opioid sensitivity;
CRC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-11.37	-0.53	1.71e-25	Colorectal cancer;
CRC	cis	rs9309473	1.000	rs13384952	chr2:73723959	C/T	cg20560298	chr2:73613845	ALMS1	0.57	6.01	0.31	4.89e-9	Metabolite levels;
CRC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.69	-10.49	-0.5	2.18e-22	IgG glycosylation;
CRC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.45	-6.35	-0.33	7.24e-10	Cognitive ability;
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.82	14.73	0.63	4.68e-38	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.82	0.31	1.36e-8	Height;
CRC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.42	-6.47	-0.34	3.51e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs789852	0.764	rs1705999	chr3:194316333	C/T	cg21106136	chr3:194405973	FAM43A	-0.72	-6.03	-0.32	4.44e-9	QT interval;
CRC	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg04586622	chr2:25135609	ADCY3	-0.51	-9.36	-0.46	1.27e-18	Body mass index in non-asthmatics;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.65	7.29	0.37	2.31e-12	Body mass index;
CRC	trans	rs6678914	1.000	rs6703244	chr1:202187520	A/G	cg19977628	chr5:1262072	TERT	0.43	6.34	0.33	7.43e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9928842	0.823	rs889514	chr16:75272512	A/G	cg09066997	chr16:75300724	BCAR1	0.67	6.93	0.36	2.21e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.48	-0.34	3.26e-10	Breast cancer;
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg15382696	chr6:118971807	C6orf204	0.6	7.67	0.39	1.9e-13	Diastolic blood pressure;
CRC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.19	0.32	1.76e-9	Mean platelet volume;
CRC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	11.33	0.53	2.34e-25	Menopause (age at onset);
CRC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.79	0.44	8.37e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.74	-0.35	7.05e-11	Aortic root size;
CRC	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.55	7.31	0.37	2.03e-12	Breast cancer;
CRC	cis	rs56146971	0.763	rs55950330	chr14:91872978	C/T	cg16433844	chr14:91963127	SMEK1	-0.58	-6.21	-0.32	1.6e-9	Alzheimer disease and age of onset;
CRC	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.42	6.48	0.34	3.4e-10	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CRC	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-6.3	-0.33	9.33e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.46	6.09	0.32	3.1e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24450365	chr7:89874355	C7orf63	0.42	6.0	0.31	5.35e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16650099	chr1:114471848	HIPK1	0.42	5.99	0.31	5.47e-9	Response to antipsychotic treatment;
CRC	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.55	-8.58	-0.43	3.93e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg23018236	chr17:30244563	NA	-0.66	-7.82	-0.4	7.33e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.72	9.48	0.46	5.22e-19	Cleft lip with or without cleft palate;
CRC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.59	7.65	0.39	2.22e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.84	-0.31	1.24e-8	High light scatter reticulocyte count;
CRC	cis	rs7113874	0.569	rs9737401	chr11:8595652	C/T	cg17679104	chr11:8615758	STK33	-0.36	-5.99	-0.31	5.52e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	0.97	10.34	0.5	6.83e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.92	-0.4	3.6e-14	Total body bone mineral density;
CRC	cis	rs2274273	0.662	rs2094436	chr14:55661495	C/G	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.75	-0.3	2.08e-8	Protein biomarker;
CRC	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg21972741	chr5:435613	AHRR	0.5	6.54	0.34	2.29e-10	Cystic fibrosis severity;
CRC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.94	-17.24	-0.69	6.43e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs990171	1.000	rs2272129	chr2:103040249	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.78	0.3	1.74e-8	Lymphocyte counts;
CRC	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.5	-6.87	-0.35	3.23e-11	Tuberculosis;
CRC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.14	-12.02	-0.55	7.44e-28	Breast cancer;
CRC	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg21496419	chr19:44306685	LYPD5	-0.35	-6.49	-0.34	3.17e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9398803	0.605	rs112166936	chr6:126733140	A/C	cg19875578	chr6:126661172	C6orf173	0.42	5.93	0.31	7.86e-9	Male-pattern baldness;
CRC	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.84	0.4	6.42e-14	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg03623178	chr6:28175578	NA	0.94	12.29	0.56	7.67e-29	Depression;
CRC	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg13491945	chr12:107078410	RFX4	0.36	6.16	0.32	2.13e-9	Heart rate;
CRC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg06494592	chr3:125709126	NA	-0.58	-6.89	-0.35	2.9100000000000002e-11	Blood pressure (smoking interaction);
CRC	cis	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-6.22	-0.32	1.53e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.68	-0.35	1.02e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.68	-0.35	1.03e-10	Metabolite levels;
CRC	trans	rs11581859	0.950	rs72730323	chr1:99387892	A/G	cg12183875	chr3:169587454	LRRC31	0.28	6.29	0.33	1.03e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.24	0.33	1.34e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg21784768	chr11:537496	LRRC56	-0.69	-6.56	-0.34	2.11e-10	Body mass index;
CRC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg15445000	chr17:37608096	MED1	0.33	5.89	0.31	9.79e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-7.52	-0.38	5.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9648716	1.000	rs17161763	chr7:140589239	A/C	cg10747023	chr7:140774559	NA	0.44	5.81	0.31	1.46e-8	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.82	8.7	0.43	1.59e-16	Plasma clusterin levels;
CRC	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg09003973	chr2:102972529	NA	0.4	5.69	0.3	2.8e-8	Asthma;
CRC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg03690763	chr11:133734501	NA	-0.34	-5.69	-0.3	2.75e-8	Childhood ear infection;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg20512303	chr5:131592959	PDLIM4	0.4	6.96	0.36	1.8e-11	Acylcarnitine levels;
CRC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.48	-7.22	-0.37	3.62e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.01e-12	Rheumatoid arthritis;
CRC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.66	11.0	0.52	3.46e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg01339444	chr6:118972232	C6orf204	0.55	6.16	0.32	2.08e-9	Diastolic blood pressure;
CRC	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg25790453	chr13:113633590	MCF2L	-0.5	-7.78	-0.39	9.66e-14	Systolic blood pressure;
CRC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.43	6.51	0.34	2.87e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10084289	chr6:111580886	KIAA1919	0.42	6.15	0.32	2.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.86	-0.31	1.13e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05365220	chr1:94375159	GCLM	0.39	5.97	0.31	6.27e-9	Schizophrenia;
CRC	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.68	11.35	0.53	1.99e-25	Itch intensity from mosquito bite;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	8.01	0.4	1.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1971762	0.504	rs1843318	chr12:53958077	C/T	cg06632207	chr12:54070931	ATP5G2	0.45	7.57	0.39	3.76e-13	Height;
CRC	trans	rs1607741	1.000	rs10010287	chr4:72711633	G/A	cg06437464	chr6:127441704	RSPO3	0.29	6.14	0.32	2.32e-9	Vitamin D levels;
CRC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.86	-11.14	-0.52	1.12e-24	Gut microbiome composition (summer);
CRC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.44	0.46	7.04e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-10.78	-0.51	2.06e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg15845792	chr6:28175446	NA	0.68	6.09	0.32	3.15e-9	Breast cancer;
CRC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.56	6.3	0.33	9.63e-10	Bipolar disorder;
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.44	-7.09	-0.36	8.09e-12	Coronary artery disease;
CRC	cis	rs9826463	0.582	rs11709758	chr3:142104427	T/C	cg20824294	chr3:142316082	PLS1	0.36	5.86	0.31	1.11e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs6496667	0.779	rs59814752	chr15:91005738	G/A	cg04176472	chr15:90893244	GABARAPL3	0.58	8.05	0.41	1.5e-14	Rheumatoid arthritis;
CRC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.38	-0.33	5.88e-10	Aortic root size;
CRC	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.54	6.1	0.32	2.99e-9	Bipolar disorder;
CRC	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	11.15	0.52	1.01e-24	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.77	9.64	0.47	1.6e-19	Obesity-related traits;
CRC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.08e-8	Morning vs. evening chronotype;
CRC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg16606324	chr3:10149918	C3orf24	0.45	6.8	0.35	4.87e-11	Alzheimer's disease;
CRC	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg06204229	chr3:52865917	ITIH4	0.58	7.94	0.4	3.2e-14	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.86	-0.55	2.96e-27	Colorectal cancer;
CRC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.42	-0.33	4.75e-10	Menopause (age at onset);
CRC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg27661571	chr11:113659931	NA	-0.7	-8.06	-0.41	1.44e-14	Hip circumference adjusted for BMI;
CRC	cis	rs4423214	0.840	rs1790340	chr11:71182589	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-7.57	-0.39	3.78e-13	Vitamin D levels;
CRC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11916186	chr1:36689760	THRAP3	0.42	6.05	0.32	4.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg07636037	chr3:49044803	WDR6	-0.65	-5.73	-0.3	2.24e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.73	-0.35	7.51e-11	Inflammatory skin disease;
CRC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.89	-0.44	3.98e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg03037974	chr15:76606532	NA	0.68	11.71	0.54	1.02e-26	Blood metabolite levels;
CRC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg17321639	chr7:2759063	NA	-0.43	-5.62	-0.3	4.12e-8	Height;
CRC	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg08923669	chr16:420230	MRPL28	-0.44	-6.24	-0.33	1.34e-9	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.25	-0.37	2.95e-12	Depression;
CRC	cis	rs9468186	1	rs9468186	chr6:27626631	A/G	cg15845792	chr6:28175446	NA	0.56	6.86	0.35	3.47e-11	Neuroticism;
CRC	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg02158880	chr13:53174818	NA	-0.43	-6.38	-0.33	5.85e-10	Lewy body disease;
CRC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.93	-0.4	3.4e-14	Gut microbiome composition (summer);
CRC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06505273	chr16:24850292	NA	0.39	5.72	0.3	2.33e-8	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06828538	chr7:5463627	TNRC18	-0.44	-6.64	-0.34	1.3100000000000001e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.66	-9.32	-0.46	1.73e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-5.81	-0.3	1.5e-8	Longevity;Endometriosis;
CRC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.61	-0.34	1.54e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.75	0.3	2.08e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg16342193	chr10:102329863	NA	-0.42	-6.63	-0.34	1.35e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.57	9.02	0.45	1.57e-17	Gestational age at birth (maternal effect);
CRC	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.23	-0.56	1.27e-28	Coffee consumption (cups per day);
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg03804128	chr16:635623	NA	0.32	7.48	0.38	7.03e-13	Height;
CRC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg18876405	chr7:65276391	NA	0.47	6.5	0.34	2.93e-10	Aortic root size;
CRC	cis	rs6545883	0.524	rs778159	chr2:61556744	T/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.78	-0.39	9.42e-14	Tuberculosis;
CRC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.59	8.98	0.44	2.14e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.01	-0.36	1.39e-11	Aortic root size;
CRC	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.66	-10.29	-0.49	1.05e-21	Ulcerative colitis;
CRC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.46	6.34	0.33	7.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg05304507	chr6:116381966	FRK	0.28	6.31	0.33	8.88e-10	Total cholesterol levels;
CRC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.63	8.51	0.42	6.43e-16	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05863116	chr5:133562407	PPP2CA	0.39	6.15	0.32	2.23e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03923535	chr7:1197113	ZFAND2A	0.67	9.56	0.47	2.77e-19	Longevity;Endometriosis;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.46	7.91	0.4	3.91e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.16	-24.71	-0.81	5.99e-77	Exhaled nitric oxide output;
CRC	cis	rs1007738	0.542	rs2279438	chr11:47204175	A/T	cg19486271	chr11:47235900	DDB2	-0.41	-5.61	-0.3	4.34e-8	Bone mineral density (hip);
CRC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.6	0.34	1.62e-10	HIV-1 control;
CRC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.71	-12.19	-0.56	1.89e-28	Body mass index;
CRC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.53	8.55	0.43	4.87e-16	Height;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-0.59	-8.17	-0.41	6.75e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-0.95	-16.74	-0.68	6.19e-46	Height;
CRC	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg05623727	chr3:50126028	RBM5	0.55	7.23	0.37	3.46e-12	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.8	15.3	0.64	2.82e-40	Prudent dietary pattern;
CRC	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.35	5.71	0.3	2.59e-8	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05778706	chr10:101372151	SLC25A28	0.53	7.68	0.39	1.84e-13	Response to antipsychotic treatment;
CRC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg23565292	chr14:50234668	KLHDC2	-0.4	-5.64	-0.3	3.75e-8	Carotid intima media thickness;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14789568	chr1:29508095	SFRS4	0.44	6.05	0.32	3.83e-9	Survival in pancreatic cancer;
CRC	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg21483461	chr5:81570383	RPS23	0.36	5.61	0.3	4.31e-8	Breast cancer;
CRC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.5	6.89	0.36	2.76e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg20041105	chr8:143859282	LYNX1	0.46	8.24	0.41	4.25e-15	Urinary tract infection frequency;
CRC	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg26176469	chr17:28951361	LRRC37B2	0.53	5.97	0.31	6.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.2	-0.32	1.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.86	-20.99	-0.76	1.12e-62	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg04969067	chr8:143858791	LYNX1	0.47	7.86	0.4	5.59e-14	Urinary tract infection frequency;
CRC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	11.41	0.53	1.19e-25	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	0.91	7.46	0.38	7.75e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg08270630	chr22:50330655	NA	0.5	5.69	0.3	2.81e-8	Schizophrenia;
CRC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.03	-0.36	1.16e-11	Reticulocyte fraction of red cells;
CRC	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.24	-0.37	3.29e-12	Inflammatory skin disease;
CRC	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg26116260	chr4:7069785	GRPEL1	-0.71	-5.82	-0.31	1.42e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg24154853	chr7:158122151	PTPRN2	0.65	10.93	0.52	6.48e-24	Calcium levels;
CRC	cis	rs2882667	0.964	rs67296915	chr5:138301599	C/T	cg09476006	chr5:138032270	NA	0.56	9.84	0.48	3.44e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.47	6.26	0.33	1.17e-9	Pulse pressure;
CRC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg02269571	chr22:50332266	NA	-0.61	-7.54	-0.38	4.53e-13	Schizophrenia;
CRC	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.32e-19	Blood protein levels;
CRC	cis	rs317865	0.737	rs73234629	chr4:16169776	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	5.72	0.3	2.4e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg02733842	chr7:1102375	C7orf50	-0.71	-8.32	-0.42	2.42e-15	Bronchopulmonary dysplasia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08028037	chr13:52027479	INTS6	0.39	5.97	0.31	6.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.42	6.9	0.36	2.6e-11	Resting heart rate;
CRC	cis	rs7113874	0.589	rs7949017	chr11:8492127	C/T	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.67	11.04	0.52	2.63e-24	Age at first birth;
CRC	cis	rs12024301	0.557	rs9633306	chr1:183638352	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.79	6.97	0.36	1.72e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg04969067	chr8:143858791	LYNX1	0.45	7.58	0.39	3.66e-13	Urinary tract infection frequency;
CRC	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.51	5.76	0.3	1.89e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.73	-8.74	-0.43	1.23e-16	Breast cancer;
CRC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.09	18.67	0.72	1.44e-53	Cognitive function;
CRC	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.4	6.98	0.36	1.61e-11	Glomerular filtration rate (creatinine);
CRC	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg22153745	chr1:153894579	GATAD2B	-0.57	-7.45	-0.38	8.54e-13	Total cholesterol levels;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02772935	chr3:125709198	NA	-0.48	-5.79	-0.3	1.6e-8	Blood pressure (smoking interaction);
CRC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.5	-9.03	-0.45	1.46e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.4	6.23	0.32	1.41e-9	Red blood cell count;
CRC	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.46	8.39	0.42	1.49e-15	Intraocular pressure;
CRC	cis	rs4964805	0.913	rs11111793	chr12:104198118	G/T	cg02344784	chr12:104178138	NT5DC3	0.5	7.05	0.36	1.03e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg23161317	chr6:28129485	ZNF389	0.39	5.85	0.31	1.17e-8	Cardiac Troponin-T levels;
CRC	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg00603274	chr11:61596626	FADS2	-0.47	-6.72	-0.35	8.18e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.4	6.27	0.33	1.15e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg24463073	chr6:118973353	C6orf204	0.52	6.9	0.36	2.6e-11	Diastolic blood pressure;
CRC	cis	rs17592366	0.517	rs1967722	chr14:35285274	A/G	cg09327582	chr14:35236912	BAZ1A	0.48	6.71	0.35	8.66e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-8.9	-0.44	3.72e-17	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11978387	chr20:52824404	PFDN4	0.48	6.97	0.36	1.76e-11	Response to antipsychotic treatment;
CRC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.35	-5.89	-0.31	9.66e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg15786705	chr6:28176104	NA	0.76	9.6	0.47	2.1e-19	Depression;
CRC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg14979609	chr8:8086686	FLJ10661	0.38	6.3	0.33	9.8e-10	Joint mobility (Beighton score);
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12172441	chr6:28176163	NA	0.53	7.32	0.37	1.96e-12	Cardiac Troponin-T levels;
CRC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg09473613	chr1:24152604	HMGCL	0.34	5.61	0.3	4.32e-8	Immature fraction of reticulocytes;
CRC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.75	-11.04	-0.52	2.63e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs17767392	0.645	rs17767296	chr14:71686784	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.85	-0.35	3.74e-11	Mitral valve prolapse;
CRC	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.51	8.79	0.44	8.62e-17	Dupuytren's disease;
CRC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.67	-0.57	3.24e-30	Alzheimer's disease;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.44	6.48	0.34	3.44e-10	Menarche (age at onset);
CRC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.39	-5.86	-0.31	1.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	5.77	0.3	1.88e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.62	9.45	0.46	6.33e-19	Hemoglobin concentration;
CRC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.77	-9.2	-0.45	4.16e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4731207	0.596	rs7778875	chr7:124645446	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs17092148	0.836	rs4911157	chr20:33167075	T/C	cg08999081	chr20:33150536	PIGU	0.51	6.21	0.32	1.6e-9	Neuroticism;
CRC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg21038819	chr17:73507788	CASKIN2	0.4	6.28	0.33	1.06e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.61	0.73	2.81e-57	Prudent dietary pattern;
CRC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.19	0.32	1.78e-9	Tonsillectomy;
CRC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.62	9.5	0.46	4.61e-19	Testicular germ cell tumor;
CRC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs7731657	0.537	rs4705907	chr5:130191437	T/A	cg08523029	chr5:130500466	HINT1	-0.46	-5.86	-0.31	1.11e-8	Fasting plasma glucose;
CRC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.68	-0.35	1.01e-10	Major depressive disorder;
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg14541582	chr5:601475	NA	-0.31	-6.34	-0.33	7.49e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg08314208	chr16:67682810	RLTPR	-0.58	-6.23	-0.32	1.47e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21985132	chr20:42086626	SFRS6	0.43	7.38	0.38	1.27e-12	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.59	-0.39	3.23e-13	Bipolar disorder;
CRC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.49	0.38	6.37e-13	Calcium levels;
CRC	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.39	-0.53	1.45e-25	Coffee consumption (cups per day);
CRC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.65	12.37	0.56	3.93e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.09	0.55	4.22e-28	Hip circumference adjusted for BMI;
CRC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.46	6.92	0.36	2.36e-11	Colorectal cancer;
CRC	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.19	0.37	4.31e-12	Hemoglobin concentration;
CRC	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.94	-0.31	7.15e-9	Pulmonary function;
CRC	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.48	7.25	0.37	3.08e-12	Testicular germ cell tumor;
CRC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	10.42	0.5	3.63e-22	Hip circumference adjusted for BMI;
CRC	cis	rs2013441	1.000	rs11870147	chr17:20216095	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.31	-0.33	9.14e-10	Obesity-related traits;
CRC	cis	rs11212617	0.967	rs4987982	chr11:108151269	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.68	0.3	2.98e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.66	-9.51	-0.46	4.23e-19	Menopause (age at onset);
CRC	cis	rs860295	0.702	rs10908472	chr1:155544256	T/C	cg02153340	chr1:155202674	NA	-0.58	-6.75	-0.35	6.59e-11	Body mass index;
CRC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg13198984	chr17:80129470	CCDC57	0.42	7.33	0.37	1.77e-12	Life satisfaction;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.61	9.1	0.45	8.84e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg25833597	chr17:30823145	MYO1D	0.34	5.64	0.3	3.7e-8	Schizophrenia;
CRC	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.55	9.29	0.46	2.1e-18	Educational attainment;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.48	-7.6	-0.39	3.02e-13	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg07125278	chr16:67683757	RLTPR	-0.56	-6.53	-0.34	2.5e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg17120908	chr11:65337727	SSSCA1	0.68	7.43	0.38	9.66e-13	Bone mineral density;
CRC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.31	-0.46	1.89e-18	Dupuytren's disease;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg03623178	chr6:28175578	NA	-0.68	-10.39	-0.5	4.69e-22	Cardiac Troponin-T levels;
CRC	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.74	-11.89	-0.55	2.3e-27	Mean platelet volume;
CRC	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.55	0.34	2.2e-10	Coronary artery disease;
CRC	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg22515636	chr2:109150313	NA	0.44	6.24	0.33	1.34e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs7976838	0.831	rs2222878	chr12:60135228	G/A	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg14008862	chr17:28927542	LRRC37B2	0.51	6.01	0.31	4.88e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6694672	0.702	rs6685259	chr1:197093098	A/T	cg13682187	chr1:196946512	CFHR5	0.58	7.96	0.4	2.83e-14	Asthma;
CRC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.79	0.39	9.12e-14	Height;
CRC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.42	8.17	0.41	6.89e-15	Iron status biomarkers (transferrin levels);
CRC	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg15654264	chr1:150340011	RPRD2	0.41	6.06	0.32	3.79e-9	Migraine;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01869960	chr2:136289456	R3HDM1;ZRANB3	0.5	6.91	0.36	2.52e-11	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-11.05	-0.52	2.42e-24	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.73	0.35	7.61e-11	Diastolic blood pressure;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.5	7.16	0.37	5.22e-12	Longevity;Endometriosis;
CRC	trans	rs57506017	0.517	rs10488192	chr7:12277081	G/A	cg26461140	chr11:72811902	FCHSD2	0.58	6.51	0.34	2.83e-10	Neuroticism;
CRC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.6	7.36	0.38	1.45e-12	Mean platelet volume;
CRC	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.53	8.83	0.44	6.21e-17	Menarche (age at onset);
CRC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg16964102	chr10:135390573	NA	0.48	6.76	0.35	6.23e-11	Gout;
CRC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg26695010	chr11:65641043	EFEMP2	-0.56	-5.76	-0.3	1.92e-8	Crohn's disease;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg23161317	chr6:28129485	ZNF389	0.45	6.38	0.33	6.09e-10	Parkinson's disease;
CRC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.5	1.25e-22	Heart rate;
CRC	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.35	7.42	0.38	1.02e-12	Migraine;
CRC	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg26727032	chr16:67993705	SLC12A4	-0.65	-9.76	-0.47	6.4e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-9.69	-0.47	1.06e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.37	7.21	0.37	3.91e-12	Tonsillectomy;
CRC	trans	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg09045935	chr12:6379348	NA	1.07	8.56	0.43	4.37e-16	Blood metabolite levels;
CRC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.18	-0.49	2.41e-21	Chronic sinus infection;
CRC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.65	-9.05	-0.45	1.25e-17	Height;
CRC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.27	0.33	1.16e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs11997175	0.967	rs60586868	chr8:33776585	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.2	0.32	1.67e-9	Body mass index;
CRC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.51	-0.34	2.78e-10	Platelet distribution width;
CRC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.36e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg02527881	chr3:46936655	PTH1R	-0.41	-7.84	-0.4	6.52e-14	Colorectal cancer;
CRC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02825527	chr7:2087843	MAD1L1	-0.47	-5.71	-0.3	2.51e-8	Bipolar disorder;
CRC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg10263370	chr3:44754102	ZNF502	-0.36	-6.08	-0.32	3.35e-9	Depressive symptoms;
CRC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.51	-7.58	-0.39	3.48e-13	Menarche (age at onset);
CRC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg25985355	chr7:65971099	NA	-0.32	-5.62	-0.3	3.97e-8	Aortic root size;
CRC	cis	rs13178541	0.551	rs4315919	chr5:135108794	G/A	cg10179196	chr5:134915088	CXCL14	-0.34	-5.91	-0.31	8.37e-9	IgG glycosylation;
CRC	cis	rs35883536	0.967	rs9433740	chr1:101133985	G/A	cg14515779	chr1:101123966	NA	0.36	6.62	0.34	1.45e-10	Monocyte count;
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.81	-9.05	-0.45	1.26e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg11887960	chr12:57824829	NA	0.59	6.59	0.34	1.79e-10	Obesity-related traits;
CRC	cis	rs12900413	0.687	rs28513927	chr15:90304471	T/G	cg24249390	chr15:90295951	MESP1	-0.57	-8.97	-0.44	2.34e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg21918786	chr6:109611834	NA	-0.36	-6.18	-0.32	1.85e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2307022	0.586	rs3785123	chr16:68386581	C/T	cg02226672	chr16:68398533	SMPD3	0.28	5.64	0.3	3.74e-8	Body mass index;
CRC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.27	0.56	9.02e-29	Platelet count;
CRC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.5	0.38	5.94e-13	Aortic root size;
CRC	cis	rs3768617	0.868	rs2296299	chr1:183104013	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.38	0.46	1.11e-18	Fuchs's corneal dystrophy;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg04518342	chr5:131593106	PDLIM4	0.43	7.04	0.36	1.14e-11	Acylcarnitine levels;
CRC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.84	11.73	0.54	9.02e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.72	9.45	0.46	6.54e-19	Coronary artery disease;
CRC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.43	-9.78	-0.47	5.21e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg21466736	chr12:48725269	NA	0.51	8.01	0.4	1.96e-14	Plateletcrit;
CRC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.85	-14.91	-0.64	8.87e-39	Height;
CRC	cis	rs12630931	1.000	rs11714920	chr3:31972205	G/C	cg21375017	chr3:31988082	OSBPL10	0.44	6.06	0.32	3.68e-9	Periodontal disease-related phenotypes;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg15845792	chr6:28175446	NA	0.68	8.97	0.44	2.28e-17	Parkinson's disease;
CRC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.61	-8.39	-0.42	1.49e-15	Iron status biomarkers;
CRC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.61	8.89	0.44	4.25e-17	Lung cancer;
CRC	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg13385794	chr1:248469461	NA	0.38	6.69	0.35	9.77e-11	Common traits (Other);
CRC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg10978503	chr1:24200527	CNR2	-0.44	-6.77	-0.35	6.02e-11	Immature fraction of reticulocytes;
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg15786705	chr6:28176104	NA	0.41	5.84	0.31	1.26e-8	Parkinson's disease;
CRC	cis	rs6076065	0.692	rs2424549	chr20:23394563	C/A	cg11657817	chr20:23433608	CST11	0.43	6.33	0.33	8.11e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.88	9.11	0.45	8.21e-18	Arsenic metabolism;
CRC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.56	6.15	0.32	2.29e-9	Initial pursuit acceleration;
CRC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.53	-10.07	-0.49	5.92e-21	Height;
CRC	cis	rs7527798	0.637	rs7515149	chr1:207838352	T/G	cg21110645	chr1:207815933	NA	-0.43	-6.64	-0.34	1.26e-10	Erythrocyte sedimentation rate;
CRC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	9.43	0.46	7.82e-19	Schizophrenia;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg06698420	chr6:107437230	NA	0.42	6.04	0.32	4.07e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.68	10.14	0.49	3.29e-21	Schizophrenia;
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg27432699	chr2:27873401	GPN1	-0.61	-9.25	-0.45	2.84e-18	Total body bone mineral density;
CRC	cis	rs807029	0.758	rs807025	chr10:102764821	C/T	cg04662943	chr10:102668895	NA	0.66	7.74	0.39	1.27e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2303319	0.504	rs1515182	chr2:162436934	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.01	-0.31	5.03e-9	Cognitive function;
CRC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	11.84	0.55	3.63e-27	Hip circumference adjusted for BMI;
CRC	cis	rs4437462	1.000	rs4437462	chr6:11310419	A/G	cg25250968	chr6:11318770	NEDD9	0.42	6.1	0.32	3.04e-9	HIV-1 susceptibility;
CRC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.6	-8.64	-0.43	2.48e-16	Menarche (age at onset);
CRC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.25	11.62	0.54	2.11e-26	Alzheimer's disease (late onset);
CRC	cis	rs6011002	0.808	rs2738787	chr20:62328375	A/G	cg01176363	chr20:62369445	LIME1	-0.75	-5.73	-0.3	2.29e-8	Dental caries;
CRC	trans	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg17903999	chr18:56338584	MALT1	0.4	6.54	0.34	2.32e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg02869306	chr7:64672164	INTS4L1	-0.36	-6.05	-0.32	3.96e-9	Aortic root size;
CRC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.47	0.42	8.41e-16	Menarche (age at onset);
CRC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.53	-10.06	-0.48	6.34e-21	Schizophrenia;
CRC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.83	0.35	4.22e-11	Mean platelet volume;
CRC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.14	-0.32	2.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.43	-6.29	-0.33	1.01e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs1223397	1.000	rs1223399	chr6:13271220	G/A	cg21538684	chr6:13274180	PHACTR1	0.46	5.67	0.3	3.06e-8	Blood pressure;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08187779	chr8:102217898	ZNF706	0.41	7.02	0.36	1.29e-11	Obesity-related traits;
CRC	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06307176	chr5:131281290	NA	0.38	5.6	0.3	4.48e-8	Life satisfaction;
CRC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg21854759	chr1:92012499	NA	-0.53	-8.64	-0.43	2.51e-16	Breast cancer;
CRC	cis	rs11750568	0.933	rs7719616	chr5:178536584	A/G	cg10208897	chr5:178548229	ADAMTS2	0.35	5.74	0.3	2.13e-8	Height;
CRC	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.92	-0.36	2.32e-11	Multiple sclerosis;
CRC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.36	0.33	6.58e-10	Morning vs. evening chronotype;
CRC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.77	13.81	0.61	1.61e-34	Anterior chamber depth;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12172441	chr6:28176163	NA	0.6	7.27	0.37	2.64e-12	Depression;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg21251018	chr6:28226885	NKAPL	0.48	6.9	0.36	2.69e-11	Depression;
CRC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg21155852	chr7:2048760	MAD1L1	-0.45	-6.42	-0.33	4.85e-10	Bipolar disorder;
CRC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.53	-10.35	-0.5	6.5600000000000005e-22	Bipolar disorder;
CRC	trans	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.7	-7.87	-0.4	5.16e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11723261	0.582	rs114199753	chr4:163520	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.52	7.23	0.37	3.46e-12	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.53	7.56	0.38	3.97e-13	Schizophrenia;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20994686	chr17:71306668	CDC42EP4	0.47	6.56	0.34	2.07e-10	Survival in pancreatic cancer;
CRC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	8.1	0.41	1.05e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17067123	0.539	rs11735192	chr4:180065076	A/C	cg26610307	chr4:180072759	NA	-0.57	-6.84	-0.35	3.85e-11	Response to hepatitis C treatment;
CRC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.06	13.05	0.58	1.14e-31	Type 2 diabetes nephropathy;
CRC	cis	rs2257205	0.667	rs4340382	chr17:56738919	G/A	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.87e-8	Pancreatic cancer;
CRC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.52	10.38	0.5	4.91e-22	Alcohol dependence;
CRC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.5	7.07	0.36	9.58e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2882667	0.898	rs2351465	chr5:138363851	A/C	cg04439458	chr5:138467593	SIL1	-0.33	-6.08	-0.32	3.36e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	0.92	17.38	0.69	1.9e-48	Height;
CRC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg03233332	chr7:66118400	NA	-0.43	-5.95	-0.31	7.02e-9	Aortic root size;
CRC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg16102536	chr7:156981717	UBE3C	-0.46	-7.83	-0.4	6.83e-14	Body mass index;
CRC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.56	-8.5	-0.42	6.79e-16	Aortic root size;
CRC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.79	-10.4	-0.5	4.39e-22	Initial pursuit acceleration;
CRC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg04880052	chr2:219191631	PNKD	-0.44	-6.95	-0.36	1.94e-11	Colorectal cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00402069	chr5:89770788	POLR3G;MBLAC2	0.49	6.2	0.32	1.67e-9	Hip circumference;
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1320333	0.772	rs35181861	chr2:679483	A/G	cg20966539	chr2:681320	NA	0.66	5.92	0.31	8.14e-9	Obesity-related traits;
CRC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg10589385	chr1:150898437	SETDB1	0.29	6.2	0.32	1.7e-9	Tonsillectomy;
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.15	-0.32	2.29e-9	Total body bone mineral density;
CRC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.54	6.65	0.34	1.21e-10	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs1376359	0.673	rs12755707	chr1:103138940	A/G	cg16220183	chr17:56609687	SEPT4	-0.44	-6.07	-0.32	3.44e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.03	14.51	0.62	3.08e-37	Vitiligo;
CRC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	trans	rs2303319	0.504	rs12473088	chr2:162485073	A/G	cg12500891	chr11:57225987	NA	-0.69	-6.05	-0.32	4.05e-9	Cognitive function;
CRC	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.05	-0.36	1.08e-11	Depression;
CRC	cis	rs727505	0.789	rs4731233	chr7:124736291	C/T	cg23710748	chr7:124431027	NA	-0.72	-12.28	-0.56	8.92e-29	Lewy body disease;
CRC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.5	-0.71	6.8e-53	Height;
CRC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.61	5.64	0.3	3.75e-8	Tuberculosis;
CRC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.5	-9.27	-0.46	2.45e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg26373071	chr5:1325741	CLPTM1L	0.46	8.12	0.41	9.42e-15	Lung cancer;
CRC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg03395651	chr16:88107091	BANP	0.61	8.18	0.41	6.46e-15	Menopause (age at onset);
CRC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.42	9.39	0.46	1.07e-18	Blood protein levels;
CRC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.45	6.58	0.34	1.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg02683197	chr6:28174875	NA	0.75	9.8	0.48	4.46e-20	Parkinson's disease;
CRC	cis	rs6433857	0.594	rs1950029	chr2:181520566	G/C	cg23363182	chr2:181467187	NA	-0.48	-7.38	-0.38	1.3e-12	Body mass index;
CRC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg06238570	chr21:40685208	BRWD1	0.73	10.29	0.49	1.01e-21	Cognitive function;
CRC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg03037974	chr15:76606532	NA	0.51	7.93	0.4	3.53e-14	Blood metabolite levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg09423085	chr2:68478351	PPP3R1	-0.4	-6.2	-0.32	1.69e-9	Aortic root size;
CRC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.66	12.18	0.56	2.04e-28	Breast cancer;
CRC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.42	8.06	0.41	1.41e-14	Ulcerative colitis;
CRC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg05585544	chr11:47624801	NA	-0.61	-10.84	-0.51	1.25e-23	Subjective well-being;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.63	-0.51	6.98e-23	Alzheimer's disease;
CRC	trans	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg04077850	chr5:125800366	GRAMD3	0.36	6.15	0.32	2.22e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17767392	0.681	rs4902922	chr14:71688207	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.68	-0.35	1.03e-10	Mitral valve prolapse;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg00490450	chr3:139108681	COPB2	0.43	6.43	0.33	4.49e-10	Obesity-related traits;
CRC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg03037974	chr15:76606532	NA	0.54	7.88	0.4	4.7e-14	Blood metabolite levels;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg08798685	chr6:27730294	NA	-0.48	-6.66	-0.34	1.12e-10	Parkinson's disease;
CRC	cis	rs2908197	0.806	rs12534035	chr7:75980946	G/C	cg10167463	chr7:75959203	YWHAG	-0.4	-5.92	-0.31	7.94e-9	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.62	-0.43	2.83e-16	Platelet count;
CRC	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.08	-0.41	1.28e-14	Type 2 diabetes;
CRC	cis	rs10982256	0.774	rs10817623	chr9:117244937	G/A	cg13636371	chr9:117264095	DFNB31	-0.31	-5.64	-0.3	3.75e-8	Bipolar disorder;
CRC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.78	0.35	5.54e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs2303319	0.504	rs72873624	chr2:162481453	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.81	11.47	0.53	7.41e-26	Cognitive function;
CRC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.6	9.61	0.47	2.03e-19	Tonsillectomy;
CRC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.92	12.7	0.57	2.35e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.84	-11.03	-0.52	2.82e-24	Obesity-related traits;
CRC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.64	-9.82	-0.48	3.92e-20	Diastolic blood pressure;
CRC	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.78e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-6.72	-0.35	7.85e-11	Schizophrenia;
CRC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.6	-0.39	3.11e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg23461800	chr14:103021989	NA	-0.75	-10.07	-0.49	5.61e-21	Platelet count;
CRC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.1	0.32	2.99e-9	Obesity-related traits;
CRC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.66	7.29	0.37	2.28e-12	Cannabis dependence symptom count;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg25164649	chr6:28176230	NA	0.6	6.15	0.32	2.27e-9	Lung cancer in ever smokers;
CRC	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-6.41	-0.33	5.19e-10	Body mass index;
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg11271282	chr2:238384023	NA	-0.48	-5.76	-0.3	1.97e-8	Prostate cancer;
CRC	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.48	7.17	0.37	4.84e-12	Dialysis-related mortality;
CRC	cis	rs4662945	0.688	rs62174140	chr2:130202893	C/T	cg05903289	chr2:130345205	NA	-0.3	-5.78	-0.3	1.74e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.65	10.83	0.51	1.44e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg15786705	chr6:28176104	NA	0.48	7.05	0.36	1.05e-11	Cardiac Troponin-T levels;
CRC	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg00319359	chr11:70116639	PPFIA1	0.55	6.04	0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.48	-9.54	-0.47	3.31e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.38e-14	Colorectal cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00906435	chr17:2304368	MNT	0.38	6.3	0.33	9.38e-10	Obesity-related traits;
CRC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.57	8.52	0.43	5.72e-16	Prostate cancer;
CRC	cis	rs4664293	0.967	rs3940435	chr2:160494783	G/A	cg08347373	chr2:160653686	CD302	-0.44	-7.22	-0.37	3.61e-12	Monocyte percentage of white cells;
CRC	cis	rs9287719	0.614	rs10929679	chr2:10723108	C/T	cg00105475	chr2:10696890	NA	0.45	7.07	0.36	9.46e-12	Prostate cancer;
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.62	-7.61	-0.39	2.95e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.72	10.25	0.49	1.43e-21	Platelet distribution width;
CRC	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg26394196	chr10:1453818	ADARB2	0.34	6.0	0.31	5.07e-9	Radiation response;
CRC	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.76	-0.47	6.37e-20	Height;
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg22561889	chr6:118971681	C6orf204	0.5	6.39	0.33	5.8e-10	Diastolic blood pressure;
CRC	cis	rs9308731	0.583	rs7567184	chr2:111931072	C/G	cg04202892	chr2:111875749	ACOXL	0.42	6.75	0.35	6.53e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg14541582	chr5:601475	NA	-0.36	-7.38	-0.38	1.32e-12	Obesity-related traits;
CRC	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.46	8.1	0.41	1.12e-14	Information processing speed;
CRC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-8.76	-0.44	1.02e-16	Body mass index;
CRC	cis	rs2811415	0.597	rs11714256	chr3:127804368	G/A	cg13719885	chr3:127795394	NA	-0.4	-5.92	-0.31	8.11e-9	Lung function (FEV1/FVC);
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.02	0.55	7.57e-28	Alzheimer's disease;
CRC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	12.56	0.57	8.16e-30	Platelet count;
CRC	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.03	0.45	1.5e-17	Dupuytren's disease;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg12273811	chr6:28175739	NA	0.5	6.63	0.34	1.38e-10	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	3.92e-9	Total body bone mineral density;
CRC	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.45	6.57	0.34	1.95e-10	Pulmonary function decline;
CRC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.44	6.12	0.32	2.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.44	0.33	4.33e-10	Diabetic kidney disease;
CRC	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	7.46	0.38	8.01e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg13685329	chr2:73460476	CCT7;C2orf7	0.51	6.21	0.32	1.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.52	8.3	0.42	2.68e-15	Menopause (age at onset);
CRC	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg23032129	chr1:109941072	SORT1	0.27	5.84	0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	trans	rs8005150	0.737	rs74074328	chr14:88490211	G/A	cg25527770	chr19:1444892	NA	-0.59	-6.43	-0.33	4.47e-10	Hepatitis B;
CRC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg12193833	chr17:30244370	NA	-0.75	-8.76	-0.44	1.01e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs17756712	0.667	rs2073006	chr6:637465	C/T	cg16786516	chr6:604617	EXOC2	0.51	6.49	0.34	3.09e-10	Vertical cup-disc ratio;
CRC	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg01475377	chr6:109611718	NA	-0.35	-6.1	-0.32	3e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.54	-7.98	-0.4	2.49e-14	Cognitive test performance;
CRC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.36	-5.63	-0.3	3.96e-8	Testicular germ cell tumor;
CRC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.68	-0.3	2.94e-8	Gout;Renal underexcretion gout;
CRC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg16576597	chr16:28551801	NUPR1	0.49	7.07	0.36	9.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg00105475	chr2:10696890	NA	-0.44	-7.12	-0.37	6.9e-12	Prostate cancer;
CRC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.01	-0.52	3.29e-24	Type 2 diabetes;
CRC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.33	-6.74	-0.35	7.26e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg26893134	chr6:116381904	FRK	0.28	8.08	0.41	1.21e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg26608667	chr7:1196370	ZFAND2A	0.35	5.67	0.3	3.1e-8	Longevity;Endometriosis;
CRC	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg05756136	chr1:119680316	WARS2	-0.53	-7.13	-0.37	6.41e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.48	-7.37	-0.38	1.37e-12	Corneal astigmatism;
CRC	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.6	-8.59	-0.43	3.44e-16	Coronary artery disease;
CRC	cis	rs460214	0.576	rs28446127	chr21:40029568	C/A	cg05519781	chr21:40033154	ERG	-0.42	-5.72	-0.3	2.43e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg19897017	chr7:2163380	MAD1L1	0.57	8.34	0.42	2.03e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.64	10.34	0.5	7.18e-22	Corneal astigmatism;
CRC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.25	0.41	3.98e-15	Menopause (age at onset);
CRC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.42	5.81	0.31	1.44e-8	Neuroticism;
CRC	cis	rs4731207	0.565	rs1031959	chr7:124627313	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.96e-9	Cutaneous malignant melanoma;
CRC	trans	rs9929218	0.677	rs12597188	chr16:68814826	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-10.53	-0.5	1.53e-22	Colorectal cancer;
CRC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-12.58	-0.57	6.95e-30	Asthma;
CRC	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg00319359	chr11:70116639	PPFIA1	0.59	6.61	0.34	1.6e-10	Coronary artery disease;
CRC	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.83	-0.35	4.12e-11	Cutaneous nevi;
CRC	cis	rs7894407	0.760	rs4917386	chr10:105007528	C/T	cg05636881	chr10:105038444	INA	-0.38	-6.07	-0.32	3.5e-9	White matter hyperintensity burden;
CRC	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.21	-0.41	5.02e-15	Total body bone mineral density;
CRC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg11212589	chr17:38028394	ZPBP2	0.46	8.78	0.44	9.42e-17	Self-reported allergy;
CRC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg26762873	chr11:5879799	OR52E8	-0.43	-6.18	-0.32	1.85e-9	DNA methylation (variation);
CRC	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs6586163	0.934	rs7897395	chr10:90754607	T/C	cg13456138	chr10:90753195	FAS	-0.43	-6.63	-0.34	1.38e-10	Chronic lymphocytic leukemia;
CRC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.66	11.43	0.53	1.06e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.71	9.94	0.48	1.51e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.68	-6.1	-0.32	2.96e-9	Depression;
CRC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.5	-6.43	-0.33	4.5e-10	Red blood cell traits;
CRC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10062221	chr8:37962833	ASH2L	0.45	6.39	0.33	5.68e-10	Response to antipsychotic treatment;
CRC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.71	11.57	0.54	3.39e-26	Dental caries;
CRC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.38	6.28	0.33	1.06e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03457587	chr19:54694791	MBOAT7;TSEN34	0.48	6.8	0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg12682573	chr17:27188876	MIR451;MIR144	-0.6	-8.79	-0.44	8.51e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.78	8.68	0.43	1.91e-16	Systolic blood pressure;
CRC	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.53	7.32	0.37	1.97e-12	Mammographic density (dense area);
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg12273811	chr6:28175739	NA	0.55	8.14	0.41	8.09e-15	Parkinson's disease;
CRC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg06470822	chr6:28175283	NA	0.59	8.66	0.43	2.23e-16	Pubertal anthropometrics;
CRC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.18	0.56	1.98e-28	Menopause (age at onset);
CRC	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg13662093	chr20:33865505	NA	-0.43	-6.16	-0.32	2.17e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs447	0.806	rs6467987	chr7:83756215	C/T	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.73	-0.3	2.27e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg17330251	chr7:94953956	PON1	-0.56	-7.42	-0.38	9.76e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1223397	0.651	rs2919686	chr6:13312641	A/G	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg24851651	chr11:66362959	CCS	-0.39	-6.77	-0.35	6.08e-11	Educational attainment (years of education);
CRC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.54	0.63	2.44e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg24110177	chr3:50126178	RBM5	0.45	6.81	0.35	4.66e-11	Menarche (age at onset);
CRC	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg12856521	chr11:46389249	DGKZ	0.73	10.56	0.5	1.21e-22	Crohn's disease;
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg08222913	chr3:52553049	STAB1	-0.32	-5.93	-0.31	7.82e-9	Bipolar disorder;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.19	-0.53	7.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs7781266	0.948	rs2346264	chr7:133536351	A/C	cg03336402	chr7:133662267	EXOC4	-0.59	-7.43	-0.38	9.37e-13	Educational attainment (college completion);
CRC	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg10494257	chr1:16342123	HSPB7	0.46	6.37	0.33	6.52e-10	Dilated cardiomyopathy;
CRC	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg16989719	chr2:238392110	NA	-0.39	-7.95	-0.4	3.07e-14	Prostate cancer;
CRC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.52	-8.14	-0.41	8.32e-15	Monocyte count;
CRC	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg17545662	chr6:170176663	C6orf70	0.53	5.82	0.31	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.41	-0.71	1.64e-52	Height;
CRC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg27661571	chr11:113659931	NA	-0.97	-11.31	-0.53	2.92e-25	Hip circumference adjusted for BMI;
CRC	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg16701003	chr16:89028210	CBFA2T3	0.44	6.9	0.36	2.73e-11	Social autistic-like traits;
CRC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.8	-0.75	6.04e-62	Myeloid white cell count;
CRC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg03037974	chr15:76606532	NA	0.75	13.63	0.6	7.48e-34	Blood metabolite levels;
CRC	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.65	-7.55	-0.38	4.28e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	0.5	8.14	0.41	8.11e-15	Intelligence (multi-trait analysis);
CRC	cis	rs282587	0.569	rs1756076	chr13:113395819	T/C	cg04656015	chr13:113407548	ATP11A	0.63	7.8	0.4	8.04e-14	Glycated hemoglobin levels;
CRC	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.78	-11.13	-0.52	1.25e-24	Platelet distribution width;
CRC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.34	2.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2303319	0.504	rs56153413	chr2:162440079	G/T	cg12500891	chr11:57225987	NA	-0.67	-6.02	-0.31	4.7e-9	Cognitive function;
CRC	cis	rs1223397	0.651	rs2919685	chr6:13311668	T/C	cg20827128	chr6:13274284	PHACTR1	0.37	5.76	0.3	1.96e-8	Blood pressure;
CRC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg14847009	chr1:175162515	KIAA0040	-0.26	-5.68	-0.3	2.9e-8	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01125366	chr10:72218306	NA	0.37	6.16	0.32	2.07e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg21285383	chr16:89894308	SPIRE2	0.35	5.97	0.31	6e-9	Vitiligo;
CRC	cis	rs2084637	0.828	rs9633954	chr11:122419907	T/A	cg21585512	chr11:122030076	LOC399959	-0.35	-6.5	-0.34	3.05e-10	Stroke;
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg12564285	chr5:131593104	PDLIM4	0.34	5.81	0.3	1.49e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg09873164	chr1:152488093	CRCT1	0.4	6.49	0.34	3.08e-10	Hair morphology;
CRC	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-8.62	-0.43	2.86e-16	Brugada syndrome;
CRC	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg00469287	chr7:23338798	C7orf30	0.46	6.07	0.32	3.51e-9	Cerebrospinal fluid biomarker levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21796443	chr7:4722378	FOXK1	0.43	6.15	0.32	2.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	13.9	0.61	7.29e-35	Chronic sinus infection;
CRC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.95	-0.52	5.2e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs977987	0.864	rs37593	chr16:75496907	T/C	cg03315344	chr16:75512273	CHST6	-0.58	-9.63	-0.47	1.69e-19	Dupuytren's disease;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg15763984	chr4:1342303	KIAA1530	0.33	5.61	0.3	4.38e-8	Obesity-related traits;
CRC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg18478394	chr8:109455254	TTC35	0.39	6.03	0.32	4.3e-9	Dupuytren's disease;
CRC	cis	rs7605827	0.866	rs13417550	chr2:15533895	A/G	cg19274914	chr2:15703543	NA	0.38	5.75	0.3	2.01e-8	Educational attainment (years of education);
CRC	cis	rs375066	0.935	rs425217	chr19:44393975	C/T	cg11993925	chr19:44307056	LYPD5	0.37	5.71	0.3	2.47e-8	Breast cancer;
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg20041105	chr8:143859282	LYNX1	0.47	8.38	0.42	1.61e-15	Urinary tract infection frequency;
CRC	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.61	7.11	0.36	7.46e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg25886479	chr11:50257625	LOC441601	0.34	5.63	0.3	3.82e-8	Coronary artery disease;
CRC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg15147215	chr3:52552868	STAB1	-0.65	-11.29	-0.53	3.36e-25	Bipolar disorder;
CRC	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	10.26	0.49	1.32e-21	Myopia (pathological);
CRC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.58	13.44	0.6	4e-33	Breast size;
CRC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.56	-8.27	-0.41	3.44e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs16975963	0.843	rs73031215	chr19:38433555	G/A	cg15135657	chr19:38346511	NA	-0.43	-5.75	-0.3	2.01e-8	Longevity;
CRC	cis	rs1545257	0.505	rs12988810	chr2:24635093	G/T	cg06627628	chr2:24431161	ITSN2	-0.48	-7.01	-0.36	1.33e-11	Sjögren's syndrome;
CRC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg16606324	chr3:10149918	C3orf24	0.66	7.7	0.39	1.65e-13	Alzheimer's disease;
CRC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg24977027	chr2:88469347	THNSL2	0.64	7.72	0.39	1.37e-13	Plasma clusterin levels;
CRC	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.74	-10.37	-0.5	5.59e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg03934865	chr2:198174659	NA	0.36	5.85	0.31	1.18e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	0.65	11.02	0.52	3.13e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.57	7.72	0.39	1.45e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.56	6.35	0.33	7.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg01851573	chr8:8652454	MFHAS1	0.44	5.78	0.3	1.71e-8	Neurocognitive impairment in HIV-1 infection (continuous);
CRC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.47	-6.28	-0.33	1.06e-9	Diabetic retinopathy;
CRC	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-6.06	-0.32	3.83e-9	Axial length;
CRC	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.65	8.29	0.42	3e-15	Breast cancer;
CRC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.59	0.39	3.23e-13	Alzheimer's disease (late onset);
CRC	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg02811702	chr13:24901961	NA	0.48	6.66	0.34	1.14e-10	Obesity-related traits;
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-7.07	-0.36	9.28e-12	Lymphocyte counts;
CRC	cis	rs12612619	0.621	rs4665943	chr2:27295885	C/T	cg00617064	chr2:27272375	NA	0.39	6.18	0.32	1.91e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.55	-8.46	-0.42	8.83e-16	Systemic sclerosis;
CRC	cis	rs7113874	0.550	rs4929949	chr11:8604593	T/C	cg20771178	chr11:8615675	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg23100626	chr2:96804247	ASTL	0.26	7.0	0.36	1.41e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg04155289	chr7:94953770	PON1	-0.6	-7.65	-0.39	2.25e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.7	0.6	4.22e-34	Menarche (age at onset);
CRC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.5	-9.81	-0.48	4.22e-20	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg15763984	chr4:1342303	KIAA1530	0.34	6.01	0.31	4.89e-9	Obesity-related traits;
CRC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.37	-0.33	6.31e-10	Alzheimer's disease (late onset);
CRC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg11887960	chr12:57824829	NA	0.58	6.42	0.33	4.65e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg18551225	chr6:44695536	NA	-0.41	-5.96	-0.31	6.36e-9	Total body bone mineral density;
CRC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	trans	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.39	-0.38	1.2e-12	Endometrial cancer;
CRC	cis	rs4662945	0.688	rs62174140	chr2:130202893	C/T	cg05962382	chr2:130345044	NA	-0.33	-5.61	-0.3	4.24e-8	Response to cytidine analogues (gemcitabine);
CRC	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.45	0.34	4.07e-10	Systemic lupus erythematosus;
CRC	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg06287003	chr12:125626642	AACS	-0.56	-6.66	-0.34	1.14e-10	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg03037974	chr15:76606532	NA	0.72	12.72	0.57	1.97e-30	Blood metabolite levels;
CRC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg00255919	chr5:131827918	IRF1	0.35	6.09	0.32	3.24e-9	Breast cancer;Mosquito bite size;
CRC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.7	0.43	1.62e-16	Morning vs. evening chronotype;
CRC	cis	rs10486722	0.606	rs2108171	chr7:41776690	G/A	cg22138096	chr7:41772439	LOC285954	0.43	5.65	0.3	3.53e-8	Pit-and-Fissure caries;
CRC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.4	-0.56	3.1e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10046574	0.831	rs111522774	chr7:135135327	C/A	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.87	0.48	2.78e-20	Fuchs's corneal dystrophy;
CRC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.51	8.64	0.43	2.49e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2270875	1.000	rs2270875	chr8:132999936	A/G	cg24184792	chr8:132919238	EFR3A	-0.61	-5.9	-0.31	9.02e-9	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.81	12.55	0.57	8.49e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24739457	chr1:205821442	NA	0.44	6.35	0.33	7.31e-10	Menarche (age at onset);
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23161317	chr6:28129485	ZNF389	0.44	5.71	0.3	2.49e-8	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00345343	chr16:89422185	ANKRD11	-0.36	-5.97	-0.31	5.99e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01069170	chr19:44031473	ETHE1	0.43	6.8	0.35	4.96e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.53	-6.62	-0.34	1.48e-10	Ulcerative colitis;
CRC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.38	5.71	0.3	2.5e-8	HDL cholesterol levels;
CRC	cis	rs12760731	0.623	rs2862378	chr1:178296566	A/G	cg00404053	chr1:178313656	RASAL2	0.71	9.05	0.45	1.31e-17	Obesity-related traits;
CRC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.44	-0.33	4.31e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05477027	chr19:46295590	DMWD	-0.51	-6.13	-0.32	2.48e-9	Diisocyanate-induced asthma;
CRC	cis	rs6921919	0.789	rs6456814	chr6:28305812	C/A	cg15845792	chr6:28175446	NA	0.46	5.87	0.31	1.04e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.78	8.02	0.4	1.92e-14	Plasma clusterin levels;
CRC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.64	7.91	0.4	4.06e-14	Menarche (age at onset);
CRC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.98	-0.52	4.02e-24	Electroencephalogram traits;
CRC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-7.76	-0.39	1.06e-13	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.53	7.83	0.4	6.73e-14	Menopause (age at onset);
CRC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.08e-14	Resting heart rate;
CRC	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.62	-9.76	-0.47	6.12e-20	Testicular germ cell tumor;
CRC	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg16724585	chr3:197361211	NA	-0.48	-7.1	-0.36	7.8e-12	Pancreatic cancer;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg11206763	chr12:56521692	ESYT1	-0.44	-6.47	-0.34	3.57e-10	Daytime sleep phenotypes;
CRC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg03340356	chr1:67600835	NA	-0.28	-6.37	-0.33	6.22e-10	Psoriasis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10723012	chr17:79995434	DCXR	0.45	6.25	0.33	1.3e-9	Anxiety disorder;
CRC	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.45	-7.44	-0.38	8.84e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.51	-0.38	5.75e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.41	-5.7	-0.3	2.64e-8	Red blood cell traits;
CRC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.58	-9.94	-0.48	1.56e-20	Schizophrenia;
CRC	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs2579500	0.885	rs2579501	chr2:97199251	G/A	cg23100626	chr2:96804247	ASTL	0.24	5.74	0.3	2.1e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10190698	chr14:50154770	POLE2	0.39	6.0	0.31	5.28e-9	Interleukin-6 levels;
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.48	7.29	0.37	2.28e-12	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.71	-8.09	-0.41	1.15e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.59	-8.72	-0.43	1.38e-16	Aortic root size;
CRC	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.5	6.53	0.34	2.51e-10	Systemic lupus erythematosus;
CRC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg19046167	chr17:80928561	B3GNTL1	0.45	7.69	0.39	1.7e-13	Breast cancer;
CRC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg13206674	chr6:150067644	NUP43	0.49	7.03	0.36	1.22e-11	Testicular germ cell tumor;
CRC	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg13615338	chr4:55094005	PDGFRA	0.42	6.01	0.31	4.81e-9	Corneal astigmatism;
CRC	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg10437265	chr15:77819839	NA	0.69	12.57	0.57	7.62e-30	Type 2 diabetes;
CRC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04880052	chr2:219191631	PNKD	-0.42	-6.65	-0.34	1.25e-10	Colorectal cancer;
CRC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.55	-7.76	-0.39	1.06e-13	IgG glycosylation;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.79	-0.3	1.61e-8	Longevity;Endometriosis;
CRC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	7.55	0.38	4.36e-13	Hip circumference adjusted for BMI;
CRC	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.91	-0.31	8.45e-9	Neuroticism;
CRC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.49	-7.07	-0.36	9.29e-12	Height;
CRC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.19	-0.32	1.77e-9	Major depressive disorder;
CRC	trans	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg07393940	chr7:158741817	NA	0.51	7.38	0.38	1.34e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	8.79	0.44	8.52e-17	Response to antipsychotic treatment;
CRC	cis	rs4731207	0.698	rs10156168	chr7:124494410	G/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs832187	0.813	rs704369	chr3:63868271	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.4	5.72	0.3	2.41e-8	Schizophrenia;
CRC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.44	-6.72	-0.35	8.23e-11	Resting heart rate;
CRC	trans	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg18187862	chr3:45730750	SACM1L	0.46	6.7	0.35	9.15e-11	Primary sclerosing cholangitis;
CRC	cis	rs7209700	0.708	rs15908	chr17:45368337	A/C	cg08085267	chr17:45401833	C17orf57	0.48	7.03	0.36	1.16e-11	IgG glycosylation;
CRC	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg08795948	chr3:128337044	NA	0.36	6.28	0.33	1.04e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-7.12	-0.37	6.62e-12	Menarche (age at onset);
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18301423	chr5:131593218	PDLIM4	0.47	8.07	0.41	1.3e-14	Acylcarnitine levels;
CRC	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.51	-5.67	-0.3	3.18e-8	Lymphocyte percentage of white cells;
CRC	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg00042356	chr1:8021962	PARK7	-0.56	-6.32	-0.33	8.27e-10	Inflammatory bowel disease;
CRC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.42	-6.22	-0.32	1.53e-9	Aortic root size;
CRC	cis	rs4234798	1.000	rs4234798	chr4:7219933	G/T	cg18431297	chr4:7219810	SORCS2	-0.64	-11.62	-0.54	2.25e-26	Insulin-like growth factors;
CRC	cis	rs9469890	0.604	rs77587944	chr6:34503644	T/G	cg17674042	chr6:34482479	PACSIN1	-0.66	-7.76	-0.39	1.1e-13	Pubertal anthropometrics;Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01084379	chr5:179160712	MAML1	-0.41	-5.96	-0.31	6.51e-9	Myopia (pathological);
CRC	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg06470822	chr6:28175283	NA	0.71	6.67	0.34	1.11e-10	Depression;
CRC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12311346	chr5:56204834	C5orf35	-0.51	-7.97	-0.4	2.58e-14	Coronary artery disease;
CRC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg09655341	chr17:79618100	PDE6G	-0.36	-6.24	-0.33	1.31e-9	Eye color traits;
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.45	6.68	0.35	1.03e-10	Plateletcrit;
CRC	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14119001	chr9:139324193	INPP5E	-0.53	-7.55	-0.38	4.32e-13	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.95	-0.31	6.82e-9	Schizophrenia;
CRC	trans	rs17723576	0.649	rs6122799	chr20:48238612	A/G	cg18830952	chr12:132606769	EP400NL	0.52	6.12	0.32	2.7e-9	Urate levels in obese individuals;
CRC	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.82	10.35	0.5	6.51e-22	Diisocyanate-induced asthma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08732623	chr10:127408269	C10orf137	0.4	6.51	0.34	2.87e-10	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06666157	chr19:4791552	FEM1A	0.52	6.82	0.35	4.48e-11	Thyroid stimulating hormone;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.48	9.72	0.47	8.5e-20	Lung cancer;
CRC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.52	8.15	0.41	7.57e-15	Colorectal cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg26859392	chr3:10143019	FANCD2;C3orf24	0.39	6.11	0.32	2.88e-9	Interleukin-6 levels;
CRC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	10.01	0.48	9.03e-21	Ileal carcinoids;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17745251	chr10:21806139	C10orf140	0.41	5.98	0.31	5.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.51	7.16	0.37	5.33e-12	Longevity;Endometriosis;
CRC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.5	-0.5	1.94e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg15450734	chr14:103541957	NA	-0.42	-6.31	-0.33	9.21e-10	Daytime sleep phenotypes;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg03623178	chr6:28175578	NA	-0.94	-12.29	-0.56	7.72e-29	Depression;
CRC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.78	14.12	0.61	9.93e-36	Mean platelet volume;
CRC	cis	rs17767392	0.958	rs34454371	chr14:71881502	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.92e-11	Mitral valve prolapse;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07280629	chr16:30583784	ZNF688	0.45	6.07	0.32	3.5e-9	Anxiety disorder;
CRC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg13086574	chr8:135490821	ZFAT	-0.37	-6.51	-0.34	2.75e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01426831	chr19:12098817	NA	0.48	6.09	0.32	3.08e-9	Thyroid stimulating hormone;
CRC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.88	0.51	9.21e-24	Motion sickness;
CRC	cis	rs4073416	0.542	rs11158603	chr14:66072040	C/T	cg03016385	chr14:66212404	NA	-0.47	-6.35	-0.33	7.06e-10	N-glycan levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04309227	chr1:26561027	CCDC21	0.44	6.33	0.33	7.99e-10	Response to antipsychotic treatment;
CRC	cis	rs860295	0.702	rs11264380	chr1:155520144	T/C	cg02153340	chr1:155202674	NA	-0.5	-6.29	-0.33	9.99e-10	Body mass index;
CRC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.18	0.37	4.78e-12	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.84e-9	Life satisfaction;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg10396713	chr8:602097	NA	-0.59	-6.15	-0.32	2.2e-9	IgG glycosylation;
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.52	8.02	0.4	1.93e-14	Pancreatic cancer;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg17147758	chr8:6949321	NA	-0.52	-7.2	-0.37	4.24e-12	Blood pressure (smoking interaction);
CRC	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg25834613	chr7:1915315	MAD1L1	-0.45	-6.42	-0.33	4.64e-10	Bipolar disorder;
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.48	7.58	0.39	3.6e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg15147215	chr3:52552868	STAB1	0.47	7.62	0.39	2.8e-13	Electroencephalogram traits;
CRC	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg10631902	chr5:14652156	NA	-0.39	-6.58	-0.34	1.89e-10	Hip circumference;Waist circumference;
CRC	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg00645731	chr22:42541494	CYP2D7P1	-0.47	-7.0	-0.36	1.47e-11	Birth weight;
CRC	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg02733842	chr7:1102375	C7orf50	-0.49	-6.29	-0.33	1.02e-9	Bronchopulmonary dysplasia;
CRC	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg01843034	chr6:37503916	NA	-0.39	-7.12	-0.37	6.78e-12	Cognitive performance;
CRC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.56	8.75	0.43	1.15e-16	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.95	15.1	0.64	1.7e-39	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11032208	chr5:95997736	CAST	0.41	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg12516270	chr8:143859308	LYNX1	0.43	7.57	0.39	3.83e-13	Urinary tract infection frequency;
CRC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg10589385	chr1:150898437	SETDB1	-0.33	-6.88	-0.35	3.09e-11	Urate levels;
CRC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.16	-0.32	2.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09414045	chr1:110162465	AMPD2	-0.42	-6.28	-0.33	1.1e-9	Myopia (pathological);
CRC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg11407215	chr2:106810146	UXS1	0.42	6.27	0.33	1.15e-9	Crohn's disease;
CRC	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.78	-7.78	-0.39	9.41e-14	Obesity;Body mass index;
CRC	trans	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg00953403	chr17:74099816	EXOC7	0.5	7.63	0.39	2.48e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs9491140	0.539	rs12210199	chr6:124684045	C/A	cg05308643	chr6:124982296	NKAIN2	0.5	6.9	0.36	2.63e-11	Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26085966	chr14:64319812	SYNE2	-0.48	-7.71	-0.39	1.51e-13	Myopia (pathological);
CRC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg15848620	chr12:58087721	OS9	-0.58	-8.19	-0.41	5.85e-15	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.65	-9.81	-0.48	4.34e-20	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.47	6.59	0.34	1.71e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	8.68	0.43	1.88e-16	Ulcerative colitis;
CRC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.98	0.31	5.76e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.4	-0.38	1.14e-12	Colorectal cancer;
CRC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg09655341	chr17:79618100	PDE6G	-0.34	-5.84	-0.31	1.26e-8	Eye color traits;
CRC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	11.81	0.55	4.54e-27	Menopause (age at onset);
CRC	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.35	-6.03	-0.32	4.4e-9	IgG glycosylation;
CRC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.48	6.97	0.36	1.77e-11	Breast cancer;
CRC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.42	-5.88	-0.31	1e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg23743428	chr13:21893420	NA	-0.39	-5.91	-0.31	8.78e-9	White matter hyperintensity burden;
CRC	cis	rs713477	1.000	rs7142204	chr14:55908436	G/T	cg13175173	chr14:55914753	NA	0.52	9.99	0.48	1.07e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg27535305	chr1:53392650	SCP2	0.39	7.02	0.36	1.29e-11	Monocyte count;
CRC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.72	0.3	2.33e-8	Monocyte percentage of white cells;
CRC	trans	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg17903999	chr18:56338584	MALT1	0.44	7.16	0.37	5.3e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.63	-0.39	2.54e-13	Mood instability;
CRC	cis	rs9463078	0.605	rs9472411	chr6:44943183	T/C	cg25276700	chr6:44698697	NA	0.25	6.22	0.32	1.5e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.72	9.89	0.48	2.28e-20	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11915997	chr19:7745524	TRAPPC5	0.43	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14546261	chr12:7052696	C12orf57	0.46	6.54	0.34	2.32e-10	Response to antipsychotic treatment;
CRC	trans	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg10756647	chr7:56101905	PSPH	-0.78	-8.04	-0.41	1.65e-14	Diabetic kidney disease;
CRC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.12	-0.32	2.64e-9	Aortic root size;
CRC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.43	5.77e-16	Colorectal cancer;
CRC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.38	6.81	0.35	4.72e-11	Primary biliary cholangitis;
CRC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.79	-14.76	-0.63	3.31e-38	Prostate cancer;
CRC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.06	0.36	1.02e-11	Neuroticism;
CRC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.98	-0.31	5.84e-9	Life satisfaction;
CRC	cis	rs2384207	0.818	rs7955036	chr12:113715251	T/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.5	6.21	0.32	1.63e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.49	7.16	0.37	5.35e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.32	6.02	0.32	4.62e-9	Blood protein levels;
CRC	cis	rs6076065	0.644	rs1056394	chr20:23337422	G/A	cg11657817	chr20:23433608	CST11	0.47	7.08	0.36	8.79e-12	Facial morphology (factor 15, philtrum width);
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.22	0.32	1.51e-9	Prudent dietary pattern;
CRC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.59	-8.62	-0.43	2.92e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.24	0.37	3.2e-12	Diisocyanate-induced asthma;
CRC	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg05110241	chr16:68378359	PRMT7	-0.49	-5.66	-0.3	3.28e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.47	0.34	3.62e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.43	-6.05	-0.32	3.93e-9	Large artery stroke;
CRC	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.91	-12.19	-0.56	1.77e-28	Exhaled nitric oxide output;
CRC	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.44	-6.37	-0.33	6.55e-10	Macular telangiectasia type 2;
CRC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.71	12.31	0.56	6.75e-29	Longevity;
CRC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.4	5.78	0.3	1.71e-8	Cleft lip with or without cleft palate;
CRC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg20387954	chr3:183756860	HTR3D	0.46	7.81	0.4	7.91e-14	Anterior chamber depth;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.53	0.34	2.56e-10	Parkinson's disease;
CRC	cis	rs728616	0.867	rs1983775	chr10:81663575	G/A	cg11900509	chr10:81946545	ANXA11	-0.62	-6.31	-0.33	8.96e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.55	9.48	0.46	5.19e-19	Age of smoking initiation;
CRC	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.34	0.65	1.91e-40	Hypertriglyceridemia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16265078	chr11:85955426	EED	0.43	6.51	0.34	2.86e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.22	-0.32	1.52e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4423214	0.840	rs1790340	chr11:71182589	T/C	cg13043300	chr11:71146211	DHCR7	-0.46	-6.21	-0.32	1.64e-9	Vitamin D levels;
CRC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.81	-10.21	-0.49	1.9e-21	Body mass index;
CRC	cis	rs9648716	1.000	rs10232557	chr7:140452363	C/G	cg10747023	chr7:140774559	NA	0.45	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.45	5.67	0.3	3.1e-8	Aortic root size;
CRC	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.87	16.65	0.68	1.45e-45	Hip circumference;
CRC	cis	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg11619707	chr19:22235551	ZNF257	0.29	5.65	0.3	3.51e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CRC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.51	7.14	0.37	6.09e-12	Cognitive function;
CRC	cis	rs7703744	0.634	rs6884061	chr5:118683431	C/T	cg02283238	chr5:118691126	TNFAIP8	0.48	6.67	0.35	1.06e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg05562828	chr17:3906858	NA	0.65	11.87	0.55	2.78e-27	Type 2 diabetes;
CRC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.45	5.8	0.3	1.53e-8	Response to diuretic therapy;
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.04	0.32	4.16e-9	Prudent dietary pattern;
CRC	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg20936604	chr3:58311152	NA	-0.72	-7.17	-0.37	4.91e-12	Cholesterol, total;
CRC	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg25019722	chr6:37503610	NA	-0.36	-6.46	-0.34	3.8e-10	Cognitive performance;
CRC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg27661571	chr11:113659931	NA	-0.47	-6.05	-0.32	3.92e-9	Hip circumference adjusted for BMI;
CRC	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg21062780	chr6:887772	NA	0.47	7.59	0.39	3.41e-13	Aging;
CRC	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.07	-0.36	9.41e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.74	12.5	0.57	1.37e-29	Longevity;
CRC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg20203395	chr5:56204925	C5orf35	-0.42	-5.64	-0.3	3.57e-8	Coronary artery disease;
CRC	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.53	7.83	0.4	6.85e-14	Corneal astigmatism;
CRC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.58	0.34	1.84e-10	Lung cancer;
CRC	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg09659197	chr4:152720779	NA	-0.42	-8.96	-0.44	2.51e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.56	-9.01	-0.44	1.76e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.48	7.27	0.37	2.65e-12	Lung cancer;
CRC	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.96	-0.31	6.63e-9	Arsenic metabolism;
CRC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg24253500	chr15:84953950	NA	0.38	6.44	0.33	4.32e-10	Schizophrenia;
CRC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.62	-10.16	-0.49	2.92e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10911390	0.744	rs11802633	chr1:183647877	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Systemic lupus erythematosus;
CRC	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg08992911	chr2:238395768	MLPH	0.59	6.01	0.31	4.81e-9	Prostate cancer;
CRC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02725872	chr8:58115012	NA	-0.47	-8.48	-0.42	7.81e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg12564285	chr5:131593104	PDLIM4	0.38	7.13	0.37	6.38e-12	Blood metabolite levels;
CRC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.76	10.12	0.49	3.78e-21	Coronary artery disease;
CRC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.14	-0.32	2.33e-9	IgG glycosylation;
CRC	cis	rs282587	0.569	rs7982564	chr13:113398930	G/A	cg04656015	chr13:113407548	ATP11A	0.61	7.69	0.39	1.68e-13	Glycated hemoglobin levels;
CRC	trans	rs559356	0.519	rs554650	chr3:34840139	G/A	cg19071035	chr6:20404090	E2F3	0.46	6.2	0.32	1.64e-9	Cognitive function;
CRC	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg15131784	chr3:139108705	COPB2	0.39	5.69	0.3	2.79e-8	Obesity-related traits;
CRC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.39	5.62	0.3	3.99e-8	Educational attainment;
CRC	cis	rs6908034	0.769	rs6916589	chr6:19761363	T/G	cg02682789	chr6:19804855	NA	0.77	6.91	0.36	2.52e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg06632207	chr12:54070931	ATP5G2	0.46	7.8	0.4	8.19e-14	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04843900	chr20:16710618	SNRPB2	0.4	6.32	0.33	8.47e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.06	12.9	0.58	4.18e-31	Vitiligo;
CRC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	9.92e-18	Bladder cancer;
CRC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg23136738	chr11:925521	AP2A2	-0.51	-8.23	-0.41	4.51e-15	Alzheimer's disease (late onset);
CRC	cis	rs2072510	0.593	rs2660892	chr12:96420978	T/C	cg09636302	chr12:96389483	HAL	-0.51	-6.18	-0.32	1.91e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg08989290	chr16:615782	NHLRC4	0.48	9.29	0.46	2.13e-18	Height;
CRC	cis	rs9549328	0.699	rs2993345	chr13:113617086	C/T	cg08614441	chr13:113633676	MCF2L	0.4	7.12	0.37	6.75e-12	Systolic blood pressure;
CRC	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.43	6.95	0.36	1.94e-11	Sitting height ratio;
CRC	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.32e-19	Systemic lupus erythematosus;
CRC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg14847009	chr1:175162515	KIAA0040	-0.26	-5.83	-0.31	1.29e-8	Alcohol dependence;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	1.02	18.4	0.71	1.8e-52	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27554769	chr1:202896170	KLHL12	0.41	6.0	0.31	5.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.624	rs1972221	chr14:55785381	C/A	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.77	-0.3	1.87e-8	Protein biomarker;
CRC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg05585544	chr11:47624801	NA	-0.63	-11.46	-0.53	8.57e-26	Subjective well-being;
CRC	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.59	-6.64	-0.34	1.28e-10	Blood protein levels;
CRC	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg03315344	chr16:75512273	CHST6	-0.53	-6.17	-0.32	2.04e-9	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.79	13.11	0.59	6.84e-32	Coronary artery disease;
CRC	cis	rs7264396	0.887	rs11698935	chr20:34075015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.33	-0.33	8.12e-10	Total cholesterol levels;
CRC	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	6.83	0.35	4.2e-11	Breast cancer;
CRC	trans	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4731207	0.623	rs4506149	chr7:124626473	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.38	-0.33	6.15e-10	Cutaneous malignant melanoma;
CRC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg18612461	chr15:75251733	NA	0.48	7.26	0.37	2.88e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.51	-7.88	-0.4	4.8e-14	Cognitive ability (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26101466	chr14:64108700	WDR89	0.39	6.21	0.32	1.64e-9	Obesity-related traits;
CRC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg05234568	chr11:5960015	NA	-0.47	-6.04	-0.32	4.11e-9	DNA methylation (variation);
CRC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg14008862	chr17:28927542	LRRC37B2	0.5	6.08	0.32	3.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.62	-9.77	-0.47	5.93e-20	Systemic lupus erythematosus;
CRC	cis	rs11166629	1.000	rs2315838	chr8:135645968	C/T	cg27224718	chr8:135614730	ZFAT	0.51	7.53	0.38	5.02e-13	Smoking quantity;
CRC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.96	-0.31	6.54e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.55	-7.89	-0.4	4.65e-14	Response to temozolomide;
CRC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.28	14.93	0.64	7.56e-39	Diabetic kidney disease;
CRC	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.11	0.36	7.4e-12	Red blood cell count;
CRC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.48	7.12	0.37	6.87e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12431939	0.598	rs4268678	chr14:51736185	G/T	cg23942311	chr14:51606299	NA	0.46	6.36	0.33	6.65e-10	Cancer;
CRC	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.24	-0.37	3.17e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg13385794	chr1:248469461	NA	0.36	6.34	0.33	7.63e-10	Common traits (Other);
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg07617317	chr6:118971624	C6orf204	0.52	6.45	0.34	3.9e-10	Renal cell carcinoma;
CRC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.4e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg02158880	chr13:53174818	NA	-0.44	-6.31	-0.33	8.78e-10	Lewy body disease;
CRC	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.79	-0.68	4.09e-46	Hip circumference;
CRC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.85	0.31	1.19e-8	Diabetic retinopathy;
CRC	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg02089348	chr4:1724449	TMEM129;TACC3	-0.4	-5.64	-0.3	3.62e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs7538876	0.903	rs730153	chr1:17749504	A/G	cg07965774	chr1:17746286	RCC2	-0.34	-6.52	-0.34	2.7e-10	Basal cell carcinoma;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg10876282	chr6:28092338	ZSCAN16	0.46	5.97	0.31	6.27e-9	Parkinson's disease;
CRC	cis	rs7427021	0.537	rs7624003	chr3:163710060	T/C	cg24587349	chr3:163632090	NA	-0.36	-5.64	-0.3	3.65e-8	Bipolar disorder;
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.91	-0.36	2.58e-11	Bipolar disorder;
CRC	cis	rs6681460	0.966	rs7542924	chr1:67143055	C/T	cg02459107	chr1:67143332	SGIP1	0.44	7.69	0.39	1.75e-13	Presence of antiphospholipid antibodies;
CRC	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.68	10.46	0.5	2.72e-22	Corneal astigmatism;
CRC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.69	-8.99	-0.44	1.96e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg08075719	chr14:103021372	NA	0.65	7.55	0.38	4.22e-13	Platelet count;
CRC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.54	8.11	0.41	1.04e-14	Breast cancer;
CRC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.5	-6.66	-0.34	1.14e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs800160	0.844	rs2651784	chr11:2347549	C/T	cg09785033	chr11:2336066	TSPAN32	-0.52	-5.92	-0.31	8.14e-9	Bacteremia;
CRC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.59	9.43	0.46	7.83e-19	Vitiligo;
CRC	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	cis	rs13082711	0.520	rs2643825	chr3:27562613	A/G	cg02860705	chr3:27208620	NA	0.41	6.08	0.32	3.36e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg15382696	chr6:118971807	C6orf204	0.48	6.28	0.33	1.06e-9	Diastolic blood pressure;
CRC	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg24562669	chr7:97807699	LMTK2	0.44	7.37	0.38	1.35e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-7.88	-0.4	4.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg23590916	chr17:43697445	MGC57346	0.71	6.93	0.36	2.25e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2403907	0.758	rs7275438	chr21:16568328	C/T	cg00407105	chr4:90231041	NA	-0.4	-6.1	-0.32	2.92e-9	Breast cancer;
CRC	cis	rs6973256	0.897	rs763644	chr7:133343349	G/C	cg10665199	chr7:133106180	EXOC4	-0.37	-5.75	-0.3	2.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12286929	0.839	rs11215375	chr11:115014002	C/T	cg04055981	chr11:115044050	NA	0.36	5.87	0.31	1.06e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg13844804	chr7:814759	HEATR2	0.63	8.14	0.41	8.33e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02825527	chr7:2087843	MAD1L1	-0.45	-5.72	-0.3	2.4e-8	Bipolar disorder;
CRC	cis	rs6741819	0.740	rs771266	chr2:7130931	A/G	cg27144453	chr2:7172511	RNF144A	-0.41	-6.07	-0.32	3.44e-9	Response to antipsychotic treatment;
CRC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.39	7.3	0.37	2.15e-12	Lung cancer;
CRC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.49	5.75	0.3	2.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg18827107	chr12:86230957	RASSF9	0.38	5.93	0.31	7.83e-9	Major depressive disorder;
CRC	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.74	-10.03	-0.48	7.62e-21	Coronary artery disease;
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg21784768	chr11:537496	LRRC56	-0.7	-6.6	-0.34	1.65e-10	Body mass index;
CRC	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-6.08	-0.32	3.38e-9	Endometrial cancer;
CRC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.17	-0.45	5.48e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg11204139	chr17:3907470	NA	0.74	12.35	0.56	4.69e-29	Type 2 diabetes;
CRC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg25344623	chr2:136566232	LCT	0.33	5.98	0.31	5.9e-9	Mosquito bite size;
CRC	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg15145174	chr5:6755386	POLS	-0.46	-6.78	-0.35	5.7e-11	Menopause (age at onset);
CRC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.59	-8.68	-0.43	1.84e-16	Height;
CRC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.65	10.94	0.52	5.74e-24	Resting heart rate;
CRC	cis	rs10274279	1.000	rs55941863	chr7:157372989	C/G	cg26886268	chr7:157387156	PTPRN2	-0.46	-5.62	-0.3	4.07e-8	Myopia (pathological);
CRC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg04657146	chr19:12876947	HOOK2	-0.46	-6.13	-0.32	2.57e-9	Bipolar disorder;
CRC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.46	-6.84	-0.35	3.89e-11	Tonsillectomy;
CRC	cis	rs12523822	0.957	rs11970674	chr6:154955611	T/C	cg20019720	chr6:154832845	CNKSR3	0.26	5.61	0.3	4.23e-8	Diabetic kidney disease;
CRC	trans	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg18187862	chr3:45730750	SACM1L	-0.45	-5.97	-0.31	6.05e-9	Primary sclerosing cholangitis;
CRC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.55	6.14	0.32	2.31e-9	Vitiligo;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg16699849	chr7:98923489	ARPC1A	-0.68	-6.2	-0.32	1.66e-9	Cognitive function;
CRC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.73	11.78	0.54	6.03e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13144136	0.687	rs13119277	chr4:10658129	C/T	cg10242279	chr4:10666415	CLNK	-0.38	-6.5	-0.34	2.93e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.53	-8.19	-0.41	5.97e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	9.83	0.48	3.75e-20	Systolic blood pressure;
CRC	cis	rs34638657	0.518	rs4889467	chr16:82169385	C/T	cg07918374	chr16:82182319	MPHOSPH6	0.41	5.91	0.31	8.39e-9	Lung adenocarcinoma;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg24560729	chr4:1342394	KIAA1530	0.35	6.42	0.33	4.64e-10	Obesity-related traits;
CRC	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg16141378	chr3:129829833	LOC729375	-0.46	-6.61	-0.34	1.58e-10	Neuroticism;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10819733	chr22:24237672	NA	-0.37	-6.31	-0.33	8.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.67	-6.66	-0.34	1.16e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg19052272	chr2:3704530	ALLC	-0.5	-6.97	-0.36	1.73e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.33e-11	Menopause (age at onset);
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23708337	chr7:1209742	NA	0.39	5.89	0.31	9.78e-9	Longevity;Endometriosis;
CRC	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg22182287	chr2:3452347	TTC15	0.38	6.06	0.32	3.71e-9	Obesity-related traits;
CRC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-11.5	-0.54	6.09e-26	Coronary artery disease;
CRC	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.45	-7.92	-0.4	3.72e-14	Common traits (Other);
CRC	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg21854759	chr1:92012499	NA	-0.51	-6.51	-0.34	2.82e-10	Eosinophil percentage of white cells;
CRC	trans	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.73	-0.39	1.28e-13	HDL cholesterol;
CRC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg04969067	chr8:143858791	LYNX1	-0.38	-6.39	-0.33	5.78e-10	Urinary tract infection frequency;
CRC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.75	10.82	0.51	1.46e-23	Reticulocyte fraction of red cells;
CRC	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg06172871	chr16:72088244	HP	0.44	6.45	0.33	4.08e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.79	-0.47	5.04e-20	Primary sclerosing cholangitis;
CRC	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.46	7.42	0.38	9.83e-13	Sitting height ratio;
CRC	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.42	0.33	4.79e-10	Hemoglobin concentration;
CRC	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg06484146	chr7:12443880	VWDE	-0.56	-7.6	-0.39	3.15e-13	Coronary artery disease;
CRC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.82	16.77	0.68	4.92e-46	Ulcerative colitis;
CRC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.68	8.94	0.44	2.78e-17	Multiple sclerosis;
CRC	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.76	13.58	0.6	1.2e-33	Oral cavity cancer;
CRC	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.12	-0.32	2.62e-9	IgE levels;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	trans	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg07817883	chr1:32538562	TMEM39B	-0.62	-7.75	-0.39	1.12e-13	Monocyte percentage of white cells;
CRC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.53	0.34	2.46e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.51	7.78	0.39	9.48e-14	Corneal astigmatism;
CRC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg18827107	chr12:86230957	RASSF9	0.44	7.29	0.37	2.3e-12	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06527052	chr1:109633875	TMEM167B	0.42	6.39	0.33	5.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg23136738	chr11:925521	AP2A2	-0.43	-7.27	-0.37	2.66e-12	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.46	5.78	0.3	1.7e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.64	7.54	0.38	4.52e-13	Menarche (age at onset);
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.56	7.21	0.37	3.96e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.31	0.37	2.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg00343986	chr7:65444356	GUSB	0.44	6.64	0.34	1.28e-10	Aortic root size;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.54	-5.67	-0.3	3.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.34	6.02	0.31	4.75e-9	Cardiovascular disease risk factors;
CRC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.34	6.04	0.32	4.07e-9	Monobrow;
CRC	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg13919466	chr1:32135498	COL16A1	-0.31	-5.9	-0.31	8.97e-9	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.69	8.66	0.43	2.21e-16	Hip circumference adjusted for BMI;
CRC	trans	rs7757969	0.500	rs10440852	chr6:112157020	G/C	cg08211895	chr2:48828358	STON1-GTF2A1L	0.31	6.07	0.32	3.57e-9	Schizophrenia;
CRC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg22834771	chr12:69754056	YEATS4	-0.4	-5.75	-0.3	2.05e-8	Blood protein levels;
CRC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.27	0.41	3.37e-15	Lung cancer;
CRC	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-12.01	-0.55	8.16e-28	Exhaled nitric oxide output;
CRC	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.45	-0.38	8.36e-13	Recombination measurement;
CRC	cis	rs17067123	0.614	rs6857116	chr4:180062542	G/A	cg26610307	chr4:180072759	NA	-0.52	-5.93	-0.31	7.73e-9	Response to hepatitis C treatment;
CRC	cis	rs3131513	0.965	rs7513516	chr1:25193009	C/T	cg22509179	chr1:25234806	RUNX3	-0.42	-6.46	-0.34	3.72e-10	Alcohol dependence;
CRC	cis	rs17401966	0.577	rs1556915	chr1:10242654	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-7.37	-0.38	1.4e-12	Hepatocellular carcinoma;
CRC	cis	rs8105895	0.935	rs10407173	chr19:22246663	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.5	6.86	0.35	3.52e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg17545662	chr6:170176663	C6orf70	0.53	5.86	0.31	1.12e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg20487152	chr13:99095054	FARP1	0.36	5.93	0.31	7.65e-9	Longevity;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg02683197	chr6:28174875	NA	0.88	10.83	0.51	1.42e-23	Depression;
CRC	cis	rs2949837	0.504	rs2342396	chr7:45968087	C/G	cg10677697	chr7:45961126	IGFBP3	0.33	5.89	0.31	9.31e-9	Sitting height ratio;
CRC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg03037974	chr15:76606532	NA	0.6	10.09	0.49	4.85e-21	Blood metabolite levels;
CRC	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.42	6.05	0.32	3.97e-9	Asthma;
CRC	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg11900509	chr10:81946545	ANXA11	-0.71	-7.22	-0.37	3.73e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg09264619	chr17:80180166	NA	0.36	6.07	0.32	3.45e-9	Life satisfaction;
CRC	cis	rs4499344	0.604	rs259287	chr19:33164859	C/T	cg08127369	chr19:33164662	ANKRD27	0.39	6.01	0.31	5.02e-9	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12900929	chr12:108154862	PRDM4	0.36	6.77	0.35	5.89e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	cis	rs17021463	0.643	rs6841656	chr4:95300532	A/G	cg11021082	chr4:95130006	SMARCAD1	0.44	6.42	0.33	4.72e-10	Testicular germ cell tumor;
CRC	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.65	10.83	0.51	1.4e-23	Subjective well-being (multi-trait analysis);
CRC	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg05527609	chr1:210001259	C1orf107	0.57	6.23	0.32	1.43e-9	Red blood cell count;
CRC	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-8.33	-0.42	2.2e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09251771	chr6:10695336	C6orf52;PAK1IP1	0.39	5.96	0.31	6.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.52	0.43	5.93e-16	Parkinson's disease;
CRC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.61	8.3	0.42	2.82e-15	Schizophrenia;
CRC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.88	8.82	0.44	6.71e-17	Plateletcrit;
CRC	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.59	9.39	0.46	1.04e-18	Itch intensity from mosquito bite;
CRC	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg21251018	chr6:28226885	NKAPL	0.4	5.99	0.31	5.41e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-0.99	-11.99	-0.55	1.03e-27	Type 2 diabetes nephropathy;
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00166722	chr3:10149974	C3orf24	0.64	7.58	0.39	3.65e-13	Alzheimer's disease;
CRC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.96e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg04132472	chr17:19861366	AKAP10	0.43	6.55	0.34	2.19e-10	Schizophrenia;
CRC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.65	-10.0	-0.48	9.8e-21	Menarche (age at onset);
CRC	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg03929089	chr4:120376271	NA	-0.68	-7.26	-0.37	2.73e-12	Axial length;
CRC	cis	rs7605827	0.538	rs62120660	chr2:15659613	T/C	cg19274914	chr2:15703543	NA	0.39	5.86	0.31	1.13e-8	Educational attainment (years of education);
CRC	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	1.11	12.99	0.58	2.06e-31	Obesity-related traits;
CRC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-5.96	-0.31	6.64e-9	Menarche (age at onset);
CRC	cis	rs4664293	0.867	rs6432557	chr2:160592210	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg16589663	chr20:23618590	CST3	0.53	6.37	0.33	6.19e-10	Chronic kidney disease;
CRC	cis	rs12745968	0.620	rs7535490	chr1:93061849	C/T	cg17283838	chr1:93427260	FAM69A	-0.48	-6.57	-0.34	1.97e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4731207	0.671	rs4731221	chr7:124481403	T/A	cg23710748	chr7:124431027	NA	0.38	6.1	0.32	2.96e-9	Cutaneous malignant melanoma;
CRC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.55	10.17	0.49	2.62e-21	HDL cholesterol levels;
CRC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.66	7.3	0.37	2.18e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.38	-5.69	-0.3	2.85e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg27068330	chr11:65405492	SIPA1	-0.47	-6.57	-0.34	2.02e-10	Breast cancer;
CRC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.13	0.32	2.58e-9	Aortic root size;
CRC	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs17162190	0.698	rs12094989	chr1:26848386	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.42	-5.89	-0.31	9.37e-9	Mean corpuscular volume;
CRC	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.7	7.63	0.39	2.58e-13	Breast cancer;
CRC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.53	-6.06	-0.32	3.64e-9	Vitiligo;
CRC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg06204229	chr3:52865917	ITIH4	0.5	5.74	0.3	2.19e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.95	0.36	1.96e-11	Bone mineral density (spine);
CRC	cis	rs4664293	0.551	rs11898293	chr2:160552593	T/C	cg08347373	chr2:160653686	CD302	0.39	6.52	0.34	2.6200000000000003e-10	Monocyte percentage of white cells;
CRC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.05	0.32	3.88e-9	Height;
CRC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.0	0.55	8.83e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311676	0.632	rs56033718	chr3:58446398	A/G	cg06643156	chr3:58380774	PXK	0.43	6.66	0.34	1.16e-10	Systemic lupus erythematosus;
CRC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg18761221	chr20:60518478	NA	0.44	7.07	0.36	9.54e-12	Body mass index;
CRC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	5.65	0.3	3.52e-8	Protein C levels;
CRC	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg13385794	chr1:248469461	NA	0.41	7.06	0.36	9.96e-12	Common traits (Other);
CRC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg11707556	chr5:10655725	ANKRD33B	0.37	6.26	0.33	1.21e-9	Coronary artery disease;
CRC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg17652424	chr22:38574118	PLA2G6	0.2	5.78	0.3	1.71e-8	Cutaneous nevi;
CRC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg02560186	chr11:3602584	NA	-0.62	-9.33	-0.46	1.65e-18	Blood pressure (smoking interaction);
CRC	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-8.25	-0.41	3.85e-15	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.73	0.35	7.61e-11	Diastolic blood pressure;
CRC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.6	8.13	0.41	8.81e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg06363034	chr20:62225388	GMEB2	-0.44	-6.56	-0.34	2.15e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs6840360	0.642	rs2709828	chr4:152355268	C/T	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.38	-0.5	4.9e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.56	8.25	0.41	3.78e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.55e-12	Diisocyanate-induced asthma;
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg01874867	chr7:94954059	PON1	0.41	5.93	0.31	7.56e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.73	-8.91	-0.44	3.53e-17	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg27588902	chr6:42928151	GNMT	0.38	5.74	0.3	2.11e-8	Blood protein levels;
CRC	cis	rs77633900	0.772	rs157778	chr15:76759444	G/C	cg21673338	chr15:77095150	SCAPER	-0.67	-6.17	-0.32	2e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.43	-6.11	-0.32	2.84e-9	Aortic root size;
CRC	trans	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg26043149	chr18:55253948	FECH	-0.49	-7.52	-0.38	5.26e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.73	-10.01	-0.48	8.9e-21	Height;
CRC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.89	-10.46	-0.5	2.76e-22	IgG glycosylation;
CRC	cis	rs4743820	0.503	rs10820834	chr9:93917440	C/T	cg14446406	chr9:93919335	NA	-0.46	-7.89	-0.4	4.41e-14	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs12541635	0.899	rs1429676	chr8:107065790	G/A	cg10147462	chr8:107024639	NA	-0.42	-7.13	-0.37	6.54e-12	Age of smoking initiation;
CRC	cis	rs2276314	0.553	rs1789501	chr18:33617060	T/A	cg05985134	chr18:33552581	C18orf21	-0.39	-6.03	-0.32	4.38e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.52	8.37	0.42	1.63e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.65	9.28	0.46	2.32e-18	Lung cancer;
CRC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-7.09	-0.36	8.28e-12	Total body bone mineral density;
CRC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg27572855	chr1:25598939	RHD	0.36	6.46	0.34	3.79e-10	Erythrocyte sedimentation rate;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg15845792	chr6:28175446	NA	1.04	13.81	0.61	1.6e-34	Depression;
CRC	cis	rs4925540	0.962	rs6689229	chr1:247241636	C/T	cg22502715	chr1:247171572	ZNF695	0.43	5.68	0.3	3.04e-8	Response to taxane treatment (docetaxel);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg21961583	chr2:170684455	UBR3	-0.39	-6.0	-0.31	5.34e-9	Aortic root size;
CRC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	11.04	0.52	2.47e-24	Mean corpuscular hemoglobin;
CRC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.59	-10.21	-0.49	1.99e-21	Iron status biomarkers;
CRC	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.26	-0.33	1.18e-9	Systemic lupus erythematosus;
CRC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.67	9.42	0.46	8.41e-19	Multiple sclerosis;
CRC	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg09654669	chr8:57350985	NA	-0.4	-5.68	-0.3	2.99e-8	Obesity-related traits;
CRC	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg14515779	chr1:101123966	NA	0.4	7.57	0.38	3.91e-13	Monocyte count;
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.59	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs995000	0.931	rs1168013	chr1:62996838	C/G	cg19896129	chr1:63156450	NA	0.41	6.44	0.33	4.12e-10	Triglyceride levels;
CRC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-12.01	-0.55	8.36e-28	Electrocardiographic conduction measures;
CRC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg21153622	chr11:89784906	NA	-0.38	-6.05	-0.32	3.83e-9	Height;
CRC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.48	8.0	0.4	2.2e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.55	9.19	0.45	4.48e-18	Systemic lupus erythematosus;
CRC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.34	0.38	1.68e-12	Aortic root size;
CRC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg15269541	chr15:43626905	ADAL	-0.49	-5.63	-0.3	3.86e-8	Lung cancer in ever smokers;
CRC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.09	0.32	3.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.68	-0.3	2.99e-8	Ulcerative colitis;
CRC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	12.79	0.58	1.12e-30	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg13047869	chr3:10149882	C3orf24	0.51	7.1	0.36	7.76e-12	Alzheimer's disease;
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.28	-0.33	1.07e-9	Lymphocyte counts;
CRC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.91e-9	Diabetic kidney disease;
CRC	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg17133734	chr15:86042851	AKAP13	0.42	6.76	0.35	6.41e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19587779	chr20:34638023	LOC647979	0.4	6.55	0.34	2.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25517755	chr10:38738941	LOC399744	-0.43	-6.29	-0.33	1e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg13206674	chr6:150067644	NUP43	0.48	6.95	0.36	1.93e-11	Testicular germ cell tumor;
CRC	cis	rs4731207	0.596	rs11761669	chr7:124586301	C/T	cg23710748	chr7:124431027	NA	0.38	6.09	0.32	3.19e-9	Cutaneous malignant melanoma;
CRC	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.34	-0.42	2.13e-15	QRS duration;
CRC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.64	8.26	0.41	3.72e-15	Dilated cardiomyopathy;
CRC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg01849466	chr14:104193079	ZFYVE21	0.42	6.41	0.33	4.95e-10	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18909525	chr9:132403873	ASB6	0.47	6.25	0.33	1.24e-9	Thyroid stimulating hormone;
CRC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg08975724	chr8:8085496	FLJ10661	0.4	6.05	0.32	4.04e-9	Neuroticism;
CRC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg16342193	chr10:102329863	NA	-0.35	-5.96	-0.31	6.56e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	trans	rs1265507	0.599	rs2077196	chr12:114869757	G/T	cg11700868	chr17:38521232	GJD3	0.42	5.99	0.31	5.5e-9	Percent mammographic density;
CRC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.59	0.43	3.61e-16	Arsenic metabolism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17841529	chr12:76953712	OSBPL8	0.43	6.01	0.31	4.85e-9	Response to antipsychotic treatment;
CRC	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg08632701	chr21:37451849	NA	-0.45	-7.11	-0.36	7.42e-12	Mitral valve prolapse;
CRC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.65	7.01	0.36	1.36e-11	Axial length;
CRC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-10.65	-0.51	5.71e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg22535103	chr8:58192502	C8orf71	-0.55	-6.85	-0.35	3.55e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg27083787	chr2:113543245	IL1A	0.44	6.35	0.33	7.26e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg02023728	chr11:77925099	USP35	-0.36	-6.16	-0.32	2.16e-9	Alzheimer's disease (survival time);
CRC	cis	rs4731207	0.536	rs10254199	chr7:124655116	C/T	cg23710748	chr7:124431027	NA	-0.43	-6.87	-0.35	3.19e-11	Cutaneous malignant melanoma;
CRC	cis	rs2013441	1.000	rs2703799	chr17:20085768	G/T	cg13482628	chr17:19912719	NA	-0.39	-5.96	-0.31	6.45e-9	Obesity-related traits;
CRC	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.69	-7.99	-0.4	2.35e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.65	-10.6	-0.5	8.65e-23	Breast cancer;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg06470822	chr6:28175283	NA	0.83	11.06	0.52	2.15e-24	Parkinson's disease;
CRC	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg05139728	chr16:28306816	SBK1	-0.34	-5.79	-0.3	1.62e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.49	-0.34	3.24e-10	Breast cancer;
CRC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.47	6.09	0.32	3.11e-9	Systemic lupus erythematosus;
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg03623178	chr6:28175578	NA	0.74	7.82	0.4	7.43e-14	Depression;
CRC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg23071808	chr14:103021642	NA	-0.64	-7.26	-0.37	2.86e-12	Platelet count;
CRC	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg09654669	chr8:57350985	NA	-0.44	-5.86	-0.31	1.12e-8	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.32	6.36	0.33	6.8e-10	Lung cancer;
CRC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.37	-5.67	-0.3	3.17e-8	Height;
CRC	cis	rs73206853	0.534	rs7131996	chr12:111073276	C/A	cg12870014	chr12:110450643	ANKRD13A	0.76	9.35	0.46	1.35e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05398773	chr8:71581521	XKR9;LACTB2	0.38	6.43	0.33	4.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.71	-12.68	-0.57	2.77e-30	Asthma;
CRC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg03233332	chr7:66118400	NA	0.45	6.18	0.32	1.93e-9	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03771385	chr2:43454876	ZFP36L2;LOC100129726	0.38	6.1	0.32	2.98e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.64	10.59	0.5	9.75e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs12620999	1.000	rs13004252	chr2:238035408	C/A	cg23555395	chr2:238036564	NA	-0.62	-8.63	-0.43	2.61e-16	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.46	-7.13	-0.37	6.49e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24761882	chr9:96214934	FAM120AOS;FAM120A	0.43	5.99	0.31	5.63e-9	Response to antipsychotic treatment;
CRC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg09165964	chr15:75287851	SCAMP5	0.57	9.15	0.45	5.96e-18	Breast cancer;
CRC	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.51	7.48	0.38	6.73e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-7.67	-0.39	1.94e-13	Vitiligo;
CRC	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.62	-8.9	-0.44	3.69e-17	Waist circumference;Body mass index;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg04053776	chr11:6947353	ZNF215	0.51	6.84	0.35	3.86e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.49	-7.29	-0.37	2.28e-12	Colorectal cancer;
CRC	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.44	-8.06	-0.41	1.38e-14	Breast cancer;
CRC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.54	7.57	0.38	3.89e-13	Mean platelet volume;
CRC	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-14.75	-0.63	3.75e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2249694	0.520	rs11815623	chr10:135329133	A/G	cg20169779	chr10:135381914	SYCE1	-0.55	-7.68	-0.39	1.85e-13	Obesity-related traits;
CRC	cis	rs780094	0.500	rs7577311	chr2:27793921	G/T	cg27432699	chr2:27873401	GPN1	0.45	5.84	0.31	1.22e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.76	-12.04	-0.55	6.44e-28	Hypospadias;
CRC	cis	rs6922632	0.867	rs62400306	chr6:24111980	A/C	cg26194775	chr6:24126114	NRSN1	-0.78	-7.93	-0.4	3.38e-14	Information processing speed;
CRC	cis	rs10982256	0.875	rs11787667	chr9:117242845	C/T	cg13636371	chr9:117264095	DFNB31	0.33	6.09	0.32	3.19e-9	Bipolar disorder;
CRC	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg14593290	chr7:50529359	DDC	0.64	8.51	0.42	6.2e-16	Malaria;
CRC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.85	-13.17	-0.59	4.08e-32	Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01255913	chr5:176074484	TSPAN17	0.37	5.99	0.31	5.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.53	7.96	0.4	2.76e-14	Lymphocyte counts;
CRC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg04800585	chr6:26043546	HIST1H2BB	-0.41	-5.9	-0.31	9.1e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg18064655	chr19:3985414	EEF2	0.41	5.99	0.31	5.43e-9	Barrett's esophagus  or Esophageal adenocarcinoma;
CRC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.62	-0.34	1.42e-10	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10387458	chr1:93645817	TMED5;CCDC18	0.41	6.59	0.34	1.72e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.35	1.01e-10	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01788360	chr4:56212215	SRD5A3	0.42	6.3	0.33	9.63e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06112835	chr11:68658793	MRPL21	0.45	6.91	0.36	2.46e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-7.02	-0.36	1.26e-11	Metabolite levels;
CRC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg25834613	chr7:1915315	MAD1L1	-0.47	-6.81	-0.35	4.71e-11	Bipolar disorder;
CRC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.44	0.46	6.83e-19	Personality dimensions;
CRC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	9.07	0.45	1.14e-17	Monocyte percentage of white cells;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg08546805	chr12:8549446	NA	-0.43	-6.55	-0.34	2.26e-10	Blood pressure (smoking interaction);
CRC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg10802521	chr3:52805072	NEK4	0.44	6.08	0.32	3.29e-9	Schizophrenia;
CRC	cis	rs449789	0.857	rs592212	chr6:159711083	G/C	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs7605827	0.930	rs7575290	chr2:15597322	C/T	cg19274914	chr2:15703543	NA	0.39	6.03	0.32	4.51e-9	Educational attainment (years of education);
CRC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg21194808	chr1:2205498	SKI	0.37	5.63	0.3	3.83e-8	Height;
CRC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00933542	chr6:150070202	PCMT1	-0.32	-6.37	-0.33	6.48e-10	Lung cancer;
CRC	cis	rs6604026	0.643	rs1360366	chr1:93330987	A/C	cg17283838	chr1:93427260	FAM69A	-0.48	-6.65	-0.34	1.19e-10	Multiple sclerosis;
CRC	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs1274963	0.601	rs784503	chr3:39197731	A/G	cg02254461	chr3:39195904	CSRNP1	-0.54	-7.84	-0.4	6.41e-14	Chronic lymphocytic leukemia;
CRC	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.69	-11.16	-0.52	1.01e-24	Idiopathic membranous nephropathy;
CRC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.61	-9.87	-0.48	2.67e-20	Monocyte count;
CRC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg16476235	chr8:21771668	DOK2	0.37	6.25	0.33	1.28e-9	Mean corpuscular volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19777900	chr20:56284917	PMEPA1	0.46	6.54	0.34	2.34e-10	Anxiety disorder;
CRC	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg05283184	chr6:79620031	NA	-0.45	-6.5	-0.34	2.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.63	9.42	0.46	8.07e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6957923	0.818	rs12538407	chr7:23521316	A/G	cg20265043	chr7:23510089	IGF2BP3	0.37	5.67	0.3	3.05e-8	Height;
CRC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.7	9.47	0.46	5.81e-19	Cognitive function;
CRC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14895029	chr7:2775587	GNA12	-0.44	-6.52	-0.34	2.67e-10	Height;
CRC	trans	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.47	-0.38	7.26e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg23136738	chr11:925521	AP2A2	-0.51	-8.23	-0.41	4.51e-15	Alzheimer's disease (late onset);
CRC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg01448562	chr3:133502909	NA	0.4	6.69	0.35	9.78e-11	Iron status biomarkers;
CRC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	5.92	0.31	8.07e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3790645	1.000	rs3790645	chr1:26884864	G/A	cg23229016	chr1:26872525	RPS6KA1	0.3	7.14	0.37	6.2e-12	Glucose homeostasis traits;
CRC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.63	10.08	0.49	5.32e-21	Monocyte count;
CRC	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.61	8.25	0.41	3.75e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6681460	0.934	rs4655631	chr1:67054907	C/G	cg02459107	chr1:67143332	SGIP1	0.49	8.49	0.42	7.32e-16	Presence of antiphospholipid antibodies;
CRC	cis	rs7274811	0.901	rs17404047	chr20:32305781	A/T	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.5	-6.2	-0.32	1.65e-9	Height;
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.26	0.41	3.61e-15	Life satisfaction;
CRC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.97	-0.31	6.13e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.64	10.29	0.49	1.01e-21	Height;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs7527798	0.592	rs1323720	chr1:207823161	T/C	cg21110645	chr1:207815933	NA	-0.4	-6.36	-0.33	6.93e-10	Erythrocyte sedimentation rate;
CRC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg14541582	chr5:601475	NA	-0.37	-7.38	-0.38	1.27e-12	Obesity-related traits;
CRC	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.02	0.36	1.26e-11	Body mass index;
CRC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.58	-9.17	-0.45	5.11e-18	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05134775	chr10:98273510	TLL2	0.41	6.91	0.36	2.54e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.71	9.43	0.46	7.56e-19	Bladder cancer;
CRC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	15.49	0.65	5.13e-41	Smoking behavior;
CRC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.28	6.5	0.34	3.03e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg03013999	chr17:37608204	MED1	-0.48	-7.42	-0.38	1.02e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11622475	1.000	rs56060232	chr14:104386165	G/C	cg20488157	chr14:104394430	TDRD9	0.69	9.81	0.48	4.28e-20	Bipolar disorder;
CRC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.78	12.42	0.56	2.62e-29	Breast cancer;
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.09	-0.32	3.23e-9	Total body bone mineral density;
CRC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.22e-22	Corneal astigmatism;
CRC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.48	-0.34	3.43e-10	IgG glycosylation;
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg22687807	chr8:143858763	LYNX1	0.51	9.15	0.45	6.04e-18	Urinary tract infection frequency;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg12728517	chr11:6947552	ZNF215	0.55	5.81	0.31	1.48e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg02683197	chr6:28174875	NA	0.68	7.33	0.37	1.81e-12	Parkinson's disease;
CRC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg21153622	chr11:89784906	NA	-0.37	-5.99	-0.31	5.61e-9	Height;
CRC	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	1.05	11.5	0.54	5.91e-26	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg25886479	chr11:50257625	LOC441601	0.34	5.6	0.3	4.46e-8	Coronary artery disease;
CRC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	8.79	0.44	8.64e-17	Lymphocyte counts;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-14.4	-0.62	8.79e-37	Systemic lupus erythematosus;
CRC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg17321639	chr7:2759063	NA	-0.38	-5.68	-0.3	3.04e-8	Height;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-6.27	-0.33	1.13e-9	Total body bone mineral density;
CRC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.62	10.15	0.49	3.01e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.62	-7.69	-0.39	1.68e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.84	12.78	0.58	1.18e-30	Menarche (age at onset);
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg12564285	chr5:131593104	PDLIM4	0.46	8.95	0.44	2.63e-17	Breast cancer;
CRC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.61	9.04	0.45	1.33e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.64	11.72	0.54	9.78e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.95	15.13	0.64	1.25e-39	Primary sclerosing cholangitis;
CRC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.5	7.71	0.39	1.49e-13	Corneal astigmatism;
CRC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-5.71	-0.3	2.5e-8	Menarche (age at onset);
CRC	cis	rs4964805	1.000	rs11111789	chr12:104191540	G/C	cg02344784	chr12:104178138	NT5DC3	0.56	8.45	0.42	9.23e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.65	-0.34	1.23e-10	Electroencephalogram traits;
CRC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.62e-17	Hip circumference adjusted for BMI;
CRC	cis	rs1539053	0.966	rs1524707	chr1:58102540	A/G	cg20292791	chr1:58089357	DAB1	0.34	6.03	0.32	4.35e-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs10512697	0.541	rs62336074	chr5:3513171	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	1.0	18.38	0.71	2.11e-52	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs6585424	1.000	rs6585454	chr10:81940701	C/T	cg11900509	chr10:81946545	ANXA11	0.73	9.04	0.45	1.38e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.67	-0.35	1.08e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg09873164	chr1:152488093	CRCT1	0.39	6.53	0.34	2.51e-10	Hair morphology;
CRC	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.57	9.74	0.47	7.35e-20	Dupuytren's disease;
CRC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.37	-5.73	-0.3	2.27e-8	Testicular germ cell tumor;
CRC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-6.18	-0.32	1.91e-9	Schizophrenia;
CRC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.84	0.51	1.28e-23	Prudent dietary pattern;
CRC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.64	-0.47	1.53e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9648716	1.000	rs10281173	chr7:140579876	A/G	cg10747023	chr7:140774559	NA	-0.43	-5.83	-0.31	1.31e-8	Type 2 diabetes;
CRC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	14.63	0.63	1.06e-37	Smoking behavior;
CRC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.16	-15.24	-0.64	4.8e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.02	0.58	1.58e-31	Platelet count;
CRC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.66e-16	Lymphocyte counts;
CRC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg03037974	chr15:76606532	NA	-0.55	-8.22	-0.41	4.68e-15	Blood metabolite levels;
CRC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.43	-6.09	-0.32	3.11e-9	Aortic root size;
CRC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.66	0.39	2.04e-13	Cognitive ability;
CRC	cis	rs4664293	0.625	rs7595852	chr2:160540167	G/C	cg08347373	chr2:160653686	CD302	0.39	6.53	0.34	2.55e-10	Monocyte percentage of white cells;
CRC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-10.28	-0.49	1.1e-21	Breast cancer;
CRC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.46	-0.38	7.88e-13	Type 2 diabetes;
CRC	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg16724585	chr3:197361211	NA	-0.54	-7.83	-0.4	6.67e-14	Pancreatic cancer;
CRC	cis	rs75422866	0.867	rs73104115	chr12:48078626	C/T	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.5	-7.74	-0.39	1.24e-13	Total body bone mineral density;
CRC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg11833968	chr6:79620685	NA	0.34	6.04	0.32	4.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.81	9.37	0.46	1.22e-18	Lung function (FEV1/FVC);
CRC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg08999081	chr20:33150536	PIGU	0.45	5.79	0.3	1.69e-8	Protein C levels;
CRC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-0.85	-12.9	-0.58	4.25e-31	Blood trace element (Zn levels);
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.54	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg10298567	chr3:47292165	KIF9	0.4	6.25	0.33	1.24e-9	Colorectal cancer;
CRC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.81	10.09	0.49	4.95e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	8.17	0.41	6.58e-15	Hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg04719120	chr6:96025338	MANEA	0.55	6.47	0.34	3.47e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.63	11.63	0.54	1.96e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg18479299	chr3:125709523	NA	-0.47	-5.96	-0.31	6.4e-9	Blood pressure (smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13937449	chr12:56320970	WIBG	0.47	6.13	0.32	2.5e-9	Thyroid stimulating hormone;
CRC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.93	0.44	2.99e-17	Schizophrenia;
CRC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.45	0.38	8.15e-13	Motion sickness;
CRC	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.54	-7.86	-0.4	5.72e-14	Red blood cell count;
CRC	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.59	11.72	0.54	9.45e-27	Weight;
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14863265	chr7:2801509	GNA12	-0.42	-5.85	-0.31	1.16e-8	Height;
CRC	cis	rs12024301	0.557	rs12029926	chr1:183640149	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.78	-7.04	-0.36	1.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.63	-0.43	2.61e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.24	-14.45	-0.62	5.42e-37	Gout;
CRC	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.38	-5.83	-0.31	1.33e-8	Endometrial cancer;
CRC	cis	rs9992667	0.955	rs9992076	chr4:38644667	C/T	cg19726192	chr4:38663646	FLJ13197	-0.66	-8.73	-0.43	1.31e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs6908034	0.660	rs111509549	chr6:19798370	A/G	cg02682789	chr6:19804855	NA	0.81	6.89	0.35	2.9100000000000002e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg14541582	chr5:601475	NA	-0.32	-6.65	-0.34	1.2e-10	Obesity-related traits;
CRC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.62	-0.3	4.17e-8	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23229228	chr3:98312354	CPOX	0.45	6.34	0.33	7.43e-10	Response to antipsychotic treatment;
CRC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16447950	chr5:562315	NA	-0.77	-10.22	-0.49	1.75e-21	Obesity-related traits;
CRC	cis	rs375066	0.623	rs1549954	chr19:44348805	C/A	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.3e-8	Breast cancer;
CRC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-8.0	-0.4	2.16e-14	Fibrinogen levels;
CRC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.92	-16.5	-0.67	5.67e-45	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.49	7.66	0.39	2.08e-13	Red blood cell count;
CRC	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg20935368	chr5:178288625	ZNF354B	0.45	7.0	0.36	1.42e-11	Sleep duration;
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg25173405	chr17:45401733	C17orf57	0.39	5.91	0.31	8.69e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.7	-11.99	-0.55	9.88e-28	Idiopathic membranous nephropathy;
CRC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg25790453	chr13:113633590	MCF2L	-0.45	-7.88	-0.4	4.69e-14	Systolic blood pressure;
CRC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.35	5.93	0.31	7.67e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs6700896	0.966	rs7542446	chr1:66091106	G/A	cg04111102	chr1:66153794	NA	0.33	5.8	0.3	1.55e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.97	0.36	1.78e-11	Diastolic blood pressure;
CRC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.58e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01101876	chr2:183580910	DNAJC10	-0.44	-6.98	-0.36	1.6e-11	Myopia (pathological);
CRC	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg12855166	chr17:30846586	MYO1D	0.37	6.16	0.32	2.14e-9	Schizophrenia;
CRC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.69	-0.3	2.86e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg10437265	chr15:77819839	NA	0.67	12.18	0.56	2.05e-28	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.26	-0.56	1.03e-28	Alzheimer's disease;
CRC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	12.68	0.57	2.91e-30	Platelet count;
CRC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.6	10.16	0.49	2.77e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs4478137	0.824	rs4691907	chr4:164223658	G/T	cg06758707	chr4:164254230	NPY1R	0.47	7.16	0.37	5.38e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-12.14	-0.56	2.93e-28	Asthma;
CRC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.4	17.21	0.69	8.73e-48	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.81	-12.48	-0.57	1.55e-29	Testicular germ cell tumor;
CRC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-11.23	-0.53	5.27e-25	Colorectal cancer;
CRC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.87	-0.31	1.08e-8	Alcohol dependence;
CRC	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg27124370	chr19:33622961	WDR88	0.48	6.93	0.36	2.16e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg20811857	chr17:78079795	GAA	-0.52	-7.89	-0.4	4.39e-14	Yeast infection;
CRC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.87	-19.89	-0.74	2.27e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg15845792	chr6:28175446	NA	0.72	5.83	0.31	1.29e-8	Depression;
CRC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.72	11.32	0.53	2.61e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.79	-0.44	8.78e-17	Response to antipsychotic treatment;
CRC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.59	8.41	0.42	1.25e-15	Longevity;
CRC	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-7.61	-0.39	2.99e-13	Prevalent atrial fibrillation;
CRC	cis	rs7147624	0.572	rs2411813	chr14:66023906	G/A	cg03016385	chr14:66212404	NA	-0.99	-8.84	-0.44	5.86e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.82	15.16	0.64	1e-39	Mean platelet volume;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg06470822	chr6:28175283	NA	0.93	12.38	0.56	3.59e-29	Parkinson's disease;
CRC	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.9e-16	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg09455208	chr3:40491958	NA	-0.35	-7.08	-0.36	8.78e-12	Renal cell carcinoma;
CRC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-9.49	-0.46	4.7e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.68	-0.43	1.85e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9903692	0.738	rs35202025	chr17:46152717	A/G	cg21215337	chr17:46176117	CBX1	0.42	7.79	0.39	8.7e-14	Pulse pressure;
CRC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.26	0.33	1.2e-9	Diabetic kidney disease;
CRC	cis	rs9648716	1.000	rs7796827	chr7:140601843	C/T	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs9487051	0.646	rs7773490	chr6:109623048	T/C	cg01475377	chr6:109611718	NA	-0.36	-5.77	-0.3	1.86e-8	Reticulocyte fraction of red cells;
CRC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.68	0.43	1.92e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-6.71	-0.35	8.57e-11	Major depressive disorder;
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg17346650	chr17:80929145	B3GNTL1	0.48	7.06	0.36	1.02e-11	Glycated hemoglobin levels;
CRC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.81	11.3	0.53	3.09e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg13565492	chr6:43139072	SRF	-0.72	-7.43	-0.38	9.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg15445000	chr17:37608096	MED1	0.36	6.27	0.33	1.14e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.52	8.66	0.43	2.11e-16	Uric acid clearance;
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.51	-0.54	5.63e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.44	-8.03	-0.4	1.74e-14	Intelligence (multi-trait analysis);
CRC	cis	rs12476592	0.602	rs6736411	chr2:63674060	G/A	cg10828910	chr2:63850056	LOC388955	0.47	5.94	0.31	7.39e-9	Childhood ear infection;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.79	13.03	0.58	1.43e-31	Longevity;Endometriosis;
CRC	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.4	-6.36	-0.33	6.59e-10	Height;
CRC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.58	8.01	0.4	1.95e-14	Menopause (age at onset);
CRC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg19046167	chr17:80928561	B3GNTL1	0.45	7.59	0.39	3.23e-13	Breast cancer;
CRC	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.53	-7.87	-0.4	5.33e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg03233332	chr7:66118400	NA	0.43	5.92	0.31	7.98e-9	Aortic root size;
CRC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.55	-0.34	2.25e-10	Monocyte percentage of white cells;
CRC	cis	rs7429990	0.965	rs34507589	chr3:47874042	C/G	cg11946769	chr3:48343235	NME6	0.57	6.54	0.34	2.32e-10	Educational attainment (years of education);
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	cis	rs6728642	0.519	rs6721921	chr2:97566501	G/A	cg26665480	chr2:98280029	ACTR1B	-0.54	-5.9	-0.31	9.2e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs2276314	0.553	rs4799842	chr18:33627968	C/A	cg19628046	chr18:33552617	C18orf21	0.46	7.13	0.37	6.22e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26778807	chr12:118498675	WSB2	0.41	6.33	0.33	8.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg10263370	chr3:44754102	ZNF502	-0.37	-6.37	-0.33	6.48e-10	Depressive symptoms;
CRC	cis	rs17162190	0.698	rs4970498	chr1:26844195	G/A	cg17456097	chr1:26900765	RPS6KA1	0.42	5.81	0.31	1.47e-8	Mean corpuscular volume;
CRC	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg23587288	chr2:27483067	SLC30A3	-0.4	-5.82	-0.31	1.42e-8	Blood metabolite levels;
CRC	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.58	-7.41	-0.38	1.07e-12	Body mass index;
CRC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.66	8.68	0.43	1.88e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.46	8.02	0.4	1.87e-14	Common traits (Other);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10317628	chr1:117113342	CD58	0.45	6.2	0.32	1.67e-9	Response to antipsychotic treatment;
CRC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.48	-9.04	-0.45	1.39e-17	Dupuytren's disease;
CRC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.06	0.32	3.71e-9	Lung cancer;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.88	19.77	0.74	6.97e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	0.91	7.93	0.4	3.57e-14	Left atrial antero-posterior diameter;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg15786705	chr6:28176104	NA	0.67	9.29	0.46	2.23e-18	Parkinson's disease;
CRC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg19980929	chr12:42632907	YAF2	0.48	7.35	0.38	1.62e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.46	-0.38	7.69e-13	Type 2 diabetes;
CRC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.24	0.67	5.52e-44	Chronic sinus infection;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22468868	chr17:58042029	RNFT1	0.42	6.55	0.34	2.21e-10	Schizophrenia;
CRC	cis	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg20159608	chr7:32802032	NA	-0.59	-7.37	-0.38	1.36e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	5.78	0.3	1.76e-8	Diabetic retinopathy;
CRC	cis	rs6460942	0.597	rs17590609	chr7:12142411	A/C	cg06484146	chr7:12443880	VWDE	-0.52	-6.27	-0.33	1.11e-9	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.53	0.73	6.22e-57	Prudent dietary pattern;
CRC	cis	rs6496667	0.779	rs8032687	chr15:90945186	C/T	cg04176472	chr15:90893244	GABARAPL3	0.59	7.69	0.39	1.72e-13	Rheumatoid arthritis;
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg04969067	chr8:143858791	LYNX1	0.45	7.54	0.38	4.72e-13	Urinary tract infection frequency;
CRC	cis	rs1887596	0.705	rs9788361	chr13:27201814	A/G	cg01312412	chr13:27282625	NA	0.45	5.75	0.3	2.01e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.66	7.41	0.38	1.1e-12	Body mass index;
CRC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.71	7.05	0.36	1.04e-11	Diabetic retinopathy;
CRC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.45	6.3	0.33	9.7e-10	Red blood cell count;
CRC	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07165851	chr6:158734300	TULP4	0.6	7.65	0.39	2.28e-13	Height;
CRC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.45	-6.64	-0.34	1.3e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.17	-0.37	5.11e-12	Major depressive disorder;
CRC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg03959625	chr15:84868606	LOC388152	0.42	6.25	0.33	1.24e-9	Schizophrenia;
CRC	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-10.53	-0.5	1.5e-22	Platelet distribution width;
CRC	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	9.16	0.45	5.83e-18	Migraine;Coronary artery disease;
CRC	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.39	-5.7	-0.3	2.63e-8	Growth-regulated protein alpha levels;
CRC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg17401720	chr7:158221031	PTPRN2	0.49	8.14	0.41	8.44e-15	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.58	8.89	0.44	4.26e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6694672	1.000	rs4915148	chr1:197035538	C/T	cg13682187	chr1:196946512	CFHR5	-0.47	-7.37	-0.38	1.38e-12	Asthma;
CRC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.4	-0.33	5.25e-10	Breast cancer;
CRC	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg08501292	chr6:25962987	TRIM38	0.89	8.35	0.42	1.87e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.86	-10.04	-0.48	7.52e-21	Breast cancer;
CRC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.81	-11.31	-0.53	2.85e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.67	0.47	1.25e-19	Platelet count;
CRC	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg25856811	chr1:152973957	SPRR3	-0.21	-5.62	-0.3	4.03e-8	Inflammatory skin disease;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg03623178	chr6:28175578	NA	0.78	6.94	0.36	2.07e-11	Breast cancer;
CRC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.67	-0.43	2.03e-16	Chronic sinus infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24469923	chr19:11925456	ZNF440	0.4	6.68	0.35	1.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg09473613	chr1:24152604	HMGCL	0.34	5.63	0.3	3.83e-8	Immature fraction of reticulocytes;
CRC	cis	rs6546324	0.615	rs4233939	chr2:67782735	A/C	cg15745817	chr2:67799979	NA	-0.51	-8.35	-0.42	1.9e-15	Endometriosis;
CRC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg24046110	chr8:143859143	LYNX1	-0.37	-6.32	-0.33	8.7e-10	Urinary tract infection frequency;
CRC	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg16989719	chr2:238392110	NA	-0.35	-5.91	-0.31	8.35e-9	Prostate cancer;
CRC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.08	0.32	3.33e-9	Tonsillectomy;
CRC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.72	0.3	2.46e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	1.95e-33	Vitiligo;
CRC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.46	-6.8	-0.35	5.03e-11	Systemic lupus erythematosus;
CRC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	10.47	0.5	2.52e-22	Bone mineral density;
CRC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.43	-6.47	-0.34	3.52e-10	Prostate cancer;
CRC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg23815491	chr16:72088622	HP	0.49	7.51	0.38	5.77e-13	Fibrinogen levels;
CRC	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg03162506	chr22:38580953	NA	0.28	6.0	0.31	5.31e-9	Cutaneous nevi;
CRC	trans	rs11165623	0.564	rs11165658	chr1:96985670	A/G	cg10631902	chr5:14652156	NA	-0.4	-7.08	-0.36	8.67e-12	Hip circumference;Waist circumference;
CRC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.61	9.24	0.45	3.26e-18	Selective IgA deficiency;
CRC	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26378065	chr17:18585709	ZNF286B	0.44	5.94	0.31	7.21e-9	Pancreatic cancer;
CRC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg08314208	chr16:67682810	RLTPR	-0.63	-6.58	-0.34	1.87e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9039	0.959	rs12925781	chr16:9216914	A/G	cg08831531	chr16:9218945	NA	0.58	6.82	0.35	4.31e-11	Menopause (age at onset);
CRC	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg12856521	chr11:46389249	DGKZ	-0.42	-6.56	-0.34	2.07e-10	Leprosy;
CRC	cis	rs3736485	0.966	rs12101730	chr15:51800733	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-6.08	-0.32	3.4e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.65	9.16	0.45	5.88e-18	Vitamin D levels;
CRC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.45	-6.36	-0.33	6.59e-10	Menarche (age at onset);
CRC	cis	rs3020333	0.875	rs2982571	chr6:152012739	A/T	cg22157087	chr6:152012887	ESR1	-0.53	-8.03	-0.4	1.78e-14	Total body bone mineral density;
CRC	trans	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg22319618	chr22:45562946	NUP50	-0.69	-7.66	-0.39	2.13e-13	Breast cancer;
CRC	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg08501292	chr6:25962987	TRIM38	0.88	6.0	0.31	5.23e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg18867708	chr6:26865862	GUSBL1	0.38	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs8099014	0.861	rs17669	chr18:56118493	C/T	cg12907477	chr18:56117327	MIR122	0.47	5.91	0.31	8.48e-9	Platelet count;
CRC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg23262073	chr20:60523788	NA	-0.45	-7.08	-0.36	8.54e-12	Body mass index;
CRC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.63	-7.19	-0.37	4.38e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6681460	1.000	rs6656550	chr1:67122552	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.38	0.42	1.51e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.73	0.39	1.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.56	6.35	0.33	7.04e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.91	-0.4	3.97e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	0.79	8.61	0.43	3e-16	Gout;Renal underexcretion gout;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg22687807	chr8:143858763	LYNX1	-0.44	-6.92	-0.36	2.32e-11	Urinary tract infection frequency;
CRC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.59	-0.34	1.78e-10	Alcohol dependence;
CRC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	8.59	0.43	3.46e-16	Lymphocyte counts;
CRC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.45	-8.32	-0.42	2.32e-15	Reticulocyte fraction of red cells;
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02018176	chr4:1364513	KIAA1530	0.47	8.01	0.4	2e-14	Obesity-related traits;
CRC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.6	8.77	0.44	1e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.62	9.19	0.45	4.7e-18	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.61	-0.3	4.38e-8	Coronary artery disease;
CRC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.61	10.41	0.5	3.98e-22	Prudent dietary pattern;
CRC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg06238570	chr21:40685208	BRWD1	0.76	10.4	0.5	4.39e-22	Cognitive function;
CRC	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg08885800	chr1:201084119	NA	-0.43	-7.78	-0.39	9.18e-14	Permanent tooth development;
CRC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg02321871	chr13:50159138	RCBTB1	-0.45	-6.32	-0.33	8.5e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.46	6.2	0.32	1.73e-9	Red blood cell count;
CRC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.5	-7.4	-0.38	1.15e-12	Height;
CRC	cis	rs8099014	0.906	rs4940693	chr18:56101171	T/G	cg19312305	chr18:56117016	MIR122	-0.4	-6.2	-0.32	1.72e-9	Platelet count;
CRC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg13628971	chr7:2884303	GNA12	0.45	7.04	0.36	1.16e-11	Height;
CRC	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg10517650	chr3:113235015	CCDC52	-0.36	-5.75	-0.3	2e-8	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.14	0.37	6.21e-12	Response to temozolomide;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25733915	chr17:40829168	PLEKHH3	0.53	6.88	0.35	3.12e-11	Thyroid stimulating hormone;
CRC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-6.57	-0.34	1.93e-10	Type 2 diabetes;
CRC	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg19875535	chr5:140030758	IK	-0.59	-9.66	-0.47	1.36e-19	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg03315344	chr16:75512273	CHST6	-0.53	-6.26	-0.33	1.2e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg17706124	chr4:3521738	LRPAP1	0.41	5.94	0.31	7.13e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
CRC	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.51	-6.03	-0.32	4.29e-9	Obesity-related traits;
CRC	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg01475377	chr6:109611718	NA	-0.35	-6.07	-0.32	3.56e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9311676	0.632	rs6785572	chr3:58361517	A/G	cg06643156	chr3:58380774	PXK	-0.44	-6.76	-0.35	6.17e-11	Systemic lupus erythematosus;
CRC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.55	7.74	0.39	1.22e-13	Melanoma;
CRC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg02449762	chr10:5661741	NA	-0.34	-5.87	-0.31	1.04e-8	Breast cancer;
CRC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.05	-0.32	3.88e-9	Menopause (age at onset);
CRC	cis	rs62229266	0.609	rs12482541	chr21:37419743	A/G	cg08632701	chr21:37451849	NA	-0.4	-6.27	-0.33	1.14e-9	Mitral valve prolapse;
CRC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.76	-0.35	6.14e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg01216370	chr2:228736459	WDR69	-0.45	-5.7	-0.3	2.68e-8	Blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03321319	chr22:22222323	MAPK1	0.37	6.04	0.32	4.06e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg21153622	chr11:89784906	NA	-0.43	-6.68	-0.35	1.03e-10	Height;
CRC	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-7.07	-0.36	9.49e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg10298567	chr3:47292165	KIF9	0.42	6.56	0.34	2.07e-10	Colorectal cancer;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6662572	0.703	rs72690847	chr1:46256929	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.0	0.31	5.08e-9	Blood protein levels;
CRC	cis	rs7635838	0.892	rs2880897	chr3:11494544	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.23	0.32	1.4e-9	HDL cholesterol;
CRC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.46	-8.86	-0.44	5.17e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.51	7.61	0.39	2.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs501120	1.000	rs527785	chr10:44762686	G/A	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.51	7.7	0.39	1.61e-13	Resting heart rate;
CRC	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg16141378	chr3:129829833	LOC729375	0.44	6.72	0.35	8.13e-11	Triglycerides;
CRC	trans	rs2303319	1.000	rs12471336	chr2:162265189	A/C	cg15640062	chr1:25757265	TMEM57	0.81	5.97	0.31	6.19e-9	Cognitive function;
CRC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.27	-0.46	2.46e-18	Body mass index;
CRC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-7.0	-0.36	1.42e-11	Systemic lupus erythematosus;
CRC	cis	rs2302190	0.882	rs9901693	chr17:56606915	C/T	cg12560992	chr17:57184187	TRIM37	0.51	6.09	0.32	3.2e-9	Vitamin D levels;
CRC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.81	-0.31	1.47e-8	Lung cancer;
CRC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.06	-15.05	-0.64	2.51e-39	Platelet count;
CRC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.55	-7.08	-0.36	9.03e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4938330	0.608	rs3830008	chr11:117093764	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.22	-0.32	1.54e-9	Blood protein levels;
CRC	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.4	-6.86	-0.35	3.48e-11	Hip circumference;Waist circumference;
CRC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.35	-0.42	1.89e-15	Body mass index;
CRC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.77	11.31	0.53	2.78e-25	High light scatter reticulocyte count;
CRC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.92	-0.44	3.24e-17	Myeloid white cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13842258	chr4:41216271	APBB2	0.42	6.49	0.34	3.1e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs812925	0.502	rs2053750	chr2:61656273	T/A	cg10580144	chr2:61372316	C2orf74	-0.32	-6.78	-0.35	5.42e-11	Immature fraction of reticulocytes;
CRC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.42	8.32	0.42	2.35e-15	Renal cell carcinoma;
CRC	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg15147215	chr3:52552868	STAB1	0.44	6.92	0.36	2.33e-11	Body mass index;
CRC	cis	rs12980942	0.810	rs3745295	chr19:41785282	T/G	cg25627403	chr19:41769009	HNRNPUL1	0.46	5.62	0.3	4.16e-8	Coronary artery disease;
CRC	cis	rs6694672	1.000	rs6694672	chr1:196945789	T/G	cg13682187	chr1:196946512	CFHR5	-0.52	-8.16	-0.41	7.37e-15	Asthma;
CRC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.64e-15	Menopause (age at onset);
CRC	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.08	0.45	1.06e-17	Corneal astigmatism;
CRC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs780094	0.500	rs12478841	chr2:27811722	A/G	cg27432699	chr2:27873401	GPN1	0.48	6.33	0.33	8.08e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs10046574	0.831	rs75959757	chr7:135170755	G/A	cg27474649	chr7:135195673	CNOT4	0.7	5.8	0.3	1.52e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.39	-0.33	5.63e-10	Bipolar disorder;
CRC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.58	9.32	0.46	1.71e-18	Type 2 diabetes;
CRC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.55	8.26	0.41	3.58e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.3	-0.33	9.71e-10	Retinal vascular caliber;
CRC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg24209194	chr3:40518798	ZNF619	0.42	6.33	0.33	8.25e-10	Renal cell carcinoma;
CRC	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg23254163	chr1:152506842	NA	0.45	8.98	0.44	2.16e-17	Hair morphology;
CRC	cis	rs3020333	0.721	rs1293936	chr6:152017691	T/G	cg22157087	chr6:152012887	ESR1	0.47	7.24	0.37	3.11e-12	Total body bone mineral density;
CRC	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.45	-7.0	-0.36	1.43e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.67	-0.54	1.4e-26	Blood trace element (Zn levels);
CRC	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-8.43	-0.42	1.09e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.59	10.79	0.51	1.91e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	0.84	13.42	0.59	4.84e-33	Cognitive function;
CRC	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg24553058	chr2:113831203	IL1F10	0.55	8.64	0.43	2.47e-16	Protein quantitative trait loci;
CRC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.38	6.95	0.36	1.95e-11	Obesity-related traits;
CRC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.49	7.01	0.36	1.33e-11	Height;
CRC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.46	6.53	0.34	2.52e-10	Melanoma;
CRC	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	7.95	0.4	2.99e-14	Lung cancer in ever smokers;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08504905	chr19:54663436	LENG1	-0.41	-5.97	-0.31	6.27e-9	Daytime sleep phenotypes;
CRC	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg27395922	chr11:50257633	LOC441601	0.48	6.16	0.32	2.16e-9	Intraocular pressure;
CRC	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.15	-0.37	5.83e-12	Total cholesterol levels;
CRC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.91	15.21	0.64	5.95e-40	Diastolic blood pressure;Systolic blood pressure;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14158573	chr20:17549682	DSTN	0.39	6.73	0.35	7.64e-11	Myopia (pathological);
CRC	cis	rs4731207	0.672	rs62478914	chr7:124456654	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.48	6.17	0.32	1.99e-9	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19161053	chr7:99036702	CPSF4;PTCD1	0.48	6.89	0.36	2.82e-11	Response to antipsychotic treatment;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg25635840	chr17:26898051	PIGS	-0.43	-6.4	-0.33	5.22e-10	Daytime sleep phenotypes;
CRC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.92	-16.78	-0.68	4.34e-46	Cognitive function;
CRC	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg13615338	chr4:55094005	PDGFRA	0.42	6.05	0.32	4e-9	Corneal astigmatism;
CRC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06671706	chr8:8559999	CLDN23	0.57	8.46	0.42	8.8e-16	Obesity-related traits;
CRC	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.43	6.83	0.35	4.15e-11	Sitting height ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06129794	chr4:53578476	SNORA26;KIAA0114	0.37	5.97	0.31	6.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4728302	0.869	rs6955279	chr7:133612113	C/T	cg10665199	chr7:133106180	EXOC4	0.4	5.92	0.31	8.3e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-6.1	-0.32	2.92e-9	Carotid intima media thickness;
CRC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-12.7	-0.57	2.36e-30	Vitiligo;
CRC	cis	rs2652834	1.000	rs2729785	chr15:63402574	G/A	cg05507819	chr15:63340323	TPM1	0.44	5.61	0.3	4.19e-8	HDL cholesterol;
CRC	cis	rs1223397	0.938	rs35511719	chr6:13282442	T/C	cg21538684	chr6:13274180	PHACTR1	0.47	5.65	0.3	3.39e-8	Blood pressure;
CRC	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.56	-7.42	-0.38	1.03e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs9525927	0.570	rs7400099	chr13:44804480	G/T	cg19190762	chr13:44806055	NA	-0.61	-8.25	-0.41	3.74e-15	Dupuytren's disease;
CRC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.94	-0.31	7.42e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.49	6.79	0.35	5.24e-11	Tonsillectomy;
CRC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-9.71	-0.47	9.15e-20	Total cholesterol levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25547232	chr19:1026491	CNN2	0.41	6.51	0.34	2.76e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18467133	chr12:100661475	SCYL2;DEPDC4	-0.4	-5.97	-0.31	6.08e-9	Myopia (pathological);
CRC	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg11204139	chr17:3907470	NA	0.64	11.14	0.52	1.11e-24	Type 2 diabetes;
CRC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.33	-0.49	7.44e-22	Aortic root size;
CRC	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.64	-9.37	-0.46	1.18e-18	Type 2 diabetes;
CRC	trans	rs783540	0.967	rs34186444	chr15:83287500	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-5.98	-0.31	5.78e-9	Schizophrenia;
CRC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.16	-0.56	2.37e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08063724	chr1:40367097	MYCL1	0.39	6.05	0.32	3.89e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.73	-13.08	-0.59	8.75e-32	Inhibitory control;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01858229	chr12:109125404	CORO1C	0.42	6.31	0.33	9.13e-10	Schizophrenia;
CRC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg05501817	chr11:14380813	RRAS2	-0.45	-5.94	-0.31	7.15e-9	Sense of smell;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08380957	chr17:58678329	PPM1D	0.47	6.63	0.34	1.41e-10	Response to antipsychotic treatment;
CRC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg05709478	chr1:6581295	PLEKHG5	0.67	7.92	0.4	3.74e-14	Body mass index;
CRC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	16.52	0.67	4.75e-45	Platelet count;
CRC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg25164649	chr6:28176230	NA	0.7	8.9	0.44	3.71e-17	Parkinson's disease;
CRC	cis	rs9682041	0.561	rs9856511	chr3:170140165	C/G	cg11886554	chr3:170076028	SKIL	0.65	7.53	0.38	4.94e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs11885103	0.543	rs1320364	chr2:563219	A/G	cg12228919	chr15:44955936	SPG11	-0.46	-6.87	-0.35	3.13e-11	Heschl's gyrus morphology;
CRC	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg21512817	chr2:216176813	ATIC	0.37	6.12	0.32	2.63e-9	Parkinson's disease;
CRC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.46	6.43	0.33	4.5e-10	Malaria;
CRC	cis	rs7173389	0.530	rs6495062	chr15:73682691	T/C	cg01796676	chr15:73680284	NA	0.56	8.54	0.43	4.88e-16	Resting heart rate;
CRC	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.62	-7.61	-0.39	2.82e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg13390004	chr1:15929781	NA	0.5	7.04	0.36	1.12e-11	Systolic blood pressure;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg27635394	chr6:26043820	HIST1H2BB	0.45	6.54	0.34	2.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.19	-0.32	1.76e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7215564	0.908	rs4536520	chr17:78660239	C/T	cg09596252	chr17:78655493	RPTOR	0.54	5.73	0.3	2.25e-8	Myopia (pathological);
CRC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.3	-0.42	2.77e-15	Type 2 diabetes;
CRC	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg14191688	chr11:70257035	CTTN	0.58	7.9	0.4	4.21e-14	Coronary artery disease;
CRC	trans	rs10504390	0.527	rs4392943	chr8:66523799	C/A	cg26403416	chr21:43771339	TFF2	0.6	6.14	0.32	2.38e-9	IgG glycosylation;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg06470822	chr6:28175283	NA	0.72	9.7	0.47	1e-19	Parkinson's disease;
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg07507251	chr3:52567010	NT5DC2	0.4	5.75	0.3	2.04e-8	Bipolar disorder;
CRC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.07	-0.36	9.33e-12	Colorectal cancer;
CRC	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg14593290	chr7:50529359	DDC	-0.6	-7.91	-0.4	3.95e-14	Malaria;
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg05313129	chr8:58192883	C8orf71	-0.41	-5.93	-0.31	7.68e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg05639522	chr1:247681581	NA	0.45	6.74	0.35	6.9e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.61	-8.32	-0.42	2.45e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg05341575	chr12:125625032	AACS	-0.34	-5.91	-0.31	8.52e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg09659197	chr4:152720779	NA	0.53	11.71	0.54	1.06e-26	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.65	-7.75	-0.39	1.18e-13	Diabetic retinopathy;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg04518342	chr5:131593106	PDLIM4	0.44	7.05	0.36	1.05e-11	Acylcarnitine levels;
CRC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.41	5.68	0.3	2.94e-8	Multiple sclerosis;
CRC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.39	0.33	5.77e-10	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02923393	chr16:1543003	TELO2	0.46	5.98	0.31	5.7e-9	Thyroid stimulating hormone;
CRC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.7	-8.87	-0.44	4.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.24	-16.45	-0.67	8.57e-45	Breast cancer;
CRC	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg06223162	chr1:101003688	GPR88	-0.36	-6.7	-0.35	8.92e-11	Monocyte count;
CRC	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg26741380	chr15:41871084	TYRO3	-0.45	-6.33	-0.33	7.82e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.48	6.98	0.36	1.65e-11	Parkinson's disease;
CRC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.65	-8.86	-0.44	5.21e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.24	-0.33	1.32e-9	Aortic root size;
CRC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18912574	chr7:65842487	NCRNA00174	0.35	6.04	0.32	4.23e-9	Aortic root size;
CRC	cis	rs9311676	0.656	rs62258140	chr3:58407083	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	0.94	11.98	0.55	1.13e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg03701575	chr16:83960119	NA	0.35	5.98	0.31	5.73e-9	Asthma;
CRC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg24562669	chr7:97807699	LMTK2	0.42	6.99	0.36	1.57e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.52	-7.96	-0.4	2.89e-14	Body mass index;
CRC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.42	-0.42	1.15e-15	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.51	8.45	0.42	9.22e-16	Uric acid clearance;
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.73	11.18	0.52	8.28e-25	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20256961	chr18:71959244	CYB5A	0.46	6.33	0.33	7.89e-10	Anxiety disorder;
CRC	cis	rs12476592	0.516	rs196124	chr2:63854138	A/G	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.37e-9	Childhood ear infection;
CRC	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.7	-11.86	-0.55	3e-27	Itch intensity from mosquito bite;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10190329	chr10:126605450	NA	-0.4	-6.5	-0.34	3.01e-10	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.36e-24	Prudent dietary pattern;
CRC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg14828511	chr1:107599125	PRMT6	0.51	6.95	0.36	1.95e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.47	0.53	7.31e-26	Coffee consumption (cups per day);
CRC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	6.39	0.33	5.79e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14051306	chr5:56248243	MIER3	0.39	6.06	0.32	3.76e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg08888203	chr3:10149979	C3orf24	0.7	9.86	0.48	2.92e-20	Alzheimer's disease;
CRC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.02	-0.4	1.92e-14	Neuroticism;
CRC	cis	rs863345	0.604	rs1342953	chr1:158464499	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.22	-0.32	1.55e-9	Pneumococcal bacteremia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07555182	chr11:82782896	RAB30	0.52	6.79	0.35	5.11e-11	Thyroid stimulating hormone;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25129765	chr6:99872940	SFRS18	0.44	6.25	0.33	1.28e-9	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.54	6.46	0.34	3.71e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg18830697	chr6:72922368	RIMS1	0.41	8.15	0.41	7.57e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.5	-5.66	-0.3	3.31e-8	Vitiligo;
CRC	trans	rs1590305	0.686	rs7337526	chr13:38061307	C/T	cg00807959	chr1:48176281	NA	0.56	5.96	0.31	6.44e-9	Hip geometry;
CRC	trans	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg25214090	chr10:38739885	LOC399744	0.41	6.44	0.33	4.27e-10	Diastolic blood pressure;
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg00383909	chr3:49044727	WDR6	0.44	5.61	0.3	4.32e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg21153622	chr11:89784906	NA	-0.49	-7.78	-0.39	9.36e-14	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01068452	chr8:53626947	RB1CC1	0.37	6.11	0.32	2.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.44	-5.69	-0.3	2.87e-8	Adiposity;
CRC	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg16141378	chr3:129829833	LOC729375	0.43	6.17	0.32	1.96e-9	Subjective well-being;
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.54e-15	Morning vs. evening chronotype;
CRC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.52	6.83	0.35	4.14e-11	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.43	6.04	0.32	4.26e-9	Platelet distribution width;
CRC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.43	-7.0	-0.36	1.48e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21972741	chr5:435613	AHRR	0.53	7.37	0.38	1.41e-12	Cystic fibrosis severity;
CRC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg02683197	chr6:28174875	NA	0.79	9.73	0.47	8.12e-20	Depression;
CRC	cis	rs3736485	0.966	rs2414110	chr15:51901302	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.51	-0.34	2.86e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg04990556	chr1:26633338	UBXN11	-0.48	-6.15	-0.32	2.31e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.45	-7.19	-0.37	4.39e-12	Monocyte count;
CRC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.02	-0.52	2.97e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.03	-0.36	1.24e-11	Joint mobility (Beighton score);
CRC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg06138825	chr16:67683817	RLTPR	-0.54	-5.64	-0.3	3.61e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg15147215	chr3:52552868	STAB1	-0.58	-9.65	-0.47	1.49e-19	Bipolar disorder;
CRC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.65	12.1	0.56	3.88e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.88	-0.35	3.05e-11	Response to antipsychotic treatment;
CRC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.48	0.34	3.38e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.88	9.24	0.45	3.09e-18	Major depressive disorder;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12172441	chr6:28176163	NA	-0.67	-8.12	-0.41	9.7e-15	Depression;
CRC	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.47	-6.03	-0.32	4.44e-9	Alopecia areata;
CRC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.23	-0.37	3.41e-12	Total body bone mineral density;
CRC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.81	0.3	1.5e-8	Monocyte percentage of white cells;
CRC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-10.17	-0.49	2.72e-21	Personality dimensions;
CRC	cis	rs9837602	0.935	rs4928149	chr3:99685686	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	6.11	0.32	2.83e-9	Breast cancer;
CRC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.61	8.84	0.44	5.88e-17	Lymphocyte counts;
CRC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.8	-0.3	1.53e-8	Vitiligo;
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg18972013	chr17:78078605	GAA	-0.39	-5.71	-0.3	2.53e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.38	-9.19	-0.45	4.44e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.51	-6.74	-0.35	7.21e-11	Glioblastoma;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	7.09	0.36	8.49e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg21620606	chr4:1342894	KIAA1530	0.51	8.03	0.4	1.77e-14	Obesity-related traits;
CRC	cis	rs7605827	0.930	rs7590340	chr2:15601441	C/T	cg19274914	chr2:15703543	NA	0.4	6.09	0.32	3.23e-9	Educational attainment (years of education);
CRC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg04586622	chr2:25135609	ADCY3	-0.57	-10.66	-0.51	5.62e-23	Body mass index;
CRC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.69	-9.29	-0.46	2.12e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg22777020	chr22:31556080	RNF185	-0.52	-5.97	-0.31	6.27e-9	Colorectal cancer;
CRC	cis	rs7539542	0.516	rs10732291	chr1:202891168	G/A	cg19681188	chr1:202830198	LOC148709	0.45	6.49	0.34	3.24e-10	Mean platelet volume;
CRC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg05501817	chr11:14380813	RRAS2	-0.47	-6.55	-0.34	2.19e-10	Sense of smell;
CRC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	0.99	12.36	0.56	4.3e-29	Type 2 diabetes nephropathy;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11645453	chr3:52864694	ITIH4	0.35	6.17	0.32	2e-9	Bipolar disorder;
CRC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg05341575	chr12:125625032	AACS	0.34	5.78	0.3	1.76e-8	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12624087	chr22:32341561	C22orf24;YWHAH	0.45	6.27	0.33	1.15e-9	Response to antipsychotic treatment;
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.51	-7.25	-0.37	2.97e-12	Longevity;Endometriosis;
CRC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-9.24	-0.45	3.05e-18	Initial pursuit acceleration;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.6	6.48	0.34	3.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.99	-0.31	5.58e-9	Hip circumference adjusted for BMI;
CRC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-6.11	-0.32	2.81e-9	Vitiligo;
CRC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.59	8.77	0.44	9.79e-17	Aortic root size;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg04342092	chr19:58095468	ZIK1	0.31	6.06	0.32	3.77e-9	Kashin-Beck disease;
CRC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.54	-9.18	-0.45	4.97e-18	Type 2 diabetes;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-6.24	-0.33	1.37e-9	Electroencephalogram traits;
CRC	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-8.06	-0.41	1.46e-14	Neuroticism;
CRC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.52	-6.09	-0.32	3.19e-9	Coronary artery calcification;
CRC	cis	rs10463316	0.817	rs730526	chr5:150789232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-6.77	-0.35	5.81e-11	Metabolite levels (Pyroglutamine);
CRC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg11843238	chr5:131593191	PDLIM4	-0.37	-7.12	-0.37	6.96e-12	Breast cancer;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg25164649	chr6:28176230	NA	0.59	8.24	0.41	4.21e-15	Parkinson's disease;
CRC	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.73	7.98	0.4	2.53e-14	Iron status biomarkers;
CRC	cis	rs8126001	0.573	rs6090043	chr20:62717930	C/T	cg03642690	chr20:62727907	OPRL1	-0.38	-5.95	-0.31	6.86e-9	Pulse pressure;Mean corpuscular volume;
CRC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-9.69	-0.47	1.03e-19	Chronic sinus infection;
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg21204522	chr6:27730016	NA	-0.68	-5.97	-0.31	6.08e-9	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.55	-0.34	2.25e-10	Eye color traits;
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg10217327	chr6:118973057	C6orf204	0.51	5.76	0.3	1.93e-8	Diastolic blood pressure;
CRC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg10760299	chr15:45669010	GATM	-0.48	-7.79	-0.39	8.74e-14	Homoarginine levels;
CRC	cis	rs7835763	0.692	rs6988721	chr8:119104040	G/A	cg11592677	chr8:119110466	EXT1	-0.38	-6.18	-0.32	1.93e-9	Autism spectrum disorder;
CRC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg03030879	chr14:75389066	RPS6KL1	0.46	7.23	0.37	3.41e-12	Height;
CRC	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.71	-7.74	-0.39	1.21e-13	Obesity;Body mass index;
CRC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.49	0.54	6.51e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-14.65	-0.63	8.89e-38	Gut microbiome composition (summer);
CRC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.93	11.11	0.52	1.43e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg00129232	chr17:37814104	STARD3	0.59	7.39	0.38	1.24e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.51	-9.13	-0.45	7.33e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg25767906	chr1:53392781	SCP2	0.4	6.48	0.34	3.38e-10	Monocyte count;
CRC	cis	rs3101457	0.530	rs9782996	chr1:244528127	C/T	cg09033006	chr1:244517177	C1orf100	0.41	5.98	0.31	5.72e-9	Smoking behavior;
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-6.54	-0.34	2.36e-10	Total body bone mineral density;
CRC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg13057898	chr1:3703894	LRRC47	0.53	7.03	0.36	1.21e-11	Red cell distribution width;
CRC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg24675056	chr1:15929824	NA	0.51	7.17	0.37	5.04e-12	Systolic blood pressure;
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg25834613	chr7:1915315	MAD1L1	-0.49	-6.59	-0.34	1.77e-10	Bipolar disorder;
CRC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.85	-0.35	3.55e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg03013999	chr17:37608204	MED1	-0.45	-6.33	-0.33	8e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.94	11.82	0.55	4.02e-27	Exhaled nitric oxide levels;
CRC	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg06042504	chr8:55087323	NA	0.43	6.69	0.35	9.39e-11	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs4130344	0.555	rs7664704	chr4:159866176	A/G	cg04008429	chr3:160167646	TRIM59	0.41	6.0	0.31	5.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.49	-0.38	6.26e-13	Bipolar disorder;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg15786705	chr6:28176104	NA	0.74	9.47	0.46	5.74e-19	Depression;
CRC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg06453172	chr10:134556979	INPP5A	-0.67	-9.03	-0.45	1.44e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg19897017	chr7:2163380	MAD1L1	0.41	6.14	0.32	2.43e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.63	10.67	0.51	5.21e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.74	-0.3	2.16e-8	Gout;Renal underexcretion gout;
CRC	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.44	-6.54	-0.34	2.32e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs1712517	1.000	rs1712517	chr10:105033015	C/T	cg05636881	chr10:105038444	INA	0.46	8.2	0.41	5.35e-15	Migraine;
CRC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.98	-0.36	1.61e-11	Neutrophil count;
CRC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg10589385	chr1:150898437	SETDB1	-0.31	-6.48	-0.34	3.26e-10	Urate levels;
CRC	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.39	-0.42	1.48e-15	Idiopathic membranous nephropathy;
CRC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.98	-0.31	5.68e-9	Gout;Renal underexcretion gout;
CRC	cis	rs939584	0.935	rs13022164	chr2:632536	A/G	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.58e-8	Body mass index;
CRC	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.75e-10	Depression;
CRC	cis	rs6840360	0.642	rs2724578	chr4:152367304	A/G	cg09659197	chr4:152720779	NA	0.33	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10155981	0.510	rs4722159	chr7:22584279	C/G	cg05062323	chr7:22590069	NA	-0.62	-7.14	-0.37	6.02e-12	Bilirubin levels;
CRC	cis	rs11971779	0.700	rs11763942	chr7:139005795	A/T	cg07862535	chr7:139043722	LUC7L2	0.75	8.51	0.42	6.38e-16	Diisocyanate-induced asthma;
CRC	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.95	-12.39	-0.56	3.35e-29	Exhaled nitric oxide output;
CRC	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.6	10.17	0.49	2.69e-21	Dupuytren's disease;
CRC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.03	10.1	0.49	4.66e-21	Lymphocyte counts;
CRC	cis	rs17818399	0.788	rs13013245	chr2:46806086	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-6.09	-0.32	3.2e-9	Height;
CRC	cis	rs932541	1.000	rs6111153	chr20:16456113	C/T	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	trans	rs35094601	0.918	rs13020860	chr2:139214346	C/T	cg25299176	chr17:1303341	YWHAE	-0.47	-6.7	-0.35	9.16e-11	Schizophrenia;
CRC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	9.22	0.45	3.67e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7572644	0.699	rs898032	chr2:28202936	C/G	cg27432699	chr2:27873401	GPN1	-0.4	-5.61	-0.3	4.22e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.5	7.45	0.38	8.24e-13	Headache;
CRC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.44	6.42	0.33	4.86e-10	Menopause (age at onset);
CRC	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg18404041	chr3:52824283	ITIH1	0.33	6.55	0.34	2.26e-10	Schizophrenia;
CRC	cis	rs2457480	0.516	rs10899989	chr10:44640048	C/T	cg09554077	chr10:44749378	NA	0.47	6.08	0.32	3.27e-9	Coronary artery disease;
CRC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.53	-7.17	-0.37	4.93e-12	Tonsillectomy;
CRC	trans	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg02674126	chr19:40336878	FBL	0.43	6.91	0.36	2.58e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs753274	0.650	rs28497965	chr19:14417402	T/G	cg25450033	chr19:14444658	NA	0.34	5.94	0.31	7.37e-9	Tumor necrosis factor beta levels;
CRC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.81	0.51	1.64e-23	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10981541	chr17:636487	FAM57A	0.37	6.33	0.33	7.81e-10	Response to antipsychotic treatment;
CRC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.48	-6.49	-0.34	3.13e-10	Multiple myeloma;
CRC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04045327	chr4:905805	GAK	-0.48	-8.2	-0.41	5.4e-15	Systemic sclerosis;
CRC	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg18830697	chr6:72922368	RIMS1	-0.4	-7.99	-0.4	2.31e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs17767392	0.881	rs67489015	chr14:71964521	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.28	-0.37	2.49e-12	Mitral valve prolapse;
CRC	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg03934865	chr2:198174659	NA	-0.47	-7.36	-0.38	1.47e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg09655341	chr17:79618100	PDE6G	0.63	7.2	0.37	4.24e-12	Dental caries;
CRC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.46e-9	Colorectal cancer;
CRC	trans	rs6847067	0.800	rs11097026	chr4:85803607	G/T	cg24769924	chr12:32553033	NA	-0.38	-6.1	-0.32	3.01e-9	Oropharynx cancer;
CRC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.48	6.14	0.32	2.41e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.45	-5.9	-0.31	9.16e-9	Longevity;Endometriosis;
CRC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.68	-10.98	-0.52	4.16e-24	Hepatocellular carcinoma;
CRC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.35	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;
CRC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.87	-15.73	-0.66	5.75e-42	Body mass index;
CRC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.72	11.38	0.53	1.64e-25	Colorectal cancer;
CRC	trans	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg17903999	chr18:56338584	MALT1	-0.39	-6.45	-0.34	4.08e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.46	6.63	0.34	1.39e-10	Tonsillectomy;
CRC	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.54	8.7	0.43	1.62e-16	Metabolite levels;
CRC	cis	rs2004318	1.000	rs2781760	chr19:55140609	C/T	cg03320607	chr19:54800032	LILRA3	-0.65	-5.69	-0.3	2.82e-8	Blood protein levels;
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg09877947	chr5:131593287	PDLIM4	0.43	8.05	0.41	1.57e-14	Breast cancer;
CRC	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.98	0.31	5.73e-9	Migraine;
CRC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg17724175	chr1:150552817	MCL1	-0.47	-7.39	-0.38	1.19e-12	Tonsillectomy;
CRC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg20203395	chr5:56204925	C5orf35	-0.44	-6.03	-0.32	4.43e-9	Coronary artery disease;
CRC	trans	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	6.57	0.34	2e-10	Mean corpuscular volume;
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg15382696	chr6:118971807	C6orf204	0.6	7.65	0.39	2.19e-13	Diastolic blood pressure;
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.5	-8.98	-0.44	2.11e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.62e-9	Life satisfaction;
CRC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg18016565	chr1:150552671	MCL1	0.41	5.78	0.3	1.73e-8	Melanoma;
CRC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.77	-0.39	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.21	0.32	1.55e-9	Bladder cancer;
CRC	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.4	5.85	0.31	1.19e-8	Platelet distribution width;
CRC	cis	rs7094131	0.523	rs10741008	chr10:22882344	T/G	cg19500236	chr10:22911537	PIP4K2A	0.36	5.63	0.3	3.93e-8	Obesity-related traits;
CRC	cis	rs6479527	0.904	rs7867925	chr9:96857990	G/A	cg14459158	chr9:96720562	NA	0.43	7.38	0.38	1.31e-12	Esophageal adenocarcinoma;
CRC	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg23100626	chr2:96804247	ASTL	-0.25	-6.66	-0.34	1.17e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.73	-11.05	-0.52	2.34e-24	Waist circumference;Body mass index;
CRC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.72	-8.17	-0.41	6.5e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.85	-0.35	3.56e-11	Inflammatory skin disease;
CRC	trans	rs2303319	0.504	rs16845960	chr2:162501613	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.76	0.68	5.2e-46	Chronic sinus infection;
CRC	cis	rs965469	0.947	rs965470	chr20:3381588	C/G	cg25506879	chr20:3388711	C20orf194	-0.4	-5.9	-0.31	9.05e-9	IFN-related cytopenia;
CRC	trans	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.91	0.36	2.48e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.39	-0.59	5.93e-33	Blood trace element (Zn levels);
CRC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.62	0.43	2.93e-16	Coffee consumption (cups per day);
CRC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.47	-7.01	-0.36	1.33e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg27535305	chr1:53392650	SCP2	-0.34	-6.1	-0.32	2.98e-9	Monocyte count;
CRC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.25	-0.45	3.02e-18	Alcohol dependence;
CRC	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg23234261	chr14:55582407	NA	-0.29	-5.89	-0.31	9.3e-9	Protein biomarker;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02891801	chr12:6472782	SCNN1A	-0.56	-6.81	-0.35	4.65e-11	Diisocyanate-induced asthma;
CRC	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.14e-9	Hair morphology;
CRC	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-10.62	-0.51	7.43e-23	Colorectal cancer;
CRC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.86	-0.58	6.07e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg01721255	chr8:58191610	C8orf71	0.47	6.02	0.31	4.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.68	-0.39	1.87e-13	Cholesterol, total;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15279766	chr6:26402511	BTN3A1	0.45	6.55	0.34	2.28e-10	Response to antipsychotic treatment;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23708337	chr7:1209742	NA	0.41	6.09	0.32	3.16e-9	Longevity;Endometriosis;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.47	6.45	0.34	3.94e-10	Longevity;Endometriosis;
CRC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.74	11.62	0.54	2.1e-26	Platelet distribution width;
CRC	cis	rs972578	0.868	rs2413727	chr22:43292114	A/G	cg01576275	chr22:43409880	NA	-0.42	-6.57	-0.34	1.93e-10	Mean platelet volume;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.1	-0.45	8.89e-18	Bipolar disorder;
CRC	cis	rs7264396	0.943	rs224395	chr20:34109427	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.97	-0.36	1.75e-11	Total cholesterol levels;
CRC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg00343986	chr7:65444356	GUSB	0.47	6.96	0.36	1.81e-11	Aortic root size;
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg07507251	chr3:52567010	NT5DC2	-0.43	-6.2	-0.32	1.68e-9	Bipolar disorder;
CRC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.59	-8.87	-0.44	4.67e-17	Aortic root size;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg24046110	chr8:143859143	LYNX1	0.48	8.32	0.42	2.3e-15	Urinary tract infection frequency;
CRC	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg23920097	chr1:209922102	NA	0.55	6.73	0.35	7.61e-11	Red blood cell count;
CRC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg13385794	chr1:248469461	NA	0.38	6.8	0.35	5.07e-11	Common traits (Other);
CRC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.41	-6.45	-0.33	4.04e-10	Bone mineral density (spine);
CRC	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.53	0.57	1.03e-29	Body mass index;
CRC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg27432699	chr2:27873401	GPN1	0.54	8.27	0.41	3.34e-15	Total body bone mineral density;
CRC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.47	6.63	0.34	1.39e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00369126	chr16:4674642	MGRN1	0.49	6.81	0.35	4.52e-11	Response to antipsychotic treatment;
CRC	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.47	5.92	0.31	8.03e-9	Metabolite levels;
CRC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.41	5.66	0.3	3.3e-8	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.43	-0.53	1.02e-25	Type 2 diabetes;
CRC	cis	rs11630290	1.000	rs72750986	chr15:63996338	C/A	cg12036633	chr15:63758958	NA	-0.56	-5.81	-0.3	1.49e-8	Iris characteristics;
CRC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	9.2	0.45	4.19e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.86	16.84	0.68	2.51e-46	White blood cell count (basophil);White blood cell count;
CRC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-10.94	-0.52	5.62e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06350524	chr2:169747178	SPC25	0.41	6.59	0.34	1.72e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.41	5.72	0.3	2.34e-8	Aortic root size;
CRC	trans	rs9914544	0.545	rs8071458	chr17:18790840	C/A	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.1	-0.32	3e-9	Educational attainment (years of education);
CRC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.57	8.05	0.41	1.57e-14	Arsenic metabolism;
CRC	cis	rs6840360	0.642	rs2709820	chr4:152384039	A/G	cg09659197	chr4:152720779	NA	0.34	6.7	0.35	9.13e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg01339444	chr6:118972232	C6orf204	0.52	5.82	0.31	1.41e-8	Diastolic blood pressure;
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.46	-9.09	-0.45	9.37e-18	Lung cancer;
CRC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg21132104	chr15:45694354	SPATA5L1	0.42	6.21	0.32	1.61e-9	Response to fenofibrate (adiponectin levels);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02506043	chr1:17765068	RCC2	0.45	6.87	0.35	3.18e-11	Schizophrenia;
CRC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.61	-0.3	4.26e-8	Aortic root size;
CRC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs56037433	1	rs56037433	chr2:162575985	G/A	cg01422129	chr2:677375	TMEM18	-0.75	-5.98	-0.31	5.77e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs10849893	0.595	rs7980819	chr12:121887194	A/G	cg01154721	chr12:121881891	KDM2B	-0.42	-6.03	-0.32	4.37e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13198984	chr17:80129470	CCDC57	-0.47	-8.21	-0.41	5.25e-15	Life satisfaction;
CRC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.42	7.89	0.4	4.45e-14	Mean corpuscular volume;
CRC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.56	-8.55	-0.43	4.67e-16	Uric acid levels;
CRC	cis	rs7731657	0.537	rs916818	chr5:130277673	G/C	cg08523029	chr5:130500466	HINT1	0.43	5.71	0.3	2.49e-8	Fasting plasma glucose;
CRC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.84	-0.31	1.22e-8	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03641858	chr19:12777774	MORG1;MAN2B1	0.39	6.4	0.33	5.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.08	0.32	3.28e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6460942	0.908	rs7781919	chr7:12235351	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.12	-0.32	2.61e-9	Coronary artery disease;
CRC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.65	10.16	0.49	2.92e-21	Huntington's disease progression;
CRC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.91	16.72	0.68	7.78e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.0	-0.52	3.43e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.31	0.64	2.6e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3764400	0.567	rs1452662	chr17:46293310	C/T	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg21856205	chr7:94953877	PON1	-0.49	-6.44	-0.33	4.12e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg27532560	chr4:187881888	NA	-0.55	-9.83	-0.48	3.65e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	11.72	0.54	9.6e-27	Menarche (age at onset);
CRC	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.86	-0.35	3.35e-11	IgG glycosylation;
CRC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.65	-7.83	-0.4	6.72e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.58	-5.84	-0.31	1.27e-8	Lung function (FVC);Lung function (FEV1);
CRC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.68	8.24	0.41	4.01e-15	Bipolar disorder;
CRC	cis	rs10274279	1.000	rs73163815	chr7:157388047	A/G	cg26886268	chr7:157387156	PTPRN2	-0.48	-5.83	-0.31	1.33e-8	Myopia (pathological);
CRC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.29	0.46	2.15e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg10556349	chr10:835070	NA	-0.38	-7.49	-0.38	6.21e-13	Survival in rectal cancer;
CRC	trans	rs948562	1.000	rs3829218	chr11:58331309	A/G	cg26660744	chr1:1573181	CDK11B	0.53	6.19	0.32	1.83e-9	Lymphoma;
CRC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.57	7.38	0.38	1.28e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg26805224	chr10:79626177	DLG5	-0.51	-7.49	-0.38	6.23e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.57	-0.5	1.14e-22	Bipolar disorder;
CRC	cis	rs6496667	1.000	rs1839972	chr15:90891354	A/G	cg04176472	chr15:90893244	GABARAPL3	0.55	8.51	0.42	6.22e-16	Rheumatoid arthritis;
CRC	cis	rs12024301	0.557	rs78535748	chr1:183620483	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg21466736	chr12:48725269	NA	0.45	6.68	0.35	1.01e-10	Glycated hemoglobin levels;
CRC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.35	0.33	7.06e-10	Axial length;
CRC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg20243544	chr17:37824526	PNMT	0.37	5.69	0.3	2.82e-8	Self-reported allergy;
CRC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.37	-0.46	1.24e-18	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg07125278	chr16:67683757	RLTPR	-0.57	-5.83	-0.31	1.29e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.33	-7.27	-0.37	2.66e-12	Total body bone mineral density;
CRC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg12790874	chr13:100310405	CLYBL	0.4	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs4073416	0.508	rs12587057	chr14:66066375	C/T	cg03016385	chr14:66212404	NA	-0.46	-6.3	-0.33	9.66e-10	N-glycan levels;
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg17178900	chr1:205818956	PM20D1	0.41	5.91	0.31	8.78e-9	Parkinson's disease;
CRC	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.8	13.47	0.6	3.13e-33	Hip circumference;
CRC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg10790698	chr19:18539756	SSBP4	-0.45	-8.64	-0.43	2.47e-16	Breast cancer;
CRC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg24375607	chr4:120327624	NA	0.48	7.63	0.39	2.56e-13	Corneal astigmatism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg14797243	chr11:68671428	IGHMBP2;MRPL21	-0.55	-6.87	-0.35	3.23e-11	Diisocyanate-induced asthma;
CRC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.71	-0.35	8.47e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.66	-0.39	2.09e-13	Gut microbiome composition (summer);
CRC	cis	rs7259376	0.936	rs1975173	chr19:22534538	C/G	cg02657401	chr19:22469223	NA	-0.32	-7.27	-0.37	2.6e-12	Menopause (age at onset);
CRC	cis	rs889398	0.802	rs2291959	chr16:69873992	T/G	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.22	-0.32	1.48e-9	Body mass index;
CRC	cis	rs10208940	0.841	rs12713645	chr2:68765627	G/A	cg12452813	chr2:68675892	NA	0.47	5.83	0.31	1.35e-8	Urate levels in lean individuals;
CRC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg03160526	chr17:80928410	B3GNTL1	0.63	8.86	0.44	5.11e-17	Glycated hemoglobin levels;
CRC	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.66	-12.06	-0.55	5.49e-28	Endometriosis;
CRC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.63	-0.3	3.91e-8	Bladder cancer;
CRC	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.59	-6.14	-0.32	2.36e-9	Coronary artery disease;
CRC	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.49	6.19	0.32	1.77e-9	Alzheimer's disease (survival time);
CRC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.69	8.89	0.44	4.09e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.25	-6.36	-0.33	6.86e-10	Lymphocyte counts;
CRC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.64	-10.25	-0.49	1.46e-21	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.51	6.04	0.32	4.16e-9	Bipolar disorder (body mass index interaction);
CRC	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.7	8.62	0.43	2.8e-16	Prostate cancer;
CRC	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg14631576	chr9:95140430	CENPP	0.33	6.18	0.32	1.88e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg20607287	chr7:12443886	VWDE	-0.55	-6.19	-0.32	1.78e-9	Coronary artery disease;
CRC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg15226275	chr6:116381976	FRK	0.3	8.59	0.43	3.64e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.88	16.66	0.68	1.28e-45	Hip circumference;
CRC	trans	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs2882667	0.931	rs10075893	chr5:138355871	A/G	cg09476006	chr5:138032270	NA	-0.43	-7.02	-0.36	1.27e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.65	12.57	0.57	7.18e-30	Menarche (age at onset);
CRC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.28	0.37	2.51e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg01420254	chr6:26195488	NA	0.49	6.18	0.32	1.89e-9	Gout;Renal underexcretion gout;
CRC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.68	0.35	1.05e-10	Dupuytren's disease;
CRC	trans	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-7.0	-0.36	1.44e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.51	-6.19	-0.32	1.76e-9	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00742472	chr14:31889912	NA	0.42	6.69	0.35	9.79e-11	Obesity-related traits;
CRC	trans	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg18288967	chr1:45987694	PRDX1	0.68	7.52	0.38	5.32e-13	Obesity-related traits;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.68	-10.11	-0.49	4.32e-21	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01457183	chr3:180707371	DNAJC19	0.37	6.14	0.32	2.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg19223190	chr17:80058835	NA	0.43	6.85	0.35	3.59e-11	Life satisfaction;
CRC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.68	0.3	3.04e-8	Neuroticism;
CRC	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.74	-0.3	2.14e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.47	0.65	6.15e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.08	0.36	8.81e-12	Hemoglobin concentration;
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.97	-0.4	2.57e-14	Bipolar disorder;
CRC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.79	12.03	0.55	7.39e-28	Cognitive function;
CRC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-9.67	-0.47	1.23e-19	Alzheimer's disease;
CRC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg14541582	chr5:601475	NA	-0.36	-7.37	-0.38	1.42e-12	Obesity-related traits;
CRC	cis	rs7120118	0.517	rs17726390	chr11:47319706	C/T	cg25783544	chr11:47291846	MADD	0.61	5.68	0.3	2.96e-8	HDL cholesterol;
CRC	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.84	7.62	0.39	2.78e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg12756093	chr1:115239321	AMPD1	0.48	7.02	0.36	1.29e-11	Autism;
CRC	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg26384229	chr12:38710491	ALG10B	0.51	6.5	0.34	2.97e-10	Morning vs. evening chronotype;
CRC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.28	-6.51	-0.34	2.81e-10	Total body bone mineral density;
CRC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.19	-0.32	1.79e-9	Dupuytren's disease;
CRC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-8.53	-0.43	5.26e-16	Menarche (age at onset);
CRC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.51	-8.31	-0.42	2.54e-15	Coronary artery disease;
CRC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.47	5.91	0.31	8.51e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.49	9.3	0.46	1.99e-18	Educational attainment (years of education);
CRC	cis	rs939584	1.000	rs7570993	chr2:652565	A/G	cg03610516	chr2:642275	NA	-0.43	-5.93	-0.31	7.78e-9	Body mass index;
CRC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-8.32	-0.42	2.4e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg05585544	chr11:47624801	NA	-0.41	-6.38	-0.33	6.15e-10	Mean corpuscular hemoglobin;
CRC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.6	-8.64	-0.43	2.55e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg20041105	chr8:143859282	LYNX1	0.44	7.94	0.4	3.33e-14	Urinary tract infection frequency;
CRC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	8.88	0.44	4.28e-17	Height;
CRC	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs7692995	1.000	rs7660642	chr4:17956017	T/C	cg08925142	chr4:18023851	LCORL	-0.51	-5.6	-0.3	4.5e-8	Height;
CRC	trans	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.03	-0.32	4.31e-9	Aortic root size;
CRC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.02	18.27	0.71	5.71e-52	Parkinson's disease;
CRC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.53	-10.22	-0.49	1.81e-21	Height;
CRC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.37	0.46	1.23e-18	Lymphocyte counts;
CRC	cis	rs1816752	0.837	rs9318530	chr13:24998557	A/G	cg02811702	chr13:24901961	NA	-0.45	-6.12	-0.32	2.59e-9	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26270738	chr6:83777272	DOPEY1	0.46	6.86	0.35	3.42e-11	Response to antipsychotic treatment;
CRC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg15226275	chr6:116381976	FRK	0.31	8.66	0.43	2.11e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.73	-0.35	7.76e-11	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg15845792	chr6:28175446	NA	0.42	5.74	0.3	2.15e-8	Depression;
CRC	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg26727032	chr16:67993705	SLC12A4	-0.61	-8.02	-0.4	1.86e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	11.68	0.54	1.34e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	0.75	5.95	0.31	6.75e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg15147215	chr3:52552868	STAB1	0.51	7.48	0.38	6.68e-13	Bipolar disorder;
CRC	cis	rs10991814	0.844	rs7860510	chr9:94128796	C/G	cg14446406	chr9:93919335	NA	0.58	6.36	0.33	6.84e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Parkinson's disease;
CRC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.6	7.91	0.4	3.86e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg13722127	chr7:150037890	RARRES2	0.5	7.94	0.4	3.32e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.42	-5.65	-0.3	3.52e-8	Carotid intima media thickness;
CRC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg19635926	chr16:89946313	TCF25	0.68	6.13	0.32	2.57e-9	Skin colour saturation;
CRC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.49	-0.34	3.15e-10	Fibrinogen levels;
CRC	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.76	-0.3	1.9e-8	Autism;
CRC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.6	-10.83	-0.51	1.4e-23	Aortic root size;
CRC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg01941586	chr1:40203715	PPIE	-0.45	-6.33	-0.33	7.9e-10	Blood protein levels;
CRC	cis	rs629535	0.773	rs681534	chr8:70056964	A/C	cg26132723	chr8:70041827	NA	0.35	5.86	0.31	1.15e-8	Dupuytren's disease;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.02	-0.4	1.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs10982256	1.000	rs4979414	chr9:117260185	C/T	cg13636371	chr9:117264095	DFNB31	0.35	6.78	0.35	5.52e-11	Bipolar disorder;
CRC	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs4141404	0.701	rs5753483	chr22:31549581	A/G	cg22777020	chr22:31556080	RNF185	-0.48	-5.77	-0.3	1.85e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg13057898	chr1:3703894	LRRC47	0.55	7.24	0.37	3.22e-12	Red cell distribution width;
CRC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.71	12.42	0.56	2.64e-29	Prudent dietary pattern;
CRC	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg11693508	chr17:37793320	STARD3	-0.64	-8.34	-0.42	2.01e-15	Bipolar disorder;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.64	6.79	0.35	5.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.63	9.82	0.48	4.07e-20	Hemoglobin concentration;
CRC	cis	rs6681460	0.932	rs523188	chr1:67174422	A/G	cg02459107	chr1:67143332	SGIP1	0.37	6.51	0.34	2.8e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.4	6.56	0.34	2.04e-10	Height;
CRC	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.26e-10	Common traits (Other);
CRC	trans	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.45	-5.81	-0.31	1.45e-8	Gut microbiome composition (summer);
CRC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.34	0.42	2.01e-15	Height;
CRC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg00343986	chr7:65444356	GUSB	0.59	8.83	0.44	6.37e-17	Aortic root size;
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg11843238	chr5:131593191	PDLIM4	0.43	8.11	0.41	9.95e-15	Breast cancer;
CRC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	9.93	0.48	1.67e-20	Coronary artery disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23819836	chr6:15663134	DTNBP1	0.38	6.02	0.31	4.59e-9	Obesity-related traits;
CRC	cis	rs16924133	0.793	rs58478170	chr11:33136631	C/T	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg11752769	chr1:207818423	CR1L	-0.55	-5.7	-0.3	2.65e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.98	-0.4	2.39e-14	Reticulocyte fraction of red cells;
CRC	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg04176472	chr15:90893244	GABARAPL3	0.35	6.07	0.32	3.51e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-8.56	-0.43	4.29e-16	Idiopathic membranous nephropathy;
CRC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.53	-9.51	-0.46	4.11e-19	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	-0.54	-8.99	-0.44	1.93e-17	Intelligence (multi-trait analysis);
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.48	6.67	0.34	1.11e-10	Height;
CRC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.58	0.43	3.85e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.43	6.29	0.33	9.91e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg25835954	chr13:50160062	RCBTB1	0.52	7.82	0.4	7.04e-14	Cortisol levels (saliva);
CRC	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11645453	chr3:52864694	ITIH4	-0.42	-7.81	-0.4	7.66e-14	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06233122	chr8:74888597	TMEM70	0.45	6.21	0.32	1.59e-9	Anxiety disorder;
CRC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.55	-7.83	-0.4	6.67e-14	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs4789693	1.000	rs4789693	chr17:80421870	A/C	cg04308225	chr17:80449738	NA	0.46	6.52	0.34	2.59e-10	Glucocorticoid-induced osteonecrosis;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg20933634	chr6:27740509	NA	0.5	6.94	0.36	2.07e-11	Parkinson's disease;
CRC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.85	11.63	0.54	1.96e-26	Asthma;
CRC	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.6	9.62	0.47	1.83e-19	Colorectal cancer;
CRC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.97	12.08	0.55	4.7e-28	IgG glycosylation;
CRC	cis	rs3849570	0.643	rs10779987	chr3:81970856	C/T	cg07356753	chr3:81810745	GBE1	-0.47	-6.42	-0.33	4.89e-10	Waist circumference;Body mass index;
CRC	cis	rs6076065	0.723	rs2424554	chr20:23415867	T/C	cg11657817	chr20:23433608	CST11	0.45	6.47	0.34	3.47e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	0.93	12.83	0.58	7.94e-31	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18029778	chr7:104654746	MLL5;LOC100216545	0.38	6.35	0.33	7.1e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.47	-8.75	-0.43	1.15e-16	Reticulocyte fraction of red cells;
CRC	cis	rs2342371	0.599	rs7618690	chr3:196146039	T/C	cg15048948	chr3:196158458	UBXN7	0.5	6.16	0.32	2.17e-9	Fat distribution (HIV);
CRC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg05341575	chr12:125625032	AACS	0.39	5.95	0.31	6.84e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2249694	0.586	rs9418987	chr10:135324409	A/G	cg16964102	chr10:135390573	NA	-0.44	-6.82	-0.35	4.39e-11	Obesity-related traits;
CRC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.05	-0.48	6.82e-21	Cognitive function;
CRC	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.65	10.94	0.52	5.64e-24	Subjective well-being (multi-trait analysis);
CRC	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.73	-7.26	-0.37	2.89e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg03623178	chr6:28175578	NA	0.58	6.39	0.33	5.64e-10	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09311052	chr1:154531418	UBE2Q1	0.53	6.89	0.36	2.85e-11	Thyroid stimulating hormone;
CRC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg21251018	chr6:28226885	NKAPL	0.49	7.8	0.4	8.17e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg25456477	chr12:86230367	RASSF9	-0.33	-5.77	-0.3	1.83e-8	Major depressive disorder;
CRC	cis	rs6504622	0.599	rs197913	chr17:44990046	G/C	cg16759221	chr17:45003025	GOSR2	-0.61	-9.72	-0.47	8.31e-20	Orofacial clefts;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.49	8.98	0.44	2.2e-17	Acylcarnitine levels;
CRC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg03160526	chr17:80928410	B3GNTL1	-0.41	-5.87	-0.31	1.07e-8	Breast cancer;
CRC	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.6	9.4	0.46	9.56e-19	Tourette's syndrome or obsessive-compulsive disorder;
CRC	trans	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg26043149	chr18:55253948	FECH	0.51	7.98	0.4	2.39e-14	Bone mineral density;
CRC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.62	-8.99	-0.44	2.04e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg07979401	chr6:33739406	LEMD2	0.46	5.96	0.31	6.32e-9	Schizophrenia;
CRC	trans	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.51	-0.38	5.79e-13	Endometrial cancer;
CRC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	11.0	0.52	3.47e-24	Motion sickness;
CRC	cis	rs728616	0.867	rs77376252	chr10:81809382	C/T	cg11900509	chr10:81946545	ANXA11	-0.56	-6.14	-0.32	2.4e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg04110750	chr16:69646130	NFAT5	-0.55	-7.63	-0.39	2.53e-13	IgE levels;
CRC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.67	-10.29	-0.49	9.9700000000000009e-22	Acne (severe);
CRC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.71	-9.33	-0.46	1.64e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.6	-8.07	-0.41	1.36e-14	Gut microbiome composition (summer);
CRC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.31	-0.46	1.88e-18	Morning vs. evening chronotype;
CRC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.36	-6.35	-0.33	7.06e-10	Erythrocyte sedimentation rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07092057	chr12:57914300	DDIT3	0.44	5.96	0.31	6.45e-9	Response to antipsychotic treatment;
CRC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.38	0.5	5.13e-22	Hemoglobin concentration;
CRC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.56	-8.01	-0.4	1.96e-14	Carotid intima media thickness;
CRC	cis	rs2579500	0.807	rs7584930	chr2:97298290	C/T	cg23100626	chr2:96804247	ASTL	-0.23	-5.65	-0.3	3.54e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg16898833	chr6:26189333	HIST1H4D	0.72	6.29	0.33	9.97e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.75	9.66	0.47	1.37e-19	Monocyte percentage of white cells;
CRC	cis	rs9906695	0.950	rs56389898	chr17:32575213	A/T	cg12698626	chr17:32581466	CCL2	0.46	5.95	0.31	6.96e-9	Monocyte percentage of white cells;
CRC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.54	7.44	0.38	9.06e-13	Cystic fibrosis severity;
CRC	cis	rs9467603	0.858	rs972087	chr6:25872579	A/G	cg08501292	chr6:25962987	TRIM38	0.79	7.9	0.4	4.18e-14	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs12144094	0.832	rs6683122	chr1:120242179	G/T	cg20995928	chr1:120229863	NA	0.43	6.04	0.32	4.21e-9	Height;
CRC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.36	-6.01	-0.31	5.05e-9	Blood metabolite levels;
CRC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg19046167	chr17:80928561	B3GNTL1	0.47	8.1	0.41	1.11e-14	Breast cancer;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3823572	0.510	rs4731991	chr7:133689090	A/G	cg03336402	chr7:133662267	EXOC4	-0.66	-9.61	-0.47	1.97e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.7	9.48	0.46	5.31e-19	Alzheimer's disease;
CRC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.8	-8.85	-0.44	5.62e-17	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.88	-13.33	-0.59	1.08e-32	Ulcerative colitis;
CRC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.38	-6.12	-0.32	2.62e-9	Iron status biomarkers;
CRC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg11212589	chr17:38028394	ZPBP2	0.48	8.9	0.44	3.88e-17	Self-reported allergy;
CRC	cis	rs995000	0.868	rs4409689	chr1:63177365	A/G	cg19896129	chr1:63156450	NA	0.43	6.66	0.34	1.13e-10	Triglyceride levels;
CRC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.93	0.31	7.73e-9	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08956724	chr16:29624832	SLC7A5P1	0.47	6.31	0.33	9.16e-10	Anxiety disorder;
CRC	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.54	8.65	0.43	2.35e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg14530993	chr4:882597	GAK	0.78	7.96	0.4	2.74e-14	Intelligence (multi-trait analysis);
CRC	trans	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg14222797	chr10:16859974	RSU1	0.64	6.37	0.33	6.35e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg21153622	chr11:89784906	NA	-0.46	-7.23	-0.37	3.45e-12	HDL cholesterol;
CRC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-12.86	-0.58	6.04e-31	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17164781	chr15:85144209	ZSCAN2	0.42	6.43	0.33	4.46e-10	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.95	0.31	6.99e-9	Rheumatoid arthritis;
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.4	-7.31	-0.37	2.02e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg13919466	chr1:32135498	COL16A1	-0.31	-5.94	-0.31	7.21e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14895029	chr7:2775587	GNA12	-0.4	-6.14	-0.32	2.43e-9	Height;
CRC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.34	5.81	0.3	1.51e-8	Emphysema distribution in smoking;
CRC	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg23815491	chr16:72088622	HP	0.46	6.78	0.35	5.58e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs4481887	0.504	rs6587439	chr1:248376070	A/G	cg00666640	chr1:248458726	OR2T12	-0.41	-6.51	-0.34	2.81e-10	Common traits (Other);
CRC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.66	-11.6	-0.54	2.63e-26	Educational attainment;
CRC	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.32	16.62	0.68	1.82e-45	Uric acid levels;
CRC	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.31	-0.37	2.03e-12	Menarche (age at onset);
CRC	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.49	-7.97	-0.4	2.54e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.55	8.18	0.41	6.45e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg18232548	chr7:50535776	DDC	-0.46	-6.44	-0.33	4.14e-10	Malaria;
CRC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.64	-0.47	1.56e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.15	0.45	6.02e-18	Parkinson's disease;
CRC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	16.33	0.67	2.62e-44	Lymphocyte percentage of white cells;
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg27432699	chr2:27873401	GPN1	-0.62	-9.48	-0.46	5.39e-19	Total body bone mineral density;
CRC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.71	-12.42	-0.57	2.57e-29	Mean corpuscular volume;
CRC	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.33	-0.33	7.94e-10	Diastolic blood pressure;
CRC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg24011408	chr12:48396354	COL2A1	0.44	6.56	0.34	2.05e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.49	6.39	0.33	5.8e-10	Alzheimer's disease (survival time);
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.47	-0.38	7.39e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.55	-8.55	-0.43	4.6e-16	Motion sickness;
CRC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.85	-9.81	-0.48	4.13e-20	Breast cancer;
CRC	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-7.91	-0.4	3.96e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg08717414	chr16:71523259	ZNF19	-0.4	-5.63	-0.3	3.85e-8	Blood protein levels;
CRC	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg12292205	chr6:26970375	C6orf41	-0.62	-7.72	-0.39	1.37e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-8.55	-0.43	4.56e-16	Plateletcrit;Platelet count;
CRC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.7	-11.77	-0.54	6.42e-27	Breast cancer;
CRC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-11.98	-0.55	1.09e-27	Body mass index;
CRC	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg02466173	chr16:30829666	NA	0.66	9.9	0.48	2.12e-20	Dementia with Lewy bodies;
CRC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.44	8.13	0.41	8.84e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.35	-0.42	1.94e-15	Platelet count;
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-11.07	-0.52	1.98e-24	Bipolar disorder;
CRC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.53	-8.93	-0.44	3.14e-17	Iron status biomarkers;
CRC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.51	8.29	0.42	3.02e-15	Aortic root size;
CRC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.56	-6.82	-0.35	4.36e-11	Body mass index;
CRC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg03395651	chr16:88107091	BANP	0.56	7.2	0.37	4.06e-12	Menopause (age at onset);
CRC	cis	rs2882667	0.690	rs311601	chr5:138053386	G/A	cg09476006	chr5:138032270	NA	0.61	10.01	0.48	8.97e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4728302	0.869	rs6955240	chr7:133581873	G/A	cg10665199	chr7:133106180	EXOC4	0.4	6.11	0.32	2.89e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg00343986	chr7:65444356	GUSB	0.41	5.86	0.31	1.1e-8	Aortic root size;
CRC	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.75	-10.24	-0.49	1.5e-21	Coronary artery disease;
CRC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.51	7.0	0.36	1.48e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg21251018	chr6:28226885	NKAPL	0.46	7.93	0.4	3.41e-14	Pubertal anthropometrics;
CRC	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.58	7.33	0.37	1.85e-12	Plateletcrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02993250	chr10:5726650	C10orf18	0.41	6.03	0.32	4.43e-9	Response to antipsychotic treatment;
CRC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.08e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00127732	chr19:42757846	ERF	0.43	6.08	0.32	3.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.73	7.27	0.37	2.6e-12	Diabetic retinopathy;
CRC	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg25856811	chr1:152973957	SPRR3	0.21	5.9	0.31	8.92e-9	Inflammatory skin disease;
CRC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	6.02	0.31	4.74e-9	Prudent dietary pattern;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg22907277	chr7:1156413	C7orf50	0.52	5.94	0.31	7.38e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12560992	chr17:57184187	TRIM37	0.53	7.37	0.38	1.41e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg16606324	chr3:10149918	C3orf24	0.71	9.83	0.48	3.77e-20	Alzheimer's disease;
CRC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.49	8.99	0.44	1.92e-17	Total body bone mineral density;
CRC	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.9	-15.19	-0.64	7.23e-40	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.16	0.45	5.78e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6663390	0.831	rs3754172	chr1:208086878	G/T	cg03990033	chr1:208084030	CD34	0.47	6.63	0.34	1.39e-10	Facial morphology (factor 18);
CRC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	8.79	0.44	8.52e-17	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg15786705	chr6:28176104	NA	0.54	7.06	0.36	1.01e-11	Parkinson's disease;
CRC	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg26695010	chr11:65641043	EFEMP2	-0.44	-6.42	-0.33	4.78e-10	Eosinophil percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09458940	chr7:23145311	KLHL7	0.46	6.31	0.33	9.2e-10	Anxiety disorder;
CRC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.64	-0.34	1.27e-10	Aortic root size;
CRC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.05	-0.52	2.28e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg12855166	chr17:30846586	MYO1D	-0.38	-6.44	-0.33	4.27e-10	Schizophrenia;
CRC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19875976	chr9:114246783	KIAA0368	0.46	6.5	0.34	2.99e-10	Response to antipsychotic treatment;
CRC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.59	-10.16	-0.49	2.85e-21	Total body bone mineral density;
CRC	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg08999081	chr20:33150536	PIGU	0.43	5.64	0.3	3.69e-8	Protein C levels;
CRC	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.73	11.63	0.54	1.97e-26	Plateletcrit;Platelet count;
CRC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg21153622	chr11:89784906	NA	-0.55	-9.25	-0.45	2.9e-18	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs7680126	0.500	rs4697717	chr4:10149784	C/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.16	-0.32	2.1e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.73	0.35	7.48e-11	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.26	-0.33	1.24e-9	Menopause (age at onset);
CRC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg08533674	chr1:46993347	NA	-0.67	-9.12	-0.45	7.82e-18	Monobrow;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27330692	chr10:72972192	UNC5B	0.44	6.02	0.31	4.54e-9	Anxiety disorder;
CRC	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.73	-9.62	-0.47	1.84e-19	Blood protein levels;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.5	5.98	0.31	5.71e-9	Depression;
CRC	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg00507830	chr2:103233733	NA	0.55	5.79	0.3	1.64e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	6.35	0.33	7.15e-10	Personality dimensions;
CRC	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg18404041	chr3:52824283	ITIH1	0.39	7.53	0.38	4.81e-13	Schizophrenia;
CRC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.82	-0.31	1.37e-8	Skin colour saturation;
CRC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg24289452	chr6:170231220	NA	-0.57	-6.49	-0.34	3.12e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg24375607	chr4:120327624	NA	0.48	7.44	0.38	8.67e-13	Corneal astigmatism;
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08219700	chr8:58056026	NA	0.55	6.5	0.34	2.99e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	trans	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-7.36	-0.38	1.51e-12	Schizophrenia;
CRC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.63	10.34	0.5	7.15e-22	Height;
CRC	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg13615338	chr4:55094005	PDGFRA	0.41	6.02	0.31	4.77e-9	Corneal astigmatism;
CRC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg04553112	chr3:125709451	NA	-0.52	-5.97	-0.31	6.13e-9	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg06896663	chr8:82754093	SNX16	-0.69	-6.17	-0.32	2.01e-9	Cognitive function;
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.8	0.3	1.54e-8	Prudent dietary pattern;
CRC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.7	-9.27	-0.46	2.55e-18	Coronary artery disease;
CRC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.59	8.64	0.43	2.43e-16	Coronary artery disease;
CRC	cis	rs9462027	0.628	rs7771778	chr6:34660324	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.32	0.33	8.42e-10	Systemic lupus erythematosus;
CRC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.5	7.98	0.4	2.44e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg26587870	chr6:27730563	NA	0.39	6.1	0.32	2.97e-9	Parkinson's disease;
CRC	cis	rs4757319	0.515	rs12809040	chr11:15431903	G/A	cg03245590	chr11:15329459	NA	0.53	9.25	0.45	2.89e-18	Breast cancer;
CRC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.72	-0.35	7.9e-11	Total cholesterol levels;
CRC	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.47	-6.52	-0.34	2.57e-10	Height;
CRC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.4	-0.46	9.71e-19	Subjective well-being;
CRC	cis	rs4588572	0.643	rs9293752	chr5:77798432	A/G	cg11547950	chr5:77652471	NA	0.44	6.52	0.34	2.6200000000000003e-10	Triglycerides;
CRC	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg13736514	chr6:26305472	NA	-0.45	-7.24	-0.37	3.18e-12	Educational attainment;
CRC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg25456477	chr12:86230367	RASSF9	0.33	5.82	0.31	1.43e-8	Major depressive disorder;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg14491479	chr8:144623711	ZC3H3	0.47	6.24	0.33	1.38e-9	Plasma plasminogen activator levels;
CRC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg07195577	chr17:27052828	TLCD1	-0.39	-5.6	-0.3	4.52e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg25019722	chr6:37503610	NA	-0.37	-6.53	-0.34	2.57e-10	Cognitive performance;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.42	-0.38	9.97e-13	Aortic root size;
CRC	cis	rs977987	0.872	rs2161648	chr16:75314629	T/G	cg03315344	chr16:75512273	CHST6	0.54	9.16	0.45	5.81e-18	Dupuytren's disease;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg08676242	chr7:75616848	TMEM120A	0.53	6.57	0.34	1.95e-10	Optic disc area;
CRC	cis	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg17948913	chr5:572064	NA	0.52	6.0	0.31	5.1e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.37	0.42	1.63e-15	Height;
CRC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.92	17.0	0.68	6.03e-47	Intelligence (multi-trait analysis);
CRC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.84	-0.31	1.27e-8	Schizophrenia;
CRC	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13736514	chr6:26305472	NA	-0.47	-7.63	-0.39	2.61e-13	Educational attainment;
CRC	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.96	0.44	2.39e-17	Fuchs's corneal dystrophy;
CRC	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.59	7.9	0.4	4.18e-14	White matter hyperintensity burden;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11820497	chr19:10654946	ATG4D	0.46	6.39	0.33	5.69e-10	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.54	7.74	0.39	1.19e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.29	6.05	0.32	3.91e-9	Homoarginine levels;
CRC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.64	-7.92	-0.4	3.61e-14	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02067639	chr14:71067412	MED6	0.41	6.56	0.34	2.1e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22800332	chr5:138775207	DNAJC18	0.46	6.05	0.32	3.92e-9	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02290350	chr8:58132656	NA	-0.6	-6.78	-0.35	5.45e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.52	-11.7	-0.54	1.14e-26	Urate levels in overweight individuals;
CRC	cis	rs3018066	0.748	rs6846579	chr4:107011756	A/G	cg01869342	chr4:106983673	TBCK	0.46	6.8	0.35	5.08e-11	Cancer;
CRC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.57	7.57	0.39	3.81e-13	Schizophrenia;
CRC	trans	rs2303319	0.582	rs62188151	chr2:162309849	C/A	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.27	-0.33	1.13e-9	Cognitive function;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg12273811	chr6:28175739	NA	0.67	10.31	0.49	8.63e-22	Cardiac Troponin-T levels;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.54	8.01	0.4	2e-14	Blood metabolite levels;
CRC	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.85	-15.05	-0.64	2.7e-39	Lewy body disease;
CRC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg19812747	chr11:111475976	SIK2	0.44	6.43	0.33	4.54e-10	Primary sclerosing cholangitis;
CRC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.76	10.53	0.5	1.52e-22	Coronary artery disease;
CRC	cis	rs965469	1.000	rs965469	chr20:3381549	T/C	cg25506879	chr20:3388711	C20orf194	-0.39	-5.75	-0.3	1.99e-8	IFN-related cytopenia;
CRC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg02741985	chr17:80059408	CCDC57	0.44	7.2	0.37	4.08e-12	Life satisfaction;
CRC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.01	-0.4	2.01e-14	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22885777	chr19:15947555	NA	0.46	7.5	0.38	6.12e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.43	-6.1	-0.32	3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.47	-9.27	-0.46	2.56e-18	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17608500	chr1:154955711	FLAD1	0.43	6.02	0.31	4.75e-9	Response to antipsychotic treatment;
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.75	-0.39	1.12e-13	Total body bone mineral density;
CRC	cis	rs9847710	0.869	rs2581793	chr3:53035655	G/A	cg04503182	chr3:53078218	SFMBT1	0.38	6.01	0.31	4.88e-9	Ulcerative colitis;
CRC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.61	8.03	0.41	1.7e-14	Orofacial clefts;
CRC	cis	rs7487075	0.619	rs67249026	chr12:46835768	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.75	0.3	2.08e-8	Itch intensity from mosquito bite;
CRC	cis	rs7635838	0.929	rs7638724	chr3:11413387	T/G	cg00170343	chr3:11313890	ATG7	0.42	6.37	0.33	6.44e-10	HDL cholesterol;
CRC	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg15382696	chr6:118971807	C6orf204	0.57	6.84	0.35	3.94e-11	Diastolic blood pressure;
CRC	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.56	6.38	0.33	6.09e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.3e-9	Prudent dietary pattern;
CRC	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.85	16.77	0.68	4.59e-46	Urate levels in lean individuals;
CRC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg16434002	chr17:42200994	HDAC5	-0.45	-6.12	-0.32	2.66e-9	Total body bone mineral density;
CRC	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.58	-7.23	-0.37	3.4e-12	Ulcerative colitis;
CRC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.36	5.61	0.3	4.23e-8	Total body bone mineral density;
CRC	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.76	-9.63	-0.47	1.7e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.57	-7.57	-0.38	3.9e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.46	6.44	0.33	4.13e-10	Lymphocyte counts;
CRC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.41	-7.3	-0.37	2.22e-12	Childhood ear infection;
CRC	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.03	0.61	2.24e-35	Colorectal cancer;
CRC	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.63	9.77	0.47	5.88e-20	Corneal astigmatism;
CRC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	6.15	0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.87	16.86	0.68	2.15e-46	Lewy body disease;
CRC	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.31	7.17	0.37	4.98e-12	Corneal astigmatism;
CRC	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg16591659	chr17:78472290	NA	0.41	5.87	0.31	1.08e-8	Fractional excretion of uric acid;
CRC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.38	-6.18	-0.32	1.9e-9	Survival in rectal cancer;
CRC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg23136738	chr11:925521	AP2A2	0.42	7.2	0.37	4.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg12573674	chr2:1569213	NA	-0.78	-8.11	-0.41	1.02e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg24375607	chr4:120327624	NA	0.43	6.68	0.35	1.03e-10	Corneal astigmatism;
CRC	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.13	0.49	3.7e-21	Corneal astigmatism;
CRC	cis	rs7638909	0.512	rs11720166	chr3:38599812	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-7.16	-0.37	5.37e-12	Electrocardiographic conduction measures;
CRC	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.7	-11.86	-0.55	2.94e-27	Itch intensity from mosquito bite;
CRC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.84	-13.3	-0.59	1.4e-32	Blood metabolite levels;
CRC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.07	0.36	9.28e-12	Hemoglobin concentration;
CRC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-9.5	-0.46	4.43e-19	Chronic sinus infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10869376	chr13:41345315	MRPS31	0.45	6.36	0.33	6.69e-10	Response to antipsychotic treatment;
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.84	-0.31	1.22e-8	Total body bone mineral density;
CRC	trans	rs800082	1.000	rs28847402	chr3:144316893	C/G	cg24215973	chr2:240111563	HDAC4	-0.52	-6.95	-0.36	1.95e-11	Smoking behavior;
CRC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.39	6.03	0.32	4.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.51	-0.38	5.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.46	-6.85	-0.35	3.65e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.52	9.19	0.45	4.67e-18	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	7.73	0.39	1.35e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg02896835	chr1:92012615	NA	-0.49	-7.15	-0.37	5.52e-12	Eosinophil percentage of white cells;
CRC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.72	-11.11	-0.52	1.43e-24	Prudent dietary pattern;
CRC	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg01843034	chr6:37503916	NA	-0.48	-8.8	-0.44	7.73e-17	Cognitive performance;
CRC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.45	-6.7	-0.35	9e-11	Height;
CRC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.92	14.66	0.63	8.32e-38	Parkinson's disease;
CRC	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.16e-13	Waist circumference;Weight;
CRC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.49	7.25	0.37	3.04e-12	Obesity-related traits;
CRC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.33	0.37	1.81e-12	Motion sickness;
CRC	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.73	0.35	7.46e-11	Axial length;
CRC	cis	rs4964805	0.770	rs11111779	chr12:104185496	G/A	cg02344784	chr12:104178138	NT5DC3	0.57	8.91	0.44	3.43e-17	Attention deficit hyperactivity disorder;
CRC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.7	7.04	0.36	1.11e-11	Tuberculosis;
CRC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.42	-9.05	-0.45	1.32e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg03037974	chr15:76606532	NA	-0.51	-7.59	-0.39	3.28e-13	Blood metabolite levels;
CRC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15369054	chr17:80825471	TBCD	-0.35	-5.87	-0.31	1.07e-8	Breast cancer;
CRC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.56	-0.34	2.13e-10	Daytime sleep phenotypes;
CRC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg09163369	chr1:210001066	C1orf107	0.5	7.02	0.36	1.26e-11	Orofacial clefts;
CRC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.66	-0.68	1.23e-45	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20284218	chr11:62648405	SLC3A2	0.41	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.69	-10.8	-0.51	1.83e-23	Blood protein levels;
CRC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.64	-6.59	-0.34	1.74e-10	Axial length;
CRC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg13722127	chr7:150037890	RARRES2	0.47	7.34	0.37	1.74e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg23254163	chr1:152506842	NA	0.43	8.51	0.42	6.08e-16	Hair morphology;
CRC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.89	10.75	0.51	2.56e-23	Exhaled nitric oxide output;
CRC	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg03929089	chr4:120376271	NA	-0.58	-6.94	-0.36	2.09e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.71	9.02	0.45	1.56e-17	Blood protein levels;
CRC	cis	rs427941	0.703	rs201443	chr7:101737688	A/T	cg06246474	chr7:101738831	CUX1	0.45	7.06	0.36	9.64e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg21251018	chr6:28226885	NKAPL	0.4	6.11	0.32	2.83e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg22676075	chr6:135203613	NA	0.42	6.49	0.34	3.24e-10	Red blood cell count;
CRC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg20684491	chr1:25596433	NA	0.45	7.96	0.4	2.75e-14	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs7605827	0.930	rs1473178	chr2:15576750	T/C	cg19274914	chr2:15703543	NA	0.39	6.02	0.31	4.78e-9	Educational attainment (years of education);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24181213	chr8:82586475	IMPA1	-0.37	-5.98	-0.31	5.89e-9	Schizophrenia;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	5.62	0.3	3.97e-8	Bipolar disorder;
CRC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.48	7.62	0.39	2.65e-13	Height;
CRC	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.84	-0.31	1.23e-8	Longevity;Endometriosis;
CRC	cis	rs938554	0.784	rs10939638	chr4:9977675	T/A	cg11266682	chr4:10021025	SLC2A9	0.35	5.64	0.3	3.62e-8	Blood metabolite levels;
CRC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.94	15.0	0.64	3.89e-39	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-8.07	-0.41	1.29e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.97	0.36	1.71e-11	Mean platelet volume;
CRC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.5	-0.38	6.17e-13	Retinal vascular caliber;
CRC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg25164649	chr6:28176230	NA	-0.61	-7.6	-0.39	3.1400000000000003e-13	Parkinson's disease;
CRC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg13198984	chr17:80129470	CCDC57	0.44	7.83	0.4	6.88e-14	Life satisfaction;
CRC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.51	8.11	0.41	1.01e-14	Red blood cell count;
CRC	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.47	-0.46	5.77e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.5	8.62	0.43	2.89e-16	Testicular germ cell tumor;
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg08222913	chr3:52553049	STAB1	-0.32	-5.83	-0.31	1.36e-8	Bipolar disorder;
CRC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00016498	chr17:40307048	RAB5C	0.44	6.11	0.32	2.83e-9	Response to antipsychotic treatment;
CRC	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.69	9.51	0.46	4.3e-19	Itch intensity from mosquito bite;
CRC	cis	rs7534824	0.582	rs17448827	chr1:101421407	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.64	0.3	3.67e-8	Refractive astigmatism;
CRC	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg24463073	chr6:118973353	C6orf204	0.48	6.21	0.32	1.61e-9	Diastolic blood pressure;
CRC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21582582	chr3:182698605	DCUN1D1	0.42	6.09	0.32	3.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.68	0.35	1.01e-10	Body mass index;
CRC	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.83	-0.4	6.72e-14	Caffeine consumption;
CRC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.35	-0.33	7.08e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.58	-0.39	3.51e-13	HDL cholesterol;
CRC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.41	8.02	0.4	1.87e-14	Mean corpuscular volume;
CRC	trans	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.82	-0.35	4.3e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4494114	1.000	rs9439081	chr1:39343012	A/G	cg25970120	chr1:39325951	RRAGC	-0.43	-5.97	-0.31	6.15e-9	Blood protein levels;
CRC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	1.01	8.22	0.41	4.68e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.51	-7.99	-0.4	2.35e-14	Airway imaging phenotypes;
CRC	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.64	-0.34	1.29e-10	Rheumatoid arthritis;
CRC	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg16898833	chr6:26189333	HIST1H4D	-0.78	-6.62	-0.34	1.45e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.67	-0.47	1.26e-19	Blood protein levels;
CRC	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.52	9.4	0.46	9.66e-19	Blood metabolite ratios;
CRC	trans	rs12517041	0.935	rs10061491	chr5:23296773	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg13798912	chr7:905769	UNC84A	0.51	5.88	0.31	1.01e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	12.33	0.56	5.45e-29	Platelet count;
CRC	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg21466736	chr12:48725269	NA	0.46	6.95	0.36	1.98e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.6	10.33	0.49	7.77e-22	Prudent dietary pattern;
CRC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.72	-8.03	-0.4	1.78e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.36	-7.37	-0.38	1.43e-12	Schizophrenia;
CRC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg02869306	chr7:64672164	INTS4L1	0.44	7.56	0.38	4.12e-13	Calcium levels;
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.67	-0.39	2.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg12273811	chr6:28175739	NA	0.61	8.81	0.44	7.35e-17	Cardiac Troponin-T levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23784313	chr12:15942613	EPS8	-0.51	-6.42	-0.33	4.7e-10	Diisocyanate-induced asthma;
CRC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.49	7.26	0.37	2.78e-12	Sjögren's syndrome;
CRC	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg10677697	chr7:45961126	IGFBP3	0.36	6.15	0.32	2.23e-9	Sitting height ratio;
CRC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	8.88	0.44	4.37e-17	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09852601	chr17:72732955	RAB37	0.38	6.19	0.32	1.82e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22078869	chr5:134241244	PCBD2	0.52	7.0	0.36	1.45e-11	Survival in pancreatic cancer;
CRC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.71	-10.97	-0.52	4.39e-24	Pancreatic cancer;
CRC	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg21452805	chr1:244014465	NA	-0.48	-6.67	-0.35	1.08e-10	RR interval (heart rate);
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg23161317	chr6:28129485	ZNF389	0.44	5.78	0.3	1.74e-8	Parkinson's disease;
CRC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.8	12.97	0.58	2.4e-31	Breast cancer;
CRC	cis	rs9463078	0.605	rs7763421	chr6:44877313	A/G	cg25276700	chr6:44698697	NA	0.25	5.98	0.31	5.86e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.42	-6.41	-0.33	5.14e-10	Red cell distribution width;
CRC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.48	-0.53	7.11e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.24e-11	Life satisfaction;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg11843238	chr5:131593191	PDLIM4	0.48	9.09	0.45	9.59e-18	Blood metabolite levels;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg18219212	chr1:16162653	FLJ37453	-0.41	-6.04	-0.32	4.19e-9	Brain structure;
CRC	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg09184832	chr6:79620586	NA	-0.45	-7.67	-0.39	1.9e-13	Intelligence (multi-trait analysis);
CRC	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.45	6.54	0.34	2.41e-10	Coronary artery disease;
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg23123621	chr4:1343375	KIAA1530	0.4	7.2	0.37	4.16e-12	Longevity;
CRC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg11003573	chr3:44754125	ZNF502	-0.34	-5.82	-0.31	1.4e-8	Depressive symptoms;
CRC	cis	rs7932354	0.617	rs7118170	chr11:46908721	C/G	cg19486271	chr11:47235900	DDB2	-0.42	-6.41	-0.33	5.01e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.53	8.27	0.41	3.34e-15	Prostate cancer;
CRC	trans	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg18288967	chr1:45987694	PRDX1	0.68	7.72	0.39	1.37e-13	Obesity-related traits;
CRC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.73	12.85	0.58	6.39e-31	Systemic lupus erythematosus;
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg11843238	chr5:131593191	PDLIM4	0.41	7.92	0.4	3.73e-14	Breast cancer;
CRC	cis	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.72	-6.07	-0.32	3.44e-9	Intelligence (multi-trait analysis);
CRC	cis	rs524281	0.773	rs2236652	chr11:66002681	G/A	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.93	0.55	1.68e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.68	0.35	1.02e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg09127314	chr1:152161683	NA	0.45	5.86	0.31	1.14e-8	Atopic dermatitis;
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg23193639	chr7:45961078	IGFBP3	0.4	6.73	0.35	7.39e-11	Sitting height ratio;
CRC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12516959	chr21:47718080	NA	0.33	5.87	0.31	1.09e-8	Testicular germ cell tumor;
CRC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.62	9.17	0.45	5.19e-18	Breast cancer;
CRC	cis	rs9491140	0.539	rs11751246	chr6:124692967	C/T	cg05308643	chr6:124982296	NKAIN2	0.52	6.93	0.36	2.28e-11	Neuroticism;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12273811	chr6:28175739	NA	0.66	10.07	0.49	5.57e-21	Cardiac Troponin-T levels;
CRC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26240231	chr7:1148101	C7orf50	-0.42	-5.61	-0.3	4.18e-8	Bronchopulmonary dysplasia;
CRC	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.89	9.92	0.48	1.88e-20	Inflammatory bowel disease;
CRC	cis	rs12692738	0.526	rs355840	chr2:165622122	C/G	cg03182029	chr2:165697222	COBLL1	0.51	5.98	0.31	5.74e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg19338460	chr6:170058176	WDR27	-0.71	-7.8	-0.4	8.04e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.76	-10.66	-0.51	5.68e-23	Schizophrenia;
CRC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.09	-0.32	3.21e-9	Height;
CRC	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.02	-0.32	4.64e-9	Adiposity;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15688767	chr3:125093330	ZNF148	0.46	6.01	0.31	4.95e-9	Thyroid stimulating hormone;
CRC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.38	-5.65	-0.3	3.41e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.57	9.44	0.46	7.1e-19	Schizophrenia;
CRC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg19980929	chr12:42632907	YAF2	0.49	7.51	0.38	5.71e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg19276012	chr2:219861030	NA	0.4	5.97	0.31	6.23e-9	Interleukin-6 levels;
CRC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.36	0.42	1.74e-15	Height;
CRC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.41	-5.76	-0.3	1.96e-8	Daytime sleep phenotypes;
CRC	cis	rs6973256	0.828	rs2016876	chr7:133395492	T/G	cg10665199	chr7:133106180	EXOC4	-0.39	-5.81	-0.31	1.44e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg18477163	chr1:228402036	OBSCN	0.42	7.04	0.36	1.14e-11	Diastolic blood pressure;
CRC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	12.01	0.55	8.59e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17465063	chr10:111985564	MXI1	0.41	6.6	0.34	1.66e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg11168104	chr5:1857477	NA	-0.4	-6.73	-0.35	7.43e-11	Cardiovascular disease risk factors;
CRC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Bladder cancer;
CRC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.43	7.0	0.36	1.48e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02951883	chr7:2050386	MAD1L1	0.41	5.61	0.3	4.38e-8	Neuroticism;
CRC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg15110403	chr19:17392923	ANKLE1	-0.35	-5.68	-0.3	2.97e-8	Systemic lupus erythematosus;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.13	-0.37	6.36e-12	Bipolar disorder;
CRC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.49	-7.6	-0.39	3.18e-13	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.69	9.64	0.47	1.54e-19	Breast cancer;
CRC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg20119798	chr7:94954144	PON1	-0.48	-6.19	-0.32	1.83e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.94	0.4	3.21e-14	Colorectal cancer;
CRC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.79	0.51	1.94e-23	Motion sickness;
CRC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.24e-9	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.24e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07254608	chr8:41997973	NA	-0.57	-7.05	-0.36	1.07e-11	Diisocyanate-induced asthma;
CRC	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.84	-14.97	-0.64	5.36e-39	Fuchs's corneal dystrophy;
CRC	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.7	9.39	0.46	1.03e-18	Coronary artery disease;
CRC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.28	0.46	2.35e-18	Height;
CRC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07701084	chr6:150067640	NUP43	0.44	6.32	0.33	8.49e-10	Lung cancer;
CRC	cis	rs9491140	0.539	rs11154226	chr6:124681785	G/A	cg19267163	chr6:125004984	NKAIN2	0.46	5.97	0.31	6.31e-9	Neuroticism;
CRC	cis	rs3736485	0.934	rs2414105	chr15:51868373	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.64	-0.34	1.3e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs519973	1.000	rs1380476	chr3:187633843	C/T	cg10168494	chr3:187635183	NA	0.5	8.53	0.43	5.59e-16	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.59	0.47	2.3e-19	Lung cancer;
CRC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25517755	chr10:38738941	LOC399744	-0.41	-5.98	-0.31	5.67e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.57	8.22	0.41	4.88e-15	Resting heart rate;
CRC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.21	-0.37	3.78e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-6.8	-0.35	4.96e-11	Body mass index;
CRC	cis	rs10071761	0.513	rs56157819	chr5:40362387	A/G	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.69	11.61	0.54	2.45e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	0.62	9.75	0.47	6.96e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs12999616	0.550	rs35358137	chr2:98502201	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	5.68	0.3	2.99e-8	Colorectal cancer;
CRC	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.66	6.75	0.35	6.57e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1223397	0.530	rs2458313	chr6:13309789	C/T	cg07912922	chr6:13274314	PHACTR1	0.4	6.24	0.33	1.34e-9	Blood pressure;
CRC	cis	rs7113874	0.569	rs11041985	chr11:8582684	A/G	cg17679104	chr11:8615758	STK33	-0.35	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.49	6.38	0.33	5.89e-10	Thyroid stimulating hormone;
CRC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-9.06	-0.45	1.19e-17	Migraine;Coronary artery disease;
CRC	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.71	-9.4	-0.46	9.34e-19	Blood pressure (smoking interaction);
CRC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg06172871	chr16:72088244	HP	0.39	5.69	0.3	2.81e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.46	0.53	8.48e-26	Monocyte percentage of white cells;
CRC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg01483505	chr11:975446	AP2A2	0.44	7.24	0.37	3.16e-12	Alzheimer's disease (late onset);
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg26554054	chr8:600488	NA	-0.52	-6.02	-0.31	4.66e-9	IgG glycosylation;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg13320257	chr7:1093903	C7orf50	-0.36	-6.15	-0.32	2.27e-9	HDL cholesterol;
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.31e-10	Bipolar disorder;
CRC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg22974920	chr21:40686053	BRWD1	0.43	6.08	0.32	3.31e-9	Cognitive function;
CRC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.24	-0.41	4.19e-15	Type 2 diabetes;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg08989290	chr16:615782	NHLRC4	0.44	8.29	0.42	2.93e-15	Height;
CRC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.51	-7.52	-0.38	5.29e-13	Coronary artery disease;
CRC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.6	-0.57	5.76e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.7	12.42	0.57	2.56e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17368874	chr8:145743346	RECQL4;LRRC14	0.52	7.52	0.38	5.3e-13	Anxiety disorder;
CRC	cis	rs9303280	0.559	rs4795408	chr17:38107627	G/A	cg26162295	chr17:38119207	GSDMA	-0.33	-5.81	-0.3	1.5e-8	Self-reported allergy;
CRC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg03030879	chr14:75389066	RPS6KL1	0.42	6.36	0.33	6.78e-10	Height;
CRC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg16447950	chr5:562315	NA	-0.83	-12.7	-0.57	2.34e-30	Obesity-related traits;
CRC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.74	-10.96	-0.52	4.85e-24	Systemic sclerosis;
CRC	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.37	5.72	0.3	2.39e-8	Reticulocyte fraction of red cells;
CRC	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg25856811	chr1:152973957	SPRR3	-0.21	-5.66	-0.3	3.22e-8	Inflammatory skin disease;
CRC	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.52	-7.12	-0.37	6.89e-12	Tuberculosis;
CRC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.63	-10.35	-0.5	6.54e-22	Depressive symptoms (multi-trait analysis);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24838029	chr1:43833615	ELOVL1	0.43	5.96	0.31	6.4e-9	Hip circumference;
CRC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg21770322	chr7:97807741	LMTK2	0.56	9.36	0.46	1.26e-18	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg21153622	chr11:89784906	NA	-0.44	-7.08	-0.36	8.62e-12	HDL cholesterol;
CRC	cis	rs72730918	0.590	rs8025974	chr15:51985275	A/G	cg14296394	chr15:51910925	DMXL2	-0.43	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22633769	chr20:60982531	CABLES2	0.47	7.05	0.36	1.06e-11	Colorectal cancer;
CRC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.36	0.62	1.21e-36	Chronic sinus infection;
CRC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg02527881	chr3:46936655	PTH1R	0.35	6.11	0.32	2.83e-9	Colorectal cancer;
CRC	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.46	6.86	0.35	3.43e-11	Neutrophil percentage of white cells;
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.67	-11.57	-0.54	3.28e-26	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7527798	0.571	rs4844611	chr1:207827538	G/C	cg09232269	chr1:207846808	CR1L	-0.45	-7.31	-0.37	2.02e-12	Erythrocyte sedimentation rate;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg00414561	chr15:23034473	NIPA2	-0.44	-6.66	-0.34	1.15e-10	Myopia (pathological);
CRC	cis	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg08112188	chr17:47440006	ZNF652	0.81	6.52	0.34	2.72e-10	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18585273	chr17:66197086	NA	0.47	6.7	0.35	9.01e-11	Response to antipsychotic treatment;
CRC	cis	rs10450586	0.863	rs7105447	chr11:27306238	A/G	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-6.03	-0.32	4.44e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.4	5.78	0.3	1.77e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14863265	chr7:2801509	GNA12	0.42	5.7	0.3	2.63e-8	Height;
CRC	cis	rs1006703	0.544	rs35299172	chr17:3834598	C/T	cg06463185	chr17:3833770	ATP2A3	0.55	6.62	0.34	1.49e-10	Glucose homeostasis traits;
CRC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.9	-9.95	-0.48	1.44e-20	Cerebrospinal P-tau181p levels;
CRC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.47	-7.02	-0.36	1.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.43	8.77	0.44	9.64e-17	Renal cell carcinoma;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg11843238	chr5:131593191	PDLIM4	0.34	6.57	0.34	1.94e-10	Blood metabolite levels;
CRC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.68	-0.35	1.05e-10	Renal cell carcinoma;
CRC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.83	0.44	6.22e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.14	-0.32	2.39e-9	Total body bone mineral density;
CRC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs427941	0.632	rs201497	chr7:101755928	A/C	cg06246474	chr7:101738831	CUX1	0.44	6.73	0.35	7.61e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	trans	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg16460994	chr15:82623834	NA	0.42	6.27	0.33	1.15e-9	Breast cancer;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg03623178	chr6:28175578	NA	0.81	11.99	0.55	1.02e-27	Parkinson's disease;
CRC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.73	10.95	0.52	5.2e-24	Immature fraction of reticulocytes;
CRC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	7.77	0.39	9.84e-14	Schizophrenia;
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.39	-6.54	-0.34	2.32e-10	Menopause (age at onset);
CRC	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.97	0.4	2.7e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2070997	1.000	rs2070997	chr9:133748083	A/G	cg01000188	chr9:133769184	QRFP	0.61	6.79	0.35	5.15e-11	Response to amphetamines;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.38	5.62	0.3	4.17e-8	Obesity-related traits;
CRC	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.73	-0.3	2.24e-8	Tuberculosis;
CRC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.51	-6.69	-0.35	9.64e-11	Glioblastoma;
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg15845792	chr6:28175446	NA	0.99	13.41	0.59	5.26e-33	Depression;
CRC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.56	6.17	0.32	2.06e-9	Cognitive function;
CRC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg21466736	chr12:48725269	NA	-0.53	-8.05	-0.41	1.52e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	9.06	0.45	1.21e-17	Cognitive test performance;
CRC	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.19	-0.32	1.84e-9	Axial length;
CRC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.69	14.23	0.62	3.75e-36	Schizophrenia;
CRC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.68	-0.3	3.02e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.16	-0.32	2.11e-9	Bipolar disorder;
CRC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg11279151	chr3:101281821	RG9MTD1	0.54	7.52	0.38	5.38e-13	Colorectal cancer;
CRC	cis	rs2811415	0.597	rs13070488	chr3:127784118	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.74	0.54	7.89e-27	Prudent dietary pattern;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.48	-6.32	-0.33	8.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	6.03	0.32	4.39e-9	Schizophrenia;
CRC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg24675056	chr1:15929824	NA	0.54	7.31	0.37	2.07e-12	Systolic blood pressure;
CRC	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg21851534	chr17:3907994	ZZEF1	-0.35	-5.73	-0.3	2.31e-8	Type 2 diabetes;
CRC	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.97	16.35	0.67	2.16e-44	Dupuytren's disease;
CRC	cis	rs6500602	0.584	rs11646063	chr16:4439209	A/G	cg08645402	chr16:4508243	NA	-0.4	-6.26	-0.33	1.19e-9	Schizophrenia;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.74	-0.3	2.1e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.72	14.36	0.62	1.21e-36	Schizophrenia;
CRC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg08551088	chr10:121631655	C10orf119	-0.47	-6.35	-0.33	7.18e-10	Select biomarker traits;
CRC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	9.48	0.46	5.15e-19	Joint mobility (Beighton score);
CRC	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.64	7.89	0.4	4.65e-14	Uric acid levels;
CRC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.02	-0.45	1.64e-17	Chronic sinus infection;
CRC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.4	-6.82	-0.35	4.34e-11	Blood metabolite levels;
CRC	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	1.09	10.13	0.49	3.48e-21	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-7.06	-0.36	9.8e-12	Mood instability;
CRC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.51	5.63	0.3	3.85e-8	Menarche (age at onset);
CRC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.39	5.63	0.3	3.78e-8	Tonsillectomy;
CRC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.39	-7.2	-0.37	4.06e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.66	10.67	0.51	5.09e-23	Height;
CRC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-19.11	-0.73	2.72e-55	Height;
CRC	cis	rs17767392	0.881	rs17767680	chr14:71997594	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.29	-0.37	2.34e-12	Mitral valve prolapse;
CRC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.75	0.68	5.43e-46	Chronic sinus infection;
CRC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	7.23	0.37	3.37e-12	Headache;
CRC	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg22852734	chr6:133119734	C6orf192	0.9	10.14	0.49	3.28e-21	Type 2 diabetes nephropathy;
CRC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.35	0.33	7.06e-10	Diabetic kidney disease;
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02290350	chr8:58132656	NA	-0.59	-7.14	-0.37	6.05e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.69	-10.5	-0.5	1.91e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.59	10.04	0.48	7.34e-21	Prudent dietary pattern;
CRC	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.19	11.24	0.53	4.98e-25	Prostate cancer;
CRC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg00343986	chr7:65444356	GUSB	-0.5	-7.52	-0.38	5.22e-13	Aortic root size;
CRC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg18099408	chr3:52552593	STAB1	0.34	5.89	0.31	9.48e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg18761221	chr20:60518478	NA	0.41	7.17	0.37	5.07e-12	Body mass index;
CRC	cis	rs1364705	1.000	rs6986732	chr8:120225428	A/C	cg27215916	chr8:120218354	NA	-0.39	-5.64	-0.3	3.73e-8	Hippocampal atrophy;
CRC	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.42	6.84	0.35	3.92e-11	Sitting height ratio;
CRC	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.72	-9.14	-0.45	6.78e-18	Prostate cancer;
CRC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.73	-9.78	-0.47	5.5e-20	Height;
CRC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-8.7	-0.43	1.63e-16	Endometrial cancer;
CRC	trans	rs6716963	0.672	rs7582395	chr2:194458906	G/T	cg00362665	chr19:19370064	HAPLN4	-0.36	-5.97	-0.31	6.06e-9	Schizophrenia;
CRC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.26	-0.37	2.74e-12	Chronic sinus infection;
CRC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.43	-0.33	4.46e-10	Total cholesterol levels;
CRC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg27661571	chr11:113659931	NA	-0.54	-6.76	-0.35	6.24e-11	Hip circumference adjusted for BMI;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.61	-0.39	2.93e-13	Bipolar disorder;
CRC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg14541582	chr5:601475	NA	-0.28	-5.87	-0.31	1.08e-8	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08831002	chr7:20826153	SP8	-0.4	-6.15	-0.32	2.27e-9	Myopia (pathological);
CRC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.64	9.32	0.46	1.76e-18	Menopause (age at onset);
CRC	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg04731861	chr2:219085781	ARPC2	-0.27	-5.78	-0.3	1.76e-8	Colorectal cancer;
CRC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.45	6.61	0.34	1.53e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg08761264	chr16:28874980	SH2B1	-0.42	-5.64	-0.3	3.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.5	-6.89	-0.36	2.77e-11	Colorectal cancer;
CRC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.68	-11.73	-0.54	8.51e-27	Personality dimensions;
CRC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.54	-8.47	-0.42	8.57e-16	Motion sickness;
CRC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg11887960	chr12:57824829	NA	-0.6	-6.68	-0.35	1.03e-10	Obesity-related traits;
CRC	trans	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	7.31	0.37	2.05e-12	Ulcerative colitis;
CRC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.47	-7.57	-0.39	3.78e-13	Obesity-related traits;
CRC	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-10.5	-0.5	1.9e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-7.99	-0.4	2.29e-14	Testicular germ cell tumor;
CRC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.96	-17.9	-0.7	1.7e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.63	6.33	0.33	8.13e-10	Major depressive disorder;
CRC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg21466736	chr12:48725269	NA	-0.52	-7.88	-0.4	4.88e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22357700	chr19:11805638	NA	0.4	6.04	0.32	4.28e-9	Myopia (pathological);
CRC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg25985355	chr7:65971099	NA	0.32	5.7	0.3	2.72e-8	Aortic root size;
CRC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.83	0.31	1.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs17539620	0.808	rs57833052	chr6:154877112	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	6.53	0.34	2.53e-10	Lipoprotein (a) levels;
CRC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.66	-0.34	1.16e-10	Lung cancer;
CRC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.62	-6.77	-0.35	6e-11	Body mass index;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg20933634	chr6:27740509	NA	0.45	6.44	0.33	4.32e-10	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs4926298	1.000	rs8104231	chr19:13159569	A/T	cg04657146	chr19:12876947	HOOK2	-0.43	-5.74	-0.3	2.12e-8	Bipolar disorder;
CRC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg05320533	chr16:89541815	ANKRD11	-0.41	-5.78	-0.3	1.78e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.14	-0.37	5.98e-12	Self-reported allergy;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.15	-0.32	2.23e-9	Bipolar disorder;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg17949981	chr6:28129498	ZNF389	0.41	5.62	0.3	4.15e-8	Cardiac Troponin-T levels;
CRC	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.76	11.36	0.53	1.95e-25	Testicular germ cell tumor;
CRC	cis	rs9549328	0.700	rs4907568	chr13:113617574	A/T	cg20742385	chr13:113633654	MCF2L	-0.56	-9.76	-0.47	6.42e-20	Systolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23503864	chr12:64616369	C12orf66	0.44	6.5	0.34	2.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.56	7.89	0.4	4.44e-14	Alcohol dependence;
CRC	trans	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.66	-12.26	-0.56	9.84e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg10820045	chr2:198174542	NA	-0.52	-8.87	-0.44	4.87e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg02033258	chr5:131593261	PDLIM4	0.32	5.65	0.3	3.48e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs7703744	0.634	rs17145248	chr5:118685011	C/T	cg17471836	chr5:118691007	TNFAIP8	0.41	5.62	0.3	4.03e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg07965774	chr1:17746286	RCC2	0.33	6.15	0.32	2.26e-9	Basal cell carcinoma;
CRC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	7.68	0.39	1.9e-13	Lung cancer in ever smokers;
CRC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.89	-16.52	-0.67	4.71e-45	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.64	11.85	0.55	3.23e-27	Calcium levels;
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.38	-6.63	-0.34	1.35e-10	Height;
CRC	trans	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg19894588	chr14:64061835	NA	-0.55	-7.53	-0.38	4.93e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs703970	0.560	rs2764817	chr10:80972653	C/G	cg20744163	chr10:80999841	ZMIZ1	-0.36	-5.74	-0.3	2.17e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	0.78	7.27	0.37	2.58e-12	Thyroid stimulating hormone;
CRC	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg20744362	chr22:50050164	C22orf34	0.32	5.82	0.31	1.38e-8	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.66e-23	Aortic root size;
CRC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.23	-14.4	-0.62	8.2e-37	Diabetic kidney disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13801712	chr1:39325720	RRAGC	0.45	6.35	0.33	6.98e-10	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16478012	chr16:87425779	FBXO31;MAP1LC3B	0.45	6.41	0.33	5.17e-10	Anxiety disorder;
CRC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.57	-7.01	-0.36	1.37e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.38	5.68	0.3	2.91e-8	Menarche (age at onset);
CRC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg11887960	chr12:57824829	NA	0.58	6.44	0.33	4.17e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.29	5.69	0.3	2.83e-8	Homoarginine levels;
CRC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg01262667	chr19:19385393	TM6SF2	0.38	6.24	0.33	1.36e-9	Tonsillectomy;
CRC	cis	rs4132509	1.000	rs6659180	chr1:243995348	C/T	cg21452805	chr1:244014465	NA	0.49	6.67	0.35	1.07e-10	RR interval (heart rate);
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg15849403	chr10:115803542	ADRB1	-0.47	-6.08	-0.32	3.35e-9	Parkinson's disease;
CRC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.39e-13	Corneal astigmatism;
CRC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.57	8.3	0.42	2.73e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18201393	chr15:75135266	ULK3	0.4	6.53	0.34	2.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg25356066	chr3:128598488	ACAD9	0.39	5.66	0.3	3.22e-8	IgG glycosylation;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.31	0.33	8.84e-10	Bipolar disorder;
CRC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.52	8.04	0.41	1.66e-14	Corneal astigmatism;
CRC	cis	rs61160187	0.750	rs1807017	chr5:60127724	T/C	cg16298547	chr5:60138761	ELOVL7	-0.28	-6.01	-0.31	4.82e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs6815814	0.808	rs7653908	chr4:38782221	G/C	cg06935464	chr4:38784597	TLR10	0.58	6.27	0.33	1.11e-9	Breast cancer;
CRC	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg13385794	chr1:248469461	NA	0.38	6.64	0.34	1.32e-10	Common traits (Other);
CRC	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-0.75	-11.28	-0.53	3.51e-25	Platelet distribution width;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22814256	chr22:41777658	TEF	0.44	6.2	0.32	1.72e-9	Response to antipsychotic treatment;
CRC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.51	-8.58	-0.43	3.92e-16	Sense of smell;
CRC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.54e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.53	-7.46	-0.38	7.68e-13	Caudate activity during reward;
CRC	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.5	-0.34	3.02e-10	Metabolite levels;
CRC	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.48	6.31	0.33	9.09e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg25171089	chr10:5708825	ASB13	0.41	5.66	0.3	3.31e-8	Menopause (age at onset);
CRC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.8	13.44	0.6	3.93e-33	Menopause (age at onset);
CRC	cis	rs7932354	0.583	rs11039014	chr11:46895378	C/T	cg19486271	chr11:47235900	DDB2	-0.4	-5.97	-0.31	6.16e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg08213375	chr14:104286397	PPP1R13B	0.4	6.2	0.32	1.65e-9	Reticulocyte count;
CRC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.81	14.15	0.62	7.69e-36	Prudent dietary pattern;
CRC	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.58	7.96	0.4	2.87e-14	Adiposity;
CRC	cis	rs6564851	0.506	rs62054666	chr16:81259721	C/G	cg05274606	chr16:81253692	PKD1L2	-0.38	-6.28	-0.33	1.05e-9	Carotenoid and tocopherol levels;
CRC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01741932	chr1:33816074	PHC2	0.43	6.23	0.32	1.42e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.56	-7.22	-0.37	3.52e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.51	0.34	2.8e-10	Renal cell carcinoma;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Parkinson's disease;
CRC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.7	0.6	4.19e-34	Menarche (age at onset);
CRC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg01483505	chr11:975446	AP2A2	0.42	6.83	0.35	4.1e-11	Alzheimer's disease (late onset);
CRC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19825600	chr2:3704501	ALLC	-0.53	-6.37	-0.33	6.52e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg12516270	chr8:143859308	LYNX1	-0.4	-6.6	-0.34	1.69e-10	Urinary tract infection frequency;
CRC	cis	rs4234284	0.556	rs13072737	chr3:126948835	C/T	cg27326032	chr3:127006922	NA	-0.49	-7.16	-0.37	5.42e-12	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CRC	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.48	-6.17	-0.32	2.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs587242	1.000	rs35729443	chr1:96897468	C/T	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.33	5.43e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.33	0.42	2.19e-15	Height;
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg07404485	chr7:94953653	PON1	-0.47	-6.14	-0.32	2.43e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg22638593	chr5:131593259	PDLIM4	-0.4	-6.54	-0.34	2.38e-10	Breast cancer;
CRC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.45	6.55	0.34	2.2e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg25174290	chr11:3078921	CARS	-0.4	-5.68	-0.3	3e-8	Calcium levels;
CRC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23939001	chr4:940644	TMEM175	-0.46	-7.67	-0.39	2.02e-13	Parkinson's disease;
CRC	cis	rs17155006	0.664	rs448342	chr7:107739727	A/G	cg05962710	chr7:107745446	LAMB4	-0.42	-7.36	-0.38	1.45e-12	Pneumococcal bacteremia;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.67	10.09	0.49	4.92e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg21431200	chr5:65017886	SGTB;NLN	0.4	6.22	0.32	1.47e-9	Menarche (age at onset);
CRC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg02527881	chr3:46936655	PTH1R	-0.36	-6.67	-0.35	1.07e-10	Colorectal cancer;
CRC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-5.71	-0.3	2.55e-8	Mean corpuscular volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21552947	chr19:893353	MED16	0.48	6.01	0.31	4.92e-9	Thyroid stimulating hormone;
CRC	cis	rs4862307	0.754	rs6846208	chr4:184991703	C/T	cg06737308	chr4:185021514	ENPP6	0.45	6.89	0.35	2.9e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.15	0.41	7.87e-15	Platelet count;
CRC	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg06781209	chr11:61594997	FADS2	-0.58	-7.36	-0.38	1.48e-12	Neutrophil count;Sum basophil neutrophil counts;
CRC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-10.81	-0.51	1.61e-23	Platelet distribution width;
CRC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.63	9.34	0.46	1.51e-18	Obesity-related traits;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg19182908	chr22:38204192	GCAT	-0.42	-6.2	-0.32	1.74e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.25	-0.49	1.37e-21	Bipolar disorder;
CRC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.92	-0.31	8.01e-9	Bipolar disorder;
CRC	cis	rs11031096	0.563	rs12289940	chr11:4224589	T/A	cg18678763	chr11:4115507	RRM1	-0.39	-6.17	-0.32	2.01e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.61	-9.08	-0.45	1.05e-17	Systolic blood pressure;
CRC	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg14515779	chr1:101123966	NA	-0.35	-6.21	-0.32	1.63e-9	Monocyte count;
CRC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg21251018	chr6:28226885	NKAPL	0.47	6.34	0.33	7.71e-10	Depression;
CRC	cis	rs3996993	0.809	rs111906843	chr6:52690014	G/A	cg20803780	chr6:52668592	GSTA1	0.36	6.34	0.33	7.41e-10	Hemoglobin concentration;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg16558177	chr4:4109446	NA	-0.62	-8.88	-0.44	4.31e-17	Blood pressure (smoking interaction);
CRC	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.66	-9.63	-0.47	1.72e-19	Type 2 diabetes;
CRC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.4	-0.59	5.83e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.43	7.67	0.39	1.98e-13	Blood metabolite ratios;
CRC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.68	10.55	0.5	1.36e-22	Monocyte count;
CRC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.44	6.76	0.35	6.12e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.03	-25.51	-0.81	6.14e-80	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.47	7.24	0.37	3.14e-12	Hemoglobin concentration;
CRC	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg14250997	chr9:106856677	SMC2	0.39	5.66	0.3	3.3e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.5	9.05	0.45	1.24e-17	Alcohol dependence;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg18758796	chr5:131593413	PDLIM4	0.39	6.31	0.33	9.03e-10	Breast cancer;
CRC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	8.3	0.42	2.81e-15	Eosinophilic esophagitis;
CRC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Blood metabolite levels;
CRC	cis	rs4481887	0.597	rs4504921	chr1:248582011	T/C	cg00666640	chr1:248458726	OR2T12	0.36	6.15	0.32	2.21e-9	Common traits (Other);
CRC	cis	rs55788414	1.000	rs7499792	chr16:81184318	C/T	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16262614	chr3:133464971	TF	0.4	7.09	0.36	8.42e-12	Iron status biomarkers;
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03043827	chr4:128981985	LARP1B	0.37	6.29	0.33	1.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	15.41	0.65	1.05e-40	Bipolar disorder;
CRC	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.5	7.01	0.36	1.33e-11	Coronary artery disease;
CRC	cis	rs7680126	0.596	rs35782983	chr4:10117728	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.77	-0.35	5.94e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg03160526	chr17:80928410	B3GNTL1	0.58	7.78	0.39	9.14e-14	Glycated hemoglobin levels;
CRC	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.65	-8.91	-0.44	3.45e-17	Cocaine dependence;
CRC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg27068330	chr11:65405492	SIPA1	0.46	6.85	0.35	3.59e-11	Acne (severe);
CRC	trans	rs8005150	0.737	rs73312845	chr14:88462861	T/A	cg25527770	chr19:1444892	NA	-0.55	-6.04	-0.32	4.12e-9	Hepatitis B;
CRC	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.49	7.74	0.39	1.24e-13	Schizophrenia;
CRC	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.3	-0.37	2.24e-12	Schizophrenia;
CRC	trans	rs12495832	0.778	rs79933115	chr3:147922205	A/G	cg10221266	chr7:153579447	NA	0.56	6.06	0.32	3.79e-9	Chin dimples;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19683457	chr6:105307726	HACE1	0.47	7.71	0.39	1.54e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19363699	chr19:11639867	ECSIT	0.44	6.17	0.32	2.05e-9	Survival in pancreatic cancer;
CRC	trans	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg09045935	chr12:6379348	NA	1.03	8.84	0.44	5.85e-17	Blood metabolite levels;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.76	-0.39	1.11e-13	Total body bone mineral density;
CRC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.75	-13.93	-0.61	5.65e-35	Age at first birth;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.42	8.61	0.43	3.18e-16	Bipolar disorder;
CRC	cis	rs9359856	0.529	rs1328017	chr6:90297603	T/C	cg13799429	chr6:90582589	CASP8AP2	0.73	7.77	0.39	9.97e-14	Bipolar disorder;
CRC	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg12756093	chr1:115239321	AMPD1	0.55	8.34	0.42	2.03e-15	Autism;
CRC	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg13611204	chr9:139324423	INPP5E	-0.4	-5.7	-0.3	2.65e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.67	8.71	0.43	1.5e-16	Uric acid levels;
CRC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.55	-0.43	4.83e-16	Morning vs. evening chronotype;
CRC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-14.83	-0.63	1.81e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg01629716	chr15:45996671	NA	0.4	8.3	0.42	2.67e-15	Waist circumference;Weight;
CRC	trans	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg17903999	chr18:56338584	MALT1	0.4	6.52	0.34	2.7e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-6.47	-0.34	3.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06307176	chr5:131281290	NA	-0.43	-6.36	-0.33	6.6e-10	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19127360	chr2:242089945	PPP1R7;PASK	0.45	6.53	0.34	2.43e-10	Anxiety disorder;
CRC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg13206674	chr6:150067644	NUP43	0.48	6.89	0.36	2.77e-11	Testicular germ cell tumor;
CRC	cis	rs6982240	0.514	rs892362	chr8:142269214	A/G	cg00672558	chr8:142262059	NA	-0.36	-5.75	-0.3	2.09e-8	Tonsillectomy;
CRC	cis	rs970548	0.909	rs55665473	chr10:46022005	G/A	cg15590007	chr10:45870220	ALOX5	0.49	6.24	0.33	1.36e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs230203	0.506	rs230194	chr20:55774345	A/G	cg13236649	chr20:55835020	BMP7	0.42	6.22	0.32	1.53e-9	Monobrow;
CRC	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.84	-0.31	1.22e-8	Height;
CRC	cis	rs294883	0.826	rs400764	chr6:159698518	A/C	cg14500486	chr6:159655392	FNDC1	-0.36	-5.82	-0.31	1.4e-8	Coronary artery disease;
CRC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-6.15	-0.32	2.24e-9	Schizophrenia;
CRC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.49	7.49	0.38	6.39e-13	Corneal astigmatism;
CRC	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg13919466	chr1:32135498	COL16A1	-0.32	-6.01	-0.31	4.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.73	-12.39	-0.56	3.43e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.43	-0.53	1.08e-25	Ulcerative colitis;
CRC	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.77	0.3	1.82e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.56	-8.32	-0.42	2.3e-15	Menopause (age at onset);
CRC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg25985355	chr7:65971099	NA	0.32	5.67	0.3	3.12e-8	Aortic root size;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg23097961	chr19:49055412	SULT2B1	0.2	6.04	0.32	4.22e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	1.12	13.05	0.58	1.19e-31	Obesity-related traits;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.13	-0.32	2.49e-9	Bipolar disorder;
CRC	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.94	-16.54	-0.67	3.8e-45	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.66	-8.84	-0.44	6.1e-17	Extraversion;
CRC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.37	-6.99	-0.36	1.54e-11	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg02466173	chr16:30829666	NA	0.63	9.56	0.47	2.81e-19	Dementia with Lewy bodies;
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.96	-22.5	-0.78	1.6e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.48	-0.46	5.22e-19	Platelet count;
CRC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.31	-6.64	-0.34	1.33e-10	Schizophrenia;
CRC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.59	8.44	0.42	1.02e-15	Response to temozolomide;
CRC	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	1.26	15.41	0.65	1.01e-40	Lung disease severity in cystic fibrosis;
CRC	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	2.09e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	7.01	0.36	1.4e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg01304814	chr3:48885189	PRKAR2A	0.86	6.24	0.33	1.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.06	0.45	1.19e-17	Dupuytren's disease;
CRC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.07	0.36	9.32e-12	Major depressive disorder;
CRC	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg03315344	chr16:75512273	CHST6	0.5	5.92	0.31	8.08e-9	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg17903999	chr18:56338584	MALT1	0.4	6.66	0.34	1.18e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-5.87	-0.31	1.08e-8	Vitiligo;
CRC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.21	-0.37	3.81e-12	Major depressive disorder;
CRC	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg20487152	chr13:99095054	FARP1	0.36	5.93	0.31	7.65e-9	Longevity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13066542	chr9:79009738	RFK	0.43	6.23	0.32	1.44e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.66	-7.69	-0.39	1.7e-13	Vitiligo;
CRC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.83	0.31	1.29e-8	Diabetic retinopathy;
CRC	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-8.05	-0.41	1.56e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg25985355	chr7:65971099	NA	-0.47	-5.65	-0.3	3.54e-8	Diabetic kidney disease;
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02725872	chr8:58115012	NA	-0.52	-7.17	-0.37	5.06e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs932541	1.000	rs6034489	chr20:16456812	G/A	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg12516270	chr8:143859308	LYNX1	0.44	7.92	0.4	3.69e-14	Urinary tract infection frequency;
CRC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.14	-0.32	2.43e-9	Alzheimer's disease (late onset);
CRC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg09911534	chr15:67153556	NA	-0.45	-6.73	-0.35	7.64e-11	Lung cancer (smoking interaction);
CRC	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.56	8.88	0.44	4.3e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg15786705	chr6:28176104	NA	0.63	8.02	0.4	1.83e-14	Parkinson's disease;
CRC	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg23920097	chr1:209922102	NA	-0.51	-6.55	-0.34	2.17e-10	Red blood cell count;
CRC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg02549819	chr16:58548995	SETD6	1.16	7.58	0.39	3.52e-13	Schizophrenia;
CRC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg13198984	chr17:80129470	CCDC57	0.43	7.56	0.38	3.92e-13	Life satisfaction;
CRC	trans	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.79	0.35	5.18e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6586163	0.872	rs7082101	chr10:90741615	C/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.08	-0.36	8.67e-12	Chronic lymphocytic leukemia;
CRC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.98	-0.4	2.5e-14	Height;
CRC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.68	-0.35	1.03e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.1	12.56	0.57	8.06e-30	Diabetic kidney disease;
CRC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-7.32	-0.37	1.97e-12	Subjective well-being;
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.45	-7.88	-0.4	4.71e-14	Lung cancer;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.46e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01077085	chr5:126112750	LMNB1	0.45	6.23	0.32	1.46e-9	Anxiety disorder;
CRC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07234876	chr8:600039	NA	-0.93	-8.14	-0.41	8.53e-15	IgG glycosylation;
CRC	cis	rs4664293	0.625	rs4664295	chr2:160520318	G/A	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.45	-5.86	-0.31	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg09654669	chr8:57350985	NA	-0.41	-5.71	-0.3	2.51e-8	Obesity-related traits;
CRC	cis	rs2274471	0.645	rs2104685	chr9:5106023	A/T	cg03390472	chr9:5043263	JAK2	-0.53	-6.38	-0.33	6.13e-10	Crohn's disease;
CRC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg02772935	chr3:125709198	NA	-0.48	-5.7	-0.3	2.66e-8	Blood pressure (smoking interaction);
CRC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.33	-0.37	1.75e-12	IgG glycosylation;
CRC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.82	-0.35	4.33e-11	Platelet distribution width;
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.17	-0.37	5.01e-12	Bipolar disorder;
CRC	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg02466173	chr16:30829666	NA	-0.66	-10.11	-0.49	4.1e-21	Dementia with Lewy bodies;
CRC	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg23627948	chr7:2760692	NA	0.47	5.66	0.3	3.34e-8	Childhood ear infection;
CRC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.64	0.34	1.29e-10	Bipolar disorder;
CRC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg08222913	chr3:52553049	STAB1	-0.34	-5.8	-0.3	1.55e-8	Bipolar disorder;
CRC	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.47	8.44	0.42	1.05e-15	Migraine;
CRC	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg01993067	chr11:68851601	TPCN2	0.51	6.03	0.32	4.33e-9	Blond vs. brown hair color;
CRC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.64	-8.92	-0.44	3.24e-17	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.48	0.38	6.66e-13	Height;
CRC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.63	-0.47	1.63e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.28e-20	Ileal carcinoids;
CRC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.39	5.89	0.31	9.62e-9	Hemoglobin concentration;
CRC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.45	0.33	4.03e-10	Aortic root size;
CRC	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.99	-18.5	-0.71	7.22e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7202877	0.572	rs4888371	chr16:75308781	G/A	cg03315344	chr16:75512273	CHST6	0.47	5.74	0.3	2.15e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.5	7.23	0.37	3.35e-12	Height;
CRC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.71	14.28	0.62	2.39e-36	Leprosy;
CRC	cis	rs720844	0.554	rs12615224	chr2:149297441	C/G	cg09247360	chr2:149335327	NA	-0.42	-5.7	-0.3	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.22	-0.37	3.6e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg21251018	chr6:28226885	NKAPL	0.38	5.72	0.3	2.34e-8	Parkinson's disease;
CRC	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.56	8.19	0.41	6.03e-15	Melanoma;
CRC	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.56	-9.68	-0.47	1.15e-19	Lung function (FVC);
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg12172441	chr6:28176163	NA	0.47	6.53	0.34	2.49e-10	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.61	0.47	1.93e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg27432699	chr2:27873401	GPN1	-0.62	-9.86	-0.48	2.97e-20	Total body bone mineral density;
CRC	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.38	-0.33	6.12e-10	IgG glycosylation;
CRC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.59	-8.3	-0.42	2.71e-15	Schizophrenia;
CRC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.05	-0.45	1.3e-17	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.63	10.66	0.51	5.44e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18913729	chr8:97274064	MTERFD1;PTDSS1	0.46	6.63	0.34	1.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg24416660	chr17:73865998	NA	-0.38	-5.76	-0.3	1.98e-8	Psoriasis;
CRC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.63	10.12	0.49	3.85e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11317019	chr17:42219250	C17orf53	0.45	6.38	0.33	6.03e-10	Response to antipsychotic treatment;
CRC	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.06	14.74	0.63	4.07e-38	Exhaled nitric oxide output;
CRC	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg14768367	chr16:72042858	DHODH	-0.6	-6.77	-0.35	5.97e-11	Blood protein levels;
CRC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	8.34	0.42	2.11e-15	Aortic root size;
CRC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg07130601	chr7:158766826	NA	-0.4	-5.78	-0.3	1.76e-8	Facial morphology (factor 20);
CRC	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.58	7.88	0.4	4.69e-14	Mammographic density (dense area);
CRC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.9	-0.31	8.8e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-8.3	-0.42	2.81e-15	Electroencephalogram traits;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-10.39	-0.5	4.81e-22	Longevity;Endometriosis;
CRC	cis	rs364477	0.904	rs279900	chr9:963897	G/C	cg13952963	chr9:998547	NA	0.57	6.13	0.32	2.53e-9	Major depressive disorder;
CRC	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg24578937	chr1:2090814	PRKCZ	-0.37	-6.9	-0.36	2.61e-11	Coronary artery disease;
CRC	cis	rs4664293	0.625	rs11899419	chr2:160545369	A/G	cg08347373	chr2:160653686	CD302	0.39	6.7	0.35	9.05e-11	Monocyte percentage of white cells;
CRC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.54e-13	Mean platelet volume;
CRC	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg00105475	chr2:10696890	NA	0.47	7.24	0.37	3.19e-12	Prostate cancer;
CRC	trans	rs9395066	0.545	rs10484627	chr6:44884267	A/T	cg04786201	chr1:17185605	NA	0.28	6.03	0.32	4.49e-9	Height;
CRC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.79	8.04	0.41	1.68e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.81	-0.35	4.67e-11	Coronary artery disease;
CRC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.73	11.75	0.54	7.2e-27	Dental caries;
CRC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.84	0.66	2.17e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7951870	0.617	rs7932354	chr11:46722221	T/C	cg19486271	chr11:47235900	DDB2	-0.49	-7.68	-0.39	1.89e-13	Schizophrenia;
CRC	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	1.09	12.84	0.58	7.36e-31	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08869571	chr19:12076348	ZNF763	0.33	6.23	0.32	1.42e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg02007433	chr3:129722099	NA	-0.5	-6.22	-0.32	1.48e-9	Blood pressure (smoking interaction);
CRC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.62	-7.48	-0.38	7.04e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg00666640	chr1:248458726	OR2T12	0.39	7.2	0.37	4.13e-12	Common traits (Other);
CRC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.56	-7.4	-0.38	1.15e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00938859	chr5:1591904	SDHAP3	0.72	7.95	0.4	3.01e-14	Breast cancer;
CRC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.66	0.39	2.03e-13	Axial length;
CRC	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg05562828	chr17:3906858	NA	-0.67	-13.23	-0.59	2.49e-32	Type 2 diabetes;
CRC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.72	10.03	0.48	8.03e-21	Breast cancer;
CRC	cis	rs4731207	0.564	rs12531844	chr7:124603900	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04866628	chr4:187026225	NA	-0.58	-7.22	-0.37	3.59e-12	Diisocyanate-induced asthma;
CRC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.56	0.43	4.47e-16	Homoarginine levels;
CRC	cis	rs9469578	1.000	rs73743328	chr6:33713550	G/A	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.24	5.69	0.3	2.82e-8	Cardiac Troponin-T levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg04865672	chr1:161087935	NIT1;PFDN2	0.43	6.07	0.32	3.52e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04376719	chr19:1028379	CNN2	0.43	6.15	0.32	2.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg03315344	chr16:75512273	CHST6	0.52	6.04	0.32	4.22e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	7.88	0.4	4.95e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.71	10.02	0.48	8.31e-21	Response to diuretic therapy;
CRC	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.39	-0.38	1.18e-12	Crohn's disease;
CRC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.59	0.34	1.73e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs17065868	0.764	rs7317779	chr13:45024461	A/C	cg10246903	chr13:45222710	NA	0.56	6.29	0.33	1.03e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg00631329	chr6:26305371	NA	-0.56	-9.3	-0.46	2.02e-18	Educational attainment;
CRC	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.79	-12.53	-0.57	1.05e-29	Blood pressure (smoking interaction);
CRC	trans	rs6600671	0.967	rs11249347	chr1:121188347	G/T	cg00646200	chr1:148855367	NA	0.34	6.2	0.32	1.72e-9	Hip geometry;
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg24503407	chr1:205819492	PM20D1	0.46	6.42	0.33	4.72e-10	Parkinson's disease;
CRC	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.71	13.05	0.58	1.18e-31	Hip circumference;
CRC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-6.47	-0.34	3.55e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs12580194	0.556	rs7955088	chr12:55732963	G/T	cg19537932	chr12:55886519	OR6C68	-0.65	-8.38	-0.42	1.53e-15	Cancer;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.54	-9.79	-0.47	5.04e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg00277334	chr10:82204260	NA	0.38	6.45	0.34	3.91e-10	Sarcoidosis;
CRC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.59	-8.21	-0.41	5.1e-15	Platelet distribution width;
CRC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.97	14.22	0.62	4.19e-36	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg20129853	chr10:51489980	NA	-0.35	-5.7	-0.3	2.67e-8	Prostate-specific antigen levels;
CRC	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs758324	0.773	rs11951407	chr5:131142661	T/C	cg25547332	chr5:131281432	NA	0.35	5.61	0.3	4.31e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21187239	chr8:97247397	UQCRB	0.44	6.15	0.32	2.22e-9	Response to antipsychotic treatment;
CRC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.2	0.49	2.12e-21	Type 2 diabetes;
CRC	cis	rs644148	0.738	rs2686768	chr19:44995990	C/T	cg15540054	chr19:45004280	ZNF180	-0.41	-5.74	-0.3	2.14e-8	Personality dimensions;
CRC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.69	9.02	0.45	1.61e-17	Breast cancer;
CRC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.65	9.7	0.47	9.54e-20	Initial pursuit acceleration;
CRC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg18876405	chr7:65276391	NA	0.47	6.49	0.34	3.08e-10	Aortic root size;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg03623178	chr6:28175578	NA	-0.95	-11.97	-0.55	1.22e-27	Depression;
CRC	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.67	10.76	0.51	2.41e-23	Testicular germ cell tumor;
CRC	cis	rs17401966	0.597	rs2180185	chr1:10246129	C/G	cg19773385	chr1:10388646	KIF1B	-0.47	-7.44	-0.38	8.93e-13	Hepatocellular carcinoma;
CRC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.61	-11.54	-0.54	4.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-6.55	-0.34	2.23e-10	Systemic lupus erythematosus;
CRC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.46	-6.45	-0.34	3.95e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08652108	chr6:44443600	NA	-0.43	-6.08	-0.32	3.35e-9	Daytime sleep phenotypes;
CRC	cis	rs4929949	0.902	rs61875898	chr11:8627224	C/A	cg02811074	chr11:8615871	STK33	0.34	5.78	0.3	1.74e-8	Body mass index;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.45	0.34	3.99e-10	Depression;
CRC	cis	rs2067615	0.831	rs1922437	chr12:107058045	C/T	cg13491945	chr12:107078410	RFX4	0.33	5.68	0.3	2.94e-8	Heart rate;
CRC	cis	rs6772849	0.930	rs12487604	chr3:128337075	T/A	cg08795948	chr3:128337044	NA	0.39	6.6	0.34	1.66e-10	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs995000	0.839	rs12090886	chr1:62981440	G/A	cg19896129	chr1:63156450	NA	-0.39	-6.0	-0.31	5.21e-9	Triglyceride levels;
CRC	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.05	-0.36	1.05e-11	Cholesterol, total;
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.61	8.98	0.44	2.09e-17	Schizophrenia;
CRC	cis	rs5758511	0.573	rs1883205	chr22:42243020	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-6.16	-0.32	2.08e-9	Birth weight;
CRC	trans	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg02936872	chr9:99801550	CTSL2	0.48	6.18	0.32	1.85e-9	Iron status biomarkers;
CRC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg10820045	chr2:198174542	NA	-0.57	-11.38	-0.53	1.66e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg17321639	chr7:2759063	NA	-0.37	-5.72	-0.3	2.42e-8	Height;
CRC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-9.1	-0.45	8.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.39	7.37	0.38	1.4e-12	Subjective well-being;
CRC	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.63	8.62	0.43	2.88e-16	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03610000	chr11:128392383	ETS1	0.42	7.1	0.36	7.75e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg11843238	chr5:131593191	PDLIM4	0.42	7.94	0.4	3.14e-14	Breast cancer;
CRC	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.4	6.29	0.33	9.87e-10	Type 1 diabetes;
CRC	cis	rs6076065	0.723	rs6137909	chr20:23344728	A/G	cg11657817	chr20:23433608	CST11	0.43	6.25	0.33	1.31e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg04166393	chr7:2884313	GNA12	0.38	5.72	0.3	2.43e-8	Height;
CRC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.42	-0.42	1.16e-15	Monocyte percentage of white cells;
CRC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg10298567	chr3:47292165	KIF9	0.4	6.25	0.33	1.3e-9	Colorectal cancer;
CRC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-10.62	-0.51	7.56e-23	Systemic lupus erythematosus;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23708337	chr7:1209742	NA	-0.39	-5.87	-0.31	1.06e-8	Longevity;Endometriosis;
CRC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.9	-0.31	8.81e-9	Life satisfaction;
CRC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.65	11.3	0.53	3.18e-25	Prostate cancer;
CRC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg00255919	chr5:131827918	IRF1	0.36	6.11	0.32	2.81e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.68	9.71	0.47	9.38e-20	Body mass index;
CRC	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg16540259	chr10:75572220	NDST2	0.38	6.15	0.32	2.21e-9	Inflammatory bowel disease;
CRC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.38	6.35	0.33	7.15e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.56	-8.11	-0.41	1.01e-14	IgG glycosylation;
CRC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.32	0.46	1.69e-18	Lung cancer;
CRC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.58	7.82	0.4	7.34e-14	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00145757	chr11:118478637	PHLDB1	0.47	6.57	0.34	1.92e-10	Response to antipsychotic treatment;
CRC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.86	-0.31	1.15e-8	Crohn's disease;
CRC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg04731861	chr2:219085781	ARPC2	-0.27	-5.69	-0.3	2.86e-8	Colorectal cancer;
CRC	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg20041105	chr8:143859282	LYNX1	-0.32	-5.65	-0.3	3.45e-8	Urinary tract infection frequency;
CRC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.79	0.35	5.29e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg20041105	chr8:143859282	LYNX1	0.46	8.31	0.42	2.48e-15	Urinary tract infection frequency;
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg00280220	chr17:61926910	NA	0.34	5.65	0.3	3.49e-8	Prudent dietary pattern;
CRC	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.61	8.99	0.44	2e-17	Bone mineral density;
CRC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.44	6.37	0.33	6.51e-10	Emphysema distribution in smoking;
CRC	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.34	-0.33	7.58e-10	Prevalent atrial fibrillation;
CRC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.81	-9.7	-0.47	9.66e-20	Initial pursuit acceleration;
CRC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg19193384	chr17:30244184	NA	-0.66	-7.59	-0.39	3.4e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.61	9.47	0.46	5.78e-19	Gestational age at birth (maternal effect);
CRC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.46e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg02683197	chr6:28174875	NA	0.7	9.57	0.47	2.57e-19	Parkinson's disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg05886006	chr1:161359784	NA	-0.4	-5.98	-0.31	5.98e-9	Daytime sleep phenotypes;
CRC	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.43	6.45	0.33	4.02e-10	Endometrial cancer;
CRC	cis	rs883565	0.569	rs7614000	chr3:39152575	C/G	cg01426195	chr3:39028469	NA	-0.42	-6.99	-0.36	1.56e-11	Handedness;
CRC	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg06484146	chr7:12443880	VWDE	-0.64	-6.66	-0.34	1.18e-10	Coronary artery disease;
CRC	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.55	8.26	0.41	3.58e-15	Blood protein levels;
CRC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.56	6.19	0.32	1.75e-9	Initial pursuit acceleration;
CRC	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.65	6.68	0.35	1.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.25	-0.41	3.78e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs1973993	0.745	rs7512263	chr1:96941158	C/A	cg10631902	chr5:14652156	NA	-0.42	-6.87	-0.35	3.26e-11	Weight;
CRC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.74	12.3	0.56	7.25e-29	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10192736	chr19:1028627	CNN2	0.41	6.21	0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.45	6.64	0.34	1.27e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.39	5.98	0.31	5.67e-9	Monocyte count;
CRC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.41	-0.33	5.18e-10	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22559639	chr12:53895182	TARBP2	0.36	6.62	0.34	1.43e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15433164	chr3:25824899	NGLY1	0.33	6.45	0.34	4.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2882667	0.838	rs11958529	chr5:138395068	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.59e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	cis	rs9928842	0.722	rs1035540	chr16:75278795	A/G	cg09066997	chr16:75300724	BCAR1	0.71	7.02	0.36	1.27e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.49	9.28	0.46	2.34e-18	Alcohol dependence;
CRC	cis	rs910187	1.000	rs910187	chr20:45841052	A/G	cg27589058	chr20:45804311	EYA2	0.35	6.37	0.33	6.47e-10	Migraine;
CRC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Body mass index;
CRC	cis	rs501916	0.833	rs11629796	chr15:48045248	A/G	cg16110827	chr15:48056943	SEMA6D	-0.47	-7.17	-0.37	4.99e-12	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg09163369	chr1:210001066	C1orf107	0.41	5.75	0.3	2.05e-8	Orofacial clefts;
CRC	cis	rs4481887	0.573	rs10888329	chr1:248404654	C/T	cg00666640	chr1:248458726	OR2T12	-0.41	-6.55	-0.34	2.16e-10	Common traits (Other);
CRC	cis	rs7632954	1.000	rs9811322	chr3:8524337	T/C	cg03495237	chr3:8533978	NA	0.33	5.89	0.31	9.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.82e-15	Mean platelet volume;
CRC	cis	rs72730918	0.564	rs6493507	chr15:51874119	C/T	cg14296394	chr15:51910925	DMXL2	-0.44	-5.72	-0.3	2.42e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.49	-0.34	3.11e-10	DNA methylation (variation);
CRC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg14847009	chr1:175162515	KIAA0040	0.27	5.87	0.31	1.09e-8	Alcohol dependence;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.49	0.42	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg08992911	chr2:238395768	MLPH	0.58	5.93	0.31	7.49e-9	Prostate cancer;
CRC	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg23167259	chr10:102495509	NA	-0.47	-6.52	-0.34	2.6e-10	Alzheimer's disease;
CRC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.29	0.42	3.02e-15	Lung cancer;
CRC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.82	-14.21	-0.62	4.78e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.26	14.65	0.63	9.07e-38	Diabetic kidney disease;
CRC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg11292332	chr7:45801988	SEPT13	-0.38	-6.83	-0.35	4.14e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs7904985	1.000	rs12358144	chr10:88114486	C/G	cg07322936	chr10:88137208	NA	-0.49	-6.57	-0.34	1.96e-10	Barrett's esophagus;
CRC	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.88	17.44	0.69	1.06e-48	Hip circumference;
CRC	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg07423050	chr13:99094983	FARP1	0.46	6.38	0.33	6.08e-10	Neuroticism;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.07	0.36	9.56e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.39	0.42	1.46e-15	Gut microbiome composition (summer);
CRC	cis	rs9649465	1.000	rs2109724	chr7:123325391	C/T	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.45	-5.62	-0.3	4.14e-8	Colorectal adenoma (advanced);
CRC	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.36	-5.61	-0.3	4.2e-8	Essential tremor;
CRC	cis	rs10274279	1.000	rs10274279	chr7:157387441	C/T	cg26886268	chr7:157387156	PTPRN2	0.45	5.69	0.3	2.76e-8	Myopia (pathological);
CRC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg15147215	chr3:52552868	STAB1	-0.66	-11.7	-0.54	1.12e-26	Electroencephalogram traits;
CRC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg11833968	chr6:79620685	NA	-0.35	-5.99	-0.31	5.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12044355	0.858	rs3738401	chr1:231830295	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.81	0.35	4.77e-11	Alzheimer's disease;
CRC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.49	6.84	0.35	3.79e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.23	-6.48	-0.34	3.34e-10	Urinary metabolites;
CRC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.58	-10.97	-0.52	4.46e-24	Eye color traits;
CRC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.81	-13.59	-0.6	1.06e-33	Height;
CRC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.61	8.28	0.42	3.03e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.52	7.69	0.39	1.76e-13	Menarche (age at onset);
CRC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.6	-9.11	-0.45	8.28e-18	Coronary artery disease;
CRC	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg06172871	chr16:72088244	HP	0.44	6.27	0.33	1.13e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.58	-10.62	-0.51	7.75e-23	Facial morphology (factor 23);
CRC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.8	-0.51	1.8e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg11176159	chr1:28213800	NA	0.3	5.8	0.3	1.56e-8	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01900965	chr4:2471727	RNF4	0.42	6.37	0.33	6.36e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.62	-7.17	-0.37	5.01e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg12365402	chr11:9010492	NRIP3	0.53	8.88	0.44	4.47e-17	Hemoglobin concentration;
CRC	trans	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg10756647	chr7:56101905	PSPH	0.73	7.62	0.39	2.71e-13	Diabetic kidney disease;
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg21155852	chr7:2048760	MAD1L1	-0.52	-6.98	-0.36	1.63e-11	Bipolar disorder;
CRC	cis	rs12580194	0.593	rs66516917	chr12:55749131	T/G	cg23425280	chr12:56401806	NA	0.45	5.66	0.3	3.26e-8	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07569756	chr17:48474564	LRRC59	0.48	6.75	0.35	6.86e-11	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.37	6.03	0.32	4.38e-9	Major depressive disorder;
CRC	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg25834613	chr7:1915315	MAD1L1	-0.5	-7.78	-0.39	9.28e-14	Bipolar disorder;
CRC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.7	0.39	1.56e-13	Mean platelet volume;
CRC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg10298567	chr3:47292165	KIF9	-0.35	-5.79	-0.3	1.64e-8	Colorectal cancer;
CRC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.57	-8.68	-0.43	1.83e-16	Lung cancer;
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	14.05	0.61	1.86e-35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.78	-14.46	-0.62	5.11e-37	Metabolic syndrome;
CRC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg01874867	chr7:94954059	PON1	0.5	6.33	0.33	7.94e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs73200209	0.744	rs11612443	chr12:116518839	A/G	cg01776926	chr12:116560359	MED13L	-0.62	-7.28	-0.37	2.51e-12	Total body bone mineral density;
CRC	cis	rs7705042	1.000	rs7705042	chr5:141492419	C/A	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.9	-0.31	9e-9	Asthma;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.13	0.32	2.58e-9	Bipolar disorder;
CRC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.9	-0.4	4.35e-14	Gut microbiome composition (summer);
CRC	cis	rs3751196	0.808	rs17034645	chr12:104218956	A/G	cg02344784	chr12:104178138	NT5DC3	-0.67	-7.1	-0.36	7.56e-12	Sense of smell;
CRC	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24249390	chr15:90295951	MESP1	-0.58	-9.29	-0.46	2.14e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.41	-6.03	-0.32	4.51e-9	Breast size;
CRC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.67	10.14	0.49	3.41e-21	Lung cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00734800	chr3:50388182	TUSC4;CYB561D2	-0.54	-6.6	-0.34	1.65e-10	Diisocyanate-induced asthma;
CRC	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.37	-5.9	-0.31	8.96e-9	Height;
CRC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.2	-0.37	4.14e-12	Mean corpuscular volume;
CRC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.64	9.6	0.47	2.18e-19	Initial pursuit acceleration;
CRC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.62	-0.39	2.64e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.58	-8.88	-0.44	4.34e-17	Height;
CRC	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.48	8.15	0.41	7.74e-15	Testicular germ cell tumor;
CRC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg03316587	chr8:142245164	NA	-0.38	-5.71	-0.3	2.46e-8	Immature fraction of reticulocytes;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.82	10.63	0.51	7.03e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.62	9.75	0.47	6.88e-20	Huntington's disease progression;
CRC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-7.05	-0.36	1.05e-11	Height;
CRC	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.58	8.67	0.43	2.01e-16	Corneal astigmatism;
CRC	cis	rs2073499	1.000	rs79536844	chr3:50375066	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.67	5.85	0.31	1.16e-8	Schizophrenia;
CRC	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs6840360	0.582	rs2709812	chr4:152335749	C/T	cg09659197	chr4:152720779	NA	-0.3	-5.77	-0.3	1.79e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.5	8.66	0.43	2.23e-16	Hypertriglyceridemia;
CRC	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg19875578	chr6:126661172	C6orf173	0.44	6.04	0.32	4.19e-9	Male-pattern baldness;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg07617317	chr6:118971624	C6orf204	0.52	6.4	0.33	5.29e-10	Diastolic blood pressure;
CRC	cis	rs6662572	0.737	rs10890356	chr1:46317924	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.9	-0.31	8.93e-9	Blood protein levels;
CRC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.94	-0.31	7.44e-9	Lung cancer;
CRC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.75	9.0	0.44	1.86e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-0.57	-5.81	-0.3	1.5e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg18827107	chr12:86230957	RASSF9	-0.4	-6.11	-0.32	2.74e-9	Major depressive disorder;
CRC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.76	0.35	6.39e-11	Body mass index;
CRC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg26816564	chr1:7831052	VAMP3	0.56	5.82	0.31	1.4e-8	Inflammatory bowel disease;
CRC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg03013999	chr17:37608204	MED1	0.43	6.49	0.34	3.21e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.43	-6.84	-0.35	3.96e-11	Corneal astigmatism;
CRC	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg17133734	chr15:86042851	AKAP13	0.41	6.47	0.34	3.48e-10	Coronary artery disease;
CRC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.47	-6.0	-0.31	5.22e-9	Aortic root size;
CRC	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.42	-6.18	-0.32	1.93e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Tonsillectomy;
CRC	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.55	10.47	0.5	2.45e-22	Lipoprotein (a) levels;
CRC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.6	0.43	3.38e-16	Homoarginine levels;
CRC	trans	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg01134436	chr17:81009848	B3GNTL1	0.72	6.76	0.35	6.27e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02290350	chr8:58132656	NA	-0.6	-7.25	-0.37	2.97e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg26816564	chr1:7831052	VAMP3	0.46	5.75	0.3	2e-8	Inflammatory bowel disease;
CRC	trans	rs10411161	0.702	rs11878586	chr19:52388576	A/G	cg22319618	chr22:45562946	NUP50	-0.65	-7.22	-0.37	3.63e-12	Breast cancer;
CRC	cis	rs6076065	0.723	rs1936013	chr20:23363989	A/G	cg11657817	chr20:23433608	CST11	0.47	6.85	0.35	3.74e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.7	-11.57	-0.54	3.29e-26	Ulcerative colitis;
CRC	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg26248373	chr2:1572462	NA	-0.8	-10.96	-0.52	4.81e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.93	0.4	3.53e-14	Aortic root size;
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	4.89e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.06	-0.32	3.64e-9	Total body bone mineral density;
CRC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.25	-0.37	3.07e-12	Major depressive disorder;
CRC	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.54	7.37	0.38	1.41e-12	Hypertension (SNP x SNP interaction);
CRC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.59	10.44	0.5	3.22e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs17681684	0.565	rs12150167	chr17:9764244	C/A	cg26853458	chr17:9805074	RCVRN	0.53	9.4	0.46	9.35e-19	GIP levels in response to oral glucose tolerance test (fasting);
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	trans	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.21	0.41	5.03e-15	Lewy body disease;
CRC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.8	-13.3	-0.59	1.41e-32	Longevity;
CRC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg13390004	chr1:15929781	NA	0.5	7.07	0.36	9.19e-12	Systolic blood pressure;
CRC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.72	10.13	0.49	3.57e-21	Coronary artery disease;
CRC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.29	-0.37	2.26e-12	Aortic root size;
CRC	cis	rs10924970	0.625	rs3806394	chr1:235489850	C/T	cg09010748	chr1:235293032	TOMM20	-0.41	-5.79	-0.3	1.64e-8	Asthma;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.55	8.26	0.41	3.57e-15	Alzheimer's disease;
CRC	trans	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg26102564	chr10:131424627	MGMT	0.39	5.74	0.3	2.2e-8	Response to temozolomide;
CRC	cis	rs3789045	0.560	rs4626956	chr1:204407298	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.81	-10.84	-0.51	1.33e-23	Educational attainment (college completion);
CRC	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.91	-13.23	-0.59	2.44e-32	Blood pressure (smoking interaction);
CRC	cis	rs7274811	0.711	rs373618	chr20:31992639	C/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	5.74	0.3	2.13e-8	Height;
CRC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.15e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.46	7.23	0.37	3.49e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs427943	0.750	rs8126717	chr21:46609110	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	6.0	0.31	5.1e-9	Body mass index;
CRC	cis	rs2730260	0.734	rs3793217	chr7:158848821	C/T	cg02254261	chr7:158964346	NA	0.49	5.72	0.3	2.39e-8	Myopia (pathological);
CRC	cis	rs10986311	0.802	rs1323761	chr9:127116942	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.4	6.03	0.32	4.52e-9	Vitiligo;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25517755	chr10:38738941	LOC399744	-0.43	-6.16	-0.32	2.14e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.57	9.3	0.46	2.01e-18	Blood protein levels;
CRC	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-1.14	-12.49	-0.57	1.4e-29	Mitochondrial DNA levels;
CRC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.43e-10	Major depressive disorder;
CRC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.5	7.89	0.4	4.61e-14	Monobrow;
CRC	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg04989706	chr14:50066350	PPIL5	-0.5	-7.08	-0.36	9.01e-12	Carotid intima media thickness;
CRC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	9.85	0.48	3.26e-20	Calcium levels;
CRC	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg00042356	chr1:8021962	PARK7	0.55	6.77	0.35	5.99e-11	Inflammatory bowel disease;
CRC	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.41	6.94	0.36	2.15e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg10756647	chr7:56101905	PSPH	0.57	6.59	0.34	1.78e-10	Diabetic kidney disease;
CRC	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg23229984	chr5:148520753	ABLIM3	0.5	7.04	0.36	1.11e-11	Breast cancer;
CRC	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg19193384	chr17:30244184	NA	0.47	5.81	0.31	1.47e-8	Hip circumference adjusted for BMI;
CRC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs11212617	0.967	rs227068	chr11:108210109	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.34	0.33	7.65e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3751196	0.901	rs116516318	chr12:104177773	C/T	cg02344784	chr12:104178138	NT5DC3	0.72	7.65	0.39	2.26e-13	Sense of smell;
CRC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.83	-10.99	-0.52	3.94e-24	Initial pursuit acceleration;
CRC	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01283712	chr14:106919294	NA	-0.35	-5.97	-0.31	5.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.29	-0.33	1.01e-9	Monocyte count;
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.72	9.56	0.47	2.94e-19	Alzheimer's disease;
CRC	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg03938978	chr2:103052716	IL18RAP	0.41	6.53	0.34	2.51e-10	Blood protein levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg18654971	chr5:54469363	MIR449C;CDC20B	-0.51	-6.17	-0.32	2e-9	Diisocyanate-induced asthma;
CRC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg23018236	chr17:30244563	NA	-0.66	-7.89	-0.4	4.54e-14	Hip circumference adjusted for BMI;
CRC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.48	-7.49	-0.38	6.6e-13	Monocyte count;
CRC	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.45	8.16	0.41	7.24e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.34	-0.42	2.11e-15	Body mass index;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.4	-7.31	-0.37	2.05e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.54	8.48	0.42	7.53e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.73	9.65	0.47	1.47e-19	Alzheimer's disease;
CRC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.77	-0.35	6.1e-11	Mean corpuscular volume;
CRC	cis	rs477692	0.618	rs7080419	chr10:131455235	A/G	cg05714579	chr10:131428358	MGMT	0.46	6.43	0.33	4.57e-10	Response to temozolomide;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg15511327	chr8:143859410	LYNX1	0.41	7.41	0.38	1.07e-12	Urinary tract infection frequency;
CRC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg07125278	chr16:67683757	RLTPR	-0.46	-5.63	-0.3	3.91e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4731207	0.592	rs6967988	chr7:124570472	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.3	-0.33	9.64e-10	Cutaneous malignant melanoma;
CRC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.59	0.34	1.7e-10	Menarche (age at onset);
CRC	cis	rs17818399	0.620	rs3087822	chr2:46852033	C/T	cg26688816	chr2:46740690	ATP6V1E2	0.4	5.95	0.31	6.78e-9	Height;
CRC	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.49	-7.87	-0.4	5.1e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.68	-11.02	-0.52	3.03e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24787592	chr19:13273612	NA	0.43	6.15	0.32	2.2e-9	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03077572	chr17:79869459	PCYT2	0.48	6.63	0.34	1.35e-10	Anxiety disorder;
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	0.71	9.42	0.46	8.32e-19	Alzheimer's disease;
CRC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.45	-7.57	-0.39	3.68e-13	P wave terminal force;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7553035	1.000	rs11800588	chr1:211689466	A/C	cg04286297	chr15:83655119	FAM103A1	-0.66	-6.04	-0.32	4.08e-9	Retinopathy in non-diabetics;
CRC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.42	-6.52	-0.34	2.59e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.48	6.62	0.34	1.45e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.47	6.9	0.36	2.7e-11	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.59	9.25	0.45	2.85e-18	Corneal astigmatism;
CRC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.59	0.43	3.65e-16	Schizophrenia;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17227014	chr4:6642450	MRFAP1	0.46	6.08	0.32	3.29e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg06223162	chr1:101003688	GPR88	-0.36	-6.66	-0.34	1.12e-10	Monocyte count;
CRC	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.51	6.81	0.35	4.6e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.49	-7.99	-0.4	2.29e-14	Body mass index;
CRC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.84	0.63	1.71e-38	Lymphocyte percentage of white cells;
CRC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	6.35	0.33	7.1e-10	Multiple sclerosis;
CRC	cis	rs6700896	0.931	rs12042779	chr1:66133950	T/C	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.54	6.66	0.34	1.12e-10	Bipolar disorder (body mass index interaction);
CRC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.45	5.8	0.3	1.53e-8	Response to diuretic therapy;
CRC	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.52	10.12	0.49	4.03e-21	Lipoprotein (a) levels;
CRC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.52	7.86	0.4	5.65e-14	Corneal astigmatism;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg02683197	chr6:28174875	NA	0.66	8.52	0.43	5.91e-16	Parkinson's disease;
CRC	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.41	0.65	1.01e-40	Bipolar disorder;
CRC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02228675	chr17:40259724	DHX58	-0.48	-6.87	-0.35	3.19e-11	Fibrinogen levels;
CRC	trans	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg03701575	chr16:83960119	NA	0.34	5.97	0.31	6.14e-9	Asthma;
CRC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	6.66	0.34	1.13e-10	Mean platelet volume;
CRC	cis	rs6761276	0.649	rs10169599	chr2:113838652	A/G	cg09040174	chr2:113837401	NA	-0.57	-8.82	-0.44	6.76e-17	Protein quantitative trait loci;
CRC	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg05562828	chr17:3906858	NA	0.66	11.83	0.55	3.85e-27	Type 2 diabetes;
CRC	cis	rs929596	0.531	rs2741019	chr2:234510688	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-5.82	-0.31	1.41e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg25251562	chr2:3704773	ALLC	-0.45	-6.65	-0.34	1.21e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00166722	chr3:10149974	C3orf24	0.57	7.8	0.4	8.13e-14	Alzheimer's disease;
CRC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.37	-7.28	-0.37	2.44e-12	Abdominal aortic aneurysm;
CRC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.83	8.44	0.42	1e-15	Fat distribution (HIV);
CRC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.42	-20.04	-0.74	5.73e-59	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg21620606	chr4:1342894	KIAA1530	0.36	5.91	0.31	8.57e-9	Obesity-related traits;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg00063174	chr2:228736253	WDR69	-0.48	-6.38	-0.33	5.97e-10	Blood pressure;
CRC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.64	10.4	0.5	4.22e-22	Height;
CRC	cis	rs9287719	0.615	rs12613769	chr2:10742290	C/T	cg00105475	chr2:10696890	NA	0.48	7.3	0.37	2.14e-12	Prostate cancer;
CRC	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.38	-0.33	6.09e-10	Subjective well-being;
CRC	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.52	-6.68	-0.35	1.01e-10	Red blood cell traits;
CRC	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.81	9.91	0.48	1.92e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg00601486	chr12:48723148	H1FNT	0.35	6.78	0.35	5.51e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03175635	chr2:203736521	ICA1L	0.45	6.28	0.33	1.04e-9	Anxiety disorder;
CRC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.78	11.92	0.55	1.77e-27	Multiple system atrophy;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.34	6.4	0.33	5.31e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.36	-0.38	1.51e-12	Testicular germ cell tumor;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg23807890	chr2:228736357	WDR69	-0.51	-7.0	-0.36	1.44e-11	Blood pressure;
CRC	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.8	6.54	0.34	2.31e-10	Economic and political preferences (immigration/crime);
CRC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.68	-10.28	-0.49	1.13e-21	Lung cancer;
CRC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.61	0.39	2.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.93	0.58	3.26e-31	Alzheimer's disease;
CRC	cis	rs6735179	0.729	rs2382560	chr2:1762828	A/G	cg19300414	chr2:1746591	PXDN	0.34	6.18	0.32	1.86e-9	Response to antipsychotic treatment;
CRC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.65	10.3	0.49	9.45e-22	Initial pursuit acceleration;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.03	-0.36	1.16e-11	Breast cancer;
CRC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Melanoma;
CRC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.56	6.79	0.35	5.1e-11	Diastolic blood pressure;
CRC	trans	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg26043149	chr18:55253948	FECH	0.53	8.11	0.41	9.94e-15	Bone mineral density;
CRC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06544989	chr22:39130855	UNC84B	0.45	7.25	0.37	3.03e-12	Menopause (age at onset);
CRC	cis	rs4731207	0.596	rs10252072	chr7:124578636	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg04731861	chr2:219085781	ARPC2	0.26	5.69	0.3	2.82e-8	Colorectal cancer;
CRC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.57	7.54	0.38	4.59e-13	Mean platelet volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19541444	chr11:73472205	RAB6A	0.43	6.01	0.31	5.02e-9	Anxiety disorder;
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	12.18	0.56	2e-28	Alzheimer's disease;
CRC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.62	7.61	0.39	2.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.44	6.4	0.33	5.49e-10	Menopause (age at onset);
CRC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.54	7.36	0.38	1.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.5	-9.07	-0.45	1.1e-17	Longevity;
CRC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.39	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs13098911	0.540	rs9877748	chr3:46111081	A/G	cg12691230	chr3:46064611	XCR1	-0.54	-6.14	-0.32	2.34e-9	Celiac disease;
CRC	cis	rs4481887	0.508	rs4474292	chr1:248396646	G/A	cg00666640	chr1:248458726	OR2T12	0.36	6.25	0.33	1.27e-9	Common traits (Other);
CRC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.38	8.71	0.43	1.51e-16	Multiple system atrophy;
CRC	cis	rs375066	0.935	rs429027	chr19:44395489	G/A	cg11993925	chr19:44307056	LYPD5	0.37	5.76	0.3	1.94e-8	Breast cancer;
CRC	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg11993925	chr19:44307056	LYPD5	-0.44	-7.18	-0.37	4.54e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg16476235	chr8:21771668	DOK2	0.39	6.42	0.33	4.88e-10	Mean corpuscular volume;
CRC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.03	0.32	4.51e-9	Dupuytren's disease;
CRC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.74e-11	Body mass index;
CRC	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-6.18	-0.32	1.91e-9	Bipolar disorder;
CRC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26240231	chr7:1148101	C7orf50	-0.42	-6.52	-0.34	2.6200000000000003e-10	Bronchopulmonary dysplasia;
CRC	trans	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.48	-0.34	3.29e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.08	-0.66	2.34e-43	Intelligence (multi-trait analysis);
CRC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.81	-0.35	4.71e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.51	9.63	0.47	1.7e-19	Alcohol dependence;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.44	-0.46	7.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg22496339	chr2:162101262	NA	-0.57	-7.98	-0.4	2.51e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	12.21	0.56	1.51e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.5	7.83	0.4	6.98e-14	Height;
CRC	cis	rs6881634	0.768	rs4704495	chr5:77624910	C/T	cg11446398	chr5:77624930	NA	0.51	8.83	0.44	6.15e-17	Hippocampal atrophy;
CRC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.57	0.38	3.89e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.46	-7.6	-0.39	3.11e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.71	10.21	0.49	1.9e-21	Cognitive function;
CRC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.48	-7.92	-0.4	3.61e-14	Major depressive disorder;
CRC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.8e-8	Colorectal cancer;
CRC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.35	-5.97	-0.31	6.17e-9	Aortic root size;
CRC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg16576597	chr16:28551801	NUPR1	-0.48	-6.89	-0.36	2.81e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs524281	0.861	rs471484	chr11:65955144	A/G	cg16950941	chr11:66035639	RAB1B	-0.57	-7.23	-0.37	3.45e-12	Electroencephalogram traits;
CRC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	trans	rs783540	0.867	rs7167880	chr15:83294436	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.92	-0.36	2.43e-11	Schizophrenia;
CRC	cis	rs4731207	0.596	rs1871774	chr7:124674898	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.23	-0.32	1.44e-9	Cutaneous malignant melanoma;
CRC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg18827107	chr12:86230957	RASSF9	-0.4	-6.12	-0.32	2.65e-9	Major depressive disorder;
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.35	0.46	1.38e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs2342371	0.756	rs4916492	chr3:196106306	G/A	cg15048948	chr3:196158458	UBXN7	0.51	6.26	0.33	1.18e-9	Fat distribution (HIV);
CRC	trans	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg26043149	chr18:55253948	FECH	0.51	7.59	0.39	3.42e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.61	9.76	0.47	6.23e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.98	0.44	2.17e-17	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15097007	chr3:49726899	MST1;RNF123	0.44	6.27	0.33	1.16e-9	Response to antipsychotic treatment;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg00063174	chr2:228736253	WDR69	-0.48	-6.48	-0.34	3.27e-10	Blood pressure;
CRC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.44	-7.83	-0.4	6.79e-14	Monocyte count;
CRC	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.56	8.29	0.42	2.88e-15	Blood protein levels;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg26608667	chr7:1196370	ZFAND2A	0.36	5.72	0.3	2.41e-8	Longevity;Endometriosis;
CRC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-0.64	-6.45	-0.34	3.89e-10	Magnesium levels;
CRC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg14631576	chr9:95140430	CENPP	-0.39	-6.75	-0.35	6.5500000000000006e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg09597638	chr17:3907349	NA	0.62	9.94	0.48	1.61e-20	Type 2 diabetes;
CRC	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg22495460	chr2:25135724	ADCY3	-0.81	-14.99	-0.64	4.59e-39	Body mass index in non-asthmatics;
CRC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.62	10.62	0.51	7.82e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg20203395	chr5:56204925	C5orf35	0.41	5.74	0.3	2.14e-8	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.08	-0.45	1.05e-17	Bipolar disorder;
CRC	cis	rs356992	0.915	rs76673	chr2:60749078	G/T	cg08426369	chr2:60753602	BCL11A	-0.55	-7.7	-0.39	1.63e-13	Educational attainment (years of education);
CRC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.42	6.63	0.34	1.41e-10	Dupuytren's disease;
CRC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg02527881	chr3:46936655	PTH1R	0.37	6.74	0.35	6.98e-11	Colorectal cancer;
CRC	cis	rs847649	0.765	rs10953383	chr7:102774076	C/T	cg18108683	chr7:102477205	FBXL13	0.52	8.27	0.41	3.35e-15	Morning vs. evening chronotype;
CRC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.44	6.34	0.33	7.45e-10	Longevity;
CRC	trans	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg26043149	chr18:55253948	FECH	0.5	7.49	0.38	6.6e-13	Bone mineral density;
CRC	cis	rs447	0.767	rs2691700	chr7:83720054	A/G	cg22846510	chr7:83753280	SEMA3A	-0.51	-6.12	-0.32	2.64e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07513332	chr6:167530253	CCR6	0.44	7.97	0.4	2.69e-14	Primary biliary cholangitis;
CRC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.67	10.12	0.49	3.94e-21	Osteoporosis;
CRC	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.59	-8.29	-0.42	2.92e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.38	7.38e-13	Lung cancer in ever smokers;
CRC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg12273811	chr6:28175739	NA	0.59	5.71	0.3	2.53e-8	Depression;
CRC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.94	-12.2	-0.56	1.65e-28	Exhaled nitric oxide output;
CRC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.47	6.33	0.33	7.94e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs11212617	0.935	rs227064	chr11:108207393	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.01	0.31	4.89e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21028142	chr17:79581711	NPLOC4	-0.33	-6.98	-0.36	1.64e-11	Eye color traits;
CRC	cis	rs8032158	0.702	rs11630780	chr15:56128445	G/T	cg02198044	chr15:56286336	NEDD4	0.37	5.93	0.31	7.68e-9	Keloid;
CRC	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg24300038	chr13:113819356	PROZ	-0.46	-5.78	-0.3	1.71e-8	Platelet distribution width;
CRC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.17	-0.45	5.23e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg17788362	chr6:86352627	SYNCRIP	0.55	7.5	0.38	5.82e-13	Smooth-surface caries;
CRC	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.41	-0.33	4.91e-10	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15113064	chr3:124774855	HEG1	0.4	6.18	0.32	1.85e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg18187862	chr3:45730750	SACM1L	0.45	6.5	0.34	3.01e-10	Primary sclerosing cholangitis;
CRC	trans	rs6011368	0.642	rs6062362	chr20:62911229	A/G	cg13869341	chr1:15865	WASH5P	0.4	5.98	0.31	5.66e-9	Clozapine-induced cytotoxicity;
CRC	trans	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg25173405	chr17:45401733	C17orf57	0.46	7.25	0.37	2.96e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-6.0	-0.31	5.17e-9	Crohn's disease;
CRC	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	9.76	0.47	6.16e-20	Bipolar disorder;
CRC	cis	rs28830936	0.509	rs6493005	chr15:41859152	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.67	-0.3	3.11e-8	Diastolic blood pressure;
CRC	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.58	7.87	0.4	5.08e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs6988985	0.594	rs12543598	chr8:143955318	T/G	cg10324643	chr8:143916377	GML	0.38	6.21	0.32	1.6e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.48	-7.44	-0.38	9.06e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.84	-11.07	-0.52	1.94e-24	Cerebrospinal P-tau181p levels;
CRC	cis	rs6545883	0.542	rs10177225	chr2:61594498	C/T	cg10580144	chr2:61372316	C2orf74	-0.37	-8.38	-0.42	1.54e-15	Tuberculosis;
CRC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs6546324	0.625	rs4260227	chr2:67843537	G/A	cg15745817	chr2:67799979	NA	-0.55	-9.38	-0.46	1.08e-18	Endometriosis;
CRC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.38	-6.19	-0.32	1.75e-9	Platelet distribution width;
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.05	0.52	2.32e-24	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25147601	chr6:159240341	EZR	0.37	6.04	0.32	4.21e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2814982	0.605	rs80254589	chr6:34478514	C/T	cg17674042	chr6:34482479	PACSIN1	-1.04	-10.82	-0.51	1.52e-23	Cholesterol, total;Total cholesterol levels;
CRC	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.2	-0.37	4.15e-12	Neuroticism;
CRC	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.28e-20	Ileal carcinoids;
CRC	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg07557337	chr11:66035873	RAB1B	0.55	5.75	0.3	2.04e-8	Airway imaging phenotypes;
CRC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.76	-12.99	-0.58	2.01e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg16447950	chr5:562315	NA	-0.85	-12.55	-0.57	8.55e-30	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02611874	chr10:46194725	NA	-0.36	-6.14	-0.32	2.39e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.31	-0.37	2e-12	Aortic root size;
CRC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.41	-5.94	-0.31	7.15e-9	Aortic root size;
CRC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.47	0.57	1.7e-29	Menopause (age at onset);
CRC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg00074818	chr8:8560427	CLDN23	0.4	7.27	0.37	2.7e-12	Obesity-related traits;
CRC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg18827107	chr12:86230957	RASSF9	-0.38	-5.84	-0.31	1.22e-8	Major depressive disorder;
CRC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	0.99	9.91	0.48	1.92e-20	Diabetic retinopathy;
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg10217327	chr6:118973057	C6orf204	0.51	5.73	0.3	2.29e-8	Diastolic blood pressure;
CRC	cis	rs2282802	0.685	rs2337138	chr5:139691664	A/C	cg26211634	chr5:139558579	C5orf32	0.43	7.26	0.37	2.84e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg22535103	chr8:58192502	C8orf71	0.44	5.73	0.3	2.3e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.81	-13.6	-0.6	9.63e-34	Cystic fibrosis severity;
CRC	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-6.78	-0.35	5.47e-11	Intelligence (multi-trait analysis);
CRC	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.63	8.19	0.41	5.82e-15	Bipolar disorder;
CRC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06470822	chr6:28175283	NA	0.66	5.63	0.3	3.82e-8	Depression;
CRC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.52	7.26	0.37	2.82e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7259376	0.869	rs11671804	chr19:22591216	A/G	cg02657401	chr19:22469223	NA	0.3	6.28	0.33	1.09e-9	Menopause (age at onset);
CRC	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.34	0.46	1.53e-18	Mean corpuscular volume;
CRC	trans	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg02674126	chr19:40336878	FBL	0.41	6.64	0.34	1.26e-10	Hyperactive-impulsive symptoms;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13468249	chr17:7154818	DULLARD;C17orf81	0.52	8.54	0.43	5.22e-16	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	0.748	rs3785098	chr16:67993643	T/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-10.78	-0.51	2.0500000000000001e-23	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.99	-0.36	1.57e-11	Asthma;
CRC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs17234274	0.622	rs4923074	chr11:23233797	T/C	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.43	6.9	0.36	2.64e-11	Sitting height ratio;
CRC	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.64	8.46	0.42	8.88e-16	Uric acid levels;
CRC	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg03929089	chr4:120376271	NA	-0.62	-6.08	-0.32	3.34e-9	Axial length;
CRC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.01	-0.48	8.91e-21	Monocyte count;
CRC	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.41	6.65	0.34	1.24e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg09085632	chr11:111637200	PPP2R1B	0.5	6.54	0.34	2.39e-10	Breast cancer;
CRC	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg14458575	chr2:238380390	NA	0.39	5.78	0.3	1.72e-8	Prostate cancer;
CRC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	10.21	0.49	1.99e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-12.13	-0.56	3.03e-28	Prostate cancer;
CRC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-5.8	-0.3	1.59e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9462846	0.881	rs34498470	chr6:42879551	C/T	cg10862848	chr6:42927986	GNMT	-0.3	-5.75	-0.3	2.07e-8	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04590956	chr2:70057467	GMCL1	0.47	6.64	0.34	1.29e-10	Response to antipsychotic treatment;
CRC	cis	rs73206853	0.563	rs73194043	chr12:111188782	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	8.56	0.43	4.32e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26701943	chr11:108369231	KDELC2	0.37	6.18	0.32	1.92e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6662572	0.737	rs10890357	chr1:46318054	T/G	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs3018066	0.748	rs72677306	chr4:106997678	T/C	cg01869342	chr4:106983673	TBCK	0.46	6.8	0.35	4.91e-11	Cancer;
CRC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.58	-9.56	-0.47	2.83e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.8	-0.4	8.11e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.62	-8.39	-0.42	1.43e-15	Blood pressure (smoking interaction);
CRC	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg09659197	chr4:152720779	NA	0.53	11.71	0.54	1.06e-26	Intelligence (multi-trait analysis);
CRC	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg20356878	chr3:121714668	ILDR1	0.52	8.22	0.41	4.87e-15	Cognitive performance;
CRC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.78	-0.3	1.76e-8	Ulcerative colitis;
CRC	trans	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.76	-0.39	1.07e-13	HDL cholesterol;
CRC	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.47	-0.46	5.55e-19	Migraine;Coronary artery disease;
CRC	cis	rs16975963	0.644	rs78644049	chr19:38113042	T/A	cg15135657	chr19:38346511	NA	-0.46	-6.28	-0.33	1.04e-9	Longevity;
CRC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg23806715	chr17:73775811	H3F3B	0.66	5.84	0.31	1.26e-8	Psoriasis;
CRC	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg00631329	chr6:26305371	NA	-0.4	-6.89	-0.36	2.86e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.39	-0.33	5.59e-10	Breast cancer;
CRC	trans	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg18288967	chr1:45987694	PRDX1	0.61	6.72	0.35	7.94e-11	Obesity-related traits;
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.79	-0.39	8.91e-14	Bipolar disorder;
CRC	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	15.28	0.64	3.22e-40	Mean corpuscular hemoglobin;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.66	-0.43	2.08e-16	Bipolar disorder;
CRC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.74	-0.3	2.11e-8	Cognitive function;
CRC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	18.55	0.71	4.45e-53	Cognitive ability;
CRC	cis	rs4750440	0.642	rs1574583	chr10:14026870	C/G	cg00551146	chr10:14014579	FRMD4A	0.47	7.49	0.38	6.42e-13	Adiponectin levels;
CRC	cis	rs17881320	0.510	rs6503699	chr17:40554261	C/G	cg05878104	chr17:40932452	WNK4	0.55	6.66	0.34	1.17e-10	Atopic dermatitis;
CRC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.43	5.94	0.31	7.14e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs77688320	0.535	rs2540441	chr2:202346669	C/T	cg00712779	chr2:202317602	STRADB;TRAK2	-0.38	-5.64	-0.3	3.7e-8	Breast cancer;
CRC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg26102564	chr10:131424627	MGMT	0.39	5.68	0.3	2.91e-8	Response to temozolomide;
CRC	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.81	8.53	0.43	5.43e-16	Gastritis;
CRC	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	0.89	7.75	0.39	1.18e-13	Fat distribution (HIV);
CRC	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	0.95	9.17	0.45	5.27e-18	Gut microbiota (bacterial taxa);
CRC	cis	rs2386661	0.826	rs11255996	chr10:5670832	G/A	cg26603656	chr10:5671107	NA	0.55	9.1	0.45	8.84e-18	Breast cancer;
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg05569086	chr8:143859399	LYNX1	0.38	6.59	0.34	1.79e-10	Urinary tract infection frequency;
CRC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.01	-0.55	8.78e-28	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg27398640	chr15:77910606	LINGO1	-0.44	-7.53	-0.38	4.81e-13	Type 2 diabetes;
CRC	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.86	14.77	0.63	3.05e-38	Monocyte count;
CRC	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg14458575	chr2:238380390	NA	0.47	8.36	0.42	1.85e-15	Prostate cancer;
CRC	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.6	-8.23	-0.41	4.3e-15	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16773881	chr3:97540493	NA	0.42	5.98	0.31	5.91e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6717918	0.924	rs6718438	chr2:233155566	T/C	ch.2.233013039R	chr2:233304795	NA	0.49	6.92	0.36	2.3e-11	Height;
CRC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.78	14.7	0.63	5.76e-38	Prudent dietary pattern;
CRC	cis	rs12760731	0.582	rs12044868	chr1:178514203	C/A	cg00404053	chr1:178313656	RASAL2	0.66	7.44	0.38	8.62e-13	Obesity-related traits;
CRC	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.95	-0.31	6.81e-9	Height;
CRC	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.83	-0.35	4.01e-11	Metabolite levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg19793034	chr4:1284190	MAEA	-0.41	-6.13	-0.32	2.5e-9	Daytime sleep phenotypes;
CRC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.09e-12	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2929278	0.617	rs575082	chr15:44110142	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.41	-5.72	-0.3	2.41e-8	Schizophrenia;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.44	0.33	4.34e-10	Depression;
CRC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	16.58	0.67	2.75e-45	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18603276	chr17:8023961	HES7	-0.4	-6.48	-0.34	3.42e-10	Obesity-related traits;
CRC	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg08501292	chr6:25962987	TRIM38	1.15	10.02	0.48	8.32e-21	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.3	0.42	2.78e-15	Coffee consumption (cups per day);
CRC	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.53	-0.34	2.47e-10	Response to antipsychotic treatment;
CRC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.55	9.4	0.46	9.29e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.41	5.63	0.3	3.82e-8	Body mass index;
CRC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.24	6.79	0.35	5.26e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.71	0.51	3.8e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.67	8.91	0.44	3.47e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12273811	chr6:28175739	NA	0.57	8.23	0.41	4.41e-15	Parkinson's disease;
CRC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg22676075	chr6:135203613	NA	0.42	6.41	0.33	5.16e-10	Red blood cell count;
CRC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.94	-0.31	7.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04827747	chr7:134855666	C7orf49	0.44	5.97	0.31	6.25e-9	Survival in pancreatic cancer;
CRC	trans	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.51	6.86	0.35	3.43e-11	Coronary artery disease;
CRC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.45	6.94	0.36	2.08e-11	Monocyte count;
CRC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.76	-7.52	-0.38	5.36e-13	Coronary artery disease;
CRC	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.81	8.46	0.42	8.99e-16	Gastritis;
CRC	cis	rs17234274	0.644	rs1482709	chr11:23219359	G/A	cg05245346	chr11:23248277	NA	0.36	5.92	0.31	8.22e-9	Cancer;
CRC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.53	8.96	0.44	2.42e-17	Dupuytren's disease;
CRC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.75	-9.98	-0.48	1.17e-20	Initial pursuit acceleration;
CRC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.69	11.19	0.52	7.66e-25	Colorectal cancer;
CRC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07154196	chr1:29214064	EPB41	-0.43	-6.5	-0.34	3.01e-10	Myopia (pathological);
CRC	cis	rs1322512	1.000	rs1631457	chr6:152946514	C/T	cg03415253	chr6:152958462	SYNE1	-0.42	-6.41	-0.33	5.07e-10	Tonometry;
CRC	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.43	-0.38	9.21e-13	Superior frontal gyrus grey matter volume;
CRC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.98	-0.4	2.49e-14	Height;
CRC	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.52	-6.88	-0.35	3e-11	Height;
CRC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.63	-0.3	3.9e-8	Erythrocyte sedimentation rate;
CRC	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg02466173	chr16:30829666	NA	-0.57	-7.36	-0.38	1.52e-12	Diastolic blood pressure;
CRC	cis	rs4700695	0.841	rs428880	chr5:65245133	C/A	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.38	5.98	0.31	5.72e-9	Reticulocyte fraction of red cells;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.46	5.7	0.3	2.71e-8	Renal function-related traits (BUN);
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	10.06	0.49	6.18e-21	Monocyte count;
CRC	cis	rs2462686	1.000	rs2965071	chr7:46001382	T/A	cg15898840	chr7:45960834	IGFBP3	0.38	5.71	0.3	2.58e-8	Major depressive disorder;
CRC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg25164649	chr6:28176230	NA	0.59	5.85	0.31	1.2e-8	Lung cancer in ever smokers;
CRC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg11915388	chr22:42470451	FAM109B	0.42	6.34	0.33	7.46e-10	Schizophrenia;
CRC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.54	-7.88	-0.4	4.69e-14	Prostate cancer;
CRC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.53	7.68	0.39	1.8e-13	Response to temozolomide;
CRC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.5	6.88	0.35	3.02e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg08999081	chr20:33150536	PIGU	0.45	5.87	0.31	1.06e-8	Protein C levels;
CRC	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.45	-7.0	-0.36	1.44e-11	Large artery stroke;
CRC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.41	-6.59	-0.34	1.79e-10	Breast cancer;
CRC	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Depression;
CRC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.6	11.12	0.52	1.31e-24	Immature fraction of reticulocytes;
CRC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg13628971	chr7:2884303	GNA12	0.41	6.28	0.33	1.06e-9	Height;
CRC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.03	-0.32	4.35e-9	Heart rate;
CRC	cis	rs9648716	1.000	rs1267618	chr7:140560018	C/T	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.56	-0.43	4.43e-16	Monocyte percentage of white cells;
CRC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	13.55	0.6	1.48e-33	Schizophrenia;
CRC	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	13.15	0.59	5.07e-32	Eotaxin levels;
CRC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.93	-0.36	2.23e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.76	9.41	0.46	8.87e-19	Developmental language disorder (linguistic errors);
CRC	trans	rs3758141	0.527	rs35761635	chr8:18698838	T/C	cg08576827	chr20:9075493	PLCB4	-0.76	-6.18	-0.32	1.91e-9	Body mass index (change over time) in gastrointestinal cancer;
CRC	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg17691542	chr6:26056736	HIST1H1C	0.92	10.33	0.49	7.45e-22	Iron status biomarkers;
CRC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.26	-0.33	1.23e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.23	-0.45	3.35e-18	Mood instability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15650170	chr7:150783791	AGAP3	0.34	6.23	0.32	1.46e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15926737	chr12:57853737	GLI1	-0.51	-6.25	-0.33	1.29e-9	Diisocyanate-induced asthma;
CRC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24308560	chr3:49941425	MST1R	0.45	7.06	0.36	9.95e-12	Intelligence (multi-trait analysis);
CRC	cis	rs35000415	0.873	rs34748780	chr7:128700153	A/G	cg19972273	chr7:128594194	NA	0.71	6.15	0.32	2.2e-9	Systemic lupus erythematosus;
CRC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.66	0.43	2.22e-16	Alzheimer's disease;
CRC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.56	0.38	4.13e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs3772130	0.583	rs58088236	chr3:121561765	C/T	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg14776518	chr15:63892607	FBXL22	0.42	6.59	0.34	1.72e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.4	6.08	0.32	3.28e-9	Endometrial cancer;
CRC	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.9	-0.4	4.36e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06112835	chr11:68658793	MRPL21	0.45	6.91	0.36	2.46e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.52	8.87	0.44	4.73e-17	Coronary artery disease;
CRC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.46	-7.15	-0.37	5.79e-12	Height;
CRC	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg10556349	chr10:835070	NA	-0.32	-6.1	-0.32	2.97e-9	Survival in rectal cancer;
CRC	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg01993067	chr11:68851601	TPCN2	0.58	6.66	0.34	1.13e-10	Blond vs. brown hair color;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06134974	chr12:51477539	CSRNP2	0.37	6.8	0.35	4.8e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.55	-10.39	-0.5	4.7e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14178714	chr15:78370200	TBC1D2B	0.39	6.04	0.32	4.11e-9	Interleukin-6 levels;
CRC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.69	10.74	0.51	2.9e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.38	6.11	0.32	2.81e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.48	7.14	0.37	5.89e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg15382696	chr6:118971807	C6orf204	0.61	8.01	0.4	2.07e-14	Diastolic blood pressure;
CRC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	8.58e-15	Life satisfaction;
CRC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.68	-7.81	-0.4	7.69e-14	Vitiligo;
CRC	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg04586622	chr2:25135609	ADCY3	-0.53	-9.67	-0.47	1.25e-19	Body mass index in non-asthmatics;
CRC	cis	rs4700695	0.925	rs4700090	chr5:65412434	C/T	cg21114390	chr5:65439923	SFRS12	-0.54	-6.29	-0.33	1.04e-9	Facial morphology (factor 19);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16189954	chr22:29138267	HSCB;CHEK2	0.41	5.99	0.31	5.61e-9	Response to antipsychotic treatment;
CRC	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.64	-7.87	-0.4	5.08e-14	Vitamin D levels;
CRC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.69	11.99	0.55	1.02e-27	Resting heart rate;
CRC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg21194808	chr1:2205498	SKI	0.43	6.33	0.33	8.04e-10	Coronary artery disease;
CRC	cis	rs2933343	0.951	rs789220	chr3:128592135	A/G	cg11901034	chr3:128598214	ACAD9	0.46	5.72	0.3	2.42e-8	IgG glycosylation;
CRC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.01	-21.05	-0.76	6.48e-63	Myeloid white cell count;
CRC	cis	rs3018066	0.831	rs4577583	chr4:106976809	T/C	cg01869342	chr4:106983673	TBCK	0.38	5.85	0.31	1.21e-8	Cancer;
CRC	trans	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg02388054	chr16:85524230	NA	-0.44	-6.23	-0.32	1.41e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg16576597	chr16:28551801	NUPR1	0.46	6.37	0.33	6.39e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg16506815	chr2:162101123	NA	-0.38	-5.66	-0.3	3.22e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CRC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg13390004	chr1:15929781	NA	0.49	6.91	0.36	2.45e-11	Systolic blood pressure;
CRC	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-6.0	-0.31	5.2e-9	Coronary artery disease;
CRC	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.96	-0.31	6.51e-9	Hip circumference adjusted for BMI;
CRC	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	7.77	0.39	1.02e-13	Coronary heart disease;
CRC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg02569458	chr12:86230093	RASSF9	0.45	7.65	0.39	2.28e-13	Major depressive disorder;
CRC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.9	17.3	0.69	3.92e-48	Intelligence (multi-trait analysis);
CRC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.91	0.44	3.57e-17	Hip circumference adjusted for BMI;
CRC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg15269541	chr15:43626905	ADAL	-0.49	-5.9	-0.31	9.27e-9	Lung cancer in ever smokers;
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.81	12.17	0.56	2.21e-28	Menarche (age at onset);
CRC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg10589385	chr1:150898437	SETDB1	-0.31	-6.53	-0.34	2.45e-10	Blood protein levels;
CRC	cis	rs10193935	0.792	rs72794590	chr2:42378392	G/A	cg27598129	chr2:42591480	NA	-0.66	-7.35	-0.38	1.61e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg19784903	chr17:45786737	TBKBP1	-0.36	-5.91	-0.31	8.47e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.77	13.64	0.6	7.11e-34	Oral cavity cancer;
CRC	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.45	7.01	0.36	1.38e-11	Schizophrenia;
CRC	cis	rs12484776	0.786	rs73165040	chr22:40538602	C/T	cg21771250	chr22:40406049	FAM83F	0.31	5.77	0.3	1.79e-8	Uterine fibroids;
CRC	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.36	0.46	1.29e-18	Common traits (Other);
CRC	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg11189052	chr15:85197271	WDR73	-0.61	-9.77	-0.47	5.95e-20	P wave terminal force;
CRC	trans	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs6460942	0.544	rs4719292	chr7:12139616	C/T	cg06484146	chr7:12443880	VWDE	-0.51	-6.06	-0.32	3.72e-9	Coronary artery disease;
CRC	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg00677455	chr12:58241039	CTDSP2	-0.43	-6.37	-0.33	6.24e-10	Multiple sclerosis;
CRC	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg07979401	chr6:33739406	LEMD2	-0.44	-5.65	-0.3	3.54e-8	Schizophrenia;
CRC	cis	rs17209837	1.000	rs45526438	chr7:87089927	G/A	cg00919237	chr7:87102261	ABCB4	-0.47	-5.63	-0.3	3.84e-8	Gallbladder cancer;
CRC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg17724175	chr1:150552817	MCL1	-0.48	-7.6	-0.39	3.18e-13	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24106215	chr1:202927166	ADIPOR1	0.44	6.06	0.32	3.8e-9	Response to antipsychotic treatment;
CRC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.84	-9.73	-0.47	7.72e-20	Breast cancer;
CRC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.21	-5.95	-0.31	6.8e-9	Urinary metabolites;
CRC	cis	rs7487075	0.893	rs1492894	chr12:46728668	C/T	cg22049899	chr12:47219821	SLC38A4	0.34	6.6	0.34	1.66e-10	Itch intensity from mosquito bite;
CRC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.45e-9	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01025762	chr7:107531363	DLD	0.43	6.11	0.32	2.81e-9	Response to antipsychotic treatment;
CRC	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg09324608	chr17:30823087	MYO1D	0.33	5.72	0.3	2.42e-8	Schizophrenia;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10858369	chr11:6476139	TRIM3	0.45	6.45	0.34	4.01e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	17.68	0.7	1.19e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06998765	chr14:75389618	RPS6KL1	-0.24	-5.82	-0.31	1.43e-8	Caffeine consumption;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11691170	chr11:130318691	ADAMTS15	-0.41	-6.29	-0.33	1.01e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01603508	chr16:30937154	FBXL19	-0.4	-6.6	-0.34	1.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.62	7.16	0.37	5.44e-12	Vitiligo;
CRC	cis	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg15105060	chr4:7024189	TBC1D14	-0.75	-5.67	-0.3	3.16e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.77	-12.22	-0.56	1.49e-28	Tonsillectomy;
CRC	cis	rs7546094	1.000	rs6666579	chr1:113132393	A/G	cg22162597	chr1:113214053	CAPZA1	0.43	6.04	0.32	4.24e-9	Platelet distribution width;
CRC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.64e-13	Diabetic retinopathy;
CRC	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.58	6.61	0.34	1.52e-10	Type 2 diabetes nephropathy;
CRC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.11	-0.41	9.81e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.52	7.99	0.4	2.28e-14	Corneal astigmatism;
CRC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.47	7.56	0.38	3.99e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-6.7	-0.35	9.21e-11	Cognitive function;
CRC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.39	6.91	0.36	2.54e-11	Primary biliary cholangitis;
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.66	8.33	0.42	2.16e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.58	10.03	0.48	7.71e-21	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.63	10.26	0.49	1.3e-21	Aortic root size;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12963246	chr6:28129442	ZNF389	0.5	5.75	0.3	2e-8	Depression;
CRC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	7.37	0.38	1.37e-12	Menarche (age at onset);
CRC	cis	rs10221833	0.602	rs355879	chr2:165633427	T/C	cg03182029	chr2:165697222	COBLL1	0.49	5.8	0.3	1.56e-8	Response to statin therapy;
CRC	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.65	-9.27	-0.46	2.54e-18	Response to temozolomide;
CRC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg18230493	chr5:56204884	C5orf35	0.6	8.95	0.44	2.64e-17	Initial pursuit acceleration;
CRC	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg18232548	chr7:50535776	DDC	-0.47	-6.57	-0.34	1.99e-10	Malaria;
CRC	cis	rs7259376	0.936	rs10454118	chr19:22559605	C/G	cg02657401	chr19:22469223	NA	0.34	7.4	0.38	1.14e-12	Menopause (age at onset);
CRC	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.43	-6.76	-0.35	6.21e-11	C-reactive protein levels;
CRC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.89	-15.29	-0.64	2.99e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.33	0.37	1.74e-12	Blood metabolite levels;
CRC	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.85	-15.13	-0.64	1.26e-39	Lewy body disease;
CRC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.52	-8.47	-0.42	8.21e-16	Sense of smell;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26379672	chr3:4534954	ITPR1	0.45	6.34	0.33	7.69e-10	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.23	0.32	1.43e-9	Lung cancer;
CRC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg03013999	chr17:37608204	MED1	0.49	7.44	0.38	8.92e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs2845885	0.744	rs2701540	chr11:63869107	T/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.67	-5.98	-0.31	5.67e-9	Body mass index;
CRC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.68	-8.41	-0.42	1.26e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.41	-7.4	-0.38	1.11e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg15997130	chr1:24165203	NA	-0.65	-8.07	-0.41	1.29e-14	Immature fraction of reticulocytes;
CRC	cis	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg02972257	chr16:68554789	NA	0.44	5.61	0.3	4.28e-8	Colorectal cancer;
CRC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg00947319	chr17:47005597	UBE2Z	-0.35	-5.99	-0.31	5.54e-9	Type 2 diabetes;
CRC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.61	-9.44	-0.46	6.9e-19	Aortic root size;
CRC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.47	-7.08	-0.36	8.62e-12	Height;
CRC	trans	rs2303319	0.504	rs72870226	chr2:162420429	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Cognitive function;
CRC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg01721255	chr8:58191610	C8orf71	0.49	6.16	0.32	2.13e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.47	-6.57	-0.34	1.99e-10	Multiple myeloma;
CRC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg12601576	chr4:906860	GAK	0.45	6.61	0.34	1.56e-10	Systemic sclerosis;
CRC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	6.43	0.33	4.43e-10	Response to antipsychotic treatment;
CRC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.04	0.32	4.14e-9	Aortic root size;
CRC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.52	7.25	0.37	3.01e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.01	-0.31	4.88e-9	Menopause (age at onset);
CRC	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg01804193	chr12:63026212	NA	0.53	5.66	0.3	3.28e-8	IgG glycosylation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04393905	chr3:53381207	DCP1A	0.49	6.18	0.32	1.92e-9	Thyroid stimulating hormone;
CRC	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg09324608	chr17:30823087	MYO1D	0.33	5.65	0.3	3.54e-8	Schizophrenia;
CRC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.99	21.36	0.76	4.12e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.92	-0.48	1.78e-20	Monocyte count;
CRC	cis	rs67981189	0.529	rs61990380	chr14:71471946	G/A	cg15910301	chr14:71632612	NA	0.3	6.03	0.32	4.37e-9	Schizophrenia;
CRC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.61	8.71	0.43	1.48e-16	Alcohol dependence;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.56	-7.39	-0.38	1.23e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.54	8.01	0.4	1.96e-14	Cognitive ability;
CRC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.3	0.33	9.6e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.5	-7.66	-0.39	2.06e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7671266	0.628	rs11734783	chr4:10240663	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	5.91	0.31	8.58e-9	Cardiovascular disease risk factors;
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.61	-0.3	4.4e-8	Extrinsic epigenetic age acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24414038	chr1:173793430	CENPL;DARS2	0.44	6.16	0.32	2.12e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12172441	chr6:28176163	NA	0.68	9.05	0.45	1.29e-17	Depression;
CRC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.68	10.06	0.48	6.34e-21	Cognitive function;
CRC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg19193384	chr17:30244184	NA	-0.62	-7.03	-0.36	1.18e-11	Hip circumference adjusted for BMI;
CRC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.77	12.6	0.57	5.43e-30	Lung cancer;
CRC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.47	7.08	0.36	8.68e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg15147215	chr3:52552868	STAB1	-0.41	-5.63	-0.3	3.88e-8	Schizophrenia;
CRC	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg24130564	chr14:104152367	KLC1	-0.4	-5.63	-0.3	3.85e-8	Body mass index;
CRC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.61e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7799006	0.929	rs745565	chr7:2256689	G/C	cg08027265	chr7:2291960	NA	-0.4	-5.98	-0.31	5.8e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.39	6.03	0.32	4.5e-9	Endometrial cancer;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg21784768	chr11:537496	LRRC56	-0.59	-5.64	-0.3	3.67e-8	Body mass index;
CRC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.81	-13.92	-0.61	5.92e-35	Body mass index;
CRC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.45	6.67	0.35	1.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg03623178	chr6:28175578	NA	0.8	11.89	0.55	2.27e-27	Cardiac Troponin-T levels;
CRC	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.58	-8.21	-0.41	4.97e-15	Mean platelet volume;
CRC	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.29	7.31	0.37	2.07e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	9.0	0.44	1.88e-17	Ulcerative colitis;
CRC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.67	-8.02	-0.4	1.87e-14	Menarche (age at onset);
CRC	cis	rs1223397	0.651	rs2439534	chr6:13305757	C/T	cg07912922	chr6:13274314	PHACTR1	-0.39	-5.99	-0.31	5.48e-9	Blood pressure;
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.66	-0.43	2.11e-16	Bipolar disorder;
CRC	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.74	-9.26	-0.45	2.78e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.66	0.57	3.43e-30	Alzheimer's disease;
CRC	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg15660573	chr17:549704	VPS53	-0.86	-15.79	-0.66	3.27e-42	Prostate cancer;
CRC	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.55e-15	Type 2 diabetes;
CRC	cis	rs11212617	0.901	rs4754301	chr11:108048541	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.46	0.34	3.67e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00745838	chr9:140100374	TMEM203;NDOR1	0.46	6.44	0.33	4.29e-10	Response to antipsychotic treatment;
CRC	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg08992911	chr2:238395768	MLPH	0.6	6.07	0.32	3.56e-9	Prostate cancer;
CRC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.63	8.94	0.44	2.79e-17	Asthma;
CRC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	9.93	0.48	1.74e-20	Hemoglobin concentration;
CRC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.27	0.56	9.74e-29	Platelet count;
CRC	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.67	9.5	0.46	4.35e-19	Personality dimensions;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03133917	chr7:155436674	RBM33	0.46	5.96	0.31	6.35e-9	Thyroid stimulating hormone;
CRC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-11.14	-0.52	1.16e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg26043149	chr18:55253948	FECH	-0.58	-8.96	-0.44	2.41e-17	Bone mineral density;
CRC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.75	13.04	0.58	1.3e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.76	9.41	0.46	8.96e-19	Type 2 diabetes;
CRC	cis	rs17152411	0.895	rs7094116	chr10:126587644	T/G	cg07906193	chr10:126599966	NA	0.56	6.4	0.33	5.22e-10	Height;
CRC	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.8	0.44	7.67e-17	Coffee consumption (cups per day);
CRC	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.96	17.77	0.7	5.17e-50	Alcohol dependence;
CRC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.61	8.63	0.43	2.58e-16	Breast cancer;
CRC	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.35	0.46	1.43e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.69	0.3	2.88e-8	Diastolic blood pressure;
CRC	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.59	-8.97	-0.44	2.32e-17	Dementia with Lewy bodies;
CRC	trans	rs1376359	0.636	rs1451040	chr1:103158738	A/G	cg16220183	chr17:56609687	SEPT4	0.45	6.13	0.32	2.58e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs4728302	0.869	rs2042456	chr7:133580447	G/A	cg10665199	chr7:133106180	EXOC4	0.42	6.32	0.33	8.64e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.64	6.7	0.35	9.13e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	9.05	0.45	1.25e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg08222913	chr3:52553049	STAB1	-0.33	-5.88	-0.31	9.89e-9	Bipolar disorder;
CRC	cis	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg00409905	chr10:38381863	ZNF37A	0.45	6.93	0.36	2.2e-11	Hemostatic factors and hematological phenotypes;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-7.67	-0.39	1.99e-13	Obesity-related traits;
CRC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.42	5.73	0.3	2.29e-8	Emphysema distribution in smoking;
CRC	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.98	-0.36	1.6e-11	Aortic root size;
CRC	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.72	-12.9	-0.58	4.4e-31	Educational attainment;
CRC	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.54	-7.66	-0.39	2.09e-13	Waist circumference;Hip circumference;
CRC	cis	rs17767392	1.000	rs17178045	chr14:71756358	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.82	-0.35	4.34e-11	Mitral valve prolapse;
CRC	cis	rs8005677	0.828	rs4981450	chr14:23389304	A/G	cg25600027	chr14:23388339	RBM23	-0.46	-6.9	-0.36	2.66e-11	Cognitive ability (multi-trait analysis);
CRC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.23	0.32	1.4e-9	Bladder cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16357719	chr16:2317538	RNPS1	0.41	6.64	0.34	1.3100000000000001e-10	Interleukin-6 levels;
CRC	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.38	5.96	0.31	6.37e-9	Endometrial cancer;
CRC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg04731861	chr2:219085781	ARPC2	-0.32	-6.82	-0.35	4.38e-11	Colorectal cancer;
CRC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.41	7.75	0.39	1.13e-13	Ulcerative colitis;
CRC	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.67	6.58	0.34	1.88e-10	Eosinophilic esophagitis;
CRC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.55	9.37	0.46	1.21e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-9.94	-0.48	1.55e-20	Dental caries;
CRC	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.88e-12	Prostate cancer;
CRC	cis	rs972578	0.837	rs5751390	chr22:43259541	A/C	cg01576275	chr22:43409880	NA	-0.4	-6.22	-0.32	1.5e-9	Mean platelet volume;
CRC	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.83	-0.31	1.29e-8	Brugada syndrome;
CRC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg21877656	chr19:58662188	ZNF329	0.65	7.05	0.36	1.08e-11	Cholesterol, total;
CRC	cis	rs11212617	0.967	rs7395528	chr11:108056708	A/C	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.5	0.34	3.03e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.1	13.39	0.59	6.08e-33	Vitiligo;
CRC	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg13119609	chr19:45449297	APOC2	0.31	5.9	0.31	9.2e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg13385794	chr1:248469461	NA	0.39	6.93	0.36	2.21e-11	Common traits (Other);
CRC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.51	-7.64	-0.39	2.43e-13	Height;
CRC	cis	rs10971721	0.822	rs56160720	chr9:33899825	T/C	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg10570241	chr7:158785291	NA	-0.51	-9.31	-0.46	1.92e-18	Facial morphology (factor 20);
CRC	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.9	21.39	0.76	3.25e-64	Longevity;
CRC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg03623178	chr6:28175578	NA	0.78	6.63	0.34	1.36e-10	Depression;
CRC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg17321639	chr7:2759063	NA	-0.38	-5.84	-0.31	1.23e-8	Height;
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg04155289	chr7:94953770	PON1	-0.62	-7.79	-0.39	8.77e-14	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.37	0.65	1.54e-40	Platelet count;
CRC	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.34	-6.05	-0.32	3.99e-9	Pneumonia;
CRC	trans	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.09	0.32	3.12e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1007738	0.507	rs61897857	chr11:47233458	G/A	cg19486271	chr11:47235900	DDB2	0.42	5.78	0.3	1.7e-8	Bone mineral density (hip);
CRC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg09876464	chr15:85330779	ZNF592	0.45	7.52	0.38	5.13e-13	P wave terminal force;
CRC	cis	rs11229555	0.609	rs34782543	chr11:58187398	G/A	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.46	0.46	6.15e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg15962314	chr1:44399869	ARTN	0.31	6.0	0.31	5.27e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg19582491	chr16:67682965	RLTPR	-0.57	-6.9	-0.36	2.67e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.47	6.44	0.33	4.2e-10	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02360337	chr11:65627185	MUS81;CFL1	0.45	6.33	0.33	7.83e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.4	5.7	0.3	2.6e-8	Axial length;
CRC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg08975724	chr8:8085496	FLJ10661	0.43	5.69	0.3	2.82e-8	Red cell distribution width;
CRC	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.23	-6.04	-0.32	4.26e-9	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.8	15.32	0.65	2.36e-40	Prudent dietary pattern;
CRC	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.88	-0.31	1.02e-8	Height;
CRC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.68	0.47	1.12e-19	Cognitive test performance;
CRC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.42	-7.96	-0.4	2.83e-14	Colorectal cancer;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Parkinson's disease;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.65	-10.26	-0.49	1.33e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9650315	0.530	rs7830138	chr8:57084125	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.44	6.4	0.33	5.39e-10	Height;
CRC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.5	-0.38	6.11e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	trans	rs4684776	0.548	rs17776719	chr3:11640481	A/G	cg20302342	chr1:156215951	PAQR6	-0.48	-6.3	-0.33	9.8e-10	Small vessel stroke;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.39	6.21	0.32	1.59e-9	Total body bone mineral density;
CRC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.82	17.2	0.69	9.75e-48	Cancer;
CRC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg22535103	chr8:58192502	C8orf71	-0.43	-5.92	-0.31	8.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6681460	0.549	rs7547794	chr1:67031878	A/G	cg02459107	chr1:67143332	SGIP1	0.34	5.63	0.3	3.78e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.91e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	7.37	0.38	1.42e-12	Parkinson's disease;
CRC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg18016565	chr1:150552671	MCL1	0.48	6.94	0.36	2.04e-11	Tonsillectomy;
CRC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.51	0.54	5.3e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	6.45	0.34	3.92e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg18830697	chr6:72922368	RIMS1	0.4	7.69	0.39	1.7e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.49	-0.34	3.19e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07165616	chr12:498868	KDM5A;CCDC77	0.53	6.86	0.35	3.39e-11	Thyroid stimulating hormone;
CRC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.45	6.58	0.34	1.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.95	-17.4	-0.69	1.56e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02290350	chr8:58132656	NA	-0.55	-6.3	-0.33	9.68e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs8005150	0.737	rs56972319	chr14:88488089	G/A	cg25527770	chr19:1444892	NA	-0.57	-6.2	-0.32	1.67e-9	Hepatitis B;
CRC	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.47	-6.03	-0.32	4.45e-9	Alopecia areata;
CRC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg00343986	chr7:65444356	GUSB	0.49	7.18	0.37	4.67e-12	Aortic root size;
CRC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.67	10.26	0.49	1.32e-21	Birth weight;
CRC	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.54	0.38	4.64e-13	Height;
CRC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.73	0.35	7.62e-11	Diabetic retinopathy;
CRC	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	cg04338863	chr8:33670619	NA	0.41	6.74	0.35	7e-11	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16720675	chr18:19284817	ABHD3	0.35	6.1	0.32	2.92e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg05030574	chr11:65189075	NEAT1	0.58	6.14	0.32	2.38e-9	Airway imaging phenotypes;
CRC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg21153622	chr11:89784906	NA	-0.42	-6.94	-0.36	2.06e-11	Coronary artery disease;
CRC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.53	7.75	0.39	1.13e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14358282	chr2:219866628	MIR375	0.38	6.02	0.31	4.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9648716	1.000	rs28529157	chr7:140614830	T/C	cg10747023	chr7:140774559	NA	0.47	6.1	0.32	2.98e-9	Type 2 diabetes;
CRC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.78	-13.86	-0.61	9.98e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg11915388	chr22:42470451	FAM109B	-0.41	-6.3	-0.33	9.81e-10	Schizophrenia;
CRC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.66	8.89	0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.53	-8.05	-0.41	1.56e-14	HDL cholesterol;
CRC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.89	-16.04	-0.66	3.41e-43	Height;
CRC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.66	-11.43	-0.53	1.01e-25	Longevity;
CRC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.89e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.64	9.02	0.45	1.57e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6076065	0.683	rs2424528	chr20:23361613	C/T	cg11657817	chr20:23433608	CST11	0.45	6.79	0.35	5.39e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.45	-7.62	-0.39	2.79e-13	Schizophrenia;
CRC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.26	-0.37	2.74e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.62	0.39	2.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17155006	0.655	rs437336	chr7:107728634	G/T	cg05962710	chr7:107745446	LAMB4	-0.35	-5.85	-0.31	1.16e-8	Pneumococcal bacteremia;
CRC	cis	rs1223397	0.938	rs9381884	chr6:13278788	A/G	cg07912922	chr6:13274314	PHACTR1	0.48	5.99	0.31	5.59e-9	Blood pressure;
CRC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.68	10.16	0.49	2.79e-21	Corneal astigmatism;
CRC	cis	rs3823572	0.564	rs2953623	chr7:133659410	C/G	cg03336402	chr7:133662267	EXOC4	-0.68	-10.78	-0.51	2.08e-23	Intelligence (multi-trait analysis);
CRC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.66	-8.04	-0.41	1.62e-14	Bronchopulmonary dysplasia;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.78	0.35	5.57e-11	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22228043	chr1:11159903	EXOSC10	0.43	6.31	0.33	9.1e-10	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg19812747	chr11:111475976	SIK2	0.48	6.97	0.36	1.75e-11	Primary sclerosing cholangitis;
CRC	cis	rs2637266	0.519	rs7923176	chr10:78298380	C/T	cg18941641	chr10:78392320	NA	0.32	5.64	0.3	3.71e-8	Pulmonary function;
CRC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-9.2	-0.45	4.22e-18	Initial pursuit acceleration;
CRC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg14074117	chr16:1909714	C16orf73	0.37	6.41	0.33	5.19e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.52	-0.34	2.59e-10	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs12467042	chr2:162526971	G/A	cg12500891	chr11:57225987	NA	-0.67	-6.12	-0.32	2.62e-9	Cognitive function;
CRC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Alcohol dependence;
CRC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.62	-7.8	-0.39	8.5e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.78	-10.53	-0.5	1.54e-22	IgG glycosylation;
CRC	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg14458575	chr2:238380390	NA	0.65	8.1	0.41	1.11e-14	Prostate cancer;
CRC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.47	-6.89	-0.35	2.9e-11	Melanoma;
CRC	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.38	5.89	0.31	9.58e-9	Endometrial cancer;
CRC	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs73200209	0.662	rs17426872	chr12:116636915	T/C	cg01776926	chr12:116560359	MED13L	-0.6	-6.97	-0.36	1.75e-11	Total body bone mineral density;
CRC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-11.56	-0.54	3.48e-26	Personality dimensions;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.7	-10.24	-0.49	1.49e-21	Menopause (age at onset);
CRC	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.63	0.57	4.47e-30	Height;
CRC	cis	rs12044355	0.858	rs1538975	chr1:231828372	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.81	0.35	4.7e-11	Alzheimer's disease;
CRC	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.73	11.51	0.54	5.61e-26	Plateletcrit;Platelet count;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.07	-0.32	3.5e-9	Obesity-related traits;
CRC	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.21	28.03	0.84	3.43e-89	Schizophrenia;
CRC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg25985355	chr7:65971099	NA	0.33	5.74	0.3	2.15e-8	Aortic root size;
CRC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	17.31	0.69	3.51e-48	Electrocardiographic conduction measures;
CRC	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.6	8.49	0.42	7.05e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs13144136	0.748	rs4697773	chr4:10668379	C/T	cg10242279	chr4:10666415	CLNK	-0.33	-5.67	-0.3	3.07e-8	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs7849270	1.000	rs3739847	chr9:131911574	A/G	cg13538475	chr9:131942899	NA	0.32	6.25	0.33	1.28e-9	Blood metabolite ratios;
CRC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.92	0.31	7.91e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	8.63	0.43	2.75e-16	Lung function (FEV1/FVC);
CRC	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg09040174	chr2:113837401	NA	0.67	10.7	0.51	4.04e-23	Protein quantitative trait loci;
CRC	trans	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg00953403	chr17:74099816	EXOC7	-0.47	-6.94	-0.36	2.05e-11	Psychosis in Alzheimer's disease;
CRC	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg12315302	chr6:26189340	HIST1H4D	0.96	6.62	0.34	1.43e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg20850243	chr13:99229849	STK24	-0.6	-6.3	-0.33	9.5e-10	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.43	-7.19	-0.37	4.34e-12	Facial morphology (factor 20);
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg18758796	chr5:131593413	PDLIM4	0.4	6.37	0.33	6.42e-10	Acylcarnitine levels;
CRC	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.53	-9.94	-0.48	1.62e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg03316587	chr8:142245164	NA	-0.38	-5.74	-0.3	2.15e-8	Immature fraction of reticulocytes;
CRC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.85	-0.31	1.19e-8	Breast cancer;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg03623178	chr6:28175578	NA	0.84	13.06	0.58	1.07e-31	Cardiac Troponin-T levels;
CRC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.47	-6.65	-0.34	1.24e-10	Mean platelet volume;
CRC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg20573242	chr4:122745356	CCNA2	0.39	5.64	0.3	3.65e-8	Type 2 diabetes;
CRC	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.74	-0.43	1.22e-16	Coffee consumption (cups per day);
CRC	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.69	7.22	0.37	3.73e-12	Childhood ear infection;
CRC	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg06634786	chr22:41940651	POLR3H	-0.43	-5.85	-0.31	1.19e-8	Neuroticism;
CRC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.63	11.69	0.54	1.18e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg03623178	chr6:28175578	NA	0.79	11.81	0.55	4.51e-27	Parkinson's disease;
CRC	cis	rs995000	0.931	rs11207996	chr1:63055470	G/A	cg19896129	chr1:63156450	NA	0.39	5.66	0.3	3.32e-8	Triglyceride levels;
CRC	cis	rs12476592	0.602	rs2421952	chr2:63749833	T/C	cg10828910	chr2:63850056	LOC388955	0.5	6.19	0.32	1.78e-9	Childhood ear infection;
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg05373962	chr22:49881684	NA	-0.39	-7.4	-0.38	1.16e-12	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg11707556	chr5:10655725	ANKRD33B	0.47	7.59	0.39	3.33e-13	Coronary artery disease;
CRC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.65	11.14	0.52	1.11e-24	Cancer;
CRC	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg24476569	chr13:95954382	ABCC4	-0.37	-5.61	-0.3	4.34e-8	Blood metabolite levels;
CRC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg14711859	chr11:8959438	ASCL3	-0.45	-7.13	-0.37	6.38e-12	Hemoglobin concentration;
CRC	cis	rs2282802	0.685	rs10051345	chr5:139670932	C/G	cg26211634	chr5:139558579	C5orf32	-0.44	-7.63	-0.39	2.51e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10971721	0.822	rs72727344	chr9:33939120	C/G	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24506662	chr3:129830295	LOC729375	0.48	6.49	0.34	3.21e-10	Anxiety disorder;
CRC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.5	6.56	0.34	2.03e-10	IgG glycosylation;
CRC	cis	rs17065868	0.649	rs9533848	chr13:45005713	C/T	cg10246903	chr13:45222710	NA	-0.51	-5.82	-0.31	1.42e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.72	-0.43	1.42e-16	Alcohol dependence;
CRC	cis	rs10886503	0.614	rs3009908	chr10:121262900	T/C	cg17804342	chr10:121271663	RGS10	-0.82	-7.77	-0.39	1.03e-13	Obstetric antiphospholipid syndrome;
CRC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.8	11.39	0.53	1.42e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg11446398	chr5:77624930	NA	-0.41	-5.81	-0.3	1.5e-8	Triglycerides;
CRC	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg17788362	chr6:86352627	SYNCRIP	0.54	7.52	0.38	5.33e-13	Smooth-surface caries;
CRC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.76	16.49	0.67	5.94e-45	Breast cancer;
CRC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg19418458	chr7:158789849	NA	-0.51	-8.8	-0.44	7.72e-17	Facial morphology (factor 20);
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21433558	chr17:40837037	CNTNAP1	0.48	7.64	0.39	2.38e-13	Colorectal or endometrial cancer;
CRC	cis	rs55788414	0.527	rs2873368	chr16:81184208	C/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07167872	chr1:205819463	PM20D1	0.42	5.86	0.31	1.12e-8	Parkinson's disease;
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.62	10.25	0.49	1.36e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs12505749	0.542	rs6849183	chr4:57329936	C/T	cg04528060	chr4:57371868	ARL9	0.54	5.75	0.3	2.09e-8	Airflow obstruction;
CRC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.18	-0.64	8.11e-40	Chronic sinus infection;
CRC	cis	rs7705042	0.826	rs6883827	chr5:141504991	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.22	0.37	3.57e-12	Asthma;
CRC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.41	8.01	0.4	1.97e-14	Mean corpuscular volume;
CRC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.75	-10.19	-0.49	2.26e-21	White matter hyperintensity burden;
CRC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.47	6.34	0.33	7.69e-10	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.7	-10.62	-0.51	7.33e-23	Cognitive function;
CRC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs6662572	0.703	rs10789482	chr1:46396704	G/A	cg08644498	chr1:46502608	NA	-0.45	-7.08	-0.36	8.76e-12	Blood protein levels;
CRC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg00129232	chr17:37814104	STARD3	0.62	7.14	0.37	6.19e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.84	-12.02	-0.55	7.45e-28	Gut microbiome composition (summer);
CRC	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg26220594	chr1:19110978	NA	-0.47	-6.47	-0.34	3.56e-10	Drug-induced liver injury (nitrofurantoin);
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg15845792	chr6:28175446	NA	0.66	9.22	0.45	3.55e-18	Parkinson's disease;
CRC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg14530993	chr4:882597	GAK	0.82	7.82	0.4	7.42e-14	Intelligence (multi-trait analysis);
CRC	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg19169023	chr15:41853346	TYRO3	-0.51	-7.77	-0.39	1.04e-13	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03670153	chr3:184079754	CLCN2;POLR2H	0.47	6.69	0.35	9.55e-11	Response to antipsychotic treatment;
CRC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.61	-8.62	-0.43	2.91e-16	Hip circumference adjusted for BMI;
CRC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.62	-10.62	-0.51	7.67e-23	White blood cell count (basophil);
CRC	cis	rs2735413	0.918	rs12924772	chr16:78083115	T/C	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9463078	0.764	rs9369516	chr6:44833598	C/T	cg25276700	chr6:44698697	NA	-0.28	-6.72	-0.35	7.84e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs16973500	0.808	rs112121746	chr16:71874983	G/A	cg00732059	chr16:71740210	PHLPP2	-0.7	-7.14	-0.37	6.01e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg18683604	chr14:51561293	TRIM9	0.31	6.08	0.32	3.32e-9	Cancer;
CRC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.44	-8.12	-0.41	9.71e-15	Reticulocyte fraction of red cells;
CRC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg26721908	chr21:47610096	LSS	0.41	6.26	0.33	1.22e-9	Testicular germ cell tumor;
CRC	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.5	5.78	0.3	1.78e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg07701084	chr6:150067640	NUP43	-0.47	-5.74	-0.3	2.16e-8	Lung cancer;
CRC	cis	rs6141769	0.542	rs6058846	chr20:31324035	A/C	cg13636640	chr20:31349939	DNMT3B	-0.43	-6.14	-0.32	2.37e-9	Subjective well-being;
CRC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.61	7.32	0.37	1.89e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.04	-0.32	4.27e-9	Heart rate;
CRC	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.59	-9.1	-0.45	9.01e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs524281	0.861	rs485857	chr11:65959519	A/G	cg16950941	chr11:66035639	RAB1B	-0.57	-7.26	-0.37	2.78e-12	Electroencephalogram traits;
CRC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.94	0.31	7.11e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg06470822	chr6:28175283	NA	0.8	12.0	0.55	9.26e-28	Parkinson's disease;
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.39	5.91	0.31	8.43e-9	Longevity;Endometriosis;
CRC	trans	rs10021731	0.718	rs2219591	chr4:115413058	G/T	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg04553112	chr3:125709451	NA	-0.51	-5.99	-0.31	5.55e-9	Blood pressure (smoking interaction);
CRC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.6	9.11	0.45	8.37e-18	Corneal astigmatism;
CRC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06656553	chr16:89960601	TCF25	-0.73	-5.99	-0.31	5.48e-9	Skin colour saturation;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-8.51	-0.42	6.25e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	trans	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg19894588	chr14:64061835	NA	-0.54	-7.2	-0.37	4.07e-12	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg01878214	chr7:45145334	TBRG4;SNORA5C;SNORA5A	-0.44	-5.99	-0.31	5.41e-9	Red cell distribution width;
CRC	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.34	-9.21	-0.45	3.8e-18	Mean corpuscular volume;
CRC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg06028605	chr16:24865363	SLC5A11	0.39	7.26	0.37	2.9e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.44	7.42	0.38	1.02e-12	Crohn's disease;
CRC	cis	rs2617583	0.509	rs10630	chr5:1462720	G/A	cg07148919	chr5:1466943	LPCAT1	-0.43	-5.68	-0.3	2.96e-8	Breast cancer;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg14711859	chr11:8959438	ASCL3	-0.52	-8.48	-0.42	7.61e-16	Hemoglobin concentration;
CRC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg07701084	chr6:150067640	NUP43	-0.47	-6.91	-0.36	2.58e-11	Testicular germ cell tumor;
CRC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg16797656	chr11:68205561	LRP5	0.37	5.85	0.31	1.18e-8	Total body bone mineral density;
CRC	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.36	-6.82	-0.35	4.25e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	13.32	0.59	1.17e-32	Alzheimer's disease;
CRC	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg02135003	chr7:105160482	PUS7	-0.52	-8.07	-0.41	1.32e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.48	7.97	0.4	2.72e-14	Coronary artery disease;
CRC	cis	rs747650	0.504	rs61896133	chr11:47115719	G/C	cg19486271	chr11:47235900	DDB2	0.44	5.89	0.31	9.76e-9	Acne (severe);
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.58	-0.34	1.89e-10	Subjective well-being;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.38	6.25	0.33	1.28e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg25344623	chr2:136566232	LCT	-0.33	-6.15	-0.32	2.24e-9	Mosquito bite size;
CRC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.57	8.22	0.41	4.63e-15	Melanoma;
CRC	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.52	7.75	0.39	1.14e-13	Intelligence (multi-trait analysis);
CRC	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg06581033	chr10:766294	NA	-0.52	-5.78	-0.3	1.71e-8	Uric acid levels;
CRC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.54	-6.3	-0.33	9.34e-10	Lymphocyte counts;
CRC	cis	rs367943	0.712	rs6867397	chr5:112725759	C/T	cg12552261	chr5:112820674	MCC	-0.35	-5.73	-0.3	2.26e-8	Type 2 diabetes;
CRC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.21	0.53	6.57e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06207460	chr9:4741011	AK3	0.5	7.95	0.4	3.03e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs1322512	1.000	rs2758784	chr6:153010489	A/G	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg05501817	chr11:14380813	RRAS2	-0.46	-6.12	-0.32	2.61e-9	Sense of smell;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10821925	chr12:29533733	ERGIC2	0.41	6.12	0.32	2.62e-9	Myopia (pathological);
CRC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.09	-0.36	8.01e-12	Gut microbiome composition (summer);
CRC	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.5	6.48	0.34	3.42e-10	Recombination rate (females);
CRC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg24011408	chr12:48396354	COL2A1	0.45	6.38	0.33	6.14e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	1.05	9.84	0.48	3.29e-20	Arsenic metabolism;
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.98	-19.62	-0.73	2.67e-57	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.41	0.53	1.25e-25	Alzheimer's disease;
CRC	cis	rs2462686	0.965	rs1525831	chr7:45994409	C/T	cg23193639	chr7:45961078	IGFBP3	0.37	5.94	0.31	7.4e-9	Major depressive disorder;
CRC	cis	rs11212617	0.935	rs227070	chr11:108211412	T/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.66	0.3	3.22e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.51	7.98	0.4	2.48e-14	Intelligence (multi-trait analysis);
CRC	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	16.87	0.68	1.91e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg03678062	chr6:149772716	ZC3H12D	0.36	6.57	0.34	1.93e-10	Dupuytren's disease;
CRC	cis	rs7849270	1.000	rs10988224	chr9:131903334	A/T	cg13538475	chr9:131942899	NA	-0.29	-5.77	-0.3	1.78e-8	Blood metabolite ratios;
CRC	cis	rs9462027	0.540	rs9366863	chr6:34688946	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.07	0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.41	-0.46	8.9e-19	Subjective well-being;
CRC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.68	-8.89	-0.44	4.1e-17	Bronchopulmonary dysplasia;
CRC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-5.63	-0.3	3.83e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.68	-0.3	3.02e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg27113153	chr11:123612418	ZNF202	-0.68	-6.06	-0.32	3.72e-9	Blood osmolality (transformed sodium);
CRC	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.78	-10.75	-0.51	2.59e-23	Bipolar disorder;
CRC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg20387954	chr3:183756860	HTR3D	0.45	7.72	0.39	1.45e-13	Anterior chamber depth;
CRC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs713477	1.000	rs8010013	chr14:55884828	A/C	cg13175173	chr14:55914753	NA	-0.48	-8.81	-0.44	7.32e-17	Pediatric bone mineral content (femoral neck);
CRC	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.04	-14.44	-0.62	6.2e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	1.06	11.32	0.53	2.52e-25	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs6604026	0.922	rs7521417	chr1:93377835	C/T	cg22128645	chr1:93425802	FAM69A	-0.41	-5.9	-0.31	9.23e-9	Multiple sclerosis;
CRC	cis	rs6662572	1.000	rs72688452	chr1:46092365	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.86	0.31	1.1e-8	Blood protein levels;
CRC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06634786	chr22:41940651	POLR3H	-0.41	-5.81	-0.31	1.45e-8	Vitiligo;
CRC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18357526	chr6:26021779	HIST1H4A	0.41	5.83	0.31	1.32e-8	Height;
CRC	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11645453	chr3:52864694	ITIH4	-0.45	-8.6	-0.43	3.37e-16	Body mass index;
CRC	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.95	-13.36	-0.59	7.99e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg06494592	chr3:125709126	NA	-0.57	-6.79	-0.35	5.14e-11	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.52	9.13	0.45	7.05e-18	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.58	8.27	0.41	3.32e-15	Coronary artery disease;
CRC	cis	rs2949837	0.603	rs1542818	chr7:45977656	G/T	cg21268650	chr7:45961089	IGFBP3	0.38	6.41	0.33	5.05e-10	Sitting height ratio;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10955293	chr1:24117561	LYPLA2	0.43	5.98	0.31	5.96e-9	Anxiety disorder;
CRC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.55	7.87	0.4	5.3e-14	Height;
CRC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7572644	0.640	rs12617113	chr2:28059937	A/G	cg27432699	chr2:27873401	GPN1	0.47	6.24	0.33	1.36e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09820084	chr6:18387507	RNF144B	0.52	6.89	0.36	2.89e-11	Thyroid stimulating hormone;
CRC	cis	rs7680126	0.596	rs17418533	chr4:10316941	T/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.63	-0.34	1.35e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.72	9.67	0.47	1.22e-19	Coronary artery disease;
CRC	cis	rs2982552	1.000	rs2982551	chr6:152061210	G/T	cg22157087	chr6:152012887	ESR1	0.45	7.12	0.37	6.91e-12	Bone properties (heel);
CRC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg09184832	chr6:79620586	NA	-0.35	-5.88	-0.31	9.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.62	-8.36	-0.42	1.85e-15	Blood protein levels;
CRC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.78	14.04	0.61	2.14e-35	Metabolic syndrome;
CRC	cis	rs11958404	0.932	rs112683473	chr5:157437819	T/C	cg05962755	chr5:157440814	NA	0.95	12.34	0.56	5.17e-29	IgG glycosylation;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08792129	chr6:99962992	USP45	0.44	6.08	0.32	3.4e-9	Anxiety disorder;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg08222913	chr3:52553049	STAB1	-0.32	-5.98	-0.31	5.87e-9	Bipolar disorder;
CRC	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.55	-0.34	2.22e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs11654801	0.646	rs35597750	chr17:20851636	G/T	cg23759823	chr7:139672531	TBXAS1	-0.39	-6.3	-0.33	9.45e-10	Mosquito bite size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27430682	chr10:65225552	JMJD1C;LOC84989	-0.38	-6.08	-0.32	3.31e-9	Myopia (pathological);
CRC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10802521	chr3:52805072	NEK4	-0.48	-6.84	-0.35	3.84e-11	Bipolar disorder;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.7	10.57	0.5	1.15e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg19338460	chr6:170058176	WDR27	-0.67	-7.42	-0.38	9.76e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-7.72	-0.39	1.38e-13	Pulmonary function;
CRC	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-5.84	-0.31	1.26e-8	Brugada syndrome;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.42	5.64	0.3	3.6e-8	Longevity;Endometriosis;
CRC	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.59	-9.31	-0.46	1.84e-18	Breast cancer;
CRC	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.76	0.39	1.06e-13	Gout;
CRC	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.59	7.53	0.38	4.99e-13	Coronary artery disease;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.77	-0.51	2.3e-23	Body mass index;
CRC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16447950	chr5:562315	NA	-0.73	-9.67	-0.47	1.24e-19	Obesity-related traits;
CRC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs3106136	0.609	rs4693000	chr4:95107657	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-6.26	-0.33	1.22e-9	Capecitabine sensitivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11008510	chr2:60782852	NA	0.45	6.71	0.35	8.69e-11	Intelligence (multi-trait analysis);
CRC	trans	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg20935933	chr6:143382018	AIG1	0.51	6.6	0.34	1.66e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs73200209	0.912	rs11067904	chr12:116529835	C/G	cg01776926	chr12:116560359	MED13L	0.47	5.97	0.31	6.23e-9	Total body bone mineral density;
CRC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.16	0.37	5.35e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.04	-0.48	7.05e-21	Monocyte count;
CRC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg23533926	chr12:111358616	MYL2	0.45	6.65	0.34	1.19e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg25972092	chr12:117363249	FBXW8	0.5	5.92	0.31	8.02e-9	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg08999081	chr20:33150536	PIGU	0.44	5.71	0.3	2.58e-8	Protein C levels;
CRC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.64	0.34	1.33e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg01339444	chr6:118972232	C6orf204	0.55	6.01	0.31	4.93e-9	Diastolic blood pressure;
CRC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.4	-6.29	-0.33	9.97e-10	Neurofibrillary tangles;
CRC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg08210727	chr20:33865349	NA	0.43	5.93	0.31	7.84e-9	Attention deficit hyperactivity disorder;
CRC	trans	rs2303319	0.504	rs1567420	chr2:162475601	C/T	cg03774468	chr3:140950104	ACPL2	0.66	6.01	0.31	5.04e-9	Cognitive function;
CRC	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg14593290	chr7:50529359	DDC	-0.63	-8.34	-0.42	2.06e-15	Malaria;
CRC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg24562669	chr7:97807699	LMTK2	0.46	7.82	0.4	7.01e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.66	9.69	0.47	1.07e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg26043149	chr18:55253948	FECH	0.53	8.16	0.41	7.05e-15	Bone mineral density;
CRC	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg19131313	chr8:1704013	NA	-0.44	-6.1	-0.32	2.96e-9	Systolic blood pressure;
CRC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.89	-16.42	-0.67	1.1e-44	Height;
CRC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg19635926	chr16:89946313	TCF25	0.6	5.96	0.31	6.53e-9	Skin colour saturation;
CRC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.98	12.85	0.58	6.38e-31	Triglycerides;
CRC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.49	7.47	0.38	7.45e-13	Type 2 diabetes;
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4908768	0.501	rs7551849	chr1:8539463	A/G	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	trans	rs9650657	0.644	rs10091386	chr8:10696620	A/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.17	-0.32	2.01e-9	Neuroticism;
CRC	cis	rs17767392	0.560	rs1008517	chr14:72041434	A/G	cg13720639	chr14:72061746	SIPA1L1	0.56	6.97	0.36	1.77e-11	Mitral valve prolapse;
CRC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.65	8.72	0.43	1.43e-16	Alcohol dependence;
CRC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.88	-14.61	-0.63	1.28e-37	Height;
CRC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.43	-7.06	-0.36	1e-11	Breast cancer;
CRC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg07125278	chr16:67683757	RLTPR	-0.57	-5.83	-0.31	1.29e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9409565	0.516	rs114766729	chr9:97069901	C/T	cg04523069	chr9:97136363	HIATL1	-0.39	-6.09	-0.32	3.19e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs938554	0.876	rs7670751	chr4:9938773	A/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.82	-0.31	1.43e-8	Blood metabolite levels;
CRC	trans	rs7671189	0.502	rs1114553	chr4:11739401	G/A	cg18054620	chr5:111191530	C5orf13	-0.3	-6.03	-0.32	4.39e-9	Obesity-related traits;
CRC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.4	6.2	0.32	1.73e-9	HDL cholesterol levels;
CRC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg13206674	chr6:150067644	NUP43	0.48	6.89	0.36	2.79e-11	Testicular germ cell tumor;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.02	25.75	0.82	7.68e-81	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg01843034	chr6:37503916	NA	-0.44	-8.26	-0.41	3.64e-15	Cognitive performance;
CRC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg24531977	chr5:56204891	C5orf35	-0.44	-6.71	-0.35	8.63e-11	Coronary artery disease;
CRC	trans	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg10756647	chr7:56101905	PSPH	0.66	7.81	0.4	7.97e-14	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11437374	chr5:169010780	CCDC99	0.41	6.57	0.34	2.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2625529	0.730	rs12912771	chr15:72162928	A/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.79	-0.35	5.13e-11	Red blood cell count;
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.28	-0.37	2.4e-12	Bipolar disorder;
CRC	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	0.56	8.78	0.44	9.36e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg05044414	chr3:183734942	ABCC5	0.47	8.08	0.41	1.21e-14	Anterior chamber depth;
CRC	cis	rs4654899	0.931	rs10799669	chr1:21172501	T/C	cg02927042	chr1:21476669	EIF4G3	0.4	6.23	0.32	1.41e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.84	13.01	0.58	1.74e-31	Smoking behavior;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25820971	chr14:21852127	SUPT16H	0.41	6.25	0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg13057898	chr1:3703894	LRRC47	0.52	6.94	0.36	2.04e-11	Red cell distribution width;
CRC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.99	0.66	5.77e-43	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11645453	chr3:52864694	ITIH4	0.31	5.69	0.3	2.89e-8	Electroencephalogram traits;
CRC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg26918954	chr5:179728553	GFPT2	-0.42	-7.13	-0.37	6.47e-12	Height;
CRC	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.59	8.52	0.43	5.96e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.71	10.86	0.51	1.13e-23	Corneal astigmatism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04445988	chr6:75994563	TMEM30A	-0.45	-6.31	-0.33	9.01e-10	Myopia (pathological);
CRC	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.52	-7.78	-0.39	9.75e-14	Schizophrenia;
CRC	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.41	-5.84	-0.31	1.24e-8	Breast cancer;
CRC	trans	rs1642645	0.831	rs6689536	chr1:42487523	T/C	cg16926213	chr1:1841314	NA	-0.42	-6.07	-0.32	3.57e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg10589385	chr1:150898437	SETDB1	0.3	6.1	0.32	3e-9	Melanoma;
CRC	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg06818126	chr11:68850279	TPCN2	-0.43	-6.0	-0.31	5.08e-9	Hair color;
CRC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.01	0.74	7.51e-59	Prudent dietary pattern;
CRC	cis	rs10503871	0.690	rs7812836	chr8:30352258	A/G	cg26383811	chr8:30366931	RBPMS	-0.47	-7.37	-0.38	1.35e-12	Metabolite levels  (X-11787);
CRC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg14541582	chr5:601475	NA	-0.33	-6.48	-0.34	3.34e-10	Obesity-related traits;
CRC	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-11.28	-0.53	3.66e-25	Exhaled nitric oxide output;
CRC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.59	10.55	0.5	1.36e-22	Schizophrenia;
CRC	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.44	-0.69	1.11e-48	Schizophrenia;
CRC	cis	rs16867335	1.000	rs35579320	chr2:181463612	T/C	cg23363182	chr2:181467187	NA	-0.49	-6.62	-0.34	1.45e-10	Survival in rectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12198157	chr3:134204547	CEP63;ANAPC13	0.42	6.14	0.32	2.34e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19109955	chr19:39138207	ACTN4	0.37	5.98	0.31	5.68e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05893365	chr16:67260970	LRRC29;TMEM208	0.42	6.11	0.32	2.89e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02952494	chr16:1818699	MAPK8IP3	-0.42	-6.95	-0.36	1.91e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs972578	1.000	rs1546860	chr22:43400329	T/C	cg01576275	chr22:43409880	NA	-0.49	-8.0	-0.4	2.13e-14	Mean platelet volume;
CRC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.54	7.2	0.37	4.23e-12	Obesity-related traits;
CRC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.91	13.0	0.58	1.85e-31	Breast cancer;
CRC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.6	-9.27	-0.45	2.59e-18	Colorectal cancer;
CRC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.58	6.35	0.33	7.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.65	9.93	0.48	1.69e-20	Initial pursuit acceleration;
CRC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.32	-6.87	-0.35	3.16e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-7.21	-0.37	3.97e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs16867321	0.951	rs9989767	chr2:181429886	C/T	cg23363182	chr2:181467187	NA	-0.53	-6.74	-0.35	6.97e-11	Obesity;
CRC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.42	5.73	0.3	2.31e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.61	8.42	0.42	1.16e-15	High light scatter reticulocyte count;
CRC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg07701084	chr6:150067640	NUP43	0.49	7.22	0.37	3.74e-12	Testicular germ cell tumor;
CRC	cis	rs6684514	1.000	rs12132919	chr1:156318141	C/A	cg16558208	chr1:156270281	VHLL	0.56	8.42	0.42	1.17e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg02175503	chr12:58329896	NA	0.71	9.77	0.47	5.89e-20	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00495681	chr13:53174319	NA	0.62	9.28	0.46	2.27e-18	Lewy body disease;
CRC	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.09	24.24	0.8	3.53e-75	Platelet distribution width;
CRC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.59	-8.1	-0.41	1.07e-14	DNA methylation (variation);
CRC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg27535305	chr1:53392650	SCP2	-0.38	-7.05	-0.36	1.03e-11	Monocyte count;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.71	-5.81	-0.31	1.48e-8	Putamen volume;
CRC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.47	-6.43	-0.33	4.44e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg18833306	chr6:118973337	C6orf204	0.45	5.95	0.31	6.94e-9	Diastolic blood pressure;
CRC	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06634786	chr22:41940651	POLR3H	-0.47	-6.27	-0.33	1.13e-9	Vitiligo;
CRC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.74	-0.43	1.22e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs10128264	0.902	rs2802360	chr10:80971196	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.38	-6.65	-0.34	1.23e-10	Response to methotrexate in juvenile idiopathic arthritis;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05622441	chr16:69419962	TERF2	0.4	6.47	0.34	3.6e-10	Obesity-related traits;
CRC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	0.98	10.96	0.52	4.8e-24	Gut microbiota (bacterial taxa);
CRC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.42	5.84	0.31	1.28e-8	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg12856521	chr11:46389249	DGKZ	0.44	7.18	0.37	4.65e-12	Leprosy;
CRC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.69	10.56	0.5	1.2e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg13390004	chr1:15929781	NA	0.53	7.27	0.37	2.66e-12	Systolic blood pressure;
CRC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.59	-8.96	-0.44	2.51e-17	Childhood ear infection;
CRC	cis	rs2569991	0.588	rs2596909	chr3:12928672	G/C	cg22481960	chr3:13008800	IQSEC1	-0.47	-6.11	-0.32	2.86e-9	Periodontitis (DPAL);
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.45	7.58	0.39	3.65e-13	Alcohol dependence;
CRC	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.39	-0.38	1.22e-12	Capecitabine sensitivity;
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.81	-0.35	4.66e-11	Intelligence (multi-trait analysis);
CRC	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.98	18.26	0.71	6.01e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.62	9.74	0.47	7.16e-20	Crohn's disease;
CRC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.45	6.57	0.34	1.93e-10	Asthma;
CRC	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg04586622	chr2:25135609	ADCY3	0.36	6.1	0.32	3e-9	Body mass index in non-asthmatics;
CRC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	6.95	0.36	1.91e-11	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16978263	chr3:160118452	SMC4;IFT80	0.52	6.68	0.35	1.03e-10	Thyroid stimulating hormone;
CRC	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.23e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.43	-0.38	9.53e-13	Coronary artery disease;
CRC	cis	rs61160187	0.522	rs2045356	chr5:59947354	C/T	cg02684056	chr5:59996105	DEPDC1B	0.41	5.94	0.31	7.14e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.34	-6.62	-0.34	1.42e-10	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07481335	chr14:65879396	FUT8;LOC645431	0.44	6.31	0.33	8.88e-10	Anxiety disorder;
CRC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.51	7.51	0.38	5.65e-13	Colorectal cancer;
CRC	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.49	-8.85	-0.44	5.6e-17	HIV-1 susceptibility;
CRC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.23	-0.41	4.5e-15	Monocyte percentage of white cells;
CRC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.77	-15.35	-0.65	1.83e-40	Refractive error;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg02683197	chr6:28174875	NA	0.81	9.98	0.48	1.15e-20	Depression;
CRC	cis	rs7725052	0.609	rs12153402	chr5:40463412	G/A	cg09067459	chr5:40385259	NA	0.4	6.68	0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg14541582	chr5:601475	NA	-0.28	-5.87	-0.31	1.08e-8	Ulcerative colitis;
CRC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.73	7.19	0.37	4.5e-12	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.51	8.36	0.42	1.82e-15	Calcium levels;
CRC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-6.15	-0.32	2.19e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs55675132	0.510	rs12130524	chr1:115287833	T/C	cg12756093	chr1:115239321	AMPD1	0.52	6.24	0.33	1.34e-9	Schizophrenia;
CRC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.01	-0.31	4.97e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg15445000	chr17:37608096	MED1	0.35	6.24	0.33	1.34e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs62189005	chr2:162562386	T/C	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.04	-0.32	4.09e-9	Total body bone mineral density;
CRC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg26587870	chr6:27730563	NA	-0.43	-6.37	-0.33	6.38e-10	Parkinson's disease;
CRC	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg24998770	chr7:37888106	TXNDC3	-0.36	-5.9	-0.31	8.94e-9	Alzheimer's disease (late onset);
CRC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-12.05	-0.55	5.98e-28	Urate levels in overweight individuals;
CRC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.62	-0.39	2.7e-13	HDL cholesterol;
CRC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.32e-19	Blood protein levels;
CRC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.69	-0.35	9.45e-11	Menopause (age at onset);
CRC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.49e-16	Homoarginine levels;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg27615366	chr5:131592974	PDLIM4	0.34	6.46	0.34	3.73e-10	Acylcarnitine levels;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg04497992	chr16:616212	NHLRC4	0.45	7.25	0.37	3.06e-12	Height;
CRC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg11522145	chr4:3412961	RGS12	-0.37	-5.8	-0.3	1.55e-8	Serum sulfate level;
CRC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.77	-0.44	9.87e-17	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09188840	chr17:4699533	PSMB6	0.38	6.14	0.32	2.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.66	10.09	0.49	5.09e-21	Initial pursuit acceleration;
CRC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.22	-16.68	-0.68	1.07e-45	Breast cancer;
CRC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg09264619	chr17:80180166	NA	0.51	7.31	0.37	1.99e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.38	-8.52	-0.43	5.62e-16	Alcohol dependence;
CRC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.85e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16214573	chr11:120081755	OAF	0.37	5.99	0.31	5.54e-9	Schizophrenia;
CRC	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.81	-14.24	-0.62	3.57e-36	Lewy body disease;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg02416716	chr11:6948024	ZNF215	0.57	5.86	0.31	1.14e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg25204440	chr1:209979598	IRF6	0.49	5.8	0.3	1.55e-8	Cleft lip with or without cleft palate;
CRC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-14.78	-0.63	2.96e-38	Vitiligo;
CRC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.05	-0.32	3.9e-9	Diabetic kidney disease;
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.59	6.13	0.32	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg15744005	chr10:104629667	AS3MT	-0.35	-6.5	-0.34	2.89e-10	Arsenic metabolism;
CRC	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg19773385	chr1:10388646	KIF1B	-0.54	-7.53	-0.38	4.86e-13	Hepatocellular carcinoma;
CRC	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.27e-25	White blood cell count (basophil);
CRC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.52	8.09	0.41	1.13e-14	Corneal astigmatism;
CRC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.47	7.38	0.38	1.34e-12	Eye color traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17392648	chr5:68788941	OCLN	0.41	6.02	0.31	4.7e-9	Response to antipsychotic treatment;
CRC	cis	rs12024301	0.557	rs12044718	chr1:183616403	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.12	0.37	6.85e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg24130564	chr14:104152367	KLC1	-0.44	-6.61	-0.34	1.54e-10	Body mass index;
CRC	cis	rs9359856	0.913	rs9362663	chr6:90307550	A/C	cg13799429	chr6:90582589	CASP8AP2	0.43	6.06	0.32	3.63e-9	Bipolar disorder;
CRC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg10760299	chr15:45669010	GATM	0.52	8.35	0.42	1.91e-15	Homoarginine levels;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.74	7.88	0.4	4.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.35e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.5	9.0	0.44	1.9e-17	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg12458913	chr13:53173898	NA	-0.75	-14.16	-0.62	7.14e-36	Lewy body disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15670579	chr15:102264312	TARSL2	-0.43	-6.42	-0.33	4.83e-10	Myopia (pathological);
CRC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-7.13	-0.37	6.24e-12	Inflammatory bowel disease;
CRC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04498913	chr7:1135747	C7orf50	-0.49	-6.02	-0.31	4.68e-9	Bronchopulmonary dysplasia;
CRC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	15.75	0.66	4.96e-42	Smoking behavior;
CRC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg27661571	chr11:113659931	NA	-0.64	-7.36	-0.38	1.44e-12	Hip circumference adjusted for BMI;
CRC	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-9.15	-0.45	6.35e-18	Corneal astigmatism;
CRC	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg21724239	chr8:58056113	NA	0.58	7.84	0.4	6.33e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.37	-5.74	-0.3	2.18e-8	Crohn's disease;
CRC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.42	-7.14	-0.37	6.14e-12	Major depressive disorder;
CRC	cis	rs4964805	0.657	rs1866294	chr12:104186795	A/G	cg02344784	chr12:104178138	NT5DC3	0.79	15.03	0.64	3.07e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.96	0.66	7.52e-43	Platelet count;
CRC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.51	8.36	0.42	1.77e-15	Aortic root size;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12273811	chr6:28175739	NA	0.74	9.41	0.46	8.58e-19	Depression;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	6.52	0.34	2.61e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.73	-11.35	-0.53	1.97e-25	Tonsillectomy;
CRC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.87	10.95	0.52	5.37e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs2882667	0.690	rs288035	chr5:138212417	A/T	cg09476006	chr5:138032270	NA	0.54	8.92	0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.62	-6.46	-0.34	3.84e-10	Initial pursuit acceleration;
CRC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.39	8.87	0.44	4.6e-17	Multiple system atrophy;
CRC	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.53	-0.34	2.49e-10	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23355997	chr17:7154831	DULLARD;C17orf81	0.51	8.19	0.41	5.89e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg17133734	chr15:86042851	AKAP13	0.43	6.86	0.35	3.49e-11	Interstitial lung disease;
CRC	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.51	-5.92	-0.31	8.22e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07685180	chr8:600429	NA	0.7	6.77	0.35	5.78e-11	IgG glycosylation;
CRC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs9891119	0.550	rs3736162	chr17:40497839	G/C	cg06270615	chr17:40516068	STAT3	-0.35	-7.42	-0.38	9.96e-13	Multiple sclerosis;Crohn's disease;
CRC	cis	rs9463078	0.528	rs12214778	chr6:44924412	A/G	cg25276700	chr6:44698697	NA	0.24	5.61	0.3	4.41e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs231513	1.000	rs231513	chr17:41965200	C/G	cg26893861	chr17:41843967	DUSP3	-0.71	-6.4	-0.33	5.27e-10	Cognitive function;
CRC	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg12365402	chr11:9010492	NRIP3	0.45	7.21	0.37	3.9e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06634786	chr22:41940651	POLR3H	-0.49	-6.48	-0.34	3.43e-10	Neuroticism;
CRC	cis	rs9469913	0.542	rs75398113	chr6:34728071	G/C	cg17674042	chr6:34482479	PACSIN1	-0.89	-7.9	-0.4	4.21e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12163800	chr17:74475355	RHBDF2	-0.36	-5.98	-0.31	5.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3849570	0.615	rs6766011	chr3:81986136	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-6.34	-0.33	7.79e-10	Waist circumference;Body mass index;
CRC	cis	rs990171	0.955	rs6720564	chr2:103079297	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.85	0.31	1.17e-8	Lymphocyte counts;
CRC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.06	-12.42	-0.56	2.67e-29	Diabetic kidney disease;
CRC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.43	6.19	0.32	1.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.76e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg14646075	chr2:228736089	WDR69	-0.44	-5.93	-0.31	7.68e-9	Blood pressure;
CRC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.58	9.83	0.48	3.55e-20	Mean corpuscular volume;
CRC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12463550	chr7:65579703	CRCP	0.75	6.82	0.35	4.5e-11	Diabetic kidney disease;
CRC	cis	rs883565	0.502	rs4496420	chr3:38942716	A/C	cg01426195	chr3:39028469	NA	0.35	5.82	0.31	1.42e-8	Handedness;
CRC	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg27129171	chr3:47204927	SETD2	-0.59	-8.53	-0.43	5.24e-16	Colorectal cancer;
CRC	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg08210727	chr20:33865349	NA	0.45	6.14	0.32	2.33e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg18301423	chr5:131593218	PDLIM4	0.37	6.25	0.33	1.27e-9	Breast cancer;
CRC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.86	15.72	0.65	6.25e-42	Lewy body disease;
CRC	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.57	0.63	1.8e-37	Hypertriglyceridemia;
CRC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.36	6.03	0.32	4.31e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.43	6.34	0.33	7.58e-10	Resting heart rate;
CRC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.96	-16.26	-0.67	4.64e-44	Height;
CRC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg10570241	chr7:158785291	NA	0.45	7.69	0.39	1.76e-13	Facial morphology (factor 20);
CRC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.23	14.72	0.63	4.77e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg23461800	chr14:103021989	NA	-0.75	-10.23	-0.49	1.61e-21	Platelet count;
CRC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg14711859	chr11:8959438	ASCL3	0.45	7.53	0.38	4.86e-13	Hemoglobin concentration;
CRC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.7	-9.11	-0.45	8.53e-18	Initial pursuit acceleration;
CRC	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg04218760	chr10:45406644	TMEM72	-0.31	-7.43	-0.38	9.21e-13	Mean corpuscular volume;
CRC	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.57	7.0	0.36	1.41e-11	Alzheimer's disease;
CRC	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.63	-10.92	-0.52	6.59e-24	Body mass index;
CRC	trans	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg11430096	chr6:110968061	CDK19	0.68	6.0	0.31	5.08e-9	Prostate cancer;
CRC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.49	6.46	0.34	3.81e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.57	6.82	0.35	4.39e-11	Lymphocyte counts;
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.29	-0.37	2.32e-12	Lymphocyte counts;
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.78	0.35	5.57e-11	Alzheimer's disease;
CRC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.79	14.89	0.63	1.12e-38	Prudent dietary pattern;
CRC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.5	6.81	0.35	4.54e-11	Type 1 diabetes nephropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04971418	chr5:93954596	C5orf36;ANKRD32	0.38	6.06	0.32	3.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.56	-6.75	-0.35	6.64e-11	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01364968	chr1:50834303	NA	0.39	6.24	0.33	1.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.94	13.62	0.6	8.18e-34	Breast cancer;
CRC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg02290350	chr8:58132656	NA	-0.39	-5.73	-0.3	2.29e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg00280220	chr17:61926910	NA	0.35	5.77	0.3	1.83e-8	Prudent dietary pattern;
CRC	cis	rs2786111	0.809	rs482526	chr1:197268763	A/C	cg13682187	chr1:196946512	CFHR5	0.29	5.69	0.3	2.89e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.36	5.9	0.31	8.92e-9	Ulcerative colitis;
CRC	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg12756093	chr1:115239321	AMPD1	-0.49	-7.15	-0.37	5.69e-12	Autism;
CRC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.51	-7.84	-0.4	6.28e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-5.91	-0.31	8.59e-9	Tuberculosis;
CRC	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg27534772	chr1:16042836	PLEKHM2	0.45	7.5	0.38	6.07e-13	Systolic blood pressure;
CRC	cis	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg10928931	chr7:144051247	ARHGEF5	0.48	5.89	0.31	9.79e-9	Obesity-related traits;
CRC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.46	-7.31	-0.37	2.1e-12	Obesity-related traits;
CRC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg12193833	chr17:30244370	NA	0.6	6.96	0.36	1.8e-11	Hip circumference adjusted for BMI;
CRC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.76	-9.41	-0.46	9.04e-19	Initial pursuit acceleration;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.47	6.49	0.34	3.13e-10	Longevity;Endometriosis;
CRC	cis	rs61996546	0.622	rs12901528	chr15:26869399	T/C	cg15066197	chr15:26874202	GABRB3	-0.39	-5.99	-0.31	5.37e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.71	8.84	0.44	5.91e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	ch.12.61764592R	chr12:63478325	NA	-0.4	-6.27	-0.33	1.14e-9	Aortic root size;
CRC	cis	rs17767392	0.958	rs2332638	chr14:72028915	A/G	cg13720639	chr14:72061746	SIPA1L1	0.56	6.97	0.36	1.72e-11	Mitral valve prolapse;
CRC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg09218773	chr11:619014	MUPCDH	-0.42	-6.15	-0.32	2.21e-9	Systemic lupus erythematosus;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02226688	chr4:83351676	ENOPH1;HNRPDL	0.44	6.3	0.33	9.33e-10	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22980722	chr21:45719818	PFKL	0.38	6.08	0.32	3.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7147624	0.572	rs72714446	chr14:65933144	G/A	cg03016385	chr14:66212404	NA	0.95	7.5	0.38	6.16e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg14459158	chr9:96720562	NA	0.44	7.31	0.37	2.11e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.52	-9.19	-0.45	4.47e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6066835	1.000	rs6095272	chr20:47357517	A/G	cg18078177	chr20:47281410	PREX1	0.65	6.05	0.32	4.01e-9	Multiple myeloma;
CRC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.81	11.76	0.54	6.78e-27	Cognitive function;
CRC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	7.42	0.38	1.02e-12	Lung cancer in ever smokers;
CRC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.61	-11.47	-0.53	7.75e-26	Hemoglobin concentration;
CRC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg09417038	chr21:47716443	C21orf57	-0.39	-6.37	-0.33	6.19e-10	Testicular germ cell tumor;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.65	6.64	0.34	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.73	-10.84	-0.51	1.31e-23	Schizophrenia;
CRC	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-7.51	-0.38	5.66e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-8.36	-0.42	1.83e-15	Gut microbiome composition (summer);
CRC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.61	9.59	0.47	2.31e-19	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.44	6.74	0.35	7e-11	Corneal astigmatism;
CRC	cis	rs75422866	0.867	rs73102195	chr12:48060092	C/T	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.55	7.95	0.4	2.97e-14	Coronary artery disease;
CRC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	11.55	0.54	3.95e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	0.99	9.54	0.47	3.31e-19	Lymphocyte percentage of white cells;
CRC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.41	-6.97	-0.36	1.73e-11	Height;
CRC	cis	rs2971970	0.519	rs10246171	chr7:133633228	T/C	cg03336402	chr7:133662267	EXOC4	0.63	9.63	0.47	1.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.91	-0.58	3.99e-31	Alzheimer's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16307860	chr1:222886951	C1orf58;AIDA	-0.38	-6.18	-0.32	1.94e-9	Aortic root size;
CRC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.48	-0.42	7.66e-16	Mean corpuscular volume;
CRC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	10.65	0.51	5.76e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs740698	0.529	rs9895414	chr17:60793399	A/C	cg20935293	chr17:60842802	MARCH10	-0.34	-6.02	-0.32	4.61e-9	Pulse pressure;
CRC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.88	10.14	0.49	3.35e-21	Psoriasis;
CRC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.64	5.86	0.31	1.12e-8	Gout;
CRC	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.96	0.36	1.85e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.93	18.42	0.71	1.44e-52	Bone mineral density;
CRC	cis	rs10804591	0.666	rs2811460	chr3:129306067	G/C	cg21885638	chr3:129306552	PLXND1	-0.4	-5.99	-0.31	5.59e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.81	-12.99	-0.58	1.93e-31	Cognitive function;
CRC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.65	12.4	0.56	3.08e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-10.21	-0.49	1.99e-21	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.83	-11.34	-0.53	2.3e-25	Initial pursuit acceleration;
CRC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.02	0.52	2.94e-24	Prudent dietary pattern;
CRC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-9.1	-0.45	9.04e-18	Bone mineral density;
CRC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg12564285	chr5:131593104	PDLIM4	0.31	5.64	0.3	3.69e-8	Blood metabolite levels;
CRC	trans	rs9914544	0.545	rs8071783	chr17:18807939	C/G	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.3	-0.33	9.69e-10	Educational attainment (years of education);
CRC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.85	0.31	1.21e-8	Prudent dietary pattern;
CRC	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.58	-6.28	-0.33	1.08e-9	Osteoarthritis;
CRC	cis	rs10242455	0.702	rs76840929	chr7:98945858	T/C	cg18809830	chr7:99032528	PTCD1	-1.05	-7.58	-0.39	3.58e-13	Blood metabolite levels;
CRC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-7.95	-0.4	2.98e-14	Gut microbiome composition (summer);
CRC	cis	rs9463078	0.625	rs538801	chr6:44875762	A/T	cg25276700	chr6:44698697	NA	0.25	6.12	0.32	2.64e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.54e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.48	4.84e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.98	-0.31	5.84e-9	Life satisfaction;
CRC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.67	0.43	2.03e-16	Schizophrenia;
CRC	trans	rs11466653	1.000	rs10856840	chr4:38777383	G/A	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-7.19	-0.37	4.36e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.45	-7.02	-0.36	1.28e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.56	8.39	0.42	1.42e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.67	8.61	0.43	3.13e-16	Schizophrenia;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02401792	chr22:46664110	TTC38	-0.4	-6.49	-0.34	3.24e-10	Aortic root size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17976829	chr10:131934431	GLRX3	-0.5	-6.32	-0.33	8.35e-10	Diisocyanate-induced asthma;
CRC	cis	rs6076065	0.723	rs4813493	chr20:23367373	G/C	cg11657817	chr20:23433608	CST11	0.45	6.69	0.35	9.76e-11	Facial morphology (factor 15, philtrum width);
CRC	trans	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06834434	chr14:75079333	LTBP2	0.54	6.81	0.35	4.71e-11	Obesity-related traits;
CRC	cis	rs7680126	0.500	rs11735668	chr4:10148655	C/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.15	-0.32	2.3e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	12.33	0.56	5.45e-29	Platelet count;
CRC	trans	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg10756647	chr7:56101905	PSPH	0.74	7.72	0.39	1.43e-13	Diabetic kidney disease;
CRC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.51	8.52	0.43	5.94e-16	Sense of smell;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02403294	chr22:38795347	LOC400927	0.41	5.98	0.31	5.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.64	-8.78	-0.44	9.15e-17	Platelet count;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs17162190	0.698	rs12045800	chr1:26845366	A/G	cg17456097	chr1:26900765	RPS6KA1	0.41	5.67	0.3	3.09e-8	Mean corpuscular volume;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg19041857	chr6:27730383	NA	-0.41	-5.96	-0.31	6.46e-9	Parkinson's disease;
CRC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.69	-12.26	-0.56	1.02e-28	Iron status biomarkers;
CRC	cis	rs972578	1.000	rs2068943	chr22:43356311	C/T	cg01576275	chr22:43409880	NA	-0.45	-7.32	-0.37	1.95e-12	Mean platelet volume;
CRC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg18016565	chr1:150552671	MCL1	0.42	6.06	0.32	3.63e-9	Melanoma;
CRC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg06238570	chr21:40685208	BRWD1	0.78	10.62	0.51	7.81e-23	Cognitive function;
CRC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.38	6.29	0.33	9.9e-10	Major depressive disorder;
CRC	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.33	8.81e-10	Cardiovascular disease risk factors;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.2	0.32	1.73e-9	Morning vs. evening chronotype;
CRC	cis	rs7527798	0.592	rs11118360	chr1:207858586	G/A	cg09232269	chr1:207846808	CR1L	-0.44	-7.01	-0.36	1.35e-11	Erythrocyte sedimentation rate;
CRC	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.63	-8.96	-0.44	2.45e-17	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23036426	chr1:10093530	UBE4B	0.45	6.05	0.32	3.93e-9	Thyroid stimulating hormone;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg27432699	chr2:27873401	GPN1	-0.5	-7.56	-0.38	4.14e-13	Total body bone mineral density;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg20387954	chr3:183756860	HTR3D	0.45	7.64	0.39	2.47e-13	Anterior chamber depth;
CRC	cis	rs642858	1.000	rs623331	chr6:140284946	C/T	cg27524944	chr6:140295369	NA	0.35	5.89	0.31	9.33e-9	Type 2 diabetes;
CRC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg22676075	chr6:135203613	NA	-0.43	-6.64	-0.34	1.3e-10	Red blood cell count;
CRC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.56	7.51	0.38	5.59e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg10096052	chr16:615709	NHLRC4	-0.34	-5.65	-0.3	3.49e-8	Height;
CRC	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	10.1	0.49	4.49e-21	Hip circumference adjusted for BMI;
CRC	trans	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg17712092	chr4:129076599	LARP1B	0.52	6.86	0.35	3.39e-11	DNA methylation (variation);
CRC	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg23127183	chr11:57508653	C11orf31	-0.52	-7.12	-0.37	6.68e-12	Schizophrenia;
CRC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.52	-8.51	-0.42	6.46e-16	Platelet count;
CRC	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.39	-7.13	-0.37	6.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.83	-15.34	-0.65	1.91e-40	Prostate cancer;
CRC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.76	0.3	1.89e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-9.93	-0.48	1.76e-20	Bipolar disorder;
CRC	cis	rs7254114	0.578	rs35248735	chr19:11312238	G/A	cg02815516	chr19:11306319	KANK2	-0.33	-6.27	-0.33	1.11e-9	Immature fraction of reticulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17216600	chr6:52442344	TRAM2	0.41	6.85	0.35	3.64e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg21747405	chr11:67723411	NA	0.46	6.11	0.32	2.86e-9	Blood pressure (smoking interaction);
CRC	cis	rs3823572	0.564	rs2971973	chr7:133644256	G/A	cg03336402	chr7:133662267	EXOC4	-0.67	-10.4	-0.5	4.3e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.45	5.63	0.3	3.92e-8	Urinary tract infection frequency;
CRC	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.61	-6.48	-0.34	3.38e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.58	8.75	0.43	1.1e-16	Blood metabolite levels;
CRC	cis	rs17152411	1.000	rs7089014	chr10:126590342	G/A	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14654948	chr6:36164803	BRPF3	0.38	6.25	0.33	1.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.24	0.67	5.59e-44	Chronic sinus infection;
CRC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.59	9.8	0.48	4.57e-20	Gestational age at birth (maternal effect);
CRC	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg21153622	chr11:89784906	NA	-0.44	-7.11	-0.36	7.07e-12	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03356490	chr19:35605867	FXYD3	0.37	6.12	0.32	2.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4664293	1.000	rs6432540	chr2:160450703	G/A	cg08347373	chr2:160653686	CD302	-0.37	-6.03	-0.32	4.29e-9	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg15445000	chr17:37608096	MED1	0.27	5.88	0.31	9.93e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.69	9.64	0.47	1.55e-19	Coronary artery disease;
CRC	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-10.47	-0.5	2.5e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4664293	0.625	rs62171646	chr2:160519074	A/C	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.97	-0.31	6.02e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg03013999	chr17:37608204	MED1	0.45	6.85	0.35	3.64e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	10.55	0.5	1.36e-22	Motion sickness;
CRC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	11.62	0.54	2.18e-26	Platelet count;
CRC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-8.22	-0.41	4.76e-15	Sudden cardiac arrest;
CRC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23422044	chr7:1970798	MAD1L1	-0.44	-6.21	-0.32	1.58e-9	Neuroticism;
CRC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.6	8.47	0.42	8.28e-16	Arsenic metabolism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04272256	chr20:17949548	C20orf72;SNX5	0.45	6.31	0.33	9.13e-10	Anxiety disorder;
CRC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg16070018	chr6:26224392	HIST1H3E	0.58	5.8	0.3	1.54e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.73	-10.11	-0.49	4.3e-21	Coronary artery disease;
CRC	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.48	7.53	0.38	4.91e-13	Monocyte percentage of white cells;
CRC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.54	-6.72	-0.35	8.22e-11	Bipolar disorder (body mass index interaction);
CRC	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.6	-6.88	-0.35	2.96e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21643547	chr1:205240462	TMCC2	-0.38	-6.08	-0.32	3.27e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.51	9.76	0.47	6.42e-20	Urate levels in lean individuals;
CRC	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg11887960	chr12:57824829	NA	0.59	6.57	0.34	2e-10	Obesity-related traits;
CRC	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.43	-5.69	-0.3	2.8e-8	Height;
CRC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg05714579	chr10:131428358	MGMT	0.5	6.99	0.36	1.54e-11	Response to temozolomide;
CRC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.65	8.54	0.43	5.01e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg00769240	chr8:12517080	NA	-0.59	-6.39	-0.33	5.53e-10	Blood pressure (smoking interaction);
CRC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-0.75	-7.75	-0.39	1.14e-13	Schizophrenia;
CRC	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg26248373	chr2:1572462	NA	-0.83	-12.14	-0.56	2.9e-28	IgG glycosylation;
CRC	cis	rs10760158	0.832	rs880823	chr9:124038467	C/A	cg14417974	chr9:124058376	GSN	-0.35	-5.89	-0.31	9.54e-9	Pulse pressure;
CRC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.81	-0.35	4.79e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.45	0.57	1.96e-29	Alzheimer's disease;
CRC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg18721089	chr20:30220636	NA	-0.36	-5.86	-0.31	1.12e-8	Mean corpuscular hemoglobin;
CRC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.23	0.37	3.39e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21365899	chr1:231558446	EGLN1	0.54	7.96	0.4	2.83e-14	Response to antipsychotic treatment;
CRC	cis	rs7605827	0.866	rs7598936	chr2:15597289	A/G	cg19274914	chr2:15703543	NA	0.39	6.0	0.31	5.11e-9	Educational attainment (years of education);
CRC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg10589385	chr1:150898437	SETDB1	0.31	6.35	0.33	7.02e-10	Melanoma;
CRC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg07090678	chr1:91966139	CDC7	0.35	5.86	0.31	1.14e-8	Breast cancer;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02290350	chr8:58132656	NA	-0.6	-6.97	-0.36	1.69e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7121446	0.521	rs11218490	chr11:121862691	A/G	cg13820391	chr11:121835505	NA	0.33	5.99	0.31	5.52e-9	Cardiovascular risk factors (age interaction);
CRC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.69	10.77	0.51	2.35e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15356780	chr14:90422831	TDP1	0.47	6.59	0.34	1.7e-10	Response to antipsychotic treatment;
CRC	cis	rs727479	0.523	rs8034835	chr15:51512664	A/G	cg19946085	chr15:51559439	CYP19A1	-0.31	-6.4	-0.33	5.36e-10	Estradiol levels;
CRC	trans	rs2321882	0.794	rs12427445	chr13:59477563	G/T	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.98	-0.31	5.86e-9	Calcium levels;
CRC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.68	7.6	0.39	3.04e-13	Vitiligo;
CRC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.33	-0.33	7.9e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	8.75	0.43	1.14e-16	Breast cancer;
CRC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.8	14.2	0.62	5.1e-36	Breast cancer;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg19350133	chr12:3948413	PARP11	-0.38	-6.04	-0.32	4.2e-9	HDL cholesterol;
CRC	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.38	6.5	0.34	2.96e-10	Sitting height ratio;
CRC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/GT	cg05169160	chr2:178484487	TTC30A	-0.64	-5.7	-0.3	2.66e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.71	-11.61	-0.54	2.41e-26	Coronary artery disease;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg09877947	chr5:131593287	PDLIM4	0.43	7.01	0.36	1.33e-11	Acylcarnitine levels;
CRC	cis	rs860295	0.702	rs56675301	chr1:155364327	T/C	cg02153340	chr1:155202674	NA	-0.57	-6.77	-0.35	5.96e-11	Body mass index;
CRC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.74	-12.94	-0.58	3.16e-31	Prostate cancer;
CRC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.6	9.23	0.45	3.28e-18	Aortic root size;
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg06470822	chr6:28175283	NA	0.77	8.08	0.41	1.23e-14	Depression;
CRC	trans	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg09070855	chr12:133302174	NA	0.4	6.04	0.32	4.12e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.49	7.12	0.37	6.68e-12	Colorectal cancer;
CRC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-16.68	-0.68	1.05e-45	Height;
CRC	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg11519256	chr10:5708881	ASB13	0.58	7.89	0.4	4.38e-14	Childhood ear infection;
CRC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.68	-9.65	-0.47	1.42e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg03037974	chr15:76606532	NA	-0.53	-7.67	-0.39	1.98e-13	Blood metabolite levels;
CRC	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.71	-11.73	-0.54	8.64e-27	Idiopathic membranous nephropathy;
CRC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.55	-7.74	-0.39	1.2e-13	IgG glycosylation;
CRC	cis	rs4664293	0.625	rs6707985	chr2:160516388	T/C	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-8.42	-0.42	1.14e-15	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13571388	chr1:26947729	NA	0.47	6.35	0.33	7.32e-10	Anxiety disorder;
CRC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg03340356	chr1:67600835	NA	0.28	6.33	0.33	8.24e-10	Psoriasis;
CRC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.6	8.64	0.43	2.47e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.89	0.51	8.54e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.65	8.87	0.44	4.91e-17	Coronary artery disease;
CRC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.75	-14.14	-0.61	8.55e-36	Body mass index;
CRC	trans	rs3849570	0.695	rs62265411	chr3:81573660	T/C	cg23387109	chr10:94051229	MARCH5;CPEB3	0.46	6.16	0.32	2.1e-9	Waist circumference;Body mass index;
CRC	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg21153622	chr11:89784906	NA	0.47	7.45	0.38	8.17e-13	HDL cholesterol;
CRC	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.62	-8.37	-0.42	1.71e-15	Blood pressure (smoking interaction);
CRC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.44	-8.3	-0.42	2.72e-15	Huntington's disease progression;
CRC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.68	-11.16	-0.52	9.45e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg21620606	chr4:1342894	KIAA1530	0.34	5.65	0.3	3.53e-8	Obesity-related traits;
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.64	11.58	0.54	2.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.81	13.66	0.6	5.58e-34	Menopause (age at onset);
CRC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.61	-9.32	-0.46	1.8e-18	Eosinophil percentage of white cells;
CRC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.54	-7.74	-0.39	1.23e-13	Coronary artery disease;
CRC	cis	rs11833313	1	rs11833313	chr12:110510470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.86	8.88	0.44	4.53e-17	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.24e-11	Life satisfaction;
CRC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-7.46	-0.38	7.68e-13	Morning vs. evening chronotype;
CRC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.38	-6.47	-0.34	3.46e-10	Alcohol dependence;
CRC	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg00631329	chr6:26305371	NA	-0.53	-8.67	-0.43	2.05e-16	Mosquito bite size;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg14711859	chr11:8959438	ASCL3	-0.44	-7.07	-0.36	9.37e-12	Hemoglobin concentration;
CRC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.55	9.69	0.47	1.1e-19	Common traits (Other);
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg21251018	chr6:28226885	NKAPL	0.46	6.46	0.34	3.67e-10	Parkinson's disease;
CRC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.83	0.63	1.91e-38	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.46	-7.44	-0.38	8.93e-13	Testicular germ cell tumor;
CRC	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg27422857	chr2:105853526	NA	-0.31	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg08888203	chr3:10149979	C3orf24	0.46	7.21	0.37	3.9e-12	Alzheimer's disease;
CRC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.53	7.54	0.38	4.57e-13	Aortic root size;
CRC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg14711859	chr11:8959438	ASCL3	-0.37	-5.8	-0.3	1.57e-8	Hemoglobin concentration;
CRC	cis	rs4494114	1.000	rs4388668	chr1:39360730	A/T	cg25970120	chr1:39325951	RRAGC	-0.42	-5.69	-0.3	2.76e-8	Blood protein levels;
CRC	cis	rs720844	0.628	rs12616115	chr2:149298053	G/A	cg09247360	chr2:149335327	NA	-0.56	-5.83	-0.31	1.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	6.15	0.32	2.29e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.79e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.49	-7.88	-0.4	4.95e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg21153622	chr11:89784906	NA	0.42	6.83	0.35	3.99e-11	Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08949862	chr2:63277672	OTX1	-0.39	-6.01	-0.31	4.82e-9	Myopia (pathological);
CRC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.58	0.34	1.83e-10	Schizophrenia;
CRC	cis	rs447	0.806	rs7808864	chr7:83723347	A/G	cg22846510	chr7:83753280	SEMA3A	-0.51	-6.71	-0.35	8.57e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.97	11.97	0.55	1.15e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.8	14.22	0.62	4.29e-36	Breast cancer;
CRC	cis	rs739496	0.542	rs10219736	chr12:111788402	C/T	cg10833066	chr12:111807467	FAM109A	0.54	7.08	0.36	8.98e-12	Platelet count;
CRC	cis	rs73206853	0.544	rs55752061	chr12:111126096	G/C	cg12870014	chr12:110450643	ANKRD13A	0.75	7.72	0.39	1.41e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.81	-0.4	7.68e-14	Hemoglobin concentration;
CRC	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg23254163	chr1:152506842	NA	0.42	7.12	0.37	7e-12	Hair morphology;
CRC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.8	-13.55	-0.6	1.58e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg15845792	chr6:28175446	NA	0.73	6.48	0.34	3.27e-10	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21528620	chr1:110753221	KCNC4	0.39	6.23	0.32	1.39e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.54	-8.72	-0.43	1.36e-16	Huntington's disease progression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07176146	chr1:35325364	C1orf212	0.4	6.21	0.32	1.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg27068330	chr11:65405492	SIPA1	0.43	6.35	0.33	7.22e-10	Acne (severe);
CRC	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg15145174	chr5:6755386	POLS	-0.44	-6.49	-0.34	3.22e-10	Menopause (age at onset);
CRC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.52	1.55e-24	Nonalcoholic fatty liver disease;
CRC	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	0.57	7.88	0.4	4.96e-14	Pulmonary function decline;
CRC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.93	-0.55	1.67e-27	Alzheimer's disease;
CRC	cis	rs7532866	0.885	rs7520137	chr1:26731035	T/G	cg17456097	chr1:26900765	RPS6KA1	-0.4	-6.01	-0.31	5.04e-9	Height;
CRC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.75	12.89	0.58	4.75e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.28	-0.37	2.51e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.55	0.34	2.15e-10	Lung cancer;
CRC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.52	8.77	0.44	9.97e-17	Systemic lupus erythematosus;
CRC	cis	rs1572438	1.000	rs873560	chr6:875559	A/G	cg21062780	chr6:887772	NA	-0.4	-6.14	-0.32	2.38e-9	Aging;
CRC	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg20607287	chr7:12443886	VWDE	-0.48	-6.32	-0.33	8.6e-10	Coronary artery disease;
CRC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg00343986	chr7:65444356	GUSB	0.49	7.34	0.38	1.64e-12	Aortic root size;
CRC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg03233332	chr7:66118400	NA	-0.45	-6.22	-0.32	1.49e-9	Aortic root size;
CRC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.7	-0.39	1.66e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg13476313	chr9:127244764	NR5A1	0.28	5.65	0.3	3.5e-8	Menarche (age at onset);
CRC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	10.44	0.5	3.03e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs12517041	1.000	rs10805749	chr5:23300740	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-5.96	-0.31	6.46e-9	Calcium levels;
CRC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg01483505	chr11:975446	AP2A2	0.46	7.67	0.39	2.02e-13	Alzheimer's disease (late onset);
CRC	cis	rs5758511	0.573	rs2284082	chr22:42240797	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.35	-5.68	-0.3	2.9e-8	Birth weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03352409	chr22:21336370	LZTR1	0.45	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13964462	chr9:132389032	METTL11A	0.47	6.51	0.34	2.83e-10	Response to antipsychotic treatment;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19881050	chr20:32700182	EIF2S2	0.39	6.18	0.32	1.91e-9	Obesity-related traits;
CRC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.65	11.73	0.54	8.92e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg26811252	chr16:29126840	RRN3P2	0.62	8.46	0.42	8.69e-16	Menopause (age at onset);
CRC	trans	rs4478147	0.636	rs4552430	chr4:87434722	G/T	cg01215037	chr19:50083917	PRRG2;NOSIP	0.45	5.99	0.31	5.58e-9	Migraine - clinic-based;
CRC	cis	rs1035144	0.505	rs11159479	chr14:81460651	C/T	cg06600135	chr14:81408086	NA	-0.53	-7.89	-0.4	4.47e-14	Male sexual orientation;
CRC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg04990556	chr1:26633338	UBXN11	-0.48	-6.15	-0.32	2.31e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.53	0.47	3.63e-19	Lymphocyte counts;
CRC	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.52	7.53	0.38	4.81e-13	Testicular germ cell tumor;
CRC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.5	10.93	0.52	6.36e-24	Alcohol dependence;
CRC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.93	-0.36	2.19e-11	Neuroticism;
CRC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.46	7.26	0.37	2.88e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.56	7.89	0.4	4.44e-14	Alcohol dependence;
CRC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs6840360	0.642	rs7678823	chr4:152357119	A/G	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg15786705	chr6:28176104	NA	0.54	7.35	0.38	1.54e-12	Parkinson's disease;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.73	-0.39	1.28e-13	Coronary artery disease;
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14893161	chr1:205819251	PM20D1	0.46	6.48	0.34	3.37e-10	Parkinson's disease;
CRC	cis	rs4728302	0.869	rs6963032	chr7:133599527	T/C	cg10665199	chr7:133106180	EXOC4	0.38	5.76	0.3	1.96e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.86	-0.44	5.1e-17	Hemoglobin concentration;
CRC	cis	rs10924970	0.649	rs11805093	chr1:235461668	T/C	cg09010748	chr1:235293032	TOMM20	-0.43	-5.92	-0.31	8.25e-9	Asthma;
CRC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-18.09	-0.71	3.02e-51	Height;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03128101	chr2:74405376	MOBKL1B	-0.51	-5.97	-0.31	6.24e-9	Monocyte percentage of white cells;
CRC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.09	-0.32	3.2e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.55	-0.57	8.76e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.66	-8.82	-0.44	6.76e-17	Hypospadias;
CRC	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg00601450	chr5:74908170	NA	0.38	5.73	0.3	2.32e-8	Age-related disease endophenotypes;
CRC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.54	-0.34	2.39e-10	Life satisfaction;
CRC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs55702914	0.712	rs12616329	chr2:198148629	T/C	cg10820045	chr2:198174542	NA	-0.39	-7.09	-0.36	8.23e-12	Major depression and alcohol dependence;
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.42	6.48	0.34	3.43e-10	Longevity;Endometriosis;
CRC	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23453622	chr17:79885647	LOC92659;MAFG	0.42	6.14	0.32	2.37e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9937943	0.720	rs112685216	chr16:74609517	G/A	cg01733217	chr16:74700730	RFWD3	0.74	8.34	0.42	2.09e-15	Neutrophil percentage of white cells;
CRC	cis	rs2811415	0.597	rs11710595	chr3:127767158	T/C	cg13719885	chr3:127795394	NA	-0.37	-5.65	-0.3	3.49e-8	Lung function (FEV1/FVC);
CRC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.93e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.42	-5.77	-0.3	1.87e-8	Diastolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07586819	chr22:38864010	KDELR3	0.47	6.57	0.34	1.95e-10	Anxiety disorder;
CRC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	8.42	0.42	1.22e-15	Menarche (age at onset);
CRC	cis	rs755249	0.567	rs67886352	chr1:39708703	G/A	cg18385671	chr1:39797026	MACF1	-0.44	-6.09	-0.32	3.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-7.77	-0.39	9.91e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.15	-0.37	5.51e-12	Breast cancer;
CRC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.35	5.82	0.31	1.42e-8	Blood metabolite levels;
CRC	cis	rs4936891	0.645	rs896891	chr11:123910740	C/T	cg22125253	chr11:123886957	OR10G4	0.42	7.8	0.4	8.25e-14	Male fertility;
CRC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg04586622	chr2:25135609	ADCY3	-0.48	-8.67	-0.43	1.96e-16	Body mass index in non-asthmatics;
CRC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg21665744	chr7:39171113	POU6F2	0.41	5.64	0.3	3.71e-8	IgG glycosylation;
CRC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.49	-7.67	-0.39	1.96e-13	Monocyte count;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg21251018	chr6:28226885	NKAPL	0.46	6.12	0.32	2.73e-9	Depression;
CRC	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.64	10.0	0.48	1.02e-20	Corneal astigmatism;
CRC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.49	-5.74	-0.3	2.12e-8	Menarche (age at onset);
CRC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg02007433	chr3:129722099	NA	-0.47	-6.5	-0.34	2.91e-10	Blood pressure (smoking interaction);
CRC	cis	rs807029	0.533	rs722435	chr10:102745062	G/T	cg04662943	chr10:102668895	NA	0.61	7.3	0.37	2.2e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.04e-12	Testicular germ cell tumor;
CRC	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.55	7.95	0.4	3.04e-14	Testicular germ cell tumor;
CRC	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg17145862	chr1:211918768	LPGAT1	-0.52	-8.6	-0.43	3.2e-16	Leprosy;
CRC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	15.8	0.66	3.04e-42	Electrocardiographic conduction measures;
CRC	cis	rs11098699	0.821	rs2047201	chr4:124233384	A/G	cg09941581	chr4:124220074	SPATA5	-0.43	-6.35	-0.33	7.09e-10	Mosquito bite size;
CRC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.29	-0.53	3.37e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.55	-7.59	-0.39	3.3e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10760158	0.769	rs10760162	chr9:124005183	C/G	cg14417974	chr9:124058376	GSN	-0.33	-5.63	-0.3	3.95e-8	Pulse pressure;
CRC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.84	-12.74	-0.57	1.71e-30	Response to antineoplastic agents;
CRC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	10.43	0.5	3.46e-22	Motion sickness;
CRC	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.01	-0.31	5.02e-9	Depression;
CRC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.57	-8.96	-0.44	2.49e-17	Height;
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.08	-0.32	3.31e-9	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.76	-0.63	3.58e-38	Diabetic kidney disease;
CRC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-5.94	-0.31	7.32e-9	Alzheimer's disease (late onset);
CRC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.43	-7.29	-0.37	2.39e-12	Height;
CRC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg10645314	chr2:3704589	ALLC	-0.45	-6.27	-0.33	1.14e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg27615366	chr5:131592974	PDLIM4	-0.32	-5.64	-0.3	3.75e-8	Breast cancer;
CRC	cis	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg07460842	chr6:66804631	NA	0.47	5.96	0.31	6.6e-9	Metabolite levels;
CRC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.62	8.87	0.44	4.65e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11679072	1.000	rs11682976	chr2:240445491	A/G	cg03276489	chr2:240449683	NA	-0.9	-7.54	-0.38	4.55e-13	Blood pressure (smoking interaction);
CRC	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.75	-7.81	-0.4	7.71e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.49	-10.2	-0.49	2e-21	Prostate cancer;
CRC	trans	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.91	-0.31	8.33e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-5.68	-0.3	2.99e-8	High light scatter reticulocyte count;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.69	-0.35	9.78e-11	Bipolar disorder;
CRC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.53	7.6	0.39	3.11e-13	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25199208	chr2:109402912	CCDC138	0.46	6.3	0.33	9.43e-10	Thyroid stimulating hormone;
CRC	cis	rs3750965	0.575	rs3892895	chr11:68884755	A/G	cg06818126	chr11:68850279	TPCN2	0.43	6.15	0.32	2.25e-9	Hair color;
CRC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.39	6.33	0.33	8.21e-10	Height;
CRC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.2	0.49	2.1e-21	Heart rate;
CRC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.83	0.55	3.73e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.52	-9.08	-0.45	1.02e-17	Sense of smell;
CRC	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg12560992	chr17:57184187	TRIM37	0.53	6.15	0.32	2.28e-9	Vitamin D levels;
CRC	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg23100626	chr2:96804247	ASTL	0.29	8.17	0.41	6.72e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15563057	chr5:139493612	PURA	0.48	6.79	0.35	5.29e-11	Response to antipsychotic treatment;
CRC	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.53	-6.76	-0.35	6.38e-11	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg08200582	chr11:442649	ANO9	-0.67	-7.3	-0.37	2.17e-12	Body mass index;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12417590	chr20:42086612	SFRS6	0.38	6.16	0.32	2.1e-9	Myopia (pathological);
CRC	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg02158880	chr13:53174818	NA	0.45	6.29	0.33	1.03e-9	Lewy body disease;
CRC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.99	21.36	0.76	4.12e-64	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.21	-0.45	4.04e-18	Alcohol dependence;
CRC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.64	-0.47	1.6e-19	Height;
CRC	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg27053337	chr8:124217698	FAM83A	0.4	5.65	0.3	3.42e-8	Urinary uromodulin levels;
CRC	cis	rs629535	0.814	rs654452	chr8:70074344	C/G	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.51e-8	Dupuytren's disease;
CRC	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.14	0.45	6.58e-18	Coffee consumption (cups per day);
CRC	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg01420254	chr6:26195488	NA	0.78	7.86	0.4	5.51e-14	Gout;Renal underexcretion gout;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17906523	chr1:94883536	ABCD3	0.48	6.83	0.35	4.09e-11	Response to antipsychotic treatment;
CRC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.58	6.43	0.33	4.45e-10	Bipolar disorder;
CRC	cis	rs1223397	0.651	rs2458310	chr6:13310308	G/C	cg20827128	chr6:13274284	PHACTR1	0.38	5.8	0.3	1.52e-8	Blood pressure;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Depression;
CRC	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.52	-7.18	-0.37	4.64e-12	Schizophrenia;
CRC	cis	rs7619833	0.506	rs1851366	chr3:27194844	T/C	cg02860705	chr3:27208620	NA	-0.37	-5.74	-0.3	2.2e-8	Breast cancer;
CRC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg08075719	chr14:103021372	NA	-0.69	-9.47	-0.46	5.8e-19	Platelet count;
CRC	trans	rs12517041	1.000	rs10079487	chr5:23294939	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg14191688	chr11:70257035	CTTN	0.47	6.38	0.33	6.11e-10	Coronary artery disease;
CRC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg15845792	chr6:28175446	NA	0.49	6.55	0.34	2.19e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	1.02	17.78	0.7	4.98e-50	Parkinson's disease;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.81	12.46	0.57	1.79e-29	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs897984	0.647	rs7203999	chr16:31017554	T/C	cg02466173	chr16:30829666	NA	0.61	9.24	0.45	3.05e-18	Dementia with Lewy bodies;
CRC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg23461800	chr14:103021989	NA	-0.75	-10.25	-0.49	1.44e-21	Platelet count;
CRC	cis	rs56146971	0.714	rs17804071	chr14:91852876	C/T	cg16433844	chr14:91963127	SMEK1	-0.55	-6.54	-0.34	2.36e-10	Alzheimer disease and age of onset;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11700415	chr19:49140818	SEC1;DBP	0.47	6.49	0.34	3.07e-10	Anxiety disorder;
CRC	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.22e-12	Bipolar disorder;
CRC	cis	rs7804356	1.000	rs4722647	chr7:26890446	G/C	cg03456212	chr7:26904342	SKAP2	-0.49	-5.63	-0.3	3.86e-8	Type 1 diabetes;
CRC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.45	5.71	0.3	2.52e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.74	-12.39	-0.56	3.53e-29	Breast cancer;
CRC	trans	rs4873772	0.834	rs4873546	chr8:48576665	T/C	cg05343739	chr1:154731938	KCNN3	0.36	6.3	0.33	9.34e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.44	-5.69	-0.3	2.85e-8	Diabetic retinopathy;
CRC	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.43	-6.5	-0.34	3.06e-10	Refractive error;
CRC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-12.41	-0.56	2.97e-29	Lymphocyte percentage of white cells;
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.71	13.99	0.61	3.12e-35	Leprosy;
CRC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.92	13.28	0.59	1.59e-32	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.66	0.3	3.31e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.43	6.44	0.33	4.32e-10	Menopause (age at onset);
CRC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.71	11.34	0.53	2.25e-25	Squamous cell carcinoma;
CRC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.92	-0.36	2.4e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.17	-0.32	1.96e-9	Aortic root size;
CRC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.36	-0.46	1.31e-18	Platelet count;
CRC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg11245181	chr6:149772854	ZC3H12D	0.51	9.01	0.44	1.72e-17	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13038108	chr4:39461155	LIAS;RPL9	0.44	6.16	0.32	2.16e-9	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.69	-0.39	1.68e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.86	-13.24	-0.59	2.32e-32	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.4	6.48	0.34	3.45e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21028142	chr17:79581711	NPLOC4	0.33	6.96	0.36	1.81e-11	Eye color traits;
CRC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	7.12	0.37	7.01e-12	Bipolar disorder;
CRC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg18016565	chr1:150552671	MCL1	-0.42	-6.26	-0.33	1.18e-9	Tonsillectomy;
CRC	cis	rs3791406	0.654	rs3752804	chr2:240029490	C/T	cg14550559	chr2:240039617	HDAC4	-0.48	-6.9	-0.36	2.73e-11	Skin aging (microtopography measurement);
CRC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.59	9.23	0.45	3.38e-18	Asthma (sex interaction);
CRC	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.72	9.65	0.47	1.44e-19	Coronary artery disease;
CRC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.45	-6.59	-0.34	1.77e-10	Uric acid clearance;
CRC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-8.13	-0.41	8.65e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.67	-9.08	-0.45	1.05e-17	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg20607287	chr7:12443886	VWDE	-0.61	-6.85	-0.35	3.67e-11	Coronary artery disease;
CRC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg18709589	chr6:96969512	KIAA0776	0.49	6.24	0.33	1.37e-9	Migraine;Coronary artery disease;
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.71	-0.39	1.55e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.81e-18	Smoking initiation;
CRC	cis	rs12580194	0.593	rs11171432	chr12:55757696	G/C	cg19537932	chr12:55886519	OR6C68	-0.67	-8.83	-0.44	6.47e-17	Cancer;
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.93	-22.17	-0.77	3.01e-67	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.45	6.85	0.35	3.58e-11	Systemic lupus erythematosus;
CRC	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg23815491	chr16:72088622	HP	0.43	6.38	0.33	6.14e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.33	0.42	2.25e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24596729	chr1:165345813	NA	0.39	6.92	0.36	2.32e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg12756093	chr1:115239321	AMPD1	0.52	7.87	0.4	5.1e-14	Autism;
CRC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg01483505	chr11:975446	AP2A2	-0.43	-7.18	-0.37	4.75e-12	Alzheimer's disease (late onset);
CRC	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.55	6.6	0.34	1.66e-10	QRS duration;
CRC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.68	-0.3	2.95e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.49	-7.62	-0.39	2.68e-13	Body mass index;
CRC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.04	0.32	4.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs61160187	0.610	rs4700397	chr5:60135962	A/G	cg16298547	chr5:60138761	ELOVL7	0.29	6.13	0.32	2.58e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17507749	chr15:85114479	UBE2QP1	0.64	9.13	0.45	7.19e-18	Schizophrenia;
CRC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.51	-8.21	-0.41	5.03e-15	Neurofibrillary tangles;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg15763984	chr4:1342303	KIAA1530	0.44	6.84	0.35	3.99e-11	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.41	6.77	0.35	5.79e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.57	-0.47	2.7e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.94	-0.31	7.09e-9	Diabetic kidney disease;
CRC	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.27	-0.41	3.4e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.46	-0.34	3.75e-10	Aortic root size;
CRC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.55	5.83	0.31	1.32e-8	Initial pursuit acceleration;
CRC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg13334819	chr7:99746414	C7orf59	-0.53	-6.92	-0.36	2.33e-11	Coronary artery disease;
CRC	trans	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg13565492	chr6:43139072	SRF	-0.72	-7.5	-0.38	6.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg23461800	chr14:103021989	NA	-0.75	-9.92	-0.48	1.9e-20	Platelet count;
CRC	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	1.16	10.16	0.49	2.94e-21	Mitochondrial DNA levels;
CRC	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.43	-7.31	-0.37	2.06e-12	Metabolite levels;
CRC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.36	6.17	0.32	2.04e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.06	0.41	1.38e-14	Menopause (age at onset);
CRC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg14541582	chr5:601475	NA	-0.33	-6.6	-0.34	1.61e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg25885038	chr17:56607967	SEPT4	-0.51	-7.7	-0.39	1.63e-13	Vitamin D levels;
CRC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.48	-0.42	7.63e-16	Gut microbiome composition (summer);
CRC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.13	0.45	7.28e-18	Mean platelet volume;
CRC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.19	-0.32	1.84e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs73206853	0.841	rs7963504	chr12:110906880	C/A	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.43e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7894051	1.000	rs7070635	chr10:135190127	T/C	cg20534287	chr10:135191450	PAOX	-0.68	-6.72	-0.35	8.04e-11	Lifespan;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09326880	chr3:43147587	C3orf39	0.38	5.97	0.31	6.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg00280220	chr17:61926910	NA	0.35	5.74	0.3	2.18e-8	Prudent dietary pattern;
CRC	cis	rs1838105	0.674	rs2873131	chr17:45166056	T/C	cg16759221	chr17:45003025	GOSR2	-0.62	-9.49	-0.46	5.03e-19	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg20608306	chr11:116969690	SIK3	-0.33	-6.33	-0.33	7.93e-10	Subjective well-being;
CRC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.83	-13.56	-0.6	1.44e-33	Height;
CRC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.75	0.35	6.64e-11	Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	0.84	9.04	0.45	1.41e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.67	14.1	0.61	1.21e-35	Schizophrenia;
CRC	cis	rs9549328	0.700	rs3011474	chr13:113617865	T/C	cg20742385	chr13:113633654	MCF2L	0.55	9.36	0.46	1.33e-18	Systolic blood pressure;
CRC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg22535103	chr8:58192502	C8orf71	0.43	5.93	0.31	7.85e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12172441	chr6:28176163	NA	0.6	7.27	0.37	2.64e-12	Parkinson's disease;
CRC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.7	-10.87	-0.51	1.05e-23	Pancreatic cancer;
CRC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.4	7.01	0.36	1.38e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9928842	0.824	rs12924999	chr16:75262425	T/G	cg09066997	chr16:75300724	BCAR1	0.68	6.36	0.33	6.83e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs720844	0.748	rs12464036	chr2:149371609	A/G	cg09247360	chr2:149335327	NA	-0.54	-5.75	-0.3	2.07e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.64	-10.26	-0.49	1.34e-21	Lewy body disease;
CRC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.7e-9	Bipolar disorder;
CRC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.79	-0.35	5.26e-11	Platelet distribution width;
CRC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.84	14.73	0.63	4.6e-38	Breast cancer;
CRC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.64	-10.45	-0.5	2.87e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg00383909	chr3:49044727	WDR6	0.44	5.64	0.3	3.76e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.58	9.4	0.46	9.52e-19	Monocyte count;
CRC	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	4.01e-16	Life satisfaction;
CRC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.64	0.43	2.47e-16	Menopause (age at onset);
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg12273811	chr6:28175739	NA	0.64	6.34	0.33	7.38e-10	Depression;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20092199	chr4:1342459	KIAA1530	-0.38	-6.03	-0.32	4.51e-9	Obesity-related traits;
CRC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg02659138	chr7:134003124	SLC35B4	0.35	6.03	0.32	4.31e-9	Mean platelet volume;
CRC	cis	rs8067545	0.532	rs56371654	chr17:19960362	G/T	cg13482628	chr17:19912719	NA	0.41	5.71	0.3	2.5e-8	Schizophrenia;
CRC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.33	-5.79	-0.3	1.63e-8	Primary biliary cholangitis;
CRC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.02	0.31	4.71e-9	Height;
CRC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.43	6.0	0.31	5.13e-9	Platelet count;
CRC	cis	rs4727963	0.755	rs6943941	chr7:122705651	G/A	cg03640110	chr7:122635026	TAS2R16	-0.33	-6.02	-0.31	4.77e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.24	14.83	0.63	1.93e-38	Lung disease severity in cystic fibrosis;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg00050312	chr17:64299065	PRKCA	0.42	5.96	0.31	6.49e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.5	7.73	0.39	1.34e-13	Response to antineoplastic agents;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg04607442	chr13:21872219	NA	0.48	6.35	0.33	7.19e-10	Hip circumference;
CRC	trans	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg09045935	chr12:6379348	NA	1.02	8.82	0.44	6.84e-17	Blood metabolite levels;
CRC	cis	rs9378357	0.850	rs9392473	chr6:3291236	C/T	cg08754725	chr6:3293098	SLC22A23	-0.8	-7.45	-0.38	8.28e-13	Obesity-related traits;
CRC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg21856205	chr7:94953877	PON1	-0.52	-6.69	-0.35	9.73e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.95	-14.09	-0.61	1.3e-35	Colorectal cancer;
CRC	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg03623178	chr6:28175578	NA	0.85	7.85	0.4	5.92e-14	Depression;
CRC	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.44	-6.31	-0.33	9.05e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	12.1	0.55	4.03e-28	Menopause (age at onset);
CRC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.89	11.19	0.52	7.79e-25	Tuberculosis;
CRC	cis	rs4731207	0.596	rs7792654	chr7:124653637	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.56	9.19	0.45	4.66e-18	Hemoglobin concentration;Hematocrit;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14086160	chr1:159895389	TAGLN2	0.4	6.62	0.34	1.48e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.52	7.78	0.39	9.18e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.5	6.07	0.32	3.6e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6141769	0.542	rs28523897	chr20:31301248	C/T	cg13636640	chr20:31349939	DNMT3B	-0.39	-5.84	-0.31	1.27e-8	Subjective well-being;
CRC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.62	7.19	0.37	4.42e-12	Vitiligo;
CRC	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg23254163	chr1:152506842	NA	0.45	8.29	0.42	2.9e-15	Hair morphology;
CRC	cis	rs4494114	0.967	rs9438978	chr1:39355058	G/T	cg25970120	chr1:39325951	RRAGC	-0.42	-5.73	-0.3	2.25e-8	Blood protein levels;
CRC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg08975724	chr8:8085496	FLJ10661	0.4	6.0	0.31	5.24e-9	Neuroticism;
CRC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.06	10.59	0.5	9.22e-23	Diabetic retinopathy;
CRC	cis	rs727479	0.502	rs3825800	chr15:51506663	A/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-6.08	-0.32	3.36e-9	Estradiol levels;
CRC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.93	-17.91	-0.7	1.51e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.57	-0.34	2.01e-10	Bipolar disorder;
CRC	cis	rs59104589	0.521	rs2240482	chr2:242405021	C/T	cg19488206	chr2:242435732	STK25	0.48	7.71	0.39	1.5e-13	Fibrinogen levels;
CRC	cis	rs2013441	0.613	rs4925082	chr17:19994673	C/T	cg13482628	chr17:19912719	NA	-0.35	-5.62	-0.3	3.97e-8	Obesity-related traits;
CRC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg16606324	chr3:10149918	C3orf24	0.47	6.91	0.36	2.5e-11	Alzheimer's disease;
CRC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg24300038	chr13:113819356	PROZ	-0.47	-6.06	-0.32	3.75e-9	Platelet distribution width;
CRC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.55	-0.34	2.24e-10	Daytime sleep phenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08023809	chr12:53645616	MFSD5	0.45	6.39	0.33	5.55e-10	Response to antipsychotic treatment;
CRC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg23758597	chr6:163146217	PARK2	-0.64	-6.5	-0.34	2.98e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.06	-0.32	3.72e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.08	-12.36	-0.56	4.53e-29	Diabetic kidney disease;
CRC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.84	-11.22	-0.53	5.99e-25	Initial pursuit acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05935374	chr11:82782929	RAB30	0.43	6.16	0.32	2.09e-9	Response to antipsychotic treatment;
CRC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-6.81	-0.35	4.75e-11	Monocyte count;
CRC	trans	rs783540	0.843	rs28374463	chr15:83299364	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.22	-0.32	1.54e-9	Schizophrenia;
CRC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.66	-11.1	-0.52	1.57e-24	P wave terminal force;
CRC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.64	-17.41	-0.69	1.47e-48	Urate levels in overweight individuals;
CRC	cis	rs965469	0.779	rs6051770	chr20:3327014	A/G	cg25506879	chr20:3388711	C20orf194	-0.37	-5.76	-0.3	1.91e-8	IFN-related cytopenia;
CRC	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.32	-6.04	-0.32	4.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17152411	1.000	rs61873277	chr10:126619331	C/A	cg07906193	chr10:126599966	NA	0.6	6.47	0.34	3.59e-10	Height;
CRC	cis	rs4908768	0.501	rs11121186	chr1:8540341	G/A	cg20416874	chr1:8611966	RERE	-0.4	-5.65	-0.3	3.41e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg18479299	chr3:125709523	NA	-0.54	-6.43	-0.33	4.52e-10	Blood pressure (smoking interaction);
CRC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.58	6.35	0.33	7.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10946940	0.965	rs10946935	chr6:27501345	T/C	cg08798685	chr6:27730294	NA	0.38	5.72	0.3	2.38e-8	Systemic lupus erythematosus;
CRC	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg03689076	chr20:33865952	NA	0.57	7.6	0.39	3.12e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.64e-13	Diabetic retinopathy;
CRC	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.44	-6.36	-0.33	6.91e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.91	-16.78	-0.68	4.41e-46	Intelligence (multi-trait analysis);
CRC	cis	rs3996993	0.809	rs4147615	chr6:52657321	A/G	cg20803780	chr6:52668592	GSTA1	0.36	6.5	0.34	2.93e-10	Hemoglobin concentration;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.48	7.29	0.37	2.3e-12	Menarche (age at onset);
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-11.22	-0.53	5.96e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.16	-0.37	5.25e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.89	14.18	0.62	5.79e-36	Menarche (age at onset);
CRC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg20608306	chr11:116969690	SIK3	0.29	5.7	0.3	2.67e-8	Blood protein levels;
CRC	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg21972741	chr5:435613	AHRR	0.5	6.74	0.35	6.96e-11	Cystic fibrosis severity;
CRC	trans	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.68	0.39	1.79e-13	Neuroticism;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg21251018	chr6:28226885	NKAPL	0.38	5.96	0.31	6.42e-9	Parkinson's disease;
CRC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.52	0.34	2.63e-10	Height;
CRC	cis	rs13412757	0.646	rs346829	chr2:8457927	G/C	cg12167548	chr2:8464763	NA	0.35	6.59	0.34	1.79e-10	Asthma;Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.63	6.12	0.32	2.59e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg22777020	chr22:31556080	RNF185	0.52	6.23	0.33	1.39e-9	Colorectal cancer;
CRC	cis	rs3106136	0.967	rs2171381	chr4:95224768	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.36	1.32e-11	Capecitabine sensitivity;
CRC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.92	0.52	6.82e-24	Systolic blood pressure;
CRC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00376283	chr12:123451042	ABCB9	-0.5	-6.5	-0.34	2.94e-10	Neutrophil percentage of white cells;
CRC	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	trans	rs57590327	0.503	rs9874184	chr3:81505439	C/T	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-6.0	-0.31	5.25e-9	Extraversion;
CRC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.69	7.28	0.37	2.49e-12	Initial pursuit acceleration;
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.41	5.97	0.31	6.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.63	-8.01	-0.4	1.98e-14	Iron status biomarkers;
CRC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.83	-0.31	1.34e-8	Skin colour saturation;
CRC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg19196414	chr17:27188595	MIR451;MIR144	0.39	5.6	0.3	4.51e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.37	6.15	0.32	2.24e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg11822372	chr1:151115635	SEMA6C	0.53	7.59	0.39	3.23e-13	Childhood ear infection;
CRC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.51	7.98	0.4	2.54e-14	Colorectal cancer;
CRC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.07	-13.4	-0.59	5.86e-33	Vitiligo;
CRC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-10.17	-0.49	2.68e-21	Personality dimensions;
CRC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg10729496	chr3:10149963	C3orf24	0.5	6.49	0.34	3.18e-10	Alzheimer's disease;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.58	-0.34	1.87e-10	Lymphocyte counts;
CRC	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg16005559	chr11:120040616	NA	0.5	7.32	0.37	1.96e-12	Stroke (pediatric);
CRC	trans	rs6956675	0.915	rs6965334	chr7:62645446	A/G	cg01314568	chr7:57830625	NA	-0.6	-8.32	-0.42	2.43e-15	Obesity-related traits;
CRC	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.52	7.41	0.38	1.07e-12	Corneal astigmatism;
CRC	trans	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg19894588	chr14:64061835	NA	0.42	6.04	0.32	4.26e-9	Glioblastoma;Glioma;
CRC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-12.86	-0.58	5.84e-31	Systemic lupus erythematosus;
CRC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	8.77	0.44	9.91e-17	Eosinophil percentage of white cells;
CRC	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	12.63	0.57	4.52e-30	Coffee consumption (cups per day);
CRC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-7.52	-0.38	5.11e-13	IgG glycosylation;
CRC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.32	0.33	8.5e-10	Morning vs. evening chronotype;
CRC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg03037974	chr15:76606532	NA	0.68	11.55	0.54	4.06e-26	Blood metabolite levels;
CRC	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-8.95	-0.44	2.68e-17	Pancreatic cancer;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg19041857	chr6:27730383	NA	-0.63	-6.9	-0.36	2.72e-11	Lung cancer in ever smokers;
CRC	cis	rs6604026	0.656	rs12074608	chr1:93411781	T/C	cg17283838	chr1:93427260	FAM69A	0.42	5.61	0.3	4.24e-8	Multiple sclerosis;
CRC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.59	9.36	0.46	1.3e-18	Anterior chamber depth;
CRC	cis	rs78761021	0.720	rs874174	chr17:9798619	C/T	cg26853458	chr17:9805074	RCVRN	-0.39	-7.46	-0.38	7.72e-13	Type 2 diabetes;
CRC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	6.53	0.34	2.5e-10	Rheumatoid arthritis;
CRC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg02475695	chr16:616220	NHLRC4	0.43	6.95	0.36	1.99e-11	Height;
CRC	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.54	-7.92	-0.4	3.6e-14	Menarche (age at onset);
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	6.01	0.31	5.02e-9	Obesity-related traits;
CRC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg01480708	chr17:30846118	MYO1D	0.38	6.15	0.32	2.19e-9	Schizophrenia;
CRC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.14	-0.41	8.53e-15	Chronic sinus infection;
CRC	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.06e-10	Hepatitis;
CRC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg04545296	chr12:48745243	ZNF641	0.33	5.86	0.31	1.1e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.73	-12.95	-0.58	2.92e-31	Prostate cancer;
CRC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.57	6.35	0.33	7.32e-10	Initial pursuit acceleration;
CRC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg03609598	chr5:56110824	MAP3K1	-0.44	-6.12	-0.32	2.72e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	8.06	0.41	1.42e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.85	-11.66	-0.54	1.59e-26	Asthma;
CRC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.6	0.3	4.53e-8	Putamen volume;
CRC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.41	-8.01	-0.4	1.98e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.43	5.81	0.3	1.51e-8	Schizophrenia;
CRC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg10298567	chr3:47292165	KIF9	-0.41	-6.57	-0.34	1.96e-10	Colorectal cancer;
CRC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.39	-6.58	-0.34	1.87e-10	Blood metabolite levels;
CRC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.55	-10.15	-0.49	3.09e-21	Intelligence (multi-trait analysis);
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg00614641	chr11:61596405	FADS2	-0.59	-7.31	-0.37	2.07e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.51	7.26	0.37	2.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.71	-11.57	-0.54	3.41e-26	Ear protrusion;
CRC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.45	7.07	0.36	9.46e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.75	-10.39	-0.5	4.6e-22	Coronary artery disease;
CRC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg01629716	chr15:45996671	NA	0.42	8.5	0.42	6.9e-16	Waist circumference;Weight;
CRC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.43	0.33	4.4e-10	Height;
CRC	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.34	5.73	0.3	2.24e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.15	0.37	5.76e-12	Red blood cell count;
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg25834613	chr7:1915315	MAD1L1	-0.48	-6.76	-0.35	6.3e-11	Bipolar disorder;
CRC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.53	-7.32	-0.37	1.86e-12	Fibrinogen levels;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.67	7.26	0.37	2.83e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.22	-6.02	-0.31	4.75e-9	Type 2 diabetes;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.57	-7.63	-0.39	2.58e-13	Extraversion;
CRC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.46	6.84	0.35	3.77e-11	Menarche (age at onset);
CRC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.62	-10.32	-0.49	7.83e-22	Colorectal cancer;
CRC	trans	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg21153622	chr11:89784906	NA	-0.51	-8.06	-0.41	1.47e-14	HDL cholesterol;
CRC	trans	rs587242	1.000	rs550739	chr1:96887109	G/A	cg10631902	chr5:14652156	NA	0.45	6.97	0.36	1.71e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg21153622	chr11:89784906	NA	-0.41	-6.78	-0.35	5.45e-11	Coronary artery disease;
CRC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.57	-6.0	-0.31	5.12e-9	White matter hyperintensity burden;
CRC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.36	-0.33	6.63e-10	Diabetic kidney disease;
CRC	cis	rs7932354	0.528	rs7125807	chr11:47041163	G/T	cg03339077	chr11:47165057	C11orf49	-0.45	-6.36	-0.33	6.92e-10	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13577407	chr3:57994372	FLNB	-0.47	-7.3	-0.37	2.23e-12	Myopia (pathological);
CRC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.46	5.67	0.3	3.21e-8	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.44	6.22	0.32	1.55e-9	Cognitive ability;
CRC	cis	rs6758955	1.000	rs73161267	chr2:10478630	C/A	cg15773312	chr2:10472214	HPCAL1	-0.73	-9.5	-0.46	4.51e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg07356753	chr3:81810745	GBE1	0.43	5.6	0.3	4.46e-8	Extraversion;
CRC	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00071950	chr4:10020882	SLC2A9	0.46	7.89	0.4	4.64e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.64	-10.41	-0.5	4.06e-22	Aortic root size;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.47	-6.07	-0.32	3.46e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.62	-0.34	1.43e-10	Mean corpuscular volume;
CRC	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.57	-5.77	-0.3	1.8e-8	Left atrial antero-posterior diameter;
CRC	cis	rs1223397	0.938	rs3817737	chr6:13279082	A/G	cg00460589	chr6:13274354	PHACTR1	0.49	5.89	0.31	9.33e-9	Blood pressure;
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.08e-13	Alzheimer's disease;
CRC	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg11130432	chr3:121712080	ILDR1	-0.5	-6.14	-0.32	2.33e-9	Multiple sclerosis;
CRC	cis	rs9682041	0.627	rs10936625	chr3:170094908	G/T	cg11886554	chr3:170076028	SKIL	-0.61	-7.46	-0.38	7.97e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg05585544	chr11:47624801	NA	-0.62	-11.41	-0.53	1.22e-25	Subjective well-being;
CRC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26240231	chr7:1148101	C7orf50	0.41	6.22	0.32	1.51e-9	Bronchopulmonary dysplasia;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.65	-0.39	2.19e-13	Total body bone mineral density;
CRC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.65	-11.72	-0.54	9.77e-27	Aortic root size;
CRC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16024904	chr19:17905718	B3GNT3	0.38	5.97	0.31	6.05e-9	Tumor biomarkers;
CRC	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg12046867	chr14:103022105	NA	0.41	6.02	0.32	4.54e-9	Platelet count;
CRC	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.5	7.04	0.36	1.16e-11	Coenzyme Q10 levels;
CRC	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.46	5.68	0.3	2.95e-8	Metabolite levels;
CRC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.39	0.33	5.69e-10	Aortic root size;
CRC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.58	-9.34	-0.46	1.48e-18	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-9.74	-0.47	7.12e-20	Height;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg02683197	chr6:28174875	NA	-0.72	-9.76	-0.47	6.11e-20	Parkinson's disease;
CRC	cis	rs4713675	0.584	rs509539	chr6:33708190	A/C	cg14003231	chr6:33640908	ITPR3	-0.39	-6.37	-0.33	6.53e-10	Plateletcrit;
CRC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg14530993	chr4:882597	GAK	0.77	7.01	0.36	1.32e-11	Parkinson's disease;
CRC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19346786	chr7:2764209	NA	-0.42	-7.03	-0.36	1.19e-11	Height;
CRC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg14828511	chr1:107599125	PRMT6	-0.52	-7.19	-0.37	4.53e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.42	6.34	0.33	7.42e-10	Type 2 diabetes;
CRC	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg17710535	chr19:10819994	QTRT1	0.46	7.12	0.37	6.84e-12	Inflammatory skin disease;
CRC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-6.38	-0.33	6.14e-10	Bipolar disorder;
CRC	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27350398	chr10:3214550	PITRM1	0.42	6.13	0.32	2.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg23161317	chr6:28129485	ZNF389	0.46	6.6	0.34	1.66e-10	Cardiac Troponin-T levels;
CRC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg03013999	chr17:37608204	MED1	0.47	7.35	0.38	1.61e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.59	8.73	0.43	1.34e-16	Type 2 diabetes;
CRC	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26850624	chr5:429559	AHRR	-0.77	-12.45	-0.57	1.99e-29	Cystic fibrosis severity;
CRC	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.35	6.22	0.32	1.48e-9	Panic disorder;
CRC	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-14.38	-0.62	1.05e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg20885578	chr2:198174922	NA	-0.44	-6.99	-0.36	1.5e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.01	0.31	4.87e-9	Ovarian reserve;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.81	-13.57	-0.6	1.31e-33	Height;
CRC	cis	rs12476592	0.602	rs11125978	chr2:63809602	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.12	0.32	2.65e-9	Childhood ear infection;
CRC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg16060761	chr17:80687452	NA	0.41	6.0	0.31	5.23e-9	Breast cancer;
CRC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.53	6.95	0.36	2.02e-11	Lymphocyte counts;
CRC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg11189052	chr15:85197271	WDR73	0.61	9.0	0.44	1.87e-17	Schizophrenia;
CRC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.39	0.33	5.77e-10	Aortic root size;
CRC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	0.96	14.91	0.64	8.72e-39	Monocyte percentage of white cells;
CRC	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	8.47	0.42	8.52e-16	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04589156	chr19:507132	C19orf20	0.46	6.34	0.33	7.53e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg20607798	chr8:58055168	NA	0.52	5.67	0.3	3.12e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.09	-0.41	1.17e-14	Coronary artery disease;
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.68	-10.79	-0.51	1.98e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.52	6.77	0.35	5.8200000000000003e-11	Height;
CRC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.16	-0.49	2.82e-21	Height;
CRC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.76	10.14	0.49	3.37e-21	Height;
CRC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	1.07	10.43	0.5	3.41e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.43	8.16	0.41	7.27e-15	Mean corpuscular volume;
CRC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg03929089	chr4:120376271	NA	-0.52	-7.15	-0.37	5.63e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	5.76	0.3	1.92e-8	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-8.92	-0.44	3.35e-17	Blood trace element (Cu levels);
CRC	cis	rs77861329	1.000	rs57335685	chr3:52098458	C/T	cg08692210	chr3:52188851	WDR51A	0.83	7.38	0.38	1.27e-12	Macrophage inflammatory protein 1b levels;
CRC	trans	rs2403907	0.758	rs2823136	chr21:16571951	G/C	cg00407105	chr4:90231041	NA	-0.39	-5.97	-0.31	6.07e-9	Breast cancer;
CRC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.72	11.91	0.55	1.93e-27	Monocyte count;
CRC	cis	rs6496667	0.586	rs7162687	chr15:90889323	C/T	cg22089800	chr15:90895588	ZNF774	-0.4	-6.24	-0.33	1.32e-9	Rheumatoid arthritis;
CRC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.9	-0.31	9.19e-9	Life satisfaction;
CRC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.23	0.32	1.47e-9	Lung cancer;
CRC	cis	rs501120	0.810	rs607592	chr10:44750215	A/G	cg09554077	chr10:44749378	NA	0.89	13.17	0.59	4.18e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg12273811	chr6:28175739	NA	0.58	8.35	0.42	1.92e-15	Cardiac Troponin-T levels;
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg16606324	chr3:10149918	C3orf24	0.7	9.45	0.46	6.5e-19	Alzheimer's disease;
CRC	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-6.34	-0.33	7.58e-10	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.84	14.03	0.61	2.31e-35	Phospholipid levels (plasma);
CRC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.84	-0.31	1.23e-8	Skin colour saturation;
CRC	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.39	5.64	0.3	3.67e-8	Coronary artery disease;
CRC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01985446	chr10:80830536	ZMIZ1	0.47	6.97	0.36	1.75e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.54	8.48	0.42	7.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs891088	0.677	rs17253937	chr19:7184801	C/T	cg09779027	chr19:7224513	INSR	-0.57	-6.15	-0.32	2.26e-9	Hip circumference adjusted for BMI;Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25404025	chr5:52777789	FST	0.43	6.01	0.31	4.93e-9	Response to antipsychotic treatment;
CRC	trans	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg10756647	chr7:56101905	PSPH	0.72	7.98	0.4	2.39e-14	Diabetic kidney disease;
CRC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.65	10.11	0.49	4.06e-21	Type 2 diabetes;
CRC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.87	-15.07	-0.64	2.15e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg15655154	chr3:113604241	GRAMD1C	0.49	8.3	0.42	2.65e-15	Diastolic blood pressure;
CRC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.8	-13.28	-0.59	1.56e-32	Obesity-related traits;
CRC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.03	10.1	0.49	4.66e-21	Lymphocyte counts;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.54	-0.34	2.34e-10	Longevity;Endometriosis;
CRC	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg16964102	chr10:135390573	NA	0.45	7.42	0.38	1.02e-12	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg07507251	chr3:52567010	NT5DC2	0.42	6.07	0.32	3.47e-9	Bipolar disorder;
CRC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.42	8.32	0.42	2.3e-15	Mean corpuscular volume;
CRC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	8.47	0.42	8.09e-16	Colorectal cancer;
CRC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.44	7.41	0.38	1.11e-12	Crohn's disease;
CRC	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.08	-12.43	-0.57	2.49e-29	Atopic dermatitis;
CRC	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22878388	chr2:105853796	NA	-0.3	-5.85	-0.31	1.18e-8	Type 2 diabetes;
CRC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.62e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.44	5.65	0.3	3.45e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.24	0.53	4.97e-25	Tonsillectomy;
CRC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.5	-0.34	2.98e-10	Response to antipsychotic treatment;
CRC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.72	11.56	0.54	3.73e-26	Dental caries;
CRC	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg13834844	chr10:102415320	NA	0.34	5.77	0.3	1.82e-8	Body mass index;
CRC	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.52	8.29	0.42	3.02e-15	HDL cholesterol;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg03623178	chr6:28175578	NA	0.75	11.28	0.53	3.55e-25	Parkinson's disease;
CRC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg16482183	chr6:26056742	HIST1H1C	0.6	8.12	0.41	9.28e-15	Iron status biomarkers;
CRC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.61	8.32	0.42	2.34e-15	Height;
CRC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.7	9.81	0.48	4.41e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs73200209	0.744	rs17426676	chr12:116595512	T/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.21	-0.37	3.98e-12	Total body bone mineral density;
CRC	cis	rs6893807	1.000	rs6893807	chr5:87965021	C/T	cg09002922	chr5:87956389	LOC645323	0.41	5.97	0.31	6.32e-9	Body mass index;
CRC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg03233332	chr7:66118400	NA	-0.45	-6.22	-0.32	1.49e-9	Aortic root size;
CRC	cis	rs7705042	0.897	rs12515668	chr5:141496090	G/T	cg07392085	chr5:141489673	NDFIP1	0.47	7.46	0.38	7.85e-13	Asthma;
CRC	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.53	6.31	0.33	9.27e-10	Blood protein levels;
CRC	cis	rs524281	0.773	rs4393319	chr11:66001878	A/T	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.7	0.35	8.98e-11	Subjective well-being;
CRC	trans	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg11693508	chr17:37793320	STARD3	0.54	6.44	0.33	4.15e-10	Neuroticism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06076054	chr21:19191045	C21orf91	0.51	6.67	0.35	1.09e-10	Thyroid stimulating hormone;
CRC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.46	6.76	0.35	6.26e-11	Menopause (age at onset);
CRC	cis	rs12580194	0.598	rs12582005	chr12:55772837	A/T	cg19537932	chr12:55886519	OR6C68	-0.7	-8.89	-0.44	4.21e-17	Cancer;
CRC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg06606381	chr12:133084897	FBRSL1	-0.98	-8.77	-0.44	1.01e-16	Depression;
CRC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.17	-0.49	2.57e-21	Monocyte count;
CRC	cis	rs185694	1.000	rs672233	chr13:30899601	G/A	cg07600127	chr13:30881527	KATNAL1	-0.57	-6.05	-0.32	4.01e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-5.83	-0.31	1.34e-8	IgG glycosylation;
CRC	trans	rs2303319	0.504	rs16845945	chr2:162480684	C/T	cg03757145	chr4:76555832	CDKL2	-0.67	-5.97	-0.31	6e-9	Cognitive function;
CRC	trans	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg15837235	chr14:94199997	PRIMA1	-0.39	-6.09	-0.32	3.19e-9	Multiple sclerosis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14824280	chr20:60718867	SS18L1;PSMA7	0.39	6.31	0.33	9.14e-10	Schizophrenia;
CRC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.49	6.91	0.36	2.53e-11	Type 1 diabetes nephropathy;
CRC	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg18753928	chr3:113234510	CCDC52	0.49	7.73	0.39	1.33e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.78	-12.97	-0.58	2.26e-31	Obesity-related traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01089060	chr10:97050836	PDLIM1	-0.38	-6.01	-0.31	4.83e-9	Myopia (pathological);
CRC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.69	-8.53	-0.43	5.56e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3736485	0.844	rs7162412	chr15:51753994	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.38	-0.33	6.02e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg23740940	chr11:68924746	NA	0.44	5.75	0.3	2.04e-8	Blond vs. brown hair color;
CRC	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	trans	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.47	0.38	7.32e-13	Endometrial cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24568548	chr11:43544500	NA	-0.4	-6.38	-0.33	5.88e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00295835	chr11:113644563	ZW10	0.53	7.47	0.38	7.16e-13	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg03037974	chr15:76606532	NA	0.69	12.06	0.55	5.61e-28	Blood metabolite levels;
CRC	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.21	-0.37	3.83e-12	Menopause (age at onset);
CRC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg20607287	chr7:12443886	VWDE	-0.65	-8.46	-0.42	8.6e-16	Coronary artery disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00869632	chr17:59940709	BRIP1	-0.41	-6.2	-0.32	1.66e-9	Aortic root size;
CRC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.42	-8.82	-0.44	6.67e-17	Bipolar disorder;
CRC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg12365402	chr11:9010492	NRIP3	0.46	7.22	0.37	3.6e-12	Hemoglobin concentration;
CRC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.77	13.46	0.6	3.42e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.58	8.65	0.43	2.31e-16	Aortic root size;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.51	-7.06	-0.36	9.97e-12	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03047724	chr7:139477895	TBXAS1;HIPK2	0.38	5.98	0.31	5.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg15445000	chr17:37608096	MED1	0.35	6.05	0.32	3.83e-9	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs5766691	1.000	rs4823597	chr22:47531320	A/G	cg15757745	chr22:47558489	TBC1D22A	0.43	5.62	0.3	3.97e-8	Longevity;
CRC	cis	rs501120	0.584	rs11238912	chr10:44695909	T/C	cg09554077	chr10:44749378	NA	0.69	7.89	0.4	4.55e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6604026	0.656	rs2811590	chr1:93367166	C/A	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs11212617	0.935	rs183459	chr11:108089197	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.11	0.32	2.81e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.39	6.6	0.34	1.68e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6694672	1.000	rs7411719	chr1:197085676	T/A	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.69e-11	Asthma;
CRC	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg01475377	chr6:109611718	NA	-0.34	-5.86	-0.31	1.15e-8	Reticulocyte fraction of red cells;
CRC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg17294928	chr15:75287854	SCAMP5	0.52	7.87	0.4	5.01e-14	Caffeine consumption;
CRC	cis	rs6460942	0.818	rs7780083	chr7:12233647	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.6	-8.5	-0.42	6.69e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg01721255	chr8:58191610	C8orf71	0.5	6.06	0.32	3.65e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.63	0.3	3.88e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.64	8.48	0.42	8e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg11843238	chr5:131593191	PDLIM4	0.43	8.17	0.41	6.74e-15	Breast cancer;
CRC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg06494592	chr3:125709126	NA	-0.55	-6.68	-0.35	1.03e-10	Blood pressure (smoking interaction);
CRC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg11833968	chr6:79620685	NA	-0.34	-5.98	-0.31	5.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg00507830	chr2:103233733	NA	0.5	5.63	0.3	3.86e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg19336497	chr11:14380999	RRAS2	0.34	5.77	0.3	1.86e-8	Adiponectin levels;Vitamin D levels;
CRC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21028142	chr17:79581711	NPLOC4	0.35	7.12	0.37	7.03e-12	Eye color traits;
CRC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg15962314	chr1:44399869	ARTN	0.3	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.48	-9.59	-0.47	2.21e-19	Subjective well-being;
CRC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.29	0.75	6.44e-60	Prudent dietary pattern;
CRC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.43	1.09e-16	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20408290	chr12:68042072	DYRK2	0.43	6.49	0.34	3.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.43	9.43	0.46	7.8e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.54	0.43	5.06e-16	Menopause (age at onset);
CRC	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg10437265	chr15:77819839	NA	-0.54	-9.05	-0.45	1.27e-17	Type 2 diabetes;
CRC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.47	8.59	0.43	3.61e-16	Immature fraction of reticulocytes;
CRC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.49	6.75	0.35	6.76e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg13844804	chr7:814759	HEATR2	0.69	8.06	0.41	1.39e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.65	-9.08	-0.45	1.01e-17	Psoriasis;
CRC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-8.36	-0.42	1.76e-15	Coronary artery disease;
CRC	cis	rs7539624	0.588	rs10916600	chr1:223897012	C/T	cg10100437	chr1:223903862	CAPN2	0.42	5.68	0.3	2.96e-8	Schizophrenia;
CRC	cis	rs2882667	0.931	rs7720150	chr5:138334069	C/A	cg09476006	chr5:138032270	NA	0.41	6.61	0.34	1.58e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg02033258	chr5:131593261	PDLIM4	0.41	7.89	0.4	4.41e-14	Breast cancer;
CRC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg03037974	chr15:76606532	NA	-0.53	-7.71	-0.39	1.49e-13	Blood metabolite levels;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg10239186	chr6:166756509	SFT2D1	-0.41	-6.17	-0.32	2.03e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.56	7.51	0.38	5.59e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.07	-0.32	3.5e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-8.22	-0.41	4.87e-15	Gut microbiome composition (summer);
CRC	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg11130432	chr3:121712080	ILDR1	-0.48	-5.96	-0.31	6.46e-9	Multiple sclerosis;
CRC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.45	5.84	0.31	1.26e-8	Platelet distribution width;
CRC	cis	rs4664293	0.647	rs7576644	chr2:160441458	T/C	cg08347373	chr2:160653686	CD302	-0.39	-6.48	-0.34	3.41e-10	Monocyte percentage of white cells;
CRC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg00129232	chr17:37814104	STARD3	0.51	7.37	0.38	1.39e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	6.81	0.35	4.75e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.57	8.55	0.43	4.87e-16	Lymphocyte counts;
CRC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-6.83	-0.35	4.06e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.51	9.1	0.45	8.8e-18	Common traits (Other);
CRC	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.79	-14.17	-0.62	6.42e-36	Lewy body disease;
CRC	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.77	10.75	0.51	2.58e-23	Systemic lupus erythematosus;
CRC	trans	rs4714291	0.802	rs2983140	chr6:40017224	A/G	cg02267698	chr19:7991119	CTXN1	-0.51	-6.94	-0.36	2.15e-11	Strep throat;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg25164649	chr6:28176230	NA	0.74	9.26	0.45	2.64e-18	Depression;
CRC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.45	-0.34	4e-10	Electroencephalogram traits;
CRC	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-5.62	-0.3	3.97e-8	Intelligence (multi-trait analysis);
CRC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	18.0	0.7	6.75e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-6.62	-0.34	1.48e-10	Major depressive disorder;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg08798685	chr6:27730294	NA	-0.41	-6.0	-0.31	5.1e-9	Parkinson's disease;
CRC	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	19.19	0.73	1.36e-55	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-8.07	-0.41	1.31e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg09659197	chr4:152720779	NA	-0.41	-8.15	-0.41	7.55e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.18	-0.32	1.86e-9	Menopause (age at onset);
CRC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg27398640	chr15:77910606	LINGO1	-0.41	-6.95	-0.36	1.94e-11	Type 2 diabetes;
CRC	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg04239558	chr2:103089729	SLC9A4	0.38	6.57	0.34	1.92e-10	Blood protein levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21676273	chr3:45635931	LIMD1	-0.51	-6.18	-0.32	1.92e-9	Diisocyanate-induced asthma;
CRC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg02560186	chr11:3602584	NA	-0.45	-6.12	-0.32	2.62e-9	Blood pressure (smoking interaction);
CRC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.43	-7.61	-0.39	2.89e-13	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08695707	chr1:197871847	C1orf53	-0.52	-6.26	-0.33	1.18e-9	Diisocyanate-induced asthma;
CRC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg19812747	chr11:111475976	SIK2	0.56	9.78	0.47	5.36e-20	Primary sclerosing cholangitis;
CRC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-9.94	-0.48	1.63e-20	Personality dimensions;
CRC	cis	rs1190596	0.689	rs2224460	chr14:102563797	A/T	cg18135206	chr14:102964638	TECPR2	-0.42	-5.65	-0.3	3.49e-8	Behavioural disinhibition (generation interaction);
CRC	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg27499820	chr13:21296301	IL17D	-0.38	-6.2	-0.32	1.65e-9	Dental caries;
CRC	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.66	-0.47	1.32e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9928842	0.770	rs8048371	chr16:75275547	C/T	cg08657710	chr16:75258780	CTRB1	-0.58	-6.89	-0.36	2.82e-11	Alcoholic chronic pancreatitis;
CRC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg01483505	chr11:975446	AP2A2	0.45	7.44	0.38	9.1e-13	Alzheimer's disease (late onset);
CRC	cis	rs282587	0.569	rs192530	chr13:113388303	A/G	cg04656015	chr13:113407548	ATP11A	0.63	7.73	0.39	1.36e-13	Glycated hemoglobin levels;
CRC	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.97	-0.44	2.29e-17	Neuroticism;
CRC	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.77	13.56	0.6	1.34e-33	Breast cancer;
CRC	trans	rs11105468	0.961	rs11105439	chr12:90251760	A/G	cg23572944	chr11:60720130	SLC15A3	-0.42	-6.04	-0.32	4.2e-9	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg05941027	chr17:61774174	LIMD2	0.36	6.4	0.33	5.23e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.95	0.44	2.65e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17592366	0.517	rs7156153	chr14:35308074	G/A	cg09327582	chr14:35236912	BAZ1A	0.48	6.86	0.35	3.36e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.51	-7.21	-0.37	3.75e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16800975	chr8:17434541	PDGFRL	0.47	7.22	0.37	3.53e-12	Interleukin-6 levels;
CRC	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.9e-31	White blood cell count (basophil);
CRC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg00990874	chr7:1149470	C7orf50	-0.6	-7.01	-0.36	1.35e-11	Bronchopulmonary dysplasia;
CRC	trans	rs7517126	0.858	rs12740961	chr1:196660733	C/T	cg00574530	chr5:134872064	NEUROG1	0.46	6.01	0.31	5.06e-9	Blood protein levels;
CRC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs669446	0.562	rs10890273	chr1:44186444	T/A	cg12908607	chr1:44402522	ARTN	-0.33	-5.74	-0.3	2.1e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.7	-0.35	8.89e-11	Height;
CRC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.76	-13.0	-0.58	1.78e-31	Prostate cancer;
CRC	cis	rs2072510	0.569	rs2540488	chr12:96426745	G/A	cg09636302	chr12:96389483	HAL	-0.52	-6.5	-0.34	3.07e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.46	5.77	0.3	1.81e-8	Metabolite levels;
CRC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04498913	chr7:1135747	C7orf50	-0.48	-5.88	-0.31	1.02e-8	Bronchopulmonary dysplasia;
CRC	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.45	6.61	0.34	1.51e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs6604026	0.778	rs11810111	chr1:93278769	C/T	cg22128645	chr1:93425802	FAM69A	-0.4	-5.63	-0.3	3.91e-8	Multiple sclerosis;
CRC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg16892393	chr17:41919603	NA	0.5	7.21	0.37	3.87e-12	Triglycerides;
CRC	cis	rs8130944	0.859	rs11702318	chr21:44112366	C/T	cg23590273	chr21:44105265	PDE9A	-0.35	-5.62	-0.3	3.99e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg25347419	chr2:177043501	NA	-0.48	-6.43	-0.33	4.54e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg18230493	chr5:56204884	C5orf35	-0.38	-5.63	-0.3	3.96e-8	Breast cancer;Breast cancer (early onset);
CRC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.92	-17.29	-0.69	4.09e-48	Height;
CRC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.5	7.58	0.39	3.58e-13	Emphysema distribution in smoking;
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.14	-0.49	3.39e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.12	9.49	0.46	4.98e-19	Mitochondrial DNA levels;
CRC	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg09597638	chr17:3907349	NA	0.71	13.21	0.59	3.02e-32	Type 2 diabetes;
CRC	cis	rs4664293	0.867	rs7589941	chr2:160584100	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg17724175	chr1:150552817	MCL1	-0.43	-6.67	-0.34	1.11e-10	Tonsillectomy;
CRC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.72	-8.17	-0.41	6.5e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs17127169	0.649	rs112466883	chr1:65471020	G/A	cg01340542	chr1:65468273	NA	0.82	5.63	0.3	3.85e-8	Sitting height ratio;
CRC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.11	-0.32	2.8e-9	Heart rate;
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.29	-0.33	9.93e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg20933634	chr6:27740509	NA	0.63	7.31	0.37	2.09e-12	Parkinson's disease;
CRC	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	20.3	0.75	5.9e-60	Metabolite levels;
CRC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.56	7.29	0.37	2.35e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.9	9.03	0.45	1.47e-17	Cognitive function;
CRC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.88	10.93	0.52	6.51e-24	Menarche (age at onset);
CRC	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.69	-7.85	-0.4	5.78e-14	Eotaxin levels;
CRC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07570687	chr10:102243282	WNT8B	0.44	5.66	0.3	3.36e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs858239	0.712	rs199650	chr7:23367189	C/T	cg00469287	chr7:23338798	C7orf30	-0.44	-6.08	-0.32	3.41e-9	Cerebrospinal fluid biomarker levels;
CRC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs28829049	0.535	rs12565185	chr1:19498309	G/A	cg13387374	chr1:19411106	UBR4	0.4	5.86	0.31	1.15e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-0.78	-7.89	-0.4	4.65e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.57	-8.9	-0.44	3.92e-17	Height;
CRC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17554472	chr22:41940697	POLR3H	-0.56	-5.66	-0.3	3.22e-8	Vitiligo;
CRC	cis	rs524281	0.954	rs549187	chr11:65898631	C/T	cg16950941	chr11:66035639	RAB1B	-0.61	-8.7	-0.43	1.62e-16	Electroencephalogram traits;
CRC	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.46	6.75	0.35	6.5500000000000006e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.43	-0.62	6.29e-37	Height;
CRC	cis	rs6735179	0.798	rs12475777	chr2:1773830	A/G	cg26137290	chr2:1776737	NA	0.46	6.17	0.32	1.98e-9	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg02158880	chr13:53174818	NA	0.67	10.31	0.49	9.09e-22	Lewy body disease;
CRC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.17	0.59	4.16e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg03289576	chr1:249153005	ZNF692	-0.46	-6.71	-0.35	8.32e-11	Daytime sleep phenotypes;
CRC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.66	0.54	1.58e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.56	6.1	0.32	2.93e-9	Coronary artery disease;
CRC	cis	rs9648716	1.000	rs6976462	chr7:140636922	T/A	cg10747023	chr7:140774559	NA	0.46	5.99	0.31	5.41e-9	Type 2 diabetes;
CRC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.98	20.97	0.76	1.32e-62	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.51	-0.38	5.64e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6973256	0.897	rs10954422	chr7:133327587	G/A	cg10665199	chr7:133106180	EXOC4	-0.37	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20307385	chr11:47447363	PSMC3	-0.45	-6.05	-0.32	3.87e-9	Schizophrenia;
CRC	cis	rs9463078	0.605	rs4711799	chr6:44765780	A/T	cg25276700	chr6:44698697	NA	0.26	6.43	0.33	4.37e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.75	-0.35	6.76e-11	Aortic root size;
CRC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.81	11.62	0.54	2.27e-26	Cognitive function;
CRC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg13390004	chr1:15929781	NA	0.5	7.16	0.37	5.45e-12	Systolic blood pressure;
CRC	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.78	8.75	0.43	1.15e-16	Neuroticism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14036097	chr4:190862158	FRG1	-0.4	-6.19	-0.32	1.82e-9	Myopia (pathological);
CRC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg15083037	chr5:83017644	HAPLN1	-0.46	-5.97	-0.31	6.03e-9	Prostate cancer;
CRC	trans	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg10756647	chr7:56101905	PSPH	0.78	7.9	0.4	4.13e-14	Diabetic kidney disease;
CRC	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg13385794	chr1:248469461	NA	0.38	6.68	0.35	1.01e-10	Common traits (Other);
CRC	trans	rs1325598	0.935	rs10798483	chr1:176799143	C/T	cg03992096	chr13:114928177	NA	-0.38	-6.08	-0.32	3.26e-9	Height;
CRC	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-13.28	-0.59	1.58e-32	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08922075	chr1:65886896	LEPR;LEPROT	0.41	6.11	0.32	2.89e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9826463	0.757	rs73240323	chr3:142294803	T/A	cg20824294	chr3:142316082	PLS1	0.42	7.0	0.36	1.42e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-7.21	-0.37	3.82e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-5.91	-0.31	8.4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.28	6.03	0.32	4.42e-9	Educational attainment (years of education);
CRC	cis	rs4925540	0.926	rs10924896	chr1:247196731	T/C	cg22502715	chr1:247171572	ZNF695	0.4	5.65	0.3	3.42e-8	Response to taxane treatment (docetaxel);
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg02475695	chr16:616220	NHLRC4	0.48	7.96	0.4	2.73e-14	Height;
CRC	cis	rs1930961	1.000	rs6004667	chr22:25874464	A/G	cg19660720	chr22:25960296	ADRBK2	-0.53	-6.94	-0.36	2.1e-11	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg17191109	chr10:126851326	NA	-0.46	-7.02	-0.36	1.25e-11	Menarche (age at onset);
CRC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.25	-0.73	7.85e-56	Primary sclerosing cholangitis;
CRC	cis	rs9292777	0.520	rs10036697	chr5:40451363	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.63	-0.34	1.41e-10	Crohn's disease;Multiple sclerosis;
CRC	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg02682789	chr6:19804855	NA	0.61	5.82	0.31	1.41e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg15660573	chr17:549704	VPS53	-0.86	-15.78	-0.66	3.56e-42	Prostate cancer;
CRC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs995000	0.965	rs3913007	chr1:62921586	T/C	cg19896129	chr1:63156450	NA	0.4	5.78	0.3	1.76e-8	Triglyceride levels;
CRC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.04e-16	Schizophrenia;
CRC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	5.81e-13	Motion sickness;
CRC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.46	-5.81	-0.3	1.5e-8	Aortic root size;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg10729496	chr3:10149963	C3orf24	0.49	6.31	0.33	9.2e-10	Alzheimer's disease;
CRC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.22e-9	Life satisfaction;
CRC	trans	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg13565492	chr6:43139072	SRF	-0.85	-6.18	-0.32	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.81	8.15	0.41	7.71e-15	Fat distribution (HIV);
CRC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg03690763	chr11:133734501	NA	0.35	5.73	0.3	2.25e-8	Childhood ear infection;
CRC	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg18551225	chr6:44695536	NA	-0.43	-5.75	-0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.49	-6.83	-0.35	4.11e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg03623178	chr6:28175578	NA	0.78	11.53	0.54	4.63e-26	Parkinson's disease;
CRC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg12856521	chr11:46389249	DGKZ	0.44	7.2	0.37	4e-12	Leprosy;
CRC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.62	-9.73	-0.47	7.88e-20	Intelligence (multi-trait analysis);
CRC	cis	rs35538253	0.522	rs10492823	chr16:72018860	G/C	cg08717414	chr16:71523259	ZNF19	-0.61	-5.68	-0.3	2.89e-8	Post bronchodilator FEV1;
CRC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.61	9.86	0.48	2.84e-20	Breast cancer;
CRC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.66	-11.87	-0.55	2.74e-27	Eye color traits;
CRC	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.43	-5.69	-0.3	2.83e-8	Height;
CRC	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.57	-8.86	-0.44	5.12e-17	Eosinophil percentage of white cells;
CRC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.43	-6.98	-0.36	1.61e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg17948913	chr5:572064	NA	0.51	5.88	0.31	1.01e-8	Obesity-related traits;
CRC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg03690763	chr11:133734501	NA	-0.35	-5.87	-0.31	1.07e-8	Childhood ear infection;
CRC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.8	0.48	4.54e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-7.23	-0.37	3.48e-12	Coronary artery disease;
CRC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg24881330	chr22:46731750	TRMU	0.67	6.12	0.32	2.64e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs2303319	0.504	rs12474470	chr2:162535336	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.16	-0.32	2.13e-9	Cognitive function;
CRC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.06	-9.28	-0.46	2.38e-18	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12934466	chr18:32820979	ZNF397	0.39	6.53	0.34	2.51e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.0	0.4	2.22e-14	Platelet count;
CRC	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	6.0	0.31	5.34e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-7.87	-0.4	5.16e-14	Menarche (age at onset);
CRC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg01483505	chr11:975446	AP2A2	0.43	6.82	0.35	4.37e-11	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12273811	chr6:28175739	NA	0.74	9.32	0.46	1.76e-18	Depression;
CRC	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.27	-0.33	1.11e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs6600671	0.934	rs12060031	chr1:121243450	A/G	cg00646200	chr1:148855367	NA	-0.34	-6.09	-0.32	3.22e-9	Hip geometry;
CRC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.62	9.5	0.46	4.55e-19	Huntington's disease progression;
CRC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.53	-8.03	-0.4	1.79e-14	Blood protein levels;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg15845792	chr6:28175446	NA	0.75	10.63	0.51	7.03e-23	Parkinson's disease;
CRC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.53	-9.3	-0.46	2e-18	Sense of smell;
CRC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.48	-9.11	-0.45	8.42e-18	Alcohol dependence;
CRC	cis	rs7546094	1.000	rs10745330	chr1:113083439	C/T	cg22162597	chr1:113214053	CAPZA1	0.43	5.81	0.31	1.46e-8	Platelet distribution width;
CRC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg12458913	chr13:53173898	NA	0.9	16.36	0.67	1.98e-44	Lewy body disease;
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg15511327	chr8:143859410	LYNX1	0.41	7.27	0.37	2.58e-12	Urinary tract infection frequency;
CRC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.6	0.39	3.1400000000000003e-13	Motion sickness;
CRC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.7	0.72	1.12e-53	Parkinson's disease;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg15226275	chr6:116381976	FRK	0.28	6.76	0.35	6.26e-11	Total cholesterol levels;
CRC	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.74	-0.3	2.11e-8	High light scatter reticulocyte count;
CRC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.67	-0.35	1.09e-10	Mean corpuscular volume;
CRC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.62	-10.98	-0.52	4.15e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	17.61	0.7	2.36e-49	Body mass index (adult);
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23161317	chr6:28129485	ZNF389	-0.44	-5.76	-0.3	1.96e-8	Depression;
CRC	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg18833306	chr6:118973337	C6orf204	0.44	5.76	0.3	1.9e-8	Diastolic blood pressure;
CRC	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.05	-0.36	1.08e-11	Cholesterol, total;
CRC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.86	0.31	1.13e-8	Diabetic retinopathy;
CRC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04221910	chr5:616842	CEP72	-0.42	-6.95	-0.36	1.96e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.62	-6.85	-0.35	3.65e-11	Childhood ear infection;
CRC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.65	10.61	0.5	8.49e-23	Platelet count;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg12172441	chr6:28176163	NA	-0.54	-7.05	-0.36	1.03e-11	Parkinson's disease;
CRC	cis	rs13315871	1.000	rs28417694	chr3:58373939	A/G	cg20936604	chr3:58311152	NA	-0.73	-6.69	-0.35	9.48e-11	Cholesterol, total;
CRC	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.51	8.33	0.42	2.15e-15	Dupuytren's disease;
CRC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.5	-0.38	5.91e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.12	10.93	0.52	6.49e-24	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.36	5.73	0.3	2.33e-8	Testicular germ cell tumor;
CRC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg07865391	chr16:88106882	BANP	0.46	6.05	0.32	3.86e-9	Menopause (age at onset);
CRC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.78	12.5	0.57	1.32e-29	Breast cancer;
CRC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.49	7.33	0.37	1.78e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.66	0.3	3.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.61	9.1	0.45	8.55e-18	Morning vs. evening chronotype;
CRC	cis	rs501120	1.000	rs554565	chr10:44755448	G/A	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13198984	chr17:80129470	CCDC57	0.48	8.46	0.42	9.02e-16	Life satisfaction;
CRC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.45	7.14	0.37	6.11e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-6.13	-0.32	2.56e-9	Life satisfaction;
CRC	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg11993925	chr19:44307056	LYPD5	0.47	7.73	0.39	1.3e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg22561889	chr6:118971681	C6orf204	-0.51	-6.65	-0.34	1.19e-10	Diastolic blood pressure;
CRC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg27534772	chr1:16042836	PLEKHM2	0.55	10.86	0.51	1.12e-23	Systolic blood pressure;
CRC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	0.76	6.17	0.32	1.98e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.45	10.23	0.49	1.66e-21	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.7	-9.1	-0.45	9.19e-18	Initial pursuit acceleration;
CRC	trans	rs2099149	0.748	rs1320925	chr12:30461980	A/G	cg15529703	chr5:17187054	LOC285696	-0.47	-6.02	-0.31	4.66e-9	Cannabis use;
CRC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.39	5.95	0.31	6.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.14	17.5	0.69	6.1e-49	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg08200770	chr17:80723486	TBCD	0.42	7.27	0.37	2.65e-12	Glycated hemoglobin levels;
CRC	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.02	-0.36	1.28e-11	Coronary artery disease;
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg21268650	chr7:45961089	IGFBP3	0.46	7.57	0.39	3.78e-13	Sitting height ratio;
CRC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg18827107	chr12:86230957	RASSF9	-0.46	-7.53	-0.38	4.82e-13	Major depressive disorder;
CRC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.37	-6.91	-0.36	2.53e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg14191688	chr11:70257035	CTTN	0.55	7.72	0.39	1.44e-13	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.91	-0.58	3.96e-31	Hemoglobin concentration;
CRC	trans	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.62	6.29	0.33	9.83e-10	Menarche (age at onset);
CRC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.72	-0.47	8.53e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg10305451	chr2:177043427	NA	-0.53	-6.82	-0.35	4.28e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.56	8.74	0.43	1.17e-16	Diastolic blood pressure;
CRC	cis	rs2274273	0.588	rs9323285	chr14:55863829	A/C	cg10130446	chr14:55658398	DLGAP5	0.42	5.83	0.31	1.33e-8	Protein biomarker;
CRC	cis	rs4731207	0.689	rs1481341	chr7:124567123	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.03	-0.32	4.52e-9	Cutaneous malignant melanoma;
CRC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.37	6.73	0.35	7.45e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg22638593	chr5:131593259	PDLIM4	-0.38	-6.32	-0.33	8.61e-10	Breast cancer;
CRC	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.57	8.0	0.4	2.17e-14	Coronary artery disease;
CRC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.98e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7731657	0.537	rs3981333	chr5:130375045	A/T	cg08523029	chr5:130500466	HINT1	-0.44	-5.86	-0.31	1.15e-8	Fasting plasma glucose;
CRC	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.48	7.86	0.4	5.43e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.44	0.46	7.29e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.38	6.23	0.32	1.4e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7333181	1.000	rs7333181	chr13:112221297	G/A	cg27543320	chr13:112200689	NA	0.5	6.2	0.32	1.69e-9	Menopause (age at onset);
CRC	trans	rs4378999	0.660	rs9824444	chr3:50782765	C/T	cg12383621	chr7:7735611	RPA3	-0.48	-6.05	-0.32	3.92e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.3	0.42	2.82e-15	Height;
CRC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.76	-0.47	6.15e-20	Hemoglobin concentration;
CRC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.5	0.6	2.45e-33	Platelet count;
CRC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.62	-11.21	-0.53	6.54e-25	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27563952	chr1:182557982	NA	0.44	6.3	0.33	9.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.68	0.39	1.84e-13	Axial length;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.49	7.84	0.4	6.43e-14	Lung cancer;
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg08546805	chr12:8549446	NA	-0.43	-6.55	-0.34	2.26e-10	Blood pressure (smoking interaction);
CRC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.39	-0.33	5.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.56	6.79	0.35	5.1e-11	Diastolic blood pressure;
CRC	trans	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg01448155	chr10:3564782	NA	0.52	6.22	0.32	1.5e-9	Lymphocyte percentage of white cells;
CRC	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg00105475	chr2:10696890	NA	0.45	7.19	0.37	4.48e-12	Prostate cancer;
CRC	cis	rs4654899	0.727	rs11805169	chr1:21156862	A/T	cg02927042	chr1:21476669	EIF4G3	0.46	7.32	0.37	1.93e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg23234261	chr14:55582407	NA	-0.29	-5.67	-0.3	3.12e-8	Protein biomarker;
CRC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.63	9.09	0.45	9.37e-18	Systolic blood pressure;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09273779	chr9:35605990	TESK1	-0.51	-6.25	-0.33	1.27e-9	Diisocyanate-induced asthma;
CRC	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.58	9.52	0.46	3.95e-19	Schizophrenia;
CRC	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg15038512	chr6:170123185	PHF10	-0.38	-5.93	-0.31	7.66e-9	Obesity-related traits;
CRC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.36	-6.04	-0.32	4.15e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg02875869	chr16:89901417	SPIRE2	-1.22	-17.09	-0.69	2.49e-47	Vitiligo;
CRC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg23625390	chr15:77176239	SCAPER	0.5	7.29	0.37	2.4e-12	Blood metabolite levels;
CRC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.75	9.11	0.45	8.14e-18	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-13.33	-0.59	1.04e-32	Blood metabolite levels;
CRC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg26028573	chr6:26043587	HIST1H2BB	0.5	7.34	0.38	1.68e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10982256	0.711	rs10817635	chr9:117288169	A/C	cg13636371	chr9:117264095	DFNB31	-0.33	-6.09	-0.32	3.21e-9	Bipolar disorder;
CRC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.72	-9.91	-0.48	1.94e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.61	-9.96	-0.48	1.33e-20	P wave terminal force;
CRC	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.61	-0.34	1.58e-10	Vitamin D levels;
CRC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.51	8.18	0.41	6.35e-15	Aortic root size;
CRC	trans	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05926928	chr17:57297772	GDPD1	-0.41	-6.26	-0.33	1.18e-9	Schizophrenia;
CRC	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.45	8.11	0.41	1.03e-14	Blood metabolite ratios;
CRC	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.4	6.12	0.32	2.71e-9	Endometrial cancer;
CRC	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg15145174	chr5:6755386	POLS	-0.47	-6.57	-0.34	1.97e-10	Menopause (age at onset);
CRC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.32	-0.42	2.45e-15	Mean corpuscular volume;
CRC	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.5	-6.21	-0.32	1.64e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.96	-0.4	2.84e-14	Total body bone mineral density;
CRC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.74	0.43	1.19e-16	Parkinson's disease;
CRC	trans	rs11885103	0.543	rs2685245	chr2:554536	C/G	cg12228919	chr15:44955936	SPG11	-0.48	-7.28	-0.37	2.46e-12	Heschl's gyrus morphology;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.98	-0.52	4.02e-24	Electroencephalogram traits;
CRC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.4	8.69	0.43	1.7e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.5	7.09	0.36	8.37e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg20387954	chr3:183756860	HTR3D	0.44	7.43	0.38	9.38e-13	Anterior chamber depth;
CRC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.29	0.42	2.84e-15	Schizophrenia;
CRC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.4	8.52	0.43	5.74e-16	Cutaneous nevi;
CRC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg00601486	chr12:48723148	H1FNT	-0.35	-6.77	-0.35	5.96e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.32	-0.59	1.17e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.44	6.36	0.33	6.8e-10	HIV-1 control;
CRC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.57e-8	Prudent dietary pattern;
CRC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24308560	chr3:49941425	MST1R	0.44	6.86	0.35	3.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.43	7.15	0.37	5.59e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09936889	chr8:102135665	NA	0.45	6.35	0.33	7.26e-10	Response to antipsychotic treatment;
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14863265	chr7:2801509	GNA12	-0.41	-5.66	-0.3	3.36e-8	Height;
CRC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg02033258	chr5:131593261	PDLIM4	-0.38	-7.13	-0.37	6.22e-12	Blood metabolite levels;
CRC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	1.17	10.93	0.52	6.24e-24	Arsenic metabolism;
CRC	cis	rs4733781	0.509	rs12550365	chr8:131136046	A/T	cg26053073	chr8:131455383	NA	-0.34	-5.63	-0.3	3.92e-8	Tuberculosis;
CRC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg21155852	chr7:2048760	MAD1L1	-0.39	-5.7	-0.3	2.65e-8	Neuroticism;
CRC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.59	9.2	0.45	4.11e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.45	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.26	-0.33	1.23e-9	Gout;Renal underexcretion gout;
CRC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.91	-15.94	-0.66	8.84e-43	Height;
CRC	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg05250797	chr16:70222502	NA	0.4	5.65	0.3	3.52e-8	IgE levels;
CRC	trans	rs2303319	0.504	rs12465645	chr2:162437639	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.0	-0.31	5.13e-9	Cognitive function;
CRC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg10760299	chr15:45669010	GATM	0.51	7.81	0.4	7.68e-14	Homoarginine levels;
CRC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg22110888	chr17:80059540	CCDC57	0.41	6.5	0.34	2.97e-10	Life satisfaction;
CRC	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg08795948	chr3:128337044	NA	0.35	5.99	0.31	5.51e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.55	7.11	0.36	7.26e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs524281	0.861	rs6591207	chr11:65949674	A/T	cg16950941	chr11:66035639	RAB1B	-0.61	-7.47	-0.38	7.15e-13	Electroencephalogram traits;
CRC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	6.89	0.36	2.77e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.67	-7.83	-0.4	6.65e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.73	-0.39	1.36e-13	Bipolar disorder;
CRC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.51	7.36	0.38	1.51e-12	Colorectal cancer;
CRC	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.51	0.42	6.07e-16	Corneal astigmatism;
CRC	trans	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg18335740	chr13:41363409	SLC25A15	0.54	8.26	0.41	3.51e-15	Lewy body disease;
CRC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.34e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	6.26	0.33	1.23e-9	Monocyte percentage of white cells;
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.85	0.61	1.06e-34	Alzheimer's disease;
CRC	trans	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.61	-9.38	-0.46	1.15e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26190281	chr1:36235743	CLSPN	0.41	6.05	0.32	3.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg18761221	chr20:60518478	NA	0.45	7.18	0.37	4.62e-12	Body mass index;
CRC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg13844804	chr7:814759	HEATR2	0.64	8.29	0.42	2.88e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.42	6.13	0.32	2.48e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg03030879	chr14:75389066	RPS6KL1	0.47	7.22	0.37	3.69e-12	Height;
CRC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs2213920	0.679	rs6478168	chr9:118225951	A/T	cg13918206	chr9:118159781	DEC1	0.63	5.99	0.31	5.5e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.58	10.77	0.51	2.35e-23	Optic cup area;
CRC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.62	-0.3	3.98e-8	Colorectal cancer;
CRC	cis	rs4774899	0.752	rs2962991	chr15:57348776	A/G	cg08128148	chr15:57256372	TCF12	-0.39	-5.66	-0.3	3.33e-8	Urinary tract infection frequency;
CRC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.25	0.33	1.28e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.58	0.43	3.87e-16	Corneal astigmatism;
CRC	cis	rs9303542	0.559	rs12938390	chr17:46614722	T/C	cg04904318	chr17:46607828	HOXB1	-0.53	-6.17	-0.32	2.02e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.21	-0.37	3.98e-12	HDL cholesterol;
CRC	cis	rs457287	0.772	rs10974804	chr9:4827719	A/T	cg14182974	chr9:4791918	RCL1	0.45	6.28	0.33	1.05e-9	Platelet count;
CRC	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21335187	chr2:88990994	RPIA	0.49	6.87	0.35	3.12e-11	Response to antipsychotic treatment;
CRC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg04362960	chr10:104952993	NT5C2	-0.42	-5.94	-0.31	7.28e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.55	8.78	0.44	8.95e-17	Mean corpuscular volume;
CRC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.44	-8.12	-0.41	9.71e-15	Reticulocyte fraction of red cells;
CRC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	0.76	6.64	0.34	1.3e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.72	-11.24	-0.53	5.05e-25	Prostate cancer;
CRC	cis	rs6743376	0.556	rs2515399	chr2:113819451	G/T	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.49	-7.57	-0.38	3.9e-13	Coronary artery disease;
CRC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.69	10.56	0.5	1.2e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4290604	0.748	rs62183337	chr2:237962838	C/T	cg23555395	chr2:238036564	NA	0.62	6.09	0.32	3.12e-9	Asthma;
CRC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.79	-0.44	8.56e-17	Alcohol dependence;
CRC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.96	15.46	0.65	6.81e-41	Monocyte percentage of white cells;
CRC	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.45	6.1	0.32	2.92e-9	Eye color traits;
CRC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.52	-0.5	1.66e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs2072510	1.000	rs2540492	chr12:96417659	C/T	cg09636302	chr12:96389483	HAL	-0.37	-5.66	-0.3	3.25e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg24253500	chr15:84953950	NA	0.37	6.18	0.32	1.92e-9	Schizophrenia;
CRC	cis	rs4819852	1.000	rs7285377	chr22:19987202	G/T	cg07821417	chr22:19972146	ARVCF	0.45	5.82	0.31	1.39e-8	Pulse pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23268892	chr14:102553431	HSP90AA1	0.39	6.03	0.32	4.48e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.92	-17.44	-0.69	1.05e-48	Coronary artery disease;
CRC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.77	-0.39	1.01e-13	Gut microbiome composition (summer);
CRC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.56	5.68	0.3	2.94e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10128264	0.934	rs1250589	chr10:80980304	C/G	cg20744163	chr10:80999841	ZMIZ1	-0.43	-7.39	-0.38	1.19e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.47	6.96	0.36	1.87e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.18	-0.37	4.75e-12	Life satisfaction;
CRC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg00769240	chr8:12517080	NA	-0.56	-6.78	-0.35	5.57e-11	Blood pressure (smoking interaction);
CRC	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.67	10.76	0.51	2.55e-23	Myopia (pathological);
CRC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.24	-0.33	1.37e-9	Colorectal cancer;
CRC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.54	8.64	0.43	2.55e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-7.81	-0.4	7.78e-14	Type 2 diabetes;
CRC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.46	6.94	0.36	2.14e-11	Menopause (age at onset);
CRC	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.73	-11.17	-0.52	8.96e-25	Waist circumference;Body mass index;
CRC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.45	-6.56	-0.34	2.1e-10	Melanoma;
CRC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg16342193	chr10:102329863	NA	0.35	5.71	0.3	2.47e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-8.72	-0.43	1.4e-16	Endometrial cancer;
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.55	8.53	0.43	5.5e-16	Longevity;Endometriosis;
CRC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16262614	chr3:133464971	TF	0.33	5.91	0.31	8.53e-9	Iron status biomarkers;
CRC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.74	8.37	0.42	1.73e-15	Body mass index;
CRC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg22834771	chr12:69754056	YEATS4	-0.42	-5.88	-0.31	9.81e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12273811	chr6:28175739	NA	0.72	9.03	0.45	1.47e-17	Depression;
CRC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.68	-9.66	-0.47	1.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.4	6.81	0.35	4.61e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CRC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg14541582	chr5:601475	NA	-0.36	-7.11	-0.36	7.3e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg05725404	chr16:58534157	NDRG4	-0.59	-5.75	-0.3	2.09e-8	Schizophrenia;
CRC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	cis	rs9311676	0.618	rs62258135	chr3:58403330	C/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19825600	chr2:3704501	ALLC	-0.61	-6.79	-0.35	5.3e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg25985355	chr7:65971099	NA	-0.49	-5.73	-0.3	2.27e-8	Diabetic kidney disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02751803	chr16:56998622	CETP	0.47	6.4	0.33	5.35e-10	Anxiety disorder;
CRC	trans	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.19	0.37	4.34e-12	Endometrial cancer;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg25164649	chr6:28176230	NA	0.62	8.85	0.44	5.46e-17	Cardiac Troponin-T levels;
CRC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.1	-0.32	3.03e-9	Bipolar disorder;
CRC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs11212617	0.934	rs609557	chr11:108084513	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.28	0.33	1.08e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.44	-5.86	-0.31	1.15e-8	Gut microbiome composition (summer);
CRC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.51	-8.38	-0.42	1.58e-15	Aortic root size;
CRC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.82	-14.57	-0.63	1.89e-37	Metabolic syndrome;
CRC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.85	-0.31	1.16e-8	Gout;Renal underexcretion gout;
CRC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs7809950	0.798	rs2701687	chr7:107304628	C/T	cg23024343	chr7:107201750	COG5	0.47	7.0	0.36	1.49e-11	Coronary artery disease;
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.88	-0.44	4.3e-17	Intelligence (multi-trait analysis);
CRC	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-6.8	-0.35	4.91e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7215564	0.908	rs74002838	chr17:78682157	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.26e-9	Myopia (pathological);
CRC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-11.72	-0.54	9.6800000000000007e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg23463467	chr20:60627584	TAF4	0.33	5.72	0.3	2.4e-8	Body mass index;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg03623178	chr6:28175578	NA	0.96	12.48	0.57	1.62e-29	Depression;
CRC	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg24289452	chr6:170231220	NA	-0.56	-6.12	-0.32	2.64e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.65	-8.66	-0.43	2.15e-16	Facial morphology (factor 19);
CRC	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg24505687	chr6:33548425	BAK1	0.32	6.24	0.33	1.33e-9	Platelet count;
CRC	cis	rs6735179	0.600	rs57620327	chr2:1778208	G/T	cg19300414	chr2:1746591	PXDN	0.37	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.11	19.05	0.72	4.69e-55	Cognitive function;
CRC	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.72	-10.3	-0.49	9.63e-22	Blood protein levels;
CRC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg01629716	chr15:45996671	NA	0.41	8.55	0.43	4.56e-16	Waist circumference;Weight;
CRC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.46	7.44	0.38	9.12e-13	Fat distribution (HIV);
CRC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg25164649	chr6:28176230	NA	0.38	5.7	0.3	2.65e-8	Pubertal anthropometrics;
CRC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.28	0.37	2.42e-12	Morning vs. evening chronotype;
CRC	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.16	-0.37	5.34e-12	Lung cancer;
CRC	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.66	8.74	0.43	1.17e-16	Body mass index;
CRC	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg21839984	chr17:30846986	MYO1D	-0.33	-5.74	-0.3	2.15e-8	Schizophrenia;
CRC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.71	10.98	0.52	4.21e-24	Tonsillectomy;
CRC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.99	-0.31	5.58e-9	Hip circumference adjusted for BMI;
CRC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.65	-8.9	-0.44	3.77e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3540	0.804	rs3743418	chr15:90934331	A/G	cg22089800	chr15:90895588	ZNF774	0.46	5.89	0.31	9.32e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23615779	chr7:143077590	ZYX	0.39	6.1	0.32	2.97e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg14847009	chr1:175162515	KIAA0040	0.28	6.42	0.33	4.72e-10	Alcohol dependence;
CRC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12463550	chr7:65579703	CRCP	0.73	6.55	0.34	2.23e-10	Diabetic kidney disease;
CRC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.56	7.74	0.39	1.23e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-9.45	-0.46	6.4e-19	Hip circumference adjusted for BMI;
CRC	cis	rs860295	0.702	rs11264366	chr1:155335411	A/T	cg02153340	chr1:155202674	NA	-0.52	-6.43	-0.33	4.51e-10	Body mass index;
CRC	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.38	5.98	0.31	5.68e-9	Height;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg03623178	chr6:28175578	NA	0.66	10.06	0.49	6.13e-21	Cardiac Troponin-T levels;
CRC	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg16989719	chr2:238392110	NA	-0.38	-7.71	-0.39	1.48e-13	Prostate cancer;
CRC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	1.03	10.11	0.49	4.33e-21	Lymphocyte counts;
CRC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.8	-0.3	1.52e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-0.93	-8.85	-0.44	5.4e-17	Post bronchodilator FEV1;
CRC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg01874867	chr7:94954059	PON1	0.49	6.31	0.33	8.91e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg00319359	chr11:70116639	PPFIA1	0.65	6.49	0.34	3.12e-10	Coronary artery disease;
CRC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.41	-5.83	-0.31	1.33e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg22535103	chr8:58192502	C8orf71	-0.44	-5.84	-0.31	1.25e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17507749	chr15:85114479	UBE2QP1	0.58	8.07	0.41	1.33e-14	Schizophrenia;
CRC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.47	7.21	0.37	3.76e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6662572	0.950	rs56093189	chr1:46234323	T/C	cg08644498	chr1:46502608	NA	0.44	6.49	0.34	3.11e-10	Blood protein levels;
CRC	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	0.56	8.76	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.77	-12.92	-0.58	3.75e-31	Obesity-related traits;
CRC	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.34	0.42	2.08e-15	Educational attainment;
CRC	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-8.35	-0.42	1.95e-15	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.69	0.47	1.08e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	8.14	0.41	8.39e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg17948913	chr5:572064	NA	0.55	6.2	0.32	1.71e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs698833	0.892	rs786618	chr2:44593929	C/T	cg04920474	chr2:44395004	PPM1B	0.42	6.11	0.32	2.87e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6066835	1.000	rs6125428	chr20:47292823	C/G	cg18078177	chr20:47281410	PREX1	0.77	5.69	0.3	2.8e-8	Multiple myeloma;
CRC	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.35	0.46	1.39e-18	Dupuytren's disease;
CRC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.67	-9.51	-0.46	4.3e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.87	0.31	1.07e-8	Major depressive disorder;
CRC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.54	-7.15	-0.37	5.58e-12	Body mass index;
CRC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.41	-0.33	4.9e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg20885578	chr2:198174922	NA	-0.44	-6.93	-0.36	2.26e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16178625	chr17:56609274	SEPT4	0.38	6.48	0.34	3.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg09355771	chr2:177043147	NA	0.68	10.3	0.49	9.55e-22	IgG glycosylation;
CRC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.68	-13.25	-0.59	2e-32	Educational attainment;
CRC	cis	rs7567389	0.600	rs3732209	chr2:128079806	A/G	cg09760422	chr2:128146352	NA	0.34	5.72	0.3	2.38e-8	Self-rated health;
CRC	cis	rs7835763	0.518	rs2468133	chr8:119095747	C/T	cg11592677	chr8:119110466	EXT1	-0.43	-7.52	-0.38	5.29e-13	Autism spectrum disorder;
CRC	cis	rs73058052	0.597	rs11878568	chr19:50095961	T/C	cg15963326	chr19:50037085	RCN3	-0.36	-5.74	-0.3	2.15e-8	Fibrinogen levels;
CRC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.6	-0.34	1.62e-10	Red cell distribution width;
CRC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16866257	chr17:61905183	FTSJ3;PSMC5	0.44	6.43	0.33	4.38e-10	Response to antipsychotic treatment;
CRC	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.37	0.46	1.19e-18	Schizophrenia;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14010720	chr20:62168878	PTK6	0.31	5.96	0.31	6.5e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.01	-0.36	1.36e-11	Bipolar disorder;
CRC	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.85	-0.31	1.19e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.52	-7.12	-0.37	6.97e-12	Intelligence (multi-trait analysis);
CRC	trans	rs2797369	0.882	rs1775644	chr6:101615409	T/C	cg26346621	chr12:6873348	NA	-0.38	-6.1	-0.32	2.96e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg10760299	chr15:45669010	GATM	0.36	5.61	0.3	4.34e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.91	-0.31	8.51e-9	Electroencephalogram traits;
CRC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.66	-11.59	-0.54	2.83e-26	Refractive error;
CRC	cis	rs6504622	0.902	rs1052586	chr17:45018463	A/G	cg16759221	chr17:45003025	GOSR2	0.47	7.46	0.38	7.58e-13	Orofacial clefts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02865149	chr11:58939797	DTX4	0.45	6.56	0.34	2.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.55	8.38	0.42	1.61e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6694672	1.000	rs1170882	chr1:196949323	C/G	cg13682187	chr1:196946512	CFHR5	-0.48	-7.61	-0.39	2.83e-13	Asthma;
CRC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-7.31	-0.37	2.09e-12	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.81	0.4	7.54e-14	Menopause (age at onset);
CRC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.99	8.45	0.42	9.59e-16	Psoriasis;
CRC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.8	-10.8	-0.51	1.79e-23	Initial pursuit acceleration;
CRC	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg13043300	chr11:71146211	DHCR7	-0.44	-5.84	-0.31	1.28e-8	Vitamin D levels;
CRC	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg26741380	chr15:41871084	TYRO3	-0.49	-6.87	-0.35	3.14e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs17162190	0.698	rs6675469	chr1:26789813	G/A	cg17456097	chr1:26900765	RPS6KA1	0.46	6.58	0.34	1.82e-10	Mean corpuscular volume;
CRC	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg27068330	chr11:65405492	SIPA1	-0.43	-5.9	-0.31	8.91e-9	Systemic lupus erythematosus;
CRC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.8	0.39	8.36e-14	Vitiligo;
CRC	cis	rs2276314	0.553	rs4799842	chr18:33627968	C/A	cg05985134	chr18:33552581	C18orf21	0.38	5.92	0.31	8.05e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg06453172	chr10:134556979	INPP5A	-0.48	-7.43	-0.38	9.23e-13	Migraine;
CRC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.66	10.52	0.5	1.68e-22	Huntington's disease progression;
CRC	cis	rs2564921	0.570	rs3821831	chr3:52853401	C/T	cg11645453	chr3:52864694	ITIH4	-0.38	-6.4	-0.33	5.37e-10	Height;
CRC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.38	6.26	0.33	1.17e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11190155	chr3:9975447	CRELD1	0.5	6.44	0.33	4.25e-10	Thyroid stimulating hormone;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.61	11.2	0.53	6.96e-25	Tonsillectomy;
CRC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.66	0.63	8.22e-38	Chronic sinus infection;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03797687	chr12:111843585	SH2B3	0.51	6.88	0.35	3.11e-11	Anxiety disorder;
CRC	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg18827107	chr12:86230957	RASSF9	-0.36	-5.77	-0.3	1.83e-8	Major depressive disorder;
CRC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.8	13.26	0.59	1.85e-32	Height;
CRC	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.57e-10	Prostate cancer;
CRC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg19622623	chr12:86230825	RASSF9	-0.36	-5.94	-0.31	7.17e-9	Major depressive disorder;
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg12516270	chr8:143859308	LYNX1	0.43	7.56	0.38	4.03e-13	Urinary tract infection frequency;
CRC	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.0	-0.31	5.08e-9	Capecitabine sensitivity;
CRC	cis	rs863345	0.625	rs10752626	chr1:158528118	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.29	-0.37	2.3e-12	Pneumococcal bacteremia;
CRC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.69	-0.47	1.04e-19	Bladder cancer;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.65	-10.19	-0.49	2.28e-21	Huntington's disease progression;
CRC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.97	-0.55	1.22e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.19	-0.32	1.75e-9	Systemic lupus erythematosus;
CRC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg03233332	chr7:66118400	NA	0.43	5.84	0.31	1.23e-8	Aortic root size;
CRC	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.61	9.9	0.48	2.08e-20	Coronary artery disease;
CRC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.66	10.65	0.51	6.11e-23	Gestational age at birth (maternal effect);
CRC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.37	-6.41	-0.33	5.03e-10	Colorectal cancer;
CRC	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg02896835	chr1:92012615	NA	0.49	5.82	0.31	1.38e-8	Eosinophil percentage of white cells;
CRC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.49	5.74	0.3	2.17e-8	Coronary artery disease;
CRC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.46	0.42	8.88e-16	Lymphocyte counts;
CRC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-6.51	-0.34	2.89e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.34	-5.62	-0.3	4.08e-8	Personality dimensions;
CRC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.63	-10.37	-0.5	5.57e-22	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg21153622	chr11:89784906	NA	-0.48	-7.69	-0.39	1.74e-13	HDL cholesterol;
CRC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.22	-0.37	3.63e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.74	0.66	5.48e-42	Platelet count;
CRC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg03340356	chr1:67600835	NA	-0.27	-6.16	-0.32	2.09e-9	Psoriasis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10835914	chr14:73493957	ZFYVE1	0.46	6.65	0.34	1.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16262614	chr3:133464971	TF	0.34	6.0	0.31	5.25e-9	Iron status biomarkers;
CRC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg11522145	chr4:3412961	RGS12	-0.41	-6.35	-0.33	7.04e-10	Serum sulfate level;
CRC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg03623178	chr6:28175578	NA	0.79	6.63	0.34	1.35e-10	Depression;
CRC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.61	-0.43	3.14e-16	Monocyte percentage of white cells;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg21620606	chr4:1342894	KIAA1530	0.4	6.94	0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg16447950	chr5:562315	NA	-0.74	-9.65	-0.47	1.44e-19	Lung disease severity in cystic fibrosis;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg26587870	chr6:27730563	NA	-0.53	-6.15	-0.32	2.26e-9	Lung cancer in ever smokers;
CRC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-9.68	-0.47	1.16e-19	Dental caries;
CRC	trans	rs1367248	0.943	rs55937534	chr2:125005052	A/T	cg07402188	chr19:40720005	MAP3K10	0.46	6.04	0.32	4.18e-9	Tonometry;
CRC	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg04586622	chr2:25135609	ADCY3	-0.56	-9.26	-0.45	2.66e-18	Body mass index;
CRC	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg20628663	chr10:43360327	NA	0.57	6.89	0.36	2.77e-11	Blood protein levels;
CRC	cis	rs6545883	0.507	rs4672427	chr2:61469250	A/G	cg10580144	chr2:61372316	C2orf74	-0.35	-7.65	-0.39	2.18e-13	Tuberculosis;
CRC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.22	0.53	5.83e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.39	-6.58	-0.34	1.88e-10	Mean arterial pressure;
CRC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.53	8.72	0.43	1.4e-16	DNA methylation (variation);
CRC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.39	5.93	0.31	7.63e-9	Mean corpuscular volume;
CRC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg15123519	chr2:136567270	LCT	0.31	5.83	0.31	1.36e-8	Mosquito bite size;
CRC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.83	-0.48	3.72e-20	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02761523	chr19:13106643	NFIX	0.41	6.18	0.32	1.9e-9	Schizophrenia;
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08219700	chr8:58056026	NA	0.59	6.71	0.35	8.27e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.49	-7.61	-0.39	2.94e-13	Aortic root size;
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.44	-0.33	4.14e-10	Blood metabolite levels;
CRC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.82	-13.31	-0.59	1.19e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.1	0.49	4.61e-21	Corneal astigmatism;
CRC	cis	rs7632954	0.867	rs9857796	chr3:8514503	A/G	cg03495237	chr3:8533978	NA	0.34	5.7	0.3	2.66e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.57	6.86	0.35	3.48e-11	Lymphocyte counts;
CRC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg03623178	chr6:28175578	NA	0.82	10.81	0.51	1.7e-23	Parkinson's disease;
CRC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	7.16	0.37	5.44e-12	Lung cancer in ever smokers;
CRC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg05044414	chr3:183734942	ABCC5	0.47	8.19	0.41	5.96e-15	Anterior chamber depth;
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.87	0.31	1.07e-8	Bipolar disorder;
CRC	cis	rs11212617	0.967	rs60683001	chr11:108257787	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.61	0.34	1.59e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.74	7.89	0.4	4.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.65	8.93	0.44	3.15e-17	Alcohol dependence;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07975834	chr1:112282151	C1orf183	0.45	6.18	0.32	1.9e-9	Anxiety disorder;
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs4481887	0.504	rs7548525	chr1:248360026	A/G	cg00666640	chr1:248458726	OR2T12	0.43	6.83	0.35	4.14e-11	Common traits (Other);
CRC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.15	0.52	1.08e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.63	7.69	0.39	1.76e-13	Type 2 diabetes nephropathy;
CRC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.78	10.89	0.51	8.6e-24	Cognitive function;
CRC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.2	-0.41	5.52e-15	Type 2 diabetes;
CRC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.68	-0.39	1.89e-13	Gut microbiome composition (summer);
CRC	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	0.9	7.76	0.39	1.12e-13	Fat distribution (HIV);
CRC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.1	-0.36	7.78e-12	Response to antipsychotic treatment;
CRC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg26043149	chr18:55253948	FECH	0.5	7.79	0.39	8.77e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	7.08	0.36	8.57e-12	Obesity-related traits;
CRC	trans	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg18335740	chr13:41363409	SLC25A15	0.53	8.32	0.42	2.34e-15	Lewy body disease;
CRC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.66	8.09	0.41	1.18e-14	Menarche (age at onset);
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.18	-0.37	4.77e-12	Breast cancer;
CRC	cis	rs17767392	0.813	rs12891975	chr14:71789862	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.45	-6.0	-0.31	5.14e-9	Mitral valve prolapse;
CRC	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.7e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-1.24	-10.24	-0.49	1.53e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-5.99	-0.31	5.51e-9	Total body bone mineral density;
CRC	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg11900509	chr10:81946545	ANXA11	-0.66	-6.6	-0.34	1.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.28	0.75	7.02e-60	Prudent dietary pattern;
CRC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	6.96	0.36	1.81e-11	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11541479	chr19:11039306	YIPF2;C19orf52	0.4	6.1	0.32	3.02e-9	Schizophrenia;
CRC	trans	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.4	0.33	5.25e-10	Schizophrenia;
CRC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.78e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.44	7.15	0.37	5.77e-12	Obesity-related traits;
CRC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg06238570	chr21:40685208	BRWD1	0.75	10.21	0.49	1.91e-21	Cognitive function;
CRC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.37	6.22	0.32	1.52e-9	Cardiovascular disease risk factors;
CRC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.95	-0.48	1.43e-20	Aortic root size;
CRC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg13390004	chr1:15929781	NA	0.53	7.41	0.38	1.07e-12	Systolic blood pressure;
CRC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.67	-7.86	-0.4	5.54e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.42	-6.73	-0.35	7.76e-11	Red blood cell count;
CRC	cis	rs7731657	0.509	rs916956	chr5:130331705	C/G	cg08523029	chr5:130500466	HINT1	-0.46	-5.91	-0.31	8.53e-9	Fasting plasma glucose;
CRC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-11.07	-0.52	2.09e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.64e-15	Menopause (age at onset);
CRC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg04607235	chr12:12878440	APOLD1	-1.01	-13.6	-0.6	1e-33	Lymphocyte counts;
CRC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.66	-0.3	3.24e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.72	-0.43	1.39e-16	Bipolar disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10706266	chr8:66546233	ARMC1	0.4	6.09	0.32	3.1e-9	Schizophrenia;
CRC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.02	10.13	0.49	3.7e-21	Opioid sensitivity;
CRC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.59	8.97	0.44	2.22e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.63	-10.0	-0.48	9.58e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg24308560	chr3:49941425	MST1R	-0.43	-6.13	-0.32	2.53e-9	Resting heart rate;
CRC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.47	6.02	0.31	4.72e-9	Obesity-related traits;
CRC	cis	rs365302	0.951	rs1762101	chr6:159643992	G/A	cg14500486	chr6:159655392	FNDC1	0.44	6.71	0.35	8.4e-11	Coronary heart disease;
CRC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs7546094	1.000	rs7415820	chr1:113169449	G/A	cg22162597	chr1:113214053	CAPZA1	-0.43	-5.88	-0.31	1.01e-8	Platelet distribution width;
CRC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-9.02	-0.45	1.65e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	0.92	9.75	0.47	6.75e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17779707	chr20:48807327	CEBPB	0.43	6.1	0.32	2.91e-9	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.72	11.06	0.52	2.22e-24	Corneal astigmatism;
CRC	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg14515779	chr1:101123966	NA	-0.35	-6.13	-0.32	2.49e-9	Monocyte count;
CRC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.81	-12.63	-0.57	4.36e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.73	-7.57	-0.39	3.81e-13	Non-glioblastoma glioma;Glioma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08089031	chr6:139456240	HECA	0.38	6.17	0.32	2.05e-9	Obesity-related traits;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12564526	chr7:66767603	PMS2L4;STAG3L4	0.38	6.21	0.32	1.61e-9	Obesity-related traits;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg11843238	chr5:131593191	PDLIM4	0.43	7.3	0.37	2.17e-12	Breast cancer;
CRC	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg25834613	chr7:1915315	MAD1L1	-0.42	-5.85	-0.31	1.19e-8	Neuroticism;
CRC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg01216370	chr2:228736459	WDR69	-0.45	-5.77	-0.3	1.85e-8	Blood pressure;
CRC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.27	0.33	1.14e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7259376	0.807	rs6511348	chr19:22557374	G/A	cg02657401	chr19:22469223	NA	-0.33	-7.01	-0.36	1.37e-11	Menopause (age at onset);
CRC	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.46	-7.09	-0.36	8.38e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.92	0.4	3.64e-14	Lung cancer;
CRC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.41e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg03469862	chr11:68924853	NA	0.45	5.74	0.3	2.17e-8	Blond vs. brown hair color;
CRC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-6.72	-0.35	7.86e-11	Alzheimer's disease (late onset);
CRC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.06	-0.32	3.7e-9	Menopause (age at onset);
CRC	cis	rs965469	1.000	rs6051713	chr20:3265779	C/T	cg25506879	chr20:3388711	C20orf194	0.37	5.63	0.3	3.88e-8	IFN-related cytopenia;
CRC	cis	rs6741819	0.654	rs771259	chr2:7123961	A/G	cg27144453	chr2:7172511	RNF144A	-0.4	-5.87	-0.31	1.06e-8	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.66	11.89	0.55	2.29e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.36	5.71	0.3	2.56e-8	Height;
CRC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg03623178	chr6:28175578	NA	0.79	6.61	0.34	1.56e-10	Depression;
CRC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.53	-6.2	-0.32	1.73e-9	Coronary artery calcification;
CRC	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.62	-9.91	-0.48	2e-20	Breast cancer;
CRC	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.68	0.3	2.98e-8	Prudent dietary pattern;
CRC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.47	6.48	0.34	3.32e-10	Alcohol dependence;
CRC	cis	rs10068717	1	rs10068717	chr5:141494934	C/T	cg07392085	chr5:141489673	NDFIP1	0.47	7.46	0.38	7.85e-13	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg02725872	chr8:58115012	NA	-0.44	-6.77	-0.35	5.86e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7849270	1.000	rs3124510	chr9:131899690	C/T	cg13538475	chr9:131942899	NA	0.33	6.37	0.33	6.28e-10	Blood metabolite ratios;
CRC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg16606324	chr3:10149918	C3orf24	0.6	8.14	0.41	8.28e-15	Alzheimer's disease;
CRC	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg07322936	chr10:88137208	NA	-0.6	-7.97	-0.4	2.64e-14	Migraine without aura;
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.78	0.35	5.57e-11	Alzheimer's disease;
CRC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.51	-7.2	-0.37	4.03e-12	Alzheimer's disease (late onset);
CRC	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.47	-0.42	8.03e-16	Hypospadias;
CRC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.42	0.62	7.31e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg13628971	chr7:2884303	GNA12	0.39	6.08	0.32	3.3e-9	Height;
CRC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06505273	chr16:24850292	NA	-0.38	-5.97	-0.31	6.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.81	0.4	7.71e-14	Height;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Depression;
CRC	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg25797454	chr6:150327115	RAET1K	0.36	6.18	0.32	1.94e-9	Alopecia areata;
CRC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.76	-0.47	6.35e-20	Height;
CRC	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.58	7.43	0.38	9.74e-13	Coronary artery disease;
CRC	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg14254433	chr6:34482411	PACSIN1	-0.67	-6.48	-0.34	3.41e-10	Chronic lymphocytic leukemia;
CRC	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg22482690	chr17:47019901	SNF8	0.48	8.12	0.41	9.53e-15	Type 2 diabetes;
CRC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.56	8.28	0.42	3.11e-15	Obesity-related traits;
CRC	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg12560992	chr17:57184187	TRIM37	0.53	6.15	0.32	2.28e-9	Vitamin D levels;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.08	-0.36	8.77e-12	Lymphocyte counts;
CRC	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg21851534	chr17:3907994	ZZEF1	0.37	6.29	0.33	9.89e-10	Type 2 diabetes;
CRC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.93	14.38	0.62	1.01e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.42	6.47	0.34	3.6e-10	Recombination rate (males);
CRC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.91	9.37	0.46	1.21e-18	Intelligence (multi-trait analysis);
CRC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs3850699	0.683	rs67646802	chr10:104303748	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.08	0.32	3.27e-9	Prostate cancer;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.62	9.11	0.45	8.14e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.94	-0.36	2.04e-11	Lung cancer;
CRC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg16486109	chr11:613632	IRF7	0.59	10.51	0.5	1.82e-22	Systemic lupus erythematosus;
CRC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.56	-9.67	-0.47	1.28e-19	Body mass index;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg22687807	chr8:143858763	LYNX1	0.49	8.78	0.44	8.82e-17	Urinary tract infection frequency;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23307708	chr5:133561976	PPP2CA	0.38	6.5	0.34	2.98e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11310629	chr13:45991975	SLC25A30	-0.52	-6.42	-0.33	4.72e-10	Diisocyanate-induced asthma;
CRC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.57	-6.11	-0.32	2.8e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12463550	chr7:65579703	CRCP	0.69	6.4	0.33	5.42e-10	Diabetic kidney disease;
CRC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	6.27	0.33	1.15e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.11e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg21620606	chr4:1342894	KIAA1530	-0.43	-6.63	-0.34	1.39e-10	Obesity-related traits;
CRC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-8.66	-0.43	2.12e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4903604	0.505	rs11623595	chr14:78037547	A/G	cg18872420	chr14:78023429	SPTLC2	0.35	6.04	0.32	4.08e-9	Gut microbiome composition (winter);
CRC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.55	8.91	0.44	3.49e-17	Intelligence (multi-trait analysis);
CRC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg09127314	chr1:152161683	NA	0.51	6.52	0.34	2.66e-10	Atopic dermatitis;
CRC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.77	0.47	5.8e-20	Bladder cancer;
CRC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.91	-11.76	-0.54	6.85e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.55	0.38	4.27e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg15845792	chr6:28175446	NA	0.46	6.32	0.33	8.72e-10	Depression;
CRC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg16989086	chr20:62203971	PRIC285	0.51	6.41	0.33	5.08e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.4	-5.7	-0.3	2.63e-8	Daytime sleep phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17727855	chr9:108007124	SLC44A1	0.37	6.06	0.32	3.76e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg06470822	chr6:28175283	NA	0.83	9.33	0.46	1.6e-18	Parkinson's disease;
CRC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.05	-0.41	1.49e-14	Coronary artery disease;
CRC	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg15654264	chr1:150340011	RPRD2	0.43	6.44	0.33	4.32e-10	Migraine;
CRC	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg18455616	chr2:99124870	INPP4A	0.34	5.72	0.3	2.41e-8	Bipolar disorder;
CRC	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.1	-0.36	7.86e-12	Body mass index;
CRC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.65	-10.88	-0.51	9.56e-24	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-1.17	-10.51	-0.5	1.87e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.86	-8.09	-0.41	1.15e-14	IgG glycosylation;
CRC	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg13491945	chr12:107078410	RFX4	0.35	6.02	0.31	4.68e-9	Heart rate;
CRC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.67	-0.39	1.98e-13	Alzheimer's disease;
CRC	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.35	-5.66	-0.3	3.21e-8	Cognitive function;
CRC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg15382696	chr6:118971807	C6orf204	0.56	6.86	0.35	3.34e-11	Diastolic blood pressure;
CRC	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	1.05	9.96	0.48	1.29e-20	Post bronchodilator FEV1;
CRC	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg20487152	chr13:99095054	FARP1	0.35	5.71	0.3	2.57e-8	Longevity;
CRC	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	6.8	0.35	4.96e-11	Lymphocyte counts;
CRC	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg09473613	chr1:24152604	HMGCL	0.35	5.76	0.3	1.97e-8	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
CRC	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.92	15.32	0.65	2.38e-40	Dupuytren's disease;
CRC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	7.36	0.38	1.5e-12	Breast cancer;
CRC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.69	-10.08	-0.49	5.32e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-14.56	-0.63	2.12e-37	Coronary artery disease;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg06470822	chr6:28175283	NA	0.87	13.71	0.6	3.75e-34	Cardiac Troponin-T levels;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.81	-15.15	-0.64	1.05e-39	Paraoxonase activity;
CRC	cis	rs6834538	0.501	rs2171278	chr4:113416438	G/A	cg10021238	chr4:113569128	MIR367;LARP7	-0.36	-5.65	-0.3	3.55e-8	Free thyroxine concentration;
CRC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.67	-10.75	-0.51	2.75e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg02033258	chr5:131593261	PDLIM4	0.35	6.76	0.35	6.28e-11	Blood metabolite levels;
CRC	trans	rs2055729	0.710	rs6981023	chr8:9746585	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.68	-0.35	1.04e-10	Multiple myeloma (hyperdiploidy);
CRC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg16558177	chr4:4109446	NA	-0.56	-6.52	-0.34	2.73e-10	Blood pressure (smoking interaction);
CRC	cis	rs4690686	0.538	rs10520346	chr4:177259088	C/G	cg17059388	chr4:177262070	NA	0.38	5.71	0.3	2.52e-8	Essential tremor;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg12273811	chr6:28175739	NA	0.55	7.67	0.39	1.92e-13	Parkinson's disease;
CRC	trans	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg10756647	chr7:56101905	PSPH	0.79	8.21	0.41	5.15e-15	Diabetic kidney disease;
CRC	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg00646200	chr1:148855367	NA	0.33	5.96	0.31	6.45e-9	Hip geometry;
CRC	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.62	10.55	0.5	1.36e-22	Prostate cancer;
CRC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg18230493	chr5:56204884	C5orf35	-0.39	-5.83	-0.31	1.34e-8	Coronary artery disease;
CRC	trans	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.63	0.34	1.35e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1572438	0.760	rs7766707	chr6:869501	C/T	cg13447295	chr6:887704	NA	-0.49	-7.11	-0.36	7.39e-12	Aging;
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-9.04	-0.45	1.34e-17	Bone mineral density;
CRC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.52	-7.76	-0.39	1.1e-13	Calcium levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00838250	chr3:186287958	TBCCD1;DNAJB11	0.48	6.25	0.33	1.27e-9	Thyroid stimulating hormone;
CRC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.4	-0.33	5.3e-10	Obesity-related traits;
CRC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.99	18.14	0.71	1.87e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.91	17.34	0.69	2.78e-48	Blood protein levels;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs11203032	0.901	rs4073283	chr10:90958000	G/C	cg16672925	chr10:90967113	CH25H	0.46	5.75	0.3	2.05e-8	Heart failure;
CRC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.48	9.1	0.45	8.59e-18	Huntington's disease progression;
CRC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.56	8.48	0.42	7.99e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-6.56	-0.34	2.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.04	14.5	0.62	3.49e-37	Exhaled nitric oxide output;
CRC	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.54	5.81	0.3	1.49e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07538248	chr1:95699815	RWDD3	0.56	6.01	0.31	4.96e-9	Interleukin-4 levels;
CRC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	6.56	0.34	2.03e-10	Schizophrenia;
CRC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.78e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.4	-7.7	-0.39	1.62e-13	Intelligence (multi-trait analysis);
CRC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg18230493	chr5:56204884	C5orf35	-0.4	-5.67	-0.3	3.14e-8	Coronary artery disease;
CRC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg12311346	chr5:56204834	C5orf35	-0.53	-8.06	-0.41	1.47e-14	Coronary artery disease;
CRC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg27661571	chr11:113659931	NA	-0.48	-6.11	-0.32	2.87e-9	Hip circumference adjusted for BMI;
CRC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.6	7.05	0.36	1.07e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.73	-13.5	-0.6	2.45e-33	Leprosy;
CRC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.28e-25	Prostate cancer;
CRC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.53	7.86	0.4	5.39e-14	Tuberculosis;
CRC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.62	10.39	0.5	4.69e-22	Colorectal cancer;
CRC	cis	rs55788414	1.000	rs35667589	chr16:81180829	A/T	cg06400318	chr16:81190750	PKD1L2	-0.66	-6.45	-0.33	4.06e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03526776	chr6:41159608	TREML2	0.41	6.96	0.36	1.79e-11	Alzheimer's disease (late onset);
CRC	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg16898833	chr6:26189333	HIST1H4D	0.68	6.1	0.32	2.96e-9	Breast cancer;
CRC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg24977027	chr2:88469347	THNSL2	0.58	6.54	0.34	2.29e-10	Plasma clusterin levels;
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.74	9.29	0.46	2.1e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.44	5.83	0.31	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg01426195	chr3:39028469	NA	-0.53	-8.56	-0.43	4.38e-16	Handedness;
CRC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.38	-6.64	-0.34	1.27e-10	Schizophrenia;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg15786705	chr6:28176104	NA	0.55	7.28	0.37	2.48e-12	Parkinson's disease;
CRC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.39	-0.53	1.52e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg18972013	chr17:78078605	GAA	-0.41	-5.92	-0.31	8.23e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg12311346	chr5:56204834	C5orf35	-0.47	-7.04	-0.36	1.15e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg20750642	chr13:99100586	FARP1	0.4	6.16	0.32	2.09e-9	Educational attainment (years of education);
CRC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.19	0.32	1.78e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02757696	chr20:33104113	DYNLRB1	0.48	6.82	0.35	4.44e-11	Response to antipsychotic treatment;
CRC	cis	rs6445967	1.000	rs6786088	chr3:58315075	T/C	cg23715586	chr3:58305044	RPP14	0.37	6.21	0.32	1.56e-9	Platelet count;
CRC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.42e-13	Schizophrenia;
CRC	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.4	5.7	0.3	2.6e-8	Axial length;
CRC	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg11900509	chr10:81946545	ANXA11	-0.72	-7.23	-0.37	3.46e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00495681	chr13:53174319	NA	0.64	9.69	0.47	1.1e-19	Lewy body disease;
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.5	-6.88	-0.35	3.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg12273811	chr6:28175739	NA	0.56	7.9	0.4	4.35e-14	Parkinson's disease;
CRC	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.41	6.42	0.33	4.72e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	9.07e-12	Putamen volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09672230	chr9:128024003	GAPVD1	0.47	6.51	0.34	2.73e-10	Response to antipsychotic treatment;
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg07404485	chr7:94953653	PON1	-0.45	-5.92	-0.31	7.97e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.52	-8.28	-0.42	3.22e-15	Red blood cell count;
CRC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.43	6.32	0.33	8.57e-10	Type 2 diabetes;
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11645453	chr3:52864694	ITIH4	0.33	5.97	0.31	6.18e-9	Bipolar disorder;
CRC	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.83	11.22	0.53	5.81e-25	IgG glycosylation;
CRC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.71	9.34	0.46	1.49e-18	High light scatter reticulocyte count;
CRC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg21194808	chr1:2205498	SKI	0.39	6.07	0.32	3.59e-9	Height;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs800082	0.516	rs1178892	chr3:144238173	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.22	0.32	1.48e-9	Smoking behavior;
CRC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg27661571	chr11:113659931	NA	-0.76	-9.53	-0.47	3.57e-19	Hip circumference adjusted for BMI;
CRC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.44	-7.04	-0.36	1.11e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.66	9.64	0.47	1.55e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg13073564	chr4:8508604	NA	0.41	6.06	0.32	3.76e-9	Response to antineoplastic agents;
CRC	cis	rs7487075	0.619	rs7959731	chr12:46839657	A/C	cg22049899	chr12:47219821	SLC38A4	-0.31	-5.74	-0.3	2.21e-8	Itch intensity from mosquito bite;
CRC	cis	rs939584	0.935	rs7567710	chr2:645372	T/G	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.64	-0.51	6.63e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6586163	1.000	rs7072828	chr10:90754953	T/G	cg13456138	chr10:90753195	FAS	-0.43	-6.6	-0.34	1.65e-10	Chronic lymphocytic leukemia;
CRC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.68	9.11	0.45	8.27e-18	Platelet count;
CRC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.57	-10.63	-0.51	7.22e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.79	-0.35	5.29e-11	Alcohol dependence;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.51	-8.45	-0.42	9.25e-16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg04774096	chr14:31676207	HECTD1	0.6	6.19	0.32	1.82e-9	Airway imaging phenotypes;
CRC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.09	-18.62	-0.72	2.35e-53	Ulcerative colitis;
CRC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.63	8.69	0.43	1.69e-16	Platelet count;
CRC	cis	rs9462027	0.606	rs3777752	chr6:34772212	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.47e-9	Systemic lupus erythematosus;
CRC	cis	rs4363385	0.934	rs6667418	chr1:152969685	A/G	cg25856811	chr1:152973957	SPRR3	-0.22	-5.67	-0.3	3.21e-8	Inflammatory skin disease;
CRC	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.84	-0.31	1.22e-8	Type 2 diabetes;
CRC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.25	0.33	1.28e-9	Rheumatoid arthritis;
CRC	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.28e-36	Hypertriglyceridemia;
CRC	cis	rs2336384	1.000	rs61776516	chr1:12047028	T/C	cg13216073	chr1:12042593	MFN2	0.49	7.12	0.37	6.82e-12	Platelet count;
CRC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.3	-0.46	2.01e-18	Intelligence (multi-trait analysis);
CRC	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg25019722	chr6:37503610	NA	-0.5	-9.29	-0.46	2.17e-18	Cognitive performance;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04880052	chr2:219191631	PNKD	-0.43	-6.94	-0.36	2.09e-11	Colorectal cancer;
CRC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02290350	chr8:58132656	NA	-0.44	-6.58	-0.34	1.91e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.44	-6.59	-0.34	1.71e-10	Ulcerative colitis;
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.64	0.3	3.64e-8	Prudent dietary pattern;
CRC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.53	5.99	0.31	5.62e-9	Vitiligo;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03328750	chr5:142150401	ARHGAP26	0.43	6.02	0.31	4.62e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14478806	chr15:80351979	ZFAND6	0.42	6.49	0.34	3.13e-10	Schizophrenia;
CRC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.64	-8.03	-0.4	1.76e-14	Iron status biomarkers;
CRC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.32	-0.53	2.52e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.0	0.36	1.47e-11	Colorectal cancer;
CRC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.34	6.35	0.33	6.96e-10	QRS complex (12-leadsum);
CRC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	6.07	0.32	3.45e-9	Schizophrenia;
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.68	-9.07	-0.45	1.11e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20650861	chr18:72264895	LOC400657	0.43	6.42	0.33	4.7e-10	Response to antipsychotic treatment;
CRC	trans	rs225245	0.531	rs321609	chr17:33880676	G/T	cg19694781	chr19:47549865	TMEM160	-0.53	-8.0	-0.4	2.1e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.65	-0.39	2.17e-13	Height;
CRC	cis	rs10512697	0.655	rs71594952	chr5:3457718	T/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.42	-6.45	-0.34	3.99e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.13	0.56	3.12e-28	Menopause (age at onset);
CRC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.47	0.38	7.38e-13	Lung cancer;
CRC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.37	-7.59	-0.39	3.26e-13	Renal cell carcinoma;
CRC	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.57	-9.18	-0.45	4.95e-18	Neuroticism;
CRC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.2	-0.32	1.7e-9	Arsenic metabolism;
CRC	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg25019722	chr6:37503610	NA	-0.41	-6.82	-0.35	4.47e-11	Cognitive performance;
CRC	cis	rs4363385	0.782	rs310126	chr1:153019416	A/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.32	-0.37	1.95e-12	Inflammatory skin disease;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.25	-0.37	2.99e-12	Height;
CRC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs7945718	0.591	rs10831892	chr11:12676272	T/A	cg25843174	chr11:12811716	TEAD1	0.39	7.07	0.36	9.43e-12	Educational attainment (years of education);
CRC	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg23229984	chr5:148520753	ABLIM3	0.5	6.82	0.35	4.28e-11	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21887597	chr15:83419354	NA	0.44	6.36	0.33	6.72e-10	Response to antipsychotic treatment;
CRC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.7	11.26	0.53	4.18e-25	Squamous cell carcinoma;
CRC	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg17456097	chr1:26900765	RPS6KA1	0.43	6.48	0.34	3.25e-10	Glucose homeostasis traits;
CRC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.19	0.45	4.41e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6504622	0.517	rs11656362	chr17:45036255	C/G	cg16759221	chr17:45003025	GOSR2	-0.72	-11.37	-0.53	1.8e-25	Orofacial clefts;
CRC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.68	6.75	0.35	6.71e-11	Diabetic retinopathy;
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.63	8.29	0.42	2.84e-15	Alzheimer's disease;
CRC	trans	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg10756647	chr7:56101905	PSPH	0.7	7.33	0.37	1.85e-12	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6589219	0.954	rs3802841	chr11:111171672	G/T	cg25129781	chr11:111156908	C11orf53	-0.31	-5.77	-0.3	1.82e-8	Colorectal cancer;
CRC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-10.89	-0.51	8.94e-24	Total cholesterol levels;
CRC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04317338	chr11:64019027	PLCB3	-0.41	-5.96	-0.31	6.47e-9	Platelet count;
CRC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.68	10.35	0.5	6.24e-22	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17496447	chr4:144435124	SMARCA5	0.49	7.0	0.36	1.48e-11	Anxiety disorder;
CRC	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.61	7.93	0.4	3.43e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4523957	0.928	rs4790072	chr17:2173497	A/G	cg16513277	chr17:2031491	SMG6	-0.55	-9.44	-0.46	6.96e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.13	-0.37	6.26e-12	Height;
CRC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-7.11	-0.37	7.1e-12	Colorectal cancer;
CRC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-15.51	-0.65	4.14e-41	Refractive error;
CRC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.46	6.95	0.36	1.96e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.1	-0.41	1.1e-14	Electroencephalogram traits;
CRC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg24011408	chr12:48396354	COL2A1	0.41	5.87	0.31	1.04e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg16989719	chr2:238392110	NA	-0.36	-5.71	-0.3	2.57e-8	Prostate cancer;
CRC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.35	-0.56	4.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25628243	chr3:196295415	WDR53;FBXO45	0.41	6.28	0.33	1.1e-9	Schizophrenia;
CRC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.58	7.73	0.39	1.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg07617317	chr6:118971624	C6orf204	-0.47	-5.93	-0.31	7.7e-9	Diastolic blood pressure;
CRC	trans	rs7821565	0.904	rs67153919	chr8:52165801	C/G	cg09187163	chr7:72721838	NSUN5	-0.41	-5.98	-0.31	5.79e-9	Tuberculosis;
CRC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg11833968	chr6:79620685	NA	-0.36	-6.13	-0.32	2.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.92	-0.36	2.41e-11	IgG glycosylation;
CRC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.66	-0.39	2.04e-13	Vitiligo;
CRC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.06	0.41	1.43e-14	Cystic fibrosis severity;
CRC	cis	rs58649573	0.509	rs4838093	chr9:126788876	G/T	cg14112217	chr9:126806003	NA	0.41	6.05	0.32	3.99e-9	Post-traumatic stress disorder;
CRC	cis	rs2745967	0.818	rs11579568	chr1:208130627	A/C	cg09788693	chr1:208063733	CD34	0.39	5.86	0.31	1.13e-8	Resting heart rate;
CRC	cis	rs61996546	0.595	rs2315906	chr15:26867573	A/G	cg15066197	chr15:26874202	GABRB3	-0.39	-5.99	-0.31	5.37e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.94	0.4	3.26e-14	Height;
CRC	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.53	-7.83	-0.4	6.8e-14	Coronary artery disease;
CRC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.2	-0.41	5.63e-15	Schizophrenia;
CRC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.98	12.1	0.55	3.94e-28	Eosinophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16924120	chr12:118814149	SUDS3	0.47	6.75	0.35	6.56e-11	Response to antipsychotic treatment;
CRC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.73	10.63	0.51	6.87e-23	Breast cancer;
CRC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg14541582	chr5:601475	NA	-0.36	-7.29	-0.37	2.3e-12	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.78	-0.72	5.61e-54	Height;
CRC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.79	0.3	1.69e-8	Lung cancer;
CRC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.36	0.75	3.43e-60	Prudent dietary pattern;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg03623178	chr6:28175578	NA	0.95	12.46	0.57	1.93e-29	Depression;
CRC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	1.97e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs2530545	0.671	rs2067575	chr7:34666534	A/G	cg14401837	chr7:34697493	NPSR1	-0.52	-5.81	-0.31	1.44e-8	IgG glycosylation;
CRC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02290350	chr8:58132656	NA	-0.44	-6.39	-0.33	5.52e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.7	11.41	0.53	1.22e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.52	0.34	2.71e-10	Life satisfaction;
CRC	cis	rs9648716	1.000	rs57248447	chr7:140573495	G/A	cg10747023	chr7:140774559	NA	0.45	5.82	0.31	1.36e-8	Type 2 diabetes;
CRC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.07	0.52	2.02e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	1.04	18.72	0.72	9.87e-54	Parkinson's disease;
CRC	cis	rs727505	0.583	rs17147421	chr7:124383948	C/T	cg23710748	chr7:124431027	NA	-0.61	-9.75	-0.47	6.51e-20	Lewy body disease;
CRC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg11212589	chr17:38028394	ZPBP2	0.43	8.03	0.4	1.71e-14	Self-reported allergy;
CRC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.4	-5.96	-0.31	6.55e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.66	-0.34	1.16e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg03609598	chr5:56110824	MAP3K1	0.55	6.56	0.34	2.13e-10	Initial pursuit acceleration;
CRC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.88	11.07	0.52	2.05e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.62	-0.34	1.44e-10	Menopause (age at onset);
CRC	trans	rs1864729	1.000	rs2439702	chr8:98272647	C/T	cg08679828	chr8:102218111	ZNF706	-0.62	-7.46	-0.38	7.69e-13	Estradiol plasma levels (breast cancer);
CRC	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.61	-0.39	2.86e-13	QT interval;
CRC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	7.27	0.37	2.7e-12	Platelet count;
CRC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg00769240	chr8:12517080	NA	-0.58	-6.84	-0.35	3.99e-11	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15087520	chr3:187871600	LPP	0.44	6.06	0.32	3.82e-9	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.69	0.47	1.04e-19	Lung cancer;
CRC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-0.87	-13.4	-0.59	5.64e-33	Platelet distribution width;
CRC	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.52	8.75	0.43	1.14e-16	Dupuytren's disease;
CRC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-11.7	-0.54	1.17e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21643547	chr1:205240462	TMCC2	-0.37	-5.95	-0.31	6.98e-9	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg10756647	chr7:56101905	PSPH	0.69	7.1	0.36	7.8e-12	Diabetic kidney disease;
CRC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg05192639	chr6:26864778	GUSBL1	0.34	6.17	0.32	2.05e-9	Schizophrenia;
CRC	cis	rs447	1.000	rs10261415	chr7:83760881	G/T	cg22846510	chr7:83753280	SEMA3A	-0.58	-7.73	-0.39	1.29e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.45	9.04	0.45	1.42e-17	Hand grip strength;
CRC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.81	-0.4	7.67e-14	Arsenic metabolism;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.83	-14.61	-0.63	1.32e-37	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg00734567	chr1:86172782	ZNHIT6	-0.38	-6.0	-0.31	5.1e-9	Urate levels in overweight individuals;
CRC	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg14003231	chr6:33640908	ITPR3	0.51	8.37	0.42	1.73e-15	Plateletcrit;
CRC	cis	rs10512697	0.803	rs11747645	chr5:3576820	A/G	cg19473799	chr5:3511975	NA	0.71	5.71	0.3	2.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.93	0.52	6.15e-24	Prudent dietary pattern;
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.45	6.31	0.33	8.79e-10	Parkinson's disease;
CRC	cis	rs4889855	0.556	rs4890040	chr17:78518408	G/A	cg16591659	chr17:78472290	NA	0.37	5.67	0.3	3.14e-8	Fractional excretion of uric acid;
CRC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs3902035	0.964	rs17349301	chr6:119002581	A/T	cg01339444	chr6:118972232	C6orf204	-0.46	-5.86	-0.31	1.11e-8	QT interval;
CRC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.14	-0.32	2.34e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.33	-6.21	-0.32	1.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10822145	1	rs10822145	chr10:64934548	C/T	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.63	-0.3	3.87e-8	Triglycerides;
CRC	cis	rs6066835	0.572	rs6125413	chr20:47257145	G/A	cg18078177	chr20:47281410	PREX1	0.78	5.96	0.31	6.37e-9	Multiple myeloma;
CRC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-5.98	-0.31	5.71e-9	Retinal vascular caliber;
CRC	cis	rs939584	0.935	rs7571957	chr2:646803	T/C	cg03610516	chr2:642275	NA	0.41	5.74	0.3	2.18e-8	Body mass index;
CRC	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg14003231	chr6:33640908	ITPR3	0.45	7.47	0.38	7.28e-13	Plateletcrit;
CRC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	trans	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg10756647	chr7:56101905	PSPH	0.73	7.94	0.4	3.18e-14	Diabetic kidney disease;
CRC	cis	rs863345	0.604	rs10908666	chr1:158500098	G/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.24	-0.33	1.35e-9	Pneumococcal bacteremia;
CRC	cis	rs2421770	0.530	rs4755396	chr11:35370624	G/A	cg13971030	chr11:35366721	SLC1A2	-0.37	-6.42	-0.33	4.85e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg03006477	chr6:74432658	CD109	0.38	6.73	0.35	7.77e-11	Blood protein levels;Calcium levels;
CRC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.54	-7.69	-0.39	1.73e-13	Aortic root size;
CRC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.27	0.37	2.71e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg14631576	chr9:95140430	CENPP	-0.3	-5.63	-0.3	3.78e-8	Height;
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	trans	rs800082	0.516	rs1726545	chr3:144244807	T/A	cg24215973	chr2:240111563	HDAC4	0.46	6.54	0.34	2.3e-10	Smoking behavior;
CRC	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.55	-0.34	2.17e-10	Metabolic traits;
CRC	cis	rs1223397	0.589	rs364493	chr6:13297020	C/T	cg20827128	chr6:13274284	PHACTR1	-0.45	-6.54	-0.34	2.35e-10	Blood pressure;
CRC	trans	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg18335740	chr13:41363409	SLC25A15	-0.63	-10.36	-0.5	5.97e-22	Lewy body disease;
CRC	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07165851	chr6:158734300	TULP4	0.61	7.72	0.39	1.41e-13	Height;
CRC	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg11887960	chr12:57824829	NA	0.52	6.41	0.33	5.08e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg12072164	chr19:44306565	LYPD5	0.35	5.63	0.3	3.91e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs12541635	1.000	rs1540420	chr8:107088426	C/T	cg10147462	chr8:107024639	NA	-0.37	-6.3	-0.33	9.62e-10	Age of smoking initiation;
CRC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.69	-13.61	-0.6	8.87e-34	Educational attainment;
CRC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.64	-12.01	-0.55	8.56e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.43	6.29	0.33	1.01e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.53	0.38	4.82e-13	Eye color traits;
CRC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.62	9.5	0.46	4.59e-19	Corneal astigmatism;
CRC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg08999081	chr20:33150536	PIGU	0.45	5.79	0.3	1.66e-8	Protein C levels;
CRC	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg24011408	chr12:48396354	COL2A1	0.39	5.66	0.3	3.27e-8	Glycated hemoglobin levels;
CRC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.74	9.21	0.45	3.83e-18	Behavioural disinhibition (generation interaction);
CRC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.25	-0.33	1.3e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10958397	chr10:127511832	BCCIP;UROS	0.48	7.04	0.36	1.16e-11	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.58	-0.6	1.19e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.79	0.44	8.66e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-15.83	-0.66	2.32e-42	Ulcerative colitis;
CRC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.73	8.74	0.43	1.18e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	10.37	0.5	5.49e-22	Bone mineral density;
CRC	trans	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.23e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.77	13.64	0.6	7.11e-34	Oral cavity cancer;
CRC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.5	-7.54	-0.38	4.57e-13	Sudden cardiac arrest;
CRC	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-6.14	-0.32	2.32e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.46	7.12	0.37	6.81e-12	Height;
CRC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg23283495	chr1:209979779	IRF6	0.5	6.95	0.36	2.02e-11	Cleft lip with or without cleft palate;
CRC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	trans	rs7821565	0.904	rs67575264	chr8:52165828	C/T	cg09187163	chr7:72721838	NSUN5	-0.41	-5.98	-0.31	5.79e-9	Tuberculosis;
CRC	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.63	9.55	0.47	3.01e-19	Adiposity;
CRC	cis	rs4494114	0.967	rs6660891	chr1:39319009	C/T	cg25970120	chr1:39325951	RRAGC	-0.44	-5.89	-0.31	9.29e-9	Blood protein levels;
CRC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg16576597	chr16:28551801	NUPR1	0.48	6.9	0.36	2.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.97	0.36	1.77e-11	Morning vs. evening chronotype;
CRC	cis	rs10924970	0.776	rs72758049	chr1:235465045	G/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.89	0.31	9.32e-9	Asthma;
CRC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.72	11.2	0.53	6.93e-25	Tonsillectomy;
CRC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.74	9.49	0.46	4.73e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	6.67	0.35	1.05e-10	Parkinson's disease;
CRC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.42e-9	Red blood cell count;
CRC	cis	rs1223397	0.938	rs17767967	chr6:13282067	C/T	cg00460589	chr6:13274354	PHACTR1	0.49	5.95	0.31	6.68e-9	Blood pressure;
CRC	trans	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.43	-6.33	-0.33	8.04e-10	Monocyte count;
CRC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.34	-5.66	-0.3	3.3e-8	Personality dimensions;
CRC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.58	6.91	0.36	2.45e-11	Bronchopulmonary dysplasia;
CRC	cis	rs2652834	1.000	rs2729781	chr15:63404265	T/A	cg05507819	chr15:63340323	TPM1	0.44	5.61	0.3	4.19e-8	HDL cholesterol;
CRC	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg08501292	chr6:25962987	TRIM38	1.08	9.74	0.47	7.5e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3736485	0.609	rs11631725	chr15:51969474	A/G	cg08986416	chr15:51914746	DMXL2	-0.39	-5.66	-0.3	3.31e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.84	15.86	0.66	1.71e-42	Dental caries;
CRC	cis	rs4908760	0.965	rs12080583	chr1:8524877	G/A	cg20416874	chr1:8611966	RERE	-0.43	-6.09	-0.32	3.2e-9	Vitiligo;
CRC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.53	-8.04	-0.41	1.61e-14	Body mass index;
CRC	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-6.97	-0.36	1.75e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg06896663	chr8:82754093	SNX16	-0.69	-5.96	-0.31	6.54e-9	Cognitive function;
CRC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.4	6.27	0.33	1.13e-9	Height;
CRC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.5	-7.74	-0.39	1.23e-13	Aortic root size;
CRC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg06204229	chr3:52865917	ITIH4	0.48	5.68	0.3	2.93e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.43	-6.64	-0.34	1.28e-10	Height;
CRC	cis	rs2342371	0.756	rs28712197	chr3:196107214	T/C	cg15048948	chr3:196158458	UBXN7	0.51	6.26	0.33	1.18e-9	Fat distribution (HIV);
CRC	cis	rs9308731	0.563	rs6760053	chr2:111932997	C/G	cg04202892	chr2:111875749	ACOXL	0.4	6.26	0.33	1.22e-9	Chronic lymphocytic leukemia;
CRC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Body mass index;
CRC	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.23	-9.95	-0.48	1.45e-20	Mitochondrial DNA levels;
CRC	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg07972458	chr1:204535000	NA	0.37	5.72	0.3	2.36e-8	Schizophrenia;
CRC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.47	-8.17	-0.41	6.78e-15	Dupuytren's disease;
CRC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-0.91	-10.41	-0.5	4.13e-22	Breast cancer;
CRC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.64	-5.84	-0.31	1.28e-8	Diabetic retinopathy;
CRC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.56	8.26	0.41	3.67e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.46	-6.87	-0.35	3.22e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.56	-0.38	4.02e-13	Mean corpuscular volume;
CRC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg00074818	chr8:8560427	CLDN23	0.4	7.27	0.37	2.69e-12	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00286986	chr8:124085360	WDR67	0.42	5.96	0.31	6.39e-9	Response to antipsychotic treatment;
CRC	cis	rs2982552	0.967	rs3020300	chr6:152058844	T/A	cg22157087	chr6:152012887	ESR1	0.39	6.12	0.32	2.66e-9	Bone properties (heel);
CRC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.9	12.27	0.56	9.28e-29	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg15226275	chr6:116381976	FRK	-0.28	-7.96	-0.4	2.8e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg14139581	chr11:64358342	SLC22A12	0.39	6.28	0.33	1.07e-9	Urate levels in obese individuals;
CRC	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.73	-9.83	-0.48	3.7e-20	Blood pressure (smoking interaction);
CRC	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg10437265	chr15:77819839	NA	0.69	12.75	0.57	1.6e-30	Type 2 diabetes;
CRC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg24253500	chr15:84953950	NA	0.38	6.4	0.33	5.33e-10	Schizophrenia;
CRC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg13628971	chr7:2884303	GNA12	0.37	5.67	0.3	3.14e-8	Height;
CRC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.4	7.7	0.39	1.64e-13	Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07582382	chr10:15001273	MEIG1	0.43	6.14	0.32	2.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24167897	chr15:63796719	USP3	0.4	6.1	0.32	2.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7259376	0.936	rs58170323	chr19:22539115	T/C	cg02657401	chr19:22469223	NA	-0.34	-7.62	-0.39	2.73e-13	Menopause (age at onset);
CRC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.8	-0.35	5.03e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2625529	0.689	rs12898728	chr15:72112853	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.71	-0.35	8.58e-11	Red blood cell count;
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg10729496	chr3:10149963	C3orf24	0.49	6.34	0.33	7.69e-10	Alzheimer's disease;
CRC	trans	rs1973993	0.651	rs60776572	chr1:96960121	C/T	cg10631902	chr5:14652156	NA	-0.42	-7.03	-0.36	1.18e-11	Weight;
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs6662572	0.703	rs55641506	chr1:46580708	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.3	0.33	9.58e-10	Blood protein levels;
CRC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.54	0.47	3.27e-19	Lymphocyte counts;
CRC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-6.65	-0.34	1.24e-10	Diastolic blood pressure;
CRC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.89	9.19	0.45	4.58e-18	Arsenic metabolism;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18297960	chr7:1142765	C7orf50	-0.44	-6.12	-0.32	2.61e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.44	6.2	0.32	1.65e-9	Cognitive ability;
CRC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg03013999	chr17:37608204	MED1	0.45	6.97	0.36	1.69e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.81	0.31	1.47e-8	Hemoglobin concentration;
CRC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.11	-28.25	-0.84	5.42e-90	Testicular germ cell tumor;
CRC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.39	5.98	0.31	5.67e-9	Crohn's disease;
CRC	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.7	0.47	9.94e-20	Blood protein levels;
CRC	cis	rs6743376	0.556	rs2251876	chr2:113818727	A/G	cg24553058	chr2:113831203	IL1F10	0.39	6.56	0.34	2.15e-10	Inflammatory biomarkers;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg03623178	chr6:28175578	NA	0.96	12.41	0.56	2.85e-29	Depression;
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg00280220	chr17:61926910	NA	0.34	5.61	0.3	4.22e-8	Prudent dietary pattern;
CRC	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.37	0.5	5.64e-22	Corneal astigmatism;
CRC	cis	rs698833	0.892	rs786418	chr2:44688413	C/T	cg04920474	chr2:44395004	PPM1B	0.41	5.98	0.31	5.86e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.22	15.04	0.64	2.8e-39	Uric acid levels;
CRC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.13	-0.41	9.03e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7300001	0.596	rs11064924	chr12:110510301	G/T	cg12870014	chr12:110450643	ANKRD13A	0.86	8.88	0.44	4.53e-17	Headache;
CRC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.78	11.51	0.54	5.56e-26	Intelligence (multi-trait analysis);
CRC	cis	rs7827545	0.545	rs6998092	chr8:135557449	A/G	cg17885191	chr8:135476712	NA	0.65	7.55	0.38	4.28e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.7	-8.1	-0.41	1.05e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg08817983	chr4:3391423	RGS12	-0.45	-6.44	-0.33	4.27e-10	Blood protein levels;
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.56	7.02	0.36	1.25e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.53	7.15	0.37	5.54e-12	Alzheimer's disease;
CRC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.24	0.37	3.17e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18899730	chr10:74057705	NA	0.38	6.02	0.31	4.58e-9	Interleukin-6 levels;
CRC	cis	rs282587	0.597	rs438116	chr13:113392149	G/C	cg04656015	chr13:113407548	ATP11A	0.61	7.47	0.38	7.3e-13	Glycated hemoglobin levels;
CRC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.52	-6.48	-0.34	3.39e-10	Colorectal cancer;
CRC	cis	rs2302190	0.941	rs6503865	chr17:56549672	A/C	cg12560992	chr17:57184187	TRIM37	0.5	5.93	0.31	7.77e-9	Vitamin D levels;
CRC	cis	rs7605827	0.930	rs11893253	chr2:15606618	A/G	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs10392	0.516	rs4141892	chr20:37590758	T/C	cg27552599	chr20:37590471	DHX35	0.38	6.05	0.32	3.94e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.89	-0.31	9.49e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09272629	chr14:78174293	ALKBH1;C14orf156	-0.42	-6.29	-0.33	9.99e-10	Myopia (pathological);
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg20512303	chr5:131592959	PDLIM4	0.4	6.72	0.35	7.95e-11	Breast cancer;
CRC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.98	-17.96	-0.7	9.63e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.48	7.71	0.39	1.49e-13	Schizophrenia;
CRC	cis	rs3772130	1.000	rs11719458	chr3:121382005	C/T	cg20356878	chr3:121714668	ILDR1	0.5	7.69	0.39	1.74e-13	Cognitive performance;
CRC	trans	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06834434	chr14:75079333	LTBP2	0.55	6.82	0.35	4.44e-11	Obesity-related traits;
CRC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.69	0.63	6.35e-38	Lymphocyte percentage of white cells;
CRC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg21115391	chr11:93143810	CCDC67	-0.39	-5.68	-0.3	2.94e-8	Pulmonary function decline;
CRC	cis	rs9463078	0.715	rs9296455	chr6:45236781	G/A	cg25276700	chr6:44698697	NA	-0.24	-5.88	-0.31	9.9e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg22687807	chr8:143858763	LYNX1	-0.45	-7.44	-0.38	9.07e-13	Urinary tract infection frequency;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05621273	chr16:81070150	ATMIN	0.48	6.2	0.32	1.71e-9	Thyroid stimulating hormone;
CRC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg24130564	chr14:104152367	KLC1	-0.44	-6.52	-0.34	2.68e-10	Body mass index;
CRC	cis	rs501120	0.584	rs11238935	chr10:44714402	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg04025307	chr7:1156635	C7orf50	0.62	6.48	0.34	3.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs711830	0.965	rs2072590	chr2:177042633	A/C	cg13092806	chr2:177043255	NA	0.73	9.28	0.46	2.36e-18	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs7333181	0.649	rs2027428	chr13:112228836	G/A	cg27543320	chr13:112200689	NA	-0.56	-9.48	-0.46	5.43e-19	Menopause (age at onset);
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.59	7.95	0.4	2.94e-14	Alzheimer's disease;
CRC	cis	rs3849570	0.555	rs9968070	chr3:82010368	G/A	cg07356753	chr3:81810745	GBE1	-0.49	-6.79	-0.35	5.15e-11	Waist circumference;Body mass index;
CRC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-5.68	-0.3	2.94e-8	Heart rate;
CRC	cis	rs4074493	1.000	rs11122198	chr1:231171139	G/A	cg22172038	chr1:231176991	FAM89A	0.37	6.32	0.33	8.68e-10	Carotid plaque burden (smoking interaction);
CRC	trans	rs6956675	0.915	rs4717501	chr7:62652936	C/T	cg01314568	chr7:57830625	NA	-0.62	-8.63	-0.43	2.7e-16	Obesity-related traits;
CRC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.54	-9.16	-0.45	5.6e-18	Iron status biomarkers;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20204401	chr17:78010341	CCDC40;TBC1D16	0.49	6.93	0.36	2.18e-11	Anxiety disorder;
CRC	trans	rs9341835	0.608	rs2800017	chr6:64158077	C/T	cg13657004	chr13:50234944	EBPL	0.38	6.54	0.34	2.42e-10	Schizophrenia;
CRC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.66	10.84	0.51	1.27e-23	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.69	10.66	0.51	5.37e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25336731	chr2:70520884	SNRPG	0.39	6.32	0.33	8.74e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	6.01	0.31	4.93e-9	Neuroticism;
CRC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-14.85	-0.63	1.62e-38	Coronary artery disease;
CRC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.7	9.61	0.47	1.9e-19	Breast cancer;
CRC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.61	-9.83	-0.48	3.71e-20	Aortic root size;
CRC	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg08645402	chr16:4508243	NA	0.51	6.56	0.34	2.11e-10	Schizophrenia;
CRC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg02820901	chr13:113351484	ATP11A	0.58	6.39	0.33	5.52e-10	Glycated hemoglobin levels;
CRC	cis	rs501120	0.929	rs528668	chr10:44762584	G/A	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-10.46	-0.5	2.64e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.12	-0.32	2.67e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-5.87	-0.31	1.07e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19717773	chr7:2847554	GNA12	-0.45	-6.59	-0.34	1.7e-10	Height;
CRC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.19	0.52	7.85e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.41	-8.06	-0.41	1.41e-14	Migraine;
CRC	cis	rs7804356	0.953	rs12534921	chr7:26877210	T/C	cg03456212	chr7:26904342	SKAP2	-0.49	-5.62	-0.3	4.1e-8	Type 1 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20863698	chr2:232328446	NCL	0.43	6.02	0.31	4.59e-9	Response to antipsychotic treatment;
CRC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.84e-10	Breast cancer;
CRC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.72	-10.33	-0.49	7.8e-22	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg22110888	chr17:80059540	CCDC57	0.39	6.31	0.33	9.23e-10	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13932364	chr1:59762531	FGGY	0.43	6.03	0.32	4.35e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07880357	chr17:52977867	TOM1L1	0.43	6.08	0.32	3.24e-9	Response to antipsychotic treatment;
CRC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg00343986	chr7:65444356	GUSB	0.49	7.19	0.37	4.31e-12	Aortic root size;
CRC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg13390004	chr1:15929781	NA	-0.51	-7.28	-0.37	2.49e-12	Systolic blood pressure;
CRC	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg14593290	chr7:50529359	DDC	-0.51	-7.7	-0.39	1.64e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-0.84	-9.88	-0.48	2.45e-20	Monocyte percentage of white cells;
CRC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg19812747	chr11:111475976	SIK2	0.48	7.35	0.38	1.56e-12	Primary sclerosing cholangitis;
CRC	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.43	7.55	0.38	4.31e-13	Information processing speed;
CRC	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg10724054	chr17:3904396	NA	-0.46	-7.57	-0.39	3.84e-13	Type 2 diabetes;
CRC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.71	0.63	5.47e-38	Breast cancer;
CRC	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.56	8.3	0.42	2.64e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs12101261	0.580	rs3783950	chr14:81448282	C/G	cg06600135	chr14:81408086	NA	-0.41	-5.99	-0.31	5.38e-9	Graves' disease;
CRC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.45	-6.82	-0.35	4.33e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg11693508	chr17:37793320	STARD3	0.65	8.49	0.42	7.33e-16	Bipolar disorder;
CRC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.5	-0.34	3.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg08761264	chr16:28874980	SH2B1	0.42	5.64	0.3	3.71e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg25173405	chr17:45401733	C17orf57	0.47	7.11	0.36	7.29e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	13.66	0.6	6.03e-34	Schizophrenia;
CRC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7731657	0.537	rs2189510	chr5:130316231	C/T	cg08523029	chr5:130500466	HINT1	-0.49	-6.16	-0.32	2.1e-9	Fasting plasma glucose;
CRC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.51	6.66	0.34	1.18e-10	Schizophrenia;
CRC	cis	rs4363385	0.703	rs4845517	chr1:153003893	T/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.69	-0.35	9.55e-11	Inflammatory skin disease;
CRC	cis	rs16975963	0.793	rs73027418	chr19:38361020	C/T	cg15135657	chr19:38346511	NA	-0.43	-5.76	-0.3	1.89e-8	Longevity;
CRC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.77	-9.22	-0.45	3.62e-18	Body mass index;
CRC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.47	7.93	0.4	3.43e-14	Major depressive disorder;
CRC	cis	rs73206853	0.563	rs10400410	chr12:111193499	C/T	cg12870014	chr12:110450643	ANKRD13A	0.56	6.03	0.32	4.33e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12476592	0.602	rs262509	chr2:63885708	A/G	cg10828910	chr2:63850056	LOC388955	0.52	6.44	0.33	4.3e-10	Childhood ear infection;
CRC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg13385521	chr17:29058706	SUZ12P	0.68	7.96	0.4	2.75e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg02820901	chr13:113351484	ATP11A	-0.54	-5.9	-0.31	9e-9	Glycated hemoglobin levels;
CRC	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.57	7.92	0.4	3.58e-14	Osteoporosis;
CRC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.43	0.38	9.23e-13	Mean platelet volume;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18301423	chr5:131593218	PDLIM4	0.44	8.17	0.41	6.63e-15	Acylcarnitine levels;
CRC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.62	9.29	0.46	2.18e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.37	0.53	1.75e-25	Prudent dietary pattern;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.45	-8.8	-0.44	8.05e-17	Alcohol dependence;
CRC	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.59	-8.82	-0.44	6.94e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.91	-0.4	3.94e-14	Vitamin D levels;
CRC	cis	rs3018066	0.748	rs7692069	chr4:106959289	C/T	cg01869342	chr4:106983673	TBCK	0.45	6.82	0.35	4.32e-11	Cancer;
CRC	cis	rs863345	0.604	rs923664	chr1:158507691	A/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg08347473	chr17:78092826	GAA	-0.32	-5.95	-0.31	7.04e-9	Yeast infection;
CRC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.33	-0.33	7.82e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.05e-16	Neuroticism;
CRC	trans	rs2303319	0.504	rs62187658	chr2:162488095	A/C	cg12500891	chr11:57225987	NA	-0.69	-6.05	-0.32	4.05e-9	Cognitive function;
CRC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.58	-7.26	-0.37	2.76e-12	Platelet distribution width;
CRC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.58	8.17	0.41	6.51e-15	Resting heart rate;
CRC	cis	rs932541	1.000	rs6111152	chr20:16456088	A/G	cg17003395	chr20:16555519	KIF16B	0.4	5.74	0.3	2.15e-8	Intelligence;
CRC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.1	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9908102	0.710	rs73981622	chr17:12914834	A/C	cg26162695	chr17:12921313	ELAC2	0.43	5.77	0.3	1.86e-8	Schizophrenia;
CRC	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg18758796	chr5:131593413	PDLIM4	0.34	5.78	0.3	1.72e-8	Blood metabolite levels;
CRC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.57	9.33	0.46	1.6e-18	Prostate cancer;
CRC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.25	-0.74	8.67e-60	Height;
CRC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.58	8.67	0.43	1.94e-16	Type 2 diabetes;
CRC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.33	-0.37	1.76e-12	Height;
CRC	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg02927042	chr1:21476669	EIF4G3	-0.45	-7.11	-0.36	7.26e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-6.45	-0.34	4.02e-10	Lymphocyte counts;
CRC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.32	-0.33	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00472445	chr6:101329307	ASCC3	0.4	6.65	0.34	1.19e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.66	-10.41	-0.5	3.97e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.78	12.99	0.58	2.01e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7703744	0.634	rs112352373	chr5:118687625	C/G	cg17471836	chr5:118691007	TNFAIP8	0.42	5.68	0.3	2.95e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21972741	chr5:435613	AHRR	0.54	7.37	0.38	1.39e-12	Cystic fibrosis severity;
CRC	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.43	-0.33	4.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	0.95	8.62	0.43	2.79e-16	Type 2 diabetes nephropathy;
CRC	cis	rs2415984	0.579	rs11157506	chr14:46976197	T/C	cg14871534	chr14:47121158	RPL10L	-0.39	-5.81	-0.31	1.46e-8	Number of children ever born;
CRC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg17321639	chr7:2759063	NA	-0.41	-6.19	-0.32	1.81e-9	Height;
CRC	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg02527881	chr3:46936655	PTH1R	0.36	6.19	0.32	1.75e-9	Colorectal cancer;
CRC	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.39e-12	HDL cholesterol;
CRC	cis	rs860295	0.702	rs12043132	chr1:155562367	T/C	cg02153340	chr1:155202674	NA	-0.49	-6.07	-0.32	3.44e-9	Body mass index;
CRC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.58	6.39	0.33	5.62e-10	Initial pursuit acceleration;
CRC	cis	rs6968419	0.609	rs73716708	chr7:115905743	T/C	cg02561103	chr7:115862891	TES	-0.41	-6.14	-0.32	2.35e-9	Intraocular pressure;
CRC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.13	0.32	2.47e-9	Cognitive ability;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.23	-0.45	3.45e-18	Electroencephalogram traits;
CRC	cis	rs17095355	0.605	rs41291880	chr10:111635785	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.78	-0.3	1.7e-8	Biliary atresia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00589895	chr3:172429056	NCEH1	0.47	6.55	0.34	2.18e-10	Response to antipsychotic treatment;
CRC	cis	rs17443541	0.507	rs12613262	chr2:200465327	T/C	cg03741458	chr2:200468445	NA	-0.36	-5.77	-0.3	1.82e-8	Intelligence (multi-trait analysis);
CRC	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	8.43	0.42	1.08e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.83	-13.79	-0.61	1.85e-34	Alcohol dependence;
CRC	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.8	11.29	0.53	3.32e-25	Obesity;Body mass index;
CRC	cis	rs2380220	0.808	rs2716069	chr6:95912976	C/G	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02905663	chr8:119123707	EXT1	0.4	6.27	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.42	8.17	0.41	6.87e-15	Hypertriglyceridemia;
CRC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11645453	chr3:52864694	ITIH4	0.32	5.71	0.3	2.46e-8	Electroencephalogram traits;
CRC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg21770322	chr7:97807741	LMTK2	0.86	19.38	0.73	2.28e-56	Breast cancer;
CRC	cis	rs3751196	0.708	rs79553328	chr12:104149708	A/G	cg02344784	chr12:104178138	NT5DC3	0.68	6.33	0.33	8.16e-10	Sense of smell;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24474130	chr6:99282348	POU3F2	0.35	6.01	0.31	5e-9	Hip circumference;
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg19913688	chr11:428466	ANO9	-0.7	-7.19	-0.37	4.26e-12	Body mass index;
CRC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.21	-0.41	5.18e-15	Chronic sinus infection;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.84	18.93	0.72	1.44e-54	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9292777	0.720	rs56694910	chr5:40401152	T/G	cg09067459	chr5:40385259	NA	-0.55	-8.97	-0.44	2.31e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg10760299	chr15:45669010	GATM	0.49	7.79	0.39	8.71e-14	Metabolite levels (small molecules and protein measures);
CRC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7120118	0.517	rs56825896	chr11:47326184	A/G	cg25783544	chr11:47291846	MADD	0.62	5.77	0.3	1.81e-8	HDL cholesterol;
CRC	cis	rs6743376	0.556	rs2515392	chr2:113817181	C/T	cg09040174	chr2:113837401	NA	0.44	6.42	0.33	4.87e-10	Inflammatory biomarkers;
CRC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.94	-0.36	2.14e-11	IgG glycosylation;
CRC	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.71	-8.82	-0.44	7.06e-17	Blood protein levels;
CRC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.28	0.33	1.07e-9	Hip circumference adjusted for BMI;
CRC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-12.49	-0.57	1.42e-29	Chronic sinus infection;
CRC	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg05729581	chr11:3078854	CARS	-0.51	-7.27	-0.37	2.57e-12	Longevity;
CRC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.62	-0.3	4.06e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs12936587	0.601	rs8068296	chr17:17554563	A/C	cg09796270	chr17:17721594	SREBF1	-0.45	-7.58	-0.39	3.45e-13	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg18551225	chr6:44695536	NA	0.41	5.6	0.3	4.52e-8	Total body bone mineral density;
CRC	trans	rs10411161	0.579	rs59305384	chr19:52387064	A/G	cg22319618	chr22:45562946	NUP50	-0.58	-6.82	-0.35	4.36e-11	Breast cancer;
CRC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg16606324	chr3:10149918	C3orf24	0.48	7.03	0.36	1.19e-11	Alzheimer's disease;
CRC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg18761221	chr20:60518478	NA	0.45	7.3	0.37	2.24e-12	Body mass index;
CRC	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.84	-8.3	-0.42	2.65e-15	Pulse pressure;
CRC	trans	rs3001167	0.867	rs10921615	chr1:194557475	A/T	cg22004422	chr13:113740730	MCF2L	-0.57	-6.32	-0.33	8.35e-10	Obesity-related traits;
CRC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg14541582	chr5:601475	NA	-0.36	-7.11	-0.36	7.3e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.64	11.28	0.53	3.58e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.62	12.96	0.58	2.67e-31	Schizophrenia;
CRC	cis	rs16852403	0.581	rs10913525	chr1:178223433	G/A	cg00404053	chr1:178313656	RASAL2	0.52	6.75	0.35	6.58e-11	Childhood ear infection;
CRC	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.68	7.65	0.39	2.23e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7680126	0.596	rs12510549	chr4:10276467	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.9	-0.31	9.04e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.65	9.39	0.46	1.01e-18	Coronary artery disease;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.79	11.7	0.54	1.14e-26	Menarche (age at onset);
CRC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg00334542	chr7:100209784	MOSPD3	-0.53	-6.82	-0.35	4.47e-11	Other erythrocyte phenotypes;
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.42	5.87	0.31	1.06e-8	Longevity;Endometriosis;
CRC	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.66	9.1	0.45	9.14e-18	White matter hyperintensity burden;
CRC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.36	-0.38	1.48e-12	Breast cancer;
CRC	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg26248373	chr2:1572462	NA	-0.83	-12.33	-0.56	5.69e-29	IgG glycosylation;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg07507251	chr3:52567010	NT5DC2	0.4	5.63	0.3	3.81e-8	Bipolar disorder;
CRC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.57	7.72	0.39	1.37e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg07423050	chr13:99094983	FARP1	0.41	6.57	0.34	1.93e-10	Longevity;
CRC	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.54	7.77	0.39	1.01e-13	Pulmonary function decline;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04119843	chr1:1284268	DVL1	0.51	6.58	0.34	1.85e-10	Thyroid stimulating hormone;
CRC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05834845	chr3:195489306	MUC4	-0.67	-7.29	-0.37	2.38e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg00507830	chr2:103233733	NA	0.5	5.63	0.3	3.86e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.62	-0.3	4.05e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg17710535	chr19:10819994	QTRT1	0.42	5.8	0.3	1.58e-8	Inflammatory skin disease;
CRC	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16447950	chr5:562315	NA	-0.71	-9.55	-0.47	3.07e-19	Obesity-related traits;
CRC	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.07	-14.44	-0.62	6.2e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9323205	0.677	rs12587080	chr14:51723079	A/C	cg23942311	chr14:51606299	NA	-0.52	-6.19	-0.32	1.78e-9	Cancer;
CRC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.66	-0.39	2.08e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg07599136	chr5:415885	AHRR	0.76	7.43	0.38	9.2e-13	Fat distribution (HIV);
CRC	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg00947319	chr17:47005597	UBE2Z	0.34	5.69	0.3	2.87e-8	Type 2 diabetes;
CRC	cis	rs4654899	0.895	rs10916865	chr1:21136610	C/T	cg02927042	chr1:21476669	EIF4G3	0.42	6.71	0.35	8.47e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-8.07	-0.41	1.36e-14	Bipolar disorder;
CRC	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg24300038	chr13:113819356	PROZ	-0.47	-6.03	-0.32	4.5e-9	Platelet distribution width;
CRC	cis	rs4728302	0.869	rs2059298	chr7:133603245	C/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.52	-0.34	2.61e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.95e-9	Depression;
CRC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.65	-0.3	3.44e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg26751094	chr13:95954534	ABCC4	-0.34	-6.03	-0.32	4.34e-9	Blood metabolite levels;
CRC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.65	9.54	0.47	3.27e-19	Breast cancer;
CRC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.53	6.63	0.34	1.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs6686842	1.000	rs6600365	chr1:41556253	C/T	cg19787969	chr8:9763211	NA	0.28	6.03	0.32	4.28e-9	Height;
CRC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg27661571	chr11:113659931	NA	-0.56	-7.24	-0.37	3.15e-12	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13580096	chr8:66546317	ARMC1	0.35	6.0	0.31	5.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.55	8.61	0.43	3.03e-16	Schizophrenia;
CRC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.49	7.48	0.38	6.88e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.42	7.88	0.4	4.77e-14	Ulcerative colitis;
CRC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.14	-15.46	-0.65	6.69e-41	Vitiligo;
CRC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.61	11.47	0.53	7.73e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg13615338	chr4:55094005	PDGFRA	0.4	5.95	0.31	6.86e-9	Corneal astigmatism;
CRC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg14008862	chr17:28927542	LRRC37B2	0.53	6.18	0.32	1.9e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg06470822	chr6:28175283	NA	0.95	13.59	0.6	1.07e-33	Parkinson's disease;
CRC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.58	-9.25	-0.45	3.02e-18	IgG glycosylation;
CRC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.54	-7.06	-0.36	9.78e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.48	0.42	7.87e-16	Schizophrenia;
CRC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.66	-8.56	-0.43	4.26e-16	Skin colour saturation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14644898	chr2:9615234	IAH1	0.48	6.24	0.33	1.37e-9	Thyroid stimulating hormone;
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg18833306	chr6:118973337	C6orf204	0.44	5.77	0.3	1.8e-8	Diastolic blood pressure;
CRC	cis	rs12930096	1.000	rs12929430	chr16:11679467	C/T	cg07439791	chr16:11680400	LITAF	0.51	5.62	0.3	4e-8	QT interval;
CRC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.38	0.33	6.09e-10	Aortic root size;
CRC	cis	rs6743226	0.934	rs6704615	chr2:242228733	A/G	cg10021735	chr2:242295487	FARP2	-0.46	-6.83	-0.35	4.18e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00802000	chr16:706648	WDR90	-0.46	-6.74	-0.35	7.19e-11	Height;
CRC	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.86	0.35	3.38e-11	Coronary artery disease;
CRC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg04450456	chr4:17643702	FAM184B	-0.36	-5.6	-0.3	4.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg17903999	chr18:56338584	MALT1	0.42	6.86	0.35	3.47e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.07	0.32	3.47e-9	Diastolic blood pressure;
CRC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	11.67	0.54	1.45e-26	Tonsillectomy;
CRC	cis	rs10924970	0.624	rs12755851	chr1:235477806	G/C	cg09010748	chr1:235293032	TOMM20	-0.4	-5.65	-0.3	3.57e-8	Asthma;
CRC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.49	-6.38	-0.33	5.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg03623178	chr6:28175578	NA	0.77	11.48	0.53	7.23e-26	Cardiac Troponin-T levels;
CRC	cis	rs990171	0.607	rs871659	chr2:102771855	C/T	cg22835712	chr2:102737379	NA	0.46	5.93	0.31	7.79e-9	Lymphocyte counts;
CRC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.54	6.81	0.35	4.57e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02290350	chr8:58132656	NA	-0.52	-5.68	-0.3	2.89e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.82	15.58	0.65	2.32e-41	Hip circumference;
CRC	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg14593290	chr7:50529359	DDC	0.56	7.24	0.37	3.13e-12	Malaria;
CRC	cis	rs1572438	0.811	rs6916781	chr6:880493	G/A	cg13447295	chr6:887704	NA	0.55	8.4	0.42	1.4e-15	Aging;
CRC	cis	rs3731896	0.752	rs11889536	chr2:220163543	A/G	cg00436969	chr2:220197716	RESP18	-0.45	-5.73	-0.3	2.28e-8	Educational attainment;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06057045	chr2:233562093	GIGYF2	-0.4	-6.0	-0.31	5.28e-9	Aortic root size;
CRC	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.62	7.39	0.38	1.2e-12	Vitamin D levels;
CRC	cis	rs17021463	0.676	rs11097421	chr4:95302915	T/C	cg11021082	chr4:95130006	SMARCAD1	0.44	6.32	0.33	8.75e-10	Testicular germ cell tumor;
CRC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg17420585	chr12:42539391	GXYLT1	-0.4	-5.78	-0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg06243866	chr13:111019493	COL4A2	-0.39	-5.85	-0.31	1.19e-8	White matter hyperintensity burden;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08442028	chr16:87425757	FBXO31;MAP1LC3B	0.44	6.15	0.32	2.3e-9	Anxiety disorder;
CRC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.98	-0.36	1.67e-11	Triglycerides;
CRC	cis	rs11212617	0.967	rs371406	chr11:108221482	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	5.97	0.31	6.15e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg03233332	chr7:66118400	NA	-0.43	-5.95	-0.31	6.81e-9	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04909336	chr12:46121883	LOC400027	0.45	6.39	0.33	5.73e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.41	6.24	0.33	1.33e-9	Electroencephalogram traits;
CRC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.08	-0.32	3.25e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17554472	chr22:41940697	POLR3H	-0.56	-5.7	-0.3	2.67e-8	Vitiligo;
CRC	trans	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.74	-11.7	-0.54	1.17e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.76	11.26	0.53	4.17e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg25190513	chr12:123201362	GPR109B	-0.51	-6.35	-0.33	7.29e-10	Adiponectin levels;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.67	-0.43	1.96e-16	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.57	8.18	0.41	6.29e-15	Primary sclerosing cholangitis;
CRC	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.41	-7.91	-0.4	3.85e-14	Migraine;
CRC	cis	rs9912789	0.687	rs9892874	chr17:79188303	G/C	cg25342872	chr17:79175132	AZI1	-0.44	-7.83	-0.4	6.57e-14	Frontotemporal dementia;
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	0.71	9.42	0.46	8.32e-19	Alzheimer's disease;
CRC	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs2257205	0.667	rs77326197	chr17:56905618	T/C	cg25885038	chr17:56607967	SEPT4	-0.53	-5.85	-0.31	1.2e-8	Pancreatic cancer;
CRC	cis	rs4664293	0.836	rs13401087	chr2:160617468	G/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22029157	chr1:209979665	IRF6	0.61	6.73	0.35	7.5e-11	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.69	0.7	1.13e-49	Platelet count;
CRC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg19582491	chr16:67682965	RLTPR	-0.57	-6.53	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12950166	chr12:122517149	MLXIP	0.4	6.28	0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.63	10.08	0.49	5.47e-21	Aortic root size;
CRC	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-8.32	-0.42	2.38e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.08	18.6	0.72	2.69e-53	Cognitive function;
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19500275	chr17:80737654	TBCD	-0.51	-7.07	-0.36	9.41e-12	Glycated hemoglobin levels;
CRC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.16	25.92	0.82	1.73e-81	IgG glycosylation;
CRC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.59	8.61	0.43	3.08e-16	Lymphocyte counts;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.45	-6.65	-0.34	1.25e-10	Parkinson's disease;
CRC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg11707556	chr5:10655725	ANKRD33B	0.46	7.71	0.39	1.48e-13	Coronary artery disease;
CRC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg03013999	chr17:37608204	MED1	-0.47	-7.31	-0.37	2.1e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg23093090	chr10:104574429	C10orf26	-0.42	-5.79	-0.3	1.65e-8	Arsenic metabolism;
CRC	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.68	12.48	0.57	1.58e-29	Hip circumference;
CRC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.34	-0.38	1.63e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.68	-9.79	-0.47	5.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg02659138	chr7:134003124	SLC35B4	0.36	6.14	0.32	2.41e-9	Mean platelet volume;
CRC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.6	-8.29	-0.42	2.86e-15	Iron status biomarkers;
CRC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.91	0.44	3.67e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.43	-7.05	-0.36	1.06e-11	Weight;
CRC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg17948913	chr5:572064	NA	0.51	5.91	0.31	8.58e-9	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.51	0.34	2.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18758796	chr5:131593413	PDLIM4	0.43	7.91	0.4	4.08e-14	Breast cancer;
CRC	cis	rs4660531	0.890	rs61229336	chr1:41834935	C/T	cg00290994	chr1:41848739	NA	0.47	6.55	0.34	2.16e-10	Bipolar disorder;
CRC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.26	-0.69	5.36e-48	Height;
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.43	-5.94	-0.31	7.16e-9	White matter hyperintensity burden;
CRC	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.4	-6.7	-0.35	9.25e-11	Vitamin D levels;
CRC	cis	rs7215564	0.822	rs10871488	chr17:78739079	T/C	cg09596252	chr17:78655493	RPTOR	-0.56	-5.89	-0.31	9.59e-9	Myopia (pathological);
CRC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.7	-0.35	9.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg26805224	chr10:79626177	DLG5	-0.46	-6.85	-0.35	3.54e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-7.39	-0.38	1.23e-12	Electroencephalogram traits;
CRC	trans	rs2303319	0.504	rs56405014	chr2:162497603	C/T	cg03757145	chr4:76555832	CDKL2	-0.66	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.39	5.83	0.31	1.29e-8	Hemoglobin concentration;
CRC	trans	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.48	-0.34	3.39e-10	Aortic root size;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg12639453	chr1:2035780	PRKCZ	0.31	5.71	0.3	2.55e-8	Height;
CRC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.68	-10.6	-0.5	8.97e-23	Motion sickness;
CRC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.59	9.75	0.47	6.74e-20	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg23807890	chr2:228736357	WDR69	0.46	6.26	0.33	1.18e-9	Blood pressure;
CRC	cis	rs17065868	0.764	rs9533868	chr13:45039441	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.78	9.46	0.46	5.95e-19	Lung function (FEV1/FVC);
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.64	0.75	2.54e-61	Prudent dietary pattern;
CRC	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg04990556	chr1:26633338	UBXN11	0.53	5.73	0.3	2.23e-8	Obesity-related traits;
CRC	trans	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	3.08e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07393458	chr17:57297757	GDPD1	0.46	6.07	0.32	3.46e-9	Anxiety disorder;
CRC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.45	-8.08	-0.41	1.21e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg13072238	chr3:49761600	GMPPB	-0.48	-5.76	-0.3	1.93e-8	Menarche (age at onset);
CRC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.44	6.32	0.33	8.43e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.61	9.7	0.47	1e-19	Height;
CRC	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.59	9.24	0.45	3.18e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-16.49	-0.67	5.75e-45	Intelligence (multi-trait analysis);
CRC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.56	7.69	0.39	1.77e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs524281	0.773	rs2017969	chr11:66039032	G/A	cg14036092	chr11:66035641	RAB1B	-0.56	-6.13	-0.32	2.56e-9	Electroencephalogram traits;
CRC	trans	rs559356	0.519	rs604721	chr3:34839735	T/C	cg19071035	chr6:20404090	E2F3	0.46	6.13	0.32	2.53e-9	Cognitive function;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10870055	chr5:43484146	C5orf28	0.46	5.98	0.31	5.78e-9	Thyroid stimulating hormone;
CRC	cis	rs2857891	0.695	rs2248341	chr11:6984677	A/T	cg04053776	chr11:6947353	ZNF215	0.4	6.22	0.32	1.49e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.29	6.19	0.32	1.84e-9	Educational attainment (years of education);
CRC	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.61	0.34	1.53e-10	Blood protein levels;
CRC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg20243544	chr17:37824526	PNMT	0.54	8.76	0.43	1.07e-16	Asthma;
CRC	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg27068330	chr11:65405492	SIPA1	0.45	6.53	0.34	2.57e-10	Acne (severe);
CRC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.53	8.1	0.41	1.11e-14	Educational attainment;
CRC	cis	rs4664293	0.625	rs6713600	chr2:160563070	T/C	cg08347373	chr2:160653686	CD302	0.39	6.53	0.34	2.44e-10	Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24580185	chr2:160143534	WDSUB1	0.46	6.37	0.33	6.44e-10	Response to antipsychotic treatment;
CRC	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.72	-0.35	7.81e-11	Putamen volume;
CRC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.29	-0.33	9.99e-10	Monocyte percentage of white cells;
CRC	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg15192750	chr16:69999425	NA	0.54	7.13	0.37	6.25e-12	IgE levels;
CRC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.94	-0.4	3.15e-14	Putamen volume;
CRC	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.52	8.77	0.44	9.5e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.64	-11.64	-0.54	1.8e-26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.61	6.86	0.35	3.38e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.53	8.48	0.42	7.59e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs8105895	0.935	rs10425828	chr19:22283077	A/G	cg02657401	chr19:22469223	NA	-0.35	-5.67	-0.3	3.06e-8	Body mass index (change over time);
CRC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-10.27	-0.49	1.17e-21	Monocyte count;
CRC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.44	5.81	0.3	1.51e-8	Total body bone mineral density;
CRC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	9.11	0.45	8.42e-18	Schizophrenia;
CRC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.62	10.59	0.5	9.94e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4400599	0.569	rs10797058	chr1:154200704	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.71	-0.3	2.49e-8	Platelet distribution width;
CRC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-9.55	-0.47	2.98e-19	Heart rate;
CRC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.76	9.82	0.48	3.95e-20	Monocyte percentage of white cells;
CRC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.4	-5.67	-0.3	3.06e-8	Menarche (age at onset);
CRC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg10760299	chr15:45669010	GATM	0.53	8.13	0.41	8.58e-15	Homoarginine levels;
CRC	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.73	10.37	0.5	5.39e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09891106	chr20:33292075	TP53INP2	0.46	6.61	0.34	1.55e-10	Intelligence (multi-trait analysis);
CRC	cis	rs501120	0.584	rs61857486	chr10:44719361	A/G	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	6.71	0.35	8.39e-11	Schizophrenia;
CRC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg18230493	chr5:56204884	C5orf35	-0.4	-5.96	-0.31	6.49e-9	Coronary artery disease;
CRC	cis	rs4973397	0.686	rs10933370	chr2:232289960	C/A	cg13347044	chr2:232276743	NA	0.39	5.79	0.3	1.62e-8	Anti-saccade response;
CRC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	9.33	0.46	1.61e-18	Eye color traits;
CRC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.61	6.44	0.33	4.22e-10	Mean platelet volume;
CRC	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.74	-0.39	1.27e-13	Bipolar disorder;
CRC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-6.39	-0.33	5.62e-10	Systemic lupus erythematosus;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.74	-11.63	-0.54	2.1e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24080313	chr3:55522631	WNT5A	0.33	6.73	0.35	7.4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-21.56	-0.77	6.79e-65	Hemostatic factors and hematological phenotypes;
CRC	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-9.39	-0.46	1.02e-18	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.51	7.32	0.37	1.97e-12	Colorectal cancer;
CRC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.43	4.48e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.72	9.58	0.47	2.4e-19	Alzheimer's disease;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg12273811	chr6:28175739	NA	0.59	7.68	0.39	1.81e-13	Parkinson's disease;
CRC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.46	-7.46	-0.38	7.73e-13	Monocyte count;
CRC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg24881330	chr22:46731750	TRMU	0.56	6.6	0.34	1.61e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.28	0.53	3.51e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.22	0.32	1.49e-9	Aortic root size;
CRC	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.73	0.43	1.26e-16	Coffee consumption (cups per day);
CRC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.2e-25	Prostate cancer;
CRC	cis	rs9443189	0.813	rs3798439	chr6:76566734	T/G	cg01950844	chr6:76311363	SENP6	-0.62	-7.42	-0.38	1.01e-12	Prostate cancer;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.9	-0.36	2.76e-11	Electroencephalogram traits;
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg05569086	chr8:143859399	LYNX1	0.4	6.93	0.36	2.2e-11	Urinary tract infection frequency;
CRC	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.47	-6.7	-0.35	9.13e-11	Breast cancer;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg02683197	chr6:28174875	NA	0.79	9.73	0.47	8.12e-20	Depression;
CRC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.48	0.38	6.79e-13	Aortic root size;
CRC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-1.06	-13.33	-0.59	1.03e-32	Orofacial clefts;
CRC	cis	rs7605827	0.930	rs11684395	chr2:15530870	A/G	cg19274914	chr2:15703543	NA	0.39	5.77	0.3	1.86e-8	Educational attainment (years of education);
CRC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.5	-6.69	-0.35	9.4e-11	Uric acid levels;
CRC	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.56	-8.75	-0.43	1.13e-16	HDL cholesterol;
CRC	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg07424746	chr4:185654737	MLF1IP	-0.6	-5.91	-0.31	8.71e-9	Blood protein levels;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23197860	chr4:113558550	LARP7;C4orf21	0.4	5.97	0.31	6.09e-9	Interleukin-6 levels;
CRC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs3889199	1.000	rs6668886	chr1:59656884	C/A	cg25881383	chr1:59680599	NA	-0.37	-5.98	-0.31	5.87e-9	Pulse pressure;
CRC	cis	rs9409565	0.586	rs7041103	chr9:97067654	A/G	cg04523069	chr9:97136363	HIATL1	-0.43	-6.0	-0.31	5.28e-9	Colorectal cancer (alcohol consumption interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03533382	chr5:126853128	PRRC1	0.47	6.76	0.35	6.22e-11	Response to antipsychotic treatment;
CRC	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.97	0.52	4.54e-24	Exhaled nitric oxide output;
CRC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.09e-15	Menopause (age at onset);
CRC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg03037974	chr15:76606532	NA	0.68	11.55	0.54	4.06e-26	Blood metabolite levels;
CRC	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.78	-13.7	-0.6	4.15e-34	Lewy body disease;
CRC	cis	rs6429082	0.510	rs2789369	chr1:235503515	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.86	0.31	1.11e-8	Adiposity;
CRC	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-1.01	-17.72	-0.7	8.48e-50	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs6840360	0.642	rs11726254	chr4:152438850	G/C	cg09659197	chr4:152720779	NA	0.33	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.44	-6.54	-0.34	2.41e-10	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.38	-6.18	-0.32	1.92e-9	Refractive error;
CRC	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg00677455	chr12:58241039	CTDSP2	-0.41	-5.86	-0.31	1.11e-8	Multiple sclerosis;
CRC	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.56	5.92	0.31	7.97e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.42	-7.08	-0.36	8.72e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.8	-13.4	-0.59	5.88e-33	Coronary artery disease;
CRC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg02135003	chr7:105160482	PUS7	-0.96	-12.75	-0.58	1.54e-30	Bipolar disorder (body mass index interaction);
CRC	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg09760422	chr2:128146352	NA	-0.3	-5.83	-0.31	1.31e-8	Protein C levels;
CRC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22433210	chr17:43662623	NA	0.8	8.34	0.42	2.06e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg15654264	chr1:150340011	RPRD2	0.37	5.81	0.31	1.46e-8	Migraine;
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.47	8.25	0.41	3.85e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.25	14.86	0.63	1.38e-38	Gout;
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg15145296	chr3:125709740	NA	-0.56	-7.15	-0.37	5.75e-12	Blood pressure (smoking interaction);
CRC	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg13385794	chr1:248469461	NA	0.4	6.75	0.35	6.58e-11	Common traits (Other);
CRC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	11.7	0.54	1.12e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.48	7.31	0.37	2.04e-12	Corneal astigmatism;
CRC	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.95	-12.65	-0.57	3.73e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.93	14.17	0.62	6.79e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.07	-0.32	3.44e-9	Height;
CRC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.95	-0.4	2.95e-14	Gut microbiome composition (summer);
CRC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.76	-9.68	-0.47	1.12e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg04362960	chr10:104952993	NT5C2	-0.42	-5.68	-0.3	2.94e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.67	10.0	0.48	9.68e-21	Acne (severe);
CRC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	6.53	0.34	2.49e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.1	0.45	8.8e-18	Platelet count;
CRC	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.64	6.21	0.32	1.62e-9	Axial length;
CRC	cis	rs1223397	0.938	rs35549743	chr6:13294354	C/T	cg07912922	chr6:13274314	PHACTR1	0.54	6.44	0.33	4.32e-10	Blood pressure;
CRC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.6	-7.79	-0.39	8.87e-14	Dilated cardiomyopathy;
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.54	6.79	0.35	5.24e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4666002	0.789	rs13023094	chr2:27910706	G/T	cg27432699	chr2:27873401	GPN1	-0.53	-6.82	-0.35	4.26e-11	Phospholipid levels (plasma);
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg01721255	chr8:58191610	C8orf71	0.45	5.76	0.3	1.96e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs16975963	0.644	rs73033129	chr19:38080535	G/T	cg15135657	chr19:38346511	NA	-0.46	-6.28	-0.33	1.09e-9	Longevity;
CRC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.48	-6.54	-0.34	2.37e-10	Tonsillectomy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22786506	chr11:116969293	SIK3	0.42	5.97	0.31	6.31e-9	Anxiety disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20817853	chr17:75084718	SCARNA16;C17orf86	0.49	6.92	0.36	2.38e-11	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg25164649	chr6:28176230	NA	0.49	7.06	0.36	1.02e-11	Parkinson's disease;
CRC	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.51	6.27	0.33	1.15e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg16447950	chr5:562315	NA	-0.84	-11.5	-0.54	6.14e-26	Lung disease severity in cystic fibrosis;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg15845792	chr6:28175446	NA	-1.02	-13.73	-0.6	3.27e-34	Depression;
CRC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg11204139	chr17:3907470	NA	0.64	11.14	0.52	1.11e-24	Type 2 diabetes;
CRC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.46	-0.38	7.91e-13	Reticulocyte fraction of red cells;
CRC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.82	0.31	1.43e-8	Homoarginine levels;
CRC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.69	-11.0	-0.52	3.42e-24	Corneal astigmatism;
CRC	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	8.06	0.41	1.4e-14	Homocysteine levels;
CRC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.65	-10.1	-0.49	4.54e-21	Testicular germ cell tumor;
CRC	trans	rs9341835	0.584	rs2622307	chr6:64152049	G/C	cg13657004	chr13:50234944	EBPL	-0.37	-6.38	-0.33	6.03e-10	Schizophrenia;
CRC	cis	rs453193	0.966	rs658243	chr2:8446695	G/T	cg12167548	chr2:8464763	NA	0.32	5.93	0.31	7.69e-9	Granulocyte percentage of myeloid white cells;
CRC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-5.74	-0.3	2.15e-8	Bladder cancer;
CRC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.75	13.34	0.59	9.27e-33	Oral cavity cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23018242	chr22:31608245	LIMK2	0.43	6.14	0.32	2.38e-9	Survival in pancreatic cancer;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg26587870	chr6:27730563	NA	-0.42	-6.28	-0.33	1.05e-9	Parkinson's disease;
CRC	cis	rs360798	0.532	rs360800	chr2:62954326	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-6.39	-0.33	5.59e-10	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.31	0.33	8.84e-10	Bipolar disorder;
CRC	cis	rs711830	0.965	rs6755777	chr2:177043226	T/G	cg13092806	chr2:177043255	NA	0.75	9.56	0.47	2.82e-19	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-6.95	-0.36	1.95e-11	Height;
CRC	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.48	6.98	0.36	1.68e-11	Breast cancer;
CRC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.47	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg04731861	chr2:219085781	ARPC2	0.27	5.7	0.3	2.63e-8	Ulcerative colitis;
CRC	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg03929089	chr4:120376271	NA	-0.55	-6.59	-0.34	1.76e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4666002	0.750	rs13021208	chr2:27901728	C/T	cg27432699	chr2:27873401	GPN1	0.55	7.0	0.36	1.47e-11	Phospholipid levels (plasma);
CRC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.63	-9.19	-0.45	4.73e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10991814	1.000	rs76067199	chr9:93959395	C/T	cg14446406	chr9:93919335	NA	0.56	6.05	0.32	4e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.61	8.21	0.41	5.26e-15	Coronary artery disease;
CRC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg26769984	chr7:1090371	C7orf50	0.38	5.82	0.31	1.4e-8	Bronchopulmonary dysplasia;
CRC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.25	0.45	3e-18	Heart rate;
CRC	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14019695	chr9:139328340	INPP5E	0.4	5.88	0.31	9.88e-9	Monocyte percentage of white cells;
CRC	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-8.33	-0.42	2.14e-15	Bone mineral density;
CRC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.9	8.87	0.44	4.67e-17	Lymphocyte counts;
CRC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.54	-8.23	-0.41	4.56e-15	Mean platelet volume;
CRC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.57	-9.85	-0.48	3.07e-20	Body mass index;
CRC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg23136738	chr11:925521	AP2A2	-0.41	-6.87	-0.35	3.15e-11	Alzheimer's disease (late onset);
CRC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.96	-0.44	2.47e-17	Height;
CRC	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.27	-0.33	1.12e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25517755	chr10:38738941	LOC399744	-0.45	-6.56	-0.34	2.07e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.41e-13	Corneal astigmatism;
CRC	cis	rs7932354	0.502	rs57323109	chr11:47193367	T/G	cg03339077	chr11:47165057	C11orf49	-0.46	-6.28	-0.33	1.06e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9287719	0.624	rs10199635	chr2:10726640	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.08	14.83	0.63	1.78e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg04518342	chr5:131593106	PDLIM4	-0.33	-5.75	-0.3	2.03e-8	Blood metabolite levels;
CRC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.46	-0.34	3.85e-10	Aortic root size;
CRC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1223397	0.938	rs3817741	chr6:13279507	A/G	cg07912922	chr6:13274314	PHACTR1	-0.47	-5.99	-0.31	5.6e-9	Blood pressure;
CRC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	trans	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06834434	chr14:75079333	LTBP2	0.57	6.88	0.35	3.1e-11	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22292364	chr19:50180326	PRMT1	0.48	6.16	0.32	2.14e-9	Thyroid stimulating hormone;
CRC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.85	0.35	3.59e-11	Rheumatoid arthritis;
CRC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.2	0.32	1.67e-9	Diabetic kidney disease;
CRC	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.32	-0.33	8.45e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg03395651	chr16:88107091	BANP	-0.55	-7.53	-0.38	4.98e-13	Menopause (age at onset);
CRC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg26043149	chr18:55253948	FECH	-0.58	-9.01	-0.44	1.76e-17	Bone mineral density;
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg18653534	chr16:772142	FAM173A	-0.35	-5.61	-0.3	4.33e-8	Height;
CRC	cis	rs12760731	0.565	rs7550699	chr1:178209584	T/G	cg00404053	chr1:178313656	RASAL2	1.11	11.45	0.53	8.6e-26	Obesity-related traits;
CRC	cis	rs4965869	0.866	rs4965866	chr15:101975931	C/T	cg12371147	chr15:101978424	PCSK6	-0.41	-5.8	-0.3	1.58e-8	Platelet-derived growth factor BB levels;
CRC	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.03	14.37	0.62	1.16e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.37	0.5	5.39e-22	Platelet count;
CRC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.61	-0.43	3.14e-16	Monocyte count;
CRC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg07828024	chr6:149772892	ZC3H12D	0.49	9.19	0.45	4.46e-18	Dupuytren's disease;
CRC	trans	rs62295889	0.602	rs60391312	chr4:12537820	C/G	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12273811	chr6:28175739	NA	0.72	9.09	0.45	9.21e-18	Depression;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.44	-7.0	-0.36	1.48e-11	Lung cancer;
CRC	cis	rs9914988	0.565	rs34039488	chr17:27320232	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.49	6.58	0.34	1.8e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.61	9.05	0.45	1.3e-17	Obesity-related traits;
CRC	trans	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.58	0.39	3.6e-13	Endometrial cancer;
CRC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.76	12.35	0.56	4.59e-29	Blood protein levels;
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.68	-0.3	3.01e-8	Bipolar disorder;
CRC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.91	-11.58	-0.54	2.99e-26	Dilated cardiomyopathy;
CRC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.38	7.38e-13	Lung cancer in ever smokers;
CRC	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg15654264	chr1:150340011	RPRD2	0.42	6.25	0.33	1.29e-9	Migraine;
CRC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.48	7.11	0.37	7.17e-12	Asthma;
CRC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg17652424	chr22:38574118	PLA2G6	-0.21	-6.62	-0.34	1.47e-10	Cutaneous nevi;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.64	-0.39	2.36e-13	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18835942	chr20:306049	SOX12	0.48	6.89	0.36	2.9100000000000002e-11	Anxiety disorder;
CRC	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.14	-0.37	5.88e-12	Capecitabine sensitivity;
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.75	-6.23	-0.32	1.45e-9	Cognitive function;
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg22687807	chr8:143858763	LYNX1	0.49	8.92	0.44	3.32e-17	Urinary tract infection frequency;
CRC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.46	9.49	0.46	4.98e-19	Renal cell carcinoma;
CRC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.34	6.0	0.31	5.11e-9	Erythrocyte sedimentation rate;
CRC	trans	rs877282	0.741	rs35865720	chr10:753022	G/A	cg22713356	chr15:30763199	NA	1.17	13.24	0.59	2.19e-32	Uric acid levels;
CRC	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	0.62	9.66	0.47	1.32e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg10820045	chr2:198174542	NA	-0.58	-11.94	-0.55	1.53e-27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg04545296	chr12:48745243	ZNF641	0.32	5.69	0.3	2.78e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg16342193	chr10:102329863	NA	-0.39	-6.28	-0.33	1.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.13	0.32	2.58e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.54	7.1	0.36	7.95e-12	Alzheimer's disease (survival time);
CRC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.81	-0.31	1.47e-8	Bipolar disorder;
CRC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.66e-23	Aortic root size;
CRC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.64	9.07	0.45	1.08e-17	Vitamin D levels;
CRC	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.63	-0.3	3.95e-8	Metabolite levels;
CRC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.52	7.54	0.38	4.49e-13	Colorectal cancer;
CRC	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.43	7.89	0.4	4.53e-14	Type 2 diabetes;
CRC	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg02869306	chr7:64672164	INTS4L1	-0.38	-6.23	-0.32	1.46e-9	Aortic root size;
CRC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.54	-0.34	2.32e-10	Breast cancer;
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg02033258	chr5:131593261	PDLIM4	0.37	6.38	0.33	6.02e-10	Breast cancer;
CRC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-6.78	-0.35	5.62e-11	Height;
CRC	cis	rs4363385	0.791	rs4041401	chr1:152985629	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.71	-0.35	8.48e-11	Inflammatory skin disease;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.52	9.68	0.47	1.19e-19	Acylcarnitine levels;
CRC	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg12700464	chr11:78128424	GAB2	-0.48	-5.72	-0.3	2.33e-8	Testicular germ cell tumor;
CRC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.59	-0.39	3.43e-13	Joint mobility (Beighton score);
CRC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.44	7.33	0.37	1.74e-12	Blood metabolite levels;
CRC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.8	-0.51	1.82e-23	Chronic sinus infection;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.76	12.64	0.57	3.87e-30	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.86	0.31	1.11e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06505273	chr16:24850292	NA	0.38	5.79	0.3	1.63e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.09	12.58	0.57	6.71e-30	Diabetic kidney disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17816495	chr19:19030203	DDX49;COPE	-0.43	-6.59	-0.34	1.74e-10	Myopia (pathological);
CRC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg19500275	chr17:80737654	TBCD	0.52	7.04	0.36	1.1e-11	Glycated hemoglobin levels;
CRC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.98	0.36	1.66e-11	Educational attainment;
CRC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.36	8.17e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7113874	0.655	rs7945659	chr11:8529925	A/T	cg02811074	chr11:8615871	STK33	-0.36	-6.0	-0.31	5.13e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.38	7.32	0.37	1.9e-12	Mean corpuscular volume;
CRC	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-12.02	-0.55	7.57e-28	Superior crus of antihelix expression;
CRC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.59	9.27	0.46	2.54e-18	Height;
CRC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.74	-0.39	1.2e-13	Chronic sinus infection;
CRC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.46	7.34	0.37	1.73e-12	Osteoporosis;
CRC	cis	rs7580658	0.895	rs62157549	chr2:128066007	A/G	cg09760422	chr2:128146352	NA	-0.29	-5.65	-0.3	3.56e-8	Protein C levels;
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.61	9.46	0.46	5.99e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg10756647	chr7:56101905	PSPH	0.67	7.34	0.38	1.69e-12	Diabetic kidney disease;
CRC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.77	11.27	0.53	3.83e-25	Height;
CRC	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg05925327	chr15:68127851	NA	-0.31	-6.01	-0.31	4.97e-9	Restless legs syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17428694	chr1:163291564	NUF2	0.39	6.06	0.32	3.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	11.99	0.55	1.01e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.21	-14.88	-0.63	1.17e-38	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.88	-0.31	9.84e-9	Life satisfaction;
CRC	cis	rs6662572	0.906	rs11582058	chr1:46245423	A/G	cg08644498	chr1:46502608	NA	-0.45	-7.22	-0.37	3.54e-12	Blood protein levels;
CRC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.91	0.44	3.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.05	-0.74	5.67e-59	Hip circumference adjusted for BMI;
CRC	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg17133734	chr15:86042851	AKAP13	0.44	7.03	0.36	1.21e-11	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.56	-8.93	-0.44	3.11e-17	Menopause (age at onset);
CRC	cis	rs9287719	0.649	rs10190673	chr2:10718618	T/C	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	trans	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg20935933	chr6:143382018	AIG1	0.53	6.78	0.35	5.42e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	14.38	0.62	1.06e-36	Menarche (age at onset);
CRC	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.42	6.14	0.32	2.32e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.91	-14.13	-0.61	8.96e-36	Longevity;
CRC	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.48	8.14	0.41	7.98e-15	Common traits (Other);
CRC	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg10437265	chr15:77819839	NA	-0.48	-8.43	-0.42	1.08e-15	Type 2 diabetes;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11311579	chr10:102106754	SCD	-0.38	-6.26	-0.33	1.19e-9	Obesity-related traits;
CRC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg08314208	chr16:67682810	RLTPR	-0.58	-6.19	-0.32	1.76e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06307176	chr5:131281290	NA	0.42	6.16	0.32	2.11e-9	Life satisfaction;
CRC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	7.85	0.4	6.06e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.07	-0.32	3.49e-9	Blood protein levels;
CRC	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg24560729	chr4:1342394	KIAA1530	0.42	6.93	0.36	2.24e-11	Obesity-related traits;
CRC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg19792802	chr11:65647270	CTSW	0.5	7.55	0.38	4.23e-13	Crohn's disease;
CRC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.21	-0.37	3.76e-12	Bipolar disorder;
CRC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.49	-0.38	6.53e-13	Cystic fibrosis severity;
CRC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.62	-9.78	-0.47	5.4e-20	Mean platelet volume;Platelet distribution width;
CRC	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg05623727	chr3:50126028	RBM5	0.53	6.94	0.36	2.09e-11	Intelligence (multi-trait analysis);
CRC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg16892393	chr17:41919603	NA	0.51	7.49	0.38	6.37e-13	Triglycerides;
CRC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.5	7.33	0.37	1.78e-12	Blood metabolite levels;
CRC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg20542592	chr8:11973495	FAM66D	0.36	6.22	0.32	1.48e-9	Retinal vascular caliber;
CRC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.43	-9.5	-0.46	4.68e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg16540259	chr10:75572220	NDST2	0.38	5.91	0.31	8.72e-9	Inflammatory bowel disease;
CRC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg23758597	chr6:163146217	PARK2	-0.64	-6.28	-0.33	1.05e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8032158	0.702	rs2288345	chr15:56122461	T/C	cg02198044	chr15:56286336	NEDD4	-0.36	-5.73	-0.3	2.33e-8	Keloid;
CRC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	0.94	14.2	0.62	5.07e-36	Cognitive function;
CRC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.59	-8.31	-0.42	2.57e-15	Mean platelet volume;Platelet distribution width;
CRC	trans	rs10242455	0.867	rs10282706	chr7:99217424	G/A	cg09045935	chr12:6379348	NA	0.59	6.63	0.34	1.37e-10	Blood metabolite levels;
CRC	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.51	-8.62	-0.43	2.82e-16	Schizophrenia;
CRC	cis	rs4889855	0.556	rs9897453	chr17:78634300	C/T	cg16591659	chr17:78472290	NA	-0.38	-5.84	-0.31	1.26e-8	Fractional excretion of uric acid;
CRC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.51	8.68	0.43	1.9e-16	Coronary artery disease;
CRC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.94	14.88	0.63	1.17e-38	Parkinson's disease;
CRC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.53	-8.85	-0.44	5.49e-17	Colorectal cancer;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg06470822	chr6:28175283	NA	0.8	11.88	0.55	2.47e-27	Parkinson's disease;
CRC	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg21153622	chr11:89784906	NA	0.47	7.44	0.38	8.86e-13	HDL cholesterol;
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.54	7.76	0.39	1.11e-13	Lung cancer;
CRC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg25767906	chr1:53392781	SCP2	0.45	7.21	0.37	3.76e-12	Monocyte count;
CRC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-5.84	-0.31	1.26e-8	Monocyte percentage of white cells;
CRC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.78	0.35	5.42e-11	Melanoma;
CRC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.29	6.07	0.32	3.54e-9	Lung cancer;
CRC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg26893134	chr6:116381904	FRK	-0.27	-7.81	-0.4	7.64e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.34	-9.63	-0.47	1.72e-19	Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03689283	chr3:196668656	NCBP2;LOC152217	0.48	6.78	0.35	5.42e-11	Response to antipsychotic treatment;
CRC	cis	rs3736485	0.932	rs10519313	chr15:51915812	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.53	-0.34	2.49e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.56	7.09	0.36	8.01e-12	Bipolar disorder;
CRC	cis	rs6735179	1.000	rs59771193	chr2:1778157	C/T	cg19300414	chr2:1746591	PXDN	0.36	6.19	0.32	1.76e-9	Response to antipsychotic treatment;
CRC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.5	6.94	0.36	2.14e-11	Lymphocyte counts;
CRC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-8.93	-0.44	3.17e-17	Educational attainment;
CRC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg20607287	chr7:12443886	VWDE	-0.63	-6.64	-0.34	1.28e-10	Coronary artery disease;
CRC	cis	rs2982552	0.773	rs62442016	chr6:152056053	C/A	cg22157087	chr6:152012887	ESR1	0.37	5.66	0.3	3.31e-8	Bone properties (heel);
CRC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.64	-9.17	-0.45	5.41e-18	DNA methylation (variation);
CRC	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.38	-0.33	6.11e-10	Systemic lupus erythematosus;
CRC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.39	-6.15	-0.32	2.21e-9	Neurofibrillary tangles;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg21548813	chr6:291882	DUSP22	-0.51	-7.1	-0.36	7.79e-12	Menopause (age at onset);
CRC	cis	rs11191205	0.686	rs12255825	chr10:103422107	A/C	cg15320455	chr10:103880129	LDB1	0.58	6.58	0.34	1.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.15	0.32	2.28e-9	Diabetic kidney disease;
CRC	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.51	-7.75	-0.39	1.19e-13	Plateletcrit;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg06494592	chr3:125709126	NA	-0.54	-6.57	-0.34	2e-10	Blood pressure (smoking interaction);
CRC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.4	6.21	0.32	1.63e-9	Red blood cell count;
CRC	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-0.47	-6.19	-0.32	1.76e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08341821	chr5:81573780	RPS23	0.46	6.43	0.33	4.54e-10	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.43	0.33	4.37e-10	Life satisfaction;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.68	9.3	0.46	2.03e-18	Vitiligo;
CRC	cis	rs854555	0.651	rs854546	chr7:94923764	A/C	cg19678392	chr7:94953810	PON1	0.44	5.99	0.31	5.35e-9	Response to TNF antagonist treatment;
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg22907277	chr7:1156413	C7orf50	0.48	5.73	0.3	2.31e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.47	-6.62	-0.34	1.43e-10	Eye color traits;
CRC	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.53	6.88	0.35	2.99e-11	Alzheimer's disease (survival time);
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg15845792	chr6:28175446	NA	0.95	13.85	0.61	1.07e-34	Parkinson's disease;
CRC	cis	rs12760731	0.565	rs12027396	chr1:178149200	T/C	cg00404053	chr1:178313656	RASAL2	1.02	10.73	0.51	3.15e-23	Obesity-related traits;
CRC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.46	-0.34	3.85e-10	Aortic root size;
CRC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.53	6.85	0.35	3.71e-11	Multiple sclerosis;
CRC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.61	-9.06	-0.45	1.15e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg10437265	chr15:77819839	NA	-0.44	-7.82	-0.4	7.14e-14	Type 2 diabetes;
CRC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg18016565	chr1:150552671	MCL1	0.42	5.9	0.31	8.82e-9	Melanoma;
CRC	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.34e-11	Response to antipsychotic treatment;
CRC	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.6	-8.59	-0.43	3.64e-16	Coronary artery disease;
CRC	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.94	-0.64	7.14e-39	Exhaled nitric oxide output;
CRC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	8.86	0.44	5.23e-17	Iron status biomarkers;
CRC	cis	rs972578	0.791	rs9607955	chr22:43216733	A/G	cg01576275	chr22:43409880	NA	-0.36	-5.63	-0.3	3.83e-8	Mean platelet volume;
CRC	cis	rs2179367	0.959	rs9322178	chr6:149693267	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.35	-5.76	-0.3	1.94e-8	Dupuytren's disease;
CRC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.26	0.37	2.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.52	-7.34	-0.38	1.65e-12	Fibrinogen levels;
CRC	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.4	5.99	0.31	5.54e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg09795085	chr6:101329169	ASCC3	-0.41	-5.71	-0.3	2.58e-8	Neuroticism;
CRC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg19682013	chr15:45996608	NA	0.32	6.57	0.34	2e-10	Waist circumference;Weight;
CRC	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.53	8.44	0.42	1.06e-15	Corneal astigmatism;
CRC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.41	-0.46	8.98e-19	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25593560	chr19:16187364	TPM4	0.38	6.04	0.32	4.2e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08635118	chr7:6144369	USP42	0.38	5.99	0.31	5.42e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18013408	chr7:100487659	UFSP1;ACHE	0.37	6.24	0.33	1.36e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg11707556	chr5:10655725	ANKRD33B	0.36	6.58	0.34	1.81e-10	Coronary artery disease;
CRC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.44	0.38	9.07e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.63	9.44	0.46	7.27e-19	Granulocyte count;Sum neutrophil eosinophil counts;
CRC	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	0.87	9.74	0.47	7.43e-20	Uric acid levels;
CRC	trans	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.77	-0.35	5.78e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.7	9.09	0.45	9.29e-18	Iron status biomarkers;
CRC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.58	8.59	0.43	3.57e-16	Prostate cancer;
CRC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.65	10.76	0.51	2.41e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7113874	0.655	rs67257872	chr11:8530218	A/G	cg02811074	chr11:8615871	STK33	-0.34	-5.76	-0.3	1.94e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg12568669	chr8:11666485	FDFT1	-0.32	-6.2	-0.32	1.74e-9	Monocyte count;
CRC	cis	rs1322512	1.000	rs2758776	chr6:153006317	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.18e-9	Tonometry;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg15845792	chr6:28175446	NA	0.7	8.22	0.41	4.63e-15	Depression;
CRC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.58	-6.98	-0.36	1.65e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17152411	0.895	rs61872119	chr10:126583534	A/G	cg07906193	chr10:126599966	NA	0.52	5.81	0.3	1.5e-8	Height;
CRC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg05132306	chr1:1846340	CALML6	0.42	6.49	0.34	3.22e-10	Body mass index;
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.55	8.76	0.43	1.03e-16	Electroencephalogram traits;
CRC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.73	0.43	1.32e-16	Rheumatoid arthritis;
CRC	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg09040174	chr2:113837401	NA	0.65	10.31	0.49	9.07e-22	Protein quantitative trait loci;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7487075	0.790	rs11183527	chr12:46946363	A/G	cg22049899	chr12:47219821	SLC38A4	0.29	5.81	0.31	1.44e-8	Itch intensity from mosquito bite;
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.9	-0.31	9.05e-9	Total body bone mineral density;
CRC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.02	10.71	0.51	3.68e-23	Skin colour saturation;
CRC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg08213375	chr14:104286397	PPP1R13B	0.57	11.69	0.54	1.26e-26	Schizophrenia;
CRC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.24	-0.37	3.29e-12	Major depressive disorder;
CRC	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.52	-0.43	5.89e-16	Biliary atresia;
CRC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.74	0.35	7.22e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.6	8.74	0.43	1.17e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.36	6.93	0.36	2.23e-11	Renal cell carcinoma;
CRC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.49	-9.58	-0.47	2.46e-19	Subjective well-being;
CRC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg18230493	chr5:56204884	C5orf35	-0.41	-5.91	-0.31	8.45e-9	Coronary artery disease;
CRC	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg13482628	chr17:19912719	NA	0.54	8.59	0.43	3.6e-16	Schizophrenia;
CRC	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg00738113	chr16:70207722	CLEC18C	0.42	6.11	0.32	2.76e-9	IgE levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25164226	chr22:47158357	TBC1D22A	0.46	6.51	0.34	2.88e-10	Response to antipsychotic treatment;
CRC	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.59	-7.78	-0.39	9.75e-14	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.7	0.47	1.01e-19	Platelet count;
CRC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.58	8.8	0.44	7.8e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.63	10.5	0.5	1.94e-22	Platelet count;
CRC	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.16	-23.51	-0.79	2.07e-72	Exhaled nitric oxide output;
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.2	-0.41	5.6e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg16486109	chr11:613632	IRF7	0.68	10.62	0.51	7.53e-23	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.96	0.48	1.32e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.36	-0.33	6.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.72	-0.35	7.92e-11	Inflammatory skin disease;
CRC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.36	-0.38	1.45e-12	Systolic blood pressure;
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.72	-0.3	2.43e-8	Life satisfaction;
CRC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.59	9.07	0.45	1.14e-17	Vitiligo;
CRC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.34	-6.14	-0.32	2.38e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26587870	chr6:27730563	NA	-0.6	-5.88	-0.31	1.02e-8	Depression;
CRC	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.63	-0.34	1.39e-10	Total body bone mineral density;
CRC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.76	-9.76	-0.47	6.15e-20	Bone mineral density;
CRC	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.66	8.96	0.44	2.55e-17	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg02018176	chr4:1364513	KIAA1530	0.39	6.58	0.34	1.88e-10	Obesity-related traits;
CRC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.53	-0.34	2.52e-10	Triglycerides;
CRC	trans	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	7.3	0.37	2.16e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-9.14	-0.45	6.8e-18	Bipolar disorder;
CRC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg10876282	chr6:28092338	ZSCAN16	0.46	6.3	0.33	9.74e-10	Parkinson's disease;
CRC	cis	rs4654899	0.865	rs6658526	chr1:21391314	A/G	cg02927042	chr1:21476669	EIF4G3	0.52	7.4	0.38	1.17e-12	Superior frontal gyrus grey matter volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17133967	chr10:60144921	TFAM	0.41	6.18	0.32	1.85e-9	Intelligence (multi-trait analysis);
CRC	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg02072170	chr3:194406190	FAM43A	0.49	8.69	0.43	1.72e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.88	-0.48	2.45e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4731207	0.596	rs3903521	chr7:124668184	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.73e-9	Cutaneous malignant melanoma;
CRC	cis	rs902774	0.818	rs73110464	chr12:53312612	C/T	cg16329197	chr12:53359506	NA	-0.56	-6.4	-0.33	5.45e-10	Prostate cancer;
CRC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-7.49	-0.38	6.52e-13	Colorectal cancer;
CRC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.75	0.51	2.57e-23	Heart rate;
CRC	cis	rs4711350	0.862	rs570749	chr6:33710229	C/T	cg07979401	chr6:33739406	LEMD2	0.48	5.95	0.31	6.9e-9	Schizophrenia;
CRC	cis	rs449789	0.857	rs543547	chr6:159702351	A/G	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.47	8.01	0.4	2.04e-14	Colorectal or endometrial cancer;
CRC	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.63	9.89	0.48	2.39e-20	Corneal astigmatism;
CRC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.55	-7.25	-0.37	3.06e-12	Systolic blood pressure;
CRC	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg10820045	chr2:198174542	NA	0.45	7.5	0.38	6.08e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg21665744	chr7:39171113	POU6F2	0.44	5.9	0.31	9.26e-9	IgG glycosylation;
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.99	0.31	5.54e-9	Breast cancer;
CRC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.76	11.1	0.52	1.61e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg19418318	chr19:17219073	MYO9B	-0.48	-7.84	-0.4	6.46e-14	Reticulocyte fraction of red cells;
CRC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-5.88	-0.31	9.87e-9	Height;
CRC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7215564	0.908	rs1471788	chr17:78672153	A/G	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.19e-9	Myopia (pathological);
CRC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.41	5.88	0.31	1.01e-8	Renal cell carcinoma;
CRC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.73	0.43	1.33e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.47	-0.34	3.54e-10	Breast cancer;
CRC	cis	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05901451	chr6:126070800	HEY2	-0.43	-6.57	-0.34	1.96e-10	Endometrial cancer;
CRC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-8.43	-0.42	1.09e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.66	8.13	0.41	8.84e-15	Menarche (age at onset);
CRC	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg02175503	chr12:58329896	NA	0.83	13.72	0.6	3.43e-34	Intelligence (multi-trait analysis);
CRC	cis	rs7781557	1.000	rs4610658	chr7:102445895	T/C	cg18108683	chr7:102477205	FBXL13	-0.51	-6.64	-0.34	1.28e-10	Colorectal adenoma (advanced);
CRC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.62	10.97	0.52	4.55e-24	Schizophrenia;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg27532560	chr4:187881888	NA	-0.57	-10.37	-0.5	5.51e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg24849736	chr1:201084428	NA	0.49	6.71	0.35	8.35e-11	Permanent tooth development;
CRC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.18	-0.41	6.09e-15	Type 2 diabetes;
CRC	cis	rs4731207	0.698	rs6466948	chr7:124444763	G/A	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.5	6.23	0.32	1.43e-9	Recombination rate (females);
CRC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.27	-0.33	1.14e-9	Aortic root size;
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg15845792	chr6:28175446	NA	0.97	13.15	0.59	4.96e-32	Depression;
CRC	cis	rs10512697	0.803	rs13172912	chr5:3578445	A/G	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg10298567	chr3:47292165	KIF9	-0.39	-6.2	-0.32	1.73e-9	Colorectal cancer;
CRC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.28	-0.46	2.3e-18	Intelligence (multi-trait analysis);
CRC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.3	0.33	9.56e-10	Rheumatoid arthritis;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20849121	chr1:12679951	NA	-0.38	-6.12	-0.32	2.72e-9	Daytime sleep phenotypes;
CRC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.93	-17.32	-0.69	3.21e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	0.6	6.87	0.35	3.31e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	0.98	10.07	0.49	5.61e-21	Gut microbiota (bacterial taxa);
CRC	trans	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.43	6.13	0.32	2.45e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.47	8.97	0.44	2.23e-17	Educational attainment (years of education);
CRC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg21251018	chr6:28226885	NKAPL	0.6	11.25	0.53	4.64e-25	Pubertal anthropometrics;
CRC	cis	rs2811415	0.597	rs9812487	chr3:127807835	G/C	cg13719885	chr3:127795394	NA	-0.39	-5.9	-0.31	9.05e-9	Lung function (FEV1/FVC);
CRC	cis	rs12745968	0.560	rs1325434	chr1:92961332	T/C	cg17283838	chr1:93427260	FAM69A	-0.45	-6.2	-0.32	1.73e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.88	-0.4	4.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.67	-0.3	3.15e-8	Neuroticism;
CRC	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg04439458	chr5:138467593	SIL1	-0.35	-5.97	-0.31	6.02e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-6.3	-0.33	9.42e-10	Psoriasis;
CRC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6479527	0.840	rs1331219	chr9:96766248	A/G	cg14459158	chr9:96720562	NA	0.38	6.99	0.36	1.51e-11	Esophageal adenocarcinoma;
CRC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.31e-10	Bipolar disorder;
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg10724054	chr17:3904396	NA	-0.48	-8.12	-0.41	9.44e-15	Type 2 diabetes;
CRC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg18827107	chr12:86230957	RASSF9	-0.49	-8.07	-0.41	1.3e-14	Major depressive disorder;
CRC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.51	9.07	0.45	1.11e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.56	8.42	0.42	1.14e-15	Lymphocyte counts;
CRC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg09654669	chr8:57350985	NA	-0.44	-6.52	-0.34	2.72e-10	Obesity-related traits;
CRC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.66	-0.47	1.38e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.14	0.45	6.61e-18	Mean platelet volume;
CRC	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.49	-7.11	-0.36	7.4e-12	Response to antidepressants in depression;
CRC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg03037974	chr15:76606532	NA	0.73	12.94	0.58	3.12e-31	Blood metabolite levels;
CRC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg00769240	chr8:12517080	NA	-0.58	-6.84	-0.35	3.99e-11	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.63e-12	Lung cancer;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04571327	chr6:97345972	NDUFAF4	0.41	6.05	0.32	3.92e-9	Myopia (pathological);
CRC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.42	-5.61	-0.3	4.19e-8	Menarche (age at onset);
CRC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg23136738	chr11:925521	AP2A2	-0.43	-7.21	-0.37	3.89e-12	Alzheimer's disease (late onset);
CRC	cis	rs4290604	0.748	rs62184776	chr2:238019306	T/G	cg23555395	chr2:238036564	NA	0.57	5.98	0.31	5.96e-9	Asthma;
CRC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	10.67	0.51	5.17e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.82e-15	Mean platelet volume;
CRC	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.82	9.11	0.45	8.14e-18	Anti-saccade response;
CRC	cis	rs2179367	0.959	rs9373589	chr6:149707288	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.03	-0.32	4.29e-9	Dupuytren's disease;
CRC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.12	-0.45	7.52e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6585424	1.000	rs35483545	chr10:81939173	T/C	cg11900509	chr10:81946545	ANXA11	-0.76	-9.33	-0.46	1.56e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10457605	chr15:48623664	DUT	0.4	6.48	0.34	3.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-9.82	-0.48	3.83e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	8.01	0.4	2.07e-14	Height;
CRC	cis	rs3751196	0.522	rs17034593	chr12:104190869	C/T	cg02344784	chr12:104178138	NT5DC3	0.69	7.05	0.36	1.06e-11	Sense of smell;
CRC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.62	10.67	0.51	5.08e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.54	0.34	2.31e-10	Schizophrenia;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.46	6.77	0.35	5.88e-11	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19305511	chr19:9694932	ZNF121	0.46	6.5	0.34	2.93e-10	Response to antipsychotic treatment;
CRC	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg12072164	chr19:44306565	LYPD5	0.41	6.41	0.33	5.16e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg23463467	chr20:60627584	TAF4	0.38	7.91	0.4	4.02e-14	Body mass index;
CRC	cis	rs354033	1.000	rs3735320	chr7:149246680	A/T	cg24335155	chr7:149193227	ZNF746	0.36	5.63	0.3	3.94e-8	Multiple sclerosis;
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.45	5.81	0.31	1.46e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg23100626	chr2:96804247	ASTL	0.28	7.97	0.4	2.59e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.6	7.02	0.36	1.24e-11	Vitiligo;
CRC	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg05507819	chr15:63340323	TPM1	0.44	5.61	0.3	4.39e-8	HDL cholesterol;
CRC	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg04749549	chr19:17459798	NA	-0.44	-7.54	-0.38	4.77e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs9908102	0.710	rs8079762	chr17:12910795	T/C	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg02725872	chr8:58115012	NA	-0.38	-7.0	-0.36	1.46e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.7	8.82	0.44	6.69e-17	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.64	11.62	0.54	2.13e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.47	0.42	8.03e-16	Rheumatoid arthritis;
CRC	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg03690763	chr11:133734501	NA	-0.35	-5.87	-0.31	1.06e-8	Childhood ear infection;
CRC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13198984	chr17:80129470	CCDC57	0.39	6.39	0.33	5.57e-10	Life satisfaction;
CRC	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.42	7.13	0.37	6.31e-12	Childhood ear infection;
CRC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.99	-0.48	1.07e-20	Height;
CRC	cis	rs3736485	0.873	rs11630336	chr15:51871643	T/C	cg08986416	chr15:51914746	DMXL2	-0.48	-6.74	-0.35	7.14e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7712401	0.791	rs154507	chr5:122200907	C/G	cg18764291	chr5:122110994	SNX2	-0.41	-6.55	-0.34	2.23e-10	Mean platelet volume;
CRC	cis	rs501120	1.000	rs620356	chr10:44761073	A/C	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg03013636	chr16:1946785	NA	0.53	6.73	0.35	7.57e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.71	0.47	9.14e-20	Cognitive test performance;
CRC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-13.76	-0.6	2.34e-34	Vitiligo;
CRC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-9.26	-0.45	2.74e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg21155778	chr12:95611301	FGD6;VEZT	-0.54	-6.13	-0.32	2.54e-9	Lung adenocarcinoma;
CRC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.6	-10.17	-0.49	2.67e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs4363385	0.782	rs4845336	chr1:153003853	C/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.72	-0.35	8.19e-11	Inflammatory skin disease;
CRC	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.29	0.37	2.34e-12	Diisocyanate-induced asthma;
CRC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.79	-0.35	5.4e-11	Lung cancer;
CRC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg11212589	chr17:38028394	ZPBP2	0.33	5.77	0.3	1.8e-8	Asthma;
CRC	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg01843034	chr6:37503916	NA	-0.41	-7.44	-0.38	8.7e-13	Cognitive performance;
CRC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.55	-8.08	-0.41	1.27e-14	Platelet distribution width;
CRC	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.44	7.02	0.36	1.31e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.51e-24	Motion sickness;
CRC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.73e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg25164649	chr6:28176230	NA	0.64	9.04	0.45	1.41e-17	Parkinson's disease;
CRC	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.93	11.66	0.54	1.56e-26	Exhaled nitric oxide levels;
CRC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg04121214	chr22:50244548	NA	0.4	5.61	0.3	4.26e-8	Schizophrenia;
CRC	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.77	0.44	9.81e-17	Mean corpuscular volume;
CRC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-12.19	-0.56	1.82e-28	Mean platelet volume;Platelet distribution width;
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg04118306	chr8:24772350	NEFM	-0.37	-6.67	-0.35	1.07e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.48	-0.34	3.27e-10	Coronary artery disease;
CRC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg00334542	chr7:100209784	MOSPD3	-0.54	-6.8	-0.35	4.82e-11	Other erythrocyte phenotypes;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6586163	0.872	rs7914490	chr10:90747447	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.08	-0.36	8.95e-12	Chronic lymphocytic leukemia;
CRC	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.58	-8.52	-0.43	5.79e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-7.95	-0.4	3.03e-14	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.51	-6.08	-0.32	3.29e-9	Body mass index;
CRC	cis	rs56399783	0.901	rs73033408	chr7:2879755	C/T	cg19731401	chr7:2775893	GNA12	0.62	6.1	0.32	2.95e-9	Childhood ear infection;
CRC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	8.43	0.42	1.06e-15	Personality dimensions;
CRC	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.73	-11.89	-0.55	2.25e-27	Mean platelet volume;
CRC	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.81	-13.7	-0.6	4.23e-34	Hip circumference;
CRC	trans	rs783540	0.967	rs1259183	chr15:83279433	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.2	-0.32	1.67e-9	Schizophrenia;
CRC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.71e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.45	9.07	0.45	1.12e-17	Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg27398640	chr15:77910606	LINGO1	-0.41	-6.85	-0.35	3.59e-11	Type 2 diabetes;
CRC	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.75	-0.3	2.03e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.62	0.43	2.95e-16	Menopause (age at onset);
CRC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.61	9.24	0.45	3.23e-18	Testicular germ cell tumor;
CRC	cis	rs1472360	0.505	rs1496526	chr8:86273899	G/A	cg21346043	chr8:86351067	CA3	-0.39	-7.05	-0.36	1.09e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg03030879	chr14:75389066	RPS6KL1	0.42	6.47	0.34	3.57e-10	Height;
CRC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg25834613	chr7:1915315	MAD1L1	-0.47	-6.78	-0.35	5.54e-11	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg25985355	chr7:65971099	NA	-0.5	-5.73	-0.3	2.25e-8	Diabetic kidney disease;
CRC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.84	-18.41	-0.71	1.59e-52	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3764400	0.567	rs12946143	chr17:46154943	C/T	cg10706073	chr17:46328419	SKAP1	-0.62	-6.7	-0.35	8.86e-11	Body mass index;
CRC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg18867708	chr6:26865862	GUSBL1	0.37	5.67	0.3	3.09e-8	Schizophrenia;
CRC	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.45	-7.06	-0.36	9.69e-12	Obesity-related traits;
CRC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.68	-8.46	-0.42	9.01e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.13	0.41	8.85e-15	Red cell distribution width;
CRC	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs9392556	0.600	rs664299	chr6:4112241	T/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.23	5.7	0.3	2.68e-8	Blood metabolite levels;
CRC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.34	5.71	0.3	2.58e-8	Emphysema distribution in smoking;
CRC	cis	rs1971762	0.527	rs6580952	chr12:53937452	C/T	cg06632207	chr12:54070931	ATP5G2	0.44	7.45	0.38	8.2e-13	Height;
CRC	cis	rs16924133	0.793	rs58883629	chr11:33128729	G/T	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs394563	0.601	rs391875	chr6:149795136	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.52	-0.34	2.67e-10	Dupuytren's disease;
CRC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg09455208	chr3:40491958	NA	0.32	6.58	0.34	1.89e-10	Renal cell carcinoma;
CRC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.7	-0.3	2.61e-8	Type 2 diabetes;
CRC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.7	9.3	0.46	2.08e-18	High light scatter reticulocyte count;
CRC	trans	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg17948913	chr5:572064	NA	0.55	6.2	0.32	1.71e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-6.27	-0.33	1.11e-9	Total body bone mineral density;
CRC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.56	8.54	0.43	4.98e-16	Aortic root size;
CRC	cis	rs1190552	0.894	rs1190546	chr14:102904966	A/G	cg18135206	chr14:102964638	TECPR2	-0.5	-6.15	-0.32	2.24e-9	Blood protein levels;
CRC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg13390004	chr1:15929781	NA	0.5	7.07	0.36	9.53e-12	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.97	17.11	0.69	2.09e-47	Menarche (age at onset);
CRC	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.9	-0.52	8.13e-24	Electroencephalogram traits;
CRC	cis	rs231513	0.871	rs231522	chr17:41954602	A/G	cg26893861	chr17:41843967	DUSP3	-0.72	-6.5	-0.34	3.05e-10	Cognitive function;
CRC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.47	7.83	0.4	6.55e-14	Major depressive disorder;
CRC	trans	rs7544372	0.945	rs2066381	chr1:240995427	G/A	cg24990238	chr5:169816960	KCNMB1;KCNIP1	-0.57	-6.29	-0.33	9.89e-10	Obesity-related traits;
CRC	cis	rs501916	0.605	rs8031169	chr15:48080330	G/C	cg16110827	chr15:48056943	SEMA6D	-0.48	-7.24	-0.37	3.13e-12	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg26603656	chr10:5671107	NA	0.44	7.53	0.38	4.82e-13	Breast cancer;
CRC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg19761014	chr17:28927070	LRRC37B2	0.6	5.94	0.31	7.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2718058	0.692	rs2709117	chr7:37787807	A/G	cg24998770	chr7:37888106	TXNDC3	0.35	5.87	0.31	1.08e-8	Alzheimer's disease (late onset);
CRC	trans	rs3001167	0.609	rs6428253	chr1:194563821	G/A	cg22004422	chr13:113740730	MCF2L	-0.61	-6.19	-0.32	1.77e-9	Obesity-related traits;
CRC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.39	6.08	0.32	3.31e-9	Methadone dose in opioid dependence;
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg15845792	chr6:28175446	NA	0.85	13.44	0.6	3.94e-33	Cardiac Troponin-T levels;
CRC	cis	rs427941	0.667	rs34247954	chr7:101740993	C/T	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.36e-24	Prudent dietary pattern;
CRC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg18512352	chr11:47633146	NA	0.34	6.55	0.34	2.28e-10	Subjective well-being;
CRC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.57	9.51	0.46	4.04e-19	Iron status biomarkers;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.2	-0.37	4.22e-12	Lymphocyte counts;
CRC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-10.93	-0.52	6.02e-24	Platelet distribution width;
CRC	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.87	-15.04	-0.64	2.92e-39	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.24	-0.37	3.19e-12	Crohn's disease;
CRC	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.45	6.09	0.32	3.07e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.97	-0.36	1.7e-11	QT interval;
CRC	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg01620082	chr3:125678407	NA	-0.6	-6.22	-0.32	1.54e-9	Depression;
CRC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.71	-0.35	8.76e-11	Menarche (age at onset);
CRC	trans	rs2890652	0.639	rs59504099	chr2:142966123	G/T	cg00809969	chr7:27181067	HOXA5	-0.67	-6.09	-0.32	3.1e-9	Body mass index;
CRC	trans	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.9e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06307176	chr5:131281290	NA	-0.43	-6.35	-0.33	7.01e-10	Life satisfaction;
CRC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.64	10.54	0.5	1.37e-22	Mean corpuscular hemoglobin;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11645453	chr3:52864694	ITIH4	0.35	6.1	0.32	3.04e-9	Bipolar disorder;
CRC	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.59	-0.39	3.31e-13	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01333225	chr19:16222203	RAB8A	0.44	6.35	0.33	7.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg06917450	chr1:38156652	C1orf109	-0.51	-7.07	-0.36	9.32e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.09	0.32	3.13e-9	Height;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg04380228	chr2:47142555	MCFD2	-0.41	-6.03	-0.32	4.51e-9	Daytime sleep phenotypes;
CRC	cis	rs12249377	0.519	rs7087400	chr10:92587180	A/G	cg14313238	chr10:92632228	RPP30	0.47	6.57	0.34	2e-10	White matter microstructure (global fractional anisotropy);
CRC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.43	6.8	0.35	4.82e-11	Blood metabolite levels;
CRC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.29	-0.42	2.95e-15	Gut microbiome composition (summer);
CRC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.62	9.03	0.45	1.52e-17	Morning vs. evening chronotype;
CRC	cis	rs12467847	0.965	rs12467810	chr2:113691060	A/G	cg12858261	chr2:113808755	IL1F8	0.4	5.85	0.31	1.22e-8	Response to amphetamines;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg25164649	chr6:28176230	NA	0.63	5.9	0.31	9.05e-9	Depression;
CRC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.87	-0.35	3.19e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25467969	chr19:17337038	OCEL1	-0.41	-6.18	-0.32	1.87e-9	Myopia (pathological);
CRC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.88	-0.35	3.06e-11	Urate levels in overweight individuals;
CRC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.74	10.8	0.51	1.73e-23	Cognitive function;
CRC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.13	0.37	6.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg08992911	chr2:238395768	MLPH	0.57	5.87	0.31	1.09e-8	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15447669	chr2:234160727	ATG16L1	0.42	5.99	0.31	5.42e-9	Response to antipsychotic treatment;
CRC	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.97	-0.31	6.27e-9	Alzheimer's disease (survival time);
CRC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.66	-8.11	-0.41	1e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.78	11.37	0.53	1.73e-25	Height;
CRC	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.51	7.3	0.37	2.24e-12	Ovarian reserve;
CRC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg02527881	chr3:46936655	PTH1R	-0.39	-7.46	-0.38	7.55e-13	Colorectal cancer;
CRC	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg00666640	chr1:248458726	OR2T12	-0.42	-7.67	-0.39	1.97e-13	Common traits (Other);
CRC	cis	rs9311676	0.594	rs55954186	chr3:58436476	G/A	cg06643156	chr3:58380774	PXK	0.42	6.2	0.32	1.73e-9	Systemic lupus erythematosus;
CRC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg15848620	chr12:58087721	OS9	-0.62	-8.5	-0.42	6.6e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23378565	chr7:2036160	MAD1L1	-0.47	-6.65	-0.34	1.25e-10	Bipolar disorder;
CRC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.08	0.32	3.33e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs12318506	0.623	rs12313311	chr12:75768327	A/T	cg04728562	chr12:75699417	CAPS2	-0.74	-5.89	-0.31	9.7e-9	Coronary artery calcification;
CRC	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.23	-0.33	1.39e-9	Fractional excretion of uric acid;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg22079747	chr2:228736145	WDR69	-0.45	-6.15	-0.32	2.29e-9	Blood pressure;
CRC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.83	-13.24	-0.59	2.27e-32	Blood metabolite levels;
CRC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.82	0.31	1.42e-8	Self-reported allergy;
CRC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg16268157	chr7:99778414	STAG3	-0.43	-5.72	-0.3	2.45e-8	Lung function (FEV1/FVC);
CRC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.84	0.51	1.3e-23	Motion sickness;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20918128	chr11:3663777	ART5	0.36	6.11	0.32	2.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.44	5.84	0.31	1.28e-8	Obesity-related traits;
CRC	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.84	-13.71	-0.6	3.9e-34	Hypospadias;
CRC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-6.01	-0.31	5.02e-9	Cognitive function;
CRC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	9.25	0.45	2.9e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg05569086	chr8:143859399	LYNX1	-0.48	-8.57	-0.43	4.02e-16	Urinary tract infection frequency;
CRC	cis	rs2013441	0.866	rs8070401	chr17:20214492	C/T	cg13482628	chr17:19912719	NA	-0.39	-5.69	-0.3	2.86e-8	Obesity-related traits;
CRC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.64	10.59	0.5	9.73e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.38	6.01	0.31	4.87e-9	Left ventricle wall thickness;
CRC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-5.84	-0.31	1.25e-8	Mean platelet volume;
CRC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.69	9.74	0.47	7.27e-20	Bladder cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25824226	chr8:110551708	EBAG9	0.45	6.15	0.32	2.31e-9	Response to antipsychotic treatment;
CRC	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg22561889	chr6:118971681	C6orf204	0.48	6.03	0.32	4.35e-9	Diastolic blood pressure;
CRC	cis	rs6681460	0.933	rs7554101	chr1:67156472	A/G	cg02459107	chr1:67143332	SGIP1	-0.36	-6.19	-0.32	1.82e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.4	0.38	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1712517	0.904	rs6584547	chr10:105065409	C/T	cg05636881	chr10:105038444	INA	0.46	8.0	0.4	2.19e-14	Migraine;
CRC	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.8	-14.32	-0.62	1.69e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06365992	chr16:87350825	NA	-0.5	-6.1	-0.32	3.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-7.17	-0.37	4.97e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	24.96	0.81	6.84e-78	Schizophrenia;
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.22	-0.49	1.76e-21	Bipolar disorder;
CRC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.72	10.12	0.49	3.77e-21	Heart rate;
CRC	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.62	8.34	0.42	2.13e-15	Coronary artery disease;
CRC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	16.26	0.67	4.86e-44	Chronic sinus infection;
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg05313129	chr8:58192883	C8orf71	-0.43	-5.83	-0.31	1.36e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.66	9.37	0.46	1.19e-18	Vitamin D levels;
CRC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.75	-14.78	-0.63	2.83e-38	Prostate cancer;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.57	10.3	0.49	9.72e-22	Tonsillectomy;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg15845792	chr6:28175446	NA	0.83	12.37	0.56	4.15e-29	Parkinson's disease;
CRC	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.89	-11.24	-0.53	5.16e-25	Exhaled nitric oxide levels;
CRC	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.44	-0.33	4.26e-10	Acne (severe);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10699881	chr4:6271512	WFS1	0.42	5.98	0.31	5.94e-9	Anxiety disorder;
CRC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.37	5.66	0.3	3.34e-8	Height;
CRC	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	10.09	0.49	4.78e-21	Myopia (pathological);
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.76	0.54	6.89e-27	Prudent dietary pattern;
CRC	trans	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	6.36	0.33	6.71e-10	Mean corpuscular volume;
CRC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	0.68	6.99	0.36	1.53e-11	Body mass index;
CRC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.86	0.4	5.53e-14	Mean corpuscular volume;
CRC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg15205204	chr1:6545172	PLEKHG5	0.41	5.77	0.3	1.85e-8	Body mass index;
CRC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg18721089	chr20:30220636	NA	-0.35	-5.63	-0.3	3.91e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.35	5.7	0.3	2.69e-8	Sitting height ratio;
CRC	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg13206674	chr6:150067644	NUP43	0.67	9.97	0.48	1.25e-20	Lung cancer;
CRC	cis	rs2084637	1.000	rs12223365	chr11:122416976	C/A	cg21585512	chr11:122030076	LOC399959	-0.38	-6.78	-0.35	5.47e-11	Stroke;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15394763	chr10:77054788	NA	0.39	6.27	0.33	1.15e-9	Obesity-related traits;
CRC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.43	6.9	0.36	2.6e-11	Height;
CRC	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.67	-11.02	-0.52	3.09e-24	Hepatocellular carcinoma;
CRC	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.4	-6.31	-0.33	9.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.38	0.33	6.1e-10	Cognitive ability;
CRC	cis	rs2227564	0.620	rs11000785	chr10:75575963	T/C	cg16540259	chr10:75572220	NDST2	0.51	7.94	0.4	3.27e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.64	-9.66	-0.47	1.39e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6788895	1.000	rs6795396	chr3:150510227	C/T	cg09723797	chr3:150481914	SIAH2	0.86	6.3	0.33	9.6e-10	Breast cancer;
CRC	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg15870184	chr7:99517151	TRIM4	0.38	6.09	0.32	3.16e-9	Parkinson's disease;
CRC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg03340356	chr1:67600835	NA	0.29	6.4	0.33	5.34e-10	Psoriasis;
CRC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg13390004	chr1:15929781	NA	0.5	7.08	0.36	8.64e-12	Systolic blood pressure;
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg12516270	chr8:143859308	LYNX1	0.44	7.79	0.39	8.89e-14	Urinary tract infection frequency;
CRC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.64	8.58	0.43	3.81e-16	Height;
CRC	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.71	10.22	0.49	1.81e-21	Obesity-related traits;
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg23123621	chr4:1343375	KIAA1530	0.32	5.64	0.3	3.65e-8	Obesity-related traits;
CRC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.67	-5.69	-0.3	2.85e-8	Diabetic retinopathy;
CRC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.62	9.17	0.45	5.4e-18	Breast cancer;
CRC	trans	rs1572438	0.619	rs9502684	chr6:866737	G/A	cg01563465	chr5:72512441	NA	0.31	6.14	0.32	2.4e-9	Aging;
CRC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs939584	0.935	rs12714413	chr2:642253	T/C	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.49	7.43	0.38	9.46e-13	Methadone dose in opioid dependence;
CRC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.32	0.33	8.69e-10	Menarche (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16868751	chr10:96162146	TBC1D12	-0.5	-6.48	-0.34	3.36e-10	Diisocyanate-induced asthma;
CRC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.62	7.4	0.38	1.18e-12	Cleft lip with or without cleft palate;
CRC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.16	13.27	0.59	1.71e-32	Diabetic kidney disease;
CRC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.67	-0.63	7.74e-38	Lymphocyte percentage of white cells;
CRC	cis	rs7605827	0.897	rs1996516	chr2:15517246	G/A	cg19274914	chr2:15703543	NA	0.39	5.94	0.31	7.35e-9	Educational attainment (years of education);
CRC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-7.79	-0.39	9.08e-14	Vitamin D levels;
CRC	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg18833306	chr6:118973337	C6orf204	0.45	5.72	0.3	2.35e-8	Diastolic blood pressure;
CRC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg10790698	chr19:18539756	SSBP4	-0.47	-8.79	-0.44	8.33e-17	Breast cancer;
CRC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.73	6.79	0.35	5.22e-11	Major depressive disorder;
CRC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	8.9	0.44	3.79e-17	Lymphocyte counts;
CRC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg02428538	chr16:24856791	SLC5A11	0.56	6.76	0.35	6.38e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg21856205	chr7:94953877	PON1	-0.51	-6.51	-0.34	2.73e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.62	10.27	0.49	1.16e-21	Hemoglobin concentration;Hematocrit;
CRC	trans	rs2303319	0.504	rs62188728	chr2:162335701	T/C	cg11875773	chr22:50468633	TTLL8	-0.68	-6.05	-0.32	3.92e-9	Cognitive function;
CRC	trans	rs3008706	0.584	rs7856877	chr9:15852445	G/C	cg15918921	chr2:74212782	NA	-0.53	-6.1	-0.32	2.9e-9	Bilirubin levels;
CRC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.24	-0.53	4.82e-25	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16435601	chr17:65822392	BPTF	0.41	6.35	0.33	7.25e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg21110645	chr1:207815933	NA	-0.38	-6.05	-0.32	4.04e-9	Erythrocyte sedimentation rate;
CRC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.54	-8.79	-0.44	8.63e-17	Coronary artery disease;
CRC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.37	0.38	1.4e-12	Menopause (age at onset);
CRC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.55	-8.34	-0.42	2.11e-15	Calcium levels;
CRC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.88	0.4	4.67e-14	Lung cancer;
CRC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg03959625	chr15:84868606	LOC388152	0.41	6.04	0.32	4.05e-9	Schizophrenia;
CRC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	7.82	0.4	7.26e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-12.73	-0.57	1.94e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.65	-9.78	-0.47	5.43e-20	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg25110126	chr1:46999211	NA	0.46	7.02	0.36	1.25e-11	Monobrow;
CRC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.35	0.69	2.37e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg12682573	chr17:27188876	MIR451;MIR144	-0.57	-7.92	-0.4	3.79e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	5.69	0.3	2.8e-8	Schizophrenia;
CRC	cis	rs7082209	1.000	rs7082209	chr10:44814336	C/T	cg09554077	chr10:44749378	NA	-0.42	-5.66	-0.3	3.38e-8	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
CRC	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-7.44	-0.38	8.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.53	-8.81	-0.44	7.21e-17	Metabolite levels;
CRC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.77	-0.44	9.76e-17	Hemoglobin concentration;
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.43	5.99	0.31	5.36e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14640386	chr17:5185735	RABEP1	-0.39	-5.98	-0.31	5.91e-9	Myopia (pathological);
CRC	cis	rs1532331	0.966	rs6451674	chr5:43110754	C/T	cg09164108	chr5:43007320	NA	0.38	5.73	0.3	2.23e-8	Menarche (age at onset);
CRC	cis	rs6743376	0.532	rs2515395	chr2:113818702	G/C	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-8.82	-0.44	7.07e-17	Monocyte percentage of white cells;
CRC	cis	rs7932354	0.528	rs11039107	chr11:47157866	G/A	cg03339077	chr11:47165057	C11orf49	-0.46	-6.36	-0.33	6.9e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs501916	1.000	rs648627	chr15:48055738	C/T	cg16110827	chr15:48056943	SEMA6D	-0.36	-6.07	-0.32	3.49e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.66	-10.21	-0.49	1.9e-21	Huntington's disease progression;
CRC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg14122633	chr5:456516	EXOC3	-0.4	-7.16	-0.37	5.37e-12	Cystic fibrosis severity;
CRC	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg17294928	chr15:75287854	SCAMP5	-0.41	-6.04	-0.32	4.14e-9	Caffeine consumption;
CRC	cis	rs490234	0.934	rs13293237	chr9:128430966	T/C	cg14078157	chr9:128172775	NA	-0.37	-6.08	-0.32	3.26e-9	Mean arterial pressure;
CRC	cis	rs9462027	0.628	rs6929567	chr6:34692735	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.34	6.07	0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg19812747	chr11:111475976	SIK2	-0.56	-9.46	-0.46	5.87e-19	Primary sclerosing cholangitis;
CRC	cis	rs12760731	0.623	rs71628283	chr1:178458450	G/A	cg00404053	chr1:178313656	RASAL2	0.95	9.31	0.46	1.93e-18	Obesity-related traits;
CRC	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.69	-12.38	-0.56	3.63e-29	Leprosy;
CRC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.43	7.36	0.38	1.47e-12	Diastolic blood pressure;
CRC	cis	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg03623178	chr6:28175578	NA	-0.7	-7.3	-0.37	2.15e-12	Depression;
CRC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.88	-0.31	9.88e-9	Type 2 diabetes;
CRC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.43	8.76	0.43	1.05e-16	Renal cell carcinoma;
CRC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.21	-0.45	4.04e-18	Alcohol dependence;
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.3	-0.33	9.31e-10	Bipolar disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15008879	chr10:22292810	DNAJC1	0.47	6.19	0.32	1.78e-9	Thyroid stimulating hormone;
CRC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.07	10.6	0.5	8.87e-23	Diabetic retinopathy;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg08034379	chr2:228736324	WDR69	-0.54	-7.27	-0.37	2.63e-12	Blood pressure;
CRC	trans	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.52	-0.34	2.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.51	8.14	0.41	8.43e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg03233332	chr7:66118400	NA	-0.44	-6.22	-0.32	1.49e-9	Aortic root size;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	10.21	0.49	1.95e-21	Lymphocyte counts;
CRC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.78	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7539118	0.623	rs12127810	chr1:189526779	C/T	cg17255063	chr4:41751830	PHOX2B	-0.57	-6.25	-0.33	1.24e-9	Daytime sleep phenotypes;
CRC	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg23684204	chr15:91497937	RCCD1	0.45	6.8	0.35	4.84e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg25456477	chr12:86230367	RASSF9	0.33	5.62	0.3	4.16e-8	Major depressive disorder;
CRC	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.06e-12	HDL cholesterol;
CRC	trans	rs1490453	0.629	rs6829009	chr4:149247221	G/C	cg09978996	chr10:70321668	TET1	-0.41	-6.03	-0.32	4.29e-9	Biochemical measures;
CRC	cis	rs1950626	0.623	rs61991083	chr14:101436435	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.75	12.07	0.55	5.21e-28	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.54	-6.82	-0.35	4.5e-11	Personality dimensions;
CRC	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.72	-6.94	-0.36	2.05e-11	Putamen volume;
CRC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs7074356	0.522	rs1591958	chr10:82062661	G/A	cg27171509	chr10:82033454	MAT1A	-0.41	-7.88	-0.4	4.76e-14	Borderline personality disorder;
CRC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg13319975	chr6:146136371	FBXO30	0.39	5.84	0.31	1.24e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.44	-6.7	-0.35	8.85e-11	Mean platelet volume;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12273811	chr6:28175739	NA	-0.74	-10.32	-0.49	7.94e-22	Depression;
CRC	cis	rs9292777	0.692	rs55904678	chr5:40397400	T/C	cg09067459	chr5:40385259	NA	-0.55	-9.01	-0.44	1.72e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg09658497	chr7:2847517	GNA12	-0.38	-6.32	-0.33	8.47e-10	Height;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg02683197	chr6:28174875	NA	0.54	6.94	0.36	2.11e-11	Parkinson's disease;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.58	8.46	0.42	8.89e-16	Parkinson's disease;
CRC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.55	8.17	0.41	6.58e-15	Obesity-related traits;
CRC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.81	11.79	0.55	5.12e-27	Response to antineoplastic agents;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg15786705	chr6:28176104	NA	0.62	6.67	0.34	1.11e-10	Depression;
CRC	trans	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.97	0.36	1.73e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.32	-0.33	8.72e-10	Caffeine consumption;
CRC	cis	rs2275731	0.505	rs7894216	chr10:16479251	C/G	cg04254609	chr10:16479192	PTER	-0.58	-8.65	-0.43	2.23e-16	Bone fracture in osteoporosis;
CRC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.22	0.49	1.82e-21	Birth weight;
CRC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.6	-7.39	-0.38	1.25e-12	Bronchopulmonary dysplasia;
CRC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.74	10.76	0.51	2.38e-23	Breast cancer;
CRC	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg08888203	chr3:10149979	C3orf24	0.69	9.55	0.47	3.13e-19	Alzheimer's disease;
CRC	cis	rs2188554	0.740	rs213945	chr7:117190703	A/G	cg09181792	chr7:117119393	CFTR	-0.33	-6.09	-0.32	3.12e-9	Esophageal adenocarcinoma;
CRC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg10760299	chr15:45669010	GATM	0.37	5.77	0.3	1.85e-8	Response to fenofibrate (adiponectin levels);
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.87	0.35	3.24e-11	Mean corpuscular volume;
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.56	7.6	0.39	3.07e-13	Alzheimer's disease;
CRC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.96	-0.4	2.83e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg02712587	chr15:40268421	EIF2AK4	-0.69	-5.86	-0.31	1.09e-8	Response to haloperidol in psychosis;
CRC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.58	0.34	1.85e-10	Rheumatoid arthritis;
CRC	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.4	-0.33	5.31e-10	Depression;
CRC	cis	rs4845875	0.626	rs7538516	chr1:11836682	C/T	cg02448276	chr1:11845238	NA	0.36	5.61	0.3	4.38e-8	Midregional pro atrial natriuretic peptide levels;
CRC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg09264619	chr17:80180166	NA	-0.36	-6.06	-0.32	3.63e-9	Life satisfaction;
CRC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg03690763	chr11:133734501	NA	-0.36	-5.94	-0.31	7.17e-9	Childhood ear infection;
CRC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.61	8.68	0.43	1.9e-16	Tuberculosis;
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg08222913	chr3:52553049	STAB1	-0.32	-5.91	-0.31	8.52e-9	Bipolar disorder;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.95	0.31	6.79e-9	Parkinson's disease;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg05258489	chr8:61593179	CHD7	-0.44	-6.29	-0.33	1.01e-9	Birth weight;Height;
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg24046110	chr8:143859143	LYNX1	0.48	8.33	0.42	2.27e-15	Urinary tract infection frequency;
CRC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-9.53	-0.47	3.61e-19	Hip circumference adjusted for BMI;
CRC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.92	16.88	0.68	1.74e-46	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg17903999	chr18:56338584	MALT1	0.42	6.94	0.36	2.1e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.47	-7.16	-0.37	5.39e-12	Height;
CRC	cis	rs6589219	0.954	rs3802840	chr11:111171646	G/T	cg25129781	chr11:111156908	C11orf53	0.31	5.64	0.3	3.66e-8	Colorectal cancer;
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08741688	chr4:3415352	RGS12	-0.36	-5.74	-0.3	2.2e-8	Parental longevity (mother's age at death);
CRC	cis	rs2179367	0.959	rs579789	chr6:149679371	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.04	-0.32	4.14e-9	Dupuytren's disease;
CRC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.65	0.39	2.31e-13	Lung cancer;
CRC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-13.65	-0.6	6.29e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.45	7.37	0.38	1.35e-12	Hemoglobin concentration;
CRC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg15445000	chr17:37608096	MED1	-0.39	-7.09	-0.36	8.1e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg08885800	chr1:201084119	NA	-0.4	-5.71	-0.3	2.57e-8	Permanent tooth development;
CRC	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs9303542	0.559	rs8079617	chr17:46610028	T/G	cg04904318	chr17:46607828	HOXB1	-0.54	-6.3	-0.33	9.71e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.83	-0.31	1.32e-8	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04015759	chr2:27718181	FNDC4	-0.36	-6.03	-0.32	4.41e-9	Myopia (pathological);
CRC	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	8.1	0.41	1.11e-14	Adiposity;
CRC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.3	5.96	0.31	6.43e-9	Personality dimensions;
CRC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.51	7.32	0.37	1.87e-12	Height;
CRC	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg13172432	chr1:205912842	SLC26A9	0.34	5.71	0.3	2.48e-8	Cystic fibrosis-related diabetes;
CRC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02228675	chr17:40259724	DHX58	-0.48	-6.8	-0.35	5.05e-11	Fibrinogen levels;
CRC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.5	6.79	0.35	5.31e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg14593290	chr7:50529359	DDC	0.57	7.89	0.4	4.57e-14	Malaria;
CRC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.67	0.43	1.97e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.51	6.78	0.35	5.55e-11	Breast cancer;
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.36	-5.65	-0.3	3.56e-8	Blood metabolite levels;
CRC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.78	-10.67	-0.51	4.89e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.87	14.34	0.62	1.51e-36	Alcohol dependence;
CRC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg15848620	chr12:58087721	OS9	-0.59	-8.1	-0.41	1.12e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.94	0.4	3.18e-14	Cognitive ability;
CRC	cis	rs9648716	0.935	rs7791924	chr7:140578070	C/A	cg10747023	chr7:140774559	NA	0.45	5.93	0.31	7.57e-9	Type 2 diabetes;
CRC	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.9	-13.07	-0.58	9.76e-32	Dupuytren's disease;
CRC	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg03418659	chr16:31128414	MYST1	0.44	6.27	0.33	1.11e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.7	12.5	0.57	1.37e-29	Oral cavity cancer;
CRC	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.1	-0.32	2.92e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.8	8.79	0.44	8.31e-17	Gout;Renal underexcretion gout;
CRC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.74	9.87	0.48	2.68e-20	Cognitive function;
CRC	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg08614441	chr13:113633676	MCF2L	-0.45	-7.84	-0.4	6.44e-14	Systolic blood pressure;
CRC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg14541582	chr5:601475	NA	-0.31	-6.54	-0.34	2.29e-10	Obesity-related traits;
CRC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.89	-0.48	2.25e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-0.84	-8.8	-0.44	7.75e-17	Gout;Renal underexcretion gout;
CRC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.39e-9	Melanoma;
CRC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.3	6.36	0.33	6.66e-10	Lung cancer;
CRC	cis	rs9322817	0.691	rs2034821	chr6:105219537	C/T	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.38e-16	Thyroid stimulating hormone;
CRC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.67	0.35	1.05e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg17810781	chr1:201082982	CACNA1S	0.49	8.37	0.42	1.7e-15	Permanent tooth development;
CRC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.01	-0.52	3.39e-24	Platelet distribution width;
CRC	cis	rs9462027	0.628	rs2764206	chr6:34712900	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	7.66	0.39	2.14e-13	Breast cancer;
CRC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg05043794	chr9:111880884	C9orf5	-0.35	-6.32	-0.33	8.36e-10	Menarche (age at onset);
CRC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.46	-6.22	-0.32	1.49e-9	Aortic root size;
CRC	cis	rs73206853	0.563	rs73194050	chr12:111200634	T/C	cg12870014	chr12:110450643	ANKRD13A	0.72	8.18	0.41	6.16e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.73	-0.35	7.56e-11	Vitamin D levels;
CRC	cis	rs2457480	0.852	rs61857485	chr10:44719292	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;
CRC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.54	-7.28	-0.37	2.41e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.69	0.39	1.69e-13	Lung cancer;
CRC	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	8.78	0.44	9.26e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg20203395	chr5:56204925	C5orf35	0.41	5.7	0.3	2.73e-8	Coronary artery disease;
CRC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	7.04	0.36	1.15e-11	Response to antipsychotic treatment;
CRC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.79	10.08	0.49	5.16e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.75	-16.49	-0.67	6.01e-45	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.38e-11	Response to antipsychotic treatment;
CRC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	12.0	0.55	9.41e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.81	-13.83	-0.61	1.3e-34	Cystic fibrosis severity;
CRC	trans	rs2303319	0.504	rs12465734	chr2:162437859	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.0	-0.31	5.13e-9	Cognitive function;
CRC	trans	rs12408261	0.843	rs7544452	chr1:189313343	A/G	cg20050113	chr2:103236861	SLC9A2	0.25	6.04	0.32	4.08e-9	Number of pregnancies;
CRC	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg09873164	chr1:152488093	CRCT1	0.37	6.26	0.33	1.18e-9	Hair morphology;
CRC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.71	10.89	0.51	8.42e-24	Corneal astigmatism;
CRC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg00999904	chr2:3704751	ALLC	-0.45	-6.68	-0.35	1.05e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg06479426	chr20:61274286	SLCO4A1	-0.41	-6.0	-0.31	5.19e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs6840360	0.642	rs2724580	chr4:152372505	A/G	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	0.99	8.46	0.42	8.82e-16	Blood protein levels;
CRC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg24289452	chr6:170231220	NA	-0.58	-6.58	-0.34	1.81e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1950626	0.623	rs4402490	chr14:101445453	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.76	-11.94	-0.55	1.55e-27	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4711336	0.712	rs942641	chr6:33687007	G/A	cg14003231	chr6:33640908	ITPR3	0.4	6.48	0.34	3.44e-10	Height;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg10876282	chr6:28092338	ZSCAN16	0.46	6.1	0.32	3e-9	Parkinson's disease;
CRC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.65	9.67	0.47	1.22e-19	Breast cancer;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg21251018	chr6:28226885	NKAPL	0.48	7.4	0.38	1.14e-12	Parkinson's disease;
CRC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.83	-0.31	1.29e-8	Alzheimer's disease (late onset);
CRC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.31	-6.92	-0.36	2.34e-11	IgG glycosylation;
CRC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	5.64	0.3	3.58e-8	Resistin levels;
CRC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.68	7.65	0.39	2.23e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-10.19	-0.49	2.33e-21	Monocyte count;
CRC	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-13.33	-0.59	1.08e-32	Ulcerative colitis;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23708337	chr7:1209742	NA	0.51	7.83	0.4	6.66e-14	Longevity;Endometriosis;
CRC	cis	rs11209185	0.509	rs9436356	chr1:68447202	A/G	cg22082780	chr1:68452167	NA	0.41	6.11	0.32	2.8e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09467605	chr19:2785488	THOP1	0.45	6.14	0.32	2.41e-9	Anxiety disorder;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg25164649	chr6:28176230	NA	0.65	9.23	0.45	3.45e-18	Parkinson's disease;
CRC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg08270630	chr22:50330655	NA	0.4	5.9	0.31	8.85e-9	Schizophrenia;
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	trans	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg02936872	chr9:99801550	CTSL2	0.48	6.22	0.32	1.48e-9	Iron status biomarkers;
CRC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.84	-0.31	1.26e-8	Blood protein levels;
CRC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	6.0	0.31	5.12e-9	Height;
CRC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.15	-0.45	5.94e-18	Intelligence (multi-trait analysis);
CRC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.37	-6.63	-0.34	1.36e-10	Menarche (age at onset);
CRC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg08314208	chr16:67682810	RLTPR	-0.55	-5.96	-0.31	6.57e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.22	-5.91	-0.31	8.61e-9	Type 2 diabetes;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg25428213	chr17:80929211	B3GNTL1	-0.52	-5.98	-0.31	5.77e-9	Body mass index;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg00685614	chr16:89118838	NA	-0.26	-6.28	-0.33	1.09e-9	Lung cancer;
CRC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.31e-17	Mean platelet volume;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg10876282	chr6:28092338	ZSCAN16	0.47	6.37	0.33	6.53e-10	Parkinson's disease;
CRC	cis	rs7113874	0.569	rs10840072	chr11:8569360	T/C	cg17679104	chr11:8615758	STK33	-0.35	-5.91	-0.31	8.67e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2398893	0.596	rs13299181	chr9:96887457	G/A	cg14459158	chr9:96720562	NA	0.45	6.42	0.33	4.79e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.29	6.0	0.31	5.17e-9	Homoarginine levels;
CRC	cis	rs747650	0.892	rs2029298	chr11:47234718	C/T	cg03339077	chr11:47165057	C11orf49	0.45	6.36	0.33	6.59e-10	Acne (severe);
CRC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.42	0.53	1.17e-25	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04787407	chr4:99916511	METAP1	0.52	6.68	0.35	1.01e-10	Thyroid stimulating hormone;
CRC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg21854759	chr1:92012499	NA	-0.53	-8.79	-0.44	8.36e-17	Breast cancer;
CRC	cis	rs812925	0.537	rs10196146	chr2:61605379	C/A	cg10580144	chr2:61372316	C2orf74	-0.33	-7.23	-0.37	3.43e-12	Immature fraction of reticulocytes;
CRC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.72	8.67	0.43	1.99e-16	Mean platelet volume;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg06470822	chr6:28175283	NA	0.94	12.8	0.58	1.0500000000000001e-30	Parkinson's disease;
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg14487702	chr8:22132665	PIWIL2	0.37	5.62	0.3	4.07e-8	Hypertriglyceridemia;
CRC	cis	rs6908034	0.607	rs76245225	chr6:19813188	T/G	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.34	-0.38	1.65e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.57	-7.97	-0.4	2.67e-14	Pancreatic cancer;
CRC	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg17652424	chr22:38574118	PLA2G6	-0.18	-5.65	-0.3	3.49e-8	Cutaneous nevi;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12646931	chr5:89770577	MBLAC2;POLR3G	0.46	6.2	0.32	1.7e-9	Anxiety disorder;
CRC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.3	6.18	0.32	1.89e-9	Lung cancer;
CRC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg10820045	chr2:198174542	NA	0.39	6.55	0.34	2.2e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4731207	0.596	rs6466965	chr7:124579726	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.71e-9	Cutaneous malignant melanoma;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg08222913	chr3:52553049	STAB1	-0.38	-7.28	-0.37	2.51e-12	Cognitive function;
CRC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.76	10.03	0.48	7.6e-21	Initial pursuit acceleration;
CRC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.39	-0.38	1.23e-12	Aortic root size;
CRC	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg15192750	chr16:69999425	NA	0.55	7.38	0.38	1.3e-12	IgE levels;
CRC	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.73	-9.3	-0.46	2.08e-18	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs6743376	0.556	rs6748448	chr2:113819419	A/G	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.92	-19.57	-0.73	4.35e-57	Urate levels in lean individuals;
CRC	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg10820045	chr2:198174542	NA	-0.55	-9.29	-0.46	2.12e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg07862535	chr7:139043722	LUC7L2	-0.61	-7.8	-0.4	8.13e-14	Diisocyanate-induced asthma;
CRC	cis	rs4824093	0.610	rs12168949	chr22:50317714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-8.61	-0.43	2.99e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.78	-10.92	-0.52	7.02e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.66	8.92	0.44	3.24e-17	Bladder cancer;
CRC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.63	9.91	0.48	1.94e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg01483505	chr11:975446	AP2A2	0.4	6.1	0.32	2.93e-9	Alzheimer's disease (late onset);
CRC	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07151155	chr5:1473589	LPCAT1	-0.42	-6.5	-0.34	2.9e-10	Breast cancer;
CRC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.48	6.94	0.36	2.12e-11	Aortic root size;
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg15786705	chr6:28176104	NA	0.78	9.75	0.47	6.51e-20	Depression;
CRC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.44	-6.49	-0.34	3.22e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg12751644	chr20:60527061	NA	-0.37	-5.67	-0.3	3.08e-8	Body mass index;
CRC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.41	-0.33	5.12e-10	Aortic root size;
CRC	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.92	7.7	0.39	1.63e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs10905065	0.895	rs1567707	chr10:5853817	G/C	cg11519256	chr10:5708881	ASB13	-0.44	-6.3	-0.33	9.4e-10	Menopause (age at onset);
CRC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg08847533	chr14:75593920	NEK9	-0.46	-6.19	-0.32	1.84e-9	IgG glycosylation;
CRC	cis	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg07356753	chr3:81810745	GBE1	0.43	5.66	0.3	3.36e-8	Extraversion;
CRC	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg14092571	chr14:90743983	NA	0.39	6.02	0.32	4.62e-9	Mortality in heart failure;
CRC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.37	-5.97	-0.31	6.27e-9	Blood metabolite levels;
CRC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	10.41	0.5	4.02e-22	Schizophrenia;
CRC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	10.87	0.51	1.04e-23	Schizophrenia;
CRC	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.61	-8.3	-0.42	2.78e-15	Body mass index;
CRC	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.14	-0.32	2.36e-9	Coronary artery disease;
CRC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg27266060	chr8:22091797	NA	0.36	5.99	0.31	5.53e-9	Hypertriglyceridemia;
CRC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg19812747	chr11:111475976	SIK2	0.44	6.43	0.33	4.57e-10	Primary sclerosing cholangitis;
CRC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.16	-0.56	2.46e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.6	-9.53	-0.47	3.64e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7827545	0.545	rs6578228	chr8:135562422	G/A	cg17885191	chr8:135476712	NA	0.65	7.57	0.39	3.69e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg06042504	chr8:55087323	NA	-0.41	-6.28	-0.33	1.08e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.63	-0.3	3.93e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs539514	0.664	rs479824	chr13:76308360	C/T	cg04757411	chr13:76259545	LMO7	-0.35	-5.84	-0.31	1.27e-8	Type 1 diabetes;
CRC	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.45	-6.23	-0.32	1.43e-9	Response to antidepressants and depression;
CRC	cis	rs9648716	1.000	rs1267646	chr7:140485690	C/T	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.14e-8	Type 2 diabetes;
CRC	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg05714579	chr10:131428358	MGMT	0.54	7.6	0.39	3.22e-13	Response to temozolomide;
CRC	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg03315344	chr16:75512273	CHST6	0.46	5.64	0.3	3.69e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg09835421	chr16:68378352	PRMT7	-0.77	-8.03	-0.4	1.78e-14	Schizophrenia;
CRC	trans	rs9676308	1.000	rs8110638	chr19:57569719	C/T	cg17664269	chr3:3080621	CNTN4	-0.65	-5.96	-0.31	6.48e-9	Colorectal cancer;
CRC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.56	7.29	0.37	2.3e-12	Gut microbiome composition (summer);
CRC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg02549819	chr16:58548995	SETD6	1.29	8.25	0.41	3.97e-15	Schizophrenia;
CRC	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.89	0.48	2.35e-20	Corneal astigmatism;
CRC	trans	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg06606381	chr12:133084897	FBRSL1	-0.57	-6.11	-0.32	2.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg12218747	chr21:37451666	NA	-0.43	-7.34	-0.38	1.68e-12	Mitral valve prolapse;
CRC	cis	rs4664293	0.967	rs7559127	chr2:160515935	T/C	cg08347373	chr2:160653686	CD302	-0.37	-6.15	-0.32	2.21e-9	Monocyte percentage of white cells;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.72	7.47	0.38	7.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg02527881	chr3:46936655	PTH1R	0.39	7.12	0.37	6.68e-12	Colorectal cancer;
CRC	cis	rs11212617	0.967	rs374443	chr11:108221665	C/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.25e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	10.2	0.49	2.06e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.37	6.35e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.65	-10.05	-0.48	6.49e-21	Bipolar disorder;
CRC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg13072238	chr3:49761600	GMPPB	0.5	5.79	0.3	1.68e-8	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23628684	chr21:30446052	CCT8	0.44	6.2	0.32	1.72e-9	Response to antipsychotic treatment;
CRC	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg16898833	chr6:26189333	HIST1H4D	0.67	5.9	0.31	8.83e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.61	9.12	0.45	7.81e-18	Lung cancer;
CRC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.42	-5.94	-0.31	7.2e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	7.03	0.36	1.23e-11	Rheumatoid arthritis;
CRC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.91	16.61	0.68	2.07e-45	Intelligence (multi-trait analysis);
CRC	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.83	12.63	0.57	4.48e-30	Chronic lymphocytic leukemia;
CRC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	11.75	0.54	7.52e-27	Schizophrenia;
CRC	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.42	-5.94	-0.31	7.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg24046110	chr8:143859143	LYNX1	0.49	8.61	0.43	3.1e-16	Urinary tract infection frequency;
CRC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg17724175	chr1:150552817	MCL1	0.47	6.93	0.36	2.28e-11	Melanoma;
CRC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.89	0.31	9.3e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs12760731	0.720	rs12048790	chr1:178407906	T/C	cg00404053	chr1:178313656	RASAL2	0.95	9.79	0.47	5.03e-20	Obesity-related traits;
CRC	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.46	-8.59	-0.43	3.67e-16	Hepatitis;
CRC	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.49	-8.02	-0.4	1.81e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.49	-7.03	-0.36	1.2e-11	DNA methylation (variation);
CRC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.61	-8.79	-0.44	8.73e-17	Menarche (age at onset);
CRC	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	8.93	0.44	2.98e-17	Pulse pressure;
CRC	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg23461800	chr14:103021989	NA	-0.67	-7.68	-0.39	1.87e-13	Platelet count;
CRC	cis	rs9469578	1.000	rs6942022	chr6:33710284	C/T	cg18708504	chr6:33715942	IP6K3	0.63	7.23	0.37	3.44e-12	Phosphorus levels;
CRC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.61	11.35	0.53	1.99e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.49	-0.62	3.8e-37	Body mass index;
CRC	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.62	0.65	1.5e-41	Bipolar disorder;
CRC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg06781209	chr11:61594997	FADS2	-0.57	-8.02	-0.4	1.84e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.8	9.14	0.45	6.82e-18	Migraine;Coronary artery disease;
CRC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.63	9.62	0.47	1.8e-19	Pancreatic cancer;
CRC	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.74e-21	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg25164649	chr6:28176230	NA	0.58	7.24	0.37	3.2e-12	Parkinson's disease;
CRC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.96	13.93	0.61	5.31e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.57	-9.17	-0.45	5.23e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.26	-0.33	1.17e-9	Systemic lupus erythematosus;
CRC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg00383909	chr3:49044727	WDR6	0.48	5.92	0.31	7.98e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.53	-7.37	-0.38	1.41e-12	Fibrinogen levels;
CRC	cis	rs375066	0.967	rs8104290	chr19:44367338	A/G	cg12072164	chr19:44306565	LYPD5	0.37	5.61	0.3	4.31e-8	Breast cancer;
CRC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg11003573	chr3:44754125	ZNF502	-0.35	-5.89	-0.31	9.62e-9	Depressive symptoms;
CRC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-9.86	-0.48	2.9e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.43	7.4	0.38	1.17e-12	Major depressive disorder;
CRC	cis	rs3736485	0.934	rs8036609	chr15:51861426	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.74	9.19	0.45	4.55e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg18232548	chr7:50535776	DDC	0.46	6.16	0.32	2.1e-9	Malaria;
CRC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg18512352	chr11:47633146	NA	-0.46	-8.61	-0.43	3e-16	Neuroticism;
CRC	cis	rs2274471	0.645	rs10815163	chr9:5122932	A/G	cg03390472	chr9:5043263	JAK2	-0.51	-5.9	-0.31	8.91e-9	Crohn's disease;
CRC	cis	rs7951870	0.645	rs57804402	chr11:46729872	T/C	cg19486271	chr11:47235900	DDB2	0.45	7.06	0.36	1.02e-11	Schizophrenia;
CRC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg02428538	chr16:24856791	SLC5A11	-0.61	-6.88	-0.35	3.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg18830697	chr6:72922368	RIMS1	-0.39	-7.83	-0.4	6.67e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.25	6.92	0.36	2.44e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg07862535	chr7:139043722	LUC7L2	-0.58	-7.53	-0.38	5.03e-13	Diisocyanate-induced asthma;
CRC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.49	-7.48	-0.38	6.67e-13	Body mass index;
CRC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.6	8.59	0.43	3.65e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.36	5.88	0.31	1e-8	Survival in rectal cancer;
CRC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg00105475	chr2:10696890	NA	0.46	7.41	0.38	1.08e-12	Prostate cancer;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg23161317	chr6:28129485	ZNF389	0.46	6.45	0.33	4.09e-10	Cardiac Troponin-T levels;
CRC	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.63	8.57	0.43	4.23e-16	Menopause (age at onset);
CRC	trans	rs1823549	1.000	rs7528732	chr1:103200189	A/G	cg08492707	chr21:34696952	IFNAR1	0.71	6.05	0.32	4.01e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg13385521	chr17:29058706	SUZ12P	0.65	7.73	0.39	1.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs524281	0.731	rs476551	chr11:66006323	G/C	cg16950941	chr11:66035639	RAB1B	-0.68	-7.95	-0.4	3.01e-14	Electroencephalogram traits;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.77	-0.51	2.31e-23	Alzheimer's disease;
CRC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.44	6.31	0.33	9.12e-10	Asthma;
CRC	cis	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg02972257	chr16:68554789	NA	0.53	6.58	0.34	1.89e-10	Colorectal cancer;
CRC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.43	-5.66	-0.3	3.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	8.35	0.42	1.86e-15	Lymphocyte counts;
CRC	cis	rs2898857	0.524	rs2072153	chr17:47390014	C/G	cg08112188	chr17:47440006	ZNF652	-0.44	-5.92	-0.31	8.17e-9	Cancer;
CRC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.37	-6.25	-0.33	1.24e-9	Blood metabolite levels;
CRC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.46	6.84	0.35	3.9e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs12760731	0.623	rs7547158	chr1:178309399	A/G	cg00404053	chr1:178313656	RASAL2	0.73	9.16	0.45	5.79e-18	Obesity-related traits;
CRC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.89	9.76	0.47	6.25e-20	Skin colour saturation;
CRC	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07165851	chr6:158734300	TULP4	0.6	7.59	0.39	3.38e-13	Height;
CRC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.31	0.33	8.84e-10	Diabetic retinopathy;
CRC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.68	10.46	0.5	2.76e-22	Monocyte count;
CRC	cis	rs7932354	0.550	rs10769208	chr11:46822240	T/C	cg19486271	chr11:47235900	DDB2	-0.43	-6.47	-0.34	3.56e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.53	9.3	0.46	2.07e-18	Body mass index;
CRC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.72	0.39	1.37e-13	Lymphocyte percentage of white cells;
CRC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.79	-13.27	-0.59	1.75e-32	Obesity-related traits;
CRC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.81	0.51	1.63e-23	Motion sickness;
CRC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.91	16.91	0.68	1.27e-46	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19737787	chr13:28492265	NA	0.41	7.19	0.37	4.49e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16576597	chr16:28551801	NUPR1	0.44	6.19	0.32	1.75e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7616330	0.775	rs6794619	chr3:71039895	A/G	cg01511742	chr3:71112437	FOXP1	-0.56	-6.53	-0.34	2.52e-10	QT interval;
CRC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.48	6.13	0.32	2.58e-9	Lymphocyte counts;
CRC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-12.7	-0.57	2.36e-30	Vitiligo;
CRC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.19	0.45	4.41e-18	Cognitive test performance;
CRC	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg06223162	chr1:101003688	GPR88	0.35	6.42	0.33	4.76e-10	Monocyte count;
CRC	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg03938978	chr2:103052716	IL18RAP	0.36	5.92	0.31	7.92e-9	Asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15064598	chr1:28879563	TRNAU1AP	0.46	6.53	0.34	2.55e-10	Anxiety disorder;
CRC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.73	10.7	0.51	3.89e-23	Cognitive function;
CRC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.47	8.52	0.43	5.79e-16	Monocyte count;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	8.01	0.4	2.02e-14	Breast cancer;
CRC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.82	-11.32	-0.53	2.69e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.83	0.51	1.44e-23	Prudent dietary pattern;
CRC	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.64	9.83	0.48	3.71e-20	Itch intensity from mosquito bite;
CRC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg01420254	chr6:26195488	NA	0.7	8.74	0.43	1.2e-16	Gout;Renal underexcretion gout;
CRC	trans	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg21153622	chr11:89784906	NA	-0.51	-8.05	-0.41	1.48e-14	HDL cholesterol;
CRC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg04450456	chr4:17643702	FAM184B	0.39	6.22	0.32	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01202521	chr16:1360231	UBE2I	-0.42	-6.19	-0.32	1.8e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.43	-6.21	-0.32	1.56e-9	Aortic root size;
CRC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.39	-5.83	-0.31	1.33e-8	Total body bone mineral density;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg20512303	chr5:131592959	PDLIM4	-0.38	-6.59	-0.34	1.71e-10	Breast cancer;
CRC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.33	0.37	1.77e-12	Electroencephalogram traits;
CRC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.82	-11.47	-0.53	7.35e-26	Platelet distribution width;
CRC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.57	-0.47	2.61e-19	Migraine;Coronary artery disease;
CRC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.51	6.92	0.36	2.31e-11	Bronchopulmonary dysplasia;
CRC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.01	-0.31	4.92e-9	Aortic root size;
CRC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg26395211	chr5:140044315	WDR55	0.38	5.63	0.3	3.92e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg14122633	chr5:456516	EXOC3	-0.4	-7.16	-0.37	5.37e-12	Cystic fibrosis severity;
CRC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg14541582	chr5:601475	NA	-0.32	-6.36	-0.33	6.83e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.05	15.02	0.64	3.46e-39	Gut microbiome composition (summer);
CRC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.68	10.22	0.49	1.81e-21	Menopause (age at onset);
CRC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg10645314	chr2:3704589	ALLC	-0.54	-6.39	-0.33	5.78e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.63	-0.39	2.59e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24701985	chr7:149535383	ZNF862	0.46	6.55	0.34	2.28e-10	Response to antipsychotic treatment;
CRC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.6	8.63	0.43	2.73e-16	Height;
CRC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.41	-7.25	-0.37	2.95e-12	Intelligence (multi-trait analysis);
CRC	trans	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg02869306	chr7:64672164	INTS4L1	0.43	6.09	0.32	3.17e-9	Aortic root size;
CRC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.32	-5.68	-0.3	2.92e-8	Metabolite levels;
CRC	cis	rs11628318	0.515	rs1190343	chr14:103100348	G/A	cg12046867	chr14:103022105	NA	-0.41	-5.62	-0.3	4.02e-8	Platelet count;
CRC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg02659138	chr7:134003124	SLC35B4	0.42	7.36	0.38	1.47e-12	Mean platelet volume;
CRC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs17767392	0.881	rs12880611	chr14:71923349	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.17	-0.37	5.11e-12	Mitral valve prolapse;
CRC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg02135003	chr7:105160482	PUS7	-0.73	-10.52	-0.5	1.68e-22	Bipolar disorder (body mass index interaction);
CRC	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.49	-6.21	-0.32	1.62e-9	Crohn's disease;
CRC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.6e-12	Motion sickness;
CRC	cis	rs4731207	0.596	rs7806530	chr7:124659884	C/T	cg23710748	chr7:124431027	NA	0.37	5.94	0.31	7.28e-9	Cutaneous malignant melanoma;
CRC	cis	rs394563	0.601	rs382720	chr6:149795261	C/T	cg11245181	chr6:149772854	ZC3H12D	0.42	6.84	0.35	3.78e-11	Dupuytren's disease;
CRC	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.48	8.59	0.43	3.44e-16	Testicular germ cell tumor;
CRC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-9.36	-0.46	1.29e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.28	0.37	2.48e-12	Endometrial cancer;
CRC	cis	rs17152411	1.000	rs10901843	chr10:126638020	A/G	cg07906193	chr10:126599966	NA	0.59	6.77	0.35	6.03e-11	Height;
CRC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.52	0.38	5.24e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.58	-7.99	-0.4	2.32e-14	Colorectal cancer;
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.07	-0.41	1.38e-14	Menopause (age at onset);
CRC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.73	10.54	0.5	1.39e-22	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg21251018	chr6:28226885	NKAPL	0.47	6.23	0.33	1.39e-9	Depression;
CRC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.84	0.35	3.79e-11	Schizophrenia;
CRC	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.69	-10.16	-0.49	2.94e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2565722	0.622	rs10945704	chr6:161290926	C/T	cg03159191	chr6:161285451	NA	-0.44	-5.98	-0.31	5.86e-9	Blood protein levels;
CRC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.55	8.62	0.43	2.82e-16	Mean platelet volume;
CRC	cis	rs883565	0.740	rs11708354	chr3:39115626	A/T	cg01426195	chr3:39028469	NA	-0.55	-8.8	-0.44	8.15e-17	Handedness;
CRC	cis	rs7120118	0.517	rs3758674	chr11:47278938	T/C	cg25783544	chr11:47291846	MADD	0.64	5.77	0.3	1.85e-8	HDL cholesterol;
CRC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.73	-10.14	-0.49	3.33e-21	Longevity;
CRC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.51	7.1	0.36	7.57e-12	Lymphocyte counts;
CRC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg12193833	chr17:30244370	NA	-0.51	-6.58	-0.34	1.87e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.64	10.8	0.51	1.85e-23	Depressive symptoms (multi-trait analysis);
CRC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg02551604	chr5:131831745	NA	-0.41	-6.31	-0.33	8.82e-10	Breast cancer;Mosquito bite size;
CRC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg03037974	chr15:76606532	NA	0.6	10.17	0.49	2.53e-21	Blood metabolite levels;
CRC	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg17456097	chr1:26900765	RPS6KA1	0.45	6.71	0.35	8.6e-11	Glucose homeostasis traits;
CRC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.73	0.51	3.18e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs516243	0.703	rs169538	chr1:10737045	T/C	cg02903756	chr1:10750680	CASZ1	-0.48	-8.29	-0.42	2.84e-15	Migraine - clinic-based;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg21204522	chr6:27730016	NA	-0.39	-5.61	-0.3	4.4e-8	Parkinson's disease;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Depression;
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.46	7.04	0.36	1.15e-11	Longevity;
CRC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg02158880	chr13:53174818	NA	0.44	6.65	0.34	1.22e-10	Lewy body disease;
CRC	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.33	-0.33	8.18e-10	Prevalent atrial fibrillation;
CRC	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.56	8.8	0.44	7.83e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.3	0.42	2.7e-15	Mean corpuscular volume;
CRC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.51	7.87	0.4	5.23e-14	Corneal astigmatism;
CRC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg25985355	chr7:65971099	NA	-0.54	-6.09	-0.32	3.09e-9	Diabetic kidney disease;
CRC	cis	rs16852403	0.861	rs11583320	chr1:178042145	T/C	cg00404053	chr1:178313656	RASAL2	0.48	6.03	0.32	4.46e-9	Childhood ear infection;
CRC	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg09654669	chr8:57350985	NA	-0.41	-5.71	-0.3	2.54e-8	Obesity-related traits;
CRC	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg24998770	chr7:37888106	TXNDC3	0.37	6.07	0.32	3.51e-9	Alzheimer's disease (late onset);
CRC	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg08501292	chr6:25962987	TRIM38	1.12	10.3	0.49	9.5e-22	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-7.21	-0.37	3.75e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07545535	chr7:76256818	POMZP3;LOC100133091	0.42	6.58	0.34	1.81e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg11693508	chr17:37793320	STARD3	0.61	7.23	0.37	3.36e-12	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.58	7.02	0.36	1.26e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12024301	0.557	rs7530521	chr1:183610653	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-8.97	-0.44	2.32e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.17	-0.49	2.64e-21	Bipolar disorder;
CRC	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg23032129	chr1:109941072	SORT1	-0.27	-5.63	-0.3	3.86e-8	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.58	-10.21	-0.49	1.98e-21	Iron status biomarkers;
CRC	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg00691999	chr4:55094011	PDGFRA	0.41	5.76	0.3	1.89e-8	Corneal astigmatism;
CRC	cis	rs2336384	1.000	rs6668386	chr1:12047233	T/C	cg13216073	chr1:12042593	MFN2	0.49	7.18	0.37	4.79e-12	Platelet count;
CRC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.62	9.51	0.46	4.28e-19	Bladder cancer;
CRC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.96	-19.75	-0.74	8.53e-58	Myeloid white cell count;
CRC	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	0.93	11.25	0.53	4.59e-25	Height;
CRC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg07884673	chr3:53033167	SFMBT1	0.69	6.12	0.32	2.67e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg10396713	chr8:602097	NA	0.58	5.83	0.31	1.33e-8	IgG glycosylation;
CRC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.61	9.7	0.47	1e-19	Height;
CRC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg25173405	chr17:45401733	C17orf57	-0.57	-9.49	-0.46	4.72e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg11843238	chr5:131593191	PDLIM4	0.44	7.41	0.38	1.09e-12	Breast cancer;
CRC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg23958373	chr8:599963	NA	-0.88	-7.74	-0.39	1.21e-13	IgG glycosylation;
CRC	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg22687807	chr8:143858763	LYNX1	-0.37	-6.51	-0.34	2.88e-10	Urinary tract infection frequency;
CRC	cis	rs883565	0.569	rs784511	chr3:39165548	A/G	cg01426195	chr3:39028469	NA	0.42	6.99	0.36	1.56e-11	Handedness;
CRC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg00745463	chr17:30367425	LRRC37B	-0.72	-8.16	-0.41	7.1e-15	Hip circumference adjusted for BMI;
CRC	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg02811702	chr13:24901961	NA	0.42	5.8	0.3	1.52e-8	Obesity-related traits;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg15845792	chr6:28175446	NA	0.92	12.48	0.57	1.64e-29	Parkinson's disease;
CRC	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg00495681	chr13:53174319	NA	-0.53	-7.98	-0.4	2.38e-14	Lewy body disease;
CRC	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg12756093	chr1:115239321	AMPD1	0.48	7.09	0.36	8.36e-12	Autism;
CRC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-6.72	-0.35	8.12e-11	Renal cell carcinoma;
CRC	cis	rs16975963	0.644	rs11666662	chr19:38154702	A/T	cg15135657	chr19:38346511	NA	0.47	6.61	0.34	1.6e-10	Longevity;
CRC	cis	rs9549328	0.520	rs36144023	chr13:113616592	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.39	0.46	1e-18	Systolic blood pressure;
CRC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg21620606	chr4:1342894	KIAA1530	0.35	5.76	0.3	1.96e-8	Obesity-related traits;
CRC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.74	9.85	0.48	3.12e-20	Platelet count;
CRC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg05874882	chr4:1763078	NA	-0.39	-7.5	-0.38	6.03e-13	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.49	6.73	0.35	7.35e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1030268	0.505	rs77112963	chr7:133259399	G/A	cg10665199	chr7:133106180	EXOC4	0.66	7.88	0.4	4.73e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg23939001	chr4:940644	TMEM175	-0.34	-6.48	-0.34	3.43e-10	Systemic sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21789898	chr13:29293245	SLC46A3	0.42	6.18	0.32	1.91e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.62	0.54	2.28e-26	Alzheimer's disease;
CRC	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg22495460	chr2:25135724	ADCY3	-0.88	-15.19	-0.64	7.68e-40	Body mass index;
CRC	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.65	10.43	0.5	3.37e-22	Corneal astigmatism;
CRC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.79	-0.35	5.39e-11	Bipolar disorder;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg21839984	chr17:30846986	MYO1D	-0.46	-7.35	-0.38	1.63e-12	Schizophrenia;
CRC	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.54	-7.63	-0.39	2.48e-13	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25621096	chr1:151032116	CDC42SE1;MLLT11	0.48	8.9	0.44	3.94e-17	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg22687807	chr8:143858763	LYNX1	0.49	8.79	0.44	8.77e-17	Urinary tract infection frequency;
CRC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.59	-0.34	1.72e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.39	-6.66	-0.34	1.18e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs35520189	0.591	rs6733001	chr2:113701447	G/A	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg19980929	chr12:42632907	YAF2	0.45	6.63	0.34	1.36e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.52	8.11	0.41	9.97e-15	Colorectal cancer;
CRC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg25456477	chr12:86230367	RASSF9	0.38	6.51	0.34	2.82e-10	Major depressive disorder;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg27615366	chr5:131592974	PDLIM4	-0.34	-6.1	-0.32	2.98e-9	Blood metabolite levels;
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.67	13.15	0.59	5.13e-32	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.49	8.29	0.42	3.01e-15	Common traits (Other);
CRC	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-7.34	-0.38	1.72e-12	Menarche (age at onset);
CRC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.56	-8.44	-0.42	1.03e-15	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg21153622	chr11:89784906	NA	0.45	7.15	0.37	5.81e-12	HDL cholesterol;
CRC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.76	0.68	5.08e-46	Chronic sinus infection;
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.52	6.97	0.36	1.79e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg20488157	chr14:104394430	TDRD9	0.68	9.85	0.48	3.03e-20	Bipolar disorder;
CRC	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.65	-11.51	-0.54	5.57e-26	Lewy body disease;
CRC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg00343986	chr7:65444356	GUSB	0.44	6.41	0.33	5.09e-10	Aortic root size;
CRC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.27	-15.22	-0.64	5.52e-40	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22919916	chr22:19110091	DGCR2	0.37	6.17	0.32	1.97e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15740437	chr3:122102855	FAM162A;CCDC58	0.42	5.97	0.31	6.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.91	0.52	7.44e-24	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.82	-11.02	-0.52	3.1e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2882667	0.690	rs160403	chr5:138058482	T/C	cg09476006	chr5:138032270	NA	0.57	10.02	0.48	8.46e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7833986	1.000	rs61690651	chr8:57096661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.81	0.35	4.56e-11	Height;
CRC	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg10437265	chr15:77819839	NA	0.69	12.38	0.56	3.8e-29	Type 2 diabetes;
CRC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.74	0.35	7.22e-11	Mood instability;
CRC	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.3	-0.33	9.56e-10	Fractional excretion of uric acid;
CRC	trans	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.75	10.53	0.5	1.58e-22	Schizophrenia;
CRC	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg23254163	chr1:152506842	NA	-0.45	-9.13	-0.45	6.92e-18	Hair morphology;
CRC	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.37	-5.76	-0.3	1.98e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16823105	chr6:97372572	KLHL32	-0.52	-6.39	-0.33	5.59e-10	Diisocyanate-induced asthma;
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.54	-7.69	-0.39	1.7e-13	Aortic root size;
CRC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg14711859	chr11:8959438	ASCL3	-0.47	-7.44	-0.38	9.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.43	6.31	0.33	8.86e-10	Obesity-related traits;
CRC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.88	0.4	4.81e-14	Platelet count;
CRC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.73	16.23	0.67	6.44e-44	Breast cancer;
CRC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg03037974	chr15:76606532	NA	0.84	17.33	0.69	2.92e-48	Blood metabolite levels;
CRC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.37	0.38	1.39e-12	Menopause (age at onset);
CRC	cis	rs4654899	0.743	rs61778528	chr1:21059837	C/T	cg02927042	chr1:21476669	EIF4G3	-0.44	-6.54	-0.34	2.33e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02290350	chr8:58132656	NA	-0.55	-8.04	-0.41	1.69e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg16434002	chr17:42200994	HDAC5	-0.49	-7.17	-0.37	5.04e-12	Total body bone mineral density;
CRC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg02527881	chr3:46936655	PTH1R	0.35	6.17	0.32	2.04e-9	Colorectal cancer;
CRC	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.3	-0.33	9.48e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02725872	chr8:58115012	NA	-0.6	-9.17	-0.45	5.2e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs10971721	0.643	rs72711741	chr9:33785111	A/G	cg13495928	chr9:33750294	PRSS3	0.66	5.92	0.31	8.05e-9	Body mass index;
CRC	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-12.55	-0.57	8.96e-30	Colorectal cancer;
CRC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.32e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6496667	0.865	rs7178103	chr15:90926799	C/T	cg04176472	chr15:90893244	GABARAPL3	0.58	7.58	0.39	3.62e-13	Rheumatoid arthritis;
CRC	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.85	-0.4	6.1e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-5.82	-0.31	1.38e-8	Major depressive disorder;
CRC	cis	rs1223397	0.651	rs2496149	chr6:13313893	A/G	cg20827128	chr6:13274284	PHACTR1	0.36	5.62	0.3	4.07e-8	Blood pressure;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Depression;
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.67	-0.35	1.05e-10	Total body bone mineral density;
CRC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.5	6.12	0.32	2.69e-9	Mean platelet volume;
CRC	cis	rs3736485	0.966	rs2305708	chr15:51909960	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.37	-0.33	6.54e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg15845792	chr6:28175446	NA	0.95	13.73	0.6	3.05e-34	Parkinson's disease;
CRC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.36	0.33	6.68e-10	Cognitive test performance;
CRC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.23	-0.32	1.44e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.57	13.44	0.6	4.15e-33	Alcohol dependence;
CRC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg08648136	chr8:956695	NA	0.31	6.15	0.32	2.23e-9	Schizophrenia;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg21577049	chr2:228736449	WDR69	-0.47	-6.22	-0.32	1.5e-9	Blood pressure;
CRC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg18225595	chr11:63971243	STIP1	0.59	7.6	0.39	3.15e-13	Mean platelet volume;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.61	-9.32	-0.46	1.78e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.65e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.44	5.88	0.31	1.01e-8	Schizophrenia;
CRC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.37	0.65	1.54e-40	Platelet count;
CRC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.12	-10.05	-0.48	6.92e-21	Diabetic kidney disease;
CRC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.67	10.86	0.51	1.07e-23	Height;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg25164649	chr6:28176230	NA	0.78	9.69	0.47	1.04e-19	Depression;
CRC	trans	rs16846053	0.792	rs55893794	chr2:162418751	G/A	cg27113153	chr11:123612418	ZNF202	-0.72	-6.15	-0.32	2.25e-9	Blood osmolality (transformed sodium);
CRC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.55	8.02	0.4	1.83e-14	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-6.83	-0.35	4.13e-11	Hepatocellular carcinoma;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.07	-28.67	-0.85	1.81e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.09	0.32	3.07e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs28655083	0.673	rs2220233	chr16:77050294	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.58	-6.85	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	1.25	10.85	0.51	1.21e-23	Arsenic metabolism;
CRC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.53	-8.47	-0.42	8.34e-16	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04118154	chr1:45140072	C1orf228;TMEM53	0.45	6.28	0.33	1.06e-9	Response to antipsychotic treatment;
CRC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	1.03	9.71	0.47	9.22e-20	Lymphocyte counts;
CRC	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.07	-14.34	-0.62	1.5e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg03753609	chr5:34656973	RAI14	0.61	6.67	0.35	1.09e-10	Airway imaging phenotypes;
CRC	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-10.51	-0.5	1.84e-22	Hepatocellular carcinoma;
CRC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.45	6.59	0.34	1.73e-10	Response to antineoplastic agents;
CRC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.78	11.93	0.55	1.63e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.49	-7.98	-0.4	2.52e-14	Coronary artery disease;
CRC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.09	-0.55	4.28e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg22192744	chr12:123187474	GPR109A	-0.4	-5.65	-0.3	3.46e-8	Adiponectin levels;
CRC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs815815	0.583	rs11125126	chr2:47395379	C/T	cg27223769	chr2:47403360	CALM2	-0.51	-6.97	-0.36	1.7e-11	Dialysis-related mortality;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17498102	chr14:71108199	TTC9	0.45	5.99	0.31	5.39e-9	Thyroid stimulating hormone;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.63	6.54	0.34	2.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg15763984	chr4:1342303	KIAA1530	0.34	5.7	0.3	2.68e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14084056	chr12:48744539	ZNF641	0.35	6.11	0.32	2.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg20356878	chr3:121714668	ILDR1	-0.51	-6.63	-0.34	1.39e-10	Multiple sclerosis;
CRC	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.43	-6.12	-0.32	2.68e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.83	13.09	0.59	8.54e-32	Menarche (age at onset);
CRC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.35	-7.51	-0.38	5.57e-13	Inflammatory skin disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15716185	chr18:60190644	ZCCHC2	0.56	8.59	0.43	3.51e-16	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.73	-0.51	3.16e-23	Bipolar disorder and schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15586420	chr15:90294517	MESP1	-0.5	-6.05	-0.32	3.96e-9	Diisocyanate-induced asthma;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.08	-0.32	3.35e-9	Bipolar disorder;
CRC	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.22	0.45	3.63e-18	Coffee consumption (cups per day);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22902534	chr3:183892754	AP2M1	0.38	6.07	0.32	3.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.6	-9.66	-0.47	1.38e-19	Migraine;
CRC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.46	-5.89	-0.31	9.64e-9	Gut microbiome composition (summer);
CRC	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs2075064	0.814	rs76496856	chr9:126780167	C/T	cg14112217	chr9:126806003	NA	0.41	5.78	0.3	1.74e-8	Waist circumference;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23956071	chr17:4710044	PLD2	0.39	6.63	0.34	1.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.28	-0.33	1.08e-9	Coronary artery disease;
CRC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.58	9.07	0.45	1.14e-17	Type 2 diabetes;
CRC	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg12315302	chr6:26189340	HIST1H4D	0.9	6.56	0.34	2.06e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14321424	chr11:46403087	MDK	0.48	6.47	0.34	3.57e-10	Hip circumference;
CRC	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg11887960	chr12:57824829	NA	0.66	7.1	0.36	7.76e-12	Obesity-related traits;
CRC	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.45	0.34	3.9e-10	Hemoglobin concentration;
CRC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	16.23	0.67	6.25e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.47	-7.85	-0.4	5.96e-14	Refractive error;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Parkinson's disease;
CRC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg00074818	chr8:8560427	CLDN23	0.41	7.36	0.38	1.44e-12	Obesity-related traits;
CRC	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.1	-15.01	-0.64	3.68e-39	Exhaled nitric oxide output;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05098230	chr7:92076734	GATAD1	0.38	6.01	0.31	5.03e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552172	0.734	rs9729027	chr1:145592073	A/T	cg11743829	chr1:145714124	CD160	0.37	5.66	0.3	3.23e-8	Breast cancer;
CRC	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.04	-0.32	4.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg11292332	chr7:45801988	SEPT13	-0.35	-6.1	-0.32	2.9e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg01304814	chr3:48885189	PRKAR2A	0.86	6.23	0.32	1.43e-9	Cognitive function;
CRC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20092199	chr4:1342459	KIAA1530	0.39	6.76	0.35	6.27e-11	Obesity-related traits;
CRC	cis	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg06470822	chr6:28175283	NA	0.86	6.93	0.36	2.27e-11	Depression;
CRC	cis	rs3743266	0.613	rs1063100	chr15:60734697	A/G	cg21667061	chr15:60772094	NARG2	-0.29	-5.8	-0.3	1.55e-8	Menarche (age at onset);
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12588279	chr6:26043732	HIST1H2BB	0.41	6.2	0.32	1.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg12963866	chr19:57752005	ZNF805	-0.42	-6.18	-0.32	1.95e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs12612619	0.689	rs1124649	chr2:27260469	G/A	cg00617064	chr2:27272375	NA	0.37	5.75	0.3	2.07e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-7.06	-0.36	9.84e-12	Total body bone mineral density;
CRC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	9.71	0.47	9.3e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17162190	0.698	rs12093376	chr1:26849973	T/C	cg17456097	chr1:26900765	RPS6KA1	0.42	5.94	0.31	7.38e-9	Mean corpuscular volume;
CRC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.93	11.51	0.54	5.35e-26	IgG glycosylation;
CRC	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.28e-11	Body mass index;
CRC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.98	0.64	4.65e-39	Mean platelet volume;
CRC	cis	rs9326248	0.773	rs1060211	chr11:117039797	G/A	cg11861562	chr11:117069780	TAGLN	0.34	6.22	0.32	1.49e-9	Blood protein levels;
CRC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.3	-0.33	9.68e-10	Acne (severe);
CRC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.15	0.32	2.26e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.58	6.5	0.34	3e-10	Bipolar disorder;
CRC	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.54	-8.5	-0.42	6.87e-16	Neuroticism;
CRC	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.51	6.38	0.33	6.02e-10	Recombination rate (females);
CRC	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.37	6.16	0.32	2.15e-9	Testicular germ cell tumor;
CRC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.68	-7.98	-0.4	2.48e-14	Systolic blood pressure;
CRC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.76	-10.44	-0.5	3.14e-22	Initial pursuit acceleration;
CRC	cis	rs10450586	1.000	rs10450586	chr11:27308483	G/C	cg10370305	chr11:27303972	NA	0.36	5.8	0.3	1.53e-8	Total body bone mineral density;
CRC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.59	-8.06	-0.41	1.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.1	0.36	7.97e-12	Ulcerative colitis;
CRC	cis	rs1524976	1.000	rs9817894	chr3:65465760	T/A	cg16238336	chr3:65465873	MAGI1	-0.53	-7.64	-0.39	2.42e-13	PR interval;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.23	5.63	0.3	3.89e-8	Parkinson's disease;
CRC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.57	6.14	0.32	2.31e-9	Initial pursuit acceleration;
CRC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.66	-12.06	-0.55	5.6e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05733361	chr15:85524456	PDE8A	0.49	6.23	0.32	1.43e-9	Thyroid stimulating hormone;
CRC	trans	rs7308116	0.546	rs2374728	chr12:108227299	A/C	cg10318744	chr14:69282256	NA	-0.4	-5.96	-0.31	6.37e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.43	7.4	0.38	1.17e-12	Cardiovascular disease risk factors;
CRC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20092199	chr4:1342459	KIAA1530	0.32	5.76	0.3	1.9e-8	Obesity-related traits;
CRC	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.9	-0.31	8.88e-9	Height;
CRC	cis	rs524281	0.773	rs10791862	chr11:66013664	T/C	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16025584	chr9:139887217	C9orf142	0.51	6.7	0.35	8.92e-11	Thyroid stimulating hormone;
CRC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg11189052	chr15:85197271	WDR73	0.59	8.37	0.42	1.72e-15	Schizophrenia;
CRC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.49	-9.24	-0.45	3.04e-18	Reticulocyte fraction of red cells;
CRC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg17321639	chr7:2759063	NA	-0.47	-6.05	-0.32	3.92e-9	Height;
CRC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	8.93	0.44	2.99e-17	Schizophrenia;
CRC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg23018236	chr17:30244563	NA	-0.57	-7.15	-0.37	5.62e-12	Hip circumference adjusted for BMI;
CRC	cis	rs2013441	1.000	rs2526483	chr17:20112216	A/G	cg13482628	chr17:19912719	NA	-0.42	-6.57	-0.34	1.95e-10	Obesity-related traits;
CRC	cis	rs7605827	0.930	rs2380649	chr2:15532612	A/C	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.06e-8	Educational attainment (years of education);
CRC	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.25	-0.37	3.06e-12	Chronic sinus infection;
CRC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.61	-0.43	3.07e-16	Breast cancer;
CRC	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.58	0.43	3.91e-16	Coffee consumption (cups per day);
CRC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-10.94	-0.52	5.62e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg15786705	chr6:28176104	NA	0.54	7.62	0.39	2.72e-13	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg11875773	chr22:50468633	TTLL8	-0.7	-6.07	-0.32	3.62e-9	Cognitive function;
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-5.98	-0.31	5.72e-9	Lung function (FEV1/FVC);
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg24046110	chr8:143859143	LYNX1	0.5	7.94	0.4	3.32e-14	Urinary tract infection frequency;
CRC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02450064	chr17:40260053	DHX58	-0.42	-6.13	-0.32	2.54e-9	Fibrinogen levels;
CRC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-14.79	-0.63	2.77e-38	Prostate cancer;
CRC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.02	23.53	0.79	1.79e-72	Multiple system atrophy;
CRC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg05192639	chr6:26864778	GUSBL1	-0.35	-6.11	-0.32	2.79e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs863345	0.548	rs857687	chr1:158577998	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-7.06	-0.36	1e-11	Pneumococcal bacteremia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16014136	chr7:89975892	GTPBP10	0.42	6.09	0.32	3.07e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24430189	chr2:128173685	NA	-0.47	-6.15	-0.32	2.21e-9	Diisocyanate-induced asthma;
CRC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.62	8.77	0.44	9.79e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-6.88	-0.35	3.03e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.59	8.45	0.42	9.43e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.15	-0.37	5.67e-12	Capecitabine sensitivity;
CRC	cis	rs883565	0.696	rs6599007	chr3:39114445	A/C	cg01426195	chr3:39028469	NA	-0.54	-8.68	-0.43	1.86e-16	Handedness;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.69	-0.35	9.47e-11	Total body bone mineral density;
CRC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.54	8.25	0.41	3.77e-15	Aortic root size;
CRC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.67	-8.2	-0.41	5.57e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.59	7.01	0.36	1.34e-11	Carotid intima media thickness;
CRC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg00717180	chr2:96193071	NA	-0.36	-6.0	-0.31	5.3e-9	HDL cholesterol;
CRC	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.95	-13.35	-0.59	8.41e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	0.81	8.55	0.43	4.7e-16	Gout;Renal underexcretion gout;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01620991	chr7:66767710	STAG3L4;PMS2L4	0.41	6.04	0.32	4.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-10.6	-0.5	8.82e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg17470449	chr10:769945	NA	0.58	7.88	0.4	4.89e-14	Uric acid levels;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	trans	rs264943	0.600	rs266055	chr2:104093800	C/A	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.8e-9	HIV-1 viral setpoint;
CRC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.83	0.55	3.69e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4731207	0.735	rs12155120	chr7:124478232	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7605827	0.930	rs2111448	chr2:15599073	T/G	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.58e-9	Educational attainment (years of education);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg09765302	chr1:159916077	IGSF9	-0.35	-6.04	-0.32	4.28e-9	HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15559560	chr2:130939084	SMPD4;FAM128B	0.46	6.25	0.33	1.24e-9	Anxiety disorder;
CRC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg20243544	chr17:37824526	PNMT	0.38	5.65	0.3	3.53e-8	Self-reported allergy;
CRC	trans	rs1376359	0.636	rs12072704	chr1:103123956	A/C	cg16220183	chr17:56609687	SEPT4	-0.47	-6.48	-0.34	3.34e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.62	-0.39	2.65e-13	Blood metabolite levels;
CRC	cis	rs13268772	0.523	rs270054	chr8:3255581	A/G	cg23564432	chr8:3253958	CSMD1	0.34	6.27	0.33	1.13e-9	Schizophrenia;
CRC	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.09	0.55	4.48e-28	Testicular germ cell tumor;
CRC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg20354231	chr13:53171401	NA	-0.45	-7.39	-0.38	1.21e-12	Lewy body disease;
CRC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.81	-0.35	4.6e-11	Body mass index;
CRC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.03	0.32	4.38e-9	Rheumatoid arthritis;
CRC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg25804541	chr17:80189381	SLC16A3	0.3	5.63	0.3	3.94e-8	Life satisfaction;
CRC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.82	0.31	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-6.24	-0.33	1.31e-9	Menopause (age at onset);
CRC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14842401	chr3:40566302	ZNF621	0.37	6.68	0.35	1.03e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.57	-9.62	-0.47	1.87e-19	Prevalent atrial fibrillation;
CRC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg27523141	chr10:43048294	ZNF37B	0.5	7.33	0.37	1.83e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg24253500	chr15:84953950	NA	0.36	5.98	0.31	5.94e-9	Schizophrenia;
CRC	cis	rs2814982	0.605	rs114032116	chr6:34468333	C/T	cg14254433	chr6:34482411	PACSIN1	-0.81	-8.61	-0.43	3.08e-16	Cholesterol, total;Total cholesterol levels;
CRC	cis	rs2160860	0.965	rs2543050	chr8:39820296	C/G	cg11363097	chr8:39792086	IDO2	-0.35	-5.65	-0.3	3.44e-8	Blood metabolite levels;
CRC	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.7	9.85	0.48	3.1e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs1528435	0.619	rs6745626	chr2:181436641	C/T	cg23363182	chr2:181467187	NA	-0.41	-6.44	-0.33	4.28e-10	Body mass index;
CRC	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.14	0.41	8.34e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.72	10.03	0.48	8.03e-21	Breast cancer;
CRC	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg20573242	chr4:122745356	CCNA2	0.43	6.47	0.34	3.46e-10	Type 2 diabetes;
CRC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.55	7.57	0.39	3.81e-13	Schizophrenia;
CRC	cis	rs4731207	0.596	rs10231491	chr7:124574091	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.33	-0.37	1.79e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.95	-0.31	6.8e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21871735	chr16:2015157	SNHG9;RPS2;SNORA78	-0.52	-6.28	-0.33	1.06e-9	Diisocyanate-induced asthma;
CRC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.43	-8.28	-0.42	3.13e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.34	2.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs459193	0.912	rs27984	chr5:55802419	C/T	cg26646659	chr5:55776364	NA	0.49	6.72	0.35	7.87e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.14	0.41	8.34e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg15193198	chr20:60906057	LAMA5	0.44	7.21	0.37	3.8e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.44	-5.95	-0.31	6.81e-9	Hip circumference adjusted for BMI;
CRC	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg08755490	chr11:65554678	OVOL1	0.41	6.03	0.32	4.51e-9	Acne (severe);
CRC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.82	-10.96	-0.52	4.91e-24	Initial pursuit acceleration;
CRC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.41	-5.75	-0.3	2.02e-8	Erythrocyte sedimentation rate;
CRC	trans	rs4785204	1.000	rs9939710	chr16:50093951	C/T	cg07960154	chr17:37760198	NEUROD2	-0.66	-6.13	-0.32	2.45e-9	Esophageal cancer (squamous cell);
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg10729496	chr3:10149963	C3orf24	0.51	6.7	0.35	9.25e-11	Alzheimer's disease;
CRC	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.51	0.38	5.65e-13	Systolic blood pressure;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg11843238	chr5:131593191	PDLIM4	0.52	9.01	0.44	1.69e-17	Acylcarnitine levels;
CRC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11031096	0.738	rs2923950	chr11:4042069	G/C	cg18678763	chr11:4115507	RRM1	0.35	5.73	0.3	2.23e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg06627628	chr2:24431161	ITSN2	-0.54	-5.93	-0.31	7.68e-9	Lymphocyte counts;
CRC	cis	rs4731207	0.594	rs6968500	chr7:124431722	G/C	cg23710748	chr7:124431027	NA	-0.43	-7.24	-0.37	3.14e-12	Cutaneous malignant melanoma;
CRC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.43	6.98	0.36	1.62e-11	Height;
CRC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg05139728	chr16:28306816	SBK1	-0.37	-6.05	-0.32	4.05e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-10.16	-0.49	2.94e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.54	-8.05	-0.41	1.57e-14	Blood protein levels;
CRC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.68	-8.95	-0.44	2.65e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.82	-0.48	3.9e-20	Height;
CRC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg11189052	chr15:85197271	WDR73	0.53	7.38	0.38	1.29e-12	Schizophrenia;
CRC	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-9.14	-0.45	6.6e-18	Coffee consumption (cups per day);
CRC	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-5.85	-0.31	1.21e-8	Schizophrenia;
CRC	cis	rs6496667	0.730	rs7176776	chr15:91049140	T/G	cg04176472	chr15:90893244	GABARAPL3	0.57	8.18	0.41	6.47e-15	Rheumatoid arthritis;
CRC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.67	9.45	0.46	6.78e-19	Vitiligo;
CRC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.6	9.57	0.47	2.64e-19	Melanoma;
CRC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg24562669	chr7:97807699	LMTK2	0.43	7.05	0.36	1.04e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg23071808	chr14:103021642	NA	0.62	6.82	0.35	4.26e-11	Platelet count;
CRC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.9	-0.31	8.87e-9	Aortic root size;
CRC	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.53	8.32	0.42	2.41e-15	Corneal astigmatism;
CRC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.86	-10.02	-0.48	8.73e-21	Breast cancer;
CRC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg08477640	chr19:41863820	B9D2	0.58	8.0	0.4	2.2e-14	Colorectal cancer;
CRC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.39	-0.33	5.63e-10	Aortic root size;
CRC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg05941027	chr17:61774174	LIMD2	0.36	6.2	0.32	1.73e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs4824093	0.610	rs73443986	chr22:50321193	C/T	cg09872104	chr7:134855509	C7orf49	-0.85	-7.8	-0.4	8.48e-14	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4664293	0.934	rs1365800	chr2:160555623	A/C	cg08347373	chr2:160653686	CD302	-0.46	-7.38	-0.38	1.29e-12	Monocyte percentage of white cells;
CRC	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg19688584	chr6:167529678	CCR6	-0.35	-6.42	-0.33	4.63e-10	Primary biliary cholangitis;
CRC	trans	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg06791473	chr12:49259579	RND1	0.61	6.03	0.32	4.5e-9	Blood protein levels;
CRC	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.96	-0.4	2.86e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg26035837	chr20:56885003	RAB22A;PPP4R1L	-0.4	-6.03	-0.32	4.44e-9	HDL cholesterol;
CRC	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.1	0.49	4.49e-21	Asthma;
CRC	cis	rs4363385	0.747	rs4845504	chr1:152960043	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.29	-0.37	2.3e-12	Inflammatory skin disease;
CRC	cis	rs4970966	0.904	rs12131809	chr1:150544640	C/T	cg17724175	chr1:150552817	MCL1	-0.48	-5.89	-0.31	9.33e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.62	9.21	0.45	4.06e-18	Subjective well-being;
CRC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.58	-6.07	-0.32	3.5e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.9	-0.31	8.82e-9	Diabetic kidney disease;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.59	-8.43	-0.42	1.13e-15	Body mass index;
CRC	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg22331349	chr19:52391350	ZNF577	0.49	6.19	0.32	1.78e-9	Breast cancer;
CRC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.86	-0.35	3.44e-11	Major depressive disorder;
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.72	-0.51	3.38e-23	Body mass index;
CRC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.65	6.76	0.35	6.47e-11	Axial length;
CRC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.53	7.18	0.37	4.67e-12	Total body bone mineral density;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg22687807	chr8:143858763	LYNX1	0.49	8.63	0.43	2.73e-16	Urinary tract infection frequency;
CRC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.15	0.32	2.28e-9	Diabetic kidney disease;
CRC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.23	-0.53	5.57e-25	Chronic sinus infection;
CRC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.82	14.84	0.63	1.74e-38	Metabolic syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06753787	chr2:220074208	ZFAND2B	0.28	6.02	0.31	4.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.51	6.49	0.34	3.2e-10	Neuroticism;
CRC	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	5.99	0.31	5.58e-9	Diastolic blood pressure;
CRC	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.76	-9.88	-0.48	2.55e-20	Neuroticism;
CRC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg25173405	chr17:45401733	C17orf57	0.39	5.81	0.31	1.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.56	-0.5	1.24e-22	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.51	6.89	0.36	2.86e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg24560729	chr4:1342394	KIAA1530	0.44	7.8	0.4	8e-14	Longevity;
CRC	cis	rs6694672	1.000	rs4350226	chr1:197132378	G/A	cg13682187	chr1:196946512	CFHR5	0.49	7.81	0.4	7.48e-14	Asthma;
CRC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.8	0.35	4.92e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs282587	0.569	rs282598	chr13:113384331	A/G	cg04656015	chr13:113407548	ATP11A	0.63	7.9	0.4	4.11e-14	Glycated hemoglobin levels;
CRC	cis	rs10971721	0.822	rs72725392	chr9:33867778	A/G	cg13495928	chr9:33750294	PRSS3	0.56	6.05	0.32	3.88e-9	Body mass index;
CRC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg07713946	chr22:31675144	LIMK2	0.37	5.74	0.3	2.18e-8	Colorectal cancer;
CRC	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.44	-6.94	-0.36	2.04e-11	HDL cholesterol;
CRC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.39	-6.67	-0.35	1.05e-10	Reticulocyte fraction of red cells;
CRC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	9.87	0.48	2.66e-20	Multiple sclerosis;
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg03959625	chr15:84868606	LOC388152	0.41	6.08	0.32	3.26e-9	Schizophrenia;
CRC	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg12458913	chr13:53173898	NA	0.54	8.61	0.43	3.09e-16	Lewy body disease;
CRC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	14.49	0.62	3.92e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg19913688	chr11:428466	ANO9	-0.72	-6.86	-0.35	3.42e-11	Body mass index;
CRC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.71	-7.96	-0.4	2.84e-14	Birth weight;
CRC	cis	rs7113874	0.589	rs2028882	chr11:8504854	A/C	cg20771178	chr11:8615675	STK33	-0.35	-5.72	-0.3	2.43e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.46	7.33	0.37	1.83e-12	Pulmonary function;
CRC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.96	0.36	1.84e-11	Mean platelet volume;
CRC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.81	0.51	1.68e-23	Coronary artery disease;
CRC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.69	10.81	0.51	1.62e-23	Blood protein levels;
CRC	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg11900509	chr10:81946545	ANXA11	-0.64	-6.66	-0.34	1.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6496667	1.000	rs7162243	chr15:90892631	G/T	cg04176472	chr15:90893244	GABARAPL3	0.54	8.13	0.41	8.55e-15	Rheumatoid arthritis;
CRC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	9.11	0.45	8.03e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12594515	0.591	rs35554150	chr15:45990298	G/A	cg22117107	chr15:45993392	NA	-0.4	-6.51	-0.34	2.86e-10	Waist circumference;Weight;
CRC	cis	rs73206853	0.698	rs73194015	chr12:111116651	C/T	cg12870014	chr12:110450643	ANKRD13A	0.73	6.66	0.34	1.15e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.53	-11.07	-0.52	2.03e-24	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.74	-14.41	-0.62	7.9e-37	Prostate cancer;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.72	11.42	0.53	1.17e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs335206	0.641	rs335210	chr5:122501864	A/G	cg16368670	chr5:122501738	PRDM6	-0.29	-6.05	-0.32	3.84e-9	QRS duration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17010941	chr8:102218219	ZNF706	0.44	6.28	0.33	1.07e-9	Anxiety disorder;
CRC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.5	8.12	0.41	9.57e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.52	8.8	0.44	7.76e-17	Dupuytren's disease;
CRC	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-6.35	-0.33	7.2e-10	Coronary artery disease;
CRC	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg11204139	chr17:3907470	NA	-0.72	-14.39	-0.62	9.34e-37	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16051027	chr20:32320358	ZNF341	0.41	6.03	0.32	4.35e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg18876405	chr7:65276391	NA	0.45	6.27	0.33	1.14e-9	Aortic root size;
CRC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.6	9.41	0.46	8.82e-19	Tuberculosis;
CRC	trans	rs514406	1.000	rs514406	chr1:53330458	A/G	cg10287303	chr10:74855401	P4HA1	0.41	6.09	0.32	3.13e-9	Monocyte count;
CRC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.17	0.62	6.37e-36	Chronic sinus infection;
CRC	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.73	-0.43	1.29e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.53	-0.5	1.59e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs73206853	0.841	rs60219027	chr12:110759843	T/G	cg12870014	chr12:110450643	ANKRD13A	0.8	7.76	0.39	1.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.58	6.12	0.32	2.73e-9	RR interval (heart rate);
CRC	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	0.49	6.32	0.33	8.52e-10	Blood protein levels;
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.4	6.84	0.35	3.9e-11	Height;
CRC	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.52	-8.6	-0.43	3.21e-16	Metabolite levels (small molecules and protein measures);
CRC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.68	9.03	0.45	1.48e-17	High light scatter reticulocyte count;
CRC	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg21970626	chr13:21893289	NA	0.42	5.83	0.31	1.33e-8	White matter hyperintensity burden;
CRC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	8.42	0.42	1.18e-15	Response to antipsychotic treatment;
CRC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.84	0.35	3.98e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	8.0	0.4	2.14e-14	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24449885	chr12:51718355	BIN2	0.36	5.99	0.31	5.4e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.46	-0.34	3.86e-10	Parkinson's disease;
CRC	cis	rs17767392	0.834	rs17767380	chr14:71747031	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.34	-0.33	7.77e-10	Mitral valve prolapse;
CRC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.68	10.13	0.49	3.48e-21	Corneal astigmatism;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02128981	chr11:58904901	NA	0.37	6.03	0.32	4.48e-9	Obesity-related traits;
CRC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.28	-0.33	1.04e-9	Coronary artery disease;
CRC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.73	11.56	0.54	3.71e-26	Dental caries;
CRC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.72	0.68	7.3e-46	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.75	-12.75	-0.58	1.51e-30	Breast cancer;
CRC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg20243544	chr17:37824526	PNMT	0.41	6.48	0.34	3.28e-10	Self-reported allergy;
CRC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.3	-0.37	2.24e-12	Self-reported allergy;
CRC	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.29	7.82	0.4	7.23e-14	Mean corpuscular volume;
CRC	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.64	6.33	0.33	7.98e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.44	-6.12	-0.32	2.67e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	9.45	0.46	6.67e-19	Alzheimer's disease;
CRC	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg09476006	chr5:138032270	NA	0.39	6.49	0.34	3.21e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg25456477	chr12:86230367	RASSF9	-0.34	-6.14	-0.32	2.39e-9	Major depressive disorder;
CRC	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.67	11.96	0.55	1.27e-27	Ulcerative colitis;
CRC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs375066	0.599	rs8106802	chr19:44350096	A/G	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.67	0.57	3.21e-30	Menopause (age at onset);
CRC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.37	-5.76	-0.3	1.94e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg02725872	chr8:58115012	NA	-0.41	-6.33	-0.33	8.11e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg15832292	chr6:96025679	MANEA	0.56	6.28	0.33	1.08e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs10971721	0.643	rs10971701	chr9:33781898	A/G	cg13495928	chr9:33750294	PRSS3	0.66	5.92	0.31	8.05e-9	Body mass index;
CRC	cis	rs6432018	0.836	rs62119427	chr2:9742068	T/C	cg12832956	chr2:9616023	IAH1	-0.37	-5.64	-0.3	3.67e-8	Heart rate variability traits;
CRC	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg10483660	chr13:112241077	NA	0.36	5.79	0.3	1.63e-8	Menarche (age at onset);
CRC	cis	rs13315871	1.000	rs11710058	chr3:58383048	G/A	cg20936604	chr3:58311152	NA	-0.71	-6.53	-0.34	2.5e-10	Cholesterol, total;
CRC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.49	6.4	0.33	5.32e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.43e-12	Life satisfaction;
CRC	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.53	0.38	4.84e-13	Height;
CRC	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.73	9.47	0.46	5.57e-19	Iron status biomarkers;
CRC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg25885038	chr17:56607967	SEPT4	-0.51	-7.72	-0.39	1.44e-13	Vitamin D levels;
CRC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.22	-0.32	1.55e-9	Aortic root size;
CRC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg22535103	chr8:58192502	C8orf71	-0.52	-6.34	-0.33	7.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.85	13.55	0.6	1.57e-33	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14280964	chr1:37940281	ZC3H12A	0.38	6.12	0.32	2.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg12172441	chr6:28176163	NA	0.54	7.44	0.38	8.97e-13	Parkinson's disease;
CRC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	0.78	8.66	0.43	2.14e-16	Gout;Renal underexcretion gout;
CRC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.56	-8.41	-0.42	1.24e-15	Body mass index;
CRC	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.83	11.82	0.55	4.2e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.57	7.52	0.38	5.4e-13	Urinary tract infection frequency;
CRC	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.52	9.22	0.45	3.57e-18	Common traits (Other);
CRC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	0.56	5.62	0.3	4.18e-8	Fat distribution (HIV);
CRC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.6	-9.2	-0.45	4.12e-18	Coronary artery disease;
CRC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-7.9	-0.4	4.11e-14	Uric acid levels;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.26	-0.56	9.81e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.34	0.38	1.64e-12	Obesity-related traits;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.53	7.41	0.38	1.1e-12	Longevity;Endometriosis;
CRC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg18827107	chr12:86230957	RASSF9	-0.38	-6.25	-0.33	1.3e-9	Major depressive disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09378497	chr16:1525169	CLCN7	0.39	6.21	0.32	1.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.68	7.65	0.39	2.23e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg20387954	chr3:183756860	HTR3D	0.45	7.63	0.39	2.53e-13	Anterior chamber depth;
CRC	cis	rs6496667	0.779	rs16944424	chr15:90983465	C/T	cg04176472	chr15:90893244	GABARAPL3	-0.59	-8.52	-0.43	5.75e-16	Rheumatoid arthritis;
CRC	cis	rs4363385	0.747	rs1984198	chr1:152958584	T/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.45	-0.38	8.07e-13	Inflammatory skin disease;
CRC	cis	rs4964805	0.657	rs4964814	chr12:104189384	A/C	cg02344784	chr12:104178138	NT5DC3	-0.78	-14.95	-0.64	6.47e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs4750440	0.733	rs2446585	chr10:14028086	C/T	cg00551146	chr10:14014579	FRMD4A	0.41	7.08	0.36	8.72e-12	Adiponectin levels;
CRC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.56	-6.1	-0.32	2.96e-9	Schizophrenia;
CRC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.74	0.43	1.21e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24981363	chr3:122512705	DIRC2;HSPBAP1	0.43	6.16	0.32	2.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg15786705	chr6:28176104	NA	0.63	8.99	0.44	2.02e-17	Cardiac Troponin-T levels;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg15786705	chr6:28176104	NA	0.5	6.19	0.32	1.81e-9	Parkinson's disease;
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.46	0.34	3.67e-10	Alzheimer's disease;
CRC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.62	-9.35	-0.46	1.42e-18	Cognitive function;
CRC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.48	7.26	0.37	2.86e-12	Corneal astigmatism;
CRC	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg09655341	chr17:79618100	PDE6G	0.59	6.75	0.35	6.71e-11	Dental caries;
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg19223190	chr17:80058835	NA	0.39	6.18	0.32	1.89e-9	Life satisfaction;
CRC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	9.55	0.47	3.19e-19	Migraine;Coronary artery disease;
CRC	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.45	-6.28	-0.33	1.07e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.54	-7.26	-0.37	2.83e-12	Glycated hemoglobin levels;
CRC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.83	15.01	0.64	3.56e-39	Breast cancer;
CRC	cis	rs863345	0.604	rs11265024	chr1:158513255	A/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.98	-0.36	1.63e-11	Pneumococcal bacteremia;
CRC	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.83	-0.31	1.32e-8	Blood pressure;
CRC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.38	-0.33	6.12e-10	Aortic root size;
CRC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.86	-0.35	3.51e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2398893	1.000	rs1411861	chr9:96763614	A/G	cg14459158	chr9:96720562	NA	0.47	7.31	0.37	2.04e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.45	-6.87	-0.35	3.17e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7739232	0.834	rs17216271	chr6:53529252	C/T	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.65	6.58	0.34	1.87e-10	Blood protein levels;
CRC	cis	rs2274273	0.624	rs10146637	chr14:55744810	G/A	cg10130446	chr14:55658398	DLGAP5	-0.42	-6.02	-0.32	4.53e-9	Protein biomarker;
CRC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.91	17.67	0.7	1.31e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.6	10.61	0.51	7.98e-23	Aortic root size;
CRC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.65	6.96	0.36	1.88e-11	Axial length;
CRC	cis	rs780094	0.500	rs4665987	chr2:27755825	G/A	cg27432699	chr2:27873401	GPN1	0.47	6.07	0.32	3.47e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-10.17	-0.49	2.62e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.61	-11.45	-0.53	8.96e-26	Educational attainment;
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg22687807	chr8:143858763	LYNX1	0.61	11.1	0.52	1.56e-24	Urinary tract infection frequency;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16909824	chr1:151299438	PI4KB	0.41	6.0	0.31	5.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs939574	0.656	rs6710315	chr2:220137991	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.65	-6.13	-0.32	2.58e-9	Platelet distribution width;
CRC	cis	rs6496667	0.779	rs7170480	chr15:90951639	C/T	cg04176472	chr15:90893244	GABARAPL3	0.64	8.14	0.41	8.09e-15	Rheumatoid arthritis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19660878	chr19:19774104	ATP13A1	0.45	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.52	7.23	0.37	3.38e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg14828511	chr1:107599125	PRMT6	-0.5	-7.25	-0.37	3.01e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.55	-7.6	-0.39	3.21e-13	Obesity-related traits;
CRC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.86	-13.8	-0.61	1.7e-34	Blood metabolite levels;
CRC	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.84	0.4	6.2e-14	Diabetic kidney disease;
CRC	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg26383811	chr8:30366931	RBPMS	0.66	9.57	0.47	2.61e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.34	-6.03	-0.32	4.43e-9	Rheumatoid arthritis;
CRC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg24209194	chr3:40518798	ZNF619	0.38	5.7	0.3	2.63e-8	Renal cell carcinoma;
CRC	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.04	-0.36	1.15e-11	Ulcerative colitis;
CRC	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.87	0.48	2.68e-20	Fuchs's corneal dystrophy;
CRC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.82	13.62	0.6	8.34e-34	Menopause (age at onset);
CRC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.47	6.98	0.36	1.66e-11	Menarche (age at onset);
CRC	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.94	-12.71	-0.57	2.18e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.97	-0.31	6.01e-9	Lung cancer;
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.46	-0.38	7.96e-13	Lymphocyte counts;
CRC	cis	rs10924970	0.649	rs10925099	chr1:235366902	C/A	cg09010748	chr1:235293032	TOMM20	-0.42	-5.82	-0.31	1.41e-8	Asthma;
CRC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg01721255	chr8:58191610	C8orf71	0.47	6.03	0.32	4.44e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg26043149	chr18:55253948	FECH	-0.48	-7.43	-0.38	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.62	-8.73	-0.43	1.35e-16	Coronary artery disease;
CRC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.49	-7.02	-0.36	1.28e-11	Lymphocyte counts;
CRC	cis	rs7113874	0.569	rs4620720	chr11:8615939	G/A	cg17679104	chr11:8615758	STK33	0.33	5.67	0.3	3.11e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13826709	chr21:46708041	POFUT2;LOC642852	0.45	6.18	0.32	1.91e-9	Anxiety disorder;
CRC	cis	rs4964805	0.672	rs11111757	chr12:104160762	G/C	cg02344784	chr12:104178138	NT5DC3	0.45	6.67	0.35	1.07e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-9.51	-0.46	4.13e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.45	-6.19	-0.32	1.8e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.61	9.05	0.45	1.24e-17	Bronchopulmonary dysplasia;
CRC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.12	-0.37	6.96e-12	IgG glycosylation;
CRC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.86	15.59	0.65	1.97e-41	Menopause (age at onset);
CRC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg26566898	chr11:117069891	TAGLN	0.42	8.54	0.43	5.16e-16	Blood protein levels;
CRC	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg26566898	chr11:117069891	TAGLN	0.4	7.12	0.37	6.73e-12	Blood protein levels;
CRC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.56	-8.19	-0.41	6.02e-15	Schizophrenia;
CRC	cis	rs6558174	0.714	rs17674754	chr8:22533388	A/G	cg03733263	chr8:22462867	KIAA1967	0.5	5.99	0.31	5.65e-9	Breast cancer;
CRC	cis	rs1971762	0.527	rs784562	chr12:53919700	A/C	cg06632207	chr12:54070931	ATP5G2	-0.48	-8.16	-0.41	7.32e-15	Height;
CRC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.27	6.09	0.32	3.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.48	-0.38	6.99e-13	Type 2 diabetes;
CRC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25517755	chr10:38738941	LOC399744	-0.4	-5.62	-0.3	4.03e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	8.08e-10	Depression;
CRC	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.59	-7.04	-0.36	1.1e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05910138	chr5:74632922	HMGCR	0.47	6.89	0.36	2.84e-11	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg00074818	chr8:8560427	CLDN23	0.34	6.23	0.32	1.42e-9	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08228715	chr17:79895357	PYCR1	0.47	6.52	0.34	2.59e-10	Anxiety disorder;
CRC	cis	rs7680126	0.596	rs10805364	chr4:10275518	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.19	-0.32	1.82e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.06	-0.45	1.23e-17	Alzheimer's disease;
CRC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.56	0.38	4.09e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.4	5.76	0.3	1.96e-8	Obesity-related traits;
CRC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.7	-0.35	8.86e-11	Cutaneous nevi;
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.38	6.27	0.33	1.16e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1891275	0.515	rs11186666	chr10:93477919	T/C	cg07889827	chr10:93443413	NA	-0.39	-6.5	-0.34	3.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg03623178	chr6:28175578	NA	0.95	12.51	0.57	1.22e-29	Depression;
CRC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.52	7.91	0.4	4.05e-14	Corneal astigmatism;
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg20041105	chr8:143859282	LYNX1	0.46	8.18	0.41	6.2e-15	Urinary tract infection frequency;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg27615366	chr5:131592974	PDLIM4	-0.33	-5.77	-0.3	1.86e-8	Breast cancer;
CRC	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-8.23	-0.41	4.38e-15	HDL cholesterol;
CRC	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.55	-7.55	-0.38	4.23e-13	Ileal carcinoids;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg15845792	chr6:28175446	NA	0.78	11.62	0.54	2.13e-26	Cardiac Troponin-T levels;
CRC	cis	rs17362650	0.653	rs10929581	chr2:9552379	C/T	cg12832956	chr2:9616023	IAH1	-0.49	-6.5	-0.34	2.98e-10	Alcohol dependence (age at onset);
CRC	cis	rs7605827	0.930	rs11902128	chr2:15515269	T/G	cg19274914	chr2:15703543	NA	0.4	6.03	0.32	4.33e-9	Educational attainment (years of education);
CRC	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-0.76	-8.43	-0.42	1.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	7.28	0.37	2.55e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs7632954	0.567	rs6768518	chr3:8534828	G/A	cg03495237	chr3:8533978	NA	0.35	6.38	0.33	5.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4494114	0.967	rs9438980	chr1:39355371	A/G	cg25970120	chr1:39325951	RRAGC	-0.42	-5.78	-0.3	1.77e-8	Blood protein levels;
CRC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg24011408	chr12:48396354	COL2A1	0.45	6.32	0.33	8.27e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg09659197	chr4:152720779	NA	0.52	11.24	0.53	4.87e-25	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.72	-8.17	-0.41	6.5e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-7.85	-0.4	5.76e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.94	-0.4	3.22e-14	Systemic lupus erythematosus;
CRC	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.85	-0.63	1.53e-38	Exhaled nitric oxide output;
CRC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.39	6.69	0.35	9.85e-11	Total body bone mineral density;
CRC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.23	-0.41	4.48e-15	Type 2 diabetes;
CRC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18876405	chr7:65276391	NA	0.49	7.72	0.39	1.42e-13	Aortic root size;
CRC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18357526	chr6:26021779	HIST1H4A	0.43	6.11	0.32	2.85e-9	Height;
CRC	cis	rs990171	1.000	rs4851588	chr2:103073505	C/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.87	0.31	1.09e-8	Lymphocyte counts;
CRC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.91	-0.4	3.85e-14	Body mass index;
CRC	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	6.78	0.35	5.73e-11	Breast cancer;
CRC	cis	rs539514	0.690	rs1092601	chr13:76309746	C/T	cg04757411	chr13:76259545	LMO7	-0.35	-5.87	-0.31	1.06e-8	Type 1 diabetes;
CRC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	trans	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-7.53	-0.38	4.98e-13	Menarche (age at onset);
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg24560729	chr4:1342394	KIAA1530	0.31	5.65	0.3	3.43e-8	Obesity-related traits;
CRC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg07212818	chr11:638076	DRD4	-0.46	-5.87	-0.31	1.07e-8	Systemic lupus erythematosus;
CRC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.59	5.84	0.31	1.23e-8	Fat distribution (HIV);
CRC	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.5	8.41	0.42	1.22e-15	Testicular germ cell tumor;
CRC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.39	8.58	0.43	3.71e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.4	6.12	0.32	2.65e-9	Monocyte count;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg03609598	chr5:56110824	MAP3K1	0.6	8.15	0.41	7.56e-15	Initial pursuit acceleration;
CRC	cis	rs7605827	0.860	rs6760297	chr2:15632472	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00802000	chr16:706648	WDR90	-0.44	-6.31	-0.33	8.99e-10	Height;
CRC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.11	-0.36	7.42e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-6.95	-0.36	2.01e-11	HDL cholesterol;
CRC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg13722127	chr7:150037890	RARRES2	-0.47	-7.64	-0.39	2.38e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.92e-9	Life satisfaction;
CRC	cis	rs10486722	0.651	rs4720404	chr7:41776699	G/A	cg22138096	chr7:41772439	LOC285954	0.48	6.2	0.32	1.7e-9	Pit-and-Fissure caries;
CRC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.51	7.03	0.36	1.19e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.68	-0.35	1.03e-10	Aortic root size;
CRC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.46	9.25	0.45	2.91e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg02389323	chr16:88786976	FAM38A	1.0	8.56	0.43	4.4e-16	Plateletcrit;
CRC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.55	-7.56	-0.38	4.16e-13	Colorectal cancer;
CRC	cis	rs4731207	0.596	rs9640828	chr7:124655481	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.8e-27	Asthma (sex interaction);
CRC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.91	-0.44	3.5e-17	Chronic sinus infection;
CRC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.85	15.15	0.64	1.08e-39	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs1062746	0.544	rs8059287	chr16:87332956	G/A	cg02258303	chr16:87377426	FBXO31	-0.51	-7.34	-0.37	1.73e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.53	-0.34	2.55e-10	Systemic lupus erythematosus;
CRC	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg21770322	chr7:97807741	LMTK2	-0.56	-8.03	-0.4	1.78e-14	Breast cancer;
CRC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.18	-0.56	2.02e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg11707556	chr5:10655725	ANKRD33B	0.47	7.6	0.39	3.2e-13	Coronary artery disease;
CRC	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.29	0.64	2.98e-40	Bipolar disorder;
CRC	cis	rs11255291	0.668	rs719748	chr10:7731885	A/G	cg00997801	chr10:7671259	ITIH5	0.41	6.18	0.32	1.9e-9	Ovarian reserve;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20092199	chr4:1342459	KIAA1530	-0.38	-6.09	-0.32	3.22e-9	Obesity-related traits;
CRC	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.38	5.69	0.3	2.87e-8	Essential tremor;
CRC	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.52	9.3	0.46	1.98e-18	Blood metabolite ratios;
CRC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.57	8.31	0.42	2.63e-15	Response to temozolomide;
CRC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.67	-8.14	-0.41	8.07e-15	Rheumatoid arthritis;
CRC	cis	rs4692589	0.931	rs12647236	chr4:170966255	A/T	cg19918862	chr4:170955249	NA	-0.38	-6.17	-0.32	2.01e-9	Anxiety disorder;
CRC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.49	8.27	0.42	3.26e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.63	-6.65	-0.34	1.2e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.6	-9.46	-0.46	6.22e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6908034	0.607	rs77753186	chr6:19812980	G/C	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.56	0.43	4.28e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	14.46	0.62	5.11e-37	Platelet count;
CRC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04731861	chr2:219085781	ARPC2	0.37	7.99	0.4	2.37e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg09184832	chr6:79620586	NA	-0.47	-8.22	-0.41	4.67e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.07	-0.71	3.63e-51	Schizophrenia;
CRC	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.12	-0.45	7.73e-18	Rheumatoid arthritis;
CRC	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg11130432	chr3:121712080	ILDR1	0.5	5.93	0.31	7.69e-9	Multiple sclerosis;
CRC	trans	rs6075982	0.749	rs6082953	chr20:22947557	C/T	cg03184243	chr8:28347962	FBXO16	0.49	6.11	0.32	2.76e-9	Obesity-related traits;
CRC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg03030879	chr14:75389066	RPS6KL1	0.53	8.51	0.42	6.42e-16	Caffeine consumption;
CRC	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.48e-17	Dupuytren's disease;
CRC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.58	9.27	0.46	2.5e-18	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04688917	chr3:179040469	ZNF639	0.43	6.01	0.31	5e-9	Response to antipsychotic treatment;
CRC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.17	0.41	6.8e-15	Parkinson's disease;
CRC	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg04110750	chr16:69646130	NFAT5	-0.53	-7.1	-0.36	7.5e-12	IgE levels;
CRC	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	6.0	0.31	5.14e-9	Diastolic blood pressure;
CRC	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.62	-0.34	1.49e-10	Educational attainment (years of education);
CRC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg06204229	chr3:52865917	ITIH4	0.51	5.86	0.31	1.13e-8	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-9.07	-0.45	1.1e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-7.69	-0.39	1.7e-13	Migraine;
CRC	cis	rs2252790	1.000	rs3021301	chr6:116670364	A/G	cg18764771	chr6:116381957	FRK	-0.22	-5.8	-0.3	1.59e-8	Fast beta electroencephalogram;
CRC	cis	rs3750082	0.889	rs9639669	chr7:32913395	T/C	cg05721444	chr7:32995514	FKBP9	0.51	7.87	0.4	5.33e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs294883	0.858	rs453265	chr6:159698936	C/T	cg14500486	chr6:159655392	FNDC1	-0.36	-5.82	-0.31	1.4e-8	Coronary artery disease;
CRC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg24562669	chr7:97807699	LMTK2	0.43	7.15	0.37	5.67e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-11.92	-0.55	1.8e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg26850624	chr5:429559	AHRR	-0.72	-11.23	-0.53	5.67e-25	Cystic fibrosis severity;
CRC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	9.09	0.45	9.66e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.25	0.33	1.24e-9	Monocyte percentage of white cells;
CRC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.84	-13.9	-0.61	6.99e-35	Cognitive function;
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg10217327	chr6:118973057	C6orf204	0.51	5.78	0.3	1.73e-8	Diastolic blood pressure;
CRC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg06238570	chr21:40685208	BRWD1	0.75	10.23	0.49	1.63e-21	Cognitive function;
CRC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.64	-8.05	-0.41	1.5e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27430182	chr3:126195181	ZXDC	0.43	6.11	0.32	2.77e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg10729496	chr3:10149963	C3orf24	0.59	7.7	0.39	1.62e-13	Alzheimer's disease;
CRC	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.46	-6.33	-0.33	7.88e-10	Obesity-related traits;
CRC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.47	-7.02	-0.36	1.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.85	-0.44	5.34e-17	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg09264619	chr17:80180166	NA	-0.37	-6.13	-0.32	2.51e-9	Life satisfaction;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23355997	chr17:7154831	DULLARD;C17orf81	0.49	6.46	0.34	3.87e-10	Hip circumference;
CRC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.85	-9.81	-0.48	4.13e-20	Breast cancer;
CRC	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.42	6.81	0.35	4.67e-11	Sitting height ratio;
CRC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.6	8.14	0.41	8.07e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg17133734	chr15:86042851	AKAP13	0.41	6.68	0.35	1.03e-10	Interstitial lung disease;
CRC	cis	rs720844	0.684	rs10928404	chr2:149311747	A/T	cg09247360	chr2:149335327	NA	-0.56	-5.75	-0.3	2.01e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2857891	0.817	rs2638094	chr11:6981488	A/G	cg22096450	chr11:6947773	ZNF215	0.61	6.21	0.32	1.63e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.41	7.79	0.39	9.1e-14	Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.6	0.54	2.6e-26	Prudent dietary pattern;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.53	-6.27	-0.33	1.16e-9	Facial morphology (factor 19);
CRC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.54	8.55	0.43	4.56e-16	Lewy body disease;
CRC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.72	11.46	0.53	8.31e-26	Monocyte count;
CRC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.46	-6.51	-0.34	2.84e-10	Mean platelet volume;
CRC	cis	rs860295	0.702	rs11264386	chr1:155559170	G/T	cg02153340	chr1:155202674	NA	-0.58	-6.75	-0.35	6.59e-11	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15680518	chr12:132414800	PUS1	0.46	6.18	0.32	1.88e-9	Thyroid stimulating hormone;
CRC	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-8.12	-0.41	9.57e-15	Coronary artery disease;
CRC	cis	rs11212617	0.967	rs620613	chr11:108185478	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.39	5.63	0.3	3.88e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.77	13.83	0.61	1.26e-34	Lewy body disease;
CRC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.37	5.61	0.3	4.23e-8	Mean corpuscular volume;
CRC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.84	-0.35	3.79e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.65	8.76	0.43	1.06e-16	Extraversion;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27493885	chr12:95467123	NR2C1	0.43	5.97	0.31	6.06e-9	Anxiety disorder;
CRC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	5.81	0.31	1.48e-8	Diabetic retinopathy;
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.77	-0.44	1e-16	Bipolar disorder;
CRC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg01987224	chr1:201084466	NA	0.53	9.98	0.48	1.15e-20	Permanent tooth development;
CRC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg13256891	chr4:100009986	ADH5	0.42	6.09	0.32	3.07e-9	Alcohol dependence;
CRC	cis	rs12024301	0.557	rs75012526	chr1:183596921	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.73	-10.51	-0.5	1.85e-22	Lung cancer;
CRC	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.53	9.49	0.46	4.72e-19	Blood metabolite ratios;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg07491357	chr18:9914943	VAPA	0.49	6.87	0.35	3.23e-11	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.45	6.3	0.33	9.74e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg08501292	chr6:25962987	TRIM38	1.11	9.7	0.47	1.03e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg15845792	chr6:28175446	NA	0.85	5.82	0.31	1.36e-8	Depression;
CRC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.61	-9.36	-0.46	1.28e-18	Aortic root size;
CRC	cis	rs3540	1.000	rs3540	chr15:91045408	G/A	cg22089800	chr15:90895588	ZNF774	0.48	7.66	0.39	2.11e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.71	10.05	0.48	6.61e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6495367	1.000	rs4778882	chr15:79382019	A/G	cg17916960	chr15:79447300	NA	0.39	6.31	0.33	9.15e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24972080	chr11:65154083	FRMD8	0.42	6.91	0.36	2.48e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.91	0.36	2.48e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4664293	0.801	rs7590595	chr2:160571709	A/G	cg08347373	chr2:160653686	CD302	-0.35	-5.62	-0.3	4.15e-8	Monocyte percentage of white cells;
CRC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-11.59	-0.54	2.92e-26	Total body bone mineral density;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.08e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.06	0.36	9.67e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg20607287	chr7:12443886	VWDE	-0.6	-6.94	-0.36	2.14e-11	Coronary artery disease;
CRC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.72	10.7	0.51	3.83e-23	Breast cancer;
CRC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.66	-0.39	2.09e-13	Coronary artery disease;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-13.33	-0.59	1.09e-32	Height;
CRC	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg26248373	chr2:1572462	NA	-0.66	-7.1	-0.36	7.65e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg09476006	chr5:138032270	NA	-0.42	-6.8	-0.35	5.04e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.45	-6.33	-0.33	8.24e-10	Coronary artery disease;
CRC	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg05320533	chr16:89541815	ANKRD11	-0.45	-6.31	-0.33	9.12e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-10.26	-0.49	1.29e-21	Blood protein levels;
CRC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.6	8.21	0.41	5.04e-15	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.29	-0.53	3.23e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.55	-8.93	-0.44	2.98e-17	Breast cancer;
CRC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg06470822	chr6:28175283	NA	0.51	7.56	0.38	3.95e-13	Pubertal anthropometrics;
CRC	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.47	7.63	0.39	2.58e-13	Schizophrenia;
CRC	cis	rs4731207	0.724	rs6968693	chr7:124549976	C/T	cg23710748	chr7:124431027	NA	-0.37	-5.98	-0.31	5.75e-9	Cutaneous malignant melanoma;
CRC	cis	rs3736485	0.932	rs11633395	chr15:51917957	G/T	cg08986416	chr15:51914746	DMXL2	-0.46	-6.38	-0.33	5.89e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.54	8.95	0.44	2.67e-17	Dupuytren's disease;
CRC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.41	6.72	0.35	8.24e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.88	-0.78	5.34e-70	Myeloid white cell count;
CRC	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.47	9.78	0.47	5.23e-20	Height;
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.51	-6.87	-0.35	3.17e-11	Glycated hemoglobin levels;
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.63	10.97	0.52	4.42e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27549887	chr15:48623952	DUT	-0.41	-6.18	-0.32	1.91e-9	Myopia (pathological);
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg15786705	chr6:28176104	NA	-0.78	-9.96	-0.48	1.35e-20	Depression;
CRC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.62	-11.16	-0.52	9.67e-25	Aortic root size;
CRC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.07	0.55	5.23e-28	Menopause (age at onset);
CRC	cis	rs7274811	0.744	rs3213183	chr20:32262962	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.39	-5.85	-0.31	1.19e-8	Height;
CRC	trans	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg18335740	chr13:41363409	SLC25A15	0.53	7.93	0.4	3.43e-14	Lewy body disease;
CRC	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg09040174	chr2:113837401	NA	0.65	10.3	0.49	9.83e-22	Protein quantitative trait loci;
CRC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.43	8.35	0.42	1.87e-15	Mean corpuscular volume;
CRC	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg19077165	chr18:44547161	KATNAL2	0.39	6.07	0.32	3.48e-9	Educational attainment;
CRC	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.4	-0.33	5.28e-10	Diastolic blood pressure;
CRC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.77	-11.65	-0.54	1.72e-26	Blood trace element (Zn levels);
CRC	cis	rs6968419	0.674	rs4730723	chr7:115904052	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.5	-0.34	2.92e-10	Intraocular pressure;
CRC	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	1.12	17.4	0.69	1.6e-48	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg05139728	chr16:28306816	SBK1	-0.37	-5.99	-0.31	5.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.54	-0.43	4.97e-16	Platelet count;
CRC	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.74	-10.14	-0.49	3.45e-21	White matter hyperintensity burden;
CRC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.71	-8.73	-0.43	1.33e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs587242	1.000	rs4341405	chr1:96902589	A/G	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg12590608	chr7:158785262	NA	0.38	6.46	0.34	3.84e-10	Facial morphology (factor 20);
CRC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg12386194	chr3:101231763	SENP7	0.48	6.86	0.35	3.45e-11	Colorectal cancer;
CRC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.39	-0.33	5.67e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg13009927	chr2:242254519	SEPT2;HDLBP	0.47	5.96	0.31	6.53e-9	Plasma plasminogen activator levels;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg20041105	chr8:143859282	LYNX1	-0.41	-6.79	-0.35	5.23e-11	Urinary tract infection frequency;
CRC	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.49	0.42	7.06e-16	Mean corpuscular volume;
CRC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.49	6.63	0.34	1.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.89	8.63	0.43	2.75e-16	Plateletcrit;
CRC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24308560	chr3:49941425	MST1R	0.4	6.01	0.31	5.01e-9	Body mass index;
CRC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.04	0.32	4.08e-9	Heart rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03672602	chr19:19754555	GMIP	0.48	6.71	0.35	8.64e-11	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.28	-0.53	3.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg07274523	chr3:49395745	GPX1	0.46	5.96	0.31	6.45e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg01475377	chr6:109611718	NA	-0.33	-5.61	-0.3	4.36e-8	Reticulocyte fraction of red cells;
CRC	trans	rs10411161	0.702	rs1433081	chr19:52390710	A/C	cg22319618	chr22:45562946	NUP50	-0.58	-6.09	-0.32	3.22e-9	Breast cancer;
CRC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg20356878	chr3:121714668	ILDR1	0.51	7.9	0.4	4.1e-14	Cognitive performance;
CRC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.83	-14.35	-0.62	1.38e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.55	-10.12	-0.49	3.81e-21	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.69	-12.89	-0.58	4.51e-31	Educational attainment;
CRC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.56	-7.71	-0.39	1.46e-13	Response to antineoplastic agents;
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.21e-15	Electroencephalogram traits;
CRC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg21856205	chr7:94953877	PON1	0.44	5.78	0.3	1.74e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.05	-0.36	1.08e-11	Depression;
CRC	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.76	8.66	0.43	2.15e-16	Neuroticism;
CRC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.74	-12.19	-0.56	1.88e-28	Idiopathic membranous nephropathy;
CRC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.64	-9.86	-0.48	3.01e-20	Cognitive function;
CRC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs703980	0.565	rs703970	chr10:80953136	A/C	cg20744163	chr10:80999841	ZMIZ1	0.33	5.89	0.31	9.73e-9	Type 2 diabetes;
CRC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg19223190	chr17:80058835	NA	-0.41	-6.53	-0.34	2.42e-10	Life satisfaction;
CRC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.08	-0.36	8.95e-12	Colorectal cancer;
CRC	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.71	-7.71	-0.39	1.54e-13	Bone mineral density;
CRC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	0.84	7.67	0.39	2.02e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.2	-0.32	1.71e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18912574	chr7:65842487	NCRNA00174	0.37	6.47	0.34	3.56e-10	Aortic root size;
CRC	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.8	-0.63	2.42e-38	Exhaled nitric oxide output;
CRC	cis	rs9463078	0.845	rs9349315	chr6:45172289	A/G	cg25276700	chr6:44698697	NA	-0.28	-6.75	-0.35	6.58e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-12.79	-0.58	1.15e-30	Obesity-related traits;
CRC	cis	rs9467160	1.000	rs9461010	chr6:24440206	T/C	cg16211469	chr6:24423932	MRS2	0.37	5.79	0.3	1.64e-8	Liver enzyme levels;
CRC	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg09654669	chr8:57350985	NA	-0.43	-5.7	-0.3	2.69e-8	Obesity-related traits;
CRC	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.09	-0.55	4.14e-28	Coffee consumption (cups per day);
CRC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.47	6.76	0.35	6.21e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.34	-0.33	7.72e-10	Diastolic blood pressure;
CRC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.62	9.16	0.45	5.83e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.58	-0.34	1.81e-10	Menopause (age at onset);
CRC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg18876405	chr7:65276391	NA	0.44	6.12	0.32	2.67e-9	Aortic root size;
CRC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg16141378	chr3:129829833	LOC729375	-0.46	-6.78	-0.35	5.43e-11	Neuroticism;
CRC	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg26211634	chr5:139558579	C5orf32	0.44	7.75	0.39	1.18e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.693	rs581447	chr1:153033269	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.6	-0.34	1.62e-10	Inflammatory skin disease;
CRC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.6	0.54	2.63e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.71	-9.22	-0.45	3.61e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.64	10.59	0.5	9.21e-23	Calcium levels;
CRC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.47	-0.5	2.42e-22	Total cholesterol levels;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.59	7.16	0.37	5.45e-12	Renal function-related traits (BUN);
CRC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg21620606	chr4:1342894	KIAA1530	0.4	6.94	0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.41	6.14	0.32	2.39e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs12760731	0.720	rs12035174	chr1:178314311	A/T	cg00404053	chr1:178313656	RASAL2	0.92	9.61	0.47	1.96e-19	Obesity-related traits;
CRC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.71	12.15	0.56	2.57e-28	Gout;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08077726	chr17:74734280	SFRS2;MFSD11	0.47	6.49	0.34	3.08e-10	Response to antipsychotic treatment;
CRC	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.52	-7.47	-0.38	7.1e-13	Eye color traits;
CRC	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg14458575	chr2:238380390	NA	0.42	6.11	0.32	2.87e-9	Prostate cancer;
CRC	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08017156	chr16:21611107	METTL9	0.49	6.81	0.35	4.54e-11	Response to antipsychotic treatment;
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg19678392	chr7:94953810	PON1	-0.59	-7.36	-0.38	1.49e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg25456477	chr12:86230367	RASSF9	0.4	6.76	0.35	6.23e-11	Major depressive disorder;
CRC	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.61	8.71	0.43	1.46e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-13.1	-0.59	7.73e-32	Schizophrenia;
CRC	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.89	-14.89	-0.63	1.07e-38	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	6.94	0.36	2.06e-11	Response to antipsychotic treatment;
CRC	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.48	-0.34	3.33e-10	Response to antipsychotic treatment;
CRC	cis	rs9903692	0.954	rs2240122	chr17:46152559	C/A	cg21215337	chr17:46176117	CBX1	0.42	7.79	0.39	8.7e-14	Pulse pressure;
CRC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	-0.66	-7.28	-0.37	2.55e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg23815491	chr16:72088622	HP	0.51	7.65	0.39	2.3e-13	Fibrinogen levels;
CRC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.38	6.41	0.33	5.12e-10	Height;
CRC	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.32e-19	Blood protein levels;
CRC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg06470822	chr6:28175283	NA	0.77	6.26	0.33	1.19e-9	Depression;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg02018176	chr4:1364513	KIAA1530	0.4	5.92	0.31	8.2e-9	Obesity-related traits;
CRC	trans	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg20935933	chr6:143382018	AIG1	0.51	6.68	0.35	1.03e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg27534772	chr1:16042836	PLEKHM2	0.51	9.45	0.46	6.71e-19	Systolic blood pressure;
CRC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.74	-12.53	-0.57	1.01e-29	DNA methylation (variation);
CRC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	0.96	9.42	0.46	8.02e-19	Diabetic retinopathy;
CRC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.91	-16.33	-0.67	2.52e-44	Intelligence (multi-trait analysis);
CRC	cis	rs661713	0.734	rs618371	chr6:90978829	G/A	cg06866423	chr6:90926672	BACH2	0.38	5.71	0.3	2.56e-8	Hypothyroidism;
CRC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.97	16.56	0.67	3.23e-45	Parkinson's disease;
CRC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.62	8.0	0.4	2.19e-14	Response to diuretic therapy;
CRC	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.49	-0.54	6.33e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6840360	0.642	rs2709842	chr4:152370637	C/T	cg09659197	chr4:152720779	NA	-0.33	-6.43	-0.33	4.55e-10	Intelligence (multi-trait analysis);
CRC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.47	6.59	0.34	1.71e-10	Parkinson's disease;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21396487	chr1:173793343	CENPL;DARS2	-0.46	-5.99	-0.31	5.61e-9	Monocyte percentage of white cells;
CRC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg05585544	chr11:47624801	NA	-0.54	-9.63	-0.47	1.65e-19	Subjective well-being;
CRC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs13098911	0.540	rs9825081	chr3:46108400	G/A	cg12691230	chr3:46064611	XCR1	-0.53	-6.09	-0.32	3.17e-9	Celiac disease;
CRC	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg16486109	chr11:613632	IRF7	0.59	10.3	0.49	9.34e-22	Systemic lupus erythematosus;
CRC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	15.31	0.64	2.58e-40	Lymphocyte percentage of white cells;
CRC	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13385794	chr1:248469461	NA	0.39	6.99	0.36	1.52e-11	Common traits (Other);
CRC	cis	rs35000415	0.938	rs35234849	chr7:128648953	T/C	cg19972273	chr7:128594194	NA	0.68	6.31	0.33	8.75e-10	Systemic lupus erythematosus;
CRC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.46	-6.75	-0.35	6.74e-11	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10735211	chr4:4310922	ZNF509	-0.39	-6.16	-0.32	2.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg05756136	chr1:119680316	WARS2	-0.52	-6.87	-0.35	3.25e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg00490450	chr3:139108681	COPB2	0.44	6.47	0.34	3.52e-10	Obesity-related traits;
CRC	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg19847866	chr10:1019161	NA	0.39	5.84	0.31	1.22e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.91	-12.31	-0.56	6.67e-29	Bronchopulmonary dysplasia;
CRC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.84	10.25	0.49	1.42e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11446398	chr5:77624930	NA	0.46	6.1	0.32	3.01e-9	Triglycerides;
CRC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.61	9.07	0.45	1.08e-17	Methadone dose in opioid dependence;
CRC	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.65	8.57	0.43	4.1e-16	Nonalcoholic fatty liver disease;
CRC	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24249390	chr15:90295951	MESP1	0.56	8.64	0.43	2.56e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.39	6.82	0.35	4.47e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg05623727	chr3:50126028	RBM5	0.53	6.97	0.36	1.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.36e-11	Prostate cancer;
CRC	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.52	8.34	0.42	2.01e-15	IgG glycosylation;
CRC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.89	0.51	8.98e-24	Platelet count;
CRC	trans	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.92	0.36	2.33e-11	Ulcerative colitis;
CRC	cis	rs4731207	0.596	rs10226659	chr7:124609868	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.95	-0.36	2.01e-11	Total cholesterol levels;
CRC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg08027265	chr7:2291960	NA	-0.37	-6.44	-0.33	4.31e-10	Schizophrenia;
CRC	cis	rs282587	0.569	rs282600	chr13:113391602	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.97	0.4	2.62e-14	Glycated hemoglobin levels;
CRC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.5	8.44	0.42	1e-15	Coronary artery disease;
CRC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg07636037	chr3:49044803	WDR6	-0.84	-6.02	-0.32	4.57e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg20243544	chr17:37824526	PNMT	0.55	8.95	0.44	2.66e-17	Asthma;
CRC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.54	-5.69	-0.3	2.86e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg24209194	chr3:40518798	ZNF619	-0.44	-6.79	-0.35	5.28e-11	Renal cell carcinoma;
CRC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.45	5.63	0.3	3.92e-8	Vitiligo;
CRC	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg21153622	chr11:89784906	NA	-0.47	-7.48	-0.38	7.01e-13	HDL cholesterol;
CRC	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg21854759	chr1:92012499	NA	0.51	6.05	0.32	3.99e-9	Eosinophil percentage of white cells;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg15786705	chr6:28176104	NA	0.49	6.44	0.33	4.26e-10	Parkinson's disease;
CRC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.35	5.73	0.3	2.21e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	9.93	0.48	1.71e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.28	-0.53	3.65e-25	Platelet distribution width;
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg15845792	chr6:28175446	NA	0.77	6.2	0.32	1.67e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg24209194	chr3:40518798	ZNF619	0.45	6.84	0.35	3.85e-11	Renal cell carcinoma;
CRC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.52	-7.96	-0.4	2.89e-14	Body mass index;
CRC	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-7.13	-0.37	6.36e-12	Metabolite levels;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg12273811	chr6:28175739	NA	0.51	6.99	0.36	1.49e-11	Parkinson's disease;
CRC	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.58	6.45	0.34	3.96e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.8	-13.93	-0.61	5.27e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	trans	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg03973167	chr4:185394988	IRF2	-0.43	-6.12	-0.32	2.64e-9	Schizophrenia;
CRC	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	14.75	0.63	3.71e-38	Mean corpuscular hemoglobin;
CRC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg14074117	chr16:1909714	C16orf73	0.46	6.79	0.35	5.13e-11	Ankle injury;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg11843238	chr5:131593191	PDLIM4	-0.45	-7.83	-0.4	6.72e-14	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04844016	chr2:65659148	SPRED2	0.54	6.96	0.36	1.85e-11	Thyroid stimulating hormone;
CRC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-7.77	-0.39	9.9e-14	Monocyte count;
CRC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-11.24	-0.53	4.89e-25	Schizophrenia;
CRC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.59	8.42	0.42	1.17e-15	Monobrow;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-0.58	-8.11	-0.41	1.03e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg25457927	chr22:38595422	NA	-0.33	-6.38	-0.33	6.13e-10	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.83	-10.33	-0.5	7.3e-22	Vitiligo;
CRC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.4	6.88	0.35	3.05e-11	Primary biliary cholangitis;
CRC	trans	rs17641971	0.662	rs1828495	chr8:49945281	C/T	cg18784943	chr17:79371681	NA	-0.38	-6.11	-0.32	2.84e-9	Blood metabolite levels;
CRC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.5	0.54	5.97e-26	Hip circumference adjusted for BMI;
CRC	cis	rs12024301	0.557	rs7531622	chr1:183644870	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.85	0.35	3.67e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.72	8.21	0.41	5.19e-15	Tuberculosis;
CRC	cis	rs9816226	0.938	rs73052046	chr3:185832414	C/T	cg00760338	chr3:185826511	ETV5	-0.7	-7.3	-0.37	2.24e-12	Obesity;Body mass index;
CRC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg11271282	chr2:238384023	NA	0.47	6.08	0.32	3.26e-9	Prostate cancer;
CRC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.55	-8.34	-0.42	2.03e-15	Systemic sclerosis;
CRC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.63	10.14	0.49	3.2e-21	Breast cancer;
CRC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg13198984	chr17:80129470	CCDC57	0.47	8.27	0.41	3.34e-15	Life satisfaction;
CRC	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.5	6.52	0.34	2.66e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-6.76	-0.35	6.24e-11	Type 2 diabetes;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.68	10.34	0.5	6.86e-22	Lymphocyte counts;
CRC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.0	-0.31	5.22e-9	Obesity-related traits;
CRC	trans	rs62295889	0.602	rs58048371	chr4:12538150	T/C	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.45	-8.23	-0.41	4.56e-15	Urate levels in overweight individuals;
CRC	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.81	10.71	0.51	3.6e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.77	10.91	0.52	7.19e-24	Orofacial clefts;
CRC	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.19	-0.53	7.33e-25	Colorectal cancer;
CRC	cis	rs6120849	0.901	rs11696967	chr20:33743609	A/C	cg24642439	chr20:33292090	TP53INP2	0.43	5.61	0.3	4.36e-8	Protein C levels;
CRC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.58	-9.56	-0.47	2.86e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.33	-0.49	7.62e-22	Monocyte count;
CRC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	trans	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.71	-0.35	8.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.26	-0.33	1.18e-9	Bipolar disorder;
CRC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.78	-0.3	1.75e-8	Aortic root size;
CRC	cis	rs75422866	0.510	rs73105814	chr12:48119600	C/G	cg14736327	chr12:48174669	SLC48A1	-0.72	-5.75	-0.3	2.05e-8	Pneumonia;
CRC	cis	rs6496667	1.000	rs7177486	chr15:90897109	G/A	cg04176472	chr15:90893244	GABARAPL3	0.6	8.04	0.41	1.69e-14	Rheumatoid arthritis;
CRC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.53	-7.32	-0.37	1.92e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.43	6.21	0.32	1.62e-9	Aortic root size;
CRC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.22	-6.3	-0.33	9.55e-10	Urinary metabolites;
CRC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.68	-9.08	-0.45	1.03e-17	Initial pursuit acceleration;
CRC	cis	rs12024301	0.557	rs16828976	chr1:183608481	T/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.83	0.35	4.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.72	-0.72	9.47e-54	Schizophrenia;
CRC	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg00691999	chr4:55094011	PDGFRA	0.4	5.93	0.31	7.46e-9	Corneal astigmatism;
CRC	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-6.04	-0.32	4.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg02725872	chr8:58115012	NA	-0.52	-6.87	-0.35	3.24e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.6	9.34	0.46	1.51e-18	Longevity;Endometriosis;
CRC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg13722127	chr7:150037890	RARRES2	0.48	8.02	0.4	1.82e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-10.56	-0.5	1.21e-22	Body mass index;
CRC	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.49	-7.17	-0.37	5.03e-12	Height;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20092199	chr4:1342459	KIAA1530	0.45	8.15	0.41	7.71e-15	Longevity;
CRC	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.54	-5.73	-0.3	2.22e-8	Vitamin D levels;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12273811	chr6:28175739	NA	0.69	8.81	0.44	7.29e-17	Depression;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	7.14	0.37	5.91e-12	Obesity-related traits;
CRC	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.92	-0.4	3.64e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs7705042	0.865	rs11739961	chr5:141508488	A/C	cg07392085	chr5:141489673	NDFIP1	0.46	7.47	0.38	7.1e-13	Asthma;
CRC	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg16077055	chr2:106428750	NCK2	-0.42	-6.24	-0.33	1.33e-9	Addiction;
CRC	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.63	-7.02	-0.36	1.24e-11	Type 2 diabetes;
CRC	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg00042356	chr1:8021962	PARK7	-0.56	-6.36	-0.33	6.57e-10	Inflammatory bowel disease;
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.18	-0.32	1.88e-9	Menopause (age at onset);
CRC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.75	12.87	0.58	5.43e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg13256891	chr4:100009986	ADH5	0.45	6.43	0.33	4.36e-10	Alcohol dependence;
CRC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs863345	0.604	rs2054992	chr1:158506015	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs3026101	0.671	rs1544399	chr17:5305887	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.59	8.71	0.43	1.48e-16	Lung cancer;
CRC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.49	9.25	0.45	2.86e-18	Renal cell carcinoma;
CRC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.71	-0.35	8.58e-11	Colorectal cancer;
CRC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.13	0.32	2.49e-9	Granulocyte percentage of myeloid white cells;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg23247704	chr1:116518985	SLC22A15	-0.73	-6.21	-0.32	1.57e-9	Cognitive function;
CRC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	7.39	0.38	1.21e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23163999	chr3:125803012	SLC41A3	-0.4	-6.03	-0.32	4.37e-9	Myopia (pathological);
CRC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.98	14.51	0.62	3.26e-37	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.57	8.19	0.41	5.76e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7945718	0.650	rs10831889	chr11:12665834	A/T	cg25843174	chr11:12811716	TEAD1	0.41	7.67	0.39	1.99e-13	Educational attainment (years of education);
CRC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.4	5.79	0.3	1.63e-8	Aortic root size;
CRC	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg23387468	chr7:139079360	LUC7L2	-0.39	-6.83	-0.35	4.19e-11	Diisocyanate-induced asthma;
CRC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.4	0.33	5.43e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg27362927	chr21:43299497	PRDM15	0.37	6.01	0.31	4.88e-9	Obesity-related traits;
CRC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.42	-0.42	1.17e-15	Monocyte percentage of white cells;
CRC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg00769240	chr8:12517080	NA	-0.54	-6.7	-0.35	9.16e-11	Blood pressure (smoking interaction);
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg19678392	chr7:94953810	PON1	-0.6	-7.35	-0.38	1.54e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg21747405	chr11:67723411	NA	-0.49	-6.16	-0.32	2.08e-9	Blood pressure (smoking interaction);
CRC	trans	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.54	0.34	2.39e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.83	-0.44	6.31e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.58	9.24	0.45	3.15e-18	Vitiligo;
CRC	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg25173405	chr17:45401733	C17orf57	-0.45	-6.95	-0.36	2e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg22178761	chr5:1008828	NKD2	-0.38	-6.01	-0.31	4.88e-9	Myopia (pathological);
CRC	cis	rs3026101	0.671	rs739768	chr17:5290703	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg00769240	chr8:12517080	NA	-0.56	-6.8	-0.35	4.87e-11	Blood pressure (smoking interaction);
CRC	cis	rs939584	0.932	rs13013021	chr2:632723	C/T	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.58e-8	Body mass index;
CRC	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg08645402	chr16:4508243	NA	0.5	6.38	0.33	5.84e-10	Schizophrenia;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg15845792	chr6:28175446	NA	0.66	9.22	0.45	3.56e-18	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.9	0.4	4.35e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs4290604	0.588	rs62183338	chr2:237969547	C/G	cg23555395	chr2:238036564	NA	0.62	6.15	0.32	2.26e-9	Asthma;
CRC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.46	0.34	3.73e-10	Melanoma;
CRC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.68	9.02	0.45	1.55e-17	IgE levels in asthmatics (D.p. specific);
CRC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg21747405	chr11:67723411	NA	-0.44	-6.27	-0.33	1.15e-9	Blood pressure (smoking interaction);
CRC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.42	6.39	0.33	5.53e-10	Platelet distribution width;
CRC	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.53	8.05	0.41	1.52e-14	Testicular germ cell tumor;
CRC	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-1.11	-18.68	-0.72	1.34e-53	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05609751	chr17:4269695	UBE2G1	0.45	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
CRC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.65	-9.73	-0.47	8e-20	Metabolic syndrome;
CRC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg24910161	chr17:38119198	GSDMA	-0.42	-7.45	-0.38	8.14e-13	Asthma;
CRC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.73	13.96	0.61	4.04e-35	Body mass index;
CRC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.43	7.34	0.38	1.68e-12	Major depressive disorder;
CRC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	1.1	12.97	0.58	2.42e-31	Obesity-related traits;
CRC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.24	-0.33	1.34e-9	Monocyte percentage of white cells;
CRC	cis	rs6840360	0.642	rs2724574	chr4:152381800	A/T	cg09659197	chr4:152720779	NA	-0.32	-6.35	-0.33	6.97e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.52	8.32	0.42	2.32e-15	Menopause (age at onset);
CRC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.36	-6.68	-0.35	1.03e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.07	-0.32	3.43e-9	Alzheimer's disease (late onset);
CRC	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.61	0.34	1.51e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg10612998	chr14:21572012	ZNF219	0.46	5.97	0.31	6.27e-9	Resistin levels;
CRC	cis	rs863345	0.604	rs1342950	chr1:158463723	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.32	-0.33	8.42e-10	Pneumococcal bacteremia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23260799	chr11:451101	PTDSS2	0.5	6.68	0.35	1.02e-10	Thyroid stimulating hormone;
CRC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.38	-6.73	-0.35	7.55e-11	Reticulocyte fraction of red cells;
CRC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg25876840	chr17:41920477	NA	0.51	7.64	0.39	2.39e-13	Triglycerides;
CRC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.45	-8.53	-0.43	5.6e-16	Intelligence (multi-trait analysis);
CRC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.98	0.31	5.9e-9	Lung cancer;
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.14	-0.45	6.65e-18	Bipolar disorder;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg15845792	chr6:28175446	NA	0.66	9.3	0.46	2.02e-18	Parkinson's disease;
CRC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17507749	chr15:85114479	UBE2QP1	0.63	8.94	0.44	2.77e-17	Schizophrenia;
CRC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-16.5	-0.67	5.24e-45	Height;
CRC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.52	7.66	0.39	2.15e-13	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17942371	chr19:796826	PTBP1	0.48	7.08	0.36	8.66e-12	Response to antipsychotic treatment;
CRC	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg09695851	chr17:3907499	NA	-0.73	-14.26	-0.62	2.91e-36	Type 2 diabetes;
CRC	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	6.03	0.32	4.49e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12292205	chr6:26970375	C6orf41	-0.52	-7.6	-0.39	3.12e-13	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.98	-0.48	1.19e-20	Extrinsic epigenetic age acceleration;
CRC	trans	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg20935933	chr6:143382018	AIG1	0.53	6.82	0.35	4.42e-11	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg10756647	chr7:56101905	PSPH	0.76	7.89	0.4	4.47e-14	Diabetic kidney disease;
CRC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21643547	chr1:205240462	TMCC2	-0.37	-6.01	-0.31	4.94e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg09877947	chr5:131593287	PDLIM4	0.38	7.21	0.37	3.96e-12	Blood metabolite levels;
CRC	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.43	-6.23	-0.32	1.43e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.35e-23	Alzheimer's disease;
CRC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.43	8.72	0.43	1.36e-16	Renal cell carcinoma;
CRC	cis	rs9296095	0.632	rs6914422	chr6:33534880	A/G	cg14003231	chr6:33640908	ITPR3	-0.46	-7.11	-0.36	7.49e-12	Platelet count;
CRC	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.76	15.0	0.64	4.08e-39	Mean corpuscular hemoglobin;
CRC	trans	rs333332	0.961	rs333333	chr3:124328388	G/A	cg08451243	chr11:1273788	MUC5B	0.41	6.49	0.34	3.17e-10	Heschl's gyrus morphology;
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.83	-0.4	6.78e-14	Electroencephalogram traits;
CRC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.57	8.3	0.42	2.66e-15	Melanoma;
CRC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	1.03	20.48	0.75	1.08e-60	Headache;
CRC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06953865	chr19:18549723	ISYNA1	-0.39	-6.01	-0.31	4.89e-9	Breast cancer;
CRC	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.56	8.11	0.41	9.82e-15	Resting heart rate;
CRC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg15147215	chr3:52552868	STAB1	0.53	9.22	0.45	3.79e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.35	-5.6	-0.3	4.42e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.03e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.31	0.37	1.98e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.5	9.28	0.46	2.3e-18	Common traits (Other);
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg02683197	chr6:28174875	NA	0.65	9.03	0.45	1.48e-17	Parkinson's disease;
CRC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.58	7.87	0.4	5.23e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs17767392	0.881	rs757850	chr14:72016006	C/G	cg13720639	chr14:72061746	SIPA1L1	0.54	7.01	0.36	1.32e-11	Mitral valve prolapse;
CRC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg11189052	chr15:85197271	WDR73	0.61	8.89	0.44	4.18e-17	Schizophrenia;
CRC	trans	rs1325598	0.935	rs1325596	chr1:176794066	G/A	cg03992096	chr13:114928177	NA	-0.38	-6.04	-0.32	4.1e-9	Height;
CRC	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.47	-5.76	-0.3	1.94e-8	Coronary artery calcification;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11866396	chr17:5322940	RPAIN;NUP88	0.46	6.36	0.33	6.74e-10	Hip circumference;
CRC	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.49	-7.52	-0.38	5.41e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.98	-0.36	1.63e-11	Vitiligo;
CRC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07513332	chr6:167530253	CCR6	-0.39	-7.01	-0.36	1.4e-11	Primary biliary cholangitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12661088	chr5:43120934	ZNF131	0.46	5.98	0.31	5.82e-9	Thyroid stimulating hormone;
CRC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	0.92	12.32	0.56	6.34e-29	Red blood cell traits;
CRC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg09915433	chr19:53449742	NA	-0.66	-10.25	-0.49	1.42e-21	Psoriasis;
CRC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg23533926	chr12:111358616	MYL2	-0.56	-8.7	-0.43	1.64e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg08314208	chr16:67682810	RLTPR	-0.65	-7.04	-0.36	1.12e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg08501292	chr6:25962987	TRIM38	1.06	9.09	0.45	9.76e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg19500275	chr17:80737654	TBCD	0.54	7.48	0.38	6.82e-13	Glycated hemoglobin levels;
CRC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.61	-0.47	1.9e-19	Type 2 diabetes;
CRC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.59	5.88	0.31	1.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.61	8.54	0.43	5.05e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.08	0.45	1.04e-17	Menarche (age at onset);
CRC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.44	7.42	0.38	1.02e-12	Crohn's disease;
CRC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg05861140	chr6:150128134	PCMT1	0.41	6.39	0.33	5.72e-10	Lung cancer;
CRC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.62	-8.12	-0.41	9.71e-15	Coronary artery disease;
CRC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg11189052	chr15:85197271	WDR73	0.64	8.98	0.44	2.15e-17	Schizophrenia;
CRC	trans	rs1823549	0.793	rs10735772	chr1:103153132	C/A	cg08492707	chr21:34696952	IFNAR1	-0.75	-6.0	-0.31	5.24e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg02033258	chr5:131593261	PDLIM4	0.5	8.84	0.44	6.01e-17	Acylcarnitine levels;
CRC	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-7.23	-0.37	3.48e-12	Coronary artery disease;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.6	-8.67	-0.43	2.02e-16	Menopause (age at onset);
CRC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg14711859	chr11:8959438	ASCL3	-0.35	-5.91	-0.31	8.64e-9	Hemoglobin concentration;
CRC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.66	8.92	0.44	3.39e-17	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.08	-0.45	1.05e-17	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.63e-12	Motion sickness;
CRC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-12.11	-0.56	3.64e-28	Vitiligo;
CRC	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.46	5.68	0.3	2.95e-8	Metabolite levels;
CRC	cis	rs7527798	0.571	rs4844611	chr1:207827538	G/C	cg21110645	chr1:207815933	NA	-0.39	-6.18	-0.32	1.9e-9	Erythrocyte sedimentation rate;
CRC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.37	0.38	1.41e-12	Calcium levels;
CRC	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg16898833	chr6:26189333	HIST1H4D	0.64	5.73	0.3	2.27e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.58	8.75	0.43	1.15e-16	Lung cancer;
CRC	cis	rs2013441	0.866	rs17686622	chr17:20020364	C/G	cg13482628	chr17:19912719	NA	-0.39	-5.72	-0.3	2.4e-8	Obesity-related traits;
CRC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.62	9.79	0.48	4.85e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.65	-8.91	-0.44	3.43e-17	Morning vs. evening chronotype;
CRC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg20989729	chr11:101981056	YAP1	0.45	6.62	0.34	1.43e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.8	14.71	0.63	5.58e-38	Metabolic syndrome;
CRC	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.0	-13.84	-0.61	1.19e-34	Exhaled nitric oxide output;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05793409	chr1:35658810	SFPQ	0.42	6.07	0.32	3.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.03	-0.45	1.48e-17	Bipolar disorder;
CRC	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-0.66	-9.41	-0.46	8.66e-19	Type 2 diabetes;
CRC	cis	rs62408225	1.000	rs55771973	chr6:90981319	T/G	cg06866423	chr6:90926672	BACH2	0.5	8.15	0.41	7.56e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.32	12.42	0.56	2.68e-29	Granulocyte percentage of myeloid white cells;
CRC	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg10263370	chr3:44754102	ZNF502	-0.38	-6.39	-0.33	5.64e-10	Depressive symptoms;
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.46	0.34	3.81e-10	Rheumatoid arthritis;
CRC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg13256891	chr4:100009986	ADH5	0.43	6.23	0.32	1.43e-9	Alcohol dependence;
CRC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.43	-6.47	-0.34	3.47e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-9.04	-0.45	1.36e-17	Menarche (age at onset);
CRC	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-1.04	-14.51	-0.62	3.1e-37	Exhaled nitric oxide output;
CRC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.44	-7.96	-0.4	2.86e-14	Huntington's disease progression;
CRC	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.84	16.5	0.67	5.37e-45	Hip circumference;
CRC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.56	-7.25	-0.37	3.02e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg09344028	chr17:70110421	NA	0.43	6.5	0.34	2.96e-10	Thyroid hormone levels;
CRC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-16.9	-0.68	1.44e-46	Height;
CRC	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.02	-0.36	1.25e-11	Menopause (age at onset);
CRC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.66	-0.3	3.28e-8	Daytime sleep phenotypes;
CRC	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	9.16	0.45	5.85e-18	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21146272	chr6:42858716	C6orf226	0.51	7.19	0.37	4.33e-12	Response to antipsychotic treatment;
CRC	cis	rs12042938	1.000	rs11122319	chr1:231808282	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.4	-0.33	5.5e-10	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg12064134	chr16:90016061	DEF8	0.57	9.46	0.46	5.93e-19	Squamous cell carcinoma;
CRC	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.38	-5.96	-0.31	6.34e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.46	-6.64	-0.34	1.28e-10	Uric acid clearance;
CRC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg25456477	chr12:86230367	RASSF9	0.38	6.43	0.33	4.41e-10	Major depressive disorder;
CRC	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.4	-5.81	-0.3	1.51e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs6600671	1.000	rs1591882	chr1:121183313	G/A	cg00646200	chr1:148855367	NA	0.36	6.62	0.34	1.5e-10	Hip geometry;
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02290350	chr8:58132656	NA	-0.57	-6.8	-0.35	5.02e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.58	6.14	0.32	2.44e-9	Breast cancer;
CRC	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.92	11.45	0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19717773	chr7:2847554	GNA12	-0.43	-6.11	-0.32	2.82e-9	Height;
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.48	7.17	0.37	4.86e-12	Body mass index;
CRC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.54	8.31	0.42	2.48e-15	Aortic root size;
CRC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.55	-7.65	-0.39	2.3e-13	Corneal structure;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.57	-10.07	-0.49	5.72e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07050827	chr2:228280252	NA	0.44	6.89	0.36	2.83e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg25985355	chr7:65971099	NA	-0.51	-5.83	-0.31	1.3e-8	Diabetic kidney disease;
CRC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-8.25	-0.41	3.81e-15	Mean platelet volume;
CRC	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg04165759	chr1:150448943	RPRD2	0.36	5.87	0.31	1.04e-8	Migraine;
CRC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg04880052	chr2:219191631	PNKD	-0.43	-6.8	-0.35	4.82e-11	Colorectal cancer;
CRC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg18016565	chr1:150552671	MCL1	0.47	6.78	0.35	5.7e-11	Tonsillectomy;
CRC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.78	-0.39	9.24e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.47	-7.16	-0.37	5.15e-12	Tonsillectomy;
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg24505167	chr7:1915268	MAD1L1	-0.42	-5.71	-0.3	2.5e-8	Neuroticism;
CRC	trans	rs2908835	0.521	rs10772472	chr12:11610348	G/A	cg03979024	chr10:419189	DIP2C	-0.39	-6.1	-0.32	3.05e-9	Information processing speed;
CRC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.55	8.01	0.4	1.95e-14	Lung cancer;
CRC	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.01	-0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.74	-6.4	-0.33	5.45e-10	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs9826463	0.702	rs56397702	chr3:142304764	C/T	cg20824294	chr3:142316082	PLS1	0.42	6.69	0.35	9.5e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg23425280	chr12:56401806	NA	0.44	5.61	0.3	4.19e-8	Cancer;
CRC	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.96	-0.31	6.39e-9	Pulmonary function;
CRC	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg10298567	chr3:47292165	KIF9	0.42	6.56	0.34	2.07e-10	Colorectal cancer;
CRC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.1	-0.32	3.05e-9	Schizophrenia;
CRC	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.41e-13	Electroencephalogram traits;
CRC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-7.46	-0.38	7.58e-13	Menarche (age at onset);
CRC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.51	7.87	0.4	5.17e-14	Emphysema distribution in smoking;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg02683197	chr6:28174875	NA	0.65	9.1	0.45	9.16e-18	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05985164	chr12:57881757	MARS	0.39	6.1	0.32	3.01e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.49	6.61	0.34	1.54e-10	Cleft lip with or without cleft palate;
CRC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg24562669	chr7:97807699	LMTK2	0.79	17.64	0.7	1.72e-49	Breast cancer;
CRC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.47	6.28	0.33	1.09e-9	Total body bone mineral density;
CRC	cis	rs16936870	0.543	rs2957094	chr8:71070527	A/T	cg14232793	chr8:71155543	NCOA2	-0.46	-5.77	-0.3	1.81e-8	QT interval;
CRC	trans	rs9561329	0.800	rs4773743	chr13:94036176	C/G	cg23072629	chr2:239195537	PER2	0.33	6.25	0.33	1.24e-9	Neuroticism (age interaction);
CRC	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg21770322	chr7:97807741	LMTK2	0.53	8.73	0.43	1.33e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.81	14.27	0.62	2.75e-36	Chronic sinus infection;
CRC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.62	-9.38	-0.46	1.14e-18	Huntington's disease progression;
CRC	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.78	-0.39	9.25e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	9.45	0.46	6.81e-19	Lymphocyte counts;
CRC	cis	rs7259376	0.875	rs1091182	chr19:22475622	G/A	cg02657401	chr19:22469223	NA	0.38	8.43	0.42	1.08e-15	Menopause (age at onset);
CRC	cis	rs9322817	0.691	rs6571207	chr6:105242161	A/C	cg02098413	chr6:105308735	HACE1	-0.44	-8.52	-0.43	5.86e-16	Thyroid stimulating hormone;
CRC	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-6.52	-0.34	2.65e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg05623727	chr3:50126028	RBM5	0.45	7.59	0.39	3.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.77	0.35	5.84e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.37	5.62	0.3	4.04e-8	Hemoglobin concentration;
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs72730918	0.540	rs2252220	chr15:51934783	G/A	cg14296394	chr15:51910925	DMXL2	-0.47	-6.32	-0.33	8.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.47	7.06	0.36	9.71e-12	Mood instability;
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.24	-0.59	2.25e-32	Alzheimer's disease;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg12172441	chr6:28176163	NA	0.5	6.67	0.35	1.09e-10	Parkinson's disease;
CRC	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.96	-0.36	1.9e-11	Dilated cardiomyopathy;
CRC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.51	8.55	0.43	4.87e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.48	-6.77	-0.35	5.98e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.62	9.99	0.48	1.05e-20	Aortic root size;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.84	-0.31	1.27e-8	Longevity;Endometriosis;
CRC	cis	rs4666002	0.665	rs2305929	chr2:28113911	A/G	cg27432699	chr2:27873401	GPN1	0.55	6.21	0.32	1.58e-9	Phospholipid levels (plasma);
CRC	cis	rs4731207	0.698	rs3815221	chr7:124481245	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.38	5.86	0.31	1.11e-8	Red blood cell count;
CRC	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.41	6.23	0.32	1.44e-9	Red blood cell count;
CRC	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.36	-6.03	-0.32	4.3e-9	Menopause (age at onset);
CRC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg15782153	chr7:917662	C7orf20	0.46	7.34	0.38	1.71e-12	Perceived unattractiveness to mosquitoes;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-7.59	-0.39	3.43e-13	Longevity;
CRC	cis	rs4499344	0.633	rs259256	chr19:33151802	C/T	cg08127369	chr19:33164662	ANKRD27	0.39	5.83	0.31	1.31e-8	Mean platelet volume;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.61	-10.35	-0.5	6.3e-22	Temperament;
CRC	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.49	9.13	0.45	6.88e-18	Common traits (Other);
CRC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.9	-0.52	7.88e-24	Electroencephalogram traits;
CRC	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.9	-11.45	-0.53	8.8e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.59	-10.47	-0.5	2.53e-22	Intelligence (multi-trait analysis);
CRC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	1.0	21.49	0.76	1.31e-64	Multiple system atrophy;
CRC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.48	-7.59	-0.39	3.33e-13	Schizophrenia;
CRC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.53	-0.47	3.47e-19	Migraine;Coronary artery disease;
CRC	cis	rs16830122	0.514	rs67849779	chr1:154611208	G/A	cg24304309	chr1:154577895	ADAR	-0.56	-8.18	-0.41	6.35e-15	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.79	0.47	4.99e-20	Hip circumference adjusted for BMI;
CRC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.56	0.5	1.2e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.95	0.31	6.7e-9	Melanoma;
CRC	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.19	-0.53	7.43e-25	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23885884	chr7:135242577	NUP205	0.44	6.23	0.32	1.42e-9	Response to antipsychotic treatment;
CRC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06544989	chr22:39130855	UNC84B	0.46	7.37	0.38	1.4e-12	Menopause (age at onset);
CRC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.38	-5.92	-0.31	8.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.83	9.88	0.48	2.57e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs12230513	0.732	rs7294659	chr12:55866519	T/C	cg19537932	chr12:55886519	OR6C68	-0.71	-9.07	-0.45	1.07e-17	Contrast sensitivity;
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.87e-11	Bipolar disorder;
CRC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.9	0.48	2.16e-20	Cognitive test performance;
CRC	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.55	8.31	0.42	2.56e-15	HDL cholesterol;
CRC	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg23127183	chr11:57508653	C11orf31	-0.53	-7.17	-0.37	5.1e-12	Schizophrenia;
CRC	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg05562828	chr17:3906858	NA	-0.47	-5.68	-0.3	2.9e-8	Type 2 diabetes;
CRC	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg23127183	chr11:57508653	C11orf31	-0.53	-7.17	-0.37	4.95e-12	Schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07243103	chr16:699355	WDR90	0.53	7.37	0.38	1.37e-12	Anxiety disorder;
CRC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.34	6.35	0.33	6.98e-10	QRS complex (12-leadsum);
CRC	cis	rs7259376	0.936	rs12983542	chr19:22590585	C/G	cg02657401	chr19:22469223	NA	0.32	6.88	0.35	3e-11	Menopause (age at onset);
CRC	cis	rs534126	1.000	rs9918515	chr7:142922662	C/T	cg04039957	chr7:143013207	CLCN1	-0.34	-6.14	-0.32	2.37e-9	Cancer;
CRC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.43	-6.23	-0.33	1.39e-9	Daytime sleep phenotypes;
CRC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.47	6.08	0.32	3.37e-9	Response to diuretic therapy;
CRC	cis	rs10208940	0.920	rs28361349	chr2:68785579	G/A	cg12452813	chr2:68675892	NA	0.47	5.95	0.31	6.88e-9	Urate levels in lean individuals;
CRC	trans	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs9463078	0.605	rs13216116	chr6:44936681	C/T	cg25276700	chr6:44698697	NA	0.24	5.89	0.31	9.66e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-6.56	-0.34	2.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.56	6.44	0.33	4.14e-10	IgG glycosylation;
CRC	cis	rs4363385	0.747	rs10788850	chr1:152963932	A/T	cg25856811	chr1:152973957	SPRR3	-0.27	-7.53	-0.38	5.01e-13	Inflammatory skin disease;
CRC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg26587870	chr6:27730563	NA	-0.6	-5.91	-0.31	8.73e-9	Depression;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.65	8.46	0.42	8.64e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.07	-0.32	3.62e-9	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.86e-9	Diabetic kidney disease;
CRC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg00343986	chr7:65444356	GUSB	0.48	7.08	0.36	8.72e-12	Aortic root size;
CRC	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.54	9.56	0.47	2.9e-19	Common traits (Other);
CRC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.08	0.32	3.37e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.23	-0.32	1.43e-9	Menopause (age at onset);
CRC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.74	-0.54	7.81e-27	Type 2 diabetes;
CRC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.07	-0.36	9.18e-12	Colorectal cancer;
CRC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.66	10.11	0.49	4.1e-21	Initial pursuit acceleration;
CRC	trans	rs7859245	1.000	rs7873626	chr9:138490710	C/T	cg14410503	chr7:47343076	TNS3	0.36	6.0	0.31	5.07e-9	Response to paliperidone in schizophrenia (negative Marder score);
CRC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.56	9.01	0.45	1.66e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.38	-11.7	-0.54	1.1e-26	Plateletcrit;
CRC	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg07636037	chr3:49044803	WDR6	-0.64	-6.05	-0.32	4e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.36	-0.56	4.36e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.64	-6.69	-0.35	9.48e-11	Birth weight;
CRC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.74e-9	Breast cancer;
CRC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg27661571	chr11:113659931	NA	-0.95	-11.14	-0.52	1.11e-24	Hip circumference adjusted for BMI;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03909902	chr12:108154529	PRDM4	0.44	6.11	0.32	2.77e-9	Survival in pancreatic cancer;
CRC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.07	-0.32	3.48e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.9	-0.31	8.82e-9	Heart rate;
CRC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.15	0.32	2.23e-9	Rheumatoid arthritis;
CRC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-9.5	-0.46	4.54e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg08501292	chr6:25962987	TRIM38	1.1	9.57	0.47	2.57e-19	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.07	-0.36	9.24e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.42	6.65	0.34	1.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg04553112	chr3:125709451	NA	-0.49	-6.07	-0.32	3.5e-9	Blood pressure (smoking interaction);
CRC	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.51	7.61	0.39	2.89e-13	Night sleep phenotypes;
CRC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.95	-17.98	-0.7	8.09e-51	Height;
CRC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.03	0.45	1.53e-17	Alzheimer's disease;
CRC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.62	14.27	0.62	2.79e-36	Airflow obstruction;
CRC	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg09829573	chr1:144692074	NBPF9	-0.41	-6.11	-0.32	2.87e-9	Hip geometry;
CRC	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.53	0.38	4.88e-13	Eye color traits;
CRC	cis	rs1524976	1.000	rs1554664	chr3:65501649	A/G	cg16238336	chr3:65465873	MAGI1	0.49	6.35	0.33	7.31e-10	PR interval;
CRC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	-0.51	-8.26	-0.41	3.52e-15	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs17095355	1.000	rs11194933	chr10:111725862	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.38	-0.42	1.55e-15	Biliary atresia;
CRC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.12	-14.99	-0.64	4.54e-39	Vitiligo;
CRC	trans	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg07817883	chr1:32538562	TMEM39B	-0.66	-7.75	-0.39	1.18e-13	Monocyte percentage of white cells;
CRC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg02421172	chr7:1938701	MAD1L1	0.44	5.9	0.31	9.26e-9	Bipolar disorder;
CRC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.53	-7.88	-0.4	4.76e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.5	-7.4	-0.38	1.17e-12	High light scatter reticulocyte count;
CRC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.81e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg17133734	chr15:86042851	AKAP13	-0.4	-6.21	-0.32	1.64e-9	Coronary artery disease;
CRC	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	0.65	6.58	0.34	1.8e-10	Pulse pressure;
CRC	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.48	8.99	0.44	2.05e-17	Common traits (Other);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18891615	chr8:101962925	YWHAZ	0.39	6.3	0.33	9.36e-10	Obesity-related traits;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs17162190	0.698	rs4659444	chr1:26825116	C/T	cg17456097	chr1:26900765	RPS6KA1	0.46	6.66	0.34	1.15e-10	Mean corpuscular volume;
CRC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.39	-0.42	1.42e-15	Hip circumference adjusted for BMI;
CRC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.75	-12.55	-0.57	8.48e-30	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg13647721	chr17:30228624	UTP6	0.57	5.65	0.3	3.4e-8	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.33	-0.33	8.22e-10	Blood metabolite levels;
CRC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.33e-22	Menopause (age at onset);
CRC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg07478791	chr1:31886160	SERINC2	-0.41	-5.65	-0.3	3.39e-8	Alcohol dependence;
CRC	cis	rs7091068	0.616	rs7920366	chr10:95497178	A/T	cg20715218	chr10:95462985	C10orf4	0.54	5.68	0.3	2.98e-8	Urinary tract infection frequency;
CRC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.75	-0.3	2.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.37	-5.68	-0.3	2.91e-8	Breast cancer;
CRC	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.68	0.3	2.98e-8	Putamen volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09463466	chr15:77925892	LINGO1	0.42	6.97	0.36	1.76e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg03037974	chr15:76606532	NA	0.7	12.57	0.57	7.07e-30	Blood metabolite levels;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg09877947	chr5:131593287	PDLIM4	0.44	7.22	0.37	3.67e-12	Breast cancer;
CRC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.66	10.76	0.51	2.5e-23	Mean platelet volume;
CRC	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg03929089	chr4:120376271	NA	0.67	6.12	0.32	2.69e-9	Myopia (pathological);
CRC	trans	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg26043149	chr18:55253948	FECH	0.46	7.05	0.36	1.05e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.65	9.03	0.45	1.48e-17	Body mass index;
CRC	cis	rs1256061	0.624	rs1760988	chr14:64696813	A/G	cg23250157	chr14:64679961	SYNE2	0.46	7.14	0.37	6.03e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.7	-13.51	-0.6	2.24e-33	Educational attainment;
CRC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.65	-7.51	-0.38	5.62e-13	Vitiligo;
CRC	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg26703956	chr19:39260304	NA	-0.38	-6.11	-0.32	2.83e-9	Heart rate;
CRC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.3	-0.49	9.59e-22	Initial pursuit acceleration;
CRC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg19635926	chr16:89946313	TCF25	0.66	6.88	0.35	3.09e-11	Skin colour saturation;
CRC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.74	-0.39	1.23e-13	Blood metabolite levels;
CRC	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.57	8.84	0.44	5.99e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.23	0.32	1.44e-9	Tonsillectomy;
CRC	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.66	9.3	0.46	1.96e-18	Multiple sclerosis;
CRC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.58	6.35	0.33	7.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.43	5.73	0.3	2.25e-8	Coronary artery disease;
CRC	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.52	0.34	2.61e-10	Schizophrenia;
CRC	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg10483660	chr13:112241077	NA	0.34	5.65	0.3	3.52e-8	Menarche (age at onset);
CRC	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.52	-7.12	-0.37	6.73e-12	Triglycerides;
CRC	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg00507830	chr2:103233733	NA	0.58	5.93	0.31	7.65e-9	Gut microbiota (bacterial taxa);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05977900	chr3:182512126	ATP11B	0.49	6.87	0.35	3.27e-11	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.57	-0.39	3.8e-13	Bladder cancer;
CRC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.29	0.33	9.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg24289452	chr6:170231220	NA	-0.6	-6.56	-0.34	2.12e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	8.69	0.43	1.71e-16	Ulcerative colitis;
CRC	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg12458913	chr13:53173898	NA	0.49	6.6	0.34	1.67e-10	Lewy body disease;
CRC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.5	9.49	0.46	4.83e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.45	6.85	0.35	3.53e-11	Red blood cell count;
CRC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.18	27.1	0.83	7.82e-86	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.21	0.37	3.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.38	0.56	3.79e-29	Height;
CRC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.61	-7.82	-0.4	7.43e-14	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg26248373	chr2:1572462	NA	-0.66	-7.21	-0.37	3.97e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18225595	chr11:63971243	STIP1	0.62	7.83	0.4	6.92e-14	Mean platelet volume;
CRC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-5.9	-0.31	9.12e-9	Total cholesterol levels;
CRC	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07165851	chr6:158734300	TULP4	0.61	7.69	0.39	1.69e-13	Height;
CRC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-6.3	-0.33	9.65e-10	Vitiligo;
CRC	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.39	0.5	4.71e-22	Corneal astigmatism;
CRC	trans	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg05376469	chr2:102649931	NA	-0.38	-6.05	-0.32	3.96e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.54	7.45	0.38	8.16e-13	Bone mineral density (hip);Bone mineral density (spine);
CRC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	5.98	0.31	5.78e-9	Tonsillectomy;
CRC	cis	rs73206853	0.686	rs73194021	chr12:111131893	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	6.07	0.32	3.62e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12143943	0.835	rs12730457	chr1:204548132	C/A	cg17419461	chr1:204415978	PIK3C2B	0.42	6.47	0.34	3.5e-10	Cognitive performance;
CRC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg23625390	chr15:77176239	SCAPER	0.39	5.61	0.3	4.21e-8	Blood metabolite levels;
CRC	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.38	-11.56	-0.54	3.59e-26	Psoriasis vulgaris;
CRC	cis	rs11958404	0.789	rs72800604	chr5:157502940	C/T	cg05962755	chr5:157440814	NA	1.04	12.82	0.58	8.27e-31	IgG glycosylation;
CRC	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-5.9	-0.31	9.05e-9	Inflammatory bowel disease;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-7.44	-0.38	8.92e-13	Chronic sinus infection;
CRC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.8	10.02	0.48	8.68e-21	Initial pursuit acceleration;
CRC	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.26	-0.45	2.73e-18	Metabolite levels;
CRC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.9	-0.4	4.15e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06488666	chr20:33104140	DYNLRB1	0.47	6.58	0.34	1.87e-10	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-7.51	-0.38	5.56e-13	Breast cancer;
CRC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-0.81	-8.16	-0.41	7.17e-15	Magnesium levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17841529	chr12:76953712	OSBPL8	0.48	7.0	0.36	1.4e-11	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18766056	chr1:39457186	AKIRIN1	0.4	6.52	0.34	2.69e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16436711	chr6:27173574	NA	0.21	6.06	0.32	3.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.46	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.43	6.14	0.32	2.37e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg02033258	chr5:131593261	PDLIM4	0.4	7.63	0.39	2.57e-13	Breast cancer;
CRC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.09	-0.49	5.04e-21	Total cholesterol levels;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13406896	chr2:10220712	CYS1	0.36	6.5	0.34	2.95e-10	Hip circumference;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01301935	chr16:69599904	NFAT5;MIR1538	0.48	6.63	0.34	1.4e-10	Response to antipsychotic treatment;
CRC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.82	11.69	0.54	1.23e-26	Multiple sclerosis;
CRC	cis	rs9361491	0.657	rs7766318	chr6:79451515	A/C	cg05283184	chr6:79620031	NA	-0.38	-5.73	-0.3	2.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-7.54	-0.38	4.68e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-5.68	-0.3	2.99e-8	High light scatter reticulocyte count;
CRC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg12458913	chr13:53173898	NA	0.53	8.47	0.42	8.13e-16	Lewy body disease;
CRC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	8.16	0.41	6.95e-15	Cognitive test performance;
CRC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.5	-0.34	3.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg08314208	chr16:67682810	RLTPR	-0.6	-6.91	-0.36	2.6e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-15.26	-0.64	3.98e-40	Vitiligo;
CRC	cis	rs230203	0.506	rs230196	chr20:55775623	C/A	cg13236649	chr20:55835020	BMP7	0.38	5.63	0.3	3.83e-8	Monobrow;
CRC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs524281	0.731	rs2430979	chr11:65813383	C/T	cg16950941	chr11:66035639	RAB1B	0.5	6.02	0.31	4.72e-9	Electroencephalogram traits;
CRC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.61	6.86	0.35	3.38e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.5	-6.16	-0.32	2.13e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.62	8.88	0.44	4.55e-17	Arsenic metabolism;
CRC	cis	rs7731657	0.537	rs2905534	chr5:130242005	C/T	cg08523029	chr5:130500466	HINT1	-0.47	-6.05	-0.32	3.95e-9	Fasting plasma glucose;
CRC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg04450456	chr4:17643702	FAM184B	0.36	5.85	0.31	1.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03637447	chr2:99061186	INPP4A	0.47	6.68	0.35	1.04e-10	Response to antipsychotic treatment;
CRC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.5	7.72	0.39	1.38e-13	Prostate cancer;
CRC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg23356831	chr14:105996513	TMEM121	0.42	7.19	0.37	4.4e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg17321639	chr7:2759063	NA	-0.54	-7.79	-0.39	8.97e-14	Height;
CRC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg20615401	chr6:28092323	ZSCAN16	0.45	5.98	0.31	5.68e-9	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07738077	chr19:53303448	ZNF28	-0.39	-6.23	-0.32	1.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.25	-0.37	3e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg05627522	chr15:75251581	NA	0.38	5.89	0.31	9.58e-9	Breast cancer;
CRC	cis	rs3736485	0.844	rs4775943	chr15:51770105	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.55	-0.34	2.18e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.09e-15	Platelet count;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.72	-10.17	-0.49	2.57e-21	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22091798	chr11:62446605	UBXN1	0.57	7.67	0.39	1.98e-13	Thyroid stimulating hormone;
CRC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg24675056	chr1:15929824	NA	0.5	6.81	0.35	4.53e-11	Systolic blood pressure;
CRC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.64	6.42	0.33	4.71e-10	Axial length;
CRC	cis	rs12431939	0.947	rs68180359	chr14:51672027	G/A	cg23942311	chr14:51606299	NA	-0.57	-6.51	-0.34	2.79e-10	Cancer;
CRC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.24	0.37	3.24e-12	Morning vs. evening chronotype;
CRC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg02049041	chr17:27085579	C17orf63	0.44	5.61	0.3	4.31e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg16606324	chr3:10149918	C3orf24	0.7	8.09	0.41	1.19e-14	Alzheimer's disease;
CRC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.37	-5.78	-0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.45	-5.95	-0.31	6.92e-9	Tuberculosis;
CRC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg23996704	chr18:44553084	KATNAL2	-0.38	-7.55	-0.38	4.33e-13	Personality dimensions;
CRC	cis	rs2084637	0.965	rs59872663	chr11:122400354	C/T	cg21585512	chr11:122030076	LOC399959	-0.4	-7.29	-0.37	2.39e-12	Stroke;
CRC	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-5.94	-0.31	7.23e-9	Blood pressure (smoking interaction);
CRC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	11.92	0.55	1.86e-27	Eye color traits;
CRC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs216303	1.000	rs216295	chr12:6154206	C/T	cg19878637	chr12:6148451	VWF	0.51	6.27	0.33	1.16e-9	Low vWF levels;
CRC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	18.04	0.71	4.57e-51	Prudent dietary pattern;
CRC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.64	11.6	0.54	2.57e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs868943	0.582	rs12203127	chr6:116468315	A/T	cg15226275	chr6:116381976	FRK	0.24	5.84	0.31	1.27e-8	Total cholesterol levels;
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.45	-0.33	4.04e-10	Lymphocyte counts;
CRC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.16	0.49	2.91e-21	Ileal carcinoids;
CRC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.67	11.63	0.54	2.01e-26	Longevity;
CRC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.45	-7.98	-0.4	2.46e-14	Monocyte count;
CRC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.8	14.22	0.62	4.28e-36	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09273779	chr9:35605990	TESK1	0.52	7.53	0.38	4.89e-13	Response to antipsychotic treatment;
CRC	cis	rs860295	0.812	rs12081192	chr1:155738044	A/G	cg02153340	chr1:155202674	NA	-0.53	-6.53	-0.34	2.44e-10	Body mass index;
CRC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.92e-9	Life satisfaction;
CRC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.44	-7.52	-0.38	5.29e-13	Height;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg24634471	chr8:143751801	JRK	0.46	6.43	0.33	4.58e-10	Urinary tract infection frequency;
CRC	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg19196414	chr17:27188595	MIR451;MIR144	-0.39	-5.65	-0.3	3.53e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.46	-6.58	-0.34	1.91e-10	Blood pressure (smoking interaction);
CRC	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.82	8.06	0.41	1.43e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.41	5.72	0.3	2.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05329982	chr11:62359210	TUT1	0.56	7.41	0.38	1.05e-12	Thyroid stimulating hormone;
CRC	cis	rs720844	0.684	rs16828967	chr2:149332672	G/A	cg09247360	chr2:149335327	NA	-0.56	-6.04	-0.32	4.27e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-0.8	-12.1	-0.56	3.82e-28	Systemic lupus erythematosus;
CRC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.48	-6.76	-0.35	6.39e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.45	-6.12	-0.32	2.61e-9	Cognitive function;
CRC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.55	8.66	0.43	2.12e-16	Cerebrospinal fluid biomarker levels;
CRC	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.66	10.52	0.5	1.65e-22	Corneal astigmatism;
CRC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg03013636	chr16:1946785	NA	0.58	6.66	0.34	1.15e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg20673091	chr1:2541236	MMEL1	0.37	6.03	0.32	4.48e-9	Ulcerative colitis;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.64	-8.89	-0.44	4.19e-17	Menopause (age at onset);
CRC	cis	rs10486722	0.607	rs11771454	chr7:41772806	A/G	cg22138096	chr7:41772439	LOC285954	-0.69	-8.23	-0.41	4.53e-15	Pit-and-Fissure caries;
CRC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.28	-0.42	3.07e-15	Morning vs. evening chronotype;
CRC	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.13	-0.32	2.45e-9	Schizophrenia;
CRC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.38	0.42	1.52e-15	Homoarginine levels;
CRC	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg14092571	chr14:90743983	NA	0.39	6.03	0.32	4.43e-9	Mortality in heart failure;
CRC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.31e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10235275	chr10:65225544	JMJD1C;LOC84989	0.38	6.36	0.33	6.92e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.36	-6.45	-0.34	3.97e-10	Menarche (age at onset);
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg15511327	chr8:143859410	LYNX1	0.46	7.61	0.39	2.95e-13	Urinary tract infection frequency;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.41	-7.51	-0.38	5.78e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs995000	0.931	rs11208000	chr1:63108374	A/G	cg05392265	chr1:68516453	DIRAS3	0.43	5.97	0.31	6.04e-9	Triglyceride levels;
CRC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.08	19.11	0.73	2.82e-55	Cognitive function;
CRC	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.62	8.06	0.41	1.44e-14	Type 2 diabetes;
CRC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg05110241	chr16:68378359	PRMT7	-0.73	-7.29	-0.37	2.31e-12	Magnesium levels;
CRC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.6	8.05	0.41	1.56e-14	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg04077850	chr5:125800366	GRAMD3	0.38	6.31	0.33	8.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.83	-0.35	4.22e-11	Height;
CRC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.34	-5.71	-0.3	2.51e-8	Mean platelet volume;
CRC	cis	rs847649	0.618	rs6465880	chr7:102515237	T/C	cg18108683	chr7:102477205	FBXL13	-0.64	-11.03	-0.52	2.87e-24	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs1223397	0.938	rs20499	chr6:13295004	C/T	cg20827128	chr6:13274284	PHACTR1	0.46	5.61	0.3	4.29e-8	Blood pressure;
CRC	cis	rs7725052	0.609	rs62357421	chr5:40460495	T/C	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.58	9.57	0.47	2.56e-19	Dental caries;
CRC	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-17.36	-0.69	2.17e-48	Schizophrenia;
CRC	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.77	0.35	6.06e-11	Mean corpuscular volume;
CRC	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.73	7.77	0.39	1.01e-13	Pulse pressure;
CRC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.55	8.16	0.41	7.26e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.8	0.55	4.73e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs728616	0.681	rs3862518	chr10:81917957	A/G	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.65	-0.3	3.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg21970626	chr13:21893289	NA	0.42	5.72	0.3	2.36e-8	White matter hyperintensity burden;
CRC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-6.54	-0.34	2.36e-10	Asthma;
CRC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.02	-0.55	8.05e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg14139581	chr11:64358342	SLC22A12	0.38	6.04	0.32	4.13e-9	Urate levels in obese individuals;
CRC	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg20608306	chr11:116969690	SIK3	-0.32	-6.12	-0.32	2.69e-9	Subjective well-being;
CRC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.78	9.47	0.46	5.6e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.33	0.53	2.31e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20529344	chr13:50707427	NA	0.21	6.55	0.34	2.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18204762	chr7:98741983	SMURF1	0.39	6.06	0.32	3.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.62	9.71	0.47	9.24e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.7	-0.39	1.66e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.57	-8.11	-0.41	1.03e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.27	-15.22	-0.64	5.52e-40	Diabetic kidney disease;
CRC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.46	-6.62	-0.34	1.45e-10	Lymphocyte counts;
CRC	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg06156847	chr2:113672199	IL1F7	-0.4	-6.0	-0.31	5.18e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.54	10.63	0.51	7.09e-23	Lipoprotein (a) levels;
CRC	trans	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	7.61	0.39	2.87e-13	Endometrial cancer;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg25164649	chr6:28176230	NA	0.6	8.46	0.42	8.81e-16	Parkinson's disease;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg00413099	chr20:30192013	ID1	-0.57	-6.38	-0.33	5.92e-10	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.6	-9.23	-0.45	3.3e-18	Breast cancer;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg10802521	chr3:52805072	NEK4	-0.46	-6.2	-0.32	1.65e-9	Schizophrenia;
CRC	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg16989719	chr2:238392110	NA	-0.38	-5.64	-0.3	3.6e-8	Prostate cancer;
CRC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg27535305	chr1:53392650	SCP2	0.39	7.07	0.36	9.43e-12	Monocyte count;
CRC	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg10517650	chr3:113235015	CCDC52	-0.38	-6.82	-0.35	4.35e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.49	-7.24	-0.37	3.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg26603656	chr10:5671107	NA	0.44	7.53	0.38	4.88e-13	Breast cancer;
CRC	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21659725	chr3:3221576	CRBN	0.66	7.32	0.37	1.94e-12	Menarche (age at onset);
CRC	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg14593290	chr7:50529359	DDC	0.54	7.55	0.38	4.4e-13	Malaria;
CRC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg02741985	chr17:80059408	CCDC57	0.44	7.29	0.37	2.34e-12	Life satisfaction;
CRC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.71	-0.35	8.58e-11	Colorectal cancer;
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18099408	chr3:52552593	STAB1	-0.63	-11.97	-0.55	1.14e-27	Electroencephalogram traits;
CRC	cis	rs12612619	0.732	rs3806520	chr2:27276202	G/A	cg00617064	chr2:27272375	NA	-0.39	-6.47	-0.34	3.49e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.82	-0.31	1.39e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.45	-0.79	3.61e-72	Myeloid white cell count;
CRC	cis	rs6088813	1.000	rs6142358	chr20:33960308	A/G	cg14752227	chr20:34000481	UQCC	0.37	5.79	0.3	1.64e-8	Height;
CRC	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.43	6.36	0.33	6.77e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg09873164	chr1:152488093	CRCT1	0.37	6.22	0.32	1.49e-9	Hair morphology;
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg06470822	chr6:28175283	NA	0.83	8.02	0.4	1.86e-14	Depression;
CRC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.51	8.17	0.41	6.92e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs10512697	0.536	rs62336073	chr5:3505717	T/C	cg19473799	chr5:3511975	NA	-0.82	-6.32	-0.33	8.41e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13464717	chr19:2269532	OAZ1	0.38	6.18	0.32	1.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.51	8.18	0.41	6.05e-15	Age at first birth;
CRC	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.09	0.36	8.5e-12	Eye color traits;
CRC	cis	rs4666002	0.871	rs10208529	chr2:27786188	A/T	cg27432699	chr2:27873401	GPN1	0.46	5.91	0.31	8.62e-9	Phospholipid levels (plasma);
CRC	cis	rs6534441	0.727	rs17768496	chr4:125419243	A/G	cg21609808	chr4:125404261	NA	0.44	6.29	0.33	1e-9	Major depressive disorder;
CRC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.79e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.49	-6.77	-0.35	6.01e-11	Type 1 diabetes nephropathy;
CRC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg09835421	chr16:68378352	PRMT7	-0.73	-7.6	-0.39	3.1e-13	Magnesium levels;
CRC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.11	0.49	4.19e-21	Bladder cancer;
CRC	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.2	-18.39	-0.71	1.85e-52	Blood pressure (smoking interaction);
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	trans	rs9908158	1	rs9908158	chr17:33890083	T/C	cg19694781	chr19:47549865	TMEM160	0.42	6.46	0.34	3.83e-10	Platelet count;Platelet distribution width;
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.46	6.9	0.36	2.68e-11	Menarche (age at onset);
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg06470822	chr6:28175283	NA	0.95	13.58	0.6	1.14e-33	Parkinson's disease;
CRC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.78	-14.57	-0.63	1.89e-37	Prostate cancer;
CRC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.6	8.48	0.42	7.85e-16	Breast cancer;
CRC	cis	rs6700896	0.966	rs1938485	chr1:66082084	A/G	cg04111102	chr1:66153794	NA	0.35	6.21	0.32	1.56e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-7.22	-0.37	3.65e-12	Coronary artery disease;
CRC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg20933634	chr6:27740509	NA	0.54	6.98	0.36	1.66e-11	Parkinson's disease;
CRC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.11	14.14	0.61	8.44e-36	Uric acid levels;
CRC	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg20647610	chr2:228736258	WDR69	-0.51	-7.01	-0.36	1.37e-11	Blood pressure;
CRC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.62	8.23	0.41	4.51e-15	Smoking initiation;
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	6.95	0.36	1.94e-11	Lymphocyte counts;
CRC	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.69	8.63	0.43	2.57e-16	Iron status biomarkers;
CRC	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.13	0.32	2.46e-9	Ovarian reserve;
CRC	cis	rs3540	0.960	rs8025842	chr15:90995471	C/T	cg22089800	chr15:90895588	ZNF774	0.51	7.97	0.4	2.56e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.64	7.16	0.37	5.19e-12	Breast cancer;
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg12516270	chr8:143859308	LYNX1	0.54	9.66	0.47	1.3e-19	Urinary tract infection frequency;
CRC	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.72	10.34	0.5	6.97e-22	Obesity-related traits;
CRC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.85	0.51	1.15e-23	Prostate cancer;
CRC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.81	8.15	0.41	7.71e-15	Fat distribution (HIV);
CRC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.36e-10	Schizophrenia;
CRC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.47	-6.3	-0.33	9.33e-10	Uric acid levels;
CRC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.52	7.44	0.38	9.08e-13	Height;
CRC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg15962314	chr1:44399869	ARTN	0.3	5.74	0.3	2.1e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.65	8.66	0.43	2.14e-16	Alzheimer's disease;
CRC	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.11	-0.71	2.34e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.07e-25	Hip circumference adjusted for BMI;
CRC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.61	-6.4	-0.33	5.25e-10	Schizophrenia;
CRC	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.83	-0.31	1.33e-8	Morning vs. evening chronotype;
CRC	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg27398640	chr15:77910606	LINGO1	-0.41	-6.83	-0.35	4.04e-11	Type 2 diabetes;
CRC	trans	rs11581859	0.950	rs17390447	chr1:99384002	A/T	cg12183875	chr3:169587454	LRRC31	-0.28	-6.26	-0.33	1.23e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg19337854	chr7:99768885	GPC2	0.44	5.96	0.31	6.63e-9	Lung function (FEV1/FVC);
CRC	cis	rs11212617	1.000	rs186593	chr11:108262439	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.5	0.34	3.04e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs947583	0.588	rs12211505	chr6:136074821	T/C	cg06563441	chr6:136217110	PDE7B	0.32	5.6	0.3	4.52e-8	Phosphorus levels;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg16558177	chr4:4109446	NA	-0.62	-8.74	-0.43	1.23e-16	Blood pressure (smoking interaction);
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20887711	chr4:1340912	KIAA1530	0.4	5.72	0.3	2.38e-8	Obesity-related traits;
CRC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.39	-6.46	-0.34	3.69e-10	IgG glycosylation;
CRC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.91	0.31	8.58e-9	IgG glycosylation;
CRC	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.36	-5.6	-0.3	4.48e-8	Myeloid white cell count;
CRC	cis	rs9648716	0.608	rs1267622	chr7:140528317	A/G	cg10747023	chr7:140774559	NA	0.45	6.2	0.32	1.71e-9	Type 2 diabetes;
CRC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.51	7.14	0.37	5.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.39	-6.23	-0.32	1.41e-9	Iron status biomarkers;
CRC	cis	rs231513	1.000	rs231518	chr17:41961451	C/T	cg26893861	chr17:41843967	DUSP3	0.7	6.52	0.34	2.72e-10	Cognitive function;
CRC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.62	8.64	0.43	2.56e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.34	5.76	0.3	1.98e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg25164649	chr6:28176230	NA	-0.58	-8.25	-0.41	3.92e-15	Parkinson's disease;
CRC	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg03264133	chr6:25882463	NA	-0.42	-5.77	-0.3	1.79e-8	Height;
CRC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.6	9.53	0.46	3.71e-19	Corneal astigmatism;
CRC	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.34	7.98	0.4	2.47e-14	Corneal astigmatism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20214692	chr10:1095144	IDI1	0.46	6.46	0.34	3.73e-10	Anxiety disorder;
CRC	cis	rs6840360	0.642	rs7657670	chr4:152353375	A/G	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.43	7.36	0.38	1.47e-12	Alcohol dependence;
CRC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg06470822	chr6:28175283	NA	-0.51	-7.03	-0.36	1.21e-11	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg02683197	chr6:28174875	NA	-0.87	-10.95	-0.52	5.53e-24	Depression;
CRC	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg19193384	chr17:30244184	NA	-0.63	-7.41	-0.38	1.09e-12	Hip circumference adjusted for BMI;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20092199	chr4:1342459	KIAA1530	0.46	8.28	0.42	3.14e-15	Longevity;
CRC	cis	rs9988450	1	rs9988450	chr1:62924448	C/T	cg19896129	chr1:63156450	NA	0.41	6.15	0.32	2.24e-9	Triglycerides;
CRC	cis	rs947583	0.588	rs12204523	chr6:136074994	C/A	cg06563441	chr6:136217110	PDE7B	0.32	5.65	0.3	3.47e-8	Phosphorus levels;
CRC	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.51	7.11	0.37	7.15e-12	Testicular germ cell tumor;
CRC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	8.95	0.44	2.71e-17	Childhood ear infection;
CRC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg16476235	chr8:21771668	DOK2	0.42	7.15	0.37	5.49e-12	Lung cancer in ever smokers;
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg05569086	chr8:143859399	LYNX1	-0.39	-6.76	-0.35	6.24e-11	Urinary tract infection frequency;
CRC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.42	9.26	0.45	2.62e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.45	-7.11	-0.37	7.11e-12	Asthma;
CRC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.75	-0.39	1.19e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.69	-10.15	-0.49	3e-21	Total body bone mineral density;
CRC	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.57	-5.9	-0.31	9.19e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.91	0.31	8.61e-9	Total body bone mineral density;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg09264619	chr17:80180166	NA	0.36	5.92	0.31	8.27e-9	Life satisfaction;
CRC	cis	rs939574	0.656	rs113370390	chr2:220132837	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	7.11	0.37	7.21e-12	Platelet distribution width;
CRC	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.36	-0.33	6.92e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg00300879	chr1:26503847	CNKSR1	0.32	6.2	0.32	1.65e-9	QRS complex (12-leadsum);
CRC	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	7.73	0.39	1.33e-13	Iron status biomarkers;
CRC	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.66	9.35	0.46	1.38e-18	Body mass index;
CRC	cis	rs6694672	1.000	rs10754214	chr1:197059892	A/G	cg13682187	chr1:196946512	CFHR5	0.43	7.0	0.36	1.41e-11	Asthma;
CRC	cis	rs13315871	1.000	rs9869276	chr3:58401076	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.87	-0.4	5.22e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs75804782	0.810	rs55694368	chr2:239317692	G/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.71	-0.3	2.51e-8	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.63	10.18	0.49	2.37e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.47	5.78	0.3	1.73e-8	Pulse pressure;
CRC	cis	rs17152411	1.000	rs17152448	chr10:126675645	C/G	cg07906193	chr10:126599966	NA	0.57	5.65	0.3	3.49e-8	Height;
CRC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.49	6.94	0.36	2.06e-11	Schizophrenia;
CRC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.47	7.37	0.38	1.38e-12	Height;
CRC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-11.3	-0.53	2.95e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs12410462	0.591	rs11802190	chr1:227635162	A/C	cg23173402	chr1:227635558	NA	0.44	5.9	0.31	9.09e-9	Major depressive disorder;
CRC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg13390004	chr1:15929781	NA	0.49	6.86	0.35	3.37e-11	Systolic blood pressure;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.22	-0.41	4.71e-15	Total body bone mineral density;
CRC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.42	-5.97	-0.31	6.21e-9	Aortic root size;
CRC	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg20488157	chr14:104394430	TDRD9	0.68	9.9	0.48	2.07e-20	Bipolar disorder;
CRC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.08	-0.41	1.29e-14	Height;
CRC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.02	10.5	0.5	1.92e-22	Diabetic retinopathy;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg15786705	chr6:28176104	NA	0.53	7.35	0.38	1.6e-12	Parkinson's disease;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.62	-0.39	2.79e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs6973256	0.897	rs9656423	chr7:133324987	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.87	0.31	1.06e-8	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-7.12	-0.37	7.02e-12	Total body bone mineral density;
CRC	trans	rs596169	0.764	rs73103335	chr1:219111028	A/C	cg09853702	chr12:47665230	NA	0.77	6.4	0.33	5.4e-10	Intraocular pressure;
CRC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.44	5.83	0.31	1.31e-8	IgG glycosylation;
CRC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05472934	chr7:22766657	IL6	0.76	12.02	0.55	7.58e-28	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CRC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.41	-9.01	-0.44	1.75e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.34	-7.08	-0.36	8.95e-12	Lung cancer;
CRC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg10760299	chr15:45669010	GATM	0.5	7.87	0.4	5.11e-14	Homoarginine levels;
CRC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.92	-17.38	-0.69	1.94e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.55	8.52	0.43	5.79e-16	Aortic root size;
CRC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.42	9.02	0.45	1.59e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.42	-6.76	-0.35	6.14e-11	Type 2 diabetes;
CRC	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.33	-0.56	5.79e-29	Exhaled nitric oxide output;
CRC	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg25482853	chr8:67687455	SGK3	1.16	13.2	0.59	3.15e-32	Obesity-related traits;
CRC	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.38	5.98	0.31	5.79e-9	Height;
CRC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.4	-8.48	-0.42	7.78e-16	Cutaneous nevi;
CRC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-13.01	-0.58	1.68e-31	Systemic lupus erythematosus;
CRC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg24849736	chr1:201084428	NA	-0.45	-6.02	-0.32	4.54e-9	Permanent tooth development;
CRC	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.64	-0.3	3.68e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.53	-0.5	1.59e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-12.58	-0.57	6.95e-30	Asthma;
CRC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02018176	chr4:1364513	KIAA1530	0.48	7.94	0.4	3.22e-14	Obesity-related traits;
CRC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.65	-8.81	-0.44	7.29e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03855706	chr16:770778	FAM173A	0.46	6.05	0.32	3.9e-9	Survival in pancreatic cancer;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.52	7.78	0.39	9.7e-14	Longevity;
CRC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	7.39	0.38	1.24e-12	Height;
CRC	cis	rs6445967	1.000	rs1913716	chr3:58308331	G/A	cg23715586	chr3:58305044	RPP14	0.35	5.88	0.31	1e-8	Platelet count;
CRC	cis	rs7259376	1.000	rs1975174	chr19:22515251	G/T	cg02657401	chr19:22469223	NA	-0.38	-8.72	-0.43	1.44e-16	Menopause (age at onset);
CRC	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.69	8.15	0.41	7.52e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg04545296	chr12:48745243	ZNF641	0.36	6.22	0.32	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-0.82	-8.53	-0.43	5.26e-16	Pediatric areal bone mineral density (radius);
CRC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.67	-8.71	-0.43	1.46e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.55	8.4	0.42	1.4e-15	Vitiligo;
CRC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	10.19	0.49	2.3e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg03160526	chr17:80928410	B3GNTL1	0.57	7.62	0.39	2.66e-13	Glycated hemoglobin levels;
CRC	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg07512295	chr2:234599026	UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.38	5.85	0.31	1.2e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.54	-6.45	-0.34	3.95e-10	HIV-1 control;
CRC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.48	-6.55	-0.34	2.16e-10	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.38	6.16	0.32	2.07e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs365302	1.000	rs375150	chr6:159650025	G/T	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg16989719	chr2:238392110	NA	-0.44	-8.0	-0.4	2.13e-14	Prostate cancer;
CRC	trans	rs11581859	1.000	rs4477298	chr1:99293842	A/G	cg12183875	chr3:169587454	LRRC31	0.27	6.27	0.33	1.13e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs9372498	0.831	rs62421535	chr6:118724565	C/A	cg15382696	chr6:118971807	C6orf204	0.56	5.62	0.3	4.18e-8	Diastolic blood pressure;
CRC	cis	rs7113874	0.589	rs10769910	chr11:8499406	T/C	cg20771178	chr11:8615675	STK33	0.34	5.67	0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.31e-17	Bipolar disorder;
CRC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.4	6.44	0.33	4.17e-10	Height;
CRC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.89	18.76	0.72	6.5e-54	Urate levels in lean individuals;
CRC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	12.03	0.55	7.11e-28	Nonalcoholic fatty liver disease;
CRC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg20119798	chr7:94954144	PON1	-0.47	-5.88	-0.31	9.89e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.38	0.33	5.94e-10	Depression;
CRC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg08288130	chr8:21771540	DOK2	0.29	5.72	0.3	2.34e-8	Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.18e-26	Prudent dietary pattern;
CRC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-10.26	-0.49	1.32e-21	Prudent dietary pattern;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.52	7.54	0.38	4.64e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg06204229	chr3:52865917	ITIH4	-0.5	-5.92	-0.31	8.08e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.21	-0.37	3.81e-12	Response to antipsychotic treatment;
CRC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.53	0.34	2.44e-10	Dupuytren's disease;
CRC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.44	-9.16	-0.45	5.85e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs282587	0.530	rs428853	chr13:113387222	T/C	cg04656015	chr13:113407548	ATP11A	0.65	8.07	0.41	1.33e-14	Glycated hemoglobin levels;
CRC	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg16141378	chr3:129829833	LOC729375	-0.42	-6.22	-0.32	1.47e-9	Neuroticism;
CRC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.29	5.9	0.31	9e-9	Personality dimensions;
CRC	trans	rs3849570	0.695	rs9830445	chr3:81508063	T/G	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-6.0	-0.31	5.25e-9	Waist circumference;Body mass index;
CRC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.91	17.8	0.7	4.22e-50	Intelligence (multi-trait analysis);
CRC	cis	rs847649	0.842	rs4729873	chr7:102731781	G/A	cg18108683	chr7:102477205	FBXL13	0.53	8.36	0.42	1.77e-15	Morning vs. evening chronotype;
CRC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.57	7.63	0.39	2.51e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.69	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25733613	chr11:111637437	PPP2R1B	0.45	6.26	0.33	1.2e-9	Survival in pancreatic cancer;
CRC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.6	-0.6	9.99e-34	Educational attainment;
CRC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.62	9.6	0.47	2.16e-19	Menarche (age at onset);
CRC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7605827	0.823	rs11689269	chr2:15621917	C/G	cg19274914	chr2:15703543	NA	0.39	6.05	0.32	3.96e-9	Educational attainment (years of education);
CRC	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.44	7.63	0.39	2.48e-13	HDL cholesterol;
CRC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg21280719	chr6:42927975	GNMT	-0.32	-6.23	-0.32	1.41e-9	Blood protein levels;
CRC	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg16914508	chr2:239161102	PER2	0.75	8.09	0.41	1.19e-14	Irritable bowel syndrome;
CRC	cis	rs2882667	0.867	rs11749045	chr5:138420960	C/T	cg04439458	chr5:138467593	SIL1	-0.31	-5.6	-0.3	4.49e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.31	-0.46	1.83e-18	Type 2 diabetes;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.37	6.41	0.33	5.12e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs73200209	0.744	rs3741768	chr12:116446445	C/T	cg01776926	chr12:116560359	MED13L	-0.63	-7.4	-0.38	1.15e-12	Total body bone mineral density;
CRC	cis	rs3857067	1.000	rs2219755	chr4:95015684	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.21	0.32	1.55e-9	Blood metabolite levels;
CRC	trans	rs9561329	0.800	rs9561335	chr13:94034057	A/T	cg23072629	chr2:239195537	PER2	0.32	6.01	0.31	5.03e-9	Neuroticism (age interaction);
CRC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17554472	chr22:41940697	POLR3H	-0.57	-6.03	-0.32	4.3e-9	Vitiligo;
CRC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.55	0.63	2.29e-37	Mean platelet volume;
CRC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg08071915	chr8:12219732	FAM66A	0.34	5.98	0.31	5.67e-9	Retinal vascular caliber;
CRC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.24	0.53	5.12e-25	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.61	-8.99	-0.44	1.95e-17	Menarche (age at onset);
CRC	trans	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg25214090	chr10:38739885	LOC399744	-0.42	-6.62	-0.34	1.5e-10	Diastolic blood pressure;
CRC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Melanoma;
CRC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.61	0.34	1.52e-10	Schizophrenia;
CRC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	8.1	0.41	1.12e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.82	0.31	1.44e-8	Diastolic blood pressure;
CRC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	6.9	0.36	2.7e-11	Reticulocyte count;
CRC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.65	9.23	0.45	3.51e-18	Alzheimer's disease;
CRC	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.34	0.65	1.91e-40	Hypertriglyceridemia;
CRC	cis	rs7487637	0.566	rs875023	chr12:48194435	A/G	cg14736327	chr12:48174669	SLC48A1	0.59	7.45	0.38	8.11e-13	Mononucleosis;
CRC	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg09659197	chr4:152720779	NA	0.51	10.69	0.51	4.4e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.63	9.09	0.45	9.66e-18	Coronary artery disease;
CRC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.35	-6.03	-0.32	4.52e-9	Aortic root size;
CRC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.34	-0.42	2.03e-15	Height;
CRC	trans	rs10243593	0.673	rs6966917	chr7:40075461	G/A	cg13911576	chr9:84174038	NA	0.34	6.0	0.31	5.32e-9	Lymphocyte counts;
CRC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg16447950	chr5:562315	NA	-0.84	-11.5	-0.54	6.14e-26	Lung disease severity in cystic fibrosis;
CRC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg07195577	chr17:27052828	TLCD1	-0.4	-6.0	-0.31	5.12e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2625529	0.730	rs2957373	chr15:72340929	T/C	cg16672083	chr15:72433130	SENP8	0.43	6.27	0.33	1.15e-9	Red blood cell count;
CRC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg08888203	chr3:10149979	C3orf24	0.7	10.03	0.48	7.85e-21	Alzheimer's disease;
CRC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	cis	rs9292777	0.733	rs348595	chr5:40323714	A/G	cg09067459	chr5:40385259	NA	-0.56	-9.61	-0.47	1.89e-19	Crohn's disease;Multiple sclerosis;
CRC	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-11.28	-0.53	3.66e-25	Exhaled nitric oxide output;
CRC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.92	14.18	0.62	5.85e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.28	-0.33	1.07e-9	Alzheimer's disease (late onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23903483	chr12:54120889	CALCOCO1	0.4	6.03	0.32	4.44e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.48	6.93	0.36	2.28e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.64	8.27	0.41	3.38e-15	Alcohol dependence;
CRC	cis	rs427941	0.550	rs1902	chr7:101768791	C/T	cg06246474	chr7:101738831	CUX1	0.37	5.66	0.3	3.27e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.66	9.35	0.46	1.38e-18	Body mass index;
CRC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.37	-6.05	-0.32	3.87e-9	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25552655	chr19:33864476	CEBPG	0.39	6.05	0.32	4.03e-9	Schizophrenia;
CRC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg24675056	chr1:15929824	NA	0.51	7.28	0.37	2.53e-12	Systolic blood pressure;
CRC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.38	-5.9	-0.31	9.03e-9	Monocyte count;
CRC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.62	9.3	0.46	1.95e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.95	-0.4	3.02e-14	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg17948913	chr5:572064	NA	0.56	6.51	0.34	2.77e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg03152288	chr2:177042942	NA	-0.57	-7.37	-0.38	1.4e-12	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.94	0.4	3.26e-14	Lymphocyte percentage of white cells;
CRC	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg13385794	chr1:248469461	NA	-0.33	-6.27	-0.33	1.15e-9	Common traits (Other);
CRC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.91	-0.31	8.64e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2811415	0.597	rs1057156	chr3:127800071	A/G	cg13719885	chr3:127795394	NA	-0.4	-5.87	-0.31	1.05e-8	Lung function (FEV1/FVC);
CRC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.66	-9.43	-0.46	7.85e-19	Lung cancer;
CRC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.73	11.89	0.55	2.26e-27	Longevity;Endometriosis;
CRC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.52	-6.44	-0.33	4.24e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.56	-7.6	-0.39	3.1400000000000003e-13	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg01721255	chr8:58191610	C8orf71	0.61	5.87	0.31	1.05e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg01874867	chr7:94954059	PON1	-0.51	-6.36	-0.33	6.79e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-6.39	-0.33	5.73e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.32	0.37	1.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4731207	0.565	rs998054	chr7:124640487	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.64	9.8	0.48	4.73e-20	Testicular germ cell tumor;
CRC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg20092199	chr4:1342459	KIAA1530	0.46	7.25	0.37	3.06e-12	Obesity-related traits;
CRC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.37	5.71	0.3	2.54e-8	Total body bone mineral density;
CRC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg05043794	chr9:111880884	C9orf5	-0.32	-5.74	-0.3	2.16e-8	Menarche (age at onset);
CRC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.68	6.58	0.34	1.89e-10	Intraocular pressure;
CRC	cis	rs939584	1.000	rs2867112	chr2:651349	T/G	cg03610516	chr2:642275	NA	-0.42	-5.89	-0.31	9.71e-9	Body mass index;
CRC	cis	rs6496667	1.000	rs8023776	chr15:90897952	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.51	-7.6	-0.39	3.04e-13	Rheumatoid arthritis;
CRC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.23	-0.32	1.4e-9	Bipolar disorder;
CRC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	8.93	0.44	3.08e-17	Menarche (age at onset);
CRC	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.74	11.37	0.53	1.7e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.15	0.45	6.1e-18	Platelet count;
CRC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.03	-0.55	7.36e-28	Primary sclerosing cholangitis;
CRC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.52	7.86	0.4	5.71e-14	Fibrinogen levels;
CRC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.42	5.97	0.31	5.99e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.4	-5.7	-0.3	2.65e-8	Platelet distribution width;
CRC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.55	-7.43	-0.38	9.72e-13	Multiple sclerosis;
CRC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.43	6.66	0.34	1.14e-10	Cleft lip with or without cleft palate;
CRC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-0.73	-7.23	-0.37	3.35e-12	Magnesium levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20910436	chr10:74856386	P4HA1	0.42	6.04	0.32	4.2e-9	Response to antipsychotic treatment;
CRC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg10298567	chr3:47292165	KIF9	-0.38	-6.22	-0.32	1.51e-9	Colorectal cancer;
CRC	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.71	-7.59	-0.39	3.23e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.55	8.03	0.4	1.81e-14	Aortic root size;
CRC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg24531977	chr5:56204891	C5orf35	0.39	6.04	0.32	4.08e-9	Coronary artery disease;
CRC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.52	-6.64	-0.34	1.26e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08642938	chr17:21117993	TMEM11	0.49	6.45	0.34	3.9e-10	Anxiety disorder;
CRC	cis	rs6681460	0.649	rs1415984	chr1:67002117	A/G	cg02459107	chr1:67143332	SGIP1	0.36	5.61	0.3	4.36e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.64	-7.1	-0.36	7.8e-12	Breast cancer;
CRC	cis	rs4731207	0.596	rs10269342	chr7:124693845	C/G	cg23710748	chr7:124431027	NA	0.42	6.76	0.35	6.39e-11	Cutaneous malignant melanoma;
CRC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.61	0.34	1.57e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.67	11.66	0.54	1.61e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.52	-5.88	-0.31	1.02e-8	Diabetic retinopathy;
CRC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14895029	chr7:2775587	GNA12	-0.45	-6.53	-0.34	2.51e-10	Height;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg11530914	chr16:67281528	FHOD1;SLC9A5	-0.4	-6.0	-0.31	5.3e-9	Daytime sleep phenotypes;
CRC	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.4	6.53	0.34	2.44e-10	Testicular germ cell tumor;
CRC	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.98	-0.31	5.91e-9	Pulmonary function;
CRC	cis	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg18131467	chr2:239335373	ASB1	-0.69	-5.95	-0.31	6.99e-9	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.25	-0.74	8.67e-60	Height;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.5	-6.91	-0.36	2.6e-11	Glycated hemoglobin levels;
CRC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12463550	chr7:65579703	CRCP	0.64	5.77	0.3	1.84e-8	Gout;
CRC	cis	rs12137294	0.829	rs1172154	chr1:205220639	T/G	cg24159697	chr1:205181237	DSTYK	-0.34	-6.08	-0.32	3.39e-9	Red cell distribution width;
CRC	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.52	7.28	0.37	2.51e-12	Glioblastoma;Glioma;
CRC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg13722127	chr7:150037890	RARRES2	0.47	7.88	0.4	4.86e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.45	6.96	0.36	1.89e-11	Monocyte count;
CRC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.75	0.35	6.87e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.71	-12.26	-0.56	9.96e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.63	10.75	0.51	2.7e-23	Prudent dietary pattern;
CRC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg11663144	chr21:46675770	NA	-0.68	-10.66	-0.51	5.41e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg27432699	chr2:27873401	GPN1	0.53	8.23	0.41	4.37e-15	Total body bone mineral density;
CRC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg15786705	chr6:28176104	NA	0.55	5.81	0.31	1.45e-8	Depression;
CRC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg07870213	chr5:140052090	DND1	-0.62	-8.22	-0.41	4.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.65	-7.51	-0.38	5.55e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.57	-10.83	-0.51	1.36e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.69	-9.18	-0.45	4.79e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs2055729	0.677	rs59880252	chr8:9741032	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.7	0.35	9.17e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.44	6.39	0.33	5.6e-10	Body mass index;
CRC	cis	rs3015497	0.646	rs2934687	chr14:51111889	G/A	cg26011998	chr14:51135199	SAV1	-0.44	-5.67	-0.3	3.08e-8	Mean platelet volume;
CRC	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg02683197	chr6:28174875	NA	-0.52	-7.14	-0.37	6.1e-12	Systemic lupus erythematosus;
CRC	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg00129232	chr17:37814104	STARD3	0.46	7.28	0.37	2.45e-12	Self-reported allergy;
CRC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.88	-0.4	4.85e-14	Morning vs. evening chronotype;
CRC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.78	9.46	0.46	6.15e-19	Body mass index;
CRC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-0.82	-9.07	-0.45	1.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.95	-0.31	6.8e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.62	8.02	0.4	1.87e-14	Alzheimer's disease;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.5	-6.88	-0.35	2.96e-11	Obesity-related traits;
CRC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg04586622	chr2:25135609	ADCY3	-0.56	-10.45	-0.5	3.03e-22	Body mass index;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23084309	chr19:6280164	MLLT1	0.38	6.06	0.32	3.72e-9	Interleukin-6 levels;
CRC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-0.56	-7.63	-0.39	2.61e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	9.22e-40	Hypertriglyceridemia;
CRC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.54	8.48	0.42	7.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg15147215	chr3:52552868	STAB1	0.6	10.19	0.49	2.21e-21	Bipolar disorder;
CRC	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.25	0.41	3.79e-15	Lung cancer;
CRC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.85	0.35	3.7e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs55638078	chr2:162524997	T/C	cg03757145	chr4:76555832	CDKL2	-0.66	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.31	12.49	0.57	1.48e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg20387954	chr3:183756860	HTR3D	0.42	7.18	0.37	4.59e-12	Anterior chamber depth;
CRC	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.55	7.17	0.37	4.92e-12	Coronary artery disease;
CRC	cis	rs1881396	0.945	rs62141291	chr2:27784034	C/T	cg27432699	chr2:27873401	GPN1	0.64	8.42	0.42	1.17e-15	Nonalcoholic fatty liver disease;
CRC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Bone mineral density;
CRC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.61	-6.81	-0.35	4.78e-11	Vitiligo;
CRC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg13844804	chr7:814759	HEATR2	0.69	8.18	0.41	6.11e-15	Cerebrospinal P-tau181p levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18570997	chr7:129710291	KLHDC10	0.49	7.49	0.38	6.3e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg19193384	chr17:30244184	NA	-0.65	-7.5	-0.38	6.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.84	-0.35	3.81e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.65	-8.31	-0.42	2.57e-15	Platelet count;
CRC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg03037974	chr15:76606532	NA	-0.55	-8.22	-0.41	4.68e-15	Blood metabolite levels;
CRC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.42	5.75	0.3	2.09e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs4363385	0.818	rs4845512	chr1:152995241	C/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.73	-0.35	7.68e-11	Inflammatory skin disease;
CRC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.63	-10.59	-0.5	9.72e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08219700	chr8:58056026	NA	0.55	6.44	0.33	4.2e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.5	6.63	0.34	1.37e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.47	6.71	0.35	8.5e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.36	0.38	1.47e-12	Breast cancer;
CRC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg03395651	chr16:88107091	BANP	0.61	8.25	0.41	3.73e-15	Menopause (age at onset);
CRC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.56	6.4	0.33	5.2e-10	Bipolar disorder;
CRC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.83	-11.68	-0.54	1.34e-26	Platelet distribution width;
CRC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25072359	chr17:41440525	NA	0.43	5.83	0.31	1.35e-8	Menopause (age at onset);
CRC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.54	8.43	0.42	1.08e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.57	8.58	0.43	3.87e-16	Educational attainment;
CRC	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.43	-0.53	1.03e-25	Coffee consumption (cups per day);
CRC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.61	9.78	0.47	5.24e-20	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.85	-0.4	5.99e-14	Homocysteine levels;
CRC	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07165851	chr6:158734300	TULP4	0.55	6.23	0.32	1.44e-9	Lipoprotein (a) - cholesterol levels;
CRC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-7.13	-0.37	6.43e-12	Type 2 diabetes;
CRC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.57	10.07	0.49	5.62e-21	Body mass index;
CRC	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.71	7.97	0.4	2.59e-14	Systolic blood pressure;
CRC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.21	14.74	0.63	4.02e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.18	-0.37	4.56e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg07699608	chr10:75541558	CHCHD1	0.58	6.25	0.33	1.28e-9	Incident atrial fibrillation;
CRC	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.16	-0.32	2.08e-9	Fractional excretion of uric acid;
CRC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg10298567	chr3:47292165	KIF9	-0.39	-6.09	-0.32	3.13e-9	Colorectal cancer;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg27454412	chr7:1067447	C7orf50	0.5	5.83	0.31	1.31e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg21153622	chr11:89784906	NA	0.44	7.06	0.36	9.64e-12	HDL cholesterol;
CRC	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.69	-9.12	-0.45	7.78e-18	Blood protein levels;
CRC	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.47	-6.62	-0.34	1.49e-10	Eye color traits;
CRC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.5	-8.5	-0.42	6.84e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg19537932	chr12:55886519	OR6C68	-0.65	-8.42	-0.42	1.16e-15	Cancer;
CRC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.39	5.62	0.3	3.99e-8	Educational attainment;
CRC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-10.12	-0.49	3.87e-21	Coronary artery disease;
CRC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.73	-10.2	-0.49	2.1e-21	Longevity;
CRC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg00246817	chr9:123691163	NA	-0.47	-5.97	-0.31	6.22e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.59	-10.12	-0.49	3.88e-21	Calcium levels;
CRC	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.71	0.47	9.15e-20	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.75	-12.81	-0.58	9.21e-31	Breast cancer;
CRC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	1.09	13.04	0.58	1.33e-31	Eosinophil percentage of granulocytes;
CRC	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg17145862	chr1:211918768	LPGAT1	-0.67	-12.34	-0.56	5.23e-29	Leprosy;
CRC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.92	-15.77	-0.66	4.2e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.58	0.34	1.86e-10	Obesity-related traits;
CRC	cis	rs2160860	0.930	rs2729484	chr8:39812080	T/C	cg11363097	chr8:39792086	IDO2	-0.39	-6.44	-0.33	4.18e-10	Blood metabolite levels;
CRC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	cis	rs7731657	0.510	rs2569257	chr5:130245468	A/G	cg08523029	chr5:130500466	HINT1	-0.49	-6.21	-0.32	1.61e-9	Fasting plasma glucose;
CRC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg02896835	chr1:92012615	NA	-0.48	-7.67	-0.39	1.92e-13	Breast cancer;
CRC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-10.89	-0.51	8.97e-24	Electrocardiographic conduction measures;
CRC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg01879757	chr17:41196368	BRCA1	-0.42	-6.24	-0.33	1.31e-9	Menopause (age at onset);
CRC	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.53	6.56	0.34	2.05e-10	Blood protein levels;
CRC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.61	-9.49	-0.46	4.73e-19	Aortic root size;
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.35	0.33	7.32e-10	Life satisfaction;
CRC	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg16898833	chr6:26189333	HIST1H4D	0.67	6.03	0.32	4.43e-9	Depression;
CRC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.28	0.42	3.05e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.28	-0.33	1.05e-9	Type 2 diabetes;
CRC	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.52	-7.06	-0.36	9.72e-12	Coronary artery disease;
CRC	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.67	-10.79	-0.51	1.98e-23	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05716599	chr10:64892916	NRBF2	0.39	5.99	0.31	5.5e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15515537	chr12:133067734	FBRSL1	0.39	6.16	0.32	2.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg23202291	chr11:1979235	NA	0.47	6.56	0.34	2.06e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg13047869	chr3:10149882	C3orf24	0.52	7.32	0.37	1.86e-12	Alzheimer's disease;
CRC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg04025307	chr7:1156635	C7orf50	0.66	7.09	0.36	8.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.52	8.07	0.41	1.29e-14	Colorectal cancer;
CRC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.49	-0.34	3.13e-10	Aortic root size;
CRC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.56	-5.99	-0.31	5.59e-9	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21762534	chr19:17580568	SLC27A1	0.44	7.16	0.37	5.35e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg18830697	chr6:72922368	RIMS1	-0.4	-8.07	-0.41	1.32e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs863345	0.604	rs11264999	chr1:158488860	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.01	-0.31	4.98e-9	Pneumococcal bacteremia;
CRC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.36e-24	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	9.38	0.46	1.1e-18	Alzheimer's disease (late onset);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22242963	chr19:48837349	TMEM143	-0.4	-6.49	-0.34	3.16e-10	Aortic root size;
CRC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.05	-0.32	3.98e-9	Menopause (age at onset);
CRC	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.42	6.79	0.35	5.2e-11	Sitting height ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14614403	chr9:20621888	MLLT3	0.41	6.44	0.33	4.18e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15988263	chr1:44412313	IPO13	0.45	6.29	0.33	1e-9	Anxiety disorder;
CRC	trans	rs2797369	0.882	rs4470856	chr6:101614466	C/A	cg26346621	chr12:6873348	NA	-0.38	-6.1	-0.32	2.96e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02450064	chr17:40260053	DHX58	-0.42	-6.13	-0.32	2.54e-9	Fibrinogen levels;
CRC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.63	-0.3	3.83e-8	Life satisfaction;
CRC	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	8.37	0.42	1.73e-15	Iron status biomarkers;
CRC	cis	rs2160860	0.965	rs2543047	chr8:39819666	A/G	cg11363097	chr8:39792086	IDO2	0.36	5.83	0.31	1.33e-8	Blood metabolite levels;
CRC	cis	rs7212590	0.748	rs7220187	chr17:57897609	C/T	cg10252138	chr17:58120427	NA	-0.53	-5.61	-0.3	4.22e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23147149	chr17:2304328	MNT	0.5	7.34	0.38	1.67e-12	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.31e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg12193833	chr17:30244370	NA	-0.76	-8.87	-0.44	4.62e-17	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15142938	chr11:59383312	OSBP	0.42	6.09	0.32	3.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg00071950	chr4:10020882	SLC2A9	0.39	5.68	0.3	2.9e-8	Psychosis and Alzheimer's disease;
CRC	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg20488157	chr14:104394430	TDRD9	-0.47	-6.35	-0.33	7.21e-10	Bipolar disorder;
CRC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg26182253	chr13:112236782	NA	0.31	6.23	0.32	1.4e-9	Hepatitis;
CRC	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg13662093	chr20:33865505	NA	-0.49	-6.54	-0.34	2.41e-10	Attention deficit hyperactivity disorder;
CRC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg10760299	chr15:45669010	GATM	0.5	7.97	0.4	2.67e-14	Homoarginine levels;
CRC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.25	-16.43	-0.67	1.02e-44	Breast cancer;
CRC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.89	-0.31	9.43e-9	Gut microbiome composition (summer);
CRC	cis	rs4664293	0.669	rs1549387	chr2:160417540	A/G	cg08347373	chr2:160653686	CD302	0.41	6.9	0.36	2.6e-11	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Parkinson's disease;
CRC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.77	10.88	0.51	9.71e-24	Neutrophil percentage of white cells;
CRC	cis	rs6741819	1.000	rs72781779	chr2:7145953	G/A	cg27144453	chr2:7172511	RNF144A	-0.42	-6.29	-0.33	1e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18313530	chr11:111749763	C11orf1;FDXACB1	0.38	6.12	0.32	2.63e-9	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.72	-8.17	-0.41	6.5e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.95	18.13	0.71	2.1e-51	Height;
CRC	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.5	7.39	0.38	1.19e-12	Asthma;
CRC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.91	-0.31	8.38e-9	Type 2 diabetes;
CRC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.25	-0.33	1.27e-9	Type 2 diabetes;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.06	-0.45	1.15e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.7	8.94	0.44	2.78e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.58	6.08	0.32	3.27e-9	Blood protein levels;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.68	-11.47	-0.53	7.67e-26	Paraoxonase activity;
CRC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.59	-0.47	2.27e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13323323	0.728	rs1004631	chr3:44592979	T/G	cg14768256	chr3:44754587	ZNF502	-0.48	-5.99	-0.31	5.36e-9	IgG glycosylation;
CRC	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.45	7.17	0.37	4.95e-12	Schizophrenia;
CRC	cis	rs16924133	0.793	rs67204237	chr11:33174541	G/A	cg05567920	chr11:33183001	CSTF3	-0.75	-5.66	-0.3	3.31e-8	Anger;
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.46	-0.34	3.78e-10	Life satisfaction;
CRC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.49	-0.62	3.8e-37	Body mass index;
CRC	trans	rs4841899	0.777	rs1980852	chr9:137422031	A/G	cg27569887	chr3:30045896	RBMS3	0.34	6.18	0.32	1.87e-9	Stem cell factor levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05210398	chr12:132470983	EP400	0.44	6.23	0.32	1.42e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.83	10.98	0.52	4.27e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.59	-6.75	-0.35	6.73e-11	Coronary artery disease;
CRC	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg16141378	chr3:129829833	LOC729375	0.46	6.55	0.34	2.21e-10	Triglycerides;
CRC	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs12541635	0.966	rs62525736	chr8:107000638	G/C	cg10147462	chr8:107024639	NA	0.45	7.28	0.37	2.43e-12	Age of smoking initiation;
CRC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.51	-8.49	-0.42	7.11e-16	Dupuytren's disease;
CRC	cis	rs2072510	0.593	rs2540493	chr12:96415842	A/C	cg22491680	chr12:96389547	HAL	-0.46	-5.73	-0.3	2.23e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.64e-18	Parkinson's disease;
CRC	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-5.62	-0.3	4.07e-8	Breast cancer;
CRC	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg23234261	chr14:55582407	NA	-0.29	-5.77	-0.3	1.86e-8	Protein biomarker;
CRC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09695851	chr17:3907499	NA	0.74	12.97	0.58	2.42e-31	Type 2 diabetes;
CRC	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg19875578	chr6:126661172	C6orf173	0.44	6.21	0.32	1.64e-9	Male-pattern baldness;
CRC	trans	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg24644049	chr4:85504048	CDS1	0.9	7.37	0.38	1.39e-12	Skin colour saturation;
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs932541	1.000	rs6105609	chr20:16457330	A/G	cg17003395	chr20:16555519	KIF16B	0.41	5.63	0.3	3.82e-8	Intelligence;
CRC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21961583	chr2:170684455	UBR3	0.43	6.14	0.32	2.32e-9	Response to antipsychotic treatment;
CRC	cis	rs1256061	0.624	rs1152578	chr14:64697037	T/C	cg23250157	chr14:64679961	SYNE2	0.46	7.21	0.37	3.79e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.78	7.74	0.39	1.22e-13	LDL cholesterol;
CRC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg22117107	chr15:45993392	NA	-0.44	-8.88	-0.44	4.52e-17	Waist circumference;Weight;
CRC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.18	0.45	4.97e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	15.52	0.65	3.71e-41	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01394034	chr12:98909208	TMPO;LOC100128191	0.37	5.97	0.31	6.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.89	-10.87	-0.51	1.05e-23	Dilated cardiomyopathy;
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg20041105	chr8:143859282	LYNX1	0.46	8.14	0.41	8.2e-15	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02063360	chr14:105452560	C14orf79	0.46	6.59	0.34	1.79e-10	Response to antipsychotic treatment;
CRC	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.51	-6.82	-0.35	4.38e-11	Adiposity;
CRC	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg04662943	chr10:102668895	NA	0.62	7.26	0.37	2.76e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.7	-0.43	1.62e-16	Aortic root size;
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.82	10.67	0.51	5.24e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7849270	1.000	rs2541161	chr9:131884802	C/T	cg13538475	chr9:131942899	NA	0.32	6.27	0.33	1.13e-9	Blood metabolite ratios;
CRC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	9.97	0.48	1.28e-20	Monocyte percentage of white cells;
CRC	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.82	-0.4	7.31e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs11229555	0.645	rs11229429	chr11:58180872	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.54	-6.0	-0.31	5.22e-9	Vitiligo;
CRC	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.47	8.28	0.42	3.15e-15	Post-traumatic stress disorder;
CRC	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg26816564	chr1:7831052	VAMP3	-0.53	-6.21	-0.32	1.56e-9	Inflammatory bowel disease;
CRC	cis	rs629535	0.699	rs539956	chr8:70033647	G/A	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.51	6.37	0.33	6.36e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17554472	chr22:41940697	POLR3H	0.56	5.71	0.3	2.55e-8	Cannabis dependence symptom count;
CRC	cis	rs4838594	0.537	rs3896665	chr10:49689413	A/G	cg17291251	chr10:49678358	ARHGAP22	0.4	6.13	0.32	2.48e-9	Daytime sleep phenotypes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04902049	chr1:36622448	MAP7D1	0.44	6.21	0.32	1.56e-9	Response to antipsychotic treatment;
CRC	trans	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg19694781	chr19:47549865	TMEM160	-0.46	-7.26	-0.37	2.77e-12	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.52	-0.46	4e-19	Capecitabine sensitivity;
CRC	cis	rs910187	0.678	rs6018328	chr20:45813180	T/C	cg27589058	chr20:45804311	EYA2	-0.39	-7.38	-0.38	1.29e-12	Migraine;
CRC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg02175503	chr12:58329896	NA	0.42	5.84	0.31	1.28e-8	Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08742288	chr5:141031147	FCHSD1	0.37	6.08	0.32	3.25e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg10756647	chr7:56101905	PSPH	-0.73	-7.62	-0.39	2.71e-13	Diabetic kidney disease;
CRC	trans	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg16141378	chr3:129829833	LOC729375	-0.47	-6.17	-0.32	1.98e-9	Red cell distribution width;
CRC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.11	-0.41	1.01e-14	Schizophrenia;
CRC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.44	6.25	0.33	1.29e-9	Calcium levels;
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.54	7.37	0.38	1.43e-12	Height;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg07919936	chr2:451875	NA	-0.48	-6.17	-0.32	2e-9	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10573190	chr2:85843190	USP39	0.47	6.5	0.34	2.92e-10	Response to antipsychotic treatment;
CRC	cis	rs6747952	0.899	rs12731	chr2:239087912	G/A	cg17459225	chr2:239074497	NA	0.46	7.93	0.4	3.51e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.56	10.0	0.48	9.94e-21	Common traits (Other);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26474270	chr16:73092823	ZFHX3	0.37	6.03	0.32	4.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11645453	chr3:52864694	ITIH4	0.33	5.83	0.31	1.29e-8	Bipolar disorder;
CRC	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg18850127	chr7:39170497	POU6F2	0.5	6.43	0.33	4.42e-10	IgG glycosylation;
CRC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg00316803	chr15:76480434	C15orf27	0.34	5.64	0.3	3.64e-8	Blood metabolite levels;
CRC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg08213375	chr14:104286397	PPP1R13B	0.37	5.84	0.31	1.25e-8	Reticulocyte count;
CRC	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.03	-0.36	1.23e-11	IgG glycosylation;
CRC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.44e-9	Homoarginine levels;
CRC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg13206674	chr6:150067644	NUP43	0.53	7.61	0.39	2.86e-13	Lung cancer;
CRC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.41	0.46	8.84e-19	Height;
CRC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.78	-0.3	1.72e-8	Lung cancer;
CRC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.25	-0.33	1.27e-9	Aortic root size;
CRC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.56	0.6	1.37e-33	Platelet count;
CRC	cis	rs11212617	1.000	rs10431060	chr11:108288228	A/C	cg14761454	chr11:108092087	ATM;NPAT	0.41	6.12	0.32	2.61e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.47	9.22	0.45	3.59e-18	Vitiligo;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg15786705	chr6:28176104	NA	0.63	9.02	0.45	1.59e-17	Cardiac Troponin-T levels;
CRC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg14711859	chr11:8959438	ASCL3	-0.5	-7.97	-0.4	2.58e-14	Hemoglobin concentration;
CRC	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg20312557	chr2:97357134	FER1L5	-0.6	-5.61	-0.3	4.38e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg18764771	chr6:116381957	FRK	0.23	6.36	0.33	6.76e-10	Cholesterol, total;LDL cholesterol;
CRC	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.72	-0.35	7.81e-11	Putamen volume;
CRC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.52	6.13	0.32	2.53e-9	Renal function-related traits (BUN);
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.81	0.44	7.57e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.08	-0.41	1.29e-14	Height;
CRC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	7.53	0.38	5e-13	Aortic root size;
CRC	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.54	-6.15	-0.32	2.2e-9	Lymphocyte percentage of white cells;
CRC	trans	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg16899823	chr10:58121153	ZWINT	-0.39	-6.03	-0.32	4.38e-9	Survival in rectal cancer;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.32	-5.7	-0.3	2.68e-8	Longevity;Endometriosis;
CRC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.49	-6.96	-0.36	1.81e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.49	8.23	0.41	4.44e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.92	-0.4	3.73e-14	Gut microbiome composition (summer);
CRC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.49	0.42	7.09e-16	Arsenic metabolism;
CRC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	9.17	0.45	5.25e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.62	-0.3	4.05e-8	Tuberculosis;
CRC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Bladder cancer;
CRC	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-0.58	-5.89	-0.31	9.55e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg09184832	chr6:79620586	NA	-0.47	-8.46	-0.42	8.66e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg08885800	chr1:201084119	NA	0.42	5.87	0.31	1.06e-8	Permanent tooth development;
CRC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg23262073	chr20:60523788	NA	-0.46	-7.24	-0.37	3.25e-12	Body mass index;
CRC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg08999081	chr20:33150536	PIGU	0.43	5.68	0.3	3e-8	Protein C levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16672449	chr3:127842622	RUVBL1	0.49	6.33	0.33	7.8e-10	Thyroid stimulating hormone;
CRC	cis	rs10971721	0.730	rs72725361	chr9:33806613	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.85	0.31	1.16e-8	Body mass index;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11122148	chr13:45150705	TSC22D1	-0.4	-6.79	-0.35	5.29e-11	Myopia (pathological);
CRC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.26	-6.36	-0.33	6.74e-10	Caffeine consumption;
CRC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.45	0.5	2.95e-22	Menopause (age at onset);
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg20062050	chr1:227730881	NA	0.36	6.09	0.32	3.18e-9	Menopause (age at onset);
CRC	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg00666640	chr1:248458726	OR2T12	0.33	6.29	0.33	9.92e-10	Common traits (Other);
CRC	cis	rs10512697	0.803	rs13190123	chr5:3578348	G/A	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.52	6.92	0.36	2.3e-11	Alzheimer's disease (survival time);
CRC	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.76	-9.28	-0.46	2.4e-18	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.78	7.97	0.4	2.56e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.63	0.34	1.36e-10	Coronary artery disease;
CRC	trans	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg19894588	chr14:64061835	NA	-0.61	-8.19	-0.41	5.88e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.48	6.43	0.33	4.38e-10	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs61160187	0.548	rs17392014	chr5:60165200	G/A	cg16298547	chr5:60138761	ELOVL7	-0.29	-6.02	-0.32	4.6e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.41	8.18	0.41	6.26e-15	Tonsillectomy;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg18301423	chr5:131593218	PDLIM4	0.38	6.32	0.33	8.74e-10	Acylcarnitine levels;
CRC	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg06287003	chr12:125626642	AACS	-0.63	-7.94	-0.4	3.26e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg03623178	chr6:28175578	NA	0.75	11.28	0.53	3.55e-25	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20420867	chr1:160175396	PEA15	0.41	6.04	0.32	4.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.75	-14.17	-0.62	6.57e-36	Body mass index;
CRC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg08314208	chr16:67682810	RLTPR	-0.54	-5.94	-0.31	7.18e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2882667	0.861	rs13176902	chr5:138393329	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-6.12	-0.32	2.63e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg18099408	chr3:52552593	STAB1	0.35	5.88	0.31	9.97e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.61	8.44	0.42	1.03e-15	Arsenic metabolism;
CRC	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-5.7	-0.3	2.61e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg15962314	chr1:44399869	ARTN	0.3	5.76	0.3	1.9e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.54	-8.9	-0.44	3.86e-17	Menarche (age at onset);
CRC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.5	9.29	0.46	2.19e-18	Total body bone mineral density;
CRC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.66	-0.39	2.06e-13	Mean corpuscular volume;
CRC	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg17218026	chr1:154582156	ADAR	0.57	9.24	0.45	3.11e-18	Blood protein levels;
CRC	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-7.97	-0.4	2.67e-14	Post bronchodilator FEV1;
CRC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg24849736	chr1:201084428	NA	0.47	6.46	0.34	3.81e-10	Permanent tooth development;
CRC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.69	11.66	0.54	1.53e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.78	11.25	0.53	4.48e-25	Breast cancer;
CRC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	6.92	0.36	2.4e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.1	-0.41	1.12e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2289681	0.525	rs34637106	chr17:42985772	C/T	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.5	-6.18	-0.32	1.89e-9	Cognitive function;
CRC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.38	-0.5	5.03e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.97	0.4	2.72e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.48	6.51	0.34	2.82e-10	HDL cholesterol;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	0.97	9.77	0.47	5.9e-20	Gut microbiota (bacterial taxa);
CRC	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg11657440	chr19:46296263	DMWD	0.58	5.93	0.31	7.81e-9	Eosinophil counts;
CRC	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.34	6.87	0.35	3.2e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs236352	0.576	rs3756905	chr6:36843777	C/T	cg10099585	chr6:36853529	C6orf89	-0.46	-6.47	-0.34	3.6e-10	Heart rate;
CRC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg17724175	chr1:150552817	MCL1	0.47	7.08	0.36	8.64e-12	Melanoma;
CRC	cis	rs6968419	0.747	rs6959237	chr7:115876365	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.31	-0.33	8.85e-10	Intraocular pressure;
CRC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.49	-0.5	2.16e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.62	-11.44	-0.53	9.41e-26	Educational attainment;
CRC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.19	-0.37	4.36e-12	QT interval;
CRC	cis	rs16924133	0.793	rs68188425	chr11:33196919	A/G	cg05567920	chr11:33183001	CSTF3	-0.78	-6.09	-0.32	3.22e-9	Anger;
CRC	cis	rs4908768	0.501	rs6577499	chr1:8612104	C/G	cg20416874	chr1:8611966	RERE	0.43	6.08	0.32	3.38e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.56	-8.11	-0.41	1.01e-14	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01778450	chr5:92920498	NR2F1	0.41	6.7	0.35	9.15e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg18187862	chr3:45730750	SACM1L	0.44	6.06	0.32	3.64e-9	Primary sclerosing cholangitis;
CRC	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.63	-8.49	-0.42	6.96e-16	Facial morphology (factor 19);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21939482	chr7:6388130	C7orf70	-0.56	-6.94	-0.36	2.15e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.59	8.86	0.44	5.17e-17	Aortic root size;
CRC	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.84	11.24	0.53	5.23e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg10729496	chr3:10149963	C3orf24	0.52	6.41	0.33	5.07e-10	Alzheimer's disease;
CRC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg14979609	chr8:8086686	FLJ10661	0.37	6.04	0.32	4.13e-9	Joint mobility (Beighton score);
CRC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.46	-0.34	3.84e-10	Reticulocyte fraction of red cells;
CRC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06481639	chr22:41940642	POLR3H	-0.5	-5.79	-0.3	1.62e-8	Vitiligo;
CRC	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg02135003	chr7:105160482	PUS7	0.51	8.03	0.4	1.7e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.66	7.65	0.39	2.29e-13	White matter hyperintensity burden;
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.25	-0.41	3.81e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.41	0.33	5e-10	Cognitive test performance;
CRC	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg19438565	chr8:143695827	ARC	-0.44	-6.08	-0.32	3.35e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.7	6.92	0.36	2.37e-11	Incident atrial fibrillation;
CRC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	trans	rs11264213	0.711	rs10752603	chr1:36161576	C/A	cg07175433	chr4:21947400	KCNIP4	0.37	6.36	0.33	6.71e-10	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08694802	chr16:15149554	NTAN1	0.45	6.04	0.32	4.27e-9	Thyroid stimulating hormone;
CRC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.61	-0.75	3.5e-61	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19721801	chr19:12807424	FBXW9	0.45	6.23	0.32	1.4e-9	Anxiety disorder;
CRC	trans	rs61883261	0.764	rs11025864	chr11:21008423	A/G	cg13263472	chr14:102593156	HSP90AA1	-0.63	-6.24	-0.33	1.32e-9	Response to amphetamines;
CRC	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.18	12.42	0.56	2.63e-29	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.46	6.44	0.33	4.12e-10	Alcohol dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22834172	chr17:37774349	NA	0.44	6.15	0.32	2.22e-9	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.49	-6.36	-0.33	6.59e-10	Gut microbiome composition (summer);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08045063	chr3:43147672	C3orf39	0.47	6.33	0.33	7.97e-10	Survival in pancreatic cancer;
CRC	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg06484146	chr7:12443880	VWDE	-0.56	-7.22	-0.37	3.67e-12	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg22110888	chr17:80059540	CCDC57	0.39	6.25	0.33	1.29e-9	Life satisfaction;
CRC	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.71	-11.22	-0.53	5.79e-25	Lung cancer;
CRC	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.41	-0.59	5.06e-33	Hypospadias;
CRC	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg24416660	chr17:73865998	NA	-0.4	-6.08	-0.32	3.34e-9	Psoriasis;
CRC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.4	6.48	0.34	3.45e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552172	0.887	rs12729321	chr1:145645820	G/T	cg11743829	chr1:145714124	CD160	-0.4	-6.09	-0.32	3.23e-9	Breast cancer;
CRC	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.52	-0.38	5.38e-13	Morning vs. evening chronotype;
CRC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.45	7.68	0.39	1.84e-13	Major depressive disorder;
CRC	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg13491945	chr12:107078410	RFX4	0.37	6.29	0.33	1.03e-9	Heart rate;
CRC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.4	5.77	0.3	1.82e-8	Rheumatoid arthritis;
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.71	11.86	0.55	2.87e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.66	9.35	0.46	1.42e-18	Vitamin D levels;
CRC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.2	0.67	8.61e-44	Chronic sinus infection;
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-6.53	-0.34	2.53e-10	Lymphocyte counts;
CRC	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.53	8.09	0.41	1.15e-14	Testicular germ cell tumor;
CRC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.33	-0.46	1.66e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg02033258	chr5:131593261	PDLIM4	0.39	6.41	0.33	5.13e-10	Blood metabolite levels;
CRC	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.87	0.35	3.14e-11	Neuroticism;
CRC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.9	-0.48	2.09e-20	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.52	6.97	0.36	1.79e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs860295	0.702	rs12041534	chr1:155407096	A/G	cg02153340	chr1:155202674	NA	0.5	6.48	0.34	3.39e-10	Body mass index;
CRC	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg22089800	chr15:90895588	ZNF774	0.49	7.91	0.4	4.07e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.46	8.42	0.42	1.18e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9549328	0.544	rs66893681	chr13:113617499	A/G	cg08614441	chr13:113633676	MCF2L	0.4	7.06	0.36	9.78e-12	Systolic blood pressure;
CRC	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.37	-6.72	-0.35	8.23e-11	Dilated cardiomyopathy;
CRC	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.35	5.62	0.3	4.12e-8	Survival in rectal cancer;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.52	9.66	0.47	1.37e-19	Acylcarnitine levels;
CRC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.85	-18.45	-0.71	1.13e-52	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	1.1	12.97	0.58	2.42e-31	Obesity-related traits;
CRC	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg15654264	chr1:150340011	RPRD2	-0.37	-5.79	-0.3	1.67e-8	Migraine;
CRC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	9.7	0.47	9.74e-20	Platelet count;
CRC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg08270630	chr22:50330655	NA	-0.43	-5.77	-0.3	1.87e-8	Schizophrenia;
CRC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.45	-8.31	-0.42	2.54e-15	Reticulocyte fraction of red cells;
CRC	cis	rs4509693	0.782	rs12268880	chr10:102495285	G/C	cg23167259	chr10:102495509	NA	-0.47	-5.87	-0.31	1.06e-8	Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.01	-0.36	1.39e-11	Breast cancer;
CRC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg25164649	chr6:28176230	NA	0.61	8.92	0.44	3.4e-17	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01246254	chr10:124134882	PLEKHA1	0.54	8.91	0.44	3.6e-17	Liver disease severity in Alagille syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22312910	chr11:65082369	CDC42EP2	0.47	6.63	0.34	1.37e-10	Anxiety disorder;
CRC	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.81	-0.35	4.51e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg20608306	chr11:116969690	SIK3	-0.34	-6.34	-0.33	7.68e-10	Subjective well-being;
CRC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg09658497	chr7:2847517	GNA12	0.37	6.03	0.32	4.43e-9	Loneliness (linear analysis);
CRC	cis	rs10413329	0.782	rs10408457	chr19:13101196	T/G	cg13338734	chr19:13113668	NFIX	0.33	5.66	0.3	3.23e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.55	-0.34	2.28e-10	Lung cancer;
CRC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.33	6.03	0.32	4.52e-9	Erythrocyte sedimentation rate;
CRC	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.27	-0.33	1.13e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.68	-12.62	-0.57	4.58e-30	Breast cancer;
CRC	cis	rs2249694	0.878	rs2480256	chr10:135352514	A/G	cg20169779	chr10:135381914	SYCE1	0.54	8.63	0.43	2.6e-16	Obesity-related traits;
CRC	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.67	7.88	0.4	4.72e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.47	5.78	0.3	1.76e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.49	-8.84	-0.44	5.9e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg07636037	chr3:49044803	WDR6	-0.63	-6.76	-0.35	6.2e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.1	0.45	9.14e-18	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16025468	chr1:119682959	WARS2	0.36	5.97	0.31	6.27e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17994379	chr17:43025264	KIF18B	0.44	6.55	0.34	2.27e-10	Response to antipsychotic treatment;
CRC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13897145	chr3:113557582	GRAMD1C	0.5	6.62	0.34	1.44e-10	Thyroid stimulating hormone;
CRC	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg26893861	chr17:41843967	DUSP3	-0.7	-6.44	-0.33	4.34e-10	Cognitive function;
CRC	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg09654669	chr8:57350985	NA	-0.39	-5.71	-0.3	2.54e-8	Obesity-related traits;
CRC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.56	-6.17	-0.32	1.97e-9	Vitiligo;
CRC	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-6.93	-0.36	2.28e-11	Osteoarthritis;
CRC	cis	rs12431939	0.571	rs12589840	chr14:51720038	A/G	cg23942311	chr14:51606299	NA	0.53	6.93	0.36	2.27e-11	Cancer;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	6.58	0.34	1.82e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.65	-8.23	-0.41	4.31e-15	Mean platelet volume;
CRC	cis	rs6546324	1.000	rs2902026	chr2:67856440	G/C	cg15745817	chr2:67799979	NA	-0.29	-5.76	-0.3	1.96e-8	Endometriosis;
CRC	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21659725	chr3:3221576	CRBN	-0.67	-7.43	-0.38	9.42e-13	Menarche (age at onset);
CRC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
CRC	cis	rs853679	1.000	rs853676	chr6:28299687	C/T	cg06470822	chr6:28175283	NA	0.65	6.56	0.34	2.04e-10	Depression;
CRC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.33	0.37	1.76e-12	Aortic root size;
CRC	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.66	-10.72	-0.51	3.52e-23	Hepatocellular carcinoma;
CRC	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg04989706	chr14:50066350	PPIL5	-0.59	-8.07	-0.41	1.35e-14	Carotid intima media thickness;
CRC	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg17410650	chr12:54324560	NA	-0.37	-6.7	-0.35	8.79e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09961100	chr19:5978428	RANBP3	0.46	6.42	0.33	4.88e-10	Anxiety disorder;
CRC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg17948913	chr5:572064	NA	0.5	5.79	0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11948739	0.501	rs4254896	chr5:130363499	C/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.96	-0.31	6.37e-9	Pediatric bone mineral content (hip);
CRC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg17724175	chr1:150552817	MCL1	0.39	6.0	0.31	5.11e-9	Melanoma;
CRC	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg06307176	chr5:131281290	NA	0.41	6.1	0.32	2.96e-9	Life satisfaction;
CRC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg20387954	chr3:183756860	HTR3D	0.42	7.17	0.37	5.04e-12	Anterior chamber depth;
CRC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.48	-6.99	-0.36	1.5e-11	Height;
CRC	trans	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg02674126	chr19:40336878	FBL	0.41	6.52	0.34	2.6200000000000003e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.63	10.0	0.48	9.8e-21	Height;
CRC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.52	7.7	0.39	1.65e-13	Blood protein levels;
CRC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.71	-11.94	-0.55	1.51e-27	Breast cancer;
CRC	cis	rs4750440	0.642	rs7921741	chr10:14030776	G/A	cg00551146	chr10:14014579	FRMD4A	0.37	5.91	0.31	8.59e-9	Adiponectin levels;
CRC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.83	13.38	0.59	6.67e-33	Platelet distribution width;
CRC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.48	7.09	0.36	8.27e-12	Obesity-related traits;
CRC	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.28	6.03	0.32	4.42e-9	Educational attainment (years of education);
CRC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.74	12.99	0.58	1.92e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg26353448	chr1:248524236	OR2T4	-0.31	-5.91	-0.31	8.39e-9	Common traits (Other);
CRC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.47	0.42	8.48e-16	Menarche (age at onset);
CRC	cis	rs4679121	0.730	rs62264698	chr3:126159711	T/G	cg05485589	chr3:126194908	ZXDC	-0.8	-5.67	-0.3	3.12e-8	Pursuit maintenance gain;
CRC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.58	8.85	0.44	5.5e-17	Alcohol dependence;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08907850	chr10:1094976	IDI1	0.54	6.98	0.36	1.63e-11	Thyroid stimulating hormone;
CRC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.39	6.47	0.34	3.58e-10	Parkinson's disease;
CRC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.67	10.89	0.51	8.91e-24	Anterior chamber depth;
CRC	cis	rs6445525	0.806	rs4688634	chr3:66008310	A/G	cg06109867	chr3:66002991	MAGI1	-0.37	-5.92	-0.31	8.08e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14083397	chr20:388473	RBCK1	0.45	6.53	0.34	2.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.75	0.3	2.01e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.61	-0.39	3e-13	Gut microbiome composition (summer);
CRC	cis	rs16867321	0.950	rs1919152	chr2:181507765	C/T	cg23363182	chr2:181467187	NA	-0.51	-6.51	-0.34	2.83e-10	Obesity;
CRC	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg06172871	chr16:72088244	HP	0.41	6.05	0.32	4e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg24438145	chr17:48624694	SPATA20	0.44	6.37	0.33	6.46e-10	Type 2 diabetes;
CRC	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.81	-14.1	-0.61	1.26e-35	Lewy body disease;
CRC	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg06092702	chr1:163392909	NA	-0.55	-8.78	-0.44	9.18e-17	Motion sickness;
CRC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.8	0.3	1.59e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.7	10.58	0.5	1.03e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	9.87	0.48	2.72e-20	Height;
CRC	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.48	-0.38	6.7e-13	Blood metabolite levels;
CRC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.6	8.92	0.44	3.39e-17	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.48	-7.73	-0.39	1.36e-13	Body mass index;
CRC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.75	-12.32	-0.56	5.96e-29	Height;
CRC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25517755	chr10:38738941	LOC399744	0.41	5.91	0.31	8.44e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg19622623	chr12:86230825	RASSF9	-0.4	-6.48	-0.34	3.3e-10	Major depressive disorder;
CRC	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.45	6.3	0.33	9.5e-10	Subjective well-being;
CRC	cis	rs4789294	0.806	rs9910471	chr17:74393478	G/C	cg06840243	chr17:74442338	UBE2O	0.41	6.04	0.32	4.22e-9	Lymphocyte percentage of white cells;
CRC	trans	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.43	-0.38	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.3	1.75e-8	Response to antipsychotic treatment;
CRC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg25124228	chr12:125621409	AACS	-0.58	-9.52	-0.46	3.8e-19	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.15	-0.37	5.67e-12	Menopause (age at onset);
CRC	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg14593290	chr7:50529359	DDC	-0.44	-6.4	-0.33	5.38e-10	Body mass index;
CRC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	10.75	0.51	2.58e-23	Personality dimensions;
CRC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.36	-7.57	-0.39	3.83e-13	Cutaneous nevi;
CRC	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.13	-0.32	2.46e-9	Schizophrenia;
CRC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.54	-6.97	-0.36	1.77e-11	IgG glycosylation;
CRC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg27565382	chr3:53032988	SFMBT1	0.81	6.46	0.34	3.82e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.53	6.35	0.33	7.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg09491104	chr22:46646882	C22orf40	-0.43	-6.38	-0.33	6.18e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.49	0.46	4.85e-19	Lung cancer;
CRC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg24300038	chr13:113819356	PROZ	0.49	6.61	0.34	1.58e-10	Platelet distribution width;
CRC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	14.66	0.63	8.41e-38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.58	-0.57	6.72e-30	Alzheimer's disease;
CRC	cis	rs56399783	0.901	rs73033407	chr7:2878857	G/C	cg19731401	chr7:2775893	GNA12	0.62	6.26	0.33	1.17e-9	Childhood ear infection;
CRC	trans	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg21153622	chr11:89784906	NA	0.45	7.14	0.37	5.85e-12	HDL cholesterol;
CRC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg24562669	chr7:97807699	LMTK2	0.42	7.04	0.36	1.1e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11645453	chr3:52864694	ITIH4	0.32	5.99	0.31	5.44e-9	Bipolar disorder;
CRC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.11	-0.37	7.15e-12	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg25456477	chr12:86230367	RASSF9	0.32	5.63	0.3	3.87e-8	Major depressive disorder;
CRC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.51	8.06	0.41	1.38e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg16606324	chr3:10149918	C3orf24	0.69	9.06	0.45	1.15e-17	Alzheimer's disease;
CRC	trans	rs11581859	0.950	rs58724269	chr1:99372616	C/T	cg12183875	chr3:169587454	LRRC31	0.27	6.43	0.33	4.37e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs9462027	0.628	rs7752060	chr6:34760325	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg12273811	chr6:28175739	NA	0.68	5.73	0.3	2.22e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.46	-0.67	7.77e-45	Hip circumference;
CRC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg10790698	chr19:18539756	SSBP4	-0.46	-8.78	-0.44	9.28e-17	Breast cancer;
CRC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.65	-8.0	-0.4	2.11e-14	Rheumatoid arthritis;
CRC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.79	14.13	0.61	9.31e-36	Mean platelet volume;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg16721101	chr20:25176146	ENTPD6	-0.7	-6.08	-0.32	3.35e-9	Cognitive function;
CRC	cis	rs911119	0.866	rs4346460	chr20:23569400	C/T	cg16589663	chr20:23618590	CST3	0.42	5.93	0.31	7.51e-9	Chronic kidney disease;
CRC	trans	rs1864729	1.000	rs2635162	chr8:98283629	C/T	cg08679828	chr8:102218111	ZNF706	-0.59	-7.52	-0.38	5.11e-13	Estradiol plasma levels (breast cancer);
CRC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs539514	0.664	rs634729	chr13:76307981	C/T	cg04757411	chr13:76259545	LMO7	-0.35	-5.97	-0.31	6.25e-9	Type 1 diabetes;
CRC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs315934	0.664	rs315921	chr2:113872051	C/T	cg24553058	chr2:113831203	IL1F10	-0.52	-5.67	-0.3	3.15e-8	Dysmenorrheic pain;
CRC	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.68	10.13	0.49	3.55e-21	Blood protein levels;
CRC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16262614	chr3:133464971	TF	0.34	6.2	0.32	1.69e-9	Iron status biomarkers;
CRC	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.6	5.72	0.3	2.43e-8	White matter integrity;
CRC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg13256891	chr4:100009986	ADH5	0.42	6.08	0.32	3.28e-9	Alcohol dependence;
CRC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.59	-8.74	-0.43	1.2e-16	Lung cancer;
CRC	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.61	8.97	0.44	2.35e-17	Schizophrenia;
CRC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-8.16	-0.41	7.37e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.53	-11.41	-0.53	1.25e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs4711350	0.862	rs602399	chr6:33713779	C/T	cg07979401	chr6:33739406	LEMD2	0.48	6.0	0.31	5.1e-9	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11801572	chr13:77601451	FBXL3	0.43	6.21	0.32	1.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs2882667	0.690	rs1651358	chr5:138081007	A/G	cg09476006	chr5:138032270	NA	-0.55	-9.64	-0.47	1.54e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs282587	0.627	rs388242	chr13:113415188	T/C	cg04656015	chr13:113407548	ATP11A	0.62	7.98	0.4	2.52e-14	Glycated hemoglobin levels;
CRC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	6.36	0.33	6.94e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs35520189	0.557	rs12617864	chr2:113714976	G/T	cg12858261	chr2:113808755	IL1F8	-0.47	-6.68	-0.35	1.02e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg12458913	chr13:53173898	NA	0.52	8.02	0.4	1.88e-14	Lewy body disease;
CRC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg20512303	chr5:131592959	PDLIM4	0.38	6.68	0.35	1.01e-10	Breast cancer;
CRC	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.64	6.56	0.34	2.1e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.6	0.34	1.68e-10	Bladder cancer;
CRC	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-25.11	-0.81	1.83e-78	Exhaled nitric oxide output;
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.34	-5.82	-0.31	1.43e-8	Monocyte count;
CRC	cis	rs17767392	0.836	rs61989383	chr14:71983644	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.87	-0.35	3.2e-11	Mitral valve prolapse;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20317180	chr19:56111252	FIZ1;ZNF524	0.48	6.27	0.33	1.14e-9	Thyroid stimulating hormone;
CRC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.58	-8.81	-0.44	7.37e-17	Body mass index;
CRC	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg22153745	chr1:153894579	GATAD2B	-0.57	-7.89	-0.4	4.58e-14	Total cholesterol levels;
CRC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg25876840	chr17:41920477	NA	-0.53	-7.8	-0.4	8.01e-14	Triglycerides;
CRC	cis	rs3751196	0.901	rs74901375	chr12:104199707	C/T	cg02344784	chr12:104178138	NT5DC3	0.69	6.98	0.36	1.67e-11	Sense of smell;
CRC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-7.13	-0.37	6.5e-12	Colorectal cancer;
CRC	cis	rs35883536	1.000	rs11586815	chr1:101089079	C/T	cg14515779	chr1:101123966	NA	-0.42	-8.11	-0.41	1.02e-14	Monocyte count;
CRC	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg08632701	chr21:37451849	NA	0.4	6.29	0.33	1.03e-9	Mitral valve prolapse;
CRC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.06e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.83	-10.86	-0.51	1.13e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg20959480	chr12:125599568	AACS	0.39	5.69	0.3	2.83e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.54	7.81	0.4	7.84e-14	Longevity;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg09877947	chr5:131593287	PDLIM4	0.44	7.99	0.4	2.37e-14	Breast cancer;
CRC	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.38	-11.56	-0.54	3.59e-26	Psoriasis vulgaris;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.44	-9.57	-0.47	2.67e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.5	0.65	4.52e-41	Bipolar disorder;
CRC	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg10437265	chr15:77819839	NA	-0.68	-12.24	-0.56	1.2e-28	Type 2 diabetes;
CRC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.48	-6.61	-0.34	1.51e-10	Aortic root size;
CRC	cis	rs7605827	0.866	rs2287275	chr2:15658828	C/T	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.8e-9	Educational attainment (years of education);
CRC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	9.32	0.46	1.78e-18	Eye color traits;
CRC	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg05283184	chr6:79620031	NA	-0.44	-6.38	-0.33	5.87e-10	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.44	6.82	0.35	4.5e-11	Monocyte count;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg27266060	chr8:22091797	NA	0.35	5.8	0.3	1.53e-8	Hypertriglyceridemia;
CRC	trans	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg07817883	chr1:32538562	TMEM39B	1.24	10.63	0.51	6.95e-23	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.13	-0.41	8.7e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.72	11.21	0.53	6.63e-25	Intelligence (multi-trait analysis);
CRC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg25972092	chr12:117363249	FBXW8	0.56	6.66	0.34	1.17e-10	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.38	0.59	6.83e-33	Chronic sinus infection;
CRC	cis	rs3018066	0.748	rs11942153	chr4:106960172	C/T	cg01869342	chr4:106983673	TBCK	0.45	6.8	0.35	4.97e-11	Cancer;
CRC	cis	rs11166629	1.000	rs1867059	chr8:135647019	A/G	cg27224718	chr8:135614730	ZFAT	0.52	7.67	0.39	1.95e-13	Smoking quantity;
CRC	cis	rs7527798	0.592	rs1323722	chr1:207823405	C/T	cg09232269	chr1:207846808	CR1L	-0.51	-8.25	-0.41	3.81e-15	Erythrocyte sedimentation rate;
CRC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg13072238	chr3:49761600	GMPPB	-0.54	-5.85	-0.31	1.19e-8	Menarche (age at onset);
CRC	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.54	9.02	0.45	1.65e-17	Dupuytren's disease;
CRC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.78	-9.79	-0.48	4.8e-20	Cognitive test performance;
CRC	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg09659197	chr4:152720779	NA	-0.42	-8.51	-0.42	6.31e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.81	13.62	0.6	8.16e-34	Menopause (age at onset);
CRC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.92	17.42	0.69	1.29e-48	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg13010199	chr12:38710504	ALG10B	-0.42	-5.94	-0.31	7.34e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.75	-0.43	1.11e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.49	7.0	0.36	1.46e-11	Schizophrenia;
CRC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.63	0.6	7.31e-34	Platelet count;
CRC	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.47	-7.78	-0.39	9.29e-14	Prevalent atrial fibrillation;
CRC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.72	-11.0	-0.52	3.61e-24	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9462027	0.527	rs11755393	chr6:34824636	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.9	-0.31	9.06e-9	Systemic lupus erythematosus;
CRC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.6	-9.37	-0.46	1.19e-18	Colorectal cancer;
CRC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg04110750	chr16:69646130	NFAT5	-0.53	-7.13	-0.37	6.45e-12	IgE levels;
CRC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.43	-6.48	-0.34	3.32e-10	Body mass index;
CRC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.79	11.59	0.54	2.81e-26	Schizophrenia;
CRC	cis	rs4478858	0.735	rs12408524	chr1:31835853	A/G	cg00250761	chr1:31883323	NA	-0.42	-7.75	-0.39	1.14e-13	Alcohol dependence;
CRC	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.49	8.52	0.43	5.72e-16	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.18	25.39	0.81	1.6e-79	IgG glycosylation;
CRC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12315302	chr6:26189340	HIST1H4D	0.77	5.99	0.31	5.51e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22664697	chr19:2819641	ZNF554	0.37	5.97	0.31	6.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg18301423	chr5:131593218	PDLIM4	0.29	5.69	0.3	2.86e-8	Blood metabolite levels;
CRC	cis	rs3018066	0.867	rs13113845	chr4:107172377	C/G	cg01869342	chr4:106983673	TBCK	-0.36	-5.63	-0.3	3.82e-8	Cancer;
CRC	cis	rs7923609	0.967	rs10509189	chr10:65264126	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.94	-0.31	7.27e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.15	0.41	7.5e-15	Lung cancer;
CRC	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.53	-9.51	-0.46	4.11e-19	Amyotrophic lateral sclerosis (age of onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22134634	chr17:57970430	TUBD1;RPS6KB1	0.44	6.01	0.31	5.03e-9	Response to antipsychotic treatment;
CRC	cis	rs11098699	0.821	rs11942230	chr4:124199453	A/G	cg09941581	chr4:124220074	SPATA5	0.41	5.95	0.31	6.87e-9	Mosquito bite size;
CRC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.63	0.3	3.95e-8	Schizophrenia;
CRC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg24308560	chr3:49941425	MST1R	-0.43	-6.18	-0.32	1.85e-9	Resting heart rate;
CRC	cis	rs11212617	0.967	rs7395528	chr11:108056708	A/C	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.39	0.33	5.8e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4664293	0.585	rs10460301	chr2:160635077	A/G	cg08347373	chr2:160653686	CD302	0.36	5.96	0.31	6.5e-9	Monocyte percentage of white cells;
CRC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.49	7.17	0.37	4.99e-12	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.58	-9.53	-0.47	3.66e-19	Obesity-related traits;
CRC	cis	rs4290604	0.748	rs4621125	chr2:238080214	G/A	cg23555395	chr2:238036564	NA	-0.61	-6.14	-0.32	2.34e-9	Asthma;
CRC	cis	rs6880778	0.505	rs7445978	chr5:40381056	A/T	cg09067459	chr5:40385259	NA	0.46	8.01	0.4	2.07e-14	Inflammatory bowel disease;
CRC	cis	rs17127169	0.536	rs112625995	chr1:65496627	A/G	cg01340542	chr1:65468273	NA	0.98	6.86	0.35	3.38e-11	Sitting height ratio;
CRC	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg05784532	chr1:230284198	GALNT2	0.43	5.79	0.3	1.66e-8	Coronary artery disease;
CRC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg04738700	chr2:239367308	NA	-0.47	-6.03	-0.32	4.44e-9	Multiple system atrophy;
CRC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.4	-6.37	-0.33	6.4e-10	Blood metabolite levels;
CRC	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17808901	chr3:39093368	WDR48	0.52	7.07	0.36	9.44e-12	Thyroid stimulating hormone;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg15786705	chr6:28176104	NA	0.64	9.21	0.45	3.94e-18	Cardiac Troponin-T levels;
CRC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.11	0.41	1.03e-14	Platelet count;
CRC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg11271282	chr2:238384023	NA	0.44	5.98	0.31	5.68e-9	Prostate cancer;
CRC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg05562828	chr17:3906858	NA	-0.65	-11.11	-0.52	1.48e-24	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09870606	chr16:74641419	GLG1	0.41	6.16	0.32	2.14e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.56	6.27	0.33	1.15e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs6662572	0.737	rs6702764	chr1:46252717	A/G	cg08644498	chr1:46502608	NA	-0.43	-6.92	-0.36	2.43e-11	Blood protein levels;
CRC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.57	-8.73	-0.43	1.27e-16	Height;
CRC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-8.91	-0.44	3.44e-17	Monocyte count;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg27094323	chr7:1216898	NA	-0.38	-6.22	-0.32	1.53e-9	Longevity;Endometriosis;
CRC	trans	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.23e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.83	0.35	4.22e-11	Mean platelet volume;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01171360	chr6:293285	DUSP22	-0.46	-6.6	-0.34	1.61e-10	Menopause (age at onset);
CRC	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg25182066	chr10:30743637	MAP3K8	-0.41	-6.08	-0.32	3.4e-9	Inflammatory bowel disease;
CRC	cis	rs858239	0.799	rs10279941	chr7:23370508	C/G	cg00469287	chr7:23338798	C7orf30	0.48	6.22	0.32	1.51e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg00186954	chr11:8933980	ST5;C11orf17	0.45	7.44	0.38	8.57e-13	Hemoglobin concentration;
CRC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00166722	chr3:10149974	C3orf24	0.41	5.76	0.3	1.95e-8	Alzheimer's disease;
CRC	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11610739	chr17:40075306	ACLY	0.41	6.0	0.31	5.22e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.49	-7.34	-0.37	1.74e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9462027	0.628	rs2764198	chr6:34706128	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.51	-8.46	-0.42	9.08e-16	Schizophrenia;
CRC	cis	rs73206853	0.841	rs6606683	chr12:110712212	T/G	cg12870014	chr12:110450643	ANKRD13A	0.8	7.72	0.39	1.39e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.73	12.66	0.57	3.42e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	9.59	0.47	2.2e-19	Height;
CRC	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs10411161	0.702	rs11878580	chr19:52388485	C/T	cg22319618	chr22:45562946	NUP50	-0.65	-7.22	-0.37	3.63e-12	Breast cancer;
CRC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg23127183	chr11:57508653	C11orf31	-0.52	-6.92	-0.36	2.38e-11	Schizophrenia;
CRC	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg04132472	chr17:19861366	AKAP10	0.44	6.79	0.35	5.22e-11	Schizophrenia;
CRC	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.56	8.3	0.42	2.74e-15	Schizophrenia;
CRC	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.38	6.87	0.35	3.18e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	0.8	8.27	0.41	3.28e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.45	5.93	0.31	7.79e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.76	0.3	1.98e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9311676	0.632	rs7624283	chr3:58369897	G/A	cg06643156	chr3:58380774	PXK	0.42	6.39	0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.41	-8.29	-0.42	2.94e-15	Renal cell carcinoma;
CRC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	5.86	0.31	1.1e-8	Tonsillectomy;
CRC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.64	-7.6	-0.39	3.17e-13	Diabetic retinopathy;
CRC	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.76	0.51	2.49e-23	Coffee consumption (cups per day);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05998513	chr10:97321375	SORBS1	0.46	6.4	0.33	5.2400000000000005e-10	Anxiety disorder;
CRC	cis	rs6496667	0.779	rs7168898	chr15:90943065	G/A	cg04176472	chr15:90893244	GABARAPL3	0.58	7.58	0.39	3.6e-13	Rheumatoid arthritis;
CRC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg12927641	chr6:109611667	NA	-0.33	-5.73	-0.3	2.25e-8	Reticulocyte fraction of red cells;
CRC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg03948781	chr1:205179583	DSTYK	0.4	5.63	0.3	3.93e-8	Red blood cell count;
CRC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.51	7.59	0.39	3.36e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs863345	0.604	rs6697656	chr1:158520737	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-7.1	-0.36	7.73e-12	Pneumococcal bacteremia;
CRC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.62	9.63	0.47	1.69e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9292777	0.777	rs12523160	chr5:40385790	A/T	cg09067459	chr5:40385259	NA	-0.56	-9.28	-0.46	2.31e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.48	-8.87	-0.44	4.67e-17	Total body bone mineral density;
CRC	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg07636037	chr3:49044803	WDR6	-0.65	-6.42	-0.33	4.88e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05961215	chr15:35280640	ZNF770	0.44	6.2	0.32	1.7e-9	Response to antipsychotic treatment;
CRC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	7.94	0.4	3.16e-14	Monocyte percentage of white cells;
CRC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20092199	chr4:1342459	KIAA1530	-0.38	-6.17	-0.32	2.02e-9	Obesity-related traits;
CRC	cis	rs12529935	0.609	rs77466181	chr6:90959209	G/A	cg06866423	chr6:90926672	BACH2	0.75	7.0	0.36	1.46e-11	Systemic lupus erythematosus;
CRC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.15e-10	Mean platelet volume;
CRC	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.72	-0.6	3.43e-34	Ulcerative colitis;
CRC	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.66	-10.27	-0.49	1.2e-21	Corneal astigmatism;
CRC	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06606381	chr12:133084897	FBRSL1	0.77	7.48	0.38	6.87e-13	Depression;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg06470822	chr6:28175283	NA	1.03	13.6	0.6	1.02e-33	Depression;
CRC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.57	-6.98	-0.36	1.59e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg21951975	chr1:209979733	IRF6	-0.43	-6.01	-0.31	4.96e-9	Cleft lip with or without cleft palate;
CRC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg18225595	chr11:63971243	STIP1	0.52	6.54	0.34	2.29e-10	Mean platelet volume;
CRC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg06462663	chr19:18546047	ISYNA1	0.45	6.82	0.35	4.31e-11	Breast cancer;
CRC	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.45	-6.67	-0.35	1.06e-10	Menarche (age at onset);
CRC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.71	11.59	0.54	2.84e-26	Dental caries;
CRC	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.71	13.5	0.6	2.37e-33	Metabolite levels;
CRC	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.49	9.91	0.48	1.98e-20	Breast cancer;
CRC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg14711859	chr11:8959438	ASCL3	-0.5	-8.07	-0.41	1.38e-14	Hemoglobin concentration;
CRC	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg16486109	chr11:613632	IRF7	0.59	10.58	0.5	1.02e-22	Systemic lupus erythematosus;
CRC	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg22561889	chr6:118971681	C6orf204	0.51	6.52	0.34	2.67e-10	Diastolic blood pressure;
CRC	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	0.89	10.86	0.51	1.1e-23	Blood protein levels;
CRC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg05501817	chr11:14380813	RRAS2	-0.43	-5.95	-0.31	6.79e-9	Vitamin D levels;
CRC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.47	6.23	0.32	1.44e-9	Multiple myeloma (IgH translocation);
CRC	trans	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.41	0.38	1.07e-12	Endometrial cancer;
CRC	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.4	-0.33	5.39e-10	Multiple sclerosis;
CRC	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-7.49	-0.38	6.19e-13	Headache;
CRC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.86	-11.69	-0.54	1.25e-26	Gut microbiome composition (summer);
CRC	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.46	-6.38	-0.33	5.99e-10	Rheumatoid arthritis;
CRC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	1.03	18.28	0.71	4.94e-52	Parkinson's disease;
CRC	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.42	-5.97	-0.31	6.14e-9	Subjective well-being;
CRC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.68	-0.3	2.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.46	7.37	0.38	1.41e-12	Tumor biomarkers;
CRC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.58	6.34	0.33	7.52e-10	Initial pursuit acceleration;
CRC	trans	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg26043149	chr18:55253948	FECH	-0.48	-7.33	-0.37	1.84e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs61160187	0.582	rs12655603	chr5:60204596	C/T	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.49	-0.34	3.16e-10	Depression;
CRC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.56	0.38	3.94e-13	Menopause (age at onset);
CRC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.5	7.61	0.39	2.92e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.47	8.13	0.41	9.13e-15	Childhood ear infection;
CRC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.13	0.32	2.58e-9	Monocyte percentage of white cells;
CRC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.41	8.98	0.44	2.16e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg18404041	chr3:52824283	ITIH1	-0.31	-5.78	-0.3	1.7e-8	Schizophrenia;
CRC	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg23435118	chr5:141488016	NDFIP1	-0.46	-7.28	-0.37	2.55e-12	Crohn's disease;
CRC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.92	18.38	0.71	2.04e-52	Bone mineral density;
CRC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.7	-8.49	-0.42	7.03e-16	Gut microbiome composition (summer);
CRC	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.49	9.13	0.45	6.88e-18	Common traits (Other);
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg12172441	chr6:28176163	NA	0.49	6.69	0.35	9.78e-11	Cardiac Troponin-T levels;
CRC	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.89	-15.36	-0.65	1.55e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.54	-8.65	-0.43	2.3e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg12193833	chr17:30244370	NA	-0.58	-7.83	-0.4	6.56e-14	Hip circumference adjusted for BMI;
CRC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-17.19	-0.69	1.05e-47	Coronary artery disease;
CRC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg19913688	chr11:428466	ANO9	-0.73	-7.4	-0.38	1.18e-12	Body mass index;
CRC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.32	-6.02	-0.31	4.66e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg12564285	chr5:131593104	PDLIM4	-0.33	-6.11	-0.32	2.83e-9	Blood metabolite levels;
CRC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.51	8.99	0.44	1.94e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.55	0.54	3.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.64	-8.97	-0.44	2.35e-17	DNA methylation (variation);
CRC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.58	9.71	0.47	9.32e-20	Total body bone mineral density;
CRC	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.43	6.35	0.33	6.98e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg03013999	chr17:37608204	MED1	0.46	7.14	0.37	5.87e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-7.09	-0.36	8.1e-12	Coronary artery disease;
CRC	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.54	-8.14	-0.41	8.3e-15	Body mass index;
CRC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	14.81	0.63	2.25e-38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs965469	1.000	rs6037590	chr20:3374085	G/A	cg25506879	chr20:3388711	C20orf194	-0.39	-5.68	-0.3	2.91e-8	IFN-related cytopenia;
CRC	cis	rs9311676	0.656	rs4339119	chr3:58389462	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.03	16.37	0.67	1.72e-44	Cognitive function;
CRC	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.4	-6.73	-0.35	7.53e-11	Vitamin D levels;
CRC	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.46	-6.06	-0.32	3.78e-9	Tuberculosis;
CRC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg03030879	chr14:75389066	RPS6KL1	0.45	7.22	0.37	3.69e-12	Caffeine consumption;
CRC	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.48	-0.38	6.89e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg02175503	chr12:58329896	NA	0.59	8.54	0.43	4.96e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg09654669	chr8:57350985	NA	-0.4	-5.73	-0.3	2.31e-8	Obesity-related traits;
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg15790184	chr11:494944	RNH1	0.61	6.25	0.33	1.26e-9	Body mass index;
CRC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.47	7.02	0.36	1.26e-11	Melanoma;
CRC	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.52	7.49	0.38	6.23e-13	Testicular germ cell tumor;
CRC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Body mass index;
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.9e-11	Electroencephalogram traits;
CRC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-11.26	-0.53	4.1e-25	Electroencephalogram traits;
CRC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.98	14.33	0.62	1.63e-36	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg20607287	chr7:12443886	VWDE	-0.56	-6.15	-0.32	2.21e-9	Coronary artery disease;
CRC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	8.96	0.44	2.55e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.44	5.9	0.31	9.24e-9	Total body bone mineral density;
CRC	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.52	9.16	0.45	5.86e-18	Common traits (Other);
CRC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.71	9.27	0.46	2.53e-18	Cleft lip with or without cleft palate;
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg26116260	chr4:7069785	GRPEL1	-0.74	-5.76	-0.3	1.91e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.1	0.32	3.06e-9	Crohn's disease;
CRC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg23533926	chr12:111358616	MYL2	-0.44	-6.44	-0.33	4.24e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg15147215	chr3:52552868	STAB1	0.42	6.94	0.36	2.11e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9549328	0.544	rs66893681	chr13:113617499	A/G	cg20742385	chr13:113633654	MCF2L	0.56	9.5	0.46	4.54e-19	Systolic blood pressure;
CRC	cis	rs17125944	0.686	rs7158645	chr14:53332152	C/T	cg00686598	chr14:53173677	PSMC6	-0.62	-6.08	-0.32	3.25e-9	Alzheimer's disease (late onset);
CRC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.68	10.31	0.49	8.96e-22	Corneal astigmatism;
CRC	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	1.13	13.26	0.59	1.97e-32	Obesity-related traits;
CRC	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg14825688	chr5:132208181	LEAP2	-0.4	-6.44	-0.33	4.19e-10	Apolipoprotein A-IV levels;
CRC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.35	6.02	0.31	4.78e-9	Primary biliary cholangitis;
CRC	cis	rs9648716	1.000	rs10282499	chr7:140449834	C/T	cg10747023	chr7:140774559	NA	0.44	5.77	0.3	1.8e-8	Type 2 diabetes;
CRC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.57	-0.47	2.66e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.27	0.64	3.58e-40	Platelet count;
CRC	cis	rs12745968	0.532	rs10874724	chr1:93088183	C/A	cg17283838	chr1:93427260	FAM69A	-0.48	-6.46	-0.34	3.7e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.41	-6.63	-0.34	1.37e-10	Refractive error;
CRC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.51	-7.45	-0.38	8.33e-13	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19462847	chr11:6633911	TAF10	0.49	7.17	0.37	4.88e-12	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg23254163	chr1:152506842	NA	0.38	6.43	0.33	4.59e-10	Hair morphology;
CRC	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.03	14.01	0.61	2.58e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg13256891	chr4:100009986	ADH5	0.45	6.46	0.34	3.85e-10	Alcohol dependence;
CRC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.74	7.65	0.39	2.18e-13	Fat distribution (HIV);
CRC	cis	rs612683	0.536	rs1335753	chr1:101027157	G/T	cg06223162	chr1:101003688	GPR88	0.35	6.3	0.33	9.44e-10	Breast cancer;
CRC	trans	rs12408261	0.685	rs4085125	chr1:189277546	A/T	cg02070205	chr10:30722105	MAP3K8	0.43	6.12	0.32	2.62e-9	Number of pregnancies;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21395147	chr1:211849137	NEK2	0.36	5.97	0.31	6.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.43	6.76	0.35	6.35e-11	Height;
CRC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg22117107	chr15:45993392	NA	-0.44	-8.88	-0.44	4.52e-17	Waist circumference;Weight;
CRC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg00290994	chr1:41848739	NA	0.56	8.37	0.42	1.66e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.6	8.14	0.41	8.14e-15	Coronary artery disease;
CRC	trans	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg18288967	chr1:45987694	PRDX1	0.68	7.43	0.38	9.51e-13	Obesity-related traits;
CRC	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg11038491	chr20:34638489	LOC647979	-0.69	-8.24	-0.41	4.17e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.89	-0.36	2.78e-11	Monocyte percentage of white cells;
CRC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.58	-8.64	-0.43	2.54e-16	Aortic root size;
CRC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-8.86	-0.44	5.15e-17	Menarche (age at onset);
CRC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg02321871	chr13:50159138	RCBTB1	-0.43	-6.13	-0.32	2.5e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26306683	chr17:18585705	ZNF286B	0.49	7.0	0.36	1.47e-11	Educational attainment (years of education);
CRC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.36	-5.77	-0.3	1.81e-8	Self-reported allergy;
CRC	cis	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg15236460	chr22:30163365	UCRC;ZMAT5	0.5	5.63	0.3	3.78e-8	Lymphocyte counts;
CRC	cis	rs4233802	1.000	rs4577299	chr2:151138798	A/C	cg25300694	chr2:151184358	NA	-0.95	-7.44	-0.38	8.95e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg02927042	chr1:21476669	EIF4G3	0.49	7.87	0.4	5.04e-14	Superior frontal gyrus grey matter volume;
CRC	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03399598	chr4:174091002	GALNT7	0.51	7.31	0.37	2.05e-12	Response to antipsychotic treatment;
CRC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.6	-7.16	-0.37	5.43e-12	Blood protein levels;
CRC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.83	-0.35	4.19e-11	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18153499	chr19:47142459	NA	0.38	6.25	0.33	1.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg23625390	chr15:77176239	SCAPER	0.4	5.77	0.3	1.84e-8	Blood metabolite levels;
CRC	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.45	-0.34	3.9e-10	Obesity-related traits;
CRC	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg20356878	chr3:121714668	ILDR1	-0.42	-5.81	-0.31	1.47e-8	Multiple sclerosis;
CRC	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg06346307	chr22:19949965	COMT	0.25	6.15	0.32	2.19e-9	Blood metabolite levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05095774	chr18:52495848	RAB27B	0.44	6.27	0.33	1.13e-9	Survival in pancreatic cancer;
CRC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.81	14.49	0.62	3.72e-37	Anterior chamber depth;
CRC	cis	rs1545257	0.537	rs11125583	chr2:24646278	C/A	cg06627628	chr2:24431161	ITSN2	-0.48	-7.1	-0.36	7.7e-12	Sjögren's syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19193201	chr18:30050907	FAM59A	0.49	8.44	0.42	1.05e-15	Liver disease severity in Alagille syndrome;
CRC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.37	-0.38	1.44e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.75	10.99	0.52	3.83e-24	Schizophrenia;
CRC	trans	rs9341835	0.740	rs7763834	chr6:64149357	T/C	cg13657004	chr13:50234944	EBPL	-0.37	-6.18	-0.32	1.91e-9	Schizophrenia;
CRC	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg15038512	chr6:170123185	PHF10	-0.4	-6.15	-0.32	2.28e-9	Obesity-related traits;
CRC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.62	-0.57	4.76e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.62	8.44	0.42	1.01e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg00316803	chr15:76480434	C15orf27	-0.39	-6.67	-0.35	1.05e-10	Blood metabolite levels;
CRC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-15.47	-0.65	5.96e-41	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2882667	0.898	rs4380651	chr5:138391072	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-5.61	-0.3	4.19e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.88	0.31	1.01e-8	Life satisfaction;
CRC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.87	-0.4	5.22e-14	Gut microbiome composition (summer);
CRC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg06470822	chr6:28175283	NA	0.46	6.16	0.32	2.07e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	9.68	0.47	1.13e-19	Mean corpuscular hemoglobin;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23844497	chr19:56135921	ZNF784	0.43	6.19	0.32	1.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg23650765	chr1:12612165	NA	0.36	7.18	0.37	4.58e-12	Optic cup area;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg12273811	chr6:28175739	NA	0.59	8.66	0.43	2.15e-16	Parkinson's disease;
CRC	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.73	11.66	0.54	1.6e-26	Plateletcrit;Platelet count;
CRC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	14.12	0.61	1e-35	Platelet count;
CRC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	14.62	0.63	1.22e-37	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23098599	chr19:15235953	ILVBL	0.39	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18912574	chr7:65842487	NCRNA00174	0.35	5.9	0.31	8.96e-9	Aortic root size;
CRC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg14541582	chr5:601475	NA	-0.27	-5.76	-0.3	1.98e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.56	8.52	0.43	5.92e-16	Fibrinogen levels;
CRC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg15448220	chr1:150897856	SETDB1	-0.45	-6.25	-0.33	1.31e-9	Blood protein levels;
CRC	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.61	9.21	0.45	3.86e-18	Dementia with Lewy bodies;
CRC	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg06606381	chr12:133084897	FBRSL1	-0.97	-6.93	-0.36	2.18e-11	Lung cancer;Intelligence (multi-trait analysis);
CRC	cis	rs6479527	0.875	rs3996241	chr9:96768979	G/T	cg14459158	chr9:96720562	NA	0.4	7.11	0.36	7.37e-12	Esophageal adenocarcinoma;
CRC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg24881330	chr22:46731750	TRMU	0.63	7.11	0.36	7.28e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4664293	0.867	rs34893664	chr2:160588777	T/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.67	11.22	0.53	5.87e-25	Cancer;
CRC	cis	rs4908768	0.539	rs1934138	chr1:8645816	G/A	cg20416874	chr1:8611966	RERE	-0.42	-6.04	-0.32	4.27e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs972578	0.967	rs4822235	chr22:43338090	T/C	cg01576275	chr22:43409880	NA	-0.47	-7.65	-0.39	2.29e-13	Mean platelet volume;
CRC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.31	0.37	2.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	6.36	0.33	6.58e-10	Lymphocyte counts;
CRC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg19223190	chr17:80058835	NA	0.42	6.79	0.35	5.1e-11	Life satisfaction;
CRC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.43	5.71	0.3	2.57e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9400239	0.622	rs1268171	chr6:109007304	C/G	cg11073813	chr6:109029018	NA	-0.4	-6.33	-0.33	7.89e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs41005	1.000	rs42357	chr2:8110896	C/T	cg03155496	chr2:8117019	LOC339788	0.4	7.12	0.37	6.88e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.37	0.5	5.39e-22	Platelet count;
CRC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.86	-0.35	3.52e-11	Mean corpuscular volume;
CRC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.27	-0.37	2.62e-12	Height;
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.62	-11.6	-0.54	2.69e-26	Hemoglobin concentration;
CRC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg05941027	chr17:61774174	LIMD2	0.34	6.06	0.32	3.68e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.66	-12.27	-0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg24416660	chr17:73865998	NA	-0.38	-5.74	-0.3	2.1e-8	Psoriasis;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg05569086	chr8:143859399	LYNX1	-0.39	-6.06	-0.32	3.81e-9	Urinary tract infection frequency;
CRC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.56	8.65	0.43	2.31e-16	Asthma (sex interaction);
CRC	cis	rs6960043	0.875	rs6976381	chr7:15048814	T/C	cg19272540	chr7:15055459	NA	-0.23	-5.86	-0.31	1.12e-8	Type 2 diabetes;
CRC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	1.02	18.42	0.71	1.38e-52	Ewing sarcoma;
CRC	cis	rs6988985	0.728	rs7003319	chr8:143954747	T/C	cg10324643	chr8:143916377	GML	0.35	5.8	0.3	1.53e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.82	15.09	0.64	1.79e-39	Anterior chamber depth;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08306513	chr11:120040083	NA	-0.5	-6.21	-0.32	1.57e-9	Diisocyanate-induced asthma;
CRC	cis	rs9648716	0.810	rs6944039	chr7:140584017	A/T	cg10747023	chr7:140774559	NA	0.44	5.88	0.31	9.82e-9	Type 2 diabetes;
CRC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.94	-0.31	7.42e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg06781209	chr11:61594997	FADS2	-0.57	-8.0	-0.4	2.11e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg23815491	chr16:72088622	HP	0.49	7.1	0.36	7.56e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.33	-5.62	-0.3	4.18e-8	Calcium levels;
CRC	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg06581033	chr10:766294	NA	-0.52	-5.77	-0.3	1.84e-8	Uric acid levels;
CRC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.4	6.52	0.34	2.7e-10	Major depressive disorder;
CRC	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.71	0.43	1.55e-16	Mean corpuscular volume;
CRC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.49	9.8	0.48	4.76e-20	Ulcerative colitis;
CRC	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.55	5.74	0.3	2.2e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26505074	chr22:31477182	SMTN	0.5	7.32	0.37	1.92e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg15440763	chr7:158190612	PTPRN2	-0.41	-6.97	-0.36	1.71e-11	Obesity-related traits;
CRC	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg21577049	chr2:228736449	WDR69	-0.44	-5.91	-0.31	8.7e-9	Blood pressure;
CRC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.43	-7.09	-0.36	8e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg15845792	chr6:28175446	NA	-1.02	-13.3	-0.59	1.4e-32	Depression;
CRC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg18016565	chr1:150552671	MCL1	0.42	5.8	0.3	1.57e-8	Urate levels;
CRC	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg08795948	chr3:128337044	NA	0.35	5.77	0.3	1.83e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02290350	chr8:58132656	NA	-0.41	-5.74	-0.3	2.21e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg10494257	chr1:16342123	HSPB7	0.44	5.75	0.3	2.02e-8	Dilated cardiomyopathy;
CRC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.88	0.31	1.01e-8	Height;
CRC	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.8	10.45	0.5	2.88e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.69	-0.35	9.81e-11	Putamen volume;
CRC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.61	9.05	0.45	1.28e-17	Systolic blood pressure;
CRC	cis	rs243505	0.762	rs10225300	chr7:148502007	G/C	cg09806900	chr7:148480153	CUL1	0.52	7.48	0.38	6.69e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	6.96e-16	Aortic root size;
CRC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-10.85	-0.51	1.2e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.94	0.48	1.59e-20	Cognitive test performance;
CRC	cis	rs4731207	0.619	rs4461840	chr7:124581065	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.09	-0.32	3.18e-9	Cutaneous malignant melanoma;
CRC	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.04	-0.45	1.41e-17	Alzheimer's disease;
CRC	trans	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg18288967	chr1:45987694	PRDX1	0.68	7.52	0.38	5.32e-13	Obesity-related traits;
CRC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.53	0.34	2.54e-10	Lung cancer;
CRC	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-0.86	-13.34	-0.59	9.22e-33	Platelet distribution width;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17128646	chr2:198363565	HSPD1;HSPE1	0.42	6.17	0.32	1.98e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.46	-6.95	-0.36	1.91e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg15845792	chr6:28175446	NA	0.8	6.4	0.33	5.31e-10	Depression;
CRC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.58	-8.34	-0.42	2.1e-15	Rheumatoid arthritis;
CRC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg27661571	chr11:113659931	NA	-0.64	-7.36	-0.38	1.44e-12	Hip circumference adjusted for BMI;
CRC	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.52	-7.94	-0.4	3.18e-14	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.37	5.88	0.31	9.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.42	-0.38	1e-12	Body mass index;
CRC	trans	rs4130344	0.555	rs7664271	chr4:159865915	C/G	cg04008429	chr3:160167646	TRIM59	0.4	6.05	0.32	3.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.85	-0.31	1.21e-8	Alcohol dependence;
CRC	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.78	-10.53	-0.5	1.54e-22	IgG glycosylation;
CRC	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg09659197	chr4:152720779	NA	0.34	6.68	0.35	1.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg20885578	chr2:198174922	NA	-0.37	-6.45	-0.34	3.91e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-7.72	-0.39	1.45e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	8.88	0.44	4.47e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.43	6.19	0.32	1.8e-9	HIV-1 control;
CRC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.7	-9.98	-0.48	1.16e-20	Cleft lip with or without cleft palate;
CRC	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.61	0.63	1.29e-37	Exhaled nitric oxide output;
CRC	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.42	6.59	0.34	1.8e-10	Red blood cell count;
CRC	cis	rs55702914	0.652	rs12151726	chr2:198273591	C/T	cg10820045	chr2:198174542	NA	0.38	6.65	0.34	1.19e-10	Major depression and alcohol dependence;
CRC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.5	0.34	3.07e-10	Morning vs. evening chronotype;
CRC	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-8.04	-0.41	1.61e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.36	0.5	6.04e-22	Corneal astigmatism;
CRC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.74	-12.37	-0.56	4.1e-29	Mean platelet volume;
CRC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.83	13.04	0.58	1.3e-31	Menarche (age at onset);
CRC	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.5	8.3	0.42	2.68e-15	Testicular germ cell tumor;
CRC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.62	9.35	0.46	1.43e-18	Breast cancer;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.59	8.88	0.44	4.57e-17	Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.48	-0.38	6.83e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.56	8.56	0.43	4.54e-16	Neurofibrillary tangles;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.69	8.32	0.42	2.45e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.43	6.75	0.35	6.5500000000000006e-11	Schizophrenia;
CRC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.41	-6.04	-0.32	4.07e-9	Renal cell carcinoma;
CRC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.45	0.71	1.09e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.48	7.63	0.39	2.5e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg23205692	chr1:25664452	TMEM50A	0.42	5.92	0.31	8.01e-9	Erythrocyte sedimentation rate;
CRC	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg20607287	chr7:12443886	VWDE	-0.53	-7.18	-0.37	4.53e-12	Coronary artery disease;
CRC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.81	11.15	0.52	1.08e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.56	8.95	0.44	2.72e-17	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.45	-8.11	-0.41	9.88e-15	Reticulocyte fraction of red cells;
CRC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.44	0.62	5.96e-37	Chronic sinus infection;
CRC	cis	rs11212617	0.967	rs11212635	chr11:108310702	T/A	cg12106634	chr11:108092400	ATM;NPAT	-0.39	-5.68	-0.3	2.96e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg09127314	chr1:152161683	NA	0.47	5.99	0.31	5.61e-9	Atopic dermatitis;
CRC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.54	9.11	0.45	8.09e-18	Calcium levels;
CRC	trans	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg26043149	chr18:55253948	FECH	-0.5	-7.65	-0.39	2.29e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg15845792	chr6:28175446	NA	-0.58	-6.04	-0.32	4.15e-9	Depression;
CRC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.12	8.39	0.42	1.43e-15	Type 2 diabetes nephropathy;
CRC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg11292332	chr7:45801988	SEPT13	-0.38	-6.95	-0.36	1.93e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.82	7.5	0.38	6.11e-13	Type 2 diabetes;
CRC	cis	rs902774	0.818	rs55958994	chr12:53301019	C/T	cg16329197	chr12:53359506	NA	-0.55	-6.0	-0.31	5.27e-9	Prostate cancer;
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg15511327	chr8:143859410	LYNX1	-0.43	-7.22	-0.37	3.69e-12	Urinary tract infection frequency;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07355693	chr12:125667907	NA	0.47	7.22	0.37	3.62e-12	Intelligence (multi-trait analysis);
CRC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.75	11.46	0.53	8.32e-26	High light scatter reticulocyte count;
CRC	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg11789530	chr4:8429930	ACOX3	-0.61	-8.26	-0.41	3.65e-15	Response to antineoplastic agents;
CRC	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.46	5.98	0.31	5.96e-9	HDL cholesterol;
CRC	cis	rs3823572	0.525	rs4546584	chr7:133704270	A/C	cg03336402	chr7:133662267	EXOC4	0.66	9.56	0.47	2.87e-19	Intelligence (multi-trait analysis);
CRC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.91	-17.23	-0.69	7.51e-48	Coronary artery disease;
CRC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg20487152	chr13:99095054	FARP1	-0.45	-6.44	-0.33	4.33e-10	Longevity;
CRC	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	ch.11.42038R	chr11:967971	AP2A2	0.55	8.83	0.44	6.37e-17	Alzheimer's disease (late onset);
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.1	-0.32	3.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.87	0.31	1.04e-8	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04068910	chr10:101989347	CHUK	0.42	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14862950	chr11:66112661	BRMS1	0.45	6.29	0.33	1.01e-9	Response to antipsychotic treatment;
CRC	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg09659197	chr4:152720779	NA	0.42	8.45	0.42	9.24e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.51	6.48	0.34	3.41e-10	Recombination rate (females);
CRC	cis	rs4363385	0.818	rs11205175	chr1:153001296	A/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.71e-12	Inflammatory skin disease;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.61	11.42	0.53	1.15e-25	Coronary artery disease;
CRC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.64	-11.02	-0.52	3.12e-24	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.75	-10.77	-0.51	2.35e-23	Blood metabolite levels;
CRC	cis	rs447	0.767	rs1468344	chr7:83748890	A/G	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.8	-0.3	1.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.2	18.64	0.72	2.04e-53	Atopic dermatitis;
CRC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg09904177	chr6:26538194	HMGN4	0.55	6.54	0.34	2.41e-10	Small cell lung carcinoma;
CRC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.47	7.08	0.36	8.98e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.64	7.51	0.38	5.79e-13	Breast cancer;
CRC	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	cg04338863	chr8:33670619	NA	0.44	7.06	0.36	9.65e-12	Body mass index;
CRC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg03162506	chr22:38580953	NA	0.26	5.69	0.3	2.77e-8	Cutaneous nevi;
CRC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.71	0.3	2.5e-8	Self-reported allergy;
CRC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.44	6.83	0.35	4.14e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs185694	0.779	rs609919	chr13:30895904	C/G	cg07600127	chr13:30881527	KATNAL1	-0.52	-5.86	-0.31	1.15e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.61	-9.53	-0.46	3.71e-19	Dental caries;
CRC	cis	rs67385638	0.802	rs11036635	chr11:5308896	C/T	cg21506790	chr11:5277210	HBG2	0.34	5.88	0.31	1.03e-8	Hemoglobin levels;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.63	7.07	0.36	9.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.6	-7.47	-0.38	7.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26801646	chr10:76970496	VDAC2	0.47	6.76	0.35	6.18e-11	Survival in pancreatic cancer;
CRC	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg13615338	chr4:55094005	PDGFRA	0.4	6.0	0.31	5.14e-9	Corneal astigmatism;
CRC	cis	rs447	1.000	rs3801655	chr7:83753335	C/G	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.71	-0.39	1.51e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg09582351	chr12:29534625	ERGIC2	-0.27	-5.76	-0.3	1.94e-8	QT interval;
CRC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.92	-0.4	3.58e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.76	10.36	0.5	5.88e-22	Cognitive function;
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg20092199	chr4:1342459	KIAA1530	0.45	7.25	0.37	3.05e-12	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg12463550	chr7:65579703	CRCP	0.67	6.15	0.32	2.2e-9	Diabetic kidney disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16599568	chr1:165567358	NA	0.53	7.78	0.39	9.59e-14	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15172729	chr11:67056446	ANKRD13D	0.41	6.45	0.34	4.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.49	-8.95	-0.44	2.7e-17	Total body bone mineral density;
CRC	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg00738113	chr16:70207722	CLEC18C	-0.41	-5.93	-0.31	7.84e-9	IgE levels;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg15763984	chr4:1342303	KIAA1530	-0.35	-6.08	-0.32	3.29e-9	Obesity-related traits;
CRC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg00166722	chr3:10149974	C3orf24	0.43	6.32	0.33	8.43e-10	Alzheimer's disease;
CRC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg21153622	chr11:89784906	NA	-0.37	-6.01	-0.31	4.99e-9	Height;
CRC	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.95	10.77	0.51	2.22e-23	Eosinophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15785704	chr17:30669010	C17orf75	0.42	5.96	0.31	6.38e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12172441	chr6:28176163	NA	0.63	7.43	0.38	9.41e-13	Depression;
CRC	trans	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.71	-0.35	8.45e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20183778	chr7:102105344	ALKBH4;LRWD1	0.41	5.99	0.31	5.52e-9	Response to antipsychotic treatment;
CRC	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg12682573	chr17:27188876	MIR451;MIR144	-0.6	-8.94	-0.44	2.83e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18891615	chr8:101962925	YWHAZ	0.41	6.69	0.35	9.66e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-9.56	-0.47	2.81e-19	Exhaled nitric oxide output;
CRC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.39e-12	Gut microbiome composition (summer);
CRC	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg17133734	chr15:86042851	AKAP13	0.44	6.93	0.36	2.19e-11	Coronary artery disease;
CRC	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg23260525	chr10:116636907	FAM160B1	0.31	6.65	0.34	1.23e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.38	-6.09	-0.32	3.19e-9	Major depressive disorder;
CRC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg16342193	chr10:102329863	NA	-0.35	-5.68	-0.3	3.04e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.6	-9.01	-0.44	1.76e-17	Diastolic blood pressure;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09455096	chr2:61765470	XPO1	-0.52	-5.97	-0.31	6.07e-9	Monocyte percentage of white cells;
CRC	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-9.56	-0.47	2.84e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6694672	1.000	rs4915309	chr1:197048781	A/T	cg13682187	chr1:196946512	CFHR5	0.47	7.35	0.38	1.56e-12	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20769334	chr22:50913335	SBF1	0.4	6.57	0.34	1.97e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg18761221	chr20:60518478	NA	0.45	7.26	0.37	2.88e-12	Body mass index;
CRC	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.67	-0.3	3.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.91	10.73	0.51	3.18e-23	Psoriasis;
CRC	trans	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg24879335	chr3:133465180	TF	0.37	6.81	0.35	4.56e-11	Iron status biomarkers;
CRC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg08772003	chr10:104629869	AS3MT	-0.36	-5.95	-0.31	6.95e-9	Arsenic metabolism;
CRC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.54	-0.38	4.69e-13	HDL cholesterol;
CRC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.67	7.19	0.37	4.39e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg05185784	chr16:90016020	DEF8	-0.53	-8.26	-0.41	3.72e-15	Melanoma;
CRC	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.71	13.8	0.61	1.74e-34	Mean corpuscular hemoglobin;
CRC	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-7.79	-0.39	8.84e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.6	-0.43	3.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.7	10.36	0.5	5.81e-22	Immature fraction of reticulocytes;
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21998383	chr1:162039240	NOS1AP	0.44	6.25	0.33	1.29e-9	Response to antipsychotic treatment;
CRC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-11.2	-0.53	7.06e-25	Dental caries;
CRC	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-6.15	-0.32	2.27e-9	Schizophrenia;
CRC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.45	-6.11	-0.32	2.81e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.47	6.87	0.35	3.27e-11	Parkinson's disease;
CRC	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.72	0.35	8.12e-11	Homocysteine levels;
CRC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.59	-8.06	-0.41	1.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.81	14.26	0.62	2.96e-36	Colorectal cancer;
CRC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.51	-8.39	-0.42	1.49e-15	Huntington's disease progression;
CRC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg03894339	chr8:19674705	INTS10	0.42	5.73	0.3	2.21e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.44	-0.42	1.04e-15	Hemoglobin concentration;
CRC	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg23231163	chr10:75533350	FUT11	-0.37	-5.89	-0.31	9.32e-9	Inflammatory bowel disease;
CRC	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg00531865	chr16:30841666	NA	0.46	6.61	0.34	1.59e-10	Dementia with Lewy bodies;
CRC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.5	7.57	0.39	3.72e-13	Total body bone mineral density;
CRC	cis	rs911119	0.837	rs2208289	chr20:23579526	A/G	cg16589663	chr20:23618590	CST3	-0.49	-7.25	-0.37	3.09e-12	Chronic kidney disease;
CRC	cis	rs7091068	0.662	rs829106	chr10:95441742	G/T	cg20715218	chr10:95462985	C10orf4	0.56	5.88	0.31	1.03e-8	Urinary tract infection frequency;
CRC	cis	rs6499129	0.558	rs9934328	chr16:67573367	G/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.04	-0.41	1.68e-14	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.69	8.16	0.41	7.37e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.67	8.98	0.44	2.06e-17	Morning vs. evening chronotype;
CRC	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg00852783	chr1:26633632	UBXN11	0.47	6.5	0.34	2.94e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.54	5.65	0.3	3.5e-8	Bipolar disorder;
CRC	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.86	-0.44	5.03e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.4	6.14	0.32	2.41e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.64	-9.52	-0.46	3.92e-19	Selective IgA deficiency;
CRC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.64	0.75	2.54e-61	Prudent dietary pattern;
CRC	trans	rs4965869	0.703	rs2643356	chr15:101971388	A/G	cg17508591	chr5:140214138	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA3;PCDHA4	0.28	6.17	0.32	2.04e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg06243084	chr11:63990629	FERMT3	0.45	7.23	0.37	3.32e-12	Platelet count;
CRC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.6	9.84	0.48	3.35e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.47	-6.97	-0.36	1.73e-11	Longevity;Endometriosis;
CRC	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg14191688	chr11:70257035	CTTN	0.42	5.85	0.31	1.18e-8	Coronary artery disease;
CRC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.18	0.32	1.89e-9	Cognitive ability;
CRC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.38	0.46	1.08e-18	Parkinson's disease;
CRC	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg13482628	chr17:19912719	NA	-0.4	-6.16	-0.32	2.09e-9	Obesity-related traits;
CRC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.62	-10.52	-0.5	1.73e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg22495460	chr2:25135724	ADCY3	-0.78	-14.35	-0.62	1.37e-36	Body mass index;
CRC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.45	-6.71	-0.35	8.44e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg19812747	chr11:111475976	SIK2	0.43	6.2	0.32	1.65e-9	Primary sclerosing cholangitis;
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg07617317	chr6:118971624	C6orf204	0.5	6.13	0.32	2.57e-9	Diastolic blood pressure;
CRC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.82	0.51	1.56e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg15147215	chr3:52552868	STAB1	-0.65	-11.29	-0.53	3.36e-25	Electroencephalogram traits;
CRC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.95	0.52	5.22e-24	Motion sickness;
CRC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.75	-0.35	6.72e-11	Aortic root size;
CRC	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.56	-7.87	-0.4	5.25e-14	Autism;
CRC	cis	rs73200209	0.744	rs61354255	chr12:116444609	A/T	cg01776926	chr12:116560359	MED13L	-0.62	-7.24	-0.37	3.15e-12	Total body bone mineral density;
CRC	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.66	11.66	0.54	1.59e-26	Prostate cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03686870	chr4:103682143	MANBA	0.4	6.4	0.33	5.35e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg05552183	chr6:42928497	GNMT	0.47	6.57	0.34	1.92e-10	Blood protein levels;
CRC	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-7.74	-0.39	1.21e-13	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06307176	chr5:131281290	NA	0.44	6.43	0.33	4.48e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg08885800	chr1:201084119	NA	0.41	5.7	0.3	2.62e-8	Permanent tooth development;
CRC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.58	-7.67	-0.39	1.97e-13	Gut microbiome composition (summer);
CRC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.6	-10.48	-0.5	2.3e-22	Schizophrenia;
CRC	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg16358738	chr2:241808595	AGXT	-0.4	-6.99	-0.36	1.57e-11	Urinary metabolites;
CRC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg03037974	chr15:76606532	NA	-0.53	-7.58	-0.39	3.5e-13	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg22902534	chr3:183892754	AP2M1	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.46	7.1	0.36	7.67e-12	Coronary heart disease;
CRC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	6.65	0.34	1.19e-10	Height;
CRC	trans	rs6693295	0.793	rs2787953	chr1:246248659	T/A	cg03680032	chr11:94965610	SESN3	0.48	6.17	0.32	1.98e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg27398640	chr15:77910606	LINGO1	-0.45	-7.78	-0.39	9.51e-14	Type 2 diabetes;
CRC	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.61	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.84	0.4	6.37e-14	Diabetic retinopathy;
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.86	0.31	1.11e-8	Refractive astigmatism;
CRC	cis	rs1507153	0.651	rs9350781	chr6:79481815	A/T	cg09184832	chr6:79620586	NA	-0.38	-6.22	-0.32	1.53e-9	Sjögren's syndrome;
CRC	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.72	9.75	0.47	6.92e-20	Coronary artery disease;
CRC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg06766960	chr11:133703094	NA	-0.41	-7.15	-0.37	5.73e-12	Childhood ear infection;
CRC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.81	-0.44	7.5e-17	Personality dimensions;
CRC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-5.88	-0.31	1.01e-8	Bipolar disorder;
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.55	-0.43	4.57e-16	Life satisfaction;
CRC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.45	7.3	0.37	2.23e-12	Menopause (age at onset);
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg12273811	chr6:28175739	NA	0.55	7.69	0.39	1.7e-13	Parkinson's disease;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.54	-6.77	-0.35	5.98e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg11245181	chr6:149772854	ZC3H12D	-0.55	-9.19	-0.45	4.73e-18	Dupuytren's disease;
CRC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg15790184	chr11:494944	RNH1	0.61	6.24	0.33	1.35e-9	Body mass index;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg15845792	chr6:28175446	NA	0.82	12.19	0.56	1.77e-28	Parkinson's disease;
CRC	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg00601450	chr5:74908170	NA	0.41	5.85	0.31	1.21e-8	Age-related disease endophenotypes;
CRC	cis	rs2179367	0.959	rs489551	chr6:149689457	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.04	-0.32	4.22e-9	Dupuytren's disease;
CRC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg15468180	chr1:107600409	PRMT6	0.42	6.29	0.33	9.84e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg14352298	chr13:112236639	NA	0.3	6.7	0.35	9.27e-11	Hepatitis;
CRC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.36	5.75	0.3	1.99e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.81	-0.35	4.52e-11	Coronary artery disease;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg20477929	chr11:70116563	PPFIA1	-0.43	-6.09	-0.32	3.2e-9	Protein C levels;
CRC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.54	-0.47	3.27e-19	Migraine;Coronary artery disease;
CRC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.49	7.76	0.39	1.06e-13	Height;
CRC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.44	6.19	0.32	1.78e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-6.42	-0.33	4.83e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4889855	0.530	rs9901467	chr17:78574008	G/A	cg16591659	chr17:78472290	NA	-0.41	-6.04	-0.32	4.18e-9	Fractional excretion of uric acid;
CRC	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.39e-12	HDL cholesterol;
CRC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.83	-0.35	4.03e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.33	-0.33	8.03e-10	Gout;Renal underexcretion gout;
CRC	cis	rs6893807	0.943	rs13166120	chr5:87948883	G/A	cg09002922	chr5:87956389	LOC645323	-0.45	-6.58	-0.34	1.91e-10	Body mass index;
CRC	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.74	-0.3	2.12e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19617932	chr12:1703704	FBXL14	0.38	6.04	0.32	4.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2223471	0.967	rs760899	chr6:50693607	T/C	cg03432817	chr6:50765336	NA	0.39	6.31	0.33	8.97e-10	Subcutaneous adipose tissue;
CRC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-8.47	-0.42	8.43e-16	Migraine;Coronary artery disease;
CRC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.64	9.22	0.45	3.65e-18	Systolic blood pressure;
CRC	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.0	14.27	0.62	2.71e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs10492002	0.800	rs7311803	chr12:81546193	A/G	cg26598540	chr8:10753147	NA	-0.32	-6.01	-0.31	5.05e-9	Response to antidepressant treatment (citalopram);
CRC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.41	8.02	0.4	1.88e-14	Mean corpuscular volume;
CRC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.44	6.35	0.33	7.05e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	1.1	10.95	0.52	5.32e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.63	-0.47	1.69e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21955402	chr17:18163716	SMCR7	0.43	6.22	0.32	1.54e-9	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg05036130	chr6:150231994	NA	0.27	5.65	0.3	3.46e-8	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23815043	chr16:88729854	MGC23284;MVD	0.47	6.81	0.35	4.68e-11	Response to antipsychotic treatment;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05127553	chr3:49823860	IP6K1	0.37	5.66	0.3	3.36e-8	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00320862	chr3:170588302	RPL22L1	0.38	6.03	0.32	4.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.77	11.26	0.53	4.18e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.47	-0.34	3.57e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.79	11.82	0.55	4.31e-27	Cognitive function;
CRC	cis	rs4731207	0.596	rs2170353	chr7:124595169	T/G	cg23710748	chr7:124431027	NA	-0.38	-5.98	-0.31	5.66e-9	Cutaneous malignant melanoma;
CRC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.86	11.49	0.54	6.38e-26	Gut microbiome composition (summer);
CRC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.77	12.66	0.57	3.48e-30	Breast cancer;
CRC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg15848620	chr12:58087721	OS9	-0.65	-9.21	-0.45	3.84e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24085258	chr19:4402334	CHAF1A	0.43	6.14	0.32	2.41e-9	Response to antipsychotic treatment;
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11645453	chr3:52864694	ITIH4	0.36	6.51	0.34	2.87e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12273811	chr6:28175739	NA	0.73	9.31	0.46	1.82e-18	Depression;
CRC	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg13385794	chr1:248469461	NA	0.37	6.56	0.34	2.1e-10	Common traits (Other);
CRC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.79	-14.5	-0.62	3.64e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.74	-12.25	-0.56	1.1e-28	Cystic fibrosis severity;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10554839	chr10:27529782	ACBD5	0.39	6.33	0.33	8.23e-10	Interleukin-6 levels;
CRC	cis	rs4144027	0.904	rs10438244	chr14:104346185	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.36	-5.89	-0.31	9.57e-9	Blood metabolite levels;
CRC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.9	13.45	0.6	3.68e-33	Triglycerides;
CRC	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg11579758	chr4:1086637	RNF212	0.41	6.77	0.35	5.96e-11	Recombination rate (males);
CRC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.73	9.51	0.46	4.3e-19	Cleft lip with or without cleft palate;
CRC	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.67	9.99	0.48	1.08e-20	Schizophrenia;
CRC	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.47	6.11	0.32	2.78e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg02772935	chr3:125709198	NA	-0.48	-6.07	-0.32	3.54e-9	Blood pressure (smoking interaction);
CRC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.55	-0.38	4.43e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.57	8.25	0.41	3.85e-15	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21962918	chr5:134094454	DDX46	0.39	6.38	0.33	5.87e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	cg04338863	chr8:33670619	NA	0.42	6.76	0.35	6.19e-11	Body mass index;
CRC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.18	-0.32	1.86e-9	Dupuytren's disease;
CRC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.51	7.7	0.39	1.59e-13	Asthma;
CRC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg19812747	chr11:111475976	SIK2	-0.57	-9.67	-0.47	1.21e-19	Primary sclerosing cholangitis;
CRC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.39	-8.07	-0.41	1.31e-14	Arsenic metabolism;
CRC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg16892393	chr17:41919603	NA	0.55	8.0	0.4	2.17e-14	Triglycerides;
CRC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.4	6.49	0.34	3.19e-10	Huntington's disease progression;
CRC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.73	0.3	2.29e-8	Bladder cancer;
CRC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.22e-17	Mean platelet volume;
CRC	cis	rs12612619	0.732	rs7560144	chr2:27280460	A/G	cg00617064	chr2:27272375	NA	-0.37	-6.14	-0.32	2.36e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.52	6.31	0.33	8.8e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2811415	0.597	rs11709484	chr3:127745068	C/T	cg13719885	chr3:127795394	NA	-0.4	-6.02	-0.32	4.62e-9	Lung function (FEV1/FVC);
CRC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	trans	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.75	0.39	1.18e-13	Menopause (age at onset);
CRC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.97e-9	Life satisfaction;
CRC	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs243505	0.528	rs6977453	chr7:148474746	A/G	cg09806900	chr7:148480153	CUL1	0.57	8.18	0.41	6.11e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.6	-9.92	-0.48	1.77e-20	P wave terminal force;
CRC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19346786	chr7:2764209	NA	-0.41	-6.83	-0.35	4.21e-11	Height;
CRC	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.29e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg14911132	chr11:61596755	FADS2	-0.55	-6.21	-0.32	1.58e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs13418455	0.691	rs62182920	chr2:181113573	G/C	cg23363182	chr2:181467187	NA	0.4	5.65	0.3	3.48e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.46	6.83	0.35	4e-11	Breast cancer;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.23	-0.32	1.46e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	7.23	0.37	3.37e-12	Coronary artery disease;
CRC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-17.39	-0.69	1.77e-48	Height;
CRC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.2	-0.45	4.31e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs4731207	0.698	rs7801140	chr7:124505761	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-6.67	-0.35	1.09e-10	Self-reported allergy;
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.33	0.75	4.47e-60	Prudent dietary pattern;
CRC	trans	rs3851050	0.651	rs10887487	chr10:81852700	A/G	cg04055819	chr10:13749602	FRMD4A	0.43	6.01	0.31	4.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs812925	0.537	rs2593620	chr2:61613261	A/G	cg10580144	chr2:61372316	C2orf74	-0.32	-7.03	-0.36	1.17e-11	Immature fraction of reticulocytes;
CRC	cis	rs394563	0.601	rs376269	chr6:149795154	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.48	-0.34	3.41e-10	Dupuytren's disease;
CRC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.46	6.94	0.36	2.07e-11	Menopause (age at onset);
CRC	cis	rs2188554	0.667	rs213949	chr7:117197031	T/A	cg09181792	chr7:117119393	CFTR	0.34	6.16	0.32	2.14e-9	Esophageal adenocarcinoma;
CRC	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg14036092	chr11:66035641	RAB1B	-0.43	-5.66	-0.3	3.3e-8	Electroencephalogram traits;
CRC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-9.5	-0.46	4.42e-19	Total body bone mineral density;
CRC	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-6.6	-0.34	1.66e-10	Coronary artery disease;
CRC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg17330251	chr7:94953956	PON1	-0.52	-6.56	-0.34	2.04e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12463550	chr7:65579703	CRCP	0.75	6.82	0.35	4.5e-11	Diabetic kidney disease;
CRC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg21466736	chr12:48725269	NA	-0.47	-7.27	-0.37	2.62e-12	Glycated hemoglobin levels;
CRC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.04	10.13	0.49	3.61e-21	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27068619	chr7:149439536	NA	0.43	6.48	0.34	3.3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.45	5.95	0.31	6.95e-9	Tuberculosis;
CRC	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg25856811	chr1:152973957	SPRR3	0.26	7.14	0.37	6.1e-12	Inflammatory skin disease;
CRC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.1	-0.36	7.5e-12	Eye color traits;
CRC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.54	-8.68	-0.43	1.88e-16	Aortic root size;
CRC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg04117972	chr1:227635322	NA	0.77	8.03	0.4	1.73e-14	Major depressive disorder;
CRC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.3	6.33	0.33	7.86e-10	Homoarginine levels;
CRC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-11.06	-0.52	2.19e-24	Hemoglobin concentration;
CRC	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.19	-0.32	1.74e-9	Caffeine consumption;
CRC	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg04837898	chr3:45731254	SACM1L	-0.35	-5.73	-0.3	2.26e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.58	-0.47	2.55e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18252515	chr7:66147081	NA	0.4	5.9	0.31	9.26e-9	Aortic root size;
CRC	cis	rs10924970	0.663	rs12749180	chr1:235364105	G/C	cg09010748	chr1:235293032	TOMM20	-0.4	-5.64	-0.3	3.72e-8	Asthma;
CRC	cis	rs11574514	1.000	rs28367503	chr16:67854534	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.02	-0.31	4.73e-9	Crohn's disease;
CRC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.53	0.43	5.48e-16	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12172441	chr6:28176163	NA	0.62	7.31	0.37	2.06e-12	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06188024	chr6:88182584	SLC35A1	0.44	6.34	0.33	7.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.33	-0.33	8.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.8	14.25	0.62	3.19e-36	Breast cancer;
CRC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.68	5.95	0.31	6.68e-9	Yeast infection;
CRC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	6.24	0.33	1.38e-9	Axial length;
CRC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.47	6.38	0.33	5.98e-10	Schizophrenia;
CRC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.5	9.65	0.47	1.5e-19	Educational attainment (years of education);
CRC	cis	rs8008758	1.000	rs8013718	chr14:101689506	C/T	cg26224664	chr14:101693935	NA	-0.39	-5.88	-0.31	1.03e-8	Body mass index (alcohol intake interaction);
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg20607798	chr8:58055168	NA	0.49	5.67	0.3	3.21e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.57	-10.12	-0.49	3.76e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4722166	0.532	rs4719713	chr7:22758811	G/A	cg05472934	chr7:22766657	IL6	0.66	10.37	0.5	5.58e-22	Lung cancer;
CRC	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg11204139	chr17:3907470	NA	-0.76	-13.78	-0.61	1.97e-34	Type 2 diabetes;
CRC	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg03929089	chr4:120376271	NA	0.63	6.15	0.32	2.29e-9	Axial length;
CRC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.06	-0.36	9.85e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.82	-9.06	-0.45	1.15e-17	Breast cancer;
CRC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.69	-8.2	-0.41	5.44e-15	Initial pursuit acceleration;
CRC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.07	0.45	1.13e-17	Parkinson's disease;
CRC	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-7.39	-0.38	1.24e-12	Coronary artery disease;
CRC	cis	rs2072510	0.569	rs17677343	chr12:96397081	T/A	cg09636302	chr12:96389483	HAL	-0.52	-6.38	-0.33	5.86e-10	Metabolite levels (small molecules and protein measures);
CRC	cis	rs10788264	0.504	rs10749452	chr10:124028141	A/G	cg09507567	chr10:124027408	NA	0.36	7.65	0.39	2.24e-13	Total body bone mineral density;
CRC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.53	-8.73	-0.43	1.31e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.6	10.5	0.5	1.98e-22	Schizophrenia;
CRC	cis	rs972578	1.000	rs733139	chr22:43390083	A/T	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.96e-14	Mean platelet volume;
CRC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg22110888	chr17:80059540	CCDC57	0.42	6.54	0.34	2.4e-10	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17437088	chr7:130698670	FLJ43663	0.41	6.94	0.36	2.1e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.7	-0.51	4.06e-23	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.582	rs56094729	chr2:162464835	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.58e-9	Cognitive function;
CRC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.76	-0.47	6.07e-20	Intelligence (multi-trait analysis);
CRC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg08741688	chr4:3415352	RGS12	-0.41	-6.04	-0.32	4.12e-9	Serum sulfate level;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14239635	chr6:116892067	RWDD1	0.52	6.88	0.35	3.12e-11	Thyroid stimulating hormone;
CRC	trans	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.48	-0.34	3.33e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8040855	0.597	rs12902942	chr15:85584804	C/T	cg10818794	chr15:86012489	AKAP13	-0.44	-5.87	-0.31	1.07e-8	Bulimia nervosa;
CRC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.47	7.28	0.37	2.46e-12	Height;
CRC	trans	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg06791473	chr12:49259579	RND1	0.61	6.03	0.32	4.5e-9	Blood protein levels;
CRC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.52	-7.92	-0.4	3.67e-14	Calcium levels;
CRC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.48	6.74	0.35	7.06e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs12230513	0.732	rs6581047	chr12:55832001	C/G	cg19537932	chr12:55886519	OR6C68	-0.73	-9.49	-0.46	5.01e-19	Contrast sensitivity;
CRC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg17810781	chr1:201082982	CACNA1S	0.48	8.07	0.41	1.3e-14	Permanent tooth development;
CRC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.6	-9.93	-0.48	1.72e-20	Calcium levels;
CRC	cis	rs7527798	0.592	rs6667118	chr1:207822724	G/T	cg09232269	chr1:207846808	CR1L	-0.47	-7.66	-0.39	2.16e-13	Erythrocyte sedimentation rate;
CRC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.66	9.98	0.48	1.19e-20	Menopause (age at onset);
CRC	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.75	-16.13	-0.66	1.62e-43	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg20814179	chr4:940893	TMEM175	0.58	9.7	0.47	9.92e-20	Sjögren's syndrome;
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.29	-0.33	1.02e-9	Bipolar disorder;
CRC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.78	-0.35	5.58e-11	Dupuytren's disease;
CRC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.33	-5.75	-0.3	2.07e-8	Erythrocyte sedimentation rate;
CRC	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg02702477	chr5:179499311	RNF130	0.83	8.65	0.43	2.24e-16	LDL cholesterol;
CRC	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg27398640	chr15:77910606	LINGO1	0.45	8.62	0.43	2.86e-16	Type 2 diabetes;
CRC	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg00105475	chr2:10696890	NA	-0.42	-6.55	-0.34	2.22e-10	Prostate cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22817198	chr14:93651628	C14orf109;MOAP1	0.39	6.05	0.32	4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg12172441	chr6:28176163	NA	0.55	7.75	0.39	1.12e-13	Cardiac Troponin-T levels;
CRC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg06219103	chr11:63990595	FERMT3	0.45	7.01	0.36	1.33e-11	Platelet count;
CRC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg03909863	chr11:638404	DRD4	-0.51	-6.85	-0.35	3.61e-11	Systemic lupus erythematosus;
CRC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.6	-7.1	-0.36	7.74e-12	Vitiligo;
CRC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.53	6.16	0.32	2.07e-9	Lymphocyte counts;
CRC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.48	7.3	0.37	2.12e-12	Corneal astigmatism;
CRC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	0.98	13.78	0.6	2.04e-34	Breast cancer;
CRC	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-9.05	-0.45	1.31e-17	Bone mineral density;
CRC	cis	rs12286929	0.898	rs11215384	chr11:115023851	C/G	cg04055981	chr11:115044050	NA	0.35	5.71	0.3	2.54e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg22638593	chr5:131593259	PDLIM4	0.39	6.39	0.33	5.55e-10	Breast cancer;
CRC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg14664628	chr15:75095509	CSK	-0.41	-6.0	-0.31	5.34e-9	Caffeine consumption;
CRC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg02135003	chr7:105160482	PUS7	-0.66	-9.96	-0.48	1.32e-20	Bipolar disorder (body mass index interaction);
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.31	-5.61	-0.3	4.29e-8	Lung cancer;
CRC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg06766960	chr11:133703094	NA	-0.42	-7.48	-0.38	6.97e-13	Childhood ear infection;
CRC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.57	-5.89	-0.31	9.63e-9	Schizophrenia;
CRC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-6.47	-0.34	3.56e-10	Platelet distribution width;
CRC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.28	-0.49	1.15e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.33	-0.33	8.03e-10	Breast cancer;
CRC	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg10437265	chr15:77819839	NA	-0.44	-7.84	-0.4	6.35e-14	Type 2 diabetes;
CRC	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg09476006	chr5:138032270	NA	-0.43	-6.6	-0.34	1.62e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.63	0.65	1.46e-41	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg02683197	chr6:28174875	NA	0.65	8.41	0.42	1.22e-15	Parkinson's disease;
CRC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.51	9.18	0.45	5.09e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg07404485	chr7:94953653	PON1	-0.47	-6.05	-0.32	3.87e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-9.18	-0.45	5.03e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.08	0.36	8.85e-12	Rheumatoid arthritis;
CRC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.92	-17.29	-0.69	4.09e-48	Height;
CRC	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg17133734	chr15:86042851	AKAP13	0.42	6.79	0.35	5.35e-11	Coronary artery disease;
CRC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.35	0.42	1.88e-15	Height;
CRC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.72	8.89	0.44	4.13e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	9.91	0.48	1.99e-20	Mean corpuscular hemoglobin;
CRC	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.53	-7.8	-0.39	8.4e-14	Response to antidepressants in depression;
CRC	cis	rs7945718	0.621	rs6485978	chr11:12678415	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs2302190	0.882	rs7216856	chr17:56472295	C/T	cg12560992	chr17:57184187	TRIM37	0.48	6.11	0.32	2.78e-9	Vitamin D levels;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.02	-0.31	4.76e-9	Depression;
CRC	trans	rs616147	0.850	rs631312	chr3:39508968	A/G	cg24004139	chr1:26670703	AIM1L	0.38	6.1	0.32	2.99e-9	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs2882667	0.931	rs3749665	chr5:138357211	A/G	cg09476006	chr5:138032270	NA	0.46	7.48	0.38	6.81e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	7.65	0.39	2.23e-13	Lewy body disease;
CRC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.17	-0.37	4.87e-12	Body mass index;
CRC	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	8.15	0.41	7.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg13414629	chr9:132935646	FREQ	0.43	6.25	0.33	1.3e-9	Alzheimer's disease (cognitive decline);
CRC	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.64	10.02	0.48	8.38e-21	Corneal astigmatism;
CRC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg00074818	chr8:8560427	CLDN23	0.42	7.44	0.38	8.59e-13	Obesity-related traits;
CRC	cis	rs4363385	0.553	rs61813181	chr1:152942177	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.59	-0.34	1.73e-10	Inflammatory skin disease;
CRC	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg13834844	chr10:102415320	NA	-0.34	-5.71	-0.3	2.57e-8	Body mass index;
CRC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.47	6.52	0.34	2.71e-10	Uric acid levels;
CRC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.57	9.11	0.45	8.4e-18	Intelligence (multi-trait analysis);
CRC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17507749	chr15:85114479	UBE2QP1	0.6	8.38	0.42	1.52e-15	Schizophrenia;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg01721255	chr8:58191610	C8orf71	0.47	5.97	0.31	6.02e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.44	5.96	0.31	6.51e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.54	8.85	0.44	5.54e-17	Metabolite levels;
CRC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.55	-7.69	-0.39	1.72e-13	Lymphocyte percentage of white cells;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg03623178	chr6:28175578	NA	0.95	12.14	0.56	2.76e-28	Parkinson's disease;
CRC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg13722127	chr7:150037890	RARRES2	0.47	7.66	0.39	2.07e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs524023	0.874	rs492175	chr11:64433078	A/G	cg06522879	chr11:64358276	SLC22A12	0.5	7.6	0.39	3.21e-13	Urate levels in obese individuals;
CRC	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg10761708	chr20:43804764	PI3	0.48	5.62	0.3	4.06e-8	Blood protein levels;
CRC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg04518342	chr5:131593106	PDLIM4	-0.32	-5.66	-0.3	3.21e-8	Blood metabolite levels;
CRC	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	1.01	12.45	0.57	1.96e-29	IgG glycosylation;
CRC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.41	5.8	0.3	1.59e-8	Parkinson's disease;
CRC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.68	-0.3	3e-8	Body mass index;
CRC	cis	rs7527798	0.614	rs11118253	chr1:207825469	G/C	cg21110645	chr1:207815933	NA	-0.39	-6.18	-0.32	1.9e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.64	8.84	0.44	6.03e-17	Lung cancer;
CRC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg10760299	chr15:45669010	GATM	0.49	7.83	0.4	6.7e-14	Homoarginine levels;
CRC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.73	-0.35	7.71e-11	Cutaneous nevi;
CRC	cis	rs3823572	0.542	rs2971971	chr7:133643848	A/G	cg03336402	chr7:133662267	EXOC4	-0.66	-10.2	-0.49	2.07e-21	Intelligence (multi-trait analysis);
CRC	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.66	-0.34	1.12e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs4664293	0.867	rs3764968	chr2:160647090	C/T	cg08347373	chr2:160653686	CD302	-0.51	-7.97	-0.4	2.62e-14	Monocyte percentage of white cells;
CRC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.74	-0.35	7.19e-11	Total body bone mineral density;
CRC	cis	rs2249694	0.878	rs2480256	chr10:135352514	A/G	cg16964102	chr10:135390573	NA	-0.39	-6.41	-0.33	5.19e-10	Obesity-related traits;
CRC	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00495681	chr13:53174319	NA	0.64	9.57	0.47	2.67e-19	Lewy body disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22428961	chr1:2344426	PEX10	0.38	6.36	0.33	6.61e-10	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11059266	chr4:48782139	FRYL	0.38	6.4	0.33	5.47e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09610735	chr10:22609918	BMI1	0.44	6.19	0.32	1.77e-9	Response to antipsychotic treatment;
CRC	cis	rs9648716	1.000	rs1267612	chr7:140511760	C/T	cg10747023	chr7:140774559	NA	0.45	5.86	0.31	1.14e-8	Type 2 diabetes;
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.51	7.4	0.38	1.12e-12	Testicular germ cell tumor;
CRC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.43	-0.33	4.42e-10	Breast cancer;
CRC	cis	rs9648716	1.000	rs6464157	chr7:140629408	T/C	cg10747023	chr7:140774559	NA	0.46	6.02	0.31	4.76e-9	Type 2 diabetes;
CRC	cis	rs995000	0.895	rs597470	chr1:62917796	T/G	cg19896129	chr1:63156450	NA	0.44	6.81	0.35	4.71e-11	Triglyceride levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22913584	chr5:81046758	SSBP2	0.4	6.06	0.32	3.63e-9	Schizophrenia;
CRC	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.45	6.82	0.35	4.5e-11	Height;
CRC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	11.05	0.52	2.36e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg13476313	chr9:127244764	NR5A1	0.29	6.06	0.32	3.83e-9	Menarche (age at onset);
CRC	cis	rs7625357	0.964	rs1421005	chr3:169351777	C/T	cg04414509	chr3:169351419	MECOM	0.63	8.97	0.44	2.34e-17	Childhood and early adolescence aggressive behavior;
CRC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg19773385	chr1:10388646	KIF1B	-0.55	-7.58	-0.39	3.49e-13	Hepatocellular carcinoma;
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg04077850	chr5:125800366	GRAMD3	0.38	6.3	0.33	9.3e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.69	-8.83	-0.44	6.35e-17	Schizophrenia;
CRC	cis	rs457287	0.772	rs10974799	chr9:4818453	G/C	cg14182974	chr9:4791918	RCL1	-0.42	-5.62	-0.3	4.12e-8	Platelet count;
CRC	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.8e-9	Endometrial cancer;
CRC	cis	rs12024301	0.557	rs10911409	chr1:183660804	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.59	-0.34	1.75e-10	Aortic root size;
CRC	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.03	-0.32	4.46e-9	Sjögren's syndrome;Systemic lupus erythematosus;
CRC	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.22	-0.32	1.52e-9	Coronary artery disease;
CRC	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.56	8.42	0.42	1.19e-15	Fuchs's corneal dystrophy;
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.6	-0.57	5.51e-30	Bipolar disorder and schizophrenia;
CRC	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.75	0.54	7.56e-27	Exhaled nitric oxide levels;
CRC	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg27534772	chr1:16042836	PLEKHM2	0.42	7.03	0.36	1.23e-11	Systolic blood pressure;
CRC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg03037974	chr15:76606532	NA	-0.57	-8.77	-0.44	1.01e-16	Blood metabolite levels;
CRC	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.83	-0.31	1.36e-8	Type 2 diabetes;
CRC	trans	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg10756647	chr7:56101905	PSPH	-0.72	-8.08	-0.41	1.28e-14	Diabetic kidney disease;
CRC	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.58	-9.14	-0.45	6.68e-18	Breast cancer;
CRC	trans	rs7302981	1.000	rs7302981	chr12:50537815	A/G	cg18430156	chr2:187558795	FAM171B	0.35	6.02	0.31	4.72e-9	Systolic blood pressure;
CRC	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg08999081	chr20:33150536	PIGU	0.37	5.83	0.31	1.33e-8	Skin pigmentation;
CRC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.67	-13.37	-0.59	7.04e-33	Bone mineral density;
CRC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.4	6.74	0.35	6.91e-11	Total body bone mineral density;
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg08744461	chr12:108079556	PWP1	-0.43	-6.08	-0.32	3.24e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg03341697	chr11:94277138	FUT4	-0.39	-5.98	-0.31	5.84e-9	Aortic root size;
CRC	trans	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.73	-0.39	1.35e-13	HDL cholesterol;
CRC	trans	rs6686842	1.000	rs213733	chr1:41576989	T/C	cg19787969	chr8:9763211	NA	0.28	5.97	0.31	6.03e-9	Height;
CRC	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-1.15	-9.25	-0.45	2.98e-18	Mitochondrial DNA levels;
CRC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.6	9.3	0.46	2.07e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2811415	0.597	rs1042912	chr3:127789695	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs9361491	0.657	rs4706730	chr6:79467903	C/T	cg05283184	chr6:79620031	NA	-0.37	-5.67	-0.3	3.16e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-7.2	-0.37	4.12e-12	Electroencephalogram traits;
CRC	cis	rs755249	0.567	rs60323161	chr1:39710459	T/C	cg18385671	chr1:39797026	MACF1	-0.44	-6.09	-0.32	3.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.67	0.6	5.38e-34	Alzheimer's disease;
CRC	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.43	6.94	0.36	2.08e-11	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08575399	chr20:60719638	PSMA7;SS18L1	0.5	7.11	0.36	7.13e-12	Response to antipsychotic treatment;
CRC	cis	rs6546324	0.625	rs4671812	chr2:67832486	C/T	cg15745817	chr2:67799979	NA	-0.57	-9.64	-0.47	1.6e-19	Endometriosis;
CRC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	9.29	0.46	2.23e-18	Hemoglobin concentration;
CRC	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	1.15	9.97	0.48	1.26e-20	Mitochondrial DNA levels;
CRC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.46	6.15	0.32	2.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg08200582	chr11:442649	ANO9	-0.7	-7.07	-0.36	9.14e-12	Body mass index;
CRC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs73206853	0.841	rs73191851	chr12:111032305	G/A	cg12870014	chr12:110450643	ANKRD13A	0.81	8.35	0.42	1.95e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.54	6.43	0.33	4.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg24463073	chr6:118973353	C6orf204	0.51	6.81	0.35	4.71e-11	Diastolic blood pressure;
CRC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.66	8.73	0.43	1.33e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.42	-5.82	-0.31	1.37e-8	Eye color traits;
CRC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.41	-0.33	4.93e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.39	5.99	0.31	5.56e-9	Mean corpuscular volume;
CRC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.5	-8.04	-0.41	1.62e-14	Monocyte count;
CRC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-5.92	-0.31	7.93e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.5	-0.34	2.9e-10	Cystic fibrosis severity;
CRC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs6544773	0.630	rs2673281	chr2:45065355	G/A	cg10208897	chr5:178548229	ADAMTS2	0.35	6.0	0.31	5.08e-9	Mosquito bite size;
CRC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.8	-0.4	8.26e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	7.07	0.36	9.12e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.64	8.8	0.44	7.72e-17	Parkinson's disease;
CRC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-6.08	-0.32	3.4e-9	Daytime sleep phenotypes;
CRC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg18016565	chr1:150552671	MCL1	0.43	6.0	0.31	5.13e-9	Melanoma;
CRC	cis	rs9322817	0.653	rs9399896	chr6:105216969	A/G	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.37e-16	Thyroid stimulating hormone;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg27470027	chr11:63684601	RCOR2	-0.36	-6.48	-0.34	3.43e-10	Brain structure;
CRC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.19	0.32	1.78e-9	Tonsillectomy;
CRC	cis	rs6427782	0.582	rs6695240	chr1:199833586	G/A	cg07208853	chr1:200005219	NR5A2	0.23	5.94	0.31	7.13e-9	Menarche (age at onset);
CRC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg19673125	chr6:150240577	RAET1G	0.29	5.63	0.3	3.82e-8	Testicular germ cell tumor;
CRC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg14530993	chr4:882597	GAK	-0.82	-7.8	-0.4	8.31e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg26587870	chr6:27730563	NA	-0.45	-6.55	-0.34	2.18e-10	Parkinson's disease;
CRC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.24	-0.53	5.14e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	0.93	11.01	0.52	3.31e-24	Type 2 diabetes nephropathy;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.06	-28.15	-0.84	1.27e-89	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	10.73	0.51	3.13e-23	Type 2 diabetes;
CRC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	10.56	0.5	1.24e-22	Motion sickness;
CRC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	10.22	0.49	1.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.05	-21.32	-0.76	5.87e-64	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg02033258	chr5:131593261	PDLIM4	0.38	6.39	0.33	5.51e-10	Acylcarnitine levels;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg27635394	chr6:26043820	HIST1H2BB	0.38	5.73	0.3	2.21e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg07978099	chr16:83986941	OSGIN1	-0.48	-6.1	-0.32	3.05e-9	Pursuit maintenance gain;
CRC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.55	6.71	0.35	8.44e-11	Vitiligo;
CRC	cis	rs7254114	0.686	rs7249565	chr19:11302807	C/T	cg02815516	chr19:11306319	KANK2	-0.36	-7.07	-0.36	9.33e-12	Immature fraction of reticulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09695362	chr17:43324895	LOC100133991	0.41	6.65	0.34	1.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.43	-0.42	1.08e-15	Hemoglobin concentration;
CRC	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.13	17.09	0.69	2.61e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06656553	chr16:89960601	TCF25	-0.55	-5.7	-0.3	2.62e-8	Skin colour saturation;
CRC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23283495	chr1:209979779	IRF6	-0.32	-5.84	-0.31	1.23e-8	Orofacial clefts;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.49	7.29	0.37	2.29e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.43	6.94	0.36	2.1e-11	Resting heart rate;
CRC	cis	rs6504622	0.818	rs11079742	chr17:45020128	A/G	cg16759221	chr17:45003025	GOSR2	0.49	7.4	0.38	1.17e-12	Orofacial clefts;
CRC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.18	-0.32	1.94e-9	Menopause (age at onset);
CRC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg27523141	chr10:43048294	ZNF37B	0.49	7.13	0.37	6.4e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.8	11.91	0.55	1.92e-27	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08180952	chr15:75744002	SIN3A	0.4	6.42	0.33	4.69e-10	Obesity-related traits;
CRC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.43	-0.33	4.47e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs10450586	0.932	rs7480595	chr11:27316623	T/C	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.46	-6.39	-0.33	5.6e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.0	0.58	1.85e-31	Alzheimer's disease;
CRC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	8.46	0.42	8.88e-16	Lymphocyte counts;
CRC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg24505167	chr7:1915268	MAD1L1	-0.46	-6.42	-0.33	4.77e-10	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg25985355	chr7:65971099	NA	-0.49	-5.73	-0.3	2.27e-8	Diabetic kidney disease;
CRC	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.28	-0.37	2.48e-12	Depression;
CRC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.96	-0.4	2.87e-14	Gut microbiome composition (summer);
CRC	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.5	-0.38	5.82e-13	Inflammatory bowel disease;
CRC	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.86	-0.55	2.96e-27	Colorectal cancer;
CRC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg18479299	chr3:125709523	NA	-0.55	-6.64	-0.34	1.3e-10	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg00129232	chr17:37814104	STARD3	0.52	6.42	0.33	4.77e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs807029	0.577	rs11190787	chr10:102758625	G/T	cg04662943	chr10:102668895	NA	0.58	6.93	0.36	2.17e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6662572	0.737	rs4388641	chr1:46522326	A/C	cg08644498	chr1:46502608	NA	0.45	7.14	0.37	6.01e-12	Blood protein levels;
CRC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	9.05	0.45	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.71	-10.61	-0.5	8.0700000000000006e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs7731657	0.537	rs971700	chr5:130361575	T/G	cg08523029	chr5:130500466	HINT1	-0.47	-6.02	-0.31	4.67e-9	Fasting plasma glucose;
CRC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg05501817	chr11:14380813	RRAS2	-0.47	-6.52	-0.34	2.59e-10	Sense of smell;
CRC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.8	-8.55	-0.43	4.58e-16	Coronary artery disease;
CRC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg19046167	chr17:80928561	B3GNTL1	0.4	6.36	0.33	6.66e-10	Breast cancer;
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-13.02	-0.58	1.56e-31	Alzheimer's disease;
CRC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	13.2	0.59	3.13e-32	Electrocardiographic conduction measures;
CRC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg13047869	chr3:10149882	C3orf24	0.44	6.51	0.34	2.82e-10	Alzheimer's disease;
CRC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02290350	chr8:58132656	NA	-0.53	-7.86	-0.4	5.64e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4936891	0.577	rs4935862	chr11:123921479	C/T	cg22125253	chr11:123886957	OR10G4	0.33	6.04	0.32	4.2e-9	Male fertility;
CRC	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg18678763	chr11:4115507	RRM1	-0.36	-5.79	-0.3	1.68e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00166722	chr3:10149974	C3orf24	0.61	8.13	0.41	9.08e-15	Alzheimer's disease;
CRC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.74	-11.47	-0.53	7.33e-26	Colorectal cancer;
CRC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.51	8.29	0.42	3.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg01314568	chr7:57830625	NA	0.64	8.47	0.42	8.08e-16	Obesity-related traits;
CRC	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.28	6.13	0.32	2.55e-9	Educational attainment (years of education);
CRC	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg23032129	chr1:109941072	SORT1	-0.28	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.96	-0.31	6.58e-9	Neuroticism;
CRC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg17691542	chr6:26056736	HIST1H1C	0.41	5.79	0.3	1.67e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6429082	0.510	rs2789367	chr1:235506918	G/C	cg26050004	chr1:235667680	B3GALNT2	0.4	5.86	0.31	1.11e-8	Adiposity;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg15845792	chr6:28175446	NA	0.79	11.81	0.55	4.37e-27	Parkinson's disease;
CRC	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-9.49	-0.46	4.8e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.78	11.25	0.53	4.74e-25	Gout;
CRC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg24560729	chr4:1342394	KIAA1530	-0.34	-5.61	-0.3	4.2e-8	Obesity-related traits;
CRC	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg10820045	chr2:198174542	NA	0.38	6.38	0.33	6.09e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs2547917	0.947	rs2591744	chr5:58715865	A/G	cg15920655	chr2:129025795	HS6ST1	0.56	5.99	0.31	5.61e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg21577049	chr2:228736449	WDR69	-0.47	-6.28	-0.33	1.09e-9	Blood pressure;
CRC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.48	6.77	0.35	5.93e-11	Breast cancer;
CRC	cis	rs478222	0.930	rs510107	chr2:25319471	G/A	cg22495460	chr2:25135724	ADCY3	0.43	6.47	0.34	3.64e-10	Type 1 diabetes;
CRC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.51	-6.0	-0.31	5.16e-9	Diastolic blood pressure;
CRC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.79	0.35	5.23e-11	Hip circumference adjusted for BMI;
CRC	cis	rs17021463	0.676	rs62320932	chr4:95307037	C/T	cg11021082	chr4:95130006	SMARCAD1	0.44	6.35	0.33	6.97e-10	Testicular germ cell tumor;
CRC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.61	8.3	0.42	2.72e-15	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12595990	chr12:49351331	ARF3	0.41	6.56	0.34	2.07e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.39	6.06	0.32	3.67e-9	Menopause (age at onset);
CRC	cis	rs938554	0.876	rs10017945	chr4:9937852	A/G	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.82	-0.31	1.4e-8	Blood metabolite levels;
CRC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.5	6.96	0.36	1.85e-11	Schizophrenia;
CRC	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg16540259	chr10:75572220	NDST2	-0.52	-7.9	-0.4	4.3e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg21251018	chr6:28226885	NKAPL	-0.45	-6.49	-0.34	3.18e-10	Depression;
CRC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	7.75	0.39	1.16e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg05679027	chr9:99775184	HIATL2	-0.41	-6.15	-0.32	2.24e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.56	-8.55	-0.43	4.74e-16	Vitiligo;
CRC	cis	rs820430	0.512	rs2120892	chr3:27249655	C/G	cg02860705	chr3:27208620	NA	0.4	6.13	0.32	2.49e-9	Hypertension;Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs3736485	0.966	rs8042221	chr15:51774613	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-6.33	-0.33	7.97e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs9583531	0.760	rs1887200	chr13:111393137	A/C	cg24331049	chr13:111365604	ING1	-0.5	-5.87	-0.31	1.04e-8	Coronary artery disease;
CRC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg15511327	chr8:143859410	LYNX1	-0.52	-9.14	-0.45	6.63e-18	Urinary tract infection frequency;
CRC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.61	8.98	0.44	2.09e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.62	11.19	0.52	7.8e-25	Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16532893	chr10:38146893	ZNF248	0.47	7.57	0.39	3.68e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.39	-5.92	-0.31	7.88e-9	Intelligence;
CRC	cis	rs860295	0.651	rs12239114	chr1:155322142	G/A	cg02153340	chr1:155202674	NA	-0.58	-6.88	-0.35	2.98e-11	Body mass index;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg15786705	chr6:28176104	NA	0.42	5.87	0.31	1.04e-8	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05900430	chr19:48825159	NA	0.46	6.22	0.32	1.51e-9	Anxiety disorder;
CRC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.88	0.31	1.02e-8	Hemoglobin concentration;
CRC	cis	rs863345	0.604	rs2051450	chr1:158464062	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.26	-0.33	1.17e-9	Pneumococcal bacteremia;
CRC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.4	6.03	0.32	4.43e-9	Height;
CRC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	7.52	0.38	5.36e-13	Height;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg18168387	chr12:120933482	DYNLL1	-0.41	-6.24	-0.33	1.31e-9	Daytime sleep phenotypes;
CRC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg19812747	chr11:111475976	SIK2	0.43	6.6	0.34	1.66e-10	Primary sclerosing cholangitis;
CRC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg24463073	chr6:118973353	C6orf204	0.55	7.34	0.38	1.7e-12	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21218476	chr17:7117863	DLG4	0.37	6.02	0.31	4.61e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.54	10.26	0.49	1.27e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.82	0.31	1.4e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.44	6.72	0.35	8.13e-11	Mean platelet volume;
CRC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06656553	chr16:89960601	TCF25	-0.63	-5.69	-0.3	2.79e-8	Skin colour saturation;
CRC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.46	7.09	0.36	8.09e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.49	6.83	0.35	4.03e-11	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17449403	chr12:48357323	TMEM106C	0.43	6.92	0.36	2.44e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg14949292	chr17:78079608	GAA	-0.42	-6.04	-0.32	4.26e-9	Yeast infection;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.07	-0.32	3.49e-9	Parkinson's disease;
CRC	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.06	20.34	0.75	3.98e-60	Schizophrenia;
CRC	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.48	-7.61	-0.39	2.96e-13	Schizophrenia;
CRC	cis	rs6066835	0.867	rs16994110	chr20:47360830	T/C	cg18078177	chr20:47281410	PREX1	0.61	5.6	0.3	4.46e-8	Multiple myeloma;
CRC	trans	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg17903999	chr18:56338584	MALT1	-0.43	-7.02	-0.36	1.25e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.52	7.09	0.36	8.21e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg14541582	chr5:601475	NA	-0.32	-6.65	-0.34	1.22e-10	Obesity-related traits;
CRC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg05979741	chr2:110873485	MALL	0.47	6.17	0.32	2.03e-9	Type 2 diabetes (age of onset);
CRC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg06096015	chr1:231504339	EGLN1	0.41	6.05	0.32	4.03e-9	Hemoglobin concentration;
CRC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg02659138	chr7:134003124	SLC35B4	0.39	6.67	0.35	1.07e-10	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12820191	chr3:186524311	RFC4	0.38	6.13	0.32	2.49e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6586163	1.000	rs6586165	chr10:90755056	T/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.29	-0.37	2.38e-12	Chronic lymphocytic leukemia;
CRC	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.55	-6.28	-0.33	1.07e-9	Post bronchodilator FEV1;
CRC	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.71	-12.04	-0.55	6.6e-28	Brugada syndrome;
CRC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.43	-6.17	-0.32	2.05e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs909002	0.849	rs10798879	chr1:32096815	T/C	cg13919466	chr1:32135498	COL16A1	-0.32	-6.1	-0.32	2.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.7	11.97	0.55	1.14e-27	Longevity;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs2932538	0.583	rs2932537	chr1:113230394	C/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.08	0.32	3.41e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-0.62	-5.96	-0.31	6.5e-9	Alzheimer's disease (late onset);
CRC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.64	0.39	2.43e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4731207	0.596	rs1871772	chr7:124678872	G/T	cg23710748	chr7:124431027	NA	-0.4	-6.28	-0.33	1.09e-9	Cutaneous malignant melanoma;
CRC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.07	-0.45	1.09e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.45	6.52	0.34	2.58e-10	Schizophrenia;
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.81	12.09	0.55	4.19e-28	Menarche (age at onset);
CRC	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.18	-0.37	4.69e-12	Caudate activity during reward;
CRC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.38	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.41	-0.71	1.62e-52	Schizophrenia;
CRC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.53	-8.04	-0.41	1.64e-14	Dementia with Lewy bodies;
CRC	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.5	-7.72	-0.39	1.45e-13	Malaria;
CRC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.37	5.99	0.31	5.59e-9	IgG glycosylation;
CRC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.61e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.65	-8.46	-0.42	8.63e-16	Extraversion;
CRC	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg25790453	chr13:113633590	MCF2L	-0.51	-8.79	-0.44	8.75e-17	Systolic blood pressure;
CRC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.41	-0.33	5.18e-10	Breast cancer;
CRC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.28	-0.37	2.47e-12	Bladder cancer;
CRC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	trans	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg00953403	chr17:74099816	EXOC7	-0.49	-7.38	-0.38	1.27e-12	Psychosis in Alzheimer's disease;
CRC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.22	-0.32	1.51e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.61	8.64	0.43	2.4e-16	Homoarginine levels;
CRC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg12273811	chr6:28175739	NA	0.67	10.11	0.49	4.27e-21	Cardiac Troponin-T levels;
CRC	cis	rs1451375	0.698	rs10899748	chr7:50646089	G/A	cg14593290	chr7:50529359	DDC	0.56	7.27	0.37	2.7e-12	Malaria;
CRC	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.62	0.47	1.79e-19	Schizophrenia;
CRC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.36	0.53	1.86e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg26668828	chr6:292823	DUSP22	-0.59	-8.61	-0.43	3.05e-16	Menopause (age at onset);
CRC	trans	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg17903999	chr18:56338584	MALT1	-0.4	-6.8	-0.35	4.96e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs17767392	0.813	rs12887261	chr14:71941979	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.34	-0.33	7.52e-10	Mitral valve prolapse;
CRC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13198984	chr17:80129470	CCDC57	0.48	8.52	0.43	5.83e-16	Life satisfaction;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.67	7.92	0.4	3.57e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	8.92	0.44	3.42e-17	Cognitive test performance;
CRC	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.68	-7.7	-0.39	1.56e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-11.98	-0.55	1.07e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11065834	chr7:131012360	MKLN1	0.38	6.03	0.32	4.51e-9	Myopia (pathological);
CRC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-5.95	-0.31	7.01e-9	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.39	0.59	6.08e-33	Vitiligo;
CRC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.58	-10.25	-0.49	1.35e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03241323	chr2:187454863	ITGAV	0.4	6.63	0.34	1.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7517126	1.000	rs7412359	chr1:196832925	G/A	cg13682187	chr1:196946512	CFHR5	-0.4	-6.35	-0.33	7.26e-10	Blood protein levels;
CRC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.46	-7.4	-0.38	1.14e-12	Height;
CRC	cis	rs10992471	0.580	rs10122383	chr9:95554675	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-5.66	-0.3	3.38e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4743820	0.651	rs4237213	chr9:93932708	A/T	cg14446406	chr9:93919335	NA	-0.75	-13.49	-0.6	2.61e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg03013999	chr17:37608204	MED1	0.48	7.43	0.38	9.6e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	10.99	0.52	3.99e-24	Motion sickness;
CRC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	8.99	0.44	1.94e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.72	0.39	1.41e-13	Testicular germ cell tumor;
CRC	cis	rs6764363	0.616	rs9813769	chr3:286023	C/T	cg02057681	chr3:285234	CHL1	0.38	5.8	0.3	1.54e-8	Sudden cardiac arrest;
CRC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg06987292	chr12:125626746	AACS	0.34	5.96	0.31	6.54e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.3	3.18e-8	Diabetic retinopathy;
CRC	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.11	-0.37	7.14e-12	Putamen volume;
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18301423	chr5:131593218	PDLIM4	0.37	7.0	0.36	1.46e-11	Breast cancer;
CRC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.55	6.66	0.34	1.12e-10	Diastolic blood pressure;
CRC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	8.07	0.41	1.31e-14	Coronary artery disease;
CRC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.78	-8.8	-0.44	8.02e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg08772003	chr10:104629869	AS3MT	-0.35	-5.8	-0.3	1.53e-8	Arsenic metabolism;
CRC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg22029157	chr1:209979665	IRF6	0.59	6.94	0.36	2.1e-11	Coronary artery disease;
CRC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg25834613	chr7:1915315	MAD1L1	0.4	5.9	0.31	8.83e-9	Bipolar disorder;
CRC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.92	11.73	0.54	9.09e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs972578	0.967	rs926353	chr22:43371507	T/A	cg01576275	chr22:43409880	NA	-0.46	-7.36	-0.38	1.52e-12	Mean platelet volume;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg06470822	chr6:28175283	NA	0.82	8.34	0.42	2.13e-15	Lung cancer in ever smokers;
CRC	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	6.25	0.33	1.27e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg12172441	chr6:28176163	NA	0.53	7.28	0.37	2.5e-12	Parkinson's disease;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg14263244	chr12:80329611	PPP1R12A	-0.4	-6.29	-0.33	9.95e-10	Aortic root size;
CRC	cis	rs9292777	0.901	rs6876242	chr5:40422938	A/C	cg09067459	chr5:40385259	NA	0.53	9.25	0.45	3.02e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.69	-11.0	-0.52	3.48e-24	Cognitive function;
CRC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg21466736	chr12:48725269	NA	0.46	7.12	0.37	6.99e-12	Glycated hemoglobin levels;
CRC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg09045935	chr12:6379348	NA	1.13	9.23	0.45	3.42e-18	Blood metabolite levels;
CRC	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg00490450	chr3:139108681	COPB2	-0.43	-6.49	-0.34	3.11e-10	Obesity-related traits;
CRC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.42	6.59	0.34	1.75e-10	High light scatter reticulocyte count;
CRC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg23262073	chr20:60523788	NA	-0.42	-6.63	-0.34	1.38e-10	Body mass index;
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.43	6.24	0.33	1.33e-9	Menarche (age at onset);
CRC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-8.15	-0.41	7.75e-15	IgG glycosylation;
CRC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.51	-8.26	-0.41	3.59e-15	Monocyte count;
CRC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg08761264	chr16:28874980	SH2B1	-0.42	-5.64	-0.3	3.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg23123621	chr4:1343375	KIAA1530	0.37	6.38	0.33	6.03e-10	Longevity;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.14	0.32	2.33e-9	Parkinson's disease;
CRC	trans	rs4276421	0.806	rs6892594	chr5:45427173	C/T	cg04793272	chr11:119020941	ABCG4	-0.37	-6.15	-0.32	2.28e-9	P wave duration;
CRC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.47	0.46	5.66e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg19193384	chr17:30244184	NA	-0.54	-6.91	-0.36	2.52e-11	Hip circumference adjusted for BMI;
CRC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.61	-9.69	-0.47	1.11e-19	Colorectal cancer;
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.85	-0.4	6.05e-14	Menopause (age at onset);
CRC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.73	0.39	1.33e-13	Colorectal cancer;
CRC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg17724175	chr1:150552817	MCL1	0.47	6.88	0.35	3.11e-11	Melanoma;
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.28	-0.42	3.18e-15	Electroencephalogram traits;
CRC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.76	12.26	0.56	1.01e-28	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.39	-6.31	-0.33	8.78e-10	Gout;Renal underexcretion gout;
CRC	cis	rs7937840	0.559	rs2000957	chr11:61877744	A/G	cg01969543	chr11:61895209	INCENP	-0.52	-7.35	-0.38	1.57e-12	Breast cancer;
CRC	cis	rs11212617	0.935	rs186591	chr11:108200142	T/G	cg12106634	chr11:108092400	ATM;NPAT	0.41	6.0	0.31	5.15e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1832871	0.521	rs62437410	chr6:158822888	G/C	cg07165851	chr6:158734300	TULP4	0.45	5.89	0.31	9.7e-9	Height;
CRC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.4	-8.5	-0.42	6.75e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.69	9.03	0.45	1.49e-17	Breast cancer;
CRC	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.5	6.72	0.35	7.91e-11	Caudate activity during reward;
CRC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg20387954	chr3:183756860	HTR3D	0.45	7.62	0.39	2.65e-13	Anterior chamber depth;
CRC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg03030879	chr14:75389066	RPS6KL1	0.42	6.46	0.34	3.75e-10	Height;
CRC	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg09003973	chr2:102972529	NA	0.4	5.76	0.3	1.91e-8	Blood protein levels;
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25314532	chr22:38349562	C22orf23;POLR2F	0.39	6.03	0.32	4.44e-9	Interleukin-6 levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07235652	chr12:109531354	ALKBH2	0.38	6.15	0.32	2.21e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17384870	chr19:52772871	ZNF766	0.42	6.47	0.34	3.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.03	-0.32	4.34e-9	Inflammatory bowel disease;
CRC	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs1524976	1.000	rs2177685	chr3:65491171	T/C	cg16238336	chr3:65465873	MAGI1	-0.53	-6.79	-0.35	5.34e-11	PR interval;
CRC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg03233332	chr7:66118400	NA	-0.45	-6.35	-0.33	7.35e-10	Aortic root size;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.45	-6.65	-0.34	1.24e-10	Parkinson's disease;
CRC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.22	0.71	9.09e-52	Cognitive ability;
CRC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.77	-10.15	-0.49	3.03e-21	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.2	0.32	1.66e-9	Prudent dietary pattern;
CRC	cis	rs7091068	0.671	rs1223296	chr10:95404621	T/C	cg20715218	chr10:95462985	C10orf4	-0.48	-5.66	-0.3	3.38e-8	Urinary tract infection frequency;
CRC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03934478	chr11:495069	RNH1	0.69	7.13	0.37	6.34e-12	Body mass index;
CRC	cis	rs6479527	0.875	rs1331216	chr9:96767722	G/A	cg14459158	chr9:96720562	NA	0.37	6.79	0.35	5.09e-11	Esophageal adenocarcinoma;
CRC	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.51	7.84	0.4	6.42e-14	Corneal astigmatism;
CRC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.11	10.98	0.52	4.31e-24	Diabetic retinopathy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08872713	chr16:56716227	MT1X	0.46	5.98	0.31	5.72e-9	Anxiety disorder;
CRC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.83	-0.48	3.62e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg15226275	chr6:116381976	FRK	0.3	8.56	0.43	4.5e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.46e-13	Schizophrenia;
CRC	cis	rs35520189	0.591	rs12466697	chr2:113709876	C/G	cg12858261	chr2:113808755	IL1F8	0.46	6.07	0.32	3.53e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg09873164	chr1:152488093	CRCT1	0.4	6.74	0.35	7.22e-11	Hair morphology;
CRC	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-6.09	-0.32	3.09e-9	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16055035	chr6:13487883	GFOD1;C6orf114	0.41	6.25	0.33	1.27e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1223397	0.651	rs2439534	chr6:13305757	C/T	cg20827128	chr6:13274284	PHACTR1	-0.4	-6.03	-0.32	4.29e-9	Blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18845289	chr12:121124611	MLEC	0.44	6.31	0.33	9.18e-10	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg14008862	chr17:28927542	LRRC37B2	0.47	5.87	0.31	1.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.57	-0.43	3.99e-16	Biliary atresia;
CRC	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg18806716	chr10:30721971	MAP3K8	0.45	6.82	0.35	4.44e-11	Inflammatory bowel disease;
CRC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.54	5.7	0.3	2.64e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.65	0.39	2.21e-13	Schizophrenia;
CRC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.17	-0.37	4.87e-12	Morning vs. evening chronotype;
CRC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.7	-9.07	-0.45	1.13e-17	Initial pursuit acceleration;
CRC	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.46	-5.61	-0.3	4.29e-8	Urinary tract infection frequency;
CRC	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg09695851	chr17:3907499	NA	-0.75	-13.13	-0.59	5.82e-32	Type 2 diabetes;
CRC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.64	-0.3	3.71e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg21251018	chr6:28226885	NKAPL	0.5	6.49	0.34	3.1e-10	Depression;
CRC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.72	-0.54	9.25e-27	Type 2 diabetes;
CRC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.24	0.37	3.2e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7527798	0.592	rs960088	chr1:207827067	A/C	cg21110645	chr1:207815933	NA	-0.39	-6.18	-0.32	1.9e-9	Erythrocyte sedimentation rate;
CRC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.44	5.66	0.3	3.28e-8	Response to diuretic therapy;
CRC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.41	-6.0	-0.31	5.21e-9	Gout;Renal underexcretion gout;
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.67	5.69	0.3	2.85e-8	Depression;
CRC	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.43	-8.36	-0.42	1.84e-15	Alcohol dependence;
CRC	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.75	-0.47	6.56e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18591801	chr3:52553433	STAB1	-0.31	-5.89	-0.31	9.67e-9	Electroencephalogram traits;
CRC	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14775751	chr10:81965438	ANXA11	-0.43	-5.7	-0.3	2.63e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.4	6.21	0.32	1.58e-9	Height;
CRC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg00677455	chr12:58241039	CTDSP2	0.49	6.47	0.34	3.59e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02836830	chr20:3767452	CENPB	0.42	6.92	0.36	2.35e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27194998	chr19:47217554	PRKD2	-0.4	-6.22	-0.32	1.47e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13045639	chr21:40555880	PSMG1	0.37	6.12	0.32	2.72e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.91	-0.4	4.04e-14	Height;
CRC	cis	rs12999616	0.817	rs35321033	chr2:98327812	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	6.43	0.33	4.6e-10	Colorectal cancer;
CRC	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	ch.11.42038R	chr11:967971	AP2A2	0.67	11.08	0.52	1.8e-24	Alzheimer's disease (late onset);
CRC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.68	9.29	0.46	2.24e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.09	-18.75	-0.72	6.99e-54	Ulcerative colitis;
CRC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg12172441	chr6:28176163	NA	-0.52	-7.19	-0.37	4.41e-12	Parkinson's disease;
CRC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.29	0.42	2.83e-15	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03582286	chr4:71571171	RUFY3	0.43	6.58	0.34	1.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2462686	0.798	rs13241830	chr7:45961058	G/A	cg23193639	chr7:45961078	IGFBP3	-0.37	-5.72	-0.3	2.37e-8	Major depressive disorder;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.69	0.35	9.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.42	5.65	0.3	3.41e-8	Tonsillectomy;
CRC	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.71	9.38	0.46	1.1e-18	Alzheimer's disease;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg06470822	chr6:28175283	NA	0.96	13.02	0.58	1.54e-31	Parkinson's disease;
CRC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg08648136	chr8:956695	NA	0.31	5.8	0.3	1.57e-8	Schizophrenia;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg06384055	chr11:17099234	RPS13	-0.49	-6.76	-0.35	6.22e-11	Protein C levels;
CRC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.92	-12.1	-0.55	3.99e-28	Vitiligo;
CRC	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.49	-7.58	-0.39	3.53e-13	Corneal structure;
CRC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.59	0.5	9.64e-23	Heart rate;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg22638593	chr5:131593259	PDLIM4	0.38	6.24	0.33	1.34e-9	Acylcarnitine levels;
CRC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.04	-0.36	1.14e-11	IgG glycosylation;
CRC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.5	-8.91	-0.44	3.62e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg12927641	chr6:109611667	NA	-0.36	-6.44	-0.33	4.15e-10	Reticulocyte fraction of red cells;
CRC	cis	rs35883536	0.967	rs4908090	chr1:101135177	A/G	cg14515779	chr1:101123966	NA	-0.39	-7.57	-0.39	3.7e-13	Monocyte count;
CRC	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.8	-0.35	5.03e-11	Platelet distribution width;
CRC	cis	rs7705042	0.865	rs449454	chr5:141533062	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.33	0.37	1.83e-12	Asthma;
CRC	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Parkinson's disease;
CRC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19046167	chr17:80928561	B3GNTL1	0.53	7.46	0.38	7.68e-13	Glycated hemoglobin levels;
CRC	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg27068330	chr11:65405492	SIPA1	0.55	6.88	0.35	2.99e-11	Glomerular filtration rate (creatinine);Chronic kidney disease;
CRC	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg18230493	chr5:56204884	C5orf35	0.41	5.96	0.31	6.36e-9	Coronary artery disease;
CRC	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.84	0.35	3.93e-11	Mean corpuscular volume;
CRC	cis	rs17023223	0.537	rs1057990	chr1:119575232	T/C	cg05756136	chr1:119680316	WARS2	-0.47	-6.38	-0.33	5.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	0.92	10.85	0.51	1.18e-23	Height;
CRC	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg14664628	chr15:75095509	CSK	-0.49	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.66	-10.5	-0.5	2.04e-22	Breast cancer;
CRC	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg16591659	chr17:78472290	NA	0.41	5.81	0.31	1.44e-8	Fractional excretion of uric acid;
CRC	cis	rs3736485	0.816	rs11070851	chr15:51763249	C/G	cg08986416	chr15:51914746	DMXL2	0.47	6.87	0.35	3.19e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.97	-0.48	1.23e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg22110888	chr17:80059540	CCDC57	-0.44	-6.79	-0.35	5.31e-11	Life satisfaction;
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.02	-0.52	3.09e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs16852403	0.548	rs28760457	chr1:178174485	G/C	cg00404053	chr1:178313656	RASAL2	0.5	6.59	0.34	1.75e-10	Childhood ear infection;
CRC	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.52	6.15	0.32	2.21e-9	Carotid intima media thickness;
CRC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.17	-0.32	1.96e-9	Bladder cancer;
CRC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.62	-10.53	-0.5	1.57e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg12193833	chr17:30244370	NA	-0.76	-8.89	-0.44	4.15e-17	Hip circumference adjusted for BMI;
CRC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	7.76	0.39	1.06e-13	Personality dimensions;
CRC	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.46	6.59	0.34	1.73e-10	Subjective well-being;
CRC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.77	-0.39	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-7.33	-0.37	1.84e-12	Neuroticism;
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08219700	chr8:58056026	NA	0.56	6.65	0.34	1.2e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg20356878	chr3:121714668	ILDR1	0.53	8.22	0.41	4.69e-15	Cognitive performance;
CRC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.74	-13.22	-0.59	2.63e-32	Asthma;
CRC	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.49	5.79	0.3	1.61e-8	QRS duration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19487718	chr4:185747708	ACSL1	0.47	6.21	0.32	1.63e-9	Thyroid stimulating hormone;
CRC	cis	rs939584	1.000	rs7588007	chr2:631255	T/C	cg03610516	chr2:642275	NA	0.43	5.61	0.3	4.36e-8	Body mass index;
CRC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04045327	chr4:905805	GAK	0.42	6.76	0.35	6.16e-11	Systemic sclerosis;
CRC	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.46	5.69	0.3	2.83e-8	Metabolite levels;
CRC	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.61	8.78	0.44	9.13e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9296736	1.000	rs4715438	chr6:53901329	G/A	cg04374786	chr6:53939321	C6orf142	-0.45	-7.3	-0.37	2.23e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13606994	chr1:44402422	ARTN	-0.34	-5.76	-0.3	1.94e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13361707	0.700	rs10055925	chr5:40688059	A/G	cg09067459	chr5:40385259	NA	-0.39	-5.62	-0.3	4.13e-8	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.49	-6.45	-0.34	3.93e-10	Body mass index;
CRC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-6.9	-0.36	2.67e-11	Aortic root size;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg08222913	chr3:52553049	STAB1	-0.41	-8.25	-0.41	3.88e-15	Electroencephalogram traits;
CRC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.56	7.6	0.39	3.13e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06505273	chr16:24850292	NA	0.38	5.62	0.3	4.13e-8	Intelligence (multi-trait analysis);
CRC	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg09873164	chr1:152488093	CRCT1	0.39	6.51	0.34	2.85e-10	Hair morphology;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg06494592	chr3:125709126	NA	-0.55	-6.43	-0.33	4.43e-10	Blood pressure (smoking interaction);
CRC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.47	6.72	0.35	7.96e-11	Type 2 diabetes;
CRC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.11	14.42	0.62	7.42e-37	Uric acid levels;
CRC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.38	-5.69	-0.3	2.82e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.9	0.31	9.12e-9	IgG glycosylation;
CRC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.6	0.57	5.45e-30	Menopause (age at onset);
CRC	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg23815491	chr16:72088622	HP	0.47	6.66	0.34	1.14e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.4	0.46	9.52e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.86	10.69	0.51	4.24e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg07318372	chr1:240071102	CHRM3	0.45	6.26	0.33	1.19e-9	Underweight status;
CRC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg02725872	chr8:58115012	NA	-0.34	-5.91	-0.31	8.68e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.32	0.42	2.32e-15	Schizophrenia;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg02683197	chr6:28174875	NA	0.84	10.18	0.49	2.42e-21	Parkinson's disease;
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.46	6.64	0.34	1.3e-10	Electroencephalogram traits;
CRC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs3736594	0.513	rs78170284	chr2:27835082	G/A	cg27432699	chr2:27873401	GPN1	0.67	8.18	0.41	6.42e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.44	-0.46	7.01e-19	Platelet count;
CRC	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg10279832	chr4:154682576	RNF175	0.38	5.81	0.31	1.47e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs11229555	0.609	rs34133416	chr11:58184720	T/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.72	0.3	2.39e-8	Protein C levels;
CRC	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.72	-11.9	-0.55	2.15e-27	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs9992667	0.955	rs12331049	chr4:38655772	C/T	cg19726192	chr4:38663646	FLJ13197	-0.72	-9.08	-0.45	1.02e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	9.33	0.46	1.59e-18	Platelet count;
CRC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.52e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4664293	0.567	rs6711125	chr2:160501551	C/T	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs10743315	0.643	rs58663385	chr12:19337070	T/C	cg02471346	chr12:19282374	PLEKHA5	0.67	6.2	0.32	1.68e-9	Gut microbiota (bacterial taxa);
CRC	trans	rs2303319	0.504	rs62188990	chr2:162540635	G/A	cg27113153	chr11:123612418	ZNF202	-0.7	-6.14	-0.32	2.35e-9	Cognitive function;
CRC	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg26805224	chr10:79626177	DLG5	-0.54	-7.98	-0.4	2.5e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs73206853	0.841	rs3026483	chr12:110780905	A/G	cg12870014	chr12:110450643	ANKRD13A	0.76	8.25	0.41	3.78e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg14003231	chr6:33640908	ITPR3	0.47	7.41	0.38	1.09e-12	Height;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13939156	chr17:80058883	NA	0.36	5.73	0.3	2.26e-8	Life satisfaction;
CRC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg21784768	chr11:537496	LRRC56	-0.69	-6.58	-0.34	1.88e-10	Body mass index;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.76	-0.3	1.95e-8	Type 2 diabetes;
CRC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.83e-12	Urinary tract infection frequency;
CRC	cis	rs11212617	0.967	rs227090	chr11:108241349	G/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.67	0.3	3.09e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6922632	1.000	rs28921123	chr6:24126112	G/A	cg26194775	chr6:24126114	NRSN1	-0.9	-8.87	-0.44	4.87e-17	Information processing speed;
CRC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.63	-6.58	-0.34	1.86e-10	Axial length;
CRC	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg20542592	chr8:11973495	FAM66D	-0.35	-6.05	-0.32	4.01e-9	Mood instability;
CRC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.25	-16.72	-0.68	7.27e-46	Breast cancer;
CRC	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.33	-0.33	8.23e-10	Diastolic blood pressure;
CRC	trans	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg03315344	chr16:75512273	CHST6	0.5	5.7	0.3	2.71e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs4654899	0.772	rs951805	chr1:21060356	A/G	cg02927042	chr1:21476669	EIF4G3	0.49	7.54	0.38	4.72e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.41	-5.62	-0.3	4.07e-8	Corneal structure;
CRC	trans	rs11581859	0.950	rs72730310	chr1:99377948	A/C	cg12183875	chr3:169587454	LRRC31	0.27	6.2	0.32	1.74e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.58	9.37	0.46	1.18e-18	Height;
CRC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.65	-9.94	-0.48	1.57e-20	Diastolic blood pressure;
CRC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.34	-0.42	2.07e-15	Monocyte percentage of white cells;
CRC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	7.44	0.38	8.94e-13	Breast cancer;
CRC	cis	rs9308731	0.583	rs6726007	chr2:111932122	A/T	cg04202892	chr2:111875749	ACOXL	0.42	6.73	0.35	7.37e-11	Chronic lymphocytic leukemia;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg23123621	chr4:1343375	KIAA1530	0.33	5.75	0.3	2.07e-8	Obesity-related traits;
CRC	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-6.55	-0.34	2.16e-10	Vitamin D levels;
CRC	trans	rs12660387	1.000	rs12663626	chr6:65264646	A/T	cg13393512	chr9:135749454	C9orf98	0.51	5.96	0.31	6.5e-9	Schizophrenia;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02807482	chr3:125708958	NA	-0.45	-5.89	-0.31	9.73e-9	Blood pressure (smoking interaction);
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-8.33	-0.42	2.25e-15	Electroencephalogram traits;
CRC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg08027265	chr7:2291960	NA	-0.38	-5.99	-0.31	5.41e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.66	9.34	0.46	1.49e-18	Menarche (age at onset);
CRC	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Parkinson's disease;
CRC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-7.61	-0.39	2.86e-13	Vitiligo;
CRC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.82	14.95	0.64	6.37e-39	Anterior chamber depth;
CRC	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg09184832	chr6:79620586	NA	-0.47	-8.24	-0.41	4.1e-15	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10457504	chr17:19281708	MAPK7	0.45	6.8	0.35	4.8e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.66	-0.3	3.3e-8	Breast cancer;
CRC	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.8	-0.3	1.59e-8	Inflammatory bowel disease;
CRC	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg11822372	chr1:151115635	SEMA6C	0.53	7.59	0.39	3.39e-13	Childhood ear infection;
CRC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.92	18.56	0.72	3.96e-53	Menopause (age at onset);
CRC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.53	-0.43	5.35e-16	Monocyte count;
CRC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.16	10.95	0.52	5.2e-24	Skin colour saturation;
CRC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-5.94	-0.31	7.45e-9	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.86	-14.21	-0.62	4.44e-36	Blood metabolite levels;
CRC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg08200582	chr11:442649	ANO9	-0.7	-7.07	-0.36	9.14e-12	Body mass index;
CRC	cis	rs12760731	0.641	rs10798605	chr1:178294872	G/A	cg00404053	chr1:178313656	RASAL2	0.82	9.9	0.48	2.17e-20	Obesity-related traits;
CRC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.82	-15.34	-0.65	1.86e-40	Dental caries;
CRC	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	9.97	0.48	1.23e-20	Lung cancer;
CRC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.85	10.38	0.5	4.96e-22	Monocyte percentage of white cells;
CRC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.81	14.31	0.62	1.89e-36	Vitiligo;
CRC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.85	-15.08	-0.64	2.05e-39	Dental caries;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03462115	chr16:29801729	KIF22	0.48	7.61	0.39	2.84e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.31	6.33	0.33	8.26e-10	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23486179	chr3:49466665	NICN1	0.48	7.94	0.4	3.16e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs6694672	1.000	rs6003	chr1:197031021	C/T	cg13682187	chr1:196946512	CFHR5	0.45	7.16	0.37	5.15e-12	Asthma;
CRC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.68	8.98	0.44	2.15e-17	Platelet count;
CRC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.51	-9.28	-0.46	2.3e-18	Intelligence (multi-trait analysis);
CRC	trans	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg26043149	chr18:55253948	FECH	0.5	7.79	0.39	8.99e-14	Bone mineral density;
CRC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-8.25	-0.41	3.75e-15	Blood metabolite levels;
CRC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.43	5.61	0.3	4.2e-8	Total body bone mineral density;
CRC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.06	19.24	0.73	8.72e-56	Schizophrenia;
CRC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.58	-9.64	-0.47	1.53e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.5	5.83	0.31	1.34e-8	Vitiligo;
CRC	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15664640	chr17:80829946	TBCD	0.66	10.38	0.5	5.25e-22	Breast cancer;
CRC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.46	-8.55	-0.43	4.68e-16	Smoking initiation;
CRC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg09876464	chr15:85330779	ZNF592	0.39	6.5	0.34	2.99e-10	P wave terminal force;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00267196	chr8:135710113	ZFAT	0.44	6.71	0.35	8.66e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.66	0.3	3.24e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg06905471	chr2:29092871	TRMT61B	-0.42	-6.12	-0.32	2.65e-9	Daytime sleep phenotypes;
CRC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.67	9.38	0.46	1.11e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23661306	chr3:57541993	PDE12	0.43	7.09	0.36	8.08e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.63	10.29	0.49	1.07e-21	Breast cancer;
CRC	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.55	9.27	0.45	2.58e-18	Dupuytren's disease;
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.76	14.46	0.62	4.88e-37	Body mass index;
CRC	trans	rs3733655	0.545	rs7674790	chr4:31149277	A/T	cg00008713	chr18:11980953	IMPA2	-0.44	-5.98	-0.31	5.68e-9	White matter hyperintensities in ischemic stroke;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14387610	chr18:59854615	PIGN;KIAA1468	0.38	6.1	0.32	3.03e-9	Obesity-related traits;
CRC	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg20885578	chr2:198174922	NA	-0.42	-6.81	-0.35	4.68e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.61	8.29	0.42	2.86e-15	Coronary artery disease;
CRC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.83	0.35	4.1e-11	Mean platelet volume;
CRC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.43	8.72	0.43	1.36e-16	Renal cell carcinoma;
CRC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg24375607	chr4:120327624	NA	0.46	7.2	0.37	4.17e-12	Corneal astigmatism;
CRC	cis	rs644148	0.785	rs2140111	chr19:44973019	A/C	cg15540054	chr19:45004280	ZNF180	-0.55	-7.1	-0.36	7.5e-12	Personality dimensions;
CRC	cis	rs11997175	0.653	rs7005254	chr8:33641781	A/T	ch.8.33884649F	chr8:33765107	NA	0.41	6.44	0.33	4.29e-10	Body mass index;
CRC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg22974920	chr21:40686053	BRWD1	-0.44	-6.09	-0.32	3.1e-9	Cognitive function;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg20933634	chr6:27740509	NA	-0.39	-5.66	-0.3	3.26e-8	Systemic lupus erythematosus;
CRC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg03684893	chr10:554711	DIP2C	0.34	5.66	0.3	3.28e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg19812747	chr11:111475976	SIK2	0.54	9.56	0.47	2.88e-19	Primary sclerosing cholangitis;
CRC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.47	6.78	0.35	5.59e-11	Lymphocyte counts;
CRC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.51	0.5	1.81e-22	Menopause (age at onset);
CRC	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.78	15.75	0.66	4.75e-42	Leprosy;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05296866	chr19:5906773	VMAC	-0.39	-6.12	-0.32	2.73e-9	HDL cholesterol;
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.59	-0.5	9.9e-23	Bipolar disorder;
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg03623178	chr6:28175578	NA	0.89	11.13	0.52	1.25e-24	Parkinson's disease;
CRC	cis	rs7172809	0.897	rs17394448	chr15:77825149	C/A	cg10437265	chr15:77819839	NA	-0.42	-7.15	-0.37	5.73e-12	Glucose homeostasis traits;
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.72	-0.51	3.45e-23	Bipolar disorder;
CRC	cis	rs78663649	0.522	rs117196542	chr19:16578257	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	-0.89	-5.91	-0.31	8.79e-9	White blood cell count;
CRC	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.79	-10.44	-0.5	3.15e-22	Migraine;
CRC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.74	-12.94	-0.58	3.18e-31	Cancer;
CRC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg24881330	chr22:46731750	TRMU	0.61	5.93	0.31	7.66e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg14593290	chr7:50529359	DDC	-0.62	-8.26	-0.41	3.57e-15	Malaria;
CRC	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-9.31	-0.46	1.82e-18	Waist circumference adjusted for body mass index;
CRC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg08027265	chr7:2291960	NA	-0.37	-6.38	-0.33	6.06e-10	Schizophrenia;
CRC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23378565	chr7:2036160	MAD1L1	0.39	5.63	0.3	3.87e-8	Bipolar disorder;
CRC	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg09596252	chr17:78655493	RPTOR	0.54	5.7	0.3	2.7e-8	Myopia (pathological);
CRC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.69	-9.1	-0.45	8.57e-18	Pancreatic cancer;
CRC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.48	5.91	0.31	8.6e-9	Lymphocyte counts;
CRC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.85	0.31	1.16e-8	Major depressive disorder;
CRC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.13	0.64	1.3e-39	Fuchs's corneal dystrophy;
CRC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.46	6.67	0.35	1.07e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.49	9.16	0.45	5.55e-18	Educational attainment (years of education);
CRC	cis	rs17209837	0.920	rs17149652	chr7:87087187	G/T	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.73	-0.43	1.3e-16	Intelligence (multi-trait analysis);
CRC	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12560992	chr17:57184187	TRIM37	0.53	7.31	0.37	1.99e-12	Testicular germ cell tumor;
CRC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	7.02	0.36	1.3e-11	Obesity-related traits;
CRC	trans	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg10756647	chr7:56101905	PSPH	0.78	8.33	0.42	2.14e-15	Diabetic kidney disease;
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-8.63	-0.43	2.64e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg18758796	chr5:131593413	PDLIM4	0.33	6.16	0.32	2.09e-9	Blood metabolite levels;
CRC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.56	7.71	0.39	1.55e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg12317470	chr15:67143691	NA	0.73	6.4	0.33	5.37e-10	Lung cancer (smoking interaction);
CRC	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.17	0.45	5.25e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-5.75	-0.3	2.04e-8	Schizophrenia;
CRC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.68	-0.35	1.02e-10	IgG glycosylation;
CRC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.23	-0.49	1.71e-21	Hepatocellular carcinoma;
CRC	cis	rs7264396	0.887	rs3818441	chr20:34046501	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.41	-0.33	5.12e-10	Total cholesterol levels;
CRC	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.49	6.73	0.35	7.49e-11	Breast cancer;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs7527798	0.592	rs960087	chr1:207826858	C/G	cg09232269	chr1:207846808	CR1L	-0.51	-8.26	-0.41	3.62e-15	Erythrocyte sedimentation rate;
CRC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.05e-29	Cognitive function;
CRC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.51	8.74	0.43	1.21e-16	Coronary artery disease;
CRC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.71	9.53	0.47	3.56e-19	Bladder cancer;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg04562611	chr16:615315	C16orf11	0.37	6.19	0.32	1.81e-9	Height;
CRC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18743068	chr10:94831650	NA	0.43	6.65	0.34	1.2e-10	Response to antipsychotic treatment;
CRC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg02659138	chr7:134003124	SLC35B4	0.39	6.79	0.35	5.23e-11	Mean platelet volume;
CRC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.61	-9.4	-0.46	9.36e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg22096450	chr11:6947773	ZNF215	0.58	6.01	0.31	4.99e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs61160187	0.582	rs67555188	chr5:60143228	T/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.77	-0.3	1.78e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg25856811	chr1:152973957	SPRR3	0.23	6.22	0.32	1.5e-9	Inflammatory skin disease;
CRC	cis	rs9341808	0.538	rs688867	chr6:80939228	A/G	cg08355045	chr6:80787529	NA	0.35	5.85	0.31	1.19e-8	Sitting height ratio;
CRC	cis	rs11679072	1.000	rs6740692	chr2:240448525	A/G	cg03276489	chr2:240449683	NA	-0.93	-9.41	-0.46	8.71e-19	Blood pressure (smoking interaction);
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg20092199	chr4:1342459	KIAA1530	0.45	7.31	0.37	2.04e-12	Obesity-related traits;
CRC	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg06581033	chr10:766294	NA	-0.51	-5.7	-0.3	2.72e-8	Uric acid levels;
CRC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.12	0.74	2.81e-59	Prudent dietary pattern;
CRC	cis	rs7605827	0.930	rs6740183	chr2:15692583	T/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs847649	0.692	rs6969054	chr7:102446569	T/C	cg18108683	chr7:102477205	FBXL13	-0.67	-11.29	-0.53	3.37e-25	Morning vs. evening chronotype;
CRC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.57e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.89	-15.95	-0.66	7.68e-43	Height;
CRC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.46	-7.11	-0.36	7.34e-12	Response to antineoplastic agents;
CRC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.56	-8.62	-0.43	2.8e-16	Personality dimensions;
CRC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.49	7.35	0.38	1.63e-12	Corneal astigmatism;
CRC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg03037974	chr15:76606532	NA	-0.75	-14.36	-0.62	1.27e-36	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12172441	chr6:28176163	NA	0.62	7.33	0.37	1.76e-12	Depression;
CRC	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg11993925	chr19:44307056	LYPD5	0.45	7.62	0.39	2.79e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.4	6.14	0.32	2.35e-9	Endometrial cancer;
CRC	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.71	-9.99	-0.48	1.07e-20	Hypospadias;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18879991	chr6:27861393	HIST1H2AM;HIST1H2BO	0.47	6.28	0.33	1.04e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg18764771	chr6:116381957	FRK	0.24	5.92	0.31	8.2e-9	Total cholesterol levels;
CRC	cis	rs597583	0.715	rs2276340	chr11:117391966	G/A	cg27161313	chr11:117392002	DSCAML1	-0.47	-5.98	-0.31	5.73e-9	Putamen volume;
CRC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.84	-14.61	-0.63	1.31e-37	Height;
CRC	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.52	-8.76	-0.43	1.05e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.73	-0.3	2.25e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.5	9.21	0.45	3.85e-18	Educational attainment (years of education);
CRC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg13844804	chr7:814759	HEATR2	0.65	8.47	0.42	8.48e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg25251562	chr2:3704773	ALLC	-0.49	-6.12	-0.32	2.62e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06544989	chr22:39130855	UNC84B	-0.46	-7.15	-0.37	5.69e-12	Menopause (age at onset);
CRC	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.54	-7.53	-0.38	4.87e-13	Longevity;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg15845792	chr6:28175446	NA	1.02	15.66	0.65	1.12e-41	Depression;
CRC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.37e-29	Cognitive function;
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-8.92	-0.44	3.35e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	8.54	0.43	5.13e-16	Cognitive test performance;
CRC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.71	10.84	0.51	1.34e-23	Corneal astigmatism;
CRC	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg10517650	chr3:113235015	CCDC52	-0.34	-6.12	-0.32	2.72e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg24578937	chr1:2090814	PRKCZ	-0.39	-7.29	-0.37	2.3e-12	Height;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg15845792	chr6:28175446	NA	0.99	13.05	0.58	1.19e-31	Depression;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.93	-0.31	7.58e-9	Depression;
CRC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.58	0.54	3.07e-26	Hip circumference adjusted for BMI;
CRC	cis	rs12580194	0.957	rs12579451	chr12:55694116	C/T	cg19537932	chr12:55886519	OR6C68	-0.51	-6.5	-0.34	3.01e-10	Cancer;
CRC	cis	rs3736485	0.844	rs56189052	chr15:51822378	T/G	cg08986416	chr15:51914746	DMXL2	-0.44	-6.18	-0.32	1.87e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.54	7.05	0.36	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9463078	0.525	rs9395058	chr6:44984069	T/A	cg25276700	chr6:44698697	NA	-0.25	-6.04	-0.32	4.16e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs305851	0.875	rs9369136	chr6:39758887	C/T	cg02386599	chr6:39769542	DAAM2	-0.37	-5.72	-0.3	2.38e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.07	20.4	0.75	2.24e-60	Primary sclerosing cholangitis;
CRC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg16928487	chr17:17741425	SREBF1	0.37	6.33	0.33	8.16e-10	Coronary artery disease or ischemic stroke;
CRC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg09127314	chr1:152161683	NA	-0.51	-5.89	-0.31	9.59e-9	Atopic dermatitis;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.12	-0.32	2.65e-9	Bipolar disorder;
CRC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.44	-6.06	-0.32	3.76e-9	Diastolic blood pressure;
CRC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.75	12.42	0.56	2.72e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg03037974	chr15:76606532	NA	-0.69	-12.1	-0.56	3.82e-28	Blood metabolite levels;
CRC	cis	rs990171	1.000	rs7597819	chr2:103092906	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.73	0.3	2.28e-8	Lymphocyte counts;
CRC	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.61	8.36	0.42	1.83e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg13072238	chr3:49761600	GMPPB	0.49	5.84	0.31	1.26e-8	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9491140	0.539	rs911959	chr6:124688755	A/G	cg19267163	chr6:125004984	NKAIN2	0.48	6.7	0.35	9e-11	Neuroticism;
CRC	cis	rs4400599	1.000	rs4845364	chr1:154141908	A/G	cg05139571	chr1:154127138	NUP210L	0.43	6.51	0.34	2.76e-10	Platelet distribution width;
CRC	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17507749	chr15:85114479	UBE2QP1	0.62	8.97	0.44	2.36e-17	Schizophrenia;
CRC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.45	-7.67	-0.39	1.94e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg09218773	chr11:619014	MUPCDH	-0.44	-6.38	-0.33	5.9e-10	Systemic lupus erythematosus;
CRC	cis	rs3857067	0.839	rs12505694	chr4:95042940	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.75	-0.3	2.07e-8	QT interval;
CRC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.59	-8.26	-0.41	3.64e-15	Arsenic metabolism;
CRC	cis	rs6479527	0.840	rs4744310	chr9:96821508	A/G	cg14459158	chr9:96720562	NA	0.38	6.71	0.35	8.37e-11	Esophageal adenocarcinoma;
CRC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.54	8.69	0.43	1.68e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00338735	chr4:53728038	RASL11B	0.45	5.94	0.31	7.44e-9	Optic nerve measurement (cup area);
CRC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	0.84	7.64	0.39	2.34e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9549328	0.565	rs35988856	chr13:113617427	T/C	cg08614441	chr13:113633676	MCF2L	0.4	7.06	0.36	9.78e-12	Systolic blood pressure;
CRC	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg21839984	chr17:30846986	MYO1D	-0.35	-6.04	-0.32	4.12e-9	Schizophrenia;
CRC	cis	rs4731207	0.596	rs10081375	chr7:124573175	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.18	-0.32	1.91e-9	Cutaneous malignant melanoma;
CRC	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.7	10.08	0.49	5.44e-21	Body mass index;
CRC	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.97	0.36	1.75e-11	Intraocular pressure;
CRC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	10.04	0.48	7.45e-21	HIV-1 control;
CRC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.61	9.64	0.47	1.5700000000000001e-19	Height;
CRC	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.57	8.7	0.43	1.58e-16	Autism;
CRC	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg27649806	chr9:35101217	STOML2	0.39	6.2	0.32	1.74e-9	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24157364	chr6:143858286	NA	0.44	5.97	0.31	6.3e-9	Anxiety disorder;
CRC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.44	-7.96	-0.4	2.86e-14	Huntington's disease progression;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg20607318	chr19:36391512	NFKBID	0.44	6.7	0.35	9.2e-11	Schizophrenia;
CRC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.71	-0.35	8.67e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-7.25	-0.37	3.05e-12	Subjective well-being;
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.93	-0.4	3.39e-14	Total body bone mineral density;
CRC	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.07	-0.36	9.29e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg24977027	chr2:88469347	THNSL2	0.52	5.94	0.31	7.21e-9	Plasma clusterin levels;
CRC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.67	7.3	0.37	2.15e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.18	-0.37	4.79e-12	Hemoglobin concentration;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg24375607	chr4:120327624	NA	0.48	7.59	0.39	3.26e-13	Corneal astigmatism;
CRC	cis	rs6840360	0.607	rs2724565	chr4:152350305	A/G	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4141404	0.740	rs4820946	chr22:31551160	A/G	cg22777020	chr22:31556080	RNF185	0.48	5.84	0.31	1.26e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-5.91	-0.31	8.57e-9	Alzheimer's disease (late onset);
CRC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.0	-0.44	1.88e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.88	-0.31	1.01e-8	Obesity-related traits;
CRC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.48	7.96	0.4	2.84e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.72	-11.24	-0.53	4.97e-25	Tonsillectomy;
CRC	cis	rs11229555	0.645	rs4367960	chr11:58194961	C/G	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg05072774	chr3:49840536	C3orf54	-0.43	-5.62	-0.3	4.12e-8	Resting heart rate;
CRC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.62	-8.7	-0.43	1.65e-16	Carotid intima media thickness;
CRC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	1.02	17.9	0.7	1.7e-50	Parkinson's disease;
CRC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.07	-0.32	3.47e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4073416	0.542	rs8019762	chr14:66087178	A/G	cg03016385	chr14:66212404	NA	-0.45	-6.2	-0.32	1.67e-9	N-glycan levels;
CRC	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.6	-0.3	4.5e-8	Morning vs. evening chronotype;
CRC	cis	rs2882667	0.861	rs10075541	chr5:138390318	C/T	cg04439458	chr5:138467593	SIL1	-0.34	-6.13	-0.32	2.45e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg12172441	chr6:28176163	NA	0.45	6.52	0.34	2.58e-10	Cardiac Troponin-T levels;
CRC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.8	-0.4	8.23e-14	Gut microbiome composition (summer);
CRC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.51	-8.68	-0.43	1.84e-16	Airway imaging phenotypes;
CRC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	6.72	0.35	7.82e-11	Rheumatoid arthritis;
CRC	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.7	-0.3	2.72e-8	Subjective well-being;
CRC	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg13385794	chr1:248469461	NA	0.39	6.93	0.36	2.28e-11	Common traits (Other);
CRC	cis	rs294883	0.858	rs9347304	chr6:159717629	C/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.81	-0.3	1.5e-8	Coronary artery disease;
CRC	cis	rs7605827	0.897	rs6431694	chr2:15523031	T/C	cg19274914	chr2:15703543	NA	0.38	5.63	0.3	3.81e-8	Educational attainment (years of education);
CRC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.75	0.39	1.15e-13	Morning vs. evening chronotype;
CRC	cis	rs13144136	0.664	rs4296670	chr4:10651160	C/T	cg10242279	chr4:10666415	CLNK	-0.35	-5.93	-0.31	7.65e-9	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	trans	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06834434	chr14:75079333	LTBP2	0.53	5.98	0.31	5.95e-9	Obesity-related traits;
CRC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06583696	chr2:26101536	ASXL2	0.52	6.86	0.35	3.37e-11	Thyroid stimulating hormone;
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.39	-7.26	-0.37	2.84e-12	Lung cancer;
CRC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg24531977	chr5:56204891	C5orf35	-0.45	-6.87	-0.35	3.18e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24308560	chr3:49941425	MST1R	-0.45	-7.12	-0.37	6.61e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg05623727	chr3:50126028	RBM5	-0.45	-7.61	-0.39	2.93e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.62	8.96	0.44	2.43e-17	Schizophrenia;
CRC	trans	rs587242	1.000	rs2011694	chr1:96884286	T/A	cg10631902	chr5:14652156	NA	0.45	7.01	0.36	1.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-8.78	-0.44	8.99e-17	Brugada syndrome;
CRC	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.39	-5.93	-0.31	7.48e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg19025524	chr12:109796872	NA	0.47	6.83	0.35	4.18e-11	Neuroticism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04127825	chr1:167503222	NA	0.48	6.08	0.32	3.26e-9	Thyroid stimulating hormone;
CRC	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg19537932	chr12:55886519	OR6C68	-0.72	-9.1	-0.45	9.11e-18	Cancer;
CRC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.44	8.86	0.44	5.01e-17	Renal cell carcinoma;
CRC	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.55	6.88	0.35	3.1e-11	Coronary artery disease;
CRC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg24634471	chr8:143751801	JRK	-0.51	-6.88	-0.35	3.09e-11	Urinary tract infection frequency;
CRC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.99	14.53	0.63	2.69e-37	Triglycerides;
CRC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-5.89	-0.31	9.75e-9	Migraine;Coronary artery disease;
CRC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11212617	1.000	rs600329	chr11:108163733	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.03	0.32	4.3e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg07404485	chr7:94953653	PON1	0.41	6.21	0.32	1.59e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.78	-0.3	1.76e-8	Blood pressure;
CRC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.63	12.05	0.55	6e-28	Coronary artery disease;
CRC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.7	-11.22	-0.53	6.02e-25	Osteoporosis;
CRC	cis	rs1532331	0.933	rs6451675	chr5:43110855	C/G	cg09164108	chr5:43007320	NA	0.38	5.73	0.3	2.33e-8	Menarche (age at onset);
CRC	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.4	6.72	0.35	7.82e-11	Sitting height ratio;
CRC	cis	rs12580194	0.593	rs61956269	chr12:55768023	C/T	cg23425280	chr12:56401806	NA	0.47	5.74	0.3	2.1e-8	Cancer;
CRC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.75	8.68	0.43	1.88e-16	Eosinophilic esophagitis;
CRC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg05926928	chr17:57297772	GDPD1	-0.42	-6.02	-0.31	4.66e-9	Schizophrenia;
CRC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.4	-7.43	-0.38	9.19e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.42	-6.33	-0.33	7.87e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.45	6.64	0.34	1.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg06462663	chr19:18546047	ISYNA1	0.52	7.94	0.4	3.13e-14	Breast cancer;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.34	0.37	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.65	10.02	0.48	8.66e-21	Lymphocyte counts;
CRC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg07713946	chr22:31675144	LIMK2	-0.4	-5.79	-0.3	1.63e-8	Colorectal cancer;
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg26587870	chr6:27730563	NA	-0.42	-6.5	-0.34	3e-10	Parkinson's disease;
CRC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg13390004	chr1:15929781	NA	0.5	7.09	0.36	8.36e-12	Systolic blood pressure;
CRC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.58	8.74	0.43	1.17e-16	Type 2 diabetes;
CRC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.97	-0.52	4.45e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs3018066	0.748	rs12509640	chr4:106996677	A/G	cg01869342	chr4:106983673	TBCK	-0.47	-6.99	-0.36	1.54e-11	Cancer;
CRC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.52	-9.14	-0.45	6.61e-18	Sense of smell;
CRC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.39	-6.87	-0.35	3.13e-11	Reticulocyte fraction of red cells;
CRC	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg02023728	chr11:77925099	USP35	-0.35	-5.73	-0.3	2.28e-8	Alzheimer's disease (survival time);
CRC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg01629716	chr15:45996671	NA	0.41	8.35	0.42	1.94e-15	Waist circumference;Weight;
CRC	trans	rs11654801	0.947	rs62056771	chr17:20900570	C/T	cg23759823	chr7:139672531	TBXAS1	-0.48	-6.76	-0.35	6.16e-11	Mosquito bite size;
CRC	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.54	-8.44	-0.42	9.91e-16	Schizophrenia;
CRC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg08992911	chr2:238395768	MLPH	0.52	5.69	0.3	2.77e-8	Prostate cancer;
CRC	cis	rs4363385	0.776	rs2879490	chr1:152947163	A/G	cg25856811	chr1:152973957	SPRR3	-0.22	-6.08	-0.32	3.38e-9	Inflammatory skin disease;
CRC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	14.42	0.62	7.16e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.68	-13.16	-0.59	4.41e-32	Educational attainment;
CRC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.73	10.39	0.5	4.53e-22	Blood metabolite levels;
CRC	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg26816564	chr1:7831052	VAMP3	-0.48	-5.87	-0.31	1.06e-8	Inflammatory bowel disease;
CRC	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg24046110	chr8:143859143	LYNX1	-0.37	-6.37	-0.33	6.29e-10	Urinary tract infection frequency;
CRC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06505273	chr16:24850292	NA	0.52	6.74	0.35	7.17e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.51	6.99	0.36	1.58e-11	Obesity-related traits;
CRC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.73	-11.38	-0.53	1.56e-25	Cognitive function;
CRC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	9.54	0.47	3.4e-19	Cognitive test performance;
CRC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg11843238	chr5:131593191	PDLIM4	-0.32	-5.93	-0.31	7.63e-9	Blood metabolite levels;
CRC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.84	-11.21	-0.53	6.45e-25	Initial pursuit acceleration;
CRC	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg26875233	chr11:93583750	C11orf90	0.35	6.84	0.35	3.78e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.62	8.83	0.44	6.36e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.28	-0.33	1.09e-9	Educational attainment;
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07165851	chr6:158734300	TULP4	0.62	7.76	0.39	1.09e-13	Height;
CRC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg02869306	chr7:64672164	INTS4L1	-0.34	-5.8	-0.3	1.59e-8	Aortic root size;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg22852276	chr20:35724169	RBL1	0.44	6.3	0.33	9.53e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2179367	0.959	rs562428	chr6:149647525	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.38	-6.02	-0.31	4.76e-9	Dupuytren's disease;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg15790184	chr11:494944	RNH1	0.59	6.1	0.32	2.95e-9	Body mass index;
CRC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.92	-0.4	3.79e-14	Gut microbiome composition (summer);
CRC	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.68	8.79	0.44	8.37e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs492478	0.892	rs115598598	chr5:3908442	C/G	cg09199442	chr11:28132951	METT5D1	-0.72	-6.15	-0.32	2.26e-9	Cognitive performance;
CRC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.61	7.7	0.39	1.63e-13	Cocaine dependence;
CRC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.75	-13.72	-0.6	3.47e-34	Prudent dietary pattern;
CRC	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg16476235	chr8:21771668	DOK2	0.37	6.02	0.32	4.6e-9	Mean corpuscular volume;
CRC	trans	rs288342	0.541	rs10931041	chr2:183685562	A/G	cg05308643	chr6:124982296	NKAIN2	0.35	5.99	0.31	5.39e-9	Recurrent major depressive disorder;
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.64	6.46	0.34	3.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Colorectal cancer;
CRC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.92e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.5	-0.34	2.96e-10	Blood pressure (smoking interaction);
CRC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.39	-0.53	1.52e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg23161317	chr6:28129485	ZNF389	0.46	6.45	0.33	4.05e-10	Cardiac Troponin-T levels;
CRC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.8	-8.59	-0.43	3.55e-16	Coronary artery disease;
CRC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg26587870	chr6:27730563	NA	-0.53	-6.25	-0.33	1.24e-9	Lung cancer in ever smokers;
CRC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	8.55	0.43	4.73e-16	Schizophrenia;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.61	8.89	0.44	4.21e-17	Lymphocyte counts;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg15786705	chr6:28176104	NA	0.59	5.91	0.31	8.44e-9	Lung cancer in ever smokers;
CRC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.42	6.01	0.31	5.04e-9	Aortic root size;
CRC	cis	rs11212617	0.840	rs228599	chr11:108107660	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.65	0.3	3.53e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg00318322	chr16:67708822	GFOD2	-0.31	-5.99	-0.31	5.54e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.83	-0.35	4.16e-11	Major depressive disorder;
CRC	cis	rs10065203	0.527	rs173948	chr5:14347771	A/G	cg26689441	chr5:14406021	TRIO	-0.39	-6.45	-0.33	4.09e-10	Paclitaxel-induced neuropathy;
CRC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.75	10.29	0.49	1e-21	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg15145296	chr3:125709740	NA	-0.53	-6.42	-0.33	4.69e-10	Blood pressure (smoking interaction);
CRC	cis	rs2415984	0.622	rs1761026	chr14:46930139	T/C	cg14871534	chr14:47121158	RPL10L	0.41	5.93	0.31	7.52e-9	Number of children ever born;
CRC	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.79	9.0	0.44	1.83e-17	Uric acid levels;
CRC	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg09597638	chr17:3907349	NA	0.44	5.66	0.3	3.27e-8	Type 2 diabetes;
CRC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	trans	rs13315871	0.615	rs7618604	chr3:58357785	G/A	cg25250853	chr2:85822726	RNF181	0.53	6.25	0.33	1.28e-9	Cholesterol, total;
CRC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.65	10.02	0.48	8.17e-21	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg10729496	chr3:10149963	C3orf24	0.48	5.61	0.3	4.19e-8	Alzheimer's disease;
CRC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.46	6.57	0.34	2e-10	Aortic root size;
CRC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.53	6.74	0.35	7.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg06766960	chr11:133703094	NA	-0.38	-6.2	-0.32	1.67e-9	Childhood ear infection;
CRC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg23625390	chr15:77176239	SCAPER	0.49	7.07	0.36	9.37e-12	Blood metabolite levels;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.59	9.27	0.46	2.48e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	8.62	0.43	2.96e-16	Schizophrenia;
CRC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.67	-7.26	-0.37	2.79e-12	Psoriasis;
CRC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.72	-12.33	-0.56	5.82e-29	Prostate cancer;
CRC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.24	0.49	1.56e-21	Alzheimer's disease (late onset);
CRC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.66	9.6	0.47	2.07e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21582582	chr3:182698605	DCUN1D1	0.55	6.66	0.34	1.13e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11229555	0.609	rs7128459	chr11:58179291	C/T	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.48	7.24	0.37	3.2e-12	Corneal astigmatism;
CRC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-5.99	-0.31	5.52e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	8.11	0.41	1.04e-14	Monocyte count;
CRC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.69	-0.3	2.75e-8	Lung cancer;
CRC	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg16898833	chr6:26189333	HIST1H4D	0.72	6.47	0.34	3.61e-10	Depression;
CRC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.42	6.8	0.35	4.86e-11	Major depressive disorder;
CRC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg23071808	chr14:103021642	NA	0.61	6.79	0.35	5.2e-11	Platelet count;
CRC	cis	rs1223397	1.000	rs1223402	chr6:13271640	G/A	cg06879394	chr6:13274151	PHACTR1	0.54	6.52	0.34	2.66e-10	Blood pressure;
CRC	cis	rs9595066	1.000	rs4942281	chr13:44708126	C/T	cg04068111	chr13:44716778	NA	-0.47	-6.0	-0.31	5.16e-9	Schizophrenia;
CRC	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.67	11.39	0.53	1.49e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.44	6.11	0.32	2.8e-9	Red blood cell count;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.73	0.39	1.34e-13	Alzheimer's disease;
CRC	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.59	9.08	0.45	9.93e-18	Morning vs. evening chronotype;
CRC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg16447950	chr5:562315	NA	-0.84	-11.04	-0.52	2.51e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.7	-9.58	-0.47	2.42e-19	Pubertal anthropometrics;
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.47	6.9	0.36	2.71e-11	Testicular germ cell tumor;
CRC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.0	0.36	1.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	8.16	0.41	7.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs698833	0.926	rs1085485	chr2:44616728	A/G	cg04920474	chr2:44395004	PPM1B	0.4	5.82	0.31	1.39e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.97	0.36	1.7e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.62	10.75	0.51	2.56e-23	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06062132	chr6:76311331	SENP6	0.43	5.98	0.31	5.77e-9	Response to antipsychotic treatment;
CRC	cis	rs4664293	0.836	rs13403371	chr2:160593114	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	1.01	12.13	0.56	3.11e-28	Iron status biomarkers;
CRC	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.6	-8.48	-0.42	7.52e-16	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg24977027	chr2:88469347	THNSL2	0.64	7.72	0.39	1.37e-13	Plasma clusterin levels;
CRC	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.33	-0.33	7.94e-10	Acne (severe);
CRC	trans	rs62295889	0.602	rs58099533	chr4:12538214	G/T	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	trans	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.88	0.35	2.95e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg13206674	chr6:150067644	NUP43	0.5	7.05	0.36	1.09e-11	Testicular germ cell tumor;
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.08	0.36	8.63e-12	Alzheimer's disease;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14593956	chr5:138677986	PAIP2	0.41	6.3	0.33	9.7e-10	Myopia (pathological);
CRC	cis	rs12541635	0.966	rs4734894	chr8:106995313	G/A	cg10147462	chr8:107024639	NA	0.45	7.43	0.38	9.67e-13	Age of smoking initiation;
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg08027265	chr7:2291960	NA	-0.38	-5.97	-0.31	6.08e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.6	-8.26	-0.41	3.66e-15	DNA methylation (variation);
CRC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-7.9	-0.4	4.31e-14	Mean corpuscular volume;
CRC	cis	rs6534441	0.824	rs28548600	chr4:125458268	A/C	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg03013999	chr17:37608204	MED1	0.49	7.54	0.38	4.77e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs3764400	0.506	rs56103412	chr17:46542302	T/A	cg10706073	chr17:46328419	SKAP1	-0.58	-5.95	-0.31	6.69e-9	Body mass index;
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg22561889	chr6:118971681	C6orf204	0.51	6.65	0.34	1.23e-10	Diastolic blood pressure;
CRC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg14122633	chr5:456516	EXOC3	-0.38	-6.71	-0.35	8.32e-11	Cystic fibrosis severity;
CRC	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg01993067	chr11:68851601	TPCN2	0.56	6.3	0.33	9.54e-10	Blond vs. brown hair color;
CRC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.36	11.14	0.52	1.1e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2188554	0.771	rs213951	chr7:117202434	A/G	cg09181792	chr7:117119393	CFTR	0.31	5.69	0.3	2.81e-8	Esophageal adenocarcinoma;
CRC	cis	rs73200209	0.912	rs17498459	chr12:116541595	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.27	-0.33	1.11e-9	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg16724585	chr3:197361211	NA	-0.48	-7.08	-0.36	8.94e-12	Pancreatic cancer;
CRC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.49	0.38	6.2800000000000005e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.73	11.02	0.52	3.06e-24	Menarche (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18162120	chr1:224621880	WDR26	-0.39	-6.14	-0.32	2.34e-9	Myopia (pathological);
CRC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.5	7.58	0.39	3.48e-13	Corneal astigmatism;
CRC	trans	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg10756647	chr7:56101905	PSPH	0.7	7.15	0.37	5.55e-12	Diabetic kidney disease;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	7.49	0.38	6.55e-13	Lymphocyte counts;
CRC	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.43	7.39	0.38	1.26e-12	Intelligence (multi-trait analysis);
CRC	trans	rs9292195	0.641	rs16877156	chr5:58427551	A/T	cg27555894	chr19:5799374	NA	-0.49	-6.24	-0.33	1.33e-9	Breast cancer;
CRC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.58	-0.47	2.44e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg24851651	chr11:66362959	CCS	0.34	5.64	0.3	3.61e-8	Educational attainment (years of education);
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.5	-6.24	-0.33	1.32e-9	Longevity;
CRC	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.2	0.32	1.65e-9	Breast cancer;
CRC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.23	6.35	0.33	7.2e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg10802521	chr3:52805072	NEK4	-0.46	-6.04	-0.32	4.14e-9	Schizophrenia;
CRC	cis	rs11574514	1.000	rs8051653	chr16:67848515	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.02	-0.31	4.73e-9	Crohn's disease;
CRC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.76	-11.96	-0.55	1.27e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg10760299	chr15:45669010	GATM	0.5	7.82	0.4	7.18e-14	Homoarginine levels;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs9359856	0.518	rs72929359	chr6:90260111	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.59	-6.83	-0.35	4.08e-11	Bipolar disorder;
CRC	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg15192750	chr16:69999425	NA	0.59	7.78	0.39	9.62e-14	IgE levels;
CRC	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg26353448	chr1:248524236	OR2T4	-0.29	-6.0	-0.31	5.17e-9	Common traits (Other);
CRC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg19622623	chr12:86230825	RASSF9	-0.38	-5.8	-0.3	1.53e-8	Major depressive disorder;
CRC	cis	rs891088	0.695	rs10411728	chr19:7194938	C/T	cg09779027	chr19:7224513	INSR	-0.61	-7.5	-0.38	6.12e-13	Hip circumference adjusted for BMI;Height;
CRC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.43	7.02	0.36	1.25e-11	Obesity-related traits;
CRC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.45	-6.57	-0.34	1.98e-10	Diastolic blood pressure;
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg02807482	chr3:125708958	NA	-0.41	-5.72	-0.3	2.37e-8	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.44	-6.78	-0.35	5.59e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs2229774	1.000	rs2229774	chr12:53605545	A/G	cg21746001	chr12:53610772	RARG	0.83	6.27	0.33	1.14e-9	Anthracycline-induced cardiotoxicity in childhood cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02717486	chr5:133512833	SKP1	0.37	5.97	0.31	6.03e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs72665486	0.527	rs11729972	chr4:91978448	C/G	cg19903196	chr1:212429231	NA	0.42	5.97	0.31	6.1e-9	Multiple myeloma;
CRC	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.32	-0.37	1.97e-12	Schizophrenia;
CRC	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg23260525	chr10:116636907	FAM160B1	0.33	6.29	0.33	1.02e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16657816	chr16:30905695	BCL7C	0.47	6.84	0.35	3.97e-11	Anxiety disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17664265	chr3:186285263	TBCCD1	0.45	6.2	0.32	1.68e-9	Response to antipsychotic treatment;
CRC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg20203395	chr5:56204925	C5orf35	-0.74	-8.72	-0.43	1.41e-16	Initial pursuit acceleration;
CRC	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg25124228	chr12:125621409	AACS	-0.51	-6.29	-0.33	1.02e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg21620606	chr4:1342894	KIAA1530	0.41	7.01	0.36	1.39e-11	Obesity-related traits;
CRC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.92	-0.48	1.83e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.42	5.77	0.3	1.85e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg10760299	chr15:45669010	GATM	0.51	7.81	0.4	7.79e-14	Homoarginine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25817788	chr6:21589024	NA	0.46	6.68	0.35	1.02e-10	Response to antipsychotic treatment;
CRC	cis	rs501120	1.000	rs665855	chr10:44757751	T/C	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.24	-0.33	1.37e-9	Daytime sleep phenotypes;
CRC	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.5	7.67	0.39	1.92e-13	Uric acid levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18771857	chr5:138609219	MATR3;SNHG4	0.39	6.01	0.31	4.99e-9	Response to antipsychotic treatment;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg12836136	chr22:38245342	EIF3L	0.44	6.82	0.35	4.48e-11	Menarche (age at onset);
CRC	cis	rs6662572	0.737	rs7530480	chr1:46399655	T/C	cg08644498	chr1:46502608	NA	-0.45	-7.08	-0.36	8.76e-12	Blood protein levels;
CRC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.92	-0.44	3.24e-17	Myeloid white cell count;
CRC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.73	0.3	2.32e-8	Educational attainment;
CRC	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.54	9.12	0.45	7.61e-18	Tourette's syndrome or obsessive-compulsive disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08377010	chr19:48673515	LIG1	0.39	6.12	0.32	2.62e-9	Schizophrenia;
CRC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg09796270	chr17:17721594	SREBF1	-0.54	-7.73	-0.39	1.29e-13	Total body bone mineral density;
CRC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	11.92	0.55	1.78e-27	Schizophrenia;
CRC	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.63	9.76	0.47	6.33e-20	Corneal astigmatism;
CRC	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-7.25	-0.37	2.92e-12	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.84	-0.35	3.78e-11	Coronary artery disease;
CRC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.49	7.44	0.38	8.57e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg09695851	chr17:3907499	NA	-0.79	-14.43	-0.62	6.36e-37	Type 2 diabetes;
CRC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.4	0.33	5.44e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.02	-0.32	4.61e-9	Menopause (age at onset);
CRC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg25193494	chr16:90016004	DEF8	0.51	7.95	0.4	3.02e-14	Squamous cell carcinoma;
CRC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-5.81	-0.3	1.5e-8	Melanoma;
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg04796162	chr7:45961102	IGFBP3	0.41	7.16	0.37	5.19e-12	Sitting height ratio;
CRC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg06917450	chr1:38156652	C1orf109	-0.46	-6.9	-0.36	2.61e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg15711740	chr2:61764176	XPO1	-0.52	-7.01	-0.36	1.33e-11	Tuberculosis;
CRC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.74	0.47	7.52e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg23996704	chr18:44553084	KATNAL2	-0.31	-6.08	-0.32	3.38e-9	Personality dimensions;
CRC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg00999904	chr2:3704751	ALLC	0.42	5.97	0.31	6e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs2857891	1.000	rs2638092	chr11:6961746	G/A	cg14883916	chr11:6947541	ZNF215	0.63	6.83	0.35	4.02e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9847710	0.967	rs2564938	chr3:53026384	C/T	cg18404041	chr3:52824283	ITIH1	0.3	5.87	0.31	1.04e-8	Ulcerative colitis;
CRC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.93	-16.89	-0.68	1.57e-46	Height;
CRC	cis	rs4664293	0.667	rs10169681	chr2:160638576	G/A	cg08347373	chr2:160653686	CD302	0.51	8.71	0.43	1.47e-16	Monocyte percentage of white cells;
CRC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.49	-9.6	-0.47	2.09e-19	Subjective well-being;
CRC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	10.13	0.49	3.73e-21	Schizophrenia;
CRC	cis	rs6804368	0.553	rs1350785	chr3:30753995	A/C	cg06106510	chr3:30762233	NA	-0.35	-5.72	-0.3	2.44e-8	Blood metabolite levels;
CRC	cis	rs6479527	0.904	rs4744316	chr9:96864456	A/C	cg14459158	chr9:96720562	NA	-0.39	-6.79	-0.35	5.29e-11	Esophageal adenocarcinoma;
CRC	cis	rs6957923	0.967	rs11773741	chr7:23484232	A/G	cg20265043	chr7:23510089	IGF2BP3	0.37	5.74	0.3	2.12e-8	Height;
CRC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.55	6.19	0.32	1.82e-9	Vitiligo;
CRC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.24	0.37	3.17e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.72e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg26816564	chr1:7831052	VAMP3	-0.49	-6.05	-0.32	3.97e-9	Inflammatory bowel disease;
CRC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.71	-0.3	2.56e-8	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07816229	chr5:154317915	GEMIN5	0.38	5.97	0.31	6.13e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg12856521	chr11:46389249	DGKZ	0.38	6.14	0.32	2.41e-9	Leprosy;
CRC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg18279126	chr7:2041391	MAD1L1	-0.39	-5.88	-0.31	9.89e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.33	-0.46	1.56e-18	Dupuytren's disease;
CRC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.56	7.62	0.39	2.7e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg19678392	chr7:94953810	PON1	-0.53	-6.76	-0.35	6.2e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.54	7.33	0.37	1.84e-12	Height;
CRC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-8.05	-0.41	1.57e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.33	-0.33	8.1e-10	Lymphocyte counts;
CRC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.9	-0.36	2.64e-11	Bipolar disorder;
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg24463073	chr6:118973353	C6orf204	0.51	6.66	0.34	1.13e-10	Renal cell carcinoma;
CRC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.28	6.46	0.34	3.75e-10	Total body bone mineral density;
CRC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg08314208	chr16:67682810	RLTPR	-0.57	-6.43	-0.33	4.6e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg02766259	chr12:125626809	AACS	-0.48	-7.7	-0.39	1.58e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-5.96	-0.31	6.47e-9	Endometrial cancer;
CRC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.45	6.74	0.35	7.22e-11	Colorectal cancer;
CRC	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.87	-0.35	3.26e-11	Schizophrenia;
CRC	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.41	6.34	0.33	7.52e-10	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CRC	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg09507567	chr10:124027408	NA	0.36	7.58	0.39	3.52e-13	Total body bone mineral density;
CRC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg18016565	chr1:150552671	MCL1	-0.42	-6.26	-0.33	1.18e-9	Tonsillectomy;
CRC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-8.38	-0.42	1.55e-15	IgG glycosylation;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg19318889	chr4:1322082	MAEA	-0.43	-6.38	-0.33	5.9e-10	Obesity-related traits;
CRC	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg12963866	chr19:57752005	ZNF805	-0.42	-6.17	-0.32	1.98e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg11833968	chr6:79620685	NA	-0.36	-6.17	-0.32	1.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg02869306	chr7:64672164	INTS4L1	0.44	6.33	0.33	7.85e-10	Aortic root size;
CRC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg08888203	chr3:10149979	C3orf24	0.48	7.33	0.37	1.74e-12	Alzheimer's disease;
CRC	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.7	9.53	0.47	3.51e-19	Menopause (age at onset);
CRC	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg17133734	chr15:86042851	AKAP13	0.42	6.72	0.35	8.23e-11	Coronary artery disease;
CRC	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.27	5.84	0.31	1.22e-8	Educational attainment (years of education);
CRC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.34	-0.38	1.68e-12	Response to antipsychotic treatment;
CRC	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.95	-0.31	6.73e-9	Metabolite levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg26035463	chr12:117627651	FBXO21	-0.49	-6.11	-0.32	2.85e-9	Diisocyanate-induced asthma;
CRC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg19812747	chr11:111475976	SIK2	-0.58	-10.08	-0.49	5.38e-21	Primary sclerosing cholangitis;
CRC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg15147215	chr3:52552868	STAB1	0.45	7.44	0.38	8.85e-13	Body mass index;
CRC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.73e-20	Lung cancer;
CRC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.3e-9	Aortic root size;
CRC	cis	rs3736485	0.934	rs28648597	chr15:51856066	T/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg14541582	chr5:601475	NA	0.33	6.49	0.34	3.22e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.47	-0.38	7.12e-13	Headache;
CRC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.59	11.88	0.55	2.57e-27	Asthma (sex interaction);
CRC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	trans	rs7690467	0.777	rs1813031	chr4:133378957	G/A	cg20215290	chr12:32831428	DNM1L	-0.4	-5.97	-0.31	5.98e-9	Eating disorders;
CRC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg12270520	chr8:146023939	ZNF517	0.36	5.78	0.3	1.76e-8	Age at first birth;
CRC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.01	12.35	0.56	4.95e-29	Cannabis dependence symptom count;
CRC	cis	rs9462846	0.919	rs34433785	chr6:42887693	A/C	cg21280719	chr6:42927975	GNMT	-0.35	-6.13	-0.32	2.47e-9	Blood protein levels;
CRC	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.77	-0.39	9.93e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6066835	0.867	rs28404239	chr20:47361176	T/C	cg18078177	chr20:47281410	PREX1	0.61	5.6	0.3	4.43e-8	Multiple myeloma;
CRC	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-0.78	-8.65	-0.43	2.34e-16	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.55	0.54	4.04e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg08798685	chr6:27730294	NA	-0.42	-6.05	-0.32	3.91e-9	Parkinson's disease;
CRC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.67	10.28	0.49	1.1e-21	Initial pursuit acceleration;
CRC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg10729496	chr3:10149963	C3orf24	0.49	5.65	0.3	3.52e-8	Alzheimer's disease;
CRC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.9	-0.4	4.28e-14	Gut microbiome composition (summer);
CRC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-8.1	-0.41	1.08e-14	Bipolar disorder;
CRC	cis	rs10946940	0.965	rs10946935	chr6:27501345	T/C	cg06470822	chr6:28175283	NA	-0.5	-6.85	-0.35	3.7e-11	Systemic lupus erythematosus;
CRC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	trans	rs12940923	0.935	rs11079342	chr17:56367633	G/C	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg19812747	chr11:111475976	SIK2	-0.47	-7.79	-0.39	8.56e-14	Primary sclerosing cholangitis;
CRC	cis	rs1555895	0.656	rs7919815	chr10:842062	C/G	cg10556349	chr10:835070	NA	-0.38	-7.01	-0.36	1.34e-11	Survival in rectal cancer;
CRC	cis	rs3026101	0.671	rs1806222	chr17:5289676	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.82	0.35	4.25e-11	Body mass index;
CRC	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg14530993	chr4:882597	GAK	0.61	5.84	0.31	1.26e-8	Parkinson's disease;
CRC	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg27053337	chr8:124217698	FAM83A	0.47	7.15	0.37	5.57e-12	Urinary uromodulin levels;
CRC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg08219700	chr8:58056026	NA	0.57	5.83	0.31	1.32e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs12580194	0.556	rs11171433	chr12:55757797	A/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.07	-0.45	1.12e-17	Cancer;
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg01339444	chr6:118972232	C6orf204	0.53	6.02	0.32	4.58e-9	Diastolic blood pressure;
CRC	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.77	12.82	0.58	8.83e-31	Eosinophil percentage of white cells;
CRC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg15845792	chr6:28175446	NA	0.71	5.88	0.31	9.84e-9	Depression;
CRC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.09	0.32	3.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12024301	0.557	rs16828985	chr1:183609830	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.01	0.36	1.33e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.76	14.29	0.62	2.31e-36	Prudent dietary pattern;
CRC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.53	8.14	0.41	8.27e-15	Aortic root size;
CRC	cis	rs501120	0.706	rs1657346	chr10:44777560	G/C	cg09554077	chr10:44749378	NA	0.74	8.09	0.41	1.16e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.76	-0.3	1.88e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.45	6.75	0.35	6.61e-11	Response to interferon beta in multiple sclerosis;
CRC	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-8.82	-0.44	6.83e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg12365402	chr11:9010492	NRIP3	0.5	8.04	0.41	1.62e-14	Hemoglobin concentration;
CRC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	7.3	0.37	2.23e-12	Hip circumference adjusted for BMI;
CRC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.65	-8.32	-0.42	2.35e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.52	8.69	0.43	1.75e-16	Coronary artery disease;
CRC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.61	-8.85	-0.44	5.41e-17	Homoarginine levels;
CRC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg15123519	chr2:136567270	LCT	0.33	6.42	0.33	4.87e-10	Mosquito bite size;
CRC	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-6.41	-0.33	5.15e-10	Systemic lupus erythematosus;
CRC	cis	rs7605827	0.897	rs10202600	chr2:15514461	T/C	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.78e-8	Educational attainment (years of education);
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07685180	chr8:600429	NA	0.75	7.14	0.37	5.86e-12	IgG glycosylation;
CRC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	9.14	0.45	6.75e-18	Mood instability;
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg13491945	chr12:107078410	RFX4	0.36	6.16	0.32	2.13e-9	Heart rate;
CRC	cis	rs17234274	0.622	rs2128495	chr11:23234356	C/T	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.54	7.72	0.39	1.45e-13	Primary sclerosing cholangitis;
CRC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs9287719	0.649	rs6714787	chr2:10729032	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.49	7.27	0.37	2.69e-12	Headache;
CRC	cis	rs2811415	0.597	rs13083602	chr3:127758532	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.59	-8.32	-0.42	2.43e-15	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-8.97	-0.44	2.3e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg16060761	chr17:80687452	NA	-0.47	-6.06	-0.32	3.8e-9	Glycated hemoglobin levels;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg07870213	chr5:140052090	DND1	0.73	8.67	0.43	2.01e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6496667	0.821	rs28459968	chr15:90919002	C/G	cg04176472	chr15:90893244	GABARAPL3	0.6	7.88	0.4	4.81e-14	Rheumatoid arthritis;
CRC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	20.12	0.74	2.92e-59	Metabolite levels;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg12172441	chr6:28176163	NA	0.46	5.99	0.31	5.42e-9	Parkinson's disease;
CRC	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	0.93	11.38	0.53	1.56e-25	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26643908	chr2:36825150	FEZ2	0.36	6.18	0.32	1.88e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.8	12.14	0.56	2.9e-28	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15733507	chr9:139965275	C9orf140	0.43	6.69	0.35	9.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg06470822	chr6:28175283	NA	0.99	13.25	0.59	2.03e-32	Depression;
CRC	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	10.1	0.49	4.52e-21	Exhaled nitric oxide output;
CRC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.18	0.32	1.88e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg27523141	chr10:43048294	ZNF37B	0.45	6.46	0.34	3.84e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.56e-12	Life satisfaction;
CRC	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg14825688	chr5:132208181	LEAP2	-0.37	-5.88	-0.31	9.93e-9	Apolipoprotein A-IV levels;
CRC	trans	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.7	-0.35	9.07e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1712517	0.545	rs3740381	chr10:105046689	G/C	cg04362960	chr10:104952993	NT5C2	-0.47	-6.15	-0.32	2.29e-9	Migraine;
CRC	cis	rs3110496	0.685	rs550818	chr17:27901975	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.47	6.3	0.33	9.42e-10	Height;
CRC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg19875535	chr5:140030758	IK	0.4	6.07	0.32	3.58e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg03623178	chr6:28175578	NA	0.48	7.1	0.36	7.87e-12	Pubertal anthropometrics;
CRC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.75	10.82	0.51	1.46e-23	High light scatter reticulocyte count;
CRC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.37	6.06	0.32	3.81e-9	Platelet distribution width;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.09	-0.41	1.13e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.62	-8.33	-0.42	2.19e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.45	-6.77	-0.35	6.01e-11	Primary sclerosing cholangitis;
CRC	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-7.03	-0.36	1.19e-11	Putamen volume;
CRC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.65	7.04	0.36	1.13e-11	Axial length;
CRC	cis	rs728616	0.867	rs61859022	chr10:81860799	G/A	cg11900509	chr10:81946545	ANXA11	-0.55	-5.81	-0.31	1.46e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.59	-9.27	-0.45	2.6e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg04727332	chr7:45960243	IGFBP3	0.37	5.84	0.31	1.26e-8	Sitting height ratio;
CRC	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.45	-6.26	-0.33	1.21e-9	Systemic sclerosis;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.81	-13.73	-0.6	3.24e-34	Height;
CRC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg16102536	chr7:156981717	UBE3C	-0.4	-6.71	-0.35	8.27e-11	Body mass index;
CRC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.51	8.5	0.42	6.81e-16	Tumor biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23134520	chr20:44485949	ACOT8;ZSWIM3	0.44	6.17	0.32	1.96e-9	Response to antipsychotic treatment;
CRC	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg25237894	chr2:233734115	C2orf82	-0.39	-6.03	-0.32	4.45e-9	Schizophrenia;
CRC	cis	rs10512697	0.803	rs71594961	chr5:3578056	T/C	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.53	-8.2	-0.41	5.32e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.6	9.17	0.45	5.11e-18	Aortic root size;
CRC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.53	7.64	0.39	2.36e-13	Prostate-specific antigen levels;
CRC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.81	-0.48	4.25e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-10.49	-0.5	2.05e-22	Initial pursuit acceleration;
CRC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.46	-8.05	-0.41	1.5e-14	Reticulocyte fraction of red cells;
CRC	cis	rs728616	0.510	rs17617406	chr10:82174556	C/T	cg11900509	chr10:81946545	ANXA11	0.52	5.96	0.31	6.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg02033258	chr5:131593261	PDLIM4	-0.33	-6.26	-0.33	1.21e-9	Blood metabolite levels;
CRC	trans	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg05679027	chr9:99775184	HIATL2	-0.41	-6.25	-0.33	1.3e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	5.92	0.31	8.27e-9	Electroencephalogram traits;
CRC	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg02491457	chr7:128862824	NA	0.53	7.7	0.39	1.65e-13	White matter hyperintensity burden;
CRC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-9.93	-0.48	1.69e-20	Colorectal cancer;
CRC	cis	rs2380220	0.808	rs2613551	chr6:95914740	G/A	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.42	6.7	0.35	9.26e-11	High light scatter reticulocyte count;
CRC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.5	-6.97	-0.36	1.72e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.45	5.81	0.3	1.49e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg18551225	chr6:44695536	NA	-0.41	-5.96	-0.31	6.36e-9	Total body bone mineral density;
CRC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg18612461	chr15:75251733	NA	-0.37	-5.6	-0.3	4.41e-8	Breast cancer;
CRC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg15440763	chr7:158190612	PTPRN2	-0.42	-6.77	-0.35	5.99e-11	Obesity-related traits;
CRC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.46	-0.38	7.69e-13	Bladder cancer;
CRC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg19223190	chr17:80058835	NA	0.39	6.3	0.33	9.57e-10	Life satisfaction;
CRC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.76	-0.68	5.2e-46	Height;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.67	7.12	0.37	7.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	1.11	10.44	0.5	3.09e-22	Arsenic metabolism;
CRC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.58	10.56	0.5	1.2e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs6956675	0.881	rs1829737	chr7:62576000	G/A	cg01314568	chr7:57830625	NA	-0.67	-9.05	-0.45	1.24e-17	Obesity-related traits;
CRC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg24375607	chr4:120327624	NA	0.48	7.63	0.39	2.56e-13	Educational attainment;
CRC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.57	-9.4	-0.46	9.34e-19	Total body bone mineral density;
CRC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.69	-9.02	-0.45	1.54e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg02033258	chr5:131593261	PDLIM4	0.46	8.67	0.43	2.04e-16	Blood metabolite levels;
CRC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg10760299	chr15:45669010	GATM	0.36	5.61	0.3	4.26e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.44	6.59	0.34	1.72e-10	Coronary artery disease;
CRC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	17.68	0.7	1.19e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.72	11.03	0.52	2.79e-24	Corneal astigmatism;
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.6	10.52	0.5	1.67e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg01134436	chr17:81009848	B3GNTL1	0.72	6.54	0.34	2.32e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs10946940	0.896	rs12208078	chr6:27498581	G/A	cg02683197	chr6:28174875	NA	-0.53	-7.25	-0.37	2.99e-12	Systemic lupus erythematosus;
CRC	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.2	0.45	4.18e-18	Blood protein levels;
CRC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.33	6.25	0.33	1.26e-9	Blood metabolite levels;
CRC	trans	rs10277209	0.932	rs1406296	chr7:109012340	T/C	cg13575011	chr19:16022472	NA	0.48	5.98	0.31	5.91e-9	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.8	9.13	0.45	7.07e-18	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.92	-17.55	-0.7	3.8e-49	Coronary artery disease;
CRC	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.7	-9.4	-0.46	9.41e-19	Blood pressure (smoking interaction);
CRC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.0	0.36	1.44e-11	Morning vs. evening chronotype;
CRC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.47	-6.94	-0.36	2.13e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13410609	chr19:50291885	AP2A1	-0.37	-6.04	-0.32	4.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4743820	0.590	rs10991785	chr9:93917111	C/T	cg14446406	chr9:93919335	NA	0.77	13.47	0.6	2.94e-33	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.66	-7.85	-0.4	5.99e-14	Ulcerative colitis;
CRC	cis	rs11679072	1.000	rs13410440	chr2:240447304	C/T	cg03276489	chr2:240449683	NA	0.87	9.07	0.45	1.13e-17	Blood pressure (smoking interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13834670	chr9:129677390	RALGPS1	-0.44	-7.18	-0.37	4.63e-12	Myopia (pathological);
CRC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-1.03	-20.89	-0.76	2.86e-62	Headache;
CRC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.73	-12.51	-0.57	1.22e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19998654	chr2:37458983	CEBPZ;C2orf56	0.42	6.75	0.35	6.52e-11	Obesity-related traits;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.67	-11.56	-0.54	3.65e-26	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.68e-10	HDL cholesterol;
CRC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg05132306	chr1:1846340	CALML6	-0.42	-6.49	-0.34	3.18e-10	Body mass index;
CRC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.52	0.5	1.69e-22	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg04731861	chr2:219085781	ARPC2	0.28	5.89	0.31	9.6e-9	Colorectal cancer;
CRC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg16989086	chr20:62203971	PRIC285	0.47	6.04	0.32	4.21e-9	Glioblastoma;
CRC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.07	0.52	1.98e-24	Monocyte percentage of white cells;
CRC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.42	6.9	0.36	2.74e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25887850	chr20:44509743	ZSWIM1	0.47	6.73	0.35	7.65e-11	Response to antipsychotic treatment;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.38	-6.11	-0.32	2.74e-9	Lymphocyte counts;
CRC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	0.98	14.93	0.64	7.78e-39	Monocyte percentage of white cells;
CRC	cis	rs6496667	0.909	rs56733567	chr15:90881557	G/T	cg04176472	chr15:90893244	GABARAPL3	0.57	6.62	0.34	1.45e-10	Rheumatoid arthritis;
CRC	trans	rs2303319	0.504	rs16846047	chr2:162561946	T/C	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-10.57	-0.5	1.15e-22	Body mass index;
CRC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.43	-0.5	3.32e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.47	5.75	0.3	2.08e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11713515	chr10:18940758	NSUN6	0.37	6.16	0.32	2.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.28	-0.33	1.04e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26281728	chr15:85923949	AKAP13	0.42	6.62	0.34	1.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	9.9	0.48	2.16e-20	Prudent dietary pattern;
CRC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.56	-7.33	-0.37	1.78e-12	Gut microbiome composition (summer);
CRC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.39	7.55	0.38	4.33e-13	Mean corpuscular volume;
CRC	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg18833306	chr6:118973337	C6orf204	0.46	5.66	0.3	3.24e-8	Diastolic blood pressure;
CRC	cis	rs6545883	0.524	rs12713435	chr2:61499789	C/T	cg10580144	chr2:61372316	C2orf74	-0.35	-7.63	-0.39	2.59e-13	Tuberculosis;
CRC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.42	-0.42	1.16e-15	Monocyte percentage of white cells;
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.04	-0.52	2.62e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg06204229	chr3:52865917	ITIH4	0.58	6.81	0.35	4.57e-11	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.59	11.25	0.53	4.68e-25	Bone mineral density;
CRC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.36	5.91	0.31	8.34e-9	Major depressive disorder;
CRC	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.31	8.07e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.02	-0.36	1.28e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.3	-0.62	1.99e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.91	-0.44	3.66e-17	Bladder cancer;
CRC	cis	rs1320333	0.772	rs2867136	chr2:701455	T/C	cg20966539	chr2:681320	NA	-0.56	-5.78	-0.3	1.73e-8	Obesity-related traits;
CRC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.57	-7.88	-0.4	4.86e-14	Gut microbiome composition (summer);
CRC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg26248373	chr2:1572462	NA	-0.71	-8.13	-0.41	8.56e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs17065868	0.764	rs6561176	chr13:45015449	T/C	cg10246903	chr13:45222710	NA	0.57	6.3	0.33	9.58e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg16964102	chr10:135390573	NA	0.44	5.81	0.31	1.46e-8	Gout;
CRC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.58	10.56	0.5	1.18e-22	Coronary artery disease;
CRC	cis	rs7605827	0.930	rs4140715	chr2:15515899	G/A	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.78e-8	Educational attainment (years of education);
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.61	-8.95	-0.44	2.6e-17	Menopause (age at onset);
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.15	-0.45	6.29e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.48	7.62	0.39	2.77e-13	Motion sickness;
CRC	cis	rs6546324	0.580	rs1430785	chr2:67869292	A/G	cg15745817	chr2:67799979	NA	-0.45	-8.29	-0.42	2.86e-15	Endometriosis;
CRC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.59	8.86	0.44	5.17e-17	Aortic root size;
CRC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.36	5.91	0.31	8.48e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.59	-9.49	-0.46	4.91e-19	Dental caries;
CRC	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	1.21	10.91	0.52	7.09e-24	Arsenic metabolism;
CRC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.38	7.07	0.36	9.07e-12	Lung cancer;
CRC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.51	7.93	0.4	3.37e-14	Height;
CRC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.43	4.17e-16	Aortic root size;
CRC	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-5.77	-0.3	1.81e-8	Body mass index;
CRC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg05623727	chr3:50126028	RBM5	0.46	7.69	0.39	1.76e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg21577049	chr2:228736449	WDR69	-0.47	-6.22	-0.32	1.5e-9	Blood pressure;
CRC	trans	rs12699921	0.632	rs2723552	chr7:17860661	T/G	cg02066331	chr6:17282778	RBM24	-0.36	-6.09	-0.32	3.23e-9	Fibrinogen levels;
CRC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.67	9.35	0.46	1.35e-18	Coronary artery disease;
CRC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.27	6.11	0.32	2.83e-9	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.81	11.98	0.55	1.08e-27	Menarche (age at onset);
CRC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.58	-8.07	-0.41	1.3e-14	Pancreatic cancer;
CRC	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	0.62	5.96	0.31	6.67e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.64	-9.37	-0.46	1.21e-18	Menarche (age at onset);
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.95	-0.4	3.02e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.97	-19.26	-0.73	6.71e-56	Height;
CRC	cis	rs7640424	0.929	rs327139	chr3:107822481	G/C	cg09227934	chr3:107805635	CD47	0.42	6.32	0.33	8.31e-10	Body mass index;
CRC	cis	rs3857067	0.736	rs2865333	chr4:95019964	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.05	-0.32	3.9e-9	QT interval;
CRC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.78	-0.35	5.69e-11	Metabolite levels;
CRC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.69	10.08	0.49	5.39e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.21	-0.32	1.6e-9	Aortic root size;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.26	-0.37	2.77e-12	Bipolar disorder;
CRC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.77	-10.34	-0.5	7.21e-22	Coronary artery disease;
CRC	cis	rs12983728	0.505	rs35511051	chr19:58665817	C/A	cg08687515	chr19:58661962	ZNF329	0.48	5.97	0.31	6.07e-9	Cholesterol, total;
CRC	cis	rs12900413	0.645	rs28507224	chr15:90305393	T/C	cg24249390	chr15:90295951	MESP1	-0.56	-9.02	-0.45	1.59e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	12.84	0.58	7.28e-31	Smoking behavior;
CRC	cis	rs9491140	0.514	rs11154227	chr6:124681816	G/A	cg05308643	chr6:124982296	NKAIN2	0.45	5.91	0.31	8.78e-9	Neuroticism;
CRC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg08347473	chr17:78092826	GAA	-0.37	-5.97	-0.31	6.08e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	6.63	0.34	1.35e-10	Schizophrenia;
CRC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.68	-0.39	1.83e-13	Arsenic metabolism;
CRC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.39	8.07	0.41	1.34e-14	Bipolar disorder;
CRC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.6	-10.78	-0.51	2.04e-23	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.37	5.64	0.3	3.69e-8	Multiple myeloma;
CRC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.41	6.06	0.32	3.74e-9	Alzheimer's disease (late onset);
CRC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.73	12.11	0.56	3.71e-28	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24418792	chr10:104153828	NFKB2	0.42	6.11	0.32	2.85e-9	Anxiety disorder;
CRC	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg00495681	chr13:53174319	NA	0.54	7.93	0.4	3.54e-14	Lewy body disease;
CRC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg16898833	chr6:26189333	HIST1H4D	0.74	6.28	0.33	1.05e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.84	-0.31	1.26e-8	Subjective well-being;
CRC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.34	6.14	0.32	2.33e-9	Mean corpuscular volume;
CRC	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg16540259	chr10:75572220	NDST2	0.38	5.98	0.31	5.77e-9	Inflammatory bowel disease;
CRC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.65	-7.64	-0.39	2.35e-13	Lung cancer in ever smokers;
CRC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.66	9.07	0.45	1.14e-17	Multiple sclerosis;
CRC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg08314208	chr16:67682810	RLTPR	-0.53	-5.73	-0.3	2.33e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	10.24	0.49	1.49e-21	Type 2 diabetes;
CRC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-6.71	-0.35	8.31e-11	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08137080	chr1:16482430	EPHA2	0.34	6.44	0.33	4.29e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs17095355	1.000	rs958086	chr10:111752548	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.3	-0.37	2.17e-12	Biliary atresia;
CRC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg23071808	chr14:103021642	NA	0.62	6.96	0.36	1.82e-11	Platelet count;
CRC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.83	-14.65	-0.63	9.06e-38	Coronary artery disease;
CRC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.1	26.81	0.83	9.1200000000000006e-85	Testicular germ cell tumor;
CRC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.56	-8.73	-0.43	1.33e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg18827107	chr12:86230957	RASSF9	-0.37	-6.01	-0.31	5.05e-9	Major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05542295	chr17:55162876	AKAP1	0.44	6.23	0.32	1.4e-9	Response to antipsychotic treatment;
CRC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.78	9.43	0.46	7.54e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg24130564	chr14:104152367	KLC1	-0.41	-5.72	-0.3	2.43e-8	Intelligence (multi-trait analysis);
CRC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.56	9.01	0.44	1.77e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.49	0.46	5.04e-19	Coffee consumption (cups per day);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10922530	chr12:124457083	CCDC92;ZNF664	0.38	6.84	0.35	3.76e-11	Interleukin-6 levels;
CRC	trans	rs800082	0.646	rs2717394	chr3:144280612	A/T	cg24215973	chr2:240111563	HDAC4	0.57	8.87	0.44	4.89e-17	Smoking behavior;
CRC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.56	7.61	0.39	3e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg23234261	chr14:55582407	NA	-0.29	-5.84	-0.31	1.24e-8	Protein biomarker;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.76	14.24	0.62	3.62e-36	Prudent dietary pattern;
CRC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg02033258	chr5:131593261	PDLIM4	0.4	7.71	0.39	1.48e-13	Breast cancer;
CRC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.59	-10.14	-0.49	3.4e-21	Iron status biomarkers;
CRC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg15038512	chr6:170123185	PHF10	-0.4	-6.15	-0.32	2.28e-9	Obesity-related traits;
CRC	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg03623178	chr6:28175578	NA	0.5	6.01	0.31	4.82e-9	Breast cancer;
CRC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.58	9.12	0.45	7.56e-18	Gestational age at birth (maternal effect);
CRC	cis	rs4363385	0.693	rs310102	chr1:153042423	T/C	cg25856811	chr1:152973957	SPRR3	-0.24	-6.58	-0.34	1.84e-10	Inflammatory skin disease;
CRC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.38	0.5	5.06e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.61	0.3	4.31e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.72	-11.09	-0.52	1.7e-24	Cognitive function;
CRC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg25456477	chr12:86230367	RASSF9	0.36	6.24	0.33	1.37e-9	Major depressive disorder;
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg13880726	chr7:1868755	MAD1L1	-0.46	-5.72	-0.3	2.42e-8	Bipolar disorder;
CRC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.34	-5.62	-0.3	4.14e-8	Diastolic blood pressure;
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg04518342	chr5:131593106	PDLIM4	0.38	6.97	0.36	1.78e-11	Blood metabolite levels;
CRC	cis	rs501120	0.584	rs1704223	chr10:44677014	C/T	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.52	8.62	0.43	2.94e-16	Schizophrenia;
CRC	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.69	-10.6	-0.5	9.1e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.39	6.57	0.34	2.03e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg10512202	chr3:45649293	LIMD1	0.4	5.66	0.3	3.33e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16143763	chr17:41116517	AARSD1	0.38	6.56	0.34	2.11e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg10756647	chr7:56101905	PSPH	-0.78	-8.04	-0.41	1.65e-14	Diabetic kidney disease;
CRC	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg10263370	chr3:44754102	ZNF502	-0.36	-5.98	-0.31	5.85e-9	Depressive symptoms;
CRC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.75	-0.39	1.17e-13	Gut microbiome composition (summer);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg00844328	chr13:33002010	N4BP2L1	-0.42	-6.1	-0.32	2.95e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.59	8.44	0.42	1.03e-15	Airflow obstruction;
CRC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.56	-15.1	-0.64	1.73e-39	Urate levels in overweight individuals;
CRC	cis	rs2929278	0.588	rs1975364	chr15:44150189	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	6.81	0.35	4.76e-11	Schizophrenia;
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg27635394	chr6:26043820	HIST1H2BB	0.4	6.06	0.32	3.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.3	-0.37	2.24e-12	Total body bone mineral density;
CRC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.27	-0.37	2.69e-12	QT interval;
CRC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.66	0.39	2.07e-13	Obesity-related traits;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.45	-6.42	-0.33	4.64e-10	Breast cancer;
CRC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg20811857	chr17:78079795	GAA	0.49	6.88	0.35	3.04e-11	Yeast infection;
CRC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.72	-0.39	1.38e-13	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11970301	chr16:30087888	PPP4C	0.47	6.7	0.35	9.09e-11	Response to antipsychotic treatment;
CRC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg05139728	chr16:28306816	SBK1	-0.39	-6.22	-0.32	1.47e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg05527609	chr1:210001259	C1orf107	-0.53	-5.62	-0.3	4.17e-8	Red blood cell count;
CRC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.42	5.97	0.31	6.06e-9	QT interval;
CRC	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg23071808	chr14:103021642	NA	0.62	6.96	0.36	1.82e-11	Platelet count;
CRC	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg04058563	chr4:185651563	MLF1IP	0.58	6.19	0.32	1.74e-9	Type 2 diabetes;
CRC	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.29	6.19	0.32	1.84e-9	Educational attainment (years of education);
CRC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.63	-8.87	-0.44	4.85e-17	DNA methylation (variation);
CRC	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg00603274	chr11:61596626	FADS2	-0.44	-6.4	-0.33	5.33e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg14711859	chr11:8959438	ASCL3	-0.48	-8.18	-0.41	6.46e-15	Hemoglobin concentration;
CRC	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg09324608	chr17:30823087	MYO1D	0.35	5.96	0.31	6.64e-9	Schizophrenia;
CRC	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.43	6.33	0.33	8.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.49	-7.03	-0.36	1.19e-11	Blood metabolite levels;
CRC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-7.37	-0.38	1.4e-12	Coronary artery disease;
CRC	cis	rs7113874	0.610	rs11041924	chr11:8463107	C/T	cg02811074	chr11:8615871	STK33	-0.36	-6.23	-0.32	1.45e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.73	-10.54	-0.5	1.38e-22	Longevity;
CRC	cis	rs11212617	0.967	rs634268	chr11:108186258	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.86	0.31	1.12e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19586645	chr17:73266642	MIF4GD	0.43	6.51	0.34	2.87e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.88	0.31	1.01e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg06470822	chr6:28175283	NA	0.66	10.08	0.49	5.48e-21	Pubertal anthropometrics;
CRC	cis	rs55702914	0.742	rs34555121	chr2:198166053	C/T	cg20885578	chr2:198174922	NA	0.35	6.06	0.32	3.7e-9	Major depression and alcohol dependence;
CRC	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.74	11.73	0.54	8.89e-27	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.23	-0.32	1.44e-9	Bipolar disorder;
CRC	cis	rs11203032	0.831	rs10509567	chr10:90945756	G/A	cg16672925	chr10:90967113	CH25H	0.45	5.63	0.3	3.93e-8	Heart failure;
CRC	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.49	8.04	0.41	1.6e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-7.64	-0.39	2.45e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.78	9.84	0.48	3.36e-20	Diisocyanate-induced asthma;
CRC	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.63	0.43	2.59e-16	Coffee consumption (cups per day);
CRC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.79	11.95	0.55	1.41e-27	Cognitive function;
CRC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.91	0.48	1.93e-20	Platelet count;
CRC	cis	rs3736594	0.513	rs56725354	chr2:27824168	G/C	cg27432699	chr2:27873401	GPN1	0.65	8.29	0.42	2.95e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00495681	chr13:53174319	NA	0.63	9.88	0.48	2.53e-20	Lewy body disease;
CRC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	7.25	0.37	2.92e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04139749	chr14:77786727	GSTZ1;POMT2	0.4	6.36	0.33	6.68e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.8	9.74	0.47	7.54e-20	Initial pursuit acceleration;
CRC	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.14	-9.02	-0.45	1.57e-17	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Parkinson's disease;
CRC	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg18612461	chr15:75251733	NA	-0.37	-5.64	-0.3	3.57e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6662572	1.000	rs72688469	chr1:46118393	T/A	cg08644498	chr1:46502608	NA	0.47	6.89	0.35	2.93e-11	Blood protein levels;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg08200582	chr11:442649	ANO9	-0.71	-7.39	-0.38	1.2e-12	Body mass index;
CRC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.9e-31	White blood cell count (basophil);
CRC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg25985355	chr7:65971099	NA	-0.46	-5.98	-0.31	5.85e-9	Diabetic kidney disease;
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.96	-0.36	1.89e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9462027	0.628	rs9462009	chr6:34716330	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs972578	0.837	rs6002963	chr22:43246146	C/T	cg01576275	chr22:43409880	NA	-0.41	-6.32	-0.33	8.72e-10	Mean platelet volume;
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.51	7.36	0.38	1.52e-12	Lymphocyte counts;
CRC	trans	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg21153622	chr11:89784906	NA	-0.48	-7.62	-0.39	2.78e-13	HDL cholesterol;
CRC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.57	8.35	0.42	1.95e-15	Obesity-related traits;
CRC	cis	rs6445967	1.000	rs12633655	chr3:58306321	T/C	cg23715586	chr3:58305044	RPP14	0.34	5.72	0.3	2.45e-8	Platelet count;
CRC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.76	-0.35	6.31e-11	Total body bone mineral density;
CRC	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg23425280	chr12:56401806	NA	0.47	5.72	0.3	2.44e-8	Cancer;
CRC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.16	-0.32	2.07e-9	Axial length;
CRC	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.92	-0.36	2.4e-11	Menopause (age at onset);
CRC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.19	-0.37	4.36e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-7.37	-0.38	1.41e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.78	-13.01	-0.58	1.61e-31	Obesity-related traits;
CRC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.56	-8.93	-0.44	2.99e-17	Sum eosinophil basophil counts;
CRC	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.88	-15.23	-0.64	4.95e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg14196790	chr5:131705035	SLC22A5	0.35	5.73	0.3	2.25e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg13385794	chr1:248469461	NA	0.38	6.68	0.35	1.01e-10	Common traits (Other);
CRC	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.72	-11.94	-0.55	1.5e-27	Ear protrusion;
CRC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.45	9.65	0.47	1.49e-19	Blood protein levels;
CRC	cis	rs972578	1.000	rs4140554	chr22:43355256	A/G	cg01576275	chr22:43409880	NA	0.44	7.03	0.36	1.21e-11	Mean platelet volume;
CRC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg04043695	chr12:129287642	SLC15A4	0.38	5.74	0.3	2.21e-8	Systemic lupus erythematosus;
CRC	cis	rs6763159	0.967	rs11130727	chr3:59642877	T/C	cg07069742	chr3:59644285	NA	-0.33	-6.57	-0.34	2.01e-10	Conotruncal heart defects;
CRC	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.47	-0.38	7.07e-13	Caudate activity during reward;
CRC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.7	10.95	0.52	5.46e-24	Corneal astigmatism;
CRC	cis	rs10503871	0.594	rs10954994	chr8:30306419	C/A	cg26383811	chr8:30366931	RBPMS	0.48	7.61	0.39	2.96e-13	Metabolite levels  (X-11787);
CRC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.48	-6.99	-0.36	1.52e-11	Height;
CRC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.62	0.3	4.14e-8	Initial pursuit acceleration;
CRC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.62	-10.09	-0.49	4.84e-21	Height;
CRC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.57	0.5	1.15e-22	Coronary artery disease;
CRC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.72	-9.6	-0.47	2.08e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	27.0	0.83	1.83e-85	Schizophrenia;
CRC	cis	rs11212617	1.000	rs227087	chr11:108244114	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.62	0.34	1.5e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg21784768	chr11:537496	LRRC56	-0.59	-5.64	-0.3	3.67e-8	Body mass index;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg15763984	chr4:1342303	KIAA1530	-0.35	-6.13	-0.32	2.5e-9	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2376015	1	rs2376015	chr1:66123774	A/G	cg04111102	chr1:66153794	NA	0.34	5.96	0.31	6.52e-9	Fibrinogen levels;
CRC	cis	rs6961069	0.749	rs4316098	chr7:80259988	C/T	cg04458919	chr7:80252533	CD36	0.34	5.98	0.31	5.72e-9	Platelet count;
CRC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.71	11.89	0.55	2.39e-27	Coronary artery disease;
CRC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.5	-7.74	-0.39	1.24e-13	Body mass index;
CRC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.55	-7.17	-0.37	4.89e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2882667	0.690	rs9942422	chr5:138272536	A/G	cg09476006	chr5:138032270	NA	0.6	10.13	0.49	3.64e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.4	-7.54	-0.38	4.58e-13	Lung cancer;
CRC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.07	0.45	1.14e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg17903999	chr18:56338584	MALT1	-0.41	-6.67	-0.35	1.06e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg00343986	chr7:65444356	GUSB	0.49	7.42	0.38	1e-12	Aortic root size;
CRC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.81	-0.31	1.48e-8	Schizophrenia;
CRC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.6	8.86	0.44	5.19e-17	Neuroticism;
CRC	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	1.02	9.32	0.46	1.8e-18	Lymphocyte counts;
CRC	cis	rs501120	0.810	rs473501	chr10:44749171	G/A	cg09554077	chr10:44749378	NA	0.9	13.3	0.59	1.4e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.17	0.52	9.08e-25	Prudent dietary pattern;
CRC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.67	-8.63	-0.43	2.76e-16	Mean platelet volume;
CRC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	16.77	0.68	4.56e-46	Platelet count;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg10099229	chr12:6960622	USP5;CDCA3	0.51	6.02	0.31	4.7e-9	Kashin-Beck disease;
CRC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.5	-7.94	-0.4	3.19e-14	Type 2 diabetes;
CRC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg03948781	chr1:205179583	DSTYK	0.41	5.77	0.3	1.88e-8	Red blood cell count;
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg12516270	chr8:143859308	LYNX1	0.43	7.57	0.39	3.83e-13	Urinary tract infection frequency;
CRC	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.43	-6.73	-0.35	7.45e-11	C-reactive protein levels;
CRC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.96	-0.31	6.67e-9	Schizophrenia;
CRC	trans	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg26043149	chr18:55253948	FECH	0.51	7.63	0.39	2.62e-13	Bone mineral density;
CRC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.94	-0.31	7.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25517755	chr10:38738941	LOC399744	-0.43	-6.2	-0.32	1.68e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.55	-0.47	3.16e-19	Platelet count;
CRC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.41	-8.12	-0.41	9.75e-15	Schizophrenia;
CRC	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.57	-8.55	-0.43	4.81e-16	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05943731	chr12:123444284	ABCB9	-0.35	-6.08	-0.32	3.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.39	5.95	0.31	7.02e-9	Colorectal cancer;
CRC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg14711859	chr11:8959438	ASCL3	0.48	8.01	0.4	2.06e-14	Hemoglobin concentration;
CRC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.19	-0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.45	6.23	0.32	1.46e-9	Coronary artery disease;
CRC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.7	-9.1	-0.45	9.03e-18	Initial pursuit acceleration;
CRC	cis	rs800160	0.720	rs2106604	chr11:2341157	G/C	cg09785033	chr11:2336066	TSPAN32	-0.5	-5.78	-0.3	1.7e-8	Bacteremia;
CRC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.14e-9	Crohn's disease;
CRC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.65	-10.77	-0.51	2.32e-23	Electrocardiographic conduction measures;
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg01721255	chr8:58191610	C8orf71	0.47	5.97	0.31	6.02e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg17133734	chr15:86042851	AKAP13	0.4	6.33	0.33	8.2e-10	Coronary artery disease;
CRC	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.14	-0.32	2.43e-9	Monocyte count;
CRC	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg17182837	chr8:41585554	ANK1	-0.61	-8.67	-0.43	2.01e-16	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg08888203	chr3:10149979	C3orf24	0.61	7.06	0.36	1.02e-11	Alzheimer's disease;
CRC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.49	5.79	0.3	1.61e-8	Gut microbiome composition (summer);
CRC	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs6988985	0.818	rs3802228	chr8:143992218	A/G	cg10324643	chr8:143916377	GML	0.4	6.72	0.35	8.24e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.91	17.53	0.69	4.84e-49	Menopause (age at onset);
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12172441	chr6:28176163	NA	0.55	6.95	0.36	1.97e-11	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10137990	chr8:145137203	GPAA1	0.37	6.16	0.32	2.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.6	-8.07	-0.41	1.29e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.61	0.34	1.51e-10	Blood protein levels;
CRC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	12.44	0.57	2.14e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.43	9.61	0.47	1.95e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.62	10.48	0.5	2.36e-22	Prudent dietary pattern;
CRC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.08	-0.45	1.05e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-16.81	-0.68	3.24e-46	Height;
CRC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.65	-0.3	3.53e-8	Erythrocyte sedimentation rate;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg07617317	chr6:118971624	C6orf204	0.47	5.9	0.31	8.84e-9	Diastolic blood pressure;
CRC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02290350	chr8:58132656	NA	-0.44	-6.39	-0.33	5.52e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.34	-0.33	7.69e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg09476006	chr5:138032270	NA	0.45	6.85	0.35	3.59e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.73	-0.39	1.32e-13	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12698784	chr3:119813316	GSK3B	0.4	6.12	0.32	2.7e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12404182	chr2:132250324	FAM128A;LOC150776	0.44	6.31	0.33	9.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs737008	0.960	rs34764020	chr16:11378359	C/T	cg00044050	chr16:11439710	C16orf75	-0.45	-6.02	-0.32	4.56e-9	Obesity-related traits;
CRC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs4731207	0.596	rs13231916	chr7:124640225	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.65	11.91	0.55	1.97e-27	Calcium levels;
CRC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg00343986	chr7:65444356	GUSB	0.43	6.05	0.32	3.87e-9	Aortic root size;
CRC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg08270630	chr22:50330655	NA	-0.43	-6.63	-0.34	1.4e-10	Schizophrenia;
CRC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.29e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02726883	chr17:29421732	NF1	0.44	6.01	0.31	4.85e-9	Survival in pancreatic cancer;
CRC	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg13385794	chr1:248469461	NA	0.38	6.77	0.35	5.95e-11	Common traits (Other);
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.89	0.31	9.77e-9	Bipolar disorder;
CRC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.41	-6.04	-0.32	4.07e-9	Type 2 diabetes;
CRC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.48	8.0	0.4	2.1e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg27490568	chr2:178487706	NA	0.41	5.91	0.31	8.49e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.69	-7.88	-0.4	4.87e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg11214544	chr1:2391121	NA	-0.59	-9.31	-0.46	1.86e-18	Non-obstructive azoospermia;
CRC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.3	6.27	0.33	1.13e-9	Homoarginine levels;
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.0	-0.31	5.34e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.55e-9	Depression;
CRC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.75	-14.28	-0.62	2.46e-36	Body mass index;
CRC	cis	rs995000	0.899	rs1183260	chr1:62945418	A/G	cg19896129	chr1:63156450	NA	-0.45	-6.89	-0.36	2.83e-11	Triglyceride levels;
CRC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.69	-0.3	2.77e-8	Aortic root size;
CRC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.47	6.9	0.36	2.68e-11	Obesity-related traits;
CRC	cis	rs4666002	0.789	rs13030973	chr2:27928797	T/C	cg27432699	chr2:27873401	GPN1	0.56	7.04	0.36	1.14e-11	Phospholipid levels (plasma);
CRC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.33	0.33	8.2e-10	Aortic root size;
CRC	cis	rs3857067	1.000	rs28840089	chr4:95000403	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.04	-0.32	4.06e-9	QT interval;
CRC	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.82	15.38	0.65	1.38e-40	Metabolite levels;
CRC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.61	8.14	0.41	8.28e-15	Urate levels in lean individuals;
CRC	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.76	-10.31	-0.49	8.66e-22	White matter hyperintensity burden;
CRC	cis	rs4930561	1.000	rs10896298	chr11:67931459	C/T	cg04465784	chr11:67976953	SUV420H1	-0.27	-5.62	-0.3	4.04e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.35	-0.38	1.59e-12	Menopause (age at onset);
CRC	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg09455208	chr3:40491958	NA	0.31	6.36	0.33	6.69e-10	Renal cell carcinoma;
CRC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.47	7.26	0.37	2.9e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.95	0.55	1.45e-27	Alzheimer's disease;
CRC	cis	rs17767392	0.834	rs61989252	chr14:71727914	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.52	-6.23	-0.32	1.41e-9	Mitral valve prolapse;
CRC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.48	6.21	0.32	1.61e-9	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10451772	chr3:127347880	PODXL2	0.43	7.45	0.38	8.15e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.43	-0.46	7.61e-19	HDL cholesterol;
CRC	cis	rs7705042	0.828	rs10875596	chr5:141495715	T/C	cg07392085	chr5:141489673	NDFIP1	0.47	7.41	0.38	1.06e-12	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02500152	chr12:48357316	TMEM106C	0.44	7.09	0.36	8.31e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg11887960	chr12:57824829	NA	0.64	7.2	0.37	4.1e-12	Obesity-related traits;
CRC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.37	0.65	1.54e-40	Platelet count;
CRC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.59	-9.99	-0.48	1.04e-20	Post bronchodilator FEV1;
CRC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.42	0.53	1.11e-25	Prudent dietary pattern;
CRC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12463550	chr7:65579703	CRCP	0.65	5.75	0.3	2.03e-8	Diabetic kidney disease;
CRC	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.65	-0.39	2.18e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg20503657	chr10:835505	NA	0.54	7.46	0.38	8.01e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.84	-10.99	-0.52	3.95e-24	Triglycerides;
CRC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.72	12.38	0.56	3.77e-29	Longevity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23426587	chr9:21335126	KLHL9	0.47	6.69	0.35	9.75e-11	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.94	-0.44	2.87e-17	Bipolar disorder;
CRC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg19041857	chr6:27730383	NA	-0.42	-5.94	-0.31	7.29e-9	Parkinson's disease;
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14363841	chr7:73185036	CLDN3	0.39	6.51	0.34	2.85e-10	Interleukin-6 levels;
CRC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.83	8.23	0.41	4.37e-15	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06589161	chr5:180618230	NA	0.4	6.47	0.34	3.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.48	5.71	0.3	2.58e-8	Schizophrenia;
CRC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.63	-9.91	-0.48	1.96e-20	Dental caries;
CRC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg00101154	chr16:420108	MRPL28	-0.53	-6.85	-0.35	3.73e-11	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg23018236	chr17:30244563	NA	-0.62	-7.83	-0.4	6.75e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6679356	0.724	rs3828068	chr1:67817872	G/A	cg24364144	chr1:67875067	SERBP1	0.43	6.66	0.34	1.14e-10	Primary biliary cholangitis;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg03729431	chr17:15848264	ADORA2B	0.41	6.52	0.34	2.66e-10	Interleukin-6 levels;
CRC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.09	-0.49	5.04e-21	Total cholesterol levels;
CRC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04013166	chr16:89971882	TCF25	-0.5	-5.62	-0.3	4.13e-8	Skin colour saturation;
CRC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.36	-5.78	-0.3	1.76e-8	Ulcerative colitis;
CRC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg05639522	chr1:247681581	NA	0.56	6.05	0.32	3.95e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.19	-0.53	7.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg19812747	chr11:111475976	SIK2	0.45	6.78	0.35	5.66e-11	Primary sclerosing cholangitis;
CRC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.35	8.06	0.41	1.42e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs524281	0.773	rs2155201	chr11:65992344	T/C	cg16950941	chr11:66035639	RAB1B	-0.7	-8.05	-0.41	1.53e-14	Electroencephalogram traits;
CRC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02429656	chr12:26275311	BHLHE41	0.41	6.16	0.32	2.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.02	-0.31	4.69e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.64	8.9	0.44	3.79e-17	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.86	-0.31	1.13e-8	Neuroticism;
CRC	trans	rs2303319	0.582	rs12464282	chr2:162448855	C/T	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.43e-9	Cognitive function;
CRC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.21	-0.32	1.58e-9	Alzheimer's disease (late onset);
CRC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.63	-8.43	-0.42	1.13e-15	Alzheimer's disease;
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg05585544	chr11:47624801	NA	0.48	8.6	0.43	3.29e-16	Subjective well-being;
CRC	cis	rs11997175	0.583	rs4739562	chr8:33844064	C/T	cg04338863	chr8:33670619	NA	-0.43	-6.04	-0.32	4.17e-9	Body mass index;
CRC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg10790698	chr19:18539756	SSBP4	-0.44	-8.44	-0.42	1e-15	Breast cancer;
CRC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.65	-0.51	5.95e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.66	9.26	0.45	2.82e-18	Menarche (age at onset);
CRC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg16141378	chr3:129829833	LOC729375	0.43	6.48	0.34	3.26e-10	Neuroticism;
CRC	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg10820045	chr2:198174542	NA	0.42	7.15	0.37	5.7e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.6	8.14	0.41	8.14e-15	Coronary artery disease;
CRC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.36	5.91	0.31	8.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.7	11.11	0.52	1.5e-24	Dental caries;
CRC	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	0.99	10.97	0.52	4.69e-24	Gut microbiota (bacterial taxa);
CRC	cis	rs11098699	0.821	rs1562063	chr4:124204110	G/A	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	trans	rs1933755	0.541	rs9375743	chr6:130907220	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.91	-6.52	-0.34	2.64e-10	Colorectal cancer (calcium intake interaction);
CRC	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.45	-6.42	-0.33	4.65e-10	Large artery stroke;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3764400	0.564	rs12602670	chr17:46104880	T/C	cg10706073	chr17:46328419	SKAP1	-0.65	-6.85	-0.35	3.56e-11	Body mass index;
CRC	trans	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.01	-0.31	5.01e-9	Total body bone mineral density;
CRC	cis	rs6586163	0.872	rs7910660	chr10:90743197	G/A	cg13456138	chr10:90753195	FAS	-0.44	-6.58	-0.34	1.84e-10	Chronic lymphocytic leukemia;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.81	9.75	0.47	6.8e-20	Developmental language disorder (linguistic errors);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20651681	chr7:50861418	GRB10	0.45	6.04	0.32	4.2e-9	Survival in pancreatic cancer;
CRC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.65	11.34	0.53	2.23e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.41	-5.88	-0.31	1.01e-8	Asthma;
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13198984	chr17:80129470	CCDC57	0.48	8.52	0.43	5.9e-16	Life satisfaction;
CRC	cis	rs9296736	0.890	rs9370258	chr6:53910988	T/G	cg04374786	chr6:53939321	C6orf142	0.44	6.89	0.35	2.93e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.39	5.73	0.3	2.26e-8	Breast cancer;
CRC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.92	-15.94	-0.66	8.83e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg13043300	chr11:71146211	DHCR7	-0.41	-5.85	-0.31	1.16e-8	Vitamin D levels;
CRC	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg12046867	chr14:103022105	NA	-0.44	-6.42	-0.33	4.76e-10	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08483723	chr3:45267960	TMEM158	0.34	6.84	0.35	3.86e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg04989706	chr14:50066350	PPIL5	-0.5	-6.88	-0.35	3.09e-11	Carotid intima media thickness;
CRC	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	1.02	9.16	0.45	5.8e-18	Lymphocyte counts;
CRC	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg02158880	chr13:53174818	NA	-0.49	-6.95	-0.36	1.96e-11	Lewy body disease;
CRC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.6	-10.33	-0.49	7.36e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.03	23.54	0.79	1.63e-72	Multiple system atrophy;
CRC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02290350	chr8:58132656	NA	-0.42	-6.14	-0.32	2.33e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.63	0.43	2.64e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg09582351	chr12:29534625	ERGIC2	-0.28	-6.02	-0.31	4.66e-9	QT interval;
CRC	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	16.02	0.66	4.19e-43	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.41	5.89	0.31	9.61e-9	Renal cell carcinoma;
CRC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.56	-7.96	-0.4	2.85e-14	White blood cell count;
CRC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.36	-6.18	-0.32	1.94e-9	Erythrocyte sedimentation rate;
CRC	cis	rs4601821	0.895	rs1055075	chr11:113239512	T/C	cg14159747	chr11:113255604	NA	0.49	9.18	0.45	4.98e-18	Alcoholic chronic pancreatitis;
CRC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.91	-10.26	-0.49	1.35e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.59	-6.87	-0.35	3.2e-11	Red cell distribution width;
CRC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg03948781	chr1:205179583	DSTYK	0.4	5.6	0.3	4.51e-8	Red blood cell count;
CRC	cis	rs1572438	0.965	rs3799324	chr6:859376	G/A	cg13447295	chr6:887704	NA	-0.44	-6.16	-0.32	2.16e-9	Aging;
CRC	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.54	0.65	3.21e-41	Bipolar disorder;
CRC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	5.67	0.3	3.1e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg01843034	chr6:37503916	NA	-0.33	-5.81	-0.3	1.48e-8	Cognitive performance;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg25164649	chr6:28176230	NA	0.52	6.83	0.35	4.2e-11	Parkinson's disease;
CRC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.27	-0.33	1.15e-9	Gout;Renal underexcretion gout;
CRC	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.54	9.04	0.45	1.33e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg11900509	chr10:81946545	ANXA11	-0.4	-6.58	-0.34	1.9e-10	Sarcoidosis;
CRC	cis	rs870825	0.655	rs6552812	chr4:185653568	C/T	cg04058563	chr4:185651563	MLF1IP	-0.76	-9.21	-0.45	3.91e-18	Blood protein levels;
CRC	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.91	-12.19	-0.56	1.77e-28	Exhaled nitric oxide output;
CRC	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.69	-10.56	-0.5	1.21e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.03	-0.52	2.86e-24	Colorectal cancer;
CRC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.67	8.52	0.43	5.83e-16	Response to diuretic therapy;
CRC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.57	-0.39	3.84e-13	Gut microbiome composition (summer);
CRC	cis	rs6534441	0.857	rs59780240	chr4:125457329	A/C	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.9	-0.44	3.88e-17	Aortic root size;
CRC	cis	rs17767392	0.914	rs35613269	chr14:71887814	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs10924970	0.601	rs4659647	chr1:235379186	G/A	cg09010748	chr1:235293032	TOMM20	-0.42	-5.89	-0.31	9.32e-9	Asthma;
CRC	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.46	-7.53	-0.38	5.02e-13	Post bronchodilator FEV1;
CRC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.89	-15.11	-0.64	1.55e-39	Height;
CRC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	0.93	17.81	0.7	3.75e-50	Height;
CRC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.47	7.13	0.37	6.43e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg15832292	chr6:96025679	MANEA	0.6	6.57	0.34	2e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14895029	chr7:2775587	GNA12	-0.4	-5.83	-0.31	1.3e-8	Height;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg04091063	chr1:19615382	AKR7A3	0.37	5.97	0.31	6.31e-9	Menarche (age at onset);
CRC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-9.49	-0.46	5.01e-19	Alcohol dependence;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.26	0.33	1.17e-9	Depression;
CRC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-10.05	-0.48	6.51e-21	Breast cancer;
CRC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs6028335	0.502	rs7265661	chr20:37586842	G/T	cg27552599	chr20:37590471	DHX35	0.39	5.97	0.31	6.23e-9	Alcohol and nicotine co-dependence;
CRC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.55	6.54	0.34	2.41e-10	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.74	-13.32	-0.59	1.1e-32	Prostate cancer;
CRC	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.48	7.01	0.36	1.38e-11	Coronary heart disease;
CRC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.67	8.97	0.44	2.34e-17	Cognitive function;
CRC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-8.33	-0.42	2.23e-15	Monocyte count;
CRC	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.55	9.28	0.46	2.28e-18	Dupuytren's disease;
CRC	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg15382696	chr6:118971807	C6orf204	0.57	6.78	0.35	5.6e-11	Diastolic blood pressure;
CRC	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg22561889	chr6:118971681	C6orf204	0.52	6.58	0.34	1.91e-10	Diastolic blood pressure;
CRC	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg08992911	chr2:238395768	MLPH	0.47	5.76	0.3	1.9e-8	Prostate cancer;
CRC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.65	9.35	0.46	1.44e-18	Lung cancer;
CRC	cis	rs1178968	0.748	rs10271751	chr7:72752062	T/C	cg25889504	chr7:72793014	NA	0.53	6.04	0.32	4.16e-9	Triglyceride levels;
CRC	cis	rs28493229	0.708	rs78084428	chr19:41160097	G/A	cg21869046	chr19:41225005	ITPKC	0.4	6.06	0.32	3.69e-9	Kawasaki disease;
CRC	cis	rs59104589	0.583	rs73018185	chr2:242241706	C/T	cg19488206	chr2:242435732	STK25	0.47	6.54	0.34	2.37e-10	Fibrinogen levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06539400	chr16:4365605	NA	-0.42	-6.16	-0.32	2.15e-9	Myopia (pathological);
CRC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.67	9.13	0.45	7.25e-18	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.72	11.41	0.53	1.22e-25	Mean corpuscular hemoglobin;
CRC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.15	-0.37	5.59e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11355319	chr5:89825117	LYSMD3	0.57	7.67	0.39	1.91e-13	Thyroid stimulating hormone;
CRC	cis	rs990171	1.000	rs6750020	chr2:102994714	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.37e-8	Lymphocyte counts;
CRC	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg12317470	chr15:67143691	NA	0.75	6.11	0.32	2.77e-9	Lung cancer (smoking interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22045829	chr13:60970476	TDRD3	0.44	5.99	0.31	5.58e-9	Anxiety disorder;
CRC	cis	rs16937	0.662	rs10900468	chr1:205163057	A/G	cg00857998	chr1:205179979	DSTYK	0.41	5.65	0.3	3.49e-8	Schizophrenia;
CRC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.65	-17.77	-0.7	5.54e-50	Urate levels in overweight individuals;
CRC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.99	17.82	0.7	3.29e-50	Menarche (age at onset);
CRC	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.42	6.58	0.34	1.82e-10	Red blood cell count;
CRC	trans	rs2303319	0.504	rs62187655	chr2:162487440	C/G	cg25193742	chr10:104614220	C10orf32	-0.73	-5.97	-0.31	6.18e-9	Cognitive function;
CRC	cis	rs12230513	0.732	rs4356858	chr12:55867290	A/T	cg19537932	chr12:55886519	OR6C68	-0.71	-8.93	-0.44	3.12e-17	Contrast sensitivity;
CRC	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-5.89	-0.31	9.69e-9	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12463550	chr7:65579703	CRCP	0.75	6.72	0.35	7.94e-11	Diabetic kidney disease;
CRC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg06238570	chr21:40685208	BRWD1	0.48	6.67	0.35	1.07e-10	Cognitive function;
CRC	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg24466277	chr1:23519622	HTR1D	-0.44	-5.95	-0.31	6.77e-9	Height;
CRC	cis	rs10046574	0.561	rs10215176	chr7:135198589	A/G	cg27474649	chr7:135195673	CNOT4	0.67	6.16	0.32	2.14e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.75	10.0	0.48	1e-20	Coronary artery disease;
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.5	-8.13	-0.41	8.89e-15	Height;
CRC	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma (childhood onset);
CRC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.24	-16.52	-0.67	4.4e-45	Breast cancer;
CRC	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.34	7.88	0.4	4.9e-14	Corneal astigmatism;
CRC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.68	0.39	1.83e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg12273811	chr6:28175739	NA	0.55	8.1	0.41	1.06e-14	Parkinson's disease;
CRC	cis	rs2415984	0.622	rs12434073	chr14:46921265	G/A	cg14871534	chr14:47121158	RPL10L	-0.41	-5.98	-0.31	5.86e-9	Number of children ever born;
CRC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg13628971	chr7:2884303	GNA12	-0.43	-6.53	-0.34	2.52e-10	Height;
CRC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg03844380	chr14:100680408	NA	0.57	6.06	0.32	3.76e-9	Body mass index;
CRC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	18.47	0.71	9.51e-53	Prudent dietary pattern;
CRC	cis	rs7632954	0.567	rs9864415	chr3:8512668	A/G	cg03495237	chr3:8533978	NA	-0.33	-6.07	-0.32	3.43e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg02938936	chr2:3718203	ALLC	0.43	5.65	0.3	3.54e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg27635394	chr6:26043820	HIST1H2BB	0.41	5.86	0.31	1.15e-8	Intelligence (multi-trait analysis);
CRC	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-0.68	-6.92	-0.36	2.33e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.12	-0.32	2.68e-9	Morning vs. evening chronotype;
CRC	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.53	7.54	0.38	4.65e-13	Testicular germ cell tumor;
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.28	-0.42	3.21e-15	Bipolar disorder;
CRC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.18	0.32	1.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.41	-5.68	-0.3	2.9e-8	Corneal structure;
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg02475695	chr16:616220	NHLRC4	0.48	8.0	0.4	2.13e-14	Height;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg10498984	chr16:28874827	SH2B1	-0.73	-6.25	-0.33	1.3e-9	Cognitive function;
CRC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg04545296	chr12:48745243	ZNF641	0.33	5.66	0.3	3.24e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.58	0.43	3.76e-16	Alzheimer's disease;
CRC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.9	-15.14	-0.64	1.18e-39	Headache;
CRC	cis	rs3741151	0.686	rs12290701	chr11:73271988	T/C	cg17517138	chr11:73019481	ARHGEF17	0.55	5.62	0.3	4.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg24519413	chr1:26490540	NA	-0.37	-6.3	-0.33	9.37e-10	Height;
CRC	cis	rs12580194	0.593	rs3935215	chr12:55792401	T/A	cg23425280	chr12:56401806	NA	0.46	5.62	0.3	4.07e-8	Cancer;
CRC	cis	rs6921919	0.789	rs13210258	chr6:28308671	G/T	cg15845792	chr6:28175446	NA	0.46	5.85	0.31	1.2e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.66	-9.54	-0.47	3.32e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7487075	0.930	rs4076484	chr12:46833912	C/G	cg17501823	chr12:47219793	SLC38A4	0.32	5.94	0.31	7.11e-9	Itch intensity from mosquito bite;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.52	10.01	0.48	9.31e-21	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Parkinson's disease;
CRC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg10298567	chr3:47292165	KIF9	0.43	7.08	0.36	8.79e-12	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08322149	chr10:46222875	FAM21C	0.42	6.1	0.32	3.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-8.45	-0.42	9.52e-16	Gut microbiome composition (summer);
CRC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.54	7.98	0.4	2.44e-14	Obesity-related traits;
CRC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02290350	chr8:58132656	NA	-0.42	-5.97	-0.31	6.16e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs972578	1.000	rs5759066	chr22:43366296	G/A	cg01576275	chr22:43409880	NA	-0.44	-7.14	-0.37	6.09e-12	Mean platelet volume;
CRC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.38	-6.64	-0.34	1.27e-10	Schizophrenia;
CRC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.3e-13	Corneal astigmatism;
CRC	cis	rs501120	0.657	rs617542	chr10:44743636	G/A	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.61	9.65	0.47	1.44e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.73	-0.3	2.23e-8	Major depressive disorder;
CRC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg11279151	chr3:101281821	RG9MTD1	0.52	7.15	0.37	5.8e-12	Colorectal cancer;
CRC	cis	rs16867321	1.000	rs10185265	chr2:181438860	G/C	cg23363182	chr2:181467187	NA	-0.54	-6.87	-0.35	3.29e-11	Obesity;
CRC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.67	-11.71	-0.54	1.04e-26	Iron status biomarkers;
CRC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02359409	chr6:42947317	PEX6	-0.59	-9.34	-0.46	1.51e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.7	-0.43	1.64e-16	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16857181	chr7:32931955	KBTBD2	0.46	6.02	0.31	4.58e-9	Thyroid stimulating hormone;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg07507251	chr3:52567010	NT5DC2	0.43	6.15	0.32	2.19e-9	Bipolar disorder;
CRC	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.49	6.3	0.33	9.54e-10	Neuroticism;
CRC	cis	rs9928842	0.941	rs8057145	chr16:75256251	A/G	cg09066997	chr16:75300724	BCAR1	0.68	6.65	0.34	1.19e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg12365402	chr11:9010492	NRIP3	0.36	6.15	0.32	2.28e-9	Hemoglobin concentration;
CRC	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.53	-8.77	-0.44	1.01e-16	Metabolite levels;
CRC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.86	-10.87	-0.51	9.9e-24	Obesity-related traits;
CRC	cis	rs775227	0.574	rs60131925	chr3:113034768	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-6.56	-0.34	2.07e-10	Dental caries;
CRC	cis	rs6662572	0.901	rs28484896	chr1:46184200	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.14	0.32	2.33e-9	Blood protein levels;
CRC	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.58	-8.63	-0.43	2.74e-16	Initial pursuit acceleration in psychotic disorders;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08949621	chr15:42265044	EHD4	0.43	6.18	0.32	1.9e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11227645	chr1:224544764	CNIH4	0.38	6.01	0.31	4.94e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.49	-7.56	-0.38	3.96e-13	Monocyte count;
CRC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-7.91	-0.4	4.04e-14	Alzheimer's disease (late onset);
CRC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.9	17.25	0.69	5.9e-48	Lewy body disease;
CRC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.66	-9.57	-0.47	2.6e-19	Osteoporosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07853084	chr13:73632891	KLF5	0.4	6.14	0.32	2.32e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.51	-7.29	-0.37	2.27e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg12100956	chr17:78086420	GAA	-0.36	-5.8	-0.3	1.54e-8	Yeast infection;
CRC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg13010199	chr12:38710504	ALG10B	0.4	5.98	0.31	5.8e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4380275	0.965	rs4315562	chr2:772723	A/G	cg27237671	chr2:676223	TMEM18	-0.43	-6.11	-0.32	2.76e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.65	10.01	0.48	8.83e-21	Ulcerative colitis;
CRC	cis	rs9462027	0.606	rs2814984	chr6:34597513	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.2	-0.32	1.66e-9	Systemic lupus erythematosus;
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.27e-9	Cognitive function;
CRC	trans	rs10139154	0.793	rs229227	chr14:31008191	T/G	cg18753625	chr19:36705707	ZNF565;ZNF146	-0.43	-6.16	-0.32	2.07e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs6076065	0.723	rs761726	chr20:23401481	G/C	cg11657817	chr20:23433608	CST11	0.44	6.44	0.33	4.36e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.23	-0.32	1.45e-9	Total body bone mineral density;
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg16606324	chr3:10149918	C3orf24	0.67	9.13	0.45	6.91e-18	Alzheimer's disease;
CRC	cis	rs3741151	0.773	rs11235770	chr11:73184002	C/T	cg17517138	chr11:73019481	ARHGEF17	0.55	5.75	0.3	1.99e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.76	9.28	0.46	2.33e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg21153622	chr11:89784906	NA	-0.49	-7.79	-0.39	9.13e-14	HDL cholesterol;
CRC	cis	rs4716602	0.573	rs34810003	chr7:156160883	T/C	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.65e-11	Anti-saccade response;
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg16606324	chr3:10149918	C3orf24	0.73	9.68	0.47	1.16e-19	Alzheimer's disease;
CRC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.86	13.12	0.59	6.23e-32	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg10761708	chr20:43804764	PI3	0.47	5.7	0.3	2.68e-8	Blood protein levels;
CRC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.59	8.52	0.43	5.8e-16	Menarche (age at onset);
CRC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06659169	chr22:20748430	ZNF74	0.38	6.18	0.32	1.86e-9	Schizophrenia;
CRC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg18230493	chr5:56204884	C5orf35	-0.59	-8.63	-0.43	2.72e-16	Initial pursuit acceleration;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-6.65	-0.34	1.21e-10	Myopia (pathological);
CRC	cis	rs2013441	1.000	rs4588033	chr17:20029901	C/G	cg13482628	chr17:19912719	NA	-0.42	-6.43	-0.33	4.61e-10	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.54	-5.65	-0.3	3.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.71	10.91	0.52	7.6e-24	Corneal astigmatism;
CRC	cis	rs3106136	0.609	rs72665612	chr4:95101183	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-6.16	-0.32	2.15e-9	Capecitabine sensitivity;
CRC	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg18200150	chr17:30822561	MYO1D	0.44	8.52	0.43	5.79e-16	Schizophrenia;
CRC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg21856205	chr7:94953877	PON1	-0.49	-6.31	-0.33	8.83e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg05709478	chr1:6581295	PLEKHG5	0.58	6.34	0.33	7.63e-10	Body mass index;
CRC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.81	11.54	0.54	4.38e-26	Cognitive function;
CRC	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg23378565	chr7:2036160	MAD1L1	-0.37	-5.84	-0.31	1.22e-8	Neuroticism;
CRC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.4	5.9	0.31	9.18e-9	Obesity-related traits;
CRC	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.57	-9.02	-0.45	1.59e-17	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg26608667	chr7:1196370	ZFAND2A	0.42	6.86	0.35	3.4e-11	Longevity;Endometriosis;
CRC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06544989	chr22:39130855	UNC84B	0.48	7.94	0.4	3.16e-14	Menopause (age at onset);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg15035382	chr19:40728255	CNTD2	-0.5	-6.17	-0.32	2.04e-9	Body mass index;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12000995	chr2:27665139	KRTCAP3	0.3	6.3	0.33	9.66e-10	Total body bone mineral density;
CRC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.52	7.01	0.36	1.37e-11	Obesity-related traits;
CRC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.28	0.33	1.06e-9	Menarche (age at onset);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12027761	chr17:38279750	MSL1	0.4	6.01	0.31	4.93e-9	Myopia (pathological);
CRC	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg16540259	chr10:75572220	NDST2	0.39	6.03	0.32	4.31e-9	Inflammatory bowel disease;
CRC	trans	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg13565492	chr6:43139072	SRF	-0.71	-7.12	-0.37	7.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18040181	chr10:76588616	MYST4	-0.41	-6.1	-0.32	2.9e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.47	0.38	7.24e-13	Endometrial cancer;
CRC	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.17	0.37	4.98e-12	Corneal astigmatism;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02018176	chr4:1364513	KIAA1530	-0.42	-7.2	-0.37	4.18e-12	Obesity-related traits;
CRC	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg12756093	chr1:115239321	AMPD1	0.52	7.97	0.4	2.59e-14	Autism;
CRC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	8.67	0.43	2e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.51	6.1	0.32	3.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.56	8.74	0.43	1.19e-16	Diastolic blood pressure;
CRC	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.38	-5.61	-0.3	4.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.47	6.4	0.33	5.21e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.31	0.56	6.48e-29	Menopause (age at onset);
CRC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.51	7.28	0.37	2.4e-12	Type 2 diabetes;
CRC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.16	-0.49	2.77e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.83	14.13	0.61	9.37e-36	Blood protein levels;
CRC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.41	-7.36	-0.38	1.47e-12	Monocyte count;
CRC	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.1	-14.67	-0.63	7.8e-38	Exhaled nitric oxide output;
CRC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.79	-0.3	1.6e-8	Lung cancer;
CRC	cis	rs6968419	0.714	rs12666168	chr7:115856681	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.42	-0.33	4.78e-10	Intraocular pressure;
CRC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg03623178	chr6:28175578	NA	0.7	10.38	0.5	5.15e-22	Cardiac Troponin-T levels;
CRC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg24675056	chr1:15929824	NA	0.53	6.94	0.36	2.04e-11	Systolic blood pressure;
CRC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	1.01	10.36	0.5	5.9e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.05	0.55	6.17e-28	Testicular germ cell tumor;
CRC	trans	rs2055729	0.677	rs6601389	chr8:9740636	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.52	0.34	2.66e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.52	-8.94	-0.44	2.87e-17	Aortic root size;
CRC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.51	8.17	0.41	6.81e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.65	8.61	0.43	3.07e-16	Alzheimer's disease;
CRC	cis	rs16867335	1.000	rs11899423	chr2:181483750	C/A	cg23363182	chr2:181467187	NA	-0.48	-6.66	-0.34	1.13e-10	Survival in rectal cancer;
CRC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.65	8.96	0.44	2.52e-17	Morning vs. evening chronotype;
CRC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.71	6.8	0.35	4.84e-11	Diabetic retinopathy;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08273200	chr1:39338480	MYCBP	-0.43	-6.32	-0.33	8.32e-10	Daytime sleep phenotypes;
CRC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg03609598	chr5:56110824	MAP3K1	0.46	6.36	0.33	6.84e-10	Coronary artery disease;
CRC	trans	rs4672229	0.523	rs2678917	chr2:58120553	A/T	cg20814774	chr4:10467319	NA	0.3	6.03	0.32	4.34e-9	Hirschsprung disease;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg15845792	chr6:28175446	NA	0.59	8.34	0.42	2.09e-15	Parkinson's disease;
CRC	cis	rs741668	0.759	rs12428399	chr13:46634939	C/G	cg06018095	chr13:46550134	ZC3H13	0.41	5.9	0.31	8.82e-9	Cerebrospinal fluid clusterin levels;
CRC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13844804	chr7:814759	HEATR2	-0.55	-5.81	-0.3	1.49e-8	Cerebrospinal P-tau181p levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14634336	chr6:111804804	REV3L	0.52	7.59	0.39	3.38e-13	Response to antipsychotic treatment;
CRC	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.5	-0.54	5.89e-26	Colorectal cancer;
CRC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.6	-9.11	-0.45	8.21e-18	Schizophrenia;
CRC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.59	8.67	0.43	1.99e-16	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	17.84	0.7	2.77e-50	Prudent dietary pattern;
CRC	cis	rs7945705	0.902	rs11042088	chr11:8843515	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.55	8.03	0.4	1.71e-14	Hemoglobin concentration;
CRC	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.54	-0.34	2.29e-10	Response to antipsychotic treatment;
CRC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg18512352	chr11:47633146	NA	-0.39	-7.66	-0.39	2.06e-13	Subjective well-being;
CRC	trans	rs800082	1.000	rs62275526	chr3:144291707	G/A	cg24215973	chr2:240111563	HDAC4	-0.51	-6.91	-0.36	2.56e-11	Smoking behavior;
CRC	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.91	-11.54	-0.54	4.09e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.48	7.72	0.39	1.4e-13	Dental caries;
CRC	cis	rs2257205	0.667	rs8071942	chr17:56778271	T/C	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs12541635	1.000	rs1896918	chr8:107090500	G/A	cg10147462	chr8:107024639	NA	-0.36	-6.12	-0.32	2.68e-9	Age of smoking initiation;
CRC	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg09040174	chr2:113837401	NA	0.64	10.17	0.49	2.58e-21	Protein quantitative trait loci;
CRC	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg20936604	chr3:58311152	NA	-0.59	-5.66	-0.3	3.23e-8	Cholesterol, total;
CRC	cis	rs7923609	0.936	rs10761778	chr10:65273782	A/G	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.94	-0.31	7.27e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.42	5.93	0.31	7.79e-9	Aortic root size;
CRC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.76	12.9	0.58	4.36e-31	Body mass index;
CRC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.52	8.27	0.41	3.45e-15	Intelligence (multi-trait analysis);
CRC	trans	rs6600671	1.000	rs4844380	chr1:121193620	A/T	cg09829573	chr1:144692074	NBPF9	-0.42	-6.26	-0.33	1.23e-9	Hip geometry;
CRC	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg15382696	chr6:118971807	C6orf204	0.58	7.38	0.38	1.29e-12	Diastolic blood pressure;
CRC	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg04920474	chr2:44395004	PPM1B	0.38	5.63	0.3	3.85e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24308560	chr3:49941425	MST1R	-0.44	-6.81	-0.35	4.69e-11	Body mass index;
CRC	cis	rs12760731	0.720	rs12060844	chr1:178280816	T/C	cg00404053	chr1:178313656	RASAL2	0.81	9.76	0.47	6.06e-20	Obesity-related traits;
CRC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.44	5.87	0.31	1.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg19812747	chr11:111475976	SIK2	0.49	7.26	0.37	2.84e-12	Primary sclerosing cholangitis;
CRC	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg15192750	chr16:69999425	NA	0.6	8.04	0.41	1.59e-14	IgE levels;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02359409	chr6:42947317	PEX6	-0.69	-11.41	-0.53	1.28e-25	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.52	7.3	0.37	2.16e-12	Melanoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26612175	chr1:100503886	HIAT1	0.44	6.36	0.33	6.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-5.68	-0.3	2.97e-8	Aortic root size;
CRC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.38	5.92	0.31	7.93e-9	Recombination rate (males);
CRC	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg06632207	chr12:54070931	ATP5G2	0.41	7.03	0.36	1.18e-11	Height;
CRC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg13010199	chr12:38710504	ALG10B	0.4	5.92	0.31	8.08e-9	Morning vs. evening chronotype;
CRC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.49	7.49	0.38	6.44e-13	Corneal astigmatism;
CRC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg03395651	chr16:88107091	BANP	-0.55	-7.47	-0.38	7.24e-13	Menopause (age at onset);
CRC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.78	-0.35	5.73e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	0.93	11.05	0.52	2.33e-24	Type 2 diabetes nephropathy;
CRC	trans	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.43	-0.33	4.39e-10	Neuroticism;
CRC	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-14.5	-0.62	3.44e-37	Colorectal cancer;
CRC	cis	rs7131987	0.641	rs2015599	chr12:29435480	G/A	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.43	-0.33	4.54e-10	QT interval;
CRC	cis	rs7527798	0.592	rs6667238	chr1:207822856	G/A	cg21110645	chr1:207815933	NA	-0.41	-6.45	-0.34	3.95e-10	Erythrocyte sedimentation rate;
CRC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18375707	chr11:64034959	PLCB3	0.46	6.46	0.34	3.81e-10	Mean platelet volume;
CRC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	9.95	0.48	1.48e-20	Cognitive test performance;
CRC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-6.77	-0.35	6.01e-11	Gut microbiome composition (summer);
CRC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.54	0.67	3.69e-45	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	0.64	9.77	0.47	6e-20	Fractional exhaled nitric oxide (childhood);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26235292	chr4:99850587	EIF4E	0.52	6.99	0.36	1.57e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.76	-6.13	-0.32	2.54e-9	Hippocampal volume;
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg22638593	chr5:131593259	PDLIM4	0.35	6.29	0.33	1.02e-9	Blood metabolite levels;
CRC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.08	0.49	5.15e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.92	11.38	0.53	1.56e-25	Exhaled nitric oxide output;
CRC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.58	-8.76	-0.43	1.08e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg10437265	chr15:77819839	NA	0.68	12.43	0.57	2.41e-29	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19409588	chr3:32148040	GPD1L	0.44	6.21	0.32	1.61e-9	Anxiety disorder;
CRC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg19812747	chr11:111475976	SIK2	0.42	6.19	0.32	1.77e-9	Primary sclerosing cholangitis;
CRC	cis	rs3026445	0.791	rs7309141	chr12:110587637	G/A	cg12870014	chr12:110450643	ANKRD13A	0.44	6.97	0.36	1.73e-11	QT interval;
CRC	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg09264619	chr17:80180166	NA	-0.49	-6.9	-0.36	2.63e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg24132527	chr5:140019269	TMCO6	-0.38	-5.97	-0.31	6.24e-9	Myopia (pathological);
CRC	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg07636037	chr3:49044803	WDR6	-0.64	-6.24	-0.33	1.32e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.49	0.34	3.21e-10	Hemoglobin concentration;
CRC	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.46	7.55	0.38	4.46e-13	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25362248	chr1:31192015	MATN1	0.4	6.02	0.31	4.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-0.98	-10.6	-0.5	8.96e-23	Cerebrospinal P-tau181p levels;
CRC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg21251018	chr6:28226885	NKAPL	0.55	9.07	0.45	1.12e-17	Cardiac Troponin-T levels;
CRC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg02569458	chr12:86230093	RASSF9	0.47	7.98	0.4	2.42e-14	Major depressive disorder;
CRC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.9	0.4	4.1e-14	Menarche (age at onset);
CRC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.78	9.08	0.45	1.02e-17	Bronchopulmonary dysplasia;
CRC	cis	rs540254	0.578	rs12117689	chr1:160782100	C/T	cg20255094	chr1:160771763	LY9	0.49	6.34	0.33	7.78e-10	Blood protein levels;
CRC	cis	rs6973256	0.583	rs2430768	chr7:133340287	T/C	cg10665199	chr7:133106180	EXOC4	-0.45	-6.92	-0.36	2.3e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.94	-18.72	-0.72	9.63e-54	Myeloid white cell count;
CRC	cis	rs727505	0.866	rs17327181	chr7:124720303	A/G	cg23710748	chr7:124431027	NA	-0.72	-12.4	-0.56	3e-29	Lewy body disease;
CRC	trans	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg10756647	chr7:56101905	PSPH	0.74	7.52	0.38	5.22e-13	Diabetic kidney disease;
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.38	5.92	0.31	7.96e-9	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.71	9.45	0.46	6.66e-19	Alzheimer's disease;
CRC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg15962314	chr1:44399869	ARTN	0.32	6.23	0.32	1.41e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.68e-10	HDL cholesterol;
CRC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg02569458	chr12:86230093	RASSF9	0.37	6.47	0.34	3.47e-10	Major depressive disorder;
CRC	cis	rs354225	0.608	rs168505	chr2:54920968	C/T	cg26097391	chr2:54893211	SPTBN1	0.51	8.39	0.42	1.5e-15	Schizophrenia;
CRC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg10790698	chr19:18539756	SSBP4	-0.44	-8.44	-0.42	1e-15	Breast cancer;
CRC	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg05585544	chr11:47624801	NA	-0.4	-6.36	-0.33	6.58e-10	Mean corpuscular hemoglobin;
CRC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.48	7.45	0.38	8.51e-13	Corneal astigmatism;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs800160	0.777	rs11022291	chr11:2345621	T/C	cg09785033	chr11:2336066	TSPAN32	-0.48	-5.72	-0.3	2.45e-8	Bacteremia;
CRC	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.0	0.52	3.62e-24	Tonsillectomy;
CRC	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.82	-0.4	7.34e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.14	-12.94	-0.58	3.11e-31	Diabetic kidney disease;
CRC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.42	7.88	0.4	4.92e-14	Mean corpuscular volume;
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.45	-0.57	2.12e-29	Alzheimer's disease;
CRC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.76	-11.31	-0.53	2.72e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg18827107	chr12:86230957	RASSF9	0.38	6.0	0.31	5.1e-9	Major depressive disorder;
CRC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.74	-0.39	1.24e-13	Gut microbiome composition (summer);
CRC	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg16753122	chr16:57506917	DOK4	0.51	5.79	0.3	1.68e-8	Blood protein levels;
CRC	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg02158880	chr13:53174818	NA	-0.44	-6.62	-0.34	1.46e-10	Lewy body disease;
CRC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	0.96	9.4	0.46	9.56e-19	IgG glycosylation;
CRC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg13072238	chr3:49761600	GMPPB	-0.52	-5.7	-0.3	2.65e-8	Menarche (age at onset);
CRC	cis	rs6604026	0.740	rs10874746	chr1:93323971	A/G	cg17283838	chr1:93427260	FAM69A	-0.45	-6.13	-0.32	2.52e-9	Multiple sclerosis;
CRC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.73	-11.32	-0.53	2.66e-25	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20284698	chr3:48956327	C3orf71;ARIH2	-0.43	-7.18	-0.37	4.57e-12	Myopia (pathological);
CRC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.89	0.44	3.97e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg07274523	chr3:49395745	GPX1	0.47	6.4	0.33	5.33e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg17145862	chr1:211918768	LPGAT1	0.57	9.46	0.46	6.05e-19	Leprosy;
CRC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	8.74	0.43	1.19e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4731207	0.596	rs10500098	chr7:124658055	C/G	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg16928487	chr17:17741425	SREBF1	-0.48	-8.44	-0.42	1.04e-15	Total body bone mineral density;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg15208630	chr4:166034127	TMEM192	-0.52	-6.5	-0.34	2.97e-10	Type 1 diabetes;
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg06935464	chr4:38784597	TLR10	-0.57	-5.62	-0.3	4.13e-8	Breast cancer;
CRC	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.28	0.33	1.09e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	6.04	0.32	4.1e-9	LDL cholesterol;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.43	6.32	0.33	8.55e-10	Obesity-related traits;
CRC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.66	-0.39	2.09e-13	Colorectal cancer;
CRC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.03	-0.36	1.17e-11	Alzheimer's disease (late onset);
CRC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.88	-16.25	-0.67	5.49e-44	Prostate cancer;
CRC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.82	-0.68	3.11e-46	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18642567	chr14:21755798	RPGRIP1	0.42	6.44	0.33	4.29e-10	Myopia (pathological);
CRC	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.54	8.44	0.42	1.03e-15	Testicular germ cell tumor;
CRC	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.7	-0.3	2.63e-8	Tuberculosis;
CRC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	0.94	9.29	0.46	2.1e-18	Skin colour saturation;
CRC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.65	-10.77	-0.51	2.23e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8050755	0.649	rs45477195	chr16:2115481	C/T	cg04515572	chr16:2107413	TSC2	-0.83	-7.87	-0.4	5.11e-14	Major depressive disorder;
CRC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.84	-0.31	1.26e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09765074	chr10:69634185	NA	-0.45	-6.3	-0.33	9.71e-10	Hip circumference;
CRC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.84	11.65	0.54	1.77e-26	Breast cancer;
CRC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.65e-9	Bladder cancer;
CRC	trans	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.4	0.42	1.31e-15	Lewy body disease;
CRC	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.98	-0.31	5.96e-9	Diastolic blood pressure;
CRC	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.5	7.98	0.4	2.46e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg09344028	chr17:70110421	NA	0.44	6.71	0.35	8.63e-11	Thyroid hormone levels;
CRC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.06e-12	HDL cholesterol;
CRC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.56	9.85	0.48	3.11e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2346160	0.867	rs2076005	chr6:167704944	A/C	cg04673565	chr6:167680447	NA	-0.33	-5.64	-0.3	3.63e-8	Parental extreme longevity (95 years and older);
CRC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.54	-9.01	-0.44	1.69e-17	Brugada syndrome;
CRC	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg16141378	chr3:129829833	LOC729375	0.4	6.11	0.32	2.78e-9	Joint mobility (Beighton score);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02923393	chr16:1543003	TELO2	-0.41	-6.0	-0.31	5.26e-9	Daytime sleep phenotypes;
CRC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs9372498	0.764	rs9320652	chr6:118720448	A/G	cg18833306	chr6:118973337	C6orf204	0.49	6.19	0.32	1.83e-9	Diastolic blood pressure;
CRC	cis	rs6908034	0.607	rs12525152	chr6:19809424	A/T	cg02682789	chr6:19804855	NA	0.74	6.54	0.34	2.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs4493873	1.000	rs10110267	chr8:92073814	G/A	cg16814680	chr8:91681699	NA	0.42	5.94	0.31	7.25e-9	Migraine - clinic-based;
CRC	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	1.16	10.78	0.51	2.07e-23	Arsenic metabolism;
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.74	-0.3	2.1e-8	Life satisfaction;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg04969067	chr8:143858791	LYNX1	-0.42	-6.66	-0.34	1.17e-10	Urinary tract infection frequency;
CRC	cis	rs13315871	0.790	rs9825431	chr3:58406694	G/C	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-5.66	-0.3	3.3e-8	QT interval;
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg25190001	chr12:49371310	WNT1	-0.34	-6.09	-0.32	3.12e-9	Total body bone mineral density;
CRC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg16797656	chr11:68205561	LRP5	0.41	6.56	0.34	2.05e-10	Total body bone mineral density;
CRC	cis	rs9648716	1.000	rs1267623	chr7:140534267	C/T	cg10747023	chr7:140774559	NA	0.45	5.84	0.31	1.27e-8	Type 2 diabetes;
CRC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-9.9	-0.48	2.12e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg02927042	chr1:21476669	EIF4G3	0.52	8.28	0.42	3.07e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	6.02	0.32	4.65e-9	Asthma;
CRC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.6	10.93	0.52	6.45e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs5756813	1.000	rs1074407	chr22:38156183	T/A	cg19894588	chr14:64061835	NA	0.62	9.17	0.45	5.43e-18	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-7.54	-0.38	4.73e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg10760299	chr15:45669010	GATM	0.5	7.99	0.4	2.37e-14	Homoarginine levels;
CRC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.85	0.35	3.63e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.4	-0.42	1.4e-15	Gut microbiome composition (summer);
CRC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.57	8.76	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg06484146	chr7:12443880	VWDE	-0.5	-6.46	-0.34	3.71e-10	Coronary artery disease;
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00166722	chr3:10149974	C3orf24	0.65	8.86	0.44	5.13e-17	Alzheimer's disease;
CRC	cis	rs2257205	0.588	rs7214266	chr17:56851920	C/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26343512	chr14:77413728	NA	0.4	6.34	0.33	7.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg23161317	chr6:28129485	ZNF389	0.43	5.62	0.3	4.16e-8	Parkinson's disease;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.91	-21.52	-0.76	1.01e-64	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.63	8.92	0.44	3.24e-17	Multiple sclerosis;
CRC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.54	7.79	0.39	8.74e-14	Height;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.61	8.72	0.43	1.35e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg03623178	chr6:28175578	NA	-0.68	-7.41	-0.38	1.1e-12	Depression;
CRC	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.78	-0.35	5.6e-11	Inflammatory skin disease;
CRC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.57	8.41	0.42	1.23e-15	Cognitive test performance;
CRC	cis	rs11229555	0.645	rs4579945	chr11:58190873	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04135372	chr2:99061383	INPP4A	-0.42	-6.05	-0.32	3.86e-9	Myopia (pathological);
CRC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.49	6.68	0.35	1.02e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs11233250	0.502	rs11233279	chr11:82412740	T/C	cg17391194	chr11:82401662	NA	0.38	5.99	0.31	5.57e-9	Glioblastoma;Glioma;
CRC	cis	rs7945718	0.535	rs7114698	chr11:12707876	C/T	cg25843174	chr11:12811716	TEAD1	0.41	7.58	0.39	3.61e-13	Educational attainment (years of education);
CRC	cis	rs2898681	0.614	rs10016904	chr4:53694296	C/A	cg00338735	chr4:53728038	RASL11B	0.43	6.5	0.34	3.04e-10	Optic nerve measurement (cup area);
CRC	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.06	-0.32	3.77e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.51e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11645453	chr3:52864694	ITIH4	0.47	8.47	0.42	8.55e-16	Bipolar disorder;
CRC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.72	8.73	0.43	1.35e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	7.7	0.39	1.64e-13	Aortic root size;
CRC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg21620606	chr4:1342894	KIAA1530	0.4	7.19	0.37	4.37e-12	Obesity-related traits;
CRC	trans	rs2383876	0.550	rs7008962	chr8:74073416	A/G	cg23880589	chr17:7826623	KCNAB3	-0.36	-6.08	-0.32	3.29e-9	Corneal curvature;
CRC	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.59	-7.34	-0.38	1.71e-12	Ulcerative colitis;
CRC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	5.96	0.31	6.35e-9	Tonsillectomy;
CRC	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.79	0.51	1.95e-23	Exhaled nitric oxide output;
CRC	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.53	7.09	0.36	8.05e-12	Itch intensity from mosquito bite;
CRC	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg21251018	chr6:28226885	NKAPL	0.41	6.32	0.33	8.73e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg13072238	chr3:49761600	GMPPB	-0.54	-5.85	-0.31	1.19e-8	Menarche (age at onset);
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.25	-0.41	3.81e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-7.06	-0.36	9.81e-12	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg18301423	chr5:131593218	PDLIM4	0.42	6.99	0.36	1.53e-11	Breast cancer;
CRC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-11.2	-0.53	7.06e-25	Dental caries;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Parkinson's disease;
CRC	cis	rs73206853	0.841	rs7959516	chr12:110622224	A/C	cg12870014	chr12:110450643	ANKRD13A	0.72	7.9	0.4	4.29e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12476592	0.602	rs6546007	chr2:63724795	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.08	0.32	3.33e-9	Childhood ear infection;
CRC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.48	-0.5	2.23e-22	Total cholesterol levels;
CRC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.8	10.57	0.5	1.09e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs755249	0.567	rs4660751	chr1:39905873	C/T	cg18385671	chr1:39797026	MACF1	-0.41	-5.84	-0.31	1.28e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.08	0.52	1.87e-24	Menopause (age at onset);
CRC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.87	0.51	1.01e-23	Motion sickness;
CRC	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	17.04	0.68	4.14e-47	Electrocardiographic conduction measures;
CRC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.78	13.76	0.6	2.41e-34	Metabolic syndrome;
CRC	cis	rs4700695	0.841	rs706681	chr5:65317913	G/T	cg21114390	chr5:65439923	SFRS12	0.59	6.91	0.36	2.5e-11	Facial morphology (factor 19);
CRC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg25985355	chr7:65971099	NA	0.5	5.91	0.31	8.43e-9	Diabetic kidney disease;
CRC	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.87	8.71	0.43	1.47e-16	Gastritis;
CRC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.79	8.22	0.41	4.73e-15	Diabetic retinopathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03759077	chr2:153575599	ARL6IP6	0.51	7.18	0.37	4.6e-12	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.88	0.55	2.61e-27	Bone mineral density;
CRC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.64	7.87	0.4	5.2e-14	Chronic sinus infection;
CRC	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.62	-8.79	-0.44	8.65e-17	Testicular germ cell tumor;
CRC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.49	7.15	0.37	5.48e-12	Blood metabolite levels;
CRC	cis	rs2929278	0.617	rs2955969	chr15:44114527	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-5.95	-0.31	6.96e-9	Schizophrenia;
CRC	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.46	-6.06	-0.32	3.72e-9	Heschl's gyrus morphology;
CRC	cis	rs282587	0.569	rs9604415	chr13:113393615	G/T	cg04656015	chr13:113407548	ATP11A	0.61	7.47	0.38	7.3e-13	Glycated hemoglobin levels;
CRC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.41	6.1	0.32	2.99e-9	Pulse pressure;
CRC	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg09873164	chr1:152488093	CRCT1	0.36	6.07	0.32	3.6e-9	Hair morphology;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg03124313	chr19:36036028	GAPDHS;TMEM147	-0.67	-6.0	-0.31	5.21e-9	Cognitive function;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26468414	chr7:106810548	HBP1	-0.51	-6.04	-0.32	4.16e-9	Monocyte percentage of white cells;
CRC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	9.61	0.47	1.98e-19	Mood instability;
CRC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.44	6.85	0.35	3.57e-11	Height;
CRC	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.52	8.83	0.44	6.58e-17	Testicular germ cell tumor;
CRC	cis	rs7739232	0.920	rs17216313	chr6:53530156	T/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.57	-7.62	-0.39	2.77e-13	Coronary artery disease;
CRC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.6	10.93	0.52	6.45e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg20512303	chr5:131592959	PDLIM4	0.4	6.83	0.35	4.21e-11	Breast cancer;
CRC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg20041105	chr8:143859282	LYNX1	-0.43	-6.93	-0.36	2.19e-11	Urinary tract infection frequency;
CRC	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg06042504	chr8:55087323	NA	-0.36	-5.72	-0.3	2.35e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg04110750	chr16:69646130	NFAT5	0.56	7.64	0.39	2.4e-13	IgE levels;
CRC	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.62	-11.66	-0.54	1.55e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.54	-0.38	4.73e-13	Height;
CRC	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.79	6.08	0.32	3.39e-9	Obesity (early onset extreme);
CRC	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.63	10.3	0.49	9.84e-22	Schizophrenia;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.26	-0.41	3.69e-15	Electroencephalogram traits;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.53	9.66	0.47	1.39e-19	Vitiligo;
CRC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg03233332	chr7:66118400	NA	0.43	6.03	0.32	4.35e-9	Aortic root size;
CRC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.68	9.25	0.45	2.82e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9322817	0.691	rs2499660	chr6:105285750	T/C	cg02098413	chr6:105308735	HACE1	0.41	8.04	0.41	1.63e-14	Thyroid stimulating hormone;
CRC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.7	9.56	0.47	2.9e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.48	-6.51	-0.34	2.78e-10	Type 1 diabetes nephropathy;
CRC	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-5.81	-0.3	1.51e-8	Coronary artery disease;
CRC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	9.9	0.48	2.07e-20	Calcium levels;
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23104823	chr14:45553408	PRPF39	0.52	6.9	0.36	2.73e-11	Thyroid stimulating hormone;
CRC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.73	-11.01	-0.52	3.29e-24	Waist circumference;Body mass index;
CRC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg22110888	chr17:80059540	CCDC57	0.43	6.66	0.34	1.17e-10	Life satisfaction;
CRC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-0.85	-12.98	-0.58	2.24e-31	Blood trace element (Zn levels);
CRC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg15269541	chr15:43626905	ADAL	-0.36	-5.64	-0.3	3.76e-8	Lung cancer;
CRC	cis	rs501120	0.657	rs115299170	chr10:44742925	T/C	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.35	-6.7	-0.35	9.14e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.28	-5.66	-0.3	3.28e-8	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7517126	1.000	rs35002268	chr1:196838511	G/A	cg13682187	chr1:196946512	CFHR5	-0.36	-5.91	-0.31	8.52e-9	Blood protein levels;
CRC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.67	10.78	0.51	2.04e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12760731	0.565	rs12026482	chr1:178155861	G/A	cg00404053	chr1:178313656	RASAL2	1.02	10.74	0.51	2.85e-23	Obesity-related traits;
CRC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.55	8.59	0.43	3.5e-16	Schizophrenia;
CRC	cis	rs10924970	0.625	rs2789366	chr1:235508270	G/A	cg09010748	chr1:235293032	TOMM20	-0.44	-6.1	-0.32	2.91e-9	Asthma;
CRC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg22110888	chr17:80059540	CCDC57	0.42	6.63	0.34	1.37e-10	Life satisfaction;
CRC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.44	6.64	0.34	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	6.5	0.34	2.95e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg27565382	chr3:53032988	SFMBT1	0.72	5.71	0.3	2.47e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.63	-6.97	-0.36	1.74e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg18230493	chr5:56204884	C5orf35	-0.41	-6.06	-0.32	3.81e-9	Coronary artery disease;
CRC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.44	-6.53	-0.34	2.56e-10	Menarche (age at onset);
CRC	cis	rs6479527	0.806	rs1933669	chr9:96743654	C/T	cg14459158	chr9:96720562	NA	0.39	7.05	0.36	1.04e-11	Esophageal adenocarcinoma;
CRC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	10.66	0.51	5.55e-23	Prudent dietary pattern;
CRC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg00428638	chr19:7224713	INSR	0.94	18.93	0.72	1.41e-54	Hypothyroidism;
CRC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.46	-6.82	-0.35	4.46e-11	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12849291	chr2:97535965	SEMA4C	0.41	6.68	0.35	1e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.58	-9.96	-0.48	1.37e-20	Menarche (age at onset);
CRC	cis	rs11212617	1.000	rs637064	chr11:108140909	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.11	0.32	2.87e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg13798912	chr7:905769	UNC84A	0.55	6.34	0.33	7.56e-10	Cerebrospinal P-tau181p levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22522926	chr2:131851181	FAM168B	0.45	6.28	0.33	1.05e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg05527609	chr1:210001259	C1orf107	-0.43	-5.64	-0.3	3.64e-8	Monobrow;
CRC	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg00919237	chr7:87102261	ABCB4	-0.52	-6.81	-0.35	4.72e-11	Gallbladder cancer;
CRC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-8.6	-0.43	3.28e-16	Uric acid levels;
CRC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.07	-17.43	-0.69	1.18e-48	Dilated cardiomyopathy;
CRC	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.52	9.29	0.46	2.13e-18	Blood metabolite ratios;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11237883	chr7:75677249	STYXL1;MDH2	0.44	6.14	0.32	2.43e-9	Response to antipsychotic treatment;
CRC	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.29	-0.37	2.4e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.39	-6.33	-0.33	7.91e-10	Mean arterial pressure;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg18585273	chr17:66197086	NA	-0.44	-6.58	-0.34	1.81e-10	Daytime sleep phenotypes;
CRC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.3	5.95	0.31	6.9e-9	Lung cancer;
CRC	cis	rs11031096	0.542	rs1452048	chr11:3965428	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-6.77	-0.35	5.95e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4605213	0.605	rs41524846	chr17:49252238	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	0.44	6.39	0.33	5.61e-10	Height;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg10596483	chr8:143751796	JRK	0.42	5.86	0.31	1.14e-8	Urinary tract infection frequency;
CRC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.64	5.86	0.31	1.12e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg08795948	chr3:128337044	NA	0.34	5.91	0.31	8.59e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.58	-6.99	-0.36	1.57e-11	Blood protein levels;
CRC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg06470822	chr6:28175283	NA	0.81	6.46	0.34	3.8e-10	Depression;
CRC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg24531977	chr5:56204891	C5orf35	0.51	7.86	0.4	5.48e-14	Coronary artery disease;
CRC	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg08533674	chr1:46993347	NA	-0.63	-8.13	-0.41	8.62e-15	Monobrow;
CRC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.38	5.66	0.3	3.3e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.49	-9.66	-0.47	1.31e-19	Urate levels in overweight individuals;
CRC	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.63	-8.09	-0.41	1.13e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.47	-7.38	-0.38	1.31e-12	Schizophrenia;
CRC	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.47	-6.52	-0.34	2.58e-10	Schizophrenia;
CRC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.8	12.0	0.55	9.4e-28	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21219203	chr4:103748293	UBE2D3	0.5	7.16	0.37	5.14e-12	Response to antipsychotic treatment;
CRC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.52	-8.48	-0.42	7.55e-16	Testicular germ cell tumor;
CRC	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.65	-9.46	-0.46	6.15e-19	Waist circumference;Body mass index;
CRC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.39	6.13	0.32	2.47e-9	Longevity;Endometriosis;
CRC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg06470822	chr6:28175283	NA	0.48	6.43	0.33	4.59e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3736594	0.513	rs1881396	chr2:27844601	G/T	cg27432699	chr2:27873401	GPN1	-0.65	-8.38	-0.42	1.54e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.62	-11.75	-0.54	7.66e-27	Educational attainment;
CRC	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.84	-10.61	-0.5	8.06e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg26061582	chr7:22766209	IL6	0.53	7.9	0.4	4.11e-14	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CRC	cis	rs3743266	0.634	rs7165874	chr15:60784609	A/T	cg21667061	chr15:60772094	NARG2	0.28	5.69	0.3	2.76e-8	Menarche (age at onset);
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.73	12.46	0.57	1.94e-29	Systemic lupus erythematosus;
CRC	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.52	7.57	0.39	3.81e-13	Corneal astigmatism;
CRC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.54	9.08	0.45	1.04e-17	Prudent dietary pattern;
CRC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.79	0.44	8.46e-17	Schizophrenia;
CRC	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.52	-7.41	-0.38	1.05e-12	Caudate activity during reward;
CRC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-9.95	-0.48	1.44e-20	Platelet distribution width;
CRC	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.61	-8.42	-0.42	1.21e-15	Coronary artery disease;
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.85	-17.78	-0.7	5.05e-50	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23367851	chr7:25165401	CYCS	0.44	6.18	0.32	1.92e-9	Response to antipsychotic treatment;
CRC	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.03	19.2	0.73	1.21e-55	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg27535305	chr1:53392650	SCP2	-0.36	-6.47	-0.34	3.56e-10	Monocyte count;
CRC	cis	rs10986311	0.775	rs3758207	chr9:127132020	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.39	-6.0	-0.31	5.1e-9	Vitiligo;
CRC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg23996704	chr18:44553084	KATNAL2	-0.34	-7.02	-0.36	1.25e-11	Personality dimensions;
CRC	trans	rs36069016	1	rs36069016	chr8:25058491	C/T	cg23013931	chr22:41214857	SLC25A17	-0.48	-5.97	-0.31	6.05e-9	Coronary artery disease;
CRC	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.48	-9.22	-0.45	3.7e-18	Hepatitis;
CRC	cis	rs17162190	0.698	rs4659443	chr1:26823631	C/T	cg17456097	chr1:26900765	RPS6KA1	0.43	6.16	0.32	2.17e-9	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.59	10.03	0.48	7.61e-21	Prudent dietary pattern;
CRC	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.64	0.63	9.82e-38	Hypertriglyceridemia;
CRC	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.53	8.48	0.42	7.9e-16	IgG glycosylation;
CRC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.9	0.36	2.64e-11	Hip circumference adjusted for BMI;
CRC	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg23740940	chr11:68924746	NA	0.44	5.75	0.3	2.04e-8	Blond vs. brown hair color;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg26587870	chr6:27730563	NA	-0.43	-6.64	-0.34	1.3e-10	Parkinson's disease;
CRC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg03013636	chr16:1946785	NA	0.54	6.78	0.35	5.45e-11	Ankle injury;
CRC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16262614	chr3:133464971	TF	0.4	7.09	0.36	8.42e-12	Iron status biomarkers;
CRC	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.64	-7.9	-0.4	4.14e-14	Pursuit maintenance gain;
CRC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.67	9.53	0.46	3.69e-19	Vitamin D levels;
CRC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.81	-13.6	-0.6	9.63e-34	Cystic fibrosis severity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04738309	chr5:111093624	C5orf13	0.47	6.67	0.35	1.12e-10	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.22	-0.64	5.61e-40	Gut microbiome composition (summer);
CRC	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9462027	0.628	rs6919654	chr6:34810739	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.02	-0.32	4.63e-9	Systemic lupus erythematosus;
CRC	cis	rs7072216	0.687	rs11189586	chr10:100154096	A/G	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.64	-0.3	3.64e-8	Metabolite levels;
CRC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.34	-0.38	1.7e-12	Type 2 diabetes;
CRC	cis	rs7605827	0.930	rs7571679	chr2:15596603	C/T	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	8.31e-9	Educational attainment (years of education);
CRC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.41	7.24	0.37	3.13e-12	Cardiovascular disease risk factors;
CRC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs4750440	0.702	rs33945078	chr10:14022425	G/A	cg00551146	chr10:14014579	FRMD4A	0.37	6.02	0.31	4.71e-9	Adiponectin levels;
CRC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.32	-7.03	-0.36	1.16e-11	IgG glycosylation;
CRC	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.48	6.91	0.36	2.55e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.53	7.92	0.4	3.73e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07307803	chr16:69600533	NFAT5;MIR1538	0.4	6.07	0.32	3.61e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25062812	chr14:25519484	STXBP6	0.39	6.04	0.32	4.12e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2413583	0.591	rs17000979	chr22:39700758	C/T	cg09612413	chr10:12085555	UPF2	-0.54	-6.25	-0.33	1.28e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.5	-9.16	-0.45	5.67e-18	Intelligence (multi-trait analysis);
CRC	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.85	-16.47	-0.67	7.23e-45	Hip circumference;
CRC	cis	rs11212617	0.967	rs227054	chr11:108257943	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.37	0.33	6.42e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg18230493	chr5:56204884	C5orf35	-0.42	-6.4	-0.33	5.34e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg08501292	chr6:25962987	TRIM38	0.84	7.76	0.39	1.1e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg07936489	chr17:37558343	FBXL20	-0.46	-6.62	-0.34	1.43e-10	Asthma;
CRC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.51	-8.31	-0.42	2.52e-15	Body mass index;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.6	-0.3	4.51e-8	Life satisfaction;
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.84	13.02	0.58	1.53e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.47	5.9	0.31	9.21e-9	Aortic root size;
CRC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.67	-8.36	-0.42	1.75e-15	Mean platelet volume;
CRC	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.13	-0.41	8.73e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.42	6.65	0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.38	7.12	0.37	6.8e-12	Mean corpuscular volume;
CRC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	9.05	0.45	1.24e-17	Alzheimer's disease;
CRC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg04121214	chr22:50244548	NA	0.4	5.71	0.3	2.47e-8	Schizophrenia;
CRC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-9.45	-0.46	6.79e-19	Colorectal cancer;
CRC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	7.42	0.38	9.79e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7703744	0.681	rs73239280	chr5:118695579	G/A	cg23917399	chr5:118691751	TNFAIP8	0.43	5.93	0.31	7.84e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.47	-6.03	-0.32	4.45e-9	Alopecia areata;
CRC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.92	11.73	0.54	9.09e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	6.32	0.33	8.51e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9296736	0.885	rs9349693	chr6:53939724	A/G	cg04374786	chr6:53939321	C6orf142	0.44	7.1	0.36	7.62e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.94	0.48	1.59e-20	Cognitive test performance;
CRC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.76	-9.71	-0.47	8.96e-20	Initial pursuit acceleration;
CRC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs6504622	0.537	rs197918	chr17:45003080	A/G	cg16759221	chr17:45003025	GOSR2	-0.72	-11.41	-0.53	1.27e-25	Orofacial clefts;
CRC	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.43	-6.23	-0.32	1.39e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	trans	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.51	0.38	5.8e-13	Endometrial cancer;
CRC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.29	5.96	0.31	6.5e-9	Homoarginine levels;
CRC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg25985355	chr7:65971099	NA	-0.49	-5.77	-0.3	1.85e-8	Diabetic kidney disease;
CRC	cis	rs9648716	0.766	rs801157	chr7:140780908	T/G	cg10747023	chr7:140774559	NA	-0.46	-6.09	-0.32	3.1e-9	Type 2 diabetes;
CRC	cis	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg08501292	chr6:25962987	TRIM38	0.83	6.43	0.33	4.44e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg23034840	chr1:205782522	SLC41A1	0.49	6.41	0.33	5.08e-10	Menarche (age at onset);
CRC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg06238570	chr21:40685208	BRWD1	0.72	10.17	0.49	2.58e-21	Cognitive function;
CRC	cis	rs9584850	0.834	rs12869627	chr13:99120452	G/A	cg07423050	chr13:99094983	FARP1	0.45	6.36	0.33	6.9e-10	Neuroticism;
CRC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg03623178	chr6:28175578	NA	0.78	6.64	0.34	1.27e-10	Breast cancer;
CRC	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg05784532	chr1:230284198	GALNT2	-0.4	-5.61	-0.3	4.29e-8	Coronary artery disease;
CRC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.58	8.54	0.43	5.12e-16	Multiple sclerosis;
CRC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.64	-9.63	-0.47	1.65e-19	Prudent dietary pattern;
CRC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg16670446	chr17:27188758	MIR451;MIR144	-0.61	-10.46	-0.5	2.74e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.63	-10.9	-0.51	8.18e-24	Gout;
CRC	cis	rs2811415	0.597	rs1007232	chr3:127801896	C/A	cg13719885	chr3:127795394	NA	-0.39	-5.85	-0.31	1.17e-8	Lung function (FEV1/FVC);
CRC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.46	7.06	0.36	9.89e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Dilated cardiomyopathy;
CRC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-7.59	-0.39	3.38e-13	Coronary artery disease;
CRC	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.03	20.07	0.74	4.35e-59	Schizophrenia;
CRC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg05569086	chr8:143859399	LYNX1	-0.64	-11.51	-0.54	5.45e-26	Urinary tract infection frequency;
CRC	cis	rs117623576	0.941	rs72784865	chr10:32443875	A/C	cg03047570	chr10:32398778	NA	-0.66	-6.28	-0.33	1.04e-9	Anti-saccade response;
CRC	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.5	-0.34	2.97e-10	Coronary artery disease;
CRC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.39	-0.33	5.82e-10	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg15145296	chr3:125709740	NA	-0.57	-6.75	-0.35	6.67e-11	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.01	9.72	0.47	8.58e-20	Lymphocyte counts;
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	0.86	7.75	0.39	1.17e-13	IgG glycosylation;
CRC	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg04176472	chr15:90893244	GABARAPL3	0.34	5.85	0.31	1.2e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.37	6.68	0.35	1.05e-10	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.5	8.19	0.41	5.82e-15	Facial morphology (factor 15, philtrum width);
CRC	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-6.09	-0.32	3.09e-9	Putamen volume;
CRC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.45	-5.94	-0.31	7.45e-9	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg12172441	chr6:28176163	NA	0.55	7.6	0.39	3.15e-13	Parkinson's disease;
CRC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.76	9.95	0.48	1.47e-20	Bladder cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11455018	chr16:30709778	SRCAP	0.46	5.97	0.31	6.21e-9	Thyroid stimulating hormone;
CRC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-12.3	-0.56	7.27e-29	Asthma;
CRC	trans	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.57e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg08314208	chr16:67682810	RLTPR	-0.48	-5.79	-0.3	1.64e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.11	-19.54	-0.73	5.48e-57	Dilated cardiomyopathy;
CRC	cis	rs4731207	0.564	rs6466972	chr7:124596249	T/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.47	5.9	0.31	9.09e-9	Metabolite levels;
CRC	trans	rs62295889	0.602	rs73096562	chr4:12542593	C/A	cg03490839	chr16:73082051	ZFHX3	0.57	6.0	0.31	5.21e-9	Obesity-related traits;
CRC	cis	rs1062746	0.520	rs67174101	chr16:87328817	G/A	cg02258303	chr16:87377426	FBXO31	-0.5	-7.34	-0.38	1.67e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.69	-8.92	-0.44	3.24e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7074356	0.688	rs34894697	chr10:82169888	T/C	cg05935833	chr10:81318306	SFTPA2	-0.45	-6.54	-0.34	2.32e-10	Borderline personality disorder;
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg19678392	chr7:94953810	PON1	-0.59	-7.46	-0.38	7.92e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg02811702	chr13:24901961	NA	0.47	6.59	0.34	1.7e-10	Obesity-related traits;
CRC	cis	rs6496667	0.779	rs2238320	chr15:90972441	C/T	cg04176472	chr15:90893244	GABARAPL3	0.6	8.52	0.43	5.97e-16	Rheumatoid arthritis;
CRC	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.68	0.3	3.03e-8	Breast cancer;
CRC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.26	14.66	0.63	8.53e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg20203395	chr5:56204925	C5orf35	-0.71	-8.56	-0.43	4.27e-16	Initial pursuit acceleration;
CRC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25517755	chr10:38738941	LOC399744	-0.43	-6.21	-0.32	1.59e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.59	-0.39	3.3e-13	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08962709	chr4:95128673	SMARCAD1	-0.43	-6.34	-0.33	7.54e-10	Interleukin-6 levels;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg06470822	chr6:28175283	NA	0.75	8.79	0.44	8.2e-17	Depression;
CRC	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg23555395	chr2:238036564	NA	-0.62	-9.6	-0.47	2.19e-19	Systemic lupus erythematosus;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12172441	chr6:28176163	NA	0.55	6.94	0.36	2.03e-11	Parkinson's disease;
CRC	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	7.07	0.36	9.5e-12	Body mass index;
CRC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.64	-10.02	-0.48	8.45e-21	Body mass index;
CRC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	1.02	16.64	0.68	1.47e-45	Testicular germ cell tumor;
CRC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.36	6.57	0.34	1.93e-10	Erythrocyte sedimentation rate;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg25164649	chr6:28176230	NA	0.62	8.94	0.44	2.82e-17	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	9.34e-17	Morning vs. evening chronotype;
CRC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.42	-7.16	-0.37	5.4e-12	Attention deficit hyperactivity disorder;
CRC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg13010199	chr12:38710504	ALG10B	0.45	6.46	0.34	3.76e-10	Morning vs. evening chronotype;
CRC	cis	rs10242455	0.702	rs57832867	chr7:98966396	C/T	cg18809830	chr7:99032528	PTCD1	-1.01	-7.57	-0.39	3.67e-13	Blood metabolite levels;
CRC	trans	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	8.25	0.41	3.96e-15	Lewy body disease;
CRC	cis	rs7605827	0.576	rs35785577	chr2:15659611	A/G	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.06e-8	Educational attainment (years of education);
CRC	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg07478791	chr1:31886160	SERINC2	-0.41	-5.74	-0.3	2.21e-8	Alcohol dependence;
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.97	-0.4	2.64e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.48	-7.62	-0.39	2.73e-13	Schizophrenia;
CRC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg27661571	chr11:113659931	NA	0.71	7.49	0.38	6.6e-13	Hip circumference adjusted for BMI;
CRC	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.47	-7.31	-0.37	2.01e-12	Schizophrenia;
CRC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.47	0.42	8.27e-16	Morning vs. evening chronotype;
CRC	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg25834613	chr7:1915315	MAD1L1	-0.48	-6.84	-0.35	3.86e-11	Neuroticism;
CRC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.42	-7.28	-0.37	2.5e-12	Height;
CRC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg19847866	chr10:1019161	NA	0.43	6.39	0.33	5.76e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg26587870	chr6:27730563	NA	0.49	7.22	0.37	3.52e-12	Parkinson's disease;
CRC	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.99	-8.1	-0.41	1.08e-14	Mitochondrial DNA levels;
CRC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg10578991	chr7:12443926	VWDE	-0.51	-5.61	-0.3	4.29e-8	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg22677401	chr17:46026860	NA	-0.68	-6.15	-0.32	2.24e-9	Cognitive function;
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6681460	0.674	rs2121051	chr1:67017177	G/A	cg02459107	chr1:67143332	SGIP1	0.4	6.15	0.32	2.22e-9	Presence of antiphospholipid antibodies;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22605943	chr3:107243790	BBX	0.48	6.84	0.35	3.77e-11	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22753607	chr9:37120306	ZCCHC7	0.43	6.05	0.32	3.91e-9	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg02741985	chr17:80059408	CCDC57	0.44	7.15	0.37	5.55e-12	Life satisfaction;
CRC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.71	-9.31	-0.46	1.82e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.59	9.58	0.47	2.5e-19	Mean corpuscular volume;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.64	9.56	0.47	2.81e-19	Lymphocyte counts;
CRC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.71	0.35	8.43e-11	Platelet count;
CRC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.49	7.28	0.37	2.55e-12	Asthma;
CRC	cis	rs11696501	0.739	rs6017637	chr20:44264190	G/A	cg11783356	chr20:44313418	WFDC10B	-0.37	-5.65	-0.3	3.41e-8	Brain structure;
CRC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24308560	chr3:49941425	MST1R	-0.46	-7.23	-0.37	3.51e-12	Intelligence (multi-trait analysis);
CRC	trans	rs10507577	0.671	rs1418618	chr13:53938770	G/A	cg06491101	chr5:39032016	RICTOR	0.44	5.97	0.31	6.17e-9	Select biomarker traits;
CRC	cis	rs55702914	0.904	rs73050839	chr2:198231218	T/G	cg10820045	chr2:198174542	NA	0.34	5.97	0.31	6.14e-9	Major depression and alcohol dependence;
CRC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg00129232	chr17:37814104	STARD3	0.56	6.6	0.34	1.62e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.91	-0.31	8.67e-9	Red blood cell count;
CRC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.73	-0.39	1.28e-13	Vitiligo;
CRC	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg16558177	chr4:4109446	NA	-0.56	-6.39	-0.33	5.52e-10	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18402987	chr7:1209562	NA	0.49	6.97	0.36	1.75e-11	Longevity;Endometriosis;
CRC	cis	rs9925964	0.933	rs4889530	chr16:31065918	T/A	cg02466173	chr16:30829666	NA	0.4	5.62	0.3	4.1e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.54	7.93	0.4	3.56e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.56	-7.66	-0.39	2.15e-13	Response to antineoplastic agents;
CRC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.45	7.38	0.38	1.3e-12	Colorectal cancer;
CRC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.58	8.48	0.42	7.96e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg13385794	chr1:248469461	NA	0.37	6.56	0.34	2.14e-10	Common traits (Other);
CRC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.63	7.67	0.39	2e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11212617	0.967	rs227061	chr11:108205329	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.02	0.32	4.56e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14272860	chr19:42580418	ZNF574	-0.42	-6.54	-0.34	2.38e-10	Myopia (pathological);
CRC	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.71	-0.3	2.5e-8	Blood metabolite levels;
CRC	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg18850127	chr7:39170497	POU6F2	0.43	5.77	0.3	1.87e-8	IgG glycosylation;
CRC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-6.04	-0.32	4.13e-9	Carotid intima media thickness;
CRC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.51	-0.34	2.73e-10	Height;
CRC	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg16964102	chr10:135390573	NA	-0.49	-6.9	-0.36	2.72e-11	Gout;
CRC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.57	8.12	0.41	9.73e-15	Selective IgA deficiency;
CRC	cis	rs727479	0.585	rs12911554	chr15:51542757	C/T	cg19946085	chr15:51559439	CYP19A1	-0.28	-5.6	-0.3	4.48e-8	Estradiol levels;
CRC	cis	rs7487075	0.859	rs3782904	chr12:46757985	T/C	cg22049899	chr12:47219821	SLC38A4	0.34	6.77	0.35	6.09e-11	Itch intensity from mosquito bite;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03827375	chr15:60771498	NARG2	0.4	6.3	0.33	9.68e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.46	6.34	0.33	7.53e-10	Cystic fibrosis severity;
CRC	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.66	11.8	0.55	4.8e-27	Superior crus of antihelix expression;
CRC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.38	-5.63	-0.3	3.78e-8	Renal cell carcinoma;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg02683197	chr6:28174875	NA	0.68	7.33	0.37	1.81e-12	Parkinson's disease;
CRC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.63	-0.47	1.7e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.38	-0.33	6.14e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.81	0.4	7.71e-14	Height;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.55	-6.26	-0.33	1.2e-9	Bipolar disorder;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg02683197	chr6:28174875	NA	0.59	8.24	0.41	4.23e-15	Parkinson's disease;
CRC	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.42	7.83	0.4	6.9e-14	Monocyte count;
CRC	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.06	0.64	2.37e-39	Bipolar disorder;
CRC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.94	11.17	0.52	8.94e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.81	0.44	7.22e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.83	-17.8	-0.7	4.02e-50	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11212617	1.000	rs227088	chr11:108243755	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.4e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.65	-7.45	-0.38	8.36e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.39	5.88	0.31	1.02e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.85	-14.49	-0.62	3.88e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.49	6.06	0.32	3.75e-9	Recombination rate (females);
CRC	cis	rs7932354	0.528	rs7937950	chr11:47098445	A/C	cg03339077	chr11:47165057	C11orf49	0.43	5.99	0.31	5.58e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg05623727	chr3:50126028	RBM5	0.46	7.41	0.38	1.1e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.46	-6.39	-0.33	5.67e-10	Diastolic blood pressure;
CRC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg15147215	chr3:52552868	STAB1	0.53	9.14	0.45	6.61e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2013441	1.000	rs12451216	chr17:20025840	C/A	cg13482628	chr17:19912719	NA	0.4	6.26	0.33	1.19e-9	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs12711979	0.513	rs7566217	chr2:3851381	A/C	cg17052675	chr2:3827356	NA	-0.33	-5.84	-0.31	1.26e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg08213375	chr14:104286397	PPP1R13B	0.46	7.43	0.38	9.15e-13	Reticulocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24167606	chr3:183103843	MCF2L2	0.33	6.01	0.31	4.88e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	1.1	19.13	0.73	2.29e-55	Schizophrenia;
CRC	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.85	-11.05	-0.52	2.41e-24	Orofacial clefts;
CRC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.64	10.18	0.49	2.46e-21	Type 2 diabetes;
CRC	trans	rs2303319	0.504	rs55821334	chr2:162452014	A/G	cg15664909	chr17:685709	GLOD4;RNMTL1	-0.67	-5.96	-0.31	6.48e-9	Cognitive function;
CRC	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg20607287	chr7:12443886	VWDE	-0.55	-5.82	-0.31	1.4e-8	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.18	-13.88	-0.61	8.21e-35	Diabetic kidney disease;
CRC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg22110888	chr17:80059540	CCDC57	0.39	6.22	0.32	1.5e-9	Life satisfaction;
CRC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.75	-0.35	6.62e-11	Vitiligo;
CRC	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.81	-0.31	1.48e-8	QT interval;
CRC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.88	-14.09	-0.61	1.3e-35	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13099106	chr12:120525172	CCDC64	0.4	5.97	0.31	6.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.42	8.44	0.42	9.98e-16	Renal cell carcinoma;
CRC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.69	11.24	0.53	5.17e-25	Chronic sinus infection;
CRC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.6	7.89	0.4	4.4e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg25182066	chr10:30743637	MAP3K8	-0.42	-6.15	-0.32	2.24e-9	Inflammatory bowel disease;
CRC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.92	11.54	0.54	4.15e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-9.08	-0.45	1.01e-17	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.6	10.2	0.49	2.13e-21	Prudent dietary pattern;
CRC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.14	-0.32	2.35e-9	Diabetic kidney disease;
CRC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.52	8.49	0.42	7.15e-16	Uric acid clearance;
CRC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.7	12.0	0.55	9.03e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg15654264	chr1:150340011	RPRD2	0.4	5.87	0.31	1.07e-8	Migraine;
CRC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.48	7.75	0.39	1.17e-13	Pulse pressure;
CRC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg01941586	chr1:40203715	PPIE	0.44	6.09	0.32	3.1e-9	Blood protein levels;
CRC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg19682013	chr15:45996608	NA	0.32	6.78	0.35	5.45e-11	Waist circumference;Weight;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07333738	chr16:765560	METRN	0.38	6.09	0.32	3.23e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.69	8.34	0.42	2.13e-15	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	15.79	0.66	3.44e-42	Electrocardiographic conduction measures;
CRC	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.96	-0.31	6.53e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs9928842	0.765	rs4479268	chr16:75224733	G/T	cg09066997	chr16:75300724	BCAR1	-0.65	-6.26	-0.33	1.18e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs2160860	0.773	rs11787449	chr8:39797174	A/G	cg11363097	chr8:39792086	IDO2	-0.43	-7.3	-0.37	2.14e-12	Blood metabolite levels;
CRC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg22638593	chr5:131593259	PDLIM4	0.39	7.25	0.37	2.96e-12	Breast cancer;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg12172441	chr6:28176163	NA	0.59	8.52	0.43	5.68e-16	Cardiac Troponin-T levels;
CRC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg17294928	chr15:75287854	SCAMP5	0.42	6.35	0.33	7.34e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg05639522	chr1:247681581	NA	0.5	7.49	0.38	6.2e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg03030879	chr14:75389066	RPS6KL1	0.54	8.83	0.44	6.45e-17	Caffeine consumption;
CRC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg13556452	chr1:2391241	NA	-0.39	-6.38	-0.33	5.92e-10	Non-obstructive azoospermia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg13038030	chr17:73267041	MIF4GD	-0.52	-6.23	-0.32	1.46e-9	Diisocyanate-induced asthma;
CRC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg24300038	chr13:113819356	PROZ	-0.47	-5.96	-0.31	6.67e-9	Platelet distribution width;
CRC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg05585544	chr11:47624801	NA	-0.61	-10.7	-0.51	4.08e-23	Neuroticism;
CRC	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.56	7.69	0.39	1.67e-13	Schizophrenia;
CRC	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.72	8.03	0.4	1.8e-14	Systolic blood pressure;
CRC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg13607699	chr17:42295918	UBTF	-0.47	-6.42	-0.33	4.67e-10	Total body bone mineral density;
CRC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.55	-8.35	-0.42	1.97e-15	Age at first birth;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17408923	chr2:109335769	RANBP2	0.52	7.38	0.38	1.26e-12	Response to antipsychotic treatment;
CRC	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.52	8.74	0.43	1.22e-16	Dupuytren's disease;
CRC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.68	0.3	2.89e-8	Tonsillectomy;
CRC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-8.53	-0.43	5.51e-16	Gut microbiome composition (summer);
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.51	7.6	0.39	3.2e-13	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg19582491	chr16:67682965	RLTPR	-0.58	-6.7	-0.35	9.02e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	0.96	8.82	0.44	7.07e-17	Type 2 diabetes nephropathy;
CRC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg15845792	chr6:28175446	NA	-0.47	-6.53	-0.34	2.54e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.32	4.53e-9	Gut microbiome composition (summer);
CRC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.64	-9.28	-0.46	2.29e-18	Menarche (age at onset);
CRC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.63	9.41	0.46	8.71e-19	Breast cancer;
CRC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.48	-0.38	6.62e-13	Colorectal cancer;
CRC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.57	7.65	0.39	2.26e-13	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.6	9.39	0.46	1.01e-18	Corneal astigmatism;
CRC	cis	rs12760731	0.641	rs11588490	chr1:178328139	T/A	cg00404053	chr1:178313656	RASAL2	0.94	9.89	0.48	2.37e-20	Obesity-related traits;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg14883916	chr11:6947541	ZNF215	0.59	6.26	0.33	1.21e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.73	12.0	0.55	9.38e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs713587	0.776	rs2118826	chr2:25191745	A/T	cg22495460	chr2:25135724	ADCY3	0.66	10.56	0.5	1.24e-22	Body mass index in non-asthmatics;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg02683197	chr6:28174875	NA	0.9	12.58	0.57	6.51e-30	Depression;
CRC	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg15845792	chr6:28175446	NA	0.77	6.87	0.35	3.26e-11	Depression;
CRC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-7.5	-0.38	5.82e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg11189052	chr15:85197271	WDR73	0.64	9.35	0.46	1.35e-18	Schizophrenia;
CRC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.4	7.42	0.38	9.98e-13	Obesity-related traits;
CRC	cis	rs447	0.943	rs10808306	chr7:83767093	G/A	cg22846510	chr7:83753280	SEMA3A	-0.61	-7.77	-0.39	9.88e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.2	-0.32	1.65e-9	Breast cancer;
CRC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.55	9.41	0.46	8.58e-19	Menarche (age at onset);
CRC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-5.77	-0.3	1.88e-8	Total body bone mineral density;
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	2.01e-9	Body mass index;
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.27	-0.37	2.7e-12	Bipolar disorder;
CRC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.44	-7.99	-0.4	2.37e-14	Reticulocyte fraction of red cells;
CRC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg04731861	chr2:219085781	ARPC2	0.31	6.2	0.32	1.69e-9	Colorectal cancer;
CRC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.8	12.48	0.57	1.55e-29	Breast cancer;
CRC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg00579200	chr11:133705235	NA	-0.41	-5.82	-0.31	1.36e-8	Childhood ear infection;
CRC	cis	rs9462027	0.606	rs2814987	chr6:34605145	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.31	-0.33	9.16e-10	Systemic lupus erythematosus;
CRC	cis	rs9491140	0.539	rs12210199	chr6:124684045	C/A	cg22366943	chr6:124882293	NKAIN2	0.55	8.02	0.4	1.93e-14	Neuroticism;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg22876561	chr7:11013721	PHF14	0.55	6.39	0.33	5.82e-10	Body mass index;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg08798685	chr6:27730294	NA	-0.43	-6.17	-0.32	2.02e-9	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg12365402	chr11:9010492	NRIP3	0.47	7.62	0.39	2.67e-13	Hemoglobin concentration;
CRC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.97	17.69	0.7	1.07e-49	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs539514	0.690	rs2761398	chr13:76316933	C/A	cg04757411	chr13:76259545	LMO7	-0.34	-5.78	-0.3	1.75e-8	Type 1 diabetes;
CRC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg16060761	chr17:80687452	NA	-0.49	-6.51	-0.34	2.89e-10	Glycated hemoglobin levels;
CRC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.66	-6.75	-0.35	6.59e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18426345	chr19:19516893	GATAD2A	0.44	6.48	0.34	3.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg25019722	chr6:37503610	NA	-0.47	-8.78	-0.44	9.33e-17	Cognitive performance;
CRC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg13206674	chr6:150067644	NUP43	0.58	8.26	0.41	3.68e-15	Lung cancer;
CRC	cis	rs6088813	1.000	rs4911491	chr20:33947285	C/G	cg14752227	chr20:34000481	UQCC	-0.37	-5.82	-0.31	1.37e-8	Height;
CRC	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.28	-0.37	2.42e-12	Type 2 diabetes;
CRC	cis	rs3736485	0.932	rs4774598	chr15:51919667	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.4	-0.33	5.23e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.97	0.36	1.69e-11	Mood instability;
CRC	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.36	-0.38	1.48e-12	Diisocyanate-induced asthma;
CRC	trans	rs8100891	0.537	rs73038232	chr19:32987653	C/T	cg08611549	chr12:108064394	NA	0.37	6.16	0.32	2.13e-9	Neuroticism;
CRC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg13722127	chr7:150037890	RARRES2	0.5	8.05	0.41	1.58e-14	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14914809	chr2:171705073	GAD1	0.39	6.12	0.32	2.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs61996546	0.622	rs4542636	chr15:26867931	C/T	cg15066197	chr15:26874202	GABRB3	-0.39	-6.02	-0.31	4.69e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.54	9.67	0.47	1.2e-19	Electroencephalogram traits;
CRC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.66	10.68	0.51	4.82e-23	Platelet count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03774484	chr12:7079822	PHB2;EMG1	-0.4	-5.97	-0.31	6.04e-9	Myopia (pathological);
CRC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.75	-11.84	-0.55	3.46e-27	Menarche (age at onset);
CRC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.16e-13	Corneal astigmatism;
CRC	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.31	-0.42	2.47e-15	Prevalent atrial fibrillation;
CRC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	0.76	6.13	0.32	2.45e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21643547	chr1:205240462	TMCC2	-0.43	-6.78	-0.35	5.71e-11	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs3824347	0.839	rs12553648	chr9:77570716	A/G	cg01251476	chr9:77566080	C9orf40	-0.4	-6.27	-0.33	1.15e-9	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.89	-0.31	9.67e-9	Colorectal cancer;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg26688472	chr2:203638928	ICA1L	-0.43	-6.43	-0.33	4.51e-10	HDL cholesterol;
CRC	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.14	-0.37	6.16e-12	Schizophrenia;
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.29	-0.46	2.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.42	-6.23	-0.32	1.46e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.13	0.52	1.23e-24	Prudent dietary pattern;
CRC	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.49	-6.83	-0.35	4.18e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);
CRC	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg02487331	chr1:146550467	NA	0.32	5.8	0.3	1.56e-8	HIV-1 control;
CRC	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg13482628	chr17:19912719	NA	-0.38	-5.84	-0.31	1.26e-8	Obesity-related traits;
CRC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.87	-0.44	4.73e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.42	6.2	0.32	1.71e-9	Psychosis in Alzheimer's disease;
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.16	0.52	9.37e-25	Prudent dietary pattern;
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.24	-0.37	3.29e-12	Bipolar disorder;
CRC	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.89	17.06	0.69	3.26e-47	Bone mineral density;
CRC	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12560992	chr17:57184187	TRIM37	0.53	7.37	0.38	1.41e-12	Testicular germ cell tumor;
CRC	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg04850286	chr10:81895943	PLAC9	0.36	6.35	0.33	6.97e-10	Sarcoidosis;
CRC	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-7.54	-0.38	4.57e-13	Schizophrenia;
CRC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-11.85	-0.55	3.26e-27	Schizophrenia;
CRC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.9	-0.48	2.1e-20	Chronic sinus infection;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg15786705	chr6:28176104	NA	0.57	5.78	0.3	1.77e-8	Lung cancer in ever smokers;
CRC	cis	rs6694672	0.867	rs2336595	chr1:197000476	T/C	cg13682187	chr1:196946512	CFHR5	0.47	7.32	0.37	1.88e-12	Asthma;
CRC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg08687515	chr19:58661962	ZNF329	0.75	8.17	0.41	6.84e-15	Cholesterol, total;
CRC	cis	rs490234	0.756	rs925473	chr9:128228026	A/G	cg14078157	chr9:128172775	NA	-0.39	-6.51	-0.34	2.81e-10	Mean arterial pressure;
CRC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.79	-0.3	1.62e-8	Migraine;Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14056668	chr15:52122448	TMOD3	0.42	5.97	0.31	6.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg07125278	chr16:67683757	RLTPR	-0.48	-6.64	-0.34	1.29e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.17	-0.52	9.18e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.33	-0.46	1.62e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1190552	0.706	rs2146426	chr14:102995068	A/G	cg18135206	chr14:102964638	TECPR2	0.49	6.06	0.32	3.8e-9	Blood protein levels;
CRC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.64	0.34	1.33e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg21251018	chr6:28226885	NKAPL	0.54	8.9	0.44	3.72e-17	Pulmonary function;
CRC	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.7	12.46	0.57	1.8e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.9	-14.88	-0.63	1.14e-38	Headache;
CRC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.46	7.04	0.36	1.15e-11	Corneal astigmatism;
CRC	cis	rs13082711	0.520	rs12486671	chr3:27556832	A/G	cg02860705	chr3:27208620	NA	0.41	6.08	0.32	3.34e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg25985355	chr7:65971099	NA	0.32	5.69	0.3	2.8e-8	Aortic root size;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.69	11.52	0.54	4.96e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.75	-14.1	-0.61	1.26e-35	Facial morphology (factor 23);
CRC	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg09873164	chr1:152488093	CRCT1	0.4	6.6	0.34	1.66e-10	Hair morphology;
CRC	cis	rs370915	0.963	rs59452206	chr4:187816484	G/T	cg19519643	chr4:187840862	NA	-0.41	-5.84	-0.31	1.23e-8	Gout;
CRC	cis	rs919433	0.756	rs7575389	chr2:198198489	A/G	cg03934865	chr2:198174659	NA	-0.38	-6.13	-0.32	2.52e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs4853036	0.629	rs34704699	chr2:70014710	G/A	cg14633329	chr9:139640053	LCN6	-0.37	-6.2	-0.32	1.66e-9	Colorectal or endometrial cancer;
CRC	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.49	-7.41	-0.38	1.09e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs61160187	0.582	rs72757187	chr5:60263766	T/A	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.74	-0.3	2.15e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs4780355	0.843	rs243325	chr16:11354497	A/G	cg00044050	chr16:11439710	C16orf75	0.4	5.69	0.3	2.83e-8	Crohn's disease and psoriasis;
CRC	trans	rs17065417	1.000	rs1149280	chr6:105454799	T/A	cg03946762	chr12:54785043	ZNF385A	-0.55	-6.25	-0.33	1.31e-9	Neuroblastoma;Sporadic neuroblastoma;
CRC	cis	rs6807306	1.000	rs2420025	chr3:167368802	A/C	cg18801567	chr3:167450363	PDCD10	-0.39	-5.65	-0.3	3.41e-8	Mean platelet volume;
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00166722	chr3:10149974	C3orf24	0.65	8.96	0.44	2.39e-17	Alzheimer's disease;
CRC	cis	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg02972257	chr16:68554789	NA	0.45	5.73	0.3	2.27e-8	Colorectal cancer;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg02683197	chr6:28174875	NA	0.67	9.18	0.45	4.91e-18	Cardiac Troponin-T levels;
CRC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.95	13.71	0.6	3.81e-34	Breast cancer;
CRC	cis	rs3736485	0.966	rs10467923	chr15:51767265	A/C	cg08986416	chr15:51914746	DMXL2	-0.43	-6.12	-0.32	2.69e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg19619003	chr1:41846758	NA	-0.38	-5.92	-0.31	8.08e-9	Bipolar disorder;
CRC	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.64	-9.45	-0.46	6.39e-19	Blood protein levels;
CRC	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.62	9.84	0.48	3.5e-20	Crohn's disease;
CRC	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg21115391	chr11:93143810	CCDC67	-0.4	-5.91	-0.31	8.77e-9	Pulmonary function decline;
CRC	cis	rs77633900	0.772	rs8031378	chr15:76657874	A/G	cg21673338	chr15:77095150	SCAPER	-0.71	-6.52	-0.34	2.59e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.53	0.47	3.57e-19	Cognitive test performance;
CRC	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.73	9.78	0.47	5.46e-20	Coronary artery disease;
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg08798685	chr6:27730294	NA	-0.61	-5.93	-0.31	7.55e-9	Depression;
CRC	cis	rs1030268	0.651	rs13222377	chr7:133466346	C/T	cg10665199	chr7:133106180	EXOC4	0.52	6.09	0.32	3.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18402987	chr7:1209562	NA	0.44	6.48	0.34	3.28e-10	Longevity;Endometriosis;
CRC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.53	-8.03	-0.4	1.78e-14	Mean corpuscular hemoglobin;
CRC	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.64	9.87	0.48	2.62e-20	Corneal astigmatism;
CRC	trans	rs12483148	1.000	rs12483148	chr21:37013621	T/C	cg02629111	chr21:18966031	BTG3	0.72	6.12	0.32	2.63e-9	Obesity-related traits;
CRC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.83	0.35	4.22e-11	Mean platelet volume;
CRC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg16576597	chr16:28551801	NUPR1	0.5	7.26	0.37	2.83e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.48	8.2	0.41	5.35e-15	Hypertriglyceridemia;
CRC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.59	-7.02	-0.36	1.25e-11	Body mass index;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg21251018	chr6:28226885	NKAPL	0.59	10.3	0.49	9.21e-22	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.8	12.0	0.55	9.4e-28	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg11693508	chr17:37793320	STARD3	-0.61	-7.49	-0.38	6.47e-13	Bipolar disorder;
CRC	cis	rs847649	0.731	rs13222980	chr7:102703898	A/G	cg18108683	chr7:102477205	FBXL13	0.52	8.2	0.41	5.36e-15	Morning vs. evening chronotype;
CRC	cis	rs6479527	0.875	rs10761313	chr9:96770793	T/C	cg14459158	chr9:96720562	NA	0.4	7.07	0.36	9.13e-12	Esophageal adenocarcinoma;
CRC	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg13172432	chr1:205912842	SLC26A9	-0.33	-5.81	-0.3	1.5e-8	Cystic fibrosis-related diabetes;
CRC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.56	-0.43	4.41e-16	Hemoglobin concentration;
CRC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.65	10.47	0.5	2.56e-22	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11138794	chr3:122283215	PARP9;DTX3L	0.43	6.92	0.36	2.43e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3018066	0.666	rs12643397	chr4:107054976	G/C	cg01869342	chr4:106983673	TBCK	0.43	5.75	0.3	2e-8	Cancer;
CRC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg26762873	chr11:5879799	OR52E8	-0.49	-7.55	-0.38	4.24e-13	DNA methylation (variation);
CRC	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.29	-0.33	9.89e-10	Obesity-related traits;
CRC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg13844804	chr7:814759	HEATR2	0.68	7.92	0.4	3.65e-14	Cerebrospinal P-tau181p levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14614337	chr9:131533978	ZER1	0.45	6.71	0.35	8.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.49	0.6	2.68e-33	Vitiligo;
CRC	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.68	11.01	0.52	3.14e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg15147215	chr3:52552868	STAB1	-0.42	-5.84	-0.31	1.28e-8	Schizophrenia;
CRC	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg20041105	chr8:143859282	LYNX1	0.32	5.73	0.3	2.31e-8	Urinary tract infection frequency;
CRC	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	0.64	9.77	0.47	6e-20	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.46	8.58	0.43	3.71e-16	Educational attainment (years of education);
CRC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.48	-8.84	-0.44	5.78e-17	Reticulocyte fraction of red cells;
CRC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-6.02	-0.31	4.67e-9	Gut microbiome composition (summer);
CRC	cis	rs3015497	0.586	rs7144714	chr14:51078585	G/A	cg09863266	chr14:51125203	SAV1	-0.3	-5.7	-0.3	2.66e-8	Mean platelet volume;
CRC	trans	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg17903999	chr18:56338584	MALT1	-0.43	-6.91	-0.36	2.48e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.35	6.07	0.32	3.43e-9	Erythrocyte sedimentation rate;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.35	0.38	1.63e-12	Lymphocyte counts;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15229027	chr14:64805542	ESR2	0.49	6.66	0.34	1.17e-10	Thyroid stimulating hormone;
CRC	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.44	-6.95	-0.36	1.97e-11	Type 1 diabetes;
CRC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.5	7.52	0.38	5.43e-13	Resting heart rate;
CRC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.16	-0.37	5.33e-12	Self-reported allergy;
CRC	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.55	-8.74	-0.43	1.22e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20538819	chr1:214724805	PTPN14	0.43	6.11	0.32	2.81e-9	Response to antipsychotic treatment;
CRC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg14541582	chr5:601475	NA	-0.27	-5.62	-0.3	4e-8	Lung disease severity in cystic fibrosis;
CRC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg19131313	chr8:1704013	NA	-0.45	-5.9	-0.31	8.88e-9	Systolic blood pressure;
CRC	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.19	-0.53	7.43e-25	Colorectal cancer;
CRC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.76	14.57	0.63	1.95e-37	Body mass index;
CRC	cis	rs294883	0.739	rs1504254	chr6:159731223	A/G	cg14500486	chr6:159655392	FNDC1	-0.36	-6.18	-0.32	1.92e-9	Coronary artery disease;
CRC	cis	rs73200209	0.744	rs17498893	chr12:116674831	G/C	cg01776926	chr12:116560359	MED13L	-0.6	-6.94	-0.36	2.12e-11	Total body bone mineral density;
CRC	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg16060761	chr17:80687452	NA	0.43	5.67	0.3	3.21e-8	Glycated hemoglobin levels;
CRC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.59	7.77	0.39	9.86e-14	Multiple sclerosis;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Parkinson's disease;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.82e-9	Bipolar disorder;
CRC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.56	7.87	0.4	5.2e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.71	10.45	0.5	2.9e-22	Longevity;
CRC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.6	-7.08	-0.36	8.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs17209837	1.000	rs2302386	chr7:87091944	A/G	cg00919237	chr7:87102261	ABCB4	-0.47	-5.63	-0.3	3.84e-8	Gallbladder cancer;
CRC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.03	19.18	0.73	1.45e-55	Primary sclerosing cholangitis;
CRC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.61	-0.39	2.96e-13	Bladder cancer;
CRC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.73	-11.44	-0.53	9.73e-26	Response to antineoplastic agents;
CRC	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-7.18	-0.37	4.74e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.71	8.44	0.42	1.03e-15	Eotaxin levels;
CRC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg03037974	chr15:76606532	NA	-0.69	-11.54	-0.54	4.27e-26	Blood metabolite levels;
CRC	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg03623178	chr6:28175578	NA	-0.67	-7.18	-0.37	4.56e-12	Depression;
CRC	cis	rs911119	0.955	rs6048945	chr20:23602228	C/T	cg16589663	chr20:23618590	CST3	0.47	6.5	0.34	2.92e-10	Chronic kidney disease;
CRC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.13	-0.41	8.93e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg10845886	chr2:3471009	TTC15	-0.41	-6.31	-0.33	9.18e-10	Neurofibrillary tangles;
CRC	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.44	-7.75	-0.39	1.16e-13	Blood metabolite levels;
CRC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.34	6.3	0.33	9.71e-10	Menarche (age at onset);
CRC	cis	rs2223471	1.000	rs6928000	chr6:50742161	G/A	cg03432817	chr6:50765336	NA	0.4	6.36	0.33	6.7e-10	Subcutaneous adipose tissue;
CRC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg12273811	chr6:28175739	NA	0.47	6.2	0.32	1.64e-9	Parkinson's disease;
CRC	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.52	7.26	0.37	2.82e-12	Response to antidepressants and depression;
CRC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.68	9.72	0.47	8.52e-20	Multiple sclerosis;
CRC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.35	-0.53	2.04e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg20512303	chr5:131592959	PDLIM4	0.38	6.56	0.34	2.09e-10	Breast cancer;
CRC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg06970220	chr1:156163860	SLC25A44	0.5	7.13	0.37	6.42e-12	Testicular germ cell tumor;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.33e-18	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10424846	chr17:33894970	NA	0.39	6.62	0.34	1.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg22638593	chr5:131593259	PDLIM4	0.36	6.56	0.34	2.12e-10	Blood metabolite levels;
CRC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.17	-0.45	5.38e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.8	7.03	0.36	1.23e-11	Major depressive disorder;
CRC	trans	rs10242455	1.000	rs28468623	chr7:98922812	C/G	cg09045935	chr12:6379348	NA	0.72	6.68	0.35	1.03e-10	Blood metabolite levels;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg21620606	chr4:1342894	KIAA1530	0.5	8.56	0.43	4.31e-16	Longevity;
CRC	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg00383909	chr3:49044727	WDR6	0.67	6.8	0.35	4.91e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.72	7.95	0.4	2.93e-14	Systolic blood pressure;
CRC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.91	16.85	0.68	2.2e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.63	10.81	0.51	1.66e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg03037974	chr15:76606532	NA	-0.54	-8.07	-0.41	1.31e-14	Blood metabolite levels;
CRC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.7	-0.39	1.6e-13	Psoriasis;
CRC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg24375607	chr4:120327624	NA	-0.47	-7.59	-0.39	3.42e-13	Corneal astigmatism;
CRC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.83	-13.32	-0.59	1.12e-32	Cognitive function;
CRC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg03934865	chr2:198174659	NA	0.36	5.81	0.31	1.44e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.46	-6.31	-0.33	9.06e-10	Total body bone mineral density;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg18833306	chr6:118973337	C6orf204	0.44	5.81	0.31	1.48e-8	Diastolic blood pressure;
CRC	cis	rs9925964	0.933	rs2303222	chr16:31085470	A/G	cg02466173	chr16:30829666	NA	0.42	5.88	0.31	1e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg12935359	chr14:103987150	CKB	-0.37	-5.8	-0.3	1.58e-8	Body mass index;
CRC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.36	7.48e-12	Menopause (age at onset);
CRC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.26	0.41	3.59e-15	Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14347670	chr6:41908995	CCND3	0.45	6.3	0.33	9.53e-10	Response to antipsychotic treatment;
CRC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.18	11.57	0.54	3.24e-26	Skin colour saturation;
CRC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.89	0.58	4.84e-31	Bone mineral density;
CRC	cis	rs13253111	0.624	rs28372101	chr8:28099384	G/T	cg26534493	chr8:28060551	NA	0.41	7.17	0.37	4.87e-12	Childhood body mass index;
CRC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.33	0.46	1.61e-18	Heart rate;
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	0.97	10.37	0.5	5.57e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs2303319	0.504	rs2175142	chr2:162450124	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.17	-0.32	2.06e-9	Cognitive function;
CRC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg19622623	chr12:86230825	RASSF9	-0.36	-5.77	-0.3	1.82e-8	Major depressive disorder;
CRC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.64	11.85	0.55	3.23e-27	Calcium levels;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.1	0.32	2.93e-9	Depression;
CRC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.52	8.35	0.42	1.96e-15	Menopause (age at onset);
CRC	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.98	-0.31	5.91e-9	Pulmonary function;
CRC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.5	7.18	0.37	4.79e-12	Bone mineral density (spine);
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02018176	chr4:1364513	KIAA1530	-0.46	-7.8	-0.4	8.03e-14	Obesity-related traits;
CRC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.71	8.11	0.41	1.04e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.7e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.65	-0.3	3.39e-8	Type 2 diabetes;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.93	15.88	0.66	1.43e-42	Menarche (age at onset);
CRC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-12.41	-0.56	2.83e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.55	-8.34	-0.42	2.11e-15	Calcium levels;
CRC	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.6	10.73	0.51	3.14e-23	Blood metabolite ratios;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.43	6.11	0.32	2.88e-9	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	16.58	0.67	2.55e-45	Platelet count;
CRC	trans	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.48	0.34	3.34e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14045725	chr17:2240967	SGSM2;TSR1	0.41	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-5.76	-0.3	1.9e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg15534755	chr11:117069859	TAGLN	0.34	6.46	0.34	3.84e-10	Blood protein levels;
CRC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs17384381	0.636	rs11161615	chr1:85906816	A/G	cg16011679	chr1:85725395	C1orf52	-0.5	-6.24	-0.33	1.37e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.8	13.22	0.59	2.77e-32	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23161317	chr6:28129485	ZNF389	-0.45	-5.75	-0.3	1.99e-8	Depression;
CRC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08144172	chr1:41849203	NA	0.35	5.83	0.31	1.29e-8	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.65	9.69	0.47	1.04e-19	Longevity;
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02807482	chr3:125708958	NA	-0.47	-5.96	-0.31	6.39e-9	Blood pressure (smoking interaction);
CRC	trans	rs9693857	0.520	rs10107887	chr8:9364664	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	6.27	0.33	1.15e-9	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20586607	chr14:50235780	KLHDC2	0.45	6.63	0.34	1.35e-10	Response to antipsychotic treatment;
CRC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg26182253	chr13:112236782	NA	0.31	6.3	0.33	9.74e-10	Hepatitis;
CRC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.66	10.89	0.51	8.49e-24	Autism spectrum disorder or schizophrenia;
CRC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.46	-0.38	7.78e-13	Height;
CRC	cis	rs4731207	0.698	rs4728009	chr7:124470961	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.22	-0.32	1.48e-9	Cutaneous malignant melanoma;
CRC	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.63	-9.64	-0.47	1.59e-19	Nonalcoholic fatty liver disease;
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg15511327	chr8:143859410	LYNX1	-0.33	-5.79	-0.3	1.66e-8	Urinary tract infection frequency;
CRC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	10.11	0.49	4.12e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	1.12	9.97	0.48	1.26e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg17948913	chr5:572064	NA	0.5	5.79	0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.46	-7.37	-0.38	1.44e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg00850481	chr1:228891306	NA	-0.39	-5.79	-0.3	1.65e-8	Chronic lymphocytic leukemia;
CRC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.43	7.04	0.36	1.16e-11	Migraine;
CRC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01065977	chr19:18549689	ISYNA1	-0.39	-6.14	-0.32	2.35e-9	Breast cancer;
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.49	7.33	0.37	1.84e-12	Longevity;Endometriosis;
CRC	cis	rs6741819	1.000	rs13398488	chr2:7142199	A/G	cg27144453	chr2:7172511	RNF144A	-0.42	-6.15	-0.32	2.26e-9	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.83	-12.68	-0.57	2.92e-30	Cognitive function;
CRC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25652642	chr19:10514370	MIR1181;CDC37	0.41	6.32	0.33	8.66e-10	Myopia (pathological);
CRC	cis	rs9925964	0.933	rs2303223	chr16:31075175	G/A	cg03418659	chr16:31128414	MYST1	0.47	6.72	0.35	7.9e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.73	0.35	7.71e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.34	5.71	0.3	2.58e-8	Emphysema distribution in smoking;
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.38	-7.01	-0.36	1.36e-11	Sarcoidosis;
CRC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg07074390	chr21:40555500	PSMG1	-0.45	-6.14	-0.32	2.44e-9	Cognitive function;
CRC	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	1.02	8.46	0.42	9.13e-16	Granulocyte percentage of myeloid white cells;
CRC	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg24505687	chr6:33548425	BAK1	0.3	5.79	0.3	1.66e-8	Platelet count;
CRC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-6.12	-0.32	2.68e-9	Lung cancer;
CRC	cis	rs7107770	0.663	rs1078532	chr11:125073484	G/A	cg27629782	chr11:125073726	PKNOX2	0.51	7.31	0.37	2.05e-12	Photic sneeze reflex;
CRC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.47	-6.61	-0.34	1.59e-10	Diastolic blood pressure;
CRC	cis	rs863345	0.547	rs10908675	chr1:158504129	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.54	0.57	9.29e-30	Alzheimer's disease;
CRC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14895029	chr7:2775587	GNA12	-0.4	-5.93	-0.31	7.5e-9	Height;
CRC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg13722127	chr7:150037890	RARRES2	0.48	8.03	0.4	1.77e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg04110750	chr16:69646130	NFAT5	-0.56	-7.62	-0.39	2.73e-13	IgE levels;
CRC	cis	rs7705042	0.865	rs12656877	chr5:141490091	T/C	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.78	-0.3	1.71e-8	Asthma;
CRC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-9.36	-0.46	1.25e-18	Pancreatic cancer;
CRC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-11.54	-0.54	4.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	ch.11.42038R	chr11:967971	AP2A2	0.58	10.11	0.49	4.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg11003573	chr3:44754125	ZNF502	0.35	5.94	0.31	7.09e-9	Depressive symptoms;
CRC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg25876840	chr17:41920477	NA	0.53	7.23	0.37	3.44e-12	Triglycerides;
CRC	cis	rs71403859	0.504	rs35203704	chr16:71959661	G/A	cg08717414	chr16:71523259	ZNF19	-0.83	-7.11	-0.37	7.17e-12	Post bronchodilator FEV1;
CRC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg15107132	chr11:63991130	FERMT3	0.38	6.2	0.32	1.73e-9	Platelet count;
CRC	cis	rs375066	0.623	rs239948	chr19:44356887	A/T	cg19542119	chr19:44331823	ZNF283	-0.41	-5.88	-0.31	1.02e-8	Breast cancer;
CRC	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg21918786	chr6:109611834	NA	-0.33	-5.73	-0.3	2.3e-8	Reticulocyte fraction of red cells;
CRC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.03	0.36	1.17e-11	Neuroticism;
CRC	cis	rs11212617	0.967	rs11605442	chr11:108077857	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.27	0.33	1.14e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.09	-0.32	3.2e-9	Morning vs. evening chronotype;
CRC	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.77	-12.25	-0.56	1.16e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2811415	0.597	rs9844891	chr3:127743260	C/T	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.1e-8	Lung function (FEV1/FVC);
CRC	cis	rs1465370	0.682	rs2268382	chr7:130027037	A/C	cg03229158	chr7:130009420	NA	0.42	5.93	0.31	7.86e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	trans	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.62	-0.39	2.78e-13	HDL cholesterol;
CRC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.89	0.55	2.32e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg08632701	chr21:37451849	NA	-0.41	-6.16	-0.32	2.17e-9	Mitral valve prolapse;
CRC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg10729496	chr3:10149963	C3orf24	-0.49	-6.54	-0.34	2.37e-10	Alzheimer's disease;
CRC	cis	rs78472555	0.954	rs2123926	chr15:100264518	T/C	cg18869061	chr15:100272053	LYSMD4	-0.55	-6.66	-0.34	1.18e-10	Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.1	21.19	0.76	1.86e-63	Cognitive function;
CRC	cis	rs4731207	0.535	rs11769711	chr7:124574924	A/T	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg03152288	chr2:177042942	NA	0.81	13.15	0.59	4.97e-32	IgG glycosylation;
CRC	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.9	-0.31	9.08e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg00601486	chr12:48723148	H1FNT	-0.35	-6.55	-0.34	2.2e-10	Glycated hemoglobin levels;
CRC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.5	10.34	0.5	6.86e-22	Bone mineral density;
CRC	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.53	-7.3	-0.37	2.22e-12	Tuberculosis;
CRC	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.43	6.85	0.35	3.7e-11	Red blood cell count;
CRC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg24675056	chr1:15929824	NA	0.52	7.18	0.37	4.69e-12	Systolic blood pressure;
CRC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.11	-0.36	7.38e-12	QT interval;
CRC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.69	0.43	1.79e-16	Rheumatoid arthritis;
CRC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg18230493	chr5:56204884	C5orf35	0.6	8.71	0.43	1.5e-16	Initial pursuit acceleration;
CRC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.43	-0.42	1.1e-15	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg22532475	chr10:104410764	TRIM8	0.34	5.8	0.3	1.58e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17065868	0.764	rs61949794	chr13:45030109	A/G	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.06	10.58	0.5	1.08e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.42	6.86	0.35	3.38e-11	Sitting height ratio;
CRC	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.18	0.49	2.53e-21	Asthma (childhood onset);
CRC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma (childhood onset);
CRC	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.78	-0.3	1.73e-8	Inflammatory bowel disease;
CRC	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.64	-10.14	-0.49	3.28e-21	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs4073416	0.542	rs12433597	chr14:66028847	T/C	cg03016385	chr14:66212404	NA	-0.45	-6.25	-0.33	1.24e-9	N-glycan levels;
CRC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.29	0.37	2.32e-12	Parkinson's disease;
CRC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg20243544	chr17:37824526	PNMT	0.55	8.43	0.42	1.08e-15	Asthma;
CRC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg18964960	chr10:1102726	WDR37	-0.44	-6.25	-0.33	1.27e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg25164649	chr6:28176230	NA	-0.74	-9.2	-0.45	4.39e-18	Depression;
CRC	cis	rs11971779	0.625	rs10260850	chr7:139003602	G/T	cg07862535	chr7:139043722	LUC7L2	0.54	6.82	0.35	4.41e-11	Diisocyanate-induced asthma;
CRC	cis	rs2411233	1.000	rs7168645	chr15:39271165	C/T	cg23129342	chr15:39283510	NA	0.31	5.65	0.3	3.48e-8	Platelet count;
CRC	cis	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg18809830	chr7:99032528	PTCD1	-0.87	-6.84	-0.35	3.98e-11	Blood metabolite levels;
CRC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg22110888	chr17:80059540	CCDC57	-0.43	-6.69	-0.35	9.49e-11	Life satisfaction;
CRC	trans	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg18187862	chr3:45730750	SACM1L	0.47	6.85	0.35	3.65e-11	Primary sclerosing cholangitis;
CRC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.57	-8.11	-0.41	1.03e-14	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs8014671	0.553	rs11628785	chr14:70908217	G/A	cg25576086	chr14:70833871	SYNJ2BP	-0.35	-5.87	-0.31	1.05e-8	Prostate cancer;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.27	-0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.49	6.88	0.35	3.07e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.28	-0.37	2.53e-12	Mean corpuscular volume;
CRC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.29	-0.42	2.99e-15	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6694672	0.867	rs10922166	chr1:197080036	G/C	cg13682187	chr1:196946512	CFHR5	0.47	7.63	0.39	2.49e-13	Asthma;
CRC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-11.5	-0.54	5.74e-26	Alzheimer's disease;
CRC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11446398	chr5:77624930	NA	-0.41	-5.88	-0.31	1e-8	Triglycerides;
CRC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.58	-0.34	1.9e-10	Renal function-related traits (BUN);
CRC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.71	10.97	0.52	4.39e-24	Tonsillectomy;
CRC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg05941027	chr17:61774174	LIMD2	0.36	6.52	0.34	2.65e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02450064	chr17:40260053	DHX58	-0.43	-6.23	-0.32	1.44e-9	Fibrinogen levels;
CRC	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg00717180	chr2:96193071	NA	-0.39	-6.47	-0.34	3.53e-10	Coronary artery disease;
CRC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02290350	chr8:58132656	NA	-0.59	-8.03	-0.4	1.7e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.53	0.71	5.15e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6662572	0.737	rs6700974	chr1:46371735	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.85	-0.31	1.21e-8	Blood protein levels;
CRC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.13	0.52	1.21e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg05552183	chr6:42928497	GNMT	0.52	7.85	0.4	5.79e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.86	-13.84	-0.61	1.22e-34	Blood metabolite levels;
CRC	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.61	6.28	0.33	1.09e-9	Breast cancer;
CRC	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	6.66	0.34	1.18e-10	Blood metabolite levels;
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-0.57	-7.96	-0.4	2.76e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.62	-0.34	1.44e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.14	-0.32	2.32e-9	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.43	6.07	0.32	3.43e-9	Body mass index;
CRC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.68	-0.47	1.15e-19	Personality dimensions;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.1	-13.98	-0.61	3.57e-35	Vitiligo;
CRC	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.08	0.32	3.36e-9	Blood protein levels;
CRC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.67	-0.3	3.15e-8	Migraine;Coronary artery disease;
CRC	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.68	-0.3	2.97e-8	Daytime sleep phenotypes;
CRC	cis	rs17065868	0.764	rs9533851	chr13:45015430	A/T	cg10246903	chr13:45222710	NA	0.58	5.65	0.3	3.45e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.45	6.41	0.33	4.92e-10	Fibrinogen levels;
CRC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.63	0.7	1.96e-49	Platelet count;
CRC	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.79	-11.22	-0.53	5.72e-25	Pulse pressure;
CRC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.11e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs1223397	0.938	rs9381884	chr6:13278788	A/G	cg20827128	chr6:13274284	PHACTR1	0.51	6.32	0.33	8.27e-10	Blood pressure;
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.4	8.16	0.41	7.41e-15	Bipolar disorder;
CRC	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg07212818	chr11:638076	DRD4	-0.44	-5.78	-0.3	1.73e-8	Systemic lupus erythematosus;
CRC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg20607287	chr7:12443886	VWDE	0.57	7.27	0.37	2.68e-12	Coronary artery disease;
CRC	cis	rs12476592	0.602	rs262484	chr2:63878015	A/G	cg10828910	chr2:63850056	LOC388955	0.48	6.06	0.32	3.74e-9	Childhood ear infection;
CRC	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.5	-0.38	6e-13	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs9465187	0.542	rs2208859	chr6:18699420	A/G	cg11414540	chr19:19313888	NR2C2AP	0.47	6.06	0.32	3.64e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	7.17	0.37	5.06e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6088813	1.000	rs6088813	chr20:33975181	C/A	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs2811415	0.627	rs1984451	chr3:127768462	C/G	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg00071950	chr4:10020882	SLC2A9	0.44	6.92	0.36	2.4e-11	Blood metabolite levels;
CRC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.14	-0.37	5.86e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.66	-6.35	-0.33	7.01e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.42	6.95	0.36	1.93e-11	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07940793	chr17:79603854	NPLOC4	0.38	5.98	0.31	5.84e-9	Obesity-related traits;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg25164649	chr6:28176230	NA	0.62	8.87	0.44	4.75e-17	Cardiac Troponin-T levels;
CRC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.24	0.67	5.52e-44	Chronic sinus infection;
CRC	cis	rs73206853	0.764	rs76142162	chr12:110884307	C/G	cg12870014	chr12:110450643	ANKRD13A	0.83	9.91	0.48	1.94e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.41	-6.43	-0.33	4.62e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.79	9.67	0.47	1.27e-19	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.64	11.87	0.55	2.79e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg06970220	chr1:156163860	SLC25A44	0.52	7.56	0.38	4.01e-13	Testicular germ cell tumor;
CRC	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg04439458	chr5:138467593	SIL1	-0.34	-5.8	-0.3	1.55e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg09127314	chr1:152161683	NA	0.5	6.59	0.34	1.75e-10	Atopic dermatitis;
CRC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.44	6.67	0.34	1.11e-10	N-glycan levels;
CRC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.45	-0.42	9.43e-16	Height;
CRC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg13402217	chr1:151584375	SNX27	0.49	6.1	0.32	2.9e-9	Plasma plasminogen activator levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12868349	chr11:71639594	RNF121;LOC100133315	0.5	7.24	0.37	3.27e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-8.01	-0.4	2.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.05	0.32	3.89e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.32	4.65e-9	Morning vs. evening chronotype;
CRC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.39	-8.62	-0.43	2.89e-16	Eye color traits;
CRC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.91	-14.4	-0.62	8.62e-37	Response to temozolomide;
CRC	cis	rs500492	0.508	rs2744147	chr16:1073146	C/G	cg09274344	chr16:1078689	NA	0.39	6.34	0.33	7.65e-10	Polycystic ovary syndrome;
CRC	cis	rs8040855	0.627	rs12905036	chr15:85637788	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-5.65	-0.3	3.41e-8	Bulimia nervosa;
CRC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.59	6.45	0.33	4.05e-10	Initial pursuit acceleration;
CRC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.82	14.5	0.62	3.42e-37	Metabolic syndrome;
CRC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.66	9.6	0.47	2.1e-19	Menopause (age at onset);
CRC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg06987292	chr12:125626746	AACS	0.36	5.64	0.3	3.61e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.48	-9.03	-0.45	1.43e-17	Intelligence (multi-trait analysis);
CRC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.53	-9.51	-0.46	4.11e-19	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs8170	1.000	rs10425939	chr19:17397244	C/T	cg04749549	chr19:17459798	NA	-0.44	-5.84	-0.31	1.23e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CRC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg07718321	chr6:96025334	MANEA	-0.54	-6.91	-0.36	2.55e-11	Behavioural disinhibition (generation interaction);
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-8.25	-0.41	3.95e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10878977	1.000	rs17106576	chr12:69823491	T/G	cg20891283	chr12:69753455	YEATS4	-0.5	-6.42	-0.33	4.86e-10	Colorectal cancer;
CRC	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.47	5.62	0.3	4.12e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg19812747	chr11:111475976	SIK2	0.53	7.65	0.39	2.23e-13	Primary sclerosing cholangitis;
CRC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg18876405	chr7:65276391	NA	0.46	6.34	0.33	7.75e-10	Aortic root size;
CRC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.47	0.73	1.07e-56	Prudent dietary pattern;
CRC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg18455616	chr2:99124870	INPP4A	0.36	5.86	0.31	1.14e-8	Bipolar disorder;
CRC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.39	-0.33	5.65e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg15043615	chr17:74025708	NA	-0.46	-6.15	-0.32	2.26e-9	Parkinson's disease;
CRC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg24209194	chr3:40518798	ZNF619	0.43	6.56	0.34	2.05e-10	Renal cell carcinoma;
CRC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg01392867	chr16:30410429	ZNF48	-0.36	-5.69	-0.3	2.83e-8	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03662467	chr18:43753538	C18orf25	0.45	6.29	0.33	9.84e-10	Response to antipsychotic treatment;
CRC	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.36	-6.88	-0.35	3.1e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs12024301	0.557	rs59983196	chr1:183591797	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2303319	0.504	rs12465645	chr2:162437639	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.01	-0.31	4.93e-9	Cognitive function;
CRC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.58	10.55	0.5	1.29e-22	Multiple system atrophy;
CRC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	16.03	0.66	3.81e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs731174	0.797	rs539585	chr1:38148123	T/G	cg06917450	chr1:38156652	C1orf109	-0.52	-7.23	-0.37	3.42e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2982552	0.844	rs3020346	chr6:152056771	C/T	cg22157087	chr6:152012887	ESR1	-0.4	-6.17	-0.32	1.96e-9	Bone properties (heel);
CRC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.65	10.27	0.49	1.21e-21	Colorectal cancer;
CRC	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	cg04338863	chr8:33670619	NA	0.44	6.95	0.36	1.96e-11	Body mass index;
CRC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.62	8.91	0.44	3.54e-17	Inflammatory bowel disease;
CRC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.3	6.05	0.32	3.93e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.85	11.63	0.54	2.03e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.47	6.63	0.34	1.42e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.62	10.33	0.49	7.53e-22	Prostate cancer;
CRC	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.47	7.45	0.38	8.11e-13	Body mass index;
CRC	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	6.89	0.36	2.81e-11	Menarche (age at onset);
CRC	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.6	6.81	0.35	4.71e-11	Osteoarthritis;
CRC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg25204440	chr1:209979598	IRF6	0.49	6.89	0.36	2.78e-11	Cleft lip with or without cleft palate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01860201	chr4:75720019	BTC	0.39	6.01	0.31	5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs939584	0.935	rs13387939	chr2:637498	C/A	cg03610516	chr2:642275	NA	0.43	5.77	0.3	1.82e-8	Body mass index;
CRC	cis	rs7731657	0.537	rs2419756	chr5:130259779	T/C	cg08523029	chr5:130500466	HINT1	0.43	5.7	0.3	2.61e-8	Fasting plasma glucose;
CRC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.76	16.49	0.67	5.94e-45	Breast cancer;
CRC	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg05784532	chr1:230284198	GALNT2	0.43	5.79	0.3	1.66e-8	Coronary artery disease;
CRC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg03037974	chr15:76606532	NA	0.66	11.49	0.54	6.38e-26	Blood metabolite levels;
CRC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-6.55	-0.34	2.19e-10	Neuroticism;
CRC	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05962382	chr2:130345044	NA	-0.44	-7.61	-0.39	2.86e-13	Response to cytidine analogues (gemcitabine);
CRC	cis	rs7487075	0.619	rs10785627	chr12:46824229	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.66	0.3	3.29e-8	Itch intensity from mosquito bite;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	trans	rs2295389	0.932	rs4900478	chr14:101315481	A/C	cg27513308	chr1:32797653	HDAC1	0.32	6.0	0.31	5.35e-9	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20284698	chr3:48956327	C3orf71;ARIH2	0.4	7.41	0.38	1.1e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23161317	chr6:28129485	ZNF389	0.5	6.21	0.32	1.57e-9	Depression;
CRC	cis	rs6496667	0.821	rs6496674	chr15:90976340	G/T	cg04176472	chr15:90893244	GABARAPL3	0.59	7.97	0.4	2.62e-14	Rheumatoid arthritis;
CRC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.6	-7.97	-0.4	2.7e-14	Schizophrenia;
CRC	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg13160058	chr8:26243215	BNIP3L	-0.49	-7.98	-0.4	2.47e-14	Red cell distribution width;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg03183877	chr10:27444699	YME1L1;MASTL	-0.41	-5.97	-0.31	6.22e-9	Daytime sleep phenotypes;
CRC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg11522145	chr4:3412961	RGS12	-0.4	-6.07	-0.32	3.46e-9	Serum sulfate level;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25699533	chr19:18682841	UBA52	0.49	6.98	0.36	1.62e-11	Response to antipsychotic treatment;
CRC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg07952391	chr2:88470173	THNSL2	-0.39	-5.73	-0.3	2.28e-8	Response to metformin (IC50);
CRC	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.95	-15.04	-0.64	2.78e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-10.79	-0.51	1.91e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs16845960	chr2:162501613	A/G	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.67	7.61	0.39	2.99e-13	Vitiligo;
CRC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.12	0.71	2.23e-51	Cognitive ability;
CRC	trans	rs4714291	0.674	rs3008837	chr6:40046725	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-6.06	-0.32	3.81e-9	Strep throat;
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.4	7.67	0.39	1.98e-13	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.67	-0.39	1.94e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.54	8.59	0.43	3.5e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.44	-6.44	-0.33	4.26e-10	Height;
CRC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.34	-9.55	-0.47	3.1400000000000002e-19	Mean corpuscular volume;
CRC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.42	0.59	4.69e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	1.04	18.16	0.71	1.47e-51	Parkinson's disease;
CRC	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg26353448	chr1:248524236	OR2T4	-0.33	-6.33	-0.33	8.18e-10	Common traits (Other);
CRC	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg14191688	chr11:70257035	CTTN	0.51	6.3	0.33	9.8e-10	Coronary artery disease;
CRC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg18490616	chr2:88469792	THNSL2	-0.39	-5.66	-0.3	3.28e-8	Response to metformin (IC50);
CRC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg23565292	chr14:50234668	KLHDC2	-0.43	-6.16	-0.32	2.13e-9	Carotid intima media thickness;
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.56	0.54	3.69e-26	Prudent dietary pattern;
CRC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.33	-0.33	7.89e-10	Parkinson's disease;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg21709803	chr11:61594965	FADS2	-0.57	-6.73	-0.35	7.66e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.68	10.35	0.5	6.37e-22	Corneal astigmatism;
CRC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.46e-11	Aortic root size;
CRC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg16606324	chr3:10149918	C3orf24	0.47	7.29	0.37	2.29e-12	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13937841	chr10:28821190	WAC	0.46	5.97	0.31	6.17e-9	Thyroid stimulating hormone;
CRC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.73	-8.38	-0.42	1.56e-15	Obesity-related traits;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.46	5.66	0.3	3.31e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.53	10.91	0.52	7.53e-24	Bone mineral density;
CRC	cis	rs2857891	0.695	rs2468986	chr11:6986027	G/C	cg04053776	chr11:6947353	ZNF215	0.37	5.73	0.3	2.22e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4731207	0.697	rs4360235	chr7:124526542	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08929303	chr1:207227076	PFKFB2	0.31	6.53	0.34	2.44e-10	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05663655	chr7:107532014	DLD	0.48	6.23	0.32	1.4e-9	Thyroid stimulating hormone;
CRC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17507749	chr15:85114479	UBE2QP1	0.64	9.4	0.46	9.36e-19	Schizophrenia;
CRC	cis	rs526821	0.553	rs510095	chr11:55289154	T/C	cg04317927	chr11:55418816	OR4S2	0.41	6.81	0.35	4.52e-11	Pediatric bone mineral density (spine);
CRC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.99	-0.31	5.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.55	7.1	0.36	7.68e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.3	-0.33	9.56e-10	Dupuytren's disease;
CRC	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.84	-11.77	-0.54	6.09e-27	Gout;
CRC	cis	rs2857891	1.000	rs2857891	chr11:6962957	C/T	cg04053776	chr11:6947353	ZNF215	0.5	6.87	0.35	3.21e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17808901	chr3:39093368	WDR48	0.46	6.73	0.35	7.36e-11	Response to antipsychotic treatment;
CRC	cis	rs73206853	0.563	rs7960749	chr12:111164369	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	8.89	0.44	4.07e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.83	0.31	1.29e-8	Life satisfaction;
CRC	cis	rs9292777	0.704	rs348594	chr5:40323938	A/G	cg09067459	chr5:40385259	NA	-0.55	-9.56	-0.47	2.88e-19	Crohn's disease;Multiple sclerosis;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.4	0.38	1.17e-12	Obesity-related traits;
CRC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.78	0.39	9.69e-14	Resting heart rate;
CRC	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.49	-7.0	-0.36	1.48e-11	Large artery stroke;
CRC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg24675056	chr1:15929824	NA	0.47	6.17	0.32	2.03e-9	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17002091	chr14:100772763	SLC25A29;MIR345	0.45	6.32	0.33	8.35e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26861593	chr1:161195893	TOMM40L	0.46	6.59	0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.35	6.29	0.33	1.04e-9	Crohn's disease;
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.54	-9.84	-0.48	3.43e-20	Bipolar disorder;
CRC	cis	rs7259376	0.748	rs1230305	chr19:22641917	C/T	cg02657401	chr19:22469223	NA	-0.35	-7.55	-0.38	4.19e-13	Menopause (age at onset);
CRC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.78	-11.01	-0.52	3.31e-24	Multiple sclerosis;
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg22110888	chr17:80059540	CCDC57	0.4	6.45	0.34	3.95e-10	Life satisfaction;
CRC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg21665744	chr7:39171113	POU6F2	0.45	5.93	0.31	7.73e-9	IgG glycosylation;
CRC	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.46	5.97	0.31	6.09e-9	Exhaled nitric oxide output;
CRC	cis	rs4964805	0.954	rs11111785	chr12:104189056	A/G	cg02344784	chr12:104178138	NT5DC3	0.56	8.51	0.42	6.45e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs1322512	0.837	rs2800627	chr6:153006507	C/A	cg03415253	chr6:152958462	SYNE1	0.4	6.03	0.32	4.39e-9	Tonometry;
CRC	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-8.49	-0.42	6.98e-16	HDL cholesterol;
CRC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg23298862	chr7:158159286	PTPRN2	-0.48	-7.91	-0.4	3.98e-14	Calcium levels;
CRC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.59	9.77	0.47	5.65e-20	Menopause (age at onset);
CRC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.59	9.18	0.45	4.97e-18	Tuberculosis;
CRC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-14.06	-0.61	1.68e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.62	10.5	0.5	1.92e-22	Prudent dietary pattern;
CRC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.61	8.79	0.44	8.32e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6694672	0.681	rs615647	chr1:197188908	T/C	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.36	2.31e-11	Asthma;
CRC	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.72	-7.48	-0.38	7.03e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg27661571	chr11:113659931	NA	-0.9	-10.42	-0.5	3.66e-22	Hip circumference adjusted for BMI;
CRC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.39	5.76	0.3	1.88e-8	Total body bone mineral density;
CRC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.68	9.81	0.48	4.26e-20	Multiple sclerosis;
CRC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.53	6.24	0.33	1.33e-9	Psoriasis;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.37	-6.53	-0.34	2.53e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.45	6.29	0.33	1.03e-9	Schizophrenia;
CRC	cis	rs12900413	0.687	rs35060998	chr15:90310294	A/G	cg24249390	chr15:90295951	MESP1	-0.58	-9.29	-0.46	2.2e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.38	-8.89	-0.44	3.97e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg07217954	chr7:1067459	C7orf50	0.55	5.71	0.3	2.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.2	-0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg18876405	chr7:65276391	NA	0.47	6.57	0.34	1.94e-10	Aortic root size;
CRC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg03037974	chr15:76606532	NA	0.63	10.79	0.51	1.93e-23	Blood metabolite levels;
CRC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-12.44	-0.57	2.29e-29	Electrocardiographic conduction measures;
CRC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.49	9.23	0.45	3.38e-18	Reticulocyte fraction of red cells;
CRC	cis	rs2346160	0.867	rs206975	chr6:167690356	A/G	cg04673565	chr6:167680447	NA	-0.38	-6.52	-0.34	2.64e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg19338460	chr6:170058176	WDR27	-0.73	-7.89	-0.4	4.53e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg11693508	chr17:37793320	STARD3	0.48	6.47	0.34	3.46e-10	Neuroticism;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg20024234	chr21:43431083	ZNF295	-0.68	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.13e-17	Dupuytren's disease;
CRC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.48	-7.51	-0.38	5.59e-13	Height;
CRC	trans	rs6472235	0.837	rs2357568	chr8:66917002	C/G	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.12	-0.32	2.62e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.65	0.3	3.51e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6586163	0.527	rs12775501	chr10:90750909	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.83	12.58	0.57	6.62e-30	Chronic lymphocytic leukemia;
CRC	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg00507830	chr2:103233733	NA	0.51	5.8	0.3	1.55e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.59	-9.42	-0.46	7.96e-19	Itch intensity from mosquito bite;
CRC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.48	-0.38	6.73e-13	Mean corpuscular volume;
CRC	trans	rs300774	0.841	rs410690	chr2:203346	G/A	cg02806739	chr17:80273242	CD7	-0.5	-6.01	-0.31	5.02e-9	Suicide attempts in bipolar disorder;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg04713951	chr22:38966166	DMC1	0.39	6.13	0.32	2.51e-9	Interleukin-6 levels;
CRC	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.47	6.83	0.35	4.22e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.17	-0.49	2.57e-21	Monocyte count;
CRC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg13628971	chr7:2884303	GNA12	0.42	6.19	0.32	1.82e-9	Height;
CRC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg03013999	chr17:37608204	MED1	-0.44	-6.8	-0.35	4.88e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.28	-14.82	-0.63	2.09e-38	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	5.84	0.31	1.25e-8	Prudent dietary pattern;
CRC	cis	rs7215564	0.730	rs2316066	chr17:78659785	A/G	cg09596252	chr17:78655493	RPTOR	0.53	5.66	0.3	3.26e-8	Myopia (pathological);
CRC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.19	11.11	0.52	1.43e-24	Intelligence (multi-trait analysis);
CRC	trans	rs1900442	0.536	rs1815346	chr13:42547580	A/G	cg02119577	chr21:40195074	ETS2	0.38	6.15	0.32	2.25e-9	Tuberculosis;
CRC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.54	-9.16	-0.45	5.61e-18	Iron status biomarkers;
CRC	cis	rs9463078	0.547	rs4714822	chr6:44742290	T/C	cg25276700	chr6:44698697	NA	0.3	7.76	0.39	1.09e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg04239558	chr2:103089729	SLC9A4	0.36	6.17	0.32	2.01e-9	Blood protein levels;
CRC	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg00290994	chr1:41848739	NA	-0.48	-7.21	-0.37	3.94e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.04	-0.32	4.25e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.47	0.42	8.2e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.58	10.64	0.51	6.62e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.22	-0.32	1.5e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.37	0.42	1.72e-15	Corneal astigmatism;
CRC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.29	0.33	1.02e-9	Lung cancer;
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.76e-22	Bipolar disorder;
CRC	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-6.51	-0.34	2.74e-10	Tuberculosis;
CRC	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.67	9.99	0.48	1.04e-20	Schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08931196	chr11:119205177	RNF26	-0.42	-6.38	-0.33	6.17e-10	Myopia (pathological);
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19046167	chr17:80928561	B3GNTL1	0.52	7.2	0.37	4.17e-12	Glycated hemoglobin levels;
CRC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	12.69	0.57	2.66e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12822507	0.783	rs10772585	chr12:12772733	T/C	cg11838227	chr12:12764436	CREBL2	0.41	5.62	0.3	4.09e-8	Systemic lupus erythematosus;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.26	-0.33	1.2e-9	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20919306	chr17:11924526	MAP2K4	0.37	6.07	0.32	3.61e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg06156847	chr2:113672199	IL1F7	-0.39	-5.99	-0.31	5.37e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg11843238	chr5:131593191	PDLIM4	0.42	6.95	0.36	1.91e-11	Breast cancer;
CRC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.64	9.87	0.48	2.78e-20	Corneal astigmatism;
CRC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.25	-0.41	3.84e-15	Bladder cancer;
CRC	cis	rs860295	0.702	rs10796943	chr1:155414729	T/C	cg02153340	chr1:155202674	NA	-0.58	-6.88	-0.35	3.04e-11	Body mass index;
CRC	cis	rs61996546	0.622	rs17560758	chr15:26836402	C/T	cg15066197	chr15:26874202	GABRB3	-0.39	-5.8	-0.3	1.58e-8	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg03030879	chr14:75389066	RPS6KL1	0.39	5.84	0.31	1.27e-8	Height;
CRC	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg15038512	chr6:170123185	PHF10	-0.39	-6.05	-0.32	3.86e-9	Obesity-related traits;
CRC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg02659138	chr7:134003124	SLC35B4	0.37	5.83	0.31	1.31e-8	Mean platelet volume;
CRC	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.27	-0.33	1.12e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg08222618	chr4:941054	TMEM175	-0.44	-7.07	-0.36	9.24e-12	Parkinson's disease;
CRC	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg01422370	chr2:73384389	NA	0.37	5.75	0.3	2.07e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.64	11.86	0.55	2.89e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.86	10.16	0.49	2.81e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.53	-7.75	-0.39	1.13e-13	White blood cell count;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg08501292	chr6:25962987	TRIM38	1.09	9.3	0.46	2.03e-18	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05001908	chr7:128045859	IMPDH1	0.44	7.35	0.38	1.61e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13404532	chr3:128483276	RAB7A	-0.37	-6.07	-0.32	3.6e-9	Obesity-related traits;
CRC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.48e-17	Morning vs. evening chronotype;
CRC	trans	rs11654801	0.947	rs3785544	chr17:20915515	C/T	cg23759823	chr7:139672531	TBXAS1	-0.47	-6.75	-0.35	6.86e-11	Mosquito bite size;
CRC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg25767906	chr1:53392781	SCP2	-0.51	-8.16	-0.41	7.02e-15	Monocyte count;
CRC	cis	rs7264396	0.887	rs6060435	chr20:34069370	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.39	6.6	0.34	1.61e-10	Total cholesterol levels;
CRC	cis	rs7259376	0.905	rs116632927	chr19:22562520	C/T	cg02657401	chr19:22469223	NA	-0.33	-7.19	-0.37	4.46e-12	Menopause (age at onset);
CRC	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.33	-0.71	3.23e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs12760731	0.668	rs10913532	chr1:178278692	A/G	cg00404053	chr1:178313656	RASAL2	0.7	8.98	0.44	2.19e-17	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg12463550	chr7:65579703	CRCP	0.71	6.54	0.34	2.33e-10	Diabetic kidney disease;
CRC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.67	12.36	0.56	4.4e-29	Total body bone mineral density;
CRC	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.55	-8.2	-0.41	5.46e-15	Vitiligo;
CRC	cis	rs4561483	0.583	rs12149833	chr16:12003723	C/T	cg08843971	chr16:11963173	GSPT1	0.5	7.46	0.38	7.84e-13	Testicular germ cell tumor;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg07167098	chr12:21654695	RECQL;GOLT1B	0.57	6.06	0.32	3.77e-9	Body mass index;
CRC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg25985355	chr7:65971099	NA	-0.48	-5.67	-0.3	3.12e-8	Diabetic kidney disease;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.48	7.32	0.37	1.89e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg21854759	chr1:92012499	NA	0.47	6.2	0.32	1.73e-9	Eosinophil percentage of white cells;
CRC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.55	8.6	0.43	3.21e-16	Aortic root size;
CRC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.18	0.56	1.98e-28	Menopause (age at onset);
CRC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.1	0.32	3e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7619833	0.620	rs13085724	chr3:27258758	C/T	cg02860705	chr3:27208620	NA	0.39	6.13	0.32	2.54e-9	Breast cancer;
CRC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.52	-7.71	-0.39	1.54e-13	Uric acid clearance;
CRC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	8.97	0.44	2.27e-17	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg17724175	chr1:150552817	MCL1	-0.54	-8.69	-0.43	1.75e-16	Tonsillectomy;
CRC	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.4	-6.3	-0.33	9.39e-10	Caffeine consumption;
CRC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.76	-0.35	6.22e-11	Colorectal cancer;
CRC	cis	rs995000	0.931	rs1168089	chr1:63113719	T/C	cg19896129	chr1:63156450	NA	-0.4	-6.23	-0.32	1.4e-9	Triglyceride levels;
CRC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.63	-10.04	-0.48	7.43e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06307176	chr5:131281290	NA	0.43	6.36	0.33	6.62e-10	Life satisfaction;
CRC	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	0.96	18.57	0.72	3.66e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs17227506	0.730	rs36106719	chr8:13457693	G/C	cg03566418	chr8:13424080	C8orf48	0.39	6.47	0.34	3.53e-10	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	trans	rs2216228	1.000	rs16924758	chr12:22364519	C/T	cg07476617	chr2:201981834	CFLAR	0.5	6.0	0.31	5.26e-9	Non-alcoholic fatty liver disease histology (lobular);
CRC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.73	0.63	4.68e-38	Chronic sinus infection;
CRC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	8.55	0.43	4.65e-16	Electrocardiographic conduction measures;
CRC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.68	-10.9	-0.52	7.79e-24	Motion sickness;
CRC	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg06219351	chr7:158114137	PTPRN2	-0.61	-9.78	-0.47	5.22e-20	Calcium levels;
CRC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.34e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.54	8.26	0.41	3.49e-15	Testicular germ cell tumor;
CRC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg01721255	chr8:58191610	C8orf71	0.48	5.89	0.31	9.6e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17767392	0.958	rs10483836	chr14:72001614	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.92	-0.36	2.34e-11	Mitral valve prolapse;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg01191114	chr3:48936118	SLC25A20	-0.68	-6.16	-0.32	2.14e-9	Cognitive function;
CRC	cis	rs11673344	0.583	rs10425719	chr19:37950798	C/G	cg11669319	chr19:37771680	NA	-0.41	-5.78	-0.3	1.73e-8	Obesity-related traits;
CRC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.38	0.42	1.57e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.31	-6.71	-0.35	8.36e-11	Educational attainment (years of education);
CRC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.21	-0.32	1.63e-9	Acne (severe);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24725560	chr11:32605793	EIF3M	0.43	6.14	0.32	2.34e-9	Response to antipsychotic treatment;
CRC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.5	-7.67	-0.39	2.01e-13	Body mass index;
CRC	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.51	-0.34	2.79e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg08314208	chr16:67682810	RLTPR	-0.55	-6.14	-0.32	2.34e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.55	-8.06	-0.41	1.43e-14	Platelet distribution width;
CRC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg20203395	chr5:56204925	C5orf35	-0.74	-8.3	-0.42	2.82e-15	Initial pursuit acceleration;
CRC	cis	rs73206853	0.563	rs16940950	chr12:111136459	A/G	cg12870014	chr12:110450643	ANKRD13A	0.8	9.08	0.45	1.04e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9467160	0.834	rs10946701	chr6:24453878	T/A	cg20631270	chr6:24437470	GPLD1	0.46	6.3	0.33	9.53e-10	Liver enzyme levels;
CRC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.46e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg14541582	chr5:601475	NA	0.36	7.27	0.37	2.63e-12	Obesity-related traits;
CRC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.74	-11.62	-0.54	2.27e-26	Platelet distribution width;
CRC	cis	rs73200209	0.744	rs56159580	chr12:116420448	T/C	cg01776926	chr12:116560359	MED13L	-0.68	-7.83	-0.4	6.65e-14	Total body bone mineral density;
CRC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.57	-0.34	1.96e-10	Coronary artery disease;
CRC	cis	rs2298450	0.550	rs9977284	chr21:37654627	T/A	cg02919814	chr21:37666008	DOPEY2	-0.44	-6.43	-0.33	4.4e-10	Schizophrenia;
CRC	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg10437265	chr15:77819839	NA	-0.53	-9.25	-0.45	2.83e-18	Type 2 diabetes;
CRC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg23461800	chr14:103021989	NA	-0.7	-8.03	-0.4	1.73e-14	Platelet count;
CRC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	10.18	0.49	2.38e-21	Total body bone mineral density;
CRC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.84	0.31	1.28e-8	Hemoglobin concentration;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg04053776	chr11:6947353	ZNF215	0.51	6.84	0.35	3.86e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.82	-0.35	4.26e-11	Neuroticism;
CRC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.84	10.38	0.5	4.98e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.97	18.69	0.72	1.23e-53	Gut microbiome composition (winter);
CRC	cis	rs939584	1.000	rs12714414	chr2:651407	A/G	cg03610516	chr2:642275	NA	-0.43	-5.97	-0.31	6.25e-9	Body mass index;
CRC	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06307176	chr5:131281290	NA	0.5	7.06	0.36	1.01e-11	Life satisfaction;
CRC	cis	rs35883536	1.000	rs871151	chr1:101123737	G/A	cg14515779	chr1:101123966	NA	-0.45	-8.79	-0.44	8.55e-17	Monocyte count;
CRC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.57	7.23	0.37	3.34e-12	Vitamin D levels;
CRC	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg25019722	chr6:37503610	NA	-0.41	-6.86	-0.35	3.47e-11	Cognitive performance;
CRC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg00255919	chr5:131827918	IRF1	-0.35	-5.75	-0.3	2.06e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg22687807	chr8:143858763	LYNX1	-0.37	-6.47	-0.34	3.46e-10	Urinary tract infection frequency;
CRC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.51	6.23	0.33	1.39e-9	Recombination rate (females);
CRC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.14	0.37	6.09e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.57	9.92	0.48	1.85e-20	Age of smoking initiation;
CRC	cis	rs4604732	0.603	rs10802513	chr1:247633919	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.4	6.61	0.34	1.59e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	6.2	0.32	1.67e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.57	-9.0	-0.44	1.79e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg14074117	chr16:1909714	C16orf73	-0.4	-5.63	-0.3	3.84e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg09163369	chr1:210001066	C1orf107	-0.49	-6.67	-0.35	1.07e-10	Orofacial clefts;
CRC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.69	8.29	0.42	2.97e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg00919237	chr7:87102261	ABCB4	-0.5	-6.59	-0.34	1.7e-10	Gallbladder cancer;
CRC	cis	rs10905065	0.930	rs10737012	chr10:5746686	G/A	cg11519256	chr10:5708881	ASB13	0.44	6.33	0.33	7.84e-10	Menopause (age at onset);
CRC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	8.55	0.43	4.67e-16	Gut microbiome composition (summer);
CRC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.59	0.34	1.72e-10	Tonsillectomy;
CRC	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.36	-5.67	-0.3	3.21e-8	Height;
CRC	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.44	-6.6	-0.34	1.65e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02290350	chr8:58132656	NA	-0.57	-6.64	-0.34	1.28e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg16358738	chr2:241808595	AGXT	-0.41	-6.0	-0.31	5.17e-9	Urinary metabolites;
CRC	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg02258303	chr16:87377426	FBXO31	-0.49	-7.35	-0.38	1.63e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs6681460	0.966	rs7524851	chr1:67093018	T/C	cg02459107	chr1:67143332	SGIP1	0.43	7.07	0.36	9.07e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.19	0.45	4.44e-18	Bladder cancer;
CRC	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg12908607	chr1:44402522	ARTN	-0.38	-6.33	-0.33	8.09e-10	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.56	8.35	0.42	1.92e-15	Hemoglobin concentration;
CRC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.73	-9.18	-0.45	4.8e-18	Initial pursuit acceleration;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.6	7.5	0.38	5.83e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.0	-0.31	5.3e-9	Monocyte percentage of white cells;
CRC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	7.95	0.4	3.02e-14	Colorectal cancer;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.87	-16.07	-0.66	2.67e-43	Coronary artery disease;
CRC	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.46	-7.39	-0.38	1.26e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs9292777	0.777	rs10512734	chr5:40393605	C/T	cg09067459	chr5:40385259	NA	0.54	8.82	0.44	6.64e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg06470822	chr6:28175283	NA	0.71	10.02	0.48	8.63e-21	Parkinson's disease;
CRC	cis	rs2565722	0.622	rs57300662	chr6:161301965	A/G	cg03159191	chr6:161285451	NA	-0.46	-6.28	-0.33	1.07e-9	Blood protein levels;
CRC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.37	0.42	1.66e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	-0.55	-9.23	-0.45	3.27e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1519814	0.915	rs6992410	chr8:121113566	T/G	cg22335954	chr8:121166405	COL14A1	-0.55	-6.23	-0.32	1.45e-9	Breast cancer;
CRC	cis	rs12476592	0.602	rs11898615	chr2:63748284	C/A	cg10828910	chr2:63850056	LOC388955	0.47	5.96	0.31	6.67e-9	Childhood ear infection;
CRC	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.43	6.39	0.33	5.61e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.19	0.41	5.89e-15	Bladder cancer;
CRC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.46	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.62	8.01	0.4	2.01e-14	Chronic kidney disease;
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.7	-9.5	-0.46	4.53e-19	Alzheimer's disease;
CRC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.73	-0.35	7.76e-11	Alzheimer's disease (late onset);
CRC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg17724175	chr1:150552817	MCL1	0.43	6.5	0.34	2.96e-10	Melanoma;
CRC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.92	-0.36	2.41e-11	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14233568	chr2:65216118	SLC1A4	0.4	6.16	0.32	2.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-8.54	-0.43	5.04e-16	Mean platelet volume;
CRC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.31	0.37	2.04e-12	Total body bone mineral density;
CRC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.46	6.55	0.34	2.25e-10	Response to temozolomide;
CRC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.57	-8.53	-0.43	5.56e-16	Menopause (age at onset);
CRC	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.82	10.66	0.51	5.69e-23	Diisocyanate-induced asthma;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg10194655	chr12:110841920	ANAPC7	-0.39	-6.27	-0.33	1.14e-9	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg17365369	chr19:52773256	ZNF766	-0.41	-6.02	-0.31	4.78e-9	Myopia (pathological);
CRC	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.85	13.08	0.58	9.14e-32	Ulcerative colitis;
CRC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.84	-14.29	-0.62	2.17e-36	Coronary artery disease;
CRC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg06494592	chr3:125709126	NA	-0.56	-6.78	-0.35	5.66e-11	Blood pressure (smoking interaction);
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.2	-0.37	4.11e-12	Bipolar disorder;
CRC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.05	-0.32	3.97e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg03732007	chr1:2071316	PRKCZ	0.4	6.65	0.34	1.2e-10	Height;
CRC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.75	13.23	0.59	2.56e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.36	5.65	0.3	3.5e-8	Reticulocyte fraction of red cells;
CRC	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.73	0.47	8.05e-20	Fuchs's corneal dystrophy;
CRC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.71	12.8	0.58	1.04e-30	Coronary artery disease;
CRC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.5	7.58	0.39	3.65e-13	Asthma;
CRC	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg26875233	chr11:93583750	C11orf90	-0.33	-6.38	-0.33	6.15e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs77861329	1.000	rs9857878	chr3:52109668	A/G	cg08692210	chr3:52188851	WDR51A	-0.84	-7.16	-0.37	5.43e-12	Macrophage inflammatory protein 1b levels;
CRC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.63	-0.34	1.39e-10	Eye color traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02326931	chr13:37572901	ALG5	0.48	6.03	0.32	4.37e-9	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg25164649	chr6:28176230	NA	0.66	8.19	0.41	6.02e-15	Parkinson's disease;
CRC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.41	6.71	0.35	8.55e-11	Resting heart rate;
CRC	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg20041105	chr8:143859282	LYNX1	-0.32	-5.65	-0.3	3.45e-8	Urinary tract infection frequency;
CRC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.52	-8.23	-0.41	4.52e-15	Neurofibrillary tangles;
CRC	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg08992911	chr2:238395768	MLPH	0.61	6.19	0.32	1.8e-9	Prostate cancer;
CRC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg20908204	chr19:46285434	DMPK	0.38	8.34	0.42	2.02e-15	Coronary artery disease;
CRC	cis	rs4804155	0.590	rs17766692	chr19:11342599	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.83	8.46	0.42	8.6e-16	HDL cholesterol;Total cholesterol levels;
CRC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg17321639	chr7:2759063	NA	-0.38	-5.68	-0.3	3.04e-8	Height;
CRC	cis	rs4731207	0.698	rs4422720	chr7:124499402	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.44	6.35	0.33	6.95e-10	Asthma;
CRC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.43	9.95	0.48	1.43e-20	Coronary artery disease;
CRC	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg06953865	chr19:18549723	ISYNA1	-0.37	-5.65	-0.3	3.56e-8	Breast cancer;
CRC	cis	rs9515201	1.000	rs9515201	chr13:111040798	A/C	cg18114040	chr13:111062247	COL4A2	-0.33	-5.82	-0.31	1.43e-8	White matter hyperintensity burden;
CRC	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg04586622	chr2:25135609	ADCY3	-0.58	-9.72	-0.47	8.37e-20	Body mass index;
CRC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.6	8.52	0.43	5.77e-16	Alcohol dependence;
CRC	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07636037	chr3:49044803	WDR6	0.6	7.25	0.37	2.91e-12	Menarche (age at onset);
CRC	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.39	5.98	0.31	5.73e-9	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10753582	chr1:170043676	KIFAP3	0.43	6.24	0.33	1.36e-9	Response to antipsychotic treatment;
CRC	cis	rs6700896	0.931	rs79050868	chr1:66120916	G/A	cg04111102	chr1:66153794	NA	0.34	5.92	0.31	8.22e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.88	14.23	0.62	3.93e-36	Blood metabolite levels;
CRC	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg25547332	chr5:131281432	NA	0.39	5.69	0.3	2.79e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	25.06	0.81	2.91e-78	IgG glycosylation;
CRC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.57	8.33	0.42	2.29e-15	Tuberculosis;
CRC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.54	-0.34	2.31e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.65	8.2	0.41	5.55e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.6	-8.22	-0.41	4.79e-15	Inflammatory bowel disease;
CRC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.78	9.46	0.46	5.95e-19	Lung function (FEV1/FVC);
CRC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg26395211	chr5:140044315	WDR55	0.38	5.62	0.3	4.01e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7572644	0.640	rs4583413	chr2:28074824	C/T	cg27432699	chr2:27873401	GPN1	0.45	6.1	0.32	3.03e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.46	7.01	0.36	1.35e-11	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg23387468	chr7:139079360	LUC7L2	-0.4	-6.82	-0.35	4.27e-11	Diisocyanate-induced asthma;
CRC	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.17	0.59	4.3e-32	Hip circumference;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs2949837	0.581	rs1542819	chr7:45978059	T/C	cg23193639	chr7:45961078	IGFBP3	0.4	6.66	0.34	1.14e-10	Sitting height ratio;
CRC	cis	rs2933343	1.000	rs876756	chr3:128627623	G/A	cg11901034	chr3:128598214	ACAD9	-0.51	-6.12	-0.32	2.73e-9	IgG glycosylation;
CRC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.37	5.92	0.31	8.07e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	5.68	0.3	3e-8	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02451362	chr17:79885650	LOC92659;MAFG	0.44	6.02	0.31	4.68e-9	Anxiety disorder;
CRC	cis	rs6427782	0.521	rs6670899	chr1:199891438	C/A	cg07208853	chr1:200005219	NR5A2	0.22	5.72	0.3	2.41e-8	Menarche (age at onset);
CRC	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.14	0.45	6.58e-18	Coffee consumption (cups per day);
CRC	cis	rs7113874	0.569	rs10160430	chr11:8599876	G/T	cg20771178	chr11:8615675	STK33	0.35	5.73	0.3	2.26e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	6.03	0.32	4.39e-9	Schizophrenia;
CRC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.58	-0.34	1.87e-10	Menopause (age at onset);
CRC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg03844506	chr4:4109441	NA	-0.51	-7.57	-0.39	3.88e-13	Blood pressure (smoking interaction);
CRC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.46	-6.79	-0.35	5.17e-11	Systemic lupus erythematosus;
CRC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.82	15.15	0.64	1.05e-39	Mean platelet volume;
CRC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-6.98	-0.36	1.61e-11	Total body bone mineral density;
CRC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg15226275	chr6:116381976	FRK	0.3	8.69	0.43	1.78e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.41	-5.7	-0.3	2.61e-8	Intelligence;
CRC	cis	rs2249694	0.520	rs7095996	chr10:135328948	G/A	cg20169779	chr10:135381914	SYCE1	-0.55	-7.68	-0.39	1.85e-13	Obesity-related traits;
CRC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.56	-10.05	-0.48	6.82e-21	Educational attainment;
CRC	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg09654669	chr8:57350985	NA	-0.43	-6.77	-0.35	5.89e-11	Obesity-related traits;
CRC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24308560	chr3:49941425	MST1R	0.44	6.94	0.36	2.05e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1572438	0.760	rs7766714	chr6:869519	C/T	cg13447295	chr6:887704	NA	-0.49	-7.11	-0.36	7.39e-12	Aging;
CRC	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.19	0.49	2.2e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg02135003	chr7:105160482	PUS7	-0.54	-8.33	-0.42	2.23e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg26205652	chr12:48591994	NA	0.47	5.92	0.31	8.15e-9	Longevity (90 years and older);
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg01216370	chr2:228736459	WDR69	-0.45	-5.69	-0.3	2.8e-8	Blood pressure;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg21620606	chr4:1342894	KIAA1530	0.35	6.15	0.32	2.19e-9	Obesity-related traits;
CRC	cis	rs10242455	0.557	rs57830676	chr7:99281363	C/T	cg18809830	chr7:99032528	PTCD1	-0.99	-7.58	-0.39	3.64e-13	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10355997	chr15:50647554	GABPB1;FLJ10038;LOC100129387	0.43	6.16	0.32	2.08e-9	Response to antipsychotic treatment;
CRC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.31	0.42	2.62e-15	Retinal vascular caliber;
CRC	cis	rs60871478	0.786	rs12536056	chr7:831351	T/A	cg13844804	chr7:814759	HEATR2	-0.65	-7.39	-0.38	1.25e-12	Cerebrospinal P-tau181p levels;
CRC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.43	7.37	0.38	1.35e-12	Major depressive disorder;
CRC	cis	rs1950626	0.833	rs34463495	chr14:101411186	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	16.09	0.66	2.16e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.48	6.9	0.36	2.68e-11	Cognitive ability;
CRC	cis	rs12249377	0.519	rs12259060	chr10:92579949	A/G	cg14313238	chr10:92632228	RPP30	0.48	6.58	0.34	1.81e-10	White matter microstructure (global fractional anisotropy);
CRC	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.26	-0.41	3.58e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9549260	0.876	rs9549258	chr13:41248026	T/C	cg21288729	chr13:41239152	FOXO1	0.49	6.19	0.32	1.84e-9	Red blood cell count;
CRC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.37	-6.71	-0.35	8.64e-11	Height;
CRC	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.55	5.85	0.31	1.2e-8	Coronary artery disease;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.27	-0.49	1.16e-21	Bipolar disorder;
CRC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.33	-0.33	8.1e-10	Total body bone mineral density;
CRC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg00339695	chr16:24857497	SLC5A11	0.25	5.95	0.31	7.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg14139581	chr11:64358342	SLC22A12	-0.39	-6.19	-0.32	1.81e-9	Urate levels in obese individuals;
CRC	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg24812749	chr6:127587940	RNF146	0.56	7.48	0.38	6.66e-13	Breast cancer;
CRC	cis	rs6988985	0.818	rs7463212	chr8:143991858	A/T	cg10324643	chr8:143916377	GML	-0.4	-6.95	-0.36	1.94e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg00601486	chr12:48723148	H1FNT	-0.34	-6.67	-0.35	1.09e-10	Glycated hemoglobin levels;
CRC	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.64	7.62	0.39	2.79e-13	Bipolar disorder;
CRC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-8.16	-0.41	6.96e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.48	5.88	0.31	9.89e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg18357645	chr12:58087776	OS9	0.5	6.83	0.35	4.06e-11	Multiple sclerosis;
CRC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.42	-0.33	4.82e-10	Lymphocyte counts;
CRC	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.58	-9.4	-0.46	9.41e-19	Migraine;
CRC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.28	-0.42	3.19e-15	Mean platelet volume;Platelet distribution width;
CRC	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.42	-0.65	9.24e-41	Exhaled nitric oxide output;
CRC	cis	rs4731207	0.533	rs1481326	chr7:124625984	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.24	-0.33	1.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.07	-0.32	3.43e-9	Diabetic kidney disease;
CRC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.97	-0.31	6.09e-9	Diabetic kidney disease;
CRC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.84	0.31	1.26e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.26	0.41	3.66e-15	Height;
CRC	cis	rs9292777	0.720	rs12514415	chr5:40435036	C/T	cg09067459	chr5:40385259	NA	-0.53	-8.63	-0.43	2.76e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.4	0.71	1.66e-52	Parkinson's disease;
CRC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.52	0.38	5.14e-13	Vitiligo;
CRC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.5	6.38	0.33	6.01e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.56	-0.5	1.25e-22	Bipolar disorder;
CRC	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg00507830	chr2:103233733	NA	0.59	5.89	0.31	9.5e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.43	-7.09	-0.36	8e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg27534772	chr1:16042836	PLEKHM2	0.43	7.12	0.37	6.95e-12	Systolic blood pressure;
CRC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.52	-0.5	1.71e-22	Total cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04252616	chr1:149646781	NA	-0.38	-6.37	-0.33	6.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	8.79	0.44	8.7e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg11189052	chr15:85197271	WDR73	0.63	9.8	0.48	4.5e-20	Schizophrenia;
CRC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.57	-8.48	-0.42	7.52e-16	Height;
CRC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.48	6.52	0.34	2.61e-10	Schizophrenia;
CRC	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.5	7.4	0.38	1.14e-12	Height;
CRC	cis	rs10128264	0.902	rs1250583	chr10:80975004	A/G	cg20744163	chr10:80999841	ZMIZ1	0.44	7.87	0.4	5.24e-14	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-0.93	-16.42	-0.67	1.17e-44	Body mass index;
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg03188948	chr7:1209495	NA	0.71	7.93	0.4	3.48e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.93	-0.31	7.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg25164649	chr6:28176230	NA	0.7	7.91	0.4	3.86e-14	Parkinson's disease;
CRC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.51	7.1	0.36	7.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.57	-7.28	-0.37	2.43e-12	Aortic root size;
CRC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg15790184	chr11:494944	RNH1	0.62	5.83	0.31	1.36e-8	Body mass index;
CRC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-8.18	-0.41	6.28e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	0.88	7.66	0.39	2.07e-13	Fat distribution (HIV);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27309920	chr12:6798957	ZNF384	0.42	6.19	0.32	1.78e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg19584864	chr3:150127772	TSC22D2	0.42	6.02	0.31	4.63e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09408520	chr2:157188965	NR4A2	0.44	6.2	0.32	1.73e-9	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.45	-5.94	-0.31	7.45e-9	Gut microbiome composition (summer);
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.28	-0.33	1.08e-9	Total body bone mineral density;
CRC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.83	-0.44	6.25e-17	Prostate cancer;
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.59	7.24	0.37	3.22e-12	Alzheimer's disease;
CRC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	9.73	0.47	7.98e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg20203395	chr5:56204925	C5orf35	-0.44	-6.28	-0.33	1.07e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.46	-5.86	-0.31	1.15e-8	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26402253	chr7:87849886	SRI	0.52	6.83	0.35	4.21e-11	Thyroid stimulating hormone;
CRC	cis	rs7429990	0.965	rs11707679	chr3:47956506	T/C	cg11946769	chr3:48343235	NME6	0.49	6.19	0.32	1.8e-9	Educational attainment (years of education);
CRC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg10760299	chr15:45669010	GATM	0.36	5.82	0.31	1.42e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.64	7.35	0.38	1.6e-12	Gut microbiome composition (summer);
CRC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.46	-8.19	-0.41	5.67e-15	Frontotemporal dementia;
CRC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.61	9.64	0.47	1.5700000000000001e-19	Height;
CRC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.32	0.53	2.54e-25	Prudent dietary pattern;
CRC	cis	rs62408225	1.000	rs6454805	chr6:90986353	A/G	cg06866423	chr6:90926672	BACH2	0.48	7.94	0.4	3.28e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-9.53	-0.47	3.61e-19	Calcium levels;
CRC	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg26353448	chr1:248524236	OR2T4	0.32	6.15	0.32	2.26e-9	Common traits (Other);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23791442	chr22:43010704	POLDIP3;RNU12	0.46	6.46	0.34	3.66e-10	Anxiety disorder;
CRC	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.44	6.67	0.35	1.09e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs4363385	0.747	rs1415970	chr1:152965741	G/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.72e-12	Inflammatory skin disease;
CRC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.49	7.23	0.37	3.36e-12	N-glycan levels;
CRC	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.59	0.34	1.77e-10	Blood protein levels;
CRC	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg24463073	chr6:118973353	C6orf204	0.55	7.16	0.37	5.24e-12	Diastolic blood pressure;
CRC	cis	rs4766646	0.619	rs4766639	chr12:110298925	A/G	cg01252219	chr12:110302105	GLTP	0.41	6.26	0.33	1.17e-9	Metabolite levels (MHPG);
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	1.03	10.45	0.5	2.99e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.86	11.66	0.54	1.6e-26	Orofacial clefts;
CRC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.65	-9.93	-0.48	1.75e-20	Testicular germ cell tumor;
CRC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.37	5.93	0.31	7.85e-9	Major depressive disorder;
CRC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.5	-0.34	3.04e-10	Body mass index;
CRC	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.58	-7.38	-0.38	1.33e-12	Fractional excretion of uric acid;
CRC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg18230493	chr5:56204884	C5orf35	-0.39	-6.05	-0.32	3.93e-9	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.89	0.44	4.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.79	-0.35	5.32e-11	Type 2 diabetes;
CRC	cis	rs740160	0.558	rs17161669	chr7:98908663	G/A	cg24650262	chr7:98904301	NA	0.55	5.8	0.3	1.56e-8	Dehydroepiandrosterone sulphate levels;
CRC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg15845792	chr6:28175446	NA	0.74	10.71	0.51	3.65e-23	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.61	-9.04	-0.45	1.34e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08449531	chr17:48610095	EPN3	0.42	6.06	0.32	3.75e-9	Response to antipsychotic treatment;
CRC	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.51	-8.32	-0.42	2.33e-15	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg09163369	chr1:210001066	C1orf107	0.6	7.74	0.39	1.26e-13	Orofacial clefts;
CRC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg00745463	chr17:30367425	LRRC37B	0.58	7.61	0.39	2.87e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg24881330	chr22:46731750	TRMU	0.66	5.72	0.3	2.36e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.2	-0.32	1.71e-9	Longevity;
CRC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.99	-0.31	5.55e-9	Inflammatory bowel disease;
CRC	trans	rs6472235	0.837	rs28402886	chr8:66927891	G/A	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.92	-0.31	7.94e-9	Depression;
CRC	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.4	5.77	0.3	1.79e-8	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12679980	chr5:43557583	PAIP1	0.38	6.17	0.32	1.99e-9	Obesity-related traits;
CRC	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg17133734	chr15:86042851	AKAP13	0.4	6.49	0.34	3.21e-10	Interstitial lung disease;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg27615366	chr5:131592974	PDLIM4	0.34	6.48	0.34	3.38e-10	Acylcarnitine levels;
CRC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.72	0.35	8.19e-11	Lung cancer;
CRC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	16.6	0.68	2.15e-45	Platelet count;
CRC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.78	13.54	0.6	1.63e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.67	9.93	0.48	1.68e-20	Breast cancer;
CRC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16262614	chr3:133464971	TF	0.33	5.91	0.31	8.53e-9	Iron status biomarkers;
CRC	cis	rs9311676	0.632	rs7610312	chr3:58374029	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg02421172	chr7:1938701	MAD1L1	0.43	6.1	0.32	3.06e-9	Bipolar disorder;
CRC	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.7	7.63	0.39	2.58e-13	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16711694	chr5:34656625	RAI14	-0.4	-6.23	-0.32	1.46e-9	Myopia (pathological);
CRC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.25e-10	Alzheimer's disease (late onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04136173	chr3:38065951	PLCD1	-0.43	-6.45	-0.34	4.1e-10	Myopia (pathological);
CRC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.68	7.47	0.38	7.35e-13	Vitiligo;
CRC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.41	-5.87	-0.31	1.08e-8	Huntington's disease progression;
CRC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.56	-8.7	-0.43	1.64e-16	Colorectal cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08086906	chr16:86588932	MTHFSD;FLJ30679	0.45	6.66	0.34	1.17e-10	Response to antipsychotic treatment;
CRC	cis	rs4692589	1.000	rs7688417	chr4:170938732	C/T	cg19918862	chr4:170955249	NA	0.39	6.34	0.33	7.47e-10	Anxiety disorder;
CRC	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.79	0.35	5.31e-11	Breast cancer;
CRC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.42	-8.12	-0.41	9.58e-15	Mean corpuscular volume;
CRC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.59	8.37	0.42	1.73e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	cg04338863	chr8:33670619	NA	0.41	6.11	0.32	2.76e-9	Body mass index;
CRC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.62	-7.87	-0.4	5.21e-14	Schizophrenia;
CRC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.56	8.37	0.42	1.62e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.64	9.69	0.47	1.05e-19	Menopause (age at onset);
CRC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.55	8.95	0.44	2.65e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	11.11	0.52	1.5e-24	Motion sickness;
CRC	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg08501292	chr6:25962987	TRIM38	0.84	7.76	0.39	1.1e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg18833306	chr6:118973337	C6orf204	0.47	6.82	0.35	4.37e-11	Renal cell carcinoma;
CRC	cis	rs3750082	0.852	rs6462425	chr7:32898595	C/A	cg05721444	chr7:32995514	FKBP9	0.48	7.47	0.38	7.45e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.54	-7.33	-0.37	1.76e-12	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19017420	chr11:64781299	ARL2	0.45	6.46	0.34	3.82e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.15e-9	Lung cancer;
CRC	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg00105475	chr2:10696890	NA	-0.47	-7.5	-0.38	6.04e-13	Prostate cancer;
CRC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg10298567	chr3:47292165	KIF9	-0.39	-6.12	-0.32	2.7e-9	Colorectal cancer;
CRC	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.31	-0.33	8.91e-10	Breast cancer;
CRC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.87	-0.31	1.06e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.69	9.38	0.46	1.15e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.4	6.06	0.32	3.78e-9	Longevity;Endometriosis;
CRC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.77	15.53	0.65	3.57e-41	Leprosy;
CRC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg10589385	chr1:150898437	SETDB1	0.32	6.77	0.35	5.94e-11	Melanoma;
CRC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.14	0.45	6.52e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg02811702	chr13:24901961	NA	0.47	6.48	0.34	3.27e-10	Obesity-related traits;
CRC	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg13385521	chr17:29058706	SUZ12P	0.64	7.63	0.39	2.55e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.83	13.12	0.59	6.38e-32	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.98	-19.42	-0.73	1.7e-56	Height;
CRC	cis	rs11195062	0.766	rs7897645	chr10:112006669	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.37	-5.61	-0.3	4.32e-8	Multiple myeloma;
CRC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg27523141	chr10:43048294	ZNF37B	0.44	6.42	0.33	4.79e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs7703744	0.681	rs73239278	chr5:118695051	G/A	cg17471836	chr5:118691007	TNFAIP8	0.43	5.94	0.31	7.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15928446	chr16:30661850	PRR14	0.42	6.23	0.32	1.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg02569458	chr12:86230093	RASSF9	0.39	6.62	0.34	1.46e-10	Major depressive disorder;
CRC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg22777020	chr22:31556080	RNF185	-0.53	-6.1	-0.32	2.92e-9	Colorectal cancer;
CRC	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.55	-7.63	-0.39	2.62e-13	Neuroticism;
CRC	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.81	-0.31	1.47e-8	Neuroticism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00779180	chr16:25117992	NA	0.44	6.03	0.32	4.52e-9	Anxiety disorder;
CRC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.42	-7.68	-0.39	1.81e-13	Huntington's disease progression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09046255	chr16:30662126	PRR14	0.36	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.25	-0.33	1.29e-9	Post bronchodilator FEV1;
CRC	cis	rs73206853	0.614	rs57154770	chr12:110814415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.77	8.38	0.42	1.59e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.65	9.42	0.46	8.41e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-6.81	-0.35	4.76e-11	Coronary artery disease;
CRC	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-10.71	-0.51	3.76e-23	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs7259376	0.902	rs10420380	chr19:22600624	C/T	cg02657401	chr19:22469223	NA	0.31	6.82	0.35	4.25e-11	Menopause (age at onset);
CRC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.67	7.38	0.38	1.27e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00474734	chr12:53645975	MFSD5	0.42	7.45	0.38	8.19e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg03646922	chr17:4167316	ANKFY1	-0.4	-6.05	-0.32	3.87e-9	Birth weight;Height;
CRC	cis	rs6997458	0.742	rs20571	chr8:86351997	G/A	cg21346043	chr8:86351067	CA3	-0.26	-5.87	-0.31	1.07e-8	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.7	-0.39	1.66e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6694672	0.850	rs10801587	chr1:197058380	C/T	cg13682187	chr1:196946512	CFHR5	0.55	8.27	0.42	3.27e-15	Asthma;
CRC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg13722127	chr7:150037890	RARRES2	0.51	7.94	0.4	3.18e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	5.65	0.3	3.4e-8	Response to antipsychotic treatment;
CRC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.6	-0.3	4.44e-8	Gout;Renal underexcretion gout;
CRC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.46	6.31	0.33	8.95e-10	Red blood cell count;
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg03623178	chr6:28175578	NA	-0.71	-7.77	-0.39	9.91e-14	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg13319975	chr6:146136371	FBXO30	0.4	6.07	0.32	3.51e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.39	6.33	0.33	8.21e-10	Height;
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.32	-0.33	8.43e-10	Electroencephalogram traits;
CRC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	ch.11.42038R	chr11:967971	AP2A2	0.6	10.27	0.49	1.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	7.79	0.39	8.75e-14	Body mass index;
CRC	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.5	9.36	0.46	1.3e-18	Weight;
CRC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.96	17.94	0.7	1.16e-50	Cognitive ability;
CRC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.77	11.22	0.53	5.97e-25	Menopause (age at onset);
CRC	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.84	0.35	3.94e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.97	-0.4	2.59e-14	Total body bone mineral density;
CRC	cis	rs11226613	0.568	rs10895769	chr11:104954019	A/C	cg04181079	chr11:104896587	CASP1	-0.41	-5.67	-0.3	3.11e-8	Bronchopulmonary dysplasia;
CRC	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-7.11	-0.36	7.37e-12	Renal cell carcinoma;
CRC	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg10437265	chr15:77819839	NA	0.63	10.81	0.51	1.58e-23	Type 2 diabetes;
CRC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.68	7.79	0.39	8.9e-14	Gut microbiome composition (summer);
CRC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.53	8.1	0.41	1.1e-14	Sudden cardiac arrest;
CRC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.6	8.48	0.42	7.98e-16	Breast cancer;
CRC	cis	rs970548	1.000	rs970548	chr10:46013277	A/C	cg15590007	chr10:45870220	ALOX5	0.49	6.34	0.33	7.78e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.32	4.61e-9	Morning vs. evening chronotype;
CRC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.5	0.46	4.39e-19	Bladder cancer;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.87	-0.31	1.06e-8	Obesity-related traits;
CRC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.53	-7.05	-0.36	1.05e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg22778903	chr21:42741698	MX2	-0.38	-6.26	-0.33	1.18e-9	Melanoma;
CRC	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.42	-6.49	-0.34	3.19e-10	Breast cancer;
CRC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg05673287	chr15:77411982	SGK269	-0.54	-8.05	-0.41	1.52e-14	Type 2 diabetes;
CRC	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg27053337	chr8:124217698	FAM83A	0.44	6.91	0.36	2.58e-11	Urinary uromodulin levels;
CRC	trans	rs2303319	0.504	rs62188990	chr2:162540635	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.22	-0.32	1.54e-9	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24715260	chr17:80056221	FASN	0.45	6.18	0.32	1.87e-9	Anxiety disorder;
CRC	cis	rs720844	0.935	rs4972380	chr2:149336522	C/T	cg09247360	chr2:149335327	NA	-0.61	-7.7	-0.39	1.5700000000000001e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg19554555	chr3:13937349	NA	0.44	6.38	0.33	5.98e-10	Ovarian reserve;
CRC	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.54	6.74	0.35	7.19e-11	Personality dimensions;
CRC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.47	-7.42	-0.38	1.02e-12	Asthma;
CRC	cis	rs600626	0.529	rs10899115	chr11:75471849	A/G	cg24262691	chr11:75473276	NA	0.53	8.11	0.41	1.01e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2742417	1.000	rs1969626	chr3:45746836	A/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs727505	0.721	rs17327715	chr7:124760611	G/C	cg23710748	chr7:124431027	NA	-0.66	-11.23	-0.53	5.42e-25	Lewy body disease;
CRC	cis	rs12505749	0.542	rs4340842	chr4:57338188	A/G	cg06922635	chr4:57371607	ARL9	-0.54	-5.79	-0.3	1.62e-8	Airflow obstruction;
CRC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.15	-0.32	2.25e-9	Longevity;Endometriosis;
CRC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg17724175	chr1:150552817	MCL1	0.44	6.69	0.35	9.45e-11	Melanoma;
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-0.58	-8.44	-0.42	9.89e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.03	0.45	1.48e-17	Bladder cancer;
CRC	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg07125278	chr16:67683757	RLTPR	-0.46	-5.95	-0.31	6.69e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg19223106	chr19:58898630	RPS5	-0.42	-6.14	-0.32	2.32e-9	Birth weight;Height;
CRC	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.37	-5.82	-0.31	1.43e-8	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-6.22	-0.32	1.52e-9	Longevity;Endometriosis;
CRC	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg23100626	chr2:96804247	ASTL	-0.29	-7.74	-0.39	1.19e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10089324	chr1:51984752	EPS15	0.43	6.11	0.32	2.78e-9	Response to antipsychotic treatment;
CRC	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg08632701	chr21:37451849	NA	-0.41	-6.4	-0.33	5.41e-10	Mitral valve prolapse;
CRC	cis	rs2811415	0.597	rs56211835	chr3:127803232	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.9	-0.31	9.25e-9	Lung function (FEV1/FVC);
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.51	7.34	0.37	1.72e-12	Alzheimer's disease;
CRC	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.78	-0.39	9.4e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg00601486	chr12:48723148	H1FNT	0.36	7.03	0.36	1.17e-11	Glycated hemoglobin levels;
CRC	trans	rs2294025	0.932	rs7816892	chr8:134169898	A/G	cg21959181	chr7:150755243	CDK5;SLC4A2	-0.35	-6.09	-0.32	3.19e-9	Graves' disease;
CRC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.37	0.46	1.23e-18	Cognitive test performance;
CRC	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg02702477	chr5:179499311	RNF130	0.54	6.22	0.32	1.52e-9	LDL cholesterol;
CRC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.26	0.33	1.22e-9	Menopause (age at onset);
CRC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.6	-7.61	-0.39	2.86e-13	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.53	-5.94	-0.31	7.38e-9	Body mass index;
CRC	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.37	6.13	0.32	2.53e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.74	9.93	0.48	1.76e-20	Coronary artery disease;
CRC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.8	14.02	0.61	2.36e-35	Breast cancer;
CRC	cis	rs2882667	0.898	rs3925110	chr5:138371365	C/G	cg04439458	chr5:138467593	SIL1	-0.33	-6.01	-0.31	5.04e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.82	11.36	0.53	1.89e-25	Cerebrospinal P-tau181p levels;
CRC	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.51	-8.47	-0.42	8.2e-16	Crohn's disease;
CRC	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.61	5.76	0.3	1.9e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg24562669	chr7:97807699	LMTK2	0.42	6.95	0.36	2.01e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.82	-0.35	4.5e-11	Response to antipsychotic treatment;
CRC	cis	rs6066835	0.867	rs6095283	chr20:47374382	G/A	cg18078177	chr20:47281410	PREX1	0.69	5.89	0.31	9.56e-9	Multiple myeloma;
CRC	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	5.74	0.3	2.13e-8	Breast cancer;
CRC	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.65	-0.34	1.25e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.95	0.31	6.82e-9	Height;
CRC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.42	6.87	0.35	3.3e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg17147758	chr8:6949321	NA	-0.52	-7.37	-0.38	1.42e-12	Blood pressure (smoking interaction);
CRC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.85	-10.09	-0.49	4.88e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.32	-0.65	2.3e-40	Exhaled nitric oxide output;
CRC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.59	-0.34	1.77e-10	Alzheimer's disease (late onset);
CRC	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg13482628	chr17:19912719	NA	-0.44	-6.69	-0.35	9.4e-11	Obesity-related traits;
CRC	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg04586622	chr2:25135609	ADCY3	0.35	5.96	0.31	6.35e-9	Body mass index in non-asthmatics;
CRC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg02527881	chr3:46936655	PTH1R	-0.34	-5.91	-0.31	8.74e-9	Colorectal cancer;
CRC	cis	rs847649	0.842	rs4729860	chr7:102625567	C/T	cg18108683	chr7:102477205	FBXL13	0.53	8.64	0.43	2.44e-16	Morning vs. evening chronotype;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-5.7	-0.3	2.67e-8	Longevity;Endometriosis;
CRC	cis	rs17767392	0.958	rs17767553	chr14:71910587	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.29	-0.37	2.34e-12	Mitral valve prolapse;
CRC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.37	6.3	0.33	9.54e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04731861	chr2:219085781	ARPC2	0.37	7.75	0.39	1.13e-13	Colorectal cancer;
CRC	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.7	-0.39	1.6e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.64	9.78	0.47	5.32e-20	Birth weight;
CRC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	5.91	0.31	8.51e-9	Personality dimensions;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20092199	chr4:1342459	KIAA1530	0.37	6.65	0.34	1.22e-10	Obesity-related traits;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg19041857	chr6:27730383	NA	-0.44	-5.94	-0.31	7.12e-9	Parkinson's disease;
CRC	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.97	0.31	6.11e-9	Axial length;
CRC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.33	-0.46	1.6e-18	Alcohol dependence;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg06872519	chr11:6947619	ZNF215	0.59	5.86	0.31	1.11e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg14003231	chr6:33640908	ITPR3	0.5	8.11	0.41	1.01e-14	Plateletcrit;
CRC	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-7.47	-0.38	7.15e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs3018066	0.666	rs7669087	chr4:107032880	A/G	cg01869342	chr4:106983673	TBCK	0.46	6.19	0.32	1.83e-9	Cancer;
CRC	trans	rs57590327	0.504	rs4856348	chr3:81502923	T/G	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.45	-6.06	-0.32	3.7e-9	Extraversion;
CRC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.51	6.84	0.35	3.91e-11	Height;
CRC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-19.37	-0.73	2.69e-56	Headache;
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg06470822	chr6:28175283	NA	0.77	8.09	0.41	1.18e-14	Depression;
CRC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.43	7.2	0.37	4.25e-12	Blood metabolite levels;
CRC	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg05527609	chr1:210001259	C1orf107	-0.55	-6.0	-0.31	5.1e-9	Red blood cell count;
CRC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg08314208	chr16:67682810	RLTPR	-0.63	-6.75	-0.35	6.58e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.59	-8.65	-0.43	2.38e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.52	7.25	0.37	2.95e-12	Longevity;Endometriosis;
CRC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.62	9.3	0.46	1.95e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg08075719	chr14:103021372	NA	-0.68	-9.22	-0.45	3.57e-18	Platelet count;
CRC	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.75	-10.05	-0.48	6.63e-21	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.63	9.77	0.47	5.82e-20	Monocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-0.63	-11.21	-0.53	6.31e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.77	-7.92	-0.4	3.73e-14	Plasma clusterin levels;
CRC	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs7215564	0.908	rs4889884	chr17:78664465	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs911119	0.913	rs3810575	chr20:23583392	G/A	cg16589663	chr20:23618590	CST3	0.42	5.76	0.3	1.95e-8	Chronic kidney disease;
CRC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	6.55	0.34	2.24e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg20628663	chr10:43360327	NA	-0.59	-6.86	-0.35	3.49e-11	Blood protein levels;
CRC	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg02264733	chr16:588086	SOLH	-0.37	-5.68	-0.3	2.9e-8	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.37	-0.38	1.38e-12	Capecitabine sensitivity;
CRC	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.5	7.49	0.38	6.44e-13	Testicular germ cell tumor;
CRC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg01831904	chr17:28903510	LRRC37B2	0.64	6.5	0.34	2.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.41	-5.67	-0.3	3.21e-8	Parkinson's disease;
CRC	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg08027265	chr7:2291960	NA	-0.36	-5.74	-0.3	2.16e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.63	10.07	0.49	5.61e-21	Motion sickness;
CRC	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.77	7.16	0.37	5.3e-12	Macrophage inflammatory protein 1b levels;
CRC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.13	14.65	0.63	9.5e-38	Uric acid levels;
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-10.33	-0.5	7.23e-22	Calcium levels;
CRC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.54	-7.75	-0.39	1.19e-13	Platelet distribution width;
CRC	cis	rs2415984	0.579	rs61993337	chr14:46965297	C/T	cg14871534	chr14:47121158	RPL10L	-0.42	-6.19	-0.32	1.83e-9	Number of children ever born;
CRC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.21	-0.32	1.56e-9	Breast cancer;
CRC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.53	-8.05	-0.41	1.58e-14	Aortic root size;
CRC	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg11038491	chr20:34638489	LOC647979	-0.59	-7.18	-0.37	4.59e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2055729	0.634	rs6601390	chr8:9740657	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.43	0.33	4.37e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.71	0.51	3.66e-23	Prudent dietary pattern;
CRC	cis	rs891088	0.614	rs41315074	chr19:7184243	C/G	cg09779027	chr19:7224513	INSR	-0.56	-5.96	-0.31	6.61e-9	Hip circumference adjusted for BMI;Height;
CRC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg18404041	chr3:52824283	ITIH1	0.35	6.4	0.33	5.36e-10	Schizophrenia;
CRC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.69	-11.46	-0.53	7.99e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	1.11	10.4	0.5	4.45e-22	Arsenic metabolism;
CRC	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.14	-0.37	6.07e-12	Alzheimer's disease (late onset);
CRC	cis	rs61160187	0.582	rs976631	chr5:60216043	T/C	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.97	-0.31	6.06e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.48	7.46	0.38	7.66e-13	HDL cholesterol;
CRC	trans	rs73162807	0.655	rs73160973	chr3:146422587	G/A	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg03959625	chr15:84868606	LOC388152	0.41	6.08	0.32	3.27e-9	Schizophrenia;
CRC	cis	rs9462846	0.853	rs9462850	chr6:42872475	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-6.47	-0.34	3.65e-10	Blood protein levels;
CRC	cis	rs939574	0.660	rs6716253	chr2:220127016	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.85	7.43	0.38	9.29e-13	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16780568	chr10:89578019	ATAD1;CFLP1	0.35	6.09	0.32	3.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.53	8.5	0.42	6.79e-16	Menopause (age at onset);
CRC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.05	0.32	3.97e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.08	-0.71	3.18e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22968175	chr19:42721878	DEDD2	0.46	5.96	0.31	6.48e-9	Thyroid stimulating hormone;
CRC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.4	6.62	0.34	1.43e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.21	-0.32	1.57e-9	Aortic root size;
CRC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.45	7.26	0.37	2.77e-12	Testicular germ cell tumor;
CRC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.39	0.42	1.46e-15	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg09127314	chr1:152161683	NA	0.47	5.99	0.31	5.57e-9	Atopic dermatitis;
CRC	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.13	-0.32	2.51e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg03929089	chr4:120376271	NA	0.59	6.07	0.32	3.62e-9	Intraocular pressure;
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.65	0.75	2.49e-61	Prudent dietary pattern;
CRC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg02569458	chr12:86230093	RASSF9	0.38	6.49	0.34	3.21e-10	Major depressive disorder;
CRC	trans	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-6.79	-0.35	5.11e-11	Breast cancer;
CRC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.13	27.34	0.83	1.06e-86	Testicular germ cell tumor;
CRC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.69	-11.04	-0.52	2.5e-24	Hepatocellular carcinoma;
CRC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg18230493	chr5:56204884	C5orf35	-0.43	-6.4	-0.33	5.29e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.67	9.53	0.46	3.69e-19	Vitamin D levels;
CRC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.43	6.6	0.34	1.66e-10	Monocyte count;
CRC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.54	-5.83	-0.31	1.35e-8	Blood protein levels;
CRC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.48	6.98	0.36	1.59e-11	Colorectal cancer;
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg04518342	chr5:131593106	PDLIM4	0.36	6.57	0.34	1.97e-10	Blood metabolite levels;
CRC	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.86	16.45	0.67	8.73e-45	Hip circumference;
CRC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12273811	chr6:28175739	NA	0.63	8.16	0.41	7.43e-15	Parkinson's disease;
CRC	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.86	9.0	0.44	1.79e-17	Gastritis;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.75	0.35	6.86e-11	Diastolic blood pressure;
CRC	trans	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg05270119	chr15:66161672	RAB11A	0.44	6.06	0.32	3.75e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg16060761	chr17:80687452	NA	-0.4	-5.78	-0.3	1.69e-8	Breast cancer;
CRC	cis	rs4731207	0.596	rs1600737	chr7:124639547	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.2	-0.32	1.68e-9	Cutaneous malignant melanoma;
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.71	0.54	1.02e-26	Prudent dietary pattern;
CRC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04013166	chr16:89971882	TCF25	0.6	5.76	0.3	1.91e-8	Skin colour saturation;
CRC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.72	7.18	0.37	4.65e-12	Fat distribution (HIV);
CRC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.8	-0.3	1.58e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.42	-0.38	1.02e-12	Bipolar disorder;
CRC	cis	rs9648716	0.766	rs511001	chr7:140782039	G/T	cg10747023	chr7:140774559	NA	-0.47	-6.11	-0.32	2.85e-9	Type 2 diabetes;
CRC	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.8	-12.72	-0.57	2e-30	Hypospadias;
CRC	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.41	-6.42	-0.33	4.65e-10	Monobrow;
CRC	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.57	-9.23	-0.45	3.44e-18	Congenital heart disease (maternal effect);
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg21747405	chr11:67723411	NA	-0.57	-8.88	-0.44	4.28e-17	Blood pressure (smoking interaction);
CRC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.56	-8.69	-0.43	1.69e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1143633	0.537	rs4447608	chr2:113605957	C/T	cg12858261	chr2:113808755	IL1F8	-0.35	-5.76	-0.3	1.97e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs7690467	0.926	rs62318141	chr4:133388785	A/C	cg19296258	chr17:78878799	RPTOR	-0.47	-6.29	-0.33	1e-9	Eating disorders;
CRC	cis	rs2252790	0.859	rs2858848	chr6:116679275	A/G	cg18764771	chr6:116381957	FRK	-0.22	-6.01	-0.31	4.85e-9	Fast beta electroencephalogram;
CRC	cis	rs7487075	0.619	rs12314541	chr12:46794766	T/C	cg22049899	chr12:47219821	SLC38A4	0.32	5.88	0.31	1.01e-8	Itch intensity from mosquito bite;
CRC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.35	-10.08	-0.49	5.32e-21	Mean corpuscular volume;
CRC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-16.89	-0.68	1.54e-46	Coronary artery disease;
CRC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	6.14	0.32	2.36e-9	Neuroticism;
CRC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.53	-0.34	2.49e-10	Mean corpuscular volume;
CRC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.73	-16.44	-0.67	9.36e-45	Intelligence (multi-trait analysis);
CRC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	8.31	0.42	2.61e-15	Eosinophilic esophagitis;
CRC	cis	rs776905	0.598	rs569557	chr13:113769917	G/A	cg09069900	chr13:113776964	F10	-0.44	-6.94	-0.36	2.11e-11	Blood protein levels;
CRC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.8	11.46	0.53	8.25e-26	Gut microbiome composition (summer);
CRC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.7e-20	Bladder cancer;
CRC	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.52	8.35	0.42	1.9e-15	Testicular germ cell tumor;
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs7584330	0.554	rs57140815	chr2:238428330	A/G	cg14458575	chr2:238380390	NA	0.43	6.04	0.32	4.26e-9	Prostate cancer;
CRC	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.81	13.36	0.59	8.15e-33	Hypertriglyceridemia;
CRC	cis	rs6840360	0.574	rs2709844	chr4:152368212	C/T	cg09659197	chr4:152720779	NA	0.33	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.38	-0.38	1.33e-12	Major depressive disorder;
CRC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.54	6.27	0.33	1.13e-9	Coronary artery calcification;
CRC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.92	0.52	6.8e-24	Prudent dietary pattern;
CRC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.01e-12	Rheumatoid arthritis;
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg00280220	chr17:61926910	NA	0.33	5.67	0.3	3.12e-8	Prudent dietary pattern;
CRC	trans	rs8012941	0.593	rs4902190	chr14:63314591	A/G	cg03143876	chr20:50808547	ZFP64	0.39	6.13	0.32	2.58e-9	Major depressive disorder;
CRC	cis	rs802075	0.967	rs554805	chr6:49653451	A/G	cg20364632	chr6:49636226	NA	-0.35	-5.78	-0.3	1.71e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg01849466	chr14:104193079	ZFYVE21	0.38	5.95	0.31	7.01e-9	Body mass index;
CRC	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.65	-7.58	-0.39	3.45e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.86	16.9	0.68	1.39e-46	Hip circumference;
CRC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.81	-0.3	1.5e-8	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00258805	chr17:29876732	NA	0.36	6.07	0.32	3.57e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.73	-0.39	1.3e-13	Mood instability;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15929228	chr2:240323491	HDAC4	0.37	6.03	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg14829155	chr15:31115871	NA	-0.6	-5.93	-0.31	7.79e-9	Hypertriglyceridemia;
CRC	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.51	5.97	0.31	6.1e-9	Bipolar disorder;
CRC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.58	9.38	0.46	1.11e-18	Tonsillectomy;
CRC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.68	10.09	0.49	4.96e-21	Corneal astigmatism;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.22	0.53	6.14e-25	Prudent dietary pattern;
CRC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.72	-0.39	1.37e-13	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07589846	chr1:212872696	BATF3	0.4	6.42	0.33	4.81e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg25243455	chr2:114033360	PAX8;LOC440839	-0.25	-5.76	-0.3	1.9e-8	Lymphocyte counts;
CRC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg22723502	chr6:26240528	HIST1H4F	-0.39	-5.95	-0.31	6.71e-9	Gout;Renal underexcretion gout;
CRC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg23262073	chr20:60523788	NA	-0.45	-6.89	-0.36	2.78e-11	Body mass index;
CRC	cis	rs7113874	0.550	rs10840084	chr11:8609274	G/A	cg20771178	chr11:8615675	STK33	0.35	5.68	0.3	3e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9494145	0.590	rs9376090	chr6:135411228	T/C	cg22676075	chr6:135203613	NA	0.59	7.51	0.38	5.48e-13	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02717630	chr16:46865118	C16orf87	0.43	7.29	0.37	2.38e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.43	8.1	0.41	1.06e-14	Childhood ear infection;
CRC	trans	rs264943	0.575	rs171952	chr2:104092943	A/G	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.94e-9	HIV-1 viral setpoint;
CRC	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.72	-8.06	-0.41	1.46e-14	Bipolar disorder;
CRC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.5	7.34	0.38	1.7e-12	Dementia with Lewy bodies;
CRC	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg23920097	chr1:209922102	NA	-0.47	-5.76	-0.3	1.91e-8	Red blood cell count;
CRC	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.56	-8.28	-0.42	3.04e-15	Cancer;
CRC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg10790698	chr19:18539756	SSBP4	-0.43	-8.31	-0.42	2.61e-15	Breast cancer;
CRC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg15445000	chr17:37608096	MED1	-0.34	-6.04	-0.32	4.2e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs6432018	1.000	rs11887863	chr2:9739429	G/T	cg12832956	chr2:9616023	IAH1	-0.37	-5.62	-0.3	4.14e-8	Heart rate variability traits;
CRC	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg17145862	chr1:211918768	LPGAT1	0.5	7.11	0.36	7.31e-12	Crohn's disease;
CRC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg10820045	chr2:198174542	NA	0.45	8.01	0.4	1.99e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7849270	0.959	rs10760591	chr9:131915028	A/G	cg13538475	chr9:131942899	NA	-0.31	-5.97	-0.31	6.05e-9	Blood metabolite ratios;
CRC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.94	0.48	1.59e-20	Cognitive test performance;
CRC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg00343986	chr7:65444356	GUSB	-0.51	-7.61	-0.39	3e-13	Aortic root size;
CRC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.16	10.93	0.52	6.45e-24	Skin colour saturation;
CRC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg24578937	chr1:2090814	PRKCZ	-0.44	-7.91	-0.4	3.86e-14	Height;
CRC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.43	6.15	0.32	2.23e-9	Erythrocyte sedimentation rate;
CRC	cis	rs3789045	0.729	rs12039968	chr1:204490674	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.95	-0.4	3.06e-14	Educational attainment (college completion);
CRC	cis	rs7517126	1.000	rs6428369	chr1:196844335	A/G	cg13682187	chr1:196946512	CFHR5	-0.35	-5.63	-0.3	3.9e-8	Blood protein levels;
CRC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.6	8.47	0.42	8.16e-16	Arsenic metabolism;
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg06238570	chr21:40685208	BRWD1	0.79	10.81	0.51	1.61e-23	Cognitive function;
CRC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg19622623	chr12:86230825	RASSF9	0.39	6.25	0.33	1.27e-9	Major depressive disorder;
CRC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg11833968	chr6:79620685	NA	-0.37	-6.47	-0.34	3.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg15845792	chr6:28175446	NA	0.96	12.86	0.58	6.21e-31	Depression;
CRC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.38	6.48	0.34	3.3e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg19812747	chr11:111475976	SIK2	0.55	9.18	0.45	4.98e-18	Primary sclerosing cholangitis;
CRC	cis	rs8177179	0.503	rs13061966	chr3:133412277	C/A	cg24879335	chr3:133465180	TF	0.31	5.64	0.3	3.75e-8	Iron status biomarkers (transferrin levels);
CRC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.01	0.64	3.59e-39	Smoking behavior;
CRC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.59	-9.18	-0.45	4.87e-18	Height;
CRC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.63	-9.03	-0.45	1.45e-17	Cognitive function;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.41	5.63	0.3	3.84e-8	Breast cancer;
CRC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.61	-8.44	-0.42	1.01e-15	DNA methylation (variation);
CRC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg16476235	chr8:21771668	DOK2	0.39	6.65	0.34	1.22e-10	Mean corpuscular volume;
CRC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg12573674	chr2:1569213	NA	-0.75	-7.87	-0.4	5.22e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.51	-8.76	-0.43	1.05e-16	Type 2 diabetes;
CRC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg21153622	chr11:89784906	NA	-0.47	-7.42	-0.38	9.85e-13	HDL cholesterol;
CRC	cis	rs887797	0.557	rs8072699	chr17:64592569	T/C	cg27019712	chr17:64599478	PRKCA	-0.36	-5.66	-0.3	3.36e-8	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
CRC	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg25124228	chr12:125621409	AACS	-0.58	-6.58	-0.34	1.88e-10	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	7.14	0.37	5.88e-12	Eye color traits;
CRC	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.73	-10.41	-0.5	3.92e-22	Systemic lupus erythematosus;
CRC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.44	6.4	0.33	5.49e-10	Menopause (age at onset);
CRC	cis	rs1552172	0.922	rs17352469	chr1:145693383	A/G	cg11743829	chr1:145714124	CD160	-0.4	-6.07	-0.32	3.49e-9	Breast cancer;
CRC	cis	rs995000	0.931	rs2131925	chr1:63025942	G/T	cg19896129	chr1:63156450	NA	-0.43	-6.67	-0.35	1.06e-10	Triglyceride levels;
CRC	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.43	6.64	0.34	1.33e-10	Body mass index;
CRC	cis	rs2969070	0.867	rs2906166	chr7:2508072	A/G	cg03277898	chr7:2518824	NA	-0.43	-6.25	-0.33	1.31e-9	Diastolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11276456	chr10:74856846	P4HA1	0.43	6.46	0.34	3.77e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg20469991	chr17:27169893	C17orf63	0.47	5.85	0.31	1.2e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.47	6.81	0.35	4.55e-11	Tonsillectomy;
CRC	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-9.46	-0.46	6.02e-19	HDL cholesterol;
CRC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.48	7.06	0.36	9.66e-12	Headache;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04542325	chr14:76452293	C14orf179	0.44	5.96	0.31	6.47e-9	Anxiety disorder;
CRC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.81	12.47	0.57	1.65e-29	Cognitive ability;
CRC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.53	8.98	0.44	2.13e-17	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg18431297	chr4:7219810	SORCS2	-0.5	-8.21	-0.41	4.96e-15	Insulin-like growth factors;
CRC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.32	0.33	8.52e-10	Obesity-related traits;
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.3	-0.37	2.12e-12	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.79	-0.44	8.78e-17	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.99	12.49	0.57	1.47e-29	Vitiligo;
CRC	trans	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.33	0.42	2.22e-15	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21655969	chr15:90792609	TTLL13	0.34	5.99	0.31	5.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg04586622	chr2:25135609	ADCY3	-0.58	-9.75	-0.47	6.53e-20	Body mass index;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg02869364	chr7:1081709	C7orf50	-0.36	-5.61	-0.3	4.24e-8	Longevity;Endometriosis;
CRC	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.12	9.63	0.47	1.74e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4727963	0.740	rs12706479	chr7:122736336	G/A	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.19e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg25164649	chr6:28176230	NA	0.76	9.56	0.47	2.82e-19	Depression;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.24	-6.15	-0.32	2.23e-9	Lymphocyte counts;
CRC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.36	12.4	0.56	3.13e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.55	8.11	0.41	1.05e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.75	-0.35	6.76e-11	Aortic root size;
CRC	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg14092571	chr14:90743983	NA	0.39	5.97	0.31	6.31e-9	Mortality in heart failure;
CRC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg08347473	chr17:78092826	GAA	-0.33	-5.64	-0.3	3.73e-8	Yeast infection;
CRC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.79	13.91	0.61	6.74e-35	Metabolic syndrome;
CRC	cis	rs55702914	0.775	rs17405686	chr2:198241861	A/G	cg10820045	chr2:198174542	NA	0.37	6.54	0.34	2.38e-10	Major depression and alcohol dependence;
CRC	cis	rs9549328	0.542	rs36172983	chr13:113616582	T/C	cg08614441	chr13:113633676	MCF2L	0.4	6.97	0.36	1.69e-11	Systolic blood pressure;
CRC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg20684491	chr1:25596433	NA	-0.43	-7.49	-0.38	6.29e-13	Erythrocyte sedimentation rate;
CRC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.28	0.49	1.11e-21	Platelet count;
CRC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.26	-14.98	-0.64	4.69e-39	Gout;
CRC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.6	7.36	0.38	1.47e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.48	0.34	3.32e-10	Diabetic kidney disease;
CRC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.57	8.17	0.41	6.87e-15	Lung cancer;
CRC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.07	0.64	2.16e-39	Primary sclerosing cholangitis;
CRC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.52	7.65	0.39	2.2e-13	Lung cancer;
CRC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-11.55	-0.54	3.78e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs6968419	0.674	rs7459355	chr7:115906775	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.42	-0.33	4.81e-10	Intraocular pressure;
CRC	cis	rs7587476	0.861	rs3768716	chr2:215635794	T/C	cg04004882	chr2:215674386	BARD1	0.58	6.62	0.34	1.48e-10	Neuroblastoma;
CRC	cis	rs12476592	0.602	rs2166497	chr2:63800159	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-6.47	-0.34	3.62e-10	Electroencephalogram traits;
CRC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg03037974	chr15:76606532	NA	-0.52	-7.9	-0.4	4.26e-14	Blood metabolite levels;
CRC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg14673194	chr17:80132900	CCDC57	-0.46	-5.86	-0.31	1.12e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	13.09	0.59	8.61e-32	Menopause (age at onset);
CRC	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.91	-0.4	4.07e-14	Body mass index;
CRC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.09	-0.41	1.18e-14	Hemoglobin concentration;
CRC	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg02766259	chr12:125626809	AACS	-0.44	-6.1	-0.32	3.02e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs539514	0.690	rs1924214	chr13:76317632	A/G	cg04757411	chr13:76259545	LMO7	-0.34	-5.78	-0.3	1.74e-8	Type 1 diabetes;
CRC	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.91	11.17	0.52	8.75e-25	Exhaled nitric oxide output;
CRC	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.57	8.92	0.44	3.42e-17	Breast cancer;
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg22561889	chr6:118971681	C6orf204	0.53	6.87	0.35	3.16e-11	Renal cell carcinoma;
CRC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.55	0.75	5.84e-61	Prudent dietary pattern;
CRC	cis	rs7259376	1.000	rs7259376	chr19:22507705	C/T	cg02657401	chr19:22469223	NA	0.37	8.29	0.42	2.89e-15	Menopause (age at onset);
CRC	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg19537932	chr12:55886519	OR6C68	-0.65	-8.42	-0.42	1.16e-15	Cancer;
CRC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.87	13.1	0.59	7.35e-32	Cognitive function;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs12541635	0.677	rs7819501	chr8:107006962	C/T	cg10147462	chr8:107024639	NA	-0.59	-9.85	-0.48	3.03e-20	Age of smoking initiation;
CRC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg19193384	chr17:30244184	NA	-0.52	-6.28	-0.33	1.1e-9	Hip circumference adjusted for BMI;
CRC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.49	-6.93	-0.36	2.24e-11	Bipolar disorder;
CRC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.61	6.5	0.34	2.99e-10	Vitiligo;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.6	-9.46	-0.46	6.04e-19	Corneal astigmatism;
CRC	cis	rs3736485	0.844	rs4774591	chr15:51770185	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.55	-0.34	2.18e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.81	0.44	7.18e-17	Coffee consumption (cups per day);
CRC	cis	rs3750082	0.889	rs4437549	chr7:32914965	C/T	cg05721444	chr7:32995514	FKBP9	0.51	7.87	0.4	5.33e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg23136738	chr11:925521	AP2A2	-0.4	-6.24	-0.33	1.34e-9	Alzheimer's disease (late onset);
CRC	cis	rs713477	0.524	rs4901560	chr14:55888533	C/T	cg13175173	chr14:55914753	NA	0.51	8.26	0.41	3.64e-15	Pediatric bone mineral content (femoral neck);
CRC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.36	5.86	0.31	1.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05000123	chr14:20937394	PNP	0.52	6.85	0.35	3.69e-11	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.46	7.39	0.38	1.25e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.08	-0.32	3.35e-9	Bipolar disorder;
CRC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.16	-0.32	2.11e-9	Schizophrenia;
CRC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-12.21	-0.56	1.58e-28	Vitiligo;
CRC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.64	11.34	0.53	2.3e-25	Schizophrenia;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19590674	chr17:25783100	NA	0.48	6.58	0.34	1.81e-10	Survival in pancreatic cancer;
CRC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.36	0.42	1.84e-15	Schizophrenia;
CRC	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-8.3	-0.42	2.8e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23926253	chr19:19303735	LOC729991-MEF2B;LOC729991;RFXANK	0.44	6.05	0.32	4.04e-9	Anxiety disorder;
CRC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.59	10.42	0.5	3.82e-22	Schizophrenia;
CRC	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.38	5.62	0.3	4.14e-8	IFN-related cytopenia;
CRC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.86e-17	Aortic root size;
CRC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Parkinson's disease;
CRC	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg08075719	chr14:103021372	NA	0.65	7.55	0.38	4.22e-13	Platelet count;
CRC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-7.24	-0.37	3.16e-12	Dental caries;
CRC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.97	-0.52	4.45e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03923535	chr7:1197113	ZFAND2A	0.66	9.25	0.45	2.97e-18	Longevity;Endometriosis;
CRC	trans	rs7821565	0.904	rs72636537	chr8:52163430	G/A	cg09187163	chr7:72721838	NSUN5	-0.41	-6.07	-0.32	3.61e-9	Tuberculosis;
CRC	trans	rs10242455	1.000	rs17161692	chr7:98953863	A/G	cg04001138	chr6:49514721	NA	0.59	5.98	0.31	5.68e-9	Blood metabolite levels;
CRC	cis	rs7937682	0.593	rs4598705	chr11:111345840	G/A	cg09085632	chr11:111637200	PPP2R1B	0.42	5.79	0.3	1.61e-8	Primary sclerosing cholangitis;
CRC	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.51	13.4	0.59	5.67e-33	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.6	0.39	3.12e-13	Blood metabolite levels;
CRC	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	6.55	0.34	2.26e-10	Body mass index;
CRC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.67	-10.84	-0.51	1.29e-23	Hepatocellular carcinoma;
CRC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.83	-9.55	-0.47	3.03e-19	Breast cancer;
CRC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	12.1	0.55	3.97e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09097040	chr12:68726427	MDM1	-0.39	-6.41	-0.33	5.08e-10	Obesity-related traits;
CRC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-8.86	-0.44	5.03e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg04117972	chr1:227635322	NA	0.55	6.4	0.33	5.39e-10	Major depressive disorder;
CRC	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.22	-0.32	1.5e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.59	7.21	0.37	3.98e-12	Body mass index;
CRC	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.84	-12.9	-0.58	4.49e-31	Response to temozolomide;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.45	-0.34	3.99e-10	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25969087	chr8:101733612	PABPC1	0.46	6.3	0.33	9.43e-10	Anxiety disorder;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg02548606	chr15:77363299	TSPAN3	0.43	5.96	0.31	6.42e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.49	0.65	5.14e-41	Colorectal cancer;
CRC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.23	15.05	0.64	2.68e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs6479527	0.806	rs1933668	chr9:96743773	A/G	cg14459158	chr9:96720562	NA	-0.4	-7.28	-0.37	2.42e-12	Esophageal adenocarcinoma;
CRC	cis	rs501120	0.564	rs11238904	chr10:44684707	C/T	cg09554077	chr10:44749378	NA	0.55	7.62	0.39	2.81e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.57	-9.51	-0.46	4.22e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg00469287	chr7:23338798	C7orf30	0.44	6.02	0.31	4.74e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-5.94	-0.31	7.08e-9	High light scatter reticulocyte count;
CRC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg03030879	chr14:75389066	RPS6KL1	0.4	6.02	0.32	4.56e-9	Height;
CRC	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26378065	chr17:18585709	ZNF286B	0.42	5.82	0.31	1.39e-8	Educational attainment (years of education);
CRC	cis	rs7572644	0.679	rs4419196	chr2:28075298	A/G	cg27432699	chr2:27873401	GPN1	0.43	5.98	0.31	5.68e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.54	7.85	0.4	5.83e-14	Multiple sclerosis;
CRC	cis	rs4867766	0.871	rs113284505	chr5:173954800	A/G	cg20434911	chr5:173954559	NA	-0.78	-9.35	-0.46	1.34e-18	Stroke;
CRC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.42	6.3	0.33	9.44e-10	Resting heart rate;
CRC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.92	0.31	7.91e-9	Prudent dietary pattern;
CRC	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg25173405	chr17:45401733	C17orf57	0.46	7.23	0.37	3.38e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg02158880	chr13:53174818	NA	0.41	6.14	0.32	2.42e-9	Lewy body disease;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.55	6.15	0.32	2.26e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	8.2	0.41	5.29e-15	Coronary artery disease;
CRC	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg14003231	chr6:33640908	ITPR3	0.49	8.01	0.4	1.98e-14	Plateletcrit;
CRC	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.57	7.85	0.4	6.02e-14	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg17903999	chr18:56338584	MALT1	-0.42	-7.08	-0.36	8.6e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.64	9.72	0.47	8.47e-20	Initial pursuit acceleration;
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg08222913	chr3:52553049	STAB1	-0.33	-6.02	-0.31	4.78e-9	Bipolar disorder;
CRC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs59104589	0.617	rs16843671	chr2:242374358	T/C	cg19488206	chr2:242435732	STK25	0.49	7.12	0.37	6.65e-12	Fibrinogen levels;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg02683197	chr6:28174875	NA	0.71	9.27	0.46	2.55e-18	Parkinson's disease;
CRC	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02421172	chr7:1938701	MAD1L1	0.42	5.64	0.3	3.61e-8	Neuroticism;
CRC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.86	14.03	0.61	2.24e-35	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.12	-0.32	2.69e-9	Tonsillectomy;
CRC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.46	6.91	0.36	2.52e-11	Menopause (age at onset);
CRC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg15911859	chr22:45810043	RIBC2;SMC1B	0.63	6.63	0.34	1.39e-10	Tonsillectomy;
CRC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg18478394	chr8:109455254	TTC35	0.39	5.95	0.31	6.73e-9	Dupuytren's disease;
CRC	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg09232269	chr1:207846808	CR1L	-0.5	-7.82	-0.4	7.03e-14	Erythrocyte sedimentation rate;
CRC	cis	rs6764363	0.527	rs7650973	chr3:276196	A/G	cg02057681	chr3:285234	CHL1	0.39	6.68	0.35	1.05e-10	Sudden cardiac arrest;
CRC	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.56	7.26	0.37	2.74e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.36	6.17	0.32	1.99e-9	DNA methylation (variation);
CRC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg11503833	chr11:492997	NA	0.44	5.63	0.3	3.81e-8	Systemic lupus erythematosus;
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg03623178	chr6:28175578	NA	-1.01	-15.74	-0.66	5.29e-42	Depression;
CRC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09019432	chr17:62503014	CCDC45;DDX5	0.44	6.13	0.32	2.5e-9	Response to antipsychotic treatment;
CRC	cis	rs9361491	0.657	rs4706730	chr6:79467903	C/T	cg09184832	chr6:79620586	NA	-0.33	-5.9	-0.31	9.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg01475377	chr6:109611718	NA	-0.36	-6.35	-0.33	6.99e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-7.58	-0.39	3.6e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03337784	chr13:41768818	KBTBD7	0.43	6.02	0.31	4.55e-9	Response to antipsychotic treatment;
CRC	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg16482183	chr6:26056742	HIST1H1C	0.85	10.66	0.51	5.33e-23	Iron status biomarkers;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs1355223	0.573	rs7125773	chr11:34723573	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.62	-0.3	4e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg14673194	chr17:80132900	CCDC57	0.48	6.19	0.32	1.78e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.59	8.87	0.44	4.85e-17	Aortic root size;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.02	0.31	4.7e-9	Prudent dietary pattern;
CRC	cis	rs860295	0.812	rs4278368	chr1:155722557	G/A	cg02153340	chr1:155202674	NA	-0.52	-6.46	-0.34	3.71e-10	Body mass index;
CRC	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg03037974	chr15:76606532	NA	-0.5	-7.26	-0.37	2.81e-12	Blood metabolite levels;
CRC	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg06632207	chr12:54070931	ATP5G2	0.49	8.48	0.42	7.63e-16	Height;
CRC	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg15147215	chr3:52552868	STAB1	0.38	5.76	0.3	1.98e-8	Schizophrenia;
CRC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.58	7.06	0.36	9.73e-12	Lymphocyte counts;
CRC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03676636	chr4:99064102	C4orf37	0.21	5.84	0.31	1.22e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.51	-8.26	-0.41	3.68e-15	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.47	-6.71	-0.35	8.55e-11	Coronary artery disease;
CRC	cis	rs8070740	0.898	rs4790770	chr17:5324893	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	7.5	0.38	5.95e-13	Menopause (age at onset);
CRC	cis	rs17095355	1.000	rs72828245	chr10:111746596	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.36	-0.42	1.75e-15	Biliary atresia;
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg11843238	chr5:131593191	PDLIM4	0.42	8.03	0.4	1.71e-14	Breast cancer;
CRC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.15	0.45	6.16e-18	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.99	0.44	2.05e-17	Morning vs. evening chronotype;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05818854	chr2:71295273	NAGK	-0.43	-6.27	-0.33	1.11e-9	HDL cholesterol;
CRC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.15	0.45	6.07e-18	Bladder cancer;
CRC	cis	rs17234274	0.549	rs4922644	chr11:23233709	G/A	cg05245346	chr11:23248277	NA	0.35	5.66	0.3	3.29e-8	Cancer;
CRC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.47	-6.49	-0.34	3.1e-10	Urinary 1,3-butadiene metabolite levels in smokers;
CRC	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	1.06	7.31	0.37	2.05e-12	Intelligence (multi-trait analysis);
CRC	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg20744362	chr22:50050164	C22orf34	0.32	5.82	0.31	1.38e-8	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.44	-5.83	-0.31	1.32e-8	Gut microbiome composition (summer);
CRC	trans	rs6600671	1.000	rs10903159	chr1:121181997	G/T	cg00646200	chr1:148855367	NA	0.34	6.22	0.32	1.49e-9	Hip geometry;
CRC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.69	9.12	0.45	7.92e-18	High light scatter reticulocyte count;
CRC	cis	rs6908843	0.532	rs79555858	chr6:166666497	G/A	cg06878426	chr6:166666287	NA	0.56	6.06	0.32	3.67e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.46	-7.19	-0.37	4.39e-12	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07491357	chr18:9914943	VAPA	0.48	6.6	0.34	1.66e-10	Response to antipsychotic treatment;
CRC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg23018236	chr17:30244563	NA	-0.58	-7.7	-0.39	1.64e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.55	8.23	0.41	4.43e-15	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10893370	chr17:30228961	UTP6	0.44	6.23	0.32	1.43e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25048357	chr11:118955763	HMBS	0.42	6.11	0.32	2.84e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2302190	0.882	rs3809709	chr17:56590559	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.11	0.32	2.81e-9	Vitamin D levels;
CRC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	13.54	0.6	1.73e-33	Total body bone mineral density;
CRC	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg01493522	chr13:37497338	NA	-0.52	-7.16	-0.37	5.21e-12	Coronary artery disease;
CRC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg02725872	chr8:58115012	NA	-0.41	-6.33	-0.33	8.11e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.54	9.8	0.48	4.62e-20	Lung cancer;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.49	-6.39	-0.33	5.7e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.86	-16.0	-0.66	4.9e-43	Paraoxonase activity;
CRC	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.44	5.85	0.31	1.19e-8	Tuberculosis;
CRC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.77	-0.35	5.83e-11	Bipolar disorder;
CRC	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	0.83	6.87	0.35	3.31e-11	Type 2 diabetes nephropathy;
CRC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00801512	chr17:28996047	NA	0.57	6.45	0.34	4.07e-10	Hip circumference adjusted for BMI;
CRC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.47	6.09	0.32	3.16e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.03	16.37	0.67	1.72e-44	Cognitive function;
CRC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.74	-12.24	-0.56	1.22e-28	Lung cancer;
CRC	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.7	11.45	0.53	8.88e-26	Itch intensity from mosquito bite;
CRC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg05552183	chr6:42928497	GNMT	-0.49	-6.08	-0.32	3.3e-9	Blood protein levels;
CRC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.08	0.36	8.6e-12	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27482438	chr7:102312200	POLR2J2	0.43	6.07	0.32	3.61e-9	Anxiety disorder;
CRC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg18016565	chr1:150552671	MCL1	-0.42	-6.22	-0.32	1.5e-9	Tonsillectomy;
CRC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.65	12.14	0.56	2.73e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	14.91	0.63	9.46e-39	Menarche (age at onset);
CRC	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg23032129	chr1:109941072	SORT1	-0.28	-5.94	-0.31	7.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.14	-0.32	2.35e-9	Diabetic kidney disease;
CRC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg20243544	chr17:37824526	PNMT	0.57	9.07	0.45	1.12e-17	Asthma;
CRC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.5	-7.19	-0.37	4.25e-12	Height;
CRC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.44	6.76	0.35	6.36e-11	Platelet count;
CRC	cis	rs12586317	0.557	rs8004288	chr14:35679288	A/G	cg07166546	chr14:35805898	NA	-0.32	-6.1	-0.32	3.01e-9	Psoriasis;
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-9.11	-0.45	8.49e-18	Bipolar disorder;
CRC	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.58	-7.97	-0.4	2.68e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	0.98	8.4	0.42	1.37e-15	Granulocyte percentage of myeloid white cells;
CRC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.06	10.36	0.5	5.88e-22	Diabetic retinopathy;
CRC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.38	8.7	0.43	1.59e-16	Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05308161	chr15:59063885	FAM63B	0.42	6.13	0.32	2.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.68	-7.81	-0.4	7.69e-14	Vitiligo;
CRC	cis	rs4731207	0.646	rs67453484	chr7:124454524	T/A	cg23710748	chr7:124431027	NA	0.38	5.98	0.31	5.89e-9	Cutaneous malignant melanoma;
CRC	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	16.0	0.66	5.06e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.24	-0.41	4.17e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.81	-12.03	-0.55	7.24e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.5	7.86	0.4	5.49e-14	Motion sickness;
CRC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.56	8.41	0.42	1.25e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs8064454	1.000	rs11651755	chr17:36099840	A/G	cg04198914	chr17:36106025	HNF1B	0.28	6.01	0.31	4.89e-9	Prostate cancer;
CRC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg11663144	chr21:46675770	NA	-0.77	-11.15	-0.52	1.08e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.43	7.1	0.36	7.77e-12	Schizophrenia;
CRC	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs6445967	1.000	rs9846885	chr3:58285789	C/T	cg23715586	chr3:58305044	RPP14	0.36	6.18	0.32	1.89e-9	Platelet count;
CRC	cis	rs501916	0.602	rs472081	chr15:48058652	G/T	cg16110827	chr15:48056943	SEMA6D	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg01874867	chr7:94954059	PON1	-0.49	-6.36	-0.33	6.6e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.39	-0.33	5.62e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.69	11.93	0.55	1.62e-27	Resting heart rate;
CRC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.5	-9.23	-0.45	3.38e-18	Dupuytren's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04441191	chr3:48130393	MAP4	-0.46	-7.26	-0.37	2.8e-12	Myopia (pathological);
CRC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.47	7.16	0.37	5.26e-12	Corneal astigmatism;
CRC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.7	0.43	1.57e-16	Height;
CRC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg13072238	chr3:49761600	GMPPB	0.5	5.84	0.31	1.25e-8	Menarche (age at onset);
CRC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg13390004	chr1:15929781	NA	0.44	6.33	0.33	7.98e-10	Systolic blood pressure;
CRC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.44e-15	Lung cancer;
CRC	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg27083787	chr2:113543245	IL1A	0.46	6.25	0.33	1.29e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg09045935	chr12:6379348	NA	1.05	8.45	0.42	9.72e-16	Blood metabolite levels;
CRC	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.81	10.19	0.49	2.33e-21	Prostate cancer;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.16	-0.32	2.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg25456477	chr12:86230367	RASSF9	0.32	5.6	0.3	4.42e-8	Major depressive disorder;
CRC	cis	rs4132509	0.696	rs10927062	chr1:243889364	A/G	cg21452805	chr1:244014465	NA	0.48	6.65	0.34	1.19e-10	RR interval (heart rate);
CRC	cis	rs7781266	0.842	rs4363141	chr7:133225346	C/T	cg03336402	chr7:133662267	EXOC4	0.49	5.78	0.3	1.71e-8	Educational attainment (college completion);
CRC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	8.5	0.42	6.78e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.5	6.86	0.35	3.48e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	7.62	0.39	2.73e-13	Breast cancer;
CRC	cis	rs9463078	0.630	rs7775717	chr6:44967761	G/A	cg25276700	chr6:44698697	NA	-0.25	-6.09	-0.32	3.22e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.6	8.77	0.44	9.79e-17	Uric acid levels;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg23978390	chr7:1156363	C7orf50	0.5	5.63	0.3	3.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.92	-0.55	1.84e-27	Alzheimer's disease;
CRC	trans	rs6956675	1.000	rs6956675	chr7:62577770	A/G	cg01314568	chr7:57830625	NA	-0.68	-9.57	-0.47	2.71e-19	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12463550	chr7:65579703	CRCP	0.71	6.52	0.34	2.65e-10	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg04025307	chr7:1156635	C7orf50	0.64	6.76	0.35	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12024301	0.557	rs11802393	chr1:183654169	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.33	-0.33	8.18e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.967	rs228588	chr11:108113331	C/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.73	0.3	2.23e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg24531977	chr5:56204891	C5orf35	0.44	6.89	0.36	2.77e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg16898833	chr6:26189333	HIST1H4D	0.89	7.39	0.38	1.2e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.52	0.5	1.67e-22	Bipolar disorder;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg02869364	chr7:1081709	C7orf50	-0.37	-5.61	-0.3	4.32e-8	Longevity;Endometriosis;
CRC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.19e-8	Type 2 diabetes;
CRC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg03623178	chr6:28175578	NA	-0.52	-7.7	-0.39	1.56e-13	Pubertal anthropometrics;
CRC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.56	-8.5	-0.42	6.79e-16	Aortic root size;
CRC	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.69	-9.74	-0.47	7.51e-20	Personality dimensions;
CRC	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17173732	chr18:60986891	BCL2	0.44	6.06	0.32	3.74e-9	Thyroid stimulating hormone;
CRC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.01	0.48	9.43e-21	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11590700	chr3:169381241	MECOM	0.47	7.73	0.39	1.29e-13	Intelligence (multi-trait analysis);
CRC	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg22192744	chr12:123187474	GPR109A	-0.4	-5.66	-0.3	3.25e-8	Adiponectin levels;
CRC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.45	6.48	0.34	3.27e-10	Cognitive test performance;
CRC	cis	rs8099014	0.906	rs4940692	chr18:56099715	A/G	cg12907477	chr18:56117327	MIR122	0.46	6.37	0.33	6.2e-10	Platelet count;
CRC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.28	-0.46	2.34e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.43	-5.67	-0.3	3.06e-8	Coronary artery disease;
CRC	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.59	-8.97	-0.44	2.32e-17	Dementia with Lewy bodies;
CRC	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg11038491	chr20:34638489	LOC647979	-0.54	-5.99	-0.31	5.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg15845792	chr6:28175446	NA	0.92	12.39	0.56	3.27e-29	Parkinson's disease;
CRC	cis	rs2860975	1.000	rs2860975	chr10:96766934	G/T	cg09036531	chr10:96991505	NA	0.43	6.0	0.31	5.23e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.51	8.0	0.4	2.18e-14	Coronary artery disease;
CRC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg02428538	chr16:24856791	SLC5A11	-0.75	-8.81	-0.44	7.42e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg13047869	chr3:10149882	C3orf24	0.39	5.95	0.31	6.8e-9	Alzheimer's disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08301299	chr16:2317849	RNPS1	0.49	6.88	0.35	2.96e-11	Survival in pancreatic cancer;
CRC	trans	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.75	10.0	0.48	1e-20	Coronary artery disease;
CRC	cis	rs6804368	0.649	rs9836912	chr3:30761581	A/G	cg06106510	chr3:30762233	NA	0.41	7.47	0.38	7.2e-13	Blood metabolite levels;
CRC	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.57	8.77	0.44	1.01e-16	Autism;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg25164649	chr6:28176230	NA	0.73	9.16	0.45	5.49e-18	Depression;
CRC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.41	6.73	0.35	7.44e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	1.01e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg12682573	chr17:27188876	MIR451;MIR144	0.62	9.4	0.46	9.58e-19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg12172441	chr6:28176163	NA	-0.42	-6.0	-0.31	5.2e-9	Cardiac Troponin-T levels;
CRC	cis	rs4867766	0.585	rs6556141	chr5:173952640	C/T	cg20434911	chr5:173954559	NA	-0.51	-6.18	-0.32	1.92e-9	Stroke;
CRC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg08270630	chr22:50330655	NA	-0.39	-5.62	-0.3	4.13e-8	Schizophrenia;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg01087382	chr6:91297190	MAP3K7	-0.46	-6.34	-0.33	7.56e-10	3-hydroxypropylmercapturic acid levels in smokers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08063013	chr11:63742144	COX8A	0.45	6.34	0.33	7.47e-10	Response to antipsychotic treatment;
CRC	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.56	7.72	0.39	1.4e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.71	0.35	8.29e-11	Menopause (age at onset);
CRC	cis	rs12476592	0.602	rs2604614	chr2:63894133	T/G	cg10828910	chr2:63850056	LOC388955	0.52	6.44	0.33	4.3e-10	Childhood ear infection;
CRC	cis	rs10905065	0.931	rs2497	chr10:5807608	A/G	cg11519256	chr10:5708881	ASB13	-0.46	-6.35	-0.33	7.18e-10	Menopause (age at onset);
CRC	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.65	-10.71	-0.51	3.57e-23	Type 2 diabetes;
CRC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg18876405	chr7:65276391	NA	0.44	6.59	0.34	1.72e-10	Aortic root size;
CRC	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	1.02	18.19	0.71	1.14e-51	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg15664640	chr17:80829946	TBCD	-0.55	-6.72	-0.35	8.27e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.5	-0.34	2.95e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.64	-0.43	2.54e-16	IgG glycosylation;
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg15383120	chr6:291909	DUSP22	-0.49	-6.95	-0.36	2.02e-11	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.62	-11.69	-0.54	1.27e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg20933634	chr6:27740509	NA	0.59	7.03	0.36	1.2e-11	Parkinson's disease;
CRC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.0	-0.36	1.42e-11	Total body bone mineral density;
CRC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.45	-0.33	4.02e-10	Aortic root size;
CRC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.15	-0.49	3.03e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg24531977	chr5:56204891	C5orf35	-0.45	-6.93	-0.36	2.25e-11	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-8.11	-0.41	1.03e-14	Hemoglobin concentration;
CRC	cis	rs4938330	0.608	rs2239012	chr11:117088362	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.05	-0.32	3.94e-9	Blood protein levels;
CRC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.43	8.1	0.41	1.06e-14	Childhood ear infection;
CRC	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.86	-0.35	3.37e-11	Mean corpuscular volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18861140	chr18:3449789	TGIF1	0.45	7.39	0.38	1.24e-12	Obesity-related traits;
CRC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg16358738	chr2:241808595	AGXT	-0.4	-6.25	-0.33	1.24e-9	Urinary metabolites;
CRC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	13.68	0.6	5.07e-34	Chronic sinus infection;
CRC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-5.76	-0.3	1.95e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.68	-0.35	1.03e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg20936604	chr3:58311152	NA	-0.76	-7.91	-0.4	4.04e-14	Cholesterol, total;
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-0.9	-9.83	-0.48	3.68e-20	Body mass index;
CRC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg06287003	chr12:125626642	AACS	-0.5	-7.39	-0.38	1.19e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1223397	0.702	rs1223400	chr6:13271242	T/C	cg20827128	chr6:13274284	PHACTR1	0.55	6.62	0.34	1.46e-10	Blood pressure;
CRC	cis	rs863345	0.564	rs10908667	chr1:158500121	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.24	-0.33	1.35e-9	Pneumococcal bacteremia;
CRC	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.5	-6.98	-0.36	1.59e-11	Schizophrenia;
CRC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	10.43	0.5	3.53e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.53	-7.27	-0.37	2.57e-12	DNA methylation (variation);
CRC	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.42	0.42	1.15e-15	Coffee consumption (cups per day);
CRC	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-6.71	-0.35	8.44e-11	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10459029	chr2:242640849	ING5	0.48	6.81	0.35	4.73e-11	Response to antipsychotic treatment;
CRC	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.08	11.38	0.53	1.56e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.76	12.37	0.56	4.12e-29	Lung cancer;
CRC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg00579200	chr11:133705235	NA	-0.39	-5.68	-0.3	3.03e-8	Childhood ear infection;
CRC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.09	-0.32	3.15e-9	Aortic root size;
CRC	cis	rs4731207	0.596	rs1481330	chr7:124631363	C/T	cg23710748	chr7:124431027	NA	-0.43	-6.94	-0.36	2.08e-11	Cutaneous malignant melanoma;
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.5	-0.42	6.61e-16	Life satisfaction;
CRC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg22777020	chr22:31556080	RNF185	-0.51	-5.86	-0.31	1.15e-8	Colorectal cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05165064	chr20:18037039	OVOL2	-0.53	-6.87	-0.35	3.19e-11	Diisocyanate-induced asthma;
CRC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg01097406	chr16:89675127	NA	0.44	8.51	0.42	6.43e-16	Hemoglobin concentration;
CRC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9487051	0.698	rs13202939	chr6:109649655	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.73	-0.3	2.22e-8	Reticulocyte fraction of red cells;
CRC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.93	0.31	7.74e-9	Breast cancer;
CRC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-9.1	-0.45	9.16e-18	IgG glycosylation;
CRC	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.71	14.1	0.61	1.25e-35	Leprosy;
CRC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg27565382	chr3:53032988	SFMBT1	0.77	6.23	0.32	1.41e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.49	-8.59	-0.43	3.44e-16	Anterior chamber depth;
CRC	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.16	-0.32	2.13e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.52	5.97	0.31	6.19e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.49	5.67	0.3	3.14e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs28655083	0.550	rs598340	chr16:77102504	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.81	0.35	4.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.69	0.51	4.22e-23	Alzheimer's disease;
CRC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.89	9.76	0.47	6.25e-20	Skin colour saturation;
CRC	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg10437265	chr15:77819839	NA	0.68	12.24	0.56	1.2e-28	Type 2 diabetes;
CRC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.58	-0.34	1.88e-10	Joint mobility (Beighton score);
CRC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.56	-0.38	4e-13	Bladder cancer;
CRC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.91	16.37	0.67	1.84e-44	Prostate cancer;
CRC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.7	0.3	2.66e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.61	9.49	0.46	4.73e-19	Aortic root size;
CRC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.33e-11	Lung cancer;
CRC	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg18165381	chr3:44552316	NA	-0.39	-5.91	-0.31	8.43e-9	Depressive symptoms;
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs62045849	0.557	rs117708030	chr16:89181220	A/G	cg08015503	chr16:89190385	ACSF3	1.04	6.26	0.33	1.19e-9	Red blood cell count;
CRC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.13	11.6	0.54	2.58e-26	Intelligence (multi-trait analysis);
CRC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.85	16.24	0.67	6e-44	Metabolic syndrome;
CRC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-17.39	-0.69	1.77e-48	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02190572	chr10:74057806	NA	0.55	7.68	0.39	1.9e-13	Anxiety disorder;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg06802599	chr6:42981650	MEA1;KLHDC3	-0.42	-6.1	-0.32	2.9e-9	Birth weight;Height;
CRC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.58	0.43	3.78e-16	Morning vs. evening chronotype;
CRC	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-0.49	-6.6	-0.34	1.64e-10	Blood protein levels;
CRC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg06238570	chr21:40685208	BRWD1	0.7	9.3	0.46	1.97e-18	Cognitive function;
CRC	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.72	-8.05	-0.41	1.52e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12476592	0.602	rs262525	chr2:63893158	A/G	cg10828910	chr2:63850056	LOC388955	0.51	6.35	0.33	7.16e-10	Childhood ear infection;
CRC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.82	9.5	0.46	4.6e-19	Gut microbiome composition (summer);
CRC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17507749	chr15:85114479	UBE2QP1	0.65	9.27	0.45	2.58e-18	Schizophrenia;
CRC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg10589385	chr1:150898437	SETDB1	0.3	6.16	0.32	2.11e-9	Melanoma;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg03623178	chr6:28175578	NA	0.97	12.38	0.56	3.55e-29	Depression;
CRC	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.78	-12.46	-0.57	1.92e-29	Plateletcrit;Platelet count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18516317	chr2:54950679	EML6	-0.39	-5.96	-0.31	6.53e-9	Myopia (pathological);
CRC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg17724175	chr1:150552817	MCL1	-0.48	-7.22	-0.37	3.65e-12	Melanoma;
CRC	cis	rs2346160	1.000	rs7753298	chr6:167664193	G/A	cg27333441	chr6:167680455	NA	0.38	6.32	0.33	8.71e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.7	-0.39	1.58e-13	Mood instability;
CRC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22133161	chr19:49891603	CCDC155	0.51	7.0	0.36	1.42e-11	Multiple sclerosis;
CRC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	0.98	9.08	0.45	1.03e-17	Pulse pressure;
CRC	cis	rs2227564	0.729	rs2633303	chr10:75645882	G/T	cg16540259	chr10:75572220	NDST2	0.41	5.64	0.3	3.59e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.46	7.01	0.36	1.39e-11	Dupuytren's disease;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg11301795	chr4:187892539	NA	-0.86	-18.69	-0.72	1.29e-53	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg21138405	chr5:131827807	IRF1	-0.36	-6.22	-0.32	1.53e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	0.87	8.73	0.43	1.27e-16	Prostate cancer;
CRC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg06138825	chr16:67683817	RLTPR	0.52	5.71	0.3	2.51e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg15845792	chr6:28175446	NA	0.73	10.46	0.5	2.64e-22	Parkinson's disease;
CRC	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg04110750	chr16:69646130	NFAT5	-0.53	-7.72	-0.39	1.45e-13	IgE levels;
CRC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.47	6.48	0.34	3.42e-10	White matter microstructure (global fractional anisotropy);
CRC	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.74e-11	Body mass index;
CRC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg13385794	chr1:248469461	NA	0.4	6.96	0.36	1.83e-11	Common traits (Other);
CRC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.25	-0.45	3.02e-18	Alcohol dependence;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.49	-7.43	-0.38	9.33e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg03526776	chr6:41159608	TREML2	0.36	6.53	0.34	2.52e-10	Alzheimer's disease (late onset);
CRC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1223397	0.938	rs9395602	chr6:13278753	C/T	cg20827128	chr6:13274284	PHACTR1	0.55	6.61	0.34	1.56e-10	Blood pressure;
CRC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.43	-0.42	1.08e-15	Hemoglobin concentration;
CRC	cis	rs4664293	0.647	rs1966530	chr2:160477408	G/A	cg08347373	chr2:160653686	CD302	-0.39	-6.74	-0.35	7.18e-11	Monocyte percentage of white cells;
CRC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.57	7.83	0.4	6.72e-14	Lung cancer;
CRC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.37	-6.82	-0.35	4.25e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.2	-0.37	4.18e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.41	6.57	0.34	1.97e-10	Height;
CRC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.51	6.35	0.33	7.21e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg12160578	chr15:63334699	TPM1	0.61	7.22	0.37	3.62e-12	Orofacial clefts;
CRC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Crohn's disease;
CRC	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.8	0.35	5.06e-11	Intraocular pressure;
CRC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.27	0.37	2.56e-12	Major depressive disorder;
CRC	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.67	6.99	0.36	1.56e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.83	-0.35	4.23e-11	Response to antipsychotic treatment;
CRC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.47	0.34	3.61e-10	Primary sclerosing cholangitis;
CRC	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.42	5.68	0.3	2.93e-8	Systemic lupus erythematosus;
CRC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg03929089	chr4:120376271	NA	0.63	6.01	0.31	4.92e-9	Axial length;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg02445447	chr2:106015594	FHL2	0.43	6.96	0.36	1.87e-11	Obesity-related traits;
CRC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.4	-6.03	-0.32	4.38e-9	Gout;Renal underexcretion gout;
CRC	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-15.37	-0.65	1.46e-40	Schizophrenia;
CRC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07701084	chr6:150067640	NUP43	0.51	7.41	0.38	1.09e-12	Testicular germ cell tumor;
CRC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg24759859	chr6:86352639	SYNCRIP	0.48	6.48	0.34	3.29e-10	Smooth-surface caries;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25744181	chr1:231664219	TSNAX-DISC1;TSNAX	0.44	6.1	0.32	3.06e-9	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-7.12	-0.37	6.69e-12	Lung cancer;
CRC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.46	6.91	0.36	2.52e-11	Menopause (age at onset);
CRC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.31	-6.93	-0.36	2.28e-11	IgG glycosylation;
CRC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg17633681	chr16:88106987	BANP	-0.78	-13.89	-0.61	7.74e-35	Menopause (age at onset);
CRC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg03013999	chr17:37608204	MED1	-0.46	-7.02	-0.36	1.29e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.61	-11.52	-0.54	4.84e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs1656402	0.906	rs7607107	chr2:233452344	T/G	cg03852847	chr2:233439513	NA	-0.41	-6.82	-0.35	4.45e-11	Non-small cell lung cancer (survival);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02545393	chr11:70244902	CTTN	0.39	6.31	0.33	9e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg19635926	chr16:89946313	TCF25	0.65	6.7	0.35	9.28e-11	Skin colour saturation;
CRC	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg08632701	chr21:37451849	NA	0.44	6.87	0.35	3.13e-11	Mitral valve prolapse;
CRC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.76	14.55	0.63	2.33e-37	Body mass index;
CRC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.9	17.66	0.7	1.46e-49	Bone mineral density;
CRC	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg23202291	chr11:1979235	NA	0.41	6.02	0.32	4.53e-9	DNA methylation (variation);
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.77	13.12	0.59	6.45e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg26061582	chr7:22766209	IL6	0.54	8.86	0.44	5.23e-17	Lung cancer;
CRC	cis	rs6604026	0.656	rs2774945	chr1:93346239	T/C	cg17283838	chr1:93427260	FAM69A	-0.44	-5.69	-0.3	2.76e-8	Multiple sclerosis;
CRC	cis	rs10924970	0.687	rs28593631	chr1:235354572	A/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.74	0.3	2.13e-8	Asthma;
CRC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-7.25	-0.37	2.93e-12	Vitiligo;
CRC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.83	0.48	3.63e-20	Bladder cancer;
CRC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	7.46	0.38	7.83e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07481194	chr14:23398747	PRMT5	0.44	5.99	0.31	5.6e-9	Response to antipsychotic treatment;
CRC	trans	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg11704114	chr12:21509398	SLCO1A2	-0.32	-6.02	-0.31	4.62e-9	Tuberculosis;
CRC	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg04165759	chr1:150448943	RPRD2	-0.34	-5.66	-0.3	3.38e-8	Migraine;
CRC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.43	6.73	0.35	7.33e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.59	8.43	0.42	1.11e-15	Menopause (age at onset);
CRC	trans	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg19894588	chr14:64061835	NA	-0.59	-7.71	-0.39	1.47e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	0.92	7.33	0.37	1.84e-12	Type 2 diabetes nephropathy;
CRC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg09473613	chr1:24152604	HMGCL	-0.34	-5.72	-0.3	2.41e-8	Immature fraction of reticulocytes;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg06470822	chr6:28175283	NA	0.83	12.2	0.56	1.72e-28	Cardiac Troponin-T levels;
CRC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.84	14.96	0.64	5.65e-39	Breast cancer;
CRC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.79	10.11	0.49	4.26e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.18	-0.41	6.47e-15	Chronic sinus infection;
CRC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg02733842	chr7:1102375	C7orf50	-0.79	-9.15	-0.45	6.2e-18	Bronchopulmonary dysplasia;
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.4e-9	Prudent dietary pattern;
CRC	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.66	-7.51	-0.38	5.64e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg27523141	chr10:43048294	ZNF37B	0.49	7.18	0.37	4.65e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg12193833	chr17:30244370	NA	-0.58	-8.01	-0.4	1.96e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.76	-0.3	1.97e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg20243544	chr17:37824526	PNMT	0.6	8.49	0.42	7.4e-16	Primary biliary cholangitis;
CRC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.84	-0.68	2.56e-46	Height;
CRC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.53	6.78	0.35	5.54e-11	Intelligence (multi-trait analysis);
CRC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg14530993	chr4:882597	GAK	0.75	6.91	0.36	2.59e-11	Parkinson's disease;
CRC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg15123519	chr2:136567270	LCT	0.34	6.57	0.34	1.95e-10	Mosquito bite size;
CRC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg04518342	chr5:131593106	PDLIM4	0.45	8.18	0.41	6.2e-15	Breast cancer;
CRC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs11212617	0.934	rs694376	chr11:108119048	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.73	0.3	2.23e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.51	7.25	0.37	2.94e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.42	1.07e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.8	0.48	4.59e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7635838	0.892	rs34830847	chr3:11437798	A/C	cg00170343	chr3:11313890	ATG7	0.41	6.35	0.33	7.03e-10	HDL cholesterol;
CRC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.8	0.3	1.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.44	5.91	0.31	8.73e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.69	-8.23	-0.41	4.32e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.56	8.41	0.42	1.25e-15	Multiple myeloma (IgH translocation);
CRC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.53	6.75	0.35	6.88e-11	Morning vs. evening chronotype;
CRC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.65	9.81	0.48	4.2e-20	Longevity;Endometriosis;
CRC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.57	7.05	0.36	1.04e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg00383909	chr3:49044727	WDR6	0.84	8.72	0.43	1.36e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs9463078	0.653	rs1411148	chr6:45043618	A/G	cg25276700	chr6:44698697	NA	-0.24	-5.82	-0.31	1.4e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg06238570	chr21:40685208	BRWD1	0.76	10.33	0.49	7.54e-22	Cognitive function;
CRC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	0.98	9.25	0.45	2.88e-18	Lymphocyte counts;
CRC	cis	rs6743226	0.934	rs7604465	chr2:242249828	C/T	cg10021735	chr2:242295487	FARP2	0.47	6.9	0.36	2.73e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.6	-10.54	-0.5	1.46e-22	Iron status biomarkers;
CRC	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg15654264	chr1:150340011	RPRD2	0.4	5.92	0.31	7.99e-9	Migraine;
CRC	cis	rs7605827	0.930	rs11676115	chr2:15602962	G/A	cg19274914	chr2:15703543	NA	0.39	5.92	0.31	8.2e-9	Educational attainment (years of education);
CRC	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21659725	chr3:3221576	CRBN	-0.69	-7.14	-0.37	6.11e-12	Menarche (age at onset);
CRC	cis	rs17713451	0.593	rs6955903	chr7:151269152	C/G	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs1887596	0.705	rs533287	chr13:27197419	G/A	cg01312412	chr13:27282625	NA	0.45	6.0	0.31	5.11e-9	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs800160	0.777	rs2521294	chr11:2348778	C/T	cg09785033	chr11:2336066	TSPAN32	-0.55	-6.48	-0.34	3.39e-10	Bacteremia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16091319	chr1:193028569	TROVE2;UCHL5	0.41	5.98	0.31	5.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.46	7.08	0.36	8.84e-12	HDL cholesterol;
CRC	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg03315344	chr16:75512273	CHST6	0.54	6.14	0.32	2.31e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs2274273	0.624	rs7155954	chr14:55750943	G/A	cg10130446	chr14:55658398	DLGAP5	-0.42	-6.0	-0.31	5.22e-9	Protein biomarker;
CRC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg21466736	chr12:48725269	NA	-0.47	-7.21	-0.37	3.97e-12	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	8.21	0.41	5.1e-15	Iron status biomarkers;
CRC	cis	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg18809830	chr7:99032528	PTCD1	-1.03	-7.68	-0.39	1.85e-13	Blood metabolite levels;
CRC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg03623178	chr6:28175578	NA	0.63	8.4	0.42	1.36e-15	Parkinson's disease;
CRC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-8.84	-0.44	5.76e-17	Hip circumference adjusted for BMI;
CRC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.51	8.45	0.42	9.22e-16	Uric acid clearance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14325169	chr10:60145452	TFAM	0.44	6.44	0.33	4.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.54	-8.38	-0.42	1.58e-15	Asthma (sex interaction);
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	trans	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg21302420	chr1:112162376	RAP1A	0.71	6.63	0.34	1.4e-10	Skin colour saturation;
CRC	cis	rs501120	1.000	rs534079	chr10:44752558	G/T	cg09554077	chr10:44749378	NA	0.89	13.32	0.59	1.14e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11574514	0.661	rs8058310	chr16:67893839	G/A	cg26727032	chr16:67993705	SLC12A4	-0.61	-5.91	-0.31	8.58e-9	Crohn's disease;
CRC	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg01843034	chr6:37503916	NA	-0.46	-8.71	-0.43	1.54e-16	Cognitive performance;
CRC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg18357645	chr12:58087776	OS9	-0.49	-5.75	-0.3	1.99e-8	Multiple sclerosis;
CRC	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.6	8.43	0.42	1.1e-15	Uric acid levels;
CRC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg00343986	chr7:65444356	GUSB	-0.42	-5.91	-0.31	8.53e-9	Aortic root size;
CRC	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.44	-0.33	4.15e-10	Prevalent atrial fibrillation;
CRC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.52	8.08	0.41	1.27e-14	Colorectal cancer;
CRC	cis	rs17092148	0.790	rs6087602	chr20:33170689	G/A	cg08999081	chr20:33150536	PIGU	0.5	6.38	0.33	5.94e-10	Neuroticism;
CRC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.69	-11.46	-0.53	8.49e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4664293	0.867	rs2303550	chr2:160637621	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.47	-0.38	7.5e-13	Monocyte percentage of white cells;
CRC	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.42	-6.12	-0.32	2.61e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.72	8.8	0.44	8.06e-17	Plateletcrit;Platelet count;
CRC	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg16141378	chr3:129829833	LOC729375	0.45	6.77	0.35	5.83e-11	Mood instability;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12232852	chr3:69129018	UBA3	0.47	6.14	0.32	2.42e-9	Thyroid stimulating hormone;
CRC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg06207120	chr15:45996521	NA	0.32	7.76	0.39	1.05e-13	Waist circumference;Weight;
CRC	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg09307838	chr4:120376055	NA	0.64	9.48	0.46	5.15e-19	Educational attainment;
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg04025307	chr7:1156635	C7orf50	0.66	7.09	0.36	8.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02290350	chr8:58132656	NA	-0.57	-8.01	-0.4	1.97e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6594535	0.922	rs3797737	chr5:111090124	C/G	cg06838283	chr5:111090142	C5orf13	0.55	8.34	0.42	2.08e-15	Chickenpox;
CRC	cis	rs9517320	1.000	rs7338549	chr13:99142745	C/T	cg07423050	chr13:99094983	FARP1	0.38	6.01	0.31	4.89e-9	Longevity;
CRC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.49	0.38	6.38e-13	Lung cancer;
CRC	cis	rs9469913	0.668	rs76967117	chr6:34603691	G/A	cg17674042	chr6:34482479	PACSIN1	-0.74	-7.11	-0.37	7.05e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.29e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.4	0.46	9.75e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.68	-9.85	-0.48	3.2e-20	Type 2 diabetes;
CRC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.52	-6.08	-0.32	3.42e-9	Vitiligo;
CRC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.58	-6.93	-0.36	2.25e-11	Body mass index;
CRC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg24585782	chr17:78113791	EIF4A3	-0.52	-7.09	-0.36	8.41e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2315504	0.568	rs8078796	chr17:38963647	G/A	cg06456531	chr17:38929184	KRT26	-0.32	-5.8	-0.3	1.6e-8	Height;
CRC	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.63	10.33	0.49	7.61e-22	Corneal astigmatism;
CRC	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.47	-0.46	5.55e-19	Migraine;Coronary artery disease;
CRC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg11843238	chr5:131593191	PDLIM4	-0.43	-7.31	-0.37	2.07e-12	Breast cancer;
CRC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.58	-0.47	2.41e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs17539620	0.507	rs6927301	chr6:154872080	G/T	cg20019720	chr6:154832845	CNKSR3	-0.34	-7.53	-0.38	5.09e-13	Lipoprotein (a) levels;
CRC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg01304814	chr3:48885189	PRKAR2A	0.81	6.26	0.33	1.23e-9	Blood protein levels;
CRC	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg01312482	chr5:178451176	ZNF879	-0.36	-6.07	-0.32	3.55e-9	Pubertal anthropometrics;
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-0.76	-7.49	-0.38	6.54e-13	IgG glycosylation;
CRC	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.88	-15.23	-0.64	4.95e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02047359	chr10:75174015	ANXA7	-0.51	-6.3	-0.33	9.78e-10	Diisocyanate-induced asthma;
CRC	cis	rs6694672	1.000	rs9427940	chr1:196943353	G/T	cg13682187	chr1:196946512	CFHR5	-0.46	-6.84	-0.35	3.79e-11	Asthma;
CRC	cis	rs7215564	0.643	rs59992540	chr17:78658265	G/A	cg09596252	chr17:78655493	RPTOR	0.53	5.66	0.3	3.26e-8	Myopia (pathological);
CRC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg21970626	chr13:21893289	NA	0.42	5.82	0.31	1.36e-8	White matter hyperintensity burden;
CRC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.59	-8.67	-0.43	2.02e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.55	7.87	0.4	5.09e-14	Tuberculosis;
CRC	cis	rs7394190	0.810	rs7394178	chr10:75421580	G/A	cg07699608	chr10:75541558	CHCHD1	0.58	6.19	0.32	1.77e-9	Incident atrial fibrillation;
CRC	trans	rs747334	0.846	rs4423105	chr10:92724446	C/G	cg19856520	chr1:39696676	MACF1	-0.32	-5.97	-0.31	6.05e-9	Fibroblast growth factor basic levels;
CRC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.49	5.7	0.3	2.6e-8	Dental caries;
CRC	cis	rs3136516	0.504	rs11038910	chr11:46543524	C/T	cg16389345	chr11:46697382	NA	0.35	5.65	0.3	3.54e-8	Venous thromboembolism;
CRC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.55	-8.63	-0.43	2.66e-16	Aortic root size;
CRC	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.55	-0.34	2.16e-10	Caffeine consumption;
CRC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg18099408	chr3:52552593	STAB1	0.34	5.82	0.31	1.38e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4664293	0.647	rs6432539	chr2:160448720	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg18230493	chr5:56204884	C5orf35	-0.59	-8.66	-0.43	2.2e-16	Initial pursuit acceleration;
CRC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg24562669	chr7:97807699	LMTK2	-0.61	-11.46	-0.53	8.22e-26	Breast cancer;
CRC	cis	rs2072510	0.932	rs10859999	chr12:96391334	A/G	cg22491680	chr12:96389547	HAL	0.39	5.98	0.31	5.66e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg20512303	chr5:131592959	PDLIM4	-0.36	-5.63	-0.3	3.9e-8	Lymphocyte counts;Fibrinogen;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12892311	chr8:8860454	ERI1	0.4	6.04	0.32	4.2e-9	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg27661571	chr11:113659931	NA	-0.81	-9.84	-0.48	3.51e-20	Hip circumference adjusted for BMI;
CRC	cis	rs10982256	0.774	rs12551529	chr9:117256896	A/G	cg13636371	chr9:117264095	DFNB31	-0.34	-6.55	-0.34	2.17e-10	Bipolar disorder;
CRC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-17.56	-0.7	3.78e-49	Coronary artery disease;
CRC	cis	rs7781266	0.790	rs73148998	chr7:133181812	C/T	cg03336402	chr7:133662267	EXOC4	0.47	5.62	0.3	4.03e-8	Educational attainment (college completion);
CRC	cis	rs2257205	0.667	rs16943186	chr17:56801848	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg24463073	chr6:118973353	C6orf204	0.52	6.84	0.35	3.84e-11	Diastolic blood pressure;
CRC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.67	-0.3	3.18e-8	Total body bone mineral density;
CRC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14895029	chr7:2775587	GNA12	-0.38	-5.76	-0.3	1.89e-8	Height;
CRC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07701084	chr6:150067640	NUP43	0.49	7.2	0.37	4.04e-12	Testicular germ cell tumor;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	7.62	0.39	2.82e-13	Lymphocyte counts;
CRC	trans	rs1376359	0.673	rs35759666	chr1:103155715	T/A	cg16220183	chr17:56609687	SEPT4	-0.45	-6.26	-0.33	1.17e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg10494257	chr1:16342123	HSPB7	0.45	6.27	0.33	1.1e-9	Dilated cardiomyopathy;
CRC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.55	8.26	0.41	3.49e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.54	8.59	0.43	3.5e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.9	-0.51	8.26e-24	Blood trace element (Zn levels);
CRC	cis	rs10229583	0.527	rs10249616	chr7:127399500	A/G	cg01233922	chr7:127693937	SND1	-0.54	-8.11	-0.41	1.05e-14	Type 2 diabetes;
CRC	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg21153622	chr11:89784906	NA	-0.45	-7.09	-0.36	8.43e-12	Height;
CRC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	17.69	0.7	1.16e-49	Platelet count;
CRC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	10.95	0.52	5.15e-24	Mean corpuscular hemoglobin;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg15845792	chr6:28175446	NA	0.9	13.11	0.59	6.83e-32	Parkinson's disease;
CRC	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg03623178	chr6:28175578	NA	0.65	6.96	0.36	1.83e-11	Parkinson's disease;
CRC	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.43	6.3	0.33	9.35e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.94	0.4	3.33e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg13607699	chr17:42295918	UBTF	0.56	7.7	0.39	1.65e-13	Total body bone mineral density;
CRC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.43	6.91	0.36	2.5e-11	Resting heart rate;
CRC	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg13931752	chr15:40660718	DISP2	0.48	5.91	0.31	8.39e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs2637266	0.538	rs11001818	chr10:78313936	A/T	cg18941641	chr10:78392320	NA	-0.36	-5.9	-0.31	9.19e-9	Pulmonary function;
CRC	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg00631329	chr6:26305371	NA	-0.46	-7.61	-0.39	2.89e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.65	-9.21	-0.45	3.97e-18	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	7.63	0.39	2.52e-13	Personality dimensions;
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.03	-0.45	1.5e-17	Bipolar disorder;
CRC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.58e-12	Height;
CRC	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg26566898	chr11:117069891	TAGLN	0.38	6.91	0.36	2.47e-11	Blood protein levels;
CRC	cis	rs4547160	0.572	rs1032494	chr12:63473125	A/G	cg26727693	chr12:63544175	AVPR1A	-0.43	-7.76	-0.39	1.08e-13	Morning vs. evening chronotype;
CRC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg10621924	chr7:39171070	POU6F2	0.41	5.64	0.3	3.73e-8	IgG glycosylation;
CRC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg01788221	chr16:89496183	ANKRD11	0.4	6.03	0.32	4.38e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.64	-8.85	-0.44	5.44e-17	Alzheimer's disease;
CRC	cis	rs10986311	0.775	rs1007185	chr9:127136644	G/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.4	-6.03	-0.32	4.41e-9	Vitiligo;
CRC	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg04880052	chr2:219191631	PNKD	0.4	6.1	0.32	3.01e-9	Colorectal cancer;
CRC	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.86	15.81	0.66	2.9e-42	Multiple myeloma;
CRC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg15445000	chr17:37608096	MED1	0.36	6.27	0.33	1.14e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.83	-16.16	-0.67	1.21e-43	Hip circumference;
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.42	-5.98	-0.31	5.82e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.3	6.4	0.33	5.48e-10	Migraine;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11028609	chr22:50312261	ALG12;CRELD2	0.4	5.96	0.31	6.53e-9	Response to antipsychotic treatment;
CRC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg06462663	chr19:18546047	ISYNA1	0.5	7.4	0.38	1.16e-12	Breast cancer;
CRC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.63	10.6	0.5	8.82e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11229555	0.574	rs66573492	chr11:58183797	G/A	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg23815491	chr16:72088622	HP	0.53	6.89	0.36	2.86e-11	Blood protein levels;
CRC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg25600027	chr14:23388339	RBM23	-0.53	-8.37	-0.42	1.63e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg00343986	chr7:65444356	GUSB	0.47	6.61	0.34	1.57e-10	Aortic root size;
CRC	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.41	-5.93	-0.31	7.53e-9	Daytime sleep phenotypes;
CRC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs4728302	0.869	rs958405	chr7:133597151	A/G	cg03336402	chr7:133662267	EXOC4	-0.44	-6.33	-0.33	8.01e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.69	-7.26	-0.37	2.85e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.59	8.56	0.43	4.53e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04915425	chr11:47236385	DDB2	0.49	6.18	0.32	1.94e-9	Thyroid stimulating hormone;
CRC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.62	6.64	0.34	1.29e-10	Initial pursuit acceleration;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.0	-0.31	5.07e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs629535	0.773	rs489206	chr8:70064883	T/C	cg26132723	chr8:70041827	NA	0.36	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.6	-9.36	-0.46	1.26e-18	Asthma (sex interaction);
CRC	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg02158880	chr13:53174818	NA	0.5	7.51	0.38	5.53e-13	Lewy body disease;
CRC	cis	rs911119	0.954	rs2405367	chr20:23622880	A/G	cg16589663	chr20:23618590	CST3	-0.63	-8.68	-0.43	1.87e-16	Chronic kidney disease;
CRC	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.43	8.07	0.41	1.33e-14	Attention deficit hyperactivity disorder and conduct disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11265468	chr6:17987657	KIF13A	0.38	6.04	0.32	4.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	5.67	0.3	3.1e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.58	-10.08	-0.49	5.23e-21	Iron status biomarkers;
CRC	cis	rs8105895	0.877	rs2359833	chr19:22242221	T/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.47	-6.72	-0.35	8.26e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.61e-13	Putamen volume;
CRC	cis	rs12898370	0.561	rs34129891	chr15:77481210	T/C	cg10437265	chr15:77819839	NA	0.53	5.93	0.31	7.55e-9	Risky sexual behaviors (alcohol dependence interaction);
CRC	trans	rs7027930	0.761	rs2131781	chr9:561426	T/A	cg27061366	chr19:13044373	FARSA	0.52	6.1	0.32	2.93e-9	Pulmonary function decline;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.59e-9	Cognitive function;
CRC	cis	rs3789045	0.615	rs11240748	chr1:204453320	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.62	-9.22	-0.45	3.52e-18	Educational attainment (college completion);
CRC	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg09659197	chr4:152720779	NA	0.32	5.81	0.31	1.44e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg03160526	chr17:80928410	B3GNTL1	0.58	7.76	0.39	1.06e-13	Glycated hemoglobin levels;
CRC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg16482183	chr6:26056742	HIST1H1C	0.42	6.14	0.32	2.31e-9	Height;
CRC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.81	-14.36	-0.62	1.24e-36	Vitiligo;
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg02683197	chr6:28174875	NA	-0.61	-8.58	-0.43	3.87e-16	Parkinson's disease;
CRC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.43	-6.99	-0.36	1.56e-11	Migraine;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02290350	chr8:58132656	NA	-0.51	-5.89	-0.31	9.42e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg11843238	chr5:131593191	PDLIM4	-0.54	-9.85	-0.48	3.13e-20	Acylcarnitine levels;
CRC	cis	rs11229555	0.574	rs12271501	chr11:58214969	T/C	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.08	-0.55	4.55e-28	Coffee consumption (cups per day);
CRC	cis	rs6545883	0.507	rs4411680	chr2:61584105	A/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.84	-0.4	6.23e-14	Tuberculosis;
CRC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.49	6.54	0.34	2.31e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.61	-9.23	-0.45	3.34e-18	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13514538	chr8:144942538	EPPK1	-0.4	-6.58	-0.34	1.91e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.79	-0.3	1.66e-8	Blood metabolite levels;
CRC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.61	9.64	0.47	1.54e-19	Systemic lupus erythematosus;
CRC	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.45	0.53	9.06e-26	Coffee consumption (cups per day);
CRC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.55	-8.2	-0.41	5.53e-15	Mean platelet volume;
CRC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.5	8.23	0.41	4.47e-15	Aortic root size;
CRC	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.63	8.43	0.42	1.11e-15	Uric acid levels;
CRC	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.14	0.45	6.59e-18	Coffee consumption (cups per day);
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3736485	0.844	rs17524813	chr15:51793533	G/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.42	-0.33	4.67e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg21951975	chr1:209979733	IRF6	0.46	5.6	0.3	4.48e-8	Cleft lip with or without cleft palate;
CRC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg11003573	chr3:44754125	ZNF502	-0.35	-6.25	-0.33	1.27e-9	Depressive symptoms;
CRC	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.72	-12.56	-0.57	7.95e-30	White blood cell count (basophil);
CRC	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg05562828	chr17:3906858	NA	0.67	12.55	0.57	8.33e-30	Type 2 diabetes;
CRC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.48	0.34	3.28e-10	Cognitive ability;
CRC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-8.56	-0.43	4.46e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg21335942	chr16:58549945	SETD6	0.86	5.72	0.3	2.39e-8	Schizophrenia;
CRC	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-5.87	-0.31	1.09e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg23018236	chr17:30244563	NA	-0.67	-8.02	-0.4	1.83e-14	Hip circumference adjusted for BMI;
CRC	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg14550559	chr2:240039617	HDAC4	-0.51	-7.62	-0.39	2.8e-13	Skin aging (microtopography measurement);
CRC	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg11946769	chr3:48343235	NME6	-0.48	-6.29	-0.33	1.02e-9	Educational attainment (years of education);
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.45	6.87	0.35	3.14e-11	Menarche (age at onset);
CRC	cis	rs9513593	1.000	rs723090	chr13:100017105	A/G	cg21788972	chr13:99853209	UBAC2	0.46	5.84	0.31	1.27e-8	Psoriasis;
CRC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	11.93	0.55	1.64e-27	Schizophrenia;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg17524151	chr16:475494	RAB11FIP3	-0.43	-6.28	-0.33	1.05e-9	Birth weight;Height;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.25	5.63	0.3	3.77e-8	Parkinson's disease;
CRC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.38	6.41	0.33	5.02e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-8.75	-0.43	1.15e-16	Uric acid levels;
CRC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.79	12.03	0.55	7.39e-28	Cognitive function;
CRC	cis	rs73206853	0.841	rs56117211	chr12:111123485	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.37	0.33	6.39e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.87	0.4	5.26e-14	Cognitive ability;
CRC	cis	rs534126	0.885	rs10274425	chr7:143016166	A/G	cg04182207	chr7:143013161	CLCN1	0.34	6.32	0.33	8.58e-10	Cancer;
CRC	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg27534772	chr1:16042836	PLEKHM2	0.43	6.95	0.36	1.92e-11	Systolic blood pressure;
CRC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.43	-6.01	-0.31	4.95e-9	Longevity;Endometriosis;
CRC	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.66	10.59	0.5	9.54e-23	Myopia (pathological);
CRC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg26721908	chr21:47610096	LSS	0.45	7.4	0.38	1.16e-12	Testicular germ cell tumor;
CRC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.99	0.36	1.5e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.1	-15.87	-0.66	1.67e-42	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs12024301	0.557	rs6674310	chr1:183603471	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.61	7.45	0.38	8.48e-13	Blood protein levels;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg15845792	chr6:28175446	NA	0.7	7.72	0.39	1.43e-13	Parkinson's disease;
CRC	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg18758796	chr5:131593413	PDLIM4	0.37	6.02	0.32	4.62e-9	Blood metabolite levels;
CRC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	8.04e-20	Intelligence (multi-trait analysis);
CRC	cis	rs727479	0.543	rs4324076	chr15:51510868	A/C	cg19946085	chr15:51559439	CYP19A1	-0.32	-6.45	-0.34	3.93e-10	Estradiol levels;
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13198984	chr17:80129470	CCDC57	0.45	8.05	0.41	1.51e-14	Life satisfaction;
CRC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg12560992	chr17:57184187	TRIM37	0.44	5.85	0.31	1.19e-8	Cognitive test performance;
CRC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg02733842	chr7:1102375	C7orf50	-0.56	-7.06	-0.36	9.85e-12	Bronchopulmonary dysplasia;
CRC	cis	rs2882667	0.861	rs13176902	chr5:138393329	T/C	cg09476006	chr5:138032270	NA	0.44	7.39	0.38	1.21e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.82	-10.96	-0.52	5.02e-24	IgG glycosylation;
CRC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg17124844	chr8:1624822	DLGAP2	-0.55	-6.52	-0.34	2.64e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg16589663	chr20:23618590	CST3	0.58	7.22	0.37	3.58e-12	Chronic kidney disease;
CRC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.45	7.68	0.39	1.84e-13	Major depressive disorder;
CRC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.92	0.31	7.95e-9	Tonsillectomy;
CRC	cis	rs1223397	0.938	rs13205692	chr6:13291560	C/T	cg20827128	chr6:13274284	PHACTR1	0.56	6.56	0.34	2.05e-10	Blood pressure;
CRC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05585630	chr7:157510462	PTPRN2	-0.42	-6.61	-0.34	1.54e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs1867631	0.585	rs6694782	chr1:67126762	C/T	cg02459107	chr1:67143332	SGIP1	-0.36	-6.31	-0.33	8.85e-10	Menopause (age at onset);
CRC	cis	rs965469	1.000	rs6051831	chr20:3373712	G/T	cg25506879	chr20:3388711	C20orf194	0.4	5.8	0.3	1.52e-8	IFN-related cytopenia;
CRC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.35	5.78	0.3	1.7e-8	Prostate-specific antigen levels;
CRC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.57	-8.9	-0.44	3.76e-17	Vitiligo;
CRC	cis	rs7731657	0.537	rs2419934	chr5:130295768	T/C	cg08523029	chr5:130500466	HINT1	-0.49	-6.17	-0.32	2.02e-9	Fasting plasma glucose;
CRC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg04553112	chr3:125709451	NA	-0.51	-5.91	-0.31	8.52e-9	Blood pressure (smoking interaction);
CRC	trans	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.06	-0.32	3.74e-9	Neuroticism;
CRC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg19635926	chr16:89946313	TCF25	0.68	6.15	0.32	2.2e-9	Skin colour saturation;
CRC	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	cg04338863	chr8:33670619	NA	0.41	7.28	0.37	2.48e-12	Body mass index;
CRC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg21251018	chr6:28226885	NKAPL	0.54	9.16	0.45	5.65e-18	Pulmonary function;
CRC	cis	rs9549328	0.700	rs3011474	chr13:113617865	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.39	0.33	5.65e-10	Systolic blood pressure;
CRC	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.53	7.8	0.39	8.47e-14	Obesity-related traits;
CRC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.55	-8.41	-0.42	1.28e-15	Selective IgA deficiency;
CRC	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg17145862	chr1:211918768	LPGAT1	0.5	7.11	0.36	7.22e-12	Crohn's disease;
CRC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.45	-6.57	-0.34	2e-10	Menarche (age at onset);
CRC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.56	6.73	0.35	7.73e-11	Gut microbiome composition (summer);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg14221884	chr12:63328524	PPM1H	-0.43	-6.38	-0.33	6.18e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.78	-10.56	-0.5	1.19e-22	Systemic lupus erythematosus;
CRC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.39	6.21	0.32	1.59e-9	Total body bone mineral density;
CRC	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg03938978	chr2:103052716	IL18RAP	0.41	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.78	-10.97	-0.52	4.54e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.29	-0.46	2.16e-18	Type 2 diabetes;
CRC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.77	14.67	0.63	7.87e-38	Body mass index;
CRC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.85	0.31	1.19e-8	Diabetic retinopathy;
CRC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg22676075	chr6:135203613	NA	0.41	6.33	0.33	7.94e-10	Red blood cell count;
CRC	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.83	13.73	0.6	3.08e-34	Height;
CRC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.45	-6.93	-0.36	2.29e-11	Menarche (age at onset);
CRC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.73	0.35	7.37e-11	Morning vs. evening chronotype;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07805724	chr3:69062774	C3orf64	0.47	6.58	0.34	1.85e-10	Anxiety disorder;
CRC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg05569086	chr8:143859399	LYNX1	0.4	6.96	0.36	1.91e-11	Urinary tract infection frequency;
CRC	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.64	11.52	0.54	5.1e-26	Blood metabolite ratios;
CRC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.53	9.12	0.45	7.9e-18	Multiple system atrophy;
CRC	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.63	8.09	0.41	1.18e-14	Bipolar disorder;
CRC	cis	rs6460942	0.659	rs28366613	chr7:12512167	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.9	-0.31	9.2e-9	Coronary artery disease;
CRC	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg22561889	chr6:118971681	C6orf204	0.55	6.59	0.34	1.73e-10	Diastolic blood pressure;
CRC	cis	rs8070740	0.947	rs3809842	chr17:5329199	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.98	0.36	1.65e-11	Menopause (age at onset);
CRC	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.55	9.43	0.46	7.48e-19	Prevalent atrial fibrillation;
CRC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.41	5.73	0.3	2.3e-8	Aortic root size;
CRC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg19812747	chr11:111475976	SIK2	0.42	6.08	0.32	3.39e-9	Primary sclerosing cholangitis;
CRC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg21877656	chr19:58662188	ZNF329	0.7	7.66	0.39	2.13e-13	Cholesterol, total;
CRC	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.16	-0.32	2.14e-9	Height;
CRC	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg09003973	chr2:102972529	NA	0.65	7.3	0.37	2.22e-12	Gut microbiota (bacterial taxa);
CRC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	7.83	0.4	6.82e-14	Colorectal cancer;
CRC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.62	-7.3	-0.37	2.13e-12	Bronchopulmonary dysplasia;
CRC	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.6	9.72	0.47	8.36e-20	Itch intensity from mosquito bite;
CRC	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg14673194	chr17:80132900	CCDC57	0.49	6.12	0.32	2.59e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg14191688	chr11:70257035	CTTN	-0.44	-5.83	-0.31	1.34e-8	Coronary artery disease;
CRC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.8	11.89	0.55	2.31e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg15786705	chr6:28176104	NA	0.56	7.35	0.38	1.55e-12	Parkinson's disease;
CRC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.12	-0.41	9.55e-15	Schizophrenia;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg18711617	chr17:49338392	MBTD1;UTP18	0.55	6.23	0.32	1.44e-9	Body mass index;
CRC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.33	5.66	0.3	3.35e-8	Erythrocyte sedimentation rate;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg16606324	chr3:10149918	C3orf24	0.62	7.91	0.4	3.93e-14	Alzheimer's disease;
CRC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.63	-9.03	-0.45	1.52e-17	Obesity-related traits;
CRC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.71	-12.93	-0.58	3.35e-31	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs896623	0.597	rs4455437	chr4:122136763	C/T	cg19463078	chr4:122099598	TNIP3	-0.39	-5.94	-0.31	7.1e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.78	-0.44	9.05e-17	Ulcerative colitis;
CRC	cis	rs1124376	1.000	rs9819628	chr3:20140837	A/G	cg05072819	chr3:20081367	KAT2B	-0.51	-6.23	-0.33	1.39e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.69	9.17	0.45	5.21e-18	Bronchopulmonary dysplasia;
CRC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg15145296	chr3:125709740	NA	-0.57	-6.75	-0.35	6.67e-11	Blood pressure (smoking interaction);
CRC	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.57	-9.47	-0.46	5.57e-19	Systemic lupus erythematosus;
CRC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	8.31	0.42	2.47e-15	Menarche (age at onset);
CRC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-6.48	-0.34	3.36e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg17724175	chr1:150552817	MCL1	-0.46	-7.28	-0.37	2.5e-12	Tonsillectomy;
CRC	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.13e-17	Dupuytren's disease;
CRC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.03	16.85	0.68	2.3e-46	IgG glycosylation;
CRC	cis	rs8099014	0.814	rs4245272	chr18:56115145	T/A	cg12907477	chr18:56117327	MIR122	0.46	5.96	0.31	6.58e-9	Platelet count;
CRC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.76	13.16	0.59	4.72e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg03959625	chr15:84868606	LOC388152	0.41	6.16	0.32	2.09e-9	Schizophrenia;
CRC	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg26248373	chr2:1572462	NA	-0.85	-11.89	-0.55	2.27e-27	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg11632617	chr15:75315747	PPCDC	-0.56	-8.05	-0.41	1.52e-14	Blood trace element (Zn levels);
CRC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg19193384	chr17:30244184	NA	-0.49	-6.73	-0.35	7.54e-11	Hip circumference adjusted for BMI;
CRC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.23	0.32	1.41e-9	Aortic root size;
CRC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.85	-0.31	1.17e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12273811	chr6:28175739	NA	-0.61	-7.89	-0.4	4.46e-14	Parkinson's disease;
CRC	cis	rs8044868	0.566	rs3812984	chr16:72207797	C/T	cg23815491	chr16:72088622	HP	0.42	6.2	0.32	1.71e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02698600	chr1:201450009	NA	0.39	6.37	0.33	6.29e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.22e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.78	0.39	9.17e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.64e-13	Diabetic retinopathy;
CRC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.52	-6.03	-0.32	4.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4936891	0.645	rs74858431	chr11:123902862	T/C	cg22125253	chr11:123886957	OR10G4	0.4	7.44	0.38	8.86e-13	Male fertility;
CRC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg05044414	chr3:183734942	ABCC5	0.48	8.3	0.42	2.77e-15	Anterior chamber depth;
CRC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.9	16.6	0.68	2.13e-45	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.82	0.51	1.53e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.56	0.34	2.07e-10	Lung cancer;
CRC	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13967864	chr9:100396098	NCBP1;TSTD2	0.46	6.27	0.33	1.13e-9	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02007933	chr16:89767497	SPATA2L	0.53	7.25	0.37	3.04e-12	Anxiety disorder;
CRC	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23612220	chr1:151129298	TNFAIP8L2	0.23	6.17	0.32	2.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-7.98	-0.4	2.47e-14	Eye color traits;
CRC	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-7.06	-0.36	9.66e-12	Coronary artery disease;
CRC	trans	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg18335740	chr13:41363409	SLC25A15	0.53	7.93	0.4	3.43e-14	Lewy body disease;
CRC	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg20607287	chr7:12443886	VWDE	-0.55	-5.98	-0.31	5.94e-9	Coronary artery disease;
CRC	cis	rs8032158	0.702	rs11632977	chr15:56131609	T/C	cg02198044	chr15:56286336	NEDD4	-0.36	-5.76	-0.3	1.97e-8	Keloid;
CRC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-0.99	-12.6	-0.57	5.6e-30	Diabetic kidney disease;
CRC	cis	rs2882667	0.690	rs288028	chr5:138221989	C/G	cg09476006	chr5:138032270	NA	0.56	9.37	0.46	1.24e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.35	-0.38	1.59e-12	Lymphocyte counts;
CRC	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg06917450	chr1:38156652	C1orf109	-0.49	-6.95	-0.36	1.92e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.36	7.2	0.37	4.18e-12	Cutaneous nevi;
CRC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.24	-14.76	-0.63	3.58e-38	Diabetic kidney disease;
CRC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.6	6.34	0.33	7.68e-10	Axial length;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12963246	chr6:28129442	ZNF389	0.5	5.9	0.31	8.91e-9	Depression;
CRC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.39	6.18	0.32	1.92e-9	Obesity-related traits;
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg02741985	chr17:80059408	CCDC57	-0.45	-7.4	-0.38	1.17e-12	Life satisfaction;
CRC	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.0	-0.31	5.07e-9	Neuroticism;
CRC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.97	-17.37	-0.69	2.04e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.65	9.75	0.47	6.84e-20	Lymphocyte counts;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00387457	chr20:34639042	LOC647979	0.46	6.06	0.32	3.64e-9	Survival in pancreatic cancer;
CRC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4954585	0.708	rs13034241	chr2:137021263	G/A	cg05194412	chr2:137003533	NA	0.44	6.82	0.35	4.34e-11	Colorectal cancer;
CRC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.65	12.37	0.56	3.93e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.27	0.53	3.96e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs11688071	chr2:15612626	T/G	cg19274914	chr2:15703543	NA	0.38	5.89	0.31	9.63e-9	Educational attainment (years of education);
CRC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.41	6.04	0.32	4.11e-9	Asthma;
CRC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.59	-8.42	-0.42	1.17e-15	Carotid intima media thickness;
CRC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.86e-17	Aortic root size;
CRC	cis	rs17641971	0.684	rs11785391	chr8:49930203	G/T	cg00325661	chr8:49890786	NA	0.36	6.33	0.33	8e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg15786705	chr6:28176104	NA	0.78	9.7	0.47	1.01e-19	Depression;
CRC	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg10820045	chr2:198174542	NA	0.38	6.34	0.33	7.67e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.76	-0.39	1.07e-13	HDL cholesterol;
CRC	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.64	12.44	0.57	2.16e-29	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.97	0.48	1.21e-20	Ileal carcinoids;
CRC	cis	rs3018066	0.867	rs60538413	chr4:106952235	G/A	cg01869342	chr4:106983673	TBCK	0.42	6.37	0.33	6.34e-10	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22608999	chr17:46184744	SNX11	0.47	6.54	0.34	2.41e-10	Response to antipsychotic treatment;
CRC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.55	-8.01	-0.4	2.06e-14	Fibrinogen levels;
CRC	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg25834613	chr7:1915315	MAD1L1	-0.5	-7.85	-0.4	6.08e-14	Bipolar disorder;
CRC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.79	-0.3	1.68e-8	Breast cancer;
CRC	cis	rs476633	0.573	rs6492995	chr15:41529712	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-8.66	-0.43	2.17e-16	Glomerular filtration rate (creatinine);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16211055	chr1:228594250	TRIM11	0.46	5.96	0.31	6.44e-9	Thyroid stimulating hormone;
CRC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.36	-6.26	-0.33	1.19e-9	Platelet count;
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg17321639	chr7:2759063	NA	-0.52	-7.03	-0.36	1.18e-11	Height;
CRC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	12.78	0.58	1.25e-30	Electrocardiographic conduction measures;
CRC	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	1.0	18.55	0.71	4.56e-53	Gut microbiome composition (winter);
CRC	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.75	6.99	0.36	1.57e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.967	rs6589017	chr11:108308504	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.4	5.83	0.31	1.33e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.46	7.03	0.36	1.18e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg00319359	chr11:70116639	PPFIA1	0.57	6.39	0.33	5.8e-10	Coronary artery disease;
CRC	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg22676075	chr6:135203613	NA	-0.65	-10.08	-0.49	5.16e-21	High light scatter reticulocyte percentage of red cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06649899	chr16:67261154	TMEM208;LRRC29	0.41	6.08	0.32	3.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12286929	0.898	rs117569901	chr11:115018509	T/G	cg04055981	chr11:115044050	NA	0.39	6.33	0.33	7.96e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg05540913	chr6:167530185	CCR6	-0.42	-7.54	-0.38	4.71e-13	Primary biliary cholangitis;
CRC	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.65	-0.34	1.25e-10	Neuroticism;
CRC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.88	0.63	1.17e-38	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.934	rs4240865	chr1:152954839	G/T	cg25856811	chr1:152973957	SPRR3	0.22	5.81	0.31	1.44e-8	Inflammatory skin disease;
CRC	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.57	8.31	0.42	2.59e-15	Testicular germ cell tumor;
CRC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.53	-9.13	-0.45	6.95e-18	Aortic root size;
CRC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.79	14.33	0.62	1.63e-36	Anterior chamber depth;
CRC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg14324370	chr2:177042789	NA	0.69	10.1	0.49	4.57e-21	IgG glycosylation;
CRC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-6.99	-0.36	1.51e-11	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-12.31	-0.56	6.7200000000000006e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16447950	chr5:562315	NA	-0.74	-9.79	-0.47	4.96e-20	Obesity-related traits;
CRC	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.61	-9.35	-0.46	1.35e-18	Hepatocellular carcinoma;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg19318889	chr4:1322082	MAEA	0.47	7.09	0.36	8.35e-12	Obesity-related traits;
CRC	cis	rs4964805	0.626	rs11111767	chr12:104176246	A/G	cg02344784	chr12:104178138	NT5DC3	-0.52	-7.78	-0.39	9.16e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg02683197	chr6:28174875	NA	0.64	7.86	0.4	5.59e-14	Parkinson's disease;
CRC	trans	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-7.27	-0.37	2.69e-12	Metabolite levels;
CRC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg23463467	chr20:60627584	TAF4	0.44	8.15	0.41	7.92e-15	Body mass index;
CRC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg25985355	chr7:65971099	NA	0.33	5.74	0.3	2.15e-8	Aortic root size;
CRC	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg13491945	chr12:107078410	RFX4	0.36	6.2	0.32	1.67e-9	Heart rate;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.23	-0.53	5.33e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-7.55	-0.38	4.32e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14211646	chr1:26758996	DHDDS	0.49	6.3	0.33	9.37e-10	Thyroid stimulating hormone;
CRC	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.08	14.73	0.63	4.38e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.95	-9.42	-0.46	8.46e-19	Breast cancer;
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.54	8.48	0.42	7.8e-16	Colorectal or endometrial cancer;
CRC	cis	rs10208940	0.920	rs11894861	chr2:68706723	C/G	cg12452813	chr2:68675892	NA	0.52	6.39	0.33	5.53e-10	Urate levels in lean individuals;
CRC	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.45	-5.91	-0.31	8.38e-9	Neuroticism;
CRC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.46	-0.5	2.69e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.17	0.64	8.74e-40	Bipolar disorder;
CRC	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.58	-7.25	-0.37	3.09e-12	Ulcerative colitis;
CRC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.88	15.0	0.64	3.98e-39	Cognitive function;
CRC	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.66	10.96	0.52	4.85e-24	Prudent dietary pattern;
CRC	cis	rs1883415	0.552	rs2328824	chr6:24507761	G/A	cg20631270	chr6:24437470	GPLD1	-0.39	-6.0	-0.31	5.3e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.36	6.03	0.32	4.52e-9	Sudden cardiac arrest;
CRC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.06	-12.44	-0.57	2.13e-29	Diabetic kidney disease;
CRC	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.1	0.49	4.69e-21	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08191566	chr7:64254770	ZNF138	0.37	6.18	0.32	1.92e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.3	0.46	2.01e-18	Hip circumference adjusted for BMI;
CRC	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg19875578	chr6:126661172	C6orf173	0.4	5.63	0.3	3.9e-8	Male-pattern baldness;
CRC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	8.04	0.41	1.67e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00832928	chr3:150329458	SELT	-0.46	-5.96	-0.31	6.43e-9	Hip circumference;
CRC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.72	-10.61	-0.5	8.28e-23	Blood trace element (Zn levels);
CRC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg02428538	chr16:24856791	SLC5A11	0.58	7.13	0.37	6.38e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.86	-10.93	-0.52	6.06e-24	Obesity-related traits;
CRC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.41	8.0	0.4	2.08e-14	Mean corpuscular volume;
CRC	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg15192750	chr16:69999425	NA	0.57	7.39	0.38	1.19e-12	IgE levels;
CRC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	9.52	0.46	3.95e-19	Neuroticism;
CRC	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg03641300	chr2:160917029	PLA2R1	-0.4	-5.7	-0.3	2.69e-8	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.45	-0.34	3.91e-10	Monocyte count;
CRC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.97	-14.52	-0.62	2.89e-37	Systemic lupus erythematosus;
CRC	cis	rs9908102	0.740	rs60875833	chr17:12912789	T/G	cg26162695	chr17:12921313	ELAC2	0.43	5.85	0.31	1.17e-8	Schizophrenia;
CRC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.52	-7.13	-0.37	6.21e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.69	-0.35	9.62e-11	Type 2 diabetes;
CRC	trans	rs12699921	0.632	rs2691594	chr7:17864816	C/G	cg15753394	chr6:17282781	RBM24	-0.36	-6.01	-0.31	5.03e-9	Fibrinogen levels;
CRC	cis	rs7213347	0.780	rs7209564	chr17:2168233	C/T	cg15816464	chr17:2026533	SMG6	0.38	6.4	0.33	5.22e-10	Total body bone mineral density;
CRC	cis	rs11098699	0.821	rs11734868	chr4:124211544	A/G	cg09941581	chr4:124220074	SPATA5	0.4	5.73	0.3	2.23e-8	Mosquito bite size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21413251	chr9:71320693	PIP5K1B	0.42	6.07	0.32	3.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.65	7.08	0.36	8.52e-12	Breast cancer;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg15845792	chr6:28175446	NA	0.51	7.22	0.37	3.68e-12	Parkinson's disease;
CRC	cis	rs3857067	1.000	rs1509940	chr4:95018758	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.06	-0.32	3.63e-9	QT interval;
CRC	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg21609526	chr1:3105151	PRDM16	0.34	5.7	0.3	2.71e-8	Migraine;
CRC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.53	11.51	0.54	5.44e-26	Alcohol dependence;
CRC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.59	7.97	0.4	2.56e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.51	8.78	0.44	9.39e-17	Aortic root size;
CRC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg24955955	chr5:415729	AHRR	0.71	6.77	0.35	5.87e-11	Fat distribution (HIV);
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg19318889	chr4:1322082	MAEA	0.41	6.3	0.33	9.63e-10	Obesity-related traits;
CRC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg18876405	chr7:65276391	NA	0.45	6.38	0.33	6.09e-10	Aortic root size;
CRC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.42	6.61	0.34	1.59e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.74	-0.39	1.26e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.6	0.54	2.6e-26	Prudent dietary pattern;
CRC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg20607287	chr7:12443886	VWDE	-0.68	-7.35	-0.38	1.59e-12	Coronary artery disease;
CRC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.8	-11.56	-0.54	3.46e-26	Height;
CRC	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.53	7.88	0.4	4.93e-14	Metabolite levels (MHPG);
CRC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.71	0.54	1e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.57	-8.99	-0.44	1.95e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg15786705	chr6:28176104	NA	0.55	7.78	0.39	9.76e-14	Parkinson's disease;
CRC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.5	-0.38	6.05e-13	Aortic root size;
CRC	cis	rs10503871	0.761	rs6997010	chr8:30365489	T/A	cg26383811	chr8:30366931	RBPMS	0.49	8.12	0.41	9.78e-15	Metabolite levels  (X-11787);
CRC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.01	-0.31	5.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.42	-9.13	-0.45	7.24e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.72	-10.24	-0.49	1.52e-21	Vitiligo;
CRC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02825527	chr7:2087843	MAD1L1	-0.46	-5.62	-0.3	4.15e-8	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27351675	chr17:16284307	UBB	0.41	6.31	0.33	9.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs16937	0.662	rs10900464	chr1:205157100	T/C	cg00857998	chr1:205179979	DSTYK	0.41	5.65	0.3	3.49e-8	Schizophrenia;
CRC	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg00105475	chr2:10696890	NA	0.45	7.09	0.36	8.03e-12	Prostate cancer;
CRC	cis	rs6691722	0.503	rs6692646	chr1:24707629	C/T	cg18323236	chr1:24743029	NIPAL3	0.39	5.68	0.3	3.01e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg24562669	chr7:97807699	LMTK2	0.43	7.15	0.37	5.66e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg13072238	chr3:49761600	GMPPB	-0.57	-5.81	-0.31	1.46e-8	Menarche (age at onset);
CRC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	15.68	0.65	8.67e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg05304507	chr6:116381966	FRK	0.31	7.98	0.4	2.38e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Depression;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg22638593	chr5:131593259	PDLIM4	0.49	9.08	0.45	1.05e-17	Acylcarnitine levels;
CRC	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-0.64	-10.79	-0.51	1.94e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg03395511	chr6:291903	DUSP22	-0.5	-6.83	-0.35	4.18e-11	Menopause (age at onset);
CRC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.55	9.78	0.47	5.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg10935138	chr17:73851978	WBP2	0.56	6.98	0.36	1.59e-11	Psoriasis;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.24e-9	Bipolar disorder;
CRC	cis	rs329648	1.000	rs329652	chr11:133769699	A/G	cg15485101	chr11:133734466	NA	0.36	5.78	0.3	1.77e-8	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6662572	0.851	rs55654017	chr1:46249299	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.64	0.3	3.71e-8	Blood protein levels;
CRC	cis	rs2179367	0.959	rs652807	chr6:149737495	A/G	cg16235748	chr6:149772707	ZC3H12D	0.34	5.79	0.3	1.62e-8	Dupuytren's disease;
CRC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24110177	chr3:50126178	RBM5	0.38	5.71	0.3	2.56e-8	Body mass index;
CRC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.46	-9.32	-0.46	1.79e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2073499	0.872	rs77097132	chr3:50301050	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	5.65	0.3	3.5e-8	Schizophrenia;
CRC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg11632617	chr15:75315747	PPCDC	-0.56	-7.73	-0.39	1.29e-13	Blood trace element (Zn levels);
CRC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-6.28	-0.33	1.05e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg15147215	chr3:52552868	STAB1	0.43	6.92	0.36	2.38e-11	Body mass index;
CRC	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg27053337	chr8:124217698	FAM83A	0.42	6.36	0.33	6.62e-10	Urinary uromodulin levels;
CRC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg05623727	chr3:50126028	RBM5	0.53	6.93	0.36	2.25e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2055729	0.645	rs6989793	chr8:9744650	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.03	-0.32	4.39e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.43	-5.62	-0.3	4.09e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg10517650	chr3:113235015	CCDC52	-0.36	-5.92	-0.31	8.19e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.57	-10.33	-0.5	7.3e-22	Acylcarnitine levels;
CRC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.34	-0.42	1.99e-15	Type 2 diabetes;
CRC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.47	7.83	0.4	6.55e-14	Major depressive disorder;
CRC	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg00042356	chr1:8021962	PARK7	0.55	6.27	0.33	1.15e-9	Inflammatory bowel disease;
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.61	-0.34	1.6e-10	Acne (severe);
CRC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.73	12.46	0.57	1.81e-29	Mean platelet volume;
CRC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.8	11.21	0.53	6.66e-25	Asthma;
CRC	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.38	-5.93	-0.31	7.8e-9	Obesity-related traits;
CRC	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.6	8.06	0.41	1.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.9	-0.55	2.05e-27	Type 2 diabetes;
CRC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg03929089	chr4:120376271	NA	-0.48	-6.82	-0.35	4.29e-11	HDL cholesterol;
CRC	trans	rs11225569	0.539	rs11225822	chr11:103345030	A/C	cg01615333	chr12:127765195	NA	-0.62	-6.02	-0.31	4.68e-9	Diisocyanate-induced asthma;
CRC	cis	rs12476592	0.602	rs262505	chr2:63861786	C/T	cg10828910	chr2:63850056	LOC388955	0.47	5.65	0.3	3.48e-8	Childhood ear infection;
CRC	cis	rs12745968	0.569	rs7521752	chr1:93017141	C/T	cg17283838	chr1:93427260	FAM69A	-0.46	-6.16	-0.32	2.13e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg23815491	chr16:72088622	HP	0.5	7.6	0.39	3.09e-13	Fibrinogen levels;
CRC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.46	0.42	9.09e-16	Arsenic metabolism;
CRC	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg09873164	chr1:152488093	CRCT1	-0.35	-6.01	-0.31	4.93e-9	Hair morphology;
CRC	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg26462239	chr17:45608823	NPEPPS	-0.44	-6.28	-0.33	1.08e-9	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg19223190	chr17:80058835	NA	0.39	6.09	0.32	3.08e-9	Life satisfaction;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.7	8.84	0.44	5.72e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17532515	0.628	rs12502572	chr4:141485134	C/T	cg09181644	chr4:141490428	UCP1	0.32	5.72	0.3	2.4e-8	Select biomarker traits;
CRC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.15	-0.37	5.79e-12	Body mass index;
CRC	trans	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg05059571	chr16:84539110	KIAA1609	0.47	7.1	0.36	7.73e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.57	0.38	3.88e-13	Lung cancer in ever smokers;
CRC	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-0.85	-11.99	-0.55	1.03e-27	Blood protein levels;
CRC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg09650180	chr20:62225654	GMEB2	-0.51	-6.83	-0.35	4.15e-11	Glioblastoma;
CRC	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg00495681	chr13:53174319	NA	0.54	7.88	0.4	4.89e-14	Lewy body disease;
CRC	cis	rs600626	0.636	rs10899109	chr11:75451201	G/A	cg24262691	chr11:75473276	NA	0.55	7.56	0.38	4.02e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.73	-11.7	-0.54	1.09e-26	Immature fraction of reticulocytes;
CRC	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg00254258	chr1:3105189	PRDM16	0.42	7.37	0.38	1.36e-12	Migraine;
CRC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg09626299	chr10:82213104	TSPAN14	-0.38	-6.51	-0.34	2.76e-10	Post bronchodilator FEV1;
CRC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.97	0.31	5.98e-9	Depression;
CRC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg05132306	chr1:1846340	CALML6	-0.51	-7.88	-0.4	4.7e-14	Body mass index;
CRC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.89	-16.04	-0.66	3.41e-43	Height;
CRC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg17321639	chr7:2759063	NA	-0.42	-5.91	-0.31	8.33e-9	Height;
CRC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.88	-17.02	-0.68	4.93e-47	Migraine;
CRC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg23533926	chr12:111358616	MYL2	-0.44	-6.45	-0.34	3.99e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg12870014	chr12:110450643	ANKRD13A	0.82	10.2	0.49	2.1e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11203032	0.831	rs10887932	chr10:90966996	C/G	cg16672925	chr10:90967113	CH25H	0.46	6.13	0.32	2.45e-9	Heart failure;
CRC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.31	6.02	0.32	4.61e-9	Monocyte percentage of white cells;
CRC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.9	-15.65	-0.65	1.22e-41	Height;
CRC	cis	rs713477	0.654	rs11158040	chr14:55914607	T/C	cg13175173	chr14:55914753	NA	-0.43	-7.78	-0.39	9.59e-14	Pediatric bone mineral content (femoral neck);
CRC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.57	-6.0	-0.31	5.12e-9	White matter hyperintensity burden;
CRC	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.84	0.31	1.25e-8	Tonsillectomy;
CRC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	8.5	0.42	6.76e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.51	6.9	0.36	2.66e-11	Triglycerides;
CRC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.47	7.83	0.4	6.76e-14	Breast cancer;
CRC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.59	0.47	2.2e-19	Cognitive test performance;
CRC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg25876840	chr17:41920477	NA	0.47	6.36	0.33	6.78e-10	Triglycerides;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07050772	chr17:48423262	XYLT2	0.38	6.0	0.31	5.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.54	-0.5	1.39e-22	Chronic sinus infection;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.13	-0.32	2.54e-9	Longevity;Endometriosis;
CRC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.27	-0.33	1.12e-9	Aortic root size;
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg19223190	chr17:80058835	NA	0.39	6.31	0.33	9.07e-10	Life satisfaction;
CRC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.76	11.76	0.54	7.03e-27	Platelet distribution width;
CRC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg19582491	chr16:67682965	RLTPR	-0.58	-6.92	-0.36	2.32e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.18	-0.52	8.29e-25	Extrinsic epigenetic age acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03053427	chr7:75649626	STYXL1	0.44	6.51	0.34	2.74e-10	Response to antipsychotic treatment;
CRC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg24849736	chr1:201084428	NA	0.64	11.68	0.54	1.33e-26	Permanent tooth development;
CRC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06544989	chr22:39130855	UNC84B	0.49	7.99	0.4	2.3e-14	Menopause (age at onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg27581118	chr15:85780523	NA	0.37	6.26	0.33	1.21e-9	Myopia (pathological);
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.88	0.31	1.03e-8	Life satisfaction;
CRC	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.43	9.86	0.48	3.02e-20	Urate levels in overweight individuals;
CRC	cis	rs73200209	0.744	rs7136498	chr12:116483993	T/G	cg01776926	chr12:116560359	MED13L	-0.64	-7.68	-0.39	1.78e-13	Total body bone mineral density;
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg23939001	chr4:940644	TMEM175	0.73	15.07	0.64	2.08e-39	Sjögren's syndrome;
CRC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.52	6.93	0.36	2.26e-11	Height;
CRC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg05540913	chr6:167530185	CCR6	0.42	7.79	0.39	8.94e-14	Primary biliary cholangitis;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.22e-22	Bipolar disorder;
CRC	trans	rs2055729	0.710	rs13257396	chr8:9736383	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.94	0.36	2.03e-11	Multiple myeloma (hyperdiploidy);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg24342377	chr7:97868109	TECPR1	0.41	6.13	0.32	2.46e-9	Birth weight;Height;
CRC	cis	rs3736485	0.816	rs11632853	chr15:51855933	T/C	cg08986416	chr15:51914746	DMXL2	-0.48	-6.97	-0.36	1.78e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.51	0.54	5.33e-26	Prudent dietary pattern;
CRC	cis	rs2274273	0.563	rs79163357	chr14:55738449	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.12	-0.32	2.67e-9	Protein biomarker;
CRC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.38	0.33	6.05e-10	Tonsillectomy;
CRC	cis	rs10924970	0.601	rs12402448	chr1:235448095	A/T	cg09010748	chr1:235293032	TOMM20	-0.42	-5.87	-0.31	1.04e-8	Asthma;
CRC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.49	0.71	7.83e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12691373	chr17:79670378	MRPL12	0.42	6.76	0.35	6.39e-11	Schizophrenia;
CRC	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg02033258	chr5:131593261	PDLIM4	-0.33	-5.88	-0.31	9.91e-9	Blood metabolite levels;
CRC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-7.09	-0.36	8.05e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.55	-9.05	-0.45	1.24e-17	Intelligence (multi-trait analysis);
CRC	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg15685922	chr1:156045208	MEX3A	-0.46	-8.23	-0.41	4.5e-15	Ischemic stroke;
CRC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.98	-0.31	5.97e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.66	-11.13	-0.52	1.25e-24	Personality dimensions;
CRC	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.48	-6.06	-0.32	3.69e-9	Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09626274	chr15:77224230	RCN2	0.47	6.35	0.33	7.13e-10	Anxiety disorder;
CRC	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.65	0.51	6.07e-23	Corneal astigmatism;
CRC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-17.24	-0.69	6.89e-48	Coronary artery disease;
CRC	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.74	-11.74	-0.54	8.38e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10924970	0.649	rs12029822	chr1:235381342	T/G	cg09010748	chr1:235293032	TOMM20	-0.42	-5.75	-0.3	2.04e-8	Asthma;
CRC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13198984	chr17:80129470	CCDC57	-0.45	-7.67	-0.39	1.93e-13	Life satisfaction;
CRC	cis	rs6066835	1.000	rs6066831	chr20:47354131	C/A	cg18078177	chr20:47281410	PREX1	0.63	5.78	0.3	1.7e-8	Multiple myeloma;
CRC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.6	-7.96	-0.4	2.83e-14	Schizophrenia;
CRC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.73	9.94	0.48	1.6e-20	Platelet count;
CRC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg23996704	chr18:44553084	KATNAL2	-0.33	-6.85	-0.35	3.54e-11	Personality dimensions;
CRC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.83	-0.31	1.3e-8	Total body bone mineral density;
CRC	cis	rs972578	0.905	rs55682747	chr22:43361928	A/T	cg01576275	chr22:43409880	NA	-0.45	-7.27	-0.37	2.62e-12	Mean platelet volume;
CRC	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg09873164	chr1:152488093	CRCT1	-0.36	-6.13	-0.32	2.48e-9	Hair morphology;
CRC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.63	9.63	0.47	1.72e-19	Corneal astigmatism;
CRC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.56	0.6	1.38e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7134594	0.677	rs2075440	chr12:109859100	C/T	cg19025524	chr12:109796872	NA	0.39	5.84	0.31	1.29e-8	HDL cholesterol;
CRC	cis	rs1223397	0.651	rs488297	chr6:13300496	C/T	cg20827128	chr6:13274284	PHACTR1	0.37	5.6	0.3	4.42e-8	Blood pressure;
CRC	cis	rs7113874	0.569	rs4418812	chr11:8612000	A/G	cg17679104	chr11:8615758	STK33	0.36	6.07	0.32	3.54e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.93	0.31	7.76e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.59	-0.39	3.26e-13	Mood instability;
CRC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg26816564	chr1:7831052	VAMP3	0.55	6.17	0.32	1.97e-9	Inflammatory bowel disease;
CRC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.62	10.18	0.49	2.46e-21	Colorectal cancer;
CRC	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg13206674	chr6:150067644	NUP43	-0.45	-5.75	-0.3	2.06e-8	Lung cancer;
CRC	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	0.9	9.07	0.45	1.09e-17	Prostate cancer;
CRC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.59	-8.67	-0.43	2.02e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs6076065	0.723	rs4813495	chr20:23391617	A/G	cg11657817	chr20:23433608	CST11	0.43	6.32	0.33	8.28e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.66	9.85	0.48	3.16e-20	Lung cancer;
CRC	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.22	-0.32	1.5e-9	Body mass index;
CRC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	9.2	0.45	4.19e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs17065868	0.764	rs9533865	chr13:45037349	C/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.62	-7.47	-0.38	7.15e-13	Hip circumference adjusted for BMI;
CRC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.43	-6.11	-0.32	2.77e-9	DNA methylation (variation);
CRC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.54	7.98	0.4	2.39e-14	Lymphocyte counts;
CRC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.51	6.35	0.33	7.31e-10	Recombination rate (females);
CRC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.37	-0.46	1.2e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg03233332	chr7:66118400	NA	-0.41	-5.63	-0.3	3.93e-8	Aortic root size;
CRC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.07	-0.36	9.44e-12	Personality dimensions;
CRC	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg12046867	chr14:103022105	NA	0.75	8.81	0.44	7.1e-17	Platelet count;
CRC	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg27205649	chr11:78285834	NARS2	0.48	6.19	0.32	1.77e-9	Alzheimer's disease (survival time);
CRC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.83	14.57	0.63	1.95e-37	Breast cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08830818	chr3:122514143	HSPBAP1;DIRC2	0.36	6.37	0.33	6.36e-10	Interleukin-6 levels;
CRC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.85	0.31	1.19e-8	Bladder cancer;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg02683197	chr6:28174875	NA	0.61	8.5	0.42	6.89e-16	Parkinson's disease;
CRC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.91	-11.41	-0.53	1.21e-25	Monocyte percentage of white cells;
CRC	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-6.82	-0.35	4.31e-11	Blood protein levels;
CRC	cis	rs728616	0.717	rs111403425	chr10:81820542	C/T	cg05935833	chr10:81318306	SFTPA2	-0.56	-6.36	-0.33	6.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.47	9.47	0.46	5.85e-19	Renal cell carcinoma;
CRC	cis	rs7572644	0.699	rs1506537	chr2:28181901	G/C	cg27432699	chr2:27873401	GPN1	-0.4	-5.62	-0.3	4.01e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.72	-0.3	2.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.37	-0.33	6.49e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.36	-0.33	6.78e-10	Bipolar disorder;
CRC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	8.45	0.42	9.62e-16	Rheumatoid arthritis;
CRC	cis	rs16975963	0.644	rs11666738	chr19:38130319	C/G	cg15135657	chr19:38346511	NA	-0.45	-6.4	-0.33	5.4e-10	Longevity;
CRC	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.55	7.54	0.38	4.57e-13	Obesity-related traits;
CRC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.4e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg03037974	chr15:76606532	NA	-0.49	-7.29	-0.37	2.38e-12	Blood metabolite levels;
CRC	cis	rs12618769	0.652	rs72823788	chr2:99213080	C/T	cg18455616	chr2:99124870	INPP4A	0.35	5.82	0.31	1.41e-8	Bipolar disorder;
CRC	cis	rs684232	0.800	rs865702	chr17:568153	A/T	cg15660573	chr17:549704	VPS53	-0.43	-6.19	-0.32	1.79e-9	Prostate cancer;
CRC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.69	10.39	0.5	4.77e-22	Menopause (age at onset);
CRC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11645453	chr3:52864694	ITIH4	0.36	6.23	0.32	1.41e-9	Bipolar disorder;
CRC	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.77	15.42	0.65	9.57e-41	Leprosy;
CRC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.66	8.27	0.41	3.29e-15	Menarche (age at onset);
CRC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.46	-7.13	-0.37	6.22e-12	Osteoporosis;
CRC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.58	10.6	0.5	8.84e-23	Multiple system atrophy;
CRC	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg24519413	chr1:26490540	NA	0.38	6.35	0.33	7.05e-10	Height;
CRC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.06	0.45	1.19e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.96	12.2	0.56	1.71e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.56	8.28	0.42	3.15e-15	Blood protein levels;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-8.04	-0.41	1.67e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg23625390	chr15:77176239	SCAPER	0.49	7.26	0.37	2.76e-12	Blood metabolite levels;
CRC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.62	9.07	0.45	1.08e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.48	-8.4	-0.42	1.37e-15	Birth weight;
CRC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.35	6.2	0.32	1.7e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.52	-6.09	-0.32	3.19e-9	Coronary artery calcification;
CRC	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.76	-10.32	-0.49	8.08e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.29	-0.33	1e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.13	0.61	8.98e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.54	8.82	0.44	7.05e-17	Testicular germ cell tumor;
CRC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg27661571	chr11:113659931	NA	0.72	7.69	0.39	1.71e-13	Hip circumference adjusted for BMI;
CRC	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.72	9.09	0.45	9.41e-18	Psoriasis;
CRC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg27615366	chr5:131592974	PDLIM4	0.34	6.32	0.33	8.75e-10	Blood metabolite levels;
CRC	trans	rs6413860	0.688	rs10802435	chr1:246859404	G/A	cg25623271	chr1:240656217	GREM2	0.44	6.17	0.32	2.04e-9	Gut microbiome composition (summer);
CRC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.63	9.52	0.46	3.96e-19	Hemoglobin concentration;
CRC	cis	rs6445967	1.000	rs14927	chr3:58305033	G/T	cg23715586	chr3:58305044	RPP14	-0.36	-5.89	-0.31	9.71e-9	Platelet count;
CRC	cis	rs2462686	1.000	rs1534150	chr7:45985290	T/C	cg15898840	chr7:45960834	IGFBP3	-0.39	-5.77	-0.3	1.87e-8	Major depressive disorder;
CRC	cis	rs9928842	0.765	rs2870467	chr16:75223881	A/G	cg09066997	chr16:75300724	BCAR1	0.66	6.19	0.32	1.77e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg06470822	chr6:28175283	NA	0.67	9.07	0.45	1.1e-17	Parkinson's disease;
CRC	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.4	-5.73	-0.3	2.3e-8	Osteoporosis;
CRC	cis	rs4692589	1.000	rs4321597	chr4:170934424	C/T	cg19918862	chr4:170955249	NA	0.38	6.22	0.32	1.48e-9	Anxiety disorder;
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.55	-9.28	-0.46	2.36e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.63	-10.32	-0.49	8.4e-22	Alzheimer's disease (late onset);
CRC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.66	9.51	0.46	4.18e-19	Bladder cancer;
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.73	9.1	0.45	9.03e-18	Iron status biomarkers;
CRC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.53	6.77	0.35	5.88e-11	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CRC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.79	-9.9	-0.48	2.1e-20	Platelet count;
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.63	-11.62	-0.54	2.13e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.98	-0.31	5.93e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg12365402	chr11:9010492	NRIP3	-0.37	-6.11	-0.32	2.81e-9	Immature fraction of reticulocytes;
CRC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.55	-7.99	-0.4	2.37e-14	Monocyte percentage of white cells;
CRC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.39	-6.08	-0.32	3.37e-9	Crohn's disease;
CRC	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg18833306	chr6:118973337	C6orf204	0.45	5.88	0.31	1.01e-8	Diastolic blood pressure;
CRC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.99	0.4	2.37e-14	Rheumatoid arthritis;
CRC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.11	0.36	7.24e-12	Hip circumference adjusted for BMI;
CRC	trans	rs10242455	0.702	rs6976017	chr7:99249999	G/A	cg09045935	chr12:6379348	NA	0.92	6.84	0.35	3.8e-11	Blood metabolite levels;
CRC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg18230493	chr5:56204884	C5orf35	0.37	5.74	0.3	2.18e-8	Coronary artery disease;
CRC	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg26182253	chr13:112236782	NA	0.31	6.25	0.33	1.26e-9	Hepatitis;
CRC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.67	10.3	0.49	9.15e-22	Corneal astigmatism;
CRC	cis	rs6684514	0.961	rs112017075	chr1:156327716	G/A	cg16558208	chr1:156270281	VHLL	0.54	8.19	0.41	5.71e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.77	-12.68	-0.57	2.79e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg18479299	chr3:125709523	NA	-0.5	-6.43	-0.33	4.44e-10	Blood pressure (smoking interaction);
CRC	cis	rs4728302	0.838	rs10225605	chr7:133591676	G/A	cg03336402	chr7:133662267	EXOC4	-0.45	-6.56	-0.34	2.04e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	trans	rs2084898	0.891	rs504236	chr11:120000263	T/C	cg10387956	chr15:72646210	HEXA	0.68	6.27	0.33	1.12e-9	Stroke (pediatric);
CRC	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-11.03	-0.52	2.81e-24	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7605827	0.893	rs2098463	chr2:15512175	C/G	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.58	-9.87	-0.48	2.69e-20	Hip circumference;
CRC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.46	-0.5	2.65e-22	Breast cancer;
CRC	cis	rs6496667	1.000	rs8042825	chr15:90897885	C/G	cg04176472	chr15:90893244	GABARAPL3	-0.49	-7.33	-0.37	1.82e-12	Rheumatoid arthritis;
CRC	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-8.61	-0.43	3.09e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.57	8.86	0.44	5.01e-17	Tuberculosis;
CRC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-8.92	-0.44	3.24e-17	Multiple myeloma (hyperdiploidy);
CRC	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs965469	1.000	rs2236107	chr20:3285821	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.7	-0.3	2.69e-8	IFN-related cytopenia;
CRC	cis	rs3767633	1.000	rs3767633	chr1:161826615	T/A	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.09	-18.12	-0.71	2.13e-51	Ulcerative colitis;
CRC	cis	rs7725052	0.609	rs4523044	chr5:40468024	C/T	cg09067459	chr5:40385259	NA	0.4	6.57	0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-12.72	-0.57	2.06e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.6	9.66	0.47	1.39e-19	Tonsillectomy;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01956267	chr2:158732380	ACVR1	0.4	5.97	0.31	6.2e-9	Interleukin-6 levels;
CRC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg11522145	chr4:3412961	RGS12	-0.41	-6.36	-0.33	6.67e-10	Serum sulfate level;
CRC	cis	rs12580194	0.593	rs13377995	chr12:55757380	C/G	cg19537932	chr12:55886519	OR6C68	-0.67	-8.83	-0.44	6.47e-17	Cancer;
CRC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	6.96e-16	Aortic root size;
CRC	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg19875535	chr5:140030758	IK	0.44	6.72	0.35	8.07e-11	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.35	-0.46	1.41e-18	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.85	-14.42	-0.62	6.98e-37	Prudent dietary pattern;
CRC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg05627522	chr15:75251581	NA	0.37	5.71	0.3	2.53e-8	Breast cancer;
CRC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.43	5.75	0.3	2.07e-8	Red cell distribution width;
CRC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.46	-0.34	3.81e-10	Life satisfaction;
CRC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg18709589	chr6:96969512	KIAA0776	0.4	5.63	0.3	3.95e-8	Headache;
CRC	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg16141378	chr3:129829833	LOC729375	0.39	6.09	0.32	3.23e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
CRC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.41	-5.69	-0.3	2.87e-8	DNA methylation (variation);
CRC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.5	-8.44	-0.42	1.01e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs910187	0.678	rs6122561	chr20:45813809	A/G	cg27589058	chr20:45804311	EYA2	-0.37	-7.31	-0.37	1.99e-12	Migraine;
CRC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.42	6.2	0.32	1.74e-9	Hemoglobin concentration;
CRC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.6	9.51	0.46	4.03e-19	Tonsillectomy;
CRC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.6	9.44	0.46	6.92e-19	IgG glycosylation;
CRC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.86	-0.4	5.37e-14	Life satisfaction;
CRC	cis	rs9914988	0.619	rs35477460	chr17:27320276	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.48	6.53	0.34	2.47e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.69	-12.2	-0.56	1.66e-28	Iron status biomarkers;
CRC	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg09659197	chr4:152720779	NA	0.4	7.84	0.4	6.22e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.66	0.3	3.24e-8	Life satisfaction;
CRC	cis	rs728616	0.558	rs12772945	chr10:82154496	C/T	cg05935833	chr10:81318306	SFTPA2	-0.58	-6.97	-0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.54	-6.85	-0.35	3.6e-11	DNA methylation (variation);
CRC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.7	9.43	0.46	7.85e-19	Bladder cancer;
CRC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.84	14.65	0.63	9e-38	Height;
CRC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.49	0.38	6.41e-13	Height;
CRC	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.33	-6.65	-0.34	1.26e-10	Cystic fibrosis severity;
CRC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.33e-10	Bipolar disorder;
CRC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.74	-0.39	1.27e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.45	-0.38	8.1e-13	Superior frontal gyrus grey matter volume;
CRC	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg21153622	chr11:89784906	NA	-0.46	-7.26	-0.37	2.75e-12	HDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09864156	chr10:70939728	SUPV3L1	0.42	6.0	0.31	5.29e-9	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.45	-5.99	-0.31	5.44e-9	Parkinson's disease;
CRC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	10.07	0.49	5.54e-21	Mean corpuscular hemoglobin;
CRC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.81	12.73	0.57	1.92e-30	Cognitive function;
CRC	cis	rs1030268	0.651	rs12707118	chr7:133474900	C/T	cg10665199	chr7:133106180	EXOC4	-0.53	-6.16	-0.32	2.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.61	8.34	0.42	2.03e-15	Coronary artery disease;
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.74	11.13	0.52	1.21e-24	Menarche (age at onset);
CRC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.99e-24	Motion sickness;
CRC	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.94e-40	Hypertriglyceridemia;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg14791747	chr16:20752902	THUMPD1	0.56	7.0	0.36	1.46e-11	Cognitive test performance;
CRC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg01874867	chr7:94954059	PON1	-0.51	-6.42	-0.33	4.74e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg05527609	chr1:210001259	C1orf107	0.49	6.14	0.32	2.34e-9	Red blood cell count;
CRC	cis	rs6499255	0.951	rs8052086	chr16:69692468	A/C	cg15192750	chr16:69999425	NA	0.59	7.93	0.4	3.45e-14	IgE levels;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg03790207	chr6:42947109	PEX6	-0.49	-6.97	-0.36	1.77e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.08	-0.36	8.63e-12	IgG glycosylation;
CRC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.6	-0.34	1.62e-10	Major depressive disorder;
CRC	cis	rs55702914	0.809	rs6738721	chr2:198182334	A/G	cg20885578	chr2:198174922	NA	-0.34	-5.84	-0.31	1.28e-8	Major depression and alcohol dependence;
CRC	cis	rs12928939	0.911	rs7202840	chr16:71824714	C/T	cg08717414	chr16:71523259	ZNF19	-0.51	-6.32	-0.33	8.64e-10	Post bronchodilator FEV1;
CRC	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.44	-5.76	-0.3	1.98e-8	Height;
CRC	cis	rs73200209	0.744	rs73198012	chr12:116463855	G/A	cg01776926	chr12:116560359	MED13L	-0.59	-6.67	-0.35	1.08e-10	Total body bone mineral density;
CRC	cis	rs4664293	0.967	rs10176436	chr2:160515394	G/A	cg08347373	chr2:160653686	CD302	-0.37	-6.15	-0.32	2.21e-9	Monocyte percentage of white cells;
CRC	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg26587870	chr6:27730563	NA	-0.43	-6.01	-0.31	4.83e-9	Breast cancer;
CRC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.99	0.31	5.52e-9	Morning vs. evening chronotype;
CRC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.08	0.32	3.31e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg15382696	chr6:118971807	C6orf204	0.6	7.72	0.39	1.38e-13	Diastolic blood pressure;
CRC	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	1.04	10.12	0.49	3.75e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.38	-6.54	-0.34	2.29e-10	Vitamin D levels;
CRC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.36	5.66	0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg19812747	chr11:111475976	SIK2	0.42	6.08	0.32	3.39e-9	Primary sclerosing cholangitis;
CRC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg15848620	chr12:58087721	OS9	-0.61	-8.58	-0.43	3.82e-16	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.75	0.3	2.01e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg09473613	chr1:24152604	HMGCL	0.34	5.87	0.31	1.07e-8	Immature fraction of reticulocytes;
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg05055821	chr7:2758924	NA	0.36	5.63	0.3	3.85e-8	Height;
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11645453	chr3:52864694	ITIH4	0.36	6.62	0.34	1.46e-10	Bipolar disorder;
CRC	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg11271282	chr2:238384023	NA	0.43	5.78	0.3	1.74e-8	Prostate cancer;
CRC	cis	rs17227506	0.693	rs4531057	chr8:13457799	C/T	cg03566418	chr8:13424080	C8orf48	-0.35	-5.99	-0.31	5.61e-9	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.59	-8.99	-0.44	2.04e-17	Dementia with Lewy bodies;
CRC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.47	6.07	0.32	3.44e-9	Response to diuretic therapy;
CRC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.43	5.87	0.31	1.06e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.8	0.3	1.59e-8	IgG glycosylation;
CRC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs863345	0.967	rs10908680	chr1:158521961	T/C	cg12129480	chr1:158549410	OR10X1	-0.26	-5.65	-0.3	3.44e-8	Pneumococcal bacteremia;
CRC	cis	rs2882667	0.690	rs17031	chr5:138270542	A/T	cg09476006	chr5:138032270	NA	0.53	8.85	0.44	5.33e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.43	6.69	0.35	9.9e-11	Red blood cell count;
CRC	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.91	-0.31	8.38e-9	Type 2 diabetes;
CRC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg02527881	chr3:46936655	PTH1R	0.36	6.49	0.34	3.23e-10	Colorectal cancer;
CRC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	10.15	0.49	3.15e-21	Total body bone mineral density;
CRC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.64	0.51	6.47e-23	Ileal carcinoids;
CRC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.53	8.48	0.42	7.71e-16	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10132348	chr4:6784379	KIAA0232	0.38	6.26	0.33	1.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg09163369	chr1:210001066	C1orf107	0.62	8.29	0.42	2.99e-15	Orofacial clefts;
CRC	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.7	-0.35	9.11e-11	Menarche (age at onset);
CRC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.43e-16	Height;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg22687807	chr8:143858763	LYNX1	-0.45	-7.44	-0.38	8.84e-13	Urinary tract infection frequency;
CRC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg11833968	chr6:79620685	NA	-0.37	-6.35	-0.33	7.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg26695010	chr11:65641043	EFEMP2	-0.41	-6.08	-0.32	3.42e-9	Eosinophil percentage of white cells;
CRC	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg14092571	chr14:90743983	NA	0.39	5.98	0.31	5.81e-9	Mortality in heart failure;
CRC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.84	0.35	3.79e-11	Schizophrenia;
CRC	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.08	-0.36	8.67e-12	Body mass index;
CRC	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.2	-0.32	1.65e-9	Breast cancer;
CRC	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg15654264	chr1:150340011	RPRD2	0.42	6.35	0.33	7.02e-10	Migraine;
CRC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.56	-8.16	-0.41	7.4e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.66	9.88	0.48	2.47e-20	Lung cancer;
CRC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.59	-8.74	-0.43	1.22e-16	Menarche (age at onset);
CRC	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg01312482	chr5:178451176	ZNF879	-0.35	-5.77	-0.3	1.81e-8	Pubertal anthropometrics;
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg22561889	chr6:118971681	C6orf204	0.51	6.6	0.34	1.69e-10	Diastolic blood pressure;
CRC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.28	6.13	0.32	2.47e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11895698	1	rs11895698	chr2:239338495	C/T	cg01134436	chr17:81009848	B3GNTL1	0.58	6.42	0.33	4.72e-10	Chronotype;
CRC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.67	8.9	0.44	3.94e-17	Coronary artery disease;
CRC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.6	-0.47	2.1e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-8.42	-0.42	1.18e-15	Chronic sinus infection;
CRC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg10305451	chr2:177043427	NA	0.72	11.21	0.53	6.62e-25	IgG glycosylation;
CRC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.08	0.32	3.37e-9	Rheumatoid arthritis;
CRC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.59	9.25	0.45	2.92e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg02527881	chr3:46936655	PTH1R	-0.34	-5.96	-0.31	6.66e-9	Colorectal cancer;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.99	-0.31	5.55e-9	Cognitive function;
CRC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.55	8.3	0.42	2.77e-15	Resting heart rate;
CRC	cis	rs2795502	0.630	rs2282443	chr10:43474169	A/G	cg20628663	chr10:43360327	NA	0.64	7.23	0.37	3.33e-12	Blood protein levels;
CRC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.12	0.32	2.65e-9	Aortic root size;
CRC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.79	12.37	0.56	4.12e-29	Coronary artery disease;
CRC	cis	rs3824347	0.804	rs10781255	chr9:77575790	C/T	cg01251476	chr9:77566080	C9orf40	0.38	5.85	0.31	1.18e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.1	-0.32	3.05e-9	Schizophrenia;
CRC	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	13.49	0.6	2.64e-33	Hip circumference;
CRC	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	8.34	0.42	2e-15	Iron status biomarkers;
CRC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.98	-0.44	2.07e-17	Aortic root size;
CRC	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg09659197	chr4:152720779	NA	0.49	10.43	0.5	3.51e-22	Intelligence (multi-trait analysis);
CRC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg13607699	chr17:42295918	UBTF	-0.48	-6.17	-0.32	1.98e-9	Total body bone mineral density;
CRC	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.43	0.42	1.07e-15	Mean corpuscular volume;
CRC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.73	-12.89	-0.58	4.56e-31	P wave terminal force;
CRC	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg09455208	chr3:40491958	NA	0.31	6.23	0.33	1.4e-9	Renal cell carcinoma;
CRC	cis	rs17092148	0.887	rs6059931	chr20:33175338	A/G	cg08999081	chr20:33150536	PIGU	0.49	6.14	0.32	2.39e-9	Neuroticism;
CRC	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	11.58	0.54	3.12e-26	Bipolar disorder;
CRC	cis	rs526821	1.000	rs526821	chr11:55306151	A/G	cg04317927	chr11:55418816	OR4S2	0.32	5.98	0.31	5.92e-9	Pediatric bone mineral density (spine);
CRC	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg23100626	chr2:96804247	ASTL	-0.28	-7.42	-0.38	9.81e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.21	0.32	1.64e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12999616	0.602	rs905484	chr2:98590083	T/A	cg26665480	chr2:98280029	ACTR1B	0.56	6.33	0.33	8.12e-10	Colorectal cancer;
CRC	cis	rs1434579	0.966	rs7246892	chr19:44928668	A/G	cg15540054	chr19:45004280	ZNF180	0.5	6.39	0.33	5.71e-10	Tuberculosis;
CRC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.36	6.06	0.32	3.79e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs6463739	0.965	rs6976317	chr7:7902349	C/G	cg09417038	chr21:47716443	C21orf57	0.4	6.09	0.32	3.12e-9	Small cell lung carcinoma;
CRC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg25834613	chr7:1915315	MAD1L1	-0.47	-6.86	-0.35	3.37e-11	Bipolar disorder;
CRC	cis	rs7932354	0.502	rs11600668	chr11:47193566	G/A	cg19486271	chr11:47235900	DDB2	0.47	6.64	0.34	1.29e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-18.86	-0.72	2.59e-54	Height;
CRC	cis	rs2971970	0.519	rs4728303	chr7:133633518	G/T	cg03336402	chr7:133662267	EXOC4	0.63	9.63	0.47	1.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg04166393	chr7:2884313	GNA12	0.37	5.67	0.3	3.05e-8	Height;
CRC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.6	-8.36	-0.42	1.76e-15	Menopause (age at onset);
CRC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.09e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg15786705	chr6:28176104	NA	0.6	6.74	0.35	7.32e-11	Parkinson's disease;
CRC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.78e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg12963866	chr19:57752005	ZNF805	-0.44	-6.54	-0.34	2.36e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.44	-7.36	-0.38	1.46e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.4	-6.66	-0.34	1.16e-10	Vitamin D levels;
CRC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.62	14.1	0.61	1.2e-35	Airflow obstruction;
CRC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg01951491	chr16:67709440	GFOD2	0.43	5.61	0.3	4.27e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.36	-0.42	1.76e-15	Asthma (sex interaction);
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.8	15.3	0.64	2.82e-40	Prudent dietary pattern;
CRC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.1	-0.41	1.08e-14	Height;
CRC	cis	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg02972257	chr16:68554789	NA	0.47	5.8	0.3	1.59e-8	Colorectal cancer;
CRC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.95	-17.8	-0.7	3.9e-50	IgG glycosylation;
CRC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.52	-7.75	-0.39	1.14e-13	Non-alcoholic fatty liver disease histology (lobular);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07584320	chr11:94964503	SESN3	0.41	6.57	0.34	1.96e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14023350	chr14:89631066	FOXN3	0.28	6.72	0.35	8.11e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.75	-13.75	-0.6	2.6e-34	Body mass index;
CRC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.57	-0.75	5.09e-61	Height;
CRC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.53	10.92	0.52	6.76e-24	Alcohol dependence;
CRC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.87	-0.31	1.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.01	-21.46	-0.76	1.61e-64	Myeloid white cell count;
CRC	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.37	6.16	0.32	2.08e-9	Sitting height ratio;
CRC	cis	rs447	1.000	rs7781923	chr7:83747200	T/G	cg22846510	chr7:83753280	SEMA3A	-0.59	-7.65	-0.39	2.29e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.51	-0.75	8.67e-61	Hip circumference adjusted for BMI;
CRC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg20194872	chr6:41519635	FOXP4	0.39	5.64	0.3	3.61e-8	Prostate cancer;
CRC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.32	-0.33	8.47e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.82	-0.58	8.7e-31	White blood cell count (basophil);
CRC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.75	10.02	0.48	8.28e-21	Platelet count;
CRC	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg14092571	chr14:90743983	NA	0.38	5.86	0.31	1.12e-8	Mortality in heart failure;
CRC	cis	rs524281	0.817	rs10896097	chr11:65967953	A/C	cg16950941	chr11:66035639	RAB1B	-0.58	-7.27	-0.37	2.6e-12	Electroencephalogram traits;
CRC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.4	0.38	1.16e-12	Mean platelet volume;
CRC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.75	12.7	0.57	2.49e-30	Body mass index;
CRC	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.49	7.32	0.37	1.87e-12	Asthma;
CRC	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg09021430	chr5:549028	NA	-0.57	-6.06	-0.32	3.79e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs972578	0.791	rs4822243	chr22:43383503	T/C	cg01576275	chr22:43409880	NA	-0.48	-7.71	-0.39	1.47e-13	Mean platelet volume;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.59	11.07	0.52	1.99e-24	Coronary artery disease;
CRC	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg08075719	chr14:103021372	NA	-0.7	-9.22	-0.45	3.63e-18	Platelet count;
CRC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.5	7.33	0.37	1.85e-12	Bladder cancer;
CRC	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg03162506	chr22:38580953	NA	0.28	6.0	0.31	5.31e-9	Cutaneous nevi;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.54	-0.34	2.37e-10	Total body bone mineral density;
CRC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.86	0.31	1.1e-8	Prudent dietary pattern;
CRC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg00947319	chr17:47005597	UBE2Z	-0.35	-5.99	-0.31	5.54e-9	Type 2 diabetes;
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11645453	chr3:52864694	ITIH4	0.33	6.05	0.32	4.01e-9	Bipolar disorder;
CRC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13798912	chr7:905769	UNC84A	0.56	6.46	0.34	3.72e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.7	8.23	0.41	4.48e-15	Phospholipid levels (plasma);
CRC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.67	-0.35	1.09e-10	Aortic root size;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.87	-0.31	1.04e-8	Longevity;Endometriosis;
CRC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.34	-5.8	-0.3	1.52e-8	Total body bone mineral density;
CRC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.18	-0.41	6.3e-15	Morning vs. evening chronotype;
CRC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.49	6.6	0.34	1.67e-10	Schizophrenia;
CRC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg02896835	chr1:92012615	NA	0.49	6.33	0.33	8.05e-10	Eosinophil percentage of white cells;
CRC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.5	6.64	0.34	1.3e-10	White matter hyperintensity burden;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.85	13.79	0.61	1.8e-34	Menarche (age at onset);
CRC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.52	7.37	0.38	1.36e-12	Corneal astigmatism;
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg22561889	chr6:118971681	C6orf204	0.51	6.52	0.34	2.72e-10	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06966887	chr5:443603	EXOC3;C5orf55	0.46	6.51	0.34	2.82e-10	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	6.83	0.35	4.2e-11	Cognitive test performance;
CRC	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.61	-10.45	-0.5	2.96e-22	Breast cancer;
CRC	cis	rs2227564	0.620	rs11000785	chr10:75575963	T/C	cg00564723	chr10:75632066	CAMK2G	-0.3	-7.4	-0.38	1.18e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	11.24	0.53	4.88e-25	Monocyte percentage of white cells;
CRC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02228675	chr17:40259724	DHX58	-0.48	-6.8	-0.35	5.05e-11	Fibrinogen levels;
CRC	cis	rs7215564	0.908	rs2316063	chr17:78663360	G/A	cg09596252	chr17:78655493	RPTOR	0.54	6.08	0.32	3.26e-9	Myopia (pathological);
CRC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg10298567	chr3:47292165	KIF9	-0.4	-6.25	-0.33	1.3e-9	Colorectal cancer;
CRC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg20243544	chr17:37824526	PNMT	0.39	5.83	0.31	1.29e-8	Self-reported allergy;
CRC	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.77	-8.23	-0.41	4.56e-15	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.0	-0.31	5.17e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7487075	0.893	rs2408508	chr12:46730600	T/C	cg22049899	chr12:47219821	SLC38A4	0.35	6.82	0.35	4.45e-11	Itch intensity from mosquito bite;
CRC	cis	rs2179367	0.959	rs537354	chr6:149665937	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.42	-6.3	-0.33	9.3e-10	Dupuytren's disease;
CRC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.45	0.6	3.78e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.15	-15.58	-0.65	2.2e-41	Vitiligo;
CRC	trans	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg01505111	chr6:125621795	HDDC2	0.38	6.02	0.31	4.68e-9	DNA methylation (variation);
CRC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg20487152	chr13:99095054	FARP1	-0.46	-6.53	-0.34	2.5e-10	Longevity;
CRC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.13	0.32	2.46e-9	Self-reported allergy;
CRC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.43	6.35	0.33	7.25e-10	Menopause (age at onset);
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.67	9.72	0.47	8.48e-20	Menarche (age at onset);
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg02475695	chr16:616220	NHLRC4	0.44	7.44	0.38	8.79e-13	Height;
CRC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.52	7.43	0.38	9.71e-13	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05329982	chr11:62359210	TUT1	0.43	6.01	0.31	4.81e-9	Response to antipsychotic treatment;
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg03623178	chr6:28175578	NA	0.77	8.37	0.42	1.67e-15	Depression;
CRC	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.49	7.05	0.36	1.07e-11	Primary sclerosing cholangitis;
CRC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.42	0.46	8e-19	Platelet count;
CRC	trans	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.84	0.35	3.84e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.43	6.87	0.35	3.26e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.93	-0.31	7.58e-9	Depression;
CRC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.88	-0.35	2.99e-11	Breast cancer;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg27615366	chr5:131592974	PDLIM4	0.32	5.68	0.3	2.98e-8	Breast cancer;
CRC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.83	11.82	0.55	4.02e-27	Cognitive function;
CRC	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs9462027	0.628	rs9380455	chr6:34690778	C/A	cg07306190	chr6:34760872	UHRF1BP1	0.34	5.97	0.31	6.27e-9	Systemic lupus erythematosus;
CRC	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg06204229	chr3:52865917	ITIH4	0.61	7.13	0.37	6.5e-12	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.22	-0.32	1.52e-9	Coronary artery disease;
CRC	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.54	9.06	0.45	1.19e-17	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11105585	chr21:45759228	C21orf2	0.4	6.29	0.33	1.01e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg03959625	chr15:84868606	LOC388152	0.41	6.07	0.32	3.55e-9	Schizophrenia;
CRC	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.62	-7.85	-0.4	6.07e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg06191203	chr2:152266755	RIF1	0.43	6.12	0.32	2.68e-9	Lung cancer;
CRC	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg24505167	chr7:1915268	MAD1L1	-0.49	-7.44	-0.38	8.84e-13	Bipolar disorder;
CRC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.9	-0.36	2.63e-11	Response to antipsychotic treatment;
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.03	-26.25	-0.82	1.1e-82	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg14593290	chr7:50529359	DDC	-0.43	-6.25	-0.33	1.29e-9	Body mass index;
CRC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	6.7	0.35	9.04e-11	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06797938	chr17:1466136	PITPNA	0.41	6.25	0.33	1.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.44	6.61	0.34	1.55e-10	Testicular germ cell tumor;
CRC	trans	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.6	0.39	3.09e-13	Endometrial cancer;
CRC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.16	-0.41	7.01e-15	Bone mineral density;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg04990556	chr1:26633338	UBXN11	-0.49	-6.25	-0.33	1.3e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.11	0.32	2.84e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.94	-0.36	2.13e-11	Monocyte percentage of white cells;
CRC	cis	rs12541635	0.677	rs55639043	chr8:107055993	C/T	cg10147462	chr8:107024639	NA	0.62	11.23	0.53	5.35e-25	Age of smoking initiation;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg16522107	chr15:65579214	PARP16	0.38	6.15	0.32	2.18e-9	Obesity-related traits;
CRC	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.51	6.96	0.36	1.87e-11	Caudate activity during reward;
CRC	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.96	-12.27	-0.56	9.23e-29	Exhaled nitric oxide levels;
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.73	-12.39	-0.56	3.46e-29	Ulcerative colitis;
CRC	trans	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg02674126	chr19:40336878	FBL	0.42	6.74	0.35	6.98e-11	Hyperactive-impulsive symptoms;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	cis	rs294883	0.739	rs962340	chr6:159729096	C/T	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg05376469	chr2:102649931	NA	-0.36	-5.97	-0.31	6.05e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.65	10.3	0.49	9.6e-22	Colorectal cancer;
CRC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.75	0.66	4.84e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.99	-12.34	-0.56	5.32e-29	Initial pursuit acceleration;
CRC	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.69	7.1	0.36	7.97e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.62	-17.0	-0.68	5.73e-47	Urate levels in overweight individuals;
CRC	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	7.38	0.38	1.29e-12	Hypertriglyceridemia;
CRC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.48	0.42	7.73e-16	Rheumatoid arthritis;
CRC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.81	-12.8	-0.58	1.02e-30	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17592812	chr19:16296137	FAM32A	0.43	6.3	0.33	9.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.66	7.59	0.39	3.24e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.42	5.83	0.31	1.31e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.89	-0.48	2.3e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg13385794	chr1:248469461	NA	0.37	6.53	0.34	2.55e-10	Common traits (Other);
CRC	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.53	8.57	0.43	4.03e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg07395648	chr5:131743802	NA	-0.41	-5.96	-0.31	6.36e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.39	5.61	0.3	4.4e-8	Lymphocyte counts;Fibrinogen;
CRC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.49	-0.38	6.26e-13	Aortic root size;
CRC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg17796960	chr10:135278976	LOC619207	-0.37	-5.65	-0.3	3.53e-8	Systemic lupus erythematosus;
CRC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.61	-0.47	1.99e-19	Monocyte percentage of white cells;
CRC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.67e-10	Bipolar disorder;
CRC	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.72	-0.3	2.43e-8	Subjective well-being;
CRC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.2	-0.37	4.18e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg15192750	chr16:69999425	NA	0.56	7.22	0.37	3.54e-12	IgE levels;
CRC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.64	-10.49	-0.5	2.13e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg13390004	chr1:15929781	NA	0.49	6.98	0.36	1.64e-11	Systolic blood pressure;
CRC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg08200582	chr11:442649	ANO9	-0.69	-7.21	-0.37	3.75e-12	Body mass index;
CRC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg16141378	chr3:129829833	LOC729375	0.41	6.11	0.32	2.78e-9	Joint mobility (Beighton score);
CRC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg27661571	chr11:113659931	NA	-0.96	-11.08	-0.52	1.89e-24	Hip circumference adjusted for BMI;
CRC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg17885791	chr6:149771845	ZC3H12D	-0.33	-5.84	-0.31	1.25e-8	Dupuytren's disease;
CRC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-9.2	-0.45	4.33e-18	Subjective well-being;
CRC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.27	-0.37	2.7e-12	Bipolar disorder;
CRC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.5	10.04	0.48	7.46e-21	Renal cell carcinoma;
CRC	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.76	-10.25	-0.49	1.46e-21	White matter hyperintensity burden;
CRC	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg08501292	chr6:25962987	TRIM38	0.84	6.5	0.34	2.92e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.68	-11.78	-0.54	5.76e-27	Prostate cancer;
CRC	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	6.19	0.32	1.75e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.48	-6.59	-0.34	1.72e-10	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05318427	chr2:85199320	KCMF1	0.52	7.55	0.38	4.3e-13	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	0.8	9.25	0.45	2.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.35	7.17	0.37	4.91e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg22182287	chr2:3452347	TTC15	0.37	5.95	0.31	6.72e-9	Obesity-related traits;
CRC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.63	10.87	0.51	1.04e-23	Prudent dietary pattern;
CRC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.59	-9.54	-0.47	3.23e-19	Hemostatic factors and hematological phenotypes;
CRC	trans	rs12940923	1.000	rs11868285	chr17:56371181	C/T	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-7.26	-0.37	2.87e-12	Aortic root size;
CRC	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg14166395	chr21:42792516	MX1	0.51	7.06	0.36	9.9e-12	IgG glycosylation;
CRC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.5	5.78	0.3	1.75e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.65e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.63	-0.47	1.65e-19	Morning vs. evening chronotype;
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	5.88	0.31	1.02e-8	Lung function (FEV1/FVC);
CRC	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.48	0.42	7.7e-16	Brugada syndrome;
CRC	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.65	10.22	0.49	1.83e-21	Height;
CRC	cis	rs11587400	0.679	rs6537834	chr1:115108870	T/C	cg12756093	chr1:115239321	AMPD1	0.43	5.9	0.31	9.27e-9	Autism;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.32	0.42	2.36e-15	Alzheimer's disease;
CRC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.25	15.72	0.65	6.58e-42	Lung disease severity in cystic fibrosis;
CRC	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.42	-0.65	9.24e-41	Exhaled nitric oxide output;
CRC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.65	12.57	0.57	7.42e-30	Coronary artery disease;
CRC	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.66	10.88	0.51	9.1e-24	Cancer;
CRC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg18512352	chr11:47633146	NA	0.35	6.88	0.35	2.96e-11	Subjective well-being;
CRC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg00343986	chr7:65444356	GUSB	-0.47	-7.07	-0.36	9.5e-12	Aortic root size;
CRC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.61	9.13	0.45	7.29e-18	Lung cancer;
CRC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.41	5.6	0.3	4.46e-8	Renal cell carcinoma;
CRC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-7.12	-0.37	6.8e-12	Subjective well-being;
CRC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg27532560	chr4:187881888	NA	-0.54	-9.87	-0.48	2.69e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg21251018	chr6:28226885	NKAPL	0.46	6.46	0.34	3.67e-10	Parkinson's disease;
CRC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg21153622	chr11:89784906	NA	-0.39	-5.97	-0.31	6.21e-9	Height;
CRC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25517755	chr10:38738941	LOC399744	-0.42	-6.1	-0.32	3.03e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs612683	0.518	rs10875287	chr1:100812908	T/C	cg06223162	chr1:101003688	GPR88	-0.32	-5.66	-0.3	3.25e-8	Breast cancer;
CRC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.42	8.09	0.41	1.16e-14	Mean corpuscular volume;
CRC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.45	7.79	0.39	8.96e-14	Childhood ear infection;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.59	-0.34	1.76e-10	Bipolar disorder;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.45	-6.31	-0.33	8.79e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg08923669	chr16:420230	MRPL28	-0.49	-6.29	-0.33	1.01e-9	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.18e-22	Bipolar disorder;
CRC	cis	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg18131467	chr2:239335373	ASB1	-0.71	-6.28	-0.33	1.06e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	7.91	0.4	4.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg25856811	chr1:152973957	SPRR3	-0.21	-5.62	-0.3	4.03e-8	Inflammatory skin disease;
CRC	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.01	0.44	1.72e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	8.89	0.44	4.24e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11229555	0.645	rs7117080	chr11:58178677	C/G	cg15696309	chr11:58395628	NA	-0.73	-9.67	-0.47	1.27e-19	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg04439458	chr5:138467593	SIL1	-0.36	-6.02	-0.32	4.62e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.46	7.17	0.37	4.83e-12	Asthma;
CRC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg08885800	chr1:201084119	NA	0.42	6.06	0.32	3.64e-9	Permanent tooth development;
CRC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.58	0.47	2.48e-19	Lung cancer;
CRC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.79	0.35	5.24e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.43	8.96	0.44	2.46e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.84	0.35	3.88e-11	Rheumatoid arthritis;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.56	-8.52	-0.43	5.72e-16	Longevity;Endometriosis;
CRC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.05	0.52	2.44e-24	Alzheimer's disease;
CRC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg03709012	chr19:19516395	GATAD2A	0.52	5.62	0.3	4.16e-8	Tonsillectomy;
CRC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22133161	chr19:49891603	CCDC155	0.48	6.3	0.33	9.42e-10	Multiple sclerosis;
CRC	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-7.62	-0.39	2.71e-13	Blood metabolite levels;
CRC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.59	0.43	3.66e-16	Height;
CRC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.01	0.31	5.04e-9	Bladder cancer;
CRC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.25	-0.33	1.28e-9	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01498160	chr12:26348463	SSPN	0.38	6.06	0.32	3.74e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.62	0.43	2.93e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.66	-8.65	-0.43	2.25e-16	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06795559	chr20:5931181	MCM8;TRMT6	0.38	6.4	0.33	5.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.32	-0.37	1.89e-12	Bipolar disorder;
CRC	cis	rs4290604	0.748	rs62183341	chr2:237973410	G/C	cg23555395	chr2:238036564	NA	0.61	6.08	0.32	3.32e-9	Asthma;
CRC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.34	0.59	9.27e-33	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	8.96	0.44	2.38e-17	Platelet count;
CRC	cis	rs13253111	1.000	rs13253111	chr8:28061974	C/T	cg26534493	chr8:28060551	NA	-0.47	-8.31	-0.42	2.56e-15	Childhood body mass index;
CRC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg03030879	chr14:75389066	RPS6KL1	0.45	7.1	0.36	7.5e-12	Height;
CRC	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.77	-8.27	-0.41	3.46e-15	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg06484146	chr7:12443880	VWDE	-0.48	-6.93	-0.36	2.19e-11	Coronary artery disease;
CRC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.33	0.42	2.17e-15	Gut microbiome composition (summer);
CRC	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg12458913	chr13:53173898	NA	0.51	8.22	0.41	4.68e-15	Lewy body disease;
CRC	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg20936604	chr3:58311152	NA	-0.71	-7.49	-0.38	6.33e-13	Cholesterol, total;
CRC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.49	-0.38	6.29e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.99	-0.44	1.97e-17	Monocyte count;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.52	6.99	0.36	1.49e-11	Longevity;Endometriosis;
CRC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.42	9.22	0.45	3.78e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.58	6.39	0.33	5.61e-10	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24480577	chr20:62169334	PTK6	0.41	6.56	0.34	2.05e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-6.54	-0.34	2.33e-10	Mosquito bite size;
CRC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.61	-9.44	-0.46	6.9e-19	Aortic root size;
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg11861562	chr11:117069780	TAGLN	0.31	6.9	0.36	2.74e-11	Blood protein levels;
CRC	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12463550	chr7:65579703	CRCP	0.75	6.82	0.35	4.5e-11	Diabetic kidney disease;
CRC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.36	6.39	0.33	5.8e-10	DNA methylation (variation);
CRC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg03037974	chr15:76606532	NA	0.71	12.66	0.57	3.3e-30	Blood metabolite levels;
CRC	cis	rs6840360	0.515	rs11099811	chr4:152320532	C/A	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.8	9.95	0.48	1.45e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs12024301	0.557	rs11811536	chr1:183604258	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.87	0.35	3.26e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.86	-0.44	5.25e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.27	-14.62	-0.63	1.2e-37	Diabetic kidney disease;
CRC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.46	-0.38	7.89e-13	Morning vs. evening chronotype;
CRC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.61	8.3	0.42	2.66e-15	Urate levels in lean individuals;
CRC	cis	rs907683	0.584	rs12991025	chr2:220284779	C/T	cg15015639	chr2:220282977	DES	0.44	7.03	0.36	1.18e-11	Resting heart rate;
CRC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.53	7.59	0.39	3.32e-13	Lung cancer;
CRC	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg15147215	chr3:52552868	STAB1	0.53	9.14	0.45	6.62e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.71	9.97	0.48	1.22e-20	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	9.71	0.47	9.45e-20	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3751196	0.808	rs17034650	chr12:104219550	G/A	cg02344784	chr12:104178138	NT5DC3	0.71	7.25	0.37	3.05e-12	Sense of smell;
CRC	cis	rs6586163	0.872	rs1926201	chr10:90746360	G/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.13	-0.37	6.43e-12	Chronic lymphocytic leukemia;
CRC	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.38	-0.71	2.03e-52	Schizophrenia;
CRC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs1355223	0.833	rs286885	chr11:34687346	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.41	5.66	0.3	3.36e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25944898	chr11:64085532	PRDX5;TRMT112	0.36	6.05	0.32	3.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.4	5.79	0.3	1.63e-8	Aortic root size;
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.42	6.26	0.33	1.2e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.76	-10.24	-0.49	1.56e-21	White matter hyperintensity burden;
CRC	trans	rs264943	0.600	rs11675977	chr2:104095893	G/A	cg24033067	chr14:24674799	TSSK4	-0.41	-6.01	-0.31	4.8e-9	HIV-1 viral setpoint;
CRC	cis	rs11038871	0.815	rs6485686	chr11:46657430	T/G	cg16389345	chr11:46697382	NA	0.35	5.65	0.3	3.49e-8	Immunoglobulin A;
CRC	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-6.46	-0.34	3.74e-10	Coronary artery disease;
CRC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.45	6.84	0.35	3.82e-11	Longevity;
CRC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.54	-8.01	-0.4	1.97e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.8	-11.67	-0.54	1.42e-26	Pubertal anthropometrics;
CRC	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.44	6.45	0.33	4.07e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	9.0	0.44	1.87e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.57	-0.67	2.97e-45	Hip circumference;
CRC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.62	-0.39	2.76e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.61	-11.46	-0.53	8.56e-26	Educational attainment;
CRC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.45	-8.3	-0.42	2.8e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.75	-12.19	-0.56	1.89e-28	Height;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg06484146	chr7:12443880	VWDE	-0.64	-6.83	-0.35	4.2e-11	Coronary artery disease;
CRC	cis	rs9928842	0.882	rs1107593	chr16:75261329	G/C	cg09066997	chr16:75300724	BCAR1	0.68	6.36	0.33	6.83e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg03013999	chr17:37608204	MED1	-0.48	-7.51	-0.38	5.62e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs10760158	0.832	rs10760172	chr9:124061902	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.73	-0.3	2.32e-8	Pulse pressure;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03533382	chr5:126853128	PRRC1	-0.57	-7.1	-0.36	7.69e-12	Diisocyanate-induced asthma;
CRC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.5	0.46	4.66e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.53	8.55	0.43	4.69e-16	Platelet count;
CRC	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.43	6.37	0.33	6.37e-10	Red blood cell count;
CRC	cis	rs3764400	0.517	rs7209042	chr17:46207792	G/C	cg10706073	chr17:46328419	SKAP1	0.58	6.26	0.33	1.22e-9	Body mass index;
CRC	cis	rs9783347	0.857	rs4150561	chr11:18354877	T/C	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	trans	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.1	-0.32	3e-9	Educational attainment (years of education);
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg03690763	chr11:133734501	NA	-0.34	-5.78	-0.3	1.71e-8	Childhood ear infection;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05765466	chr1:45957060	TESK2	0.49	6.19	0.32	1.83e-9	Thyroid stimulating hormone;
CRC	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg14458575	chr2:238380390	NA	0.65	8.02	0.4	1.82e-14	Prostate cancer;
CRC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.84	7.17	0.37	4.9e-12	Putamen volume;
CRC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.38e-30	Bone mineral density;
CRC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg03632145	chr6:24403130	MRS2	0.56	6.06	0.32	3.74e-9	Body mass index;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg21251018	chr6:28226885	NKAPL	0.59	10.3	0.49	9.21e-22	Cardiac Troponin-T levels;
CRC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg09127314	chr1:152161683	NA	0.51	6.48	0.34	3.44e-10	Atopic dermatitis;
CRC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.15	-0.37	5.67e-12	Total body bone mineral density;
CRC	cis	rs501120	0.584	rs1746034	chr10:44714768	T/C	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.55	6.91	0.36	2.52e-11	Exhaled nitric oxide output;
CRC	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.51	-11.14	-0.52	1.1e-24	Urate levels in overweight individuals;
CRC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.92	-0.36	2.32e-11	Morning vs. evening chronotype;
CRC	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.53	0.43	5.48e-16	Arsenic metabolism;
CRC	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.17	26.86	0.83	6.04e-85	Schizophrenia;
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg12564285	chr5:131593104	PDLIM4	0.33	5.72	0.3	2.4e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs6041	0.822	rs1755685	chr13:113757192	A/C	cg09069900	chr13:113776964	F10	0.43	7.04	0.36	1.14e-11	End-stage coagulation;
CRC	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.74	-9.24	-0.45	3.04e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.8	0.35	5.01e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.58	8.86	0.44	5.05e-17	Height;
CRC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.98	-0.4	2.47e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg27398640	chr15:77910606	LINGO1	-0.46	-7.77	-0.39	1.01e-13	Type 2 diabetes;
CRC	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg14003231	chr6:33640908	ITPR3	0.49	8.01	0.4	1.94e-14	Plateletcrit;
CRC	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.75	-9.25	-0.45	2.94e-18	Type 2 diabetes;
CRC	cis	rs7705042	0.865	rs249642	chr5:141524980	G/C	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.71	-0.3	2.5e-8	Asthma;
CRC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.74	12.44	0.57	2.15e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs282587	0.569	rs428270	chr13:113411956	T/G	cg04656015	chr13:113407548	ATP11A	0.64	8.28	0.42	3.04e-15	Glycated hemoglobin levels;
CRC	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.59	-9.03	-0.45	1.5e-17	Blood pressure (smoking interaction);
CRC	cis	rs7113874	0.513	rs2015629	chr11:8564426	A/T	cg02811074	chr11:8615871	STK33	-0.37	-6.23	-0.33	1.39e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-6.88	-0.35	3.03e-11	Schizophrenia;
CRC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.62	11.53	0.54	4.68e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg23202291	chr11:1979235	NA	0.48	6.59	0.34	1.78e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03923535	chr7:1197113	ZFAND2A	0.71	10.73	0.51	3.25e-23	Longevity;Endometriosis;
CRC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.56	8.08	0.41	1.28e-14	Lymphocyte counts;
CRC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.32	-5.85	-0.31	1.19e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.56	9.12	0.45	7.89e-18	Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.53	9.34	0.46	1.52e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg07423050	chr13:99094983	FARP1	-0.36	-5.83	-0.31	1.3e-8	Longevity;
CRC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg14593290	chr7:50529359	DDC	-0.45	-6.33	-0.33	7.96e-10	Systemic sclerosis;
CRC	trans	rs11885103	0.543	rs2685227	chr2:561099	T/C	cg12228919	chr15:44955936	SPG11	-0.46	-6.87	-0.35	3.13e-11	Heschl's gyrus morphology;
CRC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg23262073	chr20:60523788	NA	-0.41	-6.91	-0.36	2.47e-11	Body mass index;
CRC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.22	-0.37	3.66e-12	Morning vs. evening chronotype;
CRC	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.35	-5.74	-0.3	2.17e-8	Mean arterial pressure;
CRC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.71	-0.39	1.48e-13	Bipolar disorder;
CRC	cis	rs365302	1.000	rs542031	chr6:159651967	A/C	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs2227564	0.794	rs2688620	chr10:75684532	A/G	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.12	-0.37	7e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	8.98	0.44	2.2e-17	Platelet distribution width;
CRC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.4	-0.38	1.16e-12	Retinal vascular caliber;
CRC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.42	6.95	0.36	1.93e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.59	9.32	0.46	1.73e-18	Prostate cancer;
CRC	cis	rs2625529	0.617	rs2128112	chr15:72186286	A/T	cg16672083	chr15:72433130	SENP8	0.46	7.09	0.36	8.39e-12	Red blood cell count;
CRC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.45	6.48	0.34	3.26e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	8.98	0.44	2.17e-17	Coffee consumption (cups per day);
CRC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg12884169	chr21:40033163	ERG	0.36	7.89	0.4	4.64e-14	Coronary artery disease;
CRC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.6	9.61	0.47	1.89e-19	Tonsillectomy;
CRC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-5.7	-0.3	2.69e-8	Electroencephalogram traits;
CRC	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.08	-20.51	-0.75	8.6e-61	Schizophrenia;
CRC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.46	5.85	0.31	1.21e-8	Aortic root size;
CRC	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg27535305	chr1:53392650	SCP2	-0.31	-5.63	-0.3	3.85e-8	Monocyte count;
CRC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.73	11.54	0.54	4.38e-26	Intelligence (multi-trait analysis);
CRC	trans	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg26043149	chr18:55253948	FECH	-0.53	-7.75	-0.39	1.13e-13	Bone mineral density;
CRC	cis	rs9311676	0.632	rs57700771	chr3:58360327	G/A	cg06643156	chr3:58380774	PXK	0.43	6.73	0.35	7.6e-11	Systemic lupus erythematosus;
CRC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.55	0.43	4.64e-16	Hip circumference adjusted for BMI;
CRC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg25344623	chr2:136566232	LCT	0.32	5.81	0.31	1.47e-8	Mosquito bite size;
CRC	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.4	6.04	0.32	4.11e-9	QT interval;
CRC	cis	rs4853036	0.903	rs13021969	chr2:70117602	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-6.72	-0.35	8.12e-11	Colorectal or endometrial cancer;
CRC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg12564285	chr5:131593104	PDLIM4	0.31	5.68	0.3	2.99e-8	Blood metabolite levels;
CRC	cis	rs7517126	1.000	rs34833349	chr1:196870299	A/G	cg13682187	chr1:196946512	CFHR5	-0.42	-6.09	-0.32	3.2e-9	Blood protein levels;
CRC	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	0.96	16.25	0.67	5.03e-44	Dupuytren's disease;
CRC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.55	-0.5	1.36e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.57	8.48	0.42	7.72e-16	Response to temozolomide;
CRC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg24531977	chr5:56204891	C5orf35	-0.45	-6.9	-0.36	2.64e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg20387954	chr3:183756860	HTR3D	0.46	7.96	0.4	2.89e-14	Anterior chamber depth;
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	trans	rs4955793	0.537	rs9875529	chr3:178651680	A/T	cg11644478	chr21:40555479	PSMG1	0.66	6.06	0.32	3.69e-9	Post-traumatic stress disorder (asjusted for relatedness);
CRC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.18	0.52	8.41e-25	Cognitive ability;
CRC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09695851	chr17:3907499	NA	0.65	11.29	0.53	3.23e-25	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.21	-0.41	5.04e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4594175	0.926	rs72688713	chr14:51598375	C/T	cg23942311	chr14:51606299	NA	0.66	10.56	0.5	1.26e-22	Cancer;
CRC	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.65	-9.91	-0.48	1.97e-20	Intelligence (multi-trait analysis);
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.4	5.61	0.3	4.29e-8	Longevity;
CRC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg00074818	chr8:8560427	CLDN23	0.36	6.52	0.34	2.68e-10	Obesity-related traits;
CRC	cis	rs501120	0.713	rs676966	chr10:44739594	A/G	cg09554077	chr10:44749378	NA	-0.73	-8.33	-0.42	2.26e-15	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-8.86	-0.44	5.09e-17	Vitiligo;
CRC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.54	9.07	0.45	1.1e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.4	-0.75	2.34e-60	Myeloid white cell count;
CRC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg04545296	chr12:48745243	ZNF641	0.36	6.19	0.32	1.81e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7849270	1.000	rs34055941	chr9:131895076	T/C	cg13538475	chr9:131942899	NA	-0.31	-6.1	-0.32	2.97e-9	Blood metabolite ratios;
CRC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg04586622	chr2:25135609	ADCY3	-0.54	-10.01	-0.48	9.31e-21	Body mass index;
CRC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.53	0.43	5.49e-16	Arsenic metabolism;
CRC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.74	11.81	0.55	4.55e-27	Cognitive function;
CRC	cis	rs728616	0.867	rs2152548	chr10:81802667	G/A	cg05935833	chr10:81318306	SFTPA2	-0.64	-7.35	-0.38	1.56e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.36	-0.33	6.9e-10	Body mass index;
CRC	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg25237894	chr2:233734115	C2orf82	-0.41	-5.68	-0.3	2.98e-8	Schizophrenia;
CRC	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.03	-0.55	6.96e-28	Coffee consumption (cups per day);
CRC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.97	12.45	0.57	2.01e-29	Vitiligo;
CRC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg19622623	chr12:86230825	RASSF9	0.35	5.82	0.31	1.43e-8	Major depressive disorder;
CRC	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg26816564	chr1:7831052	VAMP3	0.6	6.36	0.33	6.59e-10	Inflammatory bowel disease;
CRC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	7.44	0.38	8.89e-13	Mean platelet volume;
CRC	cis	rs372883	0.901	rs8133749	chr21:30615935	C/T	cg24692254	chr21:30365293	RNF160	-0.37	-5.66	-0.3	3.3e-8	Pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01300405	chr19:19626978	NDUFA13;TSSK6	0.37	6.02	0.31	4.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	0.96	12.82	0.58	8.27e-31	Vitiligo;
CRC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg14541582	chr5:601475	NA	-0.35	-7.25	-0.37	3.02e-12	Obesity-related traits;
CRC	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg00042356	chr1:8021962	PARK7	0.68	8.15	0.41	7.65e-15	Inflammatory bowel disease;
CRC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10208940	0.920	rs7423646	chr2:68758180	A/G	cg12452813	chr2:68675892	NA	0.48	6.05	0.32	4.01e-9	Urate levels in lean individuals;
CRC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	cis	rs16975963	0.793	rs59616348	chr19:38447753	G/A	cg15135657	chr19:38346511	NA	-0.41	-5.62	-0.3	4.14e-8	Longevity;
CRC	trans	rs2055729	0.634	rs6601390	chr8:9740657	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.91	0.36	2.49e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg14003231	chr6:33640908	ITPR3	0.6	8.35	0.42	1.87e-15	Platelet count;
CRC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	7.87	0.4	5.12e-14	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs911119	0.913	rs3004145	chr20:23582876	C/G	cg16589663	chr20:23618590	CST3	-0.53	-7.57	-0.38	3.88e-13	Chronic kidney disease;
CRC	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.27	0.37	2.64e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1524976	0.738	rs62252647	chr3:65438217	C/T	cg16238336	chr3:65465873	MAGI1	-0.48	-6.36	-0.33	6.58e-10	PR interval;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12525736	chr1:228269915	ARF1	-0.4	-5.98	-0.31	5.93e-9	Myopia (pathological);
CRC	trans	rs12200782	0.649	rs9467744	chr6:26386711	T/C	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs4728302	0.703	rs3823572	chr7:133680601	G/A	cg10665199	chr7:133106180	EXOC4	0.4	6.25	0.33	1.27e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.47	7.57	0.38	3.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.76	13.24	0.59	2.19e-32	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-6.48	-0.34	3.36e-10	Eye color traits;
CRC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	9.1	0.45	9.12e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11184682	chr3:50365769	TUSC2	0.47	6.66	0.34	1.16e-10	Response to antipsychotic treatment;
CRC	cis	rs755249	0.567	rs3118014	chr1:39914090	G/A	cg18385671	chr1:39797026	MACF1	-0.4	-5.7	-0.3	2.71e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.51	-5.79	-0.3	1.6e-8	Coronary artery disease;
CRC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg22495460	chr2:25135724	ADCY3	-0.85	-16.47	-0.67	7.33e-45	Body mass index;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg18301423	chr5:131593218	PDLIM4	0.31	5.63	0.3	3.86e-8	Blood metabolite levels;
CRC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg18016565	chr1:150552671	MCL1	0.43	6.09	0.32	3.15e-9	Melanoma;
CRC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.82	-13.09	-0.59	8.02e-32	Blood trace element (Zn levels);
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12172441	chr6:28176163	NA	0.69	9.19	0.45	4.69e-18	Depression;
CRC	cis	rs7605827	0.893	rs4668929	chr2:15719044	C/A	cg19274914	chr2:15703543	NA	0.38	5.84	0.31	1.23e-8	Educational attainment (years of education);
CRC	cis	rs4903604	0.581	rs11159279	chr14:78036358	C/T	cg18872420	chr14:78023429	SPTLC2	0.35	6.03	0.32	4.38e-9	Gut microbiome composition (winter);
CRC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg26248373	chr2:1572462	NA	-0.66	-7.2	-0.37	4.09e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	7.49	0.38	6.54e-13	Initial pursuit acceleration;
CRC	cis	rs17767392	0.915	rs7147434	chr14:71811526	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.68	-0.35	1.02e-10	Mitral valve prolapse;
CRC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.33	0.59	1.07e-32	Menarche (age at onset);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg12575751	chr11:17297984	NUCB2	-0.41	-6.05	-0.32	4.04e-9	HDL cholesterol;
CRC	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg06581033	chr10:766294	NA	-0.52	-5.77	-0.3	1.84e-8	Uric acid levels;
CRC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg10760299	chr15:45669010	GATM	0.49	7.79	0.39	8.71e-14	Homoarginine levels;
CRC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg10802521	chr3:52805072	NEK4	0.45	6.2	0.32	1.7e-9	Schizophrenia;
CRC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.81	-0.48	4.25e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg08270630	chr22:50330655	NA	-0.4	-5.82	-0.31	1.39e-8	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07839030	chr22:50946641	LMF2;NCAPH2	0.4	6.01	0.31	4.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	10.22	0.49	1.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-6.88	-0.35	3.11e-11	Menarche (age at onset);
CRC	cis	rs12476592	0.602	rs7571325	chr2:63785914	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	11.6	0.54	2.63e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg16591659	chr17:78472290	NA	-0.43	-6.23	-0.32	1.42e-9	Fractional excretion of uric acid;
CRC	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.43	-6.9	-0.36	2.62e-11	Type 1 diabetes;
CRC	trans	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg15061682	chr13:102850387	FGF14	-0.31	-6.04	-0.32	4.21e-9	Menarche (age at onset);
CRC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.54	-8.65	-0.43	2.29e-16	Aortic root size;
CRC	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-7.99	-0.4	2.25e-14	Facial morphology (factor 19);
CRC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.85	-0.35	3.59e-11	Bladder cancer;
CRC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg11861562	chr11:117069780	TAGLN	0.33	7.31	0.37	2.06e-12	Blood protein levels;
CRC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.88	0.31	1.02e-8	Renal function-related traits (BUN);
CRC	cis	rs4728302	0.838	rs6954700	chr7:133588739	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.8	0.3	1.54e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.63	-8.86	-0.44	5.16e-17	Arsenic metabolism;
CRC	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg16358738	chr2:241808595	AGXT	-0.4	-6.99	-0.36	1.52e-11	Urinary metabolites;
CRC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.48	-0.38	7.03e-13	Educational attainment;
CRC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.79	0.63	2.66e-38	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16608617	chr2:202898681	FZD7	0.44	6.87	0.35	3.18e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg19025524	chr12:109796872	NA	-0.45	-6.05	-0.32	3.98e-9	Neuroticism;
CRC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg02175503	chr12:58329896	NA	0.59	8.38	0.42	1.56e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg05569086	chr8:143859399	LYNX1	0.38	6.74	0.35	7.09e-11	Urinary tract infection frequency;
CRC	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.63	-11.56	-0.54	3.75e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs9463078	0.617	rs9381365	chr6:45077975	G/A	cg25276700	chr6:44698697	NA	-0.24	-5.76	-0.3	1.97e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.35	-7.55	-0.38	4.22e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9287719	0.686	rs10174605	chr2:10725232	G/A	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	1.0	12.2	0.56	1.68e-28	Eosinophil percentage of granulocytes;
CRC	trans	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	3.08e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17832277	chr13:103249000	TPP2	-0.5	-5.96	-0.31	6.51e-9	Diisocyanate-induced asthma;
CRC	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg09659197	chr4:152720779	NA	0.52	11.39	0.53	1.43e-25	Intelligence (multi-trait analysis);
CRC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg02428538	chr16:24856791	SLC5A11	0.58	7.02	0.36	1.25e-11	Intelligence (multi-trait analysis);
CRC	cis	rs77861329	1.000	rs13319566	chr3:52095555	C/G	cg08692210	chr3:52188851	WDR51A	0.88	8.43	0.42	1.1e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs863345	0.604	rs1157525	chr1:158457253	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.07	-0.32	3.49e-9	Pneumococcal bacteremia;
CRC	cis	rs17767392	0.958	rs3784066	chr14:72007454	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.2	-0.37	4e-12	Mitral valve prolapse;
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.73	0.35	7.48e-11	Bipolar disorder;
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.38	0.33	6.1e-10	Depression;
CRC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.05	0.32	3.89e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg17298326	chr8:142245477	NA	-0.37	-5.65	-0.3	3.55e-8	Immature fraction of reticulocytes;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg12516270	chr8:143859308	LYNX1	-0.39	-6.44	-0.33	4.18e-10	Urinary tract infection frequency;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.55	-10.46	-0.5	2.72e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.53	-7.93	-0.4	3.45e-14	Systemic sclerosis;
CRC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.71	-10.34	-0.5	7.19e-22	Platelet distribution width;
CRC	cis	rs10986311	0.802	rs6478659	chr9:127128274	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.37	-5.64	-0.3	3.75e-8	Vitiligo;
CRC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-16.05	-0.66	3.11e-43	Prostate cancer;
CRC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.69	10.41	0.5	3.93e-22	Corneal astigmatism;
CRC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.51	9.11	0.45	8.09e-18	Sense of smell;
CRC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.77	-0.3	1.78e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.63	-9.05	-0.45	1.24e-17	Schizophrenia;
CRC	cis	rs3015497	0.646	rs2934698	chr14:51137883	G/C	cg26011998	chr14:51135199	SAV1	-0.46	-5.72	-0.3	2.39e-8	Mean platelet volume;
CRC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.78	-9.7	-0.47	9.76e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1881492	0.554	rs868746	chr2:233457831	A/G	cg03852847	chr2:233439513	NA	-0.42	-6.77	-0.35	5.92e-11	Refractive error;
CRC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.64	-11.6	-0.54	2.63e-26	Educational attainment;
CRC	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg02466173	chr16:30829666	NA	-0.59	-8.87	-0.44	4.73e-17	Dementia with Lewy bodies;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.69	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	5.66	0.3	3.33e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.44	-6.71	-0.35	8.31e-11	Monocyte count;
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00166722	chr3:10149974	C3orf24	0.65	8.86	0.44	5.13e-17	Alzheimer's disease;
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	19.33	0.73	3.76e-56	Prudent dietary pattern;
CRC	cis	rs4700695	0.841	rs957526	chr5:65345830	A/G	cg21114390	chr5:65439923	SFRS12	0.51	6.37	0.33	6.27e-10	Facial morphology (factor 19);
CRC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.87	0.31	1.07e-8	Lung cancer;
CRC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.72	10.57	0.5	1.16e-22	Immature fraction of reticulocytes;
CRC	cis	rs7932354	0.583	rs10769211	chr11:46872873	G/A	cg19486271	chr11:47235900	DDB2	-0.42	-6.34	-0.33	7.49e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.57	7.07	0.36	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4400599	0.600	rs12095767	chr1:154188028	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.65	-0.3	3.39e-8	Platelet distribution width;
CRC	trans	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg10756647	chr7:56101905	PSPH	0.69	7.49	0.38	6.21e-13	Diabetic kidney disease;
CRC	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg00373020	chr1:21041521	KIF17	0.4	6.18	0.32	1.87e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.68	0.54	1.28e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	24.41	0.8	7.86e-76	Schizophrenia;
CRC	cis	rs4363385	0.720	rs1611764	chr1:152957887	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.25	-0.37	3.01e-12	Inflammatory skin disease;
CRC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.39	6.7	0.35	9.05e-11	Total body bone mineral density;
CRC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.58	-8.09	-0.41	1.2e-14	Longevity;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.56	-10.27	-0.49	1.21e-21	Developmental language disorder (linguistic errors);
CRC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.67	-0.3	3.15e-8	Schizophrenia;
CRC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.75	-12.98	-0.58	2.18e-31	Body mass index;
CRC	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.94e-40	Colorectal cancer;
CRC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg20607287	chr7:12443886	VWDE	-0.66	-5.81	-0.3	1.51e-8	Coronary artery disease;
CRC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg11189052	chr15:85197271	WDR73	0.59	8.57	0.43	4.2e-16	Schizophrenia;
CRC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.56	-0.5	1.21e-22	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27141267	chr11:66175971	NA	0.48	6.22	0.32	1.53e-9	Thyroid stimulating hormone;
CRC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.67	9.54	0.47	3.43e-19	Lung cancer;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.32	0.69	3.11e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.43	6.97	0.36	1.75e-11	Dupuytren's disease;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10766172	chr7:27498479	NA	0.48	6.74	0.35	7.2e-11	Survival in pancreatic cancer;
CRC	cis	rs9478217	1	rs9478217	chr6:151874122	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.38	-5.9	-0.31	9.14e-9	Total body bone mineral density (age 30-45);
CRC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg17401720	chr7:158221031	PTPRN2	-0.44	-7.38	-0.38	1.28e-12	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.86	-0.31	1.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.07	-0.41	1.38e-14	Total body bone mineral density;
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.86	-19.42	-0.73	1.58e-56	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg16099169	chr2:106886729	NA	-0.39	-6.65	-0.34	1.26e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.63	-0.43	2.69e-16	Bipolar disorder;
CRC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02290350	chr8:58132656	NA	-0.56	-6.4	-0.33	5.27e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.67	9.71	0.47	8.93e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.51	7.66	0.39	2.14e-13	Corneal astigmatism;
CRC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.27	-5.61	-0.3	4.39e-8	Alcohol dependence;
CRC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12463550	chr7:65579703	CRCP	0.69	6.23	0.32	1.4e-9	Diabetic kidney disease;
CRC	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04004882	chr2:215674386	BARD1	0.65	9.04	0.45	1.38e-17	Neuroblastoma;
CRC	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.83	0.4	6.77e-14	Corneal astigmatism;
CRC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.54	-6.14	-0.32	2.32e-9	Vitiligo;
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.93	-0.31	7.53e-9	Menopause (age at onset);
CRC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg20243544	chr17:37824526	PNMT	-0.41	-6.5	-0.34	2.96e-10	Self-reported allergy;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07936430	chr16:30538244	ZNF768	0.39	6.06	0.32	3.62e-9	Obesity-related traits;
CRC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg27535305	chr1:53392650	SCP2	-0.4	-7.17	-0.37	4.94e-12	Monocyte count;
CRC	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.53	-7.44	-0.38	8.9e-13	Longevity;
CRC	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.35	5.71	0.3	2.59e-8	Menarche (age at onset);
CRC	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg03929089	chr4:120376271	NA	0.7	6.87	0.35	3.18e-11	Intraocular pressure;
CRC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg07636037	chr3:49044803	WDR6	-0.68	-6.55	-0.34	2.25e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	7.6	0.39	3.19e-13	Multiple sclerosis;
CRC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.34	-0.33	7.51e-10	Reticulocyte fraction of red cells;
CRC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg23123621	chr4:1343375	KIAA1530	0.36	5.68	0.3	3e-8	Obesity-related traits;
CRC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.57	7.9	0.4	4.36e-14	Alcohol dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11861730	chr11:128392683	ETS1	0.41	6.04	0.32	4.08e-9	Response to antipsychotic treatment;
CRC	cis	rs1562242	0.653	rs2441112	chr5:57601615	T/C	cg09002358	chr5:57541568	NA	0.84	7.78	0.39	9.62e-14	Educational attainment (years of education);
CRC	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.31	-0.33	9.11e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg21918786	chr6:109611834	NA	-0.35	-5.92	-0.31	8.13e-9	Reticulocyte fraction of red cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14791747	chr16:20752902	THUMPD1	0.41	6.33	0.33	8.01e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	0.92	13.23	0.59	2.47e-32	Breast cancer;
CRC	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.73	9.38	0.46	1.11e-18	Coronary artery disease;
CRC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	1.0	12.85	0.58	6.4e-31	Vitiligo;
CRC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	11.84	0.55	3.48e-27	Schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg26599104	chr19:40932063	SERTAD1	0.39	5.99	0.31	5.46e-9	Schizophrenia;
CRC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.14	0.37	5.91e-12	Life satisfaction;
CRC	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg10820045	chr2:198174542	NA	0.37	6.18	0.32	1.87e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg01788221	chr16:89496183	ANKRD11	-0.42	-6.22	-0.32	1.54e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-7.42	-0.38	1.04e-12	Dilated cardiomyopathy;
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.13e-22	Prudent dietary pattern;
CRC	cis	rs66569888	0.633	rs11680226	chr2:106745044	A/G	cg16099169	chr2:106886729	NA	0.4	5.89	0.31	9.49e-9	Facial morphology (factor 23);
CRC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg12193833	chr17:30244370	NA	-0.74	-8.72	-0.43	1.45e-16	Hip circumference adjusted for BMI;
CRC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg23018236	chr17:30244563	NA	-0.6	-8.06	-0.41	1.38e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.46	6.62	0.34	1.49e-10	Emphysema distribution in smoking;
CRC	cis	rs6973256	0.901	rs2991231	chr7:133321915	T/C	cg10665199	chr7:133106180	EXOC4	-0.38	-5.97	-0.31	5.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6429082	0.509	rs2803846	chr1:235521054	C/G	cg26050004	chr1:235667680	B3GALNT2	0.44	6.35	0.33	7.06e-10	Adiposity;
CRC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.44	6.49	0.34	3.17e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg06392426	chr19:10676186	KRI1	-0.56	-6.81	-0.35	4.75e-11	Red cell distribution width;
CRC	trans	rs2303319	0.504	rs55840249	chr2:162426849	C/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.12	-0.32	2.63e-9	Cognitive function;
CRC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06544989	chr22:39130855	UNC84B	0.44	6.85	0.35	3.71e-11	Menopause (age at onset);
CRC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.77	-9.77	-0.47	5.98e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.69	10.17	0.49	2.66e-21	Corneal astigmatism;
CRC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	ch.11.42038R	chr11:967971	AP2A2	-0.6	-10.2	-0.49	2.03e-21	Alzheimer's disease (late onset);
CRC	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	1.23	10.39	0.5	4.73e-22	Arsenic metabolism;
CRC	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg04662943	chr10:102668895	NA	0.61	7.13	0.37	6.44e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.38	-0.38	1.34e-12	Total body bone mineral density;
CRC	trans	rs800082	0.539	rs1178897	chr3:144241161	A/C	cg24215973	chr2:240111563	HDAC4	-0.43	-6.02	-0.31	4.79e-9	Smoking behavior;
CRC	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-6.64	-0.34	1.26e-10	Breast cancer;
CRC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg02569458	chr12:86230093	RASSF9	0.4	6.8	0.35	4.93e-11	Major depressive disorder;
CRC	cis	rs2274273	0.624	rs67412516	chr14:55853237	A/T	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.78	-0.3	1.71e-8	Protein biomarker;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg02683197	chr6:28174875	NA	0.7	9.78	0.47	5.24e-20	Parkinson's disease;
CRC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.53	-8.83	-0.44	6.38e-17	Type 2 diabetes;
CRC	cis	rs6662572	0.703	rs7556472	chr1:46339811	G/A	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs2857891	0.695	rs2857895	chr11:6982992	C/G	cg04053776	chr11:6947353	ZNF215	-0.39	-6.08	-0.32	3.41e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.32	-5.95	-0.31	7.02e-9	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.53	9.62	0.47	1.75e-19	Common traits (Other);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12232852	chr3:69129018	UBA3	0.53	7.71	0.39	1.46e-13	Response to antipsychotic treatment;
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.76	-0.51	2.49e-23	Alzheimer's disease;
CRC	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.18	-0.56	2.05e-28	Monocyte count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21605452	chr3:176915282	TBL1XR1	0.47	6.04	0.32	4.26e-9	Thyroid stimulating hormone;
CRC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.49	6.54	0.34	2.38e-10	Total body bone mineral density;
CRC	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.45	7.04	0.36	1.16e-11	Red blood cell count;
CRC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.48	-8.41	-0.42	1.28e-15	Primary biliary cholangitis;
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.92	-0.36	2.39e-11	Bipolar disorder;
CRC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-6.0	-0.31	5.32e-9	Schizophrenia;
CRC	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.42e-11	Body mass index;
CRC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26240231	chr7:1148101	C7orf50	-0.46	-6.69	-0.35	9.41e-11	Bronchopulmonary dysplasia;
CRC	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.48	9.03	0.45	1.5e-17	Educational attainment (years of education);
CRC	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg23100626	chr2:96804247	ASTL	-0.29	-7.81	-0.4	7.66e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.59	0.63	1.55e-37	Colorectal cancer;
CRC	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg05585544	chr11:47624801	NA	0.4	6.15	0.32	2.24e-9	Mean corpuscular hemoglobin;
CRC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.29	0.33	1.02e-9	Height;
CRC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.68	12.0	0.55	9.22e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.17	-0.32	1.96e-9	Aortic root size;
CRC	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg20628663	chr10:43360327	NA	0.58	6.76	0.35	6.33e-11	Pediatric bone mineral content (radius);
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.59	-10.92	-0.52	6.94e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.65e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg15786705	chr6:28176104	NA	0.81	11.69	0.54	1.25e-26	Depression;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-6.98	-0.36	1.63e-11	Longevity;Endometriosis;
CRC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.11e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05314606	chr18:46478925	NA	0.42	6.06	0.32	3.74e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg04518342	chr5:131593106	PDLIM4	0.43	6.96	0.36	1.82e-11	Breast cancer;
CRC	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg09659197	chr4:152720779	NA	-0.51	-10.96	-0.52	4.74e-24	Intelligence (multi-trait analysis);
CRC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg05203877	chr14:70655686	SLC8A3	-0.34	-6.64	-0.34	1.28e-10	Prostate cancer;
CRC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.64	-0.43	2.42e-16	Hemoglobin concentration;
CRC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.56	7.39	0.38	1.25e-12	Height;
CRC	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.38	0.46	1.13e-18	Common traits (Other);
CRC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg23262073	chr20:60523788	NA	-0.46	-7.53	-0.38	4.84e-13	Body mass index;
CRC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.32	-0.33	8.27e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.91	-16.47	-0.67	7.02e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg04837898	chr3:45731254	SACM1L	0.35	5.81	0.31	1.45e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03670816	chr5:53606426	ARL15	0.35	6.25	0.33	1.29e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg10876282	chr6:28092338	ZSCAN16	0.53	6.74	0.35	7.23e-11	Parkinson's disease;
CRC	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.47	6.39	0.33	5.61e-10	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.32	-0.33	8.44e-10	Aortic root size;
CRC	cis	rs391936	0.872	rs2059875	chr2:8448194	A/G	cg12167548	chr2:8464763	NA	0.31	5.62	0.3	4.04e-8	Selective IgA deficiency;
CRC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg24505167	chr7:1915268	MAD1L1	-0.47	-6.44	-0.33	4.35e-10	Bipolar disorder;
CRC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg09264619	chr17:80180166	NA	-0.34	-5.61	-0.3	4.4e-8	Life satisfaction;
CRC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.4	-8.55	-0.43	4.85e-16	Glomerular filtration rate (creatinine);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg01561839	chr1:224521239	NA	-0.39	-6.35	-0.33	7.17e-10	Aortic root size;
CRC	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.69	-8.02	-0.4	1.87e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12172441	chr6:28176163	NA	-0.7	-9.5	-0.46	4.46e-19	Depression;
CRC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.29	-0.33	1e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.76	11.55	0.54	4.05e-26	Menarche (age at onset);
CRC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg00186954	chr11:8933980	ST5;C11orf17	0.47	7.38	0.38	1.33e-12	Hemoglobin concentration;
CRC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.15	0.41	7.88e-15	Menopause (age at onset);
CRC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.23	-0.41	4.53e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg19812747	chr11:111475976	SIK2	0.49	7.28	0.37	2.51e-12	Primary sclerosing cholangitis;
CRC	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.9	-17.9	-0.7	1.65e-50	Bone mineral density;
CRC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.48	7.84	0.4	6.19e-14	Cystic fibrosis severity;
CRC	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-0.58	-6.87	-0.35	3.31e-11	Post bronchodilator FEV1;
CRC	cis	rs9549328	0.700	rs3011473	chr13:113618096	A/G	cg20742385	chr13:113633654	MCF2L	0.57	9.58	0.47	2.44e-19	Systolic blood pressure;
CRC	cis	rs6662572	0.671	rs10749861	chr1:46440252	A/C	cg08644498	chr1:46502608	NA	-0.46	-7.3	-0.37	2.16e-12	Blood protein levels;
CRC	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.51	-8.9	-0.44	3.95e-17	Waist-hip ratio;
CRC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1030268	0.546	rs12707100	chr7:133274376	T/C	cg10665199	chr7:133106180	EXOC4	0.65	7.8	0.39	8.38e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.15	0.45	6.1e-18	Bladder cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07760851	chr11:695000	TMEM80;DEAF1	0.45	6.55	0.34	2.28e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.53	9.31	0.46	1.89e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5747327	0.835	rs181396	chr22:18224155	A/G	cg19898043	chr22:18121309	BCL2L13	0.37	5.65	0.3	3.45e-8	Myeloid white cell count;Granulocyte count;
CRC	cis	rs6700896	0.931	rs10789192	chr1:66125770	G/A	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	12.44	0.57	2.21e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs4664293	0.867	rs2081723	chr2:160594160	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg24289452	chr6:170231220	NA	-0.7	-7.24	-0.37	3.23e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.41	-6.34	-0.33	7.46e-10	Refractive error;
CRC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg18479299	chr3:125709523	NA	-0.55	-6.58	-0.34	1.86e-10	Blood pressure (smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01080592	chr19:36248739	HSPB6;C19orf55	0.52	7.15	0.37	5.56e-12	Response to antipsychotic treatment;
CRC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.38	7.23	0.37	3.35e-12	Tonsillectomy;
CRC	cis	rs5753037	0.676	rs737945	chr22:30202774	G/C	cg01021169	chr22:30184971	ASCC2	-0.4	-6.28	-0.33	1.05e-9	Type 1 diabetes;
CRC	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg05250797	chr16:70222502	NA	0.41	5.69	0.3	2.78e-8	IgE levels;
CRC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.22e-11	Morning vs. evening chronotype;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-6.11	-0.32	2.87e-9	Obesity-related traits;
CRC	trans	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg17903999	chr18:56338584	MALT1	-0.39	-6.49	-0.34	3.08e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4363385	0.782	rs4845515	chr1:153003871	G/T	cg25856811	chr1:152973957	SPRR3	-0.24	-6.69	-0.35	9.55e-11	Inflammatory skin disease;
CRC	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg20628663	chr10:43360327	NA	0.73	7.8	0.4	8.07e-14	Blood protein levels;
CRC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg01262667	chr19:19385393	TM6SF2	0.38	6.24	0.33	1.36e-9	Tonsillectomy;
CRC	cis	rs970548	0.955	rs11239551	chr10:46026107	G/A	cg15590007	chr10:45870220	ALOX5	0.51	6.5	0.34	3.01e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.54	7.0	0.36	1.48e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg17948913	chr5:572064	NA	0.49	5.61	0.3	4.41e-8	Obesity-related traits;
CRC	cis	rs4716602	0.572	rs10271030	chr7:156159796	T/C	cg16983916	chr7:156159713	NA	-0.39	-6.73	-0.35	7.53e-11	Anti-saccade response;
CRC	trans	rs7757969	0.500	rs9487733	chr6:112158215	A/G	cg08211895	chr2:48828358	STON1-GTF2A1L	0.31	6.07	0.32	3.57e-9	Schizophrenia;
CRC	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14119001	chr9:139324193	INPP5E	-0.39	-6.22	-0.32	1.53e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23350889	chr12:133100618	FBRSL1	0.43	6.51	0.34	2.87e-10	Intelligence (multi-trait analysis);
CRC	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.42	-5.64	-0.3	3.68e-8	Coronary artery disease;
CRC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	7.78	0.39	9.67e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs12760731	0.641	rs12727289	chr1:178327027	T/C	cg00404053	chr1:178313656	RASAL2	0.85	10.33	0.49	7.65e-22	Obesity-related traits;
CRC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.36	-8.53	-0.43	5.44e-16	Mean corpuscular volume;
CRC	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.91	-13.22	-0.59	2.63e-32	Dupuytren's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14669749	chr1:2246478	NA	0.42	6.18	0.32	1.89e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12353516	chr17:19281309	MAPK7	0.44	6.39	0.33	5.81e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.64	-8.76	-0.43	1.03e-16	Coronary artery disease;
CRC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.79	9.99	0.48	1.06e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.79	0.35	5.35e-11	Coronary artery disease;
CRC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.45	-8.25	-0.41	3.94e-15	Reticulocyte fraction of red cells;
CRC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.82	0.31	1.43e-8	Morning vs. evening chronotype;
CRC	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.61	8.99	0.44	1.99e-17	Schizophrenia;
CRC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	0.98	15.34	0.65	1.88e-40	Cognitive function;
CRC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.58	0.43	3.88e-16	Lymphocyte counts;
CRC	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	27.61	0.84	1.1e-87	Testicular germ cell tumor;
CRC	cis	rs4728302	0.869	rs13231079	chr7:133604373	C/G	cg03336402	chr7:133662267	EXOC4	-0.45	-6.52	-0.34	2.58e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs16975963	0.843	rs73025630	chr19:38351284	G/A	cg15135657	chr19:38346511	NA	-0.43	-5.76	-0.3	1.89e-8	Longevity;
CRC	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg13385794	chr1:248469461	NA	0.41	7.06	0.36	9.96e-12	Common traits (Other);
CRC	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg16892393	chr17:41919603	NA	-0.54	-5.92	-0.31	8.28e-9	Cognitive function;
CRC	cis	rs59104589	0.583	rs28386824	chr2:242349893	A/G	cg19488206	chr2:242435732	STK25	0.44	6.47	0.34	3.6e-10	Fibrinogen levels;
CRC	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.52	-0.34	2.71e-10	Retinal vascular caliber;
CRC	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.09	-0.52	1.75e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs737337	0.623	rs12463177	chr19:11341680	G/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.82	9.12	0.45	7.86e-18	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.86	12.94	0.58	3.02e-31	Cognitive function;
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg08632701	chr21:37451849	NA	-0.44	-6.89	-0.36	2.78e-11	Mitral valve prolapse;
CRC	cis	rs6961069	0.749	rs1537477	chr7:80251202	A/C	cg04458919	chr7:80252533	CD36	0.36	6.46	0.34	3.86e-10	Platelet count;
CRC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg03804128	chr16:635623	NA	0.3	6.82	0.35	4.31e-11	Height;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.57	8.61	0.43	3.05e-16	Longevity;Endometriosis;
CRC	cis	rs8099014	0.559	rs9319928	chr18:56099996	T/G	cg19312305	chr18:56117016	MIR122	-0.43	-5.95	-0.31	7e-9	Platelet count;
CRC	cis	rs7625357	0.964	rs7652404	chr3:169352458	A/G	cg04414509	chr3:169351419	MECOM	0.6	8.44	0.42	1e-15	Childhood and early adolescence aggressive behavior;
CRC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.39	-5.63	-0.3	3.79e-8	Neurofibrillary tangles;
CRC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg27068330	chr11:65405492	SIPA1	-0.48	-6.08	-0.32	3.24e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04799218	chr12:7125780	LPCAT3	0.52	7.23	0.37	3.36e-12	Anxiety disorder;
CRC	cis	rs17092148	0.652	rs76324086	chr20:33079392	T/G	cg08999081	chr20:33150536	PIGU	-0.46	-5.71	-0.3	2.5e-8	Neuroticism;
CRC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.01	0.44	1.77e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs77633900	0.772	rs2957611	chr15:76704878	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-5.62	-0.3	4.15e-8	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6142102	0.961	rs2300204	chr20:32588773	G/A	cg08999081	chr20:33150536	PIGU	0.37	5.64	0.3	3.69e-8	Skin pigmentation;
CRC	cis	rs12024301	0.557	rs78324977	chr1:183598882	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.95	0.36	1.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.65	9.75	0.47	6.97e-20	Longevity;
CRC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	1.01	17.62	0.7	2.11e-49	Parkinson's disease;
CRC	trans	rs783540	0.967	rs1864699	chr15:83323318	A/G	cg18393722	chr15:85113863	UBE2QP1	0.37	6.1	0.32	2.98e-9	Schizophrenia;
CRC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.28	0.73	5.63e-56	Prudent dietary pattern;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21611145	chr19:13261629	IER2;STX10	0.39	6.02	0.31	4.72e-9	Myopia (pathological);
CRC	cis	rs3789045	0.729	rs16853822	chr1:204450341	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.61	-8.47	-0.42	8.41e-16	Educational attainment (college completion);
CRC	cis	rs6604026	0.922	rs1854797	chr1:93298756	T/C	cg17283838	chr1:93427260	FAM69A	0.45	5.77	0.3	1.83e-8	Multiple sclerosis;
CRC	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.49	-8.81	-0.44	7.1e-17	Migraine;
CRC	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.52	6.65	0.34	1.21e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27486582	chr12:120884061	TRIAP1;GATC	0.48	6.9	0.36	2.66e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.2	-0.32	1.67e-9	Alzheimer's disease (late onset);
CRC	cis	rs73206853	0.620	rs111354540	chr12:111150302	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.34	3.66e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.7	7.85	0.4	6.01e-14	Vitiligo;
CRC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.56	0.38	4.03e-13	Obesity-related traits;
CRC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.83	-14.65	-0.63	9.06e-38	Coronary artery disease;
CRC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.49	-0.54	6.32e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.77	14.5	0.62	3.51e-37	Prudent dietary pattern;
CRC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.21	-0.32	1.56e-9	Aortic root size;
CRC	cis	rs1223397	0.651	rs2458314	chr6:13309224	C/T	cg06879394	chr6:13274151	PHACTR1	0.37	5.63	0.3	3.84e-8	Blood pressure;
CRC	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-10.02	-0.48	8.67e-21	Coffee consumption (cups per day);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02076414	chr1:47779921	STIL	0.42	6.3	0.33	9.77e-10	Response to antipsychotic treatment;
CRC	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.71	9.27	0.46	2.47e-18	Blood protein levels;
CRC	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg06606381	chr12:133084897	FBRSL1	-1.1	-7.57	-0.39	3.74e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.09	18.53	0.71	5.18e-53	Cognitive function;
CRC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11547950	chr5:77652471	NA	-0.49	-7.1	-0.36	7.7e-12	Triglycerides;
CRC	cis	rs12431939	1.000	rs56220306	chr14:51648738	A/T	cg23942311	chr14:51606299	NA	-0.53	-6.11	-0.32	2.75e-9	Cancer;
CRC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg06462663	chr19:18546047	ISYNA1	0.48	7.26	0.37	2.73e-12	Breast cancer;
CRC	cis	rs910187	0.572	rs6018325	chr20:45810335	A/G	cg27589058	chr20:45804311	EYA2	-0.4	-7.69	-0.39	1.67e-13	Migraine;
CRC	cis	rs7680126	0.633	rs2024280	chr4:10291813	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-6.45	-0.34	3.98e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.46	6.31	0.33	9.1e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg05824432	chr16:2301222	DCI	-0.42	-6.08	-0.32	3.28e-9	Daytime sleep phenotypes;
CRC	cis	rs600806	0.893	rs370088	chr1:109858119	T/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.8	-0.3	1.59e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.85	14.75	0.63	3.95e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9659323	0.539	rs1750331	chr1:119494973	A/G	cg05756136	chr1:119680316	WARS2	-0.39	-5.63	-0.3	3.89e-8	Body mass index;
CRC	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11446398	chr5:77624930	NA	-0.45	-6.22	-0.32	1.49e-9	Triglycerides;
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg04518342	chr5:131593106	PDLIM4	0.43	7.82	0.4	7.22e-14	Breast cancer;
CRC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-12.7	-0.57	2.36e-30	Vitiligo;
CRC	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-5.83	-0.31	1.36e-8	Height;
CRC	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.46	7.55	0.38	4.46e-13	Schizophrenia;
CRC	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg09455208	chr3:40491958	NA	0.31	6.31	0.33	8.76e-10	Renal cell carcinoma;
CRC	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg04586622	chr2:25135609	ADCY3	-0.35	-6.02	-0.31	4.74e-9	Body mass index in non-asthmatics;
CRC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg00383909	chr3:49044727	WDR6	0.43	5.65	0.3	3.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.38	-0.33	6.02e-10	Personality dimensions;
CRC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.4	-5.71	-0.3	2.5e-8	Diastolic blood pressure;
CRC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.83	-14.3	-0.62	1.99e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.17	-0.56	2.2e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.27	-0.33	1.13e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.89	0.51	8.75e-24	Prudent dietary pattern;
CRC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg17633681	chr16:88106987	BANP	0.87	15.42	0.65	9.15e-41	Menopause (age at onset);
CRC	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.62	10.15	0.49	3.12e-21	Sum eosinophil basophil counts;Eosinophil counts;
CRC	trans	rs4869931	0.929	rs9480530	chr6:151006962	A/T	cg01367992	chr1:160766535	LY9	0.37	5.99	0.31	5.6e-9	Systolic blood pressure in sickle cell anemia;
CRC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.72	11.05	0.52	2.45e-24	Corneal astigmatism;
CRC	cis	rs12431939	0.598	rs7144511	chr14:51740243	A/G	cg23942311	chr14:51606299	NA	0.47	6.41	0.33	5.11e-10	Cancer;
CRC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Melanoma;
CRC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg25811766	chr13:21894605	NA	0.57	6.77	0.35	5.88e-11	White matter hyperintensity burden;
CRC	cis	rs6804368	0.553	rs9829308	chr3:30763073	A/C	cg06106510	chr3:30762233	NA	0.39	6.29	0.33	1.02e-9	Blood metabolite levels;
CRC	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.55	-7.73	-0.39	1.3e-13	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	13.79	0.61	1.92e-34	Schizophrenia;
CRC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg23229984	chr5:148520753	ABLIM3	0.53	7.12	0.37	6.7e-12	Breast cancer;
CRC	cis	rs5167	0.504	rs7259679	chr19:45457306	C/T	cg13119609	chr19:45449297	APOC2	0.31	5.85	0.31	1.19e-8	Blood protein levels;
CRC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.92	0.31	8.24e-9	Diabetic retinopathy;
CRC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg23127183	chr11:57508653	C11orf31	-0.53	-7.16	-0.37	5.32e-12	Schizophrenia;
CRC	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.48	-6.21	-0.32	1.6e-9	Neuroticism;
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	trans	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg16606324	chr3:10149918	C3orf24	0.69	8.17	0.41	6.69e-15	Alzheimer's disease;
CRC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg22110888	chr17:80059540	CCDC57	0.41	6.47	0.34	3.51e-10	Life satisfaction;
CRC	cis	rs13315871	1.000	rs4367085	chr3:58389235	A/G	cg20936604	chr3:58311152	NA	-0.71	-6.59	-0.34	1.75e-10	Cholesterol, total;
CRC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24308560	chr3:49941425	MST1R	0.5	8.23	0.41	4.39e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg19875578	chr6:126661172	C6orf173	0.43	5.99	0.31	5.61e-9	Male-pattern baldness;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg14092988	chr3:52407081	DNAH1	0.29	5.61	0.3	4.29e-8	Bipolar disorder;
CRC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-9.53	-0.47	3.53e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg21238619	chr17:78079768	GAA	-0.34	-5.62	-0.3	4.08e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.27	-0.62	2.67e-36	Colorectal cancer;
CRC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.76	10.11	0.49	4.18e-21	Coronary artery disease;
CRC	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg03315344	chr16:75512273	CHST6	0.5	5.9	0.31	8.85e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.6	0.43	3.33e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.62	10.03	0.48	7.92e-21	Breast cancer;
CRC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.82	11.69	0.54	1.24e-26	Cognitive function;
CRC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg05754148	chr16:3507555	NAT15	-0.7	-6.85	-0.35	3.65e-11	Tuberculosis;
CRC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.73e-20	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs79464052	0.826	rs76686252	chr5:141012013	G/A	cg05255351	chr5:1503979	LPCAT1	-0.56	-6.87	-0.35	3.22e-11	Diffuse large B cell lymphoma;
CRC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	5.91	0.31	8.32e-9	Obesity-related traits;
CRC	trans	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.69	-9.82	-0.48	3.89e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2380220	0.872	rs66723559	chr6:95956338	T/C	cg04719120	chr6:96025338	MANEA	-0.55	-6.04	-0.32	4.15e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.52	7.3	0.37	2.16e-12	Intelligence (multi-trait analysis);
CRC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.93	-17.29	-0.69	4.36e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.83	8.24	0.41	4.04e-15	Diabetic retinopathy;
CRC	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg06223162	chr1:101003688	GPR88	-0.34	-6.02	-0.31	4.73e-9	Monocyte count;
CRC	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.78	-10.96	-0.52	5.02e-24	Blood protein levels;
CRC	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.76	9.77	0.47	5.98e-20	Prostate cancer;
CRC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg18479299	chr3:125709523	NA	-0.56	-6.73	-0.35	7.71e-11	Blood pressure (smoking interaction);
CRC	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg16576597	chr16:28551801	NUPR1	-0.45	-6.39	-0.33	5.59e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg02741985	chr17:80059408	CCDC57	0.44	7.28	0.37	2.55e-12	Life satisfaction;
CRC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.38	-7.69	-0.39	1.72e-13	Arsenic metabolism;
CRC	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.69	9.6	0.47	2.06e-19	Vitiligo;
CRC	trans	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg24644049	chr4:85504048	CDS1	0.83	6.97	0.36	1.69e-11	Skin colour saturation;
CRC	cis	rs9522267	0.511	rs4773397	chr13:112245044	T/C	cg26182253	chr13:112236782	NA	0.3	5.95	0.31	6.91e-9	Hepatitis;
CRC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.38	0.38	1.32e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg02527881	chr3:46936655	PTH1R	0.36	6.28	0.33	1.05e-9	Colorectal cancer;
CRC	cis	rs17818399	0.749	rs35625984	chr2:46805908	A/G	cg21681030	chr2:46777652	RHOQ	0.44	6.18	0.32	1.93e-9	Height;
CRC	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.75	0.43	1.13e-16	Coffee consumption (cups per day);
CRC	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg06632207	chr12:54070931	ATP5G2	0.41	7.09	0.36	8.46e-12	Height;
CRC	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.54	9.36	0.46	1.28e-18	Common traits (Other);
CRC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg26805224	chr10:79626177	DLG5	-0.51	-7.46	-0.38	7.85e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg14541582	chr5:601475	NA	-0.37	-6.71	-0.35	8.52e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.5	6.42	0.33	4.77e-10	Alzheimer's disease (survival time);
CRC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.36	-7.5	-0.38	6.17e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg15654264	chr1:150340011	RPRD2	0.37	5.81	0.31	1.46e-8	Migraine;
CRC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.25	0.41	3.86e-15	Height;
CRC	cis	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg05299278	chr17:33885742	SLFN14	0.4	6.09	0.32	3.16e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg22535103	chr8:58192502	C8orf71	-0.52	-6.34	-0.33	7.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs12900463	0.813	rs186266	chr15:85402795	A/G	cg11189052	chr15:85197271	WDR73	0.46	6.35	0.33	7.23e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.38	-6.13	-0.32	2.49e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9549328	0.643	rs4907567	chr13:113617533	C/T	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.7e-13	Systolic blood pressure;
CRC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.73	-0.3	2.3e-8	Schizophrenia;
CRC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg20203395	chr5:56204925	C5orf35	0.57	7.89	0.4	4.39e-14	Initial pursuit acceleration;
CRC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg20203395	chr5:56204925	C5orf35	-0.47	-6.44	-0.33	4.15e-10	Coronary artery disease;
CRC	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.63	-0.34	1.36e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.6	9.75	0.47	6.86e-20	Itch intensity from mosquito bite;
CRC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.35	0.38	1.57e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7692995	1.000	rs6828122	chr4:18006052	A/G	cg08925142	chr4:18023851	LCORL	-0.55	-6.06	-0.32	3.73e-9	Height;
CRC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg04155289	chr7:94953770	PON1	-0.62	-7.74	-0.39	1.23e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.44	5.89	0.31	9.7e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg05941027	chr17:61774174	LIMD2	0.36	6.41	0.33	4.96e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06505273	chr16:24850292	NA	-0.47	-5.87	-0.31	1.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-7.33	-0.37	1.84e-12	Blood protein levels;
CRC	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.52	0.34	2.71e-10	Blood protein levels;
CRC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.66	7.78	0.39	9.4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.56	8.3	0.42	2.7e-15	Menopause (age at onset);
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg10876282	chr6:28092338	ZSCAN16	0.4	5.7	0.3	2.67e-8	Cardiac Troponin-T levels;
CRC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.43	1.09e-16	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13794888	chr15:75917792	SNUPN	0.49	6.45	0.34	4.09e-10	Thyroid stimulating hormone;
CRC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.16	-0.49	2.82e-21	Height;
CRC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	0.53	8.84	0.44	5.87e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.64	8.05	0.41	1.53e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-6.3	-0.33	9.65e-10	Vitiligo;
CRC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg18876405	chr7:65276391	NA	-0.46	-6.34	-0.33	7.38e-10	Aortic root size;
CRC	trans	rs800082	0.505	rs920148	chr3:144246677	A/C	cg24215973	chr2:240111563	HDAC4	0.46	6.51	0.34	2.87e-10	Smoking behavior;
CRC	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg20194872	chr6:41519635	FOXP4	0.4	5.86	0.31	1.14e-8	Prostate cancer;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg09877947	chr5:131593287	PDLIM4	0.55	9.42	0.46	8.11e-19	Acylcarnitine levels;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg11843238	chr5:131593191	PDLIM4	0.49	9.29	0.46	2.11e-18	Acylcarnitine levels;
CRC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.52	-7.65	-0.39	2.22e-13	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs12505749	0.660	rs7690100	chr4:57344320	C/A	cg06922635	chr4:57371607	ARL9	-0.55	-5.72	-0.3	2.34e-8	Airflow obstruction;
CRC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.86	-10.95	-0.52	5.39e-24	Gut microbiome composition (summer);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg17958798	chr17:7200008	NA	-0.42	-6.45	-0.34	3.97e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg03037974	chr15:76606532	NA	0.65	11.09	0.52	1.77e-24	Blood metabolite levels;
CRC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.35	5.76	0.3	1.93e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.29e-25	Chronic sinus infection;
CRC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-10.94	-0.52	5.8e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.03	0.58	1.44e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.54	-7.36	-0.38	1.46e-12	Corneal structure;
CRC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.72	8.03	0.4	1.71e-14	Psoriasis;
CRC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.84	0.31	1.28e-8	Nonalcoholic fatty liver disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08845439	chr1:151512945	TUFT1	-0.4	-5.98	-0.31	5.92e-9	Myopia (pathological);
CRC	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.54	-8.44	-0.42	9.96e-16	Schizophrenia;
CRC	cis	rs990171	0.955	rs6708413	chr2:103063369	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.48e-9	Lymphocyte counts;
CRC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.4	5.8	0.3	1.57e-8	Aortic root size;
CRC	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg16358738	chr2:241808595	AGXT	0.39	6.86	0.35	3.37e-11	Urinary metabolites;
CRC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.24	-0.41	4.03e-15	Monocyte percentage of white cells;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg03623178	chr6:28175578	NA	0.88	9.15	0.45	6.03e-18	Lung cancer in ever smokers;
CRC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-0.93	-12.8	-0.58	9.85e-31	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15844609	chr19:38806846	YIF1B	0.43	6.08	0.32	3.24e-9	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg15445000	chr17:37608096	MED1	-0.35	-6.31	-0.33	8.8e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg07617317	chr6:118971624	C6orf204	0.49	5.72	0.3	2.45e-8	Diastolic blood pressure;
CRC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg06207120	chr15:45996521	NA	0.32	7.77	0.39	1e-13	Waist circumference;Weight;
CRC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.44	-6.43	-0.33	4.42e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.73	7.56	0.38	3.97e-13	Systemic lupus erythematosus;
CRC	trans	rs3743266	0.613	rs2414669	chr15:60708824	A/G	cg23029100	chr15:76603787	ETFA	0.38	5.98	0.31	5.68e-9	Menarche (age at onset);
CRC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.39	-6.89	-0.36	2.77e-11	Reticulocyte fraction of red cells;
CRC	trans	rs10155981	0.510	rs78815495	chr7:22584529	C/T	cg10694741	chr17:37382161	STAC2	0.43	6.07	0.32	3.43e-9	Bilirubin levels;
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg13852879	chr17:77778467	NA	0.39	5.97	0.31	6.05e-9	Monocyte count;
CRC	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg25019722	chr6:37503610	NA	-0.38	-6.64	-0.34	1.3e-10	Cognitive performance;
CRC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg23758597	chr6:163146217	PARK2	-0.68	-6.94	-0.36	2.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.81	14.33	0.62	1.56e-36	Breast cancer;
CRC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Depression;
CRC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.4	-7.84	-0.4	6.26e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs3751196	0.901	rs77344054	chr12:104161253	C/T	cg02344784	chr12:104178138	NT5DC3	0.68	6.76	0.35	6.18e-11	Sense of smell;
CRC	cis	rs9462027	0.628	rs2814969	chr6:34713399	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.69	8.06	0.41	1.43e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.57	-9.17	-0.45	5.23e-18	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg27661571	chr11:113659931	NA	-0.96	-11.16	-0.52	9.58e-25	Hip circumference adjusted for BMI;
CRC	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg13385794	chr1:248469461	NA	0.37	6.34	0.33	7.37e-10	Common traits (Other);
CRC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.83	9.09	0.45	9.72e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6564851	0.506	rs11643509	chr16:81260435	A/C	cg05274606	chr16:81253692	PKD1L2	-0.37	-6.12	-0.32	2.61e-9	Carotenoid and tocopherol levels;
CRC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.73	-9.38	-0.46	1.14e-18	Coronary artery disease;
CRC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-11.5	-0.54	5.85e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg00246817	chr9:123691163	NA	-0.44	-5.75	-0.3	2.06e-8	Rheumatoid arthritis;
CRC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.76	-0.35	6.25e-11	Total body bone mineral density;
CRC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.51	-0.34	2.83e-10	Total cholesterol levels;
CRC	cis	rs17065868	0.764	rs9525955	chr13:45006463	G/A	cg10246903	chr13:45222710	NA	0.56	5.63	0.3	3.82e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-7.52	-0.38	5.27e-13	Homocysteine levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19729279	chr5:133861951	PHF15	0.4	5.96	0.31	6.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg25886479	chr11:50257625	LOC441601	-0.34	-5.7	-0.3	2.7e-8	Coronary artery disease;
CRC	cis	rs12580194	0.593	rs61956269	chr12:55768023	C/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.12	-0.45	7.47e-18	Cancer;
CRC	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.57	8.23	0.41	4.35e-15	Uric acid levels;
CRC	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.41	5.77	0.3	1.84e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	8.59	0.43	3.55e-16	Total cholesterol levels;
CRC	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.48	-0.53	7.05e-26	Coffee consumption (cups per day);
CRC	cis	rs17092148	0.652	rs2281695	chr20:33129164	T/C	cg08999081	chr20:33150536	PIGU	0.49	6.17	0.32	1.96e-9	Neuroticism;
CRC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg04166393	chr7:2884313	GNA12	0.37	5.68	0.3	3e-8	Height;
CRC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	0.98	12.57	0.57	7.09e-30	Diabetic kidney disease;
CRC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.27	-0.33	1.11e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.32	0.46	1.7e-18	Lung cancer;
CRC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.49	-9.3	-0.46	1.98e-18	Reticulocyte fraction of red cells;
CRC	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg04110750	chr16:69646130	NFAT5	-0.51	-7.42	-0.38	1.03e-12	IgE levels;
CRC	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.21	0.37	3.92e-12	Breast cancer;
CRC	cis	rs2652834	1.000	rs11637852	chr15:63397151	G/A	cg05507819	chr15:63340323	TPM1	0.47	6.08	0.32	3.41e-9	HDL cholesterol;
CRC	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.85	-15.19	-0.64	7.35e-40	Itch intensity from mosquito bite;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10062258	chr1:65885702	LEPROT;LEPR	0.37	6.05	0.32	3.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.8	-9.78	-0.47	5.44e-20	Initial pursuit acceleration;
CRC	cis	rs7680126	0.562	rs4698036	chr4:10331294	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.31	-0.33	9.08e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg16558177	chr4:4109446	NA	-0.49	-5.99	-0.31	5.37e-9	Blood pressure (smoking interaction);
CRC	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg21138405	chr5:131827807	IRF1	0.32	5.84	0.31	1.28e-8	Blood metabolite levels;
CRC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.61	9.76	0.47	6.36e-20	Aortic root size;
CRC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg23123621	chr4:1343375	KIAA1530	-0.35	-5.77	-0.3	1.87e-8	Obesity-related traits;
CRC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.34	6.88	0.35	3.01e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.37	-0.42	1.71e-15	Electroencephalogram traits;
CRC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.66	0.43	2.2e-16	Menopause (age at onset);
CRC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	8.21	0.41	5.18e-15	Mood instability;
CRC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.99	-0.36	1.58e-11	HDL cholesterol;
CRC	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.35	0.53	2e-25	Height;
CRC	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg02158880	chr13:53174818	NA	0.45	6.41	0.33	5.07e-10	Lewy body disease;
CRC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.95	-0.68	9.06e-47	Height;
CRC	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.41	-6.41	-0.33	5.09e-10	Total bilirubin levels in HIV-1 infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23439141	chr13:113951774	LAMP1	0.46	7.66	0.39	2.07e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.57	-9.45	-0.46	6.56e-19	P wave terminal force;
CRC	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg14458575	chr2:238380390	NA	0.52	6.89	0.36	2.86e-11	Prostate cancer;
CRC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs673253	0.662	rs11586016	chr1:44031793	G/C	cg10881128	chr1:44031826	PTPRF	0.23	6.55	0.34	2.18e-10	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.37	-19.19	-0.73	1.31e-55	Hip circumference adjusted for BMI;
CRC	cis	rs10045504	0.502	rs72746054	chr5:38762351	C/T	cg15396434	chr5:38725168	NA	-0.62	-6.08	-0.32	3.31e-9	Night sleep phenotypes;
CRC	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg03013999	chr17:37608204	MED1	-0.46	-6.95	-0.36	1.95e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.38	5.78	0.3	1.75e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.71	0.51	3.8e-23	Motion sickness;
CRC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.91	0.31	8.45e-9	Renal function-related traits (BUN);
CRC	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg04611788	chr3:186434169	KNG1	-0.61	-9.1	-0.45	8.64e-18	Blood protein levels;
CRC	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-6.14	-0.32	2.42e-9	Schizophrenia;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Parkinson's disease;
CRC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.43e-59	Hip circumference adjusted for BMI;
CRC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	8.5	0.42	6.72e-16	Schizophrenia;
CRC	cis	rs449789	0.857	rs1553482	chr6:159722147	T/G	cg14500486	chr6:159655392	FNDC1	-0.48	-7.42	-0.38	1.03e-12	Pulse pressure;
CRC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.33e-16	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.38	-0.33	6.13e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg10298567	chr3:47292165	KIF9	-0.37	-6.09	-0.32	3.23e-9	Colorectal cancer;
CRC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg20607287	chr7:12443886	VWDE	-0.67	-6.98	-0.36	1.65e-11	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.51	0.38	5.74e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.9	21.07	0.76	5.42e-63	Longevity;
CRC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-12.8	-0.58	1e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg10589385	chr1:150898437	SETDB1	0.3	6.08	0.32	3.34e-9	Melanoma;
CRC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06656553	chr16:89960601	TCF25	-0.56	-5.77	-0.3	1.83e-8	Skin colour saturation;
CRC	cis	rs10229583	0.563	rs10270127	chr7:127262010	G/A	cg01233922	chr7:127693937	SND1	-0.44	-6.27	-0.33	1.1e-9	Type 2 diabetes;
CRC	cis	rs938554	0.692	rs13125209	chr4:9982044	A/C	cg00071950	chr4:10020882	SLC2A9	0.48	6.73	0.35	7.5e-11	Blood metabolite levels;
CRC	cis	rs9532580	0.553	rs9549250	chr13:41225229	T/G	cg21288729	chr13:41239152	FOXO1	0.48	7.48	0.38	6.95e-13	Mean corpuscular hemoglobin;
CRC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.51	-7.17	-0.37	5.1e-12	Lymphocyte counts;
CRC	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	1.99e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.46	-6.65	-0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs6066835	0.867	rs6066844	chr20:47375153	T/C	cg18078177	chr20:47281410	PREX1	0.69	5.92	0.31	8.27e-9	Multiple myeloma;
CRC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg03233332	chr7:66118400	NA	0.46	6.4	0.33	5.23e-10	Aortic root size;
CRC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg03013999	chr17:37608204	MED1	-0.46	-6.94	-0.36	2.05e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.45	-6.44	-0.33	4.19e-10	Lymphocyte counts;
CRC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.52	-7.95	-0.4	3.08e-14	Height;
CRC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25517755	chr10:38738941	LOC399744	-0.42	-5.98	-0.31	5.66e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11627756	0.957	rs12434778	chr14:103142135	G/T	cg12046867	chr14:103022105	NA	0.44	6.03	0.32	4.41e-9	Mean platelet volume;
CRC	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.68	-0.35	1.02e-10	Vitamin D levels;
CRC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.4	-8.69	-0.43	1.77e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.38	5.96	0.31	6.4e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs73200209	0.912	rs56174185	chr12:116517258	T/C	cg01776926	chr12:116560359	MED13L	-0.52	-6.25	-0.33	1.24e-9	Total body bone mineral density;
CRC	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.81	10.22	0.49	1.73e-21	Iron status biomarkers;
CRC	cis	rs2072510	0.569	rs61937881	chr12:96393587	C/T	cg22491680	chr12:96389547	HAL	-0.5	-6.2	-0.32	1.7e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.82	11.73	0.54	8.62e-27	Multiple sclerosis;
CRC	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.45	5.74	0.3	2.18e-8	Metabolite levels;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg26304593	chr6:42947056	PEX6	-0.44	-6.24	-0.33	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.35	5.75	0.3	2e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg07414643	chr4:187882934	NA	0.37	6.47	0.34	3.47e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.47	-6.45	-0.34	3.88e-10	Superior crus of antihelix expression;
CRC	cis	rs2227564	0.729	rs2688617	chr10:75646147	A/T	cg00564723	chr10:75632066	CAMK2G	-0.34	-7.84	-0.4	6.22e-14	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00012762	chr17:72744649	SLC9A3R1	0.43	6.97	0.36	1.72e-11	Interleukin-6 levels;
CRC	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.11	-9.49	-0.46	4.7e-19	Mitochondrial DNA levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27507545	chr10:103880405	LDB1	0.45	6.05	0.32	3.83e-9	Thyroid stimulating hormone;
CRC	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.58	-8.61	-0.43	3e-16	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.02	-0.31	4.78e-9	Bipolar disorder;
CRC	cis	rs4731207	0.596	rs10280341	chr7:124583935	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.25e-9	Cutaneous malignant melanoma;
CRC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22433210	chr17:43662623	NA	0.73	8.22	0.41	4.85e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.69	10.39	0.5	4.7e-22	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11254426	chr10:127464165	MMP21	-0.4	-6.74	-0.35	7.06e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg06238570	chr21:40685208	BRWD1	0.74	10.37	0.5	5.5e-22	Cognitive function;
CRC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.78	0.39	9.25e-14	Motion sickness;
CRC	trans	rs12940923	1.000	rs34861306	chr17:56377187	G/A	cg16900910	chr15:72789182	ARIH1	0.53	6.08	0.32	3.35e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs2013441	1.000	rs2703810	chr17:20113715	C/T	cg13482628	chr17:19912719	NA	-0.42	-6.57	-0.34	1.95e-10	Obesity-related traits;
CRC	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.46	-6.7	-0.35	9.1e-11	Body mass index;
CRC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.89	0.51	8.98e-24	Platelet count;
CRC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.97	-0.48	1.28e-20	Body mass index;
CRC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.58	6.01	0.31	4.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-11.14	-0.52	1.1e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg12193833	chr17:30244370	NA	-0.73	-8.5	-0.42	6.48e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.88	-0.31	1.01e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs672059	1.000	rs652753	chr1:183156569	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.49	7.13	0.37	6.54e-12	Hypertriglyceridemia;
CRC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg14711859	chr11:8959438	ASCL3	0.38	6.35	0.33	7.19e-10	Hemoglobin concentration;
CRC	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.51	-8.22	-0.41	4.7e-15	Corneal astigmatism;
CRC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.61	-8.69	-0.43	1.73e-16	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg15786705	chr6:28176104	NA	0.73	9.26	0.45	2.63e-18	Depression;
CRC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.25	15.13	0.64	1.26e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	12.1	0.55	4e-28	Platelet count;
CRC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg00343986	chr7:65444356	GUSB	0.46	6.81	0.35	4.59e-11	Aortic root size;
CRC	cis	rs7680126	0.530	rs2903827	chr4:10175872	C/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.04	-0.32	4.27e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.67	10.09	0.49	4.88e-21	Corneal astigmatism;
CRC	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg11204139	chr17:3907470	NA	-0.73	-12.92	-0.58	3.48e-31	Type 2 diabetes;
CRC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.89	0.48	2.36e-20	Platelet count;
CRC	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs6545883	0.524	rs17482440	chr2:61548857	C/T	cg10580144	chr2:61372316	C2orf74	-0.35	-7.93	-0.4	3.4e-14	Tuberculosis;
CRC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg11212589	chr17:38028394	ZPBP2	0.34	5.9	0.31	9.02e-9	Self-reported allergy;
CRC	cis	rs2735413	0.881	rs12920025	chr16:78083005	C/T	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.51	7.29	0.37	2.26e-12	Schizophrenia;
CRC	cis	rs2072510	0.569	rs7970524	chr12:96390152	A/G	cg15438951	chr12:96389694	HAL	-0.46	-5.88	-0.31	9.93e-9	Metabolite levels (small molecules and protein measures);
CRC	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg13237843	chr11:6640720	TPP1	0.42	6.75	0.35	6.58e-11	Myopia;
CRC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23378565	chr7:2036160	MAD1L1	-0.46	-6.51	-0.34	2.85e-10	Bipolar disorder;
CRC	cis	rs6662572	0.671	rs10749861	chr1:46440252	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.7	-0.3	2.71e-8	Blood protein levels;
CRC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg04450456	chr4:17643702	FAM184B	0.41	6.72	0.35	8.23e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	0.55	6.67	0.34	1.12e-10	Prostate cancer;
CRC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg06172871	chr16:72088244	HP	0.44	6.35	0.33	7.31e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-15.19	-0.64	7.35e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.66	10.35	0.5	6.25e-22	Colorectal cancer;
CRC	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg12365402	chr11:9010492	NRIP3	0.39	6.16	0.32	2.07e-9	Hemoglobin concentration;
CRC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs642858	1.000	rs1361248	chr6:140295358	A/G	cg27524944	chr6:140295369	NA	-0.37	-6.15	-0.32	2.24e-9	Type 2 diabetes;
CRC	cis	rs12024301	0.557	rs77047385	chr1:183643180	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-6.94	-0.36	2.13e-11	Menarche (age at onset);
CRC	trans	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.59e-10	Blood metabolite levels;
CRC	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.77	8.75	0.43	1.16e-16	Lung function (FEV1/FVC);
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.65	0.54	1.65e-26	Prudent dietary pattern;
CRC	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.48	-9.11	-0.45	7.99e-18	Hepatitis;
CRC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.48	6.12	0.32	2.73e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.81	0.31	1.45e-8	Homoarginine levels;
CRC	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg03929089	chr4:120376271	NA	0.67	6.42	0.33	4.68e-10	Intraocular pressure;
CRC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.71	-0.35	8.3e-11	Height;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-10.8	-0.51	1.72e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg10761708	chr20:43804764	PI3	0.51	5.86	0.31	1.15e-8	Blood protein levels;
CRC	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.64	-10.3	-0.49	9.3e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.25	0.41	3.81e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07918374	chr16:82182319	MPHOSPH6	-0.41	-5.8	-0.3	1.52e-8	Lung adenocarcinoma;
CRC	cis	rs7107770	0.739	rs12808899	chr11:125082124	T/C	cg27629782	chr11:125073726	PKNOX2	0.53	7.75	0.39	1.16e-13	Photic sneeze reflex;
CRC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.36	-6.81	-0.35	4.74e-11	Colorectal cancer;
CRC	cis	rs1887596	0.705	rs4771004	chr13:27214082	A/G	cg01312412	chr13:27282625	NA	0.43	5.9	0.31	8.84e-9	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs6142102	0.961	rs6119447	chr20:32668576	A/G	cg08999081	chr20:33150536	PIGU	0.37	5.79	0.3	1.63e-8	Skin pigmentation;
CRC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.8	13.89	0.61	7.52e-35	Breast cancer;
CRC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.7	-0.39	1.66e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg11887960	chr12:57824829	NA	0.55	6.33	0.33	7.86e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.05	-0.45	1.27e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.15	-0.32	2.21e-9	Aortic root size;
CRC	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg11130432	chr3:121712080	ILDR1	-0.54	-6.28	-0.33	1.04e-9	Multiple sclerosis;
CRC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.93	11.07	0.52	1.98e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.59	9.21	0.45	4.06e-18	Blood metabolite levels;
CRC	cis	rs3204270	0.639	rs62080199	chr17:79627906	T/G	cg09655341	chr17:79618100	PDE6G	0.63	7.21	0.37	3.83e-12	Dental caries;
CRC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.47	0.5	2.42e-22	Diabetic retinopathy;
CRC	cis	rs11212617	1.000	rs654005	chr11:108155397	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.26	0.33	1.2e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg27205649	chr11:78285834	NARS2	0.47	5.79	0.3	1.61e-8	Alzheimer's disease (survival time);
CRC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg09218773	chr11:619014	MUPCDH	-0.42	-5.95	-0.31	6.95e-9	Systemic lupus erythematosus;
CRC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg23378565	chr7:2036160	MAD1L1	-0.51	-6.87	-0.35	3.21e-11	Bipolar disorder;
CRC	trans	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg25214090	chr10:38739885	LOC399744	0.4	6.33	0.33	8.21e-10	Diastolic blood pressure;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.09	-0.32	3.06e-9	Total body bone mineral density;
CRC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg02569458	chr12:86230093	RASSF9	0.4	6.85	0.35	3.7e-11	Major depressive disorder;
CRC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.85	8.65	0.43	2.36e-16	Major depressive disorder;
CRC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.62	-0.34	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.02	0.32	4.63e-9	Diabetic retinopathy;
CRC	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-6.18	-0.32	1.93e-9	Endometrial cancer;
CRC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.76	0.3	1.96e-8	Tonsillectomy;
CRC	cis	rs727505	0.866	rs66650870	chr7:124713194	T/C	cg23710748	chr7:124431027	NA	-0.73	-12.7	-0.57	2.47e-30	Lewy body disease;
CRC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.73	0.39	1.35e-13	Height;
CRC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg27661571	chr11:113659931	NA	-0.96	-11.22	-0.53	5.78e-25	Hip circumference adjusted for BMI;
CRC	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg15711740	chr2:61764176	XPO1	0.43	5.72	0.3	2.36e-8	Tuberculosis;
CRC	cis	rs939584	1.000	rs2867114	chr2:651380	C/T	cg03610516	chr2:642275	NA	-0.43	-5.94	-0.31	7.33e-9	Body mass index;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.05	0.32	3.88e-9	Prudent dietary pattern;
CRC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.52	-7.32	-0.37	1.97e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26714650	chr12:56694279	CS	-1.44	-11.18	-0.52	8.02e-25	Psoriasis vulgaris;
CRC	cis	rs7113874	0.524	rs9300090	chr11:8585384	G/A	cg20771178	chr11:8615675	STK33	-0.36	-5.65	-0.3	3.5e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	10.72	0.51	3.48e-23	Motion sickness;
CRC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg27535305	chr1:53392650	SCP2	0.34	6.36	0.33	6.57e-10	Monocyte count;
CRC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.72	-12.45	-0.57	1.99e-29	Prostate cancer;
CRC	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg08501292	chr6:25962987	TRIM38	0.64	6.15	0.32	2.27e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg03929089	chr4:120376271	NA	0.66	5.98	0.31	5.9e-9	Myopia (pathological);
CRC	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-6.59	-0.34	1.75e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02349096	chr19:11450198	RAB3D	0.38	6.03	0.32	4.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.57	6.19	0.32	1.83e-9	Initial pursuit acceleration;
CRC	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	13.68	0.6	4.84e-34	Exhaled nitric oxide output;
CRC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.78	8.98	0.44	2.12e-17	Lung function (FEV1/FVC);
CRC	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.23	-0.32	1.4e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6662572	0.737	rs4256763	chr1:46379518	A/G	cg08644498	chr1:46502608	NA	-0.44	-6.85	-0.35	3.69e-11	Blood protein levels;
CRC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.44	0.38	8.68e-13	Lung cancer in ever smokers;
CRC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.95	-0.4	2.95e-14	Gut microbiome composition (summer);
CRC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.59	-8.82	-0.44	6.62e-17	Aortic root size;
CRC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06656553	chr16:89960601	TCF25	-0.71	-5.96	-0.31	6.42e-9	Skin colour saturation;
CRC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.3	0.33	9.74e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.46	-6.58	-0.34	1.84e-10	Lung cancer;
CRC	cis	rs834811	0.871	rs834819	chr7:135895281	G/A	cg01726295	chr7:135938950	NA	0.4	6.92	0.36	2.31e-11	Post-traumatic stress disorder;
CRC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.78	-14.41	-0.62	7.82e-37	Metabolic syndrome;
CRC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.41	7.01	0.36	1.35e-11	Coronary artery disease;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.21	-0.32	1.59e-9	Acylcarnitine levels;
CRC	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	1.06	9.98	0.48	1.11e-20	Arsenic metabolism;
CRC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02450064	chr17:40260053	DHX58	-0.43	-6.21	-0.32	1.64e-9	Fibrinogen levels;
CRC	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.51	7.36	0.38	1.51e-12	Testicular germ cell tumor;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.73	11.69	0.54	1.19e-26	Longevity;Endometriosis;
CRC	cis	rs7781266	0.501	rs28551473	chr7:133631089	G/C	cg03336402	chr7:133662267	EXOC4	0.67	10.32	0.49	8.37e-22	Educational attainment (college completion);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08483723	chr3:45267960	TMEM158	-0.33	-6.02	-0.31	4.58e-9	Myopia (pathological);
CRC	trans	rs58106596	0.660	rs62197212	chr2:232562727	G/A	cg01370599	chr3:116745421	NA	0.88	10.4	0.5	4.42e-22	White blood cell count;Lymphocyte counts;
CRC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg12458913	chr13:53173898	NA	0.76	13.79	0.61	1.8e-34	Lewy body disease;
CRC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.95	0.58	2.85e-31	Chronic sinus infection;
CRC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.3	-0.59	1.39e-32	Extrinsic epigenetic age acceleration;
CRC	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.57	9.83	0.48	3.72e-20	Leprosy;
CRC	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.6	8.52	0.43	5.7e-16	Schizophrenia;
CRC	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.47	-5.77	-0.3	1.86e-8	Coronary artery calcification;
CRC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.5	-8.12	-0.41	9.41e-15	Huntington's disease progression;
CRC	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.26e-10	Common traits (Other);
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.49	-0.42	7.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg15763984	chr4:1342303	KIAA1530	0.49	8.72	0.43	1.38e-16	Longevity;
CRC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.24e-10	Dupuytren's disease;
CRC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.6	-6.74	-0.35	7.08e-11	Vitiligo;
CRC	cis	rs4363385	0.747	rs1415971	chr1:152965779	T/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.27	-0.37	2.72e-12	Inflammatory skin disease;
CRC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	5.72	0.3	2.44e-8	Tonsillectomy;
CRC	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg03932441	chr10:102415297	NA	0.33	5.75	0.3	2.06e-8	Body mass index;
CRC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg13206674	chr6:150067644	NUP43	0.67	9.8	0.48	4.66e-20	Lung cancer;
CRC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.42	5.87	0.31	1.08e-8	Body mass index;
CRC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.94	0.48	1.61e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	5.88	0.31	1.01e-8	Schizophrenia;
CRC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg16235748	chr6:149772707	ZC3H12D	0.37	6.8	0.35	4.97e-11	Dupuytren's disease;
CRC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-10.72	-0.51	3.44e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.38	-8.57	-0.43	4.03e-16	Multiple system atrophy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01139526	chr5:139682850	PFDN1	0.47	6.76	0.35	6.47e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.92	18.32	0.71	3.46e-52	Bone mineral density;
CRC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.82	11.25	0.53	4.73e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg08755490	chr11:65554678	OVOL1	0.43	6.39	0.33	5.53e-10	Acne (severe);
CRC	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.56	8.78	0.44	9.09e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs55788414	0.932	rs9940095	chr16:81182108	A/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.33	-9.54	-0.47	3.34e-19	Mean corpuscular volume;
CRC	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.72	0.43	1.44e-16	Coffee consumption (cups per day);
CRC	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.48	7.12	0.37	7e-12	Menopause (age at onset);
CRC	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.63	0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.52	-9.65	-0.47	1.48e-19	Longevity;Endometriosis;
CRC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.44	-5.83	-0.31	1.33e-8	Adiposity;
CRC	cis	rs2786111	0.928	rs554009	chr1:197294699	C/T	cg13682187	chr1:196946512	CFHR5	0.29	5.74	0.3	2.17e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.75	-0.47	7e-20	Primary sclerosing cholangitis;
CRC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.5	9.1	0.45	8.56e-18	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	10.63	0.51	6.88e-23	Menopause (age at onset);
CRC	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.55	10.4	0.5	4.28e-22	Urate levels in lean individuals;
CRC	cis	rs9311676	0.656	rs10866016	chr3:58390844	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-6.69	-0.35	9.55e-11	Blood metabolite levels;
CRC	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.9	-0.31	9.23e-9	Breast cancer;
CRC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg21782813	chr7:2030301	MAD1L1	0.48	7.85	0.4	6.04e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs365302	1.000	rs411523	chr6:159618790	G/A	cg14500486	chr6:159655392	FNDC1	0.53	7.76	0.39	1.05e-13	Coronary heart disease;
CRC	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.49	7.68	0.39	1.79e-13	Red blood cell count;
CRC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.74	0.43	1.23e-16	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02923393	chr16:1543003	TELO2	0.47	6.58	0.34	1.89e-10	Response to antipsychotic treatment;
CRC	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-5.91	-0.31	8.38e-9	Vitamin D levels;
CRC	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.83	-0.31	1.3e-8	Migraine;Coronary artery disease;
CRC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg08027265	chr7:2291960	NA	-0.36	-6.29	-0.33	9.91e-10	Schizophrenia;
CRC	cis	rs4494114	0.967	rs9438986	chr1:39369652	T/G	cg25970120	chr1:39325951	RRAGC	-0.42	-5.63	-0.3	3.9e-8	Blood protein levels;
CRC	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.2	26.62	0.83	4.51e-84	Schizophrenia;
CRC	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.23	11.49	0.54	6.58e-26	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08475517	chr19:2783460	SGTA	0.44	6.06	0.32	3.66e-9	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.69	0.3	2.87e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.43	6.86	0.35	3.38e-11	Obesity-related traits;
CRC	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg13491945	chr12:107078410	RFX4	0.34	5.86	0.31	1.09e-8	Heart rate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00683158	chr19:7660969	KIAA1543	0.48	7.02	0.36	1.25e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.37	-0.38	1.38e-12	Aortic root size;
CRC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg10298567	chr3:47292165	KIF9	-0.4	-6.29	-0.33	1.04e-9	Colorectal cancer;
CRC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.28	-6.41	-0.33	5.1e-10	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09311052	chr1:154531418	UBE2Q1	-0.55	-6.74	-0.35	7.3e-11	Diisocyanate-induced asthma;
CRC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.95	-0.48	1.45e-20	Coronary artery disease;
CRC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.99	0.36	1.58e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.54	8.08	0.41	1.23e-14	Insulin-like growth factors;
CRC	cis	rs6066835	0.572	rs11698365	chr20:47259527	C/T	cg18078177	chr20:47281410	PREX1	0.78	5.96	0.31	6.37e-9	Multiple myeloma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03945577	chr1:150602196	ENSA	0.45	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg23117316	chr7:135346802	PL-5283	-0.48	-6.16	-0.32	2.13e-9	Red blood cell traits;
CRC	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg26875233	chr11:93583750	C11orf90	-0.33	-6.41	-0.33	4.93e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.62	9.28	0.46	2.32e-18	Obesity-related traits;
CRC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs847649	1.000	rs4620204	chr7:102594217	T/C	cg18108683	chr7:102477205	FBXL13	0.58	9.37	0.46	1.19e-18	Morning vs. evening chronotype;
CRC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	ch.11.42038R	chr11:967971	AP2A2	0.61	10.38	0.5	4.91e-22	Alzheimer's disease (late onset);
CRC	cis	rs2882667	0.690	rs1703212	chr5:138078552	A/G	cg09476006	chr5:138032270	NA	-0.57	-10.31	-0.49	8.67e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.41	-7.78	-0.39	9.21e-14	Ulcerative colitis;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg20933634	chr6:27740509	NA	0.57	8.07	0.41	1.33e-14	Parkinson's disease;
CRC	trans	rs12702919	0.837	rs2713339	chr7:9548713	C/A	cg15597424	chr4:24472487	NA	-0.39	-6.32	-0.33	8.56e-10	PR interval in Tripanosoma cruzi seropositivity;
CRC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.39	0.38	1.21e-12	Motion sickness;
CRC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.91	15.39	0.65	1.25e-40	Body mass index (adult);
CRC	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg25547332	chr5:131281432	NA	0.39	5.73	0.3	2.25e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg04155289	chr7:94953770	PON1	-0.63	-7.73	-0.39	1.32e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	6.67	0.35	1.09e-10	Aortic root size;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.12	0.32	2.73e-9	Depression;
CRC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg09655341	chr17:79618100	PDE6G	-0.37	-6.24	-0.33	1.38e-9	Eye color traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16585985	chr1:161360266	NA	0.42	6.31	0.33	9.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.47	-9.09	-0.45	9.81e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.64	-0.3	3.72e-8	Breast cancer;
CRC	cis	rs6840360	0.642	rs2724551	chr4:152355383	T/C	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg24833071	chr7:75115655	POM121C	0.37	6.01	0.31	4.81e-9	Obesity-related traits;
CRC	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg09760422	chr2:128146352	NA	-0.36	-7.06	-0.36	9.73e-12	Protein C levels;
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg15786705	chr6:28176104	NA	0.74	9.27	0.46	2.5e-18	Depression;
CRC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.66	-0.34	1.18e-10	Alzheimer's disease (late onset);
CRC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.94	-15.38	-0.65	1.29e-40	Gut microbiota (bacterial taxa);
CRC	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg18135206	chr14:102964638	TECPR2	0.55	6.77	0.35	6e-11	Blood protein levels;
CRC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.87	-0.4	5.18e-14	Height;
CRC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.41	-7.44	-0.38	8.81e-13	Childhood ear infection;
CRC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.56	8.36	0.42	1.76e-15	Type 2 diabetes;
CRC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg08200770	chr17:80723486	TBCD	-0.45	-6.77	-0.35	5.85e-11	Glycated hemoglobin levels;
CRC	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.33	5.86	0.31	1.13e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.3e-12	Motion sickness;
CRC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg23625390	chr15:77176239	SCAPER	0.48	7.06	0.36	9.99e-12	Blood metabolite levels;
CRC	cis	rs3750082	0.889	rs3750081	chr7:32930876	T/G	cg05721444	chr7:32995514	FKBP9	0.51	7.9	0.4	4.28e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.04	-0.32	4.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.68	-10.24	-0.49	1.53e-21	Monocyte count;
CRC	cis	rs71403859	0.554	rs12373065	chr16:71870032	T/A	cg08717414	chr16:71523259	ZNF19	-0.88	-7.45	-0.38	8.19e-13	Post bronchodilator FEV1;
CRC	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg25664220	chr3:72788482	NA	-0.4	-6.09	-0.32	3.22e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-9.39	-0.46	1.05e-18	Height;
CRC	cis	rs10971721	0.822	rs118115128	chr9:33935449	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.82	9.58	0.47	2.49e-19	Obesity-related traits;
CRC	cis	rs17767392	1.000	rs17767392	chr14:71764777	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.45	6.73	0.35	7.64e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-7.18	-0.37	4.53e-12	Menarche (age at onset);
CRC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.47	6.05	0.32	4e-9	Aortic root size;
CRC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-11.38	-0.53	1.61e-25	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.86	7.04	0.36	1.14e-11	Major depressive disorder;
CRC	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-7.65	-0.39	2.29e-13	Primary sclerosing cholangitis;
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs6585424	1.000	rs2304410	chr10:81921810	T/C	cg11900509	chr10:81946545	ANXA11	-0.72	-8.81	-0.44	7.22e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.92	0.31	7.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.47	-0.38	7.35e-13	Psoriasis;
CRC	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-12.01	-0.55	8.16e-28	Exhaled nitric oxide output;
CRC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.12	-13.21	-0.59	3.05e-32	Diabetic kidney disease;
CRC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.62	-9.7	-0.47	9.63e-20	Body mass index;
CRC	cis	rs9648716	1.000	rs7785306	chr7:140619488	C/T	cg10747023	chr7:140774559	NA	0.46	6.03	0.32	4.51e-9	Type 2 diabetes;
CRC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg26304593	chr6:42947056	PEX6	-0.44	-6.23	-0.32	1.46e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-8.4	-0.42	1.38e-15	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16956745	chr1:36689900	THRAP3	0.45	6.47	0.34	3.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-7.98	-0.4	2.47e-14	Eye color traits;
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.94	0.52	5.62e-24	Prudent dietary pattern;
CRC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.91	16.6	0.68	2.2e-45	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg02527881	chr3:46936655	PTH1R	-0.35	-6.09	-0.32	3.07e-9	Colorectal cancer;
CRC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.43	7.41	0.38	1.05e-12	Vitamin D levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05697231	chr15:74286614	PML	0.41	6.07	0.32	3.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-7.81	-0.4	7.8e-14	Menarche (age at onset);
CRC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.56	7.86	0.4	5.47e-14	Lung cancer;
CRC	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg23071808	chr14:103021642	NA	-0.72	-9.36	-0.46	1.32e-18	Platelet count;
CRC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.65	11.95	0.55	1.41e-27	Aortic root size;
CRC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.44	-0.5	3.12e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg06781209	chr11:61594997	FADS2	-0.41	-5.87	-0.31	1.04e-8	Bipolar disorder;
CRC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.48	8.96	0.44	2.46e-17	Total body bone mineral density;
CRC	cis	rs6681460	0.932	rs536410	chr1:67191084	C/T	cg02459107	chr1:67143332	SGIP1	0.4	7.28	0.37	2.54e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs891088	0.695	rs10411728	chr19:7194938	C/T	cg00428638	chr19:7224713	INSR	-0.63	-7.75	-0.39	1.18e-13	Hip circumference adjusted for BMI;Height;
CRC	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.47	-6.12	-0.32	2.62e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05742564	chr16:23568708	UBFD1;EARS2	-0.44	-6.43	-0.33	4.43e-10	Myopia (pathological);
CRC	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg00919237	chr7:87102261	ABCB4	-0.51	-6.7	-0.35	9.12e-11	Gallbladder cancer;
CRC	cis	rs6074578	0.740	rs1858599	chr20:147917	A/C	cg16931068	chr20:139680	DEFB127	0.3	5.63	0.3	3.91e-8	Hirschsprung disease;
CRC	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.42	6.52	0.34	2.61e-10	Red blood cell count;
CRC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.85	-13.02	-0.58	1.48e-31	Blood metabolite levels;
CRC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg04731861	chr2:219085781	ARPC2	0.32	6.84	0.35	3.9e-11	Colorectal cancer;
CRC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.55	7.23	0.37	3.42e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg14593290	chr7:50529359	DDC	0.5	7.34	0.38	1.64e-12	Malaria;
CRC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg17085576	chr10:5658249	NA	-0.43	-6.18	-0.32	1.89e-9	Breast cancer;
CRC	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg21280719	chr6:42927975	GNMT	0.32	6.1	0.32	3.03e-9	Blood protein levels;
CRC	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	6.17	0.32	2.02e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.6	-8.09	-0.41	1.18e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg19131313	chr8:1704013	NA	-0.49	-6.08	-0.32	3.42e-9	Systolic blood pressure;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03762994	chr17:6899332	ALOX12	-0.62	-11.57	-0.54	3.4e-26	Tonsillectomy;
CRC	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.34	-0.38	1.63e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.51	-7.07	-0.36	9.42e-12	Gut microbiome composition (summer);
CRC	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.0	-0.4	2.21e-14	Response to antipsychotic treatment;
CRC	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg02023728	chr11:77925099	USP35	-0.35	-5.99	-0.31	5.35e-9	Alzheimer's disease (survival time);
CRC	trans	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.86	0.31	1.14e-8	Prudent dietary pattern;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg23161317	chr6:28129485	ZNF389	0.46	6.5	0.34	2.93e-10	Cardiac Troponin-T levels;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16687227	chr3:58477487	KCTD6	-0.41	-6.07	-0.32	3.6e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-6.78	-0.35	5.48e-11	Lymphocyte counts;
CRC	cis	rs12913538	0.519	rs7168691	chr15:62888952	A/T	cg09983546	chr15:62884068	NA	0.51	6.14	0.32	2.38e-9	Sleep depth;
CRC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg25767906	chr1:53392781	SCP2	0.4	6.54	0.34	2.39e-10	Monocyte count;
CRC	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.57	6.78	0.35	5.67e-11	Type 2 diabetes nephropathy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20584198	chr12:57637690	STAC3	0.51	7.0	0.36	1.43e-11	Thyroid stimulating hormone;
CRC	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg27534772	chr1:16042836	PLEKHM2	0.41	6.95	0.36	1.99e-11	Systolic blood pressure;
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.53	6.41	0.33	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg00677455	chr12:58241039	CTDSP2	0.54	8.2	0.41	5.29e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.71	-12.76	-0.58	1.39e-30	Educational attainment;
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.23	-0.45	3.45e-18	Electroencephalogram traits;
CRC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.71	-0.47	8.9e-20	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.51	7.84	0.4	6.37e-14	Aortic root size;
CRC	cis	rs12753569	0.748	rs1013630	chr1:76513819	G/T	cg00791851	chr1:76518896	NA	0.38	6.91	0.36	2.56e-11	Personality dimensions;
CRC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg00246817	chr9:123691163	NA	-0.44	-5.64	-0.3	3.72e-8	Rheumatoid arthritis;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.46	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14119001	chr9:139324193	INPP5E	-0.5	-7.21	-0.37	3.94e-12	White blood cell count;
CRC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.65	9.48	0.46	5.19e-19	Menopause (age at onset);
CRC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg08213375	chr14:104286397	PPP1R13B	0.57	11.69	0.54	1.22e-26	Schizophrenia;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.49	6.94	0.36	2.15e-11	Longevity;Endometriosis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08400120	chr3:169940839	PRKCI	0.49	6.44	0.33	4.3e-10	Thyroid stimulating hormone;
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg19624444	chr7:2048497	MAD1L1	0.33	5.88	0.31	1.02e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg15898840	chr7:45960834	IGFBP3	0.47	7.92	0.4	3.77e-14	Sitting height ratio;
CRC	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg10761708	chr20:43804764	PI3	0.48	5.62	0.3	4.06e-8	Blood protein levels;
CRC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg02033258	chr5:131593261	PDLIM4	0.4	7.59	0.39	3.34e-13	Breast cancer;
CRC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-6.04	-0.32	4.23e-9	Alzheimer's disease (late onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00515161	chr17:59940900	BRIP1	-0.45	-6.89	-0.36	2.81e-11	Interleukin-6 levels;
CRC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg05585544	chr11:47624801	NA	-0.61	-10.75	-0.51	2.56e-23	Subjective well-being;
CRC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.27	-0.33	1.16e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.43	-6.26	-0.33	1.2e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs35520189	0.591	rs11690185	chr2:113698136	C/T	cg12858261	chr2:113808755	IL1F8	0.47	6.28	0.33	1.05e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs4321325	0.733	rs78238478	chr2:127936306	G/A	cg11380483	chr2:127933992	NA	0.63	7.44	0.38	8.6e-13	Protein C levels;
CRC	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg21918786	chr6:109611834	NA	-0.35	-6.01	-0.31	4.88e-9	Reticulocyte fraction of red cells;
CRC	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg08600765	chr20:34638493	LOC647979	-0.62	-7.06	-0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-6.38	-0.33	5.93e-10	Systemic lupus erythematosus;
CRC	cis	rs17234274	0.622	rs1384480	chr11:23237995	C/G	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg03152288	chr2:177042942	NA	0.8	12.66	0.57	3.41e-30	IgG glycosylation;
CRC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.75	-0.35	6.53e-11	Response to antipsychotic treatment;
CRC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.24	0.33	1.31e-9	Diabetic kidney disease;
CRC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg23758597	chr6:163146217	PARK2	-0.56	-6.18	-0.32	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.63	10.19	0.49	2.26e-21	Depressive symptoms (multi-trait analysis);
CRC	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg21095983	chr6:86352623	SYNCRIP	0.48	6.83	0.35	4.16e-11	Smooth-surface caries;
CRC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.36	0.38	1.5e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.12e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg24154853	chr7:158122151	PTPRN2	-0.59	-9.85	-0.48	3.18e-20	Calcium levels;
CRC	cis	rs7705042	1.000	rs7705042	chr5:141492419	C/A	cg07392085	chr5:141489673	NDFIP1	0.47	7.41	0.38	1.06e-12	Asthma;
CRC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.33	-5.92	-0.31	8.06e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.02	10.13	0.49	3.7e-21	Opioid sensitivity;
CRC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.21	-0.32	1.58e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs62045849	0.546	rs71395385	chr16:89196279	A/G	cg08015503	chr16:89190385	ACSF3	0.95	6.22	0.32	1.48e-9	Red blood cell count;
CRC	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.52	9.15	0.45	6.07e-18	Schizophrenia;
CRC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-9.59	-0.47	2.33e-19	Body mass index;
CRC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12315302	chr6:26189340	HIST1H4D	0.75	6.25	0.33	1.31e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg15226275	chr6:116381976	FRK	0.31	8.66	0.43	2.11e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	0.98	8.97	0.44	2.31e-17	Plateletcrit;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.77	-0.35	6.02e-11	Bipolar disorder;
CRC	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.94	-12.2	-0.56	1.65e-28	Exhaled nitric oxide output;
CRC	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.74	-13.44	-0.6	3.92e-33	Oral cavity cancer;
CRC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.93	-0.4	3.38e-14	Gut microbiome composition (summer);
CRC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02668984	chr17:48172022	PDK2	0.49	6.43	0.33	4.54e-10	Thyroid stimulating hormone;
CRC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg03959625	chr15:84868606	LOC388152	0.41	6.08	0.32	3.26e-9	Schizophrenia;
CRC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg00316803	chr15:76480434	C15orf27	0.39	6.85	0.35	3.72e-11	Blood metabolite levels;
CRC	cis	rs4731207	0.596	rs1031956	chr7:124627183	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.16	-0.32	2.1e-9	Cutaneous malignant melanoma;
CRC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.59	9.22	0.45	3.66e-18	Sudden cardiac arrest;
CRC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg27395922	chr11:50257633	LOC441601	0.48	6.14	0.32	2.4e-9	Intraocular pressure;
CRC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg01518246	chr11:63870912	FLRT1;MACROD1	0.47	6.04	0.32	4.27e-9	Mean platelet volume;
CRC	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.49	11.99	0.55	9.79e-28	Granulocyte percentage of myeloid white cells;
CRC	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg01843034	chr6:37503916	NA	-0.44	-8.32	-0.42	2.31e-15	Cognitive performance;
CRC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.07	0.32	3.51e-9	Diabetic retinopathy;
CRC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.43	5.69	0.3	2.83e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.57	-0.43	4.05e-16	Chronic sinus infection;
CRC	cis	rs6694672	1.000	rs857026	chr1:197012194	T/C	cg13682187	chr1:196946512	CFHR5	0.43	6.87	0.35	3.23e-11	Asthma;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.69	8.73	0.43	1.34e-16	Hip circumference adjusted for BMI;
CRC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg04317338	chr11:64019027	PLCB3	0.61	5.98	0.31	5.71e-9	Mean platelet volume;
CRC	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.58	-7.58	-0.39	3.58e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.66	9.02	0.45	1.62e-17	Neuroblastoma;
CRC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.43	0.38	9.49e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.07	-0.41	1.38e-14	Menopause (age at onset);
CRC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.12	0.49	3.77e-21	Heart rate;
CRC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg13798780	chr7:105162888	PUS7	0.63	7.2	0.37	4.02e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.37	0.33	6.51e-10	Obesity-related traits;
CRC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	trans	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg26043149	chr18:55253948	FECH	0.53	8.12	0.41	9.3e-15	Bone mineral density;
CRC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.66	-11.05	-0.52	2.37e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.64	7.24	0.37	3.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18555811	chr3:193852889	HES1	0.4	6.15	0.32	2.2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs62408225	0.802	rs2325261	chr6:90921407	T/C	cg06866423	chr6:90926672	BACH2	0.69	13.03	0.58	1.38e-31	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs3736485	0.966	rs4775959	chr15:51891636	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.46	-0.34	3.79e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg03623178	chr6:28175578	NA	0.67	9.51	0.46	4.25e-19	Parkinson's disease;
CRC	cis	rs17767392	0.881	rs35971049	chr14:72012219	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.54	-7.01	-0.36	1.32e-11	Mitral valve prolapse;
CRC	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.44	-8.59	-0.43	3.49e-16	Migraine;
CRC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg06204229	chr3:52865917	ITIH4	0.5	5.93	0.31	7.74e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-7.02	-0.36	1.3e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.52	-0.34	2.65e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.07	-0.45	1.13e-17	Bipolar disorder;
CRC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.58	8.14	0.41	8.04e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.99	-0.55	9.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs427943	0.722	rs8126895	chr21:46609258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	5.92	0.31	7.91e-9	Body mass index;
CRC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.27	0.33	1.13e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.73	6.98	0.36	1.64e-11	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg04553112	chr3:125709451	NA	-0.51	-6.0	-0.31	5.13e-9	Blood pressure (smoking interaction);
CRC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.41	0.38	1.04e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg22676075	chr6:135203613	NA	0.41	6.26	0.33	1.22e-9	Red blood cell count;
CRC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.77	0.3	1.86e-8	Prudent dietary pattern;
CRC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	1.05	12.37	0.56	4.06e-29	Eosinophil percentage of granulocytes;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg25606773	chr6:46110412	ENPP4	0.45	6.41	0.33	4.99e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	13.5	0.6	2.38e-33	Menopause (age at onset);
CRC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	9.67	0.47	1.24e-19	Platelet count;
CRC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.78	13.01	0.58	1.65e-31	Blood protein levels;
CRC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	0.86	8.33	0.42	2.29e-15	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.41	0.33	4.97e-10	Diabetic kidney disease;
CRC	trans	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg19188899	chr13:112838565	NA	-0.43	-6.77	-0.35	5.75e-11	Systemic lupus erythematosus;
CRC	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg05714579	chr10:131428358	MGMT	0.53	7.65	0.39	2.28e-13	Response to temozolomide;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg02033258	chr5:131593261	PDLIM4	0.48	8.32	0.42	2.31e-15	Acylcarnitine levels;
CRC	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.61	-8.3	-0.42	2.77e-15	White matter hyperintensity burden;
CRC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-9.22	-0.45	3.72e-18	HDL cholesterol;
CRC	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.9	0.31	9.11e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg11843238	chr5:131593191	PDLIM4	0.34	6.62	0.34	1.5e-10	Blood metabolite levels;
CRC	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.83	-9.71	-0.47	9.23e-20	Dilated cardiomyopathy;
CRC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.96	-16.26	-0.67	4.64e-44	Height;
CRC	trans	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg02560186	chr11:3602584	NA	-0.55	-6.64	-0.34	1.29e-10	Blood pressure (smoking interaction);
CRC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.5	-7.67	-0.39	1.92e-13	Body mass index;
CRC	cis	rs10450586	0.863	rs7119628	chr11:27302716	G/A	cg10370305	chr11:27303972	NA	0.37	6.06	0.32	3.69e-9	Total body bone mineral density;
CRC	cis	rs863345	0.604	rs949397	chr1:158461951	G/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.08	-0.32	3.41e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25009629	chr6:41748519	FRS3;PRICKLE4	0.41	6.81	0.35	4.57e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg11212589	chr17:38028394	ZPBP2	0.42	7.7	0.39	1.59e-13	Self-reported allergy;
CRC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg17346650	chr17:80929145	B3GNTL1	0.47	6.73	0.35	7.74e-11	Glycated hemoglobin levels;
CRC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	15.43	0.65	8.56e-41	Smoking behavior;
CRC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.35	-0.33	7.24e-10	Alzheimer's disease (late onset);
CRC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.59	-8.06	-0.41	1.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.26	0.45	2.62e-18	Mean corpuscular volume;
CRC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg08648136	chr8:956695	NA	0.3	6.03	0.32	4.3e-9	Schizophrenia;
CRC	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.51	6.94	0.36	2.15e-11	Caudate activity during reward;
CRC	cis	rs1223397	0.651	rs2439541	chr6:13310567	T/C	cg07912922	chr6:13274314	PHACTR1	0.39	6.07	0.32	3.52e-9	Blood pressure;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.69	0.3	2.82e-8	Depression;
CRC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.57	8.45	0.42	9.31e-16	High light scatter reticulocyte count;
CRC	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg24163568	chr5:669837	TPPP	-0.43	-6.91	-0.36	2.48e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs938554	0.876	rs737267	chr4:9934744	G/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-5.63	-0.3	3.94e-8	Blood metabolite levels;
CRC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00166722	chr3:10149974	C3orf24	0.63	8.38	0.42	1.55e-15	Alzheimer's disease;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.65	9.81	0.48	4.36e-20	Longevity;Endometriosis;
CRC	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.45	7.23	0.37	3.5e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs972578	0.806	rs4822225	chr22:43310652	G/T	cg01576275	chr22:43409880	NA	-0.39	-6.0	-0.31	5.21e-9	Mean platelet volume;
CRC	trans	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg06129210	chr16:17565129	XYLT1	-0.34	-6.0	-0.31	5.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-12.46	-0.57	1.87e-29	Electrocardiographic conduction measures;
CRC	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.76	-10.25	-0.49	1.46e-21	White matter hyperintensity burden;
CRC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.58	-7.75	-0.39	1.13e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg12573674	chr2:1569213	NA	-0.75	-7.87	-0.4	5.22e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-6.36	-0.33	6.94e-10	Schizophrenia;
CRC	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg05935833	chr10:81318306	SFTPA2	-0.41	-5.89	-0.31	9.46e-9	Borderline personality disorder;
CRC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.4	6.02	0.32	4.56e-9	Longevity;Endometriosis;
CRC	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.66	11.17	0.52	8.84e-25	Cancer;
CRC	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.17	-0.32	2.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.73	0.35	7.76e-11	Menarche (age at onset);
CRC	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	14.62	0.63	1.24e-37	Mean corpuscular hemoglobin;
CRC	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.58	8.59	0.43	3.67e-16	Corneal astigmatism;
CRC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.58	-0.47	2.55e-19	Platelet count;
CRC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg25985355	chr7:65971099	NA	-0.48	-5.67	-0.3	3.15e-8	Diabetic kidney disease;
CRC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.9	0.4	4.24e-14	Menopause (age at onset);
CRC	cis	rs7517126	1.000	rs2336536	chr1:196839514	T/C	cg13682187	chr1:196946512	CFHR5	-0.36	-5.92	-0.31	7.89e-9	Blood protein levels;
CRC	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.61	9.94	0.48	1.61e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.72	-9.41	-0.46	9.19e-19	Tuberculosis;
CRC	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-5.71	-0.3	2.48e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.98	0.7	7.57e-51	Platelet count;
CRC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-8.99	-0.44	1.95e-17	Menarche (age at onset);
CRC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.8	0.3	1.52e-8	Major depressive disorder;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg12172441	chr6:28176163	NA	0.54	7.43	0.38	9.55e-13	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02290350	chr8:58132656	NA	-0.42	-6.0	-0.31	5.25e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.1	-0.32	3.05e-9	Breast cancer;
CRC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-8.69	-0.43	1.74e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.49	-6.85	-0.35	3.75e-11	Mammographic density (dense area);
CRC	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-9.09	-0.45	9.55e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.75	10.24	0.49	1.55e-21	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.61	-0.3	4.38e-8	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.37	0.5	5.39e-22	Platelet count;
CRC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.81	14.73	0.63	4.44e-38	Anterior chamber depth;
CRC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg16342193	chr10:102329863	NA	-0.38	-5.97	-0.31	6.03e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs10507419	1.000	rs17753659	chr13:35187616	T/G	cg00944431	chr1:10896004	NA	0.42	6.03	0.32	4.37e-9	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);
CRC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg02574844	chr11:5959923	NA	-0.47	-6.61	-0.34	1.56e-10	DNA methylation (variation);
CRC	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.37	-0.46	1.18e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9311676	0.632	rs34086582	chr3:58419944	C/T	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.39e-10	Systemic lupus erythematosus;
CRC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg10677697	chr7:45961126	IGFBP3	0.36	6.34	0.33	7.54e-10	Sitting height ratio;
CRC	cis	rs6694672	0.681	rs865071	chr1:197017976	G/A	cg13682187	chr1:196946512	CFHR5	0.48	7.43	0.38	9.48e-13	Asthma;
CRC	cis	rs12024301	0.557	rs10911411	chr1:183661522	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg20169779	chr10:135381914	SYCE1	0.54	8.71	0.43	1.45e-16	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16294016	chr4:190862268	FRG1	0.42	6.92	0.36	2.44e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.48	-6.06	-0.32	3.67e-9	Aortic root size;
CRC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg20744362	chr22:50050164	C22orf34	0.31	5.72	0.3	2.37e-8	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.16	11.31	0.53	2.79e-25	Skin colour saturation;
CRC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.44	5.87	0.31	1.09e-8	Schizophrenia;
CRC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.46	-6.74	-0.35	7.09e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.37	-5.64	-0.3	3.63e-8	Endometrial cancer;
CRC	cis	rs9303542	0.559	rs12603976	chr17:46617163	C/A	cg04904318	chr17:46607828	HOXB1	-0.52	-6.11	-0.32	2.82e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs77633900	0.772	rs284884	chr15:76828289	A/G	cg21673338	chr15:77095150	SCAPER	-0.71	-6.2	-0.32	1.71e-9	Non-glioblastoma glioma;Glioma;
CRC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.58	9.48	0.46	5.35e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg14458575	chr2:238380390	NA	0.45	6.46	0.34	3.83e-10	Prostate cancer;
CRC	cis	rs4666002	0.956	rs13020949	chr2:27836605	C/T	cg27432699	chr2:27873401	GPN1	0.48	6.18	0.32	1.89e-9	Phospholipid levels (plasma);
CRC	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.38	-11.34	-0.53	2.14e-25	Psoriasis vulgaris;
CRC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14828511	chr1:107599125	PRMT6	-0.54	-7.49	-0.38	6.29e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9826463	0.527	rs56088529	chr3:142146369	A/G	cg20824294	chr3:142316082	PLS1	0.35	5.64	0.3	3.61e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg16876255	chr19:9731953	ZNF561	0.68	5.71	0.3	2.5e-8	Pursuit maintenance gain;
CRC	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.25	14.99	0.64	4.45e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg11901034	chr3:128598214	ACAD9	0.52	7.56	0.38	4.1e-13	IgG glycosylation;
CRC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg07074390	chr21:40555500	PSMG1	-0.45	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg07274523	chr3:49395745	GPX1	0.47	6.41	0.33	5.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs587242	0.955	rs4949996	chr1:96965124	A/T	cg10631902	chr5:14652156	NA	0.4	6.15	0.32	2.23e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16587860	chr12:123459310	OGFOD2;ABCB9	0.43	6.12	0.32	2.64e-9	Response to antipsychotic treatment;
CRC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-1.13	-10.47	-0.5	2.57e-22	Thyroid stimulating hormone;
CRC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg04553112	chr3:125709451	NA	-0.51	-5.89	-0.31	9.55e-9	Blood pressure (smoking interaction);
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.45	6.68	0.35	1.01e-10	Obesity-related traits;
CRC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-8.13	-0.41	8.73e-15	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.3	-0.37	2.12e-12	Type 2 diabetes;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg14487702	chr8:22132665	PIWIL2	0.38	5.68	0.3	3.04e-8	Hypertriglyceridemia;
CRC	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg17691542	chr6:26056736	HIST1H1C	0.67	8.29	0.42	2.95e-15	Iron status biomarkers;
CRC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06544989	chr22:39130855	UNC84B	0.44	6.84	0.35	3.76e-11	Menopause (age at onset);
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11645453	chr3:52864694	ITIH4	0.34	6.27	0.33	1.12e-9	Electroencephalogram traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14266050	chr4:2845671	ADD1	-0.41	-6.05	-0.32	3.95e-9	Myopia (pathological);
CRC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.78	7.73	0.39	1.29e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.42	-0.38	9.83e-13	Diisocyanate-induced asthma;
CRC	cis	rs501120	0.584	rs61857484	chr10:44719215	C/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg08885800	chr1:201084119	NA	0.42	7.43	0.38	9.59e-13	Permanent tooth development;
CRC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg14122633	chr5:456516	EXOC3	-0.39	-6.89	-0.36	2.78e-11	Cystic fibrosis severity;
CRC	cis	rs7680126	0.500	rs11735668	chr4:10148655	C/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-5.9	-0.31	8.88e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.7	-0.3	2.64e-8	Blood trace element (Cu levels);
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.43	6.29	0.33	1.02e-9	Height;
CRC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.78	0.44	8.97e-17	Hip circumference adjusted for BMI;
CRC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.21	0.32	1.58e-9	Diabetic retinopathy;
CRC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.78	0.3	1.71e-8	Obesity-related traits;
CRC	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	7.79	0.39	8.75e-14	Body mass index;
CRC	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.57	8.71	0.43	1.52e-16	Testicular germ cell tumor;
CRC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg21782813	chr7:2030301	MAD1L1	-0.37	-5.73	-0.3	2.28e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	6.73	0.35	7.62e-11	Initial pursuit acceleration;
CRC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.39	-7.47	-0.38	7.34e-13	Monocyte count;Monocyte percentage of white cells;
CRC	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg12315302	chr6:26189340	HIST1H4D	0.71	6.01	0.31	5.02e-9	Depression;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.63	-10.28	-0.49	1.12e-21	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.46	-0.57	1.86e-29	Leprosy;
CRC	cis	rs10208940	0.764	rs6546420	chr2:68799454	G/A	cg12452813	chr2:68675892	NA	0.47	5.93	0.31	7.79e-9	Urate levels in lean individuals;
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.7	11.35	0.53	1.96e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.54	7.05	0.36	1.08e-11	Neutrophil percentage of white cells;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg19761014	chr17:28927070	LRRC37B2	0.58	5.85	0.31	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	6.49	0.34	3.22e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9311676	0.632	rs6774357	chr3:58361530	A/C	cg06643156	chr3:58380774	PXK	0.43	6.73	0.35	7.6e-11	Systemic lupus erythematosus;
CRC	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg25809561	chr17:30822961	MYO1D	0.51	9.16	0.45	5.77e-18	Schizophrenia;
CRC	trans	rs4733601	0.659	rs12156376	chr8:129253823	A/G	cg01372202	chr19:50097851	PRR12	0.38	5.97	0.31	6.15e-9	Diffuse large B cell lymphoma;
CRC	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.05	-0.32	3.93e-9	Systemic lupus erythematosus;
CRC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg05585544	chr11:47624801	NA	-0.5	-8.79	-0.44	8.59e-17	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23024448	chr19:51222118	NA	0.37	6.23	0.32	1.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs965469	1.000	rs2092990	chr20:3346338	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.77	-0.3	1.81e-8	IFN-related cytopenia;
CRC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.54	9.09	0.45	9.44e-18	Gestational age at birth (maternal effect);
CRC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.62	-9.97	-0.48	1.21e-20	Aortic root size;
CRC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg14711859	chr11:8959438	ASCL3	0.46	7.07	0.36	9.17e-12	Hemoglobin concentration;
CRC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-9.75	-0.47	6.55e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs17767392	0.836	rs2332640	chr14:72044547	C/T	cg13720639	chr14:72061746	SIPA1L1	0.57	7.06	0.36	1.01e-11	Mitral valve prolapse;
CRC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg05623727	chr3:50126028	RBM5	-0.45	-7.5	-0.38	5.92e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg04155289	chr7:94953770	PON1	-0.59	-7.48	-0.38	6.83e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	8.82e-9	Red blood cell count;
CRC	cis	rs932287	0.858	rs7109896	chr11:9054522	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.61	0.34	1.52e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.87	-15.89	-0.66	1.31e-42	Coronary artery disease;
CRC	trans	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.05e-13	Diabetic kidney disease;
CRC	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.74	8.53	0.43	5.62e-16	Eotaxin levels;
CRC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.64	-0.43	2.57e-16	Platelet count;
CRC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg10398005	chr11:117014888	PAFAH1B2	-0.4	-5.74	-0.3	2.2e-8	Blood protein levels;
CRC	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	0.73	7.66	0.39	2.12e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg21251018	chr6:28226885	NKAPL	0.4	6.1	0.32	2.93e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs185694	0.947	rs595451	chr13:30896848	T/C	cg07600127	chr13:30881527	KATNAL1	-0.56	-6.05	-0.32	3.94e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs12230513	0.732	rs4130004	chr12:55860773	G/T	cg19537932	chr12:55886519	OR6C68	-0.73	-9.4	-0.46	9.2e-19	Contrast sensitivity;
CRC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.12	0.41	9.56e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg15704280	chr7:45808275	SEPT13	0.61	6.02	0.31	4.62e-9	Axial length;
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.49	7.21	0.37	3.79e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg10263370	chr3:44754102	ZNF502	0.37	6.22	0.32	1.53e-9	Depressive symptoms;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.67	7.53	0.38	5.04e-13	Body mass index;
CRC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.96	-0.4	2.83e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.6	-6.68	-0.35	1.04e-10	Blood protein levels;
CRC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.67	-10.45	-0.5	2.96e-22	Testicular germ cell tumor;
CRC	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.56	5.93	0.31	7.64e-9	Mean platelet volume;
CRC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.68	0.35	1.04e-10	Tonsillectomy;
CRC	cis	rs8016982	1.000	rs8016982	chr14:81707057	C/T	cg01989461	chr14:81687754	GTF2A1	0.41	5.73	0.3	2.22e-8	Schizophrenia;
CRC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.93	-0.31	7.62e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs802075	0.764	rs13202956	chr6:49652613	C/T	cg20364632	chr6:49636226	NA	-0.41	-6.86	-0.35	3.51e-11	Bone mineral density (hip) and age at menarche;
CRC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.9	-14.88	-0.63	1.14e-38	Headache;
CRC	cis	rs9391253	0.534	rs1933802	chr6:105365891	C/G	cg02098413	chr6:105308735	HACE1	0.31	5.65	0.3	3.44e-8	Height;Age at voice drop;Puberty onset (breast development);
CRC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg01304814	chr3:48885189	PRKAR2A	0.87	6.49	0.34	3.07e-10	Cognitive function;
CRC	cis	rs2997447	0.846	rs61775419	chr1:26395539	C/T	cg24519413	chr1:26490540	NA	0.46	5.66	0.3	3.22e-8	QRS complex (12-leadsum);
CRC	cis	rs185694	0.779	rs628483	chr13:30895462	C/T	cg07600127	chr13:30881527	KATNAL1	-0.51	-5.8	-0.3	1.52e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.42	-0.42	1.16e-15	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg03013636	chr16:1946785	NA	0.55	6.89	0.36	2.82e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.57	-8.91	-0.44	3.6e-17	HDL cholesterol;
CRC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.66	9.12	0.45	7.86e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs728616	0.510	rs35671072	chr10:82172255	A/G	cg05935833	chr10:81318306	SFTPA2	-0.56	-6.86	-0.35	3.32e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.88	-13.59	-0.6	1.11e-33	Blood trace element (Zn levels);
CRC	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.41e-13	Corneal astigmatism;
CRC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg04155289	chr7:94953770	PON1	-0.6	-7.41	-0.38	1.05e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3751196	0.710	rs55993375	chr12:104220684	T/C	cg02344784	chr12:104178138	NT5DC3	0.71	7.28	0.37	2.55e-12	Sense of smell;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18402987	chr7:1209562	NA	0.42	5.92	0.31	7.97e-9	Longevity;Endometriosis;
CRC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.88	-15.84	-0.66	2.09e-42	Height;
CRC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.4	0.38	1.13e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg17147758	chr8:6949321	NA	-0.52	-7.18	-0.37	4.67e-12	Blood pressure (smoking interaction);
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.64	7.21	0.37	3.87e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.64	-9.41	-0.46	8.65e-19	Menarche (age at onset);
CRC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.47	7.31	0.37	2e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.52	-6.01	-0.31	4.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-7.7	-0.39	1.56e-13	Intelligence (multi-trait analysis);
CRC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.68	-6.81	-0.35	4.51e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-7.9	-0.4	4.16e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.29	5.97	0.31	6.12e-9	Homoarginine levels;
CRC	cis	rs601339	0.938	rs1696345	chr12:123183060	T/G	cg22192744	chr12:123187474	GPR109A	-0.4	-5.61	-0.3	4.33e-8	Adiponectin levels;
CRC	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06470822	chr6:28175283	NA	0.72	5.76	0.3	1.89e-8	Depression;
CRC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.51	10.38	0.5	4.96e-22	Bone mineral density;
CRC	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.44	5.74	0.3	2.13e-8	Recombination rate (females);
CRC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.84	0.31	1.25e-8	Tonsillectomy;
CRC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.67	9.49	0.46	4.72e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.59	9.03	0.45	1.52e-17	Extrinsic epigenetic age acceleration;
CRC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.64	7.34	0.38	1.63e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2013441	1.000	rs2058971	chr17:20219508	T/A	cg13482628	chr17:19912719	NA	-0.42	-6.55	-0.34	2.25e-10	Obesity-related traits;
CRC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.74	10.46	0.5	2.8e-22	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg18758796	chr5:131593413	PDLIM4	0.36	6.46	0.34	3.74e-10	Blood metabolite levels;
CRC	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg09760422	chr2:128146352	NA	-0.29	-5.64	-0.3	3.61e-8	Protein C levels;
CRC	cis	rs4737010	0.644	rs555466	chr8:41610346	G/A	cg17182837	chr8:41585554	ANK1	0.52	7.49	0.38	6.54e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.37	5.89	0.31	9.67e-9	Total body bone mineral density;
CRC	cis	rs7605827	0.930	rs7605727	chr2:15598693	A/G	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.45	-6.67	-0.35	1.07e-10	Breast cancer;
CRC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.8	0.7	4.05e-50	Platelet count;
CRC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.91	-0.36	2.51e-11	Alzheimer's disease (late onset);
CRC	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.58	9.94	0.48	1.58e-20	Leprosy;
CRC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg08075719	chr14:103021372	NA	-0.67	-7.91	-0.4	3.96e-14	Platelet count;
CRC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.48	-6.78	-0.35	5.6e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.49	7.12	0.37	7.01e-12	Colorectal cancer;
CRC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.36	0.38	1.44e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg19025524	chr12:109796872	NA	-0.47	-6.68	-0.35	1.02e-10	Neuroticism;
CRC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.47	-5.88	-0.31	9.99e-9	Gut microbiome composition (summer);
CRC	cis	rs8105895	0.935	rs4542784	chr19:22239751	G/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.58	11.98	0.55	1.12e-27	Airflow obstruction;
CRC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.33	5.75	0.3	2.07e-8	Blood protein levels;
CRC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg25452165	chr22:42524984	CYP2D6	0.42	6.37	0.33	6.36e-10	Schizophrenia;
CRC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg25985355	chr7:65971099	NA	-0.53	-5.98	-0.31	5.75e-9	Diabetic kidney disease;
CRC	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-5.89	-0.31	9.69e-9	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9462027	0.628	rs6937132	chr6:34799221	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	1.03	18.31	0.71	3.83e-52	Parkinson's disease;
CRC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.67	10.84	0.51	1.26e-23	Breast cancer;
CRC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.16	0.32	2.08e-9	Cognitive ability;
CRC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.86e-9	Diabetic kidney disease;
CRC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.79	0.39	8.67e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-9.8	-0.48	4.79e-20	Monocyte count;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg25164649	chr6:28176230	NA	0.7	7.91	0.4	3.86e-14	Parkinson's disease;
CRC	cis	rs11212617	0.967	rs12272183	chr11:108077181	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.38	5.7	0.3	2.65e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg06470822	chr6:28175283	NA	0.64	9.08	0.45	1.04e-17	Parkinson's disease;
CRC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg06363034	chr20:62225388	GMEB2	-0.43	-6.66	-0.34	1.13e-10	Glioblastoma;
CRC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.4	6.76	0.35	6.24e-11	Diastolic blood pressure;
CRC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg04969067	chr8:143858791	LYNX1	-0.42	-7.08	-0.36	8.99e-12	Urinary tract infection frequency;
CRC	cis	rs72730918	0.618	rs1531156	chr15:51990057	G/T	cg14296394	chr15:51910925	DMXL2	0.45	5.79	0.3	1.6e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg16141378	chr3:129829833	LOC729375	0.41	6.21	0.32	1.56e-9	Neuroticism;
CRC	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20750642	chr13:99100586	FARP1	0.39	5.7	0.3	2.7e-8	Neuroticism;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23161317	chr6:28129485	ZNF389	0.54	6.47	0.34	3.49e-10	Depression;
CRC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.61	-9.82	-0.48	3.83e-20	P wave terminal force;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.77	-0.35	6.02e-11	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg18833306	chr6:118973337	C6orf204	0.44	5.98	0.31	5.77e-9	Diastolic blood pressure;
CRC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg18876405	chr7:65276391	NA	0.45	6.32	0.33	8.5e-10	Aortic root size;
CRC	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.33	-5.87	-0.31	1.08e-8	Blood metabolite levels;
CRC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg03037974	chr15:76606532	NA	-0.49	-7.29	-0.37	2.37e-12	Blood metabolite levels;
CRC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg05139728	chr16:28306816	SBK1	-0.37	-6.12	-0.32	2.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6706785	0.660	rs6727608	chr2:240443992	T/C	cg03276489	chr2:240449683	NA	-0.53	-6.41	-0.33	4.98e-10	Conotruncal heart defects;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03195230	chr11:64073135	ESRRA	0.44	6.0	0.31	5.09e-9	Anxiety disorder;
CRC	trans	rs2380220	1.000	rs6931299	chr6:95969842	A/T	cg09420816	chr15:77925960	LINGO1	-0.59	-6.19	-0.32	1.77e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg00935504	chr16:1863053	HAGH	0.31	5.62	0.3	4.07e-8	Blood metabolite levels;
CRC	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg18758796	chr5:131593413	PDLIM4	0.34	5.96	0.31	6.35e-9	Blood metabolite levels;
CRC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.57	-0.34	1.92e-10	Total cholesterol levels;
CRC	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.53	9.48	0.46	5.15e-19	Blood metabolite ratios;
CRC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg18827107	chr12:86230957	RASSF9	-0.47	-7.82	-0.4	7.27e-14	Major depressive disorder;
CRC	trans	rs1590305	0.686	rs7337526	chr13:38061307	C/T	cg03965764	chr11:45248109	NA	-0.61	-6.17	-0.32	2.01e-9	Hip geometry;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20355731	chr12:37942439	NA	0.44	6.83	0.35	4.2e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27231188	chr1:233464510	KIAA1804	0.47	6.78	0.35	5.5e-11	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10902427	chr5:176944034	DDX41	0.45	7.56	0.38	4.16e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.5	7.42	0.38	1.03e-12	Platelet distribution width;
CRC	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.52	8.76	0.43	1.07e-16	Facial morphology (factor 15, philtrum width);
CRC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg10272801	chr16:14013773	ERCC4	-0.67	-6.07	-0.32	3.6e-9	Cognitive function;
CRC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.65	-10.45	-0.5	2.94e-22	Breast cancer;
CRC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg01657329	chr11:68192670	LRP5	-0.46	-6.58	-0.34	1.89e-10	Total body bone mineral density;
CRC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.41	-0.33	5.1e-10	Breast cancer;
CRC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg03037974	chr15:76606532	NA	-0.55	-8.23	-0.41	4.29e-15	Blood metabolite levels;
CRC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg26248373	chr2:1572462	NA	-0.64	-7.08	-0.36	8.94e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg15845792	chr6:28175446	NA	0.88	8.42	0.42	1.18e-15	Parkinson's disease;
CRC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.58	-0.34	1.85e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4073416	0.535	rs7150448	chr14:65871502	C/T	cg03016385	chr14:66212404	NA	-0.43	-5.86	-0.31	1.11e-8	N-glycan levels;
CRC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.29	-0.49	1.01e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.66	-8.0	-0.4	2.14e-14	IgG glycosylation;
CRC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.51	5.63	0.3	3.96e-8	Vitiligo;
CRC	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.08	-0.36	8.77e-12	HDL cholesterol;
CRC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.51	-7.58	-0.39	3.66e-13	Response to temozolomide;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18827097	chr2:3522506	ADI1	0.48	7.08	0.36	8.82e-12	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.01	0.31	4.88e-9	Prudent dietary pattern;
CRC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.71	10.95	0.52	5.3e-24	Corneal astigmatism;
CRC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.9	-0.31	8.92e-9	Vascular endothelial growth factor levels;
CRC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-12.05	-0.55	6.16e-28	Platelet count;
CRC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg10645314	chr2:3704589	ALLC	-0.47	-5.83	-0.31	1.31e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-1.01	-14.0	-0.61	3.04e-35	Exhaled nitric oxide output;
CRC	cis	rs4926298	1.000	rs1077151	chr19:13151108	A/G	cg23899408	chr19:12877188	HOOK2	-0.47	-6.5	-0.34	2.99e-10	Bipolar disorder;
CRC	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg22654517	chr2:96458247	NA	0.33	6.02	0.32	4.57e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.59	-8.65	-0.43	2.27e-16	Menarche (age at onset);
CRC	trans	rs6956675	1.000	rs6968327	chr7:62574489	A/G	cg01314568	chr7:57830625	NA	-0.67	-9.18	-0.45	4.9e-18	Obesity-related traits;
CRC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.68	9.02	0.45	1.55e-17	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg20356878	chr3:121714668	ILDR1	0.51	7.93	0.4	3.43e-14	Cognitive performance;
CRC	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.87	-0.31	1.07e-8	Height;
CRC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.89	-0.31	9.59e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg24562669	chr7:97807699	LMTK2	0.42	6.95	0.36	1.95e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs3857067	1.000	rs28876091	chr4:95000394	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.04	-0.32	4.06e-9	QT interval;
CRC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg25876840	chr17:41920477	NA	0.44	6.55	0.34	2.26e-10	Triglycerides;
CRC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.84	0.31	1.26e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg10729496	chr3:10149963	C3orf24	0.49	6.38	0.33	5.96e-10	Alzheimer's disease;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.69	0.35	9.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.72	8.56	0.43	4.45e-16	Response to hepatitis C treatment;
CRC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-7.41	-0.38	1.1e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.83	-0.35	4.04e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.48	7.43	0.38	9.4e-13	Corneal astigmatism;
CRC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	1.02	20.45	0.75	1.42e-60	Headache;
CRC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.44	-0.33	4.27e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg27588902	chr6:42928151	GNMT	-0.39	-7.19	-0.37	4.46e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	12.08	0.55	4.67e-28	Menopause (age at onset);
CRC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.62	-9.02	-0.45	1.61e-17	Other erythrocyte phenotypes;
CRC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.97	-11.61	-0.54	2.4e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15099042	chr20:44563274	PCIF1	0.46	6.44	0.33	4.28e-10	Anxiety disorder;
CRC	cis	rs4664293	0.836	rs2556102	chr2:160655122	C/T	cg08347373	chr2:160653686	CD302	-0.51	-7.87	-0.4	5.14e-14	Monocyte percentage of white cells;
CRC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.52	7.5	0.38	5.99e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.69	7.93	0.4	3.51e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.51	10.49	0.5	2.05e-22	Renal cell carcinoma;
CRC	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg06632207	chr12:54070931	ATP5G2	0.4	6.76	0.35	6.3e-11	Height;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg15845792	chr6:28175446	NA	-0.63	-9.49	-0.46	4.81e-19	Cardiac Troponin-T levels;
CRC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.37	-0.5	5.56e-22	Breast cancer;
CRC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg24375607	chr4:120327624	NA	0.47	7.45	0.38	8.16e-13	Corneal astigmatism;
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg07507251	chr3:52567010	NT5DC2	0.5	7.83	0.4	6.71e-14	Electroencephalogram traits;
CRC	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg03339077	chr11:47165057	C11orf49	0.44	6.27	0.33	1.14e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.06	-12.27	-0.56	9.34e-29	Diabetic kidney disease;
CRC	trans	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg25411327	chr19:5210703	PTPRS	0.58	6.0	0.31	5.21e-9	Schizophrenia;
CRC	trans	rs4684776	0.606	rs17833547	chr3:11655204	T/C	cg20302342	chr1:156215951	PAQR6	-0.45	-6.04	-0.32	4.27e-9	Small vessel stroke;
CRC	trans	rs4687833	0.874	rs1468738	chr3:118631621	C/A	cg20439624	chr19:44010874	ETHE1	-0.45	-6.04	-0.32	4.13e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CRC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.95	-17.98	-0.7	8.09e-51	Height;
CRC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.55	6.35	0.33	7.07e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.94	14.31	0.62	1.87e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.43e-13	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02679955	chr17:73521473	LLGL2	0.43	5.96	0.31	6.48e-9	Response to antipsychotic treatment;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg15845792	chr6:28175446	NA	0.64	9.61	0.47	1.97e-19	Cardiac Troponin-T levels;
CRC	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.43	6.64	0.34	1.27e-10	Red blood cell count;
CRC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.46	7.78	0.39	9.74e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.47	7.57	0.39	3.86e-13	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.22	-0.56	1.48e-28	Alzheimer's disease;
CRC	cis	rs8060686	0.748	rs3785098	chr16:67993643	T/C	cg07125278	chr16:67683757	RLTPR	-0.44	-5.69	-0.3	2.78e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.79	8.19	0.41	5.81e-15	Diabetic retinopathy;
CRC	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.69	-7.77	-0.39	1.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.47	6.62	0.34	1.46e-10	DNA methylation (variation);
CRC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg23262073	chr20:60523788	NA	-0.42	-6.69	-0.35	9.36e-11	Body mass index;
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.22e-9	Diastolic blood pressure;
CRC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.63	0.39	2.52e-13	Mean platelet volume;
CRC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.85	-0.35	3.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-10.75	-0.51	2.75e-23	Platelet distribution width;
CRC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.53	8.08	0.41	1.27e-14	Alzheimer's disease (late onset);
CRC	cis	rs13144136	0.643	rs4339204	chr4:10661011	A/T	cg10242279	chr4:10666415	CLNK	-0.37	-6.47	-0.34	3.53e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05665937	chr4:1216051	CTBP1	-0.38	-5.83	-0.31	1.36e-8	Obesity-related traits;
CRC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.77	-0.3	1.83e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12286929	0.668	rs17304149	chr11:115049180	C/T	cg04055981	chr11:115044050	NA	0.4	6.24	0.33	1.35e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.34	0.38	1.66e-12	Eye color traits;
CRC	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.71	-0.35	8.48e-11	IgG glycosylation;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.66	-11.34	-0.53	2.26e-25	Lewy body disease;
CRC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.6	10.83	0.51	1.4e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.02	0.45	1.6e-17	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs10242455	0.571	rs117370443	chr7:98975258	T/C	cg18809830	chr7:99032528	PTCD1	-0.96	-7.13	-0.37	6.4e-12	Blood metabolite levels;
CRC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08064720	chr7:152131894	MLL3	0.46	6.55	0.34	2.19e-10	Response to antipsychotic treatment;
CRC	cis	rs1223397	0.938	rs17767967	chr6:13282067	C/T	cg20827128	chr6:13274284	PHACTR1	0.55	6.55	0.34	2.19e-10	Blood pressure;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.52	-0.38	5.09e-13	Breast cancer;
CRC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.64	-9.73	-0.47	8.04e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.67	9.93	0.48	1.65e-20	Menopause (age at onset);
CRC	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg00319359	chr11:70116639	PPFIA1	0.65	6.51	0.34	2.81e-10	Coronary artery disease;
CRC	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.92	-0.36	2.41e-11	Multiple sclerosis;
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg22638593	chr5:131593259	PDLIM4	0.41	7.57	0.39	3.83e-13	Breast cancer;
CRC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	0.98	14.83	0.63	1.86e-38	Cognitive function;
CRC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.41	-7.46	-0.38	7.78e-13	Height;
CRC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg11189052	chr15:85197271	WDR73	0.61	8.94	0.44	2.8e-17	Schizophrenia;
CRC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	11.74	0.54	7.86e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg15468180	chr1:107600409	PRMT6	0.39	5.79	0.3	1.66e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20092199	chr4:1342459	KIAA1530	-0.42	-7.77	-0.39	1.02e-13	Obesity-related traits;
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg03623178	chr6:28175578	NA	0.94	13.49	0.6	2.5e-33	Depression;
CRC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.77	14.67	0.63	7.87e-38	Body mass index;
CRC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg04990556	chr1:26633338	UBXN11	-0.48	-6.17	-0.32	2.06e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10924970	0.687	rs10802438	chr1:235357543	A/G	cg09010748	chr1:235293032	TOMM20	-0.41	-5.7	-0.3	2.6e-8	Asthma;
CRC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.74	-12.74	-0.57	1.72e-30	Body mass index;
CRC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.4	7.09	0.36	8.03e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.09	0.41	1.2e-14	Menopause (age at onset);
CRC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.42	-5.63	-0.3	3.82e-8	Reticulocyte count;
CRC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.4	6.38	0.33	5.99e-10	Dupuytren's disease;
CRC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.57	0.38	3.89e-13	Lung cancer;
CRC	cis	rs12760731	0.582	rs12048597	chr1:178538316	T/A	cg00404053	chr1:178313656	RASAL2	0.63	7.09	0.36	8.37e-12	Obesity-related traits;
CRC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.51	0.69	5.94e-49	Platelet count;
CRC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.33	-5.79	-0.3	1.69e-8	Menarche (age at onset);
CRC	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg09597638	chr17:3907349	NA	0.45	5.77	0.3	1.8e-8	Type 2 diabetes;
CRC	trans	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg02869306	chr7:64672164	INTS4L1	-0.45	-6.47	-0.34	3.49e-10	Aortic root size;
CRC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg22110888	chr17:80059540	CCDC57	0.42	6.64	0.34	1.33e-10	Life satisfaction;
CRC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.49	-8.13	-0.41	8.67e-15	Huntington's disease progression;
CRC	cis	rs7692995	1.000	rs34683079	chr4:17939302	T/C	cg08925142	chr4:18023851	LCORL	-0.52	-5.81	-0.31	1.45e-8	Height;
CRC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.47	7.33	0.37	1.83e-12	Longevity;
CRC	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.47	0.38	7.39e-13	Neuroticism;
CRC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.16	-0.37	5.17e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.2	-0.41	5.32e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg21153622	chr11:89784906	NA	-0.5	-8.35	-0.42	1.94e-15	Coronary artery disease;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12172441	chr6:28176163	NA	0.6	7.2	0.37	4.23e-12	Depression;
CRC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.86	10.55	0.5	1.34e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.95	0.31	6.99e-9	Rheumatoid arthritis;
CRC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	10.78	0.51	2.09e-23	Total cholesterol levels;
CRC	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.75	-0.35	6.61e-11	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17452277	chr8:110551976	EBAG9	0.41	6.37	0.33	6.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg13491945	chr12:107078410	RFX4	-0.34	-5.83	-0.31	1.32e-8	Heart rate;
CRC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-8.45	-0.42	9.71e-16	Chronic sinus infection;
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	6.81	0.35	4.51e-11	Breast cancer;
CRC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.7	12.17	0.56	2.25e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-14.83	-0.63	1.88e-38	Vitiligo;
CRC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.46	6.82	0.35	4.33e-11	Colorectal cancer;
CRC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.77	0.3	1.87e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.64	0.75	2.54e-61	Prudent dietary pattern;
CRC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.88	-16.26	-0.67	4.65e-44	Dementia with Lewy bodies;
CRC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.46	6.53	0.34	2.51e-10	Cognitive ability;
CRC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg16447950	chr5:562315	NA	-0.81	-10.62	-0.51	7.76e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.37	-5.92	-0.31	7.9e-9	Ulcerative colitis;
CRC	cis	rs9549328	0.700	rs4907568	chr13:113617574	A/T	cg08614441	chr13:113633676	MCF2L	-0.4	-7.07	-0.36	9.06e-12	Systolic blood pressure;
CRC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.39	-6.07	-0.32	3.55e-9	Crohn's disease;
CRC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	0.99	10.21	0.49	1.91e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg12311346	chr5:56204834	C5orf35	-0.5	-7.7	-0.39	1.5700000000000001e-13	Coronary artery disease;
CRC	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.57	-5.95	-0.31	7.01e-9	QRS complex (12-leadsum);
CRC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.58	8.29	0.42	2.82e-15	Arsenic metabolism;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12273811	chr6:28175739	NA	0.72	9.05	0.45	1.25e-17	Depression;
CRC	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg15083037	chr5:83017644	HAPLN1	0.51	7.33	0.37	1.83e-12	Prostate cancer;
CRC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.75	0.43	1.13e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01769160	chr11:20408933	PRMT3	0.44	6.14	0.32	2.34e-9	Response to antipsychotic treatment;
CRC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.33	-0.46	1.67e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.42	6.24	0.33	1.38e-9	Morning vs. evening chronotype;
CRC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-19.57	-0.73	4.19e-57	Prudent dietary pattern;
CRC	cis	rs911119	0.955	rs12625716	chr20:23606845	A/G	cg16589663	chr20:23618590	CST3	-0.52	-6.95	-0.36	1.92e-11	Chronic kidney disease;
CRC	cis	rs9463078	0.547	rs2038557	chr6:44740471	G/A	cg25276700	chr6:44698697	NA	0.3	7.76	0.39	1.09e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.38	0.42	1.57e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05062674	chr16:89882627	FANCA	0.42	6.84	0.35	3.8e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg24375607	chr4:120327624	NA	0.48	7.5	0.38	6.14e-13	Corneal astigmatism;
CRC	cis	rs629535	0.821	rs497398	chr8:70037434	A/T	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.33	-0.33	7.93e-10	Aortic root size;
CRC	cis	rs3767633	0.925	rs1394070	chr1:161814020	T/G	cg09175582	chr1:161736000	ATF6	0.69	6.26	0.33	1.18e-9	IgG glycosylation;
CRC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.82	9.99	0.48	1.11e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg18721089	chr20:30220636	NA	-0.36	-5.75	-0.3	2.07e-8	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.79	-0.35	5.16e-11	Type 2 diabetes;
CRC	cis	rs4700695	0.925	rs4700692	chr5:65396279	T/C	cg21114390	chr5:65439923	SFRS12	-0.54	-6.87	-0.35	3.19e-11	Facial morphology (factor 19);
CRC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.96	-18.51	-0.71	6.54e-53	Height;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg02683197	chr6:28174875	NA	0.79	9.81	0.48	4.32e-20	Depression;
CRC	cis	rs11212617	0.935	rs12792979	chr11:108335378	C/T	cg01991180	chr11:108092276	ATM;NPAT	-0.39	-5.61	-0.3	4.3e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg23609571	chr14:70655845	SLC8A3	-0.3	-6.14	-0.32	2.35e-9	Prostate cancer;
CRC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg03340356	chr1:67600835	NA	0.3	6.73	0.35	7.62e-11	Psoriasis;
CRC	trans	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg20935933	chr6:143382018	AIG1	0.52	6.56	0.34	2.1e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs5417	0.775	rs222852	chr17:7140606	A/G	cg15655154	chr3:113604241	GRAMD1C	0.53	9.11	0.45	8e-18	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01217080	chr12:54773536	ZNF385A	0.4	6.45	0.34	3.9e-10	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.37	-5.67	-0.3	3.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.61	8.14	0.41	7.99e-15	Mean platelet volume;
CRC	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.62	-11.81	-0.55	4.59e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs6834538	0.519	rs1843728	chr4:113413127	A/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.78	-0.3	1.74e-8	Free thyroxine concentration;
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.32	-0.59	1.17e-32	Alzheimer's disease;
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.91	0.36	2.55e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	10.88	0.51	9.12e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs3789045	0.774	rs12039365	chr1:204488687	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.57	-7.95	-0.4	3.06e-14	Educational attainment (college completion);
CRC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.1	17.28	0.69	4.41e-48	Testicular germ cell tumor;
CRC	cis	rs8041447	0.832	rs7350775	chr15:63056159	A/T	cg12790106	chr15:63105204	TLN2	-0.41	-6.2	-0.32	1.64e-9	Immature fraction of reticulocytes;
CRC	cis	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg17885191	chr8:135476712	NA	0.66	7.65	0.39	2.3e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs2108622	0.958	rs79400241	chr19:15984402	C/G	cg13772218	chr19:15982569	NA	0.46	6.23	0.32	1.41e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg15511327	chr8:143859410	LYNX1	0.42	7.45	0.38	8.2e-13	Urinary tract infection frequency;
CRC	trans	rs800082	1.000	rs1405597	chr3:144314276	A/C	cg24215973	chr2:240111563	HDAC4	-0.51	-7.2	-0.37	4.05e-12	Smoking behavior;
CRC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.49	7.88	0.4	4.72e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.42	6.26	0.33	1.22e-9	Emphysema distribution in smoking;
CRC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.66	8.77	0.44	9.7e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg15845792	chr6:28175446	NA	-0.59	-6.23	-0.32	1.44e-9	Depression;
CRC	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.07	-0.32	3.59e-9	Educational attainment (years of education);
CRC	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg10724054	chr17:3904396	NA	-0.46	-7.52	-0.38	5.33e-13	Type 2 diabetes;
CRC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.69	11.31	0.53	2.9e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.68	7.65	0.39	2.23e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg06882758	chr19:58662330	ZNF329	0.73	7.69	0.39	1.71e-13	Cholesterol, total;
CRC	cis	rs992157	0.764	rs3731861	chr2:219191256	T/C	cg04880052	chr2:219191631	PNKD	-0.44	-6.55	-0.34	2.23e-10	Colorectal cancer;
CRC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-6.32	-0.33	8.69e-10	Schizophrenia;
CRC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg03233332	chr7:66118400	NA	-0.42	-5.79	-0.3	1.6e-8	Aortic root size;
CRC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	ch.11.42038R	chr11:967971	AP2A2	0.58	10.01	0.48	9.05e-21	Alzheimer's disease (late onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11140307	chr16:66730384	CMTM4	0.44	6.51	0.34	2.86e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3889199	1.000	rs3889199	chr1:59653742	A/G	cg25881383	chr1:59680599	NA	-0.37	-6.02	-0.31	4.68e-9	Pulse pressure;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg05569086	chr8:143859399	LYNX1	-0.4	-6.25	-0.33	1.27e-9	Urinary tract infection frequency;
CRC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.66	-9.38	-0.46	1.12e-18	DNA methylation (variation);
CRC	cis	rs2929278	0.588	rs688009	chr15:44156302	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	6.33	0.33	7.91e-10	Schizophrenia;
CRC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.15	0.41	7.87e-15	Platelet count;
CRC	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.83	0.4	6.88e-14	Neuroticism;
CRC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.92	-16.06	-0.66	3.01e-43	Height;
CRC	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.32	-6.6	-0.34	1.6e-10	Cutaneous nevi;
CRC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.54	0.47	3.27e-19	Lymphocyte counts;
CRC	cis	rs5745709	0.861	rs2214825	chr7:81371619	A/G	cg18944653	chr7:81381353	HGF	-0.3	-5.79	-0.3	1.64e-8	Gout;
CRC	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	9.49e-20	Hair morphology;
CRC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	0.85	8.82	0.44	7.03e-17	Skin colour saturation;
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.15	0.74	2.13e-59	Prudent dietary pattern;
CRC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg23625390	chr15:77176239	SCAPER	0.49	7.17	0.37	4.83e-12	Blood metabolite levels;
CRC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-8.41	-0.42	1.26e-15	Uric acid levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17706896	chr19:46406599	MYPOP	0.44	6.63	0.34	1.34e-10	Response to antipsychotic treatment;
CRC	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.56	-0.38	4.15e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs3791556	1.000	rs3791568	chr2:240115701	G/A	cg03281426	chr2:240109471	HDAC4	0.62	6.74	0.35	7.01e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.62	-8.8	-0.44	7.77e-17	Carotid intima media thickness;
CRC	cis	rs6546324	0.625	rs4671817	chr2:67866437	T/G	cg15745817	chr2:67799979	NA	-0.55	-9.54	-0.47	3.34e-19	Endometriosis;
CRC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg15832292	chr6:96025679	MANEA	0.58	6.02	0.32	4.57e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27499259	chr13:28400924	NA	0.48	6.18	0.32	1.89e-9	Thyroid stimulating hormone;
CRC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.34	2.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg03030879	chr14:75389066	RPS6KL1	0.47	7.36	0.38	1.49e-12	Height;
CRC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.54	-0.63	2.51e-37	Height;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg08798685	chr6:27730294	NA	-0.4	-6.02	-0.32	4.56e-9	Hepatitis A;
CRC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.57	-5.83	-0.31	1.33e-8	Systemic lupus erythematosus;
CRC	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.91	-0.31	8.53e-9	Daytime sleep phenotypes;
CRC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.42	-7.63	-0.39	2.57e-13	Height;
CRC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.45	-0.34	3.95e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9462027	0.651	rs9469885	chr6:34758716	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.01	0.55	8.67e-28	Alzheimer's disease;
CRC	trans	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.97	0.36	1.71e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg09040174	chr2:113837401	NA	0.65	10.31	0.49	9.07e-22	Protein quantitative trait loci;
CRC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	8.73	0.43	1.32e-16	Lymphocyte counts;
CRC	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.6	8.63	0.43	2.74e-16	Schizophrenia;
CRC	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	15.47	0.65	5.89e-41	Bipolar disorder;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.95e-9	Body mass index;
CRC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.54	0.34	2.31e-10	Schizophrenia;
CRC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs12473088	chr2:162485073	A/G	cg25193742	chr10:104614220	C10orf32	-0.78	-6.16	-0.32	2.17e-9	Cognitive function;
CRC	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg07513332	chr6:167530253	CCR6	-0.41	-7.24	-0.37	3.29e-12	Primary biliary cholangitis;
CRC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.43	8.74	0.43	1.19e-16	Renal cell carcinoma;
CRC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg05110241	chr16:68378359	PRMT7	-0.8	-7.84	-0.4	6.29e-14	Schizophrenia;
CRC	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.35	-6.09	-0.32	3.18e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.52	-6.13	-0.32	2.55e-9	Bipolar disorder;
CRC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26958806	chr6:27640298	NA	-0.67	-5.87	-0.31	1.05e-8	Depression;
CRC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17554472	chr22:41940697	POLR3H	-0.6	-6.07	-0.32	3.54e-9	Vitiligo;
CRC	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg24046110	chr8:143859143	LYNX1	-0.38	-6.61	-0.34	1.58e-10	Urinary tract infection frequency;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg15786705	chr6:28176104	NA	0.48	7.23	0.37	3.44e-12	Cardiac Troponin-T levels;
CRC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.63	-9.81	-0.48	4.29e-20	Body mass index;
CRC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg10729496	chr3:10149963	C3orf24	-0.53	-6.69	-0.35	9.38e-11	Alzheimer's disease;
CRC	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.02	0.32	4.65e-9	Asthma;
CRC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.62	-9.75	-0.47	6.71e-20	Huntington's disease progression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03592283	chr3:44666723	ZNF197	0.45	7.34	0.38	1.69e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.01	-0.31	5.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.38	0.46	1.07e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.85	15.74	0.66	5.3e-42	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.68	-0.51	4.61e-23	Colorectal cancer;
CRC	cis	rs9520326	1.000	rs1041062	chr13:107867751	C/A	cg07094987	chr13:107865374	FAM155A	-0.37	-5.8	-0.3	1.57e-8	Obsessive-compulsive symptoms;
CRC	cis	rs216303	0.722	rs216296	chr12:6154670	A/G	cg19878637	chr12:6148451	VWF	-0.62	-6.59	-0.34	1.71e-10	Low vWF levels;
CRC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.53	7.7	0.39	1.64e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg20203395	chr5:56204925	C5orf35	0.58	8.23	0.41	4.44e-15	Initial pursuit acceleration;
CRC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.98	0.4	2.5e-14	Colorectal cancer;
CRC	cis	rs12541635	0.677	rs2163124	chr8:107058862	G/T	cg10147462	chr8:107024639	NA	0.61	11.08	0.52	1.89e-24	Age of smoking initiation;
CRC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.61	10.23	0.49	1.62e-21	Prudent dietary pattern;
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.03	-26.25	-0.82	1.1e-82	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.4	-0.33	5.49e-10	Breast cancer;
CRC	trans	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.72	-0.39	1.4e-13	Diabetic kidney disease;
CRC	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.2	16.18	0.67	9.88e-44	Atopic dermatitis;
CRC	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.54	-0.47	3.23e-19	Prevalent atrial fibrillation;
CRC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg25985355	chr7:65971099	NA	-0.5	-5.84	-0.31	1.28e-8	Diabetic kidney disease;
CRC	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.97	-17.53	-0.69	4.67e-49	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.69	0.43	1.7e-16	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs10499694	0.735	rs2044859	chr7:50612562	A/G	cg14593290	chr7:50529359	DDC	0.49	6.96	0.36	1.87e-11	Body mass index;
CRC	cis	rs12822507	0.732	rs4555	chr12:12796872	T/C	cg11838227	chr12:12764436	CREBL2	0.41	5.65	0.3	3.54e-8	Systemic lupus erythematosus;
CRC	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.81	-10.33	-0.49	7.72e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07362569	chr17:61921086	SMARCD2	0.38	5.95	0.31	6.87e-9	Prudent dietary pattern;
CRC	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17274400	chr12:8234945	NECAP1	0.46	5.96	0.31	6.34e-9	Thyroid stimulating hormone;
CRC	cis	rs6743376	0.556	rs6733859	chr2:113819382	C/T	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg16447950	chr5:562315	NA	-0.85	-13.05	-0.58	1.17e-31	Ulcerative colitis;
CRC	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.47	7.39	0.38	1.2e-12	Brain structure;
CRC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.58	-0.34	1.82e-10	Response to antipsychotic treatment;
CRC	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.14e-26	Coffee consumption (cups per day);
CRC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg03013999	chr17:37608204	MED1	-0.48	-7.51	-0.38	5.54e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.48	5.72	0.3	2.37e-8	Gut microbiome composition (summer);
CRC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.43	-6.9	-0.36	2.68e-11	Monocyte count;
CRC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-7.33	-0.37	1.85e-12	Response to bleomycin (chromatid breaks);
CRC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.4	-6.54	-0.34	2.36e-10	Gout;Renal underexcretion gout;
CRC	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.44	-6.43	-0.33	4.47e-10	Body mass index;
CRC	trans	rs73439953	0.592	rs7237384	chr18:56604022	A/G	cg04573316	chr19:54216680	MIR519D	0.33	6.14	0.32	2.36e-9	Triptolide cytotoxicity;
CRC	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.8	-11.31	-0.53	2.77e-25	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs12580194	0.593	rs60774348	chr12:55757717	A/G	cg23425280	chr12:56401806	NA	0.47	5.78	0.3	1.76e-8	Cancer;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg15845792	chr6:28175446	NA	0.86	13.37	0.59	7.62e-33	Cardiac Troponin-T levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03433549	chr12:56498817	PA2G4	0.42	6.05	0.32	3.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.39	-7.3	-0.37	2.22e-12	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.83	-0.31	1.32e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg19582491	chr16:67682965	RLTPR	-0.59	-7.0	-0.36	1.41e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg10765900	chr13:60971006	TDRD3	0.47	5.99	0.31	5.59e-9	Myocardial infarction;
CRC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11645453	chr3:52864694	ITIH4	0.35	6.22	0.32	1.47e-9	Bipolar disorder;
CRC	cis	rs1179624	0.708	rs35887080	chr7:75260992	T/C	cg05145297	chr7:75264568	HIP1	0.56	7.73	0.39	1.28e-13	Age-related nuclear cataracts;
CRC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.75	9.58	0.47	2.38e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.57	6.35	0.33	6.99e-10	Schizophrenia;
CRC	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.71	11.14	0.52	1.11e-24	Monocyte count;
CRC	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.16	-0.45	5.58e-18	Rheumatoid arthritis;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.62	10.52	0.5	1.66e-22	Electroencephalogram traits;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	0.98	13.76	0.6	2.35e-34	Breast cancer;
CRC	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg13385794	chr1:248469461	NA	0.34	6.13	0.32	2.53e-9	Common traits (Other);
CRC	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.49	9.09	0.45	9.72e-18	Common traits (Other);
CRC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg21770322	chr7:97807741	LMTK2	0.55	9.29	0.46	2.16e-18	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg04269497	chr6:167369491	RNASET2	-0.71	-6.01	-0.31	4.99e-9	Cognitive function;
CRC	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg15903213	chr10:43522190	NA	0.76	6.65	0.34	1.2e-10	Pediatric bone mineral content (radius);
CRC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-10.68	-0.51	4.54e-23	Initial pursuit acceleration;
CRC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.48	7.12	0.37	6.97e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs11581859	1.000	rs72728530	chr1:99290529	C/T	cg12183875	chr3:169587454	LRRC31	0.27	6.21	0.32	1.58e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.96	0.36	1.86e-11	Schizophrenia;
CRC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-8.05	-0.41	1.52e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg15845792	chr6:28175446	NA	0.59	8.34	0.42	2.1e-15	Parkinson's disease;
CRC	cis	rs672059	1.000	rs1760624	chr1:183158552	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.28	0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.41	6.49	0.34	3.21e-10	Monocyte count;
CRC	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg06172871	chr16:72088244	HP	0.43	6.36	0.33	6.92e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs17681684	0.565	rs62066034	chr17:9758829	A/G	cg26853458	chr17:9805074	RCVRN	0.54	9.45	0.46	6.64e-19	GIP levels in response to oral glucose tolerance test (fasting);
CRC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.69	-0.43	1.76e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.41	-5.82	-0.31	1.4e-8	Strep throat;
CRC	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.73	-12.66	-0.57	3.39e-30	Brugada syndrome;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg06470822	chr6:28175283	NA	0.74	9.85	0.48	3.23e-20	Parkinson's disease;
CRC	cis	rs747650	0.504	rs10769227	chr11:47002614	A/T	cg19486271	chr11:47235900	DDB2	-0.44	-5.88	-0.31	1.03e-8	Acne (severe);
CRC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.43	-7.63	-0.39	2.54e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.39	5.92	0.31	8.3e-9	Red blood cell count;
CRC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	11.04	0.52	2.49e-24	Mean corpuscular hemoglobin;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20601730	chr10:7830119	ATP5C1;KIN	0.44	6.3	0.33	9.76e-10	Survival in pancreatic cancer;
CRC	cis	rs10208940	0.920	rs11893513	chr2:68760647	C/T	cg12452813	chr2:68675892	NA	0.48	5.99	0.31	5.47e-9	Urate levels in lean individuals;
CRC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg23758597	chr6:163146217	PARK2	-0.68	-6.78	-0.35	5.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.46	0.34	3.84e-10	Bladder cancer;
CRC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.51	9.88	0.48	2.58e-20	Renal cell carcinoma;
CRC	cis	rs11212617	1.000	rs7112136	chr11:108287131	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.51	0.34	2.82e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-9.0	-0.44	1.84e-17	Schizophrenia;
CRC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.66	0.63	8.58e-38	Platelet count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26618056	chr16:25043323	NA	0.37	6.17	0.32	2.05e-9	Obesity-related traits;
CRC	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg23112188	chr14:24563095	PCK2	-0.36	-6.5	-0.34	3.05e-10	IgG glycosylation;
CRC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.16	-0.32	2.12e-9	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03257047	chr6:52860152	GSTA4	0.48	6.62	0.34	1.44e-10	Response to antipsychotic treatment;
CRC	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-7.01	-0.36	1.37e-11	Schizophrenia;
CRC	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg09904177	chr6:26538194	HMGN4	0.47	6.91	0.36	2.48e-11	Intelligence (multi-trait analysis);
CRC	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg05535760	chr7:792225	HEATR2	0.98	11.34	0.53	2.19e-25	Cerebrospinal P-tau181p levels;
CRC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	cis	rs73200209	0.744	rs11612907	chr12:116495255	A/G	cg01776926	chr12:116560359	MED13L	-0.64	-7.69	-0.39	1.72e-13	Total body bone mineral density;
CRC	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.53	7.2	0.37	4.05e-12	Caudate activity during reward;
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.53	0.75	6.95e-61	Prudent dietary pattern;
CRC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.57	-0.39	3.82e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4973397	0.765	rs2290130	chr2:232263127	G/A	cg13347044	chr2:232276743	NA	0.45	6.36	0.33	6.61e-10	Anti-saccade response;
CRC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.56	9.73	0.47	7.74e-20	Coronary artery disease;
CRC	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg19636311	chr20:16710621	SNRPB2	-0.4	-6.27	-0.33	1.14e-9	Aortic root size;
CRC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs9595066	1.000	rs66786230	chr13:44711625	T/C	cg04068111	chr13:44716778	NA	-0.49	-6.28	-0.33	1.09e-9	Schizophrenia;
CRC	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-5.77	-0.3	1.84e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg11003573	chr3:44754125	ZNF502	-0.35	-6.13	-0.32	2.5e-9	Depressive symptoms;
CRC	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	7.3	0.37	2.11e-12	Coronary artery disease;
CRC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.36	7.24	0.37	3.1e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.5	7.48	0.38	7e-13	Longevity;
CRC	trans	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg26043149	chr18:55253948	FECH	-0.54	-8.31	-0.42	2.57e-15	Bone mineral density;
CRC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg06028605	chr16:24865363	SLC5A11	0.43	6.87	0.35	3.13e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.66	-8.86	-0.44	5.13e-17	Bone mineral density;
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.9	-0.36	2.73e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg04415270	chr2:102091202	RFX8	-0.36	-6.11	-0.32	2.78e-9	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.73	-0.51	3.09e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1009181	0.585	rs9379827	chr6:26153335	G/T	cg00631329	chr6:26305371	NA	-0.41	-6.2	-0.32	1.7e-9	Childhood ear infection;
CRC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.72	-12.0	-0.55	9.33e-28	Menopause (age at onset);
CRC	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-8.49	-0.42	7.01e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-5.73	-0.3	2.26e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.85	13.42	0.59	4.61e-33	Glomerular filtration rate (creatinine);
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg08546805	chr12:8549446	NA	-0.4	-6.06	-0.32	3.81e-9	Blood pressure (smoking interaction);
CRC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg10263370	chr3:44754102	ZNF502	-0.36	-5.98	-0.31	5.86e-9	Depressive symptoms;
CRC	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.99	0.36	1.55e-11	Diisocyanate-induced asthma;
CRC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg12193833	chr17:30244370	NA	-0.76	-8.88	-0.44	4.33e-17	Hip circumference adjusted for BMI;
CRC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.32	-0.67	2.74e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02972257	chr16:68554789	NA	0.63	7.27	0.37	2.59e-12	Ulcerative colitis;
CRC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.09	-0.52	1.74e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg20512303	chr5:131592959	PDLIM4	-0.38	-6.6	-0.34	1.6e-10	Breast cancer;
CRC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.86	0.31	1.11e-8	Height;
CRC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.72	8.66	0.43	2.09e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.44	6.42	0.33	4.86e-10	Menopause (age at onset);
CRC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.47	0.38	7.38e-13	Lung cancer;
CRC	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.21	-0.71	9.68e-52	Schizophrenia;
CRC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.49	7.02	0.36	1.29e-11	Breast cancer;
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-8.41	-0.42	1.27e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg27083787	chr2:113543245	IL1A	0.46	6.59	0.34	1.76e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.45	6.49	0.34	3.07e-10	Alzheimer's disease (late onset);
CRC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.62	-0.47	1.88e-19	Bladder cancer;
CRC	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg09695851	chr17:3907499	NA	0.74	12.15	0.56	2.55e-28	Type 2 diabetes;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.13	-0.37	6.43e-12	Obesity-related traits;
CRC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg15382696	chr6:118971807	C6orf204	0.6	7.53	0.38	5.03e-13	Diastolic blood pressure;
CRC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg22777020	chr22:31556080	RNF185	0.55	6.33	0.33	7.93e-10	Colorectal cancer;
CRC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.63	-10.13	-0.49	3.5e-21	Motion sickness;
CRC	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg09695851	chr17:3907499	NA	-0.48	-6.04	-0.32	4.06e-9	Type 2 diabetes;
CRC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg16989086	chr20:62203971	PRIC285	0.48	6.22	0.32	1.54e-9	Glioblastoma;
CRC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.56	-8.6	-0.43	3.41e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-0.79	-8.09	-0.41	1.2e-14	Schizophrenia;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-8.45	-0.42	9.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.13	0.49	3.74e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.54	8.6	0.43	3.37e-16	Testicular germ cell tumor;
CRC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.47	-5.97	-0.31	6.16e-9	Diastolic blood pressure;
CRC	trans	rs11814448	1.000	rs12248406	chr10:22319508	A/G	cg09300795	chr16:4042428	ADCY9	0.66	6.09	0.32	3.12e-9	Breast cancer;
CRC	cis	rs713477	0.631	rs7145182	chr14:55905231	C/G	cg13175173	chr14:55914753	NA	-0.41	-7.21	-0.37	3.79e-12	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7932354	0.528	rs12224096	chr11:47174361	C/T	cg19486271	chr11:47235900	DDB2	0.44	6.42	0.33	4.79e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7487075	0.619	rs6582645	chr12:46805144	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg05585544	chr11:47624801	NA	-0.56	-9.84	-0.48	3.44e-20	Subjective well-being;
CRC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.79	13.94	0.61	4.96e-35	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19580880	chr14:21538547	FLJ10357	0.45	6.01	0.31	5.02e-9	Anxiety disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06646493	chr1:116519019	SLC22A15	-0.38	-6.03	-0.32	4.41e-9	Myopia (pathological);
CRC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.56	-9.67	-0.47	1.28e-19	Body mass index;
CRC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg21251018	chr6:28226885	NKAPL	0.52	8.59	0.43	3.61e-16	Depression;
CRC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.19	-13.16	-0.59	4.5e-32	Diabetic kidney disease;
CRC	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.71	-6.16	-0.32	2.13e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	12.82	0.58	8.74e-31	Alzheimer's disease;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.84	14.44	0.62	5.93e-37	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg15845792	chr6:28175446	NA	0.9	11.84	0.55	3.41e-27	Parkinson's disease;
CRC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.75	0.63	3.76e-38	Platelet count;
CRC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg19812747	chr11:111475976	SIK2	0.44	6.37	0.33	6.53e-10	Primary sclerosing cholangitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21257117	chr11:65029643	POLA2	0.47	6.55	0.34	2.25e-10	Response to antipsychotic treatment;
CRC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	8.97	0.44	2.34e-17	Lymphocyte counts;
CRC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.1	-0.32	2.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg24253500	chr15:84953950	NA	0.39	6.06	0.32	3.83e-9	Schizophrenia;
CRC	cis	rs728616	0.717	rs111403425	chr10:81820542	C/T	cg11900509	chr10:81946545	ANXA11	-0.53	-5.67	-0.3	3.13e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg02560186	chr11:3602584	NA	-0.46	-6.01	-0.31	4.79e-9	Blood pressure (smoking interaction);
CRC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.32	-0.75	4.54e-60	Height;
CRC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg19682013	chr15:45996608	NA	0.29	5.9	0.31	8.97e-9	Waist circumference;Weight;
CRC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.75	0.3	2.06e-8	Monocyte percentage of white cells;
CRC	trans	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg20064139	chr20:41823021	NA	0.3	6.06	0.32	3.64e-9	Coronary artery disease;
CRC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg23463467	chr20:60627584	TAF4	0.3	5.63	0.3	3.77e-8	Body mass index;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12273811	chr6:28175739	NA	0.71	9.07	0.45	1.08e-17	Depression;
CRC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.63	10.77	0.51	2.28e-23	Mean corpuscular volume;
CRC	cis	rs672059	1.000	rs563026	chr1:183161037	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.5	-7.28	-0.37	2.41e-12	Hypertriglyceridemia;
CRC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs9359856	0.518	rs11962279	chr6:90233695	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.54	-6.14	-0.32	2.36e-9	Bipolar disorder;
CRC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.64	10.85	0.51	1.15e-23	Prostate cancer;
CRC	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.55e-15	Type 2 diabetes;
CRC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.61	-0.3	4.32e-8	Pulmonary function;
CRC	cis	rs10924970	0.967	rs12030186	chr1:235397477	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg20684491	chr1:25596433	NA	0.43	7.48	0.38	7.03e-13	Erythrocyte sedimentation rate;
CRC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.85	-0.35	3.62e-11	Schizophrenia;
CRC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg15440763	chr7:158190612	PTPRN2	0.42	6.58	0.34	1.82e-10	Obesity-related traits;
CRC	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.35	-0.42	1.94e-15	Coronary artery disease;
CRC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.57	-8.84	-0.44	5.73e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.23	0.41	4.42e-15	Lung cancer;
CRC	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26175033	chr2:43037432	NA	0.37	6.22	0.32	1.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	6.12	0.32	2.63e-9	Obesity-related traits;
CRC	cis	rs6735179	0.603	rs10164788	chr2:1753379	G/A	cg19300414	chr2:1746591	PXDN	0.44	7.54	0.38	4.73e-13	Response to antipsychotic treatment;
CRC	cis	rs245880	0.740	rs245892	chr7:29191273	T/C	cg17163760	chr7:29186267	CPVL	-0.39	-6.79	-0.35	5.41e-11	Warfarin maintenance dose;
CRC	trans	rs10242455	0.702	rs917152	chr7:99004497	T/C	cg09045935	chr12:6379348	NA	0.98	7.64	0.39	2.42e-13	Blood metabolite levels;
CRC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.39	-6.57	-0.34	1.98e-10	Personality dimensions;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg24560729	chr4:1342394	KIAA1530	0.42	7.52	0.38	5.26e-13	Longevity;
CRC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.51	9.38	0.46	1.09e-18	Vitiligo;
CRC	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg23254163	chr1:152506842	NA	0.5	10.14	0.49	3.42e-21	Hair morphology;
CRC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	5.98	0.31	5.85e-9	Rheumatoid arthritis;
CRC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	trans	rs887829	0.694	rs869283	chr2:234626287	G/A	cg14520829	chr3:18390388	SATB1	0.4	6.2	0.32	1.68e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.63	9.94	0.48	1.59e-20	Aortic root size;
CRC	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.72	7.77	0.39	1.04e-13	Breast cancer;
CRC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg23136738	chr11:925521	AP2A2	-0.41	-6.78	-0.35	5.53e-11	Alzheimer's disease (late onset);
CRC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.46	-6.06	-0.32	3.75e-9	DNA methylation (variation);
CRC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	5.93	0.31	7.55e-9	Height;
CRC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.91	-0.36	2.47e-11	Bladder cancer;
CRC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.44	-6.76	-0.35	6.3e-11	Obesity-related traits;
CRC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.78	-0.72	5.61e-54	Height;
CRC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg18827107	chr12:86230957	RASSF9	0.42	6.77	0.35	5.93e-11	Major depressive disorder;
CRC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-8.71	-0.43	1.47e-16	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg04155289	chr7:94953770	PON1	-0.61	-7.59	-0.39	3.3e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.69	-0.35	9.61e-11	Depression;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg11478273	chr8:128806682	PVT1	0.42	6.47	0.34	3.52e-10	Body mass index;
CRC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-8.78	-0.44	8.92e-17	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-5.87	-0.31	1.06e-8	Total body bone mineral density (age 45-60);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08162337	chr19:41223262	ITPKC;ADCK4	0.37	5.96	0.31	6.35e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs3001167	0.609	rs4603111	chr1:194546369	A/C	cg22004422	chr13:113740730	MCF2L	-0.6	-6.19	-0.32	1.83e-9	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.61	9.5	0.46	4.4e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.94	11.53	0.54	4.69e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.87	-14.33	-0.62	1.53e-36	Lewy body disease;
CRC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.39	6.58	0.34	1.81e-10	Eye color traits;
CRC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.53	7.2	0.37	4.23e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.32	5.92	0.31	7.99e-9	QRS complex (12-leadsum);
CRC	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.68	0.35	1.01e-10	Alzheimer's disease (survival time);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg14225146	chr17:72744664	SLC9A3R1	-0.68	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	cis	rs10046574	0.831	rs17479687	chr7:135074833	C/G	cg27474649	chr7:135195673	CNOT4	0.68	5.6	0.3	4.51e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10849893	0.557	rs10849890	chr12:121902725	T/C	cg01154721	chr12:121881891	KDM2B	-0.43	-6.21	-0.32	1.55e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-8.02	-0.4	1.92e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.74	12.17	0.56	2.18e-28	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16116313	chr12:122255002	SETD1B	-0.41	-6.39	-0.33	5.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.8	8.46	0.42	8.97e-16	Plasma clusterin levels;
CRC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg07153921	chr17:41440717	NA	-0.38	-5.74	-0.3	2.1e-8	Menopause (age at onset);
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg20933634	chr6:27740509	NA	0.59	8.66	0.43	2.1e-16	Parkinson's disease;
CRC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.88	-0.48	2.55e-20	Body mass index;
CRC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.38	-6.08	-0.32	3.28e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7258465	0.931	rs34053595	chr19:18556749	T/C	cg06462663	chr19:18546047	ISYNA1	0.44	6.39	0.33	5.79e-10	Breast cancer;
CRC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.51	7.83	0.4	6.7e-14	Aortic root size;
CRC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.41	-6.73	-0.35	7.36e-11	Monocyte count;
CRC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.74	-0.47	7.05e-20	Height;
CRC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg25876840	chr17:41920477	NA	0.6	8.57	0.43	4.04e-16	Triglycerides;
CRC	cis	rs7487075	0.786	rs2172398	chr12:46672571	A/G	cg22049899	chr12:47219821	SLC38A4	0.32	6.12	0.32	2.72e-9	Itch intensity from mosquito bite;
CRC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.74	-12.25	-0.56	1.1e-28	Breast cancer;
CRC	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.52	-9.79	-0.48	4.94e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.6	9.31	0.46	1.82e-18	Crohn's disease;
CRC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg11707556	chr5:10655725	ANKRD33B	0.36	6.58	0.34	1.81e-10	Coronary artery disease;
CRC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg22349387	chr12:9600060	DDX12	-0.36	-5.65	-0.3	3.41e-8	Breast size;
CRC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-6.74	-0.35	6.91e-11	Height;
CRC	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.68	-11.63	-0.54	1.98e-26	Type 2 diabetes;
CRC	cis	rs6504622	0.791	rs61671555	chr17:45037857	C/T	cg16759221	chr17:45003025	GOSR2	-0.5	-7.47	-0.38	7.24e-13	Orofacial clefts;
CRC	trans	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.25	-0.37	2.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22874627	chr3:31575329	STT3B	0.43	6.02	0.31	4.72e-9	Response to antipsychotic treatment;
CRC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.65	-9.68	-0.47	1.12e-19	DNA methylation (variation);
CRC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg10398005	chr11:117014888	PAFAH1B2	-0.38	-5.68	-0.3	2.95e-8	Blood protein levels;
CRC	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.07	9.25	0.45	2.99e-18	Mitochondrial DNA levels;
CRC	cis	rs2635047	0.604	rs1434527	chr18:44742868	G/T	cg19077165	chr18:44547161	KATNAL2	0.4	5.96	0.31	6.37e-9	Educational attainment;
CRC	cis	rs11212617	0.967	rs7127490	chr11:108286758	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.68	0.3	3.01e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	7.43	0.38	9.35e-13	Coffee consumption (cups per day);
CRC	cis	rs7623687	0.579	rs78807522	chr3:49056150	C/A	cg19401529	chr3:49056140	DALRD3	0.7	7.23	0.37	3.32e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.82	-0.44	6.72e-17	Bipolar disorder;
CRC	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg21851534	chr17:3907994	ZZEF1	0.37	6.45	0.33	4.08e-10	Type 2 diabetes;
CRC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.44	6.12	0.32	2.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs7301826	0.651	rs10744484	chr12:131298506	T/G	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg21951975	chr1:209979733	IRF6	0.46	5.6	0.3	4.48e-8	Cleft lip with or without cleft palate;
CRC	trans	rs6686842	1.000	rs213734	chr1:41575699	C/T	cg19787969	chr8:9763211	NA	0.28	5.97	0.31	6.03e-9	Height;
CRC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg18375707	chr11:64034959	PLCB3	0.48	5.6	0.3	4.49e-8	Mean platelet volume;
CRC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.58	-7.18	-0.37	4.7e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg02951883	chr7:2050386	MAD1L1	0.62	10.25	0.49	1.36e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.76	0.51	2.39e-23	Motion sickness;
CRC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.36	1.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg14254433	chr6:34482411	PACSIN1	-0.67	-6.48	-0.34	3.41e-10	Chronic lymphocytic leukemia;
CRC	cis	rs6908034	0.600	rs79733895	chr6:19799541	A/G	cg02682789	chr6:19804855	NA	0.81	6.89	0.35	2.9100000000000002e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.09	-0.32	3.2e-9	Mean corpuscular volume;
CRC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.49	-6.86	-0.35	3.46e-11	Height;
CRC	cis	rs7605827	0.930	rs7596435	chr2:15605091	T/C	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg04267008	chr7:1944627	MAD1L1	-0.45	-5.66	-0.3	3.26e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.04	-14.15	-0.62	7.52e-36	Exhaled nitric oxide output;
CRC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	14.84	0.63	1.66e-38	Smoking behavior;
CRC	cis	rs1545257	0.537	rs12988283	chr2:24642086	G/C	cg06627628	chr2:24431161	ITSN2	-0.47	-7.0	-0.36	1.46e-11	Sjögren's syndrome;
CRC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.56	0.57	7.8e-30	Alzheimer's disease;
CRC	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.98	12.1	0.55	3.83e-28	Lung disease severity in cystic fibrosis;
CRC	cis	rs534126	1.000	rs476826	chr7:142906434	C/T	cg04182207	chr7:143013161	CLCN1	0.31	5.63	0.3	3.8e-8	Cancer;
CRC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.65	-8.92	-0.44	3.39e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.66	-0.34	1.17e-10	Educational attainment;
CRC	cis	rs6743376	0.532	rs2251872	chr2:113818632	G/A	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.13	-0.37	6.4e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.13	-13.33	-0.59	1.06e-32	Diabetic kidney disease;
CRC	cis	rs7487075	0.619	rs10785629	chr12:46854727	G/A	cg22049899	chr12:47219821	SLC38A4	0.31	5.79	0.3	1.62e-8	Itch intensity from mosquito bite;
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-8.28	-0.42	3.08e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.79	11.0	0.52	3.61e-24	Systemic lupus erythematosus;
CRC	cis	rs6908034	0.607	rs12526109	chr6:19820089	C/A	cg02682789	chr6:19804855	NA	0.85	6.54	0.34	2.32e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs354033	0.837	rs60206402	chr7:149189637	G/A	cg24335155	chr7:149193227	ZNF746	0.41	6.22	0.32	1.48e-9	Multiple sclerosis;
CRC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg21153622	chr11:89784906	NA	-0.52	-8.86	-0.44	5.1e-17	HDL cholesterol;
CRC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.52	7.26	0.37	2.88e-12	Glioblastoma;Glioma;
CRC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.92	0.52	6.84e-24	Motion sickness;
CRC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.69	0.35	9.58e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.51	6.11	0.32	2.81e-9	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23446514	chr15:66797150	ZWILCH;SNORD18A;RPL4	0.42	6.39	0.33	5.64e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.4	0.65	1.15e-40	Fuchs's corneal dystrophy;
CRC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.42	-6.24	-0.33	1.35e-9	Type 2 diabetes;
CRC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.67	10.43	0.5	3.45e-22	Monocyte count;
CRC	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.03	0.36	1.23e-11	Red blood cell count;
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.59	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.04	19.99	0.74	9.55e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg06494592	chr3:125709126	NA	-0.56	-6.73	-0.35	7.33e-11	Blood pressure (smoking interaction);
CRC	cis	rs6725806	1.000	rs6725806	chr2:103216172	T/G	cg21010569	chr2:103233596	NA	0.44	6.19	0.32	1.82e-9	Blood protein levels;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg02683197	chr6:28174875	NA	0.57	7.44	0.38	8.73e-13	Parkinson's disease;
CRC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-16.25	-0.67	5.28e-44	Cognitive function;
CRC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.78	-0.35	5.75e-11	Aortic root size;
CRC	trans	rs12829704	0.588	rs11045917	chr12:21419948	G/A	cg22494081	chr2:11774142	GREB1	0.51	6.06	0.32	3.77e-9	Blood metabolite levels;
CRC	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.61	-6.71	-0.35	8.63e-11	Coronary artery disease;
CRC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.51	7.16	0.37	5.18e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg10437265	chr15:77819839	NA	0.68	12.16	0.56	2.36e-28	Type 2 diabetes;
CRC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	6.11	0.32	2.79e-9	Renal function-related traits (BUN);
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg19193384	chr17:30244184	NA	-0.58	-6.88	-0.35	3.08e-11	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17544762	chr6:151300474	MTHFD1L	0.5	7.53	0.38	4.86e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg18288967	chr1:45987694	PRDX1	0.68	7.73	0.39	1.3e-13	Obesity-related traits;
CRC	cis	rs73206853	0.563	rs73194040	chr12:111181106	C/T	cg12870014	chr12:110450643	ANKRD13A	0.74	8.71	0.43	1.51e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	0.78	15.73	0.66	5.89e-42	Leprosy;
CRC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.32	-0.56	6.19e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.6	9.84	0.48	3.35e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2982552	0.844	rs2982559	chr6:152055905	G/A	cg22157087	chr6:152012887	ESR1	0.37	5.81	0.3	1.48e-8	Bone properties (heel);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00862618	chr12:2904096	FKBP4	-0.45	-6.96	-0.36	1.8e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg25856811	chr1:152973957	SPRR3	-0.27	-7.35	-0.38	1.6e-12	Inflammatory skin disease;
CRC	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg09476006	chr5:138032270	NA	0.45	6.92	0.36	2.41e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs929596	0.531	rs2741012	chr2:234508963	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-5.75	-0.3	2.06e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.66	-0.39	2.06e-13	Hemoglobin concentration;
CRC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.36	6.35	0.33	7.15e-10	Systemic lupus erythematosus;
CRC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	6.87	0.35	3.18e-11	Hip circumference adjusted for BMI;
CRC	cis	rs6679356	0.587	rs946685	chr1:67815715	A/G	cg24364144	chr1:67875067	SERBP1	0.43	5.71	0.3	2.48e-8	Primary biliary cholangitis;
CRC	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg10523679	chr1:76189770	ACADM	-0.42	-5.89	-0.31	9.49e-9	Daytime sleep phenotypes;
CRC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	15.09	0.64	1.75e-39	Platelet count;
CRC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg17401720	chr7:158221031	PTPRN2	-0.44	-7.3	-0.37	2.19e-12	Obesity-related traits;
CRC	cis	rs8105895	0.935	rs10420042	chr19:22251926	T/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg09355771	chr2:177043147	NA	-0.51	-6.47	-0.34	3.56e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.79	10.21	0.49	1.93e-21	Diisocyanate-induced asthma;
CRC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.77	10.03	0.48	7.97e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.15	-12.31	-0.56	6.5e-29	Diabetic kidney disease;
CRC	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg01843034	chr6:37503916	NA	-0.4	-7.2	-0.37	4.18e-12	Cognitive performance;
CRC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.33	0.53	2.35e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10137990	chr8:145137203	GPAA1	-0.39	-6.06	-0.32	3.81e-9	Myopia (pathological);
CRC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15413566	chr7:8301971	ICA1	0.38	6.11	0.32	2.74e-9	Obesity-related traits;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg15845792	chr6:28175446	NA	0.79	11.71	0.54	1.05e-26	Cardiac Troponin-T levels;
CRC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.41	5.69	0.3	2.8e-8	Breast cancer;
CRC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.11e-16	Alcohol dependence;
CRC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07167872	chr1:205819463	PM20D1	0.43	5.88	0.31	9.87e-9	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs7781266	0.790	rs62469963	chr7:133176419	G/A	cg03336402	chr7:133662267	EXOC4	0.48	5.71	0.3	2.57e-8	Educational attainment (college completion);
CRC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.41	0.42	1.25e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg04110750	chr16:69646130	NFAT5	-0.51	-6.75	-0.35	6.86e-11	IgE levels;
CRC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-7.6	-0.39	3.07e-13	Chronic sinus infection;
CRC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.73	0.54	8.92e-27	Prudent dietary pattern;
CRC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.74	-0.47	7.45e-20	Chronic sinus infection;
CRC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.68	11.06	0.52	2.24e-24	Colorectal cancer;
CRC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.55	8.84	0.44	6.06e-17	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs3812762	0.701	rs4929915	chr11:8824418	A/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.52	-7.62	-0.39	2.72e-13	Hypospadias;
CRC	cis	rs12541635	0.739	rs7833595	chr8:107089603	G/T	cg10147462	chr8:107024639	NA	-0.54	-9.45	-0.46	6.71e-19	Age of smoking initiation;
CRC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.85	12.62	0.57	4.71e-30	Gut microbiome composition (summer);
CRC	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg18232548	chr7:50535776	DDC	-0.4	-6.13	-0.32	2.47e-9	Body mass index;
CRC	trans	rs4386084	1.000	rs12906877	chr15:50256819	T/C	cg02453146	chr1:53068587	GPX7	-0.34	-5.97	-0.31	6.13e-9	Basophil percentage of white cells;Basophil percentage of granulocytes;
CRC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg07404485	chr7:94953653	PON1	-0.45	-6.04	-0.32	4.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.92	-17.32	-0.69	3.2e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11203032	0.831	rs10887927	chr10:90940687	T/C	cg16672925	chr10:90967113	CH25H	0.44	5.7	0.3	2.6e-8	Heart failure;
CRC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7209700	0.547	rs884696	chr17:45341244	C/A	cg25173405	chr17:45401733	C17orf57	0.47	5.99	0.31	5.65e-9	IgG glycosylation;
CRC	cis	rs728616	0.764	rs56196124	chr10:81902655	A/T	cg05935833	chr10:81318306	SFTPA2	-0.56	-6.52	-0.34	2.58e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9682041	0.597	rs13076319	chr3:170104630	T/G	cg11886554	chr3:170076028	SKIL	0.66	8.14	0.41	8.4e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs10971721	0.749	rs10971741	chr9:33856867	C/G	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs76793172	0.623	rs10775546	chr19:46267534	C/T	cg11657440	chr19:46296263	DMWD	0.57	5.68	0.3	3.01e-8	Eosinophil counts;
CRC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.9	17.43	0.69	1.19e-48	Cerebrospinal fluid biomarker levels;
CRC	cis	rs282587	0.502	rs371150	chr13:113397815	C/T	cg04656015	chr13:113407548	ATP11A	0.64	8.02	0.4	1.83e-14	Glycated hemoglobin levels;
CRC	trans	rs10875595	0.836	rs2879202	chr5:140668375	G/T	cg11712506	chr5:113699683	KCNN2	0.42	5.99	0.31	5.51e-9	Pulmonary function decline;
CRC	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.91	0.55	2.03e-27	Exhaled nitric oxide levels;
CRC	trans	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05926928	chr17:57297772	GDPD1	-0.42	-6.31	-0.33	8.99e-10	Schizophrenia;
CRC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.76	-0.3	1.92e-8	Arsenic metabolism;
CRC	cis	rs2415984	0.579	rs113349829	chr14:46973973	C/A	cg14871534	chr14:47121158	RPL10L	-0.39	-5.85	-0.31	1.21e-8	Number of children ever born;
CRC	cis	rs6088813	1.000	rs6088799	chr20:33934301	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.75	-0.3	2.09e-8	Height;
CRC	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.79	-9.51	-0.46	4.25e-19	Multiple sclerosis;
CRC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg09127314	chr1:152161683	NA	0.53	6.87	0.35	3.25e-11	Atopic dermatitis;
CRC	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.39	6.04	0.32	4.14e-9	Endometrial cancer;
CRC	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg12963866	chr19:57752005	ZNF805	0.4	5.92	0.31	8.11e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg03233332	chr7:66118400	NA	-0.42	-5.86	-0.31	1.14e-8	Aortic root size;
CRC	cis	rs7580658	0.891	rs55998967	chr2:128048674	A/C	cg09760422	chr2:128146352	NA	-0.38	-7.43	-0.38	9.45e-13	Protein C levels;
CRC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.71	8.03	0.4	1.71e-14	Major depressive disorder;
CRC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.46	6.55	0.34	2.25e-10	Response to temozolomide;
CRC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-11.09	-0.52	1.74e-24	Extrinsic epigenetic age acceleration;
CRC	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.55	-7.93	-0.4	3.44e-14	Platelet distribution width;
CRC	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.16	-0.45	5.58e-18	Rheumatoid arthritis;
CRC	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.34	0.65	1.9e-40	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	6.01	0.31	4.93e-9	Life satisfaction;
CRC	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.69	-0.35	9.73e-11	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg03037974	chr15:76606532	NA	0.69	12.08	0.55	4.76e-28	Blood metabolite levels;
CRC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.52	-7.15	-0.37	5.72e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg05139728	chr16:28306816	SBK1	-0.37	-5.96	-0.31	6.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.98	-0.36	1.6e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23463467	chr20:60627584	TAF4	0.42	7.87	0.4	5.15e-14	Body mass index;
CRC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.66	-0.34	1.18e-10	Subjective well-being;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.98	0.31	5.97e-9	Bipolar disorder;
CRC	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg05585544	chr11:47624801	NA	-0.4	-6.35	-0.33	7.06e-10	Mean corpuscular hemoglobin;
CRC	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-6.22	-0.32	1.52e-9	Coronary artery disease;
CRC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg01483505	chr11:975446	AP2A2	0.41	6.59	0.34	1.74e-10	Alzheimer's disease (late onset);
CRC	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.52	6.29	0.33	9.91e-10	Cognitive test performance;
CRC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.66	-8.43	-0.42	1.11e-15	Cognitive test performance;
CRC	cis	rs9463078	0.764	rs3799968	chr6:44805377	C/T	cg25276700	chr6:44698697	NA	-0.26	-6.35	-0.33	7.14e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.55	7.15	0.37	5.69e-12	Fractional excretion of uric acid;
CRC	cis	rs7849270	0.959	rs913275	chr9:131910644	G/A	cg13538475	chr9:131942899	NA	-0.29	-5.76	-0.3	1.9e-8	Blood metabolite ratios;
CRC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg23517279	chr6:96025343	MANEA	-0.56	-6.2	-0.32	1.64e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.86	-0.44	5.05e-17	Triglycerides;
CRC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6743226	0.901	rs7599888	chr2:242248033	C/G	cg10021735	chr2:242295487	FARP2	-0.49	-6.9	-0.36	2.64e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs2882667	0.658	rs10076442	chr5:138276779	T/C	cg09476006	chr5:138032270	NA	0.58	10.16	0.49	2.89e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg22777020	chr22:31556080	RNF185	-0.53	-6.2	-0.32	1.72e-9	Colorectal cancer;
CRC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	13.09	0.59	8.57e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-6.54	-0.34	2.31e-10	Body mass index;
CRC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	14.49	0.62	3.98e-37	Smoking behavior;
CRC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.95	-0.44	2.57e-17	Morning vs. evening chronotype;
CRC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.36	-6.57	-0.34	2.02e-10	Menarche (age at onset);
CRC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4731207	0.724	rs2057907	chr7:124443684	G/A	cg23710748	chr7:124431027	NA	0.37	5.99	0.31	5.62e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.39	-0.38	1.24e-12	Aortic root size;
CRC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg10790698	chr19:18539756	SSBP4	-0.46	-8.92	-0.44	3.19e-17	Breast cancer;
CRC	cis	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg27395922	chr11:50257633	LOC441601	0.34	5.85	0.31	1.19e-8	Coronary artery disease;
CRC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.51	-7.09	-0.36	8.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6496667	1.000	rs6496669	chr15:90895265	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.54	-7.96	-0.4	2.88e-14	Rheumatoid arthritis;
CRC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.66	10.73	0.51	3.05e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.7	-0.43	1.63e-16	Triglycerides;
CRC	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg08265495	chr8:11212668	TDH	0.32	5.63	0.3	3.93e-8	Retinal vascular caliber;
CRC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg21132104	chr15:45694354	SPATA5L1	0.42	6.03	0.32	4.3e-9	Response to fenofibrate (adiponectin levels);
CRC	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.54	0.54	4.14e-26	Coffee consumption (cups per day);
CRC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.63	-11.01	-0.52	3.15e-24	Coronary artery disease;
CRC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.5	8.33	0.42	2.28e-15	Aortic root size;
CRC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.45	5.74	0.3	2.12e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg01475377	chr6:109611718	NA	-0.34	-5.9	-0.31	8.91e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.49	-6.26	-0.33	1.23e-9	Red blood cell traits;
CRC	cis	rs4964805	0.594	rs4964830	chr12:104168908	A/G	cg02344784	chr12:104178138	NT5DC3	-0.41	-6.12	-0.32	2.73e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.56	-0.5	1.22e-22	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.55	7.13	0.37	6.46e-12	IgG glycosylation;
CRC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.92	-0.36	2.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.67	0.34	1.11e-10	Melanoma;
CRC	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.39	6.97	0.36	1.76e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.47	5.86	0.31	1.1e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25803766	chr8:145150394	CYC1	0.45	6.21	0.32	1.63e-9	Anxiety disorder;
CRC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.61	-8.48	-0.42	7.6e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.55	-8.07	-0.41	1.36e-14	IgG glycosylation;
CRC	cis	rs9326248	0.813	rs4938350	chr11:117022276	A/G	cg11861562	chr11:117069780	TAGLN	0.35	6.42	0.33	4.82e-10	Blood protein levels;
CRC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.27	-5.61	-0.3	4.39e-8	Alcohol dependence;
CRC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.52	5.74	0.3	2.13e-8	IgG glycosylation;
CRC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-9.21	-0.45	3.82e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg18016565	chr1:150552671	MCL1	-0.43	-6.29	-0.33	9.83e-10	Tonsillectomy;
CRC	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg02811702	chr13:24901961	NA	0.48	6.63	0.34	1.41e-10	Obesity-related traits;
CRC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.48	6.09	0.32	3.11e-9	Obesity-related traits;
CRC	cis	rs12476592	0.602	rs6732791	chr2:63788901	C/A	cg10828910	chr2:63850056	LOC388955	0.49	6.11	0.32	2.79e-9	Childhood ear infection;
CRC	cis	rs8005677	0.798	rs35615180	chr14:23404389	T/C	cg25600027	chr14:23388339	RBM23	-0.43	-6.34	-0.33	7.59e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	6.75	0.35	6.62e-11	Lung cancer in ever smokers;
CRC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-9.44	-0.46	7.35e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22805796	chr17:79829393	ARHGDIA	0.42	6.23	0.32	1.41e-9	Intelligence (multi-trait analysis);
CRC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.57	8.62	0.43	2.84e-16	Tuberculosis;
CRC	cis	rs739496	0.542	rs7399113	chr12:111792848	G/A	cg10833066	chr12:111807467	FAM109A	0.56	7.25	0.37	3.06e-12	Platelet count;
CRC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg09582351	chr12:29534625	ERGIC2	-0.28	-6.01	-0.31	5.06e-9	QT interval;
CRC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.49	6.85	0.35	3.62e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7605827	0.930	rs7577512	chr2:15623218	G/T	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.46	6.75	0.35	6.82e-11	Subjective well-being;
CRC	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg13491945	chr12:107078410	RFX4	0.35	5.98	0.31	5.87e-9	Heart rate;
CRC	cis	rs73206853	0.841	rs3893403	chr12:111083980	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	8.27	0.41	3.31e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs3799378	0.582	rs1796518	chr6:26388672	C/T	cg09904177	chr6:26538194	HMGN4	-0.45	-5.95	-0.31	6.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg19041857	chr6:27730383	NA	-0.43	-6.07	-0.32	3.49e-9	Parkinson's disease;
CRC	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.97	0.31	6.18e-9	Lung cancer;
CRC	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.04	0.32	4.07e-9	Axial length;
CRC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs7605827	0.930	rs6760888	chr2:15537863	T/C	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.26e-9	Educational attainment (years of education);
CRC	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06307176	chr5:131281290	NA	0.42	6.22	0.32	1.54e-9	Life satisfaction;
CRC	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg21709803	chr11:61594965	FADS2	-0.45	-5.66	-0.3	3.33e-8	Neutrophil count;Sum basophil neutrophil counts;
CRC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.5	-8.36	-0.42	1.74e-15	Aortic root size;
CRC	cis	rs3751196	0.803	rs12426526	chr12:104146373	A/G	cg02344784	chr12:104178138	NT5DC3	0.67	6.39	0.33	5.83e-10	Sense of smell;
CRC	cis	rs1656402	1.000	rs1071997	chr2:233425541	A/G	cg03852847	chr2:233439513	NA	0.45	7.74	0.39	1.27e-13	Non-small cell lung cancer (survival);
CRC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.82	0.31	1.39e-8	Bladder cancer;
CRC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg11189052	chr15:85197271	WDR73	0.63	9.27	0.46	2.56e-18	Schizophrenia;
CRC	trans	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	2.94e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg02135003	chr7:105160482	PUS7	-0.89	-12.26	-0.56	9.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg10876282	chr6:28092338	ZSCAN16	0.44	5.88	0.31	9.85e-9	Parkinson's disease;
CRC	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg18551225	chr6:44695536	NA	-0.42	-6.14	-0.32	2.41e-9	Total body bone mineral density;
CRC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg04117972	chr1:227635322	NA	0.65	5.99	0.31	5.38e-9	Major depressive disorder;
CRC	cis	rs4716602	0.596	rs12698432	chr7:156158719	C/G	cg16983916	chr7:156159713	NA	0.38	6.74	0.35	7.22e-11	Anti-saccade response;
CRC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg19622623	chr12:86230825	RASSF9	-0.35	-5.71	-0.3	2.47e-8	Major depressive disorder;
CRC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06462663	chr19:18546047	ISYNA1	0.49	7.42	0.38	1.01e-12	Breast cancer;
CRC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.56	7.25	0.37	2.95e-12	Hip circumference adjusted for BMI;
CRC	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg08017634	chr8:144659831	NAPRT1	0.65	5.78	0.3	1.72e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.24	0.53	4.87e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg12365402	chr11:9010492	NRIP3	0.39	6.09	0.32	3.2e-9	Hemoglobin concentration;
CRC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.82	18.06	0.71	3.69e-51	Breast cancer;
CRC	cis	rs17209837	0.607	rs11561963	chr7:87116550	T/A	cg00919237	chr7:87102261	ABCB4	-0.5	-6.31	-0.33	9.24e-10	Gallbladder cancer;
CRC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.53	8.6	0.43	3.3e-16	Testicular germ cell tumor;
CRC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg15448220	chr1:150897856	SETDB1	-0.46	-6.52	-0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.42	-0.38	1.03e-12	Total body bone mineral density;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01185801	chr11:65265397	MALAT1	0.51	6.65	0.34	1.23e-10	Thyroid stimulating hormone;
CRC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.68	-8.44	-0.42	1.01e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.85	-14.97	-0.64	5.39e-39	Lewy body disease;
CRC	cis	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg26132723	chr8:70041827	NA	0.36	5.92	0.31	7.91e-9	Dupuytren's disease;
CRC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.52	-7.68	-0.39	1.79e-13	Coronary artery disease;
CRC	cis	rs4073416	0.518	rs2184601	chr14:65897368	T/A	cg03016385	chr14:66212404	NA	-0.42	-5.71	-0.3	2.54e-8	N-glycan levels;
CRC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg25382128	chr12:54346509	NA	-0.39	-5.71	-0.3	2.57e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.64	-7.98	-0.4	2.42e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg08314208	chr16:67682810	RLTPR	-0.49	-5.89	-0.31	9.5e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.62	14.4	0.62	8.72e-37	Airflow obstruction;
CRC	trans	rs7800418	0.723	rs56104401	chr7:26590489	C/G	cg14387656	chr2:233470847	EFHD1	0.48	6.58	0.34	1.88e-10	Cognitive function;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Parkinson's disease;
CRC	cis	rs7264396	0.887	rs224362	chr20:34062642	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.59	-0.34	1.7e-10	Total cholesterol levels;
CRC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.28	0.53	3.77e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4363385	0.818	rs557553	chr1:153010370	T/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01637218	chr1:29063669	YTHDF2	0.46	6.43	0.33	4.46e-10	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg09877947	chr5:131593287	PDLIM4	-0.45	-7.3	-0.37	2.16e-12	Breast cancer;
CRC	cis	rs539514	0.690	rs528783	chr13:76319460	T/C	cg04757411	chr13:76259545	LMO7	-0.36	-6.09	-0.32	3.12e-9	Type 1 diabetes;
CRC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.51	-6.8	-0.35	4.8e-11	Glioblastoma;
CRC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.94	-17.83	-0.7	3.13e-50	Height;
CRC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.25	0.33	1.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs623323	1.000	rs623323	chr17:700020	A/G	cg02666820	chr17:700054	NA	0.44	7.21	0.37	3.76e-12	Type 2 diabetes;
CRC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-12.98	-0.58	2.24e-31	Ulcerative colitis;
CRC	cis	rs11212617	0.901	rs2083707	chr11:108066130	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.75	0.3	1.99e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7503807	0.515	rs12946217	chr17:78686566	C/A	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.87e-8	Obesity;
CRC	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg04586622	chr2:25135609	ADCY3	0.36	6.09	0.32	3.16e-9	Body mass index in non-asthmatics;
CRC	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.57	9.65	0.47	1.45e-19	Menarche (age at onset);
CRC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.51	7.4	0.38	1.15e-12	Systemic lupus erythematosus;
CRC	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.78	-0.3	1.74e-8	Neuroticism;
CRC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.62	-8.33	-0.42	2.22e-15	Neuroticism;
CRC	cis	rs6456156	0.904	rs2023305	chr6:167524898	A/G	cg07513332	chr6:167530253	CCR6	0.37	6.53	0.34	2.51e-10	Primary biliary cholangitis;
CRC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg23758597	chr6:163146217	PARK2	-0.55	-6.12	-0.32	2.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs501120	0.584	rs680091	chr10:44738932	G/A	cg09554077	chr10:44749378	NA	0.75	8.54	0.43	5.05e-16	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.37	7.26	0.37	2.9e-12	Tonsillectomy;
CRC	cis	rs7945718	0.621	rs10831896	chr11:12693361	G/A	cg25843174	chr11:12811716	TEAD1	0.4	7.47	0.38	7.18e-13	Educational attainment (years of education);
CRC	cis	rs7503807	0.515	rs12948040	chr17:78678434	A/G	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.86e-8	Obesity;
CRC	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg07423050	chr13:99094983	FARP1	0.4	6.57	0.34	1.92e-10	Longevity;
CRC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.59	7.83	0.4	6.66e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.44	5.68	0.3	3.01e-8	Heart rate;
CRC	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.35	16.39	0.67	1.43e-44	Uric acid levels;
CRC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg20243544	chr17:37824526	PNMT	0.45	6.82	0.35	4.48e-11	Self-reported allergy;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg15845792	chr6:28175446	NA	0.68	8.97	0.44	2.33e-17	Parkinson's disease;
CRC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg25985355	chr7:65971099	NA	0.54	6.05	0.32	3.85e-9	Diabetic kidney disease;
CRC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.29	0.33	1.02e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg09003973	chr2:102972529	NA	0.72	7.85	0.4	5.81e-14	Gut microbiota (bacterial taxa);
CRC	trans	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg24644049	chr4:85504048	CDS1	0.83	7.0	0.36	1.47e-11	Skin colour saturation;
CRC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	0.84	7.63	0.39	2.54e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg02683197	chr6:28174875	NA	0.61	8.34	0.42	2.04e-15	Parkinson's disease;
CRC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.88	0.31	1.03e-8	Prudent dietary pattern;
CRC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.55	-7.28	-0.37	2.44e-12	IgG glycosylation;
CRC	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg09695851	chr17:3907499	NA	-0.79	-14.31	-0.62	1.86e-36	Type 2 diabetes;
CRC	cis	rs2737618	0.722	rs2737680	chr1:200088559	C/A	cg21825944	chr1:200113062	NR5A2	-0.52	-7.54	-0.38	4.66e-13	Uric acid levels;
CRC	cis	rs12580194	0.593	rs7487419	chr12:55769801	C/G	cg19537932	chr12:55886519	OR6C68	-0.71	-9.13	-0.45	6.89e-18	Cancer;
CRC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.76	13.28	0.59	1.65e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4654899	0.931	rs4654726	chr1:21203898	A/C	cg02927042	chr1:21476669	EIF4G3	0.4	6.48	0.34	3.39e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.06	10.66	0.51	5.35e-23	Diabetic retinopathy;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg26587870	chr6:27730563	NA	-0.43	-6.71	-0.35	8.63e-11	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02725872	chr8:58115012	NA	-0.39	-6.78	-0.35	5.63e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.96	12.36	0.56	4.54e-29	Triglycerides;
CRC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.1e-9	Obesity-related traits;
CRC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.69	9.03	0.45	1.48e-17	High light scatter reticulocyte count;
CRC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.7	-0.39	1.62e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	11.29	0.53	3.24e-25	Bipolar disorder;
CRC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.64	11.76	0.54	6.65e-27	Prostate cancer;
CRC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.38	5.9	0.31	9.09e-9	Height;
CRC	cis	rs9462027	0.651	rs7748203	chr6:34812054	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.4e-9	Systemic lupus erythematosus;
CRC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.21	-0.41	5.16e-15	Type 2 diabetes;
CRC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	7.45	0.38	8.43e-13	Menarche (age at onset);
CRC	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.91	0.48	2.05e-20	Corneal astigmatism;
CRC	cis	rs7121446	0.555	rs6589903	chr11:121863966	C/T	cg13820391	chr11:121835505	NA	0.33	6.05	0.32	4.04e-9	Cardiovascular risk factors (age interaction);
CRC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.37	-6.72	-0.35	8.11e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs12495832	0.778	rs4681145	chr3:147894103	C/G	cg10221266	chr7:153579447	NA	0.56	6.13	0.32	2.54e-9	Chin dimples;
CRC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg19812747	chr11:111475976	SIK2	-0.47	-7.79	-0.39	8.56e-14	Primary sclerosing cholangitis;
CRC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-9.22	-0.45	3.79e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.48	6.55	0.34	2.17e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs4727027	0.769	rs2140957	chr7:148758885	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.69	0.3	2.83e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.59	7.4	0.38	1.13e-12	Body mass index;
CRC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.61	10.2	0.49	2.05e-21	Prudent dietary pattern;
CRC	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg08461752	chr10:43522343	NA	-0.78	-6.03	-0.32	4.48e-9	Pediatric bone mineral content (radius);
CRC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg08888203	chr3:10149979	C3orf24	0.71	8.63	0.43	2.63e-16	Alzheimer's disease;
CRC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.6	7.79	0.39	8.76e-14	Multiple sclerosis;
CRC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg15445000	chr17:37608096	MED1	0.36	6.14	0.32	2.38e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.75	11.39	0.53	1.44e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg00383909	chr3:49044727	WDR6	0.45	5.66	0.3	3.24e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-6.95	-0.36	1.99e-11	Colorectal cancer;
CRC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.81	13.64	0.6	7.09e-34	Menopause (age at onset);
CRC	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.56	8.21	0.41	5.11e-15	Autism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02164492	chr11:46414469	NA	-0.42	-6.09	-0.32	3.2e-9	Diisocyanate-induced asthma;
CRC	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg07423050	chr13:99094983	FARP1	0.41	6.57	0.34	1.93e-10	Longevity;
CRC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.63	-9.94	-0.48	1.51e-20	Prudent dietary pattern;
CRC	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.49	8.5	0.42	6.73e-16	Testicular germ cell tumor;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg07217954	chr7:1067459	C7orf50	0.56	5.77	0.3	1.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1656402	1.000	rs3108615	chr2:233429700	C/A	cg03852847	chr2:233439513	NA	0.44	7.56	0.38	4.08e-13	Non-small cell lung cancer (survival);
CRC	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.61	8.85	0.44	5.42e-17	Uric acid levels;
CRC	cis	rs9311676	0.632	rs1126735	chr3:58413408	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	8.22e-10	Systemic lupus erythematosus;
CRC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.63	0.39	2.51e-13	Retinal vascular caliber;
CRC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.55	8.6	0.43	3.21e-16	Aortic root size;
CRC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.83	0.31	1.34e-8	Schizophrenia;
CRC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.85	13.79	0.61	1.85e-34	Blood metabolite levels;
CRC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	5.67	0.3	3.07e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.59	8.78	0.44	9.2e-17	Menopause (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25061763	chr12:62860430	MON2	0.42	6.38	0.33	5.98e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.9	0.52	7.9e-24	Platelet count;
CRC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.73	-0.3	2.24e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-10.52	-0.5	1.66e-22	Migraine;Coronary artery disease;
CRC	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.68	8.56	0.43	4.46e-16	Hip circumference adjusted for BMI;
CRC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.22	-0.49	1.73e-21	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23763197	chr11:118965649	H2AFX	0.49	7.18	0.37	4.64e-12	Response to antipsychotic treatment;
CRC	cis	rs4731207	0.698	rs6959712	chr7:124499003	T/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.31e-9	Cutaneous malignant melanoma;
CRC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.74	11.22	0.53	5.81e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.49	-9.3	-0.46	2.03e-18	Subjective well-being;
CRC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg20203395	chr5:56204925	C5orf35	-0.71	-8.15	-0.41	7.76e-15	Initial pursuit acceleration;
CRC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.05	20.4	0.75	2.3e-60	Menarche (age at onset);
CRC	trans	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg10756647	chr7:56101905	PSPH	0.71	7.28	0.37	2.5e-12	Diabetic kidney disease;
CRC	trans	rs6472235	0.837	rs7010679	chr8:66935691	A/T	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg24355006	chr19:1969744	CSNK1G2	-0.49	-8.02	-0.4	1.87e-14	Coronary artery disease;
CRC	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.63	8.58	0.43	3.74e-16	Menopause (age at onset);
CRC	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-9.69	-0.47	1.06e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.72	9.1	0.45	8.76e-18	Iron status biomarkers;
CRC	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.66	7.49	0.38	6.53e-13	Major depressive disorder;
CRC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13198984	chr17:80129470	CCDC57	-0.46	-7.94	-0.4	3.17e-14	Life satisfaction;
CRC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg24562669	chr7:97807699	LMTK2	0.44	7.3	0.37	2.17e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.69	-0.35	9.63e-11	Blood metabolite levels;
CRC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.02	0.31	4.73e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg09332974	chr1:113616366	LRIG2	0.43	6.05	0.32	4e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.7	12.97	0.58	2.27e-31	Hip circumference;
CRC	cis	rs11203032	0.831	rs4933496	chr10:90952338	T/C	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg26304593	chr6:42947056	PEX6	-0.46	-6.64	-0.34	1.28e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg21038819	chr17:73507788	CASKIN2	0.42	6.61	0.34	1.58e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	8.91	0.44	3.45e-17	Cognitive test performance;
CRC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.99	0.48	1.07e-20	Platelet count;
CRC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg04731861	chr2:219085781	ARPC2	-0.32	-6.75	-0.35	6.64e-11	Colorectal cancer;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12273811	chr6:28175739	NA	0.63	8.44	0.42	9.98e-16	Parkinson's disease;
CRC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.8	13.33	0.59	1.07e-32	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1322512	1.000	rs1744369	chr6:152946531	T/A	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	cis	rs12760731	0.720	rs34194793	chr1:178329065	G/T	cg00404053	chr1:178313656	RASAL2	0.94	9.89	0.48	2.37e-20	Obesity-related traits;
CRC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.56	6.79	0.35	5.1e-11	Diastolic blood pressure;
CRC	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.57	8.25	0.41	3.82e-15	Testicular germ cell tumor;
CRC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg01483505	chr11:975446	AP2A2	0.42	6.71	0.35	8.38e-11	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg25164649	chr6:28176230	NA	0.53	7.14	0.37	6.07e-12	Parkinson's disease;
CRC	cis	rs17713451	0.593	rs28764001	chr7:151269426	C/G	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.23	0.37	3.47e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.32	-0.37	1.89e-12	Bipolar disorder;
CRC	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-7.53	-0.38	4.98e-13	Intelligence (multi-trait analysis);
CRC	cis	rs427941	0.703	rs201458	chr7:101741439	T/C	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	6.51	0.34	2.83e-10	Breast cancer;
CRC	cis	rs6546324	0.580	rs6724133	chr2:67858671	A/G	cg15745817	chr2:67799979	NA	-0.57	-9.68	-0.47	1.16e-19	Endometriosis;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.7	-0.3	2.6e-8	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14441964	chr10:75910358	ADK;AP3M1	0.39	5.98	0.31	5.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.61	-8.93	-0.44	3.16e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg18230493	chr5:56204884	C5orf35	-0.41	-6.17	-0.32	2.05e-9	Coronary artery disease;
CRC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.58	-9.37	-0.46	1.21e-18	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg06470822	chr6:28175283	NA	1.0	13.22	0.59	2.69e-32	Depression;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00802000	chr16:706648	WDR90	-0.44	-6.35	-0.33	7.31e-10	Height;
CRC	cis	rs741668	0.931	rs4417456	chr13:46588408	T/C	cg06018095	chr13:46550134	ZC3H13	0.41	5.73	0.3	2.21e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs600231	0.508	rs34582634	chr11:65220206	G/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-7.74	-0.39	1.27e-13	Bone mineral density;
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	6.16	0.32	2.14e-9	Blood metabolite levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22468868	chr17:58042029	RNFT1	0.5	6.94	0.36	2.07e-11	Anxiety disorder;
CRC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg05585544	chr11:47624801	NA	0.5	8.9	0.44	3.78e-17	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07355262	chr7:5347698	TNRC18	-0.32	-6.02	-0.31	4.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg02683197	chr6:28174875	NA	0.67	6.22	0.32	1.53e-9	Depression;
CRC	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg05535760	chr7:792225	HEATR2	-0.64	-7.59	-0.39	3.39e-13	Cerebrospinal P-tau181p levels;
CRC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.45	-7.98	-0.4	2.52e-14	Monocyte count;
CRC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.4	5.73	0.3	2.28e-8	Aortic root size;
CRC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.84	12.82	0.58	8.77e-31	Cognitive function;
CRC	cis	rs10486722	0.607	rs6463038	chr7:41768105	G/A	cg22138096	chr7:41772439	LOC285954	0.55	7.02	0.36	1.31e-11	Pit-and-Fissure caries;
CRC	cis	rs10924970	1.000	rs4660114	chr1:235328341	G/A	cg26050004	chr1:235667680	B3GALNT2	0.4	5.97	0.31	6.04e-9	Asthma;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg03273382	chr1:205782342	SLC41A1	-0.5	-6.43	-0.33	4.36e-10	Parkinson's disease;
CRC	cis	rs35883536	1.000	rs2065784	chr1:101096056	A/G	cg14515779	chr1:101123966	NA	0.41	7.76	0.39	1.1e-13	Monocyte count;
CRC	cis	rs2637266	0.521	rs7906422	chr10:78298260	A/G	cg18941641	chr10:78392320	NA	-0.35	-5.82	-0.31	1.39e-8	Pulmonary function;
CRC	trans	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg26043149	chr18:55253948	FECH	0.51	7.82	0.4	7.29e-14	Bone mineral density;
CRC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg13722127	chr7:150037890	RARRES2	0.47	7.1	0.36	7.74e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.08	-0.36	8.83e-12	IgG glycosylation;
CRC	trans	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	7.26	0.37	2.76e-12	Ulcerative colitis;
CRC	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg26875233	chr11:93583750	C11orf90	0.31	5.88	0.31	1.02e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg12046867	chr14:103022105	NA	-0.84	-11.91	-0.55	1.93e-27	Platelet count;
CRC	cis	rs10982256	0.774	rs10759712	chr9:117253434	G/A	cg13636371	chr9:117264095	DFNB31	-0.34	-6.51	-0.34	2.78e-10	Bipolar disorder;
CRC	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.67	10.4	0.5	4.43e-22	Corneal astigmatism;
CRC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.79	-0.3	1.63e-8	Alzheimer's disease (late onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26706625	chr10:43800313	NA	0.38	6.26	0.33	1.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs2380220	0.872	rs67846436	chr6:95951521	G/T	cg04719120	chr6:96025338	MANEA	-0.55	-6.1	-0.32	2.91e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs55788414	0.932	rs2317119	chr16:81182854	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01546243	chr14:61748019	TMEM30B	0.42	6.31	0.33	8.92e-10	Response to antipsychotic treatment;
CRC	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.31	4.79e-9	Heart rate;
CRC	trans	rs948562	0.744	rs78111333	chr11:58249947	G/A	cg26660744	chr1:1573181	CDK11B	0.48	6.02	0.31	4.74e-9	Lymphoma;
CRC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg13798780	chr7:105162888	PUS7	0.69	8.2	0.41	5.36e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs2194732	chr2:162289156	G/A	cg21546874	chr1:9294571	H6PD	-0.76	-6.01	-0.31	4.89e-9	Cognitive function;
CRC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	6.05	0.32	3.99e-9	Obesity-related traits;
CRC	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.46	6.82	0.35	4.29e-11	Crohn's disease;
CRC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg14391382	chr7:866102	UNC84A	0.54	8.07	0.41	1.37e-14	Subjective well-being;
CRC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.62	-0.3	4.07e-8	Aortic root size;
CRC	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.01	-0.31	4.93e-9	Height;
CRC	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-7.16	-0.37	5.33e-12	Tuberculosis;
CRC	cis	rs7264396	0.887	rs224364	chr20:34063865	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.67	-0.35	1.07e-10	Total cholesterol levels;
CRC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.07	0.41	1.34e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs73206853	0.688	rs57837519	chr12:110961082	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	8.72	0.43	1.37e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg15786705	chr6:28176104	NA	0.73	9.31	0.46	1.85e-18	Depression;
CRC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg18230493	chr5:56204884	C5orf35	-0.41	-5.91	-0.31	8.45e-9	Coronary artery disease;
CRC	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg14631576	chr9:95140430	CENPP	-0.38	-6.6	-0.34	1.62e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs720844	0.684	rs930651	chr2:149317682	C/T	cg09247360	chr2:149335327	NA	-0.56	-6.03	-0.32	4.49e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7605827	0.930	rs6725454	chr2:15692879	C/A	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.46	6.54	0.34	2.4e-10	Cleft lip with or without cleft palate;
CRC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg07404485	chr7:94953653	PON1	-0.47	-6.24	-0.33	1.37e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg17470449	chr10:769945	NA	0.63	8.45	0.42	9.61e-16	Uric acid levels;
CRC	cis	rs12286929	0.644	rs3793957	chr11:115095654	C/T	cg04055981	chr11:115044050	NA	0.37	5.72	0.3	2.35e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.63	-0.51	6.87e-23	Monocyte count;
CRC	cis	rs834811	0.563	rs17243442	chr7:135875487	A/G	cg01726295	chr7:135938950	NA	0.34	5.71	0.3	2.48e-8	Post-traumatic stress disorder;
CRC	cis	rs17362650	1.000	rs12474969	chr2:9697067	C/T	cg12832956	chr2:9616023	IAH1	-0.44	-5.96	-0.31	6.58e-9	Alcohol dependence (age at onset);
CRC	trans	rs10133840	0.963	rs2789383	chr14:95408809	G/A	cg09075307	chr12:132547245	EP400	-0.46	-5.97	-0.31	6.3e-9	Body mass index (dietary energy interaction);
CRC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg03316587	chr8:142245164	NA	0.42	6.45	0.33	4.05e-10	Immature fraction of reticulocytes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg02113521	chr15:22892956	CYFIP1	0.4	6.55	0.34	2.19e-10	Obesity-related traits;
CRC	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.43	-5.84	-0.31	1.25e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21659725	chr3:3221576	CRBN	-0.68	-9.33	-0.46	1.64e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs783540	1.000	rs1259180	chr15:83244680	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.78	-0.35	5.69e-11	Schizophrenia;
CRC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.39	-0.56	3.47e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg13491945	chr12:107078410	RFX4	-0.35	-6.02	-0.32	4.56e-9	Heart rate;
CRC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.54	-8.3	-0.42	2.71e-15	Aortic root size;
CRC	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.15	-0.32	2.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.51	7.08	0.36	8.81e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13898548	chr5:176924827	PDLIM7	-0.4	-6.62	-0.34	1.44e-10	Obesity-related traits;
CRC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.61	9.41	0.46	8.75e-19	Corneal astigmatism;
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7113874	0.589	rs10840058	chr11:8498399	G/T	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-6.71	-0.35	8.39e-11	Hemoglobin concentration;
CRC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.65	-9.24	-0.45	3.14e-18	DNA methylation (variation);
CRC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.55	-8.63	-0.43	2.66e-16	Vitiligo;
CRC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	9.51	0.46	4.07e-19	Lymphocyte counts;
CRC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.85	-0.35	3.69e-11	Breast cancer;
CRC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg00106254	chr7:1943704	MAD1L1	0.38	5.89	0.31	9.8e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg24289452	chr6:170231220	NA	-0.67	-6.78	-0.35	5.59e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg26721908	chr21:47610096	LSS	-0.46	-7.52	-0.38	5.35e-13	Testicular germ cell tumor;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg18963330	chr11:120081890	OAF	-0.44	-6.31	-0.33	8.92e-10	Birth weight;Height;
CRC	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg18232548	chr7:50535776	DDC	-0.43	-5.66	-0.3	3.22e-8	Malaria;
CRC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	9.16	0.45	5.56e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.79	-0.35	5.37e-11	Breast cancer;
CRC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.8	-0.48	4.78e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-17.75	-0.7	6.25e-50	Height;
CRC	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.73	7.28	0.37	2.54e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06216926	chr14:92572917	ATXN3	0.45	6.61	0.34	1.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.44	6.1	0.32	3.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg02734326	chr4:10020555	SLC2A9	0.35	5.62	0.3	4.15e-8	Bone mineral density;
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg24505167	chr7:1915268	MAD1L1	-0.45	-6.28	-0.33	1.09e-9	Bipolar disorder;
CRC	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.48	7.91	0.4	3.86e-14	Refractive error;
CRC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.34e-40	Prostate cancer;
CRC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.83	8.23	0.41	4.37e-15	Diabetic retinopathy;
CRC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.53	7.96	0.4	2.76e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg10756647	chr7:56101905	PSPH	0.73	7.68	0.39	1.79e-13	Diabetic kidney disease;
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.26e-9	Prudent dietary pattern;
CRC	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.55	-7.82	-0.4	7.04e-14	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg04586622	chr2:25135609	ADCY3	-0.54	-10.07	-0.49	5.8e-21	Body mass index;
CRC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg14074117	chr16:1909714	C16orf73	0.42	5.88	0.31	1.03e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg02927042	chr1:21476669	EIF4G3	0.38	5.85	0.31	1.19e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg20512303	chr5:131592959	PDLIM4	0.41	7.25	0.37	3.04e-12	Acylcarnitine levels;
CRC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.18	0.37	4.57e-12	Rheumatoid arthritis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04703844	chr8:74207197	RPL7;RDH10	-0.55	-6.7	-0.35	8.96e-11	Diisocyanate-induced asthma;
CRC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.39	-5.79	-0.3	1.67e-8	Primary biliary cholangitis;
CRC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg02094049	chr14:103021097	NA	0.44	5.79	0.3	1.6e-8	Platelet count;
CRC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.58	7.72	0.39	1.4e-13	Mean corpuscular hemoglobin;
CRC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg25456477	chr12:86230367	RASSF9	0.38	6.32	0.33	8.37e-10	Major depressive disorder;
CRC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.63	10.03	0.48	8.12e-21	Height;
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.1	0.36	7.93e-12	Alzheimer's disease;
CRC	cis	rs72772090	0.539	rs72773989	chr5:96163613	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.09	-0.32	3.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.38	6.25	0.33	1.24e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04389262	chr14:89882592	FOXN3	0.44	6.26	0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg15123519	chr2:136567270	LCT	-0.33	-6.21	-0.32	1.62e-9	Mosquito bite size;
CRC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	7.93	0.4	3.5e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.61	8.46	0.42	8.85e-16	Arsenic metabolism;
CRC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03188948	chr7:1209495	NA	0.42	6.05	0.32	3.98e-9	Longevity;Endometriosis;
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.44	-0.33	4.29e-10	Total body bone mineral density;
CRC	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09695851	chr17:3907499	NA	0.44	6.05	0.32	3.89e-9	Type 2 diabetes;
CRC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.6	-0.43	3.37e-16	Monocyte percentage of white cells;
CRC	cis	rs7264396	0.623	rs6119609	chr20:34039394	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.02	-0.36	1.29e-11	Total cholesterol levels;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.78	9.01	0.45	1.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.43	8.74	0.43	1.18e-16	Intelligence (multi-trait analysis);
CRC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.49	-0.62	3.96e-37	Gout;
CRC	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.05	-14.75	-0.63	3.75e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.09	0.32	3.13e-9	Axial length;
CRC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24308560	chr3:49941425	MST1R	-0.44	-6.64	-0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg24519413	chr1:26490540	NA	0.41	5.64	0.3	3.62e-8	Height;
CRC	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.47e-10	Prostate cancer;
CRC	cis	rs7849270	1.000	rs3118632	chr9:131901284	G/A	cg13538475	chr9:131942899	NA	0.33	6.35	0.33	7.11e-10	Blood metabolite ratios;
CRC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.82	-13.49	-0.6	2.57e-33	Menopause (age at onset);
CRC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.87	-16.2	-0.67	8.2e-44	Coronary artery disease;
CRC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.23	-0.45	3.28e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg15571903	chr15:79123663	NA	-0.31	-6.06	-0.32	3.65e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg10645314	chr2:3704589	ALLC	-0.54	-6.29	-0.33	1.02e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.65	11.29	0.53	3.2e-25	Prostate cancer;
CRC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12273811	chr6:28175739	NA	0.61	8.84	0.44	5.98e-17	Cardiac Troponin-T levels;
CRC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	6.58	0.34	1.82e-10	Rheumatoid arthritis;
CRC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg18827107	chr12:86230957	RASSF9	-0.38	-6.05	-0.32	4.03e-9	Major depressive disorder;
CRC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.66	11.26	0.53	4.32e-25	Mean corpuscular volume;
CRC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-13.38	-0.59	6.93e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg26893134	chr6:116381904	FRK	0.27	7.96	0.4	2.77e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.05e-14	Type 2 diabetes;
CRC	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.51	8.87	0.44	4.71e-17	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	12.83	0.58	7.56e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2415984	0.579	rs1389606	chr14:46964226	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.96	0.31	6.64e-9	Number of children ever born;
CRC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg17401720	chr7:158221031	PTPRN2	-0.41	-6.74	-0.35	7.22e-11	Obesity-related traits;
CRC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.21	0.32	1.62e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs16830122	0.514	rs67849779	chr1:154611208	G/A	cg17218026	chr1:154582156	ADAR	-0.47	-6.12	-0.32	2.59e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.21e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg21620606	chr4:1342894	KIAA1530	-0.43	-7.81	-0.4	7.76e-14	Obesity-related traits;
CRC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.15	0.32	2.28e-9	Diabetic kidney disease;
CRC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.36	-6.31	-0.33	9.24e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.75	11.3	0.53	3.15e-25	High light scatter reticulocyte count;
CRC	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.36e-16	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs9903692	0.954	rs9747001	chr17:46154669	G/A	cg21215337	chr17:46176117	CBX1	0.42	7.79	0.39	8.93e-14	Pulse pressure;
CRC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg20243544	chr17:37824526	PNMT	0.56	8.95	0.44	2.59e-17	Asthma;
CRC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.62	9.46	0.46	5.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02203542	chr20:305175	SOX12	0.46	6.41	0.33	5.07e-10	Response to antipsychotic treatment;
CRC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.63	9.16	0.45	5.75e-18	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.58	9.5	0.46	4.38e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.11	-0.69	2.25e-47	Body mass index;
CRC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg19223190	chr17:80058835	NA	0.41	6.7	0.35	8.79e-11	Life satisfaction;
CRC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg23590916	chr17:43697445	MGC57346	0.73	7.27	0.37	2.72e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.57	7.33	0.37	1.75e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.56	8.7	0.43	1.57e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.92	-19.57	-0.73	4.36e-57	Urate levels in lean individuals;
CRC	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg18758796	chr5:131593413	PDLIM4	-0.33	-5.71	-0.3	2.58e-8	Blood metabolite levels;
CRC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg25174290	chr11:3078921	CARS	-0.4	-5.65	-0.3	3.5e-8	Calcium levels;
CRC	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg15382696	chr6:118971807	C6orf204	0.6	7.01	0.36	1.34e-11	Diastolic blood pressure;
CRC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg21839984	chr17:30846986	MYO1D	-0.45	-7.65	-0.39	2.28e-13	Schizophrenia;
CRC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-8.59	-0.43	3.49e-16	Personality dimensions;
CRC	cis	rs2108622	0.727	rs12610967	chr19:15977929	C/A	cg13772218	chr19:15982569	NA	0.48	6.69	0.35	9.62e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg08112188	chr17:47440006	ZNF652	0.81	6.52	0.34	2.72e-10	Prostate cancer;
CRC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.44	-5.76	-0.3	1.9e-8	Response to diuretic therapy;
CRC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.17e-13	Colorectal cancer;
CRC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg16724585	chr3:197361211	NA	-0.47	-7.08	-0.36	9.03e-12	Pancreatic cancer;
CRC	cis	rs12711979	0.512	rs1466227	chr2:3832358	T/C	cg17052675	chr2:3827356	NA	-0.35	-5.92	-0.31	7.96e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12530254	chr20:17949265	C20orf72;SNX5	0.48	6.18	0.32	1.93e-9	Anxiety disorder;
CRC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.43	8.72	0.43	1.36e-16	Renal cell carcinoma;
CRC	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.44	7.0	0.36	1.45e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6662572	0.737	rs9429187	chr1:46558927	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.25	0.33	1.29e-9	Blood protein levels;
CRC	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg11446398	chr5:77624930	NA	0.41	5.89	0.31	9.63e-9	Triglycerides;
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs728616	0.614	rs61859191	chr10:82091027	T/C	cg05935833	chr10:81318306	SFTPA2	-0.57	-7.0	-0.36	1.48e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.51	8.42	0.42	1.14e-15	Uric acid clearance;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12822074	chr11:57243865	RTN4RL2	0.37	6.23	0.32	1.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg12365402	chr11:9010492	NRIP3	0.52	8.64	0.43	2.57e-16	Hemoglobin concentration;
CRC	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-1.02	-10.21	-0.49	1.89e-21	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.54	-8.68	-0.43	1.88e-16	Aortic root size;
CRC	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg03469862	chr11:68924853	NA	0.45	5.78	0.3	1.76e-8	Blond vs. brown hair color;
CRC	cis	rs6545883	0.525	rs1177274	chr2:61368532	T/G	cg10580144	chr2:61372316	C2orf74	0.28	5.78	0.3	1.7e-8	Tuberculosis;
CRC	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	1.1	10.28	0.49	1.15e-21	Arsenic metabolism;
CRC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.33	-7.05	-0.36	1.04e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.58	-6.01	-0.31	4.91e-9	Opioid sensitivity;
CRC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.57	8.7	0.43	1.6e-16	Schizophrenia;
CRC	cis	rs3018066	0.666	rs28868894	chr4:107035282	C/T	cg01869342	chr4:106983673	TBCK	0.42	5.66	0.3	3.38e-8	Cancer;
CRC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.01	0.31	4.88e-9	Lung cancer;
CRC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.46	0.34	3.8e-10	Aortic root size;
CRC	cis	rs7091068	0.566	rs7098349	chr10:95514907	A/C	cg20715218	chr10:95462985	C10orf4	0.54	5.67	0.3	3.08e-8	Urinary tract infection frequency;
CRC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.58	6.42	0.33	4.89e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.39	-6.23	-0.32	1.4e-9	Blood metabolite levels;
CRC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.32	0.33	8.38e-10	Diabetic kidney disease;
CRC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.64	9.07	0.45	1.08e-17	Vitamin D levels;
CRC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-5.71	-0.3	2.54e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-10.72	-0.51	3.45e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg08600765	chr20:34638493	LOC647979	-0.64	-8.36	-0.42	1.73e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.56	-9.25	-0.45	3.01e-18	Lewy body disease;
CRC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.92	16.96	0.68	8.06e-47	Intelligence (multi-trait analysis);
CRC	cis	rs7259376	0.514	rs11673221	chr19:22492035	T/C	cg02657401	chr19:22469223	NA	-0.3	-6.56	-0.34	2.07e-10	Menopause (age at onset);
CRC	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.37	-0.33	6.38e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.72	-11.31	-0.53	2.92e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.48	7.45	0.38	8.22e-13	Migraine;Coronary artery disease;
CRC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.27e-11	Alzheimer's disease (late onset);
CRC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.09	-0.36	8.35e-12	Recombination measurement;
CRC	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.49	-7.58	-0.39	3.57e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.54	-0.34	2.3e-10	Aortic root size;
CRC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.44	-5.85	-0.31	1.16e-8	Gut microbiome composition (summer);
CRC	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.47e-10	Prostate cancer;
CRC	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg14352298	chr13:112236639	NA	0.3	6.71	0.35	8.5e-11	Hepatitis;
CRC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg08614441	chr13:113633676	MCF2L	-0.5	-8.87	-0.44	4.61e-17	Systolic blood pressure;
CRC	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.57	10.13	0.49	3.57e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg12172441	chr6:28176163	NA	0.48	5.66	0.3	3.34e-8	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.63	9.26	0.45	2.68e-18	Subjective well-being;
CRC	cis	rs1223397	1.000	rs1223399	chr6:13271220	G/A	cg20827128	chr6:13274284	PHACTR1	0.53	6.52	0.34	2.69e-10	Blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25883402	chr1:173837173	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.43	6.14	0.32	2.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-0.67	-9.56	-0.47	2.93e-19	Type 2 diabetes;
CRC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.62	8.42	0.42	1.16e-15	High light scatter reticulocyte count;
CRC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	9.1	0.45	8.97e-18	Monocyte percentage of white cells;
CRC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.43	-6.57	-0.34	1.91e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.13	10.49	0.5	2.06e-22	Skin colour saturation;
CRC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.09	0.32	3.08e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23508540	chr1:9884032	CLSTN1	0.43	6.77	0.35	5.98e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg24463073	chr6:118973353	C6orf204	0.49	6.65	0.34	1.22e-10	Diastolic blood pressure;
CRC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.46	6.98	0.36	1.6e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.54	7.88	0.4	4.91e-14	Resting heart rate;
CRC	cis	rs1619661	0.505	rs10899997	chr10:44683841	T/G	cg09554077	chr10:44749378	NA	0.47	7.14	0.37	6.09e-12	QT interval (ambient particulate matter interaction);
CRC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.67	-10.61	-0.51	7.86e-23	Immature fraction of reticulocytes;
CRC	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg07414643	chr4:187882934	NA	0.35	5.87	0.31	1.06e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3760982	1.000	rs11669175	chr19:44289824	A/G	cg12072164	chr19:44306565	LYPD5	0.41	6.42	0.33	4.75e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.65	-0.39	2.19e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs12936587	0.576	rs8073975	chr17:17555631	G/T	cg09796270	chr17:17721594	SREBF1	-0.46	-7.78	-0.39	9.38e-14	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09567212	chr6:37787045	ZFAND3	0.59	6.32	0.33	8.62e-10	Interleukin-4 levels;
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg18479299	chr3:125709523	NA	-0.5	-6.47	-0.34	3.65e-10	Blood pressure (smoking interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04924415	chr12:100661456	SCYL2;DEPDC4	-0.4	-6.11	-0.32	2.77e-9	Myopia (pathological);
CRC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.55	6.05	0.32	3.91e-9	Vitiligo;
CRC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg01262667	chr19:19385393	TM6SF2	0.39	6.6	0.34	1.65e-10	Tonsillectomy;
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.72	9.48	0.46	5.05e-19	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.71	0.3	2.55e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.57	-8.81	-0.44	7.32e-17	Sudden cardiac arrest;
CRC	cis	rs6834538	0.558	rs701760	chr4:113439212	C/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.39	-6.46	-0.34	3.84e-10	Free thyroxine concentration;
CRC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg11657440	chr19:46296263	DMWD	0.7	12.22	0.56	1.42e-28	Coronary artery disease;
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.63	6.54	0.34	2.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg22561889	chr6:118971681	C6orf204	0.47	5.9	0.31	8.96e-9	Diastolic blood pressure;
CRC	trans	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.76	-0.39	1.06e-13	HDL cholesterol;
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.48	8.13	0.41	9.1e-15	Sjögren's syndrome;
CRC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg21466736	chr12:48725269	NA	-0.47	-7.33	-0.37	1.81e-12	Glycated hemoglobin levels;
CRC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.64	6.64	0.34	1.26e-10	Axial length;
CRC	cis	rs11212617	0.934	rs10890834	chr11:108286443	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.61	0.34	1.52e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9303542	0.625	rs17703660	chr17:46567134	T/C	cg04904318	chr17:46607828	HOXB1	-0.51	-5.81	-0.31	1.44e-8	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.99	-0.55	9.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.93	11.66	0.54	1.56e-26	Exhaled nitric oxide levels;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15369054	chr17:80825471	TBCD	-0.35	-5.9	-0.31	8.9e-9	Breast cancer;
CRC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.6	-11.23	-0.53	5.42e-25	Coronary artery disease;
CRC	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.89	-16.02	-0.66	4.26e-43	Height;
CRC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.37	-5.8	-0.3	1.55e-8	Blood metabolite levels;
CRC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.52	6.39	0.33	5.66e-10	Birth weight;
CRC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.61	11.36	0.53	1.83e-25	Educational attainment;
CRC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.56	8.04	0.41	1.63e-14	Resting heart rate;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.57	-5.99	-0.31	5.45e-9	White matter hyperintensity burden;
CRC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.45	6.71	0.35	8.4e-11	N-glycan levels;
CRC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.72	11.92	0.55	1.85e-27	Monocyte count;
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.56	-0.5	1.26e-22	Alzheimer's disease;
CRC	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.59	-8.54	-0.43	4.96e-16	Schizophrenia;
CRC	trans	rs146671954	1	rs146671954	chr9:136934203	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-6.06	-0.32	3.65e-9	Red cell distribution width;
CRC	cis	rs9308731	1.000	rs6750599	chr2:111893869	A/T	cg04202892	chr2:111875749	ACOXL	-0.36	-5.83	-0.31	1.31e-8	Chronic lymphocytic leukemia;
CRC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.16	-12.13	-0.56	3.01e-28	Breast cancer;
CRC	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.66	6.93	0.36	2.16e-11	Childhood ear infection;
CRC	trans	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.65	0.3	3.47e-8	Prudent dietary pattern;
CRC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.71	11.57	0.54	3.39e-26	Dental caries;
CRC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg21153622	chr11:89784906	NA	0.43	6.9	0.36	2.64e-11	Coronary artery disease;
CRC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.26	0.37	2.78e-12	Motion sickness;
CRC	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg06204229	chr3:52865917	ITIH4	-0.49	-6.09	-0.32	3.18e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.86	0.48	2.82e-20	Exhaled nitric oxide output;
CRC	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg11204139	chr17:3907470	NA	-0.78	-14.23	-0.62	3.89e-36	Type 2 diabetes;
CRC	cis	rs17021463	0.676	rs13124715	chr4:95313382	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	5.94	0.31	7.06e-9	Testicular germ cell tumor;
CRC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.44	-9.18	-0.45	4.93e-18	Intelligence (multi-trait analysis);
CRC	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	0.69	10.39	0.5	4.57e-22	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.67	-10.22	-0.49	1.84e-21	Metabolic syndrome;
CRC	cis	rs1572438	0.895	rs12202771	chr6:857147	C/T	cg13447295	chr6:887704	NA	-0.42	-6.19	-0.32	1.84e-9	Aging;
CRC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.04e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.61	-9.97	-0.48	1.2e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg11861562	chr11:117069780	TAGLN	0.4	8.28	0.42	3.11e-15	Blood protein levels;
CRC	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.38	-6.4	-0.33	5.2e-10	Mean corpuscular volume;
CRC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.52	8.47	0.42	8.14e-16	Monobrow;
CRC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	5.93	0.31	7.86e-9	Schizophrenia;
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.64e-8	Prudent dietary pattern;
CRC	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13736514	chr6:26305472	NA	-0.46	-7.58	-0.39	3.67e-13	Educational attainment;
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12273811	chr6:28175739	NA	-0.76	-10.97	-0.52	4.41e-24	Depression;
CRC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.8	13.7	0.6	4.08e-34	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12075144	chr3:155588060	GMPS	0.38	6.15	0.32	2.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg27489772	chr12:121021490	NA	-0.48	-6.25	-0.33	1.26e-9	Type 1 diabetes nephropathy;
CRC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg03623178	chr6:28175578	NA	0.51	7.65	0.39	2.25e-13	Pubertal anthropometrics;
CRC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.43	5.84	0.31	1.27e-8	Total body bone mineral density;
CRC	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	6.71	0.35	8.52e-11	Lymphocyte counts;
CRC	cis	rs6662572	0.806	rs11211133	chr1:45991079	G/A	cg08644498	chr1:46502608	NA	0.42	6.0	0.31	5.12e-9	Blood protein levels;
CRC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.59	9.23	0.45	3.31e-18	Monocyte count;
CRC	cis	rs2108622	0.727	rs55954696	chr19:15981805	A/G	cg13772218	chr19:15982569	NA	0.48	6.81	0.35	4.52e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.35	-0.42	1.96e-15	Body mass index;
CRC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.38	5.7	0.3	2.67e-8	Menarche (age at onset);
CRC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.57	-0.34	1.99e-10	Reticulocyte fraction of red cells;
CRC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	18.69	0.72	1.29e-53	Prudent dietary pattern;
CRC	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg10437265	chr15:77819839	NA	0.58	10.16	0.49	2.83e-21	Type 2 diabetes;
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.54	6.65	0.34	1.22e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.15e-10	Mean platelet volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00567536	chr3:47422272	PTPN23	0.48	6.61	0.34	1.58e-10	Response to antipsychotic treatment;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg00628130	chr8:95908808	CCNE2	-0.44	-6.33	-0.33	8.21e-10	Birth weight;Height;
CRC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg19980929	chr12:42632907	YAF2	-0.43	-6.35	-0.33	7.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9925964	0.967	rs2032915	chr16:31117413	C/T	cg03418659	chr16:31128414	MYST1	0.5	7.3	0.37	2.15e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4604732	0.642	rs4489599	chr1:247635213	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.43	-7.19	-0.37	4.35e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4973397	0.519	rs1729082	chr2:232196472	T/A	cg13347044	chr2:232276743	NA	0.41	6.19	0.32	1.79e-9	Anti-saccade response;
CRC	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg14003231	chr6:33640908	ITPR3	0.49	7.95	0.4	3.04e-14	Plateletcrit;
CRC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg26353448	chr1:248524236	OR2T4	0.34	6.5	0.34	3.03e-10	Common traits (Other);
CRC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.39	0.38	1.19e-12	Lung cancer in ever smokers;
CRC	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11446398	chr5:77624930	NA	0.42	6.02	0.31	4.66e-9	Triglycerides;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16505237	chr8:145550609	DGAT1	0.42	6.22	0.32	1.48e-9	Schizophrenia;
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg20119798	chr7:94954144	PON1	-0.5	-6.34	-0.33	7.49e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg07699608	chr10:75541558	CHCHD1	0.7	6.76	0.35	6.2e-11	Incident atrial fibrillation;
CRC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg19041857	chr6:27730383	NA	-0.71	-6.71	-0.35	8.65e-11	Depression;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg24159697	chr1:205181237	DSTYK	-0.33	-6.01	-0.31	4.83e-9	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05892773	chr1:112282121	C1orf183	0.5	6.97	0.36	1.73e-11	Response to antipsychotic treatment;
CRC	cis	rs883565	0.696	rs7620304	chr3:39079623	T/A	cg01426195	chr3:39028469	NA	-0.53	-8.54	-0.43	4.97e-16	Handedness;
CRC	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.5	6.38	0.33	5.92e-10	Cholesterol, total;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05775451	chr1:228353712	C1orf69	-0.42	-6.25	-0.33	1.3e-9	Myopia (pathological);
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg15845792	chr6:28175446	NA	0.99	13.1	0.59	7.48e-32	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17079325	chr7:130131480	MEST;MESTIT1	0.24	6.16	0.32	2.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg01339444	chr6:118972232	C6orf204	0.52	5.87	0.31	1.08e-8	Diastolic blood pressure;
CRC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.64	7.87	0.4	5.33e-14	Menarche (age at onset);
CRC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg15358701	chr1:161410459	NA	-0.66	-6.88	-0.35	3.1e-11	Rheumatoid arthritis;
CRC	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg04989706	chr14:50066350	PPIL5	-0.5	-7.02	-0.36	1.25e-11	Carotid intima media thickness;
CRC	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.05	-0.32	3.87e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg12927641	chr6:109611667	NA	-0.32	-5.61	-0.3	4.19e-8	Reticulocyte fraction of red cells;
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs12024301	0.557	rs77855373	chr1:183598435	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-7.05	-0.36	1.03e-11	Tuberculosis;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg23161317	chr6:28129485	ZNF389	0.46	6.12	0.32	2.6e-9	Parkinson's disease;
CRC	cis	rs10886503	0.777	rs4752317	chr10:121264341	C/A	cg17804342	chr10:121271663	RGS10	0.78	7.55	0.38	4.29e-13	Obstetric antiphospholipid syndrome;
CRC	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg25019722	chr6:37503610	NA	-0.46	-8.64	-0.43	2.4e-16	Cognitive performance;
CRC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	11.75	0.54	7.24e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.32e-11	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.53	-8.61	-0.43	3.18e-16	Aortic root size;
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.19	0.41	5.84e-15	Life satisfaction;
CRC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.97	-0.31	6e-9	Total body bone mineral density;
CRC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg04166393	chr7:2884313	GNA12	0.41	6.3	0.33	9.8e-10	Height;
CRC	cis	rs4964805	1.000	rs4964806	chr12:104192760	C/T	cg02344784	chr12:104178138	NT5DC3	0.55	8.37	0.42	1.67e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.32	-7.02	-0.36	1.24e-11	IgG glycosylation;
CRC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg25456477	chr12:86230367	RASSF9	-0.36	-6.19	-0.32	1.76e-9	Major depressive disorder;
CRC	cis	rs62408225	1.000	rs62408222	chr6:90948476	A/G	cg06866423	chr6:90926672	BACH2	0.47	7.67	0.39	1.91e-13	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.38	-5.7	-0.3	2.63e-8	Plateletcrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16322302	chr3:49157769	USP19	0.46	6.55	0.34	2.26e-10	Response to antipsychotic treatment;
CRC	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg10437265	chr15:77819839	NA	-0.44	-7.98	-0.4	2.52e-14	Type 2 diabetes;
CRC	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.79	-0.39	8.94e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg21466736	chr12:48725269	NA	0.49	7.6	0.39	3.21e-13	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.47	6.79	0.35	5.4e-11	Lung cancer;
CRC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-7.52	-0.38	5.43e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.35	5.79	0.3	1.65e-8	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
CRC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.49	8.02	0.4	1.85e-14	Major depressive disorder;
CRC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.64	11.5	0.54	6.02e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs2625529	0.617	rs7175373	chr15:72203517	G/T	cg16672083	chr15:72433130	SENP8	0.44	6.7	0.35	9.25e-11	Red blood cell count;
CRC	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg09655341	chr17:79618100	PDE6G	0.57	5.89	0.31	9.33e-9	Dental caries;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.5	7.16	0.37	5.22e-12	Longevity;Endometriosis;
CRC	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg06296503	chr6:134217401	NA	-0.45	-7.78	-0.39	9.76e-14	Coronary artery disease;
CRC	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-6.09	-0.32	3.14e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-7.9	-0.4	4.11e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.43	0.46	7.91e-19	Alzheimer's disease;
CRC	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	7.74	0.39	1.21e-13	HIV-1 control;
CRC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.35	-5.63	-0.3	3.96e-8	Total body bone mineral density;
CRC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	9.02	0.45	1.58e-17	Schizophrenia;
CRC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg03030879	chr14:75389066	RPS6KL1	0.56	8.96	0.44	2.39e-17	Caffeine consumption;
CRC	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.83	-10.59	-0.5	9.71e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.91	0.36	2.48e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.48	-8.17	-0.41	6.59e-15	Height;
CRC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.63	-0.34	1.36e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.72	-9.17	-0.45	5.43e-18	Iron status biomarkers;
CRC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg10760299	chr15:45669010	GATM	0.49	7.79	0.39	8.71e-14	Homoarginine levels;
CRC	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.44	6.9	0.36	2.61e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.28	-0.73	5.84e-56	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg25164649	chr6:28176230	NA	0.6	7.91	0.4	3.87e-14	Parkinson's disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23442955	chr1:55680982	USP24	0.4	6.48	0.34	3.31e-10	Schizophrenia;
CRC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.5	-8.38	-0.42	1.6e-15	Diastolic blood pressure;
CRC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-8.58	-0.43	3.84e-16	Monocyte percentage of white cells;
CRC	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.45	6.28	0.33	1.07e-9	Uric acid levels;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg15511327	chr8:143859410	LYNX1	-0.4	-6.34	-0.33	7.39e-10	Urinary tract infection frequency;
CRC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.29	-0.49	1.03e-21	Tonsillectomy;
CRC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.89	0.51	8.69e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.3	-6.54	-0.34	2.31e-10	IgG glycosylation;
CRC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.6	9.78	0.47	5.3e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg13722127	chr7:150037890	RARRES2	0.41	6.4	0.33	5.5e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg16476235	chr8:21771668	DOK2	0.4	6.94	0.36	2.07e-11	Mean corpuscular volume;
CRC	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.66	7.03	0.36	1.18e-11	Chronic lymphocytic leukemia;
CRC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.42	-5.9	-0.31	8.85e-9	DNA methylation (variation);
CRC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.98	0.36	1.62e-11	Resting heart rate;
CRC	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02598441	chr17:62777298	LOC146880	-0.59	-7.0	-0.36	1.41e-11	QT interval;
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.26	-0.33	1.2e-9	Total body bone mineral density;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.11e-16	Alcohol dependence;
CRC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg11189052	chr15:85197271	WDR73	0.63	8.81	0.44	7.5e-17	Schizophrenia;
CRC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg23018236	chr17:30244563	NA	-0.59	-7.93	-0.4	3.43e-14	Hip circumference adjusted for BMI;
CRC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg21153622	chr11:89784906	NA	0.41	6.53	0.34	2.52e-10	Coronary artery disease;
CRC	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	cis	rs9323205	0.765	rs2999390	chr14:51654944	C/G	cg23942311	chr14:51606299	NA	-0.57	-9.28	-0.46	2.42e-18	Cancer;
CRC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.77	14.34	0.62	1.49e-36	Prudent dietary pattern;
CRC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.82e-15	Mean platelet volume;
CRC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.65	9.99	0.48	1.08e-20	Corneal astigmatism;
CRC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-6.2	-0.32	1.72e-9	Body mass index;
CRC	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.49	-7.52	-0.38	5.41e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17739167	0.532	rs8035074	chr15:42239779	C/T	cg20935245	chr15:42234343	EHD4	0.38	6.02	0.31	4.72e-9	Monocyte count;
CRC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg19622623	chr12:86230825	RASSF9	-0.38	-5.85	-0.31	1.18e-8	Major depressive disorder;
CRC	cis	rs8014671	0.531	rs12880777	chr14:70874695	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.36	-6.1	-0.32	2.91e-9	Prostate cancer;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg20933634	chr6:27740509	NA	0.39	5.79	0.3	1.61e-8	Parkinson's disease;
CRC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.68	9.06	0.45	1.17e-17	Multiple sclerosis;
CRC	cis	rs447	0.848	rs9969195	chr7:83753142	T/C	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.73	-0.39	1.3e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg16898833	chr6:26189333	HIST1H4D	0.68	6.24	0.33	1.35e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg20265528	chr2:105853269	NA	-0.33	-5.6	-0.3	4.51e-8	Type 2 diabetes;
CRC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg00310523	chr12:86230176	RASSF9	0.44	7.48	0.38	7.04e-13	Major depressive disorder;
CRC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg07809909	chr20:30433512	FOXS1	0.35	5.74	0.3	2.11e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.17e-8	Lung cancer;
CRC	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.56	9.58	0.47	2.43e-19	Dupuytren's disease;
CRC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.51	7.41	0.38	1.06e-12	Height;
CRC	trans	rs9630182	0.561	rs10832040	chr11:13473207	C/A	cg13741668	chr9:85679694	NA	0.37	6.03	0.32	4.51e-9	Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21705844	chr17:3539499	SHPK;CTNS	0.47	7.19	0.37	4.37e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.58	8.54	0.43	4.97e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg18876405	chr7:65276391	NA	-0.46	-6.3	-0.33	9.54e-10	Aortic root size;
CRC	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.73	9.24	0.45	3.05e-18	Iron status biomarkers;
CRC	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	17.23	0.69	7.57e-48	Smoking behavior;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06966887	chr5:443603	EXOC3;C5orf55	0.48	6.2	0.32	1.69e-9	Thyroid stimulating hormone;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15813570	chr14:64854563	MTHFD1	0.47	6.19	0.32	1.8e-9	Thyroid stimulating hormone;
CRC	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg11693508	chr17:37793320	STARD3	0.6	6.91	0.36	2.59e-11	Neuroticism;
CRC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.48	6.45	0.33	4.09e-10	Obesity-related traits;
CRC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-13.72	-0.6	3.53e-34	Blood metabolite levels;
CRC	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg09476006	chr5:138032270	NA	-0.43	-6.62	-0.34	1.46e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs834811	0.623	rs1097151	chr7:135883871	A/G	cg01726295	chr7:135938950	NA	-0.41	-7.03	-0.36	1.17e-11	Post-traumatic stress disorder;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg25767906	chr1:53392781	SCP2	0.45	7.23	0.37	3.5e-12	Monocyte count;
CRC	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg24553058	chr2:113831203	IL1F10	0.39	6.3	0.33	9.43e-10	Protein quantitative trait loci;
CRC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.72	-9.21	-0.45	4.06e-18	Initial pursuit acceleration;
CRC	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg15704280	chr7:45808275	SEPT13	-0.56	-6.84	-0.35	3.77e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.44	-6.14	-0.32	2.36e-9	Fibrinogen levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25563067	chr17:20059234	CYTSB	0.45	7.7	0.39	1.5700000000000001e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg08999081	chr20:33150536	PIGU	0.38	5.94	0.31	7.26e-9	Skin pigmentation;
CRC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.17	-12.85	-0.58	6.56e-31	Diabetic kidney disease;
CRC	cis	rs16852403	0.548	rs3748788	chr1:178202807	A/G	cg00404053	chr1:178313656	RASAL2	0.5	6.55	0.34	2.21e-10	Childhood ear infection;
CRC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.67	-0.35	1.09e-10	Aortic root size;
CRC	cis	rs911119	0.955	rs6114201	chr20:23607231	T/A	cg16589663	chr20:23618590	CST3	0.47	6.73	0.35	7.35e-11	Chronic kidney disease;
CRC	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.52	7.37	0.38	1.43e-12	Testicular germ cell tumor;
CRC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.39	-6.75	-0.35	6.5e-11	Age at first birth;
CRC	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg12046867	chr14:103022105	NA	-0.79	-10.77	-0.51	2.28e-23	Platelet count;
CRC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.47	6.38	0.33	5.95e-10	Schizophrenia;
CRC	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.7	-9.15	-0.45	5.93e-18	Multiple sclerosis;
CRC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.45	5.63	0.3	3.81e-8	Aortic root size;
CRC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.46	6.07	0.32	3.45e-9	Obesity-related traits;
CRC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg16060761	chr17:80687452	NA	-0.49	-6.62	-0.34	1.44e-10	Glycated hemoglobin levels;
CRC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg09491104	chr22:46646882	C22orf40	-0.48	-7.51	-0.38	5.72e-13	LDL cholesterol;Cholesterol, total;
CRC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.5	10.0	0.48	9.66e-21	Renal cell carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08431062	chr19:16607243	C19orf44;CALR3	0.43	6.07	0.32	3.56e-9	Response to antipsychotic treatment;
CRC	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg21115391	chr11:93143810	CCDC67	-0.4	-5.87	-0.31	1.07e-8	Pulmonary function decline;
CRC	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.64	6.72	0.35	7.95e-11	Chronic lymphocytic leukemia;
CRC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg16358738	chr2:241808595	AGXT	-0.4	-6.02	-0.31	4.76e-9	Urinary metabolites;
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.69	8.23	0.41	4.47e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs3731896	0.848	rs4485556	chr2:220157418	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.52	5.93	0.31	7.82e-9	Educational attainment;
CRC	cis	rs62158211	0.565	rs57611236	chr2:114103804	A/T	cg17784749	chr2:114082611	LOC440839	0.45	5.83	0.31	1.32e-8	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.47	-6.47	-0.34	3.46e-10	Eye color traits;
CRC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.43	-6.46	-0.34	3.78e-10	Gout;Renal underexcretion gout;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.55	0.47	3.03e-19	Type 2 diabetes;
CRC	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg23920097	chr1:209922102	NA	-0.48	-5.62	-0.3	4.1e-8	Red blood cell count;
CRC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.66	11.75	0.54	7.44e-27	Height;
CRC	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.52	8.54	0.43	5.1e-16	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.43	6.61	0.34	1.53e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs371025208	1	rs371025208	chr20:43928602	TGGGTGTGTGTGTGTAGGG/T	cg06407657	chr20:43937138	MATN4;RBPJL	0.41	6.43	0.33	4.61e-10	Parental longevity (mother's age at death);
CRC	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.53	6.2	0.32	1.71e-9	Pulse pressure;
CRC	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg16342193	chr10:102329863	NA	-0.36	-5.89	-0.31	9.47e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.56	0.67	3.28e-45	Electrocardiographic conduction measures;
CRC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.48	-7.71	-0.39	1.56e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2737618	0.651	rs2816975	chr1:200081159	A/G	cg21825944	chr1:200113062	NR5A2	-0.48	-7.17	-0.37	5.09e-12	Uric acid levels;
CRC	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg03315344	chr16:75512273	CHST6	0.48	5.84	0.31	1.27e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs17767392	0.871	rs34347034	chr14:71935513	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.17	-0.37	5.11e-12	Mitral valve prolapse;
CRC	cis	rs9463078	0.874	rs7743116	chr6:45142858	T/C	cg25276700	chr6:44698697	NA	-0.29	-6.81	-0.35	4.57e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	7.5	0.38	5.82e-13	Mean corpuscular volume;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.53	9.42	0.46	8.34e-19	Hypertriglyceridemia;
CRC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg09417038	chr21:47716443	C21orf57	-0.41	-6.8	-0.35	4.94e-11	Testicular germ cell tumor;
CRC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.49	8.19	0.41	5.89e-15	Breast cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08860546	chr16:4233762	NA	-0.42	-6.18	-0.32	1.94e-9	Myopia (pathological);
CRC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg19812747	chr11:111475976	SIK2	0.53	7.62	0.39	2.78e-13	Primary sclerosing cholangitis;
CRC	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.51	7.35	0.38	1.59e-12	Testicular germ cell tumor;
CRC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.75e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.41	0.5	3.99e-22	Heart rate;
CRC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.68	-10.3	-0.49	9.57e-22	Initial pursuit acceleration;
CRC	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg27534772	chr1:16042836	PLEKHM2	0.37	6.34	0.33	7.43e-10	Systolic blood pressure;
CRC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.25	0.41	3.79e-15	Lung cancer;
CRC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.38	0.69	1.84e-48	Blood protein levels;
CRC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.56	8.59	0.43	3.57e-16	Diastolic blood pressure;
CRC	cis	rs2949837	0.603	rs1542818	chr7:45977656	G/T	cg23193639	chr7:45961078	IGFBP3	0.4	6.66	0.34	1.14e-10	Sitting height ratio;
CRC	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.58	0.39	3.56e-13	Eye color traits;
CRC	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg00250761	chr1:31883323	NA	0.46	9.09	0.45	9.87e-18	Alcohol dependence;
CRC	cis	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg18131467	chr2:239335373	ASB1	-0.71	-6.32	-0.33	8.61e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg05623727	chr3:50126028	RBM5	-0.44	-7.47	-0.38	7.28e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.52	9.22	0.45	3.7e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.42	-9.26	-0.45	2.8e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.84	-0.48	3.48e-20	Total cholesterol levels;
CRC	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.26e-10	Common traits (Other);
CRC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg02725872	chr8:58115012	NA	-0.41	-6.38	-0.33	6.05e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.99e-24	Motion sickness;
CRC	cis	rs972578	0.747	rs5758975	chr22:43233265	C/T	cg01576275	chr22:43409880	NA	-0.39	-6.1	-0.32	2.99e-9	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg04611788	chr3:186434169	KNG1	-0.57	-8.32	-0.42	2.41e-15	Blood protein levels;
CRC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg21153622	chr11:89784906	NA	-0.43	-6.99	-0.36	1.58e-11	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17839278	chr11:47664375	MTCH2	0.45	6.11	0.32	2.77e-9	Response to antipsychotic treatment;
CRC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.5	9.07	0.45	1.13e-17	Schizophrenia;
CRC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.49	6.2	0.32	1.7e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	18.73	0.72	8.35e-54	Prudent dietary pattern;
CRC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	7.02	0.36	1.24e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.83	14.72	0.63	5.05e-38	Breast cancer;
CRC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg05623727	chr3:50126028	RBM5	-0.4	-5.96	-0.31	6.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg23625390	chr15:77176239	SCAPER	0.39	5.61	0.3	4.33e-8	Blood metabolite levels;
CRC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg24675056	chr1:15929824	NA	0.54	7.31	0.37	2.07e-12	Systolic blood pressure;
CRC	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.4	6.24	0.33	1.37e-9	Reticulocyte fraction of red cells;
CRC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.75	-9.49	-0.46	4.75e-19	Initial pursuit acceleration;
CRC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.91	17.17	0.69	1.3e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.65	9.31	0.46	1.84e-18	Schizophrenia;
CRC	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.57	8.92	0.44	3.33e-17	Brugada syndrome;
CRC	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg05283184	chr6:79620031	NA	-0.43	-6.32	-0.33	8.48e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.967	rs189037	chr11:108093833	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.66	0.3	3.26e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.62	9.06	0.45	1.16e-17	Morning vs. evening chronotype;
CRC	trans	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg24644049	chr4:85504048	CDS1	0.93	7.58	0.39	3.6e-13	Skin colour saturation;
CRC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.55	-8.22	-0.41	4.82e-15	Body mass index;
CRC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.71	10.95	0.52	5.2e-24	Corneal astigmatism;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg08798685	chr6:27730294	NA	0.53	7.53	0.38	5.09e-13	Parkinson's disease;
CRC	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.96	0.52	5.08e-24	Coffee consumption (cups per day);
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg25164649	chr6:28176230	NA	0.62	8.92	0.44	3.23e-17	Parkinson's disease;
CRC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg12923728	chr3:195709715	SDHAP1	0.6	6.29	0.33	1.03e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg11946769	chr3:48343235	NME6	-0.5	-6.59	-0.34	1.75e-10	Educational attainment (years of education);
CRC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg15845792	chr6:28175446	NA	0.44	5.74	0.3	2.15e-8	Myopia;
CRC	cis	rs10760158	0.832	rs10818519	chr9:124012935	G/C	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.46	8.0	0.4	2.21e-14	Eye color traits;
CRC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.27	0.37	2.65e-12	Motion sickness;
CRC	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	5.66	0.3	3.27e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.58	-7.52	-0.38	5.39e-13	Gut microbiome composition (summer);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21051031	chr5:93905482	C5orf36;MIR1974	-0.36	-5.99	-0.31	5.6e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg23298862	chr7:158159286	PTPRN2	0.39	6.05	0.32	3.99e-9	Calcium levels;
CRC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.15	14.73	0.63	4.62e-38	Uric acid levels;
CRC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg00745463	chr17:30367425	LRRC37B	-0.62	-7.89	-0.4	4.65e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2274273	0.615	rs17672058	chr14:55673394	C/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.81	-0.31	1.46e-8	Protein biomarker;
CRC	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg20636351	chr8:55087400	NA	-0.33	-5.96	-0.31	6.62e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.14	0.32	2.32e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.69	-10.51	-0.5	1.77e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs77633900	0.772	rs79181196	chr15:76656281	G/T	cg21673338	chr15:77095150	SCAPER	-0.74	-6.88	-0.35	3e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs28493229	0.708	rs10407431	chr19:41160870	T/C	cg21869046	chr19:41225005	ITPKC	0.41	6.15	0.32	2.26e-9	Kawasaki disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23781003	chr4:120988207	MAD2L1	0.51	7.32	0.37	1.98e-12	Response to antipsychotic treatment;
CRC	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.18	-0.37	4.58e-12	Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg04204079	chr8:58130323	NA	-0.42	-5.66	-0.3	3.32e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.36	0.33	6.58e-10	Morning vs. evening chronotype;
CRC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.46	0.38	7.65e-13	Lung cancer in ever smokers;
CRC	trans	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.83	0.4	6.99e-14	Diabetic kidney disease;
CRC	cis	rs17155006	0.612	rs435361	chr7:107738552	C/T	cg05962710	chr7:107745446	LAMB4	-0.43	-7.53	-0.38	4.79e-13	Pneumococcal bacteremia;
CRC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg27534772	chr1:16042836	PLEKHM2	0.54	10.62	0.51	7.47e-23	Systolic blood pressure;
CRC	cis	rs1519814	1.000	rs4871037	chr8:121124042	A/G	cg22335954	chr8:121166405	COL14A1	-0.55	-6.25	-0.33	1.25e-9	Breast cancer;
CRC	cis	rs289828	0.868	rs289829	chr2:152136901	A/G	cg06191203	chr2:152266755	RIF1	-0.4	-5.69	-0.3	2.87e-8	Blood protein levels;
CRC	cis	rs12024301	0.557	rs12040169	chr1:183639963	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.79	6.98	0.36	1.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.0	0.4	2.12e-14	Menarche (age at onset);
CRC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-12.76	-0.58	1.49e-30	Menarche (age at onset);
CRC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.61	-10.95	-0.52	5.42e-24	Aortic root size;
CRC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.51	5.63	0.3	3.96e-8	Vitiligo;
CRC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.82	-13.21	-0.59	2.86e-32	QT interval;
CRC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg17401720	chr7:158221031	PTPRN2	-0.4	-6.67	-0.35	1.06e-10	Obesity-related traits;
CRC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-13.78	-0.61	1.99e-34	Prostate cancer;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03309838	chr22:41215494	SLC25A17	0.44	6.35	0.33	7.21e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg11245181	chr6:149772854	ZC3H12D	-0.58	-10.47	-0.5	2.56e-22	Dupuytren's disease;
CRC	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg02524346	chr8:600233	NA	0.72	7.67	0.39	2.01e-13	IgG glycosylation;
CRC	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg19337854	chr7:99768885	GPC2	0.43	5.6	0.3	4.47e-8	Lung function (FEV1/FVC);
CRC	trans	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg18335740	chr13:41363409	SLC25A15	0.48	7.09	0.36	8.44e-12	Lewy body disease;
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-6.58	-0.34	1.88e-10	Systemic lupus erythematosus;
CRC	cis	rs9322817	0.691	rs4591886	chr6:105249970	G/C	cg02098413	chr6:105308735	HACE1	-0.44	-8.6	-0.43	3.29e-16	Thyroid stimulating hormone;
CRC	cis	rs972578	0.967	rs2068944	chr22:43356442	T/G	cg01576275	chr22:43409880	NA	-0.46	-7.41	-0.38	1.08e-12	Mean platelet volume;
CRC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	14.76	0.63	3.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg21972741	chr5:435613	AHRR	0.5	6.74	0.35	6.96e-11	Cystic fibrosis severity;
CRC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg15445000	chr17:37608096	MED1	0.26	5.71	0.3	2.54e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.51	8.99	0.44	1.92e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg17133734	chr15:86042851	AKAP13	0.39	6.06	0.32	3.78e-9	Coronary artery disease;
CRC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg03609598	chr5:56110824	MAP3K1	-0.56	-7.68	-0.39	1.86e-13	Coronary artery disease;
CRC	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.51	7.35	0.38	1.57e-12	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03352409	chr22:21336370	LZTR1	0.54	7.1	0.36	7.52e-12	Thyroid stimulating hormone;
CRC	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-1.25	-10.26	-0.49	1.27e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.48	7.76	0.39	1.06e-13	Perceived unattractiveness to mosquitoes;
CRC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	7.92	0.4	3.58e-14	Aortic root size;
CRC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.81	-0.4	7.64e-14	Cystic fibrosis severity;
CRC	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg27649806	chr9:35101217	STOML2	0.38	6.08	0.32	3.37e-9	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg05304507	chr6:116381966	FRK	-0.3	-8.07	-0.41	1.34e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.75	10.46	0.5	2.69e-22	Heart rate;
CRC	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.74	-11.75	-0.54	7.63e-27	Plateletcrit;Platelet count;
CRC	cis	rs1223397	0.651	rs2496149	chr6:13313893	A/G	cg07912922	chr6:13274314	PHACTR1	0.37	5.78	0.3	1.71e-8	Blood pressure;
CRC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.59	-8.23	-0.41	4.32e-15	Height;
CRC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16405210	chr4:1374714	KIAA1530	0.45	6.4	0.33	5.39e-10	Obesity-related traits;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg14196790	chr5:131705035	SLC22A5	0.35	6.07	0.32	3.46e-9	Blood metabolite levels;
CRC	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-6.08	-0.32	3.35e-9	Axial length;
CRC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.45	-0.42	9.73e-16	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22658884	chr19:14192470	NA	0.46	6.39	0.33	5.62e-10	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.55	0.34	2.17e-10	Lung cancer;
CRC	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	9.71	0.47	9.45e-20	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs12024301	0.557	rs12029723	chr1:183594236	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg06207120	chr15:45996521	NA	0.32	7.72	0.39	1.38e-13	Waist circumference;Weight;
CRC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.47	6.47	0.34	3.46e-10	Schizophrenia;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg08798685	chr6:27730294	NA	-0.38	-5.67	-0.3	3.16e-8	Parkinson's disease;
CRC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	6.44	0.33	4.22e-10	Menarche (age at onset);
CRC	cis	rs59104589	0.517	rs15129	chr2:242168976	T/C	cg19488206	chr2:242435732	STK25	0.39	5.96	0.31	6.49e-9	Fibrinogen levels;
CRC	cis	rs294883	0.858	rs1553481	chr6:159701771	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg17691542	chr6:26056736	HIST1H1C	0.69	8.53	0.43	5.51e-16	Iron status biomarkers;
CRC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-6.4	-0.33	5.3e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.65	0.34	1.25e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg25876840	chr17:41920477	NA	0.53	7.92	0.4	3.77e-14	Triglycerides;
CRC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.3	-5.64	-0.3	3.66e-8	Type 2 diabetes;
CRC	cis	rs4711350	0.953	rs1547668	chr6:33775446	A/G	cg07979401	chr6:33739406	LEMD2	-0.47	-6.0	-0.31	5.11e-9	Schizophrenia;
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs73206853	0.841	rs67974983	chr12:110519237	T/G	cg12870014	chr12:110450643	ANKRD13A	0.74	8.75	0.43	1.14e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05926606	chr21:40685342	BRWD1	-0.42	-6.29	-0.33	1.01e-9	Myopia (pathological);
CRC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-5.63	-0.3	3.84e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs3751196	0.908	rs12423476	chr12:104210442	C/G	cg02344784	chr12:104178138	NT5DC3	0.69	8.58	0.43	3.93e-16	Sense of smell;
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg08888203	chr3:10149979	C3orf24	0.71	8.58	0.43	3.91e-16	Alzheimer's disease;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17295864	chr8:62381505	CLVS1	-0.54	-6.68	-0.35	9.96e-11	Monocyte percentage of white cells;
CRC	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.97	0.36	1.74e-11	Mean corpuscular volume;
CRC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.94	-0.4	3.14e-14	Chronic sinus infection;
CRC	cis	rs2274471	0.591	rs7034539	chr9:5081585	C/T	cg03390472	chr9:5043263	JAK2	0.59	7.15	0.37	5.67e-12	Crohn's disease;
CRC	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg16822035	chr13:113633379	MCF2L	-0.29	-5.91	-0.31	8.49e-9	Systolic blood pressure;
CRC	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.84	-11.47	-0.53	7.38e-26	Childhood ear infection;
CRC	cis	rs6921919	0.789	rs1119211	chr6:28309136	C/G	cg21251018	chr6:28226885	NKAPL	-0.42	-6.31	-0.33	8.9e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.51	7.25	0.37	3.09e-12	Aortic root size;
CRC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.44	7.61	0.39	2.88e-13	Major depressive disorder;
CRC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.04	-0.55	6.65e-28	Bone mineral density;
CRC	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg14036092	chr11:66035641	RAB1B	0.55	7.8	0.4	8.29e-14	Gout;
CRC	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg06632207	chr12:54070931	ATP5G2	0.5	8.79	0.44	8.18e-17	Height;
CRC	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg16898833	chr6:26189333	HIST1H4D	0.72	6.01	0.31	5.01e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.01e-15	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08143133	chr22:32598570	RFPL2	0.49	7.56	0.38	4.03e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7212590	0.618	rs7217337	chr17:58023417	C/T	cg10252138	chr17:58120427	NA	-0.58	-6.28	-0.33	1.1e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg12365402	chr11:9010492	NRIP3	-0.58	-10.54	-0.5	1.37e-22	Hemoglobin concentration;
CRC	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.63	10.39	0.5	4.86e-22	Cancer;
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	6.59	0.34	1.77e-10	Diastolic blood pressure;
CRC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg16989086	chr20:62203971	PRIC285	0.51	6.48	0.34	3.36e-10	Glioblastoma;
CRC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18402987	chr7:1209562	NA	-0.46	-6.82	-0.35	4.43e-11	Longevity;Endometriosis;
CRC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17507749	chr15:85114479	UBE2QP1	0.62	8.75	0.43	1.15e-16	Schizophrenia;
CRC	cis	rs7215564	0.818	rs901063	chr17:78595696	A/T	cg09596252	chr17:78655493	RPTOR	-0.6	-5.71	-0.3	2.48e-8	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24028120	chr19:33463094	C19orf40;CCDC123	0.42	5.99	0.31	5.4e-9	Response to antipsychotic treatment;
CRC	cis	rs939584	1.000	rs7604609	chr2:643303	C/G	cg03610516	chr2:642275	NA	0.4	5.62	0.3	4.1e-8	Body mass index;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.63	9.27	0.46	2.51e-18	Breast cancer;
CRC	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	5.95	0.31	6.74e-9	Ovarian reserve;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.38	0.75	2.76e-60	Prudent dietary pattern;
CRC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.55	-0.57	8.82e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs4321325	0.668	rs56346774	chr2:127932551	G/A	cg11380483	chr2:127933992	NA	0.65	7.23	0.37	3.33e-12	Protein C levels;
CRC	cis	rs2274273	0.588	rs2880103	chr14:55737832	A/C	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.17	-0.32	2.04e-9	Protein biomarker;
CRC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg00490450	chr3:139108681	COPB2	0.43	6.4	0.33	5.38e-10	Obesity-related traits;
CRC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.55	7.6	0.39	3.08e-13	Bronchopulmonary dysplasia;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.52	7.84	0.4	6.18e-14	Intelligence (multi-trait analysis);
CRC	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.42	-7.85	-0.4	6.03e-14	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	7.06	0.36	1.02e-11	Eye color traits;
CRC	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.88	-0.31	1.03e-8	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.91e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.19	0.69	1.08e-47	Platelet count;
CRC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.66	0.54	1.62e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2411233	0.967	rs6492849	chr15:39271087	T/C	cg23129342	chr15:39283510	NA	0.31	5.65	0.3	3.48e-8	Platelet count;
CRC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.68	10.28	0.49	1.08e-21	Lung cancer;
CRC	cis	rs7605827	0.930	rs10164574	chr2:15677258	G/A	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.53e-8	Educational attainment (years of education);
CRC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.66	13.82	0.61	1.49e-34	Schizophrenia;
CRC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.11	-0.36	7.37e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.92	0.31	8.24e-9	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.64e-8	Prudent dietary pattern;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03452623	chr4:187889614	NA	-0.89	-18.87	-0.72	2.38e-54	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.71	-10.23	-0.49	1.62e-21	Inflammatory bowel disease;
CRC	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.65	8.31	0.42	2.61e-15	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg25019722	chr6:37503610	NA	-0.4	-6.72	-0.35	8.2e-11	Cognitive performance;
CRC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.47	5.98	0.31	5.7e-9	Aortic root size;
CRC	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg02770688	chr6:168491649	NA	0.63	9.15	0.45	6.24e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg01262667	chr19:19385393	TM6SF2	0.38	6.39	0.33	5.6e-10	Tonsillectomy;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg19318889	chr4:1322082	MAEA	0.45	6.71	0.35	8.68e-11	Obesity-related traits;
CRC	cis	rs73206853	0.563	rs1050587	chr12:111158161	T/C	cg12870014	chr12:110450643	ANKRD13A	0.78	9.52	0.46	3.96e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs755249	0.567	rs41270803	chr1:39766041	A/G	cg18385671	chr1:39797026	MACF1	-0.42	-5.98	-0.31	5.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.68	0.54	1.28e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6684428	0.536	rs4468206	chr1:56397362	A/T	cg19679543	chr1:56394286	NA	0.35	5.79	0.3	1.64e-8	Airflow obstruction;
CRC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.47	7.5	0.38	6.01e-13	Calcium levels;
CRC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg00579200	chr11:133705235	NA	0.39	5.7	0.3	2.62e-8	Childhood ear infection;
CRC	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg21153622	chr11:89784906	NA	0.44	7.12	0.37	6.64e-12	HDL cholesterol;
CRC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg03340356	chr1:67600835	NA	0.27	6.13	0.32	2.52e-9	Psoriasis;
CRC	trans	rs12200782	0.649	rs9467745	chr6:26386762	G/A	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.38	14.37	0.62	1.1e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg16416165	chr4:3325029	RGS12	0.44	7.39	0.38	1.25e-12	Parental longevity (mother's age at death);
CRC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg16606324	chr3:10149918	C3orf24	0.59	7.13	0.37	6.53e-12	Alzheimer's disease;
CRC	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg18064842	chr5:14874549	NA	-0.47	-7.2	-0.37	4.14e-12	Blood metabolite levels;
CRC	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06307176	chr5:131281290	NA	-0.39	-5.6	-0.3	4.46e-8	Life satisfaction;
CRC	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg00601450	chr5:74908170	NA	0.41	5.76	0.3	1.95e-8	Age-related disease endophenotypes;
CRC	cis	rs243505	0.595	rs10233740	chr7:148567263	C/T	cg09806900	chr7:148480153	CUL1	0.49	6.14	0.32	2.34e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs73198271	0.530	rs113160067	chr8:8654521	A/C	cg01851573	chr8:8652454	MFHAS1	0.55	6.92	0.36	2.4e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4731207	0.596	rs1585967	chr7:124613344	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	trans	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.8e-15	Bone mineral density;
CRC	cis	rs3026101	0.671	rs3026129	chr17:5295371	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs16852403	0.658	rs10157702	chr1:178109045	G/A	cg00404053	chr1:178313656	RASAL2	0.61	7.68	0.39	1.89e-13	Childhood ear infection;
CRC	cis	rs66679842	1	rs66679842	chr6:88171407	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.62	-0.3	4.14e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14479329	chr6:167370587	RNASET2	-0.43	-6.23	-0.32	1.45e-9	Myopia (pathological);
CRC	trans	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.69	-0.39	1.75e-13	Monocyte percentage of white cells;
CRC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.81	-0.3	1.49e-8	Alzheimer's disease (late onset);
CRC	cis	rs501120	0.535	rs10900002	chr10:44697564	A/T	cg09554077	chr10:44749378	NA	0.69	7.91	0.4	4.04e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs72730918	0.618	rs1531157	chr15:51990058	A/T	cg14296394	chr15:51910925	DMXL2	0.46	5.84	0.31	1.25e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1165668	0.785	rs2583223	chr12:104316841	G/A	cg21863207	chr12:104234989	NT5DC3	0.49	7.36	0.38	1.52e-12	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg21251018	chr6:28226885	NKAPL	0.42	6.05	0.32	3.95e-9	Depression;
CRC	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.94	0.4	3.19e-14	Height;
CRC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.94	0.52	5.69e-24	Prostate cancer;
CRC	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.85	-13.74	-0.6	2.97e-34	Gut microbiome composition (winter);
CRC	trans	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg21153622	chr11:89784906	NA	-0.47	-7.63	-0.39	2.61e-13	HDL cholesterol;
CRC	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg14003231	chr6:33640908	ITPR3	0.51	8.04	0.41	1.64e-14	Plateletcrit;
CRC	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg09029085	chr17:47094198	IGF2BP1	0.3	5.61	0.3	4.37e-8	Intelligence (multi-trait analysis);Body fat percentage;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21292957	chr21:34602922	IFNAR2	0.41	6.32	0.33	8.35e-10	Myopia (pathological);
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg21784768	chr11:537496	LRRC56	-0.7	-6.6	-0.34	1.65e-10	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09525523	chr12:16064153	DERA	0.39	6.22	0.32	1.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg27534772	chr1:16042836	PLEKHM2	0.51	9.18	0.45	5.06e-18	Systolic blood pressure;
CRC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.25	-16.7	-0.68	9.21e-46	Breast cancer;
CRC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.53	-0.38	4.79e-13	Alzheimer's disease;
CRC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.55	-8.4	-0.42	1.39e-15	Schizophrenia;
CRC	cis	rs7692995	1.000	rs7663818	chr4:17936443	C/T	cg08925142	chr4:18023851	LCORL	-0.53	-5.83	-0.31	1.34e-8	Height;
CRC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg17401720	chr7:158221031	PTPRN2	0.49	8.14	0.41	8.16e-15	Obesity-related traits;
CRC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.52	-6.18	-0.32	1.87e-9	Coronary artery calcification;
CRC	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.34	-6.69	-0.35	9.8e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6142102	0.961	rs973409	chr20:32536364	A/G	cg08999081	chr20:33150536	PIGU	0.4	5.76	0.3	1.97e-8	Skin pigmentation;
CRC	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-5.6	-0.3	4.46e-8	Height;
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20456258	chr4:962124	DGKQ	0.3	6.52	0.34	2.58e-10	Sjögren's syndrome;
CRC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.94	-12.2	-0.56	1.65e-28	Exhaled nitric oxide output;
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.51	7.68	0.39	1.78e-13	Eosinophil percentage of white cells;
CRC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	13.72	0.6	3.43e-34	Mean platelet volume;
CRC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-11.0	-0.52	3.54e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.67	-10.92	-0.52	6.77e-24	Type 2 diabetes;
CRC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.45	-6.03	-0.32	4.4e-9	Gut microbiome composition (summer);
CRC	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.57	6.27	0.33	1.14e-9	Schizophrenia;
CRC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.54	-0.34	2.39e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg10756647	chr7:56101905	PSPH	0.73	7.99	0.4	2.25e-14	Diabetic kidney disease;
CRC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.32	-0.33	8.37e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.42	5.83	0.31	1.31e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg13072238	chr3:49761600	GMPPB	-0.49	-5.72	-0.3	2.37e-8	Menarche (age at onset);
CRC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.91	0.36	2.48e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.48	-6.58	-0.34	1.85e-10	Lymphocyte counts;
CRC	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg06636001	chr8:8085503	FLJ10661	0.43	6.32	0.33	8.44e-10	Nose size;
CRC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	8.14	0.41	8.11e-15	Chronic sinus infection;
CRC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.67	0.35	1.08e-10	Obesity-related traits;
CRC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.48	-6.86	-0.35	3.42e-11	Aortic root size;
CRC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.15	0.64	1.02e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.43	-0.33	4.57e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs10743315	0.643	rs12578443	chr12:19321893	G/C	cg02471346	chr12:19282374	PLEKHA5	0.72	6.82	0.35	4.32e-11	Gut microbiota (bacterial taxa);
CRC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.45	-6.74	-0.35	6.93e-11	Monocyte percentage of white cells;
CRC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.63	-9.18	-0.45	4.78e-18	Menarche (age at onset);
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.02	-0.32	4.55e-9	Obesity-related traits;
CRC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.08e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.53	-8.47	-0.42	8.28e-16	Coronary artery disease;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg20041105	chr8:143859282	LYNX1	-0.44	-6.9	-0.36	2.74e-11	Urinary tract infection frequency;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-11.08	-0.52	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.6	10.02	0.48	8.42e-21	Prostate cancer;
CRC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg07274523	chr3:49395745	GPX1	0.47	6.07	0.32	3.48e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg22117107	chr15:45993392	NA	-0.44	-9.05	-0.45	1.27e-17	Waist circumference;Weight;
CRC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.6	-9.34	-0.46	1.52e-18	Lung cancer;
CRC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.95	13.71	0.6	3.81e-34	Breast cancer;
CRC	trans	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg17903999	chr18:56338584	MALT1	0.41	6.75	0.35	6.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.3	6.44	0.33	4.23e-10	Alcohol dependence;
CRC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.77	-14.37	-0.62	1.12e-36	Prostate cancer;
CRC	cis	rs2737618	0.551	rs2816989	chr1:200070765	G/T	cg21825944	chr1:200113062	NR5A2	0.46	6.38	0.33	6.08e-10	Uric acid levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18159324	chr12:52463368	C12orf44	0.43	6.02	0.31	4.62e-9	Response to antipsychotic treatment;
CRC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.49	7.36	0.38	1.51e-12	Type 2 diabetes;
CRC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.35	-0.46	1.43e-18	Intelligence (multi-trait analysis);
CRC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	1.03	11.46	0.53	8.45e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.76	-12.87	-0.58	5.54e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg15145174	chr5:6755386	POLS	0.48	7.05	0.36	1.05e-11	Menopause (age at onset);
CRC	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.28	-0.33	1.07e-9	Height;
CRC	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.88	0.51	9.03e-24	Ileal carcinoids;
CRC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg24562669	chr7:97807699	LMTK2	0.78	17.5	0.69	6.1e-49	Breast cancer;
CRC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.53	7.58	0.39	3.48e-13	Schizophrenia;
CRC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.93	0.64	7.73e-39	Intelligence (multi-trait analysis);
CRC	cis	rs10946940	0.632	rs9366698	chr6:27672035	C/G	cg02683197	chr6:28174875	NA	0.51	6.17	0.32	1.99e-9	Systemic lupus erythematosus;
CRC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.18	-17.19	-0.69	1.02e-47	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.62	-0.34	1.46e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg11707556	chr5:10655725	ANKRD33B	0.48	7.74	0.39	1.26e-13	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00508563	chr19:30335539	NA	0.46	7.41	0.38	1.1e-12	Schizophrenia;
CRC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.82	14.5	0.62	3.66e-37	Vitiligo;
CRC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.25	-0.33	1.28e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.46	6.56	0.34	2.08e-10	Longevity;Endometriosis;
CRC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.66	-0.47	1.34e-19	Monocyte count;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg20933634	chr6:27740509	NA	0.58	8.5	0.42	6.74e-16	Parkinson's disease;
CRC	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.45	6.71	0.35	8.43e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg03160526	chr17:80928410	B3GNTL1	0.49	7.26	0.37	2.73e-12	Glycated hemoglobin levels;
CRC	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.45	-6.37	-0.33	6.22e-10	Lung cancer;
CRC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg10802521	chr3:52805072	NEK4	-0.47	-6.33	-0.33	8.18e-10	Bipolar disorder;
CRC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.93	0.52	6.15e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02421172	chr7:1938701	MAD1L1	0.45	6.03	0.32	4.38e-9	Neuroticism;
CRC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.34	0.46	1.47e-18	Vitamin D levels;
CRC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.35	6.32	0.33	8.58e-10	Crohn's disease;
CRC	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-7.03	-0.36	1.22e-11	Colorectal cancer;
CRC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.86	-0.31	1.13e-8	Acne (severe);
CRC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-7.41	-0.38	1.1e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg02466173	chr16:30829666	NA	-0.61	-9.3	-0.46	1.95e-18	Dementia with Lewy bodies;
CRC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.65	12.17	0.56	2.14e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg09264619	chr17:80180166	NA	-0.37	-6.28	-0.33	1.04e-9	Life satisfaction;
CRC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.59	9.6	0.47	2.11e-19	Breast cancer;
CRC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.12	0.59	6.33e-32	Chronic sinus infection;
CRC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.34	-0.33	7.53e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.5	7.08	0.36	8.73e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.54	-0.38	4.73e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-6.61	-0.34	1.56e-10	Renal cell carcinoma;
CRC	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.25	-0.33	1.27e-9	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09765074	chr10:69634185	NA	-0.38	-6.26	-0.33	1.21e-9	Interleukin-6 levels;
CRC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.52	6.03	0.32	4.43e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.81	-13.31	-0.59	1.21e-32	Hypospadias;
CRC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg06740227	chr12:86229804	RASSF9	-0.37	-5.64	-0.3	3.71e-8	Major depressive disorder;
CRC	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.73	-0.39	1.34e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.13	-0.32	2.57e-9	Longevity;Endometriosis;
CRC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	10.77	0.51	2.2e-23	Mean corpuscular hemoglobin;
CRC	trans	rs2665103	0.655	rs1501367	chr15:82522816	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.14	-0.32	2.35e-9	Intelligence (multi-trait analysis);
CRC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	6.25	0.33	1.25e-9	Mean platelet volume;
CRC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg03684893	chr10:554711	DIP2C	-0.33	-5.65	-0.3	3.42e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.57	-6.51	-0.34	2.77e-10	RR interval (heart rate);
CRC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.64	-13.25	-0.59	2.01e-32	Schizophrenia;
CRC	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.29	0.33	1e-9	Hair morphology;
CRC	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.57	-6.92	-0.36	2.42e-11	Body mass index (adult);
CRC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.46	-9.34	-0.46	1.47e-18	Renal cell carcinoma;
CRC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.73	-0.57	1.93e-30	Hemoglobin concentration;
CRC	cis	rs713587	0.776	rs2118826	chr2:25191745	A/T	cg04586622	chr2:25135609	ADCY3	0.35	5.74	0.3	2.1e-8	Body mass index in non-asthmatics;
CRC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg24046110	chr8:143859143	LYNX1	-0.39	-6.77	-0.35	6.02e-11	Urinary tract infection frequency;
CRC	trans	rs17126268	0.502	rs1538826	chr1:102883645	C/T	cg18468354	chr14:36993517	NA	0.38	6.12	0.32	2.65e-9	Glomerular filtration rate;
CRC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06818126	chr11:68850279	TPCN2	0.56	8.04	0.41	1.58e-14	Hair color;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23426587	chr9:21335126	KLHL9	0.49	6.38	0.33	6.05e-10	Thyroid stimulating hormone;
CRC	trans	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg16281234	chr15:35388805	NA	-0.5	-6.37	-0.33	6.39e-10	Longevity (90 years and older);
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.08	-0.45	1.05e-17	Bipolar disorder;
CRC	cis	rs7258465	1.000	rs8111708	chr19:18558876	A/G	cg06462663	chr19:18546047	ISYNA1	0.44	6.42	0.33	4.66e-10	Breast cancer;
CRC	cis	rs9462027	0.628	rs7741437	chr6:34737553	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg12564285	chr5:131593104	PDLIM4	0.48	9.37	0.46	1.18e-18	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16695835	chr1:90460886	LOC492303;ZNF326	0.45	6.19	0.32	1.82e-9	Anxiety disorder;
CRC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.66	-0.34	1.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9311676	0.632	rs11925533	chr3:58429908	G/A	cg06643156	chr3:58380774	PXK	0.42	6.51	0.34	2.86e-10	Systemic lupus erythematosus;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg05792022	chr13:41239732	FOXO1	-0.54	-6.4	-0.33	5.2400000000000005e-10	Type 1 diabetes;
CRC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.23	0.37	3.32e-12	Aortic root size;
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.41	-7.59	-0.39	3.4e-13	Height;
CRC	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.61	-9.14	-0.45	6.37e-18	Other erythrocyte phenotypes;
CRC	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.65	10.15	0.49	3.02e-21	Corneal astigmatism;
CRC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg24562669	chr7:97807699	LMTK2	0.63	11.39	0.53	1.43e-25	Breast cancer;
CRC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.52	6.94	0.36	2.09e-11	Obesity-related traits;
CRC	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.61	6.79	0.35	5.14e-11	Coronary artery disease;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04594242	chr17:7737283	NA	0.38	5.96	0.31	6.55e-9	Schizophrenia;
CRC	cis	rs10886503	0.623	rs10787973	chr10:121257200	A/G	cg17804342	chr10:121271663	RGS10	-0.49	-5.98	-0.31	5.76e-9	Obstetric antiphospholipid syndrome;
CRC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	1.1	10.48	0.5	2.33e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.82	14.5	0.62	3.4e-37	Hip circumference;
CRC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.66	-11.09	-0.52	1.77e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs995000	0.931	rs10889354	chr1:63129082	T/C	cg19896129	chr1:63156450	NA	0.39	5.83	0.31	1.36e-8	Triglyceride levels;
CRC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg19193384	chr17:30244184	NA	-0.65	-7.56	-0.38	4.14e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4523957	0.855	rs9896535	chr17:2133205	C/T	cg16513277	chr17:2031491	SMG6	-0.52	-8.79	-0.44	8.39e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.57	9.33	0.46	1.6e-18	Lewy body disease;
CRC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg20295408	chr7:1910781	MAD1L1	-0.39	-5.62	-0.3	4.01e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.48	-0.34	3.27e-10	Coronary artery disease;
CRC	cis	rs6764363	0.504	rs4684334	chr3:278697	A/C	cg02057681	chr3:285234	CHL1	0.41	7.0	0.36	1.44e-11	Sudden cardiac arrest;
CRC	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.73	0.39	1.29e-13	Corneal astigmatism;
CRC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg16447950	chr5:562315	NA	-0.57	-9.14	-0.45	6.49e-18	Obesity-related traits;
CRC	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.54	7.67	0.39	2e-13	Response to antidepressants and depression;
CRC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.27	0.33	1.12e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.53	8.17	0.41	6.59e-15	Intelligence (multi-trait analysis);
CRC	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.93	-0.4	3.57e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10180764	chr2:128284465	IWS1	0.45	6.08	0.32	3.25e-9	Survival in pancreatic cancer;
CRC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.48	7.34	0.38	1.69e-12	Corneal astigmatism;
CRC	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.0	0.44	1.81e-17	Fuchs's corneal dystrophy;
CRC	cis	rs11212617	0.837	rs10890822	chr11:108027060	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.45e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.58	8.8	0.44	8.1e-17	Pancreatic cancer;
CRC	cis	rs6743376	0.556	rs2515391	chr2:113815997	C/T	cg24553058	chr2:113831203	IL1F10	0.39	6.44	0.33	4.13e-10	Inflammatory biomarkers;
CRC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-8.75	-0.43	1.13e-16	Platelet count;
CRC	cis	rs9463078	0.683	rs227841	chr6:44690309	A/T	cg25276700	chr6:44698697	NA	0.25	5.93	0.31	7.62e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg19683494	chr5:74908142	NA	-0.49	-6.26	-0.33	1.23e-9	Age-related disease endophenotypes;
CRC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.43	6.96	0.36	1.89e-11	Obesity-related traits;
CRC	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-6.84	-0.35	3.92e-11	Body mass index;
CRC	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg13160058	chr8:26243215	BNIP3L	-0.39	-6.87	-0.35	3.28e-11	Red cell distribution width;
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	1.01	11.43	0.53	1.09e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.0	-0.31	5.12e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-8.51	-0.42	6.31e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs863345	0.604	rs12059669	chr1:158501480	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs4731207	0.698	rs7778956	chr7:124527733	C/T	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg03623178	chr6:28175578	NA	0.68	7.02	0.36	1.24e-11	Depression;
CRC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg23517279	chr6:96025343	MANEA	0.55	6.39	0.33	5.62e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-11.95	-0.55	1.34e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg22110888	chr17:80059540	CCDC57	0.41	6.57	0.34	2.01e-10	Life satisfaction;
CRC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.44	7.4	0.38	1.12e-12	Diastolic blood pressure;
CRC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.41	-8.71	-0.43	1.56e-16	Electroencephalogram traits;
CRC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	1.14	10.61	0.5	8.13e-23	Thyroid stimulating hormone;
CRC	cis	rs55702914	0.837	rs2195507	chr2:198172336	T/C	cg10820045	chr2:198174542	NA	-0.46	-8.61	-0.43	3.05e-16	Major depression and alcohol dependence;
CRC	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.88	-16.31	-0.67	2.94e-44	Fuchs's corneal dystrophy;
CRC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.43	0.53	1.04e-25	Hip circumference adjusted for BMI;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08402873	chr20:10653164	JAG1	0.49	6.24	0.33	1.35e-9	Thyroid stimulating hormone;
CRC	cis	rs727505	0.607	rs67313231	chr7:124804532	T/A	cg23710748	chr7:124431027	NA	-0.61	-10.22	-0.49	1.82e-21	Lewy body disease;
CRC	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	7.04	0.36	1.13e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg00074818	chr8:8560427	CLDN23	0.36	6.71	0.35	8.62e-11	Obesity-related traits;
CRC	trans	rs8124695	0.764	rs6029084	chr20:39007766	C/T	cg15699267	chr20:61809557	MIR124-3	-0.53	-6.04	-0.32	4.19e-9	Dupuytren's disease;
CRC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.33	6.15	0.32	2.2e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs5745709	0.861	rs4732404	chr7:81363897	G/T	cg18944653	chr7:81381353	HGF	0.3	5.66	0.3	3.32e-8	Gout;
CRC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.82	-9.12	-0.45	7.54e-18	Breast cancer;
CRC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	5.79	0.3	1.61e-8	Renal function-related traits (BUN);
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg23123621	chr4:1343375	KIAA1530	0.38	6.89	0.35	2.9e-11	Longevity;
CRC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.51	7.62	0.39	2.77e-13	Resting heart rate;
CRC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg25985355	chr7:65971099	NA	0.46	6.2	0.32	1.68e-9	Diabetic kidney disease;
CRC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.52	8.66	0.43	2.11e-16	Uric acid clearance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24794758	chr19:54663461	LENG1	0.41	6.09	0.32	3.22e-9	Intelligence (multi-trait analysis);
CRC	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	7.36	0.38	1.52e-12	Birth weight;
CRC	cis	rs7705042	0.865	rs4912622	chr5:141490587	A/G	cg08523384	chr5:141488047	NDFIP1	0.33	5.84	0.31	1.25e-8	Asthma;
CRC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.6	-0.3	4.46e-8	Gout;Renal underexcretion gout;
CRC	cis	rs2179367	0.887	rs2789488	chr6:149725290	A/G	cg07828024	chr6:149772892	ZC3H12D	0.34	5.85	0.31	1.19e-8	Dupuytren's disease;
CRC	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg04267008	chr7:1944627	MAD1L1	-0.45	-5.78	-0.3	1.75e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg26587870	chr6:27730563	NA	-0.44	-6.65	-0.34	1.2e-10	Parkinson's disease;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2415984	0.579	rs2255935	chr14:46964271	A/G	cg14871534	chr14:47121158	RPL10L	0.4	5.96	0.31	6.64e-9	Number of children ever born;
CRC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.62	-0.47	1.84e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.61	9.66	0.47	1.36e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10888329	0.745	rs10888324	chr1:248361268	G/A	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Autism spectrum disorder;
CRC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg02527881	chr3:46936655	PTH1R	0.38	7.09	0.36	8.08e-12	Colorectal cancer;
CRC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.76	-12.99	-0.58	1.96e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.08	0.52	1.79e-24	Bone mineral density;
CRC	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg09659197	chr4:152720779	NA	0.39	7.56	0.38	4.18e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg24910161	chr17:38119198	GSDMA	-0.36	-5.94	-0.31	7.28e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.67	9.25	0.45	2.89e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-7.69	-0.39	1.68e-13	Major depressive disorder;
CRC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-7.18	-0.37	4.54e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2949837	0.581	rs1542819	chr7:45978059	T/C	cg04796162	chr7:45961102	IGFBP3	0.4	6.83	0.35	4.07e-11	Sitting height ratio;
CRC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.3	-0.33	9.38e-10	Aortic root size;
CRC	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.14	0.45	6.58e-18	Coffee consumption (cups per day);
CRC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.51	10.49	0.5	2.11e-22	Bone mineral density;
CRC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.36	-5.92	-0.31	7.92e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.56	9.64	0.47	1.54e-19	Iron status biomarkers;
CRC	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg02158880	chr13:53174818	NA	0.44	6.59	0.34	1.79e-10	Lewy body disease;
CRC	cis	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg18809830	chr7:99032528	PTCD1	-1.03	-7.68	-0.39	1.85e-13	Blood metabolite levels;
CRC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-18.75	-0.72	7.06e-54	Ulcerative colitis;
CRC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.8	12.18	0.56	1.95e-28	Mean platelet volume;Platelet distribution width;
CRC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.48	-7.8	-0.4	8.13e-14	Huntington's disease progression;
CRC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.5	-6.61	-0.34	1.55e-10	Body mass index;
CRC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.89	8.86	0.44	4.97e-17	Skin colour saturation;
CRC	cis	rs10971721	0.822	rs12376664	chr9:33808703	T/A	cg13495928	chr9:33750294	PRSS3	0.56	5.85	0.31	1.16e-8	Body mass index;
CRC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	13.13	0.59	5.98e-32	Electrocardiographic conduction measures;
CRC	cis	rs731174	0.759	rs575254	chr1:38149692	C/G	cg06917450	chr1:38156652	C1orf109	-0.51	-7.18	-0.37	4.74e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg10756647	chr7:56101905	PSPH	-0.71	-7.56	-0.38	4.01e-13	Diabetic kidney disease;
CRC	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26398333	chr1:153895721	GATAD2B	-0.44	-6.02	-0.31	4.58e-9	Energy expenditure (24h);
CRC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg11887960	chr12:57824829	NA	0.59	6.59	0.34	1.72e-10	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg04025307	chr7:1156635	C7orf50	0.63	6.74	0.35	7.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-0.98	-8.48	-0.42	7.5e-16	Post bronchodilator FEV1;
CRC	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.6	-9.67	-0.47	1.27e-19	Breast cancer;
CRC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg11262757	chr6:27280423	POM121L2	0.27	5.66	0.3	3.24e-8	Schizophrenia;
CRC	cis	rs7731657	0.537	rs72801738	chr5:130207637	A/G	cg08523029	chr5:130500466	HINT1	-0.47	-6.11	-0.32	2.84e-9	Fasting plasma glucose;
CRC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.29	-0.33	1.04e-9	Obesity-related traits;
CRC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg24300038	chr13:113819356	PROZ	-0.46	-5.69	-0.3	2.84e-8	Platelet distribution width;
CRC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19717773	chr7:2847554	GNA12	-0.49	-6.82	-0.35	4.32e-11	Height;
CRC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.59	9.68	0.47	1.18e-19	Height;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.72	12.06	0.55	5.75e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.82	-0.48	3.89e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.69	8.24	0.41	4.27e-15	Gut microbiome composition (summer);
CRC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.75	12.95	0.58	2.77e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg10760299	chr15:45669010	GATM	0.49	7.65	0.39	2.19e-13	Homoarginine levels;
CRC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.74	7.16	0.37	5.39e-12	Paclitaxel disposition in epithelial ovarian cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13321609	chr19:36119900	RBM42	0.49	6.96	0.36	1.8e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18231159	chr7:99214508	ZNF498	0.41	6.61	0.34	1.51e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg22482690	chr17:47019901	SNF8	0.45	7.34	0.38	1.71e-12	Type 2 diabetes;
CRC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg09417038	chr21:47716443	C21orf57	-0.42	-6.91	-0.36	2.59e-11	Testicular germ cell tumor;
CRC	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.94	-12.69	-0.57	2.71e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg15445000	chr17:37608096	MED1	-0.41	-8.12	-0.41	9.27e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.78	10.77	0.51	2.25e-23	Cognitive function;
CRC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.83	-0.35	4.09e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.04	-0.32	4.27e-9	Height;
CRC	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg16110827	chr15:48056943	SEMA6D	-0.49	-7.7	-0.39	1.58e-13	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.27e-13	Hip circumference adjusted for BMI;
CRC	cis	rs501120	0.810	rs684666	chr10:44745847	T/C	cg09554077	chr10:44749378	NA	0.9	13.3	0.59	1.4e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.47	7.83	0.4	6.84e-14	Major depressive disorder;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.85	-13.5	-0.6	2.41e-33	Cognitive function;
CRC	cis	rs2882667	0.931	rs10068237	chr5:138337960	T/A	cg09476006	chr5:138032270	NA	0.43	7.23	0.37	3.5e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg24553058	chr2:113831203	IL1F10	0.39	6.26	0.33	1.18e-9	Protein quantitative trait loci;
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.51	-0.34	2.82e-10	Total body bone mineral density;
CRC	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.69	-11.57	-0.54	3.25e-26	Body mass index;
CRC	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg10437265	chr15:77819839	NA	0.67	11.9	0.55	2.1e-27	Type 2 diabetes;
CRC	cis	rs10046574	0.731	rs6961685	chr7:135115985	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.49e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.91	11.44	0.53	9.34e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.49	-7.62	-0.39	2.7e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.43	6.69	0.35	9.41e-11	Blood metabolite levels;
CRC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.5	0.69	6.2e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.77	11.26	0.53	4.18e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.68	-7.54	-0.38	4.67e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg23298862	chr7:158159286	PTPRN2	-0.48	-7.92	-0.4	3.58e-14	Calcium levels;
CRC	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg18002602	chr11:66138449	SLC29A2	-0.3	-6.21	-0.32	1.58e-9	Educational attainment (years of education);
CRC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.39	-0.38	1.19e-12	Self-reported allergy;
CRC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	9.52	0.46	3.75e-19	Cognitive test performance;
CRC	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.46	-6.84	-0.35	3.92e-11	Body mass index;
CRC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.38	-5.98	-0.31	5.66e-9	Type 2 diabetes;
CRC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.89	10.18	0.49	2.48e-21	Iron status biomarkers;
CRC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02290350	chr8:58132656	NA	-0.42	-6.02	-0.31	4.7e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs800082	0.507	rs2575183	chr3:144260523	C/T	cg24215973	chr2:240111563	HDAC4	0.44	6.08	0.32	3.25e-9	Smoking behavior;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	7.41	0.38	1.06e-12	Acylcarnitine levels;
CRC	cis	rs17713451	0.542	rs73475440	chr7:151279385	A/G	cg18404559	chr7:151322523	PRKAG2	-0.54	-6.27	-0.33	1.13e-9	Interleukin-4 levels;
CRC	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg12458913	chr13:53173898	NA	0.54	8.81	0.44	7.38e-17	Lewy body disease;
CRC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.72	9.78	0.47	5.23e-20	Cognitive function;
CRC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.45	-0.42	9.39e-16	Personality dimensions;
CRC	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-8.63	-0.43	2.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	14.49	0.62	3.95e-37	Fuchs's corneal dystrophy;
CRC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg15147215	chr3:52552868	STAB1	0.49	8.13	0.41	8.58e-15	Electroencephalogram traits;
CRC	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.55	-0.34	2.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg00852783	chr1:26633632	UBXN11	0.46	7.24	0.37	3.25e-12	Obesity-related traits;
CRC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.52	9.2	0.45	4.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.52	6.89	0.35	2.9e-11	Obesity-related traits;
CRC	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.45	-8.81	-0.44	7.53e-17	Alcohol dependence;
CRC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-6.54	-0.34	2.3e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.9	-0.36	2.73e-11	IgG glycosylation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25134909	chr11:47587211	PTPMT1	0.45	6.83	0.35	4.15e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.71	8.86	0.44	5.26e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.95	-12.73	-0.57	1.82e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3885907	1.000	rs9508832	chr13:31314264	G/A	cg19953038	chr13:31306303	NA	-0.36	-5.95	-0.31	6.96e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
CRC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.8	10.57	0.5	1.09e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.61	9.03	0.45	1.48e-17	Depressive symptoms;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19812495	chr5:71616193	MRPS27;PTCD2	0.4	5.99	0.31	5.53e-9	Myopia (pathological);
CRC	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.02	-16.26	-0.67	5e-44	Schizophrenia;
CRC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.8	14.14	0.61	8.7e-36	Breast cancer;
CRC	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-8.98	-0.44	2.18e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-5.76	-0.3	1.92e-8	Menarche (age at onset);
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg19041857	chr6:27730383	NA	-0.74	-7.3	-0.37	2.23e-12	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05882699	chr10:126840591	CTBP2	0.35	6.07	0.32	3.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.51	5.87	0.31	1.05e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.64e-39	Lymphocyte percentage of white cells;
CRC	trans	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg21153622	chr11:89784906	NA	-0.43	-6.88	-0.35	3.06e-11	HDL cholesterol;
CRC	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg01426195	chr3:39028469	NA	0.45	6.45	0.33	4.03e-10	Handedness;
CRC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.5	8.22	0.41	4.87e-15	Coronary artery disease;
CRC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.53	8.63	0.43	2.72e-16	Prostate cancer;
CRC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.44	-8.06	-0.41	1.45e-14	Reticulocyte fraction of red cells;
CRC	cis	rs6662572	0.686	rs72677541	chr1:46561560	C/T	cg08644498	chr1:46502608	NA	0.45	7.18	0.37	4.64e-12	Blood protein levels;
CRC	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg16141378	chr3:129829833	LOC729375	0.51	7.37	0.38	1.39e-12	Schizophrenia;
CRC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.38	6.05	0.32	4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.13	-0.32	2.48e-9	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.81	0.35	4.65e-11	Alzheimer's disease;
CRC	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.71	0.43	1.55e-16	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.21	0.37	3.91e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg23100626	chr2:96804247	ASTL	0.26	6.76	0.35	6.45e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.44	-6.91	-0.36	2.47e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg14003231	chr6:33640908	ITPR3	0.5	8.02	0.4	1.82e-14	Plateletcrit;
CRC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.6	-8.64	-0.43	2.54e-16	Total body bone mineral density;
CRC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.47	5.77	0.3	1.84e-8	Parkinson's disease;
CRC	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.53	-7.2	-0.37	4.12e-12	Triglycerides;
CRC	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg22732515	chr19:44031385	ETHE1	0.61	9.07	0.45	1.1e-17	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs305851	0.875	rs9394629	chr6:39758362	A/G	cg02386599	chr6:39769542	DAAM2	0.38	6.06	0.32	3.67e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6662572	0.906	rs76438782	chr1:46240425	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	6.07	0.32	3.53e-9	Blood protein levels;
CRC	cis	rs7301826	0.651	rs1973834	chr12:131280157	C/T	cg11011512	chr12:131303247	STX2	0.39	5.82	0.31	1.41e-8	Plasma plasminogen activator levels;
CRC	cis	rs2160860	0.736	rs7845418	chr8:39800005	C/A	cg11363097	chr8:39792086	IDO2	-0.45	-7.65	-0.39	2.28e-13	Blood metabolite levels;
CRC	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	8.93	0.44	3.1e-17	Neuroticism;
CRC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55702914	0.837	rs2195507	chr2:198172336	T/C	cg20885578	chr2:198174922	NA	-0.35	-6.07	-0.32	3.56e-9	Major depression and alcohol dependence;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02290350	chr8:58132656	NA	-0.51	-6.35	-0.33	7.11e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.19	-0.37	4.35e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.45	-8.22	-0.41	4.68e-15	Reticulocyte fraction of red cells;
CRC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-6.17	-0.32	1.96e-9	Menarche (age at onset);
CRC	cis	rs972578	1.000	rs738377	chr22:43389570	C/T	cg01576275	chr22:43409880	NA	-0.49	-7.91	-0.4	3.96e-14	Mean platelet volume;
CRC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.45	-8.25	-0.41	3.94e-15	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg08888203	chr3:10149979	C3orf24	0.48	7.28	0.37	2.52e-12	Alzheimer's disease;
CRC	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg04586622	chr2:25135609	ADCY3	0.48	8.2	0.41	5.28e-15	Body mass index;
CRC	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.85	-10.94	-0.52	6e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11958404	0.517	rs35212858	chr5:157238942	T/C	cg05962755	chr5:157440814	NA	0.75	8.89	0.44	4.15e-17	IgG glycosylation;
CRC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg27532560	chr4:187881888	NA	-0.56	-10.23	-0.49	1.63e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg03623178	chr6:28175578	NA	0.82	7.73	0.39	1.35e-13	Parkinson's disease;
CRC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg12437481	chr16:420112	MRPL28	-0.56	-7.35	-0.38	1.58e-12	Bone mineral density (spine);Bone mineral density;
CRC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg27523141	chr10:43048294	ZNF37B	-0.49	-7.24	-0.37	3.25e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg22676075	chr6:135203613	NA	0.42	6.51	0.34	2.78e-10	Red blood cell count;
CRC	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.87	0.31	1.06e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6479527	0.875	rs7045643	chr9:96822071	G/T	cg14459158	chr9:96720562	NA	0.36	6.47	0.34	3.62e-10	Esophageal adenocarcinoma;
CRC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.7	11.02	0.52	2.97e-24	Platelet distribution width;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.68	10.18	0.49	2.4e-21	Menarche (age at onset);
CRC	cis	rs1105228	0.819	rs573814	chr6:165713998	C/T	cg20535254	chr6:165714960	C6orf118	-0.3	-6.17	-0.32	2.01e-9	Number of pregnancies;Number of children;
CRC	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.44	0.42	1.06e-15	Platelet distribution width;
CRC	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.53	8.78	0.44	9.29e-17	Facial morphology (factor 15, philtrum width);
CRC	trans	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.57	-9.77	-0.47	5.85e-20	Migraine;
CRC	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg09877947	chr5:131593287	PDLIM4	0.36	6.55	0.34	2.26e-10	Blood metabolite levels;
CRC	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.49	7.16	0.37	5.29e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg17321639	chr7:2759063	NA	-0.54	-7.05	-0.36	1.04e-11	Height;
CRC	cis	rs501120	0.584	rs11591406	chr10:44690710	G/A	cg09554077	chr10:44749378	NA	0.68	7.33	0.37	1.78e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.33	-0.37	1.8e-12	Height;
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg19223190	chr17:80058835	NA	0.39	6.12	0.32	2.66e-9	Life satisfaction;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.52	7.25	0.37	2.96e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg12273811	chr6:28175739	NA	0.56	8.01	0.4	1.98e-14	Parkinson's disease;
CRC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-8.58	-0.43	3.76e-16	Intelligence (multi-trait analysis);
CRC	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.38	-6.49	-0.34	3.18e-10	Vitamin D levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16857181	chr7:32931955	KBTBD2	0.44	6.22	0.32	1.55e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07630564	chr3:128445061	RAB7A	0.42	7.04	0.36	1.15e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.43	5.82	0.31	1.39e-8	Schizophrenia;
CRC	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg14593290	chr7:50529359	DDC	-0.61	-8.19	-0.41	5.78e-15	Malaria;
CRC	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.41	-5.99	-0.31	5.41e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-5.93	-0.31	7.47e-9	Longevity;Endometriosis;
CRC	cis	rs7626444	0.625	rs843535	chr3:196473064	G/A	cg12930392	chr3:196481615	PAK2	0.4	7.05	0.36	1.07e-11	Monocyte count;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.28	-0.33	1.05e-9	Total body bone mineral density;
CRC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg13777783	chr17:79615861	NA	-0.3	-5.69	-0.3	2.77e-8	Eye color traits;
CRC	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.75	-11.59	-0.54	2.85e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg21620606	chr4:1342894	KIAA1530	0.35	5.75	0.3	2.04e-8	Obesity-related traits;
CRC	cis	rs7259376	0.936	rs55983151	chr19:22552936	T/A	cg02657401	chr19:22469223	NA	-0.31	-6.76	-0.35	6.13e-11	Menopause (age at onset);
CRC	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg11204139	chr17:3907470	NA	0.51	6.5	0.34	3.06e-10	Type 2 diabetes;
CRC	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg05342945	chr12:48394962	COL2A1	-0.44	-5.93	-0.31	7.86e-9	Lung cancer;
CRC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.51	7.33	0.37	1.85e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-7.99	-0.4	2.37e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.93	-0.36	2.17e-11	Lung cancer;
CRC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18357526	chr6:26021779	HIST1H4A	0.42	6.08	0.32	3.24e-9	Height;
CRC	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg26805224	chr10:79626177	DLG5	-0.55	-8.24	-0.41	4.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.68	0.54	1.37e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.14	0.52	1.17e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.71	11.23	0.53	5.35e-25	Fractional exhaled nitric oxide (childhood);
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	cis	rs12286929	0.609	rs11602686	chr11:115100638	G/A	cg04055981	chr11:115044050	NA	0.37	5.7	0.3	2.6e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.15	-0.37	5.67e-12	Capecitabine sensitivity;
CRC	cis	rs7487075	1.000	rs7487075	chr12:46828918	G/A	cg17501823	chr12:47219793	SLC38A4	0.31	5.68	0.3	3.03e-8	Itch intensity from mosquito bite;
CRC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.12	0.32	2.64e-9	Rheumatoid arthritis;
CRC	cis	rs7429990	0.965	rs62260764	chr3:47990500	G/C	cg11946769	chr3:48343235	NME6	0.57	6.66	0.34	1.14e-10	Educational attainment (years of education);
CRC	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg10820045	chr2:198174542	NA	0.4	6.83	0.35	4e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.66	7.69	0.39	1.69e-13	Menarche (age at onset);
CRC	cis	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg15590007	chr10:45870220	ALOX5	0.64	6.67	0.35	1.09e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg13390004	chr1:15929781	NA	0.5	7.06	0.36	1.02e-11	Systolic blood pressure;
CRC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-7.31	-0.37	1.99e-12	Schizophrenia;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.15	0.71	1.69e-51	Parkinson's disease;
CRC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg14074117	chr16:1909714	C16orf73	0.41	5.63	0.3	3.77e-8	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs16957091	0.528	rs66932813	chr15:43088622	T/G	cg15973384	chr6:168817498	NA	0.52	6.06	0.32	3.75e-9	MGMT methylation in smokers;
CRC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.9	13.17	0.59	4.25e-32	Triglycerides;
CRC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.24e-10	Common traits (Other);
CRC	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.83	-7.81	-0.4	7.54e-14	Macrophage inflammatory protein 1b levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27014642	chr1:109791839	CELSR2	0.48	6.27	0.33	1.12e-9	Thyroid stimulating hormone;
CRC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	4.97e-11	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62187611	chr2:162431946	A/G	cg10498984	chr16:28874827	SH2B1	-0.73	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.87	-0.31	1.06e-8	Type 2 diabetes;
CRC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg16141378	chr3:129829833	LOC729375	-0.41	-6.09	-0.32	3.18e-9	Triglycerides;
CRC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.49	-6.85	-0.35	3.64e-11	Height;
CRC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg17633681	chr16:88106987	BANP	0.87	15.92	0.66	1.06e-42	Menopause (age at onset);
CRC	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	6.07	0.32	3.47e-9	Asthma;
CRC	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20503117	chr3:5164013	ARL8B	-0.63	-6.19	-0.32	1.76e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg03623178	chr6:28175578	NA	0.8	11.88	0.55	2.41e-27	Cardiac Troponin-T levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12115800	chr3:73144435	NA	0.3	6.08	0.32	3.38e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07058086	chr8:29120186	KIF13B	0.38	6.14	0.32	2.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00884529	chr7:16685823	BZW2;ANKMY2	0.48	6.44	0.33	4.32e-10	Thyroid stimulating hormone;
CRC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.45	3.13e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.41	-5.75	-0.3	2.02e-8	Neuroticism;
CRC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14895029	chr7:2775587	GNA12	-0.46	-6.67	-0.35	1.09e-10	Height;
CRC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.91	0.36	2.52e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.77	0.35	5.78e-11	Lung cancer;
CRC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.61	-0.34	1.53e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08847724	chr12:12420135	LRP6	0.44	6.2	0.32	1.7e-9	Response to antipsychotic treatment;
CRC	cis	rs7259376	0.775	rs7257134	chr19:22540857	A/T	cg02657401	chr19:22469223	NA	-0.35	-7.52	-0.38	5.33e-13	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.15e-23	Motion sickness;
CRC	cis	rs4664293	0.510	rs1968343	chr2:160568758	C/T	cg08347373	chr2:160653686	CD302	0.36	5.94	0.31	7.21e-9	Monocyte percentage of white cells;
CRC	cis	rs2084637	1.000	rs10892852	chr11:122390440	C/T	cg21585512	chr11:122030076	LOC399959	-0.41	-7.5	-0.38	5.96e-13	Stroke;
CRC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.04	-0.36	1.11e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs4676482	0.578	rs784504	chr3:39195260	G/C	cg02254461	chr3:39195904	CSRNP1	-0.64	-8.82	-0.44	7.04e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg21399703	chr1:247681439	NA	0.5	7.99	0.4	2.23e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6743376	0.532	rs2515395	chr2:113818702	G/C	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.27e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.17	0.49	2.66e-21	Platelet count;
CRC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.31	0.42	2.54e-15	Homoarginine levels;
CRC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.5	-6.22	-0.32	1.47e-9	Diastolic blood pressure;
CRC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-6.48	-0.34	3.41e-10	Menarche (age at onset);
CRC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg12193833	chr17:30244370	NA	-0.46	-6.26	-0.33	1.17e-9	Hip circumference adjusted for BMI;
CRC	cis	rs858239	1.000	rs156421	chr7:23312487	A/G	cg00469287	chr7:23338798	C7orf30	0.49	6.51	0.34	2.78e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1223397	0.938	rs9381884	chr6:13278788	A/G	cg06879394	chr6:13274151	PHACTR1	0.47	5.77	0.3	1.79e-8	Blood pressure;
CRC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-6.07	-0.32	3.46e-9	Vitiligo;
CRC	cis	rs12505749	0.542	rs6554358	chr4:57372576	A/T	cg06922635	chr4:57371607	ARL9	-0.54	-5.72	-0.3	2.35e-8	Airflow obstruction;
CRC	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.31	8.07e-9	Response to antipsychotic treatment;
CRC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12172441	chr6:28176163	NA	0.6	7.2	0.37	4.23e-12	Depression;
CRC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg02659138	chr7:134003124	SLC35B4	0.42	7.36	0.38	1.49e-12	Mean platelet volume;
CRC	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg01656853	chr19:49199172	FUT2	0.23	5.62	0.3	4.1e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CRC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19952228	chr3:122102923	FAM162A;CCDC58	0.44	6.33	0.33	8.08e-10	Anxiety disorder;
CRC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.62	-0.34	1.43e-10	Menarche (age at onset);
CRC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.52	9.14	0.45	6.52e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-8.89	-0.44	4e-17	Menarche (age at onset);
CRC	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.48	-7.0	-0.36	1.46e-11	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08050352	chr16:46864715	C16orf87	0.41	6.08	0.32	3.36e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.42	0.42	1.15e-15	Coffee consumption (cups per day);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07951519	chr17:4607306	PELP1	-0.41	-6.04	-0.32	4.09e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05612640	chr18:77748679	TXNL4A	0.4	5.98	0.31	5.73e-9	Schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24725560	chr11:32605793	EIF3M	-0.5	-6.08	-0.32	3.28e-9	Diisocyanate-induced asthma;
CRC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg14847009	chr1:175162515	KIAA0040	0.3	6.67	0.34	1.11e-10	Alcohol dependence;
CRC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg18761221	chr20:60518478	NA	0.4	6.89	0.36	2.83e-11	Body mass index;
CRC	cis	rs12024301	0.557	rs12042646	chr1:183614282	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.68	-6.38	-0.33	5.97e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg22687807	chr8:143858763	LYNX1	0.59	10.54	0.5	1.39e-22	Urinary tract infection frequency;
CRC	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.5	7.64	0.39	2.43e-13	Testicular germ cell tumor;
CRC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.56	-8.11	-0.41	9.83e-15	Longevity;
CRC	cis	rs889398	0.617	rs1566456	chr16:69900226	G/C	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.9	-0.31	8.81e-9	Body mass index;
CRC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-14.48	-0.62	4.13e-37	Height;
CRC	cis	rs2811415	0.627	rs1042911	chr3:127789594	T/G	cg13719885	chr3:127795394	NA	-0.4	-6.05	-0.32	3.83e-9	Lung function (FEV1/FVC);
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg00597713	chr6:42947103	PEX6	-0.4	-5.62	-0.3	4.18e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg09045935	chr12:6379348	NA	1.14	8.98	0.44	2.21e-17	Blood metabolite levels;
CRC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.65	-9.19	-0.45	4.59e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.54	7.36	0.38	1.44e-12	Tuberculosis;
CRC	trans	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg05376469	chr2:102649931	NA	-0.38	-6.32	-0.33	8.43e-10	Coronary artery disease;
CRC	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	1.11	10.44	0.5	3.09e-22	Arsenic metabolism;
CRC	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg11645453	chr3:52864694	ITIH4	-0.4	-7.47	-0.38	7.52e-13	Body mass index;
CRC	cis	rs16852403	0.619	rs10913509	chr1:178122784	C/G	cg00404053	chr1:178313656	RASAL2	0.59	7.54	0.38	4.58e-13	Childhood ear infection;
CRC	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg19773385	chr1:10388646	KIF1B	-0.56	-7.38	-0.38	1.3e-12	Hepatocellular carcinoma;
CRC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg21466736	chr12:48725269	NA	0.49	7.72	0.39	1.41e-13	Plateletcrit;
CRC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.74	0.3	2.14e-8	Diabetic retinopathy;
CRC	cis	rs6804368	0.553	rs7617829	chr3:30769948	C/T	cg06106510	chr3:30762233	NA	0.35	5.6	0.3	4.45e-8	Blood metabolite levels;
CRC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.76	-15.24	-0.64	4.77e-40	Refractive error;
CRC	cis	rs7394190	0.748	rs4746139	chr10:75407649	A/C	cg07699608	chr10:75541558	CHCHD1	0.61	6.21	0.32	1.57e-9	Incident atrial fibrillation;
CRC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.51	-0.38	5.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9491140	0.539	rs11154228	chr6:124686042	A/G	cg05308643	chr6:124982296	NKAIN2	0.48	6.66	0.34	1.17e-10	Neuroticism;
CRC	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-12.22	-0.56	1.39e-28	Coffee consumption (cups per day);
CRC	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg06204229	chr3:52865917	ITIH4	0.52	6.66	0.34	1.13e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	0.9	11.08	0.52	1.82e-24	Height;
CRC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	14.03	0.61	2.31e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7932354	0.528	rs1965952	chr11:47181040	G/A	cg19486271	chr11:47235900	DDB2	0.44	6.32	0.33	8.73e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.44	-5.9	-0.31	9.02e-9	Lymphocyte counts;
CRC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2e-14	Type 2 diabetes;
CRC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.82	12.31	0.56	6.59e-29	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.02	-20.61	-0.75	3.5e-61	Height;
CRC	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg16964102	chr10:135390573	NA	0.52	7.05	0.36	1.04e-11	Gout;
CRC	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.25	-0.33	1.29e-9	Neuroticism;
CRC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg08755490	chr11:65554678	OVOL1	0.42	6.15	0.32	2.24e-9	Acne (severe);
CRC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02772935	chr3:125709198	NA	-0.49	-5.71	-0.3	2.46e-8	Blood pressure (smoking interaction);
CRC	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.43	6.88	0.35	2.95e-11	Sitting height ratio;
CRC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg19812747	chr11:111475976	SIK2	0.43	6.3	0.33	9.57e-10	Primary sclerosing cholangitis;
CRC	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg08992911	chr2:238395768	MLPH	0.47	5.75	0.3	2.04e-8	Prostate cancer;
CRC	trans	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg04264129	chr7:80682238	NA	-0.4	-6.3	-0.33	9.45e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg13722127	chr7:150037890	RARRES2	0.47	7.81	0.4	7.65e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.59	7.97	0.4	2.71e-14	Adiposity;
CRC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-9.98	-0.48	1.18e-20	Prostate cancer;
CRC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	11.13	0.52	1.26e-24	Motion sickness;
CRC	cis	rs2077654	0.822	rs12293228	chr11:17436951	C/T	cg25308976	chr11:17434268	ABCC8	0.64	6.57	0.34	2.03e-10	Gout;
CRC	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.57	-10.83	-0.51	1.38e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.68	7.94	0.4	3.13e-14	Lung disease severity in cystic fibrosis;
CRC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.36	-0.67	1.93e-44	Height;
CRC	cis	rs17362650	1.000	rs13032363	chr2:9620740	T/C	cg12832956	chr2:9616023	IAH1	-0.5	-6.13	-0.32	2.55e-9	Alcohol dependence (age at onset);
CRC	cis	rs883565	0.740	rs2293312	chr3:39111140	C/A	cg01426195	chr3:39028469	NA	-0.54	-8.65	-0.43	2.36e-16	Handedness;
CRC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.52	-6.89	-0.36	2.87e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.57	-7.94	-0.4	3.17e-14	Response to antineoplastic agents;
CRC	trans	rs2303319	0.504	rs55841284	chr2:162560011	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.61	-5.99	-0.31	5.62e-9	Cognitive function;
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.55	-9.77	-0.47	6.02e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1712517	0.771	rs2008530	chr10:105058839	G/A	cg05636881	chr10:105038444	INA	0.46	7.82	0.4	7.09e-14	Migraine;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12376772	chr13:32526694	EEF1DP3	-0.4	-6.5	-0.34	2.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.67	-10.49	-0.5	2.04e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12760731	0.720	rs67857740	chr1:178402250	A/G	cg00404053	chr1:178313656	RASAL2	0.98	10.07	0.49	5.63e-21	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	11.72	0.54	9.6e-27	Alzheimer's disease;
CRC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.84	16.01	0.66	4.45e-43	Hip circumference;
CRC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.44	6.56	0.34	2.11e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg05585544	chr11:47624801	NA	-0.55	-9.67	-0.47	1.2e-19	Subjective well-being;
CRC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.84	14.68	0.63	7.14e-38	Blood protein levels;
CRC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	1.03	18.15	0.71	1.69e-51	Parkinson's disease;
CRC	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.05	0.45	1.24e-17	Dupuytren's disease;
CRC	cis	rs7113874	0.569	rs11041999	chr11:8605739	T/C	cg20771178	chr11:8615675	STK33	0.35	5.72	0.3	2.37e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-7.94	-0.4	3.33e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg17903999	chr18:56338584	MALT1	0.42	6.84	0.35	3.97e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs524281	0.861	rs7942894	chr11:65976525	T/C	cg16950941	chr11:66035639	RAB1B	-0.59	-7.06	-0.36	9.9e-12	Electroencephalogram traits;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg07991241	chr10:33269695	NA	-0.42	-6.16	-0.32	2.09e-9	Daytime sleep phenotypes;
CRC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg19847866	chr10:1019161	NA	0.44	6.49	0.34	3.15e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs1124376	0.748	rs6771367	chr3:20160266	A/T	cg05072819	chr3:20081367	KAT2B	0.46	5.79	0.3	1.61e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg24375607	chr4:120327624	NA	0.49	7.95	0.4	2.97e-14	Corneal astigmatism;
CRC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg13319975	chr6:146136371	FBXO30	0.39	5.84	0.31	1.24e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18867708	chr6:26865862	GUSBL1	0.44	6.37	0.33	6.37e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.59	8.91	0.44	3.43e-17	Subjective well-being;
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	5.7	0.3	2.64e-8	Lung function (FEV1/FVC);
CRC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.27e-17	Morning vs. evening chronotype;
CRC	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.66	-7.87	-0.4	5.27e-14	Vitamin D levels;
CRC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.4	6.65	0.34	1.21e-10	Height;
CRC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.49	7.88	0.4	4.73e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs12699921	0.632	rs2723552	chr7:17860661	T/G	cg15753394	chr6:17282781	RBM24	-0.36	-6.01	-0.31	5.03e-9	Fibrinogen levels;
CRC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.59	9.22	0.45	3.61e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1552172	0.887	rs2040085	chr1:145651861	G/A	cg11743829	chr1:145714124	CD160	-0.42	-6.29	-0.33	1.04e-9	Breast cancer;
CRC	cis	rs10071761	0.513	rs12514679	chr5:40366803	T/G	cg09067459	chr5:40385259	NA	-0.53	-7.11	-0.37	7.18e-12	Selective IgA deficiency;
CRC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.47	-5.79	-0.3	1.69e-8	Response to bleomycin (chromatid breaks);
CRC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg16342193	chr10:102329863	NA	-0.35	-5.9	-0.31	9.06e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04221910	chr5:616842	CEP72	-0.42	-6.93	-0.36	2.22e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.62	-6.9	-0.36	2.73e-11	Breast cancer;
CRC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	9.0	0.44	1.88e-17	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg02683197	chr6:28174875	NA	0.84	10.18	0.49	2.42e-21	Depression;
CRC	cis	rs926938	0.606	rs6537844	chr1:115289295	G/A	cg12756093	chr1:115239321	AMPD1	-0.52	-7.27	-0.37	2.56e-12	Autism;
CRC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.77	-0.44	9.48e-17	Bone mineral density;
CRC	cis	rs11212617	0.905	rs6589007	chr11:108040104	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.44	0.33	4.18e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg23533926	chr12:111358616	MYL2	-0.45	-6.59	-0.34	1.79e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.52	8.03	0.4	1.75e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.48	7.02	0.36	1.3e-11	Obesity-related traits;
CRC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.7	9.13	0.45	7.11e-18	Bladder cancer;
CRC	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6681460	0.934	rs4655635	chr1:67068240	T/G	cg02459107	chr1:67143332	SGIP1	0.4	6.88	0.35	3.08e-11	Presence of antiphospholipid antibodies;
CRC	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg23254163	chr1:152506842	NA	0.45	9.13	0.45	6.92e-18	Hair morphology;
CRC	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg03934865	chr2:198174659	NA	-0.39	-5.74	-0.3	2.21e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.25e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg08501292	chr6:25962987	TRIM38	-0.81	-8.24	-0.41	4.15e-15	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02396668	chr19:50528878	VRK3;ZNF473	0.5	6.41	0.33	5.02e-10	Thyroid stimulating hormone;
CRC	cis	rs6694672	0.867	rs1332662	chr1:197108427	A/G	cg13682187	chr1:196946512	CFHR5	0.43	6.93	0.36	2.19e-11	Asthma;
CRC	cis	rs4929949	0.901	rs4475924	chr11:8620009	T/C	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index;
CRC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.43	-7.41	-0.38	1.08e-12	Eye color traits;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.47	-7.57	-0.39	3.73e-13	Coronary artery disease;
CRC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.55	-8.63	-0.43	2.58e-16	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06731730	chr16:69788837	NOB1	0.4	6.02	0.31	4.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.86	-0.31	1.14e-8	High light scatter reticulocyte count;
CRC	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.71	-7.94	-0.4	3.13e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02018176	chr4:1364513	KIAA1530	-0.48	-8.21	-0.41	5.05e-15	Obesity-related traits;
CRC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.78	-0.39	9.41e-14	Aortic root size;
CRC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg01721255	chr8:58191610	C8orf71	0.61	5.87	0.31	1.05e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg24308560	chr3:49941425	MST1R	-0.42	-5.89	-0.31	9.62e-9	Resting heart rate;
CRC	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.53	8.23	0.41	4.56e-15	Corneal astigmatism;
CRC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.52	-9.15	-0.45	5.91e-18	Schizophrenia;
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.56	7.74	0.39	1.21e-13	Alzheimer's disease;
CRC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.46	6.98	0.36	1.62e-11	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07950158	chr19:45874032	ERCC2	0.51	6.58	0.34	1.91e-10	Thyroid stimulating hormone;
CRC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg07713946	chr22:31675144	LIMK2	0.4	5.95	0.31	6.81e-9	Colorectal cancer;
CRC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.72	-11.24	-0.53	5.05e-25	Prostate cancer;
CRC	cis	rs1545257	0.505	rs958352	chr2:24634240	A/G	cg06627628	chr2:24431161	ITSN2	-0.45	-6.65	-0.34	1.2e-10	Sjögren's syndrome;
CRC	cis	rs6445967	1.000	rs34611088	chr3:58312923	G/A	cg23715586	chr3:58305044	RPP14	0.35	5.92	0.31	8.13e-9	Platelet count;
CRC	trans	rs587242	1.000	rs12045626	chr1:96917476	C/T	cg10631902	chr5:14652156	NA	0.45	7.05	0.36	1.08e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg03684893	chr10:554711	DIP2C	-0.33	-5.65	-0.3	3.42e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg08314208	chr16:67682810	RLTPR	-0.5	-6.04	-0.32	4.22e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.9	0.55	2.19e-27	Exhaled nitric oxide levels;
CRC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.71	11.77	0.54	6.48e-27	Longevity;
CRC	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg24463073	chr6:118973353	C6orf204	0.51	6.73	0.35	7.51e-11	Renal cell carcinoma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01149132	chr14:68141218	VTI1B	0.47	7.21	0.37	3.97e-12	Obesity-related traits;
CRC	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg06172871	chr16:72088244	HP	0.4	5.85	0.31	1.18e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.39	-5.77	-0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9648716	1.000	rs2535946	chr7:140538008	C/T	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	trans	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg01505111	chr6:125621795	HDDC2	0.4	6.42	0.33	4.73e-10	DNA methylation (variation);
CRC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.33e-12	Motion sickness;
CRC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	14.78	0.63	3.03e-38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg18187862	chr3:45730750	SACM1L	0.44	6.28	0.33	1.06e-9	Primary sclerosing cholangitis;
CRC	cis	rs10486722	0.603	rs10250049	chr7:41774118	A/G	cg22138096	chr7:41772439	LOC285954	0.39	5.89	0.31	9.49e-9	Pit-and-Fissure caries;
CRC	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs17155006	0.702	rs446566	chr7:107730650	A/G	cg05962710	chr7:107745446	LAMB4	0.35	5.76	0.3	1.96e-8	Pneumococcal bacteremia;
CRC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.65	-8.39	-0.42	1.41e-15	Intelligence (multi-trait analysis);
CRC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.45	-0.42	9.23e-16	Neuroticism;
CRC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg27661571	chr11:113659931	NA	-0.77	-9.63	-0.47	1.71e-19	Hip circumference adjusted for BMI;
CRC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg07636037	chr3:49044803	WDR6	-0.65	-5.74	-0.3	2.13e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.11	19.05	0.72	4.69e-55	Cognitive function;
CRC	cis	rs12936587	0.811	rs12945496	chr17:17537197	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.66	-0.3	3.25e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.37	6.15	0.32	2.2e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg23625390	chr15:77176239	SCAPER	0.46	6.42	0.33	4.87e-10	Blood metabolite levels;
CRC	cis	rs7680126	0.586	rs7689060	chr4:10305463	C/G	cg11266682	chr4:10021025	SLC2A9	0.37	5.91	0.31	8.4e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.62	9.76	0.47	6.27e-20	Huntington's disease progression;
CRC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg13565492	chr6:43139072	SRF	-0.68	-7.03	-0.36	1.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg03060546	chr3:49711283	APEH	0.47	6.73	0.35	7.6e-11	Menarche (age at onset);
CRC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg27565382	chr3:53032988	SFMBT1	0.78	6.26	0.33	1.21e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.72	11.24	0.53	5.04e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.64	10.56	0.5	1.26e-22	Height;
CRC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg16892393	chr17:41919603	NA	0.47	7.16	0.37	5.32e-12	Triglycerides;
CRC	cis	rs9549328	0.589	rs36164841	chr13:113616579	A/G	cg17524180	chr13:113633600	MCF2L	0.52	9.39	0.46	1e-18	Systolic blood pressure;
CRC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.29	-0.37	2.27e-12	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10778271	chr6:64283102	PTP4A1	0.42	5.99	0.31	5.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.49	-7.73	-0.39	1.28e-13	Coronary artery disease;
CRC	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-6.15	-0.32	2.28e-9	Schizophrenia;
CRC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	9.29	0.46	2.19e-18	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6504622	0.818	rs9910899	chr17:45034342	G/C	cg16759221	chr17:45003025	GOSR2	-0.49	-7.4	-0.38	1.13e-12	Orofacial clefts;
CRC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg00129232	chr17:37814104	STARD3	0.57	7.04	0.36	1.14e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.81	0.4	7.48e-14	Diabetic retinopathy;
CRC	cis	rs59104589	0.521	rs34506685	chr2:242439988	A/G	cg19488206	chr2:242435732	STK25	0.43	6.8	0.35	4.85e-11	Fibrinogen levels;
CRC	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-0.71	-6.49	-0.34	3.17e-10	Prostate cancer;
CRC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.61	0.39	2.95e-13	Lung cancer in ever smokers;
CRC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13198984	chr17:80129470	CCDC57	0.45	8.07	0.41	1.3e-14	Life satisfaction;
CRC	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.68	0.51	4.61e-23	Hip circumference adjusted for BMI;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03969997	chr7:73256865	WBSCR27	0.44	6.42	0.33	4.78e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg15786705	chr6:28176104	NA	0.54	5.94	0.31	7.27e-9	Depression;
CRC	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.78	-11.07	-0.52	1.96e-24	Blood pressure (smoking interaction);
CRC	cis	rs6066835	0.681	rs3092222	chr20:47387628	C/T	cg18078177	chr20:47281410	PREX1	0.68	6.03	0.32	4.33e-9	Multiple myeloma;
CRC	cis	rs6662572	0.737	rs4256763	chr1:46379518	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.85	-0.31	1.21e-8	Blood protein levels;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.8	-13.46	-0.6	3.37e-33	Height;
CRC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.38	5.87	0.31	1.08e-8	Crohn's disease;
CRC	trans	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg17903999	chr18:56338584	MALT1	0.41	6.87	0.35	3.27e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg13615338	chr4:55094005	PDGFRA	0.43	6.16	0.32	2.09e-9	Corneal astigmatism;
CRC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.53	-6.33	-0.33	8.01e-10	Blood pressure (smoking interaction);
CRC	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg14593290	chr7:50529359	DDC	-0.54	-6.85	-0.35	3.64e-11	Malaria;
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.78	0.47	5.43e-20	Cognitive test performance;
CRC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.42	5.71	0.3	2.5e-8	Cognitive ability;
CRC	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg01843034	chr6:37503916	NA	-0.44	-8.19	-0.41	5.81e-15	Cognitive performance;
CRC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.57	8.55	0.43	4.85e-16	Calcium levels;
CRC	cis	rs12753569	0.934	rs6593523	chr1:76486908	C/T	cg00791851	chr1:76518896	NA	-0.38	-6.69	-0.35	9.43e-11	Personality dimensions;
CRC	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.86	14.23	0.62	3.68e-36	Alcohol dependence;
CRC	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg20607287	chr7:12443886	VWDE	-0.54	-5.69	-0.3	2.87e-8	Coronary artery disease;
CRC	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.65	-8.66	-0.43	2.2e-16	Facial morphology (factor 19);
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.49	7.54	0.38	4.54e-13	Longevity;
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.38	-5.6	-0.3	4.42e-8	Lymphocyte counts;
CRC	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg05729581	chr11:3078854	CARS	-0.51	-7.2	-0.37	4.25e-12	Longevity;
CRC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.85	13.17	0.59	4.05e-32	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.83	-0.31	1.31e-8	Depression;
CRC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg04586622	chr2:25135609	ADCY3	-0.67	-13.25	-0.59	2.06e-32	Body mass index;
CRC	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg21609526	chr1:3105151	PRDM16	0.37	6.34	0.33	7.48e-10	Migraine;
CRC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.53	8.69	0.43	1.76e-16	Breast cancer;
CRC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.61	-0.39	2.86e-13	Axial length;
CRC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.88	-14.83	-0.63	1.87e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.67	-0.43	1.93e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs3772130	0.961	rs1573819	chr3:121469646	A/C	cg20356878	chr3:121714668	ILDR1	0.51	7.92	0.4	3.72e-14	Cognitive performance;
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg09264619	chr17:80180166	NA	-0.35	-5.9	-0.31	8.84e-9	Life satisfaction;
CRC	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	cg04338863	chr8:33670619	NA	0.4	6.84	0.35	3.8e-11	Body mass index;
CRC	cis	rs9928842	0.882	rs9927264	chr16:75260241	T/C	cg09066997	chr16:75300724	BCAR1	0.7	6.67	0.35	1.08e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.8	-0.3	1.57e-8	Migraine;Coronary artery disease;
CRC	trans	rs6463739	1.000	rs6972172	chr7:7902214	C/T	cg09417038	chr21:47716443	C21orf57	0.4	6.09	0.32	3.12e-9	Small cell lung carcinoma;
CRC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.5	7.07	0.36	9.11e-12	Height;
CRC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.49	7.39	0.38	1.2e-12	Longevity;
CRC	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.73	-12.91	-0.58	3.85e-31	Inhibitory control;
CRC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.0	0.44	1.89e-17	Menarche (age at onset);
CRC	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-8.25	-0.41	3.77e-15	Schizophrenia;
CRC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg05861140	chr6:150128134	PCMT1	-0.39	-6.35	-0.33	7.28e-10	Lung cancer;
CRC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.89	16.05	0.66	3.2e-43	Coronary artery disease;
CRC	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.0	0.4	2.13e-14	Type 2 diabetes;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.65	-0.3	3.57e-8	Parkinson's disease;
CRC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	0.93	11.05	0.52	2.33e-24	Type 2 diabetes nephropathy;
CRC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.73	9.63	0.47	1.7e-19	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	1.04e-10	Menopause (age at onset);
CRC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.68	12.65	0.57	3.83e-30	Age-related hearing impairment;
CRC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.66	0.51	5.6e-23	Alzheimer's disease;
CRC	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg19537932	chr12:55886519	OR6C68	-0.7	-8.74	-0.43	1.21e-16	Contrast sensitivity;
CRC	cis	rs62408225	1.000	rs62408227	chr6:90965171	A/G	cg06866423	chr6:90926672	BACH2	0.48	7.89	0.4	4.42e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.76	11.07	0.52	1.96e-24	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06636316	chr19:30303495	CCNE1	0.39	6.23	0.32	1.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-11.28	-0.53	3.61e-25	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg17633681	chr16:88106987	BANP	0.89	15.44	0.65	7.89e-41	Menopause (age at onset);
CRC	cis	rs2969070	0.867	rs886626	chr7:2498052	A/C	cg03277898	chr7:2518824	NA	-0.43	-6.21	-0.32	1.57e-9	Diastolic blood pressure;
CRC	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.53	8.07	0.41	1.34e-14	Diastolic blood pressure;
CRC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg05754148	chr16:3507555	NAT15	0.67	6.07	0.32	3.5e-9	Tuberculosis;
CRC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg13385521	chr17:29058706	SUZ12P	0.67	7.89	0.4	4.41e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.81	0.44	7.35e-17	Morning vs. evening chronotype;
CRC	trans	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg02869306	chr7:64672164	INTS4L1	0.42	6.05	0.32	3.85e-9	Aortic root size;
CRC	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg00373020	chr1:21041521	KIF17	0.39	6.26	0.33	1.21e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.42	-6.0	-0.31	5.18e-9	Aortic root size;
CRC	cis	rs1656402	1.000	rs1656402	chr2:233426526	C/T	cg03852847	chr2:233439513	NA	0.45	7.66	0.39	2.1e-13	Non-small cell lung cancer (survival);
CRC	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.69	7.57	0.38	3.89e-13	Childhood ear infection;
CRC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.36	-0.42	1.83e-15	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08524483	chr7:5085471	RBAK	0.43	6.04	0.32	4.22e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.66	9.29	0.46	2.19e-18	Alzheimer's disease;
CRC	cis	rs11212617	1.000	rs35244261	chr11:108283808	A/C	cg12106634	chr11:108092400	ATM;NPAT	-0.39	-5.66	-0.3	3.21e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg03037974	chr15:76606532	NA	0.73	13.0	0.58	1.88e-31	Blood metabolite levels;
CRC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.11	0.45	8.5e-18	Lymphocyte counts;
CRC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.58	8.9	0.44	3.69e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.58	-7.05	-0.36	1.07e-11	Body mass index;
CRC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.37	0.33	6.42e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.9	16.62	0.68	1.87e-45	Intelligence (multi-trait analysis);
CRC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.88	0.4	4.67e-14	Lung cancer;
CRC	cis	rs9847710	0.733	rs11923593	chr3:53088790	A/G	cg18099408	chr3:52552593	STAB1	0.42	6.04	0.32	4.25e-9	Ulcerative colitis;
CRC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg14092988	chr3:52407081	DNAH1	0.38	6.69	0.35	9.33e-11	Bipolar disorder;
CRC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg23957660	chr17:17878224	LRRC48	0.43	8.23	0.41	4.43e-15	Total body bone mineral density;
CRC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.82	12.17	0.56	2.14e-28	Breast cancer;
CRC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg02527881	chr3:46936655	PTH1R	-0.35	-6.09	-0.32	3.07e-9	Colorectal cancer;
CRC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	8.2	0.41	5.34e-15	Cognitive test performance;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.53	-9.23	-0.45	3.49e-18	Aortic root size;
CRC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.9	0.55	2.04e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	5.73	0.3	2.26e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.53e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg15123519	chr2:136567270	LCT	0.33	6.39	0.33	5.65e-10	Mosquito bite size;
CRC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.8	8.1	0.41	1.08e-14	Fat distribution (HIV);
CRC	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.52	8.71	0.43	1.56e-16	Dupuytren's disease;
CRC	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.39	6.09	0.32	3.12e-9	Obesity;
CRC	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg16589663	chr20:23618590	CST3	0.54	6.92	0.36	2.3e-11	Chronic kidney disease;
CRC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg09237302	chr4:906077	GAK	0.32	6.13	0.32	2.51e-9	Systemic sclerosis;
CRC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.6	8.45	0.42	9.36e-16	Arsenic metabolism;
CRC	cis	rs12476592	0.602	rs262529	chr2:63903892	A/C	cg10828910	chr2:63850056	LOC388955	0.51	6.33	0.33	7.99e-10	Childhood ear infection;
CRC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.25	-0.41	3.85e-15	Neuroticism;
CRC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.28	0.33	1.05e-9	Obesity-related traits;
CRC	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg20356878	chr3:121714668	ILDR1	-0.46	-6.55	-0.34	2.27e-10	Multiple sclerosis;
CRC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.49	-7.59	-0.39	3.36e-13	Height;
CRC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.7	9.41	0.46	8.93e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg20647610	chr2:228736258	WDR69	-0.5	-6.76	-0.35	6.37e-11	Blood pressure;
CRC	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg09476006	chr5:138032270	NA	0.44	6.69	0.35	9.76e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg20487152	chr13:99095054	FARP1	-0.47	-6.62	-0.34	1.43e-10	Longevity;
CRC	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg03929089	chr4:120376271	NA	-0.45	-6.43	-0.33	4.48e-10	HDL cholesterol;
CRC	trans	rs4714291	0.802	rs2984430	chr6:39983741	A/G	cg02267698	chr19:7991119	CTXN1	-0.52	-7.21	-0.37	3.92e-12	Strep throat;
CRC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg13390004	chr1:15929781	NA	0.5	7.14	0.37	6.11e-12	Systolic blood pressure;
CRC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg19041857	chr6:27730383	NA	-0.43	-6.13	-0.32	2.52e-9	Parkinson's disease;
CRC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.43	6.48	0.34	3.38e-10	Mean platelet volume;
CRC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18301423	chr5:131593218	PDLIM4	0.45	8.28	0.42	3.06e-15	Acylcarnitine levels;
CRC	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.73	-15.93	-0.66	9.7e-43	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02955050	chr19:59070391	UBE2M;LOC100131691	0.38	6.24	0.33	1.36e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.6	0.5	9.04e-23	Corneal astigmatism;
CRC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg26721908	chr21:47610096	LSS	-0.48	-6.93	-0.36	2.18e-11	Testicular germ cell tumor;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg12273811	chr6:28175739	NA	0.54	7.21	0.37	3.86e-12	Parkinson's disease;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.38	9.19	0.45	4.47e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.5	-7.22	-0.37	3.55e-12	White blood cell count;
CRC	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg12935359	chr14:103987150	CKB	-0.69	-9.09	-0.45	9.79e-18	Body mass index;
CRC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-7.94	-0.4	3.33e-14	Aortic root size;
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.88	0.63	1.17e-38	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.545	rs876252	chr12:54071422	A/G	cg06632207	chr12:54070931	ATP5G2	0.51	8.87	0.44	4.88e-17	Height;
CRC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg21153622	chr11:89784906	NA	-0.37	-5.98	-0.31	5.92e-9	Coronary artery disease;
CRC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg08648136	chr8:956695	NA	-0.3	-5.64	-0.3	3.72e-8	Schizophrenia;
CRC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.52	-8.31	-0.42	2.56e-15	Caffeine consumption;
CRC	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.48	9.59	0.47	2.25e-19	Schizophrenia;
CRC	cis	rs62432291	0.681	rs397476	chr6:159639284	A/G	cg14500486	chr6:159655392	FNDC1	-0.7	-9.97	-0.48	1.21e-20	Joint mobility (Beighton score);
CRC	cis	rs12476592	0.602	rs262488	chr2:63882179	C/T	cg10828910	chr2:63850056	LOC388955	0.5	6.36	0.33	6.57e-10	Childhood ear infection;
CRC	trans	rs4276421	0.837	rs7446182	chr5:45401817	A/T	cg04793272	chr11:119020941	ABCG4	0.38	6.2	0.32	1.69e-9	P wave duration;
CRC	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.65e-11	Coronary artery disease;
CRC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg12193833	chr17:30244370	NA	-0.73	-8.49	-0.42	7.41e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg15845792	chr6:28175446	NA	0.89	5.71	0.3	2.56e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6909279	0.678	rs11155795	chr6:151851339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.38	5.88	0.31	1.02e-8	Bone mineral density;
CRC	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.91	-11.38	-0.53	1.62e-25	Hair shape;
CRC	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.98	18.19	0.71	1.16e-51	Obesity (extreme);
CRC	trans	rs12699921	0.632	rs1524776	chr7:17872093	C/A	cg02066331	chr6:17282778	RBM24	-0.36	-6.17	-0.32	2.02e-9	Fibrinogen levels;
CRC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.71	11.38	0.53	1.56e-25	Monocyte count;
CRC	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg04586622	chr2:25135609	ADCY3	-0.57	-9.71	-0.47	8.94e-20	Body mass index;
CRC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	trans	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.95	-0.36	1.98e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6662572	0.737	rs56295206	chr1:46551026	G/A	cg08644498	chr1:46502608	NA	0.43	6.61	0.34	1.53e-10	Blood protein levels;
CRC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg27523141	chr10:43048294	ZNF37B	0.47	6.89	0.36	2.87e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg17294928	chr15:75287854	SCAMP5	-0.43	-6.48	-0.34	3.29e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.53	-0.34	2.47e-10	Response to antipsychotic treatment;
CRC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg18478394	chr8:109455254	TTC35	-0.39	-5.96	-0.31	6.62e-9	Dupuytren's disease;
CRC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06656553	chr16:89960601	TCF25	-0.72	-5.86	-0.31	1.14e-8	Skin colour saturation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21412992	chr1:61547497	NFIA	0.42	6.34	0.33	7.44e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.56	6.1	0.32	2.9e-9	Coronary artery disease;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.53	-9.9	-0.48	2.14e-20	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07050827	chr2:228280252	NA	0.44	6.85	0.35	3.59e-11	Interleukin-6 levels;
CRC	trans	rs2303319	0.582	rs56094729	chr2:162464835	C/T	cg03757145	chr4:76555832	CDKL2	-0.66	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.09	0.45	9.73e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.61	9.03	0.45	1.48e-17	Corneal astigmatism;
CRC	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.85	-0.55	3.21e-27	Colorectal cancer;
CRC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.62e-10	Blood metabolite levels;
CRC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.98	-0.31	5.84e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.45	-0.34	3.98e-10	Electroencephalogram traits;
CRC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.45	6.25	0.33	1.26e-9	Aortic root size;
CRC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg02560186	chr11:3602584	NA	-0.63	-9.64	-0.47	1.62e-19	Blood pressure (smoking interaction);
CRC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.7	11.09	0.52	1.67e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg20243544	chr17:37824526	PNMT	-0.42	-6.54	-0.34	2.31e-10	Self-reported allergy;
CRC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg27366882	chr3:133540807	NA	0.4	5.93	0.31	7.46e-9	Ankle injury;
CRC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg25876840	chr17:41920477	NA	0.62	8.74	0.43	1.19e-16	Triglycerides;
CRC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.6	-0.47	2.04e-19	Migraine;Coronary artery disease;
CRC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.34	-0.53	2.27e-25	Hemoglobin concentration;
CRC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg13607699	chr17:42295918	UBTF	-0.48	-6.38	-0.33	6.17e-10	Total body bone mineral density;
CRC	trans	rs12699921	0.568	rs2691605	chr7:17877448	T/C	cg15753394	chr6:17282781	RBM24	-0.36	-6.13	-0.32	2.51e-9	Fibrinogen levels;
CRC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg23229984	chr5:148520753	ABLIM3	0.5	6.95	0.36	1.96e-11	Breast cancer;
CRC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-5.65	-0.3	3.5e-8	Platelet count;
CRC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.58	-9.57	-0.47	2.68e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg02683197	chr6:28174875	NA	0.67	6.91	0.36	2.55e-11	Depression;
CRC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.48	-6.77	-0.35	6.07e-11	Response to temozolomide;
CRC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.42	6.4	0.33	5.29e-10	Monocyte count;
CRC	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg02158880	chr13:53174818	NA	-0.44	-6.38	-0.33	6e-10	Lewy body disease;
CRC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg24829409	chr8:58192753	C8orf71	-0.53	-6.22	-0.32	1.5e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23708337	chr7:1209742	NA	0.49	7.52	0.38	5.39e-13	Longevity;Endometriosis;
CRC	cis	rs1322512	0.917	rs2489545	chr6:153006907	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	trans	rs6693295	0.605	rs6692457	chr1:246216326	A/C	cg03680032	chr11:94965610	SESN3	0.49	6.12	0.32	2.68e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg19812747	chr11:111475976	SIK2	-0.46	-6.62	-0.34	1.47e-10	Primary sclerosing cholangitis;
CRC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.86	-0.31	1.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7814319	0.700	rs11995989	chr8:97264456	C/G	cg20787634	chr8:97240163	UQCRB	-0.45	-7.22	-0.37	3.54e-12	Lung function (FVC);
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg21747405	chr11:67723411	NA	-0.58	-9.13	-0.45	6.88e-18	Blood pressure (smoking interaction);
CRC	cis	rs11212617	0.967	rs4754305	chr11:108075912	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.22	0.32	1.49e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg02158880	chr13:53174818	NA	0.54	8.63	0.43	2.65e-16	Lewy body disease;
CRC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-11.61	-0.54	2.3e-26	Chronic sinus infection;
CRC	trans	rs2303319	0.504	rs62188961	chr2:162495399	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-12.98	-0.58	2.2e-31	Blood metabolite levels;
CRC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg14541582	chr5:601475	NA	-0.36	-7.2	-0.37	4.08e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.65	10.06	0.49	6.2e-21	Monocyte count;
CRC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.76	0.43	1.07e-16	Menopause (age at onset);
CRC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.91	-0.48	1.93e-20	Coronary artery disease;
CRC	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.58	7.06	0.36	9.73e-12	Lymphocyte counts;
CRC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg08888203	chr3:10149979	C3orf24	0.49	7.26	0.37	2.76e-12	Alzheimer's disease;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg06219103	chr11:63990595	FERMT3	0.47	7.66	0.39	2.04e-13	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00185336	chr7:73153699	ABHD11	0.43	6.38	0.33	5.94e-10	Response to antipsychotic treatment;
CRC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12741539	chr12:42719903	PPHLN1;ZCRB1	0.45	6.52	0.34	2.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg15123519	chr2:136567270	LCT	0.34	6.57	0.34	1.94e-10	Mosquito bite size;
CRC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.3	-0.33	9.49e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.43	6.96	0.36	1.88e-11	Social autistic-like traits;
CRC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.8	11.11	0.52	1.4e-24	Cognitive function;
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg07332563	chr6:291687	DUSP22	-0.5	-7.05	-0.36	1.03e-11	Menopause (age at onset);
CRC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.72	9.54	0.47	3.38e-19	Cleft lip with or without cleft palate;
CRC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.38	6.1	0.32	2.92e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.53	8.45	0.42	9.33e-16	Prostate cancer;
CRC	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg01639898	chr1:32083012	HCRTR1	0.29	5.78	0.3	1.72e-8	Intelligence (multi-trait analysis);
CRC	cis	rs282587	0.502	rs416703	chr13:113399219	A/G	cg04656015	chr13:113407548	ATP11A	0.62	7.97	0.4	2.63e-14	Glycated hemoglobin levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08474403	chr1:68962753	DEPDC1	0.45	6.05	0.32	4.05e-9	Anxiety disorder;
CRC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.89	-15.51	-0.65	4.12e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg26587870	chr6:27730563	NA	-0.44	-6.64	-0.34	1.32e-10	Parkinson's disease;
CRC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.42	8.81	0.44	7.16e-17	Urinary metabolites;
CRC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg03623178	chr6:28175578	NA	0.99	12.74	0.57	1.71e-30	Depression;
CRC	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.57	-7.96	-0.4	2.73e-14	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.51	7.97	0.4	2.59e-14	Schizophrenia;
CRC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.43	6.86	0.35	3.35e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9926296	0.585	rs6500441	chr16:89828669	C/G	ch.11.1155333R	chr11:60687684	TMEM109	-0.43	-6.1	-0.32	3.04e-9	Vitiligo;
CRC	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg00319359	chr11:70116639	PPFIA1	0.65	6.19	0.32	1.76e-9	Coronary artery disease;
CRC	cis	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg25886479	chr11:50257625	LOC441601	-0.33	-5.64	-0.3	3.65e-8	Height;
CRC	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg14664628	chr15:75095509	CSK	0.47	6.81	0.35	4.59e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.47	-0.34	3.62e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.36	-0.38	1.52e-12	Bipolar disorder;
CRC	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg07807695	chr5:81608485	ATP6AP1L	-0.48	-7.59	-0.39	3.39e-13	Breast cancer;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg15147215	chr3:52552868	STAB1	-0.74	-14.83	-0.63	1.81e-38	Hemoglobin concentration;
CRC	cis	rs1519814	1.000	rs10104973	chr8:121104385	C/T	cg22335954	chr8:121166405	COL14A1	-0.5	-6.25	-0.33	1.24e-9	Breast cancer;
CRC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.44	-6.42	-0.33	4.64e-10	Macular telangiectasia type 2;
CRC	cis	rs7072216	0.922	rs2296438	chr10:100146895	T/C	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.97	-0.31	6.2e-9	Metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.46	6.76	0.35	6.11e-11	Response to antipsychotic treatment;
CRC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.91	-14.96	-0.64	5.92e-39	Multiple sclerosis;
CRC	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg07424746	chr4:185654737	MLF1IP	0.51	5.69	0.3	2.8e-8	Blood protein levels;
CRC	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.17	0.37	4.87e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg14664628	chr15:75095509	CSK	0.47	6.81	0.35	4.59e-11	Caffeine consumption;
CRC	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.64	-9.24	-0.45	3.07e-18	Type 2 diabetes;
CRC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6479527	0.840	rs1832857	chr9:96751679	T/C	cg14459158	chr9:96720562	NA	0.41	7.52	0.38	5.11e-13	Esophageal adenocarcinoma;
CRC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.43	10.05	0.48	6.76e-21	Coronary artery disease;
CRC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.28	15.26	0.64	3.9e-40	Uric acid levels;
CRC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg13206674	chr6:150067644	NUP43	0.49	7.04	0.36	1.13e-11	Testicular germ cell tumor;
CRC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	8.76	0.43	1.08e-16	Alzheimer's disease;
CRC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.5	6.67	0.35	1.09e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.08	13.41	0.59	5.35e-33	Vitiligo;
CRC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.66	0.47	1.31e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.5	6.84	0.35	3.81e-11	Pancreatic cancer;
CRC	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg18016565	chr1:150552671	MCL1	0.49	7.05	0.36	1.04e-11	Blood protein levels;
CRC	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-6.31	-0.33	9.09e-10	Schizophrenia;
CRC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg11271282	chr2:238384023	NA	0.47	6.06	0.32	3.78e-9	Prostate cancer;
CRC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg03340356	chr1:67600835	NA	0.25	5.72	0.3	2.34e-8	Psoriasis;
CRC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg21466736	chr12:48725269	NA	0.47	7.26	0.37	2.77e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.55	0.38	4.44e-13	Height;
CRC	cis	rs6908034	0.607	rs112599867	chr6:19805532	A/G	cg02682789	chr6:19804855	NA	0.8	6.74	0.35	6.9e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.17e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.56	-5.68	-0.3	3.04e-8	Hip circumference adjusted for BMI;
CRC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.72	-0.3	2.38e-8	Gut microbiome composition (summer);
CRC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.72	10.13	0.49	3.57e-21	Coronary artery disease;
CRC	trans	rs17742757	0.521	rs2736324	chr8:11328182	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.79	0.35	5.25e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09773150	chr17:3796596	CAMKK1	-0.42	-6.18	-0.32	1.84e-9	Myopia (pathological);
CRC	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg27398640	chr15:77910606	LINGO1	0.43	7.59	0.39	3.27e-13	Type 2 diabetes;
CRC	cis	rs13253111	0.624	rs13277389	chr8:28100234	G/T	cg26534493	chr8:28060551	NA	0.42	7.15	0.37	5.7e-12	Childhood body mass index;
CRC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.63	8.39	0.42	1.42e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.47	7.83	0.4	6.84e-14	Major depressive disorder;
CRC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.94	-0.4	3.16e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg00738113	chr16:70207722	CLEC18C	-0.4	-5.78	-0.3	1.72e-8	IgE levels;
CRC	cis	rs4363385	0.818	rs1750309	chr1:153013630	G/C	cg25856811	chr1:152973957	SPRR3	-0.27	-7.49	-0.38	6.23e-13	Inflammatory skin disease;
CRC	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg15234197	chr11:68924956	NA	0.42	5.8	0.3	1.57e-8	Blond vs. brown hair color;
CRC	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.81	10.48	0.5	2.25e-22	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7781266	0.790	rs11766325	chr7:133123616	A/C	cg03336402	chr7:133662267	EXOC4	0.49	5.81	0.31	1.47e-8	Educational attainment (college completion);
CRC	cis	rs995000	0.931	rs6690733	chr1:63060311	A/C	cg19896129	chr1:63156450	NA	0.42	6.45	0.34	3.95e-10	Triglyceride levels;
CRC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.41	-0.33	5.04e-10	Glycated hemoglobin levels;
CRC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.15	0.37	5.56e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.36	0.46	1.33e-18	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.47	6.32	0.33	8.68e-10	IgG glycosylation;
CRC	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.81	-14.1	-0.61	1.26e-35	Lewy body disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03425468	chr1:155164676	MIR92B	0.45	7.2	0.37	4.21e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.49	-0.34	3.21e-10	Bipolar disorder;
CRC	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg09873164	chr1:152488093	CRCT1	0.37	6.29	0.33	1e-9	Hair morphology;
CRC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.57	0.39	3.69e-13	Height;
CRC	trans	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.4	-0.5	4.44e-22	Bipolar disorder;
CRC	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.06	-0.36	1.02e-11	Schizophrenia;
CRC	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-5.66	-0.3	3.23e-8	Neuroticism;
CRC	cis	rs11212617	0.967	rs605394	chr11:108243628	C/T	cg01991180	chr11:108092276	ATM;NPAT	-0.42	-5.99	-0.31	5.43e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs17152411	1.000	rs41303609	chr10:126670613	G/T	cg07906193	chr10:126599966	NA	0.63	6.82	0.35	4.46e-11	Height;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg05569086	chr8:143859399	LYNX1	0.4	6.91	0.36	2.57e-11	Urinary tract infection frequency;
CRC	cis	rs9463078	0.691	rs12209727	chr6:45353100	C/T	cg25276700	chr6:44698697	NA	0.26	6.2	0.32	1.68e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12024301	0.557	rs6424898	chr1:183596045	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.67	-0.35	1.07e-10	Response to antipsychotic treatment;
CRC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg02869306	chr7:64672164	INTS4L1	0.34	5.62	0.3	4.15e-8	Aortic root size;
CRC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg12193833	chr17:30244370	NA	0.45	5.97	0.31	6e-9	Hip circumference adjusted for BMI;
CRC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg08798685	chr6:27730294	NA	-0.42	-6.22	-0.32	1.51e-9	Parkinson's disease;
CRC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.5	-7.22	-0.37	3.54e-12	Response to temozolomide;
CRC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.2	0.32	1.73e-9	Bladder cancer;
CRC	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.68	-11.49	-0.54	6.43e-26	White blood cell count (basophil);
CRC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.49	8.99	0.44	2e-17	Total body bone mineral density;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15704304	chr12:68881427	NA	-0.4	-6.33	-0.33	7.97e-10	Interleukin-6 levels;
CRC	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg14515779	chr1:101123966	NA	0.35	5.84	0.31	1.25e-8	Monocyte count;
CRC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.37	-6.72	-0.35	8.01e-11	Reticulocyte fraction of red cells;
CRC	cis	rs524281	0.731	rs11227433	chr11:66004693	G/A	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.72	10.71	0.51	3.72e-23	Response to antineoplastic agents;
CRC	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg14458575	chr2:238380390	NA	0.46	6.61	0.34	1.6e-10	Prostate cancer;
CRC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16447950	chr5:562315	NA	-0.83	-10.78	-0.51	2.14e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.91	17.67	0.7	1.31e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs965469	1.000	rs1040727	chr20:3264292	G/A	cg25506879	chr20:3388711	C20orf194	-0.4	-5.7	-0.3	2.71e-8	IFN-related cytopenia;
CRC	cis	rs9462027	0.630	rs7341267	chr6:34727031	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Systemic lupus erythematosus;
CRC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg21784768	chr11:537496	LRRC56	-0.7	-6.6	-0.34	1.65e-10	Body mass index;
CRC	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-0.95	-10.04	-0.48	7.06e-21	Post bronchodilator FEV1;
CRC	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.65	10.23	0.49	1.69e-21	Corneal astigmatism;
CRC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg13119609	chr19:45449297	APOC2	0.31	5.81	0.3	1.5e-8	Blood protein levels;
CRC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg26893134	chr6:116381904	FRK	0.28	8.0	0.4	2.15e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg27422857	chr2:105853526	NA	-0.34	-6.4	-0.33	5.46e-10	Type 2 diabetes;
CRC	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg03929089	chr4:120376271	NA	0.71	6.93	0.36	2.26e-11	Axial length;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11645453	chr3:52864694	ITIH4	0.37	6.63	0.34	1.38e-10	Bipolar disorder;
CRC	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.95	13.99	0.61	3.34e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg17321639	chr7:2759063	NA	-0.43	-6.46	-0.34	3.72e-10	Height;
CRC	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.34	-0.38	1.66e-12	Diisocyanate-induced asthma;
CRC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.24	-0.45	3.04e-18	Platelet count;
CRC	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg03037974	chr15:76606532	NA	-0.57	-8.66	-0.43	2.09e-16	Blood metabolite levels;
CRC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17554472	chr22:41940697	POLR3H	-0.56	-5.89	-0.31	9.48e-9	Vitiligo;
CRC	cis	rs3018066	0.806	rs4314353	chr4:107028003	A/G	cg01869342	chr4:106983673	TBCK	0.36	5.67	0.3	3.17e-8	Cancer;
CRC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg09127314	chr1:152161683	NA	0.52	6.81	0.35	4.79e-11	Atopic dermatitis;
CRC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg23283495	chr1:209979779	IRF6	0.46	6.63	0.34	1.4e-10	Cleft lip with or without cleft palate;
CRC	cis	rs6585424	1.000	rs61860045	chr10:81947397	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-9.15	-0.45	6.21e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17095355	1.000	rs72828232	chr10:111725298	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.12	-0.37	6.81e-12	Biliary atresia;
CRC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.37	2.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg12317470	chr15:67143691	NA	0.75	6.13	0.32	2.45e-9	Lung cancer (smoking interaction);
CRC	trans	rs12439619	1.000	rs12439619	chr15:82546946	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.94	-0.36	2.11e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	13.49	0.6	2.68e-33	Hypertriglyceridemia;
CRC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8141797	0.642	rs1004058	chr22:24482500	A/C	cg20894457	chr22:24584366	SUSD2	-0.61	-6.01	-0.31	4.95e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg15147215	chr3:52552868	STAB1	-0.64	-10.92	-0.52	6.97e-24	Bipolar disorder;
CRC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg08027265	chr7:2291960	NA	-0.33	-5.72	-0.3	2.34e-8	Schizophrenia;
CRC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.54	-8.1	-0.41	1.07e-14	Blood protein levels;
CRC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.03e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11212617	0.805	rs10890821	chr11:108022061	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.45	6.73	0.35	7.5e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19963142	chr11:58345608	ZFP91;LPXN;ZFP91-CNTF	0.39	6.04	0.32	4.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.86	0.31	1.13e-8	Diabetic retinopathy;
CRC	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.91	0.44	3.49e-17	Bladder cancer;
CRC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.35	-0.38	1.59e-12	Total body bone mineral density;
CRC	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg13491945	chr12:107078410	RFX4	0.34	5.85	0.31	1.19e-8	Heart rate;
CRC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg13844804	chr7:814759	HEATR2	0.62	7.98	0.4	2.51e-14	Cerebrospinal P-tau181p levels;
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg15845792	chr6:28175446	NA	0.94	11.95	0.55	1.4e-27	Parkinson's disease;
CRC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	7.56	0.38	4.1e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.52	8.58	0.43	3.77e-16	Calcium levels;
CRC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg00601486	chr12:48723148	H1FNT	0.35	6.77	0.35	6.03e-11	Glycated hemoglobin levels;
CRC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.85	-0.48	3.13e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17507749	chr15:85114479	UBE2QP1	0.66	8.77	0.44	9.86e-17	Schizophrenia;
CRC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.66	7.3	0.37	2.18e-12	Vitiligo;
CRC	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.58	-6.39	-0.33	5.58e-10	Coronary artery disease;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.28	0.33	1.04e-9	Depression;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.51	8.05	0.41	1.56e-14	Electroencephalogram traits;
CRC	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg05507819	chr15:63340323	TPM1	0.46	5.87	0.31	1.05e-8	HDL cholesterol;
CRC	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg14593290	chr7:50529359	DDC	0.57	7.88	0.4	4.85e-14	Malaria;
CRC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.42	6.19	0.32	1.77e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.99	12.98	0.58	2.16e-31	Triglycerides;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25116269	chr2:55509523	PRDXDD1P	0.46	6.45	0.34	3.89e-10	Survival in pancreatic cancer;
CRC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg16342193	chr10:102329863	NA	-0.36	-5.9	-0.31	9.08e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg02880119	chr16:3481970	NA	0.49	6.75	0.35	6.85e-11	Body mass index (adult);
CRC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.87	0.48	2.78e-20	Ileal carcinoids;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15731816	chr14:75230414	YLPM1	-0.51	-6.2	-0.32	1.67e-9	Diisocyanate-induced asthma;
CRC	cis	rs6694672	1.000	rs6656858	chr1:197113573	C/T	cg13682187	chr1:196946512	CFHR5	0.45	7.21	0.37	3.89e-12	Asthma;
CRC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg15309053	chr8:964076	NA	0.34	6.03	0.32	4.45e-9	Schizophrenia;
CRC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg07636037	chr3:49044803	WDR6	-0.71	-6.59	-0.34	1.72e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.67	0.35	1.09e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	7.15	0.37	5.54e-12	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14978304	chr1:162039761	NOS1AP	0.47	6.57	0.34	1.92e-10	Anxiety disorder;
CRC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.74	-13.59	-0.6	1.06e-33	Age at first birth;
CRC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.22	0.49	1.73e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg10305451	chr2:177043427	NA	0.7	11.19	0.53	7.42e-25	IgG glycosylation;
CRC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.36	6.25	0.33	1.29e-9	Erythrocyte sedimentation rate;
CRC	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.39	5.97	0.31	6.03e-9	Red blood cell count;
CRC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.49	-7.11	-0.36	7.23e-12	Selective IgA deficiency;
CRC	cis	rs6973256	0.897	rs2909224	chr7:133331041	C/G	cg10665199	chr7:133106180	EXOC4	-0.37	-5.66	-0.3	3.26e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg24011408	chr12:48396354	COL2A1	0.45	6.24	0.33	1.36e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs7800418	0.723	rs55716901	chr7:26590736	G/C	cg14387656	chr2:233470847	EFHD1	0.47	6.43	0.33	4.6e-10	Cognitive function;
CRC	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.49	-7.14	-0.37	5.95e-12	Sudden cardiac arrest;
CRC	cis	rs6694672	1.000	rs12731209	chr1:196947139	C/T	cg13682187	chr1:196946512	CFHR5	-0.47	-7.41	-0.38	1.1e-12	Asthma;
CRC	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.66	-0.3	3.31e-8	Height;
CRC	cis	rs9463078	0.653	rs6910974	chr6:45082169	A/T	cg25276700	chr6:44698697	NA	-0.24	-5.84	-0.31	1.22e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs2118666	0.590	rs13017777	chr2:223069625	T/C	cg09178651	chr17:42459368	ITGA2B	0.38	6.0	0.31	5.08e-9	Information processing speed;
CRC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg15845792	chr6:28175446	NA	0.68	8.53	0.43	5.38e-16	Parkinson's disease;
CRC	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg24578937	chr1:2090814	PRKCZ	0.46	8.08	0.41	1.28e-14	Coronary artery disease;
CRC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.91	17.35	0.69	2.48e-48	Blood protein levels;
CRC	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07165851	chr6:158734300	TULP4	0.62	7.68	0.39	1.84e-13	Height;
CRC	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.32	0.33	8.6e-10	Body mass index;
CRC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg19318889	chr4:1322082	MAEA	0.4	5.72	0.3	2.35e-8	Obesity-related traits;
CRC	cis	rs9648716	1.000	rs1267637	chr7:140473338	A/C	cg10747023	chr7:140774559	NA	0.44	5.64	0.3	3.71e-8	Type 2 diabetes;
CRC	trans	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg18335740	chr13:41363409	SLC25A15	0.46	7.1	0.36	7.67e-12	Lewy body disease;
CRC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg17633681	chr16:88106987	BANP	0.87	16.25	0.67	5.17e-44	Menopause (age at onset);
CRC	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.57	-8.87	-0.44	4.59e-17	Eosinophil percentage of white cells;
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	8.06	0.41	1.47e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg03623178	chr6:28175578	NA	0.94	12.29	0.56	7.67e-29	Depression;
CRC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg15445000	chr17:37608096	MED1	-0.35	-6.23	-0.32	1.43e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg10570241	chr7:158785291	NA	0.41	7.09	0.36	8.45e-12	Facial morphology (factor 20);
CRC	cis	rs7209700	0.547	rs8078614	chr17:45351505	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.6	0.34	1.61e-10	IgG glycosylation;
CRC	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg00105475	chr2:10696890	NA	0.45	7.24	0.37	3.21e-12	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03130149	chr11:3819041	PGAP2;NUP98	0.54	7.24	0.37	3.21e-12	Thyroid stimulating hormone;
CRC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg08807101	chr21:30365312	RNF160	-0.47	-6.67	-0.35	1.09e-10	Pancreatic cancer;
CRC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.15	-0.32	2.3e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	11.19	0.53	7.38e-25	Bone mineral density;
CRC	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.44	-0.62	5.77e-37	Colorectal cancer;
CRC	cis	rs13315871	1.000	rs71311871	chr3:58420613	A/G	cg20936604	chr3:58311152	NA	-0.77	-7.23	-0.37	3.49e-12	Cholesterol, total;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12112058	chr1:224622605	WDR26	0.44	6.54	0.34	2.39e-10	Response to antipsychotic treatment;
CRC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg04880052	chr2:219191631	PNKD	-0.41	-6.08	-0.32	3.25e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.48	0.5	2.22e-22	Menopause (age at onset);
CRC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg00601486	chr12:48723148	H1FNT	-0.33	-6.22	-0.32	1.53e-9	Glycated hemoglobin levels;
CRC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.58	8.04	0.41	1.69e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	0.82	8.33	0.42	2.18e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.92e-17	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs2882667	0.898	rs11952020	chr5:138395156	A/T	cg04439458	chr5:138467593	SIL1	-0.31	-5.62	-0.3	3.97e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs3889199	0.887	rs7534174	chr1:59661309	T/G	cg25881383	chr1:59680599	NA	-0.39	-6.23	-0.32	1.41e-9	Pulse pressure;
CRC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	11.8	0.55	5.03e-27	Platelet count;
CRC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.47	6.72	0.35	7.84e-11	Birth weight;
CRC	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.47	-5.63	-0.3	3.89e-8	Childhood ear infection;
CRC	cis	rs6694672	1.000	rs857021	chr1:197007479	A/G	cg13682187	chr1:196946512	CFHR5	0.45	7.07	0.36	9.61e-12	Asthma;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg15147215	chr3:52552868	STAB1	0.68	12.41	0.56	2.87e-29	Electroencephalogram traits;
CRC	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg27083787	chr2:113543245	IL1A	0.44	6.35	0.33	7.26e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.4	0.42	1.32e-15	Myopia (pathological);
CRC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg20129853	chr10:51489980	NA	-0.42	-7.13	-0.37	6.32e-12	Prostate-specific antigen levels;
CRC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.85	-12.99	-0.58	2.01e-31	Multiple myeloma;
CRC	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.77	0.6	2.29e-34	Chronic sinus infection;
CRC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.58	-10.87	-0.51	9.87e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg12516270	chr8:143859308	LYNX1	-0.39	-6.45	-0.33	4.08e-10	Urinary tract infection frequency;
CRC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg25600027	chr14:23388339	RBM23	-0.53	-8.37	-0.42	1.65e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg14711859	chr11:8959438	ASCL3	-0.42	-6.88	-0.35	3.09e-11	Tonsillectomy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27261641	chr11:95523641	FAM76B;CEP57	0.41	6.05	0.32	3.94e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg10756647	chr7:56101905	PSPH	0.76	7.91	0.4	3.95e-14	Diabetic kidney disease;
CRC	cis	rs1158570	0.500	rs2554369	chr8:131314047	C/T	cg21674704	chr8:131455249	NA	-0.42	-6.36	-0.33	6.61e-10	Platelet count;
CRC	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg18827107	chr12:86230957	RASSF9	0.36	5.69	0.3	2.79e-8	Major depressive disorder;
CRC	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.97	0.31	6.27e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.41	6.53	0.34	2.48e-10	Blood metabolite levels;
CRC	cis	rs6088813	1.000	rs2425065	chr20:33926268	A/T	cg14752227	chr20:34000481	UQCC	0.37	5.77	0.3	1.83e-8	Height;
CRC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.93	11.32	0.53	2.62e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.68	7.29	0.37	2.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.47	-8.98	-0.44	2.06e-17	Iron status biomarkers;
CRC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.58	-8.61	-0.43	3.16e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.16	11.41	0.53	1.27e-25	Skin colour saturation;
CRC	trans	rs6928289	0.545	rs12207738	chr6:137674945	C/G	cg20212336	chr13:111268714	CARKD	0.4	6.04	0.32	4.25e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-6.51	-0.34	2.83e-10	Blood trace element (Cu levels);
CRC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-14.49	-0.62	3.79e-37	Height;
CRC	cis	rs6842789	0.510	rs11098725	chr4:124919843	C/T	cg01723706	chr4:124814442	LOC285419	0.37	5.81	0.31	1.45e-8	Neuroticism;
CRC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg17948913	chr5:572064	NA	0.53	5.94	0.31	7.17e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.56	9.32	0.46	1.78e-18	Schizophrenia;
CRC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.46	7.02	0.36	1.24e-11	Dupuytren's disease;
CRC	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.35	16.39	0.67	1.43e-44	Uric acid levels;
CRC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.83	-0.31	1.35e-8	Gout;Renal underexcretion gout;
CRC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	cis	rs290268	0.669	rs10993693	chr9:93557698	C/T	cg02608019	chr9:93564028	SYK	0.47	7.16	0.37	5.29e-12	Platelet count;
CRC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.47	6.44	0.33	4.32e-10	Menarche (age at onset);
CRC	cis	rs1656402	1.000	rs4973544	chr2:233435535	G/A	cg03852847	chr2:233439513	NA	-0.43	-6.97	-0.36	1.75e-11	Non-small cell lung cancer (survival);
CRC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.56	8.22	0.41	4.65e-15	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16196077	chr10:64028521	RTKN2	0.36	6.27	0.33	1.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6604026	0.922	rs35051335	chr1:93295830	A/G	cg17283838	chr1:93427260	FAM69A	0.45	5.68	0.3	2.92e-8	Multiple sclerosis;
CRC	trans	rs12699921	0.568	rs2691605	chr7:17877448	T/C	cg02066331	chr6:17282778	RBM24	-0.36	-6.18	-0.32	1.89e-9	Fibrinogen levels;
CRC	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.52	9.12	0.45	7.6e-18	Lung function (FVC);
CRC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg15848620	chr12:58087721	OS9	-0.65	-8.94	-0.44	2.86e-17	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05862135	chr16:3074294	HCFC1R1;THOC6	0.39	6.21	0.32	1.6e-9	Schizophrenia;
CRC	cis	rs9311676	0.632	rs11714389	chr3:58447299	C/T	cg06643156	chr3:58380774	PXK	0.44	6.73	0.35	7.61e-11	Systemic lupus erythematosus;
CRC	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs12928939	0.911	rs11645725	chr16:71826883	C/T	cg08717414	chr16:71523259	ZNF19	-0.51	-6.32	-0.33	8.64e-10	Post bronchodilator FEV1;
CRC	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.82	10.51	0.5	1.88e-22	Iron status biomarkers;
CRC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg00343986	chr7:65444356	GUSB	0.46	6.62	0.34	1.49e-10	Aortic root size;
CRC	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.56	-0.47	2.92e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.43	0.69	1.17e-48	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.64	10.28	0.49	1.11e-21	Dental caries;
CRC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.56	0.63	2.05e-37	Chronic sinus infection;
CRC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.61	-9.5	-0.46	4.5e-19	Schizophrenia;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg09141835	chr16:88988174	CBFA2T3	-0.26	-5.64	-0.3	3.59e-8	Social autistic-like traits;
CRC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.22e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.51	-7.76	-0.39	1.1e-13	Diastolic blood pressure;
CRC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.97	-0.44	2.23e-17	Bipolar disorder;
CRC	cis	rs12760731	0.920	rs34440664	chr1:178477925	G/T	cg00404053	chr1:178313656	RASAL2	0.86	8.35	0.42	1.88e-15	Obesity-related traits;
CRC	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.59	8.53	0.43	5.61e-16	Schizophrenia;
CRC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.61	8.64	0.43	2.54e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.74	0.47	7.19e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.48	-8.81	-0.44	7.17e-17	Total body bone mineral density;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg12172441	chr6:28176163	NA	0.45	6.35	0.33	7.17e-10	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17956079	chr11:73358572	PLEKHB1	0.52	7.27	0.37	2.6e-12	Thyroid stimulating hormone;
CRC	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg04110750	chr16:69646130	NFAT5	-0.52	-7.11	-0.37	7.18e-12	IgE levels;
CRC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13198984	chr17:80129470	CCDC57	0.47	8.12	0.41	9.18e-15	Life satisfaction;
CRC	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.34	6.3	0.33	9.8e-10	Panic disorder;
CRC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.41	0.33	5.09e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4074493	1.000	rs4378192	chr1:231173379	C/T	cg22172038	chr1:231176991	FAM89A	0.34	5.9	0.31	9.23e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	6.37	0.33	6.2e-10	Axial length;
CRC	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.43	6.35	0.33	6.99e-10	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9287719	0.649	rs6730247	chr2:10725888	G/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.43	7.17	0.37	5.01e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-1.11	-10.01	-0.48	9.26e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs995000	0.931	rs642845	chr1:62908235	T/C	cg19896129	chr1:63156450	NA	0.44	6.84	0.35	3.76e-11	Triglyceride levels;
CRC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.86e-17	Aortic root size;
CRC	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.34	6.39	0.33	5.68e-10	Ulcerative colitis;
CRC	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.6	-6.58	-0.34	1.83e-10	Coronary artery disease;
CRC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.11	-0.41	9.85e-15	Type 2 diabetes;
CRC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.85	-14.55	-0.63	2.21e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg15368822	chr1:226070397	TMEM63A	-0.41	-6.04	-0.32	4.22e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.58	8.35	0.42	1.96e-15	Resting heart rate;
CRC	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24249390	chr15:90295951	MESP1	-0.59	-9.31	-0.46	1.87e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg17393568	chr4:190861806	FRG1	0.5	6.08	0.32	3.3e-9	Colorectal cancer;
CRC	trans	rs1607741	1.000	rs10000244	chr4:72711845	A/G	cg06437464	chr6:127441704	RSPO3	0.29	6.16	0.32	2.06e-9	Vitamin D levels;
CRC	cis	rs4936891	0.599	rs729775	chr11:123910401	C/A	cg22125253	chr11:123886957	OR10G4	-0.32	-5.94	-0.31	7.15e-9	Male fertility;
CRC	cis	rs10512697	0.655	rs13173969	chr5:3487526	G/A	cg19473799	chr5:3511975	NA	-0.83	-6.35	-0.33	7.32e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.84	10.61	0.5	8.08e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs11955398	0.692	rs897672	chr5:59996101	C/G	cg02684056	chr5:59996105	DEPDC1B	0.41	5.86	0.31	1.12e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg20243544	chr17:37824526	PNMT	0.46	7.09	0.36	8.38e-12	Self-reported allergy;
CRC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.74	0.54	8.1e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg04586622	chr2:25135609	ADCY3	-0.67	-13.75	-0.6	2.66e-34	Body mass index in non-asthmatics;
CRC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	10.04	0.48	7.31e-21	HIV-1 control;
CRC	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg08017634	chr8:144659831	NAPRT1	0.67	5.72	0.3	2.44e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.47	-9.16	-0.45	5.73e-18	Intelligence (multi-trait analysis);
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08989290	chr16:615782	NHLRC4	0.48	9.41	0.46	8.82e-19	Height;
CRC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.22e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.59	-8.21	-0.41	5.02e-15	Menopause (age at onset);
CRC	cis	rs972578	0.837	rs6002964	chr22:43246248	G/T	cg01576275	chr22:43409880	NA	-0.4	-6.21	-0.32	1.61e-9	Mean platelet volume;
CRC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.6	-0.34	1.63e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.77	-7.58	-0.39	3.47e-13	Macrophage inflammatory protein 1b levels;
CRC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	12.35	0.56	4.67e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21028142	chr17:79581711	NPLOC4	0.35	7.29	0.37	2.38e-12	Eye color traits;
CRC	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg04850286	chr10:81895943	PLAC9	0.37	6.71	0.35	8.44e-11	Sarcoidosis;
CRC	cis	rs7705042	0.828	rs11750521	chr5:141500704	T/C	cg07392085	chr5:141489673	NDFIP1	0.47	7.42	0.38	1.03e-12	Asthma;
CRC	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg08632701	chr21:37451849	NA	-0.45	-7.09	-0.36	8.4e-12	Mitral valve prolapse;
CRC	cis	rs7487075	0.893	rs1471223	chr12:46727770	A/C	cg22049899	chr12:47219821	SLC38A4	-0.35	-6.9	-0.36	2.67e-11	Itch intensity from mosquito bite;
CRC	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg21918786	chr6:109611834	NA	-0.33	-5.63	-0.3	3.77e-8	Reticulocyte fraction of red cells;
CRC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg10570241	chr7:158785291	NA	0.38	6.5	0.34	2.97e-10	Facial morphology (factor 20);
CRC	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg00738113	chr16:70207722	CLEC18C	0.43	7.47	0.38	7.16e-13	Sjögren's syndrome;
CRC	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.54	-7.86	-0.4	5.72e-14	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg02869306	chr7:64672164	INTS4L1	0.35	5.76	0.3	1.95e-8	Aortic root size;
CRC	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg24046110	chr8:143859143	LYNX1	-0.37	-6.32	-0.33	8.7e-10	Urinary tract infection frequency;
CRC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.07	17.4	0.69	1.61e-48	Cognitive function;
CRC	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	0.58	8.92	0.44	3.2e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg04110750	chr16:69646130	NFAT5	-0.53	-7.27	-0.37	2.62e-12	IgE levels;
CRC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs6546043	0.667	rs7596262	chr2:64149819	T/G	cg20306022	chr2:7947960	NA	-0.51	-6.17	-0.32	2.02e-9	Clozapine-induced agranulocytosis;
CRC	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg00919237	chr7:87102261	ABCB4	-0.53	-7.04	-0.36	1.12e-11	Gallbladder cancer;
CRC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg03233332	chr7:66118400	NA	-0.44	-6.24	-0.33	1.31e-9	Aortic root size;
CRC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.31	0.62	1.84e-36	Chronic sinus infection;
CRC	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg14191688	chr11:70257035	CTTN	0.7	8.85	0.44	5.67e-17	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22522926	chr2:131851181	FAM168B	0.49	6.34	0.33	7.55e-10	Thyroid stimulating hormone;
CRC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	8.8	0.44	8.11e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-12.41	-0.56	2.76e-29	Asthma;
CRC	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg25876840	chr17:41920477	NA	0.41	6.52	0.34	2.68e-10	Triglycerides;
CRC	trans	rs34043159	1.000	rs2286240	chr2:102440166	G/A	cg23013864	chr6:17393396	CAP2	0.41	6.0	0.31	5.24e-9	Parkinson's disease;
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.69	-7.86	-0.4	5.52e-14	Body mass index;
CRC	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg22134325	chr11:66188745	NPAS4	0.41	6.71	0.35	8.55e-11	Airway imaging phenotypes;
CRC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.68	8.2	0.41	5.37e-15	Menarche (age at onset);
CRC	trans	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg13565492	chr6:43139072	SRF	-0.73	-7.52	-0.38	5.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg04315214	chr1:2043799	PRKCZ	-0.35	-6.08	-0.32	3.38e-9	Height;
CRC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.07	0.32	3.55e-9	Height;
CRC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.24	0.37	3.25e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg22561889	chr6:118971681	C6orf204	0.52	6.62	0.34	1.45e-10	Diastolic blood pressure;
CRC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.65	-11.23	-0.53	5.35e-25	Brugada syndrome;
CRC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.95	0.44	2.57e-17	Bladder cancer;
CRC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.59	-0.47	2.27e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	10.92	0.52	6.82e-24	Systolic blood pressure;
CRC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.83	-0.31	1.29e-8	Alzheimer's disease (late onset);
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.66	-0.43	2.11e-16	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.17	-13.57	-0.6	1.26e-33	Diabetic kidney disease;
CRC	cis	rs35520189	0.591	rs12614988	chr2:113702178	A/C	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs12760731	0.517	rs11587387	chr1:178229950	C/T	cg00404053	chr1:178313656	RASAL2	1.03	10.81	0.51	1.61e-23	Obesity-related traits;
CRC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg02725872	chr8:58115012	NA	-0.41	-7.38	-0.38	1.27e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.72	0.3	2.44e-8	Multiple sclerosis;
CRC	trans	rs58106596	0.517	rs56272010	chr2:232664963	T/G	cg01370599	chr3:116745421	NA	0.46	6.02	0.31	4.64e-9	White blood cell count;Lymphocyte counts;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg14086160	chr1:159895389	TAGLN2	0.38	5.99	0.31	5.57e-9	Interleukin-6 levels;
CRC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg11212589	chr17:38028394	ZPBP2	0.34	5.93	0.31	7.48e-9	Asthma;
CRC	cis	rs4663866	1.000	rs4663865	chr2:239145960	C/T	cg16914508	chr2:239161102	PER2	-0.68	-7.52	-0.38	5.15e-13	Irritable bowel syndrome;
CRC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg15534755	chr11:117069859	TAGLN	0.33	6.32	0.33	8.44e-10	Blood protein levels;
CRC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.35	0.46	1.39e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11212617	0.934	rs679782	chr11:108116700	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.65	0.3	3.57e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg21153622	chr11:89784906	NA	-0.49	-7.75	-0.39	1.16e-13	HDL cholesterol;
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.67	7.71	0.39	1.48e-13	Body mass index;
CRC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.53	-9.03	-0.45	1.44e-17	Iron status biomarkers;
CRC	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg05925327	chr15:68127851	NA	-0.31	-6.0	-0.31	5.18e-9	Restless legs syndrome;
CRC	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.88	-16.87	-0.68	1.83e-46	Hip circumference;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg03623178	chr6:28175578	NA	0.79	11.41	0.53	1.22e-25	Cardiac Troponin-T levels;
CRC	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg26741380	chr15:41871084	TYRO3	0.45	6.2	0.32	1.73e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg08992911	chr2:238395768	MLPH	0.62	6.33	0.33	8.16e-10	Prostate cancer;
CRC	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.24	-9.92	-0.48	1.84e-20	Mitochondrial DNA levels;
CRC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12292205	chr6:26970375	C6orf41	-0.58	-6.32	-0.33	8.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.49	9.03	0.45	1.45e-17	Total body bone mineral density;
CRC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.46	-6.46	-0.34	3.68e-10	Blood pressure (smoking interaction);
CRC	cis	rs6496667	0.865	rs7171422	chr15:90904741	G/A	cg04176472	chr15:90893244	GABARAPL3	0.61	8.24	0.41	4.08e-15	Rheumatoid arthritis;
CRC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg18478394	chr8:109455254	TTC35	0.39	5.86	0.31	1.11e-8	Dupuytren's disease;
CRC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.29	0.33	9.83e-10	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg08798685	chr6:27730294	NA	-0.51	-7.12	-0.37	6.75e-12	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.52	-0.46	3.76e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg02770688	chr6:168491649	NA	0.63	9.28	0.46	2.38e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs2252790	1.000	rs2498703	chr6:116660670	A/T	cg18764771	chr6:116381957	FRK	-0.22	-5.94	-0.31	7.42e-9	Fast beta electroencephalogram;
CRC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.55	-8.54	-0.43	5.05e-16	Aortic root size;
CRC	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg00691999	chr4:55094011	PDGFRA	0.4	5.6	0.3	4.51e-8	Corneal astigmatism;
CRC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg06766960	chr11:133703094	NA	-0.34	-6.19	-0.32	1.79e-9	Childhood ear infection;
CRC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.37	-6.17	-0.32	1.99e-9	Childhood ear infection;
CRC	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.5	0.42	6.61e-16	Mean corpuscular volume;
CRC	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.51	8.71	0.43	1.48e-16	Dupuytren's disease;
CRC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.81	14.4	0.62	8.38e-37	Total body bone mineral density;
CRC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.45	6.29	0.33	1e-9	Red blood cell count;
CRC	cis	rs73206853	0.563	rs34378671	chr12:111163204	C/T	cg12870014	chr12:110450643	ANKRD13A	0.75	8.94	0.44	2.88e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg11204139	chr17:3907470	NA	0.51	6.5	0.34	3.06e-10	Type 2 diabetes;
CRC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg23262073	chr20:60523788	NA	-0.38	-6.74	-0.35	7.05e-11	Body mass index;
CRC	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.21	-0.37	3.93e-12	Venous thromboembolism;
CRC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.78	0.39	9.4e-14	Total body bone mineral density;
CRC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.85e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.96	0.44	2.48e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.42	-0.65	9.04e-41	Exhaled nitric oxide output;
CRC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.15	-0.49	2.96e-21	Total cholesterol levels;
CRC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg03909863	chr11:638404	DRD4	-0.53	-7.14	-0.37	6.12e-12	Systemic lupus erythematosus;
CRC	cis	rs4731207	0.698	rs10228682	chr7:124538036	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.66	12.35	0.56	4.77e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.51	-0.5	1.87e-22	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17968077	chr19:18314992	RAB3A	0.43	6.07	0.32	3.47e-9	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.83	-0.48	3.72e-20	Height;
CRC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Body mass index;
CRC	cis	rs12519773	0.525	rs57542119	chr5:92538853	T/C	cg18783429	chr5:92414398	NA	0.28	6.01	0.31	4.93e-9	Migraine;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03582286	chr4:71571171	RUFY3	0.43	6.9	0.36	2.74e-11	Obesity-related traits;
CRC	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.72e-11	Prostate cancer;
CRC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.47	8.09	0.41	1.2e-14	Childhood ear infection;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.3	0.37	2.14e-12	Lymphocyte counts;
CRC	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg17133734	chr15:86042851	AKAP13	-0.41	-6.87	-0.35	3.2e-11	Interstitial lung disease;
CRC	cis	rs7831492	0.548	rs10958699	chr8:41648358	C/T	cg12180191	chr8:41686706	ANK1	-0.37	-5.74	-0.3	2.13e-8	Colorectal cancer;
CRC	cis	rs12745968	0.623	rs10874732	chr1:93123559	A/T	cg17283838	chr1:93427260	FAM69A	-0.45	-6.14	-0.32	2.34e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg19193384	chr17:30244184	NA	0.49	5.69	0.3	2.78e-8	Hip circumference adjusted for BMI;
CRC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.6	11.05	0.52	2.29e-24	Immature fraction of reticulocytes;
CRC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.47	7.13	0.37	6.55e-12	Corneal astigmatism;
CRC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.62	-7.39	-0.38	1.21e-12	Tuberculosis;
CRC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.39	-6.61	-0.34	1.6e-10	Height;
CRC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg04117972	chr1:227635322	NA	0.67	6.22	0.32	1.54e-9	Major depressive disorder;
CRC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg09473613	chr1:24152604	HMGCL	0.35	5.66	0.3	3.35e-8	Immature fraction of reticulocytes;
CRC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.82	9.3	0.46	2.04e-18	Iron status biomarkers;
CRC	trans	rs1890645	0.962	rs10921865	chr1:195524821	T/C	cg13026754	chr14:94392718	FAM181A;C14orf86	-0.38	-5.99	-0.31	5.4e-9	Neonatal lupus;
CRC	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.18	-25.41	-0.81	1.42e-79	Exhaled nitric oxide output;
CRC	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.83	6.35	0.33	7.24e-10	LDL cholesterol;
CRC	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg13425515	chr18:2571394	NDC80;METTL4	0.44	6.14	0.32	2.37e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-7.35	-0.38	1.54e-12	Monocyte count;
CRC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.64	7.89	0.4	4.38e-14	Menarche (age at onset);
CRC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.42	6.26	0.33	1.2e-9	Total cholesterol levels;
CRC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.42	5.7	0.3	2.74e-8	IgG glycosylation;
CRC	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.78	10.14	0.49	3.28e-21	Height;
CRC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.52	8.47	0.42	8.39e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs972578	0.905	rs738396	chr22:43370791	G/A	cg01576275	chr22:43409880	NA	-0.45	-7.3	-0.37	2.13e-12	Mean platelet volume;
CRC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg16416165	chr4:3325029	RGS12	0.4	5.99	0.31	5.54e-9	Serum sulfate level;
CRC	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg23815491	chr16:72088622	HP	0.62	7.88	0.4	4.91e-14	Blood protein levels;
CRC	cis	rs4964805	0.710	rs1866296	chr12:104187092	G/A	cg02344784	chr12:104178138	NT5DC3	0.79	15.03	0.64	3.07e-39	Attention deficit hyperactivity disorder;
CRC	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg17788362	chr6:86352627	SYNCRIP	0.49	6.89	0.36	2.79e-11	Smooth-surface caries;
CRC	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg04586622	chr2:25135609	ADCY3	0.36	6.09	0.32	3.16e-9	Body mass index in non-asthmatics;
CRC	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg26900154	chr2:26781731	OTOF	-0.42	-6.53	-0.34	2.49e-10	Periodontal microbiota;
CRC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.87	0.51	1.02e-23	Prostate cancer;
CRC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.41e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg22110888	chr17:80059540	CCDC57	0.42	6.74	0.35	7.04e-11	Life satisfaction;
CRC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.6	8.75	0.43	1.1e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	7.42	0.38	1.01e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs2303319	0.504	rs55840249	chr2:162426849	C/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.06	-0.32	3.68e-9	Cognitive function;
CRC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.43	6.95	0.36	2.01e-11	High light scatter reticulocyte count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25978167	chr4:57301353	PAICS;PPAT	0.5	6.45	0.34	4.01e-10	Thyroid stimulating hormone;
CRC	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.6	-9.35	-0.46	1.35e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.46	-0.34	3.8e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg20159608	chr7:32802032	NA	-0.62	-7.81	-0.4	7.87e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg18479299	chr3:125709523	NA	-0.49	-6.44	-0.33	4.17e-10	Blood pressure (smoking interaction);
CRC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.81	-10.94	-0.52	5.99e-24	Initial pursuit acceleration;
CRC	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.55	9.12	0.45	7.56e-18	Dupuytren's disease;
CRC	cis	rs2235544	0.664	rs41366847	chr1:54476967	C/G	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.98	-0.31	5.9e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06100147	chr7:143059260	FAM131B	0.37	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.47	7.35	0.38	1.55e-12	Longevity;
CRC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-8.61	-0.43	3.12e-16	Bladder cancer;
CRC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.51	6.24	0.33	1.35e-9	Recombination rate (females);
CRC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.49	-7.25	-0.37	2.99e-12	Colorectal cancer;
CRC	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02825527	chr7:2087843	MAD1L1	-0.5	-6.02	-0.32	4.61e-9	Neuroticism;
CRC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg05139728	chr16:28306816	SBK1	-0.37	-5.99	-0.31	5.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.41	-6.16	-0.32	2.07e-9	Menarche (age at onset);
CRC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19717773	chr7:2847554	GNA12	-0.46	-6.66	-0.34	1.18e-10	Height;
CRC	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.49	-6.74	-0.35	6.9e-11	Tuberculosis;
CRC	trans	rs7142881	0.604	rs6571468	chr14:32288862	G/A	cg07250515	chr12:56618133	OBFC2B	0.39	6.06	0.32	3.65e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg12927641	chr6:109611667	NA	-0.35	-6.24	-0.33	1.33e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.94	17.88	0.7	2e-50	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.45	6.49	0.34	3.23e-10	Lung cancer;
CRC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.72	0.3	2.36e-8	Longevity;
CRC	cis	rs7712401	0.525	rs193541	chr5:122253304	C/T	cg18764291	chr5:122110994	SNX2	0.41	6.47	0.34	3.6e-10	Mean platelet volume;
CRC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.27	0.33	1.13e-9	Aortic root size;
CRC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.51	-5.73	-0.3	2.25e-8	Vitiligo;
CRC	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.42	-0.46	8.47e-19	Type 2 diabetes;
CRC	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-5.64	-0.3	3.57e-8	Neuroticism;
CRC	cis	rs16852403	0.548	rs10798601	chr1:178186881	C/T	cg00404053	chr1:178313656	RASAL2	0.49	6.47	0.34	3.64e-10	Childhood ear infection;
CRC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23378565	chr7:2036160	MAD1L1	-0.48	-6.66	-0.34	1.13e-10	Bipolar disorder;
CRC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.66	-7.73	-0.39	1.28e-13	Menarche (age at onset);
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg06470822	chr6:28175283	NA	0.82	12.11	0.56	3.71e-28	Parkinson's disease;
CRC	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.16e-10	Obesity-related traits;
CRC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg07636037	chr3:49044803	WDR6	-0.85	-6.05	-0.32	3.86e-9	Cognitive function;
CRC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.58	-0.34	1.8e-10	Lung cancer;
CRC	cis	rs7692995	1.000	rs11930105	chr4:17972078	C/A	cg08925142	chr4:18023851	LCORL	-0.51	-5.68	-0.3	3.03e-8	Height;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs11166629	1.000	rs966659	chr8:135639045	C/T	cg27224718	chr8:135614730	ZFAT	-0.5	-7.39	-0.38	1.24e-12	Smoking quantity;
CRC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.29	-0.46	2.22e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19427701	chr9:140196790	NRARP	-0.5	-6.0	-0.31	5.31e-9	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg26587870	chr6:27730563	NA	-0.42	-6.28	-0.33	1.05e-9	Parkinson's disease;
CRC	cis	rs860295	0.836	rs1360554	chr1:155473356	C/T	cg02153340	chr1:155202674	NA	0.43	5.62	0.3	4.03e-8	Body mass index;
CRC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.38	-6.94	-0.36	2.15e-11	Reticulocyte fraction of red cells;
CRC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.53	8.26	0.41	3.55e-15	Type 2 diabetes;
CRC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg25985355	chr7:65971099	NA	-0.53	-6.05	-0.32	3.9e-9	Diabetic kidney disease;
CRC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs12024301	0.557	rs12088165	chr1:183658099	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.68	5.86	0.31	1.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg24560729	chr4:1342394	KIAA1530	0.46	8.38	0.42	1.59e-15	Longevity;
CRC	cis	rs1863824	0.625	rs10887600	chr10:88169072	C/T	cg07322936	chr10:88137208	NA	-0.64	-8.66	-0.43	2.11e-16	Schizophrenia;
CRC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg13198984	chr17:80129470	CCDC57	0.44	7.82	0.4	7.02e-14	Life satisfaction;
CRC	cis	rs12760731	0.623	rs12239670	chr1:178377761	G/T	cg00404053	chr1:178313656	RASAL2	0.72	8.86	0.44	4.95e-17	Obesity-related traits;
CRC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg12639453	chr1:2035780	PRKCZ	-0.38	-7.12	-0.37	6.62e-12	Height;
CRC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg17321639	chr7:2759063	NA	-0.53	-6.98	-0.36	1.68e-11	Height;
CRC	cis	rs1572438	1.000	rs9379167	chr6:866372	C/T	cg21062780	chr6:887772	NA	-0.43	-6.5	-0.34	3.04e-10	Aging;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg02683197	chr6:28174875	NA	0.71	9.58	0.47	2.43e-19	Parkinson's disease;
CRC	trans	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg02674126	chr19:40336878	FBL	0.42	6.69	0.35	9.58e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg16691251	chr5:66510806	NA	0.41	7.08	0.36	8.67e-12	Breast cancer;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Parkinson's disease;
CRC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-7.19	-0.37	4.43e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.37	6.12	0.32	2.69e-9	Major depressive disorder;
CRC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg12365402	chr11:9010492	NRIP3	0.48	7.8	0.39	8.4e-14	Hemoglobin concentration;
CRC	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg04586622	chr2:25135609	ADCY3	-0.58	-9.88	-0.48	2.45e-20	Body mass index;
CRC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.55	8.06	0.41	1.38e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.43	6.91	0.36	2.5e-11	Resting heart rate;
CRC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.4	7.84	0.4	6.28e-14	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17009717	chr2:113299708	POLR1B	0.44	6.17	0.32	2.03e-9	Response to antipsychotic treatment;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24677732	chr10:6019526	IL15RA	0.42	6.61	0.34	1.53e-10	Schizophrenia;
CRC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg16989719	chr2:238392110	NA	0.46	7.84	0.4	6.16e-14	Prostate cancer;
CRC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.54	6.92	0.36	2.34e-11	Longevity;
CRC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg19223190	chr17:80058835	NA	0.41	6.49	0.34	3.13e-10	Life satisfaction;
CRC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg03013999	chr17:37608204	MED1	-0.49	-7.62	-0.39	2.81e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs6756513	0.509	rs11686934	chr2:70172116	C/T	cg02498382	chr2:70120550	SNRNP27	0.41	6.89	0.36	2.86e-11	Breast cancer;Platelet count;
CRC	cis	rs9462027	0.628	rs9469887	chr6:34758940	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg09877947	chr5:131593287	PDLIM4	0.41	6.95	0.36	1.97e-11	Blood metabolite levels;
CRC	cis	rs751837	0.591	rs2896462	chr14:103434739	A/G	cg10087771	chr14:103399429	CDC42BPB	0.65	6.28	0.33	1.06e-9	Large B-cell lymphoma;
CRC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.84	0.55	3.6e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	7.5	0.38	5.81e-13	Blood protein levels;
CRC	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.73	8.65	0.43	2.23e-16	Eotaxin levels;
CRC	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg16141378	chr3:129829833	LOC729375	0.41	6.05	0.32	3.87e-9	Neuroticism;
CRC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg15147215	chr3:52552868	STAB1	-0.65	-11.37	-0.53	1.78e-25	Electroencephalogram traits;
CRC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg14541582	chr5:601475	NA	-0.35	-6.43	-0.33	4.48e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.15e-14	Alzheimer's disease;
CRC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.84	12.0	0.55	9.21e-28	Cognitive function;
CRC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.98	-0.31	5.81e-9	Migraine;Coronary artery disease;
CRC	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.38	5.67	0.3	3.05e-8	HDL cholesterol;
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6694672	0.764	rs1415217	chr1:197151246	C/T	cg13682187	chr1:196946512	CFHR5	0.43	6.94	0.36	2.09e-11	Asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22836370	chr18:51751085	MBD2	0.49	7.11	0.36	7.39e-12	Response to antipsychotic treatment;
CRC	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-6.9	-0.36	2.6e-11	Breast cancer;
CRC	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.75	-0.3	2.01e-8	Blood pressure;
CRC	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.94	17.44	0.69	1.11e-48	Eosinophil percentage of white cells;
CRC	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.64	-10.19	-0.49	2.22e-21	Smoking behavior;
CRC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg02600515	chr11:62521696	ZBTB3	0.46	5.63	0.3	3.88e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.5	7.63	0.39	2.58e-13	Calcium levels;
CRC	cis	rs1656402	0.834	rs11676437	chr2:233453065	A/G	cg03852847	chr2:233439513	NA	-0.42	-7.26	-0.37	2.83e-12	Non-small cell lung cancer (survival);
CRC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	7.44	0.38	8.76e-13	Mean platelet volume;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.72	-11.54	-0.54	4.27e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg11430096	chr6:110968061	CDK19	0.68	5.97	0.31	5.99e-9	Prostate cancer;
CRC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.42	6.13	0.32	2.46e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg20742385	chr13:113633654	MCF2L	-0.71	-12.48	-0.57	1.53e-29	Systolic blood pressure;
CRC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.44	6.99	0.36	1.58e-11	Testicular germ cell tumor;
CRC	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.78	13.71	0.6	3.83e-34	Schizophrenia;
CRC	cis	rs17155006	0.746	rs435744	chr7:107748549	A/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs6735179	0.798	rs7589077	chr2:1773183	C/T	cg19300414	chr2:1746591	PXDN	0.38	5.85	0.31	1.21e-8	Response to antipsychotic treatment;
CRC	cis	rs11212617	0.967	rs6589019	chr11:108324961	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.39	5.67	0.3	3.17e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg05585544	chr11:47624801	NA	-0.47	-8.53	-0.43	5.42e-16	Subjective well-being;
CRC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.42	6.87	0.35	3.3e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02772935	chr3:125709198	NA	-0.49	-5.79	-0.3	1.61e-8	Blood pressure (smoking interaction);
CRC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.15	0.32	2.26e-9	Asthma;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg19960548	chr20:49407443	NA	-0.51	-6.85	-0.35	3.66e-11	Parkinson's disease;
CRC	cis	rs2882667	0.898	rs3828600	chr5:138386859	G/T	cg04439458	chr5:138467593	SIL1	-0.32	-5.74	-0.3	2.18e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.51	9.11	0.45	8.4e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.48	-6.36	-0.33	6.79e-10	Renal function-related traits (BUN);
CRC	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg17145862	chr1:211918768	LPGAT1	0.49	6.4	0.33	5.47e-10	Crohn's disease;
CRC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg17545662	chr6:170176663	C6orf70	0.57	6.4	0.33	5.21e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.53	-0.34	2.56e-10	Menopause (age at onset);
CRC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.58	-8.67	-0.43	2e-16	Obesity-related traits;
CRC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.7	7.19	0.37	4.26e-12	Schizophrenia;
CRC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg26762873	chr11:5879799	OR52E8	-0.5	-7.71	-0.39	1.48e-13	DNA methylation (variation);
CRC	trans	rs2261181	0.711	rs111477823	chr12:66279822	C/A	cg01001314	chr4:3669900	NA	0.7	6.09	0.32	3.18e-9	Type 2 diabetes;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.41	6.98	0.36	1.68e-11	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02771034	chr3:50220121	SEMA3F	-0.39	-6.2	-0.32	1.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.72	-13.18	-0.59	3.68e-32	Breast cancer;
CRC	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.66	-9.6	-0.47	2.13e-19	Type 2 diabetes;
CRC	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.39	6.6	0.34	1.64e-10	Sitting height ratio;
CRC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	16.6	0.68	2.25e-45	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.47	6.31	0.33	9.14e-10	Morning vs. evening chronotype;
CRC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04880052	chr2:219191631	PNKD	-0.42	-6.64	-0.34	1.3100000000000001e-10	Colorectal cancer;
CRC	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.47	6.84	0.35	3.98e-11	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.18	-0.32	1.85e-9	Aortic root size;
CRC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	10.08	0.49	5.25e-21	Mood instability;
CRC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25227148	chr18:32870611	ZNF271;ZNF397OS	-0.4	-6.3	-0.33	9.64e-10	Aortic root size;
CRC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.82	9.94	0.48	1.61e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg08888203	chr3:10149979	C3orf24	0.48	7.32	0.37	1.9e-12	Alzheimer's disease;
CRC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.92	-0.31	8.12e-9	Lung cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02176770	chr11:73358590	PLEKHB1	0.43	6.0	0.31	5.34e-9	Response to antipsychotic treatment;
CRC	trans	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg06791473	chr12:49259579	RND1	0.61	6.03	0.32	4.5e-9	Blood protein levels;
CRC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg10570241	chr7:158785291	NA	-0.43	-7.68	-0.39	1.88e-13	Facial morphology (factor 20);
CRC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg03609598	chr5:56110824	MAP3K1	0.44	6.26	0.33	1.23e-9	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	0.56	8.73	0.43	1.29e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9837602	0.592	rs1606481	chr3:99427552	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	5.61	0.3	4.35e-8	Breast cancer;
CRC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.48	-7.53	-0.38	4.86e-13	Monocyte count;
CRC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg14530993	chr4:882597	GAK	0.78	7.94	0.4	3.29e-14	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.76	-0.35	6.14e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.76	-0.3	1.95e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2070997	0.702	rs7457	chr9:133762826	C/T	cg01000188	chr9:133769184	QRFP	0.56	5.74	0.3	2.15e-8	Response to amphetamines;
CRC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	trans	rs2303319	0.504	rs56260047	chr2:162497225	G/T	cg04269497	chr6:167369491	RNASET2	-0.71	-6.01	-0.31	4.99e-9	Cognitive function;
CRC	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.83	6.96	0.36	1.8e-11	LDL cholesterol;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg12273811	chr6:28175739	NA	0.5	6.85	0.35	3.68e-11	Parkinson's disease;
CRC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	8.28	0.42	3.15e-15	Monocyte percentage of white cells;
CRC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg10298567	chr3:47292165	KIF9	0.38	6.03	0.32	4.42e-9	Colorectal cancer;
CRC	cis	rs11098699	0.821	rs11098703	chr4:124218462	C/G	cg09941581	chr4:124220074	SPATA5	0.43	6.36	0.33	6.83e-10	Mosquito bite size;
CRC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg13798780	chr7:105162888	PUS7	0.66	7.8	0.39	8.45e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs4654899	0.931	rs3125161	chr1:21126346	A/G	cg02927042	chr1:21476669	EIF4G3	0.45	7.12	0.37	6.64e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg18761221	chr20:60518478	NA	0.39	6.87	0.35	3.19e-11	Body mass index;
CRC	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg00601450	chr5:74908170	NA	0.41	5.76	0.3	1.95e-8	Age-related disease endophenotypes;
CRC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg09218773	chr11:619014	MUPCDH	-0.36	-5.79	-0.3	1.64e-8	Systemic lupus erythematosus;
CRC	cis	rs4664293	0.967	rs7595639	chr2:160533044	A/G	cg08347373	chr2:160653686	CD302	-0.37	-6.08	-0.32	3.32e-9	Monocyte percentage of white cells;
CRC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.7	-11.06	-0.52	2.17e-24	Coronary artery disease;
CRC	cis	rs9648716	1.000	rs1267648	chr7:140505100	A/G	cg10747023	chr7:140774559	NA	0.42	5.64	0.3	3.63e-8	Type 2 diabetes;
CRC	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.38	5.98	0.31	5.72e-9	Reticulocyte fraction of red cells;
CRC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	0.72	7.75	0.39	1.18e-13	Gout;Renal underexcretion gout;
CRC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.99	-0.4	2.24e-14	Life satisfaction;
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.14	-0.45	6.55e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-5.86	-0.31	1.13e-8	Bronchopulmonary dysplasia;
CRC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.5	-0.46	4.56e-19	Schizophrenia;
CRC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.68	-0.35	9.99e-11	Systemic lupus erythematosus;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18327994	chr9:132372705	NA	0.5	7.16	0.37	5.23e-12	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.56	0.54	3.69e-26	Prudent dietary pattern;
CRC	trans	rs7201408	0.528	rs12596252	chr16:20056993	G/A	cg07180834	chr11:85838833	NA	0.44	6.03	0.32	4.46e-9	Attention deficit hyperactivity disorder (inattention symptoms);
CRC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg05540913	chr6:167530185	CCR6	0.34	5.79	0.3	1.67e-8	Primary biliary cholangitis;
CRC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.61	10.96	0.52	4.76e-24	Schizophrenia;
CRC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg10760299	chr15:45669010	GATM	0.36	5.67	0.3	3.17e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.88	-0.61	8.21e-35	Diabetic kidney disease;
CRC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.66	10.49	0.5	2.16e-22	Sudden cardiac arrest;
CRC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.67	0.43	1.95e-16	Homoarginine levels;
CRC	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg21251018	chr6:28226885	NKAPL	0.51	5.98	0.31	5.84e-9	Depression;
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg14008862	chr17:28927542	LRRC37B2	0.56	5.8	0.3	1.6e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg16591659	chr17:78472290	NA	-0.43	-6.25	-0.33	1.25e-9	Fractional excretion of uric acid;
CRC	cis	rs938554	0.784	rs1071988	chr4:9974638	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.46	-0.34	3.75e-10	Blood metabolite levels;
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25517755	chr10:38738941	LOC399744	-0.42	-5.98	-0.31	5.66e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6681460	0.932	rs523956	chr1:67188276	A/G	cg02459107	chr1:67143332	SGIP1	-0.36	-6.04	-0.32	4.21e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs7605827	0.897	rs13004112	chr2:15604048	C/T	cg19274914	chr2:15703543	NA	0.39	6.02	0.32	4.65e-9	Educational attainment (years of education);
CRC	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-6.83	-0.35	4.04e-11	Putamen volume;
CRC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.85	-9.64	-0.47	1.52e-19	HIV-1 control;
CRC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.82	-0.35	4.33e-11	Aortic root size;
CRC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.61	-7.57	-0.39	3.84e-13	Body mass index;
CRC	trans	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.51	-8.64	-0.43	2.55e-16	Mean corpuscular volume;
CRC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg08314208	chr16:67682810	RLTPR	-0.65	-7.41	-0.38	1.08e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.0	-0.31	5.06e-9	Gout;Renal underexcretion gout;
CRC	cis	rs1519814	0.956	rs4871036	chr8:121101758	T/C	cg22335954	chr8:121166405	COL14A1	-0.54	-6.41	-0.33	5.12e-10	Breast cancer;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg15786705	chr6:28176104	NA	-0.81	-11.55	-0.54	3.79e-26	Depression;
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.73	9.63	0.47	1.7e-19	Alzheimer's disease;
CRC	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg04586622	chr2:25135609	ADCY3	-0.56	-10.38	-0.5	4.97e-22	Body mass index in non-asthmatics;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14863265	chr7:2801509	GNA12	-0.43	-5.93	-0.31	7.56e-9	Height;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg15845792	chr6:28175446	NA	0.92	12.48	0.57	1.64e-29	Parkinson's disease;
CRC	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.25	0.41	3.81e-15	Response to antipsychotic treatment;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.39	-6.96	-0.36	1.89e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs231513	0.911	rs231517	chr17:41961789	C/T	cg26893861	chr17:41843967	DUSP3	-0.7	-7.13	-0.37	6.41e-12	Cognitive function;
CRC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.7	10.06	0.49	6.03e-21	Alzheimer's disease;
CRC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17829318	chr4:37688612	RELL1	0.4	6.21	0.32	1.6e-9	Response to antipsychotic treatment;
CRC	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs4714291	0.748	rs3008829	chr6:39953963	C/T	cg02267698	chr19:7991119	CTXN1	-0.48	-6.62	-0.34	1.5e-10	Strep throat;
CRC	cis	rs7301826	0.651	rs7295705	chr12:131301885	C/T	cg11011512	chr12:131303247	STX2	0.37	5.61	0.3	4.35e-8	Plasma plasminogen activator levels;
CRC	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg12091567	chr17:66097778	LOC651250	-0.44	-5.74	-0.3	2.13e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg17724175	chr1:150552817	MCL1	-0.51	-8.1	-0.41	1.12e-14	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CRC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.46	6.37	0.33	6.41e-10	Parkinson's disease;
CRC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07513332	chr6:167530253	CCR6	0.38	6.37	0.33	6.39e-10	Primary biliary cholangitis;
CRC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg14784868	chr12:69753453	YEATS4	0.45	5.83	0.31	1.29e-8	Response to diuretic therapy;
CRC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg00316803	chr15:76480434	C15orf27	-0.38	-6.52	-0.34	2.69e-10	Blood metabolite levels;
CRC	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg03690763	chr11:133734501	NA	-0.4	-6.69	-0.35	9.84e-11	Childhood ear infection;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07254608	chr8:41997973	NA	0.44	6.28	0.33	1.07e-9	Response to antipsychotic treatment;
CRC	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg18232548	chr7:50535776	DDC	0.47	6.62	0.34	1.43e-10	Malaria;
CRC	cis	rs3750082	0.817	rs2060731	chr7:32968346	G/A	cg05721444	chr7:32995514	FKBP9	-0.5	-7.64	-0.39	2.36e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.47	6.7	0.35	9.14e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg14139581	chr11:64358342	SLC22A12	0.38	6.02	0.31	4.73e-9	Urate levels in obese individuals;
CRC	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg25482853	chr8:67687455	SGK3	0.71	8.91	0.44	3.62e-17	Obesity-related traits;
CRC	cis	rs4731207	0.596	rs6466971	chr7:124596007	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.34e-9	Cutaneous malignant melanoma;
CRC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.56	9.11	0.45	8.18e-18	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.53	-7.61	-0.39	2.87e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg27432699	chr2:27873401	GPN1	-0.51	-7.82	-0.4	7.11e-14	Total body bone mineral density;
CRC	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg11204139	chr17:3907470	NA	0.74	14.04	0.61	2.11e-35	Type 2 diabetes;
CRC	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg20356878	chr3:121714668	ILDR1	0.51	7.76	0.39	1.08e-13	Cognitive performance;
CRC	cis	rs9322817	0.691	rs2486138	chr6:105290223	G/A	cg02098413	chr6:105308735	HACE1	0.44	8.72	0.43	1.42e-16	Thyroid stimulating hormone;
CRC	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06307176	chr5:131281290	NA	-0.44	-6.46	-0.34	3.76e-10	Life satisfaction;
CRC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.65	11.92	0.55	1.86e-27	Aortic root size;
CRC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.45	6.64	0.34	1.27e-10	Cleft lip with or without cleft palate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	ch.8.34907260F	chr8:34787718	NA	0.51	7.96	0.4	2.82e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg04518342	chr5:131593106	PDLIM4	0.54	9.23	0.45	3.37e-18	Acylcarnitine levels;
CRC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.15	-0.37	5.61e-12	Joint mobility (Beighton score);
CRC	cis	rs9311676	0.656	rs7620012	chr3:58373716	G/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12751404	chr1:11866034	MTHFR;CLCN6	0.41	6.56	0.34	2.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.62	-7.98	-0.4	2.43e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.43	8.86	0.44	5.25e-17	Renal cell carcinoma;
CRC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.47	6.82	0.35	4.33e-11	Tonsillectomy;
CRC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.45	-6.55	-0.34	2.25e-10	Asthma;
CRC	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.74	-10.37	-0.5	5.59e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7605827	0.897	rs13017859	chr2:15537641	T/C	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.48	-5.9	-0.31	8.93e-9	Bronchopulmonary dysplasia;
CRC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.84	13.1	0.59	7.54e-32	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06419771	chr15:42264912	EHD4	0.49	6.96	0.36	1.84e-11	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.8	15.32	0.65	2.36e-40	Prudent dietary pattern;
CRC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	0.91	18.07	0.71	3.4e-51	Multiple system atrophy;
CRC	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21659725	chr3:3221576	CRBN	-0.68	-9.33	-0.46	1.64e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6662572	0.737	rs72692613	chr1:46399557	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.62	0.3	4.06e-8	Blood protein levels;
CRC	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.36	0.53	1.95e-25	Exhaled nitric oxide levels;
CRC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.49	6.32	0.33	8.65e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs523516	0.645	rs16525	chr17:37321605	C/T	cg20555674	chr17:37321631	ARL5C	0.4	8.38	0.42	1.59e-15	IgG glycosylation;
CRC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.5	-8.55	-0.43	4.7e-16	Total body bone mineral density;
CRC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.8	-0.4	8.25e-14	Blood metabolite levels;
CRC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06028605	chr16:24865363	SLC5A11	0.39	7.45	0.38	8.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.49	7.45	0.38	8.26e-13	Bone properties (heel);
CRC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-9.92	-0.48	1.86e-20	Height;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg22922770	chr7:98923339	ARPC1A	-0.69	-6.19	-0.32	1.77e-9	Cognitive function;
CRC	cis	rs7605827	0.930	rs11684001	chr2:15513120	C/T	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg08501292	chr6:25962987	TRIM38	0.79	6.2	0.32	1.68e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.72	10.36	0.5	6.11e-22	Obesity-related traits;
CRC	cis	rs28829049	0.597	rs71645438	chr1:19502349	G/A	cg13387374	chr1:19411106	UBR4	0.42	6.14	0.32	2.39e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs868943	0.512	rs72953957	chr6:116546543	A/G	cg26893134	chr6:116381904	FRK	0.24	5.7	0.3	2.61e-8	Total cholesterol levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17827632	chr1:161087992	PFDN2;NIT1	0.43	5.99	0.31	5.49e-9	Response to antipsychotic treatment;
CRC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.56	-6.85	-0.35	3.7e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.91	-16.21	-0.67	7.71e-44	Height;
CRC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13198984	chr17:80129470	CCDC57	-0.41	-6.76	-0.35	6.3e-11	Life satisfaction;
CRC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.72	-9.29	-0.46	2.14e-18	Initial pursuit acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05200610	chr12:72233572	TBC1D15	0.38	6.23	0.32	1.46e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	trans	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg16141378	chr3:129829833	LOC729375	0.49	7.32	0.37	1.86e-12	Mood instability;
CRC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22029157	chr1:209979665	IRF6	-0.64	-7.25	-0.37	3.06e-12	Cleft lip with or without cleft palate;
CRC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.68	-10.91	-0.52	7.11e-24	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17921034	chr13:42846375	AKAP11	0.47	6.77	0.35	5.81e-11	Response to antipsychotic treatment;
CRC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.6	8.49	0.42	7.08e-16	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.73	11.23	0.53	5.48e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg19812747	chr11:111475976	SIK2	-0.55	-9.4	-0.46	9.4e-19	Primary sclerosing cholangitis;
CRC	cis	rs41271951	0.512	rs77306500	chr1:151080096	G/C	cg11822372	chr1:151115635	SEMA6C	-0.7	-5.62	-0.3	4.02e-8	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02111504	chr5:93954110	C5orf36;ANKRD32	0.48	6.05	0.32	3.87e-9	Thyroid stimulating hormone;
CRC	cis	rs9928842	0.770	rs4888364	chr16:75279510	A/G	cg09066997	chr16:75300724	BCAR1	0.64	6.16	0.32	2.07e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-8.32	-0.42	2.41e-15	Vitiligo;
CRC	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	8.32	0.42	2.31e-15	Total cholesterol levels;
CRC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.63	10.67	0.51	4.91e-23	Intelligence (multi-trait analysis);
CRC	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg11038491	chr20:34638489	LOC647979	-0.59	-7.06	-0.36	9.96e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg20885578	chr2:198174922	NA	-0.41	-7.16	-0.37	5.29e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg08213375	chr14:104286397	PPP1R13B	0.36	5.76	0.3	1.94e-8	Reticulocyte count;
CRC	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.58	8.45	0.42	9.33e-16	Smooth-surface caries;
CRC	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg01851573	chr8:8652454	MFHAS1	-0.44	-6.64	-0.34	1.3100000000000001e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.82	-13.92	-0.61	5.7e-35	Cystic fibrosis severity;
CRC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.03	0.32	4.51e-9	Dupuytren's disease;
CRC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.16	26.9	0.83	4.44e-85	IgG glycosylation;
CRC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.47	-0.34	3.57e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg27565382	chr3:53032988	SFMBT1	0.76	6.12	0.32	2.6e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	5.09e-12	Rheumatoid arthritis;
CRC	cis	rs10071761	0.513	rs12517921	chr5:40375907	C/T	cg09067459	chr5:40385259	NA	0.49	6.95	0.36	2e-11	Selective IgA deficiency;
CRC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18912574	chr7:65842487	NCRNA00174	0.35	5.91	0.31	8.52e-9	Aortic root size;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.2	-0.32	1.71e-9	Blood metabolite levels;
CRC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	trans	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg10756647	chr7:56101905	PSPH	0.73	7.98	0.4	2.44e-14	Diabetic kidney disease;
CRC	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.35	-5.92	-0.31	8.31e-9	Height;
CRC	cis	rs990171	0.506	rs6543107	chr2:102750730	A/T	cg22835712	chr2:102737379	NA	0.41	5.62	0.3	3.98e-8	Lymphocyte counts;
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg20119798	chr7:94954144	PON1	-0.51	-6.46	-0.34	3.83e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg04155289	chr7:94953770	PON1	-0.56	-7.15	-0.37	5.66e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.55	8.01	0.4	2.03e-14	Coronary artery disease;
CRC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.62	8.37	0.42	1.64e-15	Smoking initiation;
CRC	trans	rs3008706	0.539	rs1328287	chr9:15918773	A/G	cg15918921	chr2:74212782	NA	-0.48	-5.98	-0.31	5.97e-9	Bilirubin levels;
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.87	0.31	1.04e-8	Parkinson's disease;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg22079747	chr2:228736145	WDR69	-0.44	-5.88	-0.31	1.01e-8	Blood pressure;
CRC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg16434002	chr17:42200994	HDAC5	-0.47	-6.33	-0.33	8.12e-10	Total body bone mineral density;
CRC	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.94	0.4	3.21e-14	Colorectal cancer;
CRC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	8.93	0.44	3.09e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg06581033	chr10:766294	NA	-0.51	-5.69	-0.3	2.75e-8	Uric acid levels;
CRC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.02	-10.25	-0.49	1.4e-21	Body mass index;
CRC	cis	rs10971721	0.822	rs12380143	chr9:33847586	C/T	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg03037974	chr15:76606532	NA	0.67	11.08	0.52	1.83e-24	Blood metabolite levels;
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg15534755	chr11:117069859	TAGLN	0.3	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs9891119	0.576	rs13342031	chr17:40536871	C/G	cg06270615	chr17:40516068	STAT3	-0.35	-7.24	-0.37	3.13e-12	Multiple sclerosis;Crohn's disease;
CRC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	17.02	0.68	4.77e-47	Smoking behavior;
CRC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-8.52	-0.43	5.91e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.61	-10.54	-0.5	1.37e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.43	7.6	0.39	3.05e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CRC	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.69	-10.56	-0.5	1.23e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.46	6.69	0.35	9.33e-11	Body mass index;
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.76e-9	Life satisfaction;
CRC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.45	6.88	0.35	3.04e-11	Hemoglobin concentration;
CRC	cis	rs73206853	0.841	rs118053970	chr12:110932820	C/G	cg12870014	chr12:110450643	ANKRD13A	0.76	6.63	0.34	1.34e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.79	10.62	0.51	7.77e-23	Vitiligo;
CRC	cis	rs6968419	0.755	rs3173919	chr7:115898177	G/C	cg02561103	chr7:115862891	TES	-0.44	-6.61	-0.34	1.51e-10	Intraocular pressure;
CRC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.59	9.4	0.46	9.36e-19	Tonsillectomy;
CRC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg05192639	chr6:26864778	GUSBL1	0.31	6.05	0.32	4.01e-9	Schizophrenia;
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg13047869	chr3:10149882	C3orf24	0.54	7.48	0.38	6.65e-13	Alzheimer's disease;
CRC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg03609598	chr5:56110824	MAP3K1	-0.6	-8.12	-0.41	9.67e-15	Initial pursuit acceleration;
CRC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.09	-0.45	9.8e-18	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.44	7.06	0.36	1.01e-11	Menopause (age at onset);
CRC	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg03929089	chr4:120376271	NA	0.66	5.98	0.31	5.9e-9	Myopia (pathological);
CRC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.38	5.73	0.3	2.27e-8	Mean corpuscular volume;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs12760731	0.920	rs6695982	chr1:178480733	A/G	cg00404053	chr1:178313656	RASAL2	0.57	6.85	0.35	3.65e-11	Obesity-related traits;
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg12273811	chr6:28175739	NA	0.68	8.48	0.42	7.53e-16	Parkinson's disease;
CRC	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.74	11.94	0.55	1.48e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	14.22	0.62	4.28e-36	Body mass index (adult);
CRC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-5.77	-0.3	1.78e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs17443541	0.507	rs4675719	chr2:200472364	C/T	cg03741458	chr2:200468445	NA	-0.36	-5.64	-0.3	3.61e-8	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.38	-0.38	1.33e-12	Aortic root size;
CRC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.44	5.73	0.3	2.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-1.02	-20.58	-0.75	4.48e-61	Headache;
CRC	cis	rs16858210	0.913	rs1879255	chr3:183609445	C/A	cg25686905	chr3:183603175	PARL	-0.41	-5.74	-0.3	2.18e-8	Menopause (age at onset);
CRC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	24.94	0.81	7.96e-78	IgG glycosylation;
CRC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.6	10.61	0.51	7.98e-23	Aortic root size;
CRC	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.5	-7.08	-0.36	8.73e-12	Eotaxin levels;
CRC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg02993699	chr4:3415135	RGS12	-0.4	-6.35	-0.33	6.98e-10	Serum sulfate level;
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.5	8.53	0.43	5.57e-16	Hypertriglyceridemia;
CRC	cis	rs13064447	0.753	rs9868500	chr3:12747690	A/G	cg07775309	chr3:12595852	NA	-0.36	-5.83	-0.31	1.34e-8	Major depression and alcohol dependence;
CRC	cis	rs6504950	0.800	rs9891704	chr17:53010755	A/G	cg26251398	chr17:52985966	TOM1L1	0.37	5.62	0.3	4.04e-8	Breast cancer;
CRC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.41	7.82	0.4	7.38e-14	Mean corpuscular volume;
CRC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.55	-0.38	4.32e-13	Aortic root size;
CRC	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-7.94	-0.4	3.24e-14	Response to antipsychotic treatment;
CRC	trans	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg26043149	chr18:55253948	FECH	-0.56	-8.12	-0.41	9.47e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs501120	1.000	rs620828	chr10:44760958	A/G	cg09554077	chr10:44749378	NA	0.78	11.96	0.55	1.33e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2062225	1.000	rs2128813	chr2:111758774	T/C	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs7259376	0.905	rs62118584	chr19:22541142	G/A	cg02657401	chr19:22469223	NA	-0.34	-7.52	-0.38	5.1e-13	Menopause (age at onset);
CRC	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg25547332	chr5:131281432	NA	0.39	5.73	0.3	2.25e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7572644	0.640	rs4666014	chr2:28019175	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-6.47	-0.34	3.53e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.75e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg12564285	chr5:131593104	PDLIM4	-0.31	-5.71	-0.3	2.51e-8	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg15147215	chr3:52552868	STAB1	-0.62	-10.25	-0.49	1.37e-21	Bipolar disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18635645	chr1:85667791	SYDE2	0.49	6.7	0.35	9.28e-11	Thyroid stimulating hormone;
CRC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.42	5.91	0.31	8.68e-9	Heart rate;
CRC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.51	7.36	0.38	1.49e-12	Colorectal cancer;
CRC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg03013999	chr17:37608204	MED1	0.47	7.27	0.37	2.66e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg01858300	chr15:41233997	NA	0.44	6.76	0.35	6.48e-11	Body mass index;
CRC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7259376	0.840	rs1808668	chr19:22518657	A/G	cg02657401	chr19:22469223	NA	-0.37	-8.18	-0.41	6.14e-15	Menopause (age at onset);
CRC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.38	5.68	0.3	2.95e-8	HDL cholesterol levels;
CRC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.54	-6.25	-0.33	1.29e-9	Vitiligo;
CRC	cis	rs10046574	0.561	rs11505984	chr7:135208359	G/A	cg27474649	chr7:135195673	CNOT4	0.61	5.95	0.31	7.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.45	-6.87	-0.35	3.19e-11	Cardiovascular disease risk factors;
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.0	-0.4	2.22e-14	Bipolar disorder;
CRC	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.56	0.47	2.94e-19	Coffee consumption (cups per day);
CRC	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg09476006	chr5:138032270	NA	0.44	6.78	0.35	5.71e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.7	-10.96	-0.52	5.01e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.44	-0.33	4.16e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.01	-0.36	1.36e-11	Lung cancer;
CRC	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.61	-8.53	-0.43	5.56e-16	Coronary artery disease;
CRC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg18301423	chr5:131593218	PDLIM4	0.31	5.7	0.3	2.69e-8	Blood metabolite levels;
CRC	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg09476006	chr5:138032270	NA	0.44	6.76	0.35	6.23e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.57	0.5	1.16e-22	Coronary artery disease;
CRC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.18	0.32	1.85e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.02	-0.4	1.91e-14	Menarche (age at onset);
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.4	-7.28	-0.37	2.43e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7932354	0.528	rs7103581	chr11:47072805	G/T	cg19486271	chr11:47235900	DDB2	-0.44	-6.59	-0.34	1.74e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs7215564	0.908	rs8070102	chr17:78683982	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.26e-9	Myopia (pathological);
CRC	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg26816564	chr1:7831052	VAMP3	0.62	6.6	0.34	1.6e-10	Inflammatory bowel disease;
CRC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-10.69	-0.51	4.31e-23	Body mass index;
CRC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.58	7.48	0.38	6.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.61	-9.21	-0.45	3.88e-18	Coronary artery disease;
CRC	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.57	0.43	4.13e-16	Migraine;Coronary artery disease;
CRC	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9292777	0.865	rs6871591	chr5:40406130	T/A	cg09067459	chr5:40385259	NA	0.52	9.11	0.45	8.41e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.68	8.2	0.41	5.55e-15	Menarche (age at onset);
CRC	cis	rs11209185	0.545	rs1926284	chr1:68446291	T/C	cg22082780	chr1:68452167	NA	0.39	5.98	0.31	5.89e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16931877	chr3:32726605	CNOT10	-0.39	-6.38	-0.33	6.07e-10	Myopia (pathological);
CRC	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.86	-0.44	4.95e-17	Coffee consumption (cups per day);
CRC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.75	-0.3	2.07e-8	Yeast infection;
CRC	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg06917450	chr1:38156652	C1orf109	-0.52	-7.05	-0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg13198984	chr17:80129470	CCDC57	0.43	7.56	0.38	3.92e-13	Life satisfaction;
CRC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg04880052	chr2:219191631	PNKD	0.42	6.76	0.35	6.16e-11	Colorectal cancer;
CRC	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.67	10.3	0.49	9.62e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.66	7.53	0.38	4.88e-13	Body mass index;
CRC	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.87	-14.63	-0.63	1.06e-37	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.81	-11.09	-0.52	1.77e-24	Schizophrenia;
CRC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.98	0.55	1.05e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.48	-6.17	-0.32	1.99e-9	Bipolar disorder;
CRC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.61	8.71	0.43	1.48e-16	Alcohol dependence;
CRC	cis	rs35520189	0.591	rs67995749	chr2:113700892	G/A	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-6.22	-0.32	1.53e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03535439	chr6:42981950	MEA1;KLHDC3	0.41	6.51	0.34	2.74e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg15744005	chr10:104629667	AS3MT	0.33	6.49	0.34	3.08e-10	Arsenic metabolism;
CRC	trans	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg09155362	chr15:33487289	NA	-0.53	-6.34	-0.33	7.51e-10	Waist circumference;
CRC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.42e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6804368	0.531	rs9819044	chr3:30770520	C/T	cg06106510	chr3:30762233	NA	0.35	5.7	0.3	2.73e-8	Blood metabolite levels;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.3	-5.69	-0.3	2.79e-8	Longevity;Endometriosis;
CRC	cis	rs9938149	0.618	rs35542380	chr16:88299593	G/C	cg05435882	chr16:88311214	NA	-0.47	-6.17	-0.32	1.96e-9	Corneal structure;Central corneal thickness;
CRC	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.51	8.06	0.41	1.47e-14	Mean corpuscular volume;
CRC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17554472	chr22:41940697	POLR3H	-0.56	-6.07	-0.32	3.45e-9	Vitiligo;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25118631	chr4:120206103	USP53	-0.53	-6.7	-0.35	8.84e-11	Diisocyanate-induced asthma;
CRC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.14	25.01	0.81	4.37e-78	IgG glycosylation;
CRC	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg00042356	chr1:8021962	PARK7	-0.53	-6.24	-0.33	1.36e-9	Inflammatory bowel disease;
CRC	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.41	7.88	0.4	4.8e-14	Mean corpuscular volume;
CRC	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs904251	0.686	rs931649	chr6:37466079	T/C	cg25019722	chr6:37503610	NA	-0.38	-5.61	-0.3	4.19e-8	Cognitive performance;
CRC	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg20737812	chr15:86336631	KLHL25	-0.48	-7.6	-0.39	3.16e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.67	-6.94	-0.36	2.13e-11	Menarche (age at onset);
CRC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.3	-6.09	-0.32	3.1e-9	Lung cancer;
CRC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.6	7.07	0.36	9.23e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.3	1.86e-8	Bladder cancer;
CRC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg10263370	chr3:44754102	ZNF502	-0.36	-5.99	-0.31	5.36e-9	Depressive symptoms;
CRC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24308560	chr3:49941425	MST1R	0.43	6.82	0.35	4.29e-11	Body mass index;
CRC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg19682013	chr15:45996608	NA	0.35	7.17	0.37	5.09e-12	Waist circumference;Weight;
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg24505167	chr7:1915268	MAD1L1	-0.44	-5.98	-0.31	5.89e-9	Bipolar disorder;
CRC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.81	-0.31	1.47e-8	Alzheimer's disease (late onset);
CRC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-6.79	-0.35	5.24e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg25834613	chr7:1915315	MAD1L1	-0.39	-5.88	-0.31	1.03e-8	Bipolar disorder;
CRC	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.62	-9.79	-0.47	5.03e-20	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.49	6.83	0.35	4.15e-11	Eosinophil percentage of white cells;
CRC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.9	11.58	0.54	3.04e-26	Breast cancer;
CRC	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg16558208	chr1:156270281	VHLL	0.55	8.56	0.43	4.27e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.63	11.2	0.53	6.78e-25	Bone mineral density;
CRC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.78	0.66	3.78e-42	Intelligence (multi-trait analysis);
CRC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.81	0.44	7.35e-17	Morning vs. evening chronotype;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg21251018	chr6:28226885	NKAPL	0.45	6.43	0.33	4.5e-10	Depression;
CRC	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.63	8.09	0.41	1.2e-14	Response to hepatitis C treatment;
CRC	cis	rs4132509	0.744	rs7519673	chr1:243993123	A/G	cg21452805	chr1:244014465	NA	0.61	6.34	0.33	7.61e-10	RR interval (heart rate);
CRC	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.95	0.31	6.94e-9	Renal cell carcinoma;
CRC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-8.51	-0.42	6.33e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-6.14	-0.32	2.34e-9	Schizophrenia;
CRC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.4	0.33	5.21e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.56	6.48	0.34	3.28e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.89	-11.17	-0.52	8.84e-25	Vitiligo;
CRC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.31	-15.31	-0.64	2.59e-40	Diabetic kidney disease;
CRC	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.71	-0.6	3.64e-34	Exhaled nitric oxide output;
CRC	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.78	-0.44	8.99e-17	Coffee consumption (cups per day);
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg26587870	chr6:27730563	NA	-0.56	-6.47	-0.34	3.49e-10	Lung cancer in ever smokers;
CRC	cis	rs11212617	1.000	rs654005	chr11:108155397	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.26	0.33	1.19e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs6950442	0.556	rs647318	chr7:114346537	A/C	cg08672999	chr19:52675203	ZNF836	-0.54	-6.92	-0.36	2.34e-11	Body mass index;
CRC	cis	rs9326248	0.689	rs4516002	chr11:116999059	A/G	cg11861562	chr11:117069780	TAGLN	0.37	6.04	0.32	4.15e-9	Blood protein levels;
CRC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg25171089	chr10:5708825	ASB13	0.4	5.73	0.3	2.27e-8	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.21	-0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-1.01	-11.08	-0.52	1.91e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1519814	1.000	rs10087151	chr8:121172261	C/T	cg22335954	chr8:121166405	COL14A1	-0.55	-6.88	-0.35	3.04e-11	Breast cancer;
CRC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg27532560	chr4:187881888	NA	-0.56	-10.23	-0.49	1.63e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.65e-12	Inflammatory skin disease;
CRC	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-11.06	-0.52	2.23e-24	Colorectal cancer;
CRC	cis	rs812925	0.537	rs778139	chr2:61684564	A/G	cg10580144	chr2:61372316	C2orf74	-0.33	-7.02	-0.36	1.31e-11	Immature fraction of reticulocytes;
CRC	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg23100626	chr2:96804247	ASTL	-0.27	-7.22	-0.37	3.61e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs10779751	0.762	rs1074078	chr1:11326788	C/T	cg08854313	chr1:11322531	MTOR	-0.44	-5.73	-0.3	2.25e-8	Body mass index;
CRC	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg09324608	chr17:30823087	MYO1D	0.35	5.93	0.31	7.51e-9	Schizophrenia;
CRC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.24	-0.33	1.36e-9	Total body bone mineral density;
CRC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.47	8.34	0.42	2.05e-15	Schizophrenia;
CRC	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.42	-6.3	-0.33	9.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.89	-16.19	-0.67	9.31e-44	Height;
CRC	cis	rs4973397	0.810	rs12694890	chr2:232276553	A/T	cg13347044	chr2:232276743	NA	-0.52	-7.52	-0.38	5.19e-13	Anti-saccade response;
CRC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Body mass index;
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg10589385	chr1:150898437	SETDB1	0.31	6.48	0.34	3.38e-10	Melanoma;
CRC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.73	8.31	0.42	2.61e-15	Eosinophilic esophagitis;
CRC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.55	-9.69	-0.47	1.09e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.66	11.06	0.52	2.17e-24	Mean corpuscular volume;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg15845792	chr6:28175446	NA	0.6	9.1	0.45	9.17e-18	Pubertal anthropometrics;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01437395	chr2:110962594	NPHP1	0.48	6.83	0.35	4.07e-11	Response to antipsychotic treatment;
CRC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.98	12.1	0.55	4.02e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs860295	0.812	rs10908481	chr1:155713650	T/G	cg02153340	chr1:155202674	NA	-0.52	-6.37	-0.33	6.21e-10	Body mass index;
CRC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.58	6.65	0.34	1.22e-10	Neutrophil percentage of white cells;
CRC	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.51	7.36	0.38	1.53e-12	Testicular germ cell tumor;
CRC	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg24851651	chr11:66362959	CCS	0.39	6.78	0.35	5.6e-11	Educational attainment (years of education);
CRC	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.42	8.34	0.42	2.09e-15	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.38	-6.05	-0.32	4e-9	Ulcerative colitis;
CRC	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	8.39	0.42	1.45e-15	Mean corpuscular hemoglobin;
CRC	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.75	10.01	0.48	9.2e-21	Prostate cancer;
CRC	cis	rs965469	0.843	rs6037580	chr20:3351374	A/G	cg25506879	chr20:3388711	C20orf194	-0.4	-5.83	-0.31	1.35e-8	IFN-related cytopenia;
CRC	cis	rs2084637	1.000	rs34651745	chr11:122418046	A/G	cg21585512	chr11:122030076	LOC399959	-0.37	-6.59	-0.34	1.74e-10	Stroke;
CRC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.72	12.75	0.57	1.61e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg08632701	chr21:37451849	NA	-0.42	-6.6	-0.34	1.68e-10	Mitral valve prolapse;
CRC	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.51	6.64	0.34	1.3e-10	Alzheimer's disease (survival time);
CRC	cis	rs6751744	0.514	rs12386214	chr2:160531523	C/T	cg08347373	chr2:160653686	CD302	-0.37	-6.08	-0.32	3.32e-9	Dysphagia;
CRC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.23	0.37	3.44e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg00343986	chr7:65444356	GUSB	-0.47	-6.94	-0.36	2.05e-11	Aortic root size;
CRC	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg00666640	chr1:248458726	OR2T12	0.42	7.7	0.39	1.61e-13	Common traits (Other);
CRC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.54	6.87	0.35	3.22e-11	Morning vs. evening chronotype;
CRC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.64	-0.43	2.57e-16	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24524451	chr7:140372725	ADCK2	0.39	6.42	0.33	4.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg14003231	chr6:33640908	ITPR3	0.44	7.22	0.37	3.69e-12	Height;
CRC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.46	-6.58	-0.34	1.91e-10	Blood pressure (smoking interaction);
CRC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.73	-0.51	3.14e-23	Total cholesterol levels;
CRC	trans	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg19188899	chr13:112838565	NA	-0.43	-6.62	-0.34	1.42e-10	Systemic lupus erythematosus;
CRC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-5.99	-0.31	5.47e-9	Alzheimer's disease (late onset);
CRC	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.41	-0.38	1.09e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9463078	0.683	rs227848	chr6:44698499	G/A	cg25276700	chr6:44698697	NA	0.25	5.93	0.31	7.68e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg22117107	chr15:45993392	NA	-0.41	-8.19	-0.41	5.87e-15	Waist circumference;Weight;
CRC	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	5.82	0.31	1.37e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.42	-6.13	-0.32	2.51e-9	Breast size;
CRC	trans	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg17903999	chr18:56338584	MALT1	0.41	6.9	0.36	2.62e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12024301	0.557	rs12033293	chr1:183640422	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.06	0.36	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05926606	chr21:40685342	BRWD1	0.44	7.25	0.37	3e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.2	-0.73	1.2e-55	Primary sclerosing cholangitis;
CRC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.42	0.53	1.14e-25	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg00129232	chr17:37814104	STARD3	-0.48	-7.54	-0.38	4.65e-13	Self-reported allergy;
CRC	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.52	8.77	0.44	9.5e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.77	10.66	0.51	5.37e-23	Orofacial clefts;
CRC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.8	12.19	0.56	1.84e-28	Coronary artery disease;
CRC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.62	-8.8	-0.44	7.77e-17	Carotid intima media thickness;
CRC	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04004882	chr2:215674386	BARD1	0.64	8.8	0.44	7.96e-17	Neuroblastoma;
CRC	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.47	0.42	8.36e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.9	12.76	0.58	1.44e-30	Initial pursuit acceleration;
CRC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07294406	chr7:64700536	NA	0.37	6.02	0.32	4.57e-9	Calcium levels;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg06470822	chr6:28175283	NA	0.94	13.58	0.6	1.16e-33	Parkinson's disease;
CRC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg04166393	chr7:2884313	GNA12	0.38	5.74	0.3	2.2e-8	Height;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg10201608	chr2:85788586	GGCX	-0.55	-6.7	-0.35	9.05e-11	Diisocyanate-induced asthma;
CRC	cis	rs3823572	0.564	rs2971962	chr7:133639770	G/A	cg03336402	chr7:133662267	EXOC4	0.67	10.04	0.48	7.53e-21	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00873937	chr10:69991564	ATOH7	0.45	6.04	0.32	4.16e-9	Thyroid stimulating hormone;
CRC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.55	-8.29	-0.42	2.9e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.64	-0.34	1.3100000000000001e-10	Triglycerides;
CRC	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg22495460	chr2:25135724	ADCY3	-0.86	-16.36	-0.67	1.88e-44	Body mass index in non-asthmatics;
CRC	cis	rs2730260	0.736	rs73169220	chr7:158846197	A/C	cg02254261	chr7:158964346	NA	-0.56	-6.2	-0.32	1.68e-9	Myopia (pathological);
CRC	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-6.85	-0.35	3.56e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02359409	chr6:42947317	PEX6	-0.59	-9.23	-0.45	3.5e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.57	9.12	0.45	7.74e-18	Gestational age at birth (maternal effect);
CRC	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.45	6.31	0.33	8.94e-10	Lung cancer;
CRC	cis	rs10991814	0.920	rs75779763	chr9:94060031	G/A	cg14446406	chr9:93919335	NA	0.5	5.99	0.31	5.45e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.75	12.61	0.57	5.12e-30	Urate levels in obese individuals;
CRC	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.51	8.22	0.41	4.9e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.23	0.33	1.4e-9	Lung cancer;
CRC	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.26	0.37	2.81e-12	Eye color traits;
CRC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.63	13.35	0.59	8.5e-33	Schizophrenia;
CRC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.26	-0.69	5.33e-48	Height;
CRC	cis	rs7572644	0.656	rs34096628	chr2:28060990	A/C	cg27432699	chr2:27873401	GPN1	0.45	6.11	0.32	2.79e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg16606324	chr3:10149918	C3orf24	0.69	9.52	0.46	3.91e-19	Alzheimer's disease;
CRC	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.87	-0.35	3.25e-11	Menarche (age at onset);
CRC	cis	rs6961069	0.933	rs7807607	chr7:80226885	C/T	cg04458919	chr7:80252533	CD36	-0.33	-5.75	-0.3	2.06e-8	Platelet count;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg21251018	chr6:28226885	NKAPL	0.46	6.12	0.32	2.73e-9	Depression;
CRC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.62	10.7	0.51	4.1000000000000003e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.7	12.63	0.57	4.54e-30	Anterior chamber depth;
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg27635394	chr6:26043820	HIST1H2BB	0.4	6.09	0.32	3.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9648716	1.000	rs6948703	chr7:140584438	T/C	cg10747023	chr7:140774559	NA	0.44	5.88	0.31	9.82e-9	Type 2 diabetes;
CRC	cis	rs4234798	0.585	rs13121616	chr4:7212389	A/G	cg18431297	chr4:7219810	SORCS2	0.47	7.35	0.38	1.54e-12	Insulin-like growth factors;
CRC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.65	-9.03	-0.45	1.43e-17	Refractive error;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21843114	chr4:26334859	RBPJ	-0.39	-6.39	-0.33	5.82e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg15691649	chr6:25882328	NA	-0.42	-5.62	-0.3	4.04e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6700896	0.864	rs11208691	chr1:66092570	A/G	cg04111102	chr1:66153794	NA	0.33	5.81	0.31	1.48e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4664293	0.867	rs2357531	chr2:160597418	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg15660573	chr17:549704	VPS53	-0.86	-15.78	-0.66	3.56e-42	Prostate cancer;
CRC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg07195577	chr17:27052828	TLCD1	0.42	6.01	0.31	4.85e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg26762873	chr11:5879799	OR52E8	0.42	7.11	0.37	7.18e-12	DNA methylation (variation);
CRC	cis	rs9392556	0.533	rs619439	chr6:4113929	G/A	cg10424681	chr6:4079350	C6orf201;C6orf146	0.24	6.07	0.32	3.52e-9	Blood metabolite levels;
CRC	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-16.8	-0.68	3.44e-46	Schizophrenia;
CRC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.04	-0.32	4.19e-9	Height;
CRC	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg23100626	chr2:96804247	ASTL	0.27	7.58	0.39	3.62e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.51e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.58	11.27	0.53	3.84e-25	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.26	-0.33	1.21e-9	Diabetic kidney disease;
CRC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.57	-9.45	-0.46	6.37e-19	Bipolar disorder and schizophrenia;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08679808	chr17:79886116	LOC92659;MAFG	0.37	5.99	0.31	5.38e-9	Obesity-related traits;
CRC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.79	11.59	0.54	2.72e-26	Neutrophil percentage of white cells;
CRC	cis	rs11229555	0.645	rs11229463	chr11:58210147	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg04204079	chr8:58130323	NA	-0.44	-5.71	-0.3	2.52e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6496667	0.779	rs8042913	chr15:91023147	G/C	cg04176472	chr15:90893244	GABARAPL3	0.53	7.87	0.4	5.19e-14	Rheumatoid arthritis;
CRC	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.4	5.7	0.3	2.64e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	1.06	16.7	0.68	8.9e-46	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.4	-0.33	5.21e-10	Aortic root size;
CRC	cis	rs12541635	0.966	rs4416800	chr8:106996677	T/C	cg10147462	chr8:107024639	NA	0.43	7.1	0.36	7.51e-12	Age of smoking initiation;
CRC	cis	rs3772130	1.000	rs56314138	chr3:121356656	G/A	cg20356878	chr3:121714668	ILDR1	0.49	7.65	0.39	2.22e-13	Cognitive performance;
CRC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg20487152	chr13:99095054	FARP1	-0.47	-6.68	-0.35	1.02e-10	Longevity;
CRC	cis	rs391936	0.568	rs3102955	chr2:8467647	C/T	cg12167548	chr2:8464763	NA	0.32	5.96	0.31	6.34e-9	Selective IgA deficiency;
CRC	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.47	6.9	0.36	2.68e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.760	rs9393909	chr6:28207200	A/G	cg06470822	chr6:28175283	NA	-0.6	-5.9	-0.31	9.06e-9	Depression;
CRC	cis	rs860295	0.665	rs11264367	chr1:155337338	T/C	cg02153340	chr1:155202674	NA	-0.57	-6.76	-0.35	6.48e-11	Body mass index;
CRC	cis	rs59104589	0.570	rs3771569	chr2:242382606	A/T	cg19488206	chr2:242435732	STK25	0.45	6.75	0.35	6.88e-11	Fibrinogen levels;
CRC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.88	0.4	4.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23161317	chr6:28129485	ZNF389	0.54	6.62	0.34	1.48e-10	Depression;
CRC	trans	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg06840491	chr10:48416966	GDF2	-0.35	-6.04	-0.32	4.16e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg26043149	chr18:55253948	FECH	0.53	8.16	0.41	7.05e-15	Bone mineral density;
CRC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.41	6.72	0.35	7.92e-11	Obesity-related traits;
CRC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.43	-6.62	-0.34	1.46e-10	Social autistic-like traits;
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg06494592	chr3:125709126	NA	-0.52	-6.65	-0.34	1.23e-10	Blood pressure (smoking interaction);
CRC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.02	-0.45	1.61e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.59	-0.34	1.76e-10	Bipolar disorder;
CRC	cis	rs17767392	0.846	rs34281934	chr14:71979756	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.4	-0.33	5.31e-10	Mitral valve prolapse;
CRC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.61	8.59	0.43	3.63e-16	Monobrow;
CRC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg12927641	chr6:109611667	NA	-0.38	-6.61	-0.34	1.51e-10	Reticulocyte fraction of red cells;
CRC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg18827107	chr12:86230957	RASSF9	-0.5	-8.1	-0.41	1.1e-14	Major depressive disorder;
CRC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.94	13.28	0.59	1.62e-32	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.2	-0.32	1.66e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs2303319	0.582	rs56315911	chr2:162560186	G/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.61	-5.99	-0.31	5.62e-9	Cognitive function;
CRC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.52	7.25	0.37	3.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.58	9.08	0.45	1.01e-17	Breast cancer;
CRC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg11189052	chr15:85197271	WDR73	-0.59	-8.26	-0.41	3.66e-15	Schizophrenia;
CRC	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.72	0.3	2.38e-8	Ovarian reserve;
CRC	cis	rs2933343	0.818	rs6764681	chr3:128568380	G/C	cg11901034	chr3:128598214	ACAD9	0.47	5.65	0.3	3.53e-8	IgG glycosylation;
CRC	cis	rs758324	0.812	rs477086	chr5:131284610	C/T	cg25547332	chr5:131281432	NA	-0.37	-5.89	-0.31	9.7e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs995000	0.899	rs1168030	chr1:62968491	C/T	cg19896129	chr1:63156450	NA	-0.39	-6.08	-0.32	3.29e-9	Triglyceride levels;
CRC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg00129232	chr17:37814104	STARD3	0.42	6.74	0.35	7.2e-11	Self-reported allergy;
CRC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.47	7.35	0.38	1.57e-12	Monobrow;
CRC	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.35	0.33	7e-10	Systolic blood pressure;
CRC	cis	rs73206853	0.841	rs73191816	chr12:110918564	G/A	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.43e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.4	-7.0	-0.36	1.47e-11	Reticulocyte fraction of red cells;
CRC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13844804	chr7:814759	HEATR2	-0.58	-6.16	-0.32	2.08e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg02569458	chr12:86230093	RASSF9	0.39	6.55	0.34	2.25e-10	Major depressive disorder;
CRC	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	1.09	18.65	0.72	1.74e-53	Schizophrenia;
CRC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.77	11.46	0.53	7.98e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs7976838	0.908	rs34272110	chr12:60122507	T/C	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	trans	rs7821565	0.904	rs66892367	chr8:52177170	T/C	cg09187163	chr7:72721838	NSUN5	-0.41	-5.98	-0.31	5.7e-9	Tuberculosis;
CRC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg07636037	chr3:49044803	WDR6	-0.66	-5.7	-0.3	2.62e-8	Cognitive function;
CRC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.51	-8.43	-0.42	1.07e-15	Aortic root size;
CRC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.57	8.23	0.41	4.5e-15	Melanoma;
CRC	trans	rs12301672	0.774	rs7297794	chr12:75540498	A/G	cg16347928	chr1:854838	FLJ39609	0.44	6.18	0.32	1.84e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-5.97	-0.31	6.04e-9	Alzheimer's disease (late onset);
CRC	cis	rs10924970	0.649	rs4659493	chr1:235482272	T/C	cg09010748	chr1:235293032	TOMM20	-0.4	-5.65	-0.3	3.57e-8	Asthma;
CRC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.6	8.24	0.41	4.11e-15	Methadone dose in opioid dependence;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg10117518	chr2:29117384	WDR43	0.39	6.05	0.32	3.87e-9	Interleukin-6 levels;
CRC	cis	rs3996993	0.597	rs72938158	chr6:52735179	T/A	cg20803780	chr6:52668592	GSTA1	0.39	6.6	0.34	1.61e-10	Hemoglobin concentration;
CRC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg00343986	chr7:65444356	GUSB	0.4	5.68	0.3	3.01e-8	Aortic root size;
CRC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.44	-0.38	9.04e-13	Blood metabolite levels;
CRC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.65	-10.68	-0.51	4.71e-23	Hip circumference adjusted for BMI;
CRC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.49	-7.18	-0.37	4.66e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	15.21	0.64	6.05e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg09003973	chr2:102972529	NA	0.41	5.83	0.31	1.33e-8	Blood protein levels;
CRC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.35	-0.33	6.98e-10	Aortic root size;
CRC	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.69	11.29	0.53	3.24e-25	Age at first birth;
CRC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.48	6.4	0.33	5.27e-10	Red cell distribution width;
CRC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg21747405	chr11:67723411	NA	-0.44	-6.25	-0.33	1.31e-9	Blood pressure (smoking interaction);
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs6961069	0.806	rs4728183	chr7:80256003	A/G	cg04458919	chr7:80252533	CD36	0.36	6.23	0.32	1.43e-9	Platelet count;
CRC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.94	-0.31	7.44e-9	Lung cancer;
CRC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.59	8.94	0.44	2.77e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs4684776	0.548	rs62248289	chr3:11637907	T/C	cg20302342	chr1:156215951	PAQR6	-0.48	-6.31	-0.33	9e-10	Small vessel stroke;
CRC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.36	-5.82	-0.31	1.44e-8	Reticulocyte count;
CRC	cis	rs10971721	0.822	rs72725370	chr9:33818457	A/T	cg13495928	chr9:33750294	PRSS3	0.55	5.89	0.31	9.66e-9	Body mass index;
CRC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.5	8.65	0.43	2.28e-16	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs3789045	0.560	rs1002779	chr1:204405098	T/A	cg17419461	chr1:204415978	PIK3C2B	-0.81	-10.79	-0.51	2.01e-23	Educational attainment (college completion);
CRC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.39	0.53	1.52e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.09	0.32	3.16e-9	IgG glycosylation;
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg21856205	chr7:94953877	PON1	-0.49	-6.44	-0.33	4.12e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1838105	0.674	rs1634260	chr17:45174285	G/A	cg16759221	chr17:45003025	GOSR2	-0.61	-9.17	-0.45	5.35e-18	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.71	-8.3	-0.42	2.69e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6988985	0.818	rs6471583	chr8:143991092	G/A	cg10324643	chr8:143916377	GML	0.37	5.93	0.31	7.76e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.05	0.68	3.64e-47	Platelet count;
CRC	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg06204229	chr3:52865917	ITIH4	0.57	7.88	0.4	4.95e-14	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9443189	0.950	rs6453845	chr6:76576527	G/T	cg01950844	chr6:76311363	SENP6	-0.62	-7.46	-0.38	7.93e-13	Prostate cancer;
CRC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.81	10.39	0.5	4.81e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.62	-0.54	2.28e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.6	-0.34	1.67e-10	Metabolite levels;
CRC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.77	11.74	0.54	8.16e-27	Menopause (age at onset);
CRC	cis	rs6681460	0.966	rs6588215	chr1:67141949	A/G	cg02459107	chr1:67143332	SGIP1	0.5	9.0	0.44	1.83e-17	Presence of antiphospholipid antibodies;
CRC	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.73	-12.61	-0.57	5.09e-30	White blood cell count (basophil);
CRC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg00343986	chr7:65444356	GUSB	0.43	6.37	0.33	6.49e-10	Aortic root size;
CRC	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.47	5.92	0.31	8.03e-9	Metabolite levels;
CRC	cis	rs2160860	0.585	rs11779697	chr8:39797735	C/T	cg11363097	chr8:39792086	IDO2	-0.42	-7.25	-0.37	2.94e-12	Blood metabolite levels;
CRC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-8.32	-0.42	2.37e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.34	0.69	2.56e-48	Platelet count;
CRC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg05585544	chr11:47624801	NA	0.54	9.5	0.46	4.38e-19	Subjective well-being;
CRC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg25456477	chr12:86230367	RASSF9	0.41	6.99	0.36	1.54e-11	Major depressive disorder;
CRC	trans	rs10207628	0.941	rs11887884	chr2:127848041	C/T	cg22628694	chr19:58663362	ZNF329	0.6	6.08	0.32	3.31e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.8	12.73	0.57	1.89e-30	Height;
CRC	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.3100000000000001e-10	Vitamin D levels;
CRC	cis	rs4964805	0.594	rs751448	chr12:104167185	C/T	cg02344784	chr12:104178138	NT5DC3	0.41	6.14	0.32	2.39e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.49	-7.55	-0.38	4.32e-13	Motion sickness;
CRC	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9649465	0.967	rs10224062	chr7:123304609	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-5.71	-0.3	2.56e-8	Migraine;
CRC	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.56	-7.61	-0.39	2.93e-13	Coronary artery disease;
CRC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.77	-0.35	5.76e-11	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.05	-0.32	3.97e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg05139728	chr16:28306816	SBK1	-0.37	-6.09	-0.32	3.19e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg23254163	chr1:152506842	NA	0.45	8.87	0.44	4.86e-17	Hair morphology;
CRC	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11161846	chr1:160990452	F11R	-0.47	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19355881	chr6:34759549	UHRF1BP1	0.39	6.27	0.33	1.14e-9	Obesity-related traits;
CRC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.45	6.58	0.34	1.9e-10	Vitiligo;
CRC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.41	-7.24	-0.37	3.12e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.79	-13.27	-0.59	1.75e-32	Obesity-related traits;
CRC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-10.31	-0.49	8.55e-22	Alzheimer's disease;
CRC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.55	8.91	0.44	3.49e-17	Type 2 diabetes;
CRC	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.7	10.92	0.52	6.71e-24	Plateletcrit;Platelet count;
CRC	cis	rs3823572	0.542	rs11773892	chr7:133626334	G/T	cg03336402	chr7:133662267	EXOC4	0.66	9.76	0.47	6.16e-20	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16271524	chr11:66139231	SLC29A2	0.41	6.02	0.31	4.71e-9	Response to antipsychotic treatment;
CRC	trans	rs17111396	0.627	rs12100732	chr14:81506485	G/C	cg22745369	chr6:3517953	NA	-0.43	-6.04	-0.32	4.17e-9	Uric acid levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03509965	chr14:75743987	FOS	0.39	6.09	0.32	3.09e-9	Intelligence (multi-trait analysis);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg18652453	chr5:68665041	TAF9;RAD17	-0.46	-7.09	-0.36	8.46e-12	Daytime sleep phenotypes;
CRC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.53	0.6	1.75e-33	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.44	7.01	0.36	1.36e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs863345	0.526	rs2051666	chr1:158507160	T/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.17	-0.32	2.03e-9	Pneumococcal bacteremia;
CRC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.6	0.34	1.63e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14895029	chr7:2775587	GNA12	-0.45	-6.64	-0.34	1.3e-10	Height;
CRC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg27489772	chr12:121021490	NA	-0.5	-6.56	-0.34	2.13e-10	Type 1 diabetes nephropathy;
CRC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.52	-6.89	-0.36	2.81e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg08717414	chr16:71523259	ZNF19	-0.45	-5.61	-0.3	4.36e-8	Post bronchodilator FEV1;
CRC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.75	12.89	0.58	4.55e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg02674126	chr19:40336878	FBL	0.42	6.64	0.34	1.3e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.56	8.23	0.41	4.35e-15	Tuberculosis;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-8.18	-0.41	6.34e-15	Cognitive function;
CRC	trans	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg13385794	chr1:248469461	NA	0.4	7.11	0.36	7.23e-12	Common traits (Other);
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.74	11.87	0.55	2.78e-27	Longevity;Endometriosis;
CRC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.5	9.49	0.46	4.77e-19	Smoking initiation;
CRC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.33e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.14	13.38	0.59	6.6e-33	Sexual dysfunction (female);
CRC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.66	9.64	0.47	1.6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15097876	chr10:71993604	PPA1	0.46	6.39	0.33	5.83e-10	Response to antipsychotic treatment;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg10661591	chr3:100428033	TFG	-0.52	-6.04	-0.32	4.21e-9	Type 1 diabetes;
CRC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12463550	chr7:65579703	CRCP	0.65	5.72	0.3	2.4e-8	Diabetic kidney disease;
CRC	cis	rs12024301	0.557	rs79818376	chr1:183598452	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg17089214	chr22:22089827	YPEL1	-0.57	-6.02	-0.32	4.54e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.57	7.8	0.4	8.24e-14	White matter hyperintensity burden;
CRC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg15440763	chr7:158190612	PTPRN2	0.41	6.42	0.33	4.74e-10	Obesity-related traits;
CRC	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg14458575	chr2:238380390	NA	0.53	7.01	0.36	1.36e-11	Prostate cancer;
CRC	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg11887960	chr12:57824829	NA	0.62	6.76	0.35	6.26e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.89	0.51	8.54e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.74	-11.38	-0.53	1.65e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.59	9.73	0.47	8.1e-20	Colorectal cancer;
CRC	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	8.48	0.42	7.74e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg03609598	chr5:56110824	MAP3K1	0.44	6.32	0.33	8.59e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6908034	0.607	rs113592672	chr6:19806063	G/C	cg02682789	chr6:19804855	NA	0.79	6.75	0.35	6.62e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.65	13.76	0.6	2.47e-34	Schizophrenia;
CRC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg00343986	chr7:65444356	GUSB	0.49	7.15	0.37	5.6e-12	Aortic root size;
CRC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg03678062	chr6:149772716	ZC3H12D	0.33	6.02	0.31	4.7e-9	Dupuytren's disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03610000	chr11:128392383	ETS1	-0.41	-6.32	-0.33	8.56e-10	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22479481	chr17:16120428	PIGL	0.47	6.73	0.35	7.54e-11	Response to antipsychotic treatment;
CRC	trans	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-8.33	-0.42	2.25e-15	Hemoglobin concentration;
CRC	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg11833968	chr6:79620685	NA	-0.36	-6.25	-0.33	1.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg02659138	chr7:134003124	SLC35B4	0.42	7.34	0.38	1.65e-12	Mean platelet volume;
CRC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg09355771	chr2:177043147	NA	0.66	10.09	0.49	5.07e-21	IgG glycosylation;
CRC	cis	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.82	-0.31	1.43e-8	Asthma;
CRC	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.95	0.31	6.94e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.54	8.41	0.42	1.25e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00536289	chr16:28834130	ATXN2L	0.51	7.12	0.37	6.62e-12	Anxiety disorder;
CRC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg12311346	chr5:56204834	C5orf35	-0.46	-7.06	-0.36	9.71e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.43	5.95	0.31	6.84e-9	Diastolic blood pressure;
CRC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.5	-8.01	-0.4	1.97e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-9.4	-0.46	9.27e-19	Lymphocyte counts;Red cell distribution width;
CRC	trans	rs6956675	0.915	rs4717497	chr7:62645096	A/G	cg01314568	chr7:57830625	NA	-0.65	-9.29	-0.46	2.25e-18	Obesity-related traits;
CRC	cis	rs4664293	0.625	rs7590617	chr2:160631948	A/G	cg08347373	chr2:160653686	CD302	0.43	7.42	0.38	1.03e-12	Monocyte percentage of white cells;
CRC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.83	-10.56	-0.5	1.26e-22	Gut microbiome composition (summer);
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs117623576	0.941	rs111379000	chr10:32427247	A/G	cg03047570	chr10:32398778	NA	-0.69	-7.39	-0.38	1.19e-12	Anti-saccade response;
CRC	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg04837898	chr3:45731254	SACM1L	-0.37	-6.03	-0.32	4.39e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs7671266	0.559	rs7681212	chr4:10358964	C/G	cg11266682	chr4:10021025	SLC2A9	0.42	6.53	0.34	2.5e-10	Cardiovascular disease risk factors;
CRC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg08347473	chr17:78092826	GAA	-0.37	-6.13	-0.32	2.53e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.43	-0.33	4.46e-10	Triglycerides;
CRC	cis	rs4716602	0.596	rs12386632	chr7:156158221	G/A	cg16983916	chr7:156159713	NA	-0.39	-6.92	-0.36	2.42e-11	Anti-saccade response;
CRC	cis	rs2949837	0.581	rs1852210	chr7:45994256	C/T	cg15898840	chr7:45960834	IGFBP3	0.46	7.49	0.38	6.55e-13	Sitting height ratio;
CRC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.75	-8.83	-0.44	6.23e-17	Hip circumference adjusted for BMI;
CRC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg11189052	chr15:85197271	WDR73	0.5	7.45	0.38	8.21e-13	Schizophrenia;
CRC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14671364	chr1:107599128	PRMT6	0.51	7.18	0.37	4.59e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs17213078	0.505	rs737101	chr2:106732545	C/T	cg15412446	chr2:106886593	NA	0.37	5.91	0.31	8.34e-9	Facial morphology (factor 23);
CRC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs7626444	0.625	rs1798637	chr3:196476639	C/T	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	cis	rs13144136	0.687	rs13128842	chr4:10661991	T/A	cg10242279	chr4:10666415	CLNK	-0.38	-6.66	-0.34	1.18e-10	Resistance to antihypertensive treatment in hypertension;
CRC	trans	rs12699921	0.598	rs2691607	chr7:17879103	G/A	cg15753394	chr6:17282781	RBM24	-0.36	-6.18	-0.32	1.86e-9	Fibrinogen levels;
CRC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.85	0.66	1.89e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6429082	0.967	rs1305557	chr1:235627837	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	6.77	0.35	5.91e-11	Adiposity;
CRC	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg17507749	chr15:85114479	UBE2QP1	0.52	6.64	0.34	1.3e-10	Schizophrenia;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg20933634	chr6:27740509	NA	0.57	8.06	0.41	1.38e-14	Parkinson's disease;
CRC	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg14593290	chr7:50529359	DDC	-0.5	-7.16	-0.37	5.45e-12	Systemic sclerosis;
CRC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.54	-0.43	5.04e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs10411161	0.702	rs11879319	chr19:52389592	C/T	cg22319618	chr22:45562946	NUP50	-0.61	-6.88	-0.35	2.96e-11	Breast cancer;
CRC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.39	-15.26	-0.64	4.07e-40	Plateletcrit;
CRC	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg25856811	chr1:152973957	SPRR3	0.25	6.75	0.35	6.63e-11	Inflammatory skin disease;
CRC	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	1.17	10.97	0.52	4.57e-24	Prostate cancer;
CRC	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.16	0.32	2.07e-9	Rheumatoid arthritis;
CRC	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.6	10.23	0.49	1.66e-21	Dupuytren's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02361612	chr7:130353136	COPG2	0.44	6.38	0.33	6.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6577655	0.517	rs4909293	chr8:135587888	G/A	cg17885191	chr8:135476712	NA	0.5	5.62	0.3	4.09e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.09	-0.49	4.87e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg19223190	chr17:80058835	NA	0.39	6.26	0.33	1.2e-9	Life satisfaction;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00802000	chr16:706648	WDR90	-0.44	-6.45	-0.33	4.05e-10	Height;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08577743	chr9:38621011	C9orf122;ANKRD18A	-0.53	-6.86	-0.35	3.39e-11	Diisocyanate-induced asthma;
CRC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.64	10.13	0.49	3.48e-21	Motion sickness;
CRC	cis	rs9903692	0.954	rs6847	chr17:46147807	A/T	cg10706073	chr17:46328419	SKAP1	0.42	5.65	0.3	3.55e-8	Pulse pressure;
CRC	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg15147215	chr3:52552868	STAB1	-0.43	-6.84	-0.35	3.91e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg16989086	chr20:62203971	PRIC285	-0.49	-6.39	-0.33	5.79e-10	Atopic dermatitis;
CRC	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.39	-0.33	5.54e-10	Systemic lupus erythematosus;
CRC	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg13736514	chr6:26305472	NA	-0.45	-7.3	-0.37	2.21e-12	Educational attainment;
CRC	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg15704280	chr7:45808275	SEPT13	0.61	6.27	0.33	1.14e-9	Intraocular pressure;
CRC	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.47	6.47	0.34	3.62e-10	Obesity-related traits;
CRC	trans	rs9693857	0.520	rs7821875	chr8:9359312	G/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.24	0.33	1.38e-9	Systolic blood pressure;
CRC	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg09597638	chr17:3907349	NA	-0.65	-11.3	-0.53	3.03e-25	Type 2 diabetes;
CRC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.9	-17.3	-0.69	3.95e-48	Intelligence (multi-trait analysis);
CRC	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	trans	rs800082	1.000	rs2717391	chr3:144279698	T/C	cg24215973	chr2:240111563	HDAC4	0.52	6.94	0.36	2.11e-11	Smoking behavior;
CRC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.08	10.68	0.51	4.63e-23	Skin colour saturation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20149956	chr1:249132233	ZNF672	0.39	6.17	0.32	2.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.46	-7.29	-0.37	2.38e-12	Schizophrenia;
CRC	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.44	0.33	4.28e-10	Lung cancer;
CRC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.52	-0.43	5.82e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.45	6.91	0.36	2.56e-11	Multiple myeloma (IgH translocation);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02114786	chr21:46293672	PTTG1IP	0.45	6.26	0.33	1.18e-9	Response to antipsychotic treatment;
CRC	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg22482690	chr17:47019901	SNF8	0.43	7.05	0.36	1.09e-11	Type 2 diabetes;
CRC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg24675658	chr1:53192096	ZYG11B	0.53	7.73	0.39	1.34e-13	Monocyte count;
CRC	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg09184832	chr6:79620586	NA	-0.39	-6.68	-0.35	1.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.78	-0.3	1.72e-8	Lung cancer;
CRC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.95	0.36	2e-11	Morning vs. evening chronotype;
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.6	8.3	0.42	2.66e-15	Longevity;Endometriosis;
CRC	cis	rs12760731	0.720	rs722321	chr1:178420220	C/T	cg00404053	chr1:178313656	RASAL2	1.08	11.28	0.53	3.58e-25	Obesity-related traits;
CRC	cis	rs6445525	0.935	rs4688632	chr3:66000290	A/G	cg06109867	chr3:66002991	MAGI1	-0.4	-6.79	-0.35	5.4e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs939584	1.000	rs4854348	chr2:647760	A/G	cg03610516	chr2:642275	NA	0.41	5.93	0.31	7.83e-9	Body mass index;
CRC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.07	-0.32	3.6e-9	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	18.6	0.72	2.81e-53	Prudent dietary pattern;
CRC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.73	-0.35	7.6e-11	Height;
CRC	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg13844804	chr7:814759	HEATR2	0.68	7.43	0.38	9.18e-13	Cerebrospinal P-tau181p levels;
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg15898840	chr7:45960834	IGFBP3	0.43	7.2	0.37	4.24e-12	Sitting height ratio;
CRC	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg13043300	chr11:71146211	DHCR7	-0.44	-5.84	-0.31	1.28e-8	Vitamin D levels;
CRC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.72	0.39	1.45e-13	Mean platelet volume;
CRC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.8	11.82	0.55	4.1e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.53	-8.41	-0.42	1.22e-15	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.68	-0.47	1.13e-19	Intelligence (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08877624	chr8:141521446	CHRAC1	0.38	6.36	0.33	6.88e-10	Obesity-related traits;
CRC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.68	6.85	0.35	3.55e-11	Diabetic retinopathy;
CRC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.74	-0.3	2.21e-8	Neuroticism;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg17691542	chr6:26056736	HIST1H1C	0.42	5.76	0.3	1.96e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24707616	chr17:16342815	NCRNA00188;SNORD49B;SNORD49A	0.51	6.68	0.35	1.02e-10	Thyroid stimulating hormone;
CRC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.43	7.05	0.36	1.08e-11	Height;
CRC	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg13736514	chr6:26305472	NA	-0.45	-7.34	-0.38	1.67e-12	Educational attainment;
CRC	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-5.98	-0.31	5.94e-9	Pubertal anthropometrics;
CRC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.7	-10.75	-0.51	2.57e-23	Dental caries;
CRC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-7.54	-0.38	4.53e-13	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14929913	chr10:1147979	WDR37	-0.41	-6.59	-0.34	1.71e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.76	-0.3	1.92e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08830818	chr3:122514143	HSPBAP1;DIRC2	0.34	6.18	0.32	1.95e-9	Obesity-related traits;
CRC	cis	rs10065203	0.527	rs152177	chr5:14354270	G/A	cg26689441	chr5:14406021	TRIO	-0.37	-6.19	-0.32	1.78e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.3	6.23	0.32	1.47e-9	Alcohol dependence;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg12273811	chr6:28175739	NA	-0.45	-6.75	-0.35	6.7e-11	Cardiac Troponin-T levels;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.26	-0.33	1.17e-9	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.69	10.43	0.5	3.29e-22	Lung cancer;
CRC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg03623178	chr6:28175578	NA	0.45	6.04	0.32	4.23e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg07617317	chr6:118971624	C6orf204	0.49	6.15	0.32	2.23e-9	Diastolic blood pressure;
CRC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.79	10.07	0.49	5.93e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs995000	0.931	rs11207983	chr1:63012107	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.92	-0.36	2.4e-11	Triglyceride levels;
CRC	cis	rs4363385	0.720	rs1611755	chr1:152956420	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.35	-0.38	1.63e-12	Inflammatory skin disease;
CRC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg02527881	chr3:46936655	PTH1R	-0.38	-6.89	-0.36	2.77e-11	Colorectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09133386	chr6:20404188	E2F3	0.48	6.17	0.32	2.02e-9	Thyroid stimulating hormone;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-6.45	-0.34	4e-10	Lymphocyte counts;
CRC	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg09654669	chr8:57350985	NA	-0.44	-5.93	-0.31	7.85e-9	Obesity-related traits;
CRC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.15	0.32	2.21e-9	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05226292	chr8:71520850	TRAM1	0.38	6.0	0.31	5.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg23032129	chr1:109941072	SORT1	-0.27	-5.79	-0.3	1.65e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.6	7.34	0.37	1.73e-12	Obesity (extreme);
CRC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.78	12.03	0.55	6.93e-28	Schizophrenia;
CRC	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.58e-11	Inflammatory skin disease;
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg03623178	chr6:28175578	NA	0.78	6.87	0.35	3.3e-11	Depression;
CRC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.74	9.46	0.46	5.88e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00166722	chr3:10149974	C3orf24	0.57	7.8	0.4	8.13e-14	Alzheimer's disease;
CRC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-8.33	-0.42	2.23e-15	Mean platelet volume;
CRC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg23283495	chr1:209979779	IRF6	0.48	6.85	0.35	3.68e-11	Cleft lip with or without cleft palate;
CRC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.64	-6.71	-0.35	8.33e-11	Vitiligo;
CRC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg06781209	chr11:61594997	FADS2	-0.38	-5.61	-0.3	4.33e-8	Trans fatty acid levels;
CRC	cis	rs3736594	0.513	rs62131881	chr2:27764781	G/T	cg27432699	chr2:27873401	GPN1	0.66	8.5	0.42	6.57e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.85	-0.35	3.64e-11	HDL cholesterol;
CRC	cis	rs863345	0.504	rs857707	chr1:158564383	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-7.16	-0.37	5.25e-12	Pneumococcal bacteremia;
CRC	cis	rs10229583	0.563	rs7801118	chr7:127263886	G/A	cg01233922	chr7:127693937	SND1	-0.44	-6.3	-0.33	9.77e-10	Type 2 diabetes;
CRC	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2274273	0.686	rs2182207	chr14:55589803	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.8	-0.3	1.57e-8	Protein biomarker;
CRC	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	0.57	8.85	0.44	5.32e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.64	8.66	0.43	2.14e-16	Multiple sclerosis;
CRC	cis	rs79387448	0.683	rs7571985	chr2:103147561	G/A	cg09003973	chr2:102972529	NA	0.73	8.11	0.41	9.98e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.46	-7.23	-0.37	3.33e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03813033	chr19:50380022	AKT1S1;TBC1D17	0.44	6.34	0.33	7.64e-10	Response to antipsychotic treatment;
CRC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.48	-7.6	-0.39	3.02e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1322512	1.000	rs1282551	chr6:153009944	C/T	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.66	-0.39	2.12e-13	Hemoglobin concentration;
CRC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.22e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.56	-8.64	-0.43	2.46e-16	Tonometry;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg03623178	chr6:28175578	NA	1.0	15.19	0.64	7.35e-40	Depression;
CRC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.41	-6.37	-0.33	6.52e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2077654	0.822	rs4148634	chr11:17429872	G/A	cg25308976	chr11:17434268	ABCC8	0.81	7.97	0.4	2.55e-14	Gout;
CRC	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg25856811	chr1:152973957	SPRR3	-0.25	-7.05	-0.36	1.07e-11	Inflammatory skin disease;
CRC	cis	rs11122895	0.610	rs13397902	chr2:112607505	G/C	cg23215929	chr2:112641879	ANAPC1	-0.41	-5.94	-0.31	7.16e-9	Allergic sensitization;
CRC	cis	rs1561198	0.523	rs2118177	chr2:85890293	A/G	cg02493740	chr2:85810744	VAMP5	-0.38	-5.78	-0.3	1.73e-8	Coronary artery disease;
CRC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	7.8	0.39	8.34e-14	Monocyte count;
CRC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	10.42	0.5	3.84e-22	Motion sickness;
CRC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg09417038	chr21:47716443	C21orf57	-0.5	-8.38	-0.42	1.53e-15	Testicular germ cell tumor;
CRC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.58	0.63	1.75e-37	Breast cancer;
CRC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.72	-7.86	-0.4	5.63e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-5.91	-0.31	8.34e-9	Diabetic retinopathy;
CRC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.58	-10.47	-0.5	2.47e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.56	-8.84	-0.44	5.8e-17	Motion sickness;
CRC	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-0.98	-13.52	-0.6	1.98e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.43	5.62	0.3	4e-8	Coronary artery disease;
CRC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.08	19.02	0.72	5.97e-55	Cognitive function;
CRC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.64	-9.45	-0.46	6.43e-19	Pancreatic cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20401393	chr6:4135757	PECI	0.44	6.55	0.34	2.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.5	-6.97	-0.36	1.72e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg25164649	chr6:28176230	NA	0.64	9.04	0.45	1.41e-17	Cardiac Troponin-T levels;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg08551088	chr10:121631655	C10orf119	-0.46	-6.07	-0.32	3.6e-9	Lung cancer;
CRC	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.67	6.84	0.35	3.99e-11	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14723799	chr14:50101089	C14orf104	0.42	6.27	0.33	1.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg20608306	chr11:116969690	SIK3	-0.35	-6.74	-0.35	6.96e-11	Subjective well-being;
CRC	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.07	-0.45	1.08e-17	Bone mineral density;
CRC	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.45	-6.74	-0.35	6.9e-11	Crohn's disease;
CRC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.16	0.32	2.13e-9	Melanoma;
CRC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-5.85	-0.31	1.22e-8	Lung cancer;
CRC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.42	5.84	0.31	1.27e-8	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs7690467	0.794	rs62318144	chr4:133394581	C/T	cg19296258	chr17:78878799	RPTOR	-0.47	-6.23	-0.32	1.42e-9	Eating disorders;
CRC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.51	7.25	0.37	2.95e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.74	12.89	0.58	4.56e-31	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11808854	chr20:60697627	LSM14B	0.36	6.3	0.33	9.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.02	0.4	1.92e-14	Lung cancer;
CRC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.54	9.91	0.48	2.03e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg06766960	chr11:133703094	NA	-0.32	-5.68	-0.3	2.89e-8	Childhood ear infection;
CRC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg04880052	chr2:219191631	PNKD	-0.39	-5.9	-0.31	9.12e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg09040174	chr2:113837401	NA	-0.43	-5.78	-0.3	1.74e-8	Protein quantitative trait loci;
CRC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-11.73	-0.54	8.92e-27	Initial pursuit acceleration;
CRC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.36	-0.38	1.53e-12	Height;
CRC	cis	rs3849570	0.643	rs6797240	chr3:81971856	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-6.42	-0.33	4.89e-10	Waist circumference;Body mass index;
CRC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.49	-0.34	3.2e-10	Body mass index;
CRC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.88	11.02	0.52	3.07e-24	Nonalcoholic fatty liver disease;
CRC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.1	-15.9	-0.66	1.25e-42	Hip circumference adjusted for BMI;
CRC	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg13491945	chr12:107078410	RFX4	0.35	6.0	0.31	5.12e-9	Heart rate;
CRC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.14	0.32	2.31e-9	Bipolar disorder;
CRC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs524281	0.731	rs2276036	chr11:66033430	C/T	cg14036092	chr11:66035641	RAB1B	-0.55	-6.04	-0.32	4.16e-9	Electroencephalogram traits;
CRC	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg02770688	chr6:168491649	NA	0.63	9.28	0.46	2.38e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.42	-0.5	3.73e-22	Chronic sinus infection;
CRC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.42e-9	Red blood cell count;
CRC	cis	rs10128264	0.609	rs1250591	chr10:80985374	A/G	cg20744163	chr10:80999841	ZMIZ1	-0.34	-6.0	-0.31	5.23e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.38e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.46	-6.53	-0.34	2.5e-10	Height;
CRC	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.66	-0.39	2.11e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.52	0.46	3.79e-19	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg17903999	chr18:56338584	MALT1	-0.4	-6.38	-0.33	6.05e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.72	15.63	0.65	1.47e-41	Breast cancer;
CRC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.45	7.22	0.37	3.62e-12	Menopause (age at onset);
CRC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg10820045	chr2:198174542	NA	0.48	8.41	0.42	1.24e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg11189052	chr15:85197271	WDR73	0.63	8.87	0.44	4.87e-17	Schizophrenia;
CRC	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.37	5.74	0.3	2.18e-8	Monocyte percentage of white cells;
CRC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.55	9.04	0.45	1.34e-17	Age at first birth;
CRC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.83	-0.35	4.19e-11	Lung cancer;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.29e-11	Alzheimer's disease;
CRC	cis	rs6504622	0.557	rs11654971	chr17:44998563	G/A	cg16759221	chr17:45003025	GOSR2	0.6	9.66	0.47	1.33e-19	Orofacial clefts;
CRC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg12573674	chr2:1569213	NA	-0.76	-7.84	-0.4	6.48e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.55	9.21	0.45	3.94e-18	Prostate cancer;
CRC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.03	0.4	1.71e-14	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.61	10.2	0.49	2.05e-21	Prudent dietary pattern;
CRC	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.42	-6.73	-0.35	7.57e-11	Corneal astigmatism;
CRC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06544989	chr22:39130855	UNC84B	0.45	6.92	0.36	2.35e-11	Menopause (age at onset);
CRC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.63	-8.03	-0.4	1.73e-14	Gut microbiome composition (summer);
CRC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.59	-10.69	-0.51	4.21e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.45	0.38	8.04e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	7.81	0.4	7.88e-14	Educational attainment;
CRC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.67	8.91	0.44	3.47e-17	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs6479874	0.680	rs2660213	chr10:52742229	C/A	cg15483030	chr1:5935144	NPHP4	-0.71	-6.38	-0.33	6.07e-10	Migraine;
CRC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.48	6.26	0.33	1.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7605827	0.704	rs2160695	chr2:15673478	T/A	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg22532475	chr10:104410764	TRIM8	0.34	5.8	0.3	1.58e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.63	-10.38	-0.5	5.03e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.42	-0.33	4.82e-10	Lymphocyte counts;
CRC	cis	rs4132509	1.000	rs320320	chr1:243835186	A/G	cg21452805	chr1:244014465	NA	0.42	5.76	0.3	1.98e-8	RR interval (heart rate);
CRC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.58	-0.47	2.54e-19	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.5	5.98	0.31	5.71e-9	Depression;
CRC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.27	0.33	1.16e-9	Blood metabolite levels;
CRC	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg15816464	chr17:2026533	SMG6	0.37	6.16	0.32	2.12e-9	Total body bone mineral density;
CRC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.63	10.57	0.5	1.12e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.54	-0.38	4.73e-13	Putamen volume;
CRC	cis	rs995000	0.899	rs11207985	chr1:63013786	A/G	cg19896129	chr1:63156450	NA	-0.44	-6.82	-0.35	4.3e-11	Triglyceride levels;
CRC	cis	rs354033	0.959	rs354041	chr7:149297035	A/C	cg24335155	chr7:149193227	ZNF746	0.39	6.2	0.32	1.65e-9	Multiple sclerosis;
CRC	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg09163369	chr1:210001066	C1orf107	0.6	7.74	0.39	1.26e-13	Orofacial clefts;
CRC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.57	9.24	0.45	3.19e-18	Gout;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg04923388	chr5:41904550	C5orf51	-0.42	-6.25	-0.33	1.3e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.36	8.02	0.4	1.89e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg00166722	chr3:10149974	C3orf24	0.69	7.99	0.4	2.25e-14	Alzheimer's disease;
CRC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg21770322	chr7:97807741	LMTK2	0.54	9.03	0.45	1.52e-17	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.72	-11.23	-0.53	5.47e-25	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg24463073	chr6:118973353	C6orf204	-0.51	-7.0	-0.36	1.44e-11	Diastolic blood pressure;
CRC	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06505273	chr16:24850292	NA	-0.48	-5.86	-0.31	1.15e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02450064	chr17:40260053	DHX58	-0.42	-6.11	-0.32	2.88e-9	Fibrinogen levels;
CRC	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.83	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.39	7.55	0.38	4.32e-13	Ulcerative colitis;
CRC	cis	rs10986311	0.802	rs7049097	chr9:127110457	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.41	6.17	0.32	2.04e-9	Vitiligo;
CRC	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.75	13.67	0.6	5.57e-34	Anterior chamber depth;
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg01472538	chr16:58549086	SETD6	1.12	7.38	0.38	1.3e-12	Schizophrenia;
CRC	trans	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.24	0.33	1.38e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg00738113	chr16:70207722	CLEC18C	-0.44	-6.65	-0.34	1.23e-10	IgE levels;
CRC	cis	rs4731207	0.624	rs1031955	chr7:124710858	G/C	cg23710748	chr7:124431027	NA	-0.4	-6.28	-0.33	1.07e-9	Cutaneous malignant melanoma;
CRC	cis	rs12230513	0.732	rs61957760	chr12:55859957	G/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.22	-0.45	3.61e-18	Contrast sensitivity;
CRC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12463550	chr7:65579703	CRCP	0.61	6.0	0.31	5.22e-9	Diabetic kidney disease;
CRC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.74	7.93	0.4	3.51e-14	Cognitive function;
CRC	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.6	0.34	1.69e-10	Neuroticism;
CRC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.8	0.51	1.8e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg19812747	chr11:111475976	SIK2	-0.53	-8.86	-0.44	5.06e-17	Primary sclerosing cholangitis;
CRC	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg18646521	chr2:111875858	NA	0.37	5.85	0.31	1.19e-8	Chronic lymphocytic leukemia;
CRC	cis	rs6973256	0.897	rs7777805	chr7:133337074	T/C	cg10665199	chr7:133106180	EXOC4	-0.37	-5.66	-0.3	3.26e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.49	-6.73	-0.35	7.53e-11	Intelligence (multi-trait analysis);
CRC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.59	8.69	0.43	1.73e-16	Height;
CRC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg02089348	chr4:1724449	TMEM129;TACC3	0.42	6.04	0.32	4.26e-9	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg13010199	chr12:38710504	ALG10B	0.44	6.29	0.33	1e-9	Morning vs. evening chronotype;
CRC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	1.06	12.3	0.56	7.46e-29	Iron status biomarkers;
CRC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.35	5.64	0.3	3.57e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.85	-9.22	-0.45	3.76e-18	Breast cancer;
CRC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.45	-6.47	-0.34	3.48e-10	Asthma;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg07217954	chr7:1067459	C7orf50	0.49	5.8	0.3	1.6e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.62	11.25	0.53	4.6e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.87	17.62	0.7	2.1e-49	White blood cell count;
CRC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.62	11.18	0.52	8.15e-25	Schizophrenia;
CRC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-11.26	-0.53	4.44e-25	Chronic sinus infection;
CRC	cis	rs7605827	0.930	rs6753645	chr2:15539556	G/C	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs2486012	0.737	rs6691988	chr1:44254402	A/G	cg12908607	chr1:44402522	ARTN	0.41	6.08	0.32	3.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.63	-7.43	-0.38	9.66e-13	Vitiligo;
CRC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.67	11.33	0.53	2.35e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.596	rs6466990	chr7:124691512	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.28	-0.33	1.09e-9	Cutaneous malignant melanoma;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.23	-0.32	1.41e-9	Total body bone mineral density;
CRC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02018176	chr4:1364513	KIAA1530	0.4	6.63	0.34	1.37e-10	Obesity-related traits;
CRC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.27	0.45	2.6e-18	Bladder cancer;
CRC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.5	8.75	0.43	1.13e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16078938	chr7:6769406	NA	0.39	6.0	0.31	5.19e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg27523141	chr10:43048294	ZNF37B	0.45	6.5	0.34	2.94e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.77	-9.22	-0.45	3.61e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.47	6.75	0.35	6.69e-11	Breast cancer;
CRC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	6.01	0.31	4.82e-9	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05682094	chr20:5108045	PCNA;CDS2	0.43	6.25	0.33	1.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.7	8.96	0.44	2.46e-17	Bladder cancer;
CRC	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.8	0.44	7.96e-17	Coffee consumption (cups per day);
CRC	cis	rs6681460	1.000	rs7532173	chr1:67086111	A/G	cg02459107	chr1:67143332	SGIP1	0.4	6.78	0.35	5.6e-11	Presence of antiphospholipid antibodies;
CRC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	8.95	0.44	2.71e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg15147215	chr3:52552868	STAB1	-0.42	-5.94	-0.31	7.43e-9	Bipolar disorder;
CRC	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.08	14.73	0.63	4.38e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg10298567	chr3:47292165	KIF9	0.44	7.19	0.37	4.39e-12	Colorectal cancer;
CRC	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.59	9.13	0.45	7.15e-18	HDL cholesterol;
CRC	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.54	7.83	0.4	6.59e-14	Multiple sclerosis;
CRC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.82	15.15	0.64	1.04e-39	Mean platelet volume;
CRC	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.53	-0.34	2.54e-10	Neuroticism;
CRC	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.82	-14.37	-0.62	1.11e-36	Hip circumference;
CRC	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.67	-9.83	-0.48	3.77e-20	Body mass index;
CRC	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg21521518	chr4:53727714	RASL11B	0.41	6.07	0.32	3.56e-9	Optic nerve measurement (cup area);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	0.38	6.01	0.31	4.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg18761221	chr20:60518478	NA	-0.54	-8.39	-0.42	1.41e-15	Body mass index;
CRC	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg04132472	chr17:19861366	AKAP10	0.42	6.31	0.33	9.1e-10	Schizophrenia;
CRC	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg22561889	chr6:118971681	C6orf204	0.53	6.92	0.36	2.43e-11	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19125323	chr17:74733470	MIR636;SFRS2;MFSD11	0.38	5.98	0.31	5.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.96	-0.31	6.36e-9	Neuroticism;
CRC	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.91	-0.31	8.42e-9	Pulmonary function;
CRC	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.44	-6.56	-0.34	2.14e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.47e-8	Total body bone mineral density;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.37	-0.33	6.28e-10	Parkinson's disease;
CRC	cis	rs868943	0.582	rs12214665	chr6:116466990	G/A	cg15226275	chr6:116381976	FRK	0.26	6.08	0.32	3.31e-9	Total cholesterol levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20357023	chr2:178417605	TTC30B	-0.41	-6.03	-0.32	4.45e-9	Daytime sleep phenotypes;
CRC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.95	11.96	0.55	1.24e-27	Exhaled nitric oxide levels;
CRC	cis	rs1223397	0.651	rs2496148	chr6:13313553	A/G	cg20827128	chr6:13274284	PHACTR1	0.38	5.78	0.3	1.75e-8	Blood pressure;
CRC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg13072238	chr3:49761600	GMPPB	0.53	5.81	0.31	1.48e-8	Menarche (age at onset);
CRC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg13047869	chr3:10149882	C3orf24	0.52	6.06	0.32	3.74e-9	Alzheimer's disease;
CRC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg27661571	chr11:113659931	NA	-0.94	-10.92	-0.52	7.04e-24	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.83	-0.55	3.95e-27	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09284707	chr11:107799080	RAB39	0.32	6.41	0.33	4.95e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg19336497	chr11:14380999	RRAS2	-0.34	-5.69	-0.3	2.76e-8	Vitamin D levels;
CRC	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg02023728	chr11:77925099	USP35	-0.38	-6.33	-0.33	7.88e-10	Alzheimer's disease (survival time);
CRC	cis	rs11212617	0.837	rs2070661	chr11:108043988	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.4	6.02	0.32	4.6e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.61	-9.39	-0.46	1.02e-18	Aortic root size;
CRC	cis	rs2380220	0.808	rs2716070	chr6:95912375	T/C	cg04719120	chr6:96025338	MANEA	-0.53	-5.88	-0.31	9.93e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.0	-0.31	5.21e-9	Neuroticism;
CRC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.89	17.32	0.69	3.19e-48	Migraine;
CRC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.36	11.14	0.52	1.1e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.57	-8.32	-0.42	2.41e-15	IgG glycosylation;
CRC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg14711859	chr11:8959438	ASCL3	0.46	7.53	0.38	4.82e-13	Hemoglobin concentration;
CRC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.79	13.38	0.59	6.65e-33	Menopause (age at onset);
CRC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.5	7.71	0.39	1.55e-13	Corneal astigmatism;
CRC	cis	rs11627756	0.958	rs2146429	chr14:103071816	A/T	cg12046867	chr14:103022105	NA	-0.42	-5.77	-0.3	1.81e-8	Mean platelet volume;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.45	0.42	9.82e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7225537	0.559	rs7214429	chr17:17059872	A/G	cg26176665	chr17:16994978	MPRIP	-0.36	-5.81	-0.3	1.5e-8	Mean platelet volume;
CRC	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.74	10.56	0.5	1.18e-22	Neutrophil percentage of white cells;
CRC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.49	7.77	0.39	1e-13	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01074628	chr11:74204917	LIPT2	0.43	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs62408225	1.000	rs62408237	chr6:90980345	C/G	cg06866423	chr6:90926672	BACH2	0.47	7.85	0.4	6.01e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.86	-11.19	-0.52	7.81e-25	Lung disease severity in cystic fibrosis;
CRC	trans	rs7730934	1.000	rs6894414	chr5:55252495	A/G	cg10323188	chr3:28613979	NA	0.52	6.11	0.32	2.84e-9	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00222291	chr16:22385662	CDR2	0.41	6.21	0.32	1.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.49	-7.78	-0.39	9.16e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.27	-0.53	3.95e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.75	-0.35	6.62e-11	Alzheimer's disease (late onset);
CRC	cis	rs16852403	0.548	rs623225	chr1:178211322	C/A	cg00404053	chr1:178313656	RASAL2	-0.48	-6.37	-0.33	6.21e-10	Childhood ear infection;
CRC	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg09904177	chr6:26538194	HMGN4	-0.42	-5.81	-0.3	1.51e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.53	6.35	0.33	7.35e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg14711859	chr11:8959438	ASCL3	0.55	9.86	0.48	3e-20	Hematocrit;
CRC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg19980929	chr12:42632907	YAF2	0.41	6.18	0.32	1.86e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg04166393	chr7:2884313	GNA12	0.54	7.28	0.37	2.5e-12	Height;
CRC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-13.3	-0.59	1.29e-32	Height;
CRC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4363385	0.818	rs653332	chr1:153010481	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	trans	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.4	-0.33	5.39e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.52	7.64	0.39	2.33e-13	Aortic root size;
CRC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.7e-8	Prudent dietary pattern;
CRC	cis	rs3790844	0.876	rs61486545	chr1:200008337	G/A	cg13229857	chr1:200006247	NR5A2	0.51	7.1	0.36	7.83e-12	Pancreatic cancer;
CRC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.42	7.22	0.37	3.58e-12	Primary biliary cholangitis;
CRC	cis	rs7107770	0.663	rs893973	chr11:125073643	C/A	cg27629782	chr11:125073726	PKNOX2	0.5	7.17	0.37	4.87e-12	Photic sneeze reflex;
CRC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.39	0.46	1.03e-18	Menopause (age at onset);
CRC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg23920097	chr1:209922102	NA	-0.54	-6.19	-0.32	1.79e-9	Red blood cell count;
CRC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg22834771	chr12:69754056	YEATS4	-0.41	-5.97	-0.31	6.17e-9	Blood protein levels;
CRC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	9.01	0.44	1.75e-17	Schizophrenia;
CRC	cis	rs2223471	0.692	rs9357674	chr6:50779740	A/G	cg03432817	chr6:50765336	NA	0.37	5.8	0.3	1.58e-8	Subcutaneous adipose tissue;
CRC	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg09184832	chr6:79620586	NA	-0.43	-7.32	-0.37	1.87e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg20573242	chr4:122745356	CCNA2	0.42	6.29	0.33	9.89e-10	Type 2 diabetes;
CRC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.39	6.77	0.35	5.97e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg12279128	chr22:24109851	CHCHD10	-0.43	-6.48	-0.34	3.28e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.76	10.29	0.49	9.95e-22	Cognitive function;
CRC	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.97	-0.36	1.73e-11	Type 2 diabetes;
CRC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.71	-0.35	8.3e-11	Blood metabolite levels;
CRC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08703324	chr15:43785408	TP53BP1	-0.41	-6.21	-0.32	1.61e-9	Daytime sleep phenotypes;
CRC	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg04989706	chr14:50066350	PPIL5	-0.55	-7.53	-0.38	4.78e-13	Carotid intima media thickness;
CRC	cis	rs185694	1.000	rs202099	chr13:30896874	C/T	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.33	-0.33	7.8e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg00852783	chr1:26633632	UBXN11	-0.51	-5.98	-0.31	5.68e-9	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21257117	chr11:65029643	POLA2	-0.51	-6.09	-0.32	3.21e-9	Diisocyanate-induced asthma;
CRC	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.74	-0.3	2.16e-8	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-6.19	-0.32	1.77e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.74	-0.39	1.27e-13	Gut microbiome composition (summer);
CRC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	21.61	0.77	4.37e-65	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.17	-0.37	4.96e-12	Life satisfaction;
CRC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.58	6.48	0.34	3.27e-10	Bipolar disorder;
CRC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.73	-0.3	2.25e-8	Diabetic kidney disease;
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.8	0.35	4.85e-11	Alzheimer's disease;
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg08222913	chr3:52553049	STAB1	-0.35	-6.47	-0.34	3.65e-10	Bipolar disorder;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.17	-0.37	5.09e-12	Blood metabolite levels;
CRC	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg15192750	chr16:69999425	NA	0.57	7.72	0.39	1.42e-13	IgE levels;
CRC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg07423050	chr13:99094983	FARP1	-0.43	-6.49	-0.34	3.24e-10	Educational attainment (years of education);
CRC	trans	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.23	0.32	1.39e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg20684491	chr1:25596433	NA	0.43	7.46	0.38	7.77e-13	Erythrocyte sedimentation rate;
CRC	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg08501292	chr6:25962987	TRIM38	0.56	5.92	0.31	7.89e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg19318889	chr4:1322082	MAEA	0.4	5.97	0.31	6.21e-9	Obesity-related traits;
CRC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.41	-6.94	-0.36	2.08e-11	Mean platelet volume;
CRC	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg12756093	chr1:115239321	AMPD1	0.56	8.36	0.42	1.83e-15	Autism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21195395	chr19:5981162	NA	-0.44	-7.36	-0.38	1.48e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.48	-6.31	-0.33	8.85e-10	Systemic lupus erythematosus;
CRC	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.14	11.67	0.54	1.46e-26	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg21620606	chr4:1342894	KIAA1530	0.34	5.84	0.31	1.24e-8	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.27	-14.68	-0.63	7.35e-38	Diabetic kidney disease;
CRC	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.5	0.42	6.55e-16	Coffee consumption (cups per day);
CRC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.88	-16.0	-0.66	5.02e-43	Obesity-related traits;
CRC	cis	rs10979	0.571	rs6909701	chr6:143922918	C/G	cg25407410	chr6:143891975	LOC285740	-0.59	-7.52	-0.38	5.32e-13	Hypospadias;
CRC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.58	5.84	0.31	1.24e-8	Fat distribution (HIV);
CRC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg21251018	chr6:28226885	NKAPL	0.41	6.0	0.31	5.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg24848437	chr7:2645542	IQCE	0.63	6.26	0.33	1.21e-9	Urate levels in lean individuals;
CRC	cis	rs1223397	0.651	rs202022	chr6:13302931	A/G	cg07912922	chr6:13274314	PHACTR1	-0.38	-5.99	-0.31	5.39e-9	Blood pressure;
CRC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.02	-0.32	4.63e-9	Alzheimer's disease (late onset);
CRC	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.53	7.57	0.39	3.68e-13	Response to antidepressants and depression;
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.98	21.04	0.76	6.92e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.83	13.81	0.61	1.53e-34	Tonsillectomy;
CRC	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.55	6.26	0.33	1.22e-9	Schizophrenia;
CRC	cis	rs12431939	0.744	rs12888250	chr14:51669195	C/G	cg23942311	chr14:51606299	NA	0.49	6.79	0.35	5.35e-11	Cancer;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.71	-11.18	-0.52	8.44e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.81	-13.82	-0.61	1.41e-34	Cystic fibrosis severity;
CRC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg10263370	chr3:44754102	ZNF502	-0.36	-5.92	-0.31	7.94e-9	Depressive symptoms;
CRC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.44	-6.53	-0.34	2.51e-10	Body mass index;
CRC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg23262073	chr20:60523788	NA	-0.47	-7.24	-0.37	3.29e-12	Body mass index;
CRC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.46	6.34	0.33	7.79e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.6	8.52	0.43	5.92e-16	DNA methylation (variation);
CRC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg21770322	chr7:97807741	LMTK2	0.5	8.12	0.41	9.48e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg20356878	chr3:121714668	ILDR1	0.49	6.94	0.36	2.11e-11	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15655138	chr6:37139981	PIM1	0.46	6.4	0.33	5.39e-10	Response to antipsychotic treatment;
CRC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.56	6.43	0.33	4.42e-10	Bipolar disorder;
CRC	trans	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg05376469	chr2:102649931	NA	-0.36	-6.03	-0.32	4.51e-9	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	7.54	0.38	4.77e-13	Corneal astigmatism;
CRC	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.49	-8.82	-0.44	6.68e-17	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg16576597	chr16:28551801	NUPR1	-0.48	-6.65	-0.34	1.19e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.94	-0.31	7.08e-9	Subjective well-being;
CRC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg00246817	chr9:123691163	NA	-0.47	-6.04	-0.32	4.11e-9	Rheumatoid arthritis;
CRC	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.85	10.54	0.5	1.43e-22	Uric acid levels;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.76	11.55	0.54	4.05e-26	Menarche (age at onset);
CRC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16262614	chr3:133464971	TF	-0.32	-5.66	-0.3	3.36e-8	Iron status biomarkers;
CRC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.67	-10.1	-0.49	4.64e-21	Other erythrocyte phenotypes;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21211053	chr19:49496578	GYS1;RUVBL2	-0.38	-6.42	-0.33	4.67e-10	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.19	-0.49	2.18e-21	Total cholesterol levels;
CRC	trans	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs447	1.000	rs2067693	chr7:83759570	C/T	cg22846510	chr7:83753280	SEMA3A	-0.61	-7.79	-0.39	8.85e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18357526	chr6:26021779	HIST1H4A	0.41	5.8	0.3	1.54e-8	Height;
CRC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg25985355	chr7:65971099	NA	0.51	6.0	0.31	5.23e-9	Diabetic kidney disease;
CRC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-8.25	-0.41	3.74e-15	Hemoglobin concentration;
CRC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.57	-0.39	3.84e-13	Chronic sinus infection;
CRC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.75	9.05	0.45	1.3e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs73206853	0.841	rs56324794	chr12:111086449	T/A	cg12870014	chr12:110450643	ANKRD13A	0.71	7.52	0.38	5.25e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs11212617	0.902	rs61913892	chr11:108340216	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.41	6.1	0.32	2.99e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg11553311	chr5:66541588	NA	0.48	8.12	0.41	9.49e-15	Breast cancer;
CRC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg11915388	chr22:42470451	FAM109B	-0.43	-6.51	-0.34	2.85e-10	Schizophrenia;
CRC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.52	-7.66	-0.39	2.03e-13	Blood protein levels;
CRC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg14673194	chr17:80132900	CCDC57	0.47	6.07	0.32	3.51e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.13	10.49	0.5	2.13e-22	Skin colour saturation;
CRC	cis	rs11997175	0.546	rs10808337	chr8:33583850	T/C	cg04338863	chr8:33670619	NA	0.37	6.16	0.32	2.14e-9	Body mass index;
CRC	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs7264396	0.887	rs1886696	chr20:34055706	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.35	-5.68	-0.3	3.01e-8	Total cholesterol levels;
CRC	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.56e-11	Opioid sensitivity;
CRC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	27.61	0.84	1.1e-87	Testicular germ cell tumor;
CRC	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00495681	chr13:53174319	NA	0.62	9.32	0.46	1.72e-18	Lewy body disease;
CRC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.01	-0.31	4.86e-9	Depression;
CRC	cis	rs4664293	0.669	rs13389096	chr2:160467757	G/A	cg08347373	chr2:160653686	CD302	-0.39	-6.55	-0.34	2.16e-10	Monocyte percentage of white cells;
CRC	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.75	-10.84	-0.51	1.27e-23	Blood protein levels;
CRC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.56	8.47	0.42	8.43e-16	Aortic root size;
CRC	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.65	-7.86	-0.4	5.5e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.57	-0.39	3.7e-13	Body mass index;
CRC	cis	rs2735413	0.881	rs12919672	chr16:78082760	C/G	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.62	-6.82	-0.35	4.29e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.84	14.9	0.63	1.01e-38	Breast cancer;
CRC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.16	0.32	2.15e-9	Aortic root size;
CRC	cis	rs911119	0.866	rs6048925	chr20:23579056	C/A	cg16589663	chr20:23618590	CST3	0.41	5.74	0.3	2.16e-8	Chronic kidney disease;
CRC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.21	0.69	8.33e-48	Platelet count;
CRC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg00343986	chr7:65444356	GUSB	-0.47	-6.88	-0.35	3.09e-11	Calcium levels;
CRC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.68	8.49	0.42	7.22e-16	Platelet count;
CRC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.46	6.3	0.33	9.7e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.67	9.4	0.46	9.55e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.36	5.65	0.3	3.42e-8	Monocyte percentage of white cells;
CRC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.62	7.4	0.38	1.18e-12	Cleft lip with or without cleft palate;
CRC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.93	0.36	2.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg18404041	chr3:52824283	ITIH1	0.37	7.29	0.37	2.29e-12	Schizophrenia;
CRC	cis	rs524281	0.861	rs3825067	chr11:65878419	A/G	cg14036092	chr11:66035641	RAB1B	0.46	5.66	0.3	3.3e-8	Electroencephalogram traits;
CRC	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.48	-6.82	-0.35	4.34e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.64	-0.3	3.61e-8	Life satisfaction;
CRC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.47	0.53	7.45e-26	Hip circumference adjusted for BMI;
CRC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.52	-9.44	-0.46	7.29e-19	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.58	-0.75	4.39e-61	Height;
CRC	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.39	-0.38	1.19e-12	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.83	13.48	0.6	2.7e-33	Menarche (age at onset);
CRC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.51	-9.6	-0.47	2.19e-19	Eye color traits;
CRC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16447950	chr5:562315	NA	-0.74	-9.73	-0.47	7.89e-20	Obesity-related traits;
CRC	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.23	-0.32	1.42e-9	Neuroticism;
CRC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.48	6.49	0.34	3.07e-10	Schizophrenia;
CRC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.42	-6.17	-0.32	2.04e-9	Ulcerative colitis;
CRC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.72	-10.79	-0.51	2.01e-23	Platelet distribution width;
CRC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg15845792	chr6:28175446	NA	0.73	6.16	0.32	2.08e-9	Depression;
CRC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06505273	chr16:24850292	NA	0.47	5.69	0.3	2.77e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs10924970	0.967	rs10925270	chr1:235425875	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.76	0.3	1.93e-8	Asthma;
CRC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.51	7.19	0.37	4.25e-12	Melanoma;
CRC	cis	rs4731207	0.698	rs34600520	chr7:124490938	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	1.14	9.9	0.48	2.19e-20	Mitochondrial DNA levels;
CRC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	24.82	0.81	2.21e-77	IgG glycosylation;
CRC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg20203395	chr5:56204925	C5orf35	-0.8	-8.73	-0.43	1.34e-16	Initial pursuit acceleration;
CRC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.13	-13.15	-0.59	4.8e-32	Diabetic kidney disease;
CRC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.55	9.88	0.48	2.46e-20	HDL cholesterol levels;
CRC	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg21064579	chr19:49206444	FUT2	0.47	8.26	0.41	3.51e-15	Dietary macronutrient intake;
CRC	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.58	-8.65	-0.43	2.25e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.49	8.09	0.41	1.2e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	trans	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg17903999	chr18:56338584	MALT1	0.43	7.01	0.36	1.36e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg20041105	chr8:143859282	LYNX1	0.55	9.87	0.48	2.7e-20	Urinary tract infection frequency;
CRC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.71	0.51	3.68e-23	Prudent dietary pattern;
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg13957321	chr17:43675089	NA	0.49	6.18	0.32	1.94e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg16141378	chr3:129829833	LOC729375	-0.46	-6.56	-0.34	2.12e-10	Platelet distribution width;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg07507251	chr3:52567010	NT5DC2	-0.49	-7.06	-0.36	9.91e-12	Bipolar disorder;
CRC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00791764	chr4:53727839	RASL11B	0.51	6.9	0.36	2.73e-11	Optic nerve measurement (cup area);
CRC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg03959625	chr15:84868606	LOC388152	0.42	6.33	0.33	8.21e-10	Schizophrenia;
CRC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.14	27.71	0.84	4.8e-88	Testicular germ cell tumor;
CRC	cis	rs9549328	0.670	rs2993344	chr13:113617022	C/T	cg08614441	chr13:113633676	MCF2L	0.4	7.12	0.37	6.64e-12	Systolic blood pressure;
CRC	cis	rs12580194	0.593	rs7314118	chr12:55737403	A/C	cg19537932	chr12:55886519	OR6C68	-0.66	-8.5	-0.42	6.6e-16	Cancer;
CRC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.86	-11.13	-0.52	1.25e-24	Lung disease severity in cystic fibrosis;
CRC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	6.26	0.33	1.22e-9	Schizophrenia;
CRC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.11	0.32	2.82e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs354033	1.000	rs11766910	chr7:149279620	C/T	cg24335155	chr7:149193227	ZNF746	0.36	5.63	0.3	3.93e-8	Multiple sclerosis;
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-8.01	-0.4	1.96e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.49	8.05	0.41	1.58e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.8	0.3	1.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.2	0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.39	-0.33	5.73e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.39	-5.62	-0.3	4.1e-8	Body mass index;
CRC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs9903692	0.954	rs9909933	chr17:46280232	G/T	cg21215337	chr17:46176117	CBX1	0.43	7.83	0.4	6.68e-14	Pulse pressure;
CRC	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00495681	chr13:53174319	NA	0.64	9.57	0.47	2.75e-19	Lewy body disease;
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.95	-0.36	1.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs800160	0.582	rs2521286	chr11:2341971	G/A	cg09785033	chr11:2336066	TSPAN32	-0.46	-5.64	-0.3	3.74e-8	Bacteremia;
CRC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.6	-10.98	-0.52	4.06e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7259376	0.869	rs6511346	chr19:22537574	T/C	cg02657401	chr19:22469223	NA	-0.32	-6.8	-0.35	4.8e-11	Menopause (age at onset);
CRC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.42	-0.42	1.14e-15	Neuroticism;
CRC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.22	-0.49	1.76e-21	Bipolar disorder;
CRC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.8	-11.68	-0.54	1.36e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-8.15	-0.41	7.53e-15	Bipolar disorder;
CRC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.58	9.81	0.48	4.43e-20	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg23590916	chr17:43697445	MGC57346	-0.57	-6.03	-0.32	4.4e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg27535305	chr1:53392650	SCP2	0.34	6.1	0.32	2.9e-9	Monocyte count;
CRC	cis	rs10982256	0.967	rs10982246	chr9:117250393	A/G	cg13636371	chr9:117264095	DFNB31	0.38	7.32	0.37	1.88e-12	Bipolar disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06019692	chr13:20207818	MPHOSPH8	0.38	6.01	0.31	4.97e-9	Schizophrenia;
CRC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.57	9.23	0.45	3.51e-18	Coronary artery disease;
CRC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	0.38	5.91	0.31	8.77e-9	Breast cancer;
CRC	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	7.51	0.38	5.51e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.44	6.95	0.36	1.94e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.24	-0.33	1.35e-9	Bipolar disorder;
CRC	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.58	-0.72	3.5e-53	Schizophrenia;
CRC	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	7.29	0.37	2.3e-12	LDL cholesterol;
CRC	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	0.79	8.09	0.41	1.18e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg02574844	chr11:5959923	NA	-0.43	-5.75	-0.3	2.05e-8	DNA methylation (variation);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04402966	chr7:87505783	SLC25A40;DBF4	0.4	6.24	0.33	1.36e-9	Response to antipsychotic treatment;
CRC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs12580194	0.593	rs12578879	chr12:55797773	C/T	cg19537932	chr12:55886519	OR6C68	-0.72	-9.09	-0.45	9.43e-18	Cancer;
CRC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.52	-6.0	-0.31	5.07e-9	Bipolar disorder;
CRC	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg12193833	chr17:30244370	NA	-0.64	-8.13	-0.41	8.94e-15	Hip circumference adjusted for BMI;
CRC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg23957660	chr17:17878224	LRRC48	0.38	6.83	0.35	4.2e-11	Total body bone mineral density;
CRC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.34	-0.42	2.12e-15	Hemoglobin concentration;
CRC	cis	rs7539542	0.556	rs6686801	chr1:202874730	C/T	cg19681188	chr1:202830198	LOC148709	0.47	6.8	0.35	4.94e-11	Mean platelet volume;
CRC	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.79	16.07	0.66	2.57e-43	Leprosy;
CRC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.65	-0.34	1.21e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.67	-8.04	-0.41	1.67e-14	Vitamin D levels;
CRC	cis	rs3018066	0.867	rs6843331	chr4:106958304	C/T	cg01869342	chr4:106983673	TBCK	0.42	6.43	0.33	4.38e-10	Cancer;
CRC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06544989	chr22:39130855	UNC84B	0.46	7.41	0.38	1.08e-12	Menopause (age at onset);
CRC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.5	-8.03	-0.4	1.76e-14	Caffeine consumption;
CRC	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.93	-0.36	2.27e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.45	-5.78	-0.3	1.77e-8	Aortic root size;
CRC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs3956705	0.933	rs13311772	chr7:32999810	C/T	cg05721444	chr7:32995514	FKBP9	-0.5	-7.2	-0.37	4.01e-12	Red cell distribution width;
CRC	trans	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg17903999	chr18:56338584	MALT1	0.44	7.16	0.37	5.3e-12	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2048656	0.635	rs7830613	chr8:9649769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.89	-0.36	2.88e-11	Schizophrenia;
CRC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.36	6.81	0.35	4.64e-11	QRS complex (12-leadsum);
CRC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.42	7.07	0.36	9.21e-12	Coronary artery disease;
CRC	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg24463073	chr6:118973353	C6orf204	0.51	6.47	0.34	3.56e-10	Diastolic blood pressure;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg25164649	chr6:28176230	NA	0.6	8.64	0.43	2.5e-16	Cardiac Troponin-T levels;
CRC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.65	8.83	0.44	6.42e-17	Alcohol dependence;
CRC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg03690763	chr11:133734501	NA	-0.35	-5.87	-0.31	1.07e-8	Childhood ear infection;
CRC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	6.06	0.32	3.71e-9	Height;
CRC	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg17788362	chr6:86352627	SYNCRIP	0.49	6.86	0.35	3.47e-11	Smooth-surface caries;
CRC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg02158880	chr13:53174818	NA	0.48	7.25	0.37	3.07e-12	Lewy body disease;
CRC	cis	rs6700896	0.931	rs12042807	chr1:66134052	T/C	cg04111102	chr1:66153794	NA	0.35	6.1	0.32	3.03e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.94	0.52	5.62e-24	Prudent dietary pattern;
CRC	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.4	6.26	0.33	1.23e-9	Obesity;
CRC	cis	rs6840360	0.642	rs2724568	chr4:152352223	C/G	cg09659197	chr4:152720779	NA	0.34	6.73	0.35	7.72e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg05342945	chr12:48394962	COL2A1	-0.43	-6.03	-0.32	4.36e-9	Lung cancer;
CRC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.86	-10.04	-0.48	7.52e-21	Breast cancer;
CRC	cis	rs2108225	0.714	rs10953548	chr7:107436232	G/A	cg18560240	chr7:107437656	SLC26A3	-0.6	-9.02	-0.45	1.61e-17	Ulcerative colitis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06665941	chr21:34602869	IFNAR2	-0.52	-6.34	-0.33	7.52e-10	Diisocyanate-induced asthma;
CRC	cis	rs7680126	0.596	rs4697714	chr4:10143786	A/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.25	-0.33	1.29e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.85	15.05	0.64	2.58e-39	Height;
CRC	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.6	-0.47	2.04e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2421770	0.530	rs3901811	chr11:35365675	C/T	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.67	-0.35	1.08e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.04	0.48	7.27e-21	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.54e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.45	-7.54	-0.38	4.75e-13	Prostate cancer;
CRC	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-6.85	-0.35	3.73e-11	Coronary artery disease;
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.58	-8.92	-0.44	3.3e-17	Monocyte percentage of white cells;
CRC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.12	0.32	2.66e-9	Menopause (age at onset);
CRC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.86	0.55	3.03e-27	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg11189052	chr15:85197271	WDR73	0.61	8.81	0.44	7.07e-17	Schizophrenia;
CRC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.56	6.21	0.32	1.59e-9	Vitiligo;
CRC	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg18833306	chr6:118973337	C6orf204	0.44	5.82	0.31	1.38e-8	Diastolic blood pressure;
CRC	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg12458913	chr13:53173898	NA	0.49	7.01	0.36	1.36e-11	Lewy body disease;
CRC	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-5.71	-0.3	2.47e-8	Height;
CRC	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	0.5	7.78	0.39	9.23e-14	Red blood cell count;
CRC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg16892393	chr17:41919603	NA	0.51	7.48	0.38	7.03e-13	Triglycerides;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03934478	chr11:495069	RNH1	0.67	7.36	0.38	1.45e-12	Body mass index;
CRC	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-9.77	-0.47	5.83e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	7.99	0.4	2.22e-14	Platelet count;
CRC	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg00666640	chr1:248458726	OR2T12	0.4	7.35	0.38	1.56e-12	Common traits (Other);
CRC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.43	6.9	0.36	2.7e-11	Monocyte count;
CRC	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg15571903	chr15:79123663	NA	-0.31	-6.0	-0.31	5.06e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.57	-9.84	-0.48	3.33e-20	Menarche (age at onset);
CRC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07513332	chr6:167530253	CCR6	0.38	6.25	0.33	1.27e-9	Primary biliary cholangitis;
CRC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg23018236	chr17:30244563	NA	-0.64	-7.84	-0.4	6.23e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.0	-0.4	2.15e-14	Response to antipsychotic treatment;
CRC	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.92	-13.28	-0.59	1.63e-32	Dupuytren's disease;
CRC	cis	rs7725052	0.609	rs10065527	chr5:40456628	G/A	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.7	8.78	0.44	9.05e-17	Type 2 diabetes;
CRC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	8.95	0.44	2.62e-17	Height;
CRC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.57	8.07	0.41	1.32e-14	Menarche (age at onset);
CRC	cis	rs990171	0.955	rs4070554	chr2:103074493	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.87	0.31	1.09e-8	Lymphocyte counts;
CRC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.85	0.48	3.1e-20	Alzheimer's disease (late onset);
CRC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.67	-0.34	1.11e-10	Lung cancer;
CRC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg26587870	chr6:27730563	NA	-0.38	-5.86	-0.31	1.1e-8	Cardiac Troponin-T levels;
CRC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg03609598	chr5:56110824	MAP3K1	-0.45	-6.34	-0.33	7.54e-10	Breast cancer;Breast cancer (early onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07610776	chr16:1832675	SPSB3;NUBP2	0.47	5.99	0.31	5.47e-9	Thyroid stimulating hormone;
CRC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.6	-8.94	-0.44	2.79e-17	Schizophrenia;
CRC	cis	rs1983891	1.000	rs9381080	chr6:41527698	G/C	cg20194872	chr6:41519635	FOXP4	0.4	5.75	0.3	2.04e-8	Prostate cancer;
CRC	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg13043300	chr11:71146211	DHCR7	-0.43	-5.79	-0.3	1.67e-8	Vitamin D levels;
CRC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.56	-0.47	2.8e-19	Migraine;Coronary artery disease;
CRC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.49	-0.38	6.52e-13	Colorectal cancer;
CRC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg10298567	chr3:47292165	KIF9	-0.39	-6.38	-0.33	6.13e-10	Colorectal cancer;
CRC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.84	14.97	0.64	5.48e-39	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-8.42	-0.42	1.2e-15	Uric acid levels;
CRC	cis	rs290268	0.669	rs10448310	chr9:93556174	A/G	cg02608019	chr9:93564028	SYK	0.43	6.7	0.35	9.19e-11	Platelet count;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.37	6.05	0.32	3.99e-9	Platelet count;
CRC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.58	10.43	0.5	3.43e-22	Multiple system atrophy;
CRC	cis	rs6554196	0.932	rs3819387	chr4:55527065	C/T	cg18836493	chr4:55524333	KIT	0.34	5.92	0.31	8.3e-9	Monocyte count;
CRC	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.51	-7.81	-0.4	7.86e-14	Diastolic blood pressure;
CRC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.67	-11.64	-0.54	1.9e-26	Personality dimensions;
CRC	cis	rs17362650	0.694	rs10929582	chr2:9585200	C/G	cg23886495	chr2:9695866	ADAM17	0.44	5.71	0.3	2.55e-8	Alcohol dependence (age at onset);
CRC	cis	rs7264396	0.887	rs4911503	chr20:34063095	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.2	-0.32	1.68e-9	Total cholesterol levels;
CRC	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.74	-11.14	-0.52	1.16e-24	Waist circumference;Body mass index;
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.72	12.23	0.56	1.37e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03676636	chr4:99064102	C4orf37	0.19	5.68	0.3	3.04e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg20487152	chr13:99095054	FARP1	-0.44	-6.29	-0.33	1e-9	Longevity;
CRC	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-6.57	-0.34	2e-10	Systemic lupus erythematosus;
CRC	cis	rs7904985	1.000	rs11201991	chr10:88117122	T/C	cg07322936	chr10:88137208	NA	-0.47	-6.27	-0.33	1.15e-9	Barrett's esophagus;
CRC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.01	-0.44	1.77e-17	Bipolar disorder;
CRC	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg13086574	chr8:135490821	ZFAT	-0.37	-6.26	-0.33	1.19e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs972578	0.837	rs2092211	chr22:43318765	G/T	cg01576275	chr22:43409880	NA	-0.38	-5.88	-0.31	1.01e-8	Mean platelet volume;
CRC	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.71	7.58	0.39	3.45e-13	Breast cancer;
CRC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	9.04	0.45	1.39e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13047869	chr3:10149882	C3orf24	0.5	6.91	0.36	2.51e-11	Alzheimer's disease;
CRC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-8.23	-0.41	4.38e-15	Uric acid levels;
CRC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.73	10.25	0.49	1.37e-21	Heart rate;
CRC	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.17	-0.37	4.89e-12	Capecitabine sensitivity;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07058086	chr8:29120186	KIF13B	0.38	6.23	0.32	1.42e-9	Obesity-related traits;
CRC	cis	rs12580194	0.593	rs74844018	chr12:55766871	G/A	cg19537932	chr12:55886519	OR6C68	-0.73	-9.2	-0.45	4.32e-18	Cancer;
CRC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	6.43	0.33	4.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-8.08	-0.41	1.23e-14	Mean corpuscular volume;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg25164649	chr6:28176230	NA	0.61	8.98	0.44	2.21e-17	Parkinson's disease;
CRC	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.45	7.53	0.38	4.87e-13	Airway imaging phenotypes;
CRC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	10.22	0.49	1.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.42	9.19	0.45	4.43e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.4	-0.46	9.71e-19	Subjective well-being;
CRC	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.43	5.76	0.3	1.93e-8	Blood trace element (Cu levels);
CRC	cis	rs9648716	1.000	rs6464037	chr7:140456064	A/T	cg10747023	chr7:140774559	NA	-0.44	-5.72	-0.3	2.39e-8	Type 2 diabetes;
CRC	cis	rs16852403	0.517	rs11584886	chr1:178243362	G/A	cg00404053	chr1:178313656	RASAL2	0.48	6.12	0.32	2.7e-9	Childhood ear infection;
CRC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.57	-9.13	-0.45	6.89e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs7739232	0.764	rs75874790	chr6:53521241	A/C	cg15658676	chr6:53530538	KLHL31	-0.67	-5.66	-0.3	3.32e-8	Hip circumference adjusted for BMI;
CRC	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.25	0.64	4.14e-40	Fuchs's corneal dystrophy;
CRC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.95	-17.85	-0.7	2.63e-50	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.05	-0.36	1.08e-11	Aortic root size;
CRC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.48	7.72	0.39	1.38e-13	Testicular germ cell tumor;
CRC	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.64	-7.1	-0.36	7.8e-12	Breast cancer;
CRC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg08213375	chr14:104286397	PPP1R13B	0.59	12.05	0.55	5.96e-28	Schizophrenia;
CRC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.31	-0.33	9.16e-10	Aortic root size;
CRC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.83	10.49	0.5	2.19e-22	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs4660214	0.666	rs11205828	chr1:39719346	C/T	cg11070191	chr1:39582205	MACF1	0.37	5.81	0.31	1.45e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg09003973	chr2:102972529	NA	0.73	8.01	0.4	1.97e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.39	-5.89	-0.31	9.55e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-16.72	-0.68	7.33e-46	Urate levels in overweight individuals;
CRC	cis	rs7705042	0.865	rs4912804	chr5:141493614	T/C	cg07392085	chr5:141489673	NDFIP1	0.47	7.46	0.38	7.85e-13	Asthma;
CRC	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.52	7.7	0.39	1.58e-13	Coronary artery disease;
CRC	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.41	5.82	0.31	1.42e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.78	8.39	0.42	1.44e-15	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03389848	chr2:187350541	ZC3H15	0.38	6.35	0.33	7.01e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs56146971	0.714	rs55709253	chr14:91853363	T/C	cg16433844	chr14:91963127	SMEK1	-0.52	-6.15	-0.32	2.26e-9	Alzheimer disease and age of onset;
CRC	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.66	9.38	0.46	1.13e-18	Body mass index;
CRC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg09165964	chr15:75287851	SCAMP5	0.55	8.77	0.44	9.47e-17	Breast cancer;
CRC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg27489772	chr12:121021490	NA	-0.49	-6.71	-0.35	8.69e-11	Type 1 diabetes nephropathy;
CRC	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg05874882	chr4:1763078	NA	0.4	6.86	0.35	3.35e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg24046110	chr8:143859143	LYNX1	-0.42	-6.45	-0.33	4.08e-10	Urinary tract infection frequency;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg15555727	chr8:144692268	PYCRL	-0.42	-6.34	-0.33	7.58e-10	Daytime sleep phenotypes;
CRC	trans	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg22482690	chr17:47019901	SNF8	0.48	8.06	0.41	1.48e-14	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19455953	chr2:207630073	FASTKD2;MDH1B	0.5	6.67	0.35	1.09e-10	Thyroid stimulating hormone;
CRC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.91	-16.01	-0.66	4.58e-43	Height;
CRC	cis	rs6662572	0.737	rs72677545	chr1:46571221	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.38	0.33	6.09e-10	Blood protein levels;
CRC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.63	-6.98	-0.36	1.62e-11	Menarche (age at onset);
CRC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg13072238	chr3:49761600	GMPPB	-0.48	-5.68	-0.3	2.89e-8	Menarche (age at onset);
CRC	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.73	9.71	0.47	9.45e-20	Coronary artery disease;
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg08200582	chr11:442649	ANO9	-0.71	-7.3	-0.37	2.19e-12	Body mass index;
CRC	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13478957	chr1:153700146	INTS3	0.44	6.09	0.32	3.17e-9	Response to antipsychotic treatment;
CRC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.38	-5.61	-0.3	4.21e-8	IgG glycosylation;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs8020095	0.571	rs723432	chr14:67379015	A/C	cg00791868	chr14:66963628	C14orf53	0.49	6.59	0.34	1.8e-10	Depression (quantitative trait);
CRC	cis	rs2857891	1.000	rs2595500	chr11:6963165	C/T	cg14883916	chr11:6947541	ZNF215	-0.61	-7.07	-0.36	9.62e-12	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg23127183	chr11:57508653	C11orf31	-0.52	-7.04	-0.36	1.12e-11	Schizophrenia;
CRC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.58	8.59	0.43	3.46e-16	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.51	0.46	4.2e-19	Vitamin D levels;
CRC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-7.25	-0.37	2.96e-12	Self-reported allergy;
CRC	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg14711859	chr11:8959438	ASCL3	-0.35	-5.74	-0.3	2.2e-8	Hemoglobin concentration;
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.82	-0.31	1.43e-8	Total body bone mineral density;
CRC	trans	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	7.42	0.38	9.91e-13	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.67	9.71	0.47	9.1e-20	Menopause (age at onset);
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.81	0.44	7.6e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.26	-0.49	1.28e-21	Bipolar disorder;
CRC	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg09596252	chr17:78655493	RPTOR	0.54	5.7	0.3	2.7e-8	Myopia (pathological);
CRC	cis	rs7945718	0.621	rs61879826	chr11:12684486	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.54e-21	Asthma;
CRC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.67	11.57	0.54	3.42e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-0.87	-11.15	-0.52	1.02e-24	Breast cancer;
CRC	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.52	-6.99	-0.36	1.57e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg17674042	chr6:34482479	PACSIN1	-0.92	-9.2	-0.45	4.09e-18	Chronic lymphocytic leukemia;
CRC	cis	rs7932354	0.583	rs7940578	chr11:46812227	A/G	cg19486271	chr11:47235900	DDB2	-0.42	-6.42	-0.33	4.9e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs501120	0.584	rs1615053	chr10:44677935	T/C	cg09554077	chr10:44749378	NA	0.68	7.34	0.38	1.65e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6694672	0.557	rs6671696	chr1:197083196	T/C	cg13682187	chr1:196946512	CFHR5	0.46	7.36	0.38	1.52e-12	Asthma;
CRC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.48	-0.42	7.78e-16	Monocyte count;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.63	10.08	0.49	5.32e-21	Monocyte count;
CRC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.53	8.43	0.42	1.08e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.51	-7.64	-0.39	2.32e-13	DNA methylation (variation);
CRC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg23018236	chr17:30244563	NA	-0.47	-6.55	-0.34	2.21e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.17e-23	Motion sickness;
CRC	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg16898833	chr6:26189333	HIST1H4D	0.72	6.46	0.34	3.84e-10	Breast cancer;
CRC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg25876840	chr17:41920477	NA	0.61	8.6	0.43	3.23e-16	Triglycerides;
CRC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.85	-12.66	-0.57	3.4e-30	Response to antineoplastic agents;
CRC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-10.1	-0.49	4.6e-21	Chronic sinus infection;
CRC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg06207120	chr15:45996521	NA	0.3	7.25	0.37	3e-12	Waist circumference;Weight;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16025584	chr9:139887217	C9orf142	-0.57	-7.1	-0.36	7.6e-12	Diisocyanate-induced asthma;
CRC	cis	rs10946940	0.864	rs13201411	chr6:27498217	G/C	cg08798685	chr6:27730294	NA	0.38	5.71	0.3	2.59e-8	Systemic lupus erythematosus;
CRC	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg18551225	chr6:44695536	NA	-0.41	-5.95	-0.31	6.68e-9	Total body bone mineral density;
CRC	cis	rs7120118	0.517	rs61896015	chr11:47279928	C/A	cg25783544	chr11:47291846	MADD	0.64	5.77	0.3	1.85e-8	HDL cholesterol;
CRC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.78	-0.39	9.52e-14	Hemoglobin concentration;
CRC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.7	-7.75	-0.39	1.17e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.47	7.89	0.4	4.54e-14	Total body bone mineral density;
CRC	cis	rs7725052	0.609	rs6870757	chr5:40452107	C/T	cg09067459	chr5:40385259	NA	0.38	6.33	0.33	8.18e-10	Pediatric autoimmune diseases;
CRC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.76	0.3	1.92e-8	Coronary artery disease;
CRC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.61	-0.3	4.23e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-8.45	-0.42	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-0.65	-11.45	-0.53	8.72e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg23996704	chr18:44553084	KATNAL2	-0.38	-7.62	-0.39	2.68e-13	Personality dimensions;
CRC	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg16342193	chr10:102329863	NA	-0.37	-5.97	-0.31	6.08e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg14008862	chr17:28927542	LRRC37B2	0.58	5.76	0.3	1.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.88	0.58	5.07e-31	Platelet count;
CRC	cis	rs9469913	0.668	rs112563428	chr6:34800435	C/T	cg14254433	chr6:34482411	PACSIN1	-0.64	-6.22	-0.32	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.52	-6.82	-0.35	4.39e-11	Coronary artery disease;
CRC	cis	rs6594535	0.516	rs7731407	chr5:111101027	G/T	cg06838283	chr5:111090142	C5orf13	0.39	6.14	0.32	2.43e-9	Chickenpox;
CRC	cis	rs9462027	0.606	rs2814981	chr6:34581055	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.16	-0.32	2.08e-9	Systemic lupus erythematosus;
CRC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17507749	chr15:85114479	UBE2QP1	0.65	9.29	0.46	2.15e-18	Schizophrenia;
CRC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg21153622	chr11:89784906	NA	-0.52	-8.58	-0.43	3.8e-16	HDL cholesterol;
CRC	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg15192750	chr16:69999425	NA	0.55	7.29	0.37	2.29e-12	IgE levels;
CRC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.5	-7.37	-0.38	1.39e-12	Asthma;
CRC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.51	8.29	0.42	3.02e-15	Aortic root size;
CRC	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.72	-9.28	-0.46	2.28e-18	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg01639898	chr1:32083012	HCRTR1	-0.28	-5.72	-0.3	2.34e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg09877947	chr5:131593287	PDLIM4	0.36	6.82	0.35	4.47e-11	Blood metabolite levels;
CRC	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg08015503	chr16:89190385	ACSF3	-0.94	-7.38	-0.38	1.32e-12	Red blood cell count;
CRC	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.82	0.31	1.43e-8	Male-pattern baldness;
CRC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg24375607	chr4:120327624	NA	0.48	7.54	0.38	4.62e-13	Corneal astigmatism;
CRC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg01339444	chr6:118972232	C6orf204	0.53	5.97	0.31	6.07e-9	Diastolic blood pressure;
CRC	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.32	-0.33	8.45e-10	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.48	-6.62	-0.34	1.44e-10	DNA methylation (variation);
CRC	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs7173389	1.000	rs8038766	chr15:73663314	A/G	cg01796676	chr15:73680284	NA	0.52	7.12	0.37	6.76e-12	Resting heart rate;
CRC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12311346	chr5:56204834	C5orf35	0.5	7.61	0.39	2.88e-13	Coronary artery disease;
CRC	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.85	-16.63	-0.68	1.68e-45	Hip circumference;
CRC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3996993	0.809	rs4715326	chr6:52657552	C/T	cg20803780	chr6:52668592	GSTA1	-0.38	-7.17	-0.37	5.05e-12	Hemoglobin concentration;
CRC	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.78	13.1	0.59	7.99e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg09659197	chr4:152720779	NA	0.38	7.54	0.38	4.63e-13	Intelligence (multi-trait analysis);
CRC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg14844989	chr11:31128820	NA	0.35	6.19	0.32	1.79e-9	Bone mineral density (spine);
CRC	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.5	7.61	0.39	2.84e-13	Sum neutrophil eosinophil counts;
CRC	cis	rs2811415	0.628	rs13067034	chr3:127750310	C/T	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.4	0.42	1.36e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.87	0.4	5.15e-14	Resting heart rate;
CRC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-15.92	-0.66	1.01e-42	Body mass index;
CRC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.41	-5.97	-0.31	6.07e-9	Gout;Renal underexcretion gout;
CRC	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.82	-10.94	-0.52	5.91e-24	IgG glycosylation;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	ch.11.967412F	chr11:46784048	SNORD67;CKAP5	-0.38	-6.04	-0.32	4.15e-9	Aortic root size;
CRC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.44	7.3	0.37	2.14e-12	Monocyte count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20701983	chr7:135194361	CNOT4	-0.42	-6.18	-0.32	1.87e-9	Myopia (pathological);
CRC	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.47	0.5	2.41e-22	Corneal astigmatism;
CRC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.77	9.68	0.47	1.12e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg00343986	chr7:65444356	GUSB	-0.47	-6.48	-0.34	3.41e-10	Aortic root size;
CRC	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.59	-0.39	3.28e-13	Vitamin D levels;
CRC	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.66	-0.34	1.18e-10	Coronary artery disease;
CRC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-9.7	-0.47	9.69e-20	Bipolar disorder and schizophrenia;
CRC	cis	rs6504950	0.695	rs9904377	chr17:52985982	C/T	cg26251398	chr17:52985966	TOM1L1	0.43	6.55	0.34	2.27e-10	Breast cancer;
CRC	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.54	7.6	0.39	3.18e-13	Testicular germ cell tumor;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg10876282	chr6:28092338	ZSCAN16	-0.42	-5.91	-0.31	8.48e-9	Cardiac Troponin-T levels;
CRC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.6	-9.25	-0.45	2.87e-18	Corneal astigmatism;
CRC	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg27053337	chr8:124217698	FAM83A	0.42	6.36	0.33	6.62e-10	Urinary uromodulin levels;
CRC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.84	0.4	6.37e-14	Mean platelet volume;
CRC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-8.82	-0.44	6.94e-17	Hip circumference adjusted for BMI;
CRC	cis	rs1007738	0.580	rs10501319	chr11:47174062	C/T	cg19486271	chr11:47235900	DDB2	0.42	5.76	0.3	1.92e-8	Bone mineral density (hip);
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.48	-0.34	3.33e-10	Breast cancer;
CRC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	10.2	0.49	2.05e-21	Total body bone mineral density;
CRC	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.55	6.35	0.33	7.18e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg02659138	chr7:134003124	SLC35B4	0.37	6.38	0.33	5.99e-10	Mean platelet volume;
CRC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.09	12.79	0.58	1.12e-30	Sexual dysfunction (female);
CRC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg00383909	chr3:49044727	WDR6	0.59	6.45	0.34	3.9e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg23018236	chr17:30244563	NA	-0.65	-7.78	-0.39	9.41e-14	Hip circumference adjusted for BMI;
CRC	cis	rs449789	0.524	rs4709306	chr6:159775930	G/A	cg14500486	chr6:159655392	FNDC1	-0.45	-6.77	-0.35	6.08e-11	Pulse pressure;
CRC	cis	rs4964805	0.913	rs11111795	chr12:104204830	C/A	cg02344784	chr12:104178138	NT5DC3	0.54	8.18	0.41	6.05e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs7122539	0.646	rs6591222	chr11:66551143	C/T	cg24851651	chr11:66362959	CCS	0.41	6.78	0.35	5.58e-11	HIV-1 susceptibility;
CRC	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.48	-7.08	-0.36	8.54e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.47	-8.7	-0.43	1.62e-16	Hepatitis;
CRC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.36	6.5	0.34	3.04e-10	Erythrocyte sedimentation rate;
CRC	trans	rs7179994	0.579	rs72712679	chr15:28301730	C/T	cg05237436	chr5:138533428	SIL1	0.71	6.29	0.33	1.03e-9	Shingles;
CRC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg03623178	chr6:28175578	NA	-0.66	-9.89	-0.48	2.36e-20	Cardiac Troponin-T levels;
CRC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.57	9.2	0.45	4.18e-18	Gestational age at birth (maternal effect);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15112458	chr7:104654695	MLL5;LOC100216545	0.39	6.34	0.33	7.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.74	-0.54	8.39e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.51	6.45	0.34	3.99e-10	Longevity;
CRC	cis	rs1124376	1.000	rs6774367	chr3:20163077	G/A	cg05072819	chr3:20081367	KAT2B	0.46	5.74	0.3	2.2e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.26	-0.45	2.79e-18	Prevalent atrial fibrillation;
CRC	cis	rs11212617	0.967	rs7127490	chr11:108286758	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.93	0.31	7.71e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.42	6.13	0.32	2.46e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg24879335	chr3:133465180	TF	0.32	5.77	0.3	1.86e-8	Iron status biomarkers;
CRC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.31	-0.79	1.24e-71	Myeloid white cell count;
CRC	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg19773385	chr1:10388646	KIF1B	-0.47	-7.33	-0.37	1.83e-12	Hepatocellular carcinoma;
CRC	trans	rs587242	1.000	rs12727152	chr1:96915548	G/A	cg10631902	chr5:14652156	NA	0.44	6.9	0.36	2.62e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.58	8.96	0.44	2.48e-17	HDL cholesterol;
CRC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs17209837	1.000	rs45447097	chr7:87086144	G/A	cg00919237	chr7:87102261	ABCB4	-0.5	-6.1	-0.32	3.03e-9	Gallbladder cancer;
CRC	trans	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg18335740	chr13:41363409	SLC25A15	-0.45	-6.75	-0.35	6.73e-11	Lewy body disease;
CRC	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.88	0.35	2.95e-11	Prostate cancer;
CRC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.58	-8.73	-0.43	1.3e-16	Body mass index;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.78	-0.39	9.63e-14	Breast cancer;
CRC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.36	5.86	0.31	1.13e-8	Ulcerative colitis;
CRC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.61	0.57	5.01e-30	Platelet count;
CRC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg02290350	chr8:58132656	NA	-0.46	-5.84	-0.31	1.24e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg24140574	chr1:16342155	HSPB7	0.42	6.05	0.32	3.86e-9	Systolic blood pressure;
CRC	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-11.5	-0.54	5.99e-26	Colorectal cancer;
CRC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.47	-6.88	-0.35	2.97e-11	Uric acid clearance;
CRC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.78	-9.72	-0.47	8.54e-20	Body mass index;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg18758796	chr5:131593413	PDLIM4	0.4	6.43	0.33	4.39e-10	Breast cancer;
CRC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	cis	rs9359856	0.956	rs6912680	chr6:90300010	T/G	cg13799429	chr6:90582589	CASP8AP2	0.47	6.61	0.34	1.55e-10	Bipolar disorder;
CRC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.73	11.53	0.54	4.47e-26	Colorectal cancer;
CRC	trans	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg06606381	chr12:133084897	FBRSL1	-0.57	-6.08	-0.32	3.38e-9	Depression;
CRC	cis	rs6585424	1.000	rs10466228	chr10:81924373	A/G	cg11900509	chr10:81946545	ANXA11	-0.68	-8.54	-0.43	4.9e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6662572	0.737	rs7512448	chr1:46449291	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.7	-0.3	2.71e-8	Blood protein levels;
CRC	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.93	-17.98	-0.7	7.84e-51	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09341209	chr11:2422446	TSSC4	0.39	5.98	0.31	5.93e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1545257	0.537	rs3108793	chr2:24648138	A/C	cg06627628	chr2:24431161	ITSN2	-0.45	-6.51	-0.34	2.87e-10	Sjögren's syndrome;
CRC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.51	6.97	0.36	1.7e-11	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.66	-6.35	-0.33	7.01e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.59	0.47	2.2e-19	Cognitive test performance;
CRC	cis	rs910187	0.624	rs6018311	chr20:45792634	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-6.47	-0.34	3.64e-10	Migraine;
CRC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg18016565	chr1:150552671	MCL1	-0.49	-7.04	-0.36	1.1e-11	Blood protein levels;
CRC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg14711859	chr11:8959438	ASCL3	0.38	5.92	0.31	8.09e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.72	8.35	0.42	1.86e-15	Hip circumference adjusted for BMI;
CRC	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg27398640	chr15:77910606	LINGO1	-0.41	-6.85	-0.35	3.59e-11	Type 2 diabetes;
CRC	cis	rs9311676	0.632	rs1126722	chr3:58413518	T/G	cg06643156	chr3:58380774	PXK	0.42	6.45	0.33	4.08e-10	Systemic lupus erythematosus;
CRC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.95	-0.31	6.86e-9	Morning vs. evening chronotype;
CRC	cis	rs2013441	1.000	rs2107566	chr17:20103252	C/T	cg13482628	chr17:19912719	NA	-0.44	-6.38	-0.33	6.11e-10	Obesity-related traits;
CRC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.37	5.94	0.31	7.25e-9	Cystic fibrosis severity;
CRC	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.71	-7.48	-0.38	6.99e-13	Type 2 diabetes;
CRC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.92e-17	Hip circumference adjusted for BMI;
CRC	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.51	7.86	0.4	5.46e-14	Corneal astigmatism;
CRC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.4	-5.98	-0.31	5.7e-9	Crohn's disease;
CRC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.18	0.59	3.68e-32	Alzheimer's disease;
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg24046110	chr8:143859143	LYNX1	0.47	8.18	0.41	6.22e-15	Urinary tract infection frequency;
CRC	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06307176	chr5:131281290	NA	0.41	5.97	0.31	6.13e-9	Life satisfaction;
CRC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.63	-7.14	-0.37	6.2e-12	Bronchopulmonary dysplasia;
CRC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.4	7.1	0.36	7.63e-12	Obesity-related traits;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg15786705	chr6:28176104	NA	0.78	9.7	0.47	1.01e-19	Depression;
CRC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg14671364	chr1:107599128	PRMT6	0.6	8.08	0.41	1.28e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.86	10.95	0.52	5.42e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.66	6.36	0.33	6.58e-10	Initial pursuit acceleration;
CRC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.55	-6.24	-0.33	1.38e-9	Lymphocyte counts;
CRC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg01721255	chr8:58191610	C8orf71	0.46	5.91	0.31	8.36e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-6.31	-0.33	8.99e-10	Longevity;Endometriosis;
CRC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.66	7.09	0.36	8.35e-12	Inflammatory bowel disease;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.92	0.31	8.29e-9	Parkinson's disease;
CRC	cis	rs3996993	0.809	rs7747087	chr6:52713999	G/A	cg20803780	chr6:52668592	GSTA1	-0.38	-7.11	-0.37	7.11e-12	Hemoglobin concentration;
CRC	cis	rs7705042	0.865	rs4912805	chr5:141493685	A/G	cg07392085	chr5:141489673	NDFIP1	0.47	7.41	0.38	1.06e-12	Asthma;
CRC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.59	-11.74	-0.54	8.23e-27	Asthma (sex interaction);
CRC	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg09904177	chr6:26538194	HMGN4	-0.44	-6.18	-0.32	1.89e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg24300038	chr13:113819356	PROZ	-0.46	-5.73	-0.3	2.26e-8	Platelet distribution width;
CRC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg00717180	chr2:96193071	NA	-0.37	-6.1	-0.32	2.99e-9	HDL cholesterol;
CRC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.72	10.14	0.49	3.22e-21	Response to diuretic therapy;
CRC	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.38	-0.33	6.12e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.54	9.62	0.47	1.82e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.62	-8.77	-0.44	1e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg14107975	chr11:96076498	MAML2	0.41	6.65	0.34	1.21e-10	Obesity-related traits;
CRC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-8.43	-0.42	1.09e-15	Initial pursuit acceleration;
CRC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.52	9.2	0.45	4.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg13722127	chr7:150037890	RARRES2	0.52	7.87	0.4	5.35e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.58	-0.34	1.83e-10	Coronary artery disease;
CRC	trans	rs9903692	0.954	rs875066	chr17:46139732	T/G	cg13910583	chr8:56987998	RPS20	-0.45	-6.12	-0.32	2.71e-9	Pulse pressure;
CRC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.57	-0.34	2.02e-10	Mean corpuscular volume;
CRC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9925964	0.933	rs8050894	chr16:31104509	C/G	cg03418659	chr16:31128414	MYST1	0.46	6.84	0.35	3.76e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.93	-16.59	-0.67	2.35e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.83	8.44	0.42	1e-15	Fat distribution (HIV);
CRC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.74	12.33	0.56	5.58e-29	Extrinsic epigenetic age acceleration;
CRC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.44	-7.99	-0.4	2.37e-14	Reticulocyte fraction of red cells;
CRC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	12.89	0.58	4.79e-31	Bone mineral density;
CRC	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.85	15.73	0.66	5.53e-42	Lewy body disease;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg12564285	chr5:131593104	PDLIM4	0.46	7.59	0.39	3.36e-13	Acylcarnitine levels;
CRC	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg01843034	chr6:37503916	NA	-0.37	-6.67	-0.35	1.09e-10	Cognitive performance;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.41	-7.16	-0.37	5.17e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.44	6.07	0.32	3.48e-9	Cystic fibrosis severity;
CRC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	15.75	0.66	4.86e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.46	6.18	0.32	1.88e-9	Menarche (age at onset);
CRC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.44	6.42	0.33	4.86e-10	Menopause (age at onset);
CRC	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg26162295	chr17:38119207	GSDMA	-0.37	-6.78	-0.35	5.46e-11	Asthma;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg25600027	chr14:23388339	RBM23	-0.53	-8.3	-0.42	2.72e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.71	-0.39	1.51e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg20933634	chr6:27740509	NA	0.49	6.74	0.35	7.32e-11	Parkinson's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25367318	chr6:138725211	HEBP2	0.53	7.1	0.36	7.89e-12	Thyroid stimulating hormone;
CRC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.66	9.28	0.46	2.43e-18	Vitiligo;
CRC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg03885332	chr11:832357	CD151	-0.42	-6.28	-0.33	1.05e-9	Mean platelet volume;
CRC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg14664628	chr15:75095509	CSK	0.47	6.89	0.36	2.82e-11	Caffeine consumption;
CRC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.72	9.64	0.47	1.51e-19	Pancreatic cancer;
CRC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.2	-0.45	4.18e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg07212818	chr11:638076	DRD4	-0.46	-5.84	-0.31	1.23e-8	Systemic lupus erythematosus;
CRC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg18478394	chr8:109455254	TTC35	0.38	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.63	-6.26	-0.33	1.22e-9	Schizophrenia;
CRC	cis	rs728616	0.867	rs12781912	chr10:81918128	G/T	cg11900509	chr10:81946545	ANXA11	-0.74	-8.77	-0.44	9.77e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17554472	chr22:41940697	POLR3H	0.51	5.68	0.3	2.97e-8	Vitiligo;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg06470822	chr6:28175283	NA	0.81	8.72	0.43	1.41e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.29	-0.37	2.31e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.15e-19	Blood protein levels;
CRC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.7e-10	HDL cholesterol;
CRC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.74	11.38	0.53	1.57e-25	Corneal astigmatism;
CRC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.14	13.38	0.59	6.6e-33	Sexual dysfunction (female);
CRC	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg14631576	chr9:95140430	CENPP	-0.3	-5.63	-0.3	3.78e-8	Height;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg19304507	chr22:30278992	MTMR3	0.4	6.04	0.32	4.23e-9	Interleukin-6 levels;
CRC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.56	-0.34	2.12e-10	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02756545	chr1:94884060	ABCD3	0.51	7.16	0.37	5.35e-12	Response to antipsychotic treatment;
CRC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	5.67	0.3	3.06e-8	Multiple sclerosis;
CRC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	16.79	0.68	3.83e-46	Chronic sinus infection;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20567499	chr11:107730432	SLC35F2	0.5	7.14	0.37	6.05e-12	Survival in pancreatic cancer;
CRC	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.56	6.36	0.33	6.77e-10	Osteoarthritis;
CRC	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg00042356	chr1:8021962	PARK7	-0.51	-5.96	-0.31	6.36e-9	Inflammatory bowel disease;
CRC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg27535305	chr1:53392650	SCP2	-0.36	-6.59	-0.34	1.74e-10	Monocyte count;
CRC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.57	9.55	0.47	3.1e-19	Menopause (age at onset);
CRC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.46	-7.73	-0.39	1.31e-13	Major depressive disorder;
CRC	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	12.92	0.58	3.76e-31	Nonalcoholic fatty liver disease;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg00597713	chr6:42947103	PEX6	-0.42	-6.0	-0.31	5.29e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.61	-8.44	-0.42	1.05e-15	White matter hyperintensity burden;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00753739	chr10:11653489	USP6NL	0.46	6.5	0.34	2.97e-10	Response to antipsychotic treatment;
CRC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.36	5.88	0.31	9.88e-9	Ulcerative colitis;
CRC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.43	4.17e-16	Aortic root size;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg13628960	chr20:62258574	GMEB2	0.37	6.05	0.32	3.97e-9	Schizophrenia;
CRC	trans	rs673253	0.686	rs2819333	chr1:44014573	A/T	cg24014536	chr3:23847295	UBE2E1	-0.41	-6.14	-0.32	2.39e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg13880726	chr7:1868755	MAD1L1	-0.43	-5.8	-0.3	1.55e-8	Bipolar disorder;
CRC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.54	-8.75	-0.43	1.15e-16	Coronary artery disease;
CRC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.44	-5.85	-0.31	1.21e-8	Gut microbiome composition (summer);
CRC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg10978503	chr1:24200527	CNR2	0.62	11.22	0.53	6.02e-25	Immature fraction of reticulocytes;
CRC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg08999081	chr20:33150536	PIGU	0.45	5.79	0.3	1.66e-8	Protein C levels;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg12516270	chr8:143859308	LYNX1	0.41	7.42	0.38	9.9e-13	Urinary tract infection frequency;
CRC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.54	-8.05	-0.41	1.48e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.35	6.32	0.33	8.58e-10	Crohn's disease;
CRC	cis	rs6662572	0.737	rs6687316	chr1:46581449	G/A	cg08644498	chr1:46502608	NA	0.43	7.01	0.36	1.32e-11	Blood protein levels;
CRC	cis	rs11212617	1.000	rs227093	chr11:108233939	T/A	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.97	0.31	6.03e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.84	0.31	1.24e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg20041105	chr8:143859282	LYNX1	-0.33	-5.78	-0.3	1.78e-8	Urinary tract infection frequency;
CRC	cis	rs11212617	0.967	rs227072	chr11:108212093	A/C	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.27	0.33	1.14e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg09877947	chr5:131593287	PDLIM4	0.52	9.41	0.46	8.99e-19	Blood metabolite levels;
CRC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.37	-5.93	-0.31	7.53e-9	IgG glycosylation;
CRC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.44	0.46	7.14e-19	Cognitive test performance;
CRC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.55	8.49	0.42	6.96e-16	Aortic root size;
CRC	trans	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg19894588	chr14:64061835	NA	-0.55	-7.53	-0.38	4.93e-13	Optic cup area;Vertical cup-disc ratio;
CRC	trans	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg25214090	chr10:38739885	LOC399744	-0.41	-6.31	-0.33	9.11e-10	Diastolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06739866	chr14:22314682	NA	0.42	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.558	rs61859793	chr10:81686763	A/G	cg05935833	chr10:81318306	SFTPA2	-0.62	-7.99	-0.4	2.29e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.75	-0.43	1.17e-16	Aortic root size;
CRC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.54	6.1	0.32	2.99e-9	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00166722	chr3:10149974	C3orf24	0.67	9.26	0.45	2.71e-18	Alzheimer's disease;
CRC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg01949993	chr1:183155116	LAMC2	-0.33	-5.8	-0.3	1.59e-8	Hypertriglyceridemia;
CRC	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.68	-12.21	-0.56	1.6e-28	Lewy body disease;
CRC	trans	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg26043149	chr18:55253948	FECH	0.51	7.85	0.4	5.92e-14	Bone mineral density;
CRC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg18709589	chr6:96969512	KIAA0776	-0.55	-6.77	-0.35	5.84e-11	Migraine;Coronary artery disease;
CRC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.61	-8.51	-0.42	6.32e-16	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs243505	0.559	rs734003	chr7:148505498	T/G	cg09806900	chr7:148480153	CUL1	0.54	7.69	0.39	1.69e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg15845792	chr6:28175446	NA	1.04	13.81	0.61	1.6e-34	Depression;
CRC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg08222913	chr3:52553049	STAB1	-0.31	-5.73	-0.3	2.23e-8	Bipolar disorder;
CRC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.71	-9.34	-0.46	1.53e-18	Bronchopulmonary dysplasia;
CRC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.52	-7.91	-0.4	3.91e-14	Height;
CRC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg26260408	chr4:53727979	RASL11B	0.41	5.92	0.31	8.2e-9	Optic nerve measurement (cup area);
CRC	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.87	-16.85	-0.68	2.21e-46	Hip circumference;
CRC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg23860436	chr12:58378763	NA	0.35	5.88	0.31	1.03e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.13e-17	Dupuytren's disease;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg18758796	chr5:131593413	PDLIM4	0.39	6.26	0.33	1.23e-9	Breast cancer;
CRC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.66	9.21	0.45	4.08e-18	Neuroblastoma;
CRC	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.6	6.88	0.35	3.04e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg14593290	chr7:50529359	DDC	-0.43	-6.26	-0.33	1.2e-9	Body mass index;
CRC	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.65	-10.2	-0.49	2.08e-21	Lewy body disease;
CRC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.25	-0.33	1.27e-9	IgG glycosylation;
CRC	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.12	-0.32	2.72e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg09659197	chr4:152720779	NA	0.43	8.9	0.44	3.94e-17	Intelligence (multi-trait analysis);
CRC	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg15704280	chr7:45808275	SEPT13	0.65	5.97	0.31	6.07e-9	Intraocular pressure;
CRC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.58	8.38	0.42	1.57e-15	Resting heart rate;
CRC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.57	9.45	0.46	6.45e-19	Menopause (age at onset);
CRC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.41	5.71	0.3	2.58e-8	Renal cell carcinoma;
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8022206	0.898	rs1980850	chr14:68647188	A/G	cg19578161	chr14:68482919	RAD51L1	0.43	5.76	0.3	1.95e-8	Platelet count;Mean platelet volume;
CRC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.14	-0.32	2.37e-9	Tonsillectomy;
CRC	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.63	8.71	0.43	1.54e-16	Height;
CRC	cis	rs972578	0.806	rs5758955	chr22:43217149	G/C	cg01576275	chr22:43409880	NA	-0.42	-6.56	-0.34	2.05e-10	Mean platelet volume;
CRC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.06	0.41	1.47e-14	Menopause (age at onset);
CRC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.39	6.52	0.34	2.7e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.49	6.33	0.33	8.03e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.02	-14.32	-0.62	1.72e-36	Gut microbiome composition (summer);
CRC	cis	rs9463078	0.678	rs9395088	chr6:45240267	G/A	cg25276700	chr6:44698697	NA	-0.24	-5.87	-0.31	1.04e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.88	-0.31	1.03e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09730672	chr8:86157838	CA13	0.46	6.37	0.33	6.46e-10	Anxiety disorder;
CRC	cis	rs12580194	0.593	rs12579346	chr12:55786856	A/G	cg23425280	chr12:56401806	NA	0.47	5.71	0.3	2.53e-8	Cancer;
CRC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg05304507	chr6:116381966	FRK	0.32	8.55	0.43	4.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg13837822	chr10:26931731	LOC731789	0.56	8.62	0.43	2.92e-16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-7.76	-0.39	1.07e-13	Vitiligo;
CRC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.4	-7.41	-0.38	1.09e-12	Ankle injury;
CRC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	9.16	0.45	5.76e-18	Schizophrenia;
CRC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg25985355	chr7:65971099	NA	-0.5	-5.69	-0.3	2.86e-8	Diabetic kidney disease;
CRC	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.25	0.56	1.12e-28	Exhaled nitric oxide levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24088775	chr19:12595630	ZNF709	0.4	6.4	0.33	5.31e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg14092571	chr14:90743983	NA	0.39	5.98	0.31	5.81e-9	Mortality in heart failure;
CRC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.4	5.87	0.31	1.09e-8	Obesity-related traits;
CRC	cis	rs747650	0.504	rs4752815	chr11:46978698	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.84	-0.31	1.24e-8	Acne (severe);
CRC	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	0.8	8.31	0.42	2.59e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-11.58	-0.54	3.01e-26	Asthma;
CRC	trans	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.04	0.41	1.62e-14	Menarche (age at onset);
CRC	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg23032129	chr1:109941072	SORT1	-0.29	-6.16	-0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00801512	chr17:28996047	NA	-0.6	-6.1	-0.32	2.91e-9	Height;
CRC	cis	rs4731207	0.698	rs10271687	chr7:124493731	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg03013999	chr17:37608204	MED1	0.46	7.16	0.37	5.4e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.51	-7.21	-0.37	3.77e-12	Longevity;Endometriosis;
CRC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.58	-8.61	-0.43	3.08e-16	Longevity;
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs919433	0.714	rs2333855	chr2:198200213	T/G	cg10820045	chr2:198174542	NA	-0.48	-8.41	-0.42	1.31e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	16.76	0.68	4.95e-46	Chronic sinus infection;
CRC	trans	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg04077850	chr5:125800366	GRAMD3	0.38	6.29	0.33	9.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg18612461	chr15:75251733	NA	0.47	7.2	0.37	4.03e-12	Breast cancer;
CRC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.44	6.74	0.35	7.19e-11	Monocyte count;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg10529930	chr20:5986407	CRLS1	-0.38	-6.12	-0.32	2.72e-9	Aortic root size;
CRC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.05	0.32	4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg13736514	chr6:26305472	NA	-0.45	-7.24	-0.37	3.18e-12	Educational attainment;
CRC	cis	rs17234274	0.644	rs10833965	chr11:23214880	A/G	cg05245346	chr11:23248277	NA	0.36	5.93	0.31	7.53e-9	Cancer;
CRC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.28	-0.37	2.49e-12	Life satisfaction;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	7.48	0.38	6.81e-13	Lymphocyte counts;
CRC	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.72	8.24	0.41	4.21e-15	Ulcerative colitis;
CRC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.39	-7.67	-0.39	1.97e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2944755	0.959	rs2977491	chr8:141574277	A/G	cg07466463	chr8:141574207	EIF2C2	0.4	5.96	0.31	6.33e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.33	-5.61	-0.3	4.38e-8	Personality dimensions;
CRC	trans	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg00953403	chr17:74099816	EXOC7	0.47	7.08	0.36	8.79e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	9.94	0.48	1.62e-20	Mood instability;
CRC	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.43	6.53	0.34	2.53e-10	HDL cholesterol;
CRC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.47	-0.34	3.56e-10	Platelet distribution width;
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-11.72	-0.54	9.81e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7703744	0.597	rs73237297	chr5:118691121	G/T	cg19893178	chr5:118692011	TNFAIP8	0.42	5.78	0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.87	-0.35	3.17e-11	Mean corpuscular volume;
CRC	cis	rs713477	0.845	rs4898863	chr14:55910284	T/A	cg13175173	chr14:55914753	NA	-0.47	-8.89	-0.44	4.25e-17	Pediatric bone mineral content (femoral neck);
CRC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg23758597	chr6:163146217	PARK2	-0.51	-5.9	-0.31	8.81e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.58	0.34	1.85e-10	Aortic root size;
CRC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26056348	chr7:75932317	HSPB1	0.38	6.17	0.32	1.97e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-6.64	-0.34	1.34e-10	Coronary artery disease;
CRC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	12.39	0.56	3.54e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.91e-9	Aortic root size;
CRC	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.76	0.39	1.09e-13	Breast cancer;
CRC	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.39	5.71	0.3	2.58e-8	Pulmonary function;
CRC	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg03684893	chr10:554711	DIP2C	0.37	5.65	0.3	3.5e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.29	5.98	0.31	5.72e-9	Homoarginine levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17218029	chr1:156722047	HDGF	0.38	6.12	0.32	2.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs4716602	0.596	rs10270517	chr7:156160010	A/G	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.74e-11	Anti-saccade response;
CRC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.59	8.32	0.42	2.4e-15	Arsenic metabolism;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23161317	chr6:28129485	ZNF389	0.54	6.56	0.34	2.12e-10	Depression;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19626725	chr5:178986131	RUFY1	0.33	6.09	0.32	3.21e-9	Lung cancer;
CRC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.59	6.99	0.36	1.57e-11	Menarche (age at onset);
CRC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.23	0.32	1.46e-9	Diastolic blood pressure;
CRC	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	13.62	0.6	8.16e-34	Exhaled nitric oxide output;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.86	-15.31	-0.64	2.54e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.69	12.57	0.57	7.09e-30	Blood protein levels;
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.82	13.01	0.58	1.63e-31	Menarche (age at onset);
CRC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg02569458	chr12:86230093	RASSF9	0.45	7.66	0.39	2.16e-13	Major depressive disorder;
CRC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg21784768	chr11:537496	LRRC56	-0.67	-6.21	-0.32	1.63e-9	Body mass index;
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.28	6.29	0.33	1.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg05084668	chr3:125655381	ALG1L	-0.44	-6.16	-0.32	2.09e-9	Blood pressure (smoking interaction);
CRC	trans	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg19894588	chr14:64061835	NA	-0.56	-7.49	-0.38	6.22e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	16.62	0.68	1.76e-45	Platelet count;
CRC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.5	7.65	0.39	2.18e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs939584	1.000	rs10169736	chr2:641082	A/T	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.44	-6.65	-0.34	1.25e-10	Bone properties (heel);
CRC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.61	-11.56	-0.54	3.46e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg06818126	chr11:68850279	TPCN2	-0.51	-7.16	-0.37	5.22e-12	Hair color;
CRC	cis	rs728616	0.867	rs56123058	chr10:81811072	G/A	cg11900509	chr10:81946545	ANXA11	-0.53	-5.78	-0.3	1.69e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg06470822	chr6:28175283	NA	1.01	13.28	0.59	1.55e-32	Depression;
CRC	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21659725	chr3:3221576	CRBN	0.63	7.03	0.36	1.21e-11	Menarche (age at onset);
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.37e-18	Blood pressure (smoking interaction);
CRC	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.53	7.28	0.37	2.52e-12	Hip circumference adjusted for BMI;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09880681	chr16:30538664	ZNF768	-0.53	-6.4	-0.33	5.29e-10	Diisocyanate-induced asthma;
CRC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	0.94	18.35	0.71	2.78e-52	Height;
CRC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.72e-9	Aortic root size;
CRC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.39	5.89	0.31	9.49e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	0.79	8.09	0.41	1.18e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.55	-0.38	4.38e-13	Headache;
CRC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg16434002	chr17:42200994	HDAC5	0.44	5.86	0.31	1.15e-8	Total body bone mineral density;
CRC	cis	rs7246865	0.906	rs2278997	chr19:17166981	G/A	cg19418318	chr19:17219073	MYO9B	0.42	6.81	0.35	4.61e-11	Reticulocyte fraction of red cells;
CRC	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.0	0.44	1.84e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.66	-11.37	-0.53	1.67e-25	Brugada syndrome;
CRC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.45	-0.33	4.03e-10	Aortic root size;
CRC	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.58	-6.04	-0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs9462846	0.853	rs7741552	chr6:42873823	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-6.43	-0.33	4.47e-10	Blood protein levels;
CRC	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg05714579	chr10:131428358	MGMT	0.54	7.61	0.39	2.89e-13	Response to temozolomide;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg06470822	chr6:28175283	NA	0.84	13.01	0.58	1.61e-31	Cardiac Troponin-T levels;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs741668	0.931	rs2806926	chr13:46521667	A/G	cg06018095	chr13:46550134	ZC3H13	0.43	6.34	0.33	7.39e-10	Cerebrospinal fluid clusterin levels;
CRC	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-7.88	-0.4	4.75e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg03623178	chr6:28175578	NA	-0.94	-13.51	-0.6	2.23e-33	Depression;
CRC	cis	rs7605827	0.930	rs1990754	chr2:15615910	A/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.74	9.35	0.46	1.41e-18	Iron status biomarkers;
CRC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-12.65	-0.57	3.57e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.86	-0.44	5.23e-17	Bone mineral density;
CRC	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.89	9.04	0.45	1.37e-17	Arsenic metabolism;
CRC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	11.08	0.52	1.87e-24	Schizophrenia;
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.63	9.49	0.46	4.69e-19	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03628274	chr19:18420511	LSM4	-0.38	-6.02	-0.31	4.58e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.45	-6.0	-0.31	5.19e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg21399703	chr1:247681439	NA	0.54	10.2	0.49	2.08e-21	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.14	-0.45	6.55e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.75	-12.61	-0.57	5.12e-30	Eosinophil percentage of white cells;
CRC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.55	6.09	0.32	3.15e-9	Initial pursuit acceleration;
CRC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.61	-8.98	-0.44	2.11e-17	Other erythrocyte phenotypes;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg20615401	chr6:28092323	ZSCAN16	0.42	5.61	0.3	4.21e-8	Cardiac Troponin-T levels;
CRC	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.73	11.68	0.54	1.34e-26	Plateletcrit;Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01853632	chr3:43147395	C3orf39	0.4	6.72	0.35	7.84e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.41	6.71	0.35	8.45e-11	Resting heart rate;
CRC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.63	0.3	3.9e-8	Cystic fibrosis severity;
CRC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.66e-15	Menopause (age at onset);
CRC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.64	9.03	0.45	1.44e-17	White matter hyperintensity burden;
CRC	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.5	6.72	0.35	7.91e-11	Caudate activity during reward;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08748207	chr12:46777589	NA	0.52	6.84	0.35	3.97e-11	Thyroid stimulating hormone;
CRC	cis	rs780094	0.500	rs12987055	chr2:27834152	T/C	cg27432699	chr2:27873401	GPN1	0.48	6.18	0.32	1.91e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.86	0.35	3.5e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.5	6.42	0.33	4.77e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg02825527	chr7:2087843	MAD1L1	-0.49	-5.83	-0.31	1.34e-8	Bipolar disorder;
CRC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.79	-0.39	8.71e-14	Reticulocyte fraction of red cells;
CRC	cis	rs9584850	0.789	rs7988345	chr13:99117685	A/G	cg20487152	chr13:99095054	FARP1	0.43	6.29	0.33	1.01e-9	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04088893	chr5:149340277	SLC26A2	0.45	6.4	0.33	5.31e-10	Response to antipsychotic treatment;
CRC	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.48	7.61	0.39	2.9e-13	Obesity-related traits;
CRC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.33e-29	Prostate cancer;
CRC	cis	rs8070740	0.898	rs9303192	chr17:5324836	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	7.5	0.38	5.95e-13	Menopause (age at onset);
CRC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.44	-6.34	-0.33	7.4e-10	Cognitive ability;
CRC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.51	5.67	0.3	3.08e-8	Vitiligo;
CRC	cis	rs7705042	0.865	rs9324866	chr5:141497650	A/G	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.85	-0.31	1.18e-8	Asthma;
CRC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.51	0.46	4.05e-19	Cognitive test performance;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23690033	chr15:37393574	MEIS2	0.43	6.03	0.32	4.44e-9	Anxiety disorder;
CRC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.98	-0.31	5.67e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.41	6.15	0.32	2.29e-9	Hemoglobin concentration;
CRC	cis	rs7113874	0.569	rs4418812	chr11:8612000	A/G	cg20771178	chr11:8615675	STK33	0.35	5.7	0.3	2.73e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.33e-10	Vitamin D levels;
CRC	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.55	-0.34	2.24e-10	Metabolite levels;
CRC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.43	7.03	0.36	1.2e-11	Obesity-related traits;
CRC	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.69	9.16	0.45	5.63e-18	Alzheimer's disease;
CRC	cis	rs728616	1.000	rs728616	chr10:81847914	G/T	cg05935833	chr10:81318306	SFTPA2	-0.56	-6.74	-0.35	7.13e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.42	7.2	0.37	4.01e-12	Major depressive disorder;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.88	-0.44	4.53e-17	Aortic root size;
CRC	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12560992	chr17:57184187	TRIM37	-0.55	-7.7	-0.39	1.64e-13	Testicular germ cell tumor;
CRC	cis	rs1223397	0.651	rs59639740	chr6:13310895	T/G	cg07912922	chr6:13274314	PHACTR1	0.38	6.0	0.31	5.21e-9	Blood pressure;
CRC	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.82	-14.01	-0.61	2.7e-35	Lewy body disease;
CRC	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg10437265	chr15:77819839	NA	0.7	12.76	0.58	1.43e-30	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15203618	chr11:85646125	NA	-0.38	-6.12	-0.32	2.62e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.87	-0.31	1.05e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20588892	chr5:87565114	TMEM161B	0.44	6.17	0.32	2.06e-9	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.58	8.86	0.44	5.16e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg12193833	chr17:30244370	NA	-0.63	-8.02	-0.4	1.91e-14	Hip circumference adjusted for BMI;
CRC	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	ch.8.33884649F	chr8:33765107	NA	0.41	6.02	0.31	4.73e-9	Body mass index;
CRC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.76	-9.19	-0.45	4.44e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.38	-5.82	-0.31	1.36e-8	Endometrial cancer;
CRC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg24253500	chr15:84953950	NA	0.36	6.3	0.33	9.47e-10	Schizophrenia;
CRC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.29	-0.42	2.96e-15	Alzheimer's disease (late onset);
CRC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.53	5.96	0.31	6.67e-9	Bipolar disorder;
CRC	cis	rs6662572	0.950	rs11579176	chr1:46050561	G/T	cg08644498	chr1:46502608	NA	0.49	7.04	0.36	1.12e-11	Blood protein levels;
CRC	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.81	-0.31	1.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.44	-0.38	8.64e-13	Coronary artery disease;
CRC	cis	rs11212617	0.967	rs227086	chr11:108244251	A/T	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.55	0.34	2.19e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16304302	chr12:27486485	ARNTL2	-0.41	-6.11	-0.32	2.84e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.43	-6.25	-0.33	1.26e-9	Diastolic blood pressure;
CRC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.36	0.46	1.29e-18	Vitamin D levels;
CRC	cis	rs10512697	1.000	rs17687944	chr5:3559290	A/G	cg19473799	chr5:3511975	NA	-0.73	-5.69	-0.3	2.77e-8	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09844983	chr1:28240714	RPA2	-0.51	-6.16	-0.32	2.08e-9	Diisocyanate-induced asthma;
CRC	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg00666640	chr1:248458726	OR2T12	0.43	7.64	0.39	2.42e-13	Common traits (Other);
CRC	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.82	0.4	7.25e-14	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.51	8.12	0.41	9.26e-15	Menopause (age at onset);
CRC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg18016565	chr1:150552671	MCL1	0.43	5.91	0.31	8.66e-9	Melanoma;
CRC	cis	rs7707921	1.000	rs79616997	chr5:81504600	G/T	cg17942617	chr5:81327376	ATG10	0.4	6.05	0.32	4.04e-9	Breast cancer;
CRC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg23018236	chr17:30244563	NA	-0.65	-7.74	-0.39	1.21e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.55	8.36	0.42	1.75e-15	Testicular germ cell tumor;
CRC	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.25	0.33	1.31e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs4561483	0.667	rs3743590	chr16:11930337	A/C	cg08843971	chr16:11963173	GSPT1	-0.39	-5.89	-0.31	9.62e-9	Testicular germ cell tumor;
CRC	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.53	9.04	0.45	1.35e-17	Dupuytren's disease;
CRC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.59	9.23	0.45	3.45e-18	N-glycan levels;
CRC	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	0.93	8.47	0.42	8.27e-16	Pulse pressure;
CRC	cis	rs3996993	0.772	rs3957356	chr6:52668670	T/C	cg20803780	chr6:52668592	GSTA1	-0.38	-7.01	-0.36	1.38e-11	Hemoglobin concentration;
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs10060123	1.000	rs10072241	chr5:125685150	C/T	ch.6.113866684R	chr6:113759991	NA	-0.37	-5.99	-0.31	5.61e-9	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue;
CRC	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.67	-8.78	-0.44	8.78e-17	Ileal carcinoids;
CRC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.56	6.27	0.33	1.15e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg13319975	chr6:146136371	FBXO30	0.41	6.15	0.32	2.21e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.64	9.69	0.47	1.05e-19	Pancreatic cancer;
CRC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.54	-8.2	-0.41	5.35e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.84e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7173389	0.551	rs74022957	chr15:73663239	G/A	cg01796676	chr15:73680284	NA	0.58	5.88	0.31	9.96e-9	Resting heart rate;
CRC	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg23939001	chr4:940644	TMEM175	0.37	6.43	0.33	4.43e-10	Systemic sclerosis;
CRC	cis	rs6120849	0.901	rs6060266	chr20:33733078	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.77	0.3	1.87e-8	Protein C levels;
CRC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-6.18	-0.32	1.95e-9	Fibrinogen levels;
CRC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg13647721	chr17:30228624	UTP6	0.59	5.9	0.31	9.1e-9	Hip circumference adjusted for BMI;
CRC	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.34	-6.18	-0.32	1.92e-9	Neuroticism;
CRC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-0.81	-8.27	-0.41	3.44e-15	Schizophrenia;
CRC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	9.05	0.45	1.25e-17	Cognitive test performance;
CRC	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg23127183	chr11:57508653	C11orf31	-0.53	-7.11	-0.36	7.39e-12	Schizophrenia;
CRC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg03013999	chr17:37608204	MED1	0.48	7.2	0.37	4.02e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg00419564	chr1:153508860	S100A6	-0.47	-6.31	-0.33	8.99e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	0.47	6.32	0.33	8.44e-10	Thyroid stimulating hormone;
CRC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg04880052	chr2:219191631	PNKD	-0.45	-6.66	-0.34	1.18e-10	Colorectal cancer;
CRC	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg16898833	chr6:26189333	HIST1H4D	0.85	6.28	0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg22482690	chr17:47019901	SNF8	0.47	7.94	0.4	3.2e-14	Type 2 diabetes;
CRC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.84	0.44	5.75e-17	Morning vs. evening chronotype;
CRC	cis	rs2735413	0.918	rs11646244	chr16:78082453	T/C	cg04733911	chr16:78082701	NA	-0.45	-7.41	-0.38	1.11e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	15.32	0.65	2.24e-40	Mean corpuscular hemoglobin;
CRC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.49	6.58	0.34	1.89e-10	IgG glycosylation;
CRC	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg07424746	chr4:185654737	MLF1IP	-0.65	-6.07	-0.32	3.44e-9	Blood protein levels;
CRC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.1	0.49	4.42e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg18279126	chr7:2041391	MAD1L1	0.45	6.81	0.35	4.73e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03576123	chr11:487126	PTDSS2	-1.0	-10.1	-0.49	4.63e-21	Body mass index;
CRC	cis	rs728616	0.614	rs61859199	chr10:82118613	G/T	cg05935833	chr10:81318306	SFTPA2	-0.58	-7.02	-0.36	1.28e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg01612440	chr4:3296283	NA	0.43	6.1	0.32	3.06e-9	Serum sulfate level;
CRC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.44	7.23	0.37	3.4e-12	Menopause (age at onset);
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg13264159	chr8:625131	ERICH1	0.62	6.1	0.32	3e-9	IgG glycosylation;
CRC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg24881330	chr22:46731750	TRMU	0.65	6.29	0.33	1.02e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.57	-9.14	-0.45	6.8e-18	Intelligence (multi-trait analysis);
CRC	trans	rs7976838	0.908	rs61933776	chr12:60118939	G/A	cg16974014	chr22:22007515	MIR130B	0.49	6.02	0.31	4.62e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.55	-7.61	-0.39	2.87e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7259376	0.777	rs2664067	chr19:22638066	C/T	cg02657401	chr19:22469223	NA	-0.36	-7.68	-0.39	1.89e-13	Menopause (age at onset);
CRC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.34	-0.37	1.73e-12	IgG glycosylation;
CRC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs17095355	1.000	rs11194926	chr10:111700922	A/G	cg00817464	chr10:111662876	XPNPEP1	0.62	8.14	0.41	8.08e-15	Biliary atresia;
CRC	trans	rs17607347	0.738	rs7198449	chr16:72389230	C/T	cg27230510	chr3:50404023	CACNA2D2	0.53	6.04	0.32	4.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-8.44	-0.42	1.04e-15	Personality dimensions;
CRC	cis	rs1322512	1.000	rs2800633	chr6:153010308	T/G	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01298356	chr11:64889837	FAU;MRPL49	0.42	6.16	0.32	2.13e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg02007433	chr3:129722099	NA	-0.51	-6.26	-0.33	1.19e-9	Blood pressure (smoking interaction);
CRC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.38	-6.01	-0.31	4.83e-9	Blood metabolite levels;
CRC	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.52	-6.09	-0.32	3.15e-9	Blood protein levels;
CRC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.75	0.3	2.04e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.58	7.04	0.36	1.16e-11	Body mass index;
CRC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.51	-0.62	3.13e-37	Body mass index;
CRC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.55	-9.14	-0.45	6.38e-18	Body mass index;
CRC	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.29	-0.33	9.85e-10	Eye color traits;
CRC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg24675056	chr1:15929824	NA	0.52	7.14	0.37	6.18e-12	Systolic blood pressure;
CRC	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.9	-0.31	8.88e-9	Height;
CRC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.61	9.56	0.47	2.94e-19	Aortic root size;
CRC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.01	-0.31	5.01e-9	Bipolar disorder;
CRC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.57	8.35	0.42	1.87e-15	Response to temozolomide;
CRC	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.05	21.82	0.77	6.85e-66	Multiple myeloma;
CRC	trans	rs10403021	1.000	rs10406970	chr19:30076221	A/G	cg22044635	chr17:76557109	DNAH17	0.45	6.09	0.32	3.22e-9	Diabetic retinopathy;
CRC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.51	7.37	0.38	1.36e-12	Intelligence (multi-trait analysis);
CRC	cis	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg24315188	chr7:77428849	PHTF2;TMEM60	-0.42	-5.84	-0.31	1.25e-8	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.34	-7.78	-0.39	9.3e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg11212589	chr17:38028394	ZPBP2	0.43	7.97	0.4	2.71e-14	Self-reported allergy;
CRC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg03684893	chr10:554711	DIP2C	0.32	5.64	0.3	3.65e-8	Psychosis in Alzheimer's disease;
CRC	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.64	-0.34	1.33e-10	Triglycerides;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13265914	chr8:21999630	REEP4	0.5	6.75	0.35	6.5e-11	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg06470822	chr6:28175283	NA	0.8	12.28	0.56	8.36e-29	Parkinson's disease;
CRC	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg20356878	chr3:121714668	ILDR1	0.49	7.58	0.39	3.64e-13	Cognitive performance;
CRC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-9.3	-0.46	1.96e-18	Menarche (age at onset);
CRC	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg21280719	chr6:42927975	GNMT	-0.34	-5.89	-0.31	9.44e-9	Blood protein levels;
CRC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	11.63	0.54	2e-26	Nonalcoholic fatty liver disease;
CRC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg01420254	chr6:26195488	NA	0.77	8.6	0.43	3.3e-16	Gout;Renal underexcretion gout;
CRC	cis	rs9649465	1.000	rs9641715	chr7:123348623	A/G	cg03229431	chr7:123269106	ASB15	-0.36	-5.62	-0.3	4.05e-8	Migraine;
CRC	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg16989719	chr2:238392110	NA	0.46	6.97	0.36	1.71e-11	Prostate cancer;
CRC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.48	0.34	3.31e-10	Bipolar disorder;
CRC	cis	rs4074493	1.000	rs6700792	chr1:231170013	C/T	cg22172038	chr1:231176991	FAM89A	-0.34	-5.88	-0.31	9.87e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.75	12.89	0.58	4.75e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.2	-0.41	5.41e-15	Chronic sinus infection;
CRC	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.31	1.27e-8	Coronary artery disease;
CRC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.49	0.34	3.07e-10	Lung cancer;
CRC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-7.38	-0.38	1.27e-12	Schizophrenia;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24167897	chr15:63796719	USP3	0.4	6.33	0.33	7.97e-10	Myopia (pathological);
CRC	cis	rs7558233	0.614	rs4665213	chr2:23678781	A/G	cg00747342	chr2:23700632	KLHL29	0.53	5.93	0.31	7.87e-9	Cannabis use (initiation);
CRC	cis	rs802075	0.658	rs11757820	chr6:49636941	A/C	cg20364632	chr6:49636226	NA	0.36	6.22	0.32	1.48e-9	Bone mineral density (hip) and age at menarche;
CRC	trans	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg04077850	chr5:125800366	GRAMD3	0.36	6.13	0.32	2.47e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg24644049	chr4:85504048	CDS1	0.92	7.64	0.39	2.42e-13	Skin colour saturation;
CRC	trans	rs2303319	0.504	rs55638078	chr2:162524997	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.76	-6.16	-0.32	2.13e-9	Cognitive function;
CRC	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg26805224	chr10:79626177	DLG5	-0.49	-7.29	-0.37	2.37e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6743226	1.000	rs6743226	chr2:242236972	T/C	cg10021735	chr2:242295487	FARP2	0.46	6.53	0.34	2.5e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.3	-0.33	9.48e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.18	-13.88	-0.61	8.21e-35	Diabetic kidney disease;
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg24585782	chr17:78113791	EIF4A3	-0.53	-7.36	-0.38	1.44e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.96	-0.31	6.46e-9	Obesity-related traits;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg10596483	chr8:143751796	JRK	-0.5	-6.82	-0.35	4.5e-11	Urinary tract infection frequency;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg20041105	chr8:143859282	LYNX1	0.46	8.18	0.41	6.24e-15	Urinary tract infection frequency;
CRC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.58	-7.96	-0.4	2.88e-14	Coronary artery disease;
CRC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg09237302	chr4:906077	GAK	-0.47	-8.35	-0.42	1.87e-15	Systemic sclerosis;
CRC	cis	rs669446	0.562	rs6429636	chr1:44183540	G/T	cg12908607	chr1:44402522	ARTN	-0.33	-5.63	-0.3	3.94e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-5.66	-0.3	3.26e-8	Alzheimer's disease (survival time);
CRC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-17.81	-0.7	3.71e-50	Height;
CRC	cis	rs6741819	0.740	rs771263	chr2:7128967	A/G	cg27144453	chr2:7172511	RNF144A	-0.41	-5.98	-0.31	5.73e-9	Response to antipsychotic treatment;
CRC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.76	-12.36	-0.56	4.23e-29	Breast cancer;
CRC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.9	14.49	0.62	3.98e-37	Ewing sarcoma;
CRC	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.05	-14.85	-0.63	1.57e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg26304593	chr6:42947056	PEX6	-0.45	-6.54	-0.34	2.4e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.18	-0.49	2.39e-21	Inflammatory bowel disease;
CRC	cis	rs863345	0.565	rs10908668	chr1:158501933	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs10242455	0.702	rs76702117	chr7:98916779	A/G	cg18809830	chr7:99032528	PTCD1	-1.01	-6.97	-0.36	1.72e-11	Blood metabolite levels;
CRC	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.65	-11.15	-0.52	1.01e-24	Gout;
CRC	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.55	8.13	0.41	8.74e-15	Response to temozolomide;
CRC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.92	-0.36	2.31e-11	IgG glycosylation;
CRC	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg19773385	chr1:10388646	KIF1B	-0.7	-11.51	-0.54	5.51e-26	Hepatocellular carcinoma;
CRC	cis	rs11622475	1.000	rs2273610	chr14:104387642	G/C	cg20488157	chr14:104394430	TDRD9	0.68	9.55	0.47	3e-19	Bipolar disorder;
CRC	cis	rs2013441	1.000	rs17759959	chr17:20024095	A/G	cg13482628	chr17:19912719	NA	0.41	6.32	0.33	8.47e-10	Obesity-related traits;
CRC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.21	-0.62	4.78e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-6.56	-0.34	2.07e-10	Myopia (pathological);
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-8.9	-0.44	3.72e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	11.55	0.54	3.84e-26	Bipolar disorder;
CRC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg23517279	chr6:96025343	MANEA	0.56	6.37	0.33	6.47e-10	Behavioural disinhibition (generation interaction);
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg08798685	chr6:27730294	NA	-0.41	-5.91	-0.31	8.62e-9	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-8.17	-0.41	6.82e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg08034379	chr2:228736324	WDR69	-0.53	-7.22	-0.37	3.59e-12	Blood pressure;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11355319	chr5:89825117	LYSMD3	-0.51	-6.2	-0.32	1.68e-9	Diisocyanate-induced asthma;
CRC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.49	7.99	0.4	2.31e-14	Coronary artery disease;
CRC	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg01392867	chr16:30410429	ZNF48	0.38	6.1	0.32	3e-9	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26035323	chr1:44871156	RNF220	0.37	6.18	0.32	1.92e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg24848437	chr7:2645542	IQCE	0.61	6.33	0.33	8.03e-10	Urate levels in lean individuals;
CRC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.41	-6.45	-0.33	4.04e-10	Bone mineral density (spine);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08017156	chr16:21611107	METTL9	0.42	5.99	0.31	5.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	5.97	0.31	5.99e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.41	-0.59	5.15e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.44	6.21	0.32	1.64e-9	Aortic root size;
CRC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg21724239	chr8:58056113	NA	0.57	7.36	0.38	1.52e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg06470822	chr6:28175283	NA	0.84	12.77	0.58	1.28e-30	Parkinson's disease;
CRC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.97	-0.36	1.69e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg14254433	chr6:34482411	PACSIN1	-0.67	-6.48	-0.34	3.41e-10	Chronic lymphocytic leukemia;
CRC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.52	7.21	0.37	3.82e-12	Schizophrenia;
CRC	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg22134325	chr11:66188745	NPAS4	0.37	6.11	0.32	2.86e-9	Airway imaging phenotypes;
CRC	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.55	7.16	0.37	5.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs13315871	0.858	rs9848825	chr3:58239001	A/G	cg20936604	chr3:58311152	NA	-0.67	-6.76	-0.35	6.41e-11	Cholesterol, total;
CRC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.5	-0.5	1.92e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.36	-6.04	-0.32	4.14e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-9.79	-0.47	4.95e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.95e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg09835421	chr16:68378352	PRMT7	-0.7	-7.22	-0.37	3.67e-12	Magnesium levels;
CRC	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.37	-5.65	-0.3	3.4e-8	Schizophrenia;
CRC	cis	rs2857891	0.695	rs2857884	chr11:6984879	C/G	cg04053776	chr11:6947353	ZNF215	0.4	6.24	0.33	1.33e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg12464048	chr2:102091129	RFX8	-0.42	-6.09	-0.32	3.23e-9	Chronic rhinosinusitis with nasal polyps;
CRC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.18	-17.22	-0.69	7.98e-48	Hip circumference adjusted for BMI;
CRC	cis	rs965469	0.779	rs6037581	chr20:3351595	C/T	cg25506879	chr20:3388711	C20orf194	-0.37	-5.73	-0.3	2.26e-8	IFN-related cytopenia;
CRC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg26762873	chr11:5879799	OR52E8	-0.47	-7.09	-0.36	8.33e-12	DNA methylation (variation);
CRC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.33	-9.65	-0.47	1.44e-19	Mean corpuscular volume;
CRC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.37	6.19	0.32	1.8e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.63	9.85	0.48	3.24e-20	Corneal astigmatism;
CRC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.47	7.34	0.37	1.73e-12	Fat distribution (HIV);
CRC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.26	-0.33	1.22e-9	Gout;Renal underexcretion gout;
CRC	cis	rs720844	0.748	rs35057193	chr2:149339255	A/G	cg09247360	chr2:149335327	NA	-0.57	-6.01	-0.31	5.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10450586	0.932	rs10450561	chr11:27309956	C/T	cg10370305	chr11:27303972	NA	-0.35	-5.69	-0.3	2.74e-8	Total body bone mineral density;
CRC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg20933634	chr6:27740509	NA	0.53	6.55	0.34	2.24e-10	Parkinson's disease;
CRC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.44	0.46	7.29e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12273811	chr6:28175739	NA	0.76	10.93	0.52	6.19e-24	Depression;
CRC	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.44	0.46	7.02e-19	Common traits (Other);
CRC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg11266682	chr4:10021025	SLC2A9	0.4	6.04	0.32	4.17e-9	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.18	0.37	4.6e-12	Life satisfaction;
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.58e-8	Prudent dietary pattern;
CRC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.62	11.34	0.53	2.26e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.93	0.52	6.15e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.85	-0.51	1.23e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.66	-9.27	-0.46	2.51e-18	Personality dimensions;
CRC	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg09873164	chr1:152488093	CRCT1	0.37	6.15	0.32	2.19e-9	Hair morphology;
CRC	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.54	-8.44	-0.42	1.04e-15	Monobrow;
CRC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.55	-7.84	-0.4	6.16e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.61	8.38	0.42	1.54e-15	Coronary artery disease;
CRC	cis	rs950880	0.593	rs887972	chr2:103040945	G/A	cg03938978	chr2:103052716	IL18RAP	-0.41	-5.67	-0.3	3.16e-8	Serum protein levels (sST2);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02850371	chr1:244999141	FAM36A	0.44	6.03	0.32	4.28e-9	Response to antipsychotic treatment;
CRC	cis	rs3741151	0.686	rs7941359	chr11:73158119	A/G	cg17517138	chr11:73019481	ARHGEF17	0.55	5.84	0.31	1.25e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.45	8.97	0.44	2.28e-17	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1e-20	HDL cholesterol levels;
CRC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.64	-8.11	-0.41	9.95e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-14.98	-0.64	4.91e-39	Height;
CRC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.2	-0.45	4.39e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	9.67	0.47	1.22e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg07460842	chr6:66804631	NA	0.82	9.83	0.48	3.69e-20	Exhaled nitric oxide output;
CRC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.49	-7.31	-0.37	1.98e-12	High light scatter reticulocyte count;
CRC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.47	7.05	0.36	1.09e-11	Obesity-related traits;
CRC	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.26	10.91	0.52	7.39e-24	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.81	12.37	0.56	3.97e-29	Multiple sclerosis;
CRC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg17524180	chr13:113633600	MCF2L	-0.68	-12.87	-0.58	5.53e-31	Systolic blood pressure;
CRC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.48	-6.5	-0.34	2.92e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg01874867	chr7:94954059	PON1	-0.48	-6.19	-0.32	1.81e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.53	8.59	0.43	3.65e-16	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11081703	chr12:108909056	FICD	0.38	6.22	0.32	1.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.59	9.62	0.47	1.77e-19	Mean corpuscular hemoglobin;
CRC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.09	14.79	0.63	2.54e-38	Vitiligo;
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14863265	chr7:2801509	GNA12	-0.4	-5.82	-0.31	1.41e-8	Height;
CRC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.62	9.17	0.45	5.19e-18	Breast cancer;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg06207806	chr3:122512713	DIRC2;HSPBAP1	-0.48	-5.99	-0.31	5.65e-9	Parkinson's disease;
CRC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	0.59	6.36	0.33	6.75e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.42	-0.38	1e-12	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08495106	chr7:152161143	LOC100128822	0.42	6.13	0.32	2.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.68	-10.9	-0.51	8.15e-24	Dental caries;
CRC	trans	rs1864729	1.000	rs2853320	chr8:98283523	C/G	cg08679828	chr8:102218111	ZNF706	-0.59	-7.13	-0.37	6.34e-12	Estradiol plasma levels (breast cancer);
CRC	cis	rs8105895	0.935	rs10406553	chr19:22237801	G/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19485873	chr19:48972334	CYTH2	0.39	6.03	0.32	4.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11679072	1.000	rs74002837	chr2:240449710	C/T	cg03276489	chr2:240449683	NA	-0.89	-8.87	-0.44	4.89e-17	Blood pressure (smoking interaction);
CRC	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg09179987	chr1:167433047	CD247	0.46	6.49	0.34	3.16e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs727479	0.502	rs12591172	chr15:51503727	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-6.43	-0.33	4.6e-10	Estradiol levels;
CRC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.48	7.08	0.36	8.57e-12	Obesity-related traits;
CRC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.65	9.32	0.46	1.72e-18	Vitamin D levels;
CRC	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.6	-0.3	4.5e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg22974920	chr21:40686053	BRWD1	0.43	6.08	0.32	3.39e-9	Cognitive function;
CRC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.57	7.9	0.4	4.29e-14	Cleft lip with or without cleft palate;
CRC	cis	rs1619661	0.530	rs7909598	chr10:44688935	T/C	cg09554077	chr10:44749378	NA	0.49	7.51	0.38	5.71e-13	QT interval (ambient particulate matter interaction);
CRC	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg17218026	chr1:154582156	ADAR	0.58	9.85	0.48	3.15e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg08501292	chr6:25962987	TRIM38	0.79	6.17	0.32	2e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.65	11.83	0.55	3.87e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16262614	chr3:133464971	TF	0.33	5.89	0.31	9.5e-9	Iron status biomarkers;
CRC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	ch.11.42038R	chr11:967971	AP2A2	0.56	9.37	0.46	1.18e-18	Alzheimer's disease (late onset);
CRC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-19.77	-0.74	7.1e-58	Height;
CRC	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-0.96	-9.7	-0.47	9.78e-20	Coronary artery disease;
CRC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.62	11.22	0.53	5.75e-25	Schizophrenia;
CRC	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg22089800	chr15:90895588	ZNF774	0.48	7.44	0.38	8.71e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg09659197	chr4:152720779	NA	0.52	11.24	0.53	4.87e-25	Intelligence (multi-trait analysis);
CRC	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.7	9.48	0.46	5.18e-19	Diastolic blood pressure;
CRC	cis	rs9463078	0.774	rs4510673	chr6:45350107	A/G	cg25276700	chr6:44698697	NA	0.28	6.67	0.35	1.08e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.19	14.24	0.62	3.52e-36	Eosinophil percentage of granulocytes;
CRC	cis	rs2565722	0.723	rs2489941	chr6:161285517	C/T	cg03159191	chr6:161285451	NA	-0.47	-6.29	-0.33	1e-9	Blood protein levels;
CRC	cis	rs501120	0.657	rs646890	chr10:44741710	C/T	cg09554077	chr10:44749378	NA	0.83	10.78	0.51	2.11e-23	Coronary artery disease;Coronary heart disease;
CRC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.45	8.02	0.4	1.84e-14	Intelligence (multi-trait analysis);
CRC	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.6	8.49	0.42	7.19e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.61	-9.21	-0.45	3.84e-18	Blood pressure (smoking interaction);
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg03623178	chr6:28175578	NA	0.66	10.08	0.49	5.22e-21	Cardiac Troponin-T levels;
CRC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.31	0.46	1.92e-18	Bladder cancer;
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.48	-0.34	3.33e-10	Breast cancer;
CRC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.31	-0.37	2e-12	Bipolar disorder;
CRC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg15205204	chr1:6545172	PLEKHG5	0.38	5.66	0.3	3.22e-8	Body mass index;
CRC	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.8	0.35	4.88e-11	Retinal vascular caliber;
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-8.66	-0.43	2.11e-16	Bipolar disorder;
CRC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.66	-10.25	-0.49	1.42e-21	Diastolic blood pressure;
CRC	cis	rs7804356	0.859	rs2391362	chr7:26907123	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-5.81	-0.31	1.48e-8	Type 1 diabetes;
CRC	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg09597638	chr17:3907349	NA	0.63	10.95	0.52	5.13e-24	Type 2 diabetes;
CRC	cis	rs17127169	0.649	rs41285422	chr1:65467871	T/G	cg01340542	chr1:65468273	NA	0.81	5.63	0.3	3.87e-8	Sitting height ratio;
CRC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.9	0.58	4.44e-31	Alzheimer's disease;
CRC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.54	6.74	0.35	7.01e-11	Body mass index (adult);
CRC	trans	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg07393940	chr7:158741817	NA	-0.52	-7.51	-0.38	5.44e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg21475434	chr5:93447410	FAM172A	-0.51	-6.11	-0.32	2.81e-9	Diabetic retinopathy;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.65	10.13	0.49	3.54e-21	Longevity;Endometriosis;
CRC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02725872	chr8:58115012	NA	-0.59	-8.85	-0.44	5.51e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.73	-8.51	-0.42	6.05e-16	Gut microbiome composition (summer);
CRC	cis	rs2882667	0.898	rs6867343	chr5:138374428	C/T	cg09476006	chr5:138032270	NA	0.44	7.44	0.38	9.02e-13	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22264975	chr6:90121670	RRAGD	0.33	6.3	0.33	9.37e-10	Hip circumference;
CRC	cis	rs9463078	0.764	rs3846896	chr6:44834094	G/A	cg25276700	chr6:44698697	NA	-0.27	-6.55	-0.34	2.26e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.65	-10.83	-0.51	1.44e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg11212589	chr17:38028394	ZPBP2	0.35	6.16	0.32	2.08e-9	Asthma;
CRC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg02896835	chr1:92012615	NA	-0.48	-7.67	-0.39	1.92e-13	Breast cancer;
CRC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg16060761	chr17:80687452	NA	0.43	6.23	0.33	1.39e-9	Breast cancer;
CRC	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.86	-0.55	2.96e-27	Colorectal cancer;
CRC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.18	10.99	0.52	3.92e-24	Alzheimer's disease (late onset);
CRC	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg15571903	chr15:79123663	NA	-0.34	-6.92	-0.36	2.41e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11510247	chr12:21590784	PYROXD1	0.41	6.47	0.34	3.56e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20092199	chr4:1342459	KIAA1530	0.37	6.63	0.34	1.35e-10	Obesity-related traits;
CRC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.89	-0.31	9.32e-9	Type 2 diabetes;
CRC	cis	rs2692947	0.860	rs2579520	chr2:96660300	C/T	cg23100626	chr2:96804247	ASTL	-0.24	-6.72	-0.35	7.92e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg16589663	chr20:23618590	CST3	0.58	7.62	0.39	2.78e-13	Chronic kidney disease;
CRC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg19223190	chr17:80058835	NA	0.39	6.2	0.32	1.67e-9	Life satisfaction;
CRC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.56	-5.68	-0.3	3.04e-8	Hip circumference adjusted for BMI;
CRC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.68	0.3	2.89e-8	Tonsillectomy;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25940730	chr4:16228647	TAPT1;FLJ39653	-0.45	-6.5	-0.34	3.02e-10	Myopia (pathological);
CRC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.06	0.32	3.71e-9	Lung cancer;
CRC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.44	0.33	4.34e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.45	6.89	0.35	2.9100000000000002e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.93	-21.91	-0.77	3.09e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg01605746	chr5:669925	TPPP	-0.34	-5.68	-0.3	2.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.45	-0.38	8.37e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg19338460	chr6:170058176	WDR27	-0.69	-7.6	-0.39	3.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-8.25	-0.41	3.86e-15	Attention deficit hyperactivity disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02851105	chr16:734504	JMJD8	0.47	6.34	0.33	7.38e-10	Anxiety disorder;
CRC	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.63	6.45	0.33	4.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg02993699	chr4:3415135	RGS12	-0.39	-6.51	-0.34	2.8e-10	Serum sulfate level;
CRC	cis	rs6694672	0.717	rs10733087	chr1:197055782	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.65	0.39	2.3e-13	Asthma;
CRC	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.57	-7.7	-0.39	1.5700000000000001e-13	Birth weight;
CRC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.69	0.3	2.8e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-5.73	-0.3	2.33e-8	Major depressive disorder;
CRC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.43	6.45	0.34	3.98e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	6.26	0.33	1.18e-9	Body mass index (adult);
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg08222913	chr3:52553049	STAB1	0.35	6.53	0.34	2.48e-10	Bipolar disorder;
CRC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.4	5.61	0.3	4.35e-8	Dilated cardiomyopathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13819485	chr11:118868642	CCDC84	0.51	7.2	0.37	4.2e-12	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00526316	chr1:151043472	GABPB2	0.51	7.26	0.37	2.84e-12	Response to antipsychotic treatment;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg26591144	chr17:1532201	SLC43A2	0.4	6.29	0.33	9.84e-10	Interleukin-6 levels;
CRC	cis	rs2346160	0.867	rs2989555	chr6:167704244	C/T	cg04673565	chr6:167680447	NA	-0.33	-5.67	-0.3	3.06e-8	Parental extreme longevity (95 years and older);
CRC	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg17218026	chr1:154582156	ADAR	0.55	8.79	0.44	8.58e-17	Blood protein levels;
CRC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.69	11.17	0.52	8.91e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00066449	chr7:99063909	ATP5J2	0.44	6.06	0.32	3.63e-9	Response to antipsychotic treatment;
CRC	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg15711740	chr2:61764176	XPO1	-0.52	-7.14	-0.37	6.11e-12	Tuberculosis;
CRC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg03013999	chr17:37608204	MED1	0.45	6.86	0.35	3.45e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.65	-9.33	-0.46	1.56e-18	Type 2 diabetes;
CRC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.61	9.41	0.46	8.75e-19	Corneal astigmatism;
CRC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.84e-24	Motion sickness;
CRC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.75	7.34	0.37	1.73e-12	Diabetic retinopathy;
CRC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21582582	chr3:182698605	DCUN1D1	0.53	7.65	0.39	2.17e-13	Intelligence (multi-trait analysis);
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg16268157	chr7:99778414	STAG3	-0.44	-5.82	-0.31	1.36e-8	Lung function (FEV1/FVC);
CRC	cis	rs775227	1.000	rs35341359	chr3:112994937	A/G	cg18753928	chr3:113234510	CCDC52	-0.45	-5.64	-0.3	3.6e-8	Dental caries;
CRC	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg10483660	chr13:112241077	NA	0.36	5.77	0.3	1.87e-8	Menarche (age at onset);
CRC	trans	rs728616	0.614	rs35395602	chr10:81906770	A/G	cg18543242	chr14:23290393	SLC7A7	0.45	6.08	0.32	3.29e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.77	0.54	6.44e-27	Prudent dietary pattern;
CRC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	7.5	0.38	6.01e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.67	-9.35	-0.46	1.4e-18	Exhaled nitric oxide output;
CRC	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg10437265	chr15:77819839	NA	0.67	12.5	0.57	1.31e-29	Type 2 diabetes;
CRC	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg25019722	chr6:37503610	NA	-0.44	-8.11	-0.41	1.01e-14	Cognitive performance;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	5.89	0.31	9.68e-9	Prudent dietary pattern;
CRC	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg18753928	chr3:113234510	CCDC52	-0.47	-7.33	-0.37	1.78e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.18	0.32	1.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.62	11.45	0.53	8.95e-26	Immature fraction of reticulocytes;
CRC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.31	0.33	9.17e-10	IgG glycosylation;
CRC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.43	7.4	0.38	1.17e-12	Major depressive disorder;
CRC	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg14768256	chr3:44754587	ZNF502	-0.49	-6.26	-0.33	1.2e-9	IgG glycosylation;
CRC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg19041857	chr6:27730383	NA	-0.69	-6.52	-0.34	2.68e-10	Depression;
CRC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.96	0.31	6.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2857891	0.817	rs2638101	chr11:6969131	G/A	cg04053776	chr11:6947353	ZNF215	0.39	5.64	0.3	3.68e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.49	0.5	2.13e-22	Bipolar disorder;
CRC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	9.77	0.47	5.73e-20	Bipolar disorder and schizophrenia;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22917237	chr19:18633401	ELL	0.4	6.37	0.33	6.48e-10	Schizophrenia;
CRC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.85	-0.31	1.18e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs3026101	0.723	rs1806247	chr17:5310409	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg15445000	chr17:37608096	MED1	0.27	6.09	0.32	3.22e-9	Asthma;
CRC	cis	rs9903692	0.908	rs12950402	chr17:46180114	A/G	cg21215337	chr17:46176117	CBX1	-0.43	-7.98	-0.4	2.46e-14	Pulse pressure;
CRC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.52	-7.83	-0.4	6.69e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg20399509	chr21:47717575	C21orf57	-0.37	-5.8	-0.3	1.54e-8	Testicular germ cell tumor;
CRC	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg25856811	chr1:152973957	SPRR3	-0.21	-5.69	-0.3	2.87e-8	Inflammatory skin disease;
CRC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.79	-12.75	-0.58	1.52e-30	Cognitive function;
CRC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.4	-5.95	-0.31	7.01e-9	Mean corpuscular volume;
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07685180	chr8:600429	NA	-0.63	-6.4	-0.33	5.39e-10	IgG glycosylation;
CRC	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.71	7.49	0.38	6.55e-13	Breast cancer;
CRC	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg16558208	chr1:156270281	VHLL	0.58	9.08	0.45	1.03e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg20159608	chr7:32802032	NA	-0.6	-7.25	-0.37	2.99e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs988712	0.705	rs1829469	chr11:27730556	A/G	cg10635145	chr11:27742435	BDNF	-0.4	-5.81	-0.3	1.48e-8	Obesity;
CRC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-8.31	-0.42	2.48e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg02683197	chr6:28174875	NA	0.61	8.7	0.43	1.64e-16	Parkinson's disease;
CRC	cis	rs62367758	0.683	rs316403	chr5:43072724	A/G	cg09164108	chr5:43007320	NA	-0.47	-5.79	-0.3	1.65e-8	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
CRC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg25876840	chr17:41920477	NA	0.61	8.58	0.43	3.91e-16	Triglycerides;
CRC	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.51	7.85	0.4	5.76e-14	Corneal astigmatism;
CRC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.76	-11.22	-0.53	6.03e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-6.07	-0.32	3.45e-9	Coronary artery disease;
CRC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.86	-0.35	3.35e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.58	7.43	0.38	9.74e-13	Coronary artery disease;
CRC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.52	-0.43	5.76e-16	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03387111	chr3:101292956	PCNP	0.4	6.22	0.32	1.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.36	-0.56	4.52e-29	Alzheimer's disease;
CRC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.71	10.97	0.52	4.45e-24	Corneal astigmatism;
CRC	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg22753661	chr15:79092743	ADAMTS7	0.4	5.72	0.3	2.45e-8	Coronary artery disease or large artery stroke;
CRC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.43	5.72	0.3	2.39e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.49	-7.06	-0.36	9.66e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs7705042	0.793	rs1036207	chr5:141499041	A/G	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.95	-0.31	6.98e-9	Asthma;
CRC	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg12756093	chr1:115239321	AMPD1	0.48	7.09	0.36	8.36e-12	Autism;
CRC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.67	0.43	1.97e-16	Rheumatoid arthritis;
CRC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.85	13.38	0.59	6.93e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg17775713	chr3:133465469	TF	0.32	5.84	0.31	1.22e-8	Iron status biomarkers (transferrin levels);
CRC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.27	-14.53	-0.63	2.75e-37	Diabetic kidney disease;
CRC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg10729496	chr3:10149963	C3orf24	0.51	6.89	0.35	2.92e-11	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21819024	chr1:52344978	NRD1	0.46	5.97	0.31	6.29e-9	Thyroid stimulating hormone;
CRC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg24300038	chr13:113819356	PROZ	0.46	5.67	0.3	3.09e-8	Platelet distribution width;
CRC	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.36	-6.0	-0.31	5.27e-9	Mean arterial pressure;
CRC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg19418318	chr19:17219073	MYO9B	0.49	8.23	0.41	4.53e-15	Reticulocyte fraction of red cells;
CRC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.78	-0.3	1.76e-8	Obesity-related traits;
CRC	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.67	-0.47	1.28e-19	Blood protein levels;
CRC	cis	rs812925	0.537	rs778153	chr2:61608652	A/G	cg10580144	chr2:61372316	C2orf74	-0.33	-7.38	-0.38	1.26e-12	Immature fraction of reticulocytes;
CRC	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.67	10.67	0.51	4.99e-23	Tourette's syndrome or obsessive-compulsive disorder;
CRC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.64	-0.47	1.61e-19	Extrinsic epigenetic age acceleration;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20203792	chr4:20701925	PACRGL	0.48	6.15	0.32	2.25e-9	Thyroid stimulating hormone;
CRC	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.7	-0.3	2.6e-8	Type 2 diabetes;
CRC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	8.16	0.41	7.07e-15	Height;
CRC	cis	rs55788414	0.932	rs28514797	chr16:81185070	G/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.49	6.17	0.32	1.97e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.95	-21.81	-0.77	7.06e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.61	-8.23	-0.41	4.39e-15	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.56	-7.63	-0.39	2.57e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7772172	0.502	rs2237166	chr6:16647158	C/T	cg26843612	chr6:16636157	ATXN1	0.43	6.63	0.34	1.37e-10	Educational attainment (years of education);
CRC	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-9.25	-0.45	2.96e-18	Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05421555	chr15:85924342	AKAP13	0.45	7.43	0.38	9.36e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg10437265	chr15:77819839	NA	0.59	9.97	0.48	1.23e-20	Type 2 diabetes;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02539911	chr17:58677246	PPM1D	-0.6	-7.22	-0.37	3.57e-12	Diisocyanate-induced asthma;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.73	7.7	0.39	1.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-7.28	-0.37	2.55e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17819963	chr10:135191943	PAOX	0.4	7.06	0.36	1.02e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.82	10.66	0.51	5.69e-23	Diisocyanate-induced asthma;
CRC	cis	rs16852403	0.861	rs73049336	chr1:178042298	A/T	cg00404053	chr1:178313656	RASAL2	0.48	6.03	0.32	4.46e-9	Childhood ear infection;
CRC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg26695010	chr11:65641043	EFEMP2	-0.39	-5.85	-0.31	1.19e-8	Eosinophil percentage of white cells;
CRC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.95	0.4	3e-14	Platelet count;
CRC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg23298862	chr7:158159286	PTPRN2	0.47	7.66	0.39	2.16e-13	Calcium levels;
CRC	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.47	7.99	0.4	2.29e-14	Common traits (Other);
CRC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.81	11.96	0.55	1.24e-27	Breast cancer;
CRC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.92	11.73	0.54	8.63e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	7.89	0.4	4.4e-14	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg27205649	chr11:78285834	NARS2	0.52	6.67	0.34	1.11e-10	Alzheimer's disease (survival time);
CRC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg24910161	chr17:38119198	GSDMA	0.45	7.97	0.4	2.58e-14	Asthma and hay fever;
CRC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg19688584	chr6:167529678	CCR6	-0.34	-6.32	-0.33	8.63e-10	Primary biliary cholangitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07133894	chr22:32808171	C22orf28	0.49	6.75	0.35	6.5500000000000006e-11	Response to antipsychotic treatment;
CRC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.66	9.38	0.46	1.13e-18	Vitamin D levels;
CRC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.56	7.03	0.36	1.19e-11	Response to diuretic therapy;
CRC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	cis	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg18131467	chr2:239335373	ASB1	-0.69	-6.22	-0.32	1.52e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.42	-7.15	-0.37	5.68e-12	Melanoma;
CRC	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg02158880	chr13:53174818	NA	0.4	5.63	0.3	3.91e-8	Lewy body disease;
CRC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg25456477	chr12:86230367	RASSF9	0.38	6.43	0.33	4.41e-10	Major depressive disorder;
CRC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.9	-11.44	-0.53	1e-25	Hair shape;
CRC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.65	-8.12	-0.41	9.74e-15	Immature fraction of reticulocytes;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg25164649	chr6:28176230	NA	-0.66	-9.15	-0.45	6.32e-18	Parkinson's disease;
CRC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.75	-11.86	-0.55	3.06e-27	Height;
CRC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg12273811	chr6:28175739	NA	0.54	7.21	0.37	3.86e-12	Parkinson's disease;
CRC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.47	-5.92	-0.31	8e-9	Aortic root size;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.14	-0.56	2.81e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.16	-12.12	-0.56	3.3e-28	Breast cancer;
CRC	trans	rs7604735	0.824	rs1881410	chr2:145821717	C/T	cg26010734	chr19:15344046	EPHX3	-0.35	-6.08	-0.32	3.34e-9	Coronary artery disease;
CRC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.71	-7.94	-0.4	3.27e-14	Obesity-related traits;
CRC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.47	6.51	0.34	2.73e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.96	-12.69	-0.57	2.6e-30	IgG glycosylation;
CRC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.36	0.33	6.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.61	-8.32	-0.42	2.39e-15	Height;
CRC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg06470822	chr6:28175283	NA	0.8	11.92	0.55	1.78e-27	Parkinson's disease;
CRC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.77	-0.35	6.03e-11	Total cholesterol levels;
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.5	0.6	2.34e-33	Alzheimer's disease;
CRC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.11	-0.32	2.75e-9	Morning vs. evening chronotype;
CRC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.8	-7.69	-0.39	1.67e-13	Diabetic retinopathy;
CRC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.18	-0.37	4.76e-12	IgG glycosylation;
CRC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.53	-0.38	4.97e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.58	-0.34	1.82e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg22134325	chr11:66188745	NPAS4	0.4	6.43	0.33	4.49e-10	Airway imaging phenotypes;
CRC	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg21851534	chr17:3907994	ZZEF1	0.37	6.41	0.33	5.16e-10	Type 2 diabetes;
CRC	cis	rs77861329	1.000	rs9841469	chr3:52166596	C/A	cg08692210	chr3:52188851	WDR51A	0.86	7.84	0.4	6.46e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.07e-10	Life satisfaction;
CRC	cis	rs6088813	1.000	rs56306402	chr20:33937704	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-5.73	-0.3	2.3e-8	Height;
CRC	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.41	0.33	5.02e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg16606324	chr3:10149918	C3orf24	0.7	9.64	0.47	1.61e-19	Alzheimer's disease;
CRC	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg10523679	chr1:76189770	ACADM	0.4	5.65	0.3	3.47e-8	Daytime sleep phenotypes;
CRC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	10.03	0.48	7.98e-21	Alzheimer's disease (late onset);
CRC	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg26248373	chr2:1572462	NA	-0.63	-6.64	-0.34	1.29e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.94	0.4	3.18e-14	Cognitive ability;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg20999565	chr14:68265668	ZFYVE26	-0.54	-7.07	-0.36	9.14e-12	Parkinson's disease;
CRC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg04362960	chr10:104952993	NT5C2	-0.43	-6.02	-0.32	4.58e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg02033258	chr5:131593261	PDLIM4	0.34	6.0	0.31	5.11e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23262073	chr20:60523788	NA	-0.41	-6.57	-0.34	2e-10	Body mass index;
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02725872	chr8:58115012	NA	-0.59	-9.08	-0.45	1.02e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg18876405	chr7:65276391	NA	0.45	6.27	0.33	1.11e-9	Aortic root size;
CRC	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	1.01	12.23	0.56	1.28e-28	Obesity-related traits;
CRC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg06470822	chr6:28175283	NA	0.48	6.68	0.35	1.02e-10	Depression;
CRC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.4	8.87	0.44	4.76e-17	Eye color traits;
CRC	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.96	-0.4	2.78e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg15147215	chr3:52552868	STAB1	0.5	8.61	0.43	3.13e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26546504	chr18:54318490	WDR7	0.45	6.25	0.33	1.29e-9	Anxiety disorder;
CRC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg21251018	chr6:28226885	NKAPL	0.55	9.43	0.46	7.66e-19	Pulmonary function;
CRC	cis	rs6834538	0.655	rs4428348	chr4:113423989	G/A	cg10021238	chr4:113569128	MIR367;LARP7	-0.39	-5.79	-0.3	1.67e-8	Free thyroxine concentration;
CRC	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg15131784	chr3:139108705	COPB2	0.4	5.78	0.3	1.76e-8	Obesity-related traits;
CRC	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.58	7.96	0.4	2.87e-14	Adiposity;
CRC	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.37	6.11	0.32	2.79e-9	Sitting height ratio;
CRC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.6	8.31	0.42	2.62e-15	Obesity-related traits;
CRC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.9	17.3	0.69	3.92e-48	Intelligence (multi-trait analysis);
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.87	-0.44	4.88e-17	Bipolar disorder;
CRC	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.5	-8.16	-0.41	6.96e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.07	-0.32	3.46e-9	Alzheimer's disease (late onset);
CRC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.56	-0.38	4.18e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.54	6.9	0.36	2.63e-11	Body mass index (adult);
CRC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg23996704	chr18:44553084	KATNAL2	-0.35	-7.24	-0.37	3.1e-12	Personality dimensions;
CRC	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.88	-0.51	9.38e-24	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23182539	chr10:121355708	TIAL1	-0.53	-6.52	-0.34	2.67e-10	Diisocyanate-induced asthma;
CRC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg15848620	chr12:58087721	OS9	-0.61	-8.38	-0.42	1.61e-15	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19683457	chr6:105307726	HACE1	-0.45	-6.72	-0.35	8.17e-11	Myopia (pathological);
CRC	trans	rs12200782	0.649	rs4490658	chr6:26385113	A/G	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs12550646	0.652	rs12680139	chr8:41666355	G/T	cg12180191	chr8:41686706	ANK1	-0.4	-5.88	-0.31	9.94e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CRC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.39	6.0	0.31	5.34e-9	Crohn's disease;
CRC	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg19875535	chr5:140030758	IK	0.39	6.02	0.32	4.55e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.84	12.13	0.56	2.95e-28	Cognitive function;
CRC	cis	rs10512697	0.772	rs35155570	chr5:3518273	C/T	cg19473799	chr5:3511975	NA	-0.85	-6.62	-0.34	1.44e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.95	-12.92	-0.58	3.6e-31	Hair shape;
CRC	cis	rs17152411	0.895	rs7079153	chr10:126587146	C/G	cg07906193	chr10:126599966	NA	0.56	6.43	0.33	4.37e-10	Height;
CRC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21643547	chr1:205240462	TMCC2	0.39	6.31	0.33	8.89e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.86	-0.31	1.13e-8	Life satisfaction;
CRC	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.55	9.0	0.44	1.84e-17	Corneal astigmatism;
CRC	cis	rs45544231	0.544	rs8052175	chr16:52577142	C/T	cg09051775	chr16:52580266	TOX3	-0.4	-6.37	-0.33	6.42e-10	Restless legs syndrome;
CRC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.84	14.74	0.63	4.12e-38	Breast cancer;
CRC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.9	-0.31	9.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.61	9.66	0.47	1.33e-19	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.43	6.07	0.32	3.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.98	13.68	0.6	5.03e-34	Exhaled nitric oxide output;
CRC	cis	rs3996993	0.809	rs12524918	chr6:52736180	T/C	cg20803780	chr6:52668592	GSTA1	0.37	6.85	0.35	3.6e-11	Hemoglobin concentration;
CRC	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg08271804	chr19:22816896	ZNF492	0.38	5.85	0.31	1.2e-8	Bronchopulmonary dysplasia;
CRC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.5	8.13	0.41	8.79e-15	Lipoprotein (a) levels;
CRC	cis	rs9517320	1.000	rs7338549	chr13:99142745	C/T	cg20487152	chr13:99095054	FARP1	0.35	5.7	0.3	2.72e-8	Longevity;
CRC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	5.67	0.3	3.14e-8	Mood instability;
CRC	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg06634786	chr22:41940651	POLR3H	-0.44	-5.7	-0.3	2.66e-8	Neuroticism;
CRC	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.72	7.98	0.4	2.5e-14	Iron status biomarkers;
CRC	cis	rs802075	1.000	rs360565	chr6:49657805	C/T	cg20364632	chr6:49636226	NA	-0.36	-5.88	-0.31	9.95e-9	Bone mineral density (hip) and age at menarche;
CRC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs7781266	0.500	rs2971975	chr7:133645355	G/A	cg03336402	chr7:133662267	EXOC4	-0.67	-10.46	-0.5	2.65e-22	Educational attainment (college completion);
CRC	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg18551225	chr6:44695536	NA	-0.41	-5.95	-0.31	6.68e-9	Total body bone mineral density;
CRC	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.01	-0.36	1.37e-11	IgG glycosylation;
CRC	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.45	-7.32	-0.37	1.86e-12	Refractive error;
CRC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.86	0.44	5.18e-17	Morning vs. evening chronotype;
CRC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.96	0.31	6.41e-9	Lung cancer;
CRC	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-6.46	-0.34	3.86e-10	Subjective well-being;
CRC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.69	9.81	0.48	4.15e-20	Cognitive function;
CRC	cis	rs12541635	0.967	rs4734896	chr8:107075454	T/C	cg10147462	chr8:107024639	NA	-0.38	-6.41	-0.33	5.1e-10	Age of smoking initiation;
CRC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.77	11.92	0.55	1.78e-27	Schizophrenia;
CRC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.71	11.61	0.54	2.4e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.9	-0.31	8.99e-9	Life satisfaction;
CRC	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.18	-0.37	4.62e-12	HDL cholesterol;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg08301299	chr16:2317849	RNPS1	-0.52	-6.13	-0.32	2.51e-9	Optic disc area;
CRC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.43	-9.45	-0.46	6.4e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.24	0.49	1.54e-21	Monocyte percentage of white cells;
CRC	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.61	-9.72	-0.47	8.23e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.46	6.59	0.34	1.7e-10	Subjective well-being;
CRC	cis	rs990171	0.955	rs6734736	chr2:103062880	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	5.91	0.31	8.41e-9	Lymphocyte counts;
CRC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg21709803	chr11:61594965	FADS2	-0.58	-6.8	-0.35	4.99e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.4	-0.33	5.25e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg15269541	chr15:43626905	ADAL	-0.48	-5.84	-0.31	1.26e-8	Lung cancer in ever smokers;
CRC	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg23254163	chr1:152506842	NA	0.5	10.11	0.49	4.05e-21	Hair morphology;
CRC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.63	11.52	0.54	5.02e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25907053	chr2:70369816	NA	0.45	6.31	0.33	8.79e-10	Anxiety disorder;
CRC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg20684491	chr1:25596433	NA	0.41	7.3	0.37	2.25e-12	Erythrocyte sedimentation rate;
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.55	-8.07	-0.41	1.35e-14	Rheumatoid arthritis;
CRC	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.43	-6.51	-0.34	2.85e-10	Knee osteoarthritis;
CRC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg17724175	chr1:150552817	MCL1	0.44	6.69	0.35	9.45e-11	Melanoma;
CRC	cis	rs10971721	0.822	rs72727341	chr9:33936876	C/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.18	0.45	4.87e-18	Hip circumference adjusted for BMI;
CRC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg05585544	chr11:47624801	NA	0.48	8.6	0.43	3.29e-16	Subjective well-being;
CRC	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.88	0.35	2.99e-11	Neuroticism;
CRC	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.67	10.44	0.5	3.19e-22	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs12044355	0.827	rs11586191	chr1:231831781	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.22	0.32	1.54e-9	Alzheimer's disease;
CRC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.4	-5.88	-0.31	1e-8	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01881255	chr19:40950703	SERTAD3	0.49	7.3	0.37	2.2e-12	Response to antipsychotic treatment;
CRC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg00074818	chr8:8560427	CLDN23	0.32	5.88	0.31	9.95e-9	Obesity-related traits;
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg22687807	chr8:143858763	LYNX1	0.51	8.97	0.44	2.24e-17	Urinary tract infection frequency;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg05755906	chr12:113623461	C12orf52;DDX54	-0.45	-6.38	-0.33	6.14e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg03395651	chr16:88107091	BANP	0.6	7.76	0.39	1.12e-13	Menopause (age at onset);
CRC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.22	-0.32	1.55e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	10.66	0.51	5.62e-23	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.55	-7.65	-0.39	2.28e-13	Inflammatory bowel disease;
CRC	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.76	-0.39	1.09e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.5	-7.44	-0.38	9.07e-13	Menarche (age at onset);
CRC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg09141835	chr16:88988174	CBFA2T3	0.27	5.87	0.31	1.08e-8	Social autistic-like traits;
CRC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
CRC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-8.34	-0.42	2.12e-15	Hemoglobin concentration;
CRC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.56	-0.34	2.04e-10	Subjective well-being;
CRC	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.94	-0.31	7.39e-9	Alzheimer's disease (survival time);
CRC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.58	8.59	0.43	3.57e-16	Prostate cancer;
CRC	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.51	-8.4	-0.42	1.35e-15	Sense of smell;
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.62	0.54	2.28e-26	Alzheimer's disease;
CRC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	6.78	0.35	5.45e-11	Lung function (FEV1/FVC);
CRC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-0.68	-8.31	-0.42	2.63e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	6.74	0.35	7.28e-11	Initial pursuit acceleration;
CRC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.51	7.13	0.37	6.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10274279	0.660	rs4716760	chr7:157376644	A/G	cg26886268	chr7:157387156	PTPRN2	0.46	6.49	0.34	3.17e-10	Myopia (pathological);
CRC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.57	8.56	0.43	4.54e-16	Blood protein levels;
CRC	cis	rs6504622	0.818	rs9898527	chr17:45036210	G/A	cg16759221	chr17:45003025	GOSR2	-0.5	-7.47	-0.38	7.24e-13	Orofacial clefts;
CRC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.25	15.13	0.64	1.26e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.41	5.85	0.31	1.16e-8	Blood metabolite levels;
CRC	trans	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	7.02	0.36	1.24e-11	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg05569086	chr8:143859399	LYNX1	0.4	6.96	0.36	1.91e-11	Urinary tract infection frequency;
CRC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.64	11.21	0.53	6.38e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.85	9.81	0.48	4.4e-20	Psoriasis;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.61	-0.47	1.9e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg10298567	chr3:47292165	KIF9	-0.38	-6.22	-0.32	1.47e-9	Colorectal cancer;
CRC	trans	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg06791473	chr12:49259579	RND1	-0.61	-6.05	-0.32	3.91e-9	Blood protein levels;
CRC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg18512352	chr11:47633146	NA	-0.37	-7.32	-0.37	1.97e-12	Subjective well-being;
CRC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg23283495	chr1:209979779	IRF6	0.51	7.29	0.37	2.36e-12	Cleft lip with or without cleft palate;
CRC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.72	7.73	0.39	1.31e-13	Diabetic retinopathy;
CRC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.29	0.56	7.65e-29	Menopause (age at onset);
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-7.23	-0.37	3.48e-12	Lymphocyte counts;
CRC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.4	-0.56	3e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg02880119	chr16:3481970	NA	0.43	6.05	0.32	3.91e-9	Body mass index (adult);
CRC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg18764771	chr6:116381957	FRK	0.25	6.8	0.35	4.83e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg01339444	chr6:118972232	C6orf204	0.53	6.03	0.32	4.29e-9	Diastolic blood pressure;
CRC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.76	13.03	0.58	1.46e-31	Red cell distribution width;Reticulocyte count;
CRC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg00999904	chr2:3704751	ALLC	-0.53	-6.66	-0.34	1.15e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs294883	0.858	rs9347297	chr6:159702475	G/A	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Parkinson's disease;
CRC	cis	rs59104589	0.617	rs111937035	chr2:242212177	C/T	cg19488206	chr2:242435732	STK25	0.49	7.07	0.36	9.41e-12	Fibrinogen levels;
CRC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.74	12.86	0.58	5.93e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	17.52	0.69	5.38e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	5.98	0.31	5.75e-9	Life satisfaction;
CRC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.49	0.34	3.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg22117107	chr15:45993392	NA	-0.45	-9.14	-0.45	6.79e-18	Waist circumference;Weight;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.45	6.47	0.34	3.47e-10	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg13490827	chr1:46269305	MAST2	-0.72	-6.21	-0.32	1.56e-9	Cognitive function;
CRC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg13844804	chr7:814759	HEATR2	0.68	8.14	0.41	8.45e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.53	-7.36	-0.38	1.5e-12	Primary sclerosing cholangitis;
CRC	cis	rs427941	0.575	rs201520	chr7:101770677	G/A	cg06246474	chr7:101738831	CUX1	0.37	5.66	0.3	3.27e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.05	10.89	0.51	8.72e-24	Diabetic retinopathy;
CRC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	9.15	0.45	6.03e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.92	0.31	8.24e-9	Diabetic retinopathy;
CRC	cis	rs45544231	0.569	rs1362550	chr16:52582816	C/G	cg09051775	chr16:52580266	TOX3	-0.42	-6.59	-0.34	1.77e-10	Restless legs syndrome;
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.7	-0.51	4.11e-23	Bipolar disorder;
CRC	cis	rs11627756	0.801	rs4906237	chr14:103077649	T/G	cg12046867	chr14:103022105	NA	-0.44	-5.86	-0.31	1.13e-8	Mean platelet volume;
CRC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.49	-7.6	-0.39	3.16e-13	Response to antineoplastic agents;
CRC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.54e-33	Menopause (age at onset);
CRC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.42	-6.22	-0.32	1.55e-9	Aortic root size;
CRC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg17346650	chr17:80929145	B3GNTL1	0.48	7.24	0.37	3.26e-12	Glycated hemoglobin levels;
CRC	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.72	-0.35	7.96e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6546324	0.592	rs9309402	chr2:67869338	T/C	cg15745817	chr2:67799979	NA	-0.55	-9.54	-0.47	3.34e-19	Endometriosis;
CRC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	9.37	0.46	1.21e-18	Lymphocyte counts;
CRC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg05132306	chr1:1846340	CALML6	-0.44	-6.86	-0.35	3.38e-11	Body mass index;
CRC	cis	rs6684514	0.961	rs11264463	chr1:156242806	A/G	cg16558208	chr1:156270281	VHLL	0.53	8.5	0.42	6.47e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-8.16	-0.41	7.26e-15	Hemoglobin concentration;
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-7.81	-0.4	7.79e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.67	10.08	0.49	5.26e-21	Menopause (age at onset);
CRC	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.57	-8.04	-0.41	1.68e-14	Triglycerides;
CRC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.26	14.46	0.62	5.09e-37	Diabetic kidney disease;
CRC	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.51	8.0	0.4	2.21e-14	Coronary artery disease;
CRC	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-5.75	-0.3	2.02e-8	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02702510	chr10:46090551	MARCH8	0.45	6.26	0.33	1.2e-9	Response to antipsychotic treatment;
CRC	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-5.84	-0.31	1.24e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg13401533	chr1:37979913	MEAF6	0.44	6.23	0.32	1.42e-9	Axial length;
CRC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.49	7.13	0.37	6.42e-12	Height;
CRC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg11189052	chr15:85197271	WDR73	0.58	8.43	0.42	1.1e-15	Schizophrenia;
CRC	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg20936604	chr3:58311152	NA	-0.77	-8.0	-0.4	2.15e-14	Cholesterol, total;
CRC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.13	0.45	7.14e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg20041105	chr8:143859282	LYNX1	0.46	8.12	0.41	9.33e-15	Urinary tract infection frequency;
CRC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.69	-8.42	-0.42	1.18e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00558813	chr19:14063372	PODNL1;DCAF15	0.38	6.1	0.32	3.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7932354	0.528	rs4752962	chr11:47141670	C/G	cg19486271	chr11:47235900	DDB2	0.49	7.16	0.37	5.34e-12	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs11098699	0.821	rs13148385	chr4:124206117	A/G	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.68e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.81	13.65	0.6	6.48e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20975546	chr22:18893598	DGCR6	0.39	6.04	0.32	4.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.68	-9.95	-0.48	1.41e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs7705042	0.865	rs4385236	chr5:141513396	G/A	cg08523384	chr5:141488047	NDFIP1	-0.31	-5.68	-0.3	3.02e-8	Asthma;
CRC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg02741985	chr17:80059408	CCDC57	0.44	7.29	0.37	2.38e-12	Life satisfaction;
CRC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.41	6.24	0.33	1.38e-9	Schizophrenia;
CRC	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg16898833	chr6:26189333	HIST1H4D	0.75	6.38	0.33	5.93e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.25	-0.33	1.24e-9	Mood instability;
CRC	cis	rs2019216	0.651	rs6565378	chr17:21831307	A/G	cg05591447	chr17:21909280	FLJ36000	-0.31	-5.96	-0.31	6.38e-9	Pelvic organ prolapse;
CRC	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.74	11.4	0.53	1.38e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.53	-7.77	-0.39	1.03e-13	Intelligence (multi-trait analysis);
CRC	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-6.89	-0.36	2.87e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.44	-6.7	-0.35	8.83e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CRC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.42	-5.89	-0.31	9.67e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.64	-0.43	2.54e-16	Aortic root size;
CRC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14895029	chr7:2775587	GNA12	-0.4	-5.93	-0.31	7.82e-9	Height;
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.51e-24	Motion sickness;
CRC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg20673091	chr1:2541236	MMEL1	-0.37	-5.81	-0.31	1.44e-8	Ulcerative colitis;
CRC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.37	8.32	0.42	2.32e-15	Multiple system atrophy;
CRC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg03037974	chr15:76606532	NA	-0.5	-6.95	-0.36	2.01e-11	Blood metabolite levels;
CRC	cis	rs12580194	0.593	rs7959837	chr12:55734511	G/A	cg19537932	chr12:55886519	OR6C68	-0.69	-8.71	-0.43	1.47e-16	Cancer;
CRC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12311346	chr5:56204834	C5orf35	-0.51	-7.83	-0.4	6.75e-14	Coronary artery disease;
CRC	cis	rs4478858	0.746	rs7544003	chr1:31689088	C/T	cg00250761	chr1:31883323	NA	0.31	5.81	0.31	1.44e-8	Alcohol dependence;
CRC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.54	-9.36	-0.46	1.25e-18	Migraine;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.67	10.37	0.5	5.42e-22	Lymphocyte counts;
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.46	8.06	0.41	1.42e-14	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04078321	chr6:155635785	TFB1M	0.41	6.57	0.34	1.99e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.48e-13	Type 2 diabetes;
CRC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.5	8.01	0.4	1.96e-14	Lipoprotein (a) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20552752	chr15:90895281	ZNF774	0.51	7.56	0.38	3.96e-13	Response to antipsychotic treatment;
CRC	cis	rs6120849	0.901	rs6058194	chr20:33739831	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	5.89	0.31	9.52e-9	Protein C levels;
CRC	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.75	-15.44	-0.65	7.65e-41	Leprosy;
CRC	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg15192750	chr16:69999425	NA	0.6	8.02	0.4	1.92e-14	IgE levels;
CRC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-10.05	-0.48	6.74e-21	Coronary artery disease;
CRC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.54	7.9	0.4	4.17e-14	Height;
CRC	cis	rs4481887	0.504	rs7544149	chr1:248360096	C/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs35000415	0.938	rs71581958	chr7:128665542	C/T	cg19972273	chr7:128594194	NA	0.68	6.32	0.33	8.52e-10	Systemic lupus erythematosus;
CRC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.13e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2411233	1.000	rs8034449	chr15:39278940	C/A	cg23129342	chr15:39283510	NA	0.31	5.63	0.3	3.79e-8	Platelet count;
CRC	cis	rs372883	0.530	rs55921835	chr21:30544623	A/G	cg24692254	chr21:30365293	RNF160	-0.38	-5.61	-0.3	4.31e-8	Pancreatic cancer;
CRC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.72	6.99	0.36	1.52e-11	Fat distribution (HIV);
CRC	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.7	-9.69	-0.47	1.09e-19	Pubertal anthropometrics;
CRC	cis	rs7640424	0.502	rs326359	chr3:107820619	G/A	cg09227934	chr3:107805635	CD47	0.51	9.14	0.45	6.79e-18	Body mass index;
CRC	trans	rs12495832	0.778	rs76487918	chr3:147926060	T/C	cg10221266	chr7:153579447	NA	0.56	6.12	0.32	2.6e-9	Chin dimples;
CRC	cis	rs459193	1.000	rs458741	chr5:55807837	T/C	cg18302225	chr5:55776401	NA	0.58	8.6	0.43	3.38e-16	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs6433857	0.594	rs10202422	chr2:181524944	C/T	cg23363182	chr2:181467187	NA	-0.47	-7.44	-0.38	9e-13	Body mass index;
CRC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.72	-0.39	1.41e-13	Psoriasis;
CRC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg21784768	chr11:537496	LRRC56	-0.72	-6.87	-0.35	3.26e-11	Body mass index;
CRC	cis	rs4728302	0.869	rs11770927	chr7:133593126	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.25e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.8	10.57	0.5	1.11e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg12458913	chr13:53173898	NA	0.5	7.48	0.38	6.78e-13	Lewy body disease;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.22	-0.37	3.66e-12	Bipolar disorder;
CRC	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.69	-0.39	1.71e-13	Vitamin D levels;
CRC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg22110888	chr17:80059540	CCDC57	0.38	6.07	0.32	3.61e-9	Life satisfaction;
CRC	cis	rs7605827	0.930	rs2287263	chr2:15637366	C/T	cg19274914	chr2:15703543	NA	0.38	5.81	0.3	1.5e-8	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08724901	chr15:89089781	DET1	0.46	6.41	0.33	5.14e-10	Response to antipsychotic treatment;
CRC	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.96	12.07	0.55	5.02e-28	Exhaled nitric oxide levels;
CRC	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-6.01	-0.31	4.84e-9	Coronary artery disease;
CRC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.4	-0.56	3.07e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg18876405	chr7:65276391	NA	-0.44	-6.13	-0.32	2.51e-9	Aortic root size;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg19223190	chr17:80058835	NA	0.39	6.16	0.32	2.12e-9	Life satisfaction;
CRC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.6	7.11	0.36	7.3e-12	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14705778	chr4:174254825	HMGB2	0.44	6.59	0.34	1.72e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.48	-5.76	-0.3	1.96e-8	Gut microbiome composition (summer);
CRC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.48	6.21	0.32	1.61e-9	Blood metabolite levels;
CRC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.5	-8.1	-0.41	1.09e-14	Huntington's disease progression;
CRC	cis	rs6662572	0.737	rs4660901	chr1:46445257	G/A	cg08644498	chr1:46502608	NA	-0.46	-7.3	-0.37	2.16e-12	Blood protein levels;
CRC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.91	-15.94	-0.66	8.84e-43	Height;
CRC	cis	rs2885135	1.000	rs2885135	chr1:13906527	C/G	cg04886857	chr1:13914270	PDPN	0.37	6.6	0.34	1.68e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.08	-0.32	3.27e-9	Total body bone mineral density;
CRC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	5.98	0.31	5.85e-9	Axial length;
CRC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.78	-0.47	5.21e-20	Hip circumference adjusted for BMI;
CRC	trans	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.59	-6.17	-0.32	2.01e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg16576620	chr11:61596068	FADS2	-0.45	-5.74	-0.3	2.2e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09174674	chr1:9884042	CLSTN1	-0.41	-6.21	-0.32	1.64e-9	Myopia (pathological);
CRC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.67	-8.38	-0.42	1.59e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.54	9.01	0.44	1.71e-17	Dupuytren's disease;
CRC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-20.5	-0.75	9.14e-61	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.59	-7.96	-0.4	2.89e-14	White matter hyperintensity burden;
CRC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.58e-12	Height;
CRC	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.65	-0.39	2.22e-13	Morning vs. evening chronotype;
CRC	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg22561889	chr6:118971681	C6orf204	0.5	6.39	0.33	5.81e-10	Diastolic blood pressure;
CRC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.46	6.8	0.35	4.87e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg16239906	chr20:35724590	RBL1	-0.47	-6.19	-0.32	1.74e-9	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.73	-0.43	1.32e-16	Bipolar disorder;
CRC	cis	rs11009175	0.725	rs10827170	chr10:33290343	C/G	cg00146027	chr10:33299147	NA	0.31	6.11	0.32	2.86e-9	Depression (quantitative trait);
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.09	-0.32	3.11e-9	Total body bone mineral density;
CRC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.59	7.85	0.4	6.04e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg17775713	chr3:133465469	TF	0.37	6.76	0.35	6.35e-11	Iron status biomarkers (transferrin levels);
CRC	cis	rs6662572	0.737	rs11211214	chr1:46347328	C/T	cg08644498	chr1:46502608	NA	-0.46	-7.3	-0.37	2.2e-12	Blood protein levels;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg25164649	chr6:28176230	NA	0.7	8.96	0.44	2.42e-17	Parkinson's disease;
CRC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	8.24	0.41	4.15e-15	Hip circumference adjusted for BMI;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01279709	chr13:28196083	POLR1D;LNX2	-0.53	-6.35	-0.33	7.21e-10	Diisocyanate-induced asthma;
CRC	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.84	12.77	0.58	1.27e-30	Menarche (age at onset);
CRC	cis	rs17767392	0.705	rs4899393	chr14:71739924	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.47	-5.96	-0.31	6.47e-9	Mitral valve prolapse;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.78	12.71	0.57	2.25e-30	Height;
CRC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg09873164	chr1:152488093	CRCT1	0.36	6.16	0.32	2.11e-9	Hair morphology;
CRC	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg10437265	chr15:77819839	NA	0.59	9.99	0.48	1.03e-20	Type 2 diabetes;
CRC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.45	8.52	0.43	5.96e-16	Prostate cancer;
CRC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.74	-9.08	-0.45	1.03e-17	Behavioural disinhibition (generation interaction);
CRC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.69	9.42	0.46	8.49e-19	Platelet distribution width;
CRC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.68e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.8	-10.61	-0.51	7.95e-23	Motion sickness;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg12273811	chr6:28175739	NA	0.45	7.01	0.36	1.39e-11	Pubertal anthropometrics;
CRC	cis	rs9648716	1.000	rs10255711	chr7:140608476	C/A	cg10747023	chr7:140774559	NA	0.47	6.02	0.32	4.63e-9	Type 2 diabetes;
CRC	cis	rs1009181	0.585	rs2066295	chr6:26168903	A/G	cg13736514	chr6:26305472	NA	-0.4	-5.9	-0.31	8.91e-9	Childhood ear infection;
CRC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.37	8.56	0.43	4.47e-16	Multiple system atrophy;
CRC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg00129232	chr17:37814104	STARD3	0.59	7.37	0.38	1.37e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg18196295	chr10:418757	DIP2C	-0.56	-7.77	-0.39	9.81e-14	Psychosis in Alzheimer's disease;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.54	6.34	0.33	7.39e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.6	-9.86	-0.48	2.84e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.24	0.41	4.26e-15	Birth weight;
CRC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.65	9.35	0.46	1.43e-18	Vitamin D levels;
CRC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg05044414	chr3:183734942	ABCC5	-0.34	-5.62	-0.3	4.04e-8	Anterior chamber depth;
CRC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.52	7.33	0.37	1.78e-12	Tonsillectomy;
CRC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.43	6.36	0.33	6.91e-10	Pulse pressure;
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.19	-0.37	4.28e-12	Bipolar disorder;
CRC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg15605315	chr1:45957053	TESK2	0.38	6.08	0.32	3.26e-9	High light scatter reticulocyte count;
CRC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg09658497	chr7:2847517	GNA12	-0.37	-6.13	-0.32	2.51e-9	Plateletcrit;
CRC	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.43	6.95	0.36	1.94e-11	Sitting height ratio;
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.13	-0.32	2.5e-9	Bipolar disorder;
CRC	cis	rs4523957	0.788	rs2169357	chr17:2096441	C/T	cg16513277	chr17:2031491	SMG6	-0.56	-9.45	-0.46	6.8e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12900413	0.879	rs2165072	chr15:90302629	A/G	cg24249390	chr15:90295951	MESP1	-0.63	-9.01	-0.44	1.72e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.71	-11.88	-0.55	2.46e-27	Itch intensity from mosquito bite;
CRC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.14	0.32	2.38e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04204557	chr21:46065774	KRTAP10-11;C21orf29	-0.4	-6.49	-0.34	3.18e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.26	0.33	1.18e-9	Tonsillectomy;
CRC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.34	-0.33	7.77e-10	Lymphocyte counts;
CRC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.5	-9.49	-0.46	5.01e-19	Alcohol dependence;
CRC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.02	-0.31	4.67e-9	Monocyte percentage of white cells;
CRC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.44	-6.57	-0.34	1.95e-10	Height;
CRC	cis	rs73206853	0.764	rs73191817	chr12:110918673	G/A	cg12870014	chr12:110450643	ANKRD13A	0.84	9.69	0.47	1.07e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.66	7.3	0.37	2.18e-12	Vitiligo;
CRC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.69	0.51	4.27e-23	Prudent dietary pattern;
CRC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.03e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.62	-7.2	-0.37	4.06e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg00750074	chr16:89608354	SPG7	0.39	5.76	0.3	1.9e-8	Multiple myeloma (IgH translocation);
CRC	trans	rs17661538	0.685	rs2497810	chr10:18360504	C/G	cg13235825	chr11:107574836	NA	0.49	6.01	0.31	4.99e-9	Response to antipsychotic treatment;
CRC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.54	7.17	0.37	4.97e-12	IgG glycosylation;
CRC	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg27398640	chr15:77910606	LINGO1	-0.43	-7.17	-0.37	5.13e-12	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25261059	chr19:44031185	ETHE1	0.41	6.47	0.34	3.63e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.39	5.93	0.31	7.87e-9	Hemoglobin concentration;
CRC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg13798780	chr7:105162888	PUS7	0.56	7.36	0.38	1.45e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.46	6.75	0.35	6.79e-11	Emphysema distribution in smoking;
CRC	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.69	10.7	0.51	4.14e-23	Plateletcrit;Platelet count;
CRC	cis	rs13161895	1.000	rs4700853	chr5:179473328	G/A	cg02702477	chr5:179499311	RNF130	0.55	6.26	0.33	1.18e-9	LDL cholesterol;
CRC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	8.59	0.43	3.66e-16	Height;
CRC	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg04811098	chr7:155088454	INSIG1	0.42	6.49	0.34	3.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4664293	0.647	rs12623149	chr2:160447346	A/G	cg08347373	chr2:160653686	CD302	-0.38	-6.48	-0.34	3.42e-10	Monocyte percentage of white cells;
CRC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	0.71	7.98	0.4	2.51e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.62	9.09	0.45	9.37e-18	Breast cancer;
CRC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.57	7.74	0.39	1.26e-13	Alzheimer's disease;
CRC	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg13043300	chr11:71146211	DHCR7	-0.42	-5.82	-0.31	1.37e-8	Vitamin D levels;
CRC	cis	rs9462027	0.628	rs6921363	chr6:34770820	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.92	-0.31	8.21e-9	Systemic lupus erythematosus;
CRC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg22482690	chr17:47019901	SNF8	0.48	8.01	0.4	2.01e-14	Type 2 diabetes;
CRC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.65	0.34	1.23e-10	Morning vs. evening chronotype;
CRC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	5.79	0.3	1.65e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-5.91	-0.31	8.42e-9	Coronary artery disease;
CRC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.99	0.48	1.07e-20	Platelet count;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg26801646	chr10:76970496	VDAC2	-0.45	-6.9	-0.36	2.76e-11	Birth weight;Height;
CRC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.0	0.4	2.17e-14	Alzheimer's disease;
CRC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Red blood cell count;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg19041857	chr6:27730383	NA	-0.42	-5.94	-0.31	7.29e-9	Parkinson's disease;
CRC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.79	-11.64	-0.54	1.92e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg00290994	chr1:41848739	NA	0.56	8.64	0.43	2.44e-16	Intelligence (multi-trait analysis);
CRC	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.42	6.43	0.33	4.43e-10	Recombination rate (males);
CRC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg19223190	chr17:80058835	NA	0.41	6.7	0.35	8.79e-11	Life satisfaction;
CRC	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg24024056	chr10:102415556	NA	0.36	7.19	0.37	4.34e-12	Body mass index;
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg08798685	chr6:27730294	NA	-0.63	-6.14	-0.32	2.38e-9	Breast cancer;
CRC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	6.13	0.32	2.47e-9	Menopause (age at onset);
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg22638593	chr5:131593259	PDLIM4	0.33	5.93	0.31	7.5e-9	Lung function (FEV1/FVC);
CRC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	7.72	0.39	1.38e-13	Schizophrenia;
CRC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg23996704	chr18:44553084	KATNAL2	-0.3	-5.83	-0.31	1.34e-8	Personality dimensions;
CRC	cis	rs4908760	0.868	rs12131864	chr1:8591162	A/G	cg20416874	chr1:8611966	RERE	-0.46	-6.66	-0.34	1.16e-10	Vitiligo;
CRC	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.66	-0.39	2.04e-13	Venous thromboembolism;
CRC	cis	rs35883536	0.967	rs3904673	chr1:101137162	A/C	cg14515779	chr1:101123966	NA	-0.41	-7.97	-0.4	2.69e-14	Monocyte count;
CRC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg02428538	chr16:24856791	SLC5A11	-0.54	-6.33	-0.33	7.82e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12618769	0.625	rs3769709	chr2:99187433	A/T	cg18455616	chr2:99124870	INPP4A	0.36	5.87	0.31	1.07e-8	Bipolar disorder;
CRC	cis	rs4964805	1.000	rs73192053	chr12:104190855	A/G	cg02344784	chr12:104178138	NT5DC3	0.56	8.45	0.42	9.23e-16	Attention deficit hyperactivity disorder;
CRC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.97	14.27	0.62	2.74e-36	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.68	0.63	7.01e-38	Exhaled nitric oxide output;
CRC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.75	0.54	7.35e-27	Prudent dietary pattern;
CRC	cis	rs9891119	0.524	rs3736164	chr17:40539825	T/G	cg06270615	chr17:40516068	STAT3	0.31	6.48	0.34	3.39e-10	Multiple sclerosis;Crohn's disease;
CRC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.73	9.43	0.46	7.79e-19	Body mass index;
CRC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.59	8.87	0.44	4.6e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg19223190	chr17:80058835	NA	-0.49	-7.85	-0.4	5.86e-14	Life satisfaction;
CRC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.58	6.33	0.33	8.25e-10	Initial pursuit acceleration;
CRC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	10.98	0.52	4.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.47	-0.34	3.59e-10	Schizophrenia;
CRC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.59	-8.67	-0.43	2.01e-16	Menarche (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20848987	chr17:41116355	AARSD1	0.47	6.0	0.31	5.3e-9	Thyroid stimulating hormone;
CRC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.49	4.37e-21	Heart rate;
CRC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg04362960	chr10:104952993	NT5C2	-0.42	-5.94	-0.31	7.28e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.54	7.4	0.38	1.14e-12	Urinary tract infection frequency;
CRC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-6.02	-0.32	4.6e-9	Life satisfaction;
CRC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.67	13.57	0.6	1.32e-33	Schizophrenia;
CRC	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg07636037	chr3:49044803	WDR6	-0.69	-6.99	-0.36	1.5e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21509819	chr19:6737662	GPR108	0.42	6.43	0.33	4.55e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05610740	chr12:96794311	CDK17	0.44	7.76	0.39	1.08e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.12	-21.12	-0.76	3.49e-63	Exhaled nitric oxide levels;
CRC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.46	-0.38	7.88e-13	Type 2 diabetes;
CRC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.57	-9.41	-0.46	9.04e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg12573674	chr2:1569213	NA	-0.77	-8.09	-0.41	1.13e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.68	11.3	0.53	3.18e-25	Alzheimer's disease (late onset);
CRC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg18016565	chr1:150552671	MCL1	0.42	6.06	0.32	3.8e-9	Melanoma;
CRC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-12.41	-0.56	2.97e-29	Lymphocyte percentage of white cells;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.31	-5.86	-0.31	1.13e-8	Cutaneous nevi;
CRC	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg12682573	chr17:27188876	MIR451;MIR144	-0.6	-8.99	-0.44	1.93e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg18833306	chr6:118973337	C6orf204	0.45	5.81	0.3	1.49e-8	Diastolic blood pressure;
CRC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.47	7.3	0.37	2.19e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.53	8.11	0.41	1.04e-14	Fibrinogen levels;
CRC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-9.25	-0.45	3.01e-18	Hemoglobin concentration;
CRC	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.52	7.45	0.38	8.29e-13	Testicular germ cell tumor;
CRC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg25985355	chr7:65971099	NA	0.52	5.95	0.31	6.88e-9	Gout;
CRC	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	0.95	11.76	0.54	6.68e-27	Height;
CRC	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg00935504	chr16:1863053	HAGH	0.31	5.65	0.3	3.39e-8	Blood metabolite levels;
CRC	trans	rs17056278	1.000	rs10077799	chr5:158272083	C/T	cg07204479	chr12:89915527	WDR51B;GALNT4	-0.48	-6.05	-0.32	3.92e-9	Hip circumference (psychosocial stress interaction);
CRC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg11632617	chr15:75315747	PPCDC	-0.57	-7.79	-0.39	8.82e-14	Blood trace element (Zn levels);
CRC	cis	rs10128264	0.902	rs942797	chr10:80986432	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.37	-6.41	-0.33	4.95e-10	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.13	0.37	6.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.08	-13.76	-0.6	2.34e-34	Vitiligo;
CRC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	10.8	0.51	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.63	10.13	0.49	3.71e-21	Aortic root size;
CRC	cis	rs427941	0.632	rs201503	chr7:101759595	C/G	cg06246474	chr7:101738831	CUX1	0.44	6.86	0.35	3.35e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs995000	0.931	rs656297	chr1:62907595	A/G	cg19896129	chr1:63156450	NA	0.44	6.77	0.35	5.88e-11	Triglyceride levels;
CRC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-17.34	-0.69	2.62e-48	Height;
CRC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	8.19	0.41	5.82e-15	Electrocardiographic conduction measures;
CRC	cis	rs8130944	0.828	rs4920134	chr21:44111151	T/C	cg23590273	chr21:44105265	PDE9A	-0.35	-5.62	-0.3	3.99e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2274273	0.529	rs10131562	chr14:55847015	G/A	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.82	-0.31	1.38e-8	Protein biomarker;
CRC	cis	rs972578	0.836	rs738539	chr22:43282801	A/C	cg01576275	chr22:43409880	NA	-0.41	-6.44	-0.33	4.16e-10	Mean platelet volume;
CRC	cis	rs9491140	0.539	rs11154226	chr6:124681785	G/A	cg22366943	chr6:124882293	NKAIN2	0.53	7.56	0.38	4.16e-13	Neuroticism;
CRC	cis	rs7246865	0.871	rs10421727	chr19:17225128	G/A	cg19418318	chr19:17219073	MYO9B	0.51	8.64	0.43	2.51e-16	Reticulocyte fraction of red cells;
CRC	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.56	-9.01	-0.44	1.74e-17	Neuroticism;
CRC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.3	6.44	0.33	4.23e-10	Alcohol dependence;
CRC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.77e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2625529	0.730	rs1481861	chr15:72240129	A/G	cg16672083	chr15:72433130	SENP8	0.45	6.45	0.34	3.89e-10	Red blood cell count;
CRC	cis	rs7487075	1.000	rs7976280	chr12:46800825	G/A	cg17501823	chr12:47219793	SLC38A4	0.32	5.64	0.3	3.58e-8	Itch intensity from mosquito bite;
CRC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.79	0.3	1.64e-8	Rheumatoid arthritis;
CRC	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg17294928	chr15:75287854	SCAMP5	-0.41	-6.04	-0.32	4.14e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.45	6.14	0.32	2.33e-9	Gut microbiome composition (summer);
CRC	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg18232548	chr7:50535776	DDC	0.44	6.3	0.33	9.55e-10	Malaria;
CRC	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg06935464	chr4:38784597	TLR10	0.57	5.97	0.31	6.19e-9	Breast cancer;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02290350	chr8:58132656	NA	-0.6	-6.94	-0.36	2.16e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9322817	1.000	rs9322817	chr6:105232233	A/C	cg02098413	chr6:105308735	HACE1	-0.33	-6.0	-0.31	5.09e-9	Thyroid stimulating hormone;
CRC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21643547	chr1:205240462	TMCC2	-0.46	-7.31	-0.37	2.04e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.18	0.37	4.75e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs73200209	0.912	rs10507267	chr12:116500910	T/C	cg01776926	chr12:116560359	MED13L	-0.53	-6.53	-0.34	2.53e-10	Total body bone mineral density;
CRC	cis	rs501120	0.584	rs906944	chr10:44705439	G/A	cg09554077	chr10:44749378	NA	0.65	7.61	0.39	2.94e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6504622	0.967	rs9889762	chr17:45026366	C/T	cg16759221	chr17:45003025	GOSR2	-0.49	-7.92	-0.4	3.72e-14	Orofacial clefts;
CRC	cis	rs2227564	0.678	rs2242256	chr10:75597546	C/G	cg16540259	chr10:75572220	NDST2	-0.47	-6.74	-0.35	6.97e-11	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.65	10.85	0.51	1.21e-23	Cancer;
CRC	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.83	-10.48	-0.5	2.33e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg18830697	chr6:72922368	RIMS1	-0.39	-7.83	-0.4	6.67e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.37	-7.22	-0.37	3.58e-12	Subjective well-being;
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.8e-9	Bipolar disorder;
CRC	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.73	-8.51	-0.42	6.28e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.56	10.19	0.49	2.29e-21	Cognitive performance;
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.56	-0.5	1.22e-22	Bipolar disorder;
CRC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg16060761	chr17:80687452	NA	0.4	5.95	0.31	6.88e-9	Breast cancer;
CRC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.3	0.56	7.07e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg20291162	chr17:40259547	DHX58	-0.55	-8.1	-0.41	1.06e-14	Fibrinogen levels;
CRC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.61	-7.61	-0.39	2.85e-13	Body mass index;
CRC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.43	9.0	0.44	1.8e-17	Renal cell carcinoma;
CRC	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg21849932	chr20:62369462	LIME1	-0.4	-5.64	-0.3	3.62e-8	Prostate cancer;
CRC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg07130601	chr7:158766826	NA	0.42	6.04	0.32	4.05e-9	Facial morphology (factor 20);
CRC	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg16141378	chr3:129829833	LOC729375	0.43	6.28	0.33	1.08e-9	Triglycerides;
CRC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs17767392	0.813	rs61989379	chr14:71964406	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.46	-0.34	3.81e-10	Mitral valve prolapse;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg10389584	chr19:12512226	ZNF799	0.45	6.53	0.34	2.55e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.56	-7.88	-0.4	4.9e-14	Longevity;
CRC	cis	rs1223397	0.589	rs2439540	chr6:13309342	G/A	cg07912922	chr6:13274314	PHACTR1	0.41	6.32	0.33	8.45e-10	Blood pressure;
CRC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	13.97	0.61	3.96e-35	Chronic sinus infection;
CRC	cis	rs4666002	0.956	rs3749147	chr2:27851918	G/A	cg27432699	chr2:27873401	GPN1	0.44	5.63	0.3	3.81e-8	Phospholipid levels (plasma);
CRC	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg14664628	chr15:75095509	CSK	-0.49	-5.75	-0.3	2.06e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg25456477	chr12:86230367	RASSF9	0.32	5.64	0.3	3.58e-8	Major depressive disorder;
CRC	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg15654264	chr1:150340011	RPRD2	-0.37	-5.63	-0.3	3.93e-8	Migraine;
CRC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.96	0.48	1.4e-20	Platelet count;
CRC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg05623727	chr3:50126028	RBM5	0.46	7.58	0.39	3.49e-13	Intelligence (multi-trait analysis);
CRC	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg23229984	chr5:148520753	ABLIM3	0.46	6.59	0.34	1.78e-10	Breast cancer;
CRC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.87	11.98	0.55	1.1e-27	Initial pursuit acceleration;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02359409	chr6:42947317	PEX6	0.48	7.32	0.37	1.9e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	trans	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.25	-0.33	1.24e-9	Mosquito bite size;
CRC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.33	-0.53	2.43e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs34156428	0.591	rs12577561	chr11:16806296	C/T	cg05563613	chr7:99070410	ZNF789	0.71	6.22	0.32	1.5e-9	Coronary artery disease;
CRC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.46	6.18	0.32	1.88e-9	Bladder cancer;
CRC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-6.57	-0.34	1.97e-10	Renal cell carcinoma;
CRC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-9.64	-0.47	1.62e-19	Morning vs. evening chronotype;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg26304593	chr6:42947056	PEX6	-0.46	-6.87	-0.35	3.2e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.4	6.12	0.32	2.72e-9	Mean corpuscular volume;
CRC	cis	rs4654899	0.897	rs7545133	chr1:21206143	T/G	cg02927042	chr1:21476669	EIF4G3	0.39	6.13	0.32	2.5e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.36	-0.33	6.74e-10	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23998478	chr2:121269292	NA	0.24	5.98	0.31	5.81e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg19169023	chr15:41853346	TYRO3	0.53	7.89	0.4	4.48e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4664293	0.867	rs2357529	chr2:160595433	C/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10268230	chr11:130731963	NA	0.42	6.89	0.36	2.76e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg10589385	chr1:150898437	SETDB1	0.27	5.68	0.3	2.99e-8	Melanoma;
CRC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg20129853	chr10:51489980	NA	-0.44	-7.35	-0.38	1.57e-12	Prostate-specific antigen levels;
CRC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg25790453	chr13:113633590	MCF2L	-0.54	-9.66	-0.47	1.32e-19	Systolic blood pressure;
CRC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.93	11.32	0.53	2.67e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg03623178	chr6:28175578	NA	0.92	13.05	0.58	1.2e-31	Parkinson's disease;
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.76	-0.3	1.9e-8	Life satisfaction;
CRC	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.78	-11.86	-0.55	3.04e-27	Blood pressure (smoking interaction);
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11645453	chr3:52864694	ITIH4	0.36	6.27	0.33	1.13e-9	Bipolar disorder;
CRC	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg11900509	chr10:81946545	ANXA11	-0.63	-6.41	-0.33	5.12e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.5	8.07	0.41	1.37e-14	Coronary artery disease;
CRC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.72	12.88	0.58	5.24e-31	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.91	0.31	8.72e-9	Lung cancer;
CRC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.95	0.4	3.09e-14	Menopause (age at onset);
CRC	cis	rs6976053	0.935	rs7803865	chr7:100505792	C/T	cg10426581	chr7:100472382	SRRT	-0.39	-5.97	-0.31	6.1e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg11993925	chr19:44307056	LYPD5	-0.46	-7.58	-0.39	3.44e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.42	6.57	0.34	1.97e-10	Monocyte count;
CRC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.55	-6.56	-0.34	2.03e-10	Gut microbiome composition (summer);
CRC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.86	0.35	3.52e-11	Educational attainment;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg03623178	chr6:28175578	NA	0.66	8.88	0.44	4.32e-17	Parkinson's disease;
CRC	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.51	-7.45	-0.38	8.3e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg20608306	chr11:116969690	SIK3	-0.31	-5.72	-0.3	2.4e-8	Subjective well-being;
CRC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.73	-11.53	-0.54	4.47e-26	Colorectal cancer;
CRC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	0.69	7.66	0.39	2.09e-13	Body mass index;
CRC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.49	6.89	0.35	2.9e-11	Type 1 diabetes nephropathy;
CRC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg21011830	chr19:17970855	RPL18AP3;RPL18A	0.46	5.97	0.31	6.05e-9	Type 2 diabetes (age of onset);
CRC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg01788221	chr16:89496183	ANKRD11	-0.45	-6.68	-0.35	1.03e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.13	-0.37	6.3e-12	Gut microbiome composition (summer);
CRC	cis	rs4731207	0.596	rs6466989	chr7:124690963	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.28	-0.33	1.06e-9	Cutaneous malignant melanoma;
CRC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.5	6.5	0.34	3.06e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-9.46	-0.46	6.32e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.16	-0.32	2.1e-9	Metabolite levels;
CRC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.59	0.39	3.35e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.29	-5.79	-0.3	1.63e-8	Alzheimer's disease (late onset);
CRC	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	0.58	7.15	0.37	5.49e-12	Insulin-like growth factors;
CRC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.35e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg18612461	chr15:75251733	NA	0.38	5.87	0.31	1.06e-8	Breast cancer;
CRC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.24	-0.59	2.25e-32	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.53	8.15	0.41	7.46e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.12	-0.52	1.3e-24	Type 2 diabetes;
CRC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.39	-5.86	-0.31	1.09e-8	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.49	6.41	0.33	4.98e-10	Longevity;
CRC	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.47	6.47	0.34	3.45e-10	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26551688	chr8:103822898	NA	0.35	5.98	0.31	5.96e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.53	-9.17	-0.45	5.48e-18	Aortic root size;
CRC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.51	-0.42	6.2e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.79	-0.58	1.08e-30	Prostate cancer;
CRC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.55	5.92	0.31	8.24e-9	Bipolar disorder;
CRC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.98	0.31	5.8e-9	Lung cancer;
CRC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg02560186	chr11:3602584	NA	-0.46	-6.39	-0.33	5.68e-10	Blood pressure (smoking interaction);
CRC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	14.87	0.63	1.3e-38	Platelet count;
CRC	cis	rs4481887	0.508	rs6666148	chr1:248402758	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.45	0.33	4.03e-10	Common traits (Other);
CRC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.96	-0.36	1.86e-11	Vitiligo;
CRC	cis	rs10221833	0.602	rs355887	chr2:165634262	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.77	0.3	1.79e-8	Response to statin therapy;
CRC	cis	rs9826463	0.757	rs113288103	chr3:142175321	C/T	cg20824294	chr3:142316082	PLS1	0.42	6.86	0.35	3.37e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.74e-11	Response to antipsychotic treatment;
CRC	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg02766259	chr12:125626809	AACS	-0.42	-6.26	-0.33	1.17e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.76	-0.3	1.96e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg13476313	chr9:127244764	NR5A1	0.29	5.97	0.31	6.04e-9	Menarche (age at onset);
CRC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.67	10.63	0.51	7.01e-23	Sudden cardiac arrest;
CRC	cis	rs1158570	0.564	rs2554372	chr8:131333913	A/G	cg26053073	chr8:131455383	NA	-0.4	-6.21	-0.32	1.62e-9	Platelet count;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg08541953	chr1:6259338	RPL22	-0.45	-6.29	-0.33	9.89e-10	Protein C levels;
CRC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	6.6	0.34	1.61e-10	Diastolic blood pressure;
CRC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg23625390	chr15:77176239	SCAPER	0.49	7.19	0.37	4.36e-12	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04159381	chr1:53018615	ZCCHC11	0.39	6.1	0.32	3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.59	-9.19	-0.45	4.44e-18	Aortic root size;
CRC	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.42	6.71	0.35	8.77e-11	Longevity;
CRC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.27	-0.56	9.68e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-8.49	-0.42	7.01e-16	Type 2 diabetes;
CRC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	8.04e-20	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	6.38	0.33	5.87e-10	Blood metabolite levels;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg10217327	chr6:118973057	C6orf204	0.51	5.73	0.3	2.29e-8	Diastolic blood pressure;
CRC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.96	-0.36	1.83e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg15448220	chr1:150897856	SETDB1	0.44	6.22	0.32	1.47e-9	Tonsillectomy;
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.48	7.34	0.38	1.69e-12	Intelligence (multi-trait analysis);
CRC	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.45	-7.4	-0.38	1.16e-12	Refractive error;
CRC	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-6.46	-0.34	3.86e-10	Subjective well-being;
CRC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.76	12.95	0.58	2.86e-31	Colorectal cancer;
CRC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.4	7.12	0.37	6.8e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg05623727	chr3:50126028	RBM5	-0.41	-6.91	-0.36	2.48e-11	Menarche (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08247611	chr16:71928811	KIAA0174	0.47	6.57	0.34	1.98e-10	Response to antipsychotic treatment;
CRC	cis	rs1712517	0.524	rs1712509	chr10:105013870	G/T	cg04362960	chr10:104952993	NT5C2	-0.49	-6.39	-0.33	5.71e-10	Migraine;
CRC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.69	-8.2	-0.41	5.44e-15	Initial pursuit acceleration;
CRC	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.63	10.37	0.5	5.37e-22	Schizophrenia;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg21251018	chr6:28226885	NKAPL	0.42	6.43	0.33	4.53e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg02927042	chr1:21476669	EIF4G3	0.39	6.24	0.33	1.35e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg05501817	chr11:14380813	RRAS2	-0.45	-5.94	-0.31	7.15e-9	Sense of smell;
CRC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.63	-9.18	-0.45	4.97e-18	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.58	-9.43	-0.46	7.71e-19	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00252696	chr1:31769601	ZCCHC17;SNRNP40	0.4	6.25	0.33	1.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.71	-12.21	-0.56	1.53e-28	Body mass index;
CRC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.5	8.39	0.42	1.48e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs7259376	0.704	rs1897613	chr19:22573575	G/A	cg02657401	chr19:22469223	NA	-0.3	-6.61	-0.34	1.59e-10	Menopause (age at onset);
CRC	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.57	7.75	0.39	1.14e-13	Height;
CRC	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg04132472	chr17:19861366	AKAP10	-0.4	-6.52	-0.34	2.7e-10	Schizophrenia;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.66	-10.94	-0.52	5.72e-24	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.7	9.8	0.48	4.54e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6988985	0.728	rs6471570	chr8:143957405	A/C	cg10324643	chr8:143916377	GML	0.37	6.14	0.32	2.43e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.81	14.71	0.63	5.47e-38	Anterior chamber depth;
CRC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-8.14	-0.41	7.98e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7605827	0.930	rs4668447	chr2:15516166	T/C	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.78e-8	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04798158	chr14:75179846	FCF1;KIAA0317	0.41	5.99	0.31	5.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.6	8.99	0.44	2e-17	Coronary artery disease;
CRC	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.33	-5.68	-0.3	2.99e-8	Airway imaging phenotypes;
CRC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.43e-9	Colorectal cancer;
CRC	cis	rs11212617	0.967	rs6589017	chr11:108308504	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.05	0.32	3.98e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21514356	chr4:135865523	NA	0.37	6.11	0.32	2.74e-9	Diisocyanate-induced asthma;
CRC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.63	0.57	4.45e-30	Menopause (age at onset);
CRC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.03	-0.4	1.73e-14	Hemoglobin concentration;
CRC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.64	-7.97	-0.4	2.59e-14	Lung cancer;
CRC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.81	-0.31	1.47e-8	Bladder cancer;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg15786705	chr6:28176104	NA	0.65	9.33	0.46	1.63e-18	Parkinson's disease;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05665937	chr4:1216051	CTBP1	-0.36	-5.64	-0.3	3.75e-8	Obesity-related traits;
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.42	6.01	0.31	5.01e-9	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	cis	rs17155006	0.664	rs451252	chr7:107738948	G/A	cg05962710	chr7:107745446	LAMB4	-0.43	-7.53	-0.38	4.79e-13	Pneumococcal bacteremia;
CRC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.83	14.06	0.61	1.67e-35	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.75	-0.35	6.64e-11	Total body bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23721301	chr10:112064230	SMNDC1	0.46	7.27	0.37	2.71e-12	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26396086	chr1:247494708	ZNF496	0.36	6.23	0.32	1.4e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-7.0	-0.36	1.47e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg00280220	chr17:61926910	NA	0.33	5.64	0.3	3.66e-8	Prudent dietary pattern;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05828906	chr6:126278519	HINT3	0.47	6.01	0.31	4.91e-9	Thyroid stimulating hormone;
CRC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg13722127	chr7:150037890	RARRES2	0.48	7.97	0.4	2.63e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs4722166	0.598	rs4722180	chr7:22805072	A/G	cg05472934	chr7:22766657	IL6	0.64	10.39	0.5	4.59e-22	Lung cancer;
CRC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.39e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.46	-8.75	-0.43	1.1e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08651674	chr6:7108441	RREB1	0.47	6.07	0.32	3.55e-9	Thyroid stimulating hormone;
CRC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.81	-0.4	7.9e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.5	-8.88	-0.44	4.35e-17	Height;
CRC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.5	-6.99	-0.36	1.53e-11	Melanoma;
CRC	cis	rs2882667	0.690	rs311597	chr5:138055901	A/G	cg09476006	chr5:138032270	NA	0.56	9.7	0.47	9.69e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.94	-0.31	7.17e-9	Total body bone mineral density;
CRC	cis	rs13161895	1.000	rs35973843	chr5:179466502	T/C	cg02702477	chr5:179499311	RNF130	0.55	6.26	0.33	1.18e-9	LDL cholesterol;
CRC	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg02158880	chr13:53174818	NA	-0.43	-6.54	-0.34	2.29e-10	Lewy body disease;
CRC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03909863	chr11:638404	DRD4	-0.45	-5.74	-0.3	2.18e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.68	0.35	1.04e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.63	-6.71	-0.35	8.31e-11	Osteoarthritis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19701416	chr10:28592092	NA	0.55	7.33	0.37	1.82e-12	Thyroid stimulating hormone;
CRC	cis	rs7259376	0.902	rs7248242	chr19:22575994	A/G	cg02657401	chr19:22469223	NA	0.32	6.92	0.36	2.34e-11	Menopause (age at onset);
CRC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg23533926	chr12:111358616	MYL2	-0.55	-8.38	-0.42	1.6e-15	Extrinsic epigenetic age acceleration;
CRC	cis	rs7605827	0.897	rs4668922	chr2:15675130	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg09003973	chr2:102972529	NA	0.41	5.77	0.3	1.85e-8	Blood protein levels;
CRC	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.37	-6.72	-0.35	8.23e-11	Dilated cardiomyopathy;
CRC	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.63	-8.54	-0.43	5.14e-16	Extraversion;
CRC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.98	12.29	0.56	7.67e-29	Vitiligo;
CRC	cis	rs4654899	0.897	rs1021077	chr1:21106016	A/G	cg02927042	chr1:21476669	EIF4G3	-0.44	-7.02	-0.36	1.31e-11	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17935035	chr15:40763388	CHST14	0.4	6.25	0.33	1.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-14.08	-0.61	1.45e-35	Lymphocyte percentage of white cells;
CRC	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg12458913	chr13:53173898	NA	0.53	8.27	0.41	3.34e-15	Lewy body disease;
CRC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.42	-6.04	-0.32	4.13e-9	Parkinson's disease;
CRC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.75	-11.87	-0.55	2.82e-27	Anterior chamber depth;
CRC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.98	0.4	2.43e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg15147215	chr3:52552868	STAB1	0.53	9.17	0.45	5.29e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05824535	chr16:25117957	NA	0.46	7.58	0.39	3.58e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.83	0.31	1.34e-8	IgG glycosylation;
CRC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg12193833	chr17:30244370	NA	-0.76	-8.88	-0.44	4.33e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	-0.52	-8.75	-0.43	1.11e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg18758796	chr5:131593413	PDLIM4	0.33	6.12	0.32	2.72e-9	Blood metabolite levels;
CRC	cis	rs4073416	0.568	rs1121885	chr14:66156914	A/G	cg03016385	chr14:66212404	NA	-0.42	-5.91	-0.31	8.71e-9	N-glycan levels;
CRC	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-7.18	-0.37	4.54e-12	Platelet distribution width;
CRC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.12	0.41	9.33e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg02741985	chr17:80059408	CCDC57	0.42	6.99	0.36	1.51e-11	Life satisfaction;
CRC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.73	-10.87	-0.51	1.05e-23	Platelet distribution width;
CRC	cis	rs11650494	0.710	rs57030023	chr17:47468546	T/A	cg08112188	chr17:47440006	ZNF652	0.68	6.12	0.32	2.65e-9	Prostate cancer;
CRC	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg18850127	chr7:39170497	POU6F2	0.49	6.09	0.32	3.09e-9	IgG glycosylation;
CRC	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.52	-0.34	2.71e-10	Metabolite levels (Pyroglutamine);
CRC	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.5	-7.78	-0.39	9.28e-14	Type 2 diabetes;
CRC	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg13385794	chr1:248469461	NA	0.39	6.98	0.36	1.62e-11	Common traits (Other);
CRC	cis	rs12476592	0.571	rs185499	chr2:63867523	G/T	cg10828910	chr2:63850056	LOC388955	0.5	6.24	0.33	1.37e-9	Childhood ear infection;
CRC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg16558177	chr4:4109446	NA	-0.48	-6.21	-0.32	1.62e-9	Blood pressure (smoking interaction);
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg06470822	chr6:28175283	NA	0.72	10.34	0.5	6.75e-22	Parkinson's disease;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02654935	chr6:12514489	NA	-0.5	-6.82	-0.35	4.47e-11	Hip circumference;
CRC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.67	8.57	0.43	4.02e-16	Arsenic metabolism;
CRC	trans	rs7179994	0.579	rs72712678	chr15:28301550	T/C	cg05237436	chr5:138533428	SIL1	0.71	6.29	0.33	1.03e-9	Shingles;
CRC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg18761221	chr20:60518478	NA	0.44	7.13	0.37	6.5e-12	Body mass index;
CRC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.48	-6.65	-0.34	1.22e-10	Tonsillectomy;
CRC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.39	8.37	0.42	1.62e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg26061582	chr7:22766209	IL6	0.53	8.71	0.43	1.53e-16	Lung cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg25883402	chr1:173837173	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	-0.41	-6.3	-0.33	9.51e-10	Aortic root size;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg13309018	chr9:130965761	CIZ1;DNM1	0.4	6.16	0.32	2.07e-9	Crohn's disease;
CRC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.47	7.64	0.39	2.35e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-7.09	-0.36	8.44e-12	Blood protein levels;
CRC	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg21110645	chr1:207815933	NA	-0.38	-5.66	-0.3	3.34e-8	Erythrocyte sedimentation rate;
CRC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.6	-9.5	-0.46	4.46e-19	Aortic root size;
CRC	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg19875578	chr6:126661172	C6orf173	-0.42	-6.02	-0.32	4.64e-9	Male-pattern baldness;
CRC	cis	rs12580194	1.000	rs12582734	chr12:55689572	C/A	cg19537932	chr12:55886519	OR6C68	-0.6	-8.37	-0.42	1.68e-15	Cancer;
CRC	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.74	-12.37	-0.56	3.98e-29	Eosinophil percentage of white cells;
CRC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg10589385	chr1:150898437	SETDB1	0.29	6.34	0.33	7.45e-10	Melanoma;
CRC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.3	-0.49	9.23e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg06494592	chr3:125709126	NA	-0.56	-6.61	-0.34	1.54e-10	Blood pressure (smoking interaction);
CRC	cis	rs354225	0.597	rs10176445	chr2:54845776	G/C	cg26097391	chr2:54893211	SPTBN1	0.38	5.66	0.3	3.38e-8	Schizophrenia;
CRC	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg20488157	chr14:104394430	TDRD9	0.68	9.88	0.48	2.46e-20	Bipolar disorder;
CRC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.57	-6.53	-0.34	2.54e-10	Vitiligo;
CRC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-7.28	-0.37	2.42e-12	Lung cancer;
CRC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.38e-9	Red blood cell count;
CRC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.67	-0.39	1.94e-13	Cystic fibrosis severity;
CRC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.47	6.43	0.33	4.4e-10	Schizophrenia;
CRC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg10578991	chr7:12443926	VWDE	-0.51	-5.61	-0.3	4.29e-8	Coronary artery disease;
CRC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.8	-0.44	7.87e-17	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09033691	chr11:10829409	EIF4G2	0.48	6.96	0.36	1.88e-11	Response to antipsychotic treatment;
CRC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.73	-0.3	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7849270	1.000	rs932833	chr9:131884041	T/A	cg13538475	chr9:131942899	NA	-0.29	-5.86	-0.31	1.13e-8	Blood metabolite ratios;
CRC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg22676075	chr6:135203613	NA	0.41	6.18	0.32	1.91e-9	Red blood cell count;
CRC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg22974920	chr21:40686053	BRWD1	0.45	6.33	0.33	7.89e-10	Cognitive function;
CRC	cis	rs7215564	0.908	rs8076854	chr17:78663962	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.11	0.32	2.76e-9	Myopia (pathological);
CRC	trans	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg21153622	chr11:89784906	NA	-0.5	-8.0	-0.4	2.15e-14	HDL cholesterol;
CRC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.9	-0.31	9.22e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-6.77	-0.35	6.07e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01153342	chr14:74254319	C14orf43	0.5	6.56	0.34	2.05e-10	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.83	15.11	0.64	1.48e-39	Dental caries;
CRC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.31	0.56	6.9e-29	Height;
CRC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Total cholesterol levels;
CRC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.64	9.72	0.47	8.47e-20	Initial pursuit acceleration;
CRC	trans	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg26043149	chr18:55253948	FECH	-0.51	-7.08	-0.36	8.98e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs6462411	0.591	rs917198	chr7:3876866	A/T	cg14000125	chr20:61704742	NA	0.34	6.33	0.33	7.8e-10	Quantitative traits;
CRC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17554472	chr22:41940697	POLR3H	-0.56	-6.07	-0.32	3.61e-9	Vitiligo;
CRC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.26	15.21	0.64	6.08e-40	Eosinophil percentage of granulocytes;
CRC	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.38	-6.41	-0.33	4.94e-10	Mean arterial pressure;
CRC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	9.24	0.45	3.11e-18	Alzheimer's disease;
CRC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg02135003	chr7:105160482	PUS7	-0.95	-12.62	-0.57	4.76e-30	Bipolar disorder (body mass index interaction);
CRC	cis	rs7113874	0.589	rs10769910	chr11:8499406	T/C	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg14003231	chr6:33640908	ITPR3	0.52	8.41	0.42	1.24e-15	Plateletcrit;
CRC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.72	0.35	8.08e-11	Bipolar disorder;
CRC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.28	-18.07	-0.71	3.36e-51	Hip circumference adjusted for BMI;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg03623178	chr6:28175578	NA	0.78	11.64	0.54	1.85e-26	Cardiac Troponin-T levels;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg15845792	chr6:28175446	NA	0.7	7.65	0.39	2.28e-13	Parkinson's disease;
CRC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.59	10.55	0.5	1.35e-22	Aortic root size;
CRC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.6	-9.96	-0.48	1.33e-20	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15636040	chr1:147142673	ACP6	0.43	6.29	0.33	9.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17641971	0.708	rs1511363	chr8:49901023	C/T	cg00325661	chr8:49890786	NA	0.36	6.29	0.33	1.04e-9	Blood metabolite levels;
CRC	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.03	0.55	6.99e-28	Testicular germ cell tumor;
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.91	-0.31	8.74e-9	Total body bone mineral density;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg09877947	chr5:131593287	PDLIM4	-0.58	-10.22	-0.49	1.83e-21	Acylcarnitine levels;
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg08798685	chr6:27730294	NA	-0.47	-6.48	-0.34	3.31e-10	Parkinson's disease;
CRC	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.7	-0.39	1.6e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.73	-0.51	3.19e-23	Alzheimer's disease;
CRC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg08222913	chr3:52553049	STAB1	-0.35	-6.2	-0.32	1.73e-9	Bipolar disorder;
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg20119798	chr7:94954144	PON1	-0.52	-6.48	-0.34	3.39e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.71	-0.47	9.14e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg18827107	chr12:86230957	RASSF9	-0.37	-5.73	-0.3	2.23e-8	Major depressive disorder;
CRC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10221833	0.602	rs355878	chr2:165633029	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.79	0.3	1.64e-8	Response to statin therapy;
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	5.8200000000000003e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs501916	0.634	rs8037600	chr15:48060331	A/G	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.62	-0.34	1.43e-10	Inflammatory bowel disease;Ulcerative colitis;
CRC	trans	rs72793342	0.651	rs8050463	chr16:30554159	A/G	cg10454327	chr16:85204789	NA	-0.49	-6.33	-0.33	7.95e-10	RANTES levels;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01112643	chr6:157802216	ZDHHC14	-0.48	-7.05	-0.36	1.05e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg03013999	chr17:37608204	MED1	0.45	6.87	0.35	3.15e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.4	-7.65	-0.39	2.26e-13	Subjective well-being;
CRC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.38e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg23136738	chr11:925521	AP2A2	-0.42	-7.23	-0.37	3.41e-12	Alzheimer's disease (late onset);
CRC	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg21851534	chr17:3907994	ZZEF1	-0.36	-6.0	-0.31	5.34e-9	Type 2 diabetes;
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.43e-8	Life satisfaction;
CRC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.64	11.1	0.52	1.57e-24	Prostate cancer;
CRC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.64	8.91	0.44	3.49e-17	Coronary artery disease;
CRC	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.74	-6.6	-0.34	1.68e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04427462	chr19:47218031	PRKD2	0.48	6.56	0.34	2.14e-10	Survival in pancreatic cancer;
CRC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.12	0.49	3.81e-21	Menopause (age at onset);
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.66	9.36	0.46	1.24e-18	Menarche (age at onset);
CRC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.39	0.42	1.43e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9469578	1.000	rs9469578	chr6:33706479	C/T	cg18708504	chr6:33715942	IP6K3	0.64	7.34	0.38	1.67e-12	Phosphorus levels;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18301423	chr5:131593218	PDLIM4	0.44	8.18	0.41	6.25e-15	Acylcarnitine levels;
CRC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg07718321	chr6:96025334	MANEA	0.51	5.98	0.31	5.83e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs2594989	0.836	rs347607	chr3:11268021	A/C	cg00170343	chr3:11313890	ATG7	-0.53	-6.09	-0.32	3.23e-9	Circulating chemerin levels;
CRC	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.42	5.9	0.31	9.22e-9	Response to statin therapy;
CRC	cis	rs4737010	0.630	rs569451	chr8:41623001	G/A	cg17182837	chr8:41585554	ANK1	0.54	7.58	0.39	3.5e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6844506	1.000	rs4862357	chr4:185220362	C/T	cg18317788	chr4:185205197	NA	-0.41	-5.92	-0.31	8.05e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
CRC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg17948913	chr5:572064	NA	0.55	6.33	0.33	7.93e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.93	-0.31	7.61e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.45	-6.79	-0.35	5.27e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg03469862	chr11:68924853	NA	0.46	5.91	0.31	8.56e-9	Blond vs. brown hair color;
CRC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.57	-8.95	-0.44	2.58e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-5.65	-0.3	3.46e-8	Schizophrenia;
CRC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg20885578	chr2:198174922	NA	-0.36	-6.31	-0.33	9.06e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.61	11.56	0.54	3.73e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.54	-8.66	-0.43	2.2e-16	Huntington's disease progression;
CRC	cis	rs4731207	0.698	rs962863	chr7:124558339	C/T	cg23710748	chr7:124431027	NA	0.37	5.82	0.31	1.43e-8	Cutaneous malignant melanoma;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.565	rs7776744	chr7:124599749	A/G	cg23710748	chr7:124431027	NA	-0.42	-6.7	-0.35	8.82e-11	Cutaneous malignant melanoma;
CRC	trans	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg18335740	chr13:41363409	SLC25A15	0.48	6.38	0.33	5.84e-10	Lewy body disease;
CRC	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg06042504	chr8:55087323	NA	-0.42	-6.5	-0.34	2.97e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.84	10.34	0.5	7.08e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.68	-10.6	-0.5	8.56e-23	Intelligence (multi-trait analysis);
CRC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg07416916	chr2:36825888	FEZ2	0.37	6.94	0.36	2.03e-11	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19741408	chr1:90460434	ZNF326;LOC492303	0.48	6.25	0.33	1.24e-9	Thyroid stimulating hormone;
CRC	trans	rs9771228	0.930	rs10259431	chr7:32281397	C/T	cg02979224	chr7:93204462	CALCR	0.34	5.96	0.31	6.43e-9	Cognitive ability;Verbal-numerical reasoning;
CRC	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.66	0.3	3.33e-8	Heart rate;
CRC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	8.56	0.43	4.52e-16	Total body bone mineral density;
CRC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.02	0.4	1.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.59	0.34	1.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-13.29	-0.59	1.52e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	7.21	0.37	3.84e-12	Headache;
CRC	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg09040174	chr2:113837401	NA	0.64	10.17	0.49	2.58e-21	Protein quantitative trait loci;
CRC	cis	rs990171	0.607	rs1558642	chr2:102763960	T/G	cg22835712	chr2:102737379	NA	0.46	6.01	0.31	4.97e-9	Lymphocyte counts;
CRC	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.33	5.76	0.3	1.91e-8	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.81	-11.14	-0.52	1.12e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08023809	chr12:53645616	MFSD5	0.42	6.09	0.32	3.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.42	8.33	0.42	2.27e-15	Vitiligo;
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.4	-6.21	-0.32	1.62e-9	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg21724239	chr8:58056113	NA	0.39	5.75	0.3	2.02e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.69	9.19	0.45	4.43e-18	Alzheimer's disease;
CRC	cis	rs713587	0.571	rs564667	chr2:25310860	A/T	cg22495460	chr2:25135724	ADCY3	0.39	5.77	0.3	1.87e-8	Body mass index in non-asthmatics;
CRC	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.48	-7.26	-0.37	2.75e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.77	8.62	0.43	2.95e-16	Neuroticism;
CRC	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg13902645	chr11:5959945	NA	0.45	6.88	0.35	3.11e-11	DNA methylation (variation);
CRC	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.69	0.35	9.4e-11	LDL cholesterol;
CRC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.49	-9.05	-0.45	1.25e-17	Total body bone mineral density;
CRC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.41	-0.38	1.09e-12	Monocyte percentage of white cells;
CRC	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.28	5.99	0.31	5.4e-9	Educational attainment (years of education);
CRC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.02	-0.31	4.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	1.01	9.55	0.47	3.13e-19	Lymphocyte counts;
CRC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg02527881	chr3:46936655	PTH1R	0.38	7.07	0.36	9.43e-12	Colorectal cancer;
CRC	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg05579598	chr16:88989069	CBFA2T3	0.34	6.84	0.35	3.77e-11	Social autistic-like traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20826379	chr1:16011358	PLEKHM2	0.46	6.45	0.34	4.02e-10	Response to antipsychotic treatment;
CRC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.31	-0.46	1.88e-18	Morning vs. evening chronotype;
CRC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.54	8.77	0.44	1e-16	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.27e-9	Prudent dietary pattern;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.8	-6.48	-0.34	3.35e-10	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26351039	chr19:49138730	DBP	0.42	6.58	0.34	1.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs8051149	0.738	rs2287120	chr16:87871582	G/A	cg01412419	chr16:87856264	NA	0.52	7.06	0.36	9.73e-12	Blood metabolite levels;
CRC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.38	-6.37	-0.33	6.44e-10	Blood metabolite levels;
CRC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	0.94	11.45	0.53	9.31e-26	Type 2 diabetes nephropathy;
CRC	trans	rs1436351	0.683	rs6780872	chr3:104624448	A/C	cg09862801	chr2:45396991	NA	-0.48	-6.0	-0.31	5.27e-9	Body mass index;
CRC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.72	8.64	0.43	2.54e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg02770688	chr6:168491649	NA	0.6	8.74	0.43	1.22e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs995000	0.965	rs11207981	chr1:63006087	C/A	cg19896129	chr1:63156450	NA	-0.45	-6.99	-0.36	1.52e-11	Triglyceride levels;
CRC	cis	rs2857891	0.659	rs2638110	chr11:6993922	C/T	cg04053776	chr11:6947353	ZNF215	0.41	6.4	0.33	5.22e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.76	-9.77	-0.47	5.84e-20	Blood metabolite levels;
CRC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05952120	chr17:61554416	ACE	0.4	6.53	0.34	2.54e-10	Obesity-related traits;
CRC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg15848620	chr12:58087721	OS9	-0.61	-8.36	-0.42	1.79e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg17800788	chr1:21766015	NBPF3	0.37	6.3	0.33	9.45e-10	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19374457	chr1:44412380	IPO13	0.38	6.28	0.33	1.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.55	-8.2	-0.41	5.46e-15	Vitiligo;
CRC	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27397625	chr6:42952298	PPP2R5D	-0.49	-6.08	-0.32	3.3e-9	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg02741985	chr17:80059408	CCDC57	0.44	7.17	0.37	4.94e-12	Life satisfaction;
CRC	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg13385794	chr1:248469461	NA	0.38	6.56	0.34	2.15e-10	Common traits (Other);
CRC	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.72	-0.43	1.37e-16	Metabolite levels;
CRC	cis	rs62458065	1.000	rs10246687	chr7:32465183	T/A	cg20159608	chr7:32802032	NA	-0.5	-6.31	-0.33	8.83e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04971341	chr1:52607910	ZFYVE9	0.47	6.65	0.34	1.26e-10	Response to antipsychotic treatment;
CRC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.63	8.57	0.43	3.98e-16	Intraocular pressure;
CRC	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg00666640	chr1:248458726	OR2T12	0.35	6.65	0.34	1.24e-10	Common traits (Other);
CRC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.08	0.49	5.46e-21	Systolic blood pressure;
CRC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.5	-9.36	-0.46	1.29e-18	Longevity;
CRC	trans	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	17.66	0.7	1.49e-49	Ulcerative colitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14192396	chr10:97416393	ALDH18A1	0.46	6.15	0.32	2.3e-9	Anxiety disorder;
CRC	cis	rs1383484	0.545	rs9329363	chr15:84643134	T/G	cg11189052	chr15:85197271	WDR73	-0.49	-6.05	-0.32	3.93e-9	Height;
CRC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Body mass index;
CRC	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg27661571	chr11:113659931	NA	-0.75	-9.23	-0.45	3.32e-18	Hip circumference adjusted for BMI;
CRC	cis	rs9868809	0.764	rs41290686	chr3:48604059	G/A	cg01304814	chr3:48885189	PRKAR2A	0.9	5.9	0.31	9.14e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14895029	chr7:2775587	GNA12	-0.48	-7.23	-0.37	3.34e-12	Height;
CRC	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.5	6.49	0.34	3.17e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.11	-0.45	8.18e-18	Bipolar disorder;
CRC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg21251018	chr6:28226885	NKAPL	0.4	6.09	0.32	3.12e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.47	-6.81	-0.35	4.69e-11	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11424665	chr3:129158811	IFT122;MBD4	0.37	6.22	0.32	1.49e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.57	7.07	0.36	9.15e-12	Response to diuretic therapy;
CRC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg21620606	chr4:1342894	KIAA1530	0.51	8.52	0.43	5.68e-16	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-7.45	-0.38	8.18e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7626444	0.625	rs843541	chr3:196475750	A/G	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.74e-12	Monocyte count;
CRC	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg06998765	chr14:75389618	RPS6KL1	-0.25	-5.74	-0.3	2.11e-8	Height;
CRC	cis	rs7725052	0.609	rs4559044	chr5:40452857	A/G	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.55	-5.89	-0.31	9.48e-9	Blood protein levels;
CRC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-8.83	-0.44	6.42e-17	Breast cancer;
CRC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg01304814	chr3:48885189	PRKAR2A	0.79	5.77	0.3	1.85e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg08772003	chr10:104629869	AS3MT	-0.34	-5.88	-0.31	9.88e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.44	0.33	4.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg04880052	chr2:219191631	PNKD	-0.45	-6.77	-0.35	6.06e-11	Colorectal cancer;
CRC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.72	-7.89	-0.4	4.61e-14	Psoriasis;
CRC	cis	rs1223397	0.702	rs1223400	chr6:13271242	T/C	cg21538684	chr6:13274180	PHACTR1	0.48	5.86	0.31	1.13e-8	Blood pressure;
CRC	cis	rs9584850	0.718	rs6491427	chr13:99113166	A/G	cg07423050	chr13:99094983	FARP1	0.45	6.31	0.33	9.26e-10	Neuroticism;
CRC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg16476235	chr8:21771668	DOK2	0.41	6.95	0.36	1.97e-11	Mean corpuscular volume;
CRC	trans	rs9650657	0.615	rs7012199	chr8:10696997	A/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.04	-0.32	4.22e-9	Neuroticism;
CRC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.79	-12.92	-0.58	3.65e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.2	-0.37	4.22e-12	Lymphocyte counts;
CRC	cis	rs375066	0.935	rs10421518	chr19:44381286	A/G	cg12072164	chr19:44306565	LYPD5	0.37	5.61	0.3	4.36e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12876261	chr7:56119223	PSPH;CCT6A	0.37	6.03	0.32	4.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg02353165	chr6:42928485	GNMT	0.49	6.68	0.35	1.01e-10	Blood protein levels;
CRC	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg16964102	chr10:135390573	NA	-0.37	-5.98	-0.31	5.78e-9	Obesity-related traits;
CRC	trans	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg06791473	chr12:49259579	RND1	0.62	6.08	0.32	3.32e-9	Blood protein levels;
CRC	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.8	-0.35	5.08e-11	Educational attainment;
CRC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.38	-6.22	-0.32	1.52e-9	Gout;Renal underexcretion gout;
CRC	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.51	-6.53	-0.34	2.52e-10	Inhibitory control;
CRC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.58	-0.43	3.68e-16	Monocyte percentage of white cells;
CRC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg11522145	chr4:3412961	RGS12	-0.41	-6.45	-0.33	4.03e-10	Serum sulfate level;
CRC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg27535305	chr1:53392650	SCP2	0.34	6.17	0.32	2.03e-9	Monocyte count;
CRC	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.87	0.44	4.59e-17	Coffee consumption (cups per day);
CRC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg08210727	chr20:33865349	NA	0.44	6.06	0.32	3.7e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg13798780	chr7:105162888	PUS7	0.66	8.06	0.41	1.39e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	8.28	0.42	3.2e-15	Ileal carcinoids;
CRC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	6.57	0.34	1.92e-10	Menopause (age at onset);
CRC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.37	-5.61	-0.3	4.22e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.72	0.51	3.51e-23	Motion sickness;
CRC	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	1.0	18.55	0.71	4.56e-53	Gut microbiome composition (winter);
CRC	cis	rs17127169	0.536	rs112625995	chr1:65496627	A/G	cg11989330	chr1:65468827	NA	0.89	6.32	0.33	8.3e-10	Sitting height ratio;
CRC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.73	8.72	0.43	1.44e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Dilated cardiomyopathy;
CRC	trans	rs6678914	0.966	rs12033460	chr1:202180214	A/G	cg19977628	chr5:1262072	TERT	0.42	5.99	0.31	5.37e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.45	7.2	0.37	4.14e-12	Hemoglobin concentration;
CRC	cis	rs7849270	1.000	rs7036114	chr9:131893406	C/T	cg13538475	chr9:131942899	NA	-0.31	-6.03	-0.32	4.33e-9	Blood metabolite ratios;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13035437	chr7:30634158	GARS	0.4	6.43	0.33	4.42e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg03790207	chr6:42947109	PEX6	-0.53	-7.75	-0.39	1.17e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg09873164	chr1:152488093	CRCT1	0.37	6.18	0.32	1.88e-9	Hair morphology;
CRC	cis	rs4737010	0.591	rs13282514	chr8:41619713	A/G	cg17182837	chr8:41585554	ANK1	-0.5	-7.32	-0.37	1.92e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.69	-11.28	-0.53	3.7e-25	Cognitive function;
CRC	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.46	6.86	0.35	3.46e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	9.46	0.46	6.27e-19	Bone mineral density;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg16211334	chr6:10695274	C6orf52;PAK1IP1	0.39	6.07	0.32	3.62e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.4	-7.03	-0.36	1.17e-11	Height;
CRC	cis	rs294883	0.826	rs9355265	chr6:159701137	C/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs9400239	0.661	rs1268162	chr6:109009194	A/G	cg11073813	chr6:109029018	NA	-0.42	-6.82	-0.35	4.5e-11	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg13919466	chr1:32135498	COL16A1	-0.31	-5.98	-0.31	5.78e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.64	9.47	0.46	5.62e-19	Selective IgA deficiency;
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.67	7.86	0.4	5.71e-14	Body mass index;
CRC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.86	-10.93	-0.52	6.42e-24	Obesity-related traits;
CRC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.39	0.33	5.64e-10	Morning vs. evening chronotype;
CRC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	6.06	0.32	3.69e-9	Menarche (age at onset);
CRC	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.98	10.87	0.51	9.87e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg05272587	chr13:111038400	COL4A2	0.45	7.33	0.37	1.78e-12	White matter hyperintensity burden;
CRC	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.43	6.2	0.32	1.68e-9	Asthma;
CRC	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg02158880	chr13:53174818	NA	-0.47	-7.07	-0.36	9.39e-12	Lewy body disease;
CRC	cis	rs4731207	0.596	rs10264288	chr7:124574527	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.09	-0.32	3.17e-9	Cutaneous malignant melanoma;
CRC	trans	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg10756647	chr7:56101905	PSPH	0.72	7.65	0.39	2.27e-13	Diabetic kidney disease;
CRC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg09237302	chr4:906077	GAK	0.46	8.37	0.42	1.62e-15	Systemic sclerosis;
CRC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg21620606	chr4:1342894	KIAA1530	0.51	8.16	0.41	7.43e-15	Obesity-related traits;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg14883916	chr11:6947541	ZNF215	0.59	6.26	0.33	1.21e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.69	10.52	0.5	1.68e-22	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.93	-16.32	-0.67	2.74e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.72	7.96	0.4	2.76e-14	Breast cancer;
CRC	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.85	9.15	0.45	6.24e-18	Gastritis;
CRC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.81	-14.78	-0.63	3e-38	Body mass index;
CRC	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.48	0.42	7.86e-16	Corneal astigmatism;
CRC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.54	-0.34	2.41e-10	Reticulocyte fraction of red cells;
CRC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.69	-0.35	9.69e-11	Neuroticism;
CRC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.38	-5.81	-0.3	1.49e-8	Ulcerative colitis;
CRC	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.54	-6.69	-0.35	9.5e-11	Cancer;
CRC	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.44	-6.83	-0.35	4.19e-11	Red blood cell count;
CRC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.45e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg06204229	chr3:52865917	ITIH4	0.56	7.63	0.39	2.48e-13	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1868673	1.000	rs6810143	chr3:150174510	A/T	cg04908077	chr3:150187338	NA	0.33	5.77	0.3	1.82e-8	Waist circumference;
CRC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.56	0.54	3.73e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg12172441	chr6:28176163	NA	0.55	7.48	0.38	6.69e-13	Cardiac Troponin-T levels;
CRC	cis	rs4601821	0.635	rs12282356	chr11:113208382	A/G	cg14159747	chr11:113255604	NA	0.43	8.04	0.41	1.62e-14	Alcoholic chronic pancreatitis;
CRC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg21153622	chr11:89784906	NA	-0.38	-6.15	-0.32	2.29e-9	Height;
CRC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg14844989	chr11:31128820	NA	-0.32	-5.79	-0.3	1.69e-8	Red blood cell count;
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.8	0.4	8.27e-14	Alzheimer's disease;
CRC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg18490616	chr2:88469792	THNSL2	-0.39	-5.75	-0.3	2.04e-8	Response to metformin (IC50);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08286599	chr2:191208694	INPP1	0.51	7.38	0.38	1.27e-12	Response to antipsychotic treatment;
CRC	cis	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg12458913	chr13:53173898	NA	0.56	8.95	0.44	2.6e-17	Lewy body disease;
CRC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.06	-0.32	3.76e-9	Menarche (age at onset);
CRC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.68	12.13	0.56	3.13e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.51	-9.67	-0.47	1.21e-19	Schizophrenia;
CRC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.53	0.5	1.53e-22	Hip circumference adjusted for BMI;
CRC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	9.98	0.48	1.12e-20	Platelet count;
CRC	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg02549819	chr16:58548995	SETD6	1.23	7.95	0.4	2.98e-14	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05796909	chr17:7465070	SENP3	0.38	6.0	0.31	5.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg02683197	chr6:28174875	NA	0.71	9.48	0.46	5.15e-19	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.58	8.25	0.41	3.79e-15	Lung cancer;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.83	17.94	0.7	1.18e-50	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.39	-6.34	-0.33	7.51e-10	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13703666	chr11:66115419	B3GNT1	0.51	6.7	0.35	8.85e-11	Thyroid stimulating hormone;
CRC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.58	-8.61	-0.43	3.09e-16	Aortic root size;
CRC	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.79	-0.63	2.62e-38	Exhaled nitric oxide output;
CRC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-7.94	-0.4	3.27e-14	Personality dimensions;
CRC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.53	7.5	0.38	6.09e-13	Lung cancer;
CRC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.45	-8.98	-0.44	2.15e-17	Prostate cancer;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.36	-6.8	-0.35	4.87e-11	Lymphocyte counts;
CRC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24879395	chr17:48785255	ANKRD40	0.4	6.03	0.32	4.45e-9	Schizophrenia;
CRC	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-7.11	-0.37	7.06e-12	Metabolite levels;
CRC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg19812747	chr11:111475976	SIK2	-0.58	-9.91	-0.48	2e-20	Primary sclerosing cholangitis;
CRC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.76	16.8	0.68	3.73e-46	Breast cancer;
CRC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.81	-0.4	7.53e-14	Bipolar disorder;
CRC	trans	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.47	-0.38	7.12e-13	Endometrial cancer;
CRC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg24505167	chr7:1915268	MAD1L1	-0.42	-5.88	-0.31	1e-8	Bipolar disorder;
CRC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.58	8.14	0.41	8.5e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.39	2.35e-13	Bladder cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13690588	chr1:28415118	EYA3	-0.39	-6.41	-0.33	4.97e-10	Myopia (pathological);
CRC	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.85	-14.7	-0.63	5.81e-38	Longevity;
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg17346650	chr17:80929145	B3GNTL1	0.39	5.76	0.3	1.95e-8	Glycated hemoglobin levels;
CRC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.69	-8.26	-0.41	3.72e-15	Initial pursuit acceleration;
CRC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg18225595	chr11:63971243	STIP1	0.58	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.46	-0.34	3.66e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21587861	chr12:32260103	BICD1	0.41	6.01	0.31	4.95e-9	Response to antipsychotic treatment;
CRC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.29	6.14	0.32	2.41e-9	Homoarginine levels;
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg15147215	chr3:52552868	STAB1	0.64	11.0	0.52	3.6e-24	Electroencephalogram traits;
CRC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg09127314	chr1:152161683	NA	0.53	6.69	0.35	9.52e-11	Atopic dermatitis;
CRC	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.8	-14.17	-0.62	6.58e-36	Lewy body disease;
CRC	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.62	7.98	0.4	2.41e-14	Chronic kidney disease;
CRC	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg17375396	chr11:67202808	RPS6KB2	0.34	5.83	0.31	1.32e-8	Mean corpuscular volume;
CRC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.53	0.57	1.01e-29	Menopause (age at onset);
CRC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	1.25	14.37	0.62	1.14e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.67	7.15	0.37	5.58e-12	Body mass index;
CRC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.83	-0.48	3.75e-20	Total cholesterol levels;
CRC	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg23234261	chr14:55582407	NA	-0.3	-5.93	-0.31	7.74e-9	Protein biomarker;
CRC	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.57	-9.69	-0.47	1.07e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	1.09	10.3	0.49	9.83e-22	Parkinson's disease;
CRC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.45	6.96	0.36	1.89e-11	Monocyte count;
CRC	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg14139581	chr11:64358342	SLC22A12	0.38	5.99	0.31	5.4e-9	Urate levels in obese individuals;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02284587	chr1:64971218	CACHD1	-0.41	-6.02	-0.31	4.54e-9	Interleukin-6 levels;
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg04155289	chr7:94953770	PON1	-0.62	-7.69	-0.39	1.77e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4478137	0.931	rs4057797	chr4:164245053	T/A	cg06758707	chr4:164254230	NPY1R	0.38	5.87	0.31	1.05e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.72	-11.98	-0.55	1.11e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.5	8.06	0.41	1.44e-14	Lipoprotein (a) levels;
CRC	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg01557791	chr16:72042693	DHODH	-0.58	-5.83	-0.31	1.35e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg02683197	chr6:28174875	NA	0.82	10.03	0.48	7.9e-21	Depression;
CRC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.92e-13	Motion sickness;
CRC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.8	-0.3	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.72	-8.29	-0.42	2.99e-15	Obesity-related traits;
CRC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg06207120	chr15:45996521	NA	0.32	7.66	0.39	2.08e-13	Waist circumference;Weight;
CRC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg08213375	chr14:104286397	PPP1R13B	0.58	12.0	0.55	9.44e-28	Schizophrenia;
CRC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg22496339	chr2:162101262	NA	-0.8	-13.65	-0.6	6.59e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg25856811	chr1:152973957	SPRR3	-0.22	-6.01	-0.31	4.96e-9	Inflammatory skin disease;
CRC	cis	rs73206853	0.841	rs73191828	chr12:110946121	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	7.86	0.4	5.56e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg11530914	chr16:67281528	FHOD1;SLC9A5	-0.54	-6.61	-0.34	1.58e-10	Diisocyanate-induced asthma;
CRC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-11.43	-0.53	1.08e-25	Ulcerative colitis;
CRC	cis	rs457287	0.554	rs456978	chr9:4833960	A/G	cg14182974	chr9:4791918	RCL1	0.37	5.7	0.3	2.6e-8	Platelet count;
CRC	cis	rs59104589	0.617	rs7568	chr2:242291743	A/G	cg19488206	chr2:242435732	STK25	0.47	6.65	0.34	1.19e-10	Fibrinogen levels;
CRC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.84	-12.83	-0.58	7.85e-31	Bipolar disorder and schizophrenia;
CRC	cis	rs4728302	0.838	rs7798804	chr7:133584085	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.8	0.3	1.54e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.9e-9	Hemoglobin concentration;
CRC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.52	-8.72	-0.43	1.44e-16	Iron status biomarkers;
CRC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-5.79	-0.3	1.64e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.01	0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.51	8.78	0.44	9.35e-17	Coronary artery disease;
CRC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.55	0.34	2.21e-10	Lung cancer;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	trans	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg19188899	chr13:112838565	NA	-0.41	-6.4	-0.33	5.35e-10	Systemic lupus erythematosus;
CRC	cis	rs9549328	0.700	rs4907570	chr13:113617651	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.51	0.34	2.89e-10	Systolic blood pressure;
CRC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.22	-0.45	3.64e-18	Body mass index;
CRC	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.06	-0.32	3.73e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg16342193	chr10:102329863	NA	-0.33	-5.69	-0.3	2.85e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.83	-14.01	-0.61	2.8e-35	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.74	-0.3	2.19e-8	Life satisfaction;
CRC	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.56	-7.04	-0.36	1.12e-11	Obesity (extreme);
CRC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-11.31	-0.53	2.8e-25	Asthma;
CRC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.5	6.94	0.36	2.1e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.26	6.51	0.34	2.85e-10	Iron status biomarkers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00356511	chr17:35716273	ACACA	0.39	6.25	0.33	1.24e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.41	-5.77	-0.3	1.84e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4290604	0.665	rs6761002	chr2:238038873	T/C	cg23555395	chr2:238036564	NA	-0.65	-6.64	-0.34	1.3100000000000001e-10	Asthma;
CRC	cis	rs3736594	0.527	rs62141279	chr2:27771415	C/T	cg27432699	chr2:27873401	GPN1	0.64	8.18	0.41	6.34e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9463078	0.669	rs17288334	chr6:45351391	A/G	cg25276700	chr6:44698697	NA	0.26	6.04	0.32	4.25e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.9	-0.4	4.09e-14	Monocyte percentage of white cells;
CRC	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.72	11.23	0.53	5.51e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs887797	0.557	rs9900353	chr17:64575492	A/G	cg27019712	chr17:64599478	PRKCA	0.38	5.74	0.3	2.14e-8	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg08445226	chr3:99536904	C3orf26;MIR548G	-0.42	-6.1	-0.32	2.92e-9	HDL cholesterol;
CRC	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg16989719	chr2:238392110	NA	-0.35	-6.25	-0.33	1.24e-9	Prostate cancer;
CRC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg00106254	chr7:1943704	MAD1L1	-0.37	-5.8	-0.3	1.57e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.87	15.77	0.66	3.91e-42	Alcohol dependence;
CRC	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.95	16.08	0.66	2.35e-43	Dupuytren's disease;
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg07414643	chr4:187882934	NA	0.36	6.21	0.32	1.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg21770322	chr7:97807741	LMTK2	0.52	8.44	0.42	9.92e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs73162807	0.655	rs17436397	chr3:146443282	T/C	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.5	-8.05	-0.41	1.5e-14	Aortic root size;
CRC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.55	-0.47	3.07e-19	Monocyte percentage of white cells;
CRC	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.15	0.45	6.04e-18	Coffee consumption (cups per day);
CRC	cis	rs11955398	0.521	rs6449489	chr5:60026236	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.4	-5.62	-0.3	3.98e-8	Intelligence (multi-trait analysis);
CRC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.26	0.33	1.23e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	9.09	0.45	9.43e-18	Type 2 diabetes;
CRC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs449789	0.524	rs1553480	chr6:159742596	T/C	cg14500486	chr6:159655392	FNDC1	-0.49	-7.53	-0.38	4.81e-13	Pulse pressure;
CRC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.37	8.77	0.44	9.59e-17	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.64	10.61	0.5	8.1e-23	Corneal astigmatism;
CRC	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-8.98	-0.44	2.09e-17	Rheumatoid arthritis;
CRC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.69	0.39	1.67e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.37	-6.21	-0.32	1.64e-9	Height;
CRC	cis	rs889398	0.835	rs12925429	chr16:69801539	G/A	cg00738113	chr16:70207722	CLEC18C	0.37	6.24	0.33	1.36e-9	Body mass index;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.41	-5.64	-0.3	3.6e-8	Prudent dietary pattern;
CRC	cis	rs9826463	0.757	rs73240314	chr3:142255090	T/C	cg20824294	chr3:142316082	PLS1	0.41	6.96	0.36	1.85e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.61	7.34	0.38	1.65e-12	Menarche (age at onset);
CRC	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-6.38	-0.33	5.84e-10	Inflammatory biomarkers;
CRC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.7	9.58	0.47	2.4e-19	Alzheimer's disease;
CRC	trans	rs1864585	0.520	rs17776427	chr8:10672972	G/T	cg26278703	chr11:58910052	FAM111A	0.54	6.47	0.34	3.63e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	trans	rs596169	0.649	rs3885898	chr1:219126770	T/C	cg09853702	chr12:47665230	NA	0.77	6.4	0.33	5.4e-10	Intraocular pressure;
CRC	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-7.13	-0.37	6.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg15845792	chr6:28175446	NA	0.97	13.03	0.58	1.43e-31	Depression;
CRC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.43	-20.28	-0.75	6.91e-60	Hip circumference adjusted for BMI;
CRC	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.75	7.63	0.39	2.49e-13	Neuroticism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05329982	chr11:62359210	TUT1	-0.52	-6.22	-0.32	1.48e-9	Diisocyanate-induced asthma;
CRC	cis	rs10450586	0.863	rs7102043	chr11:27305839	C/T	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.2	0.32	1.73e-9	IgG glycosylation;
CRC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	8.41	0.42	1.27e-15	Hemoglobin concentration;
CRC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.96	0.31	6.38e-9	Renal function-related traits (BUN);
CRC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.56	9.34	0.46	1.49e-18	Schizophrenia;
CRC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10819733	chr22:24237672	NA	-0.37	-6.35	-0.33	7.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.98	12.45	0.57	2.05e-29	Exhaled nitric oxide levels;
CRC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.46	6.64	0.34	1.29e-10	Lymphocyte counts;
CRC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-7.24	-0.37	3.29e-12	Major depressive disorder;
CRC	cis	rs10982256	0.622	rs4979410	chr9:117239877	C/T	cg13636371	chr9:117264095	DFNB31	0.33	6.13	0.32	2.46e-9	Bipolar disorder;
CRC	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg15147215	chr3:52552868	STAB1	-0.53	-7.69	-0.39	1.7e-13	Bipolar disorder;
CRC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-7.16	-0.37	5.15e-12	Colorectal cancer;
CRC	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg16141378	chr3:129829833	LOC729375	0.44	6.59	0.34	1.8e-10	Triglycerides;
CRC	cis	rs13144136	0.647	rs12509884	chr4:10654043	C/T	cg10242279	chr4:10666415	CLNK	-0.37	-6.39	-0.33	5.8e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.13	0.32	2.58e-9	Diabetic kidney disease;
CRC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.45	6.7	0.35	9.07e-11	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.43	8.1	0.41	1.06e-14	Childhood ear infection;
CRC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.45	0.33	4.11e-10	Lung cancer;
CRC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.45	-6.98	-0.36	1.63e-11	Hip circumference adjusted for BMI;
CRC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.86	16.5	0.67	5.46e-45	White blood cell count;
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg26721908	chr21:47610096	LSS	0.47	6.84	0.35	3.93e-11	Testicular germ cell tumor;
CRC	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg21827317	chr3:136751795	NA	0.36	5.85	0.31	1.19e-8	Neuroticism;
CRC	cis	rs2745959	0.611	rs2785644	chr1:208059691	C/T	cg09788693	chr1:208063733	CD34	0.43	5.8	0.3	1.55e-8	Resting heart rate;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04871131	chr7:94954202	PON1	-0.63	-9.63	-0.47	1.64e-19	Paraoxonase activity;
CRC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-6.44	-0.33	4.22e-10	Aortic root size;
CRC	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg12046867	chr14:103022105	NA	-0.79	-10.71	-0.51	3.73e-23	Platelet count;
CRC	cis	rs7781266	0.842	rs1364364	chr7:133244493	C/T	cg03336402	chr7:133662267	EXOC4	0.49	5.78	0.3	1.74e-8	Educational attainment (college completion);
CRC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.74	-11.88	-0.55	2.53e-27	Obesity-related traits;
CRC	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.81	0.4	7.61e-14	Height;
CRC	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.33	0.37	1.8e-12	Diisocyanate-induced asthma;
CRC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.6	-7.82	-0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	17.32	0.69	3.31e-48	Smoking behavior;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06157335	chr1:53164003	C1orf163	0.51	6.43	0.33	4.62e-10	Thyroid stimulating hormone;
CRC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg25767906	chr1:53392781	SCP2	-0.39	-6.11	-0.32	2.86e-9	Monocyte count;
CRC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.72	11.33	0.53	2.45e-25	Colorectal cancer;
CRC	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg05714579	chr10:131428358	MGMT	0.53	7.71	0.39	1.47e-13	Response to temozolomide;
CRC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.44	6.75	0.35	6.6e-11	Personality dimensions;
CRC	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.58	8.3	0.42	2.82e-15	Smooth-surface caries;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg24634471	chr8:143751801	JRK	-0.5	-6.77	-0.35	5.9e-11	Urinary tract infection frequency;
CRC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.76	13.22	0.59	2.65e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg00666640	chr1:248458726	OR2T12	0.52	8.84	0.44	5.77e-17	Common traits (Other);
CRC	cis	rs2346160	1.000	rs4709159	chr6:167664918	C/T	cg27333441	chr6:167680455	NA	-0.38	-6.22	-0.32	1.52e-9	Parental extreme longevity (95 years and older);
CRC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg21466736	chr12:48725269	NA	0.48	7.33	0.37	1.79e-12	Glycated hemoglobin levels;
CRC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg15147215	chr3:52552868	STAB1	-0.48	-8.17	-0.41	6.75e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.49	7.68	0.39	1.78e-13	Corneal astigmatism;
CRC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg06470822	chr6:28175283	NA	0.66	10.11	0.49	4.13e-21	Cardiac Troponin-T levels;
CRC	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg00277334	chr10:82204260	NA	0.37	5.93	0.31	7.57e-9	Sarcoidosis;
CRC	cis	rs12449964	0.524	rs4925093	chr17:17568946	G/T	cg16928487	chr17:17741425	SREBF1	-0.35	-5.91	-0.31	8.46e-9	Coronary artery disease or ischemic stroke;
CRC	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg11993925	chr19:44307056	LYPD5	0.46	7.58	0.39	3.5e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.77	-11.27	-0.53	3.82e-25	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg03037974	chr15:76606532	NA	0.54	9.05	0.45	1.25e-17	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16977668	chr6:86353909	SYNCRIP	0.42	6.24	0.33	1.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-8.92	-0.44	3.39e-17	Subjective well-being;
CRC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.2	-0.41	5.56e-15	Chronic sinus infection;
CRC	cis	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg09021430	chr5:549028	NA	-0.58	-6.31	-0.33	9.16e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg14458575	chr2:238380390	NA	0.47	8.24	0.41	4.19e-15	Prostate cancer;
CRC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.43	0.5	3.36e-22	Hip circumference adjusted for BMI;
CRC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.67	10.71	0.51	3.55e-23	Sudden cardiac arrest;
CRC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	10.06	0.49	6.09e-21	Lung cancer;
CRC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.57	7.71	0.39	1.5e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.68	-10.95	-0.52	5.37e-24	Motion sickness;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg18758796	chr5:131593413	PDLIM4	0.39	6.4	0.33	5.28e-10	Breast cancer;
CRC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.36e-10	Schizophrenia;
CRC	cis	rs1322512	1.000	rs9371626	chr6:153008926	G/A	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.56	8.26	0.41	3.52e-15	Lung cancer;
CRC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.39	5.67	0.3	3.08e-8	Plateletcrit;
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg22638593	chr5:131593259	PDLIM4	0.39	7.3	0.37	2.13e-12	Breast cancer;
CRC	cis	rs4731207	0.596	rs10231355	chr7:124581218	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.09	-0.32	3.18e-9	Cutaneous malignant melanoma;
CRC	cis	rs4654899	0.865	rs3856173	chr1:21114833	C/T	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.75	-0.35	6.54e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg23127183	chr11:57508653	C11orf31	-0.51	-6.75	-0.35	6.79e-11	Schizophrenia;
CRC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	0.99	14.58	0.63	1.75e-37	Breast cancer;
CRC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.84	-0.55	3.42e-27	Type 2 diabetes;
CRC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	6.01	0.31	4.96e-9	Renal function-related traits (BUN);
CRC	cis	rs62045849	0.557	rs6500533	chr16:89190065	G/A	cg08015503	chr16:89190385	ACSF3	-0.93	-7.4	-0.38	1.18e-12	Red blood cell count;
CRC	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-7.38	-0.38	1.33e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs524281	0.861	rs7941469	chr11:65900152	A/G	cg14036092	chr11:66035641	RAB1B	0.45	5.74	0.3	2.17e-8	Electroencephalogram traits;
CRC	cis	rs6504950	0.830	rs17817901	chr17:53038745	A/G	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.95	-14.01	-0.61	2.66e-35	Colorectal cancer;
CRC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.58	-6.7	-0.35	8.79e-11	Bronchopulmonary dysplasia;
CRC	cis	rs3743266	0.613	rs12442393	chr15:60734460	C/G	cg21667061	chr15:60772094	NARG2	-0.29	-5.8	-0.3	1.54e-8	Menarche (age at onset);
CRC	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.75	13.7	0.6	3.98e-34	Cancer;
CRC	cis	rs17162190	0.698	rs12046614	chr1:26851729	A/C	cg17456097	chr1:26900765	RPS6KA1	0.48	6.09	0.32	3.22e-9	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17010769	chr15:79165973	MORF4L1	0.42	6.7	0.35	8.84e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06079273	chr8:97247865	UQCRB	0.42	6.83	0.35	4.18e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.31	-0.46	1.81e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1186222	0.967	rs1179625	chr7:75255491	A/G	cg05145297	chr7:75264568	HIP1	0.48	8.42	0.42	1.21e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.2	0.45	4.14e-18	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.57	6.99	0.36	1.51e-11	Vitiligo;
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.08	0.41	1.22e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.59	-9.58	-0.47	2.38e-19	Monocyte count;
CRC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.78	-0.51	2.02e-23	Monocyte count;
CRC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.23	0.74	1.07e-59	Prudent dietary pattern;
CRC	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg23032129	chr1:109941072	SORT1	-0.27	-5.84	-0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.67	-12.17	-0.56	2.12e-28	Calcium levels;
CRC	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-6.04	-0.32	4.16e-9	Coronary artery disease;
CRC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-8.03	-0.4	1.78e-14	Longevity;
CRC	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg16691251	chr5:66510806	NA	0.44	7.76	0.39	1.09e-13	Breast cancer;
CRC	cis	rs2979489	0.624	rs62505275	chr8:30437639	C/T	cg26383811	chr8:30366931	RBPMS	-0.62	-9.3	-0.46	1.95e-18	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	trans	rs473651	0.935	rs541013	chr2:239336492	G/A	cg13521940	chr21:36262239	RUNX1	-0.41	-6.17	-0.32	1.98e-9	Multiple system atrophy;
CRC	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg00334542	chr7:100209784	MOSPD3	-0.56	-6.59	-0.34	1.71e-10	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg02725872	chr8:58115012	NA	0.36	6.07	0.32	3.53e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.42	6.54	0.34	2.37e-10	Height;
CRC	cis	rs4700695	0.925	rs414001	chr5:65383259	C/G	cg21114390	chr5:65439923	SFRS12	-0.62	-6.72	-0.35	8.15e-11	Facial morphology (factor 19);
CRC	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.54	0.47	3.31e-19	Common traits (Other);
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.73	10.19	0.49	2.26e-21	Alzheimer's disease;
CRC	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg27499820	chr13:21296301	IL17D	0.38	5.69	0.3	2.86e-8	Dental caries;
CRC	trans	rs12495832	0.778	rs1598677	chr3:147932234	A/G	cg10221266	chr7:153579447	NA	0.57	6.14	0.32	2.44e-9	Chin dimples;
CRC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.88	0.35	3.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.33	-6.81	-0.35	4.63e-11	Schizophrenia;
CRC	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.41	6.95	0.36	2.03e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.5	8.15	0.41	7.51e-15	Lipoprotein (a) levels;
CRC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.61	-9.15	-0.45	6.2e-18	Diastolic blood pressure;
CRC	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg16447950	chr5:562315	NA	-0.72	-9.03	-0.45	1.52e-17	Lung disease severity in cystic fibrosis;
CRC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg25985355	chr7:65971099	NA	-0.32	-5.67	-0.3	3.12e-8	Aortic root size;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.48	5.76	0.3	1.94e-8	Depression;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03160445	chr3:100120349	LNP1;TOMM70A	-0.51	-6.04	-0.32	4.17e-9	Diisocyanate-induced asthma;
CRC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.75	-12.11	-0.56	3.77e-28	Menopause (age at onset);
CRC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.55	-9.45	-0.46	6.59e-19	Type 2 diabetes;
CRC	cis	rs1032355	1.000	rs1032355	chr4:100539896	C/T	cg05468953	chr4:100565104	NA	-0.43	-5.84	-0.31	1.28e-8	Celiac disease;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00921722	chr16:85061575	KIAA0513	0.48	6.0	0.31	5.19e-9	Hip circumference;
CRC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.61	0.34	1.58e-10	Schizophrenia;
CRC	cis	rs17155006	0.664	rs405869	chr7:107742609	T/C	cg05962710	chr7:107745446	LAMB4	-0.43	-7.64	-0.39	2.41e-13	Pneumococcal bacteremia;
CRC	cis	rs11229555	0.598	rs1893902	chr11:58190747	A/G	cg15696309	chr11:58395628	NA	-0.81	-10.27	-0.49	1.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.95	-0.52	5.2e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.49	7.52	0.38	5.23e-13	Corneal astigmatism;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg02007433	chr3:129722099	NA	-0.61	-9.27	-0.46	2.5e-18	Blood pressure (smoking interaction);
CRC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.88e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg12856521	chr11:46389249	DGKZ	0.81	9.93	0.48	1.73e-20	Crohn's disease;
CRC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.42	6.8	0.35	4.86e-11	High light scatter reticulocyte count;
CRC	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg15192750	chr16:69999425	NA	0.58	7.64	0.39	2.43e-13	IgE levels;
CRC	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.73	-11.64	-0.54	1.91e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12760731	0.720	rs12755909	chr1:178305298	G/A	cg00404053	chr1:178313656	RASAL2	1.12	11.45	0.53	9.22e-26	Obesity-related traits;
CRC	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.51	7.27	0.37	2.72e-12	Corneal astigmatism;
CRC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-11.39	-0.53	1.46e-25	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11680855	chr19:54694179	MBOAT7;TSEN34	0.43	6.16	0.32	2.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg11204139	chr17:3907470	NA	-0.77	-14.15	-0.62	7.9e-36	Type 2 diabetes;
CRC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-11.29	-0.53	3.21e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.76	-8.28	-0.42	3.12e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg23533926	chr12:111358616	MYL2	0.49	6.95	0.36	1.97e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.5	-9.23	-0.45	3.45e-18	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.09	-0.32	3.17e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg10556349	chr10:835070	NA	-0.38	-7.38	-0.38	1.34e-12	Survival in rectal cancer;
CRC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.74	10.83	0.51	1.37e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.47	-8.74	-0.43	1.19e-16	Height;
CRC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg05044414	chr3:183734942	ABCC5	0.48	8.32	0.42	2.37e-15	Anterior chamber depth;
CRC	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg27499820	chr13:21296301	IL17D	0.44	6.14	0.32	2.32e-9	Dental caries;
CRC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.91	17.67	0.7	1.31e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg18478394	chr8:109455254	TTC35	0.39	6.0	0.31	5.12e-9	Dupuytren's disease;
CRC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.48	6.48	0.34	3.45e-10	Lymphocyte counts;
CRC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.55	7.86	0.4	5.44e-14	Pursuit maintenance gain;
CRC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.49	-7.77	-0.39	1.01e-13	Neurofibrillary tangles;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg15786705	chr6:28176104	NA	-0.78	-10.89	-0.51	8.71e-24	Depression;
CRC	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	9.26	0.45	2.81e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.83	8.82	0.44	6.99e-17	Gastritis;
CRC	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.81	0.35	4.56e-11	Body mass index;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.25	5.67	0.3	3.13e-8	Parkinson's disease;
CRC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg12223502	chr10:5658492	NA	-0.36	-5.87	-0.31	1.09e-8	Breast cancer;
CRC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.62	-8.9	-0.44	3.91e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4716602	0.596	rs10265909	chr7:156158095	T/C	cg16983916	chr7:156159713	NA	-0.39	-6.92	-0.36	2.42e-11	Anti-saccade response;
CRC	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.91	-0.4	4.04e-14	Cholesterol, total;
CRC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-6.94	-0.36	2.15e-11	Axial length;
CRC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg01483505	chr11:975446	AP2A2	0.44	7.09	0.36	8.31e-12	Alzheimer's disease (late onset);
CRC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.71	8.54	0.43	5.22e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27397625	chr6:42952298	PPP2R5D	0.51	6.81	0.35	4.67e-11	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.11e-10	Life satisfaction;
CRC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.69	-11.85	-0.55	3.36e-27	Dental caries;
CRC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.51	-0.62	3.13e-37	Body mass index;
CRC	cis	rs10924970	0.967	rs7553200	chr1:235467940	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	6.0	0.31	5.32e-9	Asthma;
CRC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.67	9.61	0.47	1.94e-19	Longevity;
CRC	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-5.69	-0.3	2.75e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.59	-0.34	1.76e-10	Fibrinogen levels;
CRC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.2	0.32	1.69e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.5	7.86	0.4	5.63e-14	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.85	-0.31	1.18e-8	Alzheimer's disease (survival time);
CRC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-12.64	-0.57	4.16e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg23123621	chr4:1343375	KIAA1530	-0.34	-6.11	-0.32	2.89e-9	Obesity-related traits;
CRC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg27565382	chr3:53032988	SFMBT1	0.7	6.16	0.32	2.07e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-7.69	-0.39	1.75e-13	Neuroticism;
CRC	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg17501823	chr12:47219793	SLC38A4	0.31	5.66	0.3	3.37e-8	Itch intensity from mosquito bite;
CRC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.58	0.47	2.53e-19	Cognitive test performance;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg00063174	chr2:228736253	WDR69	0.5	6.65	0.34	1.2e-10	Blood pressure;
CRC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg02772935	chr3:125709198	NA	-0.49	-5.74	-0.3	2.14e-8	Blood pressure (smoking interaction);
CRC	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg02158880	chr13:53174818	NA	0.48	7.28	0.37	2.42e-12	Lewy body disease;
CRC	cis	rs3751196	0.808	rs56147174	chr12:104209661	T/C	cg02344784	chr12:104178138	NT5DC3	0.7	7.14	0.37	6.08e-12	Sense of smell;
CRC	cis	rs7429990	0.932	rs2166772	chr3:48047874	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.87	-0.31	1.06e-8	Educational attainment (years of education);
CRC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.36	-6.28	-0.33	1.1e-9	Schizophrenia;
CRC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.61	-10.43	-0.5	3.53e-22	Dental caries;
CRC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.93e-18	Lymphocyte counts;
CRC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-7.13	-0.37	6.43e-12	Type 2 diabetes;
CRC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.56	-9.34	-0.46	1.54e-18	Eye color traits;
CRC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.67	8.89	0.44	4.09e-17	Morning vs. evening chronotype;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12857786	chr4:83934023	LIN54	0.52	7.46	0.38	7.55e-13	Response to antipsychotic treatment;
CRC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg20387954	chr3:183756860	HTR3D	0.43	7.37	0.38	1.42e-12	Anterior chamber depth;
CRC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.79	0.3	1.63e-8	Prudent dietary pattern;
CRC	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg13482628	chr17:19912719	NA	0.41	6.09	0.32	3.11e-9	Schizophrenia;
CRC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.4	6.04	0.32	4.07e-9	Mean corpuscular volume;
CRC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg17724175	chr1:150552817	MCL1	-0.51	-8.09	-0.41	1.17e-14	Tonsillectomy;
CRC	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.65	-0.39	2.19e-13	Thrombosis;
CRC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.19	-0.49	2.18e-21	Total cholesterol levels;
CRC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.64	0.3	3.59e-8	Tonsillectomy;
CRC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.74	-0.3	2.21e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	0.91	17.46	0.69	8.75e-49	Height;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.11	0.32	2.83e-9	Depression;
CRC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs7712401	0.755	rs1870560	chr5:122111210	G/C	cg18764291	chr5:122110994	SNX2	0.43	6.96	0.36	1.82e-11	Mean platelet volume;
CRC	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg06042504	chr8:55087323	NA	-0.37	-5.77	-0.3	1.79e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.17	0.52	8.58e-25	Tonsillectomy;
CRC	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.04	0.32	4.13e-9	HDL cholesterol;
CRC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg07507251	chr3:52567010	NT5DC2	-0.4	-5.8	-0.3	1.53e-8	Bipolar disorder;
CRC	cis	rs10950821	0.881	rs17143180	chr7:20646786	C/G	cg02470904	chr7:20686108	ABCB5	0.37	5.9	0.31	8.88e-9	Response to statin therapy;
CRC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.58	8.42	0.42	1.21e-15	Response to temozolomide;
CRC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg18827107	chr12:86230957	RASSF9	-0.4	-6.24	-0.33	1.38e-9	Major depressive disorder;
CRC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg17321639	chr7:2759063	NA	-0.4	-5.74	-0.3	2.2e-8	Height;
CRC	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.76	9.41	0.46	8.77e-19	Obesity-related traits;
CRC	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-7.01	-0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.21	0.45	4.03e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.61	-0.34	1.54e-10	Vitiligo;
CRC	trans	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.69	0.35	9.82e-11	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg24562669	chr7:97807699	LMTK2	0.5	8.5	0.42	6.53e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08209163	chr13:28024472	MTIF3	0.39	6.25	0.33	1.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg09904177	chr6:26538194	HMGN4	-0.56	-8.14	-0.41	8.52e-15	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs16846026	chr2:162537691	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.58e-9	Cognitive function;
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg15147215	chr3:52552868	STAB1	-0.62	-10.27	-0.49	1.2e-21	Bipolar disorder;
CRC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	7.08	0.36	8.54e-12	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.61	-7.93	-0.4	3.39e-14	Menopause (age at onset);
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.91	-21.44	-0.76	2.02e-64	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs449789	0.857	rs10455775	chr6:159723721	C/T	cg14500486	chr6:159655392	FNDC1	-0.49	-7.26	-0.37	2.84e-12	Pulse pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06604058	chr11:63448992	RTN3	0.46	7.41	0.38	1.04e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg22638593	chr5:131593259	PDLIM4	0.39	6.37	0.33	6.2e-10	Acylcarnitine levels;
CRC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.42	-0.5	3.65e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.64	10.27	0.49	1.24e-21	Myopia (pathological);
CRC	cis	rs17065868	0.764	rs7996107	chr13:45033506	T/C	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.52	7.8	0.4	8.25e-14	Testicular germ cell tumor;
CRC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.5	7.2	0.37	4.16e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.8	11.79	0.54	5.55e-27	Testicular germ cell tumor;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg22998610	chr11:62538411	TAF6L	0.37	6.07	0.32	3.53e-9	Obesity-related traits;
CRC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.8	13.55	0.6	1.54e-33	Menopause (age at onset);
CRC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg09218773	chr11:619014	MUPCDH	-0.44	-6.32	-0.33	8.32e-10	Systemic lupus erythematosus;
CRC	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg14003231	chr6:33640908	ITPR3	0.51	8.28	0.42	3.03e-15	Plateletcrit;
CRC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.52	7.75	0.39	1.19e-13	Schizophrenia;
CRC	cis	rs7264396	0.775	rs2296402	chr20:34054729	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.07	-0.32	3.43e-9	Total cholesterol levels;
CRC	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.66	-12.06	-0.55	5.44e-28	Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11827097	chr2:231280903	SP100	0.46	6.6	0.34	1.61e-10	Response to antipsychotic treatment;
CRC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg20607287	chr7:12443886	VWDE	-0.68	-7.26	-0.37	2.76e-12	Coronary artery disease;
CRC	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg12756093	chr1:115239321	AMPD1	0.48	6.99	0.36	1.51e-11	Autism;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg17059624	chr11:85358760	TMEM126A	-0.38	-6.02	-0.31	4.63e-9	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23850377	chr2:20251576	LAPTM4A	0.49	6.28	0.33	1.05e-9	Thyroid stimulating hormone;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg19041857	chr6:27730383	NA	-0.75	-7.32	-0.37	1.93e-12	Depression;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.08	18.41	0.71	1.56e-52	Cognitive function;
CRC	trans	rs16846053	0.681	rs62187569	chr2:162373517	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.11	-0.32	2.75e-9	Blood osmolality (transformed sodium);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27665769	chr4:2757761	TNIP2	0.41	6.25	0.33	1.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.56	8.46	0.42	9.18e-16	Hemoglobin concentration;
CRC	cis	rs7804356	1.000	rs3801803	chr7:26901740	T/C	cg03456212	chr7:26904342	SKAP2	-0.5	-5.77	-0.3	1.88e-8	Type 1 diabetes;
CRC	cis	rs12760731	0.544	rs34163217	chr1:178586984	C/T	cg00404053	chr1:178313656	RASAL2	0.6	7.19	0.37	4.26e-12	Obesity-related traits;
CRC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg08772003	chr10:104629869	AS3MT	-0.36	-6.09	-0.32	3.22e-9	Arsenic metabolism;
CRC	cis	rs10512697	0.772	rs13176060	chr5:3522987	C/T	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.54	-6.68	-0.35	1.01e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg19980929	chr12:42632907	YAF2	-0.39	-5.9	-0.31	9.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-12.75	-0.58	1.5e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg12516270	chr8:143859308	LYNX1	0.43	7.57	0.39	3.83e-13	Urinary tract infection frequency;
CRC	cis	rs2882667	0.931	rs10070021	chr5:138324706	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-5.74	-0.3	2.15e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9462027	0.585	rs2814974	chr6:34572028	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.04	-0.32	4.08e-9	Systemic lupus erythematosus;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-10.31	-0.49	8.47e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.52	7.76	0.39	1.08e-13	Coronary heart disease;
CRC	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.75	-7.89	-0.4	4.44e-14	Non-glioblastoma glioma;Glioma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01307092	chr12:53473443	SPRYD3	0.47	6.58	0.34	1.81e-10	Anxiety disorder;
CRC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.66	-0.43	2.14e-16	Chronic sinus infection;
CRC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.42e-13	Red blood cell count;
CRC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.27	0.46	2.53e-18	Intelligence (multi-trait analysis);
CRC	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg14092571	chr14:90743983	NA	0.38	5.92	0.31	8.07e-9	Mortality in heart failure;
CRC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg02089348	chr4:1724449	TMEM129;TACC3	-0.39	-5.66	-0.3	3.33e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11645453	chr3:52864694	ITIH4	0.38	6.43	0.33	4.41e-10	Bipolar disorder;
CRC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-7.51	-0.38	5.51e-13	Height;
CRC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg08314208	chr16:67682810	RLTPR	-0.65	-7.04	-0.36	1.12e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.62	14.3	0.62	2.08e-36	Airflow obstruction;
CRC	cis	rs9648716	1.000	rs10234502	chr7:140522553	C/T	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.42	0.73	1.63e-56	Prudent dietary pattern;
CRC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.4	-6.09	-0.32	3.1e-9	Monocyte count;
CRC	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.72	7.96	0.4	2.76e-14	Breast cancer;
CRC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.47	7.7	0.39	1.63e-13	Fat distribution (HIV);
CRC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.78	13.66	0.6	5.73e-34	Breast cancer;
CRC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.63	8.42	0.42	1.18e-15	High light scatter reticulocyte count;
CRC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.95	-17.85	-0.7	2.47e-50	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10691036	chr19:49622443	C19orf73;PPFIA3	0.47	6.2	0.32	1.68e-9	Anxiety disorder;
CRC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg00343986	chr7:65444356	GUSB	-0.47	-6.94	-0.36	2.05e-11	Aortic root size;
CRC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.53	-0.5	1.52e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs3018066	0.867	rs4374692	chr4:107150985	A/G	cg01869342	chr4:106983673	TBCK	-0.36	-5.63	-0.3	3.82e-8	Cancer;
CRC	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.32	5.62	0.3	4.12e-8	Heart rate;
CRC	cis	rs2077654	0.822	rs7944045	chr11:17439590	C/T	cg25308976	chr11:17434268	ABCC8	0.78	7.95	0.4	2.94e-14	Gout;
CRC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg13072238	chr3:49761600	GMPPB	-0.48	-5.68	-0.3	2.89e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.703	rs72690847	chr1:46256929	A/G	cg08644498	chr1:46502608	NA	0.44	6.85	0.35	3.61e-11	Blood protein levels;
CRC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.63	0.3	3.82e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.26	-0.37	2.84e-12	Height;
CRC	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.58	-9.16	-0.45	5.88e-18	Hyperactive-impulsive symptoms;
CRC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06544989	chr22:39130855	UNC84B	0.41	6.04	0.32	4.12e-9	Menopause (age at onset);
CRC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg14196790	chr5:131705035	SLC22A5	-0.35	-5.77	-0.3	1.87e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs73200209	0.744	rs17498480	chr12:116558916	A/T	cg01776926	chr12:116560359	MED13L	-0.6	-7.21	-0.37	3.92e-12	Total body bone mineral density;
CRC	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.65	8.76	0.43	1.06e-16	Interstitial lung disease;
CRC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.3	-5.66	-0.3	3.26e-8	Huntington's disease progression;
CRC	cis	rs7937682	0.593	rs1944118	chr11:111352032	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.41	-5.87	-0.31	1.07e-8	Primary sclerosing cholangitis;
CRC	cis	rs12024301	0.557	rs79519767	chr1:183598988	G/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-10.03	-0.48	7.85e-21	Hemoglobin concentration;
CRC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.3	-0.33	9.38e-10	Aortic root size;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.62	-12.32	-0.56	6.13e-29	HDL cholesterol levels;
CRC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.14	0.45	6.55e-18	Parkinson's disease;
CRC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.42	5.94	0.31	7.33e-9	HDL cholesterol;
CRC	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg16141378	chr3:129829833	LOC729375	-0.45	-7.18	-0.37	4.62e-12	Mood instability;
CRC	cis	rs7072216	0.881	rs7082192	chr10:100151844	T/C	cg26618903	chr10:100175079	PYROXD2	-0.36	-6.04	-0.32	4.16e-9	Metabolite levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15166552	chr3:156273067	SSR3	0.44	6.09	0.32	3.23e-9	Survival in pancreatic cancer;
CRC	cis	rs9462846	0.853	rs7758629	chr6:42871264	C/A	cg21280719	chr6:42927975	GNMT	-0.33	-6.47	-0.34	3.65e-10	Blood protein levels;
CRC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.22	-6.09	-0.32	3.12e-9	Urinary metabolites;
CRC	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.52	10.09	0.49	4.79e-21	Urate levels in lean individuals;
CRC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg24046110	chr8:143859143	LYNX1	-0.4	-5.91	-0.31	8.55e-9	Urinary tract infection frequency;
CRC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg11168104	chr5:1857477	NA	-0.39	-6.65	-0.34	1.2e-10	Cardiovascular disease risk factors;
CRC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg04362960	chr10:104952993	NT5C2	-0.41	-5.79	-0.3	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg03623178	chr6:28175578	NA	0.77	11.49	0.54	6.21e-26	Parkinson's disease;
CRC	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg00277334	chr10:82204260	NA	-0.44	-5.8	-0.3	1.55e-8	Post bronchodilator FEV1;
CRC	cis	rs117623576	0.680	rs740859	chr10:32361839	G/A	cg03047570	chr10:32398778	NA	-0.59	-6.05	-0.32	3.94e-9	Anti-saccade response;
CRC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg13722127	chr7:150037890	RARRES2	0.48	7.08	0.36	8.54e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13198984	chr17:80129470	CCDC57	0.48	8.58	0.43	3.86e-16	Life satisfaction;
CRC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	0.93	7.26	0.37	2.82e-12	Type 2 diabetes nephropathy;
CRC	cis	rs908922	0.961	rs574749	chr1:152460672	T/G	cg23254163	chr1:152506842	NA	0.41	6.71	0.35	8.42e-11	Hair morphology;
CRC	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.84	-13.64	-0.6	6.97e-34	Hypospadias;
CRC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg23093090	chr10:104574429	C10orf26	0.4	6.65	0.34	1.19e-10	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg24849736	chr1:201084428	NA	0.66	12.31	0.56	6.96e-29	Permanent tooth development;
CRC	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.47	6.83	0.35	4.02e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs73206853	0.841	rs56065235	chr12:111016287	C/T	cg12870014	chr12:110450643	ANKRD13A	0.77	7.23	0.37	3.44e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6840360	0.582	rs6813735	chr4:152326990	T/G	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.07	0.36	9.57e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-5.75	-0.3	2.08e-8	Alzheimer's disease (late onset);
CRC	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg14036092	chr11:66035641	RAB1B	0.59	8.69	0.43	1.78e-16	Gout;
CRC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17467752	chr17:38218738	THRA	0.41	6.14	0.32	2.42e-9	Asthma and hay fever;
CRC	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg23234261	chr14:55582407	NA	0.3	5.93	0.31	7.49e-9	Protein biomarker;
CRC	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.46	6.45	0.34	3.88e-10	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10243681	chr15:73925924	NPTN	0.46	6.66	0.34	1.17e-10	Response to antipsychotic treatment;
CRC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg24011408	chr12:48396354	COL2A1	-0.44	-6.32	-0.33	8.34e-10	Glycated hemoglobin levels;
CRC	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.94	-0.31	7.45e-9	Coronary artery disease;
CRC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg08773314	chr2:239334832	ASB1	0.37	7.76	0.39	1.11e-13	Multiple system atrophy;
CRC	cis	rs2160860	0.965	rs2729462	chr8:39822139	T/C	cg11363097	chr8:39792086	IDO2	-0.35	-5.6	-0.3	4.5e-8	Blood metabolite levels;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.71	-0.51	3.76e-23	Alzheimer's disease;
CRC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.69	-0.47	1.04e-19	Hip circumference adjusted for BMI;
CRC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.53	5.98	0.31	5.69e-9	Menarche (age at onset);
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	7.28	0.37	2.49e-12	Blood metabolite levels;
CRC	trans	rs6066835	0.572	rs11698365	chr20:47259527	C/T	cg21109867	chr19:55897418	RPL28	-0.84	-6.29	-0.33	1.01e-9	Multiple myeloma;
CRC	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.39	-7.01	-0.36	1.32e-11	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs11581859	0.950	rs55831817	chr1:99373559	G/T	cg12183875	chr3:169587454	LRRC31	0.28	6.4	0.33	5.49e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs10046574	0.634	rs10266715	chr7:135155366	C/T	cg27474649	chr7:135195673	CNOT4	-0.65	-5.71	-0.3	2.59e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	1.0	12.92	0.58	3.72e-31	Vitiligo;
CRC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.28	0.37	2.5e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.37	6.51	0.34	2.85e-10	Systemic lupus erythematosus;
CRC	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.64	0.34	1.29e-10	Blood protein levels;
CRC	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg01339444	chr6:118972232	C6orf204	0.51	5.61	0.3	4.29e-8	Diastolic blood pressure;
CRC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	6.24	0.33	1.35e-9	Body mass index (adult);
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.63	-0.34	1.37e-10	Lymphocyte counts;
CRC	cis	rs7487075	0.780	rs12296120	chr12:46737591	G/A	cg22049899	chr12:47219821	SLC38A4	0.36	7.31	0.37	2.08e-12	Itch intensity from mosquito bite;
CRC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg17158414	chr2:27665306	KRTCAP3	0.28	5.98	0.31	5.97e-9	Total body bone mineral density;
CRC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.82	-0.31	1.37e-8	Testicular germ cell tumor;
CRC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.45	-7.83	-0.4	6.9e-14	Eye color traits;
CRC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.35	0.42	1.88e-15	Height;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.57	9.42	0.46	8.11e-19	Hemoglobin concentration;
CRC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.65	-8.6	-0.43	3.37e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.57	8.26	0.41	3.69e-15	Lung cancer;
CRC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg16434002	chr17:42200994	HDAC5	-0.46	-6.42	-0.33	4.63e-10	Total body bone mineral density;
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.9	-0.44	3.79e-17	Bipolar disorder;
CRC	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-5.68	-0.3	2.93e-8	Coronary artery disease;
CRC	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg18200150	chr17:30822561	MYO1D	0.47	8.85	0.44	5.39e-17	Schizophrenia;
CRC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23422044	chr7:1970798	MAD1L1	-0.41	-5.67	-0.3	3.13e-8	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.47	7.04	0.36	1.11e-11	Menopause (age at onset);
CRC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.59	-10.44	-0.5	3.11e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg27535305	chr1:53392650	SCP2	-0.35	-6.16	-0.32	2.13e-9	Monocyte count;
CRC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-11.91	-0.55	2.01e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.58	8.51	0.42	6.33e-16	Neutrophil percentage of white cells;
CRC	cis	rs7680126	0.672	rs4697957	chr4:10182254	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.95	-0.31	6.92e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4731207	0.596	rs7779594	chr7:124636995	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.26	-0.33	1.17e-9	Cutaneous malignant melanoma;
CRC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg12573674	chr2:1569213	NA	-0.76	-7.84	-0.4	6.48e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg19046167	chr17:80928561	B3GNTL1	0.5	6.87	0.35	3.3e-11	Glycated hemoglobin levels;
CRC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.28	-0.46	2.41e-18	Type 2 diabetes;
CRC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.0	-0.31	5.31e-9	Primary biliary cholangitis;
CRC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg13047869	chr3:10149882	C3orf24	0.36	5.73	0.3	2.27e-8	Alzheimer's disease;
CRC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg21466736	chr12:48725269	NA	0.51	7.97	0.4	2.6e-14	Plateletcrit;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.76	9.33	0.46	1.63e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.44	6.52	0.34	2.59e-10	Body mass index;
CRC	cis	rs2077654	0.818	rs73423040	chr11:17436568	A/T	cg25308976	chr11:17434268	ABCC8	0.66	6.75	0.35	6.58e-11	Gout;
CRC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg03030879	chr14:75389066	RPS6KL1	0.43	6.54	0.34	2.35e-10	Height;
CRC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg04176472	chr15:90893244	GABARAPL3	0.36	6.16	0.32	2.12e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg08999081	chr20:33150536	PIGU	-0.42	-5.79	-0.3	1.68e-8	Neuroticism;
CRC	trans	rs8108034	0.920	rs30480	chr19:39807213	A/G	cg15829294	chr19:12606397	ZNF709	-0.51	-6.19	-0.32	1.83e-9	Lung adenocarcinoma;
CRC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.71	0.54	1e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg12564285	chr5:131593104	PDLIM4	0.33	5.87	0.31	1.08e-8	Blood metabolite levels;
CRC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.6	-7.08	-0.36	8.62e-12	Blood protein levels;
CRC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg23758597	chr6:163146217	PARK2	-0.71	-7.21	-0.37	3.75e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6504622	0.905	rs9898981	chr17:45026715	T/G	cg16759221	chr17:45003025	GOSR2	-0.52	-8.19	-0.41	6.02e-15	Orofacial clefts;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg11843238	chr5:131593191	PDLIM4	0.42	7.19	0.37	4.26e-12	Breast cancer;
CRC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.81	-9.74	-0.47	7.51e-20	Initial pursuit acceleration;
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12273811	chr6:28175739	NA	0.76	10.93	0.52	6.19e-24	Depression;
CRC	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.03	-0.32	4.39e-9	Metabolite levels;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg05874882	chr4:1763078	NA	0.38	6.44	0.33	4.16e-10	Bladder cancer;Urinary bladder cancer;
CRC	trans	rs11654801	0.755	rs11650623	chr17:20859620	G/A	cg23759823	chr7:139672531	TBXAS1	-0.39	-6.33	-0.33	8.17e-10	Mosquito bite size;
CRC	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	6.61	0.34	1.53e-10	Neuroticism;
CRC	cis	rs4073416	0.504	rs6573612	chr14:65912829	G/A	cg03016385	chr14:66212404	NA	-0.42	-5.76	-0.3	1.95e-8	N-glycan levels;
CRC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg17346650	chr17:80929145	B3GNTL1	0.35	5.63	0.3	3.92e-8	Breast cancer;
CRC	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg03037974	chr15:76606532	NA	-0.52	-6.94	-0.36	2.07e-11	Blood metabolite levels;
CRC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg15440763	chr7:158190612	PTPRN2	0.42	6.5	0.34	2.94e-10	Obesity-related traits;
CRC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-8.13	-0.41	9.06e-15	IgG glycosylation;
CRC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.29	0.33	9.85e-10	Morning vs. evening chronotype;
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg15147215	chr3:52552868	STAB1	-0.63	-10.4	-0.5	4.44e-22	Bipolar disorder;
CRC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg23229984	chr5:148520753	ABLIM3	0.51	7.06	0.36	1.02e-11	Breast cancer;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg19041857	chr6:27730383	NA	-0.73	-7.16	-0.37	5.2e-12	Breast cancer;
CRC	cis	rs4664293	0.647	rs10196064	chr2:160425965	G/A	cg08347373	chr2:160653686	CD302	-0.39	-6.59	-0.34	1.76e-10	Monocyte percentage of white cells;
CRC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.37	6.03	0.32	4.48e-9	Ulcerative colitis;
CRC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.07	-0.32	3.5e-9	Eosinophil percentage of white cells;
CRC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.78	0.66	3.53e-42	Intelligence (multi-trait analysis);
CRC	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.55	9.34	0.46	1.5e-18	Dupuytren's disease;
CRC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.65	9.33	0.46	1.59e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg27068330	chr11:65405492	SIPA1	-0.46	-6.31	-0.33	9.09e-10	Breast cancer;
CRC	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.85	-0.4	6.1e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg26695010	chr11:65641043	EFEMP2	0.45	6.88	0.35	3.08e-11	Eosinophil percentage of white cells;
CRC	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.42	6.02	0.31	4.69e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19012731	chr7:86688923	KIAA1324L	0.41	7.58	0.39	3.63e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.81	12.73	0.57	1.92e-30	Cognitive function;
CRC	cis	rs7731657	0.537	rs2158352	chr5:130309465	A/G	cg08523029	chr5:130500466	HINT1	0.45	5.66	0.3	3.38e-8	Fasting plasma glucose;
CRC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.46	7.37	0.38	1.43e-12	Obesity-related traits;
CRC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.35	-0.38	1.54e-12	Blood metabolite levels;
CRC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.42	5.63	0.3	3.94e-8	Schizophrenia;
CRC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg27565382	chr3:53032988	SFMBT1	0.65	5.68	0.3	2.94e-8	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26403198	chr8:145581686	FBXL6;GPR172A	0.44	5.99	0.31	5.65e-9	Response to antipsychotic treatment;
CRC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.33	-0.49	7.59e-22	Schizophrenia;
CRC	cis	rs10760158	0.739	rs4837819	chr9:124008434	A/G	cg14417974	chr9:124058376	GSN	-0.33	-5.6	-0.3	4.46e-8	Pulse pressure;
CRC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.47	-0.34	3.6e-10	Body mass index;
CRC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg05341575	chr12:125625032	AACS	-0.38	-5.95	-0.31	6.79e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.27	-0.37	2.61e-12	Gut microbiome composition (summer);
CRC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.26	14.66	0.63	8.53e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.03	-0.36	1.18e-11	HDL cholesterol;
CRC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.51	-6.58	-0.34	1.91e-10	Obesity-related traits;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg02033258	chr5:131593261	PDLIM4	0.36	6.78	0.35	5.69e-11	Blood metabolite levels;
CRC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00352360	chr17:37009309	RPL23;SNORA21	0.47	6.12	0.32	2.64e-9	Thyroid stimulating hormone;
CRC	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.52	6.86	0.35	3.39e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg16670446	chr17:27188758	MIR451;MIR144	0.52	8.2	0.41	5.41e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-8.52	-0.43	5.91e-16	Menarche (age at onset);
CRC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-5.93	-0.31	7.7e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-15.74	-0.66	5.05e-42	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	0.935	rs627418	chr11:108131225	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.83	0.31	1.33e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg10760299	chr15:45669010	GATM	0.51	7.74	0.39	1.25e-13	Homoarginine levels;
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg19337854	chr7:99768885	GPC2	0.47	5.95	0.31	7e-9	Lung function (FEV1/FVC);
CRC	cis	rs755249	0.529	rs3768299	chr1:39857192	C/T	cg18385671	chr1:39797026	MACF1	-0.42	-6.05	-0.32	4.02e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs780094	0.500	rs12464616	chr2:27827092	C/T	cg27432699	chr2:27873401	GPN1	0.48	6.11	0.32	2.82e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.41	-5.9	-0.31	9.22e-9	Alzheimer's disease (late onset);
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg21249729	chr9:138392748	C9orf116;MRPS2	-0.54	-6.04	-0.32	4.28e-9	Lung adenocarcinoma;
CRC	trans	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg17903999	chr18:56338584	MALT1	0.42	6.93	0.36	2.17e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg14541582	chr5:601475	NA	-0.37	-7.17	-0.37	5.13e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.47	0.34	3.56e-10	Diastolic blood pressure;
CRC	trans	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg20024234	chr21:43431083	ZNF295	-0.68	-6.17	-0.32	2.02e-9	Cognitive function;
CRC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg02158880	chr13:53174818	NA	0.65	10.08	0.49	5.47e-21	Lewy body disease;
CRC	cis	rs447	0.583	rs6977516	chr7:83785834	T/G	cg22846510	chr7:83753280	SEMA3A	-0.43	-5.93	-0.31	7.83e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02056921	chr1:901892	PLEKHN1	0.5	7.4	0.38	1.13e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.39	-0.53	1.41e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1030268	0.651	rs13222377	chr7:133466346	C/T	cg03336402	chr7:133662267	EXOC4	-0.51	-5.62	-0.3	3.99e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg04518342	chr5:131593106	PDLIM4	0.33	5.75	0.3	2.03e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg14352298	chr13:112236639	NA	0.3	6.71	0.35	8.5e-11	Hepatitis;
CRC	cis	rs7731657	0.537	rs6595968	chr5:130284843	G/C	cg08523029	chr5:130500466	HINT1	0.49	6.18	0.32	1.85e-9	Fasting plasma glucose;
CRC	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.94e-40	Hypertriglyceridemia;
CRC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.52	7.53	0.38	4.82e-13	Height;
CRC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.36	8.51	0.42	6.43e-16	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg17903999	chr18:56338584	MALT1	0.4	6.51	0.34	2.74e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg04727332	chr7:45960243	IGFBP3	-0.38	-5.86	-0.31	1.14e-8	Sitting height ratio;
CRC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04880052	chr2:219191631	PNKD	-0.42	-6.63	-0.34	1.37e-10	Colorectal cancer;
CRC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-7.65	-0.39	2.27e-13	Chronic sinus infection;
CRC	trans	rs10243593	0.673	rs773402	chr7:40073077	A/C	cg13911576	chr9:84174038	NA	-0.35	-6.05	-0.32	3.86e-9	Lymphocyte counts;
CRC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.82	0.31	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg16898833	chr6:26189333	HIST1H4D	0.87	6.41	0.33	5.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9549328	0.520	rs36144023	chr13:113616592	T/C	cg25790453	chr13:113633590	MCF2L	0.43	7.55	0.38	4.25e-13	Systolic blood pressure;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06456512	chr15:69113056	ANP32A	0.47	5.97	0.31	6.13e-9	Thyroid stimulating hormone;
CRC	trans	rs6534347	0.788	rs2069763	chr4:123377482	C/A	cg21129976	chr7:100421502	EPHB4	0.38	5.97	0.31	6.23e-9	Type 1 diabetes;
CRC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.52	-7.41	-0.38	1.07e-12	Corneal structure;
CRC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg01472538	chr16:58549086	SETD6	1.06	6.94	0.36	2.05e-11	Schizophrenia;
CRC	cis	rs1009181	0.585	rs9379827	chr6:26153335	G/T	cg13736514	chr6:26305472	NA	-0.4	-5.97	-0.31	6e-9	Childhood ear infection;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg13786165	chr15:65477609	CLPX	0.45	6.58	0.34	1.87e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-8.92	-0.44	3.31e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg03623178	chr6:28175578	NA	0.88	7.31	0.37	2.1e-12	Depression;
CRC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.6	-0.34	1.66e-10	Menarche (age at onset);
CRC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.86	-0.31	1.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.52	-8.48	-0.42	7.74e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7487075	0.893	rs4547171	chr12:46733392	A/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.45	0.34	4e-10	Itch intensity from mosquito bite;
CRC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.89	-0.44	4.24e-17	Hemoglobin concentration;
CRC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13198984	chr17:80129470	CCDC57	-0.39	-6.76	-0.35	6.14e-11	Life satisfaction;
CRC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.39	-6.01	-0.31	4.96e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.25	12.64	0.57	3.92e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.81	-0.44	7.1e-17	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg22117107	chr15:45993392	NA	0.46	9.37	0.46	1.22e-18	Waist circumference;Weight;
CRC	cis	rs13161895	1.000	rs13161895	chr5:179471201	C/T	cg02702477	chr5:179499311	RNF130	0.55	6.26	0.33	1.18e-9	LDL cholesterol;
CRC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.46	6.34	0.33	7.75e-10	Aortic root size;
CRC	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.53	-8.69	-0.43	1.75e-16	Schizophrenia;
CRC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.09e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.65	10.56	0.5	1.2e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.52	0.38	5.31e-13	Schizophrenia;
CRC	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.35	6.16	0.32	2.11e-9	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs4664293	1.000	rs4665083	chr2:160430127	C/T	cg08347373	chr2:160653686	CD302	0.45	7.42	0.38	1e-12	Monocyte percentage of white cells;
CRC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg21153622	chr11:89784906	NA	-0.43	-7.04	-0.36	1.12e-11	Height;
CRC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg09127314	chr1:152161683	NA	0.5	6.32	0.33	8.28e-10	Atopic dermatitis;
CRC	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.48	9.25	0.45	2.82e-18	Educational attainment (years of education);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17076921	chr10:75634595	CAMK2G	0.49	7.12	0.37	6.77e-12	Response to antipsychotic treatment;
CRC	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg16724585	chr3:197361211	NA	-0.48	-7.08	-0.36	8.94e-12	Pancreatic cancer;
CRC	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.77	-12.12	-0.56	3.36e-28	Body mass index;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.56	8.39	0.42	1.46e-15	Breast cancer;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg08222913	chr3:52553049	STAB1	-0.42	-8.57	-0.43	4.18e-16	Hemoglobin concentration;
CRC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.69	10.9	0.51	8.22e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.77	0.63	3.05e-38	Exhaled nitric oxide output;
CRC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.5	-9.52	-0.46	3.84e-19	Dupuytren's disease;
CRC	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg20469991	chr17:27169893	C17orf63	0.48	5.9	0.31	8.83e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4731207	0.698	rs10954049	chr7:124535450	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.47	5.95e-20	Bladder cancer;
CRC	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg26566898	chr11:117069891	TAGLN	0.39	6.96	0.36	1.8e-11	Blood protein levels;
CRC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.46	6.84	0.35	3.79e-11	Menarche (age at onset);
CRC	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.46	-6.04	-0.32	4.13e-9	Post bronchodilator FEV1;
CRC	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-5.78	-0.3	1.72e-8	Obesity (extreme);
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg08989290	chr16:615782	NHLRC4	0.45	8.7	0.43	1.61e-16	Height;
CRC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.55	7.4	0.38	1.18e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.24	0.33	1.36e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg10523679	chr1:76189770	ACADM	-0.39	-5.62	-0.3	4.18e-8	Daytime sleep phenotypes;
CRC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-8.45	-0.42	9.57e-16	IgG glycosylation;
CRC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.5	6.42	0.33	4.84e-10	Longevity;
CRC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.1	-12.69	-0.57	2.71e-30	Diabetic kidney disease;
CRC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.65	8.57	0.43	4.12e-16	Morning vs. evening chronotype;
CRC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.21	-0.32	1.58e-9	Alzheimer's disease (late onset);
CRC	cis	rs10760158	0.769	rs10818517	chr9:124004599	A/T	cg14417974	chr9:124058376	GSN	-0.33	-5.61	-0.3	4.2e-8	Pulse pressure;
CRC	trans	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg21153622	chr11:89784906	NA	-0.44	-6.72	-0.35	7.83e-11	Height;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs8141797	0.901	rs8138467	chr22:24458096	A/G	cg20894457	chr22:24584366	SUSD2	-0.64	-6.73	-0.35	7.58e-11	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs8020095	0.571	rs8003929	chr14:67533273	C/G	cg00791868	chr14:66963628	C14orf53	0.5	7.0	0.36	1.46e-11	Depression (quantitative trait);
CRC	trans	rs1864585	0.520	rs73208790	chr8:10680025	T/A	cg26278703	chr11:58910052	FAM111A	0.56	6.5	0.34	2.94e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-8.34	-0.42	2.09e-15	Coronary artery disease;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.29	-6.05	-0.32	3.88e-9	Height;
CRC	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg24553058	chr2:113831203	IL1F10	0.4	6.44	0.33	4.26e-10	Protein quantitative trait loci;
CRC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg10790698	chr19:18539756	SSBP4	-0.44	-8.39	-0.42	1.46e-15	Breast cancer;
CRC	cis	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg01251360	chr16:68772225	CDH1	-0.23	-5.69	-0.3	2.81e-8	Colorectal cancer;
CRC	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg00666640	chr1:248458726	OR2T12	0.4	7.28	0.37	2.49e-12	Common traits (Other);
CRC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg10760299	chr15:45669010	GATM	0.52	8.37	0.42	1.66e-15	Homoarginine levels;
CRC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.77	-10.5	-0.5	2.01e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.41	0.33	5.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24308560	chr3:49941425	MST1R	-0.47	-7.54	-0.38	4.47e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg15445000	chr17:37608096	MED1	-0.35	-6.23	-0.32	1.43e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg02033258	chr5:131593261	PDLIM4	-0.38	-6.37	-0.33	6.28e-10	Acylcarnitine levels;
CRC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.51	7.07	0.36	9.53e-12	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.45	-0.42	9.43e-16	Height;
CRC	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg05874882	chr4:1763078	NA	-0.37	-7.03	-0.36	1.23e-11	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.52	-7.18	-0.37	4.76e-12	Dental caries;
CRC	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.74	7.4	0.38	1.17e-12	Severe influenza A (H1N1) infection;
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.08e-13	Alzheimer's disease;
CRC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg15145296	chr3:125709740	NA	-0.48	-6.0	-0.31	5.29e-9	Blood pressure (smoking interaction);
CRC	trans	rs2637266	0.622	rs4745816	chr10:78216814	C/T	cg01717276	chr15:75949380	SNX33	-0.4	-6.05	-0.32	4e-9	Pulmonary function;
CRC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.45	5.61	0.3	4.33e-8	Schizophrenia;
CRC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.37	6.07	0.32	3.61e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg25876840	chr17:41920477	NA	0.36	5.71	0.3	2.49e-8	Triglycerides;
CRC	cis	rs6764363	0.527	rs12497412	chr3:278334	T/C	cg02057681	chr3:285234	CHL1	0.42	7.22	0.37	3.62e-12	Sudden cardiac arrest;
CRC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.62	11.09	0.52	1.65e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg21251018	chr6:28226885	NKAPL	0.57	9.97	0.48	1.24e-20	Cardiac Troponin-T levels;
CRC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-0.97	-9.55	-0.47	3e-19	Breast cancer;
CRC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.42	-6.05	-0.32	3.93e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg16898833	chr6:26189333	HIST1H4D	1.15	8.49	0.42	7.38e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.59	8.97	0.44	2.25e-17	Pancreatic cancer;
CRC	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg06156847	chr2:113672199	IL1F7	0.42	6.44	0.33	4.16e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs9528384	0.711	rs34645729	chr13:62255080	A/C	cg08375866	chr1:50799151	NA	-0.32	-6.04	-0.32	4.17e-9	Verbal declarative memory;
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.51	-7.85	-0.4	5.78e-14	Body mass index;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.86e-12	Bipolar disorder;
CRC	cis	rs3996993	0.780	rs4317409	chr6:52694489	G/A	cg20803780	chr6:52668592	GSTA1	0.36	6.44	0.33	4.25e-10	Hemoglobin concentration;
CRC	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg27422857	chr2:105853526	NA	-0.35	-6.54	-0.34	2.39e-10	Type 2 diabetes;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12738349	chr22:24236284	MIF	0.4	6.59	0.34	1.73e-10	Obesity-related traits;
CRC	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg04165759	chr1:150448943	RPRD2	0.36	5.91	0.31	8.34e-9	Migraine;
CRC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.6	-9.37	-0.46	1.19e-18	Colorectal cancer;
CRC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.69	-10.35	-0.5	6.19e-22	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25970082	chr1:119683285	WARS2	0.47	6.63	0.34	1.39e-10	Response to antipsychotic treatment;
CRC	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg06484146	chr7:12443880	VWDE	-0.61	-6.32	-0.33	8.52e-10	Coronary artery disease;
CRC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	0.88	10.35	0.5	6.2e-22	Eosinophil percentage of granulocytes;
CRC	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.69	-9.09	-0.45	9.31e-18	Blood pressure (smoking interaction);
CRC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg06219103	chr11:63990595	FERMT3	-0.38	-5.73	-0.3	2.29e-8	Platelet count;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.62	0.54	2.25e-26	Prudent dietary pattern;
CRC	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs282587	0.569	rs447717	chr13:113415038	A/G	cg04656015	chr13:113407548	ATP11A	0.62	8.04	0.41	1.61e-14	Glycated hemoglobin levels;
CRC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.64	-0.3	3.64e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.7	-11.4	-0.53	1.35e-25	Cognitive function;
CRC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.58	-8.29	-0.42	2.92e-15	Inflammatory bowel disease;
CRC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	9.66	0.47	1.3e-19	Total cholesterol levels;
CRC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.91	0.48	2.03e-20	Cognitive test performance;
CRC	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.37	-0.33	6.33e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.85	10.91	0.52	7.49e-24	Gut microbiome composition (summer);
CRC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10208940	0.920	rs10205573	chr2:68829419	A/T	cg12452813	chr2:68675892	NA	0.48	6.0	0.31	5.29e-9	Urate levels in lean individuals;
CRC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.45	6.11	0.32	2.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg24463073	chr6:118973353	C6orf204	0.51	6.81	0.35	4.71e-11	Diastolic blood pressure;
CRC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg08200582	chr11:442649	ANO9	-0.7	-7.12	-0.37	6.8e-12	Body mass index;
CRC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.7	-11.37	-0.53	1.72e-25	Monocyte percentage of white cells;
CRC	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg17710535	chr19:10819994	QTRT1	0.43	6.27	0.33	1.11e-9	Inflammatory skin disease;
CRC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.44	8.85	0.44	5.4e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.41	0.5	3.86e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.65	-7.6	-0.39	3.09e-13	Diabetic retinopathy;
CRC	cis	rs2179367	0.959	rs564961	chr6:149657227	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.08	-0.32	3.4e-9	Dupuytren's disease;
CRC	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02421172	chr7:1938701	MAD1L1	0.46	6.07	0.32	3.56e-9	Neuroticism;
CRC	cis	rs7215564	0.908	rs55886624	chr17:78658657	G/A	cg09596252	chr17:78655493	RPTOR	0.53	5.66	0.3	3.26e-8	Myopia (pathological);
CRC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.85	15.01	0.64	3.63e-39	Blood protein levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04919811	chr17:78870302	RPTOR	0.45	6.23	0.32	1.45e-9	Survival in pancreatic cancer;
CRC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg08533674	chr1:46993347	NA	0.82	10.42	0.5	3.66e-22	Monobrow;
CRC	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg11887960	chr12:57824829	NA	0.59	6.56	0.34	2.05e-10	Obesity-related traits;
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-7.93	-0.4	3.52e-14	Glycated hemoglobin levels;
CRC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.63	11.91	0.55	2.02e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg26248373	chr2:1572462	NA	-0.83	-12.33	-0.56	5.69e-29	IgG glycosylation;
CRC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.64	-10.22	-0.49	1.71e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6793245	0.801	rs6781009	chr3:38585434	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.48	-5.84	-0.31	1.24e-8	QT interval;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05030077	chr16:2255199	MLST8	0.45	6.2	0.32	1.73e-9	Survival in pancreatic cancer;
CRC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.73	-8.35	-0.42	1.96e-15	Obesity-related traits;
CRC	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.55	7.14	0.37	5.99e-12	Diisocyanate-induced asthma;
CRC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.48e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.18	-17.29	-0.69	4.03e-48	Hip circumference adjusted for BMI;
CRC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.0	-0.31	5.17e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-7.97	-0.4	2.63e-14	Post bronchodilator FEV1;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg03623178	chr6:28175578	NA	0.69	9.6	0.47	2.12e-19	Parkinson's disease;
CRC	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.92	-0.44	3.26e-17	Bipolar disorder;
CRC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-11.2	-0.53	7.26e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg01475377	chr6:109611718	NA	-0.33	-5.79	-0.3	1.62e-8	Reticulocyte fraction of red cells;
CRC	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg03929089	chr4:120376271	NA	0.56	6.43	0.33	4.42e-10	Intraocular pressure;
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.72	9.82	0.48	3.92e-20	Alzheimer's disease;
CRC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.21	-0.32	1.63e-9	Gout;Renal underexcretion gout;
CRC	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.43	0.5	3.37e-22	Corneal astigmatism;
CRC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.6	0.54	2.6e-26	Prudent dietary pattern;
CRC	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg12315302	chr6:26189340	HIST1H4D	0.91	6.25	0.33	1.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.4	-6.17	-0.32	1.98e-9	Electroencephalogram traits;
CRC	cis	rs524281	0.861	rs3953856	chr11:65965908	T/A	cg16950941	chr11:66035639	RAB1B	-0.62	-7.59	-0.39	3.28e-13	Electroencephalogram traits;
CRC	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.59	-8.5	-0.42	6.89e-16	Squamous cell lung carcinoma;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg21784768	chr11:537496	LRRC56	-0.7	-6.63	-0.34	1.39e-10	Body mass index;
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.49	0.34	3.13e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.49	6.64	0.34	1.26e-10	Pulse pressure;
CRC	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.5	-0.34	2.96e-10	Coronary artery disease;
CRC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.15	25.04	0.81	3.26e-78	IgG glycosylation;
CRC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Melanoma;
CRC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.88	-0.61	8.21e-35	Diabetic kidney disease;
CRC	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg08501292	chr6:25962987	TRIM38	0.6	6.03	0.32	4.4e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg03060546	chr3:49711283	APEH	0.4	5.61	0.3	4.38e-8	Parkinson's disease;
CRC	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.53	-0.54	4.75e-26	Colorectal cancer;
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	12.37	0.56	4.19e-29	Alzheimer's disease;
CRC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.26	-5.92	-0.31	8.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.69	-0.3	2.75e-8	Daytime sleep phenotypes;
CRC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg00105475	chr2:10696890	NA	-0.44	-6.93	-0.36	2.26e-11	Prostate cancer;
CRC	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.41	6.5	0.34	2.95e-10	Obesity;
CRC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.76e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.69	9.94	0.48	1.62e-20	Multiple sclerosis;
CRC	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.82	-0.44	7.04e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.82	-14.88	-0.63	1.23e-38	Hip circumference;
CRC	trans	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg10756647	chr7:56101905	PSPH	0.69	7.49	0.38	6.21e-13	Diabetic kidney disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11954230	chr10:105677556	OBFC1	0.47	6.61	0.34	1.59e-10	Response to antipsychotic treatment;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg10217327	chr6:118973057	C6orf204	0.51	5.86	0.31	1.12e-8	Diastolic blood pressure;
CRC	cis	rs73206853	0.841	rs11065631	chr12:110778383	A/G	cg12870014	chr12:110450643	ANKRD13A	0.84	8.83	0.44	6.5e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg00071950	chr4:10020882	SLC2A9	0.44	6.9	0.36	2.74e-11	Blood metabolite levels;
CRC	cis	rs9976767	0.932	rs9981707	chr21:43827829	T/C	cg23042151	chr21:43824109	UBASH3A	-0.37	-6.44	-0.33	4.17e-10	Type 1 diabetes;
CRC	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.4	6.12	0.32	2.65e-9	Monocyte count;
CRC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.43	-5.74	-0.3	2.17e-8	Response to diuretic therapy;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg20735442	chr6:36390970	PXT1	-0.42	-6.37	-0.33	6.47e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12463550	chr7:65579703	CRCP	0.62	5.95	0.31	6.68e-9	Diabetic kidney disease;
CRC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-7.99	-0.4	2.34e-14	Coronary artery disease;
CRC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg19318889	chr4:1322082	MAEA	0.4	5.69	0.3	2.83e-8	Obesity-related traits;
CRC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	9.81	0.48	4.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg07424746	chr4:185654737	MLF1IP	-0.6	-5.84	-0.31	1.25e-8	Blood protein levels;
CRC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg27534772	chr1:16042836	PLEKHM2	0.53	10.63	0.51	6.82e-23	Systolic blood pressure;
CRC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.55	-8.38	-0.42	1.55e-15	Height;
CRC	cis	rs9549328	0.614	rs34306822	chr13:113616499	G/A	cg25790453	chr13:113633590	MCF2L	0.43	7.55	0.38	4.25e-13	Systolic blood pressure;
CRC	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.47	0.67	7.29e-45	Electrocardiographic conduction measures;
CRC	cis	rs12541635	0.902	rs62525696	chr8:106968703	C/T	cg10147462	chr8:107024639	NA	0.44	7.13	0.37	6.32e-12	Age of smoking initiation;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.8	0.55	4.95e-27	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04531794	chr10:99609860	GOLGA7B	0.44	6.97	0.36	1.75e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-9.36	-0.46	1.28e-18	Joint mobility (Beighton score);
CRC	cis	rs2949837	0.581	rs2960437	chr7:45977352	G/A	cg21268650	chr7:45961089	IGFBP3	0.37	6.35	0.33	7e-10	Sitting height ratio;
CRC	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-7.95	-0.4	2.91e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	5.89	0.31	9.32e-9	Height;
CRC	cis	rs9925964	0.933	rs881929	chr16:31079371	G/T	cg03418659	chr16:31128414	MYST1	0.47	6.73	0.35	7.64e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.38	-7.41	-0.38	1.07e-12	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.27	0.56	9.02e-29	Platelet count;
CRC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg00343986	chr7:65444356	GUSB	0.42	6.14	0.32	2.39e-9	Aortic root size;
CRC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.51	8.78	0.44	8.9e-17	Coronary artery disease;
CRC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.75	-10.62	-0.51	7.54e-23	Platelet distribution width;
CRC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg10589385	chr1:150898437	SETDB1	0.32	6.86	0.35	3.37e-11	Melanoma;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02018176	chr4:1364513	KIAA1530	0.39	6.56	0.34	2.12e-10	Obesity-related traits;
CRC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	6.6	0.34	1.61e-10	Diastolic blood pressure;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19877921	chr17:61904685	PSMC5;FTSJ3	0.39	6.23	0.32	1.44e-9	Obesity-related traits;
CRC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.43	-9.56	-0.47	2.78e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.48	-9.16	-0.45	5.67e-18	Educational attainment (years of education);
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg17724175	chr1:150552817	MCL1	0.44	6.66	0.34	1.14e-10	Melanoma;
CRC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg06363034	chr20:62225388	GMEB2	-0.44	-6.82	-0.35	4.44e-11	Glioblastoma;
CRC	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.63	-11.17	-0.52	8.96e-25	Lewy body disease;
CRC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.62	-0.34	1.45e-10	Blood pressure (smoking interaction);
CRC	cis	rs6840360	0.642	rs10857260	chr4:152424056	C/G	cg09659197	chr4:152720779	NA	0.33	6.48	0.34	3.37e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.07e-10	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03347828	chr17:7739579	NA	0.49	6.5	0.34	2.95e-10	Thyroid stimulating hormone;
CRC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.34	-0.5	6.84e-22	Total cholesterol levels;
CRC	cis	rs7680126	0.633	rs4698014	chr4:10286301	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.99	-0.31	5.42e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.53	7.69	0.39	1.69e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg17077180	chr1:38461687	NA	-0.39	-6.0	-0.31	5.24e-9	Coronary artery disease;
CRC	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.47	6.75	0.35	6.78e-11	Prostate-specific antigen levels (conditioned on lead SNPs);
CRC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg10589385	chr1:150898437	SETDB1	0.32	6.88	0.35	3.04e-11	Melanoma;
CRC	cis	rs1950626	0.743	rs12887333	chr14:101462612	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	15.55	0.65	2.82e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg01312482	chr5:178451176	ZNF879	-0.35	-5.86	-0.31	1.1e-8	Pubertal anthropometrics;
CRC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg13753209	chr17:57696993	CLTC	0.44	5.81	0.3	1.49e-8	Hemoglobin concentration;
CRC	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg25547332	chr5:131281432	NA	0.37	5.73	0.3	2.28e-8	Life satisfaction;
CRC	cis	rs10046574	0.831	rs76054058	chr7:135093486	G/C	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.64	-9.86	-0.48	2.88e-20	IgG glycosylation;
CRC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg18827107	chr12:86230957	RASSF9	-0.38	-5.82	-0.31	1.37e-8	Major depressive disorder;
CRC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.75	0.39	1.15e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6973256	0.828	rs62471409	chr7:133371246	C/T	cg10665199	chr7:133106180	EXOC4	-0.39	-5.86	-0.31	1.14e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.23	-0.32	1.41e-9	Blood metabolite levels;
CRC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	10.9	0.52	7.82e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-10.12	-0.49	3.76e-21	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg24011408	chr12:48396354	COL2A1	0.44	6.21	0.32	1.64e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.85	11.74	0.54	7.88e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9846480	0.598	rs6439806	chr3:138057203	G/A	cg25476813	chr3:138050155	TXNDC6	-0.38	-5.66	-0.3	3.31e-8	Whole-brain volume (Alzheimer's disease interaction);
CRC	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.85	-13.66	-0.6	5.96e-34	Hypospadias;
CRC	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.87	-7.03	-0.36	1.17e-11	Putamen volume;
CRC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.76	11.48	0.53	6.93e-26	Menarche (age at onset);
CRC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-6.86	-0.35	3.33e-11	Major depressive disorder;
CRC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg11833968	chr6:79620685	NA	-0.35	-6.04	-0.32	4.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg02807482	chr3:125708958	NA	-0.41	-5.72	-0.3	2.37e-8	Blood pressure (smoking interaction);
CRC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.58	6.48	0.34	3.27e-10	Bipolar disorder;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.66	9.65	0.47	1.42e-19	Longevity;Endometriosis;
CRC	cis	rs449789	0.857	rs575681	chr6:159703534	G/A	cg14500486	chr6:159655392	FNDC1	-0.48	-7.4	-0.38	1.13e-12	Pulse pressure;
CRC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg02560186	chr11:3602584	NA	-0.46	-6.01	-0.31	4.79e-9	Blood pressure (smoking interaction);
CRC	trans	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.96	0.36	1.86e-11	Mean corpuscular volume;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg06470822	chr6:28175283	NA	0.95	13.56	0.6	1.43e-33	Parkinson's disease;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg06470822	chr6:28175283	NA	-0.78	-10.3	-0.49	9.3e-22	Parkinson's disease;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	8.27	0.41	3.43e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg18404041	chr3:52824283	ITIH1	0.34	6.23	0.32	1.41e-9	Schizophrenia;
CRC	trans	rs9693857	0.520	rs11249928	chr8:9363260	T/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.09	0.32	3.23e-9	Systolic blood pressure;
CRC	cis	rs4731207	0.596	rs6466988	chr7:124678116	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.18	-0.32	1.94e-9	Cutaneous malignant melanoma;
CRC	cis	rs13082711	0.954	rs67282221	chr3:27552752	T/A	cg02860705	chr3:27208620	NA	0.58	7.43	0.38	9.49e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg02659138	chr7:134003124	SLC35B4	0.34	5.94	0.31	7.32e-9	Mean platelet volume;
CRC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.37	-5.88	-0.31	1.01e-8	Blood metabolite levels;
CRC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg04025307	chr7:1156635	C7orf50	0.64	6.84	0.35	3.87e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7487637	0.529	rs11168245	chr12:48204499	C/G	cg14736327	chr12:48174669	SLC48A1	-0.6	-7.68	-0.39	1.85e-13	Mononucleosis;
CRC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-7.52	-0.38	5.26e-13	Lung cancer in ever smokers;
CRC	trans	rs12517041	1.000	rs2081952	chr5:23295605	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg04362960	chr10:104952993	NT5C2	-0.42	-5.9	-0.31	8.92e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.95	0.4	3e-14	Platelet count;
CRC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.6	10.75	0.51	2.58e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs55675132	0.510	rs10489526	chr1:115293527	C/A	cg12756093	chr1:115239321	AMPD1	0.52	6.24	0.33	1.34e-9	Schizophrenia;
CRC	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.06	-0.45	1.19e-17	Triglycerides;
CRC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.44	6.43	0.33	4.47e-10	HIV-1 control;
CRC	cis	rs4731207	0.596	rs1871776	chr7:124674648	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.23	-0.33	1.39e-9	Cutaneous malignant melanoma;
CRC	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg15786705	chr6:28176104	NA	0.67	6.36	0.33	6.67e-10	Depression;
CRC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.55	9.0	0.44	1.82e-17	Schizophrenia;
CRC	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg13385794	chr1:248469461	NA	0.37	6.43	0.33	4.61e-10	Common traits (Other);
CRC	cis	rs7894407	0.856	rs7093667	chr10:105080575	T/C	cg05636881	chr10:105038444	INA	0.36	5.8	0.3	1.59e-8	White matter hyperintensity burden;
CRC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.22	-0.32	1.47e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs727505	0.520	rs1454125	chr7:124862733	C/T	cg23710748	chr7:124431027	NA	-0.62	-10.3	-0.49	9.36e-22	Lewy body disease;
CRC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg19077165	chr18:44547161	KATNAL2	0.42	6.55	0.34	2.27e-10	Personality dimensions;
CRC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg13722127	chr7:150037890	RARRES2	0.49	7.66	0.39	2.13e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg16032841	chr13:111522222	C13orf29	-0.73	-9.54	-0.47	3.33e-19	Sitting height ratio;
CRC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.32	0.46	1.7e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1712517	0.838	rs6584543	chr10:104997014	G/A	cg05636881	chr10:105038444	INA	-0.47	-8.42	-0.42	1.17e-15	Migraine;
CRC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	0.97	10.48	0.5	2.24e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-5.61	-0.3	4.34e-8	Morning vs. evening chronotype;
CRC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.63	0.34	1.38e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg26043149	chr18:55253948	FECH	-0.52	-7.78	-0.39	9.57e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.59	-10.49	-0.5	2.04e-22	Waist-hip ratio;
CRC	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg01388757	chr2:102091195	RFX8	-0.35	-5.65	-0.3	3.53e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.23	-0.41	4.54e-15	Biliary atresia;
CRC	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg00507830	chr2:103233733	NA	0.49	5.65	0.3	3.56e-8	Gut microbiota (bacterial taxa);
CRC	trans	rs6886261	1.000	rs10071791	chr5:43098119	T/C	cg24995083	chr14:95787435	CLMN	0.79	6.08	0.32	3.34e-9	Conotruncal heart defects (inherited effects);
CRC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs4743820	0.651	rs10114465	chr9:93936592	C/T	cg14446406	chr9:93919335	NA	0.69	12.33	0.56	5.62e-29	Ulcerative colitis;Inflammatory bowel disease;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg25048357	chr11:118955763	HMBS	-0.44	-6.2	-0.32	1.65e-9	Underweight status;
CRC	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg00531865	chr16:30841666	NA	-0.46	-6.45	-0.33	4.09e-10	Dementia with Lewy bodies;
CRC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.65	0.57	3.55e-30	Platelet count;
CRC	trans	rs2055729	0.677	rs10098618	chr8:9741478	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.03	0.32	4.3e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	0.58	8.92	0.44	3.2e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs905456	0.868	rs6770525	chr3:30747817	A/G	cg06106510	chr3:30762233	NA	0.31	5.66	0.3	3.35e-8	Positive affect;
CRC	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.7	-9.65	-0.47	1.47e-19	Coronary artery disease;
CRC	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	7.7	0.39	1.63e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-0.94	-9.18	-0.45	5.08e-18	Post bronchodilator FEV1;
CRC	cis	rs2342371	0.756	rs12637868	chr3:196106754	G/A	cg15048948	chr3:196158458	UBXN7	0.51	6.26	0.33	1.18e-9	Fat distribution (HIV);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg24847481	chr1:100435557	SLC35A3	0.36	5.97	0.31	6.3e-9	Interleukin-6 levels;
CRC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.62	7.06	0.36	9.92e-12	Resting heart rate;
CRC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.76	-12.76	-0.58	1.43e-30	Menopause (age at onset);
CRC	cis	rs6496667	0.954	rs7162211	chr15:90892585	G/C	cg04176472	chr15:90893244	GABARAPL3	0.54	8.26	0.41	3.53e-15	Rheumatoid arthritis;
CRC	cis	rs9976767	1.000	rs3761378	chr21:43832918	C/T	cg23042151	chr21:43824109	UBASH3A	0.32	5.65	0.3	3.49e-8	Type 1 diabetes;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg25164649	chr6:28176230	NA	0.78	10.49	0.5	2.18e-22	Depression;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg15845792	chr6:28175446	NA	0.79	11.65	0.54	1.65e-26	Cardiac Troponin-T levels;
CRC	trans	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg15511327	chr8:143859410	LYNX1	0.39	6.88	0.35	3.12e-11	Urinary tract infection frequency;
CRC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.58	-0.34	1.89e-10	Total body bone mineral density;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg26587870	chr6:27730563	NA	-0.45	-6.55	-0.34	2.18e-10	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10554839	chr10:27529782	ACBD5	0.46	7.67	0.39	1.99e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.72	-10.12	-0.49	4e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.66	12.54	0.57	9.25e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg02158880	chr13:53174818	NA	0.55	8.67	0.43	1.95e-16	Lewy body disease;
CRC	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.77	-10.45	-0.5	2.86e-22	Smoking behavior;
CRC	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg13206674	chr6:150067644	NUP43	0.48	5.94	0.31	7.13e-9	Lung cancer;
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-7.13	-0.37	6.41e-12	Total body bone mineral density;
CRC	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg17788362	chr6:86352627	SYNCRIP	0.51	7.24	0.37	3.27e-12	Smooth-surface caries;
CRC	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.34	-0.42	2.1e-15	Biliary atresia;
CRC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg02683197	chr6:28174875	NA	0.46	6.38	0.33	6.1e-10	Cardiac Troponin-T levels;
CRC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14895029	chr7:2775587	GNA12	-0.46	-6.93	-0.36	2.19e-11	Height;
CRC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.85	-9.83	-0.48	3.74e-20	Monocyte percentage of white cells;
CRC	cis	rs4073416	0.534	rs7147002	chr14:66032546	T/C	cg03016385	chr14:66212404	NA	-0.45	-6.19	-0.32	1.78e-9	N-glycan levels;
CRC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.67	9.99	0.48	1.1e-20	Corneal astigmatism;
CRC	cis	rs2070997	0.938	rs4740376	chr9:133747734	C/T	cg01000188	chr9:133769184	QRFP	0.54	5.65	0.3	3.46e-8	Response to amphetamines;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg02683197	chr6:28174875	NA	0.68	9.32	0.46	1.79e-18	Parkinson's disease;
CRC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.45	6.75	0.35	6.79e-11	Platelet count;
CRC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg14541582	chr5:601475	NA	-0.27	-5.88	-0.31	1e-8	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13198984	chr17:80129470	CCDC57	0.48	8.5	0.42	6.68e-16	Life satisfaction;
CRC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.61	9.05	0.45	1.3e-17	Obesity-related traits;
CRC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.69	10.78	0.51	2.08e-23	Immature fraction of reticulocytes;
CRC	cis	rs2811415	0.597	rs9819833	chr3:127793408	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.86	-0.31	1.12e-8	Lung function (FEV1/FVC);
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.69	10.92	0.52	6.88e-24	Corneal astigmatism;
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.97	-0.44	2.23e-17	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg25804541	chr17:80189381	SLC16A3	-0.32	-6.01	-0.31	5.04e-9	Life satisfaction;
CRC	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-1.0	-10.42	-0.5	3.76e-22	Post bronchodilator FEV1;
CRC	cis	rs447	0.636	rs464	chr7:83786460	A/G	cg22846510	chr7:83753280	SEMA3A	-0.4	-5.66	-0.3	3.33e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg08501292	chr6:25962987	TRIM38	0.84	7.82	0.4	7.01e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.22	-0.71	8.68e-52	Schizophrenia;
CRC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.49	-7.58	-0.39	3.53e-13	Monocyte count;
CRC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.39	5.72	0.3	2.45e-8	Aortic root size;
CRC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.7	9.55	0.47	3.12e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.45	-0.34	3.9e-10	Obesity-related traits;
CRC	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.49	6.27	0.33	1.11e-9	Alzheimer's disease (survival time);
CRC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.56	8.39	0.42	1.42e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.62	9.36	0.46	1.3e-18	Height;
CRC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.7	-0.3	2.73e-8	Response to bleomycin (chromatid breaks);
CRC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg02741985	chr17:80059408	CCDC57	-0.45	-7.25	-0.37	2.94e-12	Life satisfaction;
CRC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-8.52	-0.43	5.93e-16	Coronary artery disease;
CRC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.36	-5.88	-0.31	9.85e-9	Total body bone mineral density;
CRC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg00310523	chr12:86230176	RASSF9	0.43	7.26	0.37	2.88e-12	Major depressive disorder;
CRC	cis	rs11212617	0.967	rs4753833	chr11:108057430	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.83	0.31	1.33e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-6.02	-0.32	4.6e-9	Lung cancer;
CRC	cis	rs7937682	0.593	rs1944123	chr11:111356407	T/C	cg09085632	chr11:111637200	PPP2R1B	0.41	5.71	0.3	2.52e-8	Primary sclerosing cholangitis;
CRC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg18099408	chr3:52552593	STAB1	0.36	6.14	0.32	2.43e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.41	-6.94	-0.36	2.06e-11	Obesity-related traits;
CRC	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.39	-0.38	1.2e-12	Inflammatory bowel disease;
CRC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.37	0.38	1.43e-12	Height;
CRC	cis	rs281302	0.621	rs373553	chr15:47749001	G/C	cg13159054	chr15:47721715	NA	-0.43	-6.42	-0.33	4.65e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.81	9.75	0.47	6.71e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-17.23	-0.69	7.32e-48	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-0.97	-14.02	-0.61	2.37e-35	Initial pursuit acceleration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14309743	chr22:50312258	ALG12;CRELD2	0.48	6.92	0.36	2.41e-11	Response to antipsychotic treatment;
CRC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.43	-6.07	-0.32	3.59e-9	Platelet distribution width;
CRC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.79	14.89	0.63	1.12e-38	Prudent dietary pattern;
CRC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.1	-0.32	2.99e-9	Height;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg21204522	chr6:27730016	NA	-0.42	-5.65	-0.3	3.43e-8	Parkinson's disease;
CRC	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg19875578	chr6:126661172	C6orf173	0.42	5.89	0.31	9.49e-9	Male-pattern baldness;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg08200770	chr17:80723486	TBCD	-0.48	-7.43	-0.38	9.65e-13	Glycated hemoglobin levels;
CRC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.48	7.65	0.39	2.26e-13	Uric acid clearance;
CRC	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.46	-6.65	-0.34	1.21e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.69	-7.91	-0.4	3.94e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	11.23	0.53	5.44e-25	Motion sickness;
CRC	cis	rs79387448	0.745	rs72993754	chr2:103151136	A/G	cg09003973	chr2:102972529	NA	0.68	7.72	0.39	1.38e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg21251018	chr6:28226885	NKAPL	0.4	6.08	0.32	3.25e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.66	-8.82	-0.44	6.76e-17	Extraversion;
CRC	trans	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg02801645	chr22:24059735	LOC91316	0.56	6.02	0.31	4.59e-9	Airway imaging phenotypes;
CRC	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.36	0.42	1.81e-15	Arsenic metabolism;
CRC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.98	-19.27	-0.73	6.62e-56	Height;
CRC	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-8.18	-0.41	6.17e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.52	0.34	2.59e-10	Homocysteine levels;
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg02683197	chr6:28174875	NA	0.61	8.7	0.43	1.64e-16	Hepatitis A;
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	9.82e-13	Body mass index;
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-0.89	-19.74	-0.74	8.98e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.88	0.4	4.67e-14	Lung cancer;
CRC	cis	rs55702914	0.746	rs4850425	chr2:198152786	T/C	cg20885578	chr2:198174922	NA	-0.36	-6.27	-0.33	1.13e-9	Major depression and alcohol dependence;
CRC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.64	9.58	0.47	2.45e-19	Blood protein levels;
CRC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	6.38	0.33	6.01e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16870442	chr8:6264181	MCPH1	0.45	6.21	0.32	1.61e-9	Response to antipsychotic treatment;
CRC	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg14593290	chr7:50529359	DDC	-0.45	-6.15	-0.32	2.19e-9	Systemic sclerosis;
CRC	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26306683	chr17:18585705	ZNF286B	0.5	7.02	0.36	1.29e-11	Educational attainment (years of education);
CRC	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.03	21.47	0.76	1.47e-64	Multiple myeloma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08020660	chr16:30076480	ALDOA	0.43	6.35	0.33	6.99e-10	Anxiety disorder;
CRC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.93	18.6	0.72	2.71e-53	Menopause (age at onset);
CRC	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	0.89	8.11	0.41	1.03e-14	LDL cholesterol;
CRC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.43	-7.16	-0.37	5.27e-12	Life satisfaction;
CRC	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.82	-14.37	-0.62	1.11e-36	Hip circumference;
CRC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.67	-0.47	1.25e-19	Height;
CRC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7301826	0.627	rs10773823	chr12:131294501	C/T	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.3	6.26	0.33	1.17e-9	Lung cancer;
CRC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs9925964	0.933	rs9939417	chr16:31053467	C/T	cg02466173	chr16:30829666	NA	0.44	5.97	0.31	6.27e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.49	6.28	0.33	1.06e-9	Exhaled nitric oxide output;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08546335	chr16:1877338	HAGH;FAHD1	0.44	6.02	0.31	4.75e-9	Anxiety disorder;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg27615366	chr5:131592974	PDLIM4	0.34	6.08	0.32	3.34e-9	Acylcarnitine levels;
CRC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.71	0.47	9.1e-20	Cognitive test performance;
CRC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.25	-16.68	-0.68	1.03e-45	Breast cancer;
CRC	cis	rs7932354	0.655	rs6485690	chr11:46798631	A/G	cg19486271	chr11:47235900	DDB2	-0.47	-7.66	-0.39	2.06e-13	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.45	-5.84	-0.31	1.26e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.32	-0.37	1.91e-12	Endometrial cancer;
CRC	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.44	-5.76	-0.3	1.9e-8	Adiposity;
CRC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.54	8.55	0.43	4.7e-16	Type 2 diabetes;
CRC	cis	rs77633900	0.772	rs283802	chr15:76791270	C/T	cg21673338	chr15:77095150	SCAPER	-0.73	-6.66	-0.34	1.16e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.15	9.46	0.46	6.23e-19	Mitochondrial DNA levels;
CRC	cis	rs79387448	0.808	rs77518775	chr2:103237642	T/C	cg21010569	chr2:103233596	NA	0.59	6.64	0.34	1.29e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.41	-5.76	-0.3	1.95e-8	Calcium levels;
CRC	cis	rs972578	1.000	rs926351	chr22:43371176	T/C	cg01576275	chr22:43409880	NA	-0.45	-7.28	-0.37	2.47e-12	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02290350	chr8:58132656	NA	-0.57	-8.44	-0.42	1.02e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.53	7.55	0.38	4.41e-13	Systemic lupus erythematosus;
CRC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	6.02	0.31	4.74e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.42	6.79	0.35	5.15e-11	Coronary artery disease;
CRC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.53	7.76	0.39	1.09e-13	Response to temozolomide;
CRC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.56	7.08	0.36	8.76e-12	Vitamin D levels;
CRC	cis	rs863345	0.625	rs6663286	chr1:158473725	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.33	-0.33	7.99e-10	Pneumococcal bacteremia;
CRC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.29	-0.64	3.04e-40	Gut microbiome composition (summer);
CRC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.73	11.46	0.53	8.32e-26	Colorectal cancer;
CRC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg01262667	chr19:19385393	TM6SF2	0.36	6.07	0.32	3.6e-9	Tonsillectomy;
CRC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.41	6.73	0.35	7.71e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	15.36	0.65	1.57e-40	Platelet count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg06622468	chr19:10491460	TYK2	0.41	6.5	0.34	2.99e-10	Obesity-related traits;
CRC	cis	rs741668	0.894	rs2031633	chr13:46596140	C/T	cg06018095	chr13:46550134	ZC3H13	0.43	5.92	0.31	7.95e-9	Cerebrospinal fluid clusterin levels;
CRC	trans	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg16482183	chr6:26056742	HIST1H1C	0.7	8.69	0.43	1.78e-16	Iron status biomarkers;
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.78	9.06	0.45	1.22e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.51	6.95	0.36	1.92e-11	Obesity-related traits;
CRC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.94	-0.4	3.16e-14	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.53	11.01	0.52	3.24e-24	Bone mineral density;
CRC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.18	-0.32	1.9e-9	Total body bone mineral density;
CRC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-8.38	-0.42	1.57e-15	Personality dimensions;
CRC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg01518246	chr11:63870912	FLRT1;MACROD1	0.46	6.17	0.32	2.05e-9	Mean platelet volume;
CRC	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg13206674	chr6:150067644	NUP43	0.44	5.94	0.31	7.21e-9	Lung cancer;
CRC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg02725872	chr8:58115012	NA	-0.36	-6.17	-0.32	2.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.44	7.27	0.37	2.65e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.89	11.25	0.53	4.75e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg04733911	chr16:78082701	NA	-0.45	-7.5	-0.38	6.09e-13	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.54	7.85	0.4	5.97e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.97	-20.15	-0.74	2.29e-59	Myeloid white cell count;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg04518342	chr5:131593106	PDLIM4	0.56	9.72	0.47	8.62e-20	Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs4700695	0.841	rs251294	chr5:65261848	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg01788221	chr16:89496183	ANKRD11	-0.4	-6.02	-0.31	4.66e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.63	11.58	0.54	3.06e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3026445	0.832	rs7975364	chr12:110602275	A/T	cg12870014	chr12:110450643	ANKRD13A	0.42	6.62	0.34	1.49e-10	QT interval;
CRC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07513332	chr6:167530253	CCR6	-0.37	-6.32	-0.33	8.66e-10	Primary biliary cholangitis;
CRC	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg02007433	chr3:129722099	NA	-0.62	-6.07	-0.32	3.47e-9	Blood pressure (smoking interaction);
CRC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-7.06	-0.36	9.89e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.52	7.61	0.39	2.91e-13	Type 2 diabetes;
CRC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14895029	chr7:2775587	GNA12	-0.4	-5.63	-0.3	3.9e-8	Height;
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.68	-0.39	1.78e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.61	-0.3	4.35e-8	Rheumatoid arthritis;
CRC	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-9.16	-0.45	5.87e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.46	6.71	0.35	8.32e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23597375	chr22:42084934	NHP2L1	0.46	6.36	0.33	6.87e-10	Anxiety disorder;
CRC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.28	6.55	0.34	2.16e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6662572	0.737	rs6680647	chr1:46345478	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.73	0.3	2.26e-8	Blood protein levels;
CRC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.66	-0.34	1.17e-10	Response to antipsychotic treatment;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	ch.1.3875151R	chr1:200949712	KIF21B	-0.39	-6.24	-0.33	1.38e-9	Aortic root size;
CRC	trans	rs11581859	0.950	rs6577238	chr1:99393710	T/C	cg12183875	chr3:169587454	LRRC31	0.28	6.3	0.33	9.59e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.56	8.8	0.44	7.86e-17	Diastolic blood pressure;
CRC	cis	rs9311676	0.656	rs11130635	chr3:58379143	A/G	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs8010715	0.816	rs762093	chr14:24591918	G/C	cg23112188	chr14:24563095	PCK2	-0.35	-7.02	-0.36	1.25e-11	IgG glycosylation;
CRC	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg08461752	chr10:43522343	NA	-0.82	-7.64	-0.39	2.45e-13	Blood protein levels;
CRC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.59	-7.58	-0.39	3.46e-13	Gut microbiome composition (summer);
CRC	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg10820045	chr2:198174542	NA	0.39	6.71	0.35	8.4e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.62	-8.67	-0.43	1.94e-16	DNA methylation (variation);
CRC	trans	rs6066835	1.000	rs73136396	chr20:47337174	T/A	cg21109867	chr19:55897418	RPL28	-0.76	-6.21	-0.32	1.59e-9	Multiple myeloma;
CRC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg02869306	chr7:64672164	INTS4L1	0.4	6.12	0.32	2.73e-9	Aortic root size;
CRC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.63	10.08	0.49	5.32e-21	Monocyte count;
CRC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.28	-5.79	-0.3	1.64e-8	Total body bone mineral density;
CRC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.37	6.28e-12	Reticulocyte fraction of red cells;
CRC	trans	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg17903999	chr18:56338584	MALT1	-0.44	-7.23	-0.37	3.5e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg22546130	chr22:19950026	COMT	0.27	7.24	0.37	3.17e-12	Blood metabolite levels;
CRC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.49	0.34	3.12e-10	Melanoma;
CRC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.41	7.98	0.4	2.47e-14	Mean corpuscular volume;
CRC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.61	-10.48	-0.5	2.22e-22	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.87	10.29	0.49	1.01e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs12580194	0.756	rs2169856	chr12:55572652	C/G	cg19537932	chr12:55886519	OR6C68	0.52	5.92	0.31	8.06e-9	Cancer;
CRC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.53	7.5	0.38	6.09e-13	Lung cancer;
CRC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-6.06	-0.32	3.68e-9	Gut microbiome composition (summer);
CRC	cis	rs10503871	0.905	rs6993734	chr8:30477733	T/C	cg26383811	chr8:30366931	RBPMS	0.45	7.29	0.37	2.36e-12	Metabolite levels  (X-11787);
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07308232	chr7:1071921	C7orf50	-0.42	-5.72	-0.3	2.36e-8	Longevity;Endometriosis;
CRC	cis	rs9612	0.950	rs60649310	chr19:44269241	A/G	cg08581076	chr19:44259116	C19orf61	0.46	5.7	0.3	2.66e-8	Exhaled nitric oxide output;
CRC	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg13206674	chr6:150067644	NUP43	0.66	9.38	0.46	1.12e-18	Lung cancer;
CRC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg08314208	chr16:67682810	RLTPR	-0.63	-7.22	-0.37	3.59e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg03060546	chr3:49711283	APEH	-0.48	-5.76	-0.3	1.9e-8	Cognitive function;
CRC	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.6	8.16	0.41	7.33e-15	Biliary atresia;
CRC	cis	rs12760731	0.720	rs10913553	chr1:178423062	G/C	cg00404053	chr1:178313656	RASAL2	0.97	10.21	0.49	1.85e-21	Obesity-related traits;
CRC	cis	rs427943	0.778	rs13047803	chr21:46622369	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	6.08	0.32	3.3e-9	Body mass index;
CRC	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	1.15	10.02	0.48	8.48e-21	Mitochondrial DNA levels;
CRC	cis	rs4757319	0.515	rs7934026	chr11:15339942	A/G	cg03245590	chr11:15329459	NA	0.53	9.34	0.46	1.51e-18	Breast cancer;
CRC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.81	-0.51	1.7e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg15511327	chr8:143859410	LYNX1	0.41	7.09	0.36	8.25e-12	Urinary tract infection frequency;
CRC	trans	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.88	-0.35	3.08e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs12476592	0.571	rs6546005	chr2:63672071	G/A	cg10828910	chr2:63850056	LOC388955	0.49	5.93	0.31	7.47e-9	Childhood ear infection;
CRC	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg00246817	chr9:123691163	NA	-0.45	-5.84	-0.31	1.22e-8	Rheumatoid arthritis;
CRC	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.71	-0.35	8.68e-11	Multiple sclerosis;
CRC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.59	-10.37	-0.5	5.7e-22	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg25809561	chr17:30822961	MYO1D	0.58	10.56	0.5	1.24e-22	Schizophrenia;
CRC	cis	rs4731207	0.724	rs57458159	chr7:124500810	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.82	0.35	4.27e-11	Obesity-related traits;
CRC	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.63	12.76	0.58	1.39e-30	Schizophrenia;
CRC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg03934865	chr2:198174659	NA	-0.45	-7.26	-0.37	2.83e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.07e-15	Major depressive disorder;
CRC	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.93	-14.86	-0.63	1.48e-38	Dupuytren's disease;
CRC	cis	rs10905065	0.965	rs2244755	chr10:5754611	G/A	cg11519256	chr10:5708881	ASB13	0.43	6.14	0.32	2.31e-9	Menopause (age at onset);
CRC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.48	6.44	0.33	4.26e-10	Pulse pressure;
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.09	0.59	8.18e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs294883	0.739	rs4709291	chr6:159730267	T/C	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg24531977	chr5:56204891	C5orf35	-0.45	-6.76	-0.35	6.34e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg23018236	chr17:30244563	NA	-0.69	-8.35	-0.42	1.89e-15	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg03233332	chr7:66118400	NA	-0.45	-6.26	-0.33	1.22e-9	Aortic root size;
CRC	trans	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg17903999	chr18:56338584	MALT1	-0.39	-6.64	-0.34	1.3100000000000001e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs73200209	0.744	rs11614312	chr12:116694851	A/G	cg01776926	chr12:116560359	MED13L	0.6	7.28	0.37	2.51e-12	Total body bone mineral density;
CRC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg27534772	chr1:16042836	PLEKHM2	0.42	7.09	0.36	8.14e-12	Systolic blood pressure;
CRC	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs3807375	1.000	rs3807375	chr7:150667210	C/T	cg10636020	chr7:150656979	KCNH2	-0.31	-5.65	-0.3	3.48e-8	Electrocardiographic traits;QT interval;
CRC	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg14768367	chr16:72042858	DHODH	-0.6	-6.53	-0.34	2.56e-10	Blood protein levels;
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg19318889	chr4:1322082	MAEA	0.43	6.45	0.33	4.08e-10	Obesity-related traits;
CRC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.53	-6.75	-0.35	6.71e-11	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg23996704	chr18:44553084	KATNAL2	-0.36	-7.39	-0.38	1.2e-12	Personality dimensions;
CRC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.62	-7.83	-0.4	6.87e-14	Gut microbiome composition (summer);
CRC	cis	rs12612619	0.591	rs12714092	chr2:27314882	G/A	cg00617064	chr2:27272375	NA	0.4	6.23	0.32	1.44e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs995000	0.931	rs1748195	chr1:63049593	C/G	cg19896129	chr1:63156450	NA	-0.38	-5.96	-0.31	6.66e-9	Triglyceride levels;
CRC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.71	0.3	2.52e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2786111	0.965	rs1415214	chr1:197283185	C/T	cg13682187	chr1:196946512	CFHR5	0.29	5.71	0.3	2.47e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.76e-9	Life satisfaction;
CRC	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.51	9.12	0.45	7.65e-18	Weight;
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.83	-0.44	6.26e-17	Bipolar disorder;
CRC	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.33	6.9	0.36	2.61e-11	Migraine;
CRC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	6.91	0.36	2.49e-11	Schizophrenia;
CRC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.52	7.47	0.38	7.08e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg08222618	chr4:941054	TMEM175	0.36	6.07	0.32	3.45e-9	Systemic sclerosis;
CRC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg14541582	chr5:601475	NA	-0.33	-6.42	-0.33	4.64e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg02428538	chr16:24856791	SLC5A11	0.56	6.71	0.35	8.45e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.61	0.3	4.22e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg25190513	chr12:123201362	GPR109B	-0.49	-6.27	-0.33	1.11e-9	Adiponectin levels;
CRC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg24884572	chr19:58661833	ZNF329	0.79	8.67	0.43	1.97e-16	Cholesterol, total;
CRC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.61	-9.36	-0.46	1.25e-18	Height;
CRC	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg23920097	chr1:209922102	NA	-0.51	-6.34	-0.33	7.36e-10	Red blood cell count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05672380	chr19:36505394	ALKBH6	0.54	7.75	0.39	1.13e-13	Response to antipsychotic treatment;
CRC	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.49	7.69	0.39	1.67e-13	Red blood cell count;
CRC	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.6	-8.21	-0.41	5.04e-15	Facial morphology (factor 19);
CRC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.55	0.47	3.13e-19	Birth weight;
CRC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg19824325	chr16:58548873	SETD6	0.9	6.09	0.32	3.09e-9	Schizophrenia;
CRC	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg23229984	chr5:148520753	ABLIM3	0.5	6.93	0.36	2.16e-11	Breast cancer;
CRC	cis	rs2077654	0.822	rs1805036	chr11:17434284	G/A	cg25308976	chr11:17434268	ABCC8	0.79	8.27	0.41	3.45e-15	Gout;
CRC	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.85	-0.55	3.21e-27	Colorectal cancer;
CRC	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.54	-6.42	-0.33	4.65e-10	Lymphocyte counts;
CRC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.53	9.19	0.45	4.7e-18	Schizophrenia;
CRC	trans	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.55	0.38	4.44e-13	Endometrial cancer;
CRC	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.51	-8.39	-0.42	1.45e-15	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16492226	chr5:83014308	HAPLN1	0.43	6.2	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.95	-0.31	7.05e-9	Blood protein levels;
CRC	cis	rs6479527	0.875	rs10821285	chr9:96791789	C/T	cg14459158	chr9:96720562	NA	0.39	6.95	0.36	1.96e-11	Esophageal adenocarcinoma;
CRC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg07507251	chr3:52567010	NT5DC2	-0.39	-6.02	-0.32	4.53e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs77861329	1.000	rs352153	chr3:52211184	A/T	cg08692210	chr3:52188851	WDR51A	0.78	7.39	0.38	1.2e-12	Macrophage inflammatory protein 1b levels;
CRC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg02527881	chr3:46936655	PTH1R	0.39	7.19	0.37	4.31e-12	Colorectal cancer;
CRC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.28	0.53	3.49e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg03623178	chr6:28175578	NA	0.75	8.36	0.42	1.77e-15	Parkinson's disease;
CRC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.47	-6.93	-0.36	2.28e-11	Type 2 diabetes;
CRC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24098762	chr5:137667672	CDC25C	0.47	7.01	0.36	1.32e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg19622623	chr12:86230825	RASSF9	0.38	5.81	0.31	1.46e-8	Major depressive disorder;
CRC	cis	rs669446	0.562	rs10890275	chr1:44194216	T/G	cg12908607	chr1:44402522	ARTN	-0.34	-5.79	-0.3	1.62e-8	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg17294928	chr15:75287854	SCAMP5	0.38	5.76	0.3	1.93e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-8.41	-0.42	1.24e-15	Vitiligo;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24479509	chr21:45209770	RRP1	0.45	6.02	0.31	4.56e-9	Anxiety disorder;
CRC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	7.13	0.37	6.33e-12	Cognitive test performance;
CRC	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.58	-8.91	-0.44	3.45e-17	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg23032129	chr1:109941072	SORT1	-0.28	-6.03	-0.32	4.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.78	13.78	0.6	2.1e-34	Breast cancer;
CRC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-6.15	-0.32	2.28e-9	Migraine;Coronary artery disease;
CRC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.47	-7.53	-0.38	5.08e-13	Iron status biomarkers;
CRC	cis	rs12936587	0.748	rs12939297	chr17:17524247	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.79	-0.3	1.68e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	10.31	0.49	8.69e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.7	9.43	0.46	7.56e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.74	-12.65	-0.57	3.75e-30	Body mass index;
CRC	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg11833968	chr6:79620685	NA	-0.35	-6.17	-0.32	1.96e-9	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22240667	chr16:14396276	NA	0.43	6.28	0.33	1.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.6	-0.39	3.05e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs653465	0.739	rs1357245	chr3:27186602	C/T	cg02860705	chr3:27208620	NA	-0.38	-5.99	-0.31	5.45e-9	Breast cancer (early onset);
CRC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.83	0.35	4.16e-11	Tonsillectomy;
CRC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-1.24	-11.09	-0.52	1.67e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.51	6.23	0.33	1.39e-9	Recombination rate (females);
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg20933634	chr6:27740509	NA	0.61	7.8	0.4	8.12e-14	Breast cancer;
CRC	cis	rs1347297	0.789	rs7589565	chr2:179282337	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.39	-5.64	-0.3	3.64e-8	Alzheimer disease and age of onset;
CRC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.51	6.53	0.34	2.46e-10	Longevity;
CRC	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg09232269	chr1:207846808	CR1L	0.46	7.5	0.38	6.09e-13	Erythrocyte sedimentation rate;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg22717211	chr17:48944309	NA	-0.4	-6.24	-0.33	1.37e-9	Aortic root size;
CRC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.17e-12	Major depressive disorder;
CRC	cis	rs2108622	0.711	rs12609820	chr19:15978057	T/C	cg13772218	chr19:15982569	NA	0.48	6.69	0.35	9.62e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs1619661	0.530	rs1627329	chr10:44691633	A/G	cg09554077	chr10:44749378	NA	0.49	7.51	0.38	5.68e-13	QT interval (ambient particulate matter interaction);
CRC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.97	-0.48	1.25e-20	Body mass index;
CRC	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.59	-8.28	-0.42	3.04e-15	Personality dimensions;
CRC	cis	rs10267417	0.603	rs12333603	chr7:19907821	C/G	cg07541023	chr7:19748670	TWISTNB	-0.5	-5.8	-0.3	1.58e-8	Night sleep phenotypes;
CRC	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs17607347	0.738	rs806733	chr16:72406328	T/C	cg27230510	chr3:50404023	CACNA2D2	-0.54	-5.99	-0.31	5.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.89	-0.31	9.47e-9	Longevity;Endometriosis;
CRC	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	0.72	7.97	0.4	2.65e-14	Mean corpuscular volume;
CRC	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.62	-0.34	1.48e-10	Educational attainment;
CRC	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.88	11.49	0.53	6.67e-26	IgG glycosylation;
CRC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.21	-0.32	1.62e-9	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.69	9.69	0.47	1.04e-19	Alzheimer's disease;
CRC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.64	8.55	0.43	4.75e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg18525740	chr5:176449647	ZNF346	0.49	6.04	0.32	4.09e-9	Breast cancer;
CRC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.49	7.91	0.4	3.97e-14	Cystic fibrosis severity;
CRC	trans	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg10756647	chr7:56101905	PSPH	0.74	7.74	0.39	1.23e-13	Diabetic kidney disease;
CRC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.57	-9.06	-0.45	1.18e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10046574	0.634	rs77474267	chr7:135098679	G/A	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.67	8.93	0.44	3.07e-17	Uric acid levels;
CRC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.76	-0.35	6.45e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.55	6.71	0.35	8.44e-11	Vitiligo;
CRC	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg03929089	chr4:120376271	NA	0.62	5.99	0.31	5.44e-9	Axial length;
CRC	cis	rs2949837	0.581	rs2965068	chr7:45974375	T/C	cg04796162	chr7:45961102	IGFBP3	0.38	6.73	0.35	7.47e-11	Sitting height ratio;
CRC	cis	rs7113874	0.569	rs4418812	chr11:8612000	A/G	cg02811074	chr11:8615871	STK33	0.35	6.0	0.31	5.19e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18099408	chr3:52552593	STAB1	-0.52	-9.11	-0.45	8.14e-18	Electroencephalogram traits;
CRC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.2	-0.45	4.18e-18	Migraine;Coronary artery disease;
CRC	trans	rs587242	1.000	rs662450	chr1:96891547	C/G	cg10631902	chr5:14652156	NA	0.45	6.9	0.36	2.7e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.56	-8.09	-0.41	1.13e-14	Homoarginine levels;
CRC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.01	-0.31	4.84e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.54	6.67	0.35	1.09e-10	Alzheimer's disease;
CRC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.79	-10.84	-0.51	1.25e-23	Cognitive function;
CRC	cis	rs17767392	0.781	rs8008605	chr14:72045544	C/G	cg13720639	chr14:72061746	SIPA1L1	0.52	5.94	0.31	7.38e-9	Mitral valve prolapse;
CRC	cis	rs154659	1.000	rs154659	chr16:89667337	C/T	cg01710450	chr16:89662404	CPNE7	0.42	5.83	0.31	1.34e-8	Tanning;
CRC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.95	-0.31	6.86e-9	Crohn's disease;
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg19913688	chr11:428466	ANO9	-0.7	-7.19	-0.37	4.26e-12	Body mass index;
CRC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.51	7.63	0.39	2.53e-13	Menarche (age at onset);
CRC	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-11.96	-0.55	1.28e-27	Plateletcrit;Platelet count;
CRC	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-6.48	-0.34	3.38e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07318372	chr1:240071102	CHRM3	-0.48	-7.24	-0.37	3.29e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	11.65	0.54	1.73e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03923535	chr7:1197113	ZFAND2A	0.52	7.68	0.39	1.84e-13	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01196388	chr7:99063916	ATP5J2	0.45	6.19	0.32	1.83e-9	Response to antipsychotic treatment;
CRC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg25956985	chr22:39795188	MAP3K7IP1	-0.44	-6.45	-0.34	4e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg08222913	chr3:52553049	STAB1	0.37	7.19	0.37	4.38e-12	Electroencephalogram traits;
CRC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13939156	chr17:80058883	NA	0.37	5.65	0.3	3.39e-8	Life satisfaction;
CRC	cis	rs990171	1.000	rs10469840	chr2:103093243	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	5.71	0.3	2.5e-8	Lymphocyte counts;
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg12100956	chr17:78086420	GAA	-0.38	-6.05	-0.32	3.95e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg11843238	chr5:131593191	PDLIM4	0.43	7.27	0.37	2.6e-12	Breast cancer;
CRC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-8.53	-0.43	5.24e-16	Sense of smell;
CRC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-9.0	-0.44	1.84e-17	Schizophrenia;
CRC	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.52	8.23	0.41	4.52e-15	Red blood cell count;
CRC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.88	0.31	1.03e-8	Diabetic retinopathy;
CRC	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg25019722	chr6:37503610	NA	-0.33	-5.74	-0.3	2.18e-8	Cognitive performance;
CRC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.54	8.0	0.4	2.09e-14	Breast cancer;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg22638593	chr5:131593259	PDLIM4	-0.41	-6.92	-0.36	2.44e-11	Blood metabolite levels;
CRC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg03948781	chr1:205179583	DSTYK	0.43	5.97	0.31	6.18e-9	Red blood cell count;
CRC	cis	rs13253111	0.624	rs7832318	chr8:28110414	A/G	cg26534493	chr8:28060551	NA	0.43	7.61	0.39	2.95e-13	Childhood body mass index;
CRC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg27523141	chr10:43048294	ZNF37B	0.5	7.35	0.38	1.55e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.83	11.03	0.52	2.88e-24	IgG glycosylation;
CRC	cis	rs9427116	1.000	rs9330261	chr1:154634998	T/A	cg24304309	chr1:154577895	ADAR	0.37	6.03	0.32	4.51e-9	Blood protein levels;
CRC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.44	0.42	9.92e-16	Menopause (age at onset);
CRC	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.88	-17.02	-0.68	4.81e-47	Hip circumference;
CRC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.48	8.02	0.4	1.9e-14	Major depressive disorder;
CRC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.44	7.12	0.37	6.79e-12	Obesity-related traits;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg17949981	chr6:28129498	ZNF389	0.41	5.71	0.3	2.54e-8	Cardiac Troponin-T levels;
CRC	cis	rs7932354	0.528	rs7947878	chr11:47028531	C/T	cg03339077	chr11:47165057	C11orf49	0.44	6.26	0.33	1.23e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.62	-8.19	-0.41	5.86e-15	Malaria;
CRC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	9.6	0.47	2.11e-19	Platelet count;
CRC	cis	rs2882667	0.898	rs2116789	chr5:138394262	G/T	cg09476006	chr5:138032270	NA	0.43	7.21	0.37	3.86e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7202877	0.610	rs1010631	chr16:75328590	C/G	cg03315344	chr16:75512273	CHST6	0.51	5.94	0.31	7.34e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.75	-15.13	-0.64	1.26e-39	Prostate cancer;
CRC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	0.84	7.67	0.39	2.02e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7756236	0.521	rs6930671	chr6:36625272	T/C	cg08179530	chr6:36648295	CDKN1A	0.38	5.63	0.3	3.85e-8	QRS duration;
CRC	cis	rs4731207	0.596	rs9641759	chr7:124666210	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.09	-0.32	3.23e-9	Cutaneous malignant melanoma;
CRC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.5	-10.09	-0.49	4.96e-21	Prostate cancer;
CRC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg24209194	chr3:40518798	ZNF619	0.38	5.66	0.3	3.28e-8	Renal cell carcinoma;
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.78	0.35	5.57e-11	Alzheimer's disease;
CRC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.78	-0.39	9.76e-14	Chronic sinus infection;
CRC	cis	rs12023718	0.588	rs10913585	chr1:178607694	C/T	cg00404053	chr1:178313656	RASAL2	0.6	7.54	0.38	4.56e-13	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	10.56	0.5	1.24e-22	Schizophrenia;
CRC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg07090678	chr1:91966139	CDC7	0.41	6.7	0.35	8.82e-11	Breast cancer;
CRC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg01874867	chr7:94954059	PON1	-0.52	-6.54	-0.34	2.29e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.4	-6.74	-0.35	6.94e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.92e-31	White blood cell count (basophil);
CRC	cis	rs6066835	1.000	rs6066815	chr20:47299870	T/C	cg18078177	chr20:47281410	PREX1	0.78	5.99	0.31	5.36e-9	Multiple myeloma;
CRC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.4	-5.92	-0.31	8.03e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6076065	0.723	rs2424545	chr20:23390876	A/G	cg11657817	chr20:23433608	CST11	-0.43	-6.26	-0.33	1.19e-9	Facial morphology (factor 15, philtrum width);
CRC	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.46	7.13	0.37	6.55e-12	HDL cholesterol;
CRC	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-8.03	-0.4	1.73e-14	Hepatocellular carcinoma;
CRC	cis	rs6496667	0.865	rs8039775	chr15:90883305	C/T	cg04176472	chr15:90893244	GABARAPL3	0.56	6.49	0.34	3.13e-10	Rheumatoid arthritis;
CRC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.5	-6.77	-0.35	5.92e-11	Lung cancer;
CRC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22577136	chr1:206644165	IKBKE	0.44	6.42	0.33	4.75e-10	Response to antipsychotic treatment;
CRC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	14.12	0.61	1.06e-35	Platelet count;
CRC	trans	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg11693508	chr17:37793320	STARD3	0.57	7.08	0.36	8.78e-12	Bipolar disorder;
CRC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04221910	chr5:616842	CEP72	0.41	6.77	0.35	5.99e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27316224	chr11:926106	AP2A2	0.37	6.0	0.31	5.21e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4970966	0.855	rs11204701	chr1:150662179	A/T	cg17724175	chr1:150552817	MCL1	-0.5	-6.23	-0.32	1.45e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg00603274	chr11:61596626	FADS2	-0.39	-5.63	-0.3	3.85e-8	Trans fatty acid levels;
CRC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.48	-6.26	-0.33	1.19e-9	Diabetic retinopathy;
CRC	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg00531865	chr16:30841666	NA	0.43	5.96	0.31	6.37e-9	Dementia with Lewy bodies;
CRC	cis	rs7725052	0.609	rs59384771	chr5:40447105	G/C	cg09067459	chr5:40385259	NA	-0.45	-7.36	-0.38	1.5e-12	Pediatric autoimmune diseases;
CRC	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.66	10.46	0.5	2.62e-22	Corneal astigmatism;
CRC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.67	-0.3	3.09e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.88	0.58	5.07e-31	Mean platelet volume;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg23943013	chr5:79551904	SERINC5	-0.42	-6.72	-0.35	8.03e-11	Brain structure;
CRC	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg07513332	chr6:167530253	CCR6	0.46	8.65	0.43	2.29e-16	Primary biliary cholangitis;
CRC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.82	15.1	0.64	1.62e-39	Mean platelet volume;
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.92	-0.4	3.81e-14	Intelligence (multi-trait analysis);
CRC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.61	0.34	1.58e-10	Schizophrenia;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg06470822	chr6:28175283	NA	0.77	10.97	0.52	4.39e-24	Parkinson's disease;
CRC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.12	0.32	2.66e-9	Life satisfaction;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg19478983	chr7:120590592	ING3	0.57	6.12	0.32	2.61e-9	Body mass index;
CRC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.69	-0.43	1.76e-16	Bipolar disorder and schizophrenia;
CRC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.13	0.37	6.4e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.61	9.09	0.45	9.46e-18	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26724186	chr19:3676340	PIP5K1C	-0.37	-6.13	-0.32	2.54e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11212617	0.967	rs227061	chr11:108205329	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.42	0.33	4.71e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs459193	1.000	rs30000	chr5:55803533	G/A	cg00049729	chr5:55776345	NA	0.39	5.8	0.3	1.58e-8	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.71	8.6	0.43	3.31e-16	Phospholipid levels (plasma);
CRC	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.48	7.71	0.39	1.49e-13	Schizophrenia;
CRC	cis	rs1335587	0.518	rs9513904	chr13:102107582	G/A	cg03165014	chr13:102106348	ITGBL1	-0.4	-5.88	-0.31	1e-8	Obesity-related traits;
CRC	trans	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg10756647	chr7:56101905	PSPH	0.73	7.68	0.39	1.79e-13	Diabetic kidney disease;
CRC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.6	-0.39	3.08e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.66	9.63	0.47	1.68e-19	Menopause (age at onset);
CRC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg25456477	chr12:86230367	RASSF9	-0.34	-5.85	-0.31	1.2e-8	Major depressive disorder;
CRC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.44	7.06	0.36	9.84e-12	Height;
CRC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.31	-0.42	2.57e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.86	-0.35	3.38e-11	IgG glycosylation;
CRC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.72	0.35	8e-11	Schizophrenia;
CRC	trans	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg20684491	chr1:25596433	NA	-0.44	-7.51	-0.38	5.5e-13	Erythrocyte sedimentation rate;
CRC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg01420254	chr6:26195488	NA	0.79	8.84	0.44	6.05e-17	Gout;Renal underexcretion gout;
CRC	trans	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.56	-9.86	-0.48	2.94e-20	Lung function (FVC);
CRC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg05501817	chr11:14380813	RRAS2	-0.46	-6.09	-0.32	3.17e-9	Sense of smell;
CRC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.31	0.56	6.9e-29	Height;
CRC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.89	8.89	0.44	4.11e-17	Lymphocyte counts;
CRC	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg21839984	chr17:30846986	MYO1D	-0.34	-5.88	-0.31	1e-8	Schizophrenia;
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg15145296	chr3:125709740	NA	-0.54	-7.02	-0.36	1.3e-11	Blood pressure (smoking interaction);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16062480	chr1:220219722	EPRS	-0.44	-6.53	-0.34	2.48e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs972578	1.000	rs4820500	chr22:43379373	C/G	cg01576275	chr22:43409880	NA	-0.46	-7.28	-0.37	2.52e-12	Mean platelet volume;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg03623178	chr6:28175578	NA	0.71	9.38	0.46	1.11e-18	Parkinson's disease;
CRC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.84	-10.77	-0.51	2.19e-23	Menarche (age at onset);
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg12564285	chr5:131593104	PDLIM4	0.45	7.5	0.38	5.81e-13	Breast cancer;
CRC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.92	-15.64	-0.65	1.34e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.1	0.52	1.62e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11212617	1.000	rs600931	chr11:108117335	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.26	0.33	1.23e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg11143507	chr3:125485238	NA	-0.58	-7.43	-0.38	9.65e-13	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg22244940	chr12:132335942	MMP17	-0.4	-6.09	-0.32	3.14e-9	Migraine;
CRC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg14828511	chr1:107599125	PRMT6	-0.56	-7.65	-0.39	2.3e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.09	0.61	1.36e-35	Platelet count;
CRC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.72	12.48	0.57	1.58e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23540765	chr19:1173635	SBNO2	0.41	6.73	0.35	7.66e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6662572	0.906	rs76438782	chr1:46240425	C/A	cg08644498	chr1:46502608	NA	0.47	7.53	0.38	5.05e-13	Blood protein levels;
CRC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.5	-6.75	-0.35	6.6e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6604026	0.630	rs35807969	chr1:93459069	T/A	cg17283838	chr1:93427260	FAM69A	0.46	5.97	0.31	6.21e-9	Multiple sclerosis;
CRC	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.46	-7.3	-0.37	2.19e-12	Schizophrenia;
CRC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.42	-6.87	-0.35	3.26e-11	Breast cancer;
CRC	cis	rs6840360	0.642	rs2709831	chr4:152379651	G/A	cg09659197	chr4:152720779	NA	0.33	6.61	0.34	1.57e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg10756647	chr7:56101905	PSPH	0.74	7.72	0.39	1.43e-13	Diabetic kidney disease;
CRC	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg00383909	chr3:49044727	WDR6	0.66	6.61	0.34	1.53e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg23978390	chr7:1156363	C7orf50	0.52	5.76	0.3	1.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.24	0.45	3.17e-18	Cognitive test performance;
CRC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.21	0.41	5.03e-15	Menopause (age at onset);
CRC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.28	0.64	3.24e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10924970	0.967	rs2382615	chr1:235454955	G/A	cg26050004	chr1:235667680	B3GALNT2	0.4	5.98	0.31	5.81e-9	Asthma;
CRC	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.49	-6.06	-0.32	3.8e-9	Coronary artery calcification;
CRC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.36	-5.98	-0.31	5.69e-9	Glycated hemoglobin levels;
CRC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg02766259	chr12:125626809	AACS	-0.48	-7.73	-0.39	1.29e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.43	7.39	0.38	1.26e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.44	7.57	0.38	3.9e-13	Childhood ear infection;
CRC	cis	rs16975963	0.843	rs73027451	chr19:38375666	C/T	cg15135657	chr19:38346511	NA	-0.42	-5.66	-0.3	3.26e-8	Longevity;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.99	-0.44	2.05e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.85	-0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg19624444	chr7:2048497	MAD1L1	-0.31	-5.63	-0.3	3.78e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg24375607	chr4:120327624	NA	0.47	7.37	0.38	1.36e-12	Corneal astigmatism;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg25164649	chr6:28176230	NA	0.6	8.64	0.43	2.5e-16	Cardiac Troponin-T levels;
CRC	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.44	-0.38	8.65e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs7725052	0.609	rs4496750	chr5:40452993	G/C	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-7.97	-0.4	2.72e-14	Major depressive disorder;
CRC	cis	rs2811415	0.597	rs998392	chr3:127768329	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.65	-0.3	3.49e-8	Lung function (FEV1/FVC);
CRC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.89	0.4	4.58e-14	Colorectal cancer;
CRC	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	5.73	0.3	2.28e-8	Joint mobility (Beighton score);
CRC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.53	8.47	0.42	8.53e-16	Intelligence (multi-trait analysis);
CRC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.56	8.95	0.44	2.7e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.7	9.69	0.47	1.09e-19	Breast cancer;
CRC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.88e-9	Hemoglobin concentration;
CRC	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.85	-0.35	3.54e-11	Coronary artery disease;
CRC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.48	7.84	0.4	6.5e-14	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14223017	chr19:2151266	AP3D1	0.45	7.16	0.37	5.31e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07165851	chr6:158734300	TULP4	0.62	7.89	0.4	4.38e-14	Height;
CRC	cis	rs11955398	0.647	rs57521726	chr5:59984897	A/T	cg02684056	chr5:59996105	DEPDC1B	0.4	5.85	0.31	1.21e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg11843238	chr5:131593191	PDLIM4	0.42	7.8	0.4	8.18e-14	Breast cancer;
CRC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.88	-0.44	4.53e-17	Aortic root size;
CRC	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg05784532	chr1:230284198	GALNT2	0.44	6.2	0.32	1.65e-9	Coronary artery disease;
CRC	cis	rs7215564	0.908	rs35253080	chr17:78700167	G/A	cg09596252	chr17:78655493	RPTOR	0.6	6.22	0.32	1.51e-9	Myopia (pathological);
CRC	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.53	7.82	0.4	7.03e-14	Intelligence (multi-trait analysis);
CRC	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg08347473	chr17:78092826	GAA	-0.35	-5.82	-0.31	1.43e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-9.59	-0.47	2.24e-19	Chronic sinus infection;
CRC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04733989	chr22:42467013	NAGA	0.41	5.81	0.3	1.51e-8	Cognitive function;
CRC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.57e-16	Chronic sinus infection;
CRC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.23	-0.32	1.41e-9	Arsenic metabolism;
CRC	cis	rs9463078	0.838	rs9395066	chr6:45095163	A/C	cg25276700	chr6:44698697	NA	-0.28	-6.81	-0.35	4.55e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.52	8.08	0.41	1.27e-14	Testicular germ cell tumor;
CRC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.51	-6.8	-0.35	5e-11	Tourette syndrome;
CRC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-7.13	-0.37	6.47e-12	Menarche (age at onset);
CRC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg06238570	chr21:40685208	BRWD1	0.71	10.1	0.49	4.5e-21	Cognitive function;
CRC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.07	0.52	1.98e-24	Monocyte percentage of white cells;
CRC	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.61	9.06	0.45	1.15e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.44	-5.93	-0.31	7.75e-9	Renal function-related traits (BUN);
CRC	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.92	-19.6	-0.73	3.23e-57	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.62	9.69	0.47	1.07e-19	Corneal astigmatism;
CRC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.65	-10.22	-0.49	1.83e-21	Height;
CRC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.39	-6.23	-0.33	1.39e-9	Blood metabolite levels;
CRC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg25767906	chr1:53392781	SCP2	0.36	5.79	0.3	1.63e-8	Monocyte count;
CRC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg13072238	chr3:49761600	GMPPB	-0.51	-5.96	-0.31	6.64e-9	Menarche (age at onset);
CRC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.02	-0.4	1.88e-14	Intelligence (multi-trait analysis);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg15113064	chr3:124774855	HEG1	0.4	6.11	0.32	2.82e-9	Interleukin-6 levels;
CRC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.54	8.58	0.43	3.75e-16	Coronary artery disease;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg11586124	chr12:58259160	NA	0.38	6.05	0.32	3.88e-9	Body mass index;
CRC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg12273811	chr6:28175739	NA	0.55	5.86	0.31	1.12e-8	Depression;
CRC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.87	0.31	1.08e-8	IgG glycosylation;
CRC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg13072238	chr3:49761600	GMPPB	-0.52	-5.92	-0.31	8.06e-9	Menarche (age at onset);
CRC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9816226	0.591	rs10513801	chr3:185822353	T/G	cg00760338	chr3:185826511	ETV5	-0.71	-5.84	-0.31	1.23e-8	Obesity;Body mass index;
CRC	cis	rs802075	1.000	rs360559	chr6:49659871	A/C	cg20364632	chr6:49636226	NA	-0.36	-5.87	-0.31	1.05e-8	Bone mineral density (hip) and age at menarche;
CRC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	9.44	0.46	7.27e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21250466	chr4:854474	GAK	-0.38	-5.99	-0.31	5.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.57	7.9	0.4	4.36e-14	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13063040	chr8:145669623	NFKBIL2	0.45	7.42	0.38	9.91e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.56	-0.34	2.04e-10	Lymphocyte counts;
CRC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.72	-0.3	2.4e-8	Type 2 diabetes;
CRC	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg27534772	chr1:16042836	PLEKHM2	0.44	7.44	0.38	8.59e-13	Systolic blood pressure;
CRC	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.36	6.07	0.32	3.58e-9	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.58	-7.62	-0.39	2.65e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-20.62	-0.75	3.25e-61	Height;
CRC	trans	rs10242455	0.702	rs59574285	chr7:99236151	C/T	cg09045935	chr12:6379348	NA	0.92	6.84	0.35	3.8e-11	Blood metabolite levels;
CRC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	7.58	0.39	3.61e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.61	11.58	0.54	3.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12618769	0.597	rs3754879	chr2:99164541	G/T	cg18455616	chr2:99124870	INPP4A	0.36	5.92	0.31	8.23e-9	Bipolar disorder;
CRC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.54	-0.38	4.68e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg18904891	chr8:8559673	CLDN23	0.55	7.65	0.39	2.18e-13	Obesity-related traits;
CRC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.65	9.52	0.46	3.85e-19	Total body bone mineral density;
CRC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.62	7.6	0.39	3.2e-13	Menarche (age at onset);
CRC	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg13385794	chr1:248469461	NA	0.4	7.11	0.36	7.23e-12	Common traits (Other);
CRC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.6	8.52	0.42	6.01e-16	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16226300	chr6:133136135	RPS12;SNORD101	0.46	7.23	0.37	3.44e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg12273811	chr6:28175739	NA	0.58	6.02	0.31	4.78e-9	Lung cancer in ever smokers;
CRC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.06	9.98	0.48	1.12e-20	Opioid sensitivity;
CRC	cis	rs3764400	0.567	rs12946208	chr17:46312129	G/A	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.93	0.36	2.24e-11	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14699228	chr3:49823994	IP6K1	0.36	6.12	0.32	2.71e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg15226275	chr6:116381976	FRK	0.3	8.52	0.42	6e-16	Cholesterol, total;LDL cholesterol;
CRC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.65	6.93	0.36	2.21e-11	Axial length;
CRC	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.36	5.62	0.3	4.01e-8	Educational attainment;
CRC	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.08	0.36	8.86e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.22	-0.32	1.47e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03923535	chr7:1197113	ZFAND2A	0.76	11.65	0.54	1.65e-26	Longevity;Endometriosis;
CRC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg15605315	chr1:45957053	TESK2	-0.39	-6.11	-0.32	2.79e-9	Red blood cell count;Reticulocyte count;
CRC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.64	10.94	0.52	5.92e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg01493522	chr13:37497338	NA	-0.5	-6.9	-0.36	2.73e-11	Coronary artery disease;
CRC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg27661571	chr11:113659931	NA	-0.94	-10.89	-0.51	8.63e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9403521	1.000	rs6915784	chr6:143984268	A/C	cg18240653	chr6:144019428	PHACTR2	-0.49	-5.79	-0.3	1.61e-8	Obesity-related traits;
CRC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.59	8.46	0.42	8.83e-16	Gut microbiome composition (summer);
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg15845792	chr6:28175446	NA	0.99	13.41	0.59	5.26e-33	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14825729	chr4:147866863	TTC29	0.36	6.63	0.34	1.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg17948913	chr5:572064	NA	0.56	6.25	0.33	1.28e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.16	0.52	9.37e-25	Prudent dietary pattern;
CRC	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.48	7.91	0.4	3.98e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15065896	chr3:37285038	GOLGA4	0.47	6.73	0.35	7.49e-11	Response to antipsychotic treatment;
CRC	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.85	-15.77	-0.66	4.18e-42	Multiple myeloma;
CRC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.61	8.94	0.44	2.9e-17	Response to temozolomide;
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.91	-17.1	-0.69	2.31e-47	Intelligence (multi-trait analysis);
CRC	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	1.23	17.7	0.7	1.06e-49	IgG glycosylation;
CRC	trans	rs9341835	0.772	rs9449233	chr6:64138234	G/T	cg13657004	chr13:50234944	EBPL	-0.37	-6.22	-0.32	1.48e-9	Schizophrenia;
CRC	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.45	6.79	0.35	5.1e-11	Neutrophil percentage of white cells;
CRC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.92	-16.92	-0.68	1.2e-46	Height;
CRC	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.52	-8.73	-0.43	1.35e-16	Congenital heart disease (maternal effect);
CRC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.07	0.32	3.62e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg26721908	chr21:47610096	LSS	-0.41	-6.46	-0.34	3.83e-10	Testicular germ cell tumor;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22769031	chr20:35580195	SAMHD1	0.44	6.28	0.33	1.08e-9	Response to antipsychotic treatment;
CRC	cis	rs672059	1.000	rs546183	chr1:183157753	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.5	7.29	0.37	2.38e-12	Hypertriglyceridemia;
CRC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg15309053	chr8:964076	NA	-0.35	-6.65	-0.34	1.25e-10	Schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27343303	chr11:34380546	NA	-0.49	-6.22	-0.32	1.49e-9	Diisocyanate-induced asthma;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg14190817	chr9:128003556	HSPA5	-0.5	-5.99	-0.31	5.63e-9	Optic disc area;
CRC	cis	rs17067123	0.614	rs1036767	chr4:180068417	G/A	cg26610307	chr4:180072759	NA	-0.56	-6.76	-0.35	6.47e-11	Response to hepatitis C treatment;
CRC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.19	0.52	7.76e-25	Prudent dietary pattern;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15397725	chr14:53019133	TXNDC16;GPR137C	0.5	7.12	0.37	6.67e-12	Response to antipsychotic treatment;
CRC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg03388025	chr16:89894329	SPIRE2	0.36	6.88	0.35	3.11e-11	Vitiligo;
CRC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.74	-9.38	-0.46	1.14e-18	Initial pursuit acceleration;
CRC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg10494973	chr17:80897199	TBCD	-0.38	-5.92	-0.31	7.93e-9	Breast cancer;
CRC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.17	-0.41	6.77e-15	Alzheimer's disease (late onset);
CRC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg23461800	chr14:103021989	NA	0.68	7.36	0.38	1.46e-12	Platelet count;
CRC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.59	-0.34	1.78e-10	Blood metabolite levels;
CRC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.33	0.49	7.43e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.44	0.33	4.12e-10	Lung cancer;
CRC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.49	-0.38	6.42e-13	Triglycerides;
CRC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	18.53	0.71	5.55e-53	Cognitive ability;
CRC	cis	rs6662572	0.737	rs7512448	chr1:46449291	A/G	cg08644498	chr1:46502608	NA	-0.46	-7.3	-0.37	2.16e-12	Blood protein levels;
CRC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg20203395	chr5:56204925	C5orf35	-0.4	-5.65	-0.3	3.51e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg00387323	chr7:6746715	ZNF12	0.61	6.03	0.32	4.31e-9	Hematocrit;Hemoglobin concentration;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg20807030	chr8:67525572	MYBL1	-0.58	-6.37	-0.33	6.46e-10	Lung adenocarcinoma;
CRC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-9.24	-0.45	3.18e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg00318322	chr16:67708822	GFOD2	-0.3	-5.74	-0.3	2.11e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.66	-7.74	-0.39	1.21e-13	Body mass index;
CRC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg00428638	chr19:7224713	INSR	0.98	20.42	0.75	1.98e-60	Hypothyroidism;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12172441	chr6:28176163	NA	0.54	6.99	0.36	1.58e-11	Parkinson's disease;
CRC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.39	5.89	0.31	9.49e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.66	-10.68	-0.51	4.84e-23	Cognitive function;
CRC	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg23234261	chr14:55582407	NA	-0.29	-5.7	-0.3	2.71e-8	Protein biomarker;
CRC	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.49	-0.38	6.43e-13	Inflammatory bowel disease;
CRC	cis	rs4499344	0.664	rs259284	chr19:33163262	T/C	cg08127369	chr19:33164662	ANKRD27	0.39	6.01	0.31	5.05e-9	Mean platelet volume;
CRC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.22	0.67	6.67e-44	Chronic sinus infection;
CRC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	7.85	0.4	5.8e-14	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23002658	chr20:52824474	PFDN4	0.46	6.59	0.34	1.73e-10	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.75	10.99	0.52	3.83e-24	Schizophrenia;
CRC	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg18806716	chr10:30721971	MAP3K8	-0.46	-6.98	-0.36	1.64e-11	Inflammatory bowel disease;
CRC	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg09659197	chr4:152720779	NA	0.4	8.44	0.42	1.05e-15	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18301423	chr5:131593218	PDLIM4	0.44	8.18	0.41	6.25e-15	Acylcarnitine levels;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg21784768	chr11:537496	LRRC56	-0.72	-6.87	-0.35	3.26e-11	Body mass index;
CRC	cis	rs1223397	0.938	rs17767967	chr6:13282067	C/T	cg06879394	chr6:13274151	PHACTR1	0.53	6.28	0.33	1.06e-9	Blood pressure;
CRC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.96	-0.31	6.32e-9	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04128394	chr6:86351353	SYNCRIP	0.43	6.35	0.33	7.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.77	7.8	0.4	8.13e-14	Diabetic retinopathy;
CRC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.96	0.4	2.84e-14	Height;
CRC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.52	10.24	0.49	1.58e-21	Alcoholic chronic pancreatitis;
CRC	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg12458913	chr13:53173898	NA	0.54	8.48	0.42	7.8e-16	Lewy body disease;
CRC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-8.73	-0.43	1.29e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-0.9	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.19e-9	Diastolic blood pressure;
CRC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.52	0.34	2.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	0.65	6.98	0.36	1.67e-11	Prostate cancer;
CRC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg22723502	chr6:26240528	HIST1H4F	0.41	6.33	0.33	8.16e-10	Gout;Renal underexcretion gout;
CRC	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	7.31	0.37	2.02e-12	Blood protein levels;
CRC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg23996704	chr18:44553084	KATNAL2	0.3	5.89	0.31	9.68e-9	Personality dimensions;
CRC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg10760299	chr15:45669010	GATM	0.52	8.23	0.41	4.56e-15	Homoarginine levels;
CRC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.34	0.42	2.04e-15	Arsenic metabolism;
CRC	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg22777020	chr22:31556080	RNF185	0.54	6.35	0.33	7.06e-10	Colorectal cancer;
CRC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.53	7.19	0.37	4.35e-12	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	1.0	15.95	0.66	8.1e-43	Primary sclerosing cholangitis;
CRC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.69	-0.47	1.06e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg17375396	chr11:67202808	RPS6KB2	0.33	5.65	0.3	3.4e-8	Mean corpuscular volume;
CRC	cis	rs9549328	0.527	rs9549622	chr13:113640064	A/C	cg17524180	chr13:113633600	MCF2L	-0.5	-6.23	-0.32	1.47e-9	Systolic blood pressure;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04915463	chr1:162039957	NOS1AP	-0.52	-6.28	-0.33	1.05e-9	Diisocyanate-induced asthma;
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg07404485	chr7:94953653	PON1	-0.45	-6.04	-0.32	4.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.43	6.29	0.33	1.04e-9	Obesity-related traits;
CRC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.07	-0.36	9.16e-12	QT interval;
CRC	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg01639898	chr1:32083012	HCRTR1	0.33	7.03	0.36	1.23e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.94	0.31	7.07e-9	Breast cancer;
CRC	cis	rs11030122	0.673	rs11030639	chr11:4039056	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-7.76	-0.39	1.06e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg23260525	chr10:116636907	FAM160B1	0.32	6.87	0.35	3.2e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.77	11.3	0.53	3.08e-25	Breast cancer;
CRC	cis	rs10905065	0.648	rs4237365	chr10:5821484	T/G	cg11519256	chr10:5708881	ASB13	-0.43	-6.16	-0.32	2.1e-9	Menopause (age at onset);
CRC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg24505167	chr7:1915268	MAD1L1	-0.34	-5.62	-0.3	4.08e-8	Neuroticism;
CRC	trans	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg06206626	chr22:26825900	ASPHD2	0.41	6.09	0.32	3.15e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg17321639	chr7:2759063	NA	-0.47	-6.2	-0.32	1.69e-9	Height;
CRC	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.57	8.28	0.42	3.18e-15	Uric acid levels;
CRC	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	0.82	8.42	0.42	1.21e-15	Gut microbiota (bacterial taxa);
CRC	cis	rs1983891	0.909	rs4714482	chr6:41528199	G/A	cg20194872	chr6:41519635	FOXP4	0.4	5.75	0.3	2.04e-8	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21685266	chr3:184971652	EHHADH	0.41	6.0	0.31	5.22e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19586645	chr17:73266642	MIF4GD	0.47	6.24	0.33	1.35e-9	Thyroid stimulating hormone;
CRC	trans	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg10756647	chr7:56101905	PSPH	0.71	7.42	0.38	1.03e-12	Diabetic kidney disease;
CRC	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.6	10.2	0.49	2.14e-21	Mean corpuscular volume;
CRC	cis	rs883565	0.654	rs6779880	chr3:39022926	G/T	cg01426195	chr3:39028469	NA	0.5	7.89	0.4	4.43e-14	Handedness;
CRC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.6	6.33	0.33	8.1e-10	Axial length;
CRC	cis	rs3018066	0.640	rs7658701	chr4:107049150	C/T	cg01869342	chr4:106983673	TBCK	0.47	6.11	0.32	2.83e-9	Cancer;
CRC	cis	rs6694672	0.717	rs7539642	chr1:197063841	A/G	cg13682187	chr1:196946512	CFHR5	0.47	7.57	0.39	3.82e-13	Asthma;
CRC	cis	rs7113874	0.569	rs9737401	chr11:8595652	C/T	cg02811074	chr11:8615871	STK33	-0.35	-6.02	-0.31	4.77e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg18833306	chr6:118973337	C6orf204	0.44	5.74	0.3	2.12e-8	Diastolic blood pressure;
CRC	cis	rs6496667	0.600	rs7174198	chr15:91083186	C/T	cg04176472	chr15:90893244	GABARAPL3	0.5	7.39	0.38	1.2e-12	Rheumatoid arthritis;
CRC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.49	6.7	0.35	9.31e-11	Type 1 diabetes nephropathy;
CRC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-8.22	-0.41	4.66e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7274811	0.901	rs17404047	chr20:32305781	A/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-6.08	-0.32	3.4e-9	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03929741	chr13:107187681	EFNB2	0.35	6.08	0.32	3.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.43	-8.54	-0.43	4.94e-16	Alcohol dependence;
CRC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.26	-17.0	-0.68	5.78e-47	Breast cancer;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg15763984	chr4:1342303	KIAA1530	-0.35	-6.0	-0.31	5.34e-9	Obesity-related traits;
CRC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	11.94	0.55	1.54e-27	Platelet count;
CRC	trans	rs6600671	1.000	rs1986111	chr1:121204788	C/T	cg09829573	chr1:144692074	NBPF9	-0.42	-6.2	-0.32	1.68e-9	Hip geometry;
CRC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg22561889	chr6:118971681	C6orf204	0.51	6.6	0.34	1.68e-10	Diastolic blood pressure;
CRC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg12845895	chr18:77676008	PQLC1	-0.39	-5.73	-0.3	2.3e-8	Schizophrenia;
CRC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13047869	chr3:10149882	C3orf24	0.52	6.87	0.35	3.26e-11	Alzheimer's disease;
CRC	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg11547950	chr5:77652471	NA	-0.49	-7.08	-0.36	9e-12	Triglycerides;
CRC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg06462663	chr19:18546047	ISYNA1	0.48	7.26	0.37	2.73e-12	Breast cancer;
CRC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.69	12.05	0.55	6.09e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.596	rs10252579	chr7:124637106	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.17	-0.32	2.01e-9	Cutaneous malignant melanoma;
CRC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.64	-0.39	2.47e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg24130564	chr14:104152367	KLC1	0.43	5.75	0.3	2.04e-8	Intelligence (multi-trait analysis);
CRC	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg06204229	chr3:52865917	ITIH4	0.55	7.59	0.39	3.41e-13	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs17756712	0.725	rs9504483	chr6:620222	C/T	cg16786516	chr6:604617	EXOC2	0.48	6.27	0.33	1.1e-9	Vertical cup-disc ratio;
CRC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-5.87	-0.31	1.08e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.36	-0.42	1.76e-15	Asthma (sex interaction);
CRC	cis	rs3018066	0.867	rs3133168	chr4:107252245	G/A	cg01869342	chr4:106983673	TBCK	0.36	5.61	0.3	4.25e-8	Cancer;
CRC	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg23254163	chr1:152506842	NA	0.45	8.92	0.44	3.34e-17	Hair morphology;
CRC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.89	-0.31	9.72e-9	Blood pressure (smoking interaction);
CRC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.65	-10.01	-0.48	9.21e-21	Corneal astigmatism;
CRC	cis	rs7671266	0.611	rs10939833	chr4:10309537	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.09	-0.32	3.19e-9	Cardiovascular disease risk factors;
CRC	cis	rs7804356	0.906	rs114978183	chr7:26852740	A/T	cg03456212	chr7:26904342	SKAP2	-0.52	-5.68	-0.3	2.98e-8	Type 1 diabetes;
CRC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.83	14.29	0.62	2.24e-36	Blood protein levels;
CRC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.31	0.33	8.81e-10	Life satisfaction;
CRC	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.44	-0.38	8.97e-13	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-6.18	-0.32	1.85e-9	Diabetic kidney disease;
CRC	trans	rs11225569	0.539	rs72987444	chr11:103314612	A/G	cg01615333	chr12:127765195	NA	-0.63	-5.97	-0.31	6.2e-9	Diisocyanate-induced asthma;
CRC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg16447950	chr5:562315	NA	-0.81	-10.49	-0.5	2.1e-22	Obesity-related traits;
CRC	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.51	0.42	6.09e-16	Mean corpuscular volume;
CRC	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	15.32	0.65	2.24e-40	Mean corpuscular hemoglobin;
CRC	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg00717180	chr2:96193071	NA	-0.36	-5.99	-0.31	5.51e-9	HDL cholesterol;
CRC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg21784768	chr11:537496	LRRC56	-0.68	-6.51	-0.34	2.8e-10	Body mass index;
CRC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.9	0.31	8.88e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-7.1	-0.36	7.66e-12	Schizophrenia;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.0	-23.15	-0.79	4.87e-71	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg15786705	chr6:28176104	NA	0.81	11.69	0.54	1.25e-26	Depression;
CRC	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.48	7.29	0.37	2.38e-12	Carotid intima media thickness;
CRC	cis	rs9648716	0.608	rs1267622	chr7:140528317	A/G	cg17554604	chr7:140774522	NA	0.44	5.9	0.31	8.81e-9	Type 2 diabetes;
CRC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg18944383	chr4:111397179	ENPEP	-0.48	-6.55	-0.34	2.19e-10	Height;
CRC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.46	6.98	0.36	1.64e-11	Corneal astigmatism;
CRC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.46	6.51	0.34	2.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.47	5.95	0.31	7.05e-9	Systolic blood pressure;
CRC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.49	9.9	0.48	2.1e-20	Prostate cancer;
CRC	cis	rs11212617	0.967	rs228608	chr11:108088900	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.32	0.33	8.58e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19309549	chr1:100435460	SLC35A3	0.46	6.59	0.34	1.79e-10	Response to antipsychotic treatment;
CRC	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.63	8.58	0.43	3.74e-16	Uric acid levels;
CRC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.19	0.45	4.44e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.96	-16.68	-0.68	1.11e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.67	0.39	1.95e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.66	-9.74	-0.47	7.06e-20	Waist circumference;Body mass index;
CRC	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	8.76	0.43	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg21770322	chr7:97807741	LMTK2	0.86	19.38	0.73	2.28e-56	Breast cancer;
CRC	trans	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg18335740	chr13:41363409	SLC25A15	-0.53	-8.25	-0.41	3.83e-15	Lewy body disease;
CRC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.86	0.58	5.89e-31	Alzheimer's disease;
CRC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg03315344	chr16:75512273	CHST6	0.52	6.17	0.32	1.97e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg10217327	chr6:118973057	C6orf204	0.52	5.64	0.3	3.65e-8	Diastolic blood pressure;
CRC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg11503833	chr11:492997	NA	0.44	5.66	0.3	3.31e-8	Systemic lupus erythematosus;
CRC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.25	-6.01	-0.31	4.84e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9659323	0.612	rs10923721	chr1:119542187	A/G	cg26570165	chr1:119541833	NA	-0.43	-7.19	-0.37	4.49e-12	Body mass index;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20049727	chr4:1981032	WHSC1	0.54	6.03	0.32	4.47e-9	Interleukin-4 levels;
CRC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg03037974	chr15:76606532	NA	0.67	11.41	0.53	1.28e-25	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg03339077	chr11:47165057	C11orf49	0.43	6.11	0.32	2.74e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.65	9.47	0.46	5.59e-19	Subjective well-being;
CRC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.54	-0.34	2.33e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.94	9.72	0.47	8.71e-20	Gut microbiota (bacterial taxa);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18473153	chr3:49726928	MST1;RNF123	0.44	6.06	0.32	3.83e-9	Anxiety disorder;
CRC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.01	-0.48	9.08e-21	Menarche (age at onset);
CRC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.78	-9.35	-0.46	1.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	13.7	0.6	4.11e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.52	-7.24	-0.37	3.1e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.73	-0.35	7.69e-11	Major depressive disorder;
CRC	cis	rs1178968	0.901	rs757937	chr7:72750159	C/T	cg25889504	chr7:72793014	NA	0.5	5.79	0.3	1.67e-8	Triglyceride levels;
CRC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.69	9.46	0.46	6.22e-19	Heart rate;
CRC	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg20936604	chr3:58311152	NA	-0.74	-6.95	-0.36	1.93e-11	Cholesterol, total;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04827747	chr7:134855666	C7orf49	0.4	6.03	0.32	4.41e-9	Schizophrenia;
CRC	cis	rs9847710	0.733	rs11923593	chr3:53088790	A/G	cg15147215	chr3:52552868	STAB1	0.42	5.67	0.3	3.15e-8	Ulcerative colitis;
CRC	cis	rs847649	0.924	rs6960428	chr7:102589706	C/G	cg18108683	chr7:102477205	FBXL13	0.57	9.33	0.46	1.65e-18	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.46	7.18	0.37	4.55e-12	Calcium levels;
CRC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.9	-0.4	4.34e-14	Intelligence (multi-trait analysis);
CRC	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.42	-6.58	-0.34	1.82e-10	Monocyte count;
CRC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.82	0.44	6.66e-17	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg25547332	chr5:131281432	NA	-0.39	-5.73	-0.3	2.27e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.39	5.8	0.3	1.59e-8	Pulse pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23224356	chr2:98206733	ANKRD36B	0.41	6.53	0.34	2.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.9	-0.4	4.34e-14	Vitiligo;
CRC	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg24289452	chr6:170231220	NA	-0.6	-6.59	-0.34	1.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13198984	chr17:80129470	CCDC57	-0.45	-7.83	-0.4	6.67e-14	Life satisfaction;
CRC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.89	12.19	0.56	1.87e-28	Height;
CRC	trans	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.49	6.17	0.32	2.02e-9	Red blood cell count;
CRC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg10263370	chr3:44754102	ZNF502	-0.38	-6.46	-0.34	3.84e-10	Depressive symptoms;
CRC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.72	-12.58	-0.57	6.62e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.55	-6.77	-0.35	6.06e-11	Diastolic blood pressure;
CRC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg05044414	chr3:183734942	ABCC5	0.47	8.18	0.41	6.18e-15	Anterior chamber depth;
CRC	cis	rs1050631	0.564	rs12185396	chr18:33738496	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.4	6.23	0.32	1.45e-9	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.88	-18.86	-0.72	2.61e-54	Longevity;
CRC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.92	-16.26	-0.67	4.73e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs3790844	0.876	rs3790845	chr1:200006861	C/T	cg07208853	chr1:200005219	NR5A2	0.36	8.93	0.44	3.07e-17	Pancreatic cancer;
CRC	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.64	10.33	0.49	7.46e-22	Corneal astigmatism;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11192808	chr8:101170185	SPAG1	0.42	6.89	0.36	2.9e-11	Obesity-related traits;
CRC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.41	8.02	0.4	1.88e-14	Mean corpuscular volume;
CRC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	5.98	0.31	5.86e-9	Neutrophil percentage of white cells;
CRC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.57	-7.62	-0.39	2.72e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg13880726	chr7:1868755	MAD1L1	-0.43	-5.71	-0.3	2.59e-8	Bipolar disorder;
CRC	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg10437265	chr15:77819839	NA	0.67	11.95	0.55	1.39e-27	Type 2 diabetes;
CRC	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg10756647	chr7:56101905	PSPH	0.77	7.97	0.4	2.55e-14	Diabetic kidney disease;
CRC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	7.89	0.4	4.53e-14	Platelet count;
CRC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21028142	chr17:79581711	NPLOC4	-0.34	-7.12	-0.37	6.79e-12	Eye color traits;
CRC	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg12658694	chr1:38397304	INPP5B	-0.53	-7.26	-0.37	2.81e-12	Coronary artery disease;
CRC	cis	rs699	0.556	rs2478520	chr1:230867197	G/A	cg07502417	chr1:230849801	AGT	0.29	5.73	0.3	2.26e-8	Coronary artery disease;
CRC	cis	rs728616	0.614	rs3934643	chr10:81736817	G/A	cg05935833	chr10:81318306	SFTPA2	-0.48	-5.74	-0.3	2.18e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg10217327	chr6:118973057	C6orf204	0.47	5.6	0.3	4.45e-8	Diastolic blood pressure;
CRC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.75	0.3	2.04e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.7	11.16	0.52	9.5e-25	Response to diuretic therapy;
CRC	cis	rs7605827	0.930	rs7606850	chr2:15678250	T/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.32	-0.42	2.42e-15	Aortic root size;
CRC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-8.4	-0.42	1.39e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg15654264	chr1:150340011	RPRD2	0.42	6.19	0.32	1.76e-9	Migraine;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10699215	chr4:10118516	WDR1	0.5	7.02	0.36	1.26e-11	Anxiety disorder;
CRC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg24140574	chr1:16342155	HSPB7	0.43	5.75	0.3	2.04e-8	Dilated cardiomyopathy;
CRC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-21.02	-0.76	8.53e-63	Primary sclerosing cholangitis;
CRC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.49	-9.33	-0.46	1.65e-18	Reticulocyte fraction of red cells;
CRC	cis	rs7546094	0.935	rs6700673	chr1:113157054	C/T	cg22162597	chr1:113214053	CAPZA1	0.44	6.03	0.32	4.39e-9	Platelet distribution width;
CRC	cis	rs9487051	0.646	rs55677234	chr6:109621974	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.66	-0.3	3.23e-8	Reticulocyte fraction of red cells;
CRC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.68	-10.91	-0.52	7.58e-24	Cognitive function;
CRC	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg17133734	chr15:86042851	AKAP13	-0.43	-6.61	-0.34	1.56e-10	Coronary artery disease;
CRC	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.59	-7.14	-0.37	6.03e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs16852403	0.583	rs10913506	chr1:178092233	G/A	cg00404053	chr1:178313656	RASAL2	0.6	7.69	0.39	1.74e-13	Childhood ear infection;
CRC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.29	-0.37	2.38e-12	Lymphocyte counts;
CRC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg00343986	chr7:65444356	GUSB	0.48	7.0	0.36	1.42e-11	Aortic root size;
CRC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.79	-0.35	5.16e-11	Acylcarnitine levels;
CRC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.03	-0.32	4.34e-9	Renal cell carcinoma;
CRC	cis	rs7074356	0.688	rs7898568	chr10:82183531	G/A	cg27171509	chr10:82033454	MAT1A	-0.36	-6.5	-0.34	2.9e-10	Borderline personality disorder;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	6.6	0.34	1.64e-10	Lymphocyte counts;
CRC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg15786705	chr6:28176104	NA	0.65	6.92	0.36	2.38e-11	Depression;
CRC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	6.56	0.34	2.11e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2346160	0.899	rs206972	chr6:167689552	C/T	cg27333441	chr6:167680455	NA	-0.34	-5.88	-0.31	1.02e-8	Parental extreme longevity (95 years and older);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24269434	chr3:126076368	KLF15	0.42	6.78	0.35	5.58e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11637544	chr11:66886765	KDM2A	-0.51	-6.12	-0.32	2.63e-9	Monocyte percentage of white cells;
CRC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.39	-0.59	5.93e-33	Blood trace element (Zn levels);
CRC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.67	7.4	0.38	1.13e-12	Vitiligo;
CRC	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.58	5.64	0.3	3.72e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg17298326	chr8:142245477	NA	0.39	6.06	0.32	3.79e-9	Immature fraction of reticulocytes;
CRC	cis	rs1656402	0.861	rs1729255	chr2:233429196	C/G	cg03852847	chr2:233439513	NA	0.41	6.79	0.35	5.34e-11	Non-small cell lung cancer (survival);
CRC	cis	rs3736485	0.764	rs55805232	chr15:51896598	C/A	cg08986416	chr15:51914746	DMXL2	-0.49	-6.88	-0.35	2.96e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.38	6.1	0.32	3.02e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303542	0.694	rs4793854	chr17:46572133	A/G	cg04904318	chr17:46607828	HOXB1	0.43	5.66	0.3	3.37e-8	Ovarian cancer;Epithelial ovarian cancer;
CRC	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg21153622	chr11:89784906	NA	-0.45	-7.18	-0.37	4.68e-12	HDL cholesterol;
CRC	cis	rs2637266	0.514	rs11516642	chr10:78473522	G/T	cg18941641	chr10:78392320	NA	-0.33	-5.77	-0.3	1.87e-8	Pulmonary function;
CRC	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.52	7.29	0.37	2.27e-12	Body mass index (adult);
CRC	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg08847533	chr14:75593920	NEK9	0.82	12.56	0.57	8.1e-30	Height;
CRC	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg21506790	chr11:5277210	HBG2	0.36	5.84	0.31	1.27e-8	Hemoglobin levels;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12963246	chr6:28129442	ZNF389	0.46	5.66	0.3	3.32e-8	Depression;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.03	-10.73	-0.51	3.17e-23	Body mass index;
CRC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.66	-0.34	1.16e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.38	-0.5	5.03e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9992667	0.955	rs28510735	chr4:38613941	G/A	cg19726192	chr4:38663646	FLJ13197	-0.59	-7.59	-0.39	3.27e-13	Eosinophil percentage of granulocytes;
CRC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg23533926	chr12:111358616	MYL2	-0.56	-8.67	-0.43	2e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg00666640	chr1:248458726	OR2T12	-0.41	-7.55	-0.38	4.34e-13	Common traits (Other);
CRC	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.6	0.34	1.68e-10	Body mass index;
CRC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.1	-0.49	4.49e-21	Height;
CRC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.25	-0.49	1.36e-21	Height;
CRC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	10.68	0.51	4.6e-23	Motion sickness;
CRC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.71	-10.51	-0.5	1.77e-22	Longevity;
CRC	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.59	-8.11	-0.41	1.02e-14	Body mass index;
CRC	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg04202892	chr2:111875749	ACOXL	0.47	7.64	0.39	2.32e-13	Chronic lymphocytic leukemia;
CRC	cis	rs6743376	0.556	rs6733859	chr2:113819382	C/T	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06544989	chr22:39130855	UNC84B	0.47	7.52	0.38	5.36e-13	Menopause (age at onset);
CRC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-8.36	-0.42	1.83e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.62	9.46	0.46	5.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.75	7.34	0.37	1.73e-12	Diabetic retinopathy;
CRC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.58	10.35	0.5	6.51e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	8.86	0.44	5.19e-17	Systolic blood pressure;
CRC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.36	6.0	0.31	5.26e-9	DNA methylation (variation);
CRC	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.09	-15.35	-0.65	1.82e-40	Exhaled nitric oxide output;
CRC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.39	-7.05	-0.36	1.05e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.55	7.71	0.39	1.55e-13	Melanoma;
CRC	trans	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg18335740	chr13:41363409	SLC25A15	0.48	7.05	0.36	1.07e-11	Lewy body disease;
CRC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.4	-6.69	-0.35	9.74e-11	Educational attainment;
CRC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg24163568	chr5:669837	TPPP	-0.43	-6.87	-0.35	3.18e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11645453	chr3:52864694	ITIH4	0.34	6.28	0.33	1.04e-9	Electroencephalogram traits;
CRC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	cis	rs7680126	0.596	rs4698029	chr4:10312798	C/G	cg11266682	chr4:10021025	SLC2A9	0.42	6.55	0.34	2.26e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs365302	1.000	rs445227	chr6:159645888	A/G	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.76e-10	Coronary heart disease;
CRC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg03037974	chr15:76606532	NA	-0.48	-6.89	-0.36	2.8e-11	Blood metabolite levels;
CRC	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg21155852	chr7:2048760	MAD1L1	-0.4	-5.62	-0.3	4.03e-8	Bipolar disorder;
CRC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.4	-5.73	-0.3	2.32e-8	Menarche (age at onset);
CRC	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.73	-15.87	-0.66	1.64e-42	Intelligence (multi-trait analysis);
CRC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	0.92	11.23	0.53	5.4e-25	Hip circumference adjusted for BMI;
CRC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.93	-15.18	-0.64	8.34e-40	Longevity;
CRC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.9	-10.05	-0.48	6.51e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg03609598	chr5:56110824	MAP3K1	0.75	8.73	0.43	1.31e-16	Initial pursuit acceleration;
CRC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.88	-0.31	9.98e-9	Lung cancer;
CRC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg21466736	chr12:48725269	NA	-0.55	-8.18	-0.41	6.36e-15	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.17e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.8	-13.03	-0.58	1.37e-31	Hypospadias;
CRC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.59	9.38	0.46	1.08e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.59	0.65	1.97e-41	Smoking behavior;
CRC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	1.02	12.14	0.56	2.72e-28	Eosinophil percentage of granulocytes;
CRC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.42	-8.01	-0.4	1.99e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg16358738	chr2:241808595	AGXT	-0.43	-7.32	-0.37	1.94e-12	Urinary metabolites;
CRC	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg16141378	chr3:129829833	LOC729375	0.57	8.12	0.41	9.42e-15	Mood instability;
CRC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.4	-5.81	-0.31	1.44e-8	Daytime sleep phenotypes;
CRC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg27535305	chr1:53392650	SCP2	0.38	7.23	0.37	3.43e-12	Monocyte count;
CRC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	8.79	0.44	8.52e-17	Response to antipsychotic treatment;
CRC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	6.35	0.33	7.31e-10	Mean platelet volume;
CRC	trans	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg25482853	chr8:67687455	SGK3	-0.49	-6.7	-0.35	8.85e-11	Obesity-related traits;
CRC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.06	0.36	1.01e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.55	-8.5	-0.42	6.61e-16	Intelligence (multi-trait analysis);
CRC	cis	rs17095355	1.000	rs12570145	chr10:111712913	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.54	-6.4	-0.33	5.34e-10	Biliary atresia;
CRC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg25804541	chr17:80189381	SLC16A3	-0.29	-5.66	-0.3	3.38e-8	Life satisfaction;
CRC	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.89	-0.31	9.66e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-8.96	-0.44	2.56e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20340149	chr2:122407145	CLASP1	0.46	7.5	0.38	5.94e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs7859245	0.819	rs10117157	chr9:138490836	T/C	cg14410503	chr7:47343076	TNS3	0.38	6.22	0.32	1.49e-9	Response to paliperidone in schizophrenia (negative Marder score);
CRC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.33	0.33	7.9e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs501120	0.733	rs587375	chr10:44745808	T/C	cg09554077	chr10:44749378	NA	0.9	13.3	0.59	1.4e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6973256	0.865	rs4728295	chr7:133322680	A/T	cg10665199	chr7:133106180	EXOC4	-0.38	-5.87	-0.31	1.04e-8	Intelligence (multi-trait analysis);
CRC	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.28	6.07	0.32	3.46e-9	Educational attainment (years of education);
CRC	cis	rs6445525	0.875	rs7636595	chr3:65992843	A/T	cg06109867	chr3:66002991	MAGI1	0.41	6.73	0.35	7.53e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.81	12.73	0.57	1.92e-30	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17969245	chr12:52463835	C12orf44	0.45	6.63	0.34	1.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-11.54	-0.54	4.11e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg19046167	chr17:80928561	B3GNTL1	0.49	6.66	0.34	1.16e-10	Glycated hemoglobin levels;
CRC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.63	-7.07	-0.36	9.46e-12	Menarche (age at onset);
CRC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.7	-11.03	-0.52	2.75e-24	Blood protein levels;
CRC	cis	rs10503871	0.625	rs13250304	chr8:30346587	G/A	cg26383811	chr8:30366931	RBPMS	0.49	7.88	0.4	4.89e-14	Metabolite levels  (X-11787);
CRC	trans	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.05e-13	Diabetic kidney disease;
CRC	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.02	-0.31	4.76e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.6	-7.07	-0.36	9.39e-12	Vitiligo;
CRC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.43	-7.23	-0.37	3.45e-12	Blood metabolite levels;
CRC	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.56	9.53	0.46	3.73e-19	Dupuytren's disease;
CRC	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg15192750	chr16:69999425	NA	-0.5	-6.91	-0.36	2.46e-11	IgE levels;
CRC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.64	0.3	3.7e-8	Lung cancer;
CRC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.24	-0.37	3.13e-12	Coronary artery disease;
CRC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	10.17	0.49	2.67e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.08	-0.32	3.36e-9	Blood protein levels;
CRC	cis	rs10924970	1.000	rs2382567	chr1:235349803	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.77	0.3	1.88e-8	Asthma;
CRC	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.66	0.34	1.15e-10	Alzheimer's disease (survival time);
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12273811	chr6:28175739	NA	0.57	8.23	0.41	4.52e-15	Parkinson's disease;
CRC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.18e-11	Waist circumference;Weight;
CRC	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.79	-0.44	8.24e-17	Coffee consumption (cups per day);
CRC	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs12692738	0.526	rs355854	chr2:165628693	T/C	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg15763984	chr4:1342303	KIAA1530	0.49	7.94	0.4	3.26e-14	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09351035	chr11:748060	TALDO1	-0.52	-6.19	-0.32	1.84e-9	Diisocyanate-induced asthma;
CRC	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-6.19	-0.32	1.83e-9	Metabolite levels;
CRC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.35	-0.38	1.57e-12	Chronic sinus infection;
CRC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.28e-13	Heart rate;
CRC	trans	rs9409565	0.826	rs9409767	chr9:97228524	T/C	cg05679027	chr9:99775184	HIATL2	-0.4	-6.13	-0.32	2.48e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.44	-6.92	-0.36	2.41e-11	Asthma;
CRC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg00319359	chr11:70116639	PPFIA1	0.64	6.36	0.33	6.89e-10	Coronary artery disease;
CRC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-6.46	-0.34	3.79e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.61	-9.39	-0.46	1.06e-18	Aortic root size;
CRC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.97	0.66	6.69e-43	Lymphocyte percentage of white cells;
CRC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	11.06	0.52	2.13e-24	Bone mineral density;
CRC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.71	-0.43	1.56e-16	Electroencephalogram traits;
CRC	trans	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg18335740	chr13:41363409	SLC25A15	0.53	7.89	0.4	4.58e-14	Lewy body disease;
CRC	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.46	-5.99	-0.31	5.6e-9	Breast cancer;
CRC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	1.25	13.89	0.61	7.8e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.77	14.48	0.62	4.35e-37	Prudent dietary pattern;
CRC	trans	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg11693508	chr17:37793320	STARD3	0.46	6.29	0.33	9.85e-10	Neuroticism;
CRC	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.11	-0.41	1.04e-14	Biliary atresia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12564526	chr7:66767603	PMS2L4;STAG3L4	-0.43	-6.46	-0.34	3.85e-10	Myopia (pathological);
CRC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.71	-8.03	-0.4	1.79e-14	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4692589	0.897	rs13145318	chr4:170991262	C/T	cg19918862	chr4:170955249	NA	-0.34	-5.66	-0.3	3.29e-8	Anxiety disorder;
CRC	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06307176	chr5:131281290	NA	0.42	6.15	0.32	2.3e-9	Life satisfaction;
CRC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.82	0.35	4.46e-11	Rheumatoid arthritis;
CRC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	6.05	0.32	3.84e-9	Renal function-related traits (BUN);
CRC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.16	0.37	5.23e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2386661	0.826	rs7073741	chr10:5671213	G/A	cg26603656	chr10:5671107	NA	0.55	9.19	0.45	4.6e-18	Breast cancer;
CRC	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.36	0.46	1.32e-18	Blood protein levels;
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg25876840	chr17:41920477	NA	0.54	7.77	0.39	1.02e-13	Triglycerides;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00166722	chr3:10149974	C3orf24	0.61	7.96	0.4	2.85e-14	Alzheimer's disease;
CRC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.6	11.2	0.53	6.8e-25	Glomerular filtration rate (creatinine);
CRC	trans	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg26043149	chr18:55253948	FECH	0.43	6.47	0.34	3.48e-10	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg23417306	chr2:180868811	CWC22	-0.45	-6.09	-0.32	3.1e-9	Schizophrenia;
CRC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.47	6.4	0.33	5.47e-10	Alcohol dependence;
CRC	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg00250761	chr1:31883323	NA	-0.43	-8.2	-0.41	5.35e-15	Alcohol dependence;
CRC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12273811	chr6:28175739	NA	0.61	8.39	0.42	1.45e-15	Parkinson's disease;
CRC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.76e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs62007496	0.562	rs8176375	chr14:103605092	G/A	cg09274347	chr14:103599552	TNFAIP2	0.51	5.77	0.3	1.81e-8	Language performance in older adults (adjusted for episodic memory);
CRC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.46	-0.34	3.66e-10	Body mass index;
CRC	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-25.23	-0.81	6.72e-79	Exhaled nitric oxide output;
CRC	cis	rs13178541	0.551	rs4315919	chr5:135108794	G/A	cg25640822	chr5:134871645	NEUROG1	-0.29	-5.77	-0.3	1.8e-8	IgG glycosylation;
CRC	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg00852783	chr1:26633632	UBXN11	-0.49	-5.64	-0.3	3.6e-8	Obesity-related traits;
CRC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.61	-8.23	-0.41	4.42e-15	Schizophrenia;
CRC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.56	8.44	0.42	1.05e-15	High light scatter reticulocyte count;
CRC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg06207120	chr15:45996521	NA	-0.32	-7.58	-0.39	3.45e-13	Waist circumference;Weight;
CRC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg10862848	chr6:42927986	GNMT	-0.29	-6.02	-0.32	4.54e-9	Blood protein levels;
CRC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.46	-0.34	3.86e-10	Parkinson's disease;
CRC	cis	rs117623576	0.941	rs7098334	chr10:32418501	G/T	cg03047570	chr10:32398778	NA	-0.8	-8.92	-0.44	3.36e-17	Anti-saccade response;
CRC	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.46	-0.34	3.68e-10	Coronary artery calcification;
CRC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.49	-5.76	-0.3	1.9e-8	Vitiligo;
CRC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.66	-12.06	-0.55	5.38e-28	Educational attainment;
CRC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.86	-10.87	-0.51	9.9e-24	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04968132	chr16:27560915	GTF3C1;KIAA0556	0.39	6.39	0.33	5.73e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	5.73	0.3	2.26e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.42	-0.38	1.01e-12	Endometrial cancer;
CRC	cis	rs6908034	0.607	rs78402429	chr6:19811690	C/A	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-8.91	-0.44	3.48e-17	HDL cholesterol;
CRC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.47	7.41	0.38	1.04e-12	Fat distribution (HIV);
CRC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.46	6.92	0.36	2.36e-11	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07730007	chr12:107377277	MTERFD3	-0.34	-5.98	-0.31	5.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.44	6.13	0.32	2.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs4654899	0.795	rs61309203	chr1:21118489	A/T	cg02927042	chr1:21476669	EIF4G3	-0.44	-6.87	-0.35	3.19e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg16127683	chr15:40268777	EIF2AK4	-0.78	-7.11	-0.37	7.18e-12	Response to haloperidol in psychosis;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg22171725	chr15:72523569	PKM2	-0.41	-6.05	-0.32	3.83e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg25547332	chr5:131281432	NA	-0.38	-5.61	-0.3	4.32e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg11833968	chr6:79620685	NA	-0.35	-6.06	-0.32	3.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.8	-16.02	-0.66	4.21e-43	Prostate cancer;
CRC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-7.58	-0.39	3.52e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21972741	chr5:435613	AHRR	0.53	7.37	0.38	1.41e-12	Cystic fibrosis severity;
CRC	cis	rs6743226	0.870	rs10933547	chr2:242230443	C/G	cg10021735	chr2:242295487	FARP2	-0.46	-6.51	-0.34	2.75e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-7.98	-0.4	2.46e-14	Fibrinogen levels;
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.77	-0.3	1.81e-8	Life satisfaction;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17049621	chr17:42635778	FZD2	0.32	5.97	0.31	6.26e-9	Myopia (pathological);
CRC	trans	rs10411161	0.702	rs8110073	chr19:52383123	C/A	cg22319618	chr22:45562946	NUP50	-0.64	-7.09	-0.36	8.37e-12	Breast cancer;
CRC	cis	rs58649573	0.552	rs2075064	chr9:126783847	C/T	cg14112217	chr9:126806003	NA	0.4	5.8	0.3	1.55e-8	Post-traumatic stress disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25057861	chr10:72142518	LRRC20	0.42	6.34	0.33	7.59e-10	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27126666	chr15:93353059	NA	0.41	6.17	0.32	2.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.98	0.66	5.9e-43	Platelet count;
CRC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04317338	chr11:64019027	PLCB3	0.42	6.22	0.32	1.48e-9	Platelet count;
CRC	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	11.23	0.53	5.48e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9908102	0.740	rs7211210	chr17:12917352	A/G	cg26162695	chr17:12921313	ELAC2	0.43	5.66	0.3	3.27e-8	Schizophrenia;
CRC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07513332	chr6:167530253	CCR6	0.38	6.25	0.33	1.27e-9	Primary biliary cholangitis;
CRC	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg25025879	chr12:53359317	NA	-0.84	-7.91	-0.4	4e-14	Prostate cancer;
CRC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.83	-0.31	1.34e-8	Bipolar disorder;
CRC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.58	9.16	0.45	5.58e-18	Melanoma;
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08219700	chr8:58056026	NA	0.59	6.71	0.35	8.27e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4839185	0.727	rs4838926	chr1:112463323	G/C	cg27510354	chr1:112429786	KCND3	0.3	5.69	0.3	2.83e-8	P wave terminal force;
CRC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-9.2	-0.45	4.21e-18	Body mass index;
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.97	15.93	0.66	9.89e-43	Menarche (age at onset);
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	1.04e-12	Body mass index;
CRC	cis	rs365302	1.000	rs422470	chr6:159649660	A/C	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Parkinson's disease;
CRC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.62	-10.02	-0.48	8.3e-21	Dental caries;
CRC	trans	rs72991	0.639	rs10790444	chr11:121235129	A/T	cg27192990	chr6:129479024	LAMA2	0.42	6.14	0.32	2.34e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.55	7.82	0.4	7.26e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg07513332	chr6:167530253	CCR6	-0.47	-8.71	-0.43	1.46e-16	Primary biliary cholangitis;
CRC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.91	0.31	8.75e-9	Diabetic kidney disease;
CRC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.53	-6.91	-0.36	2.5e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg00343986	chr7:65444356	GUSB	0.41	5.87	0.31	1.09e-8	Aortic root size;
CRC	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.48	-5.94	-0.31	7.44e-9	Ulcerative colitis;
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02725872	chr8:58115012	NA	-0.59	-9.08	-0.45	1.02e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg03929089	chr4:120376271	NA	0.65	6.03	0.32	4.45e-9	Intraocular pressure;
CRC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.67	8.82	0.44	6.9e-17	Morning vs. evening chronotype;
CRC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg20243544	chr17:37824526	PNMT	0.57	9.06	0.45	1.21e-17	Asthma;
CRC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.93	17.01	0.68	5.24e-47	Obesity-related traits;
CRC	cis	rs9443189	0.950	rs1280039	chr6:76514940	C/T	cg01950844	chr6:76311363	SENP6	0.56	6.54	0.34	2.38e-10	Prostate cancer;
CRC	cis	rs853679	0.567	rs13209596	chr6:28396190	C/A	cg21251018	chr6:28226885	NKAPL	0.42	6.06	0.32	3.79e-9	Depression;
CRC	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.86	-0.31	1.11e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CRC	cis	rs17127169	0.649	rs115401535	chr1:65484667	G/A	cg01340542	chr1:65468273	NA	0.85	5.85	0.31	1.2e-8	Sitting height ratio;
CRC	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg14003231	chr6:33640908	ITPR3	0.49	7.86	0.4	5.36e-14	Plateletcrit;
CRC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.07	0.32	3.55e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.5	-0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.57	9.52	0.46	3.94e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.6	9.17	0.45	5.34e-18	Aortic root size;
CRC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.65	9.81	0.48	4.38e-20	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.11	-12.71	-0.57	2.17e-30	Diabetic kidney disease;
CRC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-0.87	-10.15	-0.49	3.1e-21	Breast cancer;
CRC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.69	10.53	0.5	1.6e-22	Menopause (age at onset);
CRC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg21153622	chr11:89784906	NA	0.43	7.15	0.37	5.77e-12	Coronary artery disease;
CRC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-9.2	-0.45	4.11e-18	Monocyte count;
CRC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg14664628	chr15:75095509	CSK	0.43	6.33	0.33	7.89e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.71	-9.35	-0.46	1.4e-18	Coronary artery disease;
CRC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.63	-9.56	-0.47	2.86e-19	Obesity-related traits;
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.98	-0.36	1.62e-11	Bipolar disorder;
CRC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.39	5.88	0.31	1.02e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.75	8.64	0.43	2.45e-16	Eotaxin levels;
CRC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.69	10.5	0.5	1.94e-22	Menopause (age at onset);
CRC	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg15382696	chr6:118971807	C6orf204	0.6	7.45	0.38	8.42e-13	Diastolic blood pressure;
CRC	cis	rs9826463	0.757	rs75100831	chr3:142244647	T/C	cg20824294	chr3:142316082	PLS1	0.4	6.69	0.35	9.6e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.67	9.72	0.47	8.48e-20	Menopause (age at onset);
CRC	cis	rs9847710	1.000	rs12488768	chr3:53086234	C/T	cg04503182	chr3:53078218	SFMBT1	-0.44	-7.16	-0.37	5.16e-12	Ulcerative colitis;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs9513593	1.000	rs16956449	chr13:99966605	A/G	cg21788972	chr13:99853209	UBAC2	0.43	5.69	0.3	2.87e-8	Psoriasis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04977610	chr16:30366665	CD2BP2	0.39	6.38	0.33	6.18e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26322434	chr3:61237156	FHIT	0.41	6.07	0.32	3.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	1.02	9.16	0.45	5.8e-18	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01153979	chr6:79577195	IRAK1BP1	0.39	6.05	0.32	3.86e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2179367	0.959	rs9373589	chr6:149707288	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.14	-0.32	2.36e-9	Dupuytren's disease;
CRC	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.7	-13.66	-0.6	5.86e-34	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.75	-11.7	-0.54	1.08e-26	Cognitive function;
CRC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24308560	chr3:49941425	MST1R	-0.45	-7.05	-0.36	1.06e-11	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-7.34	-0.38	1.71e-12	Type 2 diabetes;
CRC	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.78	13.88	0.61	8.63e-35	Anterior chamber depth;
CRC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg13256891	chr4:100009986	ADH5	0.42	6.09	0.32	3.07e-9	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13154104	chr2:10443632	HPCAL1	-0.42	-6.2	-0.32	1.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-9.58	-0.47	2.5e-19	Calcium levels;
CRC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.57	6.26	0.33	1.23e-9	Initial pursuit acceleration;
CRC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	10.62	0.51	7.62e-23	Motion sickness;
CRC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.7	-0.39	1.58e-13	Height;
CRC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.77	-0.3	1.85e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.41	6.42	0.33	4.7e-10	Lung function (FEV1/FVC);
CRC	cis	rs629535	0.814	rs545720	chr8:70063370	T/C	cg26132723	chr8:70041827	NA	0.35	5.78	0.3	1.69e-8	Dupuytren's disease;
CRC	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg07617317	chr6:118971624	C6orf204	0.48	5.77	0.3	1.82e-8	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25016364	chr7:152457024	ACTR3B	0.46	6.58	0.34	1.9e-10	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.65	6.63	0.34	1.41e-10	Vitiligo;
CRC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.44	-6.24	-0.33	1.36e-9	Lymphocyte counts;
CRC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	8.52	0.43	5.71e-16	Platelet count;
CRC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	6.06	0.32	3.77e-9	Putamen volume;
CRC	cis	rs10944	0.598	rs594686	chr5:78275768	T/C	cg13121490	chr5:78280331	ARSB	-0.46	-6.76	-0.35	6.33e-11	Blood and toenail selenium levels;
CRC	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.38	-6.22	-0.32	1.49e-9	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg06470822	chr6:28175283	NA	0.98	12.98	0.58	2.22e-31	Depression;
CRC	cis	rs4692589	0.965	rs6842442	chr4:170933203	C/T	cg19918862	chr4:170955249	NA	0.38	6.32	0.33	8.75e-10	Anxiety disorder;
CRC	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg00277334	chr10:82204260	NA	-0.45	-5.92	-0.31	7.95e-9	Post bronchodilator FEV1;
CRC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.53	-0.34	2.48e-10	Cystic fibrosis severity;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg03623178	chr6:28175578	NA	0.64	8.52	0.43	5.68e-16	Parkinson's disease;
CRC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.05	0.45	1.31e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3736485	0.868	rs8034197	chr15:51922506	C/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.53	-0.34	2.55e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg04315214	chr1:2043799	PRKCZ	-0.39	-6.81	-0.35	4.59e-11	Height;
CRC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg03923535	chr7:1197113	ZFAND2A	0.46	6.86	0.35	3.45e-11	Longevity;Endometriosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06594919	chr10:102827590	NA	0.44	6.18	0.32	1.92e-9	Response to antipsychotic treatment;
CRC	cis	rs11212617	1.000	rs227094	chr11:108233800	C/A	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.59	0.34	1.7e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg06713675	chr4:122721982	EXOSC9	-0.39	-5.87	-0.31	1.08e-8	Type 2 diabetes;
CRC	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.71	-0.43	1.52e-16	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs459193	1.000	rs157843	chr5:55799184	G/T	cg18302225	chr5:55776401	NA	0.57	8.41	0.42	1.24e-15	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.73	-11.68	-0.54	1.35e-26	Lung cancer;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.53	6.08	0.32	3.31e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.58	-8.72	-0.43	1.38e-16	Body mass index;
CRC	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg18551225	chr6:44695536	NA	-0.4	-5.75	-0.3	2.02e-8	Total body bone mineral density;
CRC	cis	rs7617773	1.000	rs6442109	chr3:48192981	G/A	cg11946769	chr3:48343235	NME6	-0.5	-6.79	-0.35	5.37e-11	Coronary artery disease;
CRC	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.0	-0.48	1.01e-20	Bipolar disorder;
CRC	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg16898833	chr6:26189333	HIST1H4D	1.16	8.45	0.42	9.44e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.46	-6.07	-0.32	3.58e-9	Heschl's gyrus morphology;
CRC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.6	9.99	0.48	1.05e-20	Tumor biomarkers;
CRC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.69	-9.96	-0.48	1.34e-20	Gut microbiome composition (summer);
CRC	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.6	-7.13	-0.37	6.55e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg15704280	chr7:45808275	SEPT13	-0.47	-6.45	-0.34	4e-10	HDL cholesterol;
CRC	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg00666640	chr1:248458726	OR2T12	0.35	6.45	0.33	4.08e-10	Common traits (Other);
CRC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03698729	chr19:2328812	SPPL2B;LSM7	0.42	6.57	0.34	2.01e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg23161317	chr6:28129485	ZNF389	0.51	6.47	0.34	3.63e-10	Parkinson's disease;
CRC	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg00531865	chr16:30841666	NA	0.48	6.9	0.36	2.62e-11	Dementia with Lewy bodies;
CRC	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.57	-0.34	1.99e-10	Multiple sclerosis;
CRC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.44	6.94	0.36	2.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg09877947	chr5:131593287	PDLIM4	0.55	9.48	0.46	5.32e-19	Acylcarnitine levels;
CRC	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg20356878	chr3:121714668	ILDR1	-0.41	-5.77	-0.3	1.84e-8	Multiple sclerosis;
CRC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg13206674	chr6:150067644	NUP43	0.49	7.02	0.36	1.27e-11	Testicular germ cell tumor;
CRC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.1	-0.32	2.96e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4920343	0.645	rs851115	chr1:19070229	T/A	cg26220594	chr1:19110978	NA	0.36	5.67	0.3	3.09e-8	Knee osteoarthritis;
CRC	cis	rs9487051	0.698	rs9400276	chr6:109647405	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.76	-0.3	1.91e-8	Reticulocyte fraction of red cells;
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23378565	chr7:2036160	MAD1L1	0.44	6.46	0.34	3.82e-10	Bipolar disorder;
CRC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	7.02	0.36	1.25e-11	Platelet count;
CRC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.68	-11.85	-0.55	3.29e-27	Brugada syndrome;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-8.29	-0.42	3.02e-15	Bipolar disorder;
CRC	cis	rs10450586	0.932	rs10767628	chr11:27310871	C/G	cg10370305	chr11:27303972	NA	0.37	6.04	0.32	4.19e-9	Total body bone mineral density;
CRC	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.48	6.4	0.33	5.48e-10	Obesity-related traits;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.63	0.39	2.49e-13	Lung cancer;
CRC	cis	rs7680126	0.596	rs12511337	chr4:10311972	A/G	cg00071950	chr4:10020882	SLC2A9	0.46	5.98	0.31	5.71e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg17724175	chr1:150552817	MCL1	0.48	7.16	0.37	5.35e-12	Melanoma;
CRC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.63	9.28	0.46	2.39e-18	Breast cancer;
CRC	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.87	14.43	0.62	6.32e-37	Alcohol dependence;
CRC	trans	rs783540	0.934	rs7182403	chr15:83297613	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.92	-0.36	2.35e-11	Schizophrenia;
CRC	cis	rs2625529	0.556	rs35603965	chr15:72523043	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.74	0.35	6.97e-11	Red blood cell count;
CRC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.76	14.18	0.62	5.77e-36	Prudent dietary pattern;
CRC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg15848620	chr12:58087721	OS9	-0.65	-8.94	-0.44	2.88e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg03160526	chr17:80928410	B3GNTL1	-0.41	-6.11	-0.32	2.76e-9	Breast cancer;
CRC	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-13.92	-0.61	5.81e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9311676	0.609	rs11925862	chr3:58417927	A/C	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.39e-10	Systemic lupus erythematosus;
CRC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	0.94	18.34	0.71	3e-52	Height;
CRC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.69	-8.26	-0.41	3.5e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.64	0.34	1.29e-10	Depression;
CRC	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg15234197	chr11:68924956	NA	0.42	5.86	0.31	1.15e-8	Blond vs. brown hair color;
CRC	trans	rs4902562	0.838	rs6573823	chr14:68733632	A/G	cg20049727	chr4:1981032	WHSC1	0.48	6.38	0.33	5.89e-10	Systemic lupus erythematosus;
CRC	cis	rs282587	0.502	rs282603	chr13:113393984	G/A	cg04656015	chr13:113407548	ATP11A	0.55	7.19	0.37	4.27e-12	Glycated hemoglobin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12045676	chr19:18794818	CRTC1	0.47	7.15	0.37	5.73e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4654899	0.833	rs12135548	chr1:21084367	G/A	cg02927042	chr1:21476669	EIF4G3	-0.43	-6.65	-0.34	1.21e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	10.24	0.49	1.48e-21	HIV-1 control;
CRC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.73	-0.35	7.39e-11	Reticulocyte fraction of red cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12182497	chr8:42128690	IKBKB	0.44	6.29	0.33	1.01e-9	Response to antipsychotic treatment;
CRC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg16141378	chr3:129829833	LOC729375	0.46	7.09	0.36	8.19e-12	Systolic blood pressure;
CRC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.86	-0.31	1.1e-8	Calcium levels;
CRC	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.67	-11.1	-0.52	1.57e-24	Schizophrenia;
CRC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg22815214	chr1:201083145	CACNA1S	-0.51	-6.44	-0.33	4.15e-10	Permanent tooth development;
CRC	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg13334819	chr7:99746414	C7orf59	0.43	5.7	0.3	2.64e-8	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg15786705	chr6:28176104	NA	0.78	11.0	0.52	3.62e-24	Depression;
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.67	7.54	0.38	4.66e-13	Body mass index;
CRC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg27661571	chr11:113659931	NA	-0.96	-11.16	-0.52	9.58e-25	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.98	-19.57	-0.73	4.02e-57	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.2	-0.37	4.16e-12	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg03037974	chr15:76606532	NA	-0.54	-8.2	-0.41	5.41e-15	Blood metabolite levels;
CRC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg10298567	chr3:47292165	KIF9	-0.35	-5.75	-0.3	2.04e-8	Colorectal cancer;
CRC	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.68	0.54	1.28e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19151263	chr18:48724096	MEX3C	0.4	6.02	0.31	4.71e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg01657329	chr11:68192670	LRP5	-0.45	-6.32	-0.33	8.46e-10	Total body bone mineral density;
CRC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.71	0.39	1.54e-13	Mean platelet volume;
CRC	cis	rs2072510	0.593	rs2540493	chr12:96415842	A/C	cg09636302	chr12:96389483	HAL	-0.51	-6.28	-0.33	1.05e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.43	6.9	0.36	2.7e-11	Monocyte count;
CRC	cis	rs3996993	0.752	rs4538706	chr6:52694305	C/T	cg20803780	chr6:52668592	GSTA1	0.36	6.39	0.33	5.8e-10	Hemoglobin concentration;
CRC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg24881330	chr22:46731750	TRMU	0.68	8.73	0.43	1.29e-16	LDL cholesterol;Cholesterol, total;
CRC	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg23254163	chr1:152506842	NA	0.44	8.62	0.43	2.8e-16	Hair morphology;
CRC	cis	rs7605827	0.930	rs10203196	chr2:15541154	A/T	cg19274914	chr2:15703543	NA	0.4	5.92	0.31	8.18e-9	Educational attainment (years of education);
CRC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.48	6.51	0.34	2.75e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.72	0.43	1.43e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg09324608	chr17:30823087	MYO1D	0.36	6.31	0.33	8.91e-10	Schizophrenia;
CRC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.57	8.1	0.41	1.11e-14	Longevity;
CRC	cis	rs6838801	0.892	rs28515950	chr4:77575939	A/G	cg17476223	chr4:77663285	SHROOM3	0.42	5.9	0.31	9.22e-9	Cleft lip with or without cleft palate;
CRC	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.48	7.0	0.36	1.44e-11	Pulmonary function decline;
CRC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19046167	chr17:80928561	B3GNTL1	0.52	7.42	0.38	1.04e-12	Glycated hemoglobin levels;
CRC	cis	rs6952809	1.000	rs28712717	chr7:2449590	T/C	cg23289794	chr7:2394357	EIF3B	-0.41	-5.68	-0.3	2.96e-8	Multiple sclerosis;
CRC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13939156	chr17:80058883	NA	0.37	5.71	0.3	2.52e-8	Life satisfaction;
CRC	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.67	-8.93	-0.44	2.96e-17	Facial morphology (factor 19);
CRC	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.71	10.16	0.49	2.79e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.59	8.33	0.42	2.24e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.99	0.4	2.28e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.69	-8.47	-0.42	8.08e-16	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg21251018	chr6:28226885	NKAPL	0.47	6.04	0.32	4.16e-9	Depression;
CRC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.39	6.83	0.35	4.13e-11	Primary biliary cholangitis;
CRC	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg06606381	chr12:133084897	FBRSL1	-0.93	-6.66	-0.34	1.17e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.57	8.6	0.43	3.21e-16	Migraine;Coronary artery disease;
CRC	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.61	8.2	0.41	5.63e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.46	6.88	0.35	3.03e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs6694672	0.850	rs857027	chr1:197013464	T/C	cg13682187	chr1:196946512	CFHR5	0.47	7.41	0.38	1.07e-12	Asthma;
CRC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.66	-0.47	1.31e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.6e-39	Lymphocyte percentage of white cells;
CRC	cis	rs7394190	0.935	rs12570126	chr10:75416789	C/T	cg26549892	chr10:75416844	SYNPO2L	0.51	6.61	0.34	1.59e-10	Incident atrial fibrillation;
CRC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.44	0.46	7.29e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.22e-17	Mean platelet volume;
CRC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg09876464	chr15:85330779	ZNF592	0.45	7.72	0.39	1.37e-13	P wave terminal force;
CRC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg16102536	chr7:156981717	UBE3C	-0.41	-6.91	-0.36	2.55e-11	Body mass index;
CRC	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg09659197	chr4:152720779	NA	0.43	8.47	0.42	8.45e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.57	8.16	0.41	7.17e-15	Personality dimensions;
CRC	cis	rs7916697	0.520	rs12265247	chr10:70038398	A/G	cg06988349	chr10:69991859	ATOH7	0.39	6.86	0.35	3.41e-11	Optic disc area;
CRC	cis	rs1124376	0.935	rs12490215	chr3:20156185	A/G	cg05072819	chr3:20081367	KAT2B	0.46	5.91	0.31	8.32e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.43	-20.5	-0.75	9.58e-61	Hip circumference adjusted for BMI;
CRC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg15269541	chr15:43626905	ADAL	0.49	6.1	0.32	3.01e-9	Lung cancer in ever smokers;
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.6	6.37	0.33	6.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.91	0.44	3.68e-17	Mood instability;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg15786705	chr6:28176104	NA	0.78	9.7	0.47	1.01e-19	Depression;
CRC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.67	9.49	0.46	5e-19	Neuroblastoma;
CRC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.94	-18.0	-0.7	6.48e-51	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00546180	chr10:103815814	C10orf76	0.5	6.98	0.36	1.63e-11	Response to antipsychotic treatment;
CRC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.88	-0.31	9.99e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.38	-0.38	1.34e-12	Reticulocyte fraction of red cells;
CRC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.79	14.64	0.63	1.03e-37	Metabolic syndrome;
CRC	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.55	-6.11	-0.32	2.84e-9	Type 2 diabetes;
CRC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.66	6.77	0.35	5.88e-11	Plasma clusterin levels;
CRC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.94	13.01	0.58	1.66e-31	Initial pursuit acceleration;
CRC	trans	rs7690467	0.794	rs56286760	chr4:133404439	G/T	cg19296258	chr17:78878799	RPTOR	-0.46	-6.03	-0.32	4.37e-9	Eating disorders;
CRC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg23758597	chr6:163146217	PARK2	-0.7	-7.13	-0.37	6.26e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01777630	chr16:66914802	PDP2	0.49	6.69	0.35	9.38e-11	Response to antipsychotic treatment;
CRC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.46	6.61	0.34	1.51e-10	Melanoma;
CRC	cis	rs17209837	1.000	rs17149641	chr7:87086090	T/C	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.45	8.8	0.44	7.98e-17	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.53	7.72	0.39	1.38e-13	Mean platelet volume;
CRC	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	0.96	9.91	0.48	1.94e-20	Gut microbiota (bacterial taxa);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg20905760	chr15:43478003	CCNDBP1	-0.42	-6.2	-0.32	1.66e-9	Daytime sleep phenotypes;
CRC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg18230493	chr5:56204884	C5orf35	0.4	5.91	0.31	8.57e-9	Coronary artery disease;
CRC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.69	11.01	0.52	3.32e-24	Type 2 diabetes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg06537201	chr12:58330115	NA	0.43	6.53	0.34	2.54e-10	Interleukin-6 levels;
CRC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.57	-0.34	2.02e-10	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16488639	chr12:12966464	DDX47	0.41	6.2	0.32	1.71e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs17192198	0.661	rs73198552	chr12:90067938	T/C	cg17836913	chr1:54723679	SSBP3	-0.46	-6.02	-0.31	4.59e-9	Diastolic blood pressure;
CRC	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.41	6.2	0.32	1.66e-9	Endometrial cancer;
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	5.8	0.3	1.56e-8	Bipolar disorder;
CRC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.41	6.43	0.33	4.38e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2055729	0.528	rs11987861	chr8:9742206	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.06	-0.36	1.02e-11	Multiple myeloma (hyperdiploidy);
CRC	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.67	0.43	2.02e-16	Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.75	0.35	6.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.55	-9.66	-0.47	1.33e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17155006	0.746	rs401066	chr7:107747937	G/A	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.59	8.49	0.42	6.99e-16	Lung cancer;
CRC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.44	-8.3	-0.42	2.72e-15	Huntington's disease progression;
CRC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.65	-9.35	-0.46	1.38e-18	Refractive error;
CRC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	11.43	0.53	1.06e-25	Nonalcoholic fatty liver disease;
CRC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg04362960	chr10:104952993	NT5C2	0.53	7.76	0.39	1.08e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.68	-10.19	-0.49	2.27e-21	Intelligence (multi-trait analysis);
CRC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.32	6.21	0.32	1.55e-9	Blood metabolite levels;
CRC	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg17145862	chr1:211918768	LPGAT1	0.49	7.02	0.36	1.27e-11	Leprosy;
CRC	cis	rs2882667	0.861	rs11242445	chr5:138417054	G/T	cg04439458	chr5:138467593	SIL1	-0.31	-5.6	-0.3	4.42e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2569991	0.636	rs361223	chr3:12922526	T/C	cg22481960	chr3:13008800	IQSEC1	-0.52	-6.59	-0.34	1.8e-10	Periodontitis (DPAL);
CRC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg16797656	chr11:68205561	LRP5	0.38	5.94	0.31	7.29e-9	Total body bone mineral density;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22334543	chr19:3506226	FZR1	0.45	6.2	0.32	1.67e-9	Survival in pancreatic cancer;
CRC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.49	8.94	0.44	2.88e-17	Total body bone mineral density;
CRC	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg09127314	chr1:152161683	NA	0.46	5.93	0.31	7.69e-9	Atopic dermatitis;
CRC	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.52	7.73	0.39	1.34e-13	Corneal astigmatism;
CRC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.47	-0.34	3.54e-10	Breast cancer;
CRC	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg05585544	chr11:47624801	NA	-0.4	-6.33	-0.33	8.17e-10	Mean corpuscular hemoglobin;
CRC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.64	10.42	0.5	3.82e-22	Schizophrenia;
CRC	cis	rs10894147	0.756	rs1783911	chr11:129753751	G/A	cg27255275	chr11:129766154	NFRKB	0.41	5.61	0.3	4.21e-8	Obesity-related traits;
CRC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.74	7.89	0.4	4.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11997175	0.546	rs1561913	chr8:33587002	A/T	cg04338863	chr8:33670619	NA	0.35	5.93	0.31	7.49e-9	Body mass index;
CRC	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg05540913	chr6:167530185	CCR6	-0.35	-6.18	-0.32	1.85e-9	Primary biliary cholangitis;
CRC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.49	-7.37	-0.38	1.41e-12	Menarche (age at onset);
CRC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.66	8.18	0.41	6.29e-15	HIV-1 control;
CRC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs11212617	1.000	rs228598	chr11:108107497	T/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.29	0.33	9.83e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg10876282	chr6:28092338	ZSCAN16	0.4	5.71	0.3	2.52e-8	Cardiac Troponin-T levels;
CRC	cis	rs16882447	0.607	rs28701873	chr5:53489782	G/A	cg06461071	chr5:53490839	ARL15	0.34	5.6	0.3	4.48e-8	Systolic blood pressure (dietary potassium intake interaction);
CRC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.22	-15.87	-0.66	1.61e-42	Breast cancer;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg07507251	chr3:52567010	NT5DC2	0.5	7.97	0.4	2.65e-14	Electroencephalogram traits;
CRC	cis	rs12580194	0.593	rs11171416	chr12:55731490	A/G	cg19537932	chr12:55886519	OR6C68	-0.65	-8.33	-0.42	2.18e-15	Cancer;
CRC	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.61	-7.68	-0.39	1.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09777506	chr15:69112064	ANP32A	0.46	6.87	0.35	3.29e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.78	11.3	0.53	3.07e-25	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg18016565	chr1:150552671	MCL1	0.44	6.03	0.32	4.31e-9	Melanoma;
CRC	cis	rs6460942	0.908	rs6978857	chr7:12232665	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.05	-0.32	4.03e-9	Coronary artery disease;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.66	-9.69	-0.47	1.07e-19	Menopause (age at onset);
CRC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.5	7.37	0.38	1.42e-12	Colorectal cancer;
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.58	-10.87	-0.51	9.87e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.29	-6.59	-0.34	1.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.24	-0.49	1.48e-21	Bipolar disorder;
CRC	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.57	-8.05	-0.41	1.54e-14	Diisocyanate-induced asthma;
CRC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg22117107	chr15:45993392	NA	-0.43	-8.65	-0.43	2.36e-16	Waist circumference;Weight;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg20512303	chr5:131592959	PDLIM4	0.37	7.05	0.36	1.05e-11	Breast cancer;
CRC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.99	0.36	1.58e-11	Morning vs. evening chronotype;
CRC	cis	rs4660214	0.666	rs10493087	chr1:39717256	C/G	cg11070191	chr1:39582205	MACF1	0.36	5.74	0.3	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.8	9.38	0.46	1.07e-18	Type 2 diabetes;
CRC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.33	1.01e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs653465	0.679	rs12488954	chr3:27145162	G/A	cg02860705	chr3:27208620	NA	-0.36	-5.64	-0.3	3.61e-8	Breast cancer (early onset);
CRC	trans	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg10756647	chr7:56101905	PSPH	0.74	7.52	0.38	5.38e-13	Diabetic kidney disease;
CRC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.48	-7.35	-0.38	1.56e-12	Schizophrenia;
CRC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.22	13.63	0.6	7.6e-34	Diabetic kidney disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07393458	chr17:57297757	GDPD1	0.42	6.04	0.32	4.1e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08303978	chr15:65822665	PTPLAD1	0.47	6.35	0.33	7.15e-10	Anxiety disorder;
CRC	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.34	7.98	0.4	2.47e-14	Corneal astigmatism;
CRC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.7	11.45	0.53	8.8e-26	Colorectal cancer;
CRC	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.74	-0.39	1.26e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.7	11.02	0.52	2.97e-24	Monocyte count;
CRC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.42	5.7	0.3	2.74e-8	IgG glycosylation;
CRC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg10978503	chr1:24200527	CNR2	0.5	8.68	0.43	1.86e-16	Immature fraction of reticulocytes;
CRC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	10.55	0.5	1.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.52	0.57	1.15e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.49	-9.34	-0.46	1.52e-18	Reticulocyte fraction of red cells;
CRC	cis	rs4919694	0.808	rs112574306	chr10:104971159	C/T	cg04362960	chr10:104952993	NT5C2	1.18	9.39	0.46	1.06e-18	Arsenic metabolism;
CRC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	8.78	0.44	8.89e-17	Cognitive test performance;
CRC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg00343986	chr7:65444356	GUSB	0.5	7.38	0.38	1.34e-12	Aortic root size;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg21251018	chr6:28226885	NKAPL	0.38	5.73	0.3	2.24e-8	Parkinson's disease;
CRC	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	0.96	16.23	0.67	6.5e-44	Dupuytren's disease;
CRC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.85	15.01	0.64	3.63e-39	Blood protein levels;
CRC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.81	11.14	0.52	1.13e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs305851	0.716	rs7773103	chr6:39740391	C/G	cg02386599	chr6:39769542	DAAM2	-0.37	-5.72	-0.3	2.36e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.57e-10	Life satisfaction;
CRC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.17	0.32	2.02e-9	Obesity-related traits;
CRC	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	7.4	0.38	1.18e-12	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19317012	chr1:110880555	RBM15	0.38	6.16	0.32	2.1e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg19824334	chr17:73851399	WBP2	-0.42	-6.19	-0.32	1.78e-9	Underweight status;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg25164649	chr6:28176230	NA	0.65	9.23	0.45	3.45e-18	Cardiac Troponin-T levels;
CRC	trans	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg11693508	chr17:37793320	STARD3	0.5	6.69	0.35	9.65e-11	Neuroticism;
CRC	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.22	-0.45	3.65e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg22482690	chr17:47019901	SNF8	0.46	7.5	0.38	6.07e-13	Coronary heart disease;
CRC	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg26043149	chr18:55253948	FECH	0.55	8.41	0.42	1.23e-15	Bone mineral density;
CRC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.78	0.44	9.2e-17	Cognitive test performance;
CRC	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.58	0.39	3.56e-13	Eye color traits;
CRC	cis	rs3018066	0.867	rs12642691	chr4:107140732	C/T	cg01869342	chr4:106983673	TBCK	0.36	5.74	0.3	2.11e-8	Cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23396286	chr10:99258505	UBTD1;MMS19	0.49	6.37	0.33	6.52e-10	Thyroid stimulating hormone;
CRC	cis	rs2745967	0.740	rs2796252	chr1:208067308	C/A	cg09788693	chr1:208063733	CD34	0.46	6.99	0.36	1.58e-11	Resting heart rate;
CRC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.73	11.57	0.54	3.45e-26	Colorectal cancer;
CRC	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg22089800	chr15:90895588	ZNF774	0.46	7.01	0.36	1.4e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.66	-7.68	-0.39	1.86e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg09264619	chr17:80180166	NA	-0.36	-6.04	-0.32	4.22e-9	Life satisfaction;
CRC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.81	10.02	0.48	8.61e-21	Prostate cancer;
CRC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg26805224	chr10:79626177	DLG5	-0.49	-7.08	-0.36	8.72e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg15147215	chr3:52552868	STAB1	-0.52	-8.39	-0.42	1.41e-15	Electroencephalogram traits;
CRC	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.53	-7.25	-0.37	2.95e-12	Post bronchodilator FEV1;
CRC	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.72	-0.35	8.24e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-9.35	-0.46	1.42e-18	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg02820901	chr13:113351484	ATP11A	0.61	6.65	0.34	1.2e-10	Glycated hemoglobin levels;
CRC	cis	rs11212617	1.000	rs227077	chr11:108253252	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.53	0.34	2.46e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg10298567	chr3:47292165	KIF9	0.41	6.55	0.34	2.23e-10	Colorectal cancer;
CRC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.53	5.84	0.31	1.23e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	8.87	0.44	4.74e-17	Schizophrenia;
CRC	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.46	6.63	0.34	1.41e-10	Lung cancer;
CRC	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.54	6.35	0.33	7.13e-10	Menarche (age at onset);
CRC	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg25686905	chr3:183603175	PARL	-0.45	-6.41	-0.33	4.9e-10	Menopause (age at onset);
CRC	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg05562828	chr17:3906858	NA	0.66	12.32	0.56	6.19e-29	Type 2 diabetes;
CRC	cis	rs17362650	1.000	rs13032333	chr2:9620701	T/A	cg12832956	chr2:9616023	IAH1	-0.51	-6.17	-0.32	1.99e-9	Alcohol dependence (age at onset);
CRC	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.66	-10.34	-0.5	6.91e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg24503407	chr1:205819492	PM20D1	0.4	5.9	0.31	8.81e-9	Prostate cancer;
CRC	cis	rs9826463	0.582	rs11720007	chr3:142134712	T/G	cg20824294	chr3:142316082	PLS1	0.35	5.64	0.3	3.61e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	9.37	0.46	1.17e-18	Cognitive test performance;
CRC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-13.1	-0.59	7.34e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.68	0.39	1.9e-13	Lung cancer;
CRC	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg06223162	chr1:101003688	GPR88	0.34	6.32	0.33	8.46e-10	Monocyte count;
CRC	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.43	5.89	0.31	9.44e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg21155852	chr7:2048760	MAD1L1	-0.45	-5.97	-0.31	6.15e-9	Neuroticism;
CRC	cis	rs17767392	0.781	rs2108057	chr14:72022750	G/A	cg13720639	chr14:72061746	SIPA1L1	0.5	6.38	0.33	6.06e-10	Mitral valve prolapse;
CRC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg17810781	chr1:201082982	CACNA1S	0.41	6.8	0.35	5.06e-11	Permanent tooth development;
CRC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12463550	chr7:65579703	CRCP	0.7	6.44	0.33	4.33e-10	Diabetic kidney disease;
CRC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.19	-13.2	-0.59	3.1e-32	Diabetic kidney disease;
CRC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.24e-11	Life satisfaction;
CRC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.81	0.35	4.72e-11	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04266864	chr17:27224823	FLOT2;DHRS13	0.39	5.98	0.31	5.73e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.5	6.59	0.34	1.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.75	-13.41	-0.59	5.22e-33	Prostate cancer;
CRC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-7.56	-0.38	4.12e-13	Chronic sinus infection;
CRC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.92	-0.36	2.31e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs1147246	0.714	rs323851	chr12:125878105	G/A	cg23470196	chr14:102695671	RAGE	0.41	6.01	0.31	4.95e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.79	0.44	8.51e-17	Rheumatoid arthritis;
CRC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.83	12.78	0.58	1.18e-30	Menarche (age at onset);
CRC	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-5.95	-0.31	6.93e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg03623178	chr6:28175578	NA	0.56	6.54	0.34	2.34e-10	Breast cancer;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.66	-12.06	-0.55	5.6e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.49	-6.54	-0.34	2.3e-10	Blood trace element (Cu levels);
CRC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.51	8.01	0.4	2.03e-14	Personality dimensions;
CRC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.44	-7.92	-0.4	3.66e-14	Intelligence (multi-trait analysis);
CRC	trans	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.4	-7.3	-0.37	2.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.65	-10.31	-0.49	8.8e-22	Gut microbiota (bacterial taxa);
CRC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.51	6.97	0.36	1.74e-11	Alzheimer's disease;
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg00769240	chr8:12517080	NA	-0.74	-10.23	-0.49	1.64e-21	Blood pressure (smoking interaction);
CRC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.64	-0.47	1.56e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs205391	0.689	rs205412	chr16:28064827	A/G	cg05844366	chr10:91738713	NA	0.46	5.97	0.31	6.07e-9	Obesity-related traits;
CRC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.88	0.31	1.02e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs10946940	0.632	rs9366698	chr6:27672035	C/G	cg08798685	chr6:27730294	NA	-0.46	-6.26	-0.33	1.17e-9	Systemic lupus erythematosus;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg14329157	chr2:228736135	WDR69	-0.47	-6.53	-0.34	2.48e-10	Blood pressure;
CRC	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg09904177	chr6:26538194	HMGN4	-0.45	-6.27	-0.33	1.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.26	0.45	2.81e-18	Bladder cancer;
CRC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	11.71	0.54	9.98e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs7731657	0.537	rs4705851	chr5:130220592	A/G	cg08523029	chr5:130500466	HINT1	0.43	5.68	0.3	2.95e-8	Fasting plasma glucose;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg16618003	chr1:65432492	JAK1	0.48	6.23	0.32	1.46e-9	Thyroid stimulating hormone;
CRC	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.17	-0.37	5.09e-12	Capecitabine sensitivity;
CRC	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.1	-0.32	3.05e-9	Neuroticism;
CRC	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12560992	chr17:57184187	TRIM37	-0.51	-7.45	-0.38	8.55e-13	Testicular germ cell tumor;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg08989290	chr16:615782	NHLRC4	0.49	9.38	0.46	1.08e-18	Height;
CRC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.77	12.87	0.58	5.7e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.27	0.46	2.43e-18	Personality dimensions;
CRC	cis	rs6546324	0.921	rs1430788	chr2:67868412	C/T	cg15745817	chr2:67799979	NA	-0.29	-5.7	-0.3	2.7e-8	Endometriosis;
CRC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.39	-5.65	-0.3	3.51e-8	Obesity-related traits;
CRC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg27490568	chr2:178487706	NA	0.42	6.28	0.33	1.06e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.56	6.49	0.34	3.16e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.54	-8.48	-0.42	7.7e-16	Corneal astigmatism;
CRC	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.07	-0.36	9.07e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg18761221	chr20:60518478	NA	0.44	7.14	0.37	5.92e-12	Body mass index;
CRC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.86	-10.22	-0.49	1.8e-21	HIV-1 control;
CRC	cis	rs12745968	0.589	rs7541942	chr1:93021364	G/T	cg17283838	chr1:93427260	FAM69A	-0.44	-6.02	-0.32	4.61e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.66	6.77	0.35	5.88e-11	Plasma clusterin levels;
CRC	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	23.76	0.79	2.33e-73	Schizophrenia;
CRC	trans	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg24644049	chr4:85504048	CDS1	0.8	7.12	0.37	6.78e-12	Skin colour saturation;
CRC	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	cg04338863	chr8:33670619	NA	0.42	6.39	0.33	5.83e-10	Body mass index;
CRC	cis	rs8105895	0.935	rs7252550	chr19:22246017	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs2895526	0.668	rs10752272	chr10:12715060	G/T	cg00115178	chr10:12648176	CAMK1D	0.35	5.71	0.3	2.56e-8	Headache;
CRC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.09	0.32	3.19e-9	Dupuytren's disease;
CRC	trans	rs7976838	0.831	rs12824395	chr12:60129918	G/C	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.95	0.31	6.7e-9	Lung cancer;
CRC	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg20041105	chr8:143859282	LYNX1	-0.33	-5.76	-0.3	1.97e-8	Urinary tract infection frequency;
CRC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.76	-0.3	1.89e-8	Breast cancer;
CRC	trans	rs62295889	0.602	rs62295918	chr4:12537011	G/A	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.76	9.37	0.46	1.23e-18	Rheumatoid arthritis;
CRC	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	9.34	0.46	1.54e-18	Blood protein levels;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg15786705	chr6:28176104	NA	0.48	7.21	0.37	3.76e-12	Cardiac Troponin-T levels;
CRC	cis	rs4664293	0.867	rs3771721	chr2:160628155	C/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg21251018	chr6:28226885	NKAPL	0.46	6.57	0.34	1.97e-10	Depression;
CRC	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg26043149	chr18:55253948	FECH	0.52	7.92	0.4	3.67e-14	Bone mineral density;
CRC	trans	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.63	-6.82	-0.35	4.44e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.67	-0.35	1.09e-10	Mean corpuscular volume;
CRC	cis	rs11212617	1.000	rs7943165	chr11:108274890	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.67	0.35	1.07e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg12365402	chr11:9010492	NRIP3	-0.56	-10.65	-0.51	5.72e-23	Hemoglobin concentration;
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.46	7.08	0.36	8.6e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	5.93	0.31	7.6e-9	Life satisfaction;
CRC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg05341575	chr12:125625032	AACS	-0.4	-5.74	-0.3	2.14e-8	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg00261552	chr12:12764894	CREBL2	-0.4	-6.02	-0.31	4.62e-9	Aortic root size;
CRC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.41	7.87	0.4	5.04e-14	Ulcerative colitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04417954	chr15:91073943	CRTC3	0.48	6.11	0.32	2.75e-9	Thyroid stimulating hormone;
CRC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.62	9.75	0.47	6.78e-20	Colorectal cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12692042	chr18:30050872	FAM59A	0.44	6.01	0.31	4.99e-9	Anxiety disorder;
CRC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.8	-12.39	-0.56	3.3600000000000003e-29	Cognitive function;
CRC	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.19	-0.32	1.83e-9	Educational attainment;
CRC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.8	11.87	0.55	2.65e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27583038	chr1:234735904	NA	0.4	6.19	0.32	1.8e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.6	-0.3	4.53e-8	Parkinson's disease;
CRC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg21153622	chr11:89784906	NA	-0.38	-6.2	-0.32	1.74e-9	Height;
CRC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-10.89	-0.51	8.47e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.58	-9.37	-0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.698	rs6963177	chr7:124444604	T/A	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg02733842	chr7:1102375	C7orf50	-0.46	-6.29	-0.33	1.01e-9	Bronchopulmonary dysplasia;
CRC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg25876840	chr17:41920477	NA	0.56	7.59	0.39	3.26e-13	Triglycerides;
CRC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.5	6.29	0.33	1.02e-9	Bipolar disorder;
CRC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg11279151	chr3:101281821	RG9MTD1	0.53	7.1	0.36	7.68e-12	Colorectal cancer;
CRC	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.58	10.66	0.51	5.31e-23	Age of smoking initiation;
CRC	cis	rs7705042	0.897	rs12515668	chr5:141496090	G/T	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.88	-0.31	9.9e-9	Asthma;
CRC	cis	rs9463078	0.605	rs17339124	chr6:44942577	C/G	cg25276700	chr6:44698697	NA	0.25	6.22	0.32	1.5e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.54	7.4	0.38	1.14e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16257247	chr11:62554234	TMEM179B;TAF6L	0.44	6.46	0.34	3.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg13491945	chr12:107078410	RFX4	0.34	5.87	0.31	1.09e-8	Heart rate;
CRC	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	1.01	8.32	0.42	2.41e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg05341575	chr12:125625032	AACS	-0.37	-5.94	-0.31	7.33e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	-0.31	-7.28	-0.37	2.45e-12	Lymphocyte counts;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02700454	chr8:126441997	TRIB1	0.45	6.39	0.33	5.8e-10	Anxiety disorder;
CRC	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.53	7.89	0.4	4.39e-14	HDL cholesterol;
CRC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.49	0.38	6.5e-13	Motion sickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17101748	chr1:224517614	NVL	0.5	6.54	0.34	2.38e-10	Thyroid stimulating hormone;
CRC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg03395651	chr16:88107091	BANP	0.6	8.16	0.41	7.06e-15	Menopause (age at onset);
CRC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.57	-8.86	-0.44	5.21e-17	Motion sickness;
CRC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.93	-16.29	-0.67	3.69e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg04077850	chr5:125800366	GRAMD3	0.36	6.13	0.32	2.47e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	0.86	6.9	0.36	2.74e-11	Fat distribution (HIV);
CRC	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg04990556	chr1:26633338	UBXN11	0.54	5.85	0.31	1.19e-8	Obesity-related traits;
CRC	cis	rs7202877	0.656	rs37596	chr16:75498320	C/A	cg03315344	chr16:75512273	CHST6	-0.48	-6.21	-0.32	1.58e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg12365402	chr11:9010492	NRIP3	0.45	7.3	0.37	2.14e-12	Hemoglobin concentration;
CRC	trans	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg17903999	chr18:56338584	MALT1	-0.38	-6.02	-0.31	4.66e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg10911889	chr6:126070802	HEY2	0.37	5.72	0.3	2.34e-8	Brugada syndrome;
CRC	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg19338460	chr6:170058176	WDR27	-0.85	-8.59	-0.43	3.59e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.64	-8.52	-0.43	5.77e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.42	5.78	0.3	1.77e-8	Emphysema distribution in smoking;
CRC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	6.1	0.32	2.97e-9	Menarche (age at onset);
CRC	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg10802521	chr3:52805072	NEK4	0.44	5.98	0.31	5.68e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10159630	chr2:177037364	HOXD3	0.25	6.56	0.34	2.03e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.49	-7.69	-0.39	1.7e-13	Schizophrenia;
CRC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.22	0.32	1.55e-9	Axial length;
CRC	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg22134325	chr11:66188745	NPAS4	0.39	6.3	0.33	9.76e-10	Airway imaging phenotypes;
CRC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.76	-0.35	6.36e-11	Cutaneous nevi;
CRC	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.52	-10.41	-0.5	3.87e-22	Alcoholic chronic pancreatitis;
CRC	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.54	-8.81	-0.44	7.41e-17	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.42	-0.33	4.79e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg09264619	chr17:80180166	NA	-0.34	-5.76	-0.3	1.93e-8	Life satisfaction;
CRC	cis	rs2276314	0.512	rs1789506	chr18:33625370	G/A	cg05985134	chr18:33552581	C18orf21	-0.38	-6.03	-0.32	4.44e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.48	-6.54	-0.34	2.41e-10	Colorectal cancer;
CRC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg19318889	chr4:1322082	MAEA	-0.42	-6.47	-0.34	3.53e-10	Obesity-related traits;
CRC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.65	8.8	0.44	7.66e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.62	9.7	0.47	1.01e-19	Corneal astigmatism;
CRC	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.43	-6.47	-0.34	3.56e-10	Body mass index;
CRC	cis	rs10760158	0.800	rs10818520	chr9:124018673	A/T	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg25668320	chr4:144833231	NA	-0.48	-6.32	-0.33	8.58e-10	Optic disc area;
CRC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-7.14	-0.37	5.86e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.52	6.33	0.33	8e-10	Blood protein levels;
CRC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs10486722	0.624	rs11765316	chr7:41773032	A/T	cg22138096	chr7:41772439	LOC285954	0.39	5.89	0.31	9.49e-9	Pit-and-Fissure caries;
CRC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.32	-0.53	2.64e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16262614	chr3:133464971	TF	-0.35	-6.13	-0.32	2.58e-9	Iron status biomarkers;
CRC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg25456477	chr12:86230367	RASSF9	0.4	6.71	0.35	8.75e-11	Major depressive disorder;
CRC	cis	rs2346160	0.899	rs172283	chr6:167691225	T/C	cg04673565	chr6:167680447	NA	-0.39	-6.33	-0.33	7.83e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.5	-6.62	-0.34	1.44e-10	Gut microbiome composition (summer);
CRC	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg23234261	chr14:55582407	NA	-0.28	-5.86	-0.31	1.15e-8	Protein biomarker;
CRC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg03623178	chr6:28175578	NA	0.98	12.63	0.57	4.44e-30	Depression;
CRC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.04	-0.41	1.64e-14	Intelligence (multi-trait analysis);
CRC	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.7	-9.76	-0.47	6.32e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.45	-8.55	-0.43	4.78e-16	Educational attainment (years of education);
CRC	cis	rs753955	0.592	rs7325382	chr13:24350093	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.43	-5.98	-0.31	5.7e-9	Lung cancer;
CRC	cis	rs457287	0.772	rs457944	chr9:4830789	C/G	cg14182974	chr9:4791918	RCL1	-0.41	-5.75	-0.3	2.08e-8	Platelet count;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg14168621	chr7:2028884	MAD1L1	-0.43	-6.33	-0.33	7.92e-10	Lung cancer;
CRC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.49	7.04	0.36	1.15e-11	Aortic root size;
CRC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg17401720	chr7:158221031	PTPRN2	0.46	7.75	0.39	1.14e-13	Obesity-related traits;
CRC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg20203395	chr5:56204925	C5orf35	0.45	6.3	0.33	9.53e-10	Coronary artery disease;
CRC	trans	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg26043149	chr18:55253948	FECH	-0.53	-8.39	-0.42	1.42e-15	Bone mineral density;
CRC	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	9.07	0.45	1.07e-17	Schizophrenia;
CRC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.65	12.37	0.56	4.08e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg15590007	chr10:45870220	ALOX5	0.57	5.8	0.3	1.53e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.34	0.33	7.37e-10	Lung cancer;
CRC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg06042504	chr8:55087323	NA	-0.37	-5.77	-0.3	1.79e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg21620606	chr4:1342894	KIAA1530	0.36	5.89	0.31	9.62e-9	Obesity-related traits;
CRC	cis	rs17767392	0.958	rs36093218	chr14:71872073	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.89	-0.35	2.93e-11	Mitral valve prolapse;
CRC	cis	rs9487051	0.698	rs4301336	chr6:109650140	A/T	cg01475377	chr6:109611718	NA	0.36	5.65	0.3	3.56e-8	Reticulocyte fraction of red cells;
CRC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-7.36	-0.38	1.52e-12	Neuroticism;
CRC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-8.36	-0.42	1.85e-15	Chronic sinus infection;
CRC	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-6.57	-0.34	1.95e-10	Schizophrenia;
CRC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.56	8.5	0.42	6.77e-16	High light scatter reticulocyte count;
CRC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg10130564	chr11:117069849	TAGLN	0.36	6.78	0.35	5.59e-11	Blood protein levels;
CRC	trans	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg18288967	chr1:45987694	PRDX1	0.63	7.1	0.36	7.74e-12	Obesity-related traits;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg08200770	chr17:80723486	TBCD	-0.49	-7.4	-0.38	1.12e-12	Glycated hemoglobin levels;
CRC	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.07e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.1	0.32	2.93e-9	Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01646575	chr2:128785020	SAP130	0.45	6.35	0.33	7.26e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.04	-12.03	-0.55	7.26e-28	Diabetic kidney disease;
CRC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.78	-0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg11833968	chr6:79620685	NA	-0.37	-6.47	-0.34	3.53e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6546324	0.625	rs2902008	chr2:67802950	T/C	cg15745817	chr2:67799979	NA	-0.55	-9.09	-0.45	9.8e-18	Endometriosis;
CRC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.05	-0.32	3.94e-9	Diabetic kidney disease;
CRC	cis	rs4664293	0.867	rs2059698	chr2:160642416	C/T	cg08347373	chr2:160653686	CD302	0.5	7.69	0.39	1.73e-13	Monocyte percentage of white cells;
CRC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg25985355	chr7:65971099	NA	-0.53	-5.85	-0.31	1.17e-8	Diabetic kidney disease;
CRC	cis	rs995000	0.931	rs4329540	chr1:63027024	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.75	-0.35	6.74e-11	Triglyceride levels;
CRC	cis	rs6546324	0.580	rs2861684	chr2:67837380	T/C	cg15745817	chr2:67799979	NA	-0.44	-7.81	-0.4	7.73e-14	Endometriosis;
CRC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.61	10.26	0.49	1.32e-21	Tumor biomarkers;
CRC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.77	-11.07	-0.52	1.98e-24	Blood metabolite levels;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.59	6.26	0.33	1.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg13390004	chr1:15929781	NA	0.49	7.05	0.36	1.03e-11	Systolic blood pressure;
CRC	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-1.06	-10.93	-0.52	6.34e-24	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.76	10.42	0.5	3.71e-22	Systemic lupus erythematosus;
CRC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.43	6.54	0.34	2.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs6499244	0.526	rs7193221	chr16:69848721	C/G	cg00738113	chr16:70207722	CLEC18C	-0.33	-5.64	-0.3	3.75e-8	Menarche (age at onset);
CRC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.14	0.41	8.05e-15	Rheumatoid arthritis;
CRC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.04	12.91	0.58	3.83e-31	Vitiligo;
CRC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.48	-9.88	-0.48	2.44e-20	Vitiligo;
CRC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.62	-8.55	-0.43	4.62e-16	Carotid intima media thickness;
CRC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.93	-18.42	-0.71	1.5e-52	Height;
CRC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.58	-10.16	-0.49	2.82e-21	Body mass index;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.62	7.52	0.38	5.38e-13	Renal function-related traits (BUN);
CRC	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.6	8.14	0.41	8.14e-15	Coronary artery disease;
CRC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg12193833	chr17:30244370	NA	-0.61	-7.78	-0.39	9.61e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.47	-0.38	7.36e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg22182287	chr2:3452347	TTC15	0.37	5.79	0.3	1.65e-8	Obesity-related traits;
CRC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg03030879	chr14:75389066	RPS6KL1	0.4	6.1	0.32	2.98e-9	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17524854	chr12:67663046	CAND1	0.48	6.27	0.33	1.1e-9	Thyroid stimulating hormone;
CRC	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg01426195	chr3:39028469	NA	0.53	8.52	0.43	5.87e-16	Handedness;
CRC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.55	8.96	0.44	2.51e-17	Coronary artery disease;
CRC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.31	0.49	8.58e-22	Mean corpuscular volume;
CRC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.43	5.84	0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg15147215	chr3:52552868	STAB1	-0.52	-7.5	-0.38	6.14e-13	Bipolar disorder;
CRC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg02398342	chr17:80708632	TBCD;FN3K	0.55	6.77	0.35	5.99e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg15654264	chr1:150340011	RPRD2	-0.38	-5.76	-0.3	1.98e-8	Migraine;
CRC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.53	0.47	3.55e-19	Bladder cancer;
CRC	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.42	-5.77	-0.3	1.79e-8	Height;
CRC	cis	rs4731207	0.596	rs13240512	chr7:124571890	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.25	-0.33	1.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs10991814	1.000	rs59581968	chr9:93943140	C/T	cg14446406	chr9:93919335	NA	0.59	7.26	0.37	2.8e-12	Neutrophil percentage of granulocytes;
CRC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.42	-0.38	1.04e-12	Aortic root size;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-8.95	-0.44	2.69e-17	Bipolar disorder;
CRC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg05569086	chr8:143859399	LYNX1	-0.65	-11.62	-0.54	2.18e-26	Urinary tract infection frequency;
CRC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.45	-6.45	-0.34	3.99e-10	White blood cell count (basophil);Basophil percentage of white cells;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25448636	chr17:17140084	FLCN	0.41	5.98	0.31	5.94e-9	Myopia (pathological);
CRC	cis	rs2882667	0.898	rs10038121	chr5:138389602	A/G	cg09476006	chr5:138032270	NA	0.43	7.26	0.37	2.89e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.73	-11.29	-0.53	3.23e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.6	-7.73	-0.39	1.34e-13	Immature fraction of reticulocytes;
CRC	cis	rs10991814	0.920	rs7043552	chr9:94025991	G/A	cg14446406	chr9:93919335	NA	0.58	6.41	0.33	5.03e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg11901034	chr3:128598214	ACAD9	-0.5	-6.08	-0.32	3.24e-9	IgG glycosylation;
CRC	cis	rs11212617	0.905	rs3901851	chr11:108352335	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.77	0.3	1.87e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.77	8.75	0.43	1.16e-16	Lung function (FEV1/FVC);
CRC	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.51	6.14	0.32	2.31e-9	Carotid intima media thickness;
CRC	cis	rs524281	0.773	rs10791862	chr11:66013664	T/C	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.58	-9.46	-0.46	6.22e-19	P wave terminal force;
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.55	-5.92	-0.31	8.21e-9	Schizophrenia;
CRC	trans	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.59	9.67	0.47	1.29e-19	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg01262667	chr19:19385393	TM6SF2	0.37	6.17	0.32	2.05e-9	Tonsillectomy;
CRC	trans	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg19894588	chr14:64061835	NA	-0.55	-7.53	-0.38	4.93e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20307385	chr11:47447363	PSMC3	-0.48	-6.38	-0.33	5.86e-10	Subjective well-being;
CRC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg19193384	chr17:30244184	NA	-0.63	-7.17	-0.37	5.09e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.91	-0.4	3.86e-14	Monocyte percentage of white cells;
CRC	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.56	-6.24	-0.33	1.32e-9	Cancer;
CRC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.78	-11.31	-0.53	2.93e-25	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg12273811	chr6:28175739	NA	0.45	6.51	0.34	2.86e-10	Parkinson's disease;
CRC	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.56	6.38	0.33	6.03e-10	Carotid intima media thickness;
CRC	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.44	-5.83	-0.31	1.33e-8	Adiposity;
CRC	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg20400248	chr8:9005257	PPP1R3B	0.39	5.83	0.31	1.36e-8	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg09877947	chr5:131593287	PDLIM4	0.36	6.44	0.33	4.18e-10	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06700871	chr2:84686330	SUCLG1	0.4	6.02	0.31	4.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg14668889	chr17:73230827	NUP85	0.5	7.31	0.37	2.1e-12	Systemic lupus erythematosus;
CRC	cis	rs12144094	0.882	rs10218713	chr1:120247899	A/G	cg20995928	chr1:120229863	NA	0.47	6.77	0.35	5.98e-11	Height;
CRC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.52	-5.92	-0.31	8.28e-9	Lymphocyte counts;
CRC	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg20936604	chr3:58311152	NA	-0.74	-6.94	-0.36	2.05e-11	Cholesterol, total;
CRC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg09998033	chr7:158218633	PTPRN2	0.5	7.0	0.36	1.49e-11	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01220033	chr9:131419100	WDR34	0.46	6.23	0.32	1.47e-9	Response to antipsychotic treatment;
CRC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.75	12.12	0.56	3.38e-28	Menopause (age at onset);
CRC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.79	8.04	0.41	1.68e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg03934865	chr2:198174659	NA	0.35	5.63	0.3	3.9e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7705042	0.865	rs2338822	chr5:141503059	T/C	cg07392085	chr5:141489673	NDFIP1	0.45	7.15	0.37	5.54e-12	Asthma;
CRC	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.56	5.92	0.31	8.04e-9	Blood protein levels;
CRC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-7.27	-0.37	2.62e-12	Vitiligo;
CRC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs73206853	0.841	rs73191815	chr12:110914698	G/A	cg12870014	chr12:110450643	ANKRD13A	0.77	7.35	0.38	1.59e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.42	6.66	0.34	1.18e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.43	-0.33	4.6e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18373552	chr10:76871314	SAMD8	0.47	6.56	0.34	2.03e-10	Anxiety disorder;
CRC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.27	-0.37	2.6e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.32	-0.37	1.91e-12	Bipolar disorder;
CRC	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg10523679	chr1:76189770	ACADM	-0.42	-5.92	-0.31	8.22e-9	Daytime sleep phenotypes;
CRC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.73	0.43	1.35e-16	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12058391	chr8:63951472	GGH	0.43	6.03	0.32	4.29e-9	Anxiety disorder;
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-5.96	-0.31	6.54e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.561	rs12706631	chr7:124586580	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg12458913	chr13:53173898	NA	-0.53	-8.4	-0.42	1.33e-15	Lewy body disease;
CRC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Body mass index;
CRC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.91	-0.31	8.44e-9	Gut microbiome composition (summer);
CRC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.57	-0.75	5.09e-61	Height;
CRC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.92	0.31	8.13e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg13260133	chr10:104626808	NA	0.4	6.16	0.32	2.07e-9	Interleukin-6 levels;
CRC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.76	6.79	0.35	5.14e-11	Body mass index;
CRC	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg04165759	chr1:150448943	RPRD2	-0.36	-5.96	-0.31	6.48e-9	Migraine;
CRC	cis	rs17767392	0.834	rs72728406	chr14:71734992	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.42	-0.33	4.67e-10	Mitral valve prolapse;
CRC	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.67	9.29	0.46	2.22e-18	Blood protein levels;
CRC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.66	6.86	0.35	3.41e-11	Plasma clusterin levels;
CRC	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.66	9.72	0.47	8.41e-20	Schizophrenia;
CRC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.61	-10.89	-0.51	8.61e-24	Schizophrenia;
CRC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	trans	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs282587	0.569	rs9604422	chr13:113410586	C/T	cg04656015	chr13:113407548	ATP11A	0.61	7.48	0.38	6.63e-13	Glycated hemoglobin levels;
CRC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg26566898	chr11:117069891	TAGLN	0.41	8.43	0.42	1.1e-15	Blood protein levels;
CRC	cis	rs938554	0.829	rs5028843	chr4:9940806	G/A	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.82	-0.31	1.43e-8	Blood metabolite levels;
CRC	cis	rs4663866	0.901	rs3739066	chr2:239184124	G/T	cg16914508	chr2:239161102	PER2	0.75	7.84	0.4	6.47e-14	Irritable bowel syndrome;
CRC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.85	0.31	1.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.58	10.12	0.49	3.95e-21	Asthma;
CRC	cis	rs57994353	0.600	rs4400499	chr9:139305041	C/T	cg14119001	chr9:139324193	INPP5E	-0.44	-5.8	-0.3	1.6e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg26668828	chr6:292823	DUSP22	-0.58	-8.66	-0.43	2.17e-16	Menopause (age at onset);
CRC	trans	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-7.46	-0.38	8.01e-13	Menarche (age at onset);
CRC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.82	-14.08	-0.61	1.51e-35	Coronary artery disease;
CRC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg23229984	chr5:148520753	ABLIM3	0.5	6.95	0.36	1.96e-11	Breast cancer;
CRC	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	0.98	9.11	0.45	8.06e-18	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24775616	chr17:1157257	NA	0.39	6.2	0.32	1.7e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.81	14.33	0.62	1.55e-36	Vitiligo;
CRC	cis	rs7429990	0.901	rs7431567	chr3:48027832	G/T	cg11946769	chr3:48343235	NME6	-0.5	-6.43	-0.33	4.61e-10	Educational attainment (years of education);
CRC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg17321639	chr7:2759063	NA	-0.5	-6.52	-0.34	2.6200000000000003e-10	Height;
CRC	cis	rs7605827	0.930	rs7568874	chr2:15546361	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.79e-9	Educational attainment (years of education);
CRC	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.85	-14.98	-0.64	4.67e-39	Lewy body disease;
CRC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.52	7.74	0.39	1.21e-13	Lymphocyte counts;
CRC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.79	-10.4	-0.5	4.39e-22	Initial pursuit acceleration;
CRC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-10.69	-0.51	4.44e-23	Personality dimensions;
CRC	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17507749	chr15:85114479	UBE2QP1	0.62	8.97	0.44	2.36e-17	Schizophrenia;
CRC	cis	rs501120	0.564	rs2624681	chr10:44677301	G/C	cg09554077	chr10:44749378	NA	0.5	6.98	0.36	1.62e-11	Coronary artery disease;Coronary heart disease;
CRC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.63	-0.47	1.7e-19	Hip circumference adjusted for BMI;
CRC	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg27223183	chr8:87520930	FAM82B	-0.42	-5.75	-0.3	1.99e-8	Caudate activity during reward;
CRC	cis	rs9359856	0.956	rs9362664	chr6:90307703	G/A	cg13799429	chr6:90582589	CASP8AP2	0.42	6.1	0.32	2.99e-9	Bipolar disorder;
CRC	cis	rs1868673	1.000	rs1868672	chr3:150175231	T/C	cg04908077	chr3:150187338	NA	-0.33	-5.64	-0.3	3.62e-8	Waist circumference;
CRC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg04518342	chr5:131593106	PDLIM4	0.47	8.68	0.43	1.93e-16	Breast cancer;
CRC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.67	-0.3	3.14e-8	Morning vs. evening chronotype;
CRC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg04025307	chr7:1156635	C7orf50	0.64	6.66	0.34	1.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.62	-0.34	1.42e-10	Breast cancer;
CRC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.82	12.72	0.57	2.06e-30	Menarche (age at onset);
CRC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-16.03	-0.66	3.99e-43	Schizophrenia;
CRC	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg14515779	chr1:101123966	NA	-0.35	-6.36	-0.33	6.74e-10	Monocyte count;
CRC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.54	-0.47	3.44e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.06	-0.32	3.73e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.4	-7.09	-0.36	8.42e-12	Life satisfaction;
CRC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.82	12.48	0.57	1.58e-29	Cognitive ability;
CRC	cis	rs11212617	0.967	rs227067	chr11:108209360	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.75	0.3	2.06e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	13.78	0.6	2.12e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg18335740	chr13:41363409	SLC25A15	0.61	9.62	0.47	1.85e-19	Lewy body disease;
CRC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg07828024	chr6:149772892	ZC3H12D	0.46	8.29	0.42	2.91e-15	Dupuytren's disease;
CRC	trans	rs587242	0.956	rs12030748	chr1:96904404	G/A	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02290350	chr8:58132656	NA	-0.43	-6.12	-0.32	2.64e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.64	-0.39	2.32e-13	Intelligence (multi-trait analysis);
CRC	cis	rs360798	0.532	rs1022110	chr2:63046039	T/G	cg17519650	chr2:63277830	OTX1	-0.48	-6.64	-0.34	1.27e-10	Coronary artery disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01204964	chr21:35014044	ITSN1;CRYZL1	0.36	5.97	0.31	6.16e-9	Obesity-related traits;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg25164649	chr6:28176230	NA	0.6	8.62	0.43	2.96e-16	Parkinson's disease;
CRC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.23	0.37	3.48e-12	Major depressive disorder;
CRC	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg17085576	chr10:5658249	NA	-0.44	-6.11	-0.32	2.87e-9	Breast cancer;
CRC	cis	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg26816564	chr1:7831052	VAMP3	0.75	8.36	0.42	1.8e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.23	-0.32	1.45e-9	Menopause (age at onset);
CRC	cis	rs59104589	0.521	rs62190404	chr2:242401422	C/T	cg19488206	chr2:242435732	STK25	0.48	7.71	0.39	1.5e-13	Fibrinogen levels;
CRC	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg03938978	chr2:103052716	IL18RAP	0.47	7.35	0.38	1.59e-12	Blood protein levels;
CRC	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg09455208	chr3:40491958	NA	-0.29	-5.81	-0.3	1.49e-8	Renal cell carcinoma;
CRC	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg20811857	chr17:78079795	GAA	-0.37	-5.67	-0.3	3.2e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CRC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.09	0.32	3.08e-9	Heart rate;
CRC	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	7.42	0.38	1e-12	Blood protein levels;
CRC	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-9.23	-0.45	3.45e-18	Prevalent atrial fibrillation;
CRC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg11189052	chr15:85197271	WDR73	0.6	8.83	0.44	6.13e-17	Schizophrenia;
CRC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.42	6.89	0.36	2.81e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-5.64	-0.3	3.6e-8	Lung cancer;
CRC	cis	rs11166629	1.000	rs6981735	chr8:135635730	T/C	cg27224718	chr8:135614730	ZFAT	0.52	7.64	0.39	2.35e-13	Smoking quantity;
CRC	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.44	-6.68	-0.35	1.04e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.07	-0.36	9.56e-12	Aortic root size;
CRC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.57	6.85	0.35	3.56e-11	Lymphocyte counts;
CRC	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg21918786	chr6:109611834	NA	-0.33	-5.63	-0.3	3.82e-8	Reticulocyte fraction of red cells;
CRC	trans	rs17143387	0.803	rs78592156	chr10:8324943	T/C	cg00390484	chr22:20019695	C22orf25;MIR185	0.49	5.99	0.31	5.39e-9	Scalp hair shape;
CRC	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg24289452	chr6:170231220	NA	-0.59	-6.42	-0.33	4.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg02683197	chr6:28174875	NA	0.62	8.4	0.42	1.31e-15	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.98	-0.31	5.7e-9	Cognitive function;
CRC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.61	10.07	0.49	5.52e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.08	-18.17	-0.71	1.46e-51	Cognitive function;
CRC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	6.95	0.36	2e-11	Platelet count;
CRC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.55	6.19	0.32	1.82e-9	Vitiligo;
CRC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.94	11.35	0.53	2.08e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.66	7.93	0.4	3.46e-14	Menarche (age at onset);
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg22638593	chr5:131593259	PDLIM4	0.51	8.78	0.44	8.94e-17	Acylcarnitine levels;
CRC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg11843238	chr5:131593191	PDLIM4	0.43	7.36	0.38	1.52e-12	Acylcarnitine levels;
CRC	cis	rs10242455	0.702	rs75156180	chr7:98964100	G/A	cg18809830	chr7:99032528	PTCD1	-1.08	-7.75	-0.39	1.18e-13	Blood metabolite levels;
CRC	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg09659197	chr4:152720779	NA	-0.44	-8.63	-0.43	2.64e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg15145296	chr3:125709740	NA	-0.59	-6.91	-0.36	2.47e-11	Blood pressure (smoking interaction);
CRC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.1	-0.45	8.99e-18	Prostate cancer;
CRC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.51	8.4	0.42	1.38e-15	Cystic fibrosis severity;
CRC	trans	rs2303319	0.504	rs55925603	chr2:162497210	G/A	cg27113153	chr11:123612418	ZNF202	-0.68	-6.06	-0.32	3.72e-9	Cognitive function;
CRC	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg15786705	chr6:28176104	NA	0.61	8.9	0.44	3.91e-17	Parkinson's disease;
CRC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.74	0.35	7.13e-11	HIV-1 control;
CRC	cis	rs4757319	0.537	rs10832436	chr11:15430222	A/G	cg03245590	chr11:15329459	NA	0.52	9.21	0.45	3.81e-18	Breast cancer;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg07807695	chr5:81608485	ATP6AP1L	-0.49	-7.76	-0.39	1.07e-13	Breast cancer;
CRC	cis	rs6758955	0.850	rs56261863	chr2:10480339	G/A	cg15773312	chr2:10472214	HPCAL1	-0.82	-9.5	-0.46	4.43e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.98	-19.23	-0.73	8.84e-56	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-0.99	-9.66	-0.47	1.32e-19	Diabetic retinopathy;
CRC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.39	6.9	0.36	2.63e-11	Primary biliary cholangitis;
CRC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-11.39	-0.53	1.48e-25	Colorectal cancer;
CRC	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.58	8.5	0.42	6.79e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg15845792	chr6:28175446	NA	0.71	6.18	0.32	1.87e-9	Depression;
CRC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	6.78	0.35	5.63e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs6961069	0.722	rs13438282	chr7:80262224	C/T	cg04458919	chr7:80252533	CD36	0.35	6.15	0.32	2.22e-9	Platelet count;
CRC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.94	0.31	7.24e-9	Height;
CRC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.4	0.53	1.37e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.59	6.4	0.33	5.22e-10	Initial pursuit acceleration;
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.39	-9.41	-0.46	8.54e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.06	-0.55	5.45e-28	Coffee consumption (cups per day);
CRC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.44	-5.61	-0.3	4.32e-8	Menarche (age at onset);
CRC	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10982256	0.870	rs10982248	chr9:117250903	G/A	cg13636371	chr9:117264095	DFNB31	0.33	6.41	0.33	5.17e-10	Bipolar disorder;
CRC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.55	9.91	0.48	2.03e-20	Hemoglobin concentration;
CRC	cis	rs11958404	0.932	rs11950881	chr5:157410550	C/T	cg05962755	chr5:157440814	NA	0.84	10.94	0.52	5.92e-24	IgG glycosylation;
CRC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.53	7.38	0.38	1.28e-12	IgG glycosylation;
CRC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg20203395	chr5:56204925	C5orf35	0.56	6.84	0.35	3.89e-11	Initial pursuit acceleration;
CRC	trans	rs6544773	0.668	rs341603	chr2:45065376	A/G	cg10208897	chr5:178548229	ADAMTS2	0.36	6.14	0.32	2.32e-9	Mosquito bite size;
CRC	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.39	-0.33	5.72e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-6.68	-0.35	1.02e-10	Body mass index;
CRC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.52	6.3	0.33	9.68e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.82	-0.48	4.01e-20	Total cholesterol levels;
CRC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.49	9.67	0.47	1.26e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.56	0.38	4.08e-13	Height;
CRC	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	1.05	22.23	0.77	1.67e-67	Multiple myeloma;
CRC	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.63	-7.21	-0.37	3.91e-12	Ulcerative colitis;
CRC	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg09163369	chr1:210001066	C1orf107	0.51	6.67	0.35	1.05e-10	Orofacial clefts;
CRC	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg17133734	chr15:86042851	AKAP13	0.43	6.73	0.35	7.69e-11	Coronary artery disease;
CRC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.51	7.66	0.39	2.07e-13	Aortic root size;
CRC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.72	11.07	0.52	2.07e-24	Corneal astigmatism;
CRC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg18764771	chr6:116381957	FRK	0.25	7.19	0.37	4.45e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-10.4	-0.5	4.29e-22	Tonsillectomy;
CRC	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg05562828	chr17:3906858	NA	-0.66	-11.48	-0.53	7.1e-26	Type 2 diabetes;
CRC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.5	6.29	0.33	9.84e-10	Monocyte percentage of white cells;
CRC	cis	rs11997175	0.546	rs10808337	chr8:33583850	T/C	ch.8.33884649F	chr8:33765107	NA	0.43	6.67	0.35	1.06e-10	Body mass index;
CRC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.44	-6.45	-0.34	3.94e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.12	-0.41	9.74e-15	Chronic sinus infection;
CRC	cis	rs7487075	0.619	rs4768724	chr12:46848416	C/T	cg22049899	chr12:47219821	SLC38A4	0.32	5.86	0.31	1.12e-8	Itch intensity from mosquito bite;
CRC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.57	8.32	0.42	2.37e-15	Type 2 diabetes;
CRC	trans	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg08235057	chr22:21057110	TMEM191A	0.51	6.12	0.32	2.59e-9	Breast cancer;
CRC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.53	8.1	0.41	1.09e-14	Height;
CRC	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.42	6.49	0.34	3.07e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.49	-0.46	4.79e-19	Triglycerides;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg03790207	chr6:42947109	PEX6	-0.44	-6.1	-0.32	3e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg22110888	chr17:80059540	CCDC57	0.42	6.59	0.34	1.71e-10	Life satisfaction;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.53	6.75	0.35	6.69e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg15848620	chr12:58087721	OS9	-0.59	-8.04	-0.41	1.66e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.04	-0.41	1.62e-14	Breast cancer;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-8.25	-0.41	3.81e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg18478394	chr8:109455254	TTC35	0.39	6.0	0.31	5.12e-9	Dupuytren's disease;
CRC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.78	11.62	0.54	2.26e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.87	11.32	0.53	2.58e-25	Iron status biomarkers;
CRC	cis	rs62408225	1.000	rs2875584	chr6:90950628	C/T	cg06866423	chr6:90926672	BACH2	0.49	8.08	0.41	1.26e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6681460	0.549	rs7547857	chr1:67031890	A/G	cg02459107	chr1:67143332	SGIP1	0.34	5.63	0.3	3.78e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.66	7.86	0.4	5.62e-14	Lymphocyte counts;
CRC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.47	-0.5	2.42e-22	Total cholesterol levels;
CRC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.4	-6.95	-0.36	1.96e-11	Height;
CRC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg01721255	chr8:58191610	C8orf71	0.51	6.33	0.33	7.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.65	-8.64	-0.43	2.48e-16	Facial morphology (factor 19);
CRC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.56	7.53	0.38	4.85e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.73	10.45	0.5	2.97e-22	Menarche (age at onset);
CRC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg18876405	chr7:65276391	NA	0.45	6.19	0.32	1.83e-9	Aortic root size;
CRC	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg25809561	chr17:30822961	MYO1D	0.52	9.43	0.46	7.81e-19	Schizophrenia;
CRC	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg11738485	chr19:12877000	HOOK2	-0.44	-5.93	-0.31	7.86e-9	Bipolar disorder;
CRC	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.45	-0.42	9.65e-16	Alcohol dependence;
CRC	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-6.18	-0.32	1.89e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg23461800	chr14:103021989	NA	-0.68	-7.82	-0.4	7.46e-14	Platelet count;
CRC	cis	rs62432291	0.681	rs433786	chr6:159665946	T/A	cg14500486	chr6:159655392	FNDC1	-0.76	-9.16	-0.45	5.51e-18	Joint mobility (Beighton score);
CRC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.47	7.57	0.39	3.81e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg06896663	chr8:82754093	SNX16	-0.69	-5.98	-0.31	5.75e-9	Cognitive function;
CRC	trans	rs9650657	0.740	rs10481451	chr8:10649328	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.64	-0.34	1.33e-10	Neuroticism;
CRC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.77	-0.44	1e-16	Aortic root size;
CRC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.59	-0.47	2.21e-19	Subjective well-being;
CRC	cis	rs6840360	0.642	rs11735957	chr4:152427506	G/A	cg09659197	chr4:152720779	NA	0.33	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.47	8.96	0.44	2.53e-17	Renal cell carcinoma;
CRC	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-7.79	-0.39	8.97e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9309473	0.528	rs7573275	chr2:73552542	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.8	-0.3	1.53e-8	Metabolite levels;
CRC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.21	-0.37	3.99e-12	Hemoglobin concentration;
CRC	trans	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg26043149	chr18:55253948	FECH	-0.53	-7.87	-0.4	5.06e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-6.11	-0.32	2.89e-9	IgG glycosylation;
CRC	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg12072164	chr19:44306565	LYPD5	0.42	6.59	0.34	1.77e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs4731207	0.698	rs2896361	chr7:124473825	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23836594	chr17:37894258	GRB7	0.38	7.01	0.36	1.35e-11	Response to antipsychotic treatment;
CRC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg07713946	chr22:31675144	LIMK2	-0.39	-5.62	-0.3	4e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs6694672	0.764	rs6678066	chr1:197221904	A/G	cg13682187	chr1:196946512	CFHR5	0.52	5.74	0.3	2.11e-8	Asthma;
CRC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.45	-8.96	-0.44	2.38e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.68	-8.93	-0.44	3.1e-17	Multiple sclerosis;
CRC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.64	11.45	0.53	8.65e-26	Schizophrenia;
CRC	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04317338	chr11:64019027	PLCB3	0.42	5.82	0.31	1.36e-8	Platelet count;
CRC	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.97	-0.31	6.23e-9	Neuroticism;
CRC	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.18e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg16358738	chr2:241808595	AGXT	-0.4	-6.98	-0.36	1.59e-11	Urinary metabolites;
CRC	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg14664628	chr15:75095509	CSK	0.46	6.45	0.33	4.1e-10	Systemic lupus erythematosus;
CRC	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg00738113	chr16:70207722	CLEC18C	-0.42	-6.02	-0.31	4.75e-9	IgE levels;
CRC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.72	6.95	0.36	1.99e-11	Diabetic retinopathy;
CRC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.99	-0.36	1.56e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.65	-10.52	-0.5	1.68e-22	Height;
CRC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg24531977	chr5:56204891	C5orf35	-0.46	-7.0	-0.36	1.43e-11	Coronary artery disease;
CRC	cis	rs17767392	0.756	rs61991195	chr14:71747223	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.39	-0.33	5.76e-10	Mitral valve prolapse;
CRC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg19688584	chr6:167529678	CCR6	0.31	5.61	0.3	4.31e-8	Rheumatoid arthritis;
CRC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.26	0.37	2.78e-12	Motion sickness;
CRC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.74	9.35	0.46	1.38e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs427941	0.703	rs201447	chr7:101738384	C/A	cg06246474	chr7:101738831	CUX1	0.46	7.16	0.37	5.46e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg07090678	chr1:91966139	CDC7	0.42	6.8	0.35	5e-11	Breast cancer;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg25164649	chr6:28176230	NA	0.6	8.04	0.41	1.66e-14	Parkinson's disease;
CRC	cis	rs891088	0.626	rs12982656	chr19:7194609	C/T	cg09779027	chr19:7224513	INSR	-0.61	-7.5	-0.38	6.12e-13	Hip circumference adjusted for BMI;Height;
CRC	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	0.64	6.97	0.36	1.69e-11	Prostate cancer;
CRC	cis	rs2257205	0.667	rs8070407	chr17:56709172	G/A	cg25885038	chr17:56607967	SEPT4	-0.53	-5.86	-0.31	1.11e-8	Pancreatic cancer;
CRC	cis	rs847649	0.961	rs7456502	chr7:102596022	C/A	cg18108683	chr7:102477205	FBXL13	0.58	9.39	0.46	1.03e-18	Morning vs. evening chronotype;
CRC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.71	6.8	0.35	4.84e-11	Diabetic retinopathy;
CRC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.17	-0.56	2.12e-28	Alzheimer's disease;
CRC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg15382696	chr6:118971807	C6orf204	0.58	7.36	0.38	1.53e-12	Diastolic blood pressure;
CRC	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg06092702	chr1:163392909	NA	-0.52	-8.18	-0.41	6.32e-15	Motion sickness;
CRC	trans	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.95	-0.36	1.98e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.61	-0.39	2.98e-13	Waist circumference;Hip circumference;
CRC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.34	0.33	7.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	0.67	7.78	0.39	9.49e-14	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg12458913	chr13:53173898	NA	0.47	7.0	0.36	1.48e-11	Lewy body disease;
CRC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	10.22	0.49	1.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg14671364	chr1:107599128	PRMT6	-0.47	-6.64	-0.34	1.28e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6499255	0.951	rs57488237	chr16:69741571	T/C	cg04110750	chr16:69646130	NFAT5	-0.54	-7.59	-0.39	3.27e-13	IgE levels;
CRC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.55	7.44	0.38	9.13e-13	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.35	-0.33	7.06e-10	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg21620606	chr4:1342894	KIAA1530	0.38	6.42	0.33	4.82e-10	Obesity-related traits;
CRC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	1.03	20.73	0.75	1.2e-61	Headache;
CRC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-10.33	-0.49	7.74e-22	Cognitive function;
CRC	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.44	-0.38	9.1e-13	Schizophrenia;
CRC	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.56	8.32	0.42	2.4e-15	Bone mineral density;
CRC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-9.57	-0.47	2.73e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-5.91	-0.31	8.4e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg16898833	chr6:26189333	HIST1H4D	0.87	6.39	0.33	5.53e-10	Lung cancer;Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.3	0.53	3.14e-25	Tonsillectomy;
CRC	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg07636037	chr3:49044803	WDR6	0.56	6.45	0.33	4.06e-10	Menarche (age at onset);
CRC	cis	rs1975031	1	rs1975031	chr19:7217601	G/A	cg09779027	chr19:7224513	INSR	-0.83	-10.39	-0.5	4.65e-22	Perceived unattractiveness to mosquitoes;
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.65	8.75	0.43	1.12e-16	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg11866396	chr17:5322940	RPAIN;NUP88	0.41	6.64	0.34	1.3e-10	Interleukin-6 levels;
CRC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.55	-6.47	-0.34	3.47e-10	Red cell distribution width;
CRC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.72	0.39	1.41e-13	Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03617389	chr16:5147251	FAM86A	0.47	7.04	0.36	1.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.53	8.12	0.41	9.16e-15	Axial length;
CRC	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	1.16	9.8	0.48	4.56e-20	Mitochondrial DNA levels;
CRC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.45	-10.48	-0.5	2.25e-22	Coronary artery disease;
CRC	cis	rs4731207	0.564	rs6466992	chr7:124692166	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.14	-0.32	2.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg24154853	chr7:158122151	PTPRN2	0.53	8.9	0.44	3.85e-17	Calcium levels;
CRC	cis	rs4731207	0.596	rs7789392	chr7:124611076	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.23	-0.32	1.46e-9	Cutaneous malignant melanoma;
CRC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.09	-0.32	3.21e-9	Daytime sleep phenotypes;
CRC	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg24759859	chr6:86352639	SYNCRIP	0.46	6.72	0.35	8.14e-11	Smooth-surface caries;
CRC	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.53	12.2	0.56	1.67e-28	Prostate cancer;
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.52	8.71	0.43	1.56e-16	Dupuytren's disease;
CRC	cis	rs12044355	0.927	rs11577035	chr1:231835941	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.81	0.35	4.68e-11	Alzheimer's disease;
CRC	cis	rs317865	0.737	rs73234651	chr4:16196651	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	5.7	0.3	2.67e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.51	7.09	0.36	8.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.44	7.72	0.39	1.36e-13	Intelligence (multi-trait analysis);
CRC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg08773314	chr2:239334832	ASB1	0.34	7.8	0.4	8.19e-14	Multiple system atrophy;
CRC	cis	rs7605827	0.681	rs63106161	chr2:15537726	T/C	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00313973	chr10:99186293	PGAM1	0.42	6.18	0.32	1.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.4	8.63	0.43	2.6e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.77	-12.52	-0.57	1.08e-29	Idiopathic membranous nephropathy;
CRC	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg27427491	chr17:78079615	GAA	-0.45	-6.15	-0.32	2.28e-9	Yeast infection;
CRC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.78	-12.76	-0.58	1.4e-30	Height;
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg06896663	chr8:82754093	SNX16	-0.69	-5.98	-0.31	5.75e-9	Cognitive function;
CRC	cis	rs4964805	0.913	rs35945096	chr12:104201929	G/A	cg02344784	chr12:104178138	NT5DC3	0.53	7.78	0.39	9.76e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.51	7.25	0.37	3e-12	Testicular germ cell tumor;
CRC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.46	-6.84	-0.35	3.94e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.41	6.21	0.32	1.61e-9	Longevity;Endometriosis;
CRC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.8	-11.56	-0.54	3.55e-26	Body mass index;
CRC	trans	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.84	-0.35	3.87e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs216303	0.642	rs216314	chr12:6136580	T/C	cg19878637	chr12:6148451	VWF	-0.63	-7.0	-0.36	1.45e-11	Low vWF levels;
CRC	cis	rs6840360	0.642	rs11099815	chr4:152343888	G/T	cg09659197	chr4:152720779	NA	0.33	6.55	0.34	2.24e-10	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11204671	chr14:24583351	DCAF11	-0.43	-6.2	-0.32	1.69e-9	Myopia (pathological);
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg17958423	chr11:6947583	ZNF215	0.58	6.08	0.32	3.27e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg20885578	chr2:198174922	NA	0.35	5.68	0.3	2.96e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg03647239	chr10:116582469	FAM160B1	0.41	5.62	0.3	4.06e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.77	10.03	0.48	7.73e-21	Bipolar disorder;
CRC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.58	10.4	0.5	4.34e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.48	6.45	0.34	3.91e-10	Thyroid stimulating hormone;
CRC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.43	9.61	0.47	1.9e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg21155852	chr7:2048760	MAD1L1	-0.48	-6.6	-0.34	1.62e-10	Neuroticism;
CRC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-6.62	-0.34	1.48e-10	Coronary artery disease;
CRC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	10.67	0.51	5.17e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.56	-7.22	-0.37	3.52e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.58e-12	Height;
CRC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.69	-8.75	-0.43	1.12e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.65	7.97	0.4	2.56e-14	Menarche (age at onset);
CRC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.47	-0.34	3.59e-10	Blood pressure (smoking interaction);
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg25856811	chr1:152973957	SPRR3	-0.21	-5.61	-0.3	4.3e-8	Inflammatory skin disease;
CRC	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	6.45	0.34	3.98e-10	Blood metabolite levels;
CRC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg10298567	chr3:47292165	KIF9	-0.38	-6.1	-0.32	2.99e-9	Colorectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18845289	chr12:121124611	MLEC	0.47	6.17	0.32	2.03e-9	Thyroid stimulating hormone;
CRC	cis	rs2346160	0.867	rs412495	chr6:167688940	C/G	cg04673565	chr6:167680447	NA	0.33	5.64	0.3	3.59e-8	Parental extreme longevity (95 years and older);
CRC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg26695010	chr11:65641043	EFEMP2	0.42	6.32	0.33	8.3e-10	Eosinophil percentage of white cells;
CRC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.94	0.36	2.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04592292	chr19:55987591	ZNF628	0.45	7.26	0.37	2.89e-12	Liver disease severity in Alagille syndrome;
CRC	trans	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg17145862	chr1:211918768	LPGAT1	0.6	10.63	0.51	6.92e-23	Leprosy;
CRC	trans	rs2629046	0.967	rs2602681	chr2:225070767	C/T	cg02046017	chr11:70707406	SHANK2	0.36	5.99	0.31	5.36e-9	Height;
CRC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs9906695	0.796	rs11867200	chr17:32575969	A/G	cg12698626	chr17:32581466	CCL2	-0.44	-6.22	-0.32	1.47e-9	Monocyte percentage of white cells;
CRC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.47	-7.9	-0.4	4.31e-14	Breast cancer;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-8.96	-0.44	2.47e-17	Bipolar disorder;
CRC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.63	-0.34	1.34e-10	Obesity-related traits;
CRC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg25876840	chr17:41920477	NA	0.5	7.49	0.38	6.45e-13	Triglycerides;
CRC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg18301423	chr5:131593218	PDLIM4	-0.38	-6.31	-0.33	9.25e-10	Breast cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05966498	chr5:10761293	DAP	0.39	6.4	0.33	5.43e-10	Obesity-related traits;
CRC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg04731861	chr2:219085781	ARPC2	-0.31	-6.52	-0.34	2.63e-10	Colorectal cancer;
CRC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.63	-0.3	3.86e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7517126	1.000	rs6428364	chr1:196844049	C/T	cg13682187	chr1:196946512	CFHR5	-0.35	-5.82	-0.31	1.43e-8	Blood protein levels;
CRC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	6.38	0.33	5.93e-10	Height;
CRC	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.02	-0.36	1.24e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg23018236	chr17:30244563	NA	-0.65	-7.74	-0.39	1.21e-13	Hip circumference adjusted for BMI;
CRC	cis	rs55702914	0.712	rs12616329	chr2:198148629	T/C	cg20885578	chr2:198174922	NA	-0.35	-6.12	-0.32	2.63e-9	Major depression and alcohol dependence;
CRC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg09127314	chr1:152161683	NA	-0.53	-6.65	-0.34	1.24e-10	Atopic dermatitis;
CRC	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg01843034	chr6:37503916	NA	-0.43	-8.1	-0.41	1.07e-14	Cognitive performance;
CRC	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.57	-8.43	-0.42	1.13e-15	Inhibitory control;
CRC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.93	14.21	0.62	4.51e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.74	-10.54	-0.5	1.38e-22	Platelet distribution width;
CRC	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.54	7.08	0.36	9.03e-12	Alzheimer's disease (survival time);
CRC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.93	17.75	0.7	6.21e-50	Height;
CRC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.28	0.33	1.06e-9	Aortic root size;
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg10217327	chr6:118973057	C6orf204	0.51	5.75	0.3	2e-8	Diastolic blood pressure;
CRC	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.58	9.88	0.48	2.57e-20	Prudent dietary pattern;
CRC	cis	rs2811415	0.569	rs1057220	chr3:127799983	A/C	cg13719885	chr3:127795394	NA	-0.39	-5.88	-0.31	1.03e-8	Lung function (FEV1/FVC);
CRC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.83	-0.31	1.3e-8	Gut microbiome composition (summer);
CRC	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg00531865	chr16:30841666	NA	0.47	6.59	0.34	1.75e-10	Dementia with Lewy bodies;
CRC	cis	rs2530545	0.620	rs4141269	chr7:34667416	A/T	cg14401837	chr7:34697493	NPSR1	0.38	5.95	0.31	6.92e-9	IgG glycosylation;
CRC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.7	9.98	0.48	1.14e-20	Cognitive function;
CRC	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07165851	chr6:158734300	TULP4	0.6	7.65	0.39	2.28e-13	Height;
CRC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	12.91	0.58	3.82e-31	Platelet count;
CRC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg19223190	chr17:80058835	NA	0.39	6.31	0.33	9.07e-10	Life satisfaction;
CRC	cis	rs10991814	1.000	rs77983835	chr9:93956086	C/T	cg14446406	chr9:93919335	NA	0.56	6.05	0.32	4e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.6	-0.43	3.35e-16	Uric acid levels;
CRC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg13119609	chr19:45449297	APOC2	-0.35	-6.49	-0.34	3.08e-10	Blood protein levels;
CRC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.41	-0.33	4.97e-10	Alzheimer's disease (late onset);
CRC	trans	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	9.6	0.47	2.11e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg17903999	chr18:56338584	MALT1	0.42	6.72	0.35	8.23e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9462027	0.583	rs2814947	chr6:34653268	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.42e-10	Systemic lupus erythematosus;
CRC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.58	9.16	0.45	5.58e-18	Tonsillectomy;
CRC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	7.29	0.37	2.33e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.17	9.85	0.48	3.04e-20	Psoriasis vulgaris;
CRC	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	7.69	0.39	1.74e-13	Body mass index;
CRC	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.18	0.37	4.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs1223397	0.651	rs202023	chr6:13304658	C/T	cg20827128	chr6:13274284	PHACTR1	0.4	6.01	0.31	4.93e-9	Blood pressure;
CRC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	trans	rs12438356	0.686	rs76047987	chr15:69476929	C/G	cg26416341	chr12:54718712	COPZ1	0.64	5.96	0.31	6.33e-9	CTACK levels;
CRC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.77	7.67	0.39	1.93e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.44	-6.35	-0.33	7.01e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.72	12.27	0.56	9.72e-29	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7259376	0.902	rs4932763	chr19:22603922	C/A	cg02657401	chr19:22469223	NA	0.31	6.75	0.35	6.86e-11	Menopause (age at onset);
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg15786705	chr6:28176104	NA	0.55	7.78	0.39	9.76e-14	Parkinson's disease;
CRC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs9976767	0.646	rs876497	chr21:43841905	G/A	cg23042151	chr21:43824109	UBASH3A	-0.4	-6.78	-0.35	5.71e-11	Type 1 diabetes;
CRC	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg20607287	chr7:12443886	VWDE	-0.55	-6.18	-0.32	1.92e-9	Coronary artery disease;
CRC	cis	rs4964805	1.000	rs11111792	chr12:104194857	C/G	cg02344784	chr12:104178138	NT5DC3	0.55	8.33	0.42	2.21e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.46	-6.98	-0.36	1.61e-11	Testicular germ cell tumor;
CRC	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg05562828	chr17:3906858	NA	-0.66	-11.73	-0.54	8.97e-27	Type 2 diabetes;
CRC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg27523141	chr10:43048294	ZNF37B	0.44	6.48	0.34	3.27e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06307176	chr5:131281290	NA	-0.43	-6.32	-0.33	8.59e-10	Life satisfaction;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg23161317	chr6:28129485	ZNF389	0.39	5.86	0.31	1.13e-8	Cardiac Troponin-T levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg27343001	chr19:16739049	MED26	0.49	7.11	0.36	7.47e-12	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6500395	0.708	rs28449353	chr16:48555134	T/A	cg04672837	chr16:48644449	N4BP1	0.4	5.92	0.31	7.91e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24691105	chr13:50700331	DLEU2	0.38	6.01	0.31	5.05e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.5	7.33	0.37	1.75e-12	Longevity;Endometriosis;
CRC	cis	rs2179367	0.887	rs6570965	chr6:149717476	C/A	cg07828024	chr6:149772892	ZC3H12D	-0.36	-6.08	-0.32	3.31e-9	Dupuytren's disease;
CRC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.69	-10.43	-0.5	3.31e-22	Mean corpuscular hemoglobin;
CRC	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.57	6.21	0.32	1.58e-9	RR interval (heart rate);
CRC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.55	8.26	0.41	3.49e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.57	-7.98	-0.4	2.52e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.43	-6.11	-0.32	2.77e-9	DNA methylation (variation);
CRC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.66	9.6	0.47	2.07e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.43	0.33	4.61e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.28	-0.46	2.39e-18	Migraine;Coronary artery disease;
CRC	cis	rs9322817	0.593	rs9404579	chr6:105229807	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-8.16	-0.41	7.43e-15	Thyroid stimulating hormone;
CRC	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.6	-8.4	-0.42	1.35e-15	Coronary artery disease;
CRC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg13844804	chr7:814759	HEATR2	0.65	8.51	0.42	6.08e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.48	6.4	0.33	5.21e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.82	-11.2	-0.53	7.17e-25	Asthma;
CRC	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.5	6.36	0.33	6.69e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg09655341	chr17:79618100	PDE6G	-0.35	-6.01	-0.31	4.93e-9	Eye color traits;
CRC	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg04904318	chr17:46607828	HOXB1	-0.53	-6.18	-0.32	1.93e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.54	-8.95	-0.44	2.75e-17	Metabolite levels;
CRC	trans	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg21153622	chr11:89784906	NA	-0.51	-8.08	-0.41	1.22e-14	HDL cholesterol;
CRC	cis	rs7616330	0.790	rs2140131	chr3:71044545	A/G	cg01511742	chr3:71112437	FOXP1	-0.54	-6.42	-0.33	4.84e-10	QT interval;
CRC	cis	rs28829049	0.731	rs7537573	chr1:19373605	C/T	cg22333259	chr1:19394757	NA	0.35	5.62	0.3	4.02e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9549328	0.544	rs66893681	chr13:113617499	A/G	cg17524180	chr13:113633600	MCF2L	0.52	9.5	0.46	4.44e-19	Systolic blood pressure;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg08798685	chr6:27730294	NA	-0.55	-5.97	-0.31	6.01e-9	Lung cancer in ever smokers;
CRC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-8.97	-0.44	2.37e-17	Bipolar disorder;
CRC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.59e-14	Bipolar disorder;
CRC	cis	rs12024301	0.557	rs77708076	chr1:183625280	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.9	-15.65	-0.65	1.22e-41	Height;
CRC	trans	rs4272382	1	rs4272382	chr8:8433488	C/T	cg09373786	chr8:93156639	NA	0.66	5.96	0.31	6.53e-9	Response to cytidine analogues (gemcitabine);
CRC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.25	-0.41	3.82e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.58	9.42	0.46	8.11e-19	Vitiligo;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25367318	chr6:138725211	HEBP2	0.47	6.83	0.35	4.17e-11	Response to antipsychotic treatment;
CRC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.71	-11.54	-0.54	4.3e-26	Hepatocellular carcinoma;
CRC	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg03929089	chr4:120376271	NA	0.63	6.01	0.31	4.92e-9	Axial length;
CRC	cis	rs10971721	0.822	rs72729357	chr9:34041168	G/A	cg13495928	chr9:33750294	PRSS3	0.55	5.63	0.3	3.91e-8	Body mass index;
CRC	trans	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg17903999	chr18:56338584	MALT1	0.41	6.58	0.34	1.86e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.64	0.39	2.46e-13	Testicular germ cell tumor;
CRC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.42	5.78	0.3	1.69e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg15786705	chr6:28176104	NA	0.7	5.78	0.3	1.74e-8	Depression;
CRC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.58	-6.76	-0.35	6.24e-11	Bronchopulmonary dysplasia;
CRC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	7.31	0.37	2.1e-12	Breast cancer;
CRC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.57	8.69	0.43	1.7e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg24463073	chr6:118973353	C6orf204	0.5	6.32	0.33	8.29e-10	Diastolic blood pressure;
CRC	cis	rs10503871	0.625	rs4416792	chr8:30303833	A/C	cg26383811	chr8:30366931	RBPMS	0.46	7.3	0.37	2.23e-12	Metabolite levels  (X-11787);
CRC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02018176	chr4:1364513	KIAA1530	-0.45	-7.79	-0.39	8.84e-14	Obesity-related traits;
CRC	cis	rs3741151	0.686	rs11235809	chr11:73290163	A/G	cg17517138	chr11:73019481	ARHGEF17	0.56	5.81	0.31	1.48e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.29	-0.46	2.22e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.57	-0.43	3.94e-16	Hemoglobin concentration;
CRC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-8.24	-0.41	4.16e-15	Diabetic retinopathy;
CRC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg20041105	chr8:143859282	LYNX1	0.43	7.67	0.39	1.97e-13	Urinary tract infection frequency;
CRC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.4	5.78	0.3	1.69e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-1.07	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg21251018	chr6:28226885	NKAPL	0.47	6.04	0.32	4.16e-9	Depression;
CRC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.74	12.63	0.57	4.47e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.88	11.92	0.55	1.84e-27	Initial pursuit acceleration;
CRC	cis	rs7849270	1.000	rs7855278	chr9:131921365	A/C	cg13538475	chr9:131942899	NA	0.32	6.08	0.32	3.38e-9	Blood metabolite ratios;
CRC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg24879335	chr3:133465180	TF	0.32	6.02	0.32	4.58e-9	Iron status biomarkers;
CRC	trans	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg21153622	chr11:89784906	NA	0.44	6.99	0.36	1.49e-11	HDL cholesterol;
CRC	cis	rs11955398	0.625	rs12655515	chr5:59974098	G/C	cg02684056	chr5:59996105	DEPDC1B	0.41	5.94	0.31	7.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6479527	0.875	rs10435923	chr9:96781569	T/C	cg14459158	chr9:96720562	NA	0.36	6.49	0.34	3.12e-10	Esophageal adenocarcinoma;
CRC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.52e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.34	6.88	0.35	3.01e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg03690763	chr11:133734501	NA	-0.39	-6.4	-0.33	5.25e-10	Childhood ear infection;
CRC	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.42	7.86	0.4	5.64e-14	Monocyte count;
CRC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.8	-0.48	4.78e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.69	10.52	0.5	1.73e-22	Menopause (age at onset);
CRC	cis	rs3743266	0.613	rs8027901	chr15:60733464	A/C	cg21667061	chr15:60772094	NARG2	-0.28	-5.74	-0.3	2.12e-8	Menarche (age at onset);
CRC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.41	6.83	0.35	4.19e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.2	-0.32	1.68e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.55	10.1	0.49	4.47e-21	HDL cholesterol levels;
CRC	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg02466173	chr16:30829666	NA	-0.59	-8.6	-0.43	3.31e-16	Dementia with Lewy bodies;
CRC	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg10263370	chr3:44754102	ZNF502	-0.39	-6.5	-0.34	3.02e-10	Depressive symptoms;
CRC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.37	-6.45	-0.33	4.08e-10	Height;
CRC	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg27121462	chr16:89883253	FANCA	0.39	5.97	0.31	6.04e-9	Vitiligo;
CRC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10886503	0.623	rs10886504	chr10:121256112	C/A	cg17804342	chr10:121271663	RGS10	0.52	6.41	0.33	5.11e-10	Obstetric antiphospholipid syndrome;
CRC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.28	0.73	5.63e-56	Prudent dietary pattern;
CRC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg24253500	chr15:84953950	NA	0.37	6.18	0.32	1.92e-9	Schizophrenia;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Parkinson's disease;
CRC	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg04239558	chr2:103089729	SLC9A4	0.37	6.59	0.34	1.72e-10	Blood protein levels;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg16669491	chr19:19314215	NR2C2AP	-0.44	-6.43	-0.33	4.51e-10	HDL cholesterol;
CRC	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.12	-0.32	2.62e-9	Schizophrenia;
CRC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg02880119	chr16:3481970	NA	-0.41	-5.77	-0.3	1.84e-8	Body mass index (adult);
CRC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.41	6.79	0.35	5.27e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1223397	0.702	rs13191897	chr6:13288428	G/A	cg20827128	chr6:13274284	PHACTR1	0.56	6.61	0.34	1.55e-10	Blood pressure;
CRC	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg23234261	chr14:55582407	NA	-0.31	-6.25	-0.33	1.31e-9	Protein biomarker;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07982263	chr16:1359166	UBE2I	0.41	6.0	0.31	5.32e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.588	rs7158791	chr14:55828607	A/G	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.04	-0.32	4.28e-9	Protein biomarker;
CRC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.54	7.96	0.4	2.81e-14	Lung cancer;
CRC	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.73	-11.75	-0.54	7.47e-27	Plateletcrit;Platelet count;
CRC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.66	10.43	0.5	3.45e-22	Type 2 diabetes;
CRC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.83	11.55	0.54	4.04e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4731207	0.596	rs6963594	chr7:124609233	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.23	-0.32	1.46e-9	Cutaneous malignant melanoma;
CRC	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg04662943	chr10:102668895	NA	0.57	6.61	0.34	1.54e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.23	0.32	1.46e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.1e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07238657	chr1:154973705	ZBTB7B	-0.42	-6.16	-0.32	2.15e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.6	6.38	0.33	5.99e-10	Initial pursuit acceleration;
CRC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.6	9.34	0.46	1.52e-18	Height;
CRC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.19	-0.32	1.78e-9	Aortic root size;
CRC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg00484396	chr16:3507460	NAT15	-0.65	-6.48	-0.34	3.35e-10	Tuberculosis;
CRC	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg09597638	chr17:3907349	NA	0.47	7.53	0.38	4.87e-13	Type 2 diabetes;
CRC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-0.59	-11.18	-0.52	8.12e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.74	9.24	0.45	3.04e-18	Type 2 diabetes;
CRC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.49	9.73	0.47	7.65e-20	Ulcerative colitis;
CRC	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg13086574	chr8:135490821	ZFAT	-0.36	-6.06	-0.32	3.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg13256891	chr4:100009986	ADH5	0.43	6.26	0.33	1.2e-9	Alcohol dependence;
CRC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.44	6.68	0.35	1.01e-10	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg21095983	chr6:86352623	SYNCRIP	0.51	7.61	0.39	2.98e-13	Smooth-surface caries;
CRC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg04719120	chr6:96025338	MANEA	0.64	7.39	0.38	1.23e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.42	7.16	0.37	5.21e-12	Major depressive disorder;
CRC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.59	-7.62	-0.39	2.67e-13	Immature fraction of reticulocytes;
CRC	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.44	6.45	0.34	4.01e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.44	-0.33	4.34e-10	IgG glycosylation;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg25164649	chr6:28176230	NA	-0.78	-11.02	-0.52	2.93e-24	Depression;
CRC	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg25019722	chr6:37503610	NA	-0.47	-8.77	-0.44	9.97e-17	Cognitive performance;
CRC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	5.99	0.31	5.39e-9	Schizophrenia;
CRC	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.48	7.6	0.39	3.15e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.72	8.06	0.41	1.43e-14	Blood protein levels;
CRC	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.75	-0.3	2.07e-8	Yeast infection;
CRC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg06470822	chr6:28175283	NA	0.82	12.33	0.56	5.84e-29	Parkinson's disease;
CRC	trans	rs4824093	0.610	rs9627798	chr22:50317857	G/A	cg09872104	chr7:134855509	C7orf49	-0.79	-7.27	-0.37	2.67e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.78	-11.19	-0.52	7.8e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.31	5.66	0.3	3.21e-8	Mean corpuscular volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00291661	chr16:30581198	ZNF688	-0.36	-6.05	-0.32	3.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.42	0.38	1.01e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26240231	chr7:1148101	C7orf50	-0.48	-6.62	-0.34	1.46e-10	Bronchopulmonary dysplasia;
CRC	cis	rs4663866	0.901	rs2304672	chr2:239186589	C/G	cg16914508	chr2:239161102	PER2	-0.7	-7.51	-0.38	5.56e-13	Irritable bowel syndrome;
CRC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.49	0.38	6.25e-13	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05019311	chr17:4807065	CHRNE	0.45	6.83	0.35	4.13e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	8.92	0.44	3.35e-17	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.53	0.43	5.37e-16	Menopause (age at onset);
CRC	trans	rs17655565	1.000	rs73309373	chr12:52701409	C/T	cg05090392	chr7:157209531	DNAJB6	0.6	6.19	0.32	1.76e-9	Plasma amyloid beta peptide concentrations (ABx-42);
CRC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg24675056	chr1:15929824	NA	0.47	6.29	0.33	1.01e-9	Systolic blood pressure;
CRC	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg09455208	chr3:40491958	NA	0.31	6.34	0.33	7.75e-10	Renal cell carcinoma;
CRC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.56	6.76	0.35	6.39e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg09455208	chr3:40491958	NA	-0.41	-8.28	-0.42	3.06e-15	Renal cell carcinoma;
CRC	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	10.16	0.49	2.8e-21	Exhaled nitric oxide output;
CRC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	5.97e-10	Red blood cell count;
CRC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	6.03	0.32	4.37e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.49	6.85	0.35	3.74e-11	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.93	18.99	0.72	8.11e-55	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.45	0.33	4.07e-10	Lymphocyte counts;
CRC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.48	-8.98	-0.44	2.15e-17	Reticulocyte fraction of red cells;
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg10729496	chr3:10149963	C3orf24	-0.55	-7.19	-0.37	4.35e-12	Alzheimer's disease;
CRC	trans	rs11581859	0.950	rs60591961	chr1:99371878	A/C	cg12183875	chr3:169587454	LRRC31	0.27	6.43	0.33	4.37e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.48e-13	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05119084	chr18:46477127	SMAD7	0.42	7.09	0.36	8.41e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-7.16	-0.37	5.37e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg26816564	chr1:7831052	VAMP3	0.44	5.67	0.3	3.1e-8	Inflammatory bowel disease;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.81	9.75	0.47	6.8e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs965469	0.947	rs6139087	chr20:3329062	T/C	cg25506879	chr20:3388711	C20orf194	-0.39	-5.81	-0.31	1.44e-8	IFN-related cytopenia;
CRC	trans	rs7897194	0.592	rs10828066	chr10:20783978	T/C	cg12686133	chr12:4758424	NDUFA9	-0.53	-5.98	-0.31	5.78e-9	Bipolar disorder;
CRC	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.52	-0.34	2.58e-10	Coronary artery calcification;
CRC	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.67	-8.94	-0.44	2.93e-17	Hypospadias;
CRC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.21	-0.45	4.04e-18	Alcohol dependence;
CRC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.33	-0.46	1.58e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.75	-0.35	6.61e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17065868	0.764	rs73188717	chr13:45019390	G/C	cg10246903	chr13:45222710	NA	0.58	6.4	0.33	5.41e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.97	-0.36	1.74e-11	Dilated cardiomyopathy;
CRC	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-7.03	-0.36	1.22e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.59	-10.13	-0.49	3.65e-21	Body mass index;
CRC	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-6.3	-0.33	9.77e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg15511327	chr8:143859410	LYNX1	0.41	7.41	0.38	1.06e-12	Urinary tract infection frequency;
CRC	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.04e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	7.48	0.38	6.95e-13	Mean platelet volume;
CRC	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.67	-0.3	3.18e-8	Tuberculosis;
CRC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg27565382	chr3:53032988	SFMBT1	0.72	5.86	0.31	1.15e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	11.39	0.53	1.47e-25	Platelet count;
CRC	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.83	-0.44	6.34e-17	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.22	-0.37	3.61e-12	IgG glycosylation;
CRC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.86	-0.58	6.07e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.39	-5.74	-0.3	2.11e-8	IFN-related cytopenia;
CRC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26587870	chr6:27730563	NA	-0.6	-5.89	-0.31	9.43e-9	Depression;
CRC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg20203395	chr5:56204925	C5orf35	-0.71	-8.15	-0.41	7.76e-15	Initial pursuit acceleration;
CRC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.65	-7.42	-0.38	9.76e-13	Major depressive disorder;
CRC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.23	-6.74	-0.35	7.19e-11	Urinary metabolites;
CRC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg03013636	chr16:1946785	NA	0.57	6.99	0.36	1.54e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs863345	0.504	rs857714	chr1:158566972	C/T	cg12129480	chr1:158549410	OR10X1	0.33	7.1	0.36	7.65e-12	Pneumococcal bacteremia;
CRC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	ch.11.42038R	chr11:967971	AP2A2	0.58	9.98	0.48	1.16e-20	Alzheimer's disease (late onset);
CRC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.09	10.15	0.49	3.11e-21	Alzheimer's disease (late onset);
CRC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg01320579	chr17:75405842	SEPT9	-0.35	-5.65	-0.3	3.45e-8	Airflow obstruction;
CRC	cis	rs939584	1.000	rs11127487	chr2:639900	C/T	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.6	-10.83	-0.51	1.4e-23	Aortic root size;
CRC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.56	0.38	3.92e-13	Lymphocyte percentage of white cells;
CRC	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.96	0.55	1.32e-27	Coffee consumption (cups per day);
CRC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.49	-7.27	-0.37	2.66e-12	Osteoporosis;
CRC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.63	9.96	0.48	1.3e-20	Colorectal cancer;
CRC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.45	-6.2	-0.32	1.67e-9	Gut microbiome composition (summer);
CRC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.89	13.67	0.6	5.57e-34	Platelet distribution width;
CRC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg04450456	chr4:17643702	FAM184B	-0.38	-5.97	-0.31	6.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs775227	0.574	rs35765657	chr3:113078384	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-6.74	-0.35	7.03e-11	Dental caries;
CRC	cis	rs7215564	0.908	rs2340773	chr17:78744395	T/C	cg09596252	chr17:78655493	RPTOR	-0.57	-5.95	-0.31	7.01e-9	Myopia (pathological);
CRC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.84	-0.35	3.9e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg25985355	chr7:65971099	NA	-0.34	-6.05	-0.32	3.92e-9	Aortic root size;
CRC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.56	-0.34	2.07e-10	Height;
CRC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg23161317	chr6:28129485	ZNF389	0.47	6.73	0.35	7.5e-11	Cardiac Troponin-T levels;
CRC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.97e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.22e-17	Mean platelet volume;
CRC	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.72	11.29	0.53	3.4e-25	Breast cancer;
CRC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	7.16	0.37	5.28e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.69	11.29	0.53	3.23e-25	Motion sickness;
CRC	trans	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg09872104	chr7:134855509	C7orf49	-0.84	-7.38	-0.38	1.29e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15568066	chr10:43904326	HNRNPF	0.42	6.0	0.31	5.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-6.15	-0.32	2.24e-9	Body mass index;
CRC	cis	rs11229555	0.574	rs72919749	chr11:58323467	T/C	cg15696309	chr11:58395628	NA	-0.87	-9.41	-0.46	8.56e-19	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs73206853	0.764	rs28840785	chr12:110844920	C/G	cg12870014	chr12:110450643	ANKRD13A	0.85	10.18	0.49	2.4e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.89	10.39	0.5	4.63e-22	Psoriasis;
CRC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs3741151	0.892	rs61705659	chr11:73012101	T/G	cg17517138	chr11:73019481	ARHGEF17	0.69	7.33	0.37	1.82e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg19913688	chr11:428466	ANO9	-0.68	-6.94	-0.36	2.06e-11	Body mass index;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg23123621	chr4:1343375	KIAA1530	0.36	5.72	0.3	2.34e-8	Obesity-related traits;
CRC	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg20169779	chr10:135381914	SYCE1	-0.81	-11.36	-0.53	1.91e-25	Gout;
CRC	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.48	-7.58	-0.39	3.65e-13	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.79	-12.05	-0.55	5.85e-28	Gut microbiome composition (winter);
CRC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09417889	chr1:155164873	MIR92B	0.42	6.09	0.32	3.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.27	-0.33	1.16e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs73206853	0.841	rs73206886	chr12:110851190	T/G	cg12870014	chr12:110450643	ANKRD13A	0.83	10.0	0.48	1.03e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25750404	chr12:6579648	VAMP1	0.54	7.21	0.37	3.77e-12	Thyroid stimulating hormone;
CRC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.94	11.83	0.55	3.85e-27	Eosinophil percentage of granulocytes;
CRC	trans	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg09872104	chr7:134855509	C7orf49	-0.82	-6.17	-0.32	1.98e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg04880052	chr2:219191631	PNKD	0.41	6.67	0.35	1.06e-10	Colorectal cancer;
CRC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.3	0.69	3.94e-48	Platelet count;
CRC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.58	-7.43	-0.38	9.45e-13	Neuroticism;
CRC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.6	0.43	3.37e-16	Arsenic metabolism;
CRC	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.77	-0.51	2.31e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg25767906	chr1:53392781	SCP2	-0.38	-5.93	-0.31	7.8e-9	Monocyte count;
CRC	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.37	-7.31	-0.37	2.1e-12	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12989104	chr16:48645051	N4BP1	0.38	6.03	0.32	4.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg04611788	chr3:186434169	KNG1	-0.58	-8.39	-0.42	1.45e-15	Blood protein levels;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg18758796	chr5:131593413	PDLIM4	0.4	6.21	0.32	1.59e-9	Breast cancer;
CRC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-0.74	-7.77	-0.39	1.01e-13	Schizophrenia;
CRC	cis	rs12143943	0.866	rs4252713	chr1:204510528	G/A	cg17419461	chr1:204415978	PIK3C2B	0.39	6.05	0.32	4.05e-9	Cognitive performance;
CRC	cis	rs4731207	0.596	rs3900363	chr7:124667961	C/A	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.73e-9	Cutaneous malignant melanoma;
CRC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.05e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.6	6.31	0.33	9.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg04969067	chr8:143858791	LYNX1	0.42	7.05	0.36	1.06e-11	Urinary tract infection frequency;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13316255	chr15:75165642	SCAMP2	0.37	6.02	0.31	4.74e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg08222913	chr3:52553049	STAB1	0.33	5.77	0.3	1.79e-8	Bipolar disorder;
CRC	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg20356878	chr3:121714668	ILDR1	-0.44	-5.97	-0.31	6.14e-9	Multiple sclerosis;
CRC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-9.77	-0.47	5.92e-20	Colorectal cancer;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg02033258	chr5:131593261	PDLIM4	-0.48	-9.12	-0.45	7.55e-18	Acylcarnitine levels;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.73	-9.08	-0.45	1.04e-17	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg02018176	chr4:1364513	KIAA1530	-0.4	-6.61	-0.34	1.55e-10	Obesity-related traits;
CRC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.51	-8.91	-0.44	3.68e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg00814883	chr7:100076585	TSC22D4	-0.51	-5.94	-0.31	7.21e-9	Lung function (FEV1/FVC);
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10819733	chr22:24237672	NA	-0.35	-5.93	-0.31	7.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg13736514	chr6:26305472	NA	-0.45	-7.51	-0.38	5.48e-13	Educational attainment;
CRC	cis	rs12476592	0.602	rs6708804	chr2:63807269	G/A	cg10828910	chr2:63850056	LOC388955	0.49	6.24	0.33	1.34e-9	Childhood ear infection;
CRC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.86	0.4	5.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12273811	chr6:28175739	NA	0.56	7.94	0.4	3.3e-14	Parkinson's disease;
CRC	cis	rs6546324	0.625	rs2861703	chr2:67861053	T/C	cg15745817	chr2:67799979	NA	-0.55	-9.43	-0.46	7.35e-19	Endometriosis;
CRC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-9.94	-0.48	1.63e-20	Depression;
CRC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-0.96	-17.2	-0.69	9.1e-48	Height;
CRC	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.39	-6.0	-0.31	5.22e-9	Intelligence;
CRC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg09355771	chr2:177043147	NA	0.61	8.47	0.42	8.23e-16	IgG glycosylation;
CRC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04362095	chr11:63592001	C11orf84	-0.4	-5.66	-0.3	3.34e-8	Pulse pressure;
CRC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.48	7.02	0.36	1.25e-11	Bladder cancer;
CRC	cis	rs7487075	0.897	rs2897968	chr12:46763686	G/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.21	0.32	1.58e-9	Itch intensity from mosquito bite;
CRC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.42	-7.73	-0.39	1.28e-13	Huntington's disease progression;
CRC	cis	rs524281	0.506	rs512421	chr11:65985168	C/T	cg16950941	chr11:66035639	RAB1B	-0.49	-6.12	-0.32	2.69e-9	Electroencephalogram traits;
CRC	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06307176	chr5:131281290	NA	0.5	7.06	0.36	1.01e-11	Life satisfaction;
CRC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.91	-0.48	2.02e-20	Body mass index;
CRC	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.06e-10	Eye color traits;
CRC	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.63	-7.62	-0.39	2.65e-13	Vitamin D levels;
CRC	trans	rs7180079	1.000	rs1117087	chr15:64598823	T/G	cg22857141	chr5:123707481	NA	0.48	6.09	0.32	3.14e-9	Monocyte count;
CRC	cis	rs9837602	1.000	rs1688771	chr3:99503359	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.92	0.31	8.25e-9	Breast cancer;
CRC	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.34	6.16	0.32	2.18e-9	Neuroticism;
CRC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.37	5.98	0.31	5.74e-9	Height;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg18833306	chr6:118973337	C6orf204	0.44	5.75	0.3	2.04e-8	Diastolic blood pressure;
CRC	cis	rs7215564	0.730	rs34484282	chr17:78684663	G/A	cg09596252	chr17:78655493	RPTOR	0.56	6.18	0.32	1.87e-9	Myopia (pathological);
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.73	11.67	0.54	1.42e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg15845792	chr6:28175446	NA	0.74	7.07	0.36	9.34e-12	Depression;
CRC	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	6.68	0.35	1e-10	Menarche (age at onset);
CRC	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg14119001	chr9:139324193	INPP5E	-0.4	-5.97	-0.31	6.16e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs4400599	1.000	rs4540651	chr1:154128672	G/A	cg05139571	chr1:154127138	NUP210L	0.44	6.7	0.35	9.13e-11	Platelet distribution width;
CRC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.63	10.77	0.51	2.22e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg17469321	chr7:55412551	NA	-0.61	-10.47	-0.5	2.42e-22	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg14593290	chr7:50529359	DDC	-0.42	-6.0	-0.31	5.1e-9	Body mass index;
CRC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg20387954	chr3:183756860	HTR3D	0.46	7.75	0.39	1.15e-13	Anterior chamber depth;
CRC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg00310523	chr12:86230176	RASSF9	0.44	7.36	0.38	1.5e-12	Major depressive disorder;
CRC	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.38	-5.9	-0.31	8.92e-9	Red blood cell count;
CRC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	16.01	0.66	4.45e-43	Platelet count;
CRC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.94	13.66	0.6	5.88e-34	Breast cancer;
CRC	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg06484146	chr7:12443880	VWDE	-0.63	-6.47	-0.34	3.48e-10	Coronary artery disease;
CRC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg14984920	chr7:25164393	CYCS	0.44	6.22	0.32	1.53e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.16	-0.32	2.08e-9	Total body bone mineral density;
CRC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.71	0.57	2.19e-30	Menopause (age at onset);
CRC	cis	rs12745968	0.589	rs10747446	chr1:93108402	G/A	cg17283838	chr1:93427260	FAM69A	-0.47	-6.38	-0.33	5.84e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg02527881	chr3:46936655	PTH1R	0.35	5.98	0.31	5.85e-9	Colorectal cancer;
CRC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.54	-7.18	-0.37	4.78e-12	Neutrophil percentage of white cells;
CRC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.65	12.27	0.56	9.26e-29	Bone mineral density;
CRC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	trans	rs10060123	1.000	rs28712275	chr5:125684934	T/A	ch.6.113866684R	chr6:113759991	NA	-0.38	-5.99	-0.31	5.61e-9	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue;
CRC	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.56	-0.38	4.04e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	7.85	0.4	5.96e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.31	-5.83	-0.31	1.31e-8	Longevity;Endometriosis;
CRC	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.63	6.32	0.33	8.44e-10	Putamen volume;
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.52	-7.4	-0.38	1.12e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4727963	0.811	rs7458859	chr7:122711358	C/T	cg03640110	chr7:122635026	TAS2R16	0.32	5.86	0.31	1.12e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.03	0.52	2.69e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.71	-11.07	-0.52	2.01e-24	Pancreatic cancer;
CRC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg13072238	chr3:49761600	GMPPB	0.54	5.84	0.31	1.29e-8	Menarche (age at onset);
CRC	cis	rs1881396	0.947	rs4666010	chr2:27878686	T/C	cg27432699	chr2:27873401	GPN1	0.64	8.16	0.41	7.22e-15	Nonalcoholic fatty liver disease;
CRC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg04731861	chr2:219085781	ARPC2	-0.32	-6.85	-0.35	3.73e-11	Colorectal cancer;
CRC	trans	rs4591358	0.648	rs16836855	chr2:196386991	C/T	cg12742475	chr15:75233485	NA	0.31	6.23	0.32	1.43e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
CRC	cis	rs11212617	0.875	rs228597	chr11:108107009	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.36	0.33	6.87e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.32	-6.74	-0.35	6.93e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.91	-0.48	2.01e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg03665457	chr10:38645376	HSD17B7P2	0.42	6.04	0.32	4.1e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.42	6.86	0.35	3.36e-11	Obesity-related traits;
CRC	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23903597	chr17:61704154	MAP3K3	0.42	5.79	0.3	1.65e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.52	8.22	0.41	4.72e-15	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.61	10.31	0.49	9.01e-22	Prudent dietary pattern;
CRC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.35	5.66	0.3	3.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.74	0.3	2.12e-8	Renal function-related traits (BUN);
CRC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.42	-5.68	-0.3	2.9e-8	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01799862	chr16:67143802	C16orf70	0.36	6.0	0.31	5.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg02993699	chr4:3415135	RGS12	-0.4	-6.58	-0.34	1.87e-10	Serum sulfate level;
CRC	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg26811252	chr16:29126840	RRN3P2	0.61	8.31	0.42	2.62e-15	Menopause (age at onset);
CRC	cis	rs7553864	0.966	rs11161937	chr1:87614510	A/G	cg02083836	chr1:87617350	LOC339524	0.38	6.63	0.34	1.35e-10	Smoking behavior;
CRC	cis	rs62229266	0.625	rs62230813	chr21:37403432	C/T	cg08632701	chr21:37451849	NA	-0.4	-6.19	-0.32	1.8e-9	Mitral valve prolapse;
CRC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg23758597	chr6:163146217	PARK2	-0.67	-6.71	-0.35	8.57e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg17775713	chr3:133465469	TF	0.37	6.76	0.35	6.35e-11	Iron status biomarkers (transferrin levels);
CRC	cis	rs9783347	1.000	rs4150622	chr11:18365710	A/G	cg15585147	chr11:18324498	HPS5	0.43	6.19	0.32	1.8e-9	Pancreatic cancer;
CRC	cis	rs747650	0.884	rs7128325	chr11:47046554	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-6.39	-0.33	5.78e-10	Acne (severe);
CRC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16447950	chr5:562315	NA	-0.77	-10.22	-0.49	1.75e-21	Obesity-related traits;
CRC	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.69	-9.18	-0.45	4.97e-18	Blood trace element (Cu levels);
CRC	cis	rs1192419	0.502	rs6691704	chr1:92056173	T/G	cg24006770	chr1:92056542	NA	0.57	9.56	0.47	2.97e-19	Optic disc area;Optic nerve measurement (cup-to-disc ratio);
CRC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg18230493	chr5:56204884	C5orf35	0.38	5.66	0.3	3.29e-8	Coronary artery disease;
CRC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.5	6.3	0.33	9.58e-10	Methadone dose in opioid dependence;
CRC	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.25	0.45	2.87e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13948074	chr1:178511686	C1orf220	0.46	6.5	0.34	3.03e-10	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.6	0.39	3.1400000000000003e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.46	-6.98	-0.36	1.67e-11	Menopause (age at onset);
CRC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg24140574	chr1:16342155	HSPB7	0.44	6.1	0.32	3.04e-9	Dilated cardiomyopathy;
CRC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	8.45	0.42	9.44e-16	Schizophrenia;
CRC	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg09476006	chr5:138032270	NA	0.43	6.75	0.35	6.66e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.67	-0.3	3.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2708977	0.637	rs654224	chr2:97080123	A/C	cg23100626	chr2:96804247	ASTL	0.23	5.98	0.31	5.71e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.16	-9.44	-0.46	7.24e-19	Mitochondrial DNA levels;
CRC	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.19	-25.33	-0.81	2.86e-79	Exhaled nitric oxide output;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.52	7.31	0.37	2.02e-12	Longevity;Endometriosis;
CRC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg06470822	chr6:28175283	NA	0.78	7.31	0.37	2.07e-12	Depression;
CRC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.49	6.63	0.34	1.39e-10	Lymphocyte counts;
CRC	cis	rs6961069	0.745	rs1953298	chr7:80265451	C/T	cg04458919	chr7:80252533	CD36	-0.33	-5.86	-0.31	1.13e-8	Platelet count;
CRC	cis	rs7113874	0.524	rs10769921	chr11:8621143	G/A	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.36	-6.82	-0.35	4.25e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs6700896	0.966	rs7516341	chr1:66088143	T/C	cg04111102	chr1:66153794	NA	0.33	5.96	0.31	6.62e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg16898833	chr6:26189333	HIST1H4D	0.74	6.45	0.34	3.89e-10	Depression;
CRC	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.55	5.91	0.31	8.43e-9	Schizophrenia;
CRC	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.66	8.09	0.41	1.14e-14	Menarche (age at onset);
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg10729496	chr3:10149963	C3orf24	-0.55	-7.07	-0.36	9.16e-12	Alzheimer's disease;
CRC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.23	-0.37	3.45e-12	Mean corpuscular volume;
CRC	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg00531865	chr16:30841666	NA	0.47	6.78	0.35	5.6e-11	Dementia with Lewy bodies;
CRC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg15105011	chr4:940614	TMEM175	0.57	8.86	0.44	5.27e-17	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg07125278	chr16:67683757	RLTPR	-0.49	-6.77	-0.35	5.9e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.62	-10.04	-0.48	7.16e-21	Breast cancer;
CRC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	10.19	0.49	2.3e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg25985355	chr7:65971099	NA	-0.51	-5.87	-0.31	1.05e-8	Diabetic kidney disease;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg09877947	chr5:131593287	PDLIM4	0.45	7.23	0.37	3.5e-12	Breast cancer;
CRC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg21620606	chr4:1342894	KIAA1530	0.39	6.9	0.36	2.73e-11	Longevity;
CRC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.45	-7.64	-0.39	2.37e-13	P wave terminal force;
CRC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.05	-0.32	4.01e-9	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.56	11.37	0.53	1.77e-25	Information processing speed;
CRC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg23533926	chr12:111358616	MYL2	0.51	7.66	0.39	2.13e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.48	-9.59	-0.47	2.27e-19	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04501438	chr7:21466669	SP4	0.37	6.25	0.33	1.25e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.12	0.32	2.64e-9	Aortic root size;
CRC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg09355771	chr2:177043147	NA	0.71	10.98	0.52	4.29e-24	IgG glycosylation;
CRC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.38	-5.6	-0.3	4.42e-8	Lymphocyte counts;
CRC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.27	-0.46	2.43e-18	Triglycerides;
CRC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.79	7.71	0.39	1.5e-13	Diabetic retinopathy;
CRC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg11070056	chr1:107600091	PRMT6	0.38	5.62	0.3	4.08e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.35	6.14	0.32	2.33e-9	Erythrocyte sedimentation rate;
CRC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-8.83	-0.44	6.2e-17	Prudent dietary pattern;
CRC	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.5	-5.8	-0.3	1.53e-8	Coronary artery calcification;
CRC	cis	rs1996152	0.543	rs9906415	chr17:72389282	A/G	cg23221732	chr17:72383708	NA	0.43	7.19	0.37	4.34e-12	Interleukin-12p70 levels;
CRC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.68	7.58	0.39	3.61e-13	Major depressive disorder;
CRC	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.38	-0.42	1.58e-15	Brugada syndrome;
CRC	trans	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.24e-13	Endometrial cancer;
CRC	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.56	8.68	0.43	1.82e-16	Breast cancer;
CRC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg21839984	chr17:30846986	MYO1D	-0.34	-5.95	-0.31	6.99e-9	Schizophrenia;
CRC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg24011408	chr12:48396354	COL2A1	0.44	6.24	0.33	1.38e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg15832292	chr6:96025679	MANEA	0.56	6.28	0.33	1.08e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.4	7.69	0.39	1.73e-13	Mean corpuscular volume;
CRC	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	1.19	13.86	0.61	9.81e-35	Lung disease severity in cystic fibrosis;
CRC	trans	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.49	-7.93	-0.4	3.42e-14	Body mass index;
CRC	cis	rs4664293	0.632	rs2059697	chr2:160655590	A/G	cg08347373	chr2:160653686	CD302	0.45	7.58	0.39	3.48e-13	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.77	0.44	9.53e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.67	9.48	0.46	5.19e-19	Platelet count;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.66	-8.66	-0.43	2.2e-16	Hypospadias;
CRC	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14019695	chr9:139328340	INPP5E	0.41	6.14	0.32	2.38e-9	Monocyte percentage of white cells;
CRC	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.73	-10.0	-0.48	9.92e-21	Systemic lupus erythematosus;
CRC	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.62	-9.34	-0.46	1.47e-18	Obesity;
CRC	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.41	-6.25	-0.33	1.25e-9	Breast cancer;
CRC	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg21869046	chr19:41225005	ITPKC	0.43	6.69	0.35	9.61e-11	Kawasaki disease;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg12273811	chr6:28175739	NA	0.56	6.73	0.35	7.64e-11	Depression;
CRC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.72	-0.3	2.33e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.65	10.45	0.5	3.03e-22	Type 2 diabetes;
CRC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.56	-9.27	-0.45	2.58e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.71	7.58	0.39	3.45e-13	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23663824	chr4:187112650	CYP4V2	0.4	6.89	0.36	2.92e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18297960	chr7:1142765	C7orf50	-0.44	-5.86	-0.31	1.14e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.67	9.85	0.48	3.04e-20	Corneal astigmatism;
CRC	cis	rs290268	0.874	rs290990	chr9:93561695	A/G	cg02608019	chr9:93564028	SYK	-0.49	-7.9	-0.4	4.29e-14	Platelet count;
CRC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.1e-8	Bladder cancer;
CRC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg07423050	chr13:99094983	FARP1	-0.42	-5.99	-0.31	5.4e-9	Neuroticism;
CRC	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.74	-11.79	-0.54	5.41e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg08501292	chr6:25962987	TRIM38	1.03	9.09	0.45	9.68e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.58	8.76	0.43	1.03e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg06470822	chr6:28175283	NA	-0.51	-7.61	-0.39	2.91e-13	Pubertal anthropometrics;
CRC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	7.37	0.38	1.37e-12	Aortic root size;
CRC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.48	8.0	0.4	2.1e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.52	6.36	0.33	6.59e-10	Cognitive test performance;
CRC	cis	rs9462027	0.628	rs2815004	chr6:34636268	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-6.39	-0.33	5.56e-10	Post bronchodilator FEV1;
CRC	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.68	-8.15	-0.41	7.66e-15	Opioid sensitivity;
CRC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.51	8.36	0.42	1.85e-15	Metabolite levels (small molecules and protein measures);
CRC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg02659138	chr7:134003124	SLC35B4	0.35	5.75	0.3	2.06e-8	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25964984	chr22:30783371	RNF215	0.45	7.59	0.39	3.41e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.47	6.39	0.33	5.63e-10	Aortic root size;
CRC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.52	-9.15	-0.45	5.91e-18	Schizophrenia;
CRC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.37	-5.79	-0.3	1.68e-8	Breast size;
CRC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.63	8.45	0.42	9.22e-16	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24201296	chr17:37793426	STARD3	0.4	6.21	0.32	1.58e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg10298567	chr3:47292165	KIF9	0.44	7.08	0.36	9.03e-12	Colorectal cancer;
CRC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	trans	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7712401	0.791	rs6595409	chr5:122113756	G/A	cg18764291	chr5:122110994	SNX2	0.43	6.88	0.35	2.96e-11	Mean platelet volume;
CRC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-0.74	-7.63	-0.39	2.58e-13	Schizophrenia;
CRC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.72	-0.3	2.4e-8	Aortic root size;
CRC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.56	-8.15	-0.41	7.48e-15	Menarche (age at onset);
CRC	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg25171089	chr10:5708825	ASB13	0.41	5.65	0.3	3.45e-8	Menopause (age at onset);
CRC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.54	7.57	0.39	3.86e-13	Pancreatic cancer;
CRC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-8.85	-0.44	5.64e-17	Menarche (age at onset);
CRC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.89	-0.48	2.26e-20	Bladder cancer;
CRC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg21839984	chr17:30846986	MYO1D	-0.49	-7.8	-0.4	8.06e-14	Schizophrenia;
CRC	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg13722127	chr7:150037890	RARRES2	0.5	7.83	0.4	6.62e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg03623178	chr6:28175578	NA	0.73	7.35	0.38	1.57e-12	Depression;
CRC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.78	9.62	0.47	1.82e-19	Psoriasis;
CRC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.59	-7.06	-0.36	9.78e-12	Lung cancer in ever smokers;
CRC	cis	rs9549260	0.564	rs4943804	chr13:41269994	A/G	cg21288729	chr13:41239152	FOXO1	0.43	6.63	0.34	1.39e-10	Red blood cell count;
CRC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.76	7.49	0.38	6.51e-13	Diabetic retinopathy;
CRC	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.46	-6.79	-0.35	5.28e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.53	-11.2	-0.53	7.21e-25	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg05304507	chr6:116381966	FRK	0.29	7.41	0.38	1.04e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg11130432	chr3:121712080	ILDR1	-0.51	-6.08	-0.32	3.28e-9	Multiple sclerosis;
CRC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.66	-9.08	-0.45	9.95e-18	Vitiligo;
CRC	cis	rs1555895	0.656	rs10752020	chr10:840608	G/T	cg10556349	chr10:835070	NA	0.38	7.02	0.36	1.28e-11	Survival in rectal cancer;
CRC	cis	rs911119	0.955	rs7265178	chr20:23603382	C/G	cg16589663	chr20:23618590	CST3	0.45	6.32	0.33	8.44e-10	Chronic kidney disease;
CRC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg03934865	chr2:198174659	NA	0.36	5.81	0.31	1.46e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	0.58	6.66	0.34	1.18e-10	Prostate cancer;
CRC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg06470822	chr6:28175283	NA	0.74	7.97	0.4	2.58e-14	Parkinson's disease;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.5	5.78	0.3	1.75e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.84	16.47	0.67	7.33e-45	Hip circumference;
CRC	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg05044414	chr3:183734942	ABCC5	0.38	6.46	0.34	3.67e-10	Anterior chamber depth;
CRC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.52	8.2	0.41	5.31e-15	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.99	0.31	5.59e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg07862535	chr7:139043722	LUC7L2	0.54	6.87	0.35	3.19e-11	Diisocyanate-induced asthma;
CRC	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.15	12.62	0.57	4.76e-30	Mitochondrial DNA levels;
CRC	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.57	-7.3	-0.37	2.12e-12	Squamous cell lung carcinoma;
CRC	cis	rs6604026	0.922	rs11586570	chr1:93305371	A/C	cg22128645	chr1:93425802	FAM69A	-0.39	-5.72	-0.3	2.36e-8	Multiple sclerosis;
CRC	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18357526	chr6:26021779	HIST1H4A	0.49	7.28	0.37	2.43e-12	Schizophrenia;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg01684248	chr16:86536239	NA	-0.41	-5.99	-0.31	5.6e-9	Lung cancer;
CRC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.34e-11	Menopause (age at onset);
CRC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg17724175	chr1:150552817	MCL1	-0.48	-7.6	-0.39	3.18e-13	Tonsillectomy;
CRC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg21153622	chr11:89784906	NA	-0.53	-8.81	-0.44	7.35e-17	Coronary artery disease;
CRC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.31	5.89	0.31	9.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg20607287	chr7:12443886	VWDE	0.64	6.32	0.33	8.61e-10	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg15147215	chr3:52552868	STAB1	0.66	11.0	0.52	3.57e-24	Bipolar disorder;
CRC	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.44	-6.43	-0.33	4.51e-10	Macular telangiectasia type 2;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03993171	chr6:86388501	SNORD50B;SNORD50A;SNHG5	0.38	6.19	0.32	1.79e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.32	-5.9	-0.31	9.08e-9	Multiple sclerosis;
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04176437	chr19:18747727	KLHL26	0.42	6.84	0.35	3.97e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg22110888	chr17:80059540	CCDC57	0.41	6.52	0.34	2.58e-10	Life satisfaction;
CRC	trans	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg19894588	chr14:64061835	NA	-0.61	-8.12	-0.41	9.23e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-9.0	-0.44	1.91e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg13390004	chr1:15929781	NA	0.49	7.0	0.36	1.45e-11	Systolic blood pressure;
CRC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg14671364	chr1:107599128	PRMT6	0.46	6.74	0.35	7.1e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2386661	0.826	rs1132293	chr10:5681038	C/T	cg26603656	chr10:5671107	NA	0.52	8.76	0.43	1.06e-16	Breast cancer;
CRC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.62	8.22	0.41	4.83e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.73	-0.39	1.31e-13	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.64	-0.39	2.42e-13	Blood metabolite levels;
CRC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg23758597	chr6:163146217	PARK2	-0.71	-7.2	-0.37	4.25e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg09003973	chr2:102972529	NA	0.41	5.86	0.31	1.12e-8	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10082270	chr16:87425748	FBXO31;MAP1LC3B	0.48	6.53	0.34	2.48e-10	Anxiety disorder;
CRC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.44	6.3	0.33	9.63e-10	Obesity-related traits;
CRC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.69	7.1	0.36	7.77e-12	Plasma clusterin levels;
CRC	cis	rs6747952	0.899	rs2880132	chr2:239082976	G/A	cg17459225	chr2:239074497	NA	0.46	7.85	0.4	5.93e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-5.89	-0.31	9.45e-9	Lymphocyte counts;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01586524	chr8:67341819	RRS1	0.45	6.62	0.34	1.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.09	-15.35	-0.65	1.82e-40	Exhaled nitric oxide output;
CRC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.54	7.2	0.37	4.04e-12	Height;
CRC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-16.13	-0.66	1.6e-43	Ulcerative colitis;
CRC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.52	6.57	0.34	2e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4964805	0.773	rs35746861	chr12:104225284	C/T	cg02344784	chr12:104178138	NT5DC3	0.48	6.73	0.35	7.75e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg07299736	chr8:135490787	ZFAT	-0.37	-6.0	-0.31	5.28e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.6	-9.05	-0.45	1.31e-17	Dementia with Lewy bodies;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg05569086	chr8:143859399	LYNX1	-0.39	-6.43	-0.33	4.47e-10	Urinary tract infection frequency;
CRC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg21782813	chr7:2030301	MAD1L1	0.4	7.39	0.38	1.23e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg21251018	chr6:28226885	NKAPL	0.58	10.15	0.49	3.17e-21	Cardiac Troponin-T levels;
CRC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.26	0.33	1.18e-9	Tonsillectomy;
CRC	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg12728517	chr11:6947552	ZNF215	0.57	6.14	0.32	2.38e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.72	-8.29	-0.42	2.99e-15	Lung disease severity in cystic fibrosis;
CRC	cis	rs11212617	1.000	rs11212579	chr11:108150664	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.15	0.32	2.28e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Bone mineral density;
CRC	cis	rs427941	0.517	rs201530	chr7:101777382	A/G	cg06246474	chr7:101738831	CUX1	0.36	5.65	0.3	3.49e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6743376	0.556	rs1530551	chr2:113817566	C/T	cg09040174	chr2:113837401	NA	-0.43	-6.32	-0.33	8.56e-10	Inflammatory biomarkers;
CRC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg03037974	chr15:76606532	NA	0.82	16.47	0.67	6.88e-45	Blood metabolite levels;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg07336097	chr8:145670187	NFKBIL2	0.41	6.13	0.32	2.59e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.57	8.72	0.43	1.36e-16	Blood protein levels;
CRC	trans	rs11168936	0.637	rs10875942	chr12:49670854	A/G	cg05384275	chr12:56122970	CD63	-0.4	-6.02	-0.31	4.73e-9	Cancer (pleiotropy);
CRC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-9.41	-0.46	8.6e-19	Hemoglobin concentration;
CRC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg19645103	chr12:69753606	YEATS4	-0.44	-5.81	-0.3	1.49e-8	Response to diuretic therapy;
CRC	cis	rs7932354	0.502	rs57323109	chr11:47193367	T/G	cg19486271	chr11:47235900	DDB2	0.45	6.53	0.34	2.44e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.84	0.4	6.37e-14	Colorectal cancer;
CRC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	0.95	18.79	0.72	5e-54	Height;
CRC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg03013636	chr16:1946785	NA	-0.57	-6.97	-0.36	1.79e-11	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg00531865	chr16:30841666	NA	-0.45	-6.13	-0.32	2.58e-9	Multiple myeloma;
CRC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.58	-7.08	-0.36	8.54e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.22	-0.41	4.6e-15	Chronic sinus infection;
CRC	trans	rs7324845	0.688	rs1980830	chr13:46712587	C/T	cg17840719	chr5:178368253	ZNF454	-0.43	-6.0	-0.31	5.08e-9	Non-alcoholic fatty liver disease histology (other);
CRC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg04586622	chr2:25135609	ADCY3	-0.54	-10.1	-0.49	4.46e-21	Body mass index;
CRC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.64	0.3	3.6e-8	Coronary artery disease;
CRC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg14979609	chr8:8086686	FLJ10661	-0.37	-5.89	-0.31	9.46e-9	Mood instability;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg15786705	chr6:28176104	NA	0.76	9.61	0.47	1.97e-19	Depression;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg06470822	chr6:28175283	NA	0.79	10.14	0.49	3.45e-21	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.56	6.82	0.35	4.31e-11	Alzheimer's disease;
CRC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-7.29	-0.37	2.36e-12	Coronary artery disease;
CRC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg20512303	chr5:131592959	PDLIM4	0.39	6.03	0.32	4.36e-9	Lymphocyte counts;Fibrinogen;
CRC	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.56	-0.34	2.03e-10	Response to antipsychotic treatment;
CRC	cis	rs7169223	0.615	rs8038189	chr15:79099026	G/C	cg22753661	chr15:79092743	ADAMTS7	-0.47	-5.72	-0.3	2.45e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.37	-6.76	-0.35	6.25e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.07	0.45	1.13e-17	Dupuytren's disease;
CRC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00376283	chr12:123451042	ABCB9	-0.51	-6.54	-0.34	2.32e-10	Neutrophil percentage of white cells;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg15786705	chr6:28176104	NA	0.56	5.67	0.3	3.09e-8	Lung cancer in ever smokers;
CRC	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.77	-10.45	-0.5	2.92e-22	Blood protein levels;
CRC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.2	-0.32	1.68e-9	Alzheimer's disease (late onset);
CRC	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg18833306	chr6:118973337	C6orf204	0.45	5.89	0.31	9.35e-9	Renal cell carcinoma;
CRC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04880052	chr2:219191631	PNKD	-0.42	-6.71	-0.35	8.69e-11	Colorectal cancer;
CRC	trans	rs2303319	0.504	rs56407015	chr2:162455625	G/A	cg14875682	chr5:52083620	ITGA1;PELO	-0.72	-5.97	-0.31	6.06e-9	Cognitive function;
CRC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.67	7.49	0.38	6.26e-13	Major depressive disorder;
CRC	trans	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.39	-0.33	5.74e-10	Aortic root size;
CRC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg23136738	chr11:925521	AP2A2	-0.38	-5.95	-0.31	6.74e-9	Alzheimer's disease (late onset);
CRC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg00129232	chr17:37814104	STARD3	-0.59	-7.28	-0.37	2.45e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-7.53	-0.38	4.82e-13	Total body bone mineral density;
CRC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.57	9.47	0.46	5.71e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs10760158	0.832	rs4837826	chr9:124024129	C/A	cg14417974	chr9:124058376	GSN	-0.34	-5.68	-0.3	2.96e-8	Pulse pressure;
CRC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg23205692	chr1:25664452	TMEM50A	0.41	5.81	0.31	1.47e-8	Erythrocyte sedimentation rate;
CRC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.49	-0.38	6.57e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg14329157	chr2:228736135	WDR69	-0.48	-6.59	-0.34	1.77e-10	Blood pressure;
CRC	cis	rs755249	0.567	rs2018212	chr1:39905588	T/C	cg18385671	chr1:39797026	MACF1	-0.41	-5.84	-0.31	1.28e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21963583	chr11:68658836	MRPL21	0.55	9.69	0.47	1.08e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.61	-8.51	-0.42	6.07e-16	Blood pressure (smoking interaction);
CRC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.6	-7.59	-0.39	3.39e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg13476313	chr9:127244764	NR5A1	0.29	5.87	0.31	1.05e-8	Menarche (age at onset);
CRC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.81	-0.3	1.51e-8	Lung cancer;
CRC	cis	rs9463078	0.764	rs6458415	chr6:44881592	G/C	cg25276700	chr6:44698697	NA	-0.28	-6.84	-0.35	3.97e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg13476313	chr9:127244764	NR5A1	0.28	5.7	0.3	2.66e-8	Menarche (age at onset);
CRC	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg10790698	chr19:18539756	SSBP4	-0.43	-8.02	-0.4	1.92e-14	Breast cancer;
CRC	trans	rs564309	1.000	rs503203	chr1:228602660	G/C	cg24066601	chr6:26271455	HIST1H3G	0.6	6.27	0.33	1.15e-9	Hip circumference (psychosocial stress interaction);
CRC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.27	-7.03	-0.36	1.23e-11	Iron status biomarkers;
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.12	-0.37	6.71e-12	Glycated hemoglobin levels;
CRC	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.61	-0.39	2.88e-13	Bipolar disorder;
CRC	cis	rs12519773	0.555	rs1845840	chr5:92388210	G/A	cg18783429	chr5:92414398	NA	-0.35	-7.4	-0.38	1.16e-12	Migraine;
CRC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.17	-13.25	-0.59	2.03e-32	Diabetic kidney disease;
CRC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg21251018	chr6:28226885	NKAPL	-0.4	-6.16	-0.32	2.09e-9	Systemic lupus erythematosus;
CRC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.21	0.49	1.99e-21	Hemoglobin concentration;
CRC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	9.43	0.46	7.75e-19	Eye color traits;
CRC	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg13385794	chr1:248469461	NA	0.39	6.68	0.35	1.01e-10	Common traits (Other);
CRC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.38	6.01	0.31	5.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg24140574	chr1:16342155	HSPB7	0.47	6.67	0.34	1.12e-10	Dilated cardiomyopathy;
CRC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg07212818	chr11:638076	DRD4	-0.45	-5.99	-0.31	5.57e-9	Systemic lupus erythematosus;
CRC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.43	6.58	0.34	1.9e-10	Migraine;
CRC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.5e-8	Lung cancer;
CRC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.71	10.92	0.52	6.75e-24	Corneal astigmatism;
CRC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.08	0.32	3.33e-9	Tonsillectomy;
CRC	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg25173405	chr17:45401733	C17orf57	-0.47	-7.24	-0.37	3.22e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg03124313	chr19:36036028	GAPDHS;TMEM147	-0.67	-6.0	-0.31	5.21e-9	Cognitive function;
CRC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.4	-6.53	-0.34	2.43e-10	Blood metabolite levels;
CRC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg00277334	chr10:82204260	NA	0.37	6.1	0.32	2.96e-9	Sarcoidosis;
CRC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg24562669	chr7:97807699	LMTK2	0.46	7.78	0.39	9.24e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.46	6.45	0.33	4.09e-10	DNA methylation (variation);
CRC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.36	-0.56	4.36e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.89	-0.4	4.56e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.44	6.67	0.34	1.11e-10	N-glycan levels;
CRC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg24768116	chr2:27665128	KRTCAP3	0.32	6.85	0.35	3.74e-11	Total body bone mineral density;
CRC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg19582491	chr16:67682965	RLTPR	-0.56	-6.71	-0.35	8.48e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg15654264	chr1:150340011	RPRD2	0.38	5.95	0.31	7.04e-9	Migraine;
CRC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.61	-9.41	-0.46	8.68e-19	Aortic root size;
CRC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg23254163	chr1:152506842	NA	-0.41	-6.89	-0.36	2.85e-11	Hair morphology;
CRC	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.6	-0.3	4.43e-8	Red blood cell count;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg02033258	chr5:131593261	PDLIM4	0.34	6.31	0.33	8.88e-10	Lung function (FEV1/FVC);
CRC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.51	-8.12	-0.41	9.45e-15	Caffeine consumption;
CRC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.29	-0.33	1.01e-9	Mean corpuscular volume;
CRC	cis	rs812925	0.537	rs10208769	chr2:61605614	A/T	cg10580144	chr2:61372316	C2orf74	-0.33	-7.44	-0.38	8.75e-13	Immature fraction of reticulocytes;
CRC	cis	rs1223397	1.000	rs1232392	chr6:13272671	C/G	cg07912922	chr6:13274314	PHACTR1	0.52	6.37	0.33	6.5e-10	Blood pressure;
CRC	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	7.68	0.39	1.86e-13	Body mass index;
CRC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.51	8.43	0.42	1.13e-15	Major depressive disorder;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12868349	chr11:71639594	RNF121;LOC100133315	-0.56	-6.96	-0.36	1.86e-11	Diisocyanate-induced asthma;
CRC	cis	rs990171	1.000	rs2041756	chr2:103049910	C/T	cg03938978	chr2:103052716	IL18RAP	-0.47	-5.99	-0.31	5.59e-9	Lymphocyte counts;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.51	7.37	0.38	1.41e-12	Longevity;
CRC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.74	-8.87	-0.44	4.63e-17	Hemostatic factors and hematological phenotypes;
CRC	trans	rs6708331	0.517	rs7579922	chr2:70361913	A/G	cg06926377	chr15:40443853	NA	0.41	5.98	0.31	5.85e-9	Obesity-related traits;
CRC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg07636037	chr3:49044803	WDR6	-0.68	-6.53	-0.34	2.57e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg01483505	chr11:975446	AP2A2	0.45	7.39	0.38	1.21e-12	Alzheimer's disease (late onset);
CRC	cis	rs9649465	0.967	rs13239184	chr7:123314618	G/T	cg03229431	chr7:123269106	ASB15	-0.37	-5.77	-0.3	1.81e-8	Migraine;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.77	0.3	1.83e-8	Depression;
CRC	trans	rs4308415	0.753	rs1603179	chr4:67805347	A/C	cg19648955	chr2:177134095	MTX2	-0.42	-6.15	-0.32	2.19e-9	Educational attainment (years of education);
CRC	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	0.66	6.88	0.35	3.11e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg09904177	chr6:26538194	HMGN4	0.44	5.91	0.31	8.57e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg20684491	chr1:25596433	NA	0.4	6.87	0.35	3.31e-11	Erythrocyte sedimentation rate;
CRC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg09491104	chr22:46646882	C22orf40	0.39	5.85	0.31	1.16e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.76	-0.39	1.11e-13	Psoriasis;
CRC	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.4	-6.99	-0.36	1.51e-11	Hip circumference;Waist circumference;
CRC	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.79	16.55	0.67	3.37e-45	Nonalcoholic fatty liver disease;
CRC	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.93	17.25	0.69	6.18e-48	Platelet distribution width;
CRC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg00383909	chr3:49044727	WDR6	0.46	5.63	0.3	3.86e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg06470822	chr6:28175283	NA	0.59	8.16	0.41	7.29e-15	Parkinson's disease;
CRC	cis	rs7131987	0.675	rs2194515	chr12:29550383	T/C	cg09582351	chr12:29534625	ERGIC2	0.33	7.17	0.37	5.12e-12	QT interval;
CRC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.38	6.01	0.31	5.05e-9	Height;
CRC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05472934	chr7:22766657	IL6	0.77	12.55	0.57	8.65e-30	Lung cancer;
CRC	cis	rs3018066	0.867	rs13138528	chr4:107154273	T/C	cg01869342	chr4:106983673	TBCK	-0.36	-5.63	-0.3	3.82e-8	Cancer;
CRC	trans	rs10411161	0.748	rs17835306	chr19:52385266	G/A	cg22319618	chr22:45562946	NUP50	-0.69	-5.98	-0.31	5.79e-9	Breast cancer;
CRC	cis	rs9903692	0.954	rs4794441	chr17:46176456	C/T	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.44	7.84	0.4	6.32e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg17133734	chr15:86042851	AKAP13	0.41	6.43	0.33	4.42e-10	Coronary artery disease;
CRC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.47	0.42	8.43e-16	Arsenic metabolism;
CRC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07513332	chr6:167530253	CCR6	0.42	7.27	0.37	2.57e-12	Primary biliary cholangitis;
CRC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-6.6	-0.34	1.6e-10	Total body bone mineral density;
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.45	6.67	0.34	1.11e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.68	0.39	1.79e-13	Mean platelet volume;
CRC	cis	rs501120	0.584	rs2664856	chr10:44702967	G/T	cg09554077	chr10:44749378	NA	0.67	7.44	0.38	8.88e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.49	-8.73	-0.43	1.29e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs589691	0.502	rs487662	chr11:64481880	G/A	cg06522879	chr11:64358276	SLC22A12	-0.44	-6.44	-0.33	4.27e-10	Urate levels;
CRC	trans	rs6693295	0.729	rs10399630	chr1:246212561	A/T	cg03680032	chr11:94965610	SESN3	0.5	6.16	0.32	2.09e-9	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.53	-7.18	-0.37	4.61e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.75	12.75	0.58	1.51e-30	Idiopathic membranous nephropathy;
CRC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.27	-0.56	9.51e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg20750642	chr13:99100586	FARP1	-0.41	-5.84	-0.31	1.23e-8	Neuroticism;
CRC	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.86	16.15	0.66	1.31e-43	Hip circumference;
CRC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.55	9.14	0.45	6.4e-18	Schizophrenia;
CRC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.46	5.77	0.3	1.83e-8	Aortic root size;
CRC	cis	rs9826463	0.582	rs11720762	chr3:142140511	T/G	cg20824294	chr3:142316082	PLS1	0.38	6.05	0.32	3.87e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-8.02	-0.4	1.89e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.48	-8.53	-0.43	5.6e-16	Post-traumatic stress disorder;
CRC	cis	rs4973397	0.765	rs10445830	chr2:232263973	C/T	cg13347044	chr2:232276743	NA	0.44	6.25	0.33	1.24e-9	Anti-saccade response;
CRC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.44	9.75	0.47	6.67e-20	Blood protein levels;
CRC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.96	-0.31	6.46e-9	Obesity-related traits;
CRC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.36	-5.99	-0.31	5.47e-9	Mean platelet volume;Platelet distribution width;
CRC	trans	rs12554020	0.681	rs78759589	chr9:96171800	G/A	cg23291280	chr19:31847970	NA	-0.68	-6.24	-0.33	1.36e-9	Schizophrenia;
CRC	cis	rs11212617	0.967	rs625120	chr11:108095220	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.32	0.33	8.29e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg26769984	chr7:1090371	C7orf50	0.51	7.33	0.37	1.82e-12	Bronchopulmonary dysplasia;
CRC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.09	-0.36	8.3e-12	Colorectal cancer;
CRC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.3	-5.84	-0.31	1.27e-8	Renal cell carcinoma;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg15511327	chr8:143859410	LYNX1	0.39	6.92	0.36	2.4e-11	Urinary tract infection frequency;
CRC	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.57	-8.89	-0.44	4.16e-17	Motion sickness;
CRC	cis	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg18809830	chr7:99032528	PTCD1	-1.21	-8.72	-0.43	1.36e-16	Blood metabolite levels;
CRC	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.53	8.58	0.43	3.8e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs375066	0.599	rs2356439	chr19:44353131	A/G	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24249390	chr15:90295951	MESP1	-0.55	-8.46	-0.42	8.59e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.15	-0.37	5.66e-12	Inflammatory bowel disease;
CRC	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-6.99	-0.36	1.49e-11	Menarche (age at onset);
CRC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs3740540	0.507	rs10794161	chr10:126291327	C/A	cg04949429	chr10:126290192	LHPP	0.42	6.23	0.32	1.45e-9	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08437167	chr3:9885801	RPUSD3	0.41	6.11	0.32	2.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.47	-7.0	-0.36	1.42e-11	Colorectal cancer;
CRC	trans	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.85	0.35	3.68e-11	Ulcerative colitis;
CRC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.53	8.36	0.42	1.77e-15	Height;
CRC	cis	rs7095944	0.584	rs4962691	chr10:126424137	C/T	cg08799069	chr10:126477246	METTL10	-0.45	-6.93	-0.36	2.29e-11	Asthma;
CRC	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04733989	chr22:42467013	NAGA	0.4	5.62	0.3	4.12e-8	Cognitive function;
CRC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.62	9.42	0.46	8.4e-19	Testicular germ cell tumor;
CRC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.78	10.48	0.5	2.33e-22	Coronary artery disease;
CRC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg05569086	chr8:143859399	LYNX1	0.34	5.84	0.31	1.28e-8	Urinary tract infection frequency;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17697381	chr3:148709363	GYG1	0.4	6.16	0.32	2.11e-9	Myopia (pathological);
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg15382696	chr6:118971807	C6orf204	0.61	8.01	0.4	2.07e-14	Diastolic blood pressure;
CRC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg13722127	chr7:150037890	RARRES2	0.4	5.74	0.3	2.21e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg08314208	chr16:67682810	RLTPR	-0.65	-6.8	-0.35	4.91e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs11212617	0.967	rs661467	chr11:108101492	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.75	0.3	2.08e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs728616	0.867	rs56123058	chr10:81811072	G/A	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.45	-0.33	4.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.74	-0.35	7.09e-11	Response to antipsychotic treatment;
CRC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg06784218	chr1:46089804	CCDC17	-0.54	-9.15	-0.45	6.35e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1864585	0.520	rs7009920	chr8:10585162	C/T	cg26278703	chr11:58910052	FAM111A	-0.5	-5.96	-0.31	6.4e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.74	-0.3	2.19e-8	Life satisfaction;
CRC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-6.51	-0.34	2.77e-10	Platelet distribution width;
CRC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg25456477	chr12:86230367	RASSF9	0.38	6.48	0.34	3.29e-10	Major depressive disorder;
CRC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.08	12.26	0.56	1.03e-28	Psoriasis vulgaris;
CRC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg15110403	chr19:17392923	ANKLE1	-0.36	-6.0	-0.31	5.23e-9	Systemic lupus erythematosus;
CRC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg08888203	chr3:10149979	C3orf24	0.69	9.78	0.47	5.28e-20	Alzheimer's disease;
CRC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-13.38	-0.59	6.83e-33	Blood metabolite levels;
CRC	cis	rs4763879	0.739	rs7310460	chr12:9840773	A/T	cg26689682	chr12:9723402	NA	-0.34	-5.61	-0.3	4.21e-8	Type 1 diabetes;
CRC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg15440763	chr7:158190612	PTPRN2	-0.35	-5.76	-0.3	1.93e-8	Obesity-related traits;
CRC	trans	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg11693508	chr17:37793320	STARD3	0.54	7.67	0.39	1.93e-13	Bipolar disorder;
CRC	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.9e-31	White blood cell count (basophil);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25780156	chr19:1383710	NDUFS7	0.4	6.65	0.34	1.23e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg14515779	chr1:101123966	NA	0.35	6.15	0.32	2.3e-9	Monocyte count;
CRC	cis	rs77633900	0.772	rs284907	chr15:76741569	A/G	cg21673338	chr15:77095150	SCAPER	-0.74	-6.46	-0.34	3.74e-10	Non-glioblastoma glioma;Glioma;
CRC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1223397	0.938	rs20499	chr6:13295004	C/T	cg06879394	chr6:13274151	PHACTR1	0.48	5.86	0.31	1.13e-8	Blood pressure;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.61	-7.96	-0.4	2.85e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.58	9.99	0.48	1.05e-20	Facial morphology (factor 15, philtrum width);
CRC	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg00646200	chr1:148855367	NA	0.34	6.23	0.32	1.41e-9	Hip geometry;
CRC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg00316803	chr15:76480434	C15orf27	-0.35	-5.79	-0.3	1.67e-8	Blood metabolite levels;
CRC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	1.06e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	10.35	0.5	6.45e-22	HIV-1 control;
CRC	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg00750074	chr16:89608354	SPG7	-0.38	-5.63	-0.3	3.79e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.46	6.58	0.34	1.91e-10	Lymphocyte counts;
CRC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-0.73	-7.17	-0.37	4.91e-12	Schizophrenia;
CRC	cis	rs3015497	0.789	rs1389652	chr14:51125240	T/C	cg09863266	chr14:51125203	SAV1	-0.33	-6.18	-0.32	1.89e-9	Mean platelet volume;
CRC	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.53	6.08	0.32	3.31e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs7945718	0.621	rs7939509	chr11:12688130	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	5.06e-12	Educational attainment (years of education);
CRC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.87	-0.48	2.65e-20	Hip circumference adjusted for BMI;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg22885777	chr19:15947555	NA	-0.57	-6.3	-0.33	9.65e-10	Lung adenocarcinoma;
CRC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg13777783	chr17:79615861	NA	-0.3	-5.72	-0.3	2.44e-8	Eye color traits;
CRC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.69	-12.19	-0.56	1.78e-28	Prostate cancer;
CRC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg21153622	chr11:89784906	NA	-0.38	-6.05	-0.32	3.99e-9	Height;
CRC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg21251018	chr6:28226885	NKAPL	0.39	6.02	0.31	4.74e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.59	10.93	0.52	6.23e-24	Optic cup area;
CRC	cis	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.92	-0.31	7.93e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.9	-0.31	8.8e-9	Lung cancer;
CRC	cis	rs73206853	0.841	rs73191808	chr12:110904685	T/C	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.43e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.41	6.21	0.32	1.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-8.41	-0.42	1.23e-15	Uric acid levels;
CRC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.07e-25	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	cis	rs12143943	0.966	rs4950953	chr1:204575481	A/G	cg17419461	chr1:204415978	PIK3C2B	0.41	6.2	0.32	1.74e-9	Cognitive performance;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg12516270	chr8:143859308	LYNX1	0.42	7.54	0.38	4.51e-13	Urinary tract infection frequency;
CRC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.28	6.41	0.33	5.1e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.76	0.3	1.93e-8	Renal function-related traits (BUN);
CRC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg24675056	chr1:15929824	NA	-0.51	-7.12	-0.37	6.87e-12	Systolic blood pressure;
CRC	cis	rs9322817	0.691	rs1933804	chr6:105341969	G/C	cg02098413	chr6:105308735	HACE1	0.46	9.14	0.45	6.63e-18	Thyroid stimulating hormone;
CRC	trans	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.57	-0.34	1.97e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg11861562	chr11:117069780	TAGLN	0.29	6.38	0.33	5.97e-10	Blood protein levels;
CRC	cis	rs4290604	0.665	rs4432400	chr2:238058938	A/G	cg23555395	chr2:238036564	NA	-0.63	-6.54	-0.34	2.36e-10	Asthma;
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.44	8.62	0.43	2.9e-16	Iron status biomarkers (transferrin levels);
CRC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.68	-0.35	1.03e-10	Plateletcrit;
CRC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.46	7.08e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.62	8.28	0.42	3.12e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.04	24.3	0.8	2.09e-75	Multiple system atrophy;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-6.48	-0.34	3.35e-10	Electroencephalogram traits;
CRC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.57	-9.24	-0.45	3.05e-18	Breast cancer;
CRC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg23136738	chr11:925521	AP2A2	-0.51	-8.28	-0.42	3.11e-15	Alzheimer's disease (late onset);
CRC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.6	-0.39	3.03e-13	Schizophrenia;
CRC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.21	-0.56	1.6e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg16898833	chr6:26189333	HIST1H4D	0.79	6.5	0.34	2.95e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg06623486	chr1:162531613	UAP1	0.4	6.03	0.32	4.51e-9	Hip circumference;
CRC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19500275	chr17:80737654	TBCD	0.5	6.77	0.35	6.06e-11	Glycated hemoglobin levels;
CRC	cis	rs7916697	0.626	rs3858146	chr10:70013250	C/T	cg06988349	chr10:69991859	ATOH7	0.39	7.49	0.38	6.27e-13	Optic disc area;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24058025	chr1:44412156	IPO13	0.38	6.28	0.33	1.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.25	-0.41	3.74e-15	Hemoglobin concentration;
CRC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.77	0.35	5.86e-11	Hip circumference adjusted for BMI;
CRC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.53	-0.38	4.97e-13	Bladder cancer;
CRC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.76	-8.4	-0.42	1.36e-15	Major depressive disorder;
CRC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.57	0.34	1.99e-10	Morning vs. evening chronotype;
CRC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg26762873	chr11:5879799	OR52E8	-0.48	-7.51	-0.38	5.69e-13	DNA methylation (variation);
CRC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.49	7.8	0.4	8.22e-14	Red blood cell count;
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg22687807	chr8:143858763	LYNX1	0.51	9.01	0.44	1.74e-17	Urinary tract infection frequency;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00902873	chr3:127771089	SEC61A1	0.47	6.46	0.34	3.81e-10	Anxiety disorder;
CRC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.71	7.68	0.39	1.82e-13	Diabetic retinopathy;
CRC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.1	-0.59	7.41e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.61	-11.01	-0.52	3.36e-24	Iron status biomarkers;
CRC	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.77	-0.39	1.04e-13	Bipolar disorder;
CRC	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.83	-7.54	-0.38	4.63e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.97	16.76	0.68	5.2e-46	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-1.1	-12.68	-0.57	2.87e-30	Blood pressure (smoking interaction);
CRC	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg27083787	chr2:113543245	IL1A	0.44	6.25	0.33	1.25e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.84	-0.51	1.32e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.662	rs4283967	chr7:124540535	T/C	cg23710748	chr7:124431027	NA	-0.37	-5.98	-0.31	5.75e-9	Cutaneous malignant melanoma;
CRC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	0.76	6.13	0.32	2.45e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.45	-0.5	2.94e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.01	0.31	4.88e-9	Ovarian reserve;
CRC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.44	8.82	0.44	6.88e-17	Renal cell carcinoma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg03865041	chr16:71842666	AP1G1	0.41	6.24	0.33	1.34e-9	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.68	11.35	0.53	2.04e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg08213375	chr14:104286397	PPP1R13B	0.43	6.73	0.35	7.64e-11	Reticulocyte count;
CRC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.5	-9.36	-0.46	1.27e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg25922239	chr6:33757077	LEMD2	0.44	6.09	0.32	3.08e-9	Crohn's disease;
CRC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	7.16	0.37	5.47e-12	Lung cancer in ever smokers;
CRC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.11	0.32	2.84e-9	Diabetic kidney disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20364594	chr6:158981615	TMEM181	-0.4	-6.53	-0.34	2.5e-10	Myopia (pathological);
CRC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.34	0.42	1.99e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3026101	0.671	rs8077933	chr17:5299674	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg12560992	chr17:57184187	TRIM37	0.52	7.17	0.37	4.85e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.6	10.14	0.49	3.3e-21	Prudent dietary pattern;
CRC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.67	9.32	0.46	1.7e-18	Lung cancer;
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg17958423	chr11:6947583	ZNF215	0.58	6.08	0.32	3.27e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg26762873	chr11:5879799	OR52E8	-0.41	-5.9	-0.31	9.22e-9	DNA methylation (variation);
CRC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg21770322	chr7:97807741	LMTK2	0.86	19.38	0.73	2.28e-56	Breast cancer;
CRC	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.42	-6.1	-0.32	3.01e-9	QT interval;
CRC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.69	8.26	0.41	3.57e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg19894588	chr14:64061835	NA	-0.63	-8.53	-0.43	5.3e-16	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs4664293	0.802	rs13025347	chr2:160577567	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.78	-12.69	-0.57	2.61e-30	Ear protrusion;
CRC	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.55	0.34	2.26e-10	Subjective well-being;
CRC	trans	rs12699921	0.598	rs2723504	chr7:17854833	T/A	cg15753394	chr6:17282781	RBM24	-0.36	-6.03	-0.32	4.5e-9	Fibrinogen levels;
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.52	-7.32	-0.37	1.97e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg24562669	chr7:97807699	LMTK2	0.43	7.08	0.36	8.83e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.32	-0.33	8.5e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-14.98	-0.64	5.06e-39	Lymphocyte percentage of white cells;
CRC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.44	6.12	0.32	2.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs4728142	1.000	rs4728142	chr7:128573967	C/T	cg26616347	chr7:128577752	IRF5	-0.34	-5.75	-0.3	2.08e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	10.68	0.51	4.55e-23	Platelet count;
CRC	cis	rs932541	1.000	rs11699251	chr20:16456295	C/T	cg17003395	chr20:16555519	KIF16B	0.41	5.65	0.3	3.39e-8	Intelligence;
CRC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.51	8.95	0.44	2.75e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3751196	0.614	rs78661975	chr12:104183952	G/A	cg02344784	chr12:104178138	NT5DC3	0.7	7.16	0.37	5.23e-12	Sense of smell;
CRC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.41	-0.5	3.95e-22	Total cholesterol levels;
CRC	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.75	13.77	0.6	2.23e-34	Cancer;
CRC	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.83	12.61	0.57	5.15e-30	Chronic lymphocytic leukemia;
CRC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.5	-7.32	-0.37	1.96e-12	Cotinine glucuronidation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02634712	chr18:19750909	GATA6	0.41	6.1	0.32	3.01e-9	Response to antipsychotic treatment;
CRC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg00343986	chr7:65444356	GUSB	-0.45	-6.24	-0.33	1.32e-9	Aortic root size;
CRC	trans	rs800082	0.516	rs1178894	chr3:144239854	A/G	cg24215973	chr2:240111563	HDAC4	0.46	6.49	0.34	3.14e-10	Smoking behavior;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg26271690	chr1:202830559	LOC148709	-0.41	-5.98	-0.31	5.68e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	6.48	0.34	3.44e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg13183956	chr19:49652517	PPFIA3	0.41	6.09	0.32	3.12e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs8177876	0.731	rs77145371	chr16:81118660	A/G	cg09779152	chr17:73205364	NUP85	0.61	5.99	0.31	5.57e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.17	-0.32	1.95e-9	High light scatter reticulocyte count;
CRC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	8.9	0.44	3.95e-17	Cognitive test performance;
CRC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg14541582	chr5:601475	NA	-0.36	-7.3	-0.37	2.21e-12	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.59	-9.0	-0.44	1.85e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.58	7.33	0.37	1.75e-12	Gut microbiome composition (summer);
CRC	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-1.2	-11.12	-0.52	1.38e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.33e-10	Cognitive ability;
CRC	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.5	0.38	6.05e-13	Eye color traits;
CRC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.52	6.99	0.36	1.52e-11	Alzheimer's disease;
CRC	cis	rs17152411	0.895	rs11245422	chr10:126588143	T/C	cg07906193	chr10:126599966	NA	0.57	6.47	0.34	3.61e-10	Height;
CRC	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.71	-8.17	-0.41	6.71e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg10911889	chr6:126070802	HEY2	0.37	5.7	0.3	2.63e-8	Brugada syndrome;
CRC	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg24375607	chr4:120327624	NA	0.47	7.72	0.39	1.42e-13	Corneal astigmatism;
CRC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.61	-0.43	3.16e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.45	6.89	0.36	2.85e-11	Intelligence (multi-trait analysis);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01719123	chr8:28244050	ZNF395	0.44	6.04	0.32	4.07e-9	Survival in pancreatic cancer;
CRC	cis	rs990171	1.000	rs6705001	chr2:103076210	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.34e-9	Lymphocyte counts;
CRC	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.14	-0.45	6.65e-18	Triglycerides;
CRC	cis	rs4742903	0.935	rs9942894	chr9:106914905	A/G	cg21169611	chr9:106856078	SMC2	0.41	5.6	0.3	4.49e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.0	0.58	1.85e-31	Platelet count;
CRC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg15147215	chr3:52552868	STAB1	-0.65	-11.31	-0.53	2.75e-25	Electroencephalogram traits;
CRC	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-9.19	-0.45	4.55e-18	Coronary artery disease;
CRC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-7.33	-0.37	1.74e-12	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.51	0.46	4.33e-19	Type 2 diabetes;
CRC	trans	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg17903999	chr18:56338584	MALT1	0.43	7.12	0.37	6.83e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg03934865	chr2:198174659	NA	-0.39	-6.17	-0.32	2.06e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-6.64	-0.34	1.29e-10	Height;
CRC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg15445000	chr17:37608096	MED1	-0.36	-6.42	-0.33	4.67e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg20387954	chr3:183756860	HTR3D	0.45	7.68	0.39	1.79e-13	Anterior chamber depth;
CRC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg13722127	chr7:150037890	RARRES2	0.48	7.89	0.4	4.37e-14	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02685901	chr6:43597772	MAD2L1BP;GTPBP2	-0.59	-7.26	-0.37	2.87e-12	Diisocyanate-induced asthma;
CRC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.52	-8.74	-0.43	1.24e-16	Sense of smell;
CRC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg06470822	chr6:28175283	NA	0.61	9.36	0.46	1.26e-18	Pubertal anthropometrics;
CRC	cis	rs4908768	0.501	rs2016084	chr1:8613418	C/A	cg20416874	chr1:8611966	RERE	-0.44	-6.31	-0.33	9.21e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg22089800	chr15:90895588	ZNF774	0.5	7.97	0.4	2.64e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6804368	0.649	rs2372214	chr3:30766438	T/C	cg06106510	chr3:30762233	NA	0.4	7.11	0.37	7.16e-12	Blood metabolite levels;
CRC	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.52	7.53	0.38	4.78e-13	Corneal astigmatism;
CRC	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.52	8.83	0.44	6.48e-17	Dupuytren's disease;
CRC	cis	rs889398	0.741	rs10852461	chr16:69928846	T/C	cg00738113	chr16:70207722	CLEC18C	-0.35	-5.86	-0.31	1.12e-8	Body mass index;
CRC	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	0.65	5.75	0.3	2.02e-8	Fat distribution (HIV);
CRC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg04155289	chr7:94953770	PON1	-0.56	-7.02	-0.36	1.27e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.74	-0.39	1.25e-13	Colorectal cancer;
CRC	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.35	0.53	2e-25	Height;
CRC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.6	0.47	2.1e-19	Menopause (age at onset);
CRC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.82	-0.4	7.35e-14	Colorectal cancer;
CRC	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.42	-6.16	-0.32	2.1e-9	Pediatric non-alcoholic fatty liver disease activity score;
CRC	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.46	5.9	0.31	9.23e-9	Exhaled nitric oxide output;
CRC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg04362960	chr10:104952993	NT5C2	-0.4	-5.64	-0.3	3.61e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg06042504	chr8:55087323	NA	-0.36	-5.71	-0.3	2.47e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	8.14	0.41	8.49e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7215564	0.908	rs35542453	chr17:78687242	T/G	cg09596252	chr17:78655493	RPTOR	0.58	6.24	0.33	1.36e-9	Myopia (pathological);
CRC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.91	-17.2	-0.69	9.93e-48	Intelligence (multi-trait analysis);
CRC	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.22	29.74	0.85	3.03e-95	Colorectal cancer;
CRC	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.52	8.85	0.44	5.35e-17	Dupuytren's disease;
CRC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg18490616	chr2:88469792	THNSL2	0.57	5.71	0.3	2.57e-8	Plasma clusterin levels;
CRC	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.6	9.06	0.45	1.21e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2411233	0.935	rs2164011	chr15:39289029	G/A	cg23129342	chr15:39283510	NA	0.3	5.63	0.3	3.78e-8	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00605358	chr12:89747739	DUSP6	0.45	6.3	0.33	9.8e-10	Response to antipsychotic treatment;
CRC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.82	0.31	1.42e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.59	-8.71	-0.43	1.53e-16	Lung cancer;
CRC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg12223502	chr10:5658492	NA	-0.37	-5.88	-0.31	1.03e-8	Breast cancer;
CRC	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.47	-5.86	-0.31	1.14e-8	Gut microbiome composition (summer);
CRC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.83	11.37	0.53	1.75e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg16892393	chr17:41919603	NA	0.56	7.83	0.4	6.58e-14	Triglycerides;
CRC	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.68	-9.59	-0.47	2.37e-19	Personality dimensions;
CRC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.74	10.04	0.48	7.2e-21	Alzheimer's disease;
CRC	trans	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg02184673	chr11:123066560	ASAM	0.3	6.04	0.32	4.13e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.33	-0.33	8e-10	Educational attainment;
CRC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg18876405	chr7:65276391	NA	-0.46	-6.33	-0.33	7.93e-10	Aortic root size;
CRC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.49	6.92	0.36	2.35e-11	Schizophrenia;
CRC	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.62	-0.3	4.15e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg26043149	chr18:55253948	FECH	-0.44	-6.65	-0.34	1.22e-10	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg00063174	chr2:228736253	WDR69	-0.47	-6.33	-0.33	8.04e-10	Blood pressure;
CRC	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg15816464	chr17:2026533	SMG6	0.4	6.96	0.36	1.84e-11	Total body bone mineral density;
CRC	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.93	-0.36	2.19e-11	Inflammatory skin disease;
CRC	cis	rs13315871	1.000	rs71311868	chr3:58392874	A/G	cg20936604	chr3:58311152	NA	-0.73	-7.0	-0.36	1.46e-11	Cholesterol, total;
CRC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.35	-6.5	-0.34	3.03e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg12856521	chr11:46389249	DGKZ	0.73	10.56	0.5	1.21e-22	Crohn's disease;
CRC	cis	rs9837602	0.745	rs792834	chr3:99476121	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.74	0.3	2.17e-8	Breast cancer;
CRC	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.54	7.31	0.37	2.07e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.65	8.34	0.42	2.05e-15	Bone mineral density;
CRC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.15	-15.77	-0.66	3.94e-42	Vitiligo;
CRC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.68	0.35	1.02e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.22	-5.86	-0.31	1.13e-8	Type 2 diabetes;
CRC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	6.17	0.32	1.96e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.5	6.01	0.31	4.93e-9	Dental caries;
CRC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.05	-0.32	3.99e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg21251018	chr6:28226885	NKAPL	0.47	7.07	0.36	9.43e-12	Cardiac Troponin-T levels;
CRC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.93	-16.48	-0.67	6.56e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.46	-6.69	-0.35	9.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	6.11	0.32	2.88e-9	Tonsillectomy;
CRC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.61	-11.24	-0.53	5.09e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg02569458	chr12:86230093	RASSF9	0.46	7.79	0.39	8.84e-14	Major depressive disorder;
CRC	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.13	-0.37	6.28e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.71	11.05	0.52	2.39e-24	Monocyte count;
CRC	cis	rs7113874	0.569	rs10840077	chr11:8601210	A/T	cg20771178	chr11:8615675	STK33	0.35	5.75	0.3	2.05e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.59	0.47	2.27e-19	Menopause (age at onset);
CRC	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.92	0.36	2.34e-11	Mean corpuscular volume;
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-8.23	-0.41	4.37e-15	Intelligence (multi-trait analysis);
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.77	11.82	0.55	4.29e-27	Menarche (age at onset);
CRC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg05192639	chr6:26864778	GUSBL1	0.34	6.03	0.32	4.5e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg06636001	chr8:8085503	FLJ10661	0.47	7.15	0.37	5.74e-12	Myopia (pathological);
CRC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.52	-8.79	-0.44	8.46e-17	Obesity-related traits;
CRC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-6.06	-0.32	3.64e-9	Vitiligo;
CRC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	6.91	0.36	2.55e-11	Platelet count;
CRC	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.58	6.83	0.35	4.2e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1007738	0.542	rs7937410	chr11:47206082	C/G	cg19486271	chr11:47235900	DDB2	0.41	5.61	0.3	4.27e-8	Bone mineral density (hip);
CRC	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.5	5.78	0.3	1.78e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	cis	rs12580194	0.593	rs11171430	chr12:55755254	A/G	cg19537932	chr12:55886519	OR6C68	-0.67	-8.77	-0.44	9.66e-17	Cancer;
CRC	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.35e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.19	-0.45	4.45e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg20607287	chr7:12443886	VWDE	-0.42	-6.2	-0.32	1.67e-9	Coronary artery disease;
CRC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.14	-0.45	6.6e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.3	1.75e-8	Response to antipsychotic treatment;
CRC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.68	0.39	1.89e-13	Myopia (pathological);
CRC	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg22256960	chr15:77711686	NA	-0.45	-6.18	-0.32	1.84e-9	Type 2 diabetes;
CRC	cis	rs9648716	1.000	rs10263448	chr7:140618013	C/T	cg10747023	chr7:140774559	NA	0.46	5.99	0.31	5.42e-9	Type 2 diabetes;
CRC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.58	-0.34	1.89e-10	Total body bone mineral density;
CRC	cis	rs7635838	0.892	rs754015	chr3:11493945	T/C	cg00170343	chr3:11313890	ATG7	0.43	6.62	0.34	1.49e-10	HDL cholesterol;
CRC	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.77	-8.46	-0.42	8.61e-16	Neuroticism;
CRC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.5	7.7	0.39	1.62e-13	Corneal astigmatism;
CRC	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.51	8.19	0.41	5.86e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg11212589	chr17:38028394	ZPBP2	0.45	8.39	0.42	1.42e-15	Self-reported allergy;
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.49	6.8	0.35	4.97e-11	Menarche (age at onset);
CRC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.66	12.07	0.55	5.27e-28	Calcium levels;
CRC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs10924970	0.649	rs12409696	chr1:235423607	T/C	cg09010748	chr1:235293032	TOMM20	-0.41	-5.66	-0.3	3.37e-8	Asthma;
CRC	cis	rs7739232	0.920	rs77771017	chr6:53529014	C/T	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20165655	chr11:65339703	FAM89B	0.42	6.14	0.32	2.43e-9	Response to antipsychotic treatment;
CRC	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg11693508	chr17:37793320	STARD3	0.64	8.24	0.41	4.22e-15	Bipolar disorder;
CRC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg13565492	chr6:43139072	SRF	-0.72	-7.42	-0.38	9.94e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg18678763	chr11:4115507	RRM1	0.51	7.35	0.38	1.58e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.52	-8.51	-0.42	6.16e-16	Sense of smell;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05702952	chr2:173420889	PDK1	0.49	6.99	0.36	1.52e-11	Response to antipsychotic treatment;
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg22561889	chr6:118971681	C6orf204	0.51	6.65	0.34	1.26e-10	Diastolic blood pressure;
CRC	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg05540913	chr6:167530185	CCR6	0.35	6.32	0.33	8.33e-10	Primary biliary cholangitis;
CRC	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03647317	chr4:187891568	NA	-0.55	-9.99	-0.48	1.05e-20	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg18288967	chr1:45987694	PRDX1	0.68	7.72	0.39	1.37e-13	Obesity-related traits;
CRC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	6.68	0.35	9.92e-11	Diabetic retinopathy;
CRC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23903597	chr17:61704154	MAP3K3	-0.44	-6.05	-0.32	3.99e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs12295403	0.691	rs9705036	chr11:18686916	A/G	cg07538406	chr11:18686895	NA	0.51	6.92	0.36	2.31e-11	Ovarian reserve;
CRC	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.53	-8.82	-0.44	6.88e-17	Mosquito bite size;
CRC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	12.03	0.55	7.15e-28	Hip circumference adjusted for BMI;
CRC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	7.47	0.38	7.16e-13	Breast cancer;
CRC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg05132306	chr1:1846340	CALML6	-0.48	-7.53	-0.38	4.89e-13	Body mass index;
CRC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.54	-9.59	-0.47	2.21e-19	Huntington's disease progression;
CRC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	13.72	0.6	3.52e-34	Electrocardiographic conduction measures;
CRC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-7.97	-0.4	2.65e-14	Life satisfaction;
CRC	cis	rs10924970	0.967	rs4659721	chr1:235426917	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.98	0.31	5.81e-9	Asthma;
CRC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg00620190	chr6:26240307	HIST1H4F	-0.49	-5.74	-0.3	2.19e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
CRC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.71	10.3	0.49	9.55e-22	Cognitive function;
CRC	cis	rs10089	0.552	rs11955148	chr5:127557814	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	7.45	0.38	8.19e-13	Ileal carcinoids;
CRC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg20417195	chr1:21767127	NBPF3	0.4	5.8	0.3	1.54e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs16852403	0.517	rs10494512	chr1:178251680	A/G	cg00404053	chr1:178313656	RASAL2	0.45	5.91	0.31	8.61e-9	Childhood ear infection;
CRC	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg10263370	chr3:44754102	ZNF502	-0.42	-5.76	-0.3	1.91e-8	IgG glycosylation;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.58	7.85	0.4	5.85e-14	Alzheimer's disease;
CRC	cis	rs7835763	0.518	rs2445904	chr8:119095507	C/T	cg11592677	chr8:119110466	EXT1	0.41	7.08	0.36	8.88e-12	Autism spectrum disorder;
CRC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.71	-11.13	-0.52	1.2e-24	Lung cancer;
CRC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.37	6.58	0.34	1.86e-10	Erythrocyte sedimentation rate;
CRC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.56	-7.7	-0.39	1.66e-13	Response to antineoplastic agents;
CRC	trans	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.59e-14	HDL cholesterol;
CRC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.38	5.68	0.3	3.03e-8	Testicular germ cell tumor;
CRC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.47	7.15	0.37	5.7e-12	Cleft lip with or without cleft palate;
CRC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg19091447	chr20:37555378	FAM83D	0.39	5.99	0.31	5.47e-9	Age-related macular degeneration;
CRC	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	0.89	9.23	0.45	3.35e-18	Red blood cell traits;
CRC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.66	8.25	0.41	3.83e-15	Menarche (age at onset);
CRC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.46	5.61	0.3	4.24e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.58	6.61	0.34	1.55e-10	Childhood ear infection;
CRC	cis	rs9463078	0.547	rs720576	chr6:44729974	A/T	cg25276700	chr6:44698697	NA	0.31	7.79	0.39	8.85e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	11.24	0.53	4.91e-25	Tonsillectomy;
CRC	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.16e-12	Coronary artery disease;
CRC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.58	-0.34	1.91e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6988985	0.560	rs3753122	chr8:143926927	G/T	cg10324643	chr8:143916377	GML	0.35	5.93	0.31	7.71e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.47	6.09	0.32	3.07e-9	Exhaled nitric oxide output;
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.01	-0.31	4.92e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06473773	chr20:37063729	LOC388796;SNORA71D	0.45	6.38	0.33	5.97e-10	Response to antipsychotic treatment;
CRC	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg07166546	chr14:35805898	NA	-0.31	-6.11	-0.32	2.76e-9	Psoriasis;
CRC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg25164649	chr6:28176230	NA	0.49	7.15	0.37	5.67e-12	Parkinson's disease;
CRC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg12564285	chr5:131593104	PDLIM4	0.33	6.05	0.32	3.96e-9	Blood metabolite levels;
CRC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg07195577	chr17:27052828	TLCD1	0.41	5.92	0.31	7.89e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-7.24	-0.37	3.14e-12	Total body bone mineral density;
CRC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.58	-8.83	-0.44	6.38e-17	Aortic root size;
CRC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.4	6.53	0.34	2.46e-10	Height;
CRC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.43	5.77e-16	Colorectal cancer;
CRC	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg12458913	chr13:53173898	NA	-0.39	-5.69	-0.3	2.85e-8	Lewy body disease;
CRC	trans	rs10242455	0.702	rs76840929	chr7:98945858	T/C	cg09045935	chr12:6379348	NA	0.94	7.14	0.37	5.9e-12	Blood metabolite levels;
CRC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg03037974	chr15:76606532	NA	0.67	11.43	0.53	1.06e-25	Blood metabolite levels;
CRC	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg14711859	chr11:8959438	ASCL3	-0.38	-5.91	-0.31	8.33e-9	Hemoglobin concentration;
CRC	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg20415053	chr1:26527928	CATSPER4	-0.33	-5.64	-0.3	3.71e-8	Obesity-related traits;
CRC	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.14	0.37	5.89e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.47	7.34	0.37	1.73e-12	Fat distribution (HIV);
CRC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg21285383	chr16:89894308	SPIRE2	0.37	6.25	0.33	1.3e-9	Vitiligo;
CRC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg04450456	chr4:17643702	FAM184B	0.41	6.6	0.34	1.61e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg20512303	chr5:131592959	PDLIM4	0.36	6.05	0.32	3.9e-9	Breast cancer;
CRC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.35	-7.91	-0.4	3.87e-14	Mean corpuscular volume;
CRC	cis	rs7394190	0.935	rs6480708	chr10:75420114	C/A	cg07699608	chr10:75541558	CHCHD1	0.55	6.22	0.32	1.48e-9	Incident atrial fibrillation;
CRC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.42	-7.26	-0.37	2.81e-12	Major depressive disorder;
CRC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg13844804	chr7:814759	HEATR2	0.66	8.51	0.42	6.28e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.47	7.8	0.4	8.13e-14	Testicular germ cell tumor;
CRC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.34	-6.52	-0.34	2.63e-10	Colorectal cancer;
CRC	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg00587665	chr15:100533223	ADAMTS17	0.34	5.74	0.3	2.14e-8	Height;
CRC	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg18232548	chr7:50535776	DDC	-0.45	-6.3	-0.33	9.59e-10	Systemic sclerosis;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg12172441	chr6:28176163	NA	0.55	7.17	0.37	4.99e-12	Parkinson's disease;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.2	-0.37	4.05e-12	Breast cancer;
CRC	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.63	-8.31	-0.42	2.53e-15	Facial morphology (factor 19);
CRC	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg06636001	chr8:8085503	FLJ10661	0.46	6.54	0.34	2.36e-10	Retinal vascular caliber;
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-8.1	-0.41	1.09e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg12172441	chr6:28176163	NA	0.57	7.32	0.37	1.93e-12	Parkinson's disease;
CRC	cis	rs7705042	0.796	rs1835965	chr5:141501771	G/A	cg08523384	chr5:141488047	NDFIP1	-0.34	-6.08	-0.32	3.29e-9	Asthma;
CRC	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.73	-9.99	-0.48	1.06e-20	Coronary artery disease;
CRC	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.85e-16	Alcohol dependence;
CRC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.97	-0.31	6.04e-9	Cognitive function;
CRC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-7.15	-0.37	5.49e-12	Breast cancer;
CRC	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.46	8.04	0.41	1.65e-14	Testicular germ cell tumor;
CRC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.25	0.41	3.98e-15	Menopause (age at onset);
CRC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.79	-0.39	8.96e-14	Intelligence (multi-trait analysis);
CRC	trans	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg06206626	chr22:26825900	ASPHD2	0.41	6.15	0.32	2.22e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.69	11.35	0.53	2.12e-25	Mean platelet volume;
CRC	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11679072	1.000	rs6724234	chr2:240448917	G/A	cg03276489	chr2:240449683	NA	-0.96	-9.27	-0.45	2.58e-18	Blood pressure (smoking interaction);
CRC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-6.95	-0.36	2.01e-11	Response to antipsychotic treatment;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05955566	chr12:99038273	IKBIP;APAF1	0.41	6.06	0.32	3.67e-9	Interleukin-6 levels;
CRC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.69	0.47	1.04e-19	Birth weight;
CRC	cis	rs9469913	0.668	rs112563428	chr6:34800435	C/T	cg17674042	chr6:34482479	PACSIN1	-0.79	-7.81	-0.4	7.87e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.51	6.19	0.32	1.8e-9	Diastolic blood pressure;
CRC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg04586622	chr2:25135609	ADCY3	-0.54	-10.01	-0.48	8.89e-21	Body mass index;
CRC	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.71	7.58	0.39	3.45e-13	Breast cancer;
CRC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.66	12.71	0.57	2.29e-30	Prudent dietary pattern;
CRC	cis	rs4728302	0.869	rs10253633	chr7:133590869	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.85	0.31	1.22e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.78	-0.47	5.18e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.59	8.37	0.42	1.66e-15	Psoriasis;
CRC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.65	-7.78	-0.39	9.41e-14	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11105980	chr13:37393381	RFXAP	0.39	6.1	0.32	2.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	0.67	7.22	0.37	3.66e-12	Body mass index;
CRC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.43	5.82	0.31	1.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg05064044	chr6:292385	DUSP22	-0.58	-8.0	-0.4	2.16e-14	Menopause (age at onset);
CRC	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.49	7.47	0.38	7.48e-13	Testicular germ cell tumor;
CRC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.6	8.89	0.44	4.26e-17	Systolic blood pressure;
CRC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg14711859	chr11:8959438	ASCL3	0.38	6.43	0.33	4.45e-10	Hemoglobin concentration;
CRC	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.52	-9.58	-0.47	2.37e-19	Birth weight;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.93	-0.31	7.58e-9	Depression;
CRC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.33	-0.37	1.76e-12	Psoriasis;
CRC	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.33	6.37	0.33	6.29e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.73	12.0	0.55	9.38e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2617583	0.509	rs748209	chr5:1457554	A/C	cg07148919	chr5:1466943	LPCAT1	-0.45	-5.86	-0.31	1.1e-8	Breast cancer;
CRC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.62	9.4	0.46	9.25e-19	Corneal astigmatism;
CRC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.74	-10.65	-0.51	6.16e-23	Platelet distribution width;
CRC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.56	8.08	0.41	1.22e-14	Uric acid levels;
CRC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.6	10.6	0.5	8.69e-23	Schizophrenia;
CRC	trans	rs2303319	0.504	rs56407015	chr2:162455625	G/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.75	-0.3	2.07e-8	Daytime sleep phenotypes;
CRC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.51	8.98	0.44	2.07e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.53	6.75	0.35	6.88e-11	Morning vs. evening chronotype;
CRC	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg25856811	chr1:152973957	SPRR3	0.25	6.89	0.36	2.87e-11	Inflammatory skin disease;
CRC	trans	rs10242455	1.000	rs10229552	chr7:99234899	T/A	cg09045935	chr12:6379348	NA	0.6	6.6	0.34	1.65e-10	Blood metabolite levels;
CRC	cis	rs17331151	0.505	rs34182518	chr3:52743854	G/A	cg07884673	chr3:53033167	SFMBT1	0.78	5.68	0.3	2.9e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10979	0.679	rs9321918	chr6:143883460	T/C	cg25407410	chr6:143891975	LOC285740	-0.68	-9.49	-0.46	4.84e-19	Hypospadias;
CRC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.36	0.33	6.64e-10	Height;
CRC	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00338735	chr4:53728038	RASL11B	0.38	5.95	0.31	6.69e-9	Optic nerve measurement (cup area);
CRC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.29	0.53	3.29e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.27	0.33	1.16e-9	Bipolar disorder;
CRC	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.19	-0.32	1.75e-9	Systemic lupus erythematosus;
CRC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.64	-7.55	-0.38	4.45e-13	Gut microbiome composition (summer);
CRC	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.51	-7.04	-0.36	1.16e-11	Dental caries;
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.64	11.86	0.55	2.89e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6479527	0.875	rs10429556	chr9:96805635	C/T	cg14459158	chr9:96720562	NA	0.38	6.71	0.35	8.37e-11	Esophageal adenocarcinoma;
CRC	cis	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg27395922	chr11:50257633	LOC441601	0.36	5.73	0.3	2.25e-8	Coronary artery disease;
CRC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.68	-11.35	-0.53	2.06e-25	Blood protein levels;
CRC	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.74	13.51	0.6	2.17e-33	Anterior chamber depth;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10448528	chr11:123612020	ZNF202	0.45	6.4	0.33	5.21e-10	Response to antipsychotic treatment;
CRC	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.37	-0.38	1.4e-12	Inflammatory bowel disease;
CRC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	9.16	0.45	5.79e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26240231	chr7:1148101	C7orf50	-0.41	-5.79	-0.3	1.68e-8	Bronchopulmonary dysplasia;
CRC	cis	rs35520189	0.556	rs13026837	chr2:113705673	G/A	cg12858261	chr2:113808755	IL1F8	0.45	5.97	0.31	6.31e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05952120	chr17:61554416	ACE	0.48	7.83	0.4	6.93e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.52	5.71	0.3	2.54e-8	Menarche (age at onset);
CRC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.48	8.65e-21	Lung cancer;
CRC	cis	rs6499244	0.508	rs11642008	chr16:69928639	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.05	-0.32	3.97e-9	Menarche (age at onset);
CRC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.49	6.88	0.35	3.08e-11	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03512643	chr14:74486160	C14orf45;ENTPD5	-0.4	-6.17	-0.32	1.99e-9	Myopia (pathological);
CRC	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.63	-7.01	-0.36	1.32e-11	Coronary artery disease;
CRC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.48	-8.68	-0.43	1.83e-16	Eye color traits;
CRC	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.96	-0.36	1.8e-11	Schizophrenia;
CRC	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-6.96	-0.36	1.88e-11	Neutrophil percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03003858	chr8:128747873	MYC	0.39	6.49	0.34	3.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.23	-0.41	4.32e-15	Response to amphetamines;
CRC	cis	rs72730918	0.564	rs4774594	chr15:51851999	C/T	cg14296394	chr15:51910925	DMXL2	-0.45	-5.95	-0.31	6.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.4	5.77	0.3	1.86e-8	Osteoporosis;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg02158880	chr13:53174818	NA	0.49	6.82	0.35	4.44e-11	Lewy body disease;
CRC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.35	5.86	0.31	1.13e-8	Prostate-specific antigen levels;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.38	-5.78	-0.3	1.77e-8	Platelet count;
CRC	cis	rs6580110	0.837	rs749777	chr5:154074270	T/C	cg11923914	chr5:154071666	NA	-0.47	-7.12	-0.37	6.73e-12	Facial morphology (factor 9, facial height related to vertical position of nasion);
CRC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.63	-9.13	-0.45	7e-18	Response to temozolomide;
CRC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.26	-0.37	2.76e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.62	8.87	0.44	4.82e-17	Height;
CRC	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.43	6.28	0.33	1.09e-9	Blood metabolite levels;
CRC	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.27	-0.33	1.12e-9	Neuroticism;
CRC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.22e-17	Mean platelet volume;
CRC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.58	-7.45	-0.38	8.28e-13	Neuroticism;
CRC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.11	0.41	1.03e-14	Platelet count;
CRC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.84	0.63	1.67e-38	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg19025524	chr12:109796872	NA	-0.48	-6.88	-0.35	2.99e-11	Neuroticism;
CRC	cis	rs12760731	0.511	rs6697878	chr1:178611238	G/T	cg00404053	chr1:178313656	RASAL2	-0.54	-6.71	-0.35	8.43e-11	Obesity-related traits;
CRC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.74	12.62	0.57	4.92e-30	Body mass index;
CRC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.42	-6.19	-0.32	1.83e-9	Reticulocyte count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15531788	chr10:38146671	ZNF248	0.41	6.87	0.35	3.21e-11	Obesity-related traits;
CRC	cis	rs539514	0.690	rs34545980	chr13:76309637	C/A	cg04757411	chr13:76259545	LMO7	-0.35	-5.95	-0.31	6.88e-9	Type 1 diabetes;
CRC	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg16898833	chr6:26189333	HIST1H4D	0.77	6.59	0.34	1.77e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.92	0.31	7.92e-9	Prudent dietary pattern;
CRC	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg24553058	chr2:113831203	IL1F10	-0.42	-7.04	-0.36	1.14e-11	Protein quantitative trait loci;
CRC	cis	rs78077440	1.000	rs57993951	chr5:40344787	A/T	cg09067459	chr5:40385259	NA	-0.53	-5.76	-0.3	1.95e-8	Multiple sclerosis;
CRC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.55	-9.38	-0.46	1.14e-18	Menarche (age at onset);
CRC	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg10483660	chr13:112241077	NA	0.36	5.82	0.31	1.39e-8	Menarche (age at onset);
CRC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.56	-8.31	-0.42	2.49e-15	Menarche (age at onset);
CRC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg10298567	chr3:47292165	KIF9	0.37	5.85	0.31	1.16e-8	Colorectal cancer;
CRC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg21280719	chr6:42927975	GNMT	0.37	6.43	0.33	4.38e-10	Blood protein levels;
CRC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.33	-0.37	1.77e-12	Mean corpuscular volume;
CRC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.53	-8.59	-0.43	3.58e-16	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13654993	chr19:5978414	RANBP3	0.41	6.13	0.32	2.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.33	6.08	0.32	3.28e-9	Lung cancer;
CRC	cis	rs7605827	0.930	rs11680044	chr2:15607103	T/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg01388757	chr2:102091195	RFX8	0.35	5.87	0.31	1.09e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.5	7.41	0.38	1.09e-12	Dialysis-related mortality;
CRC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg12501888	chr15:85177176	SCAND2	-0.37	-5.87	-0.31	1.07e-8	P wave terminal force;
CRC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg15848620	chr12:58087721	OS9	-0.61	-8.35	-0.42	1.98e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg16898833	chr6:26189333	HIST1H4D	0.77	6.45	0.33	4.07e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.37	-0.56	4.1e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	6.92	0.36	2.35e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.41	5.65	0.3	3.49e-8	Bipolar disorder;
CRC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg11707556	chr5:10655725	ANKRD33B	0.39	6.32	0.33	8.46e-10	Coronary artery disease;
CRC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.34	0.42	2.05e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	9.16	0.45	5.66e-18	Platelet count;
CRC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.4	-19.73	-0.74	1.03e-57	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.37	-0.42	1.72e-15	Height;
CRC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.32	-5.9	-0.31	8.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg20203395	chr5:56204925	C5orf35	-0.74	-8.73	-0.43	1.32e-16	Initial pursuit acceleration;
CRC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.57	9.24	0.45	3.19e-18	Gout;
CRC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg08314208	chr16:67682810	RLTPR	-0.49	-6.08	-0.32	3.35e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.73	-12.44	-0.57	2.22e-29	Paraoxonase activity;
CRC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.66	9.83	0.48	3.8e-20	Selective IgA deficiency;
CRC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.59	8.11	0.41	1.01e-14	Mean corpuscular hemoglobin;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13285458	chr12:49212305	CACNB3	0.4	6.29	0.33	1.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg10473508	chr5:172068142	NEURL1B	-0.42	-6.26	-0.33	1.22e-9	Daytime sleep phenotypes;
CRC	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.57	8.33	0.42	2.21e-15	Schizophrenia;
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.94	-0.31	7.25e-9	Life satisfaction;
CRC	trans	rs948562	1.000	rs111901203	chr11:58297542	C/T	cg26660744	chr1:1573181	CDK11B	0.53	6.2	0.32	1.69e-9	Lymphoma;
CRC	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.53	-7.32	-0.37	1.96e-12	Total body bone mineral density;
CRC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.82	12.6	0.57	5.59e-30	Cognitive function;
CRC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.92	13.52	0.6	2.02e-33	Triglycerides;
CRC	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	9.01	0.45	1.67e-17	Fuchs's corneal dystrophy;
CRC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	0.97	8.48	0.42	7.89e-16	Blood protein levels;
CRC	cis	rs9847710	0.733	rs7613013	chr3:53077806	A/G	cg18099408	chr3:52552593	STAB1	0.4	5.85	0.31	1.16e-8	Ulcerative colitis;
CRC	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.55	-8.86	-0.44	5.08e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.12	-0.41	9.25e-15	Bipolar disorder;
CRC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08048268	chr3:133502702	NA	0.41	7.2	0.37	4.24e-12	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs11166629	1.000	rs2873014	chr8:135645860	C/T	cg27224718	chr8:135614730	ZFAT	-0.5	-7.35	-0.38	1.54e-12	Smoking quantity;
CRC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.67	-9.99	-0.48	1.09e-20	Primary biliary cholangitis;
CRC	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg26353448	chr1:248524236	OR2T4	-0.35	-6.68	-0.35	1.02e-10	Common traits (Other);
CRC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	cis	rs2630709	0.541	rs3102957	chr2:8465395	G/A	cg12167548	chr2:8464763	NA	0.35	6.8	0.35	4.98e-11	Monocyte percentage of white cells;
CRC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.01	12.62	0.57	4.94e-30	Vitiligo;
CRC	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg23254163	chr1:152506842	NA	0.49	9.8	0.48	4.6e-20	Hair morphology;
CRC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.59	0.34	1.7e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.06	-12.27	-0.56	9.34e-29	Diabetic kidney disease;
CRC	trans	rs11031096	0.641	rs232054	chr11:4123427	C/G	cg22978087	chr8:24814126	NEFL	0.32	6.01	0.31	4.93e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	0.55	6.0	0.31	5.18e-9	Coronary artery disease;
CRC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.93	15.88	0.66	1.49e-42	Parkinson's disease;
CRC	trans	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.78	-0.39	9.21e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg05756136	chr1:119680316	WARS2	-0.54	-7.39	-0.38	1.2e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-0.53	-7.63	-0.39	2.61e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.71	-0.47	9.26e-20	Heart rate;
CRC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg24308560	chr3:49941425	MST1R	-0.39	-5.61	-0.3	4.41e-8	Resting heart rate;
CRC	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.85	-14.8	-0.63	2.43e-38	Colorectal cancer;
CRC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.39	5.92	0.31	8.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.49	7.24	0.37	3.18e-12	Magnesium levels;
CRC	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg15192750	chr16:69999425	NA	0.47	6.56	0.34	2.07e-10	IgE levels;
CRC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.63	15.61	0.65	1.67e-41	HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg07274523	chr3:49395745	GPX1	0.48	6.55	0.34	2.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs2898857	0.545	rs12942379	chr17:47358733	C/T	cg11430096	chr6:110968061	CDK19	0.51	7.8	0.4	8.44e-14	Cancer;
CRC	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg14003231	chr6:33640908	ITPR3	0.52	8.41	0.42	1.24e-15	Plateletcrit;
CRC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg08222913	chr3:52553049	STAB1	-0.38	-7.43	-0.38	9.54e-13	Bipolar disorder;
CRC	cis	rs9649465	0.967	rs1008539	chr7:123305518	G/A	cg03229431	chr7:123269106	ASB15	-0.37	-5.71	-0.3	2.56e-8	Migraine;
CRC	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg16950941	chr11:66035639	RAB1B	-0.54	-7.17	-0.37	4.89e-12	Electroencephalogram traits;
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.67	8.87	0.44	4.78e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11895698	1	rs11895698	chr2:239338495	C/T	cg18131467	chr2:239335373	ASB1	-0.69	-7.45	-0.38	8.18e-13	Chronotype;
CRC	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg06522879	chr11:64358276	SLC22A12	0.57	8.95	0.44	2.62e-17	Urate levels in obese individuals;
CRC	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg00587665	chr15:100533223	ADAMTS17	0.34	5.76	0.3	1.9e-8	Height;
CRC	cis	rs17095355	0.605	rs7916801	chr10:111632445	A/G	cg00817464	chr10:111662876	XPNPEP1	0.43	5.76	0.3	1.92e-8	Biliary atresia;
CRC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.56	7.9	0.4	4.25e-14	Lung cancer;
CRC	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg27398640	chr15:77910606	LINGO1	-0.44	-8.26	-0.41	3.66e-15	Type 2 diabetes;
CRC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg13047869	chr3:10149882	C3orf24	0.52	7.2	0.37	4.24e-12	Alzheimer's disease;
CRC	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.55	-6.56	-0.34	2.05e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.91	-0.36	2.52e-11	Monocyte count;
CRC	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.25	-0.37	3e-12	Tuberculosis;
CRC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.25	6.97	0.36	1.78e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg09355771	chr2:177043147	NA	0.71	11.02	0.52	3.14e-24	IgG glycosylation;
CRC	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.63	7.83	0.4	6.75e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.36	-0.42	1.78e-15	Schizophrenia;
CRC	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.2	10.88	0.51	9.18e-24	Prostate cancer;
CRC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.66	11.79	0.54	5.46e-27	Height;
CRC	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg25790453	chr13:113633590	MCF2L	0.44	7.57	0.38	3.91e-13	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14122300	chr14:69446504	ACTN1	0.46	6.98	0.36	1.68e-11	Response to antipsychotic treatment;
CRC	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg09324608	chr17:30823087	MYO1D	0.36	6.31	0.33	9.25e-10	Schizophrenia;
CRC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.44	6.5	0.34	2.98e-10	Menopause (age at onset);
CRC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.3	0.46	2.04e-18	Bladder cancer;
CRC	cis	rs3823572	0.525	rs28588750	chr7:133629138	A/G	cg03336402	chr7:133662267	EXOC4	0.63	9.64	0.47	1.5700000000000001e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7835763	0.692	rs2445905	chr8:119104646	T/C	cg11592677	chr8:119110466	EXT1	-0.37	-6.05	-0.32	3.97e-9	Autism spectrum disorder;
CRC	cis	rs1223397	0.938	rs3734878	chr6:13288850	C/T	cg07912922	chr6:13274314	PHACTR1	0.54	6.43	0.33	4.36e-10	Blood pressure;
CRC	trans	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg26043149	chr18:55253948	FECH	-0.53	-8.23	-0.41	4.53e-15	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg22532475	chr10:104410764	TRIM8	-0.42	-6.82	-0.35	4.26e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	14.34	0.62	1.44e-36	Mean platelet volume;
CRC	cis	rs6460942	0.544	rs73287160	chr7:12143582	T/C	cg06484146	chr7:12443880	VWDE	-0.47	-5.81	-0.3	1.49e-8	Coronary artery disease;
CRC	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.64	9.19	0.45	4.43e-18	Schizophrenia;
CRC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-10.64	-0.51	6.35e-23	Personality dimensions;
CRC	cis	rs1223397	0.651	rs2496140	chr6:13309895	A/T	cg07912922	chr6:13274314	PHACTR1	0.4	6.28	0.33	1.07e-9	Blood pressure;
CRC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.62	-9.31	-0.46	1.85e-18	Breast cancer;
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg12273811	chr6:28175739	NA	0.54	5.79	0.3	1.62e-8	Depression;
CRC	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-6.4	-0.33	5.33e-10	Menarche (age at onset);
CRC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-17.98	-0.7	7.96e-51	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26815021	chr17:74733172	MIR636;MFSD11;SFRS2	0.45	6.9	0.36	2.73e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.61	9.57	0.47	2.75e-19	Vitiligo;
CRC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	10.38	0.5	4.94e-22	Mean corpuscular hemoglobin;
CRC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg02560186	chr11:3602584	NA	-0.63	-9.62	-0.47	1.78e-19	Blood pressure (smoking interaction);
CRC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg11168104	chr5:1857477	NA	-0.37	-6.41	-0.33	4.99e-10	Cardiovascular disease risk factors;
CRC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.83	15.85	0.66	1.97e-42	Metabolic syndrome;
CRC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.8	0.35	5.05e-11	Mean platelet volume;
CRC	cis	rs3736485	0.966	rs17609917	chr15:51911487	G/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.33	-0.33	8.13e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg20387954	chr3:183756860	HTR3D	0.37	6.45	0.34	3.92e-10	Anterior chamber depth;
CRC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg16606324	chr3:10149918	C3orf24	0.61	7.98	0.4	2.47e-14	Alzheimer's disease;
CRC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg22681709	chr2:178499509	PDE11A	-0.31	-5.9	-0.31	9.14e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg08314208	chr16:67682810	RLTPR	-0.49	-5.94	-0.31	7.19e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg16447950	chr5:562315	NA	-0.81	-10.62	-0.51	7.76e-23	Lung disease severity in cystic fibrosis;
CRC	trans	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.63	-10.17	-0.49	2.66e-21	P wave terminal force;
CRC	cis	rs9463078	0.764	rs9367211	chr6:44885305	T/C	cg25276700	chr6:44698697	NA	-0.26	-6.36	-0.33	6.63e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs9491140	0.539	rs980656	chr6:124690303	A/G	cg05308643	chr6:124982296	NKAIN2	0.48	6.74	0.35	7.01e-11	Neuroticism;
CRC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.84	8.11	0.41	1e-14	Lymphocyte counts;
CRC	cis	rs9992667	0.955	rs11937257	chr4:38645460	A/G	cg19726192	chr4:38663646	FLJ13197	-0.67	-8.69	-0.43	1.74e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg16606324	chr3:10149918	C3orf24	0.47	7.1	0.36	7.81e-12	Alzheimer's disease;
CRC	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.95	-13.36	-0.59	7.99e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4750440	0.706	rs11258770	chr10:14018910	G/T	cg00551146	chr10:14014579	FRMD4A	0.36	5.88	0.31	9.87e-9	Adiponectin levels;
CRC	cis	rs2257205	0.667	rs7221142	chr17:56758786	A/G	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.87e-8	Pancreatic cancer;
CRC	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg07166546	chr14:35805898	NA	-0.3	-5.89	-0.31	9.79e-9	Hip circumference adjusted for BMI;
CRC	cis	rs4664293	0.669	rs1863219	chr2:160418171	C/G	cg08347373	chr2:160653686	CD302	0.41	6.97	0.36	1.7e-11	Monocyte percentage of white cells;
CRC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.82	9.11	0.45	7.99e-18	Breast cancer;
CRC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.48	-0.38	6.93e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.36	-6.06	-0.32	3.77e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.12	10.46	0.5	2.76e-22	Skin colour saturation;
CRC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	14.93	0.64	7.62e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.89	-0.31	9.38e-9	Bladder cancer;
CRC	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.62	-8.62	-0.43	2.94e-16	Cocaine dependence;
CRC	trans	rs12517041	1.000	rs7734279	chr5:23300161	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.56	-6.2	-0.32	1.74e-9	Calcium levels;
CRC	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.77	-13.66	-0.6	5.96e-34	Oral cavity cancer;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	cis	rs4073416	0.508	rs7140341	chr14:66070417	C/G	cg03016385	chr14:66212404	NA	-0.45	-6.17	-0.32	2.05e-9	N-glycan levels;
CRC	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.62	-8.37	-0.42	1.71e-15	Blood pressure (smoking interaction);
CRC	cis	rs3741151	0.686	rs61516411	chr11:73302768	T/C	cg17517138	chr11:73019481	ARHGEF17	0.57	5.84	0.31	1.25e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.57	7.61	0.39	2.94e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg21466736	chr12:48725269	NA	-0.54	-8.07	-0.41	1.29e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07596845	chr6:82957841	IBTK	0.43	6.11	0.32	2.74e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg16606324	chr3:10149918	C3orf24	0.7	9.64	0.47	1.61e-19	Alzheimer's disease;
CRC	cis	rs7113874	0.589	rs9705253	chr11:8596483	A/T	cg20771178	chr11:8615675	STK33	-0.35	-5.72	-0.3	2.42e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg14008862	chr17:28927542	LRRC37B2	0.51	6.17	0.32	2.06e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg07699608	chr10:75541558	CHCHD1	0.61	6.38	0.33	5.97e-10	Incident atrial fibrillation;
CRC	cis	rs863345	0.604	rs1894040	chr1:158456336	C/T	cg12129480	chr1:158549410	OR10X1	0.29	6.04	0.32	4.17e-9	Pneumococcal bacteremia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22833807	chr22:36925177	EIF3D	-0.52	-6.33	-0.33	8.17e-10	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12726277	chr7:973190	ADAP1	-0.38	-6.45	-0.34	4e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2292096	0.850	rs6663728	chr1:200815179	G/A	cg07580975	chr1:200843333	NA	0.46	6.3	0.33	9.69e-10	Epilepsy;
CRC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	10.16	0.49	2.82e-21	Mood instability;
CRC	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	0.62	9.75	0.47	6.96e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs911119	0.955	rs8121283	chr20:23605002	G/C	cg16589663	chr20:23618590	CST3	0.45	6.38	0.33	6.08e-10	Chronic kidney disease;
CRC	cis	rs12024301	0.557	rs6681661	chr1:183605801	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.77	6.73	0.35	7.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.72	-0.35	7.91e-11	Eye color traits;
CRC	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg07512295	chr2:234599026	UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.38	5.85	0.31	1.2e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg09655341	chr17:79618100	PDE6G	-0.38	-6.68	-0.35	1.02e-10	Eye color traits;
CRC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	trans	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg17903999	chr18:56338584	MALT1	-0.44	-7.32	-0.37	1.9e-12	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg18232548	chr7:50535776	DDC	-0.43	-6.38	-0.33	6.17e-10	Body mass index;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19713609	chr11:819941	PNPLA2	-0.4	-6.18	-0.32	1.91e-9	Myopia (pathological);
CRC	cis	rs807029	0.577	rs3740488	chr10:102754033	A/T	cg04662943	chr10:102668895	NA	0.58	7.15	0.37	5.82e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23753457	chr11:69455870	CCND1	0.48	6.23	0.32	1.46e-9	Thyroid stimulating hormone;
CRC	trans	rs1941687	0.769	rs1493911	chr18:31356019	A/G	cg27147174	chr7:100797783	AP1S1	-0.36	-6.05	-0.32	3.85e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21659725	chr3:3221576	CRBN	0.61	6.85	0.35	3.71e-11	Menarche (age at onset);
CRC	cis	rs3823572	0.525	rs2346443	chr7:133706383	C/T	cg03336402	chr7:133662267	EXOC4	-0.65	-9.24	-0.45	3.1e-18	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg25456477	chr12:86230367	RASSF9	0.4	6.57	0.34	2e-10	Major depressive disorder;
CRC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.31e-17	Mean platelet volume;
CRC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.3	6.4	0.33	5.2400000000000005e-10	Alcohol dependence;
CRC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg04450456	chr4:17643702	FAM184B	0.39	6.31	0.33	8.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.56	8.23	0.41	4.4e-15	Melanoma;
CRC	cis	rs10806425	0.524	rs1394220	chr6:91019304	A/C	cg06866423	chr6:90926672	BACH2	0.56	10.41	0.5	3.93e-22	Celiac disease;
CRC	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-6.71	-0.35	8.48e-11	Schizophrenia;
CRC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.38	7.4	0.38	1.16e-12	Mean corpuscular volume;
CRC	cis	rs847649	0.694	rs11770319	chr7:102770170	C/G	cg18108683	chr7:102477205	FBXL13	0.52	8.32	0.42	2.3e-15	Morning vs. evening chronotype;
CRC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-19.5	-0.73	7.78e-57	Hemostatic factors and hematological phenotypes;
CRC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.77	14.65	0.63	9.65e-38	Prudent dietary pattern;
CRC	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-0.82	-7.8	-0.4	8.24e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.51	-7.09	-0.36	8.16e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.62	9.29	0.46	2.13e-18	Blood protein levels;
CRC	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg07512295	chr2:234599026	UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.38	5.79	0.3	1.6e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26839812	chr6:16129282	MYLIP	0.43	6.14	0.32	2.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg26499232	chr10:38644675	HSD17B7P2	0.37	5.61	0.3	4.28e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.58	7.99	0.4	2.26e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg21399703	chr1:247681439	NA	0.5	7.94	0.4	3.29e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg11003573	chr3:44754125	ZNF502	-0.33	-5.85	-0.31	1.16e-8	Depressive symptoms;
CRC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg10298567	chr3:47292165	KIF9	0.4	6.28	0.33	1.08e-9	Colorectal cancer;
CRC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.87	-0.31	1.06e-8	Migraine;Coronary artery disease;
CRC	trans	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg18288967	chr1:45987694	PRDX1	0.64	7.26	0.37	2.77e-12	Obesity-related traits;
CRC	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.63	8.39	0.42	1.45e-15	Chronic kidney disease;
CRC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.8	-11.54	-0.54	4.27e-26	Blood trace element (Zn levels);
CRC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg24011408	chr12:48396354	COL2A1	0.45	6.52	0.34	2.58e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.53	7.52	0.38	5.14e-13	Schizophrenia;
CRC	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg25363559	chr8:143086065	NA	-0.32	-6.03	-0.32	4.44e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs4930561	0.714	rs10896300	chr11:67953772	C/T	cg04465784	chr11:67976953	SUV420H1	0.29	5.91	0.31	8.63e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.55	8.61	0.43	3e-16	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg05585544	chr11:47624801	NA	-0.53	-9.47	-0.46	5.46e-19	Subjective well-being;
CRC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.66	-8.37	-0.42	1.63e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg27635394	chr6:26043820	HIST1H2BB	0.41	6.2	0.32	1.74e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.56	-9.0	-0.44	1.85e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.77	-0.44	9.87e-17	Prostate cancer;
CRC	cis	rs2882667	0.690	rs1651032	chr5:138078840	C/T	cg09476006	chr5:138032270	NA	-0.56	-9.98	-0.48	1.12e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.43	-6.21	-0.32	1.61e-9	Aortic root size;
CRC	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.54	-8.5	-0.42	6.78e-16	Monobrow;
CRC	cis	rs35883536	1.000	rs17403905	chr1:101107358	T/C	cg14515779	chr1:101123966	NA	-0.43	-8.3	-0.42	2.75e-15	Monocyte count;
CRC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	9.55	0.47	3.1e-19	Colorectal cancer;
CRC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.6	6.39	0.33	5.64e-10	Mean platelet volume;
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.91	-20.27	-0.75	7.51e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.81	-0.35	4.78e-11	Coronary artery disease;
CRC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.67	11.55	0.54	4.04e-26	Prostate cancer;
CRC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.5	-7.82	-0.4	7.04e-14	Calcium levels;
CRC	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg13662093	chr20:33865505	NA	0.42	5.9	0.31	9.18e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg02033258	chr5:131593261	PDLIM4	-0.3	-5.63	-0.3	3.95e-8	Blood metabolite levels;
CRC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.49	7.61	0.39	2.94e-13	Aortic root size;
CRC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg22495460	chr2:25135724	ADCY3	-0.87	-17.19	-0.69	1.03e-47	Body mass index;
CRC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg09127314	chr1:152161683	NA	0.5	6.38	0.33	5.92e-10	Atopic dermatitis;
CRC	trans	rs10242455	1.000	rs7808022	chr7:99220083	A/C	cg09045935	chr12:6379348	NA	0.61	6.76	0.35	6.46e-11	Blood metabolite levels;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.49	-6.47	-0.34	3.45e-10	Serum thyroid-stimulating hormone levels;
CRC	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg06204229	chr3:52865917	ITIH4	-0.47	-5.87	-0.31	1.05e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05903289	chr2:130345205	NA	-0.4	-7.72	-0.39	1.39e-13	Response to cytidine analogues (gemcitabine);
CRC	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.43	-8.25	-0.41	3.84e-15	Alcohol dependence;
CRC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg02659138	chr7:134003124	SLC35B4	0.38	6.45	0.34	3.96e-10	Mean platelet volume;
CRC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg15845792	chr6:28175446	NA	-0.46	-6.74	-0.35	7.17e-11	Pubertal anthropometrics;
CRC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.61	-10.04	-0.48	7.33e-21	Brugada syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19034403	chr5:162993262	NA	0.45	6.33	0.33	8.09e-10	Response to antipsychotic treatment;
CRC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-7.86	-0.4	5.68e-14	Type 2 diabetes;
CRC	cis	rs59104589	0.517	rs62186360	chr2:242166212	C/T	cg19488206	chr2:242435732	STK25	0.41	6.06	0.32	3.64e-9	Fibrinogen levels;
CRC	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.45	7.02	0.36	1.26e-11	Schizophrenia;
CRC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	8.69	0.43	1.71e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs542925	0.737	rs572745	chr6:128988809	G/T	cg23578404	chr11:64198292	NA	-0.33	-6.01	-0.31	5.06e-9	Caudate activity during reward;
CRC	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.64	9.6	0.47	2.12e-19	Height;
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.48	6.64	0.34	1.26e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	-0.65	-7.35	-0.38	1.59e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.71	-10.96	-0.52	5.03e-24	Response to simvastatin treatment (PCSK9 protein level change);
CRC	trans	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.44	-5.68	-0.3	3.04e-8	Gut microbiome composition (summer);
CRC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.47	-6.14	-0.32	2.33e-9	Response to diuretic therapy;
CRC	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.39	6.59	0.34	1.7e-10	Sitting height ratio;
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-8.07	-0.41	1.29e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.7	-11.61	-0.54	2.42e-26	Breast cancer;
CRC	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	1.05	12.72	0.57	2e-30	Diisocyanate-induced asthma;
CRC	cis	rs2857891	0.695	rs2857893	chr11:6983330	C/T	cg04053776	chr11:6947353	ZNF215	0.39	6.01	0.31	4.84e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg08501292	chr6:25962987	TRIM38	-1.02	-9.24	-0.45	3.16e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11077815	0.733	rs4516263	chr17:74432562	A/G	cg06840243	chr17:74442338	UBE2O	0.42	6.84	0.35	3.96e-11	Lymphocyte counts;
CRC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.01	0.4	1.95e-14	Menopause (age at onset);
CRC	trans	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg25214090	chr10:38739885	LOC399744	-0.39	-6.07	-0.32	3.51e-9	Diastolic blood pressure;
CRC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17261708	chr5:176794207	RGS14	0.49	8.08	0.41	1.23e-14	Hemoglobin concentration;Hematocrit;
CRC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.46	-0.5	2.79e-22	Extrinsic epigenetic age acceleration;
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg10498984	chr16:28874827	SH2B1	-0.73	-6.11	-0.32	2.82e-9	Blood osmolality (transformed sodium);
CRC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.55	-8.47	-0.42	8.01e-16	Pancreatic cancer;
CRC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.63	8.42	0.42	1.21e-15	Methadone dose in opioid dependence;
CRC	cis	rs8105895	0.935	rs10404669	chr19:22241218	T/C	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg24585782	chr17:78113791	EIF4A3	-0.52	-7.13	-0.37	6.51e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07355693	chr12:125667907	NA	0.38	5.97	0.31	6.23e-9	Obesity-related traits;
CRC	trans	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg23387109	chr10:94051229	MARCH5;CPEB3	-0.44	-5.98	-0.31	5.85e-9	Extraversion;
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18297960	chr7:1142765	C7orf50	-0.45	-6.18	-0.32	1.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs800160	0.720	rs11022259	chr11:2338256	A/G	cg09785033	chr11:2336066	TSPAN32	-0.49	-5.64	-0.3	3.66e-8	Bacteremia;
CRC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.99	-0.55	1.01e-27	Body mass index;
CRC	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.67	11.22	0.53	5.87e-25	Cancer;
CRC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg17321639	chr7:2759063	NA	-0.52	-6.9	-0.36	2.74e-11	Height;
CRC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.62	11.22	0.53	5.75e-25	Schizophrenia;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg03623178	chr6:28175578	NA	0.79	11.55	0.54	3.91e-26	Parkinson's disease;
CRC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.2	-0.32	1.69e-9	IgG glycosylation;
CRC	cis	rs834811	0.602	rs12533021	chr7:135889342	C/T	cg01726295	chr7:135938950	NA	0.35	6.07	0.32	3.49e-9	Post-traumatic stress disorder;
CRC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.58	-0.43	3.8e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg23100626	chr2:96804247	ASTL	0.27	7.07	0.36	9.57e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.52	8.23	0.41	4.52e-15	Red blood cell count;
CRC	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.44	-6.7	-0.35	9.1e-11	Height;
CRC	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.63	10.15	0.49	2.97e-21	Myopia (pathological);
CRC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.43	-6.42	-0.33	4.63e-10	Breast cancer;
CRC	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.72	8.41	0.42	1.26e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-18.16	-0.71	1.58e-51	Coronary artery disease;
CRC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg04166393	chr7:2884313	GNA12	0.39	6.05	0.32	4.04e-9	Height;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Parkinson's disease;
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.4	-8.43	-0.42	1.09e-15	Bipolar disorder;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.83	-0.31	1.36e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg00531865	chr16:30841666	NA	-0.48	-6.02	-0.32	4.54e-9	Diastolic blood pressure;
CRC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.37	6.28e-12	Reticulocyte fraction of red cells;
CRC	cis	rs9525927	0.570	rs9316074	chr13:44803181	A/G	cg19190762	chr13:44806055	NA	0.57	6.93	0.36	2.2e-11	Dupuytren's disease;
CRC	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg12858261	chr2:113808755	IL1F8	0.46	6.68	0.35	1.02e-10	Protein quantitative trait loci;
CRC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg09127314	chr1:152161683	NA	0.52	6.81	0.35	4.79e-11	Atopic dermatitis;
CRC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00700412	chr12:58011837	NA	-0.43	-6.76	-0.35	6.4e-11	Multiple sclerosis;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg15786705	chr6:28176104	NA	0.47	6.12	0.32	2.71e-9	Parkinson's disease;
CRC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.39	6.63	0.34	1.4e-10	Crohn's disease;
CRC	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.37	-6.41	-0.33	5.08e-10	Hip circumference;Waist circumference;
CRC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.59	7.23	0.37	3.44e-12	Body mass index;
CRC	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg11130432	chr3:121712080	ILDR1	0.48	5.75	0.3	2.01e-8	Multiple sclerosis;
CRC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs6496667	0.865	rs12593879	chr15:90924508	A/T	cg04176472	chr15:90893244	GABARAPL3	0.6	7.86	0.4	5.41e-14	Rheumatoid arthritis;
CRC	cis	rs4523957	0.928	rs4790321	chr17:2173499	C/T	cg16513277	chr17:2031491	SMG6	-0.55	-9.44	-0.46	6.96e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs73206853	0.640	rs35026231	chr12:110832125	A/G	cg12870014	chr12:110450643	ANKRD13A	0.85	10.18	0.49	2.4e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.48	-7.16	-0.37	5.35e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg00601486	chr12:48723148	H1FNT	-0.34	-6.67	-0.35	1.09e-10	Glycated hemoglobin levels;
CRC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-5.66	-0.3	3.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg12458913	chr13:53173898	NA	0.76	13.91	0.61	6.24e-35	Lewy body disease;
CRC	cis	rs10208940	0.764	rs6546418	chr2:68786563	G/A	cg12452813	chr2:68675892	NA	0.46	5.75	0.3	2.05e-8	Urate levels in lean individuals;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg25164649	chr6:28176230	NA	0.56	7.44	0.38	9.1e-13	Parkinson's disease;
CRC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.27	-0.33	1.15e-9	Breast cancer;
CRC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.34	-0.33	7.54e-10	Obesity-related traits;
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.84	13.62	0.6	8.16e-34	Menarche (age at onset);
CRC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	17.98	0.7	7.57e-51	Platelet count;
CRC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.38	6.5	0.34	3.04e-10	Systemic lupus erythematosus;
CRC	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs62432291	0.681	rs447637	chr6:159658726	A/G	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs72799341	0.706	rs59735493	chr16:31133100	G/A	cg02466173	chr16:30829666	NA	-0.42	-5.67	-0.3	3.17e-8	Diastolic blood pressure;
CRC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg16898833	chr6:26189333	HIST1H4D	0.89	7.28	0.37	2.4e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg09877947	chr5:131593287	PDLIM4	-0.56	-10.5	-0.5	1.99e-22	Acylcarnitine levels;
CRC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.0	0.55	9.22e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.54	-7.5	-0.38	5.9e-13	Obesity-related traits;
CRC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.94e-9	Schizophrenia;
CRC	cis	rs17601876	0.623	rs1062033	chr15:51547938	C/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-6.58	-0.34	1.85e-10	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26569395	chr2:68694513	APLF;FBXO48	0.51	6.63	0.34	1.34e-10	Hip circumference;
CRC	cis	rs447	0.767	rs6977306	chr7:83750053	G/A	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.83	-0.31	1.33e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7781266	0.790	rs4731951	chr7:133102282	G/T	cg03336402	chr7:133662267	EXOC4	-0.48	-5.72	-0.3	2.4e-8	Educational attainment (college completion);
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.02	-0.31	4.73e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs847649	1.000	rs9718453	chr7:102594976	T/G	cg18108683	chr7:102477205	FBXL13	0.58	9.37	0.46	1.17e-18	Morning vs. evening chronotype;
CRC	cis	rs12644284	0.516	rs6535908	chr4:154138086	A/G	cg05870820	chr4:154142712	TRIM2	0.42	5.85	0.31	1.18e-8	Multiple sclerosis;
CRC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.5	9.46	0.46	5.98e-19	Alcohol dependence;
CRC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.61	-6.7	-0.35	8.84e-11	Coronary artery disease;
CRC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.02	10.4	0.5	4.25e-22	Diabetic retinopathy;
CRC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.37e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs10916814	0.632	rs10799646	chr1:20903985	G/T	cg24589459	chr2:198651347	BOLL	-0.32	-6.15	-0.32	2.25e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs720844	0.507	rs13003024	chr2:149285093	A/G	cg09247360	chr2:149335327	NA	0.42	5.67	0.3	3.06e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20322375	chr12:83080681	TMTC2	0.44	6.13	0.32	2.52e-9	Anxiety disorder;
CRC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg14711859	chr11:8959438	ASCL3	0.53	9.76	0.47	6.11e-20	Hematocrit;
CRC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.88	-0.4	4.82e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.13	-0.32	2.48e-9	Height;
CRC	cis	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg05299278	chr17:33885742	SLFN14	0.4	6.08	0.32	3.4e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.42	-6.43	-0.33	4.42e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg23100626	chr2:96804247	ASTL	0.28	7.51	0.38	5.63e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.67	0.35	1.09e-10	Retinal vascular caliber;
CRC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg20615401	chr6:28092323	ZSCAN16	0.47	6.24	0.33	1.31e-9	Parkinson's disease;
CRC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.6	8.31	0.42	2.51e-15	Height;
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.27	-0.37	2.65e-12	Breast cancer;
CRC	cis	rs4728302	0.608	rs6967856	chr7:133727304	C/T	cg03336402	chr7:133662267	EXOC4	-0.43	-6.59	-0.34	1.72e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.69	-0.43	1.78e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.54	7.49	0.38	6.23e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.84	-0.31	1.23e-8	Skin colour saturation;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg21251018	chr6:28226885	NKAPL	-0.48	-6.88	-0.35	3.03e-11	Depression;
CRC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg05623727	chr3:50126028	RBM5	-0.44	-7.47	-0.38	7.28e-13	Intelligence (multi-trait analysis);
CRC	trans	rs12940923	0.748	rs56298529	chr17:56363859	T/A	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23970856	chr2:55459633	RPS27A;C2orf63	0.43	6.51	0.34	2.79e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg05683857	chr10:124030795	BTBD16	0.34	6.09	0.32	3.12e-9	Total body bone mineral density;
CRC	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg18232548	chr7:50535776	DDC	0.47	6.68	0.35	9.94e-11	Malaria;
CRC	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg20636351	chr8:55087400	NA	0.33	5.89	0.31	9.54e-9	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.75	-0.35	6.88e-11	Educational attainment (years of education);
CRC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.12	0.45	7.62e-18	Hip circumference adjusted for BMI;
CRC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.41	5.76	0.3	1.96e-8	Red blood cell count;
CRC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.79	-11.78	-0.54	5.73e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	10.65	0.51	5.97e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.14	-0.32	2.33e-9	Neuroticism;
CRC	cis	rs6429082	0.509	rs7516807	chr1:235523555	G/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.95	0.31	6.88e-9	Adiposity;
CRC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-12.2	-0.56	1.72e-28	Developmental language disorder (linguistic errors);
CRC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.64	6.6	0.34	1.62e-10	Axial length;
CRC	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09695851	chr17:3907499	NA	0.43	5.98	0.31	5.68e-9	Type 2 diabetes;
CRC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-7.93	-0.4	3.4e-14	Pancreatic cancer;
CRC	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.16e-12	Coronary artery disease;
CRC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.59	8.05	0.41	1.57e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25503565	chr17:38264529	NA	0.41	7.28	0.37	2.49e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg15490075	chr13:100150979	NA	-0.43	-5.73	-0.3	2.21e-8	Self-reported allergy;
CRC	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg17133734	chr15:86042851	AKAP13	0.42	6.78	0.35	5.47e-11	Coronary artery disease;
CRC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg02741985	chr17:80059408	CCDC57	-0.45	-7.38	-0.38	1.3e-12	Life satisfaction;
CRC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg12193833	chr17:30244370	NA	-0.56	-6.43	-0.33	4.5e-10	Hip circumference adjusted for BMI;
CRC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-10.08	-0.49	5.31e-21	Personality dimensions;
CRC	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-7.26	-0.37	2.75e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.54	7.7	0.39	1.65e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7517126	1.000	rs6428367	chr1:196844192	C/T	cg13682187	chr1:196946512	CFHR5	0.37	5.95	0.31	6.99e-9	Blood protein levels;
CRC	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg21798802	chr22:38057573	PDXP	0.35	5.68	0.3	2.93e-8	Fat distribution (HIV);
CRC	cis	rs847649	0.692	rs1541519	chr7:102466741	G/T	cg18108683	chr7:102477205	FBXL13	-0.67	-11.27	-0.53	3.79e-25	Morning vs. evening chronotype;
CRC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.11	-0.36	7.22e-12	Mean corpuscular volume;
CRC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.42	-0.38	1.02e-12	Monocyte percentage of white cells;
CRC	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.22	-0.41	4.68e-15	Total cholesterol levels;
CRC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs629535	0.814	rs477200	chr8:70059584	A/G	cg26132723	chr8:70041827	NA	0.33	5.84	0.31	1.25e-8	Dupuytren's disease;
CRC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.82	13.72	0.6	3.47e-34	Coronary artery disease;
CRC	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg25304816	chr1:36627734	MAP7D1	-0.57	-9.08	-0.45	1.02e-17	Corneal structure;
CRC	cis	rs12692738	0.526	rs355861	chr2:165629963	A/G	cg03182029	chr2:165697222	COBLL1	0.51	6.07	0.32	3.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg11632617	chr15:75315747	PPCDC	-0.54	-7.22	-0.37	3.57e-12	Blood trace element (Zn levels);
CRC	cis	rs727505	0.866	rs56216989	chr7:124729068	T/A	cg23710748	chr7:124431027	NA	-0.72	-12.33	-0.56	5.81e-29	Lewy body disease;
CRC	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.5	0.65	4.51e-41	Fuchs's corneal dystrophy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06618610	chr16:87811655	NA	0.49	6.97	0.36	1.73e-11	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg07125278	chr16:67683757	RLTPR	-0.49	-6.75	-0.35	6.86e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg11693508	chr17:37793320	STARD3	0.6	7.17	0.37	4.95e-12	Neuroticism;
CRC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg03030879	chr14:75389066	RPS6KL1	0.46	7.2	0.37	4.2e-12	Height;
CRC	trans	rs13079221	0.614	rs182403	chr3:14903391	T/C	cg18308285	chr17:7942551	ALOX15B	0.42	6.03	0.32	4.4e-9	Coronary artery disease;
CRC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.4	5.73	0.3	2.24e-8	Eosinophil percentage of white cells;
CRC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.87	15.79	0.66	3.48e-42	Coronary artery disease;
CRC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.09	-0.45	9.8e-18	Hip circumference adjusted for BMI;
CRC	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg25856811	chr1:152973957	SPRR3	-0.21	-5.66	-0.3	3.22e-8	Inflammatory skin disease;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.56	6.73	0.35	7.73e-11	Renal function-related traits (BUN);
CRC	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.46	-6.46	-0.34	3.76e-10	Lung cancer;
CRC	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg22105103	chr4:187893119	NA	0.63	11.26	0.53	4.39e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg11212589	chr17:38028394	ZPBP2	0.43	7.94	0.4	3.15e-14	Self-reported allergy;
CRC	cis	rs4481887	0.504	rs10888323	chr1:248361201	C/T	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	1.05	12.68	0.57	2.8e-30	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.99	-0.36	1.56e-11	Alzheimer's disease (late onset);
CRC	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.61	-6.7	-0.35	9.26e-11	Coronary artery disease;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg12273811	chr6:28175739	NA	0.55	5.86	0.31	1.12e-8	Depression;
CRC	cis	rs55788414	0.932	rs12103301	chr16:81181423	A/C	cg06400318	chr16:81190750	PKD1L2	-0.57	-6.41	-0.33	4.95e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg20936604	chr3:58311152	NA	-0.74	-6.94	-0.36	2.05e-11	Cholesterol, total;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.61	7.3	0.37	2.21e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg25876840	chr17:41920477	NA	0.56	7.59	0.39	3.26e-13	Triglycerides;
CRC	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg25019722	chr6:37503610	NA	-0.44	-8.29	-0.42	3.02e-15	Cognitive performance;
CRC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.46	6.65	0.34	1.19e-10	Bone mineral density (spine);
CRC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.32	2.18e-9	Alzheimer's disease (late onset);
CRC	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01270033	chr16:14165057	MKL2	0.39	6.44	0.33	4.29e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.48	-6.47	-0.34	3.47e-10	Colorectal cancer;
CRC	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.48	6.9	0.36	2.7e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs524281	0.648	rs4565902	chr11:65810045	T/G	cg16950941	chr11:66035639	RAB1B	-0.52	-5.77	-0.3	1.81e-8	Electroencephalogram traits;
CRC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg21918786	chr6:109611834	NA	-0.43	-7.47	-0.38	7.39e-13	Reticulocyte fraction of red cells;
CRC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg18016565	chr1:150552671	MCL1	0.42	5.8	0.3	1.52e-8	Melanoma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18876494	chr12:69004196	RAP1B	0.38	6.19	0.32	1.76e-9	Obesity-related traits;
CRC	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.46	6.52	0.34	2.65e-10	Coronary artery disease;
CRC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.54	8.61	0.43	3.17e-16	Prostate cancer;
CRC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.79	9.56	0.47	2.76e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.09	-0.32	3.09e-9	Putamen volume;
CRC	cis	rs17067123	0.614	rs7698554	chr4:180053504	T/C	cg26610307	chr4:180072759	NA	-0.54	-6.5	-0.34	3.01e-10	Response to hepatitis C treatment;
CRC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.46	6.09	0.32	3.1e-9	LDL cholesterol;Cholesterol, total;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16179125	chr20:57582121	CTSZ	0.45	6.48	0.34	3.43e-10	Anxiety disorder;
CRC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg20607287	chr7:12443886	VWDE	-0.67	-6.68	-0.35	1.01e-10	Coronary artery disease;
CRC	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.58	7.61	0.39	2.86e-13	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.44	5.88	0.31	9.91e-9	Schizophrenia;
CRC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.35	-7.45	-0.38	8.13e-13	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.86	0.44	5.1e-17	Hip circumference adjusted for BMI;
CRC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.58	8.66	0.43	2.13e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg11189052	chr15:85197271	WDR73	0.64	9.38	0.46	1.12e-18	Schizophrenia;
CRC	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.42	5.83	0.31	1.31e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.44	-6.35	-0.33	7e-10	Erythrocyte sedimentation rate;
CRC	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg15192750	chr16:69999425	NA	0.53	6.89	0.35	2.92e-11	IgE levels;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.22	-0.56	1.5e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12024301	0.557	rs76582181	chr1:183613508	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.6	-8.5	-0.42	6.93e-16	Subjective well-being;
CRC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.51	-7.59	-0.39	3.41e-13	Prostate cancer;
CRC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.96	14.04	0.61	1.98e-35	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.37	-6.02	-0.32	4.56e-9	Ulcerative colitis;
CRC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg23565292	chr14:50234668	KLHDC2	-0.49	-7.05	-0.36	1.04e-11	Carotid intima media thickness;
CRC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg19223190	chr17:80058835	NA	-0.51	-8.04	-0.41	1.66e-14	Life satisfaction;
CRC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.26	-0.33	1.24e-9	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.81	13.55	0.6	1.56e-33	Menopause (age at onset);
CRC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.76	-15.15	-0.64	1.02e-39	Prostate cancer;
CRC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.31	1.43e-8	Arsenic metabolism;
CRC	cis	rs6681460	0.625	rs6696812	chr1:67100309	T/C	cg02459107	chr1:67143332	SGIP1	0.32	5.7	0.3	2.61e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg09596252	chr17:78655493	RPTOR	0.52	5.83	0.31	1.33e-8	Myopia (pathological);
CRC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.57	6.14	0.32	2.31e-9	Initial pursuit acceleration;
CRC	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	18.07	0.71	3.47e-51	Smoking behavior;
CRC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-14.51	-0.62	3.13e-37	Body mass index;
CRC	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.5	6.45	0.34	4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.59	-9.23	-0.45	3.39e-18	Monocyte count;
CRC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.44	7.11	0.36	7.49e-12	Resting heart rate;
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg03623178	chr6:28175578	NA	0.8	11.74	0.54	8.21e-27	Cardiac Troponin-T levels;
CRC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg18016565	chr1:150552671	MCL1	0.44	6.06	0.32	3.76e-9	Melanoma;
CRC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg17330251	chr7:94953956	PON1	-0.59	-7.53	-0.38	4.83e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.23	-0.56	1.27e-28	Coffee consumption (cups per day);
CRC	cis	rs12541635	0.966	rs2345070	chr8:107072027	A/G	cg10147462	chr8:107024639	NA	-0.45	-7.28	-0.37	2.5e-12	Age of smoking initiation;
CRC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-12.9	-0.58	4.26e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.61	9.36	0.46	1.29e-18	Cleft lip with or without cleft palate;
CRC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.61	8.96	0.44	2.39e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.16	-0.32	2.16e-9	Bipolar disorder;
CRC	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg11579758	chr4:1086637	RNF212	0.41	6.65	0.34	1.19e-10	Recombination rate (males);
CRC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.82	9.97	0.48	1.25e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.6	0.54	2.64e-26	Prudent dietary pattern;
CRC	cis	rs7605827	0.930	rs11682580	chr2:15533272	T/C	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16036305	chr1:115053835	TRIM33	0.46	7.33	0.37	1.85e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9584850	0.834	rs4294654	chr13:99119607	G/A	cg07423050	chr13:99094983	FARP1	0.45	6.28	0.33	1.09e-9	Neuroticism;
CRC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg15845792	chr6:28175446	NA	0.74	7.78	0.39	9.45e-14	Depression;
CRC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg13798780	chr7:105162888	PUS7	0.67	7.94	0.4	3.29e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.59	0.39	3.33e-13	Lymphocyte percentage of white cells;
CRC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.7	-0.39	1.63e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.06	19.22	0.73	1.01e-55	Schizophrenia;
CRC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.05	-0.36	1.06e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg13385794	chr1:248469461	NA	0.39	6.7	0.35	9.32e-11	Common traits (Other);
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg08575122	chr10:33269417	NA	-0.42	-6.18	-0.32	1.93e-9	Birth weight;Height;
CRC	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg14345882	chr6:26364793	BTN3A2	0.4	6.31	0.33	8.8e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg20409590	chr14:70655382	SLC8A3	-0.31	-6.37	-0.33	6.48e-10	Prostate cancer;
CRC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg23750338	chr8:142222470	SLC45A4	0.45	7.66	0.39	2.05e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg12463550	chr7:65579703	CRCP	0.74	5.7	0.3	2.63e-8	Diabetic kidney disease;
CRC	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.76	9.15	0.45	6.19e-18	Response to hepatitis C treatment;
CRC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	1.03	13.16	0.59	4.45e-32	Cerebrospinal P-tau181p levels;
CRC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.52	0.34	2.57e-10	Depression;
CRC	cis	rs7835763	0.518	rs2445907	chr8:119106844	A/T	cg11592677	chr8:119110466	EXT1	-0.4	-6.59	-0.34	1.78e-10	Autism spectrum disorder;
CRC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.6	10.62	0.51	7.84e-23	Aortic root size;
CRC	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.58	9.4	0.46	9.6e-19	Corneal astigmatism;
CRC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.43	-5.99	-0.31	5.59e-9	Aortic root size;
CRC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.33e-8	Total body bone mineral density;
CRC	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.51	-8.47	-0.42	8.2e-16	Crohn's disease;
CRC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg08888203	chr3:10149979	C3orf24	0.67	9.6	0.47	2.07e-19	Alzheimer's disease;
CRC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.67	12.97	0.58	2.36e-31	Educational attainment;
CRC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.65	7.81	0.4	7.72e-14	Menarche (age at onset);
CRC	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg07972458	chr1:204535000	NA	0.37	5.72	0.3	2.36e-8	Schizophrenia;
CRC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.49	8.15	0.41	7.6e-15	Permanent tooth development;
CRC	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg22089800	chr15:90895588	ZNF774	-0.41	-5.65	-0.3	3.41e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs10905065	0.610	rs61832743	chr10:5741462	T/G	cg11519256	chr10:5708881	ASB13	-0.43	-5.96	-0.31	6.53e-9	Menopause (age at onset);
CRC	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg21798802	chr22:38057573	PDXP	0.35	5.68	0.3	2.93e-8	Fat distribution (HIV);
CRC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-6.91	-0.36	2.51e-11	Morning vs. evening chronotype;
CRC	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-7.78	-0.39	9.17e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.38	-6.11	-0.32	2.75e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.97	18.62	0.72	2.39e-53	Height;
CRC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.45	-8.25	-0.41	3.76e-15	Huntington's disease progression;
CRC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06505273	chr16:24850292	NA	0.4	5.72	0.3	2.42e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs79387448	0.745	rs7576324	chr2:103142994	G/A	cg09003973	chr2:102972529	NA	0.72	8.11	0.41	1.02e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg03037974	chr15:76606532	NA	-0.51	-7.76	-0.39	1.07e-13	Blood metabolite levels;
CRC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.37	-5.73	-0.3	2.28e-8	Blood metabolite levels;
CRC	cis	rs972578	0.875	rs6519353	chr22:43356130	A/C	cg01576275	chr22:43409880	NA	-0.45	-7.32	-0.37	1.95e-12	Mean platelet volume;
CRC	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg09507567	chr10:124027408	NA	-0.34	-7.2	-0.37	4.19e-12	Total body bone mineral density;
CRC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.48	8.1	0.41	1.06e-14	Coronary artery disease;
CRC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.46	6.31	0.33	8.9e-10	Red blood cell count;
CRC	cis	rs6565180	0.926	rs4788413	chr16:30410445	C/T	cg17640201	chr16:30407289	ZNF48	0.8	12.56	0.57	8.27e-30	Tonsillectomy;
CRC	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	7.18	0.37	4.8e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.59	10.69	0.51	4.15e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.36	5.78	0.3	1.74e-8	Height;
CRC	cis	rs17401966	0.540	rs4846219	chr1:10463888	C/A	cg19773385	chr1:10388646	KIF1B	-0.48	-7.45	-0.38	8.24e-13	Hepatocellular carcinoma;
CRC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18357526	chr6:26021779	HIST1H4A	0.42	5.97	0.31	6.13e-9	Height;
CRC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.8	14.0	0.61	3.05e-35	Vitiligo;
CRC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.41	0.5	4.01e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.85	14.98	0.64	4.8e-39	Subjective well-being;
CRC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg15147215	chr3:52552868	STAB1	0.53	9.17	0.45	5.17e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg07424746	chr4:185654737	MLF1IP	-0.64	-5.98	-0.31	5.97e-9	Blood protein levels;
CRC	cis	rs6988985	0.765	rs6431	chr8:143993765	G/A	cg10324643	chr8:143916377	GML	0.36	5.87	0.31	1.08e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.29	0.33	1.03e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.6	-10.83	-0.51	1.4e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9847710	0.838	rs2581795	chr3:53038786	C/T	cg04503182	chr3:53078218	SFMBT1	-0.37	-5.9	-0.31	9.07e-9	Ulcerative colitis;
CRC	cis	rs863345	0.604	rs10908674	chr1:158503920	A/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.71	13.66	0.6	6.07e-34	Mean corpuscular hemoglobin;
CRC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	cis	rs3018066	0.836	rs10000428	chr4:107096708	A/G	cg01869342	chr4:106983673	TBCK	0.37	5.7	0.3	2.6e-8	Cancer;
CRC	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg09455208	chr3:40491958	NA	0.32	6.41	0.33	4.94e-10	Renal cell carcinoma;
CRC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg00129232	chr17:37814104	STARD3	-0.5	-7.46	-0.38	8.03e-13	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20905760	chr15:43478003	CCNDBP1	0.43	6.02	0.31	4.61e-9	Response to antipsychotic treatment;
CRC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg10589385	chr1:150898437	SETDB1	0.27	5.94	0.31	7.06e-9	Melanoma;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg01483505	chr11:975446	AP2A2	0.44	7.34	0.37	1.74e-12	Alzheimer's disease (late onset);
CRC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.27	-0.37	2.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.84	12.96	0.58	2.62e-31	Cognitive function;
CRC	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg03929089	chr4:120376271	NA	0.64	6.24	0.33	1.38e-9	Axial length;
CRC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.62	9.75	0.47	6.92e-20	Corneal astigmatism;
CRC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.44	6.63	0.34	1.36e-10	Systemic lupus erythematosus;
CRC	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.14	0.45	6.58e-18	Coffee consumption (cups per day);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg09192942	chr16:75682004	KARS;TERF2IP	0.42	6.61	0.34	1.54e-10	Obesity-related traits;
CRC	cis	rs713477	0.505	rs9635232	chr14:55887880	T/C	cg13175173	chr14:55914753	NA	-0.45	-7.44	-0.38	9.1e-13	Pediatric bone mineral content (femoral neck);
CRC	cis	rs294883	0.858	rs10806703	chr6:159701580	G/C	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg10483660	chr13:112241077	NA	0.36	5.79	0.3	1.63e-8	Menarche (age at onset);
CRC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.57	-0.34	1.99e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs12760731	0.720	rs10913552	chr1:178411543	G/A	cg00404053	chr1:178313656	RASAL2	0.86	10.25	0.49	1.36e-21	Obesity-related traits;
CRC	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.57	-8.6	-0.43	3.3e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg00343986	chr7:65444356	GUSB	0.45	6.26	0.33	1.19e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.48	-9.63	-0.47	1.67e-19	Subjective well-being;
CRC	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg03013636	chr16:1946785	NA	-0.48	-6.04	-0.32	4.28e-9	Insulin-like growth factors;
CRC	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg15192750	chr16:69999425	NA	0.58	7.76	0.39	1.11e-13	IgE levels;
CRC	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.88	-17.12	-0.69	2e-47	Hip circumference;
CRC	trans	rs10988802	0.683	rs12343296	chr9:98398777	C/T	cg03817673	chr4:189065399	TRIML1	-0.56	-6.01	-0.31	5.04e-9	Chemerin levels;
CRC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.49	6.62	0.34	1.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg16892393	chr17:41919603	NA	0.5	7.46	0.38	7.66e-13	Triglycerides;
CRC	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.78	-8.55	-0.43	4.73e-16	Intelligence (multi-trait analysis);
CRC	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.6	-9.02	-0.45	1.59e-17	Dementia with Lewy bodies;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.56	0.38	4.1e-13	Lymphocyte counts;
CRC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.5	6.39	0.33	5.67e-10	Blood metabolite levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26326168	chr12:133405726	GOLGA3	0.45	6.37	0.33	6.52e-10	Survival in pancreatic cancer;
CRC	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.71	-8.07	-0.41	1.36e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.68	8.68	0.43	1.9e-16	Coronary artery disease;
CRC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.44	6.37	0.33	6.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg02683197	chr6:28174875	NA	0.64	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.68	-11.33	-0.53	2.36e-25	White blood cell count (basophil);
CRC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.66	-9.95	-0.48	1.4e-20	Prudent dietary pattern;
CRC	trans	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg18288967	chr1:45987694	PRDX1	0.68	7.48	0.38	6.93e-13	Obesity-related traits;
CRC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.82	14.91	0.64	8.83e-39	Mean platelet volume;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg10876282	chr6:28092338	ZSCAN16	0.49	6.62	0.34	1.45e-10	Cardiac Troponin-T levels;
CRC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.21	0.41	4.99e-15	Menopause (age at onset);
CRC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg17633681	chr16:88106987	BANP	0.72	12.29	0.56	7.63e-29	Menopause (age at onset);
CRC	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg20169779	chr10:135381914	SYCE1	-0.68	-11.67	-0.54	1.47e-26	Obesity-related traits;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02450064	chr17:40260053	DHX58	-0.43	-6.24	-0.33	1.38e-9	Fibrinogen levels;
CRC	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.48	6.95	0.36	1.92e-11	Primary sclerosing cholangitis;
CRC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.31	-0.49	9.07e-22	Tonsillectomy;
CRC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-12.8	-0.58	1e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12172441	chr6:28176163	NA	0.6	7.21	0.37	3.76e-12	Depression;
CRC	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-6.49	-0.34	3.2e-10	Diastolic blood pressure;
CRC	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg16576597	chr16:28551801	NUPR1	0.4	5.89	0.31	9.68e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.56	7.85	0.4	5.82e-14	Menarche (age at onset);
CRC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg25985355	chr7:65971099	NA	-0.48	-5.61	-0.3	4.24e-8	Diabetic kidney disease;
CRC	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.94	-0.31	7.15e-9	Alzheimer's disease (survival time);
CRC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.45	-0.46	6.72e-19	Mood instability;
CRC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.36	-5.91	-0.31	8.55e-9	Childhood ear infection;
CRC	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.59	-8.39	-0.42	1.48e-15	Type 2 diabetes;
CRC	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg12855166	chr17:30846586	MYO1D	-0.38	-6.44	-0.33	4.27e-10	Schizophrenia;
CRC	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-5.73	-0.3	2.25e-8	Schizophrenia;
CRC	cis	rs11212617	1.000	rs228591	chr11:108097333	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.46	6.78	0.35	5.56e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg07332563	chr6:291687	DUSP22	-0.48	-6.93	-0.36	2.27e-11	Menopause (age at onset);
CRC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.98	-19.31	-0.73	4.62e-56	Height;
CRC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.99	-0.4	2.23e-14	Gut microbiome composition (summer);
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg08798685	chr6:27730294	NA	-0.42	-6.22	-0.32	1.51e-9	Parkinson's disease;
CRC	cis	rs2274273	0.624	rs8015211	chr14:55841447	A/G	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.71	-0.3	2.49e-8	Protein biomarker;
CRC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg20203395	chr5:56204925	C5orf35	-0.69	-8.14	-0.41	8.04e-15	Initial pursuit acceleration;
CRC	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.15	-0.37	5.67e-12	Capecitabine sensitivity;
CRC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg12311346	chr5:56204834	C5orf35	-0.53	-8.13	-0.41	9.05e-15	Coronary artery disease;
CRC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.72	-8.33	-0.42	2.23e-15	Obesity-related traits;
CRC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg23758597	chr6:163146217	PARK2	-0.55	-6.13	-0.32	2.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.99	0.44	2.05e-17	Morning vs. evening chronotype;
CRC	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg00603274	chr11:61596626	FADS2	-0.46	-6.66	-0.34	1.15e-10	Trans fatty acid levels;
CRC	cis	rs4731207	0.596	rs1842615	chr7:124582871	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.25e-9	Cutaneous malignant melanoma;
CRC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.79	-0.8	1.7e-73	Myeloid white cell count;
CRC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg03037974	chr15:76606532	NA	-0.54	-8.2	-0.41	5.41e-15	Blood metabolite levels;
CRC	cis	rs6758955	0.850	rs73161279	chr2:10481001	T/G	cg15773312	chr2:10472214	HPCAL1	-0.82	-9.63	-0.47	1.66e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg04155289	chr7:94953770	PON1	-0.58	-7.08	-0.36	8.65e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs73058052	0.597	rs7249925	chr19:50093572	A/G	cg15963326	chr19:50037085	RCN3	-0.36	-5.71	-0.3	2.59e-8	Fibrinogen levels;
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.45	6.8	0.35	4.91e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.1	0.36	7.97e-12	Ulcerative colitis;
CRC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.52	5.71	0.3	2.5e-8	Menarche (age at onset);
CRC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.63	9.23	0.45	3.51e-18	Blood protein levels;
CRC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.59	7.18	0.37	4.66e-12	Obesity (extreme);
CRC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.44	5.79	0.3	1.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.6	9.84	0.48	3.35e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs4731207	0.698	rs4731216	chr7:124466512	T/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.92	18.25	0.71	6.78e-52	Bone mineral density;
CRC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12517041	1.000	rs7722738	chr5:23288074	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	1.96e-9	Calcium levels;
CRC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.09	0.45	9.86e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.72	9.64	0.47	1.51e-19	Pancreatic cancer;
CRC	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.5	-9.08	-0.45	1.04e-17	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.34	5.7	0.3	2.64e-8	Emphysema distribution in smoking;
CRC	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg08862778	chr1:11322643	MTOR	-0.52	-6.42	-0.33	4.64e-10	Diisocyanate-induced asthma;
CRC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-9.49	-0.46	4.74e-19	Monocyte percentage of white cells;
CRC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg10589385	chr1:150898437	SETDB1	0.29	6.08	0.32	3.29e-9	Tonsillectomy;
CRC	cis	rs7605827	0.930	rs879972	chr2:15703031	G/C	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg11189052	chr15:85197271	WDR73	0.61	8.81	0.44	7.07e-17	Schizophrenia;
CRC	cis	rs11212617	0.837	rs10890822	chr11:108027060	C/A	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.73	0.35	7.65e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.83	14.55	0.63	2.2e-37	Breast cancer;
CRC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs7705042	0.727	rs1062158	chr5:141523000	C/T	cg07392085	chr5:141489673	NDFIP1	0.45	7.26	0.37	2.75e-12	Asthma;
CRC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.76e-13	Motion sickness;
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.69	0.54	1.18e-26	Prudent dietary pattern;
CRC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.66	-10.72	-0.51	3.42e-23	Obesity-related traits;
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.34	-0.33	7.78e-10	Lymphocyte counts;
CRC	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.68	7.56	0.38	3.99e-13	Gut microbiota (bacterial taxa);
CRC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.82	14.23	0.62	3.79e-36	Chronic sinus infection;
CRC	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.31	-0.33	9.13e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.72	8.88	0.44	4.31e-17	Diisocyanate-induced asthma;
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08235057	chr22:21057110	TMEM191A	0.45	6.43	0.33	4.45e-10	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.66	-0.7	1.52e-49	Height;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg16606324	chr3:10149918	C3orf24	0.69	9.36	0.46	1.3e-18	Alzheimer's disease;
CRC	cis	rs6662572	0.853	rs2065708	chr1:45977685	A/G	cg08644498	chr1:46502608	NA	0.4	5.78	0.3	1.72e-8	Blood protein levels;
CRC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20307385	chr11:47447363	PSMC3	-0.55	-7.7	-0.39	1.65e-13	Subjective well-being;
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg25164649	chr6:28176230	NA	0.47	6.95	0.36	2e-11	Cardiac Troponin-T levels;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.99	0.31	5.53e-9	Alzheimer's disease;
CRC	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg02466173	chr16:30829666	NA	-0.42	-5.88	-0.31	9.85e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.72	11.72	0.54	9.64e-27	Type 2 diabetes;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg23161317	chr6:28129485	ZNF389	0.44	5.96	0.31	6.45e-9	Parkinson's disease;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.84e-12	Urinary tract infection frequency;
CRC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.62	9.99	0.48	1.05e-20	Aortic root size;
CRC	cis	rs7155603	0.700	rs17103360	chr14:75959341	A/G	cg01624173	chr14:75981868	NA	0.46	5.71	0.3	2.57e-8	Rheumatoid arthritis;
CRC	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.31	5.71	0.3	2.55e-8	QRS complex (12-leadsum);
CRC	cis	rs12928939	0.768	rs71386932	chr16:71816191	G/A	cg08717414	chr16:71523259	ZNF19	-0.51	-6.35	-0.33	7.13e-10	Post bronchodilator FEV1;
CRC	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.45	7.22	0.37	3.59e-12	Prostate cancer;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg09877947	chr5:131593287	PDLIM4	0.43	7.07	0.36	9.28e-12	Breast cancer;
CRC	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.52	9.1	0.45	8.75e-18	Common traits (Other);
CRC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-7.27	-0.37	2.56e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-6.46	-0.34	3.76e-10	Height;
CRC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.66	-9.65	-0.47	1.48e-19	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.9	10.76	0.51	2.49e-23	Iron status biomarkers;
CRC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg20512303	chr5:131592959	PDLIM4	0.38	6.68	0.35	1.01e-10	Breast cancer;
CRC	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.08	-0.41	1.21e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.4	-6.27	-0.33	1.12e-9	Glycated hemoglobin levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09866119	chr4:4291695	LYAR;ZNF509	0.45	6.26	0.33	1.2e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00170564	chr12:107714106	BTBD11	0.46	6.27	0.33	1.15e-9	Thyroid stimulating hormone;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.48	6.7	0.35	9.11e-11	Menarche (age at onset);
CRC	cis	rs728616	0.867	rs7893241	chr10:81954338	C/T	cg05935833	chr10:81318306	SFTPA2	-0.71	-7.59	-0.39	3.34e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.52	8.13	0.41	8.79e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Bladder cancer;
CRC	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14442939	chr10:27389572	ANKRD26	0.61	6.69	0.35	9.74e-11	Breast cancer;
CRC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.55	7.9	0.4	4.3e-14	Resting heart rate;
CRC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.65	-8.57	-0.43	4.22e-16	Gut microbiome composition (summer);
CRC	cis	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg18131467	chr2:239335373	ASB1	-0.71	-6.32	-0.33	8.61e-10	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.68	5.8	0.3	1.6e-8	Depression;
CRC	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.32	7.06	0.36	1.02e-11	Total body bone mineral density;
CRC	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.51	8.81	0.44	7.27e-17	Aortic root size;
CRC	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg06042504	chr8:55087323	NA	-0.37	-6.0	-0.31	5.25e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg09659197	chr4:152720779	NA	0.4	7.97	0.4	2.62e-14	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.97	-0.36	1.76e-11	Total body bone mineral density;
CRC	cis	rs7901135	1.000	rs1121644	chr10:60587139	C/T	cg23799393	chr10:60588674	BICC1	0.39	5.91	0.31	8.61e-9	Morning vs. evening chronotype;
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.39	-6.72	-0.35	7.92e-11	Lung cancer;
CRC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.84	12.87	0.58	5.82e-31	Cognitive function;
CRC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.98	17.41	0.69	1.4e-48	Menarche (age at onset);
CRC	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg11645453	chr3:52864694	ITIH4	0.41	7.73	0.39	1.35e-13	Body mass index;
CRC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.38	6.29	0.33	9.9e-10	Major depressive disorder;
CRC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06481639	chr22:41940642	POLR3H	0.55	6.05	0.32	3.97e-9	Vitiligo;
CRC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04731861	chr2:219085781	ARPC2	-0.37	-7.88	-0.4	4.82e-14	Colorectal cancer;
CRC	cis	rs4731207	0.596	rs1531716	chr7:124638538	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.27	-0.33	1.15e-9	Cutaneous malignant melanoma;
CRC	cis	rs4660306	0.744	rs11583290	chr1:45926363	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.97	0.36	1.71e-11	Homocysteine levels;
CRC	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.8	-0.3	1.57e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg23172400	chr8:95962367	TP53INP1	0.35	5.73	0.3	2.33e-8	Type 2 diabetes;
CRC	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.48	-0.34	3.31e-10	Red cell distribution width;
CRC	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg20387954	chr3:183756860	HTR3D	0.37	6.47	0.34	3.64e-10	Anterior chamber depth;
CRC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.69e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg03909863	chr11:638404	DRD4	-0.45	-5.6	-0.3	4.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-10.53	-0.5	1.56e-22	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg07125278	chr16:67683757	RLTPR	-0.61	-6.97	-0.36	1.7e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg21302420	chr1:112162376	RAP1A	0.7	6.61	0.34	1.52e-10	Skin colour saturation;
CRC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg22638593	chr5:131593259	PDLIM4	0.38	6.34	0.33	7.78e-10	Blood metabolite levels;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	trans	rs1286150	0.685	rs1286061	chr14:91456994	A/G	cg22761205	chr11:457256	PTDSS2	0.37	5.99	0.31	5.61e-9	Total body bone mineral density;
CRC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg25985355	chr7:65971099	NA	0.32	5.67	0.3	3.12e-8	Aortic root size;
CRC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.53	7.55	0.38	4.46e-13	Schizophrenia;
CRC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.0	22.33	0.78	7.15e-68	Multiple system atrophy;
CRC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg23625390	chr15:77176239	SCAPER	0.49	7.26	0.37	2.76e-12	Blood metabolite levels;
CRC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg17633681	chr16:88106987	BANP	0.83	14.52	0.62	2.99e-37	Menopause (age at onset);
CRC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.72	9.67	0.47	1.24e-19	Platelet count;
CRC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-11.1	-0.52	1.62e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.77	9.91	0.48	2.05e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00166722	chr3:10149974	C3orf24	0.63	8.24	0.41	4.1e-15	Alzheimer's disease;
CRC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg16476235	chr8:21771668	DOK2	0.36	6.13	0.32	2.55e-9	Lung cancer in ever smokers;
CRC	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	0.78	8.84	0.44	5.72e-17	Uric acid levels;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.63	-9.21	-0.45	3.94e-18	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.6	10.29	0.49	1.01e-21	Prudent dietary pattern;
CRC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.97	11.74	0.54	7.83e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg06307176	chr5:131281290	NA	-0.42	-6.33	-0.33	8.23e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.51	6.95	0.36	1.94e-11	Total body bone mineral density;
CRC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	8.8	0.44	7.71e-17	Multiple sclerosis;
CRC	cis	rs7429990	0.932	rs60446735	chr3:47971448	A/G	cg11946769	chr3:48343235	NME6	0.44	5.81	0.31	1.47e-8	Educational attainment (years of education);
CRC	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.37	-5.94	-0.31	7.37e-9	Height;
CRC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.68	0.3	2.98e-8	Prudent dietary pattern;
CRC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-6.29	-0.33	1e-9	Body mass index;
CRC	trans	rs11581859	0.901	rs9651145	chr1:99376910	A/G	cg12183875	chr3:169587454	LRRC31	0.27	6.2	0.32	1.74e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	ch.2.121392984R	chr2:121676514	GLI2	0.41	5.96	0.31	6.52e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg08888203	chr3:10149979	C3orf24	0.66	7.7	0.39	1.58e-13	Alzheimer's disease;
CRC	cis	rs9359856	1.000	rs2094487	chr6:90314072	T/A	cg13799429	chr6:90582589	CASP8AP2	0.44	6.25	0.33	1.26e-9	Bipolar disorder;
CRC	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.34	-0.59	9.19e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg21625146	chr5:486483	SLC9A3	0.37	5.81	0.31	1.44e-8	Cystic fibrosis severity;
CRC	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg21153622	chr11:89784906	NA	-0.45	-7.21	-0.37	3.98e-12	HDL cholesterol;
CRC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg19338460	chr6:170058176	WDR27	-0.67	-7.38	-0.38	1.32e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.96	-19.3	-0.73	5.02e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.21	0.53	6.22e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	15.75	0.66	4.84e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg16540259	chr10:75572220	NDST2	0.51	7.86	0.4	5.61e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.24	-0.45	3.04e-18	Reticulocyte fraction of red cells;
CRC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.54	0.47	3.32e-19	Menopause (age at onset);
CRC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.5	-10.91	-0.52	7.16e-24	Rheumatoid arthritis;
CRC	cis	rs7626444	0.627	rs5021326	chr3:196477628	A/T	cg12930392	chr3:196481615	PAK2	0.39	6.9	0.36	2.72e-11	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12184541	chr11:3012310	NAP1L4	0.47	6.86	0.35	3.47e-11	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg25193742	chr10:104614220	C10orf32	-0.77	-6.51	-0.34	2.87e-10	Cognitive function;
CRC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg24324837	chr19:49891574	CCDC155	-0.43	-5.73	-0.3	2.32e-8	Multiple sclerosis;
CRC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.04	10.13	0.49	3.61e-21	Lymphocyte counts;
CRC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg24977027	chr2:88469347	THNSL2	0.62	7.41	0.38	1.08e-12	Plasma clusterin levels;
CRC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	1.0	18.73	0.72	8.89e-54	Diastolic blood pressure;Systolic blood pressure;
CRC	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21659725	chr3:3221576	CRBN	0.45	6.75	0.35	6.56e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7671266	0.628	rs11734783	chr4:10240663	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	6.04	0.32	4.16e-9	Cardiovascular disease risk factors;
CRC	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs7129556	0.859	rs11237215	chr11:77247515	G/A	cg12586386	chr11:77299805	AQP11	0.4	5.66	0.3	3.38e-8	Weight loss (gastric bypass surgery);
CRC	cis	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg18809830	chr7:99032528	PTCD1	-0.93	-7.32	-0.37	1.87e-12	Blood metabolite levels;
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg18279126	chr7:2041391	MAD1L1	0.44	6.7	0.35	9.13e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.63	8.61	0.43	3.15e-16	Coronary artery disease;
CRC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.51	-8.36	-0.42	1.79e-15	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17014378	chr9:136025100	RALGDS	0.46	6.01	0.31	4.83e-9	Thyroid stimulating hormone;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.42	8.11	0.41	1e-14	Hypertriglyceridemia;
CRC	trans	rs11105468	1.000	rs56391951	chr12:90274621	G/A	cg23572944	chr11:60720130	SLC15A3	-0.43	-6.04	-0.32	4.15e-9	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg01612440	chr4:3296283	NA	-0.4	-5.77	-0.3	1.84e-8	Serum sulfate level;
CRC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.55	9.13	0.45	7.03e-18	Schizophrenia;
CRC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg18653534	chr16:772142	FAM173A	-0.36	-5.77	-0.3	1.88e-8	Height;
CRC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.49	6.45	0.34	3.94e-10	Vitiligo;
CRC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.65	-9.51	-0.46	4.28e-19	Menarche (age at onset);
CRC	cis	rs7692995	1.000	rs16896068	chr4:17944840	C/T	cg08925142	chr4:18023851	LCORL	-0.53	-6.03	-0.32	4.35e-9	Height;
CRC	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.5	6.77	0.35	5.87e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Tonsillectomy;
CRC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.88	0.68	1.67e-46	Platelet count;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.77	0.39	9.99e-14	Alzheimer's disease;
CRC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.82	-0.48	3.9e-20	Height;
CRC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.5	-8.2	-0.41	5.45e-15	Aortic root size;
CRC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg11189052	chr15:85197271	WDR73	0.62	8.85	0.44	5.51e-17	Schizophrenia;
CRC	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.63	-0.34	1.34e-10	Response to antipsychotic treatment;
CRC	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26714650	chr12:56694279	CS	-1.43	-11.59	-0.54	2.88e-26	Psoriasis vulgaris;
CRC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.53	-8.56	-0.43	4.37e-16	Aortic root size;
CRC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	8.9	0.44	3.83e-17	Monocyte percentage of white cells;
CRC	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg22687807	chr8:143858763	LYNX1	-0.37	-6.47	-0.34	3.46e-10	Urinary tract infection frequency;
CRC	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.07	-14.88	-0.63	1.18e-38	Exhaled nitric oxide output;
CRC	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.57	-7.9	-0.4	4.24e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.52	-7.26	-0.37	2.78e-12	Dental caries;
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.53	0.34	2.55e-10	Alzheimer's disease;
CRC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02290350	chr8:58132656	NA	-0.56	-6.4	-0.33	5.27e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.74	-9.68	-0.47	1.12e-19	Bone mineral density;
CRC	cis	rs9283706	0.608	rs13171572	chr5:66334552	T/A	cg11590213	chr5:66331682	MAST4	0.4	5.62	0.3	4.06e-8	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06443542	chr10:100206752	HPS1	0.41	6.53	0.34	2.47e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.47	7.27	0.37	2.7e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.63	0.39	2.59e-13	Lymphocyte percentage of white cells;
CRC	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	0.62	5.88	0.31	1.03e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.78	13.87	0.61	9.11e-35	Anterior chamber depth;
CRC	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.94	-16.39	-0.67	1.54e-44	Bipolar disorder;
CRC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	7.61	0.39	2.92e-13	Breast cancer;
CRC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-10.58	-0.5	1.03e-22	Hemoglobin concentration;
CRC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	0.97	19.05	0.72	4.76e-55	Height;
CRC	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-8.5	-0.42	6.63e-16	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.61	-8.65	-0.43	2.34e-16	Inflammatory bowel disease;
CRC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-6.35	-0.33	7.09e-10	Alzheimer's disease (late onset);
CRC	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg08071915	chr8:12219732	FAM66A	0.36	6.3	0.33	9.48e-10	Morning vs. evening chronotype;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05903289	chr2:130345205	NA	-0.36	-6.97	-0.36	1.79e-11	Response to cytidine analogues (gemcitabine);
CRC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	1.17	10.93	0.52	6.24e-24	Arsenic metabolism;
CRC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg01483505	chr11:975446	AP2A2	0.39	5.88	0.31	1.02e-8	Alzheimer's disease (late onset);
CRC	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.89	0.36	2.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg14541582	chr5:601475	NA	-0.33	-6.6	-0.34	1.61e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.44	6.73	0.35	7.57e-11	Red blood cell count;
CRC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.06	0.41	1.43e-14	Cystic fibrosis severity;
CRC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.68	11.23	0.53	5.4e-25	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.46	1.19e-18	Bladder cancer;
CRC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs11229555	0.645	rs11229427	chr11:58180275	A/C	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg16060761	chr17:80687452	NA	-0.54	-8.2	-0.41	5.57e-15	Glycated hemoglobin levels;
CRC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.74	-9.24	-0.45	3.22e-18	Smoking behavior;
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg03006477	chr6:74432658	CD109	0.38	6.54	0.34	2.4e-10	Blood protein levels;Calcium levels;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg07507251	chr3:52567010	NT5DC2	0.49	7.4	0.38	1.15e-12	Electroencephalogram traits;
CRC	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.69	9.93	0.48	1.72e-20	Obesity-related traits;
CRC	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.58	-7.43	-0.38	9.32e-13	Squamous cell lung carcinoma;
CRC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg19041857	chr6:27730383	NA	-0.6	-6.39	-0.33	5.66e-10	Lung cancer in ever smokers;
CRC	cis	rs7932354	0.528	rs1060573	chr11:47179829	A/G	cg19486271	chr11:47235900	DDB2	-0.44	-6.5	-0.34	2.98e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg25809561	chr17:30822961	MYO1D	0.52	9.52	0.46	3.97e-19	Schizophrenia;
CRC	cis	rs3736485	0.966	rs8031903	chr15:51838161	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-6.62	-0.34	1.43e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs11212617	1.000	rs228591	chr11:108097333	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.5	0.34	2.96e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.75	12.89	0.58	4.75e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.96e-18	Lymphocyte counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05492845	chr11:64002298	VEGFB	0.42	6.8	0.35	5.08e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg10723962	chr6:26240782	HIST1H4F	-0.4	-6.36	-0.33	6.94e-10	Gout;Renal underexcretion gout;
CRC	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg17456097	chr1:26900765	RPS6KA1	-0.41	-6.2	-0.32	1.7e-9	Glucose homeostasis traits;
CRC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.53	8.56	0.43	4.38e-16	Coronary artery disease;
CRC	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	0.56	8.76	0.43	1.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.61	-0.39	2.96e-13	HDL cholesterol;
CRC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.5	6.62	0.34	1.44e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.39	-5.96	-0.31	6.33e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg17724175	chr1:150552817	MCL1	-0.51	-8.29	-0.42	2.93e-15	Tonsillectomy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26644764	chr7:87849153	SRI	0.36	6.03	0.32	4.51e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6956675	0.915	rs1609795	chr7:62650531	T/C	cg01314568	chr7:57830625	NA	-0.64	-8.98	-0.44	2.16e-17	Obesity-related traits;
CRC	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg24463073	chr6:118973353	C6orf204	0.43	5.88	0.31	9.84e-9	Diastolic blood pressure;
CRC	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.48	7.0	0.36	1.48e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.7	-0.35	9e-11	Menopause (age at onset);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg11450715	chr2:171627404	NA	0.36	5.98	0.31	5.67e-9	Interleukin-6 levels;
CRC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	1.11	10.48	0.5	2.28e-22	Parkinson's disease;
CRC	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg09597638	chr17:3907349	NA	-0.66	-11.58	-0.54	2.94e-26	Type 2 diabetes;
CRC	cis	rs7113874	0.524	rs6484485	chr11:8620740	A/G	cg02811074	chr11:8615871	STK33	0.33	5.88	0.31	9.85e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.68	-9.01	-0.44	1.73e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.64	10.38	0.5	5.13e-22	Height;
CRC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.06	-17.63	-0.7	1.99e-49	Blood pressure (smoking interaction);
CRC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.13	-0.32	2.56e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.36	0.53	1.88e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs747650	0.504	rs10838641	chr11:47003304	G/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.51	-0.34	2.82e-10	Acne (severe);
CRC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	1.04	13.07	0.58	9.51e-32	IgG glycosylation;
CRC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.68	-0.35	1.03e-10	Dupuytren's disease;
CRC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.61	8.88	0.44	4.43e-17	Obesity-related traits;
CRC	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg16141378	chr3:129829833	LOC729375	-0.42	-6.23	-0.32	1.4e-9	Myopia (pathological);
CRC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.09	-19.04	-0.72	5.24e-55	Ulcerative colitis;
CRC	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.68	-0.39	1.87e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.45	-6.15	-0.32	2.25e-9	Schizophrenia;
CRC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-0.96	-9.27	-0.46	2.53e-18	Breast cancer;
CRC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.29	0.42	2.92e-15	Lung cancer;
CRC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-12.56	-0.57	7.92e-30	Cognitive function;
CRC	cis	rs2294693	0.945	rs9462668	chr6:41004194	T/C	cg14769373	chr6:40998127	UNC5CL	-0.44	-5.66	-0.3	3.29e-8	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.75	-0.35	6.85e-11	Total body bone mineral density;
CRC	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.42	6.04	0.32	4.2e-9	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg25767906	chr1:53392781	SCP2	-0.38	-5.82	-0.31	1.41e-8	Monocyte count;
CRC	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.68	0.35	9.93e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.46	5.79	0.3	1.69e-8	Bladder cancer;
CRC	cis	rs11212617	0.905	rs672964	chr11:108125471	C/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.63	0.3	3.84e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.61	-0.39	2.88e-13	Bipolar disorder;
CRC	cis	rs9658691	0.646	rs7909414	chr10:90754744	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.78	5.94	0.31	7.22e-9	Mosquito bite size;
CRC	cis	rs904251	0.686	rs1224128	chr6:37415676	C/A	cg25019722	chr6:37503610	NA	-0.4	-5.82	-0.31	1.36e-8	Cognitive performance;
CRC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.89	11.88	0.55	2.61e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs773506	0.576	rs943502	chr9:93920745	G/A	cg14446406	chr9:93919335	NA	-0.55	-9.54	-0.47	3.22e-19	Type 2 diabetes nephropathy;
CRC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg07599136	chr5:415885	AHRR	0.64	6.68	0.35	9.95e-11	Fat distribution (HIV);
CRC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.15	0.32	2.28e-9	Diabetic kidney disease;
CRC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.48	6.18	0.32	1.92e-9	Vitiligo;
CRC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg11707556	chr5:10655725	ANKRD33B	0.48	7.85	0.4	6.09e-14	Coronary artery disease;
CRC	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.83	-13.36	-0.59	8.09e-33	Cognitive function;
CRC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.56	-8.41	-0.42	1.27e-15	Menarche (age at onset);
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.24	0.37	3.23e-12	Lymphocyte counts;
CRC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg18764771	chr6:116381957	FRK	-0.24	-6.9	-0.36	2.69e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21643547	chr1:205240462	TMCC2	-0.41	-6.61	-0.34	1.59e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg03623178	chr6:28175578	NA	0.77	6.6	0.34	1.66e-10	Breast cancer;
CRC	trans	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg17903999	chr18:56338584	MALT1	0.4	6.87	0.35	3.21e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs7072216	0.687	rs10883085	chr10:100155613	A/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.78	-0.3	1.73e-8	Metabolite levels;
CRC	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.53	-8.05	-0.41	1.56e-14	HDL cholesterol;
CRC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.54	-6.84	-0.35	3.81e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7259376	0.837	rs10420149	chr19:22582925	T/G	cg02657401	chr19:22469223	NA	0.31	6.6	0.34	1.64e-10	Menopause (age at onset);
CRC	cis	rs6088813	1.000	rs6142359	chr20:33960450	T/C	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.39e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.79	-9.72	-0.47	8.72e-20	Body mass index;
CRC	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.06	0.36	9.93e-12	Menarche (age at onset);
CRC	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.62	-9.36	-0.46	1.28e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.82	13.92	0.61	5.82e-35	Menopause (age at onset);
CRC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.83	12.65	0.57	3.68e-30	Cognitive function;
CRC	cis	rs9287719	0.649	rs10803725	chr2:10732346	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	trans	rs8005150	0.737	rs7156702	chr14:88481017	T/C	cg25527770	chr19:1444892	NA	-0.58	-6.24	-0.33	1.32e-9	Hepatitis B;
CRC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.83	-0.31	1.33e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.68	-0.3	2.98e-8	Metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24138021	chr14:39644158	PNN	0.47	6.53	0.34	2.49e-10	Response to antipsychotic treatment;
CRC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-7.24	-0.37	3.16e-12	Dental caries;
CRC	cis	rs2223471	0.776	rs10948570	chr6:50646175	C/T	cg03432817	chr6:50765336	NA	-0.41	-6.4	-0.33	5.41e-10	Subcutaneous adipose tissue;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18466108	chr12:99038412	APAF1;IKBIP	-0.4	-6.0	-0.31	5.18e-9	Myopia (pathological);
CRC	cis	rs12476592	0.602	rs2121353	chr2:63899330	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.49	0.34	3.11e-10	Childhood ear infection;
CRC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg21251018	chr6:28226885	NKAPL	0.43	6.09	0.32	3.1e-9	Parkinson's disease;
CRC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg24881330	chr22:46731750	TRMU	-0.59	-6.99	-0.36	1.5e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	0.56	8.78	0.44	9.36e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13047869	chr3:10149882	C3orf24	0.51	7.07	0.36	9.31e-12	Alzheimer's disease;
CRC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.47	7.3	0.37	2.22e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25517755	chr10:38738941	LOC399744	-0.45	-6.62	-0.34	1.47e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.47	-6.81	-0.35	4.65e-11	Breast cancer;
CRC	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.59	8.04	0.41	1.59e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.42	-7.08	-0.36	8.79e-12	Mean platelet volume;Platelet distribution width;
CRC	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.69	-8.97	-0.44	2.31e-17	Educational attainment;
CRC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	10.12	0.49	3.77e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg12262378	chr17:6899522	ALOX12	-0.55	-10.49	-0.5	2.05e-22	Tonsillectomy;
CRC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg14673194	chr17:80132900	CCDC57	-0.5	-6.59	-0.34	1.7e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.5	-0.46	4.34e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs9287719	0.649	rs9973374	chr2:10716384	C/T	cg00105475	chr2:10696890	NA	0.45	7.05	0.36	1.05e-11	Prostate cancer;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg21251018	chr6:28226885	NKAPL	0.45	6.64	0.34	1.3100000000000001e-10	Parkinson's disease;
CRC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg26850624	chr5:429559	AHRR	0.71	9.59	0.47	2.29e-19	Cystic fibrosis severity;
CRC	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.44	-5.79	-0.3	1.64e-8	Adiposity;
CRC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg19824325	chr16:58548873	SETD6	0.97	6.51	0.34	2.83e-10	Schizophrenia;
CRC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg02018176	chr4:1364513	KIAA1530	0.46	7.47	0.38	7.22e-13	Obesity-related traits;
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg02683197	chr6:28174875	NA	0.79	9.73	0.47	8.12e-20	Depression;
CRC	trans	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg02674126	chr19:40336878	FBL	0.42	6.68	0.35	1.04e-10	Hyperactive-impulsive symptoms;
CRC	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg10217327	chr6:118973057	C6orf204	0.46	5.73	0.3	2.32e-8	Renal cell carcinoma;
CRC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.94	-0.31	7.23e-9	Obesity-related traits;
CRC	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg12311346	chr5:56204834	C5orf35	0.48	7.52	0.38	5.2e-13	Coronary artery disease;
CRC	cis	rs9292777	0.720	rs9292769	chr5:40397911	A/G	cg09067459	chr5:40385259	NA	0.52	8.82	0.44	7.07e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg17333051	chr19:2783644	SGTA	0.47	6.89	0.36	2.87e-11	Total cholesterol levels;
CRC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.13	-0.41	8.77e-15	Chronic sinus infection;
CRC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg16797656	chr11:68205561	LRP5	0.37	5.84	0.31	1.27e-8	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg04204079	chr8:58130323	NA	-0.45	-6.09	-0.32	3.17e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.74	10.9	0.51	8.27e-24	Breast cancer;
CRC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-9.46	-0.46	6.22e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.55	6.17	0.32	1.98e-9	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00746693	chr19:34746153	KIAA0355	0.4	6.63	0.34	1.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.57	-9.02	-0.45	1.58e-17	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg05370193	chr1:21551575	ECE1	0.36	5.68	0.3	2.99e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.53	7.82	0.4	7.13e-14	Prostate cancer;
CRC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	0.82	13.02	0.58	1.52e-31	Cognitive function;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg26587870	chr6:27730563	NA	-0.41	-6.41	-0.33	4.99e-10	Parkinson's disease;
CRC	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.83	-0.35	4.11e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg10217327	chr6:118973057	C6orf204	0.49	5.63	0.3	3.81e-8	Diastolic blood pressure;
CRC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg18232548	chr7:50535776	DDC	0.42	6.09	0.32	3.14e-9	Malaria;
CRC	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg12292205	chr6:26970375	C6orf41	-0.52	-7.46	-0.38	7.73e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg22676075	chr6:135203613	NA	0.42	6.33	0.33	8.1e-10	Red blood cell count;
CRC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	6.2	0.32	1.65e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.41	7.01	0.36	1.37e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	5.73	0.3	2.23e-8	Diabetic retinopathy;
CRC	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg11204139	chr17:3907470	NA	0.82	16.33	0.67	2.53e-44	Type 2 diabetes;
CRC	cis	rs10924970	0.967	rs2382616	chr1:235454237	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.89	0.31	9.32e-9	Asthma;
CRC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-10.37	-0.5	5.54e-22	Personality dimensions;
CRC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.67	-0.34	1.1e-10	Mean corpuscular volume;
CRC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg20742385	chr13:113633654	MCF2L	-0.71	-12.53	-0.57	1.05e-29	Systolic blood pressure;
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.73	-0.54	8.71e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs77861329	1.000	rs9815010	chr3:52196548	C/T	cg08692210	chr3:52188851	WDR51A	0.86	8.07	0.41	1.3e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg15445000	chr17:37608096	MED1	-0.35	-6.09	-0.32	3.18e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.63	7.72	0.39	1.45e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.42	0.46	8.42e-19	Monocyte percentage of white cells;
CRC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg22963979	chr7:1858916	MAD1L1	-0.69	-10.48	-0.5	2.36e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	cg04338863	chr8:33670619	NA	0.39	6.84	0.35	3.92e-11	Body mass index;
CRC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg23533926	chr12:111358616	MYL2	-0.5	-7.56	-0.38	4.1e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg24463073	chr6:118973353	C6orf204	0.52	6.99	0.36	1.51e-11	Diastolic blood pressure;
CRC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg06238570	chr21:40685208	BRWD1	0.76	10.62	0.51	7.3e-23	Cognitive function;
CRC	cis	rs6662572	0.737	rs12045409	chr1:46358720	C/T	cg08644498	chr1:46502608	NA	0.43	6.4	0.33	5.47e-10	Blood protein levels;
CRC	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg11292332	chr7:45801988	SEPT13	0.37	6.34	0.33	7.7e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs35883536	1.000	rs12409831	chr1:101107670	A/T	cg14515779	chr1:101123966	NA	-0.43	-8.3	-0.42	2.75e-15	Monocyte count;
CRC	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02097616	chr17:62675921	NA	0.5	6.81	0.35	4.77e-11	QT interval;
CRC	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21984481	chr17:79567631	NPLOC4	0.57	10.59	0.5	9.49e-23	Eye color traits;
CRC	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg12046867	chr14:103022105	NA	-0.42	-6.1	-0.32	2.94e-9	Platelet count;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg20397358	chr22:38597902	MAFF	-0.73	-6.01	-0.31	4.9e-9	Cognitive function;
CRC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.51	7.81	0.4	7.87e-14	Calcium levels;
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00166722	chr3:10149974	C3orf24	0.61	8.09	0.41	1.19e-14	Alzheimer's disease;
CRC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg05585544	chr11:47624801	NA	-0.5	-8.98	-0.44	2.06e-17	Subjective well-being;
CRC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	0.94	11.39	0.53	1.51e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs34156428	0.527	rs78181642	chr11:16807417	C/T	cg05563613	chr7:99070410	ZNF789	0.72	6.0	0.31	5.15e-9	Coronary artery disease;
CRC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.47	0.34	3.5e-10	Morning vs. evening chronotype;
CRC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg23262073	chr20:60523788	NA	-0.46	-7.24	-0.37	3.25e-12	Body mass index;
CRC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.39	-0.5	4.73e-22	Chronic sinus infection;
CRC	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.44	-0.33	4.31e-10	Neuroticism;
CRC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.67	-8.19	-0.41	5.93e-15	Bronchopulmonary dysplasia;
CRC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg16486109	chr11:613632	IRF7	0.64	11.33	0.53	2.37e-25	Systemic lupus erythematosus;
CRC	cis	rs1223397	0.589	rs364493	chr6:13297020	C/T	cg21538684	chr6:13274180	PHACTR1	-0.4	-5.93	-0.31	7.62e-9	Blood pressure;
CRC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.71	7.04	0.36	1.09e-11	Fat distribution (HIV);
CRC	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.52	-7.23	-0.37	3.34e-12	Tuberculosis;
CRC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	10.56	0.5	1.18e-22	Menarche (age at onset);
CRC	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.76	0.3	1.93e-8	Axial length;
CRC	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.53	9.89	0.48	2.34e-20	Age-related hearing impairment;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg24634471	chr8:143751801	JRK	-0.45	-6.41	-0.33	5.18e-10	Urinary tract infection frequency;
CRC	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.72	-10.13	-0.49	3.64e-21	Blood protein levels;
CRC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.52	-0.38	5.36e-13	Coronary artery disease;
CRC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-12.53	-0.57	1.06e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	8.1	0.41	1.06e-14	Height;
CRC	cis	rs10991814	0.920	rs7856668	chr9:94040209	C/A	cg14446406	chr9:93919335	NA	0.58	6.42	0.33	4.67e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	8.8e-9	Red blood cell count;
CRC	cis	rs1552172	0.922	rs12755149	chr1:145704918	T/A	cg11743829	chr1:145714124	CD160	-0.41	-6.1	-0.32	2.94e-9	Breast cancer;
CRC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg11212589	chr17:38028394	ZPBP2	0.43	8.03	0.4	1.71e-14	Self-reported allergy;
CRC	cis	rs10221833	0.602	rs355883	chr2:165633925	A/T	cg03182029	chr2:165697222	COBLL1	0.5	5.83	0.31	1.35e-8	Response to statin therapy;
CRC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.86	-0.51	1.06e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	3.13e-24	Corneal astigmatism;
CRC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.8	13.37	0.59	7.61e-33	Menopause (age at onset);
CRC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg18519450	chr2:121746027	GLI2	0.52	6.24	0.33	1.33e-9	Lymphocyte counts;
CRC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg25456477	chr12:86230367	RASSF9	0.36	6.23	0.32	1.46e-9	Major depressive disorder;
CRC	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg00691999	chr4:55094011	PDGFRA	0.41	5.76	0.3	1.89e-8	Corneal astigmatism;
CRC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg12564285	chr5:131593104	PDLIM4	0.46	7.68	0.39	1.89e-13	Breast cancer;
CRC	cis	rs6840360	0.582	rs4696260	chr4:152318924	T/C	cg09659197	chr4:152720779	NA	0.3	5.66	0.3	3.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.55	-7.76	-0.39	1.06e-13	IgG glycosylation;
CRC	trans	rs2303319	0.504	rs79046651	chr2:162326417	C/A	cg19471553	chr17:41393123	NA	-0.7	-6.07	-0.32	3.48e-9	Cognitive function;
CRC	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06544989	chr22:39130855	UNC84B	0.45	6.84	0.35	3.88e-11	Menopause (age at onset);
CRC	cis	rs62229266	0.659	rs2026259	chr21:37430627	A/G	cg08632701	chr21:37451849	NA	-0.44	-7.03	-0.36	1.22e-11	Mitral valve prolapse;
CRC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.5	7.7	0.39	1.6e-13	Aortic root size;
CRC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.97e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.9	16.62	0.68	1.87e-45	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.36e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.08	-0.32	3.32e-9	Cognitive function;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.49	6.37	0.33	6.3e-10	Thyroid stimulating hormone;
CRC	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg24375607	chr4:120327624	NA	0.4	6.46	0.34	3.72e-10	Corneal astigmatism;
CRC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-7.22	-0.37	3.71e-12	Subjective well-being;
CRC	cis	rs6066835	0.867	rs8123336	chr20:47361725	C/T	cg18078177	chr20:47281410	PREX1	-0.64	-5.67	-0.3	3.06e-8	Multiple myeloma;
CRC	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.56	-8.9	-0.44	3.78e-17	Type 2 diabetes;
CRC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.94	-0.44	2.91e-17	Aortic root size;
CRC	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg07212818	chr11:638076	DRD4	-0.45	-5.64	-0.3	3.65e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.42	8.09	0.41	1.16e-14	Mean corpuscular volume;
CRC	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.7	-11.41	-0.53	1.25e-25	Hepatocellular carcinoma;
CRC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.66	-11.44	-0.53	9.33e-26	Resting heart rate;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00243897	chr12:122326549	PSMD9	0.38	6.05	0.32	4e-9	Obesity-related traits;
CRC	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	8.3	0.42	2.7e-15	Neuroticism;
CRC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg01304814	chr3:48885189	PRKAR2A	0.83	6.05	0.32	3.92e-9	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05975219	chr16:90088916	GAS8	0.44	6.6	0.34	1.67e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.92	14.11	0.61	1.14e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.87	-9.96	-0.48	1.32e-20	Systolic blood pressure;
CRC	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.73	14.14	0.61	8.53e-36	Ulcerative colitis;
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-11.15	-0.52	1.08e-24	Body mass index;
CRC	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	6.28	0.33	1.09e-9	Coronary artery disease;
CRC	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg19637330	chr1:19110922	NA	-0.5	-6.53	-0.34	2.43e-10	Drug-induced liver injury (nitrofurantoin);
CRC	trans	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.19	0.37	4.49e-12	Ulcerative colitis;
CRC	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-0.63	-6.87	-0.35	3.14e-11	Prostate cancer;
CRC	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg18827107	chr12:86230957	RASSF9	-0.36	-5.77	-0.3	1.81e-8	Major depressive disorder;
CRC	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26306683	chr17:18585705	ZNF286B	0.47	6.84	0.35	3.92e-11	Educational attainment (years of education);
CRC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.1	-18.91	-0.72	1.65e-54	Ulcerative colitis;
CRC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg07090678	chr1:91966139	CDC7	-0.43	-7.26	-0.37	2.86e-12	Breast cancer;
CRC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.34	-6.48	-0.34	3.33e-10	Huntington's disease progression;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg11470399	chr16:23690492	PLK1	0.5	6.07	0.32	3.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg13482628	chr17:19912719	NA	-0.37	-5.72	-0.3	2.41e-8	Schizophrenia;
CRC	cis	rs2179367	0.959	rs536203	chr6:149651264	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.37	-5.94	-0.31	7.09e-9	Dupuytren's disease;
CRC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.52	-8.74	-0.43	1.22e-16	Aortic root size;
CRC	cis	rs2530545	0.619	rs6955780	chr7:34662348	C/G	cg14401837	chr7:34697493	NPSR1	0.42	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.81	-9.74	-0.47	7.33e-20	Bronchopulmonary dysplasia;
CRC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.35	-0.42	1.88e-15	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07152591	chr5:132083105	CCNI2	0.43	6.06	0.32	3.67e-9	Response to antipsychotic treatment;
CRC	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.52	8.4	0.42	1.39e-15	IgG glycosylation;
CRC	cis	rs17152411	1.000	rs10901837	chr10:126614618	G/A	cg07906193	chr10:126599966	NA	0.62	6.89	0.36	2.85e-11	Height;
CRC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.88	-14.89	-0.63	1.1e-38	Intelligence (multi-trait analysis);
CRC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.64e-39	Lymphocyte percentage of white cells;
CRC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-8.26	-0.41	3.57e-15	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg01339444	chr6:118972232	C6orf204	0.54	6.02	0.32	4.65e-9	Diastolic blood pressure;
CRC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.59	9.11	0.45	8.04e-18	Blood metabolite levels;
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.95	-0.4	3.11e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg25019722	chr6:37503610	NA	-0.38	-6.59	-0.34	1.75e-10	Cognitive performance;
CRC	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.82	10.4	0.5	4.48e-22	Iron status biomarkers;
CRC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.83	15.26	0.64	3.89e-40	Vitiligo;
CRC	trans	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.55e-9	Skin colour saturation;
CRC	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg20628663	chr10:43360327	NA	0.56	6.91	0.36	2.57e-11	Blood protein levels;
CRC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.04	12.65	0.57	3.79e-30	Nonalcoholic fatty liver disease;
CRC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	trans	rs12200782	0.577	rs3757144	chr6:26380922	G/C	cg25800765	chr12:85673347	ALX1	0.26	5.98	0.31	5.79e-9	Small cell lung carcinoma;
CRC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.38	-5.84	-0.31	1.22e-8	Gout;Renal underexcretion gout;
CRC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.66	8.82	0.44	6.68e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.75	0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-9.75	-0.47	6.88e-20	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.69	-0.39	1.76e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg14593290	chr7:50529359	DDC	-0.48	-6.87	-0.35	3.22e-11	Body mass index;
CRC	cis	rs6735179	0.688	rs2382563	chr2:1763599	T/C	cg19300414	chr2:1746591	PXDN	0.35	6.31	0.33	8.85e-10	Response to antipsychotic treatment;
CRC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.57	9.3	0.46	2.05e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.6	8.9	0.44	3.69e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1868673	1.000	rs28514580	chr3:150154365	G/T	cg04908077	chr3:150187338	NA	-0.33	-5.65	-0.3	3.49e-8	Waist circumference;
CRC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.17	-0.52	9.08e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.67	7.17	0.37	5.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg09127314	chr1:152161683	NA	0.53	6.69	0.35	9.52e-11	Atopic dermatitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01129751	chr2:42796040	MTA3	-0.39	-6.08	-0.32	3.35e-9	Myopia (pathological);
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.63	9.73	0.47	7.83e-20	Monocyte percentage of white cells;
CRC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24308560	chr3:49941425	MST1R	0.48	7.49	0.38	6.49e-13	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12172441	chr6:28176163	NA	0.63	7.43	0.38	9.41e-13	Depression;
CRC	cis	rs73206853	0.764	rs55823622	chr12:110781628	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	7.71	0.39	1.55e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.8	-12.62	-0.57	4.92e-30	Blood trace element (Zn levels);
CRC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.66	7.71	0.39	1.47e-13	Menarche (age at onset);
CRC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19717773	chr7:2847554	GNA12	0.49	6.89	0.35	2.9e-11	Height;
CRC	cis	rs10982256	1.000	rs10982256	chr9:117260834	A/G	cg13636371	chr9:117264095	DFNB31	-0.37	-7.16	-0.37	5.36e-12	Bipolar disorder;
CRC	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	11.1	0.52	1.54e-24	Personality dimensions;
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg00469287	chr7:23338798	C7orf30	0.42	5.7	0.3	2.65e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg12315302	chr6:26189340	HIST1H4D	0.72	5.79	0.3	1.66e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	8.45	0.42	9.64e-16	Menarche (age at onset);
CRC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.08	-12.66	-0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.69	-10.1	-0.49	4.6e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg24634471	chr8:143751801	JRK	-0.5	-6.74	-0.35	7.2e-11	Urinary tract infection frequency;
CRC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16262614	chr3:133464971	TF	0.33	5.81	0.3	1.49e-8	Iron status biomarkers;
CRC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.73	-12.08	-0.55	4.74e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.77	13.88	0.61	8.3e-35	Anterior chamber depth;
CRC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.86	0.31	1.12e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.2	-0.32	1.67e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.49	6.59	0.34	1.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg11915388	chr22:42470451	FAM109B	-0.38	-5.7	-0.3	2.62e-8	Schizophrenia;
CRC	cis	rs7264396	0.887	rs224370	chr20:34073379	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.92	-0.36	2.37e-11	Total cholesterol levels;
CRC	cis	rs7849270	0.959	rs713218	chr9:131900770	G/C	cg13538475	chr9:131942899	NA	-0.32	-6.36	-0.33	6.59e-10	Blood metabolite ratios;
CRC	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	cg04338863	chr8:33670619	NA	-0.33	-5.7	-0.3	2.68e-8	Body mass index;
CRC	cis	rs1863824	0.625	rs11202024	chr10:88168024	C/A	cg07322936	chr10:88137208	NA	-0.64	-8.71	-0.43	1.5e-16	Schizophrenia;
CRC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.07e-25	Hip circumference adjusted for BMI;
CRC	trans	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg10756647	chr7:56101905	PSPH	0.73	8.16	0.41	7.04e-15	Diabetic kidney disease;
CRC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-8.08	-0.41	1.29e-14	Type 2 diabetes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15013526	chr3:170588137	RPL22L1	-0.41	-6.45	-0.34	4.06e-10	Myopia (pathological);
CRC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.43	0.33	4.61e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.55	-10.27	-0.49	1.19e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.57	7.48	0.38	6.9e-13	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg19773385	chr1:10388646	KIF1B	-0.57	-7.81	-0.4	7.58e-14	Hepatocellular carcinoma;
CRC	trans	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg23387109	chr10:94051229	MARCH5;CPEB3	0.45	5.96	0.31	6.36e-9	Extraversion;
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg15898840	chr7:45960834	IGFBP3	0.47	7.84	0.4	6.19e-14	Sitting height ratio;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09060093	chr1:26202137	NA	0.4	6.07	0.32	3.5e-9	Schizophrenia;
CRC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.65	-10.63	-0.51	6.91e-23	Type 2 diabetes;
CRC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg09045935	chr12:6379348	NA	0.84	6.31	0.33	8.84e-10	Blood metabolite levels;
CRC	cis	rs846178	1	rs846178	chr4:2485615	A/C	cg16474684	chr4:2470049	RNF4	-0.46	-5.96	-0.31	6.5e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7630877	0.719	rs73057311	chr3:179664197	A/G	cg18765712	chr3:179670323	PEX5L	0.5	6.96	0.36	1.81e-11	Type 2 diabetes;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12877462	chr4:100484858	RG9MTD2;MTTP	-0.52	-6.47	-0.34	3.51e-10	Diisocyanate-induced asthma;
CRC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-8.39	-0.42	1.46e-15	Chronic sinus infection;
CRC	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.5	7.59	0.39	3.23e-13	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg25456477	chr12:86230367	RASSF9	0.37	6.38	0.33	5.98e-10	Major depressive disorder;
CRC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.77	10.89	0.51	8.67e-24	Blood trace element (Zn levels);
CRC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.63	-9.78	-0.47	5.56e-20	IgG glycosylation;
CRC	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.33	-6.33	-0.33	8.06e-10	Breast cancer;
CRC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.16	0.59	4.62e-32	Platelet count;
CRC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	trans	rs1933755	0.541	rs35616742	chr6:130917784	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.89	-6.62	-0.34	1.48e-10	Colorectal cancer (calcium intake interaction);
CRC	cis	rs4908760	0.899	rs6577496	chr1:8581227	C/A	cg20416874	chr1:8611966	RERE	-0.46	-6.6	-0.34	1.61e-10	Vitiligo;
CRC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.32	-0.42	2.45e-15	Vitiligo;
CRC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.5	-8.26	-0.41	3.64e-15	Type 2 diabetes;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg21770322	chr7:97807741	LMTK2	0.54	9.08	0.45	1.02e-17	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg12870014	chr12:110450643	ANKRD13A	0.75	8.89	0.44	4.25e-17	Itch intensity from mosquito bite;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17569080	chr11:93862630	PANX1	0.43	6.03	0.32	4.35e-9	Response to antipsychotic treatment;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.46	-6.7	-0.35	9.13e-11	Blood pressure (smoking interaction);
CRC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg27615366	chr5:131592974	PDLIM4	0.34	5.81	0.31	1.48e-8	Breast cancer;
CRC	trans	rs2303319	0.504	rs2175142	chr2:162450124	T/C	cg27113153	chr11:123612418	ZNF202	-0.7	-6.15	-0.32	2.28e-9	Cognitive function;
CRC	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.91	11.21	0.53	6.6e-25	Exhaled nitric oxide output;
CRC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg23625390	chr15:77176239	SCAPER	0.47	6.81	0.35	4.6e-11	Blood metabolite levels;
CRC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.53	-8.61	-0.43	3.18e-16	Aortic root size;
CRC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.35	-0.33	7.35e-10	Aortic root size;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.63	9.9	0.48	2.09e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.08	-12.42	-0.56	2.72e-29	Diabetic kidney disease;
CRC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-14.12	-0.61	1.04e-35	Gut microbiome composition (summer);
CRC	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg03929089	chr4:120376271	NA	0.56	6.37	0.33	6.41e-10	Intraocular pressure;
CRC	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.59	8.64	0.43	2.51e-16	Crohn's disease;
CRC	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg04662943	chr10:102668895	NA	0.62	7.28	0.37	2.51e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.13	-0.71	2.07e-51	Schizophrenia;
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg06470822	chr6:28175283	NA	0.79	12.11	0.56	3.51e-28	Parkinson's disease;
CRC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-17.98	-0.7	7.63e-51	Ulcerative colitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26869849	chr2:27632522	PPM1G	0.47	6.3	0.33	9.33e-10	Anxiety disorder;
CRC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06544989	chr22:39130855	UNC84B	-0.43	-6.48	-0.34	3.26e-10	Menopause (age at onset);
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.39	-6.98	-0.36	1.66e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg26304593	chr6:42947056	PEX6	-0.41	-5.75	-0.3	2.05e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.81	0.44	7.18e-17	Coffee consumption (cups per day);
CRC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.43	9.5	0.46	4.37e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.74	13.6	0.6	9.8e-34	Cancer;
CRC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.49	6.57	0.34	2.02e-10	Cleft lip with or without cleft palate;
CRC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.21	0.53	6.25e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-8.3	-0.42	2.74e-15	Monocyte count;
CRC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg01766193	chr7:157202248	DNAJB6	-0.34	-5.62	-0.3	3.99e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.89	-15.36	-0.65	1.55e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02290350	chr8:58132656	NA	-0.41	-6.08	-0.32	3.25e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg12172441	chr6:28176163	NA	0.54	7.07	0.36	9.53e-12	Parkinson's disease;
CRC	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-13.36	-0.59	8.21e-33	Vitiligo;
CRC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.73	-8.33	-0.42	2.18e-15	Hemostatic factors and hematological phenotypes;
CRC	trans	rs6956675	1.000	rs10229492	chr7:62580546	G/A	cg01314568	chr7:57830625	NA	-0.68	-9.3	-0.46	2.06e-18	Obesity-related traits;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03140480	chr1:2703494	NA	0.38	5.98	0.31	5.9e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.44	-5.92	-0.31	7.99e-9	Carotid intima media thickness;
CRC	cis	rs4481887	0.504	rs4508045	chr1:248373567	G/A	cg00666640	chr1:248458726	OR2T12	0.43	6.77	0.35	5.91e-11	Common traits (Other);
CRC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.83	11.88	0.55	2.57e-27	Vitiligo;
CRC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.45	-7.04	-0.36	1.16e-11	Monocyte count;
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.49	-0.54	6.44e-26	Bipolar disorder and schizophrenia;
CRC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.96e-18	Lymphocyte counts;
CRC	cis	rs7605827	0.930	rs12692275	chr2:15716781	C/T	cg19274914	chr2:15703543	NA	0.4	6.14	0.32	2.32e-9	Educational attainment (years of education);
CRC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg17775713	chr3:133465469	TF	0.35	6.28	0.33	1.07e-9	Iron status biomarkers (transferrin levels);
CRC	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.2	18.64	0.72	2.04e-53	Atopic dermatitis;
CRC	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg15282417	chr9:129245246	FAM125B	0.45	8.24	0.41	4.17e-15	Intraocular pressure;
CRC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg27523141	chr10:43048294	ZNF37B	0.5	7.23	0.37	3.41e-12	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12444390	chr22:24989260	C22orf36;GGT1	0.35	6.11	0.32	2.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg23161317	chr6:28129485	ZNF389	0.44	6.12	0.32	2.64e-9	Parkinson's disease;
CRC	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg11861562	chr11:117069780	TAGLN	0.33	6.1	0.32	3.05e-9	Blood protein levels;
CRC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.65	9.39	0.46	1.03e-18	Menopause (age at onset);
CRC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-0.91	-9.6	-0.47	2.07e-19	Hip circumference adjusted for BMI;
CRC	cis	rs7517126	1.000	rs7548070	chr1:196892322	G/A	cg13682187	chr1:196946512	CFHR5	-0.4	-5.89	-0.31	9.64e-9	Blood protein levels;
CRC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.6	10.1	0.49	4.51e-21	Prudent dietary pattern;
CRC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	8.07	0.41	1.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.82	-0.31	1.41e-8	Life satisfaction;
CRC	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg12046867	chr14:103022105	NA	0.67	8.04	0.41	1.67e-14	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18876457	chr1:160071037	NA	0.54	7.85	0.4	5.79e-14	Response to antipsychotic treatment;
CRC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.4	5.63	0.3	3.84e-8	Aortic root size;
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.53	6.85	0.35	3.63e-11	Alzheimer's disease (survival time);
CRC	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.57	-0.43	4.2e-16	Hip circumference adjusted for BMI;
CRC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.61	7.84	0.4	6.13e-14	Body mass index;
CRC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.28	0.33	1.09e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg14558114	chr2:88469736	THNSL2	-0.47	-6.86	-0.35	3.5e-11	Response to metformin (IC50);
CRC	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.42	0.33	4.71e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.66	-0.47	1.35e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg22532475	chr10:104410764	TRIM8	-0.35	-6.28	-0.33	1.06e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	cis	rs10242455	0.702	rs28753399	chr7:98997259	C/T	cg18809830	chr7:99032528	PTCD1	-1.12	-8.16	-0.41	7.01e-15	Blood metabolite levels;
CRC	trans	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg05117785	chr10:94050880	CPEB3;MARCH5	-0.43	-6.13	-0.32	2.47e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg17346650	chr17:80929145	B3GNTL1	0.47	6.84	0.35	3.82e-11	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27056425	chr6:27776039	HIST1H2AI;HIST1H2BL	0.4	6.22	0.32	1.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg19337854	chr7:99768885	GPC2	0.44	5.89	0.31	9.65e-9	Lung function (FEV1/FVC);
CRC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.5	7.36	0.38	1.49e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9549328	0.565	rs35988856	chr13:113617427	T/C	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.7e-13	Systolic blood pressure;
CRC	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg09760422	chr2:128146352	NA	-0.37	-7.15	-0.37	5.52e-12	Protein C levels;
CRC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg18479299	chr3:125709523	NA	-0.52	-6.75	-0.35	6.59e-11	Blood pressure (smoking interaction);
CRC	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg26893134	chr6:116381904	FRK	0.26	6.34	0.33	7.59e-10	Total cholesterol levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16558908	chr1:33896237	NA	0.4	6.85	0.35	3.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.53	9.27	0.46	2.46e-18	Hypertriglyceridemia;
CRC	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg07617317	chr6:118971624	C6orf204	0.5	5.9	0.31	8.8e-9	Diastolic blood pressure;
CRC	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.78	10.83	0.51	1.42e-23	Obesity;Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18604876	chr3:5164258	ARL8B	0.45	7.11	0.36	7.36e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg16486109	chr11:613632	IRF7	0.59	10.51	0.5	1.82e-22	Systemic lupus erythematosus;
CRC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.51	5.63	0.3	3.96e-8	Vitiligo;
CRC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg19193384	chr17:30244184	NA	-0.49	-6.72	-0.35	8.09e-11	Hip circumference adjusted for BMI;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19315081	chr11:10326100	ADM	0.45	6.15	0.32	2.25e-9	Thyroid stimulating hormone;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00368989	chr15:59949771	GTF2A2	0.37	6.12	0.32	2.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.5	-7.29	-0.37	2.34e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg24159697	chr1:205181237	DSTYK	-0.33	-6.01	-0.31	4.83e-9	Schizophrenia;
CRC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.62	8.84	0.44	5.9e-17	Breast cancer;
CRC	cis	rs7680126	0.596	rs11722185	chr4:10317482	C/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.73	-0.35	7.55e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26801843	chr11:34073061	CAPRIN1	0.53	6.94	0.36	2.14e-11	Thyroid stimulating hormone;
CRC	cis	rs6735179	0.729	rs2382561	chr2:1763501	C/T	cg19300414	chr2:1746591	PXDN	0.34	6.11	0.32	2.8e-9	Response to antipsychotic treatment;
CRC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.94	0.4	3.17e-14	Aortic root size;
CRC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.4	7.67	0.39	2e-13	Ulcerative colitis;
CRC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.64	11.02	0.52	2.98e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	20.18	0.74	1.67e-59	Prudent dietary pattern;
CRC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.53	-9.31	-0.46	1.89e-18	Dupuytren's disease;
CRC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg21153622	chr11:89784906	NA	-0.49	-8.32	-0.42	2.37e-15	Coronary artery disease;
CRC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.0	0.52	3.58e-24	Monocyte percentage of white cells;
CRC	cis	rs45544231	0.569	rs9933556	chr16:52548302	C/T	cg09051775	chr16:52580266	TOX3	-0.38	-6.16	-0.32	2.15e-9	Restless legs syndrome;
CRC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	7.99	0.4	2.28e-14	Lung cancer in ever smokers;
CRC	cis	rs60871478	0.786	rs7807878	chr7:833878	T/C	cg05535760	chr7:792225	HEATR2	-0.99	-12.31	-0.56	6.71e-29	Cerebrospinal P-tau181p levels;
CRC	trans	rs11165623	0.602	rs12120893	chr1:97007132	C/T	cg10631902	chr5:14652156	NA	-0.37	-6.13	-0.32	2.54e-9	Hip circumference;Waist circumference;
CRC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.66e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.44	-6.45	-0.34	3.94e-10	IgG glycosylation;
CRC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.88	-11.06	-0.52	2.22e-24	Vitiligo;
CRC	trans	rs531930	0.563	rs332607	chr6:124723354	C/T	cg04130557	chr4:186760378	SORBS2	0.46	6.05	0.32	3.85e-9	Celiac disease;
CRC	cis	rs10486722	0.603	rs10282595	chr7:41771004	T/G	cg22138096	chr7:41772439	LOC285954	0.38	5.8	0.3	1.58e-8	Pit-and-Fissure caries;
CRC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.5	-10.11	-0.49	4.04e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05918679	chr19:49122382	RPL18;SPHK2	0.41	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.74	12.57	0.57	7.46e-30	Body mass index;
CRC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-16.27	-0.67	4.48e-44	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06438815	chr21:46292710	PTTG1IP	0.43	6.39	0.33	5.51e-10	Response to antipsychotic treatment;
CRC	cis	rs524281	0.861	rs485857	chr11:65959519	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.99	-0.31	5.5e-9	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01906197	chr14:23067002	ABHD4	0.51	6.79	0.35	5.22e-11	Thyroid stimulating hormone;
CRC	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.52	-6.68	-0.35	1e-10	Testicular germ cell tumor;Testicular germ cell cancer;
CRC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg00343986	chr7:65444356	GUSB	0.49	7.22	0.37	3.53e-12	Aortic root size;
CRC	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.81	0.3	1.5e-8	Morning vs. evening chronotype;
CRC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg12064134	chr16:90016061	DEF8	-0.68	-6.02	-0.32	4.6e-9	Skin colour saturation;
CRC	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.4	5.71	0.3	2.58e-8	Daytime sleep phenotypes;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg21620606	chr4:1342894	KIAA1530	0.39	6.69	0.35	9.78e-11	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09209803	chr6:33588932	ITPR3	0.43	6.46	0.34	3.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.6	-9.65	-0.47	1.4e-19	Aortic root size;
CRC	cis	rs2982552	0.773	rs11155808	chr6:152056050	C/A	cg22157087	chr6:152012887	ESR1	0.37	5.66	0.3	3.31e-8	Bone properties (heel);
CRC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg04731861	chr2:219085781	ARPC2	0.3	5.71	0.3	2.54e-8	Colorectal cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07079421	chr22:46933261	CELSR1	-0.43	-6.84	-0.35	3.91e-11	Aortic root size;
CRC	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	5.82	0.31	1.4e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg15654264	chr1:150340011	RPRD2	0.4	5.72	0.3	2.36e-8	Migraine;
CRC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg05044414	chr3:183734942	ABCC5	0.48	8.32	0.42	2.4e-15	Anterior chamber depth;
CRC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.41	6.61	0.34	1.52e-10	Platelet count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08631137	chr12:65003794	RASSF3	0.46	6.68	0.35	1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.61	-9.56	-0.47	2.86e-19	Height;
CRC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg15145296	chr3:125709740	NA	-0.59	-6.99	-0.36	1.54e-11	Blood pressure (smoking interaction);
CRC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.46	-0.5	2.59e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	9.72	0.47	8.36e-20	Schizophrenia;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg22704520	chr2:200820451	C2orf60;C2orf47	-0.59	-6.01	-0.31	4.85e-9	Plasma thyroid-stimulating hormone levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14274609	chr10:123687846	ATE1	0.45	7.05	0.36	1.03e-11	Schizophrenia;
CRC	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.64	-10.12	-0.49	4.04e-21	Itch intensity from mosquito bite;
CRC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg12273811	chr6:28175739	NA	-0.38	-5.83	-0.31	1.35e-8	Pubertal anthropometrics;
CRC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2274273	0.624	rs7154796	chr14:55771458	T/C	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.74	-0.3	2.18e-8	Protein biomarker;
CRC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	6.6	0.34	1.62e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.67	9.72	0.47	8.8e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg04553112	chr3:125709451	NA	-0.48	-6.14	-0.32	2.33e-9	Blood pressure (smoking interaction);
CRC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.8	0.63	2.35e-38	Chronic sinus infection;
CRC	cis	rs4664293	0.647	rs4635484	chr2:160454130	T/C	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.35	-6.24	-0.33	1.36e-9	Pneumonia;
CRC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.45	-6.56	-0.34	2.04e-10	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.22	0.37	3.66e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.57	7.29	0.37	2.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12541635	0.966	rs2132471	chr8:107000963	G/A	cg10147462	chr8:107024639	NA	0.42	6.99	0.36	1.49e-11	Age of smoking initiation;
CRC	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.61	9.83	0.48	3.58e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.67	7.0	0.36	1.41e-11	Blood protein levels;
CRC	trans	rs2303319	0.504	rs62187612	chr2:162432494	A/G	cg04269497	chr6:167369491	RNASET2	-0.75	-5.99	-0.31	5.54e-9	Cognitive function;
CRC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.5	-7.75	-0.39	1.14e-13	Aortic root size;
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-6.12	-0.32	2.7e-9	Metabolite levels;
CRC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.48	-5.85	-0.31	1.2e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.57	7.56	0.38	4e-13	IgG glycosylation;
CRC	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.73	-9.61	-0.47	1.99e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg24531977	chr5:56204891	C5orf35	-0.45	-6.83	-0.35	4e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.42	-0.33	4.74e-10	Aortic root size;
CRC	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg16576597	chr16:28551801	NUPR1	0.46	6.44	0.33	4.28e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg25804541	chr17:80189381	SLC16A3	0.3	5.78	0.3	1.69e-8	Life satisfaction;
CRC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.86	-0.31	1.13e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4352210	0.963	rs7589042	chr2:37761495	C/T	cg13134662	chr9:136858680	VAV2	-0.41	-6.01	-0.31	4.89e-9	RR interval (heart rate);
CRC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.56	-0.38	4.13e-13	Morning vs. evening chronotype;
CRC	cis	rs501120	0.584	rs61857482	chr10:44716905	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.37	2.37e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.46	7.14	0.37	5.85e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.68	13.44	0.6	4.03e-33	Height;
CRC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.6	8.36	0.42	1.74e-15	Arsenic metabolism;
CRC	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.48	-7.63	-0.39	2.58e-13	Testicular germ cell tumor;
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.42	5.9	0.31	8.85e-9	Longevity;
CRC	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.56	7.31	0.37	2.05e-12	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CRC	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg17133734	chr15:86042851	AKAP13	0.42	6.86	0.35	3.32e-11	Coronary artery disease;
CRC	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.52	-7.42	-0.38	9.82e-13	Caudate activity during reward;
CRC	cis	rs10463316	0.817	rs10052992	chr5:150788602	C/T	cg03212797	chr5:150827313	SLC36A1	-0.4	-6.26	-0.33	1.23e-9	Metabolite levels (Pyroglutamine);
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.1	-0.32	3.05e-9	Total body bone mineral density;
CRC	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg01475377	chr6:109611718	NA	-0.36	-6.24	-0.33	1.34e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.55	8.16	0.41	7.26e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21028142	chr17:79581711	NPLOC4	0.33	6.96	0.36	1.81e-11	Eye color traits;
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13047869	chr3:10149882	C3orf24	0.51	6.52	0.34	2.67e-10	Alzheimer's disease;
CRC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.75	13.11	0.59	7.27e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-7.72	-0.39	1.42e-13	Major depressive disorder;
CRC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg16476235	chr8:21771668	DOK2	0.42	7.35	0.38	1.6e-12	Mean corpuscular volume;
CRC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-5.93	-0.31	7.72e-9	Migraine;Coronary artery disease;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Depression;
CRC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.65	9.84	0.48	3.51e-20	Pancreatic cancer;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg02683197	chr6:28174875	NA	0.48	6.72	0.35	8e-11	Cardiac Troponin-T levels;
CRC	cis	rs7617773	0.823	rs9839447	chr3:48194667	T/C	cg11946769	chr3:48343235	NME6	-0.51	-6.83	-0.35	4.12e-11	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-7.47	-0.38	7.42e-13	Bronchopulmonary dysplasia;
CRC	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.64	7.0	0.36	1.48e-11	Prostate cancer;
CRC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.36	-6.1	-0.32	2.92e-9	Childhood ear infection;
CRC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	11.89	0.55	2.31e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.52	-9.55	-0.47	3.19e-19	Longevity;Endometriosis;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg10868875	chr11:61596307	FADS2	-0.53	-6.36	-0.33	6.8e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.58	11.34	0.53	2.23e-25	Asthma (sex interaction);
CRC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.77	0.44	9.87e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg19401529	chr3:49056140	DALRD3	0.53	6.05	0.32	3.92e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CRC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.82	-0.31	1.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg09760422	chr2:128146352	NA	-0.32	-6.22	-0.32	1.52e-9	Protein C levels;
CRC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-14.65	-0.63	9.13e-38	Blood metabolite levels;
CRC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.78	-0.35	5.52e-11	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.52	7.92	0.4	3.8e-14	Lung cancer;
CRC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.92	0.58	3.51e-31	Alzheimer's disease;
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.47	7.62e-20	Intelligence (multi-trait analysis);
CRC	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.6	8.78	0.44	9.2e-17	Crohn's disease;
CRC	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.97	-12.68	-0.57	2.93e-30	Exhaled nitric oxide output;
CRC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.25	-0.33	1.29e-9	Mean corpuscular volume;
CRC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.12	14.43	0.62	6.27e-37	Vitiligo;
CRC	cis	rs755249	0.567	rs16825942	chr1:39662618	G/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.93	-0.31	7.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-8.25	-0.41	3.78e-15	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.79	-0.44	8.6e-17	Morning vs. evening chronotype;
CRC	cis	rs17234274	0.607	rs1482712	chr11:23218177	G/T	cg05245346	chr11:23248277	NA	0.36	5.92	0.31	8.22e-9	Cancer;
CRC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg07952391	chr2:88470173	THNSL2	0.66	6.66	0.34	1.15e-10	Plasma clusterin levels;
CRC	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg23627948	chr7:2760692	NA	0.47	5.62	0.3	3.98e-8	Childhood ear infection;
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg13047869	chr3:10149882	C3orf24	0.52	7.07	0.36	9.6e-12	Alzheimer's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg10047026	chr17:4613992	ARRB2	0.37	6.21	0.32	1.62e-9	Obesity-related traits;
CRC	cis	rs9583531	0.891	rs9521911	chr13:111370615	A/G	cg24331049	chr13:111365604	ING1	-0.62	-6.66	-0.34	1.14e-10	Coronary artery disease;
CRC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-6.59	-0.34	1.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.65	11.35	0.53	1.97e-25	Prostate cancer;
CRC	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg25344623	chr2:136566232	LCT	0.33	5.98	0.31	5.97e-9	Mosquito bite size;
CRC	cis	rs6694672	1.000	rs4915313	chr1:197049355	G/T	cg13682187	chr1:196946512	CFHR5	0.42	6.81	0.35	4.73e-11	Asthma;
CRC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.42	-6.19	-0.32	1.83e-9	Reticulocyte count;
CRC	cis	rs2327429	0.541	rs12193973	chr6:134151297	A/G	cg06643013	chr6:134217242	NA	-0.39	-6.35	-0.33	7.15e-10	Coronary artery disease;
CRC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg17724175	chr1:150552817	MCL1	0.43	6.6	0.34	1.63e-10	Tonsillectomy;
CRC	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg23920097	chr1:209922102	NA	-0.54	-6.69	-0.35	9.65e-11	Red blood cell count;
CRC	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg25856811	chr1:152973957	SPRR3	-0.22	-5.96	-0.31	6.65e-9	Inflammatory skin disease;
CRC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.4	-5.98	-0.31	5.7e-9	Crohn's disease;
CRC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.61	-0.3	4.37e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg25452165	chr22:42524984	CYP2D6	0.39	5.99	0.31	5.38e-9	Schizophrenia;
CRC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.66	10.26	0.49	1.28e-21	Methadone dose in opioid dependence;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg15845792	chr6:28175446	NA	0.65	9.11	0.45	7.98e-18	Parkinson's disease;
CRC	cis	rs2882667	0.690	rs9327830	chr5:138272249	T/C	cg09476006	chr5:138032270	NA	0.58	10.03	0.48	7.68e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.98	-0.44	2.14e-17	Bone mineral density;
CRC	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma (childhood onset);
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.29e-9	Depression;
CRC	trans	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg10075436	chr19:59084928	MZF1;LOC100131691	-0.45	-6.01	-0.31	4.84e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg24375607	chr4:120327624	NA	0.47	7.47	0.38	7.33e-13	Corneal astigmatism;
CRC	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg10820045	chr2:198174542	NA	0.41	6.93	0.36	2.2e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.85	11.59	0.54	2.91e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	1.1	10.53	0.5	1.49e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7259376	0.902	rs8100087	chr19:22601359	G/C	cg02657401	chr19:22469223	NA	0.31	6.65	0.34	1.23e-10	Menopause (age at onset);
CRC	cis	rs997295	0.570	rs11632574	chr15:67852405	A/C	cg24247231	chr15:67904302	MAP2K5	-0.34	-5.96	-0.31	6.63e-9	Motion sickness;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-9.04	-0.45	1.41e-17	Electroencephalogram traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03586379	chr3:140660603	SLC25A36	-0.42	-6.31	-0.33	9.06e-10	Myopia (pathological);
CRC	cis	rs12541635	0.902	rs13277300	chr8:107062819	C/T	cg10147462	chr8:107024639	NA	-0.39	-6.64	-0.34	1.3e-10	Age of smoking initiation;
CRC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-7.48	-0.38	6.75e-13	Bipolar disorder;
CRC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.6	-11.08	-0.52	1.8e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg12856521	chr11:46389249	DGKZ	-0.42	-6.92	-0.36	2.33e-11	Leprosy;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.55	-10.27	-0.49	1.19e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.08	-0.36	8.91e-12	Gut microbiome composition (summer);
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.52	8.16	0.41	7.29e-15	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg01305625	chr5:131593812	PDLIM4	0.32	5.66	0.3	3.34e-8	Acylcarnitine levels;
CRC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.42	-6.18	-0.32	1.87e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.04e-32	Depression;
CRC	trans	rs2211560	0.507	rs677669	chr1:61287632	A/C	cg21640187	chr6:4282172	NA	0.3	6.04	0.32	4.28e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CRC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.66	8.74	0.43	1.21e-16	Gut microbiome composition (summer);
CRC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.47	6.88	0.35	2.94e-11	Bone properties (heel);
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg08989290	chr16:615782	NHLRC4	0.48	9.14	0.45	6.5e-18	Height;
CRC	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.6	8.23	0.41	4.47e-15	Kawasaki disease;
CRC	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg15654264	chr1:150340011	RPRD2	0.38	5.95	0.31	7.02e-9	Migraine;
CRC	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs370915	0.549	rs1367933	chr4:187776591	C/T	cg12892747	chr4:187813459	NA	-0.56	-8.12	-0.41	9.57e-15	Gout;
CRC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg05623727	chr3:50126028	RBM5	-0.46	-7.62	-0.39	2.67e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.44	6.82	0.35	4.49e-11	Corneal astigmatism;
CRC	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.62	12.55	0.57	9.05e-30	Neuroticism;
CRC	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg13385794	chr1:248469461	NA	0.39	6.86	0.35	3.32e-11	Common traits (Other);
CRC	cis	rs9649465	1.000	rs10215466	chr7:123326044	G/T	cg03229431	chr7:123269106	ASB15	-0.36	-5.64	-0.3	3.7e-8	Migraine;
CRC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.07	9.18	0.45	4.96e-18	Plateletcrit;
CRC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.4	0.5	4.25e-22	Ileal carcinoids;
CRC	cis	rs10849893	0.557	rs6489812	chr12:121913559	T/A	cg01154721	chr12:121881891	KDM2B	0.44	6.19	0.32	1.81e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.73	10.16	0.49	2.86e-21	Alzheimer's disease;
CRC	cis	rs1800795	0.530	rs7805828	chr7:22758562	A/G	cg05472934	chr7:22766657	IL6	-0.43	-6.21	-0.32	1.57e-9	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CRC	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.49	6.64	0.34	1.29e-10	Obesity-related traits;
CRC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.39	-6.6	-0.34	1.61e-10	Primary biliary cholangitis;
CRC	cis	rs12745968	0.590	rs2391195	chr1:93218683	A/G	cg17283838	chr1:93427260	FAM69A	-0.44	-6.05	-0.32	3.98e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.22	-16.66	-0.68	1.26e-45	Breast cancer;
CRC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.75	-14.96	-0.64	5.75e-39	Prostate cancer;
CRC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.7	-0.39	1.56e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.47	6.38	0.33	6.16e-10	Cholesterol, total;
CRC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg20119798	chr7:94954144	PON1	-0.5	-6.41	-0.33	5.17e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg11693508	chr17:37793320	STARD3	0.61	7.03	0.36	1.23e-11	Bipolar disorder;
CRC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	7.49	0.38	6.27e-13	Parkinson's disease;
CRC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.12	-0.37	7.02e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.74	-13.44	-0.6	3.86e-33	Cancer;
CRC	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.72	12.03	0.55	7.11e-28	Colorectal cancer;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01145398	chr10:135075451	NA	-0.4	-6.0	-0.31	5.22e-9	Myopia (pathological);
CRC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.57	-0.38	3.88e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.54	-8.93	-0.44	3.1e-17	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.44	6.67	0.35	1.06e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg14847009	chr1:175162515	KIAA0040	0.3	6.67	0.34	1.11e-10	Diastolic blood pressure;
CRC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.53	12.15	0.56	2.66e-28	Breast cancer;
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg03037974	chr15:76606532	NA	0.65	11.09	0.52	1.77e-24	Blood metabolite levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21151883	chr4:7044737	CCDC96;TADA2B	0.39	5.99	0.31	5.42e-9	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-14.68	-0.63	7.22e-38	Height;
CRC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.61	-8.96	-0.44	2.43e-17	Diastolic blood pressure;
CRC	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.39	-6.15	-0.32	2.21e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs17443541	0.507	rs6753800	chr2:200462959	G/C	cg03741458	chr2:200468445	NA	-0.37	-5.85	-0.31	1.18e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7849270	1.000	rs713219	chr9:131900920	T/C	cg13538475	chr9:131942899	NA	-0.33	-6.32	-0.33	8.52e-10	Blood metabolite ratios;
CRC	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.66	10.5	0.5	2.02e-22	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20908614	chr3:130613463	ATP2C1	0.42	6.05	0.32	3.84e-9	Intelligence (multi-trait analysis);
CRC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.88	0.48	2.51e-20	Heart rate;
CRC	cis	rs9462027	0.628	rs9469892	chr6:34769101	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.06	-0.32	3.75e-9	Systemic lupus erythematosus;
CRC	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg10483660	chr13:112241077	NA	0.35	5.62	0.3	4.14e-8	Menarche (age at onset);
CRC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.01	-0.36	1.32e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg04165759	chr1:150448943	RPRD2	0.36	5.85	0.31	1.18e-8	Migraine;
CRC	cis	rs6694672	0.867	rs7523013	chr1:197153188	A/G	cg13682187	chr1:196946512	CFHR5	0.52	7.88	0.4	4.81e-14	Asthma;
CRC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg13628971	chr7:2884303	GNA12	0.39	6.07	0.32	3.51e-9	Height;
CRC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg10876282	chr6:28092338	ZSCAN16	0.47	5.74	0.3	2.12e-8	Parkinson's disease;
CRC	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg16898833	chr6:26189333	HIST1H4D	0.87	6.41	0.33	5.05e-10	Lung cancer in ever smokers;
CRC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.69	-10.81	-0.51	1.67e-23	Blood protein levels;
CRC	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.39	-0.38	1.19e-12	Intelligence (multi-trait analysis);
CRC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg06204229	chr3:52865917	ITIH4	0.49	5.7	0.3	2.61e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.55	6.76	0.35	6.4e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.69	9.12	0.45	7.92e-18	High light scatter reticulocyte count;
CRC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.56	-9.37	-0.46	1.24e-18	Personality dimensions;
CRC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.5	8.54	0.43	4.95e-16	Coronary artery disease;
CRC	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.38	-6.42	-0.33	4.69e-10	Menopause (age at onset);
CRC	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-6.78	-0.35	5.7e-11	Response to antipsychotic treatment;
CRC	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg02927042	chr1:21476669	EIF4G3	0.41	6.47	0.34	3.62e-10	Superior frontal gyrus grey matter volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19936585	chr2:139259770	SPOPL	0.38	6.1	0.32	2.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg10760299	chr15:45669010	GATM	0.5	8.03	0.41	1.7e-14	Homoarginine levels;
CRC	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.97	-0.36	1.7e-11	Inflammatory skin disease;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg15845792	chr6:28175446	NA	0.58	8.25	0.41	3.8e-15	Parkinson's disease;
CRC	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.01	-0.31	4.88e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.84	-0.31	1.23e-8	Carotid intima media thickness;
CRC	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.48	-7.8	-0.4	8.12e-14	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08806622	chr17:27279525	PHF12	0.4	6.45	0.34	3.92e-10	Obesity-related traits;
CRC	cis	rs1539053	0.932	rs1404384	chr1:58109829	A/G	cg20292791	chr1:58089357	DAB1	0.36	6.22	0.32	1.52e-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs3026101	0.671	rs9789012	chr17:5301070	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg11271282	chr2:238384023	NA	0.46	6.01	0.31	4.99e-9	Prostate cancer;
CRC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg14828511	chr1:107599125	PRMT6	0.43	6.38	0.33	6.17e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg23009290	chr3:125982568	NA	0.35	6.33	0.33	8.23e-10	Migraine;
CRC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.38	8.34	0.42	2.06e-15	Eye color traits;
CRC	trans	rs6956675	0.534	rs1806453	chr7:62641533	A/G	cg01314568	chr7:57830625	NA	0.43	6.41	0.33	5.19e-10	Obesity-related traits;
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.82	0.31	1.36e-8	Life satisfaction;
CRC	cis	rs7605827	0.930	rs3805106	chr2:15535863	C/G	cg19274914	chr2:15703543	NA	0.4	6.03	0.32	4.39e-9	Educational attainment (years of education);
CRC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.47	8.65	0.43	2.32e-16	Childhood ear infection;
CRC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.63	8.89	0.44	3.98e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.49	-6.87	-0.35	3.14e-11	Coronary artery disease;
CRC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg09491104	chr22:46646882	C22orf40	-0.42	-6.55	-0.34	2.27e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg09491104	chr22:46646882	C22orf40	-0.43	-7.13	-0.37	6.59e-12	LDL cholesterol;Cholesterol, total;
CRC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	1.09	10.3	0.49	9.83e-22	Parkinson's disease;
CRC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.63	-8.01	-0.4	1.95e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6141769	0.542	rs28456308	chr20:31273747	C/T	cg13636640	chr20:31349939	DNMT3B	-0.38	-5.74	-0.3	2.13e-8	Subjective well-being;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13555728	chr17:77071390	ENGASE	0.5	7.19	0.37	4.33e-12	Anxiety disorder;
CRC	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg16386425	chr10:429943	DIP2C	0.39	5.75	0.3	2.08e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.57	8.53	0.43	5.6e-16	Migraine;Coronary artery disease;
CRC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	trans	rs7310309	0.943	rs2307220	chr12:79985874	A/C	cg25189608	chr11:96117844	CCDC82	-0.43	-6.0	-0.31	5.23e-9	Classic bladder exstrophy;
CRC	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs73200209	0.869	rs55862915	chr12:116695932	G/A	cg01776926	chr12:116560359	MED13L	-0.47	-5.8	-0.3	1.52e-8	Total body bone mineral density;
CRC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.37	-6.7	-0.35	9.15e-11	Menarche (age at onset);
CRC	cis	rs11191205	0.686	rs10786643	chr10:103394041	A/G	cg15320455	chr10:103880129	LDB1	0.52	5.76	0.3	1.92e-8	Intelligence (multi-trait analysis);
CRC	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg01993067	chr11:68851601	TPCN2	0.56	6.33	0.33	7.99e-10	Blond vs. brown hair color;
CRC	trans	rs10269006	0.613	rs6953258	chr7:94375808	C/T	cg05903386	chr2:217555456	IGFBP5	-0.37	-6.12	-0.32	2.67e-9	Breast cancer;
CRC	cis	rs7429990	0.896	rs34448818	chr3:47841312	G/A	cg11946769	chr3:48343235	NME6	0.56	6.43	0.33	4.52e-10	Educational attainment (years of education);
CRC	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.46	5.79	0.3	1.65e-8	Systolic blood pressure;
CRC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.46	6.94	0.36	2.03e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.85	-10.64	-0.51	6.44e-23	Iron status biomarkers;
CRC	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.27	0.33	1.16e-9	Bipolar disorder;
CRC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.44	7.13	0.37	6.56e-12	Response to antineoplastic agents;
CRC	trans	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.6	-0.34	1.62e-10	High light scatter reticulocyte count;
CRC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02725872	chr8:58115012	NA	-0.39	-6.63	-0.34	1.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg12908607	chr1:44402522	ARTN	-0.42	-6.94	-0.36	2.04e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg09163369	chr1:210001066	C1orf107	0.41	5.77	0.3	1.85e-8	Orofacial clefts;
CRC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg19193384	chr17:30244184	NA	-0.58	-7.01	-0.36	1.33e-11	Hip circumference adjusted for BMI;
CRC	trans	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.48	-6.22	-0.32	1.52e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg07699608	chr10:75541558	CHCHD1	0.59	6.08	0.32	3.34e-9	Incident atrial fibrillation;
CRC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg13198984	chr17:80129470	CCDC57	0.42	7.29	0.37	2.32e-12	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20905746	chr15:79165638	MORF4L1	0.48	6.93	0.36	2.18e-11	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg12172441	chr6:28176163	NA	0.5	6.87	0.35	3.2e-11	Parkinson's disease;
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg24046110	chr8:143859143	LYNX1	0.48	8.28	0.42	3.03e-15	Urinary tract infection frequency;
CRC	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg02751453	chr18:77725136	HSBP1L1	0.46	5.69	0.3	2.8e-8	Opioid sensitivity;
CRC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.33	0.33	8.26e-10	Bipolar disorder;
CRC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	5.87	0.31	1.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.72	10.62	0.51	7.31e-23	Immature fraction of reticulocytes;
CRC	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg18165381	chr3:44552316	NA	-0.39	-5.75	-0.3	2.01e-8	Depressive symptoms;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01911186	chr12:12765398	CREBL2	0.51	7.38	0.38	1.28e-12	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.53	-7.2	-0.37	4.05e-12	Gut microbiome composition (summer);
CRC	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg24519413	chr1:26490540	NA	0.45	7.35	0.38	1.57e-12	Height;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg12172441	chr6:28176163	NA	-0.44	-6.38	-0.33	6.13e-10	Cardiac Troponin-T levels;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg15786705	chr6:28176104	NA	0.6	8.62	0.43	2.91e-16	Parkinson's disease;
CRC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.47	-9.09	-0.45	9.81e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg11130432	chr3:121712080	ILDR1	-0.52	-6.81	-0.35	4.73e-11	Multiple sclerosis;
CRC	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg02353165	chr6:42928485	GNMT	0.54	6.96	0.36	1.9e-11	Blood protein levels;
CRC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg27523141	chr10:43048294	ZNF37B	0.47	6.74	0.35	7.02e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.61	-0.54	2.41e-26	Type 2 diabetes;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg11843238	chr5:131593191	PDLIM4	0.43	8.17	0.41	6.75e-15	Breast cancer;
CRC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg18016565	chr1:150552671	MCL1	0.44	6.17	0.32	2.03e-9	Melanoma;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg20908204	chr19:46285434	DMPK	0.33	7.45	0.38	8.47e-13	Coronary artery disease;
CRC	cis	rs2573652	0.657	rs2573668	chr15:100541776	C/T	cg00587665	chr15:100533223	ADAMTS17	0.33	5.73	0.3	2.21e-8	Height;
CRC	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.67	-8.52	-0.43	5.75e-16	Dementia with Lewy bodies;
CRC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg16235748	chr6:149772707	ZC3H12D	0.37	6.65	0.34	1.25e-10	Dupuytren's disease;
CRC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.89	-0.4	4.41e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3764400	0.507	rs16954324	chr17:46324584	C/T	cg10706073	chr17:46328419	SKAP1	-0.65	-6.83	-0.35	4.09e-11	Body mass index;
CRC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.63	10.19	0.49	2.26e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-6.51	-0.34	2.8e-10	Bipolar disorder;
CRC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.16	-16.87	-0.68	1.93e-46	Hip circumference adjusted for BMI;
CRC	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg06606381	chr12:133084897	FBRSL1	-1.45	-11.27	-0.53	4.09e-25	Depression;
CRC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.4	-5.75	-0.3	1.99e-8	IgG glycosylation;
CRC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-6.42	-0.33	4.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg22809023	chr3:195622598	TNK2	0.43	5.61	0.3	4.38e-8	Pancreatic cancer;
CRC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	10.12	0.49	3.89e-21	Prudent dietary pattern;
CRC	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg12458913	chr13:53173898	NA	0.79	14.63	0.63	1.12e-37	Lewy body disease;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg22677401	chr17:46026860	NA	-0.67	-6.09	-0.32	3.14e-9	Cognitive function;
CRC	trans	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.77	-0.35	5.78e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.4	-5.76	-0.3	1.93e-8	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18450072	chr4:40058936	LOC344967;N4BP2	0.43	6.59	0.34	1.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.53	7.34	0.38	1.63e-12	Longevity;Endometriosis;
CRC	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg15704280	chr7:45808275	SEPT13	-0.47	-6.69	-0.35	9.51e-11	HDL cholesterol;
CRC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.33	-0.42	2.27e-15	Type 2 diabetes;
CRC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.5	6.36	0.33	6.72e-10	Obesity-related traits;
CRC	cis	rs17767392	0.813	rs35831373	chr14:71918421	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.37	-0.33	6.37e-10	Mitral valve prolapse;
CRC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.67	7.7	0.39	1.63e-13	Body mass index;
CRC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg16416165	chr4:3325029	RGS12	0.42	7.15	0.37	5.62e-12	Parental longevity (mother's age at death);
CRC	cis	rs17152411	0.895	rs61872121	chr10:126586795	T/C	cg07906193	chr10:126599966	NA	0.56	6.33	0.33	7.97e-10	Height;
CRC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.88	0.44	4.26e-17	Morning vs. evening chronotype;
CRC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7605827	0.866	rs11678132	chr2:15533998	C/T	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.48	7.11	0.36	7.25e-12	Headache;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15121053	chr7:138818439	TTC26	0.41	6.73	0.35	7.55e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.98	-0.48	1.13e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.44	8.6	0.43	3.2e-16	Iron status biomarkers (transferrin levels);
CRC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-6.18	-0.32	1.88e-9	Total body bone mineral density;
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.45	0.34	3.93e-10	Parkinson's disease;
CRC	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.64	-0.34	1.3e-10	Coronary artery disease;
CRC	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.03e-11	Diisocyanate-induced asthma;
CRC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg00990874	chr7:1149470	C7orf50	-0.51	-6.01	-0.31	5.01e-9	Bronchopulmonary dysplasia;
CRC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg06096015	chr1:231504339	EGLN1	0.4	6.04	0.32	4.19e-9	Hemoglobin concentration;
CRC	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg18827107	chr12:86230957	RASSF9	-0.36	-5.74	-0.3	2.15e-8	Major depressive disorder;
CRC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg13798912	chr7:905769	UNC84A	-0.7	-7.02	-0.36	1.3e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.55	7.58	0.39	3.44e-13	Lymphocyte counts;
CRC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg10589385	chr1:150898437	SETDB1	0.33	6.95	0.36	1.94e-11	Melanoma;
CRC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-11.02	-0.52	2.91e-24	Intelligence (multi-trait analysis);
CRC	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.51	-7.57	-0.39	3.82e-13	Menopause (age at onset);
CRC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.45	-5.71	-0.3	2.47e-8	Aortic root size;
CRC	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-6.98	-0.36	1.68e-11	Coronary artery disease;
CRC	cis	rs8060686	0.858	rs8051587	chr16:67796315	A/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-11.37	-0.53	1.75e-25	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.72	10.6	0.5	9.11e-23	Menarche (age at onset);
CRC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.4	6.59	0.34	1.72e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg24154853	chr7:158122151	PTPRN2	0.51	7.03	0.36	1.2e-11	Response to amphetamines;
CRC	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.07	-0.36	9.51e-12	Inflammatory bowel disease;
CRC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg21620606	chr4:1342894	KIAA1530	0.39	6.81	0.35	4.56e-11	Obesity-related traits;
CRC	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.29	0.33	1e-9	Hair morphology;
CRC	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.45	6.79	0.35	5.1e-11	Neutrophil percentage of white cells;
CRC	cis	rs629535	0.814	rs558511	chr8:70069908	C/A	cg26132723	chr8:70041827	NA	0.35	5.77	0.3	1.8e-8	Dupuytren's disease;
CRC	trans	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg26043149	chr18:55253948	FECH	-0.44	-6.65	-0.34	1.22e-10	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg00490450	chr3:139108681	COPB2	-0.48	-7.19	-0.37	4.3e-12	Obesity-related traits;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg19041857	chr6:27730383	NA	-0.46	-6.36	-0.33	6.68e-10	Parkinson's disease;
CRC	trans	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.52	-0.34	2.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg16540259	chr10:75572220	NDST2	0.51	7.86	0.4	5.61e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.93	-11.91	-0.55	1.88e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20263490	chr11:3013628	NAP1L4	0.46	6.43	0.33	4.57e-10	Anxiety disorder;
CRC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg05585544	chr11:47624801	NA	0.41	6.29	0.33	1.04e-9	Mean corpuscular hemoglobin;
CRC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg20203395	chr5:56204925	C5orf35	-0.71	-8.15	-0.41	7.76e-15	Initial pursuit acceleration;
CRC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-6.26	-0.33	1.19e-9	Vitiligo;
CRC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-6.76	-0.35	6.14e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg08501292	chr6:25962987	TRIM38	0.64	6.14	0.32	2.41e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.47	-0.42	8.45e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13198984	chr17:80129470	CCDC57	-0.48	-8.57	-0.43	3.99e-16	Life satisfaction;
CRC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg05639522	chr1:247681581	NA	0.46	6.98	0.36	1.68e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg20512303	chr5:131592959	PDLIM4	0.3	5.63	0.3	3.84e-8	Breast cancer;
CRC	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	0.64	6.99	0.36	1.54e-11	Prostate cancer;
CRC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-11.16	-0.52	9.34e-25	Platelet distribution width;
CRC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.49	-0.34	3.08e-10	Aortic root size;
CRC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg01483505	chr11:975446	AP2A2	0.41	6.53	0.34	2.48e-10	Alzheimer's disease (late onset);
CRC	cis	rs6504622	0.557	rs10853085	chr17:44995070	G/A	cg16759221	chr17:45003025	GOSR2	0.6	9.67	0.47	1.28e-19	Orofacial clefts;
CRC	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.58	8.03	0.4	1.72e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg24634471	chr8:143751801	JRK	-0.44	-6.26	-0.33	1.2e-9	Urinary tract infection frequency;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg15609273	chr13:50159867	RCBTB1	0.48	6.75	0.35	6.87e-11	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.79	-13.8	-0.61	1.73e-34	Breast cancer;
CRC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg03030879	chr14:75389066	RPS6KL1	0.55	9.12	0.45	7.84e-18	Caffeine consumption;
CRC	cis	rs6834538	0.520	rs17668083	chr4:113422875	C/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.37	-5.8	-0.3	1.55e-8	Free thyroxine concentration;
CRC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.87	10.5	0.5	2e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg21251018	chr6:28226885	NKAPL	0.4	6.01	0.31	4.96e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.62	-11.52	-0.54	5.05e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.59	0.34	1.78e-10	Bipolar disorder;
CRC	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.15	24.03	0.8	2.08e-74	Exhaled nitric oxide output;
CRC	cis	rs600806	0.850	rs4970846	chr1:109946095	A/C	cg23032129	chr1:109941072	SORT1	-0.27	-5.74	-0.3	2.16e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg10756647	chr7:56101905	PSPH	0.73	7.79	0.39	8.9e-14	Diabetic kidney disease;
CRC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.37	-5.65	-0.3	3.57e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.47	6.86	0.35	3.47e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9287719	0.601	rs13427815	chr2:10707985	C/T	cg00105475	chr2:10696890	NA	0.47	7.28	0.37	2.46e-12	Prostate cancer;
CRC	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.49	-6.05	-0.32	3.93e-9	Coronary artery calcification;
CRC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.67	9.96	0.48	1.38e-20	Corneal astigmatism;
CRC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.53	-8.55	-0.43	4.64e-16	Menopause (age at onset);
CRC	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.44	-6.35	-0.33	7.19e-10	Body mass index;
CRC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.48	-6.67	-0.35	1.1e-10	Response to angiotensin II receptor blocker therapy;
CRC	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg21153622	chr11:89784906	NA	-0.45	-7.11	-0.36	7.35e-12	HDL cholesterol;
CRC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.36	0.42	1.84e-15	Menopause (age at onset);
CRC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.82	-0.4	7.43e-14	Height;
CRC	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg08999081	chr20:33150536	PIGU	0.46	5.73	0.3	2.24e-8	Neuroticism;
CRC	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg01426195	chr3:39028469	NA	-0.55	-8.89	-0.44	3.98e-17	Handedness;
CRC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.53	-0.5	1.53e-22	Bone mineral density;
CRC	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.4	5.76	0.3	1.94e-8	Growth-regulated protein alpha levels;
CRC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.58	11.78	0.54	5.93e-27	Information processing speed;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06742493	chr19:13056745	RAD23A	0.45	7.37	0.38	1.41e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.43	8.69	0.43	1.79e-16	Renal cell carcinoma;
CRC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg03013636	chr16:1946785	NA	-0.49	-6.0	-0.31	5.1e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.62	8.94	0.44	2.94e-17	Height;
CRC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.54	8.63	0.43	2.58e-16	Menopause (age at onset);
CRC	cis	rs6066835	0.764	rs2426097	chr20:47385467	C/T	cg18078177	chr20:47281410	PREX1	0.67	5.97	0.31	6.05e-9	Multiple myeloma;
CRC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg25204440	chr1:209979598	IRF6	0.48	5.76	0.3	1.89e-8	Cleft lip with or without cleft palate;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13687825	chr8:101225344	SPAG1	0.44	6.19	0.32	1.81e-9	Anxiety disorder;
CRC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.45	-6.32	-0.33	8.38e-10	Blood pressure (smoking interaction);
CRC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg10760299	chr15:45669010	GATM	0.49	7.72	0.39	1.41e-13	Homoarginine levels;
CRC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.66	10.95	0.52	5.24e-24	Platelet count;
CRC	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.62	-0.43	2.87e-16	Urinary metabolites;
CRC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.79	14.2	0.62	5.14e-36	Mean platelet volume;
CRC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.63	-7.55	-0.38	4.39e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	6.03	0.32	4.43e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.64	8.55	0.43	4.78e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6743226	0.934	rs7565186	chr2:242249822	A/G	cg10021735	chr2:242295487	FARP2	0.47	6.9	0.36	2.73e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.77	13.31	0.59	1.26e-32	Colorectal cancer;
CRC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.56	-0.38	4.18e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6066835	0.867	rs11907586	chr20:47374058	G/A	cg18078177	chr20:47281410	PREX1	0.69	5.89	0.31	9.56e-9	Multiple myeloma;
CRC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.58	-0.43	3.73e-16	Schizophrenia;
CRC	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	7.13	0.37	6.55e-12	Menarche (age at onset);
CRC	cis	rs2227564	0.649	rs2948689	chr10:75657860	A/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.52	-0.38	5.41e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.79	-13.38	-0.59	6.52e-33	Obesity-related traits;
CRC	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.55	0.71	4.31e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6496667	0.865	rs7169251	chr15:90884262	T/C	cg04176472	chr15:90893244	GABARAPL3	0.56	6.49	0.34	3.22e-10	Rheumatoid arthritis;
CRC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.92	13.34	0.59	9.16e-33	Breast cancer;
CRC	cis	rs911119	0.955	rs8115423	chr20:23605253	T/C	cg16589663	chr20:23618590	CST3	0.45	6.35	0.33	7.25e-10	Chronic kidney disease;
CRC	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.41	6.6	0.34	1.6e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.61	-8.47	-0.42	8.09e-16	Blood protein levels;
CRC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	7.28	0.37	2.49e-12	Eye color traits;
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.02	-13.52	-0.6	1.97e-33	Alzheimer's disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16308101	chr1:67895914	SERBP1	0.49	7.75	0.39	1.13e-13	Interleukin-6 levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20647962	chr15:41136443	SPINT1	0.36	5.97	0.31	6.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.43	-6.52	-0.34	2.59e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.39	7.31	0.37	2.1e-12	IgG glycosylation;
CRC	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg13615338	chr4:55094005	PDGFRA	0.43	6.2	0.32	1.73e-9	Corneal astigmatism;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18094551	chr22:20004364	ARVCF	0.4	6.31	0.33	9.05e-10	Schizophrenia;
CRC	cis	rs9969804	0.846	rs912260	chr9:95493279	C/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.95	-0.31	6.73e-9	Height;
CRC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.3	-6.67	-0.35	1.08e-10	IgG glycosylation;
CRC	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-6.26	-0.33	1.19e-9	Schizophrenia;
CRC	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.55	8.17	0.41	6.77e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-0.99	-8.52	-0.43	5.81e-16	Post bronchodilator FEV1;
CRC	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.62	7.73	0.39	1.28e-13	Post bronchodilator FEV1;
CRC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg25164649	chr6:28176230	NA	0.72	7.98	0.4	2.4e-14	Parkinson's disease;
CRC	cis	rs75422866	0.510	rs74733564	chr12:48118427	C/G	cg14736327	chr12:48174669	SLC48A1	-0.72	-5.75	-0.3	2.05e-8	Pneumonia;
CRC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.62	0.39	2.78e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg11632617	chr15:75315747	PPCDC	-0.54	-7.27	-0.37	2.65e-12	Blood trace element (Zn levels);
CRC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.94	0.31	7.17e-9	Hemoglobin concentration;
CRC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg21747405	chr11:67723411	NA	-0.49	-6.32	-0.33	8.59e-10	Blood pressure (smoking interaction);
CRC	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg11887960	chr12:57824829	NA	0.63	6.89	0.36	2.93e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs10743315	0.643	rs75398828	chr12:19340053	T/C	cg02471346	chr12:19282374	PLEKHA5	0.67	6.18	0.32	1.91e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs501120	1.000	rs1746047	chr10:44774086	T/G	cg09554077	chr10:44749378	NA	0.78	11.78	0.54	5.88e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10769945	0.730	rs217208	chr11:1974892	C/G	cg23202291	chr11:1979235	NA	-0.46	-6.57	-0.34	1.93e-10	DNA methylation (variation);
CRC	cis	rs7539542	0.556	rs2000331	chr1:202857578	G/T	cg19681188	chr1:202830198	LOC148709	0.46	6.56	0.34	2.05e-10	Mean platelet volume;
CRC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.99	-0.4	2.36e-14	Gut microbiome composition (summer);
CRC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.6	0.5	8.53e-23	Coronary artery disease;
CRC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-9.51	-0.46	4.08e-19	Prostate cancer;
CRC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.66	10.13	0.49	3.61e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs10046574	0.519	rs112479683	chr7:135203288	G/A	cg27474649	chr7:135195673	CNOT4	0.62	5.97	0.31	6.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.59	-10.79	-0.51	1.87e-23	Intelligence (multi-trait analysis);
CRC	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.95	-13.36	-0.59	7.99e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-1.12	-19.3	-0.73	5.07e-56	Blood pressure (smoking interaction);
CRC	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg19812747	chr11:111475976	SIK2	0.46	7.22	0.37	3.58e-12	Primary sclerosing cholangitis;
CRC	cis	rs61160187	0.582	rs976630	chr5:60215481	A/C	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.94	-0.31	7.36e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.47	7.0	0.36	1.43e-11	Subjective well-being;
CRC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.59	8.8	0.44	7.76e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.45	0.38	8.22e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-13.87	-0.61	9.25e-35	Colorectal cancer;
CRC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.42	6.5	0.34	3.04e-10	Lung function (FEV1/FVC);
CRC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.91	-15.3	-0.64	2.77e-40	Blood metabolite levels;
CRC	cis	rs7089973	0.844	rs10510007	chr10:116636721	A/G	cg23260525	chr10:116636907	FAM160B1	0.31	6.72	0.35	8.05e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.41	-6.55	-0.34	2.28e-10	Bone mineral density (spine);
CRC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg20684491	chr1:25596433	NA	0.43	7.45	0.38	8.23e-13	Erythrocyte sedimentation rate;
CRC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.78	-0.35	5.73e-11	Total cholesterol levels;
CRC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-7.12	-0.37	6.67e-12	Gut microbiome composition (summer);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07003744	chr7:30325402	ZNRF2	0.46	6.04	0.32	4.1e-9	Anxiety disorder;
CRC	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg24342717	chr2:85555507	TGOLN2	-0.51	-7.32	-0.37	1.98e-12	Ear protrusion;
CRC	cis	rs7546094	1.000	rs6682737	chr1:113136229	T/C	cg22162597	chr1:113214053	CAPZA1	0.43	6.08	0.32	3.3e-9	Platelet distribution width;
CRC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.37	0.38	1.41e-12	Menopause (age at onset);
CRC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-12.03	-0.55	6.87e-28	Selective IgA deficiency;
CRC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.59	7.19	0.37	4.35e-12	Body mass index;
CRC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.82	-0.51	1.48e-23	Schizophrenia;
CRC	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.62	-0.43	2.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs11825064	0.549	rs56167774	chr11:134487221	G/T	cg00033773	chr19:12779366	MORG1;C19orf56	0.44	5.96	0.31	6.52e-9	Seasonality;
CRC	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-6.12	-0.32	2.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9462027	0.630	rs2744943	chr6:34643179	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.5e-10	Systemic lupus erythematosus;
CRC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.38	12.29	0.56	7.97e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.86	0.35	3.42e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.7	9.04	0.45	1.37e-17	Alzheimer's disease;
CRC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	10.76	0.51	2.5e-23	Body mass index;
CRC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.62	10.46	0.5	2.7e-22	Colorectal cancer;
CRC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg00129232	chr17:37814104	STARD3	-0.58	-7.26	-0.37	2.74e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.03	-0.36	1.18e-11	Cholesterol, total;
CRC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.43	5.77e-16	Colorectal cancer;
CRC	cis	rs61021925	1	rs61021925	chr12:122863659	T/C	cg23029597	chr12:123009494	RSRC2	0.43	6.16	0.32	2.16e-9	Schizophrenia;
CRC	trans	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg26043149	chr18:55253948	FECH	-0.53	-8.17	-0.41	6.52e-15	Bone mineral density;
CRC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg02869306	chr7:64672164	INTS4L1	-0.38	-6.15	-0.32	2.18e-9	Aortic root size;
CRC	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.78	-0.3	1.7e-8	Blood pressure;
CRC	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.5	7.63	0.39	2.52e-13	Testicular germ cell tumor;
CRC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-6.65	-0.34	1.26e-10	Breast cancer;Breast cancer (early onset);
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg26220594	chr1:19110978	NA	-0.46	-6.68	-0.35	1e-10	Drug-induced liver injury (nitrofurantoin);
CRC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg06470822	chr6:28175283	NA	0.83	6.79	0.35	5.23e-11	Depression;
CRC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07513332	chr6:167530253	CCR6	-0.44	-8.09	-0.41	1.14e-14	Primary biliary cholangitis;
CRC	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.52	-6.15	-0.32	2.22e-9	Coronary artery calcification;
CRC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	0.94	18.72	0.72	9.55e-54	Height;
CRC	trans	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.2	-0.37	4.18e-12	Endometrial cancer;
CRC	cis	rs832187	0.704	rs832195	chr3:63864612	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.44	6.16	0.32	2.16e-9	Schizophrenia;
CRC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-10.83	-0.51	1.44e-23	Height;
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.63	0.57	4.38e-30	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00011284	chr16:53469344	RBL2	0.49	6.46	0.34	3.83e-10	Thyroid stimulating hormone;
CRC	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.46	-6.26	-0.33	1.2e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.51	7.38	0.38	1.34e-12	Type 2 diabetes;
CRC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.59	8.17	0.41	6.78e-15	Menopause (age at onset);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14905632	chr17:38333933	RAPGEFL1	0.4	6.23	0.32	1.45e-9	Myopia (pathological);
CRC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.66	-9.13	-0.45	7.13e-18	Systemic lupus erythematosus;
CRC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02228675	chr17:40259724	DHX58	-0.49	-6.91	-0.36	2.6e-11	Fibrinogen levels;
CRC	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.42	6.48	0.34	3.34e-10	Ovarian reserve;
CRC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.65	-10.01	-0.48	9.07e-21	Diastolic blood pressure;
CRC	cis	rs6445967	1.000	rs7640866	chr3:58288362	A/G	cg23715586	chr3:58305044	RPP14	0.35	5.87	0.31	1.09e-8	Platelet count;
CRC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg06145435	chr7:1022769	CYP2W1	0.38	5.99	0.31	5.37e-9	Bronchopulmonary dysplasia;
CRC	cis	rs9925964	0.622	rs8046707	chr16:30916233	G/A	cg03418659	chr16:31128414	MYST1	0.43	6.18	0.32	1.89e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.6	9.83	0.48	3.69e-20	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg25019722	chr6:37503610	NA	-0.35	-6.07	-0.32	3.49e-9	Cognitive performance;
CRC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.68	10.28	0.49	1.09e-21	Corneal astigmatism;
CRC	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.74	7.95	0.4	3.03e-14	Breast cancer;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg21577049	chr2:228736449	WDR69	-0.44	-5.84	-0.31	1.24e-8	Blood pressure;
CRC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.57	8.45	0.42	9.33e-16	Aortic root size;
CRC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg12100956	chr17:78086420	GAA	-0.36	-5.62	-0.3	4e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.85	0.4	5.82e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3020333	0.875	rs2982573	chr6:152010534	A/G	cg22157087	chr6:152012887	ESR1	0.53	8.06	0.41	1.41e-14	Total body bone mineral density;
CRC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.38	-5.81	-0.3	1.51e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.63	9.85	0.48	3.24e-20	Corneal astigmatism;
CRC	cis	rs12024301	0.557	rs12049175	chr1:183625562	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.89	14.33	0.62	1.64e-36	Body mass index (adult);
CRC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	7.1	0.36	7.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6968419	0.747	rs12670683	chr7:115874466	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.28	-0.33	1.09e-9	Intraocular pressure;
CRC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.52	-9.98	-0.48	1.14e-20	Birth weight;
CRC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-7.47	-0.38	7.17e-13	Colorectal cancer;
CRC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.56	-0.43	4.4e-16	Chronic sinus infection;
CRC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg10589385	chr1:150898437	SETDB1	0.31	6.34	0.33	7.79e-10	Melanoma;
CRC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.89	0.58	4.74e-31	Total body bone mineral density;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10217975	chr3:52091484	DUSP7	-0.4	-6.26	-0.33	1.22e-9	Myopia (pathological);
CRC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-11.47	-0.53	7.86e-26	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg12218747	chr21:37451666	NA	-0.43	-7.3	-0.37	2.22e-12	Mitral valve prolapse;
CRC	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.48	7.65	0.39	2.26e-13	Mean corpuscular hemoglobin concentration;
CRC	trans	rs4853036	0.502	rs6717068	chr2:70009641	A/T	cg14633329	chr9:139640053	LCN6	-0.39	-6.44	-0.33	4.31e-10	Colorectal or endometrial cancer;
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.78e-15	Life satisfaction;
CRC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg23136738	chr11:925521	AP2A2	-0.42	-6.84	-0.35	3.78e-11	Alzheimer's disease (late onset);
CRC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.7	11.04	0.52	2.47e-24	Corneal astigmatism;
CRC	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.59	-9.5	-0.46	4.66e-19	Itch intensity from mosquito bite;
CRC	trans	rs9630182	0.561	rs307246	chr11:13483227	A/G	cg13741668	chr9:85679694	NA	0.37	6.0	0.31	5.31e-9	Bone mineral density;
CRC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg03934865	chr2:198174659	NA	-0.46	-7.07	-0.36	9.19e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg18512352	chr11:47633146	NA	0.36	7.07	0.36	9.23e-12	Subjective well-being;
CRC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.14e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-11.52	-0.54	4.84e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg21153622	chr11:89784906	NA	-0.43	-7.15	-0.37	5.51e-12	Height;
CRC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg18867708	chr6:26865862	GUSBL1	0.37	5.67	0.3	3.09e-8	Schizophrenia;
CRC	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.94	14.15	0.62	7.8e-36	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.66	-6.21	-0.32	1.56e-9	Alzheimer's disease (late onset);
CRC	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.72	-12.62	-0.57	4.66e-30	White blood cell count (basophil);
CRC	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.43	6.13	0.32	2.51e-9	Asthma;
CRC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.54	8.01	0.4	2.02e-14	Breast cancer;
CRC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.65	-8.64	-0.43	2.47e-16	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg25456477	chr12:86230367	RASSF9	0.39	6.45	0.34	3.89e-10	Major depressive disorder;
CRC	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg19041857	chr6:27730383	NA	-0.59	-5.65	-0.3	3.41e-8	Depression;
CRC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Depression;
CRC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.08	0.36	8.73e-12	Testicular germ cell tumor;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.59	-8.39	-0.42	1.44e-15	Menopause (age at onset);
CRC	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg04611788	chr3:186434169	KNG1	-0.57	-8.32	-0.42	2.41e-15	Adiponectin levels;
CRC	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.57	6.82	0.35	4.39e-11	Lymphocyte counts;
CRC	cis	rs1572438	0.929	rs9378520	chr6:861685	C/T	cg21062780	chr6:887772	NA	-0.4	-6.09	-0.32	3.22e-9	Aging;
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg02033258	chr5:131593261	PDLIM4	0.49	8.55	0.43	4.86e-16	Acylcarnitine levels;
CRC	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.52	-6.76	-0.35	6.46e-11	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg23161317	chr6:28129485	ZNF389	0.46	6.42	0.33	4.71e-10	Cardiac Troponin-T levels;
CRC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg15193198	chr20:60906057	LAMA5	0.39	5.91	0.31	8.76e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg19635926	chr16:89946313	TCF25	0.6	5.68	0.3	3.04e-8	Skin colour saturation;
CRC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg13722127	chr7:150037890	RARRES2	0.46	7.49	0.38	6.43e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg17724175	chr1:150552817	MCL1	0.47	6.89	0.36	2.81e-11	Melanoma;
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00166722	chr3:10149974	C3orf24	0.62	8.39	0.42	1.44e-15	Alzheimer's disease;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg21251018	chr6:28226885	NKAPL	0.38	5.74	0.3	2.13e-8	Parkinson's disease;
CRC	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg04733911	chr16:78082701	NA	-0.42	-6.69	-0.35	9.9e-11	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	10.53	0.5	1.58e-22	Motion sickness;
CRC	cis	rs501120	0.584	rs11238927	chr10:44704112	C/T	cg09554077	chr10:44749378	NA	0.67	7.47	0.38	7.27e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	7.13	0.37	6.6e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.11e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.37	-6.09	-0.32	3.09e-9	Blood metabolite levels;
CRC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.35	-7.47	-0.38	7.51e-13	Urinary metabolites;
CRC	cis	rs6563739	0.655	rs10467367	chr13:40227072	A/G	cg00026919	chr13:40226031	NA	0.47	5.85	0.31	1.17e-8	Menarche (age at onset);
CRC	cis	rs7113874	0.569	rs1446463	chr11:8566329	G/A	cg20771178	chr11:8615675	STK33	-0.36	-5.89	-0.31	9.43e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.59	8.3	0.42	2.71e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Parkinson's disease;
CRC	cis	rs7605827	0.930	rs1996517	chr2:15517330	T/C	cg19274914	chr2:15703543	NA	0.39	5.93	0.31	7.51e-9	Educational attainment (years of education);
CRC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-0.63	-5.78	-0.3	1.71e-8	Alzheimer's disease (late onset);
CRC	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg06606381	chr12:133084897	FBRSL1	-0.9	-6.95	-0.36	1.93e-11	Intelligence (multi-trait analysis);
CRC	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.99	18.63	0.72	2.21e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.65	-0.51	5.96e-23	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs12476631	chr2:162566936	A/G	cg12500891	chr11:57225987	NA	-0.67	-6.04	-0.32	4.19e-9	Cognitive function;
CRC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.9	17.78	0.7	4.91e-50	Bone mineral density;
CRC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg10578777	chr12:7781093	NA	-0.46	-6.16	-0.32	2.16e-9	HDL cholesterol levels;
CRC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.81	14.19	0.62	5.71e-36	Breast cancer;
CRC	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.78	-0.3	1.71e-8	Blood pressure;
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.52	-7.11	-0.37	7.08e-12	Intelligence (multi-trait analysis);
CRC	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.39	-6.41	-0.33	5.18e-10	Airway imaging phenotypes;
CRC	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.64	7.51	0.38	5.53e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg07166546	chr14:35805898	NA	-0.31	-5.95	-0.31	6.89e-9	Psoriasis;
CRC	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg00277334	chr10:82204260	NA	0.36	5.86	0.31	1.11e-8	Sarcoidosis;
CRC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg10820045	chr2:198174542	NA	-0.57	-11.46	-0.53	8.38e-26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg10517650	chr3:113235015	CCDC52	-0.4	-6.97	-0.36	1.73e-11	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.13	0.32	2.58e-9	Diabetic kidney disease;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02290350	chr8:58132656	NA	0.53	7.74	0.39	1.27e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	6.74	0.35	7.13e-11	Adiposity;
CRC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg18827107	chr12:86230957	RASSF9	0.37	6.11	0.32	2.76e-9	Major depressive disorder;
CRC	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.51	-0.34	2.82e-10	Coronary artery calcification;
CRC	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.86	-16.4	-0.67	1.31e-44	Hip circumference;
CRC	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	1.09	12.84	0.58	7.36e-31	Obesity-related traits;
CRC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.21	-0.32	1.64e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg00292047	chr11:33279899	HIPK3	0.6	6.36	0.33	6.86e-10	Body mass index;
CRC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.8e-9	Aortic root size;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg25204440	chr1:209979598	IRF6	0.48	6.32	0.33	8.36e-10	Cleft lip with or without cleft palate;
CRC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.88	12.45	0.57	1.97e-29	Blood trace element (Zn levels);
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg12516270	chr8:143859308	LYNX1	-0.51	-9.26	-0.45	2.68e-18	Urinary tract infection frequency;
CRC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	1.01	10.65	0.51	5.9e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7739232	0.920	rs79752040	chr6:53527285	A/G	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.63	7.2	0.37	4.15e-12	Chronic lymphocytic leukemia;
CRC	cis	rs7120118	0.517	rs12221497	chr11:47280653	G/A	cg25783544	chr11:47291846	MADD	0.64	5.77	0.3	1.85e-8	HDL cholesterol;
CRC	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.66	0.3	3.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.04	12.15	0.56	2.49e-28	Sexual dysfunction (female);
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16273041	chr11:47600972	KBTBD4;NDUFS3	0.43	6.29	0.33	1.03e-9	Response to antipsychotic treatment;
CRC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg19682013	chr15:45996608	NA	0.32	6.6	0.34	1.6e-10	Waist circumference;Weight;
CRC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.49	-7.93	-0.4	3.42e-14	Body mass index;
CRC	cis	rs7113874	0.589	rs10840051	chr11:8475180	G/C	cg02811074	chr11:8615871	STK33	-0.35	-6.04	-0.32	4.16e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.63	-9.14	-0.45	6.47e-18	Cognitive function;
CRC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.46	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg02659138	chr7:134003124	SLC35B4	-0.37	-6.39	-0.33	5.56e-10	Mean platelet volume;
CRC	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg04850286	chr10:81895943	PLAC9	0.38	6.72	0.35	7.9e-11	Sarcoidosis;
CRC	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg16141378	chr3:129829833	LOC729375	-0.44	-6.51	-0.34	2.81e-10	Neuroticism;
CRC	cis	rs1572438	0.929	rs9378520	chr6:861685	C/T	cg13447295	chr6:887704	NA	-0.46	-6.39	-0.33	5.61e-10	Aging;
CRC	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.91	-14.64	-0.63	9.67e-38	Dupuytren's disease;
CRC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg04450456	chr4:17643702	FAM184B	0.42	6.62	0.34	1.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10067538	chr16:87351824	NA	0.31	5.97	0.31	6.01e-9	Response to antipsychotic treatment;
CRC	cis	rs863345	0.564	rs34701257	chr1:158480955	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.24	-0.33	1.32e-9	Pneumococcal bacteremia;
CRC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg02560186	chr11:3602584	NA	0.54	6.98	0.36	1.68e-11	Blood pressure (smoking interaction);
CRC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.76	-0.3	1.89e-8	Breast cancer;
CRC	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.63	-10.17	-0.49	2.67e-21	Corneal astigmatism;
CRC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.38	-5.64	-0.3	3.6e-8	Red cell distribution width;
CRC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs911119	0.913	rs12710327	chr20:23569689	C/T	cg16589663	chr20:23618590	CST3	0.42	5.89	0.31	9.32e-9	Chronic kidney disease;
CRC	trans	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg26043149	chr18:55253948	FECH	-0.72	-10.42	-0.5	3.67e-22	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg15586341	chr10:73899798	ASCC1	-0.61	-6.6	-0.34	1.64e-10	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs1165668	0.816	rs1866069	chr12:104310545	G/T	cg21863207	chr12:104234989	NT5DC3	-0.43	-6.47	-0.34	3.5e-10	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.54	9.02	0.45	1.58e-17	Systemic lupus erythematosus;
CRC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg08200582	chr11:442649	ANO9	-0.71	-7.42	-0.38	1.04e-12	Body mass index;
CRC	cis	rs939584	0.825	rs13028252	chr2:632529	T/C	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.58e-8	Body mass index;
CRC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg06713675	chr4:122721982	EXOSC9	-0.39	-6.39	-0.33	5.76e-10	Type 2 diabetes;
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.63	0.43	2.7e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg09760422	chr2:128146352	NA	0.28	5.65	0.3	3.51e-8	Protein C levels;
CRC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.12	-0.32	2.61e-9	Type 2 diabetes;
CRC	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	24.92	0.81	9.12e-78	Schizophrenia;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.54	-5.74	-0.3	2.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg24289452	chr6:170231220	NA	-0.58	-6.53	-0.34	2.42e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4363385	0.693	rs490553	chr1:153033277	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.6	-0.34	1.62e-10	Inflammatory skin disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21950287	chr19:54385441	PRKCG	0.46	6.47	0.34	3.63e-10	Survival in pancreatic cancer;
CRC	cis	rs1223397	0.938	rs3817741	chr6:13279507	A/G	cg21538684	chr6:13274180	PHACTR1	-0.45	-5.71	-0.3	2.48e-8	Blood pressure;
CRC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg03233332	chr7:66118400	NA	-0.42	-5.83	-0.31	1.3e-8	Aortic root size;
CRC	trans	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	6.47	0.34	3.54e-10	Myopia (pathological);
CRC	cis	rs2735413	0.918	rs12925605	chr16:78071715	G/A	cg04733911	chr16:78082701	NA	-0.42	-6.99	-0.36	1.55e-11	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.24	11.67	0.54	1.4e-26	Prostate cancer;
CRC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg16681516	chr19:46297285	DMWD	0.38	6.09	0.32	3.12e-9	Coronary artery disease;
CRC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	7.47	0.38	7.29e-13	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-7.23	-0.37	3.4e-12	Gut microbiome composition (summer);
CRC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.69	8.14	0.41	8.53e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.6	9.27	0.46	2.47e-18	Aortic root size;
CRC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg27565382	chr3:53032988	SFMBT1	0.78	6.26	0.33	1.17e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-8.47	-0.42	8.46e-16	Intelligence (multi-trait analysis);Educational attainment (years of education);
CRC	trans	rs4378999	0.528	rs2355350	chr3:50814508	G/A	cg12383621	chr7:7735611	RPA3	-0.47	-6.01	-0.31	4.92e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.99	0.55	9.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.9	-0.31	8.81e-9	Life satisfaction;
CRC	cis	rs9292777	0.518	rs10941515	chr5:40482526	T/A	cg09067459	chr5:40385259	NA	0.44	7.33	0.37	1.78e-12	Crohn's disease;Multiple sclerosis;
CRC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-8.72	-0.43	1.42e-16	Menarche (age at onset);
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.12	-0.37	6.7e-12	Inflammatory bowel disease;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.69	9.69	0.47	1.04e-19	Alzheimer's disease;
CRC	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.82	0.35	4.45e-11	Response to antipsychotic treatment;
CRC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.53	7.45	0.38	8.15e-13	Obesity-related traits;
CRC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.64	-7.59	-0.39	3.33e-13	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00694336	chr1:114301873	PHTF1	0.47	6.71	0.35	8.68e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.22	-0.45	3.52e-18	Intelligence (multi-trait analysis);
CRC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.51	7.95	0.4	2.97e-14	Aortic root size;
CRC	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.96	-0.55	1.32e-27	Exhaled nitric oxide output;
CRC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.66	-9.92	-0.48	1.87e-20	Blood pressure (smoking interaction);
CRC	cis	rs6662572	0.737	rs11211206	chr1:46323192	A/G	cg08644498	chr1:46502608	NA	-0.45	-7.07	-0.36	9.42e-12	Blood protein levels;
CRC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg15845792	chr6:28175446	NA	0.59	8.17	0.41	6.76e-15	Parkinson's disease;
CRC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg09163369	chr1:210001066	C1orf107	0.4	5.75	0.3	2.08e-8	Orofacial clefts;
CRC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.49	7.93	0.4	3.52e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2280630	0.529	rs784495	chr3:39178899	C/T	cg01426195	chr3:39028469	NA	0.42	6.95	0.36	1.93e-11	Verbal declarative memory;
CRC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg11887960	chr12:57824829	NA	0.61	6.67	0.35	1.08e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.27e-25	White blood cell count (basophil);
CRC	cis	rs599083	0.502	rs113307519	chr11:68212641	C/T	cg16797656	chr11:68205561	LRP5	0.4	5.66	0.3	3.37e-8	Bone mineral density (spine);
CRC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg12386194	chr3:101231763	SENP7	0.5	6.89	0.35	2.9e-11	Colorectal cancer;
CRC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg19193384	chr17:30244184	NA	-0.53	-6.89	-0.36	2.85e-11	Hip circumference adjusted for BMI;
CRC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	14.84	0.63	1.66e-38	Smoking behavior;
CRC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg03623178	chr6:28175578	NA	0.91	9.62	0.47	1.85e-19	Lung cancer in ever smokers;
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg16606324	chr3:10149918	C3orf24	0.7	9.79	0.48	4.82e-20	Alzheimer's disease;
CRC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.59	10.7	0.51	3.87e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	8.87	0.44	4.67e-17	Lymphocyte counts;
CRC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-17.89	-0.7	1.75e-50	Height;
CRC	cis	rs7605827	0.930	rs7579714	chr2:15686869	A/C	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.66	-8.02	-0.4	1.89e-14	Menarche (age at onset);
CRC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.48	-0.67	6.62e-45	Height;
CRC	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.44	6.18	0.32	1.84e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs2303319	0.504	rs56965753	chr2:162597251	A/G	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg17885791	chr6:149771845	ZC3H12D	0.31	5.62	0.3	4.13e-8	Dupuytren's disease;
CRC	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.76	-0.3	1.94e-8	Pulmonary function;
CRC	trans	rs4824093	0.610	rs12168949	chr22:50317714	A/G	cg09872104	chr7:134855509	C7orf49	-0.75	-6.93	-0.36	2.25e-11	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-8.83	-0.44	6.21e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-10.87	-0.51	1.02e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	trans	rs73162807	0.655	rs73160985	chr3:146431231	A/G	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.48	6.36	0.33	6.94e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg24249390	chr15:90295951	MESP1	-0.59	-9.61	-0.47	1.93e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs10512697	0.803	rs13161713	chr5:3575234	C/G	cg19473799	chr5:3511975	NA	-0.73	-5.75	-0.3	2.09e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg03790207	chr6:42947109	PEX6	-0.52	-7.68	-0.39	1.85e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.65	-10.35	-0.5	6.62e-22	Monocyte percentage of white cells;
CRC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg11833968	chr6:79620685	NA	-0.36	-6.25	-0.33	1.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.64	11.02	0.52	3.11e-24	Prostate cancer;
CRC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg19193384	chr17:30244184	NA	-0.65	-7.48	-0.38	6.75e-13	Hip circumference adjusted for BMI;
CRC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	2.96e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11446398	chr5:77624930	NA	-0.48	-6.71	-0.35	8.6e-11	Triglycerides;
CRC	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg14593290	chr7:50529359	DDC	-0.56	-7.24	-0.37	3.15e-12	Malaria;
CRC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.16	-0.49	2.82e-21	Height;
CRC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg08200770	chr17:80723486	TBCD	-0.43	-6.46	-0.34	3.71e-10	Glycated hemoglobin levels;
CRC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg05132306	chr1:1846340	CALML6	-0.51	-7.9	-0.4	4.29e-14	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27183811	chr15:51200847	AP4E1	0.41	6.09	0.32	3.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg18833306	chr6:118973337	C6orf204	0.47	6.54	0.34	2.32e-10	Diastolic blood pressure;
CRC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.15	-0.41	7.68e-15	Hip circumference adjusted for BMI;
CRC	trans	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.47	-0.38	7.12e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.44	6.74	0.35	7.19e-11	Monocyte count;
CRC	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	cg22592108	chr5:53304441	ARL15	0.47	5.61	0.3	4.24e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
CRC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg00310523	chr12:86230176	RASSF9	-0.36	-5.92	-0.31	8.25e-9	Major depressive disorder;
CRC	cis	rs926938	0.543	rs360600	chr1:115388116	T/C	cg12756093	chr1:115239321	AMPD1	0.58	8.5	0.42	6.83e-16	Autism;
CRC	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.83	-0.31	1.3e-8	Migraine;Coronary artery disease;
CRC	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg12756093	chr1:115239321	AMPD1	-0.48	-7.12	-0.37	6.82e-12	Autism;
CRC	cis	rs7113874	0.569	rs7104646	chr11:8558841	G/T	cg17679104	chr11:8615758	STK33	-0.36	-5.89	-0.31	9.4e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.97	-0.31	5.99e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.55	0.57	8.92e-30	Platelet count;
CRC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.63	0.57	4.45e-30	Body mass index;
CRC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.8	13.69	0.6	4.46e-34	Menopause (age at onset);
CRC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg03037974	chr15:76606532	NA	-0.55	-8.22	-0.41	4.88e-15	Blood metabolite levels;
CRC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg18827107	chr12:86230957	RASSF9	-0.39	-6.01	-0.31	4.81e-9	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21936789	chr3:47620545	CSPG5	-0.4	-6.39	-0.33	5.79e-10	Myopia (pathological);
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07638098	chr22:30234508	ASCC2	0.45	6.28	0.33	1.06e-9	Response to antipsychotic treatment;
CRC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	17.85	0.7	2.5e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg06470822	chr6:28175283	NA	-0.64	-8.97	-0.44	2.26e-17	Parkinson's disease;
CRC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg03013999	chr17:37608204	MED1	-0.46	-6.98	-0.36	1.62e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.12	-0.45	7.39e-18	Body mass index;
CRC	cis	rs17127169	0.536	rs74860172	chr1:65497547	T/A	cg01340542	chr1:65468273	NA	0.98	6.86	0.35	3.38e-11	Sitting height ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06090383	chr4:174292579	SAP30	0.47	7.22	0.37	3.53e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg11003573	chr3:44754125	ZNF502	-0.34	-5.82	-0.31	1.39e-8	Depressive symptoms;
CRC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-6.23	-0.32	1.42e-9	Major depressive disorder;
CRC	cis	rs911119	0.955	rs17751897	chr20:23592714	T/C	cg16589663	chr20:23618590	CST3	0.45	6.3	0.33	9.76e-10	Chronic kidney disease;
CRC	trans	rs2055729	0.710	rs13257396	chr8:9736383	A/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.23	0.32	1.46e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg25164649	chr6:28176230	NA	-0.42	-6.14	-0.32	2.31e-9	Cardiac Troponin-T levels;
CRC	trans	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg17903999	chr18:56338584	MALT1	-0.4	-6.34	-0.33	7.56e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-5.95	-0.31	6.92e-9	Height;
CRC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	0.99	15.03	0.64	3.07e-39	Monocyte percentage of white cells;
CRC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg19318889	chr4:1322082	MAEA	0.43	6.36	0.33	6.78e-10	Obesity-related traits;
CRC	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg22508957	chr16:3507546	NAT15	-0.8	-7.69	-0.39	1.72e-13	Tuberculosis;
CRC	cis	rs11098699	0.821	rs17006775	chr4:124214850	A/G	cg09941581	chr4:124220074	SPATA5	-0.43	-6.41	-0.33	4.96e-10	Mosquito bite size;
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23378565	chr7:2036160	MAD1L1	-0.47	-6.62	-0.34	1.45e-10	Neuroticism;
CRC	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg21153622	chr11:89784906	NA	0.43	6.9	0.36	2.71e-11	HDL cholesterol;
CRC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg00769240	chr8:12517080	NA	-0.66	-7.32	-0.37	1.96e-12	Blood pressure (smoking interaction);
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg02158880	chr13:53174818	NA	0.4	5.72	0.3	2.41e-8	Lewy body disease;
CRC	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg05784532	chr1:230284198	GALNT2	0.46	6.27	0.33	1.13e-9	Coronary artery disease;
CRC	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg14458575	chr2:238380390	NA	0.46	6.51	0.34	2.8e-10	Prostate cancer;
CRC	trans	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg10756647	chr7:56101905	PSPH	-0.73	-8.07	-0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs1322512	1.000	rs1407488	chr6:152945777	G/T	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.43e-59	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02785000	chr7:100184615	FBXO24;LRCH4	0.45	6.26	0.33	1.18e-9	Response to antipsychotic treatment;
CRC	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg06243866	chr13:111019493	COL4A2	-0.43	-6.48	-0.34	3.42e-10	White matter hyperintensity burden;
CRC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg07809909	chr20:30433512	FOXS1	0.35	5.74	0.3	2.18e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.68	7.61	0.39	3e-13	Vitiligo;
CRC	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg22687807	chr8:143858763	LYNX1	-0.46	-7.68	-0.39	1.82e-13	Urinary tract infection frequency;
CRC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg21201659	chr10:121652288	SEC23IP	-0.44	-6.01	-0.31	4.84e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg09127314	chr1:152161683	NA	0.49	6.25	0.33	1.26e-9	Atopic dermatitis;
CRC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.46	-6.71	-0.35	8.75e-11	Uric acid clearance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17804635	chr8:37554071	ZNF703	0.44	6.64	0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.43	-7.36	-0.38	1.49e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.89	-11.28	-0.53	3.61e-25	Hair shape;
CRC	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs9525927	0.625	rs9533803	chr13:44820608	C/T	cg19190762	chr13:44806055	NA	0.56	6.42	0.33	4.87e-10	Dupuytren's disease;
CRC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.55	-6.97	-0.36	1.7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs616147	0.816	rs1768190	chr3:39509440	T/C	cg24004139	chr1:26670703	AIM1L	-0.37	-5.98	-0.31	5.95e-9	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg15382696	chr6:118971807	C6orf204	0.6	7.7	0.39	1.63e-13	Diastolic blood pressure;
CRC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.68	9.71	0.47	9.37e-20	Multiple sclerosis;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg24973289	chr13:45885542	NA	0.41	6.31	0.33	8.76e-10	Interleukin-6 levels;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05124756	chr4:2263820	MXD4	-0.4	-6.02	-0.31	4.57e-9	Myopia (pathological);
CRC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.76	-11.71	-0.54	1.02e-26	Testicular germ cell tumor;
CRC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.56	-7.19	-0.37	4.3e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26714650	chr12:56694279	CS	-1.4	-11.28	-0.53	3.63e-25	Psoriasis vulgaris;
CRC	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.39	-6.06	-0.32	3.74e-9	Alzheimer's disease;
CRC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.5	-7.66	-0.39	2.05e-13	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12315302	chr6:26189340	HIST1H4D	0.81	6.23	0.32	1.45e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg10431340	chr1:161279108	MPZ	-0.52	-6.96	-0.36	1.84e-11	Rheumatoid arthritis;
CRC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	8.27	0.41	3.41e-15	Cognitive test performance;
CRC	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.43	6.15	0.32	2.25e-9	Height;
CRC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24308560	chr3:49941425	MST1R	-0.44	-6.76	-0.35	6.43e-11	Intelligence (multi-trait analysis);
CRC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.21	-16.45	-0.67	8.87e-45	Breast cancer;
CRC	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.14	-0.45	6.7e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	1.17	10.93	0.52	6.24e-24	Arsenic metabolism;
CRC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs995000	0.931	rs11208000	chr1:63108374	A/G	cg19896129	chr1:63156450	NA	0.4	6.23	0.32	1.46e-9	Triglyceride levels;
CRC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.18	0.32	1.91e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg05623727	chr3:50126028	RBM5	0.45	7.54	0.38	4.71e-13	Intelligence (multi-trait analysis);
CRC	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.7	11.82	0.55	4.26e-27	Eosinophil percentage of white cells;
CRC	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.33	-7.11	-0.36	7.23e-12	Total body bone mineral density;
CRC	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.64	7.69	0.39	1.71e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.36	0.33	6.8e-10	Lung cancer;
CRC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.44	8.21	0.41	5.07e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.72	-8.29	-0.42	2.99e-15	Obesity-related traits;
CRC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.84	-12.79	-0.58	1.15e-30	Blood metabolite levels;
CRC	cis	rs10865541	0.935	rs4971502	chr2:3414029	A/G	cg22182287	chr2:3452347	TTC15	0.37	5.81	0.31	1.46e-8	Obesity-related traits;
CRC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.39	0.38	1.21e-12	Aortic root size;
CRC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.55	-7.75	-0.39	1.13e-13	Menarche (age at onset);
CRC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.48	-5.66	-0.3	3.34e-8	Menarche (age at onset);
CRC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.41	6.65	0.34	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg11189052	chr15:85197271	WDR73	0.58	8.45	0.42	9.51e-16	Schizophrenia;
CRC	cis	rs4838594	0.537	rs2377354	chr10:49696844	A/C	cg17291251	chr10:49678358	ARHGAP22	-0.42	-6.56	-0.34	2.05e-10	Daytime sleep phenotypes;
CRC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg13057898	chr1:3703894	LRRC47	0.56	7.59	0.39	3.39e-13	Red cell distribution width;
CRC	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.43	-7.37	-0.38	1.42e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.71	-0.35	8.37e-11	Breast cancer;
CRC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.5	-8.48	-0.42	7.61e-16	Type 2 diabetes;
CRC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg04450456	chr4:17643702	FAM184B	0.38	5.88	0.31	1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.65	11.69	0.54	1.24e-26	Blood metabolite ratios;
CRC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.37	-6.17	-0.32	2.04e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.45e-9	Eye color traits;
CRC	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.63	9.85	0.48	3.24e-20	Corneal astigmatism;
CRC	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.52	-0.46	3.78e-19	Prevalent atrial fibrillation;
CRC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.36	6.91	0.36	2.45e-11	Intelligence (multi-trait analysis);
CRC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.47	-8.86	-0.44	5.06e-17	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-10.19	-0.49	2.32e-21	Monocyte count;
CRC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.69	9.25	0.45	2.82e-18	High light scatter reticulocyte count;
CRC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.53	7.43	0.38	9.47e-13	Lymphocyte counts;
CRC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.4	-6.92	-0.36	2.35e-11	Reticulocyte fraction of red cells;
CRC	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg05342945	chr12:48394962	COL2A1	0.42	5.67	0.3	3.09e-8	Lung cancer;
CRC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg13798780	chr7:105162888	PUS7	0.62	7.14	0.37	6.12e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.1	-0.32	3.06e-9	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.74e-9	Depression;
CRC	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg20169779	chr10:135381914	SYCE1	-0.66	-11.29	-0.53	3.21e-25	Obesity-related traits;
CRC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.58	7.73	0.39	1.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.91	17.62	0.7	2.07e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.49	-0.5	2.16e-22	Bipolar disorder and schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03550506	chr22:32149733	DEPDC5	0.53	7.46	0.38	7.69e-13	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.32	0.33	8.64e-10	Life satisfaction;
CRC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24308560	chr3:49941425	MST1R	0.48	7.49	0.38	6.49e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.57	-7.01	-0.36	1.33e-11	Obesity (extreme);
CRC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.56	-9.67	-0.47	1.23e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs282587	0.569	rs282594	chr13:113379640	A/G	cg04656015	chr13:113407548	ATP11A	0.63	7.89	0.4	4.62e-14	Glycated hemoglobin levels;
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.83	-14.02	-0.61	2.5e-35	Monocyte count;
CRC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.77	-0.44	9.85e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.59	10.07	0.49	5.63e-21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.0	-0.31	5.22e-9	Obesity-related traits;
CRC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.46	-6.76	-0.35	6.2e-11	Platelet distribution width;
CRC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg07395648	chr5:131743802	NA	0.41	5.97	0.31	6.17e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.81	8.38	0.42	1.55e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.82	8.98	0.44	2.19e-17	Breast cancer;
CRC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.6	-8.46	-0.42	8.87e-16	Carotid intima media thickness;
CRC	trans	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg06606381	chr12:133084897	FBRSL1	-0.55	-6.22	-0.32	1.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.47	6.58	0.34	1.81e-10	Longevity;Endometriosis;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23668004	chr7:4784903	FOXK1	0.46	6.18	0.32	1.86e-9	Hip circumference;
CRC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.49	6.39	0.33	5.68e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.2100000000000001e-27	Body mass index;
CRC	cis	rs6681460	0.934	rs4655628	chr1:67052609	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.17	0.41	6.69e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg03938978	chr2:103052716	IL18RAP	0.42	6.7	0.35	8.81e-11	Blood protein levels;
CRC	cis	rs629535	0.735	rs525610	chr8:70074535	A/G	cg26132723	chr8:70041827	NA	0.35	5.71	0.3	2.51e-8	Dupuytren's disease;
CRC	cis	rs4920343	0.671	rs1010113	chr1:19071752	T/C	cg19637330	chr1:19110922	NA	0.41	6.13	0.32	2.56e-9	Knee osteoarthritis;
CRC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.3	4.23e-8	Hemoglobin concentration;
CRC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.37	6.28e-12	Reticulocyte fraction of red cells;
CRC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.5	-9.54	-0.47	3.37e-19	Body mass index;
CRC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.41	0.5	3.86e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7258465	0.931	rs34053595	chr19:18556749	T/C	cg10790698	chr19:18539756	SSBP4	-0.43	-7.96	-0.4	2.77e-14	Breast cancer;
CRC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.6	7.23	0.37	3.38e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.73	0.39	1.34e-13	Alzheimer's disease;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg24634471	chr8:143751801	JRK	-0.51	-6.88	-0.35	3.09e-11	Urinary tract infection frequency;
CRC	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.66	9.55	0.47	3.06e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg16892393	chr17:41919603	NA	0.56	7.96	0.4	2.87e-14	Triglycerides;
CRC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.58	9.35	0.46	1.41e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs2992756	0.625	rs2992752	chr1:18808526	A/C	cg14356550	chr1:18808102	KLHDC7A	-0.39	-5.78	-0.3	1.76e-8	Breast cancer;
CRC	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.52	-10.5	-0.5	1.96e-22	Urate levels in overweight individuals;
CRC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg10589385	chr1:150898437	SETDB1	0.29	6.13	0.32	2.47e-9	Tonsillectomy;
CRC	cis	rs932541	1.000	rs6043988	chr20:16455165	C/T	cg17003395	chr20:16555519	KIF16B	0.41	5.73	0.3	2.25e-8	Intelligence;
CRC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4237845	0.611	rs4534624	chr12:58332427	A/G	cg02175503	chr12:58329896	NA	0.79	12.42	0.56	2.73e-29	Intelligence (multi-trait analysis);
CRC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.26e-13	Methadone dose in opioid dependence;
CRC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.69	0.47	1.09e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg25886479	chr11:50257625	LOC441601	-0.34	-5.7	-0.3	2.7e-8	Coronary artery disease;
CRC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.51	5.71	0.3	2.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.4	0.38	1.11e-12	Eye color traits;
CRC	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.89e-17	Dupuytren's disease;
CRC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.81	12.25	0.56	1.12e-28	Cognitive function;
CRC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.45	7.18	0.37	4.53e-12	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.43	6.21	0.32	1.61e-9	Aortic root size;
CRC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.73	13.63	0.6	7.84e-34	Body mass index;
CRC	cis	rs9292777	0.720	rs4957291	chr5:40431949	G/A	cg09067459	chr5:40385259	NA	-0.53	-8.58	-0.43	3.87e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg23743428	chr13:21893420	NA	-0.38	-5.76	-0.3	1.97e-8	White matter hyperintensity burden;
CRC	trans	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.2	-0.37	4.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.63	-0.3	3.78e-8	Schizophrenia;
CRC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.84	-0.31	1.24e-8	Gut microbiome composition (summer);
CRC	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.69	-10.56	-0.5	1.2e-22	Menopause (age at onset);
CRC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.49	-8.75	-0.43	1.17e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg05623727	chr3:50126028	RBM5	0.4	5.9	0.31	9.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17065868	0.764	rs9533857	chr13:45029951	A/G	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13884470	chr9:86595151	HNRNPK;RMI1	0.43	6.11	0.32	2.82e-9	Hip circumference;
CRC	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg10437265	chr15:77819839	NA	-0.5	-8.93	-0.44	2.99e-17	Type 2 diabetes;
CRC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00166722	chr3:10149974	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.39	-7.92	-0.4	3.65e-14	Cutaneous nevi;
CRC	trans	rs4378999	0.660	rs7639301	chr3:50837991	C/G	cg12383621	chr7:7735611	RPA3	-0.48	-6.1	-0.32	2.95e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.58	7.94	0.4	3.31e-14	White matter hyperintensity burden;
CRC	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.56	-8.86	-0.44	5.22e-17	Anterior chamber depth;
CRC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.72	-7.9	-0.4	4.17e-14	Lung disease severity in cystic fibrosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20134190	chr8:99129593	POP1;HRSP12	0.47	6.94	0.36	2.04e-11	Response to antipsychotic treatment;
CRC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.44	7.2	0.37	4.2e-12	Post bronchodilator FEV1;
CRC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.42	0.42	1.16e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.74	-8.33	-0.42	2.15e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.09	18.58	0.72	3.25e-53	Cognitive function;
CRC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg23758597	chr6:163146217	PARK2	-0.66	-6.55	-0.34	2.24e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg15654264	chr1:150340011	RPRD2	0.41	6.19	0.32	1.84e-9	Migraine;
CRC	cis	rs7932354	0.528	rs747650	chr11:47176005	C/T	cg19486271	chr11:47235900	DDB2	0.45	6.71	0.35	8.36e-11	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg14352298	chr13:112236639	NA	0.3	6.87	0.35	3.17e-11	Hepatitis;
CRC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.2	-0.32	1.65e-9	Response to antipsychotic treatment;
CRC	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg10263370	chr3:44754102	ZNF502	0.37	6.31	0.33	9.25e-10	Depressive symptoms;
CRC	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.52	8.4	0.42	1.39e-15	IgG glycosylation;
CRC	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.79	-10.9	-0.52	7.88e-24	Blood pressure (smoking interaction);
CRC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-6.89	-0.36	2.87e-11	Mean platelet volume;
CRC	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	9.56	0.47	2.82e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.97	-0.78	2.42e-70	Myeloid white cell count;
CRC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.46	6.55	0.34	2.16e-10	Type 2 diabetes;
CRC	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg02158880	chr13:53174818	NA	0.43	6.46	0.34	3.8e-10	Lewy body disease;
CRC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.71	0.35	8.28e-11	Major depressive disorder;
CRC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.85	15.11	0.64	1.46e-39	Breast cancer;
CRC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.48	6.77	0.35	6.07e-11	Lung cancer;
CRC	trans	rs16846053	0.786	rs62187567	chr2:162363066	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.54e-9	Blood osmolality (transformed sodium);
CRC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.47	-7.05	-0.36	1.07e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg21138405	chr5:131827807	IRF1	0.36	6.15	0.32	2.21e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6700896	0.931	rs1892534	chr1:66105944	C/T	cg04111102	chr1:66153794	NA	0.32	5.72	0.3	2.33e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.58	-7.24	-0.37	3.21e-12	Ulcerative colitis;
CRC	cis	rs1223397	0.938	rs13205692	chr6:13291560	C/T	cg00460589	chr6:13274354	PHACTR1	0.5	6.0	0.31	5.11e-9	Blood pressure;
CRC	cis	rs17767392	0.874	rs34649709	chr14:71762296	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.49	-7.66	-0.39	2.06e-13	Type 2 diabetes;
CRC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.56	-7.13	-0.37	6.44e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.5	7.81	0.4	7.88e-14	Corneal astigmatism;
CRC	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg12072164	chr19:44306565	LYPD5	-0.41	-6.44	-0.33	4.13e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.41	-5.75	-0.3	2.01e-8	Aortic root size;
CRC	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-10.69	-0.51	4.17e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.32	4.33e-9	Heart rate;
CRC	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-6.48	-0.34	3.27e-10	Coronary artery disease;
CRC	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg23254163	chr1:152506842	NA	0.45	8.84	0.44	5.7e-17	Hair morphology;
CRC	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg09659197	chr4:152720779	NA	-0.38	-8.17	-0.41	6.75e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.97	11.38	0.53	1.58e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.72	-12.46	-0.57	1.93e-29	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06905471	chr2:29092871	TRMT61B	0.46	6.69	0.35	9.64e-11	Intelligence (multi-trait analysis);
CRC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-7.35	-0.38	1.63e-12	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.66	10.66	0.51	5.65e-23	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18252515	chr7:66147081	NA	0.38	5.65	0.3	3.52e-8	Aortic root size;
CRC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.63	0.39	2.48e-13	Motion sickness;
CRC	cis	rs11229555	0.645	rs10466659	chr11:58190112	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.66	5.67	0.3	3.13e-8	Depression;
CRC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg09218773	chr11:619014	MUPCDH	-0.43	-6.19	-0.32	1.78e-9	Systemic lupus erythematosus;
CRC	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg03013636	chr16:1946785	NA	0.58	7.08	0.36	8.69e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.54	-0.34	2.4e-10	Metabolite levels;
CRC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.75	12.38	0.56	3.8e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.67	-10.91	-0.52	7.3e-24	Breast cancer;
CRC	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg00947319	chr17:47005597	UBE2Z	0.34	5.72	0.3	2.38e-8	Type 2 diabetes;
CRC	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg03929089	chr4:120376271	NA	0.66	5.96	0.31	6.44e-9	Myopia (pathological);
CRC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.69	-7.75	-0.39	1.17e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.89	0.31	9.73e-9	Heart rate;
CRC	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2398893	0.960	rs56335449	chr9:96748795	G/A	cg14459158	chr9:96720562	NA	0.48	7.3	0.37	2.19e-12	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.22	0.32	1.51e-9	Prudent dietary pattern;
CRC	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.88	11.03	0.52	2.73e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.49	6.41	0.33	5.05e-10	Blood metabolite levels;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg01639898	chr1:32083012	HCRTR1	0.31	6.49	0.34	3.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.67	7.03	0.36	1.17e-11	Axial length;
CRC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.39	6.28	0.33	1.05e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.43	5.76	0.3	1.98e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.01	-10.66	-0.51	5.63e-23	Diabetic kidney disease;
CRC	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg10437265	chr15:77819839	NA	-0.44	-7.56	-0.38	3.95e-13	Type 2 diabetes;
CRC	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.58	-0.34	1.84e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.47	6.92	0.36	2.32e-11	Menopause (age at onset);
CRC	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg26220594	chr1:19110978	NA	-0.46	-6.73	-0.35	7.62e-11	Drug-induced liver injury (nitrofurantoin);
CRC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.32	0.53	2.52e-25	Intelligence (multi-trait analysis);
CRC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.56	-8.62	-0.43	2.89e-16	Sudden cardiac arrest;
CRC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.07	-12.49	-0.57	1.49e-29	Diabetic kidney disease;
CRC	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg02972257	chr16:68554789	NA	-0.51	-6.25	-0.33	1.25e-9	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07840538	chr7:99097998	ZNF394	0.43	6.09	0.32	3.17e-9	Response to antipsychotic treatment;
CRC	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg16974014	chr22:22007515	MIR130B	-0.43	-6.0	-0.31	5.29e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6738485	0.763	rs11681976	chr2:106841591	C/A	cg15412446	chr2:106886593	NA	-0.4	-6.51	-0.34	2.89e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.59	-9.39	-0.46	9.93e-19	Monocyte count;
CRC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg24375607	chr4:120327624	NA	0.48	7.61	0.39	2.87e-13	Corneal astigmatism;
CRC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg12193833	chr17:30244370	NA	-0.68	-8.2	-0.41	5.56e-15	Hip circumference adjusted for BMI;
CRC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.68	10.01	0.48	8.88e-21	Menopause (age at onset);
CRC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs9649465	1.000	rs11765478	chr7:123362872	A/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.61	-0.3	4.22e-8	Migraine;
CRC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17554472	chr22:41940697	POLR3H	0.56	5.65	0.3	3.4e-8	Vitiligo;
CRC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14895029	chr7:2775587	GNA12	-0.45	-6.46	-0.34	3.87e-10	Height;
CRC	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.55	-7.85	-0.4	5.84e-14	Neuroticism;
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.51	6.34	0.33	7.47e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.77	12.59	0.57	5.91e-30	Lung cancer;
CRC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.73	-0.3	2.33e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.56	7.88	0.4	4.83e-14	Lung cancer;
CRC	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.77	13.64	0.6	7.11e-34	Oral cavity cancer;
CRC	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.32	-6.14	-0.32	2.42e-9	Intelligence (multi-trait analysis);
CRC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.56	7.88	0.4	4.96e-14	Resting heart rate;
CRC	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.46	-5.76	-0.3	1.9e-8	Adiposity;
CRC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2657888	0.628	rs2638285	chr12:56886361	A/G	cg23002907	chr12:56915593	RBMS2	0.39	6.09	0.32	3.18e-9	Adiponectin levels;
CRC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.83	14.72	0.63	4.92e-38	Intelligence (multi-trait analysis);
CRC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg03395651	chr16:88107091	BANP	0.54	7.27	0.37	2.56e-12	Menopause (age at onset);
CRC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg15445000	chr17:37608096	MED1	0.36	6.28	0.33	1.08e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg26248373	chr2:1572462	NA	-0.62	-6.51	-0.34	2.74e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.9	0.31	9.24e-9	Tonsillectomy;
CRC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg13057898	chr1:3703894	LRRC47	0.5	6.58	0.34	1.87e-10	Red cell distribution width;
CRC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg00255919	chr5:131827918	IRF1	0.34	5.74	0.3	2.17e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs1429411	1.000	rs1429411	chr2:198144002	A/G	cg10820045	chr2:198174542	NA	-0.38	-6.25	-0.33	1.28e-9	Interferon alpha levels in systemic lupus erythematosus;
CRC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.62	9.99	0.48	1.03e-20	Prudent dietary pattern;
CRC	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.81	-7.64	-0.39	2.38e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs2857891	1.000	rs2595500	chr11:6963165	C/T	cg26870460	chr11:6947759	ZNF215	-0.54	-6.05	-0.32	3.9e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.36	7.3	0.37	2.15e-12	Ewing sarcoma;
CRC	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.72	10.31	0.49	8.65e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs11212617	0.967	rs227054	chr11:108257943	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.41	5.96	0.31	6.59e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-9.75	-0.47	6.84e-20	Monocyte percentage of white cells;
CRC	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	trans	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.6	10.93	0.52	6.45e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.69	-9.07	-0.45	1.1e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg09175582	chr1:161736000	ATF6	0.61	5.79	0.3	1.6e-8	IgG glycosylation;
CRC	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs669446	0.533	rs3862228	chr1:44196945	C/T	cg12908607	chr1:44402522	ARTN	-0.34	-5.88	-0.31	9.99e-9	Amyotrophic lateral sclerosis (age of onset);
CRC	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg20542592	chr8:11973495	FAM66D	-0.33	-5.64	-0.3	3.63e-8	Retinal vascular caliber;
CRC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg00531865	chr16:30841666	NA	-0.44	-5.89	-0.31	9.36e-9	Multiple myeloma;
CRC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.81	7.79	0.39	8.63e-14	Diabetic retinopathy;
CRC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg15017067	chr4:17643749	FAM184B	0.35	5.62	0.3	4.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg20935933	chr6:143382018	AIG1	0.54	6.89	0.36	2.84e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs11212617	1.000	rs2356801	chr11:108281999	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.23e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.6	8.51	0.42	6.09e-16	Lymphocyte percentage of white cells;
CRC	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.65	10.21	0.49	1.98e-21	Corneal astigmatism;
CRC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg18721089	chr20:30220636	NA	-0.36	-5.82	-0.31	1.39e-8	Mean corpuscular hemoglobin;
CRC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.73	11.44	0.53	9.82e-26	Colorectal cancer;
CRC	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.19	-0.32	1.75e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19670317	chr17:8093380	C17orf59	0.45	6.48	0.34	3.37e-10	Response to antipsychotic treatment;
CRC	cis	rs889398	0.771	rs8048550	chr16:69891759	T/G	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.28	-0.33	1.08e-9	Body mass index;
CRC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	8.08	0.41	1.24e-14	Rheumatoid arthritis;
CRC	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg04990556	chr1:26633338	UBXN11	0.55	5.67	0.3	3.15e-8	Obesity-related traits;
CRC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.43	-7.54	-0.38	4.66e-13	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg15131784	chr3:139108705	COPB2	-0.41	-5.95	-0.31	6.73e-9	Obesity-related traits;
CRC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg24675056	chr1:15929824	NA	0.53	7.29	0.37	2.38e-12	Systolic blood pressure;
CRC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.48	7.27	0.37	2.71e-12	Testicular germ cell tumor;
CRC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.45	-5.96	-0.31	6.34e-9	Aortic root size;
CRC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg21138405	chr5:131827807	IRF1	0.32	5.69	0.3	2.75e-8	Blood metabolite levels;
CRC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	0.9	11.01	0.52	3.3e-24	Hip circumference adjusted for BMI;
CRC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg08260959	chr6:26240920	HIST1H4F	-0.36	-5.74	-0.3	2.16e-8	Gout;Renal underexcretion gout;
CRC	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.81	-0.3	1.5e-8	Testicular germ cell tumor;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.46	-10.21	-0.49	1.87e-21	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	0.93	8.92	0.44	3.4e-17	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.25	-0.41	3.91e-15	QRS duration;
CRC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.11	-0.32	2.79e-9	Menopause (age at onset);
CRC	cis	rs11212617	1.000	rs7946955	chr11:108284833	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.62	0.34	1.47e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs783540	0.967	rs2567635	chr15:83262181	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.43	-0.33	4.53e-10	Schizophrenia;
CRC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.41	0.53	1.24e-25	Prudent dietary pattern;
CRC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.52	-7.2	-0.37	4.19e-12	Coronary artery disease;
CRC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.79	14.73	0.63	4.49e-38	Metabolic syndrome;
CRC	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.68	-0.35	1.05e-10	Breast cancer;
CRC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.39	-5.9	-0.31	8.95e-9	Mean corpuscular volume;
CRC	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.61	7.24	0.37	3.18e-12	Bipolar disorder;
CRC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg09659197	chr4:152720779	NA	0.52	11.26	0.53	4.19e-25	Intelligence (multi-trait analysis);
CRC	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.42	0.46	8.17e-19	Blood protein levels;
CRC	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg06223162	chr1:101003688	GPR88	-0.34	-6.15	-0.32	2.21e-9	Monocyte count;
CRC	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21659725	chr3:3221576	CRBN	0.66	7.31	0.37	2e-12	Menarche (age at onset);
CRC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.74	-0.3	2.19e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.46	6.14	0.32	2.41e-9	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg04553112	chr3:125709451	NA	-0.5	-5.7	-0.3	2.61e-8	Blood pressure (smoking interaction);
CRC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23378565	chr7:2036160	MAD1L1	-0.39	-6.05	-0.32	3.95e-9	Bipolar disorder;
CRC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	7.96	0.4	2.85e-14	Mood instability;
CRC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg00601486	chr12:48723148	H1FNT	0.35	6.72	0.35	7.85e-11	Glycated hemoglobin levels;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg07920855	chr1:185286635	IVNS1ABP	-0.43	-6.24	-0.33	1.35e-9	Birth weight;Height;
CRC	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-6.7	-0.35	9.26e-11	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.37	-0.46	1.17e-18	Platelet count;
CRC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg25303599	chr11:61595807	FADS2	-0.49	-6.53	-0.34	2.47e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs72730918	0.564	rs12708427	chr15:51909555	C/T	cg14296394	chr15:51910925	DMXL2	-0.46	-6.16	-0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.67	-0.3	3.16e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.32	-0.42	2.38e-15	Bone mineral density;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15731816	chr14:75230414	YLPM1	0.48	6.24	0.33	1.33e-9	Thyroid stimulating hormone;
CRC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.56	-9.34	-0.46	1.54e-18	Eye color traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14134710	chr21:44313311	NDUFV3	0.46	6.4	0.33	5.25e-10	Anxiety disorder;
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.91	-0.44	3.68e-17	Bipolar disorder;
CRC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.6	-10.83	-0.51	1.4e-23	Aortic root size;
CRC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.61	10.29	0.49	1.04e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.79	-9.41	-0.46	8.61e-19	Initial pursuit acceleration;
CRC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.58	8.43	0.42	1.13e-15	Menarche (age at onset);
CRC	cis	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg25886479	chr11:50257625	LOC441601	-0.34	-5.8	-0.3	1.56e-8	Coronary artery disease;
CRC	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.73	9.76	0.47	6.14e-20	Prostate cancer;
CRC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg27661571	chr11:113659931	NA	-0.97	-11.28	-0.53	3.75e-25	Hip circumference adjusted for BMI;
CRC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	5.92	0.31	8.13e-9	Schizophrenia;
CRC	cis	rs6141769	0.518	rs6058847	chr20:31324135	C/T	cg13636640	chr20:31349939	DNMT3B	-0.41	-6.05	-0.32	3.89e-9	Subjective well-being;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03203239	chr2:74735315	PCGF1	0.43	6.72	0.35	7.99e-11	Myopia (pathological);
CRC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.02	-0.36	1.26e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs73206853	0.764	rs73206868	chr12:110816835	G/T	cg12870014	chr12:110450643	ANKRD13A	0.84	10.0	0.48	1e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07540722	chr2:70056697	GMCL1	0.46	6.4	0.33	5.42e-10	Anxiety disorder;
CRC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.51	8.06	0.41	1.38e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg12560992	chr17:57184187	TRIM37	0.44	5.83	0.31	1.35e-8	Cognitive test performance;
CRC	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.76	-8.0	-0.4	2.14e-14	Non-glioblastoma glioma;Glioma;
CRC	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.42	7.56	0.38	4.07e-13	Blood metabolite ratios;
CRC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg23758597	chr6:163146217	PARK2	-0.56	-6.17	-0.32	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.65	-7.92	-0.4	3.57e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg08992911	chr2:238395768	MLPH	0.61	6.25	0.33	1.26e-9	Prostate cancer;
CRC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.77	11.02	0.52	2.96e-24	Platelet distribution width;
CRC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.56	6.43	0.33	4.5e-10	Bipolar disorder;
CRC	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg09597638	chr17:3907349	NA	0.63	11.42	0.53	1.17e-25	Type 2 diabetes;
CRC	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg23815491	chr16:72088622	HP	0.5	7.23	0.37	3.35e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg06238570	chr21:40685208	BRWD1	0.7	9.28	0.46	2.28e-18	Cognitive function;
CRC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.61	-9.98	-0.48	1.19e-20	Aortic root size;
CRC	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.71	9.88	0.48	2.52e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-9.31	-0.46	1.9e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs11212617	0.935	rs227075	chr11:108218196	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.8	0.3	1.6e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg00531865	chr16:30841666	NA	-0.44	-6.03	-0.32	4.29e-9	Multiple myeloma;
CRC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg13256891	chr4:100009986	ADH5	0.45	6.43	0.33	4.36e-10	Alcohol dependence;
CRC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.7	-8.97	-0.44	2.3e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-11.95	-0.55	1.34e-27	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg03037974	chr15:76606532	NA	0.66	11.61	0.54	2.33e-26	Blood metabolite levels;
CRC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.7e-9	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21647170	chr7:56119546	CCT6A;PSPH	0.43	6.03	0.32	4.35e-9	Response to antipsychotic treatment;
CRC	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.69	-11.91	-0.55	1.95e-27	White blood cell count (basophil);
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.77	14.51	0.62	3.1e-37	Prudent dietary pattern;
CRC	cis	rs6761276	0.727	rs6743376	chr2:113832333	C/A	cg09040174	chr2:113837401	NA	0.5	7.0	0.36	1.49e-11	Protein quantitative trait loci;
CRC	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.6	-8.31	-0.42	2.52e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-5.98	-0.31	5.84e-9	Lung cancer;
CRC	cis	rs8141797	0.901	rs5751810	chr22:24566579	G/A	cg20894457	chr22:24584366	SUSD2	0.66	6.51	0.34	2.77e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.23	-0.32	1.45e-9	Bipolar disorder;
CRC	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg20041105	chr8:143859282	LYNX1	-0.32	-5.65	-0.3	3.45e-8	Urinary tract infection frequency;
CRC	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-7.33	-0.37	1.81e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg05941027	chr17:61774174	LIMD2	0.36	6.4	0.33	5.23e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	0.96	11.44	0.53	9.55e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs9463078	0.764	rs9357464	chr6:44952441	T/C	cg25276700	chr6:44698697	NA	-0.28	-7.13	-0.37	6.58e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.75	12.46	0.57	1.85e-29	Body mass index;
CRC	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1971762	0.509	rs1247955	chr12:53964133	G/T	cg06632207	chr12:54070931	ATP5G2	-0.49	-8.29	-0.42	2.89e-15	Height;
CRC	cis	rs4692589	1.000	rs4692589	chr4:170935245	C/T	cg19918862	chr4:170955249	NA	-0.36	-5.97	-0.31	6.26e-9	Anxiety disorder;
CRC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2734839	0.964	rs1076563	chr11:113295909	A/C	cg14159747	chr11:113255604	NA	0.46	7.95	0.4	2.96e-14	Information processing speed;
CRC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-6.12	-0.32	2.6e-9	Glycated hemoglobin levels;
CRC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.5	6.85	0.35	3.66e-11	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.44	5.64	0.3	3.74e-8	Bladder cancer;
CRC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.47	-7.55	-0.38	4.35e-13	Social autistic-like traits;
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg10596483	chr8:143751796	JRK	-0.49	-6.69	-0.35	9.65e-11	Urinary tract infection frequency;
CRC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.43	7.22	0.37	3.66e-12	Primary biliary cholangitis;
CRC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.68	9.56	0.47	2.9e-19	Gestational age at birth (maternal effect);
CRC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.48	-6.75	-0.35	6.73e-11	Tonsillectomy;
CRC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.38	7.29	0.37	2.34e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg02725872	chr8:58115012	NA	-0.44	-6.46	-0.34	3.84e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	10.38	0.5	5.23e-22	Lymphocyte counts;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	0.59	10.91	0.52	7.36e-24	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09070503	chr1:36107132	PSMB2	0.44	5.96	0.31	6.5e-9	Anxiety disorder;
CRC	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg04110750	chr16:69646130	NFAT5	-0.54	-7.46	-0.38	7.78e-13	IgE levels;
CRC	cis	rs7107770	0.663	rs6590136	chr11:125073708	A/G	cg27629782	chr11:125073726	PKNOX2	0.5	7.13	0.37	6.37e-12	Photic sneeze reflex;
CRC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.5	-10.11	-0.49	4.04e-21	Intelligence (multi-trait analysis);
CRC	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg23740940	chr11:68924746	NA	0.44	5.7	0.3	2.62e-8	Blond vs. brown hair color;
CRC	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg00122941	chr17:4613640	ARRB2	-0.47	-6.4	-0.33	5.47e-10	Lymphocyte counts;
CRC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.16	-0.37	5.32e-12	Schizophrenia;
CRC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.9	10.57	0.5	1.14e-22	Eosinophil percentage of granulocytes;
CRC	trans	rs9771228	0.864	rs215606	chr7:32337443	C/T	cg02979224	chr7:93204462	CALCR	0.36	6.33	0.33	7.9e-10	Cognitive ability;Verbal-numerical reasoning;
CRC	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	7.52	0.38	5.25e-13	Breast cancer;
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12172441	chr6:28176163	NA	0.52	7.11	0.37	7.2e-12	Cardiac Troponin-T levels;
CRC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.37	6.7	0.35	9.15e-11	Crohn's disease;
CRC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.24	0.33	1.32e-9	Lung cancer;
CRC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg02869306	chr7:64672164	INTS4L1	-0.41	-6.19	-0.32	1.83e-9	Aortic root size;
CRC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg13777783	chr17:79615861	NA	-0.3	-5.67	-0.3	3.13e-8	Eye color traits;
CRC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	0.73	8.07	0.41	1.31e-14	Gout;Renal underexcretion gout;
CRC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	9.09	0.45	9.49e-18	Cognitive test performance;
CRC	cis	rs6662572	0.737	rs4474301	chr1:46255272	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.49	-6.35	-0.33	7.18e-10	Blood protein levels;
CRC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.59	7.86	0.4	5.38e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg08222913	chr3:52553049	STAB1	-0.37	-7.11	-0.36	7.38e-12	Electroencephalogram traits;
CRC	cis	rs2462686	1.000	rs2132571	chr7:45961674	C/T	cg23193639	chr7:45961078	IGFBP3	-0.36	-5.62	-0.3	4.03e-8	Major depressive disorder;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg15786705	chr6:28176104	NA	0.61	8.9	0.44	3.91e-17	Parkinson's disease;
CRC	cis	rs11212617	1.000	rs11212619	chr11:108289167	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.8	0.3	1.59e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.64	11.29	0.53	3.24e-25	Age at first birth;
CRC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.19	-0.37	4.49e-12	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10605791	chr12:122242589	SETD1B;LOC338799	0.38	6.28	0.33	1.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05564831	chr3:52568323	NT5DC2	0.33	5.6	0.3	4.41e-8	Bipolar disorder;
CRC	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg11530693	chr1:120165357	ZNF697	0.48	6.15	0.32	2.19e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs2882667	0.898	rs2043272	chr5:138390631	A/C	cg09476006	chr5:138032270	NA	0.41	6.66	0.34	1.13e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.49	9.42	0.46	8.2e-19	Renal cell carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03648789	chr2:38304037	CYP1B1	0.41	6.12	0.32	2.67e-9	Response to antipsychotic treatment;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg26587870	chr6:27730563	NA	-0.37	-5.6	-0.3	4.46e-8	Cardiac Troponin-T levels;
CRC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg03037974	chr15:76606532	NA	-0.53	-7.43	-0.38	9.63e-13	Blood metabolite levels;
CRC	cis	rs73206853	0.764	rs7312469	chr12:110889072	A/G	cg12870014	chr12:110450643	ANKRD13A	0.75	8.21	0.41	5.25e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg18833306	chr6:118973337	C6orf204	0.49	6.05	0.32	4.02e-9	Renal cell carcinoma;
CRC	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg16989719	chr2:238392110	NA	-0.38	-7.43	-0.38	9.71e-13	Prostate cancer;
CRC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg24829409	chr8:58192753	C8orf71	-0.71	-8.43	-0.42	1.08e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.58	-6.65	-0.34	1.19e-10	White matter integrity;Neutrophil percentage of white cells;
CRC	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.41	-6.38	-0.33	5.94e-10	IFN-related cytopenia;
CRC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.35	6.11	0.32	2.79e-9	Erythrocyte sedimentation rate;
CRC	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg22182287	chr2:3452347	TTC15	0.38	6.06	0.32	3.71e-9	Obesity-related traits;
CRC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12463550	chr7:65579703	CRCP	0.71	6.57	0.34	1.95e-10	Diabetic kidney disease;
CRC	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg23293999	chr7:106826042	HBP1	-0.54	-5.7	-0.3	2.6e-8	Osteoarthritis;
CRC	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg27068330	chr11:65405492	SIPA1	0.45	5.9	0.31	8.9e-9	Urate levels;
CRC	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.43	-6.52	-0.34	2.58e-10	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg10631289	chr15:39006617	NA	0.49	6.04	0.32	4.14e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CRC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg26918954	chr5:179728553	GFPT2	-0.43	-7.27	-0.37	2.58e-12	Height;
CRC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.5	6.79	0.35	5.31e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg08885800	chr1:201084119	NA	-0.41	-5.8	-0.3	1.52e-8	Permanent tooth development;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg10876282	chr6:28092338	ZSCAN16	0.47	6.43	0.33	4.62e-10	Parkinson's disease;
CRC	cis	rs2380220	0.808	rs72922390	chr6:95934317	G/A	cg04719120	chr6:96025338	MANEA	-0.55	-6.0	-0.31	5.09e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.17	0.49	2.67e-21	Birth weight;
CRC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg22535103	chr8:58192502	C8orf71	-0.44	-6.15	-0.32	2.23e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg25809561	chr17:30822961	MYO1D	0.52	9.16	0.45	5.78e-18	Schizophrenia;
CRC	cis	rs6662572	0.703	rs17855317	chr1:46500613	T/C	cg08644498	chr1:46502608	NA	0.46	7.28	0.37	2.47e-12	Blood protein levels;
CRC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.63	9.46	0.46	5.89e-19	Lung cancer;
CRC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs6585424	1.000	rs34148644	chr10:81923456	G/C	cg11900509	chr10:81946545	ANXA11	-0.76	-9.29	-0.46	2.25e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.18	-0.37	4.54e-12	Obesity-related traits;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23715237	chr8:145018300	PLEC1	0.41	6.13	0.32	2.58e-9	Myopia (pathological);
CRC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	5.87	0.31	1.06e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs25422	0.540	rs9481842	chr6:118974798	A/C	cg15382696	chr6:118971807	C6orf204	0.45	6.46	0.34	3.71e-10	Renal cell carcinoma;
CRC	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.44	-6.2	-0.32	1.71e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-10.71	-0.51	3.8e-23	Asthma;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-6.54	-0.34	2.39e-10	Electroencephalogram traits;
CRC	cis	rs4481887	0.573	rs4412629	chr1:248411399	G/T	cg00666640	chr1:248458726	OR2T12	0.41	6.98	0.36	1.63e-11	Common traits (Other);
CRC	cis	rs7493	0.516	rs13233527	chr7:95068795	T/C	cg17330251	chr7:94953956	PON1	-0.42	-5.87	-0.31	1.06e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13385794	chr1:248469461	NA	0.39	6.91	0.36	2.51e-11	Common traits (Other);
CRC	cis	rs72634258	0.519	rs35197830	chr1:7930983	A/G	cg26816564	chr1:7831052	VAMP3	0.63	7.81	0.4	7.87e-14	Inflammatory bowel disease;
CRC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.64	-0.51	6.6e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-13.27	-0.59	1.76e-32	Systemic lupus erythematosus;
CRC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg13390004	chr1:15929781	NA	0.48	6.84	0.35	3.87e-11	Systolic blood pressure;
CRC	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg22089800	chr15:90895588	ZNF774	0.45	7.34	0.38	1.7e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg26354017	chr1:205819088	PM20D1	0.43	5.91	0.31	8.4e-9	Parkinson's disease;
CRC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.54	-5.68	-0.3	2.91e-8	Schizophrenia;
CRC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg17724175	chr1:150552817	MCL1	0.48	7.04	0.36	1.12e-11	Melanoma;
CRC	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.71	8.28	0.42	3.1e-15	Educational attainment;
CRC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	15.72	0.65	6.5e-42	Platelet count;
CRC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.63	10.04	0.48	7.12e-21	Anterior chamber depth;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00724774	chr19:1812282	ATP8B3	0.45	7.09	0.36	8.43e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4926298	1.000	rs931068	chr19:13158678	A/G	cg23899408	chr19:12877188	HOOK2	-0.44	-6.12	-0.32	2.73e-9	Bipolar disorder;
CRC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg20203395	chr5:56204925	C5orf35	-0.41	-5.83	-0.31	1.35e-8	Coronary artery disease;
CRC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.56	-8.21	-0.41	5.14e-15	Fibrinogen levels;
CRC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.21	-16.45	-0.67	8.87e-45	Breast cancer;
CRC	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg27398640	chr15:77910606	LINGO1	-0.44	-7.48	-0.38	6.62e-13	Type 2 diabetes;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg03623178	chr6:28175578	NA	0.84	13.06	0.58	1.07e-31	Cardiac Troponin-T levels;
CRC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg16342193	chr10:102329863	NA	-0.36	-5.93	-0.31	7.49e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg22089800	chr15:90895588	ZNF774	0.48	7.71	0.39	1.49e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.54	-8.34	-0.42	2.12e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15985338	chr7:6048868	PMS2;AIMP2	-0.41	-5.99	-0.31	5.54e-9	Myopia (pathological);
CRC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg10790698	chr19:18539756	SSBP4	-0.46	-8.93	-0.44	3.15e-17	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25767192	chr19:52693159	PPP2R1A	0.43	6.36	0.33	6.71e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4974559	0.790	rs10012582	chr4:1324481	G/A	cg02980000	chr4:1222292	CTBP1	0.51	6.44	0.33	4.24e-10	Systolic blood pressure;
CRC	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-5.92	-0.31	7.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.43	-9.19	-0.45	4.62e-18	Blood protein levels;
CRC	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg00086871	chr4:6988644	TBC1D14	0.8	6.25	0.33	1.28e-9	Granulocyte percentage of myeloid white cells;
CRC	trans	rs6546324	0.625	rs6752799	chr2:67858503	G/A	cg00907274	chr3:27498161	SLC4A7	-0.49	-6.23	-0.32	1.44e-9	Endometriosis;
CRC	cis	rs860295	0.729	rs11264369	chr1:155359830	T/C	cg02153340	chr1:155202674	NA	0.5	6.39	0.33	5.76e-10	Body mass index;
CRC	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.47	6.94	0.36	2.04e-11	Menarche (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg27449864	chr7:73133982	STX1A	0.39	6.44	0.33	4.21e-10	Obesity-related traits;
CRC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	1.09	12.73	0.57	1.83e-30	Obesity-related traits;
CRC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.72	10.14	0.49	3.45e-21	Cerebrospinal fluid biomarker levels;
CRC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.58	-0.43	3.89e-16	Chronic sinus infection;
CRC	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg20356878	chr3:121714668	ILDR1	-0.49	-6.86	-0.35	3.39e-11	Multiple sclerosis;
CRC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12463550	chr7:65579703	CRCP	0.63	5.72	0.3	2.42e-8	Gout;
CRC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7572644	0.640	rs12464988	chr2:28058226	C/T	cg27432699	chr2:27873401	GPN1	0.45	6.11	0.32	2.79e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg26721908	chr21:47610096	LSS	-0.39	-5.99	-0.31	5.47e-9	Testicular germ cell tumor;
CRC	cis	rs17767392	0.645	rs72726657	chr14:71669966	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.01	-0.31	4.92e-9	Mitral valve prolapse;
CRC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	10.69	0.51	4.19e-23	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.53	0.34	2.46e-10	Depression;
CRC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.49	-8.47	-0.42	8.31e-16	Educational attainment;
CRC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.6	-9.37	-0.46	1.23e-18	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06925236	chr11:68039653	C11orf24	0.42	6.04	0.32	4.14e-9	Response to antipsychotic treatment;
CRC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg19630374	chr17:18023558	MYO15A	0.38	6.24	0.33	1.32e-9	Total body bone mineral density;
CRC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.65	8.76	0.43	1.06e-16	Bladder cancer;
CRC	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg21918786	chr6:109611834	NA	0.37	6.5	0.34	2.95e-10	Reticulocyte fraction of red cells;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10893370	chr17:30228961	UTP6	0.46	6.04	0.32	4.09e-9	Thyroid stimulating hormone;
CRC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.72	12.65	0.57	3.74e-30	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg20333904	chr2:240724165	NA	-0.33	-6.6	-0.34	1.64e-10	Obesity-related traits;
CRC	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07165851	chr6:158734300	TULP4	0.6	7.53	0.38	4.9e-13	Height;
CRC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.29	-15.47	-0.65	6.16e-41	Diabetic kidney disease;
CRC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.59	9.14	0.45	6.57e-18	Blood metabolite levels;
CRC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.41	-6.23	-0.33	1.39e-9	Corneal astigmatism;
CRC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg12564285	chr5:131593104	PDLIM4	0.48	8.03	0.4	1.78e-14	Breast cancer;
CRC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg18230493	chr5:56204884	C5orf35	-0.4	-5.97	-0.31	6.31e-9	Coronary artery disease;
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.73	10.08	0.49	5.45e-21	Alzheimer's disease;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg23123621	chr4:1343375	KIAA1530	0.35	5.65	0.3	3.47e-8	Obesity-related traits;
CRC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg19635926	chr16:89946313	TCF25	0.57	5.96	0.31	6.58e-9	Skin colour saturation;
CRC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg27534772	chr1:16042836	PLEKHM2	-0.53	-10.43	-0.5	3.49e-22	Systolic blood pressure;
CRC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.63	-9.83	-0.48	3.71e-20	Body mass index;
CRC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.52	-8.27	-0.41	3.3e-15	Aortic root size;
CRC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.23	0.49	1.7e-21	Ileal carcinoids;
CRC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.83	-0.35	4.02e-11	Alcohol dependence;
CRC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg22495460	chr2:25135724	ADCY3	-0.88	-17.78	-0.7	5.01e-50	Body mass index;
CRC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.48	-9.14	-0.45	6.6e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CRC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.62	8.47	0.42	8.45e-16	Methadone dose in opioid dependence;
CRC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.1	0.36	7.95e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg11130432	chr3:121712080	ILDR1	-0.5	-6.61	-0.34	1.54e-10	Multiple sclerosis;
CRC	cis	rs6534441	0.727	rs17831051	chr4:125440118	C/T	cg21609808	chr4:125404261	NA	0.39	5.63	0.3	3.77e-8	Major depressive disorder;
CRC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.69	-8.69	-0.43	1.7e-16	Body mass index;
CRC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.46	7.46	0.38	7.87e-13	Major depressive disorder;
CRC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg15848620	chr12:58087721	OS9	-0.66	-9.25	-0.45	2.85e-18	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs96067	0.805	rs11263860	chr1:36601368	C/G	cg25304816	chr1:36627734	MAP7D1	0.42	6.03	0.32	4.42e-9	Corneal structure;
CRC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg05313129	chr8:58192883	C8orf71	-0.39	-5.82	-0.31	1.38e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.57	8.83	0.44	6.34e-17	Breast cancer;
CRC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg11995313	chr8:8860691	ERI1	-0.39	-5.97	-0.31	6.1e-9	Joint mobility (Beighton score);
CRC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.76	14.55	0.63	2.33e-37	Body mass index;
CRC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg17724175	chr1:150552817	MCL1	0.41	6.35	0.33	7.19e-10	Melanoma;
CRC	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-5.61	-0.3	4.24e-8	Apolipoprotein A-IV levels;
CRC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg26838691	chr2:24397539	C2orf84	0.41	5.76	0.3	1.9e-8	Asthma;
CRC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg25985355	chr7:65971099	NA	-0.52	-6.01	-0.31	5.03e-9	Diabetic kidney disease;
CRC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.19	-0.37	4.36e-12	QT interval;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11227645	chr1:224544764	CNIH4	0.4	6.1	0.32	3.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-13.29	-0.59	1.44e-32	Chronic sinus infection;
CRC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.22	-0.32	1.54e-9	Gout;Renal underexcretion gout;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04396637	chr12:51477072	CSRNP2	0.39	6.18	0.32	1.85e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-12.16	-0.56	2.34e-28	Asthma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23838375	chr17:72732946	RAB37	-0.44	-6.81	-0.35	4.51e-11	Myopia (pathological);
CRC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg20203395	chr5:56204925	C5orf35	-0.71	-8.56	-0.43	4.27e-16	Initial pursuit acceleration;
CRC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg17085576	chr10:5658249	NA	-0.43	-6.22	-0.32	1.53e-9	Breast cancer;
CRC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.04e-16	Schizophrenia;
CRC	cis	rs7781266	0.847	rs2971970	chr7:133643778	T/G	cg03336402	chr7:133662267	EXOC4	-0.6	-7.35	-0.38	1.62e-12	Educational attainment (college completion);
CRC	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg11579758	chr4:1086637	RNF212	-0.41	-6.67	-0.35	1.1e-10	Recombination rate (males);
CRC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.33	5.73	0.3	2.27e-8	Cardiovascular disease risk factors;
CRC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.62	10.31	0.49	9.01e-22	Hemoglobin concentration;Hematocrit;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.49	6.97	0.36	1.71e-11	Corneal astigmatism;
CRC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-6.42	-0.33	4.74e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg18301423	chr5:131593218	PDLIM4	0.39	6.28	0.33	1.09e-9	Blood metabolite levels;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg03623178	chr6:28175578	NA	0.74	7.82	0.4	7.43e-14	Depression;
CRC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.59	9.15	0.45	6.28e-18	Vitiligo;
CRC	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg22482690	chr17:47019901	SNF8	0.5	8.19	0.41	5.69e-15	Type 2 diabetes;
CRC	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.45	6.87	0.35	3.22e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.42	7.34	0.38	1.68e-12	Plateletcrit;
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg27532560	chr4:187881888	NA	-0.56	-10.2	-0.49	2.05e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07181902	chr2:85829892	TMEM150A	0.44	7.29	0.37	2.26e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-5.96	-0.31	6.64e-9	Bipolar disorder;
CRC	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.53	5.87	0.31	1.07e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-1.07	-12.8	-0.58	9.93e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-6.61	-0.34	1.59e-10	Monocyte count;
CRC	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg21155852	chr7:2048760	MAD1L1	-0.47	-6.43	-0.33	4.38e-10	Bipolar disorder;
CRC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.85	-0.31	1.21e-8	Lung cancer;
CRC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.92	16.99	0.68	6.63e-47	Intelligence (multi-trait analysis);
CRC	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg09855544	chr8:135498122	ZFAT	-0.42	-5.65	-0.3	3.41e-8	Hypertension (SNP x SNP interaction);
CRC	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-6.93	-0.36	2.17e-11	Eye color traits;
CRC	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.53	7.9	0.4	4.27e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	0.95	18.79	0.72	5e-54	Height;
CRC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.53	-9.09	-0.45	9.35e-18	Iron status biomarkers;
CRC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.48	0.46	5.18e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.69	-10.63	-0.51	6.89e-23	Cystic fibrosis severity;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg14804635	chr15:75747750	SIN3A	-0.47	-6.55	-0.34	2.18e-10	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.44	-7.25	-0.37	2.97e-12	Refractive error;
CRC	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg20608306	chr11:116969690	SIK3	-0.31	-5.81	-0.31	1.47e-8	Subjective well-being;
CRC	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.37	-7.25	-0.37	3.03e-12	Migraine;
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg24634471	chr8:143751801	JRK	-0.49	-6.76	-0.35	6.45e-11	Urinary tract infection frequency;
CRC	cis	rs501120	0.810	rs684196	chr10:44745950	A/T	cg09554077	chr10:44749378	NA	0.9	13.3	0.59	1.4e-32	Coronary artery disease;Coronary heart disease;
CRC	trans	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg01879757	chr17:41196368	BRCA1	-0.42	-6.25	-0.33	1.29e-9	Menopause (age at onset);
CRC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg20243544	chr17:37824526	PNMT	0.57	8.55	0.43	4.78e-16	Asthma;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg03623178	chr6:28175578	NA	0.9	11.84	0.55	3.65e-27	Parkinson's disease;
CRC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg11598736	chr3:195384522	SDHAP2	-0.62	-6.22	-0.32	1.5e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.53	-8.85	-0.44	5.57e-17	Aortic root size;
CRC	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.41	5.94	0.31	7.44e-9	Pulmonary function;
CRC	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19324791	chr9:131182496	CERCAM	0.43	5.99	0.31	5.59e-9	Anxiety disorder;
CRC	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.74	-11.82	-0.55	4.12e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21872391	chr10:112064057	SMNDC1	0.46	6.0	0.31	5.3300000000000004e-09	Thyroid stimulating hormone;
CRC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg17724175	chr1:150552817	MCL1	-0.5	-7.93	-0.4	3.36e-14	Tonsillectomy;
CRC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.93	-0.31	7.46e-9	Endometrial cancer;
CRC	cis	rs812925	0.855	rs6545851	chr2:61498357	G/T	cg10580144	chr2:61372316	C2orf74	-0.33	-6.49	-0.34	3.16e-10	Immature fraction of reticulocytes;
CRC	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	7.49	0.38	6.2800000000000005e-13	Corneal astigmatism;
CRC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.92	-0.48	1.84e-20	Height;
CRC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.77	-11.24	-0.53	5e-25	Schizophrenia;
CRC	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00166722	chr3:10149974	C3orf24	0.53	7.42	0.38	9.82e-13	Alzheimer's disease;
CRC	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.48	8.13	0.41	8.75e-15	Testicular germ cell tumor;
CRC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-6.71	-0.35	8.44e-11	Alzheimer's disease (late onset);
CRC	trans	rs2048656	0.635	rs7830613	chr8:9649769	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.68	-0.35	9.98e-11	Schizophrenia;
CRC	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.7	8.86	0.44	5.16e-17	Blood protein levels;
CRC	cis	rs6496667	0.642	rs60597654	chr15:91066771	C/G	cg04176472	chr15:90893244	GABARAPL3	0.49	7.2	0.37	4.19e-12	Rheumatoid arthritis;
CRC	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.69	-9.85	-0.48	3.11e-20	Type 2 diabetes;
CRC	cis	rs2949837	0.581	rs2960436	chr7:45977282	G/A	cg10677697	chr7:45961126	IGFBP3	0.36	6.3	0.33	9.38e-10	Sitting height ratio;
CRC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.61	-9.42	-0.46	8.37e-19	Gestational age at birth (maternal effect);
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.68	0.35	1.01e-10	Body mass index;
CRC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.9	0.48	2.12e-20	Cognitive test performance;
CRC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg09655341	chr17:79618100	PDE6G	-0.36	-6.15	-0.32	2.2e-9	Eye color traits;
CRC	trans	rs746265	0.818	rs57115092	chr15:39590048	A/G	cg00573857	chr5:981189	NA	-0.28	-5.96	-0.31	6.5e-9	PR interval;
CRC	cis	rs4321325	0.733	rs13389505	chr2:127934888	T/C	cg11380483	chr2:127933992	NA	0.63	8.28	0.42	3.18e-15	Protein C levels;
CRC	cis	rs7487075	0.930	rs7308910	chr12:46838242	T/C	cg17501823	chr12:47219793	SLC38A4	0.31	5.62	0.3	3.98e-8	Itch intensity from mosquito bite;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25420398	chr3:133968920	RYK	0.46	7.38	0.38	1.31e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg03233332	chr7:66118400	NA	0.43	5.86	0.31	1.14e-8	Aortic root size;
CRC	cis	rs12927205	0.510	rs7185601	chr16:72035082	A/G	cg14768367	chr16:72042858	DHODH	0.77	7.03	0.36	1.23e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.26	-0.37	2.75e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	13.83	0.61	1.27e-34	Mean platelet volume;
CRC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.11	20.86	0.75	3.73e-62	Cognitive function;
CRC	cis	rs55675132	0.510	rs17544384	chr1:115295160	T/C	cg12756093	chr1:115239321	AMPD1	0.52	6.24	0.33	1.34e-9	Schizophrenia;
CRC	cis	rs2274273	0.662	rs67215571	chr14:55673723	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.81	-0.31	1.46e-8	Protein biomarker;
CRC	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg14593290	chr7:50529359	DDC	0.64	8.15	0.41	7.89e-15	Malaria;
CRC	cis	rs3018066	0.666	rs7657975	chr4:107031691	G/C	cg01869342	chr4:106983673	TBCK	0.46	6.01	0.31	4.84e-9	Cancer;
CRC	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.39	-11.42	-0.53	1.14e-25	Psoriasis vulgaris;
CRC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg05585544	chr11:47624801	NA	-0.63	-11.33	-0.53	2.48e-25	Subjective well-being;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03404566	chr17:6899310	ALOX12	-0.6	-10.64	-0.51	6.44e-23	Tonsillectomy;
CRC	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.9	-0.31	9.04e-9	Daytime sleep phenotypes;
CRC	cis	rs2811415	0.597	rs11720351	chr3:127751252	T/C	cg13719885	chr3:127795394	NA	-0.38	-5.79	-0.3	1.62e-8	Lung function (FEV1/FVC);
CRC	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.63	-0.3	3.89e-8	Coronary artery disease;
CRC	cis	rs4363385	0.934	rs1415964	chr1:152955085	T/C	cg25856811	chr1:152973957	SPRR3	-0.22	-5.82	-0.31	1.43e-8	Inflammatory skin disease;
CRC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg18479299	chr3:125709523	NA	-0.48	-6.14	-0.32	2.41e-9	Blood pressure (smoking interaction);
CRC	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.68	9.52	0.46	3.8e-19	Body mass index;
CRC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17554472	chr22:41940697	POLR3H	-0.55	-5.98	-0.31	5.91e-9	Vitiligo;
CRC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.36	-0.33	6.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11547950	chr5:77652471	NA	-0.49	-7.22	-0.37	3.57e-12	Triglycerides;
CRC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.23	0.49	1.7e-21	Ileal carcinoids;
CRC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.53	11.79	0.55	5.28e-27	Alcohol dependence;
CRC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.65	-11.14	-0.52	1.1e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.08	0.36	8.63e-12	Alzheimer's disease;
CRC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.62	8.34	0.42	2.01e-15	Urate levels in lean individuals;
CRC	trans	rs67177172	0.521	rs1486285	chr5:84595711	G/C	cg11637721	chr11:65486928	KAT5;RNASEH2C	0.36	5.98	0.31	5.95e-9	Photic sneeze reflex;
CRC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg20573242	chr4:122745356	CCNA2	0.41	6.15	0.32	2.26e-9	Type 2 diabetes;
CRC	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.62	-0.3	4.15e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9937943	0.667	rs12919002	chr16:74612377	A/G	cg01733217	chr16:74700730	RFWD3	0.75	8.35	0.42	1.98e-15	Neutrophil percentage of white cells;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.73	0.3	2.32e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg20487152	chr13:99095054	FARP1	0.42	6.2	0.32	1.65e-9	Neuroticism;
CRC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-5.83	-0.31	1.32e-8	Total body bone mineral density;
CRC	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.53	8.15	0.41	7.87e-15	Vitiligo;
CRC	cis	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg05299278	chr17:33885742	SLFN14	0.39	5.86	0.31	1.14e-8	Response to radiotherapy in cancer (late toxicity);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08334199	chr2:178128998	NFE2L2	0.4	6.05	0.32	3.96e-9	Schizophrenia;
CRC	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg13615338	chr4:55094005	PDGFRA	0.42	6.14	0.32	2.32e-9	Corneal astigmatism;
CRC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.8	14.3	0.62	2.04e-36	Breast cancer;
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.51	-6.87	-0.35	3.32e-11	Glycated hemoglobin levels;
CRC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.09	-0.32	3.2e-9	Height;
CRC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.62	10.32	0.49	8.07e-22	Prudent dietary pattern;
CRC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg21033440	chr11:65409861	SIPA1	-0.65	-8.1	-0.41	1.1e-14	Blood pressure (age interaction);
CRC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg21155852	chr7:2048760	MAD1L1	-0.51	-6.91	-0.36	2.53e-11	Bipolar disorder;
CRC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-7.83	-0.4	6.78e-14	Aortic root size;
CRC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.37	0.38	1.35e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4700695	0.841	rs402100	chr5:65266125	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.84	0.35	3.78e-11	Facial morphology (factor 19);
CRC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.79	12.06	0.55	5.67e-28	Intelligence (multi-trait analysis);
CRC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg01941586	chr1:40203715	PPIE	-0.45	-6.29	-0.33	1.04e-9	Blood protein levels;
CRC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.73	-10.65	-0.51	5.79e-23	Cognitive function;
CRC	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg19875578	chr6:126661172	C6orf173	0.42	5.81	0.31	1.45e-8	Male-pattern baldness;
CRC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.52	0.43	5.67e-16	Morning vs. evening chronotype;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.69	7.77	0.39	9.92e-14	Body mass index;
CRC	cis	rs4728302	0.869	rs10156088	chr7:133592544	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.84	0.31	1.25e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.6	-9.1	-0.45	8.83e-18	Bipolar disorder;
CRC	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg23815491	chr16:72088622	HP	0.5	7.33	0.37	1.83e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.32	2.37e-9	Tonsillectomy;
CRC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg14979609	chr8:8086686	FLJ10661	0.38	6.25	0.33	1.26e-9	Myopia;Myopia (pathological);
CRC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg12927641	chr6:109611667	NA	-0.38	-6.74	-0.35	7.22e-11	Reticulocyte fraction of red cells;
CRC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg12193833	chr17:30244370	NA	0.6	6.74	0.35	7.01e-11	Hip circumference adjusted for BMI;
CRC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.23	-0.37	3.36e-12	Response to antipsychotic treatment;
CRC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg05304507	chr6:116381966	FRK	0.31	8.43	0.42	1.11e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.33	7.55	0.38	4.28e-13	Corneal astigmatism;
CRC	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.53	8.94	0.44	2.86e-17	Dupuytren's disease;
CRC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.48	-7.51	-0.38	5.46e-13	Intelligence (multi-trait analysis);
CRC	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.49	8.04	0.41	1.62e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-7.17	-0.37	4.91e-12	Pulmonary function;
CRC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.51	8.98	0.44	2.13e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.48	6.51	0.34	2.81e-10	Schizophrenia;
CRC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.95	-0.31	6.71e-9	Total body bone mineral density;
CRC	cis	rs1639906	0.965	rs1639908	chr7:2230644	C/G	cg19897017	chr7:2163380	MAD1L1	-0.42	-6.61	-0.34	1.58e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	11.25	0.53	4.78e-25	Personality dimensions;
CRC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	5.63	0.3	3.84e-8	Aortic root size;
CRC	cis	rs939584	1.000	rs11127489	chr2:646081	C/T	cg03610516	chr2:642275	NA	0.42	5.87	0.31	1.06e-8	Body mass index;
CRC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.71	-11.1	-0.52	1.52e-24	Colorectal cancer;
CRC	cis	rs10486722	0.651	rs10951657	chr7:41781363	T/C	cg22138096	chr7:41772439	LOC285954	0.49	6.28	0.33	1.07e-9	Pit-and-Fissure caries;
CRC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.84	13.71	0.6	3.89e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-7.01	-0.36	1.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.8	-10.34	-0.5	6.98e-22	Initial pursuit acceleration;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg21403089	chr7:108166784	PNPLA8	0.51	6.15	0.32	2.22e-9	Body mass index;
CRC	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.56	8.22	0.41	4.67e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6445967	1.000	rs6791748	chr3:58308519	G/A	cg23715586	chr3:58305044	RPP14	0.36	6.02	0.31	4.67e-9	Platelet count;
CRC	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.61	-9.14	-0.45	6.5e-18	Dementia with Lewy bodies;
CRC	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.83	-13.54	-0.6	1.68e-33	Hypospadias;
CRC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.5	6.95	0.36	2.01e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	trans	rs766903	1.000	rs4761832	chr12:51694278	C/T	cg09910207	chr12:91452697	KERA	0.45	5.98	0.31	5.76e-9	Aging (time to death);
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg07617317	chr6:118971624	C6orf204	0.5	6.17	0.32	2.01e-9	Diastolic blood pressure;
CRC	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg16989719	chr2:238392110	NA	-0.37	-6.49	-0.34	3.22e-10	Prostate cancer;
CRC	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.18	0.37	4.82e-12	Mean corpuscular volume;
CRC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg15147215	chr3:52552868	STAB1	0.49	8.52	0.43	5.65e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.4	-0.33	5.46e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.1	-12.3	-0.56	7.15e-29	Diabetic kidney disease;
CRC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.48	-7.92	-0.4	3.61e-14	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16638571	chr8:81083534	TPD52	0.47	6.61	0.34	1.59e-10	Anxiety disorder;
CRC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg05627522	chr15:75251581	NA	0.5	7.6	0.39	3.04e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg25347419	chr2:177043501	NA	0.58	9.1	0.45	9.05e-18	IgG glycosylation;
CRC	trans	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg21589273	chr3:113416452	KIAA2018	0.54	5.97	0.31	6.27e-9	Iron status biomarkers;
CRC	cis	rs12760731	0.565	rs12047117	chr1:178132608	G/A	cg00404053	chr1:178313656	RASAL2	1.02	10.74	0.51	2.82e-23	Obesity-related traits;
CRC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.34	0.42	2.12e-15	Colorectal cancer;
CRC	cis	rs17601876	0.545	rs4775936	chr15:51536022	A/G	cg19946085	chr15:51559439	CYP19A1	0.3	5.73	0.3	2.29e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02421172	chr7:1938701	MAD1L1	0.46	6.09	0.32	3.18e-9	Neuroticism;
CRC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.78	-0.35	5.53e-11	Alzheimer's disease (late onset);
CRC	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg20933634	chr6:27740509	NA	0.55	7.13	0.37	6.29e-12	Breast cancer;
CRC	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg15465823	chr12:48382534	COL2A1	-0.37	-6.14	-0.32	2.43e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg16342193	chr10:102329863	NA	-0.35	-5.71	-0.3	2.56e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.61	-8.15	-0.41	7.47e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg21466736	chr12:48725269	NA	-0.53	-8.01	-0.4	1.96e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs73195822	0.527	rs73194059	chr12:111221740	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	6.98	0.36	1.61e-11	Itch intensity from mosquito bite;
CRC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.64	8.38	0.42	1.6e-15	Arsenic metabolism;
CRC	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.69	-0.54	1.19e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg10760299	chr15:45669010	GATM	0.49	7.83	0.4	6.7e-14	Homoarginine levels;
CRC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	trans	rs2303319	0.504	rs12465734	chr2:162437859	A/G	cg14875682	chr5:52083620	ITGA1;PELO	-0.75	-6.01	-0.31	5.03e-9	Cognitive function;
CRC	cis	rs73195822	0.506	rs61440260	chr12:111142855	G/T	cg12870014	chr12:110450643	ANKRD13A	0.78	9.46	0.46	6.03e-19	Itch intensity from mosquito bite;
CRC	cis	rs7487075	0.722	rs5016479	chr12:46712784	G/T	cg22049899	chr12:47219821	SLC38A4	0.34	6.3	0.33	9.67e-10	Itch intensity from mosquito bite;
CRC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.73	-0.35	7.33e-11	Menopause (age at onset);
CRC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg13390004	chr1:15929781	NA	0.48	6.9	0.36	2.74e-11	Systolic blood pressure;
CRC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg02033258	chr5:131593261	PDLIM4	-0.34	-6.07	-0.32	3.52e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.3	-0.79	1.34e-71	Myeloid white cell count;
CRC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.61	-0.39	2.86e-13	Coronary artery disease;
CRC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg05283184	chr6:79620031	NA	-0.58	-9.01	-0.44	1.68e-17	Intelligence (multi-trait analysis);
CRC	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.7	-9.84	-0.48	3.28e-20	Hypospadias;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.69	-0.3	2.76e-8	Obesity-related traits;
CRC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	0.98	20.7	0.75	1.52e-61	Multiple system atrophy;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14591243	chr3:136471577	STAG1	-0.42	-6.1	-0.32	2.9e-9	Daytime sleep phenotypes;
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.81	-0.31	1.47e-8	Neuroticism;
CRC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.46	-7.09	-0.36	8.3e-12	Blood metabolite levels;
CRC	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.64	-8.29	-0.42	2.97e-15	Extraversion;
CRC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg18612461	chr15:75251733	NA	0.39	6.16	0.32	2.09e-9	Breast cancer;
CRC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.47	-6.59	-0.34	1.74e-10	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg27535305	chr1:53392650	SCP2	-0.44	-7.72	-0.39	1.44e-13	Monocyte count;
CRC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.66	9.36	0.46	1.27e-18	Lung cancer;
CRC	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.27	-0.33	1.12e-9	Breast cancer;
CRC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.92	-0.52	6.61e-24	Blood trace element (Zn levels);
CRC	cis	rs35740288	0.929	rs11073537	chr15:86312681	G/A	cg20737812	chr15:86336631	KLHL25	-0.37	-5.71	-0.3	2.54e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20092199	chr4:1342459	KIAA1530	0.33	5.76	0.3	1.92e-8	Longevity;
CRC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.62	9.82	0.48	4e-20	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.15	-0.56	2.67e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.57	-8.65	-0.43	2.23e-16	Monocyte percentage of white cells;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg12573674	chr2:1569213	NA	-0.73	-7.8	-0.39	8.35e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.61	-9.45	-0.46	6.57e-19	Aortic root size;
CRC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.52	-9.63	-0.47	1.66e-19	Eye color traits;
CRC	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.58	10.41	0.5	3.9e-22	Blood metabolite ratios;
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg12516270	chr8:143859308	LYNX1	0.44	7.93	0.4	3.55e-14	Urinary tract infection frequency;
CRC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.74	-0.39	1.25e-13	Vitiligo;
CRC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	15.2	0.64	6.92e-40	Platelet count;
CRC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.34	-0.42	2.02e-15	Bladder cancer;
CRC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg16141378	chr3:129829833	LOC729375	0.42	6.37	0.33	6.27e-10	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18656577	chr17:8286464	RPL26	0.44	7.34	0.38	1.67e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.82	0.44	6.77e-17	Hip circumference adjusted for BMI;
CRC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.44	-7.01	-0.36	1.38e-11	Monocyte count;
CRC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg13856295	chr9:139396418	NOTCH1	0.37	5.7	0.3	2.65e-8	Monocyte percentage of white cells;
CRC	cis	rs9469578	0.892	rs73743333	chr6:33714042	G/A	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg25456477	chr12:86230367	RASSF9	0.39	6.56	0.34	2.13e-10	Major depressive disorder;
CRC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.71	10.51	0.5	1.79e-22	Response to antineoplastic agents;
CRC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.87	-12.36	-0.56	4.43e-29	Gut microbiome composition (summer);
CRC	cis	rs1656402	1.000	rs1190438	chr2:233423259	G/T	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.68	9.34	0.46	1.45e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.82	14.72	0.63	5.05e-38	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.67	-0.35	1.1e-10	Total body bone mineral density;
CRC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.53	6.78	0.35	5.62e-11	Bronchopulmonary dysplasia;
CRC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg03885332	chr11:832357	CD151	-0.42	-6.28	-0.33	1.05e-9	Mean platelet volume;
CRC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg19688584	chr6:167529678	CCR6	-0.33	-6.16	-0.32	2.16e-9	Primary biliary cholangitis;
CRC	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg00490450	chr3:139108681	COPB2	0.44	6.58	0.34	1.83e-10	Obesity-related traits;
CRC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.76	-9.41	-0.46	9.04e-19	Initial pursuit acceleration;
CRC	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.4	-7.05	-0.36	1.07e-11	Obesity-related traits;
CRC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	6.73	0.35	7.51e-11	Colorectal cancer;
CRC	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.22e-13	QT interval;
CRC	cis	rs2971970	0.519	rs62470447	chr7:133632339	C/T	cg03336402	chr7:133662267	EXOC4	0.63	9.38	0.46	1.12e-18	Intelligence (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01663232	chr2:214016940	IKZF2	-0.41	-6.07	-0.32	3.45e-9	Myopia (pathological);
CRC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-9.09	-0.45	9.25e-18	Alcohol dependence;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19981660	chr12:132434166	EP400	0.41	6.63	0.34	1.4e-10	Obesity-related traits;
CRC	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg10437265	chr15:77819839	NA	-0.66	-11.61	-0.54	2.41e-26	Type 2 diabetes;
CRC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.62	0.43	2.88e-16	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.54	-8.68	-0.43	1.84e-16	Prostate cancer;
CRC	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg10437265	chr15:77819839	NA	0.7	12.86	0.58	5.83e-31	Type 2 diabetes;
CRC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.98	0.4	2.45e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.3	-0.37	2.24e-12	Capecitabine sensitivity;
CRC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-10.71	-0.51	3.62e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-9.4	-0.46	9.42e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.66	10.36	0.5	6.08e-22	Birth weight;
CRC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.72	10.33	0.49	7.58e-22	Cognitive function;
CRC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg02033258	chr5:131593261	PDLIM4	0.32	5.66	0.3	3.31e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2179367	0.959	rs564961	chr6:149657227	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.37	-5.99	-0.31	5.48e-9	Dupuytren's disease;
CRC	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg09264619	chr17:80180166	NA	0.36	5.86	0.31	1.12e-8	Life satisfaction;
CRC	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.6	9.65	0.47	1.45e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6076065	0.723	rs743023	chr20:23400852	T/C	cg11657817	chr20:23433608	CST11	0.45	6.49	0.34	3.17e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg14036092	chr11:66035641	RAB1B	-0.48	-5.77	-0.3	1.79e-8	Electroencephalogram traits;
CRC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg27426351	chr10:43362370	NA	0.46	5.88	0.31	9.98e-9	Blood protein levels;
CRC	cis	rs10878977	1.000	rs10878977	chr12:69799690	C/T	cg20891283	chr12:69753455	YEATS4	0.46	6.13	0.32	2.51e-9	Colorectal cancer;
CRC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	17.15	0.69	1.5e-47	Platelet count;
CRC	cis	rs4589502	1.000	rs2414925	chr15:67129986	A/G	cg12317470	chr15:67143691	NA	0.73	6.73	0.35	7.44e-11	Lung cancer (smoking interaction);
CRC	cis	rs7605827	0.930	rs11691286	chr2:15558580	G/T	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.9e-9	Educational attainment (years of education);
CRC	cis	rs4478137	1.000	rs4478137	chr4:164238385	G/A	cg06758707	chr4:164254230	NPY1R	0.39	5.98	0.31	5.87e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs883565	0.771	rs1053530	chr3:39138082	A/G	cg01426195	chr3:39028469	NA	0.52	7.89	0.4	4.57e-14	Handedness;
CRC	cis	rs751837	0.591	rs10138133	chr14:103424897	A/G	cg10087771	chr14:103399429	CDC42BPB	0.66	6.47	0.34	3.46e-10	Large B-cell lymphoma;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg19041857	chr6:27730383	NA	-0.44	-6.08	-0.32	3.38e-9	Parkinson's disease;
CRC	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg15226275	chr6:116381976	FRK	0.31	7.39	0.38	1.19e-12	Total cholesterol levels;
CRC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.96	-0.36	1.82e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.56	8.35	0.42	1.88e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.52	0.43	5.95e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg15465823	chr12:48382534	COL2A1	0.38	6.23	0.32	1.44e-9	Glycated hemoglobin levels;
CRC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg05623727	chr3:50126028	RBM5	-0.41	-6.91	-0.36	2.48e-11	Menarche (age at onset);
CRC	cis	rs3772130	1.000	rs7427165	chr3:121364624	C/T	cg20356878	chr3:121714668	ILDR1	0.49	7.65	0.39	2.22e-13	Cognitive performance;
CRC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.1	10.18	0.49	2.51e-21	Opioid sensitivity;
CRC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.37	-6.17	-0.32	2.02e-9	Childhood ear infection;
CRC	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg03929089	chr4:120376271	NA	-0.62	-6.08	-0.32	3.34e-9	Intraocular pressure;
CRC	cis	rs2270875	0.696	rs10464871	chr8:132931374	C/T	cg24184792	chr8:132919238	EFR3A	-0.54	-6.11	-0.32	2.77e-9	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg09659197	chr4:152720779	NA	0.31	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
CRC	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.35	-6.01	-0.31	4.85e-9	Airway imaging phenotypes;
CRC	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg04110750	chr16:69646130	NFAT5	0.41	6.37	0.33	6.25e-10	Sjögren's syndrome;
CRC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.34	6.1	0.32	2.91e-9	Crohn's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14361641	chr2:70056642	GMCL1	0.45	6.36	0.33	6.9e-10	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg22110888	chr17:80059540	CCDC57	0.39	6.24	0.33	1.35e-9	Life satisfaction;
CRC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg03013999	chr17:37608204	MED1	-0.49	-7.68	-0.39	1.86e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs12936587	0.601	rs11655881	chr17:17553133	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.38	-5.75	-0.3	2.02e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs1712517	0.771	rs11191664	chr10:105118476	C/T	cg05636881	chr10:105038444	INA	0.46	7.92	0.4	3.81e-14	Migraine;
CRC	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg06917450	chr1:38156652	C1orf109	-0.49	-6.95	-0.36	2.02e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11679072	1.000	rs13011626	chr2:240444685	C/T	cg03276489	chr2:240449683	NA	-0.89	-7.03	-0.36	1.21e-11	Blood pressure (smoking interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15790941	chr4:39640517	C4orf34	-0.43	-6.6	-0.34	1.61e-10	Myopia (pathological);
CRC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.2	0.67	8.61e-44	Chronic sinus infection;
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	trans	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg10756647	chr7:56101905	PSPH	0.76	7.87	0.4	5.34e-14	Diabetic kidney disease;
CRC	cis	rs365302	0.723	rs391046	chr6:159646232	G/C	cg14500486	chr6:159655392	FNDC1	0.43	6.59	0.34	1.76e-10	Coronary heart disease;
CRC	cis	rs2072510	0.593	rs2660900	chr12:96405077	T/C	cg09636302	chr12:96389483	HAL	-0.51	-6.28	-0.33	1.05e-9	Metabolite levels (small molecules and protein measures);
CRC	trans	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.56	7.94	0.4	3.16e-14	Longevity;
CRC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.46	6.78	0.35	5.59e-11	Cleft lip with or without cleft palate;
CRC	cis	rs394563	0.601	rs431978	chr6:149793000	C/T	cg07828024	chr6:149772892	ZC3H12D	0.42	7.27	0.37	2.63e-12	Dupuytren's disease;
CRC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.37	5.93	0.31	7.63e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03868159	chr6:42532252	UBR2	0.41	6.12	0.32	2.66e-9	Myopia (pathological);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13647118	chr5:82373317	XRCC4;TMEM167A	0.37	6.25	0.33	1.28e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg19812747	chr11:111475976	SIK2	0.44	6.25	0.33	1.24e-9	Primary sclerosing cholangitis;
CRC	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg10820045	chr2:198174542	NA	0.33	5.67	0.3	3.09e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21229253	chr9:134406525	UCK1	0.36	6.09	0.32	3.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg17420585	chr12:42539391	GXYLT1	-0.39	-5.68	-0.3	2.89e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25132276	chr5:149546087	CDX1	0.23	6.1	0.32	2.99e-9	Survival in pancreatic cancer;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12273811	chr6:28175739	NA	0.61	8.84	0.44	5.98e-17	Cardiac Troponin-T levels;
CRC	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-1.0	-15.67	-0.65	9.85e-42	Gout;
CRC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.73	0.3	2.26e-8	Depression;
CRC	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg04439458	chr5:138467593	SIL1	0.36	6.23	0.32	1.45e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.81	0.3	1.5e-8	Monocyte percentage of white cells;
CRC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.31	0.46	1.82e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs12024301	0.557	rs74448735	chr1:183645983	T/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.73	6.43	0.33	4.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg08501292	chr6:25962987	TRIM38	0.74	7.37	0.38	1.36e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.76	-0.3	1.95e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs8005677	0.828	rs2295682	chr14:23374862	C/T	cg25600027	chr14:23388339	RBM23	-0.46	-6.99	-0.36	1.5e-11	Cognitive ability (multi-trait analysis);
CRC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.31	-0.33	9.16e-10	Aortic root size;
CRC	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.83	5.92	0.31	8.26e-9	LDL cholesterol;
CRC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.82	-10.57	-0.5	1.14e-22	Gut microbiome composition (summer);
CRC	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.44	6.65	0.34	1.23e-10	Red blood cell count;
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg15790184	chr11:494944	RNH1	0.61	6.27	0.33	1.14e-9	Body mass index;
CRC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg00343986	chr7:65444356	GUSB	-0.5	-7.31	-0.37	2.05e-12	Aortic root size;
CRC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.52	8.21	0.41	5.22e-15	Multiple system atrophy;
CRC	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	1.13	17.08	0.69	2.8e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.46	6.87	0.35	3.28e-11	Menopause (age at onset);
CRC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg03013999	chr17:37608204	MED1	0.48	7.35	0.38	1.59e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-6.39	-0.33	5.77e-10	Morning vs. evening chronotype;
CRC	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg06028605	chr16:24865363	SLC5A11	-0.34	-6.6	-0.34	1.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.5	7.18	0.37	4.8e-12	Testicular germ cell tumor;
CRC	trans	rs7142002	0.803	rs12588329	chr14:102363881	G/A	cg24202123	chr3:36422093	STAC	-0.48	-6.36	-0.33	6.64e-10	Autism;
CRC	cis	rs2882667	0.690	rs288026	chr5:138222594	A/G	cg09476006	chr5:138032270	NA	0.55	9.14	0.45	6.76e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg08481491	chr3:125900108	ALDH1L1	0.32	5.73	0.3	2.32e-8	Metabolite levels;
CRC	cis	rs7129220	0.588	rs16907481	chr11:10144108	A/T	cg23875677	chr11:10229755	SBF2	-0.53	-5.68	-0.3	3.03e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.72	6.71	0.35	8.6e-11	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.4	-5.61	-0.3	4.21e-8	Breast cancer;
CRC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg13260133	chr10:104626808	NA	0.42	6.15	0.32	2.19e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	trans	rs4714291	0.862	rs2984445	chr6:40069935	C/T	cg02267698	chr19:7991119	CTXN1	-0.51	-7.04	-0.36	1.16e-11	Strep throat;
CRC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.51	0.34	2.81e-10	Morning vs. evening chronotype;
CRC	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.51	6.49	0.34	3.13e-10	Breast cancer;
CRC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg19792802	chr11:65647270	CTSW	-0.5	-7.55	-0.38	4.23e-13	Crohn's disease;
CRC	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.57	8.92	0.44	3.28e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg03934865	chr2:198174659	NA	0.36	5.95	0.31	7.04e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg17724175	chr1:150552817	MCL1	0.49	7.23	0.37	3.4e-12	Melanoma;
CRC	cis	rs12760731	0.641	rs10494513	chr1:178252377	C/G	cg00404053	chr1:178313656	RASAL2	0.81	8.7	0.43	1.64e-16	Obesity-related traits;
CRC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	5.6	0.3	4.51e-8	IgG glycosylation;
CRC	cis	rs11650494	0.710	rs2119935	chr17:47471334	T/C	cg08112188	chr17:47440006	ZNF652	0.67	5.99	0.31	5.63e-9	Prostate cancer;
CRC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.57	-6.12	-0.32	2.73e-9	White matter hyperintensity burden;
CRC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.89	-0.44	4.12e-17	Bipolar disorder;
CRC	trans	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.26	0.33	1.23e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9826463	0.582	rs73238185	chr3:142141177	T/C	cg20824294	chr3:142316082	PLS1	0.38	6.03	0.32	4.36e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg24253500	chr15:84953950	NA	0.39	6.29	0.33	9.84e-10	Schizophrenia;
CRC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg03013999	chr17:37608204	MED1	0.47	7.13	0.37	6.39e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.4	7.07	0.36	9.06e-12	Obesity-related traits;
CRC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-9.43	-0.46	7.83e-19	Personality dimensions;
CRC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.47	-6.54	-0.34	2.29e-10	Platelet distribution width;
CRC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg26061582	chr7:22766209	IL6	0.49	7.83	0.4	6.89e-14	Lung cancer;
CRC	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.95	-9.55	-0.47	3.09e-19	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	ch.8.33884649F	chr8:33765107	NA	-0.39	-6.18	-0.32	1.94e-9	Body mass index;
CRC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg08270630	chr22:50330655	NA	-0.39	-5.61	-0.3	4.19e-8	Schizophrenia;
CRC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.65	-7.71	-0.39	1.5e-13	Blood trace element (Zn levels);
CRC	cis	rs9463078	0.691	rs3920903	chr6:45040928	T/A	cg25276700	chr6:44698697	NA	-0.24	-5.92	-0.31	8.18e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23708337	chr7:1209742	NA	0.43	6.66	0.34	1.15e-10	Longevity;Endometriosis;
CRC	cis	rs7677751	1.000	rs7677751	chr4:55124460	C/T	cg17187183	chr4:55093834	PDGFRA	0.46	6.07	0.32	3.52e-9	Corneal astigmatism;
CRC	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.81	11.73	0.54	9.04e-27	Response to antineoplastic agents;
CRC	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg00490450	chr3:139108681	COPB2	0.48	7.24	0.37	3.2e-12	Obesity-related traits;
CRC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.44	-7.87	-0.4	5.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg15147215	chr3:52552868	STAB1	-0.41	-5.78	-0.3	1.72e-8	Schizophrenia;
CRC	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.01	10.38	0.5	4.99e-22	Prostate cancer;
CRC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.62	-16.96	-0.68	8.39e-47	Urate levels in overweight individuals;
CRC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.37	0.46	1.21e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.52	6.38	0.33	5.92e-10	Morning vs. evening chronotype;
CRC	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg19582491	chr16:67682965	RLTPR	-0.39	-5.62	-0.3	4.11e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.41	5.69	0.3	2.84e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg23958373	chr8:599963	NA	-0.88	-7.74	-0.39	1.21e-13	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12655452	chr1:77685094	PIGK	0.39	6.43	0.33	4.55e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.52	6.82	0.35	4.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg05585544	chr11:47624801	NA	0.53	9.3	0.46	2.09e-18	Subjective well-being;
CRC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14895029	chr7:2775587	GNA12	-0.4	-6.11	-0.32	2.87e-9	Height;
CRC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.66	7.55	0.38	4.28e-13	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.7	-11.35	-0.53	1.97e-25	Breast cancer;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg15786705	chr6:28176104	NA	0.66	8.77	0.44	1.01e-16	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.1	0.36	7.91e-12	Extrinsic epigenetic age acceleration;
CRC	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.48	-7.3	-0.37	2.16e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.42	-5.67	-0.3	3.19e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg19980929	chr12:42632907	YAF2	-0.39	-5.89	-0.31	9.33e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.48	6.1	0.32	2.98e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg17691542	chr6:26056736	HIST1H1C	0.42	5.7	0.3	2.69e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.81	-13.82	-0.61	1.41e-34	Cystic fibrosis severity;
CRC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.38	5.88	0.31	1e-8	Height;
CRC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.51	7.42	0.38	9.95e-13	Type 2 diabetes;
CRC	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg01420254	chr6:26195488	NA	0.69	6.13	0.32	2.45e-9	Iron status biomarkers (total iron binding capacity);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12140595	chr2:220093941	ANKZF1;ATG9A	0.45	6.21	0.32	1.59e-9	Response to antipsychotic treatment;
CRC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.6	8.9	0.44	3.78e-17	Lymphocyte counts;
CRC	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.69	-0.3	2.75e-8	Daytime sleep phenotypes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06753227	chr18:9475508	RALBP1	0.5	8.18	0.41	6.19e-15	Liver disease severity in Alagille syndrome;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20913732	chr2:197791419	PGAP1	0.47	6.48	0.34	3.35e-10	Anxiety disorder;
CRC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs185694	1.000	rs653251	chr13:30894542	C/T	cg04551440	chr13:30881194	KATNAL1	-0.6	-6.38	-0.33	6.04e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.97	-0.31	6.24e-9	Metabolite levels;
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12588279	chr6:26043732	HIST1H2BB	0.48	6.9	0.36	2.72e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6076065	0.723	rs2424552	chr20:23402833	G/A	cg11657817	chr20:23433608	CST11	0.45	6.56	0.34	2.08e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2271001	0.910	rs11604483	chr11:19144579	C/T	cg00161556	chr11:19138045	ZDHHC13	0.34	5.8	0.3	1.58e-8	Gut microbiome composition (winter);
CRC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg06238570	chr21:40685208	BRWD1	0.78	10.86	0.51	1.12e-23	Cognitive function;
CRC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.58	8.73	0.43	1.3e-16	Night sleep phenotypes;
CRC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.68	8.9	0.44	3.69e-17	Morning vs. evening chronotype;
CRC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.59	-10.61	-0.5	8.46e-23	Aortic root size;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg17182837	chr8:41585554	ANK1	-0.4	-6.19	-0.32	1.8e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs8192917	0.573	rs8010409	chr14:25080289	G/A	cg01932691	chr14:25045625	CTSG	-0.59	-5.8	-0.3	1.59e-8	Vitiligo;
CRC	cis	rs16867335	1.000	rs34842451	chr2:181480525	C/T	cg23363182	chr2:181467187	NA	0.48	6.61	0.34	1.57e-10	Survival in rectal cancer;
CRC	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg15687855	chr3:44754131	ZNF502	-0.35	-5.82	-0.31	1.38e-8	Depressive symptoms;
CRC	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.64	-0.3	3.74e-8	Total body bone mineral density (age 45-60);
CRC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg01629716	chr15:45996671	NA	0.41	8.46	0.42	9.03e-16	Waist circumference;Weight;
CRC	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg07299736	chr8:135490787	ZFAT	-0.37	-6.39	-0.33	5.73e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.49	7.82	0.4	7.37e-14	Testicular germ cell tumor;
CRC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.24	-0.33	1.35e-9	Aortic root size;
CRC	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.38	-5.67	-0.3	3.19e-8	Vitamin D levels;
CRC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.43	-6.0	-0.31	5.28e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.64	9.52	0.46	3.8e-19	Breast cancer;
CRC	trans	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg21302420	chr1:112162376	RAP1A	-0.58	-6.12	-0.32	2.65e-9	Skin colour saturation;
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.07	-0.32	3.5e-9	Obesity-related traits;
CRC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.01	-0.36	1.33e-11	IgG glycosylation;
CRC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2565722	0.622	rs2465844	chr6:161297372	G/C	cg03159191	chr6:161285451	NA	-0.46	-6.34	-0.33	7.68e-10	Blood protein levels;
CRC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.68	10.98	0.52	4.28e-24	Colorectal cancer;
CRC	trans	rs3018066	0.738	rs76654812	chr4:106944699	C/T	cg02609279	chr2:182325952	ITGA4	-0.44	-6.1	-0.32	3.04e-9	Cancer;
CRC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.72	-0.35	8.24e-11	Colorectal cancer;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg17601595	chr10:13628739	PRPF18	-0.39	-6.08	-0.32	3.4e-9	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02592615	chr6:12012261	HIVEP1	-0.4	-6.21	-0.32	1.58e-9	Myopia (pathological);
CRC	trans	rs10411161	0.702	rs10403189	chr19:52400673	A/G	cg22319618	chr22:45562946	NUP50	0.57	5.97	0.31	6.21e-9	Breast cancer;
CRC	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08645402	chr16:4508243	NA	0.61	10.01	0.48	9.38e-21	Schizophrenia;
CRC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg20673091	chr1:2541236	MMEL1	0.36	5.8	0.3	1.52e-8	Ulcerative colitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21306212	chr13:79979929	RBM26	0.48	7.24	0.37	3.21e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.43	-0.33	4.37e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.8	-11.82	-0.55	4.1e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3018066	0.867	rs11931386	chr4:107167983	T/G	cg01869342	chr4:106983673	TBCK	-0.36	-5.66	-0.3	3.37e-8	Cancer;
CRC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	cis	rs1873147	1.000	rs1873149	chr15:63312428	A/C	cg12160578	chr15:63334699	TPM1	0.44	6.31	0.33	9.02e-10	Orofacial clefts;
CRC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.54	-8.68	-0.43	1.81e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.48	0.42	7.93e-16	Arsenic metabolism;
CRC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg00947319	chr17:47005597	UBE2Z	-0.35	-6.01	-0.31	4.88e-9	Type 2 diabetes;
CRC	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg26875233	chr11:93583750	C11orf90	-0.33	-6.29	-0.33	1.03e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.62	-0.43	2.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg17866984	chr6:43737767	VEGFA	-0.44	-6.68	-0.35	1.04e-10	Daytime sleep phenotypes;
CRC	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.17	-9.75	-0.47	6.94e-20	Mitochondrial DNA levels;
CRC	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg17145862	chr1:211918768	LPGAT1	-0.49	-8.14	-0.41	8.12e-15	Leprosy;
CRC	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	14.7	0.63	5.97e-38	Bipolar disorder;
CRC	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.62	-0.34	1.43e-10	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26342734	chr17:7211307	EIF5A	0.45	7.28	0.37	2.54e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.76	-0.39	1.05e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.46	6.12	0.32	2.71e-9	Plateletcrit;
CRC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-9.9	-0.48	2.13e-20	Bladder cancer;
CRC	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.7	-0.3	2.6e-8	Electroencephalogram traits;
CRC	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg18200150	chr17:30822561	MYO1D	0.44	8.53	0.43	5.26e-16	Schizophrenia;
CRC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.48	-8.8	-0.44	7.85e-17	Eye color traits;
CRC	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	7.97e-10	Hepatitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg24644049	chr4:85504048	CDS1	-0.41	-6.01	-0.31	4.83e-9	Myopia (pathological);
CRC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg19622623	chr12:86230825	RASSF9	-0.42	-6.78	-0.35	5.42e-11	Major depressive disorder;
CRC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg12573674	chr2:1569213	NA	-0.66	-7.37	-0.38	1.42e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.54	-6.77	-0.35	5.99e-11	Body mass index;
CRC	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg24046110	chr8:143859143	LYNX1	-0.43	-6.91	-0.36	2.52e-11	Urinary tract infection frequency;
CRC	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.82	-0.4	7.31e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.55	8.32	0.42	2.33e-15	Height;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg06470822	chr6:28175283	NA	0.82	12.08	0.55	4.78e-28	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg04611788	chr3:186434169	KNG1	-0.58	-8.36	-0.42	1.79e-15	Adiponectin levels;
CRC	trans	rs747334	0.846	rs10736059	chr10:92706105	C/A	cg19856520	chr1:39696676	MACF1	-0.32	-5.99	-0.31	5.45e-9	Fibroblast growth factor basic levels;
CRC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg04450456	chr4:17643702	FAM184B	0.43	6.86	0.35	3.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.65	8.7	0.43	1.65e-16	Alcohol dependence;
CRC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.4	-19.9	-0.74	2.03e-58	Hip circumference adjusted for BMI;
CRC	trans	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.39	-6.56	-0.34	2.03e-10	Schizophrenia;
CRC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.5	-9.08	-0.45	1e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.97	-0.31	6.02e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	7.1	0.36	7.95e-12	Coronary artery disease;
CRC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.7	-0.35	8.8e-11	Personality dimensions;
CRC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.66	-7.37	-0.38	1.35e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs6676180	0.514	rs868675	chr1:119773596	A/G	cg05756136	chr1:119680316	WARS2	-0.5	-7.5	-0.38	5.96e-13	Monobrow;
CRC	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.54	9.1	0.45	9.18e-18	Dupuytren's disease;
CRC	trans	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg21153622	chr11:89784906	NA	-0.48	-7.79	-0.39	8.59e-14	HDL cholesterol;
CRC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg16989086	chr20:62203971	PRIC285	0.47	6.03	0.32	4.52e-9	Glioblastoma;
CRC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg05207973	chr5:176823642	SLC34A1	0.34	5.7	0.3	2.7e-8	Hemoglobin concentration;Hematocrit;
CRC	cis	rs62408225	0.888	rs58453446	chr6:90948093	G/C	cg06866423	chr6:90926672	BACH2	0.48	7.79	0.39	9.02e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg04132472	chr17:19861366	AKAP10	0.42	6.66	0.34	1.14e-10	Schizophrenia;
CRC	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg15192750	chr16:69999425	NA	0.49	6.5	0.34	2.91e-10	IgE levels;
CRC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	1.0	15.86	0.66	1.75e-42	Primary sclerosing cholangitis;
CRC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.71	10.88	0.51	9.53e-24	Corneal astigmatism;
CRC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg21153622	chr11:89784906	NA	-0.37	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.08	-0.32	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs11212617	1.000	rs228598	chr11:108107497	T/G	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.44	0.33	4.34e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg26850624	chr5:429559	AHRR	-0.72	-11.22	-0.53	5.9e-25	Cystic fibrosis severity;
CRC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.49	7.68	0.39	1.78e-13	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03150279	chr9:127905984	SCAI	0.45	6.24	0.33	1.38e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-9.9	-0.48	2.22e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6840360	0.642	rs7698816	chr4:152352972	C/T	cg09659197	chr4:152720779	NA	0.34	6.65	0.34	1.24e-10	Intelligence (multi-trait analysis);
CRC	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg06781209	chr11:61594997	FADS2	-0.38	-5.64	-0.3	3.68e-8	Trans fatty acid levels;
CRC	cis	rs4731207	0.596	rs7799523	chr7:124592033	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.03	-0.32	4.4e-9	Cutaneous malignant melanoma;
CRC	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.15	-0.37	5.66e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.81	-0.44	7.42e-17	Bipolar disorder;
CRC	cis	rs9322817	0.691	rs6922441	chr6:105216405	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-8.51	-0.42	6.37e-16	Thyroid stimulating hormone;
CRC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.49	-9.48	-0.46	5.08e-19	Subjective well-being;
CRC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.54	8.53	0.43	5.26e-16	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13278359	chr4:170678860	C4orf27	0.41	6.16	0.32	2.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.28	-0.46	2.26e-18	Type 2 diabetes;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg27094323	chr7:1216898	NA	-0.38	-6.11	-0.32	2.8e-9	Longevity;Endometriosis;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18099408	chr3:52552593	STAB1	-0.63	-12.2	-0.56	1.66e-28	Electroencephalogram traits;
CRC	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.56	-9.84	-0.48	3.26e-20	Common traits (Other);
CRC	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg20578329	chr17:80767326	TBCD	-0.81	-9.81	-0.48	4.34e-20	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.58	0.34	1.82e-10	Bipolar disorder;
CRC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.66	10.11	0.49	4.05e-21	Corneal astigmatism;
CRC	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.5	7.36	0.38	1.46e-12	Birth weight;
CRC	cis	rs8105895	0.935	rs62111039	chr19:22287336	C/G	cg02912127	chr19:22235281	ZNF257	-0.41	-5.69	-0.3	2.77e-8	Body mass index (change over time);
CRC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.37	-0.42	1.62e-15	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.45	-6.64	-0.34	1.28e-10	Subjective well-being;
CRC	cis	rs1007738	0.580	rs61897844	chr11:47190860	G/A	cg19486271	chr11:47235900	DDB2	0.45	5.89	0.31	9.63e-9	Bone mineral density (hip);
CRC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg10589385	chr1:150898437	SETDB1	0.27	5.72	0.3	2.36e-8	Tonsillectomy;
CRC	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.88	0.31	1e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg23417306	chr2:180868811	CWC22	-0.44	-6.03	-0.32	4.31e-9	Schizophrenia;
CRC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.44	6.86	0.35	3.41e-11	Red blood cell count;
CRC	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.45	8.21	0.41	4.98e-15	Blood metabolite ratios;
CRC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06505273	chr16:24850292	NA	0.48	6.13	0.32	2.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.32	0.65	2.33e-40	Colorectal cancer;
CRC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	10.33	0.49	7.64e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg01304814	chr3:48885189	PRKAR2A	0.79	5.91	0.31	8.34e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg15845792	chr6:28175446	NA	0.71	6.18	0.32	1.89e-9	Depression;
CRC	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.33	0.37	1.78e-12	Diisocyanate-induced asthma;
CRC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.35	-0.33	7.33e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.65	6.76	0.35	6.42e-11	Axial length;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06100899	chr20:44035415	DBNDD2;SYS1-DBNDD2	0.43	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.72	-9.69	-0.47	1.09e-19	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg14530993	chr4:882597	GAK	0.62	6.3	0.33	9.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.6	6.82	0.35	4.5e-11	Coronary artery disease;
CRC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.11	0.49	4.19e-21	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04561332	chr2:20550539	NA	0.47	6.45	0.34	4e-10	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg09264619	chr17:80180166	NA	-0.5	-7.28	-0.37	2.49e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	6.75	0.35	6.82e-11	Hip circumference adjusted for BMI;
CRC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.96	0.36	1.82e-11	Rheumatoid arthritis;
CRC	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.45	6.96	0.36	1.9e-11	C-reactive protein levels;
CRC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-11.14	-0.52	1.13e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	trans	rs8097070	0.661	rs9966711	chr18:23171413	C/G	cg09418612	chr17:46019174	PNPO	0.54	6.26	0.33	1.17e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.42	-0.33	4.74e-10	Prevalent atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12633356	chr12:51318640	METTL7A	0.39	6.29	0.33	9.95e-10	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.81	11.64	0.54	1.81e-26	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10158674	chr1:51426069	FAF1	0.46	6.4	0.33	5.22e-10	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.59	8.98	0.44	2.1e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9919625	1.000	rs4307711	chr11:11592236	C/T	cg26272220	chr12:81471884	ACSS3	-0.38	-6.57	-0.34	1.99e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);Exploratory eye movement dysfunction in schizophrenia (responsive search score);
CRC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.48	7.84	0.4	6.19e-14	Cystic fibrosis severity;
CRC	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.93	0.36	2.16e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg20673091	chr1:2541236	MMEL1	0.35	5.64	0.3	3.59e-8	Ulcerative colitis;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.22	-0.32	1.49e-9	Acylcarnitine levels;
CRC	cis	rs17756712	0.667	rs72835984	chr6:642017	C/T	cg16786516	chr6:604617	EXOC2	0.51	6.49	0.34	3.09e-10	Vertical cup-disc ratio;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg15786705	chr6:28176104	NA	0.76	9.47	0.46	5.57e-19	Parkinson's disease;
CRC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.85	-13.03	-0.58	1.45e-31	Systemic lupus erythematosus;
CRC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.86	-0.4	5.41e-14	Vitiligo;
CRC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg12935359	chr14:103987150	CKB	-0.4	-6.12	-0.32	2.65e-9	Body mass index;
CRC	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg23254163	chr1:152506842	NA	0.47	8.98	0.44	2.16e-17	Hair morphology;
CRC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.11e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.39	7.52	0.38	5.15e-13	Mean corpuscular volume;
CRC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.02e-9	Prudent dietary pattern;
CRC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.58	0.7	3.1e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.57	0.57	7.49e-30	Height;
CRC	cis	rs2179367	0.881	rs2744432	chr6:149743871	A/C	cg11245181	chr6:149772854	ZC3H12D	0.39	5.78	0.3	1.73e-8	Dupuytren's disease;
CRC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.37	-6.12	-0.32	2.69e-9	Total body bone mineral density;
CRC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-9.56	-0.47	2.88e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1881396	0.531	rs4665385	chr2:27930837	C/T	cg27432699	chr2:27873401	GPN1	0.58	6.53	0.34	2.48e-10	Nonalcoholic fatty liver disease;
CRC	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.52	7.34	0.38	1.71e-12	Interstitial lung disease;
CRC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.48	7.41	0.38	1.05e-12	Monobrow;
CRC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.62	-0.34	1.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	10.67	0.51	5.17e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg20356878	chr3:121714668	ILDR1	0.51	7.9	0.4	4.1e-14	Cognitive performance;
CRC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.94	11.56	0.54	3.59e-26	Eosinophil percentage of granulocytes;
CRC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.47	-0.42	8.11e-16	Morning vs. evening chronotype;
CRC	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18357526	chr6:26021779	HIST1H4A	0.5	7.54	0.38	4.63e-13	Schizophrenia;
CRC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	16.53	0.67	4.33e-45	Smoking behavior;
CRC	trans	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg18755114	chr2:209119030	IDH1	0.4	5.99	0.31	5.6e-9	Blood protein levels;
CRC	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.47	6.82	0.35	4.38e-11	Primary sclerosing cholangitis;
CRC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.54	8.51	0.42	6.45e-16	Pancreatic cancer;
CRC	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg05714579	chr10:131428358	MGMT	0.5	6.96	0.36	1.81e-11	Response to temozolomide;
CRC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg04969067	chr8:143858791	LYNX1	0.44	7.47	0.38	7.28e-13	Urinary tract infection frequency;
CRC	trans	rs4714291	0.698	rs9296321	chr6:40118352	C/T	cg02267698	chr19:7991119	CTXN1	-0.44	-5.98	-0.31	5.74e-9	Strep throat;
CRC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg23229984	chr5:148520753	ABLIM3	0.5	7.04	0.36	1.11e-11	Breast cancer;
CRC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg21665744	chr7:39171113	POU6F2	0.45	5.96	0.31	6.67e-9	IgG glycosylation;
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg11900509	chr10:81946545	ANXA11	0.38	6.17	0.32	1.98e-9	Sarcoidosis;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17942371	chr19:796826	PTBP1	0.45	6.26	0.33	1.22e-9	Survival in pancreatic cancer;
CRC	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg22482690	chr17:47019901	SNF8	0.44	7.27	0.37	2.66e-12	Type 2 diabetes;
CRC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.11	-13.22	-0.59	2.67e-32	Vitiligo;
CRC	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg26353448	chr1:248524236	OR2T4	-0.32	-6.17	-0.32	2.02e-9	Common traits (Other);
CRC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03676636	chr4:99064102	C4orf37	0.22	5.91	0.31	8.47e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7487075	0.786	rs898242	chr12:46720819	C/T	cg22049899	chr12:47219821	SLC38A4	0.33	6.35	0.33	7.27e-10	Itch intensity from mosquito bite;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.89	-19.66	-0.73	1.85e-57	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.34	-6.6	-0.34	1.62e-10	Breast cancer;
CRC	trans	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg24644049	chr4:85504048	CDS1	0.92	7.68	0.39	1.79e-13	Skin colour saturation;
CRC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.51	6.23	0.33	1.39e-9	Recombination rate (females);
CRC	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.7	-8.71	-0.43	1.5e-16	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg15123519	chr2:136567270	LCT	0.35	6.87	0.35	3.17e-11	Mosquito bite size;
CRC	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-8.35	-0.42	1.93e-15	Bone mineral density;
CRC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg11833968	chr6:79620685	NA	-0.35	-6.04	-0.32	4.19e-9	Intelligence (multi-trait analysis);
CRC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg27068330	chr11:65405492	SIPA1	0.43	6.35	0.33	7.22e-10	Acne (severe);
CRC	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg09659197	chr4:152720779	NA	-0.45	-9.24	-0.45	3.18e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg11861562	chr11:117069780	TAGLN	0.31	7.01	0.36	1.38e-11	Blood protein levels;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg21251018	chr6:28226885	NKAPL	0.46	6.94	0.36	2.06e-11	Parkinson's disease;
CRC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.36e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.48	6.61	0.34	1.52e-10	Lymphocyte counts;
CRC	cis	rs10089	0.680	rs3805616	chr5:127520897	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.25	0.37	3e-12	Ileal carcinoids;
CRC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.61	11.44	0.53	9.33e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07732421	chr5:74633253	HMGCR	0.44	6.3	0.33	9.37e-10	Response to antipsychotic treatment;
CRC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.18	-0.32	1.91e-9	QT interval;
CRC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	17.99	0.7	7.02e-51	Smoking behavior;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12364570	chr5:134074118	CAMLG	0.42	6.17	0.32	2.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	-0.51	-8.22	-0.41	4.87e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.19	-0.37	4.29e-12	Metabolite levels;
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg10677697	chr7:45961126	IGFBP3	0.34	6.01	0.31	5.03e-9	Sitting height ratio;
CRC	cis	rs2745967	0.791	rs2785646	chr1:208076291	G/A	cg09788693	chr1:208063733	CD34	0.42	6.44	0.33	4.29e-10	Resting heart rate;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg21169611	chr9:106856078	SMC2	-0.41	-5.98	-0.31	5.86e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	8.74	0.43	1.23e-16	Cognitive test performance;
CRC	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.42	-5.93	-0.31	7.55e-9	Subjective well-being;
CRC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.72	11.41	0.53	1.22e-25	Mean corpuscular hemoglobin;
CRC	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.63	8.11	0.41	9.88e-15	Cocaine dependence;
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg19041857	chr6:27730383	NA	-0.41	-6.0	-0.31	5.3300000000000004e-09	Parkinson's disease;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.61	6.94	0.36	2.13e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg12292205	chr6:26970375	C6orf41	-0.52	-7.48	-0.38	6.69e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.52	5.73	0.3	2.22e-8	Initial pursuit acceleration;
CRC	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg01339444	chr6:118972232	C6orf204	0.57	6.13	0.32	2.54e-9	Diastolic blood pressure;
CRC	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg23234261	chr14:55582407	NA	0.29	5.65	0.3	3.56e-8	Protein biomarker;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09008063	chr16:25026527	ARHGAP17	0.43	6.1	0.32	3.04e-9	Response to antipsychotic treatment;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.64	9.6	0.47	2.07e-19	Lymphocyte counts;
CRC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.62	8.33	0.42	2.21e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.45	5.83	0.31	1.33e-8	IgG glycosylation;
CRC	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg12564285	chr5:131593104	PDLIM4	0.35	6.29	0.33	1e-9	Blood metabolite levels;
CRC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.65	7.08	0.36	8.92e-12	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26789489	chr1:16941426	NBPF1	-0.34	-6.16	-0.32	2.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1223397	0.938	rs9395602	chr6:13278753	C/T	cg07912922	chr6:13274314	PHACTR1	0.53	6.48	0.34	3.4e-10	Blood pressure;
CRC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-17.74	-0.7	7.01e-50	Primary sclerosing cholangitis;
CRC	cis	rs17824933	1.000	rs916813	chr11:60764028	A/G	cg16817237	chr11:60793675	NA	0.38	5.67	0.3	3.09e-8	Multiple sclerosis;
CRC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg10820045	chr2:198174542	NA	-0.5	-8.7	-0.43	1.59e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.37	-5.69	-0.3	2.88e-8	Mean corpuscular volume;
CRC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.3	-0.37	2.14e-12	Personality dimensions;
CRC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.34e-12	Bipolar disorder;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03052632	chr12:57634626	NDUFA4L2	-0.52	-6.38	-0.33	6.13e-10	Diisocyanate-induced asthma;
CRC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg24300038	chr13:113819356	PROZ	0.51	6.69	0.35	9.53e-11	Platelet distribution width;
CRC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.69	0.35	9.5e-11	Testicular germ cell tumor;
CRC	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.51	8.24	0.41	4.26e-15	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
CRC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	11.49	0.54	6.51e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17767392	0.846	rs34911660	chr14:71752344	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.88	-0.31	1.01e-8	Mitral valve prolapse;
CRC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg07125278	chr16:67683757	RLTPR	-0.63	-6.85	-0.35	3.56e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg00129232	chr17:37814104	STARD3	-0.45	-7.24	-0.37	3.13e-12	Lymphocyte counts;
CRC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	7.19	0.37	4.39e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs60752752	0.852	rs4355996	chr1:153371601	A/G	cg26481896	chr16:69975405	WWP2	0.51	6.26	0.33	1.21e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11645453	chr3:52864694	ITIH4	0.36	6.25	0.33	1.29e-9	Bipolar disorder;
CRC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.58	7.65	0.39	2.27e-13	IgG glycosylation;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg08045063	chr3:43147672	C3orf39	-0.42	-5.97	-0.31	6.01e-9	Birth weight;Height;
CRC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.68	8.02	0.4	1.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.74	10.97	0.52	4.67e-24	Menarche (age at onset);
CRC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-6.83	-0.35	4.01e-11	Heart rate;
CRC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	11.22	0.53	5.88e-25	Immature fraction of reticulocytes;
CRC	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.45	6.34	0.33	7.77e-10	Lung cancer;
CRC	cis	rs2811415	0.597	rs9814461	chr3:127792309	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.86	-0.31	1.12e-8	Lung function (FEV1/FVC);
CRC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg18764771	chr6:116381957	FRK	0.26	7.41	0.38	1.08e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.47	0.46	5.84e-19	Platelet count;
CRC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.47	6.78	0.35	5.53e-11	Colorectal cancer;
CRC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-14.98	-0.64	4.69e-39	Lymphocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.49	6.35	0.33	6.97e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg14711859	chr11:8959438	ASCL3	-0.42	-6.28	-0.33	1.07e-9	Hemoglobin concentration;
CRC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.53	0.43	5.37e-16	Menopause (age at onset);
CRC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.15	-0.41	7.44e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.12e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.47	7.29	0.37	2.34e-12	Menopause (age at onset);
CRC	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.9	11.57	0.54	3.2e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-9.18	-0.45	4.97e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.21	0.64	6.34e-40	Platelet count;
CRC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg10589385	chr1:150898437	SETDB1	0.32	6.83	0.35	4.05e-11	Melanoma;
CRC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.4	6.33	0.33	8.15e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg27398640	chr15:77910606	LINGO1	-0.46	-7.98	-0.4	2.48e-14	Type 2 diabetes;
CRC	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg19875578	chr6:126661172	C6orf173	0.43	6.12	0.32	2.67e-9	Male-pattern baldness;
CRC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg09127314	chr1:152161683	NA	0.49	6.31	0.33	8.78e-10	Atopic dermatitis;
CRC	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.59	8.58	0.43	3.87e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg10645314	chr2:3704589	ALLC	-0.55	-6.45	-0.34	4.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	7.42	0.38	1e-12	Schizophrenia;
CRC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg26666090	chr16:58549219	SETD6	0.92	6.25	0.33	1.26e-9	Schizophrenia;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05318427	chr2:85199320	KCMF1	0.49	6.41	0.33	5e-10	Thyroid stimulating hormone;
CRC	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.83	-13.73	-0.6	3.07e-34	Hypospadias;
CRC	cis	rs12928939	0.636	rs11639902	chr16:71755852	C/T	cg08717414	chr16:71523259	ZNF19	0.41	5.77	0.3	1.78e-8	Post bronchodilator FEV1;
CRC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.51	8.76	0.43	1.07e-16	Aortic root size;
CRC	trans	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg17903999	chr18:56338584	MALT1	0.41	6.79	0.35	5.18e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.42	5.78	0.3	1.72e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg01388757	chr2:102091195	RFX8	-0.35	-5.64	-0.3	3.7e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg19980929	chr12:42632907	YAF2	0.45	6.69	0.35	9.4e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.58	-8.7	-0.43	1.62e-16	Aortic root size;
CRC	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.67	7.37	0.38	1.4e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02290350	chr8:58132656	NA	-0.51	-5.89	-0.31	9.42e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.58	-0.39	3.59e-13	Coronary artery disease;
CRC	cis	rs7630877	0.719	rs12489992	chr3:179664925	A/C	cg18765712	chr3:179670323	PEX5L	0.49	6.91	0.36	2.46e-11	Type 2 diabetes;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg19041857	chr6:27730383	NA	-0.42	-5.87	-0.31	1.05e-8	Parkinson's disease;
CRC	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.45	0.38	8.49e-13	Eye color traits;
CRC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-6.15	-0.32	2.19e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.35	-5.87	-0.31	1.06e-8	Childhood ear infection;
CRC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-12.56	-0.57	7.72e-30	Electrocardiographic conduction measures;
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	5.83	0.31	1.3e-8	Prudent dietary pattern;
CRC	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg06484146	chr7:12443880	VWDE	-0.52	-6.92	-0.36	2.4e-11	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01671314	chr6:135502610	MYB	0.36	5.97	0.31	6.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg12458913	chr13:53173898	NA	0.56	8.69	0.43	1.71e-16	Lewy body disease;
CRC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg21155852	chr7:2048760	MAD1L1	-0.49	-6.63	-0.34	1.35e-10	Bipolar disorder;
CRC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs9891119	0.550	rs12601611	chr17:40497828	C/T	cg06270615	chr17:40516068	STAT3	-0.35	-7.49	-0.38	6.22e-13	Multiple sclerosis;Crohn's disease;
CRC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.81	7.6	0.39	3.07e-13	Diabetic retinopathy;
CRC	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg23996704	chr18:44553084	KATNAL2	-0.33	-6.72	-0.35	8.02e-11	Personality dimensions;
CRC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.01	-0.52	3.15e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.58	-7.13	-0.37	6.53e-12	Cancer;
CRC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg03013999	chr17:37608204	MED1	-0.5	-7.7	-0.39	1.61e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	9.7	0.47	9.61e-20	Cognitive test performance;
CRC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02450064	chr17:40260053	DHX58	-0.42	-6.11	-0.32	2.75e-9	Fibrinogen levels;
CRC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg25985355	chr7:65971099	NA	-0.48	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
CRC	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg01639898	chr1:32083012	HCRTR1	0.3	6.1	0.32	2.95e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg16141378	chr3:129829833	LOC729375	-0.48	-7.29	-0.37	2.37e-12	Mood instability;
CRC	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.47	-5.97	-0.31	6.29e-9	Crohn's disease;
CRC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.39	-7.81	-0.4	7.49e-14	Schizophrenia;
CRC	cis	rs365302	1.000	rs418901	chr6:159648869	T/A	cg14500486	chr6:159655392	FNDC1	0.44	6.87	0.35	3.15e-11	Coronary heart disease;
CRC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.68	0.35	1.03e-10	Lung cancer;
CRC	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.58	8.23	0.41	4.44e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg03623178	chr6:28175578	NA	0.6	8.38	0.42	1.57e-15	Parkinson's disease;
CRC	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.52	8.78	0.44	8.79e-17	Dupuytren's disease;
CRC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.54	-6.31	-0.33	8.93e-10	Red cell distribution width;
CRC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.63	-11.02	-0.52	2.9e-24	Coronary artery disease;
CRC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.11	-0.32	2.82e-9	Height;
CRC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg09658497	chr7:2847517	GNA12	-0.36	-5.97	-0.31	6.15e-9	Height;
CRC	cis	rs601339	1.000	rs35683065	chr12:123164062	G/C	cg25190513	chr12:123201362	GPR109B	-0.49	-6.06	-0.32	3.65e-9	Adiponectin levels;
CRC	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.74	11.48	0.53	7.1e-26	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg12193833	chr17:30244370	NA	-0.63	-8.27	-0.41	3.34e-15	Hip circumference adjusted for BMI;
CRC	cis	rs12760731	0.623	rs10913549	chr1:178383657	C/G	cg00404053	chr1:178313656	RASAL2	0.76	9.53	0.47	3.62e-19	Obesity-related traits;
CRC	cis	rs17401966	0.597	rs11121526	chr1:10251082	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-8.11	-0.41	1.02e-14	Hepatocellular carcinoma;
CRC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.86	-0.35	3.36e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.84	12.79	0.58	1.09e-30	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11318307	chr19:9695355	ZNF121	0.44	6.45	0.34	4.1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2730260	0.537	rs56260213	chr7:158875921	C/T	cg02254261	chr7:158964346	NA	-0.54	-6.07	-0.32	3.6e-9	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13791713	chr21:40720916	HMGN1	0.44	6.59	0.34	1.73e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg15445000	chr17:37608096	MED1	0.26	5.76	0.3	1.93e-8	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17404403	chr4:110737017	GAR1	0.38	6.03	0.32	4.38e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg14673194	chr17:80132900	CCDC57	-0.46	-5.97	-0.31	6.04e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg27398640	chr15:77910606	LINGO1	-0.47	-8.08	-0.41	1.21e-14	Type 2 diabetes;
CRC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg00343986	chr7:65444356	GUSB	0.53	7.66	0.39	2.12e-13	Calcium levels;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24375607	chr4:120327624	NA	0.43	6.59	0.34	1.72e-10	Corneal astigmatism;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg06470822	chr6:28175283	NA	0.74	10.0	0.48	9.56e-21	Parkinson's disease;
CRC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg27523141	chr10:43048294	ZNF37B	0.47	6.9	0.36	2.69e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.54	-7.69	-0.39	1.74e-13	IgG glycosylation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20480041	chr5:72251406	FCHO2	0.43	6.19	0.32	1.74e-9	Response to antipsychotic treatment;
CRC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg20607287	chr7:12443886	VWDE	-0.64	-6.73	-0.35	7.75e-11	Coronary artery disease;
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.38	6.09	0.32	3.21e-9	Age at first birth;
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-6.92	-0.36	2.41e-11	Longevity;Endometriosis;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg14631576	chr9:95140430	CENPP	-0.4	-7.13	-0.37	6.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.34	-0.33	7.65e-10	Depression;
CRC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.51	7.41	0.38	1.05e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg02811702	chr13:24901961	NA	0.48	6.66	0.34	1.14e-10	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04514556	chr3:71113948	FOXP1	0.44	6.27	0.33	1.11e-9	Intelligence (multi-trait analysis);
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.42	7.68	0.39	1.84e-13	Height;
CRC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg23719950	chr11:63933701	MACROD1	-0.55	-5.89	-0.31	9.3e-9	Mean platelet volume;
CRC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.52	7.75	0.39	1.12e-13	Breast cancer;
CRC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.62	-8.95	-0.44	2.6e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg11901034	chr3:128598214	ACAD9	-0.51	-6.23	-0.32	1.43e-9	IgG glycosylation;
CRC	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	-0.57	-8.92	-0.44	3.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg14631576	chr9:95140430	CENPP	-0.32	-5.85	-0.31	1.19e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.93	-0.55	1.6e-27	Exhaled nitric oxide output;
CRC	cis	rs12692738	0.526	rs355875	chr2:165632755	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg14768367	chr16:72042858	DHODH	0.76	6.02	0.32	4.62e-9	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.65	7.42	0.38	9.87e-13	Breast cancer;
CRC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.58e-15	Bladder cancer;
CRC	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.76	-11.51	-0.54	5.36e-26	Waist circumference;Body mass index;
CRC	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.48	7.42	0.38	9.9e-13	Type 2 diabetes;
CRC	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.52	-0.43	5.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg20936604	chr3:58311152	NA	-0.77	-7.16	-0.37	5.29e-12	Cholesterol, total;
CRC	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-13.66	-0.6	5.67e-34	Ulcerative colitis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02222290	chr10:72575603	SGPL1	0.47	6.34	0.33	7.43e-10	Anxiety disorder;
CRC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.61	-0.43	3.14e-16	Monocyte percentage of white cells;
CRC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.76	-0.35	6.25e-11	Subjective well-being;
CRC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.43	6.33	0.33	8.25e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg16060761	chr17:80687452	NA	-0.46	-6.14	-0.32	2.41e-9	Glycated hemoglobin levels;
CRC	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.58	8.19	0.41	5.94e-15	Smooth-surface caries;
CRC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.79	-12.62	-0.57	4.67e-30	Cognitive function;
CRC	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.28	0.42	3.2e-15	Mean corpuscular volume;
CRC	cis	rs7188861	0.603	rs2113260	chr16:11455993	C/T	cg00044050	chr16:11439710	C16orf75	0.41	5.62	0.3	4.04e-8	HDL cholesterol;
CRC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.66	10.97	0.52	4.63e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7202877	0.611	rs56092808	chr16:75312716	A/T	cg03315344	chr16:75512273	CHST6	0.52	5.88	0.31	1.02e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.81	0.31	1.48e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.33	0.33	8.25e-10	Renal cell carcinoma;
CRC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22303773	chr11:65030031	POLA2	0.45	6.41	0.33	5.08e-10	Response to antipsychotic treatment;
CRC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.51	-8.01	-0.4	2.06e-14	Body mass index;
CRC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.96	0.52	4.76e-24	Coronary artery disease;
CRC	cis	rs3026101	0.587	rs8066000	chr17:5310033	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.36	-0.42	1.85e-15	Body mass index;
CRC	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg00938859	chr5:1591904	SDHAP3	0.69	7.58	0.39	3.49e-13	Breast cancer;
CRC	cis	rs1867631	1.000	rs7546090	chr1:67083981	G/A	cg02459107	chr1:67143332	SGIP1	0.34	5.75	0.3	2.06e-8	Menopause (age at onset);
CRC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.69	-0.3	2.86e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.68	-0.35	1.02e-10	Plateletcrit;
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.35	1.01e-10	Bipolar disorder;
CRC	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg23254163	chr1:152506842	NA	0.45	8.9	0.44	3.87e-17	Hair morphology;
CRC	trans	rs12940923	1.000	rs12452417	chr17:56367202	G/A	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.43	6.93	0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-19.6	-0.73	3.26e-57	Ulcerative colitis;
CRC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.82	-10.15	-0.49	2.98e-21	Initial pursuit acceleration;
CRC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.1	-0.32	3.06e-9	Alzheimer's disease (late onset);
CRC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.52	-0.34	2.71e-10	Aortic root size;
CRC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg20512303	chr5:131592959	PDLIM4	0.36	6.85	0.35	3.59e-11	Breast cancer;
CRC	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg17710535	chr19:10819994	QTRT1	0.42	5.83	0.31	1.35e-8	Inflammatory skin disease;
CRC	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg01339444	chr6:118972232	C6orf204	0.58	6.17	0.32	2.02e-9	Diastolic blood pressure;
CRC	cis	rs501120	0.778	rs523297	chr10:44756557	C/T	cg09554077	chr10:44749378	NA	0.66	7.47	0.38	7.42e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.75	0.35	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.53	6.99	0.36	1.53e-11	Morning vs. evening chronotype;
CRC	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	6.42	0.33	4.71e-10	Body mass index;
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg23161317	chr6:28129485	ZNF389	0.39	5.81	0.31	1.45e-8	Cardiac Troponin-T levels;
CRC	trans	rs2055729	0.645	rs12544019	chr8:9742578	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.17	0.37	4.92e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2692947	0.826	rs7423942	chr2:96645257	G/A	cg23100626	chr2:96804247	ASTL	0.25	6.92	0.36	2.31e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg07636037	chr3:49044803	WDR6	0.76	6.16	0.32	2.07e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	7.24	0.37	3.17e-12	Lung cancer in ever smokers;
CRC	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Dilated cardiomyopathy;
CRC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.47	7.04	0.36	1.15e-11	Menopause (age at onset);
CRC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.37	6.6	0.34	1.65e-10	Dilated cardiomyopathy;
CRC	cis	rs243505	0.732	rs3800949	chr7:148479648	A/T	cg09806900	chr7:148480153	CUL1	-0.55	-8.09	-0.41	1.19e-14	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.91	-15.6	-0.65	1.89e-41	Height;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.4	0.33	5.21e-10	Depression;
CRC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.5	-7.13	-0.37	6.3e-12	Inflammatory bowel disease;
CRC	cis	rs1178968	0.818	rs6957049	chr7:72754037	G/A	cg25889504	chr7:72793014	NA	0.5	5.79	0.3	1.67e-8	Triglyceride levels;
CRC	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.69	-7.87	-0.4	5.09e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.46	-6.68	-0.35	1.03e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-12.68	-0.57	2.91e-30	Blood metabolite levels;
CRC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.83	-14.44	-0.62	5.72e-37	Breast cancer;
CRC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg02527881	chr3:46936655	PTH1R	0.33	5.7	0.3	2.67e-8	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12588279	chr6:26043732	HIST1H2BB	0.48	6.89	0.36	2.78e-11	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11586124	chr12:58259160	NA	0.43	7.29	0.37	2.39e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.51	7.83	0.4	6.7e-14	Calcium levels;
CRC	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.57	-9.18	-0.45	4.89e-18	Neuroticism;
CRC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.73	-12.15	-0.56	2.49e-28	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07025548	chr5:74632477	HMGCR	0.4	6.27	0.33	1.16e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20503117	chr3:5164013	ARL8B	0.46	6.66	0.34	1.16e-10	Intelligence (multi-trait analysis);
CRC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.74	8.38	0.42	1.58e-15	Tuberculosis;
CRC	cis	rs9409565	0.559	rs7044227	chr9:97067592	T/A	cg04523069	chr9:97136363	HIATL1	-0.43	-6.0	-0.31	5.28e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6741819	1.000	rs10929458	chr2:7147152	A/T	cg27144453	chr2:7172511	RNF144A	-0.42	-6.26	-0.33	1.23e-9	Response to antipsychotic treatment;
CRC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg12564285	chr5:131593104	PDLIM4	0.44	7.46	0.38	8e-13	Breast cancer;
CRC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	6.11	0.32	2.85e-9	Height;
CRC	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg24463073	chr6:118973353	C6orf204	0.48	6.0	0.31	5.3300000000000004e-09	Diastolic blood pressure;
CRC	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg04132472	chr17:19861366	AKAP10	0.43	6.83	0.35	4.01e-11	Schizophrenia;
CRC	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg14664628	chr15:75095509	CSK	-0.49	-5.72	-0.3	2.34e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg26043149	chr18:55253948	FECH	-0.46	-6.82	-0.35	4.27e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg23123621	chr4:1343375	KIAA1530	0.32	5.71	0.3	2.54e-8	Obesity-related traits;
CRC	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg00601450	chr5:74908170	NA	0.39	6.01	0.31	5.03e-9	Age-related disease endophenotypes;
CRC	cis	rs7487075	0.722	rs4768111	chr12:46705761	T/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.3	0.33	9.37e-10	Itch intensity from mosquito bite;
CRC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.56	7.25	0.37	2.99e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.62	9.46	0.46	5.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.63	-14.98	-0.64	4.93e-39	Airflow obstruction;
CRC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg25303599	chr11:61595807	FADS2	-0.45	-5.76	-0.3	1.9e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs17767392	0.595	rs8005925	chr14:71661292	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.47	-6.0	-0.31	5.16e-9	Mitral valve prolapse;
CRC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.41	5.71	0.3	2.47e-8	Renal cell carcinoma;
CRC	cis	rs6540556	0.521	rs1337531	chr1:209911988	T/G	cg23920097	chr1:209922102	NA	-0.48	-5.9	-0.31	8.87e-9	Red blood cell count;
CRC	cis	rs7605827	0.930	rs10929365	chr2:15531626	G/A	cg19274914	chr2:15703543	NA	0.39	5.84	0.31	1.25e-8	Educational attainment (years of education);
CRC	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.74	9.8	0.48	4.62e-20	Prostate cancer;
CRC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.9	0.52	8.12e-24	Platelet count;
CRC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	1.0	17.5	0.69	6.03e-49	Parkinson's disease;
CRC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg20607287	chr7:12443886	VWDE	-0.64	-6.66	-0.34	1.15e-10	Coronary artery disease;
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-7.72	-0.39	1.38e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.63	-0.3	3.94e-8	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs2507	0.817	rs16869	chr15:74322431	T/C	cg01992487	chr16:84268524	KCNG4	0.39	5.98	0.31	5.84e-9	Coronary artery disease;
CRC	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg09179987	chr1:167433047	CD247	0.51	7.52	0.38	5.42e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-17.02	-0.68	4.91e-47	Electrocardiographic conduction measures;
CRC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.94	14.87	0.63	1.28e-38	Primary sclerosing cholangitis;
CRC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg15465823	chr12:48382534	COL2A1	-0.38	-6.23	-0.32	1.44e-9	Glycated hemoglobin levels;
CRC	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.47	0.34	3.52e-10	Systolic blood pressure;
CRC	cis	rs62432291	0.681	rs2932988	chr6:159655402	A/G	cg14500486	chr6:159655392	FNDC1	-0.76	-10.4	-0.5	4.17e-22	Joint mobility (Beighton score);
CRC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.74	12.03	0.55	7.35e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-0.84	-9.81	-0.48	4.26e-20	Breast cancer;
CRC	cis	rs6908034	0.546	rs73376662	chr6:19806340	G/A	cg02682789	chr6:19804855	NA	0.79	6.75	0.35	6.62e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.51	8.79	0.44	8.45e-17	Testicular germ cell tumor;
CRC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg15448220	chr1:150897856	SETDB1	0.43	6.43	0.33	4.59e-10	Tonsillectomy;
CRC	cis	rs58649573	0.530	rs2159792	chr9:126778821	A/G	cg14112217	chr9:126806003	NA	0.41	5.87	0.31	1.07e-8	Post-traumatic stress disorder;
CRC	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.18	-0.37	4.58e-12	Inflammatory bowel disease;
CRC	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.62	0.34	1.44e-10	Mean corpuscular volume;
CRC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg03037974	chr15:76606532	NA	-0.52	-7.91	-0.4	4.05e-14	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.41	6.83	0.35	4.19e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.52	-10.78	-0.51	2.12e-23	Intelligence (multi-trait analysis);
CRC	cis	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg20159608	chr7:32802032	NA	-0.59	-6.93	-0.36	2.19e-11	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.65	7.53	0.38	4.98e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
CRC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg06238570	chr21:40685208	BRWD1	-0.44	-5.63	-0.3	3.82e-8	Menarche (age at onset);
CRC	trans	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg21155852	chr7:2048760	MAD1L1	-0.48	-6.33	-0.33	8.22e-10	Neuroticism;
CRC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18099408	chr3:52552593	STAB1	0.34	5.83	0.31	1.35e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2786111	0.965	rs675699	chr1:197293606	G/A	cg13682187	chr1:196946512	CFHR5	0.29	5.67	0.3	3.19e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs2386661	0.637	rs7099771	chr10:5654742	A/G	cg26603656	chr10:5671107	NA	0.4	7.21	0.37	3.86e-12	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21810621	chr11:1331345	LOC255512;TOLLIP	0.39	6.32	0.33	8.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.49	7.54	0.38	4.55e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs4731207	0.596	rs1481337	chr7:124667796	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg01843034	chr6:37503916	NA	-0.44	-8.18	-0.41	6.11e-15	Cognitive performance;
CRC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	13.58	0.6	1.14e-33	Smoking behavior;
CRC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg06238570	chr21:40685208	BRWD1	0.75	10.49	0.5	2.08e-22	Cognitive function;
CRC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06656553	chr16:89960601	TCF25	0.71	6.09	0.32	3.22e-9	Skin colour saturation;
CRC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.16	0.37	5.15e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-7.79	-0.39	9.06e-14	Obesity (extreme);
CRC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.67	-7.98	-0.4	2.44e-14	Rheumatoid arthritis;
CRC	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg18323236	chr1:24743029	NIPAL3	0.38	5.66	0.3	3.27e-8	Response to interferon beta in multiple sclerosis;
CRC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.92	-14.36	-0.62	1.23e-36	Longevity;
CRC	trans	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.6	0.39	3.19e-13	Endometrial cancer;
CRC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.56	6.92	0.36	2.35e-11	Alzheimer's disease;
CRC	cis	rs4363385	0.667	rs454245	chr1:153031979	A/C	cg25856811	chr1:152973957	SPRR3	0.24	6.6	0.34	1.68e-10	Inflammatory skin disease;
CRC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.58	-8.29	-0.42	2.92e-15	Inflammatory bowel disease;
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg08222913	chr3:52553049	STAB1	-0.37	-7.03	-0.36	1.21e-11	Electroencephalogram traits;
CRC	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg11579758	chr4:1086637	RNF212	0.41	6.57	0.34	1.96e-10	Recombination rate (males);
CRC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.27	6.19	0.32	1.8e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01547494	chr13:110790937	NA	0.44	6.15	0.32	2.23e-9	Response to antipsychotic treatment;
CRC	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg01843034	chr6:37503916	NA	-0.38	-6.77	-0.35	5.88e-11	Cognitive performance;
CRC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	1.12	8.39	0.42	1.43e-15	Type 2 diabetes nephropathy;
CRC	cis	rs1030268	0.715	rs13235840	chr7:133505091	A/T	cg10665199	chr7:133106180	EXOC4	0.55	6.09	0.32	3.09e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.43	-0.42	1.12e-15	Aortic root size;
CRC	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg24692254	chr21:30365293	RNF160	-0.39	-5.85	-0.31	1.17e-8	Pancreatic cancer;
CRC	cis	rs55702914	0.712	rs12616329	chr2:198148629	T/C	cg03934865	chr2:198174659	NA	-0.36	-6.25	-0.33	1.27e-9	Major depression and alcohol dependence;
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-6.24	-0.33	1.37e-9	Menopause (age at onset);
CRC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.03	18.7	0.72	1.12e-53	Parkinson's disease;
CRC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.45	6.43	0.33	4.58e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.02	-10.25	-0.49	1.4e-21	Body mass index;
CRC	trans	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.41	-6.24	-0.33	1.37e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.49	6.17	0.32	2.06e-9	Cholesterol, total;
CRC	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.52	-7.82	-0.4	7.31e-14	Coronary artery disease;
CRC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.77	-0.35	5.95e-11	Blood metabolite levels;
CRC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.87	-13.87	-0.61	9.35e-35	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10209635	chr21:37692467	MORC3	0.36	6.04	0.32	4.27e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg21153622	chr11:89784906	NA	-0.44	-7.26	-0.37	2.74e-12	Coronary artery disease;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.7	8.62	0.43	2.8e-16	Prostate cancer;
CRC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.47	9.25	0.45	2.94e-18	Renal cell carcinoma;
CRC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.45	-0.33	4.03e-10	Aortic root size;
CRC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg26248373	chr2:1572462	NA	-0.83	-12.38	-0.56	3.62e-29	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg21856205	chr7:94953877	PON1	-0.45	-5.91	-0.31	8.56e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg14004847	chr7:1930337	MAD1L1	0.47	6.86	0.35	3.42e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.92	-0.44	3.21e-17	Coffee consumption (cups per day);
CRC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.43	0.38	9.22e-13	Educational attainment;
CRC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg17911788	chr17:44343683	NA	0.56	6.86	0.35	3.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.63	10.85	0.51	1.18e-23	Dental caries;
CRC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.36	-0.5	5.94e-22	Monocyte count;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.95	-22.09	-0.77	6.03e-67	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg12193833	chr17:30244370	NA	-0.68	-8.2	-0.41	5.56e-15	Hip circumference adjusted for BMI;
CRC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.78	9.76	0.47	6.3e-20	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22443241	chr1:114447798	DCLRE1B;AP4B1	0.4	6.18	0.32	1.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg17710535	chr19:10819994	QTRT1	0.44	6.52	0.34	2.7e-10	Inflammatory skin disease;
CRC	cis	rs6496667	0.865	rs7162697	chr15:90889337	A/C	cg04176472	chr15:90893244	GABARAPL3	0.6	7.09	0.36	8.26e-12	Rheumatoid arthritis;
CRC	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs4663866	0.901	rs71426513	chr2:239198147	G/A	cg16914508	chr2:239161102	PER2	0.73	6.83	0.35	4.19e-11	Irritable bowel syndrome;
CRC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg15786705	chr6:28176104	NA	0.78	9.7	0.47	1.01e-19	Depression;
CRC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.86	0.51	1.08e-23	Motion sickness;
CRC	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.62	10.13	0.49	3.53e-21	Subjective well-being (multi-trait analysis);
CRC	cis	rs9467603	0.592	rs1184498	chr6:25864882	G/C	cg08501292	chr6:25962987	TRIM38	0.59	5.74	0.3	2.21e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg27523141	chr10:43048294	ZNF37B	0.5	7.23	0.37	3.41e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.94	-0.44	2.93e-17	Hip circumference adjusted for BMI;
CRC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.91	-16.17	-0.67	1.06e-43	Height;
CRC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.93	16.66	0.68	1.24e-45	IgG glycosylation;
CRC	cis	rs7945718	0.870	rs3890065	chr11:12758767	C/G	cg25843174	chr11:12811716	TEAD1	0.45	8.45	0.42	9.44e-16	Educational attainment (years of education);
CRC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg05941027	chr17:61774174	LIMD2	0.35	6.31	0.33	8.87e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22133161	chr19:49891603	CCDC155	0.51	6.51	0.34	2.8e-10	Multiple sclerosis;
CRC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.5	7.38	0.38	1.29e-12	Blood metabolite levels;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg06470822	chr6:28175283	NA	0.75	10.12	0.49	3.98e-21	Parkinson's disease;
CRC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	15.99	0.66	5.77e-43	Intelligence (multi-trait analysis);
CRC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.59	-8.21	-0.41	5.1e-15	Platelet distribution width;
CRC	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.71	14.01	0.61	2.65e-35	Leprosy;
CRC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg19678392	chr7:94953810	PON1	-0.56	-7.18	-0.37	4.53e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.13	14.67	0.63	8.07e-38	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20376421	chr12:56546193	MYL6B	0.42	6.73	0.35	7.45e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.72	8.73	0.43	1.31e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg05562828	chr17:3906858	NA	0.45	6.95	0.36	1.96e-11	Type 2 diabetes;
CRC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.57	-9.08	-0.45	9.92e-18	Tonsillectomy;
CRC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	14.2	0.62	4.86e-36	Electrocardiographic conduction measures;
CRC	cis	rs59104589	0.617	rs73002170	chr2:242325980	G/A	cg19488206	chr2:242435732	STK25	0.47	6.69	0.35	9.9e-11	Fibrinogen levels;
CRC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg26816564	chr1:7831052	VAMP3	0.56	6.03	0.32	4.29e-9	Inflammatory bowel disease;
CRC	cis	rs3736485	0.966	rs2414109	chr15:51901015	C/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.69	-0.35	9.6e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.47	-0.34	3.47e-10	Red cell distribution width;
CRC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg16447950	chr5:562315	NA	-0.84	-11.5	-0.54	6.14e-26	Lung disease severity in cystic fibrosis;
CRC	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg24505167	chr7:1915268	MAD1L1	-0.43	-5.92	-0.31	8.13e-9	Neuroticism;
CRC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	16.12	0.66	1.64e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg15147215	chr3:52552868	STAB1	-0.54	-8.28	-0.42	3.14e-15	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.64	0.6	6.69e-34	Alzheimer's disease;
CRC	cis	rs11212617	0.967	rs227040	chr11:108223391	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.54	0.34	2.3e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs57590327	0.503	rs9866374	chr3:81615311	T/C	cg07356753	chr3:81810745	GBE1	-0.52	-6.86	-0.35	3.51e-11	Extraversion;
CRC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.53	-7.67	-0.39	1.98e-13	Coronary artery disease;
CRC	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.51	-0.5	1.84e-22	Hepatocellular carcinoma;
CRC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.75	9.79	0.48	4.94e-20	Platelet count;
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg02807482	chr3:125708958	NA	-0.41	-5.68	-0.3	2.9e-8	Blood pressure (smoking interaction);
CRC	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg21153622	chr11:89784906	NA	0.46	7.41	0.38	1.05e-12	HDL cholesterol;
CRC	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.09	-0.36	8.28e-12	Capecitabine sensitivity;
CRC	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.21	-0.56	1.53e-28	Coffee consumption (cups per day);
CRC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	6.87	0.35	3.15e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs4130344	0.901	rs12506223	chr4:159685197	C/T	cg01113538	chr6:53658866	LRRC1	0.41	5.98	0.31	5.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.44	5.84	0.31	1.28e-8	Bladder cancer;
CRC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02772935	chr3:125709198	NA	-0.49	-5.8	-0.3	1.57e-8	Blood pressure (smoking interaction);
CRC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.05	-0.32	4.01e-9	Lung cancer;
CRC	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg03229431	chr7:123269106	ASB15	-0.36	-5.67	-0.3	3.21e-8	Migraine;
CRC	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.76	-0.39	1.12e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg07979401	chr6:33739406	LEMD2	-0.48	-5.92	-0.31	7.98e-9	Schizophrenia;
CRC	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg17133734	chr15:86042851	AKAP13	0.4	6.51	0.34	2.8e-10	Interstitial lung disease;
CRC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.41	6.74	0.35	7.11e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.46	8.25	0.41	3.83e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.85	-0.44	5.49e-17	Bipolar disorder;
CRC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.46	-6.81	-0.35	4.76e-11	Menarche (age at onset);
CRC	cis	rs11229555	0.645	rs11229457	chr11:58207203	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.34	-9.69	-0.47	1.04e-19	Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12302830	chr20:33297742	TP53INP2	0.43	6.36	0.33	6.77e-10	Intelligence (multi-trait analysis);
CRC	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.6	-0.43	3.21e-16	Brugada syndrome;
CRC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg19682013	chr15:45996608	NA	0.32	6.67	0.35	1.06e-10	Waist circumference;Weight;
CRC	cis	rs2411233	1.000	rs12910064	chr15:39283736	T/A	cg23129342	chr15:39283510	NA	0.3	5.68	0.3	2.92e-8	Platelet count;
CRC	cis	rs3812762	0.833	rs10500707	chr11:8817580	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.42	6.33	0.33	8.2e-10	Hypospadias;
CRC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	8.15	0.41	7.73e-15	Colorectal cancer;
CRC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.14	-13.79	-0.61	1.82e-34	Diabetic kidney disease;
CRC	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.67	11.66	0.54	1.62e-26	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.63	9.39	0.46	1.01e-18	Breast cancer;
CRC	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg11003573	chr3:44754125	ZNF502	-0.36	-6.33	-0.33	7.96e-10	Depressive symptoms;
CRC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.38	6.1	0.32	2.92e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg12172441	chr6:28176163	NA	0.47	6.17	0.32	2.06e-9	Parkinson's disease;
CRC	trans	rs2242420	0.920	rs853480	chr1:21949537	A/G	cg16903735	chr11:1903176	LSP1	0.41	6.11	0.32	2.76e-9	Hematological and biochemical traits;
CRC	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.8	7.65	0.39	2.29e-13	Arsenic metabolism;
CRC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.39	5.92	0.31	8.19e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7781557	1.000	rs17135875	chr7:102519031	T/C	cg18108683	chr7:102477205	FBXL13	-0.49	-6.37	-0.33	6.38e-10	Colorectal adenoma (advanced);
CRC	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg15711740	chr2:61764176	XPO1	-0.52	-7.08	-0.36	8.63e-12	Tuberculosis;
CRC	cis	rs3750082	0.785	rs4720085	chr7:32968136	C/T	cg05721444	chr7:32995514	FKBP9	-0.5	-7.81	-0.4	7.66e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.5	0.54	6.02e-26	Prudent dietary pattern;
CRC	trans	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.14	-0.32	2.37e-9	Total body bone mineral density;
CRC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg12273811	chr6:28175739	NA	0.5	6.69	0.35	9.68e-11	Parkinson's disease;
CRC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-7.51	-0.38	5.45e-13	Aortic root size;
CRC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.44	-5.76	-0.3	1.91e-8	Menarche (age at onset);
CRC	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.82	-15.62	-0.65	1.53e-41	Hip circumference;
CRC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.7	0.47	1.02e-19	Cognitive test performance;
CRC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	3.04e-10	Fibrinogen levels;
CRC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.68	-9.31	-0.46	1.8e-18	Metabolic syndrome;
CRC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.91	0.64	8.81e-39	Platelet count;
CRC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.82	12.48	0.57	1.58e-29	Cognitive ability;
CRC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.59	-0.5	9.79e-23	Bone mineral density;
CRC	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.58	7.88	0.4	4.86e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.47	7.51	0.38	5.76e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg25985355	chr7:65971099	NA	0.53	6.05	0.32	3.9e-9	Diabetic kidney disease;
CRC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.29e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg17321639	chr7:2759063	NA	-0.37	-5.71	-0.3	2.58e-8	Height;
CRC	trans	rs4576506	0.536	rs35257125	chr9:31500452	C/T	cg26940518	chr16:1593766	IFT140;TMEM204	-0.66	-6.02	-0.31	4.6e-9	Psychosis and Alzheimer's disease;
CRC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.29	0.46	2.22e-18	IgG glycosylation;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg26587870	chr6:27730563	NA	-0.45	-7.0	-0.36	1.46e-11	Parkinson's disease;
CRC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-13.6	-0.6	1.02e-33	Vitiligo;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg10217327	chr6:118973057	C6orf204	0.51	5.76	0.3	1.93e-8	Diastolic blood pressure;
CRC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.72e-21	Alzheimer's disease (late onset);
CRC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.42	6.07	0.32	3.55e-9	Erythrocyte sedimentation rate;
CRC	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg06795125	chr2:108905320	SULT1C2	-0.4	-6.48	-0.34	3.36e-10	Lobe size;
CRC	cis	rs17767392	0.881	rs61991199	chr14:71762542	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg10760299	chr15:45669010	GATM	0.5	7.9	0.4	4.16e-14	Homoarginine levels;
CRC	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.47	-7.35	-0.38	1.55e-12	Schizophrenia;
CRC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	6.9	0.36	2.71e-11	Reticulocyte count;
CRC	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.47	8.33	0.42	2.18e-15	Migraine;
CRC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-9.78	-0.47	5.29e-20	Total body bone mineral density;
CRC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.79	0.35	5.23e-11	Obesity-related traits;
CRC	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg01950434	chr2:97203154	ARID5A	0.47	6.91	0.36	2.51e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.74	0.39	1.2e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.5	-6.03	-0.32	4.29e-9	Cancer;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg21251018	chr6:28226885	NKAPL	0.46	6.42	0.33	4.71e-10	Parkinson's disease;
CRC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.42	-0.33	4.71e-10	Alzheimer's disease (late onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01904774	chr5:159546218	PWWP2A	0.45	6.19	0.32	1.77e-9	Anxiety disorder;
CRC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.42	6.1	0.32	2.9e-9	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14766148	chr2:128786246	SAP130	0.47	6.42	0.33	4.83e-10	Thyroid stimulating hormone;
CRC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.7	-12.18	-0.56	1.93e-28	Prostate cancer;
CRC	cis	rs7945718	0.621	rs10831890	chr11:12671211	A/G	cg25843174	chr11:12811716	TEAD1	0.39	6.99	0.36	1.55e-11	Educational attainment (years of education);
CRC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.34	6.87	0.35	3.29e-11	Renal cell carcinoma;
CRC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.7	0.39	1.61e-13	Height;
CRC	cis	rs9287719	0.649	rs2160258	chr2:10717221	T/A	cg00105475	chr2:10696890	NA	0.45	7.08	0.36	8.74e-12	Prostate cancer;
CRC	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.44	6.42	0.33	4.86e-10	Body mass index;
CRC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg12751644	chr20:60527061	NA	-0.38	-5.95	-0.31	6.72e-9	Body mass index;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg10596483	chr8:143751796	JRK	-0.48	-6.6	-0.34	1.69e-10	Urinary tract infection frequency;
CRC	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.49	-6.68	-0.35	1.01e-10	Response to antidepressants and depression;
CRC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg07713946	chr22:31675144	LIMK2	-0.4	-5.75	-0.3	2e-8	Colorectal cancer;
CRC	cis	rs9462027	0.628	rs2764197	chr6:34705055	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.11	0.36	7.27e-12	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.48	4.77e-20	Bladder cancer;
CRC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.31	-0.49	8.47e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.68	-12.04	-0.55	6.68e-28	Lewy body disease;
CRC	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg09659197	chr4:152720779	NA	-0.53	-11.86	-0.55	2.88e-27	Intelligence (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24711626	chr18:29522957	KIAA1012	0.37	6.04	0.32	4.28e-9	Schizophrenia;
CRC	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg12458913	chr13:53173898	NA	0.43	6.37	0.33	6.51e-10	Lewy body disease;
CRC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.59	-10.19	-0.49	2.27e-21	Body mass index;
CRC	cis	rs4750440	0.733	rs2446585	chr10:14028086	C/T	cg04819048	chr10:14014548	FRMD4A	0.35	5.7	0.3	2.66e-8	Adiponectin levels;
CRC	cis	rs2294693	0.945	rs932399	chr6:41011266	C/T	cg14769373	chr6:40998127	UNC5CL	-0.51	-6.62	-0.34	1.49e-10	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg02560186	chr11:3602584	NA	-0.56	-6.98	-0.36	1.63e-11	Blood pressure (smoking interaction);
CRC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.43	6.94	0.36	2.04e-11	Cleft lip with or without cleft palate;
CRC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg18478394	chr8:109455254	TTC35	0.38	5.81	0.3	1.49e-8	Dupuytren's disease;
CRC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.8	-11.39	-0.53	1.47e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.86	-8.17	-0.41	6.75e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs11229555	0.598	rs7930623	chr11:58197641	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.93	9.68	0.47	1.18e-19	Prostate cancer;
CRC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.48	6.9	0.36	2.76e-11	Cleft lip with or without cleft palate;
CRC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4731207	0.596	rs6971413	chr7:124592668	C/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07165851	chr6:158734300	TULP4	0.62	7.89	0.4	4.38e-14	Height;
CRC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg24375607	chr4:120327624	NA	0.47	7.15	0.37	5.66e-12	Corneal astigmatism;
CRC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.27	-0.46	2.44e-18	Schizophrenia;
CRC	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg02493740	chr2:85810744	VAMP5	0.36	5.78	0.3	1.77e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	6.82	0.35	4.46e-11	Obesity-related traits;
CRC	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06156847	chr2:113672199	IL1F7	-0.45	-6.78	-0.35	5.59e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7209700	0.547	rs10514919	chr17:45342129	G/T	cg17185639	chr17:45330862	ITGB3	0.37	5.74	0.3	2.12e-8	IgG glycosylation;
CRC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.82	-9.92	-0.48	1.82e-20	Initial pursuit acceleration;
CRC	cis	rs449789	0.857	rs2501175	chr6:159714412	C/T	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.11	0.45	7.97e-18	Bladder cancer;
CRC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.49	6.24	0.33	1.37e-9	Recombination rate (females);
CRC	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.52	8.95	0.44	2.62e-17	Testicular germ cell tumor;
CRC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.02e-22	Corneal astigmatism;
CRC	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.39	-6.68	-0.35	1.02e-10	Vitamin D levels;
CRC	cis	rs10486722	0.606	rs6976125	chr7:41803706	T/A	cg22138096	chr7:41772439	LOC285954	0.62	7.46	0.38	7.59e-13	Pit-and-Fissure caries;
CRC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11060661	chr22:24314208	DDT;DDTL	-0.47	-7.71	-0.39	1.51e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg16342193	chr10:102329863	NA	-0.4	-6.39	-0.33	5.63e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.74	-11.96	-0.55	1.28e-27	Plateletcrit;Platelet count;
CRC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg23533926	chr12:111358616	MYL2	0.45	6.6	0.34	1.69e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.43	6.89	0.36	2.84e-11	Sitting height ratio;
CRC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.5	0.34	3.07e-10	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01106354	chr16:68278916	PLA2G15	0.41	6.32	0.33	8.48e-10	Intelligence (multi-trait analysis);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08942682	chr3:197409980	KIAA0226	0.45	6.12	0.32	2.7e-9	Survival in pancreatic cancer;
CRC	cis	rs6662572	1.000	rs3014232	chr1:46131873	T/C	cg08644498	chr1:46502608	NA	0.45	6.79	0.35	5.14e-11	Blood protein levels;
CRC	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.5	6.38	0.33	5.92e-10	Cholesterol, total;
CRC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.43	9.43	0.46	7.8e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.49	7.0	0.36	1.46e-11	Schizophrenia;
CRC	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg14003231	chr6:33640908	ITPR3	0.49	7.99	0.4	2.34e-14	Plateletcrit;
CRC	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg05683857	chr10:124030795	BTBD16	-0.31	-5.72	-0.3	2.37e-8	Total body bone mineral density;
CRC	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg26248373	chr2:1572462	NA	-0.63	-6.54	-0.34	2.3e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.5	6.19	0.32	1.79e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2737618	0.680	rs2737686	chr1:200094347	C/T	cg21825944	chr1:200113062	NR5A2	-0.51	-7.07	-0.36	9.11e-12	Uric acid levels;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.39	-6.6	-0.34	1.7e-10	Breast cancer;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.4	-0.42	1.32e-15	Schizophrenia;
CRC	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg23587288	chr2:27483067	SLC30A3	-0.32	-5.67	-0.3	3.09e-8	Blood metabolite levels;
CRC	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21659725	chr3:3221576	CRBN	-0.66	-7.18	-0.37	4.68e-12	Menarche (age at onset);
CRC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.38	5.74	0.3	2.12e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg20203395	chr5:56204925	C5orf35	-0.41	-5.74	-0.3	2.2e-8	Breast cancer;Breast cancer (early onset);
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.23	-0.32	1.44e-9	Menopause (age at onset);
CRC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.45	5.82	0.31	1.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.52	8.23	0.41	4.52e-15	Red blood cell count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04213235	chr1:145826932	GPR89A	0.48	6.85	0.35	3.65e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.46	6.48	0.34	3.44e-10	Total body bone mineral density;
CRC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg18230493	chr5:56204884	C5orf35	-0.4	-5.92	-0.31	8.08e-9	Coronary artery disease;
CRC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.77	11.24	0.53	5.2e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.32	-0.49	8.33e-22	Chronic sinus infection;
CRC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.65	9.23	0.45	3.51e-18	Alzheimer's disease;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.92	21.19	0.76	1.96e-63	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.68	7.77	0.39	1.02e-13	Cleft lip with or without cleft palate;
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg18758796	chr5:131593413	PDLIM4	0.36	6.27	0.33	1.13e-9	Blood metabolite levels;
CRC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg11833968	chr6:79620685	NA	-0.36	-6.26	-0.33	1.23e-9	Intelligence (multi-trait analysis);
CRC	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.47	5.77	0.3	1.83e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.49	6.44	0.33	4.32e-10	Heart rate;
CRC	cis	rs9463078	0.764	rs1854547	chr6:44912366	G/A	cg25276700	chr6:44698697	NA	-0.27	-6.47	-0.34	3.5e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.79	13.4	0.59	5.55e-33	Menopause (age at onset);
CRC	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.72	10.95	0.52	5.38e-24	Waist circumference;Body mass index;
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg19046167	chr17:80928561	B3GNTL1	0.42	5.9	0.31	9.16e-9	Glycated hemoglobin levels;
CRC	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg13043300	chr11:71146211	DHCR7	-0.44	-5.98	-0.31	5.98e-9	Vitamin D levels;
CRC	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.7	8.91	0.44	3.64e-17	Coronary artery disease;
CRC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.64	9.6	0.47	2.18e-19	Initial pursuit acceleration;
CRC	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg26875233	chr11:93583750	C11orf90	0.35	6.62	0.34	1.43e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.06	-14.24	-0.62	3.54e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.28	6.19	0.32	1.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.5	8.19	0.41	5.92e-15	Coronary artery disease;
CRC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.13	-0.32	2.46e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg21770322	chr7:97807741	LMTK2	0.55	9.29	0.46	2.16e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4731207	0.698	rs7782327	chr7:124505951	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg20647610	chr2:228736258	WDR69	0.46	6.16	0.32	2.16e-9	Blood pressure;
CRC	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.67	6.85	0.35	3.54e-11	Plasma clusterin levels;
CRC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.56	-9.02	-0.45	1.61e-17	Intelligence (multi-trait analysis);
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.45	6.35	0.33	7.27e-10	Parkinson's disease;
CRC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.4	6.22	0.32	1.53e-9	HDL cholesterol levels;
CRC	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.43	6.0	0.31	5.29e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg06470822	chr6:28175283	NA	0.76	8.05	0.41	1.49e-14	Depression;
CRC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.49	0.38	6.5e-13	Hip circumference adjusted for BMI;
CRC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.52	8.47	0.42	8.23e-16	Menopause (age at onset);
CRC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg02089348	chr4:1724449	TMEM129;TACC3	-0.39	-5.76	-0.3	1.94e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs860295	0.702	rs5005770	chr1:155345043	C/T	cg02153340	chr1:155202674	NA	0.56	6.68	0.35	1.03e-10	Body mass index;
CRC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.51	7.54	0.38	4.72e-13	Corneal astigmatism;
CRC	cis	rs11212617	0.905	rs172927	chr11:108124299	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.4	5.78	0.3	1.73e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.69	-12.5	-0.57	1.3e-29	Breast cancer;
CRC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.08	0.32	3.33e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg15147215	chr3:52552868	STAB1	-0.61	-10.04	-0.48	7.46e-21	Bipolar disorder;
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg15898840	chr7:45960834	IGFBP3	0.43	7.07	0.36	9.17e-12	Sitting height ratio;
CRC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.67	10.95	0.52	5.48e-24	Mean corpuscular hemoglobin;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.84	0.51	1.24e-23	Coffee consumption (cups per day);
CRC	cis	rs7737355	0.947	rs11750739	chr5:130911743	C/T	cg25547332	chr5:131281432	NA	0.37	5.73	0.3	2.28e-8	Life satisfaction;
CRC	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg26816564	chr1:7831052	VAMP3	0.6	6.36	0.33	6.59e-10	Inflammatory bowel disease;
CRC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg03030879	chr14:75389066	RPS6KL1	0.45	6.9	0.36	2.67e-11	Height;
CRC	cis	rs720844	0.748	rs7606475	chr2:149325251	C/T	cg09247360	chr2:149335327	NA	-0.58	-6.56	-0.34	2.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2227564	0.729	rs2633303	chr10:75645882	G/T	cg00564723	chr10:75632066	CAMK2G	-0.34	-7.86	-0.4	5.47e-14	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.55	7.73	0.39	1.31e-13	Melanoma;
CRC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.52	7.26	0.37	2.87e-12	Height;
CRC	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.82	-9.04	-0.45	1.39e-17	Intelligence (multi-trait analysis);
CRC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.08	-0.36	8.66e-12	Joint mobility (Beighton score);
CRC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.72	-0.47	8.24e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.04	16.07	0.66	2.57e-43	Lymphocyte percentage of white cells;
CRC	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg25019722	chr6:37503610	NA	-0.42	-7.37	-0.38	1.4e-12	Cognitive performance;
CRC	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.62	0.3	4.06e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.73	9.86	0.48	2.87e-20	Coronary artery disease;
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg01758942	chr3:52551074	STAB1	0.29	5.64	0.3	3.72e-8	Electroencephalogram traits;
CRC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.58	-10.53	-0.5	1.58e-22	Multiple system atrophy;
CRC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.67e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9847710	0.967	rs2581778	chr3:53055311	G/A	cg04503182	chr3:53078218	SFMBT1	0.42	6.63	0.34	1.42e-10	Ulcerative colitis;
CRC	trans	rs12940923	0.935	rs11871743	chr17:56368825	A/C	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.94	0.36	2.1e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg21587861	chr12:32260103	BICD1	-0.37	-6.04	-0.32	4.18e-9	Aortic root size;
CRC	cis	rs6585424	1.000	rs12777867	chr10:81935530	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-9.31	-0.46	1.92e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.6	0.43	3.27e-16	Height;
CRC	trans	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.99	-0.31	5.61e-9	Sjögren's syndrome;Systemic lupus erythematosus;
CRC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.48	-9.47	-0.46	5.85e-19	Renal cell carcinoma;
CRC	cis	rs2275731	0.505	rs7910712	chr10:16479256	T/C	cg04254609	chr10:16479192	PTER	-0.58	-8.65	-0.43	2.23e-16	Bone fracture in osteoporosis;
CRC	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg00691999	chr4:55094011	PDGFRA	0.41	5.95	0.31	6.68e-9	Corneal astigmatism;
CRC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg20243544	chr17:37824526	PNMT	0.55	8.95	0.44	2.66e-17	Asthma;
CRC	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg15226275	chr6:116381976	FRK	0.31	7.17	0.37	4.94e-12	Total cholesterol levels;
CRC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg00750074	chr16:89608354	SPG7	-0.52	-7.9	-0.4	4.09e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.07	-0.55	5.21e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg11189052	chr15:85197271	WDR73	0.64	9.35	0.46	1.38e-18	Schizophrenia;
CRC	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg27523141	chr10:43048294	ZNF37B	0.43	6.16	0.32	2.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg12273811	chr6:28175739	NA	0.55	5.86	0.31	1.12e-8	Depression;
CRC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.65	-8.57	-0.43	4.22e-16	Gut microbiome composition (summer);
CRC	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	1.0	18.22	0.71	9.07e-52	Schizophrenia;
CRC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg11833968	chr6:79620685	NA	0.33	5.77	0.3	1.85e-8	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.77	9.86	0.48	2.89e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs12745968	0.561	rs10874726	chr1:93103099	A/T	cg17283838	chr1:93427260	FAM69A	-0.48	-6.46	-0.34	3.87e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	0.95	8.44	0.42	1.01e-15	Plateletcrit;
CRC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.29	0.46	2.2e-18	Mean platelet volume;
CRC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.87	-10.18	-0.49	2.47e-21	Initial pursuit acceleration;
CRC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23422044	chr7:1970798	MAD1L1	-0.41	-5.67	-0.3	3.07e-8	Neuroticism;
CRC	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg05784532	chr1:230284198	GALNT2	0.43	5.79	0.3	1.66e-8	Coronary artery disease;
CRC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.75	-0.43	1.1e-16	Hemoglobin concentration;
CRC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.82	-14.22	-0.62	4.33e-36	QRS duration;
CRC	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg09873164	chr1:152488093	CRCT1	0.4	6.72	0.35	7.83e-11	Hair morphology;
CRC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg17948913	chr5:572064	NA	0.56	6.38	0.33	6e-10	Lung disease severity in cystic fibrosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05342987	chr14:59655273	DAAM1	0.39	6.26	0.33	1.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg27398640	chr15:77910606	LINGO1	-0.41	-6.85	-0.35	3.59e-11	Type 2 diabetes;
CRC	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg01339444	chr6:118972232	C6orf204	0.53	6.03	0.32	4.29e-9	Diastolic blood pressure;
CRC	cis	rs727505	0.866	rs73227503	chr7:124721044	A/G	cg23710748	chr7:124431027	NA	-0.72	-12.33	-0.56	5.81e-29	Lewy body disease;
CRC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.67	-11.01	-0.52	3.35e-24	Glomerular filtration rate (creatinine);
CRC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg03804128	chr16:635623	NA	0.3	7.0	0.36	1.43e-11	Height;
CRC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.47	-7.27	-0.37	2.66e-12	Monocyte count;
CRC	cis	rs4964805	0.612	rs11111758	chr12:104161084	A/G	cg02344784	chr12:104178138	NT5DC3	0.47	7.27	0.37	2.64e-12	Attention deficit hyperactivity disorder;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16245339	chr16:451507	DECR2	0.4	6.2	0.32	1.66e-9	Myopia (pathological);
CRC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.68	-9.7	-0.47	9.86e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.66	-0.39	2.03e-13	Total body bone mineral density;
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.34	-0.5	7.06e-22	Bipolar disorder;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24760647	chr2:220408209	TMEM198;CHPF	0.43	6.03	0.32	4.4e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg27068330	chr11:65405492	SIPA1	0.43	5.62	0.3	4.16e-8	Urate levels;
CRC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.81	12.46	0.57	1.79e-29	Menarche (age at onset);
CRC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg16797656	chr11:68205561	LRP5	0.37	5.85	0.31	1.18e-8	Total body bone mineral density;
CRC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.32	-6.36	-0.33	6.67e-10	Alzheimer's disease (late onset);
CRC	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.63	9.84	0.48	3.36e-20	Corneal astigmatism;
CRC	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg07424746	chr4:185654737	MLF1IP	0.51	5.69	0.3	2.8e-8	Blood protein levels;
CRC	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.32	5.71	0.3	2.58e-8	Heart rate;
CRC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg22687807	chr8:143858763	LYNX1	0.5	8.1	0.41	1.1e-14	Urinary tract infection frequency;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01479122	chr15:32163262	NA	0.42	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.94	0.58	2.94e-31	Mean platelet volume;
CRC	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.65	0.51	6.09e-23	Ileal carcinoids;
CRC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg11189052	chr15:85197271	WDR73	0.65	9.37	0.46	1.23e-18	Schizophrenia;
CRC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04880052	chr2:219191631	PNKD	0.41	6.69	0.35	9.86e-11	Colorectal cancer;
CRC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.85	-0.31	1.19e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg23587288	chr2:27483067	SLC30A3	-0.44	-6.54	-0.34	2.37e-10	Blood metabolite levels;
CRC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg18612461	chr15:75251733	NA	0.48	7.22	0.37	3.64e-12	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01557667	chr22:43411403	NA	0.42	6.12	0.32	2.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7739232	0.920	rs77985073	chr6:53526949	C/A	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.71	-7.84	-0.4	6.33e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg03030879	chr14:75389066	RPS6KL1	0.4	6.11	0.32	2.88e-9	Coronary artery disease;
CRC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg08213375	chr14:104286397	PPP1R13B	0.43	6.83	0.35	4.21e-11	Reticulocyte count;
CRC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.72	-11.34	-0.53	2.27e-25	Cognitive function;
CRC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg01874867	chr7:94954059	PON1	-0.52	-6.46	-0.34	3.79e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg11204139	chr17:3907470	NA	0.82	16.34	0.67	2.35e-44	Type 2 diabetes;
CRC	cis	rs2811415	0.597	rs6770188	chr3:127754676	A/G	cg13719885	chr3:127795394	NA	-0.4	-6.06	-0.32	3.65e-9	Lung function (FEV1/FVC);
CRC	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	5.04e-11	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04742505	chr7:72936528	BAZ1B	0.48	6.85	0.35	3.62e-11	Response to antipsychotic treatment;
CRC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.55	-6.16	-0.32	2.11e-9	Neutrophil percentage of white cells;
CRC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.56	8.9	0.44	3.69e-17	Type 2 diabetes;
CRC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.07	0.32	3.48e-9	Rheumatoid arthritis;
CRC	cis	rs61160187	0.582	rs62372134	chr5:60202247	A/T	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.57	-0.5	1.08e-22	Chronic sinus infection;
CRC	trans	rs16846053	0.579	rs57887363	chr2:162588720	C/T	cg20749769	chr11:130029961	ST14	-0.7	-6.03	-0.32	4.32e-9	Blood osmolality (transformed sodium);
CRC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.59	-7.38	-0.38	1.3e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.08	-10.25	-0.49	1.41e-21	Skin colour saturation;
CRC	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg09659197	chr4:152720779	NA	0.42	8.71	0.43	1.47e-16	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
CRC	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg15131784	chr3:139108705	COPB2	0.42	6.11	0.32	2.74e-9	Obesity-related traits;
CRC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.58	-8.49	-0.42	7.16e-16	Dental caries;
CRC	cis	rs863345	0.625	rs12119672	chr1:158500285	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.58	6.58	0.34	1.81e-10	Neutrophil percentage of white cells;
CRC	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.54	9.75	0.47	6.77e-20	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg14329157	chr2:228736135	WDR69	-0.48	-6.55	-0.34	2.17e-10	Blood pressure;
CRC	cis	rs1712517	0.771	rs59744322	chr10:105146692	G/T	cg05636881	chr10:105038444	INA	0.46	7.92	0.4	3.8e-14	Migraine;
CRC	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.37	6.3	0.33	9.82e-10	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.2	0.49	2.12e-21	Type 2 diabetes;
CRC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.64	-0.51	6.64e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.74	7.49	0.38	6.43e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.57	7.37	0.38	1.37e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.43	-0.42	1.09e-15	Body mass index;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02564756	chr3:128902977	CNBP	-0.44	-6.4	-0.33	5.41e-10	Daytime sleep phenotypes;
CRC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg26248373	chr2:1572462	NA	-0.66	-7.1	-0.36	7.65e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.75	-9.81	-0.48	4.16e-20	Initial pursuit acceleration;
CRC	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-7.66	-0.39	2.12e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg08271804	chr19:22816896	ZNF492	0.38	5.87	0.31	1.08e-8	Bronchopulmonary dysplasia;
CRC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.49	6.27	0.33	1.12e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg00086871	chr4:6988644	TBC1D14	0.88	7.52	0.38	5.39e-13	Granulocyte percentage of myeloid white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18585273	chr17:66197086	NA	0.43	6.22	0.32	1.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg25251562	chr2:3704773	ALLC	-0.49	-6.12	-0.32	2.62e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg06494592	chr3:125709126	NA	-0.55	-6.76	-0.35	6.31e-11	Blood pressure (smoking interaction);
CRC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-8.48	-0.42	7.83e-16	Type 2 diabetes;
CRC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg10298567	chr3:47292165	KIF9	0.4	6.32	0.33	8.5e-10	Colorectal cancer;
CRC	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.72	-0.3	2.33e-8	Blood pressure;
CRC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-6.41	-0.33	5e-10	Height;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg26587870	chr6:27730563	NA	-0.38	-5.95	-0.31	6.72e-9	Parkinson's disease;
CRC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.36	-5.76	-0.3	1.88e-8	Blood metabolite levels;
CRC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.37	-8.58	-0.43	3.74e-16	Mean corpuscular volume;
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.1	-0.45	8.89e-18	Bipolar disorder;
CRC	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg23920097	chr1:209922102	NA	-0.54	-6.75	-0.35	6.81e-11	Red blood cell count;
CRC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	5.98	0.31	5.77e-9	Height;
CRC	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.79	-0.3	1.67e-8	Alzheimer's disease (survival time);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22836370	chr18:51751085	MBD2	0.46	6.73	0.35	7.43e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03923535	chr7:1197113	ZFAND2A	0.52	7.47	0.38	7.11e-13	Longevity;Endometriosis;
CRC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg07217954	chr7:1067459	C7orf50	0.55	5.72	0.3	2.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg12564285	chr5:131593104	PDLIM4	0.32	5.85	0.31	1.17e-8	Blood metabolite levels;
CRC	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.7	10.05	0.48	6.48e-21	Body mass index;
CRC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.52	-8.54	-0.43	5.08e-16	Sense of smell;
CRC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.48	8.0	0.4	2.12e-14	Breast cancer;
CRC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.66	0.34	1.12e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.72	11.95	0.55	1.38e-27	Mean platelet volume;
CRC	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.56	9.96	0.48	1.33e-20	Common traits (Other);
CRC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg16476235	chr8:21771668	DOK2	0.42	7.27	0.37	2.61e-12	Mean corpuscular volume;
CRC	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg27083787	chr2:113543245	IL1A	0.42	5.86	0.31	1.12e-8	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.47	9.47	0.46	5.48e-19	Dupuytren's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02439053	chr19:18390991	JUND	0.46	6.43	0.33	4.61e-10	Anxiety disorder;
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.83	-14.77	-0.63	3.1e-38	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.62	-0.47	1.82e-19	Migraine;Coronary artery disease;
CRC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.63	-0.54	2e-26	Type 2 diabetes;
CRC	trans	rs9395066	0.527	rs12524069	chr6:44897973	C/A	cg04786201	chr1:17185605	NA	0.28	5.98	0.31	5.92e-9	Height;
CRC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.79	12.16	0.56	2.3e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.31	6.13	0.32	2.5e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.41	-7.98	-0.4	2.48e-14	Mean corpuscular volume;
CRC	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg13206674	chr6:150067644	NUP43	-0.44	-5.68	-0.3	3.04e-8	Lung cancer;
CRC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07167872	chr1:205819463	PM20D1	0.42	5.86	0.31	1.12e-8	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.61	-8.69	-0.43	1.78e-16	Schizophrenia;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg25164649	chr6:28176230	NA	0.64	8.97	0.44	2.29e-17	Cardiac Troponin-T levels;
CRC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.76	-0.43	1.08e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg19223190	chr17:80058835	NA	0.4	6.41	0.33	5.05e-10	Life satisfaction;
CRC	trans	rs10411161	0.721	rs10401778	chr19:52384315	C/T	cg22319618	chr22:45562946	NUP50	-0.69	-7.57	-0.39	3.9e-13	Breast cancer;
CRC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.68	10.06	0.49	6.16e-21	Menopause (age at onset);
CRC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.71	0.39	1.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12760731	0.565	rs11585355	chr1:178181219	T/G	cg00404053	chr1:178313656	RASAL2	1.11	11.47	0.53	7.73e-26	Obesity-related traits;
CRC	cis	rs6432018	0.964	rs11890807	chr2:9753732	C/A	cg12832956	chr2:9616023	IAH1	-0.37	-5.61	-0.3	4.24e-8	Heart rate variability traits;
CRC	cis	rs41005	0.967	rs13430914	chr2:8114648	A/G	cg03155496	chr2:8117019	LOC339788	0.4	7.08	0.36	8.77e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.78	-7.27	-0.37	2.57e-12	Diabetic retinopathy;
CRC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.29	-0.59	1.51e-32	Blood trace element (Zn levels);
CRC	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.17	0.49	2.54e-21	Asthma;
CRC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.94	19.3	0.73	4.72e-56	Menopause (age at onset);
CRC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg23758597	chr6:163146217	PARK2	0.5	5.77	0.3	1.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.6	-9.55	-0.47	3.11e-19	Aortic root size;
CRC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.41	6.52	0.34	2.72e-10	Dupuytren's disease;
CRC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.83	0.35	4.22e-11	Mean platelet volume;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12172441	chr6:28176163	NA	0.52	6.66	0.34	1.17e-10	Parkinson's disease;
CRC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.47	-7.25	-0.37	2.96e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs73206853	0.609	rs7306167	chr12:110892449	A/G	cg12870014	chr12:110450643	ANKRD13A	0.84	9.88	0.48	2.53e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs7605827	0.930	rs2058868	chr2:15679609	A/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg08807892	chr2:162101083	NA	-0.43	-6.32	-0.33	8.68e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs35000415	0.938	rs12535158	chr7:128625019	C/T	cg19972273	chr7:128594194	NA	0.68	6.31	0.33	8.75e-10	Systemic lupus erythematosus;
CRC	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.53	9.69	0.47	1.05e-19	Schizophrenia;
CRC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.5	7.89	0.4	4.53e-14	Menopause (age at onset);
CRC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.59	8.85	0.44	5.44e-17	Aortic root size;
CRC	cis	rs863345	0.604	rs10908673	chr1:158503908	T/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16482226	chr12:70637792	CNOT2	0.45	6.34	0.33	7.67e-10	Response to antipsychotic treatment;
CRC	trans	rs596169	0.541	rs6667536	chr1:219215137	G/A	cg00778190	chr1:95068029	NA	0.75	6.5	0.34	2.89e-10	Intraocular pressure;
CRC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg10298567	chr3:47292165	KIF9	-0.4	-6.24	-0.33	1.37e-9	Colorectal cancer;
CRC	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.49	-6.35	-0.33	7.27e-10	Schizophrenia;
CRC	cis	rs4481887	0.504	rs4916109	chr1:248360659	G/A	cg00666640	chr1:248458726	OR2T12	0.44	7.07	0.36	9.39e-12	Common traits (Other);
CRC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.41	6.13	0.32	2.47e-9	Type 2 diabetes;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg12172441	chr6:28176163	NA	0.5	6.94	0.36	2.14e-11	Parkinson's disease;
CRC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.48	-7.31	-0.37	2.09e-12	Motion sickness;
CRC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.6	8.76	0.44	1.02e-16	Monobrow;
CRC	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.71	-9.92	-0.48	1.9e-20	Platelet distribution width;
CRC	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.46	12.99	0.58	2.01e-31	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12024301	0.557	rs77404665	chr1:183663284	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.59	0.34	1.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg13256891	chr4:100009986	ADH5	0.42	6.09	0.32	3.07e-9	Alcohol dependence;
CRC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	1.03	8.02	0.4	1.93e-14	Type 2 diabetes nephropathy;
CRC	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.46	6.68	0.35	1.01e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.4	6.0	0.31	5.26e-9	Mean corpuscular volume;
CRC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-10.81	-0.51	1.64e-23	Alzheimer's disease;
CRC	cis	rs12042938	0.622	rs12030517	chr1:231808385	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	5.74	0.3	2.21e-8	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.46	-7.03	-0.36	1.18e-11	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs11098699	0.821	rs7684799	chr4:124207659	C/T	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	5.68	0.3	3.01e-8	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.56	-7.52	-0.38	5.13e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7202877	0.656	rs4888370	chr16:75308230	T/C	cg03315344	chr16:75512273	CHST6	0.51	5.97	0.31	5.99e-9	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-8.38	-0.42	1.55e-15	Coronary artery disease;
CRC	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.38	-5.86	-0.31	1.15e-8	Endometrial cancer;
CRC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.71	-10.83	-0.51	1.4e-23	Tonsillectomy;
CRC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.66	8.59	0.43	3.64e-16	Hip circumference adjusted for BMI;
CRC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.6	0.34	1.64e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.35	-0.33	7.19e-10	Longevity;Endometriosis;
CRC	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg09127314	chr1:152161683	NA	0.53	6.59	0.34	1.7e-10	Atopic dermatitis;
CRC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.24e-30	Bone mineral density;
CRC	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.43	6.73	0.35	7.35e-11	Schizophrenia;
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.08	-0.32	3.35e-9	Bipolar disorder;
CRC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.52	5.91	0.31	8.37e-9	Vitiligo;
CRC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg08314208	chr16:67682810	RLTPR	-0.65	-6.67	-0.34	1.11e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg19193384	chr17:30244184	NA	-0.63	-7.36	-0.38	1.47e-12	Hip circumference adjusted for BMI;
CRC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg00814883	chr7:100076585	TSC22D4	-0.51	-6.11	-0.32	2.82e-9	Lung function (FEV1/FVC);
CRC	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.58e-11	Opioid sensitivity;
CRC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.76	12.35	0.56	4.59e-29	Blood protein levels;
CRC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg06740227	chr12:86229804	RASSF9	0.38	5.7	0.3	2.73e-8	Major depressive disorder;
CRC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.51	6.06	0.32	3.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs7671189	0.502	rs6833771	chr4:11746004	T/G	cg18054620	chr5:111191530	C5orf13	-0.3	-6.0	-0.31	5.22e-9	Obesity-related traits;
CRC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.74	-12.11	-0.56	3.73e-28	Lung cancer;
CRC	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.61	8.8	0.44	7.61e-17	Schizophrenia;
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.29	0.75	6.44e-60	Prudent dietary pattern;
CRC	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.5	6.72	0.35	7.91e-11	Caudate activity during reward;
CRC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-0.97	-19.07	-0.72	3.91e-55	Height;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.67	10.71	0.51	3.68e-23	Longevity;Endometriosis;
CRC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-16.62	-0.68	1.91e-45	Cognitive function;
CRC	cis	rs61160187	0.582	rs62367903	chr5:60318973	A/G	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.89	-0.31	9.31e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00801512	chr17:28996047	NA	0.53	6.25	0.33	1.27e-9	Hip circumference adjusted for BMI;
CRC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	0.98	10.46	0.5	2.72e-22	Diabetic retinopathy;
CRC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg04731861	chr2:219085781	ARPC2	0.28	5.77	0.3	1.85e-8	Ulcerative colitis;
CRC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg08772003	chr10:104629869	AS3MT	-0.36	-6.11	-0.32	2.84e-9	Arsenic metabolism;
CRC	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg07478791	chr1:31886160	SERINC2	-0.41	-5.67	-0.3	3.13e-8	Alcohol dependence;
CRC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.42	9.4	0.46	9.75e-19	Glomerular filtration rate (creatinine);
CRC	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.75	-0.43	1.1e-16	Educational attainment (college completion);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04408576	chr16:1524927	CLCN7	0.44	7.59	0.39	3.39e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg16102536	chr7:156981717	UBE3C	0.4	6.72	0.35	8.04e-11	Body mass index;
CRC	cis	rs990171	1.000	rs12712145	chr2:103008710	T/C	cg03938978	chr2:103052716	IL18RAP	0.47	5.89	0.31	9.5e-9	Lymphocyte counts;
CRC	cis	rs7707921	1.000	rs1543911	chr5:81504841	C/T	cg17942617	chr5:81327376	ATG10	-0.4	-6.01	-0.31	4.94e-9	Breast cancer;
CRC	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	1.01	12.62	0.57	4.62e-30	IgG glycosylation;
CRC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.2	0.32	1.73e-9	Axial length;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs4073416	0.542	rs1113962	chr14:66005798	C/T	cg03016385	chr14:66212404	NA	-0.43	-6.06	-0.32	3.73e-9	N-glycan levels;
CRC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.78	8.09	0.41	1.18e-14	Cognitive function;
CRC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.37	-0.46	1.17e-18	Platelet count;
CRC	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.73	-8.21	-0.41	5.01e-15	Psoriasis;
CRC	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.44	-6.49	-0.34	3.22e-10	Neutrophil percentage of white cells;
CRC	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11030122	0.547	rs10835324	chr11:3954928	G/C	cg18678763	chr11:4115507	RRM1	-0.39	-6.62	-0.34	1.43e-10	Mean platelet volume;Platelet distribution width;
CRC	trans	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg01831904	chr17:28903510	LRRC37B2	0.57	5.89	0.31	9.58e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg22687807	chr8:143858763	LYNX1	-0.38	-6.68	-0.35	1.04e-10	Urinary tract infection frequency;
CRC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	9.92e-11	Menopause (age at onset);
CRC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.15	0.41	7.87e-15	Platelet count;
CRC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.65	10.03	0.48	7.96e-21	Longevity;Endometriosis;
CRC	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.37e-19	Blood protein levels;
CRC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.11	-12.97	-0.58	2.38e-31	Diabetic kidney disease;
CRC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.54	-8.8	-0.44	7.94e-17	Total body bone mineral density;
CRC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	0.92	10.95	0.52	5.44e-24	Red blood cell traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg15377113	chr14:93799418	BTBD7;KIAA1409	0.41	6.45	0.34	3.96e-10	Schizophrenia;
CRC	cis	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg27395922	chr11:50257633	LOC441601	-0.35	-5.67	-0.3	3.08e-8	Coronary artery disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10459029	chr2:242640849	ING5	0.48	7.11	0.36	7.47e-12	Intelligence (multi-trait analysis);
CRC	cis	rs35123781	1.000	rs682164	chr5:139058589	A/G	cg10513866	chr5:139070639	NA	0.47	7.54	0.38	4.77e-13	Schizophrenia;
CRC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.93	-0.31	7.67e-9	Bladder cancer;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg23161317	chr6:28129485	ZNF389	0.46	6.54	0.34	2.36e-10	Parkinson's disease;
CRC	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg01312482	chr5:178451176	ZNF879	-0.37	-6.15	-0.32	2.26e-9	Pubertal anthropometrics;
CRC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	17.38	0.69	1.8e-48	Smoking behavior;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23111772	chr20:62338704	ARFRP1;ZGPAT	-0.41	-6.04	-0.32	4.24e-9	Myopia (pathological);
CRC	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.41	-5.7	-0.3	2.71e-8	Intelligence;
CRC	cis	rs554111	0.858	rs10916855	chr1:21056382	T/C	cg08890418	chr1:21044141	KIF17	0.31	5.82	0.31	1.36e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs2033908	0.620	rs10765996	chr11:12853043	A/G	cg25843174	chr11:12811716	TEAD1	-0.4	-7.04	-0.36	1.1e-11	Sitting height ratio;
CRC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg24562669	chr7:97807699	LMTK2	0.48	8.1	0.41	1.08e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.46	6.62	0.34	1.43e-10	Lung cancer;
CRC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.28	-6.41	-0.33	5.1e-10	Depressive symptoms (multi-trait analysis);
CRC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg21153622	chr11:89784906	NA	-0.38	-6.03	-0.32	4.45e-9	Height;
CRC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg21724239	chr8:58056113	NA	0.55	7.61	0.39	3.01e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg15786705	chr6:28176104	NA	0.52	7.15	0.37	5.71e-12	Parkinson's disease;
CRC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.23	0.53	5.38e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.91	11.15	0.52	1.08e-24	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg26102564	chr10:131424627	MGMT	0.39	5.68	0.3	2.91e-8	Response to temozolomide;
CRC	cis	rs6543140	0.693	rs7579737	chr2:102987361	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	7.75	0.39	1.16e-13	Blood protein levels;
CRC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.69	9.39	0.46	1.04e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.71	-0.35	8.58e-11	Colorectal cancer;
CRC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.39	6.28	0.33	1.05e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.69	-11.17	-0.52	9.09e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01834625	chr1:151254649	ZNF687	0.45	6.22	0.32	1.51e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.67	10.15	0.49	3.05e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.42	-0.33	4.71e-10	Alzheimer's disease (late onset);
CRC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.67	9.23	0.45	3.48e-18	Lung cancer;
CRC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.48	7.12	0.37	6.61e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.63	-9.87	-0.48	2.66e-20	Hepatocellular carcinoma;
CRC	trans	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg26043149	chr18:55253948	FECH	0.53	8.08	0.41	1.25e-14	Bone mineral density;
CRC	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg13043300	chr11:71146211	DHCR7	-0.44	-5.91	-0.31	8.58e-9	Vitamin D levels;
CRC	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.7	8.57	0.43	4.08e-16	Iron status biomarkers;
CRC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg11292332	chr7:45801988	SEPT13	0.35	6.09	0.32	3.07e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg20933634	chr6:27740509	NA	0.45	6.63	0.34	1.34e-10	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12365451	chr11:33279136	HIPK3	0.44	6.26	0.33	1.22e-9	Response to antipsychotic treatment;
CRC	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg21851534	chr17:3907994	ZZEF1	-0.39	-6.46	-0.34	3.7e-10	Type 2 diabetes;
CRC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.6	7.94	0.4	3.31e-14	Mean platelet volume;
CRC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26240231	chr7:1148101	C7orf50	-0.46	-6.69	-0.35	9.41e-11	Bronchopulmonary dysplasia;
CRC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.37	7.64	0.39	2.33e-13	Schizophrenia;
CRC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-8.96	-0.44	2.44e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7538876	1.000	rs942457	chr1:17739586	G/A	cg01904812	chr1:17746340	RCC2	0.33	5.67	0.3	3.2e-8	Basal cell carcinoma;
CRC	cis	rs7626444	0.647	rs843537	chr3:196473403	C/A	cg12930392	chr3:196481615	PAK2	0.38	6.73	0.35	7.73e-11	Monocyte count;
CRC	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg22089800	chr15:90895588	ZNF774	0.5	7.97	0.4	2.57e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg15226275	chr6:116381976	FRK	0.29	8.35	0.42	1.9e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg21505886	chr4:1724428	TMEM129;TACC3	-0.39	-5.62	-0.3	4.03e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.47	-6.49	-0.34	3.1e-10	Superior crus of antihelix expression;
CRC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.39	-0.33	5.72e-10	Daytime sleep phenotypes;
CRC	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	13.15	0.59	4.98e-32	Hip circumference;
CRC	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg13834844	chr10:102415320	NA	-0.35	-5.86	-0.31	1.14e-8	Body mass index;
CRC	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg02466173	chr16:30829666	NA	0.66	10.0	0.48	1.02e-20	Dementia with Lewy bodies;
CRC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.67	9.63	0.47	1.64e-19	Menopause (age at onset);
CRC	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	7.1	0.36	7.82e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg20607287	chr7:12443886	VWDE	-0.55	-5.98	-0.31	5.75e-9	Coronary artery disease;
CRC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.96	0.44	2.48e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.41	-5.82	-0.31	1.37e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	trans	rs2303319	0.504	rs12465734	chr2:162437859	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.01	-0.31	4.93e-9	Cognitive function;
CRC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg03340356	chr1:67600835	NA	0.29	6.56	0.34	2.11e-10	Psoriasis;
CRC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.59	8.53	0.43	5.29e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.87e-24	Motion sickness;
CRC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.36	-0.59	8.2e-33	Total body bone mineral density;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg02551882	chr22:31365455	MORC2;TUG1	0.39	6.03	0.32	4.53e-9	Interleukin-6 levels;
CRC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.52	-0.62	3.01e-37	Body mass index;
CRC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.95	0.44	2.61e-17	Morning vs. evening chronotype;
CRC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.69	10.48	0.5	2.23e-22	Corneal astigmatism;
CRC	trans	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg09872104	chr7:134855509	C7orf49	-0.87	-8.4	-0.42	1.33e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.5	9.54	0.47	3.24e-19	Alcohol dependence;
CRC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.42	6.38	0.33	5.88e-10	Vitiligo;
CRC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.85	10.82	0.51	1.51e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.49	-0.38	6.22e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg20243544	chr17:37824526	PNMT	0.38	5.7	0.3	2.73e-8	Self-reported allergy;
CRC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.76	14.08	0.61	1.51e-35	Oral cavity cancer;
CRC	cis	rs4722166	0.532	rs6963591	chr7:22757270	G/T	cg05472934	chr7:22766657	IL6	-0.64	-10.29	-0.49	1.04e-21	Lung cancer;
CRC	cis	rs1124376	0.688	rs11715447	chr3:20140129	A/C	cg05072819	chr3:20081367	KAT2B	0.85	8.93	0.44	3.01e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.53	7.03	0.36	1.18e-11	Height;
CRC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.75	13.43	0.6	4.36e-33	Oral cavity cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04682192	chr12:110561945	IFT81	0.44	6.26	0.33	1.17e-9	Response to antipsychotic treatment;
CRC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg24881330	chr22:46731750	TRMU	0.56	6.6	0.34	1.61e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg18225595	chr11:63971243	STIP1	0.6	6.75	0.35	6.81e-11	Mean platelet volume;
CRC	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg20356878	chr3:121714668	ILDR1	-0.47	-6.92	-0.36	2.32e-11	Multiple sclerosis;
CRC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.85	-0.31	1.21e-8	Migraine;Coronary artery disease;
CRC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.44	7.37	0.38	1.43e-12	Crohn's disease;
CRC	cis	rs10512697	0.892	rs62336107	chr5:3539570	T/C	cg19473799	chr5:3511975	NA	-0.78	-6.03	-0.32	4.37e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs12541635	0.966	rs12550587	chr8:106978289	C/T	cg10147462	chr8:107024639	NA	0.42	6.78	0.35	5.7e-11	Age of smoking initiation;
CRC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18252515	chr7:66147081	NA	-0.43	-6.24	-0.33	1.32e-9	Aortic root size;
CRC	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.22	-5.83	-0.31	1.33e-8	Type 2 diabetes;
CRC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg24675056	chr1:15929824	NA	0.51	7.06	0.36	9.73e-12	Systolic blood pressure;
CRC	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.55	-6.58	-0.34	1.88e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.19	-0.37	4.37e-12	Capecitabine sensitivity;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Parkinson's disease;
CRC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.94	-15.14	-0.64	1.15e-39	Longevity;
CRC	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg12458913	chr13:53173898	NA	0.49	6.86	0.35	3.45e-11	Lewy body disease;
CRC	cis	rs4731207	0.672	rs10249081	chr7:124468519	T/G	cg23710748	chr7:124431027	NA	0.37	6.03	0.32	4.47e-9	Cutaneous malignant melanoma;
CRC	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.97	12.06	0.55	5.31e-28	Orofacial clefts;
CRC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg02659138	chr7:134003124	SLC35B4	-0.34	-5.76	-0.3	1.9e-8	Mean platelet volume;
CRC	cis	rs4930561	0.714	rs7945995	chr11:67938302	A/G	cg04465784	chr11:67976953	SUV420H1	-0.3	-5.97	-0.31	6.07e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg10651300	chr12:53661859	ESPL1	-0.57	-6.95	-0.36	1.96e-11	Diisocyanate-induced asthma;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	trans	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg01134436	chr17:81009848	B3GNTL1	0.76	7.09	0.36	8.43e-12	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.66	9.28	0.46	2.32e-18	Vitamin D levels;
CRC	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.57	-8.68	-0.43	1.81e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13967780	chr18:46476822	SMAD7	0.44	6.42	0.33	4.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.1	-0.32	3.04e-9	Axial length;
CRC	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.74	11.19	0.53	7.41e-25	Testicular germ cell tumor;
CRC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.63	-0.68	1.72e-45	Height;
CRC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs6694672	1.000	rs10754219	chr1:197165186	C/T	cg13682187	chr1:196946512	CFHR5	0.53	8.13	0.41	8.91e-15	Asthma;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg23262020	chr14:93651423	C14orf109;MOAP1	0.37	6.0	0.31	5.13e-9	Obesity-related traits;
CRC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.59	-0.43	3.43e-16	Alcohol dependence;
CRC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.0	0.64	4.23e-39	Lymphocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg03623178	chr6:28175578	NA	0.98	12.95	0.58	2.88e-31	Depression;
CRC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.33	0.33	7.87e-10	Lung cancer;
CRC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.03e-9	Arsenic metabolism;
CRC	trans	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg05059571	chr16:84539110	KIAA1609	0.47	7.06	0.36	9.71e-12	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.83	-0.31	1.35e-8	Daytime sleep phenotypes;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg03623178	chr6:28175578	NA	1.01	13.37	0.59	7.12e-33	Depression;
CRC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-12.93	-0.58	3.44e-31	Lung function (FEV1);
CRC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.46	9.17	0.45	5.24e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg09877947	chr5:131593287	PDLIM4	0.53	9.92	0.48	1.81e-20	Acylcarnitine levels;
CRC	cis	rs7572644	0.640	rs7593136	chr2:28017792	A/G	cg27432699	chr2:27873401	GPN1	0.48	6.32	0.33	8.67e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.67	7.16	0.37	5.46e-12	D-dimer levels;
CRC	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg25547332	chr5:131281432	NA	-0.38	-5.82	-0.31	1.38e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9467160	1.000	rs12198188	chr6:24442482	A/G	cg20631270	chr6:24437470	GPLD1	0.48	6.34	0.33	7.61e-10	Liver enzyme levels;
CRC	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.82	10.85	0.51	1.21e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.51	8.92	0.44	3.39e-17	Testicular germ cell tumor;
CRC	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg04586622	chr2:25135609	ADCY3	-0.57	-9.75	-0.47	6.54e-20	Body mass index;
CRC	cis	rs3106136	0.564	rs60428594	chr4:95103466	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-6.16	-0.32	2.15e-9	Capecitabine sensitivity;
CRC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.24	-5.9	-0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.8	14.55	0.63	2.16e-37	Anterior chamber depth;
CRC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.63	-9.23	-0.45	3.51e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs17767392	0.874	rs34767050	chr14:71780957	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.99e-11	Mitral valve prolapse;
CRC	cis	rs8040855	0.627	rs12913859	chr15:85638418	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.71	-0.3	2.49e-8	Bulimia nervosa;
CRC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-19.6	-0.73	3.25e-57	Primary sclerosing cholangitis;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.25e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.57	8.97	0.44	2.22e-17	Brugada syndrome;
CRC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.75	-13.65	-0.6	6.23e-34	Body mass index;
CRC	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.51	7.42	0.38	1e-12	Testicular germ cell tumor;
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg12564285	chr5:131593104	PDLIM4	0.41	8.14	0.41	8.3e-15	Blood metabolite levels;
CRC	cis	rs73206853	0.563	rs57488849	chr12:111181785	C/T	cg12870014	chr12:110450643	ANKRD13A	0.78	8.36	0.42	1.78e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg26893134	chr6:116381904	FRK	0.26	7.61	0.39	2.98e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg06223162	chr1:101003688	GPR88	-0.34	-6.07	-0.32	3.51e-9	Monocyte count;
CRC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg14008862	chr17:28927542	LRRC37B2	0.56	5.82	0.31	1.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-10.72	-0.51	3.46e-23	Extrinsic epigenetic age acceleration;
CRC	trans	rs701145	0.556	rs191651	chr3:153973887	T/G	cg22545385	chr10:131989303	NA	-0.41	-6.0	-0.31	5.34e-9	Coronary artery disease;
CRC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.82	9.46	0.46	6.06e-19	Eosinophil percentage of granulocytes;
CRC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.58	-9.01	-0.45	1.67e-17	Coronary artery disease;
CRC	cis	rs9292777	0.901	rs114400949	chr5:40419143	G/C	cg09067459	chr5:40385259	NA	0.53	9.25	0.45	3.02e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.24	-0.41	4.09e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg06872519	chr11:6947619	ZNF215	0.58	5.79	0.3	1.68e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg18200150	chr17:30822561	MYO1D	0.46	8.8	0.44	8.13e-17	Schizophrenia;
CRC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.72	8.69	0.43	1.71e-16	Type 2 diabetes nephropathy;
CRC	cis	rs7945718	0.621	rs11022463	chr11:12685395	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	4.89e-12	Educational attainment (years of education);
CRC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.11e-14	Resting heart rate;
CRC	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	1.19	14.38	0.62	1e-36	Lung disease severity in cystic fibrosis;
CRC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg00579200	chr11:133705235	NA	-0.4	-5.76	-0.3	1.94e-8	Childhood ear infection;
CRC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.51	-0.38	5.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs12940923	1.000	rs12949848	chr17:56362067	A/G	cg16900910	chr15:72789182	ARIH1	0.54	6.21	0.32	1.61e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-6.43	-0.33	4.53e-10	Schizophrenia;
CRC	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.73	9.31	0.46	1.82e-18	Iron status biomarkers;
CRC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.31	-0.49	8.94e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.5	8.1	0.41	1.06e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.84	11.7	0.54	1.11e-26	Body mass index;
CRC	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.36	-0.38	1.52e-12	Inflammatory bowel disease;
CRC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	10.42	0.5	3.76e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg02903104	chr8:1507517	DLGAP2	-0.49	-8.26	-0.41	3.53e-15	Lung cancer;
CRC	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-8.79	-0.44	8.23e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.82	-0.35	4.26e-11	Bipolar disorder;
CRC	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-7.91	-0.4	3.82e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3751196	0.808	rs7314150	chr12:104213731	A/G	cg02344784	chr12:104178138	NT5DC3	0.69	8.05	0.41	1.53e-14	Sense of smell;
CRC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	11.77	0.54	6.41e-27	Platelet count;
CRC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg19318889	chr4:1322082	MAEA	0.4	5.68	0.3	2.94e-8	Obesity-related traits;
CRC	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.45	-7.15	-0.37	5.53e-12	Dupuytren's disease;
CRC	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.5	-6.12	-0.32	2.68e-9	Coronary artery calcification;
CRC	cis	rs138055607	1	rs138055607	chr10:75450901	C/G	cg07699608	chr10:75541558	CHCHD1	0.64	6.2	0.32	1.68e-9	Initial pursuit acceleration;
CRC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.94	-17.32	-0.69	3.16e-48	Height;
CRC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.68	9.95	0.48	1.4e-20	Lung cancer (smoking interaction);
CRC	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.55	9.35	0.46	1.39e-18	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11062677	chr19:13976917	NA	0.46	6.48	0.34	3.36e-10	Response to antipsychotic treatment;
CRC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.25	-16.93	-0.68	1.14e-46	Breast cancer;
CRC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07513332	chr6:167530253	CCR6	-0.4	-7.52	-0.38	5.11e-13	Primary biliary cholangitis;
CRC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.27	0.37	2.61e-12	Neuroticism;
CRC	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.62	11.82	0.55	4.13e-27	Menarche (age at onset);
CRC	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.88	0.51	9.46e-24	Bipolar disorder;
CRC	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg00507830	chr2:103233733	NA	0.55	5.87	0.31	1.08e-8	Gut microbiota (bacterial taxa);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03443922	chr7:107384711	CBLL1	0.49	6.19	0.32	1.74e-9	Thyroid stimulating hormone;
CRC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg17724175	chr1:150552817	MCL1	0.45	6.83	0.35	4.24e-11	Melanoma;
CRC	trans	rs75828804	0.826	rs116168751	chr16:77567902	G/A	cg19423196	chr10:82049429	MAT1A	0.51	6.08	0.32	3.39e-9	Intraocular pressure;
CRC	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg18064842	chr5:14874549	NA	0.49	7.22	0.37	3.69e-12	Blood metabolite levels;
CRC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.61	8.57	0.43	4e-16	Iron status biomarkers;
CRC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg04006718	chr10:1068667	C10orf110;IDI2	0.4	5.64	0.3	3.68e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.88	-0.31	1.02e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg17885791	chr6:149771845	ZC3H12D	0.32	5.78	0.3	1.76e-8	Dupuytren's disease;
CRC	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.71	-0.6	3.74e-34	Ulcerative colitis;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg12843489	chr17:35061545	NA	0.34	6.15	0.32	2.31e-9	Kashin-Beck disease;
CRC	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.73	0.3	2.3e-8	Educational attainment;
CRC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.91	13.0	0.58	1.85e-31	Breast cancer;
CRC	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.62	-0.39	2.78e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg15147215	chr3:52552868	STAB1	0.47	6.92	0.36	2.37e-11	Bipolar disorder;
CRC	cis	rs7112925	0.966	rs11602157	chr11:66827319	G/A	cg24851651	chr11:66362959	CCS	-0.39	-6.7	-0.35	8.9e-11	Height;
CRC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.6	10.24	0.49	1.57e-21	Prudent dietary pattern;
CRC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.35	6.35	0.33	6.98e-10	Mean corpuscular volume;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg07936430	chr16:30538244	ZNF768	-0.53	-6.47	-0.34	3.56e-10	Type 1 diabetes;
CRC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.56	8.26	0.41	3.67e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.35	-5.61	-0.3	4.21e-8	Total body bone mineral density;
CRC	cis	rs9846480	0.516	rs6439805	chr3:138056658	C/T	cg25476813	chr3:138050155	TXNDC6	-0.38	-5.73	-0.3	2.24e-8	Whole-brain volume (Alzheimer's disease interaction);
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg12172441	chr6:28176163	NA	0.58	7.61	0.39	2.96e-13	Parkinson's disease;
CRC	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg00631329	chr6:26305371	NA	-0.53	-9.1	-0.45	8.69e-18	Educational attainment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07643503	chr18:32820679	ZNF397	0.44	6.19	0.32	1.8e-9	Response to antipsychotic treatment;
CRC	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.53	0.34	2.51e-10	Blood protein levels;
CRC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg11707556	chr5:10655725	ANKRD33B	0.46	7.58	0.39	3.67e-13	Coronary artery disease;
CRC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.36	0.33	6.58e-10	Morning vs. evening chronotype;
CRC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	6.03	0.32	4.42e-9	Schizophrenia;
CRC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.91	-10.29	-0.49	1e-21	Cerebrospinal P-tau181p levels;
CRC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-11.48	-0.53	7.23e-26	Bone mineral density;
CRC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg13798912	chr7:905769	UNC84A	0.54	6.17	0.32	1.97e-9	Cerebrospinal P-tau181p levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.47	7.04	0.36	1.16e-11	Response to antipsychotic treatment;
CRC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.62	9.17	0.45	5.29e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.77	-13.86	-0.61	1.02e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2421770	0.530	rs11033084	chr11:35367408	T/G	cg13971030	chr11:35366721	SLC1A2	-0.38	-6.55	-0.34	2.18e-10	Staphylococcus aureus nasal carriage (persistent);
CRC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg18478394	chr8:109455254	TTC35	0.39	6.03	0.32	4.51e-9	Dupuytren's disease;
CRC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-7.02	-0.36	1.25e-11	Aortic root size;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11928684	chr11:47291227	MADD	0.38	6.0	0.31	5.08e-9	Obesity-related traits;
CRC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.58	-7.21	-0.37	3.88e-12	Gut microbiome composition (summer);
CRC	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12024301	0.557	rs59872949	chr1:183613649	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.01e-12	Headache;
CRC	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04621255	chr9:131581398	ENDOG	0.47	6.02	0.31	4.65e-9	Thyroid stimulating hormone;
CRC	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg02527881	chr3:46936655	PTH1R	0.38	6.77	0.35	6.09e-11	Colorectal cancer;
CRC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg13844804	chr7:814759	HEATR2	0.66	8.67	0.43	1.99e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.08	19.11	0.73	2.82e-55	Cognitive function;
CRC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.47	-6.96	-0.36	1.89e-11	Tonsillectomy;
CRC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg04880052	chr2:219191631	PNKD	0.39	5.96	0.31	6.38e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg03609598	chr5:56110824	MAP3K1	-0.6	-7.51	-0.38	5.59e-13	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.42	0.53	1.12e-25	Prudent dietary pattern;
CRC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-7.03	-0.36	1.23e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.86	-0.35	3.44e-11	Major depressive disorder;
CRC	cis	rs7804356	1.000	rs3801807	chr7:26897439	T/C	cg03456212	chr7:26904342	SKAP2	-0.5	-5.69	-0.3	2.77e-8	Type 1 diabetes;
CRC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.07	-0.41	1.34e-14	Height;
CRC	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.57	-8.12	-0.41	9.17e-15	Platelet distribution width;
CRC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.38	6.0	0.31	5.16e-9	Longevity;Endometriosis;
CRC	cis	rs6908034	0.660	rs111231540	chr6:19802226	A/C	cg02682789	chr6:19804855	NA	0.81	6.89	0.35	2.9100000000000002e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.59	-8.44	-0.42	1.05e-15	Schizophrenia;
CRC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg00074818	chr8:8560427	CLDN23	0.42	7.67	0.39	1.96e-13	Obesity-related traits;
CRC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.51	-6.89	-0.35	2.92e-11	Gut microbiome composition (summer);
CRC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg09655341	chr17:79618100	PDE6G	-0.37	-6.26	-0.33	1.21e-9	Eye color traits;
CRC	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.58	-10.44	-0.5	3.12e-22	Waist-hip ratio;
CRC	cis	rs6662572	0.737	rs6700322	chr1:46409176	G/T	cg08644498	chr1:46502608	NA	-0.44	-6.98	-0.36	1.61e-11	Blood protein levels;
CRC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.93	-0.31	7.68e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.49	-0.34	3.08e-10	Bipolar disorder;
CRC	cis	rs17092148	0.597	rs57495888	chr20:33092724	T/C	cg08999081	chr20:33150536	PIGU	-0.47	-5.74	-0.3	2.2e-8	Neuroticism;
CRC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg14122633	chr5:456516	EXOC3	-0.48	-5.66	-0.3	3.27e-8	Fat distribution (HIV);
CRC	cis	rs6681460	0.800	rs481681	chr1:67194378	G/A	cg02459107	chr1:67143332	SGIP1	-0.37	-6.34	-0.33	7.5e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.64	-0.47	1.56e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs305851	0.692	rs9380893	chr6:39745436	C/G	cg02386599	chr6:39769542	DAAM2	-0.37	-5.78	-0.3	1.75e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12315302	chr6:26189340	HIST1H4D	0.78	6.07	0.32	3.43e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg06632207	chr12:54070931	ATP5G2	0.43	7.24	0.37	3.13e-12	Height;
CRC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.61	8.13	0.41	8.6e-15	Mean platelet volume;
CRC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	1.23	10.88	0.51	9.55e-24	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
CRC	cis	rs2457480	0.850	rs11238902	chr10:44681091	C/T	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;
CRC	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg06016156	chr8:1399969	NA	-0.48	-5.78	-0.3	1.75e-8	Triglycerides;
CRC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg16141378	chr3:129829833	LOC729375	0.45	6.36	0.33	6.94e-10	Triglycerides;
CRC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.49	7.25	0.37	3.04e-12	Obesity-related traits;
CRC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.43	6.76	0.35	6.22e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.77	0.44	9.87e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.35	-0.42	1.88e-15	Blood protein levels;
CRC	cis	rs7463659	0.904	rs7826572	chr8:135433805	G/T	cg17885191	chr8:135476712	NA	-0.4	-5.89	-0.31	9.64e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.04	-0.36	1.14e-11	Colorectal cancer;
CRC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-8.79	-0.44	8.45e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs12310399	0.772	rs7971041	chr12:95526019	C/T	cg09150239	chr1:204347429	NA	0.43	6.22	0.32	1.47e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CRC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.54	8.72	0.43	1.38e-16	Hemoglobin concentration;Hematocrit;
CRC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.67	10.95	0.52	5.48e-24	Mean corpuscular hemoglobin;
CRC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.4	-6.33	-0.33	7.99e-10	Neurofibrillary tangles;
CRC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	9.52	0.46	3.78e-19	Height;
CRC	cis	rs9462027	0.628	rs1543558	chr6:34784371	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.4e-9	Systemic lupus erythematosus;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03202064	chr16:73091917	ZFHX3	0.48	6.68	0.35	1.02e-10	Anxiety disorder;
CRC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg04450456	chr4:17643702	FAM184B	0.41	6.62	0.34	1.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg16281234	chr15:35388805	NA	-0.5	-6.25	-0.33	1.3e-9	Longevity (90 years and older);
CRC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-10.35	-0.5	6.51e-22	Schizophrenia;
CRC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg12172441	chr6:28176163	NA	0.49	6.73	0.35	7.38e-11	Parkinson's disease;
CRC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.52	7.83	0.4	6.97e-14	Aortic root size;
CRC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.42	6.03	0.32	4.34e-9	Renal cell carcinoma;
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-9.05	-0.45	1.33e-17	Bipolar disorder;
CRC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg16989086	chr20:62203971	PRIC285	-0.5	-6.61	-0.34	1.55e-10	Glioblastoma;
CRC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.6	0.47	2.14e-19	Cognitive test performance;
CRC	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg24463073	chr6:118973353	C6orf204	0.54	7.13	0.37	6.33e-12	Diastolic blood pressure;
CRC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg14541582	chr5:601475	NA	-0.34	-6.46	-0.34	3.71e-10	Obesity-related traits;
CRC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	5.92	0.31	8.17e-9	Coronary artery disease;
CRC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	8.28	0.42	3.21e-15	Cognitive test performance;
CRC	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.6	-5.76	-0.3	1.89e-8	Alzheimer's disease (late onset);
CRC	trans	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg14541582	chr5:601475	NA	-0.36	-7.34	-0.38	1.66e-12	Obesity-related traits;
CRC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg21466736	chr12:48725269	NA	0.5	7.93	0.4	3.47e-14	Plateletcrit;
CRC	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.72	0.47	8.75e-20	Cognitive test performance;
CRC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.37	6.52	0.34	2.63e-10	Cardiovascular disease risk factors;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08740862	chr11:62314417	AHNAK	0.38	6.38	0.33	5.94e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg06470822	chr6:28175283	NA	0.98	13.22	0.59	2.69e-32	Depression;
CRC	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.55	8.5	0.42	6.63e-16	Diastolic blood pressure;
CRC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.66	-8.52	-0.43	5.82e-16	Gut microbiome composition (summer);
CRC	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg05579598	chr16:88989069	CBFA2T3	0.34	6.17	0.32	1.99e-9	Social autistic-like traits;
CRC	cis	rs600626	0.636	rs11236514	chr11:75451343	A/C	cg24262691	chr11:75473276	NA	-0.54	-6.99	-0.36	1.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg27129171	chr3:47204927	SETD2	0.63	8.99	0.44	1.96e-17	Birth weight;
CRC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg10298567	chr3:47292165	KIF9	0.38	5.96	0.31	6.55e-9	Colorectal cancer;
CRC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.42	6.14	0.32	2.35e-9	Bone properties (heel);
CRC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.59	-10.68	-0.51	4.67e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7951870	0.617	rs12361673	chr11:46723937	G/A	cg19486271	chr11:47235900	DDB2	-0.49	-7.68	-0.39	1.89e-13	Schizophrenia;
CRC	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.39	-0.33	5.79e-10	HDL cholesterol;
CRC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.62	10.5	0.5	1.97e-22	Prudent dietary pattern;
CRC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.29	-0.37	2.33e-12	Chronic sinus infection;
CRC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.43	1.05e-16	Aortic root size;
CRC	cis	rs9462846	0.887	rs6907869	chr6:42850919	G/T	cg21280719	chr6:42927975	GNMT	-0.31	-6.11	-0.32	2.75e-9	Blood protein levels;
CRC	trans	rs1120787	0.793	rs478765	chr18:55013866	C/T	cg19077231	chr7:100484514	SRRT	-0.54	-6.0	-0.31	5.09e-9	HIV-1 control;
CRC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	15.1	0.64	1.6e-39	Lymphocyte percentage of white cells;
CRC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24308560	chr3:49941425	MST1R	0.43	6.82	0.35	4.29e-11	Body mass index;
CRC	cis	rs375066	0.935	rs396874	chr19:44397225	G/C	cg12072164	chr19:44306565	LYPD5	0.36	5.61	0.3	4.18e-8	Breast cancer;
CRC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg12573674	chr2:1569213	NA	-0.72	-7.74	-0.39	1.27e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.64	-17.36	-0.69	2.23e-48	Urate levels in overweight individuals;
CRC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.36	0.53	1.94e-25	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.73	-0.39	1.32e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6662572	0.737	rs4660330	chr1:46458298	A/G	cg08644498	chr1:46502608	NA	-0.46	-7.38	-0.38	1.3e-12	Blood protein levels;
CRC	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.46	-6.58	-0.34	1.83e-10	IgG glycosylation;
CRC	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg26893134	chr6:116381904	FRK	0.28	6.76	0.35	6.29e-11	Total cholesterol levels;
CRC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.94	-15.69	-0.65	8.5e-42	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.6	8.15	0.41	7.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg08222913	chr3:52553049	STAB1	0.34	5.95	0.31	6.98e-9	Bipolar disorder;
CRC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.51	-8.13	-0.41	8.77e-15	Menopause (age at onset);
CRC	cis	rs6460942	0.818	rs73299043	chr7:12251595	C/G	cg06484146	chr7:12443880	VWDE	-0.59	-6.05	-0.32	3.93e-9	Coronary artery disease;
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.69	7.73	0.39	1.28e-13	Body mass index;
CRC	cis	rs1322512	0.883	rs2758814	chr6:152966367	C/T	cg03415253	chr6:152958462	SYNE1	-0.44	-6.77	-0.35	5.99e-11	Tonometry;
CRC	cis	rs6788895	1.000	rs6769917	chr3:150509604	A/T	cg09723797	chr3:150481914	SIAH2	-0.81	-6.64	-0.34	1.27e-10	Breast cancer;
CRC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.61	6.23	0.33	1.39e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg20607287	chr7:12443886	VWDE	-0.63	-6.58	-0.34	1.85e-10	Coronary artery disease;
CRC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.56	7.04	0.36	1.11e-11	Morning vs. evening chronotype;
CRC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.5	10.11	0.49	4.27e-21	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg02033258	chr5:131593261	PDLIM4	0.34	5.97	0.31	6.14e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	0.67	6.31	0.33	9.06e-10	Fat distribution (HIV);
CRC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.26	-0.41	3.59e-15	Intelligence (multi-trait analysis);
CRC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.55	6.51	0.34	2.87e-10	White matter hyperintensity burden;
CRC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.94	-0.48	1.54e-20	Mood instability;
CRC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.62	8.4	0.42	1.34e-15	High light scatter reticulocyte count;
CRC	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	9.87	0.48	2.72e-20	Bipolar disorder;
CRC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-7.69	-0.39	1.7e-13	Vitiligo;
CRC	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.6	8.31	0.42	2.61e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.86	-0.31	1.1e-8	Response to antipsychotic treatment;
CRC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.45	6.44	0.33	4.29e-10	Tonsillectomy;
CRC	cis	rs4363385	0.747	rs9659623	chr1:152965158	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.18	-0.37	4.77e-12	Inflammatory skin disease;
CRC	cis	rs17532515	0.628	rs2321272	chr4:141465244	T/C	cg09181644	chr4:141490428	UCP1	-0.32	-5.77	-0.3	1.86e-8	Select biomarker traits;
CRC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.71	-8.82	-0.44	6.8e-17	Multiple system atrophy;
CRC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg02659138	chr7:134003124	SLC35B4	0.42	7.37	0.38	1.41e-12	Mean platelet volume;
CRC	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.16	14.97	0.64	5.46e-39	Uric acid levels;
CRC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg08288130	chr8:21771540	DOK2	0.3	5.94	0.31	7.3e-9	Mean corpuscular volume;
CRC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.38	6.74	0.35	7.26e-11	Skin aging (microtopography measurement);
CRC	cis	rs2898681	0.581	rs28618986	chr4:53677902	G/C	cg00338735	chr4:53728038	RASL11B	0.38	5.71	0.3	2.46e-8	Optic nerve measurement (cup area);
CRC	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	11.02	0.52	3.08e-24	Neutrophil percentage of white cells;
CRC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.47	-6.05	-0.32	3.94e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.03	0.32	4.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg10298567	chr3:47292165	KIF9	-0.38	-6.13	-0.32	2.46e-9	Colorectal cancer;
CRC	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-6.84	-0.35	3.77e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-8.02	-0.4	1.82e-14	Bipolar disorder;
CRC	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.72	-7.95	-0.4	3e-14	Colonoscopy-negative controls vs population controls;
CRC	trans	rs12438356	0.686	rs16952914	chr15:69477442	T/A	cg26416341	chr12:54718712	COPZ1	0.64	5.96	0.31	6.33e-9	CTACK levels;
CRC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.52	-7.61	-0.39	2.89e-13	DNA methylation (variation);
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs4074493	0.963	rs6541251	chr1:231173596	T/C	cg22172038	chr1:231176991	FAM89A	0.34	5.9	0.31	8.81e-9	Carotid plaque burden (smoking interaction);
CRC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	7.05	0.36	1.09e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.59	-9.39	-0.46	9.99e-19	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg01601518	chr4:2404284	ZFYVE28	-0.37	-6.01	-0.31	5.05e-9	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05140079	chr16:57496545	POLR2C	0.48	6.74	0.35	7.05e-11	Anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09225691	chr3:98312547	CPOX	0.4	6.09	0.32	3.12e-9	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.97	12.55	0.57	8.98e-30	IgG glycosylation;
CRC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.73e-9	Life satisfaction;
CRC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg24910161	chr17:38119198	GSDMA	-0.36	-5.94	-0.31	7.28e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg00999904	chr2:3704751	ALLC	-0.52	-6.59	-0.34	1.79e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.11	-0.32	2.74e-9	Aortic root size;
CRC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.79	-11.81	-0.55	4.41e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.61	7.35	0.38	1.56e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.8	-0.35	4.85e-11	Height;
CRC	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg04132472	chr17:19861366	AKAP10	0.42	6.44	0.33	4.12e-10	Schizophrenia;
CRC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg02527881	chr3:46936655	PTH1R	0.35	6.11	0.32	2.83e-9	Colorectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12889510	chr2:204399188	RAPH1	0.49	6.93	0.36	2.29e-11	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg09264619	chr17:80180166	NA	0.36	6.02	0.32	4.65e-9	Life satisfaction;
CRC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.79	15.0	0.64	4.13e-39	Prudent dietary pattern;
CRC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	2.9e-9	Prudent dietary pattern;
CRC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg03037974	chr15:76606532	NA	0.72	13.12	0.59	6.35e-32	Blood metabolite levels;
CRC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg03233332	chr7:66118400	NA	0.41	6.02	0.32	4.55e-9	Aortic root size;
CRC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-6.31	-0.33	9.16e-10	Aortic root size;
CRC	cis	rs7849270	1.000	rs932835	chr9:131887071	A/G	cg13538475	chr9:131942899	NA	-0.31	-6.03	-0.32	4.49e-9	Blood metabolite ratios;
CRC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.53	7.05	0.36	1.06e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.5	6.39	0.33	5.67e-10	Blood metabolite levels;
CRC	trans	rs7027930	0.524	rs10758738	chr9:611017	C/T	cg27061366	chr19:13044373	FARSA	0.53	6.44	0.33	4.28e-10	Pulmonary function decline;
CRC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.4	7.64	0.39	2.42e-13	Ulcerative colitis;
CRC	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.55	8.71	0.43	1.54e-16	Mean corpuscular volume;
CRC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg02951883	chr7:2050386	MAD1L1	0.51	7.03	0.36	1.19e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.05	-0.41	1.5e-14	Height;
CRC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.36	-5.68	-0.3	2.99e-8	Ulcerative colitis;
CRC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg13777783	chr17:79615861	NA	-0.31	-6.05	-0.32	3.89e-9	Eye color traits;
CRC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.61	0.34	1.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1519814	0.956	rs6995843	chr8:121159867	C/T	cg22335954	chr8:121166405	COL14A1	-0.59	-6.83	-0.35	4.11e-11	Breast cancer;
CRC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg08999081	chr20:33150536	PIGU	0.45	5.87	0.31	1.05e-8	Protein C levels;
CRC	trans	rs2665103	0.610	rs1972460	chr15:82530630	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.11	-0.32	2.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg18612461	chr15:75251733	NA	0.48	7.26	0.37	2.88e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg09597638	chr17:3907349	NA	0.63	11.41	0.53	1.28e-25	Type 2 diabetes;
CRC	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.61	8.45	0.42	9.5e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.71	-0.3	2.56e-8	Life satisfaction;
CRC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.46	6.27	0.33	1.16e-9	Morning vs. evening chronotype;
CRC	trans	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg18187862	chr3:45730750	SACM1L	0.44	6.32	0.33	8.48e-10	Primary sclerosing cholangitis;
CRC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.59	8.45	0.42	9.26e-16	Arsenic metabolism;
CRC	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg17788362	chr6:86352627	SYNCRIP	0.55	7.87	0.4	5.26e-14	Smooth-surface caries;
CRC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.58	-10.64	-0.51	6.59e-23	Tonsillectomy;
CRC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-7.52	-0.38	5.13e-13	Headache;
CRC	cis	rs17767392	0.834	rs55863348	chr14:71724293	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.18	-0.32	1.94e-9	Mitral valve prolapse;
CRC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg00343986	chr7:65444356	GUSB	-0.46	-6.75	-0.35	6.85e-11	Aortic root size;
CRC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.67	9.99	0.48	1.1e-20	Corneal astigmatism;
CRC	cis	rs868943	0.511	rs12204724	chr6:116532430	C/T	cg15226275	chr6:116381976	FRK	0.26	6.12	0.32	2.7e-9	Total cholesterol levels;
CRC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.38	6.59	0.34	1.79e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg12273811	chr6:28175739	NA	0.54	6.01	0.31	4.89e-9	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00167275	chr10:88854588	FAM35A;GLUD1	0.42	6.86	0.35	3.45e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.44	5.64	0.3	3.6e-8	Vitiligo;
CRC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg21620606	chr4:1342894	KIAA1530	0.38	6.45	0.33	4.07e-10	Obesity-related traits;
CRC	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg07423050	chr13:99094983	FARP1	0.4	6.39	0.33	5.6e-10	Longevity;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16211055	chr1:228594250	TRIM11	-0.51	-6.15	-0.32	2.3e-9	Diisocyanate-induced asthma;
CRC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.48	-9.5	-0.46	4.65e-19	Renal cell carcinoma;
CRC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.55	7.23	0.37	3.51e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg23205692	chr1:25664452	TMEM50A	0.4	5.68	0.3	2.93e-8	Erythrocyte sedimentation rate;
CRC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg05207973	chr5:176823642	SLC34A1	0.4	5.76	0.3	1.91e-8	Urate levels in lean individuals;
CRC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-10.94	-0.52	5.79e-24	Monocyte percentage of white cells;
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg19223190	chr17:80058835	NA	0.38	6.14	0.32	2.39e-9	Life satisfaction;
CRC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs860295	0.541	rs11264359	chr1:155282829	A/G	cg02153340	chr1:155202674	NA	-0.47	-6.27	-0.33	1.11e-9	Body mass index;
CRC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.63	0.3	3.87e-8	Major depressive disorder;
CRC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.66	0.54	1.58e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.55	5.84	0.31	1.22e-8	Bipolar disorder;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25880573	chr1:24073129	TCEB3	0.46	7.28	0.37	2.51e-12	Interleukin-6 levels;
CRC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.38	-5.87	-0.31	1.05e-8	Breast cancer;
CRC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.95	18.15	0.71	1.66e-51	Height;
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.08	-0.32	3.41e-9	Menopause (age at onset);
CRC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.64e-9	Bipolar disorder;
CRC	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.47	-0.46	5.55e-19	Migraine;Coronary artery disease;
CRC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15164871	chr12:123380523	VPS37B	0.4	6.4	0.33	5.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.85	11.43	0.53	1.02e-25	Menarche (age at onset);
CRC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg05192639	chr6:26864778	GUSBL1	0.34	6.2	0.32	1.73e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg02683197	chr6:28174875	NA	0.88	10.83	0.51	1.42e-23	Depression;
CRC	cis	rs11622475	0.953	rs6576012	chr14:104400159	T/C	cg20488157	chr14:104394430	TDRD9	-0.67	-9.55	-0.47	2.98e-19	Bipolar disorder;
CRC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.55	8.85	0.44	5.3e-17	Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19729279	chr5:133861951	PHF15	0.5	6.71	0.35	8.37e-11	Thyroid stimulating hormone;
CRC	cis	rs2013441	0.931	rs12937827	chr17:20033202	G/C	cg13482628	chr17:19912719	NA	0.41	6.36	0.33	6.66e-10	Obesity-related traits;
CRC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	8.36	0.42	1.85e-15	Schizophrenia;
CRC	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.66	10.54	0.5	1.46e-22	Corneal astigmatism;
CRC	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-12.8	-0.58	1.04e-30	Blood metabolite levels;
CRC	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg04672837	chr16:48644449	N4BP1	0.42	6.01	0.31	4.84e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs9925964	0.935	rs4527034	chr16:31131614	A/G	cg03418659	chr16:31128414	MYST1	-0.48	-7.15	-0.37	5.49e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.72	11.85	0.55	3.3e-27	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.76	-9.44	-0.46	7.15e-19	Bronchopulmonary dysplasia;
CRC	cis	rs7781557	0.638	rs55781834	chr7:102572433	A/C	cg18108683	chr7:102477205	FBXL13	-0.48	-5.66	-0.3	3.3e-8	Colorectal adenoma (advanced);
CRC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-8.76	-0.43	1.03e-16	Blood pressure (smoking interaction);
CRC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.7	9.51	0.46	4.15e-19	Multiple sclerosis;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg15786705	chr6:28176104	NA	0.61	6.75	0.35	6.5e-11	Parkinson's disease;
CRC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.93	-0.36	2.18e-11	Mean corpuscular volume;
CRC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg00343986	chr7:65444356	GUSB	-0.5	-7.43	-0.38	9.64e-13	Aortic root size;
CRC	cis	rs17065868	0.764	rs55670821	chr13:45028851	A/C	cg10246903	chr13:45222710	NA	0.54	5.66	0.3	3.29e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs6735179	0.529	rs1364648	chr2:1754932	A/G	cg19300414	chr2:1746591	PXDN	-0.39	-6.4	-0.33	5.35e-10	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-6.96	-0.36	1.8e-11	Vitiligo;
CRC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg04117972	chr1:227635322	NA	0.77	8.03	0.4	1.73e-14	Major depressive disorder;
CRC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg20503657	chr10:835505	NA	-0.58	-8.51	-0.42	6.14e-16	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs995000	0.868	rs1168002	chr1:62934308	A/G	cg19896129	chr1:63156450	NA	-0.39	-5.98	-0.31	5.97e-9	Triglyceride levels;
CRC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.63	8.06	0.41	1.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.61	8.14	0.41	7.99e-15	Mean platelet volume;
CRC	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg12458913	chr13:53173898	NA	0.56	8.7	0.43	1.66e-16	Lewy body disease;
CRC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg26248373	chr2:1572462	NA	-0.66	-7.2	-0.37	4.09e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	0.63	6.15	0.32	2.26e-9	Fat distribution (HIV);
CRC	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.58	-7.08	-0.36	9.03e-12	Ulcerative colitis;
CRC	cis	rs4654899	0.931	rs2275468	chr1:21220375	T/G	cg02927042	chr1:21476669	EIF4G3	0.42	6.75	0.35	6.54e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.54	-8.91	-0.44	3.57e-17	Metabolite levels;
CRC	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg03929089	chr4:120376271	NA	0.53	6.93	0.36	2.28e-11	Intraocular pressure;
CRC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg00246817	chr9:123691163	NA	-0.47	-5.97	-0.31	6.26e-9	Rheumatoid arthritis;
CRC	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.55	-6.45	-0.34	4.03e-10	Obesity-related traits;
CRC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.48	-7.92	-0.4	3.61e-14	Major depressive disorder;
CRC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.45	7.87	0.4	5.32e-14	Eye color traits;
CRC	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.34e-11	Prostate cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09658987	chr6:83903672	PGM3;RWDD2A	-0.5	-6.23	-0.32	1.39e-9	Diisocyanate-induced asthma;
CRC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.74	-10.05	-0.48	6.86e-21	Initial pursuit acceleration;
CRC	trans	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg18288967	chr1:45987694	PRDX1	0.63	6.81	0.35	4.6e-11	Obesity-related traits;
CRC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	16.82	0.68	3e-46	Smoking behavior;
CRC	cis	rs7259376	0.936	rs7247220	chr19:22589489	C/G	cg02657401	chr19:22469223	NA	0.31	6.72	0.35	8.02e-11	Menopause (age at onset);
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.44	-6.48	-0.34	3.28e-10	Height;
CRC	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg12218747	chr21:37451666	NA	-0.43	-7.41	-0.38	1.09e-12	Mitral valve prolapse;
CRC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg20512303	chr5:131592959	PDLIM4	0.4	6.65	0.34	1.22e-10	Blood metabolite levels;
CRC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.7	10.87	0.51	1.05e-23	Corneal astigmatism;
CRC	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg10729496	chr3:10149963	C3orf24	0.59	6.86	0.35	3.42e-11	Alzheimer's disease;
CRC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.65	9.58	0.47	2.46e-19	Pancreatic cancer;
CRC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg21153622	chr11:89784906	NA	-0.37	-5.98	-0.31	5.7e-9	Height;
CRC	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg19875578	chr6:126661172	C6orf173	0.41	5.64	0.3	3.62e-8	Male-pattern baldness;
CRC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.25	-0.37	3.06e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs282587	0.569	rs385656	chr13:113413234	C/T	cg04656015	chr13:113407548	ATP11A	0.51	6.45	0.34	3.94e-10	Glycated hemoglobin levels;
CRC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-5.69	-0.3	2.84e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.28	0.53	3.65e-25	Prudent dietary pattern;
CRC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.7	0.35	9.25e-11	Lung cancer;
CRC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.57	0.47	2.63e-19	Colorectal cancer;
CRC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.33	-6.52	-0.34	2.65e-10	Abdominal aortic aneurysm;
CRC	cis	rs12900463	0.813	rs306198	chr15:85405369	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.45	-6.13	-0.32	2.57e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs7105860	1	rs7105860	chr11:27306364	G/C	cg10370305	chr11:27303972	NA	0.37	6.02	0.31	4.69e-9	Total body bone mineral density;
CRC	cis	rs1572438	0.839	rs6597297	chr6:864484	C/T	cg21062780	chr6:887772	NA	0.34	5.67	0.3	3.16e-8	Aging;
CRC	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	9.07e-12	Putamen volume;
CRC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg14541582	chr5:601475	NA	-0.37	-7.17	-0.37	5.13e-12	Lung disease severity in cystic fibrosis;
CRC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg00343986	chr7:65444356	GUSB	-0.46	-6.75	-0.35	6.76e-11	Aortic root size;
CRC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg15848620	chr12:58087721	OS9	0.54	6.25	0.33	1.3e-9	Multiple sclerosis;
CRC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.93	17.79	0.7	4.26e-50	Height;
CRC	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg06581033	chr10:766294	NA	-0.52	-5.77	-0.3	1.84e-8	Uric acid levels;
CRC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.51	7.15	0.37	5.51e-12	Melanoma;
CRC	cis	rs4731207	0.698	rs10243736	chr7:124458966	A/G	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg05585544	chr11:47624801	NA	-0.61	-10.84	-0.51	1.25e-23	Subjective well-being;
CRC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.05	0.32	4.02e-9	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10967178	chr1:6454278	ACOT7	0.48	7.42	0.38	1.02e-12	Response to antipsychotic treatment;
CRC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg18512352	chr11:47633146	NA	-0.37	-7.34	-0.38	1.7e-12	Subjective well-being;
CRC	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg19508488	chr2:152266495	RIF1	0.49	6.95	0.36	1.91e-11	Squamous cell lung carcinoma;
CRC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.65	11.71	0.54	1.06e-26	Aortic root size;
CRC	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.53	6.38	0.33	6e-10	Cognitive test performance;
CRC	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.56	6.27	0.33	1.11e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.91	-13.25	-0.59	2.05e-32	Blood pressure (smoking interaction);
CRC	cis	rs6961069	0.777	rs1761667	chr7:80244939	G/A	cg04458919	chr7:80252533	CD36	0.36	6.42	0.33	4.86e-10	Platelet count;
CRC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.17	-0.32	1.97e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-6.45	-0.33	4.07e-10	Blood metabolite levels;
CRC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.28	-0.53	3.57e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs812925	0.855	rs777592	chr2:61418343	G/C	cg10580144	chr2:61372316	C2orf74	0.33	6.63	0.34	1.38e-10	Immature fraction of reticulocytes;
CRC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg07936489	chr17:37558343	FBXL20	-0.42	-5.75	-0.3	2.03e-8	Asthma;
CRC	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-16.91	-0.68	1.33e-46	Schizophrenia;
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg01542423	chr8:126668119	NA	0.38	6.09	0.32	3.2e-9	Temperament (bipolar disorder);
CRC	cis	rs7487075	0.820	rs4586238	chr12:46719827	T/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.16	0.32	2.11e-9	Itch intensity from mosquito bite;
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.56	-8.37	-0.42	1.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.45	6.83	0.35	4.17e-11	Menopause (age at onset);
CRC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10819733	chr22:24237672	NA	-0.37	-6.35	-0.33	6.96e-10	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.7	9.21	0.45	3.89e-18	Alzheimer's disease;
CRC	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg09659197	chr4:152720779	NA	-0.5	-10.46	-0.5	2.74e-22	Intelligence (multi-trait analysis);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg23355997	chr17:7154831	DULLARD;C17orf81	0.4	6.06	0.32	3.8e-9	Interleukin-6 levels;
CRC	cis	rs10991814	0.920	rs79799877	chr9:94036245	G/A	cg14446406	chr9:93919335	NA	0.58	6.46	0.34	3.77e-10	Neutrophil percentage of granulocytes;
CRC	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.02	0.31	4.67e-9	Monocyte count;
CRC	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg10517650	chr3:113235015	CCDC52	-0.37	-5.73	-0.3	2.24e-8	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	8.37	0.42	1.73e-15	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg23136738	chr11:925521	AP2A2	-0.39	-6.03	-0.32	4.37e-9	Alzheimer's disease (late onset);
CRC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.84	15.44	0.65	7.85e-41	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg08200770	chr17:80723486	TBCD	-0.43	-6.59	-0.34	1.79e-10	Glycated hemoglobin levels;
CRC	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.5	6.2	0.32	1.66e-9	Recombination rate (females);
CRC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.86	0.4	5.41e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11229555	0.645	rs12805062	chr11:58214584	A/G	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.55	7.05	0.36	1.03e-11	Morning vs. evening chronotype;
CRC	cis	rs11650494	0.710	rs73987293	chr17:47474728	A/G	cg08112188	chr17:47440006	ZNF652	0.69	6.28	0.33	1.05e-9	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00648153	chr6:74364149	SLC17A5	0.5	6.44	0.33	4.25e-10	Thyroid stimulating hormone;
CRC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.38	6.15	0.32	2.24e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.37	0.33	6.37e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg00086871	chr4:6988644	TBC1D14	0.95	7.07	0.36	9.4e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7904985	1.000	rs10887586	chr10:88113521	G/A	cg07322936	chr10:88137208	NA	-0.49	-6.55	-0.34	2.22e-10	Barrett's esophagus;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21587861	chr12:32260103	BICD1	0.39	5.96	0.31	6.33e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7937840	0.581	rs4963462	chr11:61886672	A/T	cg01969543	chr11:61895209	INCENP	0.47	6.47	0.34	3.52e-10	Breast cancer;
CRC	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.66	-0.39	2.05e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.87	0.44	4.73e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg08923669	chr16:420230	MRPL28	-0.58	-7.37	-0.38	1.43e-12	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-7.59	-0.39	3.24e-13	Monocyte count;
CRC	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.46	0.5	2.74e-22	Corneal astigmatism;
CRC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.65	-8.08	-0.41	1.29e-14	Neuroticism;
CRC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.53	9.33	0.46	1.58e-18	Huntington's disease progression;
CRC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.94	-16.1	-0.66	2.13e-43	Parkinson's disease;
CRC	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.79	13.44	0.6	4.04e-33	Height;
CRC	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.64	8.14	0.41	8.02e-15	Iron status biomarkers;
CRC	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.53	12.05	0.55	6.18e-28	Prostate cancer;
CRC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs17067123	0.614	rs2383271	chr4:180071469	G/A	cg26610307	chr4:180072759	NA	-0.57	-6.87	-0.35	3.16e-11	Response to hepatitis C treatment;
CRC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg04586622	chr2:25135609	ADCY3	-0.54	-10.22	-0.49	1.75e-21	Body mass index;
CRC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg19046167	chr17:80928561	B3GNTL1	0.47	8.04	0.41	1.66e-14	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02472543	chr2:217277071	SMARCAL1	0.47	6.51	0.34	2.81e-10	Response to antipsychotic treatment;
CRC	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.48	6.0	0.31	5.07e-9	Metabolite levels;
CRC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.57	8.56	0.43	4.54e-16	Blood protein levels;
CRC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg21153622	chr11:89784906	NA	-0.45	-7.27	-0.37	2.58e-12	HDL cholesterol;
CRC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.61	9.63	0.47	1.64e-19	Height;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg02683197	chr6:28174875	NA	0.66	9.16	0.45	5.53e-18	Cardiac Troponin-T levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15358743	chr18:56807035	SEC11C	0.49	7.32	0.37	1.9e-12	Response to antipsychotic treatment;
CRC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.47	-6.6	-0.34	1.64e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7487075	0.820	rs7488482	chr12:46725487	C/T	cg22049899	chr12:47219821	SLC38A4	0.33	6.14	0.32	2.33e-9	Itch intensity from mosquito bite;
CRC	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.65	-9.51	-0.46	4.2e-19	Waist circumference;Body mass index;
CRC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.07	0.36	9.31e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Parkinson's disease;
CRC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.83	11.94	0.55	1.5e-27	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03543731	chr15:50474621	SLC27A2	0.45	6.46	0.34	3.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.44	5.92	0.31	8.12e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	6.29	0.33	9.84e-10	Schizophrenia;
CRC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-11.99	-0.55	9.71e-28	Height;
CRC	cis	rs6076065	1.000	rs6076065	chr20:23368411	C/A	cg11657817	chr20:23433608	CST11	0.36	5.63	0.3	3.78e-8	Facial morphology (factor 15, philtrum width);
CRC	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.17	0.64	8.74e-40	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26768918	chr15:89010461	MRPS11;MRPL46	0.46	6.36	0.33	6.63e-10	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10932289	chr17:55038442	COIL	0.37	6.04	0.32	4.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02450064	chr17:40260053	DHX58	-0.43	-6.24	-0.33	1.38e-9	Fibrinogen levels;
CRC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.28	-6.78	-0.35	5.7e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg19773385	chr1:10388646	KIF1B	-0.56	-7.86	-0.4	5.59e-14	Hepatocellular carcinoma;
CRC	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.64	8.5	0.42	6.67e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.55	-8.06	-0.41	1.42e-14	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs10924970	0.967	rs6677573	chr1:235377979	T/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.67	6.64	0.34	1.27e-10	Multiple sclerosis;
CRC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg12590608	chr7:158785262	NA	0.45	8.1	0.41	1.08e-14	Facial morphology (factor 20);
CRC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.52	5.82	0.31	1.4e-8	Vitiligo;
CRC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.46	0.42	8.99e-16	Menopause (age at onset);
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-8.95	-0.44	2.69e-17	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg07617317	chr6:118971624	C6orf204	0.47	5.69	0.3	2.79e-8	Diastolic blood pressure;
CRC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.51	7.89	0.4	4.55e-14	Corneal astigmatism;
CRC	cis	rs7605827	0.930	rs6748451	chr2:15521088	A/G	cg19274914	chr2:15703543	NA	0.38	5.72	0.3	2.41e-8	Educational attainment (years of education);
CRC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg24879335	chr3:133465180	TF	0.41	8.0	0.4	2.11e-14	Iron status biomarkers;
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg18972013	chr17:78078605	GAA	-0.39	-5.78	-0.3	1.77e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.15	-0.32	2.23e-9	Height;
CRC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02450064	chr17:40260053	DHX58	-0.43	-6.24	-0.33	1.38e-9	Fibrinogen levels;
CRC	cis	rs2072510	1.000	rs2072512	chr12:96408976	T/A	cg22491680	chr12:96389547	HAL	-0.38	-5.94	-0.31	7.3e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.57	0.34	1.99e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg27205649	chr11:78285834	NARS2	-0.45	-5.76	-0.3	1.94e-8	Alzheimer's disease (survival time);
CRC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-11.2	-0.53	7.09e-25	Menarche (age at onset);
CRC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.8	0.55	5.02e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	1.04	20.0	0.74	8.28e-59	Menarche (age at onset);
CRC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	trans	rs11581859	0.950	rs7533945	chr1:99392575	A/G	cg12183875	chr3:169587454	LRRC31	0.28	6.35	0.33	7.33e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09822051	chr1:150039084	VPS45	0.39	6.16	0.32	2.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.82	-0.31	1.43e-8	Obesity-related traits;
CRC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.47	8.45	0.42	9.37e-16	Height;
CRC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.66	10.86	0.51	1.07e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg10272801	chr16:14013773	ERCC4	-0.68	-6.07	-0.32	3.49e-9	Cognitive function;
CRC	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.78	-0.3	1.77e-8	Type 2 diabetes;
CRC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.61	-0.39	3e-13	Gut microbiome composition (summer);
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.66	-0.39	2.03e-13	Total body bone mineral density;
CRC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.67	-0.3	3.2e-8	Reticulocyte count;
CRC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg00246817	chr9:123691163	NA	-0.47	-5.97	-0.31	6.22e-9	Rheumatoid arthritis;
CRC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	9.16	0.45	5.73e-18	Multiple sclerosis;
CRC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.59	-8.59	-0.43	3.64e-16	Menarche (age at onset);
CRC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.77	0.35	5.81e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg16898833	chr6:26189333	HIST1H4D	0.94	7.7	0.39	1.64e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg10724054	chr17:3904396	NA	-0.41	-6.16	-0.32	2.11e-9	Type 2 diabetes;
CRC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	1.01	9.97	0.48	1.29e-20	Lymphocyte counts;
CRC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-7.58	-0.39	3.61e-13	Mean corpuscular hemoglobin concentration;
CRC	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg16950941	chr11:66035639	RAB1B	-0.6	-7.45	-0.38	8.56e-13	Electroencephalogram traits;
CRC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.59	6.6	0.34	1.64e-10	Lung function (FEV1/FVC);
CRC	cis	rs2252790	0.930	rs1204860	chr6:116588606	G/A	cg18764771	chr6:116381957	FRK	-0.21	-5.8	-0.3	1.53e-8	Fast beta electroencephalogram;
CRC	cis	rs2811415	0.597	rs9839092	chr3:127742108	C/T	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15138986	chr10:131935156	GLRX3	0.39	6.31	0.33	9.07e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	9.1	0.45	9.07e-18	Lymphocyte counts;
CRC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg09264619	chr17:80180166	NA	0.39	6.5	0.34	3.04e-10	Life satisfaction;
CRC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.74	-0.3	2.11e-8	High light scatter reticulocyte count;
CRC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs6496667	0.779	rs10220750	chr15:90939294	G/C	cg04176472	chr15:90893244	GABARAPL3	0.56	7.35	0.38	1.62e-12	Rheumatoid arthritis;
CRC	cis	rs7680126	0.596	rs10805364	chr4:10275518	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.21	-0.32	1.6e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg10820045	chr2:198174542	NA	0.41	7.01	0.36	1.33e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.69	-9.95	-0.48	1.49e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-12.55	-0.57	8.72e-30	Height;
CRC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.58	-8.05	-0.41	1.55e-14	Pancreatic cancer;
CRC	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.62	-8.78	-0.44	9e-17	Coronary artery disease;
CRC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.53	8.14	0.41	8.28e-15	Axial length;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg19500275	chr17:80737654	TBCD	-0.39	-5.94	-0.31	7.44e-9	Glycated hemoglobin levels;
CRC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg19980929	chr12:42632907	YAF2	-0.39	-5.9	-0.31	9.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.1e-9	Red blood cell count;
CRC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.38	-5.74	-0.3	2.15e-8	Height;
CRC	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg15234197	chr11:68924956	NA	0.44	6.08	0.32	3.25e-9	Blond vs. brown hair color;
CRC	cis	rs6662572	1.000	rs55951835	chr1:46132442	T/C	cg08644498	chr1:46502608	NA	0.48	7.04	0.36	1.13e-11	Blood protein levels;
CRC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg14711859	chr11:8959438	ASCL3	-0.48	-7.63	-0.39	2.6e-13	Hemoglobin concentration;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	ch.8.34907260F	chr8:34787718	NA	0.45	6.82	0.35	4.31e-11	Interleukin-6 levels;
CRC	cis	rs67981189	0.529	rs8010063	chr14:71510125	T/A	cg15910301	chr14:71632612	NA	0.31	6.12	0.32	2.69e-9	Schizophrenia;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg15845792	chr6:28175446	NA	0.6	7.79	0.39	8.56e-14	Parkinson's disease;
CRC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg08034379	chr2:228736324	WDR69	-0.54	-7.27	-0.37	2.62e-12	Blood pressure;
CRC	cis	rs8105895	0.935	rs28635943	chr19:22268712	G/T	cg02912127	chr19:22235281	ZNF257	-0.37	-5.65	-0.3	3.53e-8	Body mass index (change over time);
CRC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.57	0.57	7.46e-30	Body mass index;
CRC	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.44	6.04	0.32	4.12e-9	Eye color traits;
CRC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg04545296	chr12:48745243	ZNF641	0.33	5.89	0.31	9.3e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2252790	0.895	rs1204833	chr6:116572828	A/G	cg18764771	chr6:116381957	FRK	-0.22	-5.79	-0.3	1.62e-8	Fast beta electroencephalogram;
CRC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg19582491	chr16:67682965	RLTPR	-0.39	-5.62	-0.3	4.11e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00166722	chr3:10149974	C3orf24	0.68	7.96	0.4	2.81e-14	Alzheimer's disease;
CRC	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-6.83	-0.35	4.1e-11	Coronary artery disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04100724	chr12:92539208	BTG1	-0.51	-6.02	-0.31	4.54e-9	Diisocyanate-induced asthma;
CRC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.53	8.26	0.41	3.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.26	14.65	0.63	9.07e-38	Diabetic kidney disease;
CRC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.4	-6.27	-0.33	1.16e-9	Menopause (age at onset);
CRC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.79	0.35	5.4e-11	Alzheimer's disease;
CRC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg13844804	chr7:814759	HEATR2	0.6	7.68	0.39	1.9e-13	Cerebrospinal P-tau181p levels;
CRC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.85	13.52	0.6	2.01e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	8.04	0.41	1.64e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.79	-0.44	8.53e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.07	-0.55	5.16e-28	Primary sclerosing cholangitis;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg06470822	chr6:28175283	NA	0.76	8.05	0.41	1.49e-14	Depression;
CRC	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg23071808	chr14:103021642	NA	-0.64	-7.15	-0.37	5.49e-12	Platelet count;
CRC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17507749	chr15:85114479	UBE2QP1	0.63	9.03	0.45	1.51e-17	Schizophrenia;
CRC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-8.15	-0.41	7.88e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg17948913	chr5:572064	NA	0.56	6.29	0.33	1e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg17710535	chr19:10819994	QTRT1	0.46	6.63	0.34	1.41e-10	Inflammatory skin disease;
CRC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.31	12.49	0.57	1.46e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.7	7.96	0.4	2.83e-14	Major depressive disorder;
CRC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.49	-6.81	-0.35	4.62e-11	Type 1 diabetes nephropathy;
CRC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.25	-16.78	-0.68	4.42e-46	Breast cancer;
CRC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.47	5.01e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg23758597	chr6:163146217	PARK2	-0.66	-6.64	-0.34	1.29e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg20935933	chr6:143382018	AIG1	-0.44	-6.38	-0.33	5.87e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.0	-10.33	-0.5	7.29e-22	Diabetic retinopathy;
CRC	cis	rs12936587	0.692	rs12943416	chr17:17535535	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.44	-5.83	-0.31	1.29e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.73	-9.42	-0.46	8.26e-19	Initial pursuit acceleration;
CRC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs10924970	0.687	rs3765792	chr1:235355932	A/G	cg09010748	chr1:235293032	TOMM20	-0.42	-5.8	-0.3	1.53e-8	Asthma;
CRC	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.93	-14.84	-0.63	1.66e-38	Gut microbiota (bacterial taxa);
CRC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.48	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1;
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.59	11.12	0.52	1.32e-24	Tonsillectomy;
CRC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg17321639	chr7:2759063	NA	-0.47	-6.03	-0.32	4.33e-9	Height;
CRC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.13	-0.32	2.48e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs17065868	0.764	rs6561177	chr13:45015539	C/T	cg10246903	chr13:45222710	NA	0.57	6.3	0.33	9.58e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg12927641	chr6:109611667	NA	-0.33	-5.67	-0.3	3.1e-8	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
CRC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.17e-13	Colorectal cancer;
CRC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.92	0.58	3.51e-31	Alzheimer's disease;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20092199	chr4:1342459	KIAA1530	-0.38	-5.96	-0.31	6.37e-9	Obesity-related traits;
CRC	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg26182253	chr13:112236782	NA	0.31	6.29	0.33	9.96e-10	Hepatitis;
CRC	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.83e-10	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-11.54	-0.54	4.33e-26	Colorectal cancer;
CRC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-11.47	-0.53	7.71e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.57	-8.14	-0.41	8.31e-15	Longevity;
CRC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.31	-0.33	9.02e-10	Schizophrenia;
CRC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20092199	chr4:1342459	KIAA1530	0.33	5.81	0.3	1.5e-8	Longevity;
CRC	trans	rs11231420	1	rs11231420	chr11:55644734	T/C	cg27395922	chr11:50257633	LOC441601	0.41	6.68	0.35	1.04e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.1	-0.32	3.01e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.91	-0.31	8.43e-9	Colorectal cancer;
CRC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.65	9.63	0.47	1.73e-19	Vitamin D levels;
CRC	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.61	9.32	0.46	1.68e-18	Crohn's disease;
CRC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.55e-24	Motion sickness;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg18854735	chr1:1822972	GNB1	0.5	6.64	0.34	1.34e-10	Thyroid stimulating hormone;
CRC	cis	rs185694	1.000	rs185694	chr13:30885223	C/T	cg04551440	chr13:30881194	KATNAL1	0.57	6.21	0.32	1.61e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08617916	chr1:206730453	RASSF5	-0.4	-5.98	-0.31	5.85e-9	Daytime sleep phenotypes;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg19041857	chr6:27730383	NA	-0.44	-5.94	-0.31	7.12e-9	Parkinson's disease;
CRC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.28	-0.33	1.1e-9	Aortic root size;
CRC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.59	9.95	0.48	1.45e-20	Prudent dietary pattern;
CRC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg09165964	chr15:75287851	SCAMP5	-0.55	-8.64	-0.43	2.4e-16	Breast cancer;
CRC	cis	rs6840360	0.642	rs11932398	chr4:152397554	T/G	cg09659197	chr4:152720779	NA	0.34	6.64	0.34	1.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2041840	0.538	rs10196818	chr2:37576852	A/G	cg25727520	chr2:37576821	QPCT	-0.35	-6.25	-0.33	1.29e-9	Chronic lymphocytic leukemia;
CRC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg20487152	chr13:99095054	FARP1	0.47	7.28	0.37	2.45e-12	Educational attainment (years of education);
CRC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.77	-8.08	-0.41	1.26e-14	Coronary artery disease;
CRC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.55	7.26	0.37	2.85e-12	Mean platelet volume;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12963246	chr6:28129442	ZNF389	0.5	5.75	0.3	2e-8	Depression;
CRC	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.62	-0.39	2.65e-13	Inflammatory bowel disease;
CRC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.89	9.76	0.47	6.25e-20	Skin colour saturation;
CRC	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07165851	chr6:158734300	TULP4	0.61	7.75	0.39	1.18e-13	Height;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.04	0.32	4.22e-9	Parkinson's disease;
CRC	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg12315302	chr6:26189340	HIST1H4D	0.72	6.03	0.32	4.44e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.73	12.47	0.57	1.65e-29	Adiponectin levels;
CRC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.61	-0.57	5.34e-30	Type 2 diabetes;
CRC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.03e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.55	-8.63	-0.43	2.66e-16	Aortic root size;
CRC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.35	-5.66	-0.3	3.38e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.49	9.78	0.47	5.56e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10210959	chr5:112257975	REEP5	0.44	6.06	0.32	3.75e-9	Anxiety disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03771385	chr2:43454876	ZFP36L2;LOC100129726	-0.45	-6.74	-0.35	7.1e-11	Myopia (pathological);
CRC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.55	-7.77	-0.39	1.02e-13	Neuroticism;
CRC	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg08999081	chr20:33150536	PIGU	0.46	5.88	0.31	9.91e-9	Protein C levels;
CRC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.49	-7.77	-0.39	1.02e-13	Red blood cell count;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14229668	chr2:163200576	GCA	0.44	6.1	0.32	3.02e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-9.56	-0.47	2.78e-19	Monocyte percentage of white cells;
CRC	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.7	-0.3	2.62e-8	Breast cancer;
CRC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg17294928	chr15:75287854	SCAMP5	0.51	7.87	0.4	5.18e-14	Breast cancer;
CRC	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.47	0.38	7.46e-13	Iron status biomarkers;
CRC	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg19682024	chr14:74008259	HEATR4;ACOT1	0.57	8.66	0.43	2.13e-16	Blood metabolite ratios;
CRC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.13	0.37	6.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg16989086	chr20:62203971	PRIC285	0.5	6.32	0.33	8.41e-10	Glioblastoma;
CRC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.52	8.1	0.41	1.05e-14	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05397629	chr11:3848986	RHOG	-0.38	-6.08	-0.32	3.32e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.46	6.62	0.34	1.51e-10	Waist circumference;Hip circumference;
CRC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.43	6.09	0.32	3.21e-9	Schizophrenia;
CRC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg12193833	chr17:30244370	NA	-0.75	-8.72	-0.43	1.4e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg17031739	chr1:67600172	NA	0.4	6.32	0.33	8.6e-10	Psoriasis;
CRC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.52	6.59	0.34	1.76e-10	Monocyte percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26276294	chr10:30024803	SVIL	0.44	6.01	0.31	5.04e-9	Anxiety disorder;
CRC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.71	-9.31	-0.46	1.91e-18	Coronary artery disease;
CRC	cis	rs9463078	0.774	rs9381383	chr6:45271893	G/A	cg25276700	chr6:44698697	NA	-0.28	-6.73	-0.35	7.77e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg09127314	chr1:152161683	NA	0.47	6.02	0.31	4.67e-9	Atopic dermatitis;
CRC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	10.89	0.51	8.91e-24	Bone mineral density;
CRC	cis	rs6840360	0.642	rs6843639	chr4:152416015	C/T	cg09659197	chr4:152720779	NA	0.33	6.52	0.34	2.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9903692	0.954	rs2051821	chr17:46143515	T/C	cg21215337	chr17:46176117	CBX1	0.42	7.71	0.39	1.47e-13	Pulse pressure;
CRC	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg03642690	chr20:62727907	OPRL1	0.36	5.8	0.3	1.53e-8	Pulse pressure;Mean corpuscular volume;
CRC	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	6.32	0.33	8.53e-10	Refractive astigmatism;
CRC	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg25344623	chr2:136566232	LCT	0.33	6.03	0.32	4.33e-9	Mosquito bite size;
CRC	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.74	-0.39	1.21e-13	QT interval;
CRC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg18761221	chr20:60518478	NA	0.46	7.32	0.37	1.89e-12	Body mass index;
CRC	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg14458575	chr2:238380390	NA	-0.53	-7.48	-0.38	6.89e-13	Prostate cancer;
CRC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg06363034	chr20:62225388	GMEB2	-0.44	-6.8	-0.35	4.95e-11	Glioblastoma;
CRC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-10.32	-0.49	8.19e-22	Breast cancer;
CRC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg00769240	chr8:12517080	NA	-0.54	-6.7	-0.35	9.27e-11	Blood pressure (smoking interaction);
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg27094323	chr7:1216898	NA	-0.37	-6.01	-0.31	5.01e-9	Longevity;Endometriosis;
CRC	cis	rs4926298	1.000	rs1077151	chr19:13151108	A/G	cg04657146	chr19:12876947	HOOK2	-0.46	-6.17	-0.32	1.96e-9	Bipolar disorder;
CRC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.64	7.36	0.38	1.46e-12	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg25456477	chr12:86230367	RASSF9	0.34	6.08	0.32	3.29e-9	Major depressive disorder;
CRC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.25	-14.8	-0.63	2.45e-38	Diabetic kidney disease;
CRC	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.24	6.71	0.35	8.52e-11	Type 2 diabetes;
CRC	trans	rs11654801	0.812	rs11658742	chr17:20851512	G/C	cg23759823	chr7:139672531	TBXAS1	-0.39	-6.18	-0.32	1.89e-9	Mosquito bite size;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg08187779	chr8:102217898	ZNF706	0.41	6.51	0.34	2.74e-10	Body mass index;
CRC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	10.18	0.49	2.48e-21	Personality dimensions;
CRC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.51	6.0	0.31	5.21e-9	Menarche (age at onset);
CRC	cis	rs12980942	0.630	rs11881940	chr19:41808432	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.52	6.02	0.31	4.73e-9	Coronary artery disease;
CRC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-6.41	-0.33	5.06e-10	Alzheimer's disease (late onset);
CRC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.97	-18.55	-0.72	4.41e-53	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6066835	1.000	rs4431002	chr20:47316585	C/T	cg18078177	chr20:47281410	PREX1	0.66	5.68	0.3	2.92e-8	Multiple myeloma;
CRC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.56	-0.38	4.07e-13	Cystic fibrosis severity;
CRC	cis	rs17152411	0.947	rs17152408	chr10:126649007	C/T	cg07906193	chr10:126599966	NA	0.59	6.68	0.35	1.02e-10	Height;
CRC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg05627522	chr15:75251581	NA	0.5	7.55	0.38	4.22e-13	Breast cancer;
CRC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.54	-8.2	-0.41	5.3e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-21.13	-0.76	3.29e-63	Hemostatic factors and hematological phenotypes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10324419	chr4:175205038	FBXO8;KIAA1712	0.47	6.13	0.32	2.5e-9	Thyroid stimulating hormone;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg09436375	chr6:42928200	GNMT	-0.32	-5.73	-0.3	2.21e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.43	-6.51	-0.34	2.83e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.34	6.26	0.33	1.21e-9	Panic disorder;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg06470822	chr6:28175283	NA	0.79	11.91	0.55	2.02e-27	Cardiac Troponin-T levels;
CRC	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.42	-6.47	-0.34	3.55e-10	Menarche (age at onset);
CRC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg25452165	chr22:42524984	CYP2D6	-0.4	-6.05	-0.32	3.94e-9	Schizophrenia;
CRC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg03037974	chr15:76606532	NA	0.69	12.16	0.56	2.4e-28	Blood metabolite levels;
CRC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg12516270	chr8:143859308	LYNX1	-0.41	-6.38	-0.33	5.92e-10	Urinary tract infection frequency;
CRC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg07701084	chr6:150067640	NUP43	0.58	8.04	0.41	1.61e-14	Lung cancer;
CRC	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg21038819	chr17:73507788	CASKIN2	0.42	5.84	0.31	1.26e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
CRC	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg09873164	chr1:152488093	CRCT1	0.37	6.18	0.32	1.9e-9	Hair morphology;
CRC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.92	13.92	0.61	5.72e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-15.74	-0.66	5.06e-42	Intelligence (multi-trait analysis);
CRC	cis	rs17234274	0.622	rs10833980	chr11:23232587	A/G	cg05245346	chr11:23248277	NA	0.36	5.84	0.31	1.23e-8	Cancer;
CRC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.16	0.41	6.99e-15	Lung cancer;
CRC	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.36	-6.18	-0.32	1.9e-9	Menopause (age at onset);
CRC	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.81	12.57	0.57	7.2e-30	Testicular germ cell tumor;
CRC	trans	rs10858396	0.957	rs7029858	chr9:138273821	C/T	cg07360250	chr5:176830358	F12	0.45	6.0	0.31	5.16e-9	Attention deficit hyperactivity disorder;
CRC	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-14.75	-0.63	3.75e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg11117577	chr8:125551212	TATDN1;NDUFB9	0.5	6.08	0.32	3.37e-9	Intelligence (multi-trait analysis);
CRC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.43e-59	Hip circumference adjusted for BMI;
CRC	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.15	12.62	0.57	4.76e-30	Mitochondrial DNA levels;
CRC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.6	-9.36	-0.46	1.24e-18	Colorectal cancer;
CRC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.51	-5.92	-0.31	8.16e-9	Vitiligo;
CRC	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.8	0.51	1.77e-23	Exhaled nitric oxide output;
CRC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.71	0.39	1.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.75	7.65	0.39	2.18e-13	Diabetic retinopathy;
CRC	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.53	-6.83	-0.35	4.15e-11	Educational attainment;
CRC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.46	6.98	0.36	1.63e-11	Corneal astigmatism;
CRC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.65	-5.89	-0.31	9.42e-9	Diabetic retinopathy;
CRC	cis	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg17459225	chr2:239074497	NA	-0.45	-7.82	-0.4	7.15e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.27	15.87	0.66	1.59e-42	Uric acid levels;
CRC	cis	rs787274	0.850	rs7873289	chr9:115638386	G/A	cg13803584	chr9:115635662	SNX30	-0.65	-5.96	-0.31	6.41e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09455096	chr2:61765470	XPO1	-0.52	-6.27	-0.33	1.15e-9	Diisocyanate-induced asthma;
CRC	cis	rs8005677	0.798	rs61977741	chr14:23400979	G/C	cg25600027	chr14:23388339	RBM23	-0.44	-6.58	-0.34	1.81e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg19193384	chr17:30244184	NA	-0.65	-7.49	-0.38	6.26e-13	Hip circumference adjusted for BMI;
CRC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg23815491	chr16:72088622	HP	0.47	6.84	0.35	3.85e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg20636351	chr8:55087400	NA	-0.33	-5.85	-0.31	1.22e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg23161317	chr6:28129485	ZNF389	0.45	6.32	0.33	8.37e-10	Parkinson's disease;
CRC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.89	-15.24	-0.64	4.88e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.5	-6.96	-0.36	1.88e-11	Lymphocyte counts;
CRC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.74	-0.3	2.13e-8	Major depressive disorder;
CRC	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.43	-5.75	-0.3	2.02e-8	Schizophrenia;
CRC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.3	0.33	9.81e-10	Rheumatoid arthritis;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.5	7.16	0.37	5.27e-12	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg02158880	chr13:53174818	NA	0.46	6.87	0.35	3.31e-11	Lewy body disease;
CRC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.66	-10.52	-0.5	1.71e-22	Motion sickness;
CRC	cis	rs1619661	0.505	rs10793525	chr10:44683833	C/A	cg09554077	chr10:44749378	NA	0.47	7.14	0.37	6.09e-12	QT interval (ambient particulate matter interaction);
CRC	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg03929089	chr4:120376271	NA	-0.54	-6.82	-0.35	4.4e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.64	9.03	0.45	1.44e-17	White matter hyperintensity burden;
CRC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg07274523	chr3:49395745	GPX1	0.48	6.38	0.33	5.98e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.04	-0.61	2.03e-35	Exhaled nitric oxide output;
CRC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg03037974	chr15:76606532	NA	-0.7	-12.13	-0.56	3.07e-28	Blood metabolite levels;
CRC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17401966	0.540	rs58014725	chr1:10474457	T/A	cg19773385	chr1:10388646	KIF1B	-0.48	-7.45	-0.38	8.24e-13	Hepatocellular carcinoma;
CRC	cis	rs2949837	0.581	rs2965072	chr7:45980751	G/T	cg23193639	chr7:45961078	IGFBP3	0.41	6.84	0.35	3.79e-11	Sitting height ratio;
CRC	cis	rs6662572	1.000	rs6662572	chr1:46146812	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.86	0.31	1.12e-8	Blood protein levels;
CRC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.73	-0.3	2.27e-8	Longevity;Endometriosis;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg26872475	chr11:119039430	NLRX1	-0.44	-6.61	-0.34	1.59e-10	Daytime sleep phenotypes;
CRC	trans	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg07393940	chr7:158741817	NA	-0.5	-7.2	-0.37	4.24e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg02725872	chr8:58115012	NA	-0.43	-6.55	-0.34	2.2e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.68	-8.81	-0.44	7.51e-17	Blood protein levels;
CRC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-10.21	-0.49	1.95e-21	Neuroticism;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12273811	chr6:28175739	NA	0.71	9.2	0.45	4.28e-18	Depression;
CRC	cis	rs950880	0.560	rs1558619	chr2:102931550	G/T	cg09003973	chr2:102972529	NA	-0.38	-5.66	-0.3	3.29e-8	Serum protein levels (sST2);
CRC	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg25856811	chr1:152973957	SPRR3	-0.26	-6.96	-0.36	1.88e-11	Inflammatory skin disease;
CRC	trans	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg26043149	chr18:55253948	FECH	-0.49	-7.52	-0.38	5.15e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9462027	0.606	rs412392	chr6:34549699	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.94	-0.31	7.35e-9	Systemic lupus erythematosus;
CRC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.42	6.8	0.35	4.86e-11	High light scatter reticulocyte count;
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	14.58	0.63	1.69e-37	Menarche (age at onset);
CRC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.94	11.83	0.55	3.85e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.28	5.65	0.3	3.45e-8	Personality dimensions;
CRC	cis	rs9287719	0.601	rs62128635	chr2:10725334	G/C	cg00105475	chr2:10696890	NA	0.47	7.05	0.36	1.06e-11	Prostate cancer;
CRC	trans	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.33e-9	Skin colour saturation;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg26483432	chr1:149815043	HIST2H2AA3;HIST2H2AA4	0.44	6.48	0.34	3.42e-10	Interleukin-6 levels;
CRC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.6	5.64	0.3	3.71e-8	Yeast infection;
CRC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.47	0.46	5.5e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25219047	chr19:3500813	DOHH	-0.55	-6.69	-0.35	9.85e-11	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg17145862	chr1:211918768	LPGAT1	0.56	9.56	0.47	2.82e-19	Leprosy;
CRC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.79	9.53	0.46	3.7e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.65	-9.32	-0.46	1.7e-18	Obesity-related traits;
CRC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg19856771	chr13:42780042	DGKH	0.41	6.01	0.31	4.89e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs17095355	1.000	rs72828241	chr10:111744704	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-6.98	-0.36	1.59e-11	Biliary atresia;
CRC	cis	rs7692995	1.000	rs16896271	chr4:18012454	T/C	cg08925142	chr4:18023851	LCORL	-0.53	-5.89	-0.31	9.52e-9	Height;
CRC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg03678062	chr6:149772716	ZC3H12D	0.33	5.91	0.31	8.54e-9	Dupuytren's disease;
CRC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.59	8.44	0.42	1.02e-15	Response to temozolomide;
CRC	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg10437265	chr15:77819839	NA	0.67	12.49	0.57	1.39e-29	Type 2 diabetes;
CRC	cis	rs13315871	0.929	rs1047335	chr3:58280942	A/G	cg20936604	chr3:58311152	NA	-0.63	-6.27	-0.33	1.12e-9	Cholesterol, total;
CRC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg02574844	chr11:5959923	NA	0.47	6.93	0.36	2.29e-11	DNA methylation (variation);
CRC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	7.07	0.36	9.29e-12	Reticulocyte count;
CRC	cis	rs6445525	0.967	rs6792662	chr3:65996707	G/C	cg06109867	chr3:66002991	MAGI1	-0.39	-6.41	-0.33	5.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg06470822	chr6:28175283	NA	0.72	10.35	0.5	6.51e-22	Parkinson's disease;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg12273811	chr6:28175739	NA	0.44	6.34	0.33	7.69e-10	Parkinson's disease;
CRC	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-8.18	-0.41	6.3e-15	Corneal astigmatism;
CRC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg23463467	chr20:60627584	TAF4	0.36	6.38	0.33	6.13e-10	Body mass index;
CRC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.57	-8.27	-0.41	3.4e-15	IgG glycosylation;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.82e-28	Alzheimer's disease;
CRC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.92	14.06	0.61	1.66e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.83	-7.34	-0.38	1.7e-12	Putamen volume;
CRC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg00786952	chr1:21763130	NA	0.45	7.52	0.38	5.22e-13	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs634537	0.559	rs643319	chr9:22017836	A/C	cg18057959	chr10:126694753	CTBP2	-0.36	-6.14	-0.32	2.43e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg16892393	chr17:41919603	NA	0.35	5.67	0.3	3.11e-8	Triglycerides;
CRC	cis	rs4380275	1.000	rs7562792	chr2:774469	T/C	cg27237671	chr2:676223	TMEM18	-0.43	-6.18	-0.32	1.95e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
CRC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.53	8.62	0.43	2.82e-16	Colorectal cancer;
CRC	cis	rs4731207	0.596	rs1471572	chr7:124650942	C/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.27e-9	Cutaneous malignant melanoma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00424800	chr3:169755602	GPR160	-0.49	-6.03	-0.32	4.36e-9	Diisocyanate-induced asthma;
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.52	7.13	0.37	6.58e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.89	-0.44	4.05e-17	Body mass index;
CRC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg25456477	chr12:86230367	RASSF9	0.32	5.65	0.3	3.56e-8	Major depressive disorder;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.12	-0.32	2.7e-9	Cognitive function;
CRC	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg14844989	chr11:31128820	NA	0.33	5.73	0.3	2.31e-8	Red blood cell count;
CRC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg05192639	chr6:26864778	GUSBL1	0.34	6.1	0.32	3e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.7	11.22	0.53	5.89e-25	Mean platelet volume;
CRC	trans	rs10504390	0.656	rs79616747	chr8:66546593	C/A	cg26403416	chr21:43771339	TFF2	0.6	6.14	0.32	2.38e-9	IgG glycosylation;
CRC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.69	8.07	0.41	1.31e-14	Hip circumference adjusted for BMI;
CRC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.83	14.63	0.63	1.08e-37	Breast cancer;
CRC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.91	-17.34	-0.69	2.63e-48	Coronary artery disease;
CRC	cis	rs7973719	1.000	rs1839622	chr12:7334534	G/C	cg07052231	chr12:7363540	PEX5	0.5	8.16	0.41	7.04e-15	IgG glycosylation;
CRC	trans	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg11693508	chr17:37793320	STARD3	0.52	7.01	0.36	1.34e-11	Neuroticism;
CRC	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg19223190	chr17:80058835	NA	0.38	6.02	0.32	4.64e-9	Life satisfaction;
CRC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.4	-7.35	-0.38	1.55e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs17713451	0.593	rs17715460	chr7:151268858	G/A	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg02033258	chr5:131593261	PDLIM4	0.46	8.52	0.43	5.87e-16	Blood metabolite levels;
CRC	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	9.02	0.45	1.62e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.24	-0.33	1.33e-9	Tonsillectomy;
CRC	trans	rs17126268	0.502	rs1934701	chr1:102882942	A/C	cg18468354	chr14:36993517	NA	0.38	6.12	0.32	2.65e-9	Glomerular filtration rate;
CRC	cis	rs35520189	0.591	rs12623837	chr2:113702468	A/G	cg12858261	chr2:113808755	IL1F8	0.47	6.2	0.32	1.67e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.71	12.23	0.56	1.27e-28	Systemic lupus erythematosus;
CRC	cis	rs2882667	0.690	rs160398	chr5:138063439	T/G	cg09476006	chr5:138032270	NA	0.54	9.42	0.46	8.52e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.09	-0.32	3.18e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.4	5.63	0.3	3.85e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	8.45	0.42	9.38e-16	Total body bone mineral density;
CRC	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg18646521	chr2:111875858	NA	0.39	6.07	0.32	3.53e-9	Chronic lymphocytic leukemia;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.46	5.74	0.3	2.13e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg25922239	chr6:33757077	LEMD2	0.47	6.33	0.33	8.13e-10	Crohn's disease;
CRC	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg03929089	chr4:120376271	NA	0.64	6.22	0.32	1.5e-9	Axial length;
CRC	cis	rs4731207	0.698	rs10223980	chr7:124536558	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg23298862	chr7:158159286	PTPRN2	0.39	6.43	0.33	4.44e-10	Calcium levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21126573	chr17:7755257	KDM6B	0.45	6.57	0.34	2.02e-10	Intelligence (multi-trait analysis);
CRC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.57	-7.58	-0.39	3.51e-13	Coronary artery disease;
CRC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.37	-0.38	1.37e-12	Bipolar disorder;
CRC	cis	rs1223397	0.938	rs3734878	chr6:13288850	C/T	cg00460589	chr6:13274354	PHACTR1	0.5	6.01	0.31	4.79e-9	Blood pressure;
CRC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.44	5.79	0.3	1.64e-8	Daytime sleep phenotypes;
CRC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg04121214	chr22:50244548	NA	0.39	5.78	0.3	1.75e-8	Schizophrenia;
CRC	cis	rs2160860	0.773	rs11777082	chr8:39797703	G/A	cg11363097	chr8:39792086	IDO2	-0.42	-7.25	-0.37	2.94e-12	Blood metabolite levels;
CRC	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.51	6.35	0.33	7.31e-10	Recombination rate (females);
CRC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.98	-0.4	2.46e-14	Electroencephalogram traits;
CRC	cis	rs9928842	0.765	rs6564223	chr16:75225899	T/C	cg09066997	chr16:75300724	BCAR1	0.63	5.89	0.31	9.7e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg18099408	chr3:52552593	STAB1	0.33	5.78	0.3	1.76e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg16797656	chr11:68205561	LRP5	0.37	5.89	0.31	9.67e-9	Total body bone mineral density;
CRC	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.66	7.21	0.37	3.81e-12	Childhood ear infection;
CRC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg21155852	chr7:2048760	MAD1L1	0.45	6.32	0.33	8.51e-10	Bipolar disorder;
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg16268157	chr7:99778414	STAG3	-0.43	-5.72	-0.3	2.45e-8	Lung function (FEV1/FVC);
CRC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.38	6.03	0.32	4.4e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-13.04	-0.58	1.29e-31	Alzheimer's disease;
CRC	cis	rs62432291	0.681	rs2501176	chr6:159655383	A/G	cg14500486	chr6:159655392	FNDC1	-0.76	-10.4	-0.5	4.17e-22	Joint mobility (Beighton score);
CRC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.37e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11212617	0.935	rs11212543	chr11:108054922	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.3	0.33	9.61e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.26	0.64	3.8e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-6.26	-0.33	1.19e-9	Daytime sleep phenotypes;
CRC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.58	8.17	0.41	6.67e-15	Lymphocyte counts;
CRC	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg13736514	chr6:26305472	NA	-0.43	-7.19	-0.37	4.35e-12	Educational attainment;
CRC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg03030879	chr14:75389066	RPS6KL1	0.43	6.44	0.33	4.16e-10	Height;
CRC	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg24289452	chr6:170231220	NA	-0.6	-6.56	-0.34	2.12e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	18.44	0.71	1.18e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.39	-0.42	1.48e-15	Schizophrenia;
CRC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-8.29	-0.42	2.99e-15	Hemoglobin concentration;
CRC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.83	7.15	0.37	5.59e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg15845792	chr6:28175446	NA	0.86	12.58	0.57	6.56e-30	Parkinson's disease;
CRC	cis	rs73206853	0.841	rs55864430	chr12:110932355	G/T	cg12870014	chr12:110450643	ANKRD13A	0.77	7.44	0.38	8.97e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg21770322	chr7:97807741	LMTK2	0.52	8.59	0.43	3.61e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1639906	0.560	rs1639915	chr7:2258084	C/G	cg19897017	chr7:2163380	MAD1L1	0.4	5.86	0.31	1.15e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.2	0.37	4.22e-12	Motion sickness;
CRC	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.81	9.93	0.48	1.71e-20	Iron status biomarkers;
CRC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg11189052	chr15:85197271	WDR73	0.59	8.36	0.42	1.75e-15	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21798447	chr4:85504053	CDS1	0.38	6.38	0.33	5.86e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01337508	chr17:40540572	STAT3	-0.41	-6.1	-0.32	2.93e-9	Daytime sleep phenotypes;
CRC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs7605827	0.897	rs7572509	chr2:15597288	C/T	cg19274914	chr2:15703543	NA	0.38	5.81	0.3	1.49e-8	Educational attainment (years of education);
CRC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.68	7.74	0.39	1.2e-13	Vitiligo;
CRC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.51	8.25	0.41	3.79e-15	IgG glycosylation;
CRC	cis	rs7932354	0.528	rs7931260	chr11:47088303	T/C	cg03339077	chr11:47165057	C11orf49	0.43	5.95	0.31	6.94e-9	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg00310523	chr12:86230176	RASSF9	0.41	6.9	0.36	2.65e-11	Major depressive disorder;
CRC	cis	rs1075232	0.649	rs67157590	chr15:32130119	G/C	cg08481732	chr15:32323009	CHRNA7	0.64	5.63	0.3	3.9e-8	Survival in colorectal cancer (non-distant metastatic);
CRC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.56	-8.62	-0.43	2.78e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07165851	chr6:158734300	TULP4	0.62	7.76	0.39	1.07e-13	Height;
CRC	cis	rs891088	0.677	rs13306455	chr19:7184721	C/T	cg09779027	chr19:7224513	INSR	-0.57	-6.13	-0.32	2.49e-9	Hip circumference adjusted for BMI;Height;
CRC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.39	-7.56	-0.38	4.16e-13	Obesity-related traits;
CRC	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg01601518	chr4:2404284	ZFYVE28	-0.35	-5.61	-0.3	4.23e-8	Cognitive function;
CRC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	12.51	0.57	1.27e-29	Platelet count;
CRC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	0.98	13.19	0.59	3.63e-32	Breast cancer;
CRC	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-6.62	-0.34	1.47e-10	Menarche (age at onset);
CRC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.3	0.33	9.55e-10	IgG glycosylation;
CRC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg14541582	chr5:601475	NA	-0.35	-7.03	-0.36	1.23e-11	Obesity-related traits;
CRC	cis	rs7680126	0.596	rs4698029	chr4:10312798	C/G	cg00071950	chr4:10020882	SLC2A9	0.46	6.24	0.33	1.36e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs4716602	0.596	rs10261230	chr7:156159632	C/T	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.74e-11	Anti-saccade response;
CRC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg22110888	chr17:80059540	CCDC57	0.4	6.37	0.33	6.4e-10	Life satisfaction;
CRC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.52	9.11	0.45	8.26e-18	Obesity-related traits;
CRC	cis	rs728616	0.614	rs61859199	chr10:82118613	G/T	cg11900509	chr10:81946545	ANXA11	-0.56	-6.3	-0.33	9.41e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.91	-0.52	7.49e-24	Chronic sinus infection;
CRC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03885332	chr11:832357	CD151	-0.42	-6.37	-0.33	6.2e-10	Mean platelet volume;
CRC	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg12172441	chr6:28176163	NA	0.56	5.99	0.31	5.5e-9	Depression;
CRC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.81	0.31	1.48e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.64	0.34	1.29e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.6	11.14	0.52	1.12e-24	Immature fraction of reticulocytes;
CRC	cis	rs11195062	0.521	rs4562740	chr10:111951930	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-6.34	-0.33	7.76e-10	Multiple myeloma;
CRC	trans	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg10756647	chr7:56101905	PSPH	-0.78	-8.11	-0.41	1.03e-14	Diabetic kidney disease;
CRC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.91	-15.92	-0.66	1.01e-42	Cognitive function;
CRC	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	1.02	12.62	0.57	4.6e-30	IgG glycosylation;
CRC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.92	0.48	1.86e-20	Ileal carcinoids;
CRC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.2	0.32	1.69e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7487075	0.820	rs7976362	chr12:46709562	A/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.24	0.33	1.36e-9	Itch intensity from mosquito bite;
CRC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2303319	0.504	rs16845997	chr2:162521046	C/A	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.57	-8.95	-0.44	2.62e-17	Motion sickness;
CRC	trans	rs2303319	0.504	rs62189048	chr2:162613494	G/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.73	-6.16	-0.32	2.11e-9	Cognitive function;
CRC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.49	-7.31	-0.37	2.09e-12	Menarche (age at onset);
CRC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg09455208	chr3:40491958	NA	-0.43	-8.84	-0.44	6.05e-17	Renal cell carcinoma;
CRC	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg04110750	chr16:69646130	NFAT5	-0.52	-6.91	-0.36	2.54e-11	IgE levels;
CRC	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.61	8.45	0.42	9.5e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.38	0.38	1.34e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.69	8.26	0.41	3.51e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs4869931	0.858	rs9480514	chr6:150992337	C/A	cg01367992	chr1:160766535	LY9	0.38	5.99	0.31	5.4e-9	Systolic blood pressure in sickle cell anemia;
CRC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.6	-9.34	-0.46	1.49e-18	Aortic root size;
CRC	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.78	-10.8	-0.51	1.75e-23	Blood pressure (smoking interaction);
CRC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-6.97	-0.36	1.79e-11	Axial length;
CRC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.59	10.55	0.5	1.35e-22	Aortic root size;
CRC	cis	rs3764400	0.567	rs16953941	chr17:46296204	C/A	cg10706073	chr17:46328419	SKAP1	-0.61	-6.65	-0.34	1.23e-10	Body mass index;
CRC	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-8.12	-0.41	9.33e-15	Homocysteine levels;
CRC	cis	rs524281	0.861	rs10896081	chr11:65880354	A/T	cg14036092	chr11:66035641	RAB1B	-0.47	-5.72	-0.3	2.43e-8	Electroencephalogram traits;
CRC	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	1.04	14.64	0.63	1.04e-37	Exhaled nitric oxide output;
CRC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg08314208	chr16:67682810	RLTPR	-0.67	-6.98	-0.36	1.67e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.66	10.23	0.49	1.61e-21	Initial pursuit acceleration;
CRC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.63	-6.58	-0.34	1.86e-10	Axial length;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.72	-12.64	-0.57	3.9e-30	Paraoxonase activity;
CRC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg06627628	chr2:24431161	ITSN2	-0.53	-5.84	-0.31	1.27e-8	Lymphocyte counts;
CRC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	cis	rs1357245	0.692	rs73036931	chr3:27205135	G/A	cg02860705	chr3:27208620	NA	-0.39	-5.84	-0.31	1.25e-8	Breast cancer;
CRC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.26	0.41	3.54e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.44	6.03	0.32	4.44e-9	Diastolic blood pressure;
CRC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.61	10.18	0.49	2.35e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg23234261	chr14:55582407	NA	-0.29	-5.87	-0.31	1.07e-8	Protein biomarker;
CRC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.48	6.41	0.33	5.03e-10	Obesity-related traits;
CRC	cis	rs11212617	1.000	rs11212610	chr11:108274593	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.14	0.32	2.37e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.84	-14.23	-0.62	3.77e-36	Lewy body disease;
CRC	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.62	8.28	0.42	3.12e-15	Nonalcoholic fatty liver disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08305742	chr2:88354927	KRCC1	0.4	6.29	0.33	1.03e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.6	9.88	0.48	2.5e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg22495460	chr2:25135724	ADCY3	-0.85	-16.31	-0.67	3.12e-44	Body mass index;
CRC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg03340356	chr1:67600835	NA	0.26	6.0	0.31	5.14e-9	Psoriasis;
CRC	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.88	0.35	3.04e-11	Birth weight;
CRC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg05941027	chr17:61774174	LIMD2	0.34	5.81	0.3	1.51e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg10483660	chr13:112241077	NA	0.36	5.82	0.31	1.37e-8	Menarche (age at onset);
CRC	cis	rs13315871	0.860	rs9842759	chr3:58244748	C/T	cg20936604	chr3:58311152	NA	-0.67	-6.82	-0.35	4.3e-11	Cholesterol, total;
CRC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.49	-7.07	-0.36	9.39e-12	DNA methylation (variation);
CRC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.22	-0.32	1.55e-9	Aortic root size;
CRC	cis	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg11269599	chr19:52391304	ZNF577	-0.48	-5.93	-0.31	7.77e-9	Breast cancer;
CRC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	7.4	0.38	1.15e-12	Reticulocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19027619	chr1:6674655	PHF13	0.38	6.23	0.32	1.43e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg02811702	chr13:24901961	NA	0.47	6.59	0.34	1.7e-10	Obesity-related traits;
CRC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg23565292	chr14:50234668	KLHDC2	-0.4	-6.0	-0.31	5.3e-9	Carotid intima media thickness;
CRC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg19193384	chr17:30244184	NA	-0.66	-7.39	-0.38	1.22e-12	Hip circumference adjusted for BMI;
CRC	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.05	-0.32	3.95e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.69	11.0	0.52	3.61e-24	Mean corpuscular hemoglobin;
CRC	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.58	-9.26	-0.45	2.65e-18	Motion sickness;
CRC	cis	rs7932354	0.536	rs1551744	chr11:46865000	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-6.62	-0.34	1.45e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.8	12.15	0.56	2.53e-28	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9303542	0.625	rs11868098	chr17:46570869	C/G	cg04904318	chr17:46607828	HOXB1	0.43	5.62	0.3	3.98e-8	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.96	0.52	5.09e-24	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09067967	chr4:39529342	UGDH	0.36	6.13	0.32	2.54e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7264396	0.887	rs6060434	chr20:34068382	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.44	-0.33	4.22e-10	Total cholesterol levels;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg22687807	chr8:143858763	LYNX1	-0.45	-7.07	-0.36	9.33e-12	Urinary tract infection frequency;
CRC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.86	-0.44	5.18e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.42	5.8	0.3	1.58e-8	Uric acid clearance;
CRC	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.46	-6.99	-0.36	1.58e-11	HDL cholesterol levels;HDL cholesterol;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14552354	chr19:9785341	ZNF562	0.43	6.17	0.32	2.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.77	-10.3	-0.49	9.5e-22	Initial pursuit acceleration;
CRC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.15	0.32	2.19e-9	IgG glycosylation;
CRC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.4	5.92	0.31	8.17e-9	Schizophrenia;
CRC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.65	-7.64	-0.39	2.43e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	11.04	0.52	2.51e-24	Motion sickness;
CRC	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg26353448	chr1:248524236	OR2T4	-0.35	-6.57	-0.34	1.93e-10	Common traits (Other);
CRC	cis	rs1624802	1.000	rs1624802	chr12:130497472	C/T	cg15444478	chr12:130494697	NA	0.29	5.92	0.31	7.94e-9	Obesity-related traits;
CRC	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg22687807	chr8:143858763	LYNX1	0.61	10.84	0.51	1.29e-23	Urinary tract infection frequency;
CRC	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg19875578	chr6:126661172	C6orf173	0.43	5.87	0.31	1.09e-8	Male-pattern baldness;
CRC	cis	rs9549328	0.589	rs36164841	chr13:113616579	A/G	cg24588162	chr13:113633484	MCF2L	0.36	6.43	0.33	4.47e-10	Systolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11156230	chr4:83351251	HNRPDL;ENOPH1	0.52	7.14	0.37	6.11e-12	Anxiety disorder;
CRC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.41	-6.29	-0.33	1e-9	Cardiovascular disease risk factors;
CRC	trans	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg07393940	chr7:158741817	NA	-0.56	-7.84	-0.4	6.47e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.98	-0.48	1.13e-20	Colorectal cancer;
CRC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg19041857	chr6:27730383	NA	-0.71	-6.71	-0.35	8.65e-11	Depression;
CRC	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.15	0.49	3.02e-21	Corneal astigmatism;
CRC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.36	0.33	6.7e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6764363	0.527	rs3872654	chr3:282657	G/C	cg02057681	chr3:285234	CHL1	0.42	7.08	0.36	8.63e-12	Sudden cardiac arrest;
CRC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.07e-25	Hip circumference adjusted for BMI;
CRC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.7	10.81	0.51	1.71e-23	Corneal astigmatism;
CRC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.46	0.57	1.82e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg09264619	chr17:80180166	NA	0.38	6.44	0.33	4.28e-10	Life satisfaction;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg23123621	chr4:1343375	KIAA1530	0.32	5.64	0.3	3.65e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16020249	chr1:27930640	AHDC1	0.42	7.18	0.37	4.59e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.57	0.47	2.71e-19	Common traits (Other);
CRC	cis	rs10982256	0.846	rs10817622	chr9:117242575	T/C	cg13636371	chr9:117264095	DFNB31	0.34	6.3	0.33	9.49e-10	Bipolar disorder;
CRC	cis	rs7259376	0.905	rs56027264	chr19:22554354	T/C	cg02657401	chr19:22469223	NA	-0.32	-7.02	-0.36	1.3e-11	Menopause (age at onset);
CRC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.43	-20.05	-0.74	5.67e-59	Hip circumference adjusted for BMI;
CRC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.52	8.7	0.43	1.68e-16	Systemic lupus erythematosus;
CRC	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.67	7.7	0.39	1.63e-13	Phospholipid levels (plasma);
CRC	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg01843034	chr6:37503916	NA	-0.43	-8.11	-0.41	9.84e-15	Cognitive performance;
CRC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.63	0.39	2.55e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.15	11.19	0.53	7.52e-25	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22717607	chr5:10353969	MARCH6	0.38	6.22	0.32	1.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg12501888	chr15:85177176	SCAND2	-0.36	-5.81	-0.31	1.47e-8	P wave terminal force;
CRC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.61	9.65	0.47	1.44e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.7	8.88	0.44	4.39e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12745968	0.624	rs1059268	chr1:92975244	T/A	cg17283838	chr1:93427260	FAM69A	-0.48	-6.49	-0.34	3.16e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.56	-6.79	-0.35	5.29e-11	Vitiligo;
CRC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg17652424	chr22:38574118	PLA2G6	-0.21	-6.44	-0.33	4.17e-10	Cutaneous nevi;
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg05350293	chr16:89119002	NA	-0.36	-7.02	-0.36	1.26e-11	Lung cancer;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00166722	chr3:10149974	C3orf24	0.66	8.88	0.44	4.36e-17	Alzheimer's disease;
CRC	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg20607287	chr7:12443886	VWDE	-0.49	-6.84	-0.35	3.84e-11	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.89	-0.31	9.49e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg26666090	chr16:58549219	SETD6	0.94	6.4	0.33	5.36e-10	Schizophrenia;
CRC	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	6.36	0.33	6.74e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-6.6	-0.34	1.64e-10	Total body bone mineral density;
CRC	cis	rs7215564	0.908	rs4889783	chr17:78667160	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.19e-9	Myopia (pathological);
CRC	cis	rs370915	0.928	rs433477	chr4:187814866	C/G	cg19519643	chr4:187840862	NA	0.41	6.16	0.32	2.17e-9	Gout;
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7527798	0.592	rs6702222	chr1:207825627	C/T	cg21110645	chr1:207815933	NA	-0.39	-6.18	-0.32	1.9e-9	Erythrocyte sedimentation rate;
CRC	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg09659197	chr4:152720779	NA	-0.47	-10.03	-0.48	7.57e-21	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-7.93	-0.4	3.37e-14	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.57	0.34	1.93e-10	Corneal astigmatism;
CRC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.6	-8.79	-0.44	8.48e-17	Lung cancer;
CRC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.94	-0.52	5.7e-24	Bipolar disorder and schizophrenia;
CRC	trans	rs4714291	0.792	rs9471241	chr6:40080211	C/T	cg02267698	chr19:7991119	CTXN1	-0.51	-7.0	-0.36	1.43e-11	Strep throat;
CRC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-1.02	-19.9	-0.74	2.09e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.59	6.59	0.34	1.79e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.94	0.36	2.07e-11	Resting heart rate;
CRC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23903597	chr17:61704154	MAP3K3	-0.44	-5.96	-0.31	6.41e-9	Height;
CRC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	7.27	0.37	2.69e-12	Hip circumference adjusted for BMI;
CRC	trans	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.69	-0.35	9.41e-11	Menopause (age at onset);
CRC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.83	0.31	1.35e-8	Self-reported allergy;
CRC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.71	-9.2	-0.45	4.39e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg18230493	chr5:56204884	C5orf35	-0.4	-5.96	-0.31	6.6e-9	Coronary artery disease;
CRC	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg03585969	chr10:35415529	CREM	0.6	7.88	0.4	5e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.39	-0.42	1.44e-15	Gut microbiome composition (summer);
CRC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.02	-0.48	8.61e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs3804749	0.966	rs9820435	chr3:122846881	C/T	cg26084141	chr3:122786895	PDIA5	0.22	5.75	0.3	2.03e-8	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
CRC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.52	7.98	0.4	2.46e-14	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg06470822	chr6:28175283	NA	0.76	8.05	0.41	1.49e-14	Depression;
CRC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.31	-0.37	2.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg08999081	chr20:33150536	PIGU	0.44	5.65	0.3	3.39e-8	Protein C levels;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-8.09	-0.41	1.16e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg19041857	chr6:27730383	NA	-0.46	-6.42	-0.33	4.87e-10	Parkinson's disease;
CRC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.68	13.31	0.59	1.19e-32	Bone mineral density;
CRC	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.47	-7.01	-0.36	1.4e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs995000	0.931	rs11207992	chr1:63041800	T/G	cg19896129	chr1:63156450	NA	0.39	5.72	0.3	2.39e-8	Triglyceride levels;
CRC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.61	11.3	0.53	3.09e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.64e-11	Primary biliary cholangitis;
CRC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.45	-6.71	-0.35	8.44e-11	Height;
CRC	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg08075719	chr14:103021372	NA	-0.68	-7.94	-0.4	3.23e-14	Platelet count;
CRC	cis	rs9903692	0.954	rs12941295	chr17:46188187	C/G	cg21215337	chr17:46176117	CBX1	-0.41	-7.37	-0.38	1.38e-12	Pulse pressure;
CRC	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.47	6.32	0.33	8.51e-10	Schizophrenia;
CRC	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.63	10.12	0.49	3.93e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-0.95	-18.16	-0.71	1.58e-51	Coronary artery disease;
CRC	cis	rs995000	0.931	rs11207969	chr1:62911751	A/G	cg19896129	chr1:63156450	NA	0.42	6.31	0.33	8.8e-10	Triglyceride levels;
CRC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.03	-0.32	4.51e-9	Arsenic metabolism;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg22638593	chr5:131593259	PDLIM4	0.38	6.33	0.33	8.14e-10	Breast cancer;
CRC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.62	-0.47	1.81e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg26587870	chr6:27730563	NA	-0.38	-5.86	-0.31	1.1e-8	Cardiac Troponin-T levels;
CRC	cis	rs1009181	0.585	rs4486004	chr6:26167710	G/T	cg13736514	chr6:26305472	NA	-0.4	-5.85	-0.31	1.19e-8	Childhood ear infection;
CRC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.77	-0.3	1.85e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	10.03	0.48	7.98e-21	Alzheimer's disease (late onset);
CRC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.78	0.3	1.78e-8	Lung cancer;
CRC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg22676075	chr6:135203613	NA	-0.63	-9.37	-0.46	1.19e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.07	0.32	3.59e-9	Total body bone mineral density;
CRC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.44	-5.88	-0.31	1.02e-8	Gut microbiome composition (summer);
CRC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12463550	chr7:65579703	CRCP	0.75	6.82	0.35	4.5e-11	Diabetic kidney disease;
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.41	-0.56	2.77e-29	Bipolar disorder and schizophrenia;
CRC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.91	-17.23	-0.69	7.4e-48	Coronary artery disease;
CRC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.6	0.34	1.62e-10	HIV-1 control;
CRC	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg27398640	chr15:77910606	LINGO1	0.42	7.69	0.39	1.72e-13	Type 2 diabetes;
CRC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg15845792	chr6:28175446	NA	-0.75	-9.81	-0.48	4.35e-20	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.85	15.48	0.65	5.3e-41	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.49	-6.59	-0.34	1.8e-10	White matter hyperintensity burden;
CRC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.57	10.15	0.49	3.12e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg09003973	chr2:102972529	NA	0.41	5.86	0.31	1.12e-8	Blood protein levels;
CRC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.14e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg25856811	chr1:152973957	SPRR3	-0.26	-7.16	-0.37	5.44e-12	Inflammatory skin disease;
CRC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	10.93	0.52	6.07e-24	Systolic blood pressure;
CRC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.9	16.15	0.66	1.36e-43	Intelligence (multi-trait analysis);
CRC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg27366882	chr3:133540807	NA	-0.58	-8.72	-0.43	1.38e-16	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	10.35	0.5	6.34e-22	Schizophrenia;
CRC	cis	rs4716602	0.596	rs4490714	chr7:156162510	C/A	cg16983916	chr7:156159713	NA	-0.39	-6.72	-0.35	8.16e-11	Anti-saccade response;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.38	-6.78	-0.35	5.52e-11	Height;
CRC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.99e-24	Motion sickness;
CRC	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.62	-8.35	-0.42	1.91e-15	White matter hyperintensity burden;
CRC	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.83	8.44	0.42	1.04e-15	Type 2 diabetes;
CRC	cis	rs1465370	0.682	rs7811409	chr7:130024701	G/C	cg03229158	chr7:130009420	NA	0.44	6.22	0.32	1.48e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CRC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.41	7.64	0.39	2.36e-13	Mean corpuscular volume;
CRC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.14	13.38	0.59	6.6e-33	Sexual dysfunction (female);
CRC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.62	-8.75	-0.43	1.12e-16	Inflammatory bowel disease;
CRC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25517755	chr10:38738941	LOC399744	-0.41	-5.92	-0.31	8.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.2	-0.41	5.38e-15	Menarche (age at onset);
CRC	cis	rs1712517	0.771	rs61350103	chr10:105069120	A/C	cg05636881	chr10:105038444	INA	0.45	7.84	0.4	6.27e-14	Migraine;
CRC	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.74	11.12	0.52	1.32e-24	Testicular germ cell tumor;
CRC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.68	10.12	0.49	3.74e-21	Lung cancer;
CRC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.66	10.23	0.49	1.61e-21	Initial pursuit acceleration;
CRC	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.5	8.85	0.44	5.45e-17	Testicular germ cell tumor;
CRC	cis	rs225245	0.694	rs321616	chr17:33882720	C/T	cg05299278	chr17:33885742	SLFN14	0.45	7.29	0.37	2.27e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.48	-7.57	-0.38	3.89e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.55	8.95	0.44	2.61e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg20356878	chr3:121714668	ILDR1	0.52	8.05	0.41	1.49e-14	Cognitive performance;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.48	-0.38	6.81e-13	Developmental language disorder (linguistic errors);
CRC	trans	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg07817883	chr1:32538562	TMEM39B	1.23	11.25	0.53	4.71e-25	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg19812747	chr11:111475976	SIK2	-0.56	-9.61	-0.47	1.9e-19	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg12273811	chr6:28175739	NA	0.54	6.63	0.34	1.35e-10	Parkinson's disease;
CRC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	16.65	0.68	1.43e-45	Platelet count;
CRC	cis	rs9826463	0.582	rs73238145	chr3:142060559	G/A	cg20824294	chr3:142316082	PLS1	0.35	5.7	0.3	2.72e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.86	-10.61	-0.5	8.32e-23	Glomerular filtration rate (creatinine);
CRC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.7	10.83	0.51	1.42e-23	Corneal astigmatism;
CRC	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg06935464	chr4:38784597	TLR10	0.55	5.74	0.3	2.12e-8	Breast cancer;
CRC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.88	-14.96	-0.64	5.9e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg16576597	chr16:28551801	NUPR1	0.43	5.86	0.31	1.11e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05863534	chr17:34948351	DHRS11	0.37	5.97	0.31	6.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7113874	0.589	rs7120065	chr11:8484896	C/T	cg02811074	chr11:8615871	STK33	-0.36	-6.15	-0.32	2.24e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.18e-13	Motion sickness;
CRC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.02	10.48	0.5	2.23e-22	Body mass index;
CRC	cis	rs9549328	0.614	rs35872678	chr13:113617231	A/T	cg08614441	chr13:113633676	MCF2L	0.4	7.08	0.36	8.63e-12	Systolic blood pressure;
CRC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04738379	chr15:81282102	MESDC2	0.4	6.3	0.33	9.28e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05735659	chr12:48099394	RPAP3	-0.46	-7.04	-0.36	1.15e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg09355771	chr2:177043147	NA	0.65	9.66	0.47	1.36e-19	IgG glycosylation;
CRC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.61	-0.34	1.6e-10	Response to antipsychotic treatment;
CRC	cis	rs12956009	0.518	rs10163861	chr18:44820214	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.66	0.3	3.28e-8	Educational attainment (years of education);
CRC	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.59	6.39	0.33	5.54e-10	Schizophrenia;
CRC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.94	-16.63	-0.68	1.71e-45	Intelligence (multi-trait analysis);
CRC	cis	rs4804416	0.779	rs62112763	chr19:7220013	C/G	cg09779027	chr19:7224513	INSR	0.62	9.45	0.46	6.5e-19	Thyroid hormone levels;Hypothyroidism;
CRC	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.82	-13.41	-0.59	5.06e-33	Hypospadias;
CRC	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.47	6.36	0.33	6.8e-10	Lymphocyte counts;Fibrinogen;
CRC	trans	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg18335740	chr13:41363409	SLC25A15	-0.5	-7.84	-0.4	6.12e-14	Lewy body disease;
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.44	-6.23	-0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.6	7.82	0.4	7.06e-14	Mammographic density (dense area);
CRC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg15192750	chr16:69999425	NA	0.55	7.17	0.37	4.99e-12	IgE levels;
CRC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-6.82	-0.35	4.36e-11	Blood metabolite levels;
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.82	-0.4	7.48e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.83	-10.03	-0.48	7.79e-21	Initial pursuit acceleration;
CRC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-8.31	-0.42	2.53e-15	Hypospadias;
CRC	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.6	9.71	0.47	9.23e-20	Itch intensity from mosquito bite;
CRC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.8	-10.63	-0.51	7.24e-23	Initial pursuit acceleration;
CRC	trans	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.55e-9	Skin colour saturation;
CRC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	10.96	0.52	5.04e-24	Personality dimensions;
CRC	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg05784532	chr1:230284198	GALNT2	0.48	6.54	0.34	2.4e-10	Coronary artery disease;
CRC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg10760299	chr15:45669010	GATM	0.51	8.27	0.41	3.46e-15	Homoarginine levels;
CRC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg24011408	chr12:48396354	COL2A1	0.46	6.37	0.33	6.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.49	7.32	0.37	1.94e-12	Response to antineoplastic agents;
CRC	trans	rs9926664	1.000	rs11646550	chr16:85938835	C/T	cg03946896	chr1:44871606	RNF220	-0.66	-6.2	-0.32	1.68e-9	Sum basophil neutrophil counts;Neutrophil count;
CRC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.66e-10	Life satisfaction;
CRC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	11.07	0.52	1.99e-24	Motion sickness;
CRC	cis	rs10046574	0.519	rs11505985	chr7:135210197	G/T	cg27474649	chr7:135195673	CNOT4	0.61	5.95	0.31	7.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs863345	0.604	rs10908653	chr1:158455353	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-6.05	-0.32	3.87e-9	Pneumococcal bacteremia;
CRC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg06207120	chr15:45996521	NA	-0.32	-7.65	-0.39	2.22e-13	Waist circumference;Weight;
CRC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg10589385	chr1:150898437	SETDB1	0.28	6.07	0.32	3.43e-9	Melanoma;
CRC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	10.68	0.51	4.84e-23	Hip circumference adjusted for BMI;
CRC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06462663	chr19:18546047	ISYNA1	0.48	7.36	0.38	1.45e-12	Breast cancer;
CRC	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.86	-0.48	2.81e-20	Blood protein levels;
CRC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-7.33	-0.37	1.84e-12	Neuroticism;
CRC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.67	7.6	0.39	3.08e-13	Major depressive disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18222961	chr2:48009935	MSH6	-0.46	-6.83	-0.35	4.21e-11	Myopia (pathological);
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg12199221	chr5:83017078	HAPLN1	0.33	5.79	0.3	1.65e-8	Prostate cancer;
CRC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.56	8.54	0.43	5.02e-16	Fibrinogen levels;
CRC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-12.76	-0.58	1.43e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.4	5.75	0.3	1.99e-8	Obesity-related traits;
CRC	cis	rs711830	1.000	rs2113559	chr2:177031099	A/G	cg13092806	chr2:177043255	NA	0.72	8.56	0.43	4.4e-16	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.89	-0.31	9.38e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6679356	0.789	rs11209051	chr1:67798895	C/T	cg24364144	chr1:67875067	SERBP1	0.41	5.79	0.3	1.63e-8	Primary biliary cholangitis;
CRC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg07919128	chr17:18022025	MYO15A	-0.39	-6.82	-0.35	4.48e-11	Total body bone mineral density;
CRC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.37	2.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.4	5.74	0.3	2.18e-8	Height;
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.65	-0.51	5.88e-23	Alzheimer's disease;
CRC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg08200582	chr11:442649	ANO9	-0.69	-7.19	-0.37	4.32e-12	Body mass index;
CRC	trans	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg05376469	chr2:102649931	NA	-0.37	-6.01	-0.31	4.92e-9	Coronary artery disease;
CRC	cis	rs17767392	0.958	rs117821900	chr14:71985670	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.4	-0.33	5.28e-10	Mitral valve prolapse;
CRC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg20387954	chr3:183756860	HTR3D	0.46	7.76	0.39	1.1e-13	Anterior chamber depth;
CRC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg26587870	chr6:27730563	NA	-0.43	-6.72	-0.35	8.04e-11	Parkinson's disease;
CRC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg14711859	chr11:8959438	ASCL3	-0.49	-8.08	-0.41	1.26e-14	Hemoglobin concentration;
CRC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg05729581	chr11:3078854	CARS	-0.57	-8.41	-0.42	1.3e-15	Longevity;
CRC	cis	rs4731207	0.596	rs6956910	chr7:124642364	A/C	cg23710748	chr7:124431027	NA	-0.43	-6.86	-0.35	3.42e-11	Cutaneous malignant melanoma;
CRC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.86	0.51	1.14e-23	Motion sickness;
CRC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.71	0.47	9.1e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.08	20.71	0.75	1.42e-61	Triglycerides;
CRC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg04518342	chr5:131593106	PDLIM4	0.37	6.77	0.35	5.89e-11	Blood metabolite levels;
CRC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.44	-6.14	-0.32	2.36e-9	Fibrinogen levels;
CRC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.74	0.3	2.19e-8	Tonsillectomy;
CRC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-15.41	-0.65	1.03e-40	Schizophrenia;
CRC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-8.49	-0.42	7.08e-16	Intelligence (multi-trait analysis);
CRC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.43	-5.82	-0.31	1.4e-8	IgG glycosylation;
CRC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12172441	chr6:28176163	NA	0.56	7.16	0.37	5.25e-12	Parkinson's disease;
CRC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.62	-7.43	-0.38	9.74e-13	Diabetic retinopathy;
CRC	cis	rs3996993	0.809	rs4535545	chr6:52694033	C/T	cg20803780	chr6:52668592	GSTA1	-0.39	-7.28	-0.37	2.49e-12	Hemoglobin concentration;
CRC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.69	-13.02	-0.58	1.55e-31	Breast cancer;
CRC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.33e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.69	-0.35	9.41e-11	Alcohol dependence;
CRC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.55	0.54	3.78e-26	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.65	-10.12	-0.49	4.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg10589385	chr1:150898437	SETDB1	0.29	6.13	0.32	2.58e-9	Tonsillectomy;
CRC	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg22482690	chr17:47019901	SNF8	-0.5	-8.27	-0.41	3.33e-15	Type 2 diabetes;
CRC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-6.32	-0.33	8.44e-10	Coronary artery disease;
CRC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.67	10.72	0.51	3.47e-23	Breast cancer;
CRC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.68	-11.83	-0.55	3.88e-27	Asthma;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg15845792	chr6:28175446	NA	-0.66	-8.62	-0.43	2.84e-16	Parkinson's disease;
CRC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-7.44	-0.38	8.68e-13	Response to bleomycin (chromatid breaks);
CRC	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg14191688	chr11:70257035	CTTN	0.48	6.2	0.32	1.71e-9	Coronary artery disease;
CRC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.51	-0.42	6.27e-16	Total cholesterol levels;
CRC	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg16950941	chr11:66035639	RAB1B	-0.61	-7.57	-0.39	3.88e-13	Electroencephalogram traits;
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	0.7	9.53	0.46	3.69e-19	Alzheimer's disease;
CRC	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg14768367	chr16:72042858	DHODH	-0.61	-6.86	-0.35	3.37e-11	Blood protein levels;
CRC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18912574	chr7:65842487	NCRNA00174	0.35	6.04	0.32	4.24e-9	Aortic root size;
CRC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.83	11.5	0.54	6.08e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg24562669	chr7:97807699	LMTK2	0.51	8.5	0.42	6.59e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs524281	0.861	rs10750780	chr11:65974592	G/A	cg16950941	chr11:66035639	RAB1B	-0.62	-7.39	-0.38	1.23e-12	Electroencephalogram traits;
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.38	6.7	0.35	8.91e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.41	0.38	1.07e-12	Eye color traits;
CRC	cis	rs7923609	0.870	rs10822156	chr10:65080727	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.71	-0.3	2.54e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12667521	chr19:29218732	NA	0.44	6.51	0.34	2.76e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.83	-0.31	1.36e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg03233332	chr7:66118400	NA	0.45	6.22	0.32	1.55e-9	Aortic root size;
CRC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg00343986	chr7:65444356	GUSB	0.43	6.28	0.33	1.08e-9	Aortic root size;
CRC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg02683197	chr6:28174875	NA	0.87	12.16	0.56	2.47e-28	Depression;
CRC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg10589385	chr1:150898437	SETDB1	0.32	6.54	0.34	2.42e-10	Melanoma;
CRC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.6	-9.31	-0.46	1.85e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.62	-9.19	-0.45	4.48e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.54	8.69	0.43	1.78e-16	Prostate cancer;
CRC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg12273811	chr6:28175739	NA	0.63	9.42	0.46	8.17e-19	Cardiac Troponin-T levels;
CRC	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.6	10.19	0.49	2.21e-21	Dupuytren's disease;
CRC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.63	7.24	0.37	3.18e-12	Vitiligo;
CRC	cis	rs59104589	0.617	rs60132543	chr2:242344599	T/C	cg19488206	chr2:242435732	STK25	0.43	6.33	0.33	7.84e-10	Fibrinogen levels;
CRC	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg15234197	chr11:68924956	NA	0.44	6.12	0.32	2.72e-9	Blond vs. brown hair color;
CRC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-8.75	-0.43	1.16e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs847649	0.842	rs11976237	chr7:102641383	A/G	cg18108683	chr7:102477205	FBXL13	0.56	8.97	0.44	2.3e-17	Morning vs. evening chronotype;
CRC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.36	0.53	1.9e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.09	0.45	9.47e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.85	0.55	3.28e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.32	0.46	1.78e-18	Monocyte percentage of white cells;
CRC	cis	rs6429082	0.902	rs704708	chr1:235620134	T/C	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.94e-9	Adiposity;
CRC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg18709589	chr6:96969512	KIAA0776	0.51	5.72	0.3	2.43e-8	Migraine;Coronary artery disease;
CRC	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.5	7.01	0.36	1.37e-11	Metabolite levels;
CRC	cis	rs4561483	0.583	rs11075032	chr16:12004450	C/T	cg08843971	chr16:11963173	GSPT1	0.5	7.46	0.38	7.59e-13	Testicular germ cell tumor;
CRC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.49	-9.41	-0.46	8.89e-19	Neuroticism;
CRC	cis	rs863345	0.527	rs10797019	chr1:158490221	A/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	trans	rs1864729	1.000	rs1431891	chr8:98282716	A/G	cg08679828	chr8:102218111	ZNF706	-0.63	-7.54	-0.38	4.76e-13	Estradiol plasma levels (breast cancer);
CRC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.78	14.1	0.61	1.17e-35	Mean platelet volume;
CRC	cis	rs1109861	0.535	rs752379	chr10:11244600	G/A	cg24910943	chr10:11206320	CUGBP2	-0.28	-6.92	-0.36	2.42e-11	Urinary albumin-to-creatinine ratio;
CRC	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-5.68	-0.3	3.02e-8	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.46	7.34	0.38	1.69e-12	Breast cancer;
CRC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg00383909	chr3:49044727	WDR6	0.46	5.76	0.3	1.98e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg24209194	chr3:40518798	ZNF619	0.38	5.66	0.3	3.28e-8	Renal cell carcinoma;
CRC	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg04176472	chr15:90893244	GABARAPL3	0.35	6.03	0.32	4.46e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs17767392	1.000	rs35260692	chr14:71831665	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs1639906	1.000	rs1637759	chr7:2220053	C/T	cg19897017	chr7:2163380	MAD1L1	0.41	6.37	0.33	6.32e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-8.77	-0.44	1.01e-16	Bipolar disorder;
CRC	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.7	10.02	0.48	8.47e-21	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.54	-7.28	-0.37	2.42e-12	Alzheimer's disease (survival time);
CRC	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg07125278	chr16:67683757	RLTPR	-0.5	-6.91	-0.36	2.58e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg15511327	chr8:143859410	LYNX1	0.41	7.22	0.37	3.73e-12	Urinary tract infection frequency;
CRC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg19998675	chr3:182970903	MCF2L2;B3GNT5	0.44	6.18	0.32	1.92e-9	Type 2 diabetes (age of onset);
CRC	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg19683494	chr5:74908142	NA	-0.47	-6.17	-0.32	1.95e-9	Age-related disease endophenotypes;
CRC	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg03929089	chr4:120376271	NA	0.69	6.81	0.35	4.7e-11	Intraocular pressure;
CRC	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.9	-11.56	-0.54	3.5e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.06	-0.49	6.18e-21	Initial pursuit acceleration;
CRC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-0.86	-12.69	-0.57	2.63e-30	IgG glycosylation;
CRC	cis	rs1322512	0.959	rs1727053	chr6:152947596	A/G	cg03415253	chr6:152958462	SYNE1	-0.42	-6.41	-0.33	5.09e-10	Tonometry;
CRC	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.19	-0.56	1.81e-28	Migraine;Coronary artery disease;
CRC	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.84	-0.31	1.22e-8	Height;
CRC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg09264619	chr17:80180166	NA	-0.49	-6.87	-0.35	3.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg07617317	chr6:118971624	C6orf204	0.5	6.13	0.32	2.57e-9	Diastolic blood pressure;
CRC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21643547	chr1:205240462	TMCC2	-0.38	-6.08	-0.32	3.27e-9	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg24046110	chr8:143859143	LYNX1	0.47	8.04	0.41	1.64e-14	Urinary tract infection frequency;
CRC	cis	rs2257205	0.588	rs7209327	chr17:56741834	A/G	cg25885038	chr17:56607967	SEPT4	-0.52	-5.69	-0.3	2.87e-8	Pancreatic cancer;
CRC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs7113874	0.589	rs11041944	chr11:8500996	G/A	cg20771178	chr11:8615675	STK33	0.35	5.75	0.3	2e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12900413	0.959	rs11632886	chr15:90322945	A/G	cg24249390	chr15:90295951	MESP1	-0.62	-9.32	-0.46	1.72e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.36	-0.38	1.48e-12	Monocyte percentage of white cells;
CRC	cis	rs7082209	1.000	rs61856381	chr10:44811172	T/C	cg09554077	chr10:44749378	NA	0.43	5.62	0.3	4.04e-8	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
CRC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.64	-11.93	-0.55	1.63e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-9.71	-0.47	8.87e-20	Schizophrenia;
CRC	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg10724054	chr17:3904396	NA	0.47	7.54	0.38	4.63e-13	Type 2 diabetes;
CRC	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.22	-0.37	3.55e-12	Caudate activity during reward;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09399047	chr3:49059671	NDUFAF3;DALRD3	0.39	5.65	0.3	3.39e-8	Intelligence (multi-trait analysis);
CRC	trans	rs6600671	0.899	rs11249432	chr1:121283476	T/A	cg09829573	chr1:144692074	NBPF9	-0.42	-6.27	-0.33	1.14e-9	Hip geometry;
CRC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.75e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.92	0.44	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6840360	0.573	rs2407171	chr4:152256782	A/G	cg09659197	chr4:152720779	NA	0.31	5.98	0.31	5.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.9	-0.31	8.95e-9	Alcohol dependence;
CRC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.67e-13	Hip circumference adjusted for BMI;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22080282	chr18:72920932	ZADH2	0.46	6.66	0.34	1.16e-10	Response to antipsychotic treatment;
CRC	trans	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg26043149	chr18:55253948	FECH	0.54	8.53	0.43	5.34e-16	Bone mineral density;
CRC	trans	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg10756647	chr7:56101905	PSPH	0.74	7.72	0.39	1.37e-13	Diabetic kidney disease;
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02290350	chr8:58132656	NA	-0.61	-6.94	-0.36	2.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg23920097	chr1:209922102	NA	-0.51	-6.49	-0.34	3.23e-10	Red blood cell count;
CRC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.56	-8.75	-0.43	1.16e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg13482628	chr17:19912719	NA	-0.4	-6.22	-0.32	1.53e-9	Obesity-related traits;
CRC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.25	-0.33	1.25e-9	Glomerular filtration rate (creatinine);
CRC	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.39	0.46	1.06e-18	Endometrial cancer;
CRC	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	cg04338863	chr8:33670619	NA	0.42	6.72	0.35	8.03e-11	Body mass index;
CRC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	0.93	11.05	0.52	2.33e-24	Type 2 diabetes nephropathy;
CRC	trans	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg07817883	chr1:32538562	TMEM39B	-0.63	-7.0	-0.36	1.45e-11	Monocyte percentage of white cells;
CRC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.61	10.33	0.49	7.6e-22	Mean corpuscular volume;
CRC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.77	13.51	0.6	2.14e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.12e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg01312482	chr5:178451176	ZNF879	-0.37	-6.15	-0.32	2.27e-9	Pubertal anthropometrics;
CRC	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.46	8.5	0.42	6.84e-16	Neuroticism;
CRC	cis	rs17065868	0.764	rs9533860	chr13:45033061	A/T	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs7731657	0.509	rs2250348	chr5:130243531	T/A	cg08523029	chr5:130500466	HINT1	-0.47	-6.05	-0.32	3.95e-9	Fasting plasma glucose;
CRC	cis	rs17532515	0.628	rs7693034	chr4:141478679	C/G	cg09181644	chr4:141490428	UCP1	-0.32	-5.85	-0.31	1.19e-8	Select biomarker traits;
CRC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.6	-0.34	1.67e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg15145296	chr3:125709740	NA	-0.57	-6.5	-0.34	2.98e-10	Blood pressure (smoking interaction);
CRC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.7	-0.35	9.26e-11	Lymphocyte counts;
CRC	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.34	16.78	0.68	4.27e-46	Uric acid levels;
CRC	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg24375607	chr4:120327624	NA	0.52	8.12	0.41	9.4e-15	Corneal astigmatism;
CRC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg00246817	chr9:123691163	NA	-0.44	-5.74	-0.3	2.13e-8	Rheumatoid arthritis;
CRC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	1.12	10.8	0.51	1.76e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.62	-10.27	-0.49	1.17e-21	Hip circumference;
CRC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg24675056	chr1:15929824	NA	0.51	6.79	0.35	5.1e-11	Systolic blood pressure;
CRC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.44	0.62	6.24e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.68	-10.64	-0.51	6.3e-23	Huntington's disease progression;
CRC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg23815491	chr16:72088622	HP	0.49	7.51	0.38	5.77e-13	Fibrinogen levels;
CRC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.42	-0.33	4.78e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06852250	chr1:171750693	METTL13	0.4	6.04	0.32	4.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.95	-12.36	-0.56	4.34e-29	Exhaled nitric oxide output;
CRC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.39	-0.33	5.79e-10	Aortic root size;
CRC	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg04110750	chr16:69646130	NFAT5	-0.52	-6.91	-0.36	2.54e-11	IgE levels;
CRC	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.5	6.18	0.32	1.93e-9	Bipolar disorder lithium response (categorical) or schizophrenia;
CRC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.58	-9.27	-0.46	2.47e-18	Schizophrenia;
CRC	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.03	19.74	0.74	8.95e-58	Schizophrenia;
CRC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg20203395	chr5:56204925	C5orf35	-0.46	-6.35	-0.33	7.36e-10	Coronary artery disease;
CRC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.56	-7.4	-0.38	1.17e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg20356878	chr3:121714668	ILDR1	0.51	7.8	0.4	8.06e-14	Cognitive performance;
CRC	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.85	-0.35	3.69e-11	Menarche (age at onset);
CRC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.87	-0.35	3.13e-11	Lung cancer;
CRC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.14	0.49	3.43e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.65	10.87	0.51	1.03e-23	Cancer;
CRC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.42	7.24	0.37	3.13e-12	Major depressive disorder;
CRC	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.7	7.1	0.36	7.8e-12	Plasma clusterin levels;
CRC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg21770322	chr7:97807741	LMTK2	0.52	8.47	0.42	8.07e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.51	6.18	0.32	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.5	-7.06	-0.36	9.63e-12	Intelligence (multi-trait analysis);
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg25164649	chr6:28176230	NA	0.46	6.76	0.35	6.23e-11	Cardiac Troponin-T levels;
CRC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.52	-6.84	-0.35	3.97e-11	Multiple sclerosis;
CRC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.92	-12.03	-0.55	7.01e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg07930192	chr7:1003750	NA	0.69	5.74	0.3	2.14e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.37	-0.33	6.37e-10	Systolic blood pressure;
CRC	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.7	10.25	0.49	1.43e-21	Inflammatory bowel disease;
CRC	cis	rs728616	0.867	rs57257258	chr10:81844020	T/C	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.55	-0.34	2.18e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.73	-0.35	7.62e-11	Total body bone mineral density;
CRC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg03233332	chr7:66118400	NA	0.44	6.2	0.32	1.65e-9	Aortic root size;
CRC	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.45	7.05	0.36	1.04e-11	Refractive error;
CRC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.61	-8.99	-0.44	1.95e-17	Menarche (age at onset);
CRC	cis	rs370915	0.578	rs2375939	chr4:187783726	G/A	cg12892747	chr4:187813459	NA	-0.57	-8.28	-0.42	3.13e-15	Gout;
CRC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.02	18.97	0.72	1.01e-54	Primary sclerosing cholangitis;
CRC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.72	12.22	0.56	1.46e-28	Breast cancer;
CRC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg18827107	chr12:86230957	RASSF9	0.39	5.98	0.31	5.76e-9	Major depressive disorder;
CRC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.43	-5.69	-0.3	2.76e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.23	0.37	3.38e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.64	9.28	0.46	2.3e-18	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg24655899	chr17:79519568	C17orf70	-0.7	-5.98	-0.31	5.92e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23475260	chr19:36505236	ALKBH6	0.42	6.75	0.35	6.52e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-11.09	-0.52	1.68e-24	Cognitive function;
CRC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg11189052	chr15:85197271	WDR73	0.63	9.08	0.45	9.97e-18	Schizophrenia;
CRC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg03959625	chr15:84868606	LOC388152	0.4	5.61	0.3	4.29e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05358025	chr19:4868071	PLIN3	0.46	6.63	0.34	1.36e-10	Response to antipsychotic treatment;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25365794	chr17:8022404	ALOXE3	-0.5	-6.01	-0.31	4.84e-9	Diisocyanate-induced asthma;
CRC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.62	-8.88	-0.44	4.43e-17	Alzheimer's disease;
CRC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.26	-0.59	1.97e-32	Educational attainment;
CRC	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.47	7.56	0.38	4.15e-13	Body mass index;
CRC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.78	11.3	0.53	3.04e-25	Menarche (age at onset);
CRC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs1740073	0.690	rs1740071	chr6:43944859	C/T	cg14777908	chr6:43939685	NA	-0.49	-8.2	-0.41	5.32e-15	Vascular endothelial growth factor levels;
CRC	trans	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg02674126	chr19:40336878	FBL	0.42	6.74	0.35	6.98e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg25456477	chr12:86230367	RASSF9	0.36	6.11	0.32	2.82e-9	Major depressive disorder;
CRC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.71	-7.63	-0.39	2.55e-13	IgG glycosylation;
CRC	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.46	-6.55	-0.34	2.22e-10	Lung cancer;
CRC	cis	rs9549260	0.753	rs9549246	chr13:41220755	G/A	cg21288729	chr13:41239152	FOXO1	0.48	6.04	0.32	4.12e-9	Red blood cell count;
CRC	trans	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg10756647	chr7:56101905	PSPH	0.73	7.98	0.4	2.44e-14	Diabetic kidney disease;
CRC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg23136738	chr11:925521	AP2A2	-0.48	-7.63	-0.39	2.52e-13	Alzheimer's disease (late onset);
CRC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.66	10.98	0.52	4.01e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg04176472	chr15:90893244	GABARAPL3	-0.36	-5.65	-0.3	3.49e-8	Rheumatoid arthritis;
CRC	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg18646521	chr2:111875858	NA	0.4	6.31	0.33	8.84e-10	Chronic lymphocytic leukemia;
CRC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.54	8.6	0.43	3.36e-16	Type 2 diabetes;
CRC	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg13844804	chr7:814759	HEATR2	-0.64	-6.52	-0.34	2.63e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs2280381	0.510	rs1474176	chr16:86008814	A/G	cg04454285	chr16:86016317	NA	0.42	6.57	0.34	2.03e-10	Rheumatoid arthritis;
CRC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.15	-0.49	3.03e-21	Tonsillectomy;
CRC	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.51	-8.07	-0.41	1.29e-14	Anterior chamber depth;
CRC	cis	rs4716602	0.548	rs34245976	chr7:156160897	T/G	cg16983916	chr7:156159713	NA	-0.39	-6.79	-0.35	5.4e-11	Anti-saccade response;
CRC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	9.05	0.45	1.31e-17	Mean platelet volume;
CRC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.44	-9.74	-0.47	7.12e-20	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.78	0.44	9.09e-17	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.84	-0.31	1.26e-8	Depression;
CRC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg05540913	chr6:167530185	CCR6	0.33	5.75	0.3	2.09e-8	Primary biliary cholangitis;
CRC	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg14844989	chr11:31128820	NA	0.35	6.24	0.33	1.37e-9	Red blood cell count;
CRC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	9.44	0.46	6.85e-19	Schizophrenia;
CRC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.02	11.12	0.52	1.31e-24	Hip circumference adjusted for BMI;
CRC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg08071915	chr8:12219732	FAM66A	-0.34	-6.29	-0.33	1.02e-9	Retinal vascular caliber;
CRC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg09876464	chr15:85330779	ZNF592	0.39	6.45	0.34	3.96e-10	P wave terminal force;
CRC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.65	11.23	0.53	5.24e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg10437265	chr15:77819839	NA	0.67	11.9	0.55	2.1e-27	Type 2 diabetes;
CRC	cis	rs12476592	0.602	rs10469945	chr2:63816776	T/C	cg10828910	chr2:63850056	LOC388955	0.49	6.06	0.32	3.75e-9	Childhood ear infection;
CRC	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.86	-0.31	1.12e-8	Major depressive disorder;
CRC	cis	rs939584	1.000	rs7570198	chr2:648198	C/T	cg03610516	chr2:642275	NA	0.41	5.9	0.31	8.8e-9	Body mass index;
CRC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg07713946	chr22:31675144	LIMK2	0.4	5.95	0.31	6.81e-9	Colorectal cancer;
CRC	cis	rs7605827	0.930	rs2049718	chr2:15518589	A/G	cg19274914	chr2:15703543	NA	-0.37	-5.66	-0.3	3.34e-8	Educational attainment (years of education);
CRC	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.58	0.39	3.54e-13	Blood metabolite levels;
CRC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.9	-21.04	-0.76	7.13e-63	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.5	-0.34	2.94e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.26	-16.72	-0.68	7.53e-46	Breast cancer;
CRC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.55	8.45	0.42	9.38e-16	Aortic root size;
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.61	-0.3	4.25e-8	Electroencephalogram traits;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.68	11.24	0.53	5.19e-25	Height;
CRC	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.52	7.77	0.39	1.02e-13	Coronary heart disease;
CRC	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg10862848	chr6:42927986	GNMT	-0.3	-5.68	-0.3	3.04e-8	Blood protein levels;
CRC	cis	rs16867321	1.000	rs16867330	chr2:181446202	T/G	cg23363182	chr2:181467187	NA	-0.55	-7.01	-0.36	1.35e-11	Obesity;
CRC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.11	0.32	2.82e-9	Height;
CRC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.47	5.96	0.31	6.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	6.5	0.34	2.93e-10	Obesity-related traits;
CRC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.64	6.19	0.32	1.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.47	0.69	8.43e-49	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg26043149	chr18:55253948	FECH	0.47	7.45	0.38	8.18e-13	Bone mineral density;
CRC	cis	rs3026101	0.671	rs1989946	chr17:5313152	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	7.26	0.37	2.82e-12	Body mass index;
CRC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.58	9.01	0.44	1.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06771106	chr2:113671356	IL1F7	0.41	5.97	0.31	6.27e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.63	9.79	0.47	5.01e-20	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg16822035	chr13:113633379	MCF2L	-0.29	-6.01	-0.31	4.96e-9	Systolic blood pressure;
CRC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	0.99	12.71	0.57	2.26e-30	Triglycerides;
CRC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.07	-12.3	-0.56	7.44e-29	Diabetic kidney disease;
CRC	cis	rs1178968	1.000	rs1178969	chr7:72759114	A/G	cg25889504	chr7:72793014	NA	0.54	6.08	0.32	3.4e-9	Triglyceride levels;
CRC	cis	rs523516	0.645	rs16527	chr17:37322080	T/C	cg20555674	chr17:37321631	ARL5C	0.39	8.03	0.41	1.69e-14	IgG glycosylation;
CRC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs11212617	0.967	rs183460	chr11:108090710	A/C	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.25	0.33	1.28e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12541635	0.966	rs6469031	chr8:107048095	T/C	cg10147462	chr8:107024639	NA	0.45	7.56	0.38	3.98e-13	Age of smoking initiation;
CRC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	7.75	0.39	1.19e-13	Schizophrenia;
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.46	6.88	0.35	3.02e-11	Obesity-related traits;
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.5e-9	Prudent dietary pattern;
CRC	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg18335740	chr13:41363409	SLC25A15	0.55	8.72	0.43	1.42e-16	Lewy body disease;
CRC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.42	-7.37	-0.38	1.42e-12	Height;
CRC	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg04586622	chr2:25135609	ADCY3	0.47	8.41	0.42	1.23e-15	Body mass index in non-asthmatics;
CRC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05606039	chr17:73511506	TSEN54;CASKIN2	0.41	6.46	0.34	3.83e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9400239	0.622	rs1268166	chr6:109008232	T/C	cg11073813	chr6:109029018	NA	-0.41	-6.45	-0.34	3.94e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.57	7.85	0.4	6.02e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.66	-10.92	-0.52	6.61e-24	White blood cell count (basophil);
CRC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.23	-0.32	1.4e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11031096	0.738	rs11031070	chr11:4154307	T/C	cg22978087	chr8:24814126	NEFL	0.33	6.08	0.32	3.37e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07843956	chr16:692375	FAM195A	0.5	6.74	0.35	7.23e-11	Anxiety disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09252528	chr19:42901252	NA	0.47	6.55	0.34	2.19e-10	Response to antipsychotic treatment;
CRC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.35	-6.44	-0.33	4.29e-10	Childhood ear infection;
CRC	cis	rs7172809	0.607	rs78928643	chr15:77842297	A/G	cg10437265	chr15:77819839	NA	-0.36	-5.99	-0.31	5.65e-9	Glucose homeostasis traits;
CRC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.19	-15.96	-0.66	6.93e-43	Breast cancer;
CRC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.61	-9.95	-0.48	1.47e-20	Dental caries;
CRC	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg14191688	chr11:70257035	CTTN	0.42	5.85	0.31	1.18e-8	Coronary artery disease;
CRC	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg16670446	chr17:27188758	MIR451;MIR144	-0.61	-10.36	-0.5	5.96e-22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.91	16.88	0.68	1.72e-46	Intelligence (multi-trait analysis);
CRC	cis	rs863345	0.604	rs12063320	chr1:158499423	A/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs10971721	0.822	rs72725381	chr9:33851165	A/T	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.45	7.02	0.36	1.27e-11	C-reactive protein levels;
CRC	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.22	16.44	0.67	9.33e-45	Atopic dermatitis;
CRC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.08	0.36	8.79e-12	Rheumatoid arthritis;
CRC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg15147215	chr3:52552868	STAB1	-0.61	-10.04	-0.48	7.46e-21	Bipolar disorder;
CRC	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.56	5.89	0.31	9.54e-9	Blood protein levels;
CRC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-8.34	-0.42	2e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.77	-0.3	1.79e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.06	20.83	0.75	4.84e-62	Schizophrenia;
CRC	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.08	-0.36	8.67e-12	Body mass index;
CRC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.42	8.06	0.41	1.41e-14	Ulcerative colitis;
CRC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.06	-12.44	-0.57	2.13e-29	Diabetic kidney disease;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs6834538	1.000	rs2351761	chr4:113447911	A/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.44	-6.33	-0.33	8e-10	Free thyroxine concentration;
CRC	cis	rs4664293	0.647	rs6734085	chr2:160452222	C/T	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.11e-10	Monocyte percentage of white cells;
CRC	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.19	0.53	7.53e-25	Bipolar disorder;
CRC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04509940	chr21:45079326	HSF2BP;RRP1B	0.37	6.02	0.31	4.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg27432699	chr2:27873401	GPN1	0.5	7.4	0.38	1.16e-12	Total body bone mineral density;
CRC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.82	11.86	0.55	2.98e-27	Multiple sclerosis;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.8	0.44	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-10.37	-0.5	5.4e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.47	5.7	0.3	2.64e-8	Refractive astigmatism;
CRC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.6	0.43	3.24e-16	Homoarginine levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18724257	chr3:53164314	RFT1	0.49	7.04	0.36	1.13e-11	Response to antipsychotic treatment;
CRC	cis	rs17767392	0.813	rs12880291	chr14:71884567	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.5	-6.37	-0.33	6.4e-10	Mitral valve prolapse;
CRC	cis	rs12086130	0.892	rs72904801	chr1:51442137	A/G	cg07174182	chr1:51127561	FAF1	-0.73	-5.65	-0.3	3.49e-8	Hip circumference adjusted for BMI;Hip circumference;
CRC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-11.88	-0.55	2.48e-27	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7142881	0.508	rs4981109	chr14:32118067	C/T	cg10453823	chr2:190539512	ANKAR	0.41	6.12	0.32	2.74e-9	Response to iloperidone treatment (QT prolongation);
CRC	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg25456477	chr12:86230367	RASSF9	0.39	6.56	0.34	2.04e-10	Major depressive disorder;
CRC	cis	rs4692589	0.840	rs2727525	chr4:170960062	G/T	cg19918862	chr4:170955249	NA	0.37	6.05	0.32	3.87e-9	Anxiety disorder;
CRC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.41	6.24	0.33	1.38e-9	Hemoglobin concentration;
CRC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg13072238	chr3:49761600	GMPPB	-0.51	-5.78	-0.3	1.74e-8	Menarche (age at onset);
CRC	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg24910161	chr17:38119198	GSDMA	-0.38	-6.26	-0.33	1.19e-9	Myeloid white cell count;
CRC	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.68	0.3	3.01e-8	Neuroticism;
CRC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.44	-8.67	-0.43	2e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg04586622	chr2:25135609	ADCY3	-0.54	-10.01	-0.48	9.31e-21	Body mass index;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15933130	chr5:137089362	HNRNPA0	0.4	6.49	0.34	3.23e-10	Obesity-related traits;
CRC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25517755	chr10:38738941	LOC399744	-0.41	-6.1	-0.32	3.03e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7580658	0.864	rs4150454	chr2:128038544	T/C	cg09760422	chr2:128146352	NA	-0.29	-5.71	-0.3	2.54e-8	Protein C levels;
CRC	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg16989086	chr20:62203971	PRIC285	-0.48	-6.07	-0.32	3.62e-9	Atopic dermatitis;
CRC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg06243084	chr11:63990629	FERMT3	-0.4	-6.17	-0.32	2.04e-9	Platelet count;
CRC	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg19875578	chr6:126661172	C6orf173	0.44	6.2	0.32	1.69e-9	Male-pattern baldness;
CRC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.42	6.66	0.34	1.12e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-6.04	-0.32	4.28e-9	Mean corpuscular volume;
CRC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg18479299	chr3:125709523	NA	-0.49	-6.46	-0.34	3.8e-10	Blood pressure (smoking interaction);
CRC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.98	14.43	0.62	6.41e-37	IgG glycosylation;
CRC	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.11e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.13e-22	Prudent dietary pattern;
CRC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.5	7.29	0.37	2.4e-12	Blood metabolite levels;
CRC	cis	rs9837602	1.000	rs1688772	chr3:99503366	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.92	0.31	8.25e-9	Breast cancer;
CRC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.82	14.87	0.63	1.31e-38	Anterior chamber depth;
CRC	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg13919466	chr1:32135498	COL16A1	-0.31	-5.8	-0.3	1.58e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.39	0.46	1.01e-18	Bladder cancer;
CRC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.2	-0.32	1.69e-9	Bladder cancer;
CRC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.75	12.69	0.57	2.65e-30	Body mass index;
CRC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-5.96	-0.31	6.57e-9	Heart rate;
CRC	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg14631576	chr9:95140430	CENPP	-0.4	-6.87	-0.35	3.13e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg13856295	chr9:139396418	NOTCH1	-0.42	-5.64	-0.3	3.61e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.73	-0.39	1.35e-13	Height;
CRC	cis	rs7259376	0.775	rs2360621	chr19:22548669	C/T	cg02657401	chr19:22469223	NA	-0.31	-6.5	-0.34	2.98e-10	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.48	7.36	0.38	1.45e-12	Eye color traits;
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.25	0.41	3.83e-15	Life satisfaction;
CRC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg03258011	chr17:54857409	NA	-0.52	-6.45	-0.34	3.91e-10	Diisocyanate-induced asthma;
CRC	cis	rs889398	0.771	rs4985448	chr16:69899395	A/G	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.3	-0.33	9.79e-10	Body mass index;
CRC	cis	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg26695010	chr11:65641043	EFEMP2	-0.43	-5.96	-0.31	6.66e-9	Breast cancer;
CRC	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg02527881	chr3:46936655	PTH1R	-0.38	-7.05	-0.36	1.04e-11	Colorectal cancer;
CRC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.51	7.43	0.38	9.67e-13	Blood protein levels;
CRC	cis	rs2415984	0.579	rs61993339	chr14:46969266	G/A	cg14871534	chr14:47121158	RPL10L	-0.43	-6.25	-0.33	1.24e-9	Number of children ever born;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19091447	chr20:37555378	FAM83D	0.4	6.16	0.32	2.17e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.8	-10.85	-0.51	1.17e-23	Initial pursuit acceleration;
CRC	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.82	10.85	0.51	1.21e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-10.95	-0.52	5.22e-24	Exhaled nitric oxide output;
CRC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg05192639	chr6:26864778	GUSBL1	0.31	6.01	0.31	5.05e-9	Schizophrenia;
CRC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.08	-0.55	4.67e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.53	6.88	0.35	3.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.38	5.77	0.3	1.86e-8	Hemoglobin concentration;
CRC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.69	-11.42	-0.53	1.18e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.53	-7.95	-0.4	3.1e-14	Obesity-related traits;
CRC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg18612461	chr15:75251733	NA	0.38	5.93	0.31	7.78e-9	Breast cancer;
CRC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.65	0.54	1.76e-26	Prudent dietary pattern;
CRC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.45	-0.34	3.98e-10	Blood metabolite levels;
CRC	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.61	-8.68	-0.43	1.91e-16	Coronary artery disease;
CRC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.4	-7.3	-0.37	2.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.56	8.34	0.42	2.09e-15	Intelligence (multi-trait analysis);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg11239145	chr4:26320844	RBPJ	-0.53	-6.43	-0.33	4.39e-10	Type 1 diabetes;
CRC	cis	rs6024905	1.000	rs6024905	chr20:36957837	C/T	cg07053727	chr20:36965646	BPI	0.45	7.76	0.39	1.06e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	0.84	6.6	0.34	1.69e-10	Fat distribution (HIV);
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg22110888	chr17:80059540	CCDC57	0.39	6.25	0.33	1.27e-9	Life satisfaction;
CRC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg20933634	chr6:27740509	NA	0.45	6.56	0.34	2.05e-10	Parkinson's disease;
CRC	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg27017172	chr16:57497170	POLR2C	0.67	6.01	0.31	4.84e-9	Blood protein levels;
CRC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg19223190	chr17:80058835	NA	-0.45	-7.18	-0.37	4.78e-12	Life satisfaction;
CRC	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.45	-8.23	-0.41	4.56e-15	Urate levels in overweight individuals;
CRC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg18827107	chr12:86230957	RASSF9	0.39	5.96	0.31	6.52e-9	Major depressive disorder;
CRC	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.63	-7.01	-0.36	1.32e-11	Coronary artery disease;
CRC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.63	9.08	0.45	1.03e-17	Systolic blood pressure;
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.78	-0.39	9.43e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.72	-7.03	-0.36	1.2e-11	Schizophrenia;
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg03844506	chr4:4109441	NA	-0.51	-7.57	-0.39	3.88e-13	Blood pressure (smoking interaction);
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.53	-7.7	-0.39	1.61e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg19894588	chr14:64061835	NA	-0.61	-8.17	-0.41	6.48e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg24463073	chr6:118973353	C6orf204	0.52	6.97	0.36	1.69e-11	Diastolic blood pressure;
CRC	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg13615338	chr4:55094005	PDGFRA	0.4	5.62	0.3	3.97e-8	Corneal astigmatism;
CRC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.2	0.41	5.45e-15	Lung cancer;
CRC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02725872	chr8:58115012	NA	-0.41	-7.16	-0.37	5.35e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11082575	chr12:31479096	FAM60A	0.5	6.42	0.33	4.76e-10	Thyroid stimulating hormone;
CRC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.58	7.46	0.38	7.8e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg15786705	chr6:28176104	NA	0.69	9.22	0.45	3.64e-18	Parkinson's disease;
CRC	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-7.31	-0.37	1.99e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-6.0	-0.31	5.19e-9	Schizophrenia;
CRC	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.56	9.35	0.46	1.36e-18	Brugada syndrome;
CRC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.96	-0.36	1.83e-11	Response to antipsychotic treatment;
CRC	cis	rs10450586	0.863	rs7115024	chr11:27301437	G/A	cg10370305	chr11:27303972	NA	0.37	6.08	0.32	3.41e-9	Total body bone mineral density;
CRC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.3	0.33	9.4e-10	Bladder cancer;
CRC	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg25019722	chr6:37503610	NA	-0.37	-6.1	-0.32	2.96e-9	Cognitive performance;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.61	7.36	0.38	1.49e-12	Menarche (age at onset);
CRC	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.69	9.68	0.47	1.12e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.74	-0.47	7.46e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.02	23.53	0.79	1.79e-72	Multiple system atrophy;
CRC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.81	0.48	4.41e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg04165759	chr1:150448943	RPRD2	0.34	5.68	0.3	2.98e-8	Migraine;
CRC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-6.39	-0.33	5.63e-10	Immature fraction of reticulocytes;
CRC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-9.4	-0.46	9.71e-19	Monocyte percentage of white cells;
CRC	cis	rs1190552	0.846	rs11160683	chr14:102933347	A/G	cg18135206	chr14:102964638	TECPR2	0.51	6.19	0.32	1.76e-9	Blood protein levels;
CRC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.64	-10.44	-0.5	3.06e-22	Dental caries;
CRC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg15790184	chr11:494944	RNH1	0.6	6.17	0.32	1.95e-9	Body mass index;
CRC	cis	rs6429082	0.871	rs6675944	chr1:235572669	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	6.0	0.31	5.28e-9	Adiposity;
CRC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	8.31	0.42	2.54e-15	Height;
CRC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.49	6.94	0.36	2.08e-11	Schizophrenia;
CRC	cis	rs17767392	0.595	rs17177822	chr14:71656209	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.66	-0.3	3.27e-8	Mitral valve prolapse;
CRC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg00129232	chr17:37814104	STARD3	-0.43	-6.9	-0.36	2.67e-11	Self-reported allergy;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg12273811	chr6:28175739	NA	0.51	5.71	0.3	2.51e-8	Parkinson's disease;
CRC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.68	-6.57	-0.34	1.92e-10	Tuberculosis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg24511898	chr2:242576823	ATG4B;THAP4	-0.52	-6.46	-0.34	3.81e-10	Diisocyanate-induced asthma;
CRC	cis	rs12050794	0.636	rs4506844	chr15:72509138	C/T	cg16672083	chr15:72433130	SENP8	0.41	5.99	0.31	5.57e-9	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2274273	0.624	rs66464079	chr14:55766164	G/T	cg10130446	chr14:55658398	DLGAP5	-0.4	-5.67	-0.3	3.14e-8	Protein biomarker;
CRC	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.58	-8.36	-0.42	1.8e-15	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg02659138	chr7:134003124	SLC35B4	0.38	6.51	0.34	2.78e-10	Mean platelet volume;
CRC	cis	rs720844	0.684	rs7578059	chr2:149312470	G/A	cg09247360	chr2:149335327	NA	-0.58	-6.04	-0.32	4.12e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg11266682	chr4:10021025	SLC2A9	0.35	6.23	0.32	1.4e-9	Blood metabolite levels;
CRC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg11663144	chr21:46675770	NA	-0.68	-10.68	-0.51	4.68e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.82	-0.31	1.43e-8	Asthma;
CRC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.42	0.33	4.68e-10	Platelet count;
CRC	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.71	-11.07	-0.52	2.02e-24	Type 2 diabetes;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg12172441	chr6:28176163	NA	0.53	7.34	0.38	1.64e-12	Parkinson's disease;
CRC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.67	7.15	0.37	5.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg05527609	chr1:210001259	C1orf107	-0.44	-5.91	-0.31	8.38e-9	Monobrow;
CRC	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg23100626	chr2:96804247	ASTL	0.27	7.18	0.37	4.68e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg23394480	chr14:105487615	CDCA4	-0.41	-6.19	-0.32	1.84e-9	Myopia (pathological);
CRC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.5	0.54	5.78e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02904365	chr1:6761379	DNAJC11	0.44	6.3	0.33	9.71e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg10677697	chr7:45961126	IGFBP3	0.35	6.1	0.32	2.92e-9	Sitting height ratio;
CRC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-9.96	-0.48	1.36e-20	Prostate cancer;
CRC	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg06223162	chr1:101003688	GPR88	0.34	6.32	0.33	8.46e-10	Monocyte count;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.58	6.24	0.33	1.33e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.71	11.02	0.52	2.95e-24	Immature fraction of reticulocytes;
CRC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg10298567	chr3:47292165	KIF9	-0.36	-5.96	-0.31	6.6e-9	Colorectal cancer;
CRC	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.66	-7.68	-0.39	1.8e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.69	-0.39	1.7e-13	Gut microbiome composition (summer);
CRC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg24046110	chr8:143859143	LYNX1	-0.54	-9.74	-0.47	7.55e-20	Urinary tract infection frequency;
CRC	cis	rs427941	0.632	rs201493	chr7:101754865	T/C	cg06246474	chr7:101738831	CUX1	0.42	6.33	0.33	7.92e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.84	-0.31	1.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.51	-6.73	-0.35	7.63e-11	Glioblastoma;
CRC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.68	0.7	1.2e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.67	-11.29	-0.53	3.27e-25	White blood cell count (basophil);
CRC	cis	rs17155006	0.746	rs419031	chr7:107750157	G/A	cg05962710	chr7:107745446	LAMB4	-0.41	-7.33	-0.37	1.77e-12	Pneumococcal bacteremia;
CRC	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.51	-8.22	-0.41	4.87e-15	Caffeine consumption;
CRC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.54	7.93	0.4	3.56e-14	Lung cancer;
CRC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.89	9.19	0.45	4.58e-18	Arsenic metabolism;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12172441	chr6:28176163	NA	0.52	7.21	0.37	3.9e-12	Cardiac Troponin-T levels;
CRC	cis	rs17162190	0.685	rs7530096	chr1:26820218	G/A	cg17456097	chr1:26900765	RPS6KA1	0.45	6.22	0.32	1.55e-9	Mean corpuscular volume;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-11.9	-0.55	2.14e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg11886554	chr3:170076028	SKIL	0.69	8.07	0.41	1.32e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.79	0.51	1.94e-23	Exhaled nitric oxide output;
CRC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-6.88	-0.35	3.01e-11	Longevity;Endometriosis;
CRC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg20885578	chr2:198174922	NA	-0.41	-7.39	-0.38	1.24e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg09218773	chr11:619014	MUPCDH	-0.36	-5.67	-0.3	3.2e-8	Systemic lupus erythematosus;
CRC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	0.73	8.07	0.41	1.31e-14	Gout;Renal underexcretion gout;
CRC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg05192639	chr6:26864778	GUSBL1	-0.35	-6.11	-0.32	2.79e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.58	9.01	0.44	1.7e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.79	-0.44	8.78e-17	Response to antipsychotic treatment;
CRC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg03959625	chr15:84868606	LOC388152	0.42	6.36	0.33	6.88e-10	Schizophrenia;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg04518342	chr5:131593106	PDLIM4	0.44	7.22	0.37	3.59e-12	Breast cancer;
CRC	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg12365402	chr11:9010492	NRIP3	-0.57	-10.29	-0.49	1.01e-21	Hemoglobin concentration;
CRC	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.64	-10.63	-0.51	7.03e-23	Colorectal cancer;
CRC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.76	-11.55	-0.54	3.93e-26	Mean platelet volume;Platelet distribution width;
CRC	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	1.0	18.97	0.72	1.01e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs7932354	0.528	rs1060573	chr11:47179829	A/G	cg03339077	chr11:47165057	C11orf49	0.46	6.44	0.33	4.28e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.43	-0.33	4.54e-10	Menopause (age at onset);
CRC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.52	-0.38	5.36e-13	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15805921	chr6:42952109	PPP2R5D	0.44	6.41	0.33	5.12e-10	Response to antipsychotic treatment;
CRC	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.58	8.78	0.44	9.41e-17	Schizophrenia;
CRC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-9.2	-0.45	4.31e-18	Body mass index;
CRC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08089702	chr22:21822289	NA	0.48	6.83	0.35	4.2e-11	Response to antipsychotic treatment;
CRC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.31	-6.92	-0.36	2.34e-11	IgG glycosylation;
CRC	cis	rs3762318	1.000	rs3762318	chr1:67597119	A/G	cg17031739	chr1:67600172	NA	-0.5	-6.01	-0.31	4.82e-9	Leprosy;
CRC	cis	rs7926971	0.756	rs4633453	chr11:12660424	C/G	cg25843174	chr11:12811716	TEAD1	-0.33	-6.05	-0.32	4.02e-9	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01594214	chr6:123110554	SMPDL3A	-0.41	-6.09	-0.32	3.16e-9	Myopia (pathological);
CRC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.25	-0.33	1.27e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg09873164	chr1:152488093	CRCT1	0.34	5.74	0.3	2.16e-8	Hair morphology;
CRC	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-12.01	-0.55	8.16e-28	Exhaled nitric oxide output;
CRC	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg26769984	chr7:1090371	C7orf50	0.47	6.83	0.35	4.19e-11	Bronchopulmonary dysplasia;
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14863265	chr7:2801509	GNA12	-0.41	-5.62	-0.3	4.02e-8	Height;
CRC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.39	-6.31	-0.33	9.05e-10	Platelet distribution width;
CRC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.61	-9.3	-0.46	1.95e-18	Body mass index;
CRC	cis	rs9463078	0.774	rs3923353	chr6:45256482	C/G	cg25276700	chr6:44698697	NA	-0.27	-6.45	-0.33	4.11e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.5	-7.0	-0.36	1.48e-11	Multiple sclerosis;
CRC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13970591	chr19:1491289	REEP6;PCSK4	-0.53	-6.24	-0.33	1.35e-9	Monocyte percentage of white cells;
CRC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.91	-17.24	-0.69	6.89e-48	Coronary artery disease;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.7	-0.43	1.66e-16	Bipolar disorder;
CRC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg21466736	chr12:48725269	NA	-0.52	-7.93	-0.4	3.39e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg16558177	chr4:4109446	NA	-0.56	-6.7	-0.35	8.94e-11	Blood pressure (smoking interaction);
CRC	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg15711740	chr2:61764176	XPO1	-0.53	-7.21	-0.37	3.75e-12	Tuberculosis;
CRC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	6.91	0.36	2.53e-11	Lung cancer in ever smokers;
CRC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg16606324	chr3:10149918	C3orf24	0.7	9.66	0.47	1.31e-19	Alzheimer's disease;
CRC	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.4	-5.68	-0.3	2.97e-8	Intelligence;
CRC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14895029	chr7:2775587	GNA12	0.43	6.15	0.32	2.21e-9	Height;
CRC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.46	0.53	8.58e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-8.05	-0.41	1.55e-14	Mean corpuscular volume;
CRC	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.66	6.0	0.31	5.14e-9	IgG glycosylation;
CRC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.63	-11.25	-0.53	4.52e-25	Coronary artery disease;
CRC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.74	9.36	0.46	1.27e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4803480	0.678	rs3745936	chr19:42092815	T/A	cg08478046	chr19:42093086	CEACAM21	-0.31	-6.08	-0.32	3.34e-9	Schizophrenia;
CRC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.38	6.54	0.34	2.33e-10	Crohn's disease;
CRC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.44	-5.81	-0.3	1.51e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg21724239	chr8:58056113	NA	0.47	5.91	0.31	8.44e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg01193554	chr1:41846683	NA	-0.38	-6.09	-0.32	3.13e-9	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg23590916	chr17:43697445	MGC57346	-0.57	-6.14	-0.32	2.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.84	10.5	0.5	1.99e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.86	14.68	0.63	7.08e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	12.29	0.56	8.1e-29	Platelet count;
CRC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.74	-0.47	7.21e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5498	0.809	rs62130684	chr19:10408427	C/T	cg10604476	chr19:10403908	ICAM5	0.3	5.66	0.3	3.21e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CRC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg06740227	chr12:86229804	RASSF9	0.39	5.86	0.31	1.09e-8	Major depressive disorder;
CRC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.23	0.53	5.46e-25	Tonsillectomy;
CRC	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.38	-0.46	1.11e-18	Urate levels in obese individuals;
CRC	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-0.76	-7.53	-0.38	4.91e-13	Magnesium levels;
CRC	cis	rs2274273	0.624	rs67795323	chr14:55797833	G/A	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.74	-0.3	2.21e-8	Protein biomarker;
CRC	trans	rs8108034	1.000	rs39587	chr19:39806997	C/T	cg15120146	chr6:42897303	CNPY3	-0.56	-6.1	-0.32	3.04e-9	Lung adenocarcinoma;
CRC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.52	7.15	0.37	5.72e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg19640130	chr10:64028056	RTKN2	-0.34	-5.6	-0.3	4.51e-8	Rheumatoid arthritis;
CRC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.34	-6.84	-0.35	3.97e-11	Alzheimer's disease (late onset);
CRC	cis	rs4716602	0.596	rs12386634	chr7:156158373	G/A	cg16983916	chr7:156159713	NA	-0.39	-6.91	-0.36	2.45e-11	Anti-saccade response;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16794633	chr3:143690145	C3orf58	-0.43	-6.47	-0.34	3.61e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05477933	chr12:54426537	HOXC4;HOXC5	0.47	6.64	0.34	1.33e-10	Response to antipsychotic treatment;
CRC	cis	rs1434579	0.966	rs1062098	chr19:44930738	A/G	cg15540054	chr19:45004280	ZNF180	0.48	6.11	0.32	2.76e-9	Tuberculosis;
CRC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.49	-6.49	-0.34	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.4	6.63	0.34	1.38e-10	Height;
CRC	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	10.03	0.48	8.13e-21	Fuchs's corneal dystrophy;
CRC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg10130564	chr11:117069849	TAGLN	0.38	7.1	0.36	7.69e-12	Blood protein levels;
CRC	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg02560186	chr11:3602584	NA	-0.5	-5.99	-0.31	5.46e-9	Blood pressure (smoking interaction);
CRC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg20573242	chr4:122745356	CCNA2	0.41	6.1	0.32	3.01e-9	Type 2 diabetes;
CRC	cis	rs4664293	0.867	rs12620924	chr2:160602963	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.52	-0.38	5.32e-13	Monocyte percentage of white cells;
CRC	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.5	6.94	0.36	2.05e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.85	-14.46	-0.62	4.99e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.29	0.42	2.85e-15	Homoarginine levels;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-6.26	-0.33	1.22e-9	Coronary artery disease;
CRC	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-6.92	-0.36	2.31e-11	Morning vs. evening chronotype;
CRC	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg15192750	chr16:69999425	NA	0.47	6.57	0.34	2e-10	IgE levels;
CRC	cis	rs185694	1.000	rs613291	chr13:30894404	T/C	cg04551440	chr13:30881194	KATNAL1	-0.63	-6.5	-0.34	2.97e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg00129232	chr17:37814104	STARD3	-0.47	-7.39	-0.38	1.25e-12	Self-reported allergy;
CRC	cis	rs231513	0.911	rs231476	chr17:41985845	A/G	cg26893861	chr17:41843967	DUSP3	-0.63	-6.05	-0.32	4.02e-9	Cognitive function;
CRC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg18876405	chr7:65276391	NA	-0.46	-6.3	-0.33	9.31e-10	Aortic root size;
CRC	cis	rs3764400	0.567	rs208012	chr17:46258017	G/A	cg10706073	chr17:46328419	SKAP1	0.59	6.55	0.34	2.21e-10	Body mass index;
CRC	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg27398640	chr15:77910606	LINGO1	0.44	8.08	0.41	1.26e-14	Type 2 diabetes;
CRC	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg16964102	chr10:135390573	NA	0.45	7.61	0.39	2.9e-13	Obesity-related traits;
CRC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.52e-18	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg21153622	chr11:89784906	NA	-0.47	-7.53	-0.38	4.94e-13	HDL cholesterol;
CRC	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	1.12	13.05	0.58	1.19e-31	Obesity-related traits;
CRC	trans	rs11800820	0.595	rs3124127	chr1:246710987	C/T	cg26885821	chr6:124125002	NKAIN2	0.37	6.04	0.32	4.26e-9	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg05569086	chr8:143859399	LYNX1	0.4	6.96	0.36	1.91e-11	Urinary tract infection frequency;
CRC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg14530993	chr4:882597	GAK	0.83	7.53	0.38	4.82e-13	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-6.99	-0.36	1.57e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.84	13.94	0.61	4.86e-35	Tonsillectomy;
CRC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg03037974	chr15:76606532	NA	0.69	12.16	0.56	2.4e-28	Blood metabolite levels;
CRC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.72	-8.37	-0.42	1.71e-15	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.41	5.95	0.31	6.88e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.68	9.94	0.48	1.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg03013999	chr17:37608204	MED1	-0.47	-7.21	-0.37	3.87e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00166722	chr3:10149974	C3orf24	0.65	7.69	0.39	1.73e-13	Alzheimer's disease;
CRC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg12223502	chr10:5658492	NA	-0.35	-5.71	-0.3	2.51e-8	Breast cancer;
CRC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.99	-0.55	9.67e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.65	0.57	3.81e-30	Alzheimer's disease;
CRC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.36	0.46	1.32e-18	Parkinson's disease;
CRC	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.67	10.67	0.51	4.99e-23	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.67	-0.3	3.18e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg24849736	chr1:201084428	NA	0.5	6.82	0.35	4.51e-11	Permanent tooth development;
CRC	cis	rs9462027	0.675	rs34657938	chr6:34801631	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.79	7.9	0.4	4.24e-14	Diabetic retinopathy;
CRC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg22777020	chr22:31556080	RNF185	0.55	6.28	0.33	1.08e-9	Colorectal cancer;
CRC	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	21.03	0.76	7.79e-63	Exhaled nitric oxide output;
CRC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.19	0.32	1.75e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11645453	chr3:52864694	ITIH4	0.37	6.53	0.34	2.57e-10	Electroencephalogram traits;
CRC	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg10263370	chr3:44754102	ZNF502	-0.36	-6.08	-0.32	3.31e-9	Depressive symptoms;
CRC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.56	8.4	0.42	1.33e-15	Tuberculosis;
CRC	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.11	0.52	1.46e-24	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.41	-8.72	-0.43	1.42e-16	Alcohol dependence;
CRC	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	cg04338863	chr8:33670619	NA	0.4	6.84	0.35	3.8e-11	Body mass index;
CRC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.53	-8.85	-0.44	5.57e-17	Aortic root size;
CRC	cis	rs747650	0.504	rs11039080	chr11:47093084	T/C	cg19486271	chr11:47235900	DDB2	0.44	5.86	0.31	1.11e-8	Acne (severe);
CRC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.24	-0.41	4.21e-15	Gut microbiome composition (summer);
CRC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.57	-8.37	-0.42	1.64e-15	Dental caries;
CRC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.23	0.45	3.47e-18	Bladder cancer;
CRC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.49	7.57	0.39	3.72e-13	Red blood cell count;
CRC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.55	8.07	0.41	1.29e-14	Fibrinogen levels;
CRC	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.64	8.69	0.43	1.78e-16	Uric acid levels;
CRC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.68	9.46	0.46	6.05e-19	Vitiligo;
CRC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg09998033	chr7:158218633	PTPRN2	-0.58	-7.99	-0.4	2.25e-14	Obesity-related traits;
CRC	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.63	8.67	0.43	2.02e-16	Coronary artery disease;
CRC	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.17	-18.5	-0.71	6.94e-53	Atopic dermatitis;
CRC	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg12072164	chr19:44306565	LYPD5	-0.39	-6.3	-0.33	9.43e-10	Breast cancer;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg01045622	chr10:79686064	LOC100128292;DLG5	0.43	6.03	0.32	4.29e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.97	18.91	0.72	1.7e-54	Cognitive ability;
CRC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg16989086	chr20:62203971	PRIC285	0.46	5.93	0.31	7.87e-9	Glioblastoma;
CRC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.68	11.15	0.52	1.09e-24	Colorectal cancer;
CRC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.37	-8.82	-0.44	6.68e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1712517	0.873	rs7903004	chr10:105004101	G/A	cg05636881	chr10:105038444	INA	-0.47	-8.34	-0.42	2.11e-15	Migraine;
CRC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.56	-0.47	2.87e-19	Hip circumference adjusted for BMI;
CRC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg06970220	chr1:156163860	SLC25A44	0.43	6.24	0.33	1.35e-9	Testicular germ cell tumor;
CRC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.67	0.51	4.95e-23	Prudent dietary pattern;
CRC	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.64	-8.99	-0.44	1.99e-17	Psoriasis;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.98	-0.52	4.02e-24	Electroencephalogram traits;
CRC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.59	8.37	0.42	1.64e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.06	0.48	6.25e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg26353448	chr1:248524236	OR2T4	-0.3	-5.63	-0.3	3.78e-8	Common traits (Other);
CRC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06634786	chr22:41940651	POLR3H	-0.41	-5.81	-0.31	1.45e-8	Vitiligo;
CRC	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.55	-6.59	-0.34	1.8e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CRC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.39	6.98	0.36	1.61e-11	Rheumatoid arthritis;
CRC	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.5	7.32	0.37	1.9e-12	Night sleep phenotypes;
CRC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.9	12.93	0.58	3.34e-31	Triglycerides;
CRC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg01721255	chr8:58191610	C8orf71	0.49	6.08	0.32	3.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg26816564	chr1:7831052	VAMP3	-0.48	-5.76	-0.3	1.97e-8	Inflammatory bowel disease;
CRC	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg02428538	chr16:24856791	SLC5A11	0.63	7.18	0.37	4.61e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.95	-0.31	7.03e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs860295	0.702	rs34124416	chr1:155578049	C/G	cg02153340	chr1:155202674	NA	-0.51	-6.37	-0.33	6.34e-10	Body mass index;
CRC	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.43	6.14	0.32	2.41e-9	Diastolic blood pressure;
CRC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-6.45	-0.34	3.92e-10	Tonsillectomy;
CRC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.79	0.3	1.64e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.46	6.79	0.35	5.23e-11	Menarche (age at onset);
CRC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.61	9.54	0.47	3.35e-19	Corneal astigmatism;
CRC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.75	0.39	1.17e-13	Red blood cell count;
CRC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.59e-11	Primary biliary cholangitis;
CRC	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg23387468	chr7:139079360	LUC7L2	0.4	7.14	0.37	5.84e-12	Diisocyanate-induced asthma;
CRC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.54	-8.53	-0.43	5.46e-16	Motion sickness;
CRC	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg09873164	chr1:152488093	CRCT1	0.36	6.13	0.32	2.48e-9	Hair morphology;
CRC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.31	-0.37	2.1e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.45	6.31	0.33	9.24e-10	Diastolic blood pressure;
CRC	cis	rs9467160	0.520	rs9379660	chr6:24441635	C/G	cg20631270	chr6:24437470	GPLD1	0.45	7.13	0.37	6.46e-12	Liver enzyme levels;
CRC	cis	rs747650	0.884	rs7128325	chr11:47046554	G/A	cg03339077	chr11:47165057	C11orf49	0.44	6.08	0.32	3.36e-9	Acne (severe);
CRC	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.73	9.19	0.45	4.62e-18	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.42	6.56	0.34	2.04e-10	Pulmonary function decline;
CRC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.38	-7.93	-0.4	3.53e-14	Schizophrenia;
CRC	cis	rs2617583	0.530	rs905201	chr5:1457986	C/T	cg07148919	chr5:1466943	LPCAT1	-0.42	-5.72	-0.3	2.39e-8	Breast cancer;
CRC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.46	-6.71	-0.35	8.75e-11	Uric acid clearance;
CRC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg09179987	chr1:167433047	CD247	-0.53	-7.83	-0.4	6.75e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03982443	chr3:128968543	COPG	0.46	6.31	0.33	9.01e-10	Response to antipsychotic treatment;
CRC	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg23609528	chr2:113191194	RGPD5;RGPD8	0.66	5.67	0.3	3.18e-8	Yeast infection;
CRC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.39	7.56	0.38	3.96e-13	Mean corpuscular volume;
CRC	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.66	-0.39	2.04e-13	Thrombosis;
CRC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg26043149	chr18:55253948	FECH	0.48	7.35	0.38	1.54e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg02659138	chr7:134003124	SLC35B4	0.36	6.19	0.32	1.77e-9	Mean platelet volume;
CRC	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg27534772	chr1:16042836	PLEKHM2	0.45	7.63	0.39	2.52e-13	Systolic blood pressure;
CRC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg17633681	chr16:88106987	BANP	0.87	16.24	0.67	5.81e-44	Menopause (age at onset);
CRC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs10512697	0.803	rs13187916	chr5:3580499	A/G	cg19473799	chr5:3511975	NA	-0.7	-5.7	-0.3	2.71e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.42	6.14	0.32	2.32e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	9.15	0.45	6.22e-18	Parkinson's disease;
CRC	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.47	6.44	0.33	4.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs62432291	0.681	rs400477	chr6:159635943	A/C	cg14500486	chr6:159655392	FNDC1	0.78	10.53	0.5	1.56e-22	Joint mobility (Beighton score);
CRC	cis	rs11212617	0.967	rs228592	chr11:108123189	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.44	6.48	0.34	3.29e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg01483505	chr11:975446	AP2A2	0.43	6.91	0.36	2.5e-11	Alzheimer's disease (late onset);
CRC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg20684491	chr1:25596433	NA	-0.44	-7.84	-0.4	6.12e-14	Erythrocyte sedimentation rate;
CRC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.59	9.16	0.45	5.68e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-6.02	-0.32	4.65e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg05347473	chr6:146136440	FBXO30	0.37	5.91	0.31	8.46e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg12573674	chr2:1569213	NA	-0.77	-7.94	-0.4	3.17e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-6.15	-0.32	2.29e-9	Carotid intima media thickness;
CRC	cis	rs17767392	0.958	rs4140797	chr14:72162978	T/C	cg13720639	chr14:72061746	SIPA1L1	0.58	7.19	0.37	4.43e-12	Mitral valve prolapse;
CRC	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-6.13	-0.32	2.56e-9	Response to antipsychotic treatment;
CRC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	16.82	0.68	3.13e-46	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05918682	chr3:127267038	NA	0.43	6.41	0.33	5.09e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17322444	chr19:33572249	GPATCH1	0.46	6.49	0.34	3.15e-10	Response to antipsychotic treatment;
CRC	cis	rs2346268	0.605	rs13310832	chr7:133646213	T/G	cg03336402	chr7:133662267	EXOC4	-0.66	-10.33	-0.49	7.44e-22	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	5.78	0.3	1.73e-8	Cystic fibrosis severity;
CRC	cis	rs7259376	0.936	rs7256749	chr19:22592289	A/G	cg02657401	chr19:22469223	NA	0.3	6.56	0.34	2.07e-10	Menopause (age at onset);
CRC	cis	rs4731207	0.724	rs4146110	chr7:124561208	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.02	-0.31	4.78e-9	Cutaneous malignant melanoma;
CRC	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.45	-0.34	3.98e-10	Breast cancer;
CRC	cis	rs13082711	0.911	rs7637211	chr3:27419868	C/T	cg02860705	chr3:27208620	NA	0.63	8.88	0.44	4.57e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.79	0.39	9.11e-14	Corneal astigmatism;
CRC	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.73	11.64	0.54	1.85e-26	Plateletcrit;Platelet count;
CRC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.85	0.35	3.63e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.59	11.45	0.53	9.32e-26	Coronary artery disease;
CRC	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg03315344	chr16:75512273	CHST6	-0.5	-6.06	-0.32	3.83e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.92	15.21	0.64	5.94e-40	Menarche (age at onset);
CRC	cis	rs2565722	0.583	rs2465841	chr6:161295154	C/T	cg03159191	chr6:161285451	NA	-0.39	-6.0	-0.31	5.09e-9	Blood protein levels;
CRC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-7.94	-0.4	3.29e-14	Pancreatic cancer;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	11.16	0.52	1.01e-24	Alzheimer's disease;
CRC	cis	rs3026101	0.671	rs1806249	chr17:5311143	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.87	0.35	3.16e-11	Body mass index;
CRC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.82	14.81	0.63	2.23e-38	Vitiligo;
CRC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	2.92e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg12700464	chr11:78128424	GAB2	-0.47	-5.76	-0.3	1.96e-8	Testicular germ cell tumor;
CRC	cis	rs10155981	0.510	rs28439106	chr7:22592349	T/C	cg05062323	chr7:22590069	NA	-0.56	-5.85	-0.31	1.16e-8	Bilirubin levels;
CRC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.53	7.67	0.39	1.95e-13	Colorectal cancer;
CRC	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.48	6.63	0.34	1.36e-10	White matter microstructure (global fractional anisotropy);
CRC	trans	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.48	-7.0	-0.36	1.41e-11	Endometrial cancer;
CRC	trans	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg18187862	chr3:45730750	SACM1L	-0.46	-6.72	-0.35	7.8e-11	Primary sclerosing cholangitis;
CRC	cis	rs6534441	0.857	rs55698707	chr4:125456502	T/C	cg21609808	chr4:125404261	NA	0.39	5.83	0.31	1.3e-8	Major depressive disorder;
CRC	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.62	-0.39	2.8e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs3760982	1.000	rs11669175	chr19:44289824	A/G	cg21496419	chr19:44306685	LYPD5	0.34	6.46	0.34	3.68e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.76	-0.3	1.89e-8	Breast cancer;
CRC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.85	-0.35	3.58e-11	Cystic fibrosis severity;
CRC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.61	-7.46	-0.38	7.6e-13	Mean platelet volume;
CRC	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.53	8.44	0.42	9.98e-16	Sum neutrophil eosinophil counts;
CRC	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.58	-9.26	-0.45	2.66e-18	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg16447950	chr5:562315	NA	0.84	11.51	0.54	5.31e-26	Lung disease severity in cystic fibrosis;
CRC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.28	-0.37	2.5e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg24375607	chr4:120327624	NA	0.45	7.41	0.38	1.04e-12	Corneal astigmatism;
CRC	trans	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg18335740	chr13:41363409	SLC25A15	0.52	7.58	0.39	3.53e-13	Lewy body disease;
CRC	cis	rs2933343	0.553	rs35076317	chr3:128715535	T/C	cg11901034	chr3:128598214	ACAD9	-0.53	-7.12	-0.37	7e-12	IgG glycosylation;
CRC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.54	-7.07	-0.36	9.56e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg02683197	chr6:28174875	NA	0.75	9.8	0.48	4.46e-20	Parkinson's disease;
CRC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.39	-6.43	-0.33	4.59e-10	HDL cholesterol;
CRC	cis	rs6445525	0.967	rs7648741	chr3:65996570	T/C	cg06109867	chr3:66002991	MAGI1	-0.39	-6.41	-0.33	5.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11296937	chr11:64084966	PRDX5;TRMT112	0.48	7.72	0.39	1.37e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.48	8.02	0.4	1.82e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg16402443	chr7:2598526	IQCE	0.41	5.99	0.31	5.65e-9	Monocyte count;
CRC	cis	rs863345	0.584	rs10908676	chr1:158506163	C/G	cg12129480	chr1:158549410	OR10X1	-0.3	-6.31	-0.33	8.92e-10	Pneumococcal bacteremia;
CRC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02228675	chr17:40259724	DHX58	-0.5	-6.99	-0.36	1.57e-11	Fibrinogen levels;
CRC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.43	0.46	7.79e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.71	7.93	0.4	3.5e-14	Eotaxin levels;
CRC	cis	rs910187	0.641	rs3818010	chr20:45816562	A/G	cg27589058	chr20:45804311	EYA2	-0.39	-7.51	-0.38	5.63e-13	Migraine;
CRC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.81	13.57	0.6	1.26e-33	Menopause (age at onset);
CRC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.51	-8.06	-0.41	1.4e-14	Body mass index;
CRC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.53	-11.2	-0.53	7.21e-25	Intelligence (multi-trait analysis);
CRC	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.4	6.07	0.32	3.62e-9	Lung function (FEV1/FVC);
CRC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg25876840	chr17:41920477	NA	0.44	6.42	0.33	4.88e-10	Triglycerides;
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg04969067	chr8:143858791	LYNX1	-0.41	-6.19	-0.32	1.81e-9	Urinary tract infection frequency;
CRC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17507749	chr15:85114479	UBE2QP1	0.65	9.29	0.46	2.15e-18	Schizophrenia;
CRC	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.04e-8	Iron status biomarkers (total iron binding capacity);
CRC	trans	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.79	-0.35	5.1e-11	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.56	6.27	0.33	1.15e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	9.36	0.46	1.27e-18	IgG glycosylation;
CRC	trans	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg17903999	chr18:56338584	MALT1	0.41	6.77	0.35	5.9e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.6	10.52	0.5	1.63e-22	Schizophrenia;
CRC	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg00373020	chr1:21041521	KIF17	0.39	6.04	0.32	4.19e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.39	-0.38	1.21e-12	Mood instability;
CRC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	5.64	0.3	3.61e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.77	-8.71	-0.43	1.53e-16	Lung disease severity in cystic fibrosis;
CRC	cis	rs1109861	0.538	rs10905907	chr10:11219411	T/A	cg24910943	chr10:11206320	CUGBP2	0.33	8.76	0.43	1.07e-16	Urinary albumin-to-creatinine ratio;
CRC	cis	rs59104589	0.617	rs3755395	chr2:242294116	A/G	cg19488206	chr2:242435732	STK25	0.45	6.05	0.32	3.85e-9	Fibrinogen levels;
CRC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.59	8.98	0.44	2.14e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-6.03	-0.32	4.51e-9	Protein C levels;
CRC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.72	11.95	0.55	1.38e-27	Mean platelet volume;
CRC	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-6.94	-0.36	2.05e-11	Major depressive disorder;
CRC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.58	-9.96	-0.48	1.37e-20	Menarche (age at onset);
CRC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18867708	chr6:26865862	GUSBL1	-0.41	-5.72	-0.3	2.34e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.72	11.21	0.53	6.63e-25	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13047869	chr3:10149882	C3orf24	0.52	7.04	0.36	1.15e-11	Alzheimer's disease;
CRC	cis	rs73195822	0.614	rs17793540	chr12:111215575	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	7.22	0.37	3.66e-12	Itch intensity from mosquito bite;
CRC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.48	7.39	0.38	1.21e-12	Motion sickness;
CRC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg03030879	chr14:75389066	RPS6KL1	0.38	5.79	0.3	1.67e-8	IgG glycosylation;
CRC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg04731861	chr2:219085781	ARPC2	0.34	6.78	0.35	5.57e-11	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs4547160	0.606	rs12828712	chr12:63475233	G/C	cg26727693	chr12:63544175	AVPR1A	-0.41	-7.44	-0.38	8.64e-13	Morning vs. evening chronotype;
CRC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.19	0.69	1.02e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.94	-0.31	7.38e-9	Cognitive function;
CRC	cis	rs995000	0.965	rs10789116	chr1:63042738	A/G	cg19896129	chr1:63156450	NA	0.39	5.72	0.3	2.39e-8	Triglyceride levels;
CRC	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14895029	chr7:2775587	GNA12	-0.48	-7.03	-0.36	1.21e-11	Height;
CRC	trans	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.59	-0.39	3.28e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.5	-7.38	-0.38	1.27e-12	Blood protein levels;
CRC	cis	rs68149176	0.772	rs997761	chr16:87879522	A/C	cg03553613	chr16:87879502	SLC7A5	0.56	7.55	0.38	4.19e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.63	11.36	0.53	1.92e-25	Breast cancer;
CRC	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.59	8.58	0.43	3.87e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.37	6.35	0.33	7.08e-10	Height;
CRC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.49	7.08	0.36	8.56e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07355551	chr20:2489285	ZNF343	-0.51	-6.25	-0.33	1.31e-9	Diisocyanate-induced asthma;
CRC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.63	-0.3	3.81e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.65	-0.34	1.22e-10	Total body bone mineral density;
CRC	cis	rs13315871	1.000	rs71311870	chr3:58399283	T/C	cg20936604	chr3:58311152	NA	-0.75	-7.14	-0.37	5.96e-12	Cholesterol, total;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg15845792	chr6:28175446	NA	0.8	11.85	0.55	3.12e-27	Parkinson's disease;
CRC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	10.27	0.49	1.24e-21	Alzheimer's disease (late onset);
CRC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.52	-8.25	-0.41	3.79e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-6.86	-0.35	3.5e-11	Bipolar disorder;
CRC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg00343986	chr7:65444356	GUSB	0.43	6.05	0.32	3.87e-9	Aortic root size;
CRC	cis	rs2857891	0.650	rs2638087	chr11:6990516	C/T	cg04053776	chr11:6947353	ZNF215	0.42	6.37	0.33	6.33e-10	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.51	7.1	0.36	7.55e-12	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01766191	chr11:57103423	SSRP1	0.4	6.4	0.33	5.34e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.71	11.15	0.52	1.06e-24	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.27	-6.38	-0.33	5.95e-10	Urate levels in overweight individuals;
CRC	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg00507830	chr2:103233733	NA	0.58	6.05	0.32	3.86e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12273811	chr6:28175739	NA	-0.68	-8.28	-0.42	3.04e-15	Depression;
CRC	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg12855166	chr17:30846586	MYO1D	-0.38	-6.15	-0.32	2.22e-9	Schizophrenia;
CRC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.48	-7.39	-0.38	1.22e-12	Coronary artery disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05787931	chr3:52232012	ALAS1	0.4	6.21	0.32	1.6e-9	Obesity-related traits;
CRC	cis	rs2257205	0.667	rs28363312	chr17:56788293	C/A	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.7	-10.77	-0.51	2.3e-23	Type 2 diabetes;
CRC	cis	rs972578	0.776	rs2267464	chr22:43298646	T/G	cg01576275	chr22:43409880	NA	-0.42	-6.56	-0.34	2.1e-10	Mean platelet volume;
CRC	cis	rs9549328	0.542	rs36172983	chr13:113616582	T/C	cg25790453	chr13:113633590	MCF2L	0.43	7.55	0.38	4.25e-13	Systolic blood pressure;
CRC	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01490821	chr2:170684022	UBR3	0.42	6.01	0.31	4.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-9.64	-0.47	1.61e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.04	0.55	6.69e-28	Alzheimer's disease;
CRC	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-9.02	-0.45	1.59e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.05	-0.36	1.03e-11	Myopia (pathological);
CRC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg22676075	chr6:135203613	NA	0.42	6.47	0.34	3.54e-10	Red blood cell count;
CRC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.47	6.51	0.34	2.78e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.78	11.46	0.53	8.52e-26	Cognitive function;
CRC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg09165964	chr15:75287851	SCAMP5	0.49	7.74	0.39	1.2e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs9462027	0.517	rs2744973	chr6:34580221	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.82	-0.31	1.43e-8	Systemic lupus erythematosus;
CRC	cis	rs9903692	0.954	rs6847	chr17:46147807	A/T	cg21215337	chr17:46176117	CBX1	-0.41	-7.47	-0.38	7.48e-13	Pulse pressure;
CRC	cis	rs73206853	0.563	rs55885633	chr12:111189251	C/T	cg12870014	chr12:110450643	ANKRD13A	0.56	5.95	0.31	7.05e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Educational attainment;
CRC	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg17298326	chr8:142245477	NA	0.36	5.62	0.3	4e-8	Immature fraction of reticulocytes;
CRC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.25	0.53	4.55e-25	Prudent dietary pattern;
CRC	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg15147215	chr3:52552868	STAB1	0.39	5.89	0.31	9.57e-9	Schizophrenia;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.79	12.79	0.58	1.09e-30	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26559770	chr13:45563685	NUFIP1;KIAA1704	0.46	6.32	0.33	8.7e-10	Anxiety disorder;
CRC	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-8.0	-0.4	2.15e-14	Body mass index;
CRC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.63	8.57	0.43	3.97e-16	Smoking initiation;
CRC	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-7.22	-0.37	3.69e-12	Coronary artery disease;
CRC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg04969067	chr8:143858791	LYNX1	-0.42	-6.63	-0.34	1.42e-10	Urinary tract infection frequency;
CRC	cis	rs11212617	1.000	rs186593	chr11:108262439	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.64	0.34	1.3e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.5	9.41	0.46	8.79e-19	Reticulocyte fraction of red cells;
CRC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg23463467	chr20:60627584	TAF4	0.33	5.74	0.3	2.1e-8	Body mass index;
CRC	cis	rs2811415	0.627	rs9833276	chr3:127797793	T/C	cg13719885	chr3:127795394	NA	-0.4	-6.02	-0.32	4.57e-9	Lung function (FEV1/FVC);
CRC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02772935	chr3:125709198	NA	-0.49	-5.89	-0.31	9.34e-9	Blood pressure (smoking interaction);
CRC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.07	-0.52	2.04e-24	Type 2 diabetes;
CRC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.25	15.72	0.65	6.58e-42	Lung disease severity in cystic fibrosis;
CRC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.68	-9.25	-0.45	3.02e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg19500275	chr17:80737654	TBCD	0.51	6.82	0.35	4.37e-11	Glycated hemoglobin levels;
CRC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.22e-15	Morning vs. evening chronotype;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24883709	chr7:2595326	C7orf27	0.4	6.25	0.33	1.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.43	5.75	0.3	2.04e-8	Total body bone mineral density;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg03623178	chr6:28175578	NA	0.73	9.11	0.45	8.42e-18	Parkinson's disease;
CRC	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.98	20.12	0.74	2.92e-59	Metabolite levels;
CRC	cis	rs10924970	0.649	rs12753233	chr1:235487094	C/T	cg09010748	chr1:235293032	TOMM20	-0.4	-5.7	-0.3	2.69e-8	Asthma;
CRC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.62	-0.34	1.47e-10	Schizophrenia;
CRC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg17321639	chr7:2759063	NA	-0.53	-7.13	-0.37	6.31e-12	Height;
CRC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-6.56	-0.34	2.08e-10	Schizophrenia;
CRC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg13390004	chr1:15929781	NA	0.44	6.3	0.33	9.39e-10	Systolic blood pressure;
CRC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.33	-5.86	-0.31	1.14e-8	Rheumatoid arthritis;
CRC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	0.99	9.51	0.46	4.22e-19	IgG glycosylation;
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.78e-37	Extrinsic epigenetic age acceleration;
CRC	cis	rs447	1.000	rs447	chr7:83772415	A/G	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.62	-0.39	2.71e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.81	-0.4	7.99e-14	QT interval;
CRC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.33	-0.46	1.67e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.53	-0.47	3.63e-19	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18876494	chr12:69004196	RAP1B	0.41	6.6	0.34	1.7e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg23193639	chr7:45961078	IGFBP3	-0.45	-7.31	-0.37	1.98e-12	Sitting height ratio;
CRC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-7.57	-0.39	3.88e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.89	-16.41	-0.67	1.22e-44	Height;
CRC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.43	0.5	3.2800000000000002e-22	Ileal carcinoids;
CRC	cis	rs9322817	0.691	rs56075147	chr6:105337494	T/A	cg02098413	chr6:105308735	HACE1	0.46	9.22	0.45	3.78e-18	Thyroid stimulating hormone;
CRC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.52	-7.15	-0.37	5.72e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.63	8.08	0.41	1.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg09596707	chr12:66889730	GRIP1	-0.35	-5.99	-0.31	5.49e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7503807	0.515	rs12453034	chr17:78682756	G/A	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.86e-8	Obesity;
CRC	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg12160578	chr15:63334699	TPM1	0.63	7.53	0.38	5.02e-13	Orofacial clefts;
CRC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.68	7.74	0.39	1.2e-13	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg11693508	chr17:37793320	STARD3	0.61	7.79	0.39	8.82e-14	Neuroticism;
CRC	cis	rs17095355	1.000	rs17095350	chr10:111701708	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.02	-0.4	1.84e-14	Biliary atresia;
CRC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.9	17.01	0.68	5.36e-47	Blood protein levels;
CRC	cis	rs4478137	0.839	rs3967763	chr4:164239273	G/C	cg06758707	chr4:164254230	NPY1R	0.39	6.01	0.31	4.89e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	6.69	0.35	9.61e-11	Neuroticism;
CRC	cis	rs737008	0.922	rs28567501	chr16:11378928	C/A	cg00044050	chr16:11439710	C16orf75	-0.44	-5.98	-0.31	5.69e-9	Obesity-related traits;
CRC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg05501817	chr11:14380813	RRAS2	-0.46	-6.37	-0.33	6.21e-10	Sense of smell;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg23136738	chr11:925521	AP2A2	0.4	6.67	0.34	1.11e-10	Alzheimer's disease (late onset);
CRC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg20573242	chr4:122745356	CCNA2	0.42	6.25	0.33	1.27e-9	Type 2 diabetes;
CRC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.87	-11.85	-0.55	3.24e-27	Gut microbiome composition (summer);
CRC	cis	rs6662572	0.671	rs11211220	chr1:46365501	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.72	-0.3	2.4e-8	Blood protein levels;
CRC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.73	7.89	0.4	4.53e-14	Breast cancer;
CRC	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.69	8.18	0.41	6.39e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs9648716	1.000	rs6965532	chr7:140597516	G/C	cg10747023	chr7:140774559	NA	0.45	5.9	0.31	9.21e-9	Type 2 diabetes;
CRC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.42	-8.05	-0.41	1.49e-14	Ulcerative colitis;
CRC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-5.99	-0.31	5.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9976767	0.932	rs11910048	chr21:43822576	C/T	cg23042151	chr21:43824109	UBASH3A	-0.37	-6.5	-0.34	2.97e-10	Type 1 diabetes;
CRC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.68	10.22	0.49	1.71e-21	Corneal astigmatism;
CRC	cis	rs2882667	0.690	rs10044401	chr5:138237557	A/G	cg09476006	chr5:138032270	NA	0.55	9.14	0.45	6.76e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.67	10.9	0.52	7.94e-24	Schizophrenia;
CRC	cis	rs11212617	1.000	rs10431060	chr11:108288228	A/C	cg12106634	chr11:108092400	ATM;NPAT	0.41	6.08	0.32	3.34e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7835763	0.518	rs2445906	chr8:119106346	C/T	cg11592677	chr8:119110466	EXT1	-0.39	-6.45	-0.33	4.08e-10	Autism spectrum disorder;
CRC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg09264619	chr17:80180166	NA	-0.35	-5.83	-0.31	1.35e-8	Life satisfaction;
CRC	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg25876840	chr17:41920477	NA	-0.41	-6.58	-0.34	1.87e-10	Triglycerides;
CRC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.64	-7.38	-0.38	1.26e-12	Menarche (age at onset);
CRC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.54e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.59	-8.76	-0.43	1.05e-16	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06223186	chr7:1544111	INTS1	0.4	6.59	0.34	1.75e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs115344852	0.575	rs1015811	chr6:28448086	A/G	cg03623178	chr6:28175578	NA	0.48	5.8	0.3	1.57e-8	Epithelial ovarian cancer;
CRC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.83	-13.73	-0.6	3.03e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7619833	0.592	rs4973756	chr3:27248190	C/T	cg02860705	chr3:27208620	NA	0.38	5.94	0.31	7.08e-9	Breast cancer;
CRC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-10.02	-0.48	8.56e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-5.71	-0.3	2.49e-8	Longevity;
CRC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.95	0.36	1.95e-11	Cognitive test performance;
CRC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.56	6.43	0.33	4.54e-10	Gut microbiome composition (summer);
CRC	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	7.34	0.38	1.64e-12	Schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09060823	chr12:56862504	SPRYD4	-0.51	-6.17	-0.32	1.98e-9	Diisocyanate-induced asthma;
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.44	6.42	0.33	4.67e-10	Schizophrenia;
CRC	cis	rs780094	0.500	rs12473139	chr2:27765587	T/C	cg27432699	chr2:27873401	GPN1	0.47	6.08	0.32	3.26e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs9491140	0.539	rs11154232	chr6:124691494	G/A	cg22366943	chr6:124882293	NKAIN2	0.57	7.88	0.4	4.9e-14	Neuroticism;
CRC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.57	-8.37	-0.42	1.73e-15	Aortic root size;
CRC	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.4	-0.59	5.88e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.42e-11	Cholesterol, total;LDL cholesterol;
CRC	trans	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.71	0.35	8.68e-11	Ulcerative colitis;
CRC	cis	rs7487075	0.780	rs1873793	chr12:46761324	A/G	cg17501823	chr12:47219793	SLC38A4	-0.31	-5.6	-0.3	4.49e-8	Itch intensity from mosquito bite;
CRC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.81	12.21	0.56	1.56e-28	Cognitive function;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01243544	chr1:227916373	LOC100130093	0.42	5.96	0.31	6.32e-9	Response to antipsychotic treatment;
CRC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.43	7.25	0.37	3.06e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg00280220	chr17:61926910	NA	0.34	5.61	0.3	4.41e-8	Prudent dietary pattern;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10130860	chr1:43124230	PPIH	0.42	6.33	0.33	7.93e-10	Myopia (pathological);
CRC	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.72	-11.97	-0.55	1.18e-27	Ear protrusion;
CRC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.44	8.82	0.44	6.89e-17	Vitiligo;
CRC	cis	rs34599045	0.803	rs34198967	chr1:152869541	T/C	cg07796016	chr1:152779584	LCE1C	-0.75	-5.64	-0.3	3.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09502511	chr6:30539237	ABCF1	0.37	6.09	0.32	3.07e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	0.88	8.67	0.43	1.94e-16	Severe influenza A (H1N1) infection;
CRC	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.48	9.11	0.45	8.31e-18	Educational attainment (years of education);
CRC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.92	18.38	0.71	2.04e-52	Bone mineral density;
CRC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.39	0.56	3.54e-29	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs1515184	chr2:162561347	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs600806	0.854	rs3768496	chr1:109866569	T/A	cg23032129	chr1:109941072	SORT1	-0.27	-5.8	-0.3	1.59e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.95	0.31	6.92e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.78	-0.3	1.73e-8	Total body bone mineral density;
CRC	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9462027	0.628	rs9357181	chr6:34673833	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.28	0.33	1.1e-9	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.5	5.8	0.3	1.53e-8	Depression;
CRC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.52	6.13	0.32	2.47e-9	Vitiligo;
CRC	trans	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs758324	0.812	rs116369002	chr5:131242055	G/A	cg25547332	chr5:131281432	NA	-0.36	-5.68	-0.3	3.01e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-6.93	-0.36	2.27e-11	Ankle injury;
CRC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg06238570	chr21:40685208	BRWD1	0.73	10.2	0.49	2.12e-21	Cognitive function;
CRC	cis	rs59104589	0.617	rs3771566	chr2:242358299	G/T	cg19488206	chr2:242435732	STK25	0.48	7.04	0.36	1.11e-11	Fibrinogen levels;
CRC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.44	-0.38	8.66e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7737355	0.812	rs6881486	chr5:130793836	C/T	cg25547332	chr5:131281432	NA	-0.36	-5.73	-0.3	2.29e-8	Life satisfaction;
CRC	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	1.2	10.76	0.51	2.54e-23	Arsenic metabolism;
CRC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.29	0.33	1.03e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg11843238	chr5:131593191	PDLIM4	0.43	7.22	0.37	3.62e-12	Breast cancer;
CRC	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg23815491	chr16:72088622	HP	0.59	6.64	0.34	1.29e-10	Coronary artery disease;
CRC	cis	rs11212617	0.967	rs620613	chr11:108185478	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.87	0.31	1.08e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-7.82	-0.4	7.48e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.01	0.4	2.05e-14	Hip circumference adjusted for BMI;
CRC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg27615366	chr5:131592974	PDLIM4	0.32	5.76	0.3	1.92e-8	Blood metabolite levels;
CRC	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.51	8.96	0.44	2.55e-17	Weight;
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg12172441	chr6:28176163	NA	0.54	7.43	0.38	9.36e-13	Parkinson's disease;
CRC	trans	rs10267593	0.516	rs62435159	chr7:1911281	G/A	cg11693508	chr17:37793320	STARD3	0.55	7.17	0.37	4.92e-12	Coronary artery disease;
CRC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	6.03	0.32	4.46e-9	Menarche (age at onset);
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg21251018	chr6:28226885	NKAPL	0.47	6.16	0.32	2.07e-9	Depression;
CRC	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg00277334	chr10:82204260	NA	0.37	5.91	0.31	8.4e-9	Sarcoidosis;
CRC	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg10724054	chr17:3904396	NA	-0.47	-7.98	-0.4	2.52e-14	Type 2 diabetes;
CRC	cis	rs7264396	0.887	rs224343	chr20:34036699	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.99	-0.36	1.54e-11	Total cholesterol levels;
CRC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.51	7.99	0.4	2.28e-14	Menopause (age at onset);
CRC	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg12046867	chr14:103022105	NA	-0.43	-6.18	-0.32	1.88e-9	Platelet count;
CRC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.91	-0.31	8.57e-9	Gout;Renal underexcretion gout;
CRC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.4	0.59	5.5e-33	Prudent dietary pattern;
CRC	cis	rs2223471	0.652	rs2744488	chr6:50768062	C/A	cg03432817	chr6:50765336	NA	0.39	6.26	0.33	1.19e-9	Subcutaneous adipose tissue;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.73	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg03790207	chr6:42947109	PEX6	-0.52	-7.65	-0.39	2.22e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg17470449	chr10:769945	NA	0.62	8.97	0.44	2.36e-17	Uric acid levels;
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.18	-0.45	4.97e-18	Alzheimer's disease;
CRC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.07	12.59	0.57	6.34e-30	Vitiligo;
CRC	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-9.44	-0.46	7.31e-19	Colorectal cancer;
CRC	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg14844989	chr11:31128820	NA	0.34	5.9	0.31	8.98e-9	Red blood cell count;
CRC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-11.97	-0.55	1.18e-27	Pancreatic cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07886691	chr10:64028545	RTKN2	0.42	6.4	0.33	5.26e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.85	0.31	1.18e-8	Morning vs. evening chronotype;
CRC	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg24046110	chr8:143859143	LYNX1	-0.37	-6.32	-0.33	8.7e-10	Urinary tract infection frequency;
CRC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.31	5.88e-9	Heart rate;
CRC	trans	rs783540	0.967	rs17158390	chr15:83293028	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.36	-6.14	-0.32	2.36e-9	Schizophrenia;
CRC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg16540259	chr10:75572220	NDST2	0.37	5.84	0.31	1.28e-8	Inflammatory bowel disease;
CRC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg16447950	chr5:562315	NA	-0.85	-12.55	-0.57	8.97e-30	Obesity-related traits;
CRC	cis	rs9515203	0.596	rs9521731	chr13:111032699	C/G	cg15455643	chr13:111040242	COL4A2	0.42	6.76	0.35	6.37e-11	Coronary artery disease;
CRC	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.39	-0.38	1.25e-12	Headache;
CRC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.5	8.28	0.42	3.19e-15	Aortic root size;
CRC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16262614	chr3:133464971	TF	0.4	7.13	0.37	6.43e-12	Iron status biomarkers;
CRC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.79	-13.05	-0.58	1.23e-31	Height;
CRC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg00074818	chr8:8560427	CLDN23	0.35	6.47	0.34	3.45e-10	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.09	-0.32	3.19e-9	Triglycerides;
CRC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.81	0.51	1.71e-23	Motion sickness;
CRC	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg19904058	chr10:135279010	LOC619207	-0.27	-5.64	-0.3	3.64e-8	Systemic lupus erythematosus;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.28	-0.33	1.08e-9	Cognitive function;
CRC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg08222913	chr3:52553049	STAB1	0.34	6.15	0.32	2.25e-9	Bipolar disorder;
CRC	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	7.81	0.4	7.63e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.48	8.08	0.41	1.26e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs7804356	0.953	rs7785815	chr7:26852728	T/A	cg03456212	chr7:26904342	SKAP2	-0.52	-5.68	-0.3	2.98e-8	Type 1 diabetes;
CRC	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.42	0.33	4.71e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg21577049	chr2:228736449	WDR69	-0.44	-5.97	-0.31	6.27e-9	Blood pressure;
CRC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	6.97	0.36	1.77e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.12	-0.32	2.59e-9	Lung cancer;
CRC	cis	rs1867631	0.585	rs4655642	chr1:67090083	A/G	cg02459107	chr1:67143332	SGIP1	0.34	6.18	0.32	1.91e-9	Menopause (age at onset);
CRC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.5	-6.67	-0.35	1.07e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
CRC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.71	-0.3	2.47e-8	Crohn's disease;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg12172441	chr6:28176163	NA	0.53	7.33	0.37	1.85e-12	Parkinson's disease;
CRC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.52	-6.64	-0.34	1.26e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg15845792	chr6:28175446	NA	0.65	8.49	0.42	7.04e-16	Parkinson's disease;
CRC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	0.92	12.32	0.56	6.34e-29	Red blood cell traits;
CRC	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-6.71	-0.35	8.41e-11	Dental caries;
CRC	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg24596898	chr1:41849189	NA	0.34	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
CRC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.64	9.8	0.48	4.68e-20	Pancreatic cancer;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-8.41	-0.42	1.3e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg12326244	chr17:78078995	GAA	0.37	5.66	0.3	3.3e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.38	5.76	0.3	1.95e-8	Longevity;Endometriosis;
CRC	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.53	7.25	0.37	3.08e-12	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs9326248	0.861	rs494356	chr11:117071970	T/C	cg26566898	chr11:117069891	TAGLN	0.39	6.2	0.32	1.66e-9	Blood protein levels;
CRC	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17487170	chr5:133451259	TCF7	0.38	6.62	0.34	1.5e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.89	0.36	2.79e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.59	8.77	0.44	1.01e-16	Schizophrenia;
CRC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.12	-0.56	3.46e-28	Bipolar disorder and schizophrenia;
CRC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.47	-6.55	-0.34	2.26e-10	Red blood cell count;
CRC	trans	rs10411161	0.702	rs75647161	chr19:52398984	T/C	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg08798685	chr6:27730294	NA	0.39	5.92	0.31	7.97e-9	Systemic lupus erythematosus;
CRC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg05941027	chr17:61774174	LIMD2	-0.35	-6.54	-0.34	2.33e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.27	0.49	1.19e-21	Hip circumference adjusted for BMI;
CRC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.41	6.61	0.34	1.52e-10	Platelet count;
CRC	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.81	-13.09	-0.59	8.14e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg12601576	chr4:906860	GAK	-0.45	-6.3	-0.33	9.45e-10	Systemic sclerosis;
CRC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.9	-0.31	8.99e-9	Life satisfaction;
CRC	cis	rs1950626	0.623	rs34448411	chr14:101429287	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.73	11.47	0.53	7.56e-26	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg20356878	chr3:121714668	ILDR1	-0.51	-6.59	-0.34	1.73e-10	Multiple sclerosis;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.52	7.83	0.4	6.71e-14	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.4	-8.64	-0.43	2.46e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg15468180	chr1:107600409	PRMT6	-0.42	-6.36	-0.33	6.79e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs4150161	0.591	rs3759977	chr16:84221170	T/A	cg10106505	chr16:84220380	TAF1C	-1.13	-9.37	-0.46	1.24e-18	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22643867	chr2:131148877	NA	0.48	6.42	0.33	4.82e-10	Thyroid stimulating hormone;
CRC	trans	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.22	-0.56	1.39e-28	Alzheimer's disease;
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.06	0.52	2.21e-24	Prudent dietary pattern;
CRC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	trans	rs2303319	0.504	rs12469302	chr2:162433831	G/T	cg00039960	chr17:7142925	PHF23	-0.73	-6.0	-0.31	5.26e-9	Cognitive function;
CRC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.79	0.44	8.37e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg22495460	chr2:25135724	ADCY3	-0.9	-15.21	-0.64	6e-40	Body mass index;
CRC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.74	10.19	0.49	2.18e-21	Coronary artery disease;
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.7	-12.91	-0.58	3.99e-31	Electroencephalogram traits;
CRC	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.63	11.07	0.52	1.97e-24	Superior crus of antihelix expression;
CRC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg13753209	chr17:57696993	CLTC	-0.46	-5.85	-0.31	1.16e-8	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.18	0.56	1.98e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs600626	0.529	rs2004638	chr11:75471012	C/T	cg24262691	chr11:75473276	NA	0.53	8.17	0.41	6.68e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg26554054	chr8:600488	NA	-0.66	-6.11	-0.32	2.85e-9	IgG glycosylation;
CRC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.87	-0.4	5.18e-14	Height;
CRC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-9.14	-0.45	6.63e-18	Birth weight;
CRC	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg04611788	chr3:186434169	KNG1	-0.61	-9.13	-0.45	7.33e-18	Blood protein levels;
CRC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02290350	chr8:58132656	NA	-0.56	-6.57	-0.34	1.96e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg05655935	chr10:93683722	BTAF1	-0.39	-6.04	-0.32	4.24e-9	Myopia (pathological);
CRC	cis	rs4731207	0.698	rs35184624	chr7:124469587	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg03732007	chr1:2071316	PRKCZ	0.41	6.74	0.35	7.13e-11	Height;
CRC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.67	-9.95	-0.48	1.49e-20	Corneal astigmatism;
CRC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.06	0.69	3.29e-47	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02902865	chr1:12679132	DHRS3	0.43	6.14	0.32	2.36e-9	Response to antipsychotic treatment;
CRC	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.38	-5.63	-0.3	3.77e-8	IFN-related cytopenia;
CRC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.82	-0.4	7.27e-14	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19359929	chr1:3541763	TPRG1L	0.45	6.15	0.32	2.2e-9	Anxiety disorder;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.37	-0.33	6.45e-10	Depression;
CRC	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.4	-6.09	-0.32	3.19e-9	Neutrophil percentage of white cells;
CRC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.88	16.39	0.67	1.53e-44	Coronary artery disease;
CRC	trans	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.98	-0.36	1.6e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.42	6.83	0.35	4.15e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg08288130	chr8:21771540	DOK2	-0.28	-5.72	-0.3	2.4e-8	Lung cancer in ever smokers;
CRC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.85	-0.4	5.82e-14	Height;
CRC	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg22561889	chr6:118971681	C6orf204	-0.51	-6.22	-0.32	1.5e-9	Diastolic blood pressure;
CRC	cis	rs17092148	0.887	rs6058104	chr20:33271052	G/A	cg08999081	chr20:33150536	PIGU	0.49	5.92	0.31	8.12e-9	Neuroticism;
CRC	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.62	8.84	0.44	6.12e-17	White matter hyperintensity burden;
CRC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23378565	chr7:2036160	MAD1L1	0.4	5.99	0.31	5.39e-9	Bipolar disorder;
CRC	cis	rs10875943	0.751	rs56222401	chr12:49672714	A/G	cg17570948	chr12:49726661	C1QL4	-0.35	-5.95	-0.31	6.85e-9	Prostate cancer;
CRC	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.45	-5.81	-0.3	1.48e-8	Red blood cell traits;
CRC	trans	rs2303319	0.504	rs35304298	chr2:162617185	G/T	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.5	7.66	0.39	2.07e-13	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg22988483	chr14:93581567	ITPK1	-0.67	-6.03	-0.32	4.48e-9	Cognitive function;
CRC	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-9.8	-0.48	4.5e-20	Blood protein levels;
CRC	cis	rs4838594	0.549	rs11101333	chr10:49668179	A/G	cg17291251	chr10:49678358	ARHGAP22	0.42	6.63	0.34	1.41e-10	Daytime sleep phenotypes;
CRC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.79	14.89	0.63	1.12e-38	Prudent dietary pattern;
CRC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.43	6.3	0.33	9.37e-10	Alzheimer's disease (late onset);
CRC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg26805224	chr10:79626177	DLG5	-0.56	-8.34	-0.42	2.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.03	0.32	4.45e-9	Diabetic retinopathy;
CRC	cis	rs995000	0.931	rs1748197	chr1:63056112	G/A	cg19896129	chr1:63156450	NA	0.42	6.57	0.34	1.96e-10	Triglyceride levels;
CRC	cis	rs477692	0.637	rs2388331	chr10:131314173	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.32	0.37	1.92e-12	Response to temozolomide;
CRC	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg15123519	chr2:136567270	LCT	-0.33	-6.32	-0.33	8.57e-10	Mosquito bite size;
CRC	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.95	0.31	6.92e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg27534772	chr1:16042836	PLEKHM2	0.41	6.99	0.36	1.54e-11	Systolic blood pressure;
CRC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg15511327	chr8:143859410	LYNX1	0.6	10.39	0.5	4.7e-22	Urinary tract infection frequency;
CRC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.52	-7.52	-0.38	5.4e-13	Total body bone mineral density;
CRC	cis	rs858239	0.831	rs7796541	chr7:23389073	G/T	cg00469287	chr7:23338798	C7orf30	0.43	5.86	0.31	1.11e-8	Cerebrospinal fluid biomarker levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00373131	chr1:93646396	CCDC18;TMED5	0.43	6.65	0.34	1.24e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.89	-0.31	9.74e-9	Depression;
CRC	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg17133734	chr15:86042851	AKAP13	0.38	6.37	0.33	6.19e-10	Coronary artery disease;
CRC	cis	rs2274273	0.662	rs67958555	chr14:55670866	G/A	cg10130446	chr14:55658398	DLGAP5	-0.43	-5.81	-0.31	1.46e-8	Protein biomarker;
CRC	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.82	-12.68	-0.57	2.74e-30	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg07507251	chr3:52567010	NT5DC2	0.44	6.39	0.33	5.81e-10	Bipolar disorder;
CRC	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.41	6.41	0.33	5.18e-10	Obesity;
CRC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.81	8.94	0.44	2.9e-17	Breast cancer;
CRC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.61	9.83	0.48	3.73e-20	HDL cholesterol;
CRC	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.52	-8.01	-0.4	2.07e-14	HDL cholesterol;
CRC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg22676075	chr6:135203613	NA	0.41	6.35	0.33	7.03e-10	Red blood cell count;
CRC	cis	rs644148	0.748	rs542150	chr19:44967453	T/C	cg15540054	chr19:45004280	ZNF180	0.55	7.13	0.37	6.29e-12	Personality dimensions;
CRC	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.95	-12.87	-0.58	5.41e-31	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.79	-0.35	5.19e-11	Longevity;Endometriosis;
CRC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	0.95	18.41	0.71	1.56e-52	Height;
CRC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	7.82	0.4	7.36e-14	Monocyte percentage of white cells;
CRC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.78	-11.92	-0.55	1.8e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	cis	rs6840360	0.642	rs11729923	chr4:152392036	G/T	cg09659197	chr4:152720779	NA	0.34	6.64	0.34	1.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6751744	0.513	rs6738215	chr2:160453305	C/T	cg08347373	chr2:160653686	CD302	-0.38	-6.27	-0.33	1.13e-9	Dysphagia;
CRC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.15	11.25	0.53	4.71e-25	Type 2 diabetes;
CRC	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-11.56	-0.54	3.69e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg20356878	chr3:121714668	ILDR1	0.5	7.77	0.39	9.97e-14	Cognitive performance;
CRC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.58	8.92	0.44	3.32e-17	IgG glycosylation;
CRC	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg22495460	chr2:25135724	ADCY3	-0.89	-15.02	-0.64	3.53e-39	Body mass index;
CRC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.43	-0.33	4.46e-10	Daytime sleep phenotypes;
CRC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.34	5.69	0.3	2.74e-8	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.35	-7.5	-0.38	5.84e-13	Inflammatory skin disease;
CRC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.02	0.7	5.41e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.47	-6.75	-0.35	6.64e-11	Longevity;Endometriosis;
CRC	cis	rs57561814	0.826	rs116542785	chr7:22747720	G/A	cg26061582	chr7:22766209	IL6	0.69	5.92	0.31	7.91e-9	Tonsillectomy;
CRC	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-9.01	-0.44	1.68e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg06172871	chr16:72088244	HP	0.39	5.69	0.3	2.82e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg15445000	chr17:37608096	MED1	0.36	6.27	0.33	1.12e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.75	-16.64	-0.68	1.49e-45	Intelligence (multi-trait analysis);
CRC	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg06606381	chr12:133084897	FBRSL1	-0.92	-7.54	-0.38	4.53e-13	Depression;
CRC	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.81	-0.3	1.5e-8	Type 2 diabetes;
CRC	cis	rs1192414	0.515	rs6688706	chr1:92056144	A/C	cg24006770	chr1:92056542	NA	0.57	9.56	0.47	2.97e-19	Vertical cup-disc ratio;
CRC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.5	7.22	0.37	3.58e-12	Aortic root size;
CRC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.7	11.0	0.52	3.69e-24	Corneal astigmatism;
CRC	cis	rs4728142	0.564	rs10954213	chr7:128589427	G/A	cg06630958	chr7:128577819	IRF5	-0.35	-5.79	-0.3	1.68e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.5	-0.34	2.9e-10	Breast cancer;
CRC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg05139728	chr16:28306816	SBK1	-0.37	-6.1	-0.32	3e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03923535	chr7:1197113	ZFAND2A	0.64	9.17	0.45	5.39e-18	Longevity;Endometriosis;
CRC	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg07166546	chr14:35805898	NA	-0.29	-5.69	-0.3	2.78e-8	Psoriasis;
CRC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.45	-7.04	-0.36	1.13e-11	Monocyte count;
CRC	trans	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg17085576	chr10:5658249	NA	-0.42	-6.11	-0.32	2.84e-9	Breast cancer;
CRC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.39	6.57	0.34	1.98e-10	Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14242460	chr6:5261506	LYRM4;FARS2	0.38	6.19	0.32	1.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg14530993	chr4:882597	GAK	0.82	7.8	0.4	8.21e-14	Intelligence (multi-trait analysis);
CRC	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.52	6.82	0.35	4.46e-11	Coronary artery disease;
CRC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg25956985	chr22:39795188	MAP3K7IP1	-0.47	-6.75	-0.35	6.56e-11	Intelligence (multi-trait analysis);
CRC	trans	rs58106596	0.800	rs28883318	chr2:232562935	G/A	cg01370599	chr3:116745421	NA	0.53	7.24	0.37	3.26e-12	White blood cell count;Lymphocyte counts;
CRC	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.33	7.76	0.39	1.06e-13	Corneal astigmatism;
CRC	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.61	-9.34	-0.46	1.51e-18	Obesity;
CRC	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.5	8.33	0.42	2.17e-15	Schizophrenia;
CRC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.53	7.42	0.38	1.04e-12	Melanoma;
CRC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	7.79	0.39	8.98e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.49	7.34	0.38	1.68e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg25456477	chr12:86230367	RASSF9	-0.34	-5.87	-0.31	1.09e-8	Major depressive disorder;
CRC	cis	rs9828933	0.832	rs3774723	chr3:63962339	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.58	-6.59	-0.34	1.7e-10	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11604272	chr11:65769511	EIF1AD;BANF1	0.43	6.01	0.31	4.86e-9	Response to antipsychotic treatment;
CRC	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23200970	chr4:111119917	ELOVL6	0.41	6.89	0.36	2.87e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-7.49	-0.38	6.24e-13	Menarche (age at onset);
CRC	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.14	0.41	8.46e-15	Coffee consumption (cups per day);
CRC	cis	rs889398	0.617	rs6499265	chr16:69897998	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.22	-0.32	1.49e-9	Body mass index;
CRC	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg15038512	chr6:170123185	PHF10	-0.39	-6.05	-0.32	3.86e-9	Obesity-related traits;
CRC	cis	rs3812762	0.833	rs10500705	chr11:8805261	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-6.87	-0.35	3.12e-11	Hypospadias;
CRC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.4	6.34	0.33	7.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.52	8.13	0.41	8.94e-15	Corneal astigmatism;
CRC	cis	rs12760731	0.720	rs35905053	chr1:178441618	A/T	cg00404053	chr1:178313656	RASAL2	0.95	9.93	0.48	1.66e-20	Obesity-related traits;
CRC	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-7.23	-0.37	3.34e-12	Putamen volume;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18159463	chr10:104210483	C10orf95	0.43	6.1	0.32	2.96e-9	Anxiety disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22336633	chr11:17099688	RPS13	0.48	6.34	0.33	7.58e-10	Thyroid stimulating hormone;
CRC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg10298567	chr3:47292165	KIF9	-0.4	-6.72	-0.35	7.9e-11	Colorectal cancer;
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16350314	chr8:27169081	TRIM35;PTK2B	0.44	6.34	0.33	7.62e-10	Response to antipsychotic treatment;
CRC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-10.47	-0.5	2.58e-22	Schizophrenia;
CRC	cis	rs1552172	0.887	rs12725120	chr1:145661313	C/T	cg11743829	chr1:145714124	CD160	-0.41	-6.18	-0.32	1.91e-9	Breast cancer;
CRC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.53	7.22	0.37	3.68e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.36	5.64	0.3	3.65e-8	Testicular germ cell tumor;
CRC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.88	-8.96	-0.44	2.52e-17	Breast cancer;
CRC	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg14646075	chr2:228736089	WDR69	-0.43	-5.89	-0.31	9.47e-9	Blood pressure;
CRC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.08	-0.32	3.41e-9	Morning vs. evening chronotype;
CRC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg08888203	chr3:10149979	C3orf24	0.47	7.24	0.37	3.18e-12	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.47	7.57	0.38	3.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07165851	chr6:158734300	TULP4	0.63	7.96	0.4	2.75e-14	Height;
CRC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.45	6.53	0.34	2.46e-10	Alzheimer's disease (late onset);
CRC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg05623727	chr3:50126028	RBM5	0.46	7.54	0.38	4.5e-13	Intelligence (multi-trait analysis);
CRC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg14979609	chr8:8086686	FLJ10661	0.38	6.06	0.32	3.67e-9	Joint mobility (Beighton score);
CRC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.33	-5.98	-0.31	5.72e-9	Rheumatoid arthritis;
CRC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.58e-24	Corneal astigmatism;
CRC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.43	-6.09	-0.32	3.21e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.27	15.87	0.66	1.59e-42	Uric acid levels;
CRC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.78	8.2	0.41	5.3e-15	Fat distribution (HIV);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04883450	chr5:61699957	DIMT1L	0.5	6.29	0.33	9.82e-10	Thyroid stimulating hormone;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.43	6.18	0.32	1.94e-9	Coronary artery disease;
CRC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.44	9.24	0.45	3.21e-18	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08250099	chr1:6685624	THAP3	0.42	6.1	0.32	2.95e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1178968	1.000	rs6460041	chr7:72757671	A/G	cg25889504	chr7:72793014	NA	0.53	5.93	0.31	7.73e-9	Triglyceride levels;
CRC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg23463467	chr20:60627584	TAF4	0.44	8.31	0.42	2.47e-15	Body mass index;
CRC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.71	9.01	0.45	1.67e-17	Vitiligo;
CRC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.79	11.89	0.55	2.37e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.81	12.3	0.56	7.53e-29	Cognitive function;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-9.08	-0.45	1.01e-17	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg15382696	chr6:118971807	C6orf204	0.59	7.5	0.38	6.18e-13	Diastolic blood pressure;
CRC	cis	rs501120	0.584	rs11238890	chr10:44669226	A/T	cg09554077	chr10:44749378	NA	0.73	8.07	0.41	1.37e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg03233332	chr7:66118400	NA	-0.42	-5.86	-0.31	1.14e-8	Aortic root size;
CRC	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	6.89	0.36	2.81e-11	Schizophrenia;
CRC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.37	-5.95	-0.31	6.9e-9	Height;
CRC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg06634786	chr22:41940651	POLR3H	-0.47	-5.99	-0.31	5.64e-9	Neuroticism;
CRC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-7.8	-0.4	8.11e-14	Mean corpuscular volume;
CRC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.51	7.88	0.4	4.85e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.32	6.77	0.35	6e-11	Alcohol dependence;
CRC	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.55	7.03	0.36	1.17e-11	Bipolar disorder;
CRC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.03e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg08798685	chr6:27730294	NA	-0.74	-6.65	-0.34	1.22e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.71	8.9	0.44	3.72e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1950626	0.833	rs12897114	chr14:101395140	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.97	0.66	6.72e-43	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.7	7.63	0.39	2.58e-13	Breast cancer;
CRC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.56	8.99	0.44	1.93e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg18478394	chr8:109455254	TTC35	0.38	6.04	0.32	4.09e-9	Dupuytren's disease;
CRC	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-5.75	-0.3	2.05e-8	Alzheimer's disease (survival time);
CRC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.67	-9.45	-0.46	6.45e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.96	-0.31	6.58e-9	Educational attainment;
CRC	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg13057898	chr1:3703894	LRRC47	0.47	6.31	0.33	8.91e-10	Red cell distribution width;
CRC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.61	-11.68	-0.54	1.32e-26	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.62	7.2	0.37	4.11e-12	Vitiligo;
CRC	cis	rs4594175	0.962	rs4254242	chr14:51599184	A/C	cg23942311	chr14:51606299	NA	0.66	10.56	0.5	1.22e-22	Cancer;
CRC	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.93	-16.3	-0.67	3.28e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.94	-0.55	1.47e-27	Coffee consumption (cups per day);
CRC	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.65	0.3	3.52e-8	Body mass index;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25266327	chr19:16435660	KLF2	0.43	6.98	0.36	1.64e-11	Interleukin-6 levels;
CRC	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.65	10.17	0.49	2.7e-21	Intelligence (multi-trait analysis);
CRC	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.73	-11.76	-0.54	7e-27	Breast cancer;
CRC	cis	rs12928939	0.911	rs77823468	chr16:71828616	C/T	cg03805757	chr16:71968109	PKD1L3	-0.47	-6.02	-0.31	4.78e-9	Post bronchodilator FEV1;
CRC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.43	-6.92	-0.36	2.42e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.73	-0.35	7.76e-11	Menarche (age at onset);
CRC	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg19875578	chr6:126661172	C6orf173	0.41	5.64	0.3	3.69e-8	Male-pattern baldness;
CRC	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg05540913	chr6:167530185	CCR6	-0.41	-7.43	-0.38	9.52e-13	Primary biliary cholangitis;
CRC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.8	-12.72	-0.57	2e-30	Cognitive function;
CRC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg03013999	chr17:37608204	MED1	-0.45	-6.99	-0.36	1.55e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.7	13.0	0.58	1.8e-31	Body mass index;
CRC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.36	-8.55	-0.43	4.71e-16	Mean corpuscular volume;
CRC	cis	rs12692738	0.526	rs355864	chr2:165630414	A/T	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2302190	0.769	rs7215531	chr17:56493374	A/T	cg25885038	chr17:56607967	SEPT4	-0.49	-7.52	-0.38	5.09e-13	Vitamin D levels;
CRC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.51	-9.08	-0.45	1.02e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.66	10.51	0.5	1.81e-22	Corneal astigmatism;
CRC	cis	rs12476592	0.602	rs262501	chr2:63858657	A/G	cg10828910	chr2:63850056	LOC388955	-0.6	-7.23	-0.37	3.49e-12	Childhood ear infection;
CRC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.66	10.14	0.49	3.25e-21	Mood instability;
CRC	cis	rs4601821	1.000	rs3897584	chr11:113249725	C/G	cg14159747	chr11:113255604	NA	-0.47	-8.76	-0.43	1.06e-16	Alcoholic chronic pancreatitis;
CRC	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg17545662	chr6:170176663	C6orf70	0.54	5.98	0.31	5.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00166722	chr3:10149974	C3orf24	0.66	9.0	0.44	1.85e-17	Alzheimer's disease;
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg14196790	chr5:131705035	SLC22A5	0.37	6.16	0.32	2.09e-9	Blood metabolite levels;
CRC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg16141378	chr3:129829833	LOC729375	0.41	6.3	0.33	9.67e-10	Neuroticism;
CRC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	14.57	0.63	1.83e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.55	-0.75	5.92e-61	Height;
CRC	cis	rs4664293	0.867	rs7594329	chr2:160572718	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.45	-0.38	8.04e-13	Monocyte percentage of white cells;
CRC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-15.28	-0.64	3.2e-40	Lymphocyte percentage of white cells;
CRC	cis	rs902774	0.818	rs17120257	chr12:53303331	T/C	cg14581129	chr12:53358946	NA	-0.54	-5.95	-0.31	6.77e-9	Prostate cancer;
CRC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Parkinson's disease;
CRC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.67	8.93	0.44	3.04e-17	Multiple sclerosis;
CRC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg05341575	chr12:125625032	AACS	-0.41	-5.81	-0.31	1.44e-8	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2949837	0.581	rs2960436	chr7:45977282	G/A	cg15898840	chr7:45960834	IGFBP3	0.45	7.4	0.38	1.12e-12	Sitting height ratio;
CRC	cis	rs6968419	0.755	rs3807982	chr7:115898885	T/C	cg02561103	chr7:115862891	TES	-0.44	-6.59	-0.34	1.74e-10	Intraocular pressure;
CRC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg03030879	chr14:75389066	RPS6KL1	0.42	6.38	0.33	6.1e-10	Height;
CRC	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.55	-7.49	-0.38	6.34e-13	Caudate activity during reward;
CRC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.33e-13	Motion sickness;
CRC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.49	-9.9	-0.48	2.18e-20	Prostate cancer;
CRC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.65	13.87	0.61	9.58e-35	Schizophrenia;
CRC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.75	12.22	0.56	1.47e-28	Blood protein levels;
CRC	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.64	10.08	0.49	5.32e-21	Crohn's disease;
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.95	-21.81	-0.77	7.06e-66	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12780046	0.536	rs10883327	chr10:101084483	C/T	cg26459859	chr10:101118273	CNNM1	-0.46	-6.36	-0.33	6.93e-10	Non-glioblastoma glioma;
CRC	cis	rs10924970	0.781	rs10754614	chr1:235493804	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.82	0.31	1.37e-8	Asthma;
CRC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg27068330	chr11:65405492	SIPA1	-0.63	-9.46	-0.46	5.9e-19	Acne (severe);
CRC	cis	rs2737618	0.630	rs2821324	chr1:200078006	G/A	cg21825944	chr1:200113062	NR5A2	-0.48	-6.86	-0.35	3.4e-11	Uric acid levels;
CRC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.59e-10	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16269447	chr12:9600801	DDX12	0.44	6.14	0.32	2.33e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07399355	chr1:155163013	MUC1	0.49	6.27	0.33	1.15e-9	Thyroid stimulating hormone;
CRC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.57	10.27	0.49	1.2e-21	Coronary artery disease;
CRC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-11.21	-0.53	6.38e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.58	7.83	0.4	6.83e-14	Primary sclerosing cholangitis;
CRC	cis	rs8105895	0.935	rs7250905	chr19:22250743	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.49	6.99	0.36	1.5e-11	Height;
CRC	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.71	11.55	0.54	4.04e-26	Mean platelet volume;
CRC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.54	-8.88	-0.44	4.51e-17	Total body bone mineral density;
CRC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.48	7.49	0.38	6.38e-13	Corneal astigmatism;
CRC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.59	-9.23	-0.45	3.38e-18	Height;
CRC	cis	rs4666002	0.564	rs13030345	chr2:28003174	A/C	cg27432699	chr2:27873401	GPN1	-0.58	-6.81	-0.35	4.54e-11	Phospholipid levels (plasma);
CRC	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.46	6.74	0.35	7.28e-11	Primary sclerosing cholangitis;
CRC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.5	7.77	0.39	9.86e-14	Red blood cell count;
CRC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.41	5.89	0.31	9.34e-9	Aortic root size;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.72	12.11	0.56	3.52e-28	Longevity;Endometriosis;
CRC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg25985355	chr7:65971099	NA	0.53	5.93	0.31	7.52e-9	Diabetic kidney disease;
CRC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08859206	chr1:53392774	SCP2	-0.4	-6.13	-0.32	2.45e-9	Monocyte count;
CRC	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg24851651	chr11:66362959	CCS	-0.39	-6.69	-0.35	9.43e-11	Educational attainment (years of education);
CRC	cis	rs6997458	0.712	rs9987281	chr8:86348830	A/T	cg21346043	chr8:86351067	CA3	0.28	6.17	0.32	1.96e-9	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs3736485	0.934	rs114641722	chr15:51863572	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.12e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg08271804	chr19:22816896	ZNF492	0.38	5.89	0.31	9.46e-9	Bronchopulmonary dysplasia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03345567	chr19:50321589	MED25	0.45	5.98	0.31	5.87e-9	Anxiety disorder;
CRC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.81	-0.35	4.71e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg24505167	chr7:1915268	MAD1L1	-0.42	-5.81	-0.3	1.49e-8	Neuroticism;
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg19223190	chr17:80058835	NA	0.4	6.5	0.34	3.06e-10	Life satisfaction;
CRC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.84	0.4	6.37e-14	Colorectal cancer;
CRC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.94	-0.4	3.26e-14	Triglycerides;
CRC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-8.5	-0.42	6.68e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.15	28.33	0.84	3e-90	Testicular germ cell tumor;
CRC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17261708	chr5:176794207	RGS14	0.49	8.12	0.41	9.63e-15	Hemoglobin concentration;Hematocrit;
CRC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs4660214	0.724	rs3931300	chr1:39660847	A/G	cg11070191	chr1:39582205	MACF1	0.36	5.66	0.3	3.22e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs600626	0.529	rs11236525	chr11:75467545	C/G	cg24262691	chr11:75473276	NA	0.51	7.39	0.38	1.21e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg19582491	chr16:67682965	RLTPR	-0.57	-6.53	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.46	6.8	0.35	4.81e-11	Crohn's disease;
CRC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.99	0.31	5.47e-9	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13558695	chr2:25500125	DNMT3A	0.24	6.9	0.36	2.72e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.81	-12.66	-0.57	3.41e-30	Cognitive function;
CRC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.43	-6.71	-0.35	8.57e-11	Breast cancer;
CRC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg16576597	chr16:28551801	NUPR1	0.48	6.9	0.36	2.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg21138405	chr5:131827807	IRF1	-0.31	-5.7	-0.3	2.63e-8	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26221971	chr16:57318603	PLLP	0.42	6.03	0.32	4.38e-9	Response to antipsychotic treatment;
CRC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.56	7.39	0.38	1.22e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg03013999	chr17:37608204	MED1	-0.46	-6.85	-0.35	3.7e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.75	-11.92	-0.55	1.87e-27	Prudent dietary pattern;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg09655341	chr17:79618100	PDE6G	-0.35	-6.07	-0.32	3.46e-9	Eye color traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08762750	chr15:91497995	RCCD1	0.43	6.68	0.35	1e-10	Schizophrenia;
CRC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.76	9.0	0.44	1.86e-17	Eosinophilic esophagitis;
CRC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-12.27	-0.56	9.41e-29	Urinary metabolites;
CRC	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.5	8.43	0.42	1.07e-15	Dupuytren's disease;
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.77	14.5	0.62	3.51e-37	Prudent dietary pattern;
CRC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.85	0.31	1.16e-8	Melanoma;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg07360250	chr5:176830358	F12	-0.4	-6.02	-0.31	4.76e-9	Birth weight;Height;
CRC	cis	rs4234798	1.000	rs4689088	chr4:7222253	G/A	cg18431297	chr4:7219810	SORCS2	0.6	10.56	0.5	1.18e-22	Insulin-like growth factors;
CRC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.08	0.36	8.96e-12	Hip circumference adjusted for BMI;
CRC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.46	-9.19	-0.45	4.7e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	6.13	0.32	2.57e-9	Axial length;
CRC	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs12476592	0.543	rs12105140	chr2:63797218	A/G	cg10828910	chr2:63850056	LOC388955	0.47	5.79	0.3	1.62e-8	Childhood ear infection;
CRC	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.5	-0.34	2.96e-10	Capecitabine sensitivity;
CRC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.27	15.87	0.66	1.59e-42	Uric acid levels;
CRC	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	0.83	6.98	0.36	1.64e-11	LDL cholesterol;
CRC	cis	rs6546324	0.625	rs1023691	chr2:67868794	G/A	cg15745817	chr2:67799979	NA	-0.55	-9.54	-0.47	3.34e-19	Endometriosis;
CRC	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg08200770	chr17:80723486	TBCD	-0.51	-7.78	-0.39	9.74e-14	Glycated hemoglobin levels;
CRC	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-6.09	-0.32	3.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.48	6.34	0.33	7.51e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.77	7.67	0.39	1.93e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg23750338	chr8:142222470	SLC45A4	-0.37	-5.69	-0.3	2.78e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	7.23	0.37	3.3e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.65	9.94	0.48	1.6e-20	Huntington's disease progression;
CRC	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.47	6.31	0.33	8.78e-10	Cholesterol, total;
CRC	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg14352298	chr13:112236639	NA	0.29	6.67	0.35	1.06e-10	Hepatitis;
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.36	5.91	0.31	8.67e-9	Blood metabolite levels;
CRC	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.5	8.08	0.41	1.2e-14	Lipoprotein (a) levels;
CRC	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg27426351	chr10:43362370	NA	0.54	6.64	0.34	1.33e-10	Blood protein levels;
CRC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.46	7.45	0.38	8.08e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.71	9.94	0.48	1.53e-20	Menarche (age at onset);
CRC	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.56	7.56	0.38	4.11e-13	Vitamin D levels;
CRC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.68	-11.54	-0.54	4.28e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.66	8.29	0.42	3e-15	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.07	-0.32	3.49e-9	Gout;Renal underexcretion gout;
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.77	14.5	0.62	3.45e-37	Prudent dietary pattern;
CRC	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg05044414	chr3:183734942	ABCC5	0.43	7.36	0.38	1.48e-12	Anterior chamber depth;
CRC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg18512352	chr11:47633146	NA	-0.39	-7.66	-0.39	2.06e-13	Subjective well-being;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.22	0.37	3.66e-12	Lymphocyte counts;
CRC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.18	-0.32	1.89e-9	Alzheimer's disease (late onset);
CRC	cis	rs4845875	0.626	rs6697244	chr1:11838848	G/T	cg02448276	chr1:11845238	NA	0.36	5.61	0.3	4.38e-8	Midregional pro atrial natriuretic peptide levels;
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg23590916	chr17:43697445	MGC57346	0.7	7.18	0.37	4.6e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.97	0.31	6e-9	Tonsillectomy;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg02839273	chr15:85525387	PDE8A	-0.41	-6.14	-0.32	2.34e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.44	0.33	4.13e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.75	0.51	2.57e-23	Prudent dietary pattern;
CRC	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.47	7.25	0.37	2.92e-12	Testicular germ cell tumor;
CRC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26608221	chr2:74692293	MOGS	-0.43	-6.52	-0.34	2.66e-10	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18760119	chr6:127587834	RNF146	0.43	6.11	0.32	2.8e-9	Response to antipsychotic treatment;
CRC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.41	0.5	4.01e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.65	13.31	0.59	1.24e-32	Schizophrenia;
CRC	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.09	0.45	9.68e-18	Dupuytren's disease;
CRC	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.82	-15.72	-0.65	6.47e-42	Oral cavity cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13056269	chr2:136633607	MCM6	0.46	6.06	0.32	3.69e-9	Anxiety disorder;
CRC	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.36	-0.38	1.44e-12	Capecitabine sensitivity;
CRC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.68	-12.35	-0.56	4.94e-29	Prudent dietary pattern;
CRC	cis	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg04523069	chr9:97136363	HIATL1	0.36	5.62	0.3	4.05e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	3.05e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.52	-8.74	-0.43	1.2e-16	Type 2 diabetes;
CRC	cis	rs3736485	0.868	rs8023455	chr15:51936510	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.5	-0.34	2.92e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg20512303	chr5:131592959	PDLIM4	0.38	6.59	0.34	1.74e-10	Breast cancer;
CRC	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.74	9.84	0.48	3.35e-20	Prostate cancer;
CRC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg02807482	chr3:125708958	NA	-0.46	-6.05	-0.32	3.94e-9	Blood pressure (smoking interaction);
CRC	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.48	9.09	0.45	9.5e-18	Educational attainment (years of education);
CRC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.74	-0.54	7.81e-27	Type 2 diabetes;
CRC	cis	rs6968419	0.747	rs6957561	chr7:115888339	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.28	-0.33	1.06e-9	Intraocular pressure;
CRC	trans	rs4452313	0.884	rs7648912	chr3:17076560	C/G	cg24680248	chr19:8426630	NA	0.4	6.39	0.33	5.52e-10	Rheumatoid arthritis;
CRC	trans	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg25214090	chr10:38739885	LOC399744	-0.43	-6.65	-0.34	1.2e-10	Diastolic blood pressure;
CRC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.72	-0.35	8.01e-11	Aortic root size;
CRC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg27661571	chr11:113659931	NA	-0.67	-7.54	-0.38	4.55e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.59	6.66	0.34	1.12e-10	Type 2 diabetes nephropathy;
CRC	cis	rs12042938	0.600	rs4658880	chr1:231764621	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.28	0.33	1.06e-9	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.5	6.44	0.33	4.23e-10	Blood metabolite levels;
CRC	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.4	-6.62	-0.34	1.44e-10	Mean arterial pressure;
CRC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12463550	chr7:65579703	CRCP	0.72	6.52	0.34	2.59e-10	Diabetic kidney disease;
CRC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00802000	chr16:706648	WDR90	-0.44	-6.36	-0.33	6.84e-10	Height;
CRC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.56	0.54	3.61e-26	Monocyte percentage of white cells;
CRC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg18490616	chr2:88469792	THNSL2	0.58	5.85	0.31	1.22e-8	Plasma clusterin levels;
CRC	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.38	-6.45	-0.34	3.9e-10	Vitamin D levels;
CRC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.69	-10.25	-0.49	1.36e-21	Longevity;
CRC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg10729496	chr3:10149963	C3orf24	0.48	6.25	0.33	1.25e-9	Alzheimer's disease;
CRC	cis	rs7725052	0.575	rs4957303	chr5:40466277	T/C	cg09067459	chr5:40385259	NA	0.39	6.4	0.33	5.31e-10	Pediatric autoimmune diseases;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18301423	chr5:131593218	PDLIM4	-0.47	-8.27	-0.41	3.3e-15	Acylcarnitine levels;
CRC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.44	-0.46	6.97e-19	Platelet count;
CRC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-15.31	-0.65	2.48e-40	Vitiligo;
CRC	cis	rs2249694	1.000	rs2515644	chr10:135353079	A/C	cg16964102	chr10:135390573	NA	-0.38	-6.21	-0.32	1.57e-9	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.51	7.81	0.4	7.99e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.35	5.65	0.3	3.54e-8	Glycated hemoglobin levels;
CRC	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.64	8.02	0.4	1.88e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-8.3	-0.42	2.72e-15	Uric acid levels;
CRC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg23161317	chr6:28129485	ZNF389	-0.39	-5.89	-0.31	9.52e-9	Cardiac Troponin-T levels;
CRC	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.93	-0.36	2.19e-11	Inflammatory skin disease;
CRC	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.45	-6.28	-0.33	1.07e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs728616	0.867	rs12414877	chr10:81780708	A/G	cg05935833	chr10:81318306	SFTPA2	-0.74	-7.92	-0.4	3.58e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs926938	0.783	rs2144428	chr1:115269211	G/A	cg12756093	chr1:115239321	AMPD1	-0.7	-10.94	-0.52	5.89e-24	Autism;
CRC	cis	rs4750440	0.576	rs2447011	chr10:14032199	C/T	cg04819048	chr10:14014548	FRMD4A	0.36	6.0	0.31	5.31e-9	Adiponectin levels;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-10.83	-0.51	1.37e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.52	6.07	0.32	3.52e-9	Methadone dose in opioid dependence;
CRC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.58	6.58	0.34	1.87e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg16699849	chr7:98923489	ARPC1A	-0.68	-6.2	-0.32	1.66e-9	Cognitive function;
CRC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.68	0.3	3.01e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs216303	0.642	rs216318	chr12:6139261	A/C	cg19878637	chr12:6148451	VWF	-0.59	-6.55	-0.34	2.24e-10	Low vWF levels;
CRC	cis	rs4363385	0.693	rs418550	chr1:153048045	A/T	cg25856811	chr1:152973957	SPRR3	-0.23	-6.25	-0.33	1.3e-9	Inflammatory skin disease;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12273811	chr6:28175739	NA	0.73	9.97	0.48	1.29e-20	Depression;
CRC	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	7.49	0.38	6.41e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.62	-7.2	-0.37	4.17e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.99	-0.31	5.55e-9	Inflammatory bowel disease;
CRC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.56	6.06	0.32	3.78e-9	Initial pursuit acceleration;
CRC	cis	rs4664293	0.546	rs12469866	chr2:160622630	G/C	cg08347373	chr2:160653686	CD302	0.35	5.8	0.3	1.56e-8	Monocyte percentage of white cells;
CRC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.07	-0.32	3.53e-9	Height;
CRC	cis	rs7493	0.516	rs13233527	chr7:95068795	T/C	cg04155289	chr7:94953770	PON1	-0.45	-6.04	-0.32	4.15e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg20243544	chr17:37824526	PNMT	0.47	5.6	0.3	4.49e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg23996704	chr18:44553084	KATNAL2	-0.32	-6.36	-0.33	6.83e-10	Personality dimensions;
CRC	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.57	6.82	0.35	4.39e-11	Lymphocyte counts;
CRC	cis	rs9649465	0.934	rs34030532	chr7:123274992	A/G	cg03229431	chr7:123269106	ASB15	-0.42	-6.35	-0.33	7.06e-10	Migraine;
CRC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.12	-0.41	9.45e-15	Height;
CRC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.53	-0.34	2.57e-10	Response to antipsychotic treatment;
CRC	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.55e-15	Type 2 diabetes;
CRC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg07212818	chr11:638076	DRD4	-0.48	-6.15	-0.32	2.18e-9	Systemic lupus erythematosus;
CRC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.86	15.87	0.66	1.68e-42	Menopause (age at onset);
CRC	cis	rs2271001	0.955	rs12273085	chr11:19138511	G/C	cg00161556	chr11:19138045	ZDHHC13	0.35	5.67	0.3	3.16e-8	Gut microbiome composition (winter);
CRC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.47	8.17	0.41	6.84e-15	Schizophrenia;
CRC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg27661571	chr11:113659931	NA	-0.71	-8.71	-0.43	1.53e-16	Hip circumference adjusted for BMI;
CRC	cis	rs9322817	0.607	rs9404572	chr6:105149439	T/C	cg02098413	chr6:105308735	HACE1	-0.43	-8.4	-0.42	1.36e-15	Thyroid stimulating hormone;
CRC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg20243544	chr17:37824526	PNMT	0.55	8.43	0.42	1.08e-15	Asthma;
CRC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.91	-10.28	-0.49	1.15e-21	Iron status biomarkers;
CRC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.53	-7.85	-0.4	5.77e-14	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00230302	chr9:21802598	MTAP	0.44	6.31	0.33	9.23e-10	Response to antipsychotic treatment;
CRC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.63	-8.7	-0.43	1.56e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.62	8.38	0.42	1.59e-15	Platelet count;
CRC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.51	8.87	0.44	4.59e-17	Height;
CRC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg20399509	chr21:47717575	C21orf57	-0.34	-5.67	-0.3	3.06e-8	Testicular germ cell tumor;
CRC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12273811	chr6:28175739	NA	0.72	9.03	0.45	1.47e-17	Depression;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02359409	chr6:42947317	PEX6	-0.69	-11.41	-0.53	1.28e-25	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23378565	chr7:2036160	MAD1L1	-0.45	-6.37	-0.33	6.24e-10	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs9693857	0.520	rs11249927	chr8:9361606	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.15	0.32	2.19e-9	Systolic blood pressure;
CRC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.58	-0.39	3.54e-13	Total body bone mineral density;
CRC	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg14515779	chr1:101123966	NA	-0.33	-5.87	-0.31	1.04e-8	Monocyte count;
CRC	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg14515779	chr1:101123966	NA	0.41	7.59	0.39	3.29e-13	Monocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08165532	chr3:133293146	CDV3	0.4	6.45	0.34	3.91e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.1	-0.32	2.99e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.13	-0.32	2.45e-9	Aortic root size;
CRC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-0.74	-6.75	-0.35	6.89e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1950626	0.833	rs1951025	chr14:101406022	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	16.09	0.66	2.16e-43	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.73	9.74	0.47	7.23e-20	Prostate cancer;
CRC	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.48	7.46	0.38	7.73e-13	HDL cholesterol;
CRC	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.63	-9.77	-0.47	5.91e-20	Ulcerative colitis;
CRC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.89	-0.31	9.38e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs3026101	0.578	rs1806237	chr17:5295399	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.25	-0.37	3.03e-12	Bipolar disorder;
CRC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.51	6.54	0.34	2.42e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg13491945	chr12:107078410	RFX4	0.34	6.01	0.31	5.01e-9	Heart rate;
CRC	trans	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg21372672	chr17:16614065	CCDC144A	-0.39	-6.07	-0.32	3.61e-9	Educational attainment (years of education);
CRC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg12172441	chr6:28176163	NA	0.58	6.39	0.33	5.51e-10	Parkinson's disease;
CRC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.45	6.72	0.35	7.97e-11	N-glycan levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11861043	chr3:49131662	QRICH1	0.43	6.05	0.32	3.86e-9	Response to antipsychotic treatment;
CRC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.5	7.42	0.38	1e-12	Height;
CRC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.82	-9.15	-0.45	6.29e-18	Monocyte percentage of white cells;
CRC	trans	rs11466653	1.000	rs6856864	chr4:38778832	T/C	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg15962314	chr1:44399869	ARTN	0.32	6.23	0.32	1.41e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.19	-0.32	1.83e-9	Post bronchodilator FEV1;
CRC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg17949981	chr6:28129498	ZNF389	0.42	5.85	0.31	1.18e-8	Parkinson's disease;
CRC	cis	rs2625529	0.689	rs10851847	chr15:72111760	T/C	cg16672083	chr15:72433130	SENP8	-0.45	-6.77	-0.35	6.04e-11	Red blood cell count;
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs1524976	1.000	rs62255273	chr3:65452827	C/A	cg16238336	chr3:65465873	MAGI1	-0.53	-7.53	-0.38	4.96e-13	PR interval;
CRC	cis	rs9462846	0.811	rs6939207	chr6:42879486	A/G	cg21280719	chr6:42927975	GNMT	-0.34	-6.54	-0.34	2.38e-10	Blood protein levels;
CRC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.91	0.31	8.63e-9	Self-reported allergy;
CRC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.52	7.25	0.37	2.91e-12	Cognitive function;
CRC	cis	rs9783347	0.890	rs11024634	chr11:18392074	G/A	cg15585147	chr11:18324498	HPS5	0.44	6.11	0.32	2.77e-9	Pancreatic cancer;
CRC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.67	-0.39	1.97e-13	Blood metabolite levels;
CRC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.69	-8.22	-0.41	4.75e-15	Hip circumference adjusted for BMI;
CRC	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg05585544	chr11:47624801	NA	0.41	6.33	0.33	7.9e-10	Mean corpuscular hemoglobin;
CRC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg12639453	chr1:2035780	PRKCZ	-0.37	-6.93	-0.36	2.24e-11	Height;
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.54	8.28	0.42	3.07e-15	Lymphocyte counts;
CRC	cis	rs860295	0.665	rs12028416	chr1:155401161	G/T	cg02153340	chr1:155202674	NA	-0.58	-6.85	-0.35	3.57e-11	Body mass index;
CRC	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg20041105	chr8:143859282	LYNX1	-0.32	-5.7	-0.3	2.64e-8	Urinary tract infection frequency;
CRC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.98	-16.63	-0.68	1.7e-45	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.62	12.68	0.57	2.89e-30	Neuroticism;
CRC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg14711859	chr11:8959438	ASCL3	-0.51	-8.37	-0.42	1.67e-15	Hemoglobin concentration;
CRC	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.6	0.39	3.15e-13	Neuroticism;
CRC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.58	10.88	0.51	9.75e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg24130564	chr14:104152367	KLC1	-0.43	-6.45	-0.33	4.11e-10	Body mass index;
CRC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	7.07	0.36	9.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4150161	0.656	rs1056612	chr16:84211788	G/C	cg10106505	chr16:84220380	TAF1C	-0.72	-6.56	-0.34	2.14e-10	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.4	5.8	0.3	1.54e-8	Obesity-related traits;
CRC	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.67	0.35	1.09e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.53	-7.46	-0.38	7.94e-13	Menarche (age at onset);
CRC	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.98e-16	Corneal astigmatism;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg08354699	chr15:63796895	USP3	-0.52	-6.28	-0.33	1.06e-9	Type 1 diabetes;
CRC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.81	-8.45	-0.42	9.6e-16	Tuberculosis;
CRC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12315302	chr6:26189340	HIST1H4D	0.77	5.99	0.31	5.51e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg19678392	chr7:94953810	PON1	-0.61	-7.49	-0.38	6.42e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.59	8.15	0.41	7.45e-15	Arsenic metabolism;
CRC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg11190155	chr3:9975447	CRELD1	-0.43	-6.53	-0.34	2.51e-10	Aortic root size;
CRC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12172441	chr6:28176163	NA	0.51	7.07	0.36	9.54e-12	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	cis	rs7539624	0.588	rs2186006	chr1:223901545	T/C	cg10100437	chr1:223903862	CAPN2	0.45	6.33	0.33	8.07e-10	Schizophrenia;
CRC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	7.01	0.36	1.38e-11	Rheumatoid arthritis;
CRC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07701084	chr6:150067640	NUP43	0.49	7.17	0.37	4.95e-12	Testicular germ cell tumor;
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.48	5.8	0.3	1.56e-8	Lung function (FEV1/FVC);
CRC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.76	-12.43	-0.57	2.33e-29	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.95	0.4	3e-14	Platelet count;
CRC	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.68	-11.62	-0.54	2.1e-26	Lewy body disease;
CRC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-7.25	-0.37	2.91e-12	Morning vs. evening chronotype;
CRC	cis	rs4731207	0.596	rs10272889	chr7:124576641	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.12	-0.32	2.67e-9	Cutaneous malignant melanoma;
CRC	cis	rs8105895	0.935	rs62110990	chr19:22260441	G/T	cg02657401	chr19:22469223	NA	-0.35	-5.74	-0.3	2.14e-8	Body mass index (change over time);
CRC	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.56	-8.06	-0.41	1.4e-14	Carotid intima media thickness;
CRC	cis	rs10046574	0.831	rs10279987	chr7:135094763	A/G	cg27474649	chr7:135195673	CNOT4	0.64	5.68	0.3	2.95e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.65	-7.01	-0.36	1.35e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg20935933	chr6:143382018	AIG1	0.51	6.69	0.35	9.51e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.64	6.81	0.35	4.74e-11	Chronic lymphocytic leukemia;
CRC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09015484	chr9:96929106	NA	0.46	5.96	0.31	6.34e-9	Thyroid stimulating hormone;
CRC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.64	12.31	0.56	6.53e-29	Coronary artery disease;
CRC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg09877947	chr5:131593287	PDLIM4	0.43	6.86	0.35	3.41e-11	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06529439	chr2:88991002	RPIA	0.41	6.55	0.34	2.24e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg15790184	chr11:494944	RNH1	0.57	5.71	0.3	2.59e-8	Body mass index;
CRC	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.44	8.88	0.44	4.41e-17	Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14903685	chr15:70391316	TLE3	0.37	6.06	0.32	3.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.82	11.82	0.55	4.31e-27	Cognitive function;
CRC	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg15226275	chr6:116381976	FRK	0.31	7.35	0.38	1.57e-12	Total cholesterol levels;
CRC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-6.54	-0.34	2.35e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg16576597	chr16:28551801	NUPR1	0.46	7.02	0.36	1.28e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.67	-10.68	-0.51	4.82e-23	Sudden cardiac arrest;
CRC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-10.09	-0.49	5.09e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.02	10.38	0.5	4.9e-22	Diabetic retinopathy;
CRC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.6	-11.05	-0.52	2.44e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs73206853	0.719	rs28665218	chr12:110809859	C/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.86	0.4	5.46e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.58	6.0	0.31	5.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.74	9.85	0.48	3.18e-20	Coronary artery disease;
CRC	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.57	-7.92	-0.4	3.63e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	11.15	0.52	1.04e-24	Motion sickness;
CRC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.56	-8.84	-0.44	5.83e-17	Intelligence (multi-trait analysis);
CRC	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.66	8.48	0.42	7.57e-16	Uric acid levels;
CRC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.84	-15.11	-0.64	1.57e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04202892	chr2:111875749	ACOXL	0.48	7.9	0.4	4.16e-14	Chronic lymphocytic leukemia;
CRC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg00383909	chr3:49044727	WDR6	0.45	5.88	0.31	1.01e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.56	8.42	0.42	1.16e-15	HDL cholesterol;
CRC	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg20159608	chr7:32802032	NA	-0.63	-8.09	-0.41	1.13e-14	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.84	13.35	0.59	8.87e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	trans	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg13565492	chr6:43139072	SRF	-0.73	-8.04	-0.41	1.6e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg20243544	chr17:37824526	PNMT	0.57	9.06	0.45	1.21e-17	Asthma;
CRC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.43	0.62	6.73e-37	Chronic sinus infection;
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg14873739	chr2:70780723	TGFA	-0.42	-6.03	-0.32	4.37e-9	Total body bone mineral density;
CRC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg18479299	chr3:125709523	NA	-0.55	-6.61	-0.34	1.6e-10	Blood pressure (smoking interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg09011732	chr2:74730507	LOC151534;LBX2	0.42	6.64	0.34	1.27e-10	Obesity-related traits;
CRC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.43	6.3	0.33	9.55e-10	Renal cell carcinoma;
CRC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg10978503	chr1:24200527	CNR2	0.48	8.43	0.42	1.11e-15	Immature fraction of reticulocytes;
CRC	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.01	-0.31	4.94e-9	Breast cancer;
CRC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.34	0.33	7.46e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg25164649	chr6:28176230	NA	0.57	8.01	0.4	1.97e-14	Parkinson's disease;
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg02683197	chr6:28174875	NA	0.63	8.5	0.42	6.49e-16	Parkinson's disease;
CRC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.01	-10.08	-0.49	5.32e-21	Breast cancer;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg17304336	chr11:65343565	EHBP1L1	0.46	6.65	0.34	1.19e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg10760299	chr15:45669010	GATM	0.51	7.74	0.39	1.26e-13	Homoarginine levels;
CRC	cis	rs490234	0.934	rs13284832	chr9:128435126	A/C	cg14078157	chr9:128172775	NA	-0.37	-6.04	-0.32	4.18e-9	Mean arterial pressure;
CRC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg09127314	chr1:152161683	NA	0.53	6.69	0.35	9.52e-11	Atopic dermatitis;
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.71	11.09	0.52	1.65e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.64	8.77	0.44	9.78e-17	Methadone dose in opioid dependence;
CRC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.35	0.33	7.02e-10	Tonsillectomy;
CRC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg10790698	chr19:18539756	SSBP4	-0.46	-8.93	-0.44	3.15e-17	Breast cancer;
CRC	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.52	-6.72	-0.35	8.02e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19046167	chr17:80928561	B3GNTL1	0.51	7.16	0.37	5.45e-12	Glycated hemoglobin levels;
CRC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg26587870	chr6:27730563	NA	-0.56	-6.44	-0.33	4.31e-10	Lung cancer in ever smokers;
CRC	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg03929089	chr4:120376271	NA	0.63	6.06	0.32	3.73e-9	Axial length;
CRC	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg14352298	chr13:112236639	NA	0.29	6.66	0.34	1.18e-10	Hepatitis;
CRC	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.4	-5.74	-0.3	2.15e-8	Platelet distribution width;
CRC	cis	rs7705042	0.865	rs4912623	chr5:141505462	T/A	cg08523384	chr5:141488047	NDFIP1	-0.33	-5.84	-0.31	1.23e-8	Asthma;
CRC	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg20356878	chr3:121714668	ILDR1	0.52	8.21	0.41	5.11e-15	Cognitive performance;
CRC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.37	-6.64	-0.34	1.29e-10	Dupuytren's disease;
CRC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19229622	chr11:47291485	MADD	0.47	6.55	0.34	2.28e-10	Response to antipsychotic treatment;
CRC	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.33	0.46	1.56e-18	Iron status biomarkers;
CRC	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg22732515	chr19:44031385	ETHE1	0.69	10.35	0.5	6.57e-22	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.1	-0.52	1.52e-24	Type 2 diabetes;
CRC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg13844804	chr7:814759	HEATR2	0.67	8.56	0.43	4.26e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.57	-9.21	-0.45	3.98e-18	Intelligence (multi-trait analysis);
CRC	trans	rs6544773	0.764	rs340500	chr2:45080242	A/C	cg10208897	chr5:178548229	ADAMTS2	0.35	5.98	0.31	5.79e-9	Mosquito bite size;
CRC	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg00531865	chr16:30841666	NA	-0.42	-6.1	-0.32	2.93e-9	Dementia with Lewy bodies;
CRC	trans	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.44	6.25	0.33	1.29e-9	Cystic fibrosis severity;
CRC	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.63	-0.3	3.95e-8	Educational attainment (years of education);
CRC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.81	0.35	4.6e-11	Cognitive ability;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg08222913	chr3:52553049	STAB1	0.36	6.49	0.34	3.11e-10	Bipolar disorder;
CRC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg16060761	chr17:80687452	NA	-0.46	-5.95	-0.31	7.05e-9	Glycated hemoglobin levels;
CRC	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.63	8.83	0.44	6.14e-17	Type 2 diabetes;
CRC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.06e-16	Schizophrenia;
CRC	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.63	10.17	0.49	2.57e-21	Blood pressure (smoking interaction);
CRC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	7.8	0.4	8.11e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg01788221	chr16:89496183	ANKRD11	-0.43	-6.36	-0.33	6.69e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg21251018	chr6:28226885	NKAPL	0.48	6.19	0.32	1.84e-9	Depression;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	8.02	0.4	1.82e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09883524	chr16:89984247	MC1R	0.45	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.35	5.71	0.3	2.54e-8	Menarche (age at onset);
CRC	cis	rs2072510	0.593	rs2540499	chr12:96399869	A/C	cg22491680	chr12:96389547	HAL	0.47	6.06	0.32	3.81e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg15382696	chr6:118971807	C6orf204	0.59	7.1	0.36	7.52e-12	Diastolic blood pressure;
CRC	cis	rs1656402	0.906	rs2276560	chr2:233450919	C/T	cg03852847	chr2:233439513	NA	-0.39	-6.73	-0.35	7.76e-11	Non-small cell lung cancer (survival);
CRC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.98	-0.36	1.64e-11	Cognitive function;
CRC	cis	rs4964805	0.606	rs7312606	chr12:104188385	C/G	cg02344784	chr12:104178138	NT5DC3	0.79	15.0	0.64	4.21e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs4728302	0.869	rs12707130	chr7:133616739	G/T	cg03336402	chr7:133662267	EXOC4	-0.46	-6.68	-0.35	1.01e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21963583	chr11:68658836	MRPL21	0.63	11.58	0.54	3.15e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg23260525	chr10:116636907	FAM160B1	0.31	6.24	0.33	1.35e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.41	0.5	4.01e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.47	-7.19	-0.37	4.32e-12	Tonsillectomy;
CRC	trans	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg16899823	chr10:58121153	ZWINT	-0.39	-6.06	-0.32	3.76e-9	Survival in rectal cancer;
CRC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-0.73	-6.64	-0.34	1.28e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg00999904	chr2:3704751	ALLC	-0.44	-6.33	-0.33	8.03e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	20.41	0.75	2.17e-60	Prudent dietary pattern;
CRC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.66	0.57	3.38e-30	Bone mineral density;
CRC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.96	-18.49	-0.71	7.73e-53	Height;
CRC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-16.16	-0.67	1.19e-43	Electrocardiographic conduction measures;
CRC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.54	7.75	0.39	1.16e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	trans	rs2303319	0.504	rs1515182	chr2:162436934	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.0	-0.31	5.13e-9	Cognitive function;
CRC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	8.55e-15	Red blood cell count;
CRC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-6.68	-0.35	9.91e-11	Subjective well-being;
CRC	cis	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg18809830	chr7:99032528	PTCD1	-0.93	-7.58	-0.39	3.66e-13	Blood metabolite levels;
CRC	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg27205649	chr11:78285834	NARS2	0.48	5.69	0.3	2.79e-8	Alzheimer's disease (survival time);
CRC	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-6.94	-0.36	2.15e-11	Diastolic blood pressure;
CRC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg22777020	chr22:31556080	RNF185	0.54	6.27	0.33	1.12e-9	Colorectal cancer;
CRC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg02993699	chr4:3415135	RGS12	-0.41	-6.72	-0.35	7.79e-11	Serum sulfate level;
CRC	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.74	-10.41	-0.5	3.85e-22	Monocyte percentage of white cells;
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg03623178	chr6:28175578	NA	0.79	6.96	0.36	1.89e-11	Breast cancer;
CRC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg02659138	chr7:134003124	SLC35B4	0.39	6.65	0.34	1.22e-10	Mean platelet volume;
CRC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.64	8.66	0.43	2.14e-16	Multiple sclerosis;
CRC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.59	8.44	0.42	1.02e-15	Homoarginine levels;
CRC	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg20744362	chr22:50050164	C22orf34	0.34	6.21	0.32	1.55e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg12273811	chr6:28175739	NA	0.6	6.3	0.33	9.28e-10	Lung cancer in ever smokers;
CRC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.84	-0.44	6.02e-17	Hemoglobin concentration;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.73	10.62	0.51	7.64e-23	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.82	14.26	0.62	2.83e-36	Breast cancer;
CRC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.7	0.3	2.67e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-15.28	-0.64	3.27e-40	Vitiligo;
CRC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg24560729	chr4:1342394	KIAA1530	0.33	5.86	0.31	1.11e-8	Longevity;
CRC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.84	-0.35	3.85e-11	Monocyte percentage of white cells;
CRC	cis	rs7538876	0.903	rs6681150	chr1:17750685	G/A	cg07965774	chr1:17746286	RCC2	0.33	6.15	0.32	2.26e-9	Basal cell carcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03984733	chr9:116139085	HDHD3	0.47	6.02	0.31	4.74e-9	Thyroid stimulating hormone;
CRC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.7	6.45	0.34	3.98e-10	Diabetic kidney disease;
CRC	cis	rs9463078	0.585	rs4072928	chr6:45291229	A/G	cg25276700	chr6:44698697	NA	-0.24	-5.75	-0.3	2.09e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg14008862	chr17:28927542	LRRC37B2	0.54	5.79	0.3	1.66e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg23920097	chr1:209922102	NA	-0.49	-5.62	-0.3	4.03e-8	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13402292	chr21:37667921	NA	-0.38	-6.06	-0.32	3.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.53	-8.43	-0.42	1.06e-15	Sum neutrophil eosinophil counts;
CRC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.38	-0.5	5.2e-22	Breast cancer;
CRC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg04117972	chr1:227635322	NA	0.62	6.92	0.36	2.43e-11	Major depressive disorder;
CRC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.73	9.04	0.45	1.42e-17	Gestational age at birth (maternal effect);
CRC	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-0.9	-7.59	-0.39	3.32e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs60871478	0.786	rs12532534	chr7:831891	G/A	cg13798912	chr7:905769	UNC84A	-0.53	-5.99	-0.31	5.65e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.59	10.89	0.51	8.99e-24	Tonsillectomy;
CRC	cis	rs9469578	1.000	rs9469582	chr6:33715939	A/G	cg18708504	chr6:33715942	IP6K3	0.66	7.52	0.38	5.12e-13	Phosphorus levels;
CRC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg09877947	chr5:131593287	PDLIM4	0.45	7.36	0.38	1.49e-12	Breast cancer;
CRC	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.44	-8.78	-0.44	9.19e-17	Alcohol dependence;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg17147758	chr8:6949321	NA	-0.52	-7.2	-0.37	4.24e-12	Blood pressure (smoking interaction);
CRC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-0.96	-9.72	-0.47	8.81e-20	Diabetic retinopathy;
CRC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.78	11.09	0.52	1.7e-24	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.08e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg14844989	chr11:31128820	NA	0.36	6.29	0.33	1.01e-9	Red blood cell count;
CRC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.61	8.4	0.42	1.37e-15	Arsenic metabolism;
CRC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg24560729	chr4:1342394	KIAA1530	0.34	6.27	0.33	1.1e-9	Obesity-related traits;
CRC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.0	0.55	8.81e-28	Hip circumference adjusted for BMI;
CRC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.5	9.43	0.46	7.84e-19	Smoking initiation;
CRC	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg27499820	chr13:21296301	IL17D	-0.39	-5.79	-0.3	1.6e-8	Dental caries;
CRC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.64	0.34	1.3100000000000001e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg20203395	chr5:56204925	C5orf35	-0.42	-5.95	-0.31	6.75e-9	Coronary artery disease;
CRC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg26918954	chr5:179728553	GFPT2	-0.44	-7.37	-0.38	1.42e-12	Height;
CRC	cis	rs6563739	0.655	rs4476043	chr13:40225608	G/A	cg00026919	chr13:40226031	NA	0.48	6.12	0.32	2.69e-9	Menarche (age at onset);
CRC	cis	rs17532515	0.628	rs882930	chr4:141458485	T/G	cg09181644	chr4:141490428	UCP1	-0.32	-5.76	-0.3	1.89e-8	Select biomarker traits;
CRC	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg27053337	chr8:124217698	FAM83A	0.43	6.65	0.34	1.21e-10	Urinary uromodulin levels;
CRC	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg20607287	chr7:12443886	VWDE	-0.54	-5.69	-0.3	2.87e-8	Coronary artery disease;
CRC	cis	rs11212617	1.000	rs11212615	chr11:108281267	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.43	0.33	4.4e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg05303289	chr1:40506118	CAP1	0.43	6.05	0.32	3.84e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-8.1	-0.41	1.06e-14	Bipolar disorder;
CRC	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.72	-0.3	2.41e-8	Tuberculosis;
CRC	cis	rs11212617	0.870	rs227078	chr11:108250381	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.44	6.76	0.35	6.12e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-13.4	-0.59	5.88e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.38	-0.42	1.52e-15	Depression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09106556	chr19:35168274	ZNF302	0.41	6.14	0.32	2.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.81	0.48	4.27e-20	Lung cancer;
CRC	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.86	-9.28	-0.46	2.41e-18	Arsenic metabolism;
CRC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.7	0.39	1.61e-13	Mean platelet volume;
CRC	trans	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg26043149	chr18:55253948	FECH	0.54	8.28	0.42	3.09e-15	Bone mineral density;
CRC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg10729496	chr3:10149963	C3orf24	0.49	6.55	0.34	2.22e-10	Alzheimer's disease;
CRC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.45	-6.66	-0.34	1.12e-10	Cognitive test performance;
CRC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg11632617	chr15:75315747	PPCDC	-0.52	-7.05	-0.36	1.04e-11	Blood trace element (Zn levels);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04986989	chr1:146714493	CHD1L	0.44	6.03	0.32	4.35e-9	Response to antipsychotic treatment;
CRC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.63	9.72	0.47	8.34e-20	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08900073	chr11:118796721	NA	0.51	7.38	0.38	1.26e-12	Intelligence (multi-trait analysis);
CRC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.82	-9.5	-0.46	4.38e-19	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Smoking initiation;
CRC	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-0.41	-6.74	-0.35	7.31e-11	Mean arterial pressure;
CRC	cis	rs3790455	0.610	rs1171561	chr1:156455898	G/A	cg14087168	chr1:156450669	MEF2D	-0.38	-6.53	-0.34	2.52e-10	Migraine;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00807877	chr14:70095319	KIAA0247	0.39	6.18	0.32	1.88e-9	Interleukin-6 levels;
CRC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18867708	chr6:26865862	GUSBL1	0.44	6.37	0.33	6.37e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg03973167	chr4:185394988	IRF2	-0.44	-6.3	-0.33	9.77e-10	Schizophrenia;
CRC	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg19875578	chr6:126661172	C6orf173	0.42	5.86	0.31	1.15e-8	Male-pattern baldness;
CRC	cis	rs995000	0.931	rs1168020	chr1:63009956	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.82	-0.35	4.3e-11	Triglyceride levels;
CRC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.98	0.48	1.15e-20	Cognitive test performance;
CRC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.68	-10.09	-0.49	4.94e-21	Monocyte count;
CRC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg21153622	chr11:89784906	NA	-0.51	-8.55	-0.43	4.76e-16	HDL cholesterol;
CRC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg15147215	chr3:52552868	STAB1	-0.61	-10.28	-0.49	1.08e-21	Bipolar disorder;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg02375201	chr1:27114675	PIGV	0.54	5.97	0.31	6.17e-9	Body mass index;
CRC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg21132104	chr15:45694354	SPATA5L1	0.41	5.84	0.31	1.25e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-7.91	-0.4	4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4964805	1.000	rs4964794	chr12:104194418	T/C	cg02344784	chr12:104178138	NT5DC3	0.55	8.21	0.41	4.99e-15	Attention deficit hyperactivity disorder;
CRC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg04969067	chr8:143858791	LYNX1	0.45	7.58	0.39	3.66e-13	Urinary tract infection frequency;
CRC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg21681030	chr2:46777652	RHOQ	0.52	7.39	0.38	1.23e-12	Height;
CRC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.35	-0.33	7.36e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg16989086	chr20:62203971	PRIC285	-0.5	-6.38	-0.33	6.07e-10	Atopic dermatitis;
CRC	cis	rs6952808	0.724	rs7792631	chr7:1982779	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-10.18	-0.49	2.5e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11446398	chr5:77624930	NA	0.46	6.34	0.33	7.62e-10	Triglycerides;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.44	6.02	0.31	4.75e-9	Longevity;Endometriosis;
CRC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12463550	chr7:65579703	CRCP	0.69	6.3	0.33	9.48e-10	Diabetic kidney disease;
CRC	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.6	-0.3	4.45e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs12432203	1.000	rs9918	chr14:51722690	T/C	cg14592830	chr9:122318704	NA	0.61	6.19	0.32	1.78e-9	Cancer;
CRC	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.41	-5.72	-0.3	2.45e-8	Heschl's gyrus morphology;
CRC	cis	rs12079745	0.793	rs12092506	chr1:169405517	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.9	-6.06	-0.32	3.76e-9	QT interval;
CRC	cis	rs4731207	0.596	rs1026837	chr7:124673079	C/T	cg23710748	chr7:124431027	NA	-0.43	-6.72	-0.35	8e-11	Cutaneous malignant melanoma;
CRC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.46	7.78	0.39	9.67e-14	Hemoglobin concentration;
CRC	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg16068336	chr17:48637367	CACNA1G	-0.48	-6.94	-0.36	2.11e-11	Type 2 diabetes;
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg02033258	chr5:131593261	PDLIM4	0.38	6.24	0.33	1.37e-9	Acylcarnitine levels;
CRC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.65	9.75	0.47	6.68e-20	Lung cancer;
CRC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-0.58	-8.44	-0.42	9.93e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.62	9.49	0.46	4.83e-19	Crohn's disease;
CRC	cis	rs72634258	0.572	rs66692705	chr1:7938565	T/C	cg26816564	chr1:7831052	VAMP3	0.77	8.57	0.43	4.09e-16	Inflammatory bowel disease;
CRC	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.41	-6.36	-0.33	6.56e-10	IFN-related cytopenia;
CRC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.8	-11.14	-0.52	1.15e-24	Intelligence (multi-trait analysis);
CRC	cis	rs3889199	0.924	rs7517356	chr1:59679122	G/A	cg25881383	chr1:59680599	NA	-0.38	-6.19	-0.32	1.8e-9	Pulse pressure;
CRC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.3	-0.33	9.82e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08400563	chr2:201729555	CLK1	0.5	6.35	0.33	7.34e-10	Thyroid stimulating hormone;
CRC	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg01339444	chr6:118972232	C6orf204	0.55	6.01	0.31	4.93e-9	Diastolic blood pressure;
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg00343986	chr7:65444356	GUSB	0.43	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.6	8.45	0.42	9.64e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13012494	chr21:47604986	C21orf56	0.41	6.27	0.33	1.11e-9	Testicular germ cell tumor;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16347724	chr6:27782484	HIST1H2AJ;HIST1H2BM	0.43	6.43	0.33	4.47e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.53	0.43	5.25e-16	Iron status biomarkers;
CRC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.62	10.58	0.5	9.97e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.69	-0.43	1.7e-16	Aortic root size;
CRC	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.52	8.9	0.44	3.89e-17	Testicular germ cell tumor;
CRC	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg26695010	chr11:65641043	EFEMP2	0.44	6.28	0.33	1.05e-9	DNA methylation (variation);
CRC	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.75	15.17	0.64	9.02e-40	Leprosy;
CRC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.62	11.29	0.53	3.3e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg01849466	chr14:104193079	ZFYVE21	0.38	6.03	0.32	4.3e-9	Body mass index;
CRC	cis	rs7781266	0.895	rs6956399	chr7:133305729	G/A	cg03336402	chr7:133662267	EXOC4	0.49	6.02	0.31	4.77e-9	Educational attainment (college completion);
CRC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.9	16.66	0.68	1.25e-45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg07460842	chr6:66804631	NA	-0.42	-5.62	-0.3	4.11e-8	Blood trace element (Cu levels);
CRC	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg04850286	chr10:81895943	PLAC9	0.37	6.71	0.35	8.44e-11	Sarcoidosis;
CRC	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg06207120	chr15:45996521	NA	0.32	7.85	0.4	6.04e-14	Waist circumference;Weight;
CRC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	9.6	0.47	2.15e-19	Height;
CRC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.72	10.64	0.51	6.49e-23	Intelligence (multi-trait analysis);
CRC	trans	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg03060546	chr3:49711283	APEH	-0.52	-6.04	-0.32	4.06e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7827545	1.000	rs6578237	chr8:135569358	C/G	cg17885191	chr8:135476712	NA	-0.45	-6.51	-0.34	2.78e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.54	9.85	0.48	3.17e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-9.1	-0.45	8.6e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	19.01	0.72	6.94e-55	Prudent dietary pattern;
CRC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.81	0.58	9.35e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	10.94	0.52	5.88e-24	Prudent dietary pattern;
CRC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.83	-0.4	6.77e-14	Blood metabolite levels;
CRC	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20583945	chr8:144636462	GSDMD	0.5	7.09	0.36	8.22e-12	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.34	6.07	0.32	3.47e-9	Plateletcrit;Mean corpuscular volume;
CRC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.55	6.11	0.32	2.86e-9	Initial pursuit acceleration;
CRC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg00316803	chr15:76480434	C15orf27	-0.38	-6.38	-0.33	5.94e-10	Blood metabolite levels;
CRC	cis	rs9292777	0.666	rs55673407	chr5:40399074	T/A	cg09067459	chr5:40385259	NA	-0.55	-8.97	-0.44	2.31e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs1524976	1.000	rs62255277	chr3:65470507	A/G	cg16238336	chr3:65465873	MAGI1	-0.54	-7.63	-0.39	2.6e-13	PR interval;
CRC	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.19	0.64	7.56e-40	Hypertriglyceridemia;
CRC	trans	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg20935933	chr6:143382018	AIG1	0.51	6.65	0.34	1.25e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.61	-7.38	-0.38	1.34e-12	Obesity (extreme);
CRC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg19193384	chr17:30244184	NA	-0.63	-7.4	-0.38	1.15e-12	Hip circumference adjusted for BMI;
CRC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.65	-11.17	-0.52	8.86e-25	Brugada syndrome;
CRC	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg06462663	chr19:18546047	ISYNA1	0.5	7.37	0.38	1.38e-12	Breast cancer;
CRC	cis	rs4964805	0.626	rs869993	chr12:104175138	A/T	cg02344784	chr12:104178138	NT5DC3	0.57	8.77	0.44	9.48e-17	Attention deficit hyperactivity disorder;
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.61	0.34	1.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.5	8.89	0.44	4.04e-17	Common traits (Other);
CRC	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.6	8.33	0.42	2.15e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7626444	0.625	rs2686593	chr3:196477401	G/A	cg12930392	chr3:196481615	PAK2	0.41	7.3	0.37	2.23e-12	Monocyte count;
CRC	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	18.14	0.71	1.77e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.73	9.73	0.47	8.13e-20	Alzheimer's disease;
CRC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.48	-9.66	-0.47	1.33e-19	Prostate cancer;
CRC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg23758597	chr6:163146217	PARK2	-0.57	-6.35	-0.33	7.21e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.91	17.62	0.7	2.07e-49	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.93	0.48	1.73e-20	Platelet count;
CRC	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg15704280	chr7:45808275	SEPT13	-0.56	-6.95	-0.36	1.95e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.35	5.72	0.3	2.35e-8	Coronary artery disease;
CRC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg00166722	chr3:10149974	C3orf24	0.43	6.32	0.33	8.43e-10	Alzheimer's disease;
CRC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.23	-0.33	1.39e-9	Post bronchodilator FEV1;
CRC	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Colorectal cancer;
CRC	cis	rs11229555	0.645	rs7929868	chr11:58209418	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.45	-0.5	2.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg21155852	chr7:2048760	MAD1L1	-0.42	-6.14	-0.32	2.32e-9	Bipolar disorder;
CRC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.59	6.93	0.36	2.24e-11	Vitiligo;
CRC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg20119798	chr7:94954144	PON1	-0.49	-6.26	-0.33	1.21e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02097616	chr17:62675921	NA	0.45	6.68	0.35	1.05e-10	QT interval;
CRC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.61	11.57	0.54	3.44e-26	Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27438756	chr1:74663921	TNNI3K;FPGT;LRRIQ3	0.38	6.12	0.32	2.6e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.35	5.84	0.31	1.25e-8	Vitiligo;
CRC	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg17470449	chr10:769945	NA	0.51	7.05	0.36	1.03e-11	Uric acid levels;
CRC	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-0.72	-7.35	-0.38	1.59e-12	Blood protein levels;
CRC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.77	0.35	5.83e-11	HIV-1 control;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg21251018	chr6:28226885	NKAPL	0.48	7.51	0.38	5.5e-13	Parkinson's disease;
CRC	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg14593290	chr7:50529359	DDC	0.51	7.11	0.37	7.09e-12	Malaria;
CRC	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg06470822	chr6:28175283	NA	-0.62	-6.5	-0.34	3.01e-10	Depression;
CRC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.66	9.21	0.45	4.08e-18	Neuroblastoma;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg06470822	chr6:28175283	NA	0.85	12.72	0.57	2.03e-30	Parkinson's disease;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg20809690	chr4:2757764	TNIP2	0.46	6.12	0.32	2.73e-9	Hip circumference;
CRC	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.69	-9.76	-0.47	6.24e-20	Personality dimensions;
CRC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Bone mineral density;
CRC	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.18	-0.32	1.89e-9	Diastolic blood pressure;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01657694	chr22:20849950	KLHL22	0.47	6.19	0.32	1.83e-9	Anxiety disorder;
CRC	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.5	7.76	0.39	1.11e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.56	-8.88	-0.44	4.58e-17	Personality dimensions;
CRC	cis	rs10901296	0.660	rs2855198	chr9:133764606	T/C	cg01000188	chr9:133769184	QRFP	0.62	7.82	0.4	7.42e-14	Bilirubin levels;
CRC	cis	rs3018066	0.836	rs3109955	chr4:107254171	T/C	cg01869342	chr4:106983673	TBCK	0.36	5.61	0.3	4.25e-8	Cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17156767	chr19:30364462	NA	0.38	6.12	0.32	2.69e-9	Obesity-related traits;
CRC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg16797656	chr11:68205561	LRP5	0.37	5.74	0.3	2.16e-8	Total body bone mineral density;
CRC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.73	11.8	0.55	4.95e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20150972	chr6:13574573	SIRT5	0.41	7.09	0.36	8.45e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg22638593	chr5:131593259	PDLIM4	0.49	9.27	0.45	2.59e-18	Acylcarnitine levels;
CRC	cis	rs3731570	0.818	rs66730758	chr2:198341001	A/G	cg10820045	chr2:198174542	NA	0.33	5.88	0.31	9.94e-9	Morning vs. evening chronotype;
CRC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.64	7.98	0.4	2.41e-14	Menarche (age at onset);
CRC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.03	-22.68	-0.78	3.24e-69	Multiple system atrophy;
CRC	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.29	-0.33	1e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.72	11.71	0.54	1.02e-26	Monocyte count;
CRC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.49	6.57	0.34	1.95e-10	Red blood cell count;
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg07404485	chr7:94953653	PON1	-0.47	-6.24	-0.33	1.37e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.79	8.57	0.43	4.23e-16	Migraine;Coronary artery disease;
CRC	trans	rs559356	0.519	rs475330	chr3:34841244	A/G	cg19071035	chr6:20404090	E2F3	-0.45	-6.08	-0.32	3.38e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05513509	chr18:20513742	RBBP8	0.43	6.95	0.36	1.95e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	13.81	0.61	1.58e-34	Mean corpuscular hemoglobin;
CRC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg18876405	chr7:65276391	NA	0.44	6.42	0.33	4.69e-10	Aortic root size;
CRC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.39	5.8	0.3	1.57e-8	Morning vs. evening chronotype;
CRC	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.92	-0.31	8.16e-9	Type 2 diabetes;
CRC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg20092199	chr4:1342459	KIAA1530	0.46	7.25	0.37	3.06e-12	Obesity-related traits;
CRC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.67	12.14	0.56	2.73e-28	Aortic root size;
CRC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.61	9.64	0.47	1.54e-19	Systemic lupus erythematosus;
CRC	cis	rs7614311	0.731	rs3733121	chr3:63850660	C/G	cg22134162	chr3:63841271	THOC7	-0.58	-5.86	-0.31	1.1e-8	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	6.19e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg16989719	chr2:238392110	NA	-0.38	-7.43	-0.38	9.71e-13	Prostate cancer;
CRC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-5.98	-0.31	5.7e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-9.05	-0.45	1.3e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.43	6.69	0.35	9.56e-11	Corneal astigmatism;
CRC	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.56	9.54	0.47	3.26e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.57	6.5	0.34	2.9e-10	Type 2 diabetes nephropathy;
CRC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.62	10.01	0.48	9.42e-21	Breast cancer;
CRC	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg13798780	chr7:105162888	PUS7	0.6	6.04	0.32	4.25e-9	Bipolar disorder (body mass index interaction);
CRC	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.49	-7.52	-0.38	5.23e-13	Type 2 diabetes;
CRC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.4	-6.41	-0.33	5.11e-10	Type 2 diabetes;
CRC	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.72	-9.56	-0.47	2.93e-19	Coronary artery disease;
CRC	cis	rs10097731	0.808	rs80141261	chr8:82034453	T/C	cg25230327	chr8:82042993	NA	-0.81	-12.04	-0.55	6.59e-28	Serum total protein level;
CRC	cis	rs6728302	0.557	rs73002000	chr2:233254052	C/T	cg09490371	chr2:233253024	ECEL1P2	-0.72	-6.38	-0.33	5.88e-10	Height;
CRC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg16060761	chr17:80687452	NA	-0.46	-5.9	-0.31	9.22e-9	Glycated hemoglobin levels;
CRC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06505273	chr16:24850292	NA	-0.39	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.47	-7.57	-0.39	3.75e-13	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg20041105	chr8:143859282	LYNX1	0.46	8.15	0.41	7.63e-15	Urinary tract infection frequency;
CRC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04044502	chr10:64028395	RTKN2	0.45	6.39	0.33	5.52e-10	Response to antipsychotic treatment;
CRC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	8.11	0.41	1.02e-14	Personality dimensions;
CRC	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.53	-0.43	5.46e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.97	-0.4	2.6e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg22687807	chr8:143858763	LYNX1	-0.45	-7.05	-0.36	1.08e-11	Urinary tract infection frequency;
CRC	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	18.16	0.71	1.55e-51	Colorectal cancer;
CRC	cis	rs4731207	0.651	rs1525619	chr7:124654541	T/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20288518	chr10:71389959	C10orf35	0.41	6.39	0.33	5.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12286929	0.606	rs11823428	chr11:115071222	C/A	cg04055981	chr11:115044050	NA	0.43	6.87	0.35	3.3e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.85	-12.04	-0.55	6.36e-28	Blood metabolite levels;
CRC	trans	rs7976838	0.908	rs12826693	chr12:60155471	A/G	cg16974014	chr22:22007515	MIR130B	0.52	6.17	0.32	2e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg17949981	chr6:28129498	ZNF389	0.42	5.81	0.3	1.51e-8	Cardiac Troponin-T levels;
CRC	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg18232548	chr7:50535776	DDC	0.43	6.1	0.32	2.93e-9	Malaria;
CRC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.6	7.41	0.38	1.08e-12	Mean platelet volume;
CRC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-8.45	-0.42	9.79e-16	Electroencephalogram traits;
CRC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg27523141	chr10:43048294	ZNF37B	-0.45	-6.42	-0.33	4.74e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	15.21	0.64	6.36e-40	Smoking behavior;
CRC	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.71	-11.85	-0.55	3.1e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1950626	0.833	rs67456801	chr14:101399169	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.95	15.91	0.66	1.13e-42	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg08888203	chr3:10149979	C3orf24	0.48	7.33	0.37	1.74e-12	Alzheimer's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13476336	chr17:38255694	NR1D1	0.47	6.51	0.34	2.86e-10	Response to antipsychotic treatment;
CRC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg14979609	chr8:8086686	FLJ10661	0.38	6.14	0.32	2.44e-9	Joint mobility (Beighton score);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27018124	chr22:26879714	HPS4;SRRD	0.47	6.83	0.35	4.24e-11	Response to antipsychotic treatment;
CRC	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.65	-10.27	-0.49	1.19e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9322817	0.691	rs2486141	chr6:105299930	G/A	cg02098413	chr6:105308735	HACE1	0.43	8.51	0.42	6.41e-16	Thyroid stimulating hormone;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg16131300	chr5:31532187	RNASEN;C5orf22	0.49	6.89	0.36	2.89e-11	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg10437265	chr15:77819839	NA	-0.45	-8.06	-0.41	1.43e-14	Type 2 diabetes;
CRC	cis	rs9903692	0.779	rs2285863	chr17:46125978	C/G	cg21215337	chr17:46176117	CBX1	0.42	7.77	0.39	9.91e-14	Pulse pressure;
CRC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.44	-0.33	4.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.55	7.08	0.36	8.98e-12	Intelligence (multi-trait analysis);
CRC	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.49	11.42	0.53	1.12e-25	Systolic blood pressure;
CRC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs7605827	0.930	rs1861768	chr2:15625186	C/A	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.71	10.74	0.51	2.92e-23	Corneal astigmatism;
CRC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg21770322	chr7:97807741	LMTK2	0.52	8.52	0.43	5.7e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg27565382	chr3:53032988	SFMBT1	0.7	6.19	0.32	1.76e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.37	0.33	6.37e-10	Life satisfaction;
CRC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	0.55	5.87	0.31	1.08e-8	Coronary artery disease;
CRC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.5	7.46	0.38	7.97e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07591283	chr1:44412003	IPO13	0.43	6.12	0.32	2.67e-9	Response to antipsychotic treatment;
CRC	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.85	-0.4	5.97e-14	Superior frontal gyrus grey matter volume;
CRC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.58	-9.47	-0.46	5.78e-19	Paraoxonase activity;
CRC	trans	rs623264	0.920	rs671283	chr19:5470410	C/G	cg13775005	chr14:36002441	INSM2	-0.48	-5.97	-0.31	6.13e-9	Interleukin-2 receptor antagonist levels;
CRC	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.45	6.67	0.35	1.09e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs12024301	0.557	rs7531786	chr1:183595234	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.76	-12.59	-0.57	6.38e-30	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg10398005	chr11:117014888	PAFAH1B2	-0.45	-6.72	-0.35	8.03e-11	Blood protein levels;
CRC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.5	7.82	0.4	7.2e-14	Corneal astigmatism;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg20755353	chr1:1510883	SSU72	-0.37	-6.17	-0.32	1.98e-9	HDL cholesterol;
CRC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg04166393	chr7:2884313	GNA12	0.4	6.09	0.32	3.18e-9	Height;
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.24	-0.37	3.28e-12	Bipolar disorder;
CRC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.47	6.32	0.33	8.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.64	10.09	0.49	4.87e-21	Methadone dose in opioid dependence;
CRC	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg22778903	chr21:42741698	MX2	0.38	6.19	0.32	1.78e-9	Melanoma;
CRC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.58	-9.17	-0.45	5.43e-18	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.94	0.52	5.78e-24	Motion sickness;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21864845	chr1:1208426	UBE2J2	-0.49	-6.03	-0.32	4.41e-9	Diisocyanate-induced asthma;
CRC	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.74	-10.05	-0.48	6.67e-21	White matter hyperintensity burden;
CRC	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.95	-0.36	1.95e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23378565	chr7:2036160	MAD1L1	-0.5	-7.03	-0.36	1.17e-11	Bipolar disorder;
CRC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.12	-0.37	6.81e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs4853036	0.857	rs1048139	chr2:70131791	T/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.96	-0.31	6.66e-9	Colorectal or endometrial cancer;
CRC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.66	9.44	0.46	7.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs938554	0.657	rs7660895	chr4:9985445	A/G	cg00071950	chr4:10020882	SLC2A9	0.4	5.87	0.31	1.09e-8	Blood metabolite levels;
CRC	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg15654264	chr1:150340011	RPRD2	0.37	5.65	0.3	3.5e-8	Migraine;
CRC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	trans	rs6589563	0.737	rs28927680	chr11:116619073	C/G	cg21981096	chr15:96423622	NA	0.54	6.45	0.34	4.09e-10	Eosinophil counts;
CRC	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.96	-12.38	-0.56	3.67e-29	Exhaled nitric oxide output;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.73	7.7	0.39	1.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.51	0.34	2.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.51	10.1	0.49	4.6e-21	Renal cell carcinoma;
CRC	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.53	-9.88	-0.48	2.56e-20	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.52	-0.34	2.68e-10	Reticulocyte fraction of red cells;
CRC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-5.96	-0.31	6.58e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg02560186	chr11:3602584	NA	-0.63	-9.69	-0.47	1.04e-19	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.84	-12.9	-0.58	4.26e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.34	-0.33	7.65e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.09	0.32	3.17e-9	Lung cancer;
CRC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.72	0.3	2.39e-8	Vitiligo;
CRC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.6	0.39	3.15e-13	Lung cancer in ever smokers;
CRC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg09127314	chr1:152161683	NA	0.53	6.69	0.35	9.52e-11	Atopic dermatitis;
CRC	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.48	7.85	0.4	6.03e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.59	8.85	0.44	5.43e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9462027	0.628	rs3734264	chr6:34831866	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.11	-0.32	2.79e-9	Systemic lupus erythematosus;
CRC	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.54	9.15	0.45	6.06e-18	Dupuytren's disease;
CRC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.56	-8.2	-0.41	5.49e-15	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.72	-0.3	2.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg04990556	chr1:26633338	UBXN11	-0.46	-5.76	-0.3	1.98e-8	Granulocyte percentage of myeloid white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17595410	chr2:128165857	NA	0.48	6.56	0.34	2.09e-10	Anxiety disorder;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.52	8.11	0.41	9.84e-15	Red blood cell count;
CRC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.62	-9.19	-0.45	4.48e-18	Subjective well-being;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14021555	chr22:43485536	TTLL1	0.51	6.6	0.34	1.63e-10	Thyroid stimulating hormone;
CRC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	10.01	0.48	8.81e-21	Coronary artery disease;
CRC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.49	8.1	0.41	1.11e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.21	0.45	3.82e-18	Height;
CRC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.66	9.27	0.46	2.54e-18	Multiple sclerosis;
CRC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-7.98	-0.4	2.46e-14	Major depressive disorder;
CRC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg03037974	chr15:76606532	NA	-0.52	-7.75	-0.39	1.16e-13	Blood metabolite levels;
CRC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.22	-16.68	-0.68	1.07e-45	Breast cancer;
CRC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg27523141	chr10:43048294	ZNF37B	0.47	6.74	0.35	7.02e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	1.16	10.07	0.49	5.68e-21	Mitochondrial DNA levels;
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.75	0.47	6.97e-20	Alzheimer's disease;
CRC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04219446	chr17:73629082	RECQL5;LOC643008	0.41	6.1	0.32	3.04e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13445258	chr3:128369860	RPN1	0.47	6.76	0.35	6.3e-11	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.6	0.34	1.64e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg10876282	chr6:28092338	ZSCAN16	0.51	6.9	0.36	2.64e-11	Cardiac Troponin-T levels;
CRC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.67	-9.59	-0.47	2.22e-19	Menopause (age at onset);
CRC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.52	7.98	0.4	2.4e-14	Corneal astigmatism;
CRC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.62	6.22	0.32	1.48e-9	Plasma clusterin levels;
CRC	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.52	7.45	0.38	8.21e-13	Ovarian reserve;
CRC	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.51	6.69	0.35	9.79e-11	Alzheimer's disease (survival time);
CRC	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs6694672	1.000	rs1576878	chr1:196991325	A/C	cg13682187	chr1:196946512	CFHR5	0.59	8.53	0.43	5.57e-16	Asthma;
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.15	-0.32	2.22e-9	Bipolar disorder;
CRC	cis	rs3764400	0.506	rs72827851	chr17:46452495	C/A	cg10706073	chr17:46328419	SKAP1	-0.6	-6.33	-0.33	8.07e-10	Body mass index;
CRC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg16141378	chr3:129829833	LOC729375	0.48	7.37	0.38	1.38e-12	Neuroticism;
CRC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.64	-11.11	-0.52	1.44e-24	Personality dimensions;
CRC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	7.56	0.38	4.12e-13	Mean platelet volume;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg18833306	chr6:118973337	C6orf204	0.44	5.64	0.3	3.68e-8	Diastolic blood pressure;
CRC	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.03	0.32	4.41e-9	Axial length;
CRC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg01483505	chr11:975446	AP2A2	0.42	6.83	0.35	4.14e-11	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg25164649	chr6:28176230	NA	0.56	7.98	0.4	2.49e-14	Parkinson's disease;
CRC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg05192639	chr6:26864778	GUSBL1	0.33	5.91	0.31	8.78e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg25856811	chr1:152973957	SPRR3	-0.23	-6.39	-0.33	5.76e-10	Inflammatory skin disease;
CRC	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg04969067	chr8:143858791	LYNX1	-0.34	-5.82	-0.31	1.38e-8	Urinary tract infection frequency;
CRC	cis	rs427941	0.550	rs201517	chr7:101769616	G/T	cg06246474	chr7:101738831	CUX1	0.37	5.68	0.3	2.97e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6662572	0.737	rs4518839	chr1:46376690	G/T	cg08644498	chr1:46502608	NA	-0.44	-6.85	-0.35	3.69e-11	Blood protein levels;
CRC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.84	-16.84	-0.68	2.56e-46	Post bronchodilator FEV1;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08841098	chr16:55050401	NA	0.42	6.84	0.35	3.77e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.6	8.14	0.41	8.07e-15	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg14711859	chr11:8959438	ASCL3	0.42	7.03	0.36	1.23e-11	Hemoglobin concentration;
CRC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg15226275	chr6:116381976	FRK	-0.29	-8.23	-0.41	4.53e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.66	8.37	0.42	1.67e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.98	0.48	1.15e-20	Personality dimensions;
CRC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.8	-11.65	-0.54	1.64e-26	Bipolar disorder and schizophrenia;
CRC	trans	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.48	-0.34	3.32e-10	Aortic root size;
CRC	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg03037974	chr15:76606532	NA	-0.52	-7.5	-0.38	5.99e-13	Blood metabolite levels;
CRC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.74	-0.54	8.01e-27	Type 2 diabetes;
CRC	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg06606381	chr12:133084897	FBRSL1	-0.59	-5.99	-0.31	5.55e-9	Depression;
CRC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg15445000	chr17:37608096	MED1	0.35	6.18	0.32	1.87e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.94	16.49	0.67	6.22e-45	Obesity (extreme);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19250579	chr3:75487529	NA	0.41	6.18	0.32	1.92e-9	Myopia (pathological);
CRC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.5	5.95	0.31	6.72e-9	Lung function (FEV1/FVC);
CRC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg18479299	chr3:125709523	NA	-0.56	-6.6	-0.34	1.6e-10	Blood pressure (smoking interaction);
CRC	trans	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.39	-0.33	5.78e-10	Aortic root size;
CRC	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg25173405	chr17:45401733	C17orf57	-0.45	-6.89	-0.36	2.87e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs34787248	1	rs34787248	chr6:28197886	C/T	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.33	-0.33	8.13e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.61	-9.51	-0.46	4.24e-19	Bipolar disorder and schizophrenia;
CRC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.98	-0.74	1.06e-58	Height;
CRC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg21153622	chr11:89784906	NA	-0.5	-8.29	-0.42	2.93e-15	Height;
CRC	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg17470449	chr10:769945	NA	0.64	8.39	0.42	1.42e-15	Uric acid levels;
CRC	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg21918786	chr6:109611834	NA	0.37	6.5	0.34	2.95e-10	Reticulocyte fraction of red cells;
CRC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg12564285	chr5:131593104	PDLIM4	0.4	7.55	0.38	4.43e-13	Blood metabolite levels;
CRC	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	0.56	8.71	0.43	1.52e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.46	-6.99	-0.36	1.58e-11	Breast size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25460059	chr11:9595544	WEE1	0.45	6.35	0.33	7.26e-10	Response to antipsychotic treatment;
CRC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg21466736	chr12:48725269	NA	0.51	7.54	0.38	4.54e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.59	0.39	3.33e-13	Lymphocyte percentage of white cells;
CRC	cis	rs6691722	0.503	rs6656485	chr1:24707685	A/G	cg02336364	chr1:24764700	NIPAL3	0.38	6.25	0.33	1.28e-9	Response to interferon beta in multiple sclerosis;
CRC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg27661571	chr11:113659931	NA	0.62	7.23	0.37	3.45e-12	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23319046	chr18:3247432	MYL12A	0.42	6.0	0.31	5.12e-9	Anxiety disorder;
CRC	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg02023728	chr11:77925099	USP35	-0.35	-5.74	-0.3	2.1e-8	Alzheimer's disease (survival time);
CRC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.19	0.71	1.15e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs305851	0.818	rs7761456	chr6:39768005	A/C	cg02386599	chr6:39769542	DAAM2	-0.39	-6.17	-0.32	2.06e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21403089	chr7:108166784	PNPLA8	-0.44	-6.99	-0.36	1.54e-11	Myopia (pathological);
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.95	11.2	0.53	6.98e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.43	-6.8	-0.35	4.93e-11	Type 1 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04414295	chr14:102606318	WDR20;HSP90AA1	0.43	6.94	0.36	2.07e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.17	0.62	6.37e-36	Chronic sinus infection;
CRC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.62	8.37	0.42	1.65e-15	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg26721908	chr21:47610096	LSS	0.42	6.58	0.34	1.84e-10	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25845783	chr6:166756218	SFT2D1	0.43	6.11	0.32	2.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs534126	1.000	rs476826	chr7:142906434	C/T	cg04039957	chr7:143013207	CLCN1	-0.35	-6.28	-0.33	1.07e-9	Cancer;
CRC	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.77	9.75	0.47	6.85e-20	Blood protein levels;
CRC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07570687	chr10:102243282	WNT8B	0.45	5.83	0.31	1.3e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.85	9.86	0.48	2.83e-20	Psoriasis;
CRC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg07153921	chr17:41440717	NA	-0.39	-5.88	-0.31	1e-8	Menopause (age at onset);
CRC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	0.67	7.22	0.37	3.66e-12	Body mass index;
CRC	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg06484146	chr7:12443880	VWDE	-0.6	-6.61	-0.34	1.56e-10	Coronary artery disease;
CRC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07167872	chr1:205819463	PM20D1	0.43	5.96	0.31	6.67e-9	Parkinson's disease;
CRC	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.04	-14.44	-0.62	6.2e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.73	0.43	1.3e-16	Morning vs. evening chronotype;
CRC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.7	0.35	8.83e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CRC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.72	-0.47	8.53e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg26727032	chr16:67993705	SLC12A4	0.52	7.65	0.39	2.2e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.34	-6.32	-0.33	8.74e-10	Colorectal cancer;
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.71	-0.3	2.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.47	-6.66	-0.34	1.15e-10	Lymphocyte counts;
CRC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.27	-5.61	-0.3	4.39e-8	Alcohol dependence;
CRC	cis	rs2857891	0.650	rs2638087	chr11:6990516	C/T	cg22096450	chr11:6947773	ZNF215	0.51	5.97	0.31	6.31e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.43	0.33	4.61e-10	Diastolic blood pressure;
CRC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.26	0.37	2.73e-12	Asthma and hay fever;
CRC	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.62	9.04	0.45	1.33e-17	Uric acid levels;
CRC	cis	rs6694672	1.000	rs1759008	chr1:197026895	G/T	cg13682187	chr1:196946512	CFHR5	-0.47	-7.79	-0.39	8.69e-14	Asthma;
CRC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg26566898	chr11:117069891	TAGLN	0.39	7.28	0.37	2.47e-12	Blood protein levels;
CRC	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.61	-6.3	-0.33	9.3e-10	QRS complex (12-leadsum);
CRC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.77	-10.43	-0.5	3.52e-22	Blood metabolite levels;
CRC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.8	0.4	8.2e-14	Colorectal cancer;
CRC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.22	0.45	3.73e-18	Parkinson's disease;
CRC	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	1.13	10.63	0.51	6.83e-23	Arsenic metabolism;
CRC	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.67	6.4	0.33	5.39e-10	Axial length;
CRC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.4	6.11	0.32	2.83e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.8	14.04	0.61	1.97e-35	Breast cancer;
CRC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.23	-0.45	3.41e-18	Triglycerides;
CRC	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg12856521	chr11:46389249	DGKZ	0.73	10.47	0.5	2.51e-22	Crohn's disease;
CRC	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.53	-8.68	-0.43	1.88e-16	Menarche (age at onset);
CRC	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg06042504	chr8:55087323	NA	-0.43	-6.64	-0.34	1.3100000000000001e-10	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.62	-7.26	-0.37	2.75e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20769334	chr22:50913335	SBF1	-0.42	-6.38	-0.33	5.88e-10	Myopia (pathological);
CRC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg04450456	chr4:17643702	FAM184B	0.39	6.25	0.33	1.29e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3736485	0.966	rs11636170	chr15:51767087	G/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.79	-0.3	1.68e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.22	0.49	1.75e-21	Platelet count;
CRC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.55	-6.7	-0.35	9.14e-11	Body mass index;
CRC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13047869	chr3:10149882	C3orf24	0.49	6.77	0.35	5.8200000000000003e-11	Alzheimer's disease;
CRC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.88	-0.4	4.7e-14	Body mass index;
CRC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-11.76	-0.54	6.57e-27	Asthma;
CRC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.44	7.69e-17	Morning vs. evening chronotype;
CRC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.61	10.01	0.48	9.04e-21	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.97	17.14	0.69	1.62e-47	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.74	-0.43	1.22e-16	Coffee consumption (cups per day);
CRC	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.7	-11.03	-0.52	2.75e-24	Neurofibrillary tangles;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg04314247	chr1:95286125	SLC44A3	-0.46	-6.11	-0.32	2.83e-9	Type 1 diabetes;
CRC	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-8.06	-0.41	1.41e-14	Migraine;Coronary artery disease;
CRC	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	18.07	0.71	3.47e-51	Smoking behavior;
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.51	7.3	0.37	2.21e-12	Alzheimer's disease;
CRC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.42	6.49	0.34	3.15e-10	Dupuytren's disease;
CRC	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.57	8.36	0.42	1.81e-15	Schizophrenia;
CRC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	7.04	0.36	1.15e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs7215564	0.908	rs34950888	chr17:78661779	T/G	cg09596252	chr17:78655493	RPTOR	0.57	6.12	0.32	2.59e-9	Myopia (pathological);
CRC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.5	-6.73	-0.35	7.69e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4803480	1.000	rs4803480	chr19:42066279	A/G	cg08478046	chr19:42093086	CEACAM21	-0.33	-5.87	-0.31	1.06e-8	Schizophrenia;
CRC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06544989	chr22:39130855	UNC84B	0.45	6.95	0.36	1.96e-11	Menopause (age at onset);
CRC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.6	9.46	0.46	6.12e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.46	6.91	0.36	2.59e-11	Menopause (age at onset);
CRC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg02659138	chr7:134003124	SLC35B4	0.38	6.51	0.34	2.78e-10	Mean platelet volume;
CRC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg08222913	chr3:52553049	STAB1	-0.42	-8.47	-0.42	8.56e-16	Electroencephalogram traits;
CRC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.69	11.09	0.52	1.68e-24	Mean corpuscular hemoglobin;
CRC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.96	0.48	1.32e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.64	-7.95	-0.4	3.06e-14	Gut microbiome composition (summer);
CRC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.44	6.91	0.36	2.56e-11	Corneal astigmatism;
CRC	trans	rs2303319	0.504	rs55821334	chr2:162452014	A/G	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.43e-9	Cognitive function;
CRC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.9	-0.31	8.84e-9	Breast cancer;
CRC	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg27053337	chr8:124217698	FAM83A	0.45	6.82	0.35	4.48e-11	Urinary uromodulin levels;
CRC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg21138405	chr5:131827807	IRF1	0.36	6.34	0.33	7.5e-10	Breast cancer;Mosquito bite size;
CRC	cis	rs427943	0.750	rs1556317	chr21:46605694	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	5.92	0.31	7.91e-9	Body mass index;
CRC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg11189052	chr15:85197271	WDR73	0.61	8.88	0.44	4.41e-17	Schizophrenia;
CRC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.62	10.11	0.49	4.2e-21	Height;
CRC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.46	7.1	0.36	7.96e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	5.8	0.3	1.56e-8	Breast cancer;Mosquito bite size;
CRC	trans	rs4346635	0.528	rs1495489	chr4:81416501	T/C	cg13904968	chr20:56136012	PCK1	-0.19	-6.02	-0.31	4.64e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.12	-0.32	2.6e-9	Diastolic blood pressure;
CRC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.59	7.89	0.4	4.67e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7487075	0.930	rs11183468	chr12:46806261	A/T	cg17501823	chr12:47219793	SLC38A4	0.32	5.97	0.31	6.14e-9	Itch intensity from mosquito bite;
CRC	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg15226275	chr6:116381976	FRK	0.3	7.14	0.37	6.1e-12	Total cholesterol levels;
CRC	cis	rs4664293	0.585	rs35081473	chr2:160536481	G/C	cg08347373	chr2:160653686	CD302	0.36	5.92	0.31	8.09e-9	Monocyte percentage of white cells;
CRC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg15226275	chr6:116381976	FRK	0.27	7.3	0.37	2.24e-12	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2836754	1.000	rs11701004	chr21:40292102	C/G	cg20434300	chr21:40194735	ETS2	-0.34	-5.8	-0.3	1.52e-8	Crohn's disease;Body mass index;
CRC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-12.79	-0.58	1.07e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg23609528	chr2:113191194	RGPD5;RGPD8	0.63	5.61	0.3	4.26e-8	Yeast infection;
CRC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.65	9.98	0.48	1.17e-20	Hemoglobin concentration;
CRC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.62	-10.64	-0.51	6.19e-23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.59	8.06	0.41	1.41e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg07090678	chr1:91966139	CDC7	0.37	5.85	0.31	1.19e-8	Breast cancer;
CRC	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg26695010	chr11:65641043	EFEMP2	0.45	6.32	0.33	8.49e-10	DNA methylation (variation);
CRC	cis	rs3790645	1.000	rs897641	chr1:26881806	C/A	cg23229016	chr1:26872525	RPS6KA1	0.3	7.32	0.37	1.89e-12	Glucose homeostasis traits;
CRC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.4	-0.33	5.38e-10	Menopause (age at onset);
CRC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.85	10.08	0.49	5.15e-21	Psoriasis;
CRC	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.55	0.47	3.03e-19	Ileal carcinoids;
CRC	cis	rs2336384	1.000	rs2878677	chr1:12053264	C/T	cg13216073	chr1:12042593	MFN2	-0.47	-7.18	-0.37	4.74e-12	Platelet count;
CRC	cis	rs863345	0.604	rs1578763	chr1:158497414	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.49	-8.15	-0.41	7.73e-15	Huntington's disease progression;
CRC	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg08265495	chr8:11212668	TDH	-0.32	-5.72	-0.3	2.44e-8	Retinal vascular caliber;
CRC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17554472	chr22:41940697	POLR3H	-0.53	-5.65	-0.3	3.42e-8	Vitiligo;
CRC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg23071808	chr14:103021642	NA	-0.65	-7.24	-0.37	3.26e-12	Platelet count;
CRC	trans	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.43	0.33	4.46e-10	Ulcerative colitis;
CRC	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.91	15.45	0.65	6.88e-41	Gut microbiome composition (winter);
CRC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07701084	chr6:150067640	NUP43	0.54	7.65	0.39	2.24e-13	Testicular germ cell tumor;
CRC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.97	-0.31	6.25e-9	Aortic root size;
CRC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.38	0.33	6.1e-10	Cognitive ability;
CRC	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.36e-11	Response to antipsychotic treatment;
CRC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.45	-6.77	-0.35	5.98e-11	Platelet distribution width;
CRC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.43	0.33	4.6e-10	Bladder cancer;
CRC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-9.21	-0.45	3.87e-18	Total cholesterol levels;
CRC	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.41	-6.46	-0.34	3.72e-10	Sense of smell;
CRC	cis	rs2415984	0.579	rs12147941	chr14:46972907	A/G	cg14871534	chr14:47121158	RPL10L	-0.42	-6.22	-0.32	1.49e-9	Number of children ever born;
CRC	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.67	9.54	0.47	3.34e-19	Vitamin D levels;
CRC	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg23919916	chr10:103825097	HPS6	-0.69	-6.01	-0.31	4.8e-9	Cognitive function;
CRC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.07	0.52	2.05e-24	Prudent dietary pattern;
CRC	trans	rs12744310	0.887	rs35410722	chr1:41796264	C/T	cg19175123	chr10:103411746	FBXW4	0.44	6.0	0.31	5.21e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs1552172	0.853	rs2018027	chr1:145595820	A/G	cg25221984	chr1:145714143	CD160	0.36	5.69	0.3	2.8e-8	Breast cancer;
CRC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.4	5.75	0.3	2.04e-8	Aortic root size;
CRC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.51	8.6	0.43	3.42e-16	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12402495	chr1:154192844	C1orf43;UBAP2L	0.44	6.25	0.33	1.28e-9	Response to antipsychotic treatment;
CRC	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.49	-7.79	-0.39	8.69e-14	Schizophrenia;
CRC	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg23254163	chr1:152506842	NA	0.5	10.14	0.49	3.42e-21	Hair morphology;
CRC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg27535305	chr1:53392650	SCP2	-0.38	-7.19	-0.37	4.34e-12	Monocyte count;
CRC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.56	8.48	0.42	7.76e-16	Longevity;Endometriosis;
CRC	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.85	15.82	0.66	2.64e-42	Hip circumference;
CRC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.65	-0.43	2.33e-16	Height;
CRC	cis	rs17331151	0.505	rs35371456	chr3:52563462	C/T	cg07884673	chr3:53033167	SFMBT1	0.76	6.08	0.32	3.31e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg18230493	chr5:56204884	C5orf35	-0.4	-5.67	-0.3	3.18e-8	Coronary artery disease;
CRC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	10.3	0.49	9.71e-22	Mood instability;
CRC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.53	8.87	0.44	4.85e-17	Systemic lupus erythematosus;
CRC	cis	rs3015497	0.554	rs8011039	chr14:51091267	C/T	cg09863266	chr14:51125203	SAV1	-0.31	-5.92	-0.31	8.27e-9	Mean platelet volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14760355	chr2:176046503	ATP5G3	0.49	6.88	0.35	2.98e-11	Response to antipsychotic treatment;
CRC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-8.77	-0.44	9.85e-17	Monocyte percentage of white cells;
CRC	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.69	0.3	2.79e-8	Neuroticism;
CRC	cis	rs10905065	0.804	rs2175630	chr10:5834736	A/C	cg11519256	chr10:5708881	ASB13	-0.47	-6.66	-0.34	1.18e-10	Menopause (age at onset);
CRC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.62	10.52	0.5	1.7e-22	Prudent dietary pattern;
CRC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.77	11.31	0.53	2.81e-25	High light scatter reticulocyte count;
CRC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.84	14.69	0.63	6.53e-38	Blood protein levels;
CRC	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-8.86	-0.44	5.12e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-10.92	-0.52	6.84e-24	Hepatocellular carcinoma;
CRC	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.6	7.85	0.4	5.96e-14	Bipolar disorder;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg02033258	chr5:131593261	PDLIM4	0.4	7.85	0.4	5.89e-14	Breast cancer;
CRC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.47	7.04	0.36	1.1e-11	Menarche (age at onset);
CRC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg15465823	chr12:48382534	COL2A1	0.35	5.83	0.31	1.33e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.4	-0.33	5.3e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.57	8.02	0.4	1.87e-14	Resting heart rate;
CRC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.43	-6.16	-0.32	2.13e-9	Neuroticism;
CRC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.66	-7.47	-0.38	7.09e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs995000	0.868	rs1168107	chr1:63161173	A/T	cg19896129	chr1:63156450	NA	-0.45	-6.87	-0.35	3.3e-11	Triglyceride levels;
CRC	cis	rs2745959	0.548	rs2745949	chr1:208058183	T/C	cg09788693	chr1:208063733	CD34	0.48	6.34	0.33	7.74e-10	Resting heart rate;
CRC	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.78	-12.05	-0.55	6.1e-28	Response to temozolomide;
CRC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg16102536	chr7:156981717	UBE3C	0.4	6.76	0.35	6.39e-11	Body mass index;
CRC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.5	-6.79	-0.35	5.24e-11	Inflammatory bowel disease;
CRC	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.49	8.68	0.43	1.85e-16	Dietary macronutrient intake;
CRC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg03233332	chr7:66118400	NA	0.45	6.25	0.33	1.24e-9	Aortic root size;
CRC	cis	rs1760803	0.754	rs12028554	chr1:154223101	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.37	-0.33	6.46e-10	Nicotine dependence;
CRC	trans	rs11105468	0.922	rs7960337	chr12:90277578	T/C	cg23572944	chr11:60720130	SLC15A3	-0.43	-5.98	-0.31	5.8e-9	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.63	-7.9	-0.4	4.2e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg01339444	chr6:118972232	C6orf204	0.52	5.9	0.31	8.98e-9	Diastolic blood pressure;
CRC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.76	-11.47	-0.53	7.73e-26	Hemoglobin concentration;Hematocrit;
CRC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19784903	chr17:45786737	TBKBP1	-0.35	-5.82	-0.31	1.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs62408225	1.000	rs62408235	chr6:90978383	T/C	cg06866423	chr6:90926672	BACH2	0.51	8.44	0.42	1.01e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.66	10.72	0.51	3.5e-23	Monocyte percentage of white cells;
CRC	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.64	-9.77	-0.47	5.98e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.86	-0.35	3.34e-11	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-5.94	-0.31	7.38e-9	Cognitive function;
CRC	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.86	-21.11	-0.76	3.77e-63	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-0.88	-10.67	-0.51	5.23e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.41	0.42	1.3e-15	Platelet count;
CRC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.44	-0.38	8.8e-13	Colorectal cancer;
CRC	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg01493522	chr13:37497338	NA	-0.52	-7.16	-0.37	5.21e-12	Coronary artery disease;
CRC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.75	12.03	0.55	6.97e-28	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01537289	chr6:34359621	NUDT3	0.42	5.99	0.31	5.49e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2108622	0.649	rs113055956	chr19:15977312	T/A	cg13772218	chr19:15982569	NA	0.45	6.32	0.33	8.39e-10	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18099408	chr3:52552593	STAB1	0.47	7.64	0.39	2.39e-13	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27119428	chr11:133734513	NA	-0.35	-6.22	-0.32	1.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.63	-7.82	-0.4	7.25e-14	Vitamin D levels;
CRC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.61	9.51	0.46	4.06e-19	Height;
CRC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.92	14.18	0.62	5.85e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-7.4	-0.38	1.16e-12	Hemostatic factors and hematological phenotypes;
CRC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.75	-0.3	2.01e-8	Mean corpuscular volume;
CRC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.96	0.36	1.89e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.83	-13.54	-0.6	1.61e-33	Hypospadias;
CRC	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.53	-0.38	4.98e-13	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.681	rs34816332	chr10:81907967	G/A	cg11900509	chr10:81946545	ANXA11	-0.73	-8.4	-0.42	1.32e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6815814	0.950	rs9306967	chr4:38807911	G/C	cg06935464	chr4:38784597	TLR10	0.58	7.07	0.36	9.44e-12	Breast cancer;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg26668828	chr6:292823	DUSP22	-0.59	-8.68	-0.43	1.82e-16	Menopause (age at onset);
CRC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.5	-5.65	-0.3	3.47e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.53	-8.04	-0.41	1.61e-14	Body mass index;
CRC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.48	7.36	0.38	1.51e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.76	-11.37	-0.53	1.68e-25	Testicular germ cell tumor;
CRC	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.96	11.66	0.54	1.59e-26	Diisocyanate-induced asthma;
CRC	cis	rs2944591	0.505	rs2004202	chr2:233790289	C/G	cg11972305	chr2:233791962	NGEF	-0.44	-6.79	-0.35	5.31e-11	Autism spectrum disorder or schizophrenia;
CRC	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	1.27	14.14	0.61	8.27e-36	Lung disease severity in cystic fibrosis;
CRC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	0.97	10.25	0.49	1.36e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3126085	0.515	rs11204994	chr1:152358640	G/T	cg09127314	chr1:152161683	NA	-0.44	-5.85	-0.31	1.2e-8	Atopic dermatitis;
CRC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg12273811	chr6:28175739	NA	0.46	6.93	0.36	2.18e-11	Cardiac Troponin-T levels;
CRC	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg13385794	chr1:248469461	NA	0.38	6.55	0.34	2.16e-10	Common traits (Other);
CRC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.65	-8.51	-0.42	6.21e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs185694	1.000	rs846498	chr13:30900541	A/G	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.32	-0.33	8.68e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.78	0.3	1.72e-8	Bladder cancer;
CRC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.74	12.91	0.58	3.82e-31	Prudent dietary pattern;
CRC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg18876405	chr7:65276391	NA	0.45	6.31	0.33	8.87e-10	Aortic root size;
CRC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.56	0.34	2.13e-10	Personality dimensions;
CRC	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.58	7.35	0.38	1.56e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg07701084	chr6:150067640	NUP43	0.49	6.07	0.32	3.53e-9	Lung cancer;
CRC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg10790698	chr19:18539756	SSBP4	-0.43	-8.4	-0.42	1.37e-15	Breast cancer;
CRC	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.5	7.93	0.4	3.39e-14	Resting heart rate;
CRC	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.4	5.94	0.31	7.16e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.79	-0.75	6.66e-62	Height;
CRC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.51	8.14	0.41	8.43e-15	Intelligence (multi-trait analysis);
CRC	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg03433033	chr1:76189801	ACADM	-0.41	-5.87	-0.31	1.08e-8	Daytime sleep phenotypes;
CRC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.89	0.36	2.86e-11	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27649522	chr12:12877729	APOLD1	0.48	6.28	0.33	1.04e-9	Thyroid stimulating hormone;
CRC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.77	10.67	0.51	5.14e-23	Orofacial clefts;
CRC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.53	7.92	0.4	3.74e-14	Platelet distribution width;
CRC	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.76	-0.35	6.27e-11	Blood pressure;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg03844506	chr4:4109441	NA	-0.51	-7.55	-0.38	4.42e-13	Blood pressure (smoking interaction);
CRC	cis	rs10924970	0.967	rs7512798	chr1:235356425	C/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.66	0.3	3.28e-8	Asthma;
CRC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9903692	0.954	rs8077860	chr17:46185335	G/A	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg00343986	chr7:65444356	GUSB	0.45	6.22	0.32	1.52e-9	Aortic root size;
CRC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.61	11.0	0.52	3.59e-24	Coronary artery disease;
CRC	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg09218773	chr11:619014	MUPCDH	-0.44	-5.98	-0.31	5.82e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.73	0.63	4.56e-38	Mean platelet volume;
CRC	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg21681030	chr2:46777652	RHOQ	0.44	6.3	0.33	9.6e-10	Height;
CRC	cis	rs9303280	0.587	rs35123741	chr17:38092930	A/G	cg24910161	chr17:38119198	GSDMA	-0.32	-5.71	-0.3	2.59e-8	Self-reported allergy;
CRC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.43	8.88	0.44	4.42e-17	Renal cell carcinoma;
CRC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.61	-0.3	4.35e-8	Blood pressure;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg05207973	chr5:176823642	SLC34A1	0.48	7.52	0.38	5.16e-13	Hemoglobin concentration;Hematocrit;
CRC	trans	rs10060123	1.000	rs10072436	chr5:125685429	G/T	ch.6.113866684R	chr6:113759991	NA	-0.38	-5.97	-0.31	6.31e-9	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue;
CRC	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.62	9.46	0.46	6e-19	Testicular germ cell tumor;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.67	-9.4	-0.46	9.35e-19	Blood pressure (smoking interaction);
CRC	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	0.38	5.74	0.3	2.14e-8	Essential tremor;
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg01874867	chr7:94954059	PON1	-0.49	-6.36	-0.33	6.6e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06307176	chr5:131281290	NA	0.41	6.13	0.32	2.5e-9	Life satisfaction;
CRC	cis	rs3018066	0.666	rs79928816	chr4:107063479	C/A	cg01869342	chr4:106983673	TBCK	0.48	6.15	0.32	2.25e-9	Cancer;
CRC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.55	7.49	0.38	6.4e-13	Heart rate;
CRC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.74	-12.31	-0.56	6.62e-29	Breast cancer;
CRC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.12	0.32	2.71e-9	Personality dimensions;
CRC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.68	0.3	2.95e-8	Diabetic retinopathy;
CRC	trans	rs3001167	0.609	rs4642873	chr1:194553723	A/G	cg22004422	chr13:113740730	MCF2L	-0.62	-6.31	-0.33	8.84e-10	Obesity-related traits;
CRC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.47	-6.6	-0.34	1.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7692995	1.000	rs7698271	chr4:18019413	C/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs55788414	0.932	rs35066366	chr16:81185280	G/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.76	-0.35	6.2e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg04969067	chr8:143858791	LYNX1	0.44	7.51	0.38	5.59e-13	Urinary tract infection frequency;
CRC	trans	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg09324608	chr17:30823087	MYO1D	0.33	5.64	0.3	3.69e-8	Schizophrenia;
CRC	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg02927042	chr1:21476669	EIF4G3	-0.5	-8.0	-0.4	2.15e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.54	8.44	0.42	9.9e-16	Hemoglobin concentration;Hematocrit;
CRC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg11070056	chr1:107600091	PRMT6	0.42	6.05	0.32	3.95e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs10991814	0.920	rs3827826	chr9:94030185	G/A	cg14446406	chr9:93919335	NA	0.58	6.41	0.33	5.03e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg18404041	chr3:52824283	ITIH1	-0.33	-5.93	-0.31	7.83e-9	Schizophrenia;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.22	-0.32	1.49e-9	Acylcarnitine levels;
CRC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.56	-8.84	-0.44	5.75e-17	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg03623178	chr6:28175578	NA	1.0	15.19	0.64	7.35e-40	Depression;
CRC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-17.39	-0.69	1.77e-48	Height;
CRC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.44	-6.42	-0.33	4.74e-10	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.25	-0.33	1.3e-9	Coronary artery calcification;
CRC	trans	rs9903692	0.909	rs9899275	chr17:46129315	C/T	cg13910583	chr8:56987998	RPS20	-0.44	-5.99	-0.31	5.63e-9	Pulse pressure;
CRC	cis	rs6743376	0.556	rs2515394	chr2:113817765	C/T	cg09040174	chr2:113837401	NA	0.44	6.37	0.33	6.46e-10	Inflammatory biomarkers;
CRC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.42	-0.46	8.4e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.39	5.85	0.31	1.21e-8	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26399773	chr5:74633655	HMGCR	0.35	5.97	0.31	6.06e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg06818126	chr11:68850279	TPCN2	-0.49	-6.95	-0.36	1.99e-11	Hair color;
CRC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.38	0.38	1.28e-12	Motion sickness;
CRC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.7	0.35	8.93e-11	Rheumatoid arthritis;
CRC	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.58	-0.34	1.89e-10	Morning vs. evening chronotype;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09400194	chr10:81107848	PPIF	-0.5	-6.03	-0.32	4.48e-9	Diisocyanate-induced asthma;
CRC	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.81	13.42	0.59	4.81e-33	Fuchs's corneal dystrophy;
CRC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg18758796	chr5:131593413	PDLIM4	0.36	6.6	0.34	1.64e-10	Blood metabolite levels;
CRC	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.17	-0.37	4.89e-12	Capecitabine sensitivity;
CRC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg04362960	chr10:104952993	NT5C2	-0.46	-6.51	-0.34	2.83e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs524281	0.773	rs11227447	chr11:66048280	G/C	cg14036092	chr11:66035641	RAB1B	-0.54	-5.97	-0.31	6.14e-9	Electroencephalogram traits;
CRC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15503799	chr1:156737481	PRCC	0.42	6.08	0.32	3.35e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg21271767	chr15:63449808	RPS27L	0.46	6.01	0.31	4.81e-9	Plasma plasminogen activator levels;
CRC	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg17145862	chr1:211918768	LPGAT1	-0.72	-12.99	-0.58	1.97e-31	Leprosy;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01283712	chr14:106919294	NA	-0.35	-6.01	-0.31	5.04e-9	Obesity-related traits;
CRC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.44	-8.04	-0.41	1.61e-14	Reticulocyte fraction of red cells;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg12590005	chr6:35997326	MAPK14	-0.35	-6.05	-0.32	3.86e-9	Aortic root size;
CRC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	15.33	0.65	2.11e-40	Platelet count;
CRC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg03678062	chr6:149772716	ZC3H12D	0.34	6.21	0.32	1.64e-9	Dupuytren's disease;
CRC	cis	rs3789045	0.774	rs4252733	chr1:204516918	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.54	-7.61	-0.39	2.91e-13	Educational attainment (college completion);
CRC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.5	7.69	0.39	1.74e-13	Corneal astigmatism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg25721516	chr17:42276931	ATXN7L3	-0.41	-6.1	-0.32	2.92e-9	Myopia (pathological);
CRC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg05623727	chr3:50126028	RBM5	0.45	7.55	0.38	4.33e-13	Intelligence (multi-trait analysis);
CRC	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.6	12.37	0.56	3.93e-29	Airflow obstruction;
CRC	cis	rs453193	0.677	rs2630708	chr2:8447185	A/G	cg12167548	chr2:8464763	NA	0.29	5.75	0.3	2.02e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg21521518	chr4:53727714	RASL11B	0.4	5.93	0.31	7.81e-9	Optic nerve measurement (cup area);
CRC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.39	-6.23	-0.32	1.44e-9	Height;
CRC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.5	0.38	6.06e-13	Motion sickness;
CRC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg07507251	chr3:52567010	NT5DC2	-0.39	-5.99	-0.31	5.54e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.63	8.43	0.42	1.07e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.89	-20.41	-0.75	2.14e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.58	-7.79	-0.39	8.57e-14	Extraversion;
CRC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg26162295	chr17:38119207	GSDMA	-0.34	-5.7	-0.3	2.68e-8	Myeloid white cell count;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg01339444	chr6:118972232	C6orf204	0.53	6.01	0.31	5.01e-9	Diastolic blood pressure;
CRC	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg27068330	chr11:65405492	SIPA1	-0.4	-5.62	-0.3	4.13e-8	Systemic lupus erythematosus;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12273811	chr6:28175739	NA	0.76	10.83	0.51	1.43e-23	Depression;
CRC	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.57	8.24	0.41	4.18e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg20608306	chr11:116969690	SIK3	-0.31	-5.93	-0.31	7.75e-9	Blood protein levels;
CRC	trans	rs67073037	0.955	rs3924271	chr2:29167692	G/A	cg13899017	chr1:159158444	CADM3	-0.37	-6.14	-0.32	2.4e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg03948781	chr1:205179583	DSTYK	0.42	6.08	0.32	3.34e-9	Red blood cell count;
CRC	cis	rs76793172	0.588	rs659444	chr19:46284947	T/C	cg11657440	chr19:46296263	DMWD	0.56	5.63	0.3	3.78e-8	Eosinophil counts;
CRC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.78	0.39	9.25e-14	Motion sickness;
CRC	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-7.8	-0.4	8.16e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.7	10.47	0.5	2.5e-22	Body mass index;
CRC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.44	8.68	0.43	1.83e-16	Alcohol dependence;
CRC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-1.21	-11.42	-0.53	1.14e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg08847533	chr14:75593920	NEK9	0.83	13.14	0.59	5.37e-32	Height;
CRC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.83	14.67	0.63	7.46e-38	Breast cancer;
CRC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-8.34	-0.42	2e-15	Vitiligo;
CRC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.49	9.0	0.44	1.87e-17	Total body bone mineral density;
CRC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg02007433	chr3:129722099	NA	-0.46	-6.23	-0.32	1.41e-9	Blood pressure (smoking interaction);
CRC	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg22495460	chr2:25135724	ADCY3	-0.79	-14.28	-0.62	2.41e-36	Body mass index in non-asthmatics;
CRC	cis	rs2811415	0.597	rs9849210	chr3:127779633	G/T	cg13719885	chr3:127795394	NA	-0.39	-5.95	-0.31	6.69e-9	Lung function (FEV1/FVC);
CRC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.47	8.93	0.44	3.11e-17	Renal cell carcinoma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00088299	chr4:2538934	NA	0.47	6.15	0.32	2.22e-9	Anxiety disorder;
CRC	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.98	18.34	0.71	2.87e-52	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg10298567	chr3:47292165	KIF9	0.4	6.27	0.33	1.12e-9	Colorectal cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15309264	chr2:58274034	VRK2	0.46	6.05	0.32	4.03e-9	Thyroid stimulating hormone;
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg05055821	chr7:2758924	NA	-0.35	-5.61	-0.3	4.27e-8	Height;
CRC	cis	rs6546324	0.625	rs1430789	chr2:67866370	T/C	cg15745817	chr2:67799979	NA	-0.55	-9.54	-0.47	3.34e-19	Endometriosis;
CRC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	7.64	0.39	2.33e-13	Schizophrenia;
CRC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.83	-0.48	3.56e-20	Body mass index;
CRC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.83e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg02869306	chr7:64672164	INTS4L1	0.44	6.26	0.33	1.17e-9	Aortic root size;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg25164649	chr6:28176230	NA	0.61	8.88	0.44	4.57e-17	Parkinson's disease;
CRC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.53	8.36	0.42	1.81e-15	IgG glycosylation;
CRC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.94	-0.31	7.43e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs4658101	0.653	rs11165002	chr1:92048966	G/T	cg24006770	chr1:92056542	NA	-0.46	-6.7	-0.35	9.12e-11	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg25985355	chr7:65971099	NA	-0.48	-5.64	-0.3	3.67e-8	Diabetic kidney disease;
CRC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.87	-0.31	1.06e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12172441	chr6:28176163	NA	0.62	7.4	0.38	1.17e-12	Depression;
CRC	trans	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg17903999	chr18:56338584	MALT1	-0.4	-6.8	-0.35	4.96e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.55	8.86	0.44	5.16e-17	Prostate cancer;
CRC	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.63	8.25	0.41	3.89e-15	Uric acid levels;
CRC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.43	6.41	0.33	5.11e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.21	28.58	0.84	3.59e-91	Schizophrenia;
CRC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	10.71	0.51	3.72e-23	Personality dimensions;
CRC	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.48	8.08	0.41	1.24e-14	Common traits (Other);
CRC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg01483505	chr11:975446	AP2A2	0.39	5.92	0.31	8.04e-9	Alzheimer's disease (late onset);
CRC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.71	0.57	2.19e-30	Menopause (age at onset);
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.67	-0.35	1.05e-10	Bipolar disorder;
CRC	cis	rs2982552	0.844	rs3020347	chr6:152056962	T/G	cg22157087	chr6:152012887	ESR1	0.37	5.86	0.31	1.1e-8	Bone properties (heel);
CRC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.21	-0.37	3.86e-12	Bipolar disorder;
CRC	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.57	-8.15	-0.41	7.92e-15	Diisocyanate-induced asthma;
CRC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06505273	chr16:24850292	NA	0.37	5.83	0.31	1.32e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.44	6.07	0.32	3.5e-9	Systolic blood pressure;
CRC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.97	-17.1	-0.69	2.36e-47	Headache;
CRC	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.48	-6.43	-0.33	4.4e-10	Schizophrenia;
CRC	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg02569458	chr12:86230093	RASSF9	-0.39	-6.48	-0.34	3.31e-10	Major depressive disorder;
CRC	cis	rs11212617	0.967	rs4754324	chr11:108325448	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.9	0.31	9.28e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.12	-0.37	6.69e-12	QT interval;
CRC	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg06204229	chr3:52865917	ITIH4	0.55	6.47	0.34	3.64e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg14458575	chr2:238380390	NA	0.53	7.03	0.36	1.18e-11	Prostate cancer;
CRC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.63	6.45	0.34	4.08e-10	Axial length;
CRC	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.4	6.76	0.35	6.24e-11	Diastolic blood pressure;
CRC	cis	rs10991814	0.920	rs75120664	chr9:94117275	A/C	cg14446406	chr9:93919335	NA	0.59	6.66	0.34	1.13e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.6	8.35	0.42	1.92e-15	Pancreatic cancer;
CRC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg14122633	chr5:456516	EXOC3	0.4	7.06	0.36	9.65e-12	Cystic fibrosis severity;
CRC	cis	rs2223471	0.870	rs2744498	chr6:50754851	A/C	cg03432817	chr6:50765336	NA	0.38	6.02	0.32	4.62e-9	Subcutaneous adipose tissue;
CRC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-10.94	-0.52	5.7e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg00343986	chr7:65444356	GUSB	0.52	7.97	0.4	2.56e-14	Aortic root size;
CRC	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.53	7.0	0.36	1.43e-11	IgG glycosylation;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Parkinson's disease;
CRC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.59	8.25	0.41	3.96e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.0	9.41	0.46	9.08e-19	Diabetic retinopathy;
CRC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.55	-9.93	-0.48	1.73e-20	Intelligence (multi-trait analysis);
CRC	cis	rs6496667	0.865	rs7161926	chr15:90888962	A/G	cg04176472	chr15:90893244	GABARAPL3	0.58	6.84	0.35	3.82e-11	Rheumatoid arthritis;
CRC	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.65	9.64	0.47	1.6e-19	Autism;
CRC	cis	rs11212617	0.805	rs10890821	chr11:108022061	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.41	6.1	0.32	2.98e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7527798	0.592	rs2181694	chr1:207826776	G/A	cg21110645	chr1:207815933	NA	-0.43	-6.99	-0.36	1.56e-11	Erythrocyte sedimentation rate;
CRC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.12	-0.37	6.72e-12	Tuberculosis;
CRC	trans	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs41005	1.000	rs35398717	chr2:8115041	A/T	cg03155496	chr2:8117019	LOC339788	-0.39	-6.71	-0.35	8.29e-11	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg11189052	chr15:85197271	WDR73	0.54	7.55	0.38	4.31e-13	Schizophrenia;
CRC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg15790184	chr11:494944	RNH1	0.6	6.18	0.32	1.85e-9	Body mass index;
CRC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.72	0.3	2.41e-8	Homoarginine levels;
CRC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg12193833	chr17:30244370	NA	-0.74	-8.79	-0.44	8.61e-17	Hip circumference adjusted for BMI;
CRC	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg19875578	chr6:126661172	C6orf173	0.43	5.94	0.31	7.11e-9	Male-pattern baldness;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg00774050	chr4:73935472	COX18	0.4	6.04	0.32	4.06e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg12458913	chr13:53173898	NA	-0.5	-7.15	-0.37	5.81e-12	Lewy body disease;
CRC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.51	-0.34	2.73e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.8	-10.78	-0.51	2.06e-23	Initial pursuit acceleration;
CRC	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg20935368	chr5:178288625	ZNF354B	0.43	7.01	0.36	1.32e-11	Sleep duration;
CRC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.85	-11.89	-0.55	2.24e-27	Gut microbiome composition (summer);
CRC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.65	10.71	0.51	3.64e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.69	12.24	0.56	1.24e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.18e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.6	-0.43	3.21e-16	Hemoglobin concentration;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg27635394	chr6:26043820	HIST1H2BB	0.43	6.22	0.32	1.53e-9	Intelligence (multi-trait analysis);
CRC	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	8.03	0.4	1.71e-14	Platelet distribution width;
CRC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18591801	chr3:52553433	STAB1	-0.3	-5.63	-0.3	3.78e-8	Electroencephalogram traits;
CRC	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg20744362	chr22:50050164	C22orf34	0.33	5.98	0.31	5.77e-9	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.84	0.51	1.24e-23	Bone mineral density;
CRC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.62	-8.06	-0.41	1.39e-14	Schizophrenia;
CRC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.47	9.33	0.46	1.62e-18	Prostate cancer;
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.67	-0.43	1.96e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg17724175	chr1:150552817	MCL1	0.49	7.28	0.37	2.54e-12	Melanoma;
CRC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.54	8.03	0.4	1.73e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.73	0.3	2.27e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.94	-0.31	7.37e-9	Pulmonary function;
CRC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	9.55	0.47	3.1400000000000002e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.41	6.11	0.32	2.88e-9	Hemoglobin concentration;
CRC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs2257205	0.667	rs9889494	chr17:56629764	T/C	cg25885038	chr17:56607967	SEPT4	-0.56	-6.21	-0.32	1.55e-9	Pancreatic cancer;
CRC	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.21	0.32	1.62e-9	Intraocular pressure;
CRC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.62	9.01	0.44	1.72e-17	Other erythrocyte phenotypes;
CRC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg22532475	chr10:104410764	TRIM8	-0.37	-6.86	-0.35	3.51e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.72	10.18	0.49	2.52e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.13	-0.37	6.56e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs12024301	0.557	rs79753938	chr1:183623422	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.52	7.89	0.4	4.42e-14	Body mass index;
CRC	trans	rs6472827	0.645	rs16836	chr8:75114062	T/C	cg16732884	chr16:2569654	AMDHD2;ATP6V0C	0.38	5.97	0.31	6.16e-9	Uterine fibroids;
CRC	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.59	-8.21	-0.41	5e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.26	14.89	0.63	1.11e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.75	-10.01	-0.48	9.26e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg19318889	chr4:1322082	MAEA	0.43	6.47	0.34	3.54e-10	Obesity-related traits;
CRC	cis	rs427941	0.632	rs201470	chr7:101744045	G/A	cg06246474	chr7:101738831	CUX1	0.43	6.68	0.35	1.01e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg16342193	chr10:102329863	NA	0.35	5.79	0.3	1.62e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.66	12.24	0.56	1.25e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg08314208	chr16:67682810	RLTPR	-0.65	-6.89	-0.36	2.84e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg25237894	chr2:233734115	C2orf82	-0.5	-7.85	-0.4	5.78e-14	Coronary artery disease;
CRC	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.06	14.78	0.63	2.91e-38	Exhaled nitric oxide output;
CRC	cis	rs3026101	0.671	rs3026128	chr17:5293962	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg01339444	chr6:118972232	C6orf204	0.53	6.06	0.32	3.81e-9	Diastolic blood pressure;
CRC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-6.03	-0.32	4.47e-9	Life satisfaction;
CRC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg27534772	chr1:16042836	PLEKHM2	0.54	10.12	0.49	3.78e-21	Systolic blood pressure;
CRC	cis	rs11627756	0.958	rs10131189	chr14:103091440	C/G	cg12046867	chr14:103022105	NA	-0.44	-5.82	-0.31	1.37e-8	Mean platelet volume;
CRC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	6.7	0.35	9.1e-11	Body mass index;
CRC	cis	rs1109861	0.525	rs606139	chr10:11205719	A/G	cg08389350	chr10:11198709	CUGBP2	-0.35	-5.63	-0.3	3.92e-8	Urinary albumin-to-creatinine ratio;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg12290896	chr5:96038388	CAST	-0.52	-6.83	-0.35	4.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg12463550	chr7:65579703	CRCP	0.63	5.98	0.31	5.8e-9	Diabetic kidney disease;
CRC	trans	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg17903999	chr18:56338584	MALT1	-0.41	-6.48	-0.34	3.3e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg21251018	chr6:28226885	NKAPL	-0.38	-5.87	-0.31	1.09e-8	Parkinson's disease;
CRC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.84	12.66	0.57	3.49e-30	Menarche (age at onset);
CRC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.26	0.41	3.61e-15	Life satisfaction;
CRC	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.41	-6.71	-0.35	8.54e-11	Resting heart rate;
CRC	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg22732515	chr19:44031385	ETHE1	0.69	10.41	0.5	4.04e-22	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.47	6.96	0.36	1.84e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg03037974	chr15:76606532	NA	-0.52	-7.35	-0.38	1.54e-12	Blood metabolite levels;
CRC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.64	-8.13	-0.41	8.65e-15	Smoking behavior;
CRC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg22110888	chr17:80059540	CCDC57	0.42	6.67	0.35	1.1e-10	Life satisfaction;
CRC	cis	rs7703744	0.634	rs6884061	chr5:118683431	C/T	cg23917399	chr5:118691751	TNFAIP8	0.43	6.15	0.32	2.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg06781209	chr11:61594997	FADS2	-0.38	-5.74	-0.3	2.11e-8	Trans fatty acid levels;
CRC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg20203395	chr5:56204925	C5orf35	-0.66	-8.19	-0.41	5.69e-15	Initial pursuit acceleration;
CRC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.54	-11.19	-0.53	7.49e-25	Bipolar disorder;
CRC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.98	0.64	4.66e-39	Mean platelet volume;
CRC	cis	rs73200209	0.744	rs73200239	chr12:116684424	G/C	cg01776926	chr12:116560359	MED13L	-0.61	-7.27	-0.37	2.66e-12	Total body bone mineral density;
CRC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.63	0.39	2.59e-13	Lymphocyte percentage of white cells;
CRC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	trans	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg15147215	chr3:52552868	STAB1	-0.66	-11.34	-0.53	2.19e-25	Bipolar disorder;
CRC	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg05562828	chr17:3906858	NA	0.67	12.33	0.56	5.66e-29	Type 2 diabetes;
CRC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg23533926	chr12:111358616	MYL2	-0.52	-7.81	-0.4	7.93e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00166722	chr3:10149974	C3orf24	0.61	7.92	0.4	3.81e-14	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg15845792	chr6:28175446	NA	0.97	13.0	0.58	1.75e-31	Depression;
CRC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.53	-0.47	3.58e-19	Migraine;Coronary artery disease;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03425468	chr1:155164676	MIR92B	-0.43	-6.26	-0.33	1.17e-9	Myopia (pathological);
CRC	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg23167259	chr10:102495509	NA	-0.46	-6.31	-0.33	8.87e-10	Alzheimer's disease;
CRC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg05501817	chr11:14380813	RRAS2	-0.44	-6.01	-0.31	4.85e-9	Sense of smell;
CRC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-14.99	-0.64	4.38e-39	Vitiligo;
CRC	cis	rs6968419	0.747	rs1004107	chr7:115860783	A/T	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.58e-10	Intraocular pressure;
CRC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.72	-12.19	-0.56	1.89e-28	Age at first birth;
CRC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg10729496	chr3:10149963	C3orf24	0.5	6.81	0.35	4.67e-11	Alzheimer's disease;
CRC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.53	8.04	0.41	1.6e-14	Tuberculosis;
CRC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg00246817	chr9:123691163	NA	-0.47	-6.04	-0.32	4.11e-9	Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg15845792	chr6:28175446	NA	0.96	12.86	0.58	6.21e-31	Depression;
CRC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.53	-0.47	3.53e-19	Bladder cancer;
CRC	cis	rs11212617	0.935	rs227064	chr11:108207393	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.42	6.16	0.32	2.11e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg02135003	chr7:105160482	PUS7	-0.53	-8.35	-0.42	1.93e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg10760299	chr15:45669010	GATM	0.53	8.28	0.42	3.15e-15	Homoarginine levels;
CRC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.36	6.17	0.32	2.01e-9	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CRC	cis	rs7246760	1.000	rs17849496	chr19:9922223	G/A	cg16876255	chr19:9731953	ZNF561	0.69	5.68	0.3	2.92e-8	Pursuit maintenance gain;
CRC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg15763984	chr4:1342303	KIAA1530	-0.38	-5.8	-0.3	1.59e-8	Obesity-related traits;
CRC	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg09597638	chr17:3907349	NA	0.71	13.19	0.59	3.41e-32	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.64	0.3	3.68e-8	Prudent dietary pattern;
CRC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.74	12.56	0.57	7.64e-30	Oral cavity cancer;
CRC	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.76	14.77	0.63	3.17e-38	Mean corpuscular hemoglobin;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg06052471	chr11:61130074	TMEM138;CYBASC3	-0.42	-6.11	-0.32	2.75e-9	Daytime sleep phenotypes;
CRC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg03934865	chr2:198174659	NA	-0.47	-8.57	-0.43	4.2e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg11301795	chr4:187892539	NA	-0.84	-17.52	-0.69	5.23e-49	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23396286	chr10:99258505	UBTD1;MMS19	0.44	6.27	0.33	1.12e-9	Response to antipsychotic treatment;
CRC	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg19025524	chr12:109796872	NA	-0.47	-6.68	-0.35	1.01e-10	Neuroticism;
CRC	trans	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg02936872	chr9:99801550	CTSL2	0.48	6.18	0.32	1.85e-9	Iron status biomarkers;
CRC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.43	6.51	0.34	2.87e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-7.56	-0.38	4.01e-13	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.43	6.23	0.32	1.42e-9	Pneumonia;
CRC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg01987224	chr1:201084466	NA	0.54	10.01	0.48	9.48e-21	Permanent tooth development;
CRC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs4658101	0.700	rs6677520	chr1:92052231	A/G	cg24006770	chr1:92056542	NA	0.48	7.12	0.37	7e-12	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs12230513	0.732	rs7980098	chr12:55844694	A/G	cg19537932	chr12:55886519	OR6C68	-0.73	-9.52	-0.46	3.94e-19	Contrast sensitivity;
CRC	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg00603274	chr11:61596626	FADS2	-0.49	-6.92	-0.36	2.42e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.61	6.47	0.34	3.62e-10	Schizophrenia;
CRC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	5.77	0.3	1.8e-8	Depression;
CRC	cis	rs375066	0.623	rs62114569	chr19:44354624	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.42	-5.96	-0.31	6.65e-9	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg04146151	chr16:2155961	PKD1	-0.48	-6.28	-0.33	1.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs4867766	0.789	rs17725606	chr5:173956965	A/C	cg20434911	chr5:173954559	NA	-0.8	-9.11	-0.45	7.96e-18	Stroke;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg21251018	chr6:28226885	NKAPL	0.47	6.17	0.32	1.95e-9	Depression;
CRC	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	0.9	8.35	0.42	1.94e-15	Left atrial antero-posterior diameter;
CRC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg09877947	chr5:131593287	PDLIM4	0.44	8.09	0.41	1.14e-14	Breast cancer;
CRC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.44	7.52	0.38	5.28e-13	Major depressive disorder;
CRC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.29	5.69	0.3	2.83e-8	Homoarginine levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03428813	chr2:62115351	CCT4	0.5	6.32	0.33	8.47e-10	Thyroid stimulating hormone;
CRC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.95	-0.31	7.04e-9	Obesity-related traits;
CRC	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg16342193	chr10:102329863	NA	-0.4	-6.3	-0.33	9.79e-10	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs10877945	0.522	rs7297754	chr12:63443521	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.4	-6.08	-0.32	3.37e-9	Obesity-related traits;
CRC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg05192639	chr6:26864778	GUSBL1	0.39	6.73	0.35	7.74e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.58	-8.39	-0.42	1.4e-15	Lung cancer;
CRC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.66	10.05	0.48	6.87e-21	Lung cancer;
CRC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.62	0.54	2.28e-26	Alzheimer's disease;
CRC	cis	rs2530545	0.762	rs1833112	chr7:34665112	C/T	cg14401837	chr7:34697493	NPSR1	0.39	5.75	0.3	2.01e-8	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13363640	chr11:2985302	SNORA54;NAP1L4	0.38	6.0	0.31	5.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	5.71	0.3	2.54e-8	Psychosis and Alzheimer's disease;
CRC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.55	9.92	0.48	1.78e-20	Huntington's disease progression;
CRC	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.58	6.26	0.33	1.22e-9	Osteoarthritis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11224423	chr12:56136943	GDF11	0.43	7.06	0.36	1.02e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6838801	0.752	rs6817407	chr4:77616338	C/G	cg17476223	chr4:77663285	SHROOM3	-0.45	-6.06	-0.32	3.72e-9	Cleft lip with or without cleft palate;
CRC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.53	-7.59	-0.39	3.35e-13	Longevity;
CRC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.65	9.16	0.45	5.64e-18	Parkinson's disease;
CRC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-6.99	-0.36	1.57e-11	Rheumatoid arthritis;
CRC	cis	rs17767392	0.958	rs2109276	chr14:71889767	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.92	8.21	0.41	5.11e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.82	13.72	0.6	3.47e-34	Coronary artery disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg13482356	chr1:118148519	FAM46C	-0.5	-6.0	-0.31	5.29e-9	Diisocyanate-induced asthma;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.99	-0.31	5.65e-9	Cognitive function;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.63	6.52	0.34	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.55	6.34	0.33	7.61e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04221910	chr5:616842	CEP72	0.41	6.77	0.35	5.99e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.53	7.13	0.37	6.45e-12	Height;
CRC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.54	-9.67	-0.47	1.21e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	6.92	0.36	2.38e-11	Mood instability;
CRC	cis	rs9937943	0.667	rs9945	chr16:74490556	G/A	cg01733217	chr16:74700730	RFWD3	0.65	6.8	0.35	4.91e-11	Neutrophil percentage of white cells;
CRC	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.55	-10.42	-0.5	3.73e-22	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs2811415	0.597	rs10934844	chr3:127749651	T/C	cg13719885	chr3:127795394	NA	-0.39	-5.99	-0.31	5.56e-9	Lung function (FEV1/FVC);
CRC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg18016565	chr1:150552671	MCL1	0.41	5.78	0.3	1.72e-8	Melanoma;
CRC	cis	rs365302	1.000	rs419281	chr6:159642860	G/A	cg14500486	chr6:159655392	FNDC1	0.45	6.86	0.35	3.39e-11	Coronary heart disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25764190	chr19:44037015	ZNF575	-0.52	-6.36	-0.33	6.83e-10	Diisocyanate-induced asthma;
CRC	trans	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.35	-0.38	1.56e-12	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2307022	0.586	rs2279539	chr16:68395094	G/A	cg02226672	chr16:68398533	SMPD3	0.29	5.72	0.3	2.4e-8	Body mass index;
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.92	-22.45	-0.78	2.37e-68	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.74	10.5	0.5	1.91e-22	Cognitive function;
CRC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg27068330	chr11:65405492	SIPA1	0.44	6.55	0.34	2.26e-10	Acne (severe);
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.55	6.66	0.34	1.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg09659197	chr4:152720779	NA	0.42	8.71	0.43	1.47e-16	Intelligence (multi-trait analysis);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg17276082	chr9:140083193	ANAPC2;SSNA1	-0.44	-6.45	-0.34	3.94e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg21251018	chr6:28226885	NKAPL	0.47	6.3	0.33	9.69e-10	Parkinson's disease;
CRC	cis	rs12541635	0.966	rs10955409	chr8:107022586	A/C	cg10147462	chr8:107024639	NA	0.43	7.34	0.38	1.69e-12	Age of smoking initiation;
CRC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.53	-6.8	-0.35	4.83e-11	Neuroticism;
CRC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg18230493	chr5:56204884	C5orf35	-0.4	-5.79	-0.3	1.68e-8	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg21620606	chr4:1342894	KIAA1530	0.4	6.96	0.36	1.84e-11	Obesity-related traits;
CRC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg10760299	chr15:45669010	GATM	0.49	7.71	0.39	1.54e-13	Homoarginine levels;
CRC	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg20312557	chr2:97357134	FER1L5	-0.61	-5.62	-0.3	4.18e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.71	-0.51	3.59e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6534441	0.727	rs6844455	chr4:125429497	G/A	cg21609808	chr4:125404261	NA	0.42	5.94	0.31	7.18e-9	Major depressive disorder;
CRC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.63	-7.51	-0.38	5.43e-13	Hip circumference adjusted for BMI;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14067770	chr11:615950	IRF7	0.4	6.11	0.32	2.83e-9	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18719723	chr12:48395490	COL2A1	0.4	5.99	0.31	5.63e-9	Response to antipsychotic treatment;
CRC	trans	rs12663356	0.528	rs9350359	chr6:21462624	C/T	cg24023498	chr2:157199345	NA	0.39	6.0	0.31	5.07e-9	Crohn's disease;
CRC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-6.29	-0.33	9.94e-10	Vitiligo;
CRC	cis	rs12024301	0.557	rs16861394	chr1:183617693	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs4308415	0.781	rs1481265	chr4:67813982	A/G	cg19648955	chr2:177134095	MTX2	-0.42	-6.27	-0.33	1.16e-9	Educational attainment (years of education);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00873521	chr9:95056130	IARS;SNORA84	0.47	6.08	0.32	3.29e-9	Thyroid stimulating hormone;
CRC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.48	6.3	0.33	9.64e-10	Lymphocyte counts;
CRC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.73	8.44	0.42	1.03e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-6.41	-0.33	5.02e-10	Body mass index;
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.3	-0.33	9.34e-10	Bipolar disorder;
CRC	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	8.8	0.44	7.83e-17	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg15790184	chr11:494944	RNH1	0.61	5.79	0.3	1.66e-8	Body mass index;
CRC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg15358701	chr1:161410459	NA	-0.62	-6.63	-0.34	1.39e-10	Rheumatoid arthritis;
CRC	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.81	-0.4	7.94e-14	Homocysteine levels;
CRC	trans	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg10756647	chr7:56101905	PSPH	0.72	7.69	0.39	1.71e-13	Diabetic kidney disease;
CRC	trans	rs492478	0.892	rs75220787	chr5:3941016	C/T	cg09199442	chr11:28132951	METT5D1	-0.71	-6.34	-0.33	7.54e-10	Cognitive performance;
CRC	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.4	7.54	0.38	4.51e-13	Mean corpuscular volume;
CRC	cis	rs4499344	0.633	rs259229	chr19:33134425	A/G	cg08127369	chr19:33164662	ANKRD27	-0.37	-5.65	-0.3	3.46e-8	Mean platelet volume;
CRC	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg13607699	chr17:42295918	UBTF	-0.47	-6.07	-0.32	3.47e-9	Total body bone mineral density;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.57	-7.79	-0.39	8.79e-14	Intelligence (multi-trait analysis);
CRC	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.77	15.89	0.66	1.3e-42	Leprosy;
CRC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg08200582	chr11:442649	ANO9	-0.69	-7.04	-0.36	1.16e-11	Body mass index;
CRC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg14847009	chr1:175162515	KIAA0040	-0.27	-5.9	-0.31	8.91e-9	Alcohol dependence;
CRC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.59	6.93	0.36	2.25e-11	Menarche (age at onset);
CRC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg20607287	chr7:12443886	VWDE	-0.67	-6.78	-0.35	5.55e-11	Coronary artery disease;
CRC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.6	-7.78	-0.39	9.24e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.7	-7.02	-0.36	1.24e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg05527609	chr1:210001259	C1orf107	-0.56	-6.21	-0.32	1.6e-9	Red blood cell count;
CRC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-1.07	-17.84	-0.7	2.94e-50	Blood pressure (smoking interaction);
CRC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.96	-0.4	2.78e-14	Intelligence (multi-trait analysis);
CRC	cis	rs965469	1.000	rs6051810	chr20:3355384	A/G	cg25506879	chr20:3388711	C20orf194	-0.4	-5.83	-0.31	1.34e-8	IFN-related cytopenia;
CRC	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.58	-6.53	-0.34	2.44e-10	Blood protein levels;
CRC	cis	rs2415984	0.622	rs1761029	chr14:46934764	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.76	0.3	1.98e-8	Number of children ever born;
CRC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.74	7.77	0.39	9.87e-14	Diabetic retinopathy;
CRC	cis	rs4666002	0.510	rs74446114	chr2:28066122	T/C	cg27432699	chr2:27873401	GPN1	0.54	6.16	0.32	2.16e-9	Phospholipid levels (plasma);
CRC	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.72	-0.39	1.45e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.67	10.71	0.51	3.54e-23	Longevity;Endometriosis;
CRC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg12273811	chr6:28175739	NA	0.55	7.76	0.39	1.08e-13	Parkinson's disease;
CRC	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.49	7.4	0.38	1.15e-12	Testicular germ cell tumor;
CRC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.77	-0.35	5.97e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.23	0.41	4.29e-15	Menopause (age at onset);
CRC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.52	0.34	2.6200000000000003e-10	Morning vs. evening chronotype;
CRC	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.55	7.3	0.37	2.16e-12	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07483432	chr12:72079704	TMEM19	0.55	7.83	0.4	6.76e-14	Response to antipsychotic treatment;
CRC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.82	-0.72	3.98e-54	Height;
CRC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.41	7.87	0.4	5.22e-14	Mean corpuscular volume;
CRC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.69	10.61	0.5	8.49e-23	Monocyte count;
CRC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg15962314	chr1:44399869	ARTN	0.29	5.68	0.3	2.91e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.34e-40	Prostate cancer;
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg04796162	chr7:45961102	IGFBP3	0.38	6.62	0.34	1.49e-10	Sitting height ratio;
CRC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.65	10.31	0.49	8.72e-22	Blood metabolite levels;
CRC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00166722	chr3:10149974	C3orf24	0.71	7.47	0.38	7.07e-13	Alzheimer's disease;
CRC	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.55	-0.34	2.25e-10	Eye color traits;
CRC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.44	-6.02	-0.32	4.58e-9	Cognitive function;
CRC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.8	14.27	0.62	2.79e-36	Breast cancer;
CRC	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.76	15.42	0.65	9.52e-41	Leprosy;
CRC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.55	6.85	0.35	3.59e-11	Menopause (age at onset);
CRC	cis	rs2274273	0.553	rs56166765	chr14:55738018	T/C	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.17	-0.32	2.04e-9	Protein biomarker;
CRC	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.57	-8.12	-0.41	9.14e-15	Blood pressure (smoking interaction);
CRC	cis	rs13161895	1.000	rs1102191	chr5:179416210	C/T	cg02702477	chr5:179499311	RNF130	0.55	6.38	0.33	6.16e-10	LDL cholesterol;
CRC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.47	7.34	0.38	1.7e-12	Corneal astigmatism;
CRC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.14	-0.41	8.04e-15	Morning vs. evening chronotype;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg15147215	chr3:52552868	STAB1	-0.59	-9.28	-0.46	2.29e-18	Bipolar disorder;
CRC	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg14191688	chr11:70257035	CTTN	0.43	5.74	0.3	2.12e-8	Coronary artery disease;
CRC	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.57	6.62	0.34	1.47e-10	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg02023728	chr11:77925099	USP35	-0.38	-6.35	-0.33	7.09e-10	Alzheimer's disease (survival time);
CRC	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.11	25.2	0.81	8.66e-79	Colorectal cancer;
CRC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.67	9.67	0.47	1.2e-19	Body mass index;
CRC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.55	8.67	0.43	2.03e-16	Colorectal cancer;
CRC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg05044414	chr3:183734942	ABCC5	0.47	8.11	0.41	1.03e-14	Anterior chamber depth;
CRC	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg04289385	chr6:36355825	ETV7	0.38	5.61	0.3	4.25e-8	Platelet distribution width;
CRC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.43	-5.88	-0.31	1.02e-8	IgG glycosylation;
CRC	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs6988985	0.765	rs28753687	chr8:143988377	T/C	cg10324643	chr8:143916377	GML	0.37	5.89	0.31	9.65e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg23587288	chr2:27483067	SLC30A3	0.34	6.01	0.31	4.82e-9	Blood metabolite levels;
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg04553112	chr3:125709451	NA	-0.5	-6.19	-0.32	1.82e-9	Blood pressure (smoking interaction);
CRC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.6	9.96	0.48	1.31e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.71	10.96	0.52	5.0600000000000004e-24	Corneal astigmatism;
CRC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg27661571	chr11:113659931	NA	-0.96	-11.16	-0.52	1e-24	Hip circumference adjusted for BMI;
CRC	cis	rs28655083	0.509	rs285020	chr16:77099517	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.74	0.35	7.27e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.65	9.13	0.45	6.85e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.52e-18	Bladder cancer;
CRC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.44	-6.41	-0.33	5.15e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.36	-6.6	-0.34	1.6e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.09	-0.45	9.57e-18	Bipolar disorder;
CRC	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg23293999	chr7:106826042	HBP1	0.5	5.79	0.3	1.66e-8	Coronary artery disease;
CRC	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.56	7.93	0.4	3.41e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs457287	1.000	rs457287	chr9:4834394	A/G	cg14182974	chr9:4791918	RCL1	0.41	6.55	0.34	2.25e-10	Platelet count;
CRC	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg27534772	chr1:16042836	PLEKHM2	0.45	7.5	0.38	6.07e-13	Systolic blood pressure;
CRC	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg26618903	chr10:100175079	PYROXD2	0.37	6.36	0.33	6.75e-10	Metabolite levels;
CRC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.43	6.58	0.34	1.83e-10	Ulcerative colitis;
CRC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.46	6.96	0.36	1.84e-11	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27242549	chr2:113012627	ZC3H8	0.39	6.2	0.32	1.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg15654264	chr1:150340011	RPRD2	0.42	6.25	0.33	1.29e-9	Migraine;
CRC	cis	rs9311676	0.586	rs73085867	chr3:58434791	C/T	cg06643156	chr3:58380774	PXK	0.43	6.65	0.34	1.19e-10	Systemic lupus erythematosus;
CRC	cis	rs2811415	0.597	rs9810599	chr3:127749086	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.96	-0.31	6.44e-9	Lung function (FEV1/FVC);
CRC	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg02023728	chr11:77925099	USP35	-0.36	-6.15	-0.32	2.29e-9	Alzheimer's disease (survival time);
CRC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg10911889	chr6:126070802	HEY2	0.39	5.94	0.31	7.15e-9	Brugada syndrome;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27248073	chr17:6347727	FAM64A	0.46	6.19	0.32	1.78e-9	Hip circumference;
CRC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.65	-9.9	-0.48	2.06e-20	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00166722	chr3:10149974	C3orf24	0.65	8.86	0.44	5.13e-17	Alzheimer's disease;
CRC	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.6	9.43	0.46	7.91e-19	Breast cancer;
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.45	7.58	0.39	3.44e-13	Childhood ear infection;
CRC	trans	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.43	0.33	4.46e-10	Ulcerative colitis;
CRC	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.49	6.28	0.33	1.06e-9	Exhaled nitric oxide output;
CRC	cis	rs10991814	0.920	rs78704969	chr9:94118523	C/T	cg14446406	chr9:93919335	NA	0.59	6.69	0.35	9.67e-11	Neutrophil percentage of granulocytes;
CRC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.83	0.48	3.68e-20	Lung cancer;
CRC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.18	0.37	4.79e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14532426	chr21:33245908	HUNK	0.36	6.4	0.33	5.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.38	-6.07	-0.32	3.54e-9	Blood metabolite levels;
CRC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.94	0.36	2.05e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg14458575	chr2:238380390	NA	0.44	6.49	0.34	3.09e-10	Prostate cancer;
CRC	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.55	6.38	0.33	6.02e-10	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20337753	chr22:36424119	RBM9	0.41	6.37	0.33	6.55e-10	Response to antipsychotic treatment;
CRC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.93	0.31	7.63e-9	Major depressive disorder;
CRC	cis	rs72772090	0.539	rs72773991	chr5:96163775	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-5.66	-0.3	3.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14008862	chr17:28927542	LRRC37B2	0.59	5.77	0.3	1.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9287719	0.566	rs34595606	chr2:10722518	G/A	cg00105475	chr2:10696890	NA	0.48	7.3	0.37	2.2e-12	Prostate cancer;
CRC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.89	0.31	9.46e-9	Bladder cancer;
CRC	cis	rs3889199	0.924	rs35844581	chr1:59672968	G/T	cg25881383	chr1:59680599	NA	-0.38	-6.05	-0.32	4.05e-9	Pulse pressure;
CRC	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg01339444	chr6:118972232	C6orf204	0.57	6.1	0.32	3.04e-9	Diastolic blood pressure;
CRC	cis	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg15590007	chr10:45870220	ALOX5	0.61	6.02	0.31	4.79e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg12172441	chr6:28176163	NA	0.47	5.63	0.3	3.92e-8	Parkinson's disease;
CRC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.28	-5.85	-0.31	1.19e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg22777020	chr22:31556080	RNF185	-0.48	-5.74	-0.3	2.15e-8	Colorectal cancer;
CRC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.48	9.62	0.47	1.81e-19	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.49	7.18	0.37	4.56e-12	Breast cancer;
CRC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.12	10.8	0.51	1.76e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05482832	chr17:74734106	MIR636;SFRS2;MFSD11	0.39	5.98	0.31	5.86e-9	Intelligence (multi-trait analysis);
CRC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.15	0.52	1.03e-24	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.41	5.91	0.31	8.35e-9	Glycated hemoglobin levels;
CRC	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.65	-9.52	-0.46	3.76e-19	Waist circumference;Body mass index;
CRC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg03923535	chr7:1197113	ZFAND2A	0.41	5.69	0.3	2.81e-8	Longevity;Endometriosis;
CRC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.45	-0.34	4e-10	Electroencephalogram traits;
CRC	cis	rs2274273	0.600	rs10134317	chr14:55793448	C/T	cg10130446	chr14:55658398	DLGAP5	-0.42	-5.88	-0.31	1.01e-8	Protein biomarker;
CRC	cis	rs447	0.666	rs10279093	chr7:83748678	T/G	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.83	-0.31	1.33e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.71	11.92	0.55	1.83e-27	Alzheimer's disease (late onset);
CRC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.78	-13.06	-0.58	1.06e-31	Obesity-related traits;
CRC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg23034840	chr1:205782522	SLC41A1	0.44	5.81	0.31	1.46e-8	Menarche (age at onset);
CRC	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.32	0.33	8.5e-10	Morning vs. evening chronotype;
CRC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg14664628	chr15:75095509	CSK	-0.44	-6.54	-0.34	2.28e-10	Caffeine consumption;
CRC	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.72	11.23	0.53	5.64e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg05313129	chr8:58192883	C8orf71	-0.43	-5.72	-0.3	2.37e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg21268650	chr7:45961089	IGFBP3	0.36	6.12	0.32	2.66e-9	Sitting height ratio;
CRC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.09	-0.45	9.8e-18	Hip circumference adjusted for BMI;
CRC	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.48	7.62	0.39	2.65e-13	Crohn's disease;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	9.8	0.48	4.71e-20	Neuroticism;
CRC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.81	-9.05	-0.45	1.25e-17	Breast cancer;
CRC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.09	0.32	3.24e-9	Aortic root size;
CRC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg24578937	chr1:2090814	PRKCZ	-0.38	-7.0	-0.36	1.45e-11	Height;
CRC	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg05540913	chr6:167530185	CCR6	0.32	5.67	0.3	3.19e-8	Primary biliary cholangitis;
CRC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg04545296	chr12:48745243	ZNF641	0.33	5.83	0.31	1.35e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.5	-7.69	-0.39	1.73e-13	Breast size;
CRC	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.45	-6.94	-0.36	2.08e-11	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.27	14.66	0.63	8.59e-38	Diabetic kidney disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14127958	chr12:105630059	APPL2	0.45	6.11	0.32	2.75e-9	Anxiety disorder;
CRC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.14	-0.41	8.5e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs6681460	0.966	rs11208932	chr1:67097853	T/C	cg02459107	chr1:67143332	SGIP1	0.45	7.54	0.38	4.66e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.54	-10.03	-0.48	7.81e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.33	-6.22	-0.32	1.53e-9	Breast cancer;
CRC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.82	-0.48	3.87e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs9581094	0.527	rs73172130	chr13:25024985	A/G	ch.10.2420334F	chr10:115122200	NA	0.74	6.22	0.32	1.54e-9	Sudden cardiac arrest;
CRC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.97e-9	Aortic root size;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg05586854	chr2:149402972	EPC2	-0.41	-6.27	-0.33	1.15e-9	Aortic root size;
CRC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.39	5.89	0.31	9.49e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12692738	0.526	rs355868	chr2:165631194	C/T	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-7.55	-0.38	4.19e-13	Colorectal cancer;
CRC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.71	6.3	0.33	9.46e-10	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg08999081	chr20:33150536	PIGU	-0.42	-5.62	-0.3	4.16e-8	Neuroticism;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg02996269	chr4:106394692	PPA2	0.4	6.24	0.33	1.36e-9	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg01339444	chr6:118972232	C6orf204	0.56	6.27	0.33	1.16e-9	Diastolic blood pressure;
CRC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.3	-0.56	7.02e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3736594	0.546	rs6719960	chr2:27830067	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-8.12	-0.41	9.14e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.12	13.62	0.6	8.03e-34	Sexual dysfunction (female);
CRC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.5	6.75	0.35	6.69e-11	Glioblastoma;
CRC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	19.11	0.73	2.73e-55	Prudent dietary pattern;
CRC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg11833968	chr6:79620685	NA	-0.35	-6.15	-0.32	2.23e-9	Intelligence (multi-trait analysis);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08209163	chr13:28024472	MTIF3	0.38	6.17	0.32	1.96e-9	Obesity-related traits;
CRC	cis	rs6741819	0.617	rs56155927	chr2:7159401	A/C	cg27144453	chr2:7172511	RNF144A	-0.59	-7.71	-0.39	1.55e-13	Response to antipsychotic treatment;
CRC	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.56	7.49	0.38	6.53e-13	Systolic blood pressure;
CRC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.93	-16.32	-0.67	2.74e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2072510	0.569	rs7306086	chr12:96390502	T/C	cg22491680	chr12:96389547	HAL	-0.5	-6.16	-0.32	2.16e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26240231	chr7:1148101	C7orf50	-0.44	-6.41	-0.33	5.16e-10	Bronchopulmonary dysplasia;
CRC	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.49	7.17	0.37	5.06e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.5	9.46	0.46	6.3e-19	Educational attainment (years of education);
CRC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.43	-0.33	4.52e-10	Aortic root size;
CRC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	14.65	0.63	8.89e-38	Gut microbiome composition (summer);
CRC	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11446398	chr5:77624930	NA	0.41	5.92	0.31	8.16e-9	Triglycerides;
CRC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	0.66	7.63	0.39	2.52e-13	Lymphocyte counts;
CRC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.63	11.33	0.53	2.47e-25	Bone mineral density;
CRC	cis	rs73195822	0.614	rs7309777	chr12:111213964	A/G	cg12870014	chr12:110450643	ANKRD13A	0.57	5.76	0.3	1.94e-8	Itch intensity from mosquito bite;
CRC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.76	8.46	0.42	8.66e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12184888	chr8:120886450	DEPDC6	0.41	5.98	0.31	5.68e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20531781	chr7:99775012	STAG3;GPC2	0.4	6.64	0.34	1.29e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.57	-8.66	-0.43	2.13e-16	Uric acid levels;
CRC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.41	6.23	0.32	1.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.76	11.16	0.52	9.43e-25	Glomerular filtration rate (creatinine);
CRC	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.24	-0.41	4.25e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.32	-0.33	8.67e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.1	-0.41	1.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs3825932	0.961	rs11072815	chr15:79232319	C/T	cg25744700	chr15:79237217	CTSH	-0.38	-5.86	-0.31	1.11e-8	Type 1 diabetes;
CRC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg08347473	chr17:78092826	GAA	-0.38	-6.43	-0.33	4.5e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	trans	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg11070056	chr1:107600091	PRMT6	0.4	5.81	0.31	1.44e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.44	-6.77	-0.35	5.87e-11	Carotid intima media thickness;
CRC	trans	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg10756647	chr7:56101905	PSPH	0.69	7.51	0.38	5.5e-13	Diabetic kidney disease;
CRC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06544989	chr22:39130855	UNC84B	0.46	7.11	0.37	7.19e-12	Menopause (age at onset);
CRC	cis	rs6973256	0.605	rs7794168	chr7:133357606	T/C	cg10665199	chr7:133106180	EXOC4	0.49	7.81	0.4	7.78e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.51	0.6	2.08e-33	Platelet count;
CRC	trans	rs10507419	1.000	rs9541352	chr13:35182031	C/A	cg00944431	chr1:10896004	NA	0.42	6.03	0.32	4.34e-9	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);
CRC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.57	7.74	0.39	1.2e-13	IgG glycosylation;
CRC	cis	rs96067	0.805	rs4653162	chr1:36613704	G/T	cg25304816	chr1:36627734	MAP7D1	-0.46	-6.67	-0.35	1.06e-10	Corneal structure;
CRC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.46	0.6	3.33e-33	Chronic sinus infection;
CRC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.61	-9.45	-0.46	6.48e-19	Colorectal cancer;
CRC	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.64	10.58	0.5	1.03e-22	Cancer;
CRC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.55	-8.22	-0.41	4.65e-15	Systemic sclerosis;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg04166393	chr7:2884313	GNA12	0.51	6.8	0.35	4.86e-11	Height;
CRC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12667521	chr19:29218732	NA	0.47	6.65	0.34	1.2e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg07636037	chr3:49044803	WDR6	-0.79	-6.62	-0.34	1.49e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs747650	0.504	rs10838640	chr11:46984629	C/T	cg19486271	chr11:47235900	DDB2	-0.43	-6.47	-0.34	3.53e-10	Acne (severe);
CRC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg09163369	chr1:210001066	C1orf107	0.4	5.62	0.3	4e-8	Orofacial clefts;
CRC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.82	0.51	1.52e-23	Motion sickness;
CRC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.77	-0.35	5.76e-11	Response to antipsychotic treatment;
CRC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-9.19	-0.45	4.47e-18	Subjective well-being;
CRC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.66	10.41	0.5	4.04e-22	Corneal astigmatism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00334798	chr11:72929553	P2RY2	0.38	6.14	0.32	2.42e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02114082	chr10:12306459	NA	0.44	6.36	0.33	6.59e-10	Response to antipsychotic treatment;
CRC	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg08992911	chr2:238395768	MLPH	0.6	6.14	0.32	2.44e-9	Prostate cancer;
CRC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg15468180	chr1:107600409	PRMT6	-0.38	-6.06	-0.32	3.7e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.48	7.77	0.39	1.02e-13	Iron status biomarkers;
CRC	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14119001	chr9:139324193	INPP5E	0.42	6.11	0.32	2.86e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.47	8.68	0.43	1.84e-16	Neuroticism;
CRC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.17	-0.41	6.7e-15	Type 2 diabetes;
CRC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00166722	chr3:10149974	C3orf24	0.69	8.15	0.41	7.57e-15	Alzheimer's disease;
CRC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.46	0.34	3.84e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg02549819	chr16:58548995	SETD6	1.2	7.85	0.4	5.77e-14	Schizophrenia;
CRC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.21	-16.45	-0.67	8.87e-45	Breast cancer;
CRC	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.45	-7.76	-0.39	1.1e-13	Common traits (Other);
CRC	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg27398640	chr15:77910606	LINGO1	-0.43	-7.44	-0.38	8.96e-13	Type 2 diabetes;
CRC	cis	rs55702914	0.967	rs61328028	chr2:198223754	A/G	cg10820045	chr2:198174542	NA	0.35	6.04	0.32	4.15e-9	Major depression and alcohol dependence;
CRC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg26762873	chr11:5879799	OR52E8	-0.41	-6.02	-0.32	4.57e-9	DNA methylation (variation);
CRC	cis	rs728616	0.867	rs55690691	chr10:81658942	G/T	cg11900509	chr10:81946545	ANXA11	-0.62	-6.31	-0.33	8.96e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.41	8.19	0.41	5.97e-15	Tonsillectomy;
CRC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.7	0.39	1.62e-13	Platelet count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11395536	chr1:150521958	ADAMTSL4	0.38	6.45	0.34	4.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs2735413	0.711	rs12921476	chr16:78079846	G/C	cg04733911	chr16:78082701	NA	-0.45	-7.24	-0.37	3.26e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg22495460	chr2:25135724	ADCY3	-0.89	-17.5	-0.69	6.3e-49	Body mass index;
CRC	cis	rs9311676	0.609	rs62258077	chr3:58363371	T/C	cg06643156	chr3:58380774	PXK	0.44	6.8	0.35	4.98e-11	Systemic lupus erythematosus;
CRC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.08	18.29	0.71	4.62e-52	Cognitive function;
CRC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.44	-9.71	-0.47	9.39e-20	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07625546	chr4:78077996	CCNG2	0.46	6.33	0.33	8.09e-10	Response to antipsychotic treatment;
CRC	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg06209491	chr1:40138402	NT5C1A	-0.48	-7.5	-0.38	6.18e-13	Amyotrophic lateral sclerosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22629493	chr21:34961221	DONSON	0.44	6.04	0.32	4.09e-9	Anxiety disorder;
CRC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.96	-0.31	6.62e-9	Red blood cell count;
CRC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.25	-0.37	3.04e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.62	8.23	0.41	4.29e-15	Alzheimer's disease;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.63	-9.23	-0.45	3.33e-18	DNA methylation (variation);
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg14329157	chr2:228736135	WDR69	-0.47	-6.51	-0.34	2.73e-10	Blood pressure;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg19913688	chr11:428466	ANO9	-0.68	-7.0	-0.36	1.44e-11	Body mass index;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	10.51	0.5	1.82e-22	Lymphocyte counts;
CRC	trans	rs800082	1.000	rs1007564	chr3:144311843	C/T	cg24215973	chr2:240111563	HDAC4	-0.52	-7.28	-0.37	2.53e-12	Smoking behavior;
CRC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06656553	chr16:89960601	TCF25	-0.64	-5.82	-0.31	1.39e-8	Skin colour saturation;
CRC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg15744005	chr10:104629667	AS3MT	0.31	6.13	0.32	2.47e-9	Arsenic metabolism;
CRC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-9.71	-0.47	9.33e-20	Hip circumference adjusted for BMI;
CRC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.67	12.76	0.58	1.38e-30	Bone mineral density;
CRC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-16.27	-0.67	4.29e-44	Coronary artery disease;
CRC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg27094323	chr7:1216898	NA	-0.45	-7.58	-0.39	3.62e-13	Longevity;Endometriosis;
CRC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg14711859	chr11:8959438	ASCL3	-0.56	-10.65	-0.51	5.83e-23	Hematocrit;
CRC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.69	-9.7	-0.47	9.55e-20	Colorectal cancer;
CRC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.88	-0.35	2.99e-11	Breast cancer;
CRC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.9	-0.31	8.81e-9	Life satisfaction;
CRC	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	0.9	9.91	0.48	1.91e-20	Inflammatory bowel disease;
CRC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.39	6.24	0.33	1.31e-9	Lung cancer;
CRC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.55	-8.34	-0.42	2.11e-15	Calcium levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22225685	chr22:38203998	GCAT	0.46	7.46	0.38	7.74e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs728616	0.867	rs61858980	chr10:81816618	G/A	cg05935833	chr10:81318306	SFTPA2	-0.5	-6.13	-0.32	2.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg02659138	chr7:134003124	SLC35B4	0.39	6.7	0.35	9.14e-11	Mean platelet volume;
CRC	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg08501292	chr6:25962987	TRIM38	0.68	5.64	0.3	3.58e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.53	8.38	0.42	1.59e-15	Prostate cancer;
CRC	trans	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.6	0.39	3.19e-13	Endometrial cancer;
CRC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg25164649	chr6:28176230	NA	0.61	8.61	0.43	3.05e-16	Parkinson's disease;
CRC	cis	rs12024301	0.557	rs7530294	chr1:183610416	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.05	0.55	6.18e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg04518342	chr5:131593106	PDLIM4	0.58	9.99	0.48	1.06e-20	Acylcarnitine levels;
CRC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg06494592	chr3:125709126	NA	-0.56	-6.73	-0.35	7.33e-11	Blood pressure (smoking interaction);
CRC	cis	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg05299278	chr17:33885742	SLFN14	-0.4	-6.08	-0.32	3.39e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.77	-0.3	1.82e-8	Morning vs. evening chronotype;
CRC	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg08213375	chr14:104286397	PPP1R13B	0.4	6.38	0.33	5.93e-10	Reticulocyte count;
CRC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.11	-0.69	2.25e-47	Body mass index;
CRC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.52	-7.12	-0.37	6.67e-12	Gut microbiome composition (summer);
CRC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.48	6.82	0.35	4.43e-11	High light scatter reticulocyte count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19239571	chr1:100503607	HIAT1	0.39	6.84	0.35	3.83e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.77	11.64	0.54	1.92e-26	Chronic lymphocytic leukemia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17144508	chr2:128283727	IWS1	0.37	5.96	0.31	6.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.52	-7.82	-0.4	7.21e-14	Aortic root size;
CRC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg05639522	chr1:247681581	NA	-0.51	-8.58	-0.43	3.81e-16	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01921777	chr1:40839564	SMAP2	0.47	6.47	0.34	3.63e-10	Survival in pancreatic cancer;
CRC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.47	6.16	0.32	2.08e-9	Obesity-related traits;
CRC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.7	-8.21	-0.41	4.94e-15	Hemostatic factors and hematological phenotypes;
CRC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg18827107	chr12:86230957	RASSF9	0.44	6.99	0.36	1.55e-11	Major depressive disorder;
CRC	cis	rs427941	0.632	rs201508	chr7:101764199	T/G	cg06246474	chr7:101738831	CUX1	0.44	6.81	0.35	4.75e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs12618769	0.652	rs3754878	chr2:99179384	G/A	cg18455616	chr2:99124870	INPP4A	0.36	5.87	0.31	1.07e-8	Bipolar disorder;
CRC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.76	-15.38	-0.65	1.34e-40	Prostate cancer;
CRC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.49	7.19	0.37	4.44e-12	Response to antineoplastic agents;
CRC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.46	7.04	0.36	1.1e-11	Dupuytren's disease;
CRC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.69	11.86	0.55	3.01e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.6e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.83	-7.51	-0.38	5.71e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-10.0	-0.48	9.83e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.9	-0.31	8.99e-9	Life satisfaction;
CRC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg02766259	chr12:125626809	AACS	-0.39	-7.52	-0.38	5.28e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.6	9.23	0.45	3.28e-18	Aortic root size;
CRC	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.46	-7.95	-0.4	2.99e-14	Information processing speed;
CRC	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg02927042	chr1:21476669	EIF4G3	-0.38	-6.09	-0.32	3.21e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg14191688	chr11:70257035	CTTN	0.56	7.75	0.39	1.14e-13	Coronary artery disease;
CRC	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.69	10.08	0.49	5.14e-21	Inflammatory bowel disease;
CRC	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.52	-0.34	2.64e-10	Gallbladder cancer;
CRC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.36	0.38	1.49e-12	Motion sickness;
CRC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.26e-8	Heart rate;
CRC	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-6.91	-0.36	2.45e-11	Eye color traits;
CRC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.86	14.88	0.63	1.18e-38	Coronary artery disease;
CRC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06656553	chr16:89960601	TCF25	-0.68	-5.67	-0.3	3.16e-8	Skin colour saturation;
CRC	cis	rs4664293	0.625	rs10460300	chr2:160634721	C/T	cg08347373	chr2:160653686	CD302	0.43	7.42	0.38	1.03e-12	Monocyte percentage of white cells;
CRC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.67	-0.35	1.06e-10	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.69	-0.68	9.55e-46	Height;
CRC	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg16540259	chr10:75572220	NDST2	0.39	6.18	0.32	1.89e-9	Inflammatory bowel disease;
CRC	cis	rs7739232	0.920	rs74734238	chr6:53528444	T/A	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg21251018	chr6:28226885	NKAPL	-0.41	-6.39	-0.33	5.78e-10	Systemic lupus erythematosus;
CRC	cis	rs6728302	0.557	rs7600132	chr2:233248198	C/A	cg14418609	chr2:233286870	NA	-0.69	-5.86	-0.31	1.15e-8	Height;
CRC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg02527881	chr3:46936655	PTH1R	0.33	5.79	0.3	1.63e-8	Colorectal cancer;
CRC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.36	-0.53	1.9e-25	Alzheimer's disease;
CRC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.51	-7.67	-0.39	1.92e-13	Height;
CRC	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg00383909	chr3:49044727	WDR6	0.59	6.45	0.33	4.04e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg10263370	chr3:44754102	ZNF502	-0.36	-5.98	-0.31	5.66e-9	Depressive symptoms;
CRC	cis	rs7953508	0.619	rs11107114	chr12:93972927	G/A	cg18151635	chr12:93972918	NA	-0.79	-11.58	-0.54	3.01e-26	Pubertal anthropometrics;
CRC	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-14.33	-0.62	1.62e-36	Exhaled nitric oxide output;
CRC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg10589385	chr1:150898437	SETDB1	0.27	5.92	0.31	7.89e-9	Melanoma;
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.43	18.95	0.72	1.14e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.48	-10.51	-0.5	1.82e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7113874	0.543	rs7935708	chr11:8478545	C/A	cg02811074	chr11:8615871	STK33	-0.35	-6.05	-0.32	3.92e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7760949	0.963	rs7453814	chr6:13918291	C/G	cg27413430	chr6:13925136	RNF182	0.32	5.66	0.3	3.22e-8	Mean corpuscular hemoglobin concentration;
CRC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-1.13	-18.72	-0.72	9.26e-54	Blood pressure (smoking interaction);
CRC	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.52	7.53	0.38	4.99e-13	Corneal astigmatism;
CRC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.54	7.41	0.38	1.05e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg19486271	chr11:47235900	DDB2	-0.49	-7.57	-0.39	3.87e-13	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg25767906	chr1:53392781	SCP2	-0.43	-7.06	-0.36	9.82e-12	Monocyte count;
CRC	cis	rs863345	0.604	rs6689657	chr1:158462509	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.14e-9	Pneumococcal bacteremia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25312474	chr6:142468512	VTA1	0.48	7.6	0.39	3.17e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.79	-0.35	5.38e-11	Educational attainment (years of education);
CRC	cis	rs62408225	1.000	rs17513415	chr6:90947867	C/T	cg06866423	chr6:90926672	BACH2	0.49	7.94	0.4	3.12e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.37	-0.33	6.42e-10	Menopause (age at onset);
CRC	cis	rs4481887	0.573	rs6689894	chr1:248409579	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.94	0.36	2.15e-11	Common traits (Other);
CRC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	10.09	0.49	4.85e-21	Platelet count;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg18726036	chr6:35543610	FKBP5	0.35	6.02	0.31	4.56e-9	Aortic root size;
CRC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.72	8.49	0.42	6.95e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9341808	0.690	rs2505932	chr6:80839252	G/T	cg08355045	chr6:80787529	NA	0.34	5.81	0.31	1.47e-8	Sitting height ratio;
CRC	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg09654669	chr8:57350985	NA	0.38	5.61	0.3	4.27e-8	Obesity-related traits;
CRC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg25456477	chr12:86230367	RASSF9	0.34	5.99	0.31	5.54e-9	Major depressive disorder;
CRC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.91	12.25	0.56	1.14e-28	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg00738113	chr16:70207722	CLEC18C	-0.39	-6.17	-0.32	2.05e-9	IgE levels;
CRC	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	0.57	8.89	0.44	4.08e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.56	8.17	0.41	6.53e-15	Uric acid levels;
CRC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.53	-9.48	-0.46	5.19e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.72	-12.95	-0.58	2.86e-31	Educational attainment;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg19223190	chr17:80058835	NA	-0.41	-6.56	-0.34	2.05e-10	Life satisfaction;
CRC	cis	rs990171	1.000	rs11677107	chr2:103057087	C/A	cg03938978	chr2:103052716	IL18RAP	0.45	5.74	0.3	2.18e-8	Lymphocyte counts;
CRC	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-11.18	-0.52	8.3e-25	Colorectal cancer;
CRC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg24130564	chr14:104152367	KLC1	-0.45	-6.9	-0.36	2.76e-11	Body mass index;
CRC	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.82	14.7	0.63	5.77e-38	Metabolic syndrome;
CRC	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg25856811	chr1:152973957	SPRR3	-0.25	-6.78	-0.35	5.6e-11	Inflammatory skin disease;
CRC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.84	11.46	0.53	8.31e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg02725872	chr8:58115012	NA	-0.35	-5.99	-0.31	5.5e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg05373962	chr22:49881684	NA	-0.4	-7.55	-0.38	4.42e-13	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.53	0.34	2.53e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg12458913	chr13:53173898	NA	0.76	13.77	0.6	2.16e-34	Lewy body disease;
CRC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.57	6.79	0.35	5.15e-11	Neutrophil percentage of white cells;
CRC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.29	-6.77	-0.35	6.02e-11	Urate levels in overweight individuals;
CRC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.41	6.39	0.33	5.63e-10	Red blood cell count;
CRC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.8	-0.3	1.54e-8	Migraine;Coronary artery disease;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.34	-6.31	-0.33	8.84e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.33	-0.42	2.15e-15	Hip circumference adjusted for BMI;
CRC	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg22654517	chr2:96458247	NA	0.31	5.67	0.3	3.16e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg22676075	chr6:135203613	NA	0.41	6.38	0.33	6.03e-10	Red blood cell count;
CRC	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.71	0.35	8.52e-11	Lymphocyte counts;
CRC	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-6.27	-0.33	1.12e-9	Axial length;
CRC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07157834	chr1:205819609	PM20D1	0.42	5.77	0.3	1.87e-8	Parkinson's disease;
CRC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg09165964	chr15:75287851	SCAMP5	0.57	9.02	0.45	1.6e-17	Breast cancer;
CRC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.84	15.13	0.64	1.3e-39	Lewy body disease;
CRC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.23	0.71	8.43e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.41	-5.85	-0.31	1.18e-8	Platelet distribution width;
CRC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.01	12.35	0.56	4.95e-29	Vitiligo;
CRC	cis	rs4478858	0.746	rs6703593	chr1:31689284	A/C	cg00250761	chr1:31883323	NA	0.32	5.96	0.31	6.38e-9	Alcohol dependence;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21942256	chr3:156892528	NA	0.42	6.04	0.32	4.19e-9	Myopia (pathological);
CRC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg16342193	chr10:102329863	NA	-0.39	-6.23	-0.32	1.43e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3736485	0.844	rs8039073	chr15:51759906	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.5	-0.34	2.95e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19826439	chr1:226297528	NA	0.46	7.55	0.38	4.3e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2999083	0.524	rs9827325	chr3:127736174	T/C	cg13719885	chr3:127795394	NA	-0.38	-5.8	-0.3	1.59e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs1050631	0.564	rs1789549	chr18:33722425	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.37	5.68	0.3	2.96e-8	Esophageal squamous cell cancer (length of survival);
CRC	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.47	6.58	0.34	1.87e-10	Height;
CRC	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg13491945	chr12:107078410	RFX4	0.36	6.16	0.32	2.13e-9	Heart rate;
CRC	cis	rs3750082	0.692	rs34737146	chr7:32935926	G/A	cg05721444	chr7:32995514	FKBP9	0.51	6.53	0.34	2.49e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7487075	0.637	rs4438106	chr12:46715528	G/T	cg22049899	chr12:47219821	SLC38A4	0.34	6.54	0.34	2.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.2	0.41	5.63e-15	Menopause (age at onset);
CRC	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.95	-0.36	1.93e-11	Multiple sclerosis;
CRC	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg02927042	chr1:21476669	EIF4G3	-0.47	-7.58	-0.39	3.67e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg12172441	chr6:28176163	NA	0.55	7.48	0.38	6.69e-13	Parkinson's disease;
CRC	cis	rs4547160	0.781	rs10877951	chr12:63485882	T/C	cg26727693	chr12:63544175	AVPR1A	-0.42	-7.68	-0.39	1.82e-13	Morning vs. evening chronotype;
CRC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.48	7.24	0.37	3.19e-12	Motion sickness;
CRC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03923535	chr7:1197113	ZFAND2A	0.56	7.94	0.4	3.25e-14	Longevity;Endometriosis;
CRC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Depression;
CRC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.49	-7.34	-0.38	1.67e-12	Height;
CRC	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	1.25	14.29	0.62	2.3e-36	Lung disease severity in cystic fibrosis;
CRC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-7.01	-0.36	1.34e-11	Alzheimer's disease (late onset);
CRC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.51	6.7	0.35	8.79e-11	Obesity-related traits;
CRC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.47	-9.01	-0.44	1.71e-17	Iron status biomarkers;
CRC	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.47	6.63	0.34	1.42e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7619833	0.564	rs6551182	chr3:27252491	T/A	cg02860705	chr3:27208620	NA	0.37	5.82	0.31	1.42e-8	Breast cancer;
CRC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.59	9.12	0.45	7.47e-18	Type 2 diabetes;
CRC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	10.74	0.51	2.78e-23	Motion sickness;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-6.36	-0.33	6.91e-10	Breast cancer;
CRC	cis	rs6662572	0.542	rs72677553	chr1:46592278	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.4	0.33	5.26e-10	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04747728	chr16:31725053	ZNF720	0.43	6.89	0.36	2.81e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-7.0	-0.36	1.47e-11	Type 2 diabetes;
CRC	trans	rs16934284	0.706	rs11790102	chr9:119846424	T/C	cg16808373	chr11:122850140	BSX	-0.4	-5.99	-0.31	5.51e-9	Obesity-related traits;
CRC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg05709478	chr1:6581295	PLEKHG5	0.64	6.39	0.33	5.52e-10	Body mass index;
CRC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.39	0.42	1.45e-15	Rheumatoid arthritis;
CRC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.46	-6.14	-0.32	2.41e-9	Schizophrenia;
CRC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.42	0.33	4.7e-10	Lung cancer;
CRC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.52	-8.84	-0.44	6.02e-17	Aortic root size;
CRC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.88	0.35	3.1e-11	Morning vs. evening chronotype;
CRC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-8.98	-0.44	2.1e-17	Bipolar disorder;
CRC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg12855166	chr17:30846586	MYO1D	-0.38	-6.25	-0.33	1.24e-9	Schizophrenia;
CRC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.23	0.45	3.31e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg20203395	chr5:56204925	C5orf35	-0.57	-7.69	-0.39	1.77e-13	Initial pursuit acceleration;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg26741380	chr15:41871084	TYRO3	0.4	5.98	0.31	5.98e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.79	12.53	0.57	1e-29	Height;
CRC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg24562669	chr7:97807699	LMTK2	0.79	17.64	0.7	1.72e-49	Breast cancer;
CRC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.59	10.1	0.49	4.39e-21	Prudent dietary pattern;
CRC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.43	-9.45	-0.46	6.71e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.49	7.21	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23161317	chr6:28129485	ZNF389	-0.48	-5.94	-0.31	7.25e-9	Depression;
CRC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.47	6.15	0.32	2.25e-9	IgG glycosylation;
CRC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.47	7.78	0.39	9.69e-14	Type 2 diabetes;
CRC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.41	6.5	0.34	3.06e-10	Blood protein levels;
CRC	cis	rs6921919	0.848	rs56131013	chr6:28320677	G/A	cg21251018	chr6:28226885	NKAPL	0.39	5.66	0.3	3.31e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg15845792	chr6:28175446	NA	0.97	13.08	0.58	8.89e-32	Depression;
CRC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-7.98	-0.4	2.5e-14	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.44	-6.38	-0.33	6.03e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.53	7.44	0.38	8.87e-13	Pulmonary function decline;
CRC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.42	-8.07	-0.41	1.3e-14	Ulcerative colitis;
CRC	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.61	-0.47	2.01e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.22	28.25	0.84	5.77e-90	Schizophrenia;
CRC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.43	-8.05	-0.41	1.56e-14	Colorectal cancer;
CRC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg06740227	chr12:86229804	RASSF9	-0.38	-5.78	-0.3	1.74e-8	Major depressive disorder;
CRC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	15.38	0.65	1.39e-40	Platelet count;
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.4	-7.28	-0.37	2.48e-12	Lung cancer;
CRC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.9	-16.49	-0.67	5.75e-45	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg06470822	chr6:28175283	NA	0.78	9.62	0.47	1.86e-19	Parkinson's disease;
CRC	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg09659197	chr4:152720779	NA	0.3	5.68	0.3	2.93e-8	Intelligence (multi-trait analysis);
CRC	trans	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg20935933	chr6:143382018	AIG1	0.52	6.72	0.35	7.8e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg02549819	chr16:58548995	SETD6	1.16	7.58	0.39	3.52e-13	Schizophrenia;
CRC	cis	rs375066	0.623	rs7254659	chr19:44350689	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.52	-8.6	-0.43	3.41e-16	Menarche (age at onset);
CRC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg11157611	chr1:21499906	EIF4G3	0.32	5.61	0.3	4.21e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.91	-0.44	3.55e-17	Electroencephalogram traits;
CRC	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg11576217	chr1:204381098	PPP1R15B	0.55	7.14	0.37	5.9e-12	Thyroid stimulating hormone;
CRC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	1.16	14.05	0.61	1.92e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg03160526	chr17:80928410	B3GNTL1	0.47	6.9	0.36	2.62e-11	Breast cancer;
CRC	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.71	12.88	0.58	5e-31	Hip circumference;
CRC	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.99	21.34	0.76	4.66e-64	Metabolite levels;
CRC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.84	-10.1	-0.49	4.55e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.69	-11.19	-0.53	7.63e-25	Breast cancer;
CRC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	8.41	0.42	1.27e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09403165	chr15:90118814	C15orf42	0.45	6.75	0.35	6.5e-11	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19105961	chr17:4046223	CYB5D2;ZZEF1	0.45	7.43	0.38	9.71e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.67	0.54	1.42e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4494114	0.967	rs9438977	chr1:39354958	A/G	cg25970120	chr1:39325951	RRAGC	-0.45	-6.34	-0.33	7.75e-10	Blood protein levels;
CRC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.48	7.42	0.38	1e-12	Red blood cell count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26500707	chr16:50100227	HEATR3	0.45	6.37	0.33	6.52e-10	Anxiety disorder;
CRC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.64	-10.12	-0.49	3.78e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06877462	chr1:205807181	PM20D1	0.38	5.9	0.31	8.85e-9	Menarche (age at onset);
CRC	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.51	9.47	0.46	5.52e-19	Bone mineral density;
CRC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.84	0.35	3.89e-11	Rheumatoid arthritis;
CRC	cis	rs282587	0.569	rs282595	chr13:113379930	A/G	cg04656015	chr13:113407548	ATP11A	-0.64	-7.92	-0.4	3.67e-14	Glycated hemoglobin levels;
CRC	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.61	-8.97	-0.44	2.31e-17	Idiopathic osteonecrosis of the femoral head;
CRC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.47	-7.45	-0.38	8.39e-13	Coronary artery disease;
CRC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.44	-6.9	-0.36	2.66e-11	Monocyte count;
CRC	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.47	6.92	0.36	2.31e-11	Glioblastoma;Glioma;
CRC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.42	-0.33	4.89e-10	Lymphocyte counts;
CRC	cis	rs4073416	0.542	rs7143318	chr14:65940689	G/A	cg03016385	chr14:66212404	NA	-0.42	-5.83	-0.31	1.31e-8	N-glycan levels;
CRC	cis	rs12922317	0.556	rs11648938	chr16:12094149	C/T	cg02368508	chr16:12060182	TNFRSF17	0.46	7.75	0.39	1.14e-13	Schizophrenia;
CRC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg21153622	chr11:89784906	NA	0.41	6.33	0.33	8.25e-10	Height;
CRC	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	9.06	0.45	1.23e-17	Mean corpuscular volume;
CRC	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.48	-6.77	-0.35	5.97e-11	Rheumatoid arthritis;
CRC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.43	0.42	1.13e-15	Schizophrenia;
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.6	9.35	0.46	1.36e-18	Lewy body disease;
CRC	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.31	5.61	0.3	4.2e-8	Heart rate;
CRC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.57	8.86	0.44	5.26e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01172785	chr16:50092553	NA	-0.39	-6.45	-0.34	4.02e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg23425280	chr12:56401806	NA	0.48	5.93	0.31	7.76e-9	Cancer;
CRC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.53	-0.38	4.79e-13	Alzheimer's disease;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg02400139	chr5:145890299	TCERG1	-0.39	-6.19	-0.32	1.83e-9	HDL cholesterol;
CRC	cis	rs9311676	0.656	rs7642652	chr3:58373667	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg01808030	chr22:45809952	RIBC2;SMC1B	0.49	5.81	0.31	1.48e-8	Tonsillectomy;
CRC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.84	-0.35	3.88e-11	IgG glycosylation;
CRC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.58	-7.52	-0.38	5.39e-13	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08235883	chr12:122238836	LOC338799	0.47	6.48	0.34	3.34e-10	Response to antipsychotic treatment;
CRC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	5.99	0.31	5.4e-9	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.66	9.3	0.46	1.96e-18	Multiple sclerosis;
CRC	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.26	11.54	0.54	4.31e-26	Prostate cancer;
CRC	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.57	-6.44	-0.33	4.19e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.43	8.72	0.43	1.36e-16	Renal cell carcinoma;
CRC	cis	rs990171	0.955	rs4851008	chr2:103026611	G/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.82	0.31	1.4e-8	Lymphocyte counts;
CRC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.6	-0.34	1.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg15571903	chr15:79123663	NA	-0.32	-5.97	-0.31	6.08e-9	Coronary artery disease;
CRC	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.68	8.61	0.43	3.1e-16	Gastritis;
CRC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.67	-10.1	-0.49	4.64e-21	Other erythrocyte phenotypes;
CRC	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg22482690	chr17:47019901	SNF8	-0.42	-6.81	-0.35	4.65e-11	Type 2 diabetes;
CRC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.47	8.36	0.42	1.75e-15	Schizophrenia;
CRC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.5	0.46	4.59e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.24	-0.33	1.32e-9	Joint mobility (Beighton score);
CRC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-6.14	-0.32	2.43e-9	Alzheimer's disease (late onset);
CRC	trans	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg19894588	chr14:64061835	NA	0.41	5.99	0.31	5.52e-9	Glioblastoma;Glioma;
CRC	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg22482690	chr17:47019901	SNF8	0.49	8.2	0.41	5.33e-15	Type 2 diabetes;
CRC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	0.58	6.07	0.32	3.49e-9	IgG glycosylation;
CRC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.45	8.09	0.41	1.16e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.52	-6.96	-0.36	1.89e-11	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25448636	chr17:17140084	FLCN	0.48	7.07	0.36	9.12e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2336384	1.000	rs4846083	chr1:12045555	G/T	cg13216073	chr1:12042593	MFN2	0.51	7.44	0.38	8.71e-13	Platelet count;
CRC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-10.34	-0.5	6.98e-22	Colorectal cancer;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18402987	chr7:1209562	NA	0.44	6.3	0.33	9.7e-10	Longevity;Endometriosis;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	7.67	0.39	1.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.24	-0.37	3.28e-12	Bipolar disorder;
CRC	trans	rs6544773	0.550	rs2673272	chr2:45050208	C/G	cg10208897	chr5:178548229	ADAMTS2	0.35	6.12	0.32	2.63e-9	Mosquito bite size;
CRC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg00990874	chr7:1149470	C7orf50	-0.5	-5.84	-0.31	1.24e-8	Bronchopulmonary dysplasia;
CRC	cis	rs2075184	1	rs2075184	chr2:103080592	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Pediatric autoimmune diseases;
CRC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg00769240	chr8:12517080	NA	-0.56	-6.12	-0.32	2.63e-9	Blood pressure (smoking interaction);
CRC	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg21106136	chr3:194405973	FAM43A	-0.44	-6.47	-0.34	3.65e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg22561889	chr6:118971681	C6orf204	0.51	6.26	0.33	1.23e-9	Diastolic blood pressure;
CRC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.7	12.47	0.57	1.65e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg16358738	chr2:241808595	AGXT	-0.4	-6.92	-0.36	2.32e-11	Urinary metabolites;
CRC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.51	7.7	0.39	1.61e-13	Resting heart rate;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg19913688	chr11:428466	ANO9	-0.72	-7.58	-0.39	3.58e-13	Body mass index;
CRC	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.71	-0.35	8.33e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.72	10.56	0.5	1.22e-22	Immature fraction of reticulocytes;
CRC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg03233332	chr7:66118400	NA	0.45	6.36	0.33	6.69e-10	Aortic root size;
CRC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg12193833	chr17:30244370	NA	0.6	6.74	0.35	7.01e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9992667	0.955	rs922334	chr4:38616758	C/T	cg19726192	chr4:38663646	FLJ13197	-0.52	-6.7	-0.35	9.05e-11	Eosinophil percentage of granulocytes;
CRC	cis	rs4664293	0.967	rs10202187	chr2:160427646	C/T	cg08347373	chr2:160653686	CD302	-0.46	-7.43	-0.38	9.56e-13	Monocyte percentage of white cells;
CRC	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	10.09	0.49	5.04e-21	Fuchs's corneal dystrophy;
CRC	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.83	-0.31	1.33e-8	Endometrial cancer;
CRC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.64	-11.46	-0.53	8.1e-26	Schizophrenia;
CRC	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg13491945	chr12:107078410	RFX4	0.35	5.94	0.31	7.32e-9	Heart rate;
CRC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg02683197	chr6:28174875	NA	0.83	10.17	0.49	2.7e-21	Depression;
CRC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg11292332	chr7:45801988	SEPT13	-0.35	-6.27	-0.33	1.14e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.49	-6.93	-0.36	2.18e-11	Coronary artery disease;
CRC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg15848620	chr12:58087721	OS9	-0.53	-7.53	-0.38	4.86e-13	Rheumatoid arthritis;
CRC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg13010199	chr12:38710504	ALG10B	-0.43	-5.97	-0.31	6.2e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23422044	chr7:1970798	MAD1L1	0.5	6.41	0.33	4.94e-10	Bipolar disorder;
CRC	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.58	7.91	0.4	3.89e-14	Adiposity;
CRC	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg23684204	chr15:91497937	RCCD1	0.47	7.2	0.37	4.04e-12	Attention deficit hyperactivity disorder;
CRC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.57	-9.57	-0.47	2.65e-19	Calcium levels;
CRC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.24	-0.33	1.34e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.33	0.46	1.61e-18	Heart rate;
CRC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-10.29	-0.49	1.06e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.5	-0.34	2.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg27205649	chr11:78285834	NARS2	0.48	6.07	0.32	3.56e-9	Alzheimer's disease (survival time);
CRC	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	9.19e-20	Hair morphology;
CRC	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.34	5.79	0.3	1.67e-8	Major depressive disorder;
CRC	trans	rs12744310	0.887	rs17362424	chr1:41794403	A/C	cg19175123	chr10:103411746	FBXW4	-0.45	-6.08	-0.32	3.24e-9	Cognitive ability (multi-trait analysis);Intelligence;Cognitive ability;
CRC	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg04586622	chr2:25135609	ADCY3	-0.44	-7.84	-0.4	6.53e-14	Body mass index in non-asthmatics;
CRC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.43	8.56	0.43	4.25e-16	Vitiligo;
CRC	trans	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.43	-0.38	9.71e-13	Endometrial cancer;
CRC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg13844804	chr7:814759	HEATR2	0.71	8.24	0.41	4.04e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.66	11.76	0.54	6.73e-27	Height;
CRC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.16	14.97	0.64	5.46e-39	Uric acid levels;
CRC	trans	rs2303319	0.504	rs62189043	chr2:162608466	A/T	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.36	-6.91	-0.36	2.46e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2302729	0.578	rs11062299	chr12:2771738	T/C	cg19945202	chr12:2788847	CACNA1C	-0.43	-6.93	-0.36	2.28e-11	Sleep quality;
CRC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.93	-11.91	-0.55	1.88e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.52	0.34	2.64e-10	Diastolic blood pressure;
CRC	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.61	8.95	0.44	2.69e-17	Corneal astigmatism;
CRC	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg21836586	chr14:55907198	TBPL2	0.3	5.6	0.3	4.51e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs10097731	0.901	rs10464891	chr8:82042900	C/A	cg25230327	chr8:82042993	NA	-0.93	-13.69	-0.6	4.32e-34	Serum total protein level;
CRC	cis	rs9491140	1.000	rs9491142	chr6:124693017	G/A	cg22366943	chr6:124882293	NKAIN2	0.36	5.94	0.31	7.32e-9	Neuroticism;
CRC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg03037974	chr15:76606532	NA	0.66	11.44	0.53	9.38e-26	Blood metabolite levels;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs7072216	0.555	rs2296432	chr10:100184063	C/G	cg26618903	chr10:100175079	PYROXD2	-0.49	-7.34	-0.38	1.67e-12	Metabolite levels;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08802409	chr3:50649298	CISH	0.4	5.93	0.31	7.69e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg03030879	chr14:75389066	RPS6KL1	0.5	7.87	0.4	5.18e-14	Caffeine consumption;
CRC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.29	-0.42	2.88e-15	Type 2 diabetes;
CRC	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg11886554	chr3:170076028	SKIL	0.59	6.74	0.35	7.26e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg16964102	chr10:135390573	NA	-0.41	-6.76	-0.35	6.44e-11	Obesity-related traits;
CRC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.36	0.56	4.51e-29	Menopause (age at onset);
CRC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg16606324	chr3:10149918	C3orf24	0.62	8.05	0.41	1.58e-14	Alzheimer's disease;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11504634	chr17:40714731	COASY	0.42	6.04	0.32	4.17e-9	Response to antipsychotic treatment;
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.46	6.53	0.34	2.46e-10	Lymphocyte counts;
CRC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-6.94	-0.36	2.15e-11	IgG glycosylation;
CRC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.23	-0.32	1.41e-9	Blood metabolite levels;
CRC	cis	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg26132723	chr8:70041827	NA	0.35	5.72	0.3	2.41e-8	Dupuytren's disease;
CRC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.71	-0.35	8.37e-11	Menopause (age at onset);
CRC	cis	rs7665939	1.000	rs72727637	chr4:190106678	G/T	cg09826759	chr4:190284978	NA	-0.74	-6.17	-0.32	2.01e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.72	9.3	0.46	2.06e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs6534441	0.727	rs55697817	chr4:125451962	G/A	cg21609808	chr4:125404261	NA	0.44	6.28	0.33	1.08e-9	Major depressive disorder;
CRC	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.45	-0.38	8.41e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs12744221	1	rs12744221	chr1:145645606	C/T	cg11743829	chr1:145714124	CD160	-0.4	-6.09	-0.32	3.23e-9	Epilepsy (remission after treatment);
CRC	cis	rs720844	1.000	rs4972285	chr2:149340684	C/T	cg09247360	chr2:149335327	NA	0.54	7.05	0.36	1.09e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg19683494	chr5:74908142	NA	0.42	5.77	0.3	1.82e-8	Age-related disease endophenotypes;
CRC	cis	rs9828933	0.752	rs12633353	chr3:63970280	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.71	-5.98	-0.31	5.86e-9	Type 2 diabetes;
CRC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg17724175	chr1:150552817	MCL1	0.41	6.3	0.33	9.8e-10	Melanoma;
CRC	cis	rs7301826	0.627	rs1077317	chr12:131314977	C/T	cg11011512	chr12:131303247	STX2	0.39	5.85	0.31	1.18e-8	Plasma plasminogen activator levels;
CRC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg21153622	chr11:89784906	NA	-0.53	-8.81	-0.44	7.35e-17	HDL cholesterol;
CRC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.54	7.76	0.39	1.11e-13	Lung cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27457169	chr17:38804285	SMARCE1	0.44	6.25	0.33	1.26e-9	Anxiety disorder;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg06470822	chr6:28175283	NA	0.66	10.08	0.49	5.48e-21	Cardiac Troponin-T levels;
CRC	trans	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg18335740	chr13:41363409	SLC25A15	-0.5	-7.27	-0.37	2.69e-12	Lewy body disease;
CRC	trans	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg10756647	chr7:56101905	PSPH	0.76	7.85	0.4	5.78e-14	Diabetic kidney disease;
CRC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.8	-0.39	8.34e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.52	6.77	0.35	5.93e-11	Cleft lip with or without cleft palate;
CRC	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg03938978	chr2:103052716	IL18RAP	0.42	6.71	0.35	8.38e-11	Blood protein levels;
CRC	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.11	-0.36	7.43e-12	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.44	6.4	0.33	5.29e-10	Menopause (age at onset);
CRC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.19	-13.16	-0.59	4.5e-32	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06400595	chr12:56551642	MYL6B;MYL6	0.5	7.8	0.4	8.48e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06307176	chr5:131281290	NA	0.44	6.46	0.34	3.7e-10	Life satisfaction;
CRC	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.14e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.72	-10.38	-0.5	5.21e-22	Platelet distribution width;
CRC	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg03258749	chr1:151040405	MLLT11	-0.47	-7.23	-0.37	3.32e-12	Childhood ear infection;
CRC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg25876840	chr17:41920477	NA	0.51	7.64	0.39	2.33e-13	Triglycerides;
CRC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg24910161	chr17:38119198	GSDMA	-0.44	-7.82	-0.4	7.02e-14	Asthma;
CRC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg15193198	chr20:60906057	LAMA5	-0.41	-6.24	-0.33	1.33e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.32	7.05	0.36	1.08e-11	Total body bone mineral density;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.42	5.77	0.3	1.86e-8	Vitiligo;
CRC	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-5.72	-0.3	2.43e-8	High light scatter reticulocyte count;
CRC	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.34	0.65	1.93e-40	Bipolar disorder;
CRC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.67	-0.39	1.99e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.85	-0.4	6.06e-14	Intelligence (multi-trait analysis);
CRC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.59	-9.13	-0.45	7.28e-18	Height;
CRC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.42	-6.47	-0.34	3.54e-10	Alcohol dependence;
CRC	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg08632701	chr21:37451849	NA	-0.37	-5.78	-0.3	1.69e-8	Mitral valve prolapse;
CRC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.67	10.84	0.51	1.29e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.64	-10.48	-0.5	2.36e-22	Motion sickness;
CRC	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg21155852	chr7:2048760	MAD1L1	-0.46	-5.99	-0.31	5.35e-9	Neuroticism;
CRC	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg20129853	chr10:51489980	NA	-0.35	-5.7	-0.3	2.6e-8	Prostate-specific antigen levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11893236	chr16:68345102	PRMT7;SLC7A6OS	0.43	5.99	0.31	5.46e-9	Response to antipsychotic treatment;
CRC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25517755	chr10:38738941	LOC399744	-0.41	-6.09	-0.32	3.13e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.62	10.56	0.5	1.23e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg00490450	chr3:139108681	COPB2	-0.47	-7.08	-0.36	8.86e-12	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.55	0.47	3.06e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8040855	0.599	rs6496800	chr15:85728286	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.36	5.68	0.3	2.96e-8	Bulimia nervosa;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16501701	chr17:73852221	WBP2	0.43	6.05	0.32	3.89e-9	Response to antipsychotic treatment;
CRC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.53	-9.56	-0.47	2.92e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3789045	0.560	rs3747634	chr1:204411063	C/T	cg17419461	chr1:204415978	PIK3C2B	0.81	10.79	0.51	1.93e-23	Educational attainment (college completion);
CRC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.65	-0.3	3.43e-8	Reticulocyte count;
CRC	cis	rs2882667	0.654	rs825760	chr5:138139974	G/T	cg09476006	chr5:138032270	NA	-0.53	-8.86	-0.44	5.18e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.86	-11.11	-0.52	1.51e-24	Initial pursuit acceleration;
CRC	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.72	-9.7	-0.47	9.79e-20	Blood pressure (smoking interaction);
CRC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-8.55	-0.43	4.67e-16	Uric acid levels;
CRC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-9.22	-0.45	3.78e-18	Initial pursuit acceleration;
CRC	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg09659197	chr4:152720779	NA	0.31	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
CRC	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.07	0.49	5.96e-21	Corneal astigmatism;
CRC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.51	0.34	2.86e-10	Bipolar disorder;
CRC	cis	rs8044868	0.530	rs9932951	chr16:72075341	A/G	cg06172871	chr16:72088244	HP	0.44	6.26	0.33	1.2e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg13319975	chr6:146136371	FBXO30	0.43	6.33	0.33	8.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg22676075	chr6:135203613	NA	0.42	6.49	0.34	3.24e-10	Red blood cell count;
CRC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.32	-0.37	1.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg18230493	chr5:56204884	C5orf35	-0.39	-5.85	-0.31	1.22e-8	Coronary artery disease;
CRC	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg13615338	chr4:55094005	PDGFRA	0.39	5.66	0.3	3.29e-8	Corneal astigmatism;
CRC	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.42e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.74	-10.36	-0.5	6.15e-22	Systemic lupus erythematosus;
CRC	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg14664628	chr15:75095509	CSK	0.44	6.19	0.32	1.83e-9	Systemic lupus erythematosus;
CRC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	14.09	0.61	1.29e-35	Platelet count;
CRC	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	6.37	0.33	6.21e-10	Axial length;
CRC	cis	rs995000	0.931	rs11207979	chr1:62982994	G/A	cg19896129	chr1:63156450	NA	0.42	6.39	0.33	5.8e-10	Triglyceride levels;
CRC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg19622623	chr12:86230825	RASSF9	-0.39	-6.33	-0.33	7.89e-10	Major depressive disorder;
CRC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg25985355	chr7:65971099	NA	-0.51	-5.79	-0.3	1.64e-8	Diabetic kidney disease;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg25164649	chr6:28176230	NA	0.58	8.19	0.41	5.97e-15	Parkinson's disease;
CRC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.53	5.69	0.3	2.88e-8	White matter hyperintensity burden;
CRC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.11	-0.37	7.06e-12	Mean corpuscular volume;
CRC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-9.61	-0.47	1.92e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-7.57	-0.39	3.81e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg21064579	chr19:49206444	FUT2	0.51	9.11	0.45	8.09e-18	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
CRC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.58	-6.87	-0.35	3.19e-11	Bronchopulmonary dysplasia;
CRC	cis	rs77861329	0.748	rs352152	chr3:52210700	A/C	cg08692210	chr3:52188851	WDR51A	-0.5	-5.89	-0.31	9.65e-9	Macrophage inflammatory protein 1b levels;
CRC	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.52	8.0	0.4	2.15e-14	Corneal astigmatism;
CRC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	8.5	0.42	6.69e-16	Lymphocyte counts;
CRC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.83	11.29	0.53	3.31e-25	Migraine;Coronary artery disease;
CRC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-7.04	-0.36	1.13e-11	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.66	10.91	0.52	7.54e-24	Height;
CRC	cis	rs6545883	0.560	rs11677775	chr2:61503110	T/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.78	-0.39	9.61e-14	Tuberculosis;
CRC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.69	0.35	9.57e-11	Body mass index;
CRC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09065629	chr16:1709722	CRAMP1L	0.36	5.62	0.3	4.09e-8	Coronary artery disease;
CRC	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.12	-0.41	9.48e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg27101125	chr19:17392770	ANKLE1	-0.32	-5.78	-0.3	1.74e-8	Systemic lupus erythematosus;
CRC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.71	0.43	1.54e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17507749	chr15:85114479	UBE2QP1	0.41	6.13	0.32	2.57e-9	P wave terminal force;
CRC	cis	rs4547160	0.821	rs949824	chr12:63482910	C/T	cg26727693	chr12:63544175	AVPR1A	-0.41	-7.45	-0.38	8.23e-13	Morning vs. evening chronotype;
CRC	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.09	-0.64	1.81e-39	Exhaled nitric oxide output;
CRC	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.39	5.98	0.31	5.7e-9	Red blood cell count;
CRC	cis	rs600626	0.588	rs72997616	chr11:75474195	C/A	cg24262691	chr11:75473276	NA	0.54	7.47	0.38	7.26e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.5	7.62	0.39	2.67e-13	Inflammatory bowel disease;
CRC	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.81	9.93	0.48	1.65e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs6692729	0.966	rs8383	chr1:227083550	C/T	cg18027831	chr1:227083489	PSEN2	0.36	5.92	0.31	8.02e-9	Electrodermal activity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04297258	chr16:88772664	RNF166;CTU2	0.5	6.58	0.34	1.87e-10	Thyroid stimulating hormone;
CRC	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.72	0.39	1.44e-13	Motion sickness;
CRC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.41	6.61	0.34	1.55e-10	Platelet count;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg25164649	chr6:28176230	NA	0.69	10.25	0.49	1.39e-21	Cardiac Troponin-T levels;
CRC	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.49	7.45	0.38	8.28e-13	Testicular germ cell tumor;
CRC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg15786705	chr6:28176104	NA	0.71	9.2	0.45	4.11e-18	Parkinson's disease;
CRC	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-6.04	-0.32	4.23e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg10398005	chr11:117014888	PAFAH1B2	-0.39	-5.84	-0.31	1.25e-8	Blood protein levels;
CRC	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21659725	chr3:3221576	CRBN	0.61	6.88	0.35	2.99e-11	Menarche (age at onset);
CRC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.58	9.88	0.48	2.56e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.42	0.42	1.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.62	0.43	2.93e-16	Coffee consumption (cups per day);
CRC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.68	11.7	0.54	1.08e-26	Longevity;
CRC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.06	-0.32	3.66e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.0	-0.44	1.8e-17	Bipolar disorder;
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-9.02	-0.45	1.55e-17	Bipolar disorder;
CRC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24308560	chr3:49941425	MST1R	-0.5	-7.93	-0.4	3.38e-14	Intelligence (multi-trait analysis);
CRC	trans	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg11693508	chr17:37793320	STARD3	0.54	7.7	0.39	1.64e-13	Bipolar disorder;
CRC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.68e-10	HDL cholesterol;
CRC	cis	rs17601876	0.814	rs8039089	chr15:51561328	T/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-7.05	-0.36	1.08e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg15664640	chr17:80829946	TBCD	-0.56	-6.29	-0.33	1.04e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.45	6.34	0.33	7.57e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg24011408	chr12:48396354	COL2A1	0.45	6.32	0.33	8.27e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.39	19.61	0.73	2.96e-57	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2179367	0.959	rs9373592	chr6:149733255	A/T	cg11245181	chr6:149772854	ZC3H12D	-0.42	-6.21	-0.32	1.58e-9	Dupuytren's disease;
CRC	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg15192750	chr16:69999425	NA	-0.61	-8.17	-0.41	6.58e-15	IgE levels;
CRC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.38	-0.33	5.95e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.44	-7.93	-0.4	3.41e-14	Reticulocyte fraction of red cells;
CRC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.07	10.72	0.51	3.41e-23	Diabetic retinopathy;
CRC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.77	-0.3	1.85e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg04880052	chr2:219191631	PNKD	0.41	6.73	0.35	7.55e-11	Colorectal cancer;
CRC	cis	rs6499129	0.558	rs13334205	chr16:67581883	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-7.82	-0.4	7.16e-14	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg05044414	chr3:183734942	ABCC5	0.47	8.12	0.41	9.66e-15	Anterior chamber depth;
CRC	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg19407955	chr1:165599744	MGST3	-0.44	-5.63	-0.3	3.9e-8	Total ventricular volume;
CRC	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.48	-9.1	-0.45	9.18e-18	Hepatitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10622236	chr15:42120082	JMJD7;JMJD7-PLA2G4B	0.47	6.88	0.35	3.02e-11	Intelligence (multi-trait analysis);
CRC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg09163369	chr1:210001066	C1orf107	0.4	5.75	0.3	2.08e-8	Orofacial clefts;
CRC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.53	8.05	0.41	1.48e-14	Height;
CRC	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	trans	rs6479874	0.831	rs2245627	chr10:52745666	G/A	cg15483030	chr1:5935144	NPHP4	-0.71	-6.34	-0.33	7.64e-10	Migraine;
CRC	cis	rs364477	0.904	rs420062	chr9:957950	C/A	cg13952963	chr9:998547	NA	0.55	5.89	0.31	9.79e-9	Major depressive disorder;
CRC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg27661571	chr11:113659931	NA	-0.61	-8.01	-0.4	2.05e-14	Hip circumference adjusted for BMI;
CRC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19904058	chr10:135279010	LOC619207	-0.39	-7.39	-0.38	1.23e-12	Systemic lupus erythematosus;
CRC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.01	0.44	1.77e-17	Bladder cancer;
CRC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.71	11.93	0.55	1.72e-27	Facial morphology (factor 23);
CRC	cis	rs16975963	0.644	rs11665759	chr19:38039675	C/G	cg15135657	chr19:38346511	NA	-0.46	-6.24	-0.33	1.32e-9	Longevity;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg15845792	chr6:28175446	NA	-0.9	-12.11	-0.56	3.63e-28	Parkinson's disease;
CRC	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.48	-9.1	-0.45	9.18e-18	Hepatitis;
CRC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.42	6.69	0.35	9.71e-11	High light scatter reticulocyte count;
CRC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.45	-7.61	-0.39	2.91e-13	Body mass index;
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.85	15.49	0.65	5.13e-41	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.39	-0.42	1.46e-15	Bone mineral density;
CRC	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.55	8.16	0.41	7.08e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg11204139	chr17:3907470	NA	0.72	13.36	0.59	7.88e-33	Type 2 diabetes;
CRC	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.26	11.59	0.54	2.84e-26	Prostate cancer;
CRC	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04498032	chr1:155242826	CLK2	0.46	6.51	0.34	2.77e-10	Response to antipsychotic treatment;
CRC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.59	0.5	9.54e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg17512779	chr8:17104072	CNOT7;VPS37A	0.45	6.01	0.31	4.99e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg00334542	chr7:100209784	MOSPD3	-0.68	-7.86	-0.4	5.4e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20448748	chr14:31091392	SCFD1	0.4	5.98	0.31	5.7e-9	Myopia (pathological);
CRC	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg04239558	chr2:103089729	SLC9A4	0.37	6.39	0.33	5.69e-10	Blood protein levels;
CRC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.69	0.35	9.81e-11	Diabetic retinopathy;
CRC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.46	6.4	0.33	5.23e-10	Lymphocyte counts;
CRC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg03037974	chr15:76606532	NA	0.68	11.55	0.54	4.06e-26	Blood metabolite levels;
CRC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16262614	chr3:133464971	TF	0.33	5.82	0.31	1.41e-8	Iron status biomarkers;
CRC	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.99	0.31	5.4e-9	Body mass index;
CRC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.46	8.03	0.4	1.72e-14	Systemic lupus erythematosus;
CRC	trans	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg26043149	chr18:55253948	FECH	-0.49	-7.61	-0.39	2.86e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg07713946	chr22:31675144	LIMK2	0.42	6.29	0.33	1.02e-9	Colorectal cancer;
CRC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.46	0.34	3.7e-10	Aortic root size;
CRC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.74	0.39	1.28e-13	Lung cancer in ever smokers;
CRC	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.51	-6.83	-0.35	4.07e-11	Metabolite levels;
CRC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.49	7.31	0.37	2.05e-12	Headache;
CRC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg16060761	chr17:80687452	NA	0.43	6.17	0.32	2.01e-9	Breast cancer;
CRC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-5.78	-0.3	1.72e-8	Neuroticism;
CRC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.58	-0.47	2.55e-19	Platelet count;
CRC	cis	rs6840360	0.573	rs11099806	chr4:152269116	G/T	cg09659197	chr4:152720779	NA	0.34	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.74	7.99	0.4	2.22e-14	Fat distribution (HIV);
CRC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-8.09	-0.41	1.13e-14	Bipolar disorder;
CRC	cis	rs1532331	0.966	rs6870418	chr5:43111526	C/T	cg09164108	chr5:43007320	NA	0.42	6.35	0.33	7.03e-10	Menarche (age at onset);
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.44	6.48	0.34	3.41e-10	Menarche (age at onset);
CRC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.9	-0.44	3.7e-17	Alcohol dependence;
CRC	cis	rs4716602	0.596	rs10267031	chr7:156159649	A/G	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.36	2.74e-11	Anti-saccade response;
CRC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg13072238	chr3:49761600	GMPPB	-0.48	-5.71	-0.3	2.46e-8	Menarche (age at onset);
CRC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.77	-0.39	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.49	-0.38	6.35e-13	Neuroticism;
CRC	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.75	-10.28	-0.49	1.09e-21	White matter hyperintensity burden;
CRC	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.57	10.3	0.49	9.35e-22	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21156815	chr8:22526736	BIN3	0.37	6.18	0.32	1.88e-9	Obesity-related traits;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg21251018	chr6:28226885	NKAPL	0.47	6.04	0.32	4.16e-9	Depression;
CRC	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.58	8.03	0.4	1.72e-14	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11967727	chr21:47743836	PCNT;C21orf58	0.43	6.37	0.33	6.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs117623576	0.941	rs7070675	chr10:32407269	G/T	cg03047570	chr10:32398778	NA	-0.74	-7.18	-0.37	4.8e-12	Anti-saccade response;
CRC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-9.41	-0.46	8.87e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.46	-7.45	-0.38	8.25e-13	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02473953	chr16:24550417	RBBP6	0.42	5.98	0.31	5.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.58	-8.22	-0.41	4.86e-15	Height;
CRC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.36	-5.86	-0.31	1.11e-8	Total body bone mineral density;
CRC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-6.01	-0.31	4.95e-9	Eosinophil percentage of white cells;
CRC	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg16724585	chr3:197361211	NA	-0.47	-6.98	-0.36	1.64e-11	Pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11816769	chr3:52001952	PCBP4	0.4	6.86	0.35	3.49e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.59	9.04	0.45	1.37e-17	Breast cancer;
CRC	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.46	6.82	0.35	4.46e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9549260	0.599	rs12870023	chr13:41244222	T/A	cg21288729	chr13:41239152	FOXO1	0.5	7.6	0.39	3.04e-13	Red blood cell count;
CRC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.42	-7.25	-0.37	3.09e-12	Facial morphology (factor 20);
CRC	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg09873164	chr1:152488093	CRCT1	-0.39	-6.67	-0.34	1.1e-10	Hair morphology;
CRC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.69	-0.35	9.62e-11	Subjective well-being;
CRC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.46	5.71	0.3	2.46e-8	Bladder cancer;
CRC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.55	5.72	0.3	2.37e-8	Bipolar disorder;
CRC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	6.49	0.34	3.15e-10	Cognitive test performance;
CRC	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.73	-7.29	-0.37	2.37e-12	Inflammatory biomarkers;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05572765	chr14:91526669	RPS6KA5	0.44	6.42	0.33	4.84e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.46	6.52	0.34	2.57e-10	Eye color traits;
CRC	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.96	-0.31	6.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg26182253	chr13:112236782	NA	0.31	6.2	0.32	1.71e-9	Hepatitis;
CRC	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.56	-7.69	-0.39	1.68e-13	Caudate activity during reward;
CRC	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.51	-6.93	-0.36	2.26e-11	Tuberculosis;
CRC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	0.98	10.51	0.5	1.85e-22	Diabetic retinopathy;
CRC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.45	18.09	0.71	2.95e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3772130	1.000	rs3772130	chr3:121344140	A/G	cg20356878	chr3:121714668	ILDR1	0.49	7.65	0.39	2.22e-13	Cognitive performance;
CRC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg01879757	chr17:41196368	BRCA1	-0.42	-6.23	-0.32	1.44e-9	Menopause (age at onset);
CRC	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.75	-0.35	6.6e-11	Triglycerides;
CRC	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg06042504	chr8:55087323	NA	-0.36	-5.76	-0.3	1.95e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.61	8.65	0.43	2.34e-16	Arsenic metabolism;
CRC	cis	rs231513	1.000	rs231499	chr17:41973507	C/T	cg26893861	chr17:41843967	DUSP3	0.64	6.36	0.33	6.75e-10	Cognitive function;
CRC	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.36	-0.65	1.56e-40	Exhaled nitric oxide output;
CRC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg13628971	chr7:2884303	GNA12	0.4	5.88	0.31	1.03e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.67	-11.39	-0.53	1.41e-25	Dental caries;
CRC	cis	rs6952808	0.635	rs12154473	chr7:1982181	A/G	cg00106254	chr7:1943704	MAD1L1	0.41	6.26	0.33	1.2e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.81	0.4	7.75e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs17601876	0.814	rs34784350	chr15:51559552	C/T	cg19946085	chr15:51559439	CYP19A1	-0.31	-6.18	-0.32	1.84e-9	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg24588162	chr13:113633484	MCF2L	-0.34	-6.06	-0.32	3.7e-9	Systolic blood pressure;
CRC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg03030879	chr14:75389066	RPS6KL1	0.56	9.17	0.45	5.49e-18	Caffeine consumption;
CRC	cis	rs7605827	0.930	rs2380653	chr2:15635011	C/A	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.36	0.62	1.17e-36	Breast cancer;
CRC	cis	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg02254774	chr11:50257496	LOC441601	0.42	5.83	0.31	1.33e-8	Coronary artery disease;
CRC	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg02158880	chr13:53174818	NA	0.42	6.01	0.31	5.04e-9	Lewy body disease;
CRC	cis	rs10804591	0.606	rs2625998	chr3:129303744	G/A	cg21885638	chr3:129306552	PLXND1	-0.41	-6.16	-0.32	2.09e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.63	0.43	2.61e-16	Rheumatoid arthritis;
CRC	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.53	-6.57	-0.34	1.99e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg15845792	chr6:28175446	NA	0.68	8.53	0.43	5.38e-16	Parkinson's disease;
CRC	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.48	-6.85	-0.35	3.68e-11	Response to antineoplastic agents;
CRC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.66	10.95	0.52	5.16e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4728302	0.934	rs10258052	chr7:133635874	T/C	cg03336402	chr7:133662267	EXOC4	0.46	6.93	0.36	2.21e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs3789045	0.774	rs12029692	chr1:204532323	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.55	-7.75	-0.39	1.16e-13	Educational attainment (college completion);
CRC	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	5.8	0.3	1.58e-8	Schizophrenia;
CRC	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.43	-7.44	-0.38	9e-13	IgG glycosylation;
CRC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07701084	chr6:150067640	NUP43	0.49	7.17	0.37	4.95e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.57	9.79	0.48	4.82e-20	Breast cancer;
CRC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg21625146	chr5:486483	SLC9A3	0.37	5.75	0.3	2.06e-8	Cystic fibrosis severity;
CRC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg18479299	chr3:125709523	NA	-0.52	-6.17	-0.32	2.03e-9	Blood pressure (smoking interaction);
CRC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg16576597	chr16:28551801	NUPR1	0.48	6.89	0.35	2.93e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.01	0.55	8.28e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.24	0.53	5.12e-25	Prudent dietary pattern;
CRC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.91	-10.37	-0.5	5.49e-22	Breast cancer;
CRC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.46	-0.38	7.66e-13	Coronary artery disease;
CRC	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.63	7.98	0.4	2.4e-14	Cocaine dependence;
CRC	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.33	-0.33	7.88e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.5e-9	Menopause (age at onset);
CRC	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-7.4	-0.38	1.16e-12	Primary sclerosing cholangitis;
CRC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.9	-0.31	9.08e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs2012709	0.869	rs12521288	chr5:32553266	C/G	cg03755955	chr8:6424269	MCPH1	0.44	6.43	0.33	4.39e-10	Breast cancer;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02725872	chr8:58115012	NA	-0.52	-7.24	-0.37	3.13e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg15382696	chr6:118971807	C6orf204	-0.6	-7.9	-0.4	4.3e-14	Diastolic blood pressure;
CRC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg08761264	chr16:28874980	SH2B1	-0.43	-5.74	-0.3	2.15e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.53	-0.47	3.64e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.36	0.53	1.82e-25	Bone mineral density;
CRC	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.41	6.42	0.33	4.72e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.49e-20	Height;
CRC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.2	0.67	8.61e-44	Chronic sinus infection;
CRC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.68e-19	Corneal astigmatism;
CRC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.81	13.45	0.6	3.53e-33	Menopause (age at onset);
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg23247704	chr1:116518985	SLC22A15	-0.73	-6.21	-0.32	1.57e-9	Cognitive function;
CRC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.48	-7.18	-0.37	4.62e-12	Monocyte percentage of white cells;
CRC	cis	rs800160	0.777	rs2521288	chr11:2342763	T/G	cg09785033	chr11:2336066	TSPAN32	-0.51	-5.95	-0.31	6.78e-9	Bacteremia;
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg16606324	chr3:10149918	C3orf24	0.69	9.58	0.47	2.42e-19	Alzheimer's disease;
CRC	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-7.41	-0.38	1.1e-12	Neuroticism;
CRC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.67	9.98	0.48	1.13e-20	Lung cancer;
CRC	trans	rs73162807	0.546	rs17752579	chr3:146429635	G/A	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg03316587	chr8:142245164	NA	0.42	6.37	0.33	6.23e-10	Immature fraction of reticulocytes;
CRC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.76	-0.35	6.35e-11	Monocyte percentage of white cells;
CRC	cis	rs77633900	0.772	rs2469224	chr15:76651327	T/G	cg21673338	chr15:77095150	SCAPER	-0.74	-6.93	-0.36	2.29e-11	Non-glioblastoma glioma;Glioma;
CRC	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	cg04338863	chr8:33670619	NA	0.39	6.76	0.35	6.31e-11	Body mass index;
CRC	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	1.03	18.33	0.71	3.23e-52	Parkinson's disease;
CRC	cis	rs7923609	0.902	rs10822158	chr10:65094383	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.77	-0.3	1.81e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.67	-0.35	1.06e-10	Blood protein levels;
CRC	cis	rs6586163	1.000	rs7097572	chr10:90753260	A/G	cg13456138	chr10:90753195	FAS	-0.44	-6.68	-0.35	1.03e-10	Chronic lymphocytic leukemia;
CRC	cis	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg03623178	chr6:28175578	NA	0.69	7.26	0.37	2.9e-12	Depression;
CRC	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Macular telangiectasia type 2;
CRC	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.61	8.36	0.42	1.83e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.48	6.4	0.33	5.48e-10	Obesity-related traits;
CRC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg14673194	chr17:80132900	CCDC57	0.49	6.35	0.33	7.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25135801	chr17:1619658	WDR81;C17orf91	0.44	7.26	0.37	2.87e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs12541635	0.966	rs34177605	chr8:107065105	G/A	cg10147462	chr8:107024639	NA	0.47	7.77	0.39	1.04e-13	Age of smoking initiation;
CRC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	6.18	0.32	1.9e-9	Lung cancer;
CRC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg27523141	chr10:43048294	ZNF37B	0.44	6.5	0.34	3.06e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.22	-0.37	3.72e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg09873164	chr1:152488093	CRCT1	0.4	6.75	0.35	6.85e-11	Hair morphology;
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg02741985	chr17:80059408	CCDC57	0.43	7.18	0.37	4.57e-12	Life satisfaction;
CRC	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg11579758	chr4:1086637	RNF212	0.4	6.51	0.34	2.75e-10	Recombination rate (males);
CRC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg23161317	chr6:28129485	ZNF389	0.46	6.45	0.33	4.05e-10	Parkinson's disease;
CRC	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	7.84	0.4	6.5e-14	Response to antipsychotic treatment;
CRC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg03340356	chr1:67600835	NA	0.25	5.73	0.3	2.25e-8	Psoriasis;
CRC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.91	-15.51	-0.65	4.28e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg02869306	chr7:64672164	INTS4L1	0.45	6.36	0.33	6.8e-10	Aortic root size;
CRC	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.61	-8.44	-0.42	1.06e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.58	-10.41	-0.5	4.06e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs365302	1.000	rs531165	chr6:159648220	T/C	cg14500486	chr6:159655392	FNDC1	0.44	6.82	0.35	4.31e-11	Coronary heart disease;
CRC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.22e-22	Corneal astigmatism;
CRC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.73	-8.23	-0.41	4.37e-15	Obesity-related traits;
CRC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.14	0.45	6.75e-18	Bladder cancer;
CRC	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.71	9.59	0.47	2.22e-19	Obesity-related traits;
CRC	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.71	11.86	0.55	2.92e-27	Eosinophil percentage of white cells;
CRC	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.43	-6.17	-0.32	2.04e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.0	0.31	5.3300000000000004e-09	Heart rate;
CRC	cis	rs7945718	0.621	rs12281511	chr11:12677295	A/C	cg25843174	chr11:12811716	TEAD1	0.39	7.07	0.36	9.43e-12	Educational attainment (years of education);
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg20615401	chr6:28092323	ZSCAN16	0.45	5.98	0.31	5.68e-9	Cardiac Troponin-T levels;
CRC	cis	rs554111	0.686	rs519209	chr1:21043790	C/T	cg00373020	chr1:21041521	KIF17	-0.36	-5.74	-0.3	2.15e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.46	8.49	0.42	7.04e-16	Intraocular pressure;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg01874867	chr7:94954059	PON1	-0.52	-6.49	-0.34	3.14e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.69	-0.35	9.45e-11	Educational attainment (years of education);
CRC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg01721255	chr8:58191610	C8orf71	0.49	6.11	0.32	2.81e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1847505	0.559	rs2323133	chr13:61568946	G/A	cg14094164	chr13:61491000	NA	0.33	6.19	0.32	1.77e-9	Polychlorinated biphenyl levels;
CRC	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg00507830	chr2:103233733	NA	0.51	5.61	0.3	4.25e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg08798685	chr6:27730294	NA	-0.5	-6.52	-0.34	2.71e-10	Breast cancer;
CRC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg09417038	chr21:47716443	C21orf57	0.38	6.64	0.34	1.3100000000000001e-10	Testicular germ cell tumor;
CRC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.8	0.63	2.35e-38	Chronic sinus infection;
CRC	trans	rs11165623	0.602	rs7521690	chr1:97015761	A/C	cg10631902	chr5:14652156	NA	-0.42	-7.18	-0.37	4.64e-12	Hip circumference;Waist circumference;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	5.86	0.31	1.15e-8	Longevity;
CRC	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	0.65	9.87	0.48	2.72e-20	Fractional exhaled nitric oxide (childhood);
CRC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	8.23	0.41	4.43e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg23018236	chr17:30244563	NA	-0.57	-7.48	-0.38	6.78e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.23	0.32	1.41e-9	Monocyte percentage of white cells;
CRC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.05	-0.55	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.57	0.39	3.87e-13	Platelet count;
CRC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg17724175	chr1:150552817	MCL1	0.49	7.3	0.37	2.19e-12	Melanoma;
CRC	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.15	-0.32	2.22e-9	Height;
CRC	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.95	-0.31	6.86e-9	Major depressive disorder;
CRC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-6.06	-0.32	3.69e-9	Body mass index;
CRC	cis	rs10512697	0.655	rs13178645	chr5:3501248	G/A	cg19473799	chr5:3511975	NA	-0.82	-6.32	-0.33	8.41e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.58	7.2	0.37	4.21e-12	Vitiligo;
CRC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg00360718	chr10:104192479	CUEDC2	-0.43	-6.54	-0.34	2.4e-10	Daytime sleep phenotypes;
CRC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg20811857	chr17:78079795	GAA	-0.44	-6.27	-0.33	1.11e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-8.73	-0.43	1.3e-16	Menarche (age at onset);
CRC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.55	-6.89	-0.36	2.85e-11	Body mass index;
CRC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.33	0.42	2.27e-15	Vitiligo;
CRC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.65	-9.98	-0.48	1.17e-20	Cognitive function;
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg02033258	chr5:131593261	PDLIM4	0.35	6.7	0.35	9.32e-11	Blood metabolite levels;
CRC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.48	-0.34	3.43e-10	Renal cell carcinoma;
CRC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg26721908	chr21:47610096	LSS	-0.41	-6.31	-0.33	9.17e-10	Testicular germ cell tumor;
CRC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs17767392	1.000	rs34873919	chr14:71780741	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.9	-0.36	2.71e-11	Mitral valve prolapse;
CRC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.45	-8.24	-0.41	4.21e-15	Reticulocyte fraction of red cells;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg15845792	chr6:28175446	NA	0.64	9.67	0.47	1.21e-19	Cardiac Troponin-T levels;
CRC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.58	10.31	0.49	8.7e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg10996143	chr20:1373995	FKBP1A	-0.43	-6.42	-0.33	4.65e-10	Daytime sleep phenotypes;
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.08	-0.36	8.79e-12	Total body bone mineral density;
CRC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg10570241	chr7:158785291	NA	0.45	7.84	0.4	6.3e-14	Facial morphology (factor 20);
CRC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-7.19	-0.37	4.47e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs6496667	0.779	rs2301827	chr15:90969195	A/T	cg04176472	chr15:90893244	GABARAPL3	0.61	8.61	0.43	3.12e-16	Rheumatoid arthritis;
CRC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-18.44	-0.71	1.16e-52	Height;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg20933634	chr6:27740509	NA	0.51	7.35	0.38	1.62e-12	Parkinson's disease;
CRC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-6.38	-0.33	5.94e-10	Blood protein levels;Circulating chemerin levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25161976	chr11:6411824	SMPD1	0.46	6.27	0.33	1.11e-9	Anxiety disorder;
CRC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg14541582	chr5:601475	NA	-0.33	-6.59	-0.34	1.8e-10	Obesity-related traits;
CRC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-12.13	-0.56	3.07e-28	Cognitive function;
CRC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg11189052	chr15:85197271	WDR73	0.58	8.43	0.42	1.1e-15	Schizophrenia;
CRC	cis	rs11212617	0.967	rs60683001	chr11:108257787	T/C	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.5	0.34	3.03e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.07	-0.45	1.08e-17	Hip circumference adjusted for BMI;
CRC	cis	rs972578	1.000	rs738381	chr22:43404107	T/C	cg01576275	chr22:43409880	NA	-0.49	-8.14	-0.41	8.5e-15	Mean platelet volume;
CRC	cis	rs11166629	0.883	rs11778878	chr8:135599220	C/T	cg27224718	chr8:135614730	ZFAT	-0.39	-5.74	-0.3	2.1e-8	Smoking quantity;
CRC	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg25809561	chr17:30822961	MYO1D	0.56	10.01	0.48	9.17e-21	Schizophrenia;
CRC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg12573674	chr2:1569213	NA	-0.75	-7.87	-0.4	5.22e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.87	16.52	0.67	4.47e-45	Hip circumference;
CRC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.55	8.11	0.41	1.01e-14	Lung cancer;
CRC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.31	6.49	0.34	3.1e-10	Educational attainment (years of education);
CRC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.56	0.34	2.03e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.6	10.0	0.48	1.01e-20	Mean corpuscular volume;
CRC	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg18232548	chr7:50535776	DDC	0.45	6.32	0.33	8.47e-10	Malaria;
CRC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg06243084	chr11:63990629	FERMT3	0.37	5.73	0.3	2.25e-8	Platelet count;
CRC	trans	rs2055729	0.645	rs7828229	chr8:9742841	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.02	-0.36	1.27e-11	Multiple myeloma (hyperdiploidy);
CRC	cis	rs6141769	0.542	rs6057632	chr20:31319841	A/G	cg13636640	chr20:31349939	DNMT3B	-0.44	-6.35	-0.33	7.11e-10	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27367768	chr5:171615456	STK10	0.44	7.79	0.39	8.85e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.51	0.57	1.22e-29	Body mass index;
CRC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.56	9.05	0.45	1.29e-17	Mean corpuscular volume;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.7	-12.72	-0.57	2.1000000000000002e-30	Cognitive function;
CRC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	10.43	0.5	3.44e-22	Type 2 diabetes;
CRC	cis	rs7429990	0.965	rs1137524	chr3:47956424	C/T	cg11946769	chr3:48343235	NME6	0.45	5.92	0.31	8.17e-9	Educational attainment (years of education);
CRC	cis	rs10919791	0.539	rs10919786	chr1:199946176	A/G	cg13229857	chr1:200006247	NR5A2	0.45	6.77	0.35	6.06e-11	Pancreatic cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01117627	chr14:100150713	CYP46A1	0.43	6.67	0.35	1.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-10.94	-0.52	5.62e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4737010	0.644	rs518718	chr8:41611375	T/C	cg17182837	chr8:41585554	ANK1	0.53	7.6	0.39	3.1400000000000003e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg07424746	chr4:185654737	MLF1IP	-0.58	-5.76	-0.3	1.96e-8	Blood protein levels;
CRC	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.48	6.99	0.36	1.49e-11	Testicular germ cell tumor;
CRC	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.24	-0.33	1.31e-9	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16779626	chr15:41709933	RTF1	0.46	6.59	0.34	1.77e-10	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17848531	chr2:182756352	SSFA2	0.51	7.24	0.37	3.28e-12	Response to antipsychotic treatment;
CRC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg18016565	chr1:150552671	MCL1	-0.42	-6.26	-0.33	1.18e-9	Tonsillectomy;
CRC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg05192639	chr6:26864778	GUSBL1	0.33	5.66	0.3	3.34e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.83	-12.67	-0.57	3.14e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.51	-5.76	-0.3	1.93e-8	Lymphocyte percentage of white cells;
CRC	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg27398640	chr15:77910606	LINGO1	-0.33	-6.04	-0.32	4.21e-9	Type 2 diabetes;
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.51	-6.96	-0.36	1.83e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.46	7.93	0.4	3.55e-14	Common traits (Other);
CRC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs6908034	0.607	rs73376651	chr6:19805559	C/G	cg02682789	chr6:19804855	NA	0.8	6.74	0.35	6.9e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg15744005	chr10:104629667	AS3MT	-0.35	-6.26	-0.33	1.18e-9	Arsenic metabolism;
CRC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.19	-0.45	4.69e-18	Joint mobility (Beighton score);
CRC	trans	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.26	-0.33	1.2e-9	Aortic root size;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Depression;
CRC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.86	0.48	2.84e-20	Bladder cancer;
CRC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.56	-8.36	-0.42	1.75e-15	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10227393	chr19:3721525	NA	0.41	5.99	0.31	5.6e-9	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.27	-6.08	-0.32	3.25e-9	Total body bone mineral density;
CRC	trans	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg02674126	chr19:40336878	FBL	0.43	6.91	0.36	2.58e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.61	10.31	0.49	8.74e-22	Prudent dietary pattern;
CRC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg05540913	chr6:167530185	CCR6	-0.33	-5.76	-0.3	1.92e-8	Primary biliary cholangitis;
CRC	cis	rs2274471	0.582	rs57839907	chr9:5082671	T/A	cg03390472	chr9:5043263	JAK2	-0.6	-7.05	-0.36	1.03e-11	Crohn's disease;
CRC	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg18232548	chr7:50535776	DDC	-0.43	-5.62	-0.3	4.12e-8	Malaria;
CRC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-9.21	-0.45	4.04e-18	Alcohol dependence;
CRC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.56	6.93	0.36	2.18e-11	Neutrophil percentage of white cells;
CRC	cis	rs12745968	0.595	rs6604014	chr1:93215718	T/C	cg17283838	chr1:93427260	FAM69A	-0.44	-5.97	-0.31	5.99e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.65	10.03	0.48	8.03e-21	Birth weight;
CRC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg00579200	chr11:133705235	NA	-0.39	-5.65	-0.3	3.48e-8	Childhood ear infection;
CRC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.66	-8.5	-0.42	6.67e-16	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.06	-0.32	3.71e-9	Height;
CRC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg17321639	chr7:2759063	NA	-0.51	-6.79	-0.35	5.27e-11	Height;
CRC	trans	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg26043149	chr18:55253948	FECH	-0.56	-8.84	-0.44	5.8e-17	Bone mineral density;
CRC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.8	14.35	0.62	1.28e-36	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24542852	chr12:569111	B4GALNT3	0.45	7.27	0.37	2.68e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.73	-0.35	7.48e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg10217327	chr6:118973057	C6orf204	0.51	5.86	0.31	1.12e-8	Diastolic blood pressure;
CRC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.41	6.72	0.35	8.14e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg23161317	chr6:28129485	ZNF389	0.47	5.61	0.3	4.34e-8	Depression;
CRC	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.83	14.71	0.63	5.35e-38	Itch intensity from mosquito bite;
CRC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.76	-0.35	6.47e-11	Subjective well-being;
CRC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs2486012	0.649	rs1354261	chr1:44256682	A/C	cg12908607	chr1:44402522	ARTN	-0.42	-6.09	-0.32	3.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.92	-9.54	-0.47	3.29e-19	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg04969067	chr8:143858791	LYNX1	-0.34	-5.76	-0.3	1.92e-8	Urinary tract infection frequency;
CRC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	9.52	0.46	3.77e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.47	-6.03	-0.32	4.44e-9	Strep throat;
CRC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.44	5.78	0.3	1.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2160860	0.825	rs10113563	chr8:39806028	C/A	cg11363097	chr8:39792086	IDO2	-0.4	-6.7	-0.35	9.23e-11	Blood metabolite levels;
CRC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg06462663	chr19:18546047	ISYNA1	0.46	6.96	0.36	1.83e-11	Breast cancer;
CRC	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg15571903	chr15:79123663	NA	0.32	6.3	0.33	9.36e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg14593290	chr7:50529359	DDC	0.54	6.83	0.35	4.04e-11	Malaria;
CRC	cis	rs4664293	0.867	rs13022404	chr2:160589492	C/A	cg08347373	chr2:160653686	CD302	-0.49	-7.7	-0.39	1.64e-13	Monocyte percentage of white cells;
CRC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg15358701	chr1:161410459	NA	-0.61	-6.57	-0.34	2.02e-10	Rheumatoid arthritis;
CRC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.03	-0.4	1.75e-14	Height;
CRC	cis	rs4731207	0.596	rs7787605	chr7:124659982	A/G	cg23710748	chr7:124431027	NA	-0.37	-5.88	-0.31	1.03e-8	Cutaneous malignant melanoma;
CRC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.63	9.89	0.48	2.26e-20	Prostate cancer;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg22638593	chr5:131593259	PDLIM4	0.38	6.19	0.32	1.75e-9	Breast cancer;
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.28	-0.33	1.07e-9	Neuroticism;
CRC	cis	rs6700896	0.931	rs11208717	chr1:66158994	T/C	cg04111102	chr1:66153794	NA	0.34	5.87	0.31	1.04e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.2	0.37	4.01e-12	Major depressive disorder;
CRC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.56	-9.73	-0.47	7.7e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg02683197	chr6:28174875	NA	0.53	6.18	0.32	1.85e-9	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-8.59	-0.43	3.61e-16	Sense of smell;
CRC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.5	-6.87	-0.35	3.12e-11	Colorectal cancer;
CRC	trans	rs7448080	0.702	rs62371209	chr5:123306655	A/C	cg23202058	chr4:185139648	ENPP6	0.59	5.99	0.31	5.55e-9	Alcohol dependence (age at onset);
CRC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.53	7.05	0.36	1.06e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.18	0.56	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2000999	0.514	rs36061252	chr16:72217613	T/G	cg04254540	chr16:71951199	KIAA0174	-0.69	-5.78	-0.3	1.71e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.77	11.31	0.53	2.81e-25	High light scatter reticulocyte count;
CRC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg15744005	chr10:104629667	AS3MT	0.32	6.7	0.35	8.96e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	8.46	0.42	8.84e-16	Cognitive test performance;
CRC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg13010199	chr12:38710504	ALG10B	0.46	6.57	0.34	2.02e-10	Morning vs. evening chronotype;
CRC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg11843238	chr5:131593191	PDLIM4	0.32	5.94	0.31	7.33e-9	Blood metabolite levels;
CRC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.57	0.39	3.74e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.46	7.38	0.38	1.33e-12	Schizophrenia;
CRC	cis	rs2179367	0.959	rs4895788	chr6:149748091	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.02	-0.32	4.61e-9	Dupuytren's disease;
CRC	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.5	-7.79	-0.39	9.08e-14	Motion sickness;
CRC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg15845792	chr6:28175446	NA	0.59	7.85	0.4	6.08e-14	Parkinson's disease;
CRC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.86	-15.88	-0.66	1.51e-42	Dental caries;
CRC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	17.56	0.7	3.65e-49	Platelet count;
CRC	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-18.51	-0.71	6.13e-53	Schizophrenia;
CRC	trans	rs10242455	0.702	rs73397447	chr7:99010949	G/T	cg09045935	chr12:6379348	NA	1.02	8.04	0.41	1.67e-14	Blood metabolite levels;
CRC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg23978390	chr7:1156363	C7orf50	0.53	5.88	0.31	9.97e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21037892	chr2:96874728	STARD7	0.46	6.01	0.31	4.96e-9	Thyroid stimulating hormone;
CRC	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.55	9.11	0.45	8.06e-18	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	11.19	0.52	7.86e-25	Bone mineral density;
CRC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg09582351	chr12:29534625	ERGIC2	-0.29	-6.19	-0.32	1.81e-9	QT interval;
CRC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.6	8.96	0.44	2.42e-17	Subjective well-being;
CRC	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.24	-0.37	3.17e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	1.06	9.68	0.47	1.19e-19	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.16	-0.32	2.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.51	6.59	0.34	1.7e-10	Schizophrenia;
CRC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg13047869	chr3:10149882	C3orf24	0.36	5.73	0.3	2.27e-8	Alzheimer's disease;
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.51	6.91	0.36	2.54e-11	Alzheimer's disease;
CRC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.49e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg08992911	chr2:238395768	MLPH	0.61	6.25	0.33	1.26e-9	Prostate cancer;
CRC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.53	-7.52	-0.38	5.39e-13	Longevity;
CRC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.17e-11	Coronary artery disease;
CRC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.93	0.36	2.21e-11	Height;
CRC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.2	-0.56	1.68e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs73206853	0.563	rs73194026	chr12:111140219	G/T	cg12870014	chr12:110450643	ANKRD13A	0.81	9.11	0.45	8.06e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2882667	0.690	rs9327829	chr5:138261671	A/G	cg09476006	chr5:138032270	NA	-0.56	-9.3	-0.46	2.06e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-5.77	-0.3	1.85e-8	IgG glycosylation;
CRC	trans	rs2303319	0.504	rs79046651	chr2:162326417	C/A	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.27	-0.33	1.13e-9	Cognitive function;
CRC	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.62	8.9	0.44	3.8e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.39	5.7	0.3	2.73e-8	Aortic root size;
CRC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.25	-0.74	8.67e-60	Height;
CRC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.64	-0.51	6.58e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs7635838	0.892	rs4684773	chr3:11418508	C/T	cg00170343	chr3:11313890	ATG7	0.42	6.37	0.33	6.35e-10	HDL cholesterol;
CRC	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	1.03	14.37	0.62	1.14e-36	Exhaled nitric oxide output;
CRC	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04988224	chr19:49122379	RPL18;SPHK2	0.39	6.02	0.31	4.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.72	-7.86	-0.4	5.63e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg09324608	chr17:30823087	MYO1D	0.33	5.65	0.3	3.4e-8	Schizophrenia;
CRC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg02766259	chr12:125626809	AACS	-0.47	-7.64	-0.39	2.34e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg01339444	chr6:118972232	C6orf204	-0.51	-5.86	-0.31	1.1e-8	Diastolic blood pressure;
CRC	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.62	12.35	0.56	4.76e-29	Weight;
CRC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.61	-11.48	-0.53	7.12e-26	Hemoglobin concentration;
CRC	cis	rs989128	0.642	rs8077323	chr17:48626398	C/T	cg16068336	chr17:48637367	CACNA1G	-0.54	-7.73	-0.39	1.3e-13	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00521598	chr1:39339413	MYCBP	0.44	6.2	0.32	1.65e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg16077055	chr2:106428750	NCK2	0.4	5.7	0.3	2.66e-8	Addiction;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg13490827	chr1:46269305	MAST2	-0.72	-6.21	-0.32	1.56e-9	Cognitive function;
CRC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.08	0.32	3.33e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.06	0.36	9.94e-12	Personality dimensions;
CRC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.39	6.07	0.32	3.46e-9	Crohn's disease;
CRC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.5	6.95	0.36	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.46	-9.06	-0.45	1.2e-17	Renal cell carcinoma;
CRC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.64	11.13	0.52	1.22e-24	Schizophrenia;
CRC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.11	-0.36	7.38e-12	QT interval;
CRC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg02175503	chr12:58329896	NA	-0.48	-6.74	-0.35	7.19e-11	Multiple sclerosis;
CRC	trans	rs79464052	0.571	rs79215142	chr5:140999104	C/T	cg05255351	chr5:1503979	LPCAT1	-0.46	-6.09	-0.32	3.07e-9	Diffuse large B cell lymphoma;
CRC	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg18646521	chr2:111875858	NA	0.36	5.65	0.3	3.55e-8	Chronic lymphocytic leukemia;
CRC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.43	0.33	4.39e-10	Aortic root size;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg20933634	chr6:27740509	NA	0.63	7.31	0.37	2.09e-12	Parkinson's disease;
CRC	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.4	0.53	1.3e-25	Exhaled nitric oxide levels;
CRC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg12273811	chr6:28175739	NA	0.58	5.98	0.31	5.69e-9	Lung cancer in ever smokers;
CRC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg02659138	chr7:134003124	SLC35B4	0.4	6.94	0.36	2.16e-11	Mean platelet volume;
CRC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg02569458	chr12:86230093	RASSF9	0.47	7.99	0.4	2.26e-14	Major depressive disorder;
CRC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.68	9.45	0.46	6.36e-19	Vitiligo;
CRC	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg17145862	chr1:211918768	LPGAT1	-0.5	-8.21	-0.41	5.26e-15	Leprosy;
CRC	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.55	-8.2	-0.41	5.46e-15	Vitiligo;
CRC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg08798685	chr6:27730294	NA	-0.49	-6.88	-0.35	3.11e-11	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs12144094	0.882	rs12127451	chr1:120227630	C/A	cg20995928	chr1:120229863	NA	0.47	6.76	0.35	6.26e-11	Height;
CRC	cis	rs6743376	0.556	rs2515392	chr2:113817181	C/T	cg24553058	chr2:113831203	IL1F10	0.43	6.97	0.36	1.78e-11	Inflammatory biomarkers;
CRC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.45	6.57	0.34	1.96e-10	Menopause (age at onset);
CRC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.43	7.13	0.37	6.41e-12	Longevity;
CRC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg26603656	chr10:5671107	NA	0.48	8.31	0.42	2.63e-15	Breast cancer;
CRC	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	1.0	18.87	0.72	2.33e-54	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.63	-9.87	-0.48	2.64e-20	IgG glycosylation;
CRC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06671706	chr8:8559999	CLDN23	0.61	9.04	0.45	1.35e-17	Obesity-related traits;
CRC	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.42	0.33	4.71e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg24289452	chr6:170231220	NA	-0.59	-6.42	-0.33	4.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.7	-0.39	1.64e-13	Gut microbiome composition (summer);
CRC	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg13175173	chr14:55914753	NA	-0.53	-9.94	-0.48	1.62e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.42	-6.18	-0.32	1.86e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg19027507	chr1:27320128	TRNP1	-0.44	-5.98	-0.31	5.75e-9	Protein C levels;
CRC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg20908204	chr19:46285434	DMPK	-0.4	-8.18	-0.41	6.29e-15	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24023618	chr6:114292459	HDAC2	0.48	6.28	0.33	1.09e-9	Thyroid stimulating hormone;
CRC	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.48	-6.21	-0.32	1.6e-9	Neuroticism;
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-12.19	-0.56	1.84e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg10589385	chr1:150898437	SETDB1	0.33	6.95	0.36	1.92e-11	Melanoma;
CRC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.48	8.87	0.44	4.72e-17	Reticulocyte fraction of red cells;
CRC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.48	7.36	0.38	1.51e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-7.71	-0.39	1.51e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.46	6.48	0.34	3.32e-10	Cognitive ability;
CRC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.85	11.74	0.54	8.12e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.82	-0.35	4.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg01932125	chr11:77377926	RSF1	-0.39	-6.28	-0.33	1.08e-9	HDL cholesterol;
CRC	cis	rs10944	0.598	rs595479	chr5:78275651	G/C	cg13121490	chr5:78280331	ARSB	-0.45	-6.57	-0.34	1.99e-10	Blood and toenail selenium levels;
CRC	cis	rs4930561	0.677	rs7946212	chr11:67982187	T/A	cg04465784	chr11:67976953	SUV420H1	-0.3	-6.05	-0.32	3.88e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg01312482	chr5:178451176	ZNF879	0.34	5.77	0.3	1.88e-8	Pubertal anthropometrics;
CRC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg24881330	chr22:46731750	TRMU	0.56	6.6	0.34	1.61e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.56	-5.98	-0.31	5.88e-9	Bipolar disorder;
CRC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.55	-8.63	-0.43	2.66e-16	Aortic root size;
CRC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.59	9.03	0.45	1.53e-17	Blood protein levels;
CRC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.43	0.38	9.44e-13	Motion sickness;
CRC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	10.72	0.51	3.32e-23	Motion sickness;
CRC	cis	rs11212617	0.905	rs3901851	chr11:108352335	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.39	5.7	0.3	2.62e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.84	0.4	6.37e-14	Diabetic retinopathy;
CRC	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg09659197	chr4:152720779	NA	0.51	11.24	0.53	4.96e-25	Intelligence (multi-trait analysis);
CRC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg25985355	chr7:65971099	NA	-0.32	-5.62	-0.3	4.12e-8	Aortic root size;
CRC	trans	rs10858396	1.000	rs7042225	chr9:138274938	C/T	cg26979339	chr12:107168153	RIC8B	0.47	6.13	0.32	2.53e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg05132306	chr1:1846340	CALML6	-0.46	-7.18	-0.37	4.58e-12	Body mass index;
CRC	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg25588852	chr2:216877276	MREG	-0.33	-6.19	-0.32	1.8e-9	Alcohol dependence;
CRC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.65	-9.52	-0.46	3.99e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.4	-6.48	-0.34	3.28e-10	Reticulocyte count;High light scatter reticulocyte count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14108394	chr12:62997291	MIRLET7I;C12orf61	0.44	6.24	0.33	1.38e-9	Anxiety disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19223274	chr6:143381998	AIG1	-0.41	-6.18	-0.32	1.87e-9	Myopia (pathological);
CRC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.81	-11.1	-0.52	1.53e-24	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg18404041	chr3:52824283	ITIH1	0.41	7.55	0.38	4.38e-13	Schizophrenia;
CRC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.74	-0.39	1.21e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	7.25	0.37	2.91e-12	HIV-1 control;
CRC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.72	0.3	2.36e-8	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg27398640	chr15:77910606	LINGO1	0.46	7.8	0.39	8.41e-14	Type 2 diabetes;
CRC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg24289452	chr6:170231220	NA	0.62	6.43	0.33	4.56e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.04	14.64	0.63	1.04e-37	Exhaled nitric oxide output;
CRC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg20243544	chr17:37824526	PNMT	0.54	8.41	0.42	1.28e-15	Asthma;
CRC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	0.98	9.41	0.46	8.55e-19	IgG glycosylation;
CRC	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.75	8.54	0.43	5.16e-16	Systolic blood pressure;
CRC	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.65	-10.34	-0.5	7.08e-22	Hepatocellular carcinoma;
CRC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.42	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.8e-8	Colorectal cancer;
CRC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.49	5.61	0.3	4.23e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs10202249	0.716	rs80164862	chr2:154073086	G/A	cg25823578	chr14:52781312	PTGER2	-0.59	-6.08	-0.32	3.32e-9	Conotruncal heart defects (inherited effects);
CRC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.73	-0.47	8.17e-20	Chronic sinus infection;
CRC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg02741985	chr17:80059408	CCDC57	0.45	7.27	0.37	2.71e-12	Life satisfaction;
CRC	cis	rs41271951	0.512	rs11204774	chr1:151062957	C/T	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.74	-0.3	2.15e-8	Blood protein levels;
CRC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg19223190	chr17:80058835	NA	-0.39	-6.22	-0.32	1.52e-9	Life satisfaction;
CRC	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg27411982	chr8:10470053	RP1L1	-0.36	-5.8	-0.3	1.52e-8	Neuroticism;
CRC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg25164649	chr6:28176230	NA	0.59	8.32	0.42	2.36e-15	Parkinson's disease;
CRC	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.5	-9.49	-0.46	5.01e-19	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs6479527	0.904	rs10761315	chr9:96875556	A/T	cg14459158	chr9:96720562	NA	0.37	6.51	0.34	2.88e-10	Esophageal adenocarcinoma;
CRC	cis	rs418053	0.648	rs204232	chr6:13659079	T/G	cg02206980	chr6:13574034	SIRT5	-0.37	-6.1	-0.32	2.95e-9	Breast cancer;
CRC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg02741985	chr17:80059408	CCDC57	-0.41	-6.75	-0.35	6.69e-11	Life satisfaction;
CRC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg09835421	chr16:68378352	PRMT7	-0.61	-5.64	-0.3	3.73e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg11130432	chr3:121712080	ILDR1	-0.51	-6.65	-0.34	1.23e-10	Multiple sclerosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21819024	chr1:52344978	NRD1	0.44	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.29	-0.33	1.04e-9	Obesity-related traits;
CRC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.43	0.62	6.62e-37	Chronic sinus infection;
CRC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg20243544	chr17:37824526	PNMT	0.53	7.94	0.4	3.24e-14	Asthma;
CRC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.23	-0.41	4.49e-15	Bipolar disorder;
CRC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg16989719	chr2:238392110	NA	-0.44	-8.0	-0.4	2.11e-14	Prostate cancer;
CRC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.61	9.91	0.48	2e-20	Type 2 diabetes;
CRC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.39	5.96	0.31	6.48e-9	HDL cholesterol levels;
CRC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg12365402	chr11:9010492	NRIP3	0.36	6.03	0.32	4.47e-9	Hemoglobin concentration;
CRC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.6	-6.93	-0.36	2.19e-11	Vitiligo;
CRC	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg08075719	chr14:103021372	NA	0.64	7.29	0.37	2.35e-12	Platelet count;
CRC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	8.63	0.43	2.75e-16	Lung function (FEV1/FVC);
CRC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.48	7.84	0.4	6.19e-14	Cystic fibrosis severity;
CRC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.39	9.25	0.45	3.02e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.66	-12.98	-0.58	2.16e-31	Coronary artery disease;
CRC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg03013636	chr16:1946785	NA	0.58	7.09	0.36	8.32e-12	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.56	-5.75	-0.3	2.09e-8	Hip circumference adjusted for BMI;
CRC	cis	rs9287719	0.649	rs2024432	chr2:10731474	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.4	-5.98	-0.31	5.82e-9	Monocyte count;
CRC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg15309053	chr8:964076	NA	0.4	7.3	0.37	2.23e-12	Schizophrenia;
CRC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.47	6.27	0.33	1.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.75e-15	Bladder cancer;
CRC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.42	5.6	0.3	4.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12463550	chr7:65579703	CRCP	-0.68	-6.31	-0.33	9.18e-10	Diabetic kidney disease;
CRC	cis	rs2617583	0.509	rs13089	chr5:1462732	G/C	cg07148919	chr5:1466943	LPCAT1	-0.44	-5.75	-0.3	2.05e-8	Breast cancer;
CRC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.43	6.83	0.35	4.15e-11	Sitting height ratio;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15645079	chr20:3140569	FASTKD5;UBOX5	0.47	6.03	0.32	4.44e-9	Thyroid stimulating hormone;
CRC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg24289452	chr6:170231220	NA	-0.57	-6.39	-0.33	5.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.48	-6.8	-0.35	4.81e-11	Pancreatic cancer;
CRC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-6.72	-0.35	8.18e-11	Immature fraction of reticulocytes;
CRC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg19812747	chr11:111475976	SIK2	0.53	9.18	0.45	5.01e-18	Primary sclerosing cholangitis;
CRC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg23533926	chr12:111358616	MYL2	0.53	8.2	0.41	5.47e-15	Extrinsic epigenetic age acceleration;
CRC	trans	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02725872	chr8:58115012	NA	-0.58	-9.06	-0.45	1.21e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg17346650	chr17:80929145	B3GNTL1	0.48	7.08	0.36	8.88e-12	Glycated hemoglobin levels;
CRC	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg12908607	chr1:44402522	ARTN	-0.35	-6.04	-0.32	4.14e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-9.91	-0.48	1.95e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs3736594	0.513	rs60854669	chr2:27786929	T/C	cg27432699	chr2:27873401	GPN1	0.64	8.39	0.42	1.42e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs1223397	0.617	rs957176	chr6:13311526	C/T	cg07912922	chr6:13274314	PHACTR1	0.38	6.01	0.31	4.81e-9	Blood pressure;
CRC	cis	rs9468199	1.000	rs9468199	chr6:27681215	G/A	cg06470822	chr6:28175283	NA	0.51	6.24	0.33	1.34e-9	Parkinson's disease;
CRC	trans	rs867371	0.502	rs1846908	chr15:82522526	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.14	-0.32	2.35e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg00919237	chr7:87102261	ABCB4	-0.55	-7.21	-0.37	3.94e-12	Gallbladder cancer;
CRC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg18479299	chr3:125709523	NA	-0.56	-6.6	-0.34	1.6e-10	Blood pressure (smoking interaction);
CRC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.42	-6.25	-0.33	1.27e-9	Pulse pressure;
CRC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.54	5.98	0.31	5.68e-9	Schizophrenia;
CRC	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.48	0.42	7.93e-16	Arsenic metabolism;
CRC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.38	-6.12	-0.32	2.66e-9	P wave terminal force;
CRC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg09455208	chr3:40491958	NA	0.32	6.58	0.34	1.89e-10	Renal cell carcinoma;
CRC	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.99	-0.31	5.38e-9	Endometrial cancer;
CRC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.49	6.72	0.35	8.1e-11	Multiple sclerosis;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg20041105	chr8:143859282	LYNX1	-0.41	-6.78	-0.35	5.42e-11	Urinary tract infection frequency;
CRC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.5	-5.97	-0.31	6.14e-9	Gut microbiome composition (summer);
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.39	-0.38	1.2e-12	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08555160	chr16:69166339	CHTF8;CIRH1A	0.37	6.17	0.32	1.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	9.53	0.47	3.55e-19	Cognitive test performance;
CRC	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.57	5.72	0.3	2.38e-8	Fibroblast growth factor basic levels;
CRC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.48	-0.34	3.42e-10	Systemic lupus erythematosus;
CRC	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.55	9.54	0.47	3.41e-19	Facial morphology (factor 15, philtrum width);
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg15147215	chr3:52552868	STAB1	-0.64	-11.05	-0.52	2.42e-24	Bipolar disorder;
CRC	cis	rs6788895	0.661	rs73010947	chr3:150485742	T/C	cg09723797	chr3:150481914	SIAH2	0.88	6.51	0.34	2.75e-10	Breast cancer;
CRC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.41	5.89	0.31	9.68e-9	Menarche (age at onset);
CRC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.53	-0.43	5.54e-16	Monocyte percentage of white cells;
CRC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.56	-10.47	-0.5	2.58e-22	Schizophrenia;
CRC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.01	-0.4	2.01e-14	Bipolar disorder;
CRC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-7.13	-0.37	6.56e-12	Electroencephalogram traits;
CRC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.7	-11.47	-0.53	7.57e-26	Cognitive function;
CRC	cis	rs7558233	0.614	rs59454437	chr2:23682476	A/G	cg00747342	chr2:23700632	KLHL29	0.52	5.62	0.3	4.05e-8	Cannabis use (initiation);
CRC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.39	6.71	0.35	8.28e-11	Height;
CRC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg21620606	chr4:1342894	KIAA1530	0.37	6.51	0.34	2.82e-10	Longevity;
CRC	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg18753928	chr3:113234510	CCDC52	-0.49	-7.75	-0.39	1.13e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.43	-5.89	-0.31	9.77e-9	Body mass index;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg07217954	chr7:1067459	C7orf50	0.49	5.7	0.3	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.66	0.54	1.58e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.65	0.63	8.94e-38	Breast cancer;
CRC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-8.06	-0.41	1.4e-14	Total body bone mineral density;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg15845792	chr6:28175446	NA	0.9	13.11	0.59	6.83e-32	Parkinson's disease;
CRC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	6.9	0.36	2.7e-11	Mean platelet volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02853990	chr9:115480539	C9orf80	0.54	7.52	0.38	5.33e-13	Response to antipsychotic treatment;
CRC	cis	rs501120	0.584	rs11511571	chr10:44727167	T/C	cg09554077	chr10:44749378	NA	0.65	7.32	0.37	1.9e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.56	-8.9	-0.44	3.79e-17	Pulse pressure;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01735101	chr19:19774554	ATP13A1	-0.42	-6.22	-0.32	1.49e-9	Daytime sleep phenotypes;
CRC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.62	10.0	0.48	9.78e-21	Height;
CRC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.44	-6.06	-0.32	3.83e-9	Schizophrenia;
CRC	cis	rs959260	0.588	rs9894003	chr17:73405860	T/G	cg14668889	chr17:73230827	NUP85	-0.49	-5.62	-0.3	4.14e-8	Systemic lupus erythematosus;
CRC	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.11	-0.56	3.76e-28	Coffee consumption (cups per day);
CRC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	trans	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg07393940	chr7:158741817	NA	0.52	7.31	0.37	2e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.31	5.57e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7333181	1.000	rs34163870	chr13:112233682	G/C	cg27543320	chr13:112200689	NA	0.5	6.45	0.33	4.03e-10	Menopause (age at onset);
CRC	cis	rs889398	0.616	rs35808754	chr16:69771710	G/T	cg00738113	chr16:70207722	CLEC18C	0.37	6.13	0.32	2.46e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23200371	chr12:56367680	RAB5B	0.37	6.09	0.32	3.23e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.06	-0.41	1.38e-14	Depression;
CRC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	7.59	0.39	3.34e-13	Motion sickness;
CRC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg27523141	chr10:43048294	ZNF37B	-0.49	-7.07	-0.36	9.18e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.58	9.3	0.46	2.07e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	13.46	0.6	3.27e-33	Menopause (age at onset);
CRC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.3	-0.37	2.12e-12	Major depressive disorder;
CRC	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg05683857	chr10:124030795	BTBD16	0.32	5.82	0.31	1.41e-8	Total body bone mineral density;
CRC	cis	rs16936870	0.543	rs16936790	chr8:71086468	C/T	cg14232793	chr8:71155543	NCOA2	-0.46	-5.7	-0.3	2.65e-8	QT interval;
CRC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	6.78	0.35	5.45e-11	Lung function (FEV1/FVC);
CRC	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg01339444	chr6:118972232	C6orf204	0.58	6.1	0.32	2.96e-9	Diastolic blood pressure;
CRC	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg19418318	chr19:17219073	MYO9B	0.51	8.7	0.43	1.66e-16	Reticulocyte fraction of red cells;
CRC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.68	-10.91	-0.52	7.11e-24	Breast cancer;
CRC	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg04611788	chr3:186434169	KNG1	-0.6	-8.83	-0.44	6.23e-17	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03274021	chr8:130952480	FAM49B	0.45	6.43	0.33	4.57e-10	Response to antipsychotic treatment;
CRC	cis	rs7091068	0.616	rs6583905	chr10:95504022	T/G	cg20715218	chr10:95462985	C10orf4	0.54	5.71	0.3	2.46e-8	Urinary tract infection frequency;
CRC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.46	6.09	0.32	3.24e-9	Prudent dietary pattern;
CRC	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg11204139	chr17:3907470	NA	0.77	14.57	0.63	1.88e-37	Type 2 diabetes;
CRC	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg18473234	chr19:5097819	KDM4B	-0.5	-6.29	-0.33	1.03e-9	Monocyte percentage of white cells;
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.7	9.48	0.46	5.31e-19	Alzheimer's disease;
CRC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg25797454	chr6:150327115	RAET1K	0.37	6.46	0.34	3.71e-10	Alopecia areata;
CRC	cis	rs10905065	0.569	rs4750553	chr10:5728174	C/T	cg11519256	chr10:5708881	ASB13	0.44	6.09	0.32	3.14e-9	Menopause (age at onset);
CRC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg15440763	chr7:158190612	PTPRN2	0.4	6.56	0.34	2.06e-10	Obesity-related traits;
CRC	cis	rs2565722	0.583	rs2489945	chr6:161297724	A/G	cg03159191	chr6:161285451	NA	0.39	6.0	0.31	5.08e-9	Blood protein levels;
CRC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.43	6.75	0.35	6.84e-11	Monocyte count;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26197690	chr5:139936946	SRA1	0.48	6.34	0.33	7.46e-10	Anxiety disorder;
CRC	cis	rs995000	0.931	rs10493322	chr1:62905893	C/T	cg19896129	chr1:63156450	NA	0.4	5.88	0.31	9.97e-9	Triglyceride levels;
CRC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg16576597	chr16:28551801	NUPR1	0.48	6.9	0.36	2.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs1880529	0.830	rs3796929	chr4:114367980	A/G	cg05422836	chr8:81806286	NA	0.42	6.11	0.32	2.82e-9	White matter integrity (bipolar disorder risk interaction);
CRC	cis	rs13098911	0.540	rs13069742	chr3:46114216	A/G	cg12691230	chr3:46064611	XCR1	-0.55	-6.03	-0.32	4.48e-9	Celiac disease;
CRC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.08	-0.32	3.29e-9	Bladder cancer;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg24418792	chr10:104153828	NFKB2	0.39	6.47	0.34	3.6e-10	Interleukin-6 levels;
CRC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.78	-8.65	-0.43	2.3e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.47	-6.71	-0.35	8.55e-11	Coronary artery disease;
CRC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.22	-0.41	4.71e-15	Total body bone mineral density;
CRC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.57	-8.62	-0.43	2.9e-16	Menarche (age at onset);
CRC	cis	rs989128	0.642	rs8076628	chr17:48626626	G/A	cg16068336	chr17:48637367	CACNA1G	-0.54	-7.73	-0.39	1.3e-13	Type 2 diabetes;
CRC	cis	rs12079745	0.793	rs3766064	chr1:169157919	A/G	cg09363564	chr1:169337483	NME7;BLZF1	0.92	6.02	0.32	4.55e-9	QT interval;
CRC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.77	13.72	0.6	3.54e-34	DNA methylation (variation);
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.5	6.89	0.35	2.89e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.66	-10.18	-0.49	2.43e-21	Bipolar disorder and schizophrenia;
CRC	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.42	-6.66	-0.34	1.16e-10	C-reactive protein levels;
CRC	cis	rs9322817	0.691	rs4299867	chr6:105325383	G/C	cg02098413	chr6:105308735	HACE1	0.43	8.49	0.42	7.27e-16	Thyroid stimulating hormone;
CRC	cis	rs16852403	0.619	rs10798597	chr1:178108248	G/A	cg00404053	chr1:178313656	RASAL2	0.6	7.63	0.39	2.56e-13	Childhood ear infection;
CRC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24308560	chr3:49941425	MST1R	0.42	6.5	0.34	2.9e-10	Body mass index;
CRC	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg02033258	chr5:131593261	PDLIM4	0.31	5.62	0.3	3.99e-8	Blood metabolite levels;
CRC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg07636037	chr3:49044803	WDR6	-0.83	-6.81	-0.35	4.67e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg05569086	chr8:143859399	LYNX1	-0.39	-6.06	-0.32	3.81e-9	Urinary tract infection frequency;
CRC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-8.24	-0.41	4.01e-15	Monocyte count;
CRC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	13.49	0.6	2.56e-33	Platelet count;
CRC	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.53	6.51	0.34	2.8e-10	Cognitive test performance;
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.05	-0.32	4.04e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.39e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02421172	chr7:1938701	MAD1L1	0.47	6.2	0.32	1.68e-9	Neuroticism;
CRC	cis	rs7487075	0.930	rs7308910	chr12:46838242	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	6.25	0.33	1.3e-9	Itch intensity from mosquito bite;
CRC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg08222913	chr3:52553049	STAB1	-0.38	-7.35	-0.38	1.56e-12	Electroencephalogram traits;
CRC	cis	rs3750082	0.889	rs6972006	chr7:32938292	T/C	cg05721444	chr7:32995514	FKBP9	0.48	7.24	0.37	3.17e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg04837898	chr3:45731254	SACM1L	-0.35	-5.72	-0.3	2.4e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg21194808	chr1:2205498	SKI	-0.4	-6.24	-0.33	1.36e-9	Height;
CRC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.33	-5.96	-0.31	6.39e-9	Mean platelet volume;Platelet distribution width;
CRC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.84	-14.54	-0.63	2.36e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.75e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.38	-6.08	-0.32	3.28e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs4750440	0.523	rs4565800	chr10:14032326	G/C	cg00551146	chr10:14014579	FRMD4A	0.45	7.25	0.37	2.99e-12	Adiponectin levels;
CRC	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg12560992	chr17:57184187	TRIM37	0.52	6.13	0.32	2.48e-9	Vitamin D levels;
CRC	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.83	0.63	1.81e-38	Exhaled nitric oxide output;
CRC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.73	11.64	0.54	1.9e-26	Coronary artery disease;
CRC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg17147758	chr8:6949321	NA	-0.53	-7.4	-0.38	1.14e-12	Blood pressure (smoking interaction);
CRC	cis	rs11955398	0.521	rs4298206	chr5:60012235	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.4	-5.81	-0.31	1.48e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	0.58	8.92	0.44	3.2e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg12457986	chr21:27107982	ATP5J;GABPA	0.37	6.1	0.32	2.98e-9	Parkinson's disease;
CRC	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.34	0.46	1.51e-18	Fuchs's corneal dystrophy;
CRC	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.91	0.31	8.38e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg18764771	chr6:116381957	FRK	-0.23	-6.59	-0.34	1.78e-10	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2579500	0.844	rs1866444	chr2:97172125	A/G	cg23100626	chr2:96804247	ASTL	-0.24	-5.85	-0.31	1.16e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.93	11.91	0.55	1.96e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg05585544	chr11:47624801	NA	0.41	6.32	0.33	8.5e-10	Mean corpuscular hemoglobin;
CRC	cis	rs11229555	0.645	rs10896774	chr11:58175837	T/G	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg12756093	chr1:115239321	AMPD1	0.48	6.96	0.36	1.85e-11	Autism;
CRC	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.61	-7.64	-0.39	2.46e-13	Ulcerative colitis;
CRC	cis	rs4494114	0.967	rs1886748	chr1:39333775	C/A	cg25970120	chr1:39325951	RRAGC	-0.42	-5.62	-0.3	4.13e-8	Blood protein levels;
CRC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.27	0.33	1.14e-9	Bipolar disorder;
CRC	trans	rs4714291	0.832	rs2984431	chr6:39980900	T/A	cg02267698	chr19:7991119	CTXN1	-0.49	-6.71	-0.35	8.33e-11	Strep throat;
CRC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg01951491	chr16:67709440	GFOD2	0.51	5.65	0.3	3.53e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10486722	0.606	rs4720405	chr7:41806349	A/G	cg22138096	chr7:41772439	LOC285954	0.54	6.53	0.34	2.54e-10	Pit-and-Fissure caries;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03188948	chr7:1209495	NA	0.43	6.04	0.32	4.12e-9	Longevity;Endometriosis;
CRC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg07274523	chr3:49395745	GPX1	0.48	6.55	0.34	2.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.32	11.07	0.52	1.96e-24	Psoriasis vulgaris;
CRC	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.06	0.52	2.11e-24	Coffee consumption (cups per day);
CRC	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.62	8.83	0.44	6.36e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.65	10.41	0.5	4.16e-22	Corneal astigmatism;
CRC	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.96	-0.4	2.77e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs3825932	0.778	rs1036938	chr15:79237247	C/G	cg25744700	chr15:79237217	CTSH	0.4	5.99	0.31	5.35e-9	Type 1 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22319682	chr19:11998584	ZNF69	0.5	7.36	0.38	1.51e-12	Intelligence (multi-trait analysis);
CRC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.52	-11.43	-0.53	1.08e-25	Rheumatoid arthritis;
CRC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.51	8.14	0.41	8.43e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20092199	chr4:1342459	KIAA1530	0.34	5.9	0.31	8.88e-9	Obesity-related traits;
CRC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.13	-0.41	9.11e-15	Hemoglobin concentration;
CRC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.42	5.73	0.3	2.22e-8	Schizophrenia;
CRC	cis	rs243505	1.000	rs1019059	chr7:148424247	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-6.28	-0.33	1.04e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.45	5.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.64	-8.73	-0.43	1.29e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.59	-10.89	-0.51	8.5e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.84	-12.98	-0.58	2.21e-31	Blood metabolite levels;
CRC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.37	6.35	0.33	7.24e-10	Blood metabolite levels;
CRC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.44	-7.62	-0.39	2.72e-13	Height;
CRC	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg00531865	chr16:30841666	NA	0.49	6.86	0.35	3.47e-11	Dementia with Lewy bodies;
CRC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg27532560	chr4:187881888	NA	-0.56	-10.24	-0.49	1.48e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg10263370	chr3:44754102	ZNF502	-0.36	-6.08	-0.32	3.31e-9	Depressive symptoms;
CRC	cis	rs6973256	0.637	rs12707116	chr7:133424909	C/T	cg10665199	chr7:133106180	EXOC4	-0.43	-6.73	-0.35	7.75e-11	Intelligence (multi-trait analysis);
CRC	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.91	16.62	0.68	1.87e-45	Obesity (extreme);
CRC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-5.85	-0.31	1.22e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg04439458	chr5:138467593	SIL1	-0.31	-5.62	-0.3	4.16e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4731207	0.698	rs4731214	chr7:124442905	A/G	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg24562669	chr7:97807699	LMTK2	-0.41	-6.87	-0.35	3.13e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.45	5.79	0.3	1.63e-8	Aortic root size;
CRC	cis	rs9908102	0.740	rs58985615	chr17:12909988	C/A	cg26162695	chr17:12921313	ELAC2	0.43	5.81	0.31	1.48e-8	Schizophrenia;
CRC	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg02466173	chr16:30829666	NA	-0.55	-7.77	-0.39	1.03e-13	Triglycerides;
CRC	cis	rs1539053	0.966	rs11207081	chr1:58101851	A/C	cg20292791	chr1:58089357	DAB1	-0.32	-5.64	-0.3	3.7e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CRC	cis	rs4400599	0.805	rs12063830	chr1:154150911	A/G	cg05139571	chr1:154127138	NUP210L	0.42	6.27	0.33	1.12e-9	Platelet distribution width;
CRC	cis	rs7605827	0.930	rs13001923	chr2:15521264	A/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg13844804	chr7:814759	HEATR2	0.64	8.34	0.42	2.09e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg20203395	chr5:56204925	C5orf35	0.52	7.3	0.37	2.15e-12	Initial pursuit acceleration;
CRC	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.75	-0.43	1.1e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.67	7.75	0.39	1.16e-13	Eosinophil percentage of granulocytes;
CRC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04733989	chr22:42467013	NAGA	0.42	5.92	0.31	8.12e-9	Cognitive function;
CRC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg00531865	chr16:30841666	NA	-0.45	-6.13	-0.32	2.58e-9	Multiple myeloma;
CRC	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg23234261	chr14:55582407	NA	-0.3	-5.91	-0.31	8.58e-9	Protein biomarker;
CRC	cis	rs62408225	1.000	rs62408225	chr6:90956409	A/G	cg06866423	chr6:90926672	BACH2	0.5	8.24	0.41	4.14e-15	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15073462	chr3:172469117	NA	0.4	6.02	0.31	4.6e-9	Myopia (pathological);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10836402	chr12:31226622	DDX11	0.55	7.3	0.37	2.21e-12	Thyroid stimulating hormone;
CRC	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg02927042	chr1:21476669	EIF4G3	0.42	6.52	0.34	2.7e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-10.25	-0.49	1.42e-21	Monocyte count;
CRC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.79	13.42	0.59	4.56e-33	Menopause (age at onset);
CRC	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.75	0.3	2.08e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg20469991	chr17:27169893	C17orf63	0.47	5.91	0.31	8.55e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.89	-11.31	-0.53	2.94e-25	Hair shape;
CRC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.31	0.71	3.77e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.43	-0.33	4.61e-10	Coronary artery disease;
CRC	cis	rs478222	1.000	rs551573	chr2:25305504	A/G	cg22495460	chr2:25135724	ADCY3	-0.4	-6.07	-0.32	3.44e-9	Type 1 diabetes;
CRC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.43	6.4	0.33	5.38e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.37	-0.33	6.42e-10	Menopause (age at onset);
CRC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	4.04e-9	Total body bone mineral density;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg02416716	chr11:6948024	ZNF215	0.57	5.86	0.31	1.14e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-10.89	-0.51	8.4e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.62	6.98	0.36	1.63e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg17321639	chr7:2759063	NA	-0.5	-6.81	-0.35	4.69e-11	Height;
CRC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	15.05	0.64	2.59e-39	Multiple sclerosis;
CRC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.7	-0.39	1.5700000000000001e-13	Arsenic metabolism;
CRC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.91	-17.22	-0.69	8.15e-48	Coronary artery disease;
CRC	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg15654264	chr1:150340011	RPRD2	0.42	6.28	0.33	1.1e-9	Migraine;
CRC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.76	10.66	0.51	5.33e-23	Heart rate;
CRC	trans	rs12797204	0.793	rs12792825	chr11:83454878	G/A	cg07421806	chr5:128301136	SLC27A6	-0.6	-5.98	-0.31	5.66e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CRC	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg19508488	chr2:152266495	RIF1	-0.44	-6.39	-0.33	5.71e-10	Lung cancer;
CRC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-9.79	-0.47	5.17e-20	Monocyte percentage of white cells;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.66	-9.67	-0.47	1.29e-19	Menopause (age at onset);
CRC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.49	6.69	0.35	9.67e-11	Schizophrenia;
CRC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.55	0.47	3.04e-19	Cognitive test performance;
CRC	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.72	-13.16	-0.59	4.56e-32	Leprosy;
CRC	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg24463073	chr6:118973353	C6orf204	0.52	6.83	0.35	4.24e-11	Renal cell carcinoma;
CRC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.82	13.73	0.6	3.15e-34	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg15845792	chr6:28175446	NA	0.97	13.08	0.58	8.89e-32	Depression;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11061033	chr14:23375497	RBM23	0.44	6.3	0.33	9.57e-10	Survival in pancreatic cancer;
CRC	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06307176	chr5:131281290	NA	0.41	6.15	0.32	2.22e-9	Life satisfaction;
CRC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg05072774	chr3:49840536	C3orf54	-0.43	-5.65	-0.3	3.4e-8	Resting heart rate;
CRC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg21153622	chr11:89784906	NA	-0.43	-7.07	-0.36	9.14e-12	Height;
CRC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	16.75	0.68	5.87e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg18479299	chr3:125709523	NA	-0.52	-6.17	-0.32	2.03e-9	Blood pressure (smoking interaction);
CRC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.82	14.45	0.62	5.4e-37	Breast cancer;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg21856205	chr7:94953877	PON1	-0.49	-6.43	-0.33	4.48e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg00280220	chr17:61926910	NA	0.35	5.77	0.3	1.86e-8	Prudent dietary pattern;
CRC	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.91	-11.96	-0.55	1.24e-27	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.24	-14.6	-0.63	1.48e-37	Gout;
CRC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.52	7.65	0.39	2.24e-13	Blood protein levels;
CRC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.58	6.25	0.33	1.29e-9	Initial pursuit acceleration;
CRC	cis	rs6961069	0.777	rs4545029	chr7:80252518	T/G	cg04458919	chr7:80252533	CD36	0.35	6.27	0.33	1.11e-9	Platelet count;
CRC	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.85	-14.94	-0.64	6.89e-39	Lewy body disease;
CRC	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg23127183	chr11:57508653	C11orf31	-0.5	-6.48	-0.34	3.33e-10	Schizophrenia;
CRC	cis	rs12889267	0.770	rs66995536	chr14:21564859	G/A	cg02988727	chr14:21567520	ZNF219;C14orf176	0.46	6.93	0.36	2.24e-11	Hematocrit;Resting heart rate;
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	0.86	7.76	0.39	1.08e-13	IgG glycosylation;
CRC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.58	8.97	0.44	2.28e-17	Blood metabolite levels;
CRC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.73	-11.86	-0.55	3.06e-27	Blood protein levels;
CRC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.29	0.46	2.24e-18	Lung cancer;
CRC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg18876405	chr7:65276391	NA	0.47	6.47	0.34	3.55e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20798677	chr17:39968547	FKBP10;SC65	0.39	6.5	0.34	2.94e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2000999	0.514	rs12928056	chr16:72225574	C/A	cg04254540	chr16:71951199	KIAA0174	-0.74	-6.16	-0.32	2.15e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.59	-9.47	-0.46	5.74e-19	Waist circumference adjusted for body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15032444	chr6:43027766	KLC4;MRPL2	0.42	6.19	0.32	1.75e-9	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09504352	chr12:58146286	CDK4	0.52	7.37	0.38	1.38e-12	Response to antipsychotic treatment;
CRC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg23262073	chr20:60523788	NA	-0.48	-7.62	-0.39	2.72e-13	Body mass index;
CRC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.47	7.41	0.38	1.06e-12	Monobrow;
CRC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-19.34	-0.73	3.25e-56	Hemostatic factors and hematological phenotypes;
CRC	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	7.58	0.39	3.58e-13	Diisocyanate-induced asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25951811	chr14:96858416	AK7	0.39	6.64	0.34	1.29e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.64	-9.76	-0.47	6.1e-20	Diastolic blood pressure;
CRC	cis	rs3772130	0.540	rs7627354	chr3:121562434	A/C	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.44	-6.59	-0.34	1.7e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg25452165	chr22:42524984	CYP2D6	-0.41	-6.12	-0.32	2.63e-9	Schizophrenia;
CRC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-12.66	-0.57	3.42e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg03395651	chr16:88107091	BANP	0.59	8.02	0.4	1.84e-14	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17708938	chr17:73937173	FBF1	0.45	5.99	0.31	5.59e-9	Anxiety disorder;
CRC	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg06156847	chr2:113672199	IL1F7	-0.39	-5.83	-0.31	1.3e-8	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.47	6.26	0.33	1.18e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.54	-8.75	-0.43	1.15e-16	Coronary artery disease;
CRC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg09127314	chr1:152161683	NA	-0.49	-6.27	-0.33	1.15e-9	Atopic dermatitis;
CRC	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg26384229	chr12:38710491	ALG10B	0.46	6.39	0.33	5.55e-10	Morning vs. evening chronotype;
CRC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.87	0.35	3.28e-11	Body mass index;
CRC	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.64	10.08	0.49	5.4e-21	Corneal astigmatism;
CRC	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg20356878	chr3:121714668	ILDR1	-0.47	-6.77	-0.35	6.03e-11	Multiple sclerosis;
CRC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg13777783	chr17:79615861	NA	0.3	5.66	0.3	3.26e-8	Eye color traits;
CRC	cis	rs3751196	0.901	rs77013044	chr12:104197143	G/A	cg02344784	chr12:104178138	NT5DC3	0.69	7.0	0.36	1.45e-11	Sense of smell;
CRC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.38	-0.38	1.33e-12	Major depressive disorder;
CRC	cis	rs7616330	0.887	rs2100142	chr3:71112560	A/G	cg01511742	chr3:71112437	FOXP1	-0.49	-5.66	-0.3	3.27e-8	QT interval;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24082826	chr12:26985738	ITPR2	0.47	6.86	0.35	3.36e-11	Response to antipsychotic treatment;
CRC	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.57	-0.43	4.09e-16	Biliary atresia;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.67	-9.62	-0.47	1.83e-19	Menopause (age at onset);
CRC	cis	rs72730918	0.564	rs12441057	chr15:51896769	A/G	cg14296394	chr15:51910925	DMXL2	-0.44	-5.79	-0.3	1.68e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.61	-9.2	-0.45	4.25e-18	Inhibitory control;
CRC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09874177	chr12:77272943	CSRP2	0.43	5.98	0.31	5.92e-9	Response to antipsychotic treatment;
CRC	cis	rs8037137	0.915	rs77554484	chr15:91509215	C/A	cg23684204	chr15:91497937	RCCD1	0.54	5.69	0.3	2.75e-8	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CRC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.85	0.31	1.19e-8	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02567788	chr10:71992279	PPA1	0.48	6.8	0.35	4.82e-11	Response to antipsychotic treatment;
CRC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-0.85	-11.78	-0.54	5.62e-27	Intelligence (multi-trait analysis);
CRC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.77	-13.16	-0.59	4.62e-32	Ulcerative colitis;
CRC	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.49	-9.81	-0.48	4.42e-20	Alcoholic chronic pancreatitis;
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-8.08	-0.41	1.25e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg16260113	chr12:107380972	MTERFD3	-0.4	-5.67	-0.3	3.11e-8	Total body bone mineral density;
CRC	cis	rs6973256	0.605	rs12707114	chr7:133345207	C/G	cg10665199	chr7:133106180	EXOC4	0.48	7.62	0.39	2.66e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.58	-9.09	-0.45	9.7e-18	Myeloid white cell count;
CRC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.04	9.66	0.47	1.39e-19	Alzheimer's disease (late onset);
CRC	cis	rs11031096	0.516	rs7113845	chr11:3989226	C/G	cg18678763	chr11:4115507	RRM1	-0.38	-6.52	-0.34	2.64e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.62	8.98	0.44	2.2e-17	Mean corpuscular hemoglobin;
CRC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.25e-19	Tonsillectomy;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25621096	chr1:151032116	CDC42SE1;MLLT11	0.36	6.24	0.33	1.37e-9	Interleukin-6 levels;
CRC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg07074390	chr21:40555500	PSMG1	-0.46	-6.2	-0.32	1.7e-9	Cognitive function;
CRC	cis	rs854555	0.581	rs854537	chr7:94910248	C/T	cg04155289	chr7:94953770	PON1	-0.47	-6.21	-0.32	1.61e-9	Response to TNF antagonist treatment;
CRC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.47	-0.53	7.84e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.73	-0.51	3.22e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.67	-7.56	-0.38	4.06e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg10820045	chr2:198174542	NA	0.45	7.89	0.4	4.58e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg23815491	chr16:72088622	HP	-0.51	-7.67	-0.39	1.93e-13	Fibrinogen levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24520871	chr10:73074265	NA	0.5	6.71	0.35	8.7e-11	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.51	6.44	0.33	4.17e-10	Recombination rate (females);
CRC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.54	8.64	0.43	2.4e-16	Coronary artery disease;
CRC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-10.12	-0.49	4.02e-21	Height;
CRC	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.84	-0.61	1.22e-34	Ulcerative colitis;
CRC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.37	0.33	6.35e-10	Height;
CRC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.55	8.67	0.43	2e-16	Gestational age at birth (maternal effect);
CRC	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg16476235	chr8:21771668	DOK2	0.41	6.88	0.35	3.06e-11	Mean corpuscular volume;
CRC	cis	rs12024301	0.557	rs12023865	chr1:183634210	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4604732	0.603	rs10925051	chr1:247641834	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.39	6.45	0.33	4.06e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-12.26	-0.56	1.01e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs2084637	0.965	rs34614177	chr11:122411191	G/A	cg21585512	chr11:122030076	LOC399959	-0.38	-6.73	-0.35	7.6e-11	Stroke;
CRC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	16.99	0.68	6.49e-47	Lymphocyte percentage of white cells;
CRC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.52	8.08	0.41	1.28e-14	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg16576597	chr16:28551801	NUPR1	0.44	6.75	0.35	6.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-8.65	-0.43	2.35e-16	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4664293	0.625	rs2114625	chr2:160543808	C/T	cg08347373	chr2:160653686	CD302	-0.39	-6.48	-0.34	3.29e-10	Monocyte percentage of white cells;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg18185028	chr3:154042079	DHX36	0.34	5.99	0.31	5.49e-9	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04116858	chr1:159895664	TAGLN2	0.42	6.02	0.31	4.57e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00495681	chr13:53174319	NA	0.63	9.45	0.46	6.4e-19	Lewy body disease;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-8.5	-0.42	6.62e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg19694781	chr19:47549865	TMEM160	0.43	6.49	0.34	3.22e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.7	-10.69	-0.51	4.41e-23	Type 2 diabetes;
CRC	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg00732059	chr16:71740210	PHLPP2	-0.67	-6.89	-0.36	2.77e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg00105475	chr2:10696890	NA	0.45	7.26	0.37	2.75e-12	Prostate cancer;
CRC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.46	6.19	0.32	1.81e-9	Aortic root size;
CRC	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	0.95	9.0	0.44	1.83e-17	Blood protein levels;
CRC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.46	6.01	0.31	4.96e-9	Heart rate;
CRC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.36	-7.19	-0.37	4.32e-12	Lung cancer;
CRC	cis	rs12980942	0.591	rs3760660	chr19:41769025	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.45	0.34	3.93e-10	Coronary artery disease;
CRC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-8.36	-0.42	1.83e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.55	8.37	0.42	1.68e-15	HDL cholesterol;
CRC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.82	9.2	0.45	4.12e-18	Breast cancer;
CRC	cis	rs3812111	0.524	rs12193094	chr6:116540395	C/T	cg26893134	chr6:116381904	FRK	0.24	5.82	0.31	1.39e-8	Age-related macular degeneration;
CRC	cis	rs501120	0.584	rs11238906	chr10:44685925	T/C	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	1.02	20.45	0.75	1.42e-60	Headache;
CRC	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg26875233	chr11:93583750	C11orf90	-0.32	-6.27	-0.33	1.15e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg01874867	chr7:94954059	PON1	-0.51	-6.39	-0.33	5.66e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.41	-7.87	-0.4	5.09e-14	Subjective well-being;
CRC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.46	-5.84	-0.31	1.28e-8	Aortic root size;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.29	-0.37	2.32e-12	Lymphocyte counts;
CRC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.6	7.98	0.4	2.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg07713946	chr22:31675144	LIMK2	0.41	5.93	0.31	7.84e-9	Colorectal cancer;
CRC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.3	0.53	3.15e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg27094323	chr7:1216898	NA	-0.38	-6.28	-0.33	1.04e-9	Longevity;Endometriosis;
CRC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg16070123	chr10:51489643	NA	-0.34	-5.85	-0.31	1.2e-8	Prostate-specific antigen levels;
CRC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.57	8.35	0.42	1.87e-15	Response to temozolomide;
CRC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.51	-7.55	-0.38	4.4e-13	Sudden cardiac arrest;
CRC	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.56	6.71	0.35	8.78e-11	Carotid intima media thickness;
CRC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg18404041	chr3:52824283	ITIH1	-0.34	-6.06	-0.32	3.77e-9	Schizophrenia;
CRC	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.65	7.02	0.36	1.29e-11	Prostate cancer;
CRC	cis	rs9903692	0.954	rs7209730	chr17:46207499	C/T	cg21215337	chr17:46176117	CBX1	-0.42	-7.7	-0.39	1.6e-13	Pulse pressure;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg06210969	chr3:120067732	LRRC58	-0.52	-6.62	-0.34	1.44e-10	Parkinson's disease;
CRC	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg23254163	chr1:152506842	NA	0.45	8.87	0.44	4.86e-17	Hair morphology;
CRC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.76	14.25	0.62	3.18e-36	Prudent dietary pattern;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg06470822	chr6:28175283	NA	0.79	10.17	0.49	2.72e-21	Parkinson's disease;
CRC	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1.07e-22	Iron status biomarkers;
CRC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg02033258	chr5:131593261	PDLIM4	-0.33	-6.01	-0.31	4.96e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg21918786	chr6:109611834	NA	-0.35	-5.94	-0.31	7.17e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.37	-6.13	-0.32	2.46e-9	Diastolic blood pressure;
CRC	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.64	-8.37	-0.42	1.7e-15	Extraversion;
CRC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.18	0.32	1.89e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-6.19	-0.32	1.76e-9	Total body bone mineral density;
CRC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.54	-7.97	-0.4	2.6e-14	Myeloid white cell count;
CRC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.81	-0.55	4.64e-27	Type 2 diabetes;
CRC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.61e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.57	-0.34	1.94e-10	Major depressive disorder;
CRC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg12463550	chr7:65579703	CRCP	-0.63	-5.81	-0.3	1.51e-8	Diabetic kidney disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03760316	chr18:3594197	DLGAP1;FLJ35776	0.45	6.54	0.34	2.34e-10	Response to antipsychotic treatment;
CRC	cis	rs3731896	0.653	rs1567931	chr2:220199067	A/G	cg00436969	chr2:220197716	RESP18	-0.46	-5.82	-0.31	1.37e-8	Educational attainment;
CRC	cis	rs4908768	0.501	rs6702060	chr1:8607024	G/A	cg20416874	chr1:8611966	RERE	-0.46	-6.66	-0.34	1.12e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs2859741	0.546	rs3934329	chr1:37504523	C/T	cg09363841	chr1:37513479	NA	-0.45	-6.98	-0.36	1.68e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.03	-0.32	4.51e-9	Depression;
CRC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg00343986	chr7:65444356	GUSB	0.42	5.98	0.31	5.95e-9	Aortic root size;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07148139	chr13:52585813	ALG11;ATP7B	-0.45	-6.46	-0.34	3.75e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-5.69	-0.3	2.77e-8	Axial length;
CRC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.58	-5.71	-0.3	2.55e-8	Plasma clusterin levels;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg24497877	chr1:1244060	PUSL1;ACAP3	-0.4	-6.16	-0.32	2.08e-9	Aortic root size;
CRC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.12	-0.32	2.64e-9	Obesity-related traits;
CRC	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.49	-7.9	-0.4	4.31e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs17767392	0.813	rs7152842	chr14:71849740	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.44	-5.79	-0.3	1.67e-8	Mitral valve prolapse;
CRC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7945718	0.621	rs4514397	chr11:12689768	G/T	cg25843174	chr11:12811716	TEAD1	0.39	7.17	0.37	5.06e-12	Educational attainment (years of education);
CRC	cis	rs1511802	0.666	rs4862663	chr4:187119228	T/A	cg24794857	chr4:187113578	CYP4V2	0.42	6.03	0.32	4.51e-9	Blood protein levels;
CRC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.79	-10.83	-0.51	1.4e-23	Red blood cell traits;
CRC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.74	10.19	0.49	2.22e-21	Coronary artery disease;
CRC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-5.97	-0.31	6.28e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.5	7.98	0.4	2.54e-14	Crohn's disease;
CRC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.51	-7.78	-0.39	9.38e-14	Corneal astigmatism;
CRC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.65	7.41	0.38	1.09e-12	Gut microbiome composition (summer);
CRC	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg09654669	chr8:57350985	NA	-0.38	-5.63	-0.3	3.97e-8	Obesity-related traits;
CRC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.4	-7.93	-0.4	3.39e-14	Schizophrenia;
CRC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg01941586	chr1:40203715	PPIE	-0.44	-6.08	-0.32	3.28e-9	Blood protein levels;
CRC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.51	7.3	0.37	2.19e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg07617317	chr6:118971624	C6orf204	-0.35	-5.72	-0.3	2.44e-8	Electrocardiographic conduction measures;
CRC	cis	rs6534441	0.727	rs77517452	chr4:125457244	G/A	cg21609808	chr4:125404261	NA	0.41	5.8	0.3	1.59e-8	Major depressive disorder;
CRC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg09876464	chr15:85330779	ZNF592	0.43	7.14	0.37	5.89e-12	P wave terminal force;
CRC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23378565	chr7:2036160	MAD1L1	-0.44	-6.28	-0.33	1.06e-9	Bipolar disorder;
CRC	cis	rs35000415	0.873	rs12539741	chr7:128596805	C/T	cg19972273	chr7:128594194	NA	0.66	5.99	0.31	5.62e-9	Systemic lupus erythematosus;
CRC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-8.45	-0.42	9.72e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-6.09	-0.32	3.16e-9	Cognitive function;
CRC	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.17	0.32	2.04e-9	Breast cancer;
CRC	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg21972741	chr5:435613	AHRR	0.5	6.66	0.34	1.15e-10	Cystic fibrosis severity;
CRC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.49	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.85	-0.35	3.61e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.98	12.38	0.56	3.74e-29	Eosinophil percentage of granulocytes;
CRC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.39	-6.81	-0.35	4.62e-11	Childhood ear infection;
CRC	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-8.29	-0.42	2.88e-15	Bipolar disorder;
CRC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.96	0.31	6.35e-9	Tonsillectomy;
CRC	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.57	-6.64	-0.34	1.28e-10	Cancer;
CRC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.92	-0.36	2.35e-11	QT interval;
CRC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.62	0.43	2.95e-16	Menopause (age at onset);
CRC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-8.11	-0.41	1.01e-14	Schizophrenia;
CRC	cis	rs6662572	0.686	rs72690855	chr1:46266210	G/C	cg08644498	chr1:46502608	NA	0.44	6.64	0.34	1.28e-10	Blood protein levels;
CRC	cis	rs2735413	0.875	rs8055298	chr16:78084868	C/G	cg04733911	chr16:78082701	NA	0.45	7.42	0.38	1.02e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.59	8.9	0.44	3.71e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	trans	rs1572438	0.662	rs11753072	chr6:866963	G/A	cg01563465	chr5:72512441	NA	0.31	6.07	0.32	3.62e-9	Aging;
CRC	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.34	5.88	0.31	1.01e-8	Mean corpuscular hemoglobin concentration;
CRC	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.83	-10.54	-0.5	1.47e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg09264619	chr17:80180166	NA	-0.36	-6.02	-0.32	4.61e-9	Life satisfaction;
CRC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	16.95	0.68	9.34e-47	Platelet count;
CRC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg13798780	chr7:105162888	PUS7	0.64	7.31	0.37	2.09e-12	Bipolar disorder (body mass index interaction);
CRC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg24562669	chr7:97807699	LMTK2	0.42	7.01	0.36	1.39e-11	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21892522	chr3:10052995	LOC401052	0.34	6.27	0.33	1.14e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg24324837	chr19:49891574	CCDC155	0.54	7.1	0.36	7.82e-12	Multiple sclerosis;
CRC	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg16358738	chr2:241808595	AGXT	-0.41	-7.26	-0.37	2.76e-12	Urinary metabolites;
CRC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.04	0.45	1.42e-17	Resting heart rate;
CRC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	8.17	0.41	6.83e-15	Menarche (age at onset);
CRC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	13.71	0.6	3.61e-34	Menopause (age at onset);
CRC	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.64	10.08	0.49	5.22e-21	Corneal astigmatism;
CRC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Red blood cell count;
CRC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.39	6.12	0.32	2.7e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.68	0.35	9.96e-11	Bladder cancer;
CRC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-0.95	-11.38	-0.53	1.64e-25	Hip circumference adjusted for BMI;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04603834	chr13:50571387	TRIM13;DLEU2	0.47	6.04	0.32	4.15e-9	Anxiety disorder;
CRC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.74	-11.45	-0.53	8.62e-26	Blood trace element (Zn levels);
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26483432	chr1:149815043	HIST2H2AA3;HIST2H2AA4	0.48	6.48	0.34	3.29e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6445525	1.000	rs4417899	chr3:65996110	T/C	cg06109867	chr3:66002991	MAGI1	-0.39	-6.41	-0.33	5e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	7.73	0.39	1.36e-13	Endometrial cancer;
CRC	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.91	-0.31	8.33e-9	Gout;Renal underexcretion gout;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.64	9.6	0.47	2.07e-19	Lymphocyte counts;
CRC	trans	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09695851	chr17:3907499	NA	-0.45	-6.57	-0.34	1.97e-10	Type 2 diabetes;
CRC	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	9.48	0.46	5.36e-19	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs720844	0.832	rs764386	chr2:149285506	G/A	cg09247360	chr2:149335327	NA	-0.5	-6.02	-0.31	4.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.58	10.15	0.49	3.16e-21	Body mass index;
CRC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.71	10.54	0.5	1.38e-22	Menopause (age at onset);
CRC	trans	rs34476593	0.943	rs7637968	chr3:23904969	C/T	cg09448314	chr17:73496215	KIAA0195	-0.48	-6.08	-0.32	3.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs25422	0.540	rs9481842	chr6:118974798	A/C	cg22561889	chr6:118971681	C6orf204	0.39	5.63	0.3	3.95e-8	Renal cell carcinoma;
CRC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06544989	chr22:39130855	UNC84B	0.41	6.1	0.32	3.03e-9	Menopause (age at onset);
CRC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	7.47	0.38	7.48e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-8.05	-0.41	1.52e-14	Urinary metabolites;
CRC	cis	rs9583531	0.891	rs3742182	chr13:111375132	C/T	cg24331049	chr13:111365604	ING1	0.52	5.82	0.31	1.38e-8	Coronary artery disease;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs6743226	0.901	rs12478458	chr2:242237856	A/G	cg10021735	chr2:242295487	FARP2	0.46	6.57	0.34	1.92e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs73206853	0.841	rs3026486	chr12:110782532	C/T	cg12870014	chr12:110450643	ANKRD13A	0.8	7.71	0.39	1.55e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg00129232	chr17:37814104	STARD3	-0.39	-6.14	-0.32	2.4e-9	Self-reported allergy;
CRC	cis	rs17713451	0.593	rs76331945	chr7:151269055	C/T	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	trans	rs11225569	0.539	rs9787739	chr11:103333744	C/T	cg01615333	chr12:127765195	NA	-0.64	-6.03	-0.32	4.37e-9	Diisocyanate-induced asthma;
CRC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg06970220	chr1:156163860	SLC25A44	0.47	6.62	0.34	1.47e-10	Testicular germ cell tumor;
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg25193742	chr10:104614220	C10orf32	-0.76	-6.42	-0.33	4.8e-10	Cognitive function;
CRC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.76	-11.27	-0.53	3.93e-25	Refractive error;
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg23161317	chr6:28129485	ZNF389	0.46	6.51	0.34	2.86e-10	Cardiac Troponin-T levels;
CRC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.69	-8.56	-0.43	4.41e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.43	-9.48	-0.46	5.3e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08412305	chr1:167904990	DCAF6;BRP44	0.43	6.25	0.33	1.28e-9	Intelligence (multi-trait analysis);
CRC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.88	-17.0	-0.68	5.71e-47	Body mass index;
CRC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.64	-13.83	-0.61	1.34e-34	Schizophrenia;
CRC	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.42	6.82	0.35	4.42e-11	Sitting height ratio;
CRC	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	9.09	0.45	9.43e-18	Type 2 diabetes;
CRC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg16989086	chr20:62203971	PRIC285	0.51	6.54	0.34	2.41e-10	Glioblastoma;
CRC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg24308560	chr3:49941425	MST1R	-0.43	-6.2	-0.32	1.68e-9	Resting heart rate;
CRC	cis	rs2013441	0.932	rs2526488	chr17:20098617	T/A	cg13482628	chr17:19912719	NA	-0.41	-6.24	-0.33	1.33e-9	Obesity-related traits;
CRC	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg27534772	chr1:16042836	PLEKHM2	0.42	6.95	0.36	2.02e-11	Systolic blood pressure;
CRC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.09	-0.45	9.8e-18	Hip circumference adjusted for BMI;
CRC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.59	9.11	0.45	8.17e-18	Bipolar disorder;
CRC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	9.33	0.46	1.59e-18	Platelet count;
CRC	trans	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg24644049	chr4:85504048	CDS1	0.86	6.93	0.36	2.29e-11	Skin colour saturation;
CRC	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.75	0.54	7.28e-27	Exhaled nitric oxide levels;
CRC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.43	-6.0	-0.31	5.07e-9	Fibrinogen levels;
CRC	cis	rs1524976	1.000	rs11707527	chr3:65450416	G/A	cg16238336	chr3:65465873	MAGI1	-0.5	-6.91	-0.36	2.54e-11	PR interval;
CRC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg15786705	chr6:28176104	NA	0.7	5.88	0.31	1e-8	Depression;
CRC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg02683197	chr6:28174875	NA	0.85	10.5	0.5	1.96e-22	Depression;
CRC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.02	-21.94	-0.77	2.28e-66	Myeloid white cell count;
CRC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.39	6.59	0.34	1.73e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.92	9.34	0.46	1.45e-18	Platelet distribution width;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg04562611	chr16:615315	C16orf11	0.38	6.49	0.34	3.21e-10	Height;
CRC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.6	9.25	0.45	2.86e-18	Aortic root size;
CRC	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.39	-6.35	-0.33	7.21e-10	Resting heart rate;
CRC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.67	9.8	0.48	4.6e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.61	-6.32	-0.33	8.56e-10	Schizophrenia;
CRC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg02683197	chr6:28174875	NA	-0.84	-10.93	-0.52	6.1e-24	Depression;
CRC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.61	11.09	0.52	1.69e-24	Coronary artery disease;
CRC	cis	rs61996546	0.595	rs12901348	chr15:26869266	T/A	cg15066197	chr15:26874202	GABRB3	-0.39	-6.02	-0.32	4.59e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	trans	rs12517041	1.000	rs10805750	chr5:23300753	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-5.96	-0.31	6.46e-9	Calcium levels;
CRC	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.74	-10.15	-0.49	3.08e-21	Systemic lupus erythematosus;
CRC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg15309053	chr8:964076	NA	0.4	7.37	0.38	1.39e-12	Schizophrenia;
CRC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg19337854	chr7:99768885	GPC2	0.48	6.42	0.33	4.73e-10	Lung function (FEV1/FVC);
CRC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.6	8.32	0.42	2.32e-15	Arsenic metabolism;
CRC	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.65	-9.45	-0.46	6.48e-19	Intelligence (multi-trait analysis);
CRC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.52	-7.11	-0.37	7.1e-12	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs12286929	0.702	rs11215419	chr11:115081810	A/T	cg04055981	chr11:115044050	NA	0.39	6.1	0.32	2.93e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22416253	chr18:21977947	OSBPL1A	0.39	6.1	0.32	2.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.39	-6.03	-0.32	4.4e-9	Ulcerative colitis;
CRC	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg20487152	chr13:99095054	FARP1	0.36	5.88	0.31	1e-8	Longevity;
CRC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.58	-9.18	-0.45	5.09e-18	Intelligence (multi-trait analysis);
CRC	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	0.59	6.7	0.35	8.93e-11	Coronary artery disease;
CRC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.47	6.09	0.32	3.21e-9	IgG glycosylation;
CRC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.58	8.47	0.42	8.37e-16	Melanoma;
CRC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.24	-0.45	3.14e-18	Platelet count;
CRC	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg00277334	chr10:82204260	NA	0.37	5.91	0.31	8.4e-9	Sarcoidosis;
CRC	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.34	7.04	0.36	1.1e-11	Migraine;
CRC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg14604444	chr12:130766091	NA	-0.39	-6.03	-0.32	4.44e-9	Menopause (age at onset);
CRC	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.49	-9.28	-0.46	2.32e-18	Reticulocyte fraction of red cells;
CRC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00396991	chr1:161494029	HSPA6	0.43	6.55	0.34	2.16e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.57	9.6	0.47	2.08e-19	Menopause (age at onset);
CRC	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg04990556	chr1:26633338	UBXN11	-0.47	-5.77	-0.3	1.8e-8	Obesity-related traits;
CRC	trans	rs11814448	1.000	rs12248406	chr10:22319508	A/G	cg08492145	chr7:157648386	PTPRN2	0.64	6.31	0.33	8.85e-10	Breast cancer;
CRC	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg13206674	chr6:150067644	NUP43	0.47	6.25	0.33	1.29e-9	Testicular germ cell tumor;
CRC	cis	rs3731896	0.653	rs58269809	chr2:220196013	T/C	cg00436969	chr2:220197716	RESP18	-0.45	-5.72	-0.3	2.43e-8	Educational attainment;
CRC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.13	0.59	5.79e-32	Chronic sinus infection;
CRC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg09264619	chr17:80180166	NA	-0.34	-5.74	-0.3	2.12e-8	Life satisfaction;
CRC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.09	-0.32	3.14e-9	Gout;Renal underexcretion gout;
CRC	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.93	-0.58	3.26e-31	Brugada syndrome;
CRC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.39	-0.33	5.58e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.44	-7.51	-0.38	5.73e-13	Breast cancer;
CRC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.54	7.6	0.39	3.11e-13	Monobrow;
CRC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21972741	chr5:435613	AHRR	0.54	7.42	0.38	1.04e-12	Cystic fibrosis severity;
CRC	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg04837898	chr3:45731254	SACM1L	-0.34	-5.67	-0.3	3.08e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg02811702	chr13:24901961	NA	-0.46	-6.48	-0.34	3.42e-10	Obesity-related traits;
CRC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.71	11.27	0.53	4.09e-25	Intelligence (multi-trait analysis);
CRC	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg20312557	chr2:97357134	FER1L5	-0.61	-5.72	-0.3	2.41e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.44	-9.03	-0.45	1.53e-17	Blood protein levels;
CRC	cis	rs11630290	1.000	rs72750987	chr15:63999112	G/C	cg12036633	chr15:63758958	NA	-0.56	-5.81	-0.3	1.51e-8	Iris characteristics;
CRC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg23229984	chr5:148520753	ABLIM3	0.54	7.24	0.37	3.29e-12	Breast cancer;
CRC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.19	-0.32	1.77e-9	Bipolar disorder;
CRC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.23	0.37	3.48e-12	Parkinson's disease;
CRC	cis	rs8028182	0.609	rs10220738	chr15:75666546	A/T	cg20655648	chr15:75932815	IMP3	-0.42	-6.36	-0.33	6.59e-10	Sudden cardiac arrest;
CRC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.6	6.97	0.36	1.7e-11	Vitiligo;
CRC	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.34	1.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.95	-0.4	3.07e-14	Total body bone mineral density;
CRC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.48	6.77	0.35	5.84e-11	Height;
CRC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.53	-7.94	-0.4	3.23e-14	Acylcarnitine levels;
CRC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.75	-0.3	2.04e-8	Cognitive function;
CRC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.27	-15.03	-0.64	3.14e-39	Diabetic kidney disease;
CRC	cis	rs7072216	0.881	rs755126	chr10:100148951	G/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.2	-0.32	1.72e-9	Metabolite levels;
CRC	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg09873164	chr1:152488093	CRCT1	0.39	6.36	0.33	6.83e-10	Hair morphology;
CRC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.41	6.57	0.34	1.92e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs427941	0.694	rs2529094	chr7:101739617	C/T	cg06246474	chr7:101738831	CUX1	0.46	7.23	0.37	3.35e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.15	-0.32	2.24e-9	Total cholesterol levels;
CRC	cis	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg15786705	chr6:28176104	NA	0.59	6.05	0.32	3.84e-9	Depression;
CRC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg14979609	chr8:8086686	FLJ10661	0.37	5.86	0.31	1.13e-8	Mood instability;
CRC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg18375707	chr11:64034959	PLCB3	0.48	6.0	0.31	5.28e-9	Mean platelet volume;
CRC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.45	-8.95	-0.44	2.67e-17	Renal cell carcinoma;
CRC	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg00250761	chr1:31883323	NA	-0.37	-7.25	-0.37	2.96e-12	Alcohol dependence;
CRC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.37	-6.2	-0.32	1.73e-9	Breast cancer;
CRC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.3	3.81e-8	Hemoglobin concentration;
CRC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.14	-11.87	-0.55	2.78e-27	Breast cancer;
CRC	cis	rs10046574	0.831	rs10251162	chr7:135190264	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.73	-11.71	-0.54	1.03e-26	Plateletcrit;Platelet count;
CRC	cis	rs12928939	0.954	rs34998650	chr16:71829329	T/C	cg08717414	chr16:71523259	ZNF19	-0.5	-6.19	-0.32	1.75e-9	Post bronchodilator FEV1;
CRC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.02	0.36	1.27e-11	Morning vs. evening chronotype;
CRC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.98	-0.31	5.88e-9	Gout;Renal underexcretion gout;
CRC	cis	rs9826463	0.702	rs73228758	chr3:142320559	A/G	cg20824294	chr3:142316082	PLS1	0.42	6.84	0.35	3.86e-11	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg07701084	chr6:150067640	NUP43	0.44	6.26	0.33	1.18e-9	Lung cancer;
CRC	cis	rs2882667	0.619	rs6861556	chr5:138188040	C/T	cg09476006	chr5:138032270	NA	-0.55	-9.29	-0.46	2.24e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg05967129	chr7:127544716	SND1	-0.49	-6.01	-0.31	4.91e-9	Diisocyanate-induced asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14274609	chr10:123687846	ATE1	0.51	7.05	0.36	1.08e-11	Anxiety disorder;
CRC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg19193384	chr17:30244184	NA	0.48	6.09	0.32	3.08e-9	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.58	8.79	0.44	8.72e-17	Blood metabolite levels;
CRC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.82	8.53	0.43	5.3e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg15845792	chr6:28175446	NA	-0.99	-14.79	-0.63	2.76e-38	Depression;
CRC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.55	5.82	0.31	1.36e-8	Bipolar disorder;
CRC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg12564285	chr5:131593104	PDLIM4	0.5	9.67	0.47	1.27e-19	Breast cancer;
CRC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.66	10.72	0.51	3.48e-23	Motion sickness;
CRC	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.65	-10.13	-0.49	3.52e-21	Blood pressure (smoking interaction);
CRC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg19193384	chr17:30244184	NA	-0.54	-6.94	-0.36	2.14e-11	Hip circumference adjusted for BMI;
CRC	cis	rs4731207	0.596	rs1994024	chr7:124660845	A/G	cg23710748	chr7:124431027	NA	-0.38	-5.98	-0.31	5.68e-9	Cutaneous malignant melanoma;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg03919779	chr17:16284127	UBB	0.49	5.98	0.31	5.67e-9	Kashin-Beck disease;
CRC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg02560186	chr11:3602584	NA	0.46	6.51	0.34	2.79e-10	Blood pressure (smoking interaction);
CRC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg24562669	chr7:97807699	LMTK2	0.45	7.43	0.38	9.75e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.53	7.15	0.37	5.77e-12	Height;
CRC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.38	-0.33	5.88e-10	Aortic root size;
CRC	cis	rs7605827	0.836	rs4396685	chr2:15634407	C/T	cg19274914	chr2:15703543	NA	0.4	6.05	0.32	4e-9	Educational attainment (years of education);
CRC	cis	rs2742417	1.000	rs938363	chr3:45746364	T/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs12580194	0.957	rs56380243	chr12:55690727	A/G	cg19537932	chr12:55886519	OR6C68	-0.57	-7.9	-0.4	4.11e-14	Cancer;
CRC	cis	rs10924970	0.649	rs3765795	chr1:235375819	A/G	cg09010748	chr1:235293032	TOMM20	0.42	5.71	0.3	2.48e-8	Asthma;
CRC	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.53	6.36	0.33	6.58e-10	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25998860	chr5:126853954	PRRC1	0.47	6.72	0.35	8.03e-11	Response to antipsychotic treatment;
CRC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg09455208	chr3:40491958	NA	0.43	8.41	0.42	1.23e-15	Renal cell carcinoma;
CRC	cis	rs9648716	0.935	rs28605757	chr7:140631695	G/A	cg10747023	chr7:140774559	NA	0.46	6.02	0.31	4.76e-9	Type 2 diabetes;
CRC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg11271282	chr2:238384023	NA	0.45	5.71	0.3	2.54e-8	Prostate cancer;
CRC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-8.19	-0.41	6e-15	Coronary artery disease;
CRC	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-13.11	-0.59	7.17e-32	Schizophrenia;
CRC	cis	rs370915	1.000	rs9685837	chr4:187818466	C/T	cg19519643	chr4:187840862	NA	-0.48	-7.33	-0.37	1.79e-12	Gout;
CRC	trans	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg17712092	chr4:129076599	LARP1B	0.52	6.85	0.35	3.62e-11	DNA methylation (variation);
CRC	trans	rs2303319	0.504	rs62190168	chr2:162322012	A/G	cg04145477	chr6:107077629	RTN4IP1;QRSL1	-0.84	-6.27	-0.33	1.13e-9	Cognitive function;
CRC	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	9.64	0.47	1.56e-19	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.35e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.25	-6.27	-0.33	1.12e-9	Lymphocyte counts;
CRC	cis	rs294883	0.739	rs13205563	chr6:159704376	A/G	cg14500486	chr6:159655392	FNDC1	-0.35	-5.81	-0.3	1.5e-8	Coronary artery disease;
CRC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.71	6.79	0.35	5.34e-11	Diabetic retinopathy;
CRC	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.47	-0.34	3.47e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	8.3	0.42	2.65e-15	Menarche (age at onset);
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26949087	chr2:26467503	HADHB;HADHA	0.42	6.1	0.32	3.06e-9	Myopia (pathological);
CRC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.52	7.23	0.37	3.4e-12	Morning vs. evening chronotype;
CRC	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg13385794	chr1:248469461	NA	-0.38	-6.59	-0.34	1.76e-10	Common traits (Other);
CRC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.77	0.58	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.8	-0.35	4.92e-11	Aortic root size;
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.43	-0.38	9.63e-13	Breast cancer;
CRC	cis	rs17092148	0.887	rs6059928	chr20:33167349	A/G	cg08999081	chr20:33150536	PIGU	0.5	6.45	0.33	4.05e-10	Neuroticism;
CRC	cis	rs96067	0.711	rs737381	chr1:36621186	G/C	cg24686825	chr1:36642396	MAP7D1	-0.49	-6.3	-0.33	9.61e-10	Corneal structure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20503117	chr3:5164013	ARL8B	0.57	8.24	0.41	4.28e-15	Response to antipsychotic treatment;
CRC	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.13	17.0	0.68	5.86e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.79	8.65	0.43	2.34e-16	Skin colour saturation;
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg15511327	chr8:143859410	LYNX1	0.41	7.41	0.38	1.06e-12	Urinary tract infection frequency;
CRC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.87	0.31	1.04e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21685218	chr6:143771971	PEX3;ADAT2	0.43	6.22	0.32	1.52e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7172809	0.643	rs4886874	chr15:77838086	A/C	cg10437265	chr15:77819839	NA	0.37	5.96	0.31	6.38e-9	Glucose homeostasis traits;
CRC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.49	-8.61	-0.43	3.08e-16	Blood metabolite levels;
CRC	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.53	8.7	0.43	1.58e-16	Motion sickness;
CRC	cis	rs73195822	0.667	rs57302533	chr12:111245613	A/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.69	0.3	2.88e-8	Itch intensity from mosquito bite;
CRC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.58	0.7	2.92e-49	Platelet count;
CRC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.11	13.62	0.6	8.15e-34	Vitiligo;
CRC	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg15192750	chr16:69999425	NA	0.6	8.0	0.4	2.12e-14	IgE levels;
CRC	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22878388	chr2:105853796	NA	-0.36	-6.81	-0.35	4.65e-11	Type 2 diabetes;
CRC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.47	7.25	0.37	3.08e-12	Eye color traits;
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-11.87	-0.55	2.79e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.37	-6.61	-0.34	1.52e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.75	-12.98	-0.58	2.18e-31	Body mass index;
CRC	cis	rs73200209	0.744	rs17426718	chr12:116599676	A/C	cg01776926	chr12:116560359	MED13L	-0.62	-7.14	-0.37	5.98e-12	Total body bone mineral density;
CRC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.96	0.31	6.33e-9	Prudent dietary pattern;
CRC	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.45	6.89	0.36	2.87e-11	Asthma;
CRC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	6.99	0.36	1.51e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg24675056	chr1:15929824	NA	0.49	6.79	0.35	5.33e-11	Systolic blood pressure;
CRC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.19	0.49	2.27e-21	Platelet count;
CRC	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.59	0.39	3.39e-13	Breast cancer;
CRC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.51	8.98	0.44	2.07e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	10.95	0.52	5.48e-24	Mean corpuscular hemoglobin;
CRC	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg23920097	chr1:209922102	NA	-0.53	-6.67	-0.35	1.06e-10	Red blood cell count;
CRC	cis	rs10924970	0.967	rs12741262	chr1:235406849	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.79	0.3	1.64e-8	Asthma;
CRC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg07274523	chr3:49395745	GPX1	0.47	6.11	0.32	2.77e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.33	6.97	0.36	1.73e-11	Lung cancer;
CRC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg11212589	chr17:38028394	ZPBP2	0.37	6.28	0.33	1.07e-9	Asthma;
CRC	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.65	-9.7	-0.47	1.02e-19	Type 2 diabetes;
CRC	cis	rs6499255	0.951	rs60472033	chr16:69677709	A/G	cg04110750	chr16:69646130	NFAT5	-0.55	-7.51	-0.38	5.71e-13	IgE levels;
CRC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16447950	chr5:562315	NA	-0.74	-9.79	-0.47	4.96e-20	Obesity-related traits;
CRC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.63	11.94	0.55	1.47e-27	Skin aging (microtopography measurement);
CRC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.59	-0.34	1.7e-10	Major depressive disorder;
CRC	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.38	0.42	1.61e-15	Coffee consumption (cups per day);
CRC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-5.93	-0.31	7.72e-9	Migraine;Coronary artery disease;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14165241	chr9:131315156	SPTAN1	-0.38	-6.14	-0.32	2.43e-9	Obesity-related traits;
CRC	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg08501292	chr6:25962987	TRIM38	0.91	8.57	0.43	4.05e-16	Autism spectrum disorder or schizophrenia;
CRC	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.5	6.06	0.32	3.67e-9	Bipolar disorder;
CRC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg01097406	chr16:89675127	NA	-0.38	-7.19	-0.37	4.45e-12	Hemoglobin concentration;
CRC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.61	-11.06	-0.52	2.12e-24	Immature fraction of reticulocytes;
CRC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	12.61	0.57	5.01e-30	Platelet count;
CRC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.82	14.4	0.62	8.3e-37	Total body bone mineral density;
CRC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.53	7.13	0.37	6.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.76	10.78	0.51	2.12e-23	Blood metabolite levels;
CRC	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg07404485	chr7:94953653	PON1	-0.46	-6.25	-0.33	1.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.81	-0.31	1.48e-8	Life satisfaction;
CRC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-17.16	-0.69	1.42e-47	Electrocardiographic conduction measures;
CRC	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg08992911	chr2:238395768	MLPH	0.61	6.19	0.32	1.8e-9	Prostate cancer;
CRC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.83	-0.35	4.16e-11	Major depressive disorder;
CRC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.58	5.79	0.3	1.66e-8	Fat distribution (HIV);
CRC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg02741985	chr17:80059408	CCDC57	0.44	7.33	0.37	1.76e-12	Life satisfaction;
CRC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg02135003	chr7:105160482	PUS7	-0.91	-12.41	-0.56	2.87e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg24503407	chr1:205819492	PM20D1	-0.45	-6.17	-0.32	2.04e-9	White blood cell count (basophil);Basophil percentage of white cells;
CRC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04586622	chr2:25135609	ADCY3	0.54	9.95	0.48	1.49e-20	Body mass index;
CRC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.28	-0.33	1.07e-9	Arsenic metabolism;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg03623178	chr6:28175578	NA	0.79	11.66	0.54	1.54e-26	Cardiac Troponin-T levels;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg27588902	chr6:42928151	GNMT	-0.38	-6.8	-0.35	5.09e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-6.5	-0.34	3.04e-10	Fibrinogen levels;
CRC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg09264619	chr17:80180166	NA	-0.49	-7.13	-0.37	6.39e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.5	-7.83	-0.4	6.6e-14	Coronary artery disease;
CRC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.59	-7.38	-0.38	1.3e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.74	-15.92	-0.66	1.08e-42	Intelligence (multi-trait analysis);
CRC	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg14825688	chr5:132208181	LEAP2	-0.37	-5.88	-0.31	9.93e-9	Apolipoprotein A-IV levels;
CRC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.53	0.54	4.61e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	9.43	0.46	7.6e-19	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg18876405	chr7:65276391	NA	-0.44	-6.19	-0.32	1.82e-9	Aortic root size;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg02033258	chr5:131593261	PDLIM4	0.44	8.27	0.41	3.33e-15	Blood metabolite levels;
CRC	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.84	-9.12	-0.45	7.44e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-6.49	-0.34	3.21e-10	Systemic lupus erythematosus;
CRC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg00601486	chr12:48723148	H1FNT	-0.35	-6.71	-0.35	8.75e-11	Glycated hemoglobin levels;
CRC	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.48	8.92	0.44	3.28e-17	Age-related hearing impairment;
CRC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.83	-0.35	4.01e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg15147215	chr3:52552868	STAB1	-0.65	-11.29	-0.53	3.36e-25	Electroencephalogram traits;
CRC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg21251018	chr6:28226885	NKAPL	0.53	9.1	0.45	9.15e-18	Pubertal anthropometrics;
CRC	cis	rs11679072	1.000	rs11688828	chr2:240453890	T/C	cg03276489	chr2:240449683	NA	-0.9	-7.37	-0.38	1.39e-12	Blood pressure (smoking interaction);
CRC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg20354231	chr13:53171401	NA	-0.54	-8.1	-0.41	1.11e-14	Lewy body disease;
CRC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.5	7.09	0.36	8.21e-12	Coronary artery disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg04393675	chr16:28986095	SPNS1	0.41	6.65	0.34	1.24e-10	Obesity-related traits;
CRC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-5.91	-0.31	8.73e-9	High light scatter reticulocyte count;
CRC	cis	rs7626444	0.625	rs1403101	chr3:196485074	G/A	cg12930392	chr3:196481615	PAK2	0.39	7.11	0.36	7.25e-12	Monocyte count;
CRC	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.72	13.29	0.59	1.44e-32	Hip circumference;
CRC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	10.04	0.48	7.37e-21	Lung cancer;
CRC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-9.9	-0.48	2.12e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg15845792	chr6:28175446	NA	0.6	7.95	0.4	3.01e-14	Parkinson's disease;
CRC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.12	-0.41	9.77e-15	Calcium levels;
CRC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-6.8	-0.35	4.92e-11	Alzheimer's disease (late onset);
CRC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.48	0.46	5.28e-19	Lung cancer;
CRC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Depression;
CRC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs9925964	0.744	rs12716979	chr16:31011821	T/G	cg03418659	chr16:31128414	MYST1	0.44	6.55	0.34	2.26e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg10876282	chr6:28092338	ZSCAN16	0.5	6.72	0.35	7.89e-11	Cardiac Troponin-T levels;
CRC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-20.61	-0.75	3.5e-61	Height;
CRC	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg25856811	chr1:152973957	SPRR3	-0.23	-6.17	-0.32	2.01e-9	Inflammatory skin disease;
CRC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.63	-11.23	-0.53	5.3e-25	Schizophrenia;
CRC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg25767906	chr1:53392781	SCP2	0.4	6.54	0.34	2.36e-10	Monocyte count;
CRC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-5.97	-0.31	6.15e-9	Coronary artery disease;
CRC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	trans	rs1933755	0.614	rs6569693	chr6:130924497	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.79	6.0	0.31	5.35e-9	Colorectal cancer (calcium intake interaction);
CRC	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.77	8.82	0.44	6.83e-17	Eotaxin levels;
CRC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.73	-0.51	3.1e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.67	8.56	0.43	4.46e-16	Blood pressure (smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24879809	chr1:92351641	TGFBR3	0.42	6.77	0.35	6.04e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-6.23	-0.32	1.41e-9	Eye color traits;
CRC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.88	0.35	2.99e-11	Morning vs. evening chronotype;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg20512303	chr5:131592959	PDLIM4	0.41	7.08	0.36	8.81e-12	Acylcarnitine levels;
CRC	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	6.73	0.35	7.55e-11	Neutrophil percentage of white cells;
CRC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.49	7.4	0.38	1.14e-12	Motion sickness;
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg22079747	chr2:228736145	WDR69	0.42	5.69	0.3	2.8e-8	Blood pressure;
CRC	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.5	7.73	0.39	1.34e-13	Testicular germ cell tumor;
CRC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.83	-0.35	4.11e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.62	-9.09	-0.45	9.63e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7113874	0.569	rs9300091	chr11:8588823	G/A	cg02811074	chr11:8615871	STK33	-0.35	-5.97	-0.31	6.17e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.66	-0.43	2.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13244260	chr10:112632027	LOC282997;PDCD4	0.44	6.17	0.32	1.99e-9	Response to antipsychotic treatment;
CRC	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.48	7.17	0.37	4.88e-12	Asthma;
CRC	trans	rs8097070	0.661	rs9966711	chr18:23171413	C/G	cg03560053	chr19:9946083	PIN1	0.55	5.98	0.31	5.92e-9	Systemic juvenile idiopathic arthritis;
CRC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.21	-16.46	-0.67	7.6e-45	Breast cancer;
CRC	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg08992911	chr2:238395768	MLPH	0.59	6.09	0.32	3.2e-9	Prostate cancer;
CRC	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.8	12.22	0.56	1.41e-28	Testicular germ cell tumor;
CRC	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.44	-6.31	-0.33	9.05e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.45	7.51	0.38	5.74e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7781266	0.790	rs62469961	chr7:133150905	G/T	cg03336402	chr7:133662267	EXOC4	0.5	5.91	0.31	8.72e-9	Educational attainment (college completion);
CRC	cis	rs281302	0.621	rs395722	chr15:47731236	G/A	cg13159054	chr15:47721715	NA	-0.43	-6.45	-0.34	3.93e-10	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00290607	chr11:67383545	NA	-0.35	-6.02	-0.31	4.78e-9	Mean corpuscular volume;
CRC	cis	rs9287719	0.649	rs6722126	chr2:10721642	A/G	cg00105475	chr2:10696890	NA	0.43	6.8	0.35	5.06e-11	Prostate cancer;
CRC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg05941027	chr17:61774174	LIMD2	0.34	5.85	0.31	1.18e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg13043300	chr11:71146211	DHCR7	-0.46	-6.32	-0.33	8.37e-10	Vitamin D levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06926254	chr16:29972939	TMEM219	0.47	6.81	0.35	4.74e-11	Thyroid stimulating hormone;
CRC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.76	-0.35	6.45e-11	Major depressive disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07925823	chr16:68298504	SLC7A6	0.44	6.13	0.32	2.56e-9	Anxiety disorder;
CRC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.36e-29	Prostate cancer;
CRC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg19812747	chr11:111475976	SIK2	0.49	7.28	0.37	2.51e-12	Primary sclerosing cholangitis;
CRC	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.59	7.86	0.4	5.36e-14	Mammographic density (dense area);
CRC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.24	-0.41	4e-15	Bone mineral density;
CRC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.44	6.22	0.32	1.5e-9	Aortic root size;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg07683663	chr4:147096828	LSM6	0.5	6.49	0.34	3.21e-10	Thyroid stimulating hormone;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.47	0.38	7.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg14673194	chr17:80132900	CCDC57	0.49	6.28	0.33	1.07e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs995000	0.868	rs1168102	chr1:63127705	C/T	cg19896129	chr1:63156450	NA	-0.42	-6.45	-0.34	3.91e-10	Triglyceride levels;
CRC	trans	rs4698048	0.506	rs6833292	chr4:10272429	C/T	cg26043149	chr18:55253948	FECH	-0.46	-6.78	-0.35	5.58e-11	Skin aging (microtopography measurement);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01434783	chr4:124319883	SPRY1	0.43	6.31	0.33	8.98e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.71	9.8	0.48	4.67e-20	Alzheimer's disease;
CRC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.59	-7.05	-0.36	1.04e-11	Blood protein levels;
CRC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg01951491	chr16:67709440	GFOD2	-0.45	-5.92	-0.31	8.22e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.98	-21.04	-0.76	6.92e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	7.26	0.37	2.78e-12	Eye color traits;
CRC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.12	-0.32	2.69e-9	Arsenic metabolism;
CRC	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg03938978	chr2:103052716	IL18RAP	0.46	7.22	0.37	3.7e-12	Blood protein levels;
CRC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.6	-7.3	-0.37	2.15e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4728302	0.869	rs10231102	chr7:133573310	G/A	cg03336402	chr7:133662267	EXOC4	-0.41	-5.87	-0.31	1.05e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.59	0.39	3.25e-13	Lung cancer in ever smokers;
CRC	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.39	5.62	0.3	4.15e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs2882667	0.898	rs13163536	chr5:138377219	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.44e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	6.26	0.33	1.19e-9	Monocyte percentage of white cells;
CRC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-9.25	-0.45	2.89e-18	Bipolar disorder;
CRC	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.56	0.38	3.99e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg03013999	chr17:37608204	MED1	-0.48	-7.52	-0.38	5.37e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.56	-0.43	4.4e-16	Chronic sinus infection;
CRC	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg07617317	chr6:118971624	C6orf204	0.52	6.47	0.34	3.53e-10	Diastolic blood pressure;
CRC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg26176469	chr17:28951361	LRRC37B2	0.54	5.92	0.31	7.94e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs375066	0.526	rs17712224	chr19:44331594	A/C	cg19542119	chr19:44331823	ZNF283	0.41	5.74	0.3	2.1e-8	Breast cancer;
CRC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.01	15.73	0.66	5.97e-42	IgG glycosylation;
CRC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg12365402	chr11:9010492	NRIP3	-0.54	-9.81	-0.48	4.26e-20	Hemoglobin concentration;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg21097354	chr7:27179161	NA	0.31	6.59	0.34	1.75e-10	Kashin-Beck disease;
CRC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.74	-0.39	1.27e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.89	-0.31	9.45e-9	Alzheimer's disease (survival time);
CRC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.49	-0.34	3.1e-10	Aortic root size;
CRC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.23	14.95	0.64	6.45e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg15786705	chr6:28176104	NA	0.59	8.5	0.42	6.86e-16	Parkinson's disease;
CRC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.09	0.49	4.92e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24261177	chr8:96281885	C8orf37	0.42	6.01	0.31	5.04e-9	Response to antipsychotic treatment;
CRC	cis	rs57561814	0.655	rs58879058	chr7:22741822	T/C	cg26061582	chr7:22766209	IL6	0.78	6.38	0.33	6e-10	Tonsillectomy;
CRC	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.59	10.66	0.51	5.37e-23	Blood metabolite ratios;
CRC	cis	rs4692589	0.606	rs11943813	chr4:170938243	T/C	cg19918862	chr4:170955249	NA	0.53	6.99	0.36	1.57e-11	Anxiety disorder;
CRC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.61	-7.89	-0.4	4.6e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.51	8.96	0.44	2.39e-17	Prostate cancer;
CRC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.45	6.44	0.33	4.36e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg00359181	chr2:38893519	GALM	-0.55	-6.25	-0.33	1.28e-9	5-HTT brain serotonin transporter levels;
CRC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.75	10.32	0.49	7.97e-22	Cognitive function;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03459953	chr6:53659983	LRRC1	0.45	5.97	0.31	6.07e-9	Anxiety disorder;
CRC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06544989	chr22:39130855	UNC84B	-0.43	-6.26	-0.33	1.17e-9	Menopause (age at onset);
CRC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.74	-0.39	1.24e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs41005	1.000	rs193931	chr2:8107435	A/G	cg03155496	chr2:8117019	LOC339788	-0.41	-7.38	-0.38	1.34e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.83	16.15	0.67	1.25e-43	Hip circumference;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22005393	chr7:102985332	DNAJC2	0.44	6.53	0.34	2.45e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg04719120	chr6:96025338	MANEA	0.61	6.98	0.36	1.67e-11	Behavioural disinhibition (generation interaction);
CRC	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.61	9.71	0.47	9.35e-20	Breast cancer;
CRC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26240231	chr7:1148101	C7orf50	-0.47	-6.37	-0.33	6.23e-10	Bronchopulmonary dysplasia;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-11.23	-0.53	5.33e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg20673091	chr1:2541236	MMEL1	0.36	5.8	0.3	1.55e-8	Ulcerative colitis;
CRC	cis	rs3889199	0.594	rs2026954	chr1:59687055	T/C	cg25881383	chr1:59680599	NA	-0.37	-5.98	-0.31	5.85e-9	Pulse pressure;
CRC	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.43	6.21	0.32	1.62e-9	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.36	5.76	0.3	1.89e-8	Huntington's disease progression;
CRC	cis	rs3106136	0.609	rs11097407	chr4:95146135	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.69	-0.35	9.43e-11	Capecitabine sensitivity;
CRC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.56	-7.23	-0.37	3.49e-12	Platelet distribution width;
CRC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7705042	0.828	rs1036209	chr5:141498632	T/A	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.95	-0.31	6.98e-9	Asthma;
CRC	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg02466173	chr16:30829666	NA	-0.59	-8.57	-0.43	4.04e-16	Dementia with Lewy bodies;
CRC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	7.78	0.39	9.18e-14	Schizophrenia;
CRC	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	6.21	0.32	1.63e-9	Breast cancer;
CRC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.56	6.45	0.33	4.1e-10	IgG glycosylation;
CRC	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-9.21	-0.45	3.82e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	6.26	0.33	1.17e-9	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12144309	0.554	rs2476602	chr1:114396955	C/T	cg03325407	chr1:114423726	BCL2L15	0.35	6.5	0.34	2.99e-10	Coronary artery disease;
CRC	cis	rs4481887	0.504	rs7530153	chr1:248357891	T/C	cg00666640	chr1:248458726	OR2T12	0.43	7.04	0.36	1.15e-11	Common traits (Other);
CRC	cis	rs28655083	0.826	rs2134335	chr16:77079272	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-6.41	-0.33	5.04e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg02927042	chr1:21476669	EIF4G3	-0.48	-7.76	-0.39	1.05e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.52	8.21	0.41	4.94e-15	Intelligence (multi-trait analysis);
CRC	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.99	0.4	2.24e-14	Neuroticism;
CRC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.29	6.05	0.32	3.94e-9	Lung cancer;
CRC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.94	0.31	7.1e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.42	6.09	0.32	3.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg17010769	chr15:79165973	MORF4L1	-0.42	-6.11	-0.32	2.88e-9	Protein C levels;
CRC	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg01639898	chr1:32083012	HCRTR1	-0.32	-6.63	-0.34	1.38e-10	Intelligence (multi-trait analysis);
CRC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.49	6.67	0.35	1.07e-10	IgG glycosylation;
CRC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg13722127	chr7:150037890	RARRES2	0.37	6.02	0.31	4.75e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg20933634	chr6:27740509	NA	0.57	8.15	0.41	7.8e-15	Parkinson's disease;
CRC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.59	-8.65	-0.43	2.36e-16	Lymphocyte counts;
CRC	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg07699608	chr10:75541558	CHCHD1	0.58	5.82	0.31	1.41e-8	Incident atrial fibrillation;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19969113	chr12:118810441	TAOK3	0.41	6.47	0.34	3.61e-10	Obesity-related traits;
CRC	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.58	7.16	0.37	5.24e-12	Obesity (extreme);
CRC	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg05540913	chr6:167530185	CCR6	0.36	6.48	0.34	3.34e-10	Primary biliary cholangitis;
CRC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.78	-0.3	1.72e-8	Aortic root size;
CRC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.38	6.58	0.34	1.85e-10	Cardiovascular disease risk factors;
CRC	cis	rs2882667	0.931	rs10044736	chr5:138320809	A/G	cg09476006	chr5:138032270	NA	-0.39	-6.24	-0.33	1.32e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.39	-0.42	1.42e-15	Height;
CRC	cis	rs10946940	0.632	rs9366698	chr6:27672035	C/G	cg15845792	chr6:28175446	NA	0.57	7.02	0.36	1.27e-11	Systemic lupus erythematosus;
CRC	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.82	-0.55	4e-27	Colorectal cancer;
CRC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	11.98	0.55	1.1e-27	Height;
CRC	cis	rs9287719	0.614	rs6711473	chr2:10723374	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg11611856	chr9:139973337	UAP1L1	0.52	8.33	0.42	2.25e-15	Cerebrospinal fluid biomarker levels;
CRC	cis	rs7487075	0.893	rs4768115	chr12:46732519	G/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.45	0.34	4e-10	Itch intensity from mosquito bite;
CRC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.66	0.57	3.43e-30	Alzheimer's disease;
CRC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.56	-0.38	4.07e-13	Cystic fibrosis severity;
CRC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.87	0.48	2.6e-20	Cognitive test performance;
CRC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.59	-8.5	-0.42	6.56e-16	Longevity;
CRC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.33	-5.75	-0.3	2.01e-8	Menarche (age at onset);
CRC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05472934	chr7:22766657	IL6	0.77	12.55	0.57	8.65e-30	Lung cancer;
CRC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg03160526	chr17:80928410	B3GNTL1	-0.42	-6.28	-0.33	1.07e-9	Breast cancer;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02359409	chr6:42947317	PEX6	-0.65	-10.31	-0.49	8.81e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg20607287	chr7:12443886	VWDE	-0.62	-7.11	-0.36	7.47e-12	Coronary artery disease;
CRC	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.72	-12.09	-0.55	4.33e-28	Idiopathic membranous nephropathy;
CRC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	11.17	0.52	9.07e-25	Neutrophil percentage of white cells;
CRC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg22535103	chr8:58192502	C8orf71	-0.56	-6.71	-0.35	8.37e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.47	6.35	0.33	7.33e-10	Schizophrenia;
CRC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25441200	chr7:156742235	NOM1	0.42	6.23	0.32	1.4e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.92	-0.4	3.64e-14	Bipolar disorder;
CRC	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.5	7.76	0.39	1.08e-13	Red blood cell count;
CRC	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.65	10.86	0.51	1.13e-23	Subjective well-being (multi-trait analysis);
CRC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	0.84	7.66	0.39	2.1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.9	-0.31	8.86e-9	Lung cancer;
CRC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg17545662	chr6:170176663	C6orf70	0.57	6.4	0.33	5.21e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.41	-7.15	-0.37	5.63e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg19635926	chr16:89946313	TCF25	0.52	5.62	0.3	4.09e-8	Skin colour saturation;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg19982557	chr2:132250307	FAM128A;LOC150776	-0.49	-6.22	-0.32	1.52e-9	Parkinson's disease;
CRC	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	0.78	7.53	0.38	4.82e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg16724585	chr3:197361211	NA	-0.49	-7.19	-0.37	4.47e-12	Pancreatic cancer;
CRC	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.27	-0.33	1.16e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	ch.1.3259774R	chr1:166827647	TADA1	-0.5	-5.62	-0.3	4.17e-8	Refractive astigmatism;
CRC	cis	rs9322817	0.691	rs9404586	chr6:105332814	A/G	cg02098413	chr6:105308735	HACE1	0.46	9.2	0.45	4.09e-18	Thyroid stimulating hormone;
CRC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.68	0.3	2.96e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.88	-0.44	4.37e-17	Alcohol dependence;
CRC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.39	-6.85	-0.35	3.7e-11	Reticulocyte fraction of red cells;
CRC	cis	rs282587	0.569	rs7986147	chr13:113398784	A/C	cg04656015	chr13:113407548	ATP11A	0.64	7.99	0.4	2.28e-14	Glycated hemoglobin levels;
CRC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.32	-0.46	1.72e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg20615401	chr6:28092323	ZSCAN16	0.46	6.19	0.32	1.83e-9	Parkinson's disease;
CRC	trans	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.18	0.32	1.91e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02450064	chr17:40260053	DHX58	-0.43	-6.19	-0.32	1.74e-9	Fibrinogen levels;
CRC	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-6.68	-0.35	1.04e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs728616	0.867	rs61859763	chr10:81671615	A/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.71	-0.39	1.53e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.59	-10.62	-0.51	7.39e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg04586622	chr2:25135609	ADCY3	-0.55	-10.22	-0.49	1.81e-21	Body mass index in non-asthmatics;
CRC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg03013999	chr17:37608204	MED1	0.45	6.9	0.36	2.72e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6976053	0.935	rs6954151	chr7:100484917	C/T	cg10426581	chr7:100472382	SRRT	0.38	5.78	0.3	1.74e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-8.28	-0.42	3.08e-15	Hemoglobin concentration;
CRC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg05805236	chr11:65401703	PCNXL3	0.36	5.74	0.3	2.18e-8	Acne (severe);
CRC	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg25019722	chr6:37503610	NA	-0.47	-8.79	-0.44	8.44e-17	Cognitive performance;
CRC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg15845792	chr6:28175446	NA	0.46	6.67	0.35	1.06e-10	Pubertal anthropometrics;
CRC	cis	rs4073416	0.518	rs7157109	chr14:65900433	C/G	cg03016385	chr14:66212404	NA	-0.41	-5.67	-0.3	3.13e-8	N-glycan levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04674497	chr6:45346044	SUPT3H;RUNX2	0.5	7.23	0.37	3.41e-12	Response to antipsychotic treatment;
CRC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.93	-16.16	-0.67	1.14e-43	Height;
CRC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg00769240	chr8:12517080	NA	-0.57	-7.05	-0.36	1.04e-11	Blood pressure (smoking interaction);
CRC	cis	rs55871839	0.684	rs7002967	chr8:59816806	T/A	cg07426533	chr8:59803705	TOX	-0.34	-5.87	-0.31	1.06e-8	Pneumonia;
CRC	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg17182837	chr8:41585554	ANK1	-0.49	-6.34	-0.33	7.47e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.53	6.38	0.33	6e-10	Cognitive test performance;
CRC	cis	rs4132509	1.000	rs10927050	chr1:243805907	A/G	cg21452805	chr1:244014465	NA	0.46	6.17	0.32	2.04e-9	RR interval (heart rate);
CRC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.55	7.7	0.39	1.64e-13	Melanoma;
CRC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg25173405	chr17:45401733	C17orf57	0.39	5.77	0.3	1.86e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.39	0.33	5.66e-10	Electroencephalogram traits;
CRC	cis	rs2811415	0.597	rs12695504	chr3:127791388	C/G	cg13719885	chr3:127795394	NA	-0.38	-5.91	-0.31	8.78e-9	Lung function (FEV1/FVC);
CRC	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	9.95	0.48	1.51e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.59	9.58	0.47	2.5e-19	Mean corpuscular volume;
CRC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-12.93	-0.58	3.44e-31	Cognitive function;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Parkinson's disease;
CRC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.68	11.39	0.53	1.44e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	9.67	0.47	1.25e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg00255919	chr5:131827918	IRF1	-0.59	-11.57	-0.54	3.41e-26	Asthma (sex interaction);
CRC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg00603274	chr11:61596626	FADS2	-0.44	-6.4	-0.33	5.33e-10	LDL cholesterol;
CRC	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.42	-5.69	-0.3	2.84e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.71	-7.72	-0.39	1.41e-13	Psoriasis;
CRC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg18876405	chr7:65276391	NA	0.45	6.23	0.32	1.44e-9	Aortic root size;
CRC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.52	9.03	0.45	1.5e-17	Aortic root size;
CRC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg14664628	chr15:75095509	CSK	0.4	5.78	0.3	1.71e-8	Systemic lupus erythematosus;
CRC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg18016565	chr1:150552671	MCL1	0.44	6.23	0.32	1.42e-9	Melanoma;
CRC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs1532331	0.898	rs10076858	chr5:43134752	G/A	cg09164108	chr5:43007320	NA	0.39	5.93	0.31	7.84e-9	Menarche (age at onset);
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg09877947	chr5:131593287	PDLIM4	0.45	8.41	0.42	1.27e-15	Breast cancer;
CRC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.62	-10.03	-0.48	7.62e-21	Depressive symptoms (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.5	7.88	0.4	4.98e-14	Red blood cell count;
CRC	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.6	-8.19	-0.41	5.95e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.94	-0.31	7.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03990565	chr11:64885225	ZNHIT2	0.48	6.7	0.35	9.12e-11	Anxiety disorder;
CRC	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.24	0.53	5.13e-25	Coffee consumption (cups per day);
CRC	cis	rs9914988	0.830	rs7221773	chr17:27202888	C/T	cg20469991	chr17:27169893	C17orf63	-0.62	-5.84	-0.31	1.22e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	0.94	13.05	0.58	1.21e-31	Age-related macular degeneration (geographic atrophy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26726589	chr20:306364	SOX12	0.38	6.23	0.32	1.42e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12463550	chr7:65579703	CRCP	0.67	6.4	0.33	5.2e-10	Diabetic kidney disease;
CRC	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg00105475	chr2:10696890	NA	0.44	7.14	0.37	6.13e-12	Prostate cancer;
CRC	cis	rs7259376	0.936	rs59598661	chr19:22537029	T/A	cg02657401	chr19:22469223	NA	-0.33	-7.46	-0.38	7.96e-13	Menopause (age at onset);
CRC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.36	-0.56	4.3e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg23254163	chr1:152506842	NA	0.5	10.14	0.49	3.42e-21	Hair morphology;
CRC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.83	-12.24	-0.56	1.26e-28	Response to antineoplastic agents;
CRC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	11.37	0.53	1.72e-25	Electrocardiographic conduction measures;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08265551	chr1:151032119	CDC42SE1;MLLT11	0.35	6.07	0.32	3.57e-9	Obesity-related traits;
CRC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg07636037	chr3:49044803	WDR6	-0.72	-6.08	-0.32	3.38e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6496667	0.865	rs75714371	chr15:90880602	G/A	cg04176472	chr15:90893244	GABARAPL3	0.58	6.61	0.34	1.58e-10	Rheumatoid arthritis;
CRC	cis	rs6838801	0.554	rs344122	chr4:77637502	G/T	cg17476223	chr4:77663285	SHROOM3	0.46	6.1	0.32	3.02e-9	Cleft lip with or without cleft palate;
CRC	cis	rs7923609	0.812	rs10761753	chr10:65161903	G/A	cg08743896	chr10:65200160	JMJD1C	-0.43	-6.19	-0.32	1.82e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg03732007	chr1:2071316	PRKCZ	0.4	6.47	0.34	3.64e-10	Height;
CRC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg27535305	chr1:53392650	SCP2	0.39	7.07	0.36	9.43e-12	Monocyte count;
CRC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.63	0.43	2.61e-16	Rheumatoid arthritis;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09081385	chr12:120972070	RNF10	-0.43	-6.52	-0.34	2.7e-10	Interleukin-6 levels;
CRC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.84	0.35	3.89e-11	Aortic root size;
CRC	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg09873164	chr1:152488093	CRCT1	0.37	6.2	0.32	1.73e-9	Hair morphology;
CRC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.66	-0.47	1.35e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.52	8.27	0.41	3.31e-15	Aortic root size;
CRC	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg00631329	chr6:26305371	NA	-0.52	-8.72	-0.43	1.42e-16	Educational attainment;
CRC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.42	6.1	0.32	3.02e-9	Emphysema distribution in smoking;
CRC	cis	rs6504950	0.720	rs28564882	chr17:52989598	C/T	cg26251398	chr17:52985966	TOM1L1	0.42	6.16	0.32	2.14e-9	Breast cancer;
CRC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg21153622	chr11:89784906	NA	-0.46	-7.35	-0.38	1.54e-12	HDL cholesterol;
CRC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.35	-0.42	1.87e-15	Morning vs. evening chronotype;
CRC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.59	-8.77	-0.44	1e-16	Aortic root size;
CRC	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.78	13.71	0.6	3.83e-34	Schizophrenia;
CRC	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg05418105	chr22:50981406	NA	-0.59	-7.32	-0.37	1.92e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.56	0.43	4.53e-16	Coffee consumption (cups per day);
CRC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg21770322	chr7:97807741	LMTK2	0.86	19.38	0.73	2.28e-56	Breast cancer;
CRC	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.7	-0.35	8.99e-11	Eye color traits;
CRC	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.54	7.81	0.4	7.5e-14	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06544989	chr22:39130855	UNC84B	0.45	6.86	0.35	3.33e-11	Menopause (age at onset);
CRC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg27523141	chr10:43048294	ZNF37B	0.42	6.01	0.31	4.99e-9	Breast cancer;
CRC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.85	0.4	5.94e-14	Lung cancer;
CRC	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg06156847	chr2:113672199	IL1F7	-0.39	-5.96	-0.31	6.34e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.45	0.5	2.9e-22	Corneal astigmatism;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg18301423	chr5:131593218	PDLIM4	-0.38	-6.41	-0.33	5.02e-10	Breast cancer;
CRC	cis	rs12745968	0.594	rs10735781	chr1:93121107	C/G	cg17283838	chr1:93427260	FAM69A	-0.46	-6.34	-0.33	7.46e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.64	9.89	0.48	2.38e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.78	-10.28	-0.49	1.11e-21	Initial pursuit acceleration;
CRC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02725872	chr8:58115012	NA	-0.39	-6.55	-0.34	2.22e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.41	8.12	0.41	9.76e-15	Mean corpuscular volume;
CRC	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.53	-8.19	-0.41	5.93e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.71	7.23	0.37	3.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs16846053	0.786	rs72877309	chr2:162587828	A/G	cg25193742	chr10:104614220	C10orf32	-0.78	-6.44	-0.33	4.19e-10	Blood osmolality (transformed sodium);
CRC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-10.85	-0.51	1.2e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs9322817	0.691	rs4504502	chr6:105325332	A/G	cg02098413	chr6:105308735	HACE1	0.43	8.49	0.42	7.27e-16	Thyroid stimulating hormone;
CRC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.48	-7.37	-0.38	1.39e-12	Height;
CRC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.22e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.64	6.0	0.31	5.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg03233332	chr7:66118400	NA	-0.42	-5.86	-0.31	1.12e-8	Aortic root size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg00177013	chr20:62339100	ARFRP1;ZGPAT	-0.54	-6.65	-0.34	1.24e-10	Diisocyanate-induced asthma;
CRC	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.61	8.31	0.42	2.62e-15	Menopause (age at onset);
CRC	cis	rs2213920	0.679	rs4979533	chr9:118210764	C/T	cg13918206	chr9:118159781	DEC1	0.59	5.8	0.3	1.58e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs6694672	1.000	rs12092294	chr1:196966853	C/T	cg13682187	chr1:196946512	CFHR5	0.46	7.37	0.38	1.39e-12	Asthma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01926595	chr17:4851808	PFN1	0.38	6.89	0.36	2.82e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.84	15.48	0.65	5.72e-41	Metabolic syndrome;
CRC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.25	15.13	0.64	1.26e-39	Eosinophil percentage of granulocytes;
CRC	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.66	-11.27	-0.53	3.91e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs728616	0.867	rs12411407	chr10:81828231	C/T	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.42	-0.33	4.66e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg24011408	chr12:48396354	COL2A1	0.45	6.19	0.32	1.84e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.74	-10.23	-0.49	1.63e-21	Coronary artery disease;
CRC	cis	rs9584850	0.520	rs10508036	chr13:99157398	C/G	cg07423050	chr13:99094983	FARP1	-0.47	-5.9	-0.31	9.11e-9	Neuroticism;
CRC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg09264619	chr17:80180166	NA	0.51	7.3	0.37	2.17e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.3	0.33	9.51e-10	Tonsillectomy;
CRC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.74e-23	Aortic root size;
CRC	cis	rs9292777	0.897	rs6451494	chr5:40411291	T/C	cg09067459	chr5:40385259	NA	0.51	8.86	0.44	5.15e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.52	10.37	0.5	5.51e-22	Bipolar disorder;
CRC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg23262073	chr20:60523788	NA	-0.46	-7.16	-0.37	5.39e-12	Body mass index;
CRC	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.77	-8.39	-0.42	1.45e-15	Intelligence (multi-trait analysis);
CRC	cis	rs71403859	1.000	rs71403859	chr16:71640207	C/T	cg08717414	chr16:71523259	ZNF19	-1.14	-10.91	-0.52	7.62e-24	Post bronchodilator FEV1;
CRC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.58	9.39	0.46	9.98e-19	Mean corpuscular hemoglobin;
CRC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.72	0.3	2.41e-8	Homoarginine levels;
CRC	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.63	8.22	0.41	4.83e-15	Hip circumference adjusted for BMI;
CRC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg12386194	chr3:101231763	SENP7	0.49	6.84	0.35	3.77e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.46	7.29	0.37	2.33e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.28	15.26	0.64	3.9e-40	Uric acid levels;
CRC	cis	rs812925	0.512	rs7558954	chr2:61384906	T/C	cg10580144	chr2:61372316	C2orf74	0.36	8.06	0.41	1.41e-14	Immature fraction of reticulocytes;
CRC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.38	0.46	1.12e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2415984	0.540	rs1494095	chr14:46960671	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.95	0.31	6.86e-9	Number of children ever born;
CRC	cis	rs780094	0.500	rs74175068	chr2:27833502	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.43	0.33	4.42e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs524281	0.861	rs580891	chr11:65954681	A/C	cg14036092	chr11:66035641	RAB1B	-0.5	-6.3	-0.33	9.37e-10	Electroencephalogram traits;
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.72	-0.43	1.41e-16	Bipolar disorder;
CRC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.78	-0.35	5.7e-11	IgG glycosylation;
CRC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.65	-11.4	-0.53	1.35e-25	Brugada syndrome;
CRC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.51	-8.97	-0.44	2.23e-17	Plateletcrit;
CRC	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.4	6.02	0.32	4.63e-9	Endometrial cancer;
CRC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.4	7.67	0.39	2e-13	Ulcerative colitis;
CRC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg16558177	chr4:4109446	NA	-0.56	-6.52	-0.34	2.73e-10	Blood pressure (smoking interaction);
CRC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-7.69	-0.39	1.76e-13	Monocyte percentage of white cells;
CRC	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg13611204	chr9:139324423	INPP5E	-0.45	-6.32	-0.33	8.33e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2249694	0.537	rs9418988	chr10:135327632	C/T	cg16964102	chr10:135390573	NA	-0.44	-6.85	-0.35	3.59e-11	Obesity-related traits;
CRC	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-8.68	-0.43	1.86e-16	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03226425	chr6:170151538	C6orf70;TCTE3	0.46	6.45	0.34	3.94e-10	Response to antipsychotic treatment;
CRC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.87	0.48	2.71e-20	Platelet count;
CRC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg12193833	chr17:30244370	NA	-0.74	-8.72	-0.43	1.45e-16	Hip circumference adjusted for BMI;
CRC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.6	-9.24	-0.45	3.1e-18	Aortic root size;
CRC	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg08795948	chr3:128337044	NA	0.34	5.82	0.31	1.42e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg02825527	chr7:2087843	MAD1L1	-0.5	-5.91	-0.31	8.66e-9	Neuroticism;
CRC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.43	-20.42	-0.75	2e-60	Hip circumference adjusted for BMI;
CRC	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.97	-18.05	-0.71	4e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	7.97	0.4	2.55e-14	Height;
CRC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.92	-14.48	-0.62	4.3e-37	Longevity;
CRC	cis	rs747650	0.504	rs12417519	chr11:47129397	C/T	cg19486271	chr11:47235900	DDB2	0.44	5.84	0.31	1.23e-8	Acne (severe);
CRC	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.44	6.26	0.33	1.23e-9	Body mass index;
CRC	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.54	-7.53	-0.38	4.99e-13	Facial morphology (factor 19);
CRC	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.46	-6.74	-0.35	7.2e-11	Body mass index;
CRC	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.38	-6.85	-0.35	3.64e-11	Prostate cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09581281	chr1:15853227	DNAJC16	0.5	6.45	0.34	3.99e-10	Thyroid stimulating hormone;
CRC	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.85	-13.99	-0.61	3.18e-35	Hypospadias;
CRC	trans	rs6749447	0.848	rs4668029	chr2:169008965	T/C	cg01878807	chr14:24422368	DHRS4;C14orf167	0.39	6.02	0.31	4.61e-9	Blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27308707	chr10:91461150	KIF20B	0.38	6.47	0.34	3.54e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.57	-9.14	-0.45	6.61e-18	Insulin-like growth factors;
CRC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.7	-12.36	-0.56	4.21e-29	Prostate cancer;
CRC	cis	rs9039	0.550	rs12924785	chr16:9219285	T/G	cg08831531	chr16:9218945	NA	-0.39	-5.65	-0.3	3.51e-8	Menopause (age at onset);
CRC	cis	rs2708240	0.666	rs2710118	chr7:147603362	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.41	-5.94	-0.31	7.2e-9	QT interval (drug interaction);
CRC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.68	10.54	0.5	1.47e-22	Intelligence (multi-trait analysis);
CRC	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg27205649	chr11:78285834	NARS2	0.51	6.58	0.34	1.9e-10	Alzheimer's disease (survival time);
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg14875682	chr5:52083620	ITGA1;PELO	-0.8	-6.48	-0.34	3.35e-10	Cognitive function;
CRC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.34	6.71	0.35	8.74e-11	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.46	7.05	0.36	1.06e-11	Dupuytren's disease;
CRC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg15902774	chr15:75289873	SCAMP5	0.5	5.77	0.3	1.83e-8	Lung cancer;
CRC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.51	6.61	0.34	1.52e-10	Recombination rate (females);
CRC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-0.83	-9.29	-0.46	2.18e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.87	10.25	0.49	1.43e-21	Psoriasis;
CRC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.63	-0.34	1.36e-10	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs56407015	chr2:162455625	G/A	cg15664909	chr17:685709	GLOD4;RNMTL1	-0.67	-5.96	-0.31	6.48e-9	Cognitive function;
CRC	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.42	-6.7	-0.35	9.15e-11	Intelligence (multi-trait analysis);Body fat percentage;
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.58	7.8	0.39	8.47e-14	Alzheimer's disease;
CRC	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg04920474	chr2:44395004	PPM1B	0.41	6.04	0.32	4.26e-9	Anxiety disorder (factor score);
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.71	11.49	0.54	6.39e-26	Longevity;Endometriosis;
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg07617317	chr6:118971624	C6orf204	0.47	5.76	0.3	1.98e-8	Diastolic blood pressure;
CRC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.97	-0.31	6.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg02935154	chr7:12443704	VWDE	-0.44	-6.18	-0.32	1.94e-9	Coronary artery disease;
CRC	trans	rs7521492	0.783	rs1932356	chr1:163714823	G/T	cg23417011	chr5:93077375	FAM172A;POU5F2	-0.4	-6.02	-0.31	4.65e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-1.02	-10.59	-0.5	9.73e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.71	-10.86	-0.51	1.11e-23	Cognitive function;
CRC	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.72	12.03	0.55	7.11e-28	Colorectal cancer;
CRC	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg09163369	chr1:210001066	C1orf107	0.6	7.72	0.39	1.37e-13	Orofacial clefts;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs728616	0.867	rs17098720	chr10:81840236	A/G	cg05935833	chr10:81318306	SFTPA2	-0.55	-6.55	-0.34	2.18e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-8.16	-0.41	7.21e-15	Colorectal cancer;
CRC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.27	0.37	2.62e-12	Lung cancer in ever smokers;
CRC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg25767906	chr1:53392781	SCP2	0.41	6.3	0.33	9.75e-10	Monocyte count;
CRC	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg20936604	chr3:58311152	NA	-0.75	-6.89	-0.35	2.89e-11	Cholesterol, total;
CRC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.11	0.41	1.02e-14	Menopause (age at onset);
CRC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg24560729	chr4:1342394	KIAA1530	0.43	7.84	0.4	6.44e-14	Longevity;
CRC	cis	rs2270875	1.000	rs10464872	chr8:132932749	A/G	cg24184792	chr8:132919238	EFR3A	-0.68	-6.87	-0.35	3.14e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04513197	chr1:100504319	HIAT1	-0.52	-6.17	-0.32	1.99e-9	Diisocyanate-induced asthma;
CRC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.65	10.31	0.49	8.54e-22	Type 2 diabetes;
CRC	cis	rs67385638	0.802	rs72872555	chr11:5310169	G/A	cg21506790	chr11:5277210	HBG2	0.35	5.69	0.3	2.84e-8	Hemoglobin levels;
CRC	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.45	6.05	0.32	4.04e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs56399783	0.901	rs73033403	chr7:2877941	G/A	cg19731401	chr7:2775893	GNA12	0.6	6.32	0.33	8.44e-10	Childhood ear infection;
CRC	cis	rs9467160	0.871	rs13205780	chr6:24448687	C/T	cg20631270	chr6:24437470	GPLD1	0.48	6.66	0.34	1.13e-10	Liver enzyme levels;
CRC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.63	0.34	1.34e-10	Dupuytren's disease;
CRC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.11	-0.37	7.08e-12	Breast cancer;
CRC	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.87	0.35	3.21e-11	Birth weight;
CRC	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.93	-0.31	7.46e-9	Endometrial cancer;
CRC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.46	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-7.81	-0.4	7.8e-14	Vitiligo;
CRC	cis	rs6496667	1.000	rs7182544	chr15:90897480	G/C	cg04176472	chr15:90893244	GABARAPL3	0.52	7.95	0.4	3.04e-14	Rheumatoid arthritis;
CRC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg11707556	chr5:10655725	ANKRD33B	0.47	7.51	0.38	5.68e-13	Coronary artery disease;
CRC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg19688584	chr6:167529678	CCR6	-0.33	-5.82	-0.31	1.42e-8	Rheumatoid arthritis;
CRC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.5	7.04	0.36	1.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6024905	0.587	rs1579101	chr20:36966334	C/T	cg07053727	chr20:36965646	BPI	0.74	14.39	0.62	9.52e-37	Bipolar disorder and schizophrenia;
CRC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.56	8.11	0.41	1.03e-14	Melanoma;
CRC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-7.34	-0.38	1.67e-12	Itch intensity from mosquito bite;
CRC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg15786705	chr6:28176104	NA	0.71	7.18	0.37	4.59e-12	Depression;
CRC	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg00601486	chr12:48723148	H1FNT	-0.34	-6.46	-0.34	3.88e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg04518342	chr5:131593106	PDLIM4	0.38	7.1	0.36	7.78e-12	Blood metabolite levels;
CRC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.53	7.51	0.38	5.69e-13	Longevity;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg08034379	chr2:228736324	WDR69	-0.53	-7.22	-0.37	3.59e-12	Blood pressure;
CRC	cis	rs7091068	1.000	rs7091068	chr10:95420385	G/T	cg20715218	chr10:95462985	C10orf4	0.54	5.71	0.3	2.52e-8	Urinary tract infection frequency;
CRC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg15534755	chr11:117069859	TAGLN	-0.36	-6.94	-0.36	2.03e-11	Blood protein levels;
CRC	cis	rs10045504	0.502	rs72746043	chr5:38757226	T/C	cg15396434	chr5:38725168	NA	-0.63	-6.22	-0.32	1.53e-9	Night sleep phenotypes;
CRC	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg02158880	chr13:53174818	NA	0.46	7.06	0.36	9.87e-12	Lewy body disease;
CRC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.5	8.49	0.42	7.31e-16	Aortic root size;
CRC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg05623727	chr3:50126028	RBM5	-0.45	-7.37	-0.38	1.4e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.22	0.32	1.48e-9	Self-reported allergy;
CRC	cis	rs9491140	0.539	rs980658	chr6:124690371	G/A	cg19267163	chr6:125004984	NKAIN2	0.44	5.93	0.31	7.78e-9	Neuroticism;
CRC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.45	6.63	0.34	1.41e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.47	7.35	0.38	1.61e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg12564285	chr5:131593104	PDLIM4	0.32	5.67	0.3	3.08e-8	Blood metabolite levels;
CRC	cis	rs4731207	0.698	rs2158677	chr7:124443966	T/C	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.43	-6.25	-0.33	1.26e-9	Ulcerative colitis;
CRC	cis	rs427941	0.703	rs201440	chr7:101735599	C/T	cg06246474	chr7:101738831	CUX1	0.45	7.06	0.36	9.83e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12273811	chr6:28175739	NA	0.68	8.75	0.43	1.1e-16	Depression;
CRC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.06	-0.32	3.66e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.95	-12.73	-0.57	1.82e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg00531865	chr16:30841666	NA	0.49	6.98	0.36	1.66e-11	Dementia with Lewy bodies;
CRC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.66	-0.34	1.18e-10	Systemic lupus erythematosus;
CRC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.52	7.16	0.37	5.23e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13516796	chr16:5122251	ALG1	0.51	6.6	0.34	1.63e-10	Thyroid stimulating hormone;
CRC	cis	rs847851	0.630	rs9469905	chr6:34797747	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.13	-0.32	2.45e-9	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg26043149	chr18:55253948	FECH	0.49	7.89	0.4	4.57e-14	Bone mineral density;
CRC	trans	rs2303319	0.504	rs62188960	chr2:162492578	A/C	cg04269497	chr6:167369491	RNASET2	-0.74	-6.06	-0.32	3.72e-9	Cognitive function;
CRC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.83	-0.4	6.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.52	-8.44	-0.42	9.94e-16	Aortic root size;
CRC	trans	rs12210905	1.000	rs9379967	chr6:27233427	T/C	cg05005425	chr1:167687389	NA	0.62	6.33	0.33	8.22e-10	Hip circumference adjusted for BMI;
CRC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.64	6.59	0.34	1.72e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	18.63	0.72	2.17e-53	Prudent dietary pattern;
CRC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.33	-0.46	1.65e-18	Reticulocyte fraction of red cells;
CRC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	8.5	0.42	6.53e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.56	-7.82	-0.4	7.12e-14	Iron status biomarkers;
CRC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.66	8.09	0.41	1.14e-14	Menarche (age at onset);
CRC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-9.5	-0.46	4.53e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.48	6.77	0.35	5.91e-11	Colorectal cancer;
CRC	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.57	8.56	0.43	4.53e-16	Smoking behavior;
CRC	cis	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg06470822	chr6:28175283	NA	0.78	6.19	0.32	1.76e-9	Depression;
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.59	7.3	0.37	2.14e-12	Obesity (extreme);
CRC	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.61	-11.43	-0.53	1.09e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.46	-6.57	-0.34	2.03e-10	Uric acid clearance;
CRC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.54	12.03	0.55	6.94e-28	Alcohol dependence;
CRC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg02527881	chr3:46936655	PTH1R	-0.35	-6.09	-0.32	3.07e-9	Colorectal cancer;
CRC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.03	-0.32	4.49e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14277917	chr14:59655363	DAAM1	0.39	6.19	0.32	1.77e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.57	-9.07	-0.45	1.14e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg09877947	chr5:131593287	PDLIM4	0.43	6.72	0.35	7.93e-11	Breast cancer;
CRC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.67	-0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.37	-6.79	-0.35	5.11e-11	Breast cancer;
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg16060761	chr17:80687452	NA	-0.47	-6.1	-0.32	2.91e-9	Glycated hemoglobin levels;
CRC	cis	rs75422866	0.510	rs73105803	chr12:48115918	G/A	cg14736327	chr12:48174669	SLC48A1	-0.72	-5.75	-0.3	2.05e-8	Pneumonia;
CRC	cis	rs45544231	0.569	rs4784224	chr16:52580247	C/A	cg09051775	chr16:52580266	TOX3	-0.41	-6.62	-0.34	1.44e-10	Restless legs syndrome;
CRC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.72	-0.39	1.39e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9491140	0.539	rs11751246	chr6:124692967	C/T	cg19267163	chr6:125004984	NKAIN2	0.47	6.11	0.32	2.79e-9	Neuroticism;
CRC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	15.76	0.66	4.52e-42	Lymphocyte percentage of white cells;
CRC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.12	-12.72	-0.57	2.06e-30	Diabetic kidney disease;
CRC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	6.38	0.33	6.12e-10	Height;
CRC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.47	-6.58	-0.34	1.82e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.85	-12.62	-0.57	4.91e-30	Blood metabolite levels;
CRC	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg27053337	chr8:124217698	FAM83A	0.48	7.04	0.36	1.11e-11	Urinary uromodulin levels;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg03623178	chr6:28175578	NA	0.73	9.19	0.45	4.45e-18	Parkinson's disease;
CRC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.38	6.65	0.34	1.21e-10	Primary biliary cholangitis;
CRC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.55	8.92	0.44	3.33e-17	Coronary artery disease;
CRC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg25164649	chr6:28176230	NA	0.76	9.53	0.46	3.71e-19	Depression;
CRC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.38	6.58	0.34	1.8e-10	Systemic lupus erythematosus;
CRC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.21e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg09165964	chr15:75287851	SCAMP5	-0.5	-7.94	-0.4	3.33e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs11212617	0.934	rs595747	chr11:108194073	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.67	0.3	3.11e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg24977027	chr2:88469347	THNSL2	0.55	6.52	0.34	2.69e-10	Plasma clusterin levels;
CRC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.41	-6.32	-0.33	8.72e-10	Menopause (age at onset);
CRC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.66	12.38	0.56	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.87	12.3	0.56	7.52e-29	Breast cancer;
CRC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.24	14.88	0.63	1.14e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14057772	chr17:21178963	NA	0.44	6.48	0.34	3.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.79	-13.37	-0.59	7.65e-33	Obesity-related traits;
CRC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02450064	chr17:40260053	DHX58	-0.43	-6.13	-0.32	2.55e-9	Fibrinogen levels;
CRC	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg10724054	chr17:3904396	NA	-0.42	-6.64	-0.34	1.28e-10	Type 2 diabetes;
CRC	cis	rs6681460	0.966	rs10889643	chr1:67143368	G/C	cg02459107	chr1:67143332	SGIP1	0.46	7.98	0.4	2.52e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.19	11.24	0.53	5e-25	Prostate cancer;
CRC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg05639522	chr1:247681581	NA	0.45	6.99	0.36	1.53e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg08314208	chr16:67682810	RLTPR	-0.66	-6.85	-0.35	3.64e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.71	-9.28	-0.46	2.33e-18	Bone mineral density;
CRC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-9.45	-0.46	6.59e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.11	0.41	9.94e-15	Lung cancer;
CRC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.65	9.25	0.45	2.99e-18	Vitamin D levels;
CRC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg04362960	chr10:104952993	NT5C2	0.46	6.18	0.32	1.85e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs2811415	0.597	rs12695506	chr3:127791800	A/G	cg13719885	chr3:127795394	NA	-0.39	-5.94	-0.31	7.28e-9	Lung function (FEV1/FVC);
CRC	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.02	-0.32	4.54e-9	Pubertal anthropometrics;
CRC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.22	-0.37	3.62e-12	Inflammatory skin disease;
CRC	cis	rs883565	0.569	rs1274973	chr3:39160441	G/A	cg01426195	chr3:39028469	NA	-0.42	-7.0	-0.36	1.4e-11	Handedness;
CRC	cis	rs6772849	0.805	rs61159406	chr3:128336009	G/A	cg08795948	chr3:128337044	NA	0.34	6.03	0.32	4.38e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg13844804	chr7:814759	HEATR2	0.63	8.23	0.41	4.49e-15	Cerebrospinal P-tau181p levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20959894	chr7:27779871	TAX1BP1	0.4	6.81	0.35	4.71e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.73	9.9	0.48	2.08e-20	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.34	-0.5	6.98e-22	Monocyte count;
CRC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.61	-7.54	-0.38	4.64e-13	Body mass index;
CRC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.76	-12.44	-0.57	2.27e-29	Coronary artery disease;
CRC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.74	-0.39	1.22e-13	Schizophrenia;
CRC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.26	-0.41	3.58e-15	Monocyte percentage of white cells;
CRC	trans	rs12699921	0.632	rs2691613	chr7:17883981	G/A	cg15753394	chr6:17282781	RBM24	-0.36	-6.18	-0.32	1.86e-9	Fibrinogen levels;
CRC	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg08632701	chr21:37451849	NA	-0.45	-7.15	-0.37	5.77e-12	Mitral valve prolapse;
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.35	0.42	1.88e-15	Life satisfaction;
CRC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.49	0.34	3.2e-10	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15229027	chr14:64805542	ESR2	0.46	6.77	0.35	5.77e-11	Response to antipsychotic treatment;
CRC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.66	8.79	0.44	8.32e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg22687807	chr8:143858763	LYNX1	-0.45	-7.44	-0.38	9.07e-13	Urinary tract infection frequency;
CRC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.46	-0.38	7.59e-13	Morning vs. evening chronotype;
CRC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.52	8.89	0.44	4.13e-17	Aortic root size;
CRC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.51	7.08	0.36	8.81e-12	Schizophrenia;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06173978	chr16:50402162	BRD7	0.37	6.43	0.33	4.53e-10	Myopia (pathological);
CRC	cis	rs447	0.806	rs6651129	chr7:83729251	T/G	cg22846510	chr7:83753280	SEMA3A	-0.51	-6.19	-0.32	1.81e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08135327	chr2:134877962	NA	0.43	7.13	0.37	6.22e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.2	-0.37	4.17e-12	Inflammatory skin disease;
CRC	trans	rs2547917	0.947	rs2702376	chr5:58707592	C/G	cg19319774	chr19:51870582	CLDND2;ETFB	-0.57	-6.06	-0.32	3.82e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.58	-8.44	-0.42	1.01e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7274811	0.625	rs169797	chr20:31926490	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.46	6.54	0.34	2.41e-10	Height;
CRC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.41	-6.23	-0.32	1.45e-9	Electroencephalogram traits;
CRC	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg04176472	chr15:90893244	GABARAPL3	-0.38	-5.93	-0.31	7.5e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09488452	chr16:14723959	PARN	0.47	6.56	0.34	2.14e-10	Response to antipsychotic treatment;
CRC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg15193198	chr20:60906057	LAMA5	-0.42	-7.1	-0.36	7.75e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-12.49	-0.57	1.45e-29	Vitiligo;
CRC	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.81	0.35	4.63e-11	Red blood cell count;
CRC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.36	-6.18	-0.32	1.93e-9	Platelet count;
CRC	cis	rs11191205	0.644	rs10883664	chr10:103368208	C/T	cg15320455	chr10:103880129	LDB1	0.51	5.62	0.3	4.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.72	7.47	0.38	7.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg01420254	chr6:26195488	NA	0.82	8.57	0.43	4.19e-16	Gout;Renal underexcretion gout;
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.65	0.34	1.22e-10	Alzheimer's disease;
CRC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg09473613	chr1:24152604	HMGCL	-0.35	-5.88	-0.31	1.03e-8	Immature fraction of reticulocytes;
CRC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	0.94	13.51	0.6	2.13e-33	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg15044954	chr7:89874365	C7orf63	-0.55	-7.01	-0.36	1.34e-11	Diisocyanate-induced asthma;
CRC	cis	rs6743226	0.776	rs2166191	chr2:242152886	T/A	cg10021735	chr2:242295487	FARP2	0.44	6.37	0.33	6.5e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.59	-8.59	-0.43	3.52e-16	Response to temozolomide;
CRC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	11.13	0.52	1.2e-24	Motion sickness;
CRC	trans	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08071915	chr8:12219732	FAM66A	-0.35	-6.04	-0.32	4.25e-9	Neuroticism;
CRC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.7	-0.3	2.63e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.38	12.24	0.56	1.22e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.39	-5.69	-0.3	2.75e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.61	5.64	0.3	3.6e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs9837602	1.000	rs923471	chr3:99757853	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-6.26	-0.33	1.19e-9	Breast cancer;
CRC	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.46	-6.58	-0.34	1.88e-10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17261708	chr5:176794207	RGS14	0.63	9.61	0.47	1.92e-19	Hemoglobin concentration;Hematocrit;
CRC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.25e-10	Alzheimer's disease;
CRC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	0.8	11.75	0.54	7.74e-27	Neutrophil percentage of white cells;
CRC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.51	8.17	0.41	6.81e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.6e-12	Height;
CRC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.43	-5.7	-0.3	2.66e-8	Schizophrenia;
CRC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.93	0.36	2.19e-11	Cognitive test performance;
CRC	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.49	-7.17	-0.37	5e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.74	11.84	0.55	3.41e-27	Blood protein levels;
CRC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg19338460	chr6:170058176	WDR27	-0.7	-7.65	-0.39	2.25e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs7027930	0.524	rs16924559	chr9:608497	G/T	cg27061366	chr19:13044373	FARSA	0.5	6.14	0.32	2.39e-9	Pulmonary function decline;
CRC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.07	-12.49	-0.57	1.49e-29	Diabetic kidney disease;
CRC	cis	rs67981189	0.529	rs8014273	chr14:71509830	A/G	cg15910301	chr14:71632612	NA	0.31	6.12	0.32	2.69e-9	Schizophrenia;
CRC	cis	rs6445967	1.000	rs2292674	chr3:58302404	A/T	cg23715586	chr3:58305044	RPP14	0.35	5.82	0.31	1.37e-8	Platelet count;
CRC	trans	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg13565492	chr6:43139072	SRF	-0.71	-7.27	-0.37	2.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12310399	0.635	rs10859844	chr12:95573040	G/T	cg16511708	chr18:23671264	SS18	0.44	6.31	0.33	8.83e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CRC	cis	rs62458065	1.000	rs79538247	chr7:32467792	A/G	cg20159608	chr7:32802032	NA	-0.51	-6.38	-0.33	6.01e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.64	-10.37	-0.5	5.37e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.57	-0.34	2e-10	Colorectal cancer;
CRC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.51	-8.76	-0.43	1.05e-16	Type 2 diabetes;
CRC	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg27398640	chr15:77910606	LINGO1	0.45	7.72	0.39	1.45e-13	Type 2 diabetes;
CRC	trans	rs7976838	0.908	rs12812257	chr12:60137094	C/G	cg16974014	chr22:22007515	MIR130B	0.49	6.0	0.31	5.21e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.88	-0.68	1.75e-46	Height;
CRC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg19812747	chr11:111475976	SIK2	0.47	7.36	0.38	1.48e-12	Primary sclerosing cholangitis;
CRC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.62	9.91	0.48	1.96e-20	Aortic root size;
CRC	cis	rs55702914	0.628	rs12151767	chr2:198274929	C/T	cg10820045	chr2:198174542	NA	0.32	5.66	0.3	3.38e-8	Major depression and alcohol dependence;
CRC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-8.0	-0.4	2.13e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs9908102	0.740	rs7211501	chr17:12917479	A/G	cg26162695	chr17:12921313	ELAC2	0.43	5.66	0.3	3.27e-8	Schizophrenia;
CRC	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg09473613	chr1:24152604	HMGCL	-0.36	-6.1	-0.32	2.95e-9	Immature fraction of reticulocytes;
CRC	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg21452805	chr1:244014465	NA	0.5	6.93	0.36	2.26e-11	RR interval (heart rate);
CRC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg20684491	chr1:25596433	NA	0.43	7.45	0.38	8.23e-13	Erythrocyte sedimentation rate;
CRC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.38	5.8	0.3	1.54e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	1.02	9.12	0.45	7.53e-18	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-0.59	-11.12	-0.52	1.3e-24	Developmental language disorder (linguistic errors);
CRC	cis	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.43	-0.33	4.38e-10	DNA methylation (variation);
CRC	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.67	-0.39	1.93e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.55	9.15	0.45	6.15e-18	Total body bone mineral density;
CRC	cis	rs938554	0.779	rs13106991	chr4:9959011	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.83	-0.31	1.3e-8	Blood metabolite levels;
CRC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.37	-0.33	6.41e-10	Lung cancer;
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.5	-6.34	-0.33	7.58e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg04121214	chr22:50244548	NA	-0.39	-5.69	-0.3	2.81e-8	Schizophrenia;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg21620606	chr4:1342894	KIAA1530	0.51	8.18	0.41	6.17e-15	Obesity-related traits;
CRC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16447950	chr5:562315	NA	-0.83	-10.78	-0.51	2.14e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg15845792	chr6:28175446	NA	0.65	8.49	0.42	7.04e-16	Parkinson's disease;
CRC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg24140574	chr1:16342155	HSPB7	0.43	5.74	0.3	2.11e-8	Dilated cardiomyopathy;
CRC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.74	10.02	0.48	8.29e-21	Cognitive function;
CRC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.4	6.91	0.36	2.45e-11	Childhood ear infection;
CRC	cis	rs225245	0.687	rs321614	chr17:33881734	A/G	cg05299278	chr17:33885742	SLFN14	0.4	6.38	0.33	5.86e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-8.75	-0.43	1.13e-16	Bipolar disorder;
CRC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg21153622	chr11:89784906	NA	-0.44	-7.17	-0.37	4.95e-12	Coronary artery disease;
CRC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.57	-9.82	-0.48	4.01e-20	Iron status biomarkers;
CRC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.75	12.35	0.56	4.72e-29	Height;
CRC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04221910	chr5:616842	CEP72	0.41	6.7	0.35	9.26e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	1.04	18.23	0.71	8.11e-52	Parkinson's disease;
CRC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.71	12.12	0.56	3.47e-28	Gout;
CRC	trans	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg20935933	chr6:143382018	AIG1	0.52	6.78	0.35	5.71e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	9.53	0.46	3.7e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.63	-0.3	3.9e-8	Reticulocyte count;
CRC	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.69	0.3	2.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.35	-5.71	-0.3	2.46e-8	Blood metabolite levels;
CRC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg12273811	chr6:28175739	NA	0.59	7.51	0.38	5.73e-13	Parkinson's disease;
CRC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg01420254	chr6:26195488	NA	0.81	8.55	0.43	4.7e-16	Gout;Renal underexcretion gout;
CRC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.56	8.24	0.41	4.24e-15	Schizophrenia;
CRC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.57	0.34	2.02e-10	Morning vs. evening chronotype;
CRC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg24163568	chr5:669837	TPPP	-0.43	-6.92	-0.36	2.36e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.67	8.5	0.42	6.85e-16	Response to diuretic therapy;
CRC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-19.27	-0.73	6.32e-56	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg10729496	chr3:10149963	C3orf24	0.54	6.16	0.32	2.13e-9	Alzheimer's disease;
CRC	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	0.85	10.84	0.51	1.29e-23	Orofacial clefts;
CRC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.56	0.38	3.98e-13	Lung cancer;
CRC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.7	0.43	1.59e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24308560	chr3:49941425	MST1R	0.45	7.01	0.36	1.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg07507251	chr3:52567010	NT5DC2	-0.38	-5.91	-0.31	8.43e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.55	-8.39	-0.42	1.41e-15	Coronary artery disease;
CRC	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.44	-6.85	-0.35	3.65e-11	C-reactive protein levels;
CRC	cis	rs2882667	0.898	rs3925110	chr5:138371365	C/G	cg09476006	chr5:138032270	NA	0.44	7.34	0.38	1.64e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22166703	chr1:33722127	ZNF362	0.4	6.51	0.34	2.85e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg15147215	chr3:52552868	STAB1	-0.61	-10.04	-0.48	7.46e-21	Bipolar disorder;
CRC	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.48	-7.72	-0.39	1.37e-13	Coronary artery disease;
CRC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg01420254	chr6:26195488	NA	0.83	8.68	0.43	1.82e-16	Gout;Renal underexcretion gout;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04940776	chr16:29874983	LOC440356;CDIPT	0.44	6.4	0.33	5.3e-10	Intelligence (multi-trait analysis);
CRC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg03929089	chr4:120376271	NA	-0.59	-7.56	-0.38	4.04e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg25164649	chr6:28176230	NA	0.6	8.47	0.42	8.12e-16	Parkinson's disease;
CRC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg16797656	chr11:68205561	LRP5	0.39	6.12	0.32	2.63e-9	Total body bone mineral density;
CRC	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg02811702	chr13:24901961	NA	0.47	6.56	0.34	2.09e-10	Obesity-related traits;
CRC	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-6.09	-0.32	3.16e-9	Coronary artery disease;
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.46	5.63	0.3	3.93e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.3	-5.98	-0.31	5.92e-9	Breast cancer;
CRC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.41	6.52	0.34	2.68e-10	Dupuytren's disease;
CRC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.61	9.59	0.47	2.31e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg24463073	chr6:118973353	C6orf204	0.52	7.14	0.37	6.17e-12	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16333535	chr22:24093440	ZNF70	0.44	6.2	0.32	1.71e-9	Response to antipsychotic treatment;
CRC	cis	rs79387448	0.745	rs7572284	chr2:103119423	C/A	cg09003973	chr2:102972529	NA	0.69	7.61	0.39	2.85e-13	Gut microbiota (bacterial taxa);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12343791	chr22:39240109	NPTXR	0.38	6.49	0.34	3.11e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.22	0.56	1.4e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg21153622	chr11:89784906	NA	-0.39	-6.1	-0.32	3e-9	Height;
CRC	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	12.4	0.56	3.1e-29	Height;
CRC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	1.03	18.4	0.71	1.66e-52	Parkinson's disease;
CRC	trans	rs9988642	0.737	rs41494046	chr1:67722919	C/G	cg08333703	chr19:35225315	ZNF181	-0.45	-5.96	-0.31	6.51e-9	Psoriasis vulgaris;Crohn's disease;
CRC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.6	8.59	0.43	3.65e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
CRC	trans	rs7800418	0.723	rs4555996	chr7:26589827	A/G	cg14387656	chr2:233470847	EFHD1	0.47	6.51	0.34	2.79e-10	Cognitive function;
CRC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg21155852	chr7:2048760	MAD1L1	-0.5	-6.69	-0.35	9.34e-11	Bipolar disorder;
CRC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.47	-8.96	-0.44	2.52e-17	Intelligence (multi-trait analysis);
CRC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.51	8.53	0.43	5.48e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.64	10.07	0.49	5.92e-21	Height;
CRC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.37	6.92	0.36	2.37e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.49	-9.86	-0.48	2.96e-20	Prostate cancer;
CRC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-5.99	-0.31	5.59e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.82	-14.42	-0.62	6.89e-37	Vitiligo;
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.74	11.41	0.53	1.24e-25	Intelligence (multi-trait analysis);
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg19041857	chr6:27730383	NA	-0.47	-6.05	-0.32	3.86e-9	Breast cancer;
CRC	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.97	-0.31	6.29e-9	Fibrinogen levels;
CRC	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-0.99	-12.67	-0.57	2.99e-30	Blood pressure (smoking interaction);
CRC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.76	13.49	0.6	2.57e-33	Mean platelet volume;
CRC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg05585544	chr11:47624801	NA	-0.5	-8.98	-0.44	2.06e-17	Subjective well-being;
CRC	cis	rs6479527	0.875	rs10821284	chr9:96776124	T/G	cg14459158	chr9:96720562	NA	0.39	6.97	0.36	1.69e-11	Esophageal adenocarcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05630523	chr19:12886518	HOOK2	0.48	6.59	0.34	1.75e-10	Response to antipsychotic treatment;
CRC	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg15145174	chr5:6755386	POLS	-0.46	-6.8	-0.35	5e-11	Menopause (age at onset);
CRC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05555928	chr11:63887634	MACROD1	0.38	6.22	0.32	1.47e-9	Platelet count;
CRC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.01	0.4	1.95e-14	Resting heart rate;
CRC	cis	rs7113874	0.550	rs11042002	chr11:8616646	T/C	cg02811074	chr11:8615871	STK33	0.36	6.15	0.32	2.22e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.54	0.38	4.55e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.66	7.65	0.39	2.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.3	-0.49	9.48e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg10820045	chr2:198174542	NA	-0.55	-9.55	-0.47	3.11e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25574672	chr5:133562092	PPP2CA	0.4	6.43	0.33	4.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs73206853	0.841	rs55885183	chr12:110877682	A/G	cg12870014	chr12:110450643	ANKRD13A	0.75	8.18	0.41	6.45e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg03037974	chr15:76606532	NA	-0.54	-8.17	-0.41	6.88e-15	Blood metabolite levels;
CRC	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg25019722	chr6:37503610	NA	-0.42	-6.87	-0.35	3.23e-11	Cognitive performance;
CRC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.47	7.4	0.38	1.11e-12	Monobrow;
CRC	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.71	13.15	0.59	4.98e-32	Hip circumference;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26714410	chr13:45150072	TSC22D1	0.47	6.45	0.34	3.93e-10	Thyroid stimulating hormone;
CRC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg24300038	chr13:113819356	PROZ	-0.48	-6.09	-0.32	3.19e-9	Platelet distribution width;
CRC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg04362960	chr10:104952993	NT5C2	-0.4	-5.6	-0.3	4.46e-8	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-7.18	-0.37	4.56e-12	Response to antipsychotic treatment;
CRC	trans	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg13565492	chr6:43139072	SRF	-0.72	-7.39	-0.38	1.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg24375607	chr4:120327624	NA	0.48	7.55	0.38	4.25e-13	Educational attainment;
CRC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg02869306	chr7:64672164	INTS4L1	0.45	7.82	0.4	7.21e-14	Calcium levels;
CRC	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.06	-14.8	-0.63	2.51e-38	Exhaled nitric oxide output;
CRC	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.43	-0.33	4.4e-10	Depression;
CRC	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-6.65	-0.34	1.2e-10	Breast cancer;
CRC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.8	13.22	0.59	2.77e-32	Menopause (age at onset);
CRC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.61	7.86	0.4	5.69e-14	Gut microbiome composition (summer);
CRC	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg04672837	chr16:48644449	N4BP1	0.4	5.86	0.31	1.14e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.6	9.81	0.48	4.28e-20	Vitiligo;
CRC	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.12	-0.73	2.45e-55	Schizophrenia;
CRC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.16	-0.32	2.14e-9	Height;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26942392	chr20:5591638	RP5-1022P6.2	0.38	5.97	0.31	6.11e-9	Obesity-related traits;
CRC	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg00105475	chr2:10696890	NA	-0.44	-6.97	-0.36	1.77e-11	Prostate cancer;
CRC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.54	0.43	5.06e-16	Height;
CRC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.4	-5.7	-0.3	2.72e-8	Blood pressure (smoking interaction);
CRC	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg14515779	chr1:101123966	NA	-0.44	-8.42	-0.42	1.14e-15	Monocyte count;
CRC	trans	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg10756647	chr7:56101905	PSPH	-0.76	-7.87	-0.4	5.31e-14	Diabetic kidney disease;
CRC	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg09455208	chr3:40491958	NA	0.31	6.15	0.32	2.3e-9	Renal cell carcinoma;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.5	9.1	0.45	9.1e-18	Vitiligo;
CRC	cis	rs78761021	0.867	rs17681684	chr17:9792768	A/G	cg26853458	chr17:9805074	RCVRN	-0.39	-7.26	-0.37	2.73e-12	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.58	6.56	0.34	2.06e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg12046867	chr14:103022105	NA	0.76	8.56	0.43	4.35e-16	Platelet count;
CRC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.51	-8.75	-0.43	1.1e-16	Schizophrenia;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.5	5.84	0.31	1.22e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.57	-8.92	-0.44	3.21e-17	Motion sickness;
CRC	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.74	-10.8	-0.51	1.76e-23	Multiple sclerosis;
CRC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.42	-6.13	-0.32	2.58e-9	Cerebrospinal P-tau181p levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02935305	chr6:35995251	MAPK14	0.43	6.1	0.32	2.92e-9	Response to antipsychotic treatment;
CRC	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.92	-16.06	-0.66	2.83e-43	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.71	8.39	0.42	1.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg13491945	chr12:107078410	RFX4	-0.35	-6.03	-0.32	4.37e-9	Heart rate;
CRC	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-10.95	-0.52	5.22e-24	Exhaled nitric oxide output;
CRC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.41	7.82	0.4	7.1e-14	Mean corpuscular volume;
CRC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.57	-9.15	-0.45	6.22e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.96	-0.44	2.46e-17	Coffee consumption (cups per day);
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg01874867	chr7:94954059	PON1	-0.48	-6.19	-0.32	1.81e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9443189	0.901	rs2038624	chr6:76560707	T/C	cg01950844	chr6:76311363	SENP6	-0.62	-7.41	-0.38	1.04e-12	Prostate cancer;
CRC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.01	-0.31	4.86e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.76	-0.35	6.15e-11	Type 2 diabetes;
CRC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.38	-0.46	1.15e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7113874	0.550	rs2044464	chr11:8559695	G/A	cg02811074	chr11:8615871	STK33	-0.36	-6.09	-0.32	3.13e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg09165964	chr15:75287851	SCAMP5	-0.49	-7.38	-0.38	1.29e-12	Caffeine consumption;
CRC	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	6.94	0.36	2.14e-11	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs56146971	0.763	rs34854034	chr14:91870677	A/G	cg16433844	chr14:91963127	SMEK1	-0.6	-6.35	-0.33	7.26e-10	Alzheimer disease and age of onset;
CRC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-5.85	-0.31	1.22e-8	Lung cancer;
CRC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg21251018	chr6:28226885	NKAPL	0.39	5.81	0.31	1.48e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1873147	0.731	rs12902152	chr15:63313968	T/C	cg12160578	chr15:63334699	TPM1	-0.43	-5.86	-0.31	1.11e-8	Orofacial clefts;
CRC	cis	rs2274273	0.686	rs17253695	chr14:55574610	A/T	cg10130446	chr14:55658398	DLGAP5	0.43	5.8	0.3	1.57e-8	Protein biomarker;
CRC	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.77	-12.29	-0.56	7.82e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg03030879	chr14:75389066	RPS6KL1	0.43	6.54	0.34	2.35e-10	Height;
CRC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg16141378	chr3:129829833	LOC729375	0.49	7.76	0.39	1.12e-13	Neuroticism;
CRC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.68	8.87	0.44	4.69e-17	Multiple sclerosis;
CRC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.15	0.32	2.2e-9	Diabetic kidney disease;
CRC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.54e-15	Morning vs. evening chronotype;
CRC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	7.16	0.37	5.26e-12	Menarche (age at onset);
CRC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.67	9.58	0.47	2.42e-19	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs62187609	chr2:162431500	C/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.66	-6.16	-0.32	2.08e-9	Cognitive function;
CRC	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.57	9.92	0.48	1.87e-20	Leprosy;
CRC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.36	0.46	1.29e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10991814	0.841	rs79219699	chr9:94028898	C/T	cg14446406	chr9:93919335	NA	0.55	5.95	0.31	7.05e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	8.52	0.43	5.89e-16	IgG glycosylation;
CRC	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.44	-0.33	4.18e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6694672	0.764	rs668590	chr1:197220598	A/T	cg13682187	chr1:196946512	CFHR5	0.49	7.01	0.36	1.39e-11	Asthma;
CRC	trans	rs10242455	0.850	rs3779354	chr7:99052428	T/C	cg09045935	chr12:6379348	NA	0.72	7.37	0.38	1.38e-12	Blood metabolite levels;
CRC	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.6	8.7	0.43	1.65e-16	Coronary artery disease;
CRC	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg18753928	chr3:113234510	CCDC52	-0.56	-6.66	-0.34	1.18e-10	Dental caries;
CRC	cis	rs62229266	0.633	rs34259635	chr21:37403570	T/G	cg12218747	chr21:37451666	NA	-0.37	-6.19	-0.32	1.8e-9	Mitral valve prolapse;
CRC	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.49	-5.97	-0.31	5.99e-9	Metabolite levels;
CRC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.65	12.43	0.57	2.4e-29	Coronary artery disease;
CRC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg19193384	chr17:30244184	NA	-0.65	-7.58	-0.39	3.51e-13	Hip circumference adjusted for BMI;
CRC	trans	rs6956675	0.958	rs7779974	chr7:62576724	T/C	cg01314568	chr7:57830625	NA	-0.67	-9.26	-0.45	2.7e-18	Obesity-related traits;
CRC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg03340356	chr1:67600835	NA	0.24	5.78	0.3	1.71e-8	Psoriasis;
CRC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18912574	chr7:65842487	NCRNA00174	0.35	5.9	0.31	8.96e-9	Aortic root size;
CRC	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.53	-8.19	-0.41	5.93e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.65	8.93	0.44	3.15e-17	Alcohol dependence;
CRC	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.6	-5.82	-0.31	1.36e-8	White matter integrity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19547976	chr4:1737009	TACC3	-0.34	-6.05	-0.32	3.9e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.6	-0.43	3.22e-16	Chronic sinus infection;
CRC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg15123519	chr2:136567270	LCT	-0.35	-6.92	-0.36	2.35e-11	Mosquito bite size;
CRC	cis	rs3026101	0.671	rs8077471	chr17:5299356	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.5	-6.44	-0.33	4.26e-10	Blood protein levels;
CRC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg19980929	chr12:42632907	YAF2	-0.4	-6.15	-0.32	2.3e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg08501292	chr6:25962987	TRIM38	0.83	7.52	0.38	5.14e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-6.18	-0.32	1.87e-9	Post bronchodilator FEV1;
CRC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.43	-8.4	-0.42	1.4e-15	Mean corpuscular volume;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.6	11.08	0.52	1.79e-24	Immature fraction of reticulocytes;
CRC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg10298567	chr3:47292165	KIF9	0.38	5.95	0.31	6.96e-9	Colorectal cancer;
CRC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg05585544	chr11:47624801	NA	-0.52	-9.41	-0.46	8.6e-19	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21037892	chr2:96874728	STARD7	0.44	6.33	0.33	8.13e-10	Response to antipsychotic treatment;
CRC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.49	9.63	0.47	1.66e-19	Renal cell carcinoma;
CRC	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.74	-10.26	-0.49	1.29e-21	Blood protein levels;
CRC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg18646521	chr2:111875858	NA	0.39	6.2	0.32	1.64e-9	Chronic lymphocytic leukemia;
CRC	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.56	-8.84	-0.44	6.03e-17	Breast cancer;
CRC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.03	0.4	1.7e-14	Parkinson's disease;
CRC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-8.12	-0.41	9.26e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs62458065	0.850	rs28693551	chr7:32469387	G/A	cg20159608	chr7:32802032	NA	-0.56	-6.75	-0.35	6.67e-11	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.72	-9.17	-0.45	5.4e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs3996993	0.839	rs9382146	chr6:52702085	G/A	cg20803780	chr6:52668592	GSTA1	-0.36	-6.74	-0.35	7.25e-11	Hemoglobin concentration;
CRC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg19223190	chr17:80058835	NA	0.39	6.21	0.32	1.62e-9	Life satisfaction;
CRC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.66	9.74	0.47	7.39e-20	Lung cancer;
CRC	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg15192750	chr16:69999425	NA	0.58	7.69	0.39	1.69e-13	IgE levels;
CRC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.56	-7.68	-0.39	1.81e-13	Alzheimer's disease;
CRC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.57	8.54	0.43	5.15e-16	Multiple sclerosis;
CRC	trans	rs7027930	0.524	rs58960694	chr9:614630	G/A	cg27061366	chr19:13044373	FARSA	0.51	6.41	0.33	5.03e-10	Pulmonary function decline;
CRC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.03	-0.32	4.39e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4728302	0.838	rs755664	chr7:133596671	C/G	cg03336402	chr7:133662267	EXOC4	-0.44	-6.34	-0.33	7.53e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.52	-0.34	2.66e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg15763984	chr4:1342303	KIAA1530	0.5	8.42	0.42	1.17e-15	Longevity;
CRC	cis	rs7075426	0.669	rs10887608	chr10:88191938	A/G	cg07322936	chr10:88137208	NA	-0.41	-5.69	-0.3	2.78e-8	Migraine without aura;
CRC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.67	-0.35	1.06e-10	Menopause (age at onset);
CRC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.55	-10.59	-0.5	9.62e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07083667	chr17:5342657	C1QBP	0.39	6.33	0.33	8.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg21620606	chr4:1342894	KIAA1530	0.34	5.62	0.3	4.15e-8	Obesity-related traits;
CRC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.58	-6.88	-0.35	2.94e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21155796	chr2:242212141	HDLBP	0.62	6.54	0.34	2.4e-10	Prostate cancer;
CRC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.31	5.81	0.3	1.5e-8	Blood protein levels;
CRC	cis	rs73206853	0.620	rs28720928	chr12:111126609	C/T	cg12870014	chr12:110450643	ANKRD13A	0.74	7.49	0.38	6.39e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.4	0.5	4.25e-22	Ileal carcinoids;
CRC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.52	8.87	0.44	4.9e-17	Iron status biomarkers;
CRC	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-14.46	-0.62	4.86e-37	Colorectal cancer;
CRC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg17724175	chr1:150552817	MCL1	-0.54	-8.9	-0.44	3.78e-17	Tonsillectomy;
CRC	cis	rs2857891	0.817	rs2857899	chr11:6981668	A/C	cg04053776	chr11:6947353	ZNF215	0.39	5.72	0.3	2.37e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs2565722	0.713	rs2465867	chr6:161285463	G/A	cg03159191	chr6:161285451	NA	-0.47	-6.29	-0.33	1e-9	Blood protein levels;
CRC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.62	9.58	0.47	2.54e-19	Corneal astigmatism;
CRC	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.6	-9.01	-0.44	1.73e-17	Colorectal cancer;
CRC	cis	rs6433857	0.536	rs12464424	chr2:181349137	A/G	cg23363182	chr2:181467187	NA	-0.52	-7.6	-0.39	3.1e-13	Body mass index;
CRC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.59	-8.43	-0.42	1.1e-15	Platelet distribution width;
CRC	trans	rs12943633	1.000	rs12943633	chr17:37970365	C/T	cg24146408	chr3:15374317	SH3BP5	0.72	6.08	0.32	3.28e-9	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06796825	chr17:17140633	FLCN	0.39	6.01	0.31	4.95e-9	Myopia (pathological);
CRC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg10723962	chr6:26240782	HIST1H4F	-0.4	-6.62	-0.34	1.49e-10	Gout;Renal underexcretion gout;
CRC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.68	9.61	0.47	2e-19	Vitamin D levels;
CRC	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-6.62	-0.34	1.44e-10	Coronary artery disease;
CRC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-7.04	-0.36	1.16e-11	Bladder cancer;
CRC	cis	rs7113874	0.569	rs10769914	chr11:8576202	A/G	cg20771178	chr11:8615675	STK33	-0.34	-5.61	-0.3	4.37e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg00666640	chr1:248458726	OR2T12	0.51	8.68	0.43	1.91e-16	Common traits (Other);
CRC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.41	0.42	1.28e-15	Height;
CRC	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.65	8.89	0.44	3.98e-17	Coronary artery disease;
CRC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14895029	chr7:2775587	GNA12	-0.41	-6.17	-0.32	2.02e-9	Height;
CRC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.91	0.44	3.62e-17	Birth weight;
CRC	cis	rs747650	0.504	rs7126005	chr11:47041065	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-5.88	-0.31	1.03e-8	Acne (severe);
CRC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.54	8.21	0.41	5.03e-15	Breast cancer;
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.63	0.39	2.5e-13	Alzheimer's disease;
CRC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	11.15	0.52	1.03e-24	Monocyte percentage of white cells;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24542852	chr12:569111	B4GALNT3	0.43	5.96	0.31	6.5e-9	Anxiety disorder;
CRC	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.53	-7.3	-0.37	2.17e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6743376	0.532	rs2515403	chr2:113820732	T/C	cg09040174	chr2:113837401	NA	0.4	5.84	0.31	1.22e-8	Inflammatory biomarkers;
CRC	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg08314208	chr16:67682810	RLTPR	-0.62	-7.01	-0.36	1.39e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.84	-14.39	-0.62	9.73e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.6	8.0	0.4	2.16e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.44	-6.18	-0.32	1.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.51	-7.26	-0.37	2.73e-12	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22199115	chr12:90102575	LOC338758	0.45	7.17	0.37	5.07e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-6.26	-0.33	1.18e-9	Metabolite levels (Pyroglutamine);
CRC	trans	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg21659725	chr3:3221576	CRBN	0.63	6.8	0.35	4.95e-11	Menarche (age at onset);
CRC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.23e-23	Motion sickness;
CRC	cis	rs17155006	0.664	rs448559	chr7:107739485	A/G	cg05962710	chr7:107745446	LAMB4	-0.43	-7.8	-0.4	8.12e-14	Pneumococcal bacteremia;
CRC	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.71	-9.92	-0.48	1.78e-20	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg24675056	chr1:15929824	NA	0.48	6.52	0.34	2.66e-10	Systolic blood pressure;
CRC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.48	4.52e-20	Eye color traits;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02359409	chr6:42947317	PEX6	-0.58	-8.85	-0.44	5.33e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.82	-0.31	1.4e-8	Primary biliary cholangitis;
CRC	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.79	10.05	0.48	6.85e-21	Prostate cancer;
CRC	cis	rs1656402	1.000	rs1550097	chr2:233428275	C/T	cg03852847	chr2:233439513	NA	0.45	7.59	0.39	3.35e-13	Non-small cell lung cancer (survival);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13565152	chr9:35815219	HINT2	0.41	6.28	0.33	1.06e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16406212	chr2:24163862	UBXN2A	0.46	6.61	0.34	1.59e-10	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-20.88	-0.75	3.09e-62	Primary sclerosing cholangitis;
CRC	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.61	-8.1	-0.41	1.11e-14	Eosinophil percentage of granulocytes;
CRC	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.51	-8.91	-0.44	3.44e-17	Aortic root size;
CRC	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.51	6.53	0.34	2.45e-10	DNA methylation (variation);
CRC	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	1.11	12.96	0.58	2.49e-31	Obesity-related traits;
CRC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg15382696	chr6:118971807	C6orf204	0.62	8.05	0.41	1.53e-14	Diastolic blood pressure;
CRC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.71	10.4	0.5	4.47e-22	Systemic sclerosis;
CRC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.46	-0.38	7.59e-13	Morning vs. evening chronotype;
CRC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg13072238	chr3:49761600	GMPPB	0.52	5.7	0.3	2.68e-8	Menarche (age at onset);
CRC	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg05925327	chr15:68127851	NA	-0.31	-6.03	-0.32	4.4e-9	Restless legs syndrome;
CRC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.7	-12.19	-0.56	1.9e-28	Prostate cancer;
CRC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.53	6.7	0.35	8.91e-11	Morning vs. evening chronotype;
CRC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	10.98	0.52	4.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg11212589	chr17:38028394	ZPBP2	0.43	7.92	0.4	3.63e-14	Self-reported allergy;
CRC	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg09127314	chr1:152161683	NA	0.48	6.18	0.32	1.9e-9	Atopic dermatitis;
CRC	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.5	-0.34	2.95e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg09045935	chr12:6379348	NA	0.84	6.31	0.33	8.84e-10	Blood metabolite levels;
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg00612595	chr21:47717864	NA	-0.34	-5.66	-0.3	3.23e-8	Testicular germ cell tumor;
CRC	cis	rs12024301	0.557	rs10911407	chr1:183658546	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.46	-7.89	-0.4	4.41e-14	Schizophrenia;
CRC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.51	-8.44	-0.42	1.02e-15	Aortic root size;
CRC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.49	0.54	6.52e-26	Prudent dietary pattern;
CRC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	11.77	0.54	6.37e-27	Platelet count;
CRC	trans	rs10277209	1.000	rs10277209	chr7:109003574	A/G	cg13575011	chr19:16022472	NA	-0.48	-6.1	-0.32	2.93e-9	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.88	10.68	0.51	4.85e-23	Obesity-related traits;
CRC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.42	-0.33	4.8e-10	Reticulocyte fraction of red cells;
CRC	cis	rs59901009	0.863	rs2278634	chr11:10184463	C/A	cg23875677	chr11:10229755	SBF2	-0.48	-6.06	-0.32	3.73e-9	Hematocrit;Hemoglobin concentration;
CRC	cis	rs2814982	0.605	rs114032116	chr6:34468333	C/T	cg17674042	chr6:34482479	PACSIN1	-1.01	-11.04	-0.52	2.63e-24	Cholesterol, total;Total cholesterol levels;
CRC	trans	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg17903999	chr18:56338584	MALT1	0.42	6.94	0.36	2.1e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.86	-0.44	5.13e-17	Prostate cancer;
CRC	cis	rs931127	0.658	rs4244812	chr11:65480768	A/G	cg27068330	chr11:65405492	SIPA1	-0.43	-5.9	-0.31	9e-9	Systemic lupus erythematosus;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg12859382	chr3:52445103	PHF7;BAP1	0.45	6.09	0.32	3.08e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.75	-16.52	-0.67	4.6e-45	Intelligence (multi-trait analysis);
CRC	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.19	0.32	1.84e-9	Neuroticism;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg26410121	chr1:144521081	LOC728875	0.51	6.21	0.32	1.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06470822	chr6:28175283	NA	0.75	7.13	0.37	6.35e-12	Depression;
CRC	cis	rs3218092	0.872	rs3218086	chr6:41910064	C/T	cg17623882	chr6:41773611	USP49	0.47	5.61	0.3	4.4e-8	Red cell distribution width;
CRC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.84	0.55	3.47e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7680126	0.596	rs12503603	chr4:10313757	T/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.55	-0.34	2.24e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg13206674	chr6:150067644	NUP43	0.52	7.48	0.38	6.73e-13	Testicular germ cell tumor;
CRC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-11.57	-0.54	3.31e-26	Asthma;
CRC	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.57	0.34	2.02e-10	Myopia (pathological);
CRC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.65	0.34	1.22e-10	Neutrophil percentage of white cells;
CRC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.79	-9.46	-0.46	6.17e-19	Hemostatic factors and hematological phenotypes;
CRC	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.67	10.24	0.49	1.54e-21	Corneal astigmatism;
CRC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.12	-0.32	2.69e-9	Arsenic metabolism;
CRC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.22	-0.32	1.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18099408	chr3:52552593	STAB1	-0.57	-11.04	-0.52	2.52e-24	Electroencephalogram traits;
CRC	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg26394196	chr10:1453818	ADARB2	-0.33	-5.83	-0.31	1.34e-8	Radiation response;
CRC	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg15733309	chr7:157513707	PTPRN2	0.41	6.83	0.35	4.18e-11	Bipolar disorder and schizophrenia;
CRC	trans	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg00953403	chr17:74099816	EXOC7	-0.5	-7.42	-0.38	1.01e-12	Psychosis in Alzheimer's disease;
CRC	trans	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg20935933	chr6:143382018	AIG1	0.5	6.54	0.34	2.38e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09695851	chr17:3907499	NA	0.65	11.29	0.53	3.23e-25	Type 2 diabetes;
CRC	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.42	5.99	0.31	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.62	8.05	0.41	1.51e-14	Chronic kidney disease;
CRC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.58	-6.18	-0.32	1.86e-9	Schizophrenia;
CRC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.58	-0.34	1.9e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.53	-5.96	-0.31	6.42e-9	Body mass index;
CRC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.59	9.98	0.48	1.13e-20	Menopause (age at onset);
CRC	cis	rs3026101	0.671	rs1143206	chr17:5284698	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	7.47	0.38	7.09e-13	Body mass index;
CRC	cis	rs2195987	0.914	rs10416636	chr19:24108447	A/T	cg00460763	chr19:23944615	RPSAP58	0.53	5.93	0.31	7.49e-9	Testicular germ cell tumor;
CRC	trans	rs17126268	0.605	rs1856776	chr1:102876616	T/C	cg18468354	chr14:36993517	NA	0.39	6.14	0.32	2.37e-9	Glomerular filtration rate;
CRC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.79	-16.29	-0.67	3.75e-44	Electroencephalogram traits;
CRC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.63	-6.26	-0.33	1.22e-9	Schizophrenia;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg06470822	chr6:28175283	NA	0.68	9.44	0.46	6.91e-19	Parkinson's disease;
CRC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg00734567	chr1:86172782	ZNHIT6	-0.48	-7.38	-0.38	1.33e-12	Urate levels in overweight individuals;
CRC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg22815214	chr1:201083145	CACNA1S	-0.51	-6.42	-0.33	4.67e-10	Permanent tooth development;
CRC	cis	rs9463078	0.669	rs7750380	chr6:45070034	A/G	cg25276700	chr6:44698697	NA	-0.25	-5.94	-0.31	7.4e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs243505	0.708	rs243548	chr7:148396549	G/A	cg09806900	chr7:148480153	CUL1	-0.44	-5.61	-0.3	4.24e-8	Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg26043149	chr18:55253948	FECH	0.53	8.17	0.41	6.79e-15	Bone mineral density;
CRC	cis	rs3996993	0.597	rs62412900	chr6:52721568	C/T	cg20803780	chr6:52668592	GSTA1	0.39	6.84	0.35	3.96e-11	Hemoglobin concentration;
CRC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.87	0.48	2.71e-20	Platelet count;
CRC	cis	rs4664293	0.967	rs35975814	chr2:160547791	G/A	cg08347373	chr2:160653686	CD302	-0.44	-7.18	-0.37	4.55e-12	Monocyte percentage of white cells;
CRC	cis	rs524281	0.773	rs79770412	chr11:66045344	G/C	cg16950941	chr11:66035639	RAB1B	-0.72	-8.07	-0.41	1.3e-14	Electroencephalogram traits;
CRC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.6	8.55	0.43	4.74e-16	Arsenic metabolism;
CRC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg25985355	chr7:65971099	NA	-0.48	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
CRC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.77	0.6	2.29e-34	Chronic sinus infection;
CRC	cis	rs1256061	0.603	rs1152579	chr14:64695087	A/G	cg23250157	chr14:64679961	SYNE2	0.48	7.53	0.38	5.04e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.83	-0.48	3.75e-20	Total cholesterol levels;
CRC	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.98	17.96	0.7	9.17e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.61	6.86	0.35	3.38e-11	Vitiligo;
CRC	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	1.05	22.23	0.77	1.67e-67	Multiple myeloma;
CRC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg12573674	chr2:1569213	NA	-0.72	-7.73	-0.39	1.34e-13	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg04731861	chr2:219085781	ARPC2	-0.31	-6.56	-0.34	2.12e-10	Colorectal cancer;
CRC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg19812747	chr11:111475976	SIK2	0.52	7.55	0.38	4.2e-13	Primary sclerosing cholangitis;
CRC	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.91	-0.4	3.91e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-9.38	-0.46	1.11e-18	Hemoglobin concentration;
CRC	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.71	0.35	8.6e-11	Coronary artery disease;
CRC	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg09659197	chr4:152720779	NA	0.32	5.81	0.31	1.46e-8	Intelligence (multi-trait analysis);
CRC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.66	0.39	2.08e-13	Mean corpuscular volume;
CRC	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.41	-6.23	-0.33	1.39e-9	Body mass index;
CRC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg27266060	chr8:22091797	NA	0.36	6.17	0.32	2e-9	Hypertriglyceridemia;
CRC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.67	0.6	5.38e-34	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.86	0.44	5.16e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.45	7.33	0.37	1.75e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.09	10.23	0.49	1.69e-21	Skin colour saturation;
CRC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.68	-12.01	-0.55	8.36e-28	Asthma;
CRC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.41	-7.69	-0.39	1.7e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.46	7.42	0.38	1.02e-12	Aortic root size;
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.55	-0.5	1.36e-22	Alzheimer's disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg15985338	chr7:6048868	PMS2;AIMP2	0.46	7.64	0.39	2.44e-13	Obesity-related traits;
CRC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg17948913	chr5:572064	NA	0.56	6.25	0.33	1.28e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.67	-0.3	3.11e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.6	-6.32	-0.33	8.63e-10	Schizophrenia;
CRC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg08888203	chr3:10149979	C3orf24	-0.48	-7.27	-0.37	2.58e-12	Alzheimer's disease;
CRC	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.53	-7.25	-0.37	2.92e-12	Triglycerides;
CRC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg20673091	chr1:2541236	MMEL1	0.35	5.63	0.3	3.88e-8	Multiple sclerosis;
CRC	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg23260525	chr10:116636907	FAM160B1	0.32	6.94	0.36	2.04e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	5.86	0.31	1.11e-8	Tonsillectomy;
CRC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.96	0.4	2.84e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg19046167	chr17:80928561	B3GNTL1	0.51	7.34	0.38	1.65e-12	Glycated hemoglobin levels;
CRC	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg00042356	chr1:8021962	PARK7	0.7	7.39	0.38	1.24e-12	Inflammatory bowel disease;
CRC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.86	-0.35	3.41e-11	Bipolar disorder;
CRC	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.41	6.33	0.33	8.11e-10	Neuroticism;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg22079747	chr2:228736145	WDR69	-0.44	-5.94	-0.31	7.4e-9	Blood pressure;
CRC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg03874509	chr1:107600012	PRMT6	0.44	6.0	0.31	5.22e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.13	-0.52	1.21e-24	Extrinsic epigenetic age acceleration;
CRC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.29	-0.49	1.03e-21	Total cholesterol levels;
CRC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg25985355	chr7:65971099	NA	-0.51	-5.87	-0.31	1.05e-8	Diabetic kidney disease;
CRC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg13072238	chr3:49761600	GMPPB	-0.54	-5.85	-0.31	1.19e-8	Menarche (age at onset);
CRC	cis	rs4917833	0.700	rs7067691	chr10:100221081	T/C	cg19043522	chr10:100227446	HPSE2	0.38	5.81	0.3	1.5e-8	Pediatric bone mineral density (femoral neck);
CRC	trans	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06679760	chr3:49027156	P4HTM	0.48	6.34	0.33	7.51e-10	Survival in pancreatic cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	6.0	0.31	5.34e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg21466736	chr12:48725269	NA	-0.56	-8.36	-0.42	1.85e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12463550	chr7:65579703	CRCP	0.65	5.81	0.31	1.47e-8	Diabetic kidney disease;
CRC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.07	-0.45	1.13e-17	Bipolar disorder;
CRC	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-0.86	-13.34	-0.59	9.22e-33	Platelet distribution width;
CRC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-6.27	-0.33	1.15e-9	Menarche (age at onset);
CRC	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.21	0.32	1.55e-9	Ovarian reserve;
CRC	cis	rs4132509	1.000	rs10927078	chr1:243983830	C/T	cg21452805	chr1:244014465	NA	0.53	6.26	0.33	1.19e-9	RR interval (heart rate);
CRC	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg02158880	chr13:53174818	NA	0.6	9.77	0.47	5.91e-20	Lewy body disease;
CRC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg25985355	chr7:65971099	NA	-0.53	-6.08	-0.32	3.36e-9	Diabetic kidney disease;
CRC	cis	rs6577655	0.517	rs2241893	chr8:135586659	C/T	cg17885191	chr8:135476712	NA	0.5	5.77	0.3	1.84e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.7	-0.39	1.65e-13	Psoriasis;
CRC	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.01	0.52	3.15e-24	Bipolar disorder;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg08132177	chr1:856685	NA	-0.68	-6.0	-0.31	5.29e-9	Cognitive function;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11220133	chr8:48873533	MCM4;PRKDC	0.36	6.05	0.32	3.99e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.98	-0.31	5.68e-9	Monocyte percentage of white cells;
CRC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs747650	0.504	rs7124648	chr11:47044249	T/C	cg19486271	chr11:47235900	DDB2	-0.44	-5.9	-0.31	9.01e-9	Acne (severe);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg26784276	chr17:7142991	PHF23	-0.41	-6.44	-0.33	4.36e-10	Aortic root size;
CRC	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg15147215	chr3:52552868	STAB1	-0.66	-11.52	-0.54	5.15e-26	Electroencephalogram traits;
CRC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.65	0.47	1.44e-19	Birth weight;
CRC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.43	0.33	4.41e-10	Diastolic blood pressure;
CRC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.65	-0.3	3.5e-8	Cognitive function;
CRC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.41	8.77	0.44	9.81e-17	Urinary metabolites;
CRC	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.61	6.54	0.34	2.35e-10	Childhood ear infection;
CRC	cis	rs17021463	0.673	rs17565759	chr4:95280763	C/T	cg11021082	chr4:95130006	SMARCAD1	0.44	6.32	0.33	8.62e-10	Testicular germ cell tumor;
CRC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-16.18	-0.67	9.81e-44	Height;
CRC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.78	-13.38	-0.59	6.93e-33	Obesity-related traits;
CRC	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.72	-9.65	-0.47	1.42e-19	Blood pressure (smoking interaction);
CRC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	7.93	0.4	3.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg18225595	chr11:63971243	STIP1	0.58	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs853679	1.000	rs853676	chr6:28299687	C/T	cg15786705	chr6:28176104	NA	0.58	6.03	0.32	4.51e-9	Depression;
CRC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.61	10.95	0.52	5.42e-24	Aortic root size;
CRC	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.47	-6.05	-0.32	3.87e-9	Alopecia areata;
CRC	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg17182837	chr8:41585554	ANK1	-0.4	-6.21	-0.32	1.63e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CRC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.42	6.05	0.32	3.94e-9	Erythrocyte sedimentation rate;
CRC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17261708	chr5:176794207	RGS14	0.43	6.83	0.35	3.99e-11	Hemoglobin concentration;Hematocrit;
CRC	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg06209491	chr1:40138402	NT5C1A	-0.48	-7.75	-0.39	1.18e-13	Amyotrophic lateral sclerosis;
CRC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg18827107	chr12:86230957	RASSF9	-0.41	-6.18	-0.32	1.89e-9	Major depressive disorder;
CRC	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.26	0.45	2.73e-18	Blood protein levels;
CRC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg25876840	chr17:41920477	NA	0.53	7.14	0.37	5.85e-12	Triglycerides;
CRC	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg10494257	chr1:16342123	HSPB7	0.45	6.24	0.33	1.33e-9	Dilated cardiomyopathy;
CRC	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg24531977	chr5:56204891	C5orf35	-0.46	-6.97	-0.36	1.74e-11	Coronary artery disease;
CRC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.58	0.63	1.76e-37	Chronic sinus infection;
CRC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06656553	chr16:89960601	TCF25	-0.69	-6.06	-0.32	3.75e-9	Skin colour saturation;
CRC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg13736514	chr6:26305472	NA	-0.45	-7.24	-0.37	3.18e-12	Educational attainment;
CRC	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.58	6.37	0.33	6.52e-10	Type 2 diabetes;
CRC	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.4	-5.73	-0.3	2.31e-8	Strep throat;
CRC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.58	-9.34	-0.46	1.48e-18	Intelligence (multi-trait analysis);
CRC	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg14515779	chr1:101123966	NA	-0.33	-5.88	-0.31	9.88e-9	Monocyte count;
CRC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.57	8.6	0.43	3.29e-16	Aortic root size;
CRC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.91	-0.36	2.44e-11	Response to antipsychotic treatment;
CRC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg04553112	chr3:125709451	NA	-0.51	-5.71	-0.3	2.5e-8	Blood pressure (smoking interaction);
CRC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.68	0.75	1.83e-61	Prudent dietary pattern;
CRC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg24046110	chr8:143859143	LYNX1	0.46	8.05	0.41	1.57e-14	Urinary tract infection frequency;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11686940	chr15:31664433	KLF13	0.46	6.51	0.34	2.83e-10	Survival in pancreatic cancer;
CRC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	7.69	0.39	1.76e-13	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-7.42	-0.38	1.02e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.9	-15.13	-0.64	1.27e-39	Blood metabolite levels;
CRC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	10.22	0.49	1.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.51	-8.5	-0.42	6.71e-16	Aortic root size;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg25164649	chr6:28176230	NA	0.75	9.36	0.46	1.32e-18	Depression;
CRC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.52	7.7	0.39	1.66e-13	Lung cancer;
CRC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.61	-0.34	1.56e-10	Daytime sleep phenotypes;
CRC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-6.4	-0.33	5.2e-10	Height;
CRC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.44	6.88	0.35	3.02e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg13319975	chr6:146136371	FBXO30	-0.41	-6.29	-0.33	9.86e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16235707	chr5:75698461	IQGAP2	0.41	6.01	0.31	4.87e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg23234261	chr14:55582407	NA	-0.28	-5.66	-0.3	3.22e-8	Protein biomarker;
CRC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.42	-0.33	4.72e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.48	7.94	0.4	3.15e-14	Crohn's disease;
CRC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.59	7.94	0.4	3.23e-14	Systolic blood pressure;
CRC	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.41	6.04	0.32	4.26e-9	Kawasaki disease;
CRC	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg07862535	chr7:139043722	LUC7L2	0.55	7.14	0.37	5.99e-12	Diisocyanate-induced asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13541861	chr19:507806	C19orf20	0.45	6.16	0.32	2.09e-9	Anxiety disorder;
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs6432018	0.927	rs6432023	chr2:9736874	C/T	cg12832956	chr2:9616023	IAH1	-0.37	-5.62	-0.3	4.17e-8	Heart rate variability traits;
CRC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.79	13.45	0.6	3.6e-33	Menopause (age at onset);
CRC	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.55	8.68	0.43	1.84e-16	Schizophrenia;
CRC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg13385521	chr17:29058706	SUZ12P	-0.45	-5.97	-0.31	5.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.6	10.04	0.48	7.42e-21	Mean corpuscular volume;
CRC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg21770322	chr7:97807741	LMTK2	-0.52	-8.9	-0.44	3.74e-17	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.61	9.47	0.46	5.81e-19	Intelligence (multi-trait analysis);
CRC	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.96	16.91	0.68	1.28e-46	Obesity (extreme);
CRC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-16.32	-0.67	2.71e-44	Electrocardiographic conduction measures;
CRC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.75	8.9	0.44	3.94e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg25382214	chr1:3105252	PRDM16	0.41	7.1	0.36	7.88e-12	Migraine;
CRC	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	0.66	7.11	0.36	7.22e-12	Prostate cancer;
CRC	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.15	19.01	0.72	6.52e-55	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs61160187	0.556	rs4647052	chr5:60235483	C/T	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.91	-0.31	8.4e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.55	7.11	0.36	7.41e-12	Mean platelet volume;
CRC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-6.9	-0.36	2.63e-11	Renal cell carcinoma;
CRC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg22110888	chr17:80059540	CCDC57	-0.4	-6.32	-0.33	8.69e-10	Life satisfaction;
CRC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.53	7.58	0.39	3.48e-13	Schizophrenia;
CRC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.53	7.84	0.4	6.14e-14	Lung cancer;
CRC	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg12193833	chr17:30244370	NA	-0.6	-7.88	-0.4	4.82e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.68	9.31	0.46	1.94e-18	Alzheimer's disease;
CRC	trans	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg19694781	chr19:47549865	TMEM160	-0.47	-7.35	-0.38	1.54e-12	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs7692995	1.000	rs6449353	chr4:18033488	T/C	cg08925142	chr4:18023851	LCORL	-0.53	-5.98	-0.31	5.94e-9	Height;
CRC	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-1.05	-14.47	-0.62	4.53e-37	Exhaled nitric oxide output;
CRC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.52	-6.34	-0.33	7.73e-10	Obesity-related traits;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05141026	chr8:145064874	GRINA	0.42	6.39	0.33	5.59e-10	Schizophrenia;
CRC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-8.24	-0.41	4.04e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.4	-0.38	1.18e-12	Blood metabolite levels;
CRC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.82	0.35	4.46e-11	Itch intensity from mosquito bite;
CRC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg23625390	chr15:77176239	SCAPER	0.48	6.92	0.36	2.34e-11	Blood metabolite levels;
CRC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg05627522	chr15:75251581	NA	0.5	7.6	0.39	3.04e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.55	-0.43	4.57e-16	Life satisfaction;
CRC	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	12.21	0.56	1.56e-28	Coffee consumption (cups per day);
CRC	cis	rs12541635	0.966	rs4734128	chr8:107026913	G/A	cg10147462	chr8:107024639	NA	0.46	7.64	0.39	2.39e-13	Age of smoking initiation;
CRC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.74	-0.51	2.87e-23	Blood trace element (Zn levels);
CRC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.39	6.75	0.35	6.7e-11	Crohn's disease;
CRC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg01721255	chr8:58191610	C8orf71	0.5	6.21	0.32	1.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs45544231	0.544	rs1123428	chr16:52577835	A/T	cg09051775	chr16:52580266	TOX3	0.4	6.42	0.33	4.78e-10	Restless legs syndrome;
CRC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.89	-0.48	2.34e-20	Monocyte count;
CRC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.51	-9.13	-0.45	7.36e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg09003973	chr2:102972529	NA	0.41	5.86	0.31	1.12e-8	Blood protein levels;
CRC	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.66	-7.41	-0.38	1.06e-12	Osteoarthritis;
CRC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.74	-0.35	7.12e-11	Mean corpuscular volume;
CRC	cis	rs713587	0.520	rs530951	chr2:25307005	C/T	cg22495460	chr2:25135724	ADCY3	0.44	6.63	0.34	1.39e-10	Body mass index in non-asthmatics;
CRC	trans	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg26043149	chr18:55253948	FECH	-0.58	-8.67	-0.43	1.96e-16	Bone mineral density;
CRC	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg06632207	chr12:54070931	ATP5G2	0.39	6.72	0.35	8.1e-11	Height;
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg21155852	chr7:2048760	MAD1L1	-0.48	-6.31	-0.33	8.82e-10	Neuroticism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16956456	chr5:172483378	C5orf41	0.43	6.19	0.32	1.8e-9	Response to antipsychotic treatment;
CRC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06656553	chr16:89960601	TCF25	-0.68	-5.66	-0.3	3.31e-8	Skin colour saturation;
CRC	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.43	-0.38	9.31e-13	Neuroticism;
CRC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.43	-5.84	-0.31	1.29e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.4	6.04	0.32	4.18e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.66	0.34	1.18e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.68	7.72	0.39	1.46e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.79	12.98	0.58	2.2e-31	Hip circumference;
CRC	cis	rs77861329	0.702	rs12496447	chr3:52103787	T/C	cg08692210	chr3:52188851	WDR51A	0.54	6.3	0.33	9.46e-10	Macrophage inflammatory protein 1b levels;
CRC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.45	6.92	0.36	2.31e-11	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23470272	chr19:14640395	TECR;MIR639	0.4	6.36	0.33	6.69e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.36	5.77	0.3	1.82e-8	Carotid intima media thickness;
CRC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.83	12.83	0.58	8.21e-31	Platelet distribution width;
CRC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.43	6.22	0.32	1.51e-9	Schizophrenia;
CRC	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg13086574	chr8:135490821	ZFAT	-0.36	-6.33	-0.33	7.81e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg24154853	chr7:158122151	PTPRN2	0.51	7.07	0.36	9.19e-12	Response to amphetamines;
CRC	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.51	5.71	0.3	2.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6681460	0.966	rs4655646	chr1:67094336	G/A	cg02459107	chr1:67143332	SGIP1	0.44	7.14	0.37	6e-12	Presence of antiphospholipid antibodies;
CRC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.81	14.35	0.62	1.37e-36	Breast cancer;
CRC	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-1.0	-18.02	-0.7	5.28e-51	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4363385	1.000	rs310124	chr1:153020275	C/T	cg25856811	chr1:152973957	SPRR3	-0.22	-5.7	-0.3	2.67e-8	Inflammatory skin disease;
CRC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.76	-0.66	4.38e-42	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.82	-0.55	4.24e-27	Alzheimer's disease;
CRC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg05304507	chr6:116381966	FRK	0.3	8.25	0.41	3.81e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.51	0.54	5.3e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-9.53	-0.47	3.62e-19	Alcohol dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05296608	chr10:134537282	INPP5A	-0.39	-6.36	-0.33	6.93e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.63	-0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg23260525	chr10:116636907	FAM160B1	0.31	6.75	0.35	6.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg20607287	chr7:12443886	VWDE	-0.44	-5.88	-0.31	1.03e-8	Coronary artery disease;
CRC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg19635926	chr16:89946313	TCF25	0.69	6.92	0.36	2.41e-11	Skin colour saturation;
CRC	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg24972876	chr7:65420302	NA	0.38	6.56	0.34	2.05e-10	Aortic root size;
CRC	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.54	7.4	0.38	1.14e-12	Urinary tract infection frequency;
CRC	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.7	-9.85	-0.48	3.13e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.04	-17.65	-0.7	1.53e-49	Schizophrenia;
CRC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.47	-7.45	-0.38	8.36e-13	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04621255	chr9:131581398	ENDOG	0.44	6.07	0.32	3.57e-9	Response to antipsychotic treatment;
CRC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.63	9.49	0.46	4.71e-19	Lung cancer;
CRC	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg18850127	chr7:39170497	POU6F2	0.5	6.43	0.33	4.42e-10	IgG glycosylation;
CRC	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.76	-12.77	-0.58	1.35e-30	Idiopathic membranous nephropathy;
CRC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.6	-7.81	-0.4	7.9e-14	Aortic root size;
CRC	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.08	-14.86	-0.63	1.46e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.77	-12.71	-0.57	2.21e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.76	0.39	1.09e-13	Mean corpuscular hemoglobin concentration;
CRC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.2	-24.93	-0.81	8.44e-78	IgG glycosylation;
CRC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.38	6.43	0.33	4.54e-10	Schizophrenia;
CRC	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.04	-14.44	-0.62	6.2e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.99	0.4	2.31e-14	Menopause (age at onset);
CRC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.55	6.19	0.32	1.82e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.81	14.19	0.62	5.62e-36	Breast cancer;
CRC	cis	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg04733911	chr16:78082701	NA	-0.43	-7.11	-0.36	7.29e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	0.95	12.69	0.57	2.73e-30	Vitiligo;
CRC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-6.09	-0.32	3.15e-9	Vitiligo;
CRC	cis	rs73206853	0.563	rs9706102	chr12:111185391	A/G	cg12870014	chr12:110450643	ANKRD13A	0.73	8.56	0.43	4.32e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg23161317	chr6:28129485	ZNF389	0.39	5.85	0.31	1.17e-8	Pubertal anthropometrics;
CRC	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg03929089	chr4:120376271	NA	-0.7	-7.5	-0.38	5.82e-13	Axial length;
CRC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-0.83	-9.06	-0.45	1.17e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.4	6.62	0.34	1.43e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.69	9.91	0.48	1.91e-20	Cleft lip with or without cleft palate;
CRC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.18	-17.22	-0.69	7.98e-48	Hip circumference adjusted for BMI;
CRC	cis	rs6662572	0.737	rs9429093	chr1:46555252	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	6.26	0.33	1.18e-9	Blood protein levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04774914	chr12:50560863	LASS5	0.43	6.77	0.35	5.93e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs4363385	0.755	rs1933382	chr1:153003295	G/T	cg25856811	chr1:152973957	SPRR3	0.24	6.79	0.35	5.11e-11	Inflammatory skin disease;
CRC	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	13.66	0.6	5.65e-34	Exhaled nitric oxide output;
CRC	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg00319359	chr11:70116639	PPFIA1	0.59	6.61	0.34	1.6e-10	Coronary artery disease;
CRC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.49	7.91	0.4	4.07e-14	Osteoporosis;
CRC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.15	0.32	2.24e-9	Aortic root size;
CRC	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-9.79	-0.47	5.03e-20	Blood protein levels;
CRC	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg06634786	chr22:41940651	POLR3H	-0.5	-6.32	-0.33	8.73e-10	Neuroticism;
CRC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.71	-9.16	-0.45	5.88e-18	Initial pursuit acceleration;
CRC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.92	-19.06	-0.72	4.49e-55	Urate levels in lean individuals;
CRC	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg07979401	chr6:33739406	LEMD2	-0.44	-5.88	-0.31	9.87e-9	Schizophrenia;
CRC	cis	rs747650	0.926	rs11039119	chr11:47201924	G/A	cg19486271	chr11:47235900	DDB2	0.45	6.47	0.34	3.57e-10	Acne (severe);
CRC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-8.1	-0.41	1.1e-14	Gut microbiome composition (summer);
CRC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg05139728	chr16:28306816	SBK1	-0.37	-5.98	-0.31	5.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs17767392	0.881	rs7142343	chr14:72023489	T/C	cg13720639	chr14:72061746	SIPA1L1	0.56	7.17	0.37	5.05e-12	Mitral valve prolapse;
CRC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.68	11.93	0.55	1.62e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg01874867	chr7:94954059	PON1	-0.49	-6.2	-0.32	1.7e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.99	-0.31	5.52e-9	Morning vs. evening chronotype;
CRC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.48	8.02	0.4	1.82e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.47	6.58	0.34	1.83e-10	Blood metabolite levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19826439	chr1:226297528	NA	0.4	6.55	0.34	2.22e-10	Obesity-related traits;
CRC	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.7	-0.3	2.62e-8	Breast cancer;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg17084751	chr11:6953558	ZNF215	-0.51	-5.77	-0.3	1.86e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.5	8.06	0.41	1.43e-14	Cystic fibrosis severity;
CRC	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-8.27	-0.41	3.36e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg21285383	chr16:89894308	SPIRE2	0.38	6.72	0.35	8.22e-11	Vitiligo;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg17267835	chr6:161413433	MAP3K4	-0.4	-6.19	-0.32	1.76e-9	Daytime sleep phenotypes;
CRC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.58	9.16	0.45	5.65e-18	Body mass index;
CRC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	10.35	0.5	6.3e-22	Bone mineral density;
CRC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.72	0.35	8.23e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23708337	chr7:1209742	NA	0.51	7.81	0.4	7.79e-14	Longevity;Endometriosis;
CRC	cis	rs7113874	0.569	rs9300091	chr11:8588823	G/A	cg17679104	chr11:8615758	STK33	-0.36	-6.08	-0.32	3.28e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg10756647	chr7:56101905	PSPH	0.77	7.88	0.4	4.91e-14	Diabetic kidney disease;
CRC	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.83	-0.35	4.01e-11	Metabolite levels;
CRC	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.15	-0.37	5.64e-12	Capecitabine sensitivity;
CRC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.54	-9.7	-0.47	1.01e-19	Prostate cancer;
CRC	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.81	-0.4	7.94e-14	Homocysteine levels;
CRC	cis	rs3996993	0.809	rs6917325	chr6:52666273	A/G	cg20803780	chr6:52668592	GSTA1	-0.37	-6.95	-0.36	1.97e-11	Hemoglobin concentration;
CRC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.63	10.89	0.51	8.69e-24	Age at first birth;
CRC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.59	8.99	0.44	1.95e-17	Vitiligo;
CRC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	6.99	0.36	1.5e-11	Obesity-related traits;
CRC	cis	rs12580194	0.593	rs61957899	chr12:55731971	C/T	cg19537932	chr12:55886519	OR6C68	-0.64	-8.33	-0.42	2.2e-15	Cancer;
CRC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg20243544	chr17:37824526	PNMT	0.57	9.04	0.45	1.33e-17	Asthma;
CRC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg03188948	chr7:1209495	NA	0.54	6.56	0.34	2.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.8	-0.35	4.83e-11	Osteoarthritis;
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-7.09	-0.36	8.45e-12	Longevity;
CRC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.58	0.47	2.51e-19	Cognitive test performance;
CRC	cis	rs17152411	1.000	rs12571196	chr10:126597749	A/C	cg07906193	chr10:126599966	NA	0.58	5.74	0.3	2.12e-8	Height;
CRC	trans	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg03701575	chr16:83960119	NA	0.34	5.97	0.31	6.14e-9	Asthma;
CRC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg08314208	chr16:67682810	RLTPR	-0.5	-6.05	-0.32	3.99e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.7	8.94	0.44	2.78e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg00933542	chr6:150070202	PCMT1	0.33	6.67	0.34	1.11e-10	Lung cancer;
CRC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.6	-0.43	3.21e-16	Hemoglobin concentration;
CRC	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.78	-14.31	-0.62	1.94e-36	Hip circumference;
CRC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.67	9.77	0.47	6.02e-20	Alzheimer's disease;
CRC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg01216370	chr2:228736459	WDR69	-0.42	-5.72	-0.3	2.45e-8	Blood pressure;
CRC	cis	rs9287719	0.649	rs10929685	chr2:10732799	T/C	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.36	-5.73	-0.3	2.3e-8	Blood metabolite levels;
CRC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg03316587	chr8:142245164	NA	-0.4	-5.94	-0.31	7.21e-9	Immature fraction of reticulocytes;
CRC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.56	9.62	0.47	1.78e-19	Menarche (age at onset);
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.64	-0.54	1.83e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg21251018	chr6:28226885	NKAPL	0.42	5.91	0.31	8.51e-9	Depression;
CRC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.52	7.09	0.36	8.16e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	8.77	0.44	9.66e-17	Rheumatoid arthritis;
CRC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.72	-9.39	-0.46	1.07e-18	Vitiligo;
CRC	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.63	9.89	0.48	2.39e-20	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08380957	chr17:58678329	PPM1D	0.44	6.37	0.33	6.29e-10	Intelligence (multi-trait analysis);
CRC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.29	15.31	0.65	2.44e-40	Uric acid levels;
CRC	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg06606381	chr12:133084897	FBRSL1	-0.78	-6.64	-0.34	1.26e-10	Breast cancer;
CRC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.99	0.44	2.05e-17	Schizophrenia;
CRC	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg15744005	chr10:104629667	AS3MT	0.33	6.51	0.34	2.79e-10	Arsenic metabolism;
CRC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.83	-0.44	6.5e-17	Personality dimensions;
CRC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.17	0.52	9.08e-25	Prudent dietary pattern;
CRC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.72	10.08	0.49	5.16e-21	Blood metabolite levels;
CRC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10411161	0.810	rs60981935	chr19:52385281	C/T	cg22319618	chr22:45562946	NUP50	-0.69	-6.01	-0.31	4.9e-9	Breast cancer;
CRC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg24675056	chr1:15929824	NA	0.52	7.27	0.37	2.64e-12	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25697769	chr22:39097335	JOSD1	0.41	6.9	0.36	2.63e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.48	-6.71	-0.35	8.69e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-10.36	-0.5	6.02e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-6.97	-0.36	1.7e-11	Colorectal cancer;
CRC	cis	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg20159608	chr7:32802032	NA	-0.59	-7.01	-0.36	1.39e-11	Metabolite levels (HVA/MHPG ratio);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05643503	chr1:3713094	LRRC47	0.42	5.99	0.31	5.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.35	7.42	0.38	1.02e-12	Migraine;
CRC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-7.68	-0.39	1.8e-13	Alzheimer's disease (late onset);
CRC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg01262667	chr19:19385393	TM6SF2	-0.35	-5.72	-0.3	2.36e-8	Tonsillectomy;
CRC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.54	8.76	0.43	1.09e-16	Coronary artery disease;
CRC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg02683197	chr6:28174875	NA	0.69	7.44	0.38	8.81e-13	Parkinson's disease;
CRC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg23815491	chr16:72088622	HP	0.47	6.95	0.36	1.94e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.3	0.53	2.98e-25	Prudent dietary pattern;
CRC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.81	-9.5	-0.46	4.34e-19	Bronchopulmonary dysplasia;
CRC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-9.35	-0.46	1.4e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.45	-0.34	3.98e-10	Coronary artery disease;
CRC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.66	7.94	0.4	3.23e-14	IgG glycosylation;
CRC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg05691152	chr22:38092978	TRIOBP	-0.31	-5.62	-0.3	4e-8	Fat distribution (HIV);
CRC	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.53	-9.25	-0.45	2.98e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg15445000	chr17:37608096	MED1	-0.42	-8.53	-0.43	5.46e-16	Glomerular filtration rate (creatinine);
CRC	cis	rs28680850	0.541	rs4876041	chr8:1370441	T/C	cg06035437	chr8:1398411	NA	-0.42	-5.77	-0.3	1.83e-8	Triglycerides;
CRC	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.87	11.19	0.53	7.46e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg10130564	chr11:117069849	TAGLN	0.38	7.13	0.37	6.48e-12	Blood protein levels;
CRC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.75	-10.15	-0.49	3.15e-21	Initial pursuit acceleration;
CRC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-0.94	-17.39	-0.69	1.77e-48	Height;
CRC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-8.19	-0.41	5.76e-15	Hemoglobin concentration;
CRC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	8.97	0.44	2.27e-17	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg19622623	chr12:86230825	RASSF9	0.4	6.35	0.33	7.12e-10	Major depressive disorder;
CRC	cis	rs6460942	0.908	rs74801929	chr7:12232715	C/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.05	-0.32	4.03e-9	Coronary artery disease;
CRC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.66	-10.05	-0.48	6.81e-21	Other erythrocyte phenotypes;
CRC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg13319975	chr6:146136371	FBXO30	0.39	5.93	0.31	7.81e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg15654264	chr1:150340011	RPRD2	-0.39	-5.8	-0.3	1.58e-8	Migraine;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18715297	chr3:122283210	PARP9;DTX3L	0.38	6.03	0.32	4.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs35123175	1	rs35123175	chr21:45006610	CA/C	cg24875593	chr21:45153009	PDXK	-0.72	-6.21	-0.32	1.6e-9	Diastolic blood pressure;
CRC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg25344623	chr2:136566232	LCT	-0.32	-5.82	-0.31	1.37e-8	Mosquito bite size;
CRC	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg00691999	chr4:55094011	PDGFRA	0.4	5.7	0.3	2.73e-8	Corneal astigmatism;
CRC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.03	0.32	4.43e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg06470822	chr6:28175283	NA	0.8	11.94	0.55	1.56e-27	Parkinson's disease;
CRC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg02733842	chr7:1102375	C7orf50	-0.51	-6.93	-0.36	2.29e-11	Bronchopulmonary dysplasia;
CRC	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	0.59	6.65	0.34	1.21e-10	Prostate cancer;
CRC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.72	-0.54	9.6800000000000007e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10663503	chr17:8126298	C17orf44	0.45	6.33	0.33	7.81e-10	Response to antipsychotic treatment;
CRC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.75	-0.43	1.1e-16	Hemoglobin concentration;
CRC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.82	-15.74	-0.66	5.1e-42	Post bronchodilator FEV1;
CRC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.64	9.59	0.47	2.2e-19	Breast cancer;
CRC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.56	7.29	0.37	2.35e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.52	10.01	0.48	8.96e-21	Urate levels in lean individuals;
CRC	trans	rs12408261	0.685	rs4085125	chr1:189277546	A/T	cg09627744	chr16:77228780	MON1B	0.39	5.97	0.31	6.11e-9	Number of pregnancies;
CRC	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.98	10.41	0.5	4.11e-22	Mitochondrial DNA levels;
CRC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.86	10.22	0.49	1.77e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3824347	0.839	rs4537368	chr9:77587067	G/A	cg01251476	chr9:77566080	C9orf40	0.37	5.7	0.3	2.66e-8	Urinary magnesium-to-creatinine ratio;
CRC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.92	0.31	8.26e-9	Self-reported allergy;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19737787	chr13:28492265	NA	-0.39	-6.24	-0.33	1.32e-9	Myopia (pathological);
CRC	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.42	6.3	0.33	9.33e-10	Testicular germ cell tumor;
CRC	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg10517650	chr3:113235015	CCDC52	0.34	5.61	0.3	4.22e-8	Dental caries;
CRC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.57	0.38	3.89e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-8.99	-0.44	1.98e-17	Bipolar disorder;
CRC	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg09659197	chr4:152720779	NA	0.53	11.67	0.54	1.49e-26	Intelligence (multi-trait analysis);
CRC	cis	rs11212617	1.000	rs599558	chr11:108177538	C/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.79e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-9.81	-0.48	4.16e-20	Personality dimensions;
CRC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.95	-0.44	2.57e-17	Morning vs. evening chronotype;
CRC	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg06781209	chr11:61594997	FADS2	-0.38	-5.74	-0.3	2.11e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg00343986	chr7:65444356	GUSB	0.47	6.96	0.36	1.88e-11	Aortic root size;
CRC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.38	5.71	0.3	2.58e-8	Menarche (age at onset);
CRC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.45	6.64	0.34	1.29e-10	Alcohol dependence;
CRC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.55	0.43	4.83e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs742115	0.563	rs12663475	chr6:11297296	T/C	cg25250968	chr6:11318770	NEDD9	-0.39	-7.61	-0.39	2.83e-13	Coronary artery disease;
CRC	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.92	-0.4	3.64e-14	Bipolar disorder;
CRC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.56	8.4	0.42	1.37e-15	Aortic root size;
CRC	cis	rs8040855	0.547	rs17611171	chr15:85572699	T/A	cg10818794	chr15:86012489	AKAP13	-0.45	-5.94	-0.31	7.37e-9	Bulimia nervosa;
CRC	trans	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.56	-0.38	4.01e-13	Monocyte percentage of white cells;
CRC	cis	rs10208940	0.920	rs13422657	chr2:68706989	T/C	cg12452813	chr2:68675892	NA	0.52	6.43	0.33	4.44e-10	Urate levels in lean individuals;
CRC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.62	-8.78	-0.44	9.42e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	12.75	0.58	1.54e-30	Menarche (age at onset);
CRC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-6.06	-0.32	3.74e-9	Total body bone mineral density;
CRC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.3	-0.42	2.77e-15	Morning vs. evening chronotype;
CRC	cis	rs12023718	0.588	rs74471321	chr1:178605292	A/C	cg00404053	chr1:178313656	RASAL2	0.58	7.32	0.37	1.9e-12	Obesity-related traits;
CRC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.7	9.16	0.45	5.49e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg23920097	chr1:209922102	NA	-0.55	-7.03	-0.36	1.16e-11	Red blood cell count;
CRC	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg18151635	chr12:93972918	NA	-0.57	-8.24	-0.41	4.06e-15	Pubertal anthropometrics;
CRC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.54	7.77	0.39	9.92e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.57e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20569680	chr6:16129335	MYLIP	0.48	6.74	0.35	7.08e-11	Response to antipsychotic treatment;
CRC	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg24463073	chr6:118973353	C6orf204	0.52	6.83	0.35	4.24e-11	Diastolic blood pressure;
CRC	cis	rs10046574	0.561	rs17403528	chr7:135195531	C/T	cg27474649	chr7:135195673	CNOT4	0.68	6.24	0.33	1.34e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg10790698	chr19:18539756	SSBP4	-0.45	-8.61	-0.43	3.07e-16	Breast cancer;
CRC	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg04989706	chr14:50066350	PPIL5	-0.51	-7.24	-0.37	3.29e-12	Carotid intima media thickness;
CRC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.64	-9.0	-0.44	1.81e-17	DNA methylation (variation);
CRC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg21466736	chr12:48725269	NA	0.49	7.72	0.39	1.41e-13	Plateletcrit;
CRC	cis	rs6545883	0.507	rs59981505	chr2:61580529	G/T	cg10580144	chr2:61372316	C2orf74	-0.35	-7.75	-0.39	1.13e-13	Tuberculosis;
CRC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.2	-0.32	1.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs7680126	0.633	rs2868937	chr4:10303081	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-6.99	-0.36	1.5e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs3741151	0.686	rs12285885	chr11:73294478	A/G	cg17517138	chr11:73019481	ARHGEF17	0.55	5.7	0.3	2.71e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg06581033	chr10:766294	NA	-0.51	-5.68	-0.3	2.97e-8	Uric acid levels;
CRC	cis	rs10503871	0.905	rs6993952	chr8:30440564	T/C	cg26383811	chr8:30366931	RBPMS	0.46	7.41	0.38	1.11e-12	Metabolite levels  (X-11787);
CRC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.9	0.31	9.18e-9	Renal cell carcinoma;
CRC	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg21153622	chr11:89784906	NA	-0.54	-8.82	-0.44	6.58e-17	HDL cholesterol;
CRC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.41	7.89	0.4	4.54e-14	Hypertriglyceridemia;
CRC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.5	8.04	0.41	1.68e-14	Height;
CRC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	1.22	14.44	0.62	6.15e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.83	15.7	0.65	7.76e-42	Hip circumference;
CRC	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.5	9.2	0.45	4.34e-18	Neuroticism;
CRC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg16342193	chr10:102329863	NA	-0.33	-5.69	-0.3	2.8e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.08	14.73	0.63	4.38e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.63	8.89	0.44	4.23e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.47	5.96	0.31	6.64e-9	Systemic lupus erythematosus;
CRC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.87	-12.74	-0.57	1.65e-30	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.7	10.85	0.51	1.16e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.68	-0.35	1.02e-10	Breast cancer;
CRC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.62	9.11	0.45	8.28e-18	Morning vs. evening chronotype;
CRC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg24375607	chr4:120327624	NA	0.48	7.49	0.38	6.31e-13	Corneal astigmatism;
CRC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg01766193	chr7:157202248	DNAJB6	-0.35	-5.72	-0.3	2.39e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.05	14.68	0.63	7.05e-38	Exhaled nitric oxide output;
CRC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.78	-9.64	-0.47	1.52e-19	Platelet count;
CRC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg07636037	chr3:49044803	WDR6	-0.68	-6.53	-0.34	2.57e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs773506	0.655	rs4744037	chr9:93932488	C/G	cg14446406	chr9:93919335	NA	-0.45	-7.71	-0.39	1.48e-13	Type 2 diabetes nephropathy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.49	6.98	0.36	1.67e-11	Response to antipsychotic treatment;
CRC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.27	-0.33	1.14e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2882667	1.000	rs10064201	chr5:138309405	C/T	cg09476006	chr5:138032270	NA	0.45	7.35	0.38	1.53e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.74	-12.07	-0.55	5.07e-28	Body mass index;
CRC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.29	-0.33	1e-9	Bipolar disorder;
CRC	cis	rs2949837	0.581	rs2960436	chr7:45977282	G/A	cg21268650	chr7:45961089	IGFBP3	0.38	6.41	0.33	5.05e-10	Sitting height ratio;
CRC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg13057898	chr1:3703894	LRRC47	0.56	7.6	0.39	3.04e-13	Red cell distribution width;
CRC	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg19131313	chr8:1704013	NA	-0.44	-5.9	-0.31	8.84e-9	Systolic blood pressure;
CRC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.62	8.55	0.43	4.88e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg04518342	chr5:131593106	PDLIM4	-0.32	-5.7	-0.3	2.67e-8	Blood metabolite levels;
CRC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.65	0.34	1.21e-10	Lung cancer;
CRC	trans	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg24628676	chr5:59189846	PDE4D	-0.3	-6.05	-0.32	4.03e-9	Urinary tract infection frequency;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08833546	chr7:66461892	TYW1;SBDS	0.48	6.6	0.34	1.66e-10	Anxiety disorder;
CRC	cis	rs7429990	0.965	rs319696	chr3:47943861	T/C	cg11946769	chr3:48343235	NME6	0.46	5.9	0.31	8.99e-9	Educational attainment (years of education);
CRC	cis	rs4290604	0.596	rs7566199	chr2:238053391	A/G	cg23555395	chr2:238036564	NA	-0.67	-6.85	-0.35	3.58e-11	Asthma;
CRC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.51	-7.77	-0.39	1.02e-13	Diastolic blood pressure;
CRC	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg07862535	chr7:139043722	LUC7L2	-0.59	-7.62	-0.39	2.72e-13	Diisocyanate-induced asthma;
CRC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.78	-9.13	-0.45	6.9e-18	Hemostatic factors and hematological phenotypes;
CRC	cis	rs501120	0.584	rs677465	chr10:44732917	G/A	cg09554077	chr10:44749378	NA	0.66	7.26	0.37	2.83e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg19980929	chr12:42632907	YAF2	-0.39	-5.9	-0.31	9.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.7	8.3	0.42	2.82e-15	Response to hepatitis C treatment;
CRC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg19622623	chr12:86230825	RASSF9	-0.36	-5.79	-0.3	1.62e-8	Major depressive disorder;
CRC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.56	8.65	0.43	2.25e-16	Methadone dose in opioid dependence;
CRC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg20933634	chr6:27740509	NA	0.5	7.01	0.36	1.39e-11	Parkinson's disease;
CRC	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.45	5.97	0.31	6.2e-9	Systemic lupus erythematosus;
CRC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.76	10.77	0.51	2.24e-23	Heart rate;
CRC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.57	-7.01	-0.36	1.39e-11	Body mass index (adult);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22841336	chr12:57040011	ATP5B;SNORD59A	0.43	6.2	0.32	1.73e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00807959	chr1:48176281	NA	0.37	6.14	0.32	2.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.63	0.6	7.31e-34	Platelet count;
CRC	cis	rs427941	0.703	rs201448	chr7:101738860	T/C	cg06246474	chr7:101738831	CUX1	0.46	7.25	0.37	3.02e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs6662572	0.737	rs72677518	chr1:46511118	T/C	cg08644498	chr1:46502608	NA	0.47	7.52	0.38	5.41e-13	Blood protein levels;
CRC	cis	rs4662945	0.688	rs10496679	chr2:130201113	G/A	cg05962382	chr2:130345044	NA	-0.33	-5.75	-0.3	2.04e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.42	-0.59	4.9e-33	Extrinsic epigenetic age acceleration;
CRC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.79	-0.39	8.72e-14	Coronary artery disease;
CRC	cis	rs3026101	0.671	rs886361	chr17:5292762	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg24505167	chr7:1915268	MAD1L1	-0.44	-6.02	-0.31	4.77e-9	Bipolar disorder;
CRC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg15123519	chr2:136567270	LCT	-0.33	-6.18	-0.32	1.86e-9	Mosquito bite size;
CRC	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-6.92	-0.36	2.32e-11	Dental caries;
CRC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.54	7.4	0.38	1.17e-12	Bronchopulmonary dysplasia;
CRC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg19635926	chr16:89946313	TCF25	0.65	6.09	0.32	3.17e-9	Skin colour saturation;
CRC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.39	6.96	0.36	1.88e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.74	-0.35	7.19e-11	Total cholesterol levels;
CRC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-12.39	-0.56	3.34e-29	Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25208863	chr8:110656982	GOLSYN	0.4	6.23	0.32	1.39e-9	Response to antipsychotic treatment;
CRC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	12.38	0.56	3.73e-29	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.59	8.97	0.44	2.22e-17	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7015657	0.637	rs11996651	chr8:20994930	C/G	cg21446102	chr12:32831969	DNM1L	0.4	6.03	0.32	4.41e-9	Migraine with aura;
CRC	trans	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg21153622	chr11:89784906	NA	0.43	6.99	0.36	1.56e-11	HDL cholesterol;
CRC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	10.98	0.52	4.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg13385794	chr1:248469461	NA	0.37	6.51	0.34	2.82e-10	Common traits (Other);
CRC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08347042	chr19:45579378	ZNF296	0.43	6.74	0.35	7.04e-11	Schizophrenia;
CRC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.4	-7.28	-0.37	2.52e-12	Prostate cancer;
CRC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg02869306	chr7:64672164	INTS4L1	0.37	6.26	0.33	1.18e-9	Aortic root size;
CRC	cis	rs7215564	0.730	rs34806161	chr17:78573839	T/C	cg09596252	chr17:78655493	RPTOR	0.67	6.33	0.33	8.18e-10	Myopia (pathological);
CRC	cis	rs4664293	0.625	rs6745448	chr2:160555598	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.64	-0.34	1.3100000000000001e-10	Monocyte percentage of white cells;
CRC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg21770322	chr7:97807741	LMTK2	-0.52	-8.65	-0.43	2.32e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.62	0.39	2.65e-13	Alzheimer's disease;
CRC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.48	7.05	0.36	1.06e-11	Blood metabolite levels;
CRC	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	8.84	0.44	5.7e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg09876464	chr15:85330779	ZNF592	0.46	7.82	0.4	7.39e-14	P wave terminal force;
CRC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.49	-8.0	-0.4	2.19e-14	Menopause (age at onset);
CRC	cis	rs17443541	0.507	rs12622777	chr2:200465331	G/A	cg03741458	chr2:200468445	NA	-0.36	-5.77	-0.3	1.82e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.545	rs4759280	chr12:54064958	C/A	cg06632207	chr12:54070931	ATP5G2	0.5	8.61	0.43	3.11e-16	Height;
CRC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg19193384	chr17:30244184	NA	-0.65	-7.63	-0.39	2.48e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.36	5.82	0.31	1.39e-8	Survival in rectal cancer;
CRC	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.07	14.4	0.62	8.62e-37	Atopic dermatitis;
CRC	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg00042356	chr1:8021962	PARK7	0.69	7.36	0.38	1.49e-12	Inflammatory bowel disease;
CRC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.49	-7.14	-0.37	5.87e-12	DNA methylation (variation);
CRC	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	9.01	0.44	1.73e-17	Ulcerative colitis;
CRC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.75	-13.76	-0.6	2.37e-34	Prostate cancer;
CRC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.61	-6.99	-0.36	1.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	6.36	0.33	6.67e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs6600671	1.000	rs1856572	chr1:121169579	A/C	cg00646200	chr1:148855367	NA	0.35	6.35	0.33	7.24e-10	Hip geometry;
CRC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg25985355	chr7:65971099	NA	0.51	5.76	0.3	1.98e-8	Diabetic kidney disease;
CRC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.51	9.02	0.45	1.57e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg03959625	chr15:84868606	LOC388152	0.41	6.09	0.32	3.15e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20902146	chr12:101802045	ARL1	0.37	6.03	0.32	4.44e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg26205652	chr12:48591994	NA	0.48	5.92	0.31	8.04e-9	Longevity (90 years and older);
CRC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg19223190	chr17:80058835	NA	-0.39	-6.24	-0.33	1.31e-9	Life satisfaction;
CRC	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg17133734	chr15:86042851	AKAP13	0.41	6.23	0.32	1.45e-9	Interstitial lung disease;
CRC	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	1.13	10.2	0.49	2.14e-21	Arsenic metabolism;
CRC	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg02560186	chr11:3602584	NA	-0.57	-6.91	-0.36	2.45e-11	Blood pressure (smoking interaction);
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg15786705	chr6:28176104	NA	0.54	7.61	0.39	2.97e-13	Parkinson's disease;
CRC	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.9	9.7	0.47	9.87e-20	Gastritis;
CRC	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.75	-10.2	-0.49	2.08e-21	Coronary artery disease;
CRC	trans	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.07	0.36	9.08e-12	Ulcerative colitis;
CRC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg22482690	chr17:47019901	SNF8	0.5	8.26	0.41	3.58e-15	Type 2 diabetes;
CRC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-9.11	-0.45	8.5e-18	Hip circumference adjusted for BMI;
CRC	trans	rs1864729	1.000	rs1864729	chr8:98282189	G/A	cg08679828	chr8:102218111	ZNF706	-0.67	-8.01	-0.4	2.03e-14	Estradiol plasma levels (breast cancer);
CRC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg09796270	chr17:17721594	SREBF1	0.46	7.79	0.39	8.77e-14	Total body bone mineral density;
CRC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.63	-7.99	-0.4	2.33e-14	Vitamin D levels;
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.53	7.15	0.37	5.57e-12	Alzheimer's disease;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.56	-0.38	4.14e-13	Total body bone mineral density;
CRC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.38	6.41	0.33	5.02e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00236302	chr12:69004867	RAP1B	0.43	6.6	0.34	1.62e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg03929089	chr4:120376271	NA	0.69	6.76	0.35	6.46e-11	Intraocular pressure;
CRC	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg26741380	chr15:41871084	TYRO3	0.48	6.59	0.34	1.79e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	trans	rs16846053	0.786	rs72873607	chr2:162471174	G/A	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.43e-9	Blood osmolality (transformed sodium);
CRC	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	0.84	10.01	0.48	9.15e-21	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.48	8.62	0.43	2.93e-16	Childhood ear infection;
CRC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-13.24	-0.59	2.33e-32	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg26603656	chr10:5671107	NA	-0.45	-7.41	-0.38	1.08e-12	Breast cancer;
CRC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.1	0.49	4.6e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.47	0.34	3.56e-10	Aortic root size;
CRC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.77	14.07	0.61	1.57e-35	Prostate cancer;
CRC	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.78	0.3	1.77e-8	Migraine;
CRC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07640336	chr12:132677496	NA	0.45	8.01	0.4	2.02e-14	Anti-saccade response;
CRC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.61e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg12172441	chr6:28176163	NA	0.48	6.27	0.33	1.11e-9	Parkinson's disease;
CRC	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg00938859	chr5:1591904	SDHAP3	0.69	7.58	0.39	3.49e-13	Breast cancer;
CRC	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.96	17.17	0.69	1.29e-47	Gut microbiome composition (winter);
CRC	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.68	-7.84	-0.4	6.51e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.55	8.85	0.44	5.5e-17	Prostate cancer;
CRC	cis	rs1190545	0.588	rs4906213	chr14:102991021	C/T	cg18135206	chr14:102964638	TECPR2	0.56	7.34	0.38	1.71e-12	Platelet count;
CRC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.4	-6.99	-0.36	1.53e-11	Reticulocyte fraction of red cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20470275	chr5:122180934	SNX24	0.44	6.56	0.34	2.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.72	-12.48	-0.57	1.51e-29	Prostate cancer;
CRC	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.07	-0.58	9.65e-32	Exhaled nitric oxide output;
CRC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-6.13	-0.32	2.47e-9	Alzheimer's disease (late onset);
CRC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.66	-0.3	3.32e-8	Breast cancer;
CRC	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg01422370	chr2:73384389	NA	0.37	5.75	0.3	2.09e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.54	6.71	0.35	8.6e-11	Exhaled nitric oxide output;
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg06713098	chr7:45960367	IGFBP3	0.41	6.51	0.34	2.73e-10	Sitting height ratio;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11958594	chr17:80055299	FASN	0.46	6.79	0.35	5.37e-11	Response to antipsychotic treatment;
CRC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg03013636	chr16:1946785	NA	0.55	6.67	0.35	1.1e-10	Glomerular filtration rate in chronic kidney disease;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02834722	chr3:129830330	LOC729375	-0.39	-6.26	-0.33	1.18e-9	Obesity-related traits;
CRC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.3	0.46	2.04e-18	Vitamin D levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07631383	chr7:131012765	MKLN1	0.54	7.69	0.39	1.68e-13	Response to antipsychotic treatment;
CRC	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.57	7.92	0.4	3.6e-14	Coronary artery disease;
CRC	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.06	-0.41	1.47e-14	Waist circumference adjusted for body mass index;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg00628130	chr8:95908808	CCNE2	-0.46	-7.0	-0.36	1.47e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg02674126	chr19:40336878	FBL	0.43	6.89	0.36	2.84e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.59	6.89	0.35	2.92e-11	Lung function (FEV1/FVC);
CRC	cis	rs185694	1.000	rs672233	chr13:30899601	G/A	cg04551440	chr13:30881194	KATNAL1	-0.61	-6.32	-0.33	8.68e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.54	8.61	0.43	3.17e-16	Prostate cancer;
CRC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.47	7.15	0.37	5.81e-12	Breast cancer;
CRC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	cis	rs7605827	0.897	rs10929371	chr2:15662299	A/G	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.07e-8	Educational attainment (years of education);
CRC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg01879757	chr17:41196368	BRCA1	-0.4	-5.97	-0.31	6.11e-9	Menopause (age at onset);
CRC	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-11.12	-0.52	1.33e-24	Hepatocellular carcinoma;
CRC	cis	rs17443541	0.507	rs6726848	chr2:200451027	G/A	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19623624	chr10:135278901	LOC619207	-0.35	-5.75	-0.3	2.04e-8	Systemic lupus erythematosus;
CRC	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg00063174	chr2:228736253	WDR69	-0.51	-6.86	-0.35	3.49e-11	Blood pressure;
CRC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20307385	chr11:47447363	PSMC3	-0.56	-7.81	-0.4	7.68e-14	Subjective well-being;
CRC	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.49	-0.34	3.15e-10	Breast cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22746681	chr10:51912631	NA	-0.37	-6.12	-0.32	2.65e-9	Hip circumference;
CRC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg02659138	chr7:134003124	SLC35B4	0.41	6.81	0.35	4.57e-11	Mean platelet volume;
CRC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg15786705	chr6:28176104	NA	0.59	8.64	0.43	2.46e-16	Parkinson's disease;
CRC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg13390004	chr1:15929781	NA	0.51	7.2	0.37	4.22e-12	Systolic blood pressure;
CRC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.41	6.05	0.32	3.95e-9	Pulse pressure;
CRC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.82	0.31	1.4e-8	Heart rate;
CRC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg01879757	chr17:41196368	BRCA1	0.39	5.97	0.31	6.26e-9	Menopause (age at onset);
CRC	cis	rs6496667	0.779	rs62020687	chr15:90954396	C/T	cg04176472	chr15:90893244	GABARAPL3	0.63	8.16	0.41	7.15e-15	Rheumatoid arthritis;
CRC	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.49	7.47	0.38	7.48e-13	Testicular germ cell tumor;
CRC	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.1	-15.04	-0.64	2.83e-39	Exhaled nitric oxide output;
CRC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.65	10.72	0.51	3.37e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.86	0.31	1.14e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07555343	chr3:176669833	NA	-0.36	-6.81	-0.35	4.62e-11	Obesity-related traits;
CRC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.18e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg04586622	chr2:25135609	ADCY3	-0.54	-10.29	-0.49	1.04e-21	Body mass index;
CRC	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.69	-10.01	-0.48	9.16e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg25767906	chr1:53392781	SCP2	-0.48	-7.49	-0.38	6.3e-13	Monocyte count;
CRC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.92	-0.36	2.31e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs1355223	1.000	rs1355222	chr11:34758716	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.0	-0.31	5.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-12.16	-0.56	2.33e-28	Coffee consumption (cups per day);
CRC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.67	7.71	0.39	1.48e-13	Body mass index;
CRC	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg22561889	chr6:118971681	C6orf204	0.52	6.7	0.35	9.08e-11	Diastolic blood pressure;
CRC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.65	0.3	3.39e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg15107132	chr11:63991130	FERMT3	0.38	6.28	0.33	1.05e-9	Platelet count;
CRC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.93	0.52	6.15e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-0.98	-9.75	-0.47	6.54e-20	Breast cancer;
CRC	cis	rs2949837	0.581	rs1117457	chr7:45970037	G/A	cg15898840	chr7:45960834	IGFBP3	0.43	7.07	0.36	9.17e-12	Sitting height ratio;
CRC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.34	5.64	0.3	3.76e-8	Self-reported allergy;
CRC	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.38	-6.49	-0.34	3.23e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7259376	0.875	rs2116919	chr19:22491706	C/G	cg02657401	chr19:22469223	NA	-0.36	-7.92	-0.4	3.7e-14	Menopause (age at onset);
CRC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg04025307	chr7:1156635	C7orf50	0.64	6.69	0.35	9.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg02741985	chr17:80059408	CCDC57	-0.44	-7.18	-0.37	4.75e-12	Life satisfaction;
CRC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg03885332	chr11:832357	CD151	-0.43	-6.4	-0.33	5.29e-10	Mean platelet volume;
CRC	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.41	-5.97	-0.31	6.05e-9	Attention function in attention deficit hyperactive disorder;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18099408	chr3:52552593	STAB1	-0.59	-11.34	-0.53	2.27e-25	Hemoglobin concentration;
CRC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18591801	chr3:52553433	STAB1	-0.3	-5.79	-0.3	1.66e-8	Hemoglobin concentration;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg04212729	chr14:65171037	PLEKHG3	-0.44	-6.51	-0.34	2.83e-10	Daytime sleep phenotypes;
CRC	trans	rs2303319	0.504	rs62187646	chr2:162445488	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.74	-6.19	-0.32	1.81e-9	Cognitive function;
CRC	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg20607287	chr7:12443886	VWDE	-0.5	-6.73	-0.35	7.33e-11	Coronary artery disease;
CRC	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg09003973	chr2:102972529	NA	0.67	7.23	0.37	3.36e-12	Gut microbiota (bacterial taxa);
CRC	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.61	-8.92	-0.44	3.31e-17	Coronary artery disease;
CRC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.51	-0.34	2.77e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.58	-8.44	-0.42	9.95e-16	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	ch.11.42038R	chr11:967971	AP2A2	0.56	8.88	0.44	4.54e-17	Alzheimer's disease (late onset);
CRC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.84	14.66	0.63	8.66e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.62	10.27	0.49	1.22e-21	Permanent tooth development;
CRC	cis	rs4731207	0.698	rs6942933	chr7:124444522	C/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.56	8.33	0.42	2.21e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.39	-0.38	1.25e-12	Headache;
CRC	cis	rs3764400	0.567	rs2229369	chr17:46136133	G/C	cg10706073	chr17:46328419	SKAP1	-0.68	-7.09	-0.36	8.08e-12	Body mass index;
CRC	cis	rs7633770	0.735	rs12491294	chr3:46688498	G/T	cg11219411	chr3:46661640	NA	-0.39	-5.74	-0.3	2.13e-8	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg25193742	chr10:104614220	C10orf32	-0.73	-5.97	-0.31	6.18e-9	Cognitive function;
CRC	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg16476235	chr8:21771668	DOK2	0.37	6.24	0.33	1.36e-9	Mean corpuscular volume;
CRC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.68	-10.65	-0.51	5.97e-23	Huntington's disease progression;
CRC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.25	-0.33	1.26e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-10.9	-0.52	7.97e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.32	0.37	1.92e-12	Diisocyanate-induced asthma;
CRC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-7.54	-0.38	4.54e-13	Response to bleomycin (chromatid breaks);
CRC	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg09659197	chr4:152720779	NA	0.32	5.78	0.3	1.74e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg12315302	chr6:26189340	HIST1H4D	0.8	6.44	0.33	4.14e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.54	0.38	4.64e-13	Height;
CRC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg21724239	chr8:58056113	NA	0.58	7.75	0.39	1.17e-13	Developmental language disorder (linguistic errors);
CRC	trans	rs1642645	0.831	rs11210563	chr1:42494633	G/T	cg16926213	chr1:1841314	NA	-0.43	-6.11	-0.32	2.8e-9	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.6	-8.94	-0.44	2.93e-17	Migraine;Coronary artery disease;
CRC	cis	rs3736485	0.966	rs2414111	chr15:51901357	A/G	cg08986416	chr15:51914746	DMXL2	0.45	6.34	0.33	7.55e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg18833306	chr6:118973337	C6orf204	0.45	5.96	0.31	6.57e-9	Diastolic blood pressure;
CRC	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg23229984	chr5:148520753	ABLIM3	0.5	6.82	0.35	4.28e-11	Breast cancer;
CRC	cis	rs2062225	1.000	rs1157083	chr2:111754921	C/T	cg11729679	chr2:111877065	BCL2L11	-0.56	-5.64	-0.3	3.67e-8	Monocyte count;
CRC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.1	-13.54	-0.6	1.6e-33	Vitiligo;
CRC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.83	-9.09	-0.45	9.52e-18	Breast cancer;
CRC	cis	rs4889855	1.000	rs4889855	chr17:78513280	G/A	cg16591659	chr17:78472290	NA	-0.63	-6.98	-0.36	1.62e-11	Fractional excretion of uric acid;
CRC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.74	-0.47	7.45e-20	Primary sclerosing cholangitis;
CRC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.1	-20.02	-0.74	7.19e-59	Dilated cardiomyopathy;
CRC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.8	-13.22	-0.59	2.8e-32	Cystic fibrosis severity;
CRC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11645453	chr3:52864694	ITIH4	0.34	6.2	0.32	1.72e-9	Electroencephalogram traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07243161	chr6:136871709	MAP7	0.44	6.2	0.32	1.68e-9	Anxiety disorder;
CRC	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg24058013	chr18:77568902	NA	0.43	6.99	0.36	1.58e-11	Schizophrenia;
CRC	cis	rs863345	0.604	rs12044283	chr1:158463833	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.26	-0.33	1.17e-9	Pneumococcal bacteremia;
CRC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.33	-5.84	-0.31	1.23e-8	Red blood cell count;
CRC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.42	6.38	0.33	6.17e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.13	0.32	2.46e-9	Tonsillectomy;
CRC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.06	0.36	9.65e-12	Neuroticism;
CRC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.56	6.19	0.32	1.75e-9	Vitiligo;
CRC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.72	8.09	0.41	1.12e-14	Cognitive function;
CRC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.21	14.83	0.63	1.78e-38	Eosinophil percentage of granulocytes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24506767	chr6:52264762	PAQR8	0.43	6.34	0.33	7.42e-10	Thyroid stimulating hormone;
CRC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.41	6.59	0.34	1.75e-10	Huntington's disease progression;
CRC	trans	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.76	-0.39	1.07e-13	HDL cholesterol;
CRC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-12.41	-0.56	2.97e-29	Lymphocyte percentage of white cells;
CRC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.5	7.92	0.4	3.8e-14	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24225281	chr7:99097483	ZNF394	0.52	7.46	0.38	7.56e-13	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.46	6.94	0.36	2.09e-11	Corneal astigmatism;
CRC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	10.03	0.48	7.81e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg07274523	chr3:49395745	GPX1	0.45	5.69	0.3	2.88e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.92	-16.19	-0.67	9.24e-44	Height;
CRC	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg02389323	chr16:88786976	FAM38A	0.82	7.67	0.39	1.95e-13	Plateletcrit;
CRC	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.51e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.08	10.82	0.51	1.46e-23	Diabetic retinopathy;
CRC	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg20356878	chr3:121714668	ILDR1	0.51	7.94	0.4	3.22e-14	Cognitive performance;
CRC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.73	-11.3	-0.53	2.95e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.16	-0.45	5.69e-18	Schizophrenia;
CRC	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg16950941	chr11:66035639	RAB1B	-0.6	-7.46	-0.38	7.7e-13	Electroencephalogram traits;
CRC	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.12	16.96	0.68	8.7e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.44	-6.62	-0.34	1.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.37	0.33	6.54e-10	Lung cancer;
CRC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg13390004	chr1:15929781	NA	0.5	7.06	0.36	1.02e-11	Systolic blood pressure;
CRC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg24977027	chr2:88469347	THNSL2	0.63	7.75	0.39	1.14e-13	Plasma clusterin levels;
CRC	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.52	7.42	0.38	1.01e-12	Obesity-related traits;
CRC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.87	0.31	1.08e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg07513332	chr6:167530253	CCR6	-0.48	-8.72	-0.43	1.39e-16	Primary biliary cholangitis;
CRC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg19678392	chr7:94953810	PON1	-0.6	-7.35	-0.38	1.54e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg00319359	chr11:70116639	PPFIA1	0.6	6.73	0.35	7.72e-11	Coronary artery disease;
CRC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg02527881	chr3:46936655	PTH1R	-0.34	-5.92	-0.31	7.94e-9	Colorectal cancer;
CRC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.41	0.33	5.15e-10	Bipolar disorder;
CRC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.07	-17.38	-0.69	1.88e-48	Dilated cardiomyopathy;
CRC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.36	-0.33	6.57e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.62	-9.08	-0.45	1.01e-17	Subjective well-being;
CRC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.86	-14.21	-0.62	4.44e-36	Blood metabolite levels;
CRC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12315302	chr6:26189340	HIST1H4D	0.76	6.0	0.31	5.23e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3790455	0.585	rs3790460	chr1:156465029	C/G	cg14087168	chr1:156450669	MEF2D	-0.37	-6.1	-0.32	2.91e-9	Migraine;
CRC	cis	rs2415984	0.622	rs7156444	chr14:46933296	C/G	cg14871534	chr14:47121158	RPL10L	-0.42	-5.97	-0.31	6.01e-9	Number of children ever born;
CRC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.65	8.9	0.44	3.78e-17	Response to diuretic therapy;
CRC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.24	14.68	0.63	6.86e-38	Uric acid levels;
CRC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg07718321	chr6:96025334	MANEA	0.51	6.06	0.32	3.7e-9	Behavioural disinhibition (generation interaction);
CRC	trans	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg26043149	chr18:55253948	FECH	0.49	7.49	0.38	6.5e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg15147215	chr3:52552868	STAB1	0.6	9.63	0.47	1.63e-19	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.73	11.56	0.54	3.47e-26	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-8.54	-0.43	5.03e-16	Menarche (age at onset);
CRC	cis	rs55702914	0.602	rs2564372	chr2:198307813	C/T	cg10820045	chr2:198174542	NA	0.32	5.62	0.3	4.05e-8	Major depression and alcohol dependence;
CRC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.05	-0.45	1.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg10760299	chr15:45669010	GATM	0.53	8.09	0.41	1.14e-14	Homoarginine levels;
CRC	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.73	-9.8	-0.48	4.52e-20	White matter hyperintensity burden;
CRC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.56	8.74	0.43	1.24e-16	Vitiligo;
CRC	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs9323205	0.817	rs56100232	chr14:51699378	A/G	cg23942311	chr14:51606299	NA	-0.52	-6.19	-0.32	1.82e-9	Cancer;
CRC	cis	rs6076065	0.676	rs1419005	chr20:23336432	G/T	cg11657817	chr20:23433608	CST11	-0.45	-6.87	-0.35	3.19e-11	Facial morphology (factor 15, philtrum width);
CRC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.38	-6.2	-0.32	1.71e-9	Height;
CRC	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-7.86	-0.4	5.52e-14	Granulocyte percentage of myeloid white cells;
CRC	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.82	-10.94	-0.52	5.57e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.77	13.73	0.6	3.16e-34	Oral cavity cancer;
CRC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.58	-9.94	-0.48	1.62e-20	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.6	9.1	0.45	8.54e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.4	6.52	0.34	2.6200000000000003e-10	Major depressive disorder;
CRC	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	7.47	0.38	7.34e-13	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.61	9.35	0.46	1.39e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg14844989	chr11:31128820	NA	-0.34	-5.93	-0.31	7.76e-9	Red blood cell count;
CRC	cis	rs77861329	0.660	rs6778442	chr3:52148483	T/C	cg08692210	chr3:52188851	WDR51A	0.55	6.26	0.33	1.23e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.53	10.81	0.51	1.67e-23	Alcohol dependence;
CRC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg03233332	chr7:66118400	NA	0.44	6.2	0.32	1.67e-9	Aortic root size;
CRC	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg24588162	chr13:113633484	MCF2L	-0.41	-7.36	-0.38	1.49e-12	Systolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24861191	chr19:2740086	SLC39A3	0.53	7.53	0.38	4.92e-13	Response to antipsychotic treatment;
CRC	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg10217327	chr6:118973057	C6orf204	0.51	5.79	0.3	1.69e-8	Diastolic blood pressure;
CRC	cis	rs117623576	0.941	rs17488859	chr10:32386072	A/G	cg03047570	chr10:32398778	NA	0.68	6.94	0.36	2.09e-11	Anti-saccade response;
CRC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.59	-9.81	-0.48	4.14e-20	Calcium levels;
CRC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.41	5.9	0.31	8.8e-9	Mean platelet volume;
CRC	cis	rs4727963	0.792	rs10247666	chr7:122717198	A/G	cg03640110	chr7:122635026	TAS2R16	-0.31	-5.73	-0.3	2.27e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.5	-7.56	-0.38	4.17e-13	DNA methylation (variation);
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18301423	chr5:131593218	PDLIM4	0.47	8.09	0.41	1.16e-14	Acylcarnitine levels;
CRC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg24562669	chr7:97807699	LMTK2	0.42	7.06	0.36	9.86e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	0.84	8.8	0.44	7.89e-17	Skin colour saturation;
CRC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-9.25	-0.45	2.91e-18	Schizophrenia;
CRC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	11.77	0.54	6.32e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg19875535	chr5:140030758	IK	-0.53	-8.72	-0.43	1.39e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.6	-9.5	-0.46	4.58e-19	Heart rate;
CRC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg02659138	chr7:134003124	SLC35B4	0.37	6.41	0.33	5.15e-10	Mean platelet volume;
CRC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.63	11.88	0.55	2.54e-27	Coronary artery disease;
CRC	cis	rs2811415	0.597	rs13100212	chr3:127803657	G/A	cg13719885	chr3:127795394	NA	-0.4	-5.92	-0.31	8.11e-9	Lung function (FEV1/FVC);
CRC	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.38	-0.33	5.87e-10	Caffeine consumption;
CRC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg02741985	chr17:80059408	CCDC57	0.45	7.46	0.38	7.78e-13	Life satisfaction;
CRC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.56	8.23	0.41	4.44e-15	Melanoma;
CRC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.63	0.3	3.79e-8	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg27523141	chr10:43048294	ZNF37B	0.5	7.29	0.37	2.29e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg14979609	chr8:8086686	FLJ10661	0.38	6.27	0.33	1.13e-9	Joint mobility (Beighton score);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11671925	chr11:67806426	TCIRG1	0.44	6.05	0.32	3.93e-9	Response to antipsychotic treatment;
CRC	cis	rs812925	0.892	rs1186699	chr2:61662555	C/A	cg10580144	chr2:61372316	C2orf74	0.3	6.13	0.32	2.48e-9	Immature fraction of reticulocytes;
CRC	cis	rs17767392	1.000	rs17178206	chr14:71880093	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.96e-11	Mitral valve prolapse;
CRC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.67	9.42	0.46	8.41e-19	Multiple sclerosis;
CRC	cis	rs28655083	0.529	rs645878	chr16:77099974	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.81	0.35	4.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.57	-8.42	-0.42	1.17e-15	Autism;
CRC	cis	rs501120	0.657	rs11238909	chr10:44688088	C/T	cg09554077	chr10:44749378	NA	0.56	6.44	0.33	4.18e-10	Coronary artery disease;Coronary heart disease;
CRC	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.48	7.16	0.37	5.17e-12	Dialysis-related mortality;
CRC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.89	10.36	0.5	5.87e-22	Psoriasis;
CRC	cis	rs16852403	0.583	rs1855174	chr1:178063040	G/A	cg00404053	chr1:178313656	RASAL2	0.63	8.01	0.4	1.94e-14	Childhood ear infection;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18758796	chr5:131593413	PDLIM4	-0.52	-9.01	-0.44	1.7e-17	Acylcarnitine levels;
CRC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.52	7.68	0.39	1.82e-13	Blood protein levels;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg00919237	chr7:87102261	ABCB4	-0.53	-7.07	-0.36	9.33e-12	Gallbladder cancer;
CRC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-8.04	-0.41	1.65e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14911708	chr12:114404314	RBM19	-0.54	-6.67	-0.35	1.09e-10	Monocyte percentage of white cells;
CRC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.46	6.86	0.35	3.39e-11	Menopause (age at onset);
CRC	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22878388	chr2:105853796	NA	-0.33	-6.41	-0.33	5.06e-10	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00834779	chr19:12036415	ZNF700	0.47	7.08	0.36	9.01e-12	Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg25856811	chr1:152973957	SPRR3	-0.24	-6.54	-0.34	2.38e-10	Inflammatory skin disease;
CRC	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg22089800	chr15:90895588	ZNF774	-0.5	-8.11	-0.41	9.99e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg09455208	chr3:40491958	NA	-0.45	-9.18	-0.45	4.91e-18	Renal cell carcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22650146	chr1:221915355	DUSP10	0.53	6.85	0.35	3.72e-11	Thyroid stimulating hormone;
CRC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg05941027	chr17:61774174	LIMD2	0.35	6.17	0.32	1.96e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg05569086	chr8:143859399	LYNX1	0.38	6.74	0.35	7.06e-11	Urinary tract infection frequency;
CRC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-6.44	-0.33	4.3e-10	Aortic root size;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg21399703	chr1:247681439	NA	0.46	7.76	0.39	1.06e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.81	10.52	0.5	1.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs758324	0.812	rs6893957	chr5:131198780	T/C	cg25547332	chr5:131281432	NA	0.35	5.61	0.3	4.19e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.28	0.46	2.4e-18	Blood protein levels;
CRC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.91	-0.4	3.86e-14	Gut microbiome composition (summer);
CRC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.65	10.98	0.52	4.03e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22352186	chr4:1722180	TMEM129;TACC3	0.49	6.49	0.34	3.2e-10	Thyroid stimulating hormone;
CRC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.48	8.65e-21	Lung cancer;
CRC	cis	rs4727963	0.740	rs1404834	chr7:122715112	A/T	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.22e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03909863	chr11:638404	DRD4	-0.51	-6.54	-0.34	2.35e-10	Systemic lupus erythematosus;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00240809	chr16:8715546	C16orf68	0.45	6.25	0.33	1.27e-9	Anxiety disorder;
CRC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg00717180	chr2:96193071	NA	-0.36	-6.0	-0.31	5.3e-9	HDL cholesterol;
CRC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.52	7.94	0.4	3.32e-14	Colorectal cancer;
CRC	cis	rs4711350	0.862	rs530614	chr6:33714781	G/A	cg07979401	chr6:33739406	LEMD2	0.48	5.94	0.31	7.22e-9	Schizophrenia;
CRC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-10.16	-0.49	2.94e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg26805224	chr10:79626177	DLG5	-0.55	-8.24	-0.41	4.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg25164649	chr6:28176230	NA	0.75	9.41	0.46	8.75e-19	Depression;
CRC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.96	0.61	4.22e-35	Prudent dietary pattern;
CRC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.33e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-13.05	-0.58	1.21e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs938554	0.735	rs12498742	chr4:9944052	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.42	-0.33	4.69e-10	Blood metabolite levels;
CRC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg24375607	chr4:120327624	NA	0.5	7.84	0.4	6.19e-14	Corneal astigmatism;
CRC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg21770322	chr7:97807741	LMTK2	0.52	8.48	0.42	7.81e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg02683197	chr6:28174875	NA	-0.7	-8.65	-0.43	2.27e-16	Parkinson's disease;
CRC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg12172441	chr6:28176163	NA	0.55	7.14	0.37	5.96e-12	Parkinson's disease;
CRC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg03690763	chr11:133734501	NA	-0.36	-5.9	-0.31	8.92e-9	Childhood ear infection;
CRC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg20607287	chr7:12443886	VWDE	-0.66	-6.93	-0.36	2.22e-11	Coronary artery disease;
CRC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.46	0.38	7.83e-13	Menopause (age at onset);
CRC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.43	6.83	0.35	4.05e-11	Dupuytren's disease;
CRC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.4	0.33	5.33e-10	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg01420254	chr6:26195488	NA	0.75	6.21	0.32	1.58e-9	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.06	-0.55	5.45e-28	Type 2 diabetes;
CRC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.42	8.47	0.42	8.41e-16	Vitiligo;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg00789793	chr3:141329863	RASA2	-0.59	-6.19	-0.32	1.81e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg24046110	chr8:143859143	LYNX1	-0.37	-6.37	-0.33	6.29e-10	Urinary tract infection frequency;
CRC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.39	6.73	0.35	7.66e-11	Cardiovascular disease risk factors;
CRC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.53	7.25	0.37	3.02e-12	Height;
CRC	trans	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg22676075	chr6:135203613	NA	0.39	6.08	0.32	3.42e-9	Red blood cell count;
CRC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18912574	chr7:65842487	NCRNA00174	-0.35	-5.83	-0.31	1.31e-8	Aortic root size;
CRC	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg16606324	chr3:10149918	C3orf24	0.64	7.23	0.37	3.31e-12	Alzheimer's disease;
CRC	trans	rs7671189	0.522	rs2087769	chr4:11740548	A/G	cg18054620	chr5:111191530	C5orf13	-0.3	-6.03	-0.32	4.32e-9	Obesity-related traits;
CRC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.33	6.13	0.32	2.54e-9	QRS complex (12-leadsum);
CRC	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.73	-10.08	-0.49	5.37e-21	Coronary artery disease;
CRC	cis	rs243505	0.898	rs243541	chr7:148403243	A/T	cg09806900	chr7:148480153	CUL1	-0.42	-5.83	-0.31	1.32e-8	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg08533674	chr1:46993347	NA	0.63	8.13	0.41	8.62e-15	Monobrow;
CRC	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg12315302	chr6:26189340	HIST1H4D	-0.73	-5.64	-0.3	3.69e-8	Intelligence (multi-trait analysis);
CRC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.25	-0.37	2.99e-12	Height;
CRC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.65	7.94	0.4	3.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg03623178	chr6:28175578	NA	0.84	7.95	0.4	2.95e-14	Depression;
CRC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.19	-0.41	6.03e-15	Chronic sinus infection;
CRC	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.4	6.82	0.35	4.25e-11	Schizophrenia;
CRC	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg22495460	chr2:25135724	ADCY3	-0.77	-12.77	-0.58	1.33e-30	Body mass index;
CRC	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.56	-6.41	-0.33	5.04e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg06392426	chr19:10676186	KRI1	0.59	6.98	0.36	1.64e-11	Red cell distribution width;
CRC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25517755	chr10:38738941	LOC399744	0.46	6.62	0.34	1.45e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs3751196	0.901	rs56255894	chr12:104163425	G/A	cg02344784	chr12:104178138	NT5DC3	0.7	7.02	0.36	1.29e-11	Sense of smell;
CRC	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.27e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.77	9.31	0.46	1.85e-18	Body mass index;
CRC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12463550	chr7:65579703	CRCP	0.71	6.46	0.34	3.88e-10	Diabetic kidney disease;
CRC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.59	-0.34	1.74e-10	Retinal vascular caliber;
CRC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-6.21	-0.32	1.61e-9	Tonsillectomy;
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg02776659	chr21:47717406	C21orf57	0.36	5.77	0.3	1.81e-8	Testicular germ cell tumor;
CRC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg06238570	chr21:40685208	BRWD1	0.76	10.27	0.49	1.23e-21	Cognitive function;
CRC	cis	rs17253792	0.545	rs12886406	chr14:56027605	G/A	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.28e-10	Putamen volume;
CRC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.77	-13.34	-0.59	9.31e-33	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg15845792	chr6:28175446	NA	0.73	6.16	0.32	2.08e-9	Depression;
CRC	cis	rs6818397	1.000	rs6818397	chr4:3434885	A/C	cg08741688	chr4:3415352	RGS12	0.38	6.18	0.32	1.88e-9	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg10760299	chr15:45669010	GATM	0.49	7.65	0.39	2.19e-13	Homoarginine levels;
CRC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.42	6.26	0.33	1.21e-9	Platelet distribution width;
CRC	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.45	6.51	0.34	2.75e-10	Subjective well-being;
CRC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.86	0.44	5.1e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg14711859	chr11:8959438	ASCL3	-0.37	-5.85	-0.31	1.21e-8	Hemoglobin concentration;
CRC	cis	rs9906695	0.950	rs67586205	chr17:32551087	G/A	cg12698626	chr17:32581466	CCL2	0.41	5.7	0.3	2.72e-8	Monocyte percentage of white cells;
CRC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.57	-7.84	-0.4	6.21e-14	Obesity-related traits;
CRC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-8.01	-0.4	2.07e-14	Monocyte percentage of white cells;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23597370	chr4:26862044	STIM2	0.45	6.2	0.32	1.67e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.31	-0.33	9.1e-10	Bipolar disorder;
CRC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg15269541	chr15:43626905	ADAL	-0.39	-6.0	-0.31	5.18e-9	Lung cancer;
CRC	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.54	7.59	0.39	3.41e-13	Testicular germ cell tumor;
CRC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.15e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.8	-0.63	2.42e-38	Exhaled nitric oxide output;
CRC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.62	-0.39	2.8e-13	Self-reported allergy;
CRC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.34	-0.5	7.18e-22	Chronic sinus infection;
CRC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg20160996	chr11:63990575	FERMT3	0.4	6.48	0.34	3.27e-10	Platelet count;
CRC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.81	-0.72	4.3e-54	Height;
CRC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg08888203	chr3:10149979	C3orf24	0.46	7.21	0.37	3.9e-12	Alzheimer's disease;
CRC	cis	rs11209185	0.527	rs11209186	chr1:68434340	A/G	cg22082780	chr1:68452167	NA	-0.38	-5.77	-0.3	1.85e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.33	-0.33	8.13e-10	Breast cancer;
CRC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	0.9	10.79	0.51	1.99e-23	Type 2 diabetes nephropathy;
CRC	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg00631329	chr6:26305371	NA	-0.56	-9.48	-0.46	5.3e-19	Educational attainment;
CRC	cis	rs2346160	0.867	rs2989556	chr6:167704404	T/A	cg27333441	chr6:167680455	NA	-0.4	-6.58	-0.34	1.83e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg24046110	chr8:143859143	LYNX1	-0.42	-6.45	-0.33	4.08e-10	Urinary tract infection frequency;
CRC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg12682573	chr17:27188876	MIR451;MIR144	0.58	7.99	0.4	2.37e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.46	6.65	0.34	1.25e-10	Subjective well-being;
CRC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.76	-0.3	1.92e-8	Arsenic metabolism;
CRC	cis	rs501120	0.929	rs605425	chr10:44750669	T/C	cg09554077	chr10:44749378	NA	0.89	13.17	0.59	4.18e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.84	-11.4	-0.53	1.39e-25	Initial pursuit acceleration;
CRC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.45	-0.34	3.92e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg09658497	chr7:2847517	GNA12	-0.4	-6.36	-0.33	6.56e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.5	-7.67	-0.39	2.01e-13	Body mass index;
CRC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	5.86	0.31	1.1e-8	Tonsillectomy;
CRC	cis	rs6694672	0.850	rs4915316	chr1:197059928	A/G	cg13682187	chr1:196946512	CFHR5	0.43	7.0	0.36	1.41e-11	Asthma;
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg07564175	chr17:8024546	HES7	-0.55	-6.42	-0.33	4.7e-10	Type 1 diabetes;
CRC	cis	rs6504622	0.537	rs1052504	chr17:44993828	C/T	cg16759221	chr17:45003025	GOSR2	-0.65	-10.49	-0.5	2.07e-22	Orofacial clefts;
CRC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-10.52	-0.5	1.69e-22	Colorectal cancer;
CRC	cis	rs7086803	1.000	rs7916159	chr10:114500377	A/G	cg03281572	chr10:114502318	VTI1A	0.75	6.34	0.33	7.77e-10	Lung cancer;
CRC	trans	rs928391	0.948	rs2735657	chr1:156780306	A/C	cg14948448	chr4:148401661	EDNRA	-0.49	-6.02	-0.31	4.69e-9	Platelet count;
CRC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg12365402	chr11:9010492	NRIP3	-0.57	-10.74	-0.51	2.88e-23	Hemoglobin concentration;
CRC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.4	-7.54	-0.38	4.65e-13	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.84	-13.84	-0.61	1.22e-34	Hypospadias;
CRC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.63	-6.54	-0.34	2.32e-10	Type 2 diabetes;
CRC	trans	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg16379337	chr7:115850450	TES	0.37	6.0	0.31	5.25e-9	Breast cancer;
CRC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.03	-0.32	4.49e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg03037974	chr15:76606532	NA	-0.51	-7.34	-0.38	1.64e-12	Blood metabolite levels;
CRC	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg27068330	chr11:65405492	SIPA1	-0.42	-5.87	-0.31	1.09e-8	Systemic lupus erythematosus;
CRC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.57	8.45	0.42	9.23e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.51	8.45	0.42	9.22e-16	Uric acid clearance;
CRC	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg17145862	chr1:211918768	LPGAT1	-0.51	-7.31	-0.37	2.08e-12	Crohn's disease;
CRC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.69	-0.3	2.79e-8	Migraine;Coronary artery disease;
CRC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg26304593	chr6:42947056	PEX6	-0.43	-6.05	-0.32	4.02e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg10589385	chr1:150898437	SETDB1	0.31	6.68	0.35	1.04e-10	Tonsillectomy;
CRC	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg01993067	chr11:68851601	TPCN2	0.55	6.09	0.32	3.1e-9	Blond vs. brown hair color;
CRC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.64	-8.79	-0.44	8.48e-17	Schizophrenia;
CRC	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.71	13.15	0.59	4.98e-32	Hip circumference;
CRC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.58	8.64	0.43	2.4e-16	Lymphocyte counts;
CRC	cis	rs6534441	0.857	rs6846869	chr4:125454820	G/A	cg21609808	chr4:125404261	NA	0.4	5.92	0.31	8.09e-9	Major depressive disorder;
CRC	cis	rs9491140	0.539	rs11154224	chr6:124678535	G/A	cg19267163	chr6:125004984	NKAIN2	0.46	6.22	0.32	1.51e-9	Neuroticism;
CRC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg03929089	chr4:120376271	NA	0.66	6.31	0.33	9.22e-10	Axial length;
CRC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.76	-12.36	-0.56	4.23e-29	Breast cancer;
CRC	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.48	8.17	0.41	6.55e-15	Testicular germ cell tumor;
CRC	cis	rs28655083	0.552	rs76055145	chr16:77124905	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.58	-6.71	-0.35	8.75e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg07713946	chr22:31675144	LIMK2	0.41	5.85	0.31	1.21e-8	Colorectal cancer;
CRC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg14847009	chr1:175162515	KIAA0040	-0.26	-5.69	-0.3	2.87e-8	Alcohol dependence;
CRC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.55	8.04	0.41	1.58e-14	Lung cancer;
CRC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.46	6.95	0.36	1.99e-11	Coronary artery disease;
CRC	cis	rs7619833	0.512	rs12715119	chr3:27221769	T/C	cg02860705	chr3:27208620	NA	0.39	6.06	0.32	3.79e-9	Breast cancer;
CRC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg21285383	chr16:89894308	SPIRE2	0.36	6.22	0.32	1.54e-9	Vitiligo;
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg15147215	chr3:52552868	STAB1	-0.61	-10.07	-0.49	5.69e-21	Bipolar disorder;
CRC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.65	-0.39	2.22e-13	Gut microbiome composition (summer);
CRC	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.52	-6.27	-0.33	1.12e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CRC	cis	rs2625529	0.652	rs2034879	chr15:72429989	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-6.98	-0.36	1.61e-11	Red blood cell count;
CRC	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg06287003	chr12:125626642	AACS	-0.6	-6.86	-0.35	3.44e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18099408	chr3:52552593	STAB1	-0.38	-5.6	-0.3	4.5e-8	Bipolar disorder;
CRC	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.95	11.04	0.52	2.52e-24	Exhaled nitric oxide output;
CRC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	0.96	18.05	0.71	4.37e-51	Height;
CRC	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg15282417	chr9:129245246	FAM125B	0.45	8.23	0.41	4.33e-15	Intraocular pressure;
CRC	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-7.78	-0.39	9.14e-14	Hepatocellular carcinoma;
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg21856205	chr7:94953877	PON1	-0.49	-6.51	-0.34	2.88e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg02527881	chr3:46936655	PTH1R	0.35	5.98	0.31	5.85e-9	Colorectal cancer;
CRC	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24308560	chr3:49941425	MST1R	0.51	8.28	0.42	3.16e-15	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg15147215	chr3:52552868	STAB1	-0.67	-11.85	-0.55	3.22e-27	Electroencephalogram traits;
CRC	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg03162506	chr22:38580953	NA	0.27	5.82	0.31	1.4e-8	Cutaneous nevi;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09730836	chr5:111496633	NCRNA00219;SNORA13	0.42	6.18	0.32	1.84e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg18939081	chr1:31884902	SERINC2	0.34	5.6	0.3	4.43e-8	Alcohol dependence;
CRC	cis	rs12230513	0.732	rs7966770	chr12:55844717	T/C	cg19537932	chr12:55886519	OR6C68	-0.73	-9.52	-0.46	3.94e-19	Contrast sensitivity;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg03623178	chr6:28175578	NA	0.83	12.47	0.57	1.76e-29	Parkinson's disease;
CRC	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.6	11.82	0.55	4.17e-27	Neuroticism;
CRC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.28	0.37	2.52e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg14646075	chr2:228736089	WDR69	-0.45	-6.14	-0.32	2.43e-9	Blood pressure;
CRC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg03037974	chr15:76606532	NA	-0.53	-7.89	-0.4	4.63e-14	Blood metabolite levels;
CRC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.58	0.47	2.52e-19	Cognitive test performance;
CRC	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.63	-8.72	-0.43	1.39e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg17401720	chr7:158221031	PTPRN2	0.37	5.98	0.31	5.85e-9	Obesity-related traits;
CRC	trans	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg20064139	chr20:41823021	NA	-0.29	-5.96	-0.31	6.35e-9	Coronary artery disease;
CRC	cis	rs9409565	1.000	rs9409565	chr9:97251034	C/T	cg04523069	chr9:97136363	HIATL1	0.37	5.76	0.3	1.95e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.37	5.88	0.31	1.02e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-10.07	-0.49	5.79e-21	Personality dimensions;
CRC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg07507251	chr3:52567010	NT5DC2	0.45	6.8	0.35	4.98e-11	Cognitive function;
CRC	cis	rs1158570	0.500	rs2554369	chr8:131314047	C/T	cg26053073	chr8:131455383	NA	-0.41	-6.36	-0.33	6.67e-10	Platelet count;
CRC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.51	-7.31	-0.37	2.04e-12	Coronary artery disease;
CRC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.54	7.05	0.36	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.95	-19.03	-0.72	5.67e-55	Bone mineral density;
CRC	trans	rs11088226	0.645	rs2833917	chr21:33957544	C/T	cg09050820	chr6:167586206	TCP10L2	0.87	8.94	0.44	2.81e-17	Gastritis;
CRC	cis	rs17270561	0.636	rs3922681	chr6:25698481	C/T	cg16482183	chr6:26056742	HIST1H1C	0.72	8.75	0.43	1.11e-16	Iron status biomarkers;
CRC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.08	0.45	1.05e-17	Alzheimer's disease;
CRC	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11547950	chr5:77652471	NA	-0.52	-7.74	-0.39	1.26e-13	Triglycerides;
CRC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.31	-18.09	-0.71	2.95e-51	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.55	6.19	0.32	1.82e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04880052	chr2:219191631	PNKD	0.38	6.04	0.32	4.26e-9	Colorectal cancer;
CRC	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	trans	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg10756647	chr7:56101905	PSPH	0.71	7.4	0.38	1.12e-12	Diabetic kidney disease;
CRC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13198984	chr17:80129470	CCDC57	-0.47	-8.16	-0.41	7.39e-15	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04785418	chr12:42538813	GXYLT1	0.46	6.14	0.32	2.4e-9	Anxiety disorder;
CRC	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg18830697	chr6:72922368	RIMS1	0.41	8.01	0.4	2.02e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.42	0.33	4.87e-10	Height;
CRC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.03	0.4	1.74e-14	Menopause (age at onset);
CRC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.84	-18.08	-0.71	3.12e-51	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.56	8.94	0.44	2.96e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.83	-0.31	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs629535	0.814	rs604254	chr8:70059164	A/G	cg26132723	chr8:70041827	NA	0.36	5.92	0.31	8.06e-9	Dupuytren's disease;
CRC	cis	rs7107770	1.000	rs12791760	chr11:125091568	C/T	cg27629782	chr11:125073726	PKNOX2	-0.46	-5.73	-0.3	2.23e-8	Photic sneeze reflex;
CRC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.43	7.22	0.37	3.66e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21028142	chr17:79581711	NPLOC4	0.34	7.18	0.37	4.69e-12	Eye color traits;
CRC	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg13385794	chr1:248469461	NA	0.4	7.1	0.36	7.96e-12	Common traits (Other);
CRC	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	0.54	6.11	0.32	2.82e-9	Dental caries;
CRC	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg13385794	chr1:248469461	NA	-0.38	-6.82	-0.35	4.5e-11	Common traits (Other);
CRC	cis	rs17155006	0.746	rs429252	chr7:107745554	T/C	cg05962710	chr7:107745446	LAMB4	-0.41	-7.33	-0.37	1.85e-12	Pneumococcal bacteremia;
CRC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.65	6.93	0.36	2.21e-11	Axial length;
CRC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-5.85	-0.31	1.16e-8	Heart rate;
CRC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg03948781	chr1:205179583	DSTYK	0.41	5.6	0.3	4.5e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.61	-8.88	-0.44	4.4e-17	Menarche (age at onset);
CRC	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.61	-0.39	2.95e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02711726	chr17:80685570	FN3KRP	-0.51	-6.84	-0.35	3.85e-11	Glycated hemoglobin levels;
CRC	cis	rs6066835	0.867	rs73144586	chr20:47360454	G/A	cg18078177	chr20:47281410	PREX1	0.61	5.6	0.3	4.46e-8	Multiple myeloma;
CRC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.6	-11.37	-0.53	1.75e-25	Schizophrenia;
CRC	cis	rs7301826	0.651	rs10773825	chr12:131298913	G/A	cg11011512	chr12:131303247	STX2	0.37	5.61	0.3	4.35e-8	Plasma plasminogen activator levels;
CRC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.6	7.49	0.38	6.21e-13	Mean platelet volume;
CRC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg03037974	chr15:76606532	NA	-0.45	-6.93	-0.36	2.3e-11	Blood metabolite levels;
CRC	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.1	-0.32	2.93e-9	Coronary artery disease;
CRC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg03316587	chr8:142245164	NA	-0.37	-5.64	-0.3	3.63e-8	Immature fraction of reticulocytes;
CRC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-0.83	-9.76	-0.47	6.19e-20	Monocyte percentage of white cells;
CRC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg05585544	chr11:47624801	NA	-0.61	-10.85	-0.51	1.22e-23	Subjective well-being;
CRC	cis	rs3996993	0.809	rs4715353	chr6:52703766	A/G	cg20803780	chr6:52668592	GSTA1	-0.35	-6.45	-0.33	4.1e-10	Hemoglobin concentration;
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.45	-0.42	9.5e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg23254163	chr1:152506842	NA	-0.43	-8.07	-0.41	1.29e-14	Hair morphology;
CRC	cis	rs720844	0.748	rs4972375	chr2:149324132	A/C	cg09247360	chr2:149335327	NA	0.58	6.54	0.34	2.32e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg20512303	chr5:131592959	PDLIM4	-0.39	-6.65	-0.34	1.25e-10	Blood metabolite levels;
CRC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.65	9.54	0.47	3.3e-19	Menopause (age at onset);
CRC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.62	11.03	0.52	2.84e-24	Bone mineral density;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	12.42	0.57	2.56e-29	Alzheimer's disease;
CRC	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.38	5.79	0.3	1.69e-8	Red blood cell count;
CRC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.53	0.34	2.52e-10	Morning vs. evening chronotype;
CRC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-12.86	-0.58	6.04e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-8.62	-0.43	2.79e-16	Facial morphology (factor 19);
CRC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.35	0.46	1.44e-18	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs6076065	0.723	rs6083110	chr20:23373674	C/T	cg11657817	chr20:23433608	CST11	0.45	6.68	0.35	1.01e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs911119	0.866	rs2405393	chr20:23569392	G/C	cg16589663	chr20:23618590	CST3	0.42	5.93	0.31	7.51e-9	Chronic kidney disease;
CRC	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.62	6.79	0.35	5.26e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg05754148	chr16:3507555	NAT15	-0.72	-7.33	-0.37	1.8e-12	Tuberculosis;
CRC	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	0.83	9.9	0.48	2.2e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg04121214	chr22:50244548	NA	0.42	5.9	0.31	9.05e-9	Schizophrenia;
CRC	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.66	10.6	0.5	9.04e-23	Corneal astigmatism;
CRC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.84	-0.31	1.23e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs12612619	0.732	rs11126857	chr2:27297757	G/A	cg00617064	chr2:27272375	NA	0.42	7.02	0.36	1.27e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs12612619	0.732	rs11680096	chr2:27273571	T/C	cg00617064	chr2:27272375	NA	-0.38	-6.32	-0.33	8.35e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.59	0.5	9.49e-23	Iron status biomarkers;
CRC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	5.87	0.31	1.06e-8	Bipolar disorder;
CRC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg06636001	chr8:8085503	FLJ10661	0.59	8.53	0.43	5.45e-16	Neuroticism;
CRC	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04837898	chr3:45731254	SACM1L	0.34	5.66	0.3	3.37e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg16950941	chr11:66035639	RAB1B	0.66	9.53	0.46	3.68e-19	Gout;
CRC	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-9.18	-0.45	4.87e-18	Idiopathic membranous nephropathy;
CRC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.05	-0.32	3.98e-9	Menopause (age at onset);
CRC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.41	6.56	0.34	2.1e-10	Obesity-related traits;
CRC	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	0.52	5.75	0.3	2.04e-8	Insulin-like growth factors;
CRC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg27661571	chr11:113659931	NA	-0.95	-10.99	-0.52	3.76e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.56	-8.22	-0.41	4.78e-15	Glomerular filtration rate (creatinine);
CRC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.83	0.35	4.04e-11	Joint mobility (Beighton score);
CRC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.65	9.87	0.48	2.72e-20	Longevity;Endometriosis;
CRC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24308560	chr3:49941425	MST1R	0.43	6.8	0.35	5.06e-11	Body mass index;
CRC	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.78e-15	Corneal astigmatism;
CRC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg07952391	chr2:88470173	THNSL2	0.62	5.95	0.31	7.01e-9	Plasma clusterin levels;
CRC	cis	rs17767392	0.958	rs2214836	chr14:72025078	G/T	cg13720639	chr14:72061746	SIPA1L1	0.56	6.88	0.35	3.04e-11	Mitral valve prolapse;
CRC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.5	-7.48	-0.38	6.61e-13	Dementia with Lewy bodies;
CRC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.71	12.42	0.56	2.74e-29	Schizophrenia;
CRC	trans	rs800082	0.516	rs4511940	chr3:144219392	T/C	cg24215973	chr2:240111563	HDAC4	0.47	6.46	0.34	3.87e-10	Smoking behavior;
CRC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.68	9.94	0.48	1.52e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.11	-0.36	7.25e-12	Gut microbiome composition (summer);
CRC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.63	14.51	0.62	3.27e-37	Airflow obstruction;
CRC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.66	-0.39	2.06e-13	Bipolar disorder;
CRC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.31	5.13e-9	Hemoglobin concentration;
CRC	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg15282417	chr9:129245246	FAM125B	0.47	8.78	0.44	9.18e-17	Intraocular pressure;
CRC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	7.48	0.38	6.71e-13	Height;
CRC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.66	-9.62	-0.47	1.89e-19	Cognitive function;
CRC	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg11266682	chr4:10021025	SLC2A9	0.36	6.29	0.33	9.99e-10	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07489123	chr19:1812466	ATP8B3	0.38	6.02	0.31	4.62e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17714010	chr17:78968450	CHMP6	0.49	6.76	0.35	6.33e-11	Survival in pancreatic cancer;
CRC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.37e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-10.65	-0.51	5.95e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg02766259	chr12:125626809	AACS	-0.48	-7.36	-0.38	1.47e-12	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg25456477	chr12:86230367	RASSF9	0.32	5.67	0.3	3.13e-8	Major depressive disorder;
CRC	cis	rs13428823	0.928	rs3795955	chr2:25375105	T/C	cg22495460	chr2:25135724	ADCY3	-0.4	-5.67	-0.3	3.08e-8	Height;
CRC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	1.04e-10	Menopause (age at onset);
CRC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.82	-0.31	1.4e-8	Carotid intima media thickness;
CRC	cis	rs3736485	0.934	rs28393906	chr15:51867605	T/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.64	-0.34	1.33e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.62	-6.88	-0.35	2.97e-11	Blood protein levels;
CRC	cis	rs73206853	0.841	rs17792048	chr12:110866543	C/A	cg12870014	chr12:110450643	ANKRD13A	0.81	8.39	0.42	1.42e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.51	-7.25	-0.37	2.91e-12	Bronchopulmonary dysplasia;
CRC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.43	6.69	0.35	9.56e-11	Corneal astigmatism;
CRC	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.58	9.08	0.45	1.06e-17	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.81	-7.66	-0.39	2.03e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.45	-6.08	-0.32	3.29e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs7619833	0.620	rs1445111	chr3:27253971	C/T	cg02860705	chr3:27208620	NA	0.38	6.02	0.32	4.53e-9	Breast cancer;
CRC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11094939	chr2:65454430	ACTR2	0.45	6.25	0.33	1.25e-9	Response to antipsychotic treatment;
CRC	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg23815491	chr16:72088622	HP	0.5	7.23	0.37	3.35e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.92	0.31	8.09e-9	Monocyte percentage of white cells;
CRC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg06494592	chr3:125709126	NA	-0.52	-6.29	-0.33	1e-9	Blood pressure (smoking interaction);
CRC	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.58	-6.75	-0.35	6.54e-11	Height;Educational attainment;Head circumference (infant);
CRC	cis	rs9326248	0.727	rs4938347	chr11:117021759	T/A	cg11861562	chr11:117069780	TAGLN	0.34	6.29	0.33	1.02e-9	Blood protein levels;
CRC	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-6.96	-0.36	1.9e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-6.22	-0.32	1.5e-9	Menarche (age at onset);
CRC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.61	10.75	0.51	2.7e-23	Aortic root size;
CRC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg25834613	chr7:1915315	MAD1L1	-0.47	-6.78	-0.35	5.73e-11	Bipolar disorder;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg15786705	chr6:28176104	NA	0.62	6.98	0.36	1.67e-11	Depression;
CRC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg17321639	chr7:2759063	NA	-0.53	-6.96	-0.36	1.85e-11	Height;
CRC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg02741985	chr17:80059408	CCDC57	0.44	7.26	0.37	2.75e-12	Life satisfaction;
CRC	cis	rs6968419	0.755	rs6948556	chr7:115895433	T/C	cg02561103	chr7:115862891	TES	-0.43	-6.47	-0.34	3.48e-10	Intraocular pressure;
CRC	cis	rs2764208	0.576	rs6457791	chr6:34759954	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.33	1.4e-9	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02290350	chr8:58132656	NA	-0.5	-6.19	-0.32	1.75e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg04880052	chr2:219191631	PNKD	-0.44	-6.94	-0.36	2.15e-11	Colorectal cancer;
CRC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.32	-0.33	8.39e-10	Reticulocyte fraction of red cells;
CRC	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg23254163	chr1:152506842	NA	0.45	8.87	0.44	4.86e-17	Hair morphology;
CRC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.11	26.71	0.83	2.13e-84	Testicular germ cell tumor;
CRC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.58	-7.8	-0.4	8.07e-14	Response to antineoplastic agents;
CRC	cis	rs501120	0.584	rs1680636	chr10:44675941	G/A	cg09554077	chr10:44749378	NA	0.7	7.85	0.4	5.95e-14	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg19678392	chr7:94953810	PON1	-0.56	-7.06	-0.36	9.89e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.58	-0.43	3.75e-16	Personality dimensions;
CRC	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.56	5.94	0.31	7.36e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg15269541	chr15:43626905	ADAL	-0.49	-5.9	-0.31	9.27e-9	Lung cancer in ever smokers;
CRC	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.57	9.72	0.47	8.76e-20	Dupuytren's disease;
CRC	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.5	0.46	4.46e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.36	-0.33	6.71e-10	Aortic root size;
CRC	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg11212589	chr17:38028394	ZPBP2	-0.44	-8.02	-0.4	1.89e-14	Self-reported allergy;
CRC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.57	7.75	0.39	1.17e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg15382696	chr6:118971807	C6orf204	0.61	7.88	0.4	4.86e-14	Diastolic blood pressure;
CRC	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.75	9.14	0.45	6.82e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	trans	rs11581859	0.950	rs7524165	chr1:99388780	T/C	cg12183875	chr3:169587454	LRRC31	0.28	6.33	0.33	7.89e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.65	9.99	0.48	1.08e-20	Corneal astigmatism;
CRC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-8.18	-0.41	6.32e-15	Gut microbiome composition (summer);
CRC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.48	9.33	0.46	1.63e-18	Lung cancer;
CRC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.46	6.88	0.35	3.02e-11	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-6.56	-0.34	2.08e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg20607287	chr7:12443886	VWDE	-0.55	-6.18	-0.32	1.92e-9	Coronary artery disease;
CRC	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.87	-14.9	-0.63	9.57e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.37	-6.31	-0.33	9.04e-10	Blood metabolite levels;
CRC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	8.83	0.44	6.27e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs2625529	0.824	rs2415121	chr15:72134018	C/T	cg16672083	chr15:72433130	SENP8	-0.44	-6.55	-0.34	2.28e-10	Red blood cell count;
CRC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-5.84	-0.31	1.28e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.42	-6.27	-0.33	1.13e-9	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg15790184	chr11:494944	RNH1	0.63	5.99	0.31	5.37e-9	Body mass index;
CRC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.31	0.33	8.92e-10	IgG glycosylation;
CRC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg15147215	chr3:52552868	STAB1	-0.64	-11.19	-0.52	7.72e-25	Electroencephalogram traits;
CRC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg22561889	chr6:118971681	C6orf204	0.47	6.06	0.32	3.78e-9	Diastolic blood pressure;
CRC	trans	rs12200782	0.578	rs9467739	chr6:26382573	A/T	cg25800765	chr12:85673347	ALX1	0.26	5.96	0.31	6.54e-9	Small cell lung carcinoma;
CRC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11645453	chr3:52864694	ITIH4	0.37	6.41	0.33	4.91e-10	Bipolar disorder;
CRC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.48	9.22	0.45	3.54e-18	Renal cell carcinoma;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg05377417	chr17:59940892	BRIP1	-0.44	-6.94	-0.36	2.09e-11	Interleukin-6 levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14274482	chr22:50913571	SBF1	0.42	6.07	0.32	3.5e-9	Response to antipsychotic treatment;
CRC	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs7943203	0.849	rs10789665	chr11:108356680	T/C	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.72	0.3	2.45e-8	Red blood cell count;Mean corpuscular volume;
CRC	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg21153622	chr11:89784906	NA	0.44	7.12	0.37	6.64e-12	HDL cholesterol;
CRC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.65	6.67	0.35	1.08e-10	Axial length;
CRC	cis	rs4664293	0.867	rs16822558	chr2:160601007	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.51	10.26	0.49	1.26e-21	Urate levels in overweight individuals;
CRC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.39	-0.38	1.22e-12	Total body bone mineral density;
CRC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg06238570	chr21:40685208	BRWD1	0.76	10.62	0.51	7.3e-23	Cognitive function;
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg26608667	chr7:1196370	ZFAND2A	0.39	6.0	0.31	5.19e-9	Longevity;Endometriosis;
CRC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.73	-11.47	-0.53	7.42e-26	Colorectal cancer;
CRC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	10.24	0.49	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.8	13.62	0.6	8.32e-34	Menopause (age at onset);
CRC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.69	-0.47	1.05e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.43	6.38	0.33	6e-10	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg24881689	chr7:143825000	OR2A14	-0.43	-7.01	-0.36	1.32e-11	Aortic root size;
CRC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.82	12.46	0.57	1.86e-29	Cognitive function;
CRC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg00999904	chr2:3704751	ALLC	-0.57	-6.77	-0.35	6e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.62	-11.23	-0.53	5.33e-25	Aortic root size;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.61	9.6	0.47	2.14e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg05784532	chr1:230284198	GALNT2	0.48	6.54	0.34	2.4e-10	Coronary artery disease;
CRC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.05	-0.36	1.03e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.66	-0.3	3.31e-8	Pulmonary function;
CRC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.71	10.91	0.52	7.11e-24	Corneal astigmatism;
CRC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	8.27	0.41	3.46e-15	Eosinophilic esophagitis;
CRC	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg08989290	chr16:615782	NHLRC4	0.47	9.07	0.45	1.11e-17	Height;
CRC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.65	-10.04	-0.48	7.15e-21	Height;
CRC	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.85	-0.35	3.57e-11	Response to antipsychotic treatment;
CRC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg22495460	chr2:25135724	ADCY3	-0.87	-16.79	-0.68	4.07e-46	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04193083	chr17:41323562	NBR1	0.43	6.55	0.34	2.2e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg18755114	chr2:209119030	IDH1	0.42	6.34	0.33	7.67e-10	Blood protein levels;
CRC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.59	-10.01	-0.48	8.88e-21	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.69	-7.76	-0.39	1.08e-13	Body mass index;
CRC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg07636037	chr3:49044803	WDR6	-0.84	-6.02	-0.32	4.57e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg02811702	chr13:24901961	NA	0.45	6.22	0.32	1.53e-9	Obesity-related traits;
CRC	cis	rs6495367	1.000	rs6495367	chr15:79375347	C/T	cg17916960	chr15:79447300	NA	0.36	5.7	0.3	2.65e-8	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.4	8.69	0.43	1.71e-16	Glomerular filtration rate (creatinine);
CRC	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-6.64	-0.34	1.26e-10	Breast cancer;
CRC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-6.3	-0.33	9.32e-10	Menopause (age at onset);
CRC	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg26816564	chr1:7831052	VAMP3	-0.54	-6.26	-0.33	1.19e-9	Inflammatory bowel disease;
CRC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-8.64	-0.43	2.53e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26240231	chr7:1148101	C7orf50	-0.42	-5.61	-0.3	4.4e-8	Bronchopulmonary dysplasia;
CRC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.62	11.61	0.54	2.35e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.43	5.8	0.3	1.59e-8	Obesity-related traits;
CRC	cis	rs9292777	0.966	rs1445001	chr5:40431664	A/G	cg09067459	chr5:40385259	NA	0.51	8.92	0.44	3.39e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.58	13.37	0.59	7.21e-33	Breast size;
CRC	cis	rs7538876	0.903	rs6681150	chr1:17750685	G/A	cg01904812	chr1:17746340	RCC2	0.36	5.9	0.31	9.12e-9	Basal cell carcinoma;
CRC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.53	-7.85	-0.4	5.77e-14	Coronary artery disease;
CRC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.88	-0.31	1.02e-8	Diastolic blood pressure;
CRC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg27427491	chr17:78079615	GAA	-0.49	-7.09	-0.36	8.3e-12	Yeast infection;
CRC	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg09019002	chr7:102715232	ARMC10;FBXL13	0.5	6.24	0.33	1.34e-9	Plasma plasminogen activator levels;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19540316	chr13:113622750	MCF2L	-0.48	-6.29	-0.33	1e-9	Diisocyanate-induced asthma;
CRC	cis	rs6504622	0.875	rs28553405	chr17:45045895	A/G	cg16759221	chr17:45003025	GOSR2	-0.54	-8.56	-0.43	4.27e-16	Orofacial clefts;
CRC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.98	0.4	2.42e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.48	-0.34	3.26e-10	Breast cancer;
CRC	cis	rs10924970	0.967	rs7518225	chr1:235394541	A/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.78	0.3	1.71e-8	Asthma;
CRC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.37	0.33	6.37e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.73	0.54	8.92e-27	Prudent dietary pattern;
CRC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.4	6.13	0.32	2.5e-9	Mean corpuscular volume;
CRC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.17	-0.32	1.98e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg11070056	chr1:107600091	PRMT6	0.38	5.98	0.31	5.81e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17004975	chr10:81743287	NA	-0.34	-6.07	-0.32	3.48e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	8.02	0.4	1.86e-14	Schizophrenia;
CRC	cis	rs4664293	0.867	rs2357532	chr2:160597427	G/A	cg08347373	chr2:160653686	CD302	-0.47	-7.47	-0.38	7.38e-13	Monocyte percentage of white cells;
CRC	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.49	7.71	0.39	1.53e-13	Coronary artery disease;
CRC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.91	10.37	0.5	5.42e-22	Breast cancer;
CRC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-6.8	-0.35	5.02e-11	IgG glycosylation;
CRC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.87	17.34	0.69	2.58e-48	Myeloid white cell count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27498675	chr19:41945691	ATP5SL	0.48	6.18	0.32	1.94e-9	Thyroid stimulating hormone;
CRC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.54	-8.07	-0.41	1.37e-14	Facial morphology (factor 23);
CRC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.49	7.77	0.39	1e-13	Height;
CRC	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg06042504	chr8:55087323	NA	-0.37	-5.77	-0.3	1.79e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg03623178	chr6:28175578	NA	0.45	6.0	0.31	5.12e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-0.71	-7.27	-0.37	2.58e-12	Blood protein levels;
CRC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.64	10.48	0.5	2.23e-22	Extrinsic epigenetic age acceleration;
CRC	cis	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg18809830	chr7:99032528	PTCD1	-1.03	-7.7	-0.39	1.61e-13	Blood metabolite levels;
CRC	cis	rs113123495	0.609	rs2485278	chr19:5645204	A/G	cg26242866	chr19:5711310	LONP1	0.7	5.81	0.31	1.47e-8	Obsessive-compulsive symptoms;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04127825	chr1:167503222	NA	0.48	6.63	0.34	1.34e-10	Response to antipsychotic treatment;
CRC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.84	-12.38	-0.56	3.56e-29	Coronary artery disease;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg07878378	chr8:56987195	RPS20;SNORD54	-0.47	-6.08	-0.32	3.28e-9	Parkinson's disease;
CRC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg04539111	chr16:67997858	SLC12A4	-0.51	-5.91	-0.31	8.72e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg24209194	chr3:40518798	ZNF619	0.42	6.45	0.34	3.92e-10	Renal cell carcinoma;
CRC	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.38	6.3	0.33	9.4e-10	Airway imaging phenotypes;
CRC	cis	rs2811415	0.597	rs13073261	chr3:127751493	A/G	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs78761021	0.867	rs8077150	chr17:9788769	C/T	cg26853458	chr17:9805074	RCVRN	0.37	7.46	0.38	8.01e-13	Type 2 diabetes;
CRC	cis	rs9463078	0.764	rs10948190	chr6:44942300	C/T	cg25276700	chr6:44698697	NA	-0.27	-6.7	-0.35	9.04e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.51	-7.48	-0.38	6.68e-13	Urate levels;
CRC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22029157	chr1:209979665	IRF6	0.61	6.77	0.35	5.84e-11	Cleft lip with or without cleft palate;
CRC	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.35	-6.1	-0.32	3e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.82	0.35	4.28e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs6544773	0.630	rs341602	chr2:45065503	A/G	cg10208897	chr5:178548229	ADAMTS2	0.35	6.16	0.32	2.11e-9	Mosquito bite size;
CRC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.51	8.29	0.42	2.97e-15	Aortic root size;
CRC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.49	9.26	0.45	2.63e-18	Smoking initiation;
CRC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg17848003	chr1:3704513	LRRC47	0.41	5.9	0.31	8.99e-9	Red cell distribution width;
CRC	trans	rs2321882	0.834	rs17682567	chr13:59457467	T/C	cg04268950	chr11:130298854	ADAMTS8	-0.45	-5.99	-0.31	5.64e-9	Body mass index;
CRC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.91	0.36	2.56e-11	Rheumatoid arthritis;
CRC	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg01843034	chr6:37503916	NA	-0.38	-6.94	-0.36	2.05e-11	Cognitive performance;
CRC	cis	rs728616	0.614	rs1538818	chr10:82122793	G/A	cg05935833	chr10:81318306	SFTPA2	-0.58	-7.02	-0.36	1.28e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg18876405	chr7:65276391	NA	0.47	6.41	0.33	5.04e-10	Aortic root size;
CRC	trans	rs11581859	0.950	rs72730307	chr1:99373916	A/T	cg12183875	chr3:169587454	LRRC31	0.28	6.52	0.34	2.72e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.62	10.67	0.51	5.03e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.6	8.44	0.42	1.02e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.84	10.61	0.5	8.14e-23	Iron status biomarkers;
CRC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.61	10.69	0.51	4.37e-23	Aortic root size;
CRC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.84	11.56	0.54	3.48e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.71	-11.42	-0.53	1.16e-25	Plateletcrit;Platelet count;
CRC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.52	0.6	2.03e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.97	-0.55	1.22e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.75	0.3	2.07e-8	Bladder cancer;
CRC	cis	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg00564723	chr10:75632066	CAMK2G	-0.22	-5.66	-0.3	3.32e-8	Inflammatory bowel disease;
CRC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.37	0.38	1.43e-12	Lung cancer;
CRC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.36	5.93	0.31	7.65e-9	Ulcerative colitis;
CRC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.75	-10.88	-0.51	9.7e-24	Glomerular filtration rate (creatinine);
CRC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.09	0.32	3.16e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg14541582	chr5:601475	NA	-0.33	-6.45	-0.34	3.91e-10	Obesity-related traits;
CRC	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.65	8.49	0.42	7.13e-16	Uric acid levels;
CRC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.54	8.69	0.43	1.76e-16	Prostate cancer;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00699721	chr20:32950990	ITCH	0.39	6.04	0.32	4.25e-9	Myopia (pathological);
CRC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg15845792	chr6:28175446	NA	0.66	9.22	0.45	3.56e-18	Parkinson's disease;
CRC	cis	rs6921919	0.789	rs6456814	chr6:28305812	C/A	cg21251018	chr6:28226885	NKAPL	0.44	6.57	0.34	1.97e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.71	0.43	1.51e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg13072238	chr3:49761600	GMPPB	-0.51	-5.81	-0.3	1.5e-8	Menarche (age at onset);
CRC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	7.0	0.36	1.44e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.59	11.73	0.54	8.53e-27	Neuroticism;
CRC	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg00507830	chr2:103233733	NA	0.55	5.77	0.3	1.88e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.68	-0.39	1.79e-13	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17930852	chr1:45957182	TESK2	0.42	6.33	0.33	7.95e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.61	0.34	1.57e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.63	6.45	0.33	4.05e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.73	0.35	7.42e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs8141797	0.502	rs12484381	chr22:24577121	G/C	cg20894457	chr22:24584366	SUSD2	0.6	7.66	0.39	2.09e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04837898	chr3:45731254	SACM1L	0.37	6.04	0.32	4.25e-9	Hirschsprung disease;
CRC	cis	rs71403859	0.667	rs35538253	chr16:71677975	C/T	cg08717414	chr16:71523259	ZNF19	-1.0	-9.01	-0.44	1.73e-17	Post bronchodilator FEV1;
CRC	cis	rs6546324	0.592	rs2861648	chr2:67803908	C/T	cg15745817	chr2:67799979	NA	-0.53	-8.85	-0.44	5.36e-17	Endometriosis;
CRC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23151374	chr4:164415611	C4orf43	-0.52	-6.31	-0.33	8.96e-10	Diisocyanate-induced asthma;
CRC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg15511327	chr8:143859410	LYNX1	-0.38	-6.0	-0.31	5.14e-9	Urinary tract infection frequency;
CRC	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg22561889	chr6:118971681	C6orf204	0.52	6.58	0.34	1.85e-10	Diastolic blood pressure;
CRC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg04450456	chr4:17643702	FAM184B	-0.39	-6.25	-0.33	1.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.55	7.96	0.4	2.74e-14	Lung cancer;
CRC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg13390004	chr1:15929781	NA	0.53	7.41	0.38	1.07e-12	Systolic blood pressure;
CRC	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg15382696	chr6:118971807	C6orf204	-0.36	-5.71	-0.3	2.58e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
CRC	cis	rs62229266	0.633	rs743420	chr21:37387402	A/G	cg12218747	chr21:37451666	NA	-0.34	-5.83	-0.31	1.31e-8	Mitral valve prolapse;
CRC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.54	6.74	0.35	7.32e-11	Bipolar disorder (body mass index interaction);
CRC	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.45	6.77	0.35	5.98e-11	Testicular germ cell tumor;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg21354621	chr12:46384284	SFRS2IP	-0.39	-6.02	-0.31	4.77e-9	Aortic root size;
CRC	cis	rs863345	0.604	rs12041348	chr1:158482042	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	1.04e-9	Pneumococcal bacteremia;
CRC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.53	0.54	4.58e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs713477	0.654	rs998871	chr14:55918302	G/A	cg21836586	chr14:55907198	TBPL2	0.32	5.62	0.3	4.16e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg02421172	chr7:1938701	MAD1L1	0.42	5.82	0.31	1.4e-8	Bipolar disorder;
CRC	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg18764771	chr6:116381957	FRK	0.28	6.69	0.35	9.75e-11	Total cholesterol levels;
CRC	cis	rs526821	0.532	rs578067	chr11:55313690	T/G	cg04317927	chr11:55418816	OR4S2	0.38	6.49	0.34	3.24e-10	Pediatric bone mineral density (spine);
CRC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg25164649	chr6:28176230	NA	0.73	9.32	0.46	1.74e-18	Depression;
CRC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg03790207	chr6:42947109	PEX6	-0.52	-7.61	-0.39	2.84e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs375066	0.623	rs1549953	chr19:44348768	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.0	0.52	3.55e-24	Prudent dietary pattern;
CRC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.71	0.54	1.02e-26	Prudent dietary pattern;
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg25164649	chr6:28176230	NA	0.52	5.72	0.3	2.41e-8	Depression;
CRC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.56	10.13	0.49	3.68e-21	Multiple system atrophy;
CRC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-8.87	-0.44	4.83e-17	Schizophrenia;
CRC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-10.89	-0.51	8.91e-24	Developmental language disorder (linguistic errors);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08180934	chr12:16035177	STRAP	-0.42	-6.11	-0.32	2.76e-9	Myopia (pathological);
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.74	-10.55	-0.5	1.37e-22	Alzheimer's disease;
CRC	trans	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.31	-0.37	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg04121214	chr22:50244548	NA	0.42	5.89	0.31	9.4e-9	Schizophrenia;
CRC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.22	-0.37	3.53e-12	Chronic sinus infection;
CRC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg17775713	chr3:133465469	TF	0.33	5.87	0.31	1.04e-8	Iron status biomarkers;
CRC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg26805224	chr10:79626177	DLG5	-0.5	-7.38	-0.38	1.28e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.48	6.52	0.34	2.61e-10	Schizophrenia;
CRC	cis	rs4731207	0.698	rs10270784	chr7:124446208	A/T	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.51	-7.46	-0.38	7.78e-13	Schizophrenia;
CRC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-6.44	-0.33	4.13e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg15786705	chr6:28176104	NA	0.67	9.29	0.46	2.23e-18	Parkinson's disease;
CRC	cis	rs2282802	0.585	rs2189659	chr5:139697220	C/A	cg26211634	chr5:139558579	C5orf32	-0.45	-7.76	-0.39	1.05e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg03469805	chr14:105330648	KIAA0284	0.27	5.69	0.3	2.87e-8	IgG glycosylation;
CRC	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-6.85	-0.35	3.58e-11	Body mass index (adult);
CRC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.47	-6.59	-0.34	1.76e-10	Fibrinogen levels;
CRC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16262614	chr3:133464971	TF	-0.33	-5.89	-0.31	9.35e-9	Iron status biomarkers;
CRC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg21970626	chr13:21893289	NA	-0.42	-5.62	-0.3	4.06e-8	White matter hyperintensity burden;
CRC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg16141378	chr3:129829833	LOC729375	0.42	6.23	0.32	1.42e-9	Retinal vascular caliber;
CRC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.13	0.32	2.49e-9	IgG glycosylation;
CRC	cis	rs7923609	0.812	rs10822184	chr10:65337153	C/T	cg08743896	chr10:65200160	JMJD1C	0.42	5.94	0.31	7.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	1.11	12.97	0.58	2.27e-31	Obesity-related traits;
CRC	cis	rs9992667	0.910	rs4535339	chr4:38689228	A/G	cg19726192	chr4:38663646	FLJ13197	-0.7	-8.76	-0.43	1.03e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.68	9.25	0.45	2.82e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg21251018	chr6:28226885	NKAPL	0.48	7.4	0.38	1.14e-12	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16682046	chr11:82612617	PRCP;C11orf82	0.42	6.02	0.31	4.61e-9	Response to antipsychotic treatment;
CRC	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.53	-7.57	-0.39	3.7e-13	Educational attainment (college completion);
CRC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.65	7.74	0.39	1.24e-13	Bipolar disorder;
CRC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg24289452	chr6:170231220	NA	-0.62	-7.47	-0.38	7.39e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg11753193	chr8:94753277	RBM12B	-0.46	-6.82	-0.35	4.41e-11	Birth weight;Height;
CRC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.56	8.23	0.41	4.44e-15	Melanoma;
CRC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.42	-6.45	-0.34	4.01e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.33	-0.33	8.13e-10	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12171159	chr11:72504902	STARD10	0.35	6.12	0.32	2.61e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.6	9.56	0.47	2.77e-19	Breast cancer;
CRC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.34	-5.68	-0.3	2.99e-8	Aortic root size;
CRC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg04518342	chr5:131593106	PDLIM4	0.34	6.05	0.32	4.04e-9	Blood metabolite levels;
CRC	cis	rs728616	0.614	rs61859209	chr10:82128309	G/A	cg11900509	chr10:81946545	ANXA11	-0.56	-6.3	-0.33	9.41e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.88	8.23	0.41	4.57e-15	IgG glycosylation;
CRC	trans	rs16971802	1.000	rs16971802	chr17:34311387	A/G	cg07584734	chr8:49235737	NA	0.65	6.18	0.32	1.92e-9	Blood protein levels;
CRC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg00691999	chr4:55094011	PDGFRA	0.42	5.98	0.31	5.66e-9	Corneal astigmatism;
CRC	cis	rs7635838	0.892	rs9870881	chr3:11447082	A/G	cg00170343	chr3:11313890	ATG7	0.42	6.37	0.33	6.38e-10	HDL cholesterol;
CRC	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.12	-0.37	6.86e-12	Mood instability;
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg16606324	chr3:10149918	C3orf24	0.69	8.08	0.41	1.2e-14	Alzheimer's disease;
CRC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.02	0.4	1.87e-14	Joint mobility (Beighton score);
CRC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.91	16.91	0.68	1.27e-46	Intelligence (multi-trait analysis);
CRC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.6	-8.79	-0.44	8.48e-17	Lung cancer;
CRC	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	0.93	9.06	0.45	1.18e-17	Gut microbiota (bacterial taxa);
CRC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.59	-8.59	-0.43	3.44e-16	Dental caries;
CRC	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.61	8.71	0.43	1.46e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.56	-9.03	-0.45	1.48e-17	Intelligence (multi-trait analysis);
CRC	trans	rs783540	1.000	rs783531	chr15:83249119	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.37	-6.37	-0.33	6.54e-10	Schizophrenia;
CRC	cis	rs2882667	0.728	rs13181830	chr5:138280416	A/G	cg09476006	chr5:138032270	NA	-0.56	-9.8	-0.48	4.59e-20	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03647317	chr4:187891568	NA	-0.52	-9.44	-0.46	6.84e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg14345882	chr6:26364793	BTN3A2	0.42	6.45	0.33	4.08e-10	Intelligence (multi-trait analysis);
CRC	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.07	0.41	1.33e-14	Type 2 diabetes;
CRC	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.15	0.52	1.01e-24	Coffee consumption (cups per day);
CRC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.53	6.9	0.36	2.72e-11	Platelet distribution width;
CRC	cis	rs672059	1.000	rs3120034	chr1:183167051	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.39	0.42	1.45e-15	Hypertriglyceridemia;
CRC	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	12.44	0.57	2.31e-29	Electrocardiographic conduction measures;
CRC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.62	-9.69	-0.47	1.1e-19	Psychosis in Alzheimer's disease;
CRC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-7.65	-0.39	2.3e-13	Waist circumference;Hip circumference;
CRC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.48	9.09	0.45	9.27e-18	Educational attainment (years of education);
CRC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg21251018	chr6:28226885	NKAPL	0.48	7.59	0.39	3.37e-13	Cardiac Troponin-T levels;
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.94	-0.31	7.17e-9	Total body bone mineral density;
CRC	cis	rs9826463	0.582	rs73238161	chr3:142081981	A/C	cg20824294	chr3:142316082	PLS1	0.36	5.85	0.31	1.21e-8	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.5	-7.78	-0.39	9.28e-14	Type 2 diabetes;
CRC	cis	rs12230513	0.793	rs7138601	chr12:55895730	A/T	cg19537932	chr12:55886519	OR6C68	0.42	5.81	0.31	1.48e-8	Contrast sensitivity;
CRC	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.43	6.58	0.34	1.88e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs12517041	1.000	rs10059818	chr5:23292940	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg23533926	chr12:111358616	MYL2	0.45	6.65	0.34	1.25e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.75	0.3	2.04e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.6	10.49	0.5	2.08e-22	Aortic root size;
CRC	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.8	-0.39	8.43e-14	Biliary atresia;
CRC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.9	-0.36	2.65e-11	Hemoglobin concentration;
CRC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.76	13.32	0.59	1.16e-32	Prostate cancer;
CRC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.19	-17.19	-0.69	1e-47	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg06470822	chr6:28175283	NA	1.01	13.28	0.59	1.55e-32	Depression;
CRC	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg10483660	chr13:112241077	NA	0.36	5.78	0.3	1.76e-8	Menarche (age at onset);
CRC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	cis	rs7113874	0.589	rs6578968	chr11:8480719	G/T	cg02811074	chr11:8615871	STK33	-0.35	-5.96	-0.31	6.43e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.58	6.44	0.33	4.15e-10	Initial pursuit acceleration;
CRC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.65	7.49	0.38	6.24e-13	Vitiligo;
CRC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.51	7.72	0.39	1.41e-13	Corneal astigmatism;
CRC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.29	-0.56	8.2e-29	Type 2 diabetes;
CRC	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg11693508	chr17:37793320	STARD3	0.68	8.14	0.41	8.13e-15	Bipolar disorder;
CRC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.43	5.7	0.3	2.72e-8	Platelet distribution width;
CRC	cis	rs243505	1.000	rs243507	chr7:148434600	G/A	cg09806900	chr7:148480153	CUL1	-0.44	-6.19	-0.32	1.8e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-7.85	-0.4	5.82e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-6.43	-0.33	4.61e-10	Vitiligo;
CRC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.46	0.38	7.65e-13	Lung cancer in ever smokers;
CRC	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg11130432	chr3:121712080	ILDR1	-0.46	-5.86	-0.31	1.11e-8	Multiple sclerosis;
CRC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg12590608	chr7:158785262	NA	0.49	9.04	0.45	1.36e-17	Facial morphology (factor 20);
CRC	cis	rs2252521	0.524	rs1719570	chr7:29043363	T/G	cg11728747	chr7:29037910	CPVL	-0.49	-6.98	-0.36	1.66e-11	Cognitive performance;
CRC	cis	rs1403694	1.000	rs2689197	chr3:186438346	C/T	cg04611788	chr3:186434169	KNG1	-0.46	-7.02	-0.36	1.27e-11	Blood protein levels;
CRC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.37e-8	Bladder cancer;
CRC	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.54	0.34	2.37e-10	Blood protein levels;
CRC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg27535305	chr1:53392650	SCP2	-0.4	-7.17	-0.37	4.85e-12	Monocyte count;
CRC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.98	11.37	0.53	1.72e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	0.97	12.23	0.56	1.36e-28	Obesity-related traits;
CRC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	0.97	14.31	0.62	1.93e-36	Breast cancer;
CRC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.47	6.82	0.35	4.33e-11	Tonsillectomy;
CRC	trans	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg20935933	chr6:143382018	AIG1	0.5	6.47	0.34	3.65e-10	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04582424	chr1:203764710	ZC3H11A	0.42	6.14	0.32	2.32e-9	Intelligence (multi-trait analysis);
CRC	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.9	-13.02	-0.58	1.56e-31	Dupuytren's disease;
CRC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	11.99	0.55	1.01e-27	Nonalcoholic fatty liver disease;
CRC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.62	6.22	0.32	1.48e-9	Plasma clusterin levels;
CRC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-7.77	-0.39	1e-13	Subjective well-being;
CRC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg21238619	chr17:78079768	GAA	-0.48	-8.53	-0.43	5.35e-16	Yeast infection;
CRC	cis	rs6445525	0.806	rs9853428	chr3:66004122	C/G	cg06109867	chr3:66002991	MAGI1	-0.37	-5.77	-0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg17948913	chr5:572064	NA	0.52	5.95	0.31	6.79e-9	Lung disease severity in cystic fibrosis;
CRC	trans	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg17903999	chr18:56338584	MALT1	-0.4	-6.5	-0.34	2.95e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.57	8.54	0.43	4.9e-16	Lewy body disease;
CRC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.77	12.2	0.56	1.76e-28	Cognitive function;
CRC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg21335942	chr16:58549945	SETD6	0.86	5.72	0.3	2.39e-8	Schizophrenia;
CRC	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.7	-9.38	-0.46	1.07e-18	Coronary artery disease;
CRC	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.78	-13.23	-0.59	2.48e-32	Bipolar disorder;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12963246	chr6:28129442	ZNF389	0.5	5.75	0.3	2e-8	Depression;
CRC	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	6.34	0.33	7.53e-10	Blood metabolite levels;
CRC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.96	-0.31	6.43e-9	Height;
CRC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg04362960	chr10:104952993	NT5C2	-0.42	-5.92	-0.31	7.95e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg25876840	chr17:41920477	NA	-0.45	-7.11	-0.36	7.38e-12	Triglycerides;
CRC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.35	9.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26300324	chr2:38152884	FAM82A1	0.46	6.77	0.35	6.02e-11	Response to antipsychotic treatment;
CRC	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg22482690	chr17:47019901	SNF8	0.48	8.0	0.4	2.1e-14	Type 2 diabetes;
CRC	cis	rs4664293	0.647	rs10199805	chr2:160427391	G/T	cg08347373	chr2:160653686	CD302	-0.38	-6.41	-0.33	4.95e-10	Monocyte percentage of white cells;
CRC	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.6	9.67	0.47	1.27e-19	Itch intensity from mosquito bite;
CRC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg00383909	chr3:49044727	WDR6	-0.57	-6.23	-0.32	1.47e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg15485101	chr11:133734466	NA	0.4	7.25	0.37	2.92e-12	Childhood ear infection;
CRC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.51	8.15	0.41	7.5e-15	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.61	-0.34	1.57e-10	HDL cholesterol;
CRC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.41	5.68	0.3	3.04e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.62	8.85	0.44	5.44e-17	Obesity-related traits;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.31	0.37	2.09e-12	Motion sickness;
CRC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.53	-0.43	5.4e-16	IgG glycosylation;
CRC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg22815214	chr1:201083145	CACNA1S	0.51	6.43	0.33	4.44e-10	Permanent tooth development;
CRC	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.46e-18	Platelet count;
CRC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.65	-0.3	3.51e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.41	-6.75	-0.35	6.7e-11	Mean arterial pressure;
CRC	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.93	-0.31	7.47e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.51	7.42	0.38	1e-12	Testicular germ cell tumor;
CRC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg21251018	chr6:28226885	NKAPL	0.47	6.54	0.34	2.37e-10	Parkinson's disease;
CRC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.49	-0.34	3.13e-10	Aortic root size;
CRC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26850624	chr5:429559	AHRR	0.52	8.78	0.44	8.84e-17	Cystic fibrosis severity;
CRC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg23758822	chr17:41437982	NA	0.8	13.17	0.59	4.05e-32	Menopause (age at onset);
CRC	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.95	11.67	0.54	1.41e-26	Obesity-related traits;
CRC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.52	-8.83	-0.44	6.44e-17	Aortic root size;
CRC	trans	rs72956618	1.000	rs28564588	chr2:207496342	G/A	cg16073378	chr2:468413	NA	-0.67	-6.43	-0.33	4.54e-10	Tonsillectomy;
CRC	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.43	7.4	0.38	1.13e-12	Information processing speed;
CRC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Educational attainment;
CRC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg14558114	chr2:88469736	THNSL2	-0.41	-6.02	-0.32	4.55e-9	Response to metformin (IC50);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg20195957	chr2:68694673	APLF;FBXO48	0.5	6.14	0.32	2.37e-9	Diisocyanate-induced asthma;
CRC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.35	-5.81	-0.3	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23161317	chr6:28129485	ZNF389	0.45	5.81	0.3	1.5e-8	Parkinson's disease;
CRC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	7.35	0.38	1.62e-12	Platelet count;
CRC	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg13043300	chr11:71146211	DHCR7	-0.43	-5.82	-0.31	1.36e-8	Vitamin D levels;
CRC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.45	7.01	0.36	1.39e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg23417306	chr2:180868811	CWC22	0.49	6.69	0.35	9.5e-11	Schizophrenia;
CRC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.2	-0.37	4.2e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.9	-0.36	2.74e-11	Blood pressure (smoking interaction);
CRC	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.4	-6.55	-0.34	2.22e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.54	6.34	0.33	7.78e-10	Lymphocyte counts;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08655493	chr21:33765248	URB1;C21orf119	0.49	6.56	0.34	2.07e-10	Thyroid stimulating hormone;
CRC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg20119798	chr7:94954144	PON1	-0.51	-6.4	-0.33	5.35e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg13768953	chr17:7114967	DLG4	-0.31	-5.99	-0.31	5.47e-9	Diastolic blood pressure;
CRC	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs6076065	0.723	rs6083100	chr20:23358651	G/A	cg11657817	chr20:23433608	CST11	0.45	6.79	0.35	5.39e-11	Facial morphology (factor 15, philtrum width);
CRC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.88	-16.49	-0.67	5.93e-45	Coronary artery disease;
CRC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.6	7.36	0.38	1.47e-12	Mean platelet volume;
CRC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.44	7.75	0.39	1.15e-13	Childhood ear infection;
CRC	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-6.06	-0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.43	5.73	0.3	2.31e-8	Schizophrenia;
CRC	trans	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg02936872	chr9:99801550	CTSL2	-0.48	-6.18	-0.32	1.85e-9	Iron status biomarkers;
CRC	trans	rs12940923	0.872	rs59775965	chr17:56370439	T/C	cg16900910	chr15:72789182	ARIH1	0.52	5.97	0.31	6.14e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.44	8.94	0.44	2.84e-17	Renal cell carcinoma;
CRC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.65	9.06	0.45	1.22e-17	Vitiligo;
CRC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.22	0.56	1.46e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg25797454	chr6:150327115	RAET1K	0.36	6.32	0.33	8.68e-10	Alopecia areata;
CRC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.68	9.66	0.47	1.34e-19	Vitamin D levels;
CRC	cis	rs13268772	0.520	rs7819673	chr8:3241798	C/T	cg23564432	chr8:3253958	CSMD1	0.35	5.75	0.3	2.05e-8	Schizophrenia;
CRC	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg03929089	chr4:120376271	NA	0.63	6.33	0.33	8.23e-10	Axial length;
CRC	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.56	-8.99	-0.44	2.06e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.44	5.62	0.3	3.98e-8	Daytime sleep phenotypes;
CRC	cis	rs929596	0.531	rs2741022	chr2:234514273	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-5.76	-0.3	1.95e-8	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.79	0.3	1.66e-8	Electroencephalogram traits;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg08798685	chr6:27730294	NA	-0.43	-6.3	-0.33	9.81e-10	Parkinson's disease;
CRC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.27	-6.23	-0.32	1.4e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg19673125	chr6:150240577	RAET1G	0.3	5.72	0.3	2.41e-8	Testicular germ cell tumor;
CRC	cis	rs10046574	0.831	rs10243569	chr7:135063466	G/A	cg27474649	chr7:135195673	CNOT4	0.69	5.74	0.3	2.14e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg00316803	chr15:76480434	C15orf27	0.39	6.85	0.35	3.72e-11	Blood metabolite levels;
CRC	cis	rs12519773	0.501	rs10428523	chr5:92536365	G/A	cg18783429	chr5:92414398	NA	0.27	5.77	0.3	1.79e-8	Migraine;
CRC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.72	0.39	1.43e-13	Bladder cancer;
CRC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg20041105	chr8:143859282	LYNX1	0.46	8.12	0.41	9.33e-15	Urinary tract infection frequency;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08205230	chr11:67183078	ATPGD1	-0.41	-6.3	-0.33	9.41e-10	Myopia (pathological);
CRC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg11843238	chr5:131593191	PDLIM4	-0.43	-8.16	-0.41	7.09e-15	Breast cancer;
CRC	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.74	16.1	0.66	2.04e-43	Intelligence (multi-trait analysis);
CRC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg13073564	chr4:8508604	NA	0.39	5.81	0.3	1.51e-8	Response to antineoplastic agents;
CRC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.67	9.17	0.45	5.29e-18	Breast cancer;
CRC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.49	-0.46	4.75e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-6.6	-0.34	1.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-6.18	-0.32	1.84e-9	Schizophrenia;
CRC	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.45	6.74	0.35	6.98e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg23018236	chr17:30244563	NA	-0.67	-8.09	-0.41	1.19e-14	Hip circumference adjusted for BMI;
CRC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.35	-5.72	-0.3	2.4e-8	Cognitive function;
CRC	trans	rs492478	0.892	rs114618260	chr5:3911191	A/G	cg09199442	chr11:28132951	METT5D1	-0.72	-6.15	-0.32	2.26e-9	Cognitive performance;
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg21620606	chr4:1342894	KIAA1530	-0.42	-7.42	-0.38	1.04e-12	Obesity-related traits;
CRC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.72	12.12	0.56	3.35e-28	Body mass index;
CRC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.55	7.72	0.39	1.37e-13	Lymphocyte percentage of white cells;
CRC	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.02	0.45	1.6e-17	Lymphocyte counts;Red cell distribution width;
CRC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg06470822	chr6:28175283	NA	0.79	11.24	0.53	5.09e-25	Parkinson's disease;
CRC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.05	0.45	1.25e-17	Bladder cancer;
CRC	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.89	-0.36	2.82e-11	Response to antipsychotic treatment;
CRC	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg01843034	chr6:37503916	NA	-0.37	-6.34	-0.33	7.43e-10	Cognitive performance;
CRC	cis	rs7692995	1.000	rs7686082	chr4:17957576	C/T	cg08925142	chr4:18023851	LCORL	-0.53	-5.85	-0.31	1.2e-8	Height;
CRC	cis	rs77861329	0.748	rs4687805	chr3:52123313	A/G	cg08692210	chr3:52188851	WDR51A	0.53	6.01	0.31	4.85e-9	Macrophage inflammatory protein 1b levels;
CRC	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-5.84	-0.31	1.26e-8	Subjective well-being;
CRC	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg23461800	chr14:103021989	NA	-0.7	-8.05	-0.41	1.57e-14	Platelet count;
CRC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.66	7.9	0.4	4.31e-14	Vitiligo;
CRC	cis	rs7605827	0.897	rs11682528	chr2:15533183	T/C	cg19274914	chr2:15703543	NA	0.39	5.72	0.3	2.39e-8	Educational attainment (years of education);
CRC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg12935359	chr14:103987150	CKB	-0.4	-6.73	-0.35	7.55e-11	Body mass index;
CRC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.29	6.05	0.32	3.94e-9	Lung cancer;
CRC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg25344623	chr2:136566232	LCT	0.33	5.99	0.31	5.61e-9	Mosquito bite size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27397625	chr6:42952298	PPP2R5D	0.47	6.87	0.35	3.3e-11	Response to antipsychotic treatment;
CRC	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.93	-12.48	-0.57	1.55e-29	Exhaled nitric oxide output;
CRC	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.73	0.43	1.3e-16	Coffee consumption (cups per day);
CRC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.58	-0.47	2.55e-19	Coronary artery disease;
CRC	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.64	6.95	0.36	1.91e-11	Breast cancer;
CRC	trans	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.24	-0.33	1.37e-9	Aortic root size;
CRC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg25600027	chr14:23388339	RBM23	-0.53	-8.3	-0.42	2.72e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.53	-7.26	-0.37	2.85e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg07507251	chr3:52567010	NT5DC2	0.44	6.28	0.33	1.05e-9	Bipolar disorder;
CRC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	9.59	0.47	2.25e-19	Body mass index (adult);
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg06470822	chr6:28175283	NA	0.95	13.82	0.61	1.39e-34	Depression;
CRC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	12.27	0.56	9.74e-29	Platelet count;
CRC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.65	10.69	0.51	4.22e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9928842	0.882	rs9319481	chr16:75259478	T/C	cg09066997	chr16:75300724	BCAR1	0.7	6.62	0.34	1.49e-10	Alcoholic chronic pancreatitis;
CRC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.64	-10.12	-0.49	3.79e-21	Cognitive function;
CRC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	11.09	0.52	1.64e-24	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.57	8.6	0.43	3.21e-16	Aortic root size;
CRC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg13844804	chr7:814759	HEATR2	0.67	8.61	0.43	3.1e-16	Cerebrospinal P-tau181p levels;
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg04155289	chr7:94953770	PON1	-0.62	-7.79	-0.39	8.77e-14	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.17	0.59	4.28e-32	Breast cancer;
CRC	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg00373020	chr1:21041521	KIF17	0.36	5.7	0.3	2.67e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20092199	chr4:1342459	KIAA1530	0.33	5.85	0.31	1.17e-8	Longevity;
CRC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.02	0.32	4.53e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg02158880	chr13:53174818	NA	0.39	5.6	0.3	4.51e-8	Lewy body disease;
CRC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.94	-0.31	7.18e-9	Lung cancer;
CRC	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.96	12.08	0.55	4.81e-28	Exhaled nitric oxide levels;
CRC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg10645314	chr2:3704589	ALLC	0.52	6.79	0.35	5.29e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.6	9.07	0.45	1.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.52	-0.38	5.37e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13792596	chr14:64660940	SYNE2	0.39	6.02	0.31	4.59e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg13072238	chr3:49761600	GMPPB	0.51	5.61	0.3	4.24e-8	Menarche (age at onset);
CRC	cis	rs12541635	1.000	rs11992752	chr8:107083122	G/A	cg10147462	chr8:107024639	NA	-0.39	-6.45	-0.33	4.08e-10	Age of smoking initiation;
CRC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.46	7.19	0.37	4.49e-12	Longevity;
CRC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.48	-8.18	-0.41	6.46e-15	Height;
CRC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03923535	chr7:1197113	ZFAND2A	0.63	9.05	0.45	1.27e-17	Longevity;Endometriosis;
CRC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg03160526	chr17:80928410	B3GNTL1	-0.41	-5.84	-0.31	1.24e-8	Breast cancer;
CRC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg25164649	chr6:28176230	NA	0.6	8.42	0.42	1.16e-15	Parkinson's disease;
CRC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-6.24	-0.33	1.36e-9	Menarche (age at onset);
CRC	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg06223162	chr1:101003688	GPR88	0.39	6.96	0.36	1.89e-11	Breast cancer;
CRC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.58	7.72	0.39	1.45e-13	Height;Educational attainment;Head circumference (infant);
CRC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg03013999	chr17:37608204	MED1	-0.48	-7.42	-0.38	9.94e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-7.86	-0.4	5.66e-14	Hip circumference adjusted for BMI;
CRC	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.93	-0.36	2.19e-11	Inflammatory skin disease;
CRC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg10570241	chr7:158785291	NA	0.51	9.12	0.45	7.86e-18	Facial morphology (factor 20);
CRC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg24585817	chr7:64895279	NA	0.36	5.67	0.3	3.14e-8	Calcium levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07450219	chr17:78428858	NA	0.43	7.19	0.37	4.34e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg18404041	chr3:52824283	ITIH1	0.33	6.27	0.33	1.15e-9	Schizophrenia;
CRC	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.67	-7.74	-0.39	1.24e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.04	0.41	1.59e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg19683494	chr5:74908142	NA	0.46	5.82	0.31	1.37e-8	Age-related disease endophenotypes;
CRC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.85	12.82	0.58	8.9e-31	Response to antineoplastic agents;
CRC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.67	-11.57	-0.54	3.4e-26	Iron status biomarkers;
CRC	cis	rs11031096	0.542	rs11828337	chr11:3976974	T/G	cg18678763	chr11:4115507	RRM1	-0.39	-6.69	-0.35	9.38e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.44	-6.85	-0.35	3.54e-11	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13340481	chr17:27275985	PHF12	0.43	6.65	0.34	1.21e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12044355	0.892	rs12048349	chr1:231850323	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.03	0.32	4.49e-9	Alzheimer's disease;
CRC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.4	5.97	0.31	6.13e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.67	9.77	0.47	6.02e-20	Alzheimer's disease;
CRC	cis	rs7215564	0.908	rs35112467	chr17:78677562	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.09	0.32	3.09e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00629816	chr9:37784931	EXOSC3	0.44	6.15	0.32	2.19e-9	Response to antipsychotic treatment;
CRC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Bladder cancer;
CRC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.06	-0.41	1.4e-14	Monocyte percentage of white cells;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg06470822	chr6:28175283	NA	0.87	13.71	0.6	3.75e-34	Cardiac Troponin-T levels;
CRC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23262073	chr20:60523788	NA	-0.48	-7.57	-0.39	3.7e-13	Body mass index;
CRC	cis	rs902774	0.818	rs73110471	chr12:53316821	G/A	cg16329197	chr12:53359506	NA	-0.59	-6.46	-0.34	3.78e-10	Prostate cancer;
CRC	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.47	-6.44	-0.33	4.25e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.59	9.76	0.47	6.31e-20	Gestational age at birth (maternal effect);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02577203	chr11:47869805	NUP160	0.52	7.44	0.38	8.72e-13	Response to antipsychotic treatment;
CRC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg04166393	chr7:2884313	GNA12	0.4	6.07	0.32	3.51e-9	Height;
CRC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg02683197	chr6:28174875	NA	-0.85	-11.6	-0.54	2.59e-26	Depression;
CRC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.56	9.35	0.46	1.36e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.24	-16.52	-0.67	4.4e-45	Breast cancer;
CRC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.74	7.89	0.4	4.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs59104589	0.583	rs61689231	chr2:242244583	G/A	cg19488206	chr2:242435732	STK25	0.48	6.72	0.35	7.88e-11	Fibrinogen levels;
CRC	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	15.17	0.64	8.74e-40	Smoking behavior;
CRC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	5.7	0.3	2.72e-8	Obesity-related traits;
CRC	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.46	8.25	0.41	3.83e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.49	6.94	0.36	2.09e-11	Schizophrenia;
CRC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.68	9.05	0.45	1.32e-17	Multiple sclerosis;
CRC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-9.51	-0.46	4.1e-19	Prostate cancer;
CRC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.37	6.4	0.33	5.31e-10	Systemic lupus erythematosus;
CRC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.39	6.9	0.36	2.65e-11	Colorectal cancer;
CRC	trans	rs12517041	1.000	rs7734577	chr5:23290864	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.22	-0.32	1.47e-9	Bipolar disorder;
CRC	cis	rs12505749	0.542	rs6824893	chr4:57372243	A/G	cg06922635	chr4:57371607	ARL9	-0.54	-5.77	-0.3	1.87e-8	Airflow obstruction;
CRC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.8	0.35	5.05e-11	Lung cancer;
CRC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.4	-6.75	-0.35	6.85e-11	Mean arterial pressure;
CRC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg23758597	chr6:163146217	PARK2	-0.51	-5.91	-0.31	8.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.46	-7.47	-0.38	7.27e-13	Hemoglobin concentration;
CRC	cis	rs10046574	0.831	rs113826521	chr7:135167999	T/C	cg27474649	chr7:135195673	CNOT4	0.69	5.7	0.3	2.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06611277	chr10:26987120	PDSS1	0.44	6.26	0.33	1.21e-9	Response to antipsychotic treatment;
CRC	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.47	0.46	5.67e-19	Type 2 diabetes;
CRC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.54	8.68	0.43	1.89e-16	Age at first birth;
CRC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.92	-14.44	-0.62	5.78e-37	Longevity;
CRC	cis	rs7580658	0.817	rs6761447	chr2:128074573	A/T	cg09760422	chr2:128146352	NA	-0.29	-5.69	-0.3	2.81e-8	Protein C levels;
CRC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.68	-0.51	4.82e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs501120	0.564	rs4948857	chr10:44683281	C/T	cg09554077	chr10:44749378	NA	0.55	7.67	0.39	1.95e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg13615338	chr4:55094005	PDGFRA	0.4	5.62	0.3	3.97e-8	Corneal astigmatism;
CRC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.85	0.44	5.65e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.52	7.44	0.38	8.7e-13	Caudate activity during reward;
CRC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-7.17	-0.37	4.87e-12	Body mass index;
CRC	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.4	6.12	0.32	2.7e-9	Diastolic blood pressure;
CRC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-6.13	-0.32	2.46e-9	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13030908	chr1:11741533	MAD2L2	0.5	6.44	0.33	4.34e-10	Thyroid stimulating hormone;
CRC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	15.28	0.64	3.21e-40	Platelet count;
CRC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.36	-6.81	-0.35	4.78e-11	Colorectal cancer;
CRC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.01	0.36	1.35e-11	Cognitive ability;
CRC	cis	rs883565	0.655	rs6768957	chr3:39100094	G/A	cg01426195	chr3:39028469	NA	-0.54	-8.77	-0.44	9.79e-17	Handedness;
CRC	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.39	5.71	0.3	2.49e-8	Obesity-related traits;
CRC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.82	-15.01	-0.64	3.72e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg03690763	chr11:133734501	NA	0.37	6.21	0.32	1.64e-9	Childhood ear infection;
CRC	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.96	-0.4	2.86e-14	Metabolite levels (Pyroglutamine);
CRC	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.38	12.69	0.57	2.63e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.86	14.82	0.63	2.06e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg15571903	chr15:79123663	NA	-0.31	-6.08	-0.32	3.34e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	17.56	0.7	3.56e-49	Smoking behavior;
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03923535	chr7:1197113	ZFAND2A	0.65	9.32	0.46	1.74e-18	Longevity;Endometriosis;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20092199	chr4:1342459	KIAA1530	0.34	5.9	0.31	8.88e-9	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03637622	chr5:179334771	TBC1D9B	0.45	6.5	0.34	2.92e-10	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-8.71	-0.43	1.55e-16	Type 2 diabetes;
CRC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-11.18	-0.52	7.99e-25	Menarche (age at onset);
CRC	cis	rs4803480	0.935	rs1476769	chr19:42084277	C/G	cg08478046	chr19:42093086	CEACAM21	-0.33	-5.88	-0.31	1.01e-8	Schizophrenia;
CRC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.49	7.37	0.38	1.4e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.62	-0.68	1.91e-45	Electrocardiographic conduction measures;
CRC	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.97	-17.74	-0.7	7.23e-50	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.56	7.71	0.39	1.48e-13	Celiac disease or Rheumatoid arthritis;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg00920043	chr1:11333412	UBIAD1	0.43	6.02	0.31	4.75e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs17818399	0.749	rs35625984	chr2:46805908	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-6.35	-0.33	7.34e-10	Height;
CRC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.83	-10.44	-0.5	3.04e-22	Initial pursuit acceleration;
CRC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.7	10.72	0.51	3.35e-23	Tonsillectomy;
CRC	cis	rs4841398	1.000	rs4841398	chr8:10462806	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-6.26	-0.33	1.18e-9	Obesity-related traits;
CRC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.51	7.2	0.37	4e-12	Response to temozolomide;
CRC	cis	rs9400239	0.622	rs1268168	chr6:109008158	G/A	cg11073813	chr6:109029018	NA	-0.41	-6.46	-0.34	3.82e-10	Waist circumference;Body mass index;BMI (adjusted for smoking behaviour);
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.5	7.28	0.37	2.43e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.69	0.35	9.47e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	11.08	0.52	1.82e-24	Personality dimensions;
CRC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg06784218	chr1:46089804	CCDC17	-0.48	-7.8	-0.4	8.16e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.23	-0.49	1.68e-21	Total cholesterol levels;
CRC	trans	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.52	7.73	0.39	1.33e-13	Endometrial cancer;
CRC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10463316	0.817	rs7713109	chr5:150789284	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.59	-0.34	1.76e-10	Metabolite levels (Pyroglutamine);
CRC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg11843238	chr5:131593191	PDLIM4	0.43	7.31	0.37	1.98e-12	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06802374	chr4:148653449	ARHGAP10	0.43	6.06	0.32	3.74e-9	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.61	-10.42	-0.5	3.79e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs501120	0.584	rs12355852	chr10:44704280	G/T	cg09554077	chr10:44749378	NA	0.67	7.47	0.38	7.27e-13	Coronary artery disease;Coronary heart disease;
CRC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.64	-9.58	-0.47	2.47e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.55	8.08	0.41	1.25e-14	Cognitive ability;
CRC	cis	rs2795502	0.630	rs873300	chr10:43537155	C/T	cg20628663	chr10:43360327	NA	0.58	6.64	0.34	1.32e-10	Blood protein levels;
CRC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.51	7.47	0.38	7.41e-13	High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.6	9.07	0.45	1.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.96	-0.48	1.39e-20	Monocyte count;
CRC	cis	rs17767392	0.829	rs56363446	chr14:71761577	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.81	-0.35	4.7e-11	Mitral valve prolapse;
CRC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	6.07	0.32	3.59e-9	Depression;
CRC	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11446398	chr5:77624930	NA	0.47	6.27	0.33	1.1e-9	Triglycerides;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.41	-0.33	5.02e-10	Parkinson's disease;
CRC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg19812747	chr11:111475976	SIK2	-0.55	-9.25	-0.45	2.84e-18	Primary sclerosing cholangitis;
CRC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.76	13.13	0.59	6.06e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.92	11.13	0.52	1.2e-24	Exhaled nitric oxide output;
CRC	cis	rs75422866	0.867	rs73104111	chr12:48067777	A/G	cg14736327	chr12:48174669	SLC48A1	-0.79	-6.01	-0.31	4.92e-9	Pneumonia;
CRC	trans	rs1864729	1.000	rs2853312	chr8:98281319	T/C	cg08679828	chr8:102218111	ZNF706	-0.61	-7.47	-0.38	7.37e-13	Estradiol plasma levels (breast cancer);
CRC	cis	rs12024301	0.557	rs12031255	chr1:183591537	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.58	-7.91	-0.4	3.89e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	cis	rs12826942	0.959	rs12820881	chr12:42726978	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.69	0.39	1.73e-13	Coronary artery disease;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg12728517	chr11:6947552	ZNF215	0.55	5.81	0.31	1.48e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg15744005	chr10:104629667	AS3MT	-0.3	-5.72	-0.3	2.41e-8	Arsenic metabolism;
CRC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg16476235	chr8:21771668	DOK2	0.38	6.54	0.34	2.37e-10	Mean corpuscular volume;
CRC	cis	rs9903692	0.909	rs11079806	chr17:46142680	C/T	cg21215337	chr17:46176117	CBX1	0.39	7.02	0.36	1.26e-11	Pulse pressure;
CRC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.17	-0.32	2.02e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg09184832	chr6:79620586	NA	-0.47	-8.21	-0.41	4.97e-15	Intelligence (multi-trait analysis);
CRC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.61	8.82	0.44	6.62e-17	Response to temozolomide;
CRC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.31	-0.37	2.04e-12	Mean corpuscular volume;
CRC	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg15654264	chr1:150340011	RPRD2	-0.39	-5.88	-0.31	1.02e-8	Migraine;
CRC	cis	rs11031096	0.542	rs10835337	chr11:3958828	A/G	cg18678763	chr11:4115507	RRM1	0.4	6.82	0.35	4.36e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.52	5.7	0.3	2.61e-8	Vitiligo;
CRC	cis	rs2084637	1.000	rs10892853	chr11:122390886	A/G	cg21585512	chr11:122030076	LOC399959	-0.41	-7.5	-0.38	5.96e-13	Stroke;
CRC	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.53	8.47	0.42	8.51e-16	Coronary artery disease;
CRC	cis	rs6504950	0.800	rs7208123	chr17:53006339	G/A	cg26251398	chr17:52985966	TOM1L1	0.4	5.66	0.3	3.24e-8	Breast cancer;
CRC	cis	rs2565722	0.825	rs2489929	chr6:161270781	C/T	cg03159191	chr6:161285451	NA	-0.48	-5.75	-0.3	2.04e-8	Blood protein levels;
CRC	cis	rs4664293	0.609	rs12470879	chr2:160468627	T/C	cg08347373	chr2:160653686	CD302	-0.39	-6.55	-0.34	2.16e-10	Monocyte percentage of white cells;
CRC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.49	6.73	0.35	7.76e-11	Height;
CRC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.95	-0.31	7e-9	Total body bone mineral density;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02725872	chr8:58115012	NA	-0.59	-9.12	-0.45	7.59e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs9311676	0.656	rs56232415	chr3:58394850	C/T	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg02527881	chr3:46936655	PTH1R	0.34	5.92	0.31	7.97e-9	Colorectal cancer;
CRC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.66	-0.34	1.18e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg10858369	chr11:6476139	TRIM3	-0.4	-6.29	-0.33	1e-9	HDL cholesterol;
CRC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg09085632	chr11:111637200	PPP2R1B	0.55	7.39	0.38	1.21e-12	Primary sclerosing cholangitis;
CRC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-11.64	-0.54	1.85e-26	Dental caries;
CRC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.94	-17.21	-0.69	8.32e-48	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-6.0	-0.31	5.18e-9	Eosinophil percentage of white cells;
CRC	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.44	6.73	0.35	7.55e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02174006	chr10:86088279	FAM190B	0.45	6.24	0.33	1.38e-9	Response to antipsychotic treatment;
CRC	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.43	-6.59	-0.34	1.7e-10	Breast cancer;
CRC	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg13736514	chr6:26305472	NA	-0.36	-6.17	-0.32	1.99e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-0.96	-9.7	-0.47	9.78e-20	Coronary artery disease;
CRC	cis	rs972578	1.000	rs1569510	chr22:43359448	A/G	cg01576275	chr22:43409880	NA	0.44	7.07	0.36	9.54e-12	Mean platelet volume;
CRC	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg12046867	chr14:103022105	NA	-0.82	-11.82	-0.55	4.2e-27	Platelet count;
CRC	cis	rs12143943	0.966	rs898385	chr1:204579860	A/G	cg17419461	chr1:204415978	PIK3C2B	0.4	6.38	0.33	6.16e-10	Cognitive performance;
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg22638593	chr5:131593259	PDLIM4	-0.39	-6.49	-0.34	3.13e-10	Breast cancer;
CRC	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.63	12.62	0.57	4.77e-30	Neuroticism;
CRC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.51	7.24	0.37	3.24e-12	Morning vs. evening chronotype;
CRC	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg25885038	chr17:56607967	SEPT4	-0.49	-7.56	-0.38	3.99e-13	Vitamin D levels;
CRC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	0.48	8.03	0.4	1.75e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.4	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	cis	rs6700896	0.931	rs4655585	chr1:66155627	T/C	cg04111102	chr1:66153794	NA	0.33	5.78	0.3	1.74e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg24578937	chr1:2090814	PRKCZ	-0.45	-8.2	-0.41	5.4e-15	Height;
CRC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg03623178	chr6:28175578	NA	0.67	10.21	0.49	1.89e-21	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.4	-0.46	9.58e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.88	0.31	1.01e-8	Height;
CRC	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	6.25	0.33	1.3e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs2882667	0.659	rs311595	chr5:138071872	T/C	cg09476006	chr5:138032270	NA	0.58	10.33	0.49	7.58e-22	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.54	-6.78	-0.35	5.44e-11	Personality dimensions;
CRC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg25876840	chr17:41920477	NA	0.51	7.8	0.4	8.25e-14	Triglycerides;
CRC	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26306683	chr17:18585705	ZNF286B	-0.41	-6.47	-0.34	3.57e-10	Educational attainment (years of education);
CRC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.84	-0.31	1.27e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.41	-0.56	2.97e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1030268	0.577	rs13244007	chr7:133260825	A/G	cg10665199	chr7:133106180	EXOC4	0.66	7.88	0.4	4.73e-14	Intelligence (multi-trait analysis);
CRC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.66	0.34	1.15e-10	Mean platelet volume;
CRC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.52	8.17	0.41	6.91e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25589956	chr3:186545102	NA	0.36	6.31	0.33	8.76e-10	Obesity-related traits;
CRC	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.14	17.46	0.69	9.11e-49	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg03315344	chr16:75512273	CHST6	0.55	6.42	0.33	4.74e-10	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs1009181	0.585	rs2066295	chr6:26168903	A/G	cg00631329	chr6:26305371	NA	-0.41	-6.16	-0.32	2.14e-9	Childhood ear infection;
CRC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.47	6.07	0.32	3.48e-9	Response to diuretic therapy;
CRC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.39	-6.72	-0.35	8.12e-11	Longevity;Endometriosis;
CRC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.76	10.95	0.52	5.37e-24	Multiple sclerosis;
CRC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.49	8.04	0.41	1.65e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.35	-5.98	-0.31	5.86e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.53	7.45	0.38	8.19e-13	Obesity-related traits;
CRC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.48	-7.28	-0.37	2.4e-12	Motion sickness;
CRC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.87	-11.85	-0.55	3.24e-27	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11876132	chr22:25348250	NA	0.43	6.15	0.32	2.23e-9	Response to antipsychotic treatment;
CRC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg13010199	chr12:38710504	ALG10B	0.45	6.46	0.34	3.76e-10	Morning vs. evening chronotype;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26348180	chr3:193852754	HES1	0.46	6.22	0.32	1.53e-9	Survival in pancreatic cancer;
CRC	cis	rs9292777	0.966	rs1373692	chr5:40431183	A/C	cg09067459	chr5:40385259	NA	0.51	8.91	0.44	3.5e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg20092199	chr4:1342459	KIAA1530	0.32	5.72	0.3	2.38e-8	Obesity-related traits;
CRC	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.14	-0.37	6.02e-12	Schizophrenia;
CRC	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.64	-8.67	-0.43	1.98e-16	White matter hyperintensity burden;
CRC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.62	9.6	0.47	2.15e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.14e-30	Bone mineral density;
CRC	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.17	0.64	8.98e-40	Colorectal cancer;
CRC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.53	5.96	0.31	6.67e-9	Bipolar disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05647660	chr4:76439704	RCHY1;THAP6	0.47	6.61	0.34	1.56e-10	Response to antipsychotic treatment;
CRC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.51	8.09	0.41	1.19e-14	Red blood cell count;
CRC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg05555928	chr11:63887634	MACROD1	-0.39	-6.6	-0.34	1.64e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.62	-0.3	4.11e-8	Menopause (age at onset);
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7945718	0.621	rs7931351	chr11:12692162	A/T	cg25843174	chr11:12811716	TEAD1	0.41	7.55	0.38	4.33e-13	Educational attainment (years of education);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06713199	chr3:28390809	AZI2	-0.52	-6.3	-0.33	9.77e-10	Diisocyanate-induced asthma;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg12273811	chr6:28175739	NA	0.55	8.0	0.4	2.2e-14	Cardiac Troponin-T levels;
CRC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg12064134	chr16:90016061	DEF8	-0.65	-5.84	-0.31	1.22e-8	Skin colour saturation;
CRC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-6.9	-0.36	2.73e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.43	-6.3	-0.33	9.56e-10	Renal cell carcinoma;
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Depression;
CRC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	12.5	0.57	1.3e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg22192744	chr12:123187474	GPR109A	-0.4	-5.67	-0.3	3.16e-8	Adiponectin levels;
CRC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.71	10.95	0.52	5.47e-24	Corneal astigmatism;
CRC	cis	rs2742417	0.967	rs1969625	chr3:45734975	A/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.63	-0.3	3.95e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05719672	chr15:91446576	MAN2A2	0.37	6.03	0.32	4.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs847649	0.731	rs12666317	chr7:102704135	C/T	cg18108683	chr7:102477205	FBXL13	0.52	8.22	0.41	4.89e-15	Morning vs. evening chronotype;
CRC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.9	16.4	0.67	1.34e-44	Intelligence (multi-trait analysis);
CRC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.45	6.87	0.35	3.14e-11	Asthma;
CRC	cis	rs1178968	0.688	rs6951676	chr7:72753243	C/T	cg25889504	chr7:72793014	NA	0.53	6.04	0.32	4.16e-9	Triglyceride levels;
CRC	trans	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg10756647	chr7:56101905	PSPH	0.77	7.78	0.39	9.16e-14	Diabetic kidney disease;
CRC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.45e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg00280220	chr17:61926910	NA	0.33	5.64	0.3	3.66e-8	Prudent dietary pattern;
CRC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.29	6.11	0.32	2.89e-9	Homoarginine levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21824114	chr17:41322603	NBR1	0.4	6.09	0.32	3.18e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13198984	chr17:80129470	CCDC57	0.47	8.45	0.42	9.24e-16	Life satisfaction;
CRC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.65	-10.18	-0.49	2.41e-21	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09518715	chr2:238384359	NA	0.41	6.0	0.31	5.13e-9	Intelligence (multi-trait analysis);
CRC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-7.35	-0.38	1.55e-12	Cystic fibrosis severity;
CRC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg18016565	chr1:150552671	MCL1	0.44	6.13	0.32	2.54e-9	Melanoma;
CRC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.64	-11.72	-0.54	9.3e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg19041857	chr6:27730383	NA	-0.79	-6.98	-0.36	1.59e-11	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.53	6.43	0.33	4.39e-10	Bipolar disorder;
CRC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.45	0.42	9.3e-16	Height;
CRC	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg06156847	chr2:113672199	IL1F7	0.43	6.47	0.34	3.46e-10	Pulmonary function;
CRC	cis	rs9462846	0.845	rs9471964	chr6:42885664	C/A	cg10862848	chr6:42927986	GNMT	-0.27	-5.6	-0.3	4.42e-8	Blood protein levels;
CRC	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg13662093	chr20:33865505	NA	0.41	5.77	0.3	1.87e-8	Attention deficit hyperactivity disorder;
CRC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg22777020	chr22:31556080	RNF185	0.53	6.25	0.33	1.25e-9	Colorectal cancer;
CRC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.8	-0.3	1.55e-8	Breast cancer;
CRC	cis	rs6496667	1.000	rs75444304	chr15:90894246	C/T	cg04176472	chr15:90893244	GABARAPL3	0.53	8.15	0.41	7.96e-15	Rheumatoid arthritis;
CRC	cis	rs4722166	0.598	rs35658589	chr7:22800435	C/A	cg05472934	chr7:22766657	IL6	0.63	10.36	0.5	5.88e-22	Lung cancer;
CRC	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg09659197	chr4:152720779	NA	0.39	8.18	0.41	6.42e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2898681	0.581	rs936690	chr4:53691035	A/G	cg00338735	chr4:53728038	RASL11B	0.38	5.83	0.31	1.29e-8	Optic nerve measurement (cup area);
CRC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.54	-6.69	-0.35	9.48e-11	Neuroticism;
CRC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.19	-0.69	1.03e-47	Body mass index;
CRC	cis	rs9491140	1.000	rs12204812	chr6:124681503	C/A	cg22366943	chr6:124882293	NKAIN2	0.35	5.8	0.3	1.6e-8	Neuroticism;
CRC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.99	10.53	0.5	1.51e-22	Vitiligo;
CRC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.52	7.68	0.39	1.82e-13	Blood protein levels;
CRC	cis	rs2811415	0.597	rs11711138	chr3:127762761	T/A	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	trans	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg25475538	chr8:22414555	SORBS3	0.31	6.05	0.32	3.89e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.83	-0.35	4.15e-11	Total cholesterol levels;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25816545	chr2:131513066	FAM123C	0.43	6.22	0.32	1.52e-9	Hip circumference;
CRC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.69	-7.62	-0.39	2.8e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.69	-10.78	-0.51	2.16e-23	Bipolar disorder;
CRC	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg00531865	chr16:30841666	NA	-0.42	-5.98	-0.31	5.87e-9	Dementia with Lewy bodies;
CRC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2160860	0.965	rs2729456	chr8:39819808	T/G	cg11363097	chr8:39792086	IDO2	-0.37	-5.98	-0.31	5.96e-9	Blood metabolite levels;
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.64	6.67	0.35	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.85	-14.35	-0.62	1.34e-36	Longevity;
CRC	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	11.48	0.53	7.16e-26	Bone mineral density;
CRC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.29	6.04	0.32	4.14e-9	Lung cancer;
CRC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-9.14	-0.45	6.42e-18	Asthma;
CRC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg19678392	chr7:94953810	PON1	-0.52	-6.59	-0.34	1.77e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs863345	0.604	rs950260	chr1:158491520	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg03623178	chr6:28175578	NA	0.74	7.23	0.37	3.38e-12	Depression;
CRC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.72	-12.75	-0.58	1.54e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.6	10.83	0.51	1.38e-23	Blood metabolite ratios;
CRC	cis	rs1209950	0.536	rs464476	chr21:40225441	C/T	cg02119577	chr21:40195074	ETS2	-0.37	-5.97	-0.31	6.09e-9	Non-small cell lung cancer (survival);
CRC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.63	8.54	0.43	4.99e-16	Alcohol dependence;
CRC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.37	-8.67	-0.43	2.04e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.66	9.78	0.47	5.47e-20	Lung cancer;
CRC	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.72	0.47	8.37e-20	Common traits (Other);
CRC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg08888203	chr3:10149979	C3orf24	0.7	9.84	0.48	3.31e-20	Alzheimer's disease;
CRC	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs9491140	0.539	rs10872284	chr6:124685928	G/A	cg19267163	chr6:125004984	NKAIN2	0.44	6.02	0.32	4.65e-9	Neuroticism;
CRC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.77	10.68	0.51	4.51e-23	Orofacial clefts;
CRC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.42	-8.82	-0.44	6.9e-17	Urinary metabolites;
CRC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg19582491	chr16:67682965	RLTPR	-0.52	-5.88	-0.31	9.94e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.54	-8.11	-0.41	1.03e-14	Coronary artery disease;
CRC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg16486109	chr11:613632	IRF7	0.73	12.29	0.56	8.24e-29	Systemic lupus erythematosus;
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg05313129	chr8:58192883	C8orf71	-0.42	-5.85	-0.31	1.16e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg10978503	chr1:24200527	CNR2	0.49	8.75	0.43	1.12e-16	Immature fraction of reticulocytes;
CRC	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.67	10.42	0.5	3.6e-22	Corneal astigmatism;
CRC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg24011408	chr12:48396354	COL2A1	0.44	6.49	0.34	3.16e-10	Glycated hemoglobin levels;
CRC	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg10437265	chr15:77819839	NA	-0.5	-8.34	-0.42	2.06e-15	Type 2 diabetes;
CRC	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg20356878	chr3:121714668	ILDR1	0.51	8.04	0.41	1.68e-14	Cognitive performance;
CRC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg15145296	chr3:125709740	NA	-0.56	-6.7	-0.35	9e-11	Blood pressure (smoking interaction);
CRC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-8.21	-0.41	5.13e-15	Schizophrenia;
CRC	cis	rs3026101	0.578	rs1806238	chr17:5295502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.66	8.82	0.44	7e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	6.15	0.32	2.28e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg24869535	chr4:106816548	NPNT	-0.41	-6.44	-0.33	4.15e-10	Myopia (pathological);
CRC	trans	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06834434	chr14:75079333	LTBP2	0.55	6.62	0.34	1.47e-10	Obesity-related traits;
CRC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.84	-9.61	-0.47	1.95e-19	Monocyte percentage of white cells;
CRC	trans	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg05376469	chr2:102649931	NA	0.37	6.17	0.32	2.05e-9	Coronary artery disease;
CRC	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg14345882	chr6:26364793	BTN3A2	0.71	5.87	0.31	1.07e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.34	5.7	0.3	2.64e-8	Emphysema distribution in smoking;
CRC	cis	rs7605827	0.930	rs4668448	chr2:15521740	T/C	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.05e-8	Educational attainment (years of education);
CRC	trans	rs1607741	1.000	rs10012922	chr4:72712036	G/A	cg06437464	chr6:127441704	RSPO3	0.29	6.16	0.32	2.06e-9	Vitamin D levels;
CRC	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	0.59	9.2	0.45	4.08e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.69	10.95	0.52	5.3e-24	Intelligence (multi-trait analysis);
CRC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.85	16.23	0.67	6.04e-44	Metabolic syndrome;
CRC	cis	rs4654899	0.897	rs710311	chr1:21062001	T/C	cg02927042	chr1:21476669	EIF4G3	-0.42	-6.73	-0.35	7.74e-11	Superior frontal gyrus grey matter volume;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19472303	chr3:25705836	TOP2B	-0.4	-6.15	-0.32	2.25e-9	Myopia (pathological);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13014709	chr12:58148389	MARCH9	0.42	6.52	0.34	2.68e-10	Response to antipsychotic treatment;
CRC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-9.08	-0.45	1.02e-17	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.61	8.42	0.42	1.16e-15	Alzheimer's disease;
CRC	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.94	-0.31	7.15e-9	Pulmonary function;
CRC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.66	0.47	1.31e-19	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.51	-0.38	5.69e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs11191205	0.686	rs75299772	chr10:103418987	G/A	cg15320455	chr10:103880129	LDB1	0.57	6.49	0.34	3.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.4	6.6	0.34	1.64e-10	Huntington's disease progression;
CRC	cis	rs8018808	0.935	rs2242619	chr14:77895119	C/T	cg20045696	chr14:77926864	AHSA1	-0.36	-5.61	-0.3	4.27e-8	Myeloid white cell count;
CRC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.53	12.12	0.56	3.34e-28	Prostate cancer;
CRC	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.72	-12.07	-0.55	5.03e-28	Lewy body disease;
CRC	trans	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.48	-7.12	-0.37	6.86e-12	Monocyte count;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11178574	chr11:561340	RASSF7;C11orf35	0.42	6.4	0.33	5.43e-10	Myopia (pathological);
CRC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.47	-0.34	3.54e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07545948	chr6:12012569	HIVEP1	0.39	6.21	0.32	1.58e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.35	0.71	2.69e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11855759	chr17:9548802	USP43	-0.44	-6.53	-0.34	2.48e-10	Myopia (pathological);
CRC	cis	rs847649	1.000	rs13233521	chr7:102593794	C/T	cg18108683	chr7:102477205	FBXL13	0.56	8.98	0.44	2.1e-17	Morning vs. evening chronotype;
CRC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg03623178	chr6:28175578	NA	0.66	9.34	0.46	1.46e-18	Parkinson's disease;
CRC	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.45e-11	Prostate cancer;
CRC	cis	rs236352	0.576	rs6914008	chr6:36853037	T/A	cg10099585	chr6:36853529	C6orf89	-0.44	-6.2	-0.32	1.67e-9	Heart rate;
CRC	cis	rs9292777	0.720	rs4957288	chr5:40423840	C/A	cg09067459	chr5:40385259	NA	-0.55	-8.93	-0.44	3.12e-17	Crohn's disease;Multiple sclerosis;
CRC	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.81	10.22	0.49	1.73e-21	Iron status biomarkers;
CRC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.49	-7.41	-0.38	1.05e-12	High light scatter reticulocyte count;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-7.26	-0.37	2.87e-12	Height;
CRC	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg04796162	chr7:45961102	IGFBP3	0.4	6.8	0.35	4.89e-11	Sitting height ratio;
CRC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
CRC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg21251018	chr6:28226885	NKAPL	0.57	10.06	0.49	6.22e-21	Cardiac Troponin-T levels;
CRC	cis	rs17023223	0.537	rs2794312	chr1:119591046	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-6.29	-0.33	1.01e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.42	6.93	0.36	2.22e-11	Cleft lip with or without cleft palate;
CRC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.67	11.22	0.53	6.14e-25	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25097676	chr10:99051975	ARHGAP19	0.44	6.39	0.33	5.71e-10	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.35	-0.38	1.54e-12	Blood metabolite levels;
CRC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-7.21	-0.37	3.91e-12	Aortic root size;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01174859	chr7:128379317	CALU	-0.44	-6.61	-0.34	1.56e-10	Myopia (pathological);
CRC	cis	rs3823572	0.504	rs2971977	chr7:133648347	C/G	cg03336402	chr7:133662267	EXOC4	-0.66	-10.39	-0.5	4.84e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.45	6.64	0.34	1.33e-10	Subjective well-being;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.72	8.73	0.43	1.31e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg10765909	chr12:53715428	AAAS	-0.48	-6.01	-0.31	4.93e-9	Platelet distribution width;
CRC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.79	-0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.91	17.31	0.69	3.38e-48	Blood protein levels;
CRC	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.92	-21.7	-0.77	1.99e-65	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.56	-7.4	-0.38	1.17e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg24289452	chr6:170231220	NA	-0.94	-7.59	-0.39	3.43e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.85	0.31	1.16e-8	Major depressive disorder;
CRC	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg07701084	chr6:150067640	NUP43	0.47	5.86	0.31	1.11e-8	Lung cancer;
CRC	trans	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg18288967	chr1:45987694	PRDX1	0.59	6.87	0.35	3.22e-11	Obesity-related traits;
CRC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.45	-7.47	-0.38	7.49e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	13.38	0.59	6.58e-33	Schizophrenia;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg06683288	chr20:60813424	OSBPL2	0.55	6.09	0.32	3.08e-9	Body mass index;
CRC	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.89	-0.4	4.51e-14	Neuroticism;
CRC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.48	6.93	0.36	2.2e-11	Methadone dose in opioid dependence;
CRC	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-6.36	-0.33	6.83e-10	Total body bone mineral density;
CRC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.43	6.59	0.34	1.73e-10	Hemoglobin concentration;
CRC	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg27083787	chr2:113543245	IL1A	0.45	6.47	0.34	3.5e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.81	14.42	0.62	6.85e-37	Total body bone mineral density;
CRC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.68	-0.51	4.74e-23	Alzheimer's disease;
CRC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg03929089	chr4:120376271	NA	-0.56	-7.03	-0.36	1.19e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg06935464	chr4:38784597	TLR10	0.55	5.68	0.3	2.97e-8	Breast cancer;
CRC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.75	11.63	0.54	2.04e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg13856295	chr9:139396418	NOTCH1	-0.42	-5.64	-0.3	3.61e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.41	6.16	0.32	2.18e-9	Hemoglobin concentration;
CRC	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.71	0.35	8.42e-11	Coronary artery disease;
CRC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg09264619	chr17:80180166	NA	-0.36	-6.17	-0.32	2.04e-9	Life satisfaction;
CRC	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.57	-9.05	-0.45	1.29e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg11212589	chr17:38028394	ZPBP2	0.42	7.64	0.39	2.36e-13	Self-reported allergy;
CRC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.53	9.8	0.48	4.52e-20	Eye color traits;
CRC	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.75	9.77	0.47	5.9e-20	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.62	-9.41	-0.46	8.82e-19	Corneal astigmatism;
CRC	cis	rs6961069	0.713	rs1049654	chr7:80275455	A/C	cg04458919	chr7:80252533	CD36	0.35	6.24	0.33	1.34e-9	Platelet count;
CRC	trans	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs4728302	0.934	rs2971963	chr7:133641505	A/G	cg10665199	chr7:133106180	EXOC4	-0.37	-5.77	-0.3	1.88e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg25204440	chr1:209979598	IRF6	0.49	7.07	0.36	9.33e-12	Cleft lip with or without cleft palate;
CRC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.72	-11.58	-0.54	2.97e-26	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17823320	chr8:19675140	INTS10	0.42	6.17	0.32	1.97e-9	Response to antipsychotic treatment;
CRC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.52	-7.11	-0.37	7.18e-12	DNA methylation (variation);
CRC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.4	6.22	0.32	1.51e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.81	-16.69	-0.68	9.94e-46	Prostate cancer;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg05552183	chr6:42928497	GNMT	0.61	9.47	0.46	5.52e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10450586	0.863	rs7120368	chr11:27292742	C/T	cg10370305	chr11:27303972	NA	0.38	6.19	0.32	1.81e-9	Total body bone mineral density;
CRC	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg27068330	chr11:65405492	SIPA1	0.46	6.89	0.36	2.83e-11	Acne (severe);
CRC	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.39	-6.02	-0.32	4.63e-9	IFN-related cytopenia;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg06753227	chr18:9475508	RALBP1	0.48	6.37	0.33	6.55e-10	Hip circumference;
CRC	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.53	6.44	0.33	4.13e-10	QRS duration;
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg21251018	chr6:28226885	NKAPL	0.48	6.24	0.33	1.32e-9	Depression;
CRC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21582582	chr3:182698605	DCUN1D1	0.55	8.11	0.41	1.01e-14	Intelligence (multi-trait analysis);
CRC	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.7	-6.45	-0.34	3.94e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.01	-15.61	-0.65	1.66e-41	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25876656	chr1:210407480	C1orf133;SERTAD4	0.41	6.36	0.33	6.6e-10	Response to antipsychotic treatment;
CRC	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.54	-6.56	-0.34	2.13e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.85	-0.31	1.17e-8	Total body bone mineral density;
CRC	trans	rs2732480	0.967	rs2732469	chr12:48712932	T/A	cg05117785	chr10:94050880	CPEB3;MARCH5	0.45	6.37	0.33	6.44e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg20073910	chr13:32889539	BRCA2	-0.47	-6.86	-0.35	3.34e-11	HDL cholesterol;
CRC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg23920097	chr1:209922102	NA	-0.52	-6.59	-0.34	1.72e-10	Red blood cell count;
CRC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.18	-0.32	1.85e-9	Aortic root size;
CRC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.52	-9.03	-0.45	1.44e-17	Aortic root size;
CRC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg08461752	chr10:43522343	NA	-0.75	-5.98	-0.31	5.67e-9	Blood protein levels;
CRC	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.4	-5.79	-0.3	1.68e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs7633770	0.931	rs12637421	chr3:46695074	T/C	cg11219411	chr3:46661640	NA	0.64	10.58	0.5	1.07e-22	Coronary artery disease;
CRC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.78	13.49	0.6	2.68e-33	Breast cancer;
CRC	trans	rs1590305	0.786	rs61946592	chr13:38060148	T/C	cg03965764	chr11:45248109	NA	-0.6	-6.15	-0.32	2.31e-9	Hip geometry;
CRC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-9.66	-0.47	1.33e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01182386	chr15:75182373	MPI	0.38	6.07	0.32	3.55e-9	Obesity-related traits;
CRC	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg27422857	chr2:105853526	NA	-0.36	-6.75	-0.35	6.82e-11	Type 2 diabetes;
CRC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg05207973	chr5:176823642	SLC34A1	-0.43	-6.11	-0.32	2.87e-9	Urate levels in lean individuals;
CRC	trans	rs12517041	1.000	rs6890216	chr5:23299559	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg17133734	chr15:86042851	AKAP13	0.41	6.47	0.34	3.48e-10	Coronary artery disease;
CRC	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.52	7.87	0.4	5e-14	Testicular germ cell tumor;
CRC	cis	rs6479527	0.875	rs10123954	chr9:96805860	A/G	cg14459158	chr9:96720562	NA	0.38	6.71	0.35	8.37e-11	Esophageal adenocarcinoma;
CRC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.6	-7.12	-0.37	6.96e-12	Blood protein levels;
CRC	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg09659197	chr4:152720779	NA	0.32	5.71	0.3	2.48e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.51	6.48	0.34	3.41e-10	Recombination rate (females);
CRC	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.09	0.36	7.99e-12	Diisocyanate-induced asthma;
CRC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-12.8	-0.58	1.04e-30	Bipolar disorder and schizophrenia;
CRC	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.35	-6.15	-0.32	2.2e-9	Blood metabolite levels;
CRC	cis	rs282587	0.597	rs1756075	chr13:113396211	T/C	cg04656015	chr13:113407548	ATP11A	0.63	7.8	0.4	8.04e-14	Glycated hemoglobin levels;
CRC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.35	-0.42	1.89e-15	Body mass index;
CRC	cis	rs2310173	0.575	rs4851527	chr2:102622376	C/T	cg20856504	chr2:102616538	IL1R2	-0.37	-5.96	-0.31	6.45e-9	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	cis	rs4888630	0.662	rs4888631	chr16:77470374	C/G	cg10121788	chr16:77469583	ADAMTS18	0.34	5.78	0.3	1.77e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.87	-20.55	-0.75	5.78e-61	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.96	-0.36	1.82e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg09659197	chr4:152720779	NA	0.5	10.7	0.51	3.85e-23	Intelligence (multi-trait analysis);
CRC	cis	rs11166629	1.000	rs11166629	chr8:135636964	C/T	cg27224718	chr8:135614730	ZFAT	0.5	7.52	0.38	5.1e-13	Smoking quantity;
CRC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg21132104	chr15:45694354	SPATA5L1	0.41	5.76	0.3	1.89e-8	Response to fenofibrate (adiponectin levels);
CRC	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.69	-8.69	-0.43	1.68e-16	Blood protein levels;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.81	-13.69	-0.6	4.41e-34	Height;
CRC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg03934865	chr2:198174659	NA	0.36	5.78	0.3	1.77e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	1.01	12.23	0.56	1.28e-28	Obesity-related traits;
CRC	cis	rs6988985	0.765	rs10096393	chr8:143984315	T/C	cg10324643	chr8:143916377	GML	0.39	6.3	0.33	9.39e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-7.98	-0.4	2.54e-14	Brugada syndrome;
CRC	cis	rs972578	1.000	rs5751410	chr22:43393985	A/T	cg01576275	chr22:43409880	NA	-0.49	-8.02	-0.4	1.9e-14	Mean platelet volume;
CRC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg18016565	chr1:150552671	MCL1	0.43	6.18	0.32	1.9e-9	Melanoma;
CRC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-6.4	-0.33	5.2e-10	Height;
CRC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.53	-8.28	-0.42	3.06e-15	Corneal astigmatism;
CRC	trans	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg10756647	chr7:56101905	PSPH	0.75	7.61	0.39	2.98e-13	Diabetic kidney disease;
CRC	cis	rs4666002	0.917	rs4666000	chr2:27839369	T/C	cg27432699	chr2:27873401	GPN1	0.44	5.75	0.3	2.06e-8	Phospholipid levels (plasma);
CRC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.53	0.34	2.48e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12172441	chr6:28176163	NA	0.59	7.12	0.37	6.82e-12	Depression;
CRC	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.64	8.7	0.43	1.64e-16	Uric acid levels;
CRC	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.71	-0.3	2.52e-8	Blood pressure;
CRC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	7.06	0.36	1e-11	Bipolar disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04317338	chr11:64019027	PLCB3	0.42	6.47	0.34	3.63e-10	Schizophrenia;
CRC	cis	rs9303280	0.806	rs9303279	chr17:38073968	G/C	cg20243544	chr17:37824526	PNMT	-0.39	-5.77	-0.3	1.82e-8	Self-reported allergy;
CRC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	cis	rs10944	0.598	rs1841991	chr5:78276148	C/T	cg13121490	chr5:78280331	ARSB	0.46	6.72	0.35	7.98e-11	Blood and toenail selenium levels;
CRC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.43	7.24	0.37	3.24e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.83	10.32	0.49	8.05e-22	Glomerular filtration rate (creatinine);
CRC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.46	-6.94	-0.36	2.04e-11	Height;
CRC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	7.46	0.38	7.85e-13	Motion sickness;
CRC	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.82	-15.72	-0.65	6.47e-42	Oral cavity cancer;
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.59	-0.39	3.38e-13	Neuroticism;
CRC	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-7.32	-0.37	1.9e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg24879335	chr3:133465180	TF	0.31	5.63	0.3	3.8e-8	Iron status biomarkers;
CRC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.69	9.05	0.45	1.24e-17	High light scatter reticulocyte count;
CRC	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.58	7.22	0.37	3.6e-12	RR interval (heart rate);
CRC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.51	6.86	0.35	3.52e-11	Resistin levels;
CRC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.62	0.54	2.21e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg24644049	chr4:85504048	CDS1	0.9	7.41	0.38	1.05e-12	Skin colour saturation;
CRC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.9	15.61	0.65	1.72e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg15845792	chr6:28175446	NA	0.61	8.08	0.41	1.29e-14	Parkinson's disease;
CRC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg00343986	chr7:65444356	GUSB	-0.47	-6.94	-0.36	2.1e-11	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24234277	chr1:231473324	C1orf124;EXOC8	0.42	6.12	0.32	2.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.79	12.27	0.56	9.13e-29	Monocyte count;
CRC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.48	7.31	0.37	2.08e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg04824913	chr4:887549	GAK	-0.4	-6.02	-0.32	4.58e-9	Systemic sclerosis;
CRC	cis	rs4803480	0.507	rs11083627	chr19:42069900	A/G	cg08478046	chr19:42093086	CEACAM21	-0.28	-5.94	-0.31	7.32e-9	Schizophrenia;
CRC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg02560186	chr11:3602584	NA	-0.46	-6.25	-0.33	1.3e-9	Blood pressure (smoking interaction);
CRC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg13072238	chr3:49761600	GMPPB	-0.54	-5.85	-0.31	1.19e-8	Menarche (age at onset);
CRC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg25985355	chr7:65971099	NA	-0.49	-5.61	-0.3	4.28e-8	Diabetic kidney disease;
CRC	cis	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg11143507	chr3:125485238	NA	-0.58	-7.46	-0.38	7.69e-13	Blood pressure (smoking interaction);
CRC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.51	7.77	0.39	1.01e-13	Red blood cell count;
CRC	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.92	11.19	0.53	7.51e-25	Exhaled nitric oxide output;
CRC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	7.4	0.38	1.16e-12	Aortic root size;
CRC	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg14458575	chr2:238380390	NA	0.46	6.51	0.34	2.8e-10	Prostate cancer;
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	5.7	0.3	2.64e-8	Prudent dietary pattern;
CRC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.68	-0.47	1.16e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-8.06	-0.41	1.47e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.52	8.08	0.41	1.24e-14	Aortic root size;
CRC	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg11900509	chr10:81946545	ANXA11	-0.66	-6.83	-0.35	4.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg24300038	chr13:113819356	PROZ	-0.47	-5.78	-0.3	1.76e-8	Platelet distribution width;
CRC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.51	6.9	0.36	2.62e-11	Height;
CRC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.56	-0.34	2.1e-10	Electroencephalogram traits;
CRC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-11.6	-0.54	2.54e-26	Vitiligo;
CRC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg00343986	chr7:65444356	GUSB	-0.42	-6.04	-0.32	4.28e-9	Aortic root size;
CRC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg05569086	chr8:143859399	LYNX1	0.4	6.98	0.36	1.68e-11	Urinary tract infection frequency;
CRC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-10.81	-0.51	1.69e-23	Systemic lupus erythematosus;
CRC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.52	6.81	0.35	4.65e-11	Multiple sclerosis;
CRC	cis	rs6694672	0.850	rs1034162	chr1:197088303	G/A	cg13682187	chr1:196946512	CFHR5	0.43	6.97	0.36	1.69e-11	Asthma;
CRC	cis	rs9906695	0.846	rs1019109	chr17:32615120	A/G	cg12698626	chr17:32581466	CCL2	0.45	6.03	0.32	4.36e-9	Monocyte percentage of white cells;
CRC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.49	7.29	0.37	2.29e-12	Pancreatic cancer;
CRC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.38	5.97	0.31	6.12e-9	HDL cholesterol levels;
CRC	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.56	7.47	0.38	7.19e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.3	-0.33	9.77e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg23234261	chr14:55582407	NA	-0.29	-5.84	-0.31	1.25e-8	Protein biomarker;
CRC	trans	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.45	-0.34	3.9e-10	Aortic root size;
CRC	cis	rs2188554	0.740	rs6957018	chr7:117210368	C/T	cg09181792	chr7:117119393	CFTR	0.35	5.98	0.31	5.8e-9	Esophageal adenocarcinoma;
CRC	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.35	-5.99	-0.31	5.46e-9	Height;
CRC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.54	-8.11	-0.41	9.81e-15	Obesity-related traits;
CRC	trans	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg07817883	chr1:32538562	TMEM39B	-0.66	-8.12	-0.41	9.72e-15	Monocyte percentage of white cells;
CRC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.63	-0.34	1.35e-10	Neuroticism;
CRC	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.94	-0.36	2.07e-11	Metabolite levels;
CRC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.91	17.24	0.69	6.91e-48	Lewy body disease;
CRC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.65	8.9	0.44	3.76e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.48	-0.46	5.08e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25184507	chr17:7760147	CYB5D1;LSMD1	0.49	7.17	0.37	5.12e-12	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.63	10.73	0.51	3.01e-23	Prudent dietary pattern;
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.5	-6.47	-0.34	3.52e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.97	0.31	6.11e-9	Bipolar disorder;
CRC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.68	0.54	1.28e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.6	0.34	1.67e-10	Morning vs. evening chronotype;
CRC	cis	rs2949837	0.528	rs10260816	chr7:46010100	C/G	cg10677697	chr7:45961126	IGFBP3	-0.37	-6.32	-0.33	8.58e-10	Sitting height ratio;
CRC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-10.29	-0.49	1.04e-21	Extrinsic epigenetic age acceleration;
CRC	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.14	19.56	0.73	4.48e-57	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg08533674	chr1:46993347	NA	0.63	8.13	0.41	8.62e-15	Monobrow;
CRC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08886695	chr4:3369023	RGS12	-0.42	-6.59	-0.34	1.79e-10	Parental longevity (mother's age at death);
CRC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-8.27	-0.41	3.34e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg23123621	chr4:1343375	KIAA1530	-0.34	-6.03	-0.32	4.48e-9	Obesity-related traits;
CRC	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.6	8.43	0.42	1.1e-15	Uric acid levels;
CRC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.75	-11.44	-0.53	9.95e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.61	8.34	0.42	2e-15	Mean corpuscular hemoglobin;
CRC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.66	-8.08	-0.41	1.21e-14	Mean platelet volume;
CRC	cis	rs2457480	0.571	rs61857479	chr10:44705516	A/G	cg09554077	chr10:44749378	NA	0.53	7.12	0.37	6.78e-12	Coronary artery disease;
CRC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg17346650	chr17:80929145	B3GNTL1	0.47	7.13	0.37	6.45e-12	Glycated hemoglobin levels;
CRC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.39	0.53	1.47e-25	Intelligence (multi-trait analysis);
CRC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.42	-8.05	-0.41	1.56e-14	Ulcerative colitis;
CRC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.49	-0.5	2.07e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg22110888	chr17:80059540	CCDC57	-0.4	-6.26	-0.33	1.23e-9	Life satisfaction;
CRC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.73	7.5	0.38	6.15e-13	Plasma clusterin levels;
CRC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.59	9.47	0.46	5.54e-19	Facial morphology (factor 21, depth of nasal alae);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05519737	chr2:111435625	BUB1	0.41	6.11	0.32	2.85e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg03060546	chr3:49711283	APEH	0.54	6.79	0.35	5.22e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.38	-11.34	-0.53	2.14e-25	Psoriasis vulgaris;
CRC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02290350	chr8:58132656	NA	-0.6	-6.78	-0.35	5.45e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.5	7.86	0.4	5.53e-14	Dupuytren's disease;
CRC	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.68	-7.69	-0.39	1.69e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.69	7.82	0.4	7.23e-14	Major depressive disorder;
CRC	cis	rs7259376	0.902	rs10414591	chr19:22600122	G/A	cg02657401	chr19:22469223	NA	0.31	6.82	0.35	4.25e-11	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-20.11	-0.74	3.19e-59	Primary sclerosing cholangitis;
CRC	cis	rs8040855	0.627	rs3816105	chr15:85640911	G/A	cg10818794	chr15:86012489	AKAP13	-0.42	-5.65	-0.3	3.4e-8	Bulimia nervosa;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15174977	chr3:52931857	TMEM110	0.39	6.02	0.31	4.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg21918786	chr6:109611834	NA	0.36	6.17	0.32	2.02e-9	Reticulocyte fraction of red cells;
CRC	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg24955406	chr1:100503596	HIAT1	0.51	6.07	0.32	3.58e-9	Carotid intima media thickness;
CRC	cis	rs1178968	1.000	rs4717085	chr7:72764807	C/T	cg25889504	chr7:72793014	NA	0.54	6.12	0.32	2.63e-9	Triglyceride levels;
CRC	cis	rs2233152	0.520	rs56101381	chr19:41272902	T/C	cg21869046	chr19:41225005	ITPKC	0.43	6.81	0.35	4.59e-11	Kawasaki disease;
CRC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs2179367	0.959	rs579789	chr6:149679371	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.35	-5.68	-0.3	2.9e-8	Dupuytren's disease;
CRC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.44	7.03	0.36	1.18e-11	Dupuytren's disease;
CRC	cis	rs4838594	0.537	rs2166224	chr10:49696926	G/A	cg17291251	chr10:49678358	ARHGAP22	0.41	6.39	0.33	5.73e-10	Daytime sleep phenotypes;
CRC	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.33	-0.46	1.66e-18	Type 2 diabetes;
CRC	cis	rs67981189	0.529	rs61990387	chr14:71491567	A/G	cg15910301	chr14:71632612	NA	0.31	6.07	0.32	3.44e-9	Schizophrenia;
CRC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg25856811	chr1:152973957	SPRR3	-0.26	-7.26	-0.37	2.79e-12	Inflammatory skin disease;
CRC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.41	-7.84	-0.4	6.43e-14	Ulcerative colitis;
CRC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg11707556	chr5:10655725	ANKRD33B	0.35	6.41	0.33	5.17e-10	Coronary artery disease;
CRC	cis	rs9359856	0.529	rs6935307	chr6:90295350	A/G	cg13799429	chr6:90582589	CASP8AP2	0.73	7.7	0.39	1.65e-13	Bipolar disorder;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11467262	chr20:57607340	ATP5E	0.47	6.35	0.33	7.09e-10	Survival in pancreatic cancer;
CRC	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs6804368	0.649	rs9838795	chr3:30758991	C/T	cg06106510	chr3:30762233	NA	0.35	6.38	0.33	5.86e-10	Blood metabolite levels;
CRC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.48	7.04	0.36	1.11e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg10756647	chr7:56101905	PSPH	-0.79	-8.16	-0.41	7.21e-15	Diabetic kidney disease;
CRC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.85e-10	Reticulocyte fraction of red cells;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg10498984	chr16:28874827	SH2B1	-0.73	-6.28	-0.33	1.04e-9	Cognitive function;
CRC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-7.28	-0.37	2.54e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg26893134	chr6:116381904	FRK	0.25	6.75	0.35	6.63e-11	Cholesterol, total;LDL cholesterol;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05979741	chr2:110873485	MALL	0.49	7.02	0.36	1.27e-11	Response to antipsychotic treatment;
CRC	cis	rs17095355	1.000	rs12265204	chr10:111752163	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.3	-0.37	2.17e-12	Biliary atresia;
CRC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.08e-8	Morning vs. evening chronotype;
CRC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg16102536	chr7:156981717	UBE3C	-0.39	-6.66	-0.34	1.16e-10	Body mass index;
CRC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.41	5.65	0.3	3.47e-8	Longevity;Endometriosis;
CRC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg19980929	chr12:42632907	YAF2	0.44	6.51	0.34	2.88e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9814567	0.752	rs13064209	chr3:134335993	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.98	0.48	1.12e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg12365402	chr11:9010492	NRIP3	0.47	7.77	0.39	9.82e-14	Hemoglobin concentration;
CRC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg02880119	chr16:3481970	NA	-0.41	-5.8	-0.3	1.55e-8	Body mass index (adult);
CRC	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg25171089	chr10:5708825	ASB13	-0.41	-5.84	-0.31	1.25e-8	Menopause (age at onset);
CRC	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg05623727	chr3:50126028	RBM5	0.53	6.69	0.35	9.47e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.46	6.95	0.36	1.91e-11	Carotid intima media thickness;
CRC	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg12458913	chr13:53173898	NA	0.55	8.49	0.42	7.28e-16	Lewy body disease;
CRC	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-5.88	-0.31	1.03e-8	Opioid sensitivity;
CRC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.76	12.56	0.57	8.02e-30	Colorectal cancer;
CRC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-9.08	-0.45	1.05e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg12273811	chr6:28175739	NA	0.52	7.02	0.36	1.28e-11	Parkinson's disease;
CRC	trans	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg06840491	chr10:48416966	GDF2	0.34	5.98	0.31	5.79e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.66	10.56	0.5	1.18e-22	Corneal astigmatism;
CRC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg20615401	chr6:28092323	ZSCAN16	0.45	5.94	0.31	7.33e-9	Cardiac Troponin-T levels;
CRC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.71	-0.3	2.52e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs7210990	0.724	rs178826	chr17:16083684	C/T	cg01061575	chr22:45098367	PRR5-ARHGAP8;PRR5	-0.45	-6.26	-0.33	1.22e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.98	-0.4	2.5e-14	Height;
CRC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg24300038	chr13:113819356	PROZ	-0.47	-5.78	-0.3	1.76e-8	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24663636	chr14:35872875	NFKBIA	0.47	7.22	0.37	3.52e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.86	-11.89	-0.55	2.28e-27	Vitiligo;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27574168	chr18:54318782	WDR7	0.47	6.01	0.31	4.85e-9	Thyroid stimulating hormone;
CRC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg21153622	chr11:89784906	NA	-0.41	-6.78	-0.35	5.7e-11	Coronary artery disease;
CRC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.56	-8.43	-0.42	1.08e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg23234261	chr14:55582407	NA	-0.29	-5.81	-0.3	1.49e-8	Protein biomarker;
CRC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	18.46	0.71	1.04e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4731207	0.565	rs12536146	chr7:124600631	T/A	cg23710748	chr7:124431027	NA	-0.38	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2630709	0.562	rs2115366	chr2:8464031	C/T	cg12167548	chr2:8464763	NA	0.33	6.32	0.33	8.39e-10	Monocyte percentage of white cells;
CRC	cis	rs6586163	1.000	rs6586164	chr10:90752031	T/A	cg13456138	chr10:90753195	FAS	-0.44	-6.87	-0.35	3.31e-11	Chronic lymphocytic leukemia;
CRC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.4	6.41	0.33	5.03e-10	Cystic fibrosis severity;
CRC	cis	rs747650	0.699	rs4237547	chr11:47236405	C/G	cg19486271	chr11:47235900	DDB2	-0.52	-8.2	-0.41	5.28e-15	Acne (severe);
CRC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-6.99	-0.36	1.52e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs4494114	1.000	rs4494114	chr1:39339682	C/T	cg25970120	chr1:39325951	RRAGC	0.41	5.61	0.3	4.29e-8	Blood protein levels;
CRC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.53	8.27	0.41	3.43e-15	Colorectal cancer;
CRC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.72	10.53	0.5	1.48e-22	Menarche (age at onset);
CRC	cis	rs10991814	0.764	rs75062481	chr9:94094222	G/A	cg14446406	chr9:93919335	NA	0.6	6.61	0.34	1.52e-10	Neutrophil percentage of granulocytes;
CRC	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-7.81	-0.4	7.94e-14	Homocysteine levels;
CRC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg01420254	chr6:26195488	NA	0.81	8.55	0.43	4.7e-16	Gout;Renal underexcretion gout;
CRC	trans	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06834434	chr14:75079333	LTBP2	0.51	6.1	0.32	3.05e-9	Obesity-related traits;
CRC	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-6.05	-0.32	4.01e-9	Subjective well-being;
CRC	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.42	-6.29	-0.33	1.03e-9	Neutrophil percentage of white cells;
CRC	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg14345882	chr6:26364793	BTN3A2	-0.64	-5.82	-0.31	1.43e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.53	7.06	0.36	9.95e-12	Multiple sclerosis;
CRC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg12311346	chr5:56204834	C5orf35	0.5	7.65	0.39	2.28e-13	Coronary artery disease;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg12273811	chr6:28175739	NA	0.63	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.68	-0.3	2.89e-8	Neuroticism;
CRC	cis	rs713477	1.000	rs12893000	chr14:55912280	G/T	cg13175173	chr14:55914753	NA	-0.51	-9.55	-0.47	3.01e-19	Pediatric bone mineral content (femoral neck);
CRC	trans	rs6956675	0.915	rs7790432	chr7:62631824	T/C	cg01314568	chr7:57830625	NA	-0.66	-9.21	-0.45	3.98e-18	Obesity-related traits;
CRC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.54	6.34	0.33	7.71e-10	Bipolar disorder;
CRC	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg11900509	chr10:81946545	ANXA11	-0.77	-7.46	-0.38	7.71e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	6.65	0.34	1.22e-10	Platelet count;
CRC	cis	rs8099014	0.731	rs4940391	chr18:56105868	A/G	cg19312305	chr18:56117016	MIR122	-0.44	-5.96	-0.31	6.53e-9	Platelet count;
CRC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-13.13	-0.59	5.77e-32	Vitiligo;
CRC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.65	10.8	0.51	1.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs356992	0.915	rs356976	chr2:60748945	C/T	cg08426369	chr2:60753602	BCL11A	-0.47	-5.73	-0.3	2.33e-8	Educational attainment (years of education);
CRC	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.72	9.58	0.47	2.48e-19	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.82	13.38	0.59	6.95e-33	Menopause (age at onset);
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.95	0.4	2.97e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.56	7.14	0.37	6.15e-12	Neutrophil percentage of white cells;
CRC	cis	rs12024301	0.557	rs78209243	chr1:183633664	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.93	0.36	2.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.22e-23	Motion sickness;
CRC	cis	rs6662572	0.737	rs7525281	chr1:46267923	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.22	-0.32	1.52e-9	Blood protein levels;
CRC	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.57	0.47	2.64e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg20608306	chr11:116969690	SIK3	-0.32	-6.12	-0.32	2.69e-9	Subjective well-being;
CRC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12463550	chr7:65579703	CRCP	0.7	6.44	0.33	4.33e-10	Diabetic kidney disease;
CRC	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg27205649	chr11:78285834	NARS2	0.47	5.82	0.31	1.41e-8	Alzheimer's disease (survival time);
CRC	trans	rs62295889	0.602	rs56660601	chr4:12536363	G/A	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	6.5	0.34	2.98e-10	Height;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg27615366	chr5:131592974	PDLIM4	0.34	6.46	0.34	3.81e-10	Acylcarnitine levels;
CRC	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-7.05	-0.36	1.03e-11	Inflammatory skin disease;
CRC	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.54	-9.37	-0.46	1.17e-18	Schizophrenia;
CRC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg21724239	chr8:58056113	NA	0.58	7.75	0.39	1.17e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.54	-7.97	-0.4	2.66e-14	Menarche (age at onset);
CRC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-6.93	-0.36	2.22e-11	Waist circumference;Hip circumference;
CRC	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg08075719	chr14:103021372	NA	-0.66	-7.49	-0.38	6.38e-13	Platelet count;
CRC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.03	9.91	0.48	2.04e-20	Lymphocyte counts;
CRC	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.58	8.35	0.42	1.89e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.05	-0.32	4e-9	Lung cancer;
CRC	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.71	-0.3	2.49e-8	Daytime sleep phenotypes;
CRC	trans	rs2270927	0.510	rs6891108	chr5:75579152	C/A	cg13563193	chr19:33072644	PDCD5	0.68	6.15	0.32	2.29e-9	Mean corpuscular volume;
CRC	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg23920097	chr1:209922102	NA	-0.53	-6.53	-0.34	2.51e-10	Red blood cell count;
CRC	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg11130432	chr3:121712080	ILDR1	-0.51	-6.71	-0.35	8.74e-11	Multiple sclerosis;
CRC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	7.63	0.39	2.48e-13	Intelligence (multi-trait analysis);
CRC	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg04110750	chr16:69646130	NFAT5	-0.56	-7.63	-0.39	2.6e-13	IgE levels;
CRC	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg02811702	chr13:24901961	NA	0.41	5.73	0.3	2.28e-8	Obesity-related traits;
CRC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.84	-0.4	6.39e-14	Total body bone mineral density;
CRC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.59	10.52	0.5	1.7e-22	Immature fraction of reticulocytes;
CRC	cis	rs294883	0.739	rs34147307	chr6:159732212	G/A	cg14500486	chr6:159655392	FNDC1	-0.36	-6.18	-0.32	1.92e-9	Coronary artery disease;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg08558996	chr3:32775935	CNOT10	-0.38	-6.04	-0.32	4.11e-9	HDL cholesterol;
CRC	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg22689833	chr10:102415991	NA	-0.35	-6.73	-0.35	7.53e-11	Body mass index;
CRC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.02	-0.31	4.74e-9	Aortic root size;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.59	-6.89	-0.36	2.79e-11	Parkinson's disease;
CRC	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg09659197	chr4:152720779	NA	-0.54	-11.87	-0.55	2.67e-27	Intelligence (multi-trait analysis);
CRC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg21251018	chr6:28226885	NKAPL	0.39	6.04	0.32	4.08e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-6.82	-0.35	4.25e-11	Schizophrenia;
CRC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.29	6.12	0.32	2.69e-9	Lung cancer;
CRC	cis	rs457287	0.892	rs1260032	chr9:4829487	T/C	cg14182974	chr9:4791918	RCL1	0.42	6.68	0.35	1.05e-10	Platelet count;
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg16606324	chr3:10149918	C3orf24	0.69	9.43	0.46	7.91e-19	Alzheimer's disease;
CRC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.92	-0.44	3.21e-17	Alcohol dependence;
CRC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-8.31	-0.42	2.61e-15	Bipolar disorder;
CRC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.39	6.72	0.35	8.06e-11	Crohn's disease;
CRC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.56	0.47	2.92e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.83	15.15	0.64	1.07e-39	Metabolic syndrome;
CRC	cis	rs9891119	0.550	rs9912773	chr17:40510534	C/G	cg06270615	chr17:40516068	STAT3	-0.33	-6.41	-0.33	4.98e-10	Multiple sclerosis;Crohn's disease;
CRC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.86	-9.8	-0.48	4.72e-20	Breast cancer;
CRC	cis	rs11212617	1.000	rs676729	chr11:108184841	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.7	0.3	2.61e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.15	-0.37	5.67e-12	Menopause (age at onset);
CRC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg19761014	chr17:28927070	LRRC37B2	0.57	5.73	0.3	2.27e-8	Body mass index;
CRC	cis	rs7605827	0.897	rs6431697	chr2:15540034	G/C	cg19274914	chr2:15703543	NA	0.4	5.92	0.31	8.18e-9	Educational attainment (years of education);
CRC	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg19875578	chr6:126661172	C6orf173	0.42	5.77	0.3	1.88e-8	Male-pattern baldness;
CRC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.43	6.4	0.33	5.27e-10	N-glycan levels;
CRC	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.17	-25.05	-0.81	3.13e-78	Exhaled nitric oxide output;
CRC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg18764771	chr6:116381957	FRK	0.25	7.0	0.36	1.45e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2712184	0.660	rs10164732	chr2:217645669	A/T	cg05032264	chr2:217675019	NA	0.33	5.8	0.3	1.56e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CRC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.22	-0.32	1.54e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs16984718	1.000	rs16984718	chr2:18509254	C/T	cg15837382	chr1:35332106	DLGAP3	0.59	6.24	0.33	1.34e-9	Urate levels in obese individuals;
CRC	cis	rs447	0.767	rs4732543	chr7:83745910	A/G	cg22846510	chr7:83753280	SEMA3A	-0.41	-5.67	-0.3	3.21e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.41	0.33	5e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21315798	chr22:50354594	PIM3	0.4	6.16	0.32	2.12e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg11212589	chr17:38028394	ZPBP2	0.35	5.98	0.31	5.72e-9	Asthma;
CRC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.71	11.92	0.55	1.83e-27	Alzheimer's disease (late onset);
CRC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	5.78	0.3	1.76e-8	Diabetic retinopathy;
CRC	cis	rs972578	0.806	rs8140272	chr22:43222242	C/T	cg01576275	chr22:43409880	NA	-0.43	-6.81	-0.35	4.64e-11	Mean platelet volume;
CRC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.68	11.41	0.53	1.2e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg14711859	chr11:8959438	ASCL3	0.43	7.34	0.38	1.65e-12	Hemoglobin concentration;
CRC	cis	rs904251	0.686	rs2776911	chr6:37439950	T/A	cg01843034	chr6:37503916	NA	-0.38	-5.68	-0.3	2.91e-8	Cognitive performance;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg15845792	chr6:28175446	NA	0.64	9.63	0.47	1.66e-19	Pubertal anthropometrics;
CRC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.66	8.04	0.41	1.59e-14	Menarche (age at onset);
CRC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.45	5.68	0.3	3.03e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.83	-13.73	-0.6	3.07e-34	Hypospadias;
CRC	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.52	6.86	0.35	3.38e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg02549819	chr16:58548995	SETD6	1.2	7.97	0.4	2.72e-14	Schizophrenia;
CRC	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.95	11.47	0.53	7.47e-26	Blood pressure (smoking interaction);
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg17403708	chr19:6361531	CLPP	0.42	6.43	0.33	4.61e-10	Depressive symptom measurement or major depressive disorder;
CRC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.16	-0.32	2.14e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg04518342	chr5:131593106	PDLIM4	0.35	6.49	0.34	3.1e-10	Blood metabolite levels;
CRC	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg25834613	chr7:1915315	MAD1L1	-0.4	-5.88	-0.31	9.96e-9	Bipolar disorder;
CRC	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.48	-7.62	-0.39	2.72e-13	Schizophrenia;
CRC	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.68	-9.61	-0.47	1.97e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-9.35	-0.46	1.4e-18	Migraine;Coronary artery disease;
CRC	cis	rs11627756	0.957	rs4906236	chr14:103077242	G/A	cg12046867	chr14:103022105	NA	-0.44	-5.86	-0.31	1.13e-8	Mean platelet volume;
CRC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg00564723	chr10:75632066	CAMK2G	-0.25	-6.17	-0.32	2.06e-9	Inflammatory bowel disease;
CRC	cis	rs4662945	0.699	rs35045564	chr2:130213210	G/A	cg05962382	chr2:130345044	NA	-0.34	-5.75	-0.3	2.09e-8	Response to cytidine analogues (gemcitabine);
CRC	cis	rs3785888	0.548	rs197923	chr17:45008742	G/C	cg16759221	chr17:45003025	GOSR2	-0.69	-10.14	-0.49	3.38e-21	Cleft lip with or without cleft palate;
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.74	11.73	0.54	8.89e-27	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.5	6.44	0.33	4.22e-10	Obesity-related traits;
CRC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.43	-0.42	1.08e-15	Gut microbiome composition (summer);
CRC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-9.44	-0.46	7.09e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.69	9.03	0.45	1.51e-17	Uric acid levels;
CRC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.81	-11.45	-0.53	9.19e-26	Coronary artery disease;
CRC	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.17	-0.32	1.98e-9	Morning vs. evening chronotype;
CRC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.74	10.05	0.48	6.51e-21	Platelet count;
CRC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.77	11.22	0.53	6.06e-25	High light scatter reticulocyte count;
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg07617317	chr6:118971624	C6orf204	0.5	6.26	0.33	1.22e-9	Diastolic blood pressure;
CRC	cis	rs3767633	0.925	rs1806594	chr1:161858860	T/C	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	1.03e-9	IgG glycosylation;
CRC	cis	rs7120118	0.517	rs78310113	chr11:47293553	T/G	cg25783544	chr11:47291846	MADD	0.62	5.66	0.3	3.36e-8	HDL cholesterol;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg12273811	chr6:28175739	NA	0.5	6.93	0.36	2.3e-11	Parkinson's disease;
CRC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-10.62	-0.51	7.56e-23	Systemic lupus erythematosus;
CRC	cis	rs6694672	0.867	rs1759006	chr1:197031664	T/C	cg13682187	chr1:196946512	CFHR5	0.48	7.49	0.38	6.27e-13	Asthma;
CRC	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg04110750	chr16:69646130	NFAT5	-0.57	-7.45	-0.38	8.06e-13	IgE levels;
CRC	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	5.04e-11	Prostate cancer;
CRC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.35	0.56	4.64e-29	Menopause (age at onset);
CRC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.66	-0.34	1.18e-10	Systemic lupus erythematosus;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg11843238	chr5:131593191	PDLIM4	0.46	7.72	0.39	1.45e-13	Breast cancer;
CRC	cis	rs9467603	1.000	rs6902211	chr6:25767437	G/A	cg08501292	chr6:25962987	TRIM38	-0.89	-8.08	-0.41	1.23e-14	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg09877947	chr5:131593287	PDLIM4	0.47	8.69	0.43	1.71e-16	Breast cancer;
CRC	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.46	6.71	0.35	8.61e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16175725	chr12:121416796	HNF1A	0.25	6.32	0.33	8.27e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-7.52	-0.38	5.36e-13	Coronary artery disease;
CRC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.75	-0.3	2.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	8.17	0.41	6.73e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.67	-0.47	1.21e-19	Primary sclerosing cholangitis;
CRC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.5	6.09	0.32	3.23e-9	Vitiligo;
CRC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg18827107	chr12:86230957	RASSF9	0.38	5.92	0.31	8e-9	Major depressive disorder;
CRC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-7.72	-0.39	1.4e-13	Coronary artery disease;
CRC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.23	-0.32	1.46e-9	Total body bone mineral density;
CRC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg02033258	chr5:131593261	PDLIM4	0.46	8.66	0.43	2.08e-16	Acylcarnitine levels;
CRC	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg21770322	chr7:97807741	LMTK2	0.87	19.64	0.73	2.25e-57	Breast cancer;
CRC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.51	9.06	0.45	1.19e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.94	-0.55	1.5e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.54	-0.47	3.38e-19	Monocyte percentage of white cells;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	0.7	7.84	0.4	6.44e-14	Body mass index;
CRC	trans	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	6.08	0.32	3.35e-9	Menarche (age at onset);
CRC	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.59	7.3	0.37	2.14e-12	Obesity (extreme);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21224049	chr4:668623	ATP5I	-0.52	-6.25	-0.33	1.29e-9	Diisocyanate-induced asthma;
CRC	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.6	7.87	0.4	5.34e-14	Hypospadias;
CRC	cis	rs10971721	0.822	rs72725378	chr9:33842894	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.89	0.31	9.49e-9	Major depressive disorder;
CRC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.4	8.81	0.44	7.41e-17	Alcohol dependence;
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06470822	chr6:28175283	NA	0.66	5.66	0.3	3.38e-8	Depression;
CRC	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.51	-6.43	-0.33	4.55e-10	Body mass index;
CRC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg12172441	chr6:28176163	NA	0.53	7.29	0.37	2.34e-12	Parkinson's disease;
CRC	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.64	-11.74	-0.54	8.3e-27	Ulcerative colitis;
CRC	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg10437265	chr15:77819839	NA	0.69	12.75	0.57	1.62e-30	Type 2 diabetes;
CRC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.08e-20	Lung cancer;
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	7.8	0.4	8.14e-14	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.49	-0.34	3.16e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.77	0.47	5.59e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg10589385	chr1:150898437	SETDB1	0.3	6.42	0.33	4.76e-10	Tonsillectomy;
CRC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.65	-10.9	-0.52	7.91e-24	Age at first birth;
CRC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.24	14.66	0.63	8.4e-38	Uric acid levels;
CRC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.69	-0.39	1.76e-13	Gut microbiome composition (summer);
CRC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.15	-0.32	2.24e-9	Menopause (age at onset);
CRC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.88	-0.4	4.85e-14	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.65	0.3	3.46e-8	Total body bone mineral density;
CRC	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.43	-6.3	-0.33	9.74e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg12682573	chr17:27188876	MIR451;MIR144	0.59	8.53	0.43	5.4e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.15	-0.32	2.26e-9	Dupuytren's disease;
CRC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-8.02	-0.4	1.91e-14	Menarche (age at onset);
CRC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.56	-6.95	-0.36	1.97e-11	Body mass index;
CRC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg04025307	chr7:1156635	C7orf50	0.66	6.85	0.35	3.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.4	6.34	0.33	7.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.48	-7.1	-0.36	7.96e-12	High light scatter reticulocyte count;
CRC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.78	9.79	0.47	5.11e-20	Monocyte percentage of white cells;
CRC	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.42	-5.93	-0.31	7.46e-9	Subjective well-being;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19740361	chr19:45596828	NA	0.45	7.35	0.38	1.53e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg14768367	chr16:72042858	DHODH	-0.6	-6.74	-0.35	7.24e-11	Blood protein levels;
CRC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg23136738	chr11:925521	AP2A2	-0.4	-6.56	-0.34	2.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.45	-6.94	-0.36	2.1e-11	Coronary artery disease;
CRC	cis	rs6844506	1.000	rs35067299	chr4:185218513	T/C	cg18317788	chr4:185205197	NA	-0.43	-6.02	-0.32	4.55e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
CRC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-10.16	-0.49	2.94e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.26	-0.37	2.84e-12	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.42	6.93	0.36	2.24e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.73	9.51	0.46	4.24e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.89	-0.4	4.66e-14	Height;
CRC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	trans	rs62295889	0.602	rs55646236	chr4:12538095	C/T	cg03490839	chr16:73082051	ZFHX3	0.58	6.06	0.32	3.82e-9	Obesity-related traits;
CRC	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-7.91	-0.4	3.91e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.89	16.03	0.66	3.7e-43	Obesity (extreme);
CRC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.08	-14.05	-0.61	1.92e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.56	7.93	0.4	3.5e-14	Lung cancer;
CRC	cis	rs4731207	0.698	rs7794710	chr7:124561115	C/G	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg27649522	chr12:12877729	APOLD1	-0.52	-6.42	-0.33	4.87e-10	Diisocyanate-induced asthma;
CRC	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.11	0.52	1.49e-24	Bipolar disorder;
CRC	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg24998770	chr7:37888106	TXNDC3	0.37	6.09	0.32	3.08e-9	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.36	0.33	6.59e-10	Depression;
CRC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.12	0.71	2.28e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.53	-7.41	-0.38	1.04e-12	Lymphocyte percentage of white cells;
CRC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg04586622	chr2:25135609	ADCY3	-0.45	-8.04	-0.41	1.61e-14	Body mass index in non-asthmatics;
CRC	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.5	7.35	0.38	1.6e-12	Night sleep phenotypes;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03188948	chr7:1209495	NA	0.41	6.04	0.32	4.14e-9	Longevity;Endometriosis;
CRC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.7	10.95	0.52	5.42e-24	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs7072216	0.687	rs4551689	chr10:100157593	C/T	cg26618903	chr10:100175079	PYROXD2	0.34	5.61	0.3	4.37e-8	Metabolite levels;
CRC	cis	rs4700695	0.686	rs37236	chr5:65223730	C/G	cg21114390	chr5:65439923	SFRS12	0.59	6.38	0.33	5.92e-10	Facial morphology (factor 19);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17324707	chr3:122103153	FAM162A;CCDC58	0.52	7.51	0.38	5.72e-13	Response to antipsychotic treatment;
CRC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-7.65	-0.39	2.18e-13	Menarche (age at onset);
CRC	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg23254163	chr1:152506842	NA	0.45	8.85	0.44	5.3e-17	Hair morphology;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg04497992	chr16:616212	NHLRC4	0.44	6.96	0.36	1.84e-11	Height;
CRC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.45	6.19	0.32	1.74e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-17.3	-0.69	3.78e-48	Coronary artery disease;
CRC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12483801	chr4:183727862	NA	0.65	8.16	0.41	7.37e-15	Pediatric autoimmune diseases;
CRC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.84	-16.95	-0.68	9.58e-47	Post bronchodilator FEV1;
CRC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-7.73	-0.39	1.35e-13	Dilated cardiomyopathy;
CRC	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.15	0.64	1.1e-39	Hypertriglyceridemia;
CRC	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.39	0.33	5.56e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.8	15.88	0.66	1.49e-42	Mean corpuscular hemoglobin;
CRC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg05805236	chr11:65401703	PCNXL3	0.38	5.91	0.31	8.55e-9	Acne (severe);
CRC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.72	0.35	8.21e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.86	16.23	0.67	6.18e-44	Dental caries;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg24106215	chr1:202927166	ADIPOR1	0.47	6.01	0.31	5.06e-9	Thyroid stimulating hormone;
CRC	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs6662572	0.737	rs111970066	chr1:46572817	C/T	cg08644498	chr1:46502608	NA	0.46	7.36	0.38	1.45e-12	Blood protein levels;
CRC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.9	13.01	0.58	1.6e-31	Triglycerides;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg05524038	chr5:149493258	CSF1R	-0.4	-6.51	-0.34	2.75e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-6.13	-0.32	2.47e-9	Parkinson's disease;
CRC	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.4	-6.17	-0.32	2.01e-9	Endometrial cancer;
CRC	cis	rs6534441	0.727	rs6534443	chr4:125425698	C/T	cg21609808	chr4:125404261	NA	0.39	5.64	0.3	3.67e-8	Major depressive disorder;
CRC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.03	0.4	1.72e-14	Resting heart rate;
CRC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.59	7.01	0.36	1.33e-11	Type 2 diabetes nephropathy;
CRC	trans	rs459482	1.000	rs459498	chr21:42795027	G/A	cg24154722	chr2:241858322	NA	0.34	6.05	0.32	4.04e-9	IgG glycosylation;
CRC	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg17182837	chr8:41585554	ANK1	-0.48	-6.2	-0.32	1.71e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs7301826	0.627	rs4325342	chr12:131312482	G/A	cg11011512	chr12:131303247	STX2	0.38	5.7	0.3	2.7e-8	Plasma plasminogen activator levels;
CRC	cis	rs6969780	1.000	rs929249	chr7:27167537	T/C	cg26364809	chr7:27145159	NA	-0.72	-6.66	-0.34	1.15e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.48	-8.57	-0.43	3.96e-16	Blood metabolite levels;
CRC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.49	7.84	0.4	6.2e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg07507251	chr3:52567010	NT5DC2	0.4	5.98	0.31	5.83e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4727963	0.765	rs1525470	chr7:122733854	T/C	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.19e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg17031739	chr1:67600172	NA	0.44	6.96	0.36	1.84e-11	Psoriasis;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.77	8.82	0.44	6.96e-17	Eosinophilic esophagitis;
CRC	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.61	-8.81	-0.44	7.12e-17	Coronary artery disease;
CRC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.66	11.73	0.54	8.46e-27	Eye color traits;
CRC	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.35	12.74	0.57	1.69e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.44	6.5	0.34	3.01e-10	Obesity-related traits;
CRC	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg04611788	chr3:186434169	KNG1	-0.58	-8.7	-0.43	1.67e-16	Blood protein levels;
CRC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.58	8.44	0.42	1.04e-15	Lymphocyte counts;
CRC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg10729496	chr3:10149963	C3orf24	0.5	6.71	0.35	8.29e-11	Alzheimer's disease;
CRC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.65	9.47	0.46	5.59e-19	Subjective well-being;
CRC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.8	14.15	0.62	7.64e-36	Breast cancer;
CRC	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg19731401	chr7:2775893	GNA12	0.56	5.9	0.31	8.84e-9	Childhood ear infection;
CRC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.29	6.11	0.32	2.89e-9	Homoarginine levels;
CRC	cis	rs2735413	0.709	rs1319049	chr16:78084610	T/G	cg04733911	chr16:78082701	NA	0.42	6.59	0.34	1.77e-10	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.83	13.65	0.6	6.2e-34	Menarche (age at onset);
CRC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.69	9.65	0.47	1.4e-19	Alzheimer's disease;
CRC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.47	7.83	0.4	6.9e-14	Testicular germ cell tumor;
CRC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	1.01	18.25	0.71	6.98e-52	Menarche (age at onset);
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg27432699	chr2:27873401	GPN1	-0.51	-7.71	-0.39	1.49e-13	Total body bone mineral density;
CRC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.84	-9.73	-0.47	7.72e-20	Breast cancer;
CRC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg02683197	chr6:28174875	NA	0.79	9.52	0.46	3.93e-19	Parkinson's disease;
CRC	cis	rs812925	0.519	rs967968	chr2:61656056	C/G	cg10580144	chr2:61372316	C2orf74	-0.31	-6.59	-0.34	1.76e-10	Immature fraction of reticulocytes;
CRC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-15.63	-0.65	1.46e-41	Cognitive function;
CRC	cis	rs6968419	0.674	rs4730724	chr7:115905339	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.5	-0.34	2.92e-10	Intraocular pressure;
CRC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.31	0.42	2.47e-15	Lung cancer;
CRC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.6	8.04	0.41	1.63e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg19537932	chr12:55886519	OR6C68	-0.66	-8.56	-0.43	4.26e-16	Cancer;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg12500891	chr11:57225987	NA	-0.65	-6.05	-0.32	3.87e-9	Cognitive function;
CRC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.47	-6.86	-0.35	3.34e-11	Cleft lip with or without cleft palate;
CRC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.19e-11	Testicular germ cell tumor;
CRC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.45	0.42	9.3e-16	Height;
CRC	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.51	-7.18	-0.37	4.79e-12	Obesity-related traits;
CRC	cis	rs9491140	0.539	rs11154221	chr6:124675246	C/T	cg19267163	chr6:125004984	NKAIN2	0.44	5.96	0.31	6.33e-9	Neuroticism;
CRC	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.99	-0.31	5.6e-9	Educational attainment;
CRC	cis	rs7546094	1.000	rs7554916	chr1:113123734	A/C	cg22162597	chr1:113214053	CAPZA1	0.43	6.08	0.32	3.27e-9	Platelet distribution width;
CRC	cis	rs4838594	0.563	rs4838597	chr10:49679397	G/A	cg17291251	chr10:49678358	ARHGAP22	0.46	7.25	0.37	2.92e-12	Daytime sleep phenotypes;
CRC	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.52	7.9	0.4	4.23e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.56	10.01	0.48	9.4e-21	HDL cholesterol levels;
CRC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.52	-7.73	-0.39	1.36e-13	Blood protein levels;
CRC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-11.39	-0.53	1.41e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.7	0.35	8.95e-11	Hip circumference adjusted for BMI;
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg15383120	chr6:291909	DUSP22	-0.51	-7.13	-0.37	6.29e-12	Menopause (age at onset);
CRC	cis	rs11098699	0.821	rs11939262	chr4:124207018	A/G	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg05192639	chr6:26864778	GUSBL1	0.33	5.9	0.31	8.99e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.47	7.04	0.36	1.09e-11	Gait speed in old age;
CRC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.49	7.25	0.37	3.04e-12	Obesity-related traits;
CRC	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg19052272	chr2:3704530	ALLC	0.43	6.28	0.33	1.05e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg09873164	chr1:152488093	CRCT1	0.38	6.4	0.33	5.37e-10	Hair morphology;
CRC	cis	rs2811415	0.597	rs9813438	chr3:127797796	C/G	cg13719885	chr3:127795394	NA	-0.4	-5.99	-0.31	5.51e-9	Lung function (FEV1/FVC);
CRC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg13319975	chr6:146136371	FBXO30	-0.4	-5.94	-0.31	7.41e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.56	-5.73	-0.3	2.25e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	1.95e-33	Vitiligo;
CRC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.96	-0.44	2.41e-17	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22263405	chr18:42259244	SETBP1	0.37	6.34	0.33	7.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg18758796	chr5:131593413	PDLIM4	0.32	5.64	0.3	3.58e-8	Blood metabolite levels;
CRC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-20.81	-0.75	5.94e-62	Hemostatic factors and hematological phenotypes;
CRC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg00745463	chr17:30367425	LRRC37B	0.54	6.64	0.34	1.34e-10	Hip circumference adjusted for BMI;
CRC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.38e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14821008	chr6:64283529	PTP4A1	0.46	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.44	-0.38	9.06e-13	Neuroticism;
CRC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.67	11.55	0.54	3.94e-26	Gout;
CRC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.58	-8.43	-0.42	1.12e-15	Dental caries;
CRC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.61	7.96	0.4	2.84e-14	Hip circumference adjusted for BMI;
CRC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.65	-9.3	-0.46	2.06e-18	Neuroblastoma;
CRC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	6.71	0.35	8.35e-11	Neuroticism;
CRC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12756686	chr19:29218302	NA	0.45	6.32	0.33	8.59e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.63	-9.99	-0.48	1.1e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs4666002	0.956	rs4665383	chr2:27791555	C/G	cg27432699	chr2:27873401	GPN1	0.45	5.66	0.3	3.3e-8	Phospholipid levels (plasma);
CRC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.72	-7.89	-0.4	4.61e-14	Psoriasis;
CRC	cis	rs7429990	0.901	rs7433678	chr3:48037078	G/A	cg11946769	chr3:48343235	NME6	-0.45	-5.82	-0.31	1.43e-8	Educational attainment (years of education);
CRC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9311676	0.656	rs55727087	chr3:58404547	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs17767392	1.000	rs34057981	chr14:71823981	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.77	-0.35	5.81e-11	Mitral valve prolapse;
CRC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.71	-0.43	1.53e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18728699	chr15:90931313	IQGAP1	0.5	7.09	0.36	8.25e-12	Response to antipsychotic treatment;
CRC	cis	rs972578	0.836	rs5759021	chr22:43301900	A/C	cg01576275	chr22:43409880	NA	-0.4	-6.27	-0.33	1.13e-9	Mean platelet volume;
CRC	cis	rs7209700	0.742	rs999323	chr17:45371603	T/C	cg08085267	chr17:45401833	C17orf57	0.41	5.78	0.3	1.77e-8	IgG glycosylation;
CRC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg15848620	chr12:58087721	OS9	-0.42	-5.85	-0.31	1.16e-8	Multiple sclerosis;
CRC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.03	-0.32	4.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.48	-6.33	-0.33	8.24e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg19812747	chr11:111475976	SIK2	-0.59	-10.03	-0.48	7.56e-21	Primary sclerosing cholangitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09537173	chr15:85144474	ZSCAN2	0.43	6.16	0.32	2.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg06092702	chr1:163392909	NA	-0.52	-8.18	-0.41	6.42e-15	Motion sickness;
CRC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.56	0.38	4.16e-13	Height;
CRC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.44	-9.24	-0.45	3.21e-18	Intelligence (multi-trait analysis);
CRC	cis	rs7215564	0.908	rs36100789	chr17:78701117	C/T	cg09596252	chr17:78655493	RPTOR	0.61	6.5	0.34	2.92e-10	Myopia (pathological);
CRC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.8	0.55	4.78e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg15382696	chr6:118971807	C6orf204	0.58	7.4	0.38	1.11e-12	Diastolic blood pressure;
CRC	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg19193384	chr17:30244184	NA	-0.53	-6.7	-0.35	9.26e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-8.03	-0.41	1.69e-14	Intelligence (multi-trait analysis);
CRC	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg21466736	chr12:48725269	NA	0.46	7.35	0.38	1.63e-12	Plateletcrit;
CRC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.83	16.51	0.67	5.12e-45	Prostate cancer;
CRC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.48	-7.18	-0.37	4.7e-12	Menarche (age at onset);
CRC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.59	6.0	0.31	5.24e-9	Plasma clusterin levels;
CRC	cis	rs2444240	0.902	rs626225	chr11:120034115	G/A	cg04390734	chr11:120039366	NA	0.28	5.65	0.3	3.44e-8	Corneal curvature;
CRC	trans	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06834434	chr14:75079333	LTBP2	0.56	7.13	0.37	6.55e-12	Obesity-related traits;
CRC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg27532560	chr4:187881888	NA	-0.56	-10.38	-0.5	4.98e-22	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6546043	0.756	rs1362797	chr2:64128592	C/T	cg20306022	chr2:7947960	NA	-0.52	-5.98	-0.31	5.87e-9	Clozapine-induced agranulocytosis;
CRC	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.46	-0.34	3.68e-10	Coronary artery calcification;
CRC	cis	rs17152411	0.895	rs3940439	chr10:126584531	C/G	cg07906193	chr10:126599966	NA	0.57	6.47	0.34	3.48e-10	Height;
CRC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.8	-10.46	-0.5	2.64e-22	Initial pursuit acceleration;
CRC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	10.7	0.51	3.98e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.58	11.06	0.52	2.13e-24	Height;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21150049	chr12:50677498	LIMA1	0.36	6.13	0.32	2.46e-9	Obesity-related traits;
CRC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	12.45	0.57	2.06e-29	Menarche (age at onset);
CRC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg20512303	chr5:131592959	PDLIM4	0.32	6.17	0.32	1.97e-9	Breast cancer;
CRC	cis	rs7091068	0.507	rs913046	chr10:95408484	A/C	cg20715218	chr10:95462985	C10orf4	0.46	6.5	0.34	2.98e-10	Urinary tract infection frequency;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg27113153	chr11:123612418	ZNF202	-0.7	-6.17	-0.32	1.97e-9	Cognitive function;
CRC	cis	rs972578	0.936	rs6002991	chr22:43370260	C/G	cg01576275	chr22:43409880	NA	-0.45	-7.28	-0.37	2.47e-12	Mean platelet volume;
CRC	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.5	-0.34	2.99e-10	Neuroticism;
CRC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs10503871	0.625	rs4292648	chr8:30324803	C/T	cg26383811	chr8:30366931	RBPMS	0.48	7.63	0.39	2.5e-13	Metabolite levels  (X-11787);
CRC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.68	9.75	0.47	6.81e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.44	-0.46	7.01e-19	Platelet count;
CRC	cis	rs6586163	0.872	rs1926200	chr10:90746533	G/A	cg13456138	chr10:90753195	FAS	-0.44	-6.61	-0.34	1.54e-10	Chronic lymphocytic leukemia;
CRC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.69	-0.35	9.36e-11	Height;
CRC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs8023845	0.954	rs1680156	chr15:40447265	T/C	cg20259534	chr15:40453036	BUB1B	0.5	5.74	0.3	2.11e-8	Chronic lymphocytic leukemia;
CRC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.67	7.27	0.37	2.61e-12	Schizophrenia;
CRC	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-9.42	-0.46	8.39e-19	Capecitabine sensitivity;
CRC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.6	-9.84	-0.48	3.36e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.89	0.63	1.08e-38	Chronic sinus infection;
CRC	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg18131467	chr2:239335373	ASB1	-0.69	-7.49	-0.38	6.5e-13	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs7215564	0.730	rs34588273	chr17:78571465	C/T	cg09596252	chr17:78655493	RPTOR	0.68	6.37	0.33	6.19e-10	Myopia (pathological);
CRC	cis	rs6834538	0.692	rs116138196	chr4:113399192	A/G	cg10021238	chr4:113569128	MIR367;LARP7	-0.39	-5.75	-0.3	2.02e-8	Free thyroxine concentration;
CRC	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.56	6.71	0.35	8.78e-11	Carotid intima media thickness;
CRC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.63	10.12	0.49	3.83e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.75	-0.35	6.71e-11	Intelligence (multi-trait analysis);
CRC	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.39	7.54	0.38	4.66e-13	Ulcerative colitis;
CRC	cis	rs3790455	0.610	rs3790461	chr1:156469364	A/G	cg14087168	chr1:156450669	MEF2D	0.35	6.27	0.33	1.16e-9	Migraine;
CRC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.9	-15.65	-0.65	1.22e-41	Height;
CRC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg08743896	chr10:65200160	JMJD1C	-0.41	-5.93	-0.31	7.58e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23753021	chr10:89623142	PTEN;KILLIN	-0.39	-5.97	-0.31	6.24e-9	Aortic root size;
CRC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.6	10.52	0.5	1.68e-22	Body mass index;
CRC	trans	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg26043149	chr18:55253948	FECH	-0.55	-8.28	-0.42	3.07e-15	Bone mineral density;
CRC	cis	rs73206853	0.563	rs73194047	chr12:111191926	G/A	cg12870014	chr12:110450643	ANKRD13A	0.72	8.46	0.42	9.05e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00166722	chr3:10149974	C3orf24	0.65	8.86	0.44	5.13e-17	Alzheimer's disease;
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg20119798	chr7:94954144	PON1	-0.49	-6.26	-0.33	1.21e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.34	6.81	0.35	4.71e-11	Alzheimer's disease (late onset);
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03352830	chr11:487213	PTDSS2	0.65	7.4	0.38	1.15e-12	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20986421	chr1:201798455	IPO9	0.37	6.02	0.31	4.74e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg19318889	chr4:1322082	MAEA	0.4	5.74	0.3	2.13e-8	Obesity-related traits;
CRC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.43	-0.38	9.51e-13	Morning vs. evening chronotype;
CRC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg03152288	chr2:177042942	NA	0.8	13.01	0.58	1.74e-31	IgG glycosylation;
CRC	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg14664628	chr15:75095509	CSK	0.45	6.15	0.32	2.26e-9	Systemic lupus erythematosus;
CRC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.61	-0.3	4.31e-8	Lung cancer;
CRC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-14.07	-0.61	1.6e-35	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.55	8.59	0.43	3.55e-16	Breast cancer;
CRC	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.01e-17	Dupuytren's disease;
CRC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg00246817	chr9:123691163	NA	-0.47	-5.95	-0.31	6.98e-9	Rheumatoid arthritis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16585985	chr1:161360266	NA	0.42	6.0	0.31	5.3300000000000004e-09	Response to antipsychotic treatment;
CRC	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg20487152	chr13:99095054	FARP1	0.36	5.91	0.31	8.46e-9	Longevity;
CRC	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg04906043	chr13:21280425	IL17D	-0.45	-6.94	-0.36	2.12e-11	Dental caries;
CRC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg01808030	chr22:45809952	RIBC2;SMC1B	0.61	6.7	0.35	8.89e-11	Tonsillectomy;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.53	9.92	0.48	1.85e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.14	0.32	2.41e-9	Aortic root size;
CRC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.71	0.3	2.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs972578	1.000	rs4822249	chr22:43403506	C/G	cg01576275	chr22:43409880	NA	-0.51	-8.38	-0.42	1.53e-15	Mean platelet volume;
CRC	cis	rs600806	0.778	rs12145677	chr1:110023610	G/A	cg23032129	chr1:109941072	SORT1	0.26	5.62	0.3	4.11e-8	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.8	-0.35	5.09e-11	Total body bone mineral density;
CRC	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg07322936	chr10:88137208	NA	-0.59	-7.69	-0.39	1.72e-13	Schizophrenia;
CRC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.51e-13	Diabetic retinopathy;
CRC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.35	5.65	0.3	3.57e-8	Childhood ear infection;
CRC	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.01	-0.31	4.99e-9	Reticulocyte fraction of red cells;
CRC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.78	-0.3	1.78e-8	Total body bone mineral density;
CRC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg13057898	chr1:3703894	LRRC47	0.55	7.21	0.37	3.83e-12	Red cell distribution width;
CRC	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.52	6.11	0.32	2.76e-9	Blood trace element (Cu levels);
CRC	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-1.04	-10.68	-0.51	4.76e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	6.63	0.34	1.37e-10	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg26566898	chr11:117069891	TAGLN	0.31	6.46	0.34	3.69e-10	Blood protein levels;
CRC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.42	-5.66	-0.3	3.21e-8	Bipolar disorder;
CRC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg10589385	chr1:150898437	SETDB1	0.31	6.47	0.34	3.46e-10	Tonsillectomy;
CRC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.33	6.12	0.32	2.6e-9	P wave duration;
CRC	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.57	-6.31	-0.33	8.9e-10	Coronary artery disease;
CRC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.43	-6.02	-0.31	4.67e-9	Intelligence (multi-trait analysis);
CRC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg12193833	chr17:30244370	NA	0.49	6.06	0.32	3.63e-9	Hip circumference adjusted for BMI;
CRC	cis	rs863345	0.604	rs12025831	chr1:158496282	G/A	cg12129480	chr1:158549410	OR10X1	-0.27	-5.66	-0.3	3.36e-8	Pneumococcal bacteremia;
CRC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.48	7.96	0.4	2.84e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.22	0.45	3.7e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7605827	0.857	rs9973946	chr2:15631022	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs3736485	0.966	rs4775960	chr15:51891698	C/G	cg08986416	chr15:51914746	DMXL2	-0.47	-6.86	-0.35	3.39e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.82	-13.52	-0.6	2.04e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs73206853	0.841	rs73191840	chr12:110970457	A/G	cg12870014	chr12:110450643	ANKRD13A	0.81	8.45	0.42	9.67e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.61	7.76	0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-7.75	-0.39	1.19e-13	Subjective well-being;
CRC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12588279	chr6:26043732	HIST1H2BB	0.4	5.83	0.31	1.3e-8	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26462404	chr19:2270807	OAZ1	0.48	6.26	0.33	1.21e-9	Thyroid stimulating hormone;
CRC	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.92	-0.4	3.67e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.93e-18	Lymphocyte counts;
CRC	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg19875578	chr6:126661172	C6orf173	0.42	5.76	0.3	1.91e-8	Male-pattern baldness;
CRC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.35	-7.4	-0.38	1.13e-12	Cutaneous nevi;
CRC	cis	rs7923609	0.875	rs10822143	chr10:64887856	C/T	cg08743896	chr10:65200160	JMJD1C	-0.42	-5.74	-0.3	2.2e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-7.1	-0.36	7.68e-12	Neuroticism;
CRC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg16447950	chr5:562315	NA	-0.79	-10.45	-0.5	2.87e-22	Lung disease severity in cystic fibrosis;
CRC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.53	-6.7	-0.35	9.32e-11	DNA methylation (variation);
CRC	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.7	-8.04	-0.41	1.62e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg03340356	chr1:67600835	NA	-0.29	-6.54	-0.34	2.29e-10	Psoriasis;
CRC	cis	rs1975991	0.597	rs715790	chr3:187985004	A/G	cg17585528	chr3:187988060	LPP	0.49	6.91	0.36	2.46e-11	White matter integrity (bipolar disorder risk interaction);
CRC	cis	rs501120	1.000	rs671765	chr10:44752976	A/G	cg09554077	chr10:44749378	NA	0.86	12.64	0.57	3.9e-30	Coronary artery disease;Coronary heart disease;
CRC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.94	-0.31	7.44e-9	Morning vs. evening chronotype;
CRC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.47	6.13	0.32	2.49e-9	White matter hyperintensity burden;
CRC	trans	rs773506	0.965	rs298718	chr9:94081674	A/G	cg20300514	chr1:2120985	C1orf86;LOC100128003	0.4	5.98	0.31	5.86e-9	Type 2 diabetes nephropathy;
CRC	cis	rs6681460	1.000	rs4655636	chr1:67068537	A/G	cg02459107	chr1:67143332	SGIP1	0.46	8.15	0.41	7.87e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.45	-6.88	-0.35	3e-11	Menarche (age at onset);
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.61	8.58	0.43	3.86e-16	Obesity-related traits;
CRC	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.63	-8.6	-0.43	3.31e-16	White matter hyperintensity burden;
CRC	cis	rs6723226	0.610	rs458628	chr2:32515398	G/A	cg02381751	chr2:32503542	YIPF4	0.58	8.38	0.42	1.56e-15	Intelligence (multi-trait analysis);
CRC	cis	rs66573146	0.803	rs59809420	chr4:6969928	G/T	cg00086871	chr4:6988644	TBC1D14	1.07	7.19	0.37	4.43e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21659725	chr3:3221576	CRBN	0.63	7.03	0.36	1.21e-11	Menarche (age at onset);
CRC	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.13	17.09	0.69	2.61e-47	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.64	9.39	0.46	1.01e-18	Intelligence (multi-trait analysis);
CRC	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg09476006	chr5:138032270	NA	0.44	6.78	0.35	5.56e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg15571903	chr15:79123663	NA	0.3	5.83	0.31	1.33e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.19	0.32	1.78e-9	Tonsillectomy;
CRC	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.88	0.31	9.86e-9	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg12516270	chr8:143859308	LYNX1	0.44	7.79	0.39	8.89e-14	Urinary tract infection frequency;
CRC	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.46	-7.42	-0.38	9.78e-13	Refractive error;
CRC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.26	6.56	0.34	2.05e-10	Iron status biomarkers;
CRC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs2298450	0.717	rs62232368	chr21:37626011	C/T	cg02919814	chr21:37666008	DOPEY2	-0.5	-6.58	-0.34	1.84e-10	Schizophrenia;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg05021743	chr1:151810893	C2CD4D;LOC100132111	0.24	6.37	0.33	6.46e-10	Body mass index;
CRC	cis	rs12580194	0.593	rs115471673	chr12:55766516	A/G	cg23425280	chr12:56401806	NA	0.47	5.74	0.3	2.13e-8	Cancer;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.56	-7.67	-0.39	1.99e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs858239	1.000	rs199347	chr7:23293746	A/G	cg00469287	chr7:23338798	C7orf30	0.42	5.61	0.3	4.3e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg15848620	chr12:58087721	OS9	-0.64	-8.82	-0.44	6.71e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.47	5.77	0.3	1.83e-8	Metabolite levels;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg21251018	chr6:28226885	NKAPL	0.45	6.37	0.33	6.32e-10	Parkinson's disease;
CRC	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg05874882	chr4:1763078	NA	-0.38	-7.27	-0.37	2.67e-12	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs7173389	0.551	rs75372618	chr15:73680843	A/G	cg01796676	chr15:73680284	NA	0.59	5.84	0.31	1.28e-8	Resting heart rate;
CRC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.36	-6.91	-0.36	2.51e-11	Iron status biomarkers;
CRC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.5	9.46	0.46	6e-19	Alcohol dependence;
CRC	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.53	6.88	0.35	2.99e-11	Alzheimer's disease (survival time);
CRC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-7.23	-0.37	3.46e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg02683197	chr6:28174875	NA	0.75	9.8	0.48	4.46e-20	Parkinson's disease;
CRC	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg05540913	chr6:167530185	CCR6	-0.4	-7.32	-0.37	1.91e-12	Primary biliary cholangitis;
CRC	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.58	-6.22	-0.32	1.55e-9	Coronary artery disease;
CRC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg25985355	chr7:65971099	NA	0.51	5.77	0.3	1.81e-8	Diabetic kidney disease;
CRC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.44	-0.5	3.12e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg21770322	chr7:97807741	LMTK2	0.52	8.52	0.43	5.7e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.64	-10.44	-0.5	3.06e-22	Dental caries;
CRC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.23	-0.32	1.43e-9	Menopause (age at onset);
CRC	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.41	-6.97	-0.36	1.76e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg11212589	chr17:38028394	ZPBP2	0.35	6.15	0.32	2.26e-9	Asthma;
CRC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg02683197	chr6:28174875	NA	0.73	10.73	0.51	3.07e-23	Cardiac Troponin-T levels;
CRC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.01	-0.4	1.96e-14	Monocyte percentage of white cells;
CRC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-6.04	-0.32	4.11e-9	Crohn's disease;
CRC	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-0.92	-7.3	-0.37	2.14e-12	Putamen volume;
CRC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-9.23	-0.45	3.49e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2462686	1.000	rs788765	chr7:45996985	C/G	cg23193639	chr7:45961078	IGFBP3	-0.38	-5.9	-0.31	9.01e-9	Major depressive disorder;
CRC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.62	-7.7	-0.39	1.5700000000000001e-13	Schizophrenia;
CRC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg04320405	chr7:131012679	MKLN1	-0.44	-6.0	-0.31	5.27e-9	Parkinson's disease;
CRC	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	1.14	17.34	0.69	2.66e-48	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.73	-11.19	-0.53	7.47e-25	Tonsillectomy;
CRC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.94	-13.05	-0.58	1.21e-31	Vitiligo;
CRC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.97	0.52	4.49e-24	Motion sickness;
CRC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.31	-0.33	9.25e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.59	-10.21	-0.49	1.99e-21	Iron status biomarkers;
CRC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.47	-6.56	-0.34	2.14e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg15448220	chr1:150897856	SETDB1	0.42	5.99	0.31	5.36e-9	Tonsillectomy;
CRC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07362569	chr17:61921086	SMARCD2	0.36	5.6	0.3	4.41e-8	Prudent dietary pattern;
CRC	trans	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg26043149	chr18:55253948	FECH	-0.5	-7.71	-0.39	1.51e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.67	8.39	0.42	1.44e-15	Menarche (age at onset);
CRC	cis	rs16975963	0.644	rs7248397	chr19:38133211	A/G	cg15135657	chr19:38346511	NA	-0.45	-6.28	-0.33	1.06e-9	Longevity;
CRC	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.51	7.21	0.37	3.87e-12	Ovarian reserve;
CRC	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.66	-7.1	-0.36	7.51e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.79	9.0	0.44	1.83e-17	Uric acid levels;
CRC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.56	-7.64	-0.39	2.37e-13	Monobrow;
CRC	cis	rs7932354	0.528	rs4752962	chr11:47141670	C/G	cg03339077	chr11:47165057	C11orf49	-0.46	-6.36	-0.33	6.65e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs7692995	1.000	rs16896074	chr4:17947873	T/C	cg08925142	chr4:18023851	LCORL	-0.5	-5.62	-0.3	4.15e-8	Height;
CRC	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg11530693	chr1:120165357	ZNF697	0.48	6.14	0.32	2.35e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	trans	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg10756647	chr7:56101905	PSPH	0.75	7.85	0.4	6.01e-14	Diabetic kidney disease;
CRC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg10645314	chr2:3704589	ALLC	-0.55	-6.45	-0.34	4.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02591199	chr4:113066609	C4orf32	0.42	6.27	0.33	1.12e-9	Schizophrenia;
CRC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-6.67	-0.35	1.05e-10	Height;
CRC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg20885578	chr2:198174922	NA	0.4	6.2	0.32	1.69e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7605827	0.930	rs6750232	chr2:15714958	C/T	cg19274914	chr2:15703543	NA	0.41	6.15	0.32	2.25e-9	Educational attainment (years of education);
CRC	cis	rs1223397	0.651	rs2496148	chr6:13313553	A/G	cg07912922	chr6:13274314	PHACTR1	0.37	5.81	0.3	1.48e-8	Blood pressure;
CRC	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg06632207	chr12:54070931	ATP5G2	0.37	6.25	0.33	1.26e-9	Height;
CRC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.65	0.39	2.24e-13	Height;
CRC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21963583	chr11:68658836	MRPL21	0.37	6.59	0.34	1.76e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.24	0.33	1.33e-9	Life satisfaction;
CRC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.55	8.74	0.43	1.18e-16	Caffeine consumption;
CRC	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.86	-0.31	1.15e-8	Reticulocyte fraction of red cells;
CRC	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.47	8.43	0.42	1.08e-15	Blood metabolite ratios;
CRC	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.61	9.82	0.48	3.93e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs10971721	0.822	rs10971764	chr9:33880100	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg09835421	chr16:68378352	PRMT7	-0.73	-7.6	-0.39	3.1e-13	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22776125	chr6:167041314	RPS6KA2	0.44	6.34	0.33	7.61e-10	Response to antipsychotic treatment;
CRC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg04025307	chr7:1156635	C7orf50	0.64	6.66	0.34	1.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.8	-11.25	-0.53	4.66e-25	Bipolar disorder;
CRC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	6.69	0.35	9.72e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.6	8.36	0.42	1.83e-15	Plasminogen activator inhibitor type 1 levels (PAI-1);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09423085	chr2:68478351	PPP3R1	0.41	5.99	0.31	5.42e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	6.96	0.36	1.9e-11	Diisocyanate-induced asthma;
CRC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.63	13.15	0.59	4.91e-32	Schizophrenia;
CRC	cis	rs2742417	0.967	rs1883096	chr3:45750015	C/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	8e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg26816564	chr1:7831052	VAMP3	0.58	6.32	0.33	8.47e-10	Inflammatory bowel disease;
CRC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg21153622	chr11:89784906	NA	-0.38	-5.96	-0.31	6.54e-9	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03403386	chr16:69373069	COG8;NIP7	0.45	6.59	0.34	1.76e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.54	-7.49	-0.38	6.26e-13	Corneal structure;
CRC	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	9.48	0.46	5.18e-19	Migraine;Coronary artery disease;
CRC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg05623727	chr3:50126028	RBM5	-0.4	-6.09	-0.32	3.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.47	-7.11	-0.37	7.21e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.67	-9.04	-0.45	1.41e-17	Facial morphology (factor 19);
CRC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg02741985	chr17:80059408	CCDC57	-0.41	-6.56	-0.34	2.03e-10	Life satisfaction;
CRC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.57	6.39	0.33	5.7e-10	Bipolar disorder;
CRC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.64	-9.86	-0.48	3.01e-20	Cognitive function;
CRC	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.49	6.78	0.35	5.73e-11	Eosinophil percentage of white cells;
CRC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.44	-6.59	-0.34	1.7e-10	Cognitive test performance;
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg24463073	chr6:118973353	C6orf204	0.51	6.75	0.35	6.86e-11	Diastolic blood pressure;
CRC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.54	8.73	0.43	1.29e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg03037974	chr15:76606532	NA	-0.51	-7.64	-0.39	2.34e-13	Blood metabolite levels;
CRC	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg21153622	chr11:89784906	NA	0.43	6.9	0.36	2.71e-11	HDL cholesterol;
CRC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-7.09	-0.36	8.38e-12	Response to antipsychotic treatment;
CRC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg03013999	chr17:37608204	MED1	-0.49	-7.62	-0.39	2.81e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.75	0.39	1.19e-13	Menopause (age at onset);
CRC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.79	13.51	0.6	2.13e-33	Menopause (age at onset);
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.46	6.71	0.35	8.56e-11	Longevity;Endometriosis;
CRC	cis	rs12760731	0.720	rs12022731	chr1:178416358	A/G	cg00404053	chr1:178313656	RASAL2	0.96	10.09	0.49	4.81e-21	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19098826	chr2:32581711	BIRC6	0.5	7.23	0.37	3.33e-12	Response to antipsychotic treatment;
CRC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.58	-0.75	4.47e-61	Myeloid white cell count;
CRC	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.6	-7.24	-0.37	3.12e-12	Breast cancer;
CRC	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	7.4	0.38	1.13e-12	Coronary artery disease;
CRC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.68	-10.3	-0.49	9.57e-22	Initial pursuit acceleration;
CRC	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	6.35	0.33	7.2e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg00246817	chr9:123691163	NA	-0.47	-5.92	-0.31	8.01e-9	Rheumatoid arthritis;
CRC	cis	rs9287719	0.624	rs10211190	chr2:10725428	A/G	cg00105475	chr2:10696890	NA	0.45	6.98	0.36	1.62e-11	Prostate cancer;
CRC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg12172441	chr6:28176163	NA	0.54	7.07	0.36	9.53e-12	Parkinson's disease;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg21251018	chr6:28226885	NKAPL	0.49	7.47	0.38	7.1e-13	Parkinson's disease;
CRC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.66	8.82	0.44	6.68e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.76	11.9	0.55	2.17e-27	Height;
CRC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	7.12	0.37	6.78e-12	Renal function-related traits (BUN);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00167275	chr10:88854588	FAM35A;GLUD1	0.41	6.57	0.34	2e-10	Interleukin-6 levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19022667	chr13:50367295	KPNA3	0.47	6.84	0.35	3.82e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.77	-0.39	9.8e-14	Bipolar disorder;
CRC	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.74	0.35	7.32e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.92	-0.31	7.98e-9	Red blood cell count;
CRC	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.64	9.7	0.47	1e-19	Longevity;Endometriosis;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg20933634	chr6:27740509	NA	0.45	6.01	0.31	4.94e-9	Parkinson's disease;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg26304593	chr6:42947056	PEX6	-0.46	-6.76	-0.35	6.47e-11	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-5.84	-0.31	1.23e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.53	0.34	2.56e-10	Tonsillectomy;
CRC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.02	0.31	4.69e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg05639522	chr1:247681581	NA	-0.5	-8.3	-0.42	2.71e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.53	7.02	0.36	1.26e-11	Obesity-related traits;
CRC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-7.26	-0.37	2.84e-12	Self-reported allergy;
CRC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.79	10.59	0.5	9.23e-23	Cerebrospinal P-tau181p levels;
CRC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg18230493	chr5:56204884	C5orf35	-0.4	-5.67	-0.3	3.14e-8	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.25	-0.41	3.82e-15	Recombination measurement;
CRC	cis	rs7113874	0.569	rs11041962	chr11:8549623	C/T	cg02811074	chr11:8615871	STK33	-0.36	-6.09	-0.32	3.19e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.77	14.36	0.62	1.26e-36	Prudent dietary pattern;
CRC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.54	-0.34	2.32e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.53	8.18	0.41	6.45e-15	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg16606324	chr3:10149918	C3orf24	0.48	7.09	0.36	8.29e-12	Alzheimer's disease;
CRC	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg01620082	chr3:125678407	NA	0.81	6.7	0.35	8.78e-11	Depression;
CRC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.58	10.4	0.5	4.36e-22	Multiple system atrophy;
CRC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	12.11	0.56	3.6e-28	Nonalcoholic fatty liver disease;
CRC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	20.21	0.74	1.29e-59	Prudent dietary pattern;
CRC	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg22495460	chr2:25135724	ADCY3	0.66	11.01	0.52	3.24e-24	Body mass index in non-asthmatics;
CRC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.46	0.46	5.91e-19	Bladder cancer;
CRC	cis	rs9478638	0.507	rs2184406	chr6:155629678	T/C	cg06694381	chr6:155569200	TIAM2	-0.47	-6.14	-0.32	2.37e-9	Electroencephalogram traits;
CRC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.47	6.76	0.35	6.35e-11	Emphysema distribution in smoking;
CRC	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg13615338	chr4:55094005	PDGFRA	0.4	5.83	0.31	1.35e-8	Corneal astigmatism;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg12172441	chr6:28176163	NA	0.47	6.19	0.32	1.75e-9	Parkinson's disease;
CRC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.59	0.34	1.73e-10	Hip circumference adjusted for BMI;
CRC	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg15123519	chr2:136567270	LCT	-0.33	-6.32	-0.33	8.57e-10	Mosquito bite size;
CRC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.11	0.32	2.74e-9	Aortic root size;
CRC	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg21851534	chr17:3907994	ZZEF1	-0.39	-6.48	-0.34	3.36e-10	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06236748	chr11:71935846	INPPL1	0.48	6.73	0.35	7.58e-11	Response to antipsychotic treatment;
CRC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.85	-0.31	1.17e-8	Gout;Renal underexcretion gout;
CRC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg23815491	chr16:72088622	HP	0.51	7.65	0.39	2.3e-13	Fibrinogen levels;
CRC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.5	7.82	0.4	7.14e-14	Red blood cell count;
CRC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	5.94	0.31	7.27e-9	Monocyte percentage of white cells;
CRC	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.63	-9.38	-0.46	1.14e-18	Ulcerative colitis;
CRC	cis	rs17155006	0.655	rs93619	chr7:107726833	C/T	cg05962710	chr7:107745446	LAMB4	-0.35	-5.76	-0.3	1.92e-8	Pneumococcal bacteremia;
CRC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.68	-9.66	-0.47	1.3e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg07423050	chr13:99094983	FARP1	0.41	6.6	0.34	1.69e-10	Longevity;
CRC	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg13385794	chr1:248469461	NA	0.37	6.56	0.34	2.14e-10	Common traits (Other);
CRC	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.15	-0.41	7.52e-15	Morning vs. evening chronotype;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01516881	chr6:292596	DUSP22	-0.57	-8.38	-0.42	1.52e-15	Menopause (age at onset);
CRC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.65	-0.34	1.21e-10	Daytime sleep phenotypes;
CRC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg26102564	chr10:131424627	MGMT	0.38	5.63	0.3	3.9e-8	Response to temozolomide;
CRC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-14.03	-0.61	2.33e-35	Exhaled nitric oxide output;
CRC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg18833306	chr6:118973337	C6orf204	0.45	5.63	0.3	3.95e-8	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22926526	chr14:31028192	G2E3	0.37	5.97	0.31	6.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg07636037	chr3:49044803	WDR6	-0.82	-6.67	-0.35	1.06e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs11673344	0.583	rs10421436	chr19:37885503	T/C	cg11669319	chr19:37771680	NA	-0.41	-5.78	-0.3	1.73e-8	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	7.96	0.4	2.78e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18679712	chr3:14989672	NR2C2	0.42	6.35	0.33	7.3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg22638593	chr5:131593259	PDLIM4	0.32	6.02	0.32	4.54e-9	Blood metabolite levels;
CRC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg18764771	chr6:116381957	FRK	0.24	6.97	0.36	1.77e-11	Cholesterol, total;LDL cholesterol;
CRC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11645453	chr3:52864694	ITIH4	0.36	6.26	0.33	1.17e-9	Bipolar disorder;
CRC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.81	9.48	0.46	5.4e-19	HIV-1 control;
CRC	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.65	-9.68	-0.47	1.12e-19	Acne (severe);
CRC	cis	rs6743376	0.556	rs2515398	chr2:113819334	A/C	cg24553058	chr2:113831203	IL1F10	0.43	6.96	0.36	1.81e-11	Inflammatory biomarkers;
CRC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.39	-6.85	-0.35	3.7e-11	Reticulocyte fraction of red cells;
CRC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	0.95	18.47	0.71	8.95e-53	Height;
CRC	cis	rs9783347	1.000	rs4150655	chr11:18375164	A/T	cg15585147	chr11:18324498	HPS5	-0.44	-6.25	-0.33	1.28e-9	Pancreatic cancer;
CRC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.85	14.91	0.63	9.19e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg24289452	chr6:170231220	NA	-0.78	-6.96	-0.36	1.86e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.6	0.39	3.07e-13	Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.22	-0.49	1.8e-21	Bipolar disorder;
CRC	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg08314208	chr16:67682810	RLTPR	-0.49	-5.79	-0.3	1.65e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg01483505	chr11:975446	AP2A2	0.45	7.44	0.38	9.1e-13	Alzheimer's disease (late onset);
CRC	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg12516270	chr8:143859308	LYNX1	-0.4	-6.23	-0.33	1.39e-9	Urinary tract infection frequency;
CRC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.71	0.35	8.37e-11	Lung cancer;
CRC	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	1.0	18.55	0.71	4.56e-53	Gut microbiome composition (winter);
CRC	cis	rs10743315	0.732	rs17271857	chr12:19458136	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.66	-6.31	-0.33	8.99e-10	Gut microbiota (bacterial taxa);
CRC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.5	8.31	0.42	2.58e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg06462663	chr19:18546047	ISYNA1	0.52	7.94	0.4	3.13e-14	Breast cancer;
CRC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.38	-11.24	-0.53	4.91e-25	Plateletcrit;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04132851	chr1:85155548	SSX2IP	-0.49	-6.05	-0.32	3.89e-9	Diisocyanate-induced asthma;
CRC	cis	rs72627123	0.867	rs73301479	chr14:74467757	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.71	5.92	0.31	8.3e-9	Morning vs. evening chronotype;
CRC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg26762873	chr11:5879799	OR52E8	-0.4	-5.88	-0.31	1.01e-8	DNA methylation (variation);
CRC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.48	7.86	0.4	5.42e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.18	-0.32	1.86e-9	Aortic root size;
CRC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg12273811	chr6:28175739	NA	0.51	5.71	0.3	2.51e-8	Parkinson's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17145281	chr11:62420267	INTS5	0.47	6.62	0.34	1.47e-10	Response to antipsychotic treatment;
CRC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.6	8.3	0.42	2.66e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.65	10.64	0.51	6.48e-23	Platelet count;
CRC	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg04586622	chr2:25135609	ADCY3	-0.43	-7.19	-0.37	4.46e-12	Body mass index;
CRC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.32	-5.85	-0.31	1.16e-8	Menarche (age at onset);
CRC	cis	rs9648716	1.000	rs2706774	chr7:140538127	C/T	cg10747023	chr7:140774559	NA	0.44	5.76	0.3	1.94e-8	Type 2 diabetes;
CRC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.55	6.76	0.35	6.23e-11	Body mass index (adult);
CRC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.43	6.14	0.32	2.41e-9	Obesity-related traits;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.64	9.93	0.48	1.67e-20	Lymphocyte counts;
CRC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.69	-0.51	4.18e-23	Alzheimer's disease;
CRC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg25452165	chr22:42524984	CYP2D6	0.43	6.51	0.34	2.88e-10	Schizophrenia;
CRC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.22	-0.32	1.5e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.55	7.51	0.38	5.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg11833968	chr6:79620685	NA	-0.37	-6.27	-0.33	1.16e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.1	0.32	2.99e-9	Obesity-related traits;
CRC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.24e-8	Life satisfaction;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03901462	chr11:62572874	NXF1	-0.44	-6.51	-0.34	2.75e-10	Myopia (pathological);
CRC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.71	12.12	0.56	3.47e-28	Gout;
CRC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.53	-7.99	-0.4	2.27e-14	Aortic root size;
CRC	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-7.98	-0.4	2.39e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.58	8.32	0.42	2.39e-15	Coronary artery disease;
CRC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.61	0.34	1.58e-10	Schizophrenia;
CRC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg23920097	chr1:209922102	NA	-0.52	-6.53	-0.34	2.55e-10	Red blood cell count;
CRC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.68	-11.38	-0.53	1.53e-25	Caffeine consumption;
CRC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.78	9.46	0.46	5.95e-19	Lung function (FEV1/FVC);
CRC	cis	rs6496667	0.865	rs8035602	chr15:90909197	G/A	cg04176472	chr15:90893244	GABARAPL3	0.6	8.21	0.41	5.11e-15	Rheumatoid arthritis;
CRC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.6	-0.34	1.68e-10	Reticulocyte fraction of red cells;
CRC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg07212818	chr11:638076	DRD4	-0.48	-6.11	-0.32	2.81e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.61	-9.2	-0.45	4.29e-18	Coronary artery disease;
CRC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.43	-9.48	-0.46	5.3e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg15448220	chr1:150897856	SETDB1	-0.4	-5.75	-0.3	2.06e-8	Tonsillectomy;
CRC	cis	rs4727963	0.792	rs12667916	chr7:122740976	A/G	cg03640110	chr7:122635026	TAS2R16	0.35	6.33	0.33	8.19e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.67	-0.3	3.11e-8	Type 2 diabetes;
CRC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg19223190	chr17:80058835	NA	-0.45	-6.98	-0.36	1.64e-11	Life satisfaction;
CRC	cis	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg27395922	chr11:50257633	LOC441601	0.35	5.74	0.3	2.16e-8	Coronary artery disease;
CRC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.47	-6.14	-0.32	2.4e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1760803	0.754	rs2340473	chr1:154225344	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.36	6.22	0.32	1.55e-9	Nicotine dependence;
CRC	cis	rs6585424	1.000	rs61860025	chr10:81925554	G/T	cg11900509	chr10:81946545	ANXA11	-0.76	-9.32	-0.46	1.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.68	10.44	0.5	3.06e-22	Longevity;Endometriosis;
CRC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.43	-0.33	4.37e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.69	9.69	0.47	1.04e-19	Alzheimer's disease;
CRC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.88	-14.88	-0.63	1.18e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.46	6.83	0.35	4.22e-11	Emphysema distribution in smoking;
CRC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.52	-7.76	-0.39	1.06e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg00601450	chr5:74908170	NA	-0.41	-5.75	-0.3	2.08e-8	Age-related disease endophenotypes;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.48	6.51	0.34	2.84e-10	Pulse pressure;
CRC	cis	rs711830	1.000	rs2249131	chr2:177032095	C/T	cg13092806	chr2:177043255	NA	0.73	8.76	0.43	1.07e-16	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CRC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.42	0.33	4.76e-10	Renal cell carcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16565832	chr11:16760091	C11orf58	0.39	6.41	0.33	4.91e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10905065	0.717	rs11254266	chr10:5750078	G/T	cg11519256	chr10:5708881	ASB13	0.43	5.96	0.31	6.33e-9	Menopause (age at onset);
CRC	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.22	-0.37	3.55e-12	Putamen volume;
CRC	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg25173405	chr17:45401733	C17orf57	0.45	7.11	0.37	7.11e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8141797	0.901	rs4822472	chr22:24468123	C/A	cg20894457	chr22:24584366	SUSD2	-0.61	-7.43	-0.38	9.27e-13	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.57	5.81	0.31	1.47e-8	Fat distribution (HIV);
CRC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.9	16.6	0.68	2.14e-45	Intelligence (multi-trait analysis);
CRC	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.92	-0.31	8.27e-9	Orofacial clefts;
CRC	cis	rs7932354	0.502	rs7118546	chr11:47087128	C/G	cg19486271	chr11:47235900	DDB2	-0.45	-6.58	-0.34	1.84e-10	Bone mineral density (hip);Bone mineral density;
CRC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	11.83	0.55	3.68e-27	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.92	0.44	3.3e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.79	-0.39	8.94e-14	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.6	8.15	0.41	7.55e-15	Menopause (age at onset);
CRC	cis	rs9039	1.000	rs17567434	chr16:9221447	C/G	cg08831531	chr16:9218945	NA	-0.55	-7.0	-0.36	1.48e-11	Menopause (age at onset);
CRC	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg14631576	chr9:95140430	CENPP	-0.3	-5.76	-0.3	1.92e-8	Height;
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg08222913	chr3:52553049	STAB1	-0.43	-8.78	-0.44	9.42e-17	Electroencephalogram traits;
CRC	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg16099169	chr2:106886729	NA	-0.38	-6.56	-0.34	2.06e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.75	0.39	1.15e-13	Coronary artery disease;
CRC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.91	16.63	0.68	1.66e-45	Intelligence (multi-trait analysis);
CRC	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-13.34	-0.59	9.15e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	trans	rs12517041	0.935	rs10053181	chr5:23293265	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg02683197	chr6:28174875	NA	0.71	9.8	0.48	4.55e-20	Parkinson's disease;
CRC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg09473613	chr1:24152604	HMGCL	0.35	5.67	0.3	3.09e-8	Immature fraction of reticulocytes;
CRC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-6.07	-0.32	3.61e-9	Blood metabolite levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08188903	chr14:100680826	NA	-0.41	-6.01	-0.31	4.89e-9	Daytime sleep phenotypes;
CRC	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg27398640	chr15:77910606	LINGO1	0.44	7.97	0.4	2.61e-14	Type 2 diabetes;
CRC	cis	rs9463078	0.608	rs6925017	chr6:44950828	T/C	cg25276700	chr6:44698697	NA	-0.25	-6.02	-0.31	4.75e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.36	-6.86	-0.35	3.39e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg03623178	chr6:28175578	NA	1.0	15.19	0.64	7.35e-40	Depression;
CRC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg03030879	chr14:75389066	RPS6KL1	-0.43	-6.73	-0.35	7.72e-11	Height;
CRC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.84	-0.48	3.4e-20	Schizophrenia;
CRC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg19610905	chr11:61596333	FADS2	-0.62	-7.17	-0.37	5.07e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg26043149	chr18:55253948	FECH	-0.53	-8.2	-0.41	5.61e-15	Bone mineral density;
CRC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.69	11.52	0.54	4.94e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3902035	1.000	rs3902035	chr6:119000232	T/C	cg01339444	chr6:118972232	C6orf204	0.44	5.61	0.3	4.4e-8	QT interval;
CRC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.53	5.98	0.31	5.69e-9	Menarche (age at onset);
CRC	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.2	-0.41	5.42e-15	Metabolite levels (Pyroglutamine);
CRC	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-5.98	-0.31	5.74e-9	Myopia (pathological);
CRC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.39	0.71	1.94e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg10729496	chr3:10149963	C3orf24	0.49	6.78	0.35	5.57e-11	Alzheimer's disease;
CRC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.88	-0.4	4.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.55	6.68	0.35	1.03e-10	Lymphocyte counts;
CRC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg22676075	chr6:135203613	NA	0.42	6.41	0.33	5.16e-10	Red blood cell count;
CRC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg23018236	chr17:30244563	NA	-0.67	-8.0	-0.4	2.13e-14	Hip circumference adjusted for BMI;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17597744	chr8:53627099	RB1CC1	0.42	7.05	0.36	1.05e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.56	8.52	0.42	6.02e-16	Intelligence (multi-trait analysis);
CRC	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg18131467	chr2:239335373	ASB1	-0.69	-6.17	-0.32	1.99e-9	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg26741380	chr15:41871084	TYRO3	-0.46	-6.54	-0.34	2.4e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.45	6.2	0.32	1.7e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.83	0.31	1.34e-8	Gout;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg21251018	chr6:28226885	NKAPL	0.48	6.33	0.33	7.86e-10	Depression;
CRC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg16558177	chr4:4109446	NA	-0.48	-6.19	-0.32	1.84e-9	Blood pressure (smoking interaction);
CRC	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.48	-7.42	-0.38	1.01e-12	Red blood cell count;
CRC	trans	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg04077850	chr5:125800366	GRAMD3	0.38	6.44	0.33	4.14e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg08999081	chr20:33150536	PIGU	0.45	5.77	0.3	1.8e-8	Neuroticism;
CRC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-8.58	-0.43	3.71e-16	Monocyte percentage of white cells;
CRC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg15123519	chr2:136567270	LCT	0.33	6.48	0.34	3.42e-10	Mosquito bite size;
CRC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.53	7.62	0.39	2.82e-13	High light scatter reticulocyte count;
CRC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.91	-17.84	-0.7	2.75e-50	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg20512303	chr5:131592959	PDLIM4	-0.41	-7.23	-0.37	3.3e-12	Breast cancer;
CRC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.68	-7.81	-0.4	7.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.87	0.35	3.17e-11	Major depressive disorder;
CRC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg05304507	chr6:116381966	FRK	0.31	8.54	0.43	5.19e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.82	11.42	0.53	1.16e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs12753569	0.720	rs4381138	chr1:76509783	G/A	cg00791851	chr1:76518896	NA	0.38	6.83	0.35	4.15e-11	Personality dimensions;
CRC	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg05044414	chr3:183734942	ABCC5	0.45	7.64	0.39	2.35e-13	Anterior chamber depth;
CRC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.52	7.3	0.37	2.14e-12	Monocyte count;
CRC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg26893134	chr6:116381904	FRK	0.26	7.62	0.39	2.7e-13	Cholesterol, total;LDL cholesterol;
CRC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg08999081	chr20:33150536	PIGU	0.45	5.71	0.3	2.56e-8	Protein C levels;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.67	7.18	0.37	4.78e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg19223190	chr17:80058835	NA	-0.39	-6.06	-0.32	3.63e-9	Life satisfaction;
CRC	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.59	7.84	0.4	6.24e-14	Mammographic density (dense area);
CRC	cis	rs629535	0.773	rs686683	chr8:70070364	G/A	cg26132723	chr8:70041827	NA	0.35	5.77	0.3	1.8e-8	Dupuytren's disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15094104	chr5:133406808	NA	0.45	6.65	0.34	1.21e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6961069	0.745	rs1527479	chr7:80272568	C/T	cg04458919	chr7:80252533	CD36	-0.37	-6.57	-0.34	1.97e-10	Platelet count;
CRC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg25834613	chr7:1915315	MAD1L1	-0.44	-6.41	-0.33	5.17e-10	Neuroticism;
CRC	cis	rs55702914	0.628	rs56718086	chr2:198261596	A/G	cg10820045	chr2:198174542	NA	0.32	5.72	0.3	2.35e-8	Major depression and alcohol dependence;
CRC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.3	-0.33	9.6e-10	Neuroticism;
CRC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.51	8.13	0.41	9e-15	Red blood cell count;
CRC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.3	-0.33	9.34e-10	Bipolar disorder;
CRC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.55	0.54	3.78e-26	Menarche (age at onset);
CRC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.52	9.13	0.45	7.03e-18	Hypertriglyceridemia;
CRC	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.64	9.62	0.47	1.88e-19	Corneal astigmatism;
CRC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.75	-8.85	-0.44	5.57e-17	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.62	0.47	1.83e-19	Heart rate;
CRC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-5.97	-0.31	6.05e-9	Total body bone mineral density;
CRC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.37	2.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs524281	0.731	rs10791841	chr11:65808587	T/C	cg16950941	chr11:66035639	RAB1B	-0.52	-5.77	-0.3	1.81e-8	Electroencephalogram traits;
CRC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.66	-10.78	-0.51	2.02e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.83	-10.58	-0.5	1e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	13.66	0.6	6.03e-34	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24229819	chr17:41856238	DUSP3	0.48	6.7	0.35	8.9e-11	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.63	-0.39	2.55e-13	Blood metabolite levels;
CRC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.26	-0.33	1.21e-9	Lung cancer;
CRC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.84	10.36	0.5	5.83e-22	Eosinophil percentage of granulocytes;
CRC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.44	-7.89	-0.4	4.44e-14	Reticulocyte fraction of red cells;
CRC	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg13175173	chr14:55914753	NA	-0.52	-9.9	-0.48	2.06e-20	Pediatric bone mineral content (femoral neck);
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs6460942	0.908	rs6978877	chr7:12232690	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.05	-0.32	4.03e-9	Coronary artery disease;
CRC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg10298567	chr3:47292165	KIF9	-0.4	-6.47	-0.34	3.55e-10	Colorectal cancer;
CRC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg11212589	chr17:38028394	ZPBP2	0.43	8.03	0.4	1.71e-14	Self-reported allergy;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.68	-0.43	1.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	7.93	0.4	3.39e-14	Response to antipsychotic treatment;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.08	-0.36	8.77e-12	Lymphocyte counts;
CRC	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.63	11.42	0.53	1.14e-25	Blood metabolite ratios;
CRC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.83	-10.74	-0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg23136738	chr11:925521	AP2A2	-0.42	-6.98	-0.36	1.65e-11	Alzheimer's disease (late onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01466967	chr5:59995837	DEPDC1B	0.41	6.1	0.32	2.92e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg02741985	chr17:80059408	CCDC57	-0.44	-7.15	-0.37	5.61e-12	Life satisfaction;
CRC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg18479299	chr3:125709523	NA	-0.49	-6.44	-0.33	4.17e-10	Blood pressure (smoking interaction);
CRC	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg25886479	chr11:50257625	LOC441601	-0.38	-6.76	-0.35	6.18e-11	Height;
CRC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg14828511	chr1:107599125	PRMT6	0.55	7.54	0.38	4.58e-13	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg16989086	chr20:62203971	PRIC285	-0.5	-6.48	-0.34	3.44e-10	Atopic dermatitis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05281544	chr6:21597055	SOX4	0.39	6.08	0.32	3.31e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	11.32	0.53	2.59e-25	Motion sickness;
CRC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg16102536	chr7:156981717	UBE3C	0.4	6.57	0.34	2.02e-10	Body mass index;
CRC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg21399703	chr1:247681439	NA	0.49	7.71	0.39	1.46e-13	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11928684	chr11:47291227	MADD	0.39	6.21	0.32	1.63e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg03678062	chr6:149772716	ZC3H12D	0.35	6.42	0.33	4.71e-10	Dupuytren's disease;
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.57e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs911119	0.955	rs6048946	chr20:23602307	G/T	cg16589663	chr20:23618590	CST3	0.47	6.5	0.34	2.92e-10	Chronic kidney disease;
CRC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs12476592	0.571	rs964903	chr2:63741548	C/T	cg10828910	chr2:63850056	LOC388955	0.45	5.63	0.3	3.92e-8	Childhood ear infection;
CRC	cis	rs1656402	1.000	rs1190442	chr2:233422205	A/C	cg03852847	chr2:233439513	NA	0.42	7.15	0.37	5.72e-12	Non-small cell lung cancer (survival);
CRC	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.63	9.05	0.45	1.26e-17	Uric acid levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00269115	chr1:23695530	C1orf213;ZNF436	0.44	6.35	0.33	6.99e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.64	7.84	0.4	6.51e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.86	10.21	0.49	1.99e-21	Alzheimer's disease;
CRC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.64	-10.23	-0.49	1.65e-21	Glaucoma (primary open-angle);
CRC	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg11247378	chr22:39784982	NA	0.31	5.84	0.31	1.25e-8	IgG glycosylation;
CRC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg03959625	chr15:84868606	LOC388152	0.41	6.22	0.32	1.53e-9	Schizophrenia;
CRC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-7.61	-0.39	2.95e-13	Aortic root size;
CRC	cis	rs1564271	1.000	rs1564271	chr10:27011112	G/A	cg13837822	chr10:26931731	LOC731789	0.48	6.64	0.34	1.27e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg06470822	chr6:28175283	NA	-0.5	-6.94	-0.36	2.04e-11	Systemic lupus erythematosus;
CRC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg07090678	chr1:91966139	CDC7	-0.44	-6.89	-0.35	2.92e-11	Breast cancer;
CRC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.35	-0.5	6.63e-22	Body mass index;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.39	6.88	0.35	3.12e-11	Lung cancer;
CRC	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg18646521	chr2:111875858	NA	0.36	5.69	0.3	2.84e-8	Chronic lymphocytic leukemia;
CRC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.79	0.48	4.92e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg21280719	chr6:42927975	GNMT	-0.31	-5.81	-0.31	1.44e-8	Blood protein levels;
CRC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-8.91	-0.44	3.63e-17	IgG glycosylation;
CRC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10924970	0.870	rs12095886	chr1:235432249	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.77	0.3	1.83e-8	Asthma;
CRC	cis	rs16852403	0.583	rs6670912	chr1:178082410	C/T	cg00404053	chr1:178313656	RASAL2	0.63	8.03	0.4	1.79e-14	Childhood ear infection;
CRC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.53	-7.67	-0.39	1.97e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.08	0.45	1.04e-17	Parkinson's disease;
CRC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.36	-6.7	-0.35	9.23e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26378065	chr17:18585709	ZNF286B	0.41	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.54	-8.78	-0.44	9.19e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.54	-8.79	-0.44	8.63e-17	Coronary artery disease;
CRC	cis	rs7394190	0.748	rs2075641	chr10:75562108	G/A	cg07699608	chr10:75541558	CHCHD1	0.61	6.19	0.32	1.79e-9	Incident atrial fibrillation;
CRC	cis	rs10991814	0.920	rs78978656	chr9:94090130	G/A	cg14446406	chr9:93919335	NA	0.57	6.19	0.32	1.75e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.74	7.27	0.37	2.58e-12	Plasma clusterin levels;
CRC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	6.32	0.33	8.75e-10	Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg25164649	chr6:28176230	NA	0.72	9.1	0.45	9.16e-18	Depression;
CRC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.61	9.81	0.48	4.33e-20	Systemic lupus erythematosus;
CRC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.79	-11.97	-0.55	1.18e-27	Uric acid levels;
CRC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.84	12.03	0.55	6.88e-28	Cognitive function;
CRC	cis	rs732505	0.618	rs1337057	chr19:5676950	G/A	cg26242866	chr19:5711310	LONP1	0.68	6.69	0.35	9.36e-11	vWF and FVIII levels;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg06470822	chr6:28175283	NA	1.0	13.06	0.58	1.06e-31	Depression;
CRC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	13.1	0.59	7.65e-32	Chronic sinus infection;
CRC	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg16850897	chr7:100343110	ZAN	0.45	6.94	0.36	2.15e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs17767392	0.958	rs12885344	chr14:72003224	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.2	-0.37	4e-12	Mitral valve prolapse;
CRC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.07	-0.32	3.62e-9	Menopause (age at onset);
CRC	cis	rs9287719	0.649	rs10188373	chr2:10718802	A/G	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.55	-7.82	-0.4	7.27e-14	Cognitive ability;
CRC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.89	-0.44	4e-17	Platelet count;
CRC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg16102536	chr7:156981717	UBE3C	-0.4	-6.73	-0.35	7.4e-11	Body mass index;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg21177558	chr8:27677755	PBK	-0.37	-6.18	-0.32	1.92e-9	HDL cholesterol;
CRC	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.67	-0.3	3.09e-8	Blood protein levels;
CRC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg24505167	chr7:1915268	MAD1L1	-0.35	-5.73	-0.3	2.24e-8	Neuroticism;
CRC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.66	-9.83	-0.48	3.76e-20	Menopause (age at onset);
CRC	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	0.57	8.89	0.44	4.08e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	10.59	0.5	9.91e-23	Schizophrenia;
CRC	cis	rs720844	0.608	rs7592536	chr2:149346137	G/A	cg09247360	chr2:149335327	NA	0.48	6.35	0.33	7.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12252801	chr9:127951667	PPP6C	0.44	6.19	0.32	1.76e-9	Response to antipsychotic treatment;
CRC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg04025307	chr7:1156635	C7orf50	0.66	7.09	0.36	8.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.42	-13.38	-0.59	6.79e-33	Plateletcrit;
CRC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.75	10.31	0.49	8.55e-22	Glomerular filtration rate (creatinine);
CRC	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg04239558	chr2:103089729	SLC9A4	0.37	6.61	0.34	1.51e-10	Blood protein levels;
CRC	cis	rs2637266	0.600	rs11001844	chr10:78405461	A/G	cg18941641	chr10:78392320	NA	0.35	6.3	0.33	9.43e-10	Pulmonary function;
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.3	0.53	2.97e-25	Prudent dietary pattern;
CRC	cis	rs9311676	0.586	rs11707019	chr3:58398036	A/C	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	trans	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg10756647	chr7:56101905	PSPH	0.73	7.72	0.39	1.46e-13	Diabetic kidney disease;
CRC	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.48	-7.95	-0.4	3.03e-14	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.41	5.63	0.3	3.91e-8	Parkinson's disease;
CRC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.31	9.81e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.96	-17.02	-0.68	4.72e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg00976097	chr5:421733	AHRR	-0.45	-6.01	-0.31	5.02e-9	Cystic fibrosis severity;
CRC	cis	rs7192380	0.729	rs11648335	chr16:69597317	A/G	cg00738113	chr16:70207722	CLEC18C	-0.33	-5.71	-0.3	2.48e-8	Sjögren's syndrome;
CRC	trans	rs10242455	0.867	rs15524	chr7:99245914	A/G	cg09045935	chr12:6379348	NA	0.58	6.45	0.34	4.07e-10	Blood metabolite levels;
CRC	cis	rs12190007	0.846	rs9505962	chr6:169726667	A/G	cg16388071	chr6:169726476	NA	0.4	6.37	0.33	6.22e-10	Obesity-related traits;
CRC	cis	rs9462027	1.000	rs9689160	chr6:34749849	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.6	-0.3	4.42e-8	Systemic lupus erythematosus;
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg08347473	chr17:78092826	GAA	-0.37	-6.3	-0.33	9.48e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.77	8.44	0.42	1.01e-15	Systolic blood pressure;
CRC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.84	0.4	6.33e-14	Platelet count;
CRC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.78	0.35	5.48e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.44	6.37	0.33	6.51e-10	Emphysema distribution in smoking;
CRC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg24849736	chr1:201084428	NA	0.56	10.27	0.49	1.25e-21	Permanent tooth development;
CRC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.0	-0.31	5.34e-9	Diabetic kidney disease;
CRC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.64	-8.66	-0.43	2.11e-16	Refractive error;
CRC	cis	rs737008	0.922	rs376374	chr16:11370616	G/A	cg00044050	chr16:11439710	C16orf75	-0.46	-6.13	-0.32	2.55e-9	Obesity-related traits;
CRC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04731861	chr2:219085781	ARPC2	0.37	7.98	0.4	2.4e-14	Colorectal cancer;
CRC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs501120	0.925	rs559469	chr10:44752118	C/T	cg09554077	chr10:44749378	NA	-0.87	-13.03	-0.58	1.41e-31	Coronary artery disease;Coronary heart disease;
CRC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02290350	chr8:58132656	NA	-0.59	-7.0	-0.36	1.47e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.5	-10.94	-0.52	5.95e-24	Rheumatoid arthritis;
CRC	cis	rs3790844	0.501	rs12035139	chr1:199951850	G/A	cg07208853	chr1:200005219	NR5A2	0.34	9.01	0.45	1.66e-17	Pancreatic cancer;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.38	-0.33	6.12e-10	Longevity;Endometriosis;
CRC	cis	rs12999616	0.857	rs34459720	chr2:98325447	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.28	0.33	1.08e-9	Colorectal cancer;
CRC	trans	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg17903999	chr18:56338584	MALT1	0.42	6.68	0.35	1.05e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.36	0.38	1.53e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.71	0.35	8.62e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.56	0.38	4.18e-13	Motion sickness;
CRC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg16060761	chr17:80687452	NA	0.4	5.94	0.31	7.37e-9	Breast cancer;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.74	10.97	0.52	4.67e-24	Menarche (age at onset);
CRC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.09	-0.36	8.43e-12	Height;
CRC	trans	rs57506017	0.517	rs62435714	chr7:12254012	A/G	cg26461140	chr11:72811902	FCHSD2	0.61	6.97	0.36	1.76e-11	Neuroticism;
CRC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.57	7.76	0.39	1.1e-13	Alzheimer's disease;
CRC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-12.59	-0.57	5.97e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg19980929	chr12:42632907	YAF2	0.44	6.57	0.34	2.01e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs2944591	0.505	rs2592118	chr2:233792425	C/T	cg11972305	chr2:233791962	NGEF	-0.42	-6.63	-0.34	1.35e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg17788362	chr6:86352627	SYNCRIP	0.55	7.73	0.39	1.35e-13	Smooth-surface caries;
CRC	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.45	-6.64	-0.34	1.3e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-10.12	-0.49	3.77e-21	Multiple sclerosis;
CRC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg01657329	chr11:68192670	LRP5	-0.46	-6.55	-0.34	2.19e-10	Total body bone mineral density;
CRC	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg16077055	chr2:106428750	NCK2	0.39	5.64	0.3	3.74e-8	Addiction;
CRC	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg11553311	chr5:66541588	NA	0.48	8.12	0.41	9.49e-15	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg12842013	chr14:23755227	HOMEZ	0.48	6.56	0.34	2.03e-10	Anxiety disorder;
CRC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.77	9.81	0.48	4.41e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg03013999	chr17:37608204	MED1	0.47	7.14	0.37	6.13e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.54	8.77	0.44	9.91e-17	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18800192	chr19:42388471	ARHGEF1	0.4	6.44	0.33	4.33e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs16846053	0.786	rs72873645	chr2:162495047	G/A	cg01191114	chr3:48936118	SLC25A20	-0.67	-6.08	-0.32	3.35e-9	Blood osmolality (transformed sodium);
CRC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16405210	chr4:1374714	KIAA1530	-0.44	-6.05	-0.32	3.92e-9	Obesity-related traits;
CRC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.49	6.94	0.36	2.06e-11	Schizophrenia;
CRC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-6.53	-0.34	2.56e-10	Menopause (age at onset);
CRC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-0.82	-9.13	-0.45	7.35e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19862616	chr7:65841803	NCRNA00174	0.55	7.87	0.4	5.3e-14	Eotaxin levels;
CRC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.42	-5.99	-0.31	5.64e-9	Aortic root size;
CRC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg15205204	chr1:6545172	PLEKHG5	0.38	5.63	0.3	3.81e-8	Body mass index;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg04269497	chr6:167369491	RNASET2	-0.74	-6.05	-0.32	3.85e-9	Cognitive function;
CRC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09368129	chr5:140071347	HARS2;HARS	0.43	5.97	0.31	6.23e-9	Response to antipsychotic treatment;
CRC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg21466736	chr12:48725269	NA	-0.48	-7.36	-0.38	1.48e-12	Glycated hemoglobin levels;
CRC	cis	rs9308731	0.563	rs11899831	chr2:111932694	G/A	cg04202892	chr2:111875749	ACOXL	0.42	6.78	0.35	5.58e-11	Chronic lymphocytic leukemia;
CRC	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg03929089	chr4:120376271	NA	0.61	6.12	0.32	2.69e-9	Intraocular pressure;
CRC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.99	12.33	0.56	5.51e-29	Cerebrospinal P-tau181p levels;
CRC	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg24996280	chr8:143481281	TSNARE1	0.36	5.9	0.31	8.84e-9	Schizophrenia;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg21747405	chr11:67723411	NA	-0.59	-9.19	-0.45	4.46e-18	Blood pressure (smoking interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02980631	chr6:157008350	NA	-0.43	-6.63	-0.34	1.36e-10	Myopia (pathological);
CRC	cis	rs7632954	0.605	rs6794255	chr3:8522820	G/C	cg03495237	chr3:8533978	NA	0.36	6.58	0.34	1.9e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.67	11.81	0.55	4.35e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.65	8.48	0.42	7.95e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg06917634	chr15:78832804	PSMA4	0.45	6.73	0.35	7.66e-11	Sudden cardiac arrest;
CRC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.42	6.69	0.35	9.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.65	0.63	9.37e-38	Mean platelet volume;
CRC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.82	-0.31	1.43e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg20885578	chr2:198174922	NA	0.34	5.61	0.3	4.32e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.34	6.23	0.32	1.43e-9	Multiple sclerosis;
CRC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg06207120	chr15:45996521	NA	0.32	7.66	0.39	2.08e-13	Waist circumference;Weight;
CRC	cis	rs2811415	0.597	rs12695505	chr3:127791636	G/A	cg13719885	chr3:127795394	NA	-0.4	-6.01	-0.31	5.05e-9	Lung function (FEV1/FVC);
CRC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.12	-11.89	-0.55	2.32e-27	Breast cancer;
CRC	cis	rs12913538	0.547	rs4573888	chr15:62896704	A/G	cg09983546	chr15:62884068	NA	0.46	5.65	0.3	3.54e-8	Sleep depth;
CRC	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	5.85	0.31	1.2e-8	LDL cholesterol;
CRC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg00129232	chr17:37814104	STARD3	0.57	6.78	0.35	5.6e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.31	5.78e-9	Hemoglobin concentration;
CRC	cis	rs7605827	0.866	rs6752546	chr2:15630729	T/C	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.79	-0.3	1.62e-8	Daytime sleep phenotypes;
CRC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	7.49	0.38	6.26e-13	Personality dimensions;
CRC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg03013999	chr17:37608204	MED1	-0.48	-7.51	-0.38	5.62e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.59e-12	Life satisfaction;
CRC	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.7	0.51	4.1000000000000003e-23	Iron status biomarkers;
CRC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.18	-0.37	4.82e-12	Blood metabolite levels;
CRC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	16.79	0.68	3.83e-46	Chronic sinus infection;
CRC	cis	rs73200209	0.912	rs56381931	chr12:116491508	T/C	cg01776926	chr12:116560359	MED13L	-0.5	-6.16	-0.32	2.11e-9	Total body bone mineral density;
CRC	cis	rs2882667	0.522	rs7731574	chr5:138454192	A/G	cg09476006	chr5:138032270	NA	-0.36	-6.07	-0.32	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg02018176	chr4:1364513	KIAA1530	0.4	6.63	0.34	1.37e-10	Obesity-related traits;
CRC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.14	-0.32	2.33e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg10761708	chr20:43804764	PI3	0.51	5.89	0.31	9.53e-9	Blood protein levels;
CRC	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.79	-0.44	8.24e-17	Coffee consumption (cups per day);
CRC	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07165851	chr6:158734300	TULP4	0.6	7.58	0.39	3.46e-13	Height;
CRC	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg03934865	chr2:198174659	NA	-0.46	-7.27	-0.37	2.72e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg14004847	chr7:1930337	MAD1L1	-0.4	-5.92	-0.31	8.27e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22449854	chr4:169909815	CBR4	0.41	6.62	0.34	1.43e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.47	7.05	0.36	1.06e-11	Corneal astigmatism;
CRC	cis	rs7904985	1.000	rs12777097	chr10:88115638	G/A	cg07322936	chr10:88137208	NA	-0.49	-6.5	-0.34	3.03e-10	Barrett's esophagus;
CRC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.62	-0.47	1.76e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.39	-6.18	-0.32	1.85e-9	Type 2 diabetes;
CRC	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg09264619	chr17:80180166	NA	-0.34	-5.71	-0.3	2.52e-8	Life satisfaction;
CRC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.69	9.25	0.45	2.82e-18	High light scatter reticulocyte count;
CRC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.47	-6.95	-0.36	1.97e-11	Plateletcrit;
CRC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.55	8.31	0.42	2.53e-15	High light scatter reticulocyte count;
CRC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg02569458	chr12:86230093	RASSF9	0.39	6.61	0.34	1.58e-10	Major depressive disorder;
CRC	cis	rs4654899	0.931	rs4654880	chr1:21186608	C/A	cg02927042	chr1:21476669	EIF4G3	0.41	6.54	0.34	2.33e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.62	-9.74	-0.47	7.13e-20	Testicular germ cell tumor;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22954265	chr20:29520583	NA	-0.43	-5.99	-0.31	5.46e-9	Hip circumference;
CRC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg18479299	chr3:125709523	NA	-0.54	-6.28	-0.33	1.04e-9	Blood pressure (smoking interaction);
CRC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.5	6.67	0.34	1.11e-10	Tonsillectomy;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19259146	chr1:26856420	RPS6KA1	0.46	6.6	0.34	1.66e-10	Response to antipsychotic treatment;
CRC	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg21827317	chr3:136751795	NA	0.35	5.63	0.3	3.91e-8	Neuroticism;
CRC	cis	rs2971970	0.519	rs6955700	chr7:133633345	T/C	cg03336402	chr7:133662267	EXOC4	0.63	9.63	0.47	1.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12516959	chr21:47718080	NA	-0.35	-6.06	-0.32	3.82e-9	Testicular germ cell tumor;
CRC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	9.54	0.47	3.31e-19	Lymphocyte counts;
CRC	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.77	12.9	0.58	4.49e-31	Height;
CRC	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.46	7.93	0.4	3.55e-14	Common traits (Other);
CRC	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.97	-18.54	-0.71	4.73e-53	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg14004847	chr7:1930337	MAD1L1	0.44	6.01	0.31	4.85e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.9	17.25	0.69	5.9e-48	Lewy body disease;
CRC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg08533674	chr1:46993347	NA	-0.8	-10.3	-0.49	9.2e-22	Monobrow;
CRC	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg13385794	chr1:248469461	NA	0.41	7.14	0.37	5.85e-12	Common traits (Other);
CRC	cis	rs2346160	0.899	rs384974	chr6:167688418	C/T	cg27333441	chr6:167680455	NA	-0.39	-6.36	-0.33	6.59e-10	Parental extreme longevity (95 years and older);
CRC	trans	rs2303319	0.504	rs62187611	chr2:162431946	A/G	cg12500891	chr11:57225987	NA	-0.67	-5.98	-0.31	5.67e-9	Cognitive function;
CRC	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg23234261	chr14:55582407	NA	-0.3	-5.8	-0.3	1.59e-8	Protein biomarker;
CRC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.78	-0.39	9.26e-14	Personality dimensions;
CRC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg07507251	chr3:52567010	NT5DC2	0.42	6.06	0.32	3.7e-9	Bipolar disorder;
CRC	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.84	-0.35	3.98e-11	Retinal vascular caliber;
CRC	cis	rs6088813	1.000	rs6088812	chr20:33974163	T/A	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.22	0.37	3.66e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.66	8.76	0.43	1.08e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg09184832	chr6:79620586	NA	-0.46	-7.8	-0.4	8.05e-14	Intelligence (multi-trait analysis);
CRC	cis	rs56146971	0.763	rs12587463	chr14:91859967	C/T	cg16433844	chr14:91963127	SMEK1	-0.59	-6.08	-0.32	3.27e-9	Alzheimer disease and age of onset;
CRC	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg23234261	chr14:55582407	NA	-0.29	-5.75	-0.3	2.01e-8	Protein biomarker;
CRC	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg22561889	chr6:118971681	C6orf204	0.5	6.52	0.34	2.71e-10	Diastolic blood pressure;
CRC	cis	rs45544231	0.569	rs12443621	chr16:52548037	A/G	cg09051775	chr16:52580266	TOX3	-0.38	-6.16	-0.32	2.15e-9	Restless legs syndrome;
CRC	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg12964065	chr18:77638022	KCNG2	0.62	6.64	0.34	1.3100000000000001e-10	Opioid sensitivity;
CRC	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg17298326	chr8:142245477	NA	0.44	7.04	0.36	1.11e-11	Birth weight;
CRC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-9.59	-0.47	2.34e-19	Total cholesterol levels;
CRC	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.71	11.01	0.52	3.19e-24	Blood protein levels;
CRC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12884169	chr21:40033163	ERG	-0.34	-7.5	-0.38	5.84e-13	Coronary artery disease;
CRC	cis	rs2742417	1.000	rs2673038	chr3:45748632	A/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg10876282	chr6:28092338	ZSCAN16	0.49	6.5	0.34	2.92e-10	Parkinson's disease;
CRC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.88	-14.15	-0.62	7.73e-36	Blood metabolite levels;
CRC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.97	-13.74	-0.6	2.78e-34	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg03037974	chr15:76606532	NA	-0.52	-7.7	-0.39	1.66e-13	Blood metabolite levels;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.58	-8.62	-0.43	2.76e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.64	10.15	0.49	3.14e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.39	-5.64	-0.3	3.61e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.62	-10.79	-0.51	1.86e-23	Coronary artery disease;
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07157834	chr1:205819609	PM20D1	0.43	5.97	0.31	6.2e-9	Parkinson's disease;
CRC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.3	3.81e-8	Hemoglobin concentration;
CRC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.47	-8.54	-0.43	5e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs6426142	0.790	rs2050626	chr1:224824294	A/G	cg11504805	chr13:114815119	RASA3	-0.51	-5.96	-0.31	6.36e-9	Cancer;
CRC	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg18151635	chr12:93972918	NA	-0.59	-8.5	-0.42	6.66e-16	Pubertal anthropometrics;
CRC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.51	-8.6	-0.43	3.34e-16	Aortic root size;
CRC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.27	0.42	3.25e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05366401	chr14:24664722	TM9SF1	0.44	5.96	0.31	6.41e-9	Anxiety disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23934081	chr20:32951001	ITCH	0.43	6.01	0.31	4.99e-9	Anxiety disorder;
CRC	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg26384229	chr12:38710491	ALG10B	0.43	6.06	0.32	3.81e-9	Morning vs. evening chronotype;
CRC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.82	0.44	6.6e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	11.03	0.52	2.82e-24	Motion sickness;
CRC	trans	rs72956618	1.000	rs68160031	chr2:207489365	T/G	cg07171111	chr4:10462903	NA	-0.71	-6.12	-0.32	2.7e-9	Tonsillectomy;
CRC	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.01	0.36	1.32e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-6.95	-0.36	1.98e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.4	-6.84	-0.35	3.91e-11	Height;
CRC	trans	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04565464	chr8:145669602	NFKBIL2	0.45	6.74	0.35	7.18e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg20811857	chr17:78079795	GAA	-0.35	-5.87	-0.31	1.06e-8	Yeast infection;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20092199	chr4:1342459	KIAA1530	-0.38	-6.89	-0.36	2.8e-11	Obesity-related traits;
CRC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.71	11.45	0.53	9.17e-26	Dental caries;
CRC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.61	-0.39	2.93e-13	Gut microbiome composition (summer);
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.65	11.94	0.55	1.5e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-9.54	-0.47	3.28e-19	Total cholesterol levels;
CRC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.48	6.21	0.32	1.63e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs17067123	0.614	rs72712853	chr4:180066431	A/G	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	7.28e-11	Response to hepatitis C treatment;
CRC	cis	rs11212617	0.967	rs227041	chr11:108222801	G/T	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.9	0.31	8.92e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.66	-8.0	-0.4	2.1e-14	Pursuit maintenance gain;
CRC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.46	7.4e-19	Bladder cancer;
CRC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg00074818	chr8:8560427	CLDN23	0.38	6.83	0.35	4.08e-11	Obesity-related traits;
CRC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-14.94	-0.64	7.01e-39	Schizophrenia;
CRC	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.93	-15.92	-0.66	9.98e-43	Dupuytren's disease;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.08	-0.41	1.25e-14	Bipolar disorder;
CRC	trans	rs55675132	0.548	rs12138998	chr1:115377168	A/G	cg25493687	chr8:27288214	PTK2B	0.49	6.0	0.31	5.23e-9	Schizophrenia;
CRC	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg03229431	chr7:123269106	ASB15	-0.36	-5.61	-0.3	4.22e-8	Migraine;
CRC	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg06581033	chr10:766294	NA	-0.49	-5.6	-0.3	4.41e-8	Uric acid levels;
CRC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.43	6.4	0.33	5.38e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.28	-0.42	3.21e-15	Mean corpuscular volume;
CRC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.3	-0.42	2.81e-15	Electroencephalogram traits;
CRC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	7.37	0.38	1.38e-12	Breast cancer;
CRC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.5	9.96	0.48	1.31e-20	Renal cell carcinoma;
CRC	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg26248373	chr2:1572462	NA	-0.83	-12.33	-0.56	5.69e-29	IgG glycosylation;
CRC	cis	rs720844	0.748	rs35168772	chr2:149351228	A/G	cg09247360	chr2:149335327	NA	-0.62	-6.68	-0.35	9.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg25456477	chr12:86230367	RASSF9	0.38	6.48	0.34	3.29e-10	Major depressive disorder;
CRC	cis	rs4728142	0.738	rs3807306	chr7:128580680	A/C	cg14349538	chr7:128577651	IRF5	0.35	5.77	0.3	1.79e-8	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CRC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20135002	chr11:47629003	NA	0.35	5.73	0.3	2.29e-8	Subjective well-being;
CRC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.69	10.34	0.5	7.09e-22	Cognitive function;
CRC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.16	-16.9	-0.68	1.4e-46	Hip circumference adjusted for BMI;
CRC	cis	rs7626444	0.625	rs1798636	chr3:196476604	G/A	cg12930392	chr3:196481615	PAK2	0.4	7.26	0.37	2.73e-12	Monocyte count;
CRC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg23587288	chr2:27483067	SLC30A3	-0.44	-6.54	-0.34	2.36e-10	Blood metabolite levels;
CRC	cis	rs12230513	0.732	rs61956303	chr12:55818071	C/A	cg19537932	chr12:55886519	OR6C68	-0.74	-9.46	-0.46	5.95e-19	Contrast sensitivity;
CRC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.53	7.5	0.38	6.09e-13	Lung cancer;
CRC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.86	10.18	0.49	2.37e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg04969067	chr8:143858791	LYNX1	0.62	10.96	0.52	5.09e-24	Urinary tract infection frequency;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-6.28	-0.33	1.07e-9	Lymphocyte counts;
CRC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-8.0	-0.4	2.13e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg03037974	chr15:76606532	NA	-0.52	-7.89	-0.4	4.47e-14	Blood metabolite levels;
CRC	cis	rs990171	0.506	rs2041748	chr2:102756295	A/G	cg22835712	chr2:102737379	NA	0.44	6.03	0.32	4.38e-9	Lymphocyte counts;
CRC	cis	rs965469	1.000	rs6051747	chr20:3307945	T/C	cg25506879	chr20:3388711	C20orf194	-0.38	-5.62	-0.3	4.13e-8	IFN-related cytopenia;
CRC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg12193833	chr17:30244370	NA	0.45	5.97	0.31	6.01e-9	Hip circumference adjusted for BMI;
CRC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.41	6.13	0.32	2.47e-9	Type 2 diabetes;
CRC	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.73	-10.27	-0.49	1.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg15571903	chr15:79123663	NA	0.34	6.87	0.35	3.29e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.67	-11.14	-0.52	1.13e-24	Itch intensity from mosquito bite;
CRC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.01	-10.48	-0.5	2.32e-22	Body mass index;
CRC	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.71	9.58	0.47	2.51e-19	Coronary artery disease;
CRC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-9.74	-0.47	7.09e-20	Chronic sinus infection;
CRC	cis	rs1223397	1.000	rs1223403	chr6:13271812	G/A	cg06879394	chr6:13274151	PHACTR1	0.56	6.74	0.35	7.03e-11	Blood pressure;
CRC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.55	-0.47	3.09e-19	Height;
CRC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.66	-0.3	3.35e-8	Morning vs. evening chronotype;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.52	-7.06	-0.36	9.99e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.86	0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.41	7.01	0.36	1.34e-11	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.93	-17.05	-0.68	3.89e-47	Height;
CRC	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.52	10.03	0.48	7.81e-21	Urate levels in lean individuals;
CRC	trans	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg25411327	chr19:5210703	PTPRS	-0.59	-6.04	-0.32	4.15e-9	Schizophrenia;
CRC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.64	9.8	0.48	4.68e-20	Pancreatic cancer;
CRC	cis	rs3823572	0.525	rs6467514	chr7:133687618	G/T	cg03336402	chr7:133662267	EXOC4	-0.63	-9.29	-0.46	2.23e-18	Intelligence (multi-trait analysis);
CRC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.37	-19.1	-0.73	2.9e-55	Hip circumference adjusted for BMI;
CRC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.68	10.69	0.51	4.44e-23	Corneal astigmatism;
CRC	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.55	-7.76	-0.39	1.05e-13	Coronary artery disease;
CRC	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.46	7.24	0.37	3.27e-12	Platelet count;
CRC	cis	rs11212617	0.967	rs1583598	chr11:108305989	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.93	0.31	7.71e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg10298567	chr3:47292165	KIF9	0.39	6.09	0.32	3.16e-9	Colorectal cancer;
CRC	cis	rs9323205	1.000	rs7149022	chr14:51613980	A/C	cg23942311	chr14:51606299	NA	-0.58	-7.12	-0.37	6.79e-12	Cancer;
CRC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.65	11.3	0.53	3.06e-25	Prostate cancer;
CRC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20092199	chr4:1342459	KIAA1530	0.32	5.77	0.3	1.87e-8	Obesity-related traits;
CRC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.59	-8.33	-0.42	2.17e-15	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs3018066	0.720	rs10025052	chr4:106961846	C/T	cg01869342	chr4:106983673	TBCK	0.43	6.39	0.33	5.72e-10	Cancer;
CRC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg17133734	chr15:86042851	AKAP13	-0.41	-6.65	-0.34	1.21e-10	Interstitial lung disease;
CRC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg02869306	chr7:64672164	INTS4L1	-0.43	-6.4	-0.33	5.39e-10	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09352908	chr3:37017749	NA	-0.39	-6.29	-0.33	9.85e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.25	15.65	0.65	1.15e-41	Lung disease severity in cystic fibrosis;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.84	-0.51	1.29e-23	Bipolar disorder;
CRC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.58	9.09	0.45	9.78e-18	Asthma (sex interaction);
CRC	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.54	8.73	0.43	1.35e-16	Mean corpuscular volume;
CRC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-9.36	-0.46	1.25e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.59	-8.95	-0.44	2.61e-17	Height;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.84	-0.31	1.25e-8	Longevity;Endometriosis;
CRC	cis	rs4663866	1.000	rs13033501	chr2:239181860	G/A	cg16914508	chr2:239161102	PER2	0.77	7.88	0.4	4.89e-14	Irritable bowel syndrome;
CRC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg19046167	chr17:80928561	B3GNTL1	0.47	6.92	0.36	2.38e-11	Glycated hemoglobin levels;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg27615366	chr5:131592974	PDLIM4	-0.33	-5.73	-0.3	2.32e-8	Breast cancer;
CRC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.2	-0.32	1.68e-9	Total cholesterol levels;
CRC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.08	0.41	1.25e-14	Alzheimer's disease;
CRC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	8.69	0.43	1.73e-16	Lymphocyte counts;
CRC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.48	0.34	3.26e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-8.03	-0.4	1.79e-14	Blood protein levels;
CRC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.7	-0.51	3.85e-23	Alzheimer's disease;
CRC	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-9.49	-0.46	4.8e-19	Intelligence (multi-trait analysis);
CRC	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.63	-9.93	-0.48	1.71e-20	Systemic lupus erythematosus;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg02475695	chr16:616220	NHLRC4	0.47	7.69	0.39	1.77e-13	Height;
CRC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.5	-7.2	-0.37	4.24e-12	White blood cell count;
CRC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.27	0.46	2.46e-18	Smoking initiation;
CRC	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg09873164	chr1:152488093	CRCT1	0.36	5.97	0.31	5.99e-9	Hair morphology;
CRC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.92	14.06	0.61	1.66e-35	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.52	-7.61	-0.39	2.83e-13	Longevity;
CRC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.86	0.35	3.41e-11	Morning vs. evening chronotype;
CRC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.79	-0.35	5.16e-11	Total body bone mineral density;
CRC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	7.66	0.39	2.08e-13	Motion sickness;
CRC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg05313129	chr8:58192883	C8orf71	0.41	5.94	0.31	7.06e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg25804541	chr17:80189381	SLC16A3	0.32	6.13	0.32	2.51e-9	Life satisfaction;
CRC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.38	-5.87	-0.31	1.05e-8	Breast cancer;
CRC	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg26373071	chr5:1325741	CLPTM1L	-0.41	-7.02	-0.36	1.3e-11	Lung cancer;
CRC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg04121214	chr22:50244548	NA	0.42	5.86	0.31	1.12e-8	Schizophrenia;
CRC	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg00919237	chr7:87102261	ABCB4	-0.54	-7.1	-0.36	7.6e-12	Gallbladder cancer;
CRC	cis	rs113835537	0.935	rs76228630	chr11:66458676	T/C	cg22134325	chr11:66188745	NPAS4	0.38	6.39	0.33	5.81e-10	Airway imaging phenotypes;
CRC	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg21620606	chr4:1342894	KIAA1530	-0.42	-7.84	-0.4	6.21e-14	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04722249	chr2:97617061	FAM178B	0.42	6.44	0.33	4.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg15448220	chr1:150897856	SETDB1	0.48	6.83	0.35	4.16e-11	Tonsillectomy;
CRC	cis	rs3767633	0.925	rs4656335	chr1:161822078	A/G	cg09175582	chr1:161736000	ATF6	0.7	6.29	0.33	9.96e-10	IgG glycosylation;
CRC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-5.81	-0.31	1.47e-8	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26733140	chr11:63993641	NUDT22;TRPT1	-0.37	-6.44	-0.33	4.12e-10	Myopia (pathological);
CRC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.66	0.63	8.22e-38	Chronic sinus infection;
CRC	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg05250797	chr16:70222502	NA	0.4	5.66	0.3	3.33e-8	IgE levels;
CRC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.62	10.68	0.51	4.83e-23	Prudent dietary pattern;
CRC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.57	-9.0	-0.44	1.86e-17	Personality dimensions;
CRC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12292205	chr6:26970375	C6orf41	0.62	7.29	0.37	2.39e-12	Intelligence (multi-trait analysis);
CRC	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg11886554	chr3:170076028	SKIL	0.73	8.53	0.43	5.5e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg19897017	chr7:2163380	MAD1L1	0.46	6.83	0.35	4.17e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.46	6.46	0.34	3.81e-10	Fibrinogen levels;
CRC	cis	rs728616	0.867	rs78131725	chr10:81820919	C/G	cg11900509	chr10:81946545	ANXA11	-0.53	-5.67	-0.3	3.13e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.6	7.41	0.38	1.1e-12	Body mass index;
CRC	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.24	-0.33	1.37e-9	Superior frontal gyrus grey matter volume;
CRC	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.47	-7.6	-0.39	3.05e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.45	7.11	0.37	7.16e-12	C-reactive protein levels;
CRC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.48	0.46	5.18e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.5	7.97	0.4	2.7e-14	Height;
CRC	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.47	9.4	0.46	9.88e-19	Schizophrenia;
CRC	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.72	9.63	0.47	1.74e-19	Coronary artery disease;
CRC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.96e-9	Gut microbiome composition (summer);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21219327	chr11:67980012	SUV420H1	0.42	6.56	0.34	2.11e-10	Response to antipsychotic treatment;
CRC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg21251018	chr6:28226885	NKAPL	-0.42	-6.72	-0.35	8.23e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-0.9	-7.58	-0.39	3.51e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.66	-6.98	-0.36	1.67e-11	Type 2 diabetes;
CRC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.08	13.41	0.59	5.35e-33	Vitiligo;
CRC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg25456477	chr12:86230367	RASSF9	0.33	5.65	0.3	3.46e-8	Major depressive disorder;
CRC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-11.88	-0.55	2.51e-27	Mean platelet volume;Platelet distribution width;
CRC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.52	-8.19	-0.41	5.75e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20306694	chr12:51718251	BIN2	0.22	6.03	0.32	4.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.59	7.87	0.4	5.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg24675056	chr1:15929824	NA	0.47	6.31	0.33	8.87e-10	Systolic blood pressure;
CRC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg02659138	chr7:134003124	SLC35B4	0.43	7.61	0.39	2.86e-13	Mean platelet volume;
CRC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.45	6.48	0.34	3.4e-10	Cognitive ability;
CRC	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.35	5.64	0.3	3.76e-8	Menarche (age at onset);
CRC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.47	-7.02	-0.36	1.25e-11	Colorectal cancer;
CRC	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg08501292	chr6:25962987	TRIM38	0.83	7.28	0.37	2.46e-12	Autism spectrum disorder or schizophrenia;
CRC	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.06	0.52	2.21e-24	Exhaled nitric oxide output;
CRC	cis	rs4731207	0.698	rs10260710	chr7:124455986	C/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-8.24	-0.41	4.19e-15	Aortic root size;
CRC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.04	-0.32	4.07e-9	Diabetic kidney disease;
CRC	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.3	-0.46	2.07e-18	Prevalent atrial fibrillation;
CRC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.55	6.19	0.32	1.82e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg13047869	chr3:10149882	C3orf24	0.54	6.49	0.34	3.1e-10	Alzheimer's disease;
CRC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg03678062	chr6:149772716	ZC3H12D	0.34	6.09	0.32	3.08e-9	Dupuytren's disease;
CRC	cis	rs3751196	0.808	rs55949441	chr12:104217942	G/A	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg18653534	chr16:772142	FAM173A	-0.37	-5.87	-0.31	1.08e-8	Height;
CRC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.54	-6.64	-0.34	1.3100000000000001e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13768304	chr14:94547498	DDX24;IFI27L1	0.47	6.12	0.32	2.73e-9	Thyroid stimulating hormone;
CRC	cis	rs9039	1.000	rs67302637	chr16:9221100	C/T	cg08831531	chr16:9218945	NA	-0.55	-7.0	-0.36	1.48e-11	Menopause (age at onset);
CRC	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	1.12	8.78	0.44	9.16e-17	Economic and political preferences (immigration/crime);
CRC	trans	rs35785195	0.633	rs1035775	chr12:114230578	A/G	cg16898576	chr11:63449499	RTN3	-0.48	-5.97	-0.31	6.21e-9	Daytime sleep phenotypes;
CRC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.83	0.31	1.32e-8	Diabetic retinopathy;
CRC	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-7.22	-0.37	3.59e-12	Putamen volume;
CRC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.47	6.3	0.33	9.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-9.36	-0.46	1.25e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg03629926	chr19:8438839	ANGPTL4	-0.44	-6.2	-0.32	1.67e-9	Lung cancer;
CRC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg06470822	chr6:28175283	NA	-0.53	-7.95	-0.4	3.08e-14	Pubertal anthropometrics;
CRC	trans	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.29	-0.33	9.9e-10	Mosquito bite size;
CRC	cis	rs6586163	1.000	rs1324551	chr10:90751516	C/T	cg13456138	chr10:90753195	FAS	-0.44	-6.82	-0.35	4.33e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.89	-0.4	4.57e-14	Intelligence (multi-trait analysis);
CRC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.98	13.41	0.59	5.11e-33	Psoriasis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18675517	chr6:112364942	NA	0.46	6.31	0.33	9.15e-10	Anxiety disorder;
CRC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.47	-7.51	-0.38	5.54e-13	Obesity-related traits;
CRC	cis	rs6840360	0.642	rs6845648	chr4:152376050	C/T	cg09659197	chr4:152720779	NA	0.33	6.46	0.34	3.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg23996704	chr18:44553084	KATNAL2	-0.4	-7.85	-0.4	6.07e-14	Personality dimensions;
CRC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.0	12.25	0.56	1.08e-28	Uric acid levels;
CRC	cis	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.71	-0.3	2.5e-8	Blood trace element (Cu levels);
CRC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.65	0.54	1.76e-26	Prudent dietary pattern;
CRC	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.72	-12.82	-0.58	8.7e-31	Inhibitory control;
CRC	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg01871581	chr19:12707946	ZNF490	-0.76	-13.34	-0.59	9.58e-33	Bipolar disorder;
CRC	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.57	-5.85	-0.31	1.16e-8	Lung function (FVC);Lung function (FEV1);
CRC	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.52	-8.18	-0.41	6.06e-15	Corneal astigmatism;
CRC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.56	6.39	0.33	5.74e-10	Primary sclerosing cholangitis;
CRC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.5	7.32	0.37	1.9e-12	Height;
CRC	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg27398640	chr15:77910606	LINGO1	-0.43	-7.47	-0.38	7.13e-13	Type 2 diabetes;
CRC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg15226275	chr6:116381976	FRK	0.29	8.24	0.41	4.19e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.44	7.38	0.38	1.32e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg21169611	chr9:106856078	SMC2	0.43	5.79	0.3	1.61e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg16892393	chr17:41919603	NA	0.56	7.83	0.4	6.58e-14	Triglycerides;
CRC	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg10556349	chr10:835070	NA	-0.38	-7.48	-0.38	7.05e-13	Survival in rectal cancer;
CRC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.5	7.67	0.39	1.93e-13	Corneal astigmatism;
CRC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.42	-20.15	-0.74	2.3e-59	Hip circumference adjusted for BMI;
CRC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.83	8.44	0.42	1.04e-15	Fat distribution (HIV);
CRC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.7	10.94	0.52	5.58e-24	Corneal astigmatism;
CRC	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	14.74	0.63	4.03e-38	Colorectal cancer;
CRC	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg19875578	chr6:126661172	C6orf173	0.42	5.92	0.31	8.1e-9	Male-pattern baldness;
CRC	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.45	-6.31	-0.33	8.84e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg03233332	chr7:66118400	NA	-0.43	-6.05	-0.32	3.99e-9	Aortic root size;
CRC	trans	rs13182402	1.000	rs17154676	chr5:125912120	A/G	cg14920044	chr10:91296311	SLC16A12	0.51	6.03	0.32	4.52e-9	Osteoporosis;
CRC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.66	9.98	0.48	1.19e-20	Menopause (age at onset);
CRC	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg10756647	chr7:56101905	PSPH	-0.78	-8.17	-0.41	6.58e-15	Gout;
CRC	trans	rs4785204	1.000	rs13339262	chr16:50091383	C/A	cg07960154	chr17:37760198	NEUROD2	-0.67	-6.18	-0.32	1.87e-9	Esophageal cancer (squamous cell);
CRC	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.16	-0.37	5.14e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CRC	cis	rs7113874	0.589	rs9705253	chr11:8596483	A/T	cg02811074	chr11:8615871	STK33	-0.35	-6.02	-0.31	4.77e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.47	6.34	0.33	7.76e-10	Pulse pressure;
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg21251018	chr6:28226885	NKAPL	0.38	5.71	0.3	2.5e-8	Parkinson's disease;
CRC	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg15412446	chr2:106886593	NA	-0.39	-6.28	-0.33	1.08e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CRC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.74	0.3	2.17e-8	Heart rate;
CRC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.57	-9.09	-0.45	9.6e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.45	-8.5	-0.42	6.89e-16	Alcohol dependence;
CRC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.56	8.41	0.42	1.28e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg23590916	chr17:43697445	MGC57346	0.71	6.93	0.36	2.25e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.37	6.04	0.32	4.24e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.81	-0.48	4.16e-20	Blood protein levels;
CRC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.89	-0.31	9.39e-9	Life satisfaction;
CRC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.43	-0.38	9.42e-13	Schizophrenia;
CRC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.9	-0.31	8.98e-9	Calcium levels;
CRC	trans	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg09872104	chr7:134855509	C7orf49	-0.89	-7.22	-0.37	3.72e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11060661	chr22:24314208	DDT;DDTL	0.51	8.87	0.44	4.67e-17	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.83	-0.66	2.38e-42	Height;
CRC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	0.92	8.52	0.43	5.87e-16	IgG glycosylation;
CRC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.25e-9	Bladder cancer;
CRC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.66	8.66	0.43	2.18e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.04e-16	Schizophrenia;
CRC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-7.43	-0.38	9.54e-13	Schizophrenia;
CRC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg05044414	chr3:183734942	ABCC5	-0.49	-7.86	-0.4	5.36e-14	Anterior chamber depth;
CRC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-6.43	-0.33	4.46e-10	Breast cancer;
CRC	cis	rs11031096	0.542	rs6578424	chr11:3973140	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-6.8	-0.35	5.05e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.72	0.65	6.2e-42	Chronic sinus infection;
CRC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.51	-6.71	-0.35	8.57e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.25	-5.74	-0.3	2.16e-8	Coronary artery disease;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg15786705	chr6:28176104	NA	0.61	8.75	0.43	1.09e-16	Cardiac Troponin-T levels;
CRC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.68	10.77	0.51	2.25e-23	Type 2 diabetes;
CRC	cis	rs7739232	1.000	rs111278368	chr6:53530942	T/C	cg15658676	chr6:53530538	KLHL31	-0.76	-5.9	-0.31	8.9e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.13	0.45	6.85e-18	Monocyte percentage of white cells;
CRC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.65	8.64	0.43	2.46e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.84	0.55	3.47e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25518016	chr2:65092614	NA	0.44	6.17	0.32	2.01e-9	Response to antipsychotic treatment;
CRC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg19812747	chr11:111475976	SIK2	-0.57	-9.72	-0.47	8.51e-20	Primary sclerosing cholangitis;
CRC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.49	0.46	4.85e-19	Lung cancer;
CRC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg00531865	chr16:30841666	NA	-0.46	-5.98	-0.31	5.85e-9	Multiple myeloma;
CRC	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	6.94	0.36	2.03e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg01858014	chr14:56050164	KTN1	-0.77	-5.63	-0.3	3.85e-8	Putamen volume;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02290350	chr8:58132656	NA	-0.51	-6.01	-0.31	5.03e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg23298862	chr7:158159286	PTPRN2	-0.59	-9.79	-0.47	4.97e-20	Calcium levels;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.09	-0.32	3.2e-9	Cognitive function;
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.5	9.21	0.45	3.79e-18	Total body bone mineral density;
CRC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.5	7.28	0.37	2.55e-12	Height;
CRC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	7.08	0.36	8.68e-12	Hip circumference adjusted for BMI;
CRC	cis	rs4363385	0.818	rs2152994	chr1:152991060	C/T	cg25856811	chr1:152973957	SPRR3	0.23	6.43	0.33	4.43e-10	Inflammatory skin disease;
CRC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg10978503	chr1:24200527	CNR2	-0.43	-6.56	-0.34	2.09e-10	Immature fraction of reticulocytes;
CRC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.54	-9.01	-0.44	1.74e-17	Intelligence (multi-trait analysis);
CRC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.84	-12.19	-0.56	1.82e-28	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg23565292	chr14:50234668	KLHDC2	-0.4	-5.77	-0.3	1.86e-8	Carotid intima media thickness;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12273811	chr6:28175739	NA	0.73	9.36	0.46	1.34e-18	Parkinson's disease;
CRC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.14	-0.56	2.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2302190	0.882	rs3809709	chr17:56590559	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.03	-0.4	1.7e-14	Vitamin D levels;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg01692572	chr8:144910787	PUF60	-0.43	-6.81	-0.35	4.55e-11	Daytime sleep phenotypes;
CRC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg18132624	chr14:105716052	BTBD6;BRF1	-0.48	-7.98	-0.4	2.46e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.88	10.76	0.51	2.49e-23	Red blood cell traits;
CRC	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15644404	chr18:77186268	NFATC1	-0.81	-6.65	-0.34	1.23e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.55	5.95	0.31	6.71e-9	Schizophrenia;
CRC	trans	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg10756647	chr7:56101905	PSPH	0.72	8.09	0.41	1.15e-14	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09765074	chr10:69634185	NA	-0.41	-6.99	-0.36	1.55e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.77	-0.3	1.86e-8	Colorectal cancer;
CRC	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.67	-0.47	1.26e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.43	-0.33	4.5e-10	Electroencephalogram traits;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg06003594	chr17:21415244	NA	-0.38	-6.07	-0.32	3.45e-9	Myopia (pathological);
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.48	6.79	0.35	5.13e-11	Longevity;Endometriosis;
CRC	cis	rs7731657	0.537	rs72801772	chr5:130341294	G/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.79	-0.3	1.66e-8	Fasting plasma glucose;
CRC	cis	rs2276314	0.532	rs11081927	chr18:33614282	C/T	cg05985134	chr18:33552581	C18orf21	0.39	6.03	0.32	4.3e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs9826463	0.582	rs11707154	chr3:142077131	A/T	cg20824294	chr3:142316082	PLS1	0.35	5.92	0.31	8.15e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.09	-0.41	1.13e-14	Mean corpuscular volume;
CRC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.48	-6.62	-0.34	1.42e-10	Multiple myeloma;
CRC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.85	11.05	0.52	2.29e-24	Gut microbiome composition (summer);
CRC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.52	8.25	0.41	3.87e-15	Menarche (age at onset);
CRC	cis	rs7113874	0.569	rs10769914	chr11:8576202	A/G	cg17679104	chr11:8615758	STK33	-0.35	-5.9	-0.31	9.21e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg25922239	chr6:33757077	LEMD2	0.4	5.71	0.3	2.46e-8	Crohn's disease;
CRC	cis	rs17767392	0.958	rs3784064	chr14:72059551	G/A	cg13720639	chr14:72061746	SIPA1L1	0.56	7.06	0.36	1.02e-11	Mitral valve prolapse;
CRC	cis	rs62432291	0.681	rs378547	chr6:159662525	A/G	cg14500486	chr6:159655392	FNDC1	0.71	9.46	0.46	6.29e-19	Joint mobility (Beighton score);
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg26587870	chr6:27730563	NA	-0.4	-6.22	-0.32	1.48e-9	Parkinson's disease;
CRC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.11	-0.41	1.02e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg23425280	chr12:56401806	NA	0.48	5.81	0.31	1.47e-8	Cancer;
CRC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.29	-0.53	3.23e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg16358738	chr2:241808595	AGXT	-0.39	-5.87	-0.31	1.07e-8	Urinary metabolites;
CRC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.09	-0.36	7.99e-12	Myopia;Myopia (pathological);
CRC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.98	-0.4	2.5e-14	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15214069	chr9:139333582	INPP5E	0.47	6.23	0.32	1.4e-9	Thyroid stimulating hormone;
CRC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.03	-20.45	-0.75	1.51e-60	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7429990	0.965	rs4296617	chr3:48068308	T/C	cg11946769	chr3:48343235	NME6	-0.5	-6.34	-0.33	7.42e-10	Educational attainment (years of education);
CRC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.62	-8.67	-0.43	1.94e-16	DNA methylation (variation);
CRC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg23161317	chr6:28129485	ZNF389	0.38	5.67	0.3	3.16e-8	Cardiac Troponin-T levels;
CRC	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.49	9.18	0.45	4.73e-18	Educational attainment (years of education);
CRC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.45	7.42	0.38	9.93e-13	Menopause (age at onset);
CRC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.72	11.14	0.52	1.1e-24	Corneal astigmatism;
CRC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg20608306	chr11:116969690	SIK3	0.31	6.27	0.33	1.13e-9	Blood protein levels;
CRC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.36	-0.46	1.3e-18	Platelet count;
CRC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.67	9.45	0.46	6.78e-19	Vitiligo;
CRC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg19682013	chr15:45996608	NA	0.32	6.62	0.34	1.48e-10	Waist circumference;Weight;
CRC	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.02	-0.32	4.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9292777	0.777	rs1002922	chr5:40386555	T/C	cg09067459	chr5:40385259	NA	-0.56	-9.28	-0.46	2.31e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs9463078	0.770	rs9296453	chr6:45227432	C/T	cg25276700	chr6:44698697	NA	-0.27	-6.52	-0.34	2.58e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02955369	chr1:173837185	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.49	6.52	0.34	2.59e-10	Thyroid stimulating hormone;
CRC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.05	12.84	0.58	7.03e-31	Type 2 diabetes nephropathy;
CRC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.47	5.79	0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg20933634	chr6:27740509	NA	0.57	8.28	0.42	3.08e-15	Parkinson's disease;
CRC	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg07979401	chr6:33739406	LEMD2	-0.49	-5.82	-0.31	1.37e-8	Schizophrenia;
CRC	cis	rs9938149	0.705	rs7405095	chr16:88307825	C/T	cg05435882	chr16:88311214	NA	0.43	5.77	0.3	1.85e-8	Corneal structure;Central corneal thickness;
CRC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.34	6.92	0.36	2.37e-11	Renal cell carcinoma;
CRC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.62	-8.64	-0.43	2.56e-16	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05051121	chr3:139062703	MRPS22	0.49	7.0	0.36	1.47e-11	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.66	8.66	0.43	2.14e-16	Gut microbiome composition (summer);
CRC	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.64	0.39	2.41e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.52	-7.44	-0.38	8.7e-13	Caudate activity during reward;
CRC	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg27649806	chr9:35101217	STOML2	0.39	6.2	0.32	1.74e-9	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.65e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs972578	1.000	rs4822241	chr22:43369349	A/T	cg01576275	chr22:43409880	NA	-0.44	-6.92	-0.36	2.36e-11	Mean platelet volume;
CRC	cis	rs7638909	0.512	rs6793245	chr3:38599037	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	7.37	0.38	1.43e-12	Electrocardiographic conduction measures;
CRC	cis	rs2072510	0.593	rs2660892	chr12:96420978	T/C	cg15438951	chr12:96389694	HAL	-0.49	-5.82	-0.31	1.4e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg11900509	chr10:81946545	ANXA11	-0.66	-6.6	-0.34	1.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.67	11.22	0.53	5.79e-25	Cancer;
CRC	cis	rs6700896	0.966	rs12067936	chr1:66088701	C/A	cg04111102	chr1:66153794	NA	0.33	5.96	0.31	6.62e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs245880	0.702	rs245884	chr7:29188475	T/G	cg17163760	chr7:29186267	CPVL	-0.39	-6.74	-0.35	7e-11	Warfarin maintenance dose;
CRC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-7.93	-0.4	3.41e-14	Height;
CRC	cis	rs28655083	0.529	rs285018	chr16:77099065	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.45	0.33	4.06e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg07617317	chr6:118971624	C6orf204	0.48	5.77	0.3	1.82e-8	Diastolic blood pressure;
CRC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.14	-0.45	6.61e-18	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg19041857	chr6:27730383	NA	-0.76	-7.06	-0.36	1.01e-11	Depression;
CRC	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.73	9.33	0.46	1.56e-18	Iron status biomarkers;
CRC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg26838691	chr2:24397539	C2orf84	0.41	5.76	0.3	1.93e-8	Asthma;
CRC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg03037974	chr15:76606532	NA	-0.44	-6.82	-0.35	4.33e-11	Blood metabolite levels;
CRC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.89	-0.35	2.93e-11	Major depressive disorder;
CRC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.73	-0.35	7.35e-11	Monocyte percentage of white cells;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02760553	chr17:73975121	ACOX1;C17orf106	0.44	6.24	0.33	1.36e-9	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.49	8.95	0.44	2.7e-17	Total body bone mineral density;
CRC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg26850624	chr5:429559	AHRR	-0.72	-9.67	-0.47	1.27e-19	Cystic fibrosis severity;
CRC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.53	9.2	0.45	4.35e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.23e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs3026101	0.671	rs2871203	chr17:5298490	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.32e-11	Menopause (age at onset);
CRC	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg03929089	chr4:120376271	NA	-0.51	-6.3	-0.33	9.75e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	7.07	0.36	9.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-8.72	-0.43	1.36e-16	Chronic sinus infection;
CRC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-11.22	-0.53	5.96e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22650146	chr1:221915355	DUSP10	0.45	6.18	0.32	1.87e-9	Response to antipsychotic treatment;
CRC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.72	11.33	0.53	2.35e-25	Autism spectrum disorder or schizophrenia;
CRC	cis	rs883565	0.528	rs6599271	chr3:38970730	A/G	cg01426195	chr3:39028469	NA	0.38	6.4	0.33	5.37e-10	Handedness;
CRC	cis	rs77633900	0.772	rs2469554	chr15:76642700	G/C	cg21673338	chr15:77095150	SCAPER	-0.72	-6.27	-0.33	1.14e-9	Non-glioblastoma glioma;Glioma;
CRC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.34	0.33	7.71e-10	Morning vs. evening chronotype;
CRC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg16060761	chr17:80687452	NA	0.42	6.02	0.31	4.68e-9	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00367438	chr7:150780797	TMUB1	0.44	6.12	0.32	2.69e-9	Response to antipsychotic treatment;
CRC	cis	rs9311676	0.632	rs56398717	chr3:58404355	G/A	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	0.66	6.43	0.33	4.45e-10	Fat distribution (HIV);
CRC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg25164649	chr6:28176230	NA	0.65	8.58	0.43	3.87e-16	Parkinson's disease;
CRC	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg14458575	chr2:238380390	NA	0.53	6.95	0.36	1.99e-11	Prostate cancer;
CRC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.19	-0.41	5.67e-15	Height;
CRC	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg23435118	chr5:141488016	NDFIP1	-0.45	-7.1	-0.36	7.76e-12	Crohn's disease;
CRC	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.48	8.82	0.44	7.04e-17	Acylcarnitine levels;
CRC	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg23815491	chr16:72088622	HP	0.51	6.12	0.32	2.62e-9	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg19688584	chr6:167529678	CCR6	-0.33	-5.96	-0.31	6.35e-9	Primary biliary cholangitis;
CRC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.53	8.81	0.44	7.14e-17	Gout;
CRC	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.06	21.7	0.77	1.94e-65	Schizophrenia;
CRC	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg00947319	chr17:47005597	UBE2Z	-0.33	-5.7	-0.3	2.61e-8	Type 2 diabetes;
CRC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.48	0.46	5.18e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs995000	0.839	rs1168034	chr1:62963914	G/C	cg19896129	chr1:63156450	NA	-0.39	-5.96	-0.31	6.39e-9	Triglyceride levels;
CRC	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.52	0.43	5.9e-16	Corneal astigmatism;
CRC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	0.9	11.07	0.52	1.93e-24	Hip circumference adjusted for BMI;
CRC	cis	rs6694672	0.850	rs4915156	chr1:197062820	A/T	cg13682187	chr1:196946512	CFHR5	0.55	8.27	0.42	3.27e-15	Asthma;
CRC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.47	-6.84	-0.35	3.92e-11	High light scatter reticulocyte count;
CRC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.84	0.55	3.47e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2248020	0.501	rs2263368	chr11:93264680	A/C	cg15737290	chr11:93063684	CCDC67	0.45	7.29	0.37	2.37e-12	Insulin levels in response to oral glucose tolerance test (30 minutes);
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10164272	chr16:89456328	ANKRD11	-0.42	-7.01	-0.36	1.37e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17602823	chr1:28586543	SESN2	0.39	6.35	0.33	6.98e-10	Obesity-related traits;
CRC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg21856205	chr7:94953877	PON1	-0.44	-5.8	-0.3	1.56e-8	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg12172441	chr6:28176163	NA	0.53	7.09	0.36	8.34e-12	Parkinson's disease;
CRC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.65	11.34	0.53	2.24e-25	Prostate cancer;
CRC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.07	-0.41	1.36e-14	IgG glycosylation;
CRC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.52	-8.58	-0.43	3.88e-16	Schizophrenia;
CRC	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.69	9.44	0.46	7.17e-19	Coronary artery disease;
CRC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg18301423	chr5:131593218	PDLIM4	0.36	6.18	0.32	1.93e-9	Blood metabolite levels;
CRC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	11.27	0.53	4.04e-25	Menopause (age at onset);
CRC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.66	-10.09	-0.49	4.83e-21	IgG glycosylation;
CRC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.82	12.79	0.58	1.09e-30	Diastolic blood pressure;
CRC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.19	0.32	1.84e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.44	6.96	0.36	1.9e-11	Schizophrenia;
CRC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.55	5.95	0.31	6.71e-9	Schizophrenia;
CRC	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg20608306	chr11:116969690	SIK3	0.31	5.67	0.3	3.15e-8	Subjective well-being;
CRC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.57	0.43	4.05e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg05376469	chr2:102649931	NA	0.38	6.23	0.32	1.4e-9	Coronary artery disease;
CRC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.7	-8.81	-0.44	7.18e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.52	-0.34	2.61e-10	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-6.91	-0.36	2.59e-11	Platelet distribution width;
CRC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11645453	chr3:52864694	ITIH4	0.35	6.37	0.33	6.5e-10	Electroencephalogram traits;
CRC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.56	1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	0.99	13.91	0.61	6.24e-35	Breast cancer;
CRC	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg03258749	chr1:151040405	MLLT11	-0.49	-7.58	-0.39	3.66e-13	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02809009	chr19:50354510	PTOV1	0.4	6.38	0.33	6.01e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.7	7.14	0.37	5.83e-12	Blood protein levels;
CRC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.52	7.08	0.36	8.63e-12	Morning vs. evening chronotype;
CRC	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg06713675	chr4:122721982	EXOSC9	-0.4	-6.47	-0.34	3.63e-10	Type 2 diabetes;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg08833169	chr11:810149	RPLP2	0.37	6.01	0.31	4.98e-9	Interleukin-6 levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27555392	chr1:16679092	FBXO42	0.36	6.01	0.31	4.84e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	10.87	0.51	1.04e-23	Personality dimensions;
CRC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.58	0.39	3.56e-13	Eye color traits;
CRC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg10398005	chr11:117014888	PAFAH1B2	-0.41	-5.98	-0.31	5.79e-9	Blood protein levels;
CRC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.72	-0.39	1.4e-13	Neuroticism;
CRC	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.38	6.05	0.32	4.05e-9	Testicular germ cell tumor;
CRC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg19812747	chr11:111475976	SIK2	-0.56	-9.46	-0.46	5.88e-19	Primary sclerosing cholangitis;
CRC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg10978503	chr1:24200527	CNR2	-0.42	-6.43	-0.33	4.43e-10	Immature fraction of reticulocytes;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26352439	chr17:157043	RPH3AL	0.38	5.99	0.31	5.35e-9	Myopia (pathological);
CRC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.46	6.96	0.36	1.91e-11	Menopause (age at onset);
CRC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.32	-7.02	-0.36	1.24e-11	IgG glycosylation;
CRC	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.62	10.13	0.49	3.53e-21	Subjective well-being (multi-trait analysis);
CRC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.6	0.3	4.51e-8	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.54	-8.72	-0.43	1.4e-16	Neurofibrillary tangles;
CRC	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.72	-11.6	-0.54	2.56e-26	Neurofibrillary tangles;
CRC	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-6.37	-0.33	6.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	8.77	0.44	9.89e-17	Schizophrenia;
CRC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.62	-7.69	-0.39	1.68e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.57	8.82	0.44	6.74e-17	Height;
CRC	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg22654517	chr2:96458247	NA	0.32	5.72	0.3	2.43e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.52	0.34	2.65e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.74	13.4	0.59	5.43e-33	Hip circumference;
CRC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.98	-17.96	-0.7	9.76e-51	Headache;
CRC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.62	-9.99	-0.48	1.08e-20	Monocyte count;
CRC	trans	rs926326	0.789	rs62392334	chr6:25506415	A/G	cg25354657	chr11:129991445	APLP2	-0.43	-6.34	-0.33	7.39e-10	Platelet count;
CRC	cis	rs4658101	0.667	rs4658235	chr1:92049788	G/A	cg24006770	chr1:92056542	NA	0.45	6.52	0.34	2.61e-10	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.54	9.9	0.48	2.17e-20	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.53	8.63	0.43	2.65e-16	Height;
CRC	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.5	0.65	4.51e-41	Fuchs's corneal dystrophy;
CRC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.39	6.13	0.32	2.52e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.84	-10.78	-0.51	2.06e-23	Gut microbiome composition (summer);
CRC	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg16898833	chr6:26189333	HIST1H4D	1.05	7.92	0.4	3.77e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs62229266	0.659	rs2255734	chr21:37411909	T/C	cg08632701	chr21:37451849	NA	-0.4	-6.28	-0.33	1.08e-9	Mitral valve prolapse;
CRC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-6.12	-0.32	2.7e-9	Total body bone mineral density;
CRC	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs12760731	0.641	rs12691479	chr1:178328754	G/A	cg00404053	chr1:178313656	RASAL2	0.93	9.79	0.48	4.84e-20	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg22687807	chr8:143858763	LYNX1	0.51	9.1	0.45	8.59e-18	Urinary tract infection frequency;
CRC	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg14345882	chr6:26364793	BTN3A2	0.41	6.35	0.33	7.22e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg02927042	chr1:21476669	EIF4G3	-0.51	-7.76	-0.39	1.05e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs17095355	0.688	rs1349348	chr10:111794554	T/C	cg00817464	chr10:111662876	XPNPEP1	0.48	6.07	0.32	3.57e-9	Biliary atresia;
CRC	cis	rs9292777	0.720	rs10071761	chr5:40415611	T/C	cg09067459	chr5:40385259	NA	-0.54	-8.96	-0.44	2.39e-17	Crohn's disease;Multiple sclerosis;
CRC	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.29	-0.33	1.01e-9	Depression;
CRC	cis	rs3751196	0.808	rs75536713	chr12:104210958	C/T	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.56	7.98	0.4	2.47e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.73	-11.42	-0.53	1.14e-25	Cognitive function;
CRC	cis	rs9525927	0.625	rs9533802	chr13:44820059	C/T	cg19190762	chr13:44806055	NA	0.56	6.59	0.34	1.71e-10	Dupuytren's disease;
CRC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg11833968	chr6:79620685	NA	-0.37	-6.4	-0.33	5.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.46	-7.59	-0.39	3.43e-13	Monocyte count;
CRC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.61	8.53	0.43	5.32e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.4	-6.58	-0.34	1.81e-10	Mean arterial pressure;
CRC	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg06038358	chr2:128176007	PROC	-0.34	-5.68	-0.3	2.89e-8	Self-rated health;
CRC	cis	rs863345	0.604	rs10908656	chr1:158461016	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-6.04	-0.32	4.2e-9	Pneumococcal bacteremia;
CRC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.83	0.31	1.33e-8	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-20.32	-0.75	4.64e-60	Prudent dietary pattern;
CRC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.6	11.04	0.52	2.6e-24	Immature fraction of reticulocytes;
CRC	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg26182253	chr13:112236782	NA	0.31	6.23	0.32	1.4e-9	Hepatitis;
CRC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.66	-7.9	-0.4	4.15e-14	Lymphocyte counts;
CRC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.96	-0.4	2.86e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg12458913	chr13:53173898	NA	-0.54	-8.56	-0.43	4.41e-16	Lewy body disease;
CRC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-9.66	-0.47	1.35e-19	Body mass index;
CRC	cis	rs4925540	0.686	rs2642995	chr1:247172565	A/G	cg22502715	chr1:247171572	ZNF695	0.41	6.07	0.32	3.46e-9	Response to taxane treatment (docetaxel);
CRC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg24416660	chr17:73865998	NA	-0.38	-5.76	-0.3	1.91e-8	Psoriasis;
CRC	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.92	17.36	0.69	2.3e-48	Lewy body disease;
CRC	trans	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg06840491	chr10:48416966	GDF2	-0.35	-6.15	-0.32	2.2e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.68	0.3	2.95e-8	Diabetic retinopathy;
CRC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg14844989	chr11:31128820	NA	-0.36	-6.29	-0.33	1.01e-9	Red blood cell count;
CRC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.55	6.1	0.32	3.01e-9	White matter hyperintensity burden;
CRC	cis	rs6496667	0.865	rs62019351	chr15:90926557	G/A	cg04176472	chr15:90893244	GABARAPL3	0.58	7.58	0.39	3.62e-13	Rheumatoid arthritis;
CRC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg03623178	chr6:28175578	NA	0.72	9.61	0.47	2.04e-19	Parkinson's disease;
CRC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg01483505	chr11:975446	AP2A2	0.46	7.65	0.39	2.2e-13	Alzheimer's disease (late onset);
CRC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.64	11.71	0.54	1.01e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg06470822	chr6:28175283	NA	0.73	10.39	0.5	4.74e-22	Parkinson's disease;
CRC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.45	-7.05	-0.36	1.03e-11	Coronary artery disease;
CRC	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.59	-7.06	-0.36	1e-11	Dental caries;
CRC	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.77	0.63	3.05e-38	Exhaled nitric oxide output;
CRC	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.68	-7.89	-0.4	4.43e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CRC	cis	rs939584	1.000	rs7559447	chr2:645646	C/T	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs7572644	0.640	rs6744348	chr2:28018025	A/C	cg27432699	chr2:27873401	GPN1	0.45	5.64	0.3	3.65e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs4727963	0.792	rs2402627	chr7:122728102	T/C	cg03640110	chr7:122635026	TAS2R16	0.35	6.34	0.33	7.67e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CRC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg23172400	chr8:95962367	TP53INP1	0.4	6.04	0.32	4.07e-9	Type 2 diabetes;
CRC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.41	8.1	0.41	1.08e-14	Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.8	0.3	1.52e-8	Heart rate;
CRC	cis	rs6433857	0.594	rs17364750	chr2:181524361	C/G	cg23363182	chr2:181467187	NA	-0.46	-7.24	-0.37	3.2e-12	Body mass index;
CRC	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg21153622	chr11:89784906	NA	-0.45	-7.22	-0.37	3.57e-12	HDL cholesterol;
CRC	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.63	0.47	1.74e-19	Common traits (Other);
CRC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg05044414	chr3:183734942	ABCC5	0.48	8.3	0.42	2.71e-15	Anterior chamber depth;
CRC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.44	9.21	0.45	4.03e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg10589385	chr1:150898437	SETDB1	-0.31	-6.57	-0.34	1.93e-10	Blood protein levels;
CRC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg13798780	chr7:105162888	PUS7	0.68	8.04	0.41	1.59e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	0.96	11.44	0.53	9.55e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.51	-7.34	-0.37	1.74e-12	Pulmonary function decline;
CRC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.62	-0.3	3.99e-8	Bladder cancer;
CRC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg08772003	chr10:104629869	AS3MT	-0.37	-6.44	-0.33	4.33e-10	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.39	-5.98	-0.31	5.77e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs1532331	1.000	rs1532331	chr5:43116830	G/T	cg09164108	chr5:43007320	NA	0.41	6.22	0.32	1.48e-9	Menarche (age at onset);
CRC	cis	rs7605827	0.930	rs13398393	chr2:15602804	T/G	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.73e-8	Educational attainment (years of education);
CRC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg10876282	chr6:28092338	ZSCAN16	0.46	6.3	0.33	9.74e-10	Parkinson's disease;
CRC	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.43	-6.52	-0.34	2.59e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg02741985	chr17:80059408	CCDC57	0.44	7.33	0.37	1.76e-12	Life satisfaction;
CRC	trans	rs11225569	0.539	rs11225820	chr11:103342925	T/C	cg01615333	chr12:127765195	NA	-0.65	-6.17	-0.32	1.98e-9	Diisocyanate-induced asthma;
CRC	cis	rs17152411	1.000	rs1807099	chr10:126593774	C/T	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg24881330	chr22:46731750	TRMU	0.57	5.7	0.3	2.61e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	5.92	0.31	8.25e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs28643277	0.671	rs7085504	chr10:15555319	C/G	cg18315834	chr14:64909119	MTHFD1	0.42	6.13	0.32	2.48e-9	Periodontitis (CDC/AAP);
CRC	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg13086574	chr8:135490821	ZFAT	-0.36	-6.08	-0.32	3.34e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs7487075	0.647	rs12580583	chr12:46707001	C/G	cg22049899	chr12:47219821	SLC38A4	0.34	6.54	0.34	2.31e-10	Itch intensity from mosquito bite;
CRC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	1.01	17.81	0.7	3.74e-50	Primary sclerosing cholangitis;
CRC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.8	-10.27	-0.49	1.24e-21	Initial pursuit acceleration;
CRC	cis	rs3750082	0.889	rs55647647	chr7:32935020	C/T	cg05721444	chr7:32995514	FKBP9	0.49	7.46	0.38	7.87e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg14458575	chr2:238380390	NA	0.52	7.24	0.37	3.16e-12	Prostate cancer;
CRC	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.2	27.12	0.83	7.09e-86	Schizophrenia;
CRC	cis	rs1760803	0.701	rs6427509	chr1:154219718	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-5.94	-0.31	7.2e-9	Nicotine dependence;
CRC	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg09163369	chr1:210001066	C1orf107	-0.41	-5.67	-0.3	3.2e-8	Orofacial clefts;
CRC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-12.73	-0.57	1.93e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.43	6.66	0.34	1.15e-10	Height;
CRC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.55	8.02	0.4	1.84e-14	Intelligence (multi-trait analysis);
CRC	cis	rs9937943	0.512	rs13335886	chr16:74577161	C/G	cg01733217	chr16:74700730	RFWD3	-0.69	-8.53	-0.43	5.49e-16	Neutrophil percentage of white cells;
CRC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	15.13	0.64	1.25e-39	Primary sclerosing cholangitis;
CRC	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg25809561	chr17:30822961	MYO1D	-0.56	-9.87	-0.48	2.74e-20	Schizophrenia;
CRC	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-7.61	-0.39	2.98e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.71	-8.62	-0.43	2.91e-16	Multiple sclerosis;
CRC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg05044414	chr3:183734942	ABCC5	0.48	8.24	0.41	4.1e-15	Anterior chamber depth;
CRC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-5.78	-0.3	1.72e-8	Schizophrenia;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg20024234	chr21:43431083	ZNF295	-0.66	-5.99	-0.31	5.57e-9	Cognitive function;
CRC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg18099408	chr3:52552593	STAB1	0.35	6.01	0.31	4.95e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6460942	0.822	rs13340498	chr7:12233877	G/T	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.32	3.36e-9	Coronary artery disease;
CRC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg01483505	chr11:975446	AP2A2	0.4	5.92	0.31	8.22e-9	Alzheimer's disease (late onset);
CRC	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.43	6.37	0.33	6.37e-10	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.71	-9.19	-0.45	4.44e-18	Initial pursuit acceleration;
CRC	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	15.28	0.64	3.35e-40	Smoking behavior;
CRC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.53	8.9	0.44	3.72e-17	Breast cancer;
CRC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.53	-7.08	-0.36	8.95e-12	Colorectal cancer;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg08798685	chr6:27730294	NA	-0.42	-6.06	-0.32	3.72e-9	Parkinson's disease;
CRC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.56	8.64	0.43	2.5e-16	Prostate cancer;
CRC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.55	-8.41	-0.42	1.26e-15	Aortic root size;
CRC	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg21918786	chr6:109611834	NA	0.36	6.23	0.32	1.41e-9	Reticulocyte fraction of red cells;
CRC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.48	-0.38	6.62e-13	Colorectal cancer;
CRC	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg18850127	chr7:39170497	POU6F2	-0.43	-5.61	-0.3	4.26e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	6.15	0.32	2.25e-9	Menarche (age at onset);
CRC	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.73	9.78	0.47	5.39e-20	Coronary artery disease;
CRC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.6	-0.34	1.62e-10	Hemoglobin concentration;
CRC	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.72	0.54	9.5e-27	Coffee consumption (cups per day);
CRC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-8.02	-0.4	1.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg22495460	chr2:25135724	ADCY3	-0.72	-11.83	-0.55	3.81e-27	Body mass index;
CRC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.2	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.43	6.7	0.35	9.13e-11	Height;
CRC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg01941586	chr1:40203715	PPIE	-0.46	-6.34	-0.33	7.56e-10	Blood protein levels;
CRC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.47	-9.33	-0.46	1.59e-18	Renal cell carcinoma;
CRC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.8e-9	Aortic root size;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.92	-0.36	2.44e-11	Breast cancer;
CRC	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg25019722	chr6:37503610	NA	-0.47	-8.77	-0.44	9.97e-17	Cognitive performance;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.67	7.21	0.37	3.81e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg05730215	chr2:27435253	SLC5A6;C2orf28	0.42	6.53	0.34	2.43e-10	Obesity-related traits;
CRC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.3	-0.37	2.24e-12	Total body bone mineral density;
CRC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.44	5.93	0.31	7.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.65	-8.72	-0.43	1.42e-16	Alcohol dependence;
CRC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	7.75	0.39	1.15e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	6.58	0.34	1.84e-10	Diastolic blood pressure;
CRC	cis	rs6534441	0.857	rs6821873	chr4:125462941	G/A	cg21609808	chr4:125404261	NA	0.39	5.77	0.3	1.85e-8	Major depressive disorder;
CRC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.82	11.69	0.54	1.26e-26	Multiple sclerosis;
CRC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg25667490	chr4:72052924	SLC4A4	0.36	6.24	0.33	1.37e-9	Obesity-related traits;
CRC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg15786705	chr6:28176104	NA	0.69	9.84	0.48	3.5e-20	Parkinson's disease;
CRC	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg20356878	chr3:121714668	ILDR1	-0.48	-7.0	-0.36	1.45e-11	Multiple sclerosis;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.68	-10.07	-0.49	5.54e-21	Menopause (age at onset);
CRC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.59	-0.39	3.41e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg23018236	chr17:30244563	NA	-0.46	-6.26	-0.33	1.21e-9	Hip circumference adjusted for BMI;
CRC	cis	rs17401966	0.597	rs6667639	chr1:10246471	C/A	cg19773385	chr1:10388646	KIF1B	-0.52	-8.0	-0.4	2.11e-14	Hepatocellular carcinoma;
CRC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.9	14.49	0.62	3.98e-37	Ewing sarcoma;
CRC	trans	rs2303319	0.582	rs62188151	chr2:162309849	C/A	cg19471553	chr17:41393123	NA	-0.7	-6.07	-0.32	3.48e-9	Cognitive function;
CRC	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg13491945	chr12:107078410	RFX4	0.35	6.0	0.31	5.34e-9	Heart rate;
CRC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.49	-6.44	-0.33	4.12e-10	Blood metabolite levels;
CRC	trans	rs6472235	0.837	rs10092435	chr8:66936177	A/G	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg12935359	chr14:103987150	CKB	0.55	7.34	0.37	1.73e-12	Monocyte count;
CRC	cis	rs863345	0.604	rs10797018	chr1:158490112	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.25	-0.33	1.25e-9	Pneumococcal bacteremia;
CRC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg15468180	chr1:107600409	PRMT6	0.38	5.74	0.3	2.12e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-6.03	-0.32	4.38e-9	Lung cancer;
CRC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.41	-9.01	-0.44	1.72e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg06207120	chr15:45996521	NA	0.31	7.54	0.38	4.48e-13	Waist circumference;Weight;
CRC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.84	10.6	0.5	9.17e-23	Gut microbiome composition (summer);
CRC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.67	10.08	0.49	5.26e-21	Menopause (age at onset);
CRC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.41	-7.71	-0.39	1.55e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg26587870	chr6:27730563	NA	-0.43	-5.69	-0.3	2.75e-8	Depression;
CRC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.85	-14.55	-0.63	2.21e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg08314208	chr16:67682810	RLTPR	-0.54	-5.94	-0.31	7.18e-9	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.5	0.34	3.07e-10	Morning vs. evening chronotype;
CRC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.36	-6.76	-0.35	6.12e-11	Iron status biomarkers;
CRC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.36	-5.98	-0.31	5.87e-9	Lymphocyte counts;
CRC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.66	9.16	0.45	5.51e-18	Intelligence (multi-trait analysis);
CRC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.47	7.87	0.4	5.31e-14	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24008668	chr6:26158556	HIST1H2BD	0.41	6.26	0.33	1.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-6.49	-0.34	3.09e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7605827	0.930	rs6720900	chr2:15688281	T/C	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.39	-0.33	5.8e-10	Glomerular filtration rate (creatinine);
CRC	trans	rs17560407	0.620	rs13159808	chr5:88194669	T/A	cg11144641	chr5:134871566	NEUROG1	0.34	5.99	0.31	5.37e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg17948913	chr5:572064	NA	0.55	6.25	0.33	1.3e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.4	-0.5	4.44e-22	Bipolar disorder;
CRC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.5	-7.49	-0.38	6.27e-13	Coronary artery disease;
CRC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.91	-17.23	-0.69	7.42e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.03	-0.32	4.3e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10667969	chr3:149181941	NA	0.45	6.08	0.32	3.36e-9	Survival in pancreatic cancer;
CRC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.35	-0.46	1.37e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs990171	1.000	rs3755267	chr2:103038587	G/T	cg03938978	chr2:103052716	IL18RAP	-0.46	-5.76	-0.3	1.92e-8	Lymphocyte counts;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	7.24	0.37	3.16e-12	Obesity-related traits;
CRC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.45	-0.38	8.1e-13	Neuroticism;
CRC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.92	-16.74	-0.68	6.08e-46	Coronary artery disease;
CRC	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg18646521	chr2:111875858	NA	0.36	5.63	0.3	3.77e-8	Chronic lymphocytic leukemia;
CRC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg15786705	chr6:28176104	NA	0.67	9.29	0.46	2.23e-18	Parkinson's disease;
CRC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.52	-8.31	-0.42	2.56e-15	Caffeine consumption;
CRC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-6.28	-0.33	1.1e-9	Alzheimer's disease (late onset);
CRC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	13.85	0.61	1.09e-34	Platelet count;
CRC	cis	rs7605827	0.897	rs2380650	chr2:15533689	T/C	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.47	6.42	0.33	4.86e-10	Red cell distribution width;
CRC	cis	rs713477	0.505	rs1953740	chr14:55886717	G/A	cg13175173	chr14:55914753	NA	-0.45	-7.26	-0.37	2.78e-12	Pediatric bone mineral content (femoral neck);
CRC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg18761221	chr20:60518478	NA	0.41	7.39	0.38	1.26e-12	Body mass index;
CRC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.84	-0.7	2.9e-50	Height;
CRC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.69	-10.03	-0.48	7.8e-21	Inflammatory bowel disease;
CRC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06656553	chr16:89960601	TCF25	-0.56	-5.7	-0.3	2.62e-8	Skin colour saturation;
CRC	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.69	-7.82	-0.4	7.11e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-7.89	-0.4	4.59e-14	Bipolar disorder;
CRC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg07195577	chr17:27052828	TLCD1	0.42	6.06	0.32	3.63e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2786111	1.000	rs550098	chr1:197297408	A/G	cg13682187	chr1:196946512	CFHR5	0.29	5.71	0.3	2.52e-8	Lupus nephritis in systemic lupus erythematosus;
CRC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg27382691	chr15:76552771	ETFA;TYRO3P	-0.46	-6.33	-0.33	8.19e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg03623178	chr6:28175578	NA	0.63	8.4	0.42	1.36e-15	Parkinson's disease;
CRC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg18806716	chr10:30721971	MAP3K8	0.46	6.45	0.34	3.91e-10	Inflammatory bowel disease;
CRC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg03929089	chr4:120376271	NA	-0.46	-6.53	-0.34	2.51e-10	HDL cholesterol;
CRC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg11522145	chr4:3412961	RGS12	-0.41	-6.39	-0.33	5.74e-10	Serum sulfate level;
CRC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.49	0.34	3.2e-10	Rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg10760299	chr15:45669010	GATM	-0.49	-7.59	-0.39	3.39e-13	Homoarginine levels;
CRC	trans	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg19188899	chr13:112838565	NA	-0.39	-6.26	-0.33	1.23e-9	Systemic lupus erythematosus;
CRC	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.4	-5.99	-0.31	5.51e-9	Metabolic traits;
CRC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg20885578	chr2:198174922	NA	-0.39	-7.04	-0.36	1.11e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.42	-21.1	-0.76	4.36e-63	Hemostatic factors and hematological phenotypes;
CRC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.55	0.75	5.84e-61	Prudent dietary pattern;
CRC	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.8	-0.3	1.52e-8	Response to antipsychotic treatment;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg06751597	chr15:42788175	SNAP23	-0.41	-6.49	-0.34	3.25e-10	Aortic root size;
CRC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.99	-0.55	9.75e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg15147215	chr3:52552868	STAB1	-0.54	-7.78	-0.39	9.45e-14	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.94	0.44	2.79e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-13.74	-0.6	2.87e-34	Glomerular filtration rate (creatinine);
CRC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.29	6.07	0.32	3.6e-9	Homoarginine levels;
CRC	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg20356878	chr3:121714668	ILDR1	-0.43	-5.9	-0.31	8.89e-9	Multiple sclerosis;
CRC	cis	rs10046574	0.656	rs76799185	chr7:135194266	G/C	cg27474649	chr7:135195673	CNOT4	0.67	6.16	0.32	2.14e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8020095	0.571	rs10142059	chr14:67482629	A/G	cg00791868	chr14:66963628	C14orf53	0.49	6.32	0.33	8.33e-10	Depression (quantitative trait);
CRC	trans	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.76	9.41	0.46	8.96e-19	Type 2 diabetes;
CRC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.72	0.35	7.83e-11	Urate levels;
CRC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg27615366	chr5:131592974	PDLIM4	0.34	6.15	0.32	2.29e-9	Acylcarnitine levels;
CRC	cis	rs9828933	0.577	rs832193	chr3:63854445	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.81	9.4	0.46	9.83e-19	Type 2 diabetes;
CRC	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-6.3	-0.33	9.43e-10	Breast cancer;
CRC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.7	9.8	0.48	4.57e-20	Platelet distribution width;
CRC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.05	-0.32	3.97e-9	Bladder cancer;
CRC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.69	10.74	0.51	2.99e-23	Diastolic blood pressure;
CRC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.48	6.74	0.35	7.01e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-14.42	-0.62	7.34e-37	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04703227	chr1:19923504	C1orf151	0.4	6.92	0.36	2.43e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17697381	chr3:148709363	GYG1	0.4	5.96	0.31	6.51e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.45	-6.09	-0.32	3.11e-9	Diastolic blood pressure;
CRC	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.33	-6.93	-0.36	2.24e-11	Cutaneous nevi;
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.52	-7.46	-0.38	7.87e-13	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.34	-0.46	1.52e-18	Reticulocyte fraction of red cells;
CRC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.08	12.66	0.57	3.44e-30	Diabetic kidney disease;
CRC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-10.99	-0.52	3.82e-24	Alzheimer's disease;
CRC	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-9.16	-0.45	5.5e-18	Idiopathic membranous nephropathy;
CRC	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-7.47	-0.38	7.23e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg18016565	chr1:150552671	MCL1	0.44	6.44	0.33	4.19e-10	Tonsillectomy;
CRC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	6.42	0.33	4.89e-10	Monocyte percentage of white cells;
CRC	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg04110750	chr16:69646130	NFAT5	0.4	6.04	0.32	4.28e-9	Sjögren's syndrome;
CRC	cis	rs2730260	0.673	rs56236179	chr7:158843088	G/A	cg02254261	chr7:158964346	NA	-0.57	-6.31	-0.33	8.89e-10	Myopia (pathological);
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.83	-0.44	6.25e-17	Bipolar disorder;
CRC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg16141378	chr3:129829833	LOC729375	0.44	6.43	0.33	4.55e-10	Triglycerides;
CRC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.87	0.31	1.07e-8	Major depressive disorder;
CRC	trans	rs6956675	0.957	rs10236165	chr7:62596446	T/A	cg01314568	chr7:57830625	NA	-0.68	-9.32	-0.46	1.77e-18	Obesity-related traits;
CRC	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg25363559	chr8:143086065	NA	-0.34	-6.36	-0.33	6.67e-10	Amyotrophic lateral sclerosis;
CRC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.53	8.58	0.43	3.69e-16	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.69	8.29	0.42	3.01e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18350524	chr12:93835624	UBE2N	0.43	6.6	0.34	1.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.72	7.56	0.38	4.08e-13	Childhood ear infection;
CRC	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.55	7.71	0.39	1.53e-13	Triglycerides;
CRC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.7	-11.41	-0.53	1.25e-25	Hepatocellular carcinoma;
CRC	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.19	-0.32	1.74e-9	Breast cancer;
CRC	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-11.77	-0.54	6.15e-27	Exhaled nitric oxide output;
CRC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.96	15.35	0.65	1.69e-40	Primary sclerosing cholangitis;
CRC	cis	rs10760158	0.832	rs10985192	chr9:124016440	G/T	cg14417974	chr9:124058376	GSN	-0.34	-5.7	-0.3	2.62e-8	Pulse pressure;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg01044731	chr13:24554006	NA	-0.45	-6.16	-0.32	2.15e-9	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.44	-5.71	-0.3	2.51e-8	Height;
CRC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.82	0.48	4e-20	Bladder cancer;
CRC	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg26182253	chr13:112236782	NA	0.31	6.33	0.33	8.18e-10	Hepatitis;
CRC	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.87e-12	Prostate cancer;
CRC	cis	rs7487075	0.820	rs2018424	chr12:46694657	C/T	cg22049899	chr12:47219821	SLC38A4	0.31	5.92	0.31	8.32e-9	Itch intensity from mosquito bite;
CRC	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg10483660	chr13:112241077	NA	0.36	5.75	0.3	2e-8	Menarche (age at onset);
CRC	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg00250761	chr1:31883323	NA	-0.38	-7.22	-0.37	3.68e-12	Alcohol dependence;
CRC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	11.36	0.53	1.88e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.99	-18.5	-0.71	7.22e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.61	9.59	0.47	2.22e-19	Corneal astigmatism;
CRC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	5.73	0.3	2.27e-8	Prudent dietary pattern;
CRC	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.5	7.25	0.37	3.02e-12	Pulmonary function decline;
CRC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.25	-0.33	1.27e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.75	0.3	2.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs10979	0.644	rs12527367	chr6:143918718	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-8.36	-0.42	1.84e-15	Hypospadias;
CRC	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg23071808	chr14:103021642	NA	-0.64	-7.25	-0.37	2.99e-12	Platelet count;
CRC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.78	8.84	0.44	6.02e-17	Breast cancer;
CRC	cis	rs6123683	0.964	rs6127984	chr20:55824593	A/G	cg13236649	chr20:55835020	BMP7	-0.41	-5.68	-0.3	3.04e-8	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-1.0	-18.5	-0.71	7.07e-53	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.71	-0.39	1.46e-13	Response to antipsychotic treatment;
CRC	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.57	8.4	0.42	1.39e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.37	-6.19	-0.32	1.82e-9	Childhood ear infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00290498	chr5:1230850	SLC6A18	-0.37	-6.22	-0.32	1.51e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7901135	0.962	rs4948548	chr10:60570927	G/A	cg06879152	chr10:60937041	PHYHIPL	-0.37	-5.64	-0.3	3.61e-8	Morning vs. evening chronotype;
CRC	cis	rs747650	0.892	rs1976142	chr11:47225694	T/C	cg19486271	chr11:47235900	DDB2	-0.51	-7.71	-0.39	1.54e-13	Acne (severe);
CRC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg27535305	chr1:53392650	SCP2	0.38	6.97	0.36	1.77e-11	Monocyte count;
CRC	cis	rs3736485	0.966	rs10851500	chr15:51783820	T/C	cg08986416	chr15:51914746	DMXL2	-0.44	-6.46	-0.34	3.7e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.52	7.4	0.38	1.16e-12	High light scatter reticulocyte count;
CRC	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.64	6.56	0.34	2.1e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.12	10.46	0.5	2.76e-22	Skin colour saturation;
CRC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.81	-0.55	4.64e-27	Type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06391894	chr10:72142531	LRRC20	0.46	6.11	0.32	2.77e-9	Anxiety disorder;
CRC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-16.17	-0.67	1.09e-43	Cognitive function;
CRC	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg06522879	chr11:64358276	SLC22A12	0.56	8.75	0.43	1.16e-16	Urate levels in obese individuals;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg15786705	chr6:28176104	NA	0.67	6.33	0.33	7.87e-10	Depression;
CRC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.82	9.94	0.48	1.55e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.91	17.65	0.7	1.59e-49	Menopause (age at onset);
CRC	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg01843034	chr6:37503916	NA	-0.47	-8.75	-0.43	1.16e-16	Cognitive performance;
CRC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.59	9.08	0.45	1.06e-17	Aortic root size;
CRC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.88	-0.31	1.01e-8	Coronary artery disease;
CRC	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.68	-9.65	-0.47	1.46e-19	Blood trace element (Cu levels);
CRC	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.61	12.38	0.56	3.56e-29	Neuroticism;
CRC	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.52	-7.03	-0.36	1.16e-11	Triglycerides;
CRC	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	17.19	0.69	9.99e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs10512697	0.803	rs34924743	chr5:3575736	A/G	cg19473799	chr5:3511975	NA	-0.72	-5.67	-0.3	3.12e-8	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.96	-0.36	1.8e-11	Height;
CRC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	11.91	0.55	2.01e-27	Eye color traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13057196	chr4:8442503	ACOX3	0.44	6.04	0.32	4.1e-9	Anxiety disorder;
CRC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.62	8.17	0.41	6.8e-15	Alcohol dependence;
CRC	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg05527609	chr1:210001259	C1orf107	-0.58	-6.3	-0.33	9.7e-10	Red blood cell count;
CRC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06544989	chr22:39130855	UNC84B	0.46	7.52	0.38	5.24e-13	Menopause (age at onset);
CRC	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg00105475	chr2:10696890	NA	0.45	7.17	0.37	4.85e-12	Prostate cancer;
CRC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06462663	chr19:18546047	ISYNA1	0.48	7.28	0.37	2.42e-12	Breast cancer;
CRC	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.4	-5.78	-0.3	1.78e-8	Life satisfaction;
CRC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.61	9.96	0.48	1.39e-20	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CRC	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.36	0.42	1.81e-15	Corneal astigmatism;
CRC	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.74	9.84	0.48	3.35e-20	Prostate cancer;
CRC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	11.24	0.53	5.16e-25	Motion sickness;
CRC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.49	7.49	0.38	6.39e-13	Methadone dose in opioid dependence;
CRC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.52	8.79	0.44	8.27e-17	Prudent dietary pattern;
CRC	cis	rs3850699	0.683	rs67646802	chr10:104303748	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.82	-0.31	1.43e-8	Prostate cancer;
CRC	cis	rs2223471	0.875	rs2235497	chr6:50703074	G/A	cg03432817	chr6:50765336	NA	0.41	6.54	0.34	2.33e-10	Subcutaneous adipose tissue;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.02	0.4	1.87e-14	Alzheimer's disease;
CRC	cis	rs10971721	0.908	rs12376055	chr9:33831955	G/A	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01021423	chr3:48541507	SHISA5	0.39	6.47	0.34	3.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg02880119	chr16:3481970	NA	0.42	5.84	0.31	1.24e-8	Body mass index (adult);
CRC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	8.25	0.41	3.77e-15	Lung cancer in ever smokers;
CRC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.61	-9.5	-0.46	4.41e-19	Aortic root size;
CRC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg13319975	chr6:146136371	FBXO30	0.42	6.24	0.33	1.36e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.11	-0.36	7.49e-12	Schizophrenia;
CRC	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.5	9.2	0.45	4.34e-18	Weight;
CRC	cis	rs9625935	0.518	rs245008	chr22:30315736	T/C	cg01021169	chr22:30184971	ASCC2	-0.38	-5.9	-0.31	8.83e-9	Tonsillectomy;
CRC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg23758597	chr6:163146217	PARK2	-0.55	-5.62	-0.3	4.13e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11645453	chr3:52864694	ITIH4	0.37	6.55	0.34	2.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.64	9.94	0.48	1.58e-20	Crohn's disease;
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.56	7.63	0.39	2.59e-13	Alzheimer's disease;
CRC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.48	0.5	2.21e-22	Personality dimensions;
CRC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.64	-0.34	1.32e-10	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.76	9.41	0.46	8.87e-19	Developmental language disorder (linguistic errors);
CRC	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.24	0.37	3.23e-12	Body mass index;
CRC	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg05540913	chr6:167530185	CCR6	-0.35	-6.07	-0.32	3.5e-9	Primary biliary cholangitis;
CRC	cis	rs16924133	1.000	rs12286381	chr11:33224160	C/T	cg05567920	chr11:33183001	CSTF3	-0.78	-6.08	-0.32	3.39e-9	Anger;
CRC	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.61	-9.31	-0.46	1.9e-18	Eosinophil percentage of white cells;
CRC	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.48	-8.99	-0.44	2.04e-17	Hepatitis;
CRC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg09264619	chr17:80180166	NA	-0.49	-7.13	-0.37	6.39e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.82	13.39	0.59	6.26e-33	Cognitive function;
CRC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21659725	chr3:3221576	CRBN	0.66	7.32	0.37	1.94e-12	Menarche (age at onset);
CRC	cis	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.81	14.06	0.61	1.72e-35	Breast cancer;
CRC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.59	-0.43	3.63e-16	Monocyte percentage of white cells;
CRC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.48	-7.8	-0.4	8.13e-14	Huntington's disease progression;
CRC	cis	rs8060686	0.858	rs7206671	chr16:67807146	A/G	cg07125278	chr16:67683757	RLTPR	-0.47	-6.16	-0.32	2.1e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10924970	1.000	rs7339903	chr1:235337733	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.85	0.31	1.21e-8	Asthma;
CRC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-6.28	-0.33	1.1e-9	Alzheimer's disease (late onset);
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg15947007	chr7:64023509	ZNF680	-0.42	-6.37	-0.33	6.33e-10	Brain structure;
CRC	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.56	-9.02	-0.45	1.59e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg25164649	chr6:28176230	NA	0.44	6.24	0.33	1.32e-9	Parkinson's disease;
CRC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg26395211	chr5:140044315	WDR55	0.38	5.68	0.3	2.99e-8	Depressive symptoms (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23704689	chr12:110906840	GPN3;C12orf24	0.39	6.23	0.32	1.41e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	0.64	6.98	0.36	1.63e-11	Prostate cancer;
CRC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.93	17.49	0.69	6.64e-49	Height;
CRC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.46	-6.95	-0.36	1.97e-11	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg16950941	chr11:66035639	RAB1B	0.66	9.56	0.47	2.92e-19	Gout;
CRC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07498606	chr16:67313043	PLEKHG4	0.45	6.08	0.32	3.29e-9	Anxiety disorder;
CRC	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg02927042	chr1:21476669	EIF4G3	0.38	5.71	0.3	2.58e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs13315871	1.000	rs9869940	chr3:58401523	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.12	-0.37	6.99e-12	Cholesterol, total;
CRC	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg06223162	chr1:101003688	GPR88	0.34	6.32	0.33	8.46e-10	Monocyte count;
CRC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg18016565	chr1:150552671	MCL1	0.44	6.02	0.31	4.71e-9	Melanoma;
CRC	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.54	7.08	0.36	9.03e-12	Alzheimer's disease (survival time);
CRC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg07125278	chr16:67683757	RLTPR	-0.63	-7.26	-0.37	2.85e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-7.17	-0.37	4.96e-12	IgG glycosylation;
CRC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.6	8.93	0.44	3.13e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs6988985	0.728	rs10093618	chr8:143952214	A/G	cg10324643	chr8:143916377	GML	-0.35	-5.9	-0.31	9.16e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg25019722	chr6:37503610	NA	-0.5	-9.29	-0.46	2.17e-18	Cognitive performance;
CRC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg02560186	chr11:3602584	NA	-0.63	-9.54	-0.47	3.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs11212617	0.967	rs227062	chr11:108205383	G/A	cg14761454	chr11:108092087	ATM;NPAT	0.43	6.54	0.34	2.39e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4731207	0.596	rs7799771	chr7:124649937	C/A	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs12594515	0.600	rs12903858	chr15:45972166	A/G	cg22117107	chr15:45993392	NA	-0.39	-7.77	-0.39	9.97e-14	Waist circumference;Weight;
CRC	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg11900509	chr10:81946545	ANXA11	-0.65	-6.6	-0.34	1.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.32	-7.02	-0.36	1.24e-11	IgG glycosylation;
CRC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-18.27	-0.71	5.53e-52	Schizophrenia;
CRC	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.17	0.32	2.02e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	6.33	0.33	8.2e-10	Menopause (age at onset);
CRC	cis	rs3849570	0.695	rs62265411	chr3:81573660	T/C	cg07356753	chr3:81810745	GBE1	-0.53	-6.91	-0.36	2.51e-11	Waist circumference;Body mass index;
CRC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg15845792	chr6:28175446	NA	0.68	8.92	0.44	3.35e-17	Parkinson's disease;
CRC	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.62	8.72	0.43	1.35e-16	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.76	13.04	0.58	1.31e-31	Colorectal cancer;
CRC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg00579200	chr11:133705235	NA	-0.4	-5.92	-0.31	8.18e-9	Childhood ear infection;
CRC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg25956985	chr22:39795188	MAP3K7IP1	-0.46	-6.5	-0.34	2.96e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9362426	0.708	rs9342112	chr6:88092491	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	6.26	0.33	1.23e-9	Depressive episodes in bipolar disorder;
CRC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.89	-15.36	-0.65	1.55e-40	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.53	-0.46	3.68e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.08	-12.63	-0.57	4.33e-30	Diabetic kidney disease;
CRC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg19678392	chr7:94953810	PON1	-0.57	-7.2	-0.37	4.21e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg22561889	chr6:118971681	C6orf204	0.48	5.92	0.31	8.26e-9	Diastolic blood pressure;
CRC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.06	-0.36	9.86e-12	Height;
CRC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.4	6.73	0.35	7.36e-11	Childhood ear infection;
CRC	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.61	-9.61	-0.47	1.99e-19	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7703744	0.634	rs6884061	chr5:118683431	C/T	cg19893178	chr5:118692011	TNFAIP8	0.42	5.66	0.3	3.3e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.65	7.4	0.38	1.15e-12	Body mass index;
CRC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.66	-7.82	-0.4	7.38e-14	Menarche (age at onset);
CRC	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg00603274	chr11:61596626	FADS2	-0.49	-6.92	-0.36	2.42e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs3736485	0.578	rs4775968	chr15:51980821	A/G	cg08986416	chr15:51914746	DMXL2	0.39	5.75	0.3	2.03e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg12172441	chr6:28176163	NA	0.55	7.55	0.38	4.33e-13	Parkinson's disease;
CRC	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg00601450	chr5:74908170	NA	0.49	6.18	0.32	1.88e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg12927641	chr6:109611667	NA	-0.38	-6.74	-0.35	7.22e-11	Reticulocyte fraction of red cells;
CRC	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.72	-0.35	7.79e-11	Coronary artery disease;
CRC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.37	0.33	6.49e-10	Aortic root size;
CRC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.81	-10.7	-0.51	4.11e-23	Initial pursuit acceleration;
CRC	cis	rs863345	0.604	rs6666609	chr1:158498124	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-8.55	-0.43	4.67e-16	Uric acid levels;
CRC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.79	11.94	0.55	1.53e-27	Testicular germ cell tumor;
CRC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg23136738	chr11:925521	AP2A2	-0.4	-6.65	-0.34	1.21e-10	Alzheimer's disease (late onset);
CRC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.64	-8.97	-0.44	2.38e-17	Platelet count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12427896	chr2:111880694	BCL2L11	0.42	6.04	0.32	4.15e-9	Response to antipsychotic treatment;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg16339185	chr3:20227809	SGOL1	-0.45	-6.34	-0.33	7.52e-10	Birth weight;Height;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg15845792	chr6:28175446	NA	0.66	9.05	0.45	1.3e-17	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg16606324	chr3:10149918	C3orf24	0.68	9.69	0.47	1.07e-19	Alzheimer's disease;
CRC	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.55	-7.51	-0.38	5.51e-13	Coronary artery disease;
CRC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.63	-8.0	-0.4	2.22e-14	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-8.87	-0.44	4.85e-17	IgG glycosylation;
CRC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.53	-0.34	2.49e-10	Triglycerides;
CRC	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.47	6.82	0.35	4.38e-11	Primary sclerosing cholangitis;
CRC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.6	-9.2	-0.45	4.24e-18	Monocyte percentage of white cells;
CRC	cis	rs3126085	0.515	rs7514696	chr1:152363874	G/A	cg09127314	chr1:152161683	NA	-0.44	-5.84	-0.31	1.25e-8	Atopic dermatitis;
CRC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg15845792	chr6:28175446	NA	0.77	11.37	0.53	1.73e-25	Cardiac Troponin-T levels;
CRC	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.82	-14.47	-0.62	4.41e-37	Lewy body disease;
CRC	trans	rs9914544	0.545	rs7222893	chr17:18811702	A/G	cg21372672	chr17:16614065	CCDC144A	-0.4	-6.33	-0.33	8.06e-10	Educational attainment (years of education);
CRC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.92	0.31	8.32e-9	Vitiligo;
CRC	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.47	8.42	0.42	1.16e-15	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.84	15.51	0.65	4.07e-41	Lewy body disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg24542852	chr12:569111	B4GALNT3	0.4	6.32	0.33	8.46e-10	Interleukin-6 levels;
CRC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.53	-0.6	1.8e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16262614	chr3:133464971	TF	0.35	6.15	0.32	2.26e-9	Iron status biomarkers;
CRC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.53	-6.83	-0.35	4.1e-11	Body mass index;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg09564133	chr5:176738847	MXD3	0.42	5.97	0.31	6.03e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs294883	0.739	rs9457588	chr6:159732999	G/T	cg14500486	chr6:159655392	FNDC1	-0.35	-5.95	-0.31	6.68e-9	Coronary artery disease;
CRC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.7	7.77	0.39	1.02e-13	Vitiligo;
CRC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.45	0.38	8.17e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.62	10.57	0.5	1.13e-22	Prudent dietary pattern;
CRC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.39	-0.33	5.8e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.67	13.46	0.6	3.36e-33	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.34	-0.33	7.73e-10	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16420247	chr2:10442859	HPCAL1	-0.4	-6.38	-0.33	5.89e-10	Myopia (pathological);
CRC	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.46	-7.16	-0.37	5.46e-12	Asthma;
CRC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.36	5.65	0.3	3.47e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg11833968	chr6:79620685	NA	-0.37	-6.35	-0.33	7.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.35	0.33	7.02e-10	Tonsillectomy;
CRC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.46	6.94	0.36	2.03e-11	Longevity;Endometriosis;
CRC	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg21280719	chr6:42927975	GNMT	-0.43	-9.12	-0.45	7.46e-18	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03821916	chr17:58755215	BCAS3	0.4	6.25	0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg09659197	chr4:152720779	NA	-0.44	-8.72	-0.43	1.36e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg06259664	chr16:537672	RAB11FIP3	0.8	14.18	0.62	6.16e-36	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	0.97	13.77	0.6	2.17e-34	Breast cancer;
CRC	cis	rs10760158	0.832	rs4837827	chr9:124039871	C/T	cg14417974	chr9:124058376	GSN	-0.36	-6.08	-0.32	3.39e-9	Pulse pressure;
CRC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-17.2	-0.69	9.1e-48	Height;
CRC	trans	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.79	-0.51	1.87e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.93	11.81	0.55	4.37e-27	Glomerular filtration rate (creatinine);
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg09877947	chr5:131593287	PDLIM4	0.43	7.09	0.36	8.22e-12	Breast cancer;
CRC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10128264	0.902	rs1250588	chr10:80980169	T/C	cg18737081	chr10:80999807	ZMIZ1	-0.37	-6.52	-0.34	2.67e-10	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.61	-0.39	2.82e-13	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.97	0.44	2.31e-17	Mean platelet volume;
CRC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg00383909	chr3:49044727	WDR6	0.47	5.89	0.31	9.58e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.62	-11.21	-0.53	6.25e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs4700695	0.841	rs706679	chr5:65317181	A/G	cg21114390	chr5:65439923	SFRS12	-0.55	-6.63	-0.34	1.36e-10	Facial morphology (factor 19);
CRC	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.78	7.76	0.39	1.11e-13	Severe influenza A (H1N1) infection;
CRC	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.55	0.47	3.15e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.68	-8.93	-0.44	3.1e-17	Multiple sclerosis;
CRC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg21153622	chr11:89784906	NA	0.44	7.12	0.37	7.02e-12	Coronary artery disease;
CRC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg08222913	chr3:52553049	STAB1	-0.34	-6.13	-0.32	2.49e-9	Bipolar disorder;
CRC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.26	-5.92	-0.31	8.06e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.5	7.85	0.4	5.9e-14	Red blood cell count;
CRC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.49	-8.07	-0.41	1.34e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.89	15.48	0.65	5.48e-41	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.64	9.78	0.47	5.38e-20	Corneal astigmatism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13535441	chr11:73882018	C2CD3;PPME1	0.44	5.98	0.31	5.82e-9	Anxiety disorder;
CRC	trans	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.6	0.39	3.19e-13	Endometrial cancer;
CRC	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.68	-9.79	-0.47	5.01e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.41	6.02	0.32	4.64e-9	Menopause (age at onset);
CRC	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-6.18	-0.32	1.93e-9	Endometrial cancer;
CRC	trans	rs12699683	0.522	rs917796	chr7:15124846	C/T	cg24762932	chr10:23460245	NA	0.58	6.24	0.33	1.34e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg11130432	chr3:121712080	ILDR1	-0.46	-5.87	-0.31	1.05e-8	Multiple sclerosis;
CRC	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-10.55	-0.5	1.27e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.38	5.85	0.31	1.19e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8062405	0.558	rs151228	chr16:28563026	A/G	cg05139728	chr16:28306816	SBK1	-0.33	-5.82	-0.31	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.01e-15	Platelet count;
CRC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.24	-0.33	1.37e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.55	-0.47	3e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.51	-7.65	-0.39	2.21e-13	Axial length;
CRC	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.67	11.33	0.53	2.38e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg15192750	chr16:69999425	NA	0.56	7.31	0.37	2.02e-12	IgE levels;
CRC	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.47	-7.59	-0.39	3.26e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs11161851	0.550	rs11162359	chr1:75461044	G/A	cg11196437	chr1:75593865	LHX8	0.27	5.63	0.3	3.96e-8	Visceral fat;
CRC	cis	rs73200209	0.912	rs17498648	chr12:116610902	C/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.94	-0.31	7.34e-9	Total body bone mineral density;
CRC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg24375607	chr4:120327624	NA	0.48	7.72	0.39	1.45e-13	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03545677	chr2:47403996	CALM2	0.5	7.12	0.37	6.84e-12	Response to antipsychotic treatment;
CRC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.15	0.56	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.5	6.38	0.33	5.92e-10	Cholesterol, total;
CRC	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.63	-8.97	-0.44	2.37e-17	Coronary artery disease;
CRC	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.65	-9.54	-0.47	3.28e-19	Type 2 diabetes;
CRC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.7	12.41	0.56	2.94e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4908768	0.539	rs6666191	chr1:8658442	C/T	cg20416874	chr1:8611966	RERE	-0.4	-5.61	-0.3	4.25e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg10567034	chr11:70049203	FADD	0.4	6.03	0.32	4.35e-9	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg19856771	chr13:42780042	DGKH	-0.5	-6.23	-0.32	1.4e-9	Type 1 diabetes;
CRC	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.65	10.62	0.51	7.58e-23	Subjective well-being (multi-trait analysis);
CRC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.75	-0.3	2.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-7.0	-0.36	1.44e-11	IgG glycosylation;
CRC	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.45	7.22	0.37	3.52e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg02290350	chr8:58132656	NA	-0.54	-5.83	-0.31	1.33e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.59	-0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.71	11.2	0.53	6.71e-25	Cognitive ability;
CRC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.54	-9.0	-0.44	1.88e-17	Body mass index;
CRC	trans	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg15371732	chr17:78194151	SLC26A11;SGSH	0.43	6.03	0.32	4.35e-9	Cystic fibrosis severity;
CRC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.45	8.75	0.43	1.1e-16	Alcohol dependence;
CRC	trans	rs12189452	0.507	rs4957723	chr5:107157011	C/T	cg07112131	chr12:14926909	H2AFJ	0.39	6.15	0.32	2.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.51	8.36	0.42	1.77e-15	Aortic root size;
CRC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.79	0.51	2.01e-23	Prudent dietary pattern;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg15786705	chr6:28176104	NA	0.48	5.72	0.3	2.43e-8	Breast cancer;
CRC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg27535305	chr1:53392650	SCP2	-0.37	-6.77	-0.35	5.99e-11	Monocyte count;
CRC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.59	6.24	0.33	1.34e-9	Axial length;
CRC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg27068330	chr11:65405492	SIPA1	-0.63	-9.75	-0.47	6.92e-20	Acne (severe);
CRC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg06470822	chr6:28175283	NA	-0.79	-8.87	-0.44	4.66e-17	Parkinson's disease;
CRC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.79	-11.51	-0.54	5.3e-26	Intelligence (multi-trait analysis);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18852765	chr7:98030641	BAIAP2L1	0.38	6.11	0.32	2.89e-9	Schizophrenia;
CRC	cis	rs889398	0.617	rs3790082	chr16:69896754	G/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.9	-0.31	8.8e-9	Body mass index;
CRC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.36	-6.5	-0.34	3.02e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12463550	chr7:65579703	CRCP	0.63	6.04	0.32	4.17e-9	Diabetic kidney disease;
CRC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.46	6.68	0.35	1.01e-10	Colorectal cancer;
CRC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.51	6.63	0.34	1.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6076065	0.676	rs6083085	chr20:23336119	C/T	cg11657817	chr20:23433608	CST11	-0.42	-6.32	-0.33	8.62e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.39	-6.48	-0.34	3.34e-10	Alcohol dependence;
CRC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg03013636	chr16:1946785	NA	-0.52	-6.39	-0.33	5.7e-10	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs2188554	0.785	rs7789741	chr7:117206941	T/G	cg09181792	chr7:117119393	CFTR	0.35	6.1	0.32	3.05e-9	Esophageal adenocarcinoma;
CRC	cis	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg15845792	chr6:28175446	NA	0.85	5.61	0.3	4.19e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2898681	0.581	rs730247	chr4:53680696	T/G	cg00338735	chr4:53728038	RASL11B	0.39	5.92	0.31	8.08e-9	Optic nerve measurement (cup area);
CRC	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-6.33	-0.33	7.98e-10	Large artery stroke;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17115147	chr6:45345601	RUNX2;SUPT3H	0.42	7.1	0.36	7.83e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.61	-0.34	1.57e-10	Monocyte count;
CRC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg26304593	chr6:42947056	PEX6	0.39	5.62	0.3	4.07e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.51	-8.0	-0.4	2.2e-14	Monocyte count;
CRC	cis	rs7274811	0.625	rs293727	chr20:31933064	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	6.24	0.33	1.34e-9	Height;
CRC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.66	-7.87	-0.4	5.07e-14	Diabetic retinopathy;
CRC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.6	-9.35	-0.46	1.42e-18	Breast cancer;
CRC	cis	rs10911390	0.793	rs75157509	chr1:183612214	C/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.14	0.37	5.93e-12	Systemic lupus erythematosus;
CRC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg04731861	chr2:219085781	ARPC2	0.31	6.72	0.35	7.78e-11	Colorectal cancer;
CRC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	9.65	0.47	1.44e-19	Triglycerides;
CRC	trans	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg17903999	chr18:56338584	MALT1	0.41	6.74	0.35	7.13e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs932287	1.000	rs932287	chr11:9044767	A/G	cg12365402	chr11:9010492	NRIP3	-0.36	-5.9	-0.31	8.85e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.6	8.37	0.42	1.69e-15	Obesity-related traits;
CRC	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg00250761	chr1:31883323	NA	-0.38	-7.22	-0.37	3.68e-12	Alcohol dependence;
CRC	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	1.26	11.11	0.52	1.4e-24	Arsenic metabolism;
CRC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg27426351	chr10:43362370	NA	0.59	7.09	0.36	8.28e-12	Blood protein levels;
CRC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.81	-13.6	-0.6	9.63e-34	Cystic fibrosis severity;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg18058813	chr6:105307561	HACE1	-0.36	-6.05	-0.32	3.85e-9	Myopia (pathological);
CRC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-8.02	-0.4	1.91e-14	Arsenic metabolism;
CRC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18758796	chr5:131593413	PDLIM4	0.46	8.57	0.43	4e-16	Breast cancer;
CRC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.58	-6.08	-0.32	3.28e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg20354231	chr13:53171401	NA	-0.49	-7.69	-0.39	1.77e-13	Lewy body disease;
CRC	cis	rs12913538	0.962	rs12437894	chr15:62896799	A/G	cg09983546	chr15:62884068	NA	0.61	9.63	0.47	1.68e-19	Sleep depth;
CRC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg12560992	chr17:57184187	TRIM37	0.43	5.64	0.3	3.58e-8	Cognitive test performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24862861	chr10:976594	NA	0.45	6.74	0.35	7.21e-11	Intelligence (multi-trait analysis);
CRC	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.78	-14.79	-0.63	2.74e-38	Itch intensity from mosquito bite;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11454606	chr11:67888949	CHKA	0.43	7.87	0.4	5.29e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs9928842	0.882	rs11641896	chr16:75300179	T/C	cg09066997	chr16:75300724	BCAR1	0.64	5.91	0.31	8.68e-9	Alcoholic chronic pancreatitis;
CRC	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.41	5.67	0.3	3.18e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.52	7.13	0.37	6.58e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg09184832	chr6:79620586	NA	-0.46	-7.95	-0.4	3e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg12365402	chr11:9010492	NRIP3	-0.49	-8.3	-0.42	2.69e-15	Hemoglobin concentration;
CRC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.49	-7.33	-0.37	1.85e-12	Response to antineoplastic agents;
CRC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.61	-9.15	-0.45	5.99e-18	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.57	-9.18	-0.45	4.97e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.92	-0.31	8.17e-9	Life satisfaction;
CRC	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg24851651	chr11:66362959	CCS	-0.38	-6.69	-0.35	9.74e-11	Educational attainment (years of education);
CRC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.41	8.07	0.41	1.36e-14	Mean corpuscular volume;
CRC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.48	7.3	0.37	2.23e-12	Testicular germ cell tumor;
CRC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg04545296	chr12:48745243	ZNF641	0.33	5.71	0.3	2.52e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.52	-7.55	-0.38	4.37e-13	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.65	8.19	0.41	5.87e-15	Vitamin D levels;
CRC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg26587870	chr6:27730563	NA	-0.42	-6.28	-0.33	1.05e-9	Parkinson's disease;
CRC	cis	rs860772	0.500	rs1103852	chr1:158570890	A/C	cg12129480	chr1:158549410	OR10X1	0.26	5.73	0.3	2.21e-8	Lymphocyte percentage of white cells;
CRC	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg14844989	chr11:31128820	NA	0.34	6.18	0.32	1.89e-9	Red blood cell count;
CRC	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg22852734	chr6:133119734	C6orf192	0.84	7.02	0.36	1.28e-11	Type 2 diabetes nephropathy;
CRC	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.09	-15.17	-0.64	8.62e-40	Exhaled nitric oxide output;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24715473	chr16:50059017	TMEM188	0.43	6.15	0.32	2.25e-9	Response to antipsychotic treatment;
CRC	cis	rs3750082	0.889	rs7781915	chr7:32923159	T/C	cg05721444	chr7:32995514	FKBP9	0.5	7.76	0.39	1.12e-13	Glomerular filtration rate (creatinine);
CRC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.95	0.36	1.93e-11	Longevity;
CRC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.43	6.38	0.33	5.87e-10	Menopause (age at onset);
CRC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.33	-0.42	2.17e-15	Gut microbiome composition (summer);
CRC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg06238570	chr21:40685208	BRWD1	0.73	10.29	0.49	1.05e-21	Cognitive function;
CRC	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.87	-11.37	-0.53	1.66e-25	Hair shape;
CRC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.49	-0.62	3.8e-37	Body mass index;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23501767	chr5:133340570	VDAC1	0.41	6.3	0.33	9.56e-10	Schizophrenia;
CRC	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.21	-0.32	1.6e-9	Superior frontal gyrus grey matter volume;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg11625451	chr16:81349061	GAN	0.53	5.99	0.31	5.61e-9	Body mass index;
CRC	cis	rs863345	0.584	rs10797023	chr1:158497079	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-5.95	-0.31	6.94e-9	Pneumococcal bacteremia;
CRC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg08200582	chr11:442649	ANO9	-0.71	-7.33	-0.37	1.83e-12	Body mass index;
CRC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.54	-0.34	2.4e-10	Blood metabolite levels;
CRC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg12273811	chr6:28175739	NA	0.51	6.82	0.35	4.44e-11	Parkinson's disease;
CRC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg19913688	chr11:428466	ANO9	-0.72	-7.58	-0.39	3.58e-13	Body mass index;
CRC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.64	9.13	0.45	7.2e-18	Multiple sclerosis;
CRC	cis	rs4711336	0.527	rs28651968	chr6:33717424	T/C	cg14003231	chr6:33640908	ITPR3	0.44	7.08	0.36	8.83e-12	Height;
CRC	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.91	16.62	0.68	1.87e-45	Obesity (extreme);
CRC	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.51	-9.69	-0.47	1.04e-19	Hip circumference;Waist circumference;
CRC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg26893134	chr6:116381904	FRK	0.27	7.8	0.4	8.28e-14	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.61	9.5	0.46	4.6e-19	Body mass index;
CRC	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.62	8.08	0.41	1.24e-14	Height;
CRC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.43	-20.16	-0.74	1.97e-59	Hip circumference adjusted for BMI;
CRC	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.44	-6.28	-0.33	1.09e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg03013999	chr17:37608204	MED1	0.45	6.99	0.36	1.52e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2444240	1.000	rs494965	chr11:120053650	C/T	cg04390734	chr11:120039366	NA	-0.28	-5.71	-0.3	2.58e-8	Corneal curvature;
CRC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.59	9.19	0.45	4.42e-18	Aortic root size;
CRC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg08514558	chr10:81106712	PPIF	0.37	5.89	0.31	9.56e-9	Height;
CRC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg08999081	chr20:33150536	PIGU	0.44	5.73	0.3	2.25e-8	Protein C levels;
CRC	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg00086871	chr4:6988644	TBC1D14	1.02	7.7	0.39	1.65e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg19678392	chr7:94953810	PON1	-0.6	-7.49	-0.38	6.21e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs6546043	0.710	rs6546026	chr2:63923699	C/T	cg20306022	chr2:7947960	NA	-0.54	-6.09	-0.32	3.17e-9	Clozapine-induced agranulocytosis;
CRC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.06	9.93	0.48	1.71e-20	Opioid sensitivity;
CRC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.67	-0.43	1.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1223397	0.651	rs2458314	chr6:13309224	C/T	cg21538684	chr6:13274180	PHACTR1	0.4	6.48	0.34	3.37e-10	Blood pressure;
CRC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-6.82	-0.35	4.4e-11	Body mass index;
CRC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.69	9.14	0.45	6.54e-18	Alzheimer's disease;
CRC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.63	-10.58	-0.5	1.01e-22	Depressive symptoms (multi-trait analysis);
CRC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07513332	chr6:167530253	CCR6	-0.46	-8.39	-0.42	1.45e-15	Primary biliary cholangitis;
CRC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.57	9.76	0.47	6.24e-20	Intelligence (multi-trait analysis);
CRC	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.81	13.42	0.59	4.64e-33	Colorectal cancer;
CRC	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	20.51	0.75	8.58e-61	Colorectal cancer;
CRC	cis	rs7849270	1.000	rs746489	chr9:131910093	G/T	cg13538475	chr9:131942899	NA	-0.29	-5.76	-0.3	1.9e-8	Blood metabolite ratios;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg17608440	chr10:114912149	TCF7L2	0.37	6.08	0.32	3.26e-9	Aortic root size;
CRC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.73	-8.27	-0.41	3.3e-15	Obesity-related traits;
CRC	cis	rs992157	0.764	rs2891077	chr2:219184430	A/C	cg04880052	chr2:219191631	PNKD	0.4	6.08	0.32	3.32e-9	Colorectal cancer;
CRC	cis	rs755249	0.567	rs72661925	chr1:39669537	T/A	cg18385671	chr1:39797026	MACF1	-0.41	-5.93	-0.31	7.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.36e-20	Extrinsic epigenetic age acceleration;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg21768436	chr8:67341108	RRS1	-0.39	-6.25	-0.33	1.26e-9	Myopia (pathological);
CRC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg03579179	chr7:12444095	VWDE	-0.4	-5.68	-0.3	2.91e-8	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.57	-0.34	1.94e-10	Menopause (age at onset);
CRC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.46	-8.97	-0.44	2.22e-17	Prostate cancer;
CRC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09597638	chr17:3907349	NA	0.56	9.53	0.47	3.59e-19	Type 2 diabetes;
CRC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg00734567	chr1:86172782	ZNHIT6	-0.49	-7.38	-0.38	1.3e-12	Urate levels in overweight individuals;
CRC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg20387954	chr3:183756860	HTR3D	0.46	7.69	0.39	1.68e-13	Anterior chamber depth;
CRC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.9e-14	Obesity-related traits;
CRC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25517755	chr10:38738941	LOC399744	-0.45	-6.47	-0.34	3.64e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg24851651	chr11:66362959	CCS	-0.38	-6.69	-0.35	9.66e-11	Educational attainment (years of education);
CRC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.52	-9.12	-0.45	7.42e-18	Sense of smell;
CRC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02290350	chr8:58132656	NA	-0.62	-7.02	-0.36	1.27e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg25876840	chr17:41920477	NA	0.41	6.49	0.34	3.22e-10	Triglycerides;
CRC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09835421	chr16:68378352	PRMT7	-0.56	-5.69	-0.3	2.81e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.51	-5.95	-0.31	6.79e-9	Smoking behavior;
CRC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.92	0.44	3.32e-17	Total body bone mineral density;
CRC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.47	-7.17	-0.37	4.94e-12	Height;
CRC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg05673287	chr15:77411982	SGK269	-0.56	-8.71	-0.43	1.49e-16	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg25164649	chr6:28176230	NA	0.72	9.1	0.45	9.16e-18	Depression;
CRC	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg22561889	chr6:118971681	C6orf204	0.52	6.62	0.34	1.45e-10	Diastolic blood pressure;
CRC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-8.02	-0.4	1.82e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.45	5.68	0.3	2.92e-8	Initial pursuit acceleration;
CRC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.81	-0.4	7.73e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg00647820	chr17:40259828	DHX58	-0.46	-6.59	-0.34	1.78e-10	Fibrinogen levels;
CRC	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-9.81	-0.48	4.2e-20	Coffee consumption (cups per day);
CRC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	12.11	0.56	3.6e-28	Nonalcoholic fatty liver disease;
CRC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg18132624	chr14:105716052	BTBD6;BRF1	-0.51	-8.17	-0.41	6.81e-15	Mean platelet volume;Platelet distribution width;
CRC	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg21399703	chr1:247681439	NA	0.51	5.75	0.3	2e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.8	14.56	0.63	2.02e-37	Dental caries;
CRC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.63	9.13	0.45	7.11e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.08	0.32	3.4e-9	HIV-1 control;
CRC	cis	rs4731207	0.564	rs6466970	chr7:124592755	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-11.99	-0.55	1.01e-27	Body mass index;
CRC	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.38	6.89	0.36	2.84e-11	Colorectal cancer (SNP x SNP interaction);
CRC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.49	-0.34	3.12e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg02659138	chr7:134003124	SLC35B4	0.43	7.38	0.38	1.28e-12	Mean platelet volume;
CRC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	7.26	0.37	2.89e-12	Lung cancer in ever smokers;
CRC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13198984	chr17:80129470	CCDC57	0.48	8.5	0.42	6.74e-16	Life satisfaction;
CRC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.54	-7.43	-0.38	9.45e-13	Gut microbiome composition (summer);
CRC	cis	rs9427116	0.702	rs9427108	chr1:154607914	G/A	cg17218026	chr1:154582156	ADAR	0.63	10.3	0.49	9.85e-22	Blood protein levels;
CRC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.78	13.21	0.59	2.84e-32	Blood protein levels;
CRC	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-6.56	-0.34	2.11e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10097731	0.901	rs9298344	chr8:82043063	C/T	cg25230327	chr8:82042993	NA	-0.93	-13.69	-0.6	4.32e-34	Serum total protein level;
CRC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.75	-12.42	-0.57	2.56e-29	Obesity-related traits;
CRC	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	15.38	0.65	1.4e-40	Fuchs's corneal dystrophy;
CRC	trans	rs7696796	0.761	rs7670273	chr4:183162207	C/G	cg03635442	chr8:49427283	NA	-0.47	-6.03	-0.32	4.4e-9	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06221861	chr7:100425075	EPHB4	0.37	6.26	0.33	1.22e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.43	-6.04	-0.32	4.22e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.45	7.06	0.36	1.02e-11	Calcium levels;
CRC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.61e-12	Motion sickness;
CRC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25517755	chr10:38738941	LOC399744	-0.44	-6.41	-0.33	5.05e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg14515779	chr1:101123966	NA	0.39	7.21	0.37	3.93e-12	Monocyte count;
CRC	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg14345882	chr6:26364793	BTN3A2	-0.65	-5.74	-0.3	2.12e-8	Autism spectrum disorder or schizophrenia;
CRC	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg14222797	chr10:16859974	RSU1	0.62	6.41	0.33	5.02e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.54	7.17	0.37	4.88e-12	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
CRC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.15	0.32	2.28e-9	Rheumatoid arthritis;
CRC	trans	rs4942242	0.583	rs9594986	chr13:44229595	C/T	cg19169023	chr15:41853346	TYRO3	-0.46	-6.74	-0.35	6.91e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.7	-0.3	2.63e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.87	-18.92	-0.72	1.47e-54	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.86	-16.85	-0.68	2.27e-46	Oral cavity cancer;
CRC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg23262073	chr20:60523788	NA	-0.39	-6.18	-0.32	1.89e-9	Body mass index;
CRC	cis	rs12249377	0.519	rs7906960	chr10:92586205	A/G	cg14313238	chr10:92632228	RPP30	0.47	6.57	0.34	2e-10	White matter microstructure (global fractional anisotropy);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22303846	chr2:152145870	NMI	0.42	6.04	0.32	4.08e-9	Response to antipsychotic treatment;
CRC	trans	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg17903999	chr18:56338584	MALT1	-0.41	-6.6	-0.34	1.7e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg02376178	chr19:1969988	CSNK1G2	0.58	9.17	0.45	5.35e-18	Coronary artery disease;
CRC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.55	6.35	0.33	7.07e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	5.64	0.3	3.58e-8	Lung function (FEV1/FVC);
CRC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.4	12.47	0.57	1.65e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.54	6.65	0.34	1.23e-10	Morning vs. evening chronotype;
CRC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.52	0.34	2.65e-10	Morning vs. evening chronotype;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg02090014	chr7:156802340	MNX1	-0.37	-6.33	-0.33	7.81e-10	Aortic root size;
CRC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.43	6.23	0.32	1.44e-9	Aortic root size;
CRC	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg16141378	chr3:129829833	LOC729375	-0.45	-6.59	-0.34	1.74e-10	Retinal vascular caliber;
CRC	cis	rs4400599	0.594	rs7526644	chr1:154208753	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.83	-0.31	1.31e-8	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04557695	chr7:92466167	CDK6	0.38	6.36	0.33	6.65e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.67	10.46	0.5	2.64e-22	Corneal astigmatism;
CRC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.5	7.5	0.38	5.95e-13	Emphysema distribution in smoking;
CRC	cis	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg20159608	chr7:32802032	NA	-0.59	-7.06	-0.36	9.71e-12	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.47	6.61	0.34	1.54e-10	Diastolic blood pressure;
CRC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg24562669	chr7:97807699	LMTK2	0.43	7.06	0.36	9.7e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-15.83	-0.66	2.41e-42	Body mass index;
CRC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg03037974	chr15:76606532	NA	-0.56	-8.67	-0.43	1.99e-16	Blood metabolite levels;
CRC	cis	rs7692995	1.000	rs6831102	chr4:18018236	T/C	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs6681460	1.000	rs10889634	chr1:67065911	A/G	cg02459107	chr1:67143332	SGIP1	-0.48	-8.4	-0.42	1.34e-15	Presence of antiphospholipid antibodies;
CRC	cis	rs12476592	0.602	rs262526	chr2:63899478	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.49	0.34	3.11e-10	Childhood ear infection;
CRC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.43	5.61	0.3	4.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg00495681	chr13:53174319	NA	0.56	8.04	0.41	1.67e-14	Lewy body disease;
CRC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.61	10.33	0.49	7.72e-22	Resting heart rate;
CRC	cis	rs4731207	0.596	rs11767649	chr7:124637517	C/T	cg23710748	chr7:124431027	NA	0.44	6.88	0.35	3.07e-11	Cutaneous malignant melanoma;
CRC	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg15382696	chr6:118971807	C6orf204	0.6	7.66	0.39	2.05e-13	Renal cell carcinoma;
CRC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.52	6.99	0.36	1.49e-11	White blood cell count;
CRC	trans	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg02674126	chr19:40336878	FBL	0.43	6.91	0.36	2.58e-11	Hyperactive-impulsive symptoms;
CRC	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg05562828	chr17:3906858	NA	-0.46	-5.9	-0.31	9.01e-9	Type 2 diabetes;
CRC	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.56	7.47	0.38	7.19e-13	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg23517279	chr6:96025343	MANEA	0.48	5.96	0.31	6.43e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs9462027	0.628	rs2296360	chr6:34803558	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.16e-9	Systemic lupus erythematosus;
CRC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.96	0.31	6.35e-9	Tonsillectomy;
CRC	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-6.83	-0.35	4.16e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg07424746	chr4:185654737	MLF1IP	0.51	5.69	0.3	2.8e-8	Blood protein levels;
CRC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	7.85	0.4	5.94e-14	Response to antipsychotic treatment;
CRC	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.55	8.39	0.42	1.44e-15	HDL cholesterol;
CRC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs7692995	0.920	rs6849629	chr4:18009488	A/G	cg08925142	chr4:18023851	LCORL	-0.51	-5.74	-0.3	2.2e-8	Height;
CRC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-6.0	-0.31	5.25e-9	Gut microbiome composition (summer);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22738278	chr10:104220943	TMEM180	0.4	5.98	0.31	5.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.32	-0.56	6.37e-29	Bipolar disorder and schizophrenia;
CRC	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21659725	chr3:3221576	CRBN	0.66	7.35	0.38	1.63e-12	Menarche (age at onset);
CRC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.62	-6.9	-0.36	2.66e-11	Intelligence (multi-trait analysis);
CRC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.15	-25.79	-0.82	5.58e-81	IgG glycosylation;
CRC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	6.15e-10	Life satisfaction;
CRC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg15468180	chr1:107600409	PRMT6	-0.41	-6.29	-0.33	1.01e-9	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.6	10.48	0.5	2.39e-22	Aortic root size;
CRC	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	7.24	0.37	3.14e-12	Coronary artery disease;
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg12273811	chr6:28175739	NA	0.62	9.03	0.45	1.52e-17	Cardiac Troponin-T levels;
CRC	cis	rs7463659	1.000	rs7836944	chr8:135436202	A/G	cg17885191	chr8:135476712	NA	0.45	6.84	0.35	3.84e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.59	-7.32	-0.37	1.88e-12	Lung cancer;
CRC	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg04239558	chr2:103089729	SLC9A4	0.37	6.58	0.34	1.83e-10	Blood protein levels;
CRC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6534441	0.857	rs28507630	chr4:125460069	C/A	cg21609808	chr4:125404261	NA	0.39	5.77	0.3	1.85e-8	Major depressive disorder;
CRC	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-12.0	-0.55	9.55e-28	Exhaled nitric oxide output;
CRC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg17321639	chr7:2759063	NA	-0.4	-6.03	-0.32	4.4e-9	Height;
CRC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.63	8.31	0.42	2.6e-15	Menopause (age at onset);
CRC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg03690763	chr11:133734501	NA	-0.34	-5.73	-0.3	2.33e-8	Childhood ear infection;
CRC	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-12.05	-0.55	5.89e-28	Exhaled nitric oxide output;
CRC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.23	-0.37	3.43e-12	Coronary artery disease;
CRC	trans	rs4853036	0.586	rs35286755	chr2:70005173	T/G	cg14633329	chr9:139640053	LCN6	-0.39	-6.39	-0.33	5.63e-10	Colorectal or endometrial cancer;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg14883916	chr11:6947541	ZNF215	0.59	6.26	0.33	1.21e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.87	0.48	2.71e-20	Platelet count;
CRC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.39	-0.33	5.65e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg00769240	chr8:12517080	NA	-0.57	-6.84	-0.35	3.87e-11	Blood pressure (smoking interaction);
CRC	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg27398640	chr15:77910606	LINGO1	0.42	7.72	0.39	1.43e-13	Type 2 diabetes;
CRC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg18761221	chr20:60518478	NA	0.41	7.26	0.37	2.9e-12	Body mass index;
CRC	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16386425	chr10:429943	DIP2C	-0.47	-7.35	-0.38	1.55e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	1.01	12.88	0.58	5.12e-31	IgG glycosylation;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.01	-19.58	-0.73	3.71e-57	Prudent dietary pattern;
CRC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-7.27	-0.37	2.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.7	-0.39	1.56e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-5.78	-0.3	1.77e-8	Alzheimer's disease (survival time);
CRC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg15226275	chr6:116381976	FRK	0.3	8.5	0.42	6.55e-16	Cholesterol, total;LDL cholesterol;
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg19500275	chr17:80737654	TBCD	0.53	7.47	0.38	7.17e-13	Glycated hemoglobin levels;
CRC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.47	-6.28	-0.33	1.1e-9	Schizophrenia;
CRC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.55	8.83	0.44	6.46e-17	Prostate cancer;
CRC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg05627522	chr15:75251581	NA	0.5	7.54	0.38	4.55e-13	Breast cancer;
CRC	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.48	-6.88	-0.35	3.12e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs6504622	0.577	rs197915	chr17:44990522	A/G	cg16759221	chr17:45003025	GOSR2	-0.62	-10.02	-0.48	8.57e-21	Orofacial clefts;
CRC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-9.26	-0.45	2.7e-18	Initial pursuit acceleration;
CRC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.66	-9.54	-0.47	3.31e-19	DNA methylation (variation);
CRC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg07952391	chr2:88470173	THNSL2	0.62	6.27	0.33	1.15e-9	Plasma clusterin levels;
CRC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg02659138	chr7:134003124	SLC35B4	0.4	6.9	0.36	2.6e-11	Mean platelet volume;
CRC	trans	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg21153622	chr11:89784906	NA	-0.47	-7.57	-0.39	3.82e-13	HDL cholesterol;
CRC	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.61	-0.57	5.09e-30	White blood cell count (basophil);
CRC	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.55	8.61	0.43	3.15e-16	Vitiligo;
CRC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.83	-12.14	-0.56	2.89e-28	Mean platelet volume;Platelet distribution width;
CRC	cis	rs12476592	0.543	rs262531	chr2:63904951	A/C	cg10828910	chr2:63850056	LOC388955	0.5	6.24	0.33	1.38e-9	Childhood ear infection;
CRC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-9.57	-0.47	2.73e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.83	10.42	0.5	3.71e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.58	-9.14	-0.45	6.77e-18	Breast cancer;
CRC	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.62	7.49	0.38	6.2800000000000005e-13	Hypertension (SNP x SNP interaction);
CRC	trans	rs6479874	0.831	rs2660211	chr10:52747861	C/T	cg15483030	chr1:5935144	NPHP4	-0.71	-6.34	-0.33	7.64e-10	Migraine;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg25164649	chr6:28176230	NA	-0.77	-9.82	-0.48	4.09e-20	Depression;
CRC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg20243544	chr17:37824526	PNMT	0.56	8.74	0.43	1.2e-16	Asthma;
CRC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.64	6.65	0.34	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17554472	chr22:41940697	POLR3H	-0.54	-5.67	-0.3	3.14e-8	Vitiligo;
CRC	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg27534772	chr1:16042836	PLEKHM2	0.45	7.5	0.38	6.07e-13	Systolic blood pressure;
CRC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.48	7.06	0.36	1e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg03929089	chr4:120376271	NA	0.61	6.06	0.32	3.67e-9	Axial length;
CRC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg24562669	chr7:97807699	LMTK2	0.44	7.27	0.37	2.66e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg20243544	chr17:37824526	PNMT	-0.48	-5.64	-0.3	3.7e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.89	-11.28	-0.53	3.61e-25	Hair shape;
CRC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg21285383	chr16:89894308	SPIRE2	0.36	5.81	0.31	1.46e-8	Vitiligo;
CRC	cis	rs28489187	0.706	rs233095	chr1:85824816	T/C	cg17737388	chr1:85724454	C1orf52	0.37	5.61	0.3	4.2e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CRC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg03060546	chr3:49711283	APEH	0.41	5.77	0.3	1.79e-8	Menarche (age at onset);
CRC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16447950	chr5:562315	NA	-0.71	-9.55	-0.47	3.07e-19	Obesity-related traits;
CRC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.47	7.13	0.37	6.43e-12	Intelligence (multi-trait analysis);
CRC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.62	-7.94	-0.4	3.17e-14	Urate levels in lean individuals;
CRC	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	0.62	5.88	0.31	1.03e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	trans	rs9903692	0.954	rs7212202	chr17:46132723	G/C	cg13910583	chr8:56987998	RPS20	-0.44	-5.99	-0.31	5.63e-9	Pulse pressure;
CRC	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg15660573	chr17:549704	VPS53	-0.86	-15.79	-0.66	3.27e-42	Prostate cancer;
CRC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg20203395	chr5:56204925	C5orf35	-0.72	-8.29	-0.42	2.99e-15	Initial pursuit acceleration;
CRC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.31	8.42e-9	Hemoglobin concentration;
CRC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.37	5.78	0.3	1.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg15845792	chr6:28175446	NA	0.68	8.92	0.44	3.35e-17	Parkinson's disease;
CRC	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-0.72	-7.92	-0.4	3.74e-14	Post bronchodilator FEV1;
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11645453	chr3:52864694	ITIH4	0.37	6.49	0.34	3.07e-10	Bipolar disorder;
CRC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg11212589	chr17:38028394	ZPBP2	0.46	8.71	0.43	1.5e-16	Self-reported allergy;
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02421172	chr7:1938701	MAD1L1	0.42	5.69	0.3	2.77e-8	Bipolar disorder;
CRC	cis	rs7394190	0.935	rs4746140	chr10:75417249	G/C	cg26549892	chr10:75416844	SYNPO2L	-0.49	-6.35	-0.33	7.02e-10	Incident atrial fibrillation;
CRC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-9.58	-0.47	2.42e-19	Primary sclerosing cholangitis;
CRC	cis	rs3750082	0.852	rs34724897	chr7:32899526	T/A	cg05721444	chr7:32995514	FKBP9	-0.48	-7.3	-0.37	2.16e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.58	8.15	0.41	7.81e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.77	-12.14	-0.56	2.92e-28	Hypospadias;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01858300	chr15:41233997	NA	0.44	7.23	0.37	3.39e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.42	-0.33	4.84e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.71	-8.47	-0.42	8.14e-16	Body mass index;
CRC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.41	6.15	0.32	2.25e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.49	0.38	6.54e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.64	-0.47	1.58e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg15845792	chr6:28175446	NA	1.0	13.1	0.59	7.81e-32	Depression;
CRC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.5	7.44	0.38	9.05e-13	Longevity;Endometriosis;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21774377	chr6:34760070	UHRF1BP1	-0.49	-6.07	-0.32	3.52e-9	Diisocyanate-induced asthma;
CRC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg03030879	chr14:75389066	RPS6KL1	0.45	6.96	0.36	1.89e-11	Height;
CRC	trans	rs6604635	0.695	rs6658528	chr1:216722090	A/G	cg15689795	chr4:2439478	NA	0.32	6.02	0.31	4.56e-9	Gut microbiome composition (summer);
CRC	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.54	7.59	0.39	3.29e-13	Eye color traits;
CRC	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-14.39	-0.62	9.54e-37	Colorectal cancer;
CRC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.45	-6.82	-0.35	4.33e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.55	7.46	0.38	7.79e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs10097731	0.901	rs10464892	chr8:82042991	A/G	cg25230327	chr8:82042993	NA	0.88	13.29	0.59	1.49e-32	Serum total protein level;
CRC	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.27	-0.46	2.55e-18	Migraine;Coronary artery disease;
CRC	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.85	0.66	1.97e-42	Fuchs's corneal dystrophy;
CRC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.37	5.9	0.31	9.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg08213375	chr14:104286397	PPP1R13B	0.58	11.91	0.55	1.87e-27	Schizophrenia;
CRC	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.98	18.08	0.71	3.12e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.48	6.44	0.33	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.78	0.44	9.03e-17	Coffee consumption (cups per day);
CRC	trans	rs8108034	0.920	rs30480	chr19:39807213	A/G	cg09731288	chr10:112632370	PDCD4	-0.51	-6.03	-0.32	4.42e-9	Lung adenocarcinoma;
CRC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.88	10.91	0.52	7.53e-24	Glomerular filtration rate (creatinine);
CRC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg22638593	chr5:131593259	PDLIM4	-0.38	-6.3	-0.33	9.32e-10	Breast cancer;
CRC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-18.26	-0.71	6.49e-52	Schizophrenia;
CRC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.03	-0.32	4.47e-9	Menopause (age at onset);
CRC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg02741985	chr17:80059408	CCDC57	-0.46	-7.54	-0.38	4.53e-13	Life satisfaction;
CRC	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg06581033	chr10:766294	NA	-0.51	-5.62	-0.3	4.1e-8	Uric acid levels;
CRC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06544989	chr22:39130855	UNC84B	-0.39	-6.0	-0.31	5.1e-9	Menopause (age at onset);
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg02683197	chr6:28174875	NA	0.62	8.4	0.42	1.39e-15	Parkinson's disease;
CRC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg26248373	chr2:1572462	NA	-0.71	-8.13	-0.41	8.56e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg00343986	chr7:65444356	GUSB	0.49	7.19	0.37	4.31e-12	Aortic root size;
CRC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.39	6.18	0.32	1.89e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg21153622	chr11:89784906	NA	-0.43	-7.1	-0.36	7.75e-12	Coronary artery disease;
CRC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.83	-0.35	4.02e-11	Monocyte percentage of white cells;
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.72	8.5	0.42	6.95e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	11.41	0.53	1.28e-25	Schizophrenia;
CRC	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg15704280	chr7:45808275	SEPT13	0.55	7.17	0.37	5.11e-12	Intraocular pressure;
CRC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.46	6.58	0.34	1.86e-10	Lymphocyte counts;
CRC	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.43	5.66	0.3	3.29e-8	Cerebrospinal fluid biomarker levels;
CRC	trans	rs7027930	0.598	rs7022858	chr9:569681	G/A	cg27061366	chr19:13044373	FARSA	0.5	6.0	0.31	5.28e-9	Pulmonary function decline;
CRC	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg21280719	chr6:42927975	GNMT	-0.34	-5.86	-0.31	1.15e-8	Blood protein levels;
CRC	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg21251018	chr6:28226885	NKAPL	0.53	6.26	0.33	1.17e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.41	6.21	0.32	1.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.48	-8.93	-0.44	3.03e-17	Cognitive performance;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06439982	chr16:2802372	SRRM2;LOC100128788	0.48	6.71	0.35	8.38e-11	Anxiety disorder;
CRC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg08999081	chr20:33150536	PIGU	0.45	5.86	0.31	1.09e-8	Protein C levels;
CRC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	8.59	0.43	3.47e-16	Cognitive test performance;
CRC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.45	-6.18	-0.32	1.94e-9	Total body bone mineral density;
CRC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7113874	0.569	rs11041962	chr11:8549623	C/T	cg17679104	chr11:8615758	STK33	-0.35	-5.9	-0.31	8.91e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg15448220	chr1:150897856	SETDB1	-0.45	-6.6	-0.34	1.67e-10	Tonsillectomy;
CRC	cis	rs4700695	0.764	rs36299	chr5:65348120	G/T	cg21114390	chr5:65439923	SFRS12	0.59	7.19	0.37	4.36e-12	Facial morphology (factor 19);
CRC	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.52	-9.85	-0.48	3.19e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg00343986	chr7:65444356	GUSB	-0.48	-7.13	-0.37	6.25e-12	Aortic root size;
CRC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.11	0.52	1.42e-24	Prudent dietary pattern;
CRC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.48	6.39	0.33	5.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4731207	0.655	rs7808203	chr7:124502136	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs11191205	0.644	rs74926559	chr10:103378309	G/A	cg15320455	chr10:103880129	LDB1	0.59	6.47	0.34	3.64e-10	Intelligence (multi-trait analysis);
CRC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12311346	chr5:56204834	C5orf35	-0.51	-7.97	-0.4	2.58e-14	Coronary artery disease;
CRC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-11.74	-0.54	8.32e-27	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs17209837	0.831	rs56223611	chr7:87083157	C/A	cg00919237	chr7:87102261	ABCB4	-0.47	-5.7	-0.3	2.61e-8	Gallbladder cancer;
CRC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg23136738	chr11:925521	AP2A2	-0.41	-7.01	-0.36	1.32e-11	Alzheimer's disease (late onset);
CRC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg23109721	chr2:106886537	NA	0.43	5.75	0.3	1.99e-8	Facial morphology (factor 23);
CRC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg10298567	chr3:47292165	KIF9	-0.39	-6.36	-0.33	6.69e-10	Colorectal cancer;
CRC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.69	-9.12	-0.45	7.72e-18	Initial pursuit acceleration;
CRC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04880052	chr2:219191631	PNKD	-0.44	-6.93	-0.36	2.2e-11	Colorectal cancer;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Parkinson's disease;
CRC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.6	-7.65	-0.39	2.29e-13	Gut microbiome composition (summer);
CRC	cis	rs2692947	0.637	rs72492201	chr2:96630201	G/A	cg23100626	chr2:96804247	ASTL	0.26	7.03	0.36	1.18e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.57	6.5	0.34	2.93e-10	Osteoarthritis;
CRC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.86	-0.35	3.37e-11	HDL cholesterol;Metabolic syndrome;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg23414876	chr16:67197396	HSF4;FBXL8	-0.28	-6.6	-0.34	1.62e-10	HDL cholesterol;
CRC	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg22561889	chr6:118971681	C6orf204	0.5	6.39	0.33	5.8e-10	Diastolic blood pressure;
CRC	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-1.07	-14.61	-0.63	1.36e-37	Exhaled nitric oxide output;
CRC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19046167	chr17:80928561	B3GNTL1	0.48	6.73	0.35	7.59e-11	Glycated hemoglobin levels;
CRC	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg11579758	chr4:1086637	RNF212	0.4	6.61	0.34	1.58e-10	Recombination rate (males);
CRC	cis	rs4664293	0.647	rs6714917	chr2:160449453	A/C	cg08347373	chr2:160653686	CD302	-0.39	-6.49	-0.34	3.12e-10	Monocyte percentage of white cells;
CRC	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.53	-8.87	-0.44	4.92e-17	Congenital heart disease (maternal effect);
CRC	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg20936604	chr3:58311152	NA	-0.69	-6.43	-0.33	4.38e-10	Cholesterol, total;
CRC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	7.34	0.37	1.72e-12	Height;
CRC	cis	rs73206853	0.563	rs11830452	chr12:111198576	A/T	cg12870014	chr12:110450643	ANKRD13A	0.73	8.42	0.42	1.19e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg17949981	chr6:28129498	ZNF389	0.41	5.62	0.3	4.15e-8	Cardiac Troponin-T levels;
CRC	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.56	8.32	0.42	2.39e-15	Multiple myeloma (IgH translocation);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01200289	chr4:77227751	STBD1	0.48	7.45	0.38	8.17e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13198984	chr17:80129470	CCDC57	0.45	7.8	0.4	8.04e-14	Life satisfaction;
CRC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-8.28	-0.42	3.19e-15	Blood metabolite levels;
CRC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg17724175	chr1:150552817	MCL1	0.43	6.5	0.34	2.96e-10	Melanoma;
CRC	trans	rs960902	0.747	rs13009200	chr2:37712496	C/A	cg19040518	chr10:75570762	NDST2	-0.43	-5.97	-0.31	6.28e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.28	5.72	0.3	2.41e-8	Homoarginine levels;
CRC	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.48	7.53	0.38	4.79e-13	Obesity-related traits;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.43	5.84	0.31	1.22e-8	Longevity;
CRC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg13722127	chr7:150037890	RARRES2	0.53	8.03	0.4	1.73e-14	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.57	-9.16	-0.45	5.54e-18	Intelligence (multi-trait analysis);
CRC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.59	9.2	0.45	4.38e-18	Intelligence (multi-trait analysis);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01643284	chr12:105629755	APPL2	0.4	6.42	0.33	4.79e-10	Interleukin-6 levels;
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg24560729	chr4:1342394	KIAA1530	-0.4	-7.28	-0.37	2.49e-12	Obesity-related traits;
CRC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg15786705	chr6:28176104	NA	0.5	6.19	0.32	1.81e-9	Parkinson's disease;
CRC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.77	0.47	5.98e-20	Cognitive test performance;
CRC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg23719950	chr11:63933701	MACROD1	-0.58	-5.84	-0.31	1.25e-8	Mean platelet volume;
CRC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	15.74	0.66	5.14e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.46	-6.1	-0.32	2.93e-9	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-6.37	-0.33	6.48e-10	Blood metabolite levels;
CRC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.65	9.07	0.45	1.11e-17	Vitiligo;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04841346	chr1:145096723	SEC22B	0.46	6.1	0.32	2.93e-9	Survival in pancreatic cancer;
CRC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-6.81	-0.35	4.57e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.84	13.86	0.61	1e-34	Menarche (age at onset);
CRC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg04553112	chr3:125709451	NA	-0.53	-6.06	-0.32	3.68e-9	Blood pressure (smoking interaction);
CRC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg06145435	chr7:1022769	CYP2W1	0.38	5.83	0.31	1.31e-8	Bronchopulmonary dysplasia;
CRC	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-6.39	-0.33	5.79e-10	Putamen volume;
CRC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.26	0.37	2.73e-12	Alzheimer's disease;
CRC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.22	0.37	3.55e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.98	-0.31	5.76e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.45	6.16	0.32	2.13e-9	Type 2 diabetes;
CRC	cis	rs7487075	0.820	rs10785617	chr12:46699243	T/C	cg22049899	chr12:47219821	SLC38A4	0.33	6.13	0.32	2.48e-9	Itch intensity from mosquito bite;
CRC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.71	7.04	0.36	1.12e-11	Fat distribution (HIV);
CRC	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg04990556	chr1:26633338	UBXN11	-0.47	-5.78	-0.3	1.71e-8	Obesity-related traits;
CRC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	0.7	5.82	0.31	1.42e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg06204229	chr3:52865917	ITIH4	0.48	6.01	0.31	4.85e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg06204229	chr3:52865917	ITIH4	0.5	5.71	0.3	2.51e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-14.99	-0.64	4.54e-39	Vitiligo;
CRC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.56	-0.38	4e-13	Aortic root size;
CRC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.54	-6.71	-0.35	8.41e-11	Body mass index;
CRC	cis	rs4731207	0.724	rs10224946	chr7:124531338	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs10971721	0.822	rs12376279	chr9:33804254	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.89	0.31	9.66e-9	Body mass index;
CRC	cis	rs6973256	0.605	rs6467499	chr7:133348922	G/T	cg10665199	chr7:133106180	EXOC4	-0.49	-7.77	-0.39	9.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.69	7.91	0.4	4.08e-14	LDL cholesterol;Cholesterol, total;
CRC	cis	rs519973	0.930	rs541115	chr3:187638092	T/A	cg10168494	chr3:187635183	NA	0.5	8.76	0.43	1.04e-16	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13198984	chr17:80129470	CCDC57	-0.39	-6.48	-0.34	3.26e-10	Life satisfaction;
CRC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	5.69	0.3	2.76e-8	Obesity-related traits;
CRC	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.49	7.99	0.4	2.36e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg27432699	chr2:27873401	GPN1	-0.61	-9.33	-0.46	1.56e-18	Total body bone mineral density;
CRC	cis	rs6066835	1.000	rs6066833	chr20:47354494	G/C	cg18078177	chr20:47281410	PREX1	0.61	5.64	0.3	3.73e-8	Multiple myeloma;
CRC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.36	-0.33	6.73e-10	Aortic root size;
CRC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.55	8.84	0.44	5.88e-17	Coronary artery disease;
CRC	cis	rs524281	0.817	rs10791849	chr11:65890597	T/A	cg16950941	chr11:66035639	RAB1B	-0.61	-7.52	-0.38	5.31e-13	Electroencephalogram traits;
CRC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg13390004	chr1:15929781	NA	0.49	6.89	0.36	2.82e-11	Systolic blood pressure;
CRC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.97	11.84	0.55	3.53e-27	Gut microbiome composition (summer);
CRC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.73	-0.35	7.55e-11	Type 2 diabetes;
CRC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.53	8.33	0.42	2.29e-15	Menopause (age at onset);
CRC	cis	rs12541635	0.966	rs7819043	chr8:106989783	T/C	cg10147462	chr8:107024639	NA	0.42	6.9	0.36	2.74e-11	Age of smoking initiation;
CRC	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	6.07	0.32	3.47e-9	Asthma;
CRC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-6.63	-0.34	1.41e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	9.99	0.48	1.08e-20	Alzheimer's disease (late onset);
CRC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg25344623	chr2:136566232	LCT	0.32	5.89	0.31	9.71e-9	Mosquito bite size;
CRC	cis	rs9494145	0.680	rs9376092	chr6:135427144	A/C	cg22676075	chr6:135203613	NA	-0.5	-6.46	-0.34	3.71e-10	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.66	0.43	2.12e-16	Menopause (age at onset);
CRC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.83	14.93	0.64	7.87e-39	Breast cancer;
CRC	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg12560992	chr17:57184187	TRIM37	0.52	6.06	0.32	3.67e-9	Vitamin D levels;
CRC	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.36	-0.33	6.77e-10	IgE levels;
CRC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.82	0.44	6.67e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.43	6.95	0.36	1.94e-11	Sitting height ratio;
CRC	cis	rs1223397	0.702	rs1223400	chr6:13271242	T/C	cg07912922	chr6:13274314	PHACTR1	0.51	6.21	0.32	1.62e-9	Blood pressure;
CRC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.36	0.46	1.25e-18	Hip circumference adjusted for BMI;
CRC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.56	8.86	0.44	5.26e-17	Colorectal cancer;
CRC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	ch.11.42038R	chr11:967971	AP2A2	0.7	11.68	0.54	1.32e-26	Alzheimer's disease (late onset);
CRC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.82	9.97	0.48	1.25e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.55	7.5	0.38	6.13e-13	Bronchopulmonary dysplasia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17900884	chr1:6296090	ICMT	0.48	7.04	0.36	1.09e-11	Anxiety disorder;
CRC	cis	rs490234	0.841	rs13291593	chr9:128228483	A/G	cg14078157	chr9:128172775	NA	-0.35	-5.85	-0.31	1.19e-8	Mean arterial pressure;
CRC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.48	5.91	0.31	8.75e-9	Cannabis dependence symptom count;
CRC	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg01522456	chr1:115632236	TSPAN2	-0.42	-6.03	-0.32	4.5e-9	Autism;
CRC	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg20936604	chr3:58311152	NA	-0.73	-7.25	-0.37	3.06e-12	Cholesterol, total;
CRC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg13206674	chr6:150067644	NUP43	0.65	9.13	0.45	7.07e-18	Lung cancer;
CRC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg03037974	chr15:76606532	NA	0.66	11.44	0.53	9.38e-26	Blood metabolite levels;
CRC	cis	rs2565722	0.825	rs1247538	chr6:161252452	G/A	cg03159191	chr6:161285451	NA	-0.48	-5.81	-0.31	1.46e-8	Blood protein levels;
CRC	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Depression;
CRC	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.25	0.33	1.29e-9	Depressive episodes in bipolar disorder;
CRC	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg06042504	chr8:55087323	NA	-0.44	-6.82	-0.35	4.41e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.83e-9	Aortic root size;
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg07617317	chr6:118971624	C6orf204	0.52	6.4	0.33	5.29e-10	Diastolic blood pressure;
CRC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.06e-15	Menopause (age at onset);
CRC	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg01000188	chr9:133769184	QRFP	-0.68	-8.47	-0.42	8.46e-16	Bilirubin levels;
CRC	trans	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.75	9.12	0.45	7.51e-18	Eotaxin levels;
CRC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.21	-0.45	4.06e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	10.09	0.49	4.78e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.5	7.72	0.39	1.4e-13	Corneal astigmatism;
CRC	cis	rs7113874	0.569	rs2871753	chr11:8486650	A/T	cg20771178	chr11:8615675	STK33	0.34	5.67	0.3	3.07e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg12064134	chr16:90016061	DEF8	-0.69	-6.14	-0.32	2.38e-9	Skin colour saturation;
CRC	trans	rs4308415	0.781	rs13102903	chr4:67810734	A/G	cg19648955	chr2:177134095	MTX2	-0.41	-6.12	-0.32	2.7e-9	Educational attainment (years of education);
CRC	trans	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg02869306	chr7:64672164	INTS4L1	0.44	6.29	0.33	1.03e-9	Aortic root size;
CRC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.76	-13.99	-0.61	3.16e-35	Paraoxonase activity;
CRC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12463550	chr7:65579703	CRCP	-0.6	-5.81	-0.31	1.45e-8	Diabetic kidney disease;
CRC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.47	6.31	0.33	9.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg03395651	chr16:88107091	BANP	0.57	7.38	0.38	1.28e-12	Menopause (age at onset);
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.66	-10.2	-0.49	2.01e-21	Lymphocyte counts;
CRC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.5	-0.38	6.15e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7605827	0.897	rs6745621	chr2:15537866	C/A	cg19274914	chr2:15703543	NA	0.39	5.93	0.31	7.85e-9	Educational attainment (years of education);
CRC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	6.16e-10	Lung cancer;
CRC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.64	-10.09	-0.49	4.89e-21	Motion sickness;
CRC	cis	rs4722166	0.532	rs4719711	chr7:22755688	A/G	cg05472934	chr7:22766657	IL6	-0.64	-10.15	-0.49	2.98e-21	Lung cancer;
CRC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-14.87	-0.63	1.3e-38	Vitiligo;
CRC	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.51	8.72	0.43	1.39e-16	Dupuytren's disease;
CRC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.5	6.71	0.35	8.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs728616	0.867	rs12411407	chr10:81828231	C/T	cg11900509	chr10:81946545	ANXA11	-0.52	-5.7	-0.3	2.73e-8	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs727505	0.607	rs67680878	chr7:124787381	G/A	cg23710748	chr7:124431027	NA	-0.64	-10.24	-0.49	1.56e-21	Lewy body disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26355472	chr1:47134199	ATPAF1	0.44	6.24	0.33	1.34e-9	Response to antipsychotic treatment;
CRC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.78	0.47	5.38e-20	Bipolar disorder;
CRC	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	1.02	9.22	0.45	3.75e-18	Cerebrospinal fluid biomarker levels;
CRC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.78	10.35	0.5	6.49e-22	Cerebrospinal P-tau181p levels;
CRC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg15744005	chr10:104629667	AS3MT	-0.33	-6.85	-0.35	3.66e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.63	9.86	0.48	2.98e-20	Lymphocyte counts;
CRC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg00129232	chr17:37814104	STARD3	0.56	7.16	0.37	5.19e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.82	14.19	0.62	5.28e-36	Gut microbiota (bacterial taxa);
CRC	cis	rs41005	1.000	rs41007	chr2:8109043	A/G	cg03155496	chr2:8117019	LOC339788	-0.41	-7.54	-0.38	4.74e-13	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.73	7.28	0.37	2.54e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.57	-0.43	4.22e-16	Neuroticism;
CRC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	0.54	9.05	0.45	1.28e-17	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.56	8.02	0.4	1.93e-14	Melanoma;
CRC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.14	-0.32	2.42e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.52	0.34	2.71e-10	Major depressive disorder;
CRC	cis	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg21251018	chr6:28226885	NKAPL	0.4	5.65	0.3	3.45e-8	Depression;
CRC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.93	0.55	1.7e-27	Alzheimer's disease;
CRC	trans	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs3026101	0.671	rs8076560	chr17:5299527	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.71e-11	Body mass index;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.42	1.07e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.44	-6.14	-0.32	2.36e-9	Fibrinogen levels;
CRC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	7.96	0.4	2.84e-14	Height;
CRC	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.62	10.03	0.48	7.92e-21	Breast cancer;
CRC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	-0.61	-7.06	-0.36	9.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.72	-11.31	-0.53	2.73e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14373490	chr9:74979895	ZFAND5	0.45	6.15	0.32	2.18e-9	Anxiety disorder;
CRC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.62	10.45	0.5	2.98e-22	Colorectal cancer;
CRC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.69	0.47	1.07e-19	Cognitive test performance;
CRC	cis	rs236352	0.538	rs9470426	chr6:36846988	T/C	cg10099585	chr6:36853529	C6orf89	-0.45	-6.41	-0.33	5.16e-10	Heart rate;
CRC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg10589385	chr1:150898437	SETDB1	0.3	6.08	0.32	3.34e-9	Melanoma;
CRC	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.55	9.25	0.45	3.01e-18	Dupuytren's disease;
CRC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.49	7.73	0.39	1.28e-13	Height;
CRC	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg06818627	chr12:109536430	UNG	0.48	6.16	0.32	2.12e-9	Thyroid stimulating hormone;
CRC	cis	rs7849270	1.000	rs1571229	chr9:131913711	A/G	cg13538475	chr9:131942899	NA	-0.29	-5.75	-0.3	2e-8	Blood metabolite ratios;
CRC	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.61	-8.58	-0.43	3.91e-16	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.58	0.43	3.69e-16	Menopause (age at onset);
CRC	cis	rs4561483	0.603	rs11075033	chr16:12006338	C/T	cg08843971	chr16:11963173	GSPT1	0.5	7.46	0.38	7.59e-13	Testicular germ cell tumor;
CRC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg13319975	chr6:146136371	FBXO30	0.44	6.55	0.34	2.2e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.72	8.9	0.44	3.89e-17	Hemostatic factors and hematological phenotypes;
CRC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.16	-0.56	2.37e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.44	5.79	0.3	1.64e-8	Response to diuretic therapy;
CRC	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg03037974	chr15:76606532	NA	-0.52	-7.5	-0.38	5.99e-13	Blood metabolite levels;
CRC	cis	rs863345	0.584	rs6427438	chr1:158454730	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-6.05	-0.32	3.87e-9	Pneumococcal bacteremia;
CRC	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg13736514	chr6:26305472	NA	-0.45	-7.3	-0.37	2.12e-12	Educational attainment;
CRC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.44	6.63	0.34	1.41e-10	Mean platelet volume;
CRC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.54	10.64	0.51	6.38e-23	Lipoprotein (a) levels;
CRC	cis	rs12523822	0.957	rs55737042	chr6:154955676	T/C	cg20019720	chr6:154832845	CNKSR3	0.26	5.61	0.3	4.23e-8	Diabetic kidney disease;
CRC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg03161606	chr19:29218774	NA	0.54	6.26	0.33	1.21e-9	Methadone dose in opioid dependence;
CRC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-9.53	-0.47	3.61e-19	Calcium levels;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16166399	chr19:59030753	ZBTB45	-0.43	-6.36	-0.33	6.8e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg03037974	chr15:76606532	NA	-0.51	-7.29	-0.37	2.3e-12	Blood metabolite levels;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg19041857	chr6:27730383	NA	-0.42	-6.03	-0.32	4.3e-9	Parkinson's disease;
CRC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg07274523	chr3:49395745	GPX1	0.49	6.19	0.32	1.8e-9	Educational attainment;
CRC	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-8.75	-0.43	1.1e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs1376359	0.587	rs55954802	chr1:103121812	G/A	cg16220183	chr17:56609687	SEPT4	-0.46	-6.27	-0.33	1.15e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg08200770	chr17:80723486	TBCD	-0.48	-7.35	-0.38	1.59e-12	Glycated hemoglobin levels;
CRC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	11.67	0.54	1.46e-26	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.91	-16.61	-0.68	1.93e-45	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.62	10.19	0.49	2.31e-21	Subjective well-being (multi-trait analysis);
CRC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.49	-7.41	-0.38	1.06e-12	Obesity-related traits;
CRC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.55	-8.8	-0.44	7.81e-17	Depressive symptoms (multi-trait analysis);
CRC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-5.8	-0.3	1.59e-8	Obesity-related traits;
CRC	cis	rs10971721	0.822	rs10971753	chr9:33870436	C/T	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.5	-0.5	1.99e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg02741985	chr17:80059408	CCDC57	0.44	7.3	0.37	2.15e-12	Life satisfaction;
CRC	cis	rs3026101	0.624	rs1058400	chr17:5288794	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	6.63	0.34	1.38e-10	Body mass index;
CRC	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg26211634	chr5:139558579	C5orf32	-0.44	-7.75	-0.39	1.18e-13	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-6.05	-0.32	3.98e-9	Menopause (age at onset);
CRC	trans	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg21589273	chr3:113416452	KIAA2018	0.53	5.96	0.31	6.34e-9	Iron status biomarkers;
CRC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.53	0.47	3.63e-19	Lymphocyte counts;
CRC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.67	10.73	0.51	3.24e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg16606324	chr3:10149918	C3orf24	0.66	7.77	0.39	9.99e-14	Alzheimer's disease;
CRC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.95	11.22	0.53	5.91e-25	Eosinophil percentage of granulocytes;
CRC	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.76	-11.96	-0.55	1.31e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg15147215	chr3:52552868	STAB1	-0.63	-10.51	-0.5	1.83e-22	Bipolar disorder;
CRC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-11.75	-0.54	7.4e-27	Migraine;Coronary artery disease;
CRC	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.5	-7.21	-0.37	3.83e-12	Cocaine dependence;
CRC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.26	-0.49	1.33e-21	Total cholesterol levels;
CRC	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg21169611	chr9:106856078	SMC2	0.41	5.75	0.3	2.08e-8	High-grade serous ovarian cancer;Breast cancer;
CRC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.44	-8.17	-0.41	6.74e-15	Huntington's disease progression;
CRC	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-6.64	-0.34	1.26e-10	Breast cancer;
CRC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg22495460	chr2:25135724	ADCY3	-0.87	-17.11	-0.69	2.25e-47	Body mass index;
CRC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg26769984	chr7:1090371	C7orf50	0.48	6.36	0.33	6.61e-10	Bronchopulmonary dysplasia;
CRC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.6	8.89	0.44	3.98e-17	Homoarginine levels;
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.46	-0.46	6.12e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg16642045	chr4:155471719	PLRG1	0.41	6.01	0.31	5.03e-9	Interleukin-6 levels;
CRC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg14196790	chr5:131705035	SLC22A5	-0.35	-5.69	-0.3	2.8e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg22687807	chr8:143858763	LYNX1	0.51	9.05	0.45	1.24e-17	Urinary tract infection frequency;
CRC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg00531865	chr16:30841666	NA	-0.47	-6.68	-0.35	9.91e-11	Dementia with Lewy bodies;
CRC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.79	-0.3	1.6e-8	Lung cancer;
CRC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs747650	0.504	rs10838646	chr11:47036794	G/C	cg19486271	chr11:47235900	DDB2	-0.44	-5.88	-0.31	1.03e-8	Acne (severe);
CRC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.63	10.27	0.49	1.24e-21	Body mass index;
CRC	cis	rs4750440	0.523	rs4565801	chr10:14032358	G/A	cg00551146	chr10:14014579	FRMD4A	0.45	7.33	0.37	1.85e-12	Adiponectin levels;
CRC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.59	-0.43	3.64e-16	Aortic root size;
CRC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.62	7.86	0.4	5.64e-14	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.49	-0.38	6.6e-13	Major depressive disorder;
CRC	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg12856521	chr11:46389249	DGKZ	-0.43	-6.84	-0.35	3.8e-11	Leprosy;
CRC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-8.19	-0.41	5.71e-15	Homoarginine levels;
CRC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	6.0	0.31	5.24e-9	Neuroticism;
CRC	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg21918786	chr6:109611834	NA	-0.35	-5.95	-0.31	6.83e-9	Reticulocyte fraction of red cells;
CRC	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.59	-6.6	-0.34	1.66e-10	Coronary artery disease;
CRC	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.78	11.25	0.53	4.74e-25	Gout;
CRC	cis	rs7113874	0.569	rs10840077	chr11:8601210	A/T	cg17679104	chr11:8615758	STK33	0.36	6.03	0.32	4.44e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.89e-13	Corneal astigmatism;
CRC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.36	5.67	0.3	3.15e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.72	-11.72	-0.54	9.19e-27	Total body bone mineral density;
CRC	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.58	9.12	0.45	7.5e-18	HDL cholesterol;
CRC	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.54	6.99	0.36	1.52e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg02820901	chr13:113351484	ATP11A	0.6	6.65	0.34	1.23e-10	Glycated hemoglobin levels;
CRC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.74	-13.15	-0.59	5.08e-32	Prostate cancer;
CRC	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.8	13.53	0.6	1.79e-33	Gut microbiome composition (winter);
CRC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.04	-23.9	-0.8	7.05e-74	Myeloid white cell count;
CRC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.57	-7.94	-0.4	3.17e-14	Response to antineoplastic agents;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.72	8.73	0.43	1.31e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.17	0.56	2.24e-28	Chronic sinus infection;
CRC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg12564285	chr5:131593104	PDLIM4	0.45	7.59	0.39	3.28e-13	Breast cancer;
CRC	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.47	-6.9	-0.36	2.66e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06824242	chr15:38746275	FAM98B	0.44	6.08	0.32	3.4e-9	Response to antipsychotic treatment;
CRC	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.19	0.64	7.31e-40	Fuchs's corneal dystrophy;
CRC	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.62	8.61	0.43	3.07e-16	Intelligence (multi-trait analysis);
CRC	cis	rs6504950	0.830	rs1802212	chr17:53038654	A/C	cg26251398	chr17:52985966	TOM1L1	0.42	5.62	0.3	4.01e-8	Breast cancer;
CRC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.66	9.28	0.46	2.32e-18	Vitamin D levels;
CRC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.71	-12.56	-0.57	7.71e-30	Asthma;
CRC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	8.41	0.42	1.3e-15	Colorectal cancer;
CRC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg21251018	chr6:28226885	NKAPL	0.46	6.46	0.34	3.67e-10	Parkinson's disease;
CRC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.81	-14.52	-0.62	2.9e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.96	15.57	0.65	2.37e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.26	-0.33	1.21e-9	Menopause (age at onset);
CRC	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.95	-0.31	7.02e-9	Metabolite levels;
CRC	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	6.97	0.36	1.71e-11	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-9.03	-0.45	1.49e-17	Bipolar disorder;
CRC	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg11038491	chr20:34638489	LOC647979	-0.58	-7.52	-0.38	5.34e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6477694	1.000	rs6477694	chr9:111932342	C/T	cg14171727	chr9:111936775	EPB41L4B	-0.38	-6.08	-0.32	3.39e-9	Body mass index;
CRC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-6.3	-0.33	9.59e-10	Blood metabolite levels;
CRC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25372841	chr8:145675454	CYHR1	-0.36	-6.08	-0.32	3.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg20628663	chr10:43360327	NA	-0.69	-7.22	-0.37	3.56e-12	Pediatric bone mineral content (radius);
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12172441	chr6:28176163	NA	0.63	7.43	0.38	9.41e-13	Depression;
CRC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg02527881	chr3:46936655	PTH1R	0.37	6.74	0.35	6.98e-11	Colorectal cancer;
CRC	cis	rs7932354	0.528	rs7108902	chr11:47091571	C/T	cg03339077	chr11:47165057	C11orf49	0.43	5.95	0.31	6.94e-9	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00561562	chr4:144435738	SMARCA5	0.42	6.04	0.32	4.15e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6988985	0.589	rs6987382	chr8:143987191	G/A	cg10324643	chr8:143916377	GML	0.38	6.42	0.33	4.68e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.69	-10.36	-0.5	6.07e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg18016565	chr1:150552671	MCL1	-0.47	-7.14	-0.37	6.02e-12	Tonsillectomy;
CRC	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg17652424	chr22:38574118	PLA2G6	0.2	6.13	0.32	2.5e-9	Cutaneous nevi;
CRC	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.92	-0.4	3.8e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.49	7.62	0.39	2.75e-13	Eosinophil counts;
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-0.65	-11.61	-0.54	2.34e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs7680126	0.500	rs4697933	chr4:10146493	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.03	-0.32	4.38e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg26248373	chr2:1572462	NA	-0.64	-8.13	-0.41	8.85e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.42	6.41	0.33	5.04e-10	Height;
CRC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.37	6.49	0.34	3.17e-10	Crohn's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23335269	chr10:6130793	RBM17	0.4	6.44	0.33	4.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.39	-6.89	-0.36	2.79e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07570687	chr10:102243282	WNT8B	0.44	5.65	0.3	3.53e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05828906	chr6:126278519	HINT3	0.46	6.43	0.33	4.37e-10	Response to antipsychotic treatment;
CRC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.31	6.65	0.34	1.22e-10	Alcohol dependence;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg07934026	chr4:467794	ZNF721;ABCA11P	-0.53	-6.08	-0.32	3.41e-9	Optic disc area;
CRC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-7.3	-0.37	2.21e-12	IgG glycosylation;
CRC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.27	0.75	7.25e-60	Prudent dietary pattern;
CRC	trans	rs6600671	1.000	rs1591882	chr1:121183313	G/A	cg09829573	chr1:144692074	NBPF9	-0.41	-6.17	-0.32	2.01e-9	Hip geometry;
CRC	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.47	-5.61	-0.3	4.3e-8	Urinary tract infection frequency;
CRC	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg08461752	chr10:43522343	NA	-0.82	-7.64	-0.39	2.45e-13	Blood protein levels;
CRC	trans	rs2055729	0.677	rs13270146	chr8:9740595	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.01	-0.31	4.91e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.88	11.01	0.52	3.38e-24	Eosinophil percentage of granulocytes;
CRC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg27661571	chr11:113659931	NA	0.48	6.27	0.33	1.13e-9	Hip circumference adjusted for BMI;
CRC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.2	0.32	1.69e-9	Hemoglobin concentration;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10020083	chr5:176873646	PRR7	0.46	6.28	0.33	1.06e-9	Response to antipsychotic treatment;
CRC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-9.49	-0.46	5.01e-19	Alcohol dependence;
CRC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg18761221	chr20:60518478	NA	0.47	7.67	0.39	2.02e-13	Body mass index;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.75	7.95	0.4	3.04e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.62	5.85	0.31	1.19e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.51	-6.98	-0.36	1.65e-11	Response to antidepressants and depression;
CRC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg12365402	chr11:9010492	NRIP3	-0.48	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.46	-6.9	-0.36	2.73e-11	Intelligence (multi-trait analysis);
CRC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.51	7.01	0.36	1.36e-11	Morning vs. evening chronotype;
CRC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg23758597	chr6:163146217	PARK2	-0.56	-6.18	-0.32	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	6.5	0.34	3.01e-10	Homocysteine levels;
CRC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.58	-9.44	-0.46	6.96e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg02134305	chr3:49507478	DAG1	0.49	6.12	0.32	2.68e-9	Myocardial infarction;
CRC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg14711859	chr11:8959438	ASCL3	0.45	7.53	0.38	4.86e-13	Hemoglobin concentration;
CRC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.66	-9.36	-0.46	1.24e-18	DNA methylation (variation);
CRC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	10.97	0.52	4.42e-24	Platelet count;
CRC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.5	7.7	0.39	1.6e-13	Aortic root size;
CRC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.67	-7.62	-0.39	2.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-6.93	-0.36	2.19e-11	Body mass index (adult);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02838143	chr10:126606107	NA	0.45	5.96	0.31	6.33e-9	Anxiety disorder;
CRC	cis	rs6735179	0.688	rs2382562	chr2:1763509	G/A	cg19300414	chr2:1746591	PXDN	0.34	6.11	0.32	2.8e-9	Response to antipsychotic treatment;
CRC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.44	-6.54	-0.34	2.3e-10	Diastolic blood pressure;
CRC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg06243084	chr11:63990629	FERMT3	-0.39	-6.08	-0.32	3.26e-9	Platelet count;
CRC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.74	-12.15	-0.56	2.7e-28	Height;
CRC	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg14844989	chr11:31128820	NA	0.34	6.09	0.32	3.19e-9	Red blood cell count;
CRC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	7.9	0.4	4.31e-14	Schizophrenia;
CRC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.85	-0.4	6.03e-14	Major depressive disorder;
CRC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg23758597	chr6:163146217	PARK2	-0.55	-5.96	-0.31	6.42e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	cg04338863	chr8:33670619	NA	0.38	5.79	0.3	1.63e-8	Body mass index;
CRC	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg27083787	chr2:113543245	IL1A	0.42	5.93	0.31	7.84e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg21155852	chr7:2048760	MAD1L1	-0.45	-5.88	-0.31	1.03e-8	Neuroticism;
CRC	trans	rs2055729	0.677	rs59880252	chr8:9741032	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.06	0.32	3.73e-9	Multiple myeloma (hyperdiploidy);
CRC	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-7.21	-0.37	3.92e-12	Eye color traits;
CRC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.84	14.68	0.63	7.14e-38	Blood protein levels;
CRC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.83	-0.4	6.56e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg16235748	chr6:149772707	ZC3H12D	0.35	6.35	0.33	7.03e-10	Dupuytren's disease;
CRC	cis	rs12024301	0.557	rs12077933	chr1:183658222	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg19635926	chr16:89946313	TCF25	0.66	5.97	0.31	6.1e-9	Skin colour saturation;
CRC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg24675056	chr1:15929824	NA	0.54	7.43	0.38	9.67e-13	Systolic blood pressure;
CRC	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg15038512	chr6:170123185	PHF10	-0.39	-6.05	-0.32	3.86e-9	Obesity-related traits;
CRC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg22110888	chr17:80059540	CCDC57	0.4	6.34	0.33	7.4e-10	Life satisfaction;
CRC	cis	rs28493229	0.582	rs78915350	chr19:41160609	A/G	cg21869046	chr19:41225005	ITPKC	0.41	6.19	0.32	1.81e-9	Kawasaki disease;
CRC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.23	14.38	0.62	9.77e-37	Diabetic kidney disease;
CRC	cis	rs3026101	0.578	rs59605950	chr17:5303493	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	trans	rs596169	0.541	rs73111535	chr1:219222850	C/A	cg00778190	chr1:95068029	NA	0.74	6.47	0.34	3.63e-10	Intraocular pressure;
CRC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.73	0.35	7.48e-11	Bipolar disorder;
CRC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.4	6.53	0.34	2.56e-10	Schizophrenia;
CRC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.44	6.55	0.34	2.22e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg07424746	chr4:185654737	MLF1IP	0.51	5.69	0.3	2.8e-8	Blood protein levels;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.75	-8.32	-0.42	2.37e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.82	-7.02	-0.36	1.31e-11	Pediatric areal bone mineral density (radius);
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg13490827	chr1:46269305	MAST2	-0.68	-5.99	-0.31	5.44e-9	Cognitive function;
CRC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg23234261	chr14:55582407	NA	-0.29	-5.78	-0.3	1.75e-8	Protein biomarker;
CRC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	7.8	0.4	8.18e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg27094323	chr7:1216898	NA	-0.36	-5.7	-0.3	2.65e-8	Longevity;Endometriosis;
CRC	trans	rs2303319	0.504	rs60495163	chr2:162408807	C/T	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.11	-0.32	2.86e-9	Cognitive function;
CRC	cis	rs10486722	0.565	rs11773175	chr7:41795033	T/G	cg22138096	chr7:41772439	LOC285954	0.44	5.67	0.3	3.12e-8	Pit-and-Fissure caries;
CRC	cis	rs12024301	0.557	rs6686912	chr1:183603126	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.75	6.81	0.35	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.21	-0.37	3.83e-12	Capecitabine sensitivity;
CRC	cis	rs7113874	0.569	rs9300091	chr11:8588823	G/A	cg20771178	chr11:8615675	STK33	-0.34	-5.64	-0.3	3.63e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.76	-10.19	-0.49	2.21e-21	Coronary artery disease;
CRC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg16797656	chr11:68205561	LRP5	0.37	5.84	0.31	1.27e-8	Total body bone mineral density;
CRC	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.67	-0.3	3.2e-8	Breast cancer;
CRC	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	8.94	0.44	2.86e-17	Ulcerative colitis;
CRC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.81	14.11	0.61	1.14e-35	Breast cancer;
CRC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21248554	chr2:27665150	KRTCAP3	0.27	5.99	0.31	5.61e-9	Total body bone mineral density;
CRC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	8.45	0.42	9.48e-16	Hemoglobin concentration;
CRC	cis	rs2811415	0.597	rs13079887	chr3:127745248	G/A	cg13719885	chr3:127795394	NA	-0.39	-5.96	-0.31	6.44e-9	Lung function (FEV1/FVC);
CRC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	8.68	0.43	1.84e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7215564	0.908	rs4243240	chr17:78660342	T/C	cg09596252	chr17:78655493	RPTOR	0.54	5.73	0.3	2.25e-8	Myopia (pathological);
CRC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.62	9.46	0.46	5.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.58	-0.39	3.63e-13	Metabolite levels;
CRC	cis	rs4290604	0.748	rs6431514	chr2:238051064	T/C	cg23555395	chr2:238036564	NA	-0.67	-6.77	-0.35	5.83e-11	Asthma;
CRC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.43	-9.68	-0.47	1.17e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.63	7.1	0.36	7.79e-12	Menarche (age at onset);
CRC	cis	rs6479527	0.901	rs3763639	chr9:96874348	G/T	cg14459158	chr9:96720562	NA	0.41	7.12	0.37	6.64e-12	Esophageal adenocarcinoma;
CRC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.37	0.42	1.69e-15	Mean corpuscular volume;
CRC	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.63	9.79	0.47	5.04e-20	Corneal astigmatism;
CRC	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.45	5.75	0.3	1.99e-8	HDL cholesterol;
CRC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.59	-10.36	-0.5	5.81e-22	Prudent dietary pattern;
CRC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg18827107	chr12:86230957	RASSF9	-0.37	-5.72	-0.3	2.4e-8	Major depressive disorder;
CRC	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	8.04	0.41	1.64e-14	Iron status biomarkers;
CRC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-8.84	-0.44	5.97e-17	Bipolar disorder;
CRC	cis	rs4757319	0.532	rs7350480	chr11:15431408	A/G	cg03245590	chr11:15329459	NA	-0.43	-7.48	-0.38	6.72e-13	Breast cancer;
CRC	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg00318322	chr16:67708822	GFOD2	-0.31	-5.94	-0.31	7.11e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.74	-0.35	7.09e-11	Response to antipsychotic treatment;
CRC	trans	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg02869306	chr7:64672164	INTS4L1	-0.44	-6.45	-0.34	3.9e-10	Aortic root size;
CRC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.58	-0.75	4.39e-61	Height;
CRC	cis	rs6788895	1.000	rs7617507	chr3:150499595	C/T	cg09723797	chr3:150481914	SIAH2	-0.83	-6.81	-0.35	4.56e-11	Breast cancer;
CRC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.51	-9.55	-0.47	3.13e-19	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-6.96	-0.36	1.8e-11	Response to antipsychotic treatment;
CRC	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg22182287	chr2:3452347	TTC15	0.38	5.98	0.31	5.71e-9	Obesity-related traits;
CRC	cis	rs7527798	0.592	rs6684643	chr1:207846242	A/T	cg09232269	chr1:207846808	CR1L	-0.52	-8.31	-0.42	2.49e-15	Erythrocyte sedimentation rate;
CRC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.61	9.42	0.46	8.23e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4664293	0.585	rs13019325	chr2:160628990	A/G	cg08347373	chr2:160653686	CD302	0.36	5.95	0.31	6.92e-9	Monocyte percentage of white cells;
CRC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.47	-6.85	-0.35	3.57e-11	High light scatter reticulocyte count;
CRC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13198984	chr17:80129470	CCDC57	0.45	8.07	0.41	1.3e-14	Life satisfaction;
CRC	cis	rs7849270	1.000	rs2297112	chr9:131900180	G/A	cg13538475	chr9:131942899	NA	-0.32	-6.37	-0.33	6.2e-10	Blood metabolite ratios;
CRC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg20885578	chr2:198174922	NA	-0.36	-6.44	-0.33	4.19e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	7.97	0.4	2.67e-14	Aortic root size;
CRC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg04362960	chr10:104952993	NT5C2	0.5	6.14	0.32	2.38e-9	Colorectal cancer;
CRC	cis	rs6496667	0.580	rs8030736	chr15:90885866	T/C	cg04176472	chr15:90893244	GABARAPL3	0.56	6.69	0.35	9.64e-11	Rheumatoid arthritis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15563057	chr5:139493612	PURA	0.54	7.08	0.36	8.51e-12	Thyroid stimulating hormone;
CRC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg16606324	chr3:10149918	C3orf24	0.45	6.82	0.35	4.25e-11	Alzheimer's disease;
CRC	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.36	-5.62	-0.3	4.16e-8	Menopause (age at onset);
CRC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-8.77	-0.44	9.68e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs758324	0.812	rs11750031	chr5:131171251	G/A	cg25547332	chr5:131281432	NA	0.35	5.68	0.3	3.03e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.66	11.05	0.52	2.33e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs972578	0.765	rs5759081	chr22:43396445	A/G	cg01576275	chr22:43409880	NA	-0.4	-6.15	-0.32	2.21e-9	Mean platelet volume;
CRC	cis	rs7259376	0.967	rs7252056	chr19:22494052	T/A	cg02657401	chr19:22469223	NA	-0.35	-7.85	-0.4	6.02e-14	Menopause (age at onset);
CRC	trans	rs10242455	0.702	rs3823813	chr7:99049389	G/A	cg09045935	chr12:6379348	NA	1.07	7.87	0.4	5.09e-14	Blood metabolite levels;
CRC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.81	-0.35	4.52e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.95	-0.44	2.62e-17	Alcohol dependence;
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-6.23	-0.32	1.46e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	8.12	0.41	9.35e-15	Neuroticism;
CRC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg00339695	chr16:24857497	SLC5A11	0.27	6.4	0.33	5.4e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.45	-7.22	-0.37	3.56e-12	Obesity-related traits;
CRC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg20933634	chr6:27740509	NA	0.63	7.31	0.37	2.09e-12	Parkinson's disease;
CRC	cis	rs375066	0.935	rs11673020	chr19:44374631	A/G	cg12072164	chr19:44306565	LYPD5	0.37	5.61	0.3	4.31e-8	Breast cancer;
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.58	9.8	0.48	4.72e-20	Menarche (age at onset);
CRC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.36	0.33	6.65e-10	Lung cancer;
CRC	trans	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.02	-0.31	4.73e-9	Lung cancer in ever smokers;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.49	-0.62	3.9e-37	Extrinsic epigenetic age acceleration;
CRC	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-15.04	-0.64	2.94e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.58	-0.34	1.87e-10	Lymphocyte counts;
CRC	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-0.58	-5.71	-0.3	2.54e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.13	-0.37	6.43e-12	Tuberculosis;
CRC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.04	-0.32	4.11e-9	Bipolar disorder;
CRC	trans	rs3791556	1.000	rs3791568	chr2:240115701	G/A	cg00066750	chr6:126080132	HEY2	0.59	6.18	0.32	1.84e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg20607287	chr7:12443886	VWDE	-0.68	-7.35	-0.38	1.59e-12	Coronary artery disease;
CRC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	8.94	0.44	2.92e-17	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08316941	chr5:133984937	SEC24A	0.48	6.75	0.35	6.6e-11	Response to antipsychotic treatment;
CRC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.76	-13.13	-0.59	5.71e-32	Body mass index;
CRC	cis	rs394563	0.517	rs377454	chr6:149791093	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.55	-8.62	-0.43	2.89e-16	Dupuytren's disease;
CRC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	1.04	11.36	0.53	1.94e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.03	0.52	2.73e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg03934865	chr2:198174659	NA	-0.44	-6.95	-0.36	1.99e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg07828024	chr6:149772892	ZC3H12D	0.47	8.57	0.43	4.05e-16	Dupuytren's disease;
CRC	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.31	-0.37	2.08e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg11168104	chr5:1857477	NA	-0.4	-6.87	-0.35	3.16e-11	Cardiovascular disease risk factors;
CRC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.38	5.87	0.31	1.04e-8	Crohn's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13672843	chr3:10183721	VHL	0.46	6.59	0.34	1.72e-10	Anxiety disorder;
CRC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg26587870	chr6:27730563	NA	-0.66	-6.83	-0.35	4.21e-11	Depression;
CRC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23378565	chr7:2036160	MAD1L1	-0.41	-6.2	-0.32	1.67e-9	Bipolar disorder;
CRC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.41	0.38	1.05e-12	Height;
CRC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg27083787	chr2:113543245	IL1A	0.45	6.47	0.34	3.5e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.54	8.46	0.42	8.78e-16	Corneal astigmatism;
CRC	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg05072819	chr3:20081367	KAT2B	0.5	7.33	0.37	1.77e-12	Post-traumatic stress disorder;
CRC	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg26603656	chr10:5671107	NA	0.44	7.51	0.38	5.48e-13	Breast cancer;
CRC	cis	rs4731207	0.698	rs10248775	chr7:124444207	T/G	cg23710748	chr7:124431027	NA	0.37	5.96	0.31	6.53e-9	Cutaneous malignant melanoma;
CRC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg07507251	chr3:52567010	NT5DC2	0.4	5.75	0.3	2.04e-8	Bipolar disorder;
CRC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.54	-7.47	-0.38	7.5e-13	Carotid intima media thickness;
CRC	cis	rs600626	0.588	rs10793124	chr11:75452267	C/G	cg24262691	chr11:75473276	NA	0.53	7.49	0.38	6.21e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg05625103	chr10:2543513	NA	0.38	5.95	0.31	6.96e-9	Age-related hearing impairment;
CRC	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg21010569	chr2:103233596	NA	0.55	5.81	0.3	1.51e-8	Gut microbiota (bacterial taxa);
CRC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg08027265	chr7:2291960	NA	-0.37	-6.38	-0.33	5.91e-10	Schizophrenia;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.93	-16.75	-0.68	5.61e-46	Height;
CRC	cis	rs2982552	1.000	rs2982552	chr6:152059563	G/A	cg22157087	chr6:152012887	ESR1	0.37	5.76	0.3	1.96e-8	Bone properties (heel);
CRC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.74	-12.05	-0.55	5.84e-28	Pancreatic cancer;
CRC	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg19683494	chr5:74908142	NA	0.5	6.28	0.33	1.06e-9	Age-related disease endophenotypes;
CRC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.5	6.71	0.35	8.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.7	-7.88	-0.4	4.88e-14	Body mass index;
CRC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.71	-11.07	-0.52	2.01e-24	Pancreatic cancer;
CRC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.78	0.44	9.34e-17	Morning vs. evening chronotype;
CRC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg02659138	chr7:134003124	SLC35B4	0.39	6.62	0.34	1.46e-10	Mean platelet volume;
CRC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.42	5.61	0.3	4.25e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg26566898	chr11:117069891	TAGLN	0.32	6.89	0.35	2.93e-11	Blood protein levels;
CRC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.4	6.57	0.34	1.97e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.44	-0.46	6.88e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.61	10.76	0.51	2.53e-23	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13412395	chr9:102583693	NR4A3	0.43	6.18	0.32	1.87e-9	Response to antipsychotic treatment;
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg12516270	chr8:143859308	LYNX1	0.44	7.88	0.4	4.71e-14	Urinary tract infection frequency;
CRC	cis	rs7147624	0.573	rs10148699	chr14:66199662	G/A	cg03016385	chr14:66212404	NA	-1.03	-10.36	-0.5	5.94e-22	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.22	0.37	3.66e-12	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.7	8.5	0.42	6.68e-16	Breast cancer;
CRC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.15	-0.49	3.1e-21	Total cholesterol levels;
CRC	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.49	7.2	0.37	4.11e-12	Glioblastoma;Glioma;
CRC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.12	10.93	0.52	6.49e-24	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.71	0.3	2.47e-8	Total body bone mineral density;
CRC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg26061582	chr7:22766209	IL6	0.55	8.35	0.42	1.92e-15	Lung cancer;
CRC	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg23587288	chr2:27483067	SLC30A3	-0.32	-5.67	-0.3	3.09e-8	Blood metabolite levels;
CRC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg15445000	chr17:37608096	MED1	0.36	6.4	0.33	5.4e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	10.88	0.51	9.36e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg11887960	chr12:57824829	NA	0.63	6.89	0.36	2.93e-11	Lung disease severity in cystic fibrosis;
CRC	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg24851651	chr11:66362959	CCS	-0.34	-5.7	-0.3	2.61e-8	Educational attainment (years of education);
CRC	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.85	-15.17	-0.64	8.49e-40	Lewy body disease;
CRC	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.56	8.68	0.43	1.88e-16	Diastolic blood pressure;
CRC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.79	13.51	0.6	2.13e-33	Menopause (age at onset);
CRC	cis	rs2415984	0.622	rs2817568	chr14:46940986	C/G	cg14871534	chr14:47121158	RPL10L	0.42	5.93	0.31	7.82e-9	Number of children ever born;
CRC	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.73	-13.43	-0.6	4.24e-33	Leprosy;
CRC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.55	6.08	0.32	3.26e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.85	15.74	0.66	5.32e-42	Menopause (age at onset);
CRC	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	1.16	10.74	0.51	2.86e-23	Arsenic metabolism;
CRC	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg01843034	chr6:37503916	NA	-0.35	-5.84	-0.31	1.26e-8	Cognitive performance;
CRC	cis	rs2992756	0.663	rs1316327	chr1:18802387	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.4	-5.69	-0.3	2.74e-8	Breast cancer;
CRC	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.26	6.11	0.32	2.89e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.55	-8.55	-0.43	4.78e-16	Aortic root size;
CRC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg18196295	chr10:418757	DIP2C	-0.54	-7.45	-0.38	8.53e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.58	-9.22	-0.45	3.52e-18	Breast cancer;
CRC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	7.39	0.38	1.25e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg21153622	chr11:89784906	NA	-0.48	-7.68	-0.39	1.78e-13	HDL cholesterol;
CRC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	8.81	0.44	7.32e-17	Rheumatoid arthritis;
CRC	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.44	-7.37	-0.38	1.41e-12	Refractive error;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg02902800	chr4:6784175	KIAA0232	0.37	6.0	0.31	5.08e-9	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.57	6.86	0.35	3.5e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.54	8.38	0.42	1.57e-15	Diastolic blood pressure;
CRC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg02475695	chr16:616220	NHLRC4	0.45	7.2	0.37	4.08e-12	Height;
CRC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.8	-0.44	7.79e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.71	-10.83	-0.51	1.4e-23	Tonsillectomy;
CRC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.14	0.32	2.32e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs11790388	0.505	rs670410	chr9:129700537	A/G	cg08433538	chr9:129676714	RALGPS1	0.35	5.62	0.3	4.1e-8	Schizophrenia;
CRC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-5.98	-0.31	5.78e-9	IgG glycosylation;
CRC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg06494592	chr3:125709126	NA	-0.47	-5.86	-0.31	1.13e-8	Blood pressure (smoking interaction);
CRC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.55	8.16	0.41	6.95e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.49	-7.0	-0.36	1.44e-11	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.35	0.38	1.63e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.7	0.39	1.64e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.04	0.45	1.4e-17	Bladder cancer;
CRC	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-6.07	-0.32	3.55e-9	Pubertal anthropometrics;
CRC	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.46	6.65	0.34	1.2e-10	Blood metabolite levels;
CRC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.45	-6.34	-0.33	7.78e-10	Lymphocyte counts;
CRC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.42	6.51	0.34	2.76e-10	Monocyte count;
CRC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.62	-10.88	-0.51	9e-24	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	1.0	18.18	0.71	1.25e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg02683197	chr6:28174875	NA	0.56	7.16	0.37	5.29e-12	Parkinson's disease;
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.31e-17	Bipolar disorder;
CRC	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.57	8.77	0.44	9.8e-17	Breast cancer;
CRC	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.29	-0.33	9.93e-10	Daytime sleep phenotypes;
CRC	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.43	6.32	0.33	8.27e-10	Red blood cell count;
CRC	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg19875578	chr6:126661172	C6orf173	0.43	5.78	0.3	1.78e-8	Male-pattern baldness;
CRC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.58	-9.15	-0.45	6.26e-18	Body mass index;
CRC	cis	rs16975963	0.644	rs75499934	chr19:38113043	C/A	cg15135657	chr19:38346511	NA	-0.46	-6.28	-0.33	1.04e-9	Longevity;
CRC	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.66	-0.39	2.06e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.46	6.62	0.34	1.48e-10	Emphysema distribution in smoking;
CRC	cis	rs4664293	0.667	rs6432562	chr2:160648006	A/T	cg08347373	chr2:160653686	CD302	-0.55	-9.43	-0.46	7.77e-19	Monocyte percentage of white cells;
CRC	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg23136738	chr11:925521	AP2A2	-0.4	-6.63	-0.34	1.4e-10	Alzheimer's disease (late onset);
CRC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg20885578	chr2:198174922	NA	-0.44	-6.96	-0.36	1.83e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.34	0.46	1.47e-18	Coffee consumption (cups per day);
CRC	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg13491945	chr12:107078410	RFX4	0.36	6.11	0.32	2.77e-9	Heart rate;
CRC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.53	-7.43	-0.38	9.37e-13	Pancreatic cancer;
CRC	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.92	11.19	0.53	7.51e-25	Exhaled nitric oxide output;
CRC	trans	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg03041920	chr13:100310311	CLYBL	0.61	6.34	0.33	7.78e-10	Breast cancer;
CRC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.72	11.33	0.53	2.45e-25	Colorectal cancer;
CRC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.61	-8.57	-0.43	4.2e-16	DNA methylation (variation);
CRC	cis	rs12024301	0.557	rs76439498	chr1:183643395	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.64	0.34	1.27e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.72	11.37	0.53	1.78e-25	Colorectal cancer;
CRC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs10886503	0.777	rs7101354	chr10:121267016	C/T	cg17804342	chr10:121271663	RGS10	0.79	7.99	0.4	2.29e-14	Obstetric antiphospholipid syndrome;
CRC	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg18196295	chr10:418757	DIP2C	-0.53	-7.22	-0.37	3.58e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs11212617	1.000	rs228594	chr11:108104525	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.4	5.84	0.31	1.26e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.58	-8.74	-0.43	1.2e-16	Schizophrenia;
CRC	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg02158880	chr13:53174818	NA	0.45	6.84	0.35	3.95e-11	Lewy body disease;
CRC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.61	-9.72	-0.47	8.32e-20	Mean corpuscular hemoglobin concentration;
CRC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.71	10.89	0.51	8.78e-24	Corneal astigmatism;
CRC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg07404485	chr7:94953653	PON1	-0.47	-6.05	-0.32	3.87e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg21918786	chr6:109611834	NA	-0.42	-7.3	-0.37	2.15e-12	Reticulocyte fraction of red cells;
CRC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.6	7.18	0.37	4.55e-12	Type 2 diabetes nephropathy;
CRC	cis	rs9903692	0.954	rs8080662	chr17:46190819	C/T	cg21215337	chr17:46176117	CBX1	-0.41	-7.48	-0.38	6.85e-13	Pulse pressure;
CRC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.49	0.38	6.54e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg16308533	chr17:40838983	CNTNAP1	0.4	6.49	0.34	3.07e-10	Colorectal or endometrial cancer;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.87	0.31	1.05e-8	Parkinson's disease;
CRC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.15	-0.41	7.95e-15	Hemoglobin concentration;
CRC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02725872	chr8:58115012	NA	-0.41	-8.22	-0.41	4.62e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.63	-9.93	-0.48	1.74e-20	Dental caries;
CRC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-6.92	-0.36	2.43e-11	Blood metabolite levels;
CRC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg03395651	chr16:88107091	BANP	0.57	7.76	0.39	1.1e-13	Menopause (age at onset);
CRC	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg10437265	chr15:77819839	NA	0.6	9.97	0.48	1.21e-20	Type 2 diabetes;
CRC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.21	-0.32	1.63e-9	Menopause (age at onset);
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.71	-0.39	1.48e-13	Electroencephalogram traits;
CRC	cis	rs10971721	0.908	rs10971722	chr9:33828164	G/A	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.69	10.46	0.5	2.77e-22	Corneal astigmatism;
CRC	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.66	-7.93	-0.4	3.35e-14	Pursuit maintenance gain;
CRC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg14078730	chr11:63896557	MACROD1	0.35	5.61	0.3	4.34e-8	Platelet count;
CRC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.24	0.33	1.38e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.43	-5.84	-0.31	1.29e-8	IgG glycosylation;
CRC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg01472538	chr16:58549086	SETD6	1.03	6.64	0.34	1.3100000000000001e-10	Schizophrenia;
CRC	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.54	7.83	0.4	6.89e-14	Plateletcrit;
CRC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.19	-0.32	1.76e-9	Type 2 diabetes;
CRC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.5	7.14	0.37	6.18e-12	Colorectal cancer;
CRC	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg14345882	chr6:26364793	BTN3A2	0.65	5.74	0.3	2.17e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs972578	0.837	rs3788601	chr22:43327526	C/T	cg01576275	chr22:43409880	NA	-0.38	-6.05	-0.32	4e-9	Mean platelet volume;
CRC	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.64	7.57	0.39	3.9e-13	Eotaxin levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20336580	chr22:19166301	SLC25A1	0.4	6.33	0.33	7.98e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs9287719	0.624	rs10187659	chr2:10726960	C/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.54	-7.49	-0.38	6.31e-13	Body mass index;
CRC	trans	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg26043149	chr18:55253948	FECH	0.51	7.79	0.39	8.59e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2882667	0.931	rs10069528	chr5:138354027	A/G	cg09476006	chr5:138032270	NA	0.41	6.83	0.35	4.08e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg25193742	chr10:104614220	C10orf32	-0.76	-6.42	-0.33	4.8e-10	Cognitive function;
CRC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.8	-12.44	-0.57	2.23e-29	Prostate cancer;
CRC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.62	-9.48	-0.46	5.4e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.68	-0.39	1.84e-13	Gut microbiome composition (summer);
CRC	cis	rs6060717	0.654	rs8122716	chr20:34607001	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.64	-0.34	1.27e-10	Hip circumference adjusted for BMI;
CRC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg11833968	chr6:79620685	NA	0.35	5.96	0.31	6.48e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.1	-0.32	2.96e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08664652	chr17:28804287	GOSR1	0.46	6.0	0.31	5.25e-9	Thyroid stimulating hormone;
CRC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.88	0.31	1.03e-8	Diabetic retinopathy;
CRC	cis	rs55702914	0.628	rs6745660	chr2:198349536	A/G	cg10820045	chr2:198174542	NA	0.33	5.89	0.31	9.78e-9	Major depression and alcohol dependence;
CRC	cis	rs9462846	0.853	rs9296401	chr6:42875465	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-6.26	-0.33	1.21e-9	Blood protein levels;
CRC	cis	rs55788414	1.000	rs35769936	chr16:81180101	A/G	cg06400318	chr16:81190750	PKD1L2	-0.68	-6.38	-0.33	5.87e-10	Left ventricular obstructive tract defect (maternal effect);
CRC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.39	-6.98	-0.36	1.59e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg24562669	chr7:97807699	LMTK2	0.46	7.82	0.4	7.01e-14	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07466433	chr2:7005728	CMPK2	-0.43	-6.31	-0.33	8.79e-10	Myopia (pathological);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02470736	chr12:50505862	C12orf62	0.4	6.23	0.32	1.42e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.37	-6.24	-0.33	1.31e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.73	-0.47	8.17e-20	Chronic sinus infection;
CRC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg09655341	chr17:79618100	PDE6G	-0.36	-6.11	-0.32	2.75e-9	Eye color traits;
CRC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg19041857	chr6:27730383	NA	-0.71	-6.71	-0.35	8.65e-11	Depression;
CRC	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-6.02	-0.31	4.78e-9	Axial length;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.4	-7.39	-0.38	1.19e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.67	8.91	0.44	3.47e-17	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.46	0.34	3.83e-10	Cognitive ability;
CRC	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.63	-6.85	-0.35	3.7e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	5.99	0.31	5.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.76	9.2	0.45	4.29e-18	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.56	-0.6	1.36e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs4664293	0.867	rs2114626	chr2:160639970	C/T	cg08347373	chr2:160653686	CD302	0.46	7.37	0.38	1.4e-12	Monocyte percentage of white cells;
CRC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg27565382	chr3:53032988	SFMBT1	0.7	6.16	0.32	2.07e-9	Immune reponse to smallpox (secreted IL-2);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13881405	chr9:92220388	GADD45G	0.4	5.98	0.31	5.9e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.7	0.39	1.58e-13	Height;
CRC	cis	rs2949837	0.581	rs2949838	chr7:45993924	T/C	cg23193639	chr7:45961078	IGFBP3	0.41	6.97	0.36	1.7e-11	Sitting height ratio;
CRC	cis	rs16973500	0.711	rs2878491	chr16:71981218	T/G	cg00732059	chr16:71740210	PHLPP2	-0.65	-6.76	-0.35	6.38e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	trans	rs9398803	0.650	rs10499135	chr6:126626333	A/G	cg14379719	chr8:11561508	GATA4	0.38	6.09	0.32	3.08e-9	Male-pattern baldness;
CRC	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-7.77	-0.39	1.04e-13	Large artery stroke;
CRC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.65	-0.47	1.42e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.2	0.37	4.01e-12	Major depressive disorder;
CRC	cis	rs868943	0.511	rs12204724	chr6:116532430	C/T	cg26893134	chr6:116381904	FRK	0.23	5.64	0.3	3.62e-8	Total cholesterol levels;
CRC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.37	-0.33	6.46e-10	Total body bone mineral density;
CRC	cis	rs10971721	0.822	rs56172788	chr9:33865750	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-7.0	-0.36	1.47e-11	Monocyte count;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14045725	chr17:2240967	SGSM2;TSR1	0.47	7.04	0.36	1.11e-11	Response to antipsychotic treatment;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg16699849	chr7:98923489	ARPC1A	-0.68	-6.2	-0.32	1.66e-9	Cognitive function;
CRC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.44	7.5	0.38	6.02e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs4352210	0.929	rs10084269	chr2:37761211	A/T	cg13134662	chr9:136858680	VAV2	-0.41	-5.99	-0.31	5.46e-9	RR interval (heart rate);
CRC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg18827107	chr12:86230957	RASSF9	0.38	5.93	0.31	7.83e-9	Major depressive disorder;
CRC	trans	rs73162807	0.655	rs6775587	chr3:146446783	A/T	cg26896787	chr1:228603707	TRIM17	-0.59	-5.99	-0.31	5.61e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.64	-8.71	-0.43	1.45e-16	Facial morphology (factor 19);
CRC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.62	-0.3	4.07e-8	Aortic root size;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09961100	chr19:5978428	RANBP3	0.39	6.12	0.32	2.61e-9	Schizophrenia;
CRC	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg01388757	chr2:102091195	RFX8	-0.54	-7.75	-0.39	1.12e-13	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.58	8.79	0.44	8.71e-17	Autism;
CRC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.79	-0.72	5.11e-54	Height;
CRC	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.35	-5.6	-0.3	4.45e-8	Myeloid white cell count;
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.46	6.84	0.35	3.79e-11	Menarche (age at onset);
CRC	cis	rs1572438	0.868	rs9378518	chr6:861084	A/G	cg21062780	chr6:887772	NA	-0.35	-5.62	-0.3	4.02e-8	Aging;
CRC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.4	6.27	0.33	1.13e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.64	-0.34	1.28e-10	Monocyte count;
CRC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.77	9.7	0.47	9.7e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.47	6.42	0.33	4.86e-10	Mean corpuscular volume;
CRC	cis	rs10924970	0.649	rs4412584	chr1:235418146	T/C	cg09010748	chr1:235293032	TOMM20	-0.41	-5.65	-0.3	3.48e-8	Asthma;
CRC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg01941586	chr1:40203715	PPIE	-0.42	-5.86	-0.31	1.14e-8	Blood protein levels;
CRC	cis	rs3015497	0.616	rs1389650	chr14:51081449	C/T	cg09863266	chr14:51125203	SAV1	-0.31	-5.77	-0.3	1.79e-8	Mean platelet volume;
CRC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.63	8.69	0.43	1.69e-16	Platelet count;
CRC	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.64	9.88	0.48	2.42e-20	Monocyte count;
CRC	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg15147215	chr3:52552868	STAB1	0.42	6.76	0.35	6.46e-11	Body mass index;
CRC	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.68	9.73	0.47	7.8500000000000006e-20	Blood protein levels;
CRC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.59	8.85	0.44	5.52e-17	Type 2 diabetes;
CRC	cis	rs3736594	0.513	rs62138966	chr2:27819172	G/A	cg27432699	chr2:27873401	GPN1	0.63	8.03	0.41	1.69e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.61	-0.34	1.51e-10	Total body bone mineral density;
CRC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.81	11.54	0.54	4.38e-26	Cognitive function;
CRC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.64	10.59	0.5	9.21e-23	Calcium levels;
CRC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg06462663	chr19:18546047	ISYNA1	0.5	7.63	0.39	2.48e-13	Breast cancer;
CRC	cis	rs10426930	0.671	rs57900491	chr19:4995295	A/T	cg25246084	chr19:4971487	KDM4B	-0.36	-5.95	-0.31	6.8e-9	Monocyte percentage of white cells;
CRC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg11212589	chr17:38028394	ZPBP2	0.44	8.38	0.42	1.51e-15	Self-reported allergy;
CRC	cis	rs1179624	0.679	rs4731244	chr7:75267614	A/G	cg05145297	chr7:75264568	HIP1	0.62	8.59	0.43	3.66e-16	Age-related nuclear cataracts;
CRC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg07713946	chr22:31675144	LIMK2	-0.4	-5.73	-0.3	2.24e-8	Colorectal cancer;
CRC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.62	9.64	0.47	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg07393940	chr7:158741817	NA	0.51	7.38	0.38	1.34e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.68	11.48	0.53	6.79e-26	Eosinophil percentage of white cells;
CRC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11645453	chr3:52864694	ITIH4	-0.36	-6.44	-0.33	4.27e-10	Bipolar disorder;
CRC	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.58	8.32	0.42	2.43e-15	Smooth-surface caries;
CRC	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg11887960	chr12:57824829	NA	0.58	6.29	0.33	1.02e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg03948781	chr1:205179583	DSTYK	0.41	5.65	0.3	3.49e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs965469	1.000	rs6051716	chr20:3267736	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.64	-0.3	3.74e-8	IFN-related cytopenia;
CRC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.44	0.33	4.13e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01664094	chr15:75748568	SIN3A	0.43	6.15	0.32	2.2e-9	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11109510	chr2:170655290	SSB	0.4	5.97	0.31	6.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg07424746	chr4:185654737	MLF1IP	-0.57	-5.69	-0.3	2.79e-8	Blood protein levels;
CRC	cis	rs7605827	0.930	rs6431712	chr2:15691292	C/T	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.65	-8.76	-0.44	1.02e-16	Blood protein levels;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.58	10.29	0.49	9.89e-22	Developmental language disorder (linguistic errors);
CRC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.51	7.29	0.37	2.31e-12	Blood metabolite levels;
CRC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg21951975	chr1:209979733	IRF6	0.48	6.54	0.34	2.34e-10	Cleft lip with or without cleft palate;
CRC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.56	7.29	0.37	2.35e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13064447	0.789	rs55976129	chr3:12762067	T/C	cg07775309	chr3:12595852	NA	0.37	5.94	0.31	7.18e-9	Major depression and alcohol dependence;
CRC	cis	rs4664293	0.801	rs6432552	chr2:160574124	A/T	cg08347373	chr2:160653686	CD302	-0.35	-5.62	-0.3	4.15e-8	Monocyte percentage of white cells;
CRC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.6	9.3	0.46	1.98e-18	Blood metabolite levels;
CRC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg11212589	chr17:38028394	ZPBP2	0.41	7.59	0.39	3.24e-13	Self-reported allergy;
CRC	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.58	8.5	0.42	6.79e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.13	10.09	0.49	4.97e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg25508545	chr19:49467065	FTL	0.42	5.99	0.31	5.59e-9	Type 2 diabetes (age of onset);
CRC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-6.29	-0.33	9.87e-10	Menarche (age at onset);
CRC	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.5	7.37	0.38	1.37e-12	Night sleep phenotypes;
CRC	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.79	-0.35	5.28e-11	Retinal vascular caliber;
CRC	cis	rs7605827	0.930	rs1990755	chr2:15616013	C/G	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.01	-0.31	5.03e-9	Axial length;
CRC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.9	-15.52	-0.65	3.9e-41	Height;
CRC	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.42	6.95	0.36	1.96e-11	Mean corpuscular volume;
CRC	cis	rs9616064	0.704	rs41346347	chr22:46958507	A/C	cg05621596	chr22:47072043	GRAMD4	-0.57	-8.88	-0.44	4.32e-17	Urate levels in obese individuals;
CRC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.84	14.53	0.63	2.7e-37	Height;
CRC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.59	-10.53	-0.5	1.57e-22	Aortic root size;
CRC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	5.66	0.3	3.22e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg02772935	chr3:125709198	NA	-0.46	-5.98	-0.31	5.91e-9	Blood pressure (smoking interaction);
CRC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.66	-9.78	-0.47	5.53e-20	Initial pursuit acceleration;
CRC	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg02811702	chr13:24901961	NA	0.47	6.56	0.34	2.09e-10	Obesity-related traits;
CRC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-0.7	-8.06	-0.41	1.47e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs11212617	0.967	rs186594	chr11:108265854	A/T	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.34	0.33	7.41e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.28	-0.56	8.36e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.04	-0.32	4.18e-9	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.68e-16	Menopause (age at onset);
CRC	cis	rs459193	1.000	rs40271	chr5:55796319	A/G	cg18302225	chr5:55776401	NA	-0.59	-8.74	-0.43	1.21e-16	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs28655083	0.529	rs1485794	chr16:77101977	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.74	0.35	7.26e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.5	7.42	0.38	1.03e-12	Uric acid levels;
CRC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.67	-10.68	-0.51	4.84e-23	Sudden cardiac arrest;
CRC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg03959625	chr15:84868606	LOC388152	0.41	6.07	0.32	3.55e-9	Schizophrenia;
CRC	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.5	-0.38	6.11e-13	Depression;
CRC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.93	11.11	0.52	1.43e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.94	11.14	0.52	1.1e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg05623727	chr3:50126028	RBM5	0.41	6.32	0.33	8.31e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg20933634	chr6:27740509	NA	0.58	8.63	0.43	2.69e-16	Parkinson's disease;
CRC	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg22089800	chr15:90895588	ZNF774	0.49	7.91	0.4	3.9e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg04450456	chr4:17643702	FAM184B	0.41	6.7	0.35	8.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.4	6.28	0.33	1.09e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs41005	1.000	rs41004	chr2:8111580	C/T	cg03155496	chr2:8117019	LOC339788	0.4	7.11	0.36	7.35e-12	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-8.07	-0.41	1.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg08210727	chr20:33865349	NA	0.49	6.15	0.32	2.19e-9	Attention deficit hyperactivity disorder;
CRC	trans	rs12517041	1.000	rs34157151	chr5:23289755	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.4	6.42	0.33	4.67e-10	Longevity;
CRC	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14169450	chr9:139327907	INPP5E	0.36	5.67	0.3	3.21e-8	Monocyte percentage of white cells;
CRC	trans	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-6.89	-0.36	2.8e-11	Endometrial cancer;
CRC	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.56	9.98	0.48	1.18e-20	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.44	7.06	0.36	9.87e-12	Resting heart rate;
CRC	cis	rs2380220	0.808	rs2613553	chr6:95916704	A/G	cg04719120	chr6:96025338	MANEA	-0.53	-5.86	-0.31	1.14e-8	Behavioural disinhibition (generation interaction);
CRC	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg26811252	chr16:29126840	RRN3P2	0.72	9.81	0.48	4.4e-20	Menopause (age at onset);
CRC	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.48	-7.07	-0.36	9.1e-12	Coronary heart disease;
CRC	cis	rs2795502	0.506	rs11819501	chr10:43465544	C/T	cg08461752	chr10:43522343	NA	-0.68	-6.35	-0.33	7.15e-10	Blood protein levels;
CRC	cis	rs2982552	0.873	rs3020305	chr6:152064487	T/C	cg22157087	chr6:152012887	ESR1	0.38	5.81	0.3	1.5e-8	Bone properties (heel);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg11568364	chr10:126432734	FAM53B	0.42	6.21	0.32	1.59e-9	Intelligence (multi-trait analysis);
CRC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg06781209	chr11:61594997	FADS2	-0.38	-5.74	-0.3	2.11e-8	Trans fatty acid levels;
CRC	cis	rs860295	0.702	rs10908470	chr1:155527013	A/C	cg02153340	chr1:155202674	NA	-0.53	-6.35	-0.33	7.32e-10	Body mass index;
CRC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.66	-0.39	2.04e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.64	-8.47	-0.42	8.04e-16	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.4	-0.5	4.29e-22	Total cholesterol levels;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-9.89	-0.48	2.36e-20	Monocyte count;
CRC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-5.89	-0.31	9.62e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.69	-0.43	1.74e-16	Aortic root size;
CRC	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	1.09	12.84	0.58	7.36e-31	Lung disease severity in cystic fibrosis;
CRC	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.78	-12.46	-0.57	1.92e-29	Plateletcrit;Platelet count;
CRC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg06238570	chr21:40685208	BRWD1	-0.68	-9.11	-0.45	8e-18	Cognitive function;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg12703194	chr16:3086867	CCDC64B	-0.38	-6.02	-0.31	4.53e-9	Myopia (pathological);
CRC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg18972013	chr17:78078605	GAA	-0.41	-5.8	-0.3	1.53e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg09040174	chr2:113837401	NA	0.43	5.79	0.3	1.64e-8	Protein quantitative trait loci;
CRC	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.7	8.62	0.43	2.8e-16	Prostate cancer;
CRC	cis	rs9937943	0.667	rs12934000	chr16:74623420	T/G	cg01733217	chr16:74700730	RFWD3	0.71	8.03	0.4	1.76e-14	Neutrophil percentage of white cells;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21287330	chr17:7154245	C17orf81;DULLARD	0.39	6.06	0.32	3.68e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.6	9.23	0.45	3.31e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.91	11.42	0.53	1.15e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg17948913	chr5:572064	NA	0.56	6.25	0.33	1.28e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02290350	chr8:58132656	NA	-0.6	-8.3	-0.42	2.8e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.41	-6.2	-0.32	1.68e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg07090678	chr1:91966139	CDC7	0.36	5.85	0.31	1.18e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27401989	chr12:53774447	SP1	0.39	6.02	0.31	4.53e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.19	-26.05	-0.82	5.89e-82	Exhaled nitric oxide output;
CRC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-6.97	-0.36	1.75e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg15445000	chr17:37608096	MED1	0.27	6.06	0.32	3.81e-9	Asthma;
CRC	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.41	-0.38	1.05e-12	Caudate activity during reward;
CRC	cis	rs1950626	0.569	rs4143956	chr14:101434356	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.75	12.07	0.55	5.21e-28	Pelvic organ prolapse (moderate/severe);
CRC	trans	rs1265507	0.577	rs1807094	chr12:114869797	C/A	cg11700868	chr17:38521232	GJD3	0.42	5.99	0.31	5.5e-9	Percent mammographic density;
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs12711979	0.528	rs1823860	chr2:3867013	A/G	cg17052675	chr2:3827356	NA	-0.37	-5.92	-0.31	7.94e-9	Itch intensity from mosquito bite adjusted by bite size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11889002	chr15:52030128	LYSMD2	0.39	6.09	0.32	3.16e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.72	-0.35	8.11e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	7.36	0.38	1.45e-12	Height;
CRC	trans	rs2303319	0.504	rs62187570	chr2:162373899	C/G	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.54e-9	Cognitive function;
CRC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05958510	chr12:89746351	DUSP6	0.42	6.12	0.32	2.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.53	7.88	0.4	4.97e-14	Response to temozolomide;
CRC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.4	6.31	0.33	8.88e-10	Height;
CRC	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg00105475	chr2:10696890	NA	0.45	7.15	0.37	5.48e-12	Prostate cancer;
CRC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.59	-10.62	-0.51	7.43e-23	Aortic root size;
CRC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.67	-0.47	1.21e-19	Heart rate;
CRC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.42	-7.43	-0.38	9.42e-13	Colorectal or endometrial cancer;
CRC	cis	rs959260	0.541	rs61417295	chr17:73356848	T/C	cg14668889	chr17:73230827	NUP85	0.49	5.68	0.3	2.93e-8	Systemic lupus erythematosus;
CRC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.59	8.93	0.44	3.13e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.57	7.4	0.38	1.15e-12	Height;
CRC	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07513332	chr6:167530253	CCR6	0.37	6.01	0.31	4.81e-9	Primary biliary cholangitis;
CRC	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.48	6.54	0.34	2.35e-10	Mean corpuscular volume;
CRC	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.74	8.0	0.4	2.19e-14	Systolic blood pressure;
CRC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.23	-0.32	1.44e-9	Aortic root size;
CRC	cis	rs9462027	0.628	rs7745097	chr6:34794434	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.13	-0.32	2.45e-9	Systemic lupus erythematosus;
CRC	cis	rs8105895	0.935	rs1968446	chr19:22279047	A/C	cg02657401	chr19:22469223	NA	-0.35	-5.67	-0.3	3.06e-8	Body mass index (change over time);
CRC	cis	rs5751901	1.000	rs5751901	chr22:24992266	C/T	cg15363607	chr22:24998974	GGT1	0.43	6.81	0.35	4.58e-11	Protein quantitative trait loci;
CRC	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg08632701	chr21:37451849	NA	-0.42	-6.35	-0.33	6.98e-10	Mitral valve prolapse;
CRC	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.65	10.48	0.5	2.33e-22	Cancer;
CRC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.44	-6.53	-0.34	2.56e-10	Menarche (age at onset);
CRC	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.43	7.85	0.4	5.82e-14	Blood metabolite ratios;
CRC	cis	rs939574	0.512	rs2276638	chr2:220145286	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.55	6.26	0.33	1.21e-9	Platelet distribution width;
CRC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.54	0.47	3.33e-19	Intelligence (multi-trait analysis);
CRC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-7.23	-0.37	3.31e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.74	-0.47	7.09e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg25456477	chr12:86230367	RASSF9	0.33	5.69	0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg04121214	chr22:50244548	NA	0.41	5.91	0.31	8.44e-9	Schizophrenia;
CRC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.46	6.93	0.36	2.19e-11	Menopause (age at onset);
CRC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg00531865	chr16:30841666	NA	-0.46	-6.09	-0.32	3.22e-9	Multiple myeloma;
CRC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.96	0.31	6.66e-9	Tonsillectomy;
CRC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg03037974	chr15:76606532	NA	-0.54	-7.99	-0.4	2.22e-14	Blood metabolite levels;
CRC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.36	5.74	0.3	2.21e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	5.86	0.31	1.13e-8	Tonsillectomy;
CRC	cis	rs6586163	0.872	rs7910825	chr10:90743341	G/A	cg13456138	chr10:90753195	FAS	-0.44	-6.58	-0.34	1.84e-10	Chronic lymphocytic leukemia;
CRC	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg12573674	chr2:1569213	NA	-0.74	-7.3	-0.37	2.21e-12	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.69	11.62	0.54	2.27e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2282802	0.635	rs269767	chr5:139536922	A/G	cg26211634	chr5:139558579	C5orf32	0.4	6.97	0.36	1.74e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.39	-0.38	1.22e-12	Bipolar disorder;
CRC	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.91	-0.36	2.52e-11	Dilated cardiomyopathy;
CRC	cis	rs501120	0.568	rs471451	chr10:44754785	G/C	cg09554077	chr10:44749378	NA	0.68	6.53	0.34	2.44e-10	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg22723502	chr6:26240528	HIST1H4F	-0.38	-5.86	-0.31	1.14e-8	Gout;Renal underexcretion gout;
CRC	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.48	-10.29	-0.49	9.93e-22	Urate levels in overweight individuals;
CRC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.41	-7.52	-0.38	5.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.34	-6.07	-0.32	3.47e-9	Rheumatoid arthritis;
CRC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.84	14.18	0.62	5.99e-36	Height;
CRC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.54	-8.3	-0.42	2.67e-15	Aortic root size;
CRC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg00601486	chr12:48723148	H1FNT	0.35	6.73	0.35	7.35e-11	Glycated hemoglobin levels;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.0	-0.31	5.24e-9	Cognitive function;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg09601704	chr17:8027427	HES7	0.38	6.23	0.32	1.39e-9	Interleukin-6 levels;
CRC	cis	rs9311474	0.841	rs352139	chr3:52258372	T/C	cg15147215	chr3:52552868	STAB1	-0.51	-8.38	-0.42	1.59e-15	Electroencephalogram traits;
CRC	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg01987224	chr1:201084466	NA	-0.54	-10.39	-0.5	4.62e-22	Permanent tooth development;
CRC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.54	-0.5	1.39e-22	Chronic sinus infection;
CRC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs375066	0.901	rs1978723	chr19:44383800	C/T	cg12072164	chr19:44306565	LYPD5	-0.37	-5.77	-0.3	1.82e-8	Breast cancer;
CRC	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.82	12.43	0.57	2.36e-29	Chronic lymphocytic leukemia;
CRC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.28	6.19	0.32	1.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9814567	1.000	rs9985341	chr3:134232840	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-5.86	-0.31	1.13e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg04176472	chr15:90893244	GABARAPL3	0.32	5.64	0.3	3.65e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs294883	0.767	rs9346785	chr6:159704151	T/C	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs12760731	0.622	rs71628291	chr1:178573743	G/A	cg00404053	chr1:178313656	RASAL2	0.65	6.95	0.36	1.96e-11	Obesity-related traits;
CRC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.47	6.16	0.32	2.09e-9	Obesity-related traits;
CRC	cis	rs4722166	0.532	rs4719712	chr7:22755807	C/T	cg05472934	chr7:22766657	IL6	0.67	10.47	0.5	2.42e-22	Lung cancer;
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg02741985	chr17:80059408	CCDC57	0.43	7.11	0.36	7.42e-12	Life satisfaction;
CRC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.38	-6.95	-0.36	1.91e-11	Reticulocyte fraction of red cells;
CRC	cis	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg27102117	chr16:15229624	NA	0.37	5.89	0.31	9.3e-9	Triglycerides;
CRC	cis	rs7487075	0.780	rs1873793	chr12:46761324	A/G	cg22049899	chr12:47219821	SLC38A4	-0.35	-7.2	-0.37	4.16e-12	Itch intensity from mosquito bite;
CRC	cis	rs9311676	0.632	rs11130637	chr3:58405573	C/G	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs61864810	1	rs61864810	chr12:46682009	G/A	cg22049899	chr12:47219821	SLC38A4	0.3	5.89	0.31	9.31e-9	Itch intensity from mosquito bite;
CRC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.35	6.26	0.33	1.18e-9	Erythrocyte sedimentation rate;
CRC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.07	-12.6	-0.57	5.61e-30	Diabetic kidney disease;
CRC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.75	10.96	0.52	5e-24	Longevity;
CRC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.68	0.39	1.82e-13	Diabetic retinopathy;
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-11.4	-0.53	1.32e-25	Bipolar disorder and schizophrenia;
CRC	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.64	-9.93	-0.48	1.67e-20	Corneal astigmatism;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00992913	chr1:156698515	C1orf66;ISG20L2	0.45	6.22	0.32	1.51e-9	Anxiety disorder;
CRC	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.48	5.77	0.3	1.86e-8	Carotid intima media thickness;
CRC	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-7.75	-0.39	1.19e-13	Post bronchodilator FEV1;
CRC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-8.96	-0.44	2.47e-17	Chronic sinus infection;
CRC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.79	-16.41	-0.67	1.22e-44	Electroencephalogram traits;
CRC	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.72	-11.56	-0.54	3.6e-26	Breast cancer;
CRC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.45	6.08	0.32	3.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3015497	0.789	rs2356457	chr14:51116863	C/T	cg09863266	chr14:51125203	SAV1	-0.32	-5.96	-0.31	6.59e-9	Mean platelet volume;
CRC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.56	-6.73	-0.35	7.73e-11	Mean platelet volume;
CRC	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg00531865	chr16:30841666	NA	-0.51	-5.84	-0.31	1.28e-8	Diastolic blood pressure;
CRC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.65	11.78	0.54	5.9e-27	Prudent dietary pattern;
CRC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.81	-0.35	4.65e-11	Aortic root size;
CRC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26958806	chr6:27640298	NA	0.63	5.62	0.3	4.08e-8	Depression;
CRC	cis	rs4363385	0.791	rs10788855	chr1:153002359	A/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.79	-0.35	5.23e-11	Inflammatory skin disease;
CRC	cis	rs7680126	0.596	rs74778870	chr4:10298583	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.87	-0.31	1.04e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.4	0.33	5.45e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2302729	0.545	rs3794291	chr12:2769665	C/T	cg19945202	chr12:2788847	CACNA1C	-0.5	-7.98	-0.4	2.43e-14	Sleep quality;
CRC	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11446398	chr5:77624930	NA	0.42	6.01	0.31	5.01e-9	Triglycerides;
CRC	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg08890418	chr1:21044141	KIF17	0.31	5.65	0.3	3.46e-8	Facial morphology (factor 17, height of vermillion upper lip);
CRC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg14008862	chr17:28927542	LRRC37B2	0.54	5.68	0.3	2.91e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4737010	0.644	rs522407	chr8:41610969	G/A	cg17182837	chr8:41585554	ANK1	0.53	7.55	0.38	4.41e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CRC	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.65	-8.83	-0.44	6.25e-17	Blood protein levels;
CRC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg03037974	chr15:76606532	NA	0.68	11.55	0.54	4.06e-26	Blood metabolite levels;
CRC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg19913688	chr11:428466	ANO9	0.66	6.98	0.36	1.67e-11	Body mass index;
CRC	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg05502645	chr19:1971281	CSNK1G2	0.47	7.28	0.37	2.51e-12	Coronary artery disease;
CRC	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg06223162	chr1:101003688	GPR88	-0.34	-6.13	-0.32	2.45e-9	Monocyte count;
CRC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.31	0.62	1.84e-36	Chronic sinus infection;
CRC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-11.28	-0.53	3.61e-25	Glomerular filtration rate (creatinine);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg03276813	chr2:182757157	SSFA2	-0.42	-6.34	-0.33	7.69e-10	Aortic root size;
CRC	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.77	0.47	5.98e-20	Cognitive test performance;
CRC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.98	0.31	5.73e-9	Renal function-related traits (BUN);
CRC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	8.2	0.41	5.27e-15	Menarche (age at onset);
CRC	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.46	8.59	0.43	3.56e-16	Intraocular pressure;
CRC	cis	rs720844	0.684	rs34881950	chr2:149303493	C/A	cg09247360	chr2:149335327	NA	-0.57	-5.95	-0.31	6.69e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs10858396	0.957	rs7029858	chr9:138273821	C/T	cg26979339	chr12:107168153	RIC8B	0.49	6.45	0.34	3.93e-10	Attention deficit hyperactivity disorder;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg24028350	chr3:33482811	UBP1	-0.41	-6.07	-0.32	3.49e-9	Daytime sleep phenotypes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10143842	chr3:88198517	C3orf38	0.47	6.4	0.33	5.4e-10	Anxiety disorder;
CRC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.28	0.42	3.08e-15	Alzheimer's disease;
CRC	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-8.01	-0.4	2.03e-14	HDL cholesterol;
CRC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg09796270	chr17:17721594	SREBF1	-0.41	-6.6	-0.34	1.66e-10	Total body bone mineral density;
CRC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.58	8.69	0.43	1.7e-16	Bipolar disorder;
CRC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.05	-0.32	3.94e-9	Joint mobility (Beighton score);
CRC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg15786705	chr6:28176104	NA	0.62	8.81	0.44	7.1e-17	Cardiac Troponin-T levels;
CRC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.64	9.64	0.47	1.61e-19	Lymphocyte counts;
CRC	trans	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.54	0.38	4.75e-13	Endometrial cancer;
CRC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-5.98	-0.31	5.79e-9	Alzheimer's disease (late onset);
CRC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.88	11.07	0.52	2.05e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.65	0.75	2.49e-61	Prudent dietary pattern;
CRC	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg01858014	chr14:56050164	KTN1	-0.73	-5.65	-0.3	3.4e-8	Putamen volume;
CRC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg24562669	chr7:97807699	LMTK2	0.47	7.84	0.4	6.48e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg12046867	chr14:103022105	NA	-0.82	-11.52	-0.54	4.93e-26	Platelet count;
CRC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.37	-0.42	1.73e-15	Bipolar disorder and schizophrenia;
CRC	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.55	-6.05	-0.32	4.01e-9	Neutrophil percentage of white cells;
CRC	cis	rs12898370	0.561	rs11630770	chr15:77469643	A/G	cg05673287	chr15:77411982	SGK269	0.53	5.8	0.3	1.57e-8	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs2252521	0.583	rs317706	chr7:29097265	C/T	cg11728747	chr7:29037910	CPVL	-0.49	-6.95	-0.36	2e-11	Cognitive performance;
CRC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg02741985	chr17:80059408	CCDC57	0.45	7.44	0.38	9.06e-13	Life satisfaction;
CRC	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg22561889	chr6:118971681	C6orf204	0.51	6.65	0.34	1.26e-10	Diastolic blood pressure;
CRC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.47	6.31	0.33	8.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25365794	chr17:8022404	ALOXE3	0.52	7.54	0.38	4.56e-13	Response to antipsychotic treatment;
CRC	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg19731401	chr7:2775893	GNA12	0.53	6.22	0.32	1.53e-9	Childhood ear infection;
CRC	cis	rs7082209	1.000	rs4491167	chr10:44810820	T/A	cg09554077	chr10:44749378	NA	0.43	5.62	0.3	4.04e-8	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
CRC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.45	-6.61	-0.34	1.54e-10	Asthma;
CRC	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg02569458	chr12:86230093	RASSF9	0.39	6.56	0.34	2.15e-10	Major depressive disorder;
CRC	cis	rs7089973	0.934	rs12771956	chr10:116576228	C/G	cg23260525	chr10:116636907	FAM160B1	0.31	5.97	0.31	6.21e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04175895	chr11:64851783	CDCA5;ZFPL1	-0.4	-6.11	-0.32	2.85e-9	Obesity-related traits;
CRC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.54	0.57	9.24e-30	Bone mineral density;
CRC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg27523141	chr10:43048294	ZNF37B	-0.49	-7.2	-0.37	4.01e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.55	7.07	0.36	9.2e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.15e-23	Motion sickness;
CRC	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg14825688	chr5:132208181	LEAP2	-0.41	-6.53	-0.34	2.49e-10	Apolipoprotein A-IV levels;
CRC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.32	0.42	2.36e-15	Alzheimer's disease;
CRC	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg07701084	chr6:150067640	NUP43	0.54	7.44	0.38	8.71e-13	Lung cancer;
CRC	cis	rs3026101	0.671	rs1806240	chr17:5298320	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	6.84	0.35	3.98e-11	Body mass index;
CRC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.88	0.31	9.98e-9	Renal function-related traits (BUN);
CRC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.65	9.54	0.47	3.3e-19	Menopause (age at onset);
CRC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg19223190	chr17:80058835	NA	0.4	6.5	0.34	3.06e-10	Life satisfaction;
CRC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	9.09	0.45	9.67e-18	Cognitive test performance;
CRC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	14.16	0.62	7.28e-36	Electrocardiographic conduction measures;
CRC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.24	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10065203	0.527	rs181927	chr5:14351946	G/T	cg26689441	chr5:14406021	TRIO	-0.36	-6.04	-0.32	4.14e-9	Paclitaxel-induced neuropathy;
CRC	cis	rs6460942	0.908	rs112897715	chr7:12241541	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-6.22	-0.32	1.47e-9	Coronary artery disease;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14966992	chr3:127842884	RUVBL1	0.45	6.2	0.32	1.7e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg24011408	chr12:48396354	COL2A1	0.45	6.55	0.34	2.21e-10	Glycated hemoglobin levels;
CRC	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.39	0.46	1.04e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.61	9.51	0.46	4.28e-19	Aortic root size;
CRC	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.08	-0.32	3.35e-9	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.43	0.46	7.65e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.4	-0.33	5.22e-10	Blood pressure (smoking interaction);
CRC	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.45	-0.34	3.98e-10	Depression;
CRC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.7	11.76	0.54	7.07e-27	Alzheimer's disease (late onset);
CRC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.48	6.78	0.35	5.54e-11	Aortic root size;
CRC	trans	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg24644049	chr4:85504048	CDS1	0.9	7.57	0.39	3.72e-13	Skin colour saturation;
CRC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.8	13.18	0.59	3.91e-32	Menopause (age at onset);
CRC	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg25856811	chr1:152973957	SPRR3	-0.27	-7.49	-0.38	6.31e-13	Inflammatory skin disease;
CRC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.29	6.41	0.33	4.92e-10	Intelligence (multi-trait analysis);
CRC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.5	-9.06	-0.45	1.15e-17	Longevity;
CRC	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg21153622	chr11:89784906	NA	-0.46	-7.26	-0.37	2.75e-12	HDL cholesterol;
CRC	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.34	-5.84	-0.31	1.27e-8	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.62	-9.73	-0.47	7.9e-20	Sudden cardiac arrest;
CRC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18375707	chr11:64034959	PLCB3	0.46	6.46	0.34	3.81e-10	Mean platelet volume;
CRC	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg10510935	chr1:4059661	NA	0.39	5.88	0.31	9.86e-9	Interleukin-17 levels;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg05569086	chr8:143859399	LYNX1	0.39	6.58	0.34	1.81e-10	Urinary tract infection frequency;
CRC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.24	-0.33	1.35e-9	Aortic root size;
CRC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.6	-9.54	-0.47	3.45e-19	Systemic lupus erythematosus;
CRC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.76	-10.47	-0.5	2.5e-22	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.68	-11.61	-0.54	2.41e-26	Lewy body disease;
CRC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-7.1	-0.36	7.78e-12	Tuberculosis;
CRC	cis	rs72730918	0.590	rs12324531	chr15:51921358	T/C	cg14296394	chr15:51910925	DMXL2	-0.47	-6.32	-0.33	8.69e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.41	6.62	0.34	1.5e-10	Major depressive disorder;
CRC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.47	8.09	0.41	1.14e-14	Schizophrenia;
CRC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.67	-0.39	1.95e-13	Response to antipsychotic treatment;
CRC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg11833968	chr6:79620685	NA	-0.36	-6.16	-0.32	2.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.72	-11.23	-0.53	5.26e-25	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.54	8.75	0.43	1.15e-16	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06632829	chr19:45394476	TOMM40	0.43	5.97	0.31	6.28e-9	Response to antipsychotic treatment;
CRC	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24249390	chr15:90295951	MESP1	-0.58	-9.3	-0.46	1.95e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg21302420	chr1:112162376	RAP1A	0.77	6.85	0.35	3.64e-11	Skin colour saturation;
CRC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.34	0.42	2.01e-15	Platelet count;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg21747405	chr11:67723411	NA	-0.57	-8.92	-0.44	3.38e-17	Blood pressure (smoking interaction);
CRC	cis	rs11233250	0.502	rs1497104	chr11:82411635	C/T	cg17391194	chr11:82401662	NA	-0.38	-5.91	-0.31	8.35e-9	Glioblastoma;Glioma;
CRC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.8	9.97	0.48	1.2e-20	Eosinophil percentage of granulocytes;
CRC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.51	-5.89	-0.31	9.36e-9	Vitiligo;
CRC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	10.04	0.48	7.38e-21	Chronic sinus infection;
CRC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00166722	chr3:10149974	C3orf24	0.71	9.41	0.46	8.98e-19	Alzheimer's disease;
CRC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.41	0.33	5.07e-10	Menarche (age at onset);
CRC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.65	-11.53	-0.54	4.59e-26	Prudent dietary pattern;
CRC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg25304816	chr1:36627734	MAP7D1	0.47	7.08	0.36	9.02e-12	Corneal structure;
CRC	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.23	-31.48	-0.87	2.93e-101	Colorectal cancer;
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.3	0.53	2.97e-25	Prudent dietary pattern;
CRC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg21153622	chr11:89784906	NA	-0.5	-8.33	-0.42	2.15e-15	HDL cholesterol;
CRC	trans	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.88	0.35	2.96e-11	Cognitive test performance;
CRC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.4	5.86	0.31	1.14e-8	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.81	-0.31	1.45e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18357526	chr6:26021779	HIST1H4A	0.43	6.06	0.32	3.79e-9	Height;
CRC	cis	rs73206853	0.841	rs9783428	chr12:111068096	C/T	cg12870014	chr12:110450643	ANKRD13A	0.71	7.54	0.38	4.51e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.64	8.38	0.42	1.6e-15	Alzheimer's disease;
CRC	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.75	-0.43	1.1e-16	Coffee consumption (cups per day);
CRC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18375707	chr11:64034959	PLCB3	0.46	6.29	0.33	9.86e-10	Mean platelet volume;
CRC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.27e-20	Hip circumference adjusted for BMI;
CRC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.66	-9.46	-0.46	6.16e-19	Menopause (age at onset);
CRC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.52	8.4	0.42	1.39e-15	Gout;
CRC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg00734567	chr1:86172782	ZNHIT6	-0.4	-5.66	-0.3	3.36e-8	Urate levels in overweight individuals;
CRC	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg17470449	chr10:769945	NA	0.51	7.4	0.38	1.18e-12	Uric acid levels;
CRC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.69	-0.35	9.4e-11	Response to antipsychotic treatment;
CRC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.7	11.72	0.54	9.41e-27	Alzheimer's disease (late onset);
CRC	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02598441	chr17:62777298	LOC146880	-0.54	-7.08	-0.36	8.78e-12	QT interval;
CRC	cis	rs990171	0.913	rs1403554	chr2:103083453	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Lymphocyte counts;
CRC	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.58	-9.08	-0.45	1.04e-17	Aortic root size;
CRC	cis	rs3790844	0.955	rs3790848	chr1:200006111	C/A	cg07208853	chr1:200005219	NR5A2	0.34	8.22	0.41	4.91e-15	Pancreatic cancer;
CRC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg08798685	chr6:27730294	NA	-0.64	-6.17	-0.32	1.98e-9	Depression;
CRC	cis	rs728616	0.558	rs2880599	chr10:82164435	A/G	cg11900509	chr10:81946545	ANXA11	-0.56	-6.24	-0.33	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.34	5.77	0.3	1.88e-8	Major depressive disorder;
CRC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.69	10.51	0.5	1.83e-22	Menopause (age at onset);
CRC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.08	13.14	0.59	5.59e-32	Sexual dysfunction (female);
CRC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg00343986	chr7:65444356	GUSB	-0.46	-6.82	-0.35	4.32e-11	Aortic root size;
CRC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	14.74	0.63	3.98e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.62	10.52	0.5	1.68e-22	Colorectal cancer;
CRC	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.45	6.44	0.33	4.31e-10	Height;
CRC	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg11189052	chr15:85197271	WDR73	0.61	8.41	0.42	1.25e-15	Schizophrenia;
CRC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.39	6.85	0.35	3.66e-11	Primary biliary cholangitis;
CRC	trans	rs660498	0.641	rs72810095	chr10:27732984	T/G	cg13661793	chr10:32399026	NA	-0.33	-5.99	-0.31	5.52e-9	Asthma (childhood onset);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08005411	chr12:69753742	YEATS4	0.46	6.04	0.32	4.25e-9	Survival in pancreatic cancer;
CRC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.25	0.37	3.03e-12	Aortic root size;
CRC	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.58	0.5	1e-22	Iron status biomarkers;
CRC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-6.14	-0.32	2.41e-9	Coronary artery disease;
CRC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg19812747	chr11:111475976	SIK2	0.42	6.21	0.32	1.57e-9	Primary sclerosing cholangitis;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg20769334	chr22:50913335	SBF1	0.38	6.21	0.32	1.63e-9	Obesity-related traits;
CRC	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg09655341	chr17:79618100	PDE6G	0.55	6.5	0.34	2.95e-10	Dental caries;
CRC	cis	rs2415984	0.579	rs10140977	chr14:46955156	T/A	cg14871534	chr14:47121158	RPL10L	-0.43	-6.2	-0.32	1.74e-9	Number of children ever born;
CRC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg25164649	chr6:28176230	NA	0.47	6.88	0.35	2.98e-11	Cardiac Troponin-T levels;
CRC	cis	rs7539542	0.536	rs12091234	chr1:202855508	C/T	cg19681188	chr1:202830198	LOC148709	0.46	6.57	0.34	1.98e-10	Mean platelet volume;
CRC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.09	18.81	0.72	4.31e-54	Cognitive function;
CRC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.54	8.51	0.42	6.18e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg21475434	chr5:93447410	FAM172A	-0.45	-6.31	-0.33	9.06e-10	Diabetic retinopathy;
CRC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.65	8.84	0.44	5.72e-17	Morning vs. evening chronotype;
CRC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.96	0.31	6.51e-9	Putamen volume;
CRC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.09	18.38	0.71	2.07e-52	Cognitive function;
CRC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg22638593	chr5:131593259	PDLIM4	0.4	7.41	0.38	1.08e-12	Breast cancer;
CRC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg19812747	chr11:111475976	SIK2	-0.59	-10.07	-0.49	5.54e-21	Primary sclerosing cholangitis;
CRC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-5.82	-0.31	1.39e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.89	0.4	4.46e-14	Lymphocyte percentage of white cells;
CRC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg10298567	chr3:47292165	KIF9	0.39	6.06	0.32	3.64e-9	Colorectal cancer;
CRC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.92	-0.36	2.4e-11	Electroencephalogram traits;
CRC	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg17133734	chr15:86042851	AKAP13	0.42	6.54	0.34	2.33e-10	Coronary artery disease;
CRC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.5	-6.23	-0.32	1.47e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg05562828	chr17:3906858	NA	0.67	12.29	0.56	8.24e-29	Type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19907326	chr13:33002597	N4BP2L1	0.45	6.67	0.35	1.1e-10	Response to antipsychotic treatment;
CRC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.47	6.44	0.33	4.28e-10	Lymphocyte counts;
CRC	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	12.0	0.55	9.01e-28	Coffee consumption (cups per day);
CRC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.94	-0.31	7.33e-9	Total body bone mineral density;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg02114082	chr10:12306459	NA	-0.41	-6.24	-0.33	1.35e-9	Daytime sleep phenotypes;
CRC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.09e-15	Menopause (age at onset);
CRC	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.75	0.3	2.08e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg02319466	chr17:76381040	PGS1	0.38	6.05	0.32	3.95e-9	HDL cholesterol levels;
CRC	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	7.96	0.4	2.88e-14	Mean corpuscular volume;
CRC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg03037974	chr15:76606532	NA	0.69	11.69	0.54	1.23e-26	Blood metabolite levels;
CRC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.53	6.96	0.36	1.9e-11	Height;
CRC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg07809909	chr20:30433512	FOXS1	0.35	5.74	0.3	2.19e-8	Mean corpuscular hemoglobin;
CRC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.75	8.68	0.43	1.88e-16	Eosinophilic esophagitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15985400	chr11:76091674	PRKRIR	-0.43	-6.33	-0.33	8.2e-10	Myopia (pathological);
CRC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.59	10.04	0.48	7.33e-21	Prudent dietary pattern;
CRC	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg04920474	chr2:44395004	PPM1B	0.41	5.73	0.3	2.32e-8	Height;
CRC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.84	10.66	0.51	5.53e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg09760422	chr2:128146352	NA	-0.36	-7.1	-0.36	7.51e-12	Protein C levels;
CRC	trans	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg05679027	chr9:99775184	HIATL2	-0.4	-6.09	-0.32	3.07e-9	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.51	0.46	4.05e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4908768	0.501	rs6668508	chr1:8574118	C/T	cg20416874	chr1:8611966	RERE	-0.45	-6.46	-0.34	3.66e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs12431410	0.550	rs12896125	chr14:60202416	T/C	cg00846580	chr14:60632234	DHRS7	-0.38	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	cis	rs889398	0.594	rs1466863	chr16:69904138	A/T	cg00738113	chr16:70207722	CLEC18C	0.32	5.76	0.3	1.92e-8	Body mass index;
CRC	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.4	-7.69	-0.39	1.7e-13	Migraine;
CRC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	8.1	0.41	1.1e-14	Platelet count;
CRC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg20041105	chr8:143859282	LYNX1	0.47	8.27	0.41	3.44e-15	Urinary tract infection frequency;
CRC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg09417038	chr21:47716443	C21orf57	-0.42	-6.94	-0.36	2.06e-11	Testicular germ cell tumor;
CRC	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.52	-0.38	5.31e-13	Caudate activity during reward;
CRC	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg14345882	chr6:26364793	BTN3A2	0.42	6.56	0.34	2.13e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.58	-7.78	-0.39	9.52e-14	Myopia;
CRC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.61	-9.06	-0.45	1.18e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs3823572	0.542	rs62470448	chr7:133635618	T/A	cg03336402	chr7:133662267	EXOC4	0.68	10.4	0.5	4.22e-22	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg13043300	chr11:71146211	DHCR7	-0.46	-6.35	-0.33	7.16e-10	Vitamin D levels;
CRC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.15	27.57	0.84	1.66e-87	Testicular germ cell tumor;
CRC	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg14458575	chr2:238380390	NA	0.5	6.56	0.34	2.03e-10	Prostate cancer;
CRC	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-7.11	-0.36	7.42e-12	Response to antipsychotic treatment;
CRC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.71	0.57	2.18e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7429990	0.803	rs6776963	chr3:47830741	A/C	cg11946769	chr3:48343235	NME6	-0.45	-5.74	-0.3	2.1e-8	Educational attainment (years of education);
CRC	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.55	9.8	0.48	4.6e-20	Leprosy;
CRC	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg11003573	chr3:44754125	ZNF502	-0.41	-5.85	-0.31	1.18e-8	IgG glycosylation;
CRC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg23750338	chr8:142222470	SLC45A4	0.45	7.61	0.39	2.88e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18912574	chr7:65842487	NCRNA00174	0.35	6.09	0.32	3.11e-9	Aortic root size;
CRC	trans	rs12495832	0.778	rs736658	chr3:147935768	T/C	cg10221266	chr7:153579447	NA	0.56	6.12	0.32	2.6e-9	Chin dimples;
CRC	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg09659197	chr4:152720779	NA	0.32	5.82	0.31	1.39e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.67	-0.35	1.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs62229266	0.682	rs2835224	chr21:37370030	A/T	cg12218747	chr21:37451666	NA	-0.42	-7.08	-0.36	8.98e-12	Mitral valve prolapse;
CRC	trans	rs7671189	0.502	rs10939368	chr4:11740262	C/T	cg18054620	chr5:111191530	C5orf13	-0.3	-6.04	-0.32	4.16e-9	Obesity-related traits;
CRC	cis	rs2013441	1.000	rs8074047	chr17:20176703	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.3	-0.33	9.31e-10	Obesity-related traits;
CRC	cis	rs4481887	0.504	rs4916113	chr1:248377292	C/T	cg00666640	chr1:248458726	OR2T12	0.4	6.88	0.35	3.08e-11	Common traits (Other);
CRC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.69	-0.3	2.79e-8	Schizophrenia;
CRC	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	6.96	0.36	1.9e-11	Diisocyanate-induced asthma;
CRC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg04969067	chr8:143858791	LYNX1	0.45	7.67	0.39	1.97e-13	Urinary tract infection frequency;
CRC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg25985355	chr7:65971099	NA	-0.5	-5.74	-0.3	2.13e-8	Diabetic kidney disease;
CRC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.6	7.98	0.4	2.51e-14	Height;
CRC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.85	-14.49	-0.62	3.9e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7394190	0.748	rs78985317	chr10:75514465	C/T	cg07699608	chr10:75541558	CHCHD1	0.68	6.69	0.35	9.59e-11	Incident atrial fibrillation;
CRC	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg00105475	chr2:10696890	NA	0.45	7.21	0.37	3.91e-12	Prostate cancer;
CRC	cis	rs4478858	0.746	rs10914328	chr1:31688406	A/G	cg00250761	chr1:31883323	NA	0.31	5.88	0.31	1.01e-8	Alcohol dependence;
CRC	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-7.56	-0.38	4.09e-13	Bone mineral density;
CRC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg05623727	chr3:50126028	RBM5	0.45	7.6	0.39	3.11e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg25456477	chr12:86230367	RASSF9	-0.34	-5.92	-0.31	8.24e-9	Major depressive disorder;
CRC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg25834613	chr7:1915315	MAD1L1	0.41	6.25	0.33	1.27e-9	Bipolar disorder;
CRC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.07e-8	Life satisfaction;
CRC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg03790207	chr6:42947109	PEX6	-0.51	-7.51	-0.38	5.62e-13	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg20698410	chr1:19661425	NA	-0.27	-5.97	-0.31	6.12e-9	Myeloid white cell count;
CRC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.14	-0.32	2.34e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg17218026	chr1:154582156	ADAR	-0.62	-10.11	-0.49	4.1e-21	Blood protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00177013	chr20:62339100	ARFRP1;ZGPAT	0.47	6.07	0.32	3.48e-9	Thyroid stimulating hormone;
CRC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.36	-7.79	-0.39	8.76e-14	Colorectal cancer;
CRC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.43	-0.42	1.08e-15	Gut microbiome composition (summer);
CRC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-8.04	-0.41	1.61e-14	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12463550	chr7:65579703	CRCP	0.65	5.72	0.3	2.4e-8	Diabetic kidney disease;
CRC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.55	-8.15	-0.41	7.84e-15	Fibrinogen levels;
CRC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg05192639	chr6:26864778	GUSBL1	0.34	6.04	0.32	4.27e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17152411	1.000	rs7914110	chr10:126599886	C/G	cg07906193	chr10:126599966	NA	0.62	6.87	0.35	3.18e-11	Height;
CRC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12667521	chr19:29218732	NA	0.43	6.33	0.33	8.23e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg09127314	chr1:152161683	NA	0.52	6.52	0.34	2.67e-10	Atopic dermatitis;
CRC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.67	7.73	0.39	1.29e-13	Vitiligo;
CRC	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg18404041	chr3:52824283	ITIH1	0.33	6.62	0.34	1.42e-10	Schizophrenia;
CRC	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.55	-6.78	-0.35	5.68e-11	Pursuit maintenance gain;
CRC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.19	0.49	2.27e-21	Platelet count;
CRC	cis	rs6604026	0.656	rs2481712	chr1:93351477	G/A	cg17283838	chr1:93427260	FAM69A	-0.42	-5.63	-0.3	3.87e-8	Multiple sclerosis;
CRC	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.47	7.1	0.36	7.52e-12	Red blood cell count;
CRC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-7.91	-0.4	3.85e-14	Gut microbiome composition (summer);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg22902534	chr3:183892754	AP2M1	-0.72	-6.24	-0.33	1.32e-9	Cognitive function;
CRC	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.72	-9.7	-0.47	9.79e-20	Blood pressure (smoking interaction);
CRC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg23018236	chr17:30244563	NA	-0.49	-6.49	-0.34	3.24e-10	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.32	-0.33	8.6e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.66	10.29	0.49	1.02e-21	Itch intensity from mosquito bite;
CRC	cis	rs9549328	0.520	rs36144023	chr13:113616592	T/C	cg08614441	chr13:113633676	MCF2L	0.4	6.97	0.36	1.69e-11	Systolic blood pressure;
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg10729496	chr3:10149963	C3orf24	0.5	6.77	0.35	5.95e-11	Alzheimer's disease;
CRC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.63	8.73	0.43	1.31e-16	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.53	7.69	0.39	1.73e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.66	-7.89	-0.4	4.55e-14	Ulcerative colitis;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg07217954	chr7:1067459	C7orf50	0.55	5.71	0.3	2.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.74	10.05	0.48	6.58e-21	Alzheimer's disease;
CRC	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg04248312	chr19:17393744	ANKLE1	-0.88	-11.01	-0.52	3.27e-24	Systemic lupus erythematosus;
CRC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.1	0.49	4.6e-21	Bladder cancer;
CRC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg22687807	chr8:143858763	LYNX1	0.5	8.88	0.44	4.38e-17	Urinary tract infection frequency;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg03160526	chr17:80928410	B3GNTL1	0.58	7.75	0.39	1.13e-13	Glycated hemoglobin levels;
CRC	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-14.02	-0.61	2.54e-35	Exhaled nitric oxide output;
CRC	cis	rs17767392	0.958	rs55883127	chr14:71980236	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.26	-0.37	2.77e-12	Mitral valve prolapse;
CRC	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.57	10.01	0.48	9.09e-21	Common traits (Other);
CRC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.68	10.31	0.49	8.81e-22	Corneal astigmatism;
CRC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.52	-8.47	-0.42	8.39e-16	Testicular germ cell tumor;
CRC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.73	-0.3	2.21e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg04662567	chr6:169592167	NA	-0.36	-6.1	-0.32	2.92e-9	Pulse pressure;
CRC	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg10761708	chr20:43804764	PI3	0.51	5.79	0.3	1.62e-8	Blood protein levels;
CRC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg18876405	chr7:65276391	NA	0.45	6.31	0.33	9.26e-10	Aortic root size;
CRC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg15848620	chr12:58087721	OS9	-0.63	-8.95	-0.44	2.73e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.38	-0.46	1.08e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4664293	0.647	rs1549385	chr2:160439051	C/T	cg08347373	chr2:160653686	CD302	-0.39	-6.53	-0.34	2.57e-10	Monocyte percentage of white cells;
CRC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.51	9.76	0.47	6.05e-20	Schizophrenia;
CRC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.48	7.4	0.38	1.12e-12	Motion sickness;
CRC	cis	rs8105895	0.935	rs8108651	chr19:22251464	A/G	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg01355875	chr4:10118935	WDR1	0.47	5.97	0.31	6.29e-9	Type 2 diabetes (age of onset);
CRC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.72	-0.43	1.38e-16	Total cholesterol levels;
CRC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg20750642	chr13:99100586	FARP1	0.41	6.22	0.32	1.53e-9	Educational attainment (years of education);
CRC	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg22674798	chr1:3096360	PRDM16	0.34	7.0	0.36	1.43e-11	Migraine;
CRC	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.66	10.77	0.51	2.27e-23	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg19025524	chr12:109796872	NA	-0.48	-6.97	-0.36	1.7e-11	Neuroticism;
CRC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs11229555	0.574	rs12292024	chr11:58186716	C/T	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg10596483	chr8:143751796	JRK	-0.45	-6.4	-0.33	5.49e-10	Urinary tract infection frequency;
CRC	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg14352298	chr13:112236639	NA	-0.29	-6.67	-0.35	1.09e-10	Hepatitis;
CRC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.93	16.14	0.66	1.36e-43	IgG glycosylation;
CRC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.67	9.73	0.47	7.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.52	-0.5	1.68e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.11	0.45	8.02e-18	Mean platelet volume;
CRC	cis	rs965469	1.000	rs6139103	chr20:3361140	T/C	cg25506879	chr20:3388711	C20orf194	-0.39	-5.63	-0.3	3.89e-8	IFN-related cytopenia;
CRC	cis	rs2257205	0.667	rs7213035	chr17:56857281	A/G	cg25885038	chr17:56607967	SEPT4	-0.53	-5.75	-0.3	2.07e-8	Pancreatic cancer;
CRC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg23018236	chr17:30244563	NA	-0.67	-8.02	-0.4	1.83e-14	Hip circumference adjusted for BMI;
CRC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.68	7.94	0.4	3.33e-14	IgG glycosylation;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21925064	chr5:148724958	GRPEL2	0.39	6.11	0.32	2.75e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.69	8.31	0.42	2.63e-15	Initial pursuit acceleration;
CRC	cis	rs7487075	0.820	rs7967549	chr12:46723692	G/A	cg22049899	chr12:47219821	SLC38A4	0.34	6.61	0.34	1.58e-10	Itch intensity from mosquito bite;
CRC	cis	rs1656402	1.000	rs1190444	chr2:233421679	G/A	cg03852847	chr2:233439513	NA	0.42	6.95	0.36	1.95e-11	Non-small cell lung cancer (survival);
CRC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.53	-0.38	4.99e-13	Blood metabolite levels;
CRC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.7	-0.3	2.62e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg09765074	chr10:69634185	NA	0.45	6.99	0.36	1.54e-11	Myopia (pathological);
CRC	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg04989706	chr14:50066350	PPIL5	-0.49	-6.92	-0.36	2.32e-11	Carotid intima media thickness;
CRC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18225595	chr11:63971243	STIP1	0.62	7.82	0.4	7.38e-14	Mean platelet volume;
CRC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.62	-9.5	-0.46	4.35e-19	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.45	6.52	0.34	2.57e-10	Tonsillectomy;
CRC	cis	rs3823572	0.526	rs2971966	chr7:133642559	A/G	cg03336402	chr7:133662267	EXOC4	-0.66	-10.27	-0.49	1.22e-21	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs2380657	chr2:15678482	T/C	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27051171	chr2:7005923	CMPK2	0.4	6.53	0.34	2.49e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	1.12	10.35	0.5	6.61e-22	Arsenic metabolism;
CRC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.71	10.25	0.49	1.43e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.45	0.33	4.03e-10	Tonsillectomy;
CRC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg03623178	chr6:28175578	NA	0.78	6.83	0.35	4.03e-11	Depression;
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	13.22	0.59	2.63e-32	Alzheimer's disease;
CRC	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.34	-6.11	-0.32	2.78e-9	HIV-1 control;
CRC	cis	rs4964805	0.626	rs11111771	chr12:104179271	A/G	cg02344784	chr12:104178138	NT5DC3	-0.54	-8.02	-0.4	1.82e-14	Attention deficit hyperactivity disorder;
CRC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg21856205	chr7:94953877	PON1	-0.52	-6.57	-0.34	2.01e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.87	-0.35	3.25e-11	Menarche (age at onset);
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg21251018	chr6:28226885	NKAPL	0.47	6.23	0.33	1.39e-9	Parkinson's disease;
CRC	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.41	-6.83	-0.35	4.12e-11	Mean arterial pressure;
CRC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.55	-8.3	-0.42	2.68e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.75e-11	Aortic root size;
CRC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.7	-13.51	-0.6	2.24e-33	Educational attainment;
CRC	cis	rs12980942	0.872	rs12327659	chr19:41796472	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.46	5.77	0.3	1.79e-8	Coronary artery disease;
CRC	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg09596252	chr17:78655493	RPTOR	0.54	5.7	0.3	2.7e-8	Myopia (pathological);
CRC	cis	rs7605827	0.893	rs6733695	chr2:15525714	T/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.68	-9.89	-0.48	2.31e-20	Blood protein levels;
CRC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-7.72	-0.39	1.41e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.64	9.7	0.47	1.03e-19	Total cholesterol levels;
CRC	cis	rs6694672	0.867	rs10737687	chr1:197108693	C/T	cg13682187	chr1:196946512	CFHR5	0.42	6.72	0.35	8.15e-11	Asthma;
CRC	cis	rs501120	0.925	rs492152	chr10:44757677	C/T	cg09554077	chr10:44749378	NA	0.78	11.8	0.55	5e-27	Coronary artery disease;Coronary heart disease;
CRC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg10298567	chr3:47292165	KIF9	-0.35	-5.82	-0.31	1.36e-8	Colorectal cancer;
CRC	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.45	6.37	0.33	6.47e-10	Hair color;
CRC	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg00469287	chr7:23338798	C7orf30	0.42	5.65	0.3	3.48e-8	Cerebrospinal fluid biomarker levels;
CRC	cis	rs55702914	0.628	rs17730989	chr2:198362524	C/T	cg10820045	chr2:198174542	NA	0.34	6.14	0.32	2.35e-9	Major depression and alcohol dependence;
CRC	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg23071808	chr14:103021642	NA	-0.71	-9.34	-0.46	1.53e-18	Platelet count;
CRC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.46	6.69	0.35	9.34e-11	Melanoma;
CRC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.6	7.82	0.4	7.45e-14	Gut microbiome composition (summer);
CRC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.57	-7.18	-0.37	4.62e-12	Orofacial clefts;
CRC	cis	rs9462027	0.628	rs9462006	chr6:34710327	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.49e-9	Systemic lupus erythematosus;
CRC	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg11887960	chr12:57824829	NA	0.59	6.68	0.35	1.01e-10	Obesity-related traits;
CRC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.16	0.32	2.15e-9	Dupuytren's disease;
CRC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.32	-5.7	-0.3	2.63e-8	Height;
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.15	-0.37	5.59e-12	Breast cancer;
CRC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.57	-7.69	-0.39	1.7e-13	Colorectal cancer;
CRC	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg20356878	chr3:121714668	ILDR1	0.49	7.58	0.39	3.64e-13	Cognitive performance;
CRC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.52	9.63	0.47	1.63e-19	Vitiligo;
CRC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg12516270	chr8:143859308	LYNX1	0.59	10.82	0.51	1.56e-23	Urinary tract infection frequency;
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.68	9.74	0.47	7.42e-20	Alzheimer's disease;
CRC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.71	-11.6	-0.54	2.56e-26	Osteoporosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02185971	chr7:6388334	C7orf70	0.42	6.43	0.33	4.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg15147215	chr3:52552868	STAB1	-0.43	-6.09	-0.32	3.12e-9	Schizophrenia;
CRC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg23758597	chr6:163146217	PARK2	-0.51	-5.9	-0.31	8.81e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.74	9.91	0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18912574	chr7:65842487	NCRNA00174	0.36	6.1	0.32	2.99e-9	Aortic root size;
CRC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25517755	chr10:38738941	LOC399744	-0.4	-5.91	-0.31	8.75e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.35	0.38	1.55e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10411161	0.702	rs8110461	chr19:52383569	A/C	cg22319618	chr22:45562946	NUP50	-0.68	-7.53	-0.38	4.85e-13	Breast cancer;
CRC	trans	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg05044414	chr3:183734942	ABCC5	0.35	5.81	0.31	1.44e-8	Anterior chamber depth;
CRC	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.53	8.13	0.41	8.78e-15	HDL cholesterol;
CRC	cis	rs7605827	0.930	rs6718736	chr2:15525875	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.05e-8	Educational attainment (years of education);
CRC	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.19	-0.45	4.51e-18	Total bilirubin levels in HIV-1 infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14748682	chr11:6624841	ILK;RRP8	0.36	5.96	0.31	6.33e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.85	13.44	0.6	3.84e-33	Platelet distribution width;
CRC	cis	rs231513	0.954	rs425135	chr17:41984517	A/C	cg26893861	chr17:41843967	DUSP3	-0.64	-6.49	-0.34	3.16e-10	Cognitive function;
CRC	cis	rs728616	0.614	rs61859198	chr10:82114628	C/A	cg11900509	chr10:81946545	ANXA11	-0.57	-6.43	-0.33	4.53e-10	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg13034943	chr12:132379564	ULK1	-0.69	-5.96	-0.31	6.33e-9	Cognitive function;
CRC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.61	8.08	0.41	1.23e-14	Mean platelet volume;
CRC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-19.61	-0.73	3.04e-57	Height;
CRC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-7.6	-0.39	3.12e-13	Longevity;
CRC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.91	0.36	2.58e-11	Response to antipsychotic treatment;
CRC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg02683197	chr6:28174875	NA	0.58	7.56	0.38	4.16e-13	Parkinson's disease;
CRC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.34	-9.74	-0.47	7.48e-20	Mean corpuscular volume;
CRC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg19812747	chr11:111475976	SIK2	-0.55	-9.2	-0.45	4.26e-18	Primary sclerosing cholangitis;
CRC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg19193384	chr17:30244184	NA	-0.53	-6.66	-0.34	1.15e-10	Hip circumference adjusted for BMI;
CRC	cis	rs9549328	0.589	rs34144481	chr13:113617322	T/G	cg24588162	chr13:113633484	MCF2L	0.36	6.5	0.34	2.95e-10	Systolic blood pressure;
CRC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.89	-13.08	-0.58	8.97e-32	Height;
CRC	cis	rs2298450	0.575	rs2268299	chr21:37660161	G/A	cg02919814	chr21:37666008	DOPEY2	-0.43	-6.22	-0.32	1.48e-9	Schizophrenia;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg02683197	chr6:28174875	NA	0.63	8.77	0.44	9.62e-17	Parkinson's disease;
CRC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.16	13.27	0.59	1.71e-32	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.73	0.43	1.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12789522	chr15:78423758	CIB2	0.4	6.77	0.35	5.8200000000000003e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg26805224	chr10:79626177	DLG5	-0.39	-5.82	-0.31	1.41e-8	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg05393297	chr12:53359155	NA	-1.06	-10.23	-0.49	1.6e-21	Prostate cancer;
CRC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg02475695	chr16:616220	NHLRC4	0.47	7.84	0.4	6.12e-14	Height;
CRC	cis	rs7301826	0.651	rs4759519	chr12:131289508	G/A	cg11011512	chr12:131303247	STX2	0.37	5.6	0.3	4.44e-8	Plasma plasminogen activator levels;
CRC	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	8.28	0.42	3.2e-15	Mean corpuscular volume;
CRC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.68	-10.4	-0.5	4.37e-22	Menarche (age at onset);
CRC	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg02811702	chr13:24901961	NA	0.47	6.55	0.34	2.16e-10	Obesity-related traits;
CRC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.42	6.78	0.35	5.45e-11	Testicular germ cell tumor;
CRC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg02683197	chr6:28174875	NA	0.64	7.86	0.4	5.59e-14	Parkinson's disease;
CRC	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg01969543	chr11:61895209	INCENP	-0.52	-7.46	-0.38	7.59e-13	Breast cancer;
CRC	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg27205649	chr11:78285834	NARS2	0.48	6.25	0.33	1.28e-9	Alzheimer's disease (survival time);
CRC	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg07979401	chr6:33739406	LEMD2	-0.47	-5.78	-0.3	1.71e-8	Schizophrenia;
CRC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02290350	chr8:58132656	NA	-0.44	-6.59	-0.34	1.75e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-7.08	-0.36	9.03e-12	Lymphocyte counts;
CRC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.66	-7.92	-0.4	3.71e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.5	6.79	0.35	5.31e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	trans	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg26043149	chr18:55253948	FECH	-0.49	-7.61	-0.39	2.86e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23666278	chr2:171785822	GORASP2	0.37	6.75	0.35	6.62e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.47	-7.58	-0.39	3.55e-13	Platelet count;
CRC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.5	-8.2	-0.41	5.45e-15	Aortic root size;
CRC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg22495460	chr2:25135724	ADCY3	-0.87	-16.6	-0.68	2.16e-45	Body mass index in non-asthmatics;
CRC	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.53	8.94	0.44	2.81e-17	Testicular germ cell tumor;
CRC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg24562669	chr7:97807699	LMTK2	0.45	7.6	0.39	3.16e-13	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg03929089	chr4:120376271	NA	0.68	6.93	0.36	2.2e-11	Intraocular pressure;
CRC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.89	-0.44	4.04e-17	Alcohol dependence;
CRC	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg26248373	chr2:1572462	NA	-0.58	-5.98	-0.31	5.67e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06656553	chr16:89960601	TCF25	-0.69	-6.06	-0.32	3.75e-9	Skin colour saturation;
CRC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.61	-10.81	-0.51	1.7e-23	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs9659323	0.706	rs1409160	chr1:119583854	C/A	cg26570165	chr1:119541833	NA	-0.35	-5.83	-0.31	1.32e-8	Body mass index;
CRC	cis	rs970548	0.954	rs11239571	chr10:46087892	A/G	cg15590007	chr10:45870220	ALOX5	-0.47	-6.17	-0.32	2.06e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-0.92	-11.52	-0.54	5.2e-26	Blood pressure (smoking interaction);
CRC	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.16	-0.32	2.18e-9	Height;
CRC	cis	rs6968419	0.714	rs3807980	chr7:115893647	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.37	-0.33	6.22e-10	Intraocular pressure;
CRC	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg26958806	chr6:27640298	NA	0.93	6.56	0.34	2.11e-10	Depression;
CRC	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg22482690	chr17:47019901	SNF8	-0.43	-6.95	-0.36	2e-11	Type 2 diabetes;
CRC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.44	6.32	0.33	8.49e-10	Longevity;Endometriosis;
CRC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-0.8	-9.15	-0.45	6.2e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.45	6.86	0.35	3.32e-11	Menopause (age at onset);
CRC	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.97	-0.48	1.21e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6445525	0.837	rs9810565	chr3:66003182	A/G	cg06109867	chr3:66002991	MAGI1	-0.36	-5.81	-0.31	1.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg09141835	chr16:88988174	CBFA2T3	0.27	6.1	0.32	2.93e-9	Social autistic-like traits;
CRC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs7517126	1.000	rs34924297	chr1:196865583	G/A	cg13682187	chr1:196946512	CFHR5	-0.36	-5.61	-0.3	4.28e-8	Blood protein levels;
CRC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.26	-0.33	1.17e-9	Tonsillectomy;
CRC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.38	5.95	0.31	6.92e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.61	-9.47	-0.46	5.68e-19	Mean corpuscular hemoglobin concentration;
CRC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.57	-8.39	-0.42	1.48e-15	Longevity;
CRC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.69	-10.26	-0.49	1.34e-21	Total body bone mineral density;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.31	0.42	2.58e-15	Alzheimer's disease;
CRC	cis	rs7605827	0.930	rs12692268	chr2:15595519	A/G	cg19274914	chr2:15703543	NA	0.4	6.04	0.32	4.18e-9	Educational attainment (years of education);
CRC	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg19773385	chr1:10388646	KIF1B	-0.56	-7.86	-0.4	5.59e-14	Hepatocellular carcinoma;
CRC	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.73	9.58	0.47	2.45e-19	Coronary artery disease;
CRC	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06307176	chr5:131281290	NA	0.41	5.89	0.31	9.38e-9	Life satisfaction;
CRC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg11833968	chr6:79620685	NA	-0.35	-6.05	-0.32	3.84e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg18612461	chr15:75251733	NA	0.37	5.82	0.31	1.43e-8	Breast cancer;
CRC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.77	0.35	6.05e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs9847710	0.869	rs2564917	chr3:53037695	C/T	cg04503182	chr3:53078218	SFMBT1	0.39	6.14	0.32	2.38e-9	Ulcerative colitis;
CRC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	7.78	0.39	9.29e-14	Body mass index;
CRC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.91	-17.23	-0.69	7.51e-48	Coronary artery disease;
CRC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.26	-0.33	1.23e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7113874	0.569	rs4929942	chr11:8625096	A/G	cg20771178	chr11:8615675	STK33	0.34	5.73	0.3	2.25e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg14671364	chr1:107599128	PRMT6	-0.52	-7.02	-0.36	1.28e-11	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg15845792	chr6:28175446	NA	0.95	13.76	0.6	2.35e-34	Depression;
CRC	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.65	-8.88	-0.44	4.33e-17	Extraversion;
CRC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.67	-9.23	-0.45	3.41e-18	Platelet count;
CRC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.22	-0.32	1.54e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.43	5.61	0.3	4.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg18655438	chr5:1077845	SLC12A7	0.46	6.7	0.35	9.19e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.57	10.14	0.49	3.26e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg06042504	chr8:55087323	NA	-0.43	-6.75	-0.35	6.83e-11	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg10802521	chr3:52805072	NEK4	0.48	6.58	0.34	1.8e-10	Schizophrenia;
CRC	cis	rs12580194	0.593	rs4590978	chr12:55725086	G/T	cg23425280	chr12:56401806	NA	0.48	5.81	0.31	1.45e-8	Cancer;
CRC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-8.08	-0.41	1.27e-14	Major depressive disorder;
CRC	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg14631576	chr9:95140430	CENPP	0.32	6.17	0.32	2.02e-9	Height;
CRC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.44	5.9	0.31	8.93e-9	Total body bone mineral density;
CRC	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-6.96	-0.36	1.85e-11	Caudate activity during reward;
CRC	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg08501292	chr6:25962987	TRIM38	1.06	9.09	0.45	9.85e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.33	5.67	0.3	3.17e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.42	6.87	0.35	3.3e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.61	6.78	0.35	5.44e-11	Coronary artery disease;
CRC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.48	0.38	6.96e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.51	8.96	0.44	2.39e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.23	-0.32	1.46e-9	Lung cancer;
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg22638593	chr5:131593259	PDLIM4	0.33	5.98	0.31	5.96e-9	Blood metabolite levels;
CRC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.77	0.3	1.86e-8	Prudent dietary pattern;
CRC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.46	-7.75	-0.39	1.15e-13	P wave terminal force;
CRC	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.38	-5.63	-0.3	3.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.38	5.79	0.3	1.65e-8	HDL cholesterol levels;
CRC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.35	-6.76	-0.35	6.22e-11	Colorectal cancer;
CRC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.89	-0.31	9.37e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2462686	1.000	rs2462327	chr7:45993039	C/A	cg23193639	chr7:45961078	IGFBP3	-0.37	-5.75	-0.3	2.06e-8	Major depressive disorder;
CRC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.67	-0.34	1.11e-10	Schizophrenia;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.65	6.85	0.35	3.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg13590978	chr10:43134234	ZNF33B	0.71	5.72	0.3	2.38e-8	Blood protein levels;
CRC	cis	rs2857891	1.000	rs2595500	chr11:6963165	C/T	cg04053776	chr11:6947353	ZNF215	-0.49	-7.02	-0.36	1.3e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg19131313	chr8:1704013	NA	-0.44	-5.82	-0.31	1.4e-8	Systolic blood pressure;
CRC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.34	-6.2	-0.32	1.67e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg25600027	chr14:23388339	RBM23	-0.53	-8.3	-0.42	2.72e-15	Cognitive ability (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.51	9.05	0.45	1.28e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.86	-0.44	5.23e-17	Total body bone mineral density;
CRC	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg08999081	chr20:33150536	PIGU	0.46	5.71	0.3	2.54e-8	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11073926	chr1:43855438	MED8;C1orf84	0.36	5.96	0.31	6.44e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20887711	chr4:1340912	KIAA1530	0.39	5.69	0.3	2.88e-8	Obesity-related traits;
CRC	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg12964065	chr18:77638022	KCNG2	-0.45	-6.26	-0.33	1.21e-9	Opioid sensitivity;
CRC	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg20312557	chr2:97357134	FER1L5	-0.61	-5.67	-0.3	3.19e-8	Erectile dysfunction and prostate cancer treatment;
CRC	cis	rs860295	0.702	rs1556488	chr1:155540660	T/G	cg02153340	chr1:155202674	NA	-0.51	-6.32	-0.33	8.35e-10	Body mass index;
CRC	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.55	-7.46	-0.38	7.78e-13	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.33	6.94e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7113874	0.524	rs4612809	chr11:8620038	T/C	cg17679104	chr11:8615758	STK33	0.34	5.8	0.3	1.59e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-8.78	-0.44	9.36e-17	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg11522145	chr4:3412961	RGS12	0.37	5.77	0.3	1.81e-8	Serum sulfate level;
CRC	trans	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg16141378	chr3:129829833	LOC729375	0.51	7.79	0.39	9.11e-14	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12028816	chr17:7232827	NEURL4	0.43	6.9	0.36	2.74e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-8.76	-0.44	1.02e-16	Body mass index;
CRC	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.63	-9.78	-0.47	5.24e-20	Blood pressure (smoking interaction);
CRC	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.52	0.54	5.15e-26	Coffee consumption (cups per day);
CRC	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg18217622	chr6:170732253	NA	0.66	6.73	0.35	7.4e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-6.77	-0.35	6.01e-11	Intelligence (multi-trait analysis);
CRC	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg00490450	chr3:139108681	COPB2	0.48	7.24	0.37	3.2e-12	Obesity-related traits;
CRC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.37	-6.27	-0.33	1.13e-9	Reticulocyte fraction of red cells;
CRC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.17	0.59	4.34e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.83	15.18	0.64	8.26e-40	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.78	13.6	0.6	9.97e-34	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-10.45	-0.5	2.93e-22	Body mass index;
CRC	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.24	0.37	3.21e-12	Eye color traits;
CRC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.49	6.78	0.35	5.71e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.47	7.35	0.38	1.59e-12	Height;
CRC	trans	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg10756647	chr7:56101905	PSPH	0.73	7.68	0.39	1.79e-13	Diabetic kidney disease;
CRC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.06	10.8	0.51	1.79e-23	Skin colour saturation;
CRC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.5	0.38	6.01e-13	Calcium levels;
CRC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg02741985	chr17:80059408	CCDC57	0.44	7.24	0.37	3.25e-12	Life satisfaction;
CRC	cis	rs73200209	0.912	rs59560959	chr12:116476998	C/G	cg01776926	chr12:116560359	MED13L	-0.5	-6.09	-0.32	3.24e-9	Total body bone mineral density;
CRC	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg00603274	chr11:61596626	FADS2	-0.43	-6.43	-0.33	4.52e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg01483505	chr11:975446	AP2A2	-0.41	-6.7	-0.35	9.25e-11	Alzheimer's disease (late onset);
CRC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.28	-0.46	2.28e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs17443541	0.507	rs4675699	chr2:200451389	A/C	cg03741458	chr2:200468445	NA	-0.38	-5.95	-0.31	6.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-7.6	-0.39	3.08e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.44	6.37	0.33	6.51e-10	Emphysema distribution in smoking;
CRC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.51	8.24	0.41	4.17e-15	Monocyte count;
CRC	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.6	-7.54	-0.38	4.71e-13	Ulcerative colitis;
CRC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg24130564	chr14:104152367	KLC1	0.42	5.72	0.3	2.46e-8	Intelligence (multi-trait analysis);
CRC	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.96	-0.31	6.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.54	0.34	2.37e-10	Depression;
CRC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs12476592	0.571	rs1031221	chr2:63742810	C/T	cg10828910	chr2:63850056	LOC388955	-0.49	-6.14	-0.32	2.38e-9	Childhood ear infection;
CRC	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg01392867	chr16:30410429	ZNF48	0.38	6.09	0.32	3.24e-9	Tonsillectomy;
CRC	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.09	-11.23	-0.53	5.66e-25	Atopic dermatitis;
CRC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.56	6.58	0.34	1.91e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	0.53	8.95	0.44	2.62e-17	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg22561889	chr6:118971681	C6orf204	0.52	6.7	0.35	9.08e-11	Diastolic blood pressure;
CRC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.69	-0.35	9.62e-11	Type 2 diabetes;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.32	0.33	8.68e-10	Blood metabolite levels;
CRC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.64	-0.34	1.29e-10	Response to antipsychotic treatment;
CRC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.93	17.07	0.69	3.07e-47	Height;
CRC	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg22687807	chr8:143858763	LYNX1	-0.37	-6.56	-0.34	2.06e-10	Urinary tract infection frequency;
CRC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg20684491	chr1:25596433	NA	-0.43	-7.41	-0.38	1.11e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg02741985	chr17:80059408	CCDC57	0.42	6.95	0.36	1.96e-11	Life satisfaction;
CRC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg16606324	chr3:10149918	C3orf24	0.47	6.91	0.36	2.5e-11	Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg15147215	chr3:52552868	STAB1	-0.59	-9.77	-0.47	5.68e-20	Bipolar disorder;
CRC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.49	7.77	0.39	1.01e-13	Height;
CRC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs9292777	0.720	rs16869934	chr5:40397352	C/T	cg09067459	chr5:40385259	NA	-0.53	-8.64	-0.43	2.42e-16	Crohn's disease;Multiple sclerosis;
CRC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	7.18	0.37	4.54e-12	Prudent dietary pattern;
CRC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-7.22	-0.37	3.68e-12	Body mass index (adult);
CRC	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.11	0.32	2.75e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg21153622	chr11:89784906	NA	-0.41	-6.83	-0.35	4.16e-11	Coronary artery disease;
CRC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.23	-0.37	3.43e-12	Body mass index;
CRC	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.45	-6.97	-0.36	1.79e-11	Atrial fibrillation;
CRC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg07090678	chr1:91966139	CDC7	0.45	6.99	0.36	1.54e-11	Breast cancer;
CRC	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg26605046	chr4:2439731	NA	-0.4	-7.01	-0.36	1.33e-11	Cognitive function;
CRC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg02659138	chr7:134003124	SLC35B4	0.37	5.94	0.31	7.34e-9	Mean platelet volume;
CRC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.82	15.01	0.64	3.75e-39	Vitiligo;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.6	-0.34	1.64e-10	Acylcarnitine levels;
CRC	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.39	6.06	0.32	3.66e-9	Endometrial cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04234156	chr10:7860746	TAF3	0.44	6.03	0.32	4.43e-9	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.73	-0.39	1.33e-13	Gut microbiome composition (summer);
CRC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.69	-0.35	9.5e-11	Alcohol dependence;
CRC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-7.97	-0.4	2.57e-14	Bipolar disorder;
CRC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-6.25	-0.33	1.3e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.5	-8.17	-0.41	6.89e-15	Post bronchodilator FEV1;
CRC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-9.8	-0.48	4.46e-20	Prostate cancer;
CRC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.52	-5.98	-0.31	5.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.46	7.12	0.37	6.87e-12	Longevity;
CRC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg25804541	chr17:80189381	SLC16A3	0.31	5.9	0.31	8.94e-9	Life satisfaction;
CRC	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg18232548	chr7:50535776	DDC	-0.48	-6.48	-0.34	3.3e-10	Malaria;
CRC	cis	rs4132509	1.000	rs4565696	chr1:243918083	C/T	cg21452805	chr1:244014465	NA	0.48	6.32	0.33	8.33e-10	RR interval (heart rate);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20172593	chr5:94891168	ARSK;TTC37	0.45	6.23	0.32	1.46e-9	Response to antipsychotic treatment;
CRC	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg12046867	chr14:103022105	NA	-0.77	-9.14	-0.45	6.39e-18	Platelet count;
CRC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.6	-0.3	4.51e-8	Lung cancer;
CRC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.15e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-7.18	-0.37	4.71e-12	Monocyte count;
CRC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.43	-8.5	-0.42	6.6e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.71	10.19	0.49	2.19e-21	Longevity;
CRC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.52	-7.65	-0.39	2.2e-13	Lung cancer;
CRC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.69	-0.39	1.74e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.43	-8.37	-0.42	1.72e-15	Subjective well-being;
CRC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06656553	chr16:89960601	TCF25	-0.7	-5.76	-0.3	1.93e-8	Skin colour saturation;
CRC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.48	-6.09	-0.32	3.08e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.56	8.52	0.42	5.98e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.67	11.77	0.54	6.32e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.86	-20.99	-0.76	1.12e-62	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	5.7	0.3	2.66e-8	Rheumatoid arthritis;
CRC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg23136738	chr11:925521	AP2A2	-0.51	-8.24	-0.41	4.15e-15	Alzheimer's disease (late onset);
CRC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02869364	chr7:1081709	C7orf50	-0.46	-6.23	-0.32	1.4e-9	Bronchopulmonary dysplasia;
CRC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.69	9.47	0.46	5.58e-19	Vitiligo;
CRC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg15763984	chr4:1342303	KIAA1530	0.48	8.35	0.42	1.97e-15	Longevity;
CRC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg00310523	chr12:86230176	RASSF9	0.45	7.54	0.38	4.49e-13	Major depressive disorder;
CRC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.75	11.35	0.53	2.12e-25	High light scatter reticulocyte count;
CRC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.42	6.66	0.34	1.12e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.46	-6.54	-0.34	2.33e-10	Height;
CRC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.78	-13.01	-0.58	1.67e-31	Coronary artery disease;
CRC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg06470822	chr6:28175283	NA	0.72	10.13	0.49	3.53e-21	Parkinson's disease;
CRC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.18	-0.41	6.11e-15	Chronic sinus infection;
CRC	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg04202892	chr2:111875749	ACOXL	0.42	6.79	0.35	5.3e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.65	0.57	3.55e-30	Platelet count;
CRC	cis	rs12369635	0.929	rs3851667	chr12:129550552	G/T	cg01909103	chr12:129572610	TMEM132D	0.74	7.27	0.37	2.65e-12	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.63	-0.51	6.98e-23	Alzheimer's disease;
CRC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.63	-9.15	-0.45	6.12e-18	Menarche (age at onset);
CRC	cis	rs9635542	0.920	rs759196	chr16:5006078	C/T	cg06510647	chr16:5006106	NA	-0.62	-6.64	-0.34	1.3100000000000001e-10	Lung cancer (asbestos exposure interaction);Cancer;
CRC	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg23254163	chr1:152506842	NA	-0.45	-9.14	-0.45	6.52e-18	Hair morphology;
CRC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.79	-0.35	5.16e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg06243866	chr13:111019493	COL4A2	-0.4	-6.12	-0.32	2.7e-9	Coronary artery disease;
CRC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg15440763	chr7:158190612	PTPRN2	-0.41	-6.51	-0.34	2.8e-10	Obesity-related traits;
CRC	cis	rs6662572	0.737	rs56368769	chr1:46451739	A/G	cg08644498	chr1:46502608	NA	0.46	7.09	0.36	8.14e-12	Blood protein levels;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg00597713	chr6:42947103	PEX6	-0.4	-5.67	-0.3	3.16e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg26587870	chr6:27730563	NA	-0.38	-6.06	-0.32	3.81e-9	Parkinson's disease;
CRC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.47	-7.63	-0.39	2.58e-13	Bone mineral density;
CRC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.49	-7.68	-0.39	1.83e-13	Red blood cell count;
CRC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.66	-0.39	2.14e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg06634786	chr22:41940651	POLR3H	0.44	5.76	0.3	1.97e-8	Neuroticism;
CRC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.43	9.59	0.47	2.25e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg23422044	chr7:1970798	MAD1L1	-0.43	-6.04	-0.32	4.12e-9	Neuroticism;
CRC	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg02527881	chr3:46936655	PTH1R	0.35	5.98	0.31	5.85e-9	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08755283	chr5:118324104	DTWD2	0.47	7.78	0.39	9.29e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg15511327	chr8:143859410	LYNX1	0.41	7.33	0.37	1.81e-12	Urinary tract infection frequency;
CRC	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg10483660	chr13:112241077	NA	0.37	5.97	0.31	5.99e-9	Menarche (age at onset);
CRC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.6	-0.3	4.49e-8	Total body bone mineral density;
CRC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg21770322	chr7:97807741	LMTK2	0.56	9.36	0.46	1.33e-18	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.54	6.78	0.35	5.46e-11	Platelet distribution width;
CRC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.73	9.93	0.48	1.73e-20	Coronary artery disease;
CRC	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg05925327	chr15:68127851	NA	0.32	6.04	0.32	4.13e-9	Restless legs syndrome;
CRC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	7.16	0.37	5.44e-12	Lung cancer in ever smokers;
CRC	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.92	-0.4	3.64e-14	Superior frontal gyrus grey matter volume;
CRC	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.24	14.83	0.63	1.93e-38	Lung disease severity in cystic fibrosis;
CRC	cis	rs6741819	0.740	rs1797554	chr2:7131854	G/A	cg27144453	chr2:7172511	RNF144A	-0.39	-5.68	-0.3	2.99e-8	Response to antipsychotic treatment;
CRC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.54	7.96	0.4	2.81e-14	Lung cancer;
CRC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg11292332	chr7:45801988	SEPT13	0.35	6.23	0.32	1.44e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg00677455	chr12:58241039	CTDSP2	0.57	8.41	0.42	1.23e-15	Intelligence (multi-trait analysis);
CRC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg21770322	chr7:97807741	LMTK2	0.85	19.36	0.73	2.8e-56	Breast cancer;
CRC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.65	-10.63	-0.51	6.72e-23	Hepatocellular carcinoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11050527	chr8:54755511	ATP6V1H	0.43	6.11	0.32	2.84e-9	Response to antipsychotic treatment;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21308111	chr8:23082634	TNFRSF10A	0.48	6.31	0.33	8.86e-10	Thyroid stimulating hormone;
CRC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	8.01	0.4	2.02e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.41	1.53e-14	Cognitive performance;
CRC	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.94	-0.31	7.15e-9	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	1.06	14.77	0.63	3.26e-38	Exhaled nitric oxide output;
CRC	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.81	10.27	0.49	1.22e-21	Prostate cancer;
CRC	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg12223502	chr10:5658492	NA	-0.37	-5.9	-0.31	8.99e-9	Breast cancer;
CRC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg10589385	chr1:150898437	SETDB1	0.27	5.82	0.31	1.41e-8	Melanoma;
CRC	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	6.65	0.34	1.25e-10	Lymphocyte counts;
CRC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.49	6.79	0.35	5.28e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg09760422	chr2:128146352	NA	-0.36	-7.0	-0.36	1.4e-11	Protein C levels;
CRC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg05313129	chr8:58192883	C8orf71	-0.42	-6.27	-0.33	1.17e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6504622	0.537	rs1662596	chr17:44993118	C/T	cg16759221	chr17:45003025	GOSR2	-0.69	-11.08	-0.52	1.87e-24	Orofacial clefts;
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg08888203	chr3:10149979	C3orf24	0.71	8.57	0.43	4.18e-16	Alzheimer's disease;
CRC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-7.02	-0.36	1.31e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs62229266	0.633	rs34259635	chr21:37403570	T/G	cg08632701	chr21:37451849	NA	-0.41	-6.33	-0.33	8.07e-10	Mitral valve prolapse;
CRC	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.63	0.43	2.62e-16	Corneal astigmatism;
CRC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.87	-19.83	-0.74	4.13e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg23293999	chr7:106826042	HBP1	-0.5	-5.83	-0.31	1.31e-8	Coronary artery disease;
CRC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20887711	chr4:1340912	KIAA1530	0.41	5.86	0.31	1.1e-8	Obesity-related traits;
CRC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs294883	0.739	rs4709292	chr6:159730274	C/T	cg14500486	chr6:159655392	FNDC1	-0.36	-6.19	-0.32	1.81e-9	Coronary artery disease;
CRC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg16670446	chr17:27188758	MIR451;MIR144	0.6	10.0	0.48	9.73e-21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.5	0.65	4.63e-41	Smoking behavior;
CRC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.53	9.45	0.46	6.61e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs524281	0.773	rs2298468	chr11:66042962	G/A	cg16950941	chr11:66035639	RAB1B	-0.72	-8.16	-0.41	7.42e-15	Electroencephalogram traits;
CRC	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg10437265	chr15:77819839	NA	0.67	11.95	0.55	1.41e-27	Type 2 diabetes;
CRC	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg09873164	chr1:152488093	CRCT1	0.33	5.63	0.3	3.89e-8	Hair morphology;
CRC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.45	3.69e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg24289452	chr6:170231220	NA	-0.78	-6.91	-0.36	2.57e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.3	-16.58	-0.67	2.75e-45	Uric acid levels;
CRC	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-7.54	-0.38	4.49e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.59	-7.99	-0.4	2.28e-14	Response to antineoplastic agents;
CRC	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	12.51	0.57	1.2e-29	Coffee consumption (cups per day);
CRC	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.53	-6.36	-0.33	6.72e-10	Coronary artery calcification;
CRC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.93	11.11	0.52	1.43e-24	Eosinophil percentage of granulocytes;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg11843238	chr5:131593191	PDLIM4	-0.44	-7.37	-0.38	1.36e-12	Breast cancer;
CRC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.07	0.32	3.47e-9	Aortic root size;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25101273	chr2:196522935	SLC39A10	0.46	6.47	0.34	3.59e-10	Response to antipsychotic treatment;
CRC	cis	rs17767392	0.881	rs34993988	chr14:71923692	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.16	-0.37	5.3e-12	Mitral valve prolapse;
CRC	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.24e-37	Colorectal cancer;
CRC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg27661571	chr11:113659931	NA	-0.96	-11.08	-0.52	1.9e-24	Hip circumference adjusted for BMI;
CRC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.34	0.38	1.68e-12	Major depressive disorder;
CRC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.99	-10.76	-0.51	2.5e-23	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.4	5.71	0.3	2.5e-8	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.69	-0.57	2.6e-30	Alzheimer's disease;
CRC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	11.78	0.54	5.68e-27	Menarche (age at onset);
CRC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.8	0.35	4.99e-11	Melanoma;
CRC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.11	-0.41	1.04e-14	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-10.96	-0.52	4.75e-24	Asthma;
CRC	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.84	-0.31	1.26e-8	Arsenic metabolism;
CRC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.62	9.18	0.45	5.01e-18	Breast cancer;
CRC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg09355771	chr2:177043147	NA	-0.51	-6.49	-0.34	3.14e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg09127314	chr1:152161683	NA	0.52	6.8	0.35	5.05e-11	Atopic dermatitis;
CRC	cis	rs524281	0.861	rs6591207	chr11:65949674	A/T	cg14036092	chr11:66035641	RAB1B	-0.5	-6.06	-0.32	3.69e-9	Electroencephalogram traits;
CRC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.52	6.21	0.32	1.57e-9	Renal function-related traits (BUN);
CRC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.34	-6.75	-0.35	6.62e-11	Alzheimer's disease (late onset);
CRC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.24	-0.41	4.19e-15	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16263701	chr12:48213605	HDAC7	0.44	6.29	0.33	1e-9	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26634885	chr17:43209687	PLCD3;ACBD4	0.44	7.24	0.37	3.1e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.83	-11.96	-0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg19773385	chr1:10388646	KIF1B	-0.46	-7.41	-0.38	1.07e-12	Hepatocellular carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25840210	chr13:45152287	NA	0.42	6.16	0.32	2.08e-9	Intelligence (multi-trait analysis);
CRC	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.75	13.33	0.59	1.02e-32	Lewy body disease;
CRC	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	7.13	0.37	6.35e-12	Mean corpuscular volume;
CRC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.596	rs1531715	chr7:124638207	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.27	-0.33	1.15e-9	Cutaneous malignant melanoma;
CRC	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	1.1	19.13	0.73	2.29e-55	Schizophrenia;
CRC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.55	7.29	0.37	2.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.79	0.44	8.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs17443541	0.507	rs6709301	chr2:200466505	G/A	cg03741458	chr2:200468445	NA	-0.36	-5.77	-0.3	1.82e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.25	0.45	2.94e-18	Monocyte percentage of white cells;
CRC	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg01312482	chr5:178451176	ZNF879	-0.35	-5.95	-0.31	6.76e-9	Pubertal anthropometrics;
CRC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg03316587	chr8:142245164	NA	-0.39	-5.9	-0.31	8.92e-9	Immature fraction of reticulocytes;
CRC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg18761221	chr20:60518478	NA	0.48	7.78	0.39	9.17e-14	Body mass index;
CRC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg24560729	chr4:1342394	KIAA1530	0.39	6.17	0.32	1.99e-9	Obesity-related traits;
CRC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg20203395	chr5:56204925	C5orf35	-0.54	-7.55	-0.38	4.3e-13	Coronary artery disease;
CRC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-18.74	-0.72	7.97e-54	Height;
CRC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg02683197	chr6:28174875	NA	-0.52	-7.3	-0.37	2.14e-12	Systemic lupus erythematosus;
CRC	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-5.71	-0.3	2.48e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11149768	chr20:4129361	SMOX	0.49	6.62	0.34	1.44e-10	Survival in pancreatic cancer;
CRC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.86	14.87	0.63	1.3e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18099408	chr3:52552593	STAB1	0.47	7.95	0.4	2.98e-14	Electroencephalogram traits;
CRC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.36	0.38	1.49e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.87	-20.32	-0.75	4.87e-60	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6499129	0.702	rs8044843	chr16:67318242	A/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.56	-0.34	2.09e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.27e-12	Bipolar disorder;
CRC	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.44	-6.43	-0.33	4.58e-10	Magnesium levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16917537	chr7:73098262	DNAJC30;WBSCR22	0.43	6.05	0.32	3.98e-9	Response to antipsychotic treatment;
CRC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.91	17.38	0.69	1.84e-48	Blood protein levels;
CRC	cis	rs4676482	0.796	rs4676609	chr3:39214256	C/T	cg02254461	chr3:39195904	CSRNP1	0.63	8.62	0.43	2.83e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.83	17.41	0.69	1.41e-48	Cancer;
CRC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg22676075	chr6:135203613	NA	0.39	6.03	0.32	4.51e-9	Red blood cell count;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14049615	chr4:87928107	AFF1	0.38	6.05	0.32	4.02e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.77	-13.03	-0.58	1.39e-31	Obesity-related traits;
CRC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.39	-8.18	-0.41	6.36e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg16898833	chr6:26189333	HIST1H4D	1.14	8.46	0.42	8.89e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6564851	0.506	rs7187615	chr16:81254052	G/A	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.69	-0.3	2.83e-8	Carotenoid and tocopherol levels;
CRC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-11.31	-0.53	2.89e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.5	-0.54	6.17e-26	Coffee consumption (cups per day);
CRC	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg20744362	chr22:50050164	C22orf34	0.36	6.57	0.34	1.93e-10	Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.66	-0.34	1.12e-10	Aortic root size;
CRC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.61	-7.92	-0.4	3.64e-14	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19071342	chr2:85789035	GGCX	0.42	6.13	0.32	2.54e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.44	5.73	0.3	2.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.65	-0.39	2.22e-13	QT interval;
CRC	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg09476006	chr5:138032270	NA	0.45	6.85	0.35	3.59e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.88	-16.15	-0.66	1.27e-43	Coronary artery disease;
CRC	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.39	-5.78	-0.3	1.75e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	11.28	0.53	3.64e-25	Nonalcoholic fatty liver disease;
CRC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.91	-17.2	-0.69	9.93e-48	Intelligence (multi-trait analysis);
CRC	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg20356878	chr3:121714668	ILDR1	-0.52	-7.7	-0.39	1.66e-13	Multiple sclerosis;
CRC	cis	rs629535	0.773	rs569064	chr8:70065967	A/G	cg26132723	chr8:70041827	NA	0.36	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.37	6.13	0.32	2.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg09264619	chr17:80180166	NA	0.35	5.88	0.31	1.02e-8	Life satisfaction;
CRC	cis	rs3751196	1.000	rs3751196	chr12:104157502	G/A	cg02344784	chr12:104178138	NT5DC3	0.7	7.11	0.37	7.16e-12	Sense of smell;
CRC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.81	0.48	4.41e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg23104823	chr14:45553408	PRPF39	-0.54	-6.68	-0.35	1.02e-10	Diisocyanate-induced asthma;
CRC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.64	-9.27	-0.46	2.55e-18	Subjective well-being;
CRC	cis	rs3751196	1.000	rs74981851	chr12:104176212	C/A	cg02344784	chr12:104178138	NT5DC3	0.73	7.73	0.39	1.3e-13	Sense of smell;
CRC	trans	rs867371	0.502	rs28610286	chr15:82525655	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.15	-0.32	2.25e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.81	12.31	0.56	6.55e-29	Testicular germ cell tumor;
CRC	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.48	8.27	0.41	3.36e-15	Testicular germ cell tumor;
CRC	cis	rs77861329	1.000	rs352150	chr3:52209995	A/G	cg08692210	chr3:52188851	WDR51A	0.83	7.8	0.39	8.46e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.05	0.32	4.01e-9	Height;
CRC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.54	7.99	0.4	2.24e-14	Glomerular filtration rate (creatinine);
CRC	cis	rs653465	0.739	rs56259835	chr3:27166202	C/T	cg02860705	chr3:27208620	NA	-0.39	-6.09	-0.32	3.22e-9	Breast cancer (early onset);
CRC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg01874867	chr7:94954059	PON1	-0.49	-6.35	-0.33	7.25e-10	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.66	6.96	0.36	1.9e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-7.94	-0.4	3.13e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.59	8.38	0.42	1.59e-15	Obesity-related traits;
CRC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.82	0.31	1.41e-8	Systemic lupus erythematosus;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13336335	chr8:42751664	RNF170;HOOK3	0.39	6.04	0.32	4.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg04518342	chr5:131593106	PDLIM4	0.46	8.61	0.43	3.07e-16	Breast cancer;
CRC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.41	8.14	0.41	8.43e-15	Renal cell carcinoma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13370280	chr6:137539688	IFNGR1	0.45	6.03	0.32	4.37e-9	Thyroid stimulating hormone;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25163015	chr11:64052221	BAD;GPR137	0.41	6.44	0.33	4.22e-10	Myopia (pathological);
CRC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.35	-5.85	-0.31	1.16e-8	Height;
CRC	cis	rs1274963	0.601	rs2063634	chr3:39196452	A/G	cg02254461	chr3:39195904	CSRNP1	-0.52	-7.58	-0.39	3.61e-13	Chronic lymphocytic leukemia;
CRC	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.73	-12.88	-0.58	5.19e-31	White blood cell count (basophil);
CRC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.47	7.58	0.39	3.61e-13	Uric acid clearance;
CRC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12516959	chr21:47718080	NA	-0.33	-5.73	-0.3	2.31e-8	Testicular germ cell tumor;
CRC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg00745463	chr17:30367425	LRRC37B	-0.57	-6.93	-0.36	2.28e-11	Hip circumference adjusted for BMI;
CRC	cis	rs970548	0.862	rs10900230	chr10:46130389	C/T	cg15590007	chr10:45870220	ALOX5	0.43	5.74	0.3	2.16e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.66	-9.61	-0.47	2.03e-19	Cognitive function;
CRC	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.73	-0.39	1.3e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.26	-5.72	-0.3	2.42e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.74	11.17	0.52	8.95e-25	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.89	-0.31	9.46e-9	Crohn's disease;
CRC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg07952391	chr2:88470173	THNSL2	-0.42	-6.2	-0.32	1.66e-9	Response to metformin (IC50);
CRC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.76	0.3	1.95e-8	Height;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.3	-6.68	-0.35	9.98e-11	Total body bone mineral density;
CRC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.8	13.57	0.6	1.27e-33	Menopause (age at onset);
CRC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7849270	1.000	rs7021449	chr9:131899312	T/C	cg13538475	chr9:131942899	NA	-0.33	-6.35	-0.33	7.18e-10	Blood metabolite ratios;
CRC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.35	5.63	0.3	3.81e-8	Mean platelet volume;Platelet distribution width;
CRC	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.61	8.4	0.42	1.34e-15	Iron status biomarkers;
CRC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-12.53	-0.57	1.06e-29	Glomerular filtration rate (creatinine);
CRC	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.63	8.83	0.44	6.14e-17	Type 2 diabetes;
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg05735659	chr12:48099394	RPAP3	-0.71	-6.27	-0.33	1.11e-9	Temperament (bipolar disorder);
CRC	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.4	-5.82	-0.31	1.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.75	0.35	6.86e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.6	-8.16	-0.41	7.25e-15	White matter hyperintensity burden;
CRC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg02135003	chr7:105160482	PUS7	-0.9	-11.7	-0.54	1.09e-26	Bipolar disorder (body mass index interaction);
CRC	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg05805236	chr11:65401703	PCNXL3	0.41	6.83	0.35	4.08e-11	Systemic lupus erythematosus;
CRC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.54	0.38	4.72e-13	Motion sickness;
CRC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.04	18.28	0.71	5.31e-52	Blood pressure (smoking interaction);
CRC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.73	-12.5	-0.57	1.29e-29	Ulcerative colitis;
CRC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg23533926	chr12:111358616	MYL2	0.51	7.68	0.39	1.84e-13	Extrinsic epigenetic age acceleration;
CRC	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.4	6.2	0.32	1.65e-9	Endometrial cancer;
CRC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	10.23	0.49	1.7e-21	Menopause (age at onset);
CRC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.54	-8.78	-0.44	8.92e-17	Total body bone mineral density;
CRC	cis	rs7202877	0.519	rs4887811	chr16:75307251	C/T	cg03315344	chr16:75512273	CHST6	0.47	5.77	0.3	1.86e-8	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg22561889	chr6:118971681	C6orf204	0.53	6.83	0.35	4.16e-11	Diastolic blood pressure;
CRC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.52	-7.13	-0.37	6.23e-12	Gut microbiome composition (summer);
CRC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.64	-10.5	-0.5	1.98e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg07884673	chr3:53033167	SFMBT1	0.7	6.15	0.32	2.23e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.46	0.65	6.33e-41	Fuchs's corneal dystrophy;
CRC	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.74	7.92	0.4	3.68e-14	Breast cancer;
CRC	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.67	-9.92	-0.48	1.81e-20	Acne (severe);
CRC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.66	-0.34	1.16e-10	Bipolar disorder;
CRC	cis	rs9311676	0.618	rs11130639	chr3:58406004	G/T	cg06643156	chr3:58380774	PXK	0.42	6.38	0.33	5.84e-10	Systemic lupus erythematosus;
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-7.31	-0.37	2.04e-12	Lymphocyte counts;
CRC	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-7.16	-0.37	5.44e-12	Schizophrenia;
CRC	cis	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.62	-0.3	4.11e-8	Blood trace element (Cu levels);
CRC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.91	-17.21	-0.69	8.65e-48	Obesity-related traits;
CRC	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.64	-0.34	1.33e-10	Vitamin D levels;
CRC	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	15.34	0.65	1.9e-40	Colorectal cancer;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg15786705	chr6:28176104	NA	0.55	7.52	0.38	5.29e-13	Parkinson's disease;
CRC	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.65	9.75	0.47	6.65e-20	Dementia with Lewy bodies;
CRC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg21620606	chr4:1342894	KIAA1530	0.51	8.19	0.41	5.83e-15	Obesity-related traits;
CRC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg10978503	chr1:24200527	CNR2	0.62	11.34	0.53	2.2e-25	Immature fraction of reticulocytes;
CRC	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg06470822	chr6:28175283	NA	0.75	6.71	0.35	8.62e-11	Depression;
CRC	cis	rs3736485	0.808	rs2124875	chr15:51833369	T/A	cg08986416	chr15:51914746	DMXL2	-0.49	-7.08	-0.36	8.98e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg00677455	chr12:58241039	CTDSP2	0.51	7.83	0.4	6.82e-14	Intelligence (multi-trait analysis);
CRC	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	8.0	0.4	2.12e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.63	0.34	1.38e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg26043149	chr18:55253948	FECH	-0.5	-7.78	-0.39	9.21e-14	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10489525	0.583	rs1967711	chr1:115630967	C/T	cg01522456	chr1:115632236	TSPAN2	0.63	9.03	0.45	1.47e-17	Autism;
CRC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg04586622	chr2:25135609	ADCY3	-0.55	-10.22	-0.49	1.8e-21	Body mass index;
CRC	cis	rs1511802	0.666	rs62350519	chr4:187119701	G/A	cg24794857	chr4:187113578	CYP4V2	0.41	5.97	0.31	6.14e-9	Blood protein levels;
CRC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.57	7.9	0.4	4.36e-14	Alcohol dependence;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19043042	chr14:100705857	YY1	0.43	6.08	0.32	3.31e-9	Response to antipsychotic treatment;
CRC	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg23625390	chr15:77176239	SCAPER	-0.7	-10.13	-0.49	3.6e-21	Blood metabolite levels;
CRC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg10298567	chr3:47292165	KIF9	-0.39	-6.02	-0.32	4.64e-9	Colorectal cancer;
CRC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.43	5.71	0.3	2.57e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-0.89	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.56	-8.13	-0.41	9.05e-15	Carotid intima media thickness;
CRC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.48	-6.18	-0.32	1.95e-9	Childhood ear infection;
CRC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg25456477	chr12:86230367	RASSF9	0.38	6.34	0.33	7.41e-10	Major depressive disorder;
CRC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.82	-13.48	-0.6	2.92e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs6686842	0.897	rs2802565	chr1:41551819	T/A	cg19787969	chr8:9763211	NA	0.28	6.05	0.32	3.99e-9	Height;
CRC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg25985355	chr7:65971099	NA	-0.52	-5.97	-0.31	6.08e-9	Diabetic kidney disease;
CRC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg24011408	chr12:48396354	COL2A1	-0.44	-6.49	-0.34	3.14e-10	Glycated hemoglobin levels;
CRC	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg02158880	chr13:53174818	NA	0.46	7.07	0.36	9.57e-12	Lewy body disease;
CRC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.42	6.12	0.32	2.7e-9	Erythrocyte sedimentation rate;
CRC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.54	7.84	0.4	6.25e-14	Resting heart rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12628196	chr7:127672458	SND1;LRRC4	0.26	6.39	0.33	5.59e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.33	6.96e-10	Diabetic kidney disease;
CRC	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.52	7.99	0.4	2.32e-14	Sum neutrophil eosinophil counts;
CRC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.4	-7.8	-0.4	8.02e-14	Subjective well-being;
CRC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.92	-15.96	-0.66	6.99e-43	Height;
CRC	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.83	-10.63	-0.51	6.99e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg08992911	chr2:238395768	MLPH	0.57	5.97	0.31	6.16e-9	Prostate cancer;
CRC	cis	rs7945718	0.781	rs11022505	chr11:12822366	A/G	cg25843174	chr11:12811716	TEAD1	-0.45	-8.15	-0.41	7.68e-15	Educational attainment (years of education);
CRC	cis	rs1572438	0.760	rs7766707	chr6:869501	C/T	cg21062780	chr6:887772	NA	-0.38	-5.98	-0.31	5.78e-9	Aging;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg15511327	chr8:143859410	LYNX1	0.4	7.26	0.37	2.78e-12	Urinary tract infection frequency;
CRC	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	6.86	0.35	3.48e-11	Lymphocyte counts;
CRC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.61	7.57	0.39	3.71e-13	Alzheimer's disease;
CRC	trans	rs1390943	1.000	rs13253777	chr8:20071770	C/G	cg06710349	chr5:139737425	NA	-0.44	-6.0	-0.31	5.28e-9	Circulating myeloperoxidase levels (serum);
CRC	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.27	-0.33	1.12e-9	Breast cancer;
CRC	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-7.89	-0.4	4.41e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg05623727	chr3:50126028	RBM5	0.46	7.69	0.39	1.76e-13	Intelligence (multi-trait analysis);
CRC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg00677455	chr12:58241039	CTDSP2	0.64	8.6	0.43	3.27e-16	Multiple sclerosis;
CRC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.58	9.67	0.47	1.28e-19	Intelligence (multi-trait analysis);
CRC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16035780	chr5:759353	NA	0.45	5.68	0.3	2.93e-8	Lung disease severity in cystic fibrosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08806622	chr17:27279525	PHF12	0.4	6.32	0.33	8.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6840360	0.582	rs11732918	chr4:152319045	C/T	cg09659197	chr4:152720779	NA	0.33	6.32	0.33	8.5e-10	Intelligence (multi-trait analysis);
CRC	cis	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg18131467	chr2:239335373	ASB1	-0.73	-6.26	-0.33	1.18e-9	Morning vs. evening chronotype;Chronotype;
CRC	trans	rs10021731	0.692	rs1585448	chr4:115412206	G/T	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs1223397	0.651	rs2496154	chr6:13315031	A/G	cg07912922	chr6:13274314	PHACTR1	0.37	5.75	0.3	2.04e-8	Blood pressure;
CRC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.56	-8.08	-0.41	1.22e-14	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-6.17	-0.32	2.05e-9	Aortic root size;
CRC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg24253500	chr15:84953950	NA	0.38	6.11	0.32	2.75e-9	Schizophrenia;
CRC	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06307176	chr5:131281290	NA	0.43	6.38	0.33	6.19e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg04906043	chr13:21280425	IL17D	0.44	6.89	0.36	2.85e-11	Dental caries;
CRC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.67	0.51	4.86e-23	Sudden cardiac arrest;
CRC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg11271282	chr2:238384023	NA	-0.47	-6.09	-0.32	3.14e-9	Prostate cancer;
CRC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.31	0.33	8.84e-10	Diabetic retinopathy;
CRC	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.48	-0.38	7.01e-13	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02725872	chr8:58115012	NA	-0.39	-6.47	-0.34	3.62e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.51	8.17	0.41	6.92e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CRC	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg15704280	chr7:45808275	SEPT13	0.61	6.02	0.31	4.62e-9	Axial length;
CRC	cis	rs1800795	0.553	rs1524099	chr7:22781657	G/A	cg05472934	chr7:22766657	IL6	0.54	7.9	0.4	4.32e-14	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CRC	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	5.97	0.31	6.2e-9	Asthma;
CRC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.55	-0.47	2.99e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	12.06	0.55	5.69e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.71	-0.35	8.66e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.56	0.34	2.06e-10	Lung cancer;
CRC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21972741	chr5:435613	AHRR	0.54	7.38	0.38	1.31e-12	Cystic fibrosis severity;
CRC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.62	-8.35	-0.42	1.91e-15	Alcohol dependence;
CRC	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.37	-5.93	-0.31	7.74e-9	Inflammatory bowel disease;
CRC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	0.95	9.46	0.46	5.94e-19	Diabetic retinopathy;
CRC	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg22134325	chr11:66188745	NPAS4	0.37	6.05	0.32	3.89e-9	Airway imaging phenotypes;
CRC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.44	7.29	0.37	2.34e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg00531865	chr16:30841666	NA	-0.46	-6.44	-0.33	4.32e-10	Dementia with Lewy bodies;
CRC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg21285383	chr16:89894308	SPIRE2	0.34	5.71	0.3	2.53e-8	Vitiligo;
CRC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg11657440	chr19:46296263	DMWD	0.7	12.35	0.56	4.62e-29	Coronary artery disease;
CRC	cis	rs9513593	1.000	rs12100212	chr13:99966921	C/T	cg21788972	chr13:99853209	UBAC2	0.44	5.72	0.3	2.37e-8	Psoriasis;
CRC	cis	rs7632954	0.632	rs7633250	chr3:8515693	G/A	cg03495237	chr3:8533978	NA	0.36	6.6	0.34	1.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.25	0.53	4.67e-25	Prudent dietary pattern;
CRC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg21466736	chr12:48725269	NA	0.48	7.23	0.37	3.42e-12	Glycated hemoglobin levels;
CRC	cis	rs939584	0.825	rs7564711	chr2:639061	T/G	cg03610516	chr2:642275	NA	0.42	5.64	0.3	3.67e-8	Body mass index;
CRC	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-6.54	-0.34	2.33e-10	Axial length;
CRC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.46	0.57	1.82e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.68	9.85	0.48	3.13e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-7.81	-0.4	7.62e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.62	9.42	0.46	8.49e-19	Corneal astigmatism;
CRC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.1	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg18827107	chr12:86230957	RASSF9	-0.39	-5.99	-0.31	5.37e-9	Major depressive disorder;
CRC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25517755	chr10:38738941	LOC399744	-0.43	-6.27	-0.33	1.16e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg05132306	chr1:1846340	CALML6	-0.45	-6.93	-0.36	2.28e-11	Body mass index;
CRC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.81	9.63	0.47	1.67e-19	Inflammatory bowel disease;
CRC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg02659138	chr7:134003124	SLC35B4	0.43	7.39	0.38	1.19e-12	Mean platelet volume;
CRC	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.39	-5.94	-0.31	7.27e-9	Educational attainment (years of education);
CRC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.46	5.74	0.3	2.11e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	8.34	0.42	2.11e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg13482628	chr17:19912719	NA	-0.4	-6.2	-0.32	1.72e-9	Obesity-related traits;
CRC	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.06	0.52	2.21e-24	Exhaled nitric oxide output;
CRC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.93	14.14	0.61	8.81e-36	Blood metabolite levels;Acylcarnitine levels;
CRC	trans	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg10756647	chr7:56101905	PSPH	0.73	8.07	0.41	1.36e-14	Diabetic kidney disease;
CRC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.15	0.32	2.29e-9	Menarche (age at onset);
CRC	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.74	-10.29	-0.49	1.05e-21	Coronary artery disease;
CRC	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.73	-15.99	-0.66	5.53e-43	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03236992	chr16:78133292	WWOX	0.42	6.06	0.32	3.68e-9	Response to antipsychotic treatment;
CRC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.32	-6.77	-0.35	6e-11	Homoarginine levels;
CRC	cis	rs1950626	0.615	rs12893486	chr14:101463800	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	15.09	0.64	1.74e-39	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs17152411	0.895	rs7900929	chr10:126584999	A/C	cg07906193	chr10:126599966	NA	0.58	6.93	0.36	2.16e-11	Height;
CRC	cis	rs16924133	0.655	rs72906792	chr11:33190386	C/A	cg05567920	chr11:33183001	CSTF3	-0.78	-6.09	-0.32	3.22e-9	Anger;
CRC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.4	-0.38	1.17e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg09163369	chr1:210001066	C1orf107	-0.58	-7.15	-0.37	5.55e-12	Orofacial clefts;
CRC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg27068330	chr11:65405492	SIPA1	0.46	6.85	0.35	3.59e-11	Acne (severe);
CRC	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.97	-0.31	6.18e-9	Neuroticism;
CRC	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg27068330	chr11:65405492	SIPA1	-0.42	-5.8	-0.3	1.55e-8	Systemic lupus erythematosus;
CRC	cis	rs6751744	0.513	rs10173538	chr2:160569276	C/T	cg08347373	chr2:160653686	CD302	-0.39	-6.42	-0.33	4.82e-10	Dysphagia;
CRC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-10.01	-0.48	8.91e-21	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15823064	chr1:87794194	LMO4	0.39	6.62	0.34	1.45e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4237845	0.611	rs2888288	chr12:58329935	G/C	cg02175503	chr12:58329896	NA	0.77	12.0	0.55	9.01e-28	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg20615401	chr6:28092323	ZSCAN16	0.47	6.24	0.33	1.34e-9	Parkinson's disease;
CRC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	1.0	18.93	0.72	1.43e-54	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.68	-0.43	1.83e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.54	7.43	0.38	9.52e-13	Resting heart rate;
CRC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.35	6.66	0.34	1.18e-10	Mean corpuscular volume;
CRC	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg10820045	chr2:198174542	NA	-0.35	-5.71	-0.3	2.57e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.5	-6.67	-0.35	1.07e-10	Glioblastoma;
CRC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.83	14.53	0.63	2.8e-37	Breast cancer;
CRC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.77	0.39	1.01e-13	Motion sickness;
CRC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.74e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.55	6.15	0.32	2.25e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.59	-0.34	1.75e-10	Menopause (age at onset);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05360402	chr5:110848191	STARD4	0.48	6.22	0.32	1.55e-9	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.88	0.31	1.01e-8	Parkinson's disease;
CRC	cis	rs7264396	0.887	rs736031	chr20:34048625	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.41	-0.33	5.12e-10	Total cholesterol levels;
CRC	trans	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.62	-0.34	1.43e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.45	-5.91	-0.31	8.38e-9	Neuroticism;
CRC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.81	-8.42	-0.42	1.18e-15	Tuberculosis;
CRC	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg23425280	chr12:56401806	NA	0.47	5.72	0.3	2.44e-8	Cancer;
CRC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg21155852	chr7:2048760	MAD1L1	-0.53	-7.23	-0.37	3.5e-12	Bipolar disorder;
CRC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.24e-11	Life satisfaction;
CRC	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.41	5.84	0.31	1.29e-8	Blood metabolite levels;
CRC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	7.92	0.4	3.57e-14	Red cell distribution width;
CRC	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.43	-6.2	-0.32	1.71e-9	Body mass index;
CRC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg19223190	chr17:80058835	NA	0.4	6.33	0.33	7.89e-10	Life satisfaction;
CRC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-5.93	-0.31	7.74e-9	Menarche (age at onset);
CRC	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg11003573	chr3:44754125	ZNF502	-0.37	-6.5	-0.34	2.93e-10	Depressive symptoms;
CRC	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.45	-0.34	4.03e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4073416	0.707	rs761830	chr14:66212986	G/A	cg03016385	chr14:66212404	NA	-0.42	-5.77	-0.3	1.8e-8	N-glycan levels;
CRC	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg16589663	chr20:23618590	CST3	0.57	7.3	0.37	2.16e-12	Chronic kidney disease;
CRC	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.61	-8.75	-0.43	1.16e-16	Diisocyanate-induced asthma;
CRC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.61	-10.95	-0.52	5.43e-24	Aortic root size;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22995176	chr7:76139470	UPK3B	0.4	6.36	0.33	6.9e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07685180	chr8:600429	NA	0.6	6.54	0.34	2.38e-10	IgG glycosylation;
CRC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg21854759	chr1:92012499	NA	-0.52	-8.63	-0.43	2.61e-16	Breast cancer;
CRC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg16141378	chr3:129829833	LOC729375	0.42	6.39	0.33	5.65e-10	Neuroticism;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00550498	chr19:12251208	ZNF20	0.4	6.65	0.34	1.24e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13198984	chr17:80129470	CCDC57	-0.39	-6.63	-0.34	1.41e-10	Life satisfaction;
CRC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.45	-6.32	-0.33	8.47e-10	Bipolar disorder;
CRC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	8.83	0.44	6.56e-17	Cognitive test performance;
CRC	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19863210	chr8:142139002	DENND3	0.44	6.35	0.33	6.99e-10	Anxiety disorder;
CRC	cis	rs524281	0.861	rs12049852	chr11:65884702	T/C	cg14036092	chr11:66035641	RAB1B	-0.47	-5.99	-0.31	5.61e-9	Electroencephalogram traits;
CRC	cis	rs2882667	0.929	rs17207828	chr5:138299835	A/G	cg09476006	chr5:138032270	NA	0.44	6.88	0.35	3.04e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg03243895	chr9:131314908	SPTAN1	-0.42	-6.02	-0.31	4.6e-9	Myopia (pathological);
CRC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.52	8.34	0.42	2.03e-15	Body mass index;
CRC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.59	-7.98	-0.4	2.46e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.91	-0.31	8.38e-9	Type 2 diabetes;
CRC	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg19338460	chr6:170058176	WDR27	-0.77	-8.27	-0.41	3.35e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg25182066	chr10:30743637	MAP3K8	-0.41	-5.98	-0.31	5.7e-9	Inflammatory bowel disease;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg21251018	chr6:28226885	NKAPL	-0.47	-6.2	-0.32	1.73e-9	Depression;
CRC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg27615366	chr5:131592974	PDLIM4	-0.34	-6.1	-0.32	2.98e-9	Breast cancer;
CRC	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.47	9.03	0.45	1.45e-17	Educational attainment (years of education);
CRC	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.62	-9.41	-0.46	8.91e-19	Testicular germ cell tumor;
CRC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.55	0.34	2.19e-10	Schizophrenia;
CRC	cis	rs911119	0.955	rs6036474	chr20:23604414	G/A	cg16589663	chr20:23618590	CST3	0.54	7.07	0.36	9.51e-12	Chronic kidney disease;
CRC	cis	rs834811	0.583	rs1121039	chr7:135879442	G/C	cg01726295	chr7:135938950	NA	0.38	6.46	0.34	3.87e-10	Post-traumatic stress disorder;
CRC	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.67	-11.69	-0.54	1.23e-26	Eye color traits;
CRC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.68	-0.35	1.05e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg04731861	chr2:219085781	ARPC2	0.28	5.89	0.31	9.71e-9	Ulcerative colitis;
CRC	cis	rs6586163	1.000	rs1926195	chr10:90753758	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.51	-7.37	-0.38	1.39e-12	Chronic lymphocytic leukemia;
CRC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.08	0.36	8.55e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg19425870	chr11:3876808	STIM1	-0.52	-6.03	-0.32	4.4e-9	Optic disc area;
CRC	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.7	11.58	0.54	3.02e-26	Itch intensity from mosquito bite;
CRC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg02683197	chr6:28174875	NA	0.65	9.06	0.45	1.19e-17	Parkinson's disease;
CRC	trans	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.53	7.94	0.4	3.22e-14	Endometrial cancer;
CRC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6694672	0.764	rs877897	chr1:197103975	G/A	cg13682187	chr1:196946512	CFHR5	0.46	7.37	0.38	1.38e-12	Asthma;
CRC	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg09659197	chr4:152720779	NA	0.32	5.81	0.31	1.44e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg19223190	chr17:80058835	NA	0.38	6.09	0.32	3.15e-9	Life satisfaction;
CRC	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg12315302	chr6:26189340	HIST1H4D	0.99	6.93	0.36	2.22e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg06207120	chr15:45996521	NA	0.32	7.75	0.39	1.14e-13	Waist circumference;Weight;
CRC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.45	-5.73	-0.3	2.25e-8	Gut microbiome composition (summer);
CRC	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg16338278	chr11:67432957	ALDH3B2	-0.42	-5.89	-0.31	9.77e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
CRC	cis	rs10046574	0.908	rs997530	chr7:135054147	T/C	cg27474649	chr7:135195673	CNOT4	0.6	5.65	0.3	3.51e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg02807482	chr3:125708958	NA	-0.42	-5.73	-0.3	2.32e-8	Blood pressure (smoking interaction);
CRC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.17	-0.37	4.87e-12	Morning vs. evening chronotype;
CRC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.06	0.48	6.44e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.67	8.6	0.43	3.31e-16	Schizophrenia;
CRC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06998765	chr14:75389618	RPS6KL1	0.24	5.91	0.31	8.37e-9	Caffeine consumption;
CRC	cis	rs9486719	1.000	rs11153070	chr6:97039720	C/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.35	-0.42	1.94e-15	Migraine;Coronary artery disease;
CRC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.69	10.44	0.5	3.21e-22	Menopause (age at onset);
CRC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg00769240	chr8:12517080	NA	-0.56	-6.07	-0.32	3.43e-9	Blood pressure (smoking interaction);
CRC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg02741985	chr17:80059408	CCDC57	0.42	6.82	0.35	4.4e-11	Life satisfaction;
CRC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	11.79	0.55	5.24e-27	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg25864757	chr3:47206301	SETD2	-0.4	-6.12	-0.32	2.63e-9	Brain structure;
CRC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.5	6.95	0.36	1.98e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg10589385	chr1:150898437	SETDB1	0.3	6.23	0.32	1.41e-9	Tonsillectomy;
CRC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg18016565	chr1:150552671	MCL1	0.45	6.36	0.33	6.85e-10	Melanoma;
CRC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.6	7.34	0.37	1.73e-12	Obesity (extreme);
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.94	0.31	7.26e-9	Prudent dietary pattern;
CRC	trans	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg17903999	chr18:56338584	MALT1	-0.42	-6.86	-0.35	3.46e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	16.85	0.68	2.34e-46	Platelet count;
CRC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.68	11.62	0.54	2.13e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.56	-9.02	-0.45	1.56e-17	Intelligence (multi-trait analysis);
CRC	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.61	-0.34	1.58e-10	Vitamin D levels;
CRC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.07	-12.27	-0.56	9.03e-29	Vitiligo;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16285240	chr10:112327411	SMC3	0.44	6.4	0.33	5.36e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg04586622	chr2:25135609	ADCY3	-0.55	-9.27	-0.46	2.48e-18	Body mass index;
CRC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.12	10.45	0.5	2.84e-22	Skin colour saturation;
CRC	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.55	-8.18	-0.41	6.37e-15	Vitiligo;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07870854	chr16:791252	NARFL	0.39	6.48	0.34	3.41e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.01	-0.4	1.95e-14	Triglycerides;
CRC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.15	0.32	2.24e-9	Rheumatoid arthritis;
CRC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.61	-0.3	4.37e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs9311676	0.609	rs11719450	chr3:58456811	A/G	cg06643156	chr3:58380774	PXK	-0.44	-6.65	-0.34	1.2e-10	Systemic lupus erythematosus;
CRC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	9.0	0.44	1.87e-17	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.82	-0.35	4.4e-11	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	0.81	11.1	0.52	1.63e-24	Neutrophil percentage of white cells;
CRC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.67	-0.3	3.14e-8	Heart rate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17643699	chr12:27091484	FGFR1OP2;C12orf11	0.41	6.95	0.36	2.02e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg25164649	chr6:28176230	NA	0.62	8.82	0.44	6.67e-17	Parkinson's disease;
CRC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.67e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	8.27	0.41	3.43e-15	Breast cancer;
CRC	cis	rs6838801	0.892	rs7656480	chr4:77574194	A/G	cg17476223	chr4:77663285	SHROOM3	0.42	5.86	0.31	1.14e-8	Cleft lip with or without cleft palate;
CRC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg14196790	chr5:131705035	SLC22A5	0.35	5.71	0.3	2.56e-8	Breast cancer;Mosquito bite size;
CRC	cis	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg05299278	chr17:33885742	SLFN14	0.4	6.08	0.32	3.39e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs4478858	0.746	rs12136121	chr1:31689743	G/C	cg00250761	chr1:31883323	NA	0.31	5.92	0.31	8.29e-9	Alcohol dependence;
CRC	cis	rs12580194	0.593	rs11832308	chr12:55755506	C/A	cg19537932	chr12:55886519	OR6C68	-0.67	-8.83	-0.44	6.47e-17	Cancer;
CRC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.38	5.82	0.31	1.42e-8	Longevity;
CRC	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.36	-6.76	-0.35	6.39e-11	Breast cancer;
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-11.17	-0.52	9.26e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg20356878	chr3:121714668	ILDR1	-0.46	-7.45	-0.38	8.45e-13	Multiple sclerosis;
CRC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16447950	chr5:562315	NA	-0.74	-9.79	-0.47	5.09e-20	Obesity-related traits;
CRC	cis	rs12295403	0.964	rs61886869	chr11:18688508	C/T	cg07538406	chr11:18686895	NA	-0.43	-6.28	-0.33	1.06e-9	Ovarian reserve;
CRC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.82	-0.31	1.43e-8	Alzheimer's disease (late onset);
CRC	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg15396367	chr9:139972779	UAP1L1	0.45	6.84	0.35	3.91e-11	Cerebrospinal fluid biomarker levels;
CRC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.82	-0.4	7.44e-14	Total body bone mineral density;
CRC	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.05	-14.75	-0.63	3.75e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg08888203	chr3:10149979	C3orf24	0.48	7.47	0.38	7.32e-13	Alzheimer's disease;
CRC	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg21251018	chr6:28226885	NKAPL	0.38	6.14	0.32	2.35e-9	Parkinson's disease;
CRC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.55	-7.63	-0.39	2.54e-13	Intelligence (multi-trait analysis);
CRC	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-8.85	-0.44	5.43e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	13.58	0.6	1.17e-33	Alzheimer's disease;
CRC	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.46	-8.33	-0.42	2.19e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg04586622	chr2:25135609	ADCY3	-0.42	-6.95	-0.36	1.92e-11	Body mass index;
CRC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.89	-0.51	8.75e-24	Eye color traits;
CRC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.16	-0.69	1.36e-47	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13362313	chr19:18794263	CRTC1	0.44	6.16	0.32	2.18e-9	Anxiety disorder;
CRC	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.48	-7.27	-0.37	2.62e-12	Red blood cell count;
CRC	cis	rs4926298	1.000	rs10423745	chr19:13176815	T/C	cg04657146	chr19:12876947	HOOK2	-0.43	-5.76	-0.3	1.94e-8	Bipolar disorder;
CRC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.82	-12.95	-0.58	2.81e-31	Cognitive function;
CRC	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg06307176	chr5:131281290	NA	0.46	6.37	0.33	6.36e-10	Life satisfaction;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.7	10.71	0.51	3.68e-23	Corneal astigmatism;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg27635394	chr6:26043820	HIST1H2BB	0.4	5.78	0.3	1.75e-8	Intelligence (multi-trait analysis);
CRC	cis	rs16975963	0.644	rs35205379	chr19:38176842	C/T	cg15135657	chr19:38346511	NA	0.46	6.38	0.33	5.86e-10	Longevity;
CRC	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.99	-0.4	2.34e-14	Bipolar disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg26859586	chr10:104953231	NT5C2	-0.4	-6.17	-0.32	1.99e-9	Myopia (pathological);
CRC	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg12458913	chr13:53173898	NA	0.39	5.69	0.3	2.8e-8	Lewy body disease;
CRC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg02158880	chr13:53174818	NA	0.54	8.56	0.43	4.31e-16	Lewy body disease;
CRC	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.48	-7.69	-0.39	1.74e-13	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02018176	chr4:1364513	KIAA1530	0.42	7.04	0.36	1.12e-11	Longevity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04810377	chr16:11761964	SNN	0.36	5.98	0.31	5.71e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.65	0.47	1.44e-19	Birth weight;
CRC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg16606324	chr3:10149918	C3orf24	-0.48	-7.2	-0.37	4.21e-12	Alzheimer's disease;
CRC	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.18	0.64	8.37e-40	Bipolar disorder;
CRC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09065629	chr16:1709722	CRAMP1L	0.36	5.64	0.3	3.69e-8	Coronary artery disease;
CRC	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.75	9.35	0.46	1.4e-18	Type 2 diabetes;
CRC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg15845792	chr6:28175446	NA	0.97	12.98	0.58	2.13e-31	Depression;
CRC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.26	0.53	4.35e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.06	-12.44	-0.57	2.13e-29	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06803689	chr22:29949796	THOC5	0.39	6.32	0.33	8.75e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.38	-0.33	6.18e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.75	-10.25	-0.49	1.45e-21	Coronary artery disease;
CRC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg03160526	chr17:80928410	B3GNTL1	-0.41	-5.83	-0.31	1.3e-8	Breast cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10190698	chr14:50154770	POLE2	0.46	7.33	0.37	1.77e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg15845792	chr6:28175446	NA	0.82	11.41	0.53	1.29e-25	Parkinson's disease;
CRC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.6	-9.41	-0.46	8.9e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	8.21	0.41	5.17e-15	Platelet distribution width;
CRC	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg14003231	chr6:33640908	ITPR3	0.5	7.97	0.4	2.56e-14	Plateletcrit;
CRC	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.45	7.75	0.39	1.19e-13	Post-traumatic stress disorder;
CRC	cis	rs4666002	0.789	rs6727388	chr2:27932587	A/G	cg27432699	chr2:27873401	GPN1	0.55	6.75	0.35	6.62e-11	Phospholipid levels (plasma);
CRC	trans	rs10411161	0.702	rs7256926	chr19:52391988	A/G	cg22319618	chr22:45562946	NUP50	-0.58	-6.01	-0.31	4.92e-9	Breast cancer;
CRC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg13319975	chr6:146136371	FBXO30	0.41	6.1	0.32	2.94e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11581859	0.950	rs72730329	chr1:99395390	T/A	cg12183875	chr3:169587454	LRRC31	0.28	6.34	0.33	7.78e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg17321639	chr7:2759063	NA	-0.53	-7.05	-0.36	1.06e-11	Height;
CRC	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg23254163	chr1:152506842	NA	0.46	8.89	0.44	4.15e-17	Hair morphology;
CRC	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.75	-0.43	1.15e-16	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22950391	chr6:28109938	ZNF192	0.45	6.48	0.34	3.44e-10	Response to antipsychotic treatment;
CRC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.81	11.52	0.54	4.9e-26	Cognitive function;
CRC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.63	-9.03	-0.45	1.45e-17	Cognitive function;
CRC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg18301423	chr5:131593218	PDLIM4	0.3	5.76	0.3	1.91e-8	Blood metabolite levels;
CRC	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00376283	chr12:123451042	ABCB9	-0.53	-6.34	-0.33	7.4e-10	Neutrophil percentage of white cells;
CRC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg01831904	chr17:28903510	LRRC37B2	0.6	6.09	0.32	3.23e-9	Body mass index;
CRC	trans	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg10756647	chr7:56101905	PSPH	0.78	8.01	0.4	1.97e-14	Diabetic kidney disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01517273	chr1:154599968	ADAR	0.47	6.01	0.31	4.93e-9	Thyroid stimulating hormone;
CRC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg20243544	chr17:37824526	PNMT	0.37	5.64	0.3	3.58e-8	Self-reported allergy;
CRC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg01262667	chr19:19385393	TM6SF2	-0.38	-6.33	-0.33	7.89e-10	Tonsillectomy;
CRC	cis	rs10489525	0.583	rs12034918	chr1:115626285	C/T	cg01522456	chr1:115632236	TSPAN2	0.49	6.94	0.36	2.11e-11	Autism;
CRC	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg25885038	chr17:56607967	SEPT4	-0.51	-7.7	-0.39	1.63e-13	Vitamin D levels;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg08467595	chr3:13009117	IQSEC1	0.36	6.09	0.32	3.16e-9	Obesity-related traits;
CRC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.43	0.46	7.91e-19	Alzheimer's disease;
CRC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07570687	chr10:102243282	WNT8B	0.44	5.66	0.3	3.36e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg14530993	chr4:882597	GAK	0.82	7.77	0.39	1.04e-13	Intelligence (multi-trait analysis);
CRC	trans	rs11654801	0.853	rs11658389	chr17:20880718	G/A	cg23759823	chr7:139672531	TBXAS1	-0.41	-5.98	-0.31	5.96e-9	Mosquito bite size;
CRC	cis	rs990171	0.874	rs6419573	chr2:103027103	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.73	0.3	2.23e-8	Lymphocyte counts;
CRC	trans	rs67073037	0.869	rs11677485	chr2:29146094	T/C	cg13899017	chr1:159158444	CADM3	-0.35	-5.99	-0.31	5.39e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	cis	rs2836754	1.000	rs2836753	chr21:40291187	A/G	cg20434300	chr21:40194735	ETS2	-0.35	-6.05	-0.32	3.89e-9	Crohn's disease;Body mass index;
CRC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.71	-0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs41271951	0.512	rs12074309	chr1:151087827	T/C	cg11822372	chr1:151115635	SEMA6C	-0.72	-5.83	-0.31	1.35e-8	Blood protein levels;
CRC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.48	-0.34	3.35e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg15445000	chr17:37608096	MED1	-0.34	-6.04	-0.32	4.2e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs653465	0.739	rs7641830	chr3:27208003	G/A	cg02860705	chr3:27208620	NA	0.39	6.03	0.32	4.49e-9	Breast cancer (early onset);
CRC	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg09127314	chr1:152161683	NA	0.49	6.28	0.33	1.07e-9	Atopic dermatitis;
CRC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg24289452	chr6:170231220	NA	-0.73	-6.46	-0.34	3.79e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs356992	0.915	rs168562	chr2:60747192	T/C	cg08426369	chr2:60753602	BCL11A	0.53	7.34	0.38	1.71e-12	Educational attainment (years of education);
CRC	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg24860332	chr8:6827800	DEFA10P	-0.47	-6.69	-0.35	9.47e-11	IgA nephropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20313298	chr4:708468	PCGF3	-0.38	-5.97	-0.31	6.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.16	-0.41	7.38e-15	QRS duration;
CRC	cis	rs2179367	0.887	rs506268	chr6:149685617	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.4	-6.27	-0.33	1.16e-9	Dupuytren's disease;
CRC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.47	6.91	0.36	2.54e-11	Headache;
CRC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	8.3	0.42	2.78e-15	Iron status biomarkers;
CRC	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.63	12.42	0.56	2.67e-29	HDL cholesterol levels;
CRC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	9.55	0.47	3.04e-19	Cognitive test performance;
CRC	cis	rs747650	0.504	rs11600292	chr11:46958698	A/G	cg19486271	chr11:47235900	DDB2	0.44	6.06	0.32	3.74e-9	Acne (severe);
CRC	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg25834613	chr7:1915315	MAD1L1	-0.43	-5.98	-0.31	5.85e-9	Neuroticism;
CRC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	5.88	0.31	9.99e-9	Height;
CRC	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.12	-0.41	9.48e-15	Superior frontal gyrus grey matter volume;
CRC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.76	11.15	0.52	1.03e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg19338460	chr6:170058176	WDR27	-0.59	-6.71	-0.35	8.32e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg05132306	chr1:1846340	CALML6	-0.5	-7.55	-0.38	4.26e-13	Body mass index;
CRC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.98	-0.31	5.84e-9	Life satisfaction;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21678189	chr6:10838625	NA	0.41	6.52	0.34	2.68e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03591917	chr3:197476477	FYTTD1;KIAA0226	0.46	5.96	0.31	6.51e-9	Thyroid stimulating hormone;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27150186	chr21:26979856	MRPL39	0.39	6.11	0.32	2.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg17724175	chr1:150552817	MCL1	-0.42	-6.41	-0.33	5.17e-10	Melanoma;
CRC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-8.21	-0.41	5.21e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7605827	0.930	rs1528622	chr2:15557535	A/T	cg19274914	chr2:15703543	NA	0.37	5.68	0.3	2.89e-8	Educational attainment (years of education);
CRC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg11070056	chr1:107600091	PRMT6	-0.39	-5.64	-0.3	3.75e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.47	-6.66	-0.34	1.17e-10	Large artery stroke;
CRC	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-7.11	-0.36	7.24e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs2625529	0.689	rs12161990	chr15:72202440	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.47	0.34	3.47e-10	Red blood cell count;
CRC	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.87	0.35	3.22e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	trans	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	6.98	0.36	1.59e-11	Ulcerative colitis;
CRC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.9	16.44	0.67	9.63e-45	Prostate cancer;
CRC	cis	rs17067123	0.614	rs55983301	chr4:180070495	A/G	cg26610307	chr4:180072759	NA	-0.56	-6.72	-0.35	7.84e-11	Response to hepatitis C treatment;
CRC	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.42	6.84	0.35	3.92e-11	Sitting height ratio;
CRC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.44	7.03	0.36	1.18e-11	Dupuytren's disease;
CRC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg21951975	chr1:209979733	IRF6	0.49	6.6	0.34	1.64e-10	Cleft lip with or without cleft palate;
CRC	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.49	7.11	0.37	7.1e-12	Pulmonary function decline;
CRC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.63	-0.47	1.69e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.62	-0.3	4.06e-8	Aortic root size;
CRC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg01657329	chr11:68192670	LRP5	0.46	6.78	0.35	5.46e-11	Total body bone mineral density;
CRC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.78	11.27	0.53	3.88e-25	Intelligence (multi-trait analysis);
CRC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.51	-0.46	4.32e-19	Neuroticism;
CRC	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg01028140	chr2:1542097	TPO	-0.57	-5.78	-0.3	1.72e-8	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.74	7.56	0.38	4.17e-13	Diabetic retinopathy;
CRC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg21251018	chr6:28226885	NKAPL	0.48	7.54	0.38	4.73e-13	Parkinson's disease;
CRC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.63	0.57	4.38e-30	Alzheimer's disease;
CRC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.56	-0.43	4.49e-16	Coronary artery disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24447660	chr3:127872092	EEFSEC	0.51	6.62	0.34	1.48e-10	Anxiety disorder;
CRC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg02560186	chr11:3602584	NA	-0.47	-6.3	-0.33	9.33e-10	Blood pressure (smoking interaction);
CRC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.08	13.48	0.6	2.85e-33	Vitiligo;
CRC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg19622623	chr12:86230825	RASSF9	-0.37	-5.64	-0.3	3.62e-8	Major depressive disorder;
CRC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.08	26.29	0.82	7.78e-83	Testicular germ cell tumor;
CRC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.49	5.89	0.31	9.58e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.42	6.66	0.34	1.14e-10	Type 2 diabetes;
CRC	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg17710535	chr19:10819994	QTRT1	0.43	6.0	0.31	5.19e-9	Inflammatory skin disease;
CRC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-6.94	-0.36	2.15e-11	Axial length;
CRC	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.71	-8.16	-0.41	7.39e-15	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4700695	0.841	rs251612	chr5:65275023	G/A	cg21114390	chr5:65439923	SFRS12	0.63	6.59	0.34	1.73e-10	Facial morphology (factor 19);
CRC	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg04586622	chr2:25135609	ADCY3	-0.42	-6.95	-0.36	1.92e-11	Body mass index;
CRC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25517755	chr10:38738941	LOC399744	-0.42	-6.09	-0.32	3.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg00343986	chr7:65444356	GUSB	-0.5	-7.51	-0.38	5.55e-13	Aortic root size;
CRC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.35	6.79	0.35	5.15e-11	Renal cell carcinoma;
CRC	trans	rs2270927	0.510	rs31244	chr5:75594743	G/A	cg13563193	chr19:33072644	PDCD5	0.71	6.15	0.32	2.28e-9	Mean corpuscular volume;
CRC	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.98	-0.36	1.64e-11	IgG glycosylation;
CRC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg11663144	chr21:46675770	NA	-0.74	-11.86	-0.55	2.97e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg05234568	chr11:5960015	NA	-0.47	-5.99	-0.31	5.61e-9	DNA methylation (variation);
CRC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg09877947	chr5:131593287	PDLIM4	-0.44	-7.27	-0.37	2.67e-12	Breast cancer;
CRC	cis	rs55882075	0.634	rs11249657	chr5:179111637	G/C	cg14593053	chr5:179126677	CANX	0.47	6.88	0.35	3.09e-11	Monocyte percentage of white cells;
CRC	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.88	-0.31	1e-8	Response to antipsychotic treatment;
CRC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.74	-9.09	-0.45	9.65e-18	Body mass index;
CRC	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg04110750	chr16:69646130	NFAT5	0.45	5.9	0.31	9e-9	IgE levels;
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.45	6.51	0.34	2.74e-10	Bipolar disorder;
CRC	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg23702412	chr14:70655803	SLC8A3	-0.29	-5.6	-0.3	4.47e-8	Prostate cancer;
CRC	cis	rs4684776	0.676	rs11714563	chr3:11313214	A/G	cg00170343	chr3:11313890	ATG7	-0.51	-5.91	-0.31	8.53e-9	Small vessel stroke;
CRC	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.36	-0.69	2.22e-48	Schizophrenia;
CRC	trans	rs2303319	0.504	rs1449641	chr2:162619567	T/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg22638593	chr5:131593259	PDLIM4	0.31	5.72	0.3	2.38e-8	Blood metabolite levels;
CRC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg27615366	chr5:131592974	PDLIM4	0.32	5.66	0.3	3.26e-8	Breast cancer;
CRC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.9	-15.44	-0.65	7.62e-41	Blood metabolite levels;
CRC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg19980929	chr12:42632907	YAF2	0.42	6.37	0.33	6.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.57	9.22	0.45	3.67e-18	Breast cancer;
CRC	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.51	-8.08	-0.41	1.26e-14	Red cell distribution width;
CRC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg11663144	chr21:46675770	NA	-0.69	-10.58	-0.5	1.04e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-11.04	-0.52	2.52e-24	Prudent dietary pattern;
CRC	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.39	-7.6	-0.39	3.15e-13	Response to cytidine analogues (gemcitabine);
CRC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	5.68	0.3	2.92e-8	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs12900413	0.687	rs12902809	chr15:90305617	C/G	cg24249390	chr15:90295951	MESP1	-0.55	-8.75	-0.43	1.17e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22336747	chr1:161087401	PFDN2;NIT1	0.43	6.35	0.33	7.08e-10	Response to antipsychotic treatment;
CRC	cis	rs9463078	0.605	rs1578676	chr6:44906861	G/A	cg25276700	chr6:44698697	NA	0.25	6.1	0.32	3.04e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.64	8.37	0.42	1.66e-15	Schizophrenia;
CRC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.71	12.4	0.56	3.23e-29	Metabolic syndrome;
CRC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13844804	chr7:814759	HEATR2	0.69	8.11	0.41	9.89e-15	Cerebrospinal P-tau181p levels;
CRC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg11235426	chr6:292522	DUSP22	-0.56	-8.0	-0.4	2.21e-14	Menopause (age at onset);
CRC	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg09127314	chr1:152161683	NA	0.47	6.04	0.32	4.25e-9	Atopic dermatitis;
CRC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.95	0.4	3e-14	Platelet count;
CRC	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg22495460	chr2:25135724	ADCY3	-0.9	-14.95	-0.64	6.53e-39	Body mass index;
CRC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.48	-5.79	-0.3	1.65e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.57	-8.43	-0.42	1.09e-15	Menarche (age at onset);
CRC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg22110888	chr17:80059540	CCDC57	0.4	6.41	0.33	5.11e-10	Life satisfaction;
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13198984	chr17:80129470	CCDC57	-0.46	-8.17	-0.41	6.53e-15	Life satisfaction;
CRC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.74	7.88	0.4	4.86e-14	Cognitive function;
CRC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.58	8.67	0.43	1.94e-16	Type 2 diabetes;
CRC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	11.71	0.54	1.01e-26	Prudent dietary pattern;
CRC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg09264619	chr17:80180166	NA	0.37	6.13	0.32	2.47e-9	Life satisfaction;
CRC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.51	6.11	0.32	2.81e-9	Gut microbiome composition (summer);
CRC	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-13.84	-0.61	1.2e-34	Ulcerative colitis;
CRC	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	cg04338863	chr8:33670619	NA	0.37	6.07	0.32	3.5e-9	Body mass index;
CRC	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg13334819	chr7:99746414	C7orf59	-0.56	-7.12	-0.37	6.88e-12	Coronary artery disease;
CRC	trans	rs7448080	0.702	rs1422867	chr5:123306950	T/C	cg23202058	chr4:185139648	ENPP6	0.59	6.06	0.32	3.77e-9	Alcohol dependence (age at onset);
CRC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.46	-9.15	-0.45	5.96e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.64	12.01	0.55	8.37e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2882667	0.898	rs13182437	chr5:138387149	T/C	cg09476006	chr5:138032270	NA	0.44	7.31	0.37	2.03e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg08222913	chr3:52553049	STAB1	-0.32	-5.94	-0.31	7.35e-9	Bipolar disorder;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11100077	chr12:56546410	MYL6B	0.46	6.23	0.32	1.4e-9	Anxiety disorder;
CRC	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.76	0.35	6.4e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.69	-10.53	-0.5	1.55e-22	Diastolic blood pressure;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09723155	chr17:79633271	C17orf90;CCDC137	-0.5	-5.97	-0.31	6.06e-9	Diisocyanate-induced asthma;
CRC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05665937	chr4:1216051	CTBP1	-0.37	-5.61	-0.3	4.4e-8	Obesity-related traits;
CRC	cis	rs7827545	1.000	rs6578235	chr8:135568022	C/T	cg07299736	chr8:135490787	ZFAT	-0.38	-6.47	-0.34	3.48e-10	Hypertension (SNP x SNP interaction);
CRC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg16989719	chr2:238392110	NA	-0.45	-7.64	-0.39	2.32e-13	Prostate cancer;
CRC	cis	rs73206853	0.841	rs56122570	chr12:110816291	G/A	cg12870014	chr12:110450643	ANKRD13A	0.75	8.12	0.41	9.6e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6076065	0.755	rs3746734	chr20:23349765	C/T	cg11657817	chr20:23433608	CST11	0.44	6.58	0.34	1.84e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-10.72	-0.51	3.37e-23	Motion sickness;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg11916186	chr1:36689760	THRAP3	-0.42	-6.19	-0.32	1.82e-9	Daytime sleep phenotypes;
CRC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.48	-9.06	-0.45	1.22e-17	Dupuytren's disease;
CRC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.45	0.42	9.69e-16	Lymphocyte counts;
CRC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.5	8.09	0.41	1.13e-14	Lipoprotein (a) levels;
CRC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.14	0.32	2.38e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg25456477	chr12:86230367	RASSF9	0.35	6.05	0.32	4.01e-9	Major depressive disorder;
CRC	trans	rs17112901	1.000	rs17669480	chr10:102066065	T/C	cg12052765	chr10:50816963	SLC18A3;CHAT	-0.48	-6.22	-0.32	1.49e-9	Obesity-related traits;
CRC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.03	-0.36	1.22e-11	Aortic root size;
CRC	trans	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg18761221	chr20:60518478	NA	0.52	8.55	0.43	4.59e-16	Body mass index;
CRC	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.63	10.59	0.5	9.54e-23	Tuberculosis;
CRC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg23533926	chr12:111358616	MYL2	-0.56	-8.7	-0.43	1.65e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.63	-7.48	-0.38	6.82e-13	Diabetic retinopathy;
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.32	-6.98	-0.36	1.63e-11	IgG glycosylation;
CRC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg23996704	chr18:44553084	KATNAL2	-0.37	-7.36	-0.38	1.52e-12	Personality dimensions;
CRC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg24884572	chr19:58661833	ZNF329	0.74	8.09	0.41	1.16e-14	Cholesterol, total;
CRC	cis	rs4654899	0.606	rs651085	chr1:21097783	A/G	cg02927042	chr1:21476669	EIF4G3	0.38	5.9	0.31	9.21e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.42	6.43	0.33	4.4e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.87	0.31	1.07e-8	Homoarginine levels;
CRC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg03609598	chr5:56110824	MAP3K1	-0.43	-5.8	-0.3	1.54e-8	Coronary artery disease;
CRC	cis	rs3026445	0.928	rs12296821	chr12:110629266	A/G	cg12870014	chr12:110450643	ANKRD13A	0.39	6.16	0.32	2.12e-9	QT interval;
CRC	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg08501292	chr6:25962987	TRIM38	0.88	6.11	0.32	2.84e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	8.88	0.44	4.49e-17	Mean platelet volume;
CRC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg23565292	chr14:50234668	KLHDC2	-0.4	-5.64	-0.3	3.75e-8	Carotid intima media thickness;
CRC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.99	0.52	3.97e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	5.1e-12	Life satisfaction;
CRC	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.81	14.08	0.61	1.46e-35	Hip circumference;
CRC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-7.51	-0.38	5.55e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-10.04	-0.48	7.52e-21	Breast cancer;
CRC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.39	0.56	3.27e-29	Alzheimer's disease;
CRC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.66	10.78	0.51	2.13e-23	Lung cancer;
CRC	cis	rs11212617	1.000	rs11212617	chr11:108283161	G/T	cg12106634	chr11:108092400	ATM;NPAT	0.4	5.8	0.3	1.59e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.58	9.4	0.46	9.86e-19	Tonsillectomy;
CRC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.73	0.39	1.36e-13	Lung cancer;
CRC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	10.7	0.51	4.08e-23	Personality dimensions;
CRC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.94	-0.58	2.96e-31	Alzheimer's disease;
CRC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.37	0.62	1.08e-36	Mean platelet volume;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21215323	chr15:41220556	DLL4	-0.49	-6.09	-0.32	3.1e-9	Diisocyanate-induced asthma;
CRC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.49	6.85	0.35	3.66e-11	Schizophrenia;
CRC	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-7.82	-0.4	7.46e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.51	7.63	0.39	2.6e-13	Prostate cancer;
CRC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16447950	chr5:562315	NA	-0.83	-10.81	-0.51	1.71e-23	Lung disease severity in cystic fibrosis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11668638	chr6:42952412	PPP2R5D	0.48	6.81	0.35	4.59e-11	Response to antipsychotic treatment;
CRC	cis	rs9549328	0.614	rs35872678	chr13:113617231	A/T	cg25790453	chr13:113633590	MCF2L	0.44	7.62	0.39	2.75e-13	Systolic blood pressure;
CRC	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9891119	0.526	rs4103200	chr17:40507065	G/C	cg06270615	chr17:40516068	STAT3	-0.36	-7.66	-0.39	2.05e-13	Multiple sclerosis;Crohn's disease;
CRC	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg18232548	chr7:50535776	DDC	-0.4	-6.11	-0.32	2.76e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04833878	chr14:104167610	KLC1;XRCC3	-0.38	-6.79	-0.35	5.3e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.11	-25.56	-0.82	3.8e-80	Testicular germ cell tumor;
CRC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-6.22	-0.32	1.52e-9	Diabetic retinopathy;
CRC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.57	-7.99	-0.4	2.32e-14	Pancreatic cancer;
CRC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.33	-0.33	8.13e-10	Alzheimer's disease (late onset);
CRC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg12273811	chr6:28175739	NA	0.45	6.48	0.34	3.4e-10	Parkinson's disease;
CRC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg06238570	chr21:40685208	BRWD1	0.73	10.25	0.49	1.42e-21	Cognitive function;
CRC	cis	rs6585424	1.000	rs35497678	chr10:81921078	C/T	cg11900509	chr10:81946545	ANXA11	-0.72	-8.81	-0.44	7.22e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9828933	0.882	rs3733127	chr3:63988174	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.55	-6.15	-0.32	2.26e-9	Type 2 diabetes;
CRC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.33	-6.26	-0.33	1.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs7259376	0.869	rs8110636	chr19:22600827	G/A	cg02657401	chr19:22469223	NA	0.31	6.65	0.34	1.23e-10	Menopause (age at onset);
CRC	cis	rs9463078	0.774	rs9357480	chr6:45219512	G/A	cg25276700	chr6:44698697	NA	-0.27	-6.55	-0.34	2.19e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.39	-0.33	5.61e-10	Renal cell carcinoma;
CRC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg16743903	chr16:89593216	SPG7	-0.39	-5.93	-0.31	7.85e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg21399703	chr1:247681439	NA	0.52	9.69	0.47	1.07e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs12931792	0.687	rs8057425	chr16:30182541	T/C	cg17640201	chr16:30407289	ZNF48	0.44	6.38	0.33	6.1e-10	Tonsillectomy;
CRC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.51	8.11	0.41	1.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs10021731	0.718	rs10028232	chr4:115408800	G/A	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs11948739	0.573	rs12332505	chr5:130337348	T/G	cg08523029	chr5:130500466	HINT1	-0.44	-5.76	-0.3	1.98e-8	Pediatric bone mineral content (hip);
CRC	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.59	-0.43	3.52e-16	Alcohol dependence;
CRC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.2	-0.45	4.33e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.9	-20.19	-0.74	1.56e-59	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.36	0.46	1.34e-18	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg21302420	chr1:112162376	RAP1A	0.7	6.56	0.34	2.06e-10	Skin colour saturation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11599998	chr3:160283537	KPNA4	0.36	6.01	0.31	4.95e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.74	-0.35	7.07e-11	Putamen volume;
CRC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg14004847	chr7:1930337	MAD1L1	0.43	6.14	0.32	2.38e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg27534772	chr1:16042836	PLEKHM2	0.41	6.94	0.36	2.06e-11	Systolic blood pressure;
CRC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17554472	chr22:41940697	POLR3H	0.56	5.76	0.3	1.93e-8	Vitiligo;
CRC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg00316803	chr15:76480434	C15orf27	-0.42	-7.3	-0.37	2.17e-12	Blood metabolite levels;
CRC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg26587870	chr6:27730563	NA	-0.62	-6.08	-0.32	3.36e-9	Depression;
CRC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg20607287	chr7:12443886	VWDE	-0.68	-7.26	-0.37	2.76e-12	Coronary artery disease;
CRC	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg13385794	chr1:248469461	NA	0.42	7.59	0.39	3.26e-13	Common traits (Other);
CRC	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-7.45	-0.38	8.3e-13	Waist circumference;Body mass index;
CRC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.43	-6.22	-0.32	1.53e-9	Response to metformin (IC50);
CRC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.53	-0.34	2.54e-10	Daytime sleep phenotypes;
CRC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.53	6.76	0.35	6.43e-11	Morning vs. evening chronotype;
CRC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02772935	chr3:125709198	NA	-0.5	-5.71	-0.3	2.53e-8	Blood pressure (smoking interaction);
CRC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	12.36	0.56	4.2e-29	Hip circumference adjusted for BMI;
CRC	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg13385794	chr1:248469461	NA	0.38	6.76	0.35	6.25e-11	Common traits (Other);
CRC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.55	0.34	2.19e-10	Schizophrenia;
CRC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg15786705	chr6:28176104	NA	0.58	8.14	0.41	8.31e-15	Parkinson's disease;
CRC	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.46	6.86	0.35	3.5e-11	Breast cancer;
CRC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.68	0.39	1.88e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg14507137	chr6:158980977	TMEM181	0.46	6.58	0.34	1.9e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4700695	0.764	rs152941	chr5:65241446	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.88	0.35	3.05e-11	Facial morphology (factor 19);
CRC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.9	-0.31	9.26e-9	Heart rate;
CRC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.42	-6.0	-0.31	5.25e-9	Aortic root size;
CRC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.44	9.48	0.46	5.22e-19	Blood protein levels;
CRC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.84	-10.88	-0.51	9.11e-24	Initial pursuit acceleration;
CRC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.59	9.14	0.45	6.48e-18	Aortic root size;
CRC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.53	0.47	3.57e-19	Cognitive test performance;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg01919652	chr6:150259930	NA	-0.69	-5.99	-0.31	5.48e-9	Cognitive function;
CRC	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus;
CRC	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg20356878	chr3:121714668	ILDR1	0.51	7.9	0.4	4.1e-14	Cognitive performance;
CRC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.57	7.8	0.39	8.36e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg14036092	chr11:66035641	RAB1B	0.46	6.21	0.32	1.62e-9	Electroencephalogram traits;
CRC	cis	rs2249694	1.000	rs4240522	chr10:135355557	C/T	cg16964102	chr10:135390573	NA	-0.43	-7.04	-0.36	1.11e-11	Obesity-related traits;
CRC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.42	6.03	0.32	4.34e-9	Renal cell carcinoma;
CRC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	1.11	10.34	0.5	6.94e-22	Intelligence (multi-trait analysis);
CRC	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg14844989	chr11:31128820	NA	0.35	6.3	0.33	9.75e-10	Red blood cell count;
CRC	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg00603274	chr11:61596626	FADS2	-0.48	-6.89	-0.36	2.85e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs11696501	0.688	rs6073850	chr20:44301084	C/T	cg11783356	chr20:44313418	WFDC10B	-0.43	-5.72	-0.3	2.34e-8	Brain structure;
CRC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg19193384	chr17:30244184	NA	-0.53	-6.88	-0.35	3.1e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg16797656	chr11:68205561	LRP5	0.36	5.72	0.3	2.36e-8	Total body bone mineral density;
CRC	trans	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02854695	chr19:50832032	KCNC3	-0.38	-5.97	-0.31	6.29e-9	Myopia (pathological);
CRC	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.95	-12.38	-0.56	3.81e-29	Exhaled nitric oxide output;
CRC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg22815214	chr1:201083145	CACNA1S	0.58	9.37	0.46	1.22e-18	Permanent tooth development;
CRC	trans	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg26043149	chr18:55253948	FECH	-0.54	-8.27	-0.41	3.35e-15	Bone mineral density;
CRC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.73	0.35	7.48e-11	Bipolar disorder;
CRC	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs728616	0.867	rs1983776	chr10:81663695	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-7.74	-0.39	1.21e-13	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg10494257	chr1:16342123	HSPB7	0.44	6.12	0.32	2.65e-9	Dilated cardiomyopathy;
CRC	cis	rs12760731	0.565	rs35038893	chr1:178168417	C/T	cg00404053	chr1:178313656	RASAL2	1.05	10.93	0.52	6.36e-24	Obesity-related traits;
CRC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.53	8.02	0.4	1.89e-14	Longevity;Endometriosis;
CRC	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	7.48	0.38	6.81e-13	Schizophrenia;
CRC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg09626299	chr10:82213104	TSPAN14	-0.37	-6.18	-0.32	1.93e-9	Post bronchodilator FEV1;
CRC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.66	-0.34	1.15e-10	Bipolar disorder;
CRC	cis	rs16975963	0.644	rs73037036	chr19:38161070	A/T	cg15135657	chr19:38346511	NA	-0.47	-6.56	-0.34	2.15e-10	Longevity;
CRC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.51	0.42	6.25e-16	Height;
CRC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	7.96	0.4	2.84e-14	Height;
CRC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs2637266	0.505	rs10824434	chr10:78441162	T/C	cg18941641	chr10:78392320	NA	-0.34	-5.61	-0.3	4.39e-8	Pulmonary function;
CRC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-8.44	-0.42	1.03e-15	Systolic blood pressure;
CRC	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg09127314	chr1:152161683	NA	0.47	6.02	0.31	4.67e-9	Atopic dermatitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26311208	chr1:59012484	OMA1	0.39	6.22	0.32	1.52e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	15.81	0.66	2.74e-42	Smoking behavior;
CRC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.79	-0.51	1.91e-23	Body mass index;
CRC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg19824325	chr16:58548873	SETD6	1.0	6.84	0.35	3.87e-11	Schizophrenia;
CRC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.38	-7.71	-0.39	1.49e-13	Arsenic metabolism;
CRC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.49	6.68	0.35	1.02e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06532184	chr4:16227813	FLJ39653;TAPT1	0.37	6.0	0.31	5.26e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.94	-18.29	-0.71	4.76e-52	Height;
CRC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.87	-0.48	2.65e-20	Hip circumference adjusted for BMI;
CRC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.0	14.52	0.62	2.96e-37	Lymphocyte percentage of white cells;
CRC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg08222913	chr3:52553049	STAB1	-0.38	-7.43	-0.38	9.54e-13	Bipolar disorder;
CRC	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg05569086	chr8:143859399	LYNX1	-0.39	-6.17	-0.32	1.96e-9	Urinary tract infection frequency;
CRC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.76	-12.1	-0.55	4.09e-28	Multiple myeloma;
CRC	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg09184832	chr6:79620586	NA	0.37	6.2	0.32	1.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9372498	0.764	rs4593396	chr6:118722514	A/G	cg18833306	chr6:118973337	C6orf204	0.49	6.19	0.32	1.83e-9	Diastolic blood pressure;
CRC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.4	5.8	0.3	1.54e-8	Obesity-related traits;
CRC	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.37	-6.71	-0.35	8.54e-11	Response to paliperidone in schizophrenia (CGI-S score);
CRC	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg09455208	chr3:40491958	NA	0.32	6.38	0.33	5.99e-10	Renal cell carcinoma;
CRC	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.72	9.02	0.45	1.65e-17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.38	-0.33	6.15e-10	Bipolar disorder;
CRC	cis	rs13315871	1.000	rs78248959	chr3:58455068	G/A	cg20936604	chr3:58311152	NA	-0.72	-6.7	-0.35	8.82e-11	Cholesterol, total;
CRC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg06363034	chr20:62225388	GMEB2	-0.44	-6.8	-0.35	5e-11	Glioblastoma;
CRC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21643547	chr1:205240462	TMCC2	-0.45	-7.24	-0.37	3.17e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg15845792	chr6:28175446	NA	0.95	13.73	0.6	3.05e-34	Parkinson's disease;
CRC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.73	-13.89	-0.61	7.95e-35	Facial morphology (factor 23);
CRC	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.57	-10.26	-0.49	1.3e-21	Blood metabolite ratios;
CRC	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.07	-0.36	9.44e-12	Depression;
CRC	cis	rs7258465	0.965	rs748609	chr19:18560282	T/C	cg10790698	chr19:18539756	SSBP4	-0.45	-8.57	-0.43	4.22e-16	Breast cancer;
CRC	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.42	-6.73	-0.35	7.72e-11	Corneal astigmatism;
CRC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.88e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.48	7.85	0.4	5.97e-14	Crohn's disease;
CRC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.9	7.49	0.38	6.2800000000000005e-13	Schizophrenia;
CRC	cis	rs2257205	0.667	rs11651859	chr17:56731926	G/T	cg25885038	chr17:56607967	SEPT4	-0.53	-5.79	-0.3	1.62e-8	Pancreatic cancer;
CRC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.39	6.03	0.32	4.46e-9	Endometrial cancer;
CRC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg18827107	chr12:86230957	RASSF9	-0.38	-5.84	-0.31	1.26e-8	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18940588	chr22:27053464	MIAT	0.36	6.43	0.33	4.49e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.55	9.4	0.46	9.91e-19	Facial morphology (factor 15, philtrum width);
CRC	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-9.79	-0.47	5.08e-20	Bipolar disorder;
CRC	cis	rs6840360	0.642	rs11099819	chr4:152430178	T/C	cg09659197	chr4:152720779	NA	0.33	6.67	0.35	1.08e-10	Intelligence (multi-trait analysis);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg10478199	chr2:71175792	ATP6V1B1	0.43	6.12	0.32	2.59e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.64	12.01	0.55	8.37e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01475735	chr3:40494733	NA	0.48	6.74	0.35	6.93e-11	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.83	-0.35	4.03e-11	Total body bone mineral density;
CRC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg05527609	chr1:210001259	C1orf107	-0.57	-6.37	-0.33	6.3e-10	Red blood cell count;
CRC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.16	0.37	5.31e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-9.91	-0.48	1.97e-20	Bipolar disorder;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11528995	chr1:117210575	IGSF3	0.44	6.07	0.32	3.53e-9	Hip circumference;
CRC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.83	-0.55	3.9e-27	Type 2 diabetes;
CRC	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.65	6.92	0.36	2.38e-11	Breast cancer;
CRC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.37	0.33	6.29e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.61	10.23	0.49	1.69e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs394563	0.517	rs385303	chr6:149779064	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.51	-7.84	-0.4	6.47e-14	Dupuytren's disease;
CRC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.78	9.63	0.47	1.74e-19	Cognitive test performance;
CRC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg18721089	chr20:30220636	NA	-0.36	-5.93	-0.31	7.48e-9	Mean corpuscular volume;
CRC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.44	6.38	0.33	5.94e-10	Melanoma;
CRC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.29	0.42	2.91e-15	Height;
CRC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.13	-13.15	-0.59	4.8e-32	Diabetic kidney disease;
CRC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	10.88	0.51	9.12e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-12.06	-0.55	5.67e-28	Body mass index;
CRC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg10760299	chr15:45669010	GATM	0.49	7.65	0.39	2.19e-13	Homoarginine levels;
CRC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.61	10.21	0.49	1.96e-21	Prudent dietary pattern;
CRC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.51	-7.6	-0.39	3.07e-13	Calcium levels;
CRC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg01097406	chr16:89675127	NA	0.35	6.63	0.34	1.36e-10	Hemoglobin concentration;
CRC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.33	-0.33	8.19e-10	Body mass index;
CRC	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.98	13.67	0.6	5.54e-34	Exhaled nitric oxide output;
CRC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.89	17.42	0.69	1.34e-48	Obesity-related traits;
CRC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.64	-8.5	-0.42	6.68e-16	Dilated cardiomyopathy;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg00265863	chr1:28286348	XKR8	0.43	6.07	0.32	3.6e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.52	-7.93	-0.4	3.54e-14	Mean corpuscular hemoglobin;
CRC	cis	rs713587	0.571	rs2918630	chr2:25314186	A/G	cg22495460	chr2:25135724	ADCY3	0.41	6.17	0.32	1.95e-9	Body mass index in non-asthmatics;
CRC	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg00291366	chr1:12616550	NA	0.6	10.8	0.51	1.78e-23	Optic cup area;
CRC	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.75	13.3	0.59	1.39e-32	Insulin-like growth factors;
CRC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.37	-0.33	6.46e-10	Total body bone mineral density;
CRC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.61	-9.96	-0.48	1.36e-20	Dental caries;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14676443	chr19:58963245	ZNF324B	0.49	6.82	0.35	4.42e-11	Response to antipsychotic treatment;
CRC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.53	-9.9	-0.48	2.13e-20	Dupuytren's disease;
CRC	cis	rs12760731	0.565	rs116253445	chr1:178216962	C/T	cg00404053	chr1:178313656	RASAL2	1.03	10.81	0.51	1.61e-23	Obesity-related traits;
CRC	cis	rs1552172	0.845	rs35880546	chr1:145713071	T/C	cg11743829	chr1:145714124	CD160	-0.41	-5.88	-0.31	9.92e-9	Breast cancer;
CRC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24308560	chr3:49941425	MST1R	0.44	6.9	0.36	2.74e-11	Body mass index;
CRC	cis	rs10512697	0.803	rs71594962	chr5:3578127	A/G	cg19473799	chr5:3511975	NA	-0.73	-5.8	-0.3	1.53e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs10971721	0.822	rs115554740	chr9:33860886	C/G	cg13495928	chr9:33750294	PRSS3	0.55	5.93	0.31	7.7e-9	Body mass index;
CRC	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.49	5.73	0.3	2.3e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg23533926	chr12:111358616	MYL2	-0.56	-8.73	-0.43	1.3e-16	Extrinsic epigenetic age acceleration;
CRC	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.61	-9.38	-0.46	1.14e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.1	-0.32	3.05e-9	Arsenic metabolism;
CRC	cis	rs9296736	1.000	rs9296736	chr6:53924697	A/G	cg04374786	chr6:53939321	C6orf142	0.45	7.21	0.37	3.98e-12	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs2303319	0.504	rs1006428	chr2:162592559	A/C	cg22922770	chr7:98923339	ARPC1A	-0.67	-5.98	-0.31	5.68e-9	Cognitive function;
CRC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	9.95	0.48	1.43e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs12541635	0.966	rs2217391	chr8:107063126	A/G	cg10147462	chr8:107024639	NA	0.44	7.31	0.37	2.06e-12	Age of smoking initiation;
CRC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16262614	chr3:133464971	TF	-0.33	-5.85	-0.31	1.2e-8	Iron status biomarkers;
CRC	cis	rs501916	1.000	rs599111	chr15:48053334	G/T	cg16110827	chr15:48056943	SEMA6D	-0.37	-6.1	-0.32	2.98e-9	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg01557791	chr16:72042693	DHODH	-0.52	-7.19	-0.37	4.34e-12	Fibrinogen levels;
CRC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	-0.42	-5.64	-0.3	3.76e-8	Schizophrenia;
CRC	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg26805224	chr10:79626177	DLG5	-0.46	-6.85	-0.35	3.67e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.38	-6.73	-0.35	7.55e-11	Reticulocyte fraction of red cells;
CRC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.16	0.45	5.82e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.46	-7.33	-0.37	1.83e-12	Testicular germ cell tumor;
CRC	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-5.95	-0.31	6.75e-9	Lung function (FVC);Lung function (FEV1);
CRC	cis	rs2481665	0.765	rs2481678	chr1:62634020	T/C	cg18591186	chr1:62594603	INADL	-0.47	-6.65	-0.34	1.2e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.72	-12.55	-0.57	8.32e-30	White blood cell count (basophil);
CRC	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.53	-6.81	-0.35	4.69e-11	Pulse pressure;
CRC	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.46	6.68	0.35	1.01e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7301826	0.651	rs10734981	chr12:131297895	C/G	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.45	-6.49	-0.34	3.25e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg07817883	chr1:32538562	TMEM39B	1.33	11.14	0.52	1.11e-24	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg08501292	chr6:25962987	TRIM38	0.72	7.21	0.37	3.94e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.16	0.41	7.02e-15	Menopause (age at onset);
CRC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.67	-10.57	-0.5	1.16e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.65	-7.64	-0.39	2.46e-13	Intelligence (multi-trait analysis);
CRC	cis	rs3736485	0.844	rs8041197	chr15:51865877	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.54	-0.34	2.35e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg09003973	chr2:102972529	NA	0.85	9.24	0.45	3.2e-18	Gut microbiota (bacterial taxa);
CRC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg09654669	chr8:57350985	NA	-0.42	-6.01	-0.31	5.03e-9	Obesity-related traits;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg23981150	chr1:161111090	NA	0.42	6.06	0.32	3.67e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs41271951	0.512	rs76649628	chr1:151041851	A/G	cg11822372	chr1:151115635	SEMA6C	-0.71	-5.73	-0.3	2.3e-8	Blood protein levels;
CRC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.7	0.39	1.62e-13	Platelet count;
CRC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.7	-9.1	-0.45	9.12e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26010175	chr3:135969053	PCCB	0.39	6.42	0.33	4.71e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	9.59	0.47	2.32e-19	Type 2 diabetes;
CRC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.9	-15.28	-0.64	3.4e-40	Height;
CRC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.56	0.43	4.47e-16	Homoarginine levels;
CRC	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.6	0.39	3.2e-13	Joint mobility (Beighton score);
CRC	cis	rs10242455	0.702	rs116671616	chr7:98954558	C/T	cg18809830	chr7:99032528	PTCD1	-1.06	-7.7	-0.39	1.61e-13	Blood metabolite levels;
CRC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.5	-7.78	-0.39	9.27e-14	Aortic root size;
CRC	cis	rs9462027	0.583	rs2814995	chr6:34621171	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.29	-0.33	1e-9	Systemic lupus erythematosus;
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.63	-10.02	-0.48	8.57e-21	Monocyte percentage of white cells;
CRC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.19	-0.56	1.92e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg06156847	chr2:113672199	IL1F7	-0.4	-6.09	-0.32	3.12e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.39	-0.33	5.74e-10	Mood instability;
CRC	cis	rs582297	1	rs582297	chr11:108165407	C/G	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.04e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CRC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02290350	chr8:58132656	NA	-0.51	-6.57	-0.34	1.98e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.97	0.4	2.71e-14	Height;
CRC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg09417038	chr21:47716443	C21orf57	0.38	6.63	0.34	1.35e-10	Testicular germ cell tumor;
CRC	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.94	17.3	0.69	3.73e-48	Alcohol dependence;
CRC	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg12458913	chr13:53173898	NA	-0.49	-7.28	-0.37	2.4e-12	Lewy body disease;
CRC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.81	10.04	0.48	7.3e-21	Eosinophil percentage of granulocytes;
CRC	cis	rs243505	0.898	rs243537	chr7:148408278	A/G	cg09806900	chr7:148480153	CUL1	-0.43	-6.01	-0.31	4.96e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg08992911	chr2:238395768	MLPH	0.52	6.09	0.32	3.17e-9	Prostate cancer;
CRC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-6.22	-0.32	1.53e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.48	7.1	0.36	7.65e-12	Colorectal cancer;
CRC	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.49	0.34	3.21e-10	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs427941	0.562	rs6970800	chr7:101780471	T/C	cg06246474	chr7:101738831	CUX1	0.45	6.9	0.36	2.63e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg15786705	chr6:28176104	NA	0.63	8.99	0.44	2.02e-17	Cardiac Troponin-T levels;
CRC	cis	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.83	-0.31	1.35e-8	Triglycerides;
CRC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.84	15.46	0.65	6.6e-41	Metabolic syndrome;
CRC	cis	rs4321325	0.733	rs4284779	chr2:127946500	T/C	cg11380483	chr2:127933992	NA	0.58	7.13	0.37	6.4e-12	Protein C levels;
CRC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.41	-0.53	1.25e-25	Migraine;Coronary artery disease;
CRC	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.32	-0.37	1.97e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09341209	chr11:2422446	TSSC4	0.39	6.29	0.33	1.04e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs56371522	chr2:162491109	G/A	cg01191114	chr3:48936118	SLC25A20	-0.69	-6.0	-0.31	5.27e-9	Cognitive function;
CRC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.68	10.18	0.49	2.4e-21	Menarche (age at onset);
CRC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.47	-0.38	7.21e-13	Educational attainment;
CRC	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg18232548	chr7:50535776	DDC	-0.46	-6.53	-0.34	2.54e-10	Malaria;
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg14196790	chr5:131705035	SLC22A5	0.35	6.15	0.32	2.18e-9	Blood metabolite levels;
CRC	trans	rs2055729	0.557	rs7000542	chr8:9881135	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.3	0.33	9.59e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg04553112	chr3:125709451	NA	-0.53	-6.09	-0.32	3.2e-9	Blood pressure (smoking interaction);
CRC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg11245181	chr6:149772854	ZC3H12D	-0.52	-8.75	-0.43	1.1e-16	Dupuytren's disease;
CRC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-9.93	-0.48	1.71e-20	Cognitive function;
CRC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.56	8.12	0.41	9.67e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.86	-0.44	5.21e-17	Alcohol dependence;
CRC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.59	-8.82	-0.44	6.62e-17	Aortic root size;
CRC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.94	0.4	3.21e-14	Colorectal cancer;
CRC	cis	rs2274273	0.624	rs10132453	chr14:55840851	C/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-6.13	-0.32	2.46e-9	Protein biomarker;
CRC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.64	-9.91	-0.48	2.03e-20	Coronary artery disease;
CRC	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-0.4	-7.15	-0.37	5.48e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.34	7.88	0.4	4.91e-14	Corneal astigmatism;
CRC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg10820045	chr2:198174542	NA	0.48	8.51	0.42	6.21e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg06042504	chr8:55087323	NA	-0.36	-5.72	-0.3	2.35e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg03623178	chr6:28175578	NA	0.61	8.65	0.43	2.32e-16	Hepatitis A;
CRC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg14711859	chr11:8959438	ASCL3	0.39	6.5	0.34	2.9e-10	Hemoglobin concentration;
CRC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg04990556	chr1:26633338	UBXN11	-0.48	-6.01	-0.31	5.05e-9	Granulocyte percentage of myeloid white cells;
CRC	trans	rs10403021	0.765	rs4805432	chr19:30069721	A/G	cg22044635	chr17:76557109	DNAH17	0.43	5.97	0.31	6.15e-9	Diabetic retinopathy;
CRC	cis	rs12889267	0.722	rs2319626	chr14:21565149	G/C	cg02988727	chr14:21567520	ZNF219;C14orf176	0.46	6.93	0.36	2.24e-11	Hematocrit;Resting heart rate;
CRC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.1	-0.49	4.58e-21	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07580707	chr3:14220061	XPC;LSM3	0.41	6.48	0.34	3.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-7.44	-0.38	8.61e-13	Breast cancer;
CRC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	11.82	0.55	4.11e-27	Chronic sinus infection;
CRC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.49	7.68	0.39	1.83e-13	Eye color traits;
CRC	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	trans	rs10242455	0.702	rs6977165	chr7:99269397	T/C	cg09045935	chr12:6379348	NA	0.92	6.92	0.36	2.36e-11	Blood metabolite levels;
CRC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.35	-6.0	-0.31	5.31e-9	Primary biliary cholangitis;
CRC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.57	7.38	0.38	1.33e-12	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg03934865	chr2:198174659	NA	-0.45	-8.11	-0.41	9.84e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg10263370	chr3:44754102	ZNF502	-0.39	-6.57	-0.34	1.95e-10	Depressive symptoms;
CRC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.42	6.51	0.34	2.84e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg27523141	chr10:43048294	ZNF37B	0.45	6.46	0.34	3.84e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg16950941	chr11:66035639	RAB1B	-0.6	-7.43	-0.38	9.29e-13	Electroencephalogram traits;
CRC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.59	10.65	0.51	6e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.43	-8.74	-0.43	1.21e-16	Bipolar disorder;
CRC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.49	7.3	0.37	2.16e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg03609598	chr5:56110824	MAP3K1	0.41	5.7	0.3	2.69e-8	Coronary artery disease;
CRC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.79	11.94	0.55	1.57e-27	Intelligence (multi-trait analysis);
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg15147215	chr3:52552868	STAB1	-0.72	-14.31	-0.62	1.9e-36	Electroencephalogram traits;
CRC	cis	rs8020095	0.571	rs8022657	chr14:67390499	C/T	cg00791868	chr14:66963628	C14orf53	0.47	6.3	0.33	9.6e-10	Depression (quantitative trait);
CRC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-9.25	-0.45	3e-18	Response to antipsychotic treatment;
CRC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.42	-0.33	4.71e-10	Alzheimer's disease (late onset);
CRC	cis	rs9323205	0.765	rs2999388	chr14:51654157	A/G	cg23942311	chr14:51606299	NA	0.62	9.88	0.48	2.46e-20	Cancer;
CRC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg17764715	chr19:33622953	WDR88	0.45	6.48	0.34	3.43e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.9	16.59	0.67	2.38e-45	Intelligence (multi-trait analysis);
CRC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.32	-0.59	1.12e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.44	5.86	0.31	1.13e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg04398451	chr17:18023971	MYO15A	-0.35	-5.76	-0.3	1.93e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs3018066	0.589	rs4339284	chr4:107029457	G/A	cg01869342	chr4:106983673	TBCK	0.41	5.72	0.3	2.42e-8	Cancer;
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12172441	chr6:28176163	NA	0.64	7.53	0.38	5.03e-13	Depression;
CRC	cis	rs9826463	0.757	rs77081474	chr3:142294634	T/C	cg20824294	chr3:142316082	PLS1	0.42	7.07	0.36	9.31e-12	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-8.14	-0.41	8.23e-15	Axial length;
CRC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.6	-9.24	-0.45	3.1e-18	Aortic root size;
CRC	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.34	-0.42	2.08e-15	Waist circumference adjusted for body mass index;
CRC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-5.88	-0.31	9.96e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9908102	0.710	rs7211164	chr17:12917212	C/T	cg26162695	chr17:12921313	ELAC2	0.42	5.63	0.3	3.93e-8	Schizophrenia;
CRC	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07165851	chr6:158734300	TULP4	0.6	7.53	0.38	4.9e-13	Height;
CRC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-10.35	-0.5	6.44e-22	Coronary artery disease;
CRC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg19041857	chr6:27730383	NA	-0.66	-6.84	-0.35	3.93e-11	Depression;
CRC	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg08265495	chr8:11212668	TDH	-0.32	-5.65	-0.3	3.55e-8	Retinal vascular caliber;
CRC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.54	-8.66	-0.43	2.2e-16	Huntington's disease progression;
CRC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.44	5.92	0.31	8.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.44	8.15	0.41	7.7e-15	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-11.61	-0.54	2.3e-26	Chronic sinus infection;
CRC	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg15382696	chr6:118971807	C6orf204	0.59	7.63	0.39	2.54e-13	Diastolic blood pressure;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Depression;
CRC	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg07212818	chr11:638076	DRD4	-0.45	-5.89	-0.31	9.33e-9	Systemic lupus erythematosus;
CRC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg19622623	chr12:86230825	RASSF9	0.39	5.95	0.31	6.81e-9	Major depressive disorder;
CRC	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.67	-8.03	-0.4	1.77e-14	Alzheimer's disease;
CRC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.7	0.57	2.33e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.14	-0.32	2.35e-9	Diabetic kidney disease;
CRC	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg10570241	chr7:158785291	NA	0.42	7.11	0.36	7.32e-12	Facial morphology (factor 20);
CRC	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.95	0.36	1.97e-11	Subjective well-being;
CRC	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.35	-0.33	6.97e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.59	-8.9	-0.44	3.77e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg00316803	chr15:76480434	C15orf27	-0.38	-6.5	-0.34	2.94e-10	Blood metabolite levels;
CRC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg24130564	chr14:104152367	KLC1	-0.45	-6.75	-0.35	6.75e-11	Body mass index;
CRC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg24375607	chr4:120327624	NA	0.49	7.67	0.39	1.91e-13	Corneal astigmatism;
CRC	cis	rs12580194	0.593	rs61956292	chr12:55803346	T/C	cg19537932	chr12:55886519	OR6C68	-0.72	-9.16	-0.45	5.6e-18	Cancer;
CRC	cis	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg14761454	chr11:108092087	ATM;NPAT	-0.4	-5.87	-0.31	1.08e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14217534	chr12:49525474	TUBA1B	-0.44	-6.37	-0.33	6.4e-10	Daytime sleep phenotypes;
CRC	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg09596252	chr17:78655493	RPTOR	-0.64	-5.8	-0.3	1.55e-8	Myopia (pathological);
CRC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.63	-7.85	-0.4	5.97e-14	Body mass index;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13952954	chr19:59066605	CHMP2A	0.41	6.22	0.32	1.55e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.82	-0.35	4.37e-11	Coronary artery disease;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03646922	chr17:4167316	ANKFY1	0.46	6.6	0.34	1.68e-10	Survival in pancreatic cancer;
CRC	cis	rs7394190	1.000	rs10824026	chr10:75421208	A/G	cg07699608	chr10:75541558	CHCHD1	0.52	6.14	0.32	2.37e-9	Incident atrial fibrillation;
CRC	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg11887960	chr12:57824829	NA	0.58	6.5	0.34	3.04e-10	Obesity-related traits;
CRC	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.85	-13.66	-0.6	5.96e-34	Hypospadias;
CRC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.61	-7.26	-0.37	2.88e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9522267	0.737	rs9515455	chr13:112239671	A/G	cg10483660	chr13:112241077	NA	0.38	7.04	0.36	1.12e-11	Hepatitis;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg05805236	chr11:65401703	PCNXL3	-0.42	-6.7	-0.35	9.18e-11	Acne (severe);
CRC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Depression;
CRC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.96	-0.48	1.3e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.97	-17.79	-0.7	4.48e-50	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14511745	chr11:47573874	CUGBP1	0.44	6.48	0.34	3.3e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.52	6.0	0.31	5.32e-9	Dental caries;
CRC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.59	-9.43	-0.46	7.6e-19	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg02396143	chr1:29063512	YTHDF2	-0.66	-5.96	-0.31	6.48e-9	Cognitive function;
CRC	trans	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg17903999	chr18:56338584	MALT1	0.41	6.69	0.35	9.69e-11	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17482197	chr20:56285683	PMEPA1	0.38	6.44	0.33	4.32e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs73206853	0.764	rs55913108	chr12:110816507	T/C	cg12870014	chr12:110450643	ANKRD13A	0.84	10.0	0.48	1e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.54	7.7	0.39	1.62e-13	Lymphocyte percentage of white cells;
CRC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.52	8.27	0.41	3.34e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.48	-0.34	3.33e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg13240639	chr22:30162856	UCRC;ZMAT5	0.5	5.98	0.31	5.94e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.01	0.31	4.96e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg13491945	chr12:107078410	RFX4	0.36	6.13	0.32	2.47e-9	Heart rate;
CRC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07513332	chr6:167530253	CCR6	-0.34	-5.92	-0.31	7.93e-9	Primary biliary cholangitis;
CRC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.65	-10.21	-0.49	1.97e-21	Motion sickness;
CRC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.84	-0.4	6.17e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	16.41	0.67	1.23e-44	Primary sclerosing cholangitis;
CRC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.14	-0.52	1.12e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg12365402	chr11:9010492	NRIP3	-0.37	-6.07	-0.32	3.48e-9	Hematocrit;
CRC	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg02569219	chr17:2266849	SGSM2	0.4	6.76	0.35	6.47e-11	Proinsulin levels;
CRC	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.65	-0.54	1.7e-26	Psoriasis vulgaris;
CRC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.68	10.65	0.51	6.05e-23	Blood protein levels;
CRC	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg07424746	chr4:185654737	MLF1IP	-0.59	-5.82	-0.31	1.4e-8	Blood protein levels;
CRC	cis	rs1572438	0.831	rs4960373	chr6:855764	A/C	cg21062780	chr6:887772	NA	-0.34	-5.62	-0.3	4.12e-8	Aging;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg03412310	chr8:55014671	LYPLA1	0.44	6.12	0.32	2.65e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs11212617	0.967	rs7942014	chr11:108326174	G/C	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.74	0.3	2.17e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.87	-17.19	-0.69	1.02e-47	Hip circumference;
CRC	cis	rs17042140	0.904	rs6540844	chr1:214680378	C/T	cg16144317	chr1:214725524	PTPN14	0.52	6.79	0.35	5.19e-11	Plasma thyroid-stimulating hormone levels;
CRC	trans	rs2303319	0.504	rs62188990	chr2:162540635	G/A	cg10272801	chr16:14013773	ERCC4	-0.68	-6.01	-0.31	4.95e-9	Cognitive function;
CRC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.61	8.57	0.43	4.2e-16	Schizophrenia;
CRC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg26176469	chr17:28951361	LRRC37B2	-0.51	-6.0	-0.31	5.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.63	-6.95	-0.36	1.99e-11	Cerebrospinal P-tau181p levels;
CRC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.45	-7.97	-0.4	2.71e-14	Rheumatoid arthritis;
CRC	trans	rs9903692	0.954	rs34750858	chr17:46132937	T/A	cg13910583	chr8:56987998	RPS20	-0.44	-5.99	-0.31	5.63e-9	Pulse pressure;
CRC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.48	6.36	0.33	6.71e-10	IgG glycosylation;
CRC	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.31	5.99	0.31	5.54e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.68	-9.29	-0.46	2.2e-18	Vitiligo;
CRC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11645453	chr3:52864694	ITIH4	0.36	6.14	0.32	2.32e-9	Bipolar disorder;
CRC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg08075719	chr14:103021372	NA	0.58	7.72	0.39	1.45e-13	Platelet count;
CRC	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.59	-8.77	-0.44	1.01e-16	Schizophrenia;
CRC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.59	-9.45	-0.46	6.41e-19	Aortic root size;
CRC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16447950	chr5:562315	NA	-0.77	-10.22	-0.49	1.75e-21	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02290350	chr8:58132656	NA	-0.44	-6.39	-0.33	5.52e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg08222913	chr3:52553049	STAB1	-0.34	-6.39	-0.33	5.78e-10	Electroencephalogram traits;
CRC	cis	rs11212617	1.000	rs7946955	chr11:108284833	A/G	cg14761454	chr11:108092087	ATM;NPAT	0.45	6.9	0.36	2.72e-11	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.52	8.16	0.41	7e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs8010715	0.816	rs1134340	chr14:24594213	C/T	cg23112188	chr14:24563095	PCK2	-0.35	-6.93	-0.36	2.21e-11	IgG glycosylation;
CRC	cis	rs9549328	0.565	rs36145949	chr13:113616608	T/C	cg20742385	chr13:113633654	MCF2L	0.55	9.39	0.46	1.01e-18	Systolic blood pressure;
CRC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg20243544	chr17:37824526	PNMT	0.55	8.83	0.44	6.13e-17	Asthma;
CRC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.99	0.31	5.44e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg18165381	chr3:44552316	NA	-0.38	-5.64	-0.3	3.73e-8	Depressive symptoms;
CRC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.04	10.53	0.5	1.57e-22	Skin colour saturation;
CRC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	8.86	0.44	5.1e-17	Rheumatoid arthritis;
CRC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.27	-0.33	1.15e-9	Breast cancer;
CRC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.46	6.48	0.34	3.41e-10	Aortic root size;
CRC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.68	11.27	0.53	3.85e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg06238570	chr21:40685208	BRWD1	0.75	10.49	0.5	2.08e-22	Cognitive function;
CRC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg12437481	chr16:420112	MRPL28	-0.65	-8.39	-0.42	1.47e-15	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg16070123	chr10:51489643	NA	-0.32	-5.61	-0.3	4.4e-8	Prostate-specific antigen levels;
CRC	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg01761236	chr14:102990251	NA	-0.3	-6.0	-0.31	5.28e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-6.06	-0.32	3.71e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.31	-6.92	-0.36	2.4e-11	Total body bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19459508	chr3:160282885	KPNA4	0.44	6.1	0.32	3.04e-9	Anxiety disorder;
CRC	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.54	0.34	2.33e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg11598736	chr3:195384522	SDHAP2	0.63	6.36	0.33	6.85e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs9658691	0.790	rs4345878	chr10:90756511	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.77	5.61	0.3	4.39e-8	Mosquito bite size;
CRC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.65	12.05	0.55	5.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.39	6.31	0.33	9.04e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs449789	0.524	rs4709299	chr6:159751033	C/T	cg14500486	chr6:159655392	FNDC1	0.5	7.6	0.39	3.11e-13	Pulse pressure;
CRC	trans	rs4714291	0.832	rs9471244	chr6:40092331	A/G	cg02267698	chr19:7991119	CTXN1	0.5	6.88	0.35	2.97e-11	Strep throat;
CRC	trans	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg05376469	chr2:102649931	NA	0.38	6.28	0.33	1.09e-9	Coronary artery disease;
CRC	trans	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg17903999	chr18:56338584	MALT1	-0.44	-7.2	-0.37	4.15e-12	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09631309	chr2:37458880	CEBPZ;C2orf56	0.42	6.06	0.32	3.82e-9	Intelligence (multi-trait analysis);
CRC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg03030879	chr14:75389066	RPS6KL1	0.47	7.32	0.37	1.96e-12	Height;
CRC	cis	rs6534441	0.697	rs58154336	chr4:125466363	C/T	cg21609808	chr4:125404261	NA	0.41	5.64	0.3	3.68e-8	Major depressive disorder;
CRC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg02683197	chr6:28174875	NA	0.56	7.37	0.38	1.4e-12	Parkinson's disease;
CRC	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg04837898	chr3:45731254	SACM1L	-0.34	-5.67	-0.3	3.06e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs17767392	0.881	rs17767686	chr14:72006744	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.15	-0.37	5.62e-12	Mitral valve prolapse;
CRC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.59	9.2	0.45	4.27e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.55	6.76	0.35	6.4e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.78	12.41	0.56	2.98e-29	Breast cancer;
CRC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.52	7.45	0.38	8.46e-13	Colorectal cancer;
CRC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.71	-0.3	2.57e-8	Life satisfaction;
CRC	trans	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg20935933	chr6:143382018	AIG1	0.51	6.68	0.35	1.02e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.21	0.32	1.64e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.02	0.4	1.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.44	6.42	0.33	4.86e-10	Menopause (age at onset);
CRC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg20487152	chr13:99095054	FARP1	-0.47	-6.81	-0.35	4.68e-11	Longevity;
CRC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.54	5.93	0.31	7.69e-9	Initial pursuit acceleration;
CRC	cis	rs2013441	1.000	rs1992562	chr17:20218793	A/C	cg13482628	chr17:19912719	NA	-0.42	-6.15	-0.32	2.31e-9	Obesity-related traits;
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg01339444	chr6:118972232	C6orf204	0.54	6.02	0.32	4.65e-9	Diastolic blood pressure;
CRC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.37	-0.33	6.31e-10	Alzheimer's disease (late onset);
CRC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.48	7.48	0.38	6.72e-13	Corneal astigmatism;
CRC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.67	-8.47	-0.42	8.11e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	6.41	0.33	5.04e-10	Obesity-related traits;
CRC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg03188948	chr7:1209495	NA	0.42	5.71	0.3	2.55e-8	Longevity;Endometriosis;
CRC	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg08034379	chr2:228736324	WDR69	-0.53	-7.22	-0.37	3.59e-12	Blood pressure;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15942382	chr10:98273924	TLL2	0.39	5.98	0.31	5.84e-9	Myopia (pathological);
CRC	cis	rs1403694	1.000	rs2651640	chr3:186438393	G/A	cg04611788	chr3:186434169	KNG1	-0.46	-7.02	-0.36	1.27e-11	Blood protein levels;
CRC	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02757696	chr20:33104113	DYNLRB1	0.45	6.63	0.34	1.37e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg10494257	chr1:16342123	HSPB7	-0.45	-6.32	-0.33	8.5e-10	Dilated cardiomyopathy;
CRC	cis	rs863345	0.604	rs10797021	chr1:158490341	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.23	-0.32	1.44e-9	Pneumococcal bacteremia;
CRC	cis	rs6662572	0.851	rs55654017	chr1:46249299	T/G	cg08644498	chr1:46502608	NA	0.46	7.18	0.37	4.77e-12	Blood protein levels;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg06537201	chr12:58330115	NA	-0.45	-6.74	-0.35	7.29e-11	Brain structure;
CRC	cis	rs9648716	1.000	rs1267635	chr7:140491678	G/A	cg10747023	chr7:140774559	NA	0.44	5.67	0.3	3.1e-8	Type 2 diabetes;
CRC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.75	13.52	0.6	1.98e-33	Anterior chamber depth;
CRC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.41	-6.55	-0.34	2.16e-10	Platelet count;
CRC	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg27053337	chr8:124217698	FAM83A	0.35	5.77	0.3	1.87e-8	Urinary uromodulin levels;
CRC	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.32	-0.67	2.77e-44	Hip circumference;
CRC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	6.79	0.35	5.28e-11	Mean corpuscular volume;
CRC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg26260408	chr4:53727979	RASL11B	0.41	5.82	0.31	1.37e-8	Optic nerve measurement (cup area);
CRC	cis	rs4664293	0.546	rs1991373	chr2:160516225	A/T	cg08347373	chr2:160653686	CD302	0.39	6.58	0.34	1.91e-10	Monocyte percentage of white cells;
CRC	cis	rs7113874	0.589	rs11041944	chr11:8500996	G/A	cg02811074	chr11:8615871	STK33	0.37	6.24	0.33	1.33e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.68	-12.15	-0.56	2.49e-28	Lewy body disease;
CRC	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg14003231	chr6:33640908	ITPR3	0.5	7.98	0.4	2.51e-14	Height;
CRC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	0.99	14.58	0.63	1.75e-37	Breast cancer;
CRC	trans	rs473976	1.000	rs1943946	chr18:40414893	A/C	cg09252331	chr1:15655927	FHAD1	-0.48	-6.19	-0.32	1.82e-9	Gut microbiome composition (summer);
CRC	cis	rs12024301	0.557	rs11809046	chr1:183648131	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg10724054	chr17:3904396	NA	-0.47	-7.74	-0.39	1.26e-13	Type 2 diabetes;
CRC	cis	rs3018066	0.666	rs4521418	chr4:107029363	T/A	cg01869342	chr4:106983673	TBCK	0.42	5.65	0.3	3.5e-8	Cancer;
CRC	cis	rs10512697	1.000	rs34840936	chr5:3568755	G/C	cg19473799	chr5:3511975	NA	-0.76	-5.81	-0.31	1.44e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs713477	0.935	rs4901567	chr14:55912698	C/T	cg13175173	chr14:55914753	NA	-0.48	-9.1	-0.45	8.71e-18	Pediatric bone mineral content (femoral neck);
CRC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg06074448	chr4:187884817	NA	-0.6	-11.07	-0.52	2.06e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.08	0.45	9.92e-18	Bladder cancer;
CRC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.12	0.32	2.62e-9	Hemoglobin concentration;
CRC	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.52	9.61	0.47	2.02e-19	Alcoholic chronic pancreatitis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg09060823	chr12:56862504	SPRYD4	0.48	6.17	0.32	2e-9	Thyroid stimulating hormone;
CRC	cis	rs427943	0.750	rs7281416	chr21:46605839	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	5.92	0.31	7.91e-9	Body mass index;
CRC	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-6.38	-0.33	6.18e-10	Metabolite levels;
CRC	cis	rs6743226	0.901	rs7592138	chr2:242218915	G/A	cg10021735	chr2:242295487	FARP2	0.46	6.55	0.34	2.25e-10	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg09873164	chr1:152488093	CRCT1	0.34	5.81	0.31	1.47e-8	Hair morphology;
CRC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	10.69	0.51	4.4e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4321325	0.733	rs111245735	chr2:127942522	A/C	cg11380483	chr2:127933992	NA	0.62	7.24	0.37	3.27e-12	Protein C levels;
CRC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.64	-11.73	-0.54	8.99e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.9	-11.42	-0.53	1.15e-25	Vitiligo;
CRC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.55	8.81	0.44	7.18e-17	Gout;
CRC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.13	10.49	0.5	2.13e-22	Skin colour saturation;
CRC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.51	-7.89	-0.4	4.47e-14	Longevity;Endometriosis;
CRC	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.49	8.27	0.41	3.45e-15	Common traits (Other);
CRC	cis	rs4920343	0.698	rs851121	chr1:19087765	C/T	cg19637330	chr1:19110922	NA	0.39	5.82	0.31	1.39e-8	Knee osteoarthritis;
CRC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.52	-9.42	-0.46	8.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05889321	chr10:97416837	ALDH18A1	0.53	7.38	0.38	1.31e-12	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg09264619	chr17:80180166	NA	-0.37	-6.17	-0.32	1.97e-9	Life satisfaction;
CRC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg09876464	chr15:85330779	ZNF592	0.46	7.88	0.4	4.83e-14	P wave terminal force;
CRC	trans	rs4276421	0.837	rs7706140	chr5:45474814	A/C	cg04793272	chr11:119020941	ABCG4	-0.4	-6.51	-0.34	2.82e-10	P wave duration;
CRC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-9.2	-0.45	4.09e-18	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.49	7.72	0.39	1.41e-13	Red blood cell count;
CRC	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg12458913	chr13:53173898	NA	0.5	7.97	0.4	2.57e-14	Lewy body disease;
CRC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.18	-0.32	1.89e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg15147215	chr3:52552868	STAB1	-0.64	-11.07	-0.52	1.98e-24	Bipolar disorder;
CRC	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.45	-8.81	-0.44	7.53e-17	Alcohol dependence;
CRC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.2	0.32	1.67e-9	Renal function-related traits (BUN);
CRC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg10978503	chr1:24200527	CNR2	0.61	11.11	0.52	1.42e-24	Immature fraction of reticulocytes;
CRC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.53	0.34	2.5e-10	Rheumatoid arthritis;
CRC	cis	rs2487048	0.761	rs1800976	chr9:107690709	C/G	cg14470647	chr9:107690075	ABCA1	-0.38	-5.7	-0.3	2.62e-8	Intraocular pressure;
CRC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg19046167	chr17:80928561	B3GNTL1	0.49	6.85	0.35	3.71e-11	Glycated hemoglobin levels;
CRC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	9.32	0.46	1.77e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg14003231	chr6:33640908	ITPR3	-0.5	-8.06	-0.41	1.45e-14	Plateletcrit;
CRC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.19	-0.37	4.3e-12	Bipolar disorder;
CRC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.13	-0.49	3.5e-21	Total cholesterol levels;
CRC	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.95	-0.48	1.5e-20	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.11	0.41	9.94e-15	Lung cancer;
CRC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.75	11.06	0.52	2.1e-24	Response to antineoplastic agents;
CRC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-6.95	-0.36	1.95e-11	Height;
CRC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.87	-0.55	2.69e-27	Alzheimer's disease;
CRC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg03609598	chr5:56110824	MAP3K1	-0.45	-6.13	-0.32	2.57e-9	Coronary artery disease;
CRC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.73	11.96	0.55	1.28e-27	Monocyte count;
CRC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.15	0.41	7.88e-15	Menopause (age at onset);
CRC	cis	rs10155981	0.510	rs4722158	chr7:22584183	G/A	cg05062323	chr7:22590069	NA	-0.61	-5.72	-0.3	2.42e-8	Bilirubin levels;
CRC	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.49	7.9	0.4	4.33e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.19	-0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.45	6.52	0.34	2.6200000000000003e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg17764715	chr19:33622953	WDR88	0.45	6.48	0.34	3.38e-10	Bone properties (heel);
CRC	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.6	-6.65	-0.34	1.25e-10	Coronary artery disease;
CRC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.96	-18.42	-0.71	1.43e-52	Height;
CRC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-6.75	-0.35	6.8e-11	Cognitive function;
CRC	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg05805236	chr11:65401703	PCNXL3	-0.39	-6.05	-0.32	3.86e-9	Acne (severe);
CRC	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-7.01	-0.36	1.32e-11	Coronary artery disease;
CRC	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.58	-0.34	1.91e-10	Multiple sclerosis;
CRC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg00769240	chr8:12517080	NA	-0.57	-6.72	-0.35	8.17e-11	Blood pressure (smoking interaction);
CRC	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg09659197	chr4:152720779	NA	0.43	8.33	0.42	2.21e-15	Intelligence (multi-trait analysis);
CRC	cis	rs3741151	0.686	rs60860405	chr11:73248673	A/C	cg17517138	chr11:73019481	ARHGEF17	0.55	5.86	0.31	1.1e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.84	12.68	0.57	2.92e-30	Menarche (age at onset);
CRC	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	8.01	0.4	1.94e-14	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs524281	0.861	rs11607393	chr11:65875149	C/A	cg16950941	chr11:66035639	RAB1B	-0.6	-7.35	-0.38	1.59e-12	Electroencephalogram traits;
CRC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-16.46	-0.67	7.75e-45	Height;
CRC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.2	-0.32	1.72e-9	Aortic root size;
CRC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.53	7.97	0.4	2.65e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-11.28	-0.53	3.66e-25	Asthma;
CRC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.46	-6.5	-0.34	2.97e-10	Lymphocyte counts;
CRC	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg23229984	chr5:148520753	ABLIM3	-0.43	-5.84	-0.31	1.29e-8	Breast cancer;
CRC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-7.42	-0.38	1e-12	Self-reported allergy;
CRC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.13	0.64	1.23e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23708337	chr7:1209742	NA	0.45	6.56	0.34	2.05e-10	Longevity;Endometriosis;
CRC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.67	-8.62	-0.43	2.95e-16	Gut microbiome composition (summer);
CRC	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg14768367	chr16:72042858	DHODH	-0.56	-6.06	-0.32	3.72e-9	Blood protein levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01511104	chr20:5107621	CDS2;PCNA	0.43	5.98	0.31	5.71e-9	Response to antipsychotic treatment;
CRC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.74	-11.7	-0.54	1.13e-26	Prudent dietary pattern;
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg02033258	chr5:131593261	PDLIM4	0.41	6.16	0.32	2.18e-9	Breast cancer;
CRC	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.63	-7.94	-0.4	3.28e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs6586163	0.843	rs7069061	chr10:90754909	A/G	cg13456138	chr10:90753195	FAS	-0.43	-6.63	-0.34	1.38e-10	Chronic lymphocytic leukemia;
CRC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-7.31	-0.37	2.03e-12	Response to antipsychotic treatment;
CRC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.5	9.74	0.47	7.45e-20	Renal cell carcinoma;
CRC	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.52	-5.99	-0.31	5.4e-9	Prion diseases;
CRC	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.81	-0.4	7.49e-14	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.47	-0.34	3.47e-10	Breast cancer;
CRC	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg16591659	chr17:78472290	NA	0.39	5.74	0.3	2.1e-8	Fractional excretion of uric acid;
CRC	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-7.97	-0.4	2.7e-14	Urate levels in overweight individuals;
CRC	cis	rs3751196	1.000	rs12425283	chr12:104176292	T/C	cg02344784	chr12:104178138	NT5DC3	0.73	7.73	0.39	1.3e-13	Sense of smell;
CRC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg20203395	chr5:56204925	C5orf35	0.58	7.81	0.4	7.96e-14	Initial pursuit acceleration;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08834152	chr2:73441314	SMYD5	0.49	6.47	0.34	3.5e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	10.17	0.49	2.59e-21	Schizophrenia;
CRC	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.52	8.54	0.43	5.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.94	0.44	2.77e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	18.81	0.72	4.07e-54	Prudent dietary pattern;
CRC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.58	8.64	0.43	2.43e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.45	6.27	0.33	1.14e-9	Neuroticism;
CRC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.77	-13.0	-0.58	1.76e-31	Breast cancer;
CRC	cis	rs863345	0.604	rs2317970	chr1:158504770	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.12e-9	Pneumococcal bacteremia;
CRC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.44	-9.57	-0.47	2.56e-19	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg05192639	chr6:26864778	GUSBL1	0.32	6.07	0.32	3.45e-9	Schizophrenia;
CRC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.61	-9.73	-0.47	7.98e-20	Intelligence (multi-trait analysis);
CRC	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.5	-7.6	-0.39	3.13e-13	Type 2 diabetes;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10245697	chr20:3869582	PANK2	0.4	6.15	0.32	2.26e-9	Myopia (pathological);
CRC	cis	rs6604026	0.630	rs2391177	chr1:93353943	G/A	cg17283838	chr1:93427260	FAM69A	-0.44	-5.91	-0.31	8.61e-9	Multiple sclerosis;
CRC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-10.63	-0.51	6.96e-23	Extrinsic epigenetic age acceleration;
CRC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.68	10.09	0.49	4.78e-21	Corneal astigmatism;
CRC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg19337854	chr7:99768885	GPC2	0.48	6.42	0.33	4.73e-10	Lung function (FEV1/FVC);
CRC	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg15192750	chr16:69999425	NA	0.57	7.49	0.38	6.52e-13	IgE levels;
CRC	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.32	-0.33	8.56e-10	Systemic lupus erythematosus;
CRC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg06219103	chr11:63990595	FERMT3	-0.38	-5.7	-0.3	2.74e-8	Platelet count;
CRC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.09	18.65	0.72	1.87e-53	Cognitive function;
CRC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.62	7.53	0.38	5.05e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg18230493	chr5:56204884	C5orf35	0.6	8.91	0.44	3.62e-17	Initial pursuit acceleration;
CRC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.52	-6.05	-0.32	3.92e-9	Coronary artery calcification;
CRC	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.64	-8.73	-0.43	1.33e-16	White matter hyperintensity burden;
CRC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.74	-11.47	-0.53	7.78e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.76	10.1	0.49	4.37e-21	Coronary artery disease;
CRC	cis	rs17023223	0.537	rs2645305	chr1:119561365	A/G	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.37	3.97e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg13729891	chr17:7108468	DLG4	-0.41	-6.03	-0.32	4.52e-9	Diastolic blood pressure;
CRC	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.59	8.65	0.43	2.26e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.8	-0.3	1.58e-8	Total cholesterol levels;
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg03609598	chr5:56110824	MAP3K1	-0.59	-7.91	-0.4	3.82e-14	Initial pursuit acceleration;
CRC	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.67	9.98	0.48	1.13e-20	Autism;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg23807890	chr2:228736357	WDR69	-0.46	-6.68	-0.35	1.02e-10	Blood pressure;
CRC	cis	rs7953508	0.741	rs1498707	chr12:93997128	G/A	cg18151635	chr12:93972918	NA	-0.52	-7.66	-0.39	2.08e-13	Pubertal anthropometrics;
CRC	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.61	-10.02	-0.48	8.4e-21	Neuroticism;
CRC	cis	rs728616	0.867	rs56271768	chr10:81837051	T/G	cg05935833	chr10:81318306	SFTPA2	-0.51	-6.15	-0.32	2.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg02713581	chr15:63449717	RPS27L	0.41	5.98	0.31	5.81e-9	Metabolic traits;
CRC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.76	10.73	0.51	3.25e-23	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6728302	0.557	rs2741321	chr2:233280239	A/G	cg14418609	chr2:233286870	NA	0.7	6.5	0.34	2.93e-10	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21482170	chr19:6737889	GPR108	0.48	6.74	0.35	6.95e-11	Response to antipsychotic treatment;
CRC	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26850624	chr5:429559	AHRR	-0.77	-12.39	-0.56	3.3600000000000003e-29	Cystic fibrosis severity;
CRC	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-7.28	-0.37	2.48e-12	Schizophrenia;
CRC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg04731861	chr2:219085781	ARPC2	-0.27	-5.83	-0.31	1.3e-8	Colorectal cancer;
CRC	cis	rs17401966	0.522	rs10492969	chr1:10286358	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-7.46	-0.38	7.55e-13	Hepatocellular carcinoma;
CRC	cis	rs61160187	0.582	rs12654306	chr5:60184856	A/C	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	0.98	9.97	0.48	1.28e-20	Diabetic retinopathy;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-7.82	-0.4	7.11e-14	Total body bone mineral density;
CRC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.48	4.84e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13128441	0.593	rs7672067	chr4:5154673	G/A	cg24266670	chr11:115630629	NA	-0.4	-5.97	-0.31	6.31e-9	Celiac disease;
CRC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg19318889	chr4:1322082	MAEA	0.39	5.69	0.3	2.86e-8	Obesity-related traits;
CRC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.39	-7.03	-0.36	1.22e-11	Childhood ear infection;
CRC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg02033258	chr5:131593261	PDLIM4	0.41	7.74	0.39	1.26e-13	Breast cancer;
CRC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.12	-0.32	2.7e-9	Neuroticism;
CRC	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg24466277	chr1:23519622	HTR1D	-0.44	-5.93	-0.31	7.77e-9	Height;
CRC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg15147215	chr3:52552868	STAB1	-0.62	-10.31	-0.49	8.6e-22	Bipolar disorder;
CRC	cis	rs2013441	0.670	rs12937327	chr17:19978984	C/T	cg13482628	chr17:19912719	NA	0.43	6.06	0.32	3.81e-9	Obesity-related traits;
CRC	cis	rs7264396	0.887	rs2236159	chr20:34102189	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.45	-0.34	3.98e-10	Total cholesterol levels;
CRC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.42	-6.25	-0.33	1.25e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.71	11.06	0.52	2.21e-24	Corneal astigmatism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg09685351	chr22:45148319	ARHGAP8;PRR5-ARHGAP8	-0.43	-6.19	-0.32	1.79e-9	Diisocyanate-induced asthma;
CRC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	9.96	0.48	1.34e-20	Platelet count;
CRC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg15205204	chr1:6545172	PLEKHG5	0.41	5.87	0.31	1.04e-8	Body mass index;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25443968	chr17:21118207	TMEM11	0.46	6.16	0.32	2.17e-9	Thyroid stimulating hormone;
CRC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.39	5.94	0.31	7.3e-9	HDL cholesterol levels;
CRC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.91	-0.31	8.4e-9	Calcium levels;
CRC	cis	rs6988985	0.728	rs1114761	chr8:143928956	C/T	cg10324643	chr8:143916377	GML	-0.38	-6.33	-0.33	7.97e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs4664293	0.836	rs13016015	chr2:160646529	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.5	-0.38	6.09e-13	Monocyte percentage of white cells;
CRC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9938149	0.706	rs6540220	chr16:88315515	G/C	cg05435882	chr16:88311214	NA	-0.43	-5.74	-0.3	2.21e-8	Corneal structure;Central corneal thickness;
CRC	cis	rs2072510	0.569	rs7134860	chr12:96390358	C/A	cg22491680	chr12:96389547	HAL	-0.5	-6.16	-0.32	2.16e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg22110888	chr17:80059540	CCDC57	0.41	6.41	0.33	5.17e-10	Life satisfaction;
CRC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.03	10.24	0.49	1.55e-21	Lymphocyte counts;
CRC	cis	rs2013441	0.613	rs9901125	chr17:20008929	A/G	cg13482628	chr17:19912719	NA	0.38	5.82	0.31	1.37e-8	Obesity-related traits;
CRC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg14008862	chr17:28927542	LRRC37B2	0.53	5.85	0.31	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs868943	0.512	rs10456903	chr6:116541384	A/G	cg15226275	chr6:116381976	FRK	0.26	6.05	0.32	3.88e-9	Total cholesterol levels;
CRC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg11292332	chr7:45801988	SEPT13	-0.38	-7.02	-0.36	1.26e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg20607287	chr7:12443886	VWDE	-0.56	-6.15	-0.32	2.21e-9	Coronary artery disease;
CRC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.66	-6.95	-0.36	1.98e-11	Coronary artery disease;
CRC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg14074117	chr16:1909714	C16orf73	0.41	5.66	0.3	3.28e-8	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg08798685	chr6:27730294	NA	-0.43	-6.23	-0.32	1.46e-9	Parkinson's disease;
CRC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.85	10.08	0.49	5.15e-21	Psoriasis;
CRC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25517755	chr10:38738941	LOC399744	0.46	6.72	0.35	7.91e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.62	-0.3	4e-8	Colorectal cancer;
CRC	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.36	0.38	1.47e-12	Eye color traits;
CRC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg24874828	chr4:187887005	NA	-0.34	-5.71	-0.3	2.49e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg13385794	chr1:248469461	NA	0.36	6.34	0.33	7.63e-10	Common traits (Other);
CRC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg17321639	chr7:2759063	NA	-0.51	-7.04	-0.36	1.15e-11	Height;
CRC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	8.85	0.44	5.43e-17	Schizophrenia;
CRC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-7.23	-0.37	3.35e-12	Total body bone mineral density;
CRC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.68	10.6	0.5	8.86e-23	Huntington's disease progression;
CRC	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg14459158	chr9:96720562	NA	0.48	7.65	0.39	2.27e-13	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg17218026	chr1:154582156	ADAR	0.59	9.9	0.48	2.06e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.01	-0.4	1.99e-14	Bipolar disorder;
CRC	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.37	-0.38	1.38e-12	Caudate activity during reward;
CRC	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.65	-9.91	-0.48	2e-20	Corneal astigmatism;
CRC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.53	-6.2	-0.32	1.74e-9	Bipolar disorder;
CRC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.57	-9.78	-0.47	5.3e-20	Iron status biomarkers;
CRC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.79	10.9	0.51	8.19e-24	Cognitive function;
CRC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.54	-8.1	-0.41	1.07e-14	Blood protein levels;
CRC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.27	-0.33	1.16e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg17321639	chr7:2759063	NA	-0.39	-5.85	-0.31	1.17e-8	Height;
CRC	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	15.18	0.64	8.37e-40	Bipolar disorder;
CRC	trans	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg04077850	chr5:125800366	GRAMD3	0.4	6.66	0.34	1.14e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.45	6.02	0.31	4.73e-9	Bladder cancer;
CRC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.72	11.6	0.54	2.68e-26	Lung cancer;
CRC	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.08	-15.25	-0.64	4.51e-40	Exhaled nitric oxide output;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.55	-8.46	-0.42	8.77e-16	Longevity;Endometriosis;
CRC	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.85	15.97	0.66	6.51e-43	Hip circumference;
CRC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.53	-0.34	2.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.07	-0.41	1.34e-14	Morning vs. evening chronotype;
CRC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg27094323	chr7:1216898	NA	-0.36	-5.8	-0.3	1.59e-8	Longevity;Endometriosis;
CRC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.08e-13	Gut microbiome composition (summer);
CRC	cis	rs2274471	0.645	rs12237834	chr9:5093646	C/T	cg03390472	chr9:5043263	JAK2	-0.6	-7.06	-0.36	1.02e-11	Crohn's disease;
CRC	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg23202291	chr11:1979235	NA	0.44	5.96	0.31	6.48e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.49	6.85	0.35	3.67e-11	Aortic root size;
CRC	trans	rs6472235	0.778	rs2357657	chr8:66936490	C/A	cg07884673	chr3:53033167	SFMBT1	-0.45	-6.03	-0.32	4.47e-9	Myopia (pathological);Plateletcrit;
CRC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.45	6.82	0.35	4.26e-11	Menopause (age at onset);
CRC	trans	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg17903999	chr18:56338584	MALT1	0.42	6.93	0.36	2.23e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.57	8.9	0.44	3.96e-17	Type 2 diabetes;
CRC	cis	rs4731207	0.623	rs34865746	chr7:124639919	T/A	cg23710748	chr7:124431027	NA	-0.42	-6.69	-0.35	9.45e-11	Cutaneous malignant melanoma;
CRC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg00316803	chr15:76480434	C15orf27	-0.35	-5.79	-0.3	1.63e-8	Blood metabolite levels;
CRC	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	6.89	0.36	2.8e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16221875	chr6:21588597	NA	0.46	6.62	0.34	1.45e-10	Response to antipsychotic treatment;
CRC	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg20737812	chr15:86336631	KLHL25	-0.44	-6.99	-0.36	1.52e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg08167214	chr16:81040017	CENPN;C16orf61	-0.42	-6.07	-0.32	3.58e-9	Daytime sleep phenotypes;
CRC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-9.72	-0.47	8.55e-20	Cognitive function;
CRC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.46	5.92	0.31	8.3e-9	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.8	-0.3	1.57e-8	Lung cancer;
CRC	cis	rs12760731	0.582	rs6676116	chr1:178566778	G/A	cg00404053	chr1:178313656	RASAL2	0.66	7.38	0.38	1.29e-12	Obesity-related traits;
CRC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.39	-6.11	-0.32	2.8e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.33	-0.42	2.25e-15	Type 2 diabetes;
CRC	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg23254163	chr1:152506842	NA	-0.48	-9.71	-0.47	9.2e-20	Hair morphology;
CRC	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg25930673	chr12:123319894	HIP1R	0.69	5.85	0.31	1.17e-8	Adiponectin levels;
CRC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.67	-9.74	-0.47	7.34e-20	Menopause (age at onset);
CRC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.95	-0.36	1.91e-11	Lung cancer;
CRC	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg05756136	chr1:119680316	WARS2	0.52	7.14	0.37	6.01e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.38	-5.89	-0.31	9.77e-9	Monocyte count;
CRC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.44	5.97	0.31	6.17e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CRC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.39	-0.71	1.96e-52	Height;
CRC	trans	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg25214090	chr10:38739885	LOC399744	0.4	6.12	0.32	2.73e-9	Diastolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03278989	chr19:54693461	MBOAT7;TSEN34	0.41	6.38	0.33	5.91e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	8.44	0.42	9.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.54	10.42	0.5	3.71e-22	Acylcarnitine levels;
CRC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	9.13	0.45	6.96e-18	Lymphocyte counts;
CRC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-7.34	-0.38	1.72e-12	Menarche (age at onset);
CRC	trans	rs7553035	1.000	rs7542785	chr1:211691580	A/T	cg04286297	chr15:83655119	FAM103A1	-0.67	-6.02	-0.31	4.66e-9	Retinopathy in non-diabetics;
CRC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.39	7.04	0.36	1.13e-11	Longevity;
CRC	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.44	-6.48	-0.34	3.28e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs970548	0.954	rs10900221	chr10:45988597	G/A	cg15590007	chr10:45870220	ALOX5	0.48	6.03	0.32	4.49e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.73	-8.31	-0.42	2.6e-15	Obesity-related traits;
CRC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg14829360	chr17:73884958	NA	-0.44	-6.34	-0.33	7.57e-10	Psoriasis;
CRC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18834200	chr2:172017416	TLK1	0.5	7.37	0.38	1.4e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg09237302	chr4:906077	GAK	-0.43	-7.28	-0.37	2.41e-12	Systemic sclerosis;
CRC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.49	7.09	0.36	8.17e-12	Height;
CRC	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg10298567	chr3:47292165	KIF9	0.41	6.38	0.33	5.89e-10	Colorectal cancer;
CRC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg21620606	chr4:1342894	KIAA1530	0.52	9.57	0.47	2.74e-19	Longevity;
CRC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	13.67	0.6	5.57e-34	Alzheimer's disease;
CRC	trans	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg10756647	chr7:56101905	PSPH	0.69	7.1	0.36	7.8e-12	Diabetic kidney disease;
CRC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg02560186	chr11:3602584	NA	-0.63	-9.54	-0.47	3.23e-19	Blood pressure (smoking interaction);
CRC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-14.45	-0.62	5.58e-37	Systemic lupus erythematosus;
CRC	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg02702477	chr5:179499311	RNF130	0.7	7.39	0.38	1.19e-12	LDL cholesterol;
CRC	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.73	10.31	0.49	8.54e-22	Systemic lupus erythematosus;
CRC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	7.19	0.37	4.47e-12	Iron status biomarkers;
CRC	trans	rs12699921	0.632	rs2723501	chr7:17854532	A/C	cg15753394	chr6:17282781	RBM24	0.37	6.33	0.33	7.84e-10	Fibrinogen levels;
CRC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-0.96	-11.53	-0.54	4.55e-26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs9992667	0.955	rs28491682	chr4:38640889	T/C	cg19726192	chr4:38663646	FLJ13197	-0.67	-8.6	-0.43	3.31e-16	Eosinophil percentage of granulocytes;
CRC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.74	11.83	0.55	3.96e-27	Neutrophil count;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18402987	chr7:1209562	NA	0.45	6.45	0.34	3.98e-10	Longevity;Endometriosis;
CRC	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.74	-9.95	-0.48	1.47e-20	Pubertal anthropometrics;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23163999	chr3:125803012	SLC41A3	0.37	5.97	0.31	6.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.63	-0.3	3.86e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg26587870	chr6:27730563	NA	-0.6	-6.0	-0.31	5.32e-9	Breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16104446	chr8:48873951	MCM4;PRKDC	-0.55	-6.72	-0.35	7.85e-11	Diisocyanate-induced asthma;
CRC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg16447950	chr5:562315	NA	-0.85	-12.53	-0.57	1.01e-29	Obesity-related traits;
CRC	trans	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg10756647	chr7:56101905	PSPH	-0.73	-7.62	-0.39	2.71e-13	Diabetic kidney disease;
CRC	cis	rs7731657	0.510	rs986496	chr5:130282172	C/T	cg08523029	chr5:130500466	HINT1	0.49	6.19	0.32	1.83e-9	Fasting plasma glucose;
CRC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.17	-0.45	5.32e-18	Alcohol dependence;
CRC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.67	9.02	0.45	1.59e-17	Breast cancer;
CRC	cis	rs6060717	0.610	rs6060755	chr20:34606915	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.34	-0.33	7.44e-10	Hip circumference adjusted for BMI;
CRC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.6	7.89	0.4	4.4e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.52	-6.9	-0.36	2.75e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.54	6.98	0.36	1.62e-11	Height;Educational attainment;Head circumference (infant);
CRC	cis	rs7172809	0.643	rs61097729	chr15:77834358	C/G	cg10437265	chr15:77819839	NA	-0.37	-5.97	-0.31	6.13e-9	Glucose homeostasis traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15450734	chr14:103541957	NA	0.48	6.25	0.33	1.27e-9	Thyroid stimulating hormone;
CRC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg12273811	chr6:28175739	NA	0.53	7.64	0.39	2.4e-13	Parkinson's disease;
CRC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg15848620	chr12:58087721	OS9	-0.64	-9.04	-0.45	1.35e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg10978503	chr1:24200527	CNR2	0.61	11.06	0.52	2.22e-24	Immature fraction of reticulocytes;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.57	-10.58	-0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.38	12.03	0.55	6.85e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.73	13.12	0.59	6.19e-32	Hip circumference;
CRC	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.2e-12	Prostate cancer;
CRC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.81	10.1	0.49	4.39e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02290350	chr8:58132656	NA	-0.51	-6.39	-0.33	5.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.48	7.59	0.39	3.36e-13	Eye color traits;
CRC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.44	-0.33	4.26e-10	Mood instability;
CRC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.16	-0.52	9.81e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.47	6.88	0.35	3.09e-11	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02139671	chr12:123237174	DENR	0.44	6.08	0.32	3.29e-9	Response to antipsychotic treatment;
CRC	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg20542592	chr8:11973495	FAM66D	0.34	5.9	0.31	8.92e-9	Retinal vascular caliber;
CRC	cis	rs858239	0.863	rs274058	chr7:23391509	C/G	cg00469287	chr7:23338798	C7orf30	0.47	6.32	0.33	8.33e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-6.43	-0.33	4.54e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	6.39	0.33	5.56e-10	Obesity-related traits;
CRC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.73	12.02	0.55	8e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.38	-5.79	-0.3	1.63e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs6681460	0.932	rs603750	chr1:67177488	A/G	cg02459107	chr1:67143332	SGIP1	0.38	6.6	0.34	1.69e-10	Presence of antiphospholipid antibodies;
CRC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.72	11.45	0.53	8.76e-26	Tonsillectomy;
CRC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.62	8.22	0.41	4.87e-15	Gut microbiome composition (summer);
CRC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.82	11.84	0.55	3.62e-27	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25026715	chr17:26989248	SUPT6H;SDF2	0.39	6.91	0.36	2.56e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg08743896	chr10:65200160	JMJD1C	-0.43	-6.2	-0.32	1.7e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.75	10.26	0.49	1.33e-21	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.46	9.25	0.45	2.98e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.15	-0.37	5.83e-12	Total cholesterol levels;
CRC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.93	-0.66	9.48e-43	Height;
CRC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.82	14.15	0.62	8.01e-36	Coronary artery disease;
CRC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs7725052	0.609	rs6874477	chr5:40457892	C/T	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.56	8.68	0.43	1.82e-16	Breast cancer;
CRC	cis	rs2730260	0.537	rs73169248	chr7:158891742	T/G	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.56	8.48	0.42	7.99e-16	Schizophrenia;
CRC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg05569086	chr8:143859399	LYNX1	0.4	6.88	0.35	3.01e-11	Urinary tract infection frequency;
CRC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.45	0.38	8.38e-13	Blood metabolite levels;
CRC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.55	8.37	0.42	1.62e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.62	-9.97	-0.48	1.23e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.85	16.13	0.66	1.55e-43	Hip circumference;
CRC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.47	0.38	7.29e-13	Testicular germ cell tumor;
CRC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.52	6.52	0.34	2.68e-10	Methadone dose in opioid dependence;
CRC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg23136738	chr11:925521	AP2A2	-0.41	-6.86	-0.35	3.48e-11	Alzheimer's disease (late onset);
CRC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.6	8.73	0.43	1.26e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-10.0	-0.48	9.53e-21	Extrinsic epigenetic age acceleration;
CRC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.83	-0.31	1.36e-8	Lung cancer;
CRC	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg24848437	chr7:2645542	IQCE	0.56	5.98	0.31	5.87e-9	Urate levels in lean individuals;
CRC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.5	7.01	0.36	1.37e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg09127314	chr1:152161683	NA	0.46	5.93	0.31	7.69e-9	Atopic dermatitis;
CRC	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.38	5.84	0.31	1.25e-8	Red blood cell count;
CRC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg15147215	chr3:52552868	STAB1	0.4	5.66	0.3	3.31e-8	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19951424	chr15:89182208	ISG20	0.4	5.99	0.31	5.42e-9	Response to antipsychotic treatment;
CRC	cis	rs6662572	0.901	rs58692133	chr1:46067269	G/A	cg08644498	chr1:46502608	NA	0.46	6.6	0.34	1.67e-10	Blood protein levels;
CRC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-0.57	-8.24	-0.41	4.03e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg02741985	chr17:80059408	CCDC57	0.4	6.59	0.34	1.74e-10	Life satisfaction;
CRC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg21153622	chr11:89784906	NA	-0.38	-6.05	-0.32	3.99e-9	Height;
CRC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.67	6.96	0.36	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.62	6.88	0.35	3.02e-11	Coronary artery disease;
CRC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.32	0.33	8.47e-10	Lung cancer;
CRC	cis	rs6662572	0.737	rs6429590	chr1:46457250	T/C	cg08644498	chr1:46502608	NA	0.46	7.18	0.37	4.79e-12	Blood protein levels;
CRC	cis	rs7215564	0.908	rs8074870	chr17:78684132	T/C	cg09596252	chr17:78655493	RPTOR	0.58	6.24	0.33	1.36e-9	Myopia (pathological);
CRC	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg15048948	chr3:196158458	UBXN7	-0.49	-6.05	-0.32	3.89e-9	Fat distribution (HIV);
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg16447950	chr5:562315	NA	-0.84	-11.5	-0.54	6.14e-26	Lung disease severity in cystic fibrosis;
CRC	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg24519413	chr1:26490540	NA	0.37	6.29	0.33	1.01e-9	Height;
CRC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.7	-10.61	-0.5	8.03e-23	Tonsillectomy;
CRC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg24375607	chr4:120327624	NA	0.48	7.64	0.39	2.32e-13	Corneal astigmatism;
CRC	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.85	10.3	0.49	9.44e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg24998770	chr7:37888106	TXNDC3	-0.36	-5.9	-0.31	8.94e-9	Alzheimer's disease (late onset);
CRC	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-8.71	-0.43	1.51e-16	IgG glycosylation;
CRC	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.37	-7.78	-0.39	9.29e-14	Migraine;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17749468	chr2:202316740	STRADB;TRAK2	0.4	6.1	0.32	3.02e-9	Schizophrenia;
CRC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.81	-13.83	-0.61	1.3e-34	Cystic fibrosis severity;
CRC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.81	10.08	0.49	5.5e-21	Initial pursuit acceleration;
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.72	0.35	8.08e-11	Bipolar disorder;
CRC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.73	0.39	1.35e-13	Mean platelet volume;
CRC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.07	-0.32	3.55e-9	Breast cancer;Breast cancer (early onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04896168	chr1:86968543	NA	0.42	7.55	0.38	4.4e-13	Liver disease severity in Alagille syndrome;
CRC	trans	rs17041	0.783	rs7760776	chr6:108794758	T/A	cg06439005	chr5:172754848	STC2	-0.37	-5.99	-0.31	5.46e-9	Obesity-related traits;
CRC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.75	-12.49	-0.57	1.45e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12900413	0.687	rs12908489	chr15:90304269	A/G	cg24249390	chr15:90295951	MESP1	-0.57	-8.72	-0.43	1.39e-16	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs7572644	0.640	rs11901133	chr2:28069713	T/G	cg27432699	chr2:27873401	GPN1	0.45	6.1	0.32	3.03e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CRC	cis	rs6594713	0.643	rs10077431	chr5:112927686	A/C	cg12552261	chr5:112820674	MCC	-0.46	-6.09	-0.32	3.2e-9	Brain cytoarchitecture;
CRC	cis	rs2882667	0.898	rs6882330	chr5:138382182	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-5.99	-0.31	5.53e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.3	0.56	7.14e-29	Menopause (age at onset);
CRC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	15.05	0.64	2.61e-39	Multiple sclerosis;
CRC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.63	10.16	0.49	2.94e-21	Huntington's disease progression;
CRC	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg17156803	chr10:102416598	NA	-0.33	-5.64	-0.3	3.72e-8	Body mass index;
CRC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.46	6.47	0.34	3.65e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.43	0.5	3.54e-22	Systolic blood pressure;
CRC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-7.87	-0.4	5.02e-14	Gut microbiome composition (summer);
CRC	trans	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg17903999	chr18:56338584	MALT1	-0.42	-6.99	-0.36	1.52e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.39	0.38	1.24e-12	Breast cancer;
CRC	cis	rs55702914	0.809	rs6738721	chr2:198182334	A/G	cg10820045	chr2:198174542	NA	-0.49	-9.15	-0.45	6.19e-18	Major depression and alcohol dependence;
CRC	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg14593290	chr7:50529359	DDC	-0.51	-7.59	-0.39	3.32e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
CRC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.74	-0.3	2.21e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg02741985	chr17:80059408	CCDC57	-0.41	-6.7	-0.35	9.13e-11	Life satisfaction;
CRC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.4	-6.67	-0.35	1.1e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	15.65	0.65	1.16e-41	Leprosy;
CRC	cis	rs9287719	0.600	rs10197187	chr2:10726639	A/T	cg00105475	chr2:10696890	NA	0.44	7.0	0.36	1.43e-11	Prostate cancer;
CRC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	cis	rs989128	0.642	rs8076628	chr17:48626626	G/A	cg24438145	chr17:48624694	SPATA20	0.52	7.41	0.38	1.04e-12	Type 2 diabetes;
CRC	cis	rs4073416	0.542	rs9323460	chr14:65933199	T/G	cg03016385	chr14:66212404	NA	-0.41	-5.65	-0.3	3.45e-8	N-glycan levels;
CRC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.46	-7.24	-0.37	3.12e-12	Bipolar disorder and schizophrenia;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06385324	chr16:2014621	SNHG9;SNORA78;RPS2	-0.47	-5.96	-0.31	6.45e-9	Diisocyanate-induced asthma;
CRC	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg08645402	chr16:4508243	NA	0.54	7.43	0.38	9.53e-13	Schizophrenia;
CRC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.6	-0.3	4.5e-8	Morning vs. evening chronotype;
CRC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.77	0.3	1.88e-8	Homoarginine levels;
CRC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12273811	chr6:28175739	NA	0.61	8.84	0.44	5.98e-17	Cardiac Troponin-T levels;
CRC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.57	-6.26	-0.33	1.18e-9	White matter hyperintensity burden;
CRC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.43	-0.33	4.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg23815491	chr16:72088622	HP	0.52	7.96	0.4	2.74e-14	Fibrinogen levels;
CRC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-5.75	-0.3	2.08e-8	Alzheimer's disease (late onset);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg04408225	chr14:95623684	DICER1;FLJ45244	-0.41	-6.01	-0.31	4.98e-9	Myopia (pathological);
CRC	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.84	10.26	0.49	1.32e-21	Exhaled nitric oxide output;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg25164649	chr6:28176230	NA	0.75	9.32	0.46	1.72e-18	Depression;
CRC	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.43	-8.27	-0.41	3.44e-15	Migraine;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.54	-10.28	-0.49	1.09e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7605827	0.897	rs6708187	chr2:15684964	T/A	cg19274914	chr2:15703543	NA	0.38	5.8	0.3	1.59e-8	Educational attainment (years of education);
CRC	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.6	8.38	0.42	1.59e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.63	6.5	0.34	2.99e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.97	-0.48	1.28e-20	Body mass index;
CRC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.07	-0.32	3.52e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs860295	0.702	rs34620961	chr1:155649827	G/C	cg02153340	chr1:155202674	NA	-0.58	-6.97	-0.36	1.7e-11	Body mass index;
CRC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg12365402	chr11:9010492	NRIP3	-0.51	-9.1	-0.45	8.74e-18	Hemoglobin concentration;
CRC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg10589385	chr1:150898437	SETDB1	0.33	6.98	0.36	1.68e-11	Melanoma;
CRC	cis	rs6988985	0.728	rs1134095	chr8:143954290	A/G	cg10324643	chr8:143916377	GML	-0.34	-5.65	-0.3	3.55e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07590406	chr3:58292066	RPP14	-0.56	-6.93	-0.36	2.18e-11	Diisocyanate-induced asthma;
CRC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.63	8.24	0.41	4.14e-15	Bronchopulmonary dysplasia;
CRC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.75	10.32	0.49	7.97e-22	Cognitive function;
CRC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg00933542	chr6:150070202	PCMT1	0.3	6.1	0.32	2.9e-9	Lung cancer;
CRC	cis	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg18809830	chr7:99032528	PTCD1	-1.12	-8.14	-0.41	7.97e-15	Blood metabolite levels;
CRC	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.53	-0.38	4.98e-13	Menarche (age at onset);
CRC	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.98	0.31	5.72e-9	Migraine;
CRC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg24011408	chr12:48396354	COL2A1	0.47	6.39	0.33	5.64e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.4	-0.56	3.16e-29	Alzheimer's disease;
CRC	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.85	10.75	0.51	2.7e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.71	0.6	3.81e-34	Breast cancer;
CRC	cis	rs12760731	0.777	rs6701080	chr1:178382261	A/C	cg00404053	chr1:178313656	RASAL2	1.16	11.74	0.54	8.13e-27	Obesity-related traits;
CRC	cis	rs6066835	1.000	rs6066832	chr20:47354132	C/A	cg18078177	chr20:47281410	PREX1	0.63	5.78	0.3	1.7e-8	Multiple myeloma;
CRC	cis	rs776905	0.598	rs561241	chr13:113760034	T/C	cg09069900	chr13:113776964	F10	-0.49	-7.45	-0.38	8.3e-13	Blood protein levels;
CRC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg04731861	chr2:219085781	ARPC2	0.3	6.29	0.33	1.01e-9	Colorectal cancer;
CRC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg00074818	chr8:8560427	CLDN23	0.41	7.36	0.38	1.44e-12	Obesity-related traits;
CRC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.56	9.87	0.48	2.67e-20	Huntington's disease progression;
CRC	trans	rs11581859	0.950	rs7529415	chr1:99370765	C/G	cg12183875	chr3:169587454	LRRC31	-0.27	-6.29	-0.33	1e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.41	-8.65	-0.43	2.39e-16	Bipolar disorder;
CRC	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg15382696	chr6:118971807	C6orf204	0.6	7.95	0.4	3.06e-14	Diastolic blood pressure;
CRC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg10911889	chr6:126070802	HEY2	0.38	5.68	0.3	3.03e-8	Brugada syndrome;
CRC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.6	-6.27	-0.33	1.11e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12745968	0.589	rs10782937	chr1:93103201	T/C	cg17283838	chr1:93427260	FAM69A	-0.48	-6.46	-0.34	3.87e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11645453	chr3:52864694	ITIH4	0.35	6.11	0.32	2.81e-9	Bipolar disorder;
CRC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.43	6.87	0.35	3.26e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.64	8.85	0.44	5.61e-17	Coronary artery disease;
CRC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg03395511	chr6:291903	DUSP22	-0.51	-6.91	-0.36	2.53e-11	Menopause (age at onset);
CRC	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg09873164	chr1:152488093	CRCT1	0.36	5.92	0.31	7.89e-9	Hair morphology;
CRC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.58	-0.43	3.8e-16	Life satisfaction;
CRC	cis	rs9491140	0.539	rs11154232	chr6:124691494	G/A	cg19267163	chr6:125004984	NKAIN2	0.54	6.89	0.35	2.9e-11	Neuroticism;
CRC	trans	rs783540	0.934	rs36109438	chr15:83264459	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.38	-6.43	-0.33	4.53e-10	Schizophrenia;
CRC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg03623178	chr6:28175578	NA	0.87	12.94	0.58	2.98e-31	Parkinson's disease;
CRC	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.13	-0.41	9.12e-15	Coffee consumption (cups per day);
CRC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.38	6.59	0.34	1.71e-10	Primary biliary cholangitis;
CRC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.1	0.32	2.91e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.52	-9.26	-0.45	2.63e-18	Coronary artery disease;
CRC	cis	rs1572438	0.931	rs9406099	chr6:867030	A/G	cg13447295	chr6:887704	NA	-0.47	-6.84	-0.35	3.98e-11	Aging;
CRC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.4	-0.33	5.41e-10	Monocyte percentage of white cells;
CRC	cis	rs13315871	0.929	rs13066351	chr3:58398215	C/T	cg20936604	chr3:58311152	NA	-0.77	-7.28	-0.37	2.55e-12	Cholesterol, total;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26743555	chr16:67194948	TRADD;FBXL8	0.43	6.02	0.31	4.7e-9	Response to antipsychotic treatment;
CRC	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.6	8.44	0.42	1.02e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs16867335	1.000	rs76934807	chr2:181488585	T/A	cg23363182	chr2:181467187	NA	-0.5	-6.38	-0.33	6.18e-10	Survival in rectal cancer;
CRC	trans	rs469722	0.965	rs32238	chr5:127693525	A/C	cg14939821	chr10:128947230	DOCK1;FAM196A	-0.31	-6.46	-0.34	3.74e-10	Cancer;
CRC	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	9.28	0.46	2.3e-18	Iron status biomarkers;
CRC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.71	0.75	1.47e-61	Prudent dietary pattern;
CRC	cis	rs89107	0.576	rs4307206	chr6:118813320	A/C	cg15382696	chr6:118971807	C6orf204	0.36	5.7	0.3	2.71e-8	Cardiac structure and function;
CRC	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.0	-0.31	5.3300000000000004e-09	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07394347	chr3:37285773	GOLGA4	0.47	6.72	0.35	7.98e-11	Response to antipsychotic treatment;
CRC	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.42	-0.65	9.04e-41	Exhaled nitric oxide output;
CRC	trans	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.51	7.59	0.39	3.37e-13	Endometrial cancer;
CRC	cis	rs7605827	0.930	rs11681044	chr2:15717058	G/A	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	1.02e-8	Educational attainment (years of education);
CRC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.86	12.98	0.58	2.24e-31	Cognitive function;
CRC	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg20356878	chr3:121714668	ILDR1	0.52	7.99	0.4	2.31e-14	Cognitive performance;
CRC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.8	15.29	0.64	2.98e-40	Prudent dietary pattern;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25381775	chr1:6259495	RPL22	0.37	6.01	0.31	5.03e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg21770322	chr7:97807741	LMTK2	0.52	8.59	0.43	3.48e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg18016565	chr1:150552671	MCL1	-0.4	-5.7	-0.3	2.66e-8	Melanoma;
CRC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg00339695	chr16:24857497	SLC5A11	-0.26	-6.17	-0.32	2.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs891088	0.614	rs41315074	chr19:7184243	C/G	cg00428638	chr19:7224713	INSR	-0.54	-5.78	-0.3	1.7e-8	Hip circumference adjusted for BMI;Height;
CRC	cis	rs73206853	0.620	rs73194023	chr12:111137940	G/A	cg12870014	chr12:110450643	ANKRD13A	0.76	6.49	0.34	3.24e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.65	8.51	0.42	6.42e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	8.42	0.42	1.18e-15	Platelet count;
CRC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-8.37	-0.42	1.72e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9462027	0.628	rs2814991	chr6:34615443	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.23	-0.32	1.41e-9	Systemic lupus erythematosus;
CRC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-8.15	-0.41	7.64e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg20512303	chr5:131592959	PDLIM4	0.36	6.77	0.35	6.09e-11	Breast cancer;
CRC	cis	rs7212590	0.748	rs8074176	chr17:57861995	G/A	cg10252138	chr17:58120427	NA	-0.55	-5.98	-0.31	5.93e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg04518342	chr5:131593106	PDLIM4	0.36	6.78	0.35	5.52e-11	Blood metabolite levels;
CRC	cis	rs3823572	0.504	rs2953633	chr7:133644052	A/C	cg03336402	chr7:133662267	EXOC4	-0.66	-10.28	-0.49	1.14e-21	Intelligence (multi-trait analysis);
CRC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.23	15.05	0.64	2.68e-39	Eosinophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16229772	chr11:535615	HRAS	0.43	6.37	0.33	6.23e-10	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.06	13.33	0.59	1.06e-32	Vitiligo;
CRC	cis	rs17713451	0.593	rs78218801	chr7:151269007	G/A	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg05784532	chr1:230284198	GALNT2	0.44	6.19	0.32	1.75e-9	Coronary artery disease;
CRC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg07274523	chr3:49395745	GPX1	0.46	6.27	0.33	1.11e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg19913688	chr11:428466	ANO9	-0.7	-6.88	-0.35	3.01e-11	Body mass index;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02203542	chr20:305175	SOX12	0.42	6.17	0.32	1.99e-9	Schizophrenia;
CRC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.7	-10.11	-0.49	4.13e-21	Vitiligo;
CRC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg21951975	chr1:209979733	IRF6	0.47	5.62	0.3	4.05e-8	Cleft lip with or without cleft palate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21548116	chr4:100009993	ADH5	0.37	5.98	0.31	5.81e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.68	9.63	0.47	1.72e-19	Body mass index;
CRC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.64	-9.66	-0.47	1.34e-19	Mean platelet volume;Platelet distribution width;
CRC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-6.33	-0.33	7.97e-10	Menarche (age at onset);
CRC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.14	0.32	2.4e-9	Prudent dietary pattern;
CRC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg11292332	chr7:45801988	SEPT13	-0.39	-7.05	-0.36	1.05e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.56	0.34	2.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26778029	chr7:74072136	GTF2I	0.41	6.05	0.32	4.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.13	21.01	0.76	9.76e-63	Cognitive function;
CRC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.96	0.31	6.41e-9	Lung cancer;
CRC	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg09596252	chr17:78655493	RPTOR	0.6	5.63	0.3	3.79e-8	Myopia (pathological);
CRC	cis	rs2415984	0.622	rs61993296	chr14:46934216	C/T	cg14871534	chr14:47121158	RPL10L	-0.44	-6.18	-0.32	1.86e-9	Number of children ever born;
CRC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.94	-17.88	-0.7	2e-50	Intelligence (multi-trait analysis);
CRC	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.84	-11.81	-0.55	4.57e-27	Platelet distribution width;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24704015	chr2:230931896	SLC16A14	0.42	6.64	0.34	1.3e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7731657	0.537	rs13355897	chr5:130360622	G/A	cg08523029	chr5:130500466	HINT1	-0.45	-5.83	-0.31	1.3e-8	Fasting plasma glucose;
CRC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg27432699	chr2:27873401	GPN1	-0.52	-7.96	-0.4	2.91e-14	Total body bone mineral density;
CRC	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.66	-10.7	-0.51	4.01e-23	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	14.06	0.61	1.71e-35	Alzheimer's disease;
CRC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.39	0.33	5.77e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg15845792	chr6:28175446	NA	0.67	6.68	0.35	9.96e-11	Depression;
CRC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.31	-0.49	9.07e-22	Tonsillectomy;
CRC	cis	rs9649465	0.967	rs12539091	chr7:123291314	C/T	cg03229431	chr7:123269106	ASB15	-0.37	-5.67	-0.3	3.14e-8	Migraine;
CRC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.67	-8.88	-0.44	4.26e-17	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.59	-8.74	-0.43	1.25e-16	Obesity-related traits;
CRC	trans	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg24628676	chr5:59189846	PDE4D	-0.3	-6.08	-0.32	3.26e-9	Urinary tract infection frequency;
CRC	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.39	-6.02	-0.32	4.6e-9	Obesity;
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.55	8.29	0.42	2.93e-15	Obesity-related traits;
CRC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.98	0.36	1.6e-11	Coronary artery disease;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg25164649	chr6:28176230	NA	0.79	11.08	0.52	1.9e-24	Depression;
CRC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.46	5.8	0.3	1.53e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs73206853	0.640	rs3825390	chr12:110976409	A/C	cg12870014	chr12:110450643	ANKRD13A	0.77	9.69	0.47	1.05e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg17321639	chr7:2759063	NA	-0.53	-7.04	-0.36	1.15e-11	Height;
CRC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg00255919	chr5:131827918	IRF1	-0.37	-6.27	-0.33	1.11e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.83	11.96	0.55	1.28e-27	Gut microbiome composition (summer);
CRC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.95	0.31	6.72e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.44	-6.27	-0.33	1.15e-9	Aortic root size;
CRC	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg16342193	chr10:102329863	NA	-0.35	-5.62	-0.3	4e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg18833306	chr6:118973337	C6orf204	0.45	6.01	0.31	4.81e-9	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg16669491	chr19:19314215	NR2C2AP	0.49	6.85	0.35	3.62e-11	Response to antipsychotic treatment;
CRC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.49	5.65	0.3	3.42e-8	Gut microbiome composition (summer);
CRC	cis	rs7619833	0.715	rs4973766	chr3:27413566	C/T	cg02860705	chr3:27208620	NA	0.39	5.79	0.3	1.61e-8	Breast cancer;
CRC	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.48	7.18	0.37	4.56e-12	Red blood cell count;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.71	11.61	0.54	2.4e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg12193833	chr17:30244370	NA	-0.59	-7.76	-0.39	1.06e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.63	9.87	0.48	2.75e-20	Blood metabolite levels;
CRC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.64	6.78	0.35	5.72e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	9.4	0.46	9.63e-19	Nonalcoholic fatty liver disease;
CRC	cis	rs7605827	0.897	rs6431698	chr2:15540156	G/C	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.79e-9	Educational attainment (years of education);
CRC	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-15.04	-0.64	2.94e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg08200582	chr11:442649	ANO9	-0.71	-7.33	-0.37	1.83e-12	Body mass index;
CRC	cis	rs7804356	1.000	rs6461979	chr7:26888918	T/C	cg03456212	chr7:26904342	SKAP2	-0.5	-5.69	-0.3	2.85e-8	Type 1 diabetes;
CRC	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.76	10.09	0.49	5.05e-21	Coronary artery disease;
CRC	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	cg04338863	chr8:33670619	NA	0.42	6.76	0.35	6.19e-11	Body mass index;
CRC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg19622623	chr12:86230825	RASSF9	-0.41	-6.77	-0.35	5.76e-11	Major depressive disorder;
CRC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.62	0.3	4.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg18512352	chr11:47633146	NA	-0.33	-6.36	-0.33	6.65e-10	Subjective well-being;
CRC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	11.91	0.55	1.9e-27	Platelet count;
CRC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.55	-8.3	-0.42	2.68e-15	Schizophrenia;
CRC	cis	rs4743820	0.651	rs73494914	chr9:93923108	G/A	cg14446406	chr9:93919335	NA	0.81	14.88	0.63	1.24e-38	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg14844989	chr11:31128820	NA	-0.34	-5.9	-0.31	9.08e-9	Red blood cell count;
CRC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg27661571	chr11:113659931	NA	-0.96	-11.11	-0.52	1.42e-24	Hip circumference adjusted for BMI;
CRC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.48	-7.44	-0.38	8.6e-13	Type 2 diabetes;
CRC	trans	rs660498	0.785	rs9418630	chr10:27734215	G/A	cg13661793	chr10:32399026	NA	-0.33	-5.99	-0.31	5.51e-9	Asthma (childhood onset);
CRC	cis	rs3751196	0.808	rs17034640	chr12:104218137	A/G	cg02344784	chr12:104178138	NT5DC3	-0.65	-7.23	-0.37	3.4e-12	Sense of smell;
CRC	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.64	7.58	0.39	3.65e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg06470822	chr6:28175283	NA	0.98	13.09	0.59	8.7e-32	Depression;
CRC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-7.67	-0.39	1.92e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-5.97	-0.31	6.28e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.94	0.31	7.39e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	3.08e-24	Corneal astigmatism;
CRC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.84	-0.31	1.22e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.7	0.35	9.06e-11	Resting heart rate;
CRC	cis	rs1403694	1.000	rs1403694	chr3:186439998	T/C	cg04611788	chr3:186434169	KNG1	-0.46	-7.13	-0.37	6.6e-12	Blood protein levels;
CRC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg20512303	chr5:131592959	PDLIM4	0.29	5.69	0.3	2.87e-8	Blood metabolite levels;
CRC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.43	-7.19	-0.37	4.49e-12	Major depressive disorder;
CRC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg19688584	chr6:167529678	CCR6	-0.32	-5.73	-0.3	2.25e-8	Primary biliary cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01747036	chr13:113140125	TUBGCP3	-0.39	-6.04	-0.32	4.1e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.84	-0.31	1.26e-8	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs2898857	0.504	rs12937923	chr17:47408475	G/A	cg11430096	chr6:110968061	CDK19	-0.49	-7.43	-0.38	9.2e-13	Cancer;
CRC	trans	rs2303319	0.504	rs961421	chr2:162626099	G/C	cg04551154	chr10:95462393	C10orf4	-0.74	-6.34	-0.33	7.76e-10	Cognitive function;
CRC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.44	-6.73	-0.35	7.71e-11	Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11797222	chr15:66679417	MAP2K1	0.4	6.11	0.32	2.8e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.78	-12.46	-0.57	1.92e-29	Plateletcrit;Platelet count;
CRC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg23565292	chr14:50234668	KLHDC2	-0.4	-5.7	-0.3	2.66e-8	Carotid intima media thickness;
CRC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.08	-0.36	8.59e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg03070588	chr12:109490239	USP30	0.56	5.98	0.31	5.7e-9	Body mass index;
CRC	cis	rs526821	0.595	rs608964	chr11:55339266	G/A	cg04317927	chr11:55418816	OR4S2	0.39	6.6	0.34	1.68e-10	Pediatric bone mineral density (spine);
CRC	cis	rs6694672	1.000	rs9427657	chr1:196943321	A/G	cg13682187	chr1:196946512	CFHR5	-0.47	-6.99	-0.36	1.56e-11	Asthma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01796184	chr1:200708096	CAMSAP1L1	0.47	6.66	0.34	1.16e-10	Response to antipsychotic treatment;
CRC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.76	-0.3	1.89e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-17.87	-0.7	2.13e-50	Height;
CRC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs6921919	0.848	rs6903823	chr6:28322296	A/G	cg21251018	chr6:28226885	NKAPL	0.41	5.78	0.3	1.74e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.63	-9.83	-0.48	3.76e-20	Cognitive function;
CRC	trans	rs10021731	0.692	rs11722162	chr4:115411616	C/T	cg25927708	chr2:119603813	EN1	-0.33	-6.01	-0.31	4.92e-9	Optic disc area;
CRC	cis	rs8105895	0.778	rs10401922	chr19:22253252	T/A	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.81	13.5	0.6	2.34e-33	Height;
CRC	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.76	10.2	0.49	2.11e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.47	7.31	0.37	2.04e-12	Capecitabine sensitivity;
CRC	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg12924262	chr12:102091054	CHPT1	0.55	8.13	0.41	9.12e-15	Blood protein levels;
CRC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.43	0.46	7.56e-19	Bladder cancer;
CRC	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.77	15.53	0.65	3.57e-41	Leprosy;
CRC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.61	9.7	0.47	9.88e-20	Mean corpuscular hemoglobin;
CRC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.68e-19	Corneal astigmatism;
CRC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.3	-0.37	2.15e-12	Reticulocyte fraction of red cells;
CRC	cis	rs12936587	0.569	rs8073683	chr17:17555596	C/T	cg09796270	chr17:17721594	SREBF1	-0.45	-7.54	-0.38	4.74e-13	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	7.07	0.36	9.28e-12	Breast cancer;
CRC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.78	11.48	0.53	7.05e-26	High light scatter reticulocyte count;
CRC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.79	-0.39	8.68e-14	Longevity;Endometriosis;
CRC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg21784768	chr11:537496	LRRC56	-0.7	-6.67	-0.35	1.07e-10	Body mass index;
CRC	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00495681	chr13:53174319	NA	0.58	8.77	0.44	1.01e-16	Lewy body disease;
CRC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.14	0.74	2.41e-59	Prudent dietary pattern;
CRC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.23	0.53	5.38e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.94e-9	Schizophrenia;
CRC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
CRC	cis	rs7605827	0.893	rs7575722	chr2:15597551	G/A	cg19274914	chr2:15703543	NA	0.39	5.96	0.31	6.58e-9	Educational attainment (years of education);
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.99	-0.4	2.24e-14	Total body bone mineral density;
CRC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.02	-20.56	-0.75	5.24e-61	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26734620	chr12:56694298	CS	-0.62	-5.93	-0.31	7.84e-9	Psoriasis vulgaris;
CRC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.61	-9.99	-0.48	1.08e-20	Tuberculosis;
CRC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.81	0.35	4.57e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.55	6.47	0.34	3.59e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg06042504	chr8:55087323	NA	-0.36	-5.76	-0.3	1.95e-8	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.54	0.34	2.37e-10	Bone mineral density;
CRC	cis	rs7680126	0.596	rs4698032	chr4:10316582	T/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.79	-0.3	1.6e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.17	25.75	0.82	7.25e-81	IgG glycosylation;
CRC	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.25	14.99	0.64	4.45e-39	Lung disease severity in cystic fibrosis;
CRC	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	1.12	16.54	0.67	3.97e-45	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg18683604	chr14:51561293	TRIM9	0.3	6.11	0.32	2.84e-9	Cancer;
CRC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	0.81	6.37	0.33	6.5e-10	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs55788414	0.932	rs8048115	chr16:81182554	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.78	-0.35	5.73e-11	Left ventricular obstructive tract defect (maternal effect);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02060698	chr6:108881455	FOXO3	0.47	6.63	0.34	1.38e-10	Response to antipsychotic treatment;
CRC	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.46	7.54	0.38	4.63e-13	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.53	7.19	0.37	4.51e-12	Caudate activity during reward;
CRC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.67	-0.3	3.07e-8	Schizophrenia;
CRC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.87	0.31	1.06e-8	Tonsillectomy;
CRC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.71	7.97	0.4	2.64e-14	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.47	6.76	0.35	6.21e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.39	-7.0	-0.36	1.45e-11	Reticulocyte fraction of red cells;
CRC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06544989	chr22:39130855	UNC84B	-0.43	-6.32	-0.33	8.67e-10	Menopause (age at onset);
CRC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.23	-0.41	4.56e-15	Height;
CRC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.45	5.86	0.31	1.13e-8	Total body bone mineral density;
CRC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg15309053	chr8:964076	NA	0.34	6.03	0.32	4.44e-9	Schizophrenia;
CRC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg22638593	chr5:131593259	PDLIM4	-0.38	-6.32	-0.33	8.68e-10	Breast cancer;
CRC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.81	-12.8	-0.58	1.02e-30	Cognitive function;
CRC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.5	10.97	0.52	4.61e-24	Alcohol dependence;
CRC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-13.35	-0.59	8.55e-33	Glomerular filtration rate (creatinine);
CRC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.6	-7.41	-0.38	1.06e-12	Obesity (extreme);
CRC	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.72	0.3	2.37e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.91e-11	Primary biliary cholangitis;
CRC	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.58	-6.0	-0.31	5.11e-9	Opioid sensitivity;
CRC	cis	rs9650315	0.530	rs68005065	chr8:57090308	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.45	6.29	0.33	9.96e-10	Height;
CRC	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg06522879	chr11:64358276	SLC22A12	-0.59	-9.38	-0.46	1.11e-18	Urate levels in obese individuals;
CRC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg27534772	chr1:16042836	PLEKHM2	0.56	10.79	0.51	1.98e-23	Systolic blood pressure;
CRC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	5.89	0.31	9.3e-9	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	12.11	0.56	3.74e-28	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs4437462	0.945	rs16871246	chr6:11312080	G/A	cg25250968	chr6:11318770	NEDD9	-0.4	-5.86	-0.31	1.1e-8	HIV-1 susceptibility;
CRC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.42	9.18	0.45	4.89e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.48	-5.89	-0.31	9.37e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg09659197	chr4:152720779	NA	0.52	11.24	0.53	4.87e-25	Intelligence (multi-trait analysis);
CRC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg03623178	chr6:28175578	NA	0.53	6.1	0.32	2.94e-9	Breast cancer;
CRC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.52	10.62	0.51	7.35e-23	Bone mineral density;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg11237535	chr17:78075184	GAA	0.47	6.64	0.34	1.3100000000000001e-10	Anxiety disorder;
CRC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.43	8.11	0.41	9.96e-15	Childhood ear infection;
CRC	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg21251018	chr6:28226885	NKAPL	0.39	5.93	0.31	7.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs58649573	0.530	rs7049026	chr9:126786918	A/C	cg14112217	chr9:126806003	NA	0.4	5.76	0.3	1.97e-8	Post-traumatic stress disorder;
CRC	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.61	-5.69	-0.3	2.78e-8	Yeast infection;
CRC	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.65	9.72	0.47	8.71e-20	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs12438356	0.686	rs16952899	chr15:69468885	T/C	cg16612806	chr11:124592229	NA	-0.42	-6.24	-0.33	1.35e-9	CTACK levels;
CRC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg23625390	chr15:77176239	SCAPER	0.5	7.16	0.37	5.43e-12	Blood metabolite levels;
CRC	cis	rs7605827	0.930	rs4140713	chr2:15536128	C/T	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.33	-0.56	5.79e-29	Exhaled nitric oxide output;
CRC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.63	-0.75	2.81e-61	Height;
CRC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.63	0.43	2.76e-16	Menopause (age at onset);
CRC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.09	-0.41	1.15e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg15843009	chr14:69864932	ERH;SLC39A9	-0.66	-5.96	-0.31	6.38e-9	Cognitive function;
CRC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg02725872	chr8:58115012	NA	-0.35	-5.99	-0.31	5.5e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.55	8.02	0.4	1.92e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16226300	chr6:133136135	RPS12;SNORD101	-0.42	-6.3	-0.33	9.56e-10	Brain structure;
CRC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.58	10.0	0.48	9.56e-21	Intelligence (multi-trait analysis);
CRC	cis	rs6973256	0.605	rs13237435	chr7:133347570	C/T	cg10665199	chr7:133106180	EXOC4	-0.47	-7.47	-0.38	7.47e-13	Intelligence (multi-trait analysis);
CRC	trans	rs11661542	0.967	rs11082043	chr18:20222985	C/G	cg00692559	chr1:156737950	PRCC	-0.41	-5.97	-0.31	5.99e-9	Intracranial aneurysm;
CRC	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.61	8.13	0.41	8.57e-15	HDL cholesterol levels;HDL cholesterol;
CRC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg01987224	chr1:201084466	NA	0.52	9.88	0.48	2.46e-20	Permanent tooth development;
CRC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.5	8.51	0.42	6.17e-16	Coronary artery disease;
CRC	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg10437265	chr15:77819839	NA	0.55	7.31	0.37	2.01e-12	Risky sexual behaviors (alcohol dependence interaction);
CRC	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.59	7.5	0.38	5.91e-13	RR interval (heart rate);
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12273811	chr6:28175739	NA	0.61	8.88	0.44	4.33e-17	Cardiac Troponin-T levels;
CRC	trans	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg19188899	chr13:112838565	NA	-0.41	-6.4	-0.33	5.35e-10	Systemic lupus erythematosus;
CRC	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.33	7.66	0.39	2.15e-13	Corneal astigmatism;
CRC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.77	-0.72	5.95e-54	Height;
CRC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.08	-0.49	5.46e-21	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg20203395	chr5:56204925	C5orf35	0.43	6.14	0.32	2.31e-9	Coronary artery disease;
CRC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.78	12.81	0.58	9.18e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.66	-10.15	-0.49	3.15e-21	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.76	-14.53	-0.63	2.74e-37	Body mass index;
CRC	cis	rs12541635	0.934	rs1353450	chr8:107035120	A/G	cg10147462	chr8:107024639	NA	-0.46	-7.92	-0.4	3.66e-14	Age of smoking initiation;
CRC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg18758796	chr5:131593413	PDLIM4	0.34	6.06	0.32	3.65e-9	Blood metabolite levels;
CRC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg14828511	chr1:107599125	PRMT6	0.52	7.13	0.37	6.56e-12	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.41	6.21	0.32	1.61e-9	Endometrial cancer;
CRC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.51	7.1	0.36	7.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.14	-0.41	7.99e-15	Hemoglobin concentration;
CRC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg24560729	chr4:1342394	KIAA1530	0.43	7.4	0.38	1.16e-12	Longevity;
CRC	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg12315302	chr6:26189340	HIST1H4D	0.77	6.0	0.31	5.13e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg02683197	chr6:28174875	NA	0.82	10.05	0.48	6.9e-21	Depression;
CRC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg25985355	chr7:65971099	NA	0.32	5.71	0.3	2.54e-8	Aortic root size;
CRC	cis	rs7705042	0.686	rs10068466	chr5:141524612	C/T	cg07392085	chr5:141489673	NDFIP1	-0.41	-5.96	-0.31	6.36e-9	Asthma;
CRC	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.12	-0.32	2.62e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg18523371	chr4:108911521	HADH	0.49	6.1	0.32	2.95e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9361491	0.605	rs1185343	chr6:79436190	G/C	cg05283184	chr6:79620031	NA	-0.37	-5.69	-0.3	2.84e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-5.64	-0.3	3.62e-8	Major depressive disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20693608	chr4:113152836	AP1AR	0.36	6.11	0.32	2.87e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg03923535	chr7:1197113	ZFAND2A	0.57	8.19	0.41	5.85e-15	Longevity;Endometriosis;
CRC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.62	9.4	0.46	9.33e-19	Testicular germ cell tumor;
CRC	cis	rs10911390	0.744	rs12034563	chr1:183591769	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.76	6.93	0.36	2.16e-11	Systemic lupus erythematosus;
CRC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.94	-0.4	3.15e-14	Putamen volume;
CRC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg10298567	chr3:47292165	KIF9	0.38	6.09	0.32	3.06e-9	Colorectal cancer;
CRC	trans	rs3807766	0.581	rs6954104	chr7:77693258	C/T	cg24378470	chr17:9478950	WDR16;STX8	-0.51	-7.07	-0.36	9.57e-12	3-hydroxypropylmercapturic acid levels in smokers;
CRC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.35	-0.33	7.27e-10	Alzheimer's disease (late onset);
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.17	0.37	5.1e-12	Life satisfaction;
CRC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg18288967	chr1:45987694	PRDX1	0.68	7.19	0.37	4.41e-12	Obesity-related traits;
CRC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg14541582	chr5:601475	NA	-0.33	-6.6	-0.34	1.61e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.7	-9.3	-0.46	2.05e-18	Alzheimer's disease;
CRC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg06287003	chr12:125626642	AACS	-0.58	-7.5	-0.38	5.99e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	5.83	0.31	1.36e-8	Mood instability;
CRC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.46	6.96	0.36	1.84e-11	Menopause (age at onset);
CRC	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg09659197	chr4:152720779	NA	0.31	5.64	0.3	3.65e-8	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg17903999	chr18:56338584	MALT1	-0.42	-6.72	-0.35	8e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs919433	0.756	rs7575389	chr2:198198489	A/G	cg20885578	chr2:198174922	NA	-0.35	-5.75	-0.3	2.08e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2072510	0.593	rs2660838	chr12:96416383	T/C	cg15438951	chr12:96389694	HAL	-0.48	-5.83	-0.31	1.32e-8	Metabolite levels (small molecules and protein measures);
CRC	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg04218760	chr10:45406644	TMEM72	-0.31	-7.41	-0.38	1.05e-12	Mean corpuscular volume;
CRC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-9.84	-0.48	3.49e-20	Menarche (age at onset);
CRC	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg15234197	chr11:68924956	NA	0.42	5.8	0.3	1.57e-8	Blond vs. brown hair color;
CRC	cis	rs501120	0.810	rs535176	chr10:44747059	C/T	cg09554077	chr10:44749378	NA	0.89	13.2	0.59	3.2e-32	Coronary artery disease;Coronary heart disease;
CRC	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.47	5.7	0.3	2.67e-8	Coronary artery calcification;
CRC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13198984	chr17:80129470	CCDC57	0.47	8.31	0.42	2.54e-15	Life satisfaction;
CRC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg26260408	chr4:53727979	RASL11B	0.49	5.61	0.3	4.29e-8	Optic nerve measurement (cup area);
CRC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11446398	chr5:77624930	NA	0.46	6.1	0.32	3.02e-9	Triglycerides;
CRC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs2108622	0.727	rs7253684	chr19:15981126	C/T	cg13772218	chr19:15982569	NA	0.48	6.81	0.35	4.52e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.56	6.36	0.33	6.77e-10	Osteoarthritis;
CRC	cis	rs4658101	0.689	rs6604044	chr1:92051670	C/T	cg24006770	chr1:92056542	NA	0.46	6.8	0.35	4.96e-11	Optic disc area;Vertical cup-disc ratio;
CRC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-8.12	-0.41	9.29e-15	Type 2 diabetes;
CRC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg25452165	chr22:42524984	CYP2D6	-0.43	-6.88	-0.35	3.09e-11	Cognitive function;
CRC	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.47	9.04	0.45	1.43e-17	Educational attainment (years of education);
CRC	cis	rs6834538	1.000	rs6816676	chr4:113483843	T/C	cg10021238	chr4:113569128	MIR367;LARP7	-0.46	-6.54	-0.34	2.32e-10	Free thyroxine concentration;
CRC	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg18232548	chr7:50535776	DDC	0.45	5.86	0.31	1.12e-8	Malaria;
CRC	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.57	10.17	0.49	2.73e-21	Menarche (age at onset);
CRC	cis	rs720844	1.000	rs12619201	chr2:149333358	T/C	cg09247360	chr2:149335327	NA	-0.61	-7.69	-0.39	1.68e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.84	-0.35	3.9e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg11843238	chr5:131593191	PDLIM4	0.49	9.29	0.46	2.11e-18	Acylcarnitine levels;
CRC	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg23100626	chr2:96804247	ASTL	0.27	7.11	0.36	7.24e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg03233332	chr7:66118400	NA	0.45	6.29	0.33	9.96e-10	Aortic root size;
CRC	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.88	0.31	1.02e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9303542	0.694	rs9906950	chr17:46577167	A/G	cg04904318	chr17:46607828	HOXB1	0.46	6.02	0.32	4.57e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.67	-0.3	3.09e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg13206674	chr6:150067644	NUP43	0.48	6.95	0.36	1.93e-11	Testicular germ cell tumor;
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg15786705	chr6:28176104	NA	0.68	10.18	0.49	2.51e-21	Cardiac Troponin-T levels;
CRC	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.48	-8.96	-0.44	2.52e-17	Intelligence (multi-trait analysis);
CRC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.73	-9.77	-0.47	5.67e-20	Initial pursuit acceleration;
CRC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.28	-0.42	3.07e-15	Bladder cancer;
CRC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg11632617	chr15:75315747	PPCDC	-0.52	-7.01	-0.36	1.32e-11	Blood trace element (Zn levels);
CRC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg09655341	chr17:79618100	PDE6G	-0.35	-6.05	-0.32	3.92e-9	Eye color traits;
CRC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-14.46	-0.62	5.11e-37	Blood metabolite levels;
CRC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.98	-19.27	-0.73	6.62e-56	Height;
CRC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg17724175	chr1:150552817	MCL1	0.49	7.18	0.37	4.57e-12	Melanoma;
CRC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.74	12.97	0.58	2.27e-31	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.74	-0.47	7.57e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.67	10.04	0.48	7.41e-21	Corneal astigmatism;
CRC	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.67	8.92	0.44	3.39e-17	Uric acid levels;
CRC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.47	6.65	0.34	1.21e-10	Response to temozolomide;
CRC	cis	rs4664293	0.647	rs2162023	chr2:160426230	G/C	cg08347373	chr2:160653686	CD302	-0.39	-6.59	-0.34	1.76e-10	Monocyte percentage of white cells;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg03804128	chr16:635623	NA	0.28	6.49	0.34	3.2e-10	Height;
CRC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg27661571	chr11:113659931	NA	0.62	7.23	0.37	3.45e-12	Hip circumference adjusted for BMI;
CRC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.33	5.62	0.3	4.02e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg27398640	chr15:77910606	LINGO1	-0.42	-7.0	-0.36	1.43e-11	Type 2 diabetes;
CRC	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg16898833	chr6:26189333	HIST1H4D	0.85	6.28	0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.47	5.9	0.31	9.21e-9	Aortic root size;
CRC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.66	-6.97	-0.36	1.79e-11	Axial length;
CRC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.92	16.91	0.68	1.29e-46	Intelligence (multi-trait analysis);
CRC	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg02811702	chr13:24901961	NA	0.47	6.59	0.34	1.7e-10	Obesity-related traits;
CRC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg05585544	chr11:47624801	NA	-0.62	-11.41	-0.53	1.22e-25	Subjective well-being;
CRC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.68	0.39	1.89e-13	Major depressive disorder;
CRC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.81	12.55	0.57	8.49e-30	Glomerular filtration rate (creatinine);
CRC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.61	-9.95	-0.48	1.45e-20	Aortic root size;
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.71	9.49	0.46	4.86e-19	Alzheimer's disease;
CRC	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-7.22	-0.37	3.71e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.19	-26.05	-0.82	5.89e-82	Exhaled nitric oxide output;
CRC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	9.16	0.45	5.66e-18	Platelet count;
CRC	cis	rs939574	0.722	rs55951006	chr2:220132151	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.86	7.88	0.4	4.93e-14	Platelet distribution width;
CRC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg25956985	chr22:39795188	MAP3K7IP1	0.45	6.71	0.35	8.53e-11	IgG glycosylation;
CRC	cis	rs4731207	0.596	rs7794538	chr7:124648850	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.99e-9	Cutaneous malignant melanoma;
CRC	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg21251018	chr6:28226885	NKAPL	0.39	6.1	0.32	2.91e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.61	6.56	0.34	2.03e-10	Axial length;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20959894	chr7:27779871	TAX1BP1	-0.39	-6.03	-0.32	4.49e-9	Myopia (pathological);
CRC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.51	8.56	0.43	4.3e-16	Aortic root size;
CRC	cis	rs939317	0.678	rs843372	chr3:183996213	C/T	cg09405238	chr3:183994500	ECE2	0.52	6.15	0.32	2.23e-9	Menarche (age at onset);
CRC	cis	rs3736485	0.966	rs7170444	chr15:51890500	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.42	-0.33	4.76e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9891119	0.576	rs6503696	chr17:40499804	C/T	cg06270615	chr17:40516068	STAT3	-0.35	-7.56	-0.38	3.99e-13	Multiple sclerosis;Crohn's disease;
CRC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.8	14.25	0.62	3.13e-36	Breast cancer;
CRC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-9.5	-0.46	4.4e-19	Prudent dietary pattern;
CRC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg25164649	chr6:28176230	NA	0.6	8.62	0.43	2.96e-16	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs62187656	chr2:162487699	A/G	cg10272801	chr16:14013773	ERCC4	-0.69	-6.02	-0.31	4.59e-9	Cognitive function;
CRC	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg26597838	chr10:835615	NA	0.58	7.29	0.37	2.37e-12	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.54	-8.3	-0.42	2.71e-15	Aortic root size;
CRC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	6.19	0.32	1.78e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13198984	chr17:80129470	CCDC57	-0.48	-8.56	-0.43	4.49e-16	Life satisfaction;
CRC	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.49	7.47	0.38	7.49e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CRC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.35	5.78	0.3	1.7e-8	Prostate-specific antigen levels;
CRC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.44	5.73	0.3	2.33e-8	Bladder cancer;
CRC	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg07617317	chr6:118971624	C6orf204	0.49	6.0	0.31	5.29e-9	Diastolic blood pressure;
CRC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.62	-9.25	-0.45	2.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-8.99	-0.44	2.03e-17	Metabolite levels;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg08125682	chr16:11038455	CLEC16A	0.44	5.97	0.31	6.28e-9	Hip circumference;
CRC	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-7.65	-0.39	2.29e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs1887596	0.607	rs9553870	chr13:27170716	G/A	cg01312412	chr13:27282625	NA	0.43	5.7	0.3	2.72e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg10729496	chr3:10149963	C3orf24	-0.53	-7.14	-0.37	6.18e-12	Alzheimer's disease;
CRC	cis	rs2274273	0.624	rs10143136	chr14:55743528	G/A	cg10130446	chr14:55658398	DLGAP5	-0.41	-5.82	-0.31	1.43e-8	Protein biomarker;
CRC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg21251018	chr6:28226885	NKAPL	0.47	7.37	0.38	1.43e-12	Parkinson's disease;
CRC	cis	rs231513	0.911	rs124722	chr17:41956002	T/G	cg26893861	chr17:41843967	DUSP3	-0.67	-6.76	-0.35	6.29e-11	Cognitive function;
CRC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.37	-6.09	-0.32	3.17e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.14e-30	Bone mineral density;
CRC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg24585817	chr7:64895279	NA	0.36	5.67	0.3	3.11e-8	Calcium levels;
CRC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.67	7.17	0.37	5.14e-12	Axial length;
CRC	cis	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg07392085	chr5:141489673	NDFIP1	0.46	7.24	0.37	3.17e-12	Asthma;
CRC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.62	-0.34	1.48e-10	Life satisfaction;
CRC	cis	rs9463078	0.774	rs9357484	chr6:45265882	C/A	cg25276700	chr6:44698697	NA	-0.28	-6.72	-0.35	8.12e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	7.23	0.37	3.35e-12	Personality dimensions;
CRC	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.5	8.12	0.41	9.57e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg13385794	chr1:248469461	NA	0.4	7.29	0.37	2.35e-12	Common traits (Other);
CRC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.36	0.33	6.92e-10	Parkinson's disease;
CRC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.81	-0.4	7.64e-14	Cystic fibrosis severity;
CRC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-9.57	-0.47	2.73e-19	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.92	-0.4	3.66e-14	Neuroticism;
CRC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.62	-9.24	-0.45	3.24e-18	Subjective well-being;
CRC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.42	5.73	0.3	2.27e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.87	-16.76	-0.68	5.07e-46	Multiple myeloma;
CRC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.46	7.66	0.39	2.07e-13	Pulse pressure;
CRC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg22638593	chr5:131593259	PDLIM4	0.38	6.29	0.33	1e-9	Breast cancer;
CRC	cis	rs6681460	0.625	rs12127199	chr1:67103742	T/C	cg02459107	chr1:67143332	SGIP1	0.32	5.71	0.3	2.49e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-5.69	-0.3	2.85e-8	Joint mobility (Beighton score);
CRC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.35	-9.76	-0.47	6.33e-20	Mean corpuscular volume;
CRC	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.48	-9.0	-0.44	1.85e-17	Hepatitis;
CRC	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg23127183	chr11:57508653	C11orf31	0.47	6.43	0.33	4.51e-10	Schizophrenia;
CRC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg14711859	chr11:8959438	ASCL3	-0.47	-7.4	-0.38	1.17e-12	Hemoglobin concentration;
CRC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.75	0.35	6.77e-11	Schizophrenia;
CRC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.5	0.34	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.56	8.33	0.42	2.29e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.76	15.74	0.66	5.35e-42	Prostate cancer;
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	0.92	8.51	0.42	6.18e-16	IgG glycosylation;
CRC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.79	14.1	0.61	1.24e-35	Breast cancer;
CRC	cis	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg14515779	chr1:101123966	NA	-0.44	-8.39	-0.42	1.46e-15	Monocyte count;
CRC	cis	rs1062746	0.520	rs17770996	chr16:87330207	G/A	cg02258303	chr16:87377426	FBXO31	-0.51	-7.42	-0.38	9.82e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg22956015	chr17:38279503	MSL1	-0.47	-6.52	-0.34	2.64e-10	Protein C levels;
CRC	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg16068336	chr17:48637367	CACNA1G	-0.5	-7.3	-0.37	2.22e-12	Type 2 diabetes;
CRC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-5.96	-0.31	6.48e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7487075	0.619	rs9971879	chr12:46806773	T/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.67	0.3	3.17e-8	Itch intensity from mosquito bite;
CRC	cis	rs1364705	1.000	rs61600037	chr8:120225613	T/C	cg27215916	chr8:120218354	NA	-0.39	-5.64	-0.3	3.73e-8	Hippocampal atrophy;
CRC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.77	-10.7	-0.51	4.08e-23	Gut microbiome composition (winter);
CRC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg17948913	chr5:572064	NA	0.55	6.25	0.33	1.29e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs4453791	0.652	rs55991947	chr3:39077763	G/A	cg02254461	chr3:39195904	CSRNP1	0.45	5.76	0.3	1.97e-8	Social communication problems;
CRC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.73	9.99	0.48	1.09e-20	Cognitive function;
CRC	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.55	-8.31	-0.42	2.52e-15	Monobrow;
CRC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.77	-9.64	-0.47	1.5700000000000001e-19	Bronchopulmonary dysplasia;
CRC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.36	-0.33	6.81e-10	Bipolar disorder;
CRC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg15147215	chr3:52552868	STAB1	0.46	7.86	0.4	5.47e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.54	-0.34	2.31e-10	Neuroticism;
CRC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.6	-7.15	-0.37	5.78e-12	Body mass index;
CRC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	9.08	0.45	1.04e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	0.8	6.53	0.34	2.47e-10	Economic and political preferences (immigration/crime);
CRC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.82	-10.79	-0.51	1.94e-23	Obesity-related traits;
CRC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.86	-0.31	1.15e-8	Monobrow;
CRC	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.08	-15.25	-0.64	4.51e-40	Exhaled nitric oxide output;
CRC	cis	rs12630931	0.862	rs13099690	chr3:31982261	G/T	cg21375017	chr3:31988082	OSBPL10	0.42	5.76	0.3	1.94e-8	Periodontal disease-related phenotypes;
CRC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.51	8.23	0.41	4.35e-15	Prudent dietary pattern;
CRC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.8	14.37	0.62	1.08e-36	Breast cancer;
CRC	cis	rs2249296	0.715	rs2791465	chr1:86908698	C/T	cg17424433	chr1:86913263	CLCA2	-0.41	-5.72	-0.3	2.46e-8	Crohn's disease-related phenotypes;
CRC	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg00531865	chr16:30841666	NA	-0.44	-6.3	-0.33	9.71e-10	Dementia with Lewy bodies;
CRC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg07636037	chr3:49044803	WDR6	-0.67	-6.89	-0.36	2.89e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs1572511	0.710	rs12121835	chr1:177628511	A/G	cg10064897	chr1:46598380	PIK3R3	0.43	6.45	0.34	4.02e-10	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.35	0.46	1.39e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg18016565	chr1:150552671	MCL1	0.44	6.04	0.32	4.07e-9	Melanoma;
CRC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13198984	chr17:80129470	CCDC57	0.47	8.46	0.42	9.01e-16	Life satisfaction;
CRC	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.74	10.2	0.49	2.03e-21	Coronary artery disease;
CRC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-8.9	-0.44	3.71e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11212617	0.967	rs4237579	chr11:108279201	A/G	cg01991180	chr11:108092276	ATM;NPAT	0.43	6.39	0.33	5.72e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.59	-10.74	-0.51	2.88e-23	Age of smoking initiation;
CRC	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.65	-10.25	-0.49	1.46e-21	Smoking behavior;
CRC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-8.52	-0.43	5.77e-16	Chronic sinus infection;
CRC	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.4	-5.73	-0.3	2.26e-8	Neuroticism;
CRC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.52	7.34	0.38	1.65e-12	Schizophrenia;
CRC	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg16914508	chr2:239161102	PER2	0.74	7.99	0.4	2.26e-14	Irritable bowel syndrome;
CRC	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.64	8.08	0.41	1.28e-14	Uric acid levels;
CRC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.67	12.08	0.55	4.85e-28	Aortic root size;
CRC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14895029	chr7:2775587	GNA12	0.4	6.03	0.32	4.38e-9	Height;
CRC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.55	-0.7	3.84e-49	Body mass index;
CRC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.46	6.5	0.34	2.91e-10	Pulse pressure;
CRC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg04731861	chr2:219085781	ARPC2	0.3	6.23	0.32	1.44e-9	Colorectal cancer;
CRC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.75	13.13	0.59	5.82e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs17767392	0.958	rs2108049	chr14:71962394	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.57	-7.19	-0.37	4.29e-12	Mitral valve prolapse;
CRC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.73	6.79	0.35	5.22e-11	Major depressive disorder;
CRC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.3	-6.57	-0.34	2.01e-10	IgG glycosylation;
CRC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.93	-14.35	-0.62	1.31e-36	Systemic lupus erythematosus;
CRC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-9.22	-0.45	3.72e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg20169779	chr10:135381914	SYCE1	0.55	8.87	0.44	4.66e-17	Obesity-related traits;
CRC	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.15	-0.45	6.31e-18	Migraine;Coronary artery disease;
CRC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg04586622	chr2:25135609	ADCY3	-0.56	-10.18	-0.49	2.42e-21	Body mass index;
CRC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.6	-11.3	-0.53	2.95e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.58	8.85	0.44	5.47e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg02869306	chr7:64672164	INTS4L1	-0.35	-5.9	-0.31	8.87e-9	Aortic root size;
CRC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.8	12.74	0.57	1.64e-30	Multiple sclerosis;
CRC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.66	10.82	0.51	1.46e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1572438	1.000	rs9328455	chr6:864095	C/T	cg13447295	chr6:887704	NA	-0.45	-6.26	-0.33	1.19e-9	Aging;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18879991	chr6:27861393	HIST1H2AM;HIST1H2BO	0.42	6.23	0.32	1.42e-9	Interleukin-6 levels;
CRC	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg03938978	chr2:103052716	IL18RAP	-0.45	-6.96	-0.36	1.9e-11	Blood protein levels;
CRC	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.55	9.45	0.46	6.4e-19	Dupuytren's disease;
CRC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.44	7.55	0.38	4.35e-13	Childhood ear infection;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.51	0.34	2.8e-10	Bipolar disorder;
CRC	cis	rs2617583	0.509	rs62331137	chr5:1459573	A/G	cg07148919	chr5:1466943	LPCAT1	-0.45	-5.87	-0.31	1.08e-8	Breast cancer;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg01626434	chr5:42993978	NA	-0.45	-6.39	-0.33	5.62e-10	Hip circumference;
CRC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg15440763	chr7:158190612	PTPRN2	-0.41	-6.73	-0.35	7.62e-11	Obesity-related traits;
CRC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.93	11.28	0.53	3.59e-25	Eosinophil percentage of granulocytes;
CRC	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.43	-0.33	4.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.39	-6.13	-0.32	2.5e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.47	7.02	0.36	1.27e-11	Menopause (age at onset);
CRC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-7.58	-0.39	3.61e-13	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.46	-0.53	7.94e-26	Colorectal cancer;
CRC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.37	-6.38	-0.33	5.88e-10	Schizophrenia;
CRC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.45	6.3	0.33	9.48e-10	Red blood cell count;
CRC	cis	rs741668	0.931	rs61953331	chr13:46589471	C/T	cg06018095	chr13:46550134	ZC3H13	0.41	5.73	0.3	2.21e-8	Cerebrospinal fluid clusterin levels;
CRC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.91	0.31	8.38e-9	Prudent dietary pattern;
CRC	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg10862848	chr6:42927986	GNMT	-0.31	-5.87	-0.31	1.07e-8	Blood protein levels;
CRC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.67	10.27	0.49	1.24e-21	Corneal astigmatism;
CRC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.65e-10	Diabetic kidney disease;
CRC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	10.9	0.52	7.77e-24	Coronary artery disease;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg20119798	chr7:94954144	PON1	-0.5	-6.25	-0.33	1.26e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.49	7.59	0.39	3.42e-13	Dialysis-related mortality;
CRC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.42	6.17	0.32	1.99e-9	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
CRC	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg18833306	chr6:118973337	C6orf204	0.44	5.76	0.3	1.9e-8	Diastolic blood pressure;
CRC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg02033258	chr5:131593261	PDLIM4	0.34	6.79	0.35	5.18e-11	Blood metabolite levels;
CRC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg13798912	chr7:905769	UNC84A	0.52	6.06	0.32	3.71e-9	Cerebrospinal P-tau181p levels;
CRC	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.89	-9.39	-0.46	1.05e-18	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.44	6.67	0.35	1.07e-10	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.52	-7.86	-0.4	5.51e-14	Height;
CRC	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.58	0.63	1.7e-37	Colorectal cancer;
CRC	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.73	-7.29	-0.37	2.37e-12	Inflammatory biomarkers;
CRC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.43	-20.51	-0.75	8.67e-61	Hip circumference adjusted for BMI;
CRC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.85	-14.5	-0.62	3.46e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg18876405	chr7:65276391	NA	0.45	6.15	0.32	2.24e-9	Aortic root size;
CRC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.67	10.35	0.5	6.55e-22	Corneal astigmatism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02461806	chr17:4046409	ZZEF1;CYB5D2	0.43	6.33	0.33	7.84e-10	Intelligence (multi-trait analysis);
CRC	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.66	10.77	0.51	2.27e-23	Eosinophil percentage of white cells;
CRC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg06470822	chr6:28175283	NA	0.48	6.38	0.33	6.04e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg06223162	chr1:101003688	GPR88	-0.39	-7.26	-0.37	2.78e-12	Breast cancer;
CRC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.31	-0.33	9.05e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.79	10.86	0.51	1.09e-23	Height;
CRC	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg22561889	chr6:118971681	C6orf204	0.5	6.52	0.34	2.71e-10	Diastolic blood pressure;
CRC	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.7	9.66	0.47	1.31e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.42	-5.98	-0.31	5.8e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	9.34	0.46	1.54e-18	Eye color traits;
CRC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg22495460	chr2:25135724	ADCY3	-0.87	-17.16	-0.69	1.36e-47	Body mass index;
CRC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg15786705	chr6:28176104	NA	0.74	9.57	0.47	2.68e-19	Depression;
CRC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.47	7.17	0.37	5.06e-12	Corneal astigmatism;
CRC	cis	rs9648716	1.000	rs6464159	chr7:140630266	G/C	cg10747023	chr7:140774559	NA	0.46	6.02	0.31	4.76e-9	Type 2 diabetes;
CRC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.77	14.05	0.61	1.83e-35	Oral cavity cancer;
CRC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.44	-6.15	-0.32	2.23e-9	Longevity;Endometriosis;
CRC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.64	11.63	0.54	1.99e-26	Body mass index;
CRC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-5.73	-0.3	2.32e-8	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.31e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg13949903	chr17:74349974	PRPSAP1	0.42	6.11	0.32	2.8e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg20874811	chr17:54991629	TRIM25	-0.43	-6.15	-0.32	2.28e-9	Underweight status;
CRC	cis	rs853679	1.000	rs853678	chr6:28297313	T/A	cg15786705	chr6:28176104	NA	0.55	5.97	0.31	6.08e-9	Depression;
CRC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg15786705	chr6:28176104	NA	0.77	9.75	0.47	6.92e-20	Depression;
CRC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.87	14.28	0.62	2.54e-36	Cognitive function;
CRC	cis	rs17713451	0.593	rs76747376	chr7:151269240	T/C	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	0.62	10.37	0.5	5.32e-22	Prudent dietary pattern;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.67	10.38	0.5	4.99e-22	Longevity;Endometriosis;
CRC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	15.09	0.64	1.79e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6499255	0.904	rs12595927	chr16:69716338	C/G	cg15192750	chr16:69999425	NA	0.59	7.48	0.38	6.93e-13	IgE levels;
CRC	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg26741380	chr15:41871084	TYRO3	-0.45	-6.24	-0.33	1.34e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06462663	chr19:18546047	ISYNA1	0.48	7.36	0.38	1.47e-12	Breast cancer;
CRC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg03623178	chr6:28175578	NA	0.75	8.28	0.42	3.23e-15	Parkinson's disease;
CRC	cis	rs1178968	1.000	rs7793764	chr7:72759953	G/T	cg25889504	chr7:72793014	NA	0.48	5.65	0.3	3.42e-8	Triglyceride levels;
CRC	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.78	8.76	0.43	1.07e-16	Neuroticism;
CRC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg03258749	chr1:151040405	MLLT11	0.55	8.5	0.42	6.71e-16	Childhood ear infection;
CRC	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.6	-6.73	-0.35	7.7e-11	Blood protein levels;
CRC	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg10279832	chr4:154682576	RNF175	0.38	5.63	0.3	3.89e-8	Response to statins (LDL cholesterol change);
CRC	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg18099408	chr3:52552593	STAB1	0.33	5.62	0.3	4.05e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-6.3	-0.33	9.68e-10	Menarche (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04027074	chr6:144471431	STX11	0.38	6.31	0.33	8.81e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.36	6.79	0.35	5.29e-11	Schizophrenia;
CRC	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg01339444	chr6:118972232	C6orf204	0.49	5.92	0.31	8.04e-9	Diastolic blood pressure;
CRC	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-7.29	-0.37	2.28e-12	Post bronchodilator FEV1;
CRC	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.02	-0.31	4.77e-9	Schizophrenia;
CRC	cis	rs972578	1.000	rs5751405	chr22:43361079	G/A	cg01576275	chr22:43409880	NA	-0.44	-7.14	-0.37	6.09e-12	Mean platelet volume;
CRC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.44	-5.89	-0.31	9.43e-9	Gut microbiome composition (summer);
CRC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.4	0.42	1.38e-15	Height;
CRC	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg23254163	chr1:152506842	NA	-0.45	-9.14	-0.45	6.49e-18	Hair morphology;
CRC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07701084	chr6:150067640	NUP43	0.4	5.83	0.31	1.33e-8	Testicular germ cell tumor;
CRC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.35	-0.33	7.26e-10	Breast cancer;
CRC	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.57	9.62	0.47	1.79e-19	Eye color traits;
CRC	cis	rs62408225	1.000	rs1847472	chr6:90973159	A/C	cg06866423	chr6:90926672	BACH2	-0.52	-8.77	-0.44	9.7e-17	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg12573674	chr2:1569213	NA	-0.77	-8.05	-0.41	1.51e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg23234261	chr14:55582407	NA	-0.3	-5.91	-0.31	8.58e-9	Protein biomarker;
CRC	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg02766259	chr12:125626809	AACS	-0.44	-6.14	-0.32	2.38e-9	Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.92	-17.3	-0.69	3.99e-48	Coronary artery disease;
CRC	cis	rs4731207	0.565	rs4355714	chr7:124627521	T/G	cg23710748	chr7:124431027	NA	-0.39	-6.26	-0.33	1.22e-9	Cutaneous malignant melanoma;
CRC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg01788221	chr16:89496183	ANKRD11	-0.44	-6.57	-0.34	1.94e-10	Multiple myeloma (IgH translocation);
CRC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	1.98e-13	Gut microbiome composition (summer);
CRC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg23136738	chr11:925521	AP2A2	-0.5	-7.94	-0.4	3.32e-14	Alzheimer's disease (late onset);
CRC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.47	6.71	0.35	8.66e-11	Pulse pressure;
CRC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.63	10.9	0.52	7.95e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10392	0.543	rs62204117	chr20:37565335	T/C	cg27552599	chr20:37590471	DHX35	0.37	5.71	0.3	2.55e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs7695597	0.708	rs7680050	chr4:185181276	C/T	cg18317788	chr4:185205197	NA	-0.34	-5.69	-0.3	2.8e-8	Night sleep phenotypes;
CRC	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.69	-0.39	1.76e-13	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.82	-17.71	-0.7	8.87e-50	Prostate cancer;
CRC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	8.43	0.42	1.1e-15	Height;
CRC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-0.98	-19.12	-0.73	2.57e-55	Height;
CRC	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg08501292	chr6:25962987	TRIM38	1.01	9.29	0.46	2.17e-18	Autism spectrum disorder or schizophrenia;
CRC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.75	7.65	0.39	2.18e-13	Diabetic retinopathy;
CRC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-8.81	-0.44	7.09e-17	Coronary artery disease;
CRC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.41	-0.38	1.05e-12	Chronic sinus infection;
CRC	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.65	-9.93	-0.48	1.7e-20	Corneal astigmatism;
CRC	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.76	13.82	0.61	1.43e-34	Ulcerative colitis;
CRC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg02811702	chr13:24901961	NA	0.48	6.6	0.34	1.68e-10	Obesity-related traits;
CRC	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.07	-0.36	9.21e-12	Multiple myeloma (hyperdiploidy);
CRC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-1.07	-18.37	-0.71	2.34e-52	Blood pressure (smoking interaction);
CRC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.27	-0.33	1.13e-9	Type 2 diabetes;
CRC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.96	18.16	0.71	1.53e-51	Cognitive ability;
CRC	cis	rs12024301	0.557	rs6673809	chr1:183603060	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	-0.72	-6.4	-0.33	5.33e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg06632207	chr12:54070931	ATP5G2	0.39	6.72	0.35	8.14e-11	Height;
CRC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.98	-0.31	5.84e-9	Body mass index;
CRC	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.49	7.96	0.4	2.83e-14	Brugada syndrome;
CRC	cis	rs6662572	0.703	rs4660909	chr1:46477326	G/C	cg08644498	chr1:46502608	NA	-0.47	-7.46	-0.38	7.64e-13	Blood protein levels;
CRC	cis	rs2307022	0.542	rs4783624	chr16:68409947	T/C	cg02226672	chr16:68398533	SMPD3	0.29	5.69	0.3	2.86e-8	Body mass index;
CRC	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21659725	chr3:3221576	CRBN	0.67	7.26	0.37	2.87e-12	Menarche (age at onset);
CRC	cis	rs7692995	1.000	rs16896245	chr4:18005608	C/T	cg08925142	chr4:18023851	LCORL	-0.55	-6.06	-0.32	3.73e-9	Height;
CRC	trans	rs2055729	0.601	rs12546952	chr8:9744002	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.27	-0.37	2.65e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.66	11.75	0.54	7.39e-27	Height;
CRC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.79	-13.11	-0.59	7.1e-32	Menopause (age at onset);
CRC	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg00250761	chr1:31883323	NA	-0.38	-7.06	-0.36	9.67e-12	Alcohol dependence;
CRC	cis	rs7259376	0.871	rs2360622	chr19:22570622	T/C	cg02657401	chr19:22469223	NA	-0.32	-7.0	-0.36	1.48e-11	Menopause (age at onset);
CRC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.56	-0.43	4.43e-16	Hemoglobin concentration;
CRC	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg00277334	chr10:82204260	NA	-0.37	-6.02	-0.32	4.54e-9	Sarcoidosis;
CRC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-7.24	-0.37	3.26e-12	Height;
CRC	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.65	9.04	0.45	1.36e-17	Hair shape;
CRC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.37	-6.43	-0.33	4.4e-10	Height;
CRC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	7.73	0.39	1.31e-13	Hip circumference adjusted for BMI;
CRC	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg26875233	chr11:93583750	C11orf90	-0.31	-6.03	-0.32	4.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	trans	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg03060546	chr3:49711283	APEH	-0.59	-6.3	-0.33	9.33e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.35	-5.79	-0.3	1.67e-8	Iron status biomarkers;
CRC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg11212589	chr17:38028394	ZPBP2	0.43	7.95	0.4	2.96e-14	Self-reported allergy;
CRC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg11245181	chr6:149772854	ZC3H12D	-0.55	-9.07	-0.45	1.12e-17	Dupuytren's disease;
CRC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.94	0.55	1.55e-27	Alzheimer's disease;
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg13047869	chr3:10149882	C3orf24	0.53	6.49	0.34	3.25e-10	Alzheimer's disease;
CRC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg16892393	chr17:41919603	NA	0.6	8.63	0.43	2.61e-16	Triglycerides;
CRC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.71	9.27	0.46	2.53e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs28493229	0.708	rs78900506	chr19:41160096	T/C	cg21869046	chr19:41225005	ITPKC	0.4	6.06	0.32	3.69e-9	Kawasaki disease;
CRC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-8.13	-0.41	8.97e-15	Vitiligo;
CRC	cis	rs6479527	0.904	rs3847307	chr9:96865638	C/T	cg14459158	chr9:96720562	NA	0.37	6.74	0.35	7.29e-11	Esophageal adenocarcinoma;
CRC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.51	8.03	0.4	1.8e-14	Height;
CRC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg25985355	chr7:65971099	NA	-0.54	-6.07	-0.32	3.54e-9	Diabetic kidney disease;
CRC	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.55	8.36	0.42	1.83e-15	HDL cholesterol;
CRC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg03623178	chr6:28175578	NA	0.48	6.66	0.34	1.17e-10	Depression;
CRC	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.43	-8.37	-0.42	1.68e-15	Alcohol dependence;
CRC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg04611788	chr3:186434169	KNG1	-0.57	-8.32	-0.42	2.41e-15	Blood protein levels;
CRC	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg07807695	chr5:81608485	ATP6AP1L	0.47	7.38	0.38	1.3e-12	Breast cancer;
CRC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.35	5.7	0.3	2.66e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg12172441	chr6:28176163	NA	0.45	6.55	0.34	2.25e-10	Cardiac Troponin-T levels;
CRC	cis	rs526821	0.595	rs624478	chr11:55340778	C/G	cg04317927	chr11:55418816	OR4S2	0.38	6.55	0.34	2.21e-10	Pediatric bone mineral density (spine);
CRC	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg26566898	chr11:117069891	TAGLN	0.38	6.89	0.36	2.79e-11	Blood protein levels;
CRC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.84	13.86	0.61	1e-34	Menarche (age at onset);
CRC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.73	0.54	8.59e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15212440	chr10:104474465	SFXN2;ARL3	0.42	6.02	0.31	4.61e-9	Response to antipsychotic treatment;
CRC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.67	-0.3	3.09e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-7.23	-0.37	3.32e-12	Lymphocyte counts;
CRC	cis	rs6585424	1.000	rs11202031	chr10:81944043	G/C	cg11900509	chr10:81946545	ANXA11	-0.72	-8.58	-0.43	3.83e-16	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg19193384	chr17:30244184	NA	-0.49	-6.69	-0.35	9.5e-11	Hip circumference adjusted for BMI;
CRC	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.68	9.55	0.47	3.05e-19	Blood protein levels;
CRC	trans	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg06875740	chr19:51307921	C19orf48	-0.66	-6.0	-0.31	5.19e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25842470	chr1:2472373	NA	-0.41	-6.19	-0.32	1.8e-9	Interleukin-6 levels;
CRC	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-11.02	-0.52	2.96e-24	Exhaled nitric oxide output;
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.54	-10.18	-0.49	2.45e-21	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg01457183	chr3:180707371	DNAJC19	-0.4	-6.27	-0.33	1.16e-9	Myopia (pathological);
CRC	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.73	10.74	0.51	2.79e-23	Immature fraction of reticulocytes;
CRC	trans	rs5756813	0.646	rs3788528	chr22:38146433	T/C	cg19894588	chr14:64061835	NA	0.49	6.48	0.34	3.37e-10	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg00250761	chr1:31883323	NA	-0.38	-7.23	-0.37	3.44e-12	Alcohol dependence;
CRC	cis	rs7538876	0.903	rs6688886	chr1:17753639	G/A	cg01904812	chr1:17746340	RCC2	0.36	5.85	0.31	1.16e-8	Basal cell carcinoma;
CRC	cis	rs13315871	1.000	rs4075403	chr3:58411445	G/C	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08883955	chr16:11945066	RSL1D1	0.54	6.89	0.36	2.83e-11	Thyroid stimulating hormone;
CRC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	8.91	0.44	3.46e-17	Mean platelet volume;
CRC	cis	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16745844	chr11:23258850	NA	-0.33	-5.86	-0.31	1.14e-8	Cancer;
CRC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.49	-5.72	-0.3	2.34e-8	Vitiligo;
CRC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.42	5.93	0.31	7.62e-9	Coronary artery disease;
CRC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.81	-0.72	4.3e-54	Height;
CRC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.66	6.81	0.35	4.72e-11	Axial length;
CRC	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.53	-0.34	2.43e-10	Retinal vascular caliber;
CRC	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg27398640	chr15:77910606	LINGO1	-0.41	-6.83	-0.35	4.04e-11	Type 2 diabetes;
CRC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg20243544	chr17:37824526	PNMT	0.38	5.73	0.3	2.28e-8	Self-reported allergy;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg03623178	chr6:28175578	NA	0.93	13.55	0.6	1.58e-33	Depression;
CRC	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg09659197	chr4:152720779	NA	0.53	11.71	0.54	1.01e-26	Intelligence (multi-trait analysis);
CRC	cis	rs1887596	0.629	rs1625599	chr13:27257688	C/T	cg01312412	chr13:27282625	NA	-0.44	-5.96	-0.31	6.54e-9	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg10589385	chr1:150898437	SETDB1	0.28	5.89	0.31	9.36e-9	Melanoma;
CRC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16447950	chr5:562315	NA	-0.54	-8.21	-0.41	5.21e-15	Obesity-related traits;
CRC	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg06060754	chr5:176797920	RGS14	0.55	8.68	0.43	1.82e-16	Hemoglobin concentration;Hematocrit;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02615599	chr7:150725389	ABCB8	0.44	6.4	0.33	5.41e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg19875578	chr6:126661172	C6orf173	0.42	5.94	0.31	7.34e-9	Male-pattern baldness;
CRC	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg09659197	chr4:152720779	NA	0.42	8.32	0.42	2.35e-15	Intelligence (multi-trait analysis);
CRC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.46	6.82	0.35	4.44e-11	Menopause (age at onset);
CRC	cis	rs9547692	0.938	rs17217404	chr13:37466215	C/T	cg01493522	chr13:37497338	NA	-0.55	-7.43	-0.38	9.46e-13	Coronary artery disease;
CRC	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.18	26.37	0.82	3.89e-83	Schizophrenia;
CRC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg15145296	chr3:125709740	NA	-0.6	-7.07	-0.36	9.42e-12	Blood pressure (smoking interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03398387	chr6:160114178	SOD2	0.44	6.31	0.33	9.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.23	11.44	0.53	9.66e-26	Alzheimer's disease (late onset);
CRC	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg20200711	chr11:2211776	NA	0.47	6.55	0.34	2.19e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CRC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg06138825	chr16:67683817	RLTPR	-0.52	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9487051	0.646	rs9487049	chr6:109615905	A/T	cg01475377	chr6:109611718	NA	-0.36	-5.64	-0.3	3.69e-8	Reticulocyte fraction of red cells;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.66	6.97	0.36	1.74e-11	Axial length;
CRC	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	7.62	0.39	2.68e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6066835	1.000	rs6095244	chr20:47318774	T/C	cg18078177	chr20:47281410	PREX1	0.68	5.67	0.3	3.09e-8	Multiple myeloma;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14863265	chr7:2801509	GNA12	-0.4	-5.8	-0.3	1.53e-8	Height;
CRC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg15786705	chr6:28176104	NA	0.74	9.35	0.46	1.41e-18	Depression;
CRC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.82	-0.31	1.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26098650	chr11:120207939	ARHGEF12	0.47	7.55	0.38	4.23e-13	Response to antipsychotic treatment;
CRC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.59	9.6	0.47	2.13e-19	Prostate cancer;
CRC	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.72	-0.39	1.43e-13	Intelligence (multi-trait analysis);
CRC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg14530993	chr4:882597	GAK	0.79	7.62	0.39	2.68e-13	Intelligence (multi-trait analysis);
CRC	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg21839984	chr17:30846986	MYO1D	-0.33	-5.64	-0.3	3.68e-8	Schizophrenia;
CRC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.39	0.33	5.7e-10	Cognitive ability;
CRC	cis	rs9403521	0.580	rs9376772	chr6:143960454	T/C	cg18240653	chr6:144019428	PHACTR2	-0.56	-5.69	-0.3	2.74e-8	Obesity-related traits;
CRC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg19223190	chr17:80058835	NA	0.39	6.17	0.32	2.02e-9	Life satisfaction;
CRC	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-1.01	-9.03	-0.45	1.47e-17	Post bronchodilator FEV1;
CRC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.04	0.32	4.09e-9	Glioblastoma;
CRC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.05	-0.32	3.97e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg02659138	chr7:134003124	SLC35B4	0.37	6.28	0.33	1.06e-9	Mean platelet volume;
CRC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.56	-0.43	4.34e-16	Aortic root size;
CRC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg02018176	chr4:1364513	KIAA1530	0.4	5.74	0.3	2.15e-8	Obesity-related traits;
CRC	cis	rs13315871	1.000	rs1131052	chr3:58411530	A/T	cg20936604	chr3:58311152	NA	-0.76	-7.15	-0.37	5.74e-12	Cholesterol, total;
CRC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.67	-10.82	-0.51	1.53e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.69	-0.39	1.76e-13	Personality dimensions;
CRC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg03690763	chr11:133734501	NA	-0.39	-6.38	-0.33	6.1e-10	Childhood ear infection;
CRC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg03060546	chr3:49711283	APEH	0.41	5.86	0.31	1.13e-8	Parkinson's disease;
CRC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-6.86	-0.35	3.47e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3857067	1.000	rs3846292	chr4:95027717	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.22	-0.32	1.55e-9	QT interval;
CRC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.97	-19.03	-0.72	5.79e-55	Height;
CRC	cis	rs12230513	0.732	rs7971742	chr12:55848486	A/G	cg19537932	chr12:55886519	OR6C68	-0.72	-9.44	-0.46	7.08e-19	Contrast sensitivity;
CRC	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.74	7.94	0.4	3.13e-14	Breast cancer;
CRC	trans	rs7821565	0.904	rs57224283	chr8:52164724	G/A	cg09187163	chr7:72721838	NSUN5	-0.41	-5.98	-0.31	5.79e-9	Tuberculosis;
CRC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.54	0.65	3.3e-41	Parkinson's disease;
CRC	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26248373	chr2:1572462	NA	-0.86	-12.67	-0.57	3.01e-30	IgG glycosylation;
CRC	cis	rs9549328	0.565	rs35371379	chr13:113616715	T/C	cg24588162	chr13:113633484	MCF2L	0.36	6.4	0.33	5.22e-10	Systolic blood pressure;
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.65	7.94	0.4	3.19e-14	Body mass index;
CRC	cis	rs1322512	0.958	rs74608294	chr6:152944818	T/C	cg03415253	chr6:152958462	SYNE1	-0.41	-6.38	-0.33	6.06e-10	Tonometry;
CRC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.58	-0.43	3.77e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	cg04338863	chr8:33670619	NA	0.42	6.72	0.35	8.03e-11	Body mass index;
CRC	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.62	-7.7	-0.39	1.63e-13	Subcortical brain region volumes;Hippocampal volume;
CRC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg03948781	chr1:205179583	DSTYK	0.41	5.6	0.3	4.5e-8	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.43	6.03	0.32	4.53e-9	Bipolar disorder;
CRC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg02741985	chr17:80059408	CCDC57	-0.46	-7.78	-0.39	9.53e-14	Life satisfaction;
CRC	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.43	6.61	0.34	1.53e-10	Monocyte count;
CRC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.59	8.87	0.44	4.64e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.61	8.53	0.43	5.32e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04055981	chr11:115044050	NA	-0.42	-6.8	-0.35	4.87e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.29	0.42	2.87e-15	Height;
CRC	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.17	26.69	0.83	2.66e-84	Schizophrenia;
CRC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.31	-0.33	9.24e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4523957	0.855	rs12603057	chr17:2112567	T/C	cg16513277	chr17:2031491	SMG6	-0.52	-8.51	-0.42	6.2e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2949837	0.581	rs1496499	chr7:45979023	T/G	cg04727332	chr7:45960243	IGFBP3	0.37	5.88	0.31	1e-8	Sitting height ratio;
CRC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-6.64	-0.34	1.28e-10	Subjective well-being;
CRC	cis	rs2179367	0.959	rs237034	chr6:149711862	A/C	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.18	-0.32	1.93e-9	Dupuytren's disease;
CRC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg09264619	chr17:80180166	NA	0.36	6.08	0.32	3.4e-9	Life satisfaction;
CRC	cis	rs7849270	1.000	rs10988214	chr9:131883752	A/G	cg13538475	chr9:131942899	NA	-0.29	-5.86	-0.31	1.13e-8	Blood metabolite ratios;
CRC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg23533926	chr12:111358616	MYL2	-0.52	-7.87	-0.4	5.24e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.46	-9.06	-0.45	1.16e-17	Subjective well-being;
CRC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.82	-0.44	6.77e-17	Chronic sinus infection;
CRC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.77	9.25	0.45	2.92e-18	Eosinophilic esophagitis;
CRC	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg01858014	chr14:56050164	KTN1	-0.81	-6.11	-0.32	2.87e-9	Putamen volume;
CRC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg15733309	chr7:157513707	PTPRN2	0.3	5.71	0.3	2.53e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs501120	0.584	rs61857460	chr10:44688877	A/C	cg09554077	chr10:44749378	NA	0.68	7.29	0.37	2.38e-12	Coronary artery disease;Coronary heart disease;
CRC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.0	-0.36	1.47e-11	IgG glycosylation;
CRC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.61	8.94	0.44	2.82e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg02509730	chr13:100310205	CLYBL	0.4	5.65	0.3	3.5e-8	Obesity-related traits;
CRC	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.81	-14.45	-0.62	5.5e-37	Lewy body disease;
CRC	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-9.24	-0.45	3.06e-18	Amyotrophic lateral sclerosis (sporadic);
CRC	trans	rs1161463	0.834	rs1161471	chr13:29424482	T/C	cg16311697	chr3:124249497	KALRN	-0.44	-6.04	-0.32	4.27e-9	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
CRC	cis	rs6557786	0.636	rs17052934	chr8:24840319	A/C	cg02106941	chr8:24772137	NEFM	-0.29	-6.06	-0.32	3.79e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CRC	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.67	-10.55	-0.5	1.31e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg13256891	chr4:100009986	ADH5	-0.41	-6.12	-0.32	2.64e-9	Alcohol dependence;
CRC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg21251018	chr6:28226885	NKAPL	-0.47	-7.59	-0.39	3.24e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg05585544	chr11:47624801	NA	-0.6	-10.86	-0.51	1.11e-23	Subjective well-being;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25161386	chr17:27621177	NUFIP2	0.52	6.69	0.35	9.56e-11	Thyroid stimulating hormone;
CRC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	0.84	13.39	0.59	6.15e-33	Cognitive function;
CRC	cis	rs12922317	0.538	rs446289	chr16:12070486	T/G	cg09319797	chr16:12061715	TNFRSF17	-0.34	-5.7	-0.3	2.67e-8	Schizophrenia;
CRC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg25804541	chr17:80189381	SLC16A3	-0.3	-5.84	-0.31	1.23e-8	Life satisfaction;
CRC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.47	6.6	0.34	1.6e-10	Height;
CRC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.49	7.63	0.39	2.63e-13	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25373372	chr6:82462656	FAM46A	-0.4	-6.27	-0.33	1.15e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10208940	0.920	rs6751531	chr2:68794528	G/T	cg12452813	chr2:68675892	NA	0.47	5.95	0.31	6.88e-9	Urate levels in lean individuals;
CRC	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg12046867	chr14:103022105	NA	-0.81	-11.48	-0.53	7.02e-26	Platelet count;
CRC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.47	-0.46	5.62e-19	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg03929089	chr4:120376271	NA	-0.46	-6.52	-0.34	2.59e-10	HDL cholesterol;
CRC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg08314208	chr16:67682810	RLTPR	-0.49	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.96	0.31	6.35e-9	Tonsillectomy;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23501767	chr5:133340570	VDAC1	0.4	5.96	0.31	6.56e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-8.68	-0.43	1.84e-16	Menarche (age at onset);
CRC	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	0.98	8.0	0.4	2.12e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg00343986	chr7:65444356	GUSB	-0.5	-7.44	-0.38	8.98e-13	Aortic root size;
CRC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	9.75	0.47	6.88e-20	Cognitive test performance;
CRC	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg02820901	chr13:113351484	ATP11A	0.51	5.64	0.3	3.73e-8	Glycated hemoglobin levels;
CRC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.45	5.76	0.3	1.95e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg13565492	chr6:43139072	SRF	-0.7	-7.18	-0.37	4.76e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.83	-14.12	-0.61	9.88e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg01312482	chr5:178451176	ZNF879	-0.36	-5.96	-0.31	6.61e-9	Pubertal anthropometrics;
CRC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg15845792	chr6:28175446	NA	0.48	6.47	0.34	3.64e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg02770688	chr6:168491649	NA	0.6	8.57	0.43	3.98e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17776353	chr10:88516420	BMPR1A	0.41	6.15	0.32	2.25e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.55	0.34	2.16e-10	Body mass index;
CRC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.81	12.63	0.57	4.21e-30	Menarche (age at onset);
CRC	trans	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg25835954	chr13:50160062	RCBTB1	0.54	8.04	0.41	1.64e-14	Cortisol levels (saliva);
CRC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.4	-6.29	-0.33	9.97e-10	Neurofibrillary tangles;
CRC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.82	0.44	6.9e-17	Morning vs. evening chronotype;
CRC	cis	rs2859741	0.608	rs480411	chr1:37476077	T/C	cg09363841	chr1:37513479	NA	-0.54	-9.23	-0.45	3.46e-18	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CRC	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-6.08	-0.32	3.35e-9	Axial length;
CRC	cis	rs2742417	1.000	rs2742369	chr3:45754487	C/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.95e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs294883	0.739	rs9456390	chr6:159732797	G/C	cg14500486	chr6:159655392	FNDC1	-0.36	-6.16	-0.32	2.11e-9	Coronary artery disease;
CRC	cis	rs4663866	0.901	rs74877878	chr2:239198565	C/T	cg16914508	chr2:239161102	PER2	0.74	7.45	0.38	8.17e-13	Irritable bowel syndrome;
CRC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.6	7.28	0.37	2.53e-12	Mean platelet volume;
CRC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.89	-0.31	9.43e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg22529645	chr1:3704559	LRRC47	0.43	5.78	0.3	1.73e-8	Red cell distribution width;
CRC	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.6	0.34	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg13471352	chr2:39944470	TMEM178	0.36	6.21	0.32	1.6e-9	Aortic root size;
CRC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg22117107	chr15:45993392	NA	-0.44	-8.89	-0.44	4.14e-17	Waist circumference;Weight;
CRC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg01721255	chr8:58191610	C8orf71	0.45	5.86	0.31	1.11e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	0.96	12.91	0.58	3.84e-31	Vitiligo;
CRC	cis	rs2882667	0.898	rs6863347	chr5:138361135	C/T	cg09476006	chr5:138032270	NA	0.44	6.84	0.35	3.95e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07094533	chr2:233415452	TIGD1;EIF4E2	0.46	6.32	0.33	8.57e-10	Anxiety disorder;
CRC	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-7.64	-0.39	2.44e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg27661571	chr11:113659931	NA	-0.76	-9.48	-0.46	5.31e-19	Hip circumference adjusted for BMI;
CRC	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.55	-8.24	-0.41	4.23e-15	Body mass index;
CRC	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.64	-0.34	1.27e-10	Putamen volume;
CRC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg12193833	chr17:30244370	NA	-0.63	-8.06	-0.41	1.39e-14	Hip circumference adjusted for BMI;
CRC	cis	rs17767392	0.958	rs12433040	chr14:72030555	G/A	cg13720639	chr14:72061746	SIPA1L1	0.56	6.88	0.35	3.04e-11	Mitral valve prolapse;
CRC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.91	13.13	0.59	5.95e-32	Initial pursuit acceleration;
CRC	cis	rs7605827	0.930	rs2003592	chr2:15552153	C/T	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.06e-8	Educational attainment (years of education);
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg01125814	chr2:71559310	ZNF638	0.39	6.01	0.31	4.83e-9	Myopia;
CRC	cis	rs375066	0.623	rs2356438	chr19:44353083	G/A	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.01	0.31	4.95e-9	Systemic lupus erythematosus;
CRC	cis	rs4700695	0.925	rs381549	chr5:65383371	A/G	cg21114390	chr5:65439923	SFRS12	-0.62	-6.72	-0.35	8.15e-11	Facial morphology (factor 19);
CRC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.01	-0.31	4.88e-9	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Depression;
CRC	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.46	6.7	0.35	8.98e-11	Subjective well-being;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21512275	chr2:157198069	NA	0.49	7.03	0.36	1.21e-11	Response to antipsychotic treatment;
CRC	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.13	0.49	3.5e-21	Asthma;
CRC	cis	rs10486722	0.624	rs2330259	chr7:41762712	A/G	cg22138096	chr7:41772439	LOC285954	-0.39	-5.87	-0.31	1.08e-8	Pit-and-Fissure caries;
CRC	cis	rs4766646	0.619	rs9645838	chr12:110291572	A/G	cg01252219	chr12:110302105	GLTP	0.42	6.34	0.33	7.58e-10	Metabolite levels (MHPG);
CRC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.31	0.65	2.46e-40	Chronic sinus infection;
CRC	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.79	13.3	0.59	1.36e-32	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg12682573	chr17:27188876	MIR451;MIR144	0.6	8.33	0.42	2.25e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.32e-9	Crohn's disease;
CRC	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.25	0.53	4.59e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.2	0.53	6.89e-25	Coffee consumption (cups per day);
CRC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.61	11.32	0.53	2.56e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg04880052	chr2:219191631	PNKD	-0.43	-6.8	-0.35	4.82e-11	Colorectal cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg09634226	chr8:52811768	PCMTD1	0.41	6.01	0.31	5.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.73	-8.33	-0.42	2.19e-15	Obesity-related traits;
CRC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.71	-11.77	-0.54	6.4e-27	Cognitive function;
CRC	cis	rs9549328	0.670	rs35992827	chr13:113616752	G/A	cg24588162	chr13:113633484	MCF2L	0.33	5.99	0.31	5.44e-9	Systolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03007208	chr19:36266554	SNX26	0.39	6.02	0.31	4.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg25767906	chr1:53392781	SCP2	0.45	7.12	0.37	6.95e-12	Monocyte count;
CRC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14895029	chr7:2775587	GNA12	-0.42	-5.97	-0.31	6.03e-9	Height;
CRC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.71	0.35	8.54e-11	Menarche (age at onset);
CRC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.28	0.42	3.17e-15	Mood instability;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04729070	chr8:67837953	SNHG6	0.44	6.09	0.32	3.13e-9	Response to antipsychotic treatment;
CRC	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	11.58	0.54	3.12e-26	Bipolar disorder;
CRC	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-5.65	-0.3	3.48e-8	Coronary artery disease;
CRC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg07718321	chr6:96025334	MANEA	-0.58	-7.22	-0.37	3.52e-12	Behavioural disinhibition (generation interaction);
CRC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	6.29	0.33	1e-9	Axial length;
CRC	trans	rs8005150	0.737	rs4418995	chr14:88468480	G/A	cg25527770	chr19:1444892	NA	-0.56	-6.21	-0.32	1.64e-9	Hepatitis B;
CRC	cis	rs9311676	0.656	rs55964615	chr3:58389120	A/T	cg06643156	chr3:58380774	PXK	0.41	6.22	0.32	1.55e-9	Systemic lupus erythematosus;
CRC	cis	rs12541635	0.701	rs2029878	chr8:107025283	A/G	cg10147462	chr8:107024639	NA	0.52	9.25	0.45	2.99e-18	Age of smoking initiation;
CRC	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.4	-7.1	-0.36	7.94e-12	Hepatitis;
CRC	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.77	8.64	0.43	2.48e-16	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03482004	chr22:38349721	POLR2F;C22orf23	0.4	6.4	0.33	5.44e-10	Intelligence (multi-trait analysis);
CRC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.86	-0.35	3.41e-11	Cutaneous nevi;
CRC	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg06634786	chr22:41940651	POLR3H	-0.45	-6.08	-0.32	3.26e-9	Neuroticism;
CRC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.68	7.6	0.39	3.04e-13	Vitiligo;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01139627	chr1:94344929	DNTTIP2	0.4	6.03	0.32	4.42e-9	Schizophrenia;
CRC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg03934865	chr2:198174659	NA	-0.47	-7.25	-0.37	2.96e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg18196295	chr10:418757	DIP2C	-0.55	-8.06	-0.41	1.43e-14	Psychosis in Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25448812	chr11:46402210	MDK	0.38	6.09	0.32	3.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.65	8.66	0.43	2.14e-16	Alzheimer's disease;
CRC	cis	rs13272623	0.502	rs268594	chr8:71513130	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.46	6.41	0.33	5.07e-10	IgG glycosylation;
CRC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12311346	chr5:56204834	C5orf35	-0.53	-8.13	-0.41	9.03e-15	Coronary artery disease;
CRC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.33	12.69	0.57	2.61e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	17.23	0.69	7.2e-48	Electrocardiographic conduction measures;
CRC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.48	-7.52	-0.38	5.19e-13	Height;
CRC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.4	-6.03	-0.32	4.35e-9	Heart rate;
CRC	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.17	0.64	8.93e-40	Colorectal cancer;
CRC	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg25482853	chr8:67687455	SGK3	0.99	12.23	0.56	1.28e-28	Lung disease severity in cystic fibrosis;
CRC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.31e-9	Systemic lupus erythematosus;
CRC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg26695010	chr11:65641043	EFEMP2	-0.58	-6.37	-0.33	6.19e-10	Inflammatory bowel disease;
CRC	cis	rs2033908	0.620	rs10765993	chr11:12849185	C/G	cg25843174	chr11:12811716	TEAD1	-0.43	-7.58	-0.39	3.66e-13	Sitting height ratio;
CRC	trans	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.4	-6.4	-0.33	5.32e-10	Mean corpuscular volume;
CRC	cis	rs751837	0.591	rs34407983	chr14:103429786	T/C	cg10087771	chr14:103399429	CDC42BPB	0.67	6.37	0.33	6.45e-10	Large B-cell lymphoma;
CRC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.53	0.57	1.01e-29	Menopause (age at onset);
CRC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.48	8.82	0.44	7.04e-17	Acylcarnitine levels;
CRC	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.51	6.71	0.35	8.67e-11	Coronary artery disease;
CRC	cis	rs6496667	0.779	rs113088230	chr15:90888489	T/C	cg04176472	chr15:90893244	GABARAPL3	0.58	6.84	0.35	3.82e-11	Rheumatoid arthritis;
CRC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.67	-8.99	-0.44	1.98e-17	Morning vs. evening chronotype;
CRC	cis	rs2257205	0.667	rs6503876	chr17:56814988	G/C	cg25885038	chr17:56607967	SEPT4	-0.53	-5.82	-0.31	1.4e-8	Pancreatic cancer;
CRC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-9.69	-0.47	1.06e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs938554	0.784	rs11726102	chr4:9951664	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.91	-0.31	8.72e-9	Blood metabolite levels;
CRC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.17	-0.45	5.15e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02825527	chr7:2087843	MAD1L1	-0.49	-5.93	-0.31	7.7e-9	Neuroticism;
CRC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg22777020	chr22:31556080	RNF185	-0.53	-6.2	-0.32	1.72e-9	Colorectal cancer;
CRC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.78	13.21	0.59	2.87e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg23018236	chr17:30244563	NA	-0.47	-6.64	-0.34	1.28e-10	Hip circumference adjusted for BMI;
CRC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.4	7.65	0.39	2.28e-13	Ulcerative colitis;
CRC	cis	rs4664293	0.833	rs3764969	chr2:160620848	G/A	cg08347373	chr2:160653686	CD302	-0.44	-6.98	-0.36	1.61e-11	Monocyte percentage of white cells;
CRC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-6.24	-0.33	1.37e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.57	8.26	0.41	3.55e-15	Parkinson's disease;
CRC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.37	6.41	0.33	5.04e-10	Primary biliary cholangitis;
CRC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.02	-0.4	1.82e-14	Type 2 diabetes;
CRC	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg03229431	chr7:123269106	ASB15	-0.36	-5.67	-0.3	3.21e-8	Migraine;
CRC	cis	rs66573146	1.000	rs6852613	chr4:7035637	G/A	cg00086871	chr4:6988644	TBC1D14	0.88	6.83	0.35	4.07e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.7	0.51	4.01e-23	Motion sickness;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg16857335	chr19:47633940	SAE1	0.44	6.07	0.32	3.53e-9	Anxiety disorder;
CRC	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.16	-0.32	2.15e-9	Blood pressure;
CRC	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.82	-9.93	-0.48	1.72e-20	Dilated cardiomyopathy;
CRC	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.35	5.77	0.3	1.87e-8	Sitting height ratio;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg18301423	chr5:131593218	PDLIM4	0.32	5.94	0.31	7.34e-9	Lung function (FEV1/FVC);
CRC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.52	7.17	0.37	5.12e-12	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26074148	chr5:71615866	PTCD2;MRPS27	0.47	6.02	0.31	4.59e-9	Thyroid stimulating hormone;
CRC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.43	6.44	0.33	4.34e-10	Obesity-related traits;
CRC	cis	rs9648716	1.000	rs6944385	chr7:140614387	A/T	cg10747023	chr7:140774559	NA	0.47	6.1	0.32	2.98e-9	Type 2 diabetes;
CRC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.56	8.61	0.43	2.99e-16	Intelligence (multi-trait analysis);
CRC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg03395511	chr6:291903	DUSP22	-0.48	-6.74	-0.35	7.02e-11	Menopause (age at onset);
CRC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.81	14.79	0.63	2.69e-38	Metabolic syndrome;
CRC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.4	-6.68	-0.35	1.02e-10	Breast cancer;
CRC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.6	9.53	0.47	3.52e-19	Corneal astigmatism;
CRC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-8.88	-0.44	4.29e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.15	-0.45	6.09e-18	Chronic sinus infection;
CRC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg15845792	chr6:28175446	NA	0.98	13.03	0.58	1.45e-31	Depression;
CRC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs539514	0.690	rs480929	chr13:76312773	G/A	cg04757411	chr13:76259545	LMO7	-0.36	-6.05	-0.32	4.04e-9	Type 1 diabetes;
CRC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08234897	chr7:151217114	RHEB	0.45	6.01	0.31	4.96e-9	Anxiety disorder;
CRC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg25834613	chr7:1915315	MAD1L1	0.52	8.82	0.44	6.9e-17	Bipolar disorder;
CRC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.54	-8.29	-0.42	2.97e-15	Aortic root size;
CRC	cis	rs10208940	0.920	rs13400463	chr2:68723912	G/A	cg12452813	chr2:68675892	NA	0.51	6.35	0.33	7.33e-10	Urate levels in lean individuals;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18122411	chr2:122513043	TSN	0.39	6.07	0.32	3.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg16342193	chr10:102329863	NA	-0.35	-5.88	-0.31	1.03e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6761276	0.525	rs12711752	chr2:113837840	C/T	cg12858261	chr2:113808755	IL1F8	-0.35	-5.6	-0.3	4.51e-8	Protein quantitative trait loci;
CRC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg06654549	chr5:1875058	NA	0.39	5.78	0.3	1.75e-8	Cardiovascular disease risk factors;
CRC	cis	rs375066	0.762	rs10424336	chr19:44392100	C/T	cg12072164	chr19:44306565	LYPD5	0.39	5.8	0.3	1.57e-8	Breast cancer;
CRC	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg14593290	chr7:50529359	DDC	0.59	7.9	0.4	4.2e-14	Malaria;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09894072	chr16:68279486	PLA2G15	0.49	6.97	0.36	1.71e-11	Response to antipsychotic treatment;
CRC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.91	14.0	0.61	2.88e-35	Systemic lupus erythematosus;
CRC	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg11579758	chr4:1086637	RNF212	0.4	6.62	0.34	1.44e-10	Recombination rate (males);
CRC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.43	7.07	0.36	9.39e-12	Height;
CRC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.63	10.17	0.49	2.65e-21	Monocyte count;
CRC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg18612461	chr15:75251733	NA	0.37	5.87	0.31	1.06e-8	Breast cancer;
CRC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg19193384	chr17:30244184	NA	0.47	5.76	0.3	1.97e-8	Hip circumference adjusted for BMI;
CRC	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg02927042	chr1:21476669	EIF4G3	-0.49	-7.66	-0.39	2.11e-13	Superior frontal gyrus grey matter volume;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.85	15.67	0.65	9.64e-42	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	6.1	0.32	3.06e-9	Prudent dietary pattern;
CRC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.59	8.95	0.44	2.64e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6534441	0.727	rs77274206	chr4:125462188	G/C	cg21609808	chr4:125404261	NA	0.41	5.76	0.3	1.95e-8	Major depressive disorder;
CRC	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg12935359	chr14:103987150	CKB	-0.52	-7.31	-0.37	2.03e-12	Monocyte count;
CRC	cis	rs2949837	0.581	rs924140	chr7:45963114	C/T	cg04796162	chr7:45961102	IGFBP3	0.4	7.0	0.36	1.42e-11	Sitting height ratio;
CRC	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg22815214	chr1:201083145	CACNA1S	-0.53	-8.7	-0.43	1.62e-16	Permanent tooth development;
CRC	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg19875535	chr5:140030758	IK	0.4	6.12	0.32	2.64e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg26695010	chr11:65641043	EFEMP2	-0.39	-5.97	-0.31	6.06e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.66	-0.51	5.63e-23	Initial pursuit acceleration;
CRC	cis	rs17767392	0.958	rs12896986	chr14:71922893	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.17	-0.37	5.11e-12	Mitral valve prolapse;
CRC	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.62	-10.17	-0.49	2.56e-21	Neuroticism;
CRC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	7.27	0.37	2.66e-12	Mean platelet volume;
CRC	cis	rs3751196	0.808	rs56143748	chr12:104217196	C/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.5	6.69	0.35	9.72e-11	Caudate activity during reward;
CRC	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.41	-5.63	-0.3	3.78e-8	Coronary artery disease;
CRC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.69	-8.95	-0.44	2.61e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg05935833	chr10:81318306	SFTPA2	-0.74	-8.21	-0.41	4.94e-15	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg23254163	chr1:152506842	NA	0.5	10.09	0.49	4.75e-21	Hair morphology;
CRC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	8.0	0.4	2.14e-14	Motion sickness;
CRC	trans	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.47	0.38	7.24e-13	Endometrial cancer;
CRC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.86	-15.24	-0.64	4.59e-40	Body mass index;
CRC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-8.71	-0.43	1.56e-16	Electroencephalogram traits;
CRC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.76	-0.54	6.7399999999999993e-27	Type 2 diabetes;
CRC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	12.36	0.56	4.47e-29	Lymphocyte percentage of white cells;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg10217327	chr6:118973057	C6orf204	0.53	5.94	0.31	7.14e-9	Diastolic blood pressure;
CRC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	7.99	0.4	2.25e-14	Height;
CRC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.7	-0.35	8.85e-11	Aortic root size;
CRC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11645453	chr3:52864694	ITIH4	0.35	6.3	0.33	9.46e-10	Electroencephalogram traits;
CRC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.27	0.45	2.57e-18	Mean platelet volume;
CRC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-0.57	-7.96	-0.4	2.76e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.73	9.51	0.46	4.24e-19	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.58	-0.34	1.81e-10	Bipolar disorder;
CRC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.4	-0.33	5.3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs17539620	0.529	rs11753075	chr6:154875085	A/G	cg20019720	chr6:154832845	CNKSR3	0.34	7.67	0.39	1.95e-13	Lipoprotein (a) levels;
CRC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg12311346	chr5:56204834	C5orf35	0.53	8.13	0.41	8.65e-15	Coronary artery disease;
CRC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-9.04	-0.45	1.38e-17	Joint mobility (Beighton score);
CRC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg13390004	chr1:15929781	NA	0.43	6.24	0.33	1.37e-9	Systolic blood pressure;
CRC	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.39	5.75	0.3	2.07e-8	Growth-regulated protein alpha levels;
CRC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.24	0.69	6.35e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg27101125	chr19:17392770	ANKLE1	-0.33	-5.85	-0.31	1.19e-8	Systemic lupus erythematosus;
CRC	cis	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg04733911	chr16:78082701	NA	-0.44	-7.37	-0.38	1.38e-12	Systolic blood pressure (alcohol consumption interaction);
CRC	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.46	-0.34	3.68e-10	Coronary artery calcification;
CRC	cis	rs427941	0.632	rs201490	chr7:101751910	C/T	cg06246474	chr7:101738831	CUX1	0.44	6.73	0.35	7.61e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs11098699	0.821	rs13110588	chr4:124220676	A/G	cg09941581	chr4:124220074	SPATA5	-0.41	-6.2	-0.32	1.67e-9	Mosquito bite size;
CRC	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.09	0.45	9.42e-18	Dupuytren's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25718402	chr17:7165909	CLDN7	0.5	6.75	0.35	6.89e-11	Thyroid stimulating hormone;
CRC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.68	9.87	0.48	2.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.73	8.8	0.44	7.83e-17	Type 2 diabetes nephropathy;
CRC	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.46	8.01	0.4	1.94e-14	Common traits (Other);
CRC	cis	rs3823572	0.564	rs1986870	chr7:133660109	A/G	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.51	-7.1	-0.36	7.86e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.5	-6.15	-0.32	2.3e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs3864277	0.510	rs31478	chr5:131423475	T/C	cg11843238	chr5:131593191	PDLIM4	0.32	5.76	0.3	1.97e-8	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs236352	0.576	rs9380618	chr6:36853543	A/G	cg10099585	chr6:36853529	C6orf89	-0.45	-6.29	-0.33	9.94e-10	Heart rate;
CRC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.27	-0.41	3.34e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.79	-9.35	-0.46	1.4e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7725052	0.608	rs7717304	chr5:40481206	C/T	cg09067459	chr5:40385259	NA	0.35	5.73	0.3	2.24e-8	Pediatric autoimmune diseases;
CRC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.42	6.41	0.33	4.97e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.87	12.21	0.56	1.52e-28	Triglycerides;
CRC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.67	8.01	0.4	2.06e-14	Gut microbiome composition (summer);
CRC	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.07	0.36	9.57e-12	Intelligence (multi-trait analysis);
CRC	cis	rs6973256	0.569	rs12532950	chr7:133434286	C/T	cg10665199	chr7:133106180	EXOC4	0.44	6.88	0.35	2.97e-11	Intelligence (multi-trait analysis);
CRC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12273811	chr6:28175739	NA	0.63	8.03	0.4	1.75e-14	Parkinson's disease;
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.63	0.57	4.38e-30	Alzheimer's disease;
CRC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.51	6.88	0.35	3.01e-11	Height;
CRC	cis	rs2737618	0.698	rs2737681	chr1:200091864	C/T	cg21825944	chr1:200113062	NR5A2	-0.52	-7.39	-0.38	1.22e-12	Uric acid levels;
CRC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.67	10.13	0.49	3.54e-21	Gestational age at birth (maternal effect);
CRC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.66	-10.39	-0.5	4.6e-22	Height;
CRC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg03162506	chr22:38580953	NA	0.26	5.69	0.3	2.77e-8	Cutaneous nevi;
CRC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.42	-6.26	-0.33	1.22e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg13615338	chr4:55094005	PDGFRA	0.41	5.89	0.31	9.78e-9	Corneal astigmatism;
CRC	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg14768367	chr16:72042858	DHODH	-0.58	-6.58	-0.34	1.9e-10	Blood protein levels;
CRC	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.58	6.84	0.35	3.95e-11	Platelet count;
CRC	cis	rs9292777	0.518	rs10056760	chr5:40482599	C/T	cg09067459	chr5:40385259	NA	0.39	6.4	0.33	5.36e-10	Crohn's disease;Multiple sclerosis;
CRC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.45	0.42	9.23e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.08	10.63	0.51	7.1e-23	Diabetic retinopathy;
CRC	cis	rs6844506	1.000	rs4862356	chr4:185220262	A/G	cg18317788	chr4:185205197	NA	0.44	6.32	0.33	8.38e-10	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
CRC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.56	8.92	0.44	3.2e-17	Gout;
CRC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg16989086	chr20:62203971	PRIC285	0.5	6.47	0.34	3.65e-10	Glioblastoma;
CRC	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg26205652	chr12:48591994	NA	0.47	5.65	0.3	3.57e-8	Longevity (90 years and older);
CRC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.77	-0.3	1.88e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.67	-10.36	-0.5	5.87e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg18827107	chr12:86230957	RASSF9	-0.39	-5.91	-0.31	8.56e-9	Major depressive disorder;
CRC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.17	-0.32	2e-9	Extrinsic epigenetic age acceleration;
CRC	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.36	0.53	1.95e-25	Exhaled nitric oxide levels;
CRC	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.58	-8.02	-0.4	1.9e-14	Cancer;
CRC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.61	-10.03	-0.48	7.82e-21	Aortic root size;
CRC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg02033258	chr5:131593261	PDLIM4	0.41	7.82	0.4	7.26e-14	Breast cancer;
CRC	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg24463073	chr6:118973353	C6orf204	0.52	6.83	0.35	4.24e-11	Diastolic blood pressure;
CRC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.61	-11.33	-0.53	2.39e-25	Immature fraction of reticulocytes;
CRC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg08634762	chr5:134074437	CAMLG	0.44	6.25	0.33	1.3e-9	Anxiety disorder;
CRC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.92	-0.36	2.44e-11	Height;
CRC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg20041105	chr8:143859282	LYNX1	0.45	8.09	0.41	1.16e-14	Urinary tract infection frequency;
CRC	cis	rs12692738	0.526	rs355856	chr2:165628977	T/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.53	7.9	0.4	4.36e-14	Subjective well-being;
CRC	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.66	9.21	0.45	3.96e-18	White matter hyperintensity burden;
CRC	cis	rs4867766	0.871	rs2242419	chr5:173959332	C/T	cg20434911	chr5:173954559	NA	0.73	8.7	0.43	1.57e-16	Stroke;
CRC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.69	-8.77	-0.44	9.65e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs4880487	0.888	rs72760998	chr10:1251203	T/C	cg03183215	chr10:1252341	ADARB2	-0.28	-5.66	-0.3	3.3e-8	Migraine;
CRC	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg22561889	chr6:118971681	C6orf204	0.51	6.56	0.34	2.06e-10	Diastolic blood pressure;
CRC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.42	-6.79	-0.35	5.16e-11	Type 2 diabetes;
CRC	cis	rs12024301	0.557	rs10494564	chr1:183654232	A/T	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.38	5.7	0.3	2.72e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg07507251	chr3:52567010	NT5DC2	-0.38	-5.75	-0.3	2.04e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs12476592	0.602	rs262472	chr2:63833616	G/A	cg10828910	chr2:63850056	LOC388955	0.5	6.1	0.32	2.95e-9	Childhood ear infection;
CRC	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.29	-0.33	1.01e-9	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg16898833	chr6:26189333	HIST1H4D	0.74	6.39	0.33	5.68e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg19792802	chr11:65647270	CTSW	0.5	7.55	0.38	4.23e-13	Crohn's disease;
CRC	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.55	-8.67	-0.43	1.96e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.91	-21.28	-0.76	8.56e-64	Longevity;
CRC	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.47	-7.04	-0.36	1.13e-11	Schizophrenia;
CRC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg09835421	chr16:68378352	PRMT7	-0.77	-8.1	-0.41	1.1e-14	Schizophrenia;
CRC	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg15282417	chr9:129245246	FAM125B	0.44	8.25	0.41	3.85e-15	Intraocular pressure;
CRC	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.74	-16.13	-0.66	1.56e-43	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg02527881	chr3:46936655	PTH1R	0.4	7.18	0.37	4.75e-12	Colorectal cancer;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg05999729	chr2:98369433	NA	-0.4	-6.13	-0.32	2.57e-9	HDL cholesterol;
CRC	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg16822035	chr13:113633379	MCF2L	-0.29	-5.93	-0.31	7.57e-9	Systolic blood pressure;
CRC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	cis	rs365302	0.767	rs412690	chr6:159613544	G/A	cg14500486	chr6:159655392	FNDC1	0.6	8.63	0.43	2.63e-16	Coronary heart disease;
CRC	cis	rs1656402	1.000	rs1210070	chr2:233423788	C/G	cg03852847	chr2:233439513	NA	0.45	7.71	0.39	1.54e-13	Non-small cell lung cancer (survival);
CRC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg27523141	chr10:43048294	ZNF37B	0.45	6.47	0.34	3.65e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.45	7.54	0.38	4.47e-13	Alcohol dependence;
CRC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.76	9.15	0.45	6.19e-18	Response to hepatitis C treatment;
CRC	cis	rs4604732	0.642	rs4472786	chr1:247636518	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.62	0.34	1.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.68	-9.89	-0.48	2.31e-20	Blood protein levels;
CRC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.68	11.08	0.52	1.79e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs6834538	1.000	rs1486864	chr4:113465766	G/T	cg10021238	chr4:113569128	MIR367;LARP7	-0.46	-6.78	-0.35	5.72e-11	Free thyroxine concentration;
CRC	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.37	-5.94	-0.31	7.35e-9	Height;
CRC	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.72	10.9	0.52	7.75e-24	Waist circumference;Body mass index;
CRC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.52	8.33	0.42	2.21e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg24531977	chr5:56204891	C5orf35	0.45	7.0	0.36	1.47e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-6.93	-0.36	2.26e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	trans	rs7859245	1.000	rs7859245	chr9:138490597	A/G	cg14410503	chr7:47343076	TNS3	0.37	6.18	0.32	1.89e-9	Response to paliperidone in schizophrenia (negative Marder score);
CRC	cis	rs6700896	0.966	rs10889570	chr1:66088084	C/G	cg04111102	chr1:66153794	NA	0.33	5.92	0.31	7.88e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-8.46	-0.42	9.06e-16	Idiopathic membranous nephropathy;
CRC	cis	rs3812762	0.618	rs11042072	chr11:8822032	A/G	cg14711859	chr11:8959438	ASCL3	0.46	7.0	0.36	1.45e-11	Hypospadias;
CRC	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg14036092	chr11:66035641	RAB1B	-0.44	-5.84	-0.31	1.28e-8	Electroencephalogram traits;
CRC	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.37e-11	Prostate cancer;
CRC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.25	-16.69	-0.68	9.69e-46	Breast cancer;
CRC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.53	6.43	0.33	4.54e-10	Coronary artery calcification;
CRC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.4	-7.62	-0.39	2.73e-13	Subjective well-being;
CRC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs3020333	0.653	rs851984	chr6:152023191	G/A	cg22157087	chr6:152012887	ESR1	0.48	7.21	0.37	3.75e-12	Total body bone mineral density;
CRC	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.68	-7.87	-0.4	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg14593290	chr7:50529359	DDC	0.44	6.47	0.34	3.47e-10	Systemic sclerosis;
CRC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.71	0.54	1.02e-26	Prudent dietary pattern;
CRC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-6.45	-0.34	3.89e-10	Subjective well-being;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg07185584	chr20:19997881	NAA20	-0.43	-6.4	-0.33	5.34e-10	Daytime sleep phenotypes;
CRC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs698833	0.886	rs2927433	chr2:44580737	T/A	cg04920474	chr2:44395004	PPM1B	0.41	6.14	0.32	2.44e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg18758796	chr5:131593413	PDLIM4	0.34	6.19	0.32	1.76e-9	Blood metabolite levels;
CRC	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.82	-10.13	-0.49	3.73e-21	Exhaled nitric oxide output;
CRC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.51	-7.46	-0.38	7.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-6.78	-0.35	5.51e-11	Breast cancer;Breast cancer (early onset);
CRC	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg18646521	chr2:111875858	NA	0.37	5.77	0.3	1.87e-8	Chronic lymphocytic leukemia;
CRC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg13628971	chr7:2884303	GNA12	0.44	6.95	0.36	1.99e-11	Height;
CRC	cis	rs2969070	1.000	rs917079	chr7:2514181	C/T	cg03277898	chr7:2518824	NA	-0.45	-6.63	-0.34	1.4e-10	Diastolic blood pressure;
CRC	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.65	-11.06	-0.52	2.27e-24	Obesity-related traits;
CRC	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg19773385	chr1:10388646	KIF1B	0.48	6.62	0.34	1.42e-10	Hepatocellular carcinoma;
CRC	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.38	0.38	1.32e-12	Blood metabolite levels;
CRC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs6546324	0.559	rs4381768	chr2:67779388	T/C	cg15745817	chr2:67799979	NA	-0.52	-8.3	-0.42	2.63e-15	Endometriosis;
CRC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg11843238	chr5:131593191	PDLIM4	0.35	6.42	0.33	4.68e-10	Lung function (FEV1/FVC);
CRC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg23298862	chr7:158159286	PTPRN2	0.39	6.16	0.32	2.1e-9	Calcium levels;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.52	-0.34	2.61e-10	Bipolar disorder;
CRC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.65	-10.12	-0.49	3.77e-21	Blood pressure (smoking interaction);
CRC	cis	rs281302	0.621	rs6493278	chr15:47730015	C/T	cg13159054	chr15:47721715	NA	0.36	5.72	0.3	2.35e-8	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.26	-6.53	-0.34	2.46e-10	Lymphocyte counts;
CRC	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.4	-6.48	-0.34	3.35e-10	Mean arterial pressure;
CRC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.36	-6.62	-0.34	1.46e-10	Lymphocyte counts;
CRC	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.79	-12.87	-0.58	5.35e-31	Hypospadias;
CRC	cis	rs2493151	1.000	rs1317181	chr1:230873488	G/T	cg07502417	chr1:230849801	AGT	0.31	5.98	0.31	5.81e-9	Blood protein levels;
CRC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg04497992	chr16:616212	NHLRC4	0.44	6.96	0.36	1.89e-11	Height;
CRC	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg16591659	chr17:78472290	NA	0.42	6.02	0.31	4.77e-9	Fractional excretion of uric acid;
CRC	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.56	7.9	0.4	4.27e-14	Osteoporosis;
CRC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.54	8.73	0.43	1.26e-16	Prostate cancer;
CRC	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-8.69	-0.43	1.71e-16	Coronary artery disease;
CRC	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.63	-0.34	1.34e-10	Response to antipsychotic treatment;
CRC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.54	7.35	0.38	1.56e-12	Height;
CRC	cis	rs12530845	0.830	rs73721678	chr7:135355710	T/G	cg23117316	chr7:135346802	PL-5283	-0.45	-6.21	-0.32	1.57e-9	Red blood cell traits;
CRC	cis	rs56873913	0.904	rs7251295	chr19:50096859	G/C	cg15963326	chr19:50037085	RCN3	-0.37	-5.81	-0.31	1.47e-8	Schizophrenia;
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg20512303	chr5:131592959	PDLIM4	0.35	6.59	0.34	1.75e-10	Breast cancer;
CRC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-0.66	-11.36	-0.53	1.85e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg07742235	chr11:69308752	NA	0.37	6.11	0.32	2.82e-9	Aortic root size;
CRC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.41	6.84	0.35	3.85e-11	Childhood ear infection;
CRC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg12564285	chr5:131593104	PDLIM4	-0.36	-6.5	-0.34	2.96e-10	Blood metabolite levels;
CRC	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg27205649	chr11:78285834	NARS2	0.48	5.83	0.31	1.35e-8	Alzheimer's disease (survival time);
CRC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.21	-0.32	1.58e-9	Tonsillectomy;
CRC	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-8.61	-0.43	3.14e-16	Facial morphology (factor 19);
CRC	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.45	6.87	0.35	3.2e-11	Asthma;
CRC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.74	11.69	0.54	1.24e-26	Platelet distribution width;
CRC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg01788221	chr16:89496183	ANKRD11	-0.44	-6.85	-0.35	3.75e-11	Multiple myeloma (IgH translocation);
CRC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.45	-5.72	-0.3	2.43e-8	Gut microbiome composition (summer);
CRC	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg20387954	chr3:183756860	HTR3D	0.46	7.93	0.4	3.46e-14	Anterior chamber depth;
CRC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg23123621	chr4:1343375	KIAA1530	-0.36	-6.46	-0.34	3.74e-10	Obesity-related traits;
CRC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.51	7.6	0.39	3.1400000000000003e-13	Emphysema distribution in smoking;
CRC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg13256891	chr4:100009986	ADH5	0.46	6.33	0.33	7.9e-10	Alcohol dependence;
CRC	cis	rs1223397	0.702	rs13191897	chr6:13288428	G/A	cg06879394	chr6:13274151	PHACTR1	0.54	6.23	0.33	1.39e-9	Blood pressure;
CRC	cis	rs9648716	1.000	rs7803738	chr7:140442819	C/T	cg10747023	chr7:140774559	NA	0.45	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	cis	rs7635838	0.892	rs12163566	chr3:11483096	T/A	cg00170343	chr3:11313890	ATG7	0.41	6.29	0.33	1.02e-9	HDL cholesterol;
CRC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg15845792	chr6:28175446	NA	0.59	7.63	0.39	2.61e-13	Parkinson's disease;
CRC	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg27565382	chr3:53032988	SFMBT1	0.7	6.19	0.32	1.76e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.74	7.58	0.39	3.47e-13	Diabetic retinopathy;
CRC	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.56	10.23	0.49	1.62e-21	Cognitive performance;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08722104	chr11:47448306	PSMC3	0.56	7.24	0.37	3.18e-12	Thyroid stimulating hormone;
CRC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.72	0.43	1.44e-16	Total body bone mineral density;
CRC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg23815491	chr16:72088622	HP	0.51	7.69	0.39	1.77e-13	Fibrinogen levels;
CRC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-8.02	-0.4	1.93e-14	Gut microbiome composition (summer);
CRC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.68	-12.64	-0.57	3.93e-30	Breast cancer;
CRC	cis	rs2179367	0.959	rs9377212	chr6:149704901	G/C	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.34	-0.33	7.73e-10	Dupuytren's disease;
CRC	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.95	11.2	0.53	7.25e-25	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs970548	0.954	rs61854096	chr10:45981184	A/C	cg15590007	chr10:45870220	ALOX5	0.47	5.97	0.31	6.15e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CRC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg12365402	chr11:9010492	NRIP3	-0.61	-11.51	-0.54	5.62e-26	Hemoglobin concentration;
CRC	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.41	0.46	9.01e-19	Blood protein levels;
CRC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.47	-0.38	7.32e-13	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	17.31	0.69	3.4e-48	Smoking behavior;
CRC	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg16898833	chr6:26189333	HIST1H4D	0.75	6.55	0.34	2.26e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.61	-8.98	-0.44	2.11e-17	Other erythrocyte phenotypes;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg13047869	chr3:10149882	C3orf24	0.57	6.77	0.35	5.94e-11	Alzheimer's disease;
CRC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg27588902	chr6:42928151	GNMT	-0.34	-5.61	-0.3	4.2e-8	Blood protein levels;
CRC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.6	7.86	0.4	5.4e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.38	-0.38	1.3e-12	Height;
CRC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg21770322	chr7:97807741	LMTK2	0.52	8.56	0.43	4.41e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.74	12.39	0.56	3.31e-29	Body mass index;
CRC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg12516270	chr8:143859308	LYNX1	-0.4	-6.29	-0.33	9.94e-10	Urinary tract infection frequency;
CRC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	7.17	0.37	4.85e-12	Rheumatoid arthritis;
CRC	cis	rs6880778	0.505	rs10072596	chr5:40407033	A/G	cg09067459	chr5:40385259	NA	0.45	7.79	0.39	8.88e-14	Inflammatory bowel disease;
CRC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.75	-0.3	2.08e-8	Lung cancer;
CRC	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-6.39	-0.33	5.66e-10	Response to bleomycin (chromatid breaks);
CRC	trans	rs55675132	0.548	rs79671603	chr1:115377698	A/T	cg25493687	chr8:27288214	PTK2B	0.49	6.0	0.31	5.23e-9	Schizophrenia;
CRC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.58	6.16	0.32	2.15e-9	Axial length;
CRC	cis	rs2882667	0.690	rs160402	chr5:138059288	G/T	cg09476006	chr5:138032270	NA	0.56	9.65	0.47	1.4e-19	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	6.54	0.34	2.42e-10	Rheumatoid arthritis;
CRC	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.5	-0.34	2.93e-10	Coronary artery calcification;
CRC	cis	rs10128264	0.935	rs1250575	chr10:80963546	A/G	cg20744163	chr10:80999841	ZMIZ1	0.34	6.1	0.32	2.99e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg01193554	chr1:41846683	NA	-0.38	-6.11	-0.32	2.78e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.43	5.7	0.3	2.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg20487152	chr13:99095054	FARP1	-0.46	-7.05	-0.36	1.05e-11	Longevity;
CRC	cis	rs863345	0.604	rs4373761	chr1:158464634	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.29	-0.33	9.9e-10	Pneumococcal bacteremia;
CRC	cis	rs6496667	0.865	rs7169196	chr15:90877484	C/T	cg04176472	chr15:90893244	GABARAPL3	0.6	7.17	0.37	5.13e-12	Rheumatoid arthritis;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg23161317	chr6:28129485	ZNF389	0.47	6.64	0.34	1.28e-10	Parkinson's disease;
CRC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.49	7.22	0.37	3.69e-12	Height;
CRC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg04545296	chr12:48745243	ZNF641	0.33	5.75	0.3	2.05e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7429990	0.932	rs7630685	chr3:48131170	G/C	cg11946769	chr3:48343235	NME6	-0.47	-5.93	-0.31	7.73e-9	Educational attainment (years of education);
CRC	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg04289385	chr6:36355825	ETV7	0.39	5.71	0.3	2.48e-8	Mean platelet volume;
CRC	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg09491104	chr22:46646882	C22orf40	-0.37	-5.82	-0.31	1.4e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	16.21	0.67	7.23e-44	Chronic sinus infection;
CRC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.43	6.48	0.34	3.32e-10	Longevity;Endometriosis;
CRC	cis	rs7173389	0.551	rs78060843	chr15:73683583	G/T	cg01796676	chr15:73680284	NA	0.6	5.92	0.31	8.09e-9	Resting heart rate;
CRC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.86	9.7	0.47	9.59e-20	Type 2 diabetes nephropathy;
CRC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg23161317	chr6:28129485	ZNF389	0.46	6.46	0.34	3.68e-10	Cardiac Troponin-T levels;
CRC	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg18833306	chr6:118973337	C6orf204	0.46	5.88	0.31	1.01e-8	Diastolic blood pressure;
CRC	cis	rs77861329	1.000	rs2304505	chr3:52184760	T/C	cg08692210	chr3:52188851	WDR51A	0.83	7.76	0.39	1.08e-13	Macrophage inflammatory protein 1b levels;
CRC	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg12483005	chr1:23474871	LUZP1	0.39	5.63	0.3	3.85e-8	Height;
CRC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.59	-11.06	-0.52	2.24e-24	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.96	-0.36	1.85e-11	Height;
CRC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.91	16.88	0.68	1.72e-46	Intelligence (multi-trait analysis);
CRC	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Dilated cardiomyopathy;
CRC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg20203395	chr5:56204925	C5orf35	-0.73	-8.7	-0.43	1.66e-16	Initial pursuit acceleration;
CRC	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg18232548	chr7:50535776	DDC	0.46	6.46	0.34	3.68e-10	Malaria;
CRC	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg27398640	chr15:77910606	LINGO1	-0.44	-7.53	-0.38	5e-13	Type 2 diabetes;
CRC	cis	rs7605827	0.704	rs3732001	chr2:15536872	T/C	cg19274914	chr2:15703543	NA	0.39	5.87	0.31	1.06e-8	Educational attainment (years of education);
CRC	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg26383811	chr8:30366931	RBPMS	-0.67	-9.7	-0.47	1.01e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs12523822	0.913	rs2056370	chr6:154967167	T/G	cg20019720	chr6:154832845	CNKSR3	0.27	5.82	0.31	1.4e-8	Diabetic kidney disease;
CRC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16262614	chr3:133464971	TF	0.4	7.09	0.36	8.42e-12	Iron status biomarkers;
CRC	cis	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg07460842	chr6:66804631	NA	-0.43	-5.78	-0.3	1.72e-8	Blood trace element (Cu levels);
CRC	trans	rs56052703	0.702	rs10421428	chr19:13433348	C/T	cg07875759	chr21:43639080	ABCG1	0.48	6.21	0.32	1.59e-9	Proteinuria and chronic kidney disease;
CRC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13198984	chr17:80129470	CCDC57	-0.48	-8.47	-0.42	8.34e-16	Life satisfaction;
CRC	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.83	-0.4	6.68e-14	Homocysteine levels;
CRC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg19582491	chr16:67682965	RLTPR	0.53	6.08	0.32	3.25e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13198984	chr17:80129470	CCDC57	0.45	8.01	0.4	1.99e-14	Life satisfaction;
CRC	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02825527	chr7:2087843	MAD1L1	-0.5	-6.07	-0.32	3.54e-9	Neuroticism;
CRC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg06028605	chr16:24865363	SLC5A11	-0.44	-6.98	-0.36	1.62e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6504622	0.755	rs34038545	chr17:45144907	G/C	cg16759221	chr17:45003025	GOSR2	0.44	6.76	0.35	6.26e-11	Orofacial clefts;
CRC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.83	-12.82	-0.58	8.3e-31	Response to antineoplastic agents;
CRC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg02527881	chr3:46936655	PTH1R	0.32	5.72	0.3	2.42e-8	Colorectal cancer;
CRC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg07636037	chr3:49044803	WDR6	-0.84	-6.41	-0.33	5.07e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs4499344	0.577	rs259289	chr19:33164927	G/C	cg08127369	chr19:33164662	ANKRD27	0.39	6.01	0.31	5.02e-9	Mean platelet volume;
CRC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.65	7.04	0.36	1.13e-11	Axial length;
CRC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.89	10.65	0.51	5.85e-23	Dilated cardiomyopathy;
CRC	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.48	-8.88	-0.44	4.54e-17	Hip circumference;Waist circumference;
CRC	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21643547	chr1:205240462	TMCC2	-0.41	-6.65	-0.34	1.23e-10	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs9969804	0.782	rs10761169	chr9:95515033	T/C	cg14631576	chr9:95140430	CENPP	-0.31	-5.64	-0.3	3.59e-8	Height;
CRC	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.75	-0.3	2.01e-8	Blood pressure;
CRC	cis	rs7705042	0.793	rs10463348	chr5:141502035	G/T	cg08523384	chr5:141488047	NDFIP1	-0.34	-6.08	-0.32	3.29e-9	Asthma;
CRC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	12.17	0.56	2.2e-28	Bone mineral density;
CRC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg25985355	chr7:65971099	NA	-0.49	-5.85	-0.31	1.19e-8	Diabetic kidney disease;
CRC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-10.11	-0.49	4.11e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg19812747	chr11:111475976	SIK2	-0.59	-10.14	-0.49	3.31e-21	Primary sclerosing cholangitis;
CRC	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg09659197	chr4:152720779	NA	-0.49	-10.52	-0.5	1.65e-22	Intelligence (multi-trait analysis);
CRC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.55	7.26	0.37	2.74e-12	Schizophrenia;
CRC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.47	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.48	-10.5	-0.5	1.96e-22	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs939584	0.935	rs10166979	chr2:640701	A/G	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg25834613	chr7:1915315	MAD1L1	0.39	6.05	0.32	3.96e-9	Bipolar disorder;
CRC	cis	rs12476592	0.602	rs964880	chr2:63826932	C/A	cg10828910	chr2:63850056	LOC388955	0.5	6.13	0.32	2.54e-9	Childhood ear infection;
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg24046110	chr8:143859143	LYNX1	0.47	8.18	0.41	6.22e-15	Urinary tract infection frequency;
CRC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.43	0.38	9.28e-13	Major depressive disorder;
CRC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg00750074	chr16:89608354	SPG7	-0.49	-7.3	-0.37	2.25e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-0.83	-12.79	-0.58	1.11e-30	Blood trace element (Zn levels);
CRC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	14.99	0.64	4.43e-39	Chronic sinus infection;
CRC	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg12046867	chr14:103022105	NA	-0.77	-9.19	-0.45	4.41e-18	Platelet count;
CRC	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg21153622	chr11:89784906	NA	-0.49	-8.18	-0.41	6.47e-15	HDL cholesterol;
CRC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.56	6.21	0.32	1.59e-9	Initial pursuit acceleration;
CRC	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-6.58	-0.34	1.83e-10	Coronary artery disease;
CRC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.27	-0.33	1.16e-9	Bipolar disorder;
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg10729496	chr3:10149963	C3orf24	0.5	6.78	0.35	5.69e-11	Alzheimer's disease;
CRC	cis	rs3790645	0.645	rs3790644	chr1:26884676	G/A	cg23229016	chr1:26872525	RPS6KA1	0.29	5.82	0.31	1.41e-8	Glucose homeostasis traits;
CRC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg16606324	chr3:10149918	C3orf24	0.64	8.43	0.42	1.13e-15	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25662041	chr5:176759170	LMAN2	0.26	5.96	0.31	6.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9463078	0.647	rs6933449	chr6:45325151	G/C	cg25276700	chr6:44698697	NA	0.25	5.94	0.31	7.36e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.56	-7.01	-0.36	1.34e-11	Bronchopulmonary dysplasia;
CRC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	7.52	0.38	5.35e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.58	-10.2	-0.49	2.15e-21	Iron status biomarkers;
CRC	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.56	8.32	0.42	2.39e-15	Multiple myeloma (IgH translocation);
CRC	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.98	12.39	0.56	3.49e-29	Orofacial clefts;
CRC	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg16342193	chr10:102329863	NA	-0.34	-5.68	-0.3	2.92e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-9.24	-0.45	3.2e-18	Neuranatomic and neurocognitive phenotypes;
CRC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.4	-6.72	-0.35	8.13e-11	Total body bone mineral density;
CRC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg11833968	chr6:79620685	NA	-0.34	-5.67	-0.3	3.11e-8	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg21251018	chr6:28226885	NKAPL	0.46	6.57	0.34	1.97e-10	Depression;
CRC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg21138405	chr5:131827807	IRF1	0.31	5.65	0.3	3.43e-8	Blood metabolite levels;
CRC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.44	6.22	0.32	1.54e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18876405	chr7:65276391	NA	-0.51	-8.49	-0.42	6.96e-16	Aortic root size;
CRC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.43	8.88	0.44	4.37e-17	Renal cell carcinoma;
CRC	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg20356878	chr3:121714668	ILDR1	-0.48	-6.58	-0.34	1.91e-10	Multiple sclerosis;
CRC	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg01216370	chr2:228736459	WDR69	-0.45	-5.7	-0.3	2.68e-8	Blood pressure;
CRC	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.45	-6.44	-0.33	4.17e-10	Body mass index;
CRC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	6.13	0.32	2.57e-9	Tonsillectomy;
CRC	cis	rs1950626	0.796	rs7152870	chr14:101389987	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.92	-14.82	-0.63	1.95e-38	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.58	-8.39	-0.42	1.41e-15	Waist circumference;Body mass index;
CRC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.46	0.34	3.71e-10	Renal cell carcinoma;
CRC	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg01191920	chr7:158217561	PTPRN2	-0.74	-11.91	-0.55	1.87e-27	Obesity-related traits;
CRC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.78	-0.35	5.59e-11	Blood metabolite levels;
CRC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg18758796	chr5:131593413	PDLIM4	-0.32	-5.66	-0.3	3.37e-8	Blood metabolite levels;
CRC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.66	8.29	0.42	3e-15	Menarche (age at onset);
CRC	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg22153745	chr1:153894579	GATAD2B	-0.57	-7.45	-0.38	8.11e-13	Total cholesterol levels;
CRC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.54	0.47	3.27e-19	Bladder cancer;
CRC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.69	0.35	9.55e-11	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.49	-0.42	7.34e-16	Monocyte percentage of white cells;
CRC	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-8.34	-0.42	2.03e-15	Bone mineral density;
CRC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.88	11.26	0.53	4.43e-25	Iron status biomarkers;
CRC	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.39	-0.38	1.22e-12	Multiple myeloma (hyperdiploidy);
CRC	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11446398	chr5:77624930	NA	-0.46	-6.24	-0.33	1.32e-9	Triglycerides;
CRC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg24675056	chr1:15929824	NA	0.49	6.77	0.35	5.87e-11	Systolic blood pressure;
CRC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.03	0.36	1.21e-11	Joint mobility (Beighton score);
CRC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	10.38	0.5	4.9e-22	Systolic blood pressure;
CRC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-0.55	-6.75	-0.35	6.73e-11	Depression;
CRC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	9.27	0.46	2.56e-18	Migraine;Coronary artery disease;
CRC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	16.9	0.68	1.47e-46	Platelet count;
CRC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.9	0.52	7.66e-24	Prudent dietary pattern;
CRC	cis	rs9525927	0.625	rs9533801	chr13:44816569	A/G	cg19190762	chr13:44806055	NA	0.46	5.97	0.31	6.16e-9	Dupuytren's disease;
CRC	cis	rs9467711	0.720	rs1417998	chr6:26162019	T/A	cg16898833	chr6:26189333	HIST1H4D	0.66	6.14	0.32	2.37e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.6	6.17	0.32	1.98e-9	Blood protein levels;
CRC	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg08807101	chr21:30365312	RNF160	-0.52	-7.19	-0.37	4.37e-12	Pancreatic cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27547812	chr1:26437414	PDIK1L	0.45	5.97	0.31	6.05e-9	Anxiety disorder;
CRC	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.86	-20.9	-0.76	2.59e-62	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg17724175	chr1:150552817	MCL1	0.48	7.08	0.36	8.66e-12	Melanoma;
CRC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg00597713	chr6:42947103	PEX6	0.42	6.03	0.32	4.43e-9	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.1	21.14	0.76	3.07e-63	Cognitive function;
CRC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.89	14.95	0.64	6.56e-39	Cognitive function;
CRC	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-6.1	-0.32	3.01e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.42	-7.06	-0.36	1e-11	Testicular germ cell tumor;
CRC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg11189052	chr15:85197271	WDR73	0.6	8.83	0.44	6.13e-17	Schizophrenia;
CRC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.3	-6.1	-0.32	3.06e-9	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg03623178	chr6:28175578	NA	0.74	8.24	0.41	4.24e-15	Depression;
CRC	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.66	-10.78	-0.51	2.04e-23	Hepatocellular carcinoma;
CRC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.76	-0.3	1.92e-8	Migraine;Coronary artery disease;
CRC	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg00507830	chr2:103233733	NA	0.54	6.0	0.31	5.34e-9	Gut microbiota (bacterial taxa);
CRC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	0.91	8.39	0.42	1.43e-15	Plateletcrit;
CRC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg27523141	chr10:43048294	ZNF37B	0.44	6.44	0.33	4.17e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg11027325	chr2:239148674	HES6	0.39	6.47	0.34	3.59e-10	Obesity-related traits;
CRC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.68	10.3	0.49	9.6e-22	Menopause (age at onset);
CRC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-10.36	-0.5	5.97e-22	Sudden cardiac arrest;
CRC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.59	9.43	0.46	7.86e-19	Tonsillectomy;
CRC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.6	-10.39	-0.5	4.76e-22	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.59	-8.98	-0.44	2.1e-17	Height;
CRC	cis	rs10946940	0.896	rs12208078	chr6:27498581	G/A	cg06470822	chr6:28175283	NA	-0.5	-6.85	-0.35	3.7e-11	Systemic lupus erythematosus;
CRC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.52	8.27	0.41	3.38e-15	Selective IgA deficiency;
CRC	cis	rs7605827	0.930	rs11893303	chr2:15613715	G/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.43	-6.15	-0.32	2.31e-9	Response to metformin (IC50);
CRC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	12.33	0.56	5.69e-29	Cognitive ability;
CRC	cis	rs959260	0.588	rs12938183	chr17:73320433	G/C	cg14668889	chr17:73230827	NUP85	-0.51	-7.5	-0.38	5.85e-13	Systemic lupus erythematosus;
CRC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg23018236	chr17:30244563	NA	-0.64	-7.5	-0.38	6.12e-13	Hip circumference adjusted for BMI;
CRC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.06	0.32	3.7e-9	Rheumatoid arthritis;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg02416716	chr11:6948024	ZNF215	0.58	5.98	0.31	5.9e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.25	0.33	1.28e-9	Rheumatoid arthritis;
CRC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.82	0.7	3.44e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs4684776	0.500	rs35913374	chr3:11639274	T/C	cg20302342	chr1:156215951	PAQR6	-0.48	-6.3	-0.33	9.8e-10	Small vessel stroke;
CRC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg21839984	chr17:30846986	MYO1D	-0.35	-5.9	-0.31	9.24e-9	Schizophrenia;
CRC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18912574	chr7:65842487	NCRNA00174	-0.36	-6.14	-0.32	2.44e-9	Aortic root size;
CRC	cis	rs1950626	0.532	rs61991120	chr14:101455222	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.76	12.31	0.56	6.42e-29	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg10517650	chr3:113235015	CCDC52	-0.41	-7.29	-0.37	2.4e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	7.06	0.36	1.01e-11	Cognitive test performance;
CRC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12315302	chr6:26189340	HIST1H4D	0.81	6.23	0.32	1.45e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.59	-9.24	-0.45	3.11e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg05874882	chr4:1763078	NA	-0.4	-7.22	-0.37	3.57e-12	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.37	-5.9	-0.31	8.91e-9	Red cell distribution width;
CRC	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.9	-11.45	-0.53	8.8e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	trans	rs12406019	0.510	rs2025614	chr1:78618151	G/A	cg20826526	chr3:156266748	SSR3	-0.49	-7.32	-0.37	1.95e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs16852403	0.548	rs316280	chr1:178158085	C/T	cg00404053	chr1:178313656	RASAL2	0.5	6.51	0.34	2.77e-10	Childhood ear infection;
CRC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.49	9.89	0.48	2.26e-20	Inflammatory bowel disease;Ulcerative colitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12416259	chr10:60028969	CISD1;IPMK	0.39	6.22	0.32	1.55e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.51	-8.49	-0.42	7.27e-16	Airway imaging phenotypes;
CRC	cis	rs7074356	0.831	rs12764048	chr10:82148963	A/G	cg05935833	chr10:81318306	SFTPA2	-0.58	-7.06	-0.36	9.74e-12	Borderline personality disorder;
CRC	cis	rs7692995	1.000	rs1585334	chr4:18018944	C/T	cg08925142	chr4:18023851	LCORL	-0.51	-5.81	-0.3	1.5e-8	Height;
CRC	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.01	9.38	0.46	1.09e-18	Severe influenza A (H1N1) infection;
CRC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.61	9.43	0.46	7.73e-19	Gestational age at birth (maternal effect);
CRC	cis	rs932541	1.000	rs6111155	chr20:16456461	C/A	cg17003395	chr20:16555519	KIF16B	0.42	5.75	0.3	2.02e-8	Intelligence;
CRC	cis	rs3751196	0.808	rs60378307	chr12:104206707	A/G	cg02344784	chr12:104178138	NT5DC3	0.7	7.1	0.36	7.96e-12	Sense of smell;
CRC	cis	rs889398	0.594	rs2133799	chr16:69913026	C/T	cg00738113	chr16:70207722	CLEC18C	-0.34	-5.92	-0.31	7.97e-9	Body mass index;
CRC	trans	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.59	-0.34	1.72e-10	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.5	7.22	0.37	3.56e-12	Longevity;Endometriosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10140087	chr19:42746897	GSK3A	0.46	6.57	0.34	1.91e-10	Intelligence (multi-trait analysis);
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg16369786	chr1:63153804	DOCK7	-0.41	-6.07	-0.32	3.53e-9	Daytime sleep phenotypes;
CRC	cis	rs644148	0.836	rs2571110	chr19:45000712	T/C	cg15540054	chr19:45004280	ZNF180	-0.59	-8.24	-0.41	4.27e-15	Personality dimensions;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21302420	chr1:112162376	RAP1A	0.37	6.03	0.32	4.31e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.77	13.41	0.59	5.19e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-11.24	-0.53	4.91e-25	Bipolar disorder and schizophrenia;
CRC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.51	5.97	0.31	6.25e-9	Renal function-related traits (BUN);
CRC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.77	9.25	0.45	3.03e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.74	11.49	0.54	6.37e-26	Longevity;Endometriosis;
CRC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.58	8.02	0.4	1.88e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.71	5.96	0.31	6.39e-9	Breast cancer;
CRC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg03395651	chr16:88107091	BANP	0.57	7.8	0.39	8.39e-14	Menopause (age at onset);
CRC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.49	-7.52	-0.38	5.24e-13	Cognitive function;
CRC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.58	-9.15	-0.45	6.16e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg14021555	chr22:43485536	TTLL1	-0.51	-6.17	-0.32	1.98e-9	Diisocyanate-induced asthma;
CRC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.71	-7.77	-0.39	1.04e-13	Major depressive disorder;
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg26587870	chr6:27730563	NA	-0.67	-6.81	-0.35	4.76e-11	Breast cancer;
CRC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-10.37	-0.5	5.67e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.21	-16.57	-0.67	2.78e-45	Breast cancer;
CRC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.02	-10.25	-0.49	1.4e-21	Body mass index;
CRC	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.44	6.96	0.36	1.87e-11	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg20615401	chr6:28092323	ZSCAN16	0.44	5.76	0.3	1.88e-8	Cardiac Troponin-T levels;
CRC	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg19748678	chr4:122722346	EXOSC9	0.48	6.72	0.35	8.08e-11	Type 2 diabetes;
CRC	cis	rs73206853	0.841	rs56251637	chr12:110833869	T/G	cg12870014	chr12:110450643	ANKRD13A	0.78	8.56	0.43	4.41e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.47	-0.38	7.25e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs9354654	0.826	rs1514351	chr6:68694074	T/C	cg06657852	chr16:86786582	NA	0.41	6.01	0.31	4.89e-9	Classic bladder exstrophy;
CRC	cis	rs4908768	0.501	rs6577494	chr1:8576925	C/T	cg20416874	chr1:8611966	RERE	-0.46	-6.57	-0.34	1.95e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.25	0.45	2.94e-18	Monocyte percentage of white cells;
CRC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg07919128	chr17:18022025	MYO15A	0.36	5.74	0.3	2.19e-8	Total body bone mineral density;
CRC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.38	-6.25	-0.33	1.27e-9	HDL cholesterol;
CRC	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg01849466	chr14:104193079	ZFYVE21	0.4	5.61	0.3	4.41e-8	Body mass index;
CRC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.91	-0.36	2.48e-11	Aortic root size;
CRC	cis	rs938554	0.736	rs11734219	chr4:9977154	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	5.64	0.3	3.62e-8	Blood metabolite levels;
CRC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.37	7.24	0.37	3.28e-12	Tonsillectomy;
CRC	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	11.35	0.53	2e-25	Height;
CRC	cis	rs883565	0.740	rs11925218	chr3:39081171	C/A	cg01426195	chr3:39028469	NA	-0.53	-8.54	-0.43	4.97e-16	Handedness;
CRC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.41	6.67	0.35	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.57	9.97	0.48	1.29e-20	Age of smoking initiation;
CRC	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.96	-0.36	1.91e-11	Coronary artery disease;
CRC	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.56	7.27	0.37	2.61e-12	Coronary artery disease;
CRC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg18876405	chr7:65276391	NA	0.4	5.67	0.3	3.2e-8	Aortic root size;
CRC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-9.26	-0.45	2.72e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.57	8.47	0.42	8.51e-16	Type 2 diabetes;
CRC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.57	-10.39	-0.5	4.84e-22	Educational attainment;
CRC	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.42	-5.93	-0.31	7.84e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.15	10.28	0.49	1.08e-21	Arsenic metabolism;
CRC	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.61	-8.69	-0.43	1.69e-16	Coronary artery disease;
CRC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg08314208	chr16:67682810	RLTPR	-0.66	-7.0	-0.36	1.44e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.71	10.47	0.5	2.45e-22	Corneal astigmatism;
CRC	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.46	7.92	0.4	3.72e-14	Common traits (Other);
CRC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17507749	chr15:85114479	UBE2QP1	0.66	9.38	0.46	1.14e-18	Schizophrenia;
CRC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-8.63	-0.43	2.69e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.63	-11.4	-0.53	1.35e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17497049	chr19:56110871	FIZ1;ZNF524	0.43	6.28	0.33	1.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.5	8.54	0.43	5.03e-16	Dupuytren's disease;
CRC	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg14711859	chr11:8959438	ASCL3	-0.41	-6.53	-0.34	2.48e-10	Hemoglobin concentration;
CRC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg11212589	chr17:38028394	ZPBP2	0.48	8.89	0.44	4.21e-17	Self-reported allergy;
CRC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg21620606	chr4:1342894	KIAA1530	0.39	6.53	0.34	2.46e-10	Obesity-related traits;
CRC	cis	rs4711336	1.000	rs11759396	chr6:33656654	C/G	cg14003231	chr6:33640908	ITPR3	0.51	8.19	0.41	5.69e-15	Height;
CRC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.74	12.69	0.57	2.68e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.87	0.51	1.01e-23	Motion sickness;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.37	-5.93	-0.31	7.66e-9	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05491346	chr10:127512596	BCCIP;UROS	0.44	5.99	0.31	5.37e-9	Response to antipsychotic treatment;
CRC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.5	8.45	0.42	9.4e-16	Primary biliary cholangitis;
CRC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.66	11.06	0.52	2.17e-24	Mean corpuscular volume;
CRC	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.6	8.38	0.42	1.56e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.44	-8.61	-0.43	3.18e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg03233332	chr7:66118400	NA	-0.45	-6.26	-0.33	1.21e-9	Aortic root size;
CRC	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg12682573	chr17:27188876	MIR451;MIR144	0.57	7.01	0.36	1.32e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.68	-8.14	-0.41	8.09e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.57	-5.9	-0.31	9.05e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg22561889	chr6:118971681	C6orf204	0.47	5.9	0.31	8.96e-9	Diastolic blood pressure;
CRC	cis	rs4664293	0.625	rs34573069	chr2:160500072	T/A	cg08347373	chr2:160653686	CD302	0.39	6.68	0.35	1.03e-10	Monocyte percentage of white cells;
CRC	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg24140574	chr1:16342155	HSPB7	0.47	6.67	0.35	1.1e-10	Dilated cardiomyopathy;
CRC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.52	9.22	0.45	3.59e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.52e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.13	-0.41	8.58e-15	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13834670	chr9:129677390	RALGPS1	0.37	6.5	0.34	3e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg15744005	chr10:104629667	AS3MT	0.3	6.06	0.32	3.82e-9	Arsenic metabolism;
CRC	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	21.01	0.76	9.79e-63	Colorectal cancer;
CRC	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-7.83	-0.4	6.65e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06544989	chr22:39130855	UNC84B	0.44	6.45	0.34	4.01e-10	Menopause (age at onset);
CRC	cis	rs4654899	0.828	rs6668591	chr1:21066557	A/G	cg02927042	chr1:21476669	EIF4G3	-0.44	-6.84	-0.35	3.88e-11	Superior frontal gyrus grey matter volume;
CRC	cis	rs860295	0.702	rs2048431	chr1:155618630	G/A	cg02153340	chr1:155202674	NA	-0.54	-6.54	-0.34	2.38e-10	Body mass index;
CRC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.67	-9.86	-0.48	2.93e-20	Intelligence (multi-trait analysis);
CRC	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg09654669	chr8:57350985	NA	-0.44	-5.86	-0.31	1.12e-8	Obesity-related traits;
CRC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.52	-6.15	-0.32	2.2e-9	Multiple sclerosis;
CRC	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg17524180	chr13:113633600	MCF2L	0.52	9.32	0.46	1.71e-18	Systolic blood pressure;
CRC	cis	rs4478137	0.931	rs7687423	chr4:164250797	C/T	cg06758707	chr4:164254230	NPY1R	-0.36	-5.63	-0.3	3.87e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
CRC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.61	9.06	0.45	1.18e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.54	8.69	0.43	1.77e-16	Aortic root size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25789201	chr7:72395803	POM121	-0.51	-6.09	-0.32	3.09e-9	Diisocyanate-induced asthma;
CRC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13047869	chr3:10149882	C3orf24	0.52	6.87	0.35	3.26e-11	Alzheimer's disease;
CRC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.34	0.33	7.4e-10	Platelet count;
CRC	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg00031303	chr3:195681400	NA	0.45	6.23	0.32	1.41e-9	Bronchopulmonary dysplasia;
CRC	cis	rs7725052	0.581	rs10036578	chr5:40451057	C/A	cg09067459	chr5:40385259	NA	-0.4	-6.64	-0.34	1.3100000000000001e-10	Pediatric autoimmune diseases;
CRC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.71	9.58	0.47	2.51e-19	Alzheimer's disease;
CRC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg15147215	chr3:52552868	STAB1	0.53	9.12	0.45	7.54e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.7	-0.35	9.11e-11	Total cholesterol levels;
CRC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.38	-6.51	-0.34	2.83e-10	DNA methylation (variation);
CRC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-7.06	-0.36	9.84e-12	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg02592271	chr2:27665507	KRTCAP3	0.26	5.82	0.31	1.37e-8	Total body bone mineral density;
CRC	trans	rs2055729	0.677	rs10104353	chr8:9740358	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.33	-0.33	8.13e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.53e-15	Bladder cancer;
CRC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.93	-0.31	7.47e-9	Life satisfaction;
CRC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.43	7.65	0.39	2.18e-13	Height;
CRC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg16342193	chr10:102329863	NA	-0.34	-5.76	-0.3	1.93e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.67	-8.86	-0.44	5.1e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg06581033	chr10:766294	NA	0.5	5.72	0.3	2.42e-8	Uric acid levels;
CRC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-16.05	-0.66	3.12e-43	Chronic sinus infection;
CRC	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg10724054	chr17:3904396	NA	-0.46	-7.44	-0.38	8.65e-13	Type 2 diabetes;
CRC	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg12458913	chr13:53173898	NA	0.58	9.23	0.45	3.32e-18	Lewy body disease;
CRC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.43	-6.94	-0.36	2.11e-11	Monocyte count;
CRC	cis	rs4731207	0.596	rs2170354	chr7:124665919	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.0	-0.31	5.29e-9	Cutaneous malignant melanoma;
CRC	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg23071808	chr14:103021642	NA	-0.63	-7.34	-0.37	1.74e-12	Platelet count;
CRC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg04155289	chr7:94953770	PON1	-0.62	-7.71	-0.39	1.55e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.54	6.39	0.33	5.63e-10	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs12467625	chr2:162603387	C/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs7632954	1.000	rs7632954	chr3:8527882	C/T	cg03495237	chr3:8533978	NA	0.33	5.84	0.31	1.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg10377582	chr12:51612794	POU6F1	-0.3	-5.77	-0.3	1.8e-8	Cisplatin-induced ototoxicity;
CRC	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.52	-9.84	-0.48	3.33e-20	Pediatric bone mineral content (femoral neck);
CRC	cis	rs2530545	0.619	rs6955781	chr7:34662349	C/T	cg14401837	chr7:34697493	NPSR1	0.42	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.69	0.43	1.69e-16	Menopause (age at onset);
CRC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.6	8.03	0.4	1.76e-14	Height;
CRC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.49	7.26	0.37	2.87e-12	Bone properties (heel);
CRC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg06470822	chr6:28175283	NA	1.0	13.31	0.59	1.27e-32	Depression;
CRC	cis	rs3015497	0.789	rs11621971	chr14:51124527	C/T	cg09863266	chr14:51125203	SAV1	0.33	6.21	0.32	1.59e-9	Mean platelet volume;
CRC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.95	-0.31	6.8e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.57	6.42	0.33	4.71e-10	Bipolar disorder;
CRC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.93	-0.36	2.29e-11	Cystic fibrosis severity;
CRC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.41	-6.05	-0.32	4.03e-9	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23916948	chr1:155108399	RAG1AP1	0.44	6.47	0.34	3.63e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.26	6.56	0.34	2.05e-10	Iron status biomarkers;
CRC	cis	rs243505	0.667	rs10249029	chr7:148576042	C/T	cg09806900	chr7:148480153	CUL1	0.45	6.4	0.33	5.46e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.62	0.72	2.28e-53	Parkinson's disease;
CRC	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg04176472	chr15:90893244	GABARAPL3	0.36	6.32	0.33	8.45e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.56	8.02	0.4	1.87e-14	Melanoma;
CRC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.6	8.5	0.42	6.87e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.71	-10.86	-0.51	1.11e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CRC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.22	-0.56	1.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg25456477	chr12:86230367	RASSF9	0.39	6.44	0.33	4.26e-10	Major depressive disorder;
CRC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg21153622	chr11:89784906	NA	-0.42	-6.9	-0.36	2.6e-11	Height;
CRC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.61	-9.31	-0.46	1.92e-18	Height;
CRC	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs11212617	0.967	rs662218	chr11:108194528	C/A	cg01991180	chr11:108092276	ATM;NPAT	0.4	5.65	0.3	3.47e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg12273811	chr6:28175739	NA	0.57	8.34	0.42	2.14e-15	Parkinson's disease;
CRC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg00105475	chr2:10696890	NA	-0.45	-7.28	-0.37	2.44e-12	Prostate cancer;
CRC	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.56	8.0	0.4	2.17e-14	Adiposity;
CRC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.61	-8.3	-0.42	2.66e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg19566272	chr6:139695824	CITED2	0.44	6.21	0.32	1.63e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24293567	chr9:135754124	C9orf98;C9orf9	0.49	7.02	0.36	1.26e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.77	9.97	0.48	1.21e-20	Height;
CRC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.32	-6.97	-0.36	1.72e-11	IgG glycosylation;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg10512748	chr1:28844557	SNHG3-RCC1;RCC1	0.53	6.82	0.35	4.34e-11	Thyroid stimulating hormone;
CRC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.6	8.13	0.41	8.9e-15	Neutrophil percentage of white cells;
CRC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.18	-0.37	4.82e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	0.74	8.28	0.42	3.17e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.88	-13.88	-0.61	8.77e-35	Urate levels;
CRC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg20673091	chr1:2541236	MMEL1	0.37	5.91	0.31	8.45e-9	Ulcerative colitis;
CRC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.66	10.75	0.51	2.73e-23	Lung cancer;
CRC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.66	-0.34	1.17e-10	Educational attainment;
CRC	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg05370193	chr1:21551575	ECE1	0.36	5.74	0.3	2.19e-8	Superior frontal gyrus grey matter volume;
CRC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-8.08	-0.41	1.25e-14	Total body bone mineral density;
CRC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.61	-9.02	-0.45	1.58e-17	Subjective well-being;
CRC	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg09659197	chr4:152720779	NA	0.41	8.62	0.43	2.82e-16	Intelligence (multi-trait analysis);
CRC	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg14515779	chr1:101123966	NA	-0.43	-8.39	-0.42	1.49e-15	Monocyte count;
CRC	cis	rs6534441	0.857	rs7670240	chr4:125460187	T/G	cg21609808	chr4:125404261	NA	0.38	5.75	0.3	2.07e-8	Major depressive disorder;
CRC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg21251018	chr6:28226885	NKAPL	0.49	7.75	0.39	1.13e-13	Myopia;
CRC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.95	14.57	0.63	1.89e-37	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09400194	chr10:81107848	PPIF	0.45	6.28	0.33	1.1e-9	Response to antipsychotic treatment;
CRC	cis	rs61160187	0.518	rs62372133	chr5:60202177	T/G	cg16298547	chr5:60138761	ELOVL7	-0.28	-5.93	-0.31	7.59e-9	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.98	-0.4	2.4e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg02527881	chr3:46936655	PTH1R	0.38	7.06	0.36	9.69e-12	Colorectal cancer;
CRC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.72	-0.43	1.42e-16	Alcohol dependence;
CRC	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	7.5	0.38	6.05e-13	Coronary artery disease;
CRC	trans	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg09045935	chr12:6379348	NA	1.06	8.41	0.42	1.29e-15	Blood metabolite levels;
CRC	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.47	6.84	0.35	3.98e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-7.69	-0.39	1.76e-13	Longevity;
CRC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.62	9.16	0.45	5.49e-18	Blood protein levels;
CRC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.62	-10.67	-0.51	5.16e-23	Prudent dietary pattern;
CRC	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.62	-6.03	-0.32	4.5e-9	Yeast infection;
CRC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	7.68	0.39	1.9e-13	Lung cancer in ever smokers;
CRC	cis	rs243505	1.000	rs1019058	chr7:148424243	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-6.28	-0.33	1.04e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-9.4	-0.46	9.42e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.62	-10.9	-0.52	7.76e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	15.96	0.66	7.52e-43	Platelet count;
CRC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.43	6.67	0.35	1.09e-10	Corneal astigmatism;
CRC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg19812747	chr11:111475976	SIK2	-0.5	-7.99	-0.4	2.23e-14	Primary sclerosing cholangitis;
CRC	cis	rs7113874	0.589	rs10769910	chr11:8499406	T/C	cg17679104	chr11:8615758	STK33	0.35	5.74	0.3	2.17e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00587304	chr3:172468157	NA	0.49	6.85	0.35	3.68e-11	Response to antipsychotic treatment;
CRC	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg00587665	chr15:100533223	ADAMTS17	0.42	7.5	0.38	6.15e-13	Height;
CRC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.41	6.94	0.36	2.1e-11	Facial morphology (factor 20);
CRC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.98	-18.76	-0.72	6.4e-54	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg18512352	chr11:47633146	NA	-0.4	-7.82	-0.4	7.23e-14	Subjective well-being;
CRC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.19	-0.53	7.42e-25	Eye color traits;
CRC	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.54	-8.31	-0.42	2.46e-15	Schizophrenia;
CRC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.25	-16.75	-0.68	5.7e-46	Breast cancer;
CRC	trans	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg24644049	chr4:85504048	CDS1	0.9	7.46	0.38	7.69e-13	Skin colour saturation;
CRC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg15145296	chr3:125709740	NA	-0.57	-6.64	-0.34	1.29e-10	Blood pressure (smoking interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg21062897	chr14:50999680	MAP4K5;ATL1	0.37	6.13	0.32	2.51e-9	Obesity-related traits;
CRC	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg05585544	chr11:47624801	NA	0.41	6.32	0.33	8.5e-10	Mean corpuscular hemoglobin;
CRC	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.59	8.18	0.41	6.07e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.98	-0.36	1.64e-11	Menopause (age at onset);
CRC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg13010199	chr12:38710504	ALG10B	0.43	6.26	0.33	1.21e-9	Morning vs. evening chronotype;
CRC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.48	-7.03	-0.36	1.19e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg04202892	chr2:111875749	ACOXL	0.48	7.75	0.39	1.14e-13	Chronic lymphocytic leukemia;
CRC	cis	rs3736485	0.837	rs4774593	chr15:51821845	A/G	cg08986416	chr15:51914746	DMXL2	-0.49	-7.06	-0.36	9.93e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs6928289	0.527	rs9494736	chr6:137673055	A/G	cg24169820	chr12:121711996	CAMKK2	-0.41	-6.04	-0.32	4.24e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.41	6.01	0.31	4.82e-9	Morning vs. evening chronotype;
CRC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.56	6.27	0.33	1.15e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.69	10.73	0.51	3.09e-23	Immature fraction of reticulocytes;
CRC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.57	-7.13	-0.37	6.41e-12	Body mass index;
CRC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.51	0.34	2.77e-10	Diastolic blood pressure;
CRC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.64	11.85	0.55	3.21e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.69	-9.04	-0.45	1.36e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	1e-20	HDL cholesterol levels;
CRC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.57	8.42	0.42	1.19e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.56	8.34	0.42	2.09e-15	Intelligence (multi-trait analysis);
CRC	cis	rs17152411	1.000	rs733402	chr10:126594152	T/C	cg07906193	chr10:126599966	NA	0.58	6.52	0.34	2.69e-10	Height;
CRC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-11.51	-0.54	5.54e-26	Mean platelet volume;Platelet distribution width;
CRC	trans	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg21153622	chr11:89784906	NA	-0.47	-7.58	-0.39	3.59e-13	HDL cholesterol;
CRC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg04362960	chr10:104952993	NT5C2	-0.43	-6.1	-0.32	2.92e-9	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01516881	chr6:292596	DUSP22	-0.55	-8.04	-0.41	1.63e-14	Menopause (age at onset);
CRC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.66	11.15	0.52	1.07e-24	Prudent dietary pattern;
CRC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.39	5.94	0.31	7.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg04132472	chr17:19861366	AKAP10	0.44	6.86	0.35	3.36e-11	Schizophrenia;
CRC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg25456477	chr12:86230367	RASSF9	0.35	6.21	0.32	1.62e-9	Major depressive disorder;
CRC	cis	rs4731207	0.672	rs3213667	chr7:124480869	T/C	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.51	7.98	0.4	2.49e-14	Corneal astigmatism;
CRC	cis	rs6604026	0.698	rs10874744	chr1:93306317	G/A	cg17283838	chr1:93427260	FAM69A	-0.47	-6.65	-0.34	1.24e-10	Multiple sclerosis;
CRC	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.83	15.85	0.66	1.92e-42	Hip circumference;
CRC	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.83	-0.55	3.79e-27	Coffee consumption (cups per day);
CRC	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg09760422	chr2:128146352	NA	-0.32	-6.17	-0.32	2.01e-9	Protein C levels;
CRC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.96e-8	Bladder cancer;
CRC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-7.96	-0.4	2.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.35	0.33	7.06e-10	Height;
CRC	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.52	-0.43	5.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.44	6.45	0.34	4.01e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs7709909	0.720	rs408626	chr5:79951133	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.43	7.09	0.36	8.24e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
CRC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg25164649	chr6:28176230	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.55	0.34	2.22e-10	Diabetic kidney disease;
CRC	trans	rs2303319	0.504	rs16846026	chr2:162537691	T/C	cg03757145	chr4:76555832	CDKL2	-0.66	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs3736485	0.966	rs11070862	chr15:51902227	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-6.53	-0.34	2.56e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.42	6.36	0.33	6.93e-10	Ovarian reserve;
CRC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	12.65	0.57	3.8e-30	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.48	7.38	0.38	1.32e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.51	7.7	0.39	1.61e-13	Resting heart rate;
CRC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	trans	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg13565492	chr6:43139072	SRF	-0.71	-7.1	-0.36	7.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24674680	chr1:227174512	CABC1	0.4	7.21	0.37	3.89e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs12956009	0.583	rs11082575	chr18:44905068	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-6.17	-0.32	1.98e-9	Educational attainment (years of education);
CRC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.82	-10.91	-0.52	7.64e-24	Initial pursuit acceleration;
CRC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.73	11.05	0.52	2.35e-24	Corneal astigmatism;
CRC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.88	-0.4	4.85e-14	Intelligence (multi-trait analysis);
CRC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.94	9.94	0.48	1.61e-20	Inflammatory bowel disease;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg21204522	chr6:27730016	NA	-0.67	-5.89	-0.31	9.79e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.98	-18.06	-0.71	3.87e-51	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.5	4.36e-22	Chronic sinus infection;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.4	6.11	0.32	2.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.67	-8.48	-0.42	7.53e-16	Gut microbiome composition (summer);
CRC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.43	5.87	0.31	1.05e-8	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.19	-0.37	4.3e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs12760731	0.565	rs12044522	chr1:178190180	G/T	cg00404053	chr1:178313656	RASAL2	1.05	10.9	0.52	7.99e-24	Obesity-related traits;
CRC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg11843238	chr5:131593191	PDLIM4	-0.31	-5.7	-0.3	2.64e-8	Blood metabolite levels;
CRC	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg17470449	chr10:769945	NA	0.64	8.62	0.43	2.87e-16	Uric acid levels;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00223186	chr1:180472200	ACBD6	0.42	6.28	0.33	1.04e-9	Schizophrenia;
CRC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.59	10.5	0.5	1.95e-22	Aortic root size;
CRC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.22	-0.32	1.51e-9	Tonsillectomy;
CRC	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.61	7.96	0.4	2.78e-14	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17554553	chr10:31321002	ZNF438	0.36	6.14	0.32	2.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.6	-0.39	3.09e-13	Total body bone mineral density;
CRC	trans	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg26043149	chr18:55253948	FECH	0.54	8.24	0.41	4.04e-15	Bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15832314	chr15:40401289	BMF	0.41	6.0	0.31	5.24e-9	Response to antipsychotic treatment;
CRC	cis	rs3018066	0.768	rs4355394	chr4:106946814	C/G	cg01869342	chr4:106983673	TBCK	0.4	6.11	0.32	2.77e-9	Cancer;
CRC	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg23627948	chr7:2760692	NA	0.47	5.63	0.3	3.79e-8	Childhood ear infection;
CRC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg24289452	chr6:170231220	NA	-0.62	-9.03	-0.45	1.49e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.01	18.96	0.72	1.05e-54	Prudent dietary pattern;
CRC	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.46	6.88	0.35	3.11e-11	Crohn's disease;
CRC	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.31	0.37	2.04e-12	Platelet distribution width;
CRC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.8	14.21	0.62	4.48e-36	Breast cancer;
CRC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.79	0.51	1.99e-23	Skin colour saturation;
CRC	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.75	9.1	0.45	8.77e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
CRC	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg01692110	chr13:113365389	ATP11A	-0.49	-5.93	-0.31	7.65e-9	Glycated hemoglobin levels;
CRC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg00745463	chr17:30367425	LRRC37B	-0.86	-9.48	-0.46	5.41e-19	Hip circumference adjusted for BMI;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.35	-0.33	7.23e-10	Cognitive function;
CRC	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-1.05	-10.04	-0.48	7.5e-21	Post bronchodilator FEV1;
CRC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.68	8.65	0.43	2.27e-16	Psoriasis;
CRC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.69	0.39	1.69e-13	Mean platelet volume;
CRC	cis	rs911119	1.000	rs3088162	chr20:23607752	C/A	cg16589663	chr20:23618590	CST3	0.58	7.72	0.39	1.41e-13	Chronic kidney disease;
CRC	cis	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg18809830	chr7:99032528	PTCD1	-1.08	-8.07	-0.41	1.3e-14	Blood metabolite levels;
CRC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.52	-9.75	-0.47	6.75e-20	Longevity;
CRC	trans	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg05376469	chr2:102649931	NA	0.38	6.45	0.34	3.95e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.27	-0.37	2.57e-12	Bipolar disorder;
CRC	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.66	9.86	0.48	2.89e-20	Longevity;Endometriosis;
CRC	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg15664640	chr17:80829946	TBCD	-0.55	-6.08	-0.32	3.31e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CRC	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg09659197	chr4:152720779	NA	0.31	5.63	0.3	3.8e-8	Intelligence (multi-trait analysis);
CRC	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.61	-6.21	-0.32	1.59e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg27398640	chr15:77910606	LINGO1	-0.41	-6.85	-0.35	3.59e-11	Type 2 diabetes;
CRC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.47	6.28	0.33	1.06e-9	Morning vs. evening chronotype;
CRC	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.48	7.35	0.38	1.6e-12	Motion sickness;
CRC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.48	-0.38	6.67e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.5	-6.81	-0.35	4.69e-11	Glioblastoma;
CRC	trans	rs4902562	0.838	rs6573823	chr14:68733632	A/G	cg15776653	chr6:26538476	HMGN4	0.46	5.96	0.31	6.35e-9	Systemic lupus erythematosus;
CRC	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.56	8.1	0.41	1.1e-14	Schizophrenia;
CRC	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.09	0.49	4.82e-21	Asthma (childhood onset);
CRC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.68	-9.93	-0.48	1.71e-20	Cognitive function;
CRC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.4	6.02	0.31	4.68e-9	Multiple myeloma (IgH translocation);
CRC	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.77	12.02	0.55	7.44e-28	Body mass index;
CRC	cis	rs6973256	0.605	rs7808879	chr7:133345471	A/T	cg10665199	chr7:133106180	EXOC4	0.49	7.71	0.39	1.52e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1983891	0.774	rs6935446	chr6:41514372	A/G	cg20194872	chr6:41519635	FOXP4	0.39	5.6	0.3	4.51e-8	Prostate cancer;
CRC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.38	7.39e-13	Lung cancer in ever smokers;
CRC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.55	10.56	0.5	1.24e-22	Acylcarnitine levels;
CRC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg12223502	chr10:5658492	NA	-0.37	-5.91	-0.31	8.63e-9	Breast cancer;
CRC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.95	-0.31	6.73e-9	Diabetic retinopathy;
CRC	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg16558208	chr1:156270281	VHLL	0.58	9.04	0.45	1.34e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.48	-7.44	-0.38	8.69e-13	Multiple myeloma (IgH translocation);
CRC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	9.62	0.47	1.78e-19	Bipolar disorder and schizophrenia;
CRC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg05835009	chr4:710272	PCGF3	0.53	7.08	0.36	9e-12	White blood cell count;
CRC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	0.63	6.86	0.35	3.53e-11	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	7.19	0.37	4.52e-12	Aortic root size;
CRC	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.79	14.32	0.62	1.73e-36	Anterior chamber depth;
CRC	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg04239558	chr2:103089729	SLC9A4	0.37	6.6	0.34	1.64e-10	Blood protein levels;
CRC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.85	12.21	0.56	1.54e-28	Gut microbiome composition (summer);
CRC	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg26870460	chr11:6947759	ZNF215	0.56	5.88	0.31	1.01e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg06074448	chr4:187884817	NA	0.5	8.13	0.41	9.02e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs728616	0.614	rs61859196	chr10:82109048	A/G	cg05935833	chr10:81318306	SFTPA2	-0.6	-7.28	-0.37	2.52e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.01	-0.36	1.39e-11	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg22110888	chr17:80059540	CCDC57	0.43	6.79	0.35	5.35e-11	Life satisfaction;
CRC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg22676075	chr6:135203613	NA	0.4	6.06	0.32	3.67e-9	Red blood cell count;
CRC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.68	8.2	0.41	5.37e-15	Menarche (age at onset);
CRC	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg04989706	chr14:50066350	PPIL5	-0.49	-6.92	-0.36	2.32e-11	Carotid intima media thickness;
CRC	cis	rs372883	0.600	rs2832291	chr21:30734388	C/T	cg24692254	chr21:30365293	RNF160	0.58	8.69	0.43	1.76e-16	Pancreatic cancer;
CRC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.4	0.46	9.67e-19	Personality dimensions;
CRC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.76	10.02	0.48	8.79e-21	Blood trace element (Zn levels);
CRC	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	20.16	0.74	2.01e-59	Metabolite levels;
CRC	trans	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg09872104	chr7:134855509	C7orf49	-0.8	-6.57	-0.34	1.99e-10	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.42	-5.99	-0.31	5.36e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	9.37	0.46	1.24e-18	Alzheimer's disease;
CRC	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg09659197	chr4:152720779	NA	-0.54	-11.64	-0.54	1.86e-26	Intelligence (multi-trait analysis);
CRC	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg00562011	chr11:252351	PSMD13	0.53	6.17	0.32	2.04e-9	Menarche (age at onset);
CRC	cis	rs10924970	0.967	rs3765793	chr1:235368277	T/A	cg26050004	chr1:235667680	B3GALNT2	0.39	5.77	0.3	1.8e-8	Asthma;
CRC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.51	6.76	0.35	6.28e-11	Height;
CRC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.7e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.34	-5.63	-0.3	3.78e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg24505167	chr7:1915268	MAD1L1	-0.45	-6.3	-0.33	9.35e-10	Bipolar disorder;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg08125682	chr16:11038455	CLEC16A	-0.42	-6.36	-0.33	6.68e-10	Myopia (pathological);
CRC	cis	rs6663390	0.831	rs2267894	chr1:208085735	G/A	cg03990033	chr1:208084030	CD34	0.48	6.44	0.33	4.23e-10	Facial morphology (factor 18);
CRC	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.64	9.88	0.48	2.45e-20	Itch intensity from mosquito bite;
CRC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.51	-8.54	-0.43	4.92e-16	Aortic root size;
CRC	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.74	10.43	0.5	3.4e-22	IgG glycosylation;
CRC	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.49	6.31	0.33	9.24e-10	Cholesterol, total;
CRC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.68	10.08	0.49	5.36e-21	Intelligence (multi-trait analysis);
CRC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.51	-7.3	-0.37	2.17e-12	Neuroticism;
CRC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.24	-0.37	3.28e-12	Bipolar disorder;
CRC	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-9.05	-0.45	1.31e-17	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs3106136	0.609	rs12500027	chr4:95107918	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-6.3	-0.33	9.32e-10	Capecitabine sensitivity;
CRC	trans	rs12210905	1.000	rs67310631	chr6:27233243	T/A	cg05005425	chr1:167687389	NA	0.62	6.29	0.33	1.03e-9	Hip circumference adjusted for BMI;
CRC	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-7.29	-0.37	2.27e-12	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03066081	chr17:77784036	NA	0.48	6.95	0.36	1.96e-11	Response to antipsychotic treatment;
CRC	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.53	7.54	0.38	4.53e-13	Response to antidepressants and depression;
CRC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.89	-12.09	-0.55	4.3e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.8	-0.35	5.08e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.57	-0.34	2.01e-10	Bipolar disorder;
CRC	cis	rs449789	0.502	rs529281	chr6:159708505	T/C	cg14500486	chr6:159655392	FNDC1	-0.48	-7.29	-0.37	2.38e-12	Pulse pressure;
CRC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.77	-10.95	-0.52	5.41e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.73	8.38	0.42	1.52e-15	Systolic blood pressure;
CRC	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.49	6.31	0.33	9.24e-10	Cholesterol, total;
CRC	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.51	0.46	4.31e-19	Common traits (Other);
CRC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg26061582	chr7:22766209	IL6	0.54	8.84	0.44	5.95e-17	Lung cancer;
CRC	trans	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	6.11	0.32	2.74e-9	Metabolite levels;
CRC	cis	rs7212590	0.655	rs16943969	chr17:58031153	A/G	cg10252138	chr17:58120427	NA	-0.59	-6.33	-0.33	7.87e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CRC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.52	8.11	0.41	9.97e-15	Colorectal cancer;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg10876282	chr6:28092338	ZSCAN16	0.44	5.88	0.31	9.85e-9	Parkinson's disease;
CRC	trans	rs2303319	0.504	rs56407015	chr2:162455625	G/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.43e-9	Cognitive function;
CRC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg12728517	chr11:6947552	ZNF215	0.55	5.81	0.31	1.48e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.48	7.3	0.37	2.12e-12	Corneal astigmatism;
CRC	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg07392085	chr5:141489673	NDFIP1	0.46	7.33	0.37	1.85e-12	Asthma;
CRC	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg08779649	chr13:50194554	NA	0.35	6.76	0.35	6.34e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg15147215	chr3:52552868	STAB1	0.48	8.12	0.41	9.24e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs877282	0.797	rs35927768	chr10:753095	T/C	cg17470449	chr10:769945	NA	0.61	7.82	0.4	7e-14	Uric acid levels;
CRC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11584989	chr19:19387371	SF4	0.57	5.78	0.3	1.72e-8	Bipolar disorder;
CRC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.61	11.42	0.53	1.13e-25	Coronary artery disease;
CRC	cis	rs427941	0.703	rs201445	chr7:101737921	G/T	cg06246474	chr7:101738831	CUX1	0.46	7.16	0.37	5.46e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs2013441	0.711	rs1682297	chr17:20384920	C/T	cg13482628	chr17:19912719	NA	0.42	6.32	0.33	8.54e-10	Obesity-related traits;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg26812362	chr6:167040675	RPS6KA2	0.48	6.72	0.35	8.05e-11	Anxiety disorder;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg21204522	chr6:27730016	NA	-0.41	-5.61	-0.3	4.28e-8	Parkinson's disease;
CRC	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.72	11.16	0.52	9.79e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs35520189	0.591	rs12466653	chr2:113700988	A/G	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.54	0.43	5.02e-16	Morning vs. evening chronotype;
CRC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.79	10.86	0.51	1.11e-23	Cognitive function;
CRC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17691542	chr6:26056736	HIST1H1C	0.54	8.16	0.41	7.07e-15	Height;
CRC	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-7.6	-0.39	3.06e-13	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.58	9.59	0.47	2.22e-19	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.773	rs2404777	chr5:131172803	C/A	cg25547332	chr5:131281432	NA	0.35	5.68	0.3	3.03e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.22	0.41	4.91e-15	Platelet count;
CRC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24308560	chr3:49941425	MST1R	0.47	7.37	0.38	1.42e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.63	11.78	0.54	5.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.4	-6.3	-0.33	9.68e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.75e-8	Lung cancer;
CRC	cis	rs4664293	0.836	rs73967923	chr2:160658265	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.35	-0.33	7.13e-10	Monocyte percentage of white cells;
CRC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg16102536	chr7:156981717	UBE3C	0.4	6.77	0.35	5.77e-11	Body mass index;
CRC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.14	-0.37	5.98e-12	QT interval;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17864040	chr1:78148524	ZZZ3	0.45	6.54	0.34	2.35e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.48	7.68	0.39	1.86e-13	Osteoporosis;
CRC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.8	12.22	0.56	1.46e-28	Glomerular filtration rate (creatinine);
CRC	trans	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg11693508	chr17:37793320	STARD3	0.54	6.21	0.32	1.6e-9	Neuroticism;
CRC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.34	3.94e-10	Electroencephalogram traits;
CRC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.54	-8.1	-0.41	1.1e-14	Prostate cancer;
CRC	cis	rs2070997	0.816	rs6597643	chr9:133725830	C/T	cg01000188	chr9:133769184	QRFP	-0.5	-6.0	-0.31	5.22e-9	Response to amphetamines;
CRC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-12.23	-0.56	1.31e-28	Primary sclerosing cholangitis;
CRC	cis	rs6840360	0.607	rs2724547	chr4:152365576	G/A	cg09659197	chr4:152720779	NA	0.34	6.7	0.35	8.91e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.5	-6.02	-0.31	4.66e-9	Carotid intima media thickness;
CRC	cis	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg16989086	chr20:62203971	PRIC285	0.51	6.44	0.33	4.3e-10	Atopic dermatitis;
CRC	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg09659197	chr4:152720779	NA	-0.51	-10.81	-0.51	1.62e-23	Intelligence (multi-trait analysis);
CRC	cis	rs6973256	0.583	rs2345943	chr7:133340630	A/G	cg10665199	chr7:133106180	EXOC4	-0.47	-7.32	-0.37	1.96e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.75	-11.86	-0.55	3e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03067192	chr7:72300134	SBDSP;TYW1B	0.51	6.77	0.35	5.9e-11	Anxiety disorder;
CRC	trans	rs7757969	0.500	rs58691769	chr6:112159068	C/T	cg08211895	chr2:48828358	STON1-GTF2A1L	0.31	6.07	0.32	3.57e-9	Schizophrenia;
CRC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg08222913	chr3:52553049	STAB1	-0.36	-6.85	-0.35	3.68e-11	Electroencephalogram traits;
CRC	trans	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg10756647	chr7:56101905	PSPH	0.75	8.22	0.41	4.6e-15	Diabetic kidney disease;
CRC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg10760299	chr15:45669010	GATM	-0.48	-7.5	-0.38	5.92e-13	Homoarginine levels;
CRC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg10589385	chr1:150898437	SETDB1	0.32	6.52	0.34	2.59e-10	Melanoma;
CRC	cis	rs12476592	0.543	rs262511	chr2:63889944	C/A	cg10828910	chr2:63850056	LOC388955	0.5	6.26	0.33	1.23e-9	Childhood ear infection;
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg20512303	chr5:131592959	PDLIM4	0.34	6.45	0.33	4.04e-10	Breast cancer;
CRC	cis	rs7605827	0.897	rs1990756	chr2:15616030	C/T	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.83e-9	Educational attainment (years of education);
CRC	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg09659197	chr4:152720779	NA	0.5	10.75	0.51	2.66e-23	Intelligence (multi-trait analysis);
CRC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.67	10.35	0.5	6.65e-22	Longevity;Endometriosis;
CRC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.94	11.87	0.55	2.63e-27	IgG glycosylation;
CRC	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-7.75	-0.39	1.17e-13	Opioid sensitivity;
CRC	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg05585544	chr11:47624801	NA	0.41	6.32	0.33	8.5e-10	Mean corpuscular hemoglobin;
CRC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	7.1	0.36	7.62e-12	Motion sickness;
CRC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg22638593	chr5:131593259	PDLIM4	0.42	7.86	0.4	5.51e-14	Breast cancer;
CRC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.64	11.39	0.53	1.44e-25	Prostate cancer;
CRC	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg10217327	chr6:118973057	C6orf204	0.51	5.76	0.3	1.93e-8	Diastolic blood pressure;
CRC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.39	-0.38	1.23e-12	Aortic root size;
CRC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.45	-0.5	2.92e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg01858014	chr14:56050164	KTN1	-0.81	-6.11	-0.32	2.87e-9	Putamen volume;
CRC	cis	rs4728302	0.838	rs10225115	chr7:133591435	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.87	0.31	1.04e-8	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg20936604	chr3:58311152	NA	-0.76	-7.14	-0.37	5.92e-12	Cholesterol, total;
CRC	trans	rs6749447	0.848	rs1517330	chr2:169002552	T/C	cg01878807	chr14:24422368	DHRS4;C14orf167	0.41	6.33	0.33	7.83e-10	Blood pressure;
CRC	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.41	7.04	0.36	1.12e-11	Sitting height ratio;
CRC	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.57	7.38	0.38	1.33e-12	Coronary artery disease;
CRC	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.67	8.23	0.41	4.33e-15	Obesity (extreme);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23979971	chr5:138677953	PAIP2	0.4	6.4	0.33	5.36e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.41	6.73	0.35	7.45e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	9.87	0.48	2.64e-20	Prudent dietary pattern;
CRC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.54	9.77	0.47	5.67e-20	Height;
CRC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg16447950	chr5:562315	NA	-0.83	-11.29	-0.53	3.41e-25	Lung disease severity in cystic fibrosis;
CRC	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.34	-6.1	-0.32	2.9e-9	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10233691	chr16:67062760	CBFB	0.37	6.06	0.32	3.67e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-17.95	-0.7	1.01e-50	Schizophrenia;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg23978390	chr7:1156363	C7orf50	0.51	5.72	0.3	2.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg00677455	chr12:58241039	CTDSP2	0.56	6.78	0.35	5.6e-11	Multiple sclerosis;
CRC	cis	rs858239	0.899	rs5850	chr7:23314547	C/T	cg00469287	chr7:23338798	C7orf30	0.47	5.91	0.31	8.63e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs6764363	0.506	rs13091217	chr3:277778	A/G	cg02057681	chr3:285234	CHL1	0.41	7.01	0.36	1.37e-11	Sudden cardiac arrest;
CRC	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.12	17.34	0.69	2.69e-48	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs1864729	1.000	rs2853318	chr8:98283509	A/T	cg08679828	chr8:102218111	ZNF706	-0.59	-7.13	-0.37	6.34e-12	Estradiol plasma levels (breast cancer);
CRC	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.33	-6.05	-0.32	3.92e-9	Panic disorder;
CRC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg08798685	chr6:27730294	NA	-0.61	-5.78	-0.3	1.73e-8	Breast cancer;
CRC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.58	-8.0	-0.4	2.08e-14	DNA methylation (variation);
CRC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.8	0.48	4.79e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg07274523	chr3:49395745	GPX1	0.46	6.23	0.32	1.43e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg14593290	chr7:50529359	DDC	0.46	6.78	0.35	5.53e-11	Malaria;
CRC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.46	-7.14	-0.37	6.14e-12	Height;
CRC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.55	-7.23	-0.37	3.5e-12	Platelet distribution width;
CRC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.44	5.95	0.31	6.73e-9	Schizophrenia;
CRC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg17545662	chr6:170176663	C6orf70	0.57	6.45	0.34	3.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.53	-9.02	-0.45	1.64e-17	Type 2 diabetes;
CRC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg16476235	chr8:21771668	DOK2	0.39	6.66	0.34	1.13e-10	Mean corpuscular volume;
CRC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg00769240	chr8:12517080	NA	-0.55	-6.41	-0.33	5.09e-10	Blood pressure (smoking interaction);
CRC	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg20356878	chr3:121714668	ILDR1	0.47	6.4	0.33	5.22e-10	Multiple sclerosis;
CRC	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.41	-6.05	-0.32	4.02e-9	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04104609	chr2:219523980	ZNF142;BCS1L	0.41	6.12	0.32	2.64e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.1	0.32	2.93e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg18016565	chr1:150552671	MCL1	0.43	5.89	0.31	9.59e-9	Melanoma;
CRC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.41	-5.8	-0.3	1.52e-8	Aortic root size;
CRC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-7.72	-0.39	1.44e-13	Gut microbiome composition (summer);
CRC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.67	-0.3	3.07e-8	Lung cancer;
CRC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.38	6.58	0.34	1.86e-10	Reticulocyte fraction of red cells;
CRC	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.72	-7.54	-0.38	4.61e-13	Type 2 diabetes;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg20933634	chr6:27740509	NA	0.58	8.63	0.43	2.69e-16	Parkinson's disease;
CRC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg02321871	chr13:50159138	RCBTB1	-0.43	-6.13	-0.32	2.5e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg14470647	chr9:107690075	ABCA1	-0.38	-5.7	-0.3	2.62e-8	Intraocular pressure;
CRC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.72	-9.26	-0.45	2.63e-18	Initial pursuit acceleration;
CRC	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.88	-0.31	1e-8	Metabolite levels;
CRC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.08	0.32	3.39e-9	Aortic root size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07145255	chr5:59995354	DEPDC1B	-0.51	-6.22	-0.32	1.55e-9	Diisocyanate-induced asthma;
CRC	cis	rs7487075	0.964	rs2408497	chr12:46796751	A/G	cg22049899	chr12:47219821	SLC38A4	0.33	6.53	0.34	2.53e-10	Itch intensity from mosquito bite;
CRC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg19223190	chr17:80058835	NA	0.38	6.17	0.32	2e-9	Life satisfaction;
CRC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.46	6.92	0.36	2.33e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg01320579	chr17:75405842	SEPT9	0.35	5.62	0.3	4.18e-8	Airflow obstruction;
CRC	trans	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg20935933	chr6:143382018	AIG1	0.52	6.6	0.34	1.67e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg06223162	chr1:101003688	GPR88	-0.36	-6.62	-0.34	1.44e-10	Monocyte count;
CRC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.64	-9.25	-0.45	2.98e-18	Subjective well-being;
CRC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.51	7.72	0.39	1.4e-13	Aortic root size;
CRC	cis	rs12143943	0.866	rs3789052	chr1:204494283	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.06	-0.32	3.8e-9	Cognitive performance;
CRC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-8.56	-0.43	4.25e-16	Platelet count;
CRC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.89	-15.25	-0.64	4.4e-40	Cognitive function;
CRC	cis	rs6838801	0.892	rs10029193	chr4:77576894	G/A	cg17476223	chr4:77663285	SHROOM3	0.42	5.84	0.31	1.28e-8	Cleft lip with or without cleft palate;
CRC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.98	0.4	2.38e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.81	13.73	0.6	3.13e-34	Dementia with Lewy bodies;
CRC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.23	-0.45	3.37e-18	Developmental language disorder (linguistic errors);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13456812	chr6:167369504	RNASET2	0.45	6.32	0.33	8.36e-10	Response to antipsychotic treatment;
CRC	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg16691251	chr5:66510806	NA	0.46	8.15	0.41	7.58e-15	Breast cancer;
CRC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.91	-0.4	3.92e-14	Gut microbiome composition (summer);
CRC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg18683604	chr14:51561293	TRIM9	0.32	6.23	0.32	1.46e-9	Cancer;
CRC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg15147215	chr3:52552868	STAB1	-0.55	-8.45	-0.42	9.79e-16	Bipolar disorder;
CRC	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.61	-0.39	2.95e-13	Metabolite levels (Pyroglutamine);
CRC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	10.17	0.49	2.66e-21	Platelet count;
CRC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg02741985	chr17:80059408	CCDC57	0.43	7.15	0.37	5.66e-12	Life satisfaction;
CRC	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg09003973	chr2:102972529	NA	0.41	5.77	0.3	1.85e-8	Blood protein levels;
CRC	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-6.62	-0.34	1.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Colorectal cancer;
CRC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.27	-0.49	1.22e-21	Colorectal cancer;
CRC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.21	-0.73	1.09e-55	Primary sclerosing cholangitis;
CRC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.68	10.32	0.49	8.06e-22	Corneal astigmatism;
CRC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.7	10.36	0.5	6.11e-22	Immature fraction of reticulocytes;
CRC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg03233332	chr7:66118400	NA	-0.45	-6.35	-0.33	7.16e-10	Aortic root size;
CRC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-17.98	-0.7	7.61e-51	Height;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01511126	chr1:40506125	CAP1	0.45	6.07	0.32	3.46e-9	Survival in pancreatic cancer;
CRC	cis	rs77861329	1.000	rs17051957	chr3:52099441	A/G	cg08692210	chr3:52188851	WDR51A	0.81	8.14	0.41	8.15e-15	Macrophage inflammatory protein 1b levels;
CRC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.55	-0.38	4.21e-13	Breast cancer;
CRC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg24560729	chr4:1342394	KIAA1530	-0.34	-6.25	-0.33	1.25e-9	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07951810	chr12:65153561	GNS	0.41	6.2	0.32	1.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.83	10.74	0.51	2.96e-23	Gut microbiome composition (summer);
CRC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.79	-0.44	8.78e-17	Response to antipsychotic treatment;
CRC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.64	-7.72	-0.39	1.37e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.29	-15.43	-0.65	8.74e-41	Diabetic kidney disease;
CRC	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg19875578	chr6:126661172	C6orf173	0.41	5.64	0.3	3.69e-8	Male-pattern baldness;
CRC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.57	-11.21	-0.53	6.19e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs9549328	0.670	rs61963562	chr13:113616523	T/G	cg17524180	chr13:113633600	MCF2L	0.52	9.39	0.46	1e-18	Systolic blood pressure;
CRC	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.59	-6.54	-0.34	2.32e-10	Blood protein levels;
CRC	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.32	-6.73	-0.35	7.78e-11	Educational attainment (years of education);
CRC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.51	7.31	0.37	1.98e-12	Obesity-related traits;
CRC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.91e-9	Hemoglobin concentration;
CRC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg16434002	chr17:42200994	HDAC5	-0.47	-6.38	-0.33	6.16e-10	Total body bone mineral density;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg23161317	chr6:28129485	ZNF389	0.46	6.42	0.33	4.71e-10	Parkinson's disease;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24184350	chr6:11094094	LOC221710	0.48	6.62	0.34	1.49e-10	Anxiety disorder;
CRC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.08	-0.32	3.42e-9	Blood metabolite levels;
CRC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.57	-0.75	5.09e-61	Height;
CRC	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.67	-0.35	1.08e-10	Eye color traits;
CRC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.93	13.41	0.59	4.97e-33	Breast cancer;
CRC	cis	rs2227564	0.830	rs2675667	chr10:75683832	G/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.12	-0.37	7e-12	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.91	-7.68	-0.39	1.83e-13	Acne (severe);
CRC	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg09695851	chr17:3907499	NA	-0.76	-14.18	-0.62	6.22e-36	Type 2 diabetes;
CRC	trans	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg19894588	chr14:64061835	NA	-0.63	-8.62	-0.43	2.78e-16	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.44	-0.38	8.91e-13	Morning vs. evening chronotype;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg17084751	chr11:6953558	ZNF215	-0.53	-5.95	-0.31	6.99e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs3823572	0.542	rs2971961	chr7:133639737	G/A	cg03336402	chr7:133662267	EXOC4	0.66	10.12	0.49	3.87e-21	Intelligence (multi-trait analysis);
CRC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.5	-0.34	2.97e-10	Total body bone mineral density;
CRC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-7.9	-0.4	4.12e-14	Aortic root size;
CRC	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs62432291	0.764	rs433256	chr6:159660105	C/T	cg14500486	chr6:159655392	FNDC1	-0.75	-10.23	-0.49	1.6e-21	Joint mobility (Beighton score);
CRC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg03030879	chr14:75389066	RPS6KL1	-0.39	-5.83	-0.31	1.33e-8	Coronary artery disease;
CRC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.68	-11.18	-0.52	8.18e-25	Hepatocellular carcinoma;
CRC	trans	rs16873450	0.527	rs11982084	chr7:23782716	G/C	cg19535980	chr5:159519152	PWWP2A	-0.41	-5.99	-0.31	5.43e-9	Verbal memory performance (residualized delayed recall level);
CRC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.46	6.31	0.33	8.9e-10	Red blood cell count;
CRC	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.61	-7.37	-0.38	1.38e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	-0.51	-8.36	-0.42	1.83e-15	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg02071957	chr16:19191409	SYT17	0.42	6.02	0.31	4.77e-9	Intelligence (multi-trait analysis);
CRC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.42	-20.2	-0.74	1.43e-59	Hip circumference adjusted for BMI;
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg03623178	chr6:28175578	NA	0.96	12.57	0.57	7.23e-30	Depression;
CRC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.74	12.57	0.57	7.46e-30	Body mass index;
CRC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg10760299	chr15:45669010	GATM	0.51	8.27	0.41	3.46e-15	Homoarginine levels;
CRC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg09127314	chr1:152161683	NA	0.5	6.38	0.33	5.88e-10	Atopic dermatitis;
CRC	cis	rs73200209	0.744	rs61939680	chr12:116493867	G/A	cg01776926	chr12:116560359	MED13L	-0.64	-7.35	-0.38	1.57e-12	Total body bone mineral density;
CRC	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.43	0.46	7.38e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg24505167	chr7:1915268	MAD1L1	-0.49	-7.51	-0.38	5.64e-13	Bipolar disorder;
CRC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.38	-6.08	-0.32	3.28e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.86	0.35	3.52e-11	Educational attainment;
CRC	cis	rs4965006	0.915	rs7969545	chr12:132419157	C/T	cg00588090	chr12:132412438	PUS1	-0.47	-6.26	-0.33	1.21e-9	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-6.83	-0.35	4.11e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.51	7.89	0.4	4.49e-14	Corneal astigmatism;
CRC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	7.43	0.38	9.57e-13	Colorectal cancer;
CRC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.68	-8.57	-0.43	3.94e-16	Behavioural disinhibition (generation interaction);
CRC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.64	8.76	0.43	1.06e-16	Height;
CRC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.27	-0.75	7.31e-60	Myeloid white cell count;
CRC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg24560729	chr4:1342394	KIAA1530	0.39	6.27	0.33	1.15e-9	Obesity-related traits;
CRC	trans	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.6	-9.36	-0.46	1.25e-18	Aortic root size;
CRC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg09417038	chr21:47716443	C21orf57	-0.42	-6.93	-0.36	2.21e-11	Testicular germ cell tumor;
CRC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg10876282	chr6:28092338	ZSCAN16	0.49	6.57	0.34	1.99e-10	Parkinson's disease;
CRC	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.6	-10.23	-0.49	1.6e-21	Asthma;
CRC	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.83	-10.56	-0.5	1.23e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.67	11.24	0.53	4.9e-25	Cancer;
CRC	trans	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg21153622	chr11:89784906	NA	0.47	7.44	0.38	8.86e-13	HDL cholesterol;
CRC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.66	-8.54	-0.43	4.94e-16	Mean platelet volume;
CRC	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00376283	chr12:123451042	ABCB9	-0.54	-7.18	-0.37	4.78e-12	Neutrophil percentage of white cells;
CRC	cis	rs7546094	1.000	rs12728001	chr1:113076756	T/C	cg22162597	chr1:113214053	CAPZA1	0.41	5.69	0.3	2.83e-8	Platelet distribution width;
CRC	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.98	-0.48	1.19e-20	Colorectal cancer;
CRC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg26816564	chr1:7831052	VAMP3	0.51	5.83	0.31	1.34e-8	Inflammatory bowel disease;
CRC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	6.95	0.36	2.02e-11	Schizophrenia;
CRC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.86	0.44	5.13e-17	Bladder cancer;
CRC	cis	rs9549328	0.565	rs35371379	chr13:113616715	T/C	cg25790453	chr13:113633590	MCF2L	0.43	7.51	0.38	5.75e-13	Systolic blood pressure;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg21800906	chr11:32914818	QSER1	-0.42	-6.3	-0.33	9.43e-10	Daytime sleep phenotypes;
CRC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg19980929	chr12:42632907	YAF2	-0.41	-6.27	-0.33	1.16e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs6586163	1.000	rs3824729	chr10:90752616	A/G	cg13456138	chr10:90753195	FAS	-0.44	-6.8	-0.35	5.07e-11	Chronic lymphocytic leukemia;
CRC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg16797656	chr11:68205561	LRP5	0.37	5.83	0.31	1.3e-8	Total body bone mineral density;
CRC	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg05250797	chr16:70222502	NA	0.4	5.69	0.3	2.85e-8	IgE levels;
CRC	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.39	-6.33	-0.33	7.91e-10	Mean arterial pressure;
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg02683197	chr6:28174875	NA	-0.88	-12.39	-0.56	3.29e-29	Depression;
CRC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	8.17	0.41	6.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.57	-0.5	1.14e-22	Bipolar disorder;
CRC	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.74	-11.13	-0.52	1.26e-24	Waist circumference;Body mass index;
CRC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg22777020	chr22:31556080	RNF185	-0.45	-5.8	-0.3	1.52e-8	Paclitaxel-induced neuropathy;
CRC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg08888203	chr3:10149979	C3orf24	0.69	9.74	0.47	7.48e-20	Alzheimer's disease;
CRC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.86	0.35	3.39e-11	Lung cancer;
CRC	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.46	6.66	0.34	1.18e-10	Subjective well-being;
CRC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg20607287	chr7:12443886	VWDE	-0.65	-8.35	-0.42	1.96e-15	Coronary artery disease;
CRC	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.66	10.07	0.49	5.64e-21	Bipolar disorder;
CRC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.44	-8.16	-0.41	7.05e-15	Intelligence (multi-trait analysis);
CRC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.59	7.71	0.39	1.48e-13	Coronary artery disease;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.79	0.51	2e-23	Bone mineral density;
CRC	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg14593290	chr7:50529359	DDC	-0.56	-7.8	-0.4	8.2e-14	Malaria;
CRC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.68	-8.41	-0.42	1.26e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.56	8.09	0.41	1.15e-14	Resting heart rate;
CRC	trans	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg18335740	chr13:41363409	SLC25A15	0.56	8.91	0.44	3.43e-17	Lewy body disease;
CRC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg16342193	chr10:102329863	NA	-0.36	-5.94	-0.31	7.21e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.57	-8.13	-0.41	8.99e-15	Rheumatoid arthritis;
CRC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.83	-0.35	4.17e-11	HDL cholesterol;
CRC	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.19	-0.49	2.27e-21	Colorectal cancer;
CRC	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	0.94	8.13	0.41	8.82e-15	Lifespan;
CRC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	6.37	0.33	6.35e-10	Height;
CRC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.63	7.34	0.38	1.73e-12	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.82	13.33	0.59	1e-32	Menopause (age at onset);
CRC	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.66	-9.12	-0.45	7.53e-18	Autism;
CRC	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-7.5	-0.38	5.85e-13	D-dimer levels;
CRC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.71	-11.97	-0.55	1.2e-27	Breast cancer;
CRC	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.58	7.96	0.4	2.87e-14	Adiposity;
CRC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg22110888	chr17:80059540	CCDC57	0.39	6.2	0.32	1.71e-9	Life satisfaction;
CRC	cis	rs7527798	0.592	rs6702222	chr1:207825627	C/T	cg09232269	chr1:207846808	CR1L	-0.45	-7.31	-0.37	2.02e-12	Erythrocyte sedimentation rate;
CRC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.64	-8.59	-0.43	3.43e-16	Alcohol dependence;
CRC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-8.57	-0.43	3.95e-16	Hemoglobin concentration;
CRC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg26874164	chr19:58962979	ZNF324B	0.4	5.86	0.31	1.12e-8	Uric acid clearance;
CRC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.79	13.3	0.59	1.29e-32	Blood protein levels;
CRC	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg08501292	chr6:25962987	TRIM38	1.08	9.37	0.46	1.19e-18	Intelligence (multi-trait analysis);
CRC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.02	-0.32	4.63e-9	Alzheimer's disease (late onset);
CRC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.8	0.51	1.84e-23	Prudent dietary pattern;
CRC	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.45	-0.46	6.49e-19	Type 2 diabetes;
CRC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.19	-0.52	7.81e-25	Eye color traits;
CRC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11645453	chr3:52864694	ITIH4	0.34	6.29	0.33	1.02e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.94	-0.31	7.18e-9	Type 2 diabetes;
CRC	cis	rs7333181	0.649	rs7339379	chr13:112237995	A/G	cg27543320	chr13:112200689	NA	-0.53	-9.48	-0.46	5.35e-19	Menopause (age at onset);
CRC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.72	8.35	0.42	1.93e-15	Tuberculosis;
CRC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.61	9.02	0.45	1.59e-17	Morning vs. evening chronotype;
CRC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-13.24	-0.59	2.32e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-7.96	-0.4	2.88e-14	Type 2 diabetes;
CRC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.78	-11.51	-0.54	5.41e-26	Menopause (age at onset);
CRC	cis	rs1639906	0.560	rs1637730	chr7:2260928	T/C	cg19897017	chr7:2163380	MAD1L1	0.41	5.93	0.31	7.8e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-7.12	-0.37	6.97e-12	Neuroticism;
CRC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.61	10.84	0.51	1.34e-23	Schizophrenia;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg03232753	chr17:29233269	C17orf42	-0.4	-5.98	-0.31	5.9e-9	Daytime sleep phenotypes;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.71	-10.96	-0.52	5e-24	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.59	6.29	0.33	1.01e-9	RR interval (heart rate);
CRC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg15763984	chr4:1342303	KIAA1530	0.48	8.36	0.42	1.83e-15	Longevity;
CRC	trans	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.17	0.41	6.63e-15	Ulcerative colitis;
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg15786705	chr6:28176104	NA	0.78	9.83	0.48	3.57e-20	Parkinson's disease;
CRC	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.35	5.61	0.3	4.24e-8	Menarche (age at onset);
CRC	trans	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg26043149	chr18:55253948	FECH	0.54	8.11	0.41	9.99e-15	Bone mineral density;
CRC	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.92	11.34	0.53	2.21e-25	Exhaled nitric oxide output;
CRC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.23	-0.41	4.53e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.67	11.65	0.54	1.71e-26	Blood protein levels;
CRC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	15.08	0.64	1.97e-39	Schizophrenia;
CRC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.69	9.28	0.46	2.36e-18	High light scatter reticulocyte count;
CRC	cis	rs6662572	1.000	rs7541935	chr1:46217493	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.76	0.3	1.94e-8	Blood protein levels;
CRC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg08350549	chr3:99591722	C3orf26;FILIP1L;MIR548G	-0.38	-5.87	-0.31	1.05e-8	Breast cancer;
CRC	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg23807890	chr2:228736357	WDR69	-0.47	-6.58	-0.34	1.9e-10	Blood pressure;
CRC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg14061069	chr19:46274453	DMPK	0.67	12.48	0.57	1.64e-29	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg15845792	chr6:28175446	NA	0.8	11.85	0.55	3.22e-27	Parkinson's disease;
CRC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.92	-11.14	-0.52	1.17e-24	Initial pursuit acceleration;
CRC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg20203395	chr5:56204925	C5orf35	-0.51	-6.38	-0.33	5.98e-10	Type 2 diabetes;
CRC	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.6	-6.76	-0.35	6.35e-11	Blood protein levels;
CRC	cis	rs7635838	0.892	rs9852530	chr3:11466469	C/T	cg00170343	chr3:11313890	ATG7	0.41	6.29	0.33	1.03e-9	HDL cholesterol;
CRC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12463550	chr7:65579703	CRCP	0.7	6.26	0.33	1.22e-9	Diabetic kidney disease;
CRC	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.5	6.49	0.34	3.17e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-7.96	-0.4	2.9e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.4	6.18	0.32	1.86e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs9359856	0.518	rs12662171	chr6:90193898	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.51	-5.62	-0.3	4.04e-8	Bipolar disorder;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg20933634	chr6:27740509	NA	0.42	5.85	0.31	1.21e-8	Parkinson's disease;
CRC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.71	10.46	0.5	2.62e-22	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07974125	chr4:57843509	C4orf14	0.44	5.98	0.31	5.7e-9	Response to antipsychotic treatment;
CRC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg05627522	chr15:75251581	NA	0.38	5.72	0.3	2.46e-8	Breast cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17585343	chr11:43702103	HSD17B12	0.42	6.23	0.32	1.43e-9	Response to antipsychotic treatment;
CRC	cis	rs720844	0.684	rs16828816	chr2:149305525	A/T	cg09247360	chr2:149335327	NA	-0.57	-5.98	-0.31	5.8e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.76	0.39	1.07e-13	Lung cancer;
CRC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg07865391	chr16:88106882	BANP	0.44	5.82	0.31	1.42e-8	Menopause (age at onset);
CRC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.43	-6.13	-0.32	2.53e-9	Daytime sleep phenotypes;
CRC	trans	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg18335740	chr13:41363409	SLC25A15	0.55	8.45	0.42	9.31e-16	Lewy body disease;
CRC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.68	-11.97	-0.55	1.16e-27	Brugada syndrome;
CRC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.25	-0.41	3.73e-15	Type 2 diabetes;
CRC	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg11900509	chr10:81946545	ANXA11	-0.68	-6.82	-0.35	4.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg27661571	chr11:113659931	NA	-0.71	-8.85	-0.44	5.32e-17	Hip circumference adjusted for BMI;
CRC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg05084668	chr3:125655381	ALG1L	-0.44	-6.16	-0.32	2.09e-9	Blood pressure (smoking interaction);
CRC	cis	rs1165668	0.755	rs10735390	chr12:104311731	A/G	cg21863207	chr12:104234989	NT5DC3	0.47	7.01	0.36	1.34e-11	Coronary heart disease (SNP X SNP interaction);
CRC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.13	10.76	0.51	2.47e-23	Skin colour saturation;
CRC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.43	6.85	0.35	3.67e-11	High light scatter reticulocyte count;
CRC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg21251018	chr6:28226885	NKAPL	0.46	6.44	0.33	4.18e-10	Parkinson's disease;
CRC	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.84	-16.67	-0.68	1.21e-45	Hip circumference;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg06481699	chr7:101458740	CUX1	0.42	6.91	0.36	2.45e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg22677401	chr17:46026860	NA	-0.67	-6.07	-0.32	3.57e-9	Cognitive function;
CRC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.58	8.92	0.44	3.27e-17	Blood metabolite levels;
CRC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.41	-0.38	1.1e-12	Major depressive disorder;
CRC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg10494973	chr17:80897199	TBCD	-0.36	-5.63	-0.3	3.87e-8	Breast cancer;
CRC	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.58	-9.03	-0.45	1.46e-17	HDL cholesterol;
CRC	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg02466173	chr16:30829666	NA	-0.69	-9.6	-0.47	2.06e-19	Dementia with Lewy bodies;
CRC	trans	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg20935933	chr6:143382018	AIG1	0.54	6.96	0.36	1.86e-11	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs3093024	0.904	rs3093017	chr6:167541258	C/G	cg07741184	chr6:167504864	NA	-0.39	-7.0	-0.36	1.41e-11	Rheumatoid arthritis;
CRC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg23533926	chr12:111358616	MYL2	-0.52	-7.85	-0.4	6.11e-14	Extrinsic epigenetic age acceleration;
CRC	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.04	14.04	0.61	1.99e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14169450	chr9:139327907	INPP5E	0.35	5.63	0.3	3.77e-8	Monocyte percentage of white cells;
CRC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.85	-12.09	-0.55	4.26e-28	Type 2 diabetes;
CRC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.74	0.3	2.18e-8	Diabetic retinopathy;
CRC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.44	6.0	0.31	5.14e-9	Lymphocyte percentage of white cells;
CRC	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg27053337	chr8:124217698	FAM83A	0.42	6.3	0.33	9.38e-10	Urinary uromodulin levels;
CRC	cis	rs6429082	0.509	rs6699315	chr1:235525253	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.44	-6.38	-0.33	5.87e-10	Adiposity;
CRC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg05569086	chr8:143859399	LYNX1	0.37	6.35	0.33	7.29e-10	Urinary tract infection frequency;
CRC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.58	-8.87	-0.44	4.75e-17	Height;
CRC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.78	-10.68	-0.51	4.68e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg24300038	chr13:113819356	PROZ	-0.47	-5.78	-0.3	1.76e-8	Platelet distribution width;
CRC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.62	-11.16	-0.52	1e-24	Aortic root size;
CRC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.38	0.46	1.07e-18	Personality dimensions;
CRC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg19812747	chr11:111475976	SIK2	0.42	6.23	0.32	1.44e-9	Primary sclerosing cholangitis;
CRC	trans	rs7461897	0.511	rs1383916	chr8:26825245	A/G	cg19592942	chr8:12294380	FAM86B2	-0.62	-5.97	-0.31	6.17e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
CRC	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg23032129	chr1:109941072	SORT1	-0.27	-5.8	-0.3	1.57e-8	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg01483063	chr10:112836471	ADRA2A	0.45	6.33	0.33	7.81e-10	Response to antipsychotic treatment;
CRC	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg09659197	chr4:152720779	NA	0.4	7.79	0.39	9.01e-14	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg03623178	chr6:28175578	NA	0.48	6.59	0.34	1.77e-10	Depression;
CRC	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg20487152	chr13:99095054	FARP1	-0.35	-5.85	-0.31	1.2e-8	Longevity;
CRC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.52	7.52	0.38	5.12e-13	Lung cancer;
CRC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg22723502	chr6:26240528	HIST1H4F	-0.37	-5.78	-0.3	1.74e-8	Gout;Renal underexcretion gout;
CRC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg24562669	chr7:97807699	LMTK2	0.44	7.47	0.38	7.1e-13	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21468420	chr4:24474668	NA	0.46	6.6	0.34	1.68e-10	Response to antipsychotic treatment;
CRC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg20354231	chr13:53171401	NA	-0.43	-6.95	-0.36	1.99e-11	Lewy body disease;
CRC	trans	rs11466653	1.000	rs6825115	chr4:38778833	G/A	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4731207	0.596	rs1021080	chr7:124633805	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.26	-0.33	1.23e-9	Cutaneous malignant melanoma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg22081084	chr1:89990230	LRRC8B	-0.5	-6.22	-0.32	1.49e-9	Diisocyanate-induced asthma;
CRC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.46	6.22	0.32	1.54e-9	Schizophrenia;
CRC	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.41	6.34	0.33	7.48e-10	Recombination rate (males);
CRC	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.54	7.82	0.4	7.45e-14	Pulmonary function decline;
CRC	cis	rs10924970	0.649	rs12036412	chr1:235398812	T/C	cg09010748	chr1:235293032	TOMM20	-0.42	-5.77	-0.3	1.86e-8	Asthma;
CRC	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.99	-0.36	1.51e-11	Inflammatory skin disease;
CRC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg03623178	chr6:28175578	NA	0.66	10.08	0.49	5.38e-21	Cardiac Troponin-T levels;
CRC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.59	6.66	0.34	1.17e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.48	0.73	9.51e-57	Prudent dietary pattern;
CRC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	7.51	0.38	5.54e-13	Motion sickness;
CRC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg12183467	chr14:104352244	NA	-0.48	-6.67	-0.35	1.05e-10	Bipolar disorder;
CRC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02725872	chr8:58115012	NA	-0.57	-9.07	-0.45	1.09e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.05	-17.93	-0.7	1.27e-50	Dilated cardiomyopathy;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg21620606	chr4:1342894	KIAA1530	0.53	9.5	0.46	4.66e-19	Longevity;
CRC	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.98	0.31	5.84e-9	Lung cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15903931	chr8:124780424	FAM91A1	0.44	6.42	0.33	4.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.34	-6.07	-0.32	3.47e-9	Rheumatoid arthritis;
CRC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.59	-10.94	-0.52	5.61e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg06223162	chr1:101003688	GPR88	-0.34	-6.11	-0.32	2.86e-9	Monocyte count;
CRC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.5	7.1	0.36	7.6e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.69	-7.47	-0.38	7.35e-13	Psoriasis;
CRC	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.57	8.56	0.43	4.28e-16	Inhibitory control;
CRC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.65	7.89	0.4	4.56e-14	Menarche (age at onset);
CRC	cis	rs863345	0.625	rs4609418	chr1:158464728	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.35	-0.33	7.19e-10	Pneumococcal bacteremia;
CRC	cis	rs4731207	0.698	rs4728012	chr7:124481798	C/T	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.59	8.91	0.44	3.49e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.66	-8.53	-0.43	5.24e-16	Bone mineral density;
CRC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.53	8.46	0.42	9.15e-16	Asthma;
CRC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	1.14	10.91	0.52	7.39e-24	Arsenic metabolism;
CRC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.45	-0.34	3.94e-10	Bipolar disorder;
CRC	cis	rs7463659	1.000	rs7836944	chr8:135436202	A/G	cg09855544	chr8:135498122	ZFAT	0.4	6.2	0.32	1.72e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12172441	chr6:28176163	NA	0.64	7.65	0.39	2.26e-13	Depression;
CRC	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.85	14.89	0.63	1.04e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-0.89	-9.35	-0.46	1.38e-18	Body mass index;
CRC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.71	0.35	8.61e-11	Aortic root size;
CRC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.66	10.99	0.52	4e-24	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.75	13.24	0.59	2.22e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.13	-0.37	6.27e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5.18e-37	Prudent dietary pattern;
CRC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.82	13.07	0.58	9.67e-32	Menarche (age at onset);
CRC	trans	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02375201	chr1:27114675	PIGV	0.41	6.39	0.33	5.61e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.64	-9.6	-0.47	2.06e-19	Menarche (age at onset);
CRC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.63	0.43	2.7e-16	Schizophrenia;
CRC	cis	rs9783347	0.961	rs2061163	chr11:18322924	A/C	cg15585147	chr11:18324498	HPS5	0.43	5.94	0.31	7.25e-9	Pancreatic cancer;
CRC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-15.07	-0.64	2.18e-39	Schizophrenia;
CRC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.31	0.37	2.05e-12	Calcium levels;
CRC	trans	rs564309	0.681	rs11581974	chr1:228617063	A/G	cg24066601	chr6:26271455	HIST1H3G	0.6	6.81	0.35	4.66e-11	Hip circumference (psychosocial stress interaction);
CRC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.76	-11.8	-0.55	5.07e-27	Immature fraction of reticulocytes;
CRC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.74	12.34	0.56	5.26e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7725052	0.609	rs4329064	chr5:40459315	A/G	cg09067459	chr5:40385259	NA	-0.4	-6.68	-0.35	9.91e-11	Pediatric autoimmune diseases;
CRC	cis	rs7605827	0.897	rs11693457	chr2:15612683	A/C	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17271592	chr1:149821902	HIST2H2AA4;HIST2H2AA3	0.45	6.63	0.34	1.41e-10	Liver disease severity in Alagille syndrome;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25722142	chr6:139695762	CITED2	0.5	7.34	0.38	1.69e-12	Response to antipsychotic treatment;
CRC	cis	rs73186030	0.920	rs73186050	chr3:122039928	C/T	cg16331599	chr3:121796627	CD86	0.5	5.74	0.3	2.12e-8	Serum parathyroid hormone levels;
CRC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg26304593	chr6:42947056	PEX6	-0.45	-6.66	-0.34	1.13e-10	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg18478394	chr8:109455254	TTC35	0.42	6.24	0.33	1.36e-9	Dupuytren's disease;
CRC	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.78	10.1	0.49	4.44e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.6	-0.39	3.03e-13	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26361754	chr2:206790750	NA	0.43	6.91	0.36	2.5e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg27432699	chr2:27873401	GPN1	-0.51	-7.77	-0.39	9.82e-14	Total body bone mineral density;
CRC	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.29	6.03	0.32	4.48e-9	Height;
CRC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.82	-0.44	7.03e-17	Bipolar disorder;
CRC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.74	0.3	2.17e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.13	-0.37	6.56e-12	QT interval;
CRC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.04	0.32	4.06e-9	Bladder cancer;
CRC	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg10437265	chr15:77819839	NA	0.69	12.74	0.57	1.76e-30	Type 2 diabetes;
CRC	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg09659197	chr4:152720779	NA	0.37	7.57	0.39	3.87e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1223397	1.000	rs1223399	chr6:13271220	G/A	cg00460589	chr6:13274354	PHACTR1	0.45	5.61	0.3	4.39e-8	Blood pressure;
CRC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg11292332	chr7:45801988	SEPT13	-0.38	-6.71	-0.35	8.43e-11	Extrinsic epigenetic age acceleration;
CRC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.57	10.74	0.51	2.98e-23	Eye color traits;
CRC	trans	rs925098	0.577	rs2724470	chr4:17996046	A/G	cg03864326	chr16:67927170	PSKH1	-0.41	-6.26	-0.33	1.17e-9	Birth weight;Height;
CRC	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg17830980	chr10:43048298	ZNF37B	0.39	5.97	0.31	6.17e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.1	-15.04	-0.64	2.83e-39	Exhaled nitric oxide output;
CRC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.72	0.51	3.43e-23	Hip circumference adjusted for BMI;
CRC	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg23387468	chr7:139079360	LUC7L2	-0.4	-6.71	-0.35	8.39e-11	Diisocyanate-induced asthma;
CRC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.45	6.54	0.34	2.41e-10	Intelligence (multi-trait analysis);
CRC	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.74	-10.24	-0.49	1.52e-21	Smoking behavior;
CRC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.47	-7.25	-0.37	2.96e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg15786705	chr6:28176104	NA	0.7	5.73	0.3	2.25e-8	Depression;
CRC	cis	rs73206853	0.841	rs4131850	chr12:110812553	G/A	cg12870014	chr12:110450643	ANKRD13A	0.77	8.38	0.42	1.59e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.53	-8.68	-0.43	1.88e-16	Menarche (age at onset);
CRC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.55	-7.66	-0.39	2.1e-13	Corneal structure;
CRC	cis	rs9463078	0.683	rs227855	chr6:44702352	T/C	cg25276700	chr6:44698697	NA	0.26	6.06	0.32	3.79e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-5.84	-0.31	1.24e-8	Waist circumference;Hip circumference;
CRC	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.74	-10.07	-0.49	5.75e-21	Coronary artery disease;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.49	-7.1	-0.36	7.72e-12	Longevity;Endometriosis;
CRC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.6	9.22	0.45	3.61e-18	Aortic root size;
CRC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.85	-12.45	-0.57	2.12e-29	Platelet distribution width;
CRC	cis	rs863345	0.584	rs6672789	chr1:158497139	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-5.9	-0.31	8.89e-9	Pneumococcal bacteremia;
CRC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.5	7.0	0.36	1.43e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.33	-6.74	-0.35	7.19e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.45	0.38	8.11e-13	Body mass index;
CRC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg08755490	chr11:65554678	OVOL1	0.44	6.34	0.33	7.57e-10	Acne (severe);
CRC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.47	7.52	0.38	5.37e-13	Menopause (age at onset);
CRC	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.77	8.93	0.44	3.06e-17	Inflammatory bowel disease;
CRC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.54	-7.37	-0.38	1.35e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.63	9.73	0.47	8.1e-20	Parkinson's disease;
CRC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.59	8.03	0.41	1.69e-14	Menopause (age at onset);
CRC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-5.71	-0.3	2.47e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07618626	chr3:32726534	CNOT10	0.4	6.17	0.32	1.96e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg14664628	chr15:75095509	CSK	0.55	6.56	0.34	2.12e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.36	-8.12	-0.41	9.76e-15	Total body bone mineral density;
CRC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.37	-6.71	-0.35	8.71e-11	Height;
CRC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.7	-11.49	-0.53	6.66e-26	Longevity;
CRC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.31	0.53	2.9e-25	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.51	-7.81	-0.4	7.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg17321639	chr7:2759063	NA	0.53	7.26	0.37	2.75e-12	Height;
CRC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg01629716	chr15:45996671	NA	0.41	8.5	0.42	6.75e-16	Waist circumference;Weight;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg02683197	chr6:28174875	NA	0.75	9.84	0.48	3.43e-20	Parkinson's disease;
CRC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.27	12.24	0.56	1.19e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg12856521	chr11:46389249	DGKZ	0.76	10.57	0.5	1.14e-22	Crohn's disease;
CRC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg09877947	chr5:131593287	PDLIM4	0.51	9.4	0.46	9.88e-19	Blood metabolite levels;
CRC	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.73	-7.46	-0.38	7.68e-13	Non-glioblastoma glioma;Glioma;
CRC	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg14593290	chr7:50529359	DDC	0.49	7.1	0.36	7.86e-12	Malaria;
CRC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.96	0.52	4.92e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg09163369	chr1:210001066	C1orf107	0.41	5.79	0.3	1.68e-8	Orofacial clefts;
CRC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg06470822	chr6:28175283	NA	0.84	12.77	0.58	1.28e-30	Parkinson's disease;
CRC	trans	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg10756647	chr7:56101905	PSPH	0.74	7.95	0.4	3.07e-14	Diabetic kidney disease;
CRC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg15845792	chr6:28175446	NA	0.76	11.21	0.53	6.42e-25	Cardiac Troponin-T levels;
CRC	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg10437265	chr15:77819839	NA	0.69	12.72	0.57	1.96e-30	Type 2 diabetes;
CRC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.54e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.7	-10.78	-0.51	2.14e-23	Type 2 diabetes;
CRC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.56	7.33	0.37	1.82e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14363996	chr9:140122076	NA	0.4	6.17	0.32	2.03e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.35	-6.44	-0.33	4.2e-10	Menarche (age at onset);
CRC	cis	rs4728302	0.643	rs2346442	chr7:133705907	A/G	cg03336402	chr7:133662267	EXOC4	0.44	6.7	0.35	9.23e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg22495460	chr2:25135724	ADCY3	-0.89	-15.38	-0.65	1.29e-40	Body mass index;
CRC	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.2	-0.32	1.7e-9	IgE levels;
CRC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.55	-8.06	-0.41	1.43e-14	Schizophrenia;
CRC	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.64	10.02	0.48	8.38e-21	Cognitive test performance;
CRC	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	1.01	12.23	0.56	1.32e-28	Obesity-related traits;
CRC	cis	rs7113874	0.589	rs7112153	chr11:8461178	T/C	cg17679104	chr11:8615758	STK33	-0.34	-5.67	-0.3	3.16e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg10756647	chr7:56101905	PSPH	-0.69	-7.26	-0.37	2.75e-12	Diabetic kidney disease;
CRC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.77	0.3	1.84e-8	Hemoglobin concentration;
CRC	cis	rs2019216	1.000	rs3751916	chr17:21909270	T/C	cg05591447	chr17:21909280	FLJ36000	-0.35	-7.08	-0.36	8.78e-12	Pelvic organ prolapse;
CRC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.6	9.71	0.47	9.1e-20	Personality dimensions;
CRC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg23136738	chr11:925521	AP2A2	-0.5	-7.94	-0.4	3.32e-14	Alzheimer's disease (late onset);
CRC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.33	-0.49	7.45e-22	Tonsillectomy;
CRC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg10298567	chr3:47292165	KIF9	0.45	7.26	0.37	2.8e-12	Colorectal cancer;
CRC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18357526	chr6:26021779	HIST1H4A	0.39	5.6	0.3	4.47e-8	Height;
CRC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.36	0.42	1.76e-15	Height;
CRC	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.93	-17.08	-0.69	2.88e-47	Height;
CRC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.72	-11.38	-0.53	1.64e-25	Colorectal cancer;
CRC	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg09659197	chr4:152720779	NA	0.32	5.75	0.3	2.09e-8	Intelligence (multi-trait analysis);
CRC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-6.3	-0.33	9.65e-10	Menopause (age at onset);
CRC	trans	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg13565492	chr6:43139072	SRF	-0.72	-7.5	-0.38	6.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.47	-0.46	5.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-12.73	-0.57	1.79e-30	Blood metabolite levels;
CRC	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.2	-0.41	5.29e-15	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27304813	chr3:120068385	LRRC58	0.46	6.66	0.34	1.14e-10	Response to antipsychotic treatment;
CRC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.39	-5.6	-0.3	4.46e-8	Red cell distribution width;Reticulocyte count;
CRC	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg06102954	chr21:42741788	MX2	0.4	6.12	0.32	2.64e-9	Melanoma;
CRC	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg22495460	chr2:25135724	ADCY3	-0.73	-11.97	-0.55	1.19e-27	Body mass index;
CRC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.49	-6.85	-0.35	3.62e-11	Intelligence (multi-trait analysis);
CRC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.3	3.18e-8	Diabetic retinopathy;
CRC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	1.0	13.1	0.59	7.92e-32	Triglycerides;
CRC	cis	rs12692738	0.526	rs355858	chr2:165629457	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg12273811	chr6:28175739	NA	0.39	5.67	0.3	3.06e-8	Pubertal anthropometrics;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10513276	chr9:115095793	ROD1	0.44	6.2	0.32	1.67e-9	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-12.78	-0.58	1.17e-30	Vitiligo;
CRC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.48	6.24	0.33	1.33e-9	Huntington's disease progression;
CRC	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg12855166	chr17:30846586	MYO1D	-0.34	-5.65	-0.3	3.48e-8	Schizophrenia;
CRC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.33	0.42	2.17e-15	Gut microbiome composition (summer);
CRC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.44	-8.75	-0.43	1.16e-16	IgG glycosylation;
CRC	cis	rs3018066	0.589	rs6835216	chr4:107027530	G/T	cg01869342	chr4:106983673	TBCK	0.42	5.65	0.3	3.5e-8	Cancer;
CRC	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.4	6.55	0.34	2.25e-10	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
CRC	cis	rs2857891	0.909	rs56026267	chr11:6940211	T/C	cg17958423	chr11:6947583	ZNF215	0.58	6.08	0.32	3.27e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.53	-6.67	-0.35	1.08e-10	Plateletcrit;
CRC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg19812747	chr11:111475976	SIK2	0.43	6.09	0.32	3.18e-9	Primary sclerosing cholangitis;
CRC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	7.36	0.38	1.51e-12	Menarche (age at onset);
CRC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.62	-9.48	-0.46	5.06e-19	Menopause (age at onset);
CRC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.68	7.89	0.4	4.43e-14	Rheumatoid arthritis;
CRC	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg16476235	chr8:21771668	DOK2	0.43	7.31	0.37	2.03e-12	Mean corpuscular volume;
CRC	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg10724054	chr17:3904396	NA	-0.38	-6.1	-0.32	2.91e-9	Type 2 diabetes;
CRC	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-11.35	-0.53	2.01e-25	Coffee consumption (cups per day);
CRC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.56	-6.37	-0.33	6.29e-10	Body mass index;
CRC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.41	7.23	0.37	3.42e-12	Reticulocyte fraction of red cells;
CRC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.5	-7.15	-0.37	5.75e-12	DNA methylation (variation);
CRC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.69	12.31	0.56	6.55e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg00343986	chr7:65444356	GUSB	-0.52	-7.77	-0.39	1.01e-13	Aortic root size;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	5.95	0.31	6.79e-9	Parkinson's disease;
CRC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.64	-0.47	1.6e-19	Height;
CRC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.46	-6.47	-0.34	3.55e-10	DNA methylation (variation);
CRC	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.73	9.26	0.45	2.71e-18	Iron status biomarkers;
CRC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.63	11.53	0.54	4.68e-26	Glomerular filtration rate (creatinine);
CRC	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.66	-9.68	-0.47	1.16e-19	Type 2 diabetes;
CRC	cis	rs6694672	1.000	rs4915345	chr1:197102839	A/C	cg13682187	chr1:196946512	CFHR5	0.51	8.05	0.41	1.55e-14	Asthma;
CRC	cis	rs17601876	0.814	rs749292	chr15:51558731	A/G	cg19946085	chr15:51559439	CYP19A1	0.35	7.18	0.37	4.68e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CRC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.67	10.07	0.49	5.84e-21	Selective IgA deficiency;
CRC	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg06223162	chr1:101003688	GPR88	0.34	6.32	0.33	8.46e-10	Monocyte count;
CRC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.63	-0.39	2.57e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.65	-11.2	-0.53	7.06e-25	Dental caries;
CRC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.39	6.64	0.34	1.32e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg20684491	chr1:25596433	NA	0.42	7.3	0.37	2.18e-12	Erythrocyte sedimentation rate;
CRC	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.49	-8.77	-0.44	9.49e-17	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-7.34	-0.38	1.64e-12	Total body bone mineral density;
CRC	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.45	9.02	0.45	1.59e-17	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	6.81	0.35	4.55e-11	LDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04100492	chr1:1677730	SLC35E2	0.4	6.1	0.32	2.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.43	7.41	0.38	1.1e-12	Vitamin D levels;
CRC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg04053776	chr11:6947353	ZNF215	0.51	6.83	0.35	4.14e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg00857998	chr1:205179979	DSTYK	0.41	5.85	0.31	1.19e-8	Red blood cell count;
CRC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	8.12	0.41	9.18e-15	Mood instability;
CRC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.71	-6.7	-0.35	9.32e-11	Diabetic retinopathy;
CRC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	11.17	0.52	8.58e-25	Tonsillectomy;
CRC	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-11.59	-0.54	2.88e-26	Height;
CRC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-5.89	-0.31	9.5e-9	Tonsillectomy;
CRC	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.56	10.13	0.49	3.62e-21	Cognitive performance;
CRC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.76	-0.3	1.89e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.59	8.32	0.42	2.29e-15	Intelligence (multi-trait analysis);
CRC	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg15571903	chr15:79123663	NA	0.31	5.98	0.31	5.95e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CRC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.48	-6.64	-0.34	1.3e-10	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg20573242	chr4:122745356	CCNA2	0.41	6.14	0.32	2.4e-9	Type 2 diabetes;
CRC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.59	7.71	0.39	1.53e-13	Gut microbiome composition (summer);
CRC	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.61	8.36	0.42	1.83e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg05941027	chr17:61774174	LIMD2	0.35	6.44	0.33	4.13e-10	Hip circumference adjusted for BMI;Body mass index;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg19936585	chr2:139259770	SPOPL	-0.4	-6.1	-0.32	2.94e-9	Myopia (pathological);
CRC	cis	rs10106298	1.000	rs17773903	chr8:103685172	A/G	cg10187029	chr8:103597600	NA	0.48	6.65	0.34	1.23e-10	Schizophrenia;
CRC	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.12	-0.37	6.73e-12	Inflammatory bowel disease;
CRC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.51	7.38	0.38	1.28e-12	Corneal astigmatism;
CRC	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.62	8.05	0.41	1.56e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.11	-0.41	1.04e-14	Hemoglobin concentration;
CRC	trans	rs67073037	0.955	rs12620680	chr2:29144611	C/T	cg13899017	chr1:159158444	CADM3	-0.36	-6.09	-0.32	3.16e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00039960	chr17:7142925	PHF23	0.4	6.1	0.32	3.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg26554054	chr8:600488	NA	0.61	5.8	0.3	1.56e-8	IgG glycosylation;
CRC	trans	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.5	7.47	0.38	7.32e-13	Endometrial cancer;
CRC	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.59	7.21	0.37	3.77e-12	Post bronchodilator FEV1;
CRC	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.47	5.98	0.31	5.87e-9	Neuroticism;
CRC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.07	-18.43	-0.71	1.27e-52	Cognitive function;
CRC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg19223190	chr17:80058835	NA	0.41	6.62	0.34	1.5e-10	Life satisfaction;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14239635	chr6:116892067	RWDD1	0.46	6.56	0.34	2.06e-10	Response to antipsychotic treatment;
CRC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	7.28	0.37	2.5e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs531930	1.000	rs486550	chr6:124738091	A/G	cg05308643	chr6:124982296	NKAIN2	-0.42	-5.81	-0.3	1.49e-8	Celiac disease;
CRC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg19193384	chr17:30244184	NA	-0.65	-7.57	-0.39	3.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.7	-8.66	-0.43	2.15e-16	Obesity-related traits;
CRC	trans	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-0.65	-11.45	-0.53	8.72e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs6496667	0.779	rs2074581	chr15:91009147	T/G	cg04176472	chr15:90893244	GABARAPL3	0.53	7.5	0.38	6.06e-13	Rheumatoid arthritis;
CRC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg18612461	chr15:75251733	NA	-0.38	-5.99	-0.31	5.64e-9	Systemic lupus erythematosus;
CRC	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.44	-7.21	-0.37	3.94e-12	Sleep quality;
CRC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.69	-0.39	1.72e-13	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs6600671	0.967	rs4844613	chr1:121173773	T/C	cg09829573	chr1:144692074	NBPF9	-0.41	-6.29	-0.33	9.83e-10	Hip geometry;
CRC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg00383909	chr3:49044727	WDR6	0.62	6.51	0.34	2.8e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg11168104	chr5:1857477	NA	-0.38	-6.63	-0.34	1.42e-10	Cardiovascular disease risk factors;
CRC	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.45	-6.45	-0.34	3.91e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg02049041	chr17:27085579	C17orf63	0.44	5.61	0.3	4.31e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs3996993	0.597	rs55906003	chr6:52733927	C/T	cg20803780	chr6:52668592	GSTA1	0.39	7.0	0.36	1.47e-11	Hemoglobin concentration;
CRC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.6	9.45	0.46	6.36e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.48	8.45	0.42	9.27e-16	Systemic lupus erythematosus;
CRC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.49	9.18	0.45	4.86e-18	Smoking initiation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17157516	chr1:35332203	DLGAP3	0.43	6.2	0.32	1.73e-9	Response to antipsychotic treatment;
CRC	cis	rs11229555	0.645	rs4517537	chr11:58213695	G/A	cg15696309	chr11:58395628	NA	-0.82	-10.31	-0.49	8.59e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.96	-17.68	-0.7	1.16e-49	Height;
CRC	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-10.71	-0.51	3.59e-23	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg10622236	chr15:42120082	JMJD7;JMJD7-PLA2G4B	-0.43	-6.39	-0.33	5.72e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs117623576	0.680	rs12269122	chr10:32367864	C/T	cg03047570	chr10:32398778	NA	-0.62	-6.92	-0.36	2.39e-11	Anti-saccade response;
CRC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg20615401	chr6:28092323	ZSCAN16	0.47	6.27	0.33	1.16e-9	Cardiac Troponin-T levels;
CRC	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.25	-0.33	1.28e-9	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg21620606	chr4:1342894	KIAA1530	0.5	8.16	0.41	7.39e-15	Obesity-related traits;
CRC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.09	18.81	0.72	4.31e-54	Cognitive function;
CRC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.77	13.51	0.6	2.17e-33	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6998277	0.830	rs17186961	chr8:103630028	G/A	cg10187029	chr8:103597600	NA	0.9	13.11	0.59	7.2e-32	Migraine;
CRC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.63	-11.17	-0.52	8.85e-25	Mean corpuscular hemoglobin;
CRC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.58	-6.07	-0.32	3.5e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.4	6.22	0.32	1.53e-9	HDL cholesterol levels;
CRC	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.53	-6.9	-0.36	2.67e-11	Height;
CRC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.79	-9.9	-0.48	2.1e-20	Platelet count;
CRC	cis	rs12826942	0.718	rs12827742	chr12:42542861	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	6.46	0.34	3.69e-10	Coronary artery disease;
CRC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.57	-7.63	-0.39	2.49e-13	DNA methylation (variation);
CRC	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg17470449	chr10:769945	NA	0.57	7.87	0.4	5.29e-14	Uric acid levels;
CRC	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.33	0.42	2.14e-15	Coffee consumption (cups per day);
CRC	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.72	-10.97	-0.52	4.7e-24	Waist circumference;Body mass index;
CRC	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.49	-7.58	-0.39	3.45e-13	Type 2 diabetes;
CRC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.53	0.43	5.37e-16	Menopause (age at onset);
CRC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	8.13	0.41	8.59e-15	Monocyte count;
CRC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.89	0.4	4.53e-14	Lung cancer;
CRC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-6.39	-0.33	5.51e-10	Breast cancer;
CRC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg06243084	chr11:63990629	FERMT3	-0.39	-6.16	-0.32	2.1e-9	Platelet count;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg25050353	chr11:119599427	PVRL1	0.38	6.02	0.31	4.58e-9	Schizophrenia;
CRC	cis	rs243505	0.762	rs734002	chr7:148505788	A/G	cg09806900	chr7:148480153	CUL1	0.41	6.2	0.32	1.71e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.77	-12.68	-0.57	2.93e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs16924133	0.793	rs11032153	chr11:33153026	G/A	cg05567920	chr11:33183001	CSTF3	-0.78	-5.92	-0.31	7.95e-9	Anger;
CRC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.8	0.3	1.54e-8	Height;
CRC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.8	0.4	8.18e-14	Menopause (age at onset);
CRC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.81	-10.01	-0.48	8.99e-21	Initial pursuit acceleration;
CRC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.71	11.81	0.55	4.64e-27	Breast cancer;
CRC	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.38	6.48	0.34	3.3e-10	Sitting height ratio;
CRC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg19046167	chr17:80928561	B3GNTL1	0.43	6.71	0.35	8.61e-11	Breast cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23602684	chr14:24584099	DCAF11	0.44	6.0	0.31	5.24e-9	Anxiety disorder;
CRC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg24130564	chr14:104152367	KLC1	-0.43	-5.81	-0.31	1.45e-8	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.698	rs12537161	chr7:124538590	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.05	-0.32	3.86e-9	Cutaneous malignant melanoma;
CRC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg17401720	chr7:158221031	PTPRN2	-0.49	-8.08	-0.41	1.24e-14	Obesity-related traits;
CRC	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.88	-0.31	1.03e-8	Pulmonary function;
CRC	cis	rs6968419	0.674	rs11767092	chr7:115907865	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.2	-0.32	1.66e-9	Intraocular pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23435730	chr3:127770634	SEC61A1	0.41	6.29	0.33	1.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12560992	chr17:57184187	TRIM37	0.53	7.22	0.37	3.53e-12	Testicular germ cell tumor;
CRC	cis	rs17162190	0.698	rs6690458	chr1:26789787	T/C	cg17456097	chr1:26900765	RPS6KA1	0.47	6.62	0.34	1.5e-10	Mean corpuscular volume;
CRC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.61	6.24	0.33	1.32e-9	Axial length;
CRC	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.56	7.27	0.37	2.61e-12	Coronary artery disease;
CRC	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	18.11	0.71	2.51e-51	Coffee consumption;Coffee consumption (cups per day);
CRC	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.46	-0.34	3.87e-10	Depression;
CRC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs1572438	0.811	rs6916731	chr6:880428	G/C	cg21062780	chr6:887772	NA	0.41	6.71	0.35	8.31e-11	Aging;
CRC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.92	-8.23	-0.41	4.33e-15	Putamen volume;
CRC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg09835421	chr16:68378352	PRMT7	-0.77	-7.94	-0.4	3.2e-14	Schizophrenia;
CRC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.45	6.9	0.36	2.6e-11	Colorectal cancer;
CRC	cis	rs17092148	0.887	rs932542	chr20:33171368	G/C	cg08999081	chr20:33150536	PIGU	0.5	6.17	0.32	2.02e-9	Neuroticism;
CRC	cis	rs17767392	0.958	rs34469007	chr14:71916923	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.56	-7.11	-0.36	7.27e-12	Mitral valve prolapse;
CRC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.36	5.91	0.31	8.56e-9	Alcohol dependence;
CRC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.48	-6.25	-0.33	1.29e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.38	7.5	0.38	5.95e-13	Tonsillectomy;
CRC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-0.88	-10.39	-0.5	4.67e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.45	-7.21	-0.37	3.86e-12	Testicular germ cell tumor;
CRC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-12.22	-0.56	1.4e-28	Vitiligo;
CRC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg25164649	chr6:28176230	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg09713000	chr3:186524298	RFC4	0.45	6.03	0.32	4.37e-9	Anxiety disorder;
CRC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.15e-25	Hip circumference adjusted for BMI;
CRC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.34	0.42	2e-15	Gut microbiome composition (summer);
CRC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.28	14.73	0.63	4.44e-38	Diabetic kidney disease;
CRC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.54	-5.64	-0.3	3.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs6956675	1.000	rs7801458	chr7:62597651	A/G	cg01314568	chr7:57830625	NA	-0.68	-9.37	-0.46	1.15e-18	Obesity-related traits;
CRC	cis	rs4422723	0.724	rs10279261	chr7:133589846	C/T	cg03336402	chr7:133662267	EXOC4	-0.42	-6.11	-0.32	2.8e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.44	0.38	8.68e-13	Height;
CRC	cis	rs9547692	1.000	rs604279	chr13:37471254	G/C	cg01493522	chr13:37497338	NA	-0.43	-6.25	-0.33	1.31e-9	Coronary artery disease;
CRC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.29	-0.49	9.95e-22	Bone mineral density;
CRC	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.38	-0.56	3.59e-29	Exhaled nitric oxide output;
CRC	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	7.87	0.4	5.21e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs847649	0.731	rs2298854	chr7:102729631	T/G	cg18108683	chr7:102477205	FBXL13	0.53	8.12	0.41	9.44e-15	Morning vs. evening chronotype;
CRC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.68	9.56	0.47	2.84e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.42	-6.46	-0.34	3.8e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg23417306	chr2:180868811	CWC22	-0.42	-5.73	-0.3	2.22e-8	Schizophrenia;
CRC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg02880119	chr16:3481970	NA	0.41	5.86	0.31	1.1e-8	Body mass index (adult);
CRC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.53e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.49	6.86	0.35	3.53e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.26	-0.33	1.17e-9	Educational attainment;
CRC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg00745463	chr17:30367425	LRRC37B	-0.55	-6.91	-0.36	2.54e-11	Hip circumference adjusted for BMI;
CRC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.28e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	7.46	0.38	7.95e-13	Coronary artery disease;
CRC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.41	-0.33	5.11e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg04287289	chr16:89883240	FANCA	0.61	9.57	0.47	2.63e-19	Vitiligo;
CRC	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.61	7.32	0.37	1.88e-12	Carotid intima media thickness;
CRC	cis	rs7635838	0.892	rs6792718	chr3:11434380	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.32	0.33	8.44e-10	HDL cholesterol;
CRC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg00745463	chr17:30367425	LRRC37B	0.58	7.55	0.38	4.37e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg14541582	chr5:601475	NA	-0.36	-7.29	-0.37	2.3e-12	Obesity-related traits;
CRC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg19077165	chr18:44547161	KATNAL2	0.43	6.71	0.35	8.7e-11	Personality dimensions;
CRC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.67	-0.39	1.95e-13	Response to antipsychotic treatment;
CRC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.65	10.7	0.51	4.03e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg16950941	chr11:66035639	RAB1B	-0.61	-7.54	-0.38	4.59e-13	Electroencephalogram traits;
CRC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.58	9.77	0.47	5.67e-20	Menopause (age at onset);
CRC	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg10263370	chr3:44754102	ZNF502	-0.36	-5.92	-0.31	8.3e-9	Depressive symptoms;
CRC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.53	-0.34	2.53e-10	Subjective well-being;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21012871	chr20:42939451	FITM2	0.43	6.24	0.33	1.33e-9	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.56	6.58	0.34	1.91e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.9	-0.31	9.11e-9	Mean corpuscular volume;
CRC	cis	rs4746091	0.760	rs56235440	chr10:73390724	G/A	cg22763136	chr10:73395000	CDH23	0.43	5.93	0.31	7.51e-9	Selective IgA deficiency;
CRC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.54	8.16	0.41	7.21e-15	Morning vs. evening chronotype;
CRC	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg13615338	chr4:55094005	PDGFRA	0.41	5.86	0.31	1.11e-8	Corneal astigmatism;
CRC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.72	-11.66	-0.54	1.55e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.54	0.47	3.37e-19	Blood protein levels;
CRC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-6.07	-0.32	3.51e-9	Tonsillectomy;
CRC	cis	rs758324	0.773	rs40819	chr5:131305384	G/T	cg25547332	chr5:131281432	NA	-0.36	-5.76	-0.3	1.95e-8	Alzheimer's disease in APOE e4- carriers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03965198	chr11:125932701	CDON	0.45	5.96	0.31	6.37e-9	Anxiety disorder;
CRC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.6	0.3	4.53e-8	Putamen volume;
CRC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.12	-0.32	2.71e-9	Alzheimer's disease (late onset);
CRC	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.76	-0.35	6.27e-11	Inflammatory skin disease;
CRC	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg23032129	chr1:109941072	SORT1	-0.27	-5.84	-0.31	1.24e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.69	10.37	0.5	5.39e-22	Cognitive function;
CRC	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.71	-7.11	-0.37	7.06e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22133161	chr19:49891603	CCDC155	0.51	6.65	0.34	1.21e-10	Multiple sclerosis;
CRC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.98	-0.31	5.86e-9	Life satisfaction;
CRC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg17330251	chr7:94953956	PON1	-0.58	-7.44	-0.38	8.81e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg13722127	chr7:150037890	RARRES2	0.48	7.45	0.38	8.04e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.05	19.96	0.74	1.21e-58	Schizophrenia;
CRC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	ch.11.42038R	chr11:967971	AP2A2	0.6	10.26	0.49	1.35e-21	Alzheimer's disease (late onset);
CRC	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.51	-5.86	-0.31	1.13e-8	Coronary artery disease;
CRC	cis	rs9925964	0.744	rs12716979	chr16:31011821	T/G	cg02466173	chr16:30829666	NA	0.41	5.85	0.31	1.19e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg25019722	chr6:37503610	NA	-0.35	-6.07	-0.32	3.48e-9	Cognitive performance;
CRC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.97	-19.07	-0.72	3.93e-55	Height;
CRC	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.66	-10.72	-0.51	3.52e-23	Hepatocellular carcinoma;
CRC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg04607235	chr12:12878440	APOLD1	-1.01	-13.78	-0.6	2.03e-34	Lymphocyte counts;
CRC	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.74	0.39	1.27e-13	Platelet count;
CRC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg19635926	chr16:89946313	TCF25	0.62	5.73	0.3	2.3e-8	Skin colour saturation;
CRC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg02733842	chr7:1102375	C7orf50	-0.55	-6.92	-0.36	2.38e-11	Bronchopulmonary dysplasia;
CRC	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.49	-7.88	-0.4	4.7e-14	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.71	-0.35	8.32e-11	Cutaneous nevi;
CRC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg13319975	chr6:146136371	FBXO30	0.44	6.64	0.34	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg00947319	chr17:47005597	UBE2Z	-0.34	-5.88	-0.31	1.02e-8	Type 2 diabetes;
CRC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.63	-8.51	-0.42	6.43e-16	Gut microbiome composition (summer);
CRC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.53	-9.45	-0.46	6.68e-19	Lung cancer;
CRC	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.51	8.36	0.42	1.82e-15	Aortic root size;
CRC	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg00105475	chr2:10696890	NA	0.46	7.42	0.38	1.01e-12	Prostate cancer;
CRC	cis	rs17227506	0.900	rs1105406	chr8:13447025	G/A	cg03566418	chr8:13424080	C8orf48	0.35	6.35	0.33	7.31e-10	Nonsyndromic cleft lip with cleft palate;
CRC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.54	-8.07	-0.41	1.38e-14	Height;
CRC	cis	rs9311676	0.656	rs11130634	chr3:58379123	A/C	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.58	-7.1	-0.36	7.97e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg08896387	chr1:24191740	FUCA1	0.51	6.89	0.36	2.77e-11	Immature fraction of reticulocytes;
CRC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg20512303	chr5:131592959	PDLIM4	0.39	6.75	0.35	6.7e-11	Breast cancer;
CRC	cis	rs57920188	0.640	rs10915600	chr1:4082105	T/G	cg10510935	chr1:4059661	NA	0.4	5.92	0.31	7.9e-9	Interleukin-17 levels;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20783262	chr1:68152310	GADD45A	0.43	6.61	0.34	1.56e-10	Myopia (pathological);
CRC	cis	rs4237845	0.611	rs4583019	chr12:58316745	T/C	cg00677455	chr12:58241039	CTDSP2	0.43	6.23	0.32	1.45e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.84	14.73	0.63	4.33e-38	Breast cancer;
CRC	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg24046110	chr8:143859143	LYNX1	0.36	6.27	0.33	1.17e-9	Urinary tract infection frequency;
CRC	cis	rs5758511	0.573	rs4501042	chr22:42245763	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.37	-5.97	-0.31	6.13e-9	Birth weight;
CRC	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg08632701	chr21:37451849	NA	-0.44	-6.77	-0.35	5.9e-11	Mitral valve prolapse;
CRC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.53	6.01	0.31	5.01e-9	Vitiligo;
CRC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.63	0.39	2.51e-13	Iron status biomarkers;
CRC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg18016565	chr1:150552671	MCL1	0.48	6.88	0.35	3.02e-11	Tonsillectomy;
CRC	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.65	9.24	0.45	3.05e-18	Body mass index;
CRC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.57	-10.08	-0.49	5.26e-21	Intelligence (multi-trait analysis);
CRC	cis	rs2302190	0.882	rs3744111	chr17:56607959	G/A	cg12560992	chr17:57184187	TRIM37	0.5	5.87	0.31	1.05e-8	Vitamin D levels;
CRC	cis	rs10944	0.598	rs1717570	chr5:78276474	C/T	cg13121490	chr5:78280331	ARSB	0.43	6.16	0.32	2.18e-9	Blood and toenail selenium levels;
CRC	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg23234261	chr14:55582407	NA	-0.29	-5.8	-0.3	1.58e-8	Protein biomarker;
CRC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.89	-15.31	-0.64	2.57e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.79	0.35	5.35e-11	Neuroticism;
CRC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.33	6.41	0.33	4.91e-10	Renal cell carcinoma;
CRC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg18721089	chr20:30220636	NA	0.36	5.66	0.3	3.27e-8	Mean corpuscular hemoglobin;
CRC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02290350	chr8:58132656	NA	-0.59	-8.02	-0.4	1.88e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.71	8.19	0.41	5.78e-15	Eotaxin levels;
CRC	trans	rs2303319	0.504	rs62188988	chr2:162531068	T/C	cg27342122	chr8:133787442	PHF20L1	-0.7	-6.02	-0.31	4.64e-9	Cognitive function;
CRC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg02766259	chr12:125626809	AACS	-0.45	-7.74	-0.39	1.27e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.96	-0.36	1.9e-11	Electroencephalogram traits;
CRC	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.58	9.05	0.45	1.32e-17	Blood protein levels;
CRC	cis	rs9322817	0.691	rs4460239	chr6:105325562	C/T	cg02098413	chr6:105308735	HACE1	0.43	8.45	0.42	9.74e-16	Thyroid stimulating hormone;
CRC	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg07884673	chr3:53033167	SFMBT1	0.78	6.22	0.32	1.53e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.71	9.42	0.46	8.02e-19	Bladder cancer;
CRC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.46	-6.64	-0.34	1.29e-10	Bipolar disorder;
CRC	cis	rs7605827	0.930	rs2052438	chr2:15701951	G/A	cg19274914	chr2:15703543	NA	0.37	5.62	0.3	4.13e-8	Educational attainment (years of education);
CRC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.39	-0.33	5.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg19318889	chr4:1322082	MAEA	0.4	5.68	0.3	2.94e-8	Obesity-related traits;
CRC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.5	-0.38	6.06e-13	HDL cholesterol;
CRC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.82	12.67	0.57	3.21e-30	Glomerular filtration rate (creatinine);
CRC	trans	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg10756647	chr7:56101905	PSPH	0.73	8.12	0.41	9.55e-15	Diabetic kidney disease;
CRC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg00343986	chr7:65444356	GUSB	0.46	6.82	0.35	4.27e-11	Aortic root size;
CRC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.62	-0.39	2.79e-13	Gut microbiome composition (summer);
CRC	cis	rs955333	0.565	rs7770413	chr6:154904487	A/G	cg20019720	chr6:154832845	CNKSR3	0.34	6.14	0.32	2.34e-9	Diabetic kidney disease;
CRC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.67	11.61	0.54	2.47e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.59	-7.2	-0.37	4.04e-12	Ulcerative colitis;
CRC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg23254163	chr1:152506842	NA	0.37	6.35	0.33	6.96e-10	Hair morphology;
CRC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.25	-0.45	2.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	6.8	0.35	4.96e-11	Lymphocyte counts;
CRC	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.79	-0.3	1.68e-8	Blood pressure;
CRC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.81	-0.3	1.51e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9462846	0.853	rs7740879	chr6:42873379	C/T	cg21280719	chr6:42927975	GNMT	0.32	6.39	0.33	5.58e-10	Blood protein levels;
CRC	trans	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg18335740	chr13:41363409	SLC25A15	0.54	8.26	0.41	3.51e-15	Lewy body disease;
CRC	cis	rs12760731	0.720	rs71628282	chr1:178449993	C/G	cg00404053	chr1:178313656	RASAL2	1.16	11.88	0.55	2.6e-27	Obesity-related traits;
CRC	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-6.44	-0.33	4.33e-10	Coronary artery disease;
CRC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.79	-0.35	5.4e-11	Lung cancer;
CRC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.41	-7.25	-0.37	2.96e-12	Height;
CRC	cis	rs4731207	0.698	rs10233589	chr7:124468599	G/A	cg23710748	chr7:124431027	NA	0.37	6.05	0.32	3.86e-9	Cutaneous malignant melanoma;
CRC	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	9.04	0.45	1.42e-17	Ulcerative colitis;
CRC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	0.98	13.77	0.6	2.19e-34	Breast cancer;
CRC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.58	9.76	0.47	6.18e-20	Menopause (age at onset);
CRC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg12193833	chr17:30244370	NA	-0.57	-8.0	-0.4	2.11e-14	Hip circumference adjusted for BMI;
CRC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.45	6.24	0.33	1.34e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.63	10.37	0.5	5.47e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13198984	chr17:80129470	CCDC57	0.45	8.01	0.4	1.99e-14	Life satisfaction;
CRC	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.59	-8.34	-0.42	2.05e-15	Plateletcrit;Platelet count;
CRC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg14728415	chr7:32535168	LSM5;AVL9	0.45	6.48	0.34	3.28e-10	Cognitive ability;
CRC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg22687807	chr8:143858763	LYNX1	0.47	7.62	0.39	2.72e-13	Urinary tract infection frequency;
CRC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg13798912	chr7:905769	UNC84A	0.51	5.81	0.31	1.45e-8	Cerebrospinal P-tau181p levels;
CRC	trans	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg18187862	chr3:45730750	SACM1L	-0.58	-7.51	-0.38	5.78e-13	Primary sclerosing cholangitis;
CRC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.37	6.11	0.32	2.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.53	-7.28	-0.37	2.47e-12	Coronary artery disease;
CRC	cis	rs7301826	0.651	rs10744483	chr12:131298206	C/A	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.49	6.49	0.34	3.08e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CRC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	7.88	0.4	4.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	1.05	12.29	0.56	8.25e-29	Hip circumference adjusted for BMI;
CRC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.97	-16.9	-0.68	1.42e-46	Obesity-related traits;
CRC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.82	-15.78	-0.66	3.61e-42	Post bronchodilator FEV1;
CRC	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.42	6.91	0.36	2.59e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.48	7.29	0.37	2.35e-12	Testicular germ cell tumor;
CRC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.64	7.26	0.37	2.79e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg23461800	chr14:103021989	NA	0.62	8.23	0.41	4.56e-15	Platelet count;
CRC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02421172	chr7:1938701	MAD1L1	0.44	5.84	0.31	1.29e-8	Neuroticism;
CRC	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg02927042	chr1:21476669	EIF4G3	-0.45	-7.39	-0.38	1.26e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs17065868	0.764	rs56773929	chr13:45038130	G/A	cg10246903	chr13:45222710	NA	0.54	5.69	0.3	2.79e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg12172441	chr6:28176163	NA	0.48	6.17	0.32	1.96e-9	Parkinson's disease;
CRC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.28	-0.53	3.61e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.46	-7.28	-0.37	2.48e-12	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg00579200	chr11:133705235	NA	0.39	5.79	0.3	1.67e-8	Childhood ear infection;
CRC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg25767906	chr1:53392781	SCP2	0.47	7.49	0.38	6.24e-13	Monocyte count;
CRC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-7.22	-0.37	3.64e-12	Lymphocyte counts;
CRC	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.51	-8.39	-0.42	1.41e-15	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.74	12.6	0.57	5.83e-30	Body mass index;
CRC	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg12458913	chr13:53173898	NA	0.48	7.11	0.36	7.38e-12	Lewy body disease;
CRC	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg09659197	chr4:152720779	NA	0.49	10.43	0.5	3.46e-22	Intelligence (multi-trait analysis);
CRC	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	0.89	10.1	0.49	4.41e-21	Uric acid levels;
CRC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22029157	chr1:209979665	IRF6	0.61	6.76	0.35	6.47e-11	Coronary artery disease;
CRC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	9.05	0.45	1.26e-17	Mood instability;
CRC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.98	-0.31	5.92e-9	Life satisfaction;
CRC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.6	-6.31	-0.33	9.25e-10	Schizophrenia;
CRC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.61	9.12	0.45	7.81e-18	Lung cancer;
CRC	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.5	7.5	0.38	5.95e-13	Uric acid levels;
CRC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02290350	chr8:58132656	NA	-0.6	-6.94	-0.36	2.16e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.6	8.59	0.43	3.49e-16	Birth weight;
CRC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg04800585	chr6:26043546	HIST1H2BB	0.53	7.77	0.39	1.04e-13	Intelligence (multi-trait analysis);
CRC	cis	rs2949837	0.581	rs2960434	chr7:45972977	A/G	cg04796162	chr7:45961102	IGFBP3	0.38	6.62	0.34	1.49e-10	Sitting height ratio;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg14727880	chr9:19049247	RRAGA	0.56	6.19	0.32	1.78e-9	Body mass index;
CRC	trans	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08048268	chr3:133502702	NA	0.41	7.17	0.37	4.92e-12	Alcohol consumption (transferrin glycosylation);
CRC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg07195577	chr17:27052828	TLCD1	0.42	6.02	0.32	4.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	trans	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs3736485	0.966	rs7173880	chr15:51785433	C/A	cg08986416	chr15:51914746	DMXL2	-0.44	-6.46	-0.34	3.66e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg11632617	chr15:75315747	PPCDC	-0.53	-7.11	-0.37	7.14e-12	Blood trace element (Zn levels);
CRC	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.55	-8.06	-0.41	1.44e-14	Neuroticism;
CRC	cis	rs10450586	0.863	rs10767631	chr11:27315853	C/G	cg10370305	chr11:27303972	NA	0.35	5.69	0.3	2.76e-8	Total body bone mineral density;
CRC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.61	9.19	0.45	4.4e-18	Testicular germ cell tumor;
CRC	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.55	5.98	0.31	5.82e-9	RR interval (heart rate);
CRC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.27	0.33	1.14e-9	Bipolar disorder;
CRC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.1	-0.41	1.11e-14	Coronary artery disease;
CRC	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.61	-8.41	-0.42	1.28e-15	Body mass index;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg23161317	chr6:28129485	ZNF389	0.46	6.46	0.34	3.68e-10	Cardiac Troponin-T levels;
CRC	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-6.92	-0.36	2.43e-11	Eye color traits;
CRC	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.58	8.31	0.42	2.56e-15	Uric acid levels;
CRC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.08	-0.32	3.35e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg10820045	chr2:198174542	NA	-0.49	-7.76	-0.39	1.05e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.82	-14.38	-0.62	1.04e-36	Lewy body disease;
CRC	cis	rs10991814	0.925	rs10991809	chr9:93946555	G/A	cg14446406	chr9:93919335	NA	0.46	6.16	0.32	2.08e-9	Neutrophil percentage of granulocytes;
CRC	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg09659197	chr4:152720779	NA	0.53	11.71	0.54	1.06e-26	Intelligence (multi-trait analysis);
CRC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.54	-9.27	-0.46	2.49e-18	Type 2 diabetes;
CRC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	9.37	0.46	1.16e-18	Schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11464238	chr7:140179466	MKRN1	0.39	6.43	0.33	4.37e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.44	6.64	0.34	1.28e-10	Joint mobility (Beighton score);
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg19334895	chr19:18942619	UPF1	0.4	6.02	0.31	4.6e-9	Body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg18827738	chr6:112408577	TUBE1;C6orf225	0.45	6.25	0.33	1.28e-9	Anxiety disorder;
CRC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.72	-13.02	-0.58	1.59e-31	Educational attainment;
CRC	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.32	5.63	0.3	3.81e-8	Panic disorder;
CRC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.45	7.44	0.38	8.92e-13	Colorectal cancer;
CRC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.07	-0.36	9.09e-12	HDL cholesterol;
CRC	cis	rs3823572	0.564	rs6949760	chr7:133676101	C/A	cg03336402	chr7:133662267	EXOC4	-0.68	-9.97	-0.48	1.27e-20	Intelligence (multi-trait analysis);
CRC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.98	-0.36	1.63e-11	Morning vs. evening chronotype;
CRC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg19913688	chr11:428466	ANO9	-0.69	-7.03	-0.36	1.22e-11	Body mass index;
CRC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.38	0.33	5.94e-10	Personality dimensions;
CRC	cis	rs6546324	0.625	rs2861681	chr2:67830139	A/G	cg15745817	chr2:67799979	NA	-0.55	-9.07	-0.45	1.1e-17	Endometriosis;
CRC	cis	rs12745968	0.525	rs6603997	chr1:93062611	C/G	cg17283838	chr1:93427260	FAM69A	-0.45	-6.17	-0.32	2.06e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg11003573	chr3:44754125	ZNF502	-0.33	-5.61	-0.3	4.33e-8	Depressive symptoms;
CRC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.54	8.44	0.42	1.03e-15	Pancreatic cancer;
CRC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.66	-9.37	-0.46	1.22e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14019695	chr9:139328340	INPP5E	0.4	6.06	0.32	3.68e-9	Monocyte percentage of white cells;
CRC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.01	-0.31	4.99e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.54	-7.84	-0.4	6.49e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg05639522	chr1:247681581	NA	-0.51	-8.24	-0.41	4.12e-15	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg21153622	chr11:89784906	NA	-0.47	-7.4	-0.38	1.13e-12	HDL cholesterol;
CRC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg24300038	chr13:113819356	PROZ	0.49	6.37	0.33	6.44e-10	Platelet distribution width;
CRC	cis	rs6694672	1.000	rs1170883	chr1:196951471	C/T	cg13682187	chr1:196946512	CFHR5	-0.5	-7.68	-0.39	1.8e-13	Asthma;
CRC	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg24024056	chr10:102415556	NA	-0.36	-7.3	-0.37	2.17e-12	Body mass index;
CRC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.77	14.5	0.62	3.45e-37	Prudent dietary pattern;
CRC	trans	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg00953403	chr17:74099816	EXOC7	0.5	7.1	0.36	7.5e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-5.73	-0.3	2.24e-8	Major depressive disorder;
CRC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.83	0.35	4.14e-11	Melanoma;
CRC	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg00071950	chr4:10020882	SLC2A9	0.49	6.45	0.33	4.04e-10	Blood metabolite levels;
CRC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.53	-8.03	-0.4	1.79e-14	Blood protein levels;
CRC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.36	-6.54	-0.34	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs2333194	0.846	rs6574118	chr14:73811992	A/G	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.41	-6.2	-0.32	1.65e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.61	9.35	0.46	1.4e-18	Alzheimer's disease (late onset);
CRC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.52	-0.34	2.68e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01261044	chr14:35451962	SRP54	0.58	7.63	0.39	2.48e-13	Thyroid stimulating hormone;
CRC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.24	0.41	4.06e-15	Menarche (age at onset);
CRC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg09264619	chr17:80180166	NA	0.51	7.3	0.37	2.17e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg02659138	chr7:134003124	SLC35B4	0.38	6.23	0.32	1.43e-9	Mean platelet volume;
CRC	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	0.83	9.87	0.48	2.67e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.79	-9.88	-0.48	2.44e-20	Platelet count;
CRC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.42	9.02	0.45	1.59e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg26248373	chr2:1572462	NA	-0.81	-11.92	-0.55	1.74e-27	IgG glycosylation;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg18459342	chr8:81084056	TPD52	0.42	6.65	0.34	1.21e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg01710450	chr16:89662404	CPNE7	-0.47	-6.48	-0.34	3.27e-10	Tanning;
CRC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.91	13.19	0.59	3.58e-32	Breast cancer;
CRC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.46	7.03	0.36	1.21e-11	Dupuytren's disease;
CRC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-12.73	-0.57	1.88e-30	Extrinsic epigenetic age acceleration;
CRC	cis	rs4234798	0.605	rs4689639	chr4:7213469	C/T	cg18431297	chr4:7219810	SORCS2	-0.47	-7.31	-0.37	2.05e-12	Insulin-like growth factors;
CRC	cis	rs9462027	0.628	rs2814953	chr6:34697767	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.05	-0.32	3.84e-9	Systemic lupus erythematosus;
CRC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.53	5.96	0.31	6.67e-9	Bipolar disorder;
CRC	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg01312482	chr5:178451176	ZNF879	-0.36	-6.07	-0.32	3.55e-9	Pubertal anthropometrics;
CRC	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.55	-8.89	-0.44	4.13e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs3018066	0.748	rs11097912	chr4:107000462	C/T	cg01869342	chr4:106983673	TBCK	0.44	6.62	0.34	1.48e-10	Cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg27043427	chr17:65362820	PSMD12	0.47	5.98	0.31	5.96e-9	Anxiety disorder;
CRC	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	6.0	0.31	5.18e-9	Axial length;
CRC	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.32	5.7	0.3	2.67e-8	Heart rate;
CRC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.98	0.66	6.08e-43	Chronic sinus infection;
CRC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.34	-6.33	-0.33	8.23e-10	Dupuytren's disease;
CRC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs1376359	0.673	rs7543104	chr1:103126190	C/A	cg16220183	chr17:56609687	SEPT4	-0.45	-6.03	-0.32	4.48e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.11	0.32	2.84e-9	Aortic root size;
CRC	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.37	-6.13	-0.32	2.46e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.56	8.75	0.43	1.15e-16	Schizophrenia;
CRC	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg12870014	chr12:110450643	ANKRD13A	0.86	10.4	0.5	4.27e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03090513	chr2:208394450	CREB1	0.4	6.61	0.34	1.57e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.97	-0.44	2.27e-17	Aortic root size;
CRC	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.53	-7.47	-0.38	7.41e-13	Non-substance related behavioral disinhibition;
CRC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.98	21.22	0.76	1.46e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.08e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11165623	0.602	rs7527155	chr1:97016690	T/C	cg10631902	chr5:14652156	NA	-0.36	-6.17	-0.32	2.05e-9	Hip circumference;Waist circumference;
CRC	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg21153622	chr11:89784906	NA	-0.44	-7.11	-0.36	7.07e-12	HDL cholesterol;
CRC	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.97	-16.6	-0.68	2.2e-45	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.45	-8.32	-0.42	2.32e-15	Reticulocyte fraction of red cells;
CRC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs12230513	0.732	rs4343668	chr12:55868936	G/T	cg19537932	chr12:55886519	OR6C68	-0.71	-8.99	-0.44	1.95e-17	Contrast sensitivity;
CRC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.85	0.55	3.28e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.98	12.61	0.57	5.13e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.84	11.52	0.54	4.86e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.15	0.41	7.64e-15	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62189052	chr2:162623869	C/G	cg25193742	chr10:104614220	C10orf32	-0.76	-6.46	-0.34	3.66e-10	Cognitive function;
CRC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg09264619	chr17:80180166	NA	-0.35	-5.81	-0.31	1.48e-8	Life satisfaction;
CRC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-18.1	-0.71	2.56e-51	Schizophrenia;
CRC	cis	rs3767633	0.925	rs2055539	chr1:161807866	T/C	cg09175582	chr1:161736000	ATF6	0.69	6.27	0.33	1.14e-9	IgG glycosylation;
CRC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg19812747	chr11:111475976	SIK2	-0.58	-9.92	-0.48	1.8e-20	Primary sclerosing cholangitis;
CRC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.78	-15.86	-0.66	1.81e-42	Prostate cancer;
CRC	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.51	8.78	0.44	9e-17	Dupuytren's disease;
CRC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.43e-13	Type 2 diabetes;
CRC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.8	14.25	0.62	3.19e-36	Breast cancer;
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg08222913	chr3:52553049	STAB1	-0.37	-6.98	-0.36	1.67e-11	Electroencephalogram traits;
CRC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.87	0.31	1.08e-8	IgG glycosylation;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg10498984	chr16:28874827	SH2B1	-0.73	-6.3	-0.33	9.75e-10	Cognitive function;
CRC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.69	8.89	0.44	4.24e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs3889199	0.629	rs7526027	chr1:59683994	T/C	cg25881383	chr1:59680599	NA	-0.38	-6.23	-0.32	1.41e-9	Pulse pressure;
CRC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	6.55	0.34	2.19e-10	Schizophrenia;
CRC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	10.85	0.51	1.15e-23	Motion sickness;
CRC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.88	-0.31	1.02e-8	Diastolic blood pressure;
CRC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.74	10.14	0.49	3.29e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.77	0.35	5.94e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	trans	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg06791473	chr12:49259579	RND1	0.61	5.99	0.31	5.45e-9	Blood protein levels;
CRC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.59	9.22	0.45	3.55e-18	Body mass index;
CRC	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.43	6.25	0.33	1.28e-9	Intelligence (multi-trait analysis);
CRC	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg06606381	chr12:133084897	FBRSL1	-1.44	-10.94	-0.52	5.61e-24	Depression;
CRC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.7	-0.54	1.13e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg00601450	chr5:74908170	NA	0.46	5.85	0.31	1.21e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.58	-8.75	-0.43	1.11e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.51e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10002492	0.666	rs11727304	chr4:12480889	A/G	cg05702448	chr1:167905194	DCAF6;BRP44	0.46	5.96	0.31	6.54e-9	IgG glycosylation;
CRC	cis	rs540254	0.619	rs4656932	chr1:160779495	C/T	cg20255094	chr1:160771763	LY9	0.43	5.9	0.31	8.83e-9	Blood protein levels;
CRC	cis	rs7259376	0.593	rs1091180	chr19:22476882	G/T	cg02657401	chr19:22469223	NA	0.3	6.56	0.34	2.07e-10	Menopause (age at onset);
CRC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	0.34	5.68	0.3	3.03e-8	Personality dimensions;
CRC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18867708	chr6:26865862	GUSBL1	0.42	6.02	0.32	4.59e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.59	6.64	0.34	1.26e-10	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.25	0.41	3.98e-15	Menopause (age at onset);
CRC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	-0.51	-8.22	-0.41	4.81e-15	Intelligence (multi-trait analysis);
CRC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg11292332	chr7:45801988	SEPT13	-0.36	-6.32	-0.33	8.73e-10	Extrinsic epigenetic age acceleration;
CRC	trans	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg02869306	chr7:64672164	INTS4L1	-0.42	-6.1	-0.32	3.04e-9	Aortic root size;
CRC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.45	-6.13	-0.32	2.55e-9	Gut microbiome composition (summer);
CRC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-6.8	-0.35	4.89e-11	Response to antipsychotic treatment;
CRC	cis	rs12618769	0.625	rs78518453	chr2:99213899	T/C	cg18455616	chr2:99124870	INPP4A	0.35	5.82	0.31	1.41e-8	Bipolar disorder;
CRC	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-8.9	-0.44	3.82e-17	Hyperactive-impulsive symptoms;
CRC	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg26061582	chr7:22766209	IL6	0.94	6.98	0.36	1.68e-11	Tonsillectomy;
CRC	cis	rs2949837	0.655	rs11977526	chr7:46008110	G/A	cg04796162	chr7:45961102	IGFBP3	0.47	7.87	0.4	5.24e-14	Sitting height ratio;
CRC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.55	5.66	0.3	3.27e-8	Breast cancer;
CRC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.9	16.65	0.68	1.44e-45	Intelligence (multi-trait analysis);
CRC	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.46	-6.93	-0.36	2.24e-11	Large artery stroke;
CRC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg10298567	chr3:47292165	KIF9	-0.39	-6.15	-0.32	2.2e-9	Colorectal cancer;
CRC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.19	0.32	1.8e-9	IgG glycosylation;
CRC	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.81	0.7	3.55e-50	Electrocardiographic conduction measures;
CRC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.81	13.64	0.6	7.09e-34	Menopause (age at onset);
CRC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-5.62	-0.3	4.03e-8	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.58	0.54	2.98e-26	Alzheimer's disease;
CRC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.89	0.31	9.41e-9	Depression;
CRC	cis	rs3771570	1.000	rs41266959	chr2:242275579	G/A	cg21155796	chr2:242212141	HDLBP	0.62	6.65	0.34	1.25e-10	Prostate cancer;
CRC	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg22687807	chr8:143858763	LYNX1	-0.38	-6.67	-0.35	1.1e-10	Urinary tract infection frequency;
CRC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.84	-11.25	-0.53	4.62e-25	Initial pursuit acceleration;
CRC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg03934865	chr2:198174659	NA	0.36	5.82	0.31	1.42e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg16141378	chr3:129829833	LOC729375	-0.48	-7.04	-0.36	1.11e-11	Neuroticism;
CRC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-7.93	-0.4	3.42e-14	Aortic root size;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg16647868	chr5:131706066	SLC22A5	-0.46	-6.1	-0.32	2.93e-9	Diisocyanate-induced asthma;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14823287	chr2:74684720	WBP1;INO80B	0.47	6.22	0.32	1.5e-9	Anxiety disorder;
CRC	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg14352298	chr13:112236639	NA	0.29	6.57	0.34	1.95e-10	Hepatitis;
CRC	cis	rs7605827	0.930	rs10179765	chr2:15541249	C/T	cg19274914	chr2:15703543	NA	0.4	5.94	0.31	7.2e-9	Educational attainment (years of education);
CRC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.24	0.33	1.31e-9	Diabetic kidney disease;
CRC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg01262667	chr19:19385393	TM6SF2	0.36	5.88	0.31	1.01e-8	Tonsillectomy;
CRC	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.58	-9.49	-0.46	5.01e-19	Body mass index;
CRC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.54	-7.95	-0.4	2.92e-14	Alzheimer's disease (late onset);
CRC	cis	rs4803480	0.720	rs4141218	chr19:42081907	T/C	cg08478046	chr19:42093086	CEACAM21	-0.32	-6.09	-0.32	3.17e-9	Schizophrenia;
CRC	cis	rs6764363	0.778	rs17012663	chr3:285806	G/T	cg02057681	chr3:285234	CHL1	-0.39	-5.61	-0.3	4.22e-8	Sudden cardiac arrest;
CRC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.9	17.49	0.69	6.72e-49	Bone mineral density;
CRC	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	0.85	6.65	0.34	1.24e-10	Fat distribution (HIV);
CRC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg12365402	chr11:9010492	NRIP3	-0.45	-6.87	-0.35	3.31e-11	Hemoglobin concentration;
CRC	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg14631576	chr9:95140430	CENPP	-0.39	-7.2	-0.37	4.23e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.63	0.34	1.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CRC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg25985355	chr7:65971099	NA	-0.51	-5.77	-0.3	1.79e-8	Gout;
CRC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg03623178	chr6:28175578	NA	0.59	8.35	0.42	1.96e-15	Parkinson's disease;
CRC	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg22089800	chr15:90895588	ZNF774	0.48	7.61	0.39	2.9e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.61	-10.7	-0.51	3.96e-23	Coronary artery disease;
CRC	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.08	-11.45	-0.53	8.94e-26	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs6546324	0.625	rs2902024	chr2:67836718	T/C	cg15745817	chr2:67799979	NA	-0.44	-7.92	-0.4	3.79e-14	Endometriosis;
CRC	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	7.84	0.4	6.28e-14	Bipolar disorder;
CRC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg16060761	chr17:80687452	NA	-0.45	-5.77	-0.3	1.85e-8	Glycated hemoglobin levels;
CRC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.68	-10.51	-0.5	1.76e-22	Hip circumference adjusted for BMI;
CRC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.94	11.56	0.54	3.59e-26	Eosinophil percentage of granulocytes;
CRC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg18196295	chr10:418757	DIP2C	0.45	6.52	0.34	2.59e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs11212617	1.000	rs619972	chr11:108169619	C/T	cg14761454	chr11:108092087	ATM;NPAT	0.39	5.6	0.3	4.49e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg17143303	chr17:33734764	NA	-0.4	-5.99	-0.31	5.35e-9	HDL cholesterol;
CRC	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-10.39	-0.5	4.54e-22	Colorectal cancer;
CRC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg03623178	chr6:28175578	NA	-0.49	-7.25	-0.37	2.9e-12	Pubertal anthropometrics;
CRC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.59	6.98	0.36	1.68e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs931812	0.756	rs4734497	chr8:101934971	T/C	cg20993868	chr7:22813445	NA	0.42	7.74	0.39	1.25e-13	Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.82	-9.06	-0.45	1.15e-17	Breast cancer;
CRC	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.58	0.39	3.56e-13	Eye color traits;
CRC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.46	5.99	0.31	5.55e-9	Height;
CRC	trans	rs2303319	0.504	rs55650699	chr2:162388931	T/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.1	-0.32	3.04e-9	Cognitive function;
CRC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg04989706	chr14:50066350	PPIL5	-0.61	-8.24	-0.41	4.18e-15	Carotid intima media thickness;
CRC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg20487152	chr13:99095054	FARP1	-0.46	-6.66	-0.34	1.14e-10	Longevity;
CRC	cis	rs10991814	0.920	rs7874056	chr9:94087622	A/C	cg14446406	chr9:93919335	NA	0.59	6.78	0.35	5.66e-11	Neutrophil percentage of granulocytes;
CRC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.7	0.3	2.71e-8	Depression;
CRC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.49	-9.62	-0.47	1.75e-19	Subjective well-being;
CRC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-15.43	-0.65	8.48e-41	Schizophrenia;
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg10876282	chr6:28092338	ZSCAN16	0.49	6.78	0.35	5.55e-11	Cardiac Troponin-T levels;
CRC	cis	rs4731207	0.698	rs12533560	chr7:124561882	T/C	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.5e-9	Cutaneous malignant melanoma;
CRC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.12	-0.32	2.7e-9	Morning vs. evening chronotype;
CRC	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg20356878	chr3:121714668	ILDR1	-0.43	-6.1	-0.32	3e-9	Multiple sclerosis;
CRC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	8.4	0.42	1.39e-15	Body mass index;
CRC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	6.15	0.32	2.31e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7394190	0.748	rs11000771	chr10:75524458	T/G	cg07699608	chr10:75541558	CHCHD1	0.58	6.11	0.32	2.89e-9	Incident atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22757384	chr3:183353803	KLHL24	0.45	6.42	0.33	4.85e-10	Response to antipsychotic treatment;
CRC	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.34	-0.37	1.74e-12	Morning vs. evening chronotype;
CRC	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg18232548	chr7:50535776	DDC	-0.43	-5.62	-0.3	4.05e-8	Malaria;
CRC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.55	7.45	0.38	8.5e-13	Heart rate;
CRC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.43	-6.18	-0.32	1.93e-9	Aortic root size;
CRC	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg15654264	chr1:150340011	RPRD2	0.37	5.81	0.31	1.46e-8	Migraine;
CRC	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-7.18	-0.37	4.62e-12	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg06470822	chr6:28175283	NA	0.91	13.28	0.59	1.54e-32	Parkinson's disease;
CRC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg13319975	chr6:146136371	FBXO30	-0.4	-5.95	-0.31	6.77e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg20469991	chr17:27169893	C17orf63	-0.67	-7.38	-0.38	1.32e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	6.0	0.31	5.3300000000000004e-09	Prudent dietary pattern;
CRC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.54	7.56	0.38	4.02e-13	Pancreatic cancer;
CRC	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg27398640	chr15:77910606	LINGO1	-0.44	-7.53	-0.38	4.89e-13	Type 2 diabetes;
CRC	cis	rs2160860	0.745	rs3739319	chr8:39785321	C/T	cg11363097	chr8:39792086	IDO2	-0.39	-6.63	-0.34	1.35e-10	Blood metabolite levels;
CRC	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.88	-0.35	3.02e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22601191	chr20:60968625	CABLES2	0.36	6.18	0.32	1.88e-9	Colorectal cancer;
CRC	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	6.48	0.34	3.37e-10	Homocysteine levels;
CRC	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.43	6.58	0.34	1.82e-10	Endometrial cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13904493	chr1:233464194	KIAA1804	0.45	6.42	0.33	4.84e-10	Anxiety disorder;
CRC	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.36	-0.33	6.89e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg10724054	chr17:3904396	NA	0.42	6.88	0.35	3.06e-11	Type 2 diabetes;
CRC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.69	10.74	0.51	2.99e-23	Diastolic blood pressure;
CRC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.46	-0.5	2.73e-22	Chronic sinus infection;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05676562	chr16:30102457	TBX6	-0.36	-6.25	-0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.09	0.32	3.18e-9	Depression;
CRC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	0.97	11.11	0.52	1.49e-24	Vitiligo;
CRC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.65	10.27	0.49	1.19e-21	Methadone dose in opioid dependence;
CRC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg08027265	chr7:2291960	NA	-0.36	-6.05	-0.32	4e-9	Schizophrenia;
CRC	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.77	8.62	0.43	2.95e-16	Neuroticism;
CRC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg03037974	chr15:76606532	NA	-0.52	-7.89	-0.4	4.59e-14	Blood metabolite levels;
CRC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg09264619	chr17:80180166	NA	-0.36	-6.04	-0.32	4.23e-9	Life satisfaction;
CRC	trans	rs2303319	0.504	rs62189041	chr2:162599506	T/C	cg12500891	chr11:57225987	NA	-0.65	-6.06	-0.32	3.77e-9	Cognitive function;
CRC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.46	-7.59	-0.39	3.41e-13	Monocyte count;
CRC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg25452165	chr22:42524984	CYP2D6	-0.4	-5.7	-0.3	2.69e-8	Cognitive function;
CRC	trans	rs7604735	0.853	rs12474485	chr2:145810833	A/C	cg26010734	chr19:15344046	EPHX3	-0.37	-5.98	-0.31	5.79e-9	Coronary artery disease;
CRC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg19622623	chr12:86230825	RASSF9	0.4	6.15	0.32	2.22e-9	Major depressive disorder;
CRC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.72	0.39	1.44e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-8.04	-0.41	1.65e-14	Gut microbiome composition (summer);
CRC	cis	rs185694	1.000	rs200505	chr13:30900868	G/T	cg07600127	chr13:30881527	KATNAL1	-0.57	-6.05	-0.32	4.01e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
CRC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.44	7.54	0.38	4.53e-13	Childhood ear infection;
CRC	cis	rs11212617	0.967	rs583725	chr11:108165075	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.07	0.32	3.56e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg05569086	chr8:143859399	LYNX1	-0.39	-6.43	-0.33	4.54e-10	Urinary tract infection frequency;
CRC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.71	-0.39	1.46e-13	Blood metabolite levels;
CRC	trans	rs4478147	0.569	rs72665740	chr4:87459950	C/T	cg01215037	chr19:50083917	PRRG2;NOSIP	0.45	5.97	0.31	6.1e-9	Migraine - clinic-based;
CRC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.6	0.39	3.07e-13	Mean platelet volume;
CRC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.06	-10.04	-0.48	7.5e-21	Diabetic retinopathy;
CRC	cis	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg05299278	chr17:33885742	SLFN14	0.41	6.11	0.32	2.76e-9	Response to radiotherapy in cancer (late toxicity);
CRC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.52	0.38	5.18e-13	Motion sickness;
CRC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg06470822	chr6:28175283	NA	0.78	11.17	0.52	8.89e-25	Parkinson's disease;
CRC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.89	13.6	0.6	9.75e-34	Menarche (age at onset);
CRC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.29	0.56	7.75e-29	Alzheimer's disease;
CRC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02825527	chr7:2087843	MAD1L1	-0.51	-6.15	-0.32	2.26e-9	Neuroticism;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg03623178	chr6:28175578	NA	0.65	9.92	0.48	1.85e-20	Cardiac Troponin-T levels;
CRC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.79	-10.04	-0.48	7.48e-21	Initial pursuit acceleration;
CRC	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-6.99	-0.36	1.56e-11	HDL cholesterol;
CRC	trans	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg11693508	chr17:37793320	STARD3	0.57	7.07	0.36	9.28e-12	Bipolar disorder;
CRC	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg23254163	chr1:152506842	NA	0.47	9.16	0.45	5.65e-18	Hair morphology;
CRC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.51	-8.2	-0.41	5.36e-15	Huntington's disease progression;
CRC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.47	-6.6	-0.34	1.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Alcohol dependence;
CRC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.53	7.81	0.4	7.95e-14	Response to temozolomide;
CRC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.45	-7.03	-0.36	1.2e-11	Axial length;
CRC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.51	-7.91	-0.4	4e-14	Multiple myeloma (IgH translocation);
CRC	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.13	-0.32	2.57e-9	Breast cancer;
CRC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.59	9.25	0.45	2.97e-18	Height;
CRC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg21251018	chr6:28226885	NKAPL	0.47	6.04	0.32	4.16e-9	Depression;
CRC	cis	rs812925	0.519	rs1186696	chr2:61660483	A/C	cg10580144	chr2:61372316	C2orf74	0.31	6.58	0.34	1.87e-10	Immature fraction of reticulocytes;
CRC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.77	-7.99	-0.4	2.25e-14	Coronary artery disease;
CRC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.97	0.4	2.67e-14	Cognitive ability;
CRC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	6.36	0.33	6.94e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.67	8.98	0.44	2.06e-17	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs911119	0.955	rs1011226	chr20:23605833	G/T	cg16589663	chr20:23618590	CST3	-0.47	-6.84	-0.35	3.83e-11	Chronic kidney disease;
CRC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg02683197	chr6:28174875	NA	0.84	10.31	0.49	8.48e-22	Depression;
CRC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.19	11.69	0.54	1.18e-26	Skin colour saturation;
CRC	cis	rs6564851	0.506	rs72831381	chr16:81258083	C/G	cg05274606	chr16:81253692	PKD1L2	-0.35	-5.65	-0.3	3.53e-8	Carotenoid and tocopherol levels;
CRC	trans	rs12829704	0.588	rs71446763	chr12:21418398	G/A	cg22494081	chr2:11774142	GREB1	0.51	6.07	0.32	3.61e-9	Blood metabolite levels;
CRC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.46	0.42	8.66e-16	Bipolar disorder and schizophrenia;
CRC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.22	-0.64	5.61e-40	Gut microbiome composition (summer);
CRC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-10.21	-0.49	1.99e-21	Monocyte count;
CRC	cis	rs4731207	0.724	rs4383910	chr7:124540841	A/C	cg23710748	chr7:124431027	NA	-0.37	-5.98	-0.31	5.75e-9	Cutaneous malignant melanoma;
CRC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.92	-15.71	-0.65	6.66e-42	Height;
CRC	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.52	-0.38	5.21e-13	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.64	6.9	0.36	2.68e-11	Vitiligo;
CRC	cis	rs11696501	0.739	rs6104285	chr20:44295416	A/G	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.61	-0.3	4.4e-8	Brain structure;
CRC	cis	rs460214	0.564	rs464519	chr21:40024182	A/G	cg05519781	chr21:40033154	ERG	-0.44	-6.4	-0.33	5.2e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.67	12.75	0.58	1.53e-30	Bone mineral density;
CRC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18420555	chr7:66053803	NA	0.36	5.67	0.3	3.11e-8	Aortic root size;
CRC	cis	rs2179367	0.959	rs504985	chr6:149658978	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-5.99	-0.31	5.48e-9	Dupuytren's disease;
CRC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.44	-6.28	-0.33	1.05e-9	Menarche (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg21515243	chr18:21033072	RIOK3	-0.51	-6.38	-0.33	6.01e-10	Diisocyanate-induced asthma;
CRC	trans	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg07393940	chr7:158741817	NA	0.5	7.23	0.37	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg03013999	chr17:37608204	MED1	-0.47	-7.34	-0.38	1.7e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.65	-0.6	6.24e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg07460842	chr6:66804631	NA	-0.43	-5.78	-0.3	1.72e-8	Blood trace element (Cu levels);
CRC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.54	8.0	0.4	2.16e-14	Height;
CRC	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.52	9.3	0.46	1.98e-18	Blood metabolite ratios;
CRC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.86	11.17	0.52	8.81e-25	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg27432699	chr2:27873401	GPN1	-0.4	-6.01	-0.31	5.04e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.45	8.96	0.44	2.45e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.04	0.45	1.38e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg24644049	chr4:85504048	CDS1	0.68	6.1	0.32	2.91e-9	Skin colour saturation;
CRC	trans	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg24434056	chr13:112550360	NA	0.36	6.18	0.32	1.92e-9	Cleft lip with or without cleft palate;
CRC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg15845792	chr6:28175446	NA	1.01	13.54	0.6	1.59e-33	Parkinson's disease;
CRC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-12.51	-0.57	1.25e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	0.57	6.78	0.35	5.61e-11	Prostate cancer;
CRC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.39	7.01	0.36	1.38e-11	Cardiovascular disease risk factors;
CRC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.68	9.34	0.46	1.45e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg03060546	chr3:49711283	APEH	-0.42	-6.02	-0.31	4.72e-9	Menarche (age at onset);
CRC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg02527881	chr3:46936655	PTH1R	0.35	6.09	0.32	3.07e-9	Colorectal cancer;
CRC	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg15898840	chr7:45960834	IGFBP3	0.45	7.34	0.38	1.69e-12	Sitting height ratio;
CRC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg02018176	chr4:1364513	KIAA1530	0.47	7.65	0.39	2.25e-13	Obesity-related traits;
CRC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg20092199	chr4:1342459	KIAA1530	0.34	5.77	0.3	1.82e-8	Obesity-related traits;
CRC	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg00086871	chr4:6988644	TBC1D14	0.96	7.53	0.38	4.89e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg15790184	chr11:494944	RNH1	-0.57	-5.79	-0.3	1.62e-8	Body mass index;
CRC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	8.89	0.44	4.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg00850481	chr1:228891306	NA	-0.39	-5.97	-0.31	6.14e-9	Chronic lymphocytic leukemia;
CRC	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.59	8.65	0.43	2.3e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-10.49	-0.5	2.05e-22	Initial pursuit acceleration;
CRC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.55	6.18	0.32	1.88e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.61	8.42	0.42	1.18e-15	Neutrophil percentage of white cells;
CRC	cis	rs17023223	0.537	rs56708249	chr1:119593205	C/G	cg05756136	chr1:119680316	WARS2	-0.47	-6.3	-0.33	9.79e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-8.96	-0.44	2.56e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg24375607	chr4:120327624	NA	0.47	7.53	0.38	4.91e-13	Corneal astigmatism;
CRC	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	20.1	0.74	3.54e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg15448220	chr1:150897856	SETDB1	0.47	6.77	0.35	6.05e-11	Tonsillectomy;
CRC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.58	-8.7	-0.43	1.65e-16	Asthma;
CRC	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.2	0.45	4.34e-18	Dupuytren's disease;
CRC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.65	-0.39	2.22e-13	Gut microbiome composition (summer);
CRC	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg13206674	chr6:150067644	NUP43	0.59	7.03	0.36	1.23e-11	Lung cancer;
CRC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	trans	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg13565492	chr6:43139072	SRF	-0.72	-7.44	-0.38	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	15.11	0.64	1.53e-39	Platelet count;
CRC	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	0.96	7.32	0.37	1.96e-12	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg19622623	chr12:86230825	RASSF9	-0.36	-5.94	-0.31	7.17e-9	Major depressive disorder;
CRC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.3	0.33	9.3e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs418053	0.624	rs4715451	chr6:13638984	A/G	cg02206980	chr6:13574034	SIRT5	-0.37	-6.13	-0.32	2.53e-9	Breast cancer;
CRC	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg22495460	chr2:25135724	ADCY3	-0.78	-14.12	-0.61	1.03e-35	Body mass index in non-asthmatics;
CRC	cis	rs910873	0.505	rs6058099	chr20:33249134	C/T	cg08999081	chr20:33150536	PIGU	0.49	5.91	0.31	8.58e-9	Melanoma;
CRC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-5.79	-0.3	1.67e-8	Longevity;Endometriosis;
CRC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.59	10.03	0.48	7.61e-21	Prudent dietary pattern;
CRC	cis	rs17767392	0.846	rs68073803	chr14:71757679	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.54	-6.87	-0.35	3.2e-11	Mitral valve prolapse;
CRC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.3	0.33	9.78e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.4	-0.46	9.71e-19	Subjective well-being;
CRC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	1.11	13.07	0.58	9.87e-32	Obesity-related traits;
CRC	cis	rs4700695	0.841	rs36303	chr5:65350374	A/G	cg21114390	chr5:65439923	SFRS12	-0.67	-6.88	-0.35	3.01e-11	Facial morphology (factor 19);
CRC	cis	rs3136516	0.772	rs7947747	chr11:46852839	A/G	cg19486271	chr11:47235900	DDB2	-0.34	-5.64	-0.3	3.76e-8	Venous thromboembolism;
CRC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg21251018	chr6:28226885	NKAPL	0.5	8.71	0.43	1.53e-16	Pubertal anthropometrics;
CRC	trans	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.78	0.35	5.72e-11	Ulcerative colitis;
CRC	cis	rs863345	0.625	rs12075903	chr1:158458932	A/G	cg12129480	chr1:158549410	OR10X1	-0.29	-6.07	-0.32	3.49e-9	Pneumococcal bacteremia;
CRC	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg15382696	chr6:118971807	C6orf204	0.59	7.63	0.39	2.54e-13	Diastolic blood pressure;
CRC	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg07478791	chr1:31886160	SERINC2	-0.41	-5.67	-0.3	3.13e-8	Alcohol dependence;
CRC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.68	9.09	0.45	9.75e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	6.77	0.35	5.77e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg00738113	chr16:70207722	CLEC18C	0.47	8.05	0.41	1.51e-14	Sjögren's syndrome;
CRC	cis	rs12760731	0.565	rs57247289	chr1:178090138	G/A	cg00404053	chr1:178313656	RASAL2	1.0	10.61	0.51	7.86e-23	Obesity-related traits;
CRC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	11.29	0.53	3.23e-25	Motion sickness;
CRC	cis	rs4664293	0.902	rs13391919	chr2:160560160	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.21	-0.32	1.61e-9	Monocyte percentage of white cells;
CRC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.35	9.5e-11	Lung cancer;
CRC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.59	8.59	0.43	3.53e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.81	13.74	0.6	2.82e-34	Coronary artery disease;
CRC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.81	12.53	0.57	1.04e-29	Menarche (age at onset);
CRC	trans	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg10756647	chr7:56101905	PSPH	0.71	7.57	0.39	3.91e-13	Diabetic kidney disease;
CRC	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg11822372	chr1:151115635	SEMA6C	0.54	7.76	0.39	1.05e-13	Childhood ear infection;
CRC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg21770322	chr7:97807741	LMTK2	0.52	8.52	0.43	5.7e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.57	8.28	0.42	3.21e-15	Intelligence (multi-trait analysis);
CRC	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-10.83	-0.51	1.45e-23	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12620999	0.878	rs59725626	chr2:237970010	G/A	cg23555395	chr2:238036564	NA	0.52	8.09	0.41	1.19e-14	Systemic lupus erythematosus;
CRC	cis	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg18131467	chr2:239335373	ASB1	-0.7	-6.06	-0.32	3.71e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.4	7.57	0.38	3.89e-13	Alzheimer's disease (late onset);
CRC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.76	0.7	5.87e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg06781209	chr11:61594997	FADS2	-0.38	-5.81	-0.3	1.49e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
CRC	cis	rs4728302	0.869	rs6943986	chr7:133616965	G/A	cg03336402	chr7:133662267	EXOC4	-0.47	-6.88	-0.35	3.05e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	1.02	20.3	0.75	5.5e-60	Headache;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03682117	chr10:116581829	FAM160B1	0.39	6.01	0.31	4.79e-9	Intelligence (multi-trait analysis);
CRC	cis	rs995000	0.899	rs1168045	chr1:62982891	C/T	cg19896129	chr1:63156450	NA	-0.45	-7.02	-0.36	1.24e-11	Triglyceride levels;
CRC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	3.08e-24	Corneal astigmatism;
CRC	cis	rs12476592	0.571	rs196125	chr2:63859268	C/T	cg10828910	chr2:63850056	LOC388955	0.49	6.19	0.32	1.76e-9	Childhood ear infection;
CRC	cis	rs9323205	0.953	rs61144314	chr14:51620556	G/A	cg23942311	chr14:51606299	NA	-0.58	-7.13	-0.37	6.53e-12	Cancer;
CRC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg12193833	chr17:30244370	NA	-0.73	-8.67	-0.43	2.07e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.27	-0.33	1.12e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg11843238	chr5:131593191	PDLIM4	0.44	7.33	0.37	1.85e-12	Acylcarnitine levels;
CRC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.84	0.4	6.31e-14	Cognitive ability;
CRC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.56	6.93	0.36	2.18e-11	Neutrophil percentage of white cells;
CRC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.44	8.94	0.44	2.84e-17	Renal cell carcinoma;
CRC	cis	rs4664293	0.867	rs10194483	chr2:160596394	G/A	cg08347373	chr2:160653686	CD302	-0.46	-7.36	-0.38	1.49e-12	Monocyte percentage of white cells;
CRC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg06207120	chr15:45996521	NA	0.31	7.56	0.38	4.02e-13	Waist circumference;Weight;
CRC	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.61	9.66	0.47	1.39e-19	Corneal astigmatism;
CRC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.79	13.8	0.61	1.67e-34	Breast cancer;
CRC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.35	5.73	0.3	2.33e-8	Psychosis in Alzheimer's disease;
CRC	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg11693508	chr17:37793320	STARD3	-0.64	-7.93	-0.4	3.54e-14	Bipolar disorder;
CRC	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.44	7.83	0.4	6.69e-14	Blood metabolite ratios;
CRC	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg23254163	chr1:152506842	NA	0.45	8.99	0.44	2e-17	Hair morphology;
CRC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.49	7.95	0.4	2.96e-14	Height;
CRC	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07165851	chr6:158734300	TULP4	0.61	7.72	0.39	1.41e-13	Height;
CRC	cis	rs447	0.806	rs2372033	chr7:83746313	C/T	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.71	-0.3	2.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg26893134	chr6:116381904	FRK	0.28	8.26	0.41	3.58e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-11.78	-0.54	5.72e-27	Cognitive function;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15527401	chr19:59071099	UBE2M;LOC100131691	0.52	6.89	0.36	2.93e-11	Thyroid stimulating hormone;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg20713816	chr5:89705801	CETN3	0.36	5.97	0.31	6.12e-9	Interleukin-6 levels;
CRC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg18301423	chr5:131593218	PDLIM4	0.38	6.39	0.33	5.63e-10	Breast cancer;
CRC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.42	-5.63	-0.3	3.93e-8	Reticulocyte count;
CRC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.48	7.73	0.39	1.34e-13	Hemoglobin concentration;
CRC	cis	rs6662572	0.737	rs4660315	chr1:46270942	G/C	cg08644498	chr1:46502608	NA	-0.44	-7.0	-0.36	1.4e-11	Blood protein levels;
CRC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.83	15.58	0.65	2.3e-41	Metabolic syndrome;
CRC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg18230493	chr5:56204884	C5orf35	-0.39	-5.76	-0.3	1.91e-8	Coronary artery disease;
CRC	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.55	-8.32	-0.42	2.31e-15	Schizophrenia;
CRC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.35	-0.5	6.51e-22	Chronic sinus infection;
CRC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.6	8.83	0.44	6.53e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.69	8.97	0.44	2.22e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.48	-6.89	-0.36	2.77e-11	Uric acid clearance;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15191848	chr19:59084942	MZF1;LOC100131691	0.44	6.07	0.32	3.57e-9	Anxiety disorder;
CRC	trans	rs2898857	0.504	rs7214496	chr17:47384611	C/G	cg11430096	chr6:110968061	CDK19	0.53	7.97	0.4	2.64e-14	Cancer;
CRC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg24977027	chr2:88469347	THNSL2	-0.33	-5.6	-0.3	4.52e-8	Response to metformin (IC50);
CRC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.38	9.18	0.45	4.96e-18	Diastolic blood pressure;
CRC	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.59	0.43	3.56e-16	Coffee consumption (cups per day);
CRC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-6.12	-0.32	2.63e-9	IgG glycosylation;
CRC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	1.01	10.1	0.49	4.47e-21	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg03690763	chr11:133734501	NA	-0.39	-6.4	-0.33	5.25e-10	Childhood ear infection;
CRC	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.52	7.19	0.37	4.29e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17470723	chr8:74884337	TCEB1	0.41	6.76	0.35	6.32e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg13385794	chr1:248469461	NA	0.4	7.1	0.36	7.96e-12	Common traits (Other);
CRC	cis	rs6604026	0.698	rs4847384	chr1:93382279	T/C	cg17283838	chr1:93427260	FAM69A	-0.49	-6.75	-0.35	6.54e-11	Multiple sclerosis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04232466	chr8:21988724	HR	0.52	6.89	0.36	2.93e-11	Thyroid stimulating hormone;
CRC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg07130601	chr7:158766826	NA	0.42	6.0	0.31	5.26e-9	Facial morphology (factor 20);
CRC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg20243544	chr17:37824526	PNMT	-0.43	-5.66	-0.3	3.28e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.81	-13.82	-0.61	1.41e-34	Cystic fibrosis severity;
CRC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.97	0.36	1.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.73	0.47	7.65e-20	Alzheimer's disease (late onset);
CRC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00857998	chr1:205179979	DSTYK	0.43	5.78	0.3	1.7e-8	Red blood cell count;
CRC	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.68	9.03	0.45	1.48e-17	Uric acid levels;
CRC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.69	11.35	0.53	2.04e-25	Alzheimer's disease (late onset);
CRC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.61	8.91	0.44	3.63e-17	Lymphocyte counts;
CRC	trans	rs12940923	1.000	rs11867412	chr17:56382512	C/T	cg16900910	chr15:72789182	ARIH1	0.55	6.2	0.32	1.73e-9	Circulating myeloperoxidase levels (plasma);
CRC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg04976154	chr16:1532411	NA	-0.42	-8.26	-0.41	3.61e-15	Bone mineral density;
CRC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	6.94	0.36	2.12e-11	Aortic root size;
CRC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.39	-0.59	6.42e-33	Extrinsic epigenetic age acceleration;
CRC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg20387954	chr3:183756860	HTR3D	0.45	7.64	0.39	2.47e-13	Anterior chamber depth;
CRC	cis	rs6684514	0.961	rs68170055	chr1:156332331	C/G	cg16558208	chr1:156270281	VHLL	0.54	8.16	0.41	7.09e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.52	9.67	0.47	1.21e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.98	0.36	1.6e-11	Lung cancer;
CRC	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.39	6.03	0.32	4.5e-9	Endometrial cancer;
CRC	cis	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg02972257	chr16:68554789	NA	-0.56	-6.99	-0.36	1.51e-11	Ulcerative colitis;
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.45	6.02	0.31	4.73e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.48	7.44	0.38	8.72e-13	Mean platelet volume;
CRC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.52	-7.23	-0.37	3.31e-12	Intelligence (multi-trait analysis);
CRC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.53	8.93	0.44	3.14e-17	Acylcarnitine levels;
CRC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.44	6.38	0.33	6.11e-10	Obesity-related traits;
CRC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.05e-29	Cognitive function;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16239906	chr20:35724590	RBL1	0.42	6.25	0.33	1.24e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg12564285	chr5:131593104	PDLIM4	0.35	6.32	0.33	8.3e-10	Blood metabolite levels;
CRC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.57	8.53	0.43	5.38e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg11480627	chr11:70672876	SHANK2	0.31	6.3	0.33	9.27e-10	Interleukin-6 levels;
CRC	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg21918786	chr6:109611834	NA	-0.35	-6.04	-0.32	4.19e-9	Reticulocyte fraction of red cells;
CRC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg04673462	chr1:38461896	NA	-0.38	-5.84	-0.31	1.27e-8	Coronary artery disease;
CRC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16447950	chr5:562315	NA	-0.75	-9.78	-0.47	5.49e-20	Obesity-related traits;
CRC	cis	rs7113874	0.569	rs7131358	chr11:8558333	G/C	cg20771178	chr11:8615675	STK33	-0.35	-5.86	-0.31	1.12e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg03690763	chr11:133734501	NA	-0.35	-5.8	-0.3	1.59e-8	Childhood ear infection;
CRC	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.5	9.28	0.46	2.31e-18	Attention deficit hyperactivity disorder and conduct disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14782929	chr1:204544645	NA	-0.4	-6.1	-0.32	2.98e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.13	0.49	3.54e-21	Ileal carcinoids;
CRC	cis	rs9826463	0.582	rs55687115	chr3:142148372	G/A	cg20824294	chr3:142316082	PLS1	0.38	6.05	0.32	3.87e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.65	-9.5	-0.46	4.63e-19	Acne (severe);
CRC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	6.06	0.32	3.77e-9	Putamen volume;
CRC	cis	rs9462846	0.845	rs9471959	chr6:42884517	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-6.21	-0.32	1.57e-9	Blood protein levels;
CRC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.63	10.26	0.49	1.3e-21	Calcium levels;
CRC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.68	-10.93	-0.52	6.28e-24	Hepatocellular carcinoma;
CRC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg19318889	chr4:1322082	MAEA	0.44	6.77	0.35	5.92e-11	Obesity-related traits;
CRC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.69	-11.81	-0.55	4.47e-27	Educational attainment;
CRC	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-7.89	-0.4	4.55e-14	Airway imaging phenotypes;
CRC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.32	6.58	0.34	1.89e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7209700	0.600	rs7218632	chr17:45365153	A/G	cg08085267	chr17:45401833	C17orf57	0.44	6.32	0.33	8.29e-10	IgG glycosylation;
CRC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.59	9.95	0.48	1.45e-20	Prudent dietary pattern;
CRC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.44	5.68	0.3	2.93e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.47	-0.42	8.37e-16	Monocyte percentage of white cells;
CRC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.78	7.13	0.37	6.35e-12	Diabetic retinopathy;
CRC	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.61	-0.39	2.92e-13	Vitamin D levels;
CRC	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.48	-6.94	-0.36	2.14e-11	Coronary artery disease;
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.94	22.28	0.78	1.13e-67	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	0.57	6.66	0.34	1.17e-10	Prostate cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18597434	chr13:76055871	TBC1D4	0.49	7.05	0.36	1.09e-11	Response to antipsychotic treatment;
CRC	cis	rs11212617	1.000	rs228590	chr11:108096141	A/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.39	0.33	5.57e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08997445	chr19:57947026	ZNF749	0.39	6.08	0.32	3.37e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17162190	0.659	rs12024530	chr1:26812298	G/A	cg17456097	chr1:26900765	RPS6KA1	0.44	6.07	0.32	3.45e-9	Mean corpuscular volume;
CRC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-8.68	-0.43	1.89e-16	Type 2 diabetes;
CRC	trans	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg26043149	chr18:55253948	FECH	0.51	7.91	0.4	3.95e-14	Bone mineral density;
CRC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg21155852	chr7:2048760	MAD1L1	-0.47	-6.51	-0.34	2.83e-10	Neuroticism;
CRC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.05	13.07	0.58	1.02e-31	Vitiligo;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg26587870	chr6:27730563	NA	-0.43	-6.71	-0.35	8.63e-11	Parkinson's disease;
CRC	cis	rs4523957	0.890	rs9908888	chr17:2102453	G/C	cg16513277	chr17:2031491	SMG6	-0.52	-8.7	-0.43	1.61e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.6	8.45	0.42	9.42e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg10523679	chr1:76189770	ACADM	-0.41	-5.87	-0.31	1.06e-8	Daytime sleep phenotypes;
CRC	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg06606381	chr12:133084897	FBRSL1	0.62	6.21	0.32	1.63e-9	Depression;
CRC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg02033258	chr5:131593261	PDLIM4	0.35	6.17	0.32	2.06e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.16	-0.37	5.28e-12	Bipolar disorder;
CRC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-12.63	-0.57	4.3e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.89	0.51	8.73e-24	Motion sickness;
CRC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.37	-7.09	-0.36	8.19e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.52	6.6	0.34	1.65e-10	Morning vs. evening chronotype;
CRC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.91	18.01	0.7	6.06e-51	Bone mineral density;
CRC	cis	rs9287719	0.674	rs12620209	chr2:10720441	T/C	cg00105475	chr2:10696890	NA	0.45	7.06	0.36	9.97e-12	Prostate cancer;
CRC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.61	11.2	0.53	6.72e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.81	0.35	4.75e-11	Monocyte percentage of white cells;
CRC	cis	rs6908034	0.607	rs112659166	chr6:19807409	C/T	cg02682789	chr6:19804855	NA	0.79	6.79	0.35	5.11e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg18252515	chr7:66147081	NA	-0.52	-6.96	-0.36	1.87e-11	Corneal structure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03884976	chr16:577621	SOLH;C16orf10	0.4	5.99	0.31	5.38e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.52	0.46	3.9e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.48	6.8	0.35	4.89e-11	Caffeine consumption;
CRC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.54	8.44	0.42	1.03e-15	Pancreatic cancer;
CRC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.69	0.39	1.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	10.85	0.51	1.2e-23	Motion sickness;
CRC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.72	0.47	8.59e-20	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs10971721	0.822	rs10971792	chr9:33920953	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.97	0.31	6.15e-9	Body mass index;
CRC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg03233332	chr7:66118400	NA	-0.41	-5.65	-0.3	3.52e-8	Aortic root size;
CRC	cis	rs17767392	0.918	rs34725136	chr14:71760422	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.86	-0.35	3.45e-11	Mitral valve prolapse;
CRC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg25164649	chr6:28176230	NA	0.61	8.98	0.44	2.21e-17	Parkinson's disease;
CRC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.4	6.74	0.35	6.98e-11	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
CRC	cis	rs4132462	0.821	rs7422793	chr2:212603778	T/C	cg15635483	chr2:212618994	ERBB4	-0.39	-6.12	-0.32	2.73e-9	Intelligence (multi-trait analysis);
CRC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg21153622	chr11:89784906	NA	-0.52	-8.71	-0.43	1.46e-16	HDL cholesterol;
CRC	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11446398	chr5:77624930	NA	0.44	6.43	0.33	4.5e-10	Triglycerides;
CRC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg08546805	chr12:8549446	NA	-0.44	-6.62	-0.34	1.48e-10	Blood pressure (smoking interaction);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01153979	chr6:79577195	IRAK1BP1	0.45	7.18	0.37	4.56e-12	Obesity-related traits;
CRC	cis	rs713587	0.520	rs487617	chr2:25309756	C/G	cg22495460	chr2:25135724	ADCY3	0.44	6.5	0.34	3.04e-10	Body mass index in non-asthmatics;
CRC	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.84	9.52	0.46	3.83e-19	Iron status biomarkers;
CRC	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg14673194	chr17:80132900	CCDC57	0.48	6.19	0.32	1.82e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08037420	chr3:172428855	NCEH1	0.48	6.73	0.35	7.35e-11	Response to antipsychotic treatment;
CRC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg13092806	chr2:177043255	NA	0.81	13.22	0.59	2.65e-32	IgG glycosylation;
CRC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.9	-16.49	-0.67	6.23e-45	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	7.29	0.37	2.33e-12	Lymphocyte counts;
CRC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.18	-0.32	1.92e-9	IgG glycosylation;
CRC	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.37	5.8	0.3	1.56e-8	Breast cancer;
CRC	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg19537932	chr12:55886519	OR6C68	-0.71	-9.1	-0.45	8.8e-18	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02326858	chr1:151253959	ZNF687	0.52	7.4	0.38	1.16e-12	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.98	0.55	1.09e-27	Bone mineral density;
CRC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.18	27.1	0.83	7.82e-86	IgG glycosylation;
CRC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.46	6.86	0.35	3.51e-11	Intelligence (multi-trait analysis);
CRC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	1.0	11.15	0.52	1.04e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg25985355	chr7:65971099	NA	0.54	6.13	0.32	2.57e-9	Diabetic kidney disease;
CRC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.59	8.86	0.44	5.04e-17	Aortic root size;
CRC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.41	6.18	0.32	1.91e-9	Hemoglobin concentration;
CRC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.48	9.32	0.46	1.76e-18	Iron status biomarkers (transferrin levels);
CRC	cis	rs8141797	1.000	rs8141797	chr22:24582041	C/T	cg20894457	chr22:24584366	SUSD2	-0.62	-7.95	-0.4	3.09e-14	Amyotrophic lateral sclerosis;Coronary artery disease;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05592406	chr12:118542027	VSIG10	-0.55	-6.47	-0.34	3.49e-10	Monocyte percentage of white cells;
CRC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.78	0.51	2.07e-23	Motion sickness;
CRC	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg11887960	chr12:57824829	NA	0.59	6.66	0.34	1.15e-10	Obesity-related traits;
CRC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.69	8.18	0.41	6.3e-15	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.79	9.75	0.47	6.64e-20	Neuroticism (multi-trait analysis);Neuroticism;
CRC	cis	rs10982256	0.870	rs1408525	chr9:117274994	C/T	cg13636371	chr9:117264095	DFNB31	0.37	7.2	0.37	4.2e-12	Bipolar disorder;
CRC	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.63	-0.3	3.78e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.66	-6.81	-0.35	4.63e-11	Depression;
CRC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.57	8.1	0.41	1.1e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-9.34	-0.46	1.47e-18	Developmental language disorder (linguistic errors);
CRC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	0.97	8.99	0.44	1.99e-17	Pulse pressure;
CRC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.09	-0.32	3.11e-9	Gout;Renal underexcretion gout;
CRC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.01	0.36	1.34e-11	Morning vs. evening chronotype;
CRC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.51	-6.11	-0.32	2.86e-9	Coronary artery calcification;
CRC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.77	13.4	0.59	5.64e-33	Breast cancer;
CRC	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.02	0.4	1.89e-14	Response to antipsychotic treatment;
CRC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06634786	chr22:41940651	POLR3H	0.44	5.62	0.3	4.02e-8	Vitiligo;
CRC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.47	7.42	0.38	9.83e-13	Age-related hearing impairment;
CRC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.84	-12.2	-0.56	1.64e-28	Mean platelet volume;Platelet distribution width;
CRC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.52	-9.8	-0.48	4.57e-20	Schizophrenia;
CRC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.95	-18.72	-0.72	9.67e-54	Myeloid white cell count;
CRC	cis	rs17092148	0.887	rs6120684	chr20:33179788	A/G	cg08999081	chr20:33150536	PIGU	0.49	6.25	0.33	1.29e-9	Neuroticism;
CRC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.44	-5.86	-0.31	1.15e-8	Gut microbiome composition (summer);
CRC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.84	-0.31	1.26e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.48	7.31	0.37	2e-12	Red blood cell count;
CRC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-12.78	-0.58	1.16e-30	Cognitive function;
CRC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00339695	chr16:24857497	SLC5A11	0.27	6.39	0.33	5.57e-10	Intelligence (multi-trait analysis);
CRC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg12564285	chr5:131593104	PDLIM4	0.34	5.93	0.31	7.53e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs73206853	0.614	rs117546059	chr12:110508632	T/C	cg12870014	chr12:110450643	ANKRD13A	0.79	7.19	0.37	4.39e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs17155006	0.746	rs420753	chr7:107746253	A/G	cg05962710	chr7:107745446	LAMB4	-0.41	-7.44	-0.38	8.61e-13	Pneumococcal bacteremia;
CRC	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg23250157	chr14:64679961	SYNE2	0.43	6.37	0.33	6.52e-10	Atrial fibrillation;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04452770	chr12:53267981	NA	0.46	6.32	0.33	8.48e-10	Response to antipsychotic treatment;
CRC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.36	-7.47	-0.38	7.23e-13	Cutaneous nevi;
CRC	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.45	6.48	0.34	3.27e-10	Macular telangiectasia type 2;
CRC	cis	rs1322512	1.000	rs1727052	chr6:152947175	T/C	cg03415253	chr6:152958462	SYNE1	-0.41	-6.37	-0.33	6.5e-10	Tonometry;
CRC	cis	rs4654899	0.931	rs10799671	chr1:21196764	C/T	cg02927042	chr1:21476669	EIF4G3	0.4	6.39	0.33	5.67e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.06	-0.32	3.65e-9	Total body bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04662714	chr4:68567018	LOC550112;UBA6	0.45	6.16	0.32	2.1e-9	Response to antipsychotic treatment;
CRC	cis	rs2637266	0.600	rs12770441	chr10:78384983	C/T	cg18941641	chr10:78392320	NA	-0.37	-6.39	-0.33	5.52e-10	Pulmonary function;
CRC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.42	-5.86	-0.31	1.12e-8	DNA methylation (variation);
CRC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.89	-15.93	-0.66	9.4e-43	Height;
CRC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.46	6.76	0.35	6.47e-11	Methadone dose in opioid dependence;
CRC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.53	7.43	0.38	9.24e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.39	5.75	0.3	2.07e-8	Growth-regulated protein alpha levels;
CRC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.57	-8.33	-0.42	2.23e-15	Longevity;
CRC	cis	rs7605827	0.897	rs7425203	chr2:15697410	A/G	cg19274914	chr2:15703543	NA	0.39	5.8	0.3	1.57e-8	Educational attainment (years of education);
CRC	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg27534772	chr1:16042836	PLEKHM2	0.45	7.5	0.38	6.07e-13	Systolic blood pressure;
CRC	cis	rs73206853	0.764	rs76044375	chr12:110901339	C/T	cg12870014	chr12:110450643	ANKRD13A	0.74	7.9	0.4	4.21e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.53	-0.38	4.78e-13	Total body bone mineral density;
CRC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg25767906	chr1:53392781	SCP2	-0.42	-6.65	-0.34	1.24e-10	Monocyte count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg15555402	chr12:19593456	AEBP2	-0.38	-6.07	-0.32	3.6e-9	Myopia (pathological);
CRC	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg06632207	chr12:54070931	ATP5G2	-0.36	-6.02	-0.32	4.61e-9	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04226401	chr1:100818170	CDC14A	0.41	6.0	0.31	5.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-5.92	-0.31	7.89e-9	Schizophrenia;
CRC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg12172441	chr6:28176163	NA	0.45	6.57	0.34	1.97e-10	Cardiac Troponin-T levels;
CRC	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg00691999	chr4:55094011	PDGFRA	0.43	6.02	0.31	4.77e-9	Corneal astigmatism;
CRC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.42	-5.98	-0.31	5.83e-9	Aortic root size;
CRC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg03233332	chr7:66118400	NA	0.45	6.2	0.32	1.69e-9	Aortic root size;
CRC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg24209194	chr3:40518798	ZNF619	0.44	6.79	0.35	5.32e-11	Renal cell carcinoma;
CRC	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.26	-0.33	1.2e-9	Schizophrenia;
CRC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg24977027	chr2:88469347	THNSL2	-0.6	-7.23	-0.37	3.51e-12	Plasma clusterin levels;
CRC	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg05072819	chr3:20081367	KAT2B	0.47	6.82	0.35	4.36e-11	Post-traumatic stress disorder;
CRC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg19824325	chr16:58548873	SETD6	0.91	6.09	0.32	3.08e-9	Schizophrenia;
CRC	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg24519413	chr1:26490540	NA	0.37	6.26	0.33	1.23e-9	Height;
CRC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg08314208	chr16:67682810	RLTPR	-0.52	-6.22	-0.32	1.54e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg20243544	chr17:37824526	PNMT	0.56	8.97	0.44	2.35e-17	Asthma;
CRC	cis	rs7707921	1.000	rs891159	chr5:81491087	A/G	cg17942617	chr5:81327376	ATG10	0.4	6.03	0.32	4.49e-9	Breast cancer;
CRC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg00074818	chr8:8560427	CLDN23	0.35	6.52	0.34	2.57e-10	Obesity-related traits;
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg14329157	chr2:228736135	WDR69	-0.48	-6.59	-0.34	1.77e-10	Blood pressure;
CRC	cis	rs1223397	0.651	rs453877	chr6:13297463	G/T	cg07912922	chr6:13274314	PHACTR1	0.37	5.74	0.3	2.16e-8	Blood pressure;
CRC	cis	rs3764400	0.508	rs72823519	chr17:46061885	G/T	cg10706073	chr17:46328419	SKAP1	-0.65	-6.33	-0.33	7.99e-10	Body mass index;
CRC	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.51	-0.57	1.18e-29	Idiopathic membranous nephropathy;
CRC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg08975724	chr8:8085496	FLJ10661	0.41	6.07	0.32	3.47e-9	Neuroticism;
CRC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.65	-0.68	1.36e-45	Height;
CRC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg07491357	chr18:9914943	VAPA	0.44	6.41	0.33	5.13e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.55	-6.32	-0.33	8.6e-10	Blood protein levels;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02352945	chr3:38496316	LOC100128640;ACVR2B	0.44	6.11	0.32	2.79e-9	Survival in pancreatic cancer;
CRC	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg01426195	chr3:39028469	NA	-0.52	-8.31	-0.42	2.49e-15	Handedness;
CRC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.07	-25.04	-0.81	3.5e-78	Testicular germ cell tumor;
CRC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.79	9.52	0.46	3.98e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.39	7.08	0.36	8.81e-12	Height;
CRC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.53	8.43	0.42	1.08e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.73	-12.13	-0.56	3.02e-28	Idiopathic membranous nephropathy;
CRC	cis	rs7259376	0.875	rs6511345	chr19:22537436	T/C	cg02657401	chr19:22469223	NA	-0.33	-7.27	-0.37	2.63e-12	Menopause (age at onset);
CRC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.45	-5.98	-0.31	5.89e-9	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg08222913	chr3:52553049	STAB1	-0.34	-6.34	-0.33	7.69e-10	Bipolar disorder;
CRC	cis	rs3736485	0.966	rs7161973	chr15:51854163	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.56	-0.34	2.04e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.47	-0.38	7.19e-13	Morning vs. evening chronotype;
CRC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg21251018	chr6:28226885	NKAPL	0.49	7.75	0.39	1.18e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.72	9.47	0.46	5.57e-19	Cleft lip with or without cleft palate;
CRC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	6.12	0.32	2.67e-9	Menarche (age at onset);
CRC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg19913688	chr11:428466	ANO9	-0.7	-7.21	-0.37	3.76e-12	Body mass index;
CRC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.53	11.74	0.54	8.27e-27	Alcohol dependence;
CRC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.75	12.66	0.57	3.28e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.85	10.2	0.49	2.04e-21	Psoriasis;
CRC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.71	-7.35	-0.38	1.54e-12	Systemic lupus erythematosus;
CRC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.37	3.53e-12	Blood metabolite levels;
CRC	cis	rs17767392	0.794	rs17767362	chr14:71733790	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.53	-6.46	-0.34	3.78e-10	Mitral valve prolapse;
CRC	cis	rs6088813	0.925	rs1540928	chr20:33961845	C/A	cg14752227	chr20:34000481	UQCC	-0.36	-5.62	-0.3	3.99e-8	Height;
CRC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-6.51	-0.34	2.81e-10	Subjective well-being;
CRC	cis	rs4728302	0.905	rs7459333	chr7:133628701	G/A	cg03336402	chr7:133662267	EXOC4	0.41	5.95	0.31	6.85e-9	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs4363385	0.818	rs10788854	chr1:153002320	C/T	cg25856811	chr1:152973957	SPRR3	-0.25	-6.79	-0.35	5.23e-11	Inflammatory skin disease;
CRC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.54	-6.65	-0.34	1.21e-10	Diastolic blood pressure;
CRC	cis	rs600626	0.578	rs11821808	chr11:75451187	C/T	cg24262691	chr11:75473276	NA	0.53	7.76	0.39	1.05e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	20.57	0.75	5.01e-61	Prudent dietary pattern;
CRC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.52	-0.34	2.58e-10	Schizophrenia;
CRC	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg11553311	chr5:66541588	NA	0.45	7.52	0.38	5.12e-13	Breast cancer;
CRC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.66	-10.21	-0.49	1.9e-21	Huntington's disease progression;
CRC	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	14.9	0.63	1.01e-38	Hypertriglyceridemia;
CRC	trans	rs2303319	0.504	rs12470743	chr2:162611202	G/A	cg22988483	chr14:93581567	ITPK1	-0.66	-6.07	-0.32	3.52e-9	Cognitive function;
CRC	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg14458575	chr2:238380390	NA	0.46	6.53	0.34	2.47e-10	Prostate cancer;
CRC	trans	rs9903692	0.954	rs875065	chr17:46139569	C/T	cg13910583	chr8:56987998	RPS20	-0.44	-5.99	-0.31	5.63e-9	Pulse pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03022368	chr16:83986702	OSGIN1	0.44	6.12	0.32	2.72e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4321325	0.733	rs75834205	chr2:127947237	G/T	cg11380483	chr2:127933992	NA	0.62	7.02	0.36	1.25e-11	Protein C levels;
CRC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	7.86	0.4	5.42e-14	Colorectal cancer;
CRC	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.72	-7.25	-0.37	3.09e-12	Non-glioblastoma glioma;Glioma;
CRC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-14.54	-0.63	2.42e-37	Height;
CRC	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.69	0.51	4.46e-23	Iron status biomarkers;
CRC	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.96	15.65	0.65	1.23e-41	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.51	-0.5	1.87e-22	Bipolar disorder and schizophrenia;
CRC	cis	rs13144136	0.687	rs11723092	chr4:10651891	G/A	cg10242279	chr4:10666415	CLNK	-0.37	-6.43	-0.33	4.58e-10	Resistance to antihypertensive treatment in hypertension;
CRC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg23087241	chr11:134123413	THYN1;ACAD8	-0.44	-6.07	-0.32	3.47e-9	Select biomarker traits;
CRC	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg01339444	chr6:118972232	C6orf204	0.53	5.99	0.31	5.48e-9	Diastolic blood pressure;
CRC	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-7.52	-0.38	5.35e-13	Cystic fibrosis severity;
CRC	trans	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07923305	chr1:46598507	PIK3R3	0.47	6.69	0.35	9.63e-11	Response to antipsychotic treatment;
CRC	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.71	7.95	0.4	2.95e-14	Systolic blood pressure;
CRC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg03013999	chr17:37608204	MED1	0.45	6.74	0.35	7.08e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs12101261	0.536	rs2371463	chr14:81457788	G/A	cg06600135	chr14:81408086	NA	0.39	5.68	0.3	2.94e-8	Graves' disease;
CRC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg22110888	chr17:80059540	CCDC57	0.43	6.65	0.34	1.26e-10	Life satisfaction;
CRC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.4	0.33	5.35e-10	Cognitive test performance;
CRC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg00186954	chr11:8933980	ST5;C11orf17	0.38	6.09	0.32	3.13e-9	Hemoglobin concentration;
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	7.42	0.38	9.86e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg25281562	chr12:121454272	C12orf43	0.44	6.16	0.32	2.1e-9	N-glycan levels;
CRC	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-7.96	-0.4	2.9e-14	Homocysteine levels;
CRC	cis	rs755249	0.567	rs16826000	chr1:39713860	G/T	cg18385671	chr1:39797026	MACF1	-0.42	-5.99	-0.31	5.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.85	0.48	3.04e-20	Hip circumference adjusted for BMI;
CRC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-8.45	-0.42	9.58e-16	Gut microbiome composition (summer);
CRC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	11.44	0.53	1e-25	Platelet count;
CRC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg19682013	chr15:45996608	NA	0.33	6.78	0.35	5.7e-11	Waist circumference;Weight;
CRC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	10.71	0.51	3.81e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	12.31	0.56	6.45e-29	Platelet count;
CRC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.59	8.38	0.42	1.59e-15	Obesity-related traits;
CRC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg07507251	chr3:52567010	NT5DC2	0.4	5.75	0.3	2.04e-8	Bipolar disorder;
CRC	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.5	5.75	0.3	2.03e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg10169971	chr6:83902988	RWDD2A;PGM3	-0.42	-6.63	-0.34	1.37e-10	Myopia (pathological);
CRC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg26248373	chr2:1572462	NA	-0.8	-11.01	-0.52	3.36e-24	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs728616	0.614	rs61859191	chr10:82091027	T/C	cg11900509	chr10:81946545	ANXA11	-0.54	-6.11	-0.32	2.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.41	-5.75	-0.3	2.02e-8	Neuroticism;
CRC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.75	-9.4	-0.46	9.56e-19	Body mass index;
CRC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.63	8.56	0.43	4.54e-16	Smoking initiation;
CRC	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg20019720	chr6:154832845	CNKSR3	0.56	11.05	0.52	2.33e-24	Lipoprotein (a) levels;
CRC	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.92	-11.51	-0.54	5.56e-26	Exhaled nitric oxide output;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09755102	chr1:33283495	S100PBP;YARS	0.45	6.29	0.33	1.04e-9	Response to antipsychotic treatment;
CRC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.7	0.39	1.62e-13	Platelet count;
CRC	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.7	10.28	0.49	1.15e-21	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.51	-7.05	-0.36	1.08e-11	Inflammatory bowel disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15585372	chr7:97910571	BRI3	0.47	6.88	0.35	3.09e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00012992	chr14:61788345	PRKCH	0.39	6.55	0.34	2.27e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4889855	0.614	rs7209676	chr17:78500751	T/C	cg16591659	chr17:78472290	NA	-0.64	-7.79	-0.39	8.62e-14	Fractional excretion of uric acid;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg25656237	chr2:98703423	VWA3B	0.45	6.48	0.34	3.44e-10	Response to antipsychotic treatment;
CRC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg01472538	chr16:58549086	SETD6	1.12	7.38	0.38	1.28e-12	Schizophrenia;
CRC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.54	-6.33	-0.33	8.08e-10	Lymphocyte counts;
CRC	cis	rs12541635	0.739	rs10955412	chr8:107075592	T/C	cg10147462	chr8:107024639	NA	-0.54	-9.19	-0.45	4.4e-18	Age of smoking initiation;
CRC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg22777020	chr22:31556080	RNF185	-0.52	-5.9	-0.31	8.86e-9	Colorectal cancer;
CRC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg25452165	chr22:42524984	CYP2D6	-0.41	-6.12	-0.32	2.63e-9	Schizophrenia;
CRC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.78	-10.78	-0.51	2.15e-23	Initial pursuit acceleration;
CRC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.42	6.77	0.35	6.08e-11	High light scatter reticulocyte count;
CRC	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.49	0.34	3.2e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.53	-0.34	2.55e-10	Blood pressure (smoking interaction);
CRC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg18016565	chr1:150552671	MCL1	0.42	6.05	0.32	3.98e-9	Melanoma;
CRC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.44	-6.82	-0.35	4.49e-11	Height;
CRC	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg14631576	chr9:95140430	CENPP	-0.31	-5.9	-0.31	8.88e-9	Height;
CRC	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg03433033	chr1:76189801	ACADM	-0.42	-6.0	-0.31	5.09e-9	Daytime sleep phenotypes;
CRC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.41	6.37	0.33	6.38e-10	Monocyte count;
CRC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.9	0.36	2.7e-11	Menopause (age at onset);
CRC	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.85	15.79	0.66	3.45e-42	Multiple myeloma;
CRC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-10.19	-0.49	2.18e-21	Total cholesterol levels;
CRC	cis	rs7680126	0.626	rs11721501	chr4:10189135	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-6.72	-0.35	7.9e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs2179367	0.959	rs9390677	chr6:149710497	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.41	-6.15	-0.32	2.25e-9	Dupuytren's disease;
CRC	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.53	7.52	0.38	5.24e-13	Pulmonary function decline;
CRC	cis	rs62007496	0.520	rs8005906	chr14:103610845	C/T	cg09274347	chr14:103599552	TNFAIP2	0.54	5.9	0.31	9.18e-9	Language performance in older adults (adjusted for episodic memory);
CRC	cis	rs11203032	0.831	rs10887926	chr10:90940358	G/A	cg16672925	chr10:90967113	CH25H	0.45	5.72	0.3	2.42e-8	Heart failure;
CRC	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg26182253	chr13:112236782	NA	0.31	6.25	0.33	1.26e-9	Hepatitis;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.46	7.3	0.37	2.14e-12	Obesity-related traits;
CRC	cis	rs9303542	0.625	rs7225995	chr17:46596268	G/C	cg04904318	chr17:46607828	HOXB1	-0.57	-6.65	-0.34	1.2e-10	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.17	0.59	4.34e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.25	0.33	1.3e-9	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg21782813	chr7:2030301	MAD1L1	0.39	6.87	0.35	3.25e-11	Testicular germ cell tumor;
CRC	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.03	-0.36	1.18e-11	Body mass index;
CRC	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-15.0	-0.64	4.17e-39	Dementia and core Alzheimer's disease neuropathologic changes;
CRC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.68	-6.07	-0.32	3.43e-9	Diabetic kidney disease;
CRC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.37	6.45	0.34	4e-10	Crohn's disease;
CRC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	10.96	0.52	4.82e-24	Prudent dietary pattern;
CRC	cis	rs7632954	0.596	rs7611030	chr3:8511921	C/T	cg03495237	chr3:8533978	NA	-0.34	-6.26	-0.33	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.2	-0.45	4.3e-18	Menarche (age at onset);
CRC	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg23425280	chr12:56401806	NA	0.47	6.02	0.31	4.68e-9	Cancer;
CRC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg15786705	chr6:28176104	NA	0.62	8.75	0.43	1.12e-16	Cardiac Troponin-T levels;
CRC	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg05935833	chr10:81318306	SFTPA2	-0.71	-8.05	-0.41	1.48e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg05627522	chr15:75251581	NA	0.37	5.68	0.3	2.9e-8	Caffeine consumption;
CRC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.54	-8.34	-0.42	2e-15	Asthma (sex interaction);
CRC	cis	rs524281	0.637	rs7126075	chr11:65940563	T/G	cg16950941	chr11:66035639	RAB1B	-0.61	-7.45	-0.38	8.09e-13	Electroencephalogram traits;
CRC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.51	5.65	0.3	3.46e-8	Hip circumference adjusted for BMI;
CRC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg15147215	chr3:52552868	STAB1	-0.78	-15.5	-0.65	4.72e-41	Electroencephalogram traits;
CRC	cis	rs11212617	0.967	rs11212616	chr11:108281322	T/A	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.25	0.33	1.26e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs7072216	0.770	rs7909131	chr10:100171471	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-6.77	-0.35	5.77e-11	Metabolite levels;
CRC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	0.84	9.04	0.45	1.41e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg20936604	chr3:58311152	NA	-0.71	-7.11	-0.36	7.46e-12	Cholesterol, total;
CRC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.48	6.22	0.32	1.51e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg22535103	chr8:58192502	C8orf71	-0.49	-5.69	-0.3	2.77e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.84	16.29	0.67	3.65e-44	Hip circumference;
CRC	cis	rs7113874	0.569	rs9300092	chr11:8590492	A/G	cg02811074	chr11:8615871	STK33	0.35	5.91	0.31	8.77e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.43	-7.13	-0.37	6.48e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23378565	chr7:2036160	MAD1L1	-0.41	-5.63	-0.3	3.94e-8	Neuroticism;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg01866597	chr16:837896	RPUSD1;CHTF18	-0.5	-6.02	-0.31	4.64e-9	Diisocyanate-induced asthma;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg13602232	chr19:36505322	ALKBH6	-0.44	-6.5	-0.34	2.99e-10	Daytime sleep phenotypes;
CRC	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg12458913	chr13:53173898	NA	0.48	7.11	0.36	7.46e-12	Lewy body disease;
CRC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.98	0.55	1.1e-27	Platelet count;
CRC	cis	rs7591163	0.883	rs16824023	chr2:228720877	G/A	cg20647610	chr2:228736258	WDR69	-0.45	-6.53	-0.34	2.55e-10	Blood pressure;
CRC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	12.13	0.56	2.95e-28	Alzheimer's disease;
CRC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg02033258	chr5:131593261	PDLIM4	0.42	6.88	0.35	3.01e-11	Breast cancer;
CRC	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg07699608	chr10:75541558	CHCHD1	0.57	5.85	0.31	1.21e-8	Incident atrial fibrillation;
CRC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	8.71	0.43	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-0.98	-9.75	-0.47	6.54e-20	Breast cancer;
CRC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.5	-7.32	-0.37	1.86e-12	Schizophrenia;
CRC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.29	0.33	1.02e-9	Aortic root size;
CRC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.79	-0.39	8.8e-14	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15687855	chr3:44754131	ZNF502	-0.34	-5.84	-0.31	1.26e-8	Depressive symptoms;
CRC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.99	0.55	9.92e-28	Hip circumference adjusted for BMI;
CRC	cis	rs9309473	0.950	rs7567585	chr2:73751966	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.61	-0.3	4.36e-8	Metabolite levels;
CRC	cis	rs727479	0.502	rs28757200	chr15:51504061	C/T	cg19946085	chr15:51559439	CYP19A1	-0.29	-5.98	-0.31	5.92e-9	Estradiol levels;
CRC	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg08501292	chr6:25962987	TRIM38	0.73	7.28	0.37	2.4e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs727479	0.502	rs7180552	chr15:51506768	T/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-5.95	-0.31	6.85e-9	Estradiol levels;
CRC	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg27417294	chr10:81904244	PLAC9	0.36	5.68	0.3	3e-8	Sarcoidosis;
CRC	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.68	-12.16	-0.56	2.45e-28	Lewy body disease;
CRC	cis	rs4731207	0.698	rs6945104	chr7:124557915	A/G	cg23710748	chr7:124431027	NA	-0.37	-5.99	-0.31	5.48e-9	Cutaneous malignant melanoma;
CRC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg19812747	chr11:111475976	SIK2	0.44	6.48	0.34	3.26e-10	Primary sclerosing cholangitis;
CRC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.26	-0.41	3.58e-15	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg06470822	chr6:28175283	NA	1.0	13.3	0.59	1.3e-32	Depression;
CRC	cis	rs10971721	0.822	rs10971763	chr9:33879777	G/A	cg13495928	chr9:33750294	PRSS3	0.56	5.95	0.31	6.96e-9	Body mass index;
CRC	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg15131784	chr3:139108705	COPB2	0.39	5.63	0.3	3.83e-8	Obesity-related traits;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23260635	chr1:151584664	SNX27	0.44	6.81	0.35	4.79e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-6.31	-0.33	9.1e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-11.85	-0.55	3.24e-27	Asthma;
CRC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.76	13.12	0.59	6.3e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.51	-7.21	-0.37	3.76e-12	Menarche (age at onset);
CRC	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.48	-7.56	-0.38	3.98e-13	Metabolite levels (small molecules and protein measures);
CRC	trans	rs6544773	0.727	rs506123	chr2:45077318	C/T	cg10208897	chr5:178548229	ADAMTS2	0.35	6.03	0.32	4.37e-9	Mosquito bite size;
CRC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.47	7.33	0.37	1.83e-12	Motion sickness;
CRC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	9.95	0.48	1.47e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	0.98	10.46	0.5	2.72e-22	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg27491609	chr17:62779607	LOC146880	-0.39	-6.43	-0.33	4.58e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.29	0.37	2.27e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7258465	0.931	rs11673604	chr19:18540988	T/C	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.91	-0.31	8.64e-9	Breast cancer;
CRC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.36	-0.33	6.81e-10	Breast cancer;
CRC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.61	-9.45	-0.46	6.73e-19	Menarche (age at onset);
CRC	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.56	-9.92	-0.48	1.85e-20	Lung function (FVC);
CRC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.85	-0.4	5.91e-14	Height;
CRC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	12.05	0.55	5.78e-28	Schizophrenia;
CRC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.65	8.65	0.43	2.26e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.52	7.68	0.39	1.8e-13	Corneal astigmatism;
CRC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg18867708	chr6:26865862	GUSBL1	0.37	5.74	0.3	2.17e-8	Schizophrenia;
CRC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.47	-9.38	-0.46	1.14e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg20512303	chr5:131592959	PDLIM4	0.42	7.36	0.38	1.44e-12	Acylcarnitine levels;
CRC	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.28e-11	Body mass index;
CRC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.6	-10.31	-0.49	8.96e-22	Body mass index;
CRC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.45	-0.38	8.54e-13	Morning vs. evening chronotype;
CRC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg15445000	chr17:37608096	MED1	-0.33	-5.76	-0.3	1.9e-8	Glomerular filtration rate (creatinine);
CRC	trans	rs2303319	0.504	rs62189053	chr2:162624324	G/A	cg22902534	chr3:183892754	AP2M1	-0.7	-6.07	-0.32	3.56e-9	Cognitive function;
CRC	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-9.85	-0.48	3.16e-20	Blood protein levels;
CRC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.65	11.49	0.54	6.32e-26	Mean corpuscular volume;
CRC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.48	7.55	0.38	4.32e-13	Eye color traits;
CRC	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.92	0.31	8.17e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs17023223	0.537	rs2645295	chr1:119582448	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-6.19	-0.32	1.77e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs3018066	0.748	rs6823347	chr4:106962725	G/A	cg01869342	chr4:106983673	TBCK	0.43	6.39	0.33	5.72e-10	Cancer;
CRC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.62	10.74	0.51	2.84e-23	Aortic root size;
CRC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg20908204	chr19:46285434	DMPK	-0.35	-6.81	-0.35	4.77e-11	Coronary artery disease;
CRC	cis	rs447	1.000	rs6977099	chr7:83762428	C/A	cg22846510	chr7:83753280	SEMA3A	-0.61	-7.8	-0.39	8.35e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg27523141	chr10:43048294	ZNF37B	0.49	7.21	0.37	3.99e-12	Extrinsic epigenetic age acceleration;
CRC	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.56	7.57	0.39	3.68e-13	Primary sclerosing cholangitis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22745781	chr7:16461244	ISPD	0.38	6.32	0.33	8.56e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.47	-6.57	-0.34	1.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg00666640	chr1:248458726	OR2T12	-0.47	-8.07	-0.41	1.3e-14	Common traits (Other);
CRC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.95	-0.31	6.84e-9	Life satisfaction;
CRC	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.07	-14.89	-0.63	1.12e-38	Exhaled nitric oxide output;
CRC	trans	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg26043149	chr18:55253948	FECH	0.49	7.44	0.38	8.59e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7849270	1.000	rs3739843	chr9:131882961	G/A	cg13538475	chr9:131942899	NA	-0.29	-5.83	-0.31	1.32e-8	Blood metabolite ratios;
CRC	cis	rs1519814	0.956	rs6469900	chr8:121117378	C/T	cg22335954	chr8:121166405	COL14A1	-0.55	-6.19	-0.32	1.77e-9	Breast cancer;
CRC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.77	-0.39	1.02e-13	Systolic blood pressure;
CRC	cis	rs9491140	0.539	rs11154231	chr6:124687586	T/C	cg22366943	chr6:124882293	NKAIN2	0.56	8.44	0.42	1.05e-15	Neuroticism;
CRC	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.64	-9.03	-0.45	1.53e-17	Coronary artery disease;
CRC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.33	5.94	0.31	7.35e-9	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.56	9.02	0.45	1.59e-17	Asthma;
CRC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.55	-8.41	-0.42	1.26e-15	Aortic root size;
CRC	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg15711740	chr2:61764176	XPO1	-0.53	-7.13	-0.37	6.34e-12	Tuberculosis;
CRC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.42	-5.82	-0.31	1.38e-8	DNA methylation (variation);
CRC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	5.86	0.31	1.1e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg24438145	chr17:48624694	SPATA20	0.44	6.42	0.33	4.72e-10	Type 2 diabetes;
CRC	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg12856521	chr11:46389249	DGKZ	0.58	8.55	0.43	4.7e-16	Leprosy;
CRC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.7	-0.39	1.61e-13	Total body bone mineral density;
CRC	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.53	-7.34	-0.38	1.69e-12	Schizophrenia;
CRC	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.31	0.46	1.92e-18	Bladder cancer;
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg14433983	chr11:636460	DRD4	-0.42	-6.09	-0.32	3.15e-9	Systemic lupus erythematosus;
CRC	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg00469287	chr7:23338798	C7orf30	-0.43	-5.68	-0.3	3.01e-8	Cerebrospinal fluid biomarker levels;
CRC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-15.78	-0.66	3.79e-42	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03586379	chr3:140660603	SLC25A36	0.42	6.83	0.35	4.12e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.4	5.77	0.3	1.82e-8	Aortic root size;
CRC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg15358701	chr1:161410459	NA	-0.62	-6.63	-0.34	1.39e-10	Rheumatoid arthritis;
CRC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.68	11.85	0.55	3.22e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg05585544	chr11:47624801	NA	-0.62	-10.82	-0.51	1.47e-23	Subjective well-being;
CRC	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg14191688	chr11:70257035	CTTN	0.47	6.03	0.32	4.39e-9	Coronary artery disease;
CRC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.49	-9.5	-0.46	4.65e-19	Prostate cancer;
CRC	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.5	8.21	0.41	4.97e-15	Schizophrenia;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-8.09	-0.41	1.16e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12172441	chr6:28176163	NA	-0.69	-9.38	-0.46	1.13e-18	Depression;
CRC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg09658497	chr7:2847517	GNA12	-0.43	-6.62	-0.34	1.48e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs1223397	0.938	rs34505804	chr6:13292514	G/A	cg06879394	chr6:13274151	PHACTR1	0.53	6.21	0.32	1.57e-9	Blood pressure;
CRC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.65	9.44	0.46	6.99e-19	Menopause (age at onset);
CRC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.63	8.4	0.42	1.39e-15	Alcohol dependence;
CRC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.41	-5.66	-0.3	3.34e-8	DNA methylation (variation);
CRC	trans	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.26	0.33	1.23e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.54	9.33	0.46	1.58e-18	Dupuytren's disease;
CRC	cis	rs7174755	0.637	rs113002386	chr15:68464713	C/T	cg22576950	chr15:68522787	CLN6	0.38	5.94	0.31	7.2e-9	Major depressive disorder;
CRC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.69	-10.79	-0.51	1.88e-23	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	8.26	0.41	3.59e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.78	-12.09	-0.55	4.45e-28	Cognitive function;
CRC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.97	11.93	0.55	1.69e-27	Eosinophil percentage of granulocytes;
CRC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.63	-11.37	-0.53	1.69e-25	Height;
CRC	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.49	-7.84	-0.4	6.43e-14	Plateletcrit;
CRC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg02175503	chr12:58329896	NA	0.48	6.02	0.32	4.64e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.45	-0.42	9.47e-16	Waist circumference adjusted for body mass index;
CRC	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.57	-6.98	-0.36	1.64e-11	Ulcerative colitis;
CRC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.66	-12.12	-0.56	3.43e-28	Aortic root size;
CRC	cis	rs727505	0.607	rs17387389	chr7:124784751	T/C	cg23710748	chr7:124431027	NA	-0.64	-10.24	-0.49	1.56e-21	Lewy body disease;
CRC	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg15147215	chr3:52552868	STAB1	0.6	10.09	0.49	4.9e-21	Electroencephalogram traits;
CRC	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.74	-8.12	-0.41	9.21e-15	Bipolar disorder;
CRC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13606994	chr1:44402422	ARTN	-0.36	-6.07	-0.32	3.53e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.92e-13	Motion sickness;
CRC	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.53	0.57	1.01e-29	Menopause (age at onset);
CRC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.41	-0.38	1.09e-12	Total body bone mineral density;
CRC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.79	-0.47	4.97e-20	Body mass index;
CRC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg03623178	chr6:28175578	NA	0.63	8.42	0.42	1.21e-15	Parkinson's disease;
CRC	cis	rs1223397	0.938	rs17700321	chr6:13280666	G/T	cg21538684	chr6:13274180	PHACTR1	0.46	5.64	0.3	3.58e-8	Blood pressure;
CRC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.39	17.14	0.69	1.59e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27184628	chr4:17616433	MED28	0.44	6.21	0.32	1.6e-9	Response to antipsychotic treatment;
CRC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.69	-11.49	-0.54	6.36e-26	Breast cancer;
CRC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg00383909	chr3:49044727	WDR6	0.46	5.73	0.3	2.3e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	trans	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg00953403	chr17:74099816	EXOC7	-0.46	-6.3	-0.33	9.47e-10	Psychosis in Alzheimer's disease;
CRC	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.39	6.21	0.32	1.57e-9	Response to Dalcetrapib treatment in acute coronary syndrome;
CRC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.52	-8.29	-0.42	2.92e-15	Monocyte count;
CRC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg13844804	chr7:814759	HEATR2	0.69	8.16	0.41	7.04e-15	Cerebrospinal P-tau181p levels;
CRC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19717773	chr7:2847554	GNA12	0.43	7.64	0.39	2.44e-13	Loneliness (linear analysis);
CRC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.49	7.44	0.38	8.62e-13	Corneal astigmatism;
CRC	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.21	-0.32	1.59e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.37	-6.71	-0.35	8.56e-11	Dupuytren's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16082007	chr3:134093380	AMOTL2	0.42	6.03	0.32	4.3e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.57	-8.61	-0.43	3.18e-16	Blood protein levels;
CRC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.49	-0.75	9.84e-61	Height;
CRC	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.89	-0.36	2.8e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg15123519	chr2:136567270	LCT	0.34	6.57	0.34	1.94e-10	Mosquito bite size;
CRC	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg12458913	chr13:53173898	NA	0.52	8.02	0.4	1.88e-14	Lewy body disease;
CRC	cis	rs728616	0.681	rs55899456	chr10:82050646	G/A	cg05935833	chr10:81318306	SFTPA2	-0.61	-7.1	-0.36	7.55e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.38	7.38e-13	Lung cancer in ever smokers;
CRC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-7.17	-0.37	5.01e-12	Total body bone mineral density;
CRC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	8.51	0.42	6.1e-16	Height;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.46	-6.17	-0.32	1.99e-9	Longevity;Endometriosis;
CRC	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.41	6.42	0.33	4.72e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
CRC	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg15282417	chr9:129245246	FAM125B	0.44	8.06	0.41	1.46e-14	Intraocular pressure;
CRC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.62	0.43	2.83e-16	Menopause (age at onset);
CRC	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg20356878	chr3:121714668	ILDR1	-0.48	-6.92	-0.36	2.43e-11	Multiple sclerosis;
CRC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.6	7.48	0.38	6.9e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.71	11.6	0.54	2.59e-26	Intelligence (multi-trait analysis);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg07560096	chr11:86383182	ME3	-0.5	-6.15	-0.32	2.21e-9	Diisocyanate-induced asthma;
CRC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.78e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg20908204	chr19:46285434	DMPK	-0.35	-7.01	-0.36	1.38e-11	Coronary artery disease;
CRC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.78	13.2	0.59	3.24e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs73206853	0.534	rs12302069	chr12:110512359	A/G	cg12870014	chr12:110450643	ANKRD13A	0.86	8.85	0.44	5.65e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.71	9.42	0.46	7.95e-19	Alzheimer's disease;
CRC	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.4	-5.66	-0.3	3.34e-8	Schizophrenia;
CRC	cis	rs13315871	1.000	rs71311857	chr3:58323377	A/G	cg20936604	chr3:58311152	NA	-0.78	-7.38	-0.38	1.34e-12	Cholesterol, total;
CRC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.58	-0.34	1.8e-10	Lung cancer;
CRC	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg00792783	chr2:198669748	PLCL1	0.29	5.6	0.3	4.49e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	8.65	0.43	2.28e-16	Menopause (age at onset);
CRC	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg19875578	chr6:126661172	C6orf173	0.44	6.27	0.33	1.16e-9	Male-pattern baldness;
CRC	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg10517650	chr3:113235015	CCDC52	-0.37	-6.58	-0.34	1.83e-10	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	14.32	0.62	1.66e-36	Chronic sinus infection;
CRC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.07	0.32	3.55e-9	Height;
CRC	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg20356878	chr3:121714668	ILDR1	-0.48	-6.91	-0.36	2.51e-11	Multiple sclerosis;
CRC	cis	rs755249	0.567	rs4660543	chr1:39678990	A/G	cg18385671	chr1:39797026	MACF1	-0.44	-6.36	-0.33	6.62e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg16405210	chr4:1374714	KIAA1530	0.41	5.76	0.3	1.96e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01772563	chr7:95064399	PON2	0.39	6.02	0.31	4.57e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg12273811	chr6:28175739	NA	0.63	9.13	0.45	6.88e-18	Cardiac Troponin-T levels;
CRC	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.52	9.3	0.46	1.98e-18	Blood metabolite ratios;
CRC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg18612461	chr15:75251733	NA	0.38	5.87	0.31	1.06e-8	Breast cancer;
CRC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.72	12.01	0.55	8.56e-28	Cognitive function;
CRC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.81	12.48	0.57	1.62e-29	Menarche (age at onset);
CRC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.39	0.33	5.51e-10	Rheumatoid arthritis;
CRC	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg25797454	chr6:150327115	RAET1K	0.37	6.25	0.33	1.25e-9	Alopecia areata;
CRC	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.45	6.55	0.34	2.23e-10	Primary sclerosing cholangitis;
CRC	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.1	-0.32	3.05e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	0.53	5.84	0.31	1.27e-8	Insulin-like growth factors;
CRC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.85	-0.31	1.18e-8	Lung cancer;
CRC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18867708	chr6:26865862	GUSBL1	0.43	6.21	0.32	1.6e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18357526	chr6:26021779	HIST1H4A	0.41	5.79	0.3	1.64e-8	Height;
CRC	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.91	-0.4	3.94e-14	Vitamin D levels;
CRC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.47	6.35	0.33	7.15e-10	Lymphocyte counts;
CRC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	17.69	0.7	1.13e-49	Platelet count;
CRC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.3	-6.57	-0.34	2.02e-10	IgG glycosylation;
CRC	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.64	9.78	0.47	5.32e-20	Birth weight;
CRC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.83	11.47	0.53	7.62e-26	Cerebrospinal P-tau181p levels;
CRC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20307385	chr11:47447363	PSMC3	-0.55	-7.75	-0.39	1.19e-13	Subjective well-being;
CRC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.94	-17.32	-0.69	3.26e-48	Height;
CRC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.74	10.83	0.51	1.37e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.78	8.85	0.44	5.33e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-6.56	-0.34	2.05e-10	Schizophrenia;
CRC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg17948913	chr5:572064	NA	0.56	6.25	0.33	1.28e-9	Lung disease severity in cystic fibrosis;
CRC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg10729496	chr3:10149963	C3orf24	0.53	6.92	0.36	2.41e-11	Alzheimer's disease;
CRC	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.44	-5.77	-0.3	1.8e-8	Height;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03201274	chr1:27693242	MAP3K6	0.45	6.97	0.36	1.74e-11	Response to antipsychotic treatment;
CRC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.62	-6.67	-0.35	1.08e-10	Cerebrospinal P-tau181p levels;
CRC	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.62	-0.39	2.8e-13	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs17234274	0.622	rs1586076	chr11:23237286	T/C	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12484590	chr1:156475177	NA	0.46	6.6	0.34	1.61e-10	Response to antipsychotic treatment;
CRC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.97	-0.31	6e-9	Gut microbiome composition (summer);
CRC	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.62	-8.41	-0.42	1.3e-15	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.7	8.92	0.44	3.2e-17	Bladder cancer;
CRC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.58	9.35	0.46	1.41e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.44	9.23	0.45	3.49e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-7.86	-0.4	5.67e-14	Longevity;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19046167	chr17:80928561	B3GNTL1	0.49	6.67	0.35	1.09e-10	Glycated hemoglobin levels;
CRC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.45	8.96	0.44	2.41e-17	Renal cell carcinoma;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg17809276	chr1:172501547	C1orf9	-0.59	-5.99	-0.31	5.46e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg16670446	chr17:27188758	MIR451;MIR144	0.55	8.52	0.43	5.75e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.8	-10.38	-0.5	4.95e-22	Type 2 diabetes;
CRC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.32	-7.14	-0.37	5.94e-12	IgG glycosylation;
CRC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.44	-6.22	-0.32	1.49e-9	Menarche (age at onset);
CRC	cis	rs4908768	0.501	rs6677736	chr1:8552804	A/T	cg20416874	chr1:8611966	RERE	-0.45	-6.42	-0.33	4.68e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CRC	cis	rs11997175	0.713	rs4327826	chr8:33654807	T/G	ch.8.33884649F	chr8:33765107	NA	0.37	5.73	0.3	2.22e-8	Body mass index;
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg21238619	chr17:78079768	GAA	-0.34	-5.76	-0.3	1.95e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.15	0.32	2.2e-9	Diabetic kidney disease;
CRC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.79	0.39	8.61e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs959260	0.541	rs58935635	chr17:73357744	C/T	cg14668889	chr17:73230827	NUP85	0.49	5.68	0.3	2.93e-8	Systemic lupus erythematosus;
CRC	cis	rs7086803	1.000	rs7088860	chr10:114486867	A/G	cg03281572	chr10:114502318	VTI1A	0.68	5.7	0.3	2.62e-8	Lung cancer;
CRC	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.23	-0.41	4.39e-15	Mean corpuscular volume;
CRC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.56	8.62	0.43	2.81e-16	Breast cancer;
CRC	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.77	-12.18	-0.56	1.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg21251018	chr6:28226885	NKAPL	0.4	6.12	0.32	2.61e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-10.84	-0.51	1.32e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg21155852	chr7:2048760	MAD1L1	-0.52	-6.99	-0.36	1.54e-11	Bipolar disorder;
CRC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg23136738	chr11:925521	AP2A2	-0.39	-6.47	-0.34	3.49e-10	Alzheimer's disease (late onset);
CRC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.53	-10.08	-0.49	5.13e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.44	-5.89	-0.31	9.43e-9	Gut microbiome composition (summer);
CRC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	9.64	0.47	1.51e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.49	8.59	0.43	3.61e-16	Hypertriglyceridemia;
CRC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.52	9.18	0.45	4.74e-18	Hypertriglyceridemia;
CRC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg02475695	chr16:616220	NHLRC4	0.47	7.68	0.39	1.78e-13	Height;
CRC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	8.54	0.43	5.14e-16	Height;
CRC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.48	7.08	0.36	8.57e-12	Obesity-related traits;
CRC	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.76	-10.82	-0.51	1.47e-23	Multiple sclerosis;
CRC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.19	0.45	4.61e-18	Heart rate;
CRC	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.67	-7.68	-0.39	1.82e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs3741151	0.892	rs77127734	chr11:73018413	T/A	cg17517138	chr11:73019481	ARHGEF17	0.68	7.22	0.37	3.52e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.58	-0.47	2.53e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	0.72	9.15	0.45	6.25e-18	Prostate cancer;
CRC	cis	rs6681460	0.625	rs2872079	chr1:67130071	G/A	cg02459107	chr1:67143332	SGIP1	0.34	6.15	0.32	2.21e-9	Presence of antiphospholipid antibodies;
CRC	cis	rs2302190	0.882	rs12939703	chr17:56611090	G/C	cg25885038	chr17:56607967	SEPT4	-0.52	-7.88	-0.4	4.76e-14	Vitamin D levels;
CRC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.49	7.37	0.38	1.37e-12	Corneal astigmatism;
CRC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	9.53	0.47	3.57e-19	Cognitive test performance;
CRC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.05	-0.45	1.31e-17	Electroencephalogram traits;
CRC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.47	-6.51	-0.34	2.82e-10	Height;
CRC	trans	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg17903999	chr18:56338584	MALT1	0.42	6.98	0.36	1.63e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-6.0	-0.31	5.24e-9	Gut microbiome composition (summer);
CRC	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg03929089	chr4:120376271	NA	-0.66	-6.57	-0.34	1.92e-10	Axial length;
CRC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg24977027	chr2:88469347	THNSL2	-0.33	-5.68	-0.3	3.04e-8	Response to metformin (IC50);
CRC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg00406319	chr10:126851303	NA	-0.4	-5.67	-0.3	3.18e-8	Menarche (age at onset);
CRC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg25164649	chr6:28176230	NA	0.38	5.67	0.3	3.07e-8	Pubertal anthropometrics;
CRC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg27068330	chr11:65405492	SIPA1	-0.48	-6.63	-0.34	1.37e-10	Breast cancer;
CRC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17554472	chr22:41940697	POLR3H	0.55	5.65	0.3	3.52e-8	Vitiligo;
CRC	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.46	6.9	0.36	2.68e-11	Asthma;
CRC	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.86	16.19	0.67	8.72e-44	Hip circumference;
CRC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.66	-0.34	1.14e-10	Alzheimer's disease (late onset);
CRC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.35	-5.97	-0.31	6.25e-9	Personality dimensions;
CRC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.24	-13.52	-0.6	1.9e-33	Diabetic kidney disease;
CRC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.15	-0.32	2.23e-9	Schizophrenia;
CRC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg22495460	chr2:25135724	ADCY3	-0.98	-20.87	-0.75	3.29e-62	Body mass index;
CRC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.29	6.08	0.32	3.37e-9	Lung cancer;
CRC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.62	8.71	0.43	1.48e-16	Multiple sclerosis;
CRC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.51	7.47	0.38	7.51e-13	Pancreatic cancer;
CRC	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.65	10.1	0.49	4.61e-21	Corneal astigmatism;
CRC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.46	5.79	0.3	1.6e-8	Aortic root size;
CRC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.63	-12.51	-0.57	1.23e-29	Asthma (sex interaction);
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg25733613	chr11:111637437	PPP2R1B	0.52	6.29	0.33	1.01e-9	Kashin-Beck disease;
CRC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg04731861	chr2:219085781	ARPC2	-0.3	-6.1	-0.32	2.9e-9	Colorectal cancer;
CRC	cis	rs524281	0.506	rs2298466	chr11:66011280	T/C	cg16950941	chr11:66035639	RAB1B	-0.5	-6.13	-0.32	2.5e-9	Electroencephalogram traits;
CRC	trans	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg19188899	chr13:112838565	NA	-0.42	-6.45	-0.34	3.93e-10	Systemic lupus erythematosus;
CRC	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.57	-7.01	-0.36	1.36e-11	Cancer;
CRC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg03844506	chr4:4109441	NA	-0.51	-7.57	-0.39	3.88e-13	Blood pressure (smoking interaction);
CRC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21643547	chr1:205240462	TMCC2	-0.45	-7.25	-0.37	2.98e-12	Mean corpuscular volume;Mean platelet volume;
CRC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs1320333	0.772	rs2903491	chr2:686688	T/A	cg20966539	chr2:681320	NA	0.65	5.99	0.31	5.42e-9	Obesity-related traits;
CRC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.51	-6.93	-0.36	2.27e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg03690763	chr11:133734501	NA	-0.36	-5.9	-0.31	8.92e-9	Childhood ear infection;
CRC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.69	-9.96	-0.48	1.33e-20	Platelet distribution width;
CRC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.4	0.42	1.35e-15	Platelet count;
CRC	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg11887960	chr12:57824829	NA	0.59	6.56	0.34	2.05e-10	Obesity-related traits;
CRC	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11446398	chr5:77624930	NA	0.46	6.33	0.33	7.82e-10	Triglycerides;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.54	-7.15	-0.37	5.63e-12	Coronary artery disease;
CRC	cis	rs524281	0.773	rs10791861	chr11:66008470	G/A	cg14036092	chr11:66035641	RAB1B	-0.56	-6.35	-0.33	7.22e-10	Electroencephalogram traits;
CRC	cis	rs10971721	0.822	rs12377970	chr9:34021267	T/C	cg13495928	chr9:33750294	PRSS3	0.55	5.63	0.3	3.81e-8	Body mass index;
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02825527	chr7:2087843	MAD1L1	-0.49	-5.79	-0.3	1.6e-8	Bipolar disorder;
CRC	cis	rs7553864	0.966	rs11161935	chr1:87614191	G/A	cg02083836	chr1:87617350	LOC339524	0.35	6.24	0.33	1.36e-9	Smoking behavior;
CRC	cis	rs73206853	0.563	rs9300316	chr12:111196204	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	7.45	0.38	8.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs3741151	0.686	rs12277924	chr11:73219678	T/C	cg17517138	chr11:73019481	ARHGEF17	0.55	5.92	0.31	7.97e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg00428638	chr19:7224713	INSR	0.95	19.89	0.74	2.35e-58	Hypothyroidism;
CRC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.59	0.57	6.38e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs12580194	0.556	rs11171433	chr12:55757797	A/T	cg23425280	chr12:56401806	NA	0.47	5.78	0.3	1.76e-8	Cancer;
CRC	cis	rs7605827	0.897	rs34191114	chr2:15670691	C/A	cg19274914	chr2:15703543	NA	0.39	5.84	0.31	1.23e-8	Educational attainment (years of education);
CRC	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00938859	chr5:1591904	SDHAP3	0.66	6.07	0.32	3.52e-9	Breast cancer;
CRC	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg14646075	chr2:228736089	WDR69	0.42	5.6	0.3	4.45e-8	Blood pressure;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg13148469	chr1:28969864	TAF12	-0.41	-6.12	-0.32	2.67e-9	Myopia (pathological);
CRC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-6.23	-0.32	1.46e-9	Response to metformin (IC50);
CRC	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	6.03	0.32	4.49e-9	Autism spectrum disorder or schizophrenia;
CRC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.69	11.07	0.52	1.98e-24	Type 2 diabetes;
CRC	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	5.79	0.3	1.65e-8	Diastolic blood pressure;
CRC	cis	rs4731207	0.596	rs1481343	chr7:124652271	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.25	-0.33	1.24e-9	Cutaneous malignant melanoma;
CRC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-6.58	-0.34	1.91e-10	Blood pressure (smoking interaction);
CRC	trans	rs17331304	0.516	rs13114953	chr4:12188297	A/G	cg17170088	chr8:145159375	SHARPIN;MAF1	0.45	6.11	0.32	2.8e-9	Positive affect;
CRC	cis	rs16973500	0.808	rs1049794	chr16:71950450	C/T	cg00732059	chr16:71740210	PHLPP2	-0.67	-6.89	-0.36	2.77e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.52	8.86	0.44	5.15e-17	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.76	0.35	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.47	6.64	0.34	1.32e-10	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04389328	chr22:20104991	RANBP1;TRMT2A	0.39	6.18	0.32	1.93e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.48	9.22	0.45	3.54e-18	Renal cell carcinoma;
CRC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.85	-0.35	3.69e-11	Neuroticism;
CRC	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.54	9.7	0.47	1.01e-19	Common traits (Other);
CRC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.52	7.09	0.36	8.04e-12	Developmental language disorder (linguistic errors);
CRC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-16.09	-0.66	2.26e-43	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06423533	chr19:4909366	UHRF1	0.48	6.61	0.34	1.59e-10	Anxiety disorder;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13450310	chr1:39874390	KIAA0754;MACF1	0.41	6.3	0.33	9.71e-10	Response to antipsychotic treatment;
CRC	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.48	7.43	0.38	9.72e-13	Longevity;
CRC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02290350	chr8:58132656	NA	-0.51	-6.39	-0.33	5.68e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12588279	chr6:26043732	HIST1H2BB	0.45	6.73	0.35	7.47e-11	Intelligence (multi-trait analysis);
CRC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.59	-0.47	2.35e-19	Body mass index;
CRC	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.62	12.41	0.56	2.9e-29	Weight;
CRC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.78	-0.47	5.18e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg19635926	chr16:89946313	TCF25	0.57	5.96	0.31	6.58e-9	Skin colour saturation;
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.49	7.15	0.37	5.58e-12	Height;
CRC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.49	6.53	0.34	2.53e-10	Obesity-related traits;
CRC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.63	0.54	1.97e-26	Intelligence (multi-trait analysis);
CRC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.22	0.41	4.66e-15	Mood instability;
CRC	cis	rs2276314	0.553	rs1789501	chr18:33617060	T/A	cg19628046	chr18:33552617	C18orf21	-0.4	-6.23	-0.32	1.4e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
CRC	cis	rs995000	0.868	rs880694	chr1:63173284	C/T	cg19896129	chr1:63156450	NA	-0.44	-6.79	-0.35	5.09e-11	Triglyceride levels;
CRC	cis	rs6499255	0.951	rs7186002	chr16:69751065	C/G	cg15192750	chr16:69999425	NA	0.54	7.1	0.36	7.55e-12	IgE levels;
CRC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	11.05	0.52	2.28e-24	Platelet count;
CRC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.46	5.71	0.3	2.57e-8	Aortic root size;
CRC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.67	-11.23	-0.53	5.55e-25	Urate levels;
CRC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg07713946	chr22:31675144	LIMK2	0.41	6.19	0.32	1.81e-9	Colorectal cancer;
CRC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg03037974	chr15:76606532	NA	-0.52	-7.17	-0.37	5e-12	Blood metabolite levels;
CRC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	7.13	0.37	6.55e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg15226275	chr6:116381976	FRK	-0.31	-8.89	-0.44	4.08e-17	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	9.19	0.45	4.41e-18	Cognitive test performance;
CRC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.74	10.54	0.5	1.46e-22	High light scatter reticulocyte count;
CRC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg26587870	chr6:27730563	NA	-0.63	-5.88	-0.31	9.85e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg03395651	chr16:88107091	BANP	0.55	7.29	0.37	2.31e-12	Menopause (age at onset);
CRC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.55	10.13	0.49	3.53e-21	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21257117	chr11:65029643	POLA2	0.47	6.04	0.32	4.21e-9	Thyroid stimulating hormone;
CRC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	1.06	9.73	0.47	7.93e-20	Autism spectrum disorder or schizophrenia;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg14475554	chr1:209799191	LAMB3	0.4	6.07	0.32	3.61e-9	Myopia (pathological);
CRC	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.54	-5.98	-0.31	5.94e-9	Obesity-related traits;
CRC	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.33	-6.35	-0.33	7.28e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.62	-9.5	-0.46	4.66e-19	Cognitive function;
CRC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.6	-8.23	-0.41	4.37e-15	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg11130432	chr3:121712080	ILDR1	-0.52	-6.81	-0.35	4.73e-11	Multiple sclerosis;
CRC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg25985355	chr7:65971099	NA	0.33	5.83	0.31	1.33e-8	Aortic root size;
CRC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.8	-13.45	-0.6	3.5e-33	Cystic fibrosis severity;
CRC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-6.53	-0.34	2.44e-10	Longevity;Endometriosis;
CRC	cis	rs990171	1.000	rs917997	chr2:103070568	T/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.89	0.31	9.34e-9	Lymphocyte counts;
CRC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg12365402	chr11:9010492	NRIP3	-0.38	-6.47	-0.34	3.47e-10	Hemoglobin concentration;
CRC	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.1	22.73	0.78	1.94e-69	Schizophrenia;
CRC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.77	0.44	9.64e-17	Morning vs. evening chronotype;
CRC	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.18	14.67	0.63	7.58e-38	Mitochondrial DNA levels;
CRC	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.62	7.74	0.39	1.25e-13	Neuroblastoma;
CRC	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg07699608	chr10:75541558	CHCHD1	0.69	6.89	0.36	2.79e-11	Incident atrial fibrillation;
CRC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.76	10.17	0.49	2.73e-21	Platelet distribution width;
CRC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg25164649	chr6:28176230	NA	0.65	8.58	0.43	3.87e-16	Parkinson's disease;
CRC	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg19875578	chr6:126661172	C6orf173	0.43	5.9	0.31	9.18e-9	Male-pattern baldness;
CRC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.53	0.47	3.56e-19	Intelligence (multi-trait analysis);
CRC	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.55	8.22	0.41	4.87e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg19338460	chr6:170058176	WDR27	-0.71	-7.8	-0.4	8.04e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.65	-8.05	-0.41	1.51e-14	Body mass index;
CRC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg11843238	chr5:131593191	PDLIM4	0.43	8.44	0.42	9.92e-16	Breast cancer;
CRC	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.64	0.39	2.46e-13	Testicular germ cell tumor;
CRC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg11245181	chr6:149772854	ZC3H12D	-0.53	-8.98	-0.44	2.14e-17	Dupuytren's disease;
CRC	cis	rs1552172	0.853	rs2018027	chr1:145595820	A/G	cg11743829	chr1:145714124	CD160	0.37	5.87	0.31	1.04e-8	Breast cancer;
CRC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.62	8.38	0.42	1.51e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg21251018	chr6:28226885	NKAPL	0.48	6.17	0.32	2.02e-9	Depression;
CRC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.6	-9.34	-0.46	1.53e-18	Body mass index;
CRC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.73	12.61	0.57	5.41e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg08888203	chr3:10149979	C3orf24	0.7	10.01	0.48	8.99e-21	Alzheimer's disease;
CRC	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.49	7.69	0.39	1.74e-13	Obesity-related traits;
CRC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.45	5.98	0.31	5.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3736485	0.934	rs4143723	chr15:51867172	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-6.64	-0.34	1.29e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Depression;
CRC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	14.98	0.64	4.77e-39	Smoking behavior;
CRC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.54	-0.34	2.31e-10	Retinal vascular caliber;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01164326	chr16:66460784	BEAN	0.43	6.93	0.36	2.23e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.93	-12.55	-0.57	8.48e-30	Exhaled nitric oxide output;
CRC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.61	0.43	3.06e-16	Retinal vascular caliber;
CRC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg22431228	chr1:16359049	CLCNKA	-0.33	-5.68	-0.3	3e-8	Dilated cardiomyopathy;
CRC	trans	rs6462411	0.646	rs10273444	chr7:3923414	A/G	cg24598187	chr5:96253798	ERAP2	-0.5	-6.01	-0.31	4.98e-9	Quantitative traits;
CRC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.61	10.76	0.51	2.53e-23	Aortic root size;
CRC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.83	-0.31	1.33e-8	Total body bone mineral density;
CRC	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.13	17.53	0.69	4.94e-49	Gout;Urate levels;Serum uric acid levels;
CRC	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.8	13.75	0.6	2.71e-34	Hip circumference;
CRC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg08132177	chr1:856685	NA	-0.68	-6.0	-0.31	5.29e-9	Cognitive function;
CRC	cis	rs9682041	0.561	rs6444928	chr3:170147875	A/G	cg11886554	chr3:170076028	SKIL	0.63	7.02	0.36	1.24e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CRC	trans	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg24644049	chr4:85504048	CDS1	0.93	7.5	0.38	5.89e-13	Skin colour saturation;
CRC	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg05139728	chr16:28306816	SBK1	-0.34	-5.79	-0.3	1.62e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg13628971	chr7:2884303	GNA12	0.38	5.61	0.3	4.25e-8	Height;
CRC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.16	11.41	0.53	1.27e-25	Skin colour saturation;
CRC	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.53	-0.34	2.54e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	cg04338863	chr8:33670619	NA	0.44	7.06	0.36	9.65e-12	Body mass index;
CRC	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg13086574	chr8:135490821	ZFAT	-0.37	-6.26	-0.33	1.19e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg06470822	chr6:28175283	NA	0.81	12.15	0.56	2.52e-28	Parkinson's disease;
CRC	cis	rs539514	0.587	rs9530466	chr13:76323774	T/C	cg04757411	chr13:76259545	LMO7	-0.37	-5.84	-0.31	1.24e-8	Type 1 diabetes;
CRC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.76	-9.35	-0.46	1.41e-18	Bronchopulmonary dysplasia;
CRC	cis	rs6662572	0.686	rs72692639	chr1:46446096	A/G	cg08644498	chr1:46502608	NA	0.46	7.09	0.36	8.14e-12	Blood protein levels;
CRC	cis	rs4400599	0.772	rs4579747	chr1:154153106	A/G	cg05139571	chr1:154127138	NUP210L	0.42	6.27	0.33	1.12e-9	Platelet distribution width;
CRC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.15	-15.81	-0.66	2.72e-42	Vitiligo;
CRC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg21466736	chr12:48725269	NA	-0.51	-7.61	-0.39	2.93e-13	Glycated hemoglobin levels;
CRC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg24110177	chr3:50126178	RBM5	0.42	5.78	0.3	1.7e-8	Intelligence (multi-trait analysis);
CRC	trans	rs948562	0.947	rs17489568	chr11:58390007	C/G	cg26660744	chr1:1573181	CDK11B	0.54	6.1	0.32	2.94e-9	Lymphoma;
CRC	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.45	7.8	0.4	8.31e-14	Common traits (Other);
CRC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg02135003	chr7:105160482	PUS7	-0.92	-12.46	-0.57	1.94e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.91	0.36	2.59e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.44	7.05	0.36	1.03e-11	Height;
CRC	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.85	-0.61	1.12e-34	Hypospadias;
CRC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	10.39	0.5	4.71e-22	Hip circumference adjusted for BMI;
CRC	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg11130432	chr3:121712080	ILDR1	-0.48	-6.22	-0.32	1.48e-9	Multiple sclerosis;
CRC	cis	rs2267708	0.509	rs6959972	chr7:124617108	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.17	-0.32	1.96e-9	Chronic lymphocytic leukemia;
CRC	cis	rs1524976	1.000	rs62255282	chr3:65485422	C/T	cg16238336	chr3:65465873	MAGI1	-0.54	-6.91	-0.36	2.45e-11	PR interval;
CRC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.52	-8.65	-0.43	2.34e-16	Metabolite levels;
CRC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.09	-0.41	1.14e-14	Subjective well-being;
CRC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.4	6.99	0.36	1.58e-11	Obesity-related traits;
CRC	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg21452805	chr1:244014465	NA	0.54	7.26	0.37	2.77e-12	RR interval (heart rate);
CRC	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg02811702	chr13:24901961	NA	0.45	6.22	0.32	1.53e-9	Obesity-related traits;
CRC	cis	rs7680126	0.596	rs4698031	chr4:10315921	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.04	-0.32	4.17e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.1	12.56	0.57	7.89e-30	Sexual dysfunction (female);
CRC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.6	-10.52	-0.5	1.65e-22	Dupuytren's disease;
CRC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.4	6.5	0.34	3.02e-10	Height;
CRC	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	12.63	0.57	4.38e-30	Alzheimer's disease;
CRC	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg21153622	chr11:89784906	NA	0.46	7.34	0.38	1.68e-12	HDL cholesterol;
CRC	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg15382696	chr6:118971807	C6orf204	0.61	7.77	0.39	1.01e-13	Diastolic blood pressure;
CRC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg24209194	chr3:40518798	ZNF619	0.42	6.43	0.33	4.54e-10	Renal cell carcinoma;
CRC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.37	-0.5	5.51e-22	Chronic sinus infection;
CRC	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.82	0.44	6.77e-17	Dupuytren's disease;
CRC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	13.87	0.61	9.28e-35	Smoking behavior;
CRC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.16	26.9	0.83	4.44e-85	IgG glycosylation;
CRC	trans	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg17903999	chr18:56338584	MALT1	-0.39	-6.23	-0.32	1.44e-9	Liver enzyme levels (alkaline phosphatase);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26297968	chr2:211035960	C2orf67	0.46	6.32	0.33	8.73e-10	Survival in pancreatic cancer;
CRC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.39e-26	Prudent dietary pattern;
CRC	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.44	-6.99	-0.36	1.54e-11	Sleep quality;
CRC	cis	rs364477	0.904	rs279898	chr9:965191	C/T	cg13952963	chr9:998547	NA	0.57	6.07	0.32	3.53e-9	Major depressive disorder;
CRC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg21856205	chr7:94953877	PON1	-0.48	-6.28	-0.33	1.1e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.8	14.42	0.62	6.98e-37	Breast cancer;
CRC	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.48	6.98	0.36	1.68e-11	Breast cancer;
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg09877947	chr5:131593287	PDLIM4	-0.45	-7.47	-0.38	7.26e-13	Blood metabolite levels;
CRC	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.64	9.01	0.44	1.74e-17	White matter hyperintensity burden;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.68	7.98	0.4	2.44e-14	Body mass index;
CRC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.49	0.42	6.96e-16	Menopause (age at onset);
CRC	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.68	12.66	0.57	3.27e-30	Age-related hearing impairment;
CRC	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.73	-8.06	-0.41	1.38e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg20607287	chr7:12443886	VWDE	-0.66	-6.41	-0.33	5.17e-10	Coronary artery disease;
CRC	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17467752	chr17:38218738	THRA	-0.4	-5.65	-0.3	3.47e-8	Myeloid white cell count;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg25164649	chr6:28176230	NA	0.61	7.93	0.4	3.36e-14	Parkinson's disease;
CRC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	7.49	0.38	6.2800000000000005e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.44	8.9	0.44	3.72e-17	Renal cell carcinoma;
CRC	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.46	8.78	0.44	8.85e-17	Hepatitis;
CRC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.46	-10.31	-0.49	8.47e-22	Plasma homocysteine levels (post-methionine load test);
CRC	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg04586622	chr2:25135609	ADCY3	-0.52	-8.85	-0.44	5.55e-17	Body mass index;
CRC	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.3	1.75e-8	Response to antipsychotic treatment;
CRC	trans	rs3923380	0.683	rs10004356	chr4:77465025	A/G	cg04105282	chr10:99790170	CRTAC1	0.35	6.11	0.32	2.85e-9	Craniofacial microsomia;
CRC	cis	rs7705042	0.865	rs6863411	chr5:141513204	A/T	cg08523384	chr5:141488047	NDFIP1	-0.32	-5.76	-0.3	1.91e-8	Asthma;
CRC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.65	-10.67	-0.51	5.23e-23	Dental caries;
CRC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.09	0.32	3.22e-9	Crohn's disease;
CRC	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.43	5.81	0.31	1.48e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6681460	0.634	rs12143964	chr1:67010266	T/G	cg02459107	chr1:67143332	SGIP1	0.35	5.6	0.3	4.43e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs3736485	0.966	rs11070860	chr15:51892654	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-6.47	-0.34	3.56e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.04	0.45	1.36e-17	Dupuytren's disease;
CRC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.22	-16.66	-0.68	1.26e-45	Breast cancer;
CRC	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.55	8.13	0.41	9.09e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg15382696	chr6:118971807	C6orf204	0.61	7.95	0.4	3.01e-14	Diastolic blood pressure;
CRC	cis	rs2415984	0.579	rs2642103	chr14:46963280	C/T	cg14871534	chr14:47121158	RPL10L	0.4	6.0	0.31	5.12e-9	Number of children ever born;
CRC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg08798685	chr6:27730294	NA	-0.62	-6.06	-0.32	3.82e-9	Depression;
CRC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.62	9.71	0.47	9.4e-20	Corneal astigmatism;
CRC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg12193833	chr17:30244370	NA	-0.75	-8.79	-0.44	8.51e-17	Hip circumference adjusted for BMI;
CRC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	17.58	0.7	2.89e-49	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-6.94	-0.36	2.11e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.94	0.31	7.06e-9	IgG glycosylation;
CRC	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg16482183	chr6:26056742	HIST1H1C	0.85	10.66	0.51	5.33e-23	Iron status biomarkers;
CRC	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.47	-6.14	-0.32	2.36e-9	Platelet distribution width;
CRC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.63	10.97	0.52	4.5e-24	Schizophrenia;
CRC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.03e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg17948913	chr5:572064	NA	0.51	5.85	0.31	1.16e-8	Obesity-related traits;
CRC	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg08992911	chr2:238395768	MLPH	0.62	6.81	0.35	4.64e-11	Prostate cancer;
CRC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.55	7.9	0.4	4.33e-14	Melanoma;
CRC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.42	8.08	0.41	1.22e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CRC	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.12	-0.37	6.67e-12	Metabolite levels (Pyroglutamine);
CRC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg20243544	chr17:37824526	PNMT	0.53	7.92	0.4	3.7e-14	Asthma;
CRC	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg21153622	chr11:89784906	NA	-0.48	-7.55	-0.38	4.34e-13	HDL cholesterol;
CRC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
CRC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-7.6	-0.39	3.06e-13	Total body bone mineral density;
CRC	trans	rs4130344	0.555	rs7664704	chr4:159866176	A/G	cg10773016	chr4:6690812	NA	0.42	6.31	0.33	9.19e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.63	-0.3	3.94e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.44	-6.6	-0.34	1.65e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg17724175	chr1:150552817	MCL1	0.49	7.28	0.37	2.47e-12	Melanoma;
CRC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.5	7.5	0.38	6.12e-13	Longevity;Endometriosis;
CRC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04132851	chr1:85155548	SSX2IP	0.46	6.07	0.32	3.5e-9	Thyroid stimulating hormone;
CRC	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg09760422	chr2:128146352	NA	-0.35	-6.83	-0.35	4.09e-11	Protein C levels;
CRC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	12.43	0.57	2.41e-29	Chronic sinus infection;
CRC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.68	-11.72	-0.54	9.33e-27	Schizophrenia;
CRC	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg18764771	chr6:116381957	FRK	0.26	6.33	0.33	8.2e-10	Total cholesterol levels;
CRC	cis	rs972578	0.765	rs713717	chr22:43396109	C/T	cg01576275	chr22:43409880	NA	-0.4	-6.23	-0.32	1.46e-9	Mean platelet volume;
CRC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.01	16.36	0.67	1.94e-44	Cognitive function;
CRC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.43	5.69	0.3	2.83e-8	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg19683962	chr4:108852534	CYP2U1	0.4	6.9	0.36	2.69e-11	Obesity-related traits;
CRC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg25797454	chr6:150327115	RAET1K	-0.37	-6.31	-0.33	8.83e-10	Alopecia areata;
CRC	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.3	0.46	2.04e-18	Blood protein levels;
CRC	trans	rs4942242	0.740	rs6561137	chr13:44231965	A/T	cg19169023	chr15:41853346	TYRO3	-0.46	-6.78	-0.35	5.6e-11	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.52	7.51	0.38	5.5e-13	Pulmonary function decline;
CRC	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg04415270	chr2:102091202	RFX8	-0.37	-6.24	-0.33	1.32e-9	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.7	-7.5	-0.38	5.9e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.51	7.82	0.4	7.34e-14	Calcium levels;
CRC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg19582491	chr16:67682965	RLTPR	-0.58	-6.91	-0.36	2.5e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.62	10.18	0.49	2.48e-21	Subjective well-being (multi-trait analysis);
CRC	cis	rs6973256	0.604	rs6975134	chr7:133531432	T/C	cg03336402	chr7:133662267	EXOC4	-0.4	-5.65	-0.3	3.4e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.44	-6.22	-0.32	1.47e-9	Bipolar disorder;
CRC	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg18232548	chr7:50535776	DDC	-0.41	-6.11	-0.32	2.88e-9	Body mass index;
CRC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.73	-12.16	-0.56	2.48e-28	Paraoxonase activity;
CRC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.43	-0.33	4.54e-10	Menopause (age at onset);
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.05	-0.36	1.03e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs6741819	0.826	rs12465410	chr2:7136373	G/A	cg27144453	chr2:7172511	RNF144A	-0.41	-5.97	-0.31	5.98e-9	Response to antipsychotic treatment;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg24672547	chr12:6977222	TPI1	0.43	6.17	0.32	1.97e-9	Anxiety disorder;
CRC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.64	6.77	0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.504	rs6587434	chr1:248355563	G/A	cg00666640	chr1:248458726	OR2T12	0.43	7.05	0.36	1.05e-11	Common traits (Other);
CRC	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.54	9.0	0.44	1.86e-17	Dupuytren's disease;
CRC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg23123621	chr4:1343375	KIAA1530	0.34	6.31	0.33	8.96e-10	Obesity-related traits;
CRC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.61	0.3	4.21e-8	Renal function-related traits (BUN);
CRC	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.54	7.6	0.39	3.18e-13	Testicular germ cell tumor;
CRC	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg21452805	chr1:244014465	NA	0.44	6.03	0.32	4.37e-9	RR interval (heart rate);
CRC	cis	rs9549328	0.643	rs4907567	chr13:113617533	C/T	cg20742385	chr13:113633654	MCF2L	0.56	9.5	0.46	4.54e-19	Systolic blood pressure;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03609636	chr11:102323712	TMEM123	0.45	6.55	0.34	2.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.63	10.25	0.49	1.39e-21	Aortic root size;
CRC	trans	rs9914544	0.524	rs8071147	chr17:18790678	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.1	-0.32	3e-9	Educational attainment (years of education);
CRC	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.4	6.17	0.32	1.99e-9	Endometrial cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00351210	chr15:91073794	CRTC3	0.45	6.37	0.33	6.47e-10	Anxiety disorder;
CRC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.67	9.82	0.48	3.95e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg12193833	chr17:30244370	NA	-0.73	-8.49	-0.42	7.41e-16	Hip circumference adjusted for BMI;
CRC	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg13491945	chr12:107078410	RFX4	0.33	5.62	0.3	4.03e-8	Heart rate;
CRC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.59	9.16	0.45	5.72e-18	Prostate cancer;
CRC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.4	6.12	0.32	2.69e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.5	7.55	0.38	4.29e-13	Corneal astigmatism;
CRC	trans	rs9395066	0.545	rs12525009	chr6:44875843	C/T	cg04786201	chr1:17185605	NA	0.29	6.09	0.32	3.17e-9	Height;
CRC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.4	-7.24	-0.37	3.19e-12	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-1.03	-14.2	-0.62	4.96e-36	Exhaled nitric oxide output;
CRC	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg01312482	chr5:178451176	ZNF879	-0.35	-5.74	-0.3	2.13e-8	Pubertal anthropometrics;
CRC	cis	rs995000	0.931	rs10889331	chr1:62943007	G/T	cg19896129	chr1:63156450	NA	-0.39	-6.02	-0.31	4.78e-9	Triglyceride levels;
CRC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg23996704	chr18:44553084	KATNAL2	-0.38	-7.61	-0.39	2.93e-13	Personality dimensions;
CRC	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs9303542	0.559	rs12946931	chr17:46614080	T/C	cg04904318	chr17:46607828	HOXB1	-0.53	-6.17	-0.32	2.02e-9	Ovarian cancer;Epithelial ovarian cancer;
CRC	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.34	5.63	0.3	3.88e-8	Intelligence (multi-trait analysis);
CRC	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.98	-0.55	1.12e-27	Coffee consumption (cups per day);
CRC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.61	-0.3	4.21e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.53	8.87	0.44	4.85e-17	Systemic lupus erythematosus;
CRC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.71	-12.84	-0.58	7e-31	Dental caries;
CRC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.38	5.81	0.3	1.49e-8	Height;
CRC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.68	11.76	0.54	6.81e-27	Hemoglobin concentration;
CRC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.44	0.38	8.98e-13	Colonoscopy-negative controls vs population controls;
CRC	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg19818293	chr12:96429861	LTA4H	-0.44	-6.07	-0.32	3.58e-9	Protein C levels;
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	6.33	0.33	7.89e-10	Lymphocyte counts;
CRC	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.79e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	18.09	0.71	2.94e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg12458913	chr13:53173898	NA	0.59	9.31	0.46	1.87e-18	Lewy body disease;
CRC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.56	8.27	0.41	3.38e-15	Colonoscopy-negative controls vs population controls;
CRC	trans	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.27	-0.33	1.13e-9	Depression;
CRC	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.78	-8.68	-0.43	1.87e-16	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg10876282	chr6:28092338	ZSCAN16	0.5	6.71	0.35	8.65e-11	Parkinson's disease;
CRC	cis	rs12286929	0.679	rs11601041	chr11:115083348	A/G	cg04055981	chr11:115044050	NA	0.38	5.87	0.31	1.04e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg19624444	chr7:2048497	MAD1L1	0.33	5.9	0.31	9.16e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs12044355	0.827	rs16854783	chr1:231827371	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.42	-5.97	-0.31	6.19e-9	Alzheimer's disease;
CRC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg25174290	chr11:3078921	CARS	-0.4	-5.65	-0.3	3.5e-8	Calcium levels;
CRC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.46	-6.06	-0.32	3.68e-9	Total body bone mineral density;
CRC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.35	-0.46	1.43e-18	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	6.96	0.36	1.88e-11	Neutrophil percentage of white cells;
CRC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.4	6.77	0.35	5.79e-11	Total body bone mineral density;
CRC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.33	5.77	0.3	1.85e-8	Emphysema distribution in smoking;
CRC	cis	rs17092148	0.887	rs4911431	chr20:33158318	G/A	cg08999081	chr20:33150536	PIGU	0.51	6.26	0.33	1.19e-9	Neuroticism;
CRC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	7.27	0.37	2.6e-12	Aortic root size;
CRC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.64	11.59	0.54	2.84e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.48	6.72	0.35	8.1e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.61	-0.34	1.59e-10	Acne (severe);
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg02998992	chr17:19265610	B9D1	0.38	6.1	0.32	2.95e-9	Obesity-related traits;
CRC	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.53	-9.25	-0.45	2.86e-18	Lung function (FVC);
CRC	cis	rs62229266	0.659	rs62230814	chr21:37403546	G/A	cg12218747	chr21:37451666	NA	-0.36	-6.16	-0.32	2.16e-9	Mitral valve prolapse;
CRC	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg23815491	chr16:72088622	HP	0.56	6.76	0.35	6.48e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CRC	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg14458575	chr2:238380390	NA	0.68	9.17	0.45	5.27e-18	Prostate cancer;
CRC	trans	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg10756647	chr7:56101905	PSPH	0.74	7.74	0.39	1.23e-13	Diabetic kidney disease;
CRC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.59	-6.24	-0.33	1.33e-9	Schizophrenia;
CRC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.68	10.4	0.5	4.24e-22	Initial pursuit acceleration;
CRC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.85	-0.4	6.11e-14	Intelligence (multi-trait analysis);
CRC	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.74	11.4	0.53	1.38e-25	QRS interval (sulfonylurea treatment interaction);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07919955	chr2:233415416	EIF4E2;TIGD1	0.44	6.26	0.33	1.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs501120	1.000	rs1746048	chr10:44775824	A/G	cg09554077	chr10:44749378	NA	-0.73	-10.85	-0.51	1.23e-23	Coronary artery disease;Coronary heart disease;
CRC	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg21747405	chr11:67723411	NA	-0.49	-6.2	-0.32	1.74e-9	Blood pressure (smoking interaction);
CRC	trans	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06834434	chr14:75079333	LTBP2	0.55	6.91	0.36	2.51e-11	Obesity-related traits;
CRC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	15.71	0.65	6.8e-42	Lymphocyte percentage of white cells;
CRC	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.77	9.45	0.46	6.33e-19	Type 2 diabetes;
CRC	trans	rs66573146	0.901	rs55659111	chr4:7012338	G/T	cg07817883	chr1:32538562	TMEM39B	1.69	12.41	0.56	2.99e-29	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4664293	0.967	rs1006192	chr2:160567589	G/T	cg08347373	chr2:160653686	CD302	-0.44	-7.16	-0.37	5.3e-12	Monocyte percentage of white cells;
CRC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg17294928	chr15:75287854	SCAMP5	0.57	8.72	0.43	1.42e-16	Breast cancer;
CRC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.55	-8.73	-0.43	1.27e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg22800045	chr5:56110881	MAP3K1	-0.54	-5.78	-0.3	1.73e-8	Initial pursuit acceleration;
CRC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.85	11.55	0.54	3.84e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10274279	0.660	rs10278007	chr7:157372906	C/G	cg26886268	chr7:157387156	PTPRN2	-0.43	-5.77	-0.3	1.83e-8	Myopia (pathological);
CRC	cis	rs7692995	1.000	rs6841793	chr4:17933810	C/G	cg08925142	chr4:18023851	LCORL	-0.52	-5.82	-0.31	1.41e-8	Height;
CRC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	7.47	0.38	7.44e-13	Motion sickness;
CRC	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg27205649	chr11:78285834	NARS2	0.47	6.01	0.31	4.93e-9	Alzheimer's disease (survival time);
CRC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.74	-12.24	-0.56	1.22e-28	Lung cancer;
CRC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.38	-7.01	-0.36	1.35e-11	Colorectal cancer;
CRC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.59	-9.71	-0.47	9.05e-20	Neuroticism;
CRC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.9	-17.21	-0.69	8.44e-48	Intelligence (multi-trait analysis);
CRC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.4	-6.01	-0.31	4.99e-9	Hemoglobin concentration;
CRC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.54	-0.34	2.29e-10	Breast cancer;
CRC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	trans	rs12438356	0.686	rs8043162	chr15:69487209	G/A	cg26416341	chr12:54718712	COPZ1	0.65	6.0	0.31	5.07e-9	CTACK levels;
CRC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg17321639	chr7:2759063	NA	-0.38	-5.8	-0.3	1.57e-8	Height;
CRC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.86	16.42	0.67	1.1e-44	Dental caries;
CRC	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.7	8.78	0.44	9.05e-17	Type 2 diabetes;
CRC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.72	-9.87	-0.48	2.67e-20	Venous thromboembolism (SNP x SNP interaction);
CRC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.54	7.74	0.39	1.19e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg02725872	chr8:58115012	NA	-0.32	-5.79	-0.3	1.61e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-10.37	-0.5	5.31e-22	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20921688	chr2:71357800	MCEE;MPHOSPH10	0.45	6.32	0.33	8.66e-10	Response to antipsychotic treatment;
CRC	cis	rs6840360	0.642	rs2709818	chr4:152382634	A/G	cg09659197	chr4:152720779	NA	0.33	6.57	0.34	1.94e-10	Intelligence (multi-trait analysis);
CRC	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.54	-8.29	-0.42	2.93e-15	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.83	-0.35	4.24e-11	Asthma;
CRC	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.48	6.18	0.32	1.91e-9	Tuberculosis;
CRC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-6.45	-0.33	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.53	-9.3	-0.46	2.09e-18	Sense of smell;
CRC	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg18099408	chr3:52552593	STAB1	-0.49	-8.38	-0.42	1.51e-15	Electroencephalogram traits;
CRC	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.43	-0.33	4.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg03469862	chr11:68924853	NA	0.47	6.03	0.32	4.33e-9	Blond vs. brown hair color;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg15538837	chr1:226250361	H3F3A;LOC440926	0.48	6.18	0.32	1.85e-9	Thyroid stimulating hormone;
CRC	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.77	8.79	0.44	8.57e-17	Gut microbiota (bacterial taxa);
CRC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.33	-6.08	-0.32	3.4e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-5.94	-0.31	7.35e-9	Total body bone mineral density;
CRC	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.63	7.63	0.39	2.56e-13	Intelligence (multi-trait analysis);
CRC	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.72	11.02	0.52	2.98e-24	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.55	8.26	0.41	3.59e-15	Blood protein levels;
CRC	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg19025524	chr12:109796872	NA	-0.47	-6.77	-0.35	5.8e-11	Neuroticism;
CRC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.54	-9.67	-0.47	1.21e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.28	-0.56	8.67e-29	Alzheimer's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16293249	chr2:112812957	TMEM87B	0.4	6.17	0.32	2.05e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22834172	chr17:37774349	NA	0.42	6.12	0.32	2.73e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.69	-12.33	-0.56	5.45e-29	Iron status biomarkers;
CRC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.67	-0.3	3.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg21037378	chr4:142142045	ZNF330	-0.5	-6.08	-0.32	3.29e-9	Hirschsprung disease;
CRC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg15147215	chr3:52552868	STAB1	-0.61	-10.01	-0.48	9.16e-21	Bipolar disorder;
CRC	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.09	0.36	8.48e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg23283495	chr1:209979779	IRF6	0.48	6.83	0.35	4.21e-11	Cleft lip with or without cleft palate;
CRC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-20.6	-0.75	3.83e-61	Hemostatic factors and hematological phenotypes;
CRC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg07507251	chr3:52567010	NT5DC2	-0.39	-5.75	-0.3	2.09e-8	Electroencephalogram traits;
CRC	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg01339444	chr6:118972232	C6orf204	0.53	6.06	0.32	3.76e-9	Diastolic blood pressure;
CRC	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.58	8.15	0.41	7.89e-15	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg16606324	chr3:10149918	C3orf24	0.66	7.74	0.39	1.19e-13	Alzheimer's disease;
CRC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg02569458	chr12:86230093	RASSF9	0.45	7.66	0.39	2.16e-13	Major depressive disorder;
CRC	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg13385794	chr1:248469461	NA	-0.39	-6.87	-0.35	3.28e-11	Common traits (Other);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17998333	chr10:121356721	TIAL1	0.44	6.11	0.32	2.79e-9	Response to antipsychotic treatment;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00727112	chr4:159690372	FNIP2	0.47	6.45	0.34	4.02e-10	Response to antipsychotic treatment;
CRC	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.77	8.7	0.43	1.65e-16	Neuroticism;
CRC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	9.66	0.47	1.3e-19	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg15786705	chr6:28176104	NA	0.6	6.19	0.32	1.78e-9	Depression;
CRC	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg13919466	chr1:32135498	COL16A1	-0.31	-5.81	-0.31	1.44e-8	Intelligence (multi-trait analysis);
CRC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.74	-0.39	1.27e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.47	-6.54	-0.34	2.3e-10	Platelet distribution width;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	5.91	0.31	8.43e-9	Prudent dietary pattern;
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	11.06	0.52	2.24e-24	Prudent dietary pattern;
CRC	cis	rs317865	0.867	rs7668729	chr4:16180391	A/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	-0.55	-5.81	-0.31	1.46e-8	Kidney disease (early stage) in type 1 diabetes;
CRC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	14.41	0.62	7.61e-37	Chronic sinus infection;
CRC	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.95	-12.53	-0.57	1.06e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.6	10.52	0.5	1.71e-22	Schizophrenia;
CRC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.7	-0.3	2.66e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20135002	chr11:47629003	NA	0.35	5.73	0.3	2.29e-8	Subjective well-being;
CRC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	10.6	0.5	8.86e-23	Alzheimer's disease;
CRC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-8.9	-0.44	3.71e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.42	9.26	0.45	2.8e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg26116260	chr4:7069785	GRPEL1	-0.6	-5.77	-0.3	1.79e-8	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4964805	0.657	rs11111781	chr12:104187440	C/T	cg02344784	chr12:104178138	NT5DC3	0.78	15.04	0.64	2.92e-39	Attention deficit hyperactivity disorder;
CRC	trans	rs11671005	0.610	rs2305122	chr19:59056752	G/C	cg22037779	chr5:139682734	PFDN1	-0.53	-6.18	-0.32	1.9e-9	Mean platelet volume;
CRC	cis	rs11098699	0.821	rs11735364	chr4:124185679	T/C	cg09941581	chr4:124220074	SPATA5	0.4	5.74	0.3	2.12e-8	Mosquito bite size;
CRC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-0.61	-8.58	-0.43	3.85e-16	Mean platelet volume;Platelet distribution width;
CRC	cis	rs972578	1.000	rs3819677	chr22:43386691	C/G	cg01576275	chr22:43409880	NA	-0.48	-7.69	-0.39	1.68e-13	Mean platelet volume;
CRC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg18404041	chr3:52824283	ITIH1	-0.41	-7.6	-0.39	3.03e-13	Schizophrenia;
CRC	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg02820901	chr13:113351484	ATP11A	-0.64	-6.85	-0.35	3.65e-11	Glycated hemoglobin levels;
CRC	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg16589663	chr20:23618590	CST3	0.57	7.36	0.38	1.51e-12	Chronic kidney disease;
CRC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg22155724	chr5:176794405	RGS14	0.41	5.78	0.3	1.7e-8	Hemoglobin concentration;Hematocrit;
CRC	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg00738113	chr16:70207722	CLEC18C	-0.43	-6.51	-0.34	2.73e-10	IgE levels;
CRC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.42	6.56	0.34	2.14e-10	Monocyte count;
CRC	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-10.47	-0.5	2.42e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.16	-10.54	-0.5	1.45e-22	Alzheimer's disease (late onset);
CRC	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-7.18	-0.37	4.55e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.76	0.39	1.08e-13	Lung cancer;
CRC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.41	-7.04	-0.36	1.11e-11	Height;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18022193	chr19:913536	C19orf22	0.42	6.32	0.33	8.53e-10	Schizophrenia;
CRC	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.65	0.63	9.3e-38	Colorectal cancer;
CRC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.92	-0.4	3.69e-14	Bipolar disorder and schizophrenia;
CRC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.54	8.8	0.44	7.77e-17	Coronary artery disease;
CRC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg02683197	chr6:28174875	NA	0.63	8.57	0.43	4.06e-16	Parkinson's disease;
CRC	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg10263370	chr3:44754102	ZNF502	-0.36	-6.1	-0.32	2.98e-9	Depressive symptoms;
CRC	cis	rs1681630	0.848	rs1631174	chr11:47974373	A/C	cg05585544	chr11:47624801	NA	-0.42	-7.02	-0.36	1.25e-11	Height;
CRC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.34	1.51e-10	Lung cancer;
CRC	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.57	0.5	1.1e-22	Coffee consumption (cups per day);
CRC	cis	rs892085	0.681	rs10417071	chr19:10872431	G/T	cg17710535	chr19:10819994	QTRT1	0.38	5.8	0.3	1.59e-8	Psoriasis vulgaris;Psoriasis;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg21251018	chr6:28226885	NKAPL	0.47	6.16	0.32	2.07e-9	Depression;
CRC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.54	-8.24	-0.41	4.05e-15	Height;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09430391	chr4:46392972	GABRA2	0.41	6.3	0.33	9.67e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.56	-7.65	-0.39	2.21e-13	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.69	10.07	0.49	5.76e-21	Menopause (age at onset);
CRC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.56	7.61	0.39	3e-13	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg20607287	chr7:12443886	VWDE	-0.56	-6.15	-0.32	2.21e-9	Coronary artery disease;
CRC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.3	-0.33	9.32e-10	Aortic root size;
CRC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg06987292	chr12:125626746	AACS	-0.35	-6.02	-0.32	4.54e-9	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	14.69	0.63	6.23e-38	Lymphocyte percentage of white cells;
CRC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.71	12.56	0.57	7.87e-30	Dental caries;
CRC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-7.21	-0.37	3.83e-12	Neuroticism;
CRC	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.66	-10.83	-0.51	1.36e-23	Neuroblastoma (high-risk);
CRC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	16.03	0.66	3.87e-43	Platelet count;
CRC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02359409	chr6:42947317	PEX6	-0.7	-11.85	-0.55	3.11e-27	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.8	-0.3	1.58e-8	Total cholesterol levels;
CRC	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.49	6.91	0.36	2.51e-11	Tuberculosis;
CRC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.65	0.34	1.26e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.7	-0.43	1.67e-16	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02081364	chr1:247267551	ZNF669	0.44	6.09	0.32	3.09e-9	Response to antipsychotic treatment;
CRC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg16558208	chr1:156270281	VHLL	0.58	9.08	0.45	1.03e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs9467160	0.817	rs12194966	chr6:24437611	G/A	cg20631270	chr6:24437470	GPLD1	0.52	5.88	0.31	9.88e-9	Liver enzyme levels;
CRC	cis	rs1405069	0.809	rs1046279	chr6:36932571	C/T	cg26433444	chr6:36932349	PI16	-0.37	-6.68	-0.35	1.03e-10	Chemerin levels;
CRC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.64	9.16	0.45	5.63e-18	Multiple sclerosis;
CRC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg15691649	chr6:25882328	NA	-0.43	-5.83	-0.31	1.35e-8	Intelligence (multi-trait analysis);
CRC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg02018176	chr4:1364513	KIAA1530	-0.46	-7.6	-0.39	3.18e-13	Obesity-related traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12502759	chr12:99039019	APAF1;IKBIP	0.48	7.18	0.37	4.79e-12	Response to antipsychotic treatment;
CRC	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	9.59	0.47	2.26e-19	Type 2 diabetes;
CRC	cis	rs4664293	0.667	rs3815876	chr2:160640151	A/G	cg08347373	chr2:160653686	CD302	-0.5	-8.61	-0.43	3.16e-16	Monocyte percentage of white cells;
CRC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg25243455	chr2:114033360	PAX8;LOC440839	-0.31	-7.28	-0.37	2.45e-12	Lymphocyte counts;
CRC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Parkinson's disease;
CRC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	11.18	0.52	8.06e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2072510	0.569	rs7134975	chr12:96390420	C/A	cg22491680	chr12:96389547	HAL	-0.5	-6.16	-0.32	2.16e-9	Metabolite levels (small molecules and protein measures);
CRC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-7.31	-0.37	2.07e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg24505167	chr7:1915268	MAD1L1	-0.4	-5.87	-0.31	1.06e-8	Bipolar disorder;
CRC	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg16989719	chr2:238392110	NA	-0.44	-8.0	-0.4	2.11e-14	Prostate cancer;
CRC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.54	0.38	4.7e-13	Schizophrenia;
CRC	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg01843034	chr6:37503916	NA	-0.33	-5.86	-0.31	1.14e-8	Cognitive performance;
CRC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg20387954	chr3:183756860	HTR3D	0.44	7.55	0.38	4.43e-13	Anterior chamber depth;
CRC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.53	-7.7	-0.39	1.61e-13	Menarche (age at onset);
CRC	cis	rs2882667	0.690	rs7446631	chr5:138227065	A/G	cg09476006	chr5:138032270	NA	0.56	10.02	0.48	8.34e-21	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg14191688	chr11:70257035	CTTN	0.57	7.86	0.4	5.55e-14	Coronary artery disease;
CRC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.51	7.79	0.39	8.79e-14	Corneal astigmatism;
CRC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.5	7.85	0.4	5.94e-14	Red blood cell count;
CRC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg14671364	chr1:107599128	PRMT6	0.49	6.56	0.34	2.11e-10	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.39	6.06	0.32	3.69e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10352719	chr14:24769404	DHRS1;C14orf21	0.45	6.41	0.33	5.01e-10	Response to antipsychotic treatment;
CRC	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.09	-0.45	9.54e-18	Bone mineral density;
CRC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.38	-8.86	-0.44	5.01e-17	Mean corpuscular volume;
CRC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18912574	chr7:65842487	NCRNA00174	0.36	6.16	0.32	2.15e-9	Aortic root size;
CRC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg10911889	chr6:126070802	HEY2	0.38	5.7	0.3	2.73e-8	Brugada syndrome;
CRC	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg02702477	chr5:179499311	RNF130	-0.56	-6.48	-0.34	3.35e-10	LDL cholesterol;
CRC	cis	rs1971762	0.527	rs7972401	chr12:53940046	T/C	cg06632207	chr12:54070931	ATP5G2	0.45	7.64	0.39	2.44e-13	Height;
CRC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.84	-10.92	-0.52	6.54e-24	Initial pursuit acceleration;
CRC	cis	rs17767392	0.881	rs35054229	chr14:71785202	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.55	-6.95	-0.36	1.99e-11	Mitral valve prolapse;
CRC	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.59	-8.95	-0.44	2.61e-17	Plateletcrit;
CRC	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.55	8.49	0.42	7.11e-16	Corneal astigmatism;
CRC	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg22482690	chr17:47019901	SNF8	0.48	8.06	0.41	1.46e-14	Type 2 diabetes;
CRC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg02659138	chr7:134003124	SLC35B4	0.38	6.51	0.34	2.78e-10	Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02504136	chr16:84698702	NA	0.38	5.96	0.31	6.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.44	-6.56	-0.34	2.1e-10	Height;
CRC	cis	rs911119	0.657	rs2104005	chr20:23630761	G/A	cg16589663	chr20:23618590	CST3	0.6	7.12	0.37	6.91e-12	Chronic kidney disease;
CRC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.49	7.25	0.37	3.04e-12	Obesity-related traits;
CRC	cis	rs4789294	0.806	rs1466003	chr17:74435359	A/G	cg06840243	chr17:74442338	UBE2O	-0.42	-6.06	-0.32	3.79e-9	Lymphocyte percentage of white cells;
CRC	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.57	-10.83	-0.51	1.38e-23	Itch intensity from mosquito bite adjusted by bite size;
CRC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.58	7.98	0.4	2.46e-14	Menopause (age at onset);
CRC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.66	-11.0	-0.52	3.68e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg00071950	chr4:10020882	SLC2A9	0.49	6.41	0.33	5.05e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14895029	chr7:2775587	GNA12	-0.46	-6.69	-0.35	9.46e-11	Height;
CRC	cis	rs427941	0.703	rs1637257	chr7:101740606	T/G	cg06246474	chr7:101738831	CUX1	0.46	7.24	0.37	3.2e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
CRC	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.35	-6.37	-0.33	6.35e-10	Panic disorder;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg16551326	chr19:42759518	ERF	-0.41	-6.13	-0.32	2.49e-9	Daytime sleep phenotypes;
CRC	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.53	8.51	0.42	6.28e-16	Corneal astigmatism;
CRC	cis	rs7113874	0.569	rs7104646	chr11:8558841	G/T	cg02811074	chr11:8615871	STK33	-0.36	-6.06	-0.32	3.69e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.96	-0.31	6.63e-9	Reticulocyte count;
CRC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs9891119	0.602	rs3785898	chr17:40515120	G/T	cg06270615	chr17:40516068	STAT3	-0.34	-7.41	-0.38	1.07e-12	Multiple sclerosis;Crohn's disease;
CRC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.1	-0.36	7.92e-12	Bipolar disorder;
CRC	cis	rs12024301	0.557	rs11802816	chr1:183654689	T/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-7.29	-0.37	2.4e-12	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.79	6.08	0.32	3.39e-9	Obesity (early onset extreme);
CRC	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg15654264	chr1:150340011	RPRD2	0.37	5.81	0.31	1.46e-8	Migraine;
CRC	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.56	10.99	0.52	4e-24	Weight;
CRC	cis	rs995000	0.965	rs10889338	chr1:62984897	C/T	cg19896129	chr1:63156450	NA	0.41	5.96	0.31	6.34e-9	Triglyceride levels;
CRC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg18478394	chr8:109455254	TTC35	0.38	5.89	0.31	9.79e-9	Dupuytren's disease;
CRC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.72	0.35	8.21e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.38	-6.75	-0.35	6.73e-11	Reticulocyte fraction of red cells;
CRC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-15.24	-0.64	4.66e-40	Lymphocyte percentage of white cells;
CRC	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg26762873	chr11:5879799	OR52E8	0.39	5.82	0.31	1.39e-8	DNA methylation (variation);
CRC	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.53	-6.5	-0.34	2.9e-10	Body mass index;
CRC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22133161	chr19:49891603	CCDC155	0.5	6.92	0.36	2.42e-11	Multiple sclerosis;
CRC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.19	-13.16	-0.59	4.5e-32	Diabetic kidney disease;
CRC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg02880119	chr16:3481970	NA	0.42	5.93	0.31	7.75e-9	Body mass index (adult);
CRC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg15845792	chr6:28175446	NA	0.96	13.94	0.61	5.17e-35	Parkinson's disease;
CRC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.63	7.67	0.39	2e-13	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-8.61	-0.43	3.02e-16	Bipolar disorder;
CRC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.7	-10.54	-0.5	1.4e-22	Initial pursuit acceleration;
CRC	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg22448308	chr15:81293687	MESDC1	0.51	7.05	0.36	1.07e-11	Anxiety disorder;
CRC	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.72	9.24	0.45	3.07e-18	Iron status biomarkers;
CRC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.58	9.12	0.45	7.38e-18	Body mass index;
CRC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	9.96	0.48	1.39e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.18	-17.14	-0.69	1.57e-47	Hip circumference adjusted for BMI;
CRC	cis	rs4926298	1.000	rs8104231	chr19:13159569	A/T	cg11738485	chr19:12877000	HOOK2	-0.42	-5.83	-0.31	1.33e-8	Bipolar disorder;
CRC	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg12046867	chr14:103022105	NA	-0.83	-11.84	-0.55	3.52e-27	Platelet count;
CRC	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg12870014	chr12:110450643	ANKRD13A	0.85	10.3	0.49	9.63e-22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg14979609	chr8:8086686	FLJ10661	0.38	6.05	0.32	3.87e-9	Joint mobility (Beighton score);
CRC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg23229984	chr5:148520753	ABLIM3	0.5	6.95	0.36	1.96e-11	Breast cancer;
CRC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.65	9.92	0.48	1.82e-20	Tuberculosis;
CRC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.74	-11.78	-0.54	5.9e-27	Menopause (age at onset);
CRC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.72	-0.35	8.23e-11	Menopause (age at onset);
CRC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.01	-0.31	4.86e-9	Gut microbiome composition (summer);
CRC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.63	-0.47	1.71e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg06713675	chr4:122721982	EXOSC9	-0.38	-6.25	-0.33	1.26e-9	Type 2 diabetes;
CRC	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.54	7.49	0.38	6.25e-13	Schizophrenia (inflammation and infection response interaction);
CRC	trans	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	5.95e-12	Ulcerative colitis;
CRC	cis	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg04523069	chr9:97136363	HIATL1	0.36	5.61	0.3	4.33e-8	Colorectal cancer (alcohol consumption interaction);
CRC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.48	6.97	0.36	1.79e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.69	8.83	0.44	6.19e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.44	-6.68	-0.35	1e-10	Intelligence (multi-trait analysis);
CRC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-8.63	-0.43	2.62e-16	Uric acid levels;
CRC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg08314208	chr16:67682810	RLTPR	-0.61	-6.45	-0.34	4e-10	HDL cholesterol;
CRC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg19635926	chr16:89946313	TCF25	0.65	6.09	0.32	3.17e-9	Skin colour saturation;
CRC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.8	14.15	0.62	7.64e-36	Breast cancer;
CRC	trans	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg21153622	chr11:89784906	NA	0.48	7.68	0.39	1.83e-13	HDL cholesterol;
CRC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.14	-0.32	2.4e-9	Bipolar disorder;
CRC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.52	7.47	0.38	7.08e-13	Intelligence (multi-trait analysis);
CRC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.52	7.52	0.38	5.33e-13	Pancreatic cancer;
CRC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg06138825	chr16:67683817	RLTPR	0.55	5.86	0.31	1.15e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.8	-0.3	1.52e-8	Total body bone mineral density;
CRC	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.52	8.9	0.44	3.96e-17	Dupuytren's disease;
CRC	cis	rs12143943	0.934	rs4951406	chr1:204554603	A/G	cg17419461	chr1:204415978	PIK3C2B	0.42	6.35	0.33	7.03e-10	Cognitive performance;
CRC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.47	-8.29	-0.42	2.88e-15	Primary biliary cholangitis;
CRC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg02449762	chr10:5661741	NA	-0.33	-5.8	-0.3	1.54e-8	Breast cancer;
CRC	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.37	-0.33	6.34e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	11.59	0.54	2.72e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.57	8.4	0.42	1.38e-15	Aortic root size;
CRC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg06713675	chr4:122721982	EXOSC9	-0.36	-5.64	-0.3	3.62e-8	Type 2 diabetes;
CRC	cis	rs10392	0.516	rs3752293	chr20:37570725	A/G	cg27552599	chr20:37590471	DHX35	-0.37	-5.63	-0.3	3.88e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CRC	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg23254163	chr1:152506842	NA	0.44	8.67	0.43	2.07e-16	Hair morphology;
CRC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.47	-7.61	-0.39	2.83e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg18404041	chr3:52824283	ITIH1	0.34	6.39	0.33	5.78e-10	Schizophrenia;
CRC	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.53	7.01	0.36	1.32e-11	Alzheimer's disease (survival time);
CRC	cis	rs10046574	0.831	rs10250306	chr7:135165275	G/A	cg27474649	chr7:135195673	CNOT4	0.65	5.8	0.3	1.57e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.52	8.9	0.44	3.92e-17	Aortic root size;
CRC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-13.24	-0.59	2.32e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs290268	0.647	rs1333637	chr9:93557066	C/T	cg02608019	chr9:93564028	SYK	-0.45	-6.81	-0.35	4.66e-11	Platelet count;
CRC	trans	rs17661538	0.685	rs2497809	chr10:18360244	A/G	cg13235825	chr11:107574836	NA	0.49	6.01	0.31	4.99e-9	Response to antipsychotic treatment;
CRC	cis	rs12760731	0.623	rs7530725	chr1:178385456	G/A	cg00404053	chr1:178313656	RASAL2	0.77	9.0	0.44	1.83e-17	Obesity-related traits;
CRC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg16476235	chr8:21771668	DOK2	0.4	7.05	0.36	1.06e-11	Mean corpuscular volume;
CRC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	9.32	0.46	1.68e-18	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.49	6.06	0.32	3.79e-9	Gut microbiome composition (summer);
CRC	cis	rs7692995	1.000	rs2125654	chr4:18025368	A/T	cg08925142	chr4:18023851	LCORL	-0.49	-5.76	-0.3	1.98e-8	Height;
CRC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg19500275	chr17:80737654	TBCD	0.49	6.73	0.35	7.36e-11	Glycated hemoglobin levels;
CRC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg00334542	chr7:100209784	MOSPD3	-0.55	-6.79	-0.35	5.14e-11	Other erythrocyte phenotypes;
CRC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.65	-17.77	-0.7	5.54e-50	Urate levels in overweight individuals;
CRC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.29	0.42	2.98e-15	Vitiligo;
CRC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.63	8.18	0.41	6.06e-15	Gut microbiome composition (summer);
CRC	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg19193384	chr17:30244184	NA	-0.57	-7.05	-0.36	1.09e-11	Hip circumference adjusted for BMI;
CRC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg07074390	chr21:40555500	PSMG1	-0.46	-6.2	-0.32	1.7e-9	Cognitive function;
CRC	cis	rs2742417	0.967	rs2742441	chr3:45748429	G/A	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	7.98e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg26805224	chr10:79626177	DLG5	-0.45	-6.69	-0.35	9.47e-11	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.39e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7731657	0.537	rs4706002	chr5:130373830	C/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.85	-0.31	1.18e-8	Fasting plasma glucose;
CRC	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg11887960	chr12:57824829	NA	-0.58	-6.39	-0.33	5.75e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs9826463	0.582	rs7633870	chr3:142118914	A/G	cg20824294	chr3:142316082	PLS1	0.36	5.9	0.31	9.06e-9	QRS duration in Tripanosoma cruzi seropositivity;
CRC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg23018236	chr17:30244563	NA	-0.58	-7.7	-0.39	1.64e-13	Hip circumference adjusted for BMI;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02359409	chr6:42947317	PEX6	-0.57	-8.96	-0.44	2.41e-17	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg18016565	chr1:150552671	MCL1	0.42	5.88	0.31	1e-8	Melanoma;
CRC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	14.99	0.64	4.31e-39	Platelet count;
CRC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg20684491	chr1:25596433	NA	0.41	7.0	0.36	1.44e-11	Erythrocyte sedimentation rate;
CRC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs6496667	0.779	rs8039719	chr15:90958584	C/G	cg04176472	chr15:90893244	GABARAPL3	0.6	7.72	0.39	1.45e-13	Rheumatoid arthritis;
CRC	cis	rs1179624	0.679	rs4731231	chr7:75264463	A/G	cg05145297	chr7:75264568	HIP1	0.6	8.19	0.41	5.83e-15	Age-related nuclear cataracts;
CRC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.81	-0.31	1.44e-8	Type 2 diabetes;
CRC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.81	-0.44	7.09e-17	Bipolar disorder and schizophrenia;
CRC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.49	6.55	0.34	2.17e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.26e-11	Alzheimer's disease (late onset);
CRC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.49	-8.19	-0.41	5.96e-15	Type 2 diabetes;
CRC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg19682013	chr15:45996608	NA	0.35	7.16	0.37	5.19e-12	Waist circumference;Weight;
CRC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg05139728	chr16:28306816	SBK1	-0.34	-5.82	-0.31	1.4e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.77	0.63	3.19e-38	Exhaled nitric oxide output;
CRC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg13010199	chr12:38710504	ALG10B	0.4	5.74	0.3	2.13e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg07332563	chr6:291687	DUSP22	-0.47	-6.66	-0.34	1.17e-10	Menopause (age at onset);
CRC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg11212589	chr17:38028394	ZPBP2	0.35	6.08	0.32	3.24e-9	Asthma;
CRC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.57	9.46	0.46	6.22e-19	Schizophrenia;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg02021460	chr16:19729639	C16orf88;IQCK	0.46	6.44	0.33	4.12e-10	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg25856811	chr1:152973957	SPRR3	-0.23	-6.44	-0.33	4.29e-10	Inflammatory skin disease;
CRC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.92	18.5	0.71	7.1e-53	Bone mineral density;
CRC	cis	rs7121446	0.521	rs12293988	chr11:121852633	C/T	cg13820391	chr11:121835505	NA	0.31	5.78	0.3	1.72e-8	Cardiovascular risk factors (age interaction);
CRC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.55	-8.81	-0.44	7.52e-17	Huntington's disease progression;
CRC	cis	rs9648716	1.000	rs4140846	chr7:140509716	T/C	cg10747023	chr7:140774559	NA	0.44	5.8	0.3	1.52e-8	Type 2 diabetes;
CRC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg01879757	chr17:41196368	BRCA1	0.43	6.54	0.34	2.36e-10	Menopause (age at onset);
CRC	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.52	8.54	0.43	5.16e-16	Metabolite levels (small molecules and protein measures);
CRC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg01262667	chr19:19385393	TM6SF2	0.36	5.91	0.31	8.43e-9	Tonsillectomy;
CRC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.47	-7.51	-0.38	5.78e-13	Breast cancer;
CRC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.4	-6.22	-0.32	1.5e-9	Total body bone mineral density;
CRC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.59	-10.89	-0.51	8.72e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.26	0.45	2.62e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg07195577	chr17:27052828	TLCD1	0.42	6.08	0.32	3.28e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.64	-9.99	-0.48	1.03e-20	Testicular germ cell tumor;
CRC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.56	-5.86	-0.31	1.13e-8	White matter hyperintensity burden;
CRC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06544989	chr22:39130855	UNC84B	0.47	7.49	0.38	6.43e-13	Menopause (age at onset);
CRC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.59	11.88	0.55	2.57e-27	Asthma (sex interaction);
CRC	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24249390	chr15:90295951	MESP1	-0.58	-9.27	-0.46	2.53e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25471478	chr19:3721572	NA	0.37	6.1	0.32	3.05e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg03689076	chr20:33865952	NA	0.58	7.63	0.39	2.48e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.69	-11.92	-0.55	1.77e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9494145	0.648	rs9373124	chr6:135423209	T/C	cg22676075	chr6:135203613	NA	0.44	5.78	0.3	1.71e-8	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CRC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.84	-14.71	-0.63	5.58e-38	Intelligence (multi-trait analysis);
CRC	cis	rs9649465	1.000	rs6950659	chr7:123361910	C/T	cg03229431	chr7:123269106	ASB15	-0.36	-5.67	-0.3	3.21e-8	Migraine;
CRC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg12193833	chr17:30244370	NA	-0.75	-8.8	-0.44	7.92e-17	Hip circumference adjusted for BMI;
CRC	trans	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	13.51	0.6	2.23e-33	Schizophrenia;
CRC	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.87	-11.17	-0.52	8.7e-25	Hair shape;
CRC	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	cg04338863	chr8:33670619	NA	0.43	6.76	0.35	6.28e-11	Body mass index;
CRC	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06307176	chr5:131281290	NA	0.4	6.0	0.31	5.26e-9	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.82	0.44	6.9e-17	Morning vs. evening chronotype;
CRC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.59	-6.13	-0.32	2.49e-9	White matter hyperintensity burden;
CRC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.15	10.8	0.51	1.85e-23	Skin colour saturation;
CRC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg02135003	chr7:105160482	PUS7	-0.93	-12.36	-0.56	4.2e-29	Bipolar disorder (body mass index interaction);
CRC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.59	9.37	0.46	1.18e-18	Tonsillectomy;
CRC	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.04	-0.32	4.12e-9	Metabolite levels;
CRC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg22532475	chr10:104410764	TRIM8	0.33	5.62	0.3	4e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-0.84	-18.03	-0.71	4.84e-51	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.72	-0.39	1.4e-13	Neuroticism;
CRC	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg26727032	chr16:67993705	SLC12A4	-0.63	-8.64	-0.43	2.43e-16	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	7.74	0.39	1.22e-13	Schizophrenia;
CRC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.76	-12.9	-0.58	4.36e-31	Body mass index;
CRC	cis	rs6921919	0.789	rs1119211	chr6:28309136	C/G	cg15845792	chr6:28175446	NA	-0.44	-5.66	-0.3	3.37e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.45	7.19	0.37	4.42e-12	Menopause (age at onset);
CRC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.71	-8.46	-0.42	8.68e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg06204229	chr3:52865917	ITIH4	-0.47	-5.9	-0.31	9.19e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.97	15.89	0.66	1.42e-42	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg12560992	chr17:57184187	TRIM37	0.49	6.01	0.31	4.93e-9	Vitamin D levels;
CRC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.48	7.42	0.38	1e-12	Corneal astigmatism;
CRC	cis	rs3018066	0.867	rs4307042	chr4:107067830	C/G	cg01869342	chr4:106983673	TBCK	0.37	5.72	0.3	2.43e-8	Cancer;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00056719	chr12:53845867	PCBP2	0.48	6.59	0.34	1.77e-10	Anxiety disorder;
CRC	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	0.63	6.8	0.35	4.92e-11	Prostate cancer;
CRC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg23625390	chr15:77176239	SCAPER	0.47	6.85	0.35	3.61e-11	Blood metabolite levels;
CRC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.65	-10.73	-0.51	3.01e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11212617	0.967	rs228589	chr11:108093208	A/T	cg14761454	chr11:108092087	ATM;NPAT	0.42	6.4	0.33	5.22e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg23100626	chr2:96804247	ASTL	0.27	7.11	0.36	7.42e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	0.9	10.33	0.49	7.81e-22	Type 2 diabetes nephropathy;
CRC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.96	0.36	1.89e-11	Aortic root size;
CRC	cis	rs1364705	1.000	rs1364705	chr8:120224806	C/T	cg27215916	chr8:120218354	NA	0.45	6.3	0.33	9.68e-10	Hippocampal atrophy;
CRC	cis	rs9323205	0.954	rs9672122	chr14:51582391	A/G	cg23942311	chr14:51606299	NA	-0.54	-6.25	-0.33	1.25e-9	Cancer;
CRC	cis	rs16975963	0.843	rs73041004	chr19:38263430	T/C	cg15135657	chr19:38346511	NA	-0.44	-5.9	-0.31	9.09e-9	Longevity;
CRC	cis	rs6496044	0.963	rs11853972	chr15:86062440	A/G	cg17133734	chr15:86042851	AKAP13	0.4	6.12	0.32	2.65e-9	Interstitial lung disease;
CRC	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	15.25	0.64	4.49e-40	Bipolar disorder;
CRC	cis	rs73206853	0.764	rs73206878	chr12:110835015	A/C	cg12870014	chr12:110450643	ANKRD13A	0.8	7.66	0.39	2.05e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg15445000	chr17:37608096	MED1	0.37	6.39	0.33	5.68e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg15147215	chr3:52552868	STAB1	-0.63	-10.52	-0.5	1.72e-22	Bipolar disorder;
CRC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.7	0.43	1.61e-16	Morning vs. evening chronotype;
CRC	cis	rs9549328	0.670	rs2993344	chr13:113617022	C/T	cg24588162	chr13:113633484	MCF2L	0.36	6.56	0.34	2.08e-10	Systolic blood pressure;
CRC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-7.41	-0.38	1.09e-12	Chronic sinus infection;
CRC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.54	-6.22	-0.32	1.51e-9	Lymphocyte counts;
CRC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg06287003	chr12:125626642	AACS	-0.52	-7.43	-0.38	9.35e-13	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg04518342	chr5:131593106	PDLIM4	0.39	7.54	0.38	4.68e-13	Blood metabolite levels;
CRC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.31	-6.36	-0.33	6.79e-10	Renal cell carcinoma;
CRC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.91	-17.93	-0.7	1.21e-50	Obesity-related traits;
CRC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg14711859	chr11:8959438	ASCL3	-0.49	-8.11	-0.41	1.05e-14	Hemoglobin concentration;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.89	20.92	0.76	2.13e-62	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg20354231	chr13:53171401	NA	-0.43	-6.87	-0.35	3.22e-11	Lewy body disease;
CRC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.15	0.71	1.71e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-9.28	-0.46	2.4e-18	Lymphocyte counts;
CRC	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg11645453	chr3:52864694	ITIH4	-0.4	-7.43	-0.38	9.61e-13	Body mass index;
CRC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg02880119	chr16:3481970	NA	-0.43	-6.05	-0.32	4e-9	Body mass index (adult);
CRC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.7	7.87	0.4	5.11e-14	Diabetic retinopathy;
CRC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg21724239	chr8:58056113	NA	0.58	7.75	0.39	1.17e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.6	0.34	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg10761708	chr20:43804764	PI3	0.5	5.68	0.3	2.93e-8	Blood protein levels;
CRC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.52	-6.84	-0.35	3.98e-11	Menarche (age at onset);
CRC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.84	-11.22	-0.53	5.99e-25	Type 2 diabetes;
CRC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg24011408	chr12:48396354	COL2A1	0.47	6.36	0.33	6.59e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	cis	rs7605827	0.930	rs6719652	chr2:15571679	T/G	cg19274914	chr2:15703543	NA	0.37	5.67	0.3	3.19e-8	Educational attainment (years of education);
CRC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-8.19	-0.41	5.93e-15	Axial length;
CRC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.13	0.52	1.19e-24	Prudent dietary pattern;
CRC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.0	0.4	2.21e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.83	0.55	3.79e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.64	10.87	0.51	1.02e-23	Prostate cancer;
CRC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	10.9	0.51	8.26e-24	Motion sickness;
CRC	cis	rs2811415	0.597	rs9845369	chr3:127743443	G/C	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.1e-8	Lung function (FEV1/FVC);
CRC	cis	rs13144136	0.687	rs11726388	chr4:10660245	G/A	cg10242279	chr4:10666415	CLNK	-0.36	-6.21	-0.32	1.58e-9	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.67	9.45	0.46	6.71e-19	Lung cancer;
CRC	trans	rs6550704	0.687	rs9865314	chr3:22634337	A/G	cg14489649	chr17:40021376	KLHL11	-0.46	-6.81	-0.35	4.61e-11	Daytime sleep phenotypes;
CRC	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.44	7.51	0.38	5.6e-13	HDL cholesterol;
CRC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg21251018	chr6:28226885	NKAPL	0.45	6.62	0.34	1.43e-10	Parkinson's disease;
CRC	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02228675	chr17:40259724	DHX58	-0.49	-6.91	-0.36	2.6e-11	Fibrinogen levels;
CRC	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg17885191	chr8:135476712	NA	0.53	7.47	0.38	7.13e-13	Hypertension (SNP x SNP interaction);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22812733	chr3:58571389	NA	0.44	5.99	0.31	5.48e-9	Survival in pancreatic cancer;
CRC	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg21601837	chr3:125900065	ALDH1L1	-0.36	-5.97	-0.31	6.03e-9	Metabolite levels;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25940730	chr4:16228647	TAPT1;FLJ39653	0.47	6.15	0.32	2.29e-9	Hip circumference;
CRC	cis	rs3762318	1.000	rs12069782	chr1:67600101	C/T	cg17031739	chr1:67600172	NA	0.48	6.0	0.31	5.13e-9	Leprosy;
CRC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-6.94	-0.36	2.12e-11	IgG glycosylation;
CRC	trans	rs2172802	0.638	rs7675385	chr4:62502229	A/G	cg25787300	chr7:101599518	CUX1	-0.43	-5.98	-0.31	5.92e-9	Partial epilepsies;
CRC	trans	rs8123881	0.733	rs7268466	chr20:15810676	C/T	cg03674076	chr20:524243	CSNK2A1	0.55	6.16	0.32	2.11e-9	Body mass index;
CRC	cis	rs17401966	0.540	rs6541084	chr1:10285447	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-7.46	-0.38	7.55e-13	Hepatocellular carcinoma;
CRC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg06207120	chr15:45996521	NA	0.32	7.85	0.4	6.04e-14	Waist circumference;Weight;
CRC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.11	-0.32	2.74e-9	Arsenic metabolism;
CRC	cis	rs883565	0.655	rs4676628	chr3:39095965	G/A	cg01426195	chr3:39028469	NA	-0.54	-8.77	-0.44	9.85e-17	Handedness;
CRC	cis	rs73200209	0.912	rs55841728	chr12:116645455	C/A	cg01776926	chr12:116560359	MED13L	-0.48	-5.81	-0.31	1.48e-8	Total body bone mineral density;
CRC	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-0.98	-10.81	-0.51	1.68e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.47	7.15	0.37	5.64e-12	Colorectal cancer;
CRC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.39	5.89	0.31	9.46e-9	Pulse pressure;
CRC	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg27398640	chr15:77910606	LINGO1	-0.4	-6.71	-0.35	8.58e-11	Type 2 diabetes;
CRC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.71	0.51	3.81e-23	Prudent dietary pattern;
CRC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg03383789	chr16:5148781	FAM86A	-0.36	-5.98	-0.31	5.92e-9	Brain structure;
CRC	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg24304309	chr1:154577895	ADAR	0.34	5.6	0.3	4.5e-8	Blood protein levels;
CRC	trans	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg02674126	chr19:40336878	FBL	0.39	6.22	0.32	1.47e-9	Hyperactive-impulsive symptoms;
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg12273811	chr6:28175739	NA	0.68	5.65	0.3	3.46e-8	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.76	13.19	0.59	3.51e-32	Extrinsic epigenetic age acceleration;
CRC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.94	0.36	2.08e-11	Mean platelet volume;
CRC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.72	-11.63	-0.54	2.05e-26	Lung cancer;
CRC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.78	-0.35	5.54e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17554472	chr22:41940697	POLR3H	-0.54	-5.88	-0.31	1.02e-8	Vitiligo;
CRC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.93	17.49	0.69	6.56e-49	Height;
CRC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg24851651	chr11:66362959	CCS	-0.34	-5.64	-0.3	3.69e-8	Educational attainment (years of education);
CRC	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.37	-6.4	-0.33	5.36e-10	Sitting height ratio;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.45	6.37	0.33	6.4e-10	Longevity;Endometriosis;
CRC	cis	rs9491140	0.539	rs980657	chr6:124690330	C/T	cg19267163	chr6:125004984	NKAIN2	0.42	5.71	0.3	2.51e-8	Neuroticism;
CRC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.65	-11.79	-0.54	5.53e-27	Breast cancer;
CRC	cis	rs9292777	0.748	rs12519453	chr5:40387173	G/A	cg09067459	chr5:40385259	NA	-0.56	-9.28	-0.46	2.31e-18	Crohn's disease;Multiple sclerosis;
CRC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg21138405	chr5:131827807	IRF1	-0.36	-6.26	-0.33	1.21e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.65	7.79	0.39	9.06e-14	Lymphocyte counts;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00004055	chr16:66586745	CKLF	0.5	7.21	0.37	3.79e-12	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg16606324	chr3:10149918	C3orf24	0.69	9.7	0.47	1.02e-19	Alzheimer's disease;
CRC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.9	0.55	2.04e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.25	0.45	2.98e-18	Bladder cancer;
CRC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg15468180	chr1:107600409	PRMT6	0.36	5.75	0.3	2.09e-8	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs354225	0.626	rs6740893	chr2:54834380	G/A	cg26097391	chr2:54893211	SPTBN1	0.4	5.85	0.31	1.19e-8	Schizophrenia;
CRC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg15445000	chr17:37608096	MED1	-0.36	-6.14	-0.32	2.38e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.74	10.83	0.51	1.37e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.43	-6.24	-0.33	1.33e-9	Body mass index;
CRC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.58	-7.78	-0.39	9.72e-14	Colorectal cancer;
CRC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg00745463	chr17:30367425	LRRC37B	0.59	7.61	0.39	2.84e-13	Hip circumference adjusted for BMI;
CRC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg20673091	chr1:2541236	MMEL1	0.36	5.8	0.3	1.52e-8	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs9786986	0.665	rs1874129	chr1:235700023	T/G	cg08848088	chr1:235714526	GNG4	0.52	6.01	0.31	4.88e-9	Body mass index;
CRC	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.44	7.68	0.39	1.81e-13	HDL cholesterol;
CRC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.43	-8.13	-0.41	8.92e-15	Childhood ear infection;
CRC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.55	-0.43	4.67e-16	Initial pursuit acceleration;
CRC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.53	8.05	0.41	1.53e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.77	13.64	0.6	6.76e-34	Oral cavity cancer;
CRC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12273811	chr6:28175739	NA	0.75	10.72	0.51	3.32e-23	Depression;
CRC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.04	-24.66	-0.81	9.1e-77	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.57	0.5	1.14e-22	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.47	-5.86	-0.31	1.14e-8	Gut microbiome composition (summer);
CRC	cis	rs2811415	0.561	rs9839328	chr3:127763216	T/C	cg13719885	chr3:127795394	NA	-0.36	-5.62	-0.3	4.1e-8	Lung function (FEV1/FVC);
CRC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg15790184	chr11:494944	RNH1	0.62	6.91	0.36	2.5e-11	Body mass index;
CRC	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.73	10.49	0.5	2.15e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.8	-0.3	1.56e-8	Coronary artery disease;
CRC	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.88	-0.31	1.02e-8	Pulmonary function;
CRC	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg05540913	chr6:167530185	CCR6	-0.41	-7.43	-0.38	9.65e-13	Primary biliary cholangitis;
CRC	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.46	6.58	0.34	1.84e-10	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.58	6.39	0.33	5.62e-10	Initial pursuit acceleration;
CRC	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	13.97	0.61	3.82e-35	Ulcerative colitis;
CRC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg06882758	chr19:58662330	ZNF329	0.77	8.08	0.41	1.24e-14	Cholesterol, total;
CRC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg10911889	chr6:126070802	HEY2	0.39	5.92	0.31	7.99e-9	Brugada syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21463023	chr3:42623862	SEC22C	0.43	6.1	0.32	3.06e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.56	-0.38	4.18e-13	Bladder cancer;
CRC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.75	-10.49	-0.5	2.1e-22	Blood metabolite levels;
CRC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.65	-11.35	-0.53	2.06e-25	Prostate cancer;
CRC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-6.4	-0.33	5.34e-10	Diabetic retinopathy;
CRC	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg17524180	chr13:113633600	MCF2L	-0.61	-11.14	-0.52	1.15e-24	Systolic blood pressure;
CRC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.63	12.1	0.55	3.9e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg25538649	chr17:74734108	MIR636;SFRS2;MFSD11	0.44	6.03	0.32	4.36e-9	Anxiety disorder;
CRC	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.45	-6.5	-0.34	2.94e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs62458065	1.000	rs979355	chr7:32463933	A/G	cg20159608	chr7:32802032	NA	0.51	6.6	0.34	1.61e-10	Metabolite levels (HVA/MHPG ratio);
CRC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-6.32	-0.33	8.49e-10	Blood metabolite levels;
CRC	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg05925327	chr15:68127851	NA	-0.31	-6.01	-0.31	4.84e-9	Restless legs syndrome;
CRC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.6	10.25	0.49	1.36e-21	Resting heart rate;
CRC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.11	0.36	7.49e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.81	-0.35	4.52e-11	Coronary artery disease;
CRC	cis	rs2811415	0.531	rs9850146	chr3:127744122	G/T	cg13719885	chr3:127795394	NA	-0.37	-5.69	-0.3	2.74e-8	Lung function (FEV1/FVC);
CRC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.29	6.02	0.32	4.55e-9	Homoarginine levels;
CRC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.86	-12.88	-0.58	5.09e-31	Platelet distribution width;
CRC	cis	rs11203032	0.831	rs12570154	chr10:90951027	T/C	cg16672925	chr10:90967113	CH25H	0.45	5.74	0.3	2.17e-8	Heart failure;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.59	-0.34	1.75e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.49	6.53	0.34	2.54e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg17724175	chr1:150552817	MCL1	0.48	7.08	0.36	8.66e-12	Melanoma;
CRC	trans	rs13315871	0.654	rs11711261	chr3:58343696	C/A	cg25250853	chr2:85822726	RNF181	0.53	6.35	0.33	7.16e-10	Cholesterol, total;
CRC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13844804	chr7:814759	HEATR2	-0.56	-5.86	-0.31	1.12e-8	Cerebrospinal P-tau181p levels;
CRC	trans	rs10242455	0.867	rs13362853	chr7:99223147	T/C	cg09045935	chr12:6379348	NA	0.61	6.72	0.35	7.84e-11	Blood metabolite levels;
CRC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.74	0.39	1.26e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg02290350	chr8:58132656	NA	-0.46	-5.84	-0.31	1.24e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg03929089	chr4:120376271	NA	-0.55	-6.99	-0.36	1.52e-11	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.42	6.13	0.32	2.57e-9	Daytime sleep phenotypes;
CRC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg21466736	chr12:48725269	NA	-0.56	-8.32	-0.42	2.36e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27537591	chr10:116697898	TRUB1	0.47	6.82	0.35	4.37e-11	Intelligence (multi-trait analysis);
CRC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg18301423	chr5:131593218	PDLIM4	-0.39	-6.51	-0.34	2.75e-10	Breast cancer;
CRC	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.58	-8.45	-0.42	9.66e-16	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CRC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.59	9.27	0.46	2.54e-18	Height;
CRC	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg14458575	chr2:238380390	NA	0.67	11.52	0.54	5.1e-26	Prostate cancer;
CRC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-9.89	-0.48	2.27e-20	Hip circumference adjusted for BMI;
CRC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.92	18.25	0.71	6.78e-52	Bone mineral density;
CRC	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg09264619	chr17:80180166	NA	-0.48	-6.88	-0.35	3.07e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-6.22	-0.32	1.5e-9	Bipolar disorder;
CRC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg16342193	chr10:102329863	NA	-0.36	-5.99	-0.31	5.62e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	5.15e-15	Morning vs. evening chronotype;
CRC	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-6.84	-0.35	3.97e-11	Metabolite levels;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg06470822	chr6:28175283	NA	1.0	13.33	0.59	1.06e-32	Depression;
CRC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.44	0.33	4.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.24	5.9	0.31	8.81e-9	Coronary artery disease;
CRC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg14711859	chr11:8959438	ASCL3	0.38	6.43	0.33	4.45e-10	Hemoglobin concentration;
CRC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg03037974	chr15:76606532	NA	0.66	11.44	0.53	9.38e-26	Blood metabolite levels;
CRC	cis	rs7703744	0.681	rs73239280	chr5:118695579	G/A	cg19893178	chr5:118692011	TNFAIP8	0.45	6.05	0.32	3.86e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26227975	chr3:9773404	BRPF1	0.41	6.11	0.32	2.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.43	6.52	0.34	2.7e-10	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.79	-10.23	-0.49	1.59e-21	Bone mineral density (spine);Bone mineral density;
CRC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.32	2.36e-9	Diabetic kidney disease;
CRC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-7.24	-0.37	3.14e-12	Bipolar disorder;
CRC	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.69	-6.4	-0.33	5.48e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.82	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11003009	chr5:74632112	HMGCR	0.39	6.29	0.33	1.04e-9	Response to antipsychotic treatment;
CRC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.61	-9.2	-0.45	4.17e-18	Schizophrenia;
CRC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18358588	chr6:26660131	ZNF322A	0.42	6.55	0.34	2.23e-10	Interleukin-6 levels;
CRC	trans	rs800082	1.000	rs2575194	chr3:144284871	C/T	cg24215973	chr2:240111563	HDAC4	0.49	6.74	0.35	7.03e-11	Smoking behavior;
CRC	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.77	10.76	0.51	2.39e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CRC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.74	12.1	0.55	3.95e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg12573674	chr2:1569213	NA	-0.77	-8.05	-0.41	1.51e-14	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.06	12.88	0.58	5.3e-31	Type 2 diabetes nephropathy;
CRC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25517755	chr10:38738941	LOC399744	-0.41	-5.95	-0.31	6.82e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.84	12.49	0.57	1.42e-29	Blood metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12847584	chr20:42839925	C20orf111	0.45	6.42	0.33	4.74e-10	Response to antipsychotic treatment;
CRC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.5	8.07	0.41	1.32e-14	Height;
CRC	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.98	-0.31	5.91e-9	Pulmonary function;
CRC	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.53	-7.16	-0.37	5.38e-12	Adiposity;
CRC	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.47	7.66	0.39	2.16e-13	Refractive error;
CRC	cis	rs12580194	0.593	rs61956275	chr12:55786423	G/A	cg23425280	chr12:56401806	NA	0.47	5.71	0.3	2.53e-8	Cancer;
CRC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	6.0	0.31	5.1e-9	Diabetic retinopathy;
CRC	cis	rs863345	0.534	rs10797009	chr1:158446048	T/A	cg12129480	chr1:158549410	OR10X1	-0.29	-6.17	-0.32	1.99e-9	Pneumococcal bacteremia;
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.92	-0.55	1.84e-27	Alzheimer's disease;
CRC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.6	10.05	0.48	6.56e-21	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg22561889	chr6:118971681	C6orf204	0.44	6.05	0.32	3.97e-9	Diastolic blood pressure;
CRC	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg25856811	chr1:152973957	SPRR3	-0.25	-6.82	-0.35	4.51e-11	Inflammatory skin disease;
CRC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.28	0.53	3.5e-25	Prudent dietary pattern;
CRC	cis	rs9462846	0.853	rs34455103	chr6:42875128	C/G	cg21280719	chr6:42927975	GNMT	-0.33	-6.23	-0.32	1.45e-9	Blood protein levels;
CRC	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg07978099	chr16:83986941	OSGIN1	-0.55	-6.66	-0.34	1.14e-10	Pursuit maintenance gain;
CRC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg03623178	chr6:28175578	NA	0.48	6.68	0.35	1.02e-10	Pulmonary function;
CRC	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.55	9.45	0.46	6.51e-19	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg03909863	chr11:638404	DRD4	-0.49	-6.43	-0.33	4.47e-10	Systemic lupus erythematosus;
CRC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg19041857	chr6:27730383	NA	-0.41	-5.99	-0.31	5.45e-9	Parkinson's disease;
CRC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.43	-6.15	-0.32	2.2e-9	Parkinson's disease;
CRC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg19223190	chr17:80058835	NA	-0.39	-6.25	-0.33	1.27e-9	Life satisfaction;
CRC	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.72	-7.85	-0.4	5.9e-14	Obesity-related traits;
CRC	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg16141378	chr3:129829833	LOC729375	0.44	6.61	0.34	1.56e-10	Neuroticism;
CRC	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.61	-8.54	-0.43	5.23e-16	White matter hyperintensity burden;
CRC	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg15654264	chr1:150340011	RPRD2	-0.41	-6.04	-0.32	4.18e-9	Migraine;
CRC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.42	-6.04	-0.32	4.22e-9	Carotid intima media thickness;
CRC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.67	6.98	0.36	1.65e-11	Axial length;
CRC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.7	-0.35	9.04e-11	Major depressive disorder;
CRC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.61	9.67	0.47	1.25e-19	Breast cancer;
CRC	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg27422857	chr2:105853526	NA	-0.32	-6.12	-0.32	2.71e-9	Type 2 diabetes;
CRC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.42	0.33	4.83e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.81	12.23	0.56	1.27e-28	Obesity-related traits;
CRC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg04450456	chr4:17643702	FAM184B	0.38	6.16	0.32	2.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.49	6.33	0.33	7.83e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg18232548	chr7:50535776	DDC	0.44	6.25	0.33	1.24e-9	Malaria;
CRC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.57	-8.0	-0.4	2.17e-14	Pancreatic cancer;
CRC	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg00646200	chr1:148855367	NA	0.35	6.38	0.33	6.17e-10	Hip geometry;
CRC	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.51	6.71	0.35	8.67e-11	Coronary artery disease;
CRC	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	11.27	0.53	3.9e-25	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12703194	chr16:3086867	CCDC64B	0.43	7.43	0.38	9.54e-13	Liver disease severity in Alagille syndrome;
CRC	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg20169779	chr10:135381914	SYCE1	0.65	11.01	0.52	3.24e-24	Obesity-related traits;
CRC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-14.92	-0.64	7.98e-39	Height;
CRC	cis	rs2033908	0.620	rs1992335	chr11:12851717	A/C	cg25843174	chr11:12811716	TEAD1	-0.4	-7.25	-0.37	3.08e-12	Sitting height ratio;
CRC	trans	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.29	0.37	2.25e-12	Endometrial cancer;
CRC	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg10217327	chr6:118973057	C6orf204	0.56	6.16	0.32	2.13e-9	Diastolic blood pressure;
CRC	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.61	10.31	0.49	8.56e-22	Tuberculosis;
CRC	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.46	-0.38	7.88e-13	Menarche (age at onset);
CRC	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg10437265	chr15:77819839	NA	0.42	7.33	0.37	1.74e-12	Type 2 diabetes;
CRC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg02741985	chr17:80059408	CCDC57	0.42	6.93	0.36	2.22e-11	Life satisfaction;
CRC	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.48	-8.19	-0.41	5.87e-15	Endometriosis;
CRC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg24562669	chr7:97807699	LMTK2	0.44	7.27	0.37	2.71e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.84	10.67	0.51	5.09e-23	Triglycerides;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg19027507	chr1:27320128	TRNP1	0.47	6.83	0.35	4.17e-11	Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17265729	chr1:89990859	LRRC8B	0.41	5.97	0.31	6.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg19875535	chr5:140030758	IK	0.42	6.46	0.34	3.66e-10	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.58	-9.74	-0.47	7.53e-20	Tonsillectomy;
CRC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg14673194	chr17:80132900	CCDC57	-0.5	-6.59	-0.34	1.7e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg24046110	chr8:143859143	LYNX1	-0.43	-6.55	-0.34	2.24e-10	Urinary tract infection frequency;
CRC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg03351412	chr1:154909251	PMVK	0.52	7.39	0.38	1.2e-12	Prostate cancer;
CRC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.53	-7.3	-0.37	2.17e-12	DNA methylation (variation);
CRC	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.88	0.35	3.04e-11	Primary sclerosing cholangitis;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg27635394	chr6:26043820	HIST1H2BB	0.46	6.67	0.35	1.09e-10	Intelligence (multi-trait analysis);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26716323	chr7:22862328	TOMM7	0.5	6.7	0.35	9.18e-11	Thyroid stimulating hormone;
CRC	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.68	-12.34	-0.56	5.36e-29	Leprosy;
CRC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.53	-0.38	4.84e-13	Alzheimer's disease;
CRC	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg09003973	chr2:102972529	NA	0.42	5.93	0.31	7.87e-9	Blood protein levels;
CRC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.19	-0.41	5.68e-15	Monocyte percentage of white cells;
CRC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.79	10.17	0.49	2.62e-21	Iron status biomarkers;
CRC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.52	8.14	0.41	8.08e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	5.68	0.3	3.01e-8	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg02683197	chr6:28174875	NA	0.63	8.62	0.43	2.81e-16	Parkinson's disease;
CRC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.84	-0.31	1.27e-8	Heart rate;
CRC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-7.15	-0.37	5.67e-12	Colorectal cancer;
CRC	trans	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.43	0.33	4.46e-10	Ulcerative colitis;
CRC	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.55	-6.56	-0.34	2.05e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs745570	1.000	rs745570	chr17:77781725	A/G	cg04986373	chr17:77768687	CBX8	0.45	6.81	0.35	4.61e-11	Breast cancer;
CRC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg22110888	chr17:80059540	CCDC57	0.38	6.08	0.32	3.31e-9	Life satisfaction;
CRC	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.43	0.33	4.58e-10	Lymphocyte counts;
CRC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.42	-9.13	-0.45	7.21e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg15845792	chr6:28175446	NA	1.04	13.89	0.61	7.67e-35	Parkinson's disease;
CRC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.02	12.48	0.57	1.56e-29	Iron status biomarkers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19318326	chr6:111580704	KIAA1919	0.44	6.22	0.32	1.5e-9	Response to antipsychotic treatment;
CRC	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg24375607	chr4:120327624	NA	0.48	7.25	0.37	3.02e-12	Corneal astigmatism;
CRC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg01483505	chr11:975446	AP2A2	0.43	6.87	0.35	3.3e-11	Alzheimer's disease (late onset);
CRC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg25164649	chr6:28176230	NA	0.67	10.08	0.49	5.35e-21	Cardiac Troponin-T levels;
CRC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.99	-0.31	5.43e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg25164649	chr6:28176230	NA	0.59	8.24	0.41	4.21e-15	Parkinson's disease;
CRC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.88	-14.1	-0.61	1.17e-35	Blood metabolite levels;
CRC	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	0.99	9.16	0.45	5.85e-18	Lymphocyte counts;
CRC	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg09655341	chr17:79618100	PDE6G	0.52	6.06	0.32	3.75e-9	Dental caries;
CRC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.61	-0.43	3.12e-16	Monocyte percentage of white cells;
CRC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.7	11.76	0.54	7.07e-27	Alzheimer's disease (late onset);
CRC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg06470822	chr6:28175283	NA	-1.0	-15.26	-0.64	3.87e-40	Depression;
CRC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26850624	chr5:429559	AHRR	0.52	8.87	0.44	4.87e-17	Cystic fibrosis severity;
CRC	cis	rs7712401	0.791	rs10071135	chr5:122146978	C/G	cg18764291	chr5:122110994	SNX2	0.36	5.79	0.3	1.62e-8	Mean platelet volume;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg15786705	chr6:28176104	NA	-0.54	-7.05	-0.36	1.04e-11	Parkinson's disease;
CRC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	0.99	12.71	0.57	2.26e-30	Triglycerides;
CRC	cis	rs6429082	0.510	rs3806393	chr1:235492546	T/G	cg26050004	chr1:235667680	B3GALNT2	0.39	5.79	0.3	1.64e-8	Adiposity;
CRC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.77	7.63	0.39	2.56e-13	Tuberculosis;
CRC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.42	6.33e-16	Prostate cancer;
CRC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-19.28	-0.73	5.86e-56	Primary sclerosing cholangitis;
CRC	cis	rs294883	0.712	rs9456392	chr6:159733077	C/T	cg14500486	chr6:159655392	FNDC1	-0.36	-6.05	-0.32	3.83e-9	Coronary artery disease;
CRC	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg27171509	chr10:82033454	MAT1A	-0.48	-8.58	-0.43	3.84e-16	Borderline personality disorder;
CRC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg16724585	chr3:197361211	NA	-0.48	-7.1	-0.36	7.62e-12	Pancreatic cancer;
CRC	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.27	-0.71	5.57e-52	Schizophrenia;
CRC	trans	rs12517041	1.000	rs7721619	chr5:23292676	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg16892393	chr17:41919603	NA	0.47	7.08	0.36	8.59e-12	Triglycerides;
CRC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg16342193	chr10:102329863	NA	-0.4	-6.41	-0.33	4.91e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.33	0.37	1.76e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13497285	chr20:8000588	TMX4	-0.51	-5.96	-0.31	6.48e-9	Monocyte percentage of white cells;
CRC	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.8	-0.4	8.25e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.55	-7.58	-0.39	3.6e-13	Lung cancer;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.66	6.94	0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2811415	0.597	rs13063604	chr3:127804730	G/A	cg13719885	chr3:127795394	NA	-0.4	-5.92	-0.31	8.11e-9	Lung function (FEV1/FVC);
CRC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Depression;
CRC	cis	rs2811415	0.597	rs9854763	chr3:127797890	A/G	cg13719885	chr3:127795394	NA	-0.4	-6.02	-0.32	4.57e-9	Lung function (FEV1/FVC);
CRC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.45	9.15	0.45	6.15e-18	Renal cell carcinoma;
CRC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.45	7.53	0.38	5.06e-13	P wave terminal force;
CRC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg10760299	chr15:45669010	GATM	0.5	7.95	0.4	2.96e-14	Homoarginine levels;
CRC	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.58	8.74	0.43	1.19e-16	Lewy body disease;
CRC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	0.92	17.32	0.69	3.13e-48	Height;
CRC	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg22777020	chr22:31556080	RNF185	0.46	5.76	0.3	1.9e-8	Colorectal cancer;
CRC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.47	7.11	0.36	7.28e-12	Aortic root size;
CRC	trans	rs78049276	0.512	rs7659823	chr4:148398877	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-7.38	-0.38	1.31e-12	Pulse pressure;
CRC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg25356066	chr3:128598488	ACAD9	0.39	5.64	0.3	3.6e-8	IgG glycosylation;
CRC	cis	rs3789045	0.560	rs1008833	chr1:204426295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.82	-10.97	-0.52	4.58e-24	Educational attainment (college completion);
CRC	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.8	-0.35	4.91e-11	Schizophrenia;
CRC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.72	-13.08	-0.58	9.12e-32	Prostate cancer;
CRC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.39	6.07	0.32	3.46e-9	Crohn's disease;
CRC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.58	9.15	0.45	6.33e-18	Obesity-related traits;
CRC	cis	rs6681460	0.674	rs7543607	chr1:67012592	G/T	cg02459107	chr1:67143332	SGIP1	0.36	5.87	0.31	1.09e-8	Presence of antiphospholipid antibodies;
CRC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.1	21.46	0.76	1.66e-64	Cognitive function;
CRC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	6.22	0.32	1.51e-9	Height;
CRC	cis	rs12692738	0.526	rs355871	chr2:165632068	A/G	cg03182029	chr2:165697222	COBLL1	0.5	5.86	0.31	1.11e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-7.05	-0.36	1.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg23807890	chr2:228736357	WDR69	-0.51	-7.04	-0.36	1.15e-11	Blood pressure;
CRC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.41	5.67	0.3	3.08e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CRC	trans	rs473976	1.000	rs531438	chr18:40435595	C/T	cg09252331	chr1:15655927	FHAD1	-0.46	-6.28	-0.33	1.07e-9	Gut microbiome composition (summer);
CRC	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg00603274	chr11:61596626	FADS2	0.49	6.88	0.35	3.05e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg14638840	chr8:82644585	CHMP4C	0.42	5.99	0.31	5.62e-9	Thyroid stimulating hormone;
CRC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.83	0.35	4.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.58	-7.55	-0.38	4.42e-13	Obesity;Body mass index;
CRC	cis	rs17401966	0.597	rs3903151	chr1:10260592	A/G	cg19773385	chr1:10388646	KIF1B	-0.55	-8.43	-0.42	1.11e-15	Hepatocellular carcinoma;
CRC	cis	rs4731207	0.698	rs6960683	chr7:124530368	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.32	3.65e-9	Cutaneous malignant melanoma;
CRC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg19622623	chr12:86230825	RASSF9	-0.37	-5.68	-0.3	2.96e-8	Major depressive disorder;
CRC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.63	8.62	0.43	2.84e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.49	7.18	0.37	4.56e-12	Breast cancer;
CRC	cis	rs294883	0.858	rs6900041	chr6:159715226	G/C	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	11.25	0.53	4.69e-25	Tonsillectomy;
CRC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.43	9.47	0.46	5.8e-19	Glomerular filtration rate (creatinine);
CRC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg22495460	chr2:25135724	ADCY3	-0.85	-16.22	-0.67	6.71e-44	Body mass index;
CRC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg09417038	chr21:47716443	C21orf57	-0.42	-6.94	-0.36	2.06e-11	Testicular germ cell tumor;
CRC	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg14191688	chr11:70257035	CTTN	0.4	5.62	0.3	4.07e-8	Coronary artery disease;
CRC	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg10724054	chr17:3904396	NA	0.47	7.59	0.39	3.36e-13	Type 2 diabetes;
CRC	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg13919466	chr1:32135498	COL16A1	-0.31	-5.91	-0.31	8.7e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg17031739	chr1:67600172	NA	-0.4	-6.24	-0.33	1.31e-9	Psoriasis;
CRC	trans	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg21153622	chr11:89784906	NA	-0.49	-7.78	-0.39	9.36e-14	HDL cholesterol;
CRC	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.53	0.46	3.69e-19	Ileal carcinoids;
CRC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03352830	chr11:487213	PTDSS2	0.66	7.13	0.37	6.45e-12	Body mass index;
CRC	cis	rs713587	0.571	rs2917916	chr2:25316336	A/C	cg22495460	chr2:25135724	ADCY3	0.39	5.76	0.3	1.89e-8	Body mass index in non-asthmatics;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.51	-6.9	-0.36	2.64e-11	Intelligence (multi-trait analysis);
CRC	trans	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg17903999	chr18:56338584	MALT1	0.4	6.68	0.35	1.01e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg05304507	chr6:116381966	FRK	0.28	6.37	0.33	6.2e-10	Total cholesterol levels;
CRC	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg11900509	chr10:81946545	ANXA11	-0.54	-5.9	-0.31	9.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.52	-9.95	-0.48	1.5e-20	Height;
CRC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.53	-6.36	-0.33	6.76e-10	Diastolic blood pressure;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04232674	chr1:150601743	ENSA	0.45	6.09	0.32	3.16e-9	Response to antipsychotic treatment;
CRC	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg18646521	chr2:111875858	NA	0.4	6.31	0.33	8.87e-10	Chronic lymphocytic leukemia;
CRC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.04	0.41	1.6e-14	Life satisfaction;
CRC	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.71	8.18	0.41	6.46e-15	Systolic blood pressure;
CRC	cis	rs6840360	0.642	rs2724567	chr4:152351160	C/T	cg09659197	chr4:152720779	NA	-0.33	-6.58	-0.34	1.9e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.64	8.95	0.44	2.68e-17	Vitiligo;
CRC	trans	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-6.41	-0.33	5.04e-10	Menarche (age at onset);
CRC	trans	rs10242455	0.702	rs6956305	chr7:99241310	A/G	cg09045935	chr12:6379348	NA	0.92	6.84	0.35	3.8e-11	Blood metabolite levels;
CRC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg13126279	chr21:47581558	C21orf56	0.4	6.09	0.32	3.1e-9	Testicular germ cell tumor;
CRC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.28	5.91	0.31	8.48e-9	Homoarginine levels;
CRC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg02741985	chr17:80059408	CCDC57	0.45	7.36	0.38	1.51e-12	Life satisfaction;
CRC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.47	-0.34	3.53e-10	Reticulocyte fraction of red cells;
CRC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg18827107	chr12:86230957	RASSF9	-0.38	-6.25	-0.33	1.3e-9	Major depressive disorder;
CRC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg24562669	chr7:97807699	LMTK2	0.42	6.97	0.36	1.78e-11	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1873147	1.000	rs1873147	chr15:63312632	G/A	cg12160578	chr15:63334699	TPM1	-0.4	-5.75	-0.3	2.07e-8	Orofacial clefts;
CRC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21028142	chr17:79581711	NPLOC4	0.35	7.24	0.37	3.17e-12	Eye color traits;
CRC	cis	rs6496667	0.779	rs8034045	chr15:90947899	T/C	cg04176472	chr15:90893244	GABARAPL3	0.61	8.13	0.41	8.79e-15	Rheumatoid arthritis;
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.95	-0.31	7.03e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.48	6.58	0.34	1.81e-10	Multiple sclerosis;
CRC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg21153622	chr11:89784906	NA	-0.37	-6.0	-0.31	5.27e-9	Height;
CRC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.45	6.49	0.34	3.09e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg12564285	chr5:131593104	PDLIM4	0.48	9.3	0.46	2.06e-18	Breast cancer;
CRC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.57	8.65	0.43	2.29e-16	Calcium levels;
CRC	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.63	9.44	0.46	7.13e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.91	0.4	4.03e-14	Mean corpuscular volume;
CRC	cis	rs965469	0.947	rs1854834	chr20:3376619	C/T	cg25506879	chr20:3388711	C20orf194	-0.39	-5.63	-0.3	3.94e-8	IFN-related cytopenia;
CRC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg15445000	chr17:37608096	MED1	-0.35	-5.72	-0.3	2.36e-8	Glomerular filtration rate (creatinine);
CRC	cis	rs6586163	0.843	rs1926199	chr10:90746660	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.5	-7.21	-0.37	3.77e-12	Chronic lymphocytic leukemia;
CRC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.51	7.16	0.37	5.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.4	0.38	1.13e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.6	7.64	0.39	2.4e-13	Body mass index;
CRC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.43	8.96	0.44	2.46e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg24463073	chr6:118973353	C6orf204	0.51	6.68	0.35	1.04e-10	Diastolic blood pressure;
CRC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.09	18.64	0.72	1.93e-53	Cognitive function;
CRC	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.53	7.49	0.38	6.32e-13	Glioblastoma;Glioma;
CRC	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg09760422	chr2:128146352	NA	-0.36	-6.65	-0.34	1.21e-10	Self-rated health;
CRC	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.56	-8.68	-0.43	1.84e-16	Type 2 diabetes;
CRC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.22	0.32	1.47e-9	Bladder cancer;
CRC	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	8.61	0.43	3.13e-16	Initial pursuit acceleration in psychotic disorders;
CRC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.53	9.7	0.47	1.01e-19	Total body bone mineral density;
CRC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.49	8.13	0.41	9.12e-15	Hemoglobin concentration;
CRC	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	1.05	21.76	0.77	1.12e-65	Multiple myeloma;
CRC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs1223397	0.651	rs59639740	chr6:13310895	T/G	cg20827128	chr6:13274284	PHACTR1	0.38	5.81	0.3	1.5e-8	Blood pressure;
CRC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.44	6.54	0.34	2.4e-10	Platelet distribution width;
CRC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-17.71	-0.7	8.85e-50	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	11.3	0.53	2.96e-25	Prudent dietary pattern;
CRC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.55	0.34	2.15e-10	Lung cancer;
CRC	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.78	9.44	0.46	7e-19	Type 2 diabetes;
CRC	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.72	-12.01	-0.55	8.64e-28	Idiopathic membranous nephropathy;
CRC	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg11266682	chr4:10021025	SLC2A9	0.33	5.97	0.31	6.16e-9	Blood metabolite levels;
CRC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.6	0.34	1.68e-10	Bipolar disorder;
CRC	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg15448220	chr1:150897856	SETDB1	-0.5	-6.08	-0.32	3.38e-9	Urate levels;
CRC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg21251018	chr6:28226885	NKAPL	0.42	6.06	0.32	3.81e-9	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06092729	chr12:64845451	TBK1	0.4	6.19	0.32	1.81e-9	Intelligence (multi-trait analysis);
CRC	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg27053337	chr8:124217698	FAM83A	0.42	5.97	0.31	6.24e-9	Urinary uromodulin levels;
CRC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	0.96	7.4	0.38	1.13e-12	Type 2 diabetes nephropathy;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg21715088	chr18:74534568	NA	0.5	6.85	0.35	3.67e-11	Anxiety disorder;
CRC	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.53	7.49	0.38	6.32e-13	Glioblastoma;Glioma;
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-8.06	-0.41	1.4e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.79	13.57	0.6	1.3e-33	Menopause (age at onset);
CRC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg13072238	chr3:49761600	GMPPB	-0.48	-5.68	-0.3	2.89e-8	Menarche (age at onset);
CRC	cis	rs17253792	0.545	rs75276278	chr14:56024341	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.61	-0.34	1.56e-10	Putamen volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg20707008	chr6:160210612	MRPL18;TCP1	0.49	6.44	0.33	4.12e-10	Thyroid stimulating hormone;
CRC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.49	5.78	0.3	1.73e-8	Depression;
CRC	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.76	15.43	0.65	8.47e-41	Mean corpuscular hemoglobin;
CRC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.52	6.98	0.36	1.6e-11	Alzheimer's disease;
CRC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.82	-11.68	-0.54	1.37e-26	Gut microbiome composition (summer);
CRC	cis	rs7692995	1.000	rs12513324	chr4:18006951	C/T	cg08925142	chr4:18023851	LCORL	-0.55	-6.07	-0.32	3.53e-9	Height;
CRC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13198984	chr17:80129470	CCDC57	0.46	8.13	0.41	9e-15	Life satisfaction;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17510133	chr11:17298268	NUCB2	0.46	6.5	0.34	2.99e-10	Anxiety disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22261612	chr11:117187137	BACE1	0.37	6.13	0.32	2.45e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.68	-0.35	1.02e-10	Bipolar disorder;
CRC	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg26248373	chr2:1572462	NA	-0.7	-8.19	-0.41	5.66e-15	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.85	16.15	0.67	1.24e-43	Dental caries;
CRC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02421172	chr7:1938701	MAD1L1	0.42	5.67	0.3	3.12e-8	Bipolar disorder;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg17766062	chr2:75062663	HK2	0.46	6.16	0.32	2.1e-9	Thyroid stimulating hormone;
CRC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.82	-0.44	6.62e-17	Aortic root size;
CRC	cis	rs6741819	0.617	rs4669127	chr2:7160439	G/A	cg27144453	chr2:7172511	RNF144A	-0.56	-7.64	-0.39	2.37e-13	Response to antipsychotic treatment;
CRC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.74	11.35	0.53	2.08e-25	Menarche (age at onset);
CRC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06636001	chr8:8085503	FLJ10661	0.46	5.8	0.3	1.53e-8	Obesity-related traits;
CRC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.4	-7.25	-0.37	2.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.51	-7.16	-0.37	5.15e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.73	0.3	2.27e-8	Total body bone mineral density;
CRC	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg27326032	chr3:127006922	NA	-0.53	-7.67	-0.39	2.02e-13	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg19315081	chr11:10326100	ADM	0.42	6.28	0.33	1.09e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs7107770	0.739	rs4936994	chr11:125081440	G/C	cg27629782	chr11:125073726	PKNOX2	0.53	7.85	0.4	6.04e-14	Photic sneeze reflex;
CRC	cis	rs10128264	0.902	rs1250587	chr10:80978021	A/G	cg18737081	chr10:80999807	ZMIZ1	-0.37	-6.52	-0.34	2.67e-10	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.71	10.97	0.52	4.67e-24	Corneal astigmatism;
CRC	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.14	-0.37	5.85e-12	Metabolite levels (Pyroglutamine);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08023809	chr12:53645616	MFSD5	0.47	6.28	0.33	1.06e-9	Survival in pancreatic cancer;
CRC	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13385794	chr1:248469461	NA	0.39	6.99	0.36	1.52e-11	Common traits (Other);
CRC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.65	9.04	0.45	1.33e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8040855	0.965	rs11073990	chr15:85711301	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-5.81	-0.3	1.51e-8	Bulimia nervosa;
CRC	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.61	0.47	1.97e-19	Coffee consumption (cups per day);
CRC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg02993699	chr4:3415135	RGS12	-0.41	-6.58	-0.34	1.8e-10	Serum sulfate level;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17071181	chr3:171757786	FNDC3B	0.39	6.08	0.32	3.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.55	-0.38	4.43e-13	Blood metabolite levels;
CRC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.33	-0.37	1.83e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg25182066	chr10:30743637	MAP3K8	-0.41	-6.08	-0.32	3.4e-9	Inflammatory bowel disease;
CRC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg15845792	chr6:28175446	NA	1.02	15.66	0.65	1.12e-41	Depression;
CRC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.66	10.42	0.5	3.55e-22	Sudden cardiac arrest;
CRC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg22110888	chr17:80059540	CCDC57	0.4	6.48	0.34	3.37e-10	Life satisfaction;
CRC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.94	0.31	7.44e-9	Melanoma;
CRC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.54	6.51	0.34	2.76e-10	Carotid intima media thickness;
CRC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.06	-0.32	3.8e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2842895	0.735	rs4585612	chr6:7153152	C/T	cg17652435	chr17:36103066	HNF1B	-0.37	-6.04	-0.32	4.23e-9	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI;
CRC	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-7.95	-0.4	2.92e-14	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	5.67	0.3	3.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg13491945	chr12:107078410	RFX4	0.35	6.01	0.31	5e-9	Heart rate;
CRC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg24046110	chr8:143859143	LYNX1	0.59	10.44	0.5	3.06e-22	Urinary tract infection frequency;
CRC	trans	rs4591358	0.648	rs17177798	chr2:196386076	A/G	cg12742475	chr15:75233485	NA	0.31	6.27	0.33	1.15e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
CRC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.34	1.25e-10	Alzheimer's disease (late onset);
CRC	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.96	-0.31	6.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.44	-0.33	4.17e-10	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg20503657	chr10:835505	NA	-0.59	-8.07	-0.41	1.29e-14	Eosinophil percentage of granulocytes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg11355319	chr5:89825117	LYSMD3	0.45	6.45	0.34	3.99e-10	Response to antipsychotic treatment;
CRC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.82	-10.55	-0.5	1.33e-22	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg17321639	chr7:2759063	NA	-0.37	-5.62	-0.3	4.14e-8	Height;
CRC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.2	-0.53	7.11e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.44	7.53	0.38	4.86e-13	Childhood ear infection;
CRC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.62	9.38	0.46	1.07e-18	Testicular germ cell tumor;
CRC	cis	rs2882667	0.898	rs11956089	chr5:138394604	G/T	cg04439458	chr5:138467593	SIL1	0.33	6.0	0.31	5.18e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg18827107	chr12:86230957	RASSF9	-0.38	-6.21	-0.32	1.58e-9	Major depressive disorder;
CRC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.57	0.54	3.22e-26	Prudent dietary pattern;
CRC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg26162295	chr17:38119207	GSDMA	-0.37	-6.71	-0.35	8.6e-11	Asthma;
CRC	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	9.48	0.46	5.36e-19	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg06581033	chr10:766294	NA	-0.51	-5.71	-0.3	2.49e-8	Uric acid levels;
CRC	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06307176	chr5:131281290	NA	-0.42	-6.27	-0.33	1.11e-9	Life satisfaction;
CRC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05535760	chr7:792225	HEATR2	0.91	11.34	0.53	2.2e-25	Cerebrospinal P-tau181p levels;
CRC	cis	rs12630931	0.895	rs13099369	chr3:31982251	C/G	cg21375017	chr3:31988082	OSBPL10	0.42	5.76	0.3	1.94e-8	Periodontal disease-related phenotypes;
CRC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg00343986	chr7:65444356	GUSB	0.49	7.42	0.38	1.01e-12	Aortic root size;
CRC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-12.35	-0.56	4.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.45	-6.06	-0.32	3.71e-9	Schizophrenia;
CRC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg03233332	chr7:66118400	NA	-0.43	-5.95	-0.31	6.69e-9	Aortic root size;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01069804	chr15:63449582	RPS27L	0.43	6.09	0.32	3.17e-9	Intelligence (multi-trait analysis);
CRC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.52	-8.37	-0.42	1.64e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CRC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.6	6.76	0.35	6.25e-11	Bipolar disorder;
CRC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-0.83	-9.39	-0.46	1.03e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.21	-14.12	-0.61	1.06e-35	Diabetic kidney disease;
CRC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.75	-0.35	6.62e-11	Height;
CRC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg10760299	chr15:45669010	GATM	0.52	8.37	0.42	1.66e-15	Homoarginine levels;
CRC	cis	rs6074578	0.541	rs6077481	chr20:149975	C/T	cg16931068	chr20:139680	DEFB127	0.28	5.64	0.3	3.74e-8	Hirschsprung disease;
CRC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg04204079	chr8:58130323	NA	-0.45	-5.78	-0.3	1.71e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.67	11.51	0.54	5.29e-26	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg09473613	chr1:24152604	HMGCL	0.35	5.85	0.31	1.22e-8	Immature fraction of reticulocytes;
CRC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.73	12.61	0.57	5.08e-30	Longevity;
CRC	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg20356878	chr3:121714668	ILDR1	0.51	7.75	0.39	1.19e-13	Cognitive performance;
CRC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.1	-0.32	2.99e-9	Heart rate;
CRC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg24560729	chr4:1342394	KIAA1530	0.43	7.47	0.38	7.22e-13	Longevity;
CRC	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg05591447	chr17:21909280	FLJ36000	-0.31	-5.96	-0.31	6.45e-9	Pelvic organ prolapse;
CRC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.5	6.68e-22	Corneal astigmatism;
CRC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	8.99	0.44	1.94e-17	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-8.75	-0.43	1.13e-16	Breast cancer;
CRC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.14	13.54	0.6	1.72e-33	Sexual dysfunction (female);
CRC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg25985355	chr7:65971099	NA	-0.54	-6.04	-0.32	4.13e-9	Diabetic kidney disease;
CRC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.75	-0.3	2.09e-8	Bipolar disorder and schizophrenia;
CRC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	1.04	13.3	0.59	1.37e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg04025307	chr7:1156635	C7orf50	0.63	6.63	0.34	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg03315344	chr16:75512273	CHST6	-0.5	-5.81	-0.31	1.46e-8	Type 2 diabetes;Type 1 diabetes;
CRC	trans	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10865541	0.902	rs10206964	chr2:3425948	T/C	cg22182287	chr2:3452347	TTC15	0.4	6.27	0.33	1.11e-9	Obesity-related traits;
CRC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	12.02	0.55	8e-28	Alzheimer's disease;
CRC	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.35	-5.8	-0.3	1.56e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CRC	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.78	-0.39	9.41e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs629535	0.814	rs488231	chr8:70064993	T/C	cg26132723	chr8:70041827	NA	0.36	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.84	-15.47	-0.65	6.1e-41	Bipolar disorder;
CRC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	9.27	0.46	2.49e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.73	11.64	0.54	1.85e-26	Plateletcrit;Platelet count;
CRC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.0	0.31	5.22e-9	Diabetic kidney disease;
CRC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-11.15	-0.52	1.04e-24	Colorectal cancer;
CRC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-11.1	-0.52	1.59e-24	Personality dimensions;
CRC	cis	rs3731896	0.653	rs908194	chr2:220198247	A/G	cg00436969	chr2:220197716	RESP18	-0.46	-5.82	-0.31	1.37e-8	Educational attainment;
CRC	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg13385794	chr1:248469461	NA	0.39	6.63	0.34	1.4e-10	Common traits (Other);
CRC	cis	rs4731207	0.565	rs12538641	chr7:124600671	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.27e-9	Cutaneous malignant melanoma;
CRC	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-10.27	-0.49	1.19e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg11212589	chr17:38028394	ZPBP2	0.45	8.28	0.42	3.21e-15	Self-reported allergy;
CRC	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg23234261	chr14:55582407	NA	-0.29	-5.78	-0.3	1.73e-8	Protein biomarker;
CRC	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-14.15	-0.62	7.62e-36	Exhaled nitric oxide output;
CRC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.71	10.93	0.52	6.41e-24	Corneal astigmatism;
CRC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.66	-10.57	-0.5	1.08e-22	Sudden cardiac arrest;
CRC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg16476235	chr8:21771668	DOK2	-0.41	-7.14	-0.37	6.1e-12	Lung cancer in ever smokers;
CRC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.02	0.31	4.73e-9	Bladder cancer;
CRC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-7.18	-0.37	4.53e-12	Lung cancer;
CRC	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.46	5.7	0.3	2.63e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.43	6.3	0.33	9.73e-10	Height;
CRC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04073039	chr3:49158377	USP19	0.4	5.95	0.31	6.99e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg18404041	chr3:52824283	ITIH1	0.34	6.39	0.33	5.78e-10	Schizophrenia;
CRC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.57	-0.34	2.01e-10	Subjective well-being;
CRC	cis	rs10242455	0.702	rs3823813	chr7:99049389	G/A	cg18809830	chr7:99032528	PTCD1	-1.27	-8.96	-0.44	2.42e-17	Blood metabolite levels;
CRC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.39	-0.33	5.6e-10	Lung cancer;
CRC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.48	0.38	6.86e-13	Motion sickness;
CRC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18912574	chr7:65842487	NCRNA00174	0.35	5.94	0.31	7.17e-9	Aortic root size;
CRC	cis	rs12024301	0.557	rs10911395	chr1:183634257	C/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.38	-5.94	-0.31	7.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.48	-9.1	-0.45	9.18e-18	Hepatitis;
CRC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.52	8.24	0.41	4.03e-15	Red blood cell count;
CRC	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.7	-10.84	-0.51	1.34e-23	Type 2 diabetes;
CRC	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg16898833	chr6:26189333	HIST1H4D	0.76	6.58	0.34	1.88e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg25985355	chr7:65971099	NA	0.33	5.62	0.3	4.08e-8	Cotinine glucuronidation;
CRC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.53	7.51	0.38	5.65e-13	Lung cancer;
CRC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.5	-7.92	-0.4	3.73e-14	Age at first birth;
CRC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg25985355	chr7:65971099	NA	0.51	5.72	0.3	2.46e-8	Diabetic kidney disease;
CRC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.64	11.17	0.52	9.2e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.55	7.39	0.38	1.21e-12	Intelligence (multi-trait analysis);
CRC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.34	16.88	0.68	1.71e-46	Uric acid levels;
CRC	trans	rs797680	0.856	rs6541404	chr1:93743434	A/T	cg05406791	chr12:10875874	CSDA	0.36	6.11	0.32	2.89e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CRC	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	0.96	10.02	0.48	8.1899999999999992e-21	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg03013999	chr17:37608204	MED1	0.47	7.31	0.37	2.05e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	5.84	0.31	1.28e-8	Rheumatoid arthritis;
CRC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.75	-0.51	2.65e-23	Aortic root size;
CRC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.31	-0.33	8.97e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.16	0.37	5.26e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg11657817	chr20:23433608	CST11	0.44	6.56	0.34	2.11e-10	Facial morphology (factor 15, philtrum width);
CRC	cis	rs10486722	0.606	rs10951658	chr7:41788734	A/G	cg22138096	chr7:41772439	LOC285954	0.46	5.99	0.31	5.49e-9	Pit-and-Fissure caries;
CRC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.62	-9.25	-0.45	3.02e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg14186256	chr22:23484241	RTDR1	0.45	5.82	0.31	1.36e-8	Serum parathyroid hormone levels;
CRC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg06470822	chr6:28175283	NA	0.49	6.73	0.35	7.72e-11	Pulmonary function;
CRC	cis	rs2333194	0.772	rs8016034	chr14:73812188	C/A	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.39	-5.88	-0.31	9.99e-9	Bipolar disorder with mood-incongruent psychosis;
CRC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-11.35	-0.53	2.08e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Parkinson's disease;
CRC	cis	rs4728302	0.869	rs13233715	chr7:133617471	C/T	cg03336402	chr7:133662267	EXOC4	-0.45	-6.49	-0.34	3.21e-10	Intelligence;Intelligence (multi-trait analysis);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06586599	chr19:7587541	MCOLN1	0.39	6.0	0.31	5.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	5.82	0.31	1.39e-8	Obesity-related traits;
CRC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	8.23	0.41	4.36e-15	Height;
CRC	cis	rs7546094	0.967	rs351372	chr1:113059220	A/T	cg22162597	chr1:113214053	CAPZA1	0.42	5.94	0.31	7.33e-9	Platelet distribution width;
CRC	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg15192750	chr16:69999425	NA	0.58	7.82	0.4	7.29e-14	IgE levels;
CRC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06656553	chr16:89960601	TCF25	-0.68	-5.71	-0.3	2.55e-8	Skin colour saturation;
CRC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.54	9.23	0.45	3.43e-18	Iron status biomarkers;
CRC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.38	-6.0	-0.31	5.14e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.58	8.7	0.43	1.58e-16	Intelligence (multi-trait analysis);
CRC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.63	8.33	0.42	2.22e-15	High light scatter reticulocyte count;
CRC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.64	9.16	0.45	5.68e-18	Menopause (age at onset);
CRC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	1.0	16.32	0.67	2.68e-44	Parkinson's disease;
CRC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg14541582	chr5:601475	NA	-0.34	-6.66	-0.34	1.17e-10	Lung disease severity in cystic fibrosis;
CRC	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg14593290	chr7:50529359	DDC	-0.43	-6.34	-0.33	7.76e-10	Body mass index;
CRC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.16	0.41	7.4e-15	Rheumatoid arthritis;
CRC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.88	-14.79	-0.63	2.76e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.58	0.39	3.66e-13	Height;
CRC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-12.45	-0.57	2.03e-29	Body mass index;
CRC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-6.71	-0.35	8.51e-11	Major depressive disorder;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02018176	chr4:1364513	KIAA1530	0.38	6.34	0.33	7.65e-10	Obesity-related traits;
CRC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg21251018	chr6:28226885	NKAPL	0.47	7.26	0.37	2.83e-12	Cardiac Troponin-T levels;
CRC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.75	10.26	0.49	1.33e-21	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-6.39	-0.33	5.79e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.84	15.13	0.64	1.27e-39	Multiple myeloma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10243681	chr15:73925924	NPTN	0.41	6.01	0.31	5.04e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.56	7.8	0.39	8.41e-14	Height;
CRC	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.1	0.41	1.09e-14	Gout;
CRC	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.74	7.38	0.38	1.29e-12	Severe influenza A (H1N1) infection;
CRC	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.59	7.62	0.39	2.65e-13	Hypospadias;
CRC	cis	rs7731657	0.537	rs13355837	chr5:130360537	C/T	cg08523029	chr5:130500466	HINT1	-0.45	-5.83	-0.31	1.3e-8	Fasting plasma glucose;
CRC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg02869364	chr7:1081709	C7orf50	-0.37	-6.14	-0.32	2.33e-9	Longevity;Endometriosis;
CRC	cis	rs7072216	0.881	rs2182168	chr10:100148353	C/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.2	-0.32	1.66e-9	Metabolite levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22459930	chr17:6544061	TXNDC17;KIAA0753	0.4	5.99	0.31	5.57e-9	Response to antipsychotic treatment;
CRC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg13390004	chr1:15929781	NA	0.5	6.9	0.36	2.6e-11	Systolic blood pressure;
CRC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.38	6.62	0.34	1.48e-10	Schizophrenia;
CRC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.52	8.44	0.42	9.98e-16	Body mass index;
CRC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg09264619	chr17:80180166	NA	-0.36	-6.1	-0.32	3e-9	Life satisfaction;
CRC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.49	7.75	0.39	1.18e-13	Red blood cell count;
CRC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.53	-8.8	-0.44	7.76e-17	Aortic root size;
CRC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-7.84	-0.4	6.44e-14	Type 2 diabetes;
CRC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.7	-9.89	-0.48	2.31e-20	Vitiligo;
CRC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.46	8.01	0.4	1.95e-14	IgG glycosylation;
CRC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.44	-6.5	-0.34	3.04e-10	Pancreatic cancer;
CRC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.64	-9.84	-0.48	3.51e-20	Coronary artery disease;
CRC	cis	rs9549328	0.699	rs2993345	chr13:113617086	C/T	cg20742385	chr13:113633654	MCF2L	0.56	9.53	0.46	3.72e-19	Systolic blood pressure;
CRC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.5	8.04	0.41	1.67e-14	Crohn's disease;
CRC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.51	7.86	0.4	5.44e-14	Aortic root size;
CRC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.68	11.28	0.53	3.51e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.52	8.62	0.43	2.78e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg03339077	chr11:47165057	C11orf49	0.48	6.94	0.36	2.1e-11	Acne (severe);
CRC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.77	14.46	0.62	5e-37	Prudent dietary pattern;
CRC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg02725872	chr8:58115012	NA	-0.44	-6.61	-0.34	1.51e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-9.66	-0.47	1.32e-19	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	8.21	0.41	5.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.26	14.66	0.63	8.53e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg08795948	chr3:128337044	NA	0.35	6.17	0.32	1.95e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-7.77	-0.39	9.78e-14	Body mass index;
CRC	cis	rs6988985	0.560	rs5301	chr8:143955273	T/C	cg10324643	chr8:143916377	GML	0.39	6.58	0.34	1.85e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.11	0.37	7.07e-12	Alzheimer's disease;
CRC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-6.55	-0.34	2.19e-10	Blood metabolite levels;
CRC	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.4	0.42	1.36e-15	Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg08929303	chr1:207227076	PFKFB2	-0.33	-6.7	-0.35	9.13e-11	Underweight status;
CRC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-10.81	-0.51	1.69e-23	Systemic lupus erythematosus;
CRC	trans	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg18288967	chr1:45987694	PRDX1	0.69	7.68	0.39	1.79e-13	Obesity-related traits;
CRC	cis	rs10986311	0.706	rs7851278	chr9:127102939	T/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.4	5.95	0.31	6.72e-9	Vitiligo;
CRC	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg21064579	chr19:49206444	FUT2	0.48	8.33	0.42	2.23e-15	Dietary macronutrient intake;
CRC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	7.37	0.38	1.41e-12	Height;
CRC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.82	0.48	3.88e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9783347	0.925	rs3802968	chr11:18343878	A/G	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.81	8.56	0.43	4.31e-16	Plasma clusterin levels;
CRC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.46	-7.52	-0.38	5.35e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.54	-8.81	-0.44	7.44e-17	Colorectal cancer;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25152348	chr22:50946712	NCAPH2;LMF2	0.53	7.58	0.39	3.63e-13	Survival in pancreatic cancer;
CRC	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.62	9.0	0.44	1.79e-17	Coronary artery disease;
CRC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.84	18.44	0.71	1.15e-52	Breast cancer;
CRC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.17	-0.37	4.98e-12	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs12983728	0.505	rs35511051	chr19:58665817	C/A	cg21294424	chr19:58662284	ZNF329	0.5	6.36	0.33	6.88e-10	Cholesterol, total;
CRC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-7.33	-0.37	1.83e-12	Schizophrenia;
CRC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-6.09	-0.32	3.21e-9	Superior frontal gyrus grey matter volume;
CRC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg11833968	chr6:79620685	NA	-0.37	-6.4	-0.33	5.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.5	6.98	0.36	1.66e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.61	-7.61	-0.39	2.89e-13	Ulcerative colitis;
CRC	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.71	9.25	0.45	2.99e-18	Prostate cancer;
CRC	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.4	-6.36	-0.33	6.58e-10	Height;
CRC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.34	6.08	0.32	3.36e-9	Erythrocyte sedimentation rate;
CRC	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.56	8.47	0.42	8.49e-16	HDL cholesterol;
CRC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.72	-0.43	1.37e-16	Hemoglobin concentration;
CRC	cis	rs17155006	0.702	rs418255	chr7:107730034	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-5.88	-0.31	9.91e-9	Pneumococcal bacteremia;
CRC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	10.07	0.49	5.72e-21	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg00603274	chr11:61596626	FADS2	-0.44	-6.39	-0.33	5.71e-10	Trans fatty acid levels;
CRC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-1.21	-11.42	-0.53	1.14e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.39	-6.79	-0.35	5.17e-11	Reticulocyte fraction of red cells;
CRC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.77	8.16	0.41	7.02e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00694302	chr12:47609865	LOC100233209;FAM113B	0.47	7.04	0.36	1.15e-11	Interleukin-6 levels;
CRC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.67	9.75	0.47	6.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs12143943	0.934	rs12027855	chr1:204595544	C/A	cg17419461	chr1:204415978	PIK3C2B	0.43	6.86	0.35	3.34e-11	Cognitive performance;
CRC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.57	8.55	0.43	4.85e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.35	16.39	0.67	1.43e-44	Uric acid levels;
CRC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.62	10.03	0.48	7.81e-21	Breast cancer;
CRC	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg25856811	chr1:152973957	SPRR3	-0.27	-7.38	-0.38	1.3e-12	Inflammatory skin disease;
CRC	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.31	-0.33	8.83e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.68	11.43	0.53	1.1e-25	Alzheimer's disease (late onset);
CRC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.56	-9.63	-0.47	1.65e-19	Migraine;
CRC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.68	8.22	0.41	4.71e-15	Menarche (age at onset);
CRC	trans	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg21153622	chr11:89784906	NA	-0.49	-7.78	-0.39	9.36e-14	HDL cholesterol;
CRC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.84	0.48	3.28e-20	Vitamin D levels;
CRC	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg14631576	chr9:95140430	CENPP	-0.32	-5.95	-0.31	6.89e-9	Height;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg16148674	chr11:14380065	RRAS2	-0.4	-6.1	-0.32	3.03e-9	Myopia (pathological);
CRC	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg21839984	chr17:30846986	MYO1D	-0.33	-5.62	-0.3	4.03e-8	Schizophrenia;
CRC	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg16141378	chr3:129829833	LOC729375	0.47	6.93	0.36	2.19e-11	Neuroticism;
CRC	cis	rs9039	0.921	rs9929699	chr16:9218270	A/G	cg08831531	chr16:9218945	NA	-0.56	-7.8	-0.4	8.3e-14	Menopause (age at onset);
CRC	trans	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg17903999	chr18:56338584	MALT1	0.41	6.54	0.34	2.39e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs1552172	0.887	rs12750384	chr1:145681484	T/C	cg11743829	chr1:145714124	CD160	-0.43	-6.46	-0.34	3.75e-10	Breast cancer;
CRC	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.57	10.1	0.49	4.39e-21	Age of smoking initiation;
CRC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.39	-5.85	-0.31	1.19e-8	Mean corpuscular volume;
CRC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-6.81	-0.35	4.65e-11	Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14032529	chr10:114712217	TCF7L2	0.42	6.98	0.36	1.66e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg03315344	chr16:75512273	CHST6	-0.5	-6.04	-0.32	4.22e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg23018236	chr17:30244563	NA	-0.58	-7.85	-0.4	6.09e-14	Hip circumference adjusted for BMI;
CRC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.61	9.27	0.46	2.51e-18	Corneal astigmatism;
CRC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg02527881	chr3:46936655	PTH1R	-0.35	-6.09	-0.32	3.07e-9	Colorectal cancer;
CRC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.8	-11.17	-0.52	9.24e-25	Venous thromboembolism (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20563921	chr11:62420975	INTS5	0.5	7.07	0.36	9.41e-12	Response to antipsychotic treatment;
CRC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg09582351	chr12:29534625	ERGIC2	0.31	6.59	0.34	1.78e-10	QT interval;
CRC	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	9.73	0.47	7.78e-20	Bipolar disorder;
CRC	cis	rs6545883	0.894	rs4672423	chr2:61435275	C/T	cg15711740	chr2:61764176	XPO1	0.42	5.66	0.3	3.27e-8	Tuberculosis;
CRC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.71	0.35	8.51e-11	Blood metabolite levels;
CRC	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.54	-7.4	-0.38	1.12e-12	Psychosis in Alzheimer's disease;
CRC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg02475695	chr16:616220	NHLRC4	0.46	7.59	0.39	3.22e-13	Height;
CRC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg00343986	chr7:65444356	GUSB	-0.47	-6.52	-0.34	2.69e-10	Aortic root size;
CRC	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg15192750	chr16:69999425	NA	0.47	6.57	0.34	2.01e-10	IgE levels;
CRC	cis	rs629535	0.814	rs614050	chr8:70065642	G/A	cg26132723	chr8:70041827	NA	0.36	5.82	0.31	1.41e-8	Dupuytren's disease;
CRC	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg07125278	chr16:67683757	RLTPR	-0.47	-6.1	-0.32	2.98e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.67	0.63	7.49e-38	Intelligence (multi-trait analysis);
CRC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.46	5.75	0.3	2.06e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.52	8.85	0.44	5.32e-17	Aortic root size;
CRC	cis	rs780094	0.528	rs1728918	chr2:27635463	C/T	cg03023068	chr2:27486122	SLC30A3	0.39	5.86	0.31	1.1e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CRC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.56	8.18	0.41	6.08e-15	Melanoma;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00679716	chr14:23067188	ABHD4	0.47	6.59	0.34	1.76e-10	Response to antipsychotic treatment;
CRC	cis	rs16975963	0.793	rs11666497	chr19:38464262	C/T	cg15135657	chr19:38346511	NA	-0.44	-5.8	-0.3	1.56e-8	Longevity;
CRC	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg14631576	chr9:95140430	CENPP	-0.41	-7.34	-0.37	1.73e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs972578	0.837	rs4822201	chr22:43227272	T/G	cg01576275	chr22:43409880	NA	-0.4	-6.34	-0.33	7.73e-10	Mean platelet volume;
CRC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.52	8.58	0.43	3.85e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.83	14.33	0.62	1.64e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.52	7.3	0.37	2.16e-12	Melanoma;
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.78	9.68	0.47	1.17e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg27534772	chr1:16042836	PLEKHM2	0.54	10.11	0.49	4.15e-21	Systolic blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21852761	chr6:130340620	L3MBTL3	0.38	6.04	0.32	4.08e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.99	-0.58	1.9e-31	White blood cell count (basophil);
CRC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg00786952	chr1:21763130	NA	0.49	8.25	0.41	3.95e-15	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.18	-0.37	4.66e-12	IgG glycosylation;
CRC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg03161606	chr19:29218774	NA	0.54	6.2	0.32	1.68e-9	Methadone dose in opioid dependence;
CRC	trans	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14769373	chr6:40998127	UNC5CL	-0.44	-5.85	-0.31	1.19e-8	Gastric cancer;Non-cardia gastric cancer;
CRC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.85	-14.43	-0.62	6.29e-37	Height;
CRC	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.47	7.76	0.39	1.08e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CRC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg02772935	chr3:125709198	NA	-0.48	-6.03	-0.32	4.36e-9	Blood pressure (smoking interaction);
CRC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.63	0.3	3.82e-8	Bladder cancer;
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.95	-0.52	5.12e-24	Alzheimer's disease;
CRC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg25985355	chr7:65971099	NA	-0.52	-5.98	-0.31	5.81e-9	Diabetic kidney disease;
CRC	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg21280719	chr6:42927975	GNMT	-0.32	-5.96	-0.31	6.49e-9	Blood protein levels;
CRC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.6	9.79	0.48	4.86e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.8	-8.75	-0.43	1.1e-16	Intelligence (multi-trait analysis);
CRC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg02527881	chr3:46936655	PTH1R	0.37	6.77	0.35	5.97e-11	Colorectal cancer;
CRC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.3	-0.42	2.79e-15	Monocyte percentage of white cells;
CRC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-1.02	-12.09	-0.55	4.3e-28	Hip circumference adjusted for BMI;
CRC	cis	rs12760731	0.720	rs12037817	chr1:178261750	A/G	cg00404053	chr1:178313656	RASAL2	0.93	9.67	0.47	1.27e-19	Obesity-related traits;
CRC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.1	-0.32	2.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs11673344	0.528	rs491326	chr19:37410939	G/A	cg18947437	chr10:1231002	ADARB2	-0.36	-6.39	-0.33	5.73e-10	Obesity-related traits;
CRC	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg10517650	chr3:113235015	CCDC52	-0.38	-6.03	-0.32	4.48e-9	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.68	-10.47	-0.5	2.49e-22	Liver enzyme levels (gamma-glutamyl transferase);
CRC	trans	rs4276421	0.806	rs13169726	chr5:45445069	G/A	cg04793272	chr11:119020941	ABCG4	-0.39	-6.42	-0.33	4.83e-10	P wave duration;
CRC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg13606994	chr1:44402422	ARTN	-0.36	-5.99	-0.31	5.51e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	6.31	0.33	9.07e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg19223190	chr17:80058835	NA	0.4	6.32	0.33	8.57e-10	Life satisfaction;
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg13490827	chr1:46269305	MAST2	-0.69	-6.05	-0.32	4.03e-9	Cognitive function;
CRC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.48	5.67	0.3	3.17e-8	Dental caries;
CRC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.76	-9.75	-0.47	6.9e-20	Initial pursuit acceleration;
CRC	cis	rs11212617	0.967	rs7118967	chr11:108057856	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.38	5.71	0.3	2.48e-8	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.47	6.01	0.31	4.85e-9	Aortic root size;
CRC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.38	5.89	0.31	9.57e-9	Alzheimer's disease (late onset);
CRC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.73	0.39	1.34e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.57	7.98	0.4	2.4e-14	Lung cancer;
CRC	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.64	9.38	0.46	1.09e-18	Bipolar disorder;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26685501	chr1:38019921	SNIP1	0.43	6.77	0.35	5.91e-11	Obesity-related traits;
CRC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg24046110	chr8:143859143	LYNX1	0.5	8.67	0.43	1.94e-16	Urinary tract infection frequency;
CRC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.57	-9.33	-0.46	1.66e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CRC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.34	-5.72	-0.3	2.42e-8	Body mass index;
CRC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.85	-0.31	1.19e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs4523957	0.928	rs216183	chr17:2173923	A/G	cg16513277	chr17:2031491	SMG6	0.55	9.34	0.46	1.53e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg19678392	chr7:94953810	PON1	-0.59	-7.31	-0.37	2.09e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.91	8.44	0.42	1.06e-15	Platelet distribution width;
CRC	cis	rs1887596	0.705	rs2776435	chr13:27217535	T/C	cg01312412	chr13:27282625	NA	0.42	5.77	0.3	1.86e-8	Facial morphology (factor 3, length of philtrum);
CRC	cis	rs6772849	0.896	rs9816260	chr3:128352083	A/T	cg08795948	chr3:128337044	NA	0.36	6.28	0.33	1.04e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.59	9.01	0.45	1.66e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.53	-7.31	-0.37	2.02e-12	Dental caries;
CRC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.59	10.46	0.5	2.73e-22	Aortic root size;
CRC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.51	7.49	0.38	6.56e-13	Multiple sclerosis;
CRC	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.55	9.62	0.47	1.79e-19	Common traits (Other);
CRC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg09165964	chr15:75287851	SCAMP5	-0.5	-7.81	-0.4	7.86e-14	Caffeine consumption;
CRC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23378565	chr7:2036160	MAD1L1	-0.4	-6.04	-0.32	4.08e-9	Bipolar disorder;
CRC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.47	-5.9	-0.31	9.03e-9	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.54	8.68	0.43	1.92e-16	Prostate cancer;
CRC	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	5.82	0.31	1.4e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.66	11.56	0.54	3.65e-26	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22654626	chr19:18699620	C19orf60	0.45	6.33	0.33	7.88e-10	Survival in pancreatic cancer;
CRC	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-8.2	-0.41	5.58e-15	Hepatocellular carcinoma;
CRC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.36	0.56	4.4e-29	Chronic sinus infection;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20067688	chr20:30449097	DUSP15	0.47	6.81	0.35	4.69e-11	Anxiety disorder;
CRC	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.62	8.3	0.42	2.81e-15	Biliary atresia;
CRC	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.58	-9.17	-0.45	5.17e-18	Breast cancer;
CRC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	ch.11.42038R	chr11:967971	AP2A2	0.57	9.04	0.45	1.37e-17	Alzheimer's disease (late onset);
CRC	trans	rs343496	0.941	rs10975412	chr9:6049547	A/G	cg24311644	chr8:1654216	DLGAP2	-0.47	-6.06	-0.32	3.81e-9	Asthma and hay fever;
CRC	cis	rs17767392	0.881	rs1859643	chr14:72055468	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.55	-7.06	-0.36	1.02e-11	Mitral valve prolapse;
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.45	5.74	0.3	2.11e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.84	0.35	3.8e-11	Morning vs. evening chronotype;
CRC	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-8.35	-0.42	1.95e-15	Metabolite levels (Pyroglutamine);
CRC	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.54	-7.38	-0.38	1.3e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.15	-0.37	5.65e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20368377	chr13:23499360	NA	-0.35	-6.25	-0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-9.36	-0.46	1.32e-18	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.65	9.76	0.47	6.33e-20	Lung cancer;
CRC	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.69	8.71	0.43	1.54e-16	Hip circumference adjusted for BMI;
CRC	cis	rs7546094	0.967	rs910697	chr1:113063125	A/G	cg22162597	chr1:113214053	CAPZA1	0.41	5.88	0.31	1.03e-8	Platelet distribution width;
CRC	cis	rs8105895	0.935	rs7247228	chr19:22250136	C/T	cg02657401	chr19:22469223	NA	-0.34	-5.65	-0.3	3.56e-8	Body mass index (change over time);
CRC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.26	-0.37	2.76e-12	Mean corpuscular volume;
CRC	cis	rs751837	0.591	rs12100549	chr14:103417030	C/T	cg10087771	chr14:103399429	CDC42BPB	0.6	6.18	0.32	1.93e-9	Large B-cell lymphoma;
CRC	cis	rs453193	0.573	rs2630744	chr2:8464827	A/T	cg12167548	chr2:8464763	NA	-0.37	-6.87	-0.35	3.32e-11	Granulocyte percentage of myeloid white cells;
CRC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.52	-7.09	-0.36	8.12e-12	IgG glycosylation;
CRC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.61	10.1	0.49	4.69e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg17948913	chr5:572064	NA	0.55	5.85	0.31	1.2e-8	Lung disease severity in cystic fibrosis;
CRC	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg25809561	chr17:30822961	MYO1D	0.57	10.51	0.5	1.87e-22	Schizophrenia;
CRC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg21972741	chr5:435613	AHRR	0.48	6.35	0.33	7.04e-10	Cystic fibrosis severity;
CRC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg02869306	chr7:64672164	INTS4L1	0.45	7.9	0.4	4.36e-14	Calcium levels;
CRC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	1.05	19.14	0.73	2.13e-55	Parkinson's disease;
CRC	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Intelligence (multi-trait analysis);
CRC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.96	-0.4	2.83e-14	Total cholesterol levels;
CRC	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg19537932	chr12:55886519	OR6C68	-0.72	-9.1	-0.45	9.11e-18	Cancer;
CRC	cis	rs10046574	0.831	rs77263000	chr7:135099419	C/T	cg27474649	chr7:135195673	CNOT4	0.69	5.71	0.3	2.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.4	-6.63	-0.34	1.35e-10	Mean corpuscular volume;
CRC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.6	0.54	2.6e-26	Monocyte percentage of white cells;
CRC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.42	7.12	0.37	6.87e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19386303	chr19:47104863	CALM3	0.46	6.43	0.33	4.52e-10	Survival in pancreatic cancer;
CRC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-6.82	-0.35	4.38e-11	Type 2 diabetes;
CRC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21963583	chr11:68658836	MRPL21	-0.41	-6.99	-0.36	1.5e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.78	-10.53	-0.5	1.54e-22	IgG glycosylation;
CRC	cis	rs2929278	0.617	rs3087657	chr15:44063859	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	6.73	0.35	7.44e-11	Schizophrenia;
CRC	cis	rs11212617	1.000	rs1003623	chr11:108152582	C/T	cg12106634	chr11:108092400	ATM;NPAT	0.42	6.12	0.32	2.71e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.55	-7.97	-0.4	2.61e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg27216355	chr16:71599010	NA	0.45	6.01	0.31	4.9e-9	Thyroid stimulating hormone;
CRC	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.04	-0.45	1.41e-17	Alzheimer's disease;
CRC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg11843238	chr5:131593191	PDLIM4	0.36	6.53	0.34	2.56e-10	Blood metabolite levels;
CRC	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.7	-6.58	-0.34	1.89e-10	Response to haloperidol in psychosis;
CRC	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg22561889	chr6:118971681	C6orf204	0.52	6.7	0.35	9.08e-11	Diastolic blood pressure;
CRC	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.98	20.38	0.75	2.87e-60	Metabolite levels;
CRC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.41	-6.21	-0.32	1.61e-9	Height;
CRC	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.54	-7.6	-0.39	3.05e-13	Autism;
CRC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.48	-7.17	-0.37	5.07e-12	Corneal astigmatism;
CRC	cis	rs787274	0.850	rs4979176	chr9:115641181	A/G	cg13803584	chr9:115635662	SNX30	0.64	6.37	0.33	6.5e-10	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-6.06	-0.32	3.71e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	10.65	0.51	6.06e-23	Motion sickness;
CRC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg04586622	chr2:25135609	ADCY3	-0.55	-10.22	-0.49	1.81e-21	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22806587	chr15:75871813	PTPN9	0.47	7.85	0.4	5.9e-14	Liver disease severity in Alagille syndrome;
CRC	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg07125278	chr16:67683757	RLTPR	-0.5	-6.92	-0.36	2.37e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.68	7.07	0.36	9.15e-12	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg01721255	chr8:58191610	C8orf71	0.46	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs368123	0.686	rs2774226	chr6:160700386	G/A	cg19643109	chr6:160697625	NA	-0.34	-6.27	-0.33	1.17e-9	Waist circumference;
CRC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.6	8.99	0.44	2.04e-17	Methadone dose in opioid dependence;
CRC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg10298567	chr3:47292165	KIF9	-0.36	-5.83	-0.31	1.3e-8	Colorectal cancer;
CRC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg21620606	chr4:1342894	KIAA1530	0.38	6.4	0.33	5.46e-10	Obesity-related traits;
CRC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.71	-11.2	-0.53	7.05e-25	Breast cancer;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg03704503	chr10:76994576	COMTD1	-0.41	-6.2	-0.32	1.72e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.74	7.63	0.39	2.51e-13	Diabetic retinopathy;
CRC	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00147160	chr1:26503991	CNKSR1	0.31	6.15	0.32	2.21e-9	Height;
CRC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.53	6.27	0.33	1.15e-9	Renal function-related traits (BUN);
CRC	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.39	-6.65	-0.34	1.19e-10	Life satisfaction;
CRC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg13628971	chr7:2884303	GNA12	0.41	6.15	0.32	2.23e-9	Height;
CRC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06505273	chr16:24850292	NA	0.39	6.05	0.32	3.9e-9	Intelligence (multi-trait analysis);
CRC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.5	0.65	4.69e-41	Gut microbiome composition (summer);
CRC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	1.09	12.84	0.58	7.36e-31	Obesity-related traits;
CRC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg10820045	chr2:198174542	NA	-0.54	-10.61	-0.5	8.11e-23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg09597638	chr17:3907349	NA	-0.64	-10.99	-0.52	3.95e-24	Type 2 diabetes;
CRC	cis	rs7894051	1.000	rs11101723	chr10:135192139	C/A	cg20534287	chr10:135191450	PAOX	0.77	5.85	0.31	1.21e-8	Lifespan;
CRC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg05729581	chr11:3078854	CARS	-0.53	-7.54	-0.38	4.54e-13	Longevity;
CRC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.12	-12.85	-0.58	6.69e-31	Diabetic kidney disease;
CRC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.38	-6.09	-0.32	3.19e-9	Major depressive disorder;
CRC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-7.61	-0.39	2.86e-13	Monocyte count;
CRC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.23	0.32	1.45e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03270197	chr6:166796579	BRP44L	0.49	6.62	0.34	1.42e-10	Thyroid stimulating hormone;
CRC	trans	rs6678914	1.000	rs2167588	chr1:202190369	C/T	cg19977628	chr5:1262072	TERT	0.4	5.96	0.31	6.34e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.13	10.49	0.5	2.06e-22	Skin colour saturation;
CRC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9467160	1.000	rs10946700	chr6:24442158	G/T	cg16211469	chr6:24423932	MRS2	0.35	5.67	0.3	3.06e-8	Liver enzyme levels;
CRC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.38	-6.41	-0.33	5.08e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs863345	0.604	rs10797013	chr1:158465506	G/C	cg12129480	chr1:158549410	OR10X1	-0.29	-6.11	-0.32	2.86e-9	Pneumococcal bacteremia;
CRC	cis	rs11212617	0.837	rs4754298	chr11:108023284	G/A	cg12106634	chr11:108092400	ATM;NPAT	0.44	6.57	0.34	1.94e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs6504622	1.000	rs4968286	chr17:45017645	T/C	cg16759221	chr17:45003025	GOSR2	0.45	6.92	0.36	2.37e-11	Orofacial clefts;
CRC	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.56	8.4	0.42	1.33e-15	Blood protein levels;
CRC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.58	-10.3	-0.49	9.65e-22	Developmental language disorder (linguistic errors);
CRC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.35	-0.53	2.04e-25	Hemoglobin concentration;
CRC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-12.11	-0.56	3.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.44	-6.14	-0.32	2.36e-9	Fibrinogen levels;
CRC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.41	-6.68	-0.35	1.01e-10	Coronary artery disease;
CRC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg04155289	chr7:94953770	PON1	-0.56	-7.02	-0.36	1.27e-11	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.72	-12.17	-0.56	2.17e-28	Cognitive function;
CRC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-8.98	-0.44	2.16e-17	Bipolar disorder;
CRC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.37	-0.38	1.35e-12	Morning vs. evening chronotype;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg04025307	chr7:1156635	C7orf50	0.64	6.81	0.35	4.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.33	12.33	0.56	5.8e-29	Granulocyte percentage of myeloid white cells;
CRC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.91	-16.07	-0.66	2.65e-43	Height;
CRC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.87	-0.31	1.07e-8	Parkinson's disease;
CRC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg18477163	chr1:228402036	OBSCN	0.42	7.04	0.36	1.13e-11	Diastolic blood pressure;
CRC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.77	0.35	6.09e-11	Ulcerative colitis;
CRC	cis	rs7781266	0.790	rs1364503	chr7:133083504	T/C	cg03336402	chr7:133662267	EXOC4	-0.48	-5.81	-0.31	1.46e-8	Educational attainment (college completion);
CRC	cis	rs728616	0.614	rs55720611	chr10:81790299	G/A	cg05935833	chr10:81318306	SFTPA2	-0.52	-6.97	-0.36	1.71e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-7.19	-0.37	4.36e-12	Lung cancer;
CRC	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg01339444	chr6:118972232	C6orf204	0.54	6.01	0.31	4.89e-9	Diastolic blood pressure;
CRC	trans	rs72956618	1.000	rs68160031	chr2:207489365	T/G	cg16073378	chr2:468413	NA	-0.65	-6.35	-0.33	7.35e-10	Tonsillectomy;
CRC	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg03146154	chr1:46216737	IPP	-0.45	-6.07	-0.32	3.52e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.47	5.98	0.31	5.82e-9	Aortic root size;
CRC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg00343986	chr7:65444356	GUSB	0.48	6.93	0.36	2.27e-11	Calcium levels;
CRC	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.51	7.27	0.37	2.72e-12	Corneal astigmatism;
CRC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.44	0.33	4.15e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.6	-9.58	-0.47	2.45e-19	Body mass index;
CRC	cis	rs3790455	0.560	rs1171557	chr1:156451264	C/T	cg14087168	chr1:156450669	MEF2D	-0.37	-6.03	-0.32	4.45e-9	Migraine;
CRC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg10876282	chr6:28092338	ZSCAN16	0.48	6.6	0.34	1.68e-10	Cardiac Troponin-T levels;
CRC	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.61	-8.56	-0.43	4.51e-16	Coronary artery disease;
CRC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.97	12.29	0.56	8.01e-29	Cerebrospinal P-tau181p levels;
CRC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg07507251	chr3:52567010	NT5DC2	0.42	6.04	0.32	4.11e-9	Bipolar disorder;
CRC	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.77	9.83	0.48	3.7e-20	Height;
CRC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.01	0.48	9.17e-21	Platelet count;
CRC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.8	-0.35	5.06e-11	Response to antipsychotic treatment;
CRC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.98	21.22	0.76	1.46e-63	Cerebrospinal fluid biomarker levels;
CRC	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg01420254	chr6:26195488	NA	0.66	5.85	0.31	1.21e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs10971721	0.822	rs72725376	chr9:33841929	A/G	cg13495928	chr9:33750294	PRSS3	0.55	5.9	0.31	9.17e-9	Body mass index;
CRC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg10729496	chr3:10149963	C3orf24	0.46	6.16	0.32	2.12e-9	Alzheimer's disease;
CRC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg00601486	chr12:48723148	H1FNT	0.35	6.6	0.34	1.61e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.43	6.9	0.36	2.73e-11	Sitting height ratio;
CRC	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.86	15.73	0.66	5.58e-42	Hip circumference;
CRC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg20041105	chr8:143859282	LYNX1	0.44	7.93	0.4	3.35e-14	Urinary tract infection frequency;
CRC	trans	rs8012941	0.593	rs4902190	chr14:63314591	A/G	cg24626003	chr11:6502573	ARFIP2;FXC1	0.38	5.98	0.31	5.94e-9	Major depressive disorder;
CRC	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.56	5.87	0.31	1.04e-8	Blood protein levels;
CRC	cis	rs6840360	0.607	rs6815320	chr4:152432500	T/C	cg09659197	chr4:152720779	NA	0.33	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.22	-0.32	1.51e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	trans	rs11581859	0.950	rs7555367	chr1:99374045	T/G	cg12183875	chr3:169587454	LRRC31	0.28	6.54	0.34	2.41e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs1105228	0.808	rs557386	chr6:165716293	T/C	cg20535254	chr6:165714960	C6orf118	-0.28	-5.79	-0.3	1.62e-8	Number of pregnancies;Number of children;
CRC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	11.69	0.54	1.25e-26	Mean corpuscular hemoglobin;
CRC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.33	5.65	0.3	3.42e-8	Schizophrenia;
CRC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.39	-5.93	-0.31	7.47e-9	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.34	-9.21	-0.45	3.85e-18	Mean corpuscular volume;
CRC	cis	rs3750965	0.959	rs3168115	chr11:68858090	A/T	cg06818126	chr11:68850279	TPCN2	0.48	6.91	0.36	2.57e-11	Hair color;
CRC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.5	8.72	0.43	1.44e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.75	-11.76	-0.54	6.87e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg06908895	chr20:25038786	ACSS1	-0.63	-7.64	-0.39	2.41e-13	Diisocyanate-induced asthma;
CRC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.36	-7.47	-0.38	7.23e-13	Cutaneous nevi;
CRC	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.73	9.17	0.45	5.12e-18	Coronary artery disease;
CRC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg06470822	chr6:28175283	NA	0.81	6.57	0.34	2.03e-10	Depression;
CRC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.94	-0.4	3.25e-14	NT-proBNP levels in acute coronary syndrome;
CRC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg02741985	chr17:80059408	CCDC57	0.43	7.13	0.37	6.48e-12	Life satisfaction;
CRC	cis	rs7172809	0.643	rs11855272	chr15:77840790	G/A	cg10437265	chr15:77819839	NA	-0.35	-5.7	-0.3	2.62e-8	Glucose homeostasis traits;
CRC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.98	12.32	0.56	6.13e-29	Vitiligo;
CRC	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.38	6.02	0.31	4.77e-9	Height;
CRC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.4	7.66	0.39	2.15e-13	Colorectal cancer;
CRC	trans	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg26043149	chr18:55253948	FECH	-0.5	-7.72	-0.39	1.39e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	5.74	0.3	2.16e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg14673194	chr17:80132900	CCDC57	0.49	6.35	0.33	7.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03179478	chr3:150264694	SERP1;EIF2A	-0.41	-6.0	-0.31	5.14e-9	HDL cholesterol;
CRC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-15.1	-0.64	1.72e-39	Schizophrenia;
CRC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.37	4.84e-12	Reticulocyte fraction of red cells;
CRC	cis	rs1158570	0.500	rs2670890	chr8:131314923	G/A	cg21674704	chr8:131455249	NA	0.44	6.58	0.34	1.9e-10	Platelet count;
CRC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.54	9.88	0.48	2.54e-20	HDL cholesterol levels;
CRC	cis	rs2857891	0.909	rs17191140	chr11:6944283	G/A	cg26870460	chr11:6947759	ZNF215	0.59	6.06	0.32	3.68e-9	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg19980929	chr12:42632907	YAF2	0.44	6.64	0.34	1.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.92	-0.48	1.83e-20	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7503807	0.515	rs12946206	chr17:78687270	G/T	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.87e-8	Obesity;
CRC	cis	rs10924970	0.805	rs2789363	chr1:235519034	A/T	cg26050004	chr1:235667680	B3GALNT2	0.44	6.32	0.33	8.62e-10	Asthma;
CRC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.19	-0.37	4.45e-12	Blood metabolite levels;
CRC	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg15382696	chr6:118971807	C6orf204	0.61	7.77	0.39	1.01e-13	Diastolic blood pressure;
CRC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	10.49	0.5	2.13e-22	Systolic blood pressure;
CRC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.49	-0.38	6.57e-13	Schizophrenia;
CRC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg03037974	chr15:76606532	NA	0.66	10.91	0.52	7.2e-24	Blood metabolite levels;
CRC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.57	-9.88	-0.48	2.42e-20	Iron status biomarkers;
CRC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg07636037	chr3:49044803	WDR6	-0.68	-6.53	-0.34	2.57e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.52	-8.6	-0.43	3.34e-16	Tourette's syndrome or obsessive-compulsive disorder;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg03623178	chr6:28175578	NA	0.83	12.47	0.57	1.76e-29	Parkinson's disease;
CRC	cis	rs524281	0.814	rs2270448	chr11:65835931	G/T	cg16950941	chr11:66035639	RAB1B	-0.58	-7.33	-0.37	1.84e-12	Electroencephalogram traits;
CRC	cis	rs12826942	0.879	rs7312066	chr12:42766380	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.39	0.38	1.26e-12	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07000785	chr1:68150823	GADD45A	0.44	6.12	0.32	2.69e-9	Response to antipsychotic treatment;
CRC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg11503833	chr11:492997	NA	0.57	5.95	0.31	6.75e-9	Body mass index;
CRC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.59	9.04	0.45	1.36e-17	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.45	7.71	0.39	1.46e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg05784532	chr1:230284198	GALNT2	0.44	6.19	0.32	1.75e-9	Coronary artery disease;
CRC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.6	10.04	0.48	7.2e-21	Mean corpuscular volume;
CRC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.73	-0.35	7.52e-11	Intelligence (multi-trait analysis);
CRC	cis	rs12024301	0.557	rs16861453	chr1:183646538	C/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.73	6.43	0.33	4.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg23356831	chr14:105996513	TMEM121	0.45	7.48	0.38	7.04e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CRC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.44	-6.08	-0.32	3.25e-9	Corneal structure;
CRC	cis	rs10512697	1.000	rs17637034	chr5:3566549	T/C	cg19473799	chr5:3511975	NA	-0.78	-5.94	-0.31	7.27e-9	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	8.93	0.44	3.09e-17	Personality dimensions;
CRC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-10.81	-0.51	1.62e-23	Alzheimer's disease;
CRC	cis	rs7532866	0.885	rs7552065	chr1:26731951	G/T	cg17456097	chr1:26900765	RPS6KA1	-0.4	-6.01	-0.31	5.04e-9	Height;
CRC	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.49	-6.06	-0.32	3.8e-9	Coronary artery calcification;
CRC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg18876405	chr7:65276391	NA	-0.45	-6.05	-0.32	4e-9	Aortic root size;
CRC	cis	rs10208940	0.920	rs13400155	chr2:68723636	G/A	cg12452813	chr2:68675892	NA	0.51	6.35	0.33	7.33e-10	Urate levels in lean individuals;
CRC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.46	-6.51	-0.34	2.77e-10	Platelet distribution width;
CRC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg23136738	chr11:925521	AP2A2	-0.42	-7.09	-0.36	8.19e-12	Alzheimer's disease (late onset);
CRC	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.39	-0.33	5.82e-10	LDL cholesterol levels;LDL cholesterol;
CRC	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-9.16	-0.45	5.81e-18	Metabolite levels;
CRC	cis	rs11191205	0.686	rs11191092	chr10:103449251	T/C	cg15320455	chr10:103880129	LDB1	0.57	6.26	0.33	1.18e-9	Intelligence (multi-trait analysis);
CRC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.58	-0.47	2.54e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs61160187	0.582	rs58646987	chr5:60275694	C/T	cg16298547	chr5:60138761	ELOVL7	-0.27	-5.73	-0.3	2.26e-8	Educational attainment (years of education);Educational attainment (college completion);
CRC	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-6.52	-0.34	2.67e-10	Mean corpuscular hemoglobin concentration;
CRC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.2	-0.41	5.45e-15	Aortic root size;
CRC	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.49	7.03	0.36	1.19e-11	Corneal astigmatism;
CRC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg16892393	chr17:41919603	NA	0.6	8.64	0.43	2.54e-16	Triglycerides;
CRC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg26354017	chr1:205819088	PM20D1	0.43	5.96	0.31	6.41e-9	Parkinson's disease;
CRC	trans	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg17903999	chr18:56338584	MALT1	-0.4	-6.69	-0.35	9.69e-11	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg21251018	chr6:28226885	NKAPL	0.42	6.2	0.32	1.74e-9	Parkinson's disease;
CRC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-0.89	-10.1	-0.49	4.58e-21	Breast cancer;
CRC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.44	7.06	0.36	9.84e-12	Height;
CRC	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	0.97	8.87	0.44	4.8e-17	Lymphocyte counts;
CRC	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	7.47	0.38	7.34e-13	Mean corpuscular volume;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg07522440	chr7:143317300	FAM115C	-0.4	-5.97	-0.31	6.05e-9	Myopia (pathological);
CRC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg14664628	chr15:75095509	CSK	0.46	6.69	0.35	9.73e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg05139728	chr16:28306816	SBK1	-0.36	-5.87	-0.31	1.08e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.85	0.31	1.17e-8	Systemic lupus erythematosus;
CRC	cis	rs7605827	0.930	rs10184585	chr2:15683091	G/A	cg19274914	chr2:15703543	NA	0.39	5.82	0.31	1.4e-8	Educational attainment (years of education);
CRC	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.86	-15.33	-0.65	2.04e-40	Colorectal cancer;
CRC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-7.91	-0.4	3.87e-14	Colorectal cancer;
CRC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.33	-0.37	1.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs6662572	0.686	rs113117837	chr1:46278158	G/A	cg08644498	chr1:46502608	NA	0.44	6.85	0.35	3.61e-11	Blood protein levels;
CRC	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg17691542	chr6:26056736	HIST1H1C	-0.48	-6.73	-0.35	7.55e-11	Blood metabolite levels;
CRC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.36	-5.8	-0.3	1.53e-8	Total body bone mineral density;
CRC	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.9	-0.4	4.13e-14	Biliary atresia;
CRC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg21251018	chr6:28226885	NKAPL	0.39	5.75	0.3	2e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg02972257	chr16:68554789	NA	-0.49	-6.45	-0.33	4.07e-10	Ulcerative colitis;
CRC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.85	-9.81	-0.48	4.13e-20	Breast cancer;
CRC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.45	-7.52	-0.38	5.33e-13	Facial morphology (factor 20);
CRC	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.53	7.19	0.37	4.51e-12	Caudate activity during reward;
CRC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.47	7.07	0.36	9.44e-12	Menarche (age at onset);
CRC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-8.65	-0.43	2.29e-16	Platelet count;
CRC	cis	rs6700896	0.832	rs11208693	chr1:66108063	C/T	cg04111102	chr1:66153794	NA	0.32	5.66	0.3	3.22e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.68	10.78	0.51	2.0500000000000001e-23	Intelligence (multi-trait analysis);
CRC	cis	rs12476592	0.602	rs10865340	chr2:63824049	C/G	cg10828910	chr2:63850056	LOC388955	0.48	5.86	0.31	1.15e-8	Childhood ear infection;
CRC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.94	13.67	0.6	5.36e-34	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01338834	chr21:40720919	HMGN1	0.43	6.34	0.33	7.44e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.38	6.06	0.32	3.79e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.55	8.72	0.43	1.43e-16	Intelligence (multi-trait analysis);
CRC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg17724175	chr1:150552817	MCL1	0.51	7.51	0.38	5.78e-13	Melanoma;
CRC	cis	rs9992667	0.868	rs113071828	chr4:38665818	G/A	cg19726192	chr4:38663646	FLJ13197	-0.71	-9.0	-0.44	1.81e-17	Eosinophil percentage of granulocytes;
CRC	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.69	-10.15	-0.49	3.19e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.12	0.32	2.63e-9	Rheumatoid arthritis;
CRC	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	1.27	11.16	0.52	1.01e-24	Arsenic metabolism;
CRC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg26695010	chr11:65641043	EFEMP2	0.4	6.04	0.32	4.22e-9	Sum eosinophil basophil counts;Eosinophil counts;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03291336	chr15:69114244	ANP32A	0.39	6.0	0.31	5.34e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4664293	0.836	rs4664300	chr2:160600438	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.39	6.13	0.32	2.57e-9	Alzheimer's disease (late onset);
CRC	cis	rs4731207	0.698	rs4728010	chr7:124481420	T/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	8.73	0.43	1.32e-16	Educational attainment;
CRC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.41	8.14	0.41	8.28e-15	Tonsillectomy;
CRC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.55	-0.34	2.15e-10	Total cholesterol levels;
CRC	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.0	-0.31	5.3e-9	Retinal vascular caliber;
CRC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg16358738	chr2:241808595	AGXT	-0.39	-5.82	-0.31	1.42e-8	Urinary metabolites;
CRC	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg04783338	chr16:23160430	USP31	0.37	6.19	0.32	1.74e-9	Parkinson's disease;
CRC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	10.75	0.51	2.69e-23	Motion sickness;
CRC	cis	rs12024301	0.557	rs12068757	chr1:183663856	G/A	cg11505048	chr1:183622726	RGL1;APOBEC4	0.71	6.24	0.33	1.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs117623576	0.680	rs16932874	chr10:32358438	T/C	cg03047570	chr10:32398778	NA	-0.58	-6.48	-0.34	3.42e-10	Anti-saccade response;
CRC	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21659725	chr3:3221576	CRBN	-0.66	-9.07	-0.45	1.08e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg01874867	chr7:94954059	PON1	-0.49	-6.25	-0.33	1.27e-9	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.72	-8.96	-0.44	2.54e-17	Alzheimer's disease;
CRC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.98	-0.36	1.65e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	7.98	0.4	2.53e-14	Platelet count;
CRC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	15.24	0.64	4.6e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs4664293	1.000	rs4664293	chr2:160505752	T/C	cg08347373	chr2:160653686	CD302	-0.38	-6.24	-0.33	1.38e-9	Monocyte percentage of white cells;
CRC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.65	-9.89	-0.48	2.31e-20	Testicular germ cell tumor;
CRC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg18827107	chr12:86230957	RASSF9	-0.45	-7.42	-0.38	9.97e-13	Major depressive disorder;
CRC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.59	11.92	0.55	1.77e-27	Asthma (sex interaction);
CRC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.35	8.12	0.41	9.56e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.23	14.37	0.62	1.07e-36	Diabetic kidney disease;
CRC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.75	14.2	0.62	5.17e-36	Prudent dietary pattern;
CRC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-7.86	-0.4	5.71e-14	Intelligence (multi-trait analysis);
CRC	cis	rs3736485	0.844	rs79654603	chr15:51884862	G/A	cg08986416	chr15:51914746	DMXL2	-0.47	-6.47	-0.34	3.6e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.62	8.3	0.42	2.65e-15	Alzheimer's disease;
CRC	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg21918786	chr6:109611834	NA	-0.36	-6.1	-0.32	3e-9	Reticulocyte fraction of red cells;
CRC	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.6	-0.34	1.66e-10	Depression;
CRC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.4	0.42	1.36e-15	Height;
CRC	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg12964065	chr18:77638022	KCNG2	0.66	6.69	0.35	9.56e-11	Opioid sensitivity;
CRC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.54	8.25	0.41	3.77e-15	Aortic root size;
CRC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.46	-6.04	-0.32	4.12e-9	Gut microbiome composition (summer);
CRC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg21782813	chr7:2030301	MAD1L1	0.47	7.68	0.39	1.82e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.44	-7.21	-0.37	3.85e-12	Hemoglobin concentration;
CRC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg13880726	chr7:1868755	MAD1L1	-0.47	-5.67	-0.3	3.11e-8	Bipolar disorder;
CRC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.43	0.57	2.4e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.63	-9.83	-0.48	3.71e-20	Cognitive function;
CRC	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.5	7.82	0.4	7.3e-14	Hair shape;
CRC	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg16416165	chr4:3325029	RGS12	-0.37	-5.69	-0.3	2.77e-8	Mean platelet volume;
CRC	trans	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg26043149	chr18:55253948	FECH	-0.56	-8.84	-0.44	5.8e-17	Bone mineral density;
CRC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.87e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2179367	0.959	rs9322178	chr6:149693267	G/C	cg07828024	chr6:149772892	ZC3H12D	-0.39	-6.26	-0.33	1.17e-9	Dupuytren's disease;
CRC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg25164649	chr6:28176230	NA	0.77	9.5	0.46	4.6e-19	Depression;
CRC	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06307176	chr5:131281290	NA	0.38	5.6	0.3	4.48e-8	Life satisfaction;
CRC	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg13385794	chr1:248469461	NA	0.36	6.21	0.32	1.59e-9	Common traits (Other);
CRC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-6.58	-0.34	1.83e-10	Subjective well-being;
CRC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.4	5.6	0.3	4.47e-8	Uric acid clearance;
CRC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.43	7.32	0.37	1.95e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.75	-10.32	-0.49	8.2e-22	Coronary artery disease;
CRC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg00129232	chr17:37814104	STARD3	0.57	6.78	0.35	5.6e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.39	0.38	1.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.95	15.73	0.66	5.97e-42	Primary sclerosing cholangitis;
CRC	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00495681	chr13:53174319	NA	-0.55	-7.99	-0.4	2.32e-14	Lewy body disease;
CRC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.72	-11.48	-0.53	7.21e-26	Colorectal cancer;
CRC	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.61	0.3	4.26e-8	Soluble interleukin-2 receptor subunit alpha;
CRC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.17	-0.45	5.13e-18	Reticulocyte fraction of red cells;
CRC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.61	8.91	0.44	3.57e-17	Sudden cardiac arrest;
CRC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.71	-0.35	8.59e-11	Alzheimer's disease (late onset);
CRC	cis	rs6534441	0.579	rs312496	chr4:125449506	C/A	cg21609808	chr4:125404261	NA	0.36	5.78	0.3	1.76e-8	Major depressive disorder;
CRC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.69	9.31	0.46	1.85e-18	High light scatter reticulocyte count;
CRC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg10589385	chr1:150898437	SETDB1	0.32	6.83	0.35	4.05e-11	Melanoma;
CRC	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-10.56	-0.5	1.26e-22	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.86	-15.13	-0.64	1.29e-39	Body mass index;
CRC	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg11693508	chr17:37793320	STARD3	0.57	6.51	0.34	2.86e-10	Neuroticism;
CRC	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg07506560	chr2:240697449	NA	0.52	6.81	0.35	4.54e-11	Obesity-related traits;
CRC	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg12160578	chr15:63334699	TPM1	0.61	7.2	0.37	4.11e-12	Orofacial clefts;
CRC	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg16964102	chr10:135390573	NA	0.43	7.16	0.37	5.46e-12	Obesity-related traits;
CRC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.65	9.35	0.46	1.35e-18	Schizophrenia;
CRC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.63	-0.34	1.35e-10	Menopause (age at onset);
CRC	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.51	7.42	0.38	1e-12	Testicular germ cell tumor;
CRC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02290350	chr8:58132656	NA	-0.58	-8.13	-0.41	9.08e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.69	-12.5	-0.57	1.38e-29	Obesity-related traits;
CRC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-8.19	-0.41	5.98e-15	Type 2 diabetes;
CRC	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg09163369	chr1:210001066	C1orf107	-0.6	-7.61	-0.39	2.87e-13	Orofacial clefts;
CRC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.67	11.13	0.52	1.28e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11446398	chr5:77624930	NA	0.41	5.97	0.31	6.26e-9	Triglycerides;
CRC	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.42	-6.03	-0.32	4.29e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.08	0.36	8.82e-12	Hip circumference adjusted for BMI;
CRC	cis	rs10208940	0.920	rs11886343	chr2:68750336	G/A	cg12452813	chr2:68675892	NA	0.48	6.05	0.32	4.01e-9	Urate levels in lean individuals;
CRC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg24375607	chr4:120327624	NA	0.43	6.59	0.34	1.71e-10	Corneal astigmatism;
CRC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.45	6.82	0.35	4.26e-11	Menopause (age at onset);
CRC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.57	7.08	0.36	8.83e-12	Body mass index (adult);
CRC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	11.45	0.53	9.19e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CRC	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.54	-7.2	-0.37	4e-12	Testicular germ cell tumor;
CRC	cis	rs2160860	0.729	rs6984887	chr8:39801352	C/T	cg11363097	chr8:39792086	IDO2	-0.45	-7.57	-0.39	3.81e-13	Blood metabolite levels;
CRC	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg24848339	chr3:12840334	CAND2	0.35	6.52	0.34	2.6e-10	QRS complex (12-leadsum);
CRC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	13.77	0.6	2.25e-34	Alzheimer's disease;
CRC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.28	5.82	0.31	1.43e-8	Homoarginine levels;
CRC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg00106254	chr7:1943704	MAD1L1	0.41	6.28	0.33	1.08e-9	Bipolar disorder and schizophrenia;
CRC	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07307426	chr15:89089587	DET1	0.5	6.68	0.35	1.05e-10	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg09003973	chr2:102972529	NA	0.41	5.61	0.3	4.31e-8	Blood protein levels;
CRC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.66	-0.3	3.24e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg15110403	chr19:17392923	ANKLE1	-0.36	-6.09	-0.32	3.13e-9	Systemic lupus erythematosus;
CRC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg24046110	chr8:143859143	LYNX1	0.45	7.75	0.39	1.17e-13	Urinary tract infection frequency;
CRC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11645453	chr3:52864694	ITIH4	-0.4	-7.22	-0.37	3.72e-12	Bipolar disorder;
CRC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg19318889	chr4:1322082	MAEA	0.4	5.74	0.3	2.13e-8	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08693344	chr16:56691562	MT1F	0.39	6.86	0.35	3.38e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg11245181	chr6:149772854	ZC3H12D	0.54	9.56	0.47	2.95e-19	Dupuytren's disease;
CRC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-8.07	-0.41	1.3e-14	Major depressive disorder;
CRC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	8.09	0.41	1.16e-14	Platelet count;
CRC	cis	rs4700695	0.841	rs251614	chr5:65228251	C/G	cg21114390	chr5:65439923	SFRS12	-0.5	-6.32	-0.33	8.68e-10	Facial morphology (factor 19);
CRC	cis	rs6563739	0.655	rs4254189	chr13:40212417	G/A	cg00026919	chr13:40226031	NA	0.45	5.68	0.3	3e-8	Menarche (age at onset);
CRC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.45	7.7	0.39	1.65e-13	Childhood ear infection;
CRC	cis	rs6076065	0.723	rs2424536	chr20:23381601	C/T	cg11657817	chr20:23433608	CST11	0.45	6.71	0.35	8.65e-11	Facial morphology (factor 15, philtrum width);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23761332	chr2:208393956	CREB1	0.44	6.47	0.34	3.49e-10	Response to antipsychotic treatment;
CRC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.64	9.05	0.45	1.31e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.68	9.21	0.45	4.07e-18	Breast cancer;
CRC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-8.67	-0.43	1.93e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.49	7.62	0.39	2.77e-13	Corneal astigmatism;
CRC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs7274811	0.625	rs169797	chr20:31926490	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.4	-5.64	-0.3	3.72e-8	Height;
CRC	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg16898833	chr6:26189333	HIST1H4D	0.95	6.45	0.34	3.99e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18679886	chr7:107531975	DLD	0.45	6.23	0.32	1.41e-9	Response to antipsychotic treatment;
CRC	trans	rs1569175	0.850	rs3106088	chr2:200907393	A/C	cg19477977	chr2:235599692	NA	0.68	6.16	0.32	2.09e-9	Response to treatment for acute lymphoblastic leukemia;
CRC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.62	0.57	4.84e-30	Menopause (age at onset);
CRC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.6	0.3	4.5e-8	Diabetic retinopathy;
CRC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg13319975	chr6:146136371	FBXO30	0.43	6.45	0.34	3.96e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-7.49	-0.38	6.29e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.46	-6.02	-0.32	4.6e-9	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs12699921	0.566	rs2723515	chr7:17855466	A/G	cg02066331	chr6:17282778	RBM24	-0.36	-6.25	-0.33	1.27e-9	Fibrinogen levels;
CRC	cis	rs3790844	0.515	rs35094784	chr1:199949274	T/C	cg07208853	chr1:200005219	NR5A2	0.35	8.83	0.44	6.14e-17	Pancreatic cancer;
CRC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.37	6.33e-12	Reticulocyte fraction of red cells;
CRC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg02741985	chr17:80059408	CCDC57	0.44	7.21	0.37	3.78e-12	Life satisfaction;
CRC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16606324	chr3:10149918	C3orf24	0.71	9.54	0.47	3.33e-19	Alzheimer's disease;
CRC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.51	8.48	0.42	7.61e-16	Coronary artery disease;
CRC	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg11993925	chr19:44307056	LYPD5	0.47	7.74	0.39	1.25e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg02683197	chr6:28174875	NA	0.85	10.52	0.5	1.71e-22	Depression;
CRC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg02683197	chr6:28174875	NA	0.85	10.27	0.49	1.16e-21	Depression;
CRC	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.52	6.79	0.35	5.37e-11	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg24848437	chr7:2645542	IQCE	0.59	6.09	0.32	3.21e-9	Urate levels in lean individuals;
CRC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.88	8.67	0.43	1.96e-16	Lymphocyte counts;
CRC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg15448220	chr1:150897856	SETDB1	0.45	6.41	0.33	5.09e-10	Tonsillectomy;
CRC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg18225595	chr11:63971243	STIP1	0.59	6.24	0.33	1.35e-9	Mean platelet volume;
CRC	cis	rs62408225	0.962	rs905671	chr6:90983850	A/T	cg06866423	chr6:90926672	BACH2	0.48	8.03	0.4	1.74e-14	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs7147624	0.572	rs72714470	chr14:65979173	G/A	cg03016385	chr14:66212404	NA	1.02	7.99	0.4	2.32e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.73	9.9	0.48	2.21e-20	Coronary artery disease;
CRC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.63	10.75	0.51	2.7e-23	Prudent dietary pattern;
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg15845792	chr6:28175446	NA	0.73	6.45	0.34	3.9e-10	Breast cancer;
CRC	cis	rs4964805	0.865	rs4964289	chr12:104204191	G/A	cg02344784	chr12:104178138	NT5DC3	0.49	6.8	0.35	4.83e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.86	-0.35	3.45e-11	Alcohol dependence;
CRC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg14107975	chr11:96076498	MAML2	0.41	6.71	0.35	8.76e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg03774468	chr3:140950104	ACPL2	-0.65	-6.07	-0.32	3.61e-9	Cognitive function;
CRC	cis	rs2857891	1.000	rs2857891	chr11:6962957	C/T	cg14883916	chr11:6947541	ZNF215	0.62	6.8	0.35	5e-11	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.63	-0.34	1.39e-10	Menopause (age at onset);
CRC	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.47	-6.51	-0.34	2.83e-10	Eye color traits;
CRC	cis	rs2108622	0.727	rs3093193	chr19:15991914	C/G	cg13772218	chr19:15982569	NA	0.48	6.83	0.35	4e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg16606324	chr3:10149918	C3orf24	0.47	7.29	0.37	2.29e-12	Alzheimer's disease;
CRC	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.52	8.02	0.4	1.94e-14	Corneal astigmatism;
CRC	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.78	-0.3	1.76e-8	Blood pressure;
CRC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.65	0.43	2.34e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.83	15.49	0.65	4.79e-41	Vitiligo;
CRC	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.37	6.28	0.33	1.06e-9	Sitting height ratio;
CRC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.23	14.5	0.62	3.54e-37	Eosinophil percentage of granulocytes;
CRC	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg13385794	chr1:248469461	NA	0.38	6.75	0.35	6.84e-11	Common traits (Other);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14663065	chr3:41241630	CTNNB1	0.45	6.53	0.34	2.48e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.5	6.08	0.32	3.3e-9	Neutrophil percentage of white cells;
CRC	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.65	7.01	0.36	1.34e-11	Prostate cancer;
CRC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23161317	chr6:28129485	ZNF389	0.52	6.35	0.33	6.97e-10	Depression;
CRC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.03	-0.7	5.04e-51	Height;
CRC	cis	rs995000	0.899	rs1781212	chr1:62977419	G/A	cg19896129	chr1:63156450	NA	-0.45	-6.91	-0.36	2.54e-11	Triglyceride levels;
CRC	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg03929089	chr4:120376271	NA	0.65	6.3	0.33	9.41e-10	Intraocular pressure;
CRC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	8.33	0.42	2.14e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg20356878	chr3:121714668	ILDR1	-0.42	-5.99	-0.31	5.37e-9	Multiple sclerosis;
CRC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.88	19.92	0.74	1.77e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg12172441	chr6:28176163	NA	0.59	8.41	0.42	1.23e-15	Cardiac Troponin-T levels;
CRC	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg09003973	chr2:102972529	NA	0.72	7.88	0.4	4.83e-14	Gut microbiota (bacterial taxa);
CRC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.56	9.06	0.45	1.16e-17	Coronary artery disease;
CRC	trans	rs2303319	0.504	rs1006427	chr2:162592328	T/C	cg04551154	chr10:95462393	C10orf4	-0.75	-6.37	-0.33	6.43e-10	Cognitive function;
CRC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg16102536	chr7:156981717	UBE3C	0.41	6.77	0.35	5.78e-11	Body mass index;
CRC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.51	8.18	0.41	6.39e-15	Intelligence (multi-trait analysis);
CRC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.67	9.53	0.46	3.69e-19	Vitamin D levels;
CRC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-9.67	-0.47	1.25e-19	Menarche (age at onset);
CRC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg27068330	chr11:65405492	SIPA1	-0.42	-6.15	-0.32	2.29e-9	Acne (severe);
CRC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.58	0.47	2.43e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.78	12.63	0.57	4.43e-30	Lung cancer;
CRC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.5	7.02	0.36	1.31e-11	Aortic root size;
CRC	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.56	-9.11	-0.45	7.97e-18	Testicular germ cell tumor;
CRC	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg10761708	chr20:43804764	PI3	0.48	5.62	0.3	4.06e-8	Blood protein levels;
CRC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12172441	chr6:28176163	NA	0.56	7.16	0.37	5.25e-12	Parkinson's disease;
CRC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.56	-8.47	-0.42	8.28e-16	Systemic sclerosis;
CRC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.11	-0.32	2.88e-9	Lung cancer;
CRC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg06634786	chr22:41940651	POLR3H	-0.49	-6.18	-0.32	1.93e-9	Neuroticism;
CRC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.18	-0.41	6.43e-15	Monocyte percentage of white cells;
CRC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12273811	chr6:28175739	NA	0.69	8.83	0.44	6.17e-17	Depression;
CRC	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.22	0.32	1.55e-9	Lung cancer;
CRC	cis	rs41271951	0.512	rs115968379	chr1:151050087	A/C	cg11822372	chr1:151115635	SEMA6C	-0.7	-5.62	-0.3	4.02e-8	Blood protein levels;
CRC	cis	rs447	0.895	rs1468345	chr7:83748974	A/G	cg22846510	chr7:83753280	SEMA3A	-0.6	-7.79	-0.39	8.91e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.83	13.69	0.6	4.6e-34	Height;
CRC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.34	-6.15	-0.32	2.31e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg24562669	chr7:97807699	LMTK2	0.44	7.29	0.37	2.39e-12	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	8.68	0.43	1.81e-16	Menopause (age at onset);
CRC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.5	9.54	0.47	3.24e-19	Alcohol dependence;
CRC	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg11900509	chr10:81946545	ANXA11	-0.69	-7.23	-0.37	3.49e-12	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.74	-0.3	2.19e-8	Red blood cell count;
CRC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02290350	chr8:58132656	NA	-0.57	-7.91	-0.4	4.05e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg09264619	chr17:80180166	NA	-0.34	-5.81	-0.3	1.5e-8	Life satisfaction;
CRC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.41	0.38	1.06e-12	Electroencephalogram traits;
CRC	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg09003973	chr2:102972529	NA	0.86	9.04	0.45	1.43e-17	Gut microbiota (bacterial taxa);
CRC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg00246817	chr9:123691163	NA	-0.47	-6.01	-0.31	4.99e-9	Rheumatoid arthritis;
CRC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-6.57	-0.34	1.92e-10	Bipolar disorder;
CRC	cis	rs6662572	0.703	rs56278140	chr1:46357544	G/A	cg08644498	chr1:46502608	NA	0.44	6.84	0.35	3.82e-11	Blood protein levels;
CRC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.64	0.43	2.57e-16	Lymphocyte counts;
CRC	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.48	6.66	0.34	1.16e-10	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg19812747	chr11:111475976	SIK2	0.5	7.91	0.4	4.01e-14	Primary sclerosing cholangitis;
CRC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.72	11.65	0.54	1.67e-26	Dental caries;
CRC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.36	-7.57	-0.39	3.83e-13	Cutaneous nevi;
CRC	cis	rs7121446	0.520	rs7943463	chr11:121850960	T/C	cg13820391	chr11:121835505	NA	0.33	5.91	0.31	8.74e-9	Cardiovascular risk factors (age interaction);
CRC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.45	6.64	0.34	1.27e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.85	-0.35	3.67e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg10589385	chr1:150898437	SETDB1	-0.29	-6.14	-0.32	2.37e-9	Tonsillectomy;
CRC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg03037974	chr15:76606532	NA	0.66	11.45	0.53	9.04e-26	Blood metabolite levels;
CRC	cis	rs3751196	0.808	rs74623221	chr12:104211491	C/T	cg02344784	chr12:104178138	NT5DC3	0.71	7.54	0.38	4.58e-13	Sense of smell;
CRC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.52	9.12	0.45	7.89e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09175928	chr16:68344995	PRMT7;SLC7A6OS	0.42	6.31	0.33	9.16e-10	Schizophrenia;
CRC	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.08	0.32	3.36e-9	Blood protein levels;
CRC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.42	6.66	0.34	1.15e-10	Blood metabolite levels;
CRC	cis	rs460214	0.576	rs28446127	chr21:40029568	C/A	cg21578987	chr21:40029669	ERG	0.41	5.9	0.31	8.85e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.34	-0.33	7.72e-10	Reticulocyte fraction of red cells;
CRC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg14847009	chr1:175162515	KIAA0040	0.3	6.81	0.35	4.78e-11	Alcohol dependence;
CRC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.0	0.44	1.83e-17	Parkinson's disease;
CRC	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg08501292	chr6:25962987	TRIM38	0.82	7.5	0.38	6.11e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.46	5.97	0.31	6.09e-9	IgG glycosylation;
CRC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.61	12.61	0.57	5.09e-30	Schizophrenia;
CRC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.68	12.41	0.56	2.84e-29	Body mass index;
CRC	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg00732059	chr16:71740210	PHLPP2	-0.64	-6.67	-0.35	1.1e-10	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03424826	chr18:59561551	RNF152	0.42	6.86	0.35	3.4e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs11229555	0.645	rs10896775	chr11:58175989	A/T	cg15696309	chr11:58395628	NA	-0.81	-10.45	-0.5	2.9e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg10729496	chr3:10149963	C3orf24	0.55	7.08	0.36	8.63e-12	Alzheimer's disease;
CRC	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-10.53	-0.5	1.5e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg25876840	chr17:41920477	NA	0.53	7.88	0.4	4.83e-14	Triglycerides;
CRC	cis	rs2257205	0.667	rs78253932	chr17:56804101	C/G	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.14	0.41	8.29e-15	Lung cancer;
CRC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg24675056	chr1:15929824	NA	0.47	6.26	0.33	1.2e-9	Systolic blood pressure;
CRC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.55	8.97	0.44	2.3e-17	Breast cancer;
CRC	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.16	-0.37	5.35e-12	Red blood cell count;
CRC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg08888203	chr3:10149979	C3orf24	0.7	8.5	0.42	6.9e-16	Alzheimer's disease;
CRC	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg08795948	chr3:128337044	NA	0.34	5.78	0.3	1.72e-8	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.56	9.04	0.45	1.36e-17	Coronary artery disease;
CRC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-6.35	-0.33	7.08e-10	Alzheimer's disease (late onset);
CRC	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.34	-0.33	7.45e-10	Coronary artery disease;
CRC	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.44	-6.78	-0.35	5.46e-11	Asthma;
CRC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.54	8.58	0.43	3.86e-16	Height;
CRC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.56	6.1	0.32	2.92e-9	Vitiligo;
CRC	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.18	-0.32	1.84e-9	Height;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.36	-0.33	6.91e-10	Total body bone mineral density;
CRC	trans	rs10050311	0.698	rs78818211	chr4:87636388	C/T	cg00004207	chr2:38977301	SFRS7	0.5	6.07	0.32	3.56e-9	Insulin-related traits;
CRC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.52	6.99	0.36	1.58e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.37	6.66	0.34	1.16e-10	Breast cancer;
CRC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.93	-0.4	3.5e-14	Gut microbiome composition (summer);
CRC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.6	0.3	4.43e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.44	6.37	0.33	6.51e-10	Emphysema distribution in smoking;
CRC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg22529645	chr1:3704559	LRRC47	0.43	5.81	0.3	1.5e-8	Red cell distribution width;
CRC	cis	rs13315871	0.929	rs7634153	chr3:58237501	G/A	cg20936604	chr3:58311152	NA	-0.67	-6.76	-0.35	6.41e-11	Cholesterol, total;
CRC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.73	8.83	0.44	6.36e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.54	0.34	2.31e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.7	-7.75	-0.39	1.17e-13	Lung disease severity in cystic fibrosis;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg15790184	chr11:494944	RNH1	0.59	6.1	0.32	2.95e-9	Body mass index;
CRC	trans	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg24644049	chr4:85504048	CDS1	0.73	6.83	0.35	4.1e-11	Skin colour saturation;
CRC	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.24	6.61	0.34	1.59e-10	Type 2 diabetes;
CRC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	10.76	0.51	2.39e-23	Platelet count;
CRC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.25	-0.41	3.89e-15	Neuroticism;
CRC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.67	-9.95	-0.48	1.41e-20	Intelligence (multi-trait analysis);
CRC	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	6.19	0.32	1.8e-9	Morning vs. evening chronotype;
CRC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.33	0.46	1.57e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.58	-8.61	-0.43	3.07e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2882667	0.690	rs288036	chr5:138210895	C/A	cg09476006	chr5:138032270	NA	0.54	8.92	0.44	3.21e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg06840491	chr10:48416966	GDF2	-0.35	-6.07	-0.32	3.43e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.52	7.29	0.37	2.31e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07892339	chr1:156721493	HDGF	0.44	6.17	0.32	2.04e-9	Response to antipsychotic treatment;
CRC	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg12560992	chr17:57184187	TRIM37	0.5	6.33	0.33	8.19e-10	Vitamin D levels;
CRC	trans	rs12432203	0.831	rs72622424	chr14:51730989	T/A	cg14592830	chr9:122318704	NA	0.57	5.98	0.31	5.77e-9	Cancer;
CRC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg20933634	chr6:27740509	NA	0.59	8.66	0.43	2.1e-16	Parkinson's disease;
CRC	trans	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg11693508	chr17:37793320	STARD3	0.71	8.79	0.44	8.21e-17	Bipolar disorder;
CRC	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg19773385	chr1:10388646	KIF1B	-0.58	-8.15	-0.41	7.49e-15	Hepatocellular carcinoma;
CRC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.65	-9.58	-0.47	2.46e-19	Total body bone mineral density;
CRC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.54	-7.12	-0.37	6.84e-12	Glycated hemoglobin levels;
CRC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.41	8.87	0.44	4.63e-17	Glomerular filtration rate (creatinine);
CRC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.67	10.98	0.52	4.14e-24	Height;
CRC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.11	19.31	0.73	4.39e-56	Cognitive function;
CRC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.54	0.43	5.2e-16	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20349076	chr11:118992192	HINFP	0.4	6.49	0.34	3.16e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg13390004	chr1:15929781	NA	0.49	7.0	0.36	1.45e-11	Systolic blood pressure;
CRC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.6	9.41	0.46	8.81e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg19131313	chr8:1704013	NA	0.49	5.92	0.31	8.27e-9	Systolic blood pressure;
CRC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.75	13.0	0.58	1.81e-31	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg04415270	chr2:102091202	RFX8	-0.6	-8.61	-0.43	3.16e-16	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.65	10.67	0.51	4.95e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.34	3.1e-10	Lung cancer;
CRC	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.47	-7.4	-0.38	1.13e-12	Brain structure;
CRC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.86	14.73	0.63	4.66e-38	Intelligence (multi-trait analysis);
CRC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg07713946	chr22:31675144	LIMK2	0.38	5.89	0.31	9.68e-9	Colorectal cancer;
CRC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.5	9.9	0.48	2.19e-20	Renal cell carcinoma;
CRC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.72	12.18	0.56	1.96e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.58	6.35	0.33	7.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.92	16.95	0.68	9.27e-47	Intelligence (multi-trait analysis);
CRC	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg21918786	chr6:109611834	NA	0.36	6.29	0.33	1.03e-9	Reticulocyte fraction of red cells;
CRC	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg10761708	chr20:43804764	PI3	0.44	5.66	0.3	3.38e-8	Blood protein levels;
CRC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg25804541	chr17:80189381	SLC16A3	-0.31	-5.97	-0.31	6.08e-9	Life satisfaction;
CRC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.83	-0.31	1.3e-8	Carotid intima media thickness;
CRC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-7.28	-0.37	2.5e-12	Colorectal cancer;
CRC	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.46	0.42	8.99e-16	Mean corpuscular volume;
CRC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	10.28	0.49	1.13e-21	Systolic blood pressure;
CRC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg16892393	chr17:41919603	NA	0.49	7.55	0.38	4.32e-13	Triglycerides;
CRC	cis	rs12612619	0.732	rs6547401	chr2:27284845	A/G	cg00617064	chr2:27272375	NA	-0.37	-6.17	-0.32	1.97e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs6429082	0.509	rs2789362	chr1:235521235	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	6.72	0.35	7.81e-11	Adiposity;
CRC	cis	rs10760158	0.832	rs10760171	chr9:124058359	C/T	cg14417974	chr9:124058376	GSN	-0.34	-5.75	-0.3	2.04e-8	Pulse pressure;
CRC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.51	7.96	0.4	2.86e-14	Emphysema distribution in smoking;
CRC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-6.91	-0.36	2.5e-11	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs10512697	0.803	rs1867709	chr5:3576091	C/A	cg19473799	chr5:3511975	NA	-0.72	-5.67	-0.3	3.12e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg10517650	chr3:113235015	CCDC52	-0.37	-6.49	-0.34	3.16e-10	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.72	0.3	2.42e-8	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.46	-7.3	-0.37	2.14e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg09998033	chr7:158218633	PTPRN2	0.49	6.88	0.35	2.99e-11	Obesity-related traits;
CRC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	9.51	0.46	4.18e-19	Alzheimer's disease;
CRC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.94	17.29	0.69	4.4e-48	Intelligence (multi-trait analysis);
CRC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.44	6.49	0.34	3.23e-10	Menopause (age at onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02924619	chr14:65007171	HSPA2	0.47	6.34	0.33	7.66e-10	Anxiety disorder;
CRC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.9	-0.44	3.9e-17	Prostate cancer;
CRC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.8	9.86	0.48	2.95e-20	Lung function (FEV1/FVC);
CRC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07570687	chr10:102243282	WNT8B	0.44	5.64	0.3	3.61e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.37	5.89	0.31	9.38e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.77	-0.35	5.94e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.77	-10.45	-0.5	2.96e-22	White matter hyperintensity burden;
CRC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.98	0.48	1.15e-20	Cognitive test performance;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00300664	chr10:65224816	JMJD1C;LOC84989	0.46	6.45	0.34	4.03e-10	Response to antipsychotic treatment;
CRC	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg09659197	chr4:152720779	NA	-0.49	-10.63	-0.51	6.74e-23	Intelligence (multi-trait analysis);
CRC	cis	rs9847710	0.791	rs6808387	chr3:53079732	C/T	cg04503182	chr3:53078218	SFMBT1	-0.45	-7.15	-0.37	5.55e-12	Ulcerative colitis;
CRC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-10.74	-0.51	2.83e-23	Personality dimensions;
CRC	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.92	-19.11	-0.73	2.74e-55	Urate levels in lean individuals;
CRC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg18230493	chr5:56204884	C5orf35	-0.38	-5.64	-0.3	3.57e-8	Coronary artery disease;
CRC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	13.7	0.6	4.21e-34	Menarche (age at onset);
CRC	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.64	-10.05	-0.48	6.88e-21	Coronary artery disease;
CRC	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg12756093	chr1:115239321	AMPD1	0.56	8.32	0.42	2.42e-15	Autism;
CRC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.33	-0.33	8.04e-10	Alzheimer's disease (late onset);
CRC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.38	6.14	0.32	2.4e-9	Ulcerative colitis;
CRC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.87	-0.31	1.08e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs3757247	0.729	rs4706361	chr6:90915910	T/C	cg06866423	chr6:90926672	BACH2	0.47	8.07	0.41	1.34e-14	Vitiligo;Type 1 diabetes;
CRC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg09264619	chr17:80180166	NA	-0.51	-7.35	-0.38	1.55e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg16405210	chr4:1374714	KIAA1530	0.42	5.98	0.31	5.89e-9	Obesity-related traits;
CRC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg26695010	chr11:65641043	EFEMP2	-0.4	-5.76	-0.3	1.89e-8	Eosinophil percentage of white cells;
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.63	-9.91	-0.48	2.05e-20	Monocyte percentage of white cells;
CRC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.91	0.4	3.83e-14	Cognitive ability;
CRC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.73	12.35	0.56	4.83e-29	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.77	8.71	0.43	1.45e-16	Lung disease severity in cystic fibrosis;
CRC	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg13385794	chr1:248469461	NA	0.34	6.18	0.32	1.86e-9	Common traits (Other);
CRC	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg21153622	chr11:89784906	NA	-0.44	-7.09	-0.36	8.32e-12	HDL cholesterol;
CRC	cis	rs12913538	0.755	rs12915312	chr15:62895475	G/C	cg09983546	chr15:62884068	NA	0.46	6.2	0.32	1.67e-9	Sleep depth;
CRC	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.34	6.14	0.32	2.42e-9	Inattentive symptoms;
CRC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	6.14	0.32	2.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg06223162	chr1:101003688	GPR88	-0.31	-5.72	-0.3	2.34e-8	Breast cancer;
CRC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.46	-9.14	-0.45	6.83e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.09	-0.36	8.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.67	10.5	0.5	1.9e-22	Gestational age at birth (maternal effect);
CRC	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg07470512	chr20:32255052	NECAB3;C20orf134	-0.45	-5.95	-0.31	6.98e-9	Height;
CRC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25517755	chr10:38738941	LOC399744	0.45	6.57	0.34	1.93e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg12927641	chr6:109611667	NA	-0.37	-6.61	-0.34	1.52e-10	Reticulocyte fraction of red cells;
CRC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.5	-7.68	-0.39	1.89e-13	Monocyte count;
CRC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg07718321	chr6:96025334	MANEA	0.44	5.97	0.31	6.19e-9	Behavioural disinhibition (generation interaction);
CRC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-0.84	-12.29	-0.56	8.14e-29	Platelet distribution width;
CRC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.96	-0.36	1.9e-11	Obesity-related traits;
CRC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.36	-5.74	-0.3	2.15e-8	Ulcerative colitis;
CRC	cis	rs4363385	0.679	rs6686286	chr1:152984562	T/C	cg25856811	chr1:152973957	SPRR3	-0.26	-7.09	-0.36	8.28e-12	Inflammatory skin disease;
CRC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.1	10.9	0.52	7.71e-24	Diabetic retinopathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01708236	chr6:44233446	NFKBIE	0.39	6.04	0.32	4.19e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.83	-12.27	-0.56	9.4e-29	Gut microbiome composition (summer);
CRC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.73	11.54	0.54	4.38e-26	Intelligence (multi-trait analysis);
CRC	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-14.7	-0.63	5.76e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-6.56	-0.34	2.03e-10	Coronary artery disease;
CRC	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg27083787	chr2:113543245	IL1A	0.46	6.59	0.34	1.76e-10	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.45	7.31	0.37	2.08e-12	Colonoscopy-negative controls vs population controls;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11913218	chr1:10754156	CASZ1	0.37	6.49	0.34	3.22e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg14530993	chr4:882597	GAK	0.8	7.51	0.38	5.67e-13	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13674574	chr14:64971270	ZBTB25;ZBTB1	0.43	6.1	0.32	2.97e-9	Anxiety disorder;
CRC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.59	-7.51	-0.38	5.75e-13	Gut microbiome composition (summer);
CRC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-8.34	-0.42	1.99e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg02018176	chr4:1364513	KIAA1530	0.47	7.7	0.39	1.5700000000000001e-13	Obesity-related traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22998610	chr11:62538411	TAF6L	0.4	6.43	0.33	4.38e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg12564285	chr5:131593104	PDLIM4	0.4	7.61	0.39	2.92e-13	Blood metabolite levels;
CRC	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg13736514	chr6:26305472	NA	-0.36	-6.17	-0.32	1.99e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07005090	chr11:59522827	STX3	0.38	5.98	0.31	5.78e-9	Schizophrenia;
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.56	6.58	0.34	1.91e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-10.05	-0.48	6.89e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.58	-0.34	1.9e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CRC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-7.3	-0.37	2.24e-12	Total body bone mineral density;
CRC	cis	rs9308731	0.966	rs4849442	chr2:111934219	C/T	cg04202892	chr2:111875749	ACOXL	0.36	5.72	0.3	2.43e-8	Chronic lymphocytic leukemia;
CRC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	0.53	8.91	0.44	3.55e-17	Intelligence (multi-trait analysis);
CRC	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg24851651	chr11:66362959	CCS	-0.39	-6.86	-0.35	3.45e-11	Educational attainment (years of education);
CRC	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.46	-6.69	-0.35	9.65e-11	Breast cancer;
CRC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg12682573	chr17:27188876	MIR451;MIR144	-0.57	-7.89	-0.4	4.43e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.18	0.32	1.89e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7429990	0.965	rs7651237	chr3:48105528	A/G	cg11946769	chr3:48343235	NME6	-0.58	-6.88	-0.35	2.99e-11	Educational attainment (years of education);
CRC	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg26695010	chr11:65641043	EFEMP2	0.41	5.97	0.31	6.06e-9	DNA methylation (variation);
CRC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.5	5.82	0.31	1.38e-8	Depression;
CRC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg19913688	chr11:428466	ANO9	-0.7	-7.19	-0.37	4.26e-12	Body mass index;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg22924680	chr5:43557135	PAIP1	0.36	5.98	0.31	5.72e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg10729496	chr3:10149963	C3orf24	0.49	5.77	0.3	1.83e-8	Alzheimer's disease;
CRC	trans	rs4276421	0.776	rs7717787	chr5:45466616	C/G	cg04793272	chr11:119020941	ABCG4	-0.4	-6.57	-0.34	1.95e-10	P wave duration;
CRC	cis	rs9302690	1.000	rs9302690	chr16:57442968	G/A	cg27017172	chr16:57497170	POLR2C	0.58	5.99	0.31	5.42e-9	Blood protein levels;
CRC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.97	-18.38	-0.71	2.06e-52	Cognitive ability;
CRC	cis	rs6681460	1.000	rs7524818	chr1:67072031	C/T	cg02459107	chr1:67143332	SGIP1	0.45	7.84	0.4	6.45e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.36	-6.82	-0.35	4.24e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg05527609	chr1:210001259	C1orf107	-0.57	-6.34	-0.33	7.45e-10	Red blood cell count;
CRC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18252515	chr7:66147081	NA	0.4	5.8	0.3	1.57e-8	Aortic root size;
CRC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.31	-0.37	1.99e-12	Coronary artery disease;
CRC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-9.22	-0.45	3.72e-18	Total body bone mineral density;
CRC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.77	11.71	0.54	1.07e-26	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg20512303	chr5:131592959	PDLIM4	0.41	7.21	0.37	3.95e-12	Acylcarnitine levels;
CRC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	0.93	13.48	0.6	2.71e-33	Breast cancer;
CRC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.36	7.99	0.4	2.28e-14	Multiple system atrophy;
CRC	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg24140574	chr1:16342155	HSPB7	0.47	6.65	0.34	1.19e-10	Dilated cardiomyopathy;
CRC	trans	rs1390943	1.000	rs13253777	chr8:20071770	C/G	cg13714271	chr9:33076774	SMU1	-0.45	-6.24	-0.33	1.32e-9	Circulating myeloperoxidase levels (serum);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05422897	chr2:113403145	SLC20A1	0.45	6.16	0.32	2.07e-9	Response to antipsychotic treatment;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16484842	chr20:57556086	TH1L	0.46	6.74	0.35	7.04e-11	Intelligence (multi-trait analysis);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18759346	chr3:149470375	COMMD2	0.43	6.06	0.32	3.71e-9	Response to antipsychotic treatment;
CRC	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg21153622	chr11:89784906	NA	-0.48	-7.72	-0.39	1.45e-13	HDL cholesterol;
CRC	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.52	7.68	0.39	1.82e-13	Corneal astigmatism;
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg09883849	chr7:12510863	NA	0.69	5.98	0.31	5.74e-9	Temperament (bipolar disorder);
CRC	cis	rs6142102	0.961	rs2377957	chr20:32554473	A/G	cg08999081	chr20:33150536	PIGU	0.4	6.18	0.32	1.94e-9	Skin pigmentation;
CRC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19717773	chr7:2847554	GNA12	-0.49	-6.72	-0.35	8.1e-11	Height;
CRC	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.74	13.05	0.58	1.14e-31	Coronary artery disease;
CRC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.41	7.91	0.4	4.04e-14	Mean corpuscular volume;
CRC	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg22495460	chr2:25135724	ADCY3	-0.67	-11.27	-0.53	4.04e-25	Body mass index in non-asthmatics;
CRC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.63	7.14	0.37	5.98e-12	Cannabis dependence symptom count;
CRC	cis	rs16858210	0.618	rs6794500	chr3:183620769	A/G	cg25686905	chr3:183603175	PARL	-0.47	-5.83	-0.31	1.34e-8	Menopause (age at onset);
CRC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-5.67	-0.3	3.07e-8	Neuroticism;
CRC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.63	-6.63	-0.34	1.38e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs62432291	0.681	rs3003174	chr6:159655326	T/C	cg14500486	chr6:159655392	FNDC1	-0.76	-10.4	-0.5	4.17e-22	Joint mobility (Beighton score);
CRC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.8	14.02	0.61	2.36e-35	Breast cancer;
CRC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	11.57	0.54	3.23e-26	Prudent dietary pattern;
CRC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.54	8.17	0.41	6.9e-15	Heart rate;
CRC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg13798780	chr7:105162888	PUS7	0.68	8.08	0.41	1.27e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.45	5.89	0.31	9.73e-9	Heart rate;
CRC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	11.12	0.52	1.33e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.43	6.99	0.36	1.58e-11	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg25441200	chr7:156742235	NOM1	0.49	6.4	0.33	5.47e-10	Thyroid stimulating hormone;
CRC	cis	rs12760731	0.545	rs34112873	chr1:178519943	C/T	cg00404053	chr1:178313656	RASAL2	0.64	7.3	0.37	2.24e-12	Obesity-related traits;
CRC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-6.03	-0.32	4.3e-9	Gut microbiome composition (summer);
CRC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg10298567	chr3:47292165	KIF9	-0.42	-6.93	-0.36	2.16e-11	Colorectal cancer;
CRC	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg03651054	chr13:50194643	NA	0.29	5.64	0.3	3.7e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.48	-6.7	-0.35	8.81e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.49	7.3	0.37	2.23e-12	Dialysis-related mortality;
CRC	cis	rs728616	0.681	rs11815284	chr10:82023142	G/T	cg05935833	chr10:81318306	SFTPA2	-0.47	-6.28	-0.33	1.08e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.64	8.64	0.43	2.44e-16	Gut microbiome composition (summer);
CRC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.08	-0.32	3.39e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs3018066	0.720	rs55633564	chr4:106981560	G/T	cg01869342	chr4:106983673	TBCK	0.46	6.83	0.35	4.1e-11	Cancer;
CRC	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.53	-8.3	-0.42	2.68e-15	Hyperactive-impulsive symptoms;
CRC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.72	12.11	0.56	3.75e-28	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs716595	0.786	rs10509912	chr10:112029405	T/A	cg19584136	chr10:111975951	MXI1	-0.56	-6.13	-0.32	2.56e-9	Normalized brain volume;
CRC	cis	rs12144094	1.000	rs12139860	chr1:120262848	G/T	cg20995928	chr1:120229863	NA	0.48	5.86	0.31	1.11e-8	Height;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg25420398	chr3:133968920	RYK	0.41	6.38	0.33	6.1e-10	Interleukin-6 levels;
CRC	cis	rs10512697	0.803	rs34007257	chr5:3576503	C/T	cg19473799	chr5:3511975	NA	-0.73	-5.72	-0.3	2.34e-8	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg00990874	chr7:1149470	C7orf50	-0.54	-6.19	-0.32	1.79e-9	Bronchopulmonary dysplasia;
CRC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.79	10.86	0.51	1.11e-23	Cognitive function;
CRC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.56	-7.76	-0.39	1.1e-13	DNA methylation (variation);
CRC	cis	rs8032158	0.963	rs56333939	chr15:56124535	T/C	cg02198044	chr15:56286336	NEDD4	-0.39	-6.0	-0.31	5.12e-9	Keloid;
CRC	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg23127183	chr11:57508653	C11orf31	-0.53	-7.17	-0.37	4.95e-12	Schizophrenia;
CRC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.84	0.55	3.59e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs2051211	0.947	rs60479981	chr3:38568611	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.77	-0.3	1.87e-8	QRS duration;
CRC	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.86	0.4	5.46e-14	Corneal astigmatism;
CRC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.37	5.71	0.3	2.58e-8	Cystic fibrosis severity;
CRC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg13385521	chr17:29058706	SUZ12P	0.64	7.64	0.39	2.42e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.14	0.37	6.11e-12	Ulcerative colitis;
CRC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg19913688	chr11:428466	ANO9	-0.65	-6.58	-0.34	1.83e-10	Body mass index;
CRC	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.49	6.89	0.36	2.86e-11	Schizophrenia;
CRC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-10.06	-0.48	6.31e-21	Cognitive function;
CRC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg21138405	chr5:131827807	IRF1	0.35	6.03	0.32	4.33e-9	Breast cancer;Mosquito bite size;
CRC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.6	-9.36	-0.46	1.29e-18	Colorectal cancer;
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.82	11.82	0.55	4.14e-27	Colorectal cancer;
CRC	cis	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg18131467	chr2:239335373	ASB1	-0.71	-6.28	-0.33	1.06e-9	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.92	0.36	2.35e-11	Colonoscopy-negative controls vs population controls;
CRC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg10298567	chr3:47292165	KIF9	0.38	6.11	0.32	2.74e-9	Colorectal cancer;
CRC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-8.23	-0.41	4.39e-15	Mean platelet volume;
CRC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg21153622	chr11:89784906	NA	-0.48	-8.09	-0.41	1.17e-14	Coronary artery disease;
CRC	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg13798912	chr7:905769	UNC84A	0.57	6.13	0.32	2.48e-9	Cerebrospinal P-tau181p levels;
CRC	trans	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg26043149	chr18:55253948	FECH	-0.52	-7.84	-0.4	6.49e-14	Bone mineral density;
CRC	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg09829573	chr1:144692074	NBPF9	-0.4	-5.97	-0.31	6.28e-9	Hip geometry;
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg19223190	chr17:80058835	NA	-0.42	-6.72	-0.35	7.89e-11	Life satisfaction;
CRC	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.34	0.46	1.45e-18	Ileal carcinoids;
CRC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.62	-0.43	2.95e-16	Body mass index;
CRC	cis	rs9311676	0.656	rs62258120	chr3:58391128	G/A	cg06643156	chr3:58380774	PXK	0.41	6.33	0.33	7.82e-10	Systemic lupus erythematosus;
CRC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.77	0.35	5.77e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.64	-9.45	-0.46	6.38e-19	Intelligence (multi-trait analysis);
CRC	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg17517138	chr11:73019481	ARHGEF17	0.55	6.13	0.32	2.53e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg19682013	chr15:45996608	NA	0.32	6.7	0.35	9.09e-11	Waist circumference;Weight;
CRC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.6	9.65	0.47	1.49e-19	Personality dimensions;
CRC	cis	rs6066835	0.867	rs6090901	chr20:47370788	T/C	cg18078177	chr20:47281410	PREX1	0.69	5.92	0.31	8.29e-9	Multiple myeloma;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg08108993	chr17:38136923	PSMD3	0.5	6.24	0.33	1.33e-9	Thyroid stimulating hormone;
CRC	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.48	-8.12	-0.41	9.74e-15	Endometriosis;
CRC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.54	8.69	0.43	1.78e-16	Mean corpuscular hemoglobin concentration;
CRC	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.24e-37	Hypertriglyceridemia;
CRC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	7.53	0.38	4.89e-13	Motion sickness;
CRC	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-6.68	-0.35	1.03e-10	Eye color traits;
CRC	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.63	9.76	0.47	6.33e-20	Corneal astigmatism;
CRC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.47	5.79	0.3	1.67e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.04	12.76	0.58	1.48e-30	Nonalcoholic fatty liver disease;
CRC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.76	13.64	0.6	7.08e-34	Anterior chamber depth;
CRC	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg14345882	chr6:26364793	BTN3A2	0.65	5.73	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.56	6.36	0.33	6.62e-10	Skin colour saturation;
CRC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.93	-0.48	1.76e-20	Extrinsic epigenetic age acceleration;
CRC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	8.55	0.43	4.8e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.44	0.38	8.73e-13	Alzheimer's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg25626508	chr5:54469057	CDC20B;MIR449C	0.37	6.05	0.32	4.01e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7487075	0.619	rs4768718	chr12:46834336	G/C	cg22049899	chr12:47219821	SLC38A4	0.31	5.75	0.3	2.08e-8	Itch intensity from mosquito bite;
CRC	cis	rs4654899	0.733	rs10799677	chr1:21318456	A/C	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.66	-0.34	1.14e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs932541	1.000	rs6043991	chr20:16457369	C/T	cg17003395	chr20:16555519	KIF16B	0.41	5.62	0.3	4e-8	Intelligence;
CRC	trans	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg26043149	chr18:55253948	FECH	0.51	7.96	0.4	2.86e-14	Bone mineral density;
CRC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.61	-7.61	-0.39	2.96e-13	Body mass index;
CRC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.66	9.65	0.47	1.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.4	18.96	0.72	1.04e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7632954	0.904	rs968160	chr3:8523334	G/A	cg03495237	chr3:8533978	NA	0.33	5.63	0.3	3.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs4838594	0.563	rs9794032	chr10:49681286	A/G	cg17291251	chr10:49678358	ARHGAP22	0.46	7.26	0.37	2.82e-12	Daytime sleep phenotypes;
CRC	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg06522879	chr11:64358276	SLC22A12	0.55	8.66	0.43	2.12e-16	Urate levels in obese individuals;
CRC	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.47	8.77	0.44	9.67e-17	Educational attainment (years of education);
CRC	cis	rs2013441	1.000	rs972966	chr17:20030992	G/C	cg13482628	chr17:19912719	NA	0.39	6.09	0.32	3.08e-9	Obesity-related traits;
CRC	cis	rs6540556	0.834	rs11119337	chr1:209934133	A/G	cg23920097	chr1:209922102	NA	-0.49	-6.33	-0.33	7.98e-10	Red blood cell count;
CRC	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg23750338	chr8:142222470	SLC45A4	0.39	5.87	0.31	1.06e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.73	9.77	0.47	5.73e-20	Alzheimer's disease;
CRC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-6.27	-0.33	1.14e-9	Aortic root size;
CRC	trans	rs10139154	0.782	rs229221	chr14:31004226	T/C	cg18753625	chr19:36705707	ZNF565;ZNF146	-0.42	-5.99	-0.31	5.38e-9	Amyotrophic lateral sclerosis;
CRC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.87	-0.58	5.46e-31	Hemoglobin concentration;
CRC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.85	12.84	0.58	7.12e-31	Longevity;
CRC	trans	rs4378999	0.660	rs9820606	chr3:50771819	G/A	cg12383621	chr7:7735611	RPA3	-0.48	-6.05	-0.32	3.92e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CRC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.78	11.99	0.55	9.62e-28	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg17294928	chr15:75287854	SCAMP5	0.6	9.42	0.46	8.38e-19	Breast cancer;
CRC	cis	rs7923609	0.841	rs10761786	chr10:65336207	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.7	-0.3	2.69e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.54	8.55	0.43	4.78e-16	Colorectal cancer;
CRC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg13390004	chr1:15929781	NA	0.49	7.0	0.36	1.45e-11	Systolic blood pressure;
CRC	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.5	8.29	0.42	2.92e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-7.38	-0.38	1.32e-12	Total body bone mineral density;
CRC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg24560729	chr4:1342394	KIAA1530	0.44	7.99	0.4	2.3e-14	Longevity;
CRC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg16070123	chr10:51489643	NA	-0.34	-5.85	-0.31	1.2e-8	Prostate-specific antigen levels;
CRC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg21153622	chr11:89784906	NA	-0.49	-8.13	-0.41	8.82e-15	Coronary artery disease;
CRC	cis	rs4731207	0.564	rs10260039	chr7:124603546	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.22	-0.32	1.47e-9	Cutaneous malignant melanoma;
CRC	cis	rs2249694	0.520	rs7911139	chr10:135323525	T/C	cg20169779	chr10:135381914	SYCE1	-0.53	-7.24	-0.37	3.18e-12	Obesity-related traits;
CRC	cis	rs7781557	1.000	rs7790451	chr7:102465988	G/A	cg18108683	chr7:102477205	FBXL13	-0.5	-6.62	-0.34	1.46e-10	Colorectal adenoma (advanced);
CRC	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.54	9.63	0.47	1.74e-19	Common traits (Other);
CRC	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.67	11.44	0.53	1e-25	Subjective well-being (multi-trait analysis);
CRC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-20.61	-0.75	3.6e-61	Height;
CRC	cis	rs2882667	0.652	rs6596463	chr5:138444926	A/G	cg09476006	chr5:138032270	NA	0.43	6.99	0.36	1.5e-11	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	12.29	0.56	8.09e-29	Nonalcoholic fatty liver disease;
CRC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.65	10.37	0.5	5.65e-22	Huntington's disease progression;
CRC	cis	rs12024301	0.557	rs79746696	chr1:183608776	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	6.83	0.35	4.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg15845792	chr6:28175446	NA	0.82	12.17	0.56	2.24e-28	Parkinson's disease;
CRC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg13319975	chr6:146136371	FBXO30	0.44	6.54	0.34	2.4e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg04990556	chr1:26633338	UBXN11	-0.48	-6.09	-0.32	3.22e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.64	-8.97	-0.44	2.27e-17	DNA methylation (variation);
CRC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg25985355	chr7:65971099	NA	-0.48	-5.69	-0.3	2.87e-8	Diabetic kidney disease;
CRC	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-8.22	-0.41	4.68e-15	HDL cholesterol;
CRC	cis	rs3825932	0.744	rs11072818	chr15:79236933	A/G	cg25744700	chr15:79237217	CTSH	0.4	5.99	0.31	5.35e-9	Type 1 diabetes;
CRC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.9	-0.31	9e-9	Heart rate;
CRC	trans	rs2303319	0.504	rs62189047	chr2:162613314	T/A	cg11326919	chr17:43324904	LOC100133991	-0.64	-5.97	-0.31	5.99e-9	Cognitive function;
CRC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.22	0.73	9.69e-56	Parkinson's disease;
CRC	cis	rs802075	0.765	rs2145331	chr6:49598877	G/C	cg20364632	chr6:49636226	NA	-0.34	-5.64	-0.3	3.64e-8	Bone mineral density (hip) and age at menarche;
CRC	trans	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.38	5.99	0.31	5.6e-9	Obesity;
CRC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg17724175	chr1:150552817	MCL1	0.47	6.91	0.36	2.47e-11	Melanoma;
CRC	cis	rs1178968	0.901	rs2528705	chr7:72791238	A/G	cg25889504	chr7:72793014	NA	0.55	6.02	0.32	4.61e-9	Triglyceride levels;
CRC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13198984	chr17:80129470	CCDC57	0.43	7.5	0.38	6.19e-13	Life satisfaction;
CRC	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.43	6.09	0.32	3.11e-9	Body mass index;
CRC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg11189052	chr15:85197271	WDR73	0.63	8.8	0.44	7.65e-17	Schizophrenia;
CRC	cis	rs59104589	0.583	rs3771573	chr2:242387346	G/A	cg19488206	chr2:242435732	STK25	0.49	7.12	0.37	6.8e-12	Fibrinogen levels;
CRC	cis	rs6969780	0.915	rs17471520	chr7:27178790	T/C	cg26364809	chr7:27145159	NA	-0.75	-6.96	-0.36	1.87e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	12.22	0.56	1.46e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.75	7.89	0.4	4.65e-14	Cognitive function;
CRC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.37	-0.46	1.21e-18	Bipolar disorder and schizophrenia;
CRC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs13144136	0.687	rs11725559	chr4:10654270	A/G	cg10242279	chr4:10666415	CLNK	0.37	6.22	0.32	1.5e-9	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg09582351	chr12:29534625	ERGIC2	0.36	7.77	0.39	1.01e-13	QT interval;
CRC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-10.36	-0.5	5.7e-22	Tonsillectomy;
CRC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg19622623	chr12:86230825	RASSF9	-0.37	-5.62	-0.3	4.06e-8	Major depressive disorder;
CRC	cis	rs56307353	0.513	rs2041120	chr19:1961474	C/T	cg08800497	chr19:1970008	CSNK1G2	0.7	11.39	0.53	1.52e-25	Coronary artery disease;
CRC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.54	0.47	3.36e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19500275	chr17:80737654	TBCD	0.53	7.15	0.37	5.5e-12	Glycated hemoglobin levels;
CRC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg00597713	chr6:42947103	PEX6	-0.4	-5.62	-0.3	4.12e-8	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-6.16	-0.32	2.1e-9	Aortic root size;
CRC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.47	-6.81	-0.35	4.53e-11	Lymphocyte counts;
CRC	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.47	-0.34	3.59e-10	Capecitabine sensitivity;
CRC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg02135003	chr7:105160482	PUS7	-0.96	-12.76	-0.58	1.42e-30	Bipolar disorder (body mass index interaction);
CRC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg11189052	chr15:85197271	WDR73	-0.63	-9.33	-0.46	1.57e-18	Schizophrenia;
CRC	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg23378565	chr7:2036160	MAD1L1	-0.38	-6.49	-0.34	3.07e-10	Bipolar disorder;
CRC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg03623178	chr6:28175578	NA	0.85	11.62	0.54	2.25e-26	Depression;
CRC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.87	0.55	2.62e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1109861	1.000	rs1109861	chr10:11246269	A/C	cg24910943	chr10:11206320	CUGBP2	0.21	5.74	0.3	2.11e-8	Urinary albumin-to-creatinine ratio;
CRC	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg18830697	chr6:72922368	RIMS1	-0.4	-8.05	-0.41	1.58e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CRC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-10.75	-0.51	2.75e-23	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg06470822	chr6:28175283	NA	1.0	13.22	0.59	2.7e-32	Depression;
CRC	cis	rs11627756	0.958	rs4906238	chr14:103077702	G/A	cg12046867	chr14:103022105	NA	-0.42	-5.72	-0.3	2.36e-8	Mean platelet volume;
CRC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg14191688	chr11:70257035	CTTN	0.49	6.59	0.34	1.79e-10	Coronary artery disease;
CRC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg19622623	chr12:86230825	RASSF9	-0.4	-6.43	-0.33	4.53e-10	Major depressive disorder;
CRC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.66	12.02	0.55	7.8e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.52	-9.33	-0.46	1.59e-18	Educational attainment;
CRC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.49	8.29	0.42	2.99e-15	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.38	6.52	0.34	2.65e-10	Frontotemporal dementia;
CRC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.46	7.02	0.36	1.24e-11	Dupuytren's disease;
CRC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg02089348	chr4:1724449	TMEM129;TACC3	0.38	5.64	0.3	3.73e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-11.11	-0.52	1.42e-24	Hepatocellular carcinoma;
CRC	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg08533674	chr1:46993347	NA	-0.51	-6.89	-0.35	2.92e-11	Monobrow;
CRC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.41	7.88	0.4	4.72e-14	Hypertriglyceridemia;
CRC	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	7.86	0.4	5.5e-14	Response to antipsychotic treatment;
CRC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg10544611	chr16:67998164	SLC12A4	-0.53	-5.64	-0.3	3.66e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg12183467	chr14:104352244	NA	0.54	7.41	0.38	1.11e-12	Bipolar disorder;
CRC	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.58	9.55	0.47	3.1e-19	Mean corpuscular volume;
CRC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg02089348	chr4:1724449	TMEM129;TACC3	-0.4	-5.82	-0.31	1.43e-8	Bladder cancer;Urinary bladder cancer;
CRC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.48	9.3	0.46	2.09e-18	Breast cancer;
CRC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.33	6.93	0.36	2.18e-11	Renal cell carcinoma;
CRC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.63	8.88	0.44	4.3e-17	Homoarginine levels;
CRC	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.52	-7.57	-0.39	3.67e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs10982256	0.870	rs10817625	chr9:117247587	A/T	cg13636371	chr9:117264095	DFNB31	0.31	5.9	0.31	8.85e-9	Bipolar disorder;
CRC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.71	-11.96	-0.55	1.25e-27	Breast cancer;
CRC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg08798685	chr6:27730294	NA	-0.57	-6.32	-0.33	8.54e-10	Lung cancer in ever smokers;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02422812	chr5:154062204	NA	0.43	6.1	0.32	2.98e-9	Response to antipsychotic treatment;
CRC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg02321871	chr13:50159138	RCBTB1	-0.44	-6.17	-0.32	2e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.38	-7.95	-0.4	3.05e-14	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.05	-0.32	4.04e-9	Total body bone mineral density;
CRC	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.47	-6.59	-0.34	1.76e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg00063174	chr2:228736253	WDR69	-0.5	-6.73	-0.35	7.7e-11	Blood pressure;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25408707	chr6:160393049	IGF2R	0.41	6.29	0.33	1.04e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.37	6.22	0.32	1.51e-9	Blood metabolite levels;
CRC	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.47	-6.05	-0.32	3.87e-9	Alopecia areata;
CRC	cis	rs12760731	0.517	rs34437852	chr1:178228721	T/C	cg00404053	chr1:178313656	RASAL2	1.13	11.64	0.54	1.86e-26	Obesity-related traits;
CRC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-12.45	-0.57	2.09e-29	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg10756647	chr7:56101905	PSPH	0.73	7.79	0.39	8.92e-14	Diabetic kidney disease;
CRC	cis	rs713477	0.631	rs7145182	chr14:55905231	C/G	cg21836586	chr14:55907198	TBPL2	0.31	5.6	0.3	4.52e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.49e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs3736485	0.966	rs11634180	chr15:51895757	G/C	cg08986416	chr15:51914746	DMXL2	-0.47	-6.7	-0.35	9e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.81	13.21	0.59	3.04e-32	Height;
CRC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg05623727	chr3:50126028	RBM5	0.45	7.23	0.37	3.47e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.81	-9.05	-0.45	1.23e-17	Breast cancer;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg23172898	chr14:34931803	C14orf147	-0.41	-6.13	-0.32	2.55e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	8.92	0.44	3.24e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg10437265	chr15:77819839	NA	-0.48	-8.37	-0.42	1.64e-15	Type 2 diabetes;
CRC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.77	9.81	0.48	4.41e-20	Developmental language disorder (linguistic errors);
CRC	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.57	10.3	0.49	9.35e-22	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg01482980	chr7:92861284	CCDC132	0.46	5.96	0.31	6.43e-9	Thyroid stimulating hormone;
CRC	cis	rs10924970	0.967	rs12731177	chr1:235463173	T/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.89	0.31	9.61e-9	Asthma;
CRC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-6.2	-0.32	1.7e-9	Reticulocyte count;
CRC	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	6.37	0.33	6.54e-10	Lymphocyte counts;
CRC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.47	6.49	0.34	3.13e-10	Longevity;Endometriosis;
CRC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.36	7.29	0.37	2.39e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs9903692	0.697	rs6504024	chr17:46165586	T/C	cg21215337	chr17:46176117	CBX1	0.42	7.78	0.39	9.74e-14	Pulse pressure;
CRC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-7.22	-0.37	3.72e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.55	8.28	0.42	3.08e-15	High light scatter reticulocyte count;
CRC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-7.62	-0.39	2.66e-13	Vitiligo;
CRC	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg27053337	chr8:124217698	FAM83A	0.43	6.59	0.34	1.74e-10	Urinary uromodulin levels;
CRC	trans	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg09872104	chr7:134855509	C7orf49	-0.82	-7.2	-0.37	4e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg18016565	chr1:150552671	MCL1	0.45	6.27	0.33	1.13e-9	Melanoma;
CRC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.0	-0.4	2.22e-14	Morning vs. evening chronotype;
CRC	cis	rs7209700	0.662	rs8066295	chr17:45348203	A/G	cg17185639	chr17:45330862	ITGB3	-0.36	-5.85	-0.31	1.2e-8	IgG glycosylation;
CRC	trans	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg03060546	chr3:49711283	APEH	-0.55	-6.05	-0.32	3.94e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-7.25	-0.37	2.98e-12	Chronic sinus infection;
CRC	cis	rs858239	1.000	rs156407	chr7:23315639	G/A	cg00469287	chr7:23338798	C7orf30	0.47	6.31	0.33	8.77e-10	Cerebrospinal fluid biomarker levels;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.26	-0.37	2.81e-12	Longevity;Endometriosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05531134	chr21:19192027	C21orf91	0.37	6.07	0.32	3.51e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2033908	0.502	rs12361858	chr11:12857064	C/T	cg25843174	chr11:12811716	TEAD1	-0.38	-6.7	-0.35	9.01e-11	Sitting height ratio;
CRC	cis	rs3760982	0.967	rs12463346	chr19:44292244	A/G	cg11993925	chr19:44307056	LYPD5	0.49	8.02	0.4	1.94e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg14515779	chr1:101123966	NA	-0.34	-5.97	-0.31	6.17e-9	Monocyte count;
CRC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06544989	chr22:39130855	UNC84B	0.46	7.42	0.38	1.03e-12	Menopause (age at onset);
CRC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg23018236	chr17:30244563	NA	0.5	5.93	0.31	7.48e-9	Hip circumference adjusted for BMI;
CRC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-8.63	-0.43	2.64e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.36	5.86	0.31	1.13e-8	Ulcerative colitis;
CRC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg01483505	chr11:975446	AP2A2	0.41	6.59	0.34	1.74e-10	Alzheimer's disease (late onset);
CRC	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	8.39	0.42	1.43e-15	Response to antipsychotic treatment;
CRC	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg02927042	chr1:21476669	EIF4G3	-0.46	-7.36	-0.38	1.44e-12	Superior frontal gyrus grey matter volume;
CRC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.4	-7.97	-0.4	2.61e-14	Vitiligo;
CRC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.56	7.39	0.38	1.2e-12	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.51	7.51	0.38	5.58e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs17209837	1.000	rs45607141	chr7:87087025	A/G	cg00919237	chr7:87102261	ABCB4	-0.49	-6.03	-0.32	4.4e-9	Gallbladder cancer;
CRC	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.08	-0.32	3.42e-9	Autism spectrum disorder or schizophrenia;
CRC	trans	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg00738113	chr16:70207722	CLEC18C	-0.38	-5.73	-0.3	2.23e-8	IgE levels;
CRC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg12193833	chr17:30244370	NA	0.56	6.15	0.32	2.24e-9	Hip circumference adjusted for BMI;
CRC	trans	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03909902	chr12:108154529	PRDM4	-0.43	-6.06	-0.32	3.62e-9	Morning vs. evening chronotype;
CRC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg05304507	chr6:116381966	FRK	0.3	8.24	0.41	4.08e-15	Cholesterol, total;LDL cholesterol;
CRC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg11861562	chr11:117069780	TAGLN	-0.42	-9.24	-0.45	3.27e-18	Blood protein levels;
CRC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.61	9.12	0.45	7.81e-18	Lung cancer;
CRC	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.57	9.22	0.45	3.7e-18	Migraine;
CRC	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.59	8.59	0.43	3.42e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	9.37	0.46	1.21e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.05	0.32	4e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg17031739	chr1:67600172	NA	0.42	6.57	0.34	1.91e-10	Psoriasis;
CRC	cis	rs7209700	1.000	rs7209700	chr17:45351118	A/G	cg08085267	chr17:45401833	C17orf57	0.46	6.4	0.33	5.42e-10	IgG glycosylation;
CRC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.49	8.52	0.43	5.75e-16	Hypertriglyceridemia;
CRC	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.54	-0.34	2.29e-10	Acne (severe);
CRC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg26587870	chr6:27730563	NA	-0.66	-6.65	-0.34	1.24e-10	Breast cancer;
CRC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.05e-29	Cognitive function;
CRC	trans	rs1923243	0.749	rs12042085	chr1:73602245	T/G	cg07861564	chr12:119616618	HSPB8	-0.32	-5.99	-0.31	5.58e-9	Migraine;
CRC	cis	rs714027	1.000	rs714027	chr22:30577771	A/G	cg11564601	chr22:30592435	NA	0.38	5.63	0.3	3.86e-8	Lymphocyte counts;
CRC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-7.47	-0.38	7.48e-13	Type 2 diabetes;
CRC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-8.03	-0.4	1.79e-14	Blood protein levels;
CRC	trans	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.49	-0.34	3.15e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.74	9.6	0.47	2.05e-19	Height;
CRC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg20203395	chr5:56204925	C5orf35	-0.46	-6.42	-0.33	4.8e-10	Coronary artery disease;
CRC	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg06484146	chr7:12443880	VWDE	-0.5	-6.46	-0.34	3.71e-10	Coronary artery disease;
CRC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg25456477	chr12:86230367	RASSF9	-0.36	-6.07	-0.32	3.43e-9	Major depressive disorder;
CRC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.53	0.43	5.55e-16	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs4481887	0.604	rs6694598	chr1:248409490	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.55	0.34	2.26e-10	Common traits (Other);
CRC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg19223190	chr17:80058835	NA	0.39	6.31	0.33	9.07e-10	Life satisfaction;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg14258366	chr7:41982794	NA	0.39	6.39	0.33	5.53e-10	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-6.57	-0.34	1.96e-10	Schizophrenia;
CRC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09631055	chr7:157211098	NA	0.37	5.98	0.31	5.82e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg13385794	chr1:248469461	NA	0.41	7.2	0.37	4.23e-12	Common traits (Other);
CRC	trans	rs4698169	0.510	rs675984	chr4:17123821	A/G	cg25490145	chr17:80358850	C17orf101	-0.46	-7.28	-0.37	2.51e-12	Temperament (bipolar disorder);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg04776910	chr19:58874233	ZNF497	0.47	6.62	0.34	1.44e-10	Anxiety disorder;
CRC	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.5	-7.41	-0.38	1.05e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.72	9.32	0.46	1.73e-18	Iron status biomarkers;
CRC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.21	14.81	0.63	2.26e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.36	-5.79	-0.3	1.62e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.47	-7.9	-0.4	4.12e-14	Bipolar disorder;
CRC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg21155852	chr7:2048760	MAD1L1	-0.48	-6.62	-0.34	1.43e-10	Bipolar disorder;
CRC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg01304814	chr3:48885189	PRKAR2A	0.79	6.01	0.31	4.79e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs7113874	0.569	rs11041983	chr11:8580619	A/G	cg02811074	chr11:8615871	STK33	-0.34	-5.86	-0.31	1.14e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.38	0.42	1.54e-15	Gut microbiome composition (summer);
CRC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.56	-8.48	-0.42	7.78e-16	Uric acid levels;
CRC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.52	9.15	0.45	5.92e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs853679	1.000	rs853679	chr6:28296863	C/A	cg03623178	chr6:28175578	NA	0.64	6.81	0.35	4.77e-11	Depression;
CRC	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg02135003	chr7:105160482	PUS7	-0.52	-7.96	-0.4	2.73e-14	Bipolar disorder (body mass index interaction);
CRC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg06494592	chr3:125709126	NA	-0.57	-6.81	-0.35	4.74e-11	Blood pressure (smoking interaction);
CRC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg24881330	chr22:46731750	TRMU	0.59	5.79	0.3	1.66e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.51	9.24	0.45	3.07e-18	Vitiligo;
CRC	cis	rs9322817	0.607	rs7772567	chr6:105155782	C/A	cg02098413	chr6:105308735	HACE1	-0.43	-8.36	-0.42	1.82e-15	Thyroid stimulating hormone;
CRC	cis	rs16867321	0.951	rs13413574	chr2:181364491	A/G	cg23363182	chr2:181467187	NA	-0.49	-6.09	-0.32	3.16e-9	Obesity;
CRC	cis	rs9322817	0.691	rs2499659	chr6:105286124	A/T	cg02098413	chr6:105308735	HACE1	0.44	8.72	0.43	1.41e-16	Thyroid stimulating hormone;
CRC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.84	-10.79	-0.51	1.93e-23	Initial pursuit acceleration;
CRC	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-6.5	-0.34	3.03e-10	Eye color traits;
CRC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg15147215	chr3:52552868	STAB1	-0.57	-8.99	-0.44	1.97e-17	Bipolar disorder;
CRC	cis	rs17234274	0.622	rs2403823	chr11:23233044	C/G	cg05245346	chr11:23248277	NA	0.34	5.63	0.3	3.79e-8	Cancer;
CRC	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg14345882	chr6:26364793	BTN3A2	0.76	6.31	0.33	9.13e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03788995	chr7:148334381	NA	-0.34	-5.99	-0.31	5.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg15654264	chr1:150340011	RPRD2	-0.4	-5.91	-0.31	8.48e-9	Migraine;
CRC	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.84	9.52	0.46	3.83e-19	Iron status biomarkers;
CRC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.83	-9.99	-0.48	1.11e-20	Bronchopulmonary dysplasia;
CRC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg22532475	chr10:104410764	TRIM8	-0.37	-6.81	-0.35	4.6e-11	Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs6840360	0.617	rs2724564	chr4:152349962	G/T	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg22153745	chr1:153894579	GATAD2B	-0.55	-7.62	-0.39	2.65e-13	Total cholesterol levels;
CRC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-6.01	-0.31	4.88e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00776808	chr7:107220968	BCAP29	0.42	6.64	0.34	1.32e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg09659197	chr4:152720779	NA	-0.41	-8.39	-0.42	1.46e-15	Intelligence (multi-trait analysis);
CRC	cis	rs2811415	0.597	rs67763343	chr3:127803163	C/T	cg13719885	chr3:127795394	NA	-0.4	-5.92	-0.31	8.11e-9	Lung function (FEV1/FVC);
CRC	trans	rs2303319	0.504	rs55638078	chr2:162524997	T/C	cg12500891	chr11:57225987	NA	-0.68	-6.07	-0.32	3.55e-9	Cognitive function;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21910613	chr1:27191950	NA	0.39	6.02	0.31	4.68e-9	Myopia (pathological);
CRC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.52	7.06	0.36	9.79e-12	Morning vs. evening chronotype;
CRC	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	8.05	0.41	1.56e-14	Adiposity;
CRC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.38e-11	Lung cancer;
CRC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.66	10.69	0.51	4.44e-23	Platelet count;
CRC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.61	9.57	0.47	2.61e-19	Aortic root size;
CRC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.75	0.35	6.67e-11	Lung cancer;
CRC	trans	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg21153622	chr11:89784906	NA	0.44	7.09	0.36	8.08e-12	HDL cholesterol;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07780777	chr8:59323842	UBXN2B	0.37	6.25	0.33	1.26e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.55	-8.86	-0.44	5.14e-17	Neurofibrillary tangles;
CRC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg13777783	chr17:79615861	NA	-0.29	-5.63	-0.3	3.91e-8	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg04753786	chr19:48281744	SEPW1	0.41	6.08	0.32	3.3e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.09	-0.32	3.09e-9	Putamen volume;
CRC	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.54	7.72	0.39	1.39e-13	Pulmonary function decline;
CRC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.16	-0.49	2.82e-21	Height;
CRC	cis	rs1873147	1.000	rs12443295	chr15:63313666	C/T	cg12160578	chr15:63334699	TPM1	-0.41	-5.81	-0.31	1.44e-8	Orofacial clefts;
CRC	trans	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg18335740	chr13:41363409	SLC25A15	0.52	7.52	0.38	5.24e-13	Lewy body disease;
CRC	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg10510935	chr1:4059661	NA	0.38	5.7	0.3	2.69e-8	Interleukin-17 levels;
CRC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.36	-0.46	1.25e-18	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.71	10.29	0.49	9.9e-22	Corneal astigmatism;
CRC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.14	0.41	8.16e-15	Menopause (age at onset);
CRC	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg00691999	chr4:55094011	PDGFRA	0.42	6.07	0.32	3.5e-9	Corneal astigmatism;
CRC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-8.12	-0.41	9.26e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs995000	0.965	rs3850634	chr1:63050598	T/G	cg19896129	chr1:63156450	NA	0.39	5.66	0.3	3.32e-8	Triglyceride levels;
CRC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	9.4	0.46	9.33e-19	Monocyte count;
CRC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg02993699	chr4:3415135	RGS12	-0.39	-6.33	-0.33	7.89e-10	Serum sulfate level;
CRC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.5	8.2	0.41	5.51e-15	Major depressive disorder;
CRC	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.94	19.06	0.72	4.17e-55	Metabolite levels;
CRC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	7.13	0.37	6.31e-12	Longevity;
CRC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.55	-8.13	-0.41	8.63e-15	Cisplatin-induced ototoxicity;
CRC	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.38	5.88	0.31	9.94e-9	Endometrial cancer;
CRC	trans	rs34156428	0.591	rs12577561	chr11:16806296	C/T	cg02875130	chr19:1848745	REXO1	0.74	6.32	0.33	8.45e-10	Coronary artery disease;
CRC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.43	8.83	0.44	6.56e-17	Intelligence (multi-trait analysis);
CRC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.47	6.41	0.33	5.17e-10	Schizophrenia;
CRC	trans	rs2303319	0.504	rs62189051	chr2:162622318	G/A	cg20024234	chr21:43431083	ZNF295	-0.66	-5.96	-0.31	6.5e-9	Cognitive function;
CRC	cis	rs9549328	0.564	rs34556022	chr13:113617437	G/A	cg20742385	chr13:113633654	MCF2L	0.56	9.5	0.46	4.54e-19	Systolic blood pressure;
CRC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.47	6.73	0.35	7.52e-11	Melanoma;
CRC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.77	11.89	0.55	2.35e-27	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg22110888	chr17:80059540	CCDC57	-0.41	-6.38	-0.33	6.13e-10	Life satisfaction;
CRC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg02033258	chr5:131593261	PDLIM4	0.36	6.77	0.35	6.11e-11	Blood metabolite levels;
CRC	trans	rs9825823	0.617	rs2083264	chr3:61074229	A/G	cg18167349	chr12:51664410	SMAGP	0.43	6.0	0.31	5.29e-9	Depressive symptom measurement or major depressive disorder;
CRC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.82	0.35	4.39e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.46	5.69	0.3	2.79e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg13385521	chr17:29058706	SUZ12P	0.65	7.71	0.39	1.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg21399703	chr1:247681439	NA	-0.52	-9.57	-0.47	2.6e-19	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg01475377	chr6:109611718	NA	-0.34	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19472303	chr3:25705836	TOP2B	0.36	5.99	0.31	5.56e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.73	-12.2	-0.56	1.69e-28	Itch intensity from mosquito bite;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg09368805	chr7:5603387	NA	-0.42	-6.17	-0.32	1.97e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.64	9.05	0.45	1.27e-17	Menarche (age at onset);
CRC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.46	8.02	0.4	1.85e-14	HDL cholesterol;
CRC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.18	-0.32	1.87e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg19635926	chr16:89946313	TCF25	0.63	5.68	0.3	3.01e-8	Skin colour saturation;
CRC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.47	-7.48	-0.38	6.66e-13	Iron status biomarkers;
CRC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.12	20.81	0.75	5.55e-62	Cognitive function;
CRC	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg25457927	chr22:38595422	NA	-0.3	-5.89	-0.31	9.4e-9	Mammographic density (dense area);Percent mammographic density;
CRC	cis	rs12936587	0.569	rs8073683	chr17:17555596	C/T	cg04398451	chr17:18023971	MYO15A	0.35	5.91	0.31	8.77e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.88	0.4	4.82e-14	Menopause (age at onset);
CRC	cis	rs7517126	1.000	rs2878717	chr1:196843582	C/T	cg13682187	chr1:196946512	CFHR5	-0.38	-6.27	-0.33	1.16e-9	Blood protein levels;
CRC	cis	rs4964805	0.657	rs11111783	chr12:104188523	A/G	cg02344784	chr12:104178138	NT5DC3	0.79	15.08	0.64	1.95e-39	Attention deficit hyperactivity disorder;
CRC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-9.66	-0.47	1.35e-19	Body mass index;
CRC	cis	rs453193	0.800	rs186975	chr2:8442736	C/G	cg12167548	chr2:8464763	NA	-0.35	-6.37	-0.33	6.46e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	9.99	0.48	1.07e-20	Platelet count;
CRC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.95	-0.36	2.01e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.48	-6.81	-0.35	4.64e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg15123519	chr2:136567270	LCT	0.35	6.87	0.35	3.17e-11	Mosquito bite size;
CRC	cis	rs11948739	0.501	rs2419755	chr5:130252835	A/G	cg08523029	chr5:130500466	HINT1	0.42	5.69	0.3	2.86e-8	Pediatric bone mineral content (hip);
CRC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.4	-5.78	-0.3	1.72e-8	Aortic root size;
CRC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.44	6.53	0.34	2.54e-10	Menopause (age at onset);
CRC	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg02466173	chr16:30829666	NA	0.62	9.3	0.46	1.96e-18	Dementia with Lewy bodies;
CRC	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.6	10.43	0.5	3.36e-22	Common traits (Other);
CRC	cis	rs642858	1.000	rs4895579	chr6:140303401	G/A	cg27524944	chr6:140295369	NA	-0.36	-5.95	-0.31	6.76e-9	Type 2 diabetes;
CRC	cis	rs2346160	0.836	rs206991	chr6:167699378	A/G	cg27333441	chr6:167680455	NA	-0.4	-6.57	-0.34	2.01e-10	Parental extreme longevity (95 years and older);
CRC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.44	-0.46	7.01e-19	Platelet count;
CRC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.43	7.34	0.38	1.69e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.44	6.85	0.35	3.57e-11	Bipolar disorder and schizophrenia;
CRC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.56	9.13	0.45	7.33e-18	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg13198984	chr17:80129470	CCDC57	0.42	7.39	0.38	1.19e-12	Life satisfaction;
CRC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.71	9.38	0.46	1.08e-18	Bladder cancer;
CRC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.52	7.46	0.38	7.72e-13	Multiple sclerosis;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05477027	chr19:46295590	DMWD	0.54	7.02	0.36	1.26e-11	Thyroid stimulating hormone;
CRC	cis	rs3736594	0.513	rs59876138	chr2:27792323	A/C	cg27432699	chr2:27873401	GPN1	0.64	8.5	0.42	6.81e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CRC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.26	-6.22	-0.32	1.52e-9	Caffeine consumption;
CRC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-7.08	-0.36	8.67e-12	Colorectal cancer;
CRC	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.82	10.62	0.51	7.55e-23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6756513	0.520	rs6546560	chr2:70173690	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-7.99	-0.4	2.24e-14	Breast cancer;Platelet count;
CRC	trans	rs9341835	0.772	rs9294197	chr6:64135648	A/G	cg13657004	chr13:50234944	EBPL	-0.36	-6.03	-0.32	4.42e-9	Schizophrenia;
CRC	trans	rs4958351	0.719	rs74739622	chr5:153221968	T/A	cg03074421	chr9:126102037	NA	-0.38	-6.01	-0.31	4.88e-9	Asparaginase hypersensitivity in acute lymphoblastic leukemia;
CRC	cis	rs1943345	0.530	rs501155	chr11:82919893	G/T	cg07047830	chr11:82868014	PCF11	0.42	6.04	0.32	4.23e-9	Obesity-related traits;
CRC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg24300038	chr13:113819356	PROZ	-0.46	-5.62	-0.3	4.01e-8	Platelet distribution width;
CRC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.88	0.4	4.94e-14	Mean corpuscular hemoglobin concentration;
CRC	trans	rs3001167	1.000	rs10921612	chr1:194548819	T/G	cg22004422	chr13:113740730	MCF2L	-0.53	-5.97	-0.31	6.02e-9	Obesity-related traits;
CRC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.47	-7.13	-0.37	6.22e-12	Colorectal cancer;
CRC	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.77	-12.82	-0.58	8.94e-31	Bipolar disorder;
CRC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	9.92e-11	Menopause (age at onset);
CRC	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg13385794	chr1:248469461	NA	0.37	6.49	0.34	3.15e-10	Common traits (Other);
CRC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.38	5.95	0.31	6.69e-9	Acylcarnitine levels;
CRC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.06e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.47	-6.69	-0.35	9.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg22638593	chr5:131593259	PDLIM4	0.5	8.67	0.43	1.95e-16	Acylcarnitine levels;
CRC	cis	rs6546324	0.625	rs6746394	chr2:67845021	A/C	cg15745817	chr2:67799979	NA	-0.57	-9.66	-0.47	1.37e-19	Endometriosis;
CRC	trans	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	10.71	0.51	3.67e-23	Systolic blood pressure;
CRC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.22	-0.37	3.66e-12	Bipolar disorder;
CRC	cis	rs1712517	0.771	rs10883857	chr10:105127587	A/C	cg05636881	chr10:105038444	INA	-0.44	-7.4	-0.38	1.14e-12	Migraine;
CRC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.4	-8.11	-0.41	1.02e-14	Schizophrenia;
CRC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg09218773	chr11:619014	MUPCDH	-0.36	-5.79	-0.3	1.64e-8	Systemic lupus erythematosus;
CRC	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg15147215	chr3:52552868	STAB1	-0.43	-6.05	-0.32	3.92e-9	Schizophrenia;
CRC	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-9.62	-0.47	1.79e-19	Myopia (pathological);
CRC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg16606324	chr3:10149918	C3orf24	0.66	7.77	0.39	9.99e-14	Alzheimer's disease;
CRC	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.52	8.77	0.44	9.83e-17	Prostate cancer;
CRC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg08798685	chr6:27730294	NA	-0.42	-6.26	-0.33	1.23e-9	Parkinson's disease;
CRC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.77	0.35	6.05e-11	Tonsillectomy;
CRC	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.57	-8.54	-0.43	5.08e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CRC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg26666090	chr16:58549219	SETD6	0.94	6.49	0.34	3.19e-10	Schizophrenia;
CRC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-8.93	-0.44	3.09e-17	Chronic sinus infection;
CRC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.6	8.4	0.42	1.31e-15	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.44	0.42	1.06e-15	Height;
CRC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.37	5.77	0.3	1.85e-8	Life satisfaction;
CRC	cis	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg14668889	chr17:73230827	NUP85	0.49	6.96	0.36	1.84e-11	Systemic lupus erythematosus;
CRC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg23996704	chr18:44553084	KATNAL2	-0.36	-6.89	-0.36	2.78e-11	Personality dimensions;
CRC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.55	-8.07	-0.41	1.36e-14	IgG glycosylation;
CRC	cis	rs7605827	0.930	rs2111454	chr2:15522331	G/A	cg19274914	chr2:15703543	NA	0.39	5.9	0.31	8.92e-9	Educational attainment (years of education);
CRC	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg13385794	chr1:248469461	NA	0.38	6.65	0.34	1.26e-10	Common traits (Other);
CRC	trans	rs9936075	0.553	rs13337052	chr16:7373470	C/T	cg11804928	chr17:38220298	THRA	-0.35	-6.19	-0.32	1.83e-9	Platelet-derived growth factor BB levels;
CRC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-7.74	-0.39	1.27e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9515201	1.000	rs9515201	chr13:111040798	A/C	cg11096515	chr13:111062287	COL4A2	-0.32	-5.89	-0.31	9.53e-9	White matter hyperintensity burden;
CRC	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.6	9.61	0.47	2e-19	Corneal astigmatism;
CRC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.62	9.63	0.47	1.68e-19	Corneal astigmatism;
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.43	0.33	4.52e-10	Depression;
CRC	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.56	-6.82	-0.35	4.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07932290	chr14:74252976	C14orf43	0.44	6.09	0.32	3.09e-9	Response to antipsychotic treatment;
CRC	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12560992	chr17:57184187	TRIM37	0.52	7.27	0.37	2.56e-12	Testicular germ cell tumor;
CRC	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg00105475	chr2:10696890	NA	0.45	7.3	0.37	2.19e-12	Prostate cancer;
CRC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.75	-11.04	-0.52	2.5300000000000002e-24	Schizophrenia;
CRC	cis	rs2857891	0.817	rs2239730	chr11:6977175	G/C	cg12728517	chr11:6947552	ZNF215	0.49	5.77	0.3	1.84e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.83	-14.35	-0.62	1.38e-36	Height;
CRC	cis	rs939584	0.932	rs13387091	chr2:650980	G/A	cg03610516	chr2:642275	NA	-0.43	-5.73	-0.3	2.29e-8	Body mass index;
CRC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg25876840	chr17:41920477	NA	0.51	7.63	0.39	2.62e-13	Triglycerides;
CRC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.31	6.7e-9	Hemoglobin concentration;
CRC	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg19773385	chr1:10388646	KIF1B	0.45	6.93	0.36	2.22e-11	Hepatocellular carcinoma;
CRC	cis	rs7517126	1.000	rs13375144	chr1:196841690	C/T	cg13682187	chr1:196946512	CFHR5	-0.37	-6.02	-0.32	4.6e-9	Blood protein levels;
CRC	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg05935833	chr10:81318306	SFTPA2	-0.73	-8.0	-0.4	2.14e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.68	10.53	0.5	1.51e-22	Corneal astigmatism;
CRC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.62	-0.3	4.11e-8	Gout;Renal underexcretion gout;
CRC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg05887092	chr17:76393375	PGS1	-0.55	-9.97	-0.48	1.28e-20	HDL cholesterol levels;
CRC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	10.43	0.5	3.45e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-0.56	-6.18	-0.32	1.94e-9	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.42	-8.07	-0.41	1.3e-14	Ulcerative colitis;
CRC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	15.29	0.64	3.08e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg18833306	chr6:118973337	C6orf204	0.44	5.71	0.3	2.54e-8	Diastolic blood pressure;
CRC	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.81	8.55	0.43	4.61e-16	Gastritis;
CRC	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg09659197	chr4:152720779	NA	0.41	8.44	0.42	1.06e-15	Intelligence (multi-trait analysis);
CRC	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.64	9.78	0.47	5.44e-20	Mean corpuscular hemoglobin;
CRC	cis	rs4400599	0.642	rs4072431	chr1:154167116	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.71	-0.3	2.48e-8	Platelet distribution width;
CRC	cis	rs6988985	0.728	rs4736311	chr8:143952700	A/G	cg10324643	chr8:143916377	GML	0.37	6.05	0.32	4.01e-9	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.59	-9.89	-0.48	2.35e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.58	-7.39	-0.38	1.19e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.78	-0.51	2.09e-23	Body mass index;
CRC	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg13533061	chr17:74712429	JMJD6	-0.46	-6.96	-0.36	1.86e-11	Retinal arteriolar caliber;
CRC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.53	-0.43	5.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.63	0.34	1.42e-10	Morning vs. evening chronotype;
CRC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-0.93	-16.5	-0.67	5.26e-45	Body mass index;
CRC	cis	rs2811415	0.627	rs13313895	chr3:127752084	T/C	cg13719885	chr3:127795394	NA	-0.37	-5.67	-0.3	3.19e-8	Lung function (FEV1/FVC);
CRC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.36	-0.33	6.84e-10	Monocyte percentage of white cells;
CRC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg09417038	chr21:47716443	C21orf57	-0.4	-6.45	-0.34	3.93e-10	Testicular germ cell tumor;
CRC	cis	rs6484504	0.576	rs9971609	chr11:31434104	C/T	cg14844989	chr11:31128820	NA	0.34	5.93	0.31	7.55e-9	Red blood cell count;
CRC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg21782813	chr7:2030301	MAD1L1	0.4	7.38	0.38	1.33e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.52	7.73	0.39	1.3e-13	Breast cancer;
CRC	cis	rs7538876	0.967	rs2800696	chr1:17730238	A/T	cg01904812	chr1:17746340	RCC2	0.34	5.73	0.3	2.28e-8	Basal cell carcinoma;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05059663	chr17:13972631	COX10	0.44	6.77	0.35	5.94e-11	Intelligence (multi-trait analysis);
CRC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg07636037	chr3:49044803	WDR6	-0.81	-6.66	-0.34	1.14e-10	Cognitive function;
CRC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg10760299	chr15:45669010	GATM	0.5	7.99	0.4	2.37e-14	Homoarginine levels;
CRC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.62	8.87	0.44	4.65e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.95e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg06650216	chr7:138145531	TRIM24	0.46	6.4	0.33	5.44e-10	Anxiety disorder;
CRC	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	8.21	0.41	5.1e-15	Iron status biomarkers;
CRC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.51	7.9	0.4	4.36e-14	Motion sickness;
CRC	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.41	5.76	0.3	1.89e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.75	12.28	0.56	8.4e-29	Intelligence (multi-trait analysis);
CRC	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg23234261	chr14:55582407	NA	-0.28	-5.91	-0.31	8.74e-9	Protein biomarker;
CRC	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg05935833	chr10:81318306	SFTPA2	-0.71	-7.95	-0.4	2.95e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23712980	chr20:30795555	POFUT1;PLAGL2	0.45	6.17	0.32	2e-9	Anxiety disorder;
CRC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.49	7.55	0.38	4.2e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-17.39	-0.69	1.77e-48	Height;
CRC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg19622623	chr12:86230825	RASSF9	-0.35	-5.69	-0.3	2.8e-8	Major depressive disorder;
CRC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.15	-0.74	2.29e-59	Primary sclerosing cholangitis;
CRC	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05776763	chr14:75348391	DLST	0.43	6.22	0.32	1.49e-9	Intelligence (multi-trait analysis);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01690029	chr3:125314090	OSBPL11	0.46	6.27	0.33	1.14e-9	Anxiety disorder;
CRC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.59	9.1	0.45	8.92e-18	Corneal astigmatism;
CRC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-13.75	-0.6	2.69e-34	Extrinsic epigenetic age acceleration;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16551665	chr17:30814028	CDK5R1	0.42	6.14	0.32	2.37e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.64	9.59	0.47	2.37e-19	Breast cancer;
CRC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.37	5.85	0.31	1.17e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.33	4.59e-10	Blood metabolite levels;
CRC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	1.03	8.74	0.43	1.19e-16	Granulocyte percentage of myeloid white cells;
CRC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.72	0.35	8.12e-11	Morning vs. evening chronotype;
CRC	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.69	8.95	0.44	2.7e-17	Breast cancer;
CRC	trans	rs6956675	0.831	rs4718878	chr7:62656497	T/C	cg01314568	chr7:57830625	NA	-0.62	-8.88	-0.44	4.38e-17	Obesity-related traits;
CRC	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-6.96	-0.36	1.88e-11	Neutrophil percentage of white cells;
CRC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg23298862	chr7:158159286	PTPRN2	0.39	6.16	0.32	2.1e-9	Calcium levels;
CRC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.59	7.8	0.39	8.43e-14	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.44	-9.71	-0.47	9.25e-20	Glomerular filtration rate (creatinine);
CRC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.97	-0.31	6.25e-9	Vitiligo;
CRC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.18	-0.32	1.91e-9	Arsenic metabolism;
CRC	cis	rs17234274	0.644	rs1482713	chr11:23216886	A/G	cg05245346	chr11:23248277	NA	0.36	5.92	0.31	8.22e-9	Cancer;
CRC	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg06484146	chr7:12443880	VWDE	-0.48	-6.96	-0.36	1.82e-11	Coronary artery disease;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24123057	chr8:11660089	FDFT1	0.41	6.47	0.34	3.62e-10	Myopia (pathological);
CRC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.65	10.06	0.49	6.2e-21	Monocyte count;
CRC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.21	-0.37	3.95e-12	Morning vs. evening chronotype;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02562419	chr6:159049626	TMEM181	-0.4	-6.37	-0.33	6.46e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg01483505	chr11:975446	AP2A2	0.41	6.23	0.33	1.39e-9	Alzheimer's disease (late onset);
CRC	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.46	-6.83	-0.35	4.02e-11	Body mass index;
CRC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg22110888	chr17:80059540	CCDC57	-0.41	-6.39	-0.33	5.58e-10	Life satisfaction;
CRC	cis	rs6604026	0.740	rs2893225	chr1:93368496	G/C	cg17283838	chr1:93427260	FAM69A	-0.5	-6.83	-0.35	4.09e-11	Multiple sclerosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg03729431	chr17:15848264	ADORA2B	0.43	5.99	0.31	5.42e-9	Anxiety disorder;
CRC	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg06470822	chr6:28175283	NA	0.69	6.48	0.34	3.33e-10	Depression;
CRC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.66	12.54	0.57	9.56e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs7703744	0.634	rs17145248	chr5:118685011	C/T	cg23985447	chr5:118691066	TNFAIP8	0.4	5.64	0.3	3.74e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs834811	0.602	rs6950690	chr7:135890568	G/A	cg01726295	chr7:135938950	NA	0.35	6.08	0.32	3.32e-9	Post-traumatic stress disorder;
CRC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.47	9.51	0.46	4.13e-19	Bone mineral density;
CRC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg25985355	chr7:65971099	NA	-0.32	-5.72	-0.3	2.4e-8	Aortic root size;
CRC	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.73	-11.54	-0.54	4.16e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg06470822	chr6:28175283	NA	0.68	9.51	0.46	4.09e-19	Parkinson's disease;
CRC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.51	7.12	0.37	6.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.53	7.29	0.37	2.32e-12	Schizophrenia;
CRC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.41	-6.22	-0.32	1.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg24562669	chr7:97807699	LMTK2	0.4	6.61	0.34	1.55e-10	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.55	-7.63	-0.39	2.51e-13	Triglycerides;
CRC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.08	18.07	0.71	3.42e-51	Cognitive function;
CRC	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg03315344	chr16:75512273	CHST6	-0.52	-6.19	-0.32	1.84e-9	Type 2 diabetes;Type 1 diabetes;
CRC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg27539214	chr16:67997921	SLC12A4	0.5	6.37	0.33	6.54e-10	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.65	8.33	0.42	2.18e-15	Cisplatin-induced ototoxicity;
CRC	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg08890418	chr1:21044141	KIF17	0.32	6.02	0.32	4.56e-9	Facial morphology (factor 17, height of vermillion upper lip);
CRC	trans	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg03800765	chr3:11313984	ATG7	-0.41	-6.09	-0.32	3.22e-9	Inflammatory skin disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03469472	chr1:173991446	NA	0.49	6.44	0.33	4.25e-10	Thyroid stimulating hormone;
CRC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg12218747	chr21:37451666	NA	-0.37	-6.18	-0.32	1.92e-9	Mitral valve prolapse;
CRC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.69	12.21	0.56	1.57e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.92	13.92	0.61	5.72e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs4363385	0.693	rs582345	chr1:153033406	G/A	cg25856811	chr1:152973957	SPRR3	-0.24	-6.6	-0.34	1.62e-10	Inflammatory skin disease;
CRC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-11.07	-0.52	2.01e-24	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg19223190	chr17:80058835	NA	0.39	6.26	0.33	1.21e-9	Life satisfaction;
CRC	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.49	-0.46	4.98e-19	Prevalent atrial fibrillation;
CRC	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.74	7.47	0.38	7.21e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg05192639	chr6:26864778	GUSBL1	0.32	6.08	0.32	3.39e-9	Schizophrenia;
CRC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.67	-0.39	2.01e-13	Gut microbiome composition (summer);
CRC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.57	-8.79	-0.44	8.5e-17	Uric acid levels;
CRC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg15786705	chr6:28176104	NA	0.72	9.27	0.46	2.5e-18	Parkinson's disease;
CRC	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.42	-6.01	-0.31	5.05e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs939584	1.000	rs7571967	chr2:646839	T/G	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	7.68	0.39	1.84e-13	Breast cancer;
CRC	cis	rs12580194	0.593	rs61957943	chr12:55749330	A/G	cg19537932	chr12:55886519	OR6C68	-0.69	-8.95	-0.44	2.63e-17	Cancer;
CRC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-11.27	-0.53	3.98e-25	Developmental language disorder (linguistic errors);
CRC	trans	rs2303319	0.504	rs56009150	chr2:162598582	T/C	cg23919916	chr10:103825097	HPS6	-0.69	-5.99	-0.31	5.59e-9	Cognitive function;
CRC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.81	10.14	0.49	3.29e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.6	-6.95	-0.36	2.01e-11	Neutrophil percentage of white cells;
CRC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg23136738	chr11:925521	AP2A2	-0.4	-6.19	-0.32	1.77e-9	Alzheimer's disease (late onset);
CRC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.59	8.71	0.43	1.49e-16	Homoarginine levels;
CRC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg17633681	chr16:88106987	BANP	0.82	14.11	0.61	1.12e-35	Menopause (age at onset);
CRC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg22110888	chr17:80059540	CCDC57	-0.42	-6.63	-0.34	1.35e-10	Life satisfaction;
CRC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.01	-0.4	2.02e-14	Height;
CRC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg02683197	chr6:28174875	NA	0.52	5.98	0.31	5.91e-9	Breast cancer;
CRC	cis	rs11191205	0.645	rs12255642	chr10:103456726	A/G	cg15320455	chr10:103880129	LDB1	0.55	5.95	0.31	7.03e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg12463550	chr7:65579703	CRCP	0.62	5.97	0.31	6.09e-9	Diabetic kidney disease;
CRC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg00601486	chr12:48723148	H1FNT	-0.34	-6.67	-0.35	1.1e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	1.09	9.57	0.47	2.6e-19	Arsenic metabolism;
CRC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.81	14.98	0.64	4.66e-39	Mean platelet volume;
CRC	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg04672837	chr16:48644449	N4BP1	0.43	6.22	0.32	1.47e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs73206853	0.563	rs73194032	chr12:111162182	G/A	cg12870014	chr12:110450643	ANKRD13A	0.75	8.94	0.44	2.88e-17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-9.71	-0.47	9.27e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.36	5.67	0.3	3.1e-8	Crohn's disease;
CRC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.72	-0.51	3.41e-23	Alzheimer's disease;
CRC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg23996704	chr18:44553084	KATNAL2	0.28	5.7	0.3	2.69e-8	Personality dimensions;
CRC	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.62	8.87	0.44	4.64e-17	Cancer;
CRC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg19193384	chr17:30244184	NA	-0.64	-7.42	-0.38	1.04e-12	Hip circumference adjusted for BMI;
CRC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.07	-0.36	9.07e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.45	-0.38	8.29e-13	Mean corpuscular volume;
CRC	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg12046867	chr14:103022105	NA	-0.78	-9.17	-0.45	5.22e-18	Platelet count;
CRC	cis	rs891088	0.677	rs13306455	chr19:7184721	C/T	cg00428638	chr19:7224713	INSR	-0.56	-6.04	-0.32	4.08e-9	Hip circumference adjusted for BMI;Height;
CRC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg11168104	chr5:1857477	NA	-0.38	-6.59	-0.34	1.8e-10	Cardiovascular disease risk factors;
CRC	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	0.57	8.85	0.44	5.32e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs73206853	0.841	rs55754138	chr12:110869335	G/T	cg12870014	chr12:110450643	ANKRD13A	0.76	8.24	0.41	4.16e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.42	6.04	0.32	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg20936604	chr3:58311152	NA	-0.77	-7.31	-0.37	2.1e-12	Cholesterol, total;
CRC	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg12856521	chr11:46389249	DGKZ	0.43	6.73	0.35	7.62e-11	Leprosy;
CRC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.77	-0.35	6.02e-11	Alcohol dependence;
CRC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06656553	chr16:89960601	TCF25	-0.7	-5.97	-0.31	6.14e-9	Skin colour saturation;
CRC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.46	6.05	0.32	4.03e-9	Response to diuretic therapy;
CRC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg08888203	chr3:10149979	C3orf24	0.72	8.59	0.43	3.67e-16	Alzheimer's disease;
CRC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.62	8.75	0.43	1.11e-16	Height;
CRC	cis	rs2742417	1.000	rs2673037	chr3:45749094	A/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.92	-0.31	8e-9	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.57	-9.23	-0.45	3.44e-18	Congenital heart disease (maternal effect);
CRC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.92	-0.31	8.11e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.37	6.57	0.34	1.98e-10	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	11.44	0.53	1.01e-25	Prudent dietary pattern;
CRC	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg15845792	chr6:28175446	NA	0.73	6.86	0.35	3.38e-11	Depression;
CRC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	10.25	0.49	1.45e-21	Lymphocyte counts;
CRC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.51	8.29	0.42	3.02e-15	Aortic root size;
CRC	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg06223162	chr1:101003688	GPR88	-0.32	-5.61	-0.3	4.29e-8	Monocyte count;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg20935933	chr6:143382018	AIG1	-0.47	-7.35	-0.38	1.59e-12	Myopia (pathological);
CRC	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg23100626	chr2:96804247	ASTL	0.24	6.33	0.33	7.96e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CRC	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg00738113	chr16:70207722	CLEC18C	0.41	7.01	0.36	1.33e-11	Sjögren's syndrome;
CRC	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.51	-0.46	4.2e-19	Type 2 diabetes;
CRC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-10.56	-0.5	1.22e-22	Retinal vascular caliber;
CRC	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg10820045	chr2:198174542	NA	-0.44	-7.08	-0.36	9.03e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.67	-11.24	-0.53	5.14e-25	Extrinsic epigenetic age acceleration;
CRC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-6.0	-0.31	5.12e-9	Cognitive function;
CRC	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg22495460	chr2:25135724	ADCY3	-0.89	-15.31	-0.64	2.54e-40	Body mass index;
CRC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6694672	1.000	rs1115246	chr1:197037449	A/G	cg13682187	chr1:196946512	CFHR5	0.48	7.42	0.38	9.89e-13	Asthma;
CRC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.55	-0.43	4.61e-16	Chronic sinus infection;
CRC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.25	-0.37	3.03e-12	Bladder cancer;
CRC	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-0.91	-7.77	-0.39	1.02e-13	Blood protein levels;
CRC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.6	8.55	0.43	4.74e-16	Arsenic metabolism;
CRC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg11292332	chr7:45801988	SEPT13	-0.35	-6.16	-0.32	2.15e-9	Breast cancer;
CRC	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg01388757	chr2:102091195	RFX8	-0.37	-5.7	-0.3	2.62e-8	Chronic rhinosinusitis with nasal polyps;
CRC	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.49	6.3	0.33	9.73e-10	Alzheimer's disease (survival time);
CRC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg15205204	chr1:6545172	PLEKHG5	0.4	5.73	0.3	2.26e-8	Body mass index;
CRC	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.84	-9.13	-0.45	7.35e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg14664628	chr15:75095509	CSK	0.55	6.56	0.34	2.07e-10	Systemic lupus erythematosus and Systemic sclerosis;
CRC	trans	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg11693508	chr17:37793320	STARD3	0.46	6.19	0.32	1.82e-9	Bipolar disorder;
CRC	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.94	15.24	0.64	4.91e-40	Migraine;
CRC	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.91	-0.64	9.44e-39	Exhaled nitric oxide output;
CRC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg15691649	chr6:25882328	NA	-0.53	-6.65	-0.34	1.2e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg19223190	chr17:80058835	NA	0.4	6.36	0.33	6.88e-10	Life satisfaction;
CRC	cis	rs11098699	0.784	rs7684146	chr4:124207309	C/A	cg09941581	chr4:124220074	SPATA5	0.4	5.87	0.31	1.08e-8	Mosquito bite size;
CRC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg15448220	chr1:150897856	SETDB1	-0.47	-6.92	-0.36	2.44e-11	Tonsillectomy;
CRC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-7.77	-0.39	1e-13	Subjective well-being;
CRC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.81	-0.44	7.15e-17	Hemoglobin concentration;
CRC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.56	-9.34	-0.46	1.54e-18	Eye color traits;
CRC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.53	0.43	5.37e-16	Menopause (age at onset);
CRC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.71	-0.47	9.26e-20	Heart rate;
CRC	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg14092571	chr14:90743983	NA	0.4	6.23	0.32	1.4e-9	Mortality in heart failure;
CRC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg08222913	chr3:52553049	STAB1	-0.35	-6.51	-0.34	2.88e-10	Electroencephalogram traits;
CRC	trans	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg20935933	chr6:143382018	AIG1	0.5	6.46	0.34	3.68e-10	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.61	7.18	0.37	4.75e-12	Lymphocyte counts;
CRC	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg03929089	chr4:120376271	NA	-0.63	-6.78	-0.35	5.65e-11	Axial length;
CRC	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg06042504	chr8:55087323	NA	-0.38	-5.9	-0.31	9.06e-9	Pelvic organ prolapse (moderate/severe);
CRC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	9.41	0.46	8.84e-19	Height;
CRC	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.74	9.84	0.48	3.35e-20	Prostate cancer;
CRC	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.42	6.06	0.32	3.73e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.34	0.33	7.78e-10	Bipolar disorder;
CRC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.23	-16.9	-0.68	1.4300000000000001e-46	Breast cancer;
CRC	cis	rs62432291	0.681	rs1699442	chr6:159655918	A/C	cg14500486	chr6:159655392	FNDC1	0.74	9.9	0.48	2.08e-20	Joint mobility (Beighton score);
CRC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.9	0.31	8.9e-9	Hemoglobin concentration;
CRC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.46	6.3	0.33	9.4e-10	Bladder cancer;
CRC	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg10483660	chr13:112241077	NA	0.36	5.81	0.3	1.49e-8	Menarche (age at onset);
CRC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.87	-0.4	5.24e-14	Extrinsic epigenetic age acceleration;
CRC	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.52	-0.46	4e-19	Capecitabine sensitivity;
CRC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.58	-11.3	-0.53	3.09e-25	Asthma (sex interaction);
CRC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-7.24	-0.37	3.29e-12	Major depressive disorder;
CRC	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg10437265	chr15:77819839	NA	0.7	12.76	0.58	1.43e-30	Type 2 diabetes;
CRC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-12.5	-0.57	1.32e-29	Prostate cancer;
CRC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg03623178	chr6:28175578	NA	0.97	12.38	0.56	3.55e-29	Depression;
CRC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.45	5.67	0.3	3.1e-8	Aortic root size;
CRC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.72	-10.45	-0.5	2.92e-22	Lung cancer;
CRC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg10298567	chr3:47292165	KIF9	-0.39	-5.99	-0.31	5.52e-9	Colorectal cancer;
CRC	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg23254163	chr1:152506842	NA	0.49	9.71	0.47	9.49e-20	Hair morphology;
CRC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg20615401	chr6:28092323	ZSCAN16	0.44	5.77	0.3	1.82e-8	Parkinson's disease;
CRC	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.69	0.3	2.81e-8	Putamen volume;
CRC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.56	-0.47	2.79e-19	Subjective well-being;
CRC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	6.41	0.33	4.94e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs939584	1.000	rs35142762	chr2:636790	T/C	cg03610516	chr2:642275	NA	-0.42	-5.66	-0.3	3.3e-8	Body mass index;
CRC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.5	-7.84	-0.4	6.21e-14	Monocyte count;
CRC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.54	-6.89	-0.36	2.86e-11	Neuroticism;
CRC	trans	rs7474896	0.778	rs35215319	chr10:37908999	G/T	cg16724811	chr16:15130678	PDXDC1	-0.62	-6.12	-0.32	2.72e-9	Obesity (extreme);
CRC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.51	8.73	0.43	1.35e-16	Aortic root size;
CRC	cis	rs12403795	1.000	rs12403795	chr1:150278389	A/G	cg17724175	chr1:150552817	MCL1	-0.6	-6.99	-0.36	1.54e-11	Illicit drug use;
CRC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00815214	chr21:47717953	NA	-0.4	-6.6	-0.34	1.69e-10	Testicular germ cell tumor;
CRC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.46	-5.82	-0.31	1.39e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg15845792	chr6:28175446	NA	0.94	13.84	0.61	1.17e-34	Parkinson's disease;
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg06470822	chr6:28175283	NA	0.8	11.94	0.55	1.51e-27	Parkinson's disease;
CRC	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.44	-7.1	-0.36	7.67e-12	Refractive error;
CRC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.69	10.41	0.5	3.93e-22	Corneal astigmatism;
CRC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg17911788	chr17:44343683	NA	0.55	7.04	0.36	1.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.81	-0.31	1.44e-8	Type 2 diabetes;
CRC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.51	-6.56	-0.34	2.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.66	-0.3	3.38e-8	Aortic root size;
CRC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-1.06	-11.92	-0.55	1.86e-27	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13795627	chr1:157015873	ARHGEF11	0.41	7.1	0.36	7.58e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-8.28	-0.42	3.21e-15	Type 2 diabetes;
CRC	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.48	-7.56	-0.38	4.18e-13	Birth weight;
CRC	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	cg04338863	chr8:33670619	NA	0.44	6.49	0.34	3.15e-10	Body mass index;
CRC	trans	rs12517041	1.000	rs58571178	chr5:23294196	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-6.17	-0.32	2.05e-9	Calcium levels;
CRC	cis	rs11679072	0.850	rs11679075	chr2:240444254	C/T	cg03276489	chr2:240449683	NA	-0.93	-7.0	-0.36	1.45e-11	Blood pressure (smoking interaction);
CRC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.6	9.05	0.45	1.3e-17	Systolic blood pressure;
CRC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.92	-16.17	-0.67	1.04e-43	Height;
CRC	trans	rs660498	0.785	rs2478251	chr10:27739063	A/T	cg13661793	chr10:32399026	NA	0.33	5.99	0.31	5.37e-9	Asthma (childhood onset);
CRC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.64	-12.01	-0.55	8.56e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.48	7.09	0.36	8.37e-12	Bone properties (heel);
CRC	trans	rs2303319	0.504	rs12474470	chr2:162535336	T/C	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.13	-0.32	2.58e-9	Cognitive function;
CRC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg10876282	chr6:28092338	ZSCAN16	0.44	5.88	0.31	9.85e-9	Parkinson's disease;
CRC	cis	rs9907295	0.818	rs4795089	chr17:34119397	C/T	cg14527050	chr17:34077244	GAS2L2	0.61	5.68	0.3	2.91e-8	Fibroblast growth factor basic levels;
CRC	cis	rs4664293	0.867	rs34392518	chr2:160605878	G/T	cg08347373	chr2:160653686	CD302	-0.46	-7.39	-0.38	1.24e-12	Monocyte percentage of white cells;
CRC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg03623178	chr6:28175578	NA	0.57	8.06	0.41	1.43e-14	Parkinson's disease;
CRC	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg26603656	chr10:5671107	NA	0.42	6.81	0.35	4.58e-11	Breast cancer;
CRC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.83	-0.35	4.16e-11	Major depressive disorder;
CRC	cis	rs282587	0.569	rs166865	chr13:113384879	A/G	cg04656015	chr13:113407548	ATP11A	0.58	7.39	0.38	1.2e-12	Glycated hemoglobin levels;
CRC	cis	rs1536827	0.620	rs10857735	chr10:135336230	A/C	cg16964102	chr10:135390573	NA	-0.46	-5.75	-0.3	2.05e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.1	-0.32	3.06e-9	Obesity-related traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg04238871	chr10:126431886	FAM53B	-0.52	-6.3	-0.33	9.29e-10	Diisocyanate-induced asthma;
CRC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.91	-10.41	-0.5	4.13e-22	Breast cancer;
CRC	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-9.59	-0.47	2.22e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.56	-8.96	-0.44	2.44e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg23758597	chr6:163146217	PARK2	-0.65	-6.58	-0.34	1.91e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.18	0.32	1.87e-9	Axial length;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg15763984	chr4:1342303	KIAA1530	0.48	8.05	0.41	1.52e-14	Longevity;
CRC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.58	-8.49	-0.42	7e-16	Dental caries;
CRC	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg16482183	chr6:26056742	HIST1H1C	-0.72	-9.15	-0.45	6.11e-18	Iron status biomarkers;
CRC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.62	-11.07	-0.52	2.07e-24	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.8	-12.36	-0.56	4.26e-29	Blood pressure (smoking interaction);
CRC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg08314208	chr16:67682810	RLTPR	-0.65	-6.8	-0.35	4.91e-11	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs9938149	0.706	rs7498700	chr16:88320620	T/C	cg05435882	chr16:88311214	NA	-0.47	-6.26	-0.33	1.23e-9	Corneal structure;Central corneal thickness;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg10128753	chr12:53693453	C12orf10	0.57	8.1	0.41	1.09e-14	Response to antipsychotic treatment;
CRC	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	7.04	0.36	1.14e-11	Diisocyanate-induced asthma;
CRC	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.23	18.84	0.72	3.1e-54	Atopic dermatitis;
CRC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.15	-0.32	2.25e-9	Aortic root size;
CRC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg03037974	chr15:76606532	NA	0.69	12.13	0.56	3.19e-28	Blood metabolite levels;
CRC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.18	0.32	1.89e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs7301826	0.610	rs4759791	chr12:131296495	A/G	cg11011512	chr12:131303247	STX2	0.37	5.62	0.3	4.1e-8	Plasma plasminogen activator levels;
CRC	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	24.84	0.81	1.83e-77	Exhaled nitric oxide output;
CRC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.47	8.35	0.42	1.86e-15	Immature fraction of reticulocytes;
CRC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.39	-5.84	-0.31	1.26e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg03395651	chr16:88107091	BANP	0.6	7.9	0.4	4.18e-14	Menopause (age at onset);
CRC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.93	-0.31	7.47e-9	Depression;
CRC	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.48	7.7	0.39	1.56e-13	Schizophrenia;
CRC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg07828024	chr6:149772892	ZC3H12D	0.47	8.73	0.43	1.3e-16	Dupuytren's disease;
CRC	cis	rs12541635	0.934	rs62527400	chr8:107054229	G/A	cg10147462	chr8:107024639	NA	0.46	7.63	0.39	2.48e-13	Age of smoking initiation;
CRC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.44	6.22	0.32	1.5e-9	Longevity;Endometriosis;
CRC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.82	-13.98	-0.61	3.61e-35	Menopause (age at onset);
CRC	trans	rs3008706	0.539	rs9407665	chr9:15854139	T/C	cg15918921	chr2:74212782	NA	-0.52	-6.08	-0.32	3.28e-9	Bilirubin levels;
CRC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg17724175	chr1:150552817	MCL1	0.41	6.3	0.33	9.34e-10	Melanoma;
CRC	cis	rs2836754	1.000	rs2836753	chr21:40291187	A/G	cg16734191	chr21:40194848	ETS2	-0.31	-5.66	-0.3	3.23e-8	Crohn's disease;Body mass index;
CRC	cis	rs7301826	0.651	rs10734979	chr12:131288954	T/C	cg11011512	chr12:131303247	STX2	0.37	5.6	0.3	4.44e-8	Plasma plasminogen activator levels;
CRC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.72	-0.39	1.45e-13	Intelligence (multi-trait analysis);
CRC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.32	-0.33	8.58e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg24579212	chr6:112408909	TUBE1;C6orf225	0.5	5.98	0.31	5.76e-9	Intelligence (multi-trait analysis);
CRC	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg23032129	chr1:109941072	SORT1	-0.28	-5.99	-0.31	5.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.48	-7.8	-0.39	8.46e-14	Testicular germ cell tumor;
CRC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-11.26	-0.53	4.41e-25	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg04128746	chr10:128995134	FAM196A;DOCK1	-0.36	-6.05	-0.32	3.98e-9	Plateletcrit;Platelet count;
CRC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.2	0.45	4.22e-18	Parkinson's disease;
CRC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.8	-0.55	5.04e-27	Type 2 diabetes;
CRC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.34	-5.96	-0.31	6.47e-9	Total body bone mineral density;
CRC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	12.61	0.57	5.15e-30	Alzheimer's disease;
CRC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-12.03	-0.55	7.32e-28	Developmental language disorder (linguistic errors);
CRC	cis	rs4731207	0.596	rs28817916	chr7:124588550	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg00450029	chr8:599525	NA	-0.61	-5.87	-0.31	1.05e-8	IgG glycosylation;
CRC	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg12756093	chr1:115239321	AMPD1	0.47	6.84	0.35	3.86e-11	Autism;
CRC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.6	-0.34	1.63e-10	Systemic lupus erythematosus;
CRC	cis	rs1472360	0.505	rs2645049	chr8:86272555	A/G	cg21346043	chr8:86351067	CA3	-0.37	-6.82	-0.35	4.43e-11	Mean corpuscular hemoglobin concentration;
CRC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg15845792	chr6:28175446	NA	0.77	6.1	0.32	3.04e-9	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
CRC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-7.91	-0.4	4.04e-14	Height;
CRC	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg10523679	chr1:76189770	ACADM	-0.39	-5.62	-0.3	4.18e-8	Daytime sleep phenotypes;
CRC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg02319466	chr17:76381040	PGS1	0.37	5.87	0.31	1.07e-8	HDL cholesterol levels;
CRC	trans	rs11581859	0.950	rs7524256	chr1:99358761	T/C	cg12183875	chr3:169587454	LRRC31	0.26	6.07	0.32	3.54e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg22777020	chr22:31556080	RNF185	-0.51	-5.94	-0.31	7.35e-9	Colorectal cancer;
CRC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg24253500	chr15:84953950	NA	0.34	5.71	0.3	2.47e-8	Schizophrenia;
CRC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.72	10.08	0.49	5.16e-21	Blood metabolite levels;
CRC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.04	0.36	1.14e-11	Glomerular filtration rate (creatinine);
CRC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.84	-0.4	6.18e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg12072164	chr19:44306565	LYPD5	-0.45	-7.09	-0.36	8.4e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg15534755	chr11:117069859	TAGLN	0.33	6.01	0.31	4.91e-9	Blood protein levels;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17910969	chr17:73521755	LLGL2	0.46	6.05	0.32	3.92e-9	Anxiety disorder;
CRC	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg21827317	chr3:136751795	NA	0.35	5.8	0.3	1.58e-8	Neuroticism;
CRC	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg11900509	chr10:81946545	ANXA11	-0.65	-6.71	-0.35	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.92	-11.95	-0.55	1.39e-27	Glomerular filtration rate (creatinine);
CRC	trans	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg22039215	chr3:195716632	SDHAP1	-0.44	-6.08	-0.32	3.39e-9	Total body bone mineral density;
CRC	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.51	-8.1	-0.41	1.05e-14	Corneal astigmatism;
CRC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	7.39	0.38	1.2e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.51	-0.46	4.17e-19	Migraine;Coronary artery disease;
CRC	cis	rs294883	0.821	rs10945598	chr6:159701456	A/G	cg14500486	chr6:159655392	FNDC1	-0.35	-5.75	-0.3	2.09e-8	Coronary artery disease;
CRC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.5	-6.95	-0.36	1.94e-11	Coronary artery disease;
CRC	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.18	-0.37	4.67e-12	Capecitabine sensitivity;
CRC	cis	rs600626	0.529	rs58411334	chr11:75467350	G/T	cg24262691	chr11:75473276	NA	0.49	6.17	0.32	2.03e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs11650494	0.516	rs2233660	chr17:47492366	C/T	cg08112188	chr17:47440006	ZNF652	-0.82	-7.59	-0.39	3.27e-13	Prostate cancer;
CRC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.91	17.35	0.69	2.48e-48	Blood protein levels;
CRC	cis	rs501120	0.543	rs800331	chr10:44806378	C/T	cg09554077	chr10:44749378	NA	0.46	6.2	0.32	1.65e-9	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg18230493	chr5:56204884	C5orf35	0.6	8.87	0.44	4.71e-17	Initial pursuit acceleration;
CRC	cis	rs807029	0.533	rs735137	chr10:102735835	C/G	cg04662943	chr10:102668895	NA	0.64	7.64	0.39	2.41e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.4	-5.94	-0.31	7.06e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CRC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg25164649	chr6:28176230	NA	0.78	9.66	0.47	1.33e-19	Depression;
CRC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.01	0.31	4.9e-9	Obesity-related traits;
CRC	cis	rs4494114	1.000	rs3790441	chr1:39352492	G/A	cg25970120	chr1:39325951	RRAGC	-0.42	-5.74	-0.3	2.18e-8	Blood protein levels;
CRC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.76	-0.43	1.06e-16	Schizophrenia;
CRC	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.61	7.99	0.4	2.28e-14	Cocaine dependence;
CRC	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.51	7.11	0.37	7.16e-12	Response to antidepressants and depression;
CRC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg19193384	chr17:30244184	NA	-0.66	-7.6	-0.39	3.13e-13	Hip circumference adjusted for BMI;
CRC	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.36	-6.03	-0.32	4.34e-9	Menopause (age at onset);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06464432	chr16:71917996	ZNF821;ATXN1L	0.45	6.21	0.32	1.61e-9	Response to antipsychotic treatment;
CRC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	12.8	0.58	1.03e-30	Alzheimer's disease;
CRC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.47	-9.44	-0.46	6.97e-19	Prostate cancer;
CRC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg19318889	chr4:1322082	MAEA	0.4	6.0	0.31	5.31e-9	Obesity-related traits;
CRC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-12.27	-0.56	9.63e-29	Developmental language disorder (linguistic errors);
CRC	cis	rs1322512	1.000	rs2758779	chr6:153008022	T/A	cg03415253	chr6:152958462	SYNE1	0.4	6.04	0.32	4.14e-9	Tonometry;
CRC	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.08	-0.32	3.3e-9	Schizophrenia;
CRC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg15269541	chr15:43626905	ADAL	-0.36	-5.69	-0.3	2.74e-8	Lung cancer;
CRC	cis	rs9323205	0.677	rs12586581	chr14:51722938	G/A	cg23942311	chr14:51606299	NA	-0.52	-6.13	-0.32	2.52e-9	Cancer;
CRC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg22117107	chr15:45993392	NA	-0.44	-9.09	-0.45	9.56e-18	Waist circumference;Weight;
CRC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.68	-0.3	3.02e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs863345	0.564	rs10908662	chr1:158489200	C/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.27	-0.33	1.13e-9	Pneumococcal bacteremia;
CRC	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg14631576	chr9:95140430	CENPP	-0.39	-6.77	-0.35	6.01e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.73	-11.11	-0.52	1.5e-24	Tonsillectomy;
CRC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg19223190	chr17:80058835	NA	0.39	6.27	0.33	1.12e-9	Life satisfaction;
CRC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.83	-13.15	-0.59	4.88e-32	Blood metabolite levels;
CRC	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.49	5.74	0.3	2.21e-8	Dental caries;
CRC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg21620606	chr4:1342894	KIAA1530	-0.34	-5.91	-0.31	8.59e-9	Obesity-related traits;
CRC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.19	0.41	5.85e-15	Lung cancer;
CRC	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	7.01	0.36	1.33e-11	Autism spectrum disorder or schizophrenia;
CRC	cis	rs12230513	0.732	rs61957764	chr12:55867916	G/A	cg19537932	chr12:55886519	OR6C68	-0.71	-8.93	-0.44	3.12e-17	Contrast sensitivity;
CRC	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg00250761	chr1:31883323	NA	-0.39	-7.26	-0.37	2.78e-12	Alcohol dependence;
CRC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.74	7.01	0.36	1.34e-11	Paclitaxel disposition in epithelial ovarian cancer;
CRC	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg00290994	chr1:41848739	NA	0.46	6.95	0.36	1.93e-11	Intelligence (multi-trait analysis);
CRC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.71	-11.49	-0.54	6.21e-26	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg07936489	chr17:37558343	FBXL20	-0.46	-6.63	-0.34	1.4e-10	Asthma;
CRC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.2	-15.72	-0.65	6.5e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.73	7.39	0.38	1.23e-12	Systolic blood pressure;
CRC	cis	rs2971970	0.519	rs6968008	chr7:133632324	C/T	cg03336402	chr7:133662267	EXOC4	0.63	9.63	0.47	1.65e-19	Intelligence (multi-trait analysis);
CRC	cis	rs728616	0.558	rs12414691	chr10:82156982	A/T	cg11900509	chr10:81946545	ANXA11	-0.56	-6.24	-0.33	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg13198984	chr17:80129470	CCDC57	0.42	7.29	0.37	2.32e-12	Life satisfaction;
CRC	cis	rs35520189	0.591	rs12466604	chr2:113703064	G/A	cg12858261	chr2:113808755	IL1F8	0.49	6.87	0.35	3.29e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CRC	cis	rs28719689	0.527	rs6558435	chr8:1215445	C/T	cg03565240	chr8:1204483	NA	-0.44	-5.7	-0.3	2.68e-8	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7209700	0.547	rs55845779	chr17:45354751	G/A	cg08085267	chr17:45401833	C17orf57	0.54	6.4	0.33	5.22e-10	IgG glycosylation;
CRC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.61	9.54	0.47	3.44e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-5.94	-0.31	7.13e-9	Lung cancer;
CRC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.33	6.8	0.35	5.08e-11	Intelligence (multi-trait analysis);
CRC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.24	0.41	4.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs4803480	0.935	rs758349	chr19:42085106	T/C	cg08478046	chr19:42093086	CEACAM21	-0.31	-5.65	-0.3	3.46e-8	Schizophrenia;
CRC	cis	rs4666002	0.636	rs2272406	chr2:27892023	A/T	cg27432699	chr2:27873401	GPN1	0.56	6.96	0.36	1.86e-11	Phospholipid levels (plasma);
CRC	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.04	0.45	1.41e-17	Fuchs's corneal dystrophy;
CRC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-6.81	-0.35	4.64e-11	Developmental language disorder (linguistic errors);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21317428	chr17:1157267	NA	0.35	6.05	0.32	3.98e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs62295889	0.602	rs6448916	chr4:12546096	C/T	cg03490839	chr16:73082051	ZFHX3	0.57	6.0	0.31	5.21e-9	Obesity-related traits;
CRC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.5	6.95	0.36	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.59	9.05	0.45	1.29e-17	Obesity;
CRC	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.66	7.86	0.4	5.53e-14	Obesity (extreme);
CRC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.55	-7.29	-0.37	2.27e-12	Obesity-related traits;
CRC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg04450456	chr4:17643702	FAM184B	0.41	6.29	0.33	1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.68	-0.39	1.88e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.61	-8.47	-0.42	8.56e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg03623178	chr6:28175578	NA	-0.67	-6.77	-0.35	6e-11	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05477027	chr19:46295590	DMWD	0.44	6.14	0.32	2.37e-9	Response to antipsychotic treatment;
CRC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg17467752	chr17:38218738	THRA	-0.37	-5.65	-0.3	3.39e-8	Self-reported allergy;
CRC	cis	rs7192750	0.517	rs152827	chr16:72126753	C/G	cg14768367	chr16:72042858	DHODH	0.85	6.44	0.33	4.18e-10	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.51	5.82	0.31	1.37e-8	Dental caries;
CRC	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.43	-6.25	-0.33	1.3e-9	Asthma;
CRC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg24881330	chr22:46731750	TRMU	0.68	8.69	0.43	1.79e-16	LDL cholesterol;Cholesterol, total;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23780514	chr18:71959249	CYB5A	0.49	6.67	0.35	1.06e-10	Thyroid stimulating hormone;
CRC	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg03037974	chr15:76606532	NA	-0.53	-7.59	-0.39	3.24e-13	Blood metabolite levels;
CRC	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.72	9.38	0.46	1.12e-18	Blood protein levels;
CRC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.31	5.13e-9	Hemoglobin concentration;
CRC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16447950	chr5:562315	NA	-0.76	-10.03	-0.48	7.77e-21	Obesity-related traits;
CRC	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.38	0.46	1.13e-18	Blood protein levels;
CRC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg05941027	chr17:61774174	LIMD2	0.33	5.61	0.3	4.37e-8	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00166722	chr3:10149974	C3orf24	0.67	9.23	0.45	3.37e-18	Alzheimer's disease;
CRC	trans	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg07817883	chr1:32538562	TMEM39B	1.51	13.3	0.59	1.33e-32	Granulocyte percentage of myeloid white cells;
CRC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg15786705	chr6:28176104	NA	0.63	9.02	0.45	1.59e-17	Parkinson's disease;
CRC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.46	-6.16	-0.32	2.15e-9	Diastolic blood pressure;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg14911132	chr11:61596755	FADS2	-0.57	-6.4	-0.33	5.45e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.31	0.49	8.66e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7894407	0.856	rs10883855	chr10:105092447	A/G	cg05636881	chr10:105038444	INA	0.38	6.04	0.32	4.15e-9	White matter hyperintensity burden;
CRC	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg23234261	chr14:55582407	NA	-0.29	-5.84	-0.31	1.25e-8	Protein biomarker;
CRC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.42	9.31	0.46	1.91e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs6694672	0.867	rs4915337	chr1:197091537	A/T	cg13682187	chr1:196946512	CFHR5	0.47	7.63	0.39	2.49e-13	Asthma;
CRC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg08772003	chr10:104629869	AS3MT	-0.36	-6.04	-0.32	4.07e-9	Arsenic metabolism;
CRC	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.12	-0.32	2.6e-9	Diastolic blood pressure;
CRC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	6.07	0.32	3.53e-9	Cognitive test performance;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12056857	chr12:100593408	ACTR6	0.42	6.79	0.35	5.36e-11	Liver disease severity in Alagille syndrome;
CRC	trans	rs2797369	0.713	rs4615398	chr6:101539082	C/T	cg26346621	chr12:6873348	NA	-0.4	-6.01	-0.31	4.87e-9	Renal function-related traits (eGRFcrea);
CRC	cis	rs3736485	0.932	rs2278989	chr15:51914716	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-6.52	-0.34	2.72e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7712401	0.791	rs1531340	chr5:122108017	G/A	cg18764291	chr5:122110994	SNX2	0.42	6.69	0.35	9.63e-11	Mean platelet volume;
CRC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.55	7.71	0.39	1.48e-13	Height;
CRC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.43	-0.62	6.29e-37	Height;
CRC	cis	rs7394190	0.935	rs6480708	chr10:75420114	C/A	cg26549892	chr10:75416844	SYNPO2L	-0.5	-6.32	-0.33	8.46e-10	Incident atrial fibrillation;
CRC	cis	rs758324	0.812	rs3756287	chr5:131135478	A/G	cg25547332	chr5:131281432	NA	0.36	5.75	0.3	2.08e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.44	6.49	0.34	3.14e-10	Calcium levels;
CRC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.7	0.35	8.88e-11	Cognitive ability;
CRC	cis	rs2252521	0.583	rs161050	chr7:29099273	A/G	cg11728747	chr7:29037910	CPVL	-0.48	-6.93	-0.36	2.28e-11	Cognitive performance;
CRC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.43	7.71	0.39	1.48e-13	Height;
CRC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.58	-10.14	-0.49	3.43e-21	Iron status biomarkers;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg01994328	chr10:30723347	MAP3K8	0.38	6.19	0.32	1.84e-9	Obesity-related traits;
CRC	cis	rs7429990	0.965	rs9846062	chr3:47998966	A/G	cg11946769	chr3:48343235	NME6	0.45	5.89	0.31	9.52e-9	Educational attainment (years of education);
CRC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	7.75	0.39	1.18e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.28	-0.33	1.06e-9	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.89	-16.04	-0.66	3.41e-43	Height;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15427393	chr19:44037695	ZNF575	0.45	6.17	0.32	1.96e-9	Anxiety disorder;
CRC	cis	rs4664293	0.867	rs10166694	chr2:160594891	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.23	0.37	3.37e-12	Total body bone mineral density;
CRC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.73	-8.34	-0.42	2.06e-15	Developmental language disorder (linguistic errors);
CRC	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.54	7.91	0.4	3.94e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.79	10.86	0.51	1.11e-23	Cognitive function;
CRC	cis	rs2274273	0.624	rs7150763	chr14:55839801	A/G	cg10130446	chr14:55658398	DLGAP5	-0.44	-6.26	-0.33	1.18e-9	Protein biomarker;
CRC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-13.46	-0.6	3.28e-33	Blood trace element (Zn levels);
CRC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.61	9.95	0.48	1.41e-20	Aortic root size;
CRC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.55	-9.04	-0.45	1.37e-17	Total body bone mineral density;
CRC	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.69	-9.08	-0.45	1.02e-17	Blood pressure (smoking interaction);
CRC	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-5.99	-0.31	5.37e-9	Height;
CRC	cis	rs6921919	0.848	rs6903652	chr6:28322120	C/G	cg21251018	chr6:28226885	NKAPL	0.41	5.78	0.3	1.77e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.36	0.33	6.76e-10	Major depressive disorder;
CRC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.75	0.43	1.14e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs3823572	0.564	rs2346274	chr7:133660841	G/A	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg22676075	chr6:135203613	NA	0.4	6.25	0.33	1.27e-9	Red blood cell count;
CRC	cis	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg07460842	chr6:66804631	NA	-0.43	-5.81	-0.3	1.48e-8	Blood trace element (Cu levels);
CRC	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg12756093	chr1:115239321	AMPD1	0.52	7.97	0.4	2.59e-14	Autism;
CRC	cis	rs10140922	0.567	rs2415263	chr14:35630319	A/C	cg07166546	chr14:35805898	NA	0.28	5.67	0.3	3.12e-8	Hip circumference adjusted for BMI;
CRC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.74	-13.15	-0.59	4.94e-32	Prostate cancer;
CRC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	8.45	0.42	9.3e-16	Height;
CRC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg27068330	chr11:65405492	SIPA1	0.44	6.51	0.34	2.78e-10	Acne (severe);
CRC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg03609598	chr5:56110824	MAP3K1	-0.44	-5.82	-0.31	1.37e-8	Coronary artery disease;
CRC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg15845792	chr6:28175446	NA	0.77	6.18	0.32	1.93e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04476341	chr5:669733	TPPP	-0.42	-6.85	-0.35	3.53e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.38	6.64	0.34	1.26e-10	Height;
CRC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.77	15.65	0.65	1.23e-41	Prostate cancer;
CRC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.25	0.45	2.96e-18	Parkinson's disease;
CRC	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg18230493	chr5:56204884	C5orf35	-0.4	-5.65	-0.3	3.43e-8	Coronary artery disease;
CRC	cis	rs7503807	0.515	rs12939413	chr17:78679449	C/T	cg00549398	chr17:78725201	RPTOR	0.43	5.77	0.3	1.86e-8	Obesity;
CRC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.54	6.94	0.36	2.12e-11	Bronchopulmonary dysplasia;
CRC	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.4	-5.91	-0.31	8.35e-9	IFN-related cytopenia;
CRC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.77	9.69	0.47	1.08e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.49	6.78	0.35	5.75e-11	Coronary artery disease;
CRC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.44	-5.84	-0.31	1.23e-8	Pulse pressure;
CRC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-6.81	-0.35	4.61e-11	Bipolar disorder;
CRC	cis	rs10128264	1.000	rs2802364	chr10:80960486	G/C	cg20744163	chr10:80999841	ZMIZ1	-0.42	-7.33	-0.37	1.8e-12	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs2637266	0.539	rs11001888	chr10:78572048	C/G	cg18941641	chr10:78392320	NA	-0.35	-5.85	-0.31	1.21e-8	Pulmonary function;
CRC	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.41	6.94	0.36	2.15e-11	Intelligence (multi-trait analysis);
CRC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.48	6.52	0.34	2.72e-10	Aortic root size;
CRC	trans	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg21153622	chr11:89784906	NA	-0.5	-8.0	-0.4	2.09e-14	HDL cholesterol;
CRC	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.53	-8.76	-0.43	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.25	-0.37	3.08e-12	Schizophrenia;
CRC	cis	rs4481887	0.504	rs7522945	chr1:248357857	C/A	cg00666640	chr1:248458726	OR2T12	0.43	6.98	0.36	1.61e-11	Common traits (Other);
CRC	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-12.46	-0.57	1.81e-29	Idiopathic membranous nephropathy;
CRC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg16606324	chr3:10149918	C3orf24	0.67	7.89	0.4	4.39e-14	Alzheimer's disease;
CRC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.79	14.08	0.61	1.43e-35	Metabolic syndrome;
CRC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	14.32	0.62	1.75e-36	Chronic sinus infection;
CRC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.55	-0.75	6.02e-61	Height;
CRC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg19041857	chr6:27730383	NA	-0.48	-6.12	-0.32	2.68e-9	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
CRC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg10790698	chr19:18539756	SSBP4	0.43	8.12	0.41	9.54e-15	Breast cancer;
CRC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	10.66	0.51	5.53e-23	Hip circumference adjusted for BMI;
CRC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg25456477	chr12:86230367	RASSF9	0.33	5.63	0.3	3.87e-8	Major depressive disorder;
CRC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg20129853	chr10:51489980	NA	-0.36	-5.87	-0.31	1.08e-8	Prostate-specific antigen levels;
CRC	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg17545662	chr6:170176663	C6orf70	0.51	5.68	0.3	2.97e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg04990556	chr1:26633338	UBXN11	0.56	6.02	0.32	4.53e-9	Obesity-related traits;
CRC	cis	rs11716531	0.504	rs648103	chr3:27550301	T/C	cg02860705	chr3:27208620	NA	-0.43	-6.53	-0.34	2.52e-10	Diastolic blood pressure;
CRC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.79	0.44	8.51e-17	Morning vs. evening chronotype;
CRC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs11587400	0.634	rs7553926	chr1:115202215	A/G	cg12756093	chr1:115239321	AMPD1	-0.44	-6.12	-0.32	2.7e-9	Autism;
CRC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg11833968	chr6:79620685	NA	-0.37	-6.48	-0.34	3.34e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	6.11	0.32	2.81e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.49	-9.27	-0.45	2.61e-18	Alcohol dependence;
CRC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-6.05	-0.32	3.98e-9	Reticulocyte count;
CRC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.43	7.59	0.39	3.36e-13	Lung cancer;
CRC	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.64	9.26	0.45	2.73e-18	Uric acid levels;
CRC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.69	9.69	0.47	1.04e-19	Alzheimer's disease;
CRC	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.6	-0.34	1.66e-10	Metabolite levels;
CRC	trans	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg21153622	chr11:89784906	NA	-0.44	-7.06	-0.36	9.71e-12	HDL cholesterol;
CRC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	5.93	0.31	7.49e-9	Protein C levels;
CRC	cis	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg02972257	chr16:68554789	NA	-0.6	-7.28	-0.37	2.46e-12	Ulcerative colitis;
CRC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg17333051	chr19:2783644	SGTA	-0.43	-6.93	-0.36	2.18e-11	Total cholesterol levels;
CRC	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg10437265	chr15:77819839	NA	0.58	10.4	0.5	4.44e-22	Type 2 diabetes;
CRC	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.52	-7.21	-0.37	3.81e-12	Tuberculosis;
CRC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.31	12.49	0.57	1.46e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg05784532	chr1:230284198	GALNT2	0.42	5.84	0.31	1.26e-8	Coronary artery disease;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00142735	chr15:64454827	PPIB	0.43	5.99	0.31	5.42e-9	Response to antipsychotic treatment;
CRC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg08896387	chr1:24191740	FUCA1	0.49	6.27	0.33	1.14e-9	Immature fraction of reticulocytes;
CRC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	1.03	20.52	0.75	7.72e-61	Headache;
CRC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg21770322	chr7:97807741	LMTK2	0.51	8.29	0.42	2.88e-15	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs56100249	chr2:162415157	T/C	cg14875682	chr5:52083620	ITGA1;PELO	-0.79	-6.36	-0.33	6.65e-10	Cognitive function;
CRC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg08222913	chr3:52553049	STAB1	-0.34	-5.97	-0.31	6.17e-9	Bipolar disorder;
CRC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-19.99	-0.74	9.26e-59	Primary sclerosing cholangitis;
CRC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.76	-14.38	-0.62	1.04e-36	Body mass index;
CRC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-19.61	-0.73	2.95e-57	Prudent dietary pattern;
CRC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.12	-0.32	2.71e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	5.8	0.3	1.52e-8	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1891275	0.515	rs1418161	chr10:93484655	C/G	cg07889827	chr10:93443413	NA	-0.39	-6.5	-0.34	3.05e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9549328	0.670	rs2993344	chr13:113617022	C/T	cg25790453	chr13:113633590	MCF2L	0.44	7.66	0.39	2.09e-13	Systolic blood pressure;
CRC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	16.82	0.68	2.91e-46	Platelet count;
CRC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg12172441	chr6:28176163	NA	0.55	6.94	0.36	2.05e-11	Parkinson's disease;
CRC	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.49	8.74	0.43	1.18e-16	Blood metabolite ratios;
CRC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.41e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.22	0.64	5.91e-40	Colorectal cancer;
CRC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.53	7.33	0.37	1.79e-12	Lung cancer;
CRC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	11.44	0.53	9.46e-26	Prudent dietary pattern;
CRC	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.49	8.92	0.44	3.24e-17	Neuroticism;
CRC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.45	5.88	0.31	1.01e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg24578937	chr1:2090814	PRKCZ	-0.39	-7.17	-0.37	4.86e-12	Height;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02309717	chr12:32908817	YARS2	0.51	6.56	0.34	2.13e-10	Thyroid stimulating hormone;
CRC	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-6.99	-0.36	1.57e-11	Menarche (age at onset);
CRC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg19193384	chr17:30244184	NA	-0.64	-7.46	-0.38	7.99e-13	Hip circumference adjusted for BMI;
CRC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg15845792	chr6:28175446	NA	0.77	6.2	0.32	1.67e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CRC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg27615366	chr5:131592974	PDLIM4	-0.34	-6.08	-0.32	3.36e-9	Acylcarnitine levels;
CRC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg07507251	chr3:52567010	NT5DC2	-0.41	-6.43	-0.33	4.59e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs10503871	0.816	rs3779639	chr8:30407991	A/G	cg26383811	chr8:30366931	RBPMS	-0.44	-7.2	-0.37	4.18e-12	Metabolite levels  (X-11787);
CRC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg10729496	chr3:10149963	C3orf24	0.54	7.0	0.36	1.41e-11	Alzheimer's disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05986781	chr7:127291658	SND1	0.47	6.01	0.31	4.96e-9	Thyroid stimulating hormone;
CRC	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-6.21	-0.32	1.64e-9	Inflammatory biomarkers;
CRC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg09491104	chr22:46646882	C22orf40	-0.45	-7.06	-0.36	1e-11	LDL cholesterol;Cholesterol, total;
CRC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.35	0.42	1.88e-15	Height;
CRC	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.48	-7.21	-0.37	3.82e-12	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	20.71	0.75	1.47e-61	Prudent dietary pattern;
CRC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.53	9.39	0.46	1.03e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.36	0.46	1.28e-18	Mean platelet volume;
CRC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg18230493	chr5:56204884	C5orf35	-0.41	-5.93	-0.31	7.58e-9	Coronary artery disease;
CRC	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg04110750	chr16:69646130	NFAT5	-0.49	-6.5	-0.34	2.99e-10	IgE levels;
CRC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg03233332	chr7:66118400	NA	0.45	6.16	0.32	2.08e-9	Aortic root size;
CRC	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.45	6.29	0.33	1.03e-9	White matter microstructure (global fractional anisotropy);
CRC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.46	6.32	0.33	8.28e-10	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.51	0.57	1.18e-29	Mean platelet volume;
CRC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.44	7.2	0.37	4.02e-12	Menopause (age at onset);
CRC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg06494592	chr3:125709126	NA	-0.56	-6.78	-0.35	5.65e-11	Blood pressure (smoking interaction);
CRC	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.59	9.25	0.45	2.85e-18	Corneal astigmatism;
CRC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-6.1	-0.32	2.94e-9	Daytime sleep phenotypes;
CRC	trans	rs7210990	0.724	rs178826	chr17:16083684	C/T	cg24449302	chr15:66679100	MAP2K1	-0.43	-6.58	-0.34	1.87e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
CRC	cis	rs758324	0.738	rs648304	chr5:131286708	T/C	cg25547332	chr5:131281432	NA	-0.36	-5.79	-0.3	1.61e-8	Alzheimer's disease in APOE e4- carriers;
CRC	cis	rs2579500	0.844	rs2579503	chr2:97176634	A/G	cg23100626	chr2:96804247	ASTL	-0.23	-5.6	-0.3	4.49e-8	Eosinophil counts;Eosinophil percentage of white cells;
CRC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.83	-14.54	-0.63	2.35e-37	Height;
CRC	trans	rs1456896	0.796	rs1456895	chr7:50312228	G/A	cg02134594	chr1:3632713	TP73	0.38	6.27	0.33	1.1e-9	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.69	-0.47	1.05e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.47	-6.43	-0.33	4.55e-10	Gut microbiome composition (summer);
CRC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-7.22	-0.37	3.66e-12	Bipolar disorder;
CRC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg14844989	chr11:31128820	NA	-0.34	-6.04	-0.32	4.28e-9	Red blood cell count;
CRC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg16342193	chr10:102329863	NA	-0.35	-5.83	-0.31	1.29e-8	Palmitoleic acid (16:1n-7) levels;
CRC	trans	rs2303319	0.504	rs62189046	chr2:162612371	C/G	cg27342122	chr8:133787442	PHF20L1	-0.72	-6.12	-0.32	2.68e-9	Cognitive function;
CRC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg15383120	chr6:291909	DUSP22	-0.51	-7.22	-0.37	3.54e-12	Menopause (age at onset);
CRC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.48	6.65	0.34	1.21e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CRC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg23750338	chr8:142222470	SLC45A4	0.45	7.42	0.38	1e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	5.93	0.31	7.65e-9	IgG glycosylation;
CRC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg03037974	chr15:76606532	NA	-0.55	-8.28	-0.42	3.21e-15	Blood metabolite levels;
CRC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg11189052	chr15:85197271	WDR73	0.61	9.0	0.44	1.87e-17	Schizophrenia;
CRC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.61	-9.33	-0.46	1.66e-18	Monocyte percentage of white cells;
CRC	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg03929089	chr4:120376271	NA	0.62	5.99	0.31	5.44e-9	Axial length;
CRC	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.58	-8.3	-0.42	2.8e-15	Obesity;
CRC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.55	7.82	0.4	7.08e-14	IgG glycosylation;
CRC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.68	9.35	0.46	1.41e-18	Coronary artery disease;
CRC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg20933634	chr6:27740509	NA	-0.58	-6.8	-0.35	5e-11	Depression;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg26608667	chr7:1196370	ZFAND2A	0.41	6.69	0.35	9.64e-11	Longevity;Endometriosis;
CRC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.37	6.0	0.31	5.27e-9	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-6.7	-0.35	9.31e-11	Height;
CRC	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg15145174	chr5:6755386	POLS	-0.44	-6.49	-0.34	3.22e-10	Menopause (age at onset);
CRC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg21770322	chr7:97807741	LMTK2	0.5	8.23	0.41	4.49e-15	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg18833306	chr6:118973337	C6orf204	0.45	5.95	0.31	6.95e-9	Diastolic blood pressure;
CRC	trans	rs11466653	1.000	rs6852188	chr4:38778980	A/T	cg11403706	chr22:49042600	FAM19A5	0.62	6.11	0.32	2.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg23976632	chr12:120875743	COX6A1	-0.4	-6.33	-0.33	8.04e-10	Aortic root size;
CRC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg18402987	chr7:1209562	NA	0.43	6.39	0.33	5.64e-10	Longevity;Endometriosis;
CRC	cis	rs28655083	0.529	rs1847161	chr16:77097796	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.49	7.08	0.36	8.81e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4731207	0.596	rs10257712	chr7:124598079	A/G	cg23710748	chr7:124431027	NA	-0.38	-5.97	-0.31	6.11e-9	Cutaneous malignant melanoma;
CRC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.9	-0.52	7.69e-24	Bipolar disorder and schizophrenia;
CRC	cis	rs6662572	1.000	rs11585275	chr1:46095989	T/C	cg08644498	chr1:46502608	NA	0.43	6.0	0.31	5.2e-9	Blood protein levels;
CRC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	5.78	0.3	1.76e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs1443512	0.947	rs1822438	chr12:54342326	A/C	cg25382128	chr12:54346509	NA	-0.39	-5.99	-0.31	5.5e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CRC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.45	-7.24	-0.37	3.24e-12	Menopause (age at onset);
CRC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg04518342	chr5:131593106	PDLIM4	-0.32	-5.7	-0.3	2.67e-8	Blood metabolite levels;
CRC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.88	-0.4	4.97e-14	Gut microbiome composition (summer);
CRC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg23018236	chr17:30244563	NA	-0.67	-8.03	-0.4	1.78e-14	Hip circumference adjusted for BMI;
CRC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.45	6.25	0.33	1.3e-9	Red blood cell count;
CRC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-10.31	-0.49	8.99e-22	Total cholesterol levels;
CRC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-6.05	-0.32	3.92e-9	Obesity-related traits;
CRC	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.77	12.04	0.55	6.61e-28	Breast cancer;
CRC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg24011408	chr12:48396354	COL2A1	-0.44	-6.5	-0.34	3.05e-10	Glycated hemoglobin levels;
CRC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.34	-6.23	-0.32	1.43e-9	Mean corpuscular volume;
CRC	cis	rs2444240	1.000	rs494965	chr11:120053650	C/T	cg16005559	chr11:120040616	NA	-0.36	-5.84	-0.31	1.25e-8	Corneal curvature;
CRC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.52	-6.45	-0.34	3.98e-10	Diastolic blood pressure;
CRC	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.5	-6.58	-0.34	1.89e-10	Inhibitory control;
CRC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.57	8.29	0.42	2.89e-15	Obesity-related traits;
CRC	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg04586622	chr2:25135609	ADCY3	-0.58	-9.98	-0.48	1.12e-20	Body mass index;
CRC	trans	rs9328321	0.528	rs9378430	chr6:5574319	C/T	cg27322103	chr7:23513335	NA	-0.44	-6.25	-0.33	1.29e-9	Obesity (early onset extreme);
CRC	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-18.65	-0.72	1.85e-53	Schizophrenia;
CRC	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	7.17	0.37	5.07e-12	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg05501817	chr11:14380813	RRAS2	-0.48	-6.7	-0.35	8.95e-11	Sense of smell;
CRC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg27535305	chr1:53392650	SCP2	0.38	7.22	0.37	3.52e-12	Monocyte count;
CRC	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg10761708	chr20:43804764	PI3	0.48	5.6	0.3	4.48e-8	Blood protein levels;
CRC	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg09654669	chr8:57350985	NA	-0.4	-5.6	-0.3	4.49e-8	Obesity-related traits;
CRC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.49	9.28	0.46	2.34e-18	Alcohol dependence;
CRC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg11189052	chr15:85197271	WDR73	0.56	7.53	0.38	5.02e-13	Autism spectrum disorder or schizophrenia;
CRC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.51	7.87	0.4	5.24e-14	Corneal astigmatism;
CRC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.39	-7.84	-0.4	6.35e-14	Renal cell carcinoma;
CRC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.86	-10.87	-0.51	9.9e-24	Obesity-related traits;
CRC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg06470822	chr6:28175283	NA	0.84	10.83	0.51	1.39e-23	Parkinson's disease;
CRC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.29	-0.33	9.82e-10	Bipolar disorder;
CRC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.68	-8.5	-0.42	6.62e-16	Developmental language disorder (linguistic errors);
CRC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg20811857	chr17:78079795	GAA	-0.34	-5.6	-0.3	4.42e-8	Yeast infection;
CRC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.51	8.71	0.43	1.49e-16	Schizophrenia;
CRC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	8.85	0.44	5.5e-17	Menarche (age at onset);
CRC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.66	9.79	0.47	4.99e-20	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.14	0.32	2.36e-9	Hip circumference adjusted for BMI;Body mass index;
CRC	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.38	-0.33	6.16e-10	Breast cancer;
CRC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.38	7.27	0.37	2.71e-12	Mean corpuscular volume;
CRC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.69	9.64	0.47	1.58e-19	Chronic sinus infection;
CRC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-5.7	-0.3	2.62e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg17023122	chr1:144479586	NA	0.42	6.03	0.32	4.45e-9	Hip geometry;
CRC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg22110888	chr17:80059540	CCDC57	-0.39	-6.18	-0.32	1.92e-9	Life satisfaction;
CRC	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg15192750	chr16:69999425	NA	0.48	6.42	0.33	4.81e-10	IgE levels;
CRC	trans	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg07393940	chr7:158741817	NA	-0.53	-7.71	-0.39	1.53e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.73	8.12	0.41	9.21e-15	Blood protein levels;
CRC	cis	rs17155006	0.718	rs370533	chr7:107746215	G/C	cg05962710	chr7:107745446	LAMB4	-0.43	-7.58	-0.39	3.62e-13	Pneumococcal bacteremia;
CRC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-6.48	-0.34	3.28e-10	Menopause (age at onset);
CRC	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.9	0.55	2.09e-27	Exhaled nitric oxide levels;
CRC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.66	10.8	0.51	1.79e-23	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs6011368	0.765	rs6062683	chr20:62891887	G/A	cg13869341	chr1:15865	WASH5P	0.4	5.99	0.31	5.59e-9	Clozapine-induced cytotoxicity;
CRC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg25985355	chr7:65971099	NA	0.32	5.71	0.3	2.54e-8	Aortic root size;
CRC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.5	-6.82	-0.35	4.3e-11	Body mass index;
CRC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg15147215	chr3:52552868	STAB1	0.64	10.77	0.51	2.33e-23	Bipolar disorder;
CRC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg00316803	chr15:76480434	C15orf27	-0.35	-5.81	-0.31	1.46e-8	Blood metabolite levels;
CRC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg17724175	chr1:150552817	MCL1	-0.51	-8.29	-0.42	2.96e-15	Tonsillectomy;
CRC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.31	-6.39	-0.33	5.75e-10	Intelligence (multi-trait analysis);
CRC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.4	0.33	5.21e-10	Depression;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21395782	chr19:19626814	NDUFA13;TSSK6	0.44	6.48	0.34	3.32e-10	Response to antipsychotic treatment;
CRC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.76	-0.39	1.07e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	6.43	0.33	4.53e-10	Aortic root size;
CRC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21028142	chr17:79581711	NPLOC4	0.38	8.32	0.42	2.38e-15	Eye color traits;
CRC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	7.01	0.36	1.34e-11	Headache;
CRC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg01788221	chr16:89496183	ANKRD11	-0.39	-5.71	-0.3	2.55e-8	Multiple myeloma (IgH translocation);
CRC	cis	rs1552172	0.887	rs12750384	chr1:145681484	T/C	cg25221984	chr1:145714143	CD160	-0.38	-5.71	-0.3	2.51e-8	Breast cancer;
CRC	cis	rs6681460	0.966	rs1325261	chr1:67110516	G/A	cg02459107	chr1:67143332	SGIP1	0.45	7.69	0.39	1.75e-13	Presence of antiphospholipid antibodies;
CRC	cis	rs6804368	0.553	rs13078791	chr3:30766889	C/T	cg06106510	chr3:30762233	NA	0.37	6.07	0.32	3.45e-9	Blood metabolite levels;
CRC	cis	rs73206853	0.764	rs55991901	chr12:110962702	C/A	cg12870014	chr12:110450643	ANKRD13A	0.71	7.68	0.39	1.86e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-5.66	-0.3	3.27e-8	Vitiligo;
CRC	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.66	-9.57	-0.47	2.66e-19	Type 2 diabetes;
CRC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.87	-19.83	-0.74	4.13e-58	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	trans	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg18335740	chr13:41363409	SLC25A15	0.47	7.0	0.36	1.41e-11	Lewy body disease;
CRC	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.64	-7.52	-0.38	5.19e-13	Ulcerative colitis;
CRC	cis	rs10733682	0.524	rs10987419	chr9:129462594	T/C	cg00232160	chr9:129468157	NA	0.34	5.81	0.3	1.51e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg06470822	chr6:28175283	NA	0.71	10.07	0.49	5.85e-21	Parkinson's disease;
CRC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.47	-8.08	-0.41	1.25e-14	Sense of smell;
CRC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	14.75	0.63	3.76e-38	Platelet count;
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg17780098	chr1:201476311	CSRP1	0.44	6.18	0.32	1.87e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	0.99	11.9	0.55	2.11e-27	Vitiligo;
CRC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg18827107	chr12:86230957	RASSF9	-0.38	-5.82	-0.31	1.37e-8	Major depressive disorder;
CRC	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	15.62	0.65	1.5e-41	Fuchs's corneal dystrophy;
CRC	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-6.43	-0.33	4.57e-10	Eye color traits;
CRC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.95	13.32	0.59	1.16e-32	Breast cancer;
CRC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.61	-8.87	-0.44	4.59e-17	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01012308	chr16:3767753	TRAP1	0.46	6.36	0.33	6.63e-10	Anxiety disorder;
CRC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.39	6.95	0.36	1.94e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg01422370	chr2:73384389	NA	0.4	6.35	0.33	6.95e-10	Intelligence (multi-trait analysis);
CRC	cis	rs992157	0.764	rs2382827	chr2:219184387	G/A	cg04880052	chr2:219191631	PNKD	0.4	6.08	0.32	3.32e-9	Colorectal cancer;
CRC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg25164649	chr6:28176230	NA	0.6	8.67	0.43	2.04e-16	Parkinson's disease;
CRC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.53	-9.84	-0.48	3.29e-20	Coronary artery disease;
CRC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.81	-11.42	-0.53	1.17e-25	Coronary artery disease;
CRC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.56	8.25	0.41	3.76e-15	Glomerular filtration rate (creatinine);
CRC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.48	7.94	0.4	3.31e-14	Perceived unattractiveness to mosquitoes;
CRC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.13	10.45	0.5	2.85e-22	Skin colour saturation;
CRC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.37	0.33	6.35e-10	Menarche (age at onset);
CRC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.41	-5.74	-0.3	2.15e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.83	13.31	0.59	1.24e-32	Tonsillectomy;
CRC	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg10724054	chr17:3904396	NA	-0.38	-6.1	-0.32	2.91e-9	Type 2 diabetes;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16296880	chr4:39367793	RFC1	0.38	6.2	0.32	1.72e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs6678914	0.966	rs12033508	chr1:202180401	A/G	cg19977628	chr5:1262072	TERT	0.42	5.99	0.31	5.37e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
CRC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	14.8	0.63	2.35e-38	Chronic sinus infection;
CRC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.51	6.96	0.36	1.82e-11	Morning vs. evening chronotype;
CRC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.7	7.16	0.37	5.26e-12	Initial pursuit acceleration;
CRC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg13722127	chr7:150037890	RARRES2	0.4	5.73	0.3	2.27e-8	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	6.17	0.32	2.06e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.52	7.59	0.39	3.34e-13	N-glycan levels;
CRC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.62	12.92	0.58	3.52e-31	Schizophrenia;
CRC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.31	-0.42	2.52e-15	Height;
CRC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.05	-0.48	6.61e-21	Height;
CRC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.73	9.56	0.47	2.93e-19	Blood protein levels;
CRC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg26838691	chr2:24397539	C2orf84	0.4	5.67	0.3	3.05e-8	Asthma;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00441754	chr19:45394894	TOMM40	0.5	6.34	0.33	7.56e-10	Hip circumference;
CRC	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg11189052	chr15:85197271	WDR73	0.5	7.49	0.38	6.2800000000000005e-13	Schizophrenia;
CRC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.42	-6.29	-0.33	1.01e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg14119001	chr9:139324193	INPP5E	-0.43	-5.8	-0.3	1.54e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-5.71	-0.3	2.56e-8	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.45	-6.22	-0.32	1.48e-9	Lung cancer;
CRC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg19622623	chr12:86230825	RASSF9	-0.38	-5.85	-0.31	1.18e-8	Major depressive disorder;
CRC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.45	6.74	0.35	7.31e-11	Acne (severe);
CRC	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.48	7.27	0.37	2.71e-12	Testicular germ cell tumor;
CRC	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg04989706	chr14:50066350	PPIL5	-0.5	-7.08	-0.36	8.72e-12	Carotid intima media thickness;
CRC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02725872	chr8:58115012	NA	-0.38	-6.33	-0.33	7.81e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.26	-0.33	1.22e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	0.57	8.89	0.44	4.21e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg04870010	chr2:131099943	IMP4;CCDC115	0.51	6.42	0.33	4.79e-10	Thyroid stimulating hormone;
CRC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.39	-7.57	-0.39	3.69e-13	Lung cancer;
CRC	cis	rs7039377	0.541	rs7850196	chr9:38671574	G/T	cg14625731	chr9:38672608	NA	-0.36	-5.77	-0.3	1.85e-8	Obesity-related traits;
CRC	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.56	-8.45	-0.42	9.82e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.73	-0.35	7.35e-11	Total body bone mineral density;
CRC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg19193384	chr17:30244184	NA	0.53	5.95	0.31	6.73e-9	Hip circumference adjusted for BMI;
CRC	cis	rs3751196	0.808	rs76281167	chr12:104220034	A/G	cg02344784	chr12:104178138	NT5DC3	0.71	7.25	0.37	3.05e-12	Sense of smell;
CRC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg03013999	chr17:37608204	MED1	0.47	7.31	0.37	2e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg16670446	chr17:27188758	MIR451;MIR144	0.53	8.4	0.42	1.32e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg10723962	chr6:26240782	HIST1H4F	-0.39	-6.27	-0.33	1.15e-9	Gout;Renal underexcretion gout;
CRC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.43	7.45	0.38	8.2e-13	Childhood ear infection;
CRC	cis	rs4746091	0.526	rs4747176	chr10:73402498	A/G	cg22763136	chr10:73395000	CDH23	0.35	5.98	0.31	5.83e-9	Selective IgA deficiency;
CRC	trans	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	7.42	0.38	9.91e-13	Morning vs. evening chronotype;Chronotype;
CRC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg15845792	chr6:28175446	NA	0.8	11.91	0.55	1.99e-27	Cardiac Troponin-T levels;
CRC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg08213375	chr14:104286397	PPP1R13B	0.36	5.75	0.3	2e-8	Reticulocyte count;
CRC	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg27083787	chr2:113543245	IL1A	0.44	6.07	0.32	3.43e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CRC	cis	rs9463078	0.764	rs2396370	chr6:44946472	A/G	cg25276700	chr6:44698697	NA	-0.28	-6.77	-0.35	6e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.62	-8.38	-0.42	1.52e-15	Colorectal cancer;
CRC	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg22495460	chr2:25135724	ADCY3	0.39	5.75	0.3	2.02e-8	Body mass index in non-asthmatics;
CRC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.23	-0.32	1.45e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs12760731	0.565	rs12028023	chr1:178087408	G/A	cg00404053	chr1:178313656	RASAL2	1.06	11.28	0.53	3.67e-25	Obesity-related traits;
CRC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.37	-8.7	-0.43	1.57e-16	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs13088645	0.532	rs12695613	chr3:134166572	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.53	0.34	2.43e-10	Coronary artery disease;
CRC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.78	0.66	3.83e-42	Platelet count;
CRC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.53	7.53	0.38	4.9e-13	Schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00373665	chr1:234735703	NA	0.51	7.25	0.37	3.05e-12	Response to antipsychotic treatment;
CRC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg04204079	chr8:58130323	NA	-0.46	-5.84	-0.31	1.22e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs2933343	1.000	rs2630252	chr3:128624772	T/C	cg11901034	chr3:128598214	ACAD9	-0.51	-6.2	-0.32	1.71e-9	IgG glycosylation;
CRC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.81	14.41	0.62	8.09e-37	Breast cancer;
CRC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.19	0.45	4.44e-18	Bladder cancer;
CRC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-10.0	-0.48	9.53e-21	Heart rate;
CRC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg14541582	chr5:601475	NA	-0.36	-7.23	-0.37	3.43e-12	Obesity-related traits;
CRC	trans	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg05270119	chr15:66161672	RAB11A	0.44	6.06	0.32	3.75e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CRC	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg02135003	chr7:105160482	PUS7	-0.53	-8.34	-0.42	2.05e-15	Bipolar disorder (body mass index interaction);
CRC	cis	rs12612619	0.732	rs10865461	chr2:27292651	T/C	cg00617064	chr2:27272375	NA	-0.38	-6.43	-0.33	4.47e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CRC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.69	-11.17	-0.52	9.09e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.55	7.83	0.4	6.92e-14	Blood metabolite levels;
CRC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.52	-0.38	5.28e-13	Heart rate;
CRC	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg17885191	chr8:135476712	NA	0.54	7.41	0.38	1.06e-12	Hypertension (SNP x SNP interaction);
CRC	trans	rs657075	0.595	rs35719560	chr5:131584395	T/C	cg24629898	chr13:20718496	GJA3	0.39	6.04	0.32	4.23e-9	Rheumatoid arthritis;
CRC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-9.95	-0.48	1.47e-20	Coronary artery disease;
CRC	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.41	-6.81	-0.35	4.64e-11	Mean arterial pressure;
CRC	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg24998770	chr7:37888106	TXNDC3	0.38	6.07	0.32	3.48e-9	Alzheimer's disease (late onset);
CRC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.6	-8.22	-0.41	4.79e-15	Urate levels in lean individuals;
CRC	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.56	7.98	0.4	2.43e-14	Osteoporosis;
CRC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.62	8.31	0.42	2.62e-15	Gut microbiome composition (summer);
CRC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg25251562	chr2:3704773	ALLC	-0.49	-6.12	-0.32	2.62e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CRC	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg25019722	chr6:37503610	NA	-0.46	-8.64	-0.43	2.4e-16	Cognitive performance;
CRC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	9.0	0.44	1.82e-17	Pulse pressure;
CRC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg21770322	chr7:97807741	LMTK2	0.57	9.52	0.46	3.93e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg20630647	chr19:41531805	NA	0.37	6.56	0.34	2.12e-10	DDT metabolite (p,p'-DDE levels);
CRC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.38	6.5	0.34	2.93e-10	Primary biliary cholangitis;
CRC	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-8.07	-0.41	1.32e-14	Mean corpuscular volume;
CRC	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.63	0.39	2.5e-13	Testicular germ cell tumor;
CRC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg20041105	chr8:143859282	LYNX1	-0.44	-7.25	-0.37	2.93e-12	Urinary tract infection frequency;
CRC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.57	-8.6	-0.43	3.23e-16	Height;
CRC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.41	6.67	0.35	1.08e-10	Colonoscopy-negative controls vs population controls;
CRC	trans	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg13565492	chr6:43139072	SRF	-0.71	-7.39	-0.38	1.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.46	7.89	0.4	4.64e-14	Common traits (Other);
CRC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.69	-12.23	-0.56	1.3e-28	Asthma;
CRC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.48	-7.55	-0.38	4.31e-13	Height;
CRC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.8	10.66	0.51	5.61e-23	Cerebrospinal P-tau181p levels;
CRC	trans	rs2274459	0.778	rs2281917	chr6:33655728	G/C	cg18356190	chr4:74964260	CXCL2	0.4	6.04	0.32	4.13e-9	Obesity (extreme);
CRC	trans	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg10756647	chr7:56101905	PSPH	0.74	7.7	0.39	1.66e-13	Diabetic kidney disease;
CRC	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.62	-7.2	-0.37	4.17e-12	Ulcerative colitis;
CRC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.63	8.91	0.44	3.45e-17	Height;
CRC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.66	-8.01	-0.4	2.03e-14	Menarche (age at onset);
CRC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	13.33	0.59	1.07e-32	Bone mineral density;
CRC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12588279	chr6:26043732	HIST1H2BB	0.51	7.29	0.37	2.38e-12	Intelligence (multi-trait analysis);
CRC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg05569086	chr8:143859399	LYNX1	0.39	6.74	0.35	7.07e-11	Urinary tract infection frequency;
CRC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.45	6.92	0.36	2.32e-11	Height;
CRC	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.95	-13.35	-0.59	8.41e-33	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.44	7.06	0.36	1.01e-11	Schizophrenia;
CRC	trans	rs2303319	0.504	rs12467613	chr2:162603216	G/T	cg23247704	chr1:116518985	SLC22A15	-0.72	-6.14	-0.32	2.42e-9	Cognitive function;
CRC	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.79	0.68	4.11e-46	Electrocardiographic conduction measures;
CRC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg21770322	chr7:97807741	LMTK2	0.52	8.45	0.42	9.87e-16	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.42	9.24	0.45	3.16e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	10.0	0.48	1.01e-20	Cognitive test performance;
CRC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.83	-0.31	1.33e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.68	0.35	1e-10	Mean corpuscular volume;
CRC	cis	rs10450586	0.932	rs10835152	chr11:27311217	T/G	cg10370305	chr11:27303972	NA	0.35	5.7	0.3	2.68e-8	Total body bone mineral density;
CRC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	6.29	0.33	9.83e-10	Tonsillectomy;
CRC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.32	0.42	2.33e-15	Arsenic metabolism;
CRC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	11.11	0.52	1.5e-24	Tonsillectomy;
CRC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg21251018	chr6:28226885	NKAPL	-0.42	-5.97	-0.31	6.12e-9	Parkinson's disease;
CRC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.87	-13.96	-0.61	4.02e-35	Blood metabolite levels;
CRC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg18709589	chr6:96969512	KIAA0776	-0.39	-5.62	-0.3	3.99e-8	Headache;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg11450715	chr2:171627404	NA	-0.38	-5.98	-0.31	5.86e-9	Myopia (pathological);
CRC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.69	-9.88	-0.48	2.4e-20	Alzheimer's disease;
CRC	cis	rs2857891	0.862	rs957747	chr11:6966814	A/G	cg04053776	chr11:6947353	ZNF215	0.42	5.87	0.31	1.06e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.54	7.81	0.4	7.8e-14	Cognitive ability;
CRC	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg02117656	chr17:79614917	TSPAN10	0.44	6.93	0.36	2.22e-11	Myopia;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg27216355	chr16:71599010	NA	-0.4	-5.98	-0.31	5.74e-9	HDL cholesterol;
CRC	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg04132472	chr17:19861366	AKAP10	0.43	6.56	0.34	2.14e-10	Schizophrenia;
CRC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-5.72	-0.3	2.43e-8	Intelligence (multi-trait analysis);
CRC	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	15.01	0.64	3.66e-39	Colorectal cancer;
CRC	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg16558208	chr1:156270281	VHLL	0.58	9.08	0.45	1.03e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
CRC	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-7.59	-0.39	3.38e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-9.05	-0.45	1.29e-17	Extrinsic epigenetic age acceleration;
CRC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	11.06	0.52	2.24e-24	Motion sickness;
CRC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18099408	chr3:52552593	STAB1	-0.43	-6.96	-0.36	1.8e-11	Bipolar disorder;
CRC	cis	rs4731207	0.596	rs723444	chr7:124659224	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.04	-0.32	4.26e-9	Cutaneous malignant melanoma;
CRC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.3	1.96e-8	Bladder cancer;
CRC	cis	rs3849570	0.643	rs1851928	chr3:81975395	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-6.5	-0.34	3.06e-10	Waist circumference;Body mass index;
CRC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg24562669	chr7:97807699	LMTK2	0.44	7.38	0.38	1.32e-12	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs2303319	0.504	rs58622044	chr2:162596287	A/G	cg13034943	chr12:132379564	ULK1	-0.69	-5.96	-0.31	6.33e-9	Cognitive function;
CRC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13844804	chr7:814759	HEATR2	-0.54	-5.76	-0.3	1.94e-8	Cerebrospinal P-tau181p levels;
CRC	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	1.07	18.21	0.71	9.6e-52	Schizophrenia;
CRC	cis	rs16975963	0.644	rs12151280	chr19:38067890	A/C	cg15135657	chr19:38346511	NA	-0.44	-6.25	-0.33	1.26e-9	Longevity;
CRC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg07217954	chr7:1067459	C7orf50	0.57	5.9	0.31	9.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs524281	0.861	rs535395	chr11:65906534	A/G	cg14036092	chr11:66035641	RAB1B	0.48	6.08	0.32	3.42e-9	Electroencephalogram traits;
CRC	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.94	-0.31	7.24e-9	Granulocyte percentage of myeloid white cells;
CRC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.49	7.11	0.36	7.34e-12	Colorectal cancer;
CRC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.49	-6.67	-0.35	1.07e-10	Type 1 diabetes nephropathy;
CRC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg19635926	chr16:89946313	TCF25	0.66	5.98	0.31	5.71e-9	Skin colour saturation;
CRC	trans	rs944990	0.595	rs10123378	chr9:96375217	C/T	cg16357719	chr16:2317538	RNPS1	0.45	7.1	0.36	7.84e-12	Body mass index;
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.54	-9.97	-0.48	1.2e-20	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7605827	0.930	rs11893272	chr2:15613796	C/T	cg19274914	chr2:15703543	NA	0.39	5.95	0.31	6.89e-9	Educational attainment (years of education);
CRC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.34	-0.46	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg14844989	chr11:31128820	NA	0.36	6.42	0.33	4.69e-10	Red blood cell count;
CRC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.58	8.61	0.43	3.14e-16	Colonoscopy-negative controls vs population controls;
CRC	trans	rs2303319	0.504	rs62189054	chr2:162624654	C/G	cg22627826	chr19:1240265	ATP5D	-0.72	-6.24	-0.33	1.37e-9	Cognitive function;
CRC	cis	rs17067123	0.614	rs11727059	chr4:180065225	G/A	cg26610307	chr4:180072759	NA	-0.56	-6.74	-0.35	7.28e-11	Response to hepatitis C treatment;
CRC	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	6.3	0.33	9.81e-10	Ovarian reserve;
CRC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg11168104	chr5:1857477	NA	-0.39	-6.8	-0.35	4.96e-11	Cardiovascular disease risk factors;
CRC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.59	9.01	0.45	1.66e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs3823572	0.511	rs2971982	chr7:133657698	C/T	cg03336402	chr7:133662267	EXOC4	-0.67	-10.62	-0.51	7.59e-23	Intelligence (multi-trait analysis);
CRC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg09264619	chr17:80180166	NA	0.38	6.28	0.33	1.08e-9	Life satisfaction;
CRC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.87	-0.44	4.63e-17	Bipolar disorder;
CRC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.5	7.63	0.39	2.49e-13	Psychosis in Alzheimer's disease;
CRC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg15147215	chr3:52552868	STAB1	-0.62	-10.17	-0.49	2.64e-21	Bipolar disorder;
CRC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.69	9.33	0.46	1.63e-18	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs289828	0.868	rs6747782	chr2:152138115	A/G	cg06191203	chr2:152266755	RIF1	-0.4	-5.76	-0.3	1.96e-8	Blood protein levels;
CRC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.43	-5.81	-0.31	1.44e-8	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg02659138	chr7:134003124	SLC35B4	0.36	6.19	0.32	1.77e-9	Mean platelet volume;
CRC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.35	6.72	0.35	8.02e-11	Mean corpuscular volume;
CRC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.73	-9.53	-0.47	3.57e-19	Bone mineral density;
CRC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg09876464	chr15:85330779	ZNF592	0.44	7.36	0.38	1.46e-12	P wave terminal force;
CRC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	6.25	0.33	1.25e-9	Mean platelet volume;
CRC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	0.52	8.8	0.44	7.78e-17	Mean platelet volume;Platelet distribution width;
CRC	cis	rs17641971	0.684	rs4873093	chr8:49974740	G/T	cg00325661	chr8:49890786	NA	0.37	6.51	0.34	2.89e-10	Blood metabolite levels;
CRC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.75	-0.35	6.69e-11	Total body bone mineral density;
CRC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.52	7.92	0.4	3.74e-14	Longevity;
CRC	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg03938978	chr2:103052716	IL18RAP	0.41	6.55	0.34	2.21e-10	Blood protein levels;
CRC	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg00919237	chr7:87102261	ABCB4	-0.54	-7.14	-0.37	6.18e-12	Gallbladder cancer;
CRC	cis	rs2882667	0.654	rs10044432	chr5:138274896	C/T	cg09476006	chr5:138032270	NA	0.57	9.22	0.45	3.72e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.46	6.57	0.34	1.98e-10	Coronary artery disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg08399230	chr16:4665037	FAM100A	0.35	6.38	0.33	6.04e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.86	14.9	0.63	9.92e-39	Intelligence (multi-trait analysis);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12459316	chr3:101292891	PCNP	0.39	5.97	0.31	6.12e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs62229266	0.659	rs2835258	chr21:37424365	G/A	cg08632701	chr21:37451849	NA	-0.42	-6.48	-0.34	3.43e-10	Mitral valve prolapse;
CRC	cis	rs4853036	0.904	rs12713683	chr2:70156321	G/A	cg02498382	chr2:70120550	SNRNP27	-0.45	-6.79	-0.35	5.39e-11	Colorectal or endometrial cancer;
CRC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.8	0.48	4.54e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg06207120	chr15:45996521	NA	-0.32	-7.9	-0.4	4.33e-14	Waist circumference;Weight;
CRC	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.75	7.63	0.39	2.48e-13	Severe influenza A (H1N1) infection;
CRC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.8	-11.53	-0.54	4.5e-26	Cognitive function;
CRC	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.44	6.8	0.35	5.09e-11	Obesity-related traits;
CRC	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg18753928	chr3:113234510	CCDC52	-0.48	-7.62	-0.39	2.79e-13	Response to simvastatin treatment (PCSK9 protein level change);
CRC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.62	9.62	0.47	1.88e-19	Corneal astigmatism;
CRC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg22815214	chr1:201083145	CACNA1S	0.5	7.07	0.36	9.41e-12	Permanent tooth development;
CRC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.42	-5.66	-0.3	3.22e-8	Schizophrenia;
CRC	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.64	-0.39	2.32e-13	Vitamin D levels;
CRC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.69	-9.36	-0.46	1.25e-18	Vitiligo;
CRC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00166722	chr3:10149974	C3orf24	0.66	7.71	0.39	1.49e-13	Alzheimer's disease;
CRC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg12172441	chr6:28176163	NA	0.5	6.59	0.34	1.73e-10	Parkinson's disease;
CRC	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	7.0	0.36	1.41e-11	Immune response to smallpox vaccine (IL-6);
CRC	cis	rs2457480	0.516	rs10899994	chr10:44656695	A/G	cg09554077	chr10:44749378	NA	0.44	5.64	0.3	3.62e-8	Coronary artery disease;
CRC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg16268157	chr7:99778414	STAG3	-0.43	-5.72	-0.3	2.45e-8	Lung function (FEV1/FVC);
CRC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.78	13.81	0.61	1.62e-34	Mean platelet volume;
CRC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.62	-10.91	-0.52	7.22e-24	Cotinine glucuronidation;
CRC	trans	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.49	-7.29	-0.37	2.28e-12	Colorectal cancer;
CRC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-9.0	-0.44	1.88e-17	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs28655083	0.509	rs285024	chr16:77099844	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.74	0.35	7.27e-11	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg20933634	chr6:27740509	NA	0.54	6.98	0.36	1.63e-11	Parkinson's disease;
CRC	cis	rs847851	0.612	rs7768189	chr6:34742450	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.24	-0.33	1.36e-9	Colonoscopy-negative controls vs population controls;
CRC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.29	6.02	0.32	4.62e-9	Homoarginine levels;
CRC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.39	-7.55	-0.38	4.19e-13	Colorectal cancer;
CRC	trans	rs75828804	0.826	rs277506	chr16:77544440	C/T	cg19423196	chr10:82049429	MAT1A	0.5	6.05	0.32	4.02e-9	Intraocular pressure;
CRC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.4	6.0	0.31	5.17e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.46	-7.89	-0.4	4.53e-14	Major depressive disorder;
CRC	cis	rs62229266	0.659	rs62230814	chr21:37403546	G/A	cg08632701	chr21:37451849	NA	-0.39	-6.18	-0.32	1.89e-9	Mitral valve prolapse;
CRC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg15845792	chr6:28175446	NA	0.58	5.88	0.31	1e-8	Depression;
CRC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.13	24.49	0.8	4.1e-76	IgG glycosylation;
CRC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg12564285	chr5:131593104	PDLIM4	0.31	5.6	0.3	4.45e-8	Blood metabolite levels;
CRC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg06238570	chr21:40685208	BRWD1	0.79	10.91	0.52	7.57e-24	Cognitive function;
CRC	cis	rs7626444	0.625	rs2686595	chr3:196475142	G/C	cg12930392	chr3:196481615	PAK2	0.41	7.3	0.37	2.23e-12	Monocyte count;
CRC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.43	-20.38	-0.75	2.82e-60	Hip circumference adjusted for BMI;
CRC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.12	-0.32	2.64e-9	Bipolar disorder;
CRC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.48	6.51	0.34	2.76e-10	Schizophrenia;
CRC	cis	rs9463078	0.665	rs9367214	chr6:45025912	G/A	cg25276700	chr6:44698697	NA	-0.24	-5.77	-0.3	1.81e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.42	6.89	0.35	2.9100000000000002e-11	Resting heart rate;
CRC	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg09127314	chr1:152161683	NA	0.47	5.99	0.31	5.61e-9	Atopic dermatitis;
CRC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg15147215	chr3:52552868	STAB1	-0.47	-7.63	-0.39	2.61e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs2160860	0.773	rs7832080	chr8:39799757	T/C	cg11363097	chr8:39792086	IDO2	-0.45	-7.65	-0.39	2.28e-13	Blood metabolite levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg23127064	chr11:842615	TSPAN4;POLR2L	0.38	6.17	0.32	2e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.44	0.33	4.17e-10	Life satisfaction;
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23235460	chr3:187871625	LPP	0.47	6.33	0.33	8.03e-10	Survival in pancreatic cancer;
CRC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg06671706	chr8:8559999	CLDN23	0.62	9.09	0.45	9.32e-18	Obesity-related traits;
CRC	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.61	-0.34	1.56e-10	Monocyte count;
CRC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-6.99	-0.36	1.5e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.51	-7.73	-0.39	1.32e-13	Diastolic blood pressure;
CRC	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-8.39	-0.42	1.49e-15	QT interval;
CRC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.59	-0.39	3.24e-13	Arsenic metabolism;
CRC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-5.97	-0.31	6.08e-9	Crohn's disease;
CRC	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg13919466	chr1:32135498	COL16A1	-0.4	-7.69	-0.39	1.71e-13	Intelligence (multi-trait analysis);
CRC	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.89	-11.35	-0.53	2.09e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs806215	0.666	rs12672945	chr7:127510489	A/G	cg25922125	chr7:127225783	GCC1	-0.49	-5.97	-0.31	6.14e-9	Type 2 diabetes;
CRC	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg16141378	chr3:129829833	LOC729375	0.49	7.57	0.39	3.72e-13	Mood instability;
CRC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.82	-15.21	-0.64	6.17e-40	Breast cancer;
CRC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.13	-0.32	2.49e-9	Lung cancer;
CRC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	7.44	0.38	8.75e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.77	9.33	0.46	1.62e-18	Type 2 diabetes;
CRC	cis	rs17767392	0.626	rs11158898	chr14:71685205	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.81	-0.35	4.66e-11	Mitral valve prolapse;
CRC	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.76	13.06	0.58	1.06e-31	Idiopathic membranous nephropathy;
CRC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg05207973	chr5:176823642	SLC34A1	-0.39	-5.9	-0.31	9.17e-9	Urate levels in lean individuals;
CRC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.53	8.14	0.41	8.27e-15	Aortic root size;
CRC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg18512352	chr11:47633146	NA	-0.4	-7.78	-0.39	9.39e-14	Subjective well-being;
CRC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-7.5	-0.38	5.98e-13	Gut microbiome composition (summer);
CRC	cis	rs698833	0.828	rs1067341	chr2:44623687	G/A	cg04920474	chr2:44395004	PPM1B	0.41	6.22	0.32	1.52e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg22654517	chr2:96458247	NA	0.32	5.75	0.3	2.06e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg19537932	chr12:55886519	OR6C68	-0.64	-8.33	-0.42	2.19e-15	Cancer;
CRC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg18827107	chr12:86230957	RASSF9	-0.41	-6.73	-0.35	7.76e-11	Major depressive disorder;
CRC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.45	7.28	0.37	2.53e-12	Corneal astigmatism;
CRC	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg01422370	chr2:73384389	NA	0.37	5.78	0.3	1.72e-8	Intelligence (multi-trait analysis);
CRC	cis	rs2971970	0.519	rs2346270	chr7:133647033	G/A	cg03336402	chr7:133662267	EXOC4	-0.66	-10.29	-0.49	1e-21	Intelligence (multi-trait analysis);
CRC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg02560186	chr11:3602584	NA	-0.56	-7.1	-0.36	7.58e-12	Blood pressure (smoking interaction);
CRC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.62	7.33	0.37	1.78e-12	Lymphocyte counts;
CRC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.4	-0.46	9.71e-19	Subjective well-being;
CRC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.06	-28.72	-0.85	1.21e-91	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7264396	0.887	rs224347	chr20:34037523	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.0	-0.36	1.47e-11	Total cholesterol levels;
CRC	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.59	8.55	0.43	4.8e-16	Corneal astigmatism;
CRC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.81	12.32	0.56	6.05e-29	Cognitive function;
CRC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg20607287	chr7:12443886	VWDE	-0.49	-6.72	-0.35	7.96e-11	Coronary artery disease;
CRC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.64	7.89	0.4	4.38e-14	Menarche (age at onset);
CRC	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.75	12.81	0.58	9.74e-31	Height;
CRC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg15786705	chr6:28176104	NA	0.48	7.18	0.37	4.74e-12	Pubertal anthropometrics;
CRC	trans	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg14003231	chr6:33640908	ITPR3	0.46	7.36	0.38	1.5e-12	Height;
CRC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.54	-0.47	3.27e-19	Migraine;Coronary artery disease;
CRC	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.73	9.79	0.47	4.96e-20	Coronary artery disease;
CRC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-12.93	-0.58	3.43e-31	Blood metabolite levels;
CRC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.64	6.42	0.33	4.71e-10	Axial length;
CRC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.62	9.17	0.45	5.2e-18	Morning vs. evening chronotype;
CRC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.56	-8.87	-0.44	4.58e-17	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24441022	chr1:154946677	SHC1;CKS1B	0.49	7.1	0.36	7.78e-12	Response to antipsychotic treatment;
CRC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg18032046	chr6:28092343	ZSCAN16	0.52	6.23	0.32	1.46e-9	Depression;
CRC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.05	0.32	3.89e-9	Aortic root size;
CRC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.5	8.53	0.43	5.31e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs6496667	0.865	rs62019277	chr15:90880438	C/T	cg04176472	chr15:90893244	GABARAPL3	0.58	6.61	0.34	1.58e-10	Rheumatoid arthritis;
CRC	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.73	-10.08	-0.49	5.37e-21	Coronary artery disease;
CRC	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.46	7.82	0.4	7.13e-14	Post-traumatic stress disorder;
CRC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	5.88	0.31	1.03e-8	Breast cancer;
CRC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23161317	chr6:28129485	ZNF389	-0.45	-6.21	-0.32	1.56e-9	Parkinson's disease;
CRC	cis	rs9463078	0.585	rs718112	chr6:44859451	T/G	cg25276700	chr6:44698697	NA	0.25	6.03	0.32	4.29e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CRC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.92	-16.26	-0.67	4.73e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg24562669	chr7:97807699	LMTK2	0.46	7.82	0.4	7.01e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.51	7.49	0.38	6.2800000000000005e-13	Corneal astigmatism;
CRC	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.55	-8.84	-0.44	5.86e-17	Depressive symptoms (multi-trait analysis);
CRC	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-20.51	-0.75	8.7e-61	Exhaled nitric oxide output;
CRC	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg00603274	chr11:61596626	FADS2	-0.43	-6.45	-0.34	4e-10	Trans fatty acid levels;
CRC	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.64	0.63	1.01e-37	Fuchs's corneal dystrophy;
CRC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.47	6.24	0.33	1.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg15448220	chr1:150897856	SETDB1	0.45	6.43	0.33	4.42e-10	Tonsillectomy;
CRC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg24253500	chr15:84953950	NA	0.38	6.48	0.34	3.43e-10	Schizophrenia;
CRC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06671706	chr8:8559999	CLDN23	0.61	9.04	0.45	1.35e-17	Obesity-related traits;
CRC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg03948781	chr1:205179583	DSTYK	0.4	5.63	0.3	3.93e-8	Red blood cell count;
CRC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-7.62	-0.39	2.7e-13	HDL cholesterol;
CRC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.97	-18.64	-0.72	1.89e-53	Height;
CRC	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14119001	chr9:139324193	INPP5E	-0.44	-6.17	-0.32	2.05e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
CRC	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	14.22	0.62	4.28e-36	Hypertriglyceridemia;
CRC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.4	6.33	0.33	8.15e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs7546094	0.935	rs7554345	chr1:113122956	T/G	cg22162597	chr1:113214053	CAPZA1	0.43	6.08	0.32	3.31e-9	Platelet distribution width;
CRC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21643547	chr1:205240462	TMCC2	0.45	7.27	0.37	2.72e-12	Mean corpuscular volume;Mean platelet volume;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05913198	chr10:21822977	MLLT10	0.33	6.13	0.32	2.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg23018236	chr17:30244563	NA	-0.57	-7.44	-0.38	8.82e-13	Hip circumference adjusted for BMI;
CRC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.41	6.25	0.33	1.31e-9	HDL cholesterol levels;
CRC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg27121462	chr16:89883253	FANCA	0.45	6.78	0.35	5.59e-11	Vitiligo;
CRC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20092199	chr4:1342459	KIAA1530	0.44	7.54	0.38	4.65e-13	Longevity;
CRC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg25344623	chr2:136566232	LCT	0.32	5.81	0.31	1.47e-8	Mosquito bite size;
CRC	cis	rs7605827	0.930	rs7595512	chr2:15678368	C/T	cg19274914	chr2:15703543	NA	0.39	5.89	0.31	9.66e-9	Educational attainment (years of education);
CRC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-10.28	-0.49	1.1e-21	Prudent dietary pattern;
CRC	cis	rs1712517	0.740	rs11191663	chr10:105118462	C/T	cg05636881	chr10:105038444	INA	0.47	8.08	0.41	1.2e-14	Migraine;
CRC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg21335942	chr16:58549945	SETD6	0.91	5.86	0.31	1.13e-8	Schizophrenia;
CRC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.5	-7.23	-0.37	3.39e-12	White blood cell count (basophil);White blood cell count;
CRC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.7	11.05	0.52	2.3e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.15	-0.37	5.68e-12	Gut microbiome composition (summer);
CRC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.57	8.84	0.44	6.09e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.37	0.38	1.39e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00473834	chr3:23987430	NR1D2	0.45	5.97	0.31	6.06e-9	Survival in pancreatic cancer;
CRC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg19622623	chr12:86230825	RASSF9	-0.41	-6.59	-0.34	1.7e-10	Major depressive disorder;
CRC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg13880726	chr7:1868755	MAD1L1	-0.49	-5.99	-0.31	5.45e-9	Bipolar disorder;
CRC	cis	rs2276314	0.512	rs7234973	chr18:33450336	A/G	cg05985134	chr18:33552581	C18orf21	0.4	5.97	0.31	6.3e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.94	16.6	0.68	2.23e-45	IgG glycosylation;
CRC	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.34	6.02	0.32	4.56e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.1	-0.55	3.95e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg05044414	chr3:183734942	ABCC5	0.36	5.95	0.31	6.91e-9	Anterior chamber depth;
CRC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.02	12.07	0.55	4.94e-28	Vitiligo;
CRC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.58	6.38	0.33	6.16e-10	Initial pursuit acceleration;
CRC	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.8	0.44	8.13e-17	Coffee consumption (cups per day);
CRC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.43	-6.72	-0.35	8.02e-11	Iron status biomarkers;
CRC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.47	8.97	0.44	2.25e-17	Renal cell carcinoma;
CRC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.66	-7.95	-0.4	3.11e-14	Rheumatoid arthritis;
CRC	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg12756093	chr1:115239321	AMPD1	0.47	6.84	0.35	3.86e-11	Autism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13521891	chr12:95466445	NR2C1	0.44	6.4	0.33	5.22e-10	Response to antipsychotic treatment;
CRC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.75	12.95	0.58	2.8e-31	Extrinsic epigenetic age acceleration;
CRC	cis	rs12541635	0.967	rs13256474	chr8:107086419	T/C	cg10147462	chr8:107024639	NA	-0.39	-6.49	-0.34	3.22e-10	Age of smoking initiation;
CRC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg06606381	chr12:133084897	FBRSL1	-0.92	-7.56	-0.38	4e-13	Depression;
CRC	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.61	8.36	0.42	1.83e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg03623178	chr6:28175578	NA	0.98	12.66	0.57	3.31e-30	Depression;
CRC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.24	0.41	4.24e-15	Rheumatoid arthritis;
CRC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg15848620	chr12:58087721	OS9	0.59	7.89	0.4	4.56e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg25457927	chr22:38595422	NA	-0.29	-6.02	-0.32	4.56e-9	Triglycerides;
CRC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.62	-8.6	-0.43	3.29e-16	Obesity-related traits;
CRC	cis	rs2310173	0.575	rs719248	chr2:102623875	C/T	cg20856504	chr2:102616538	IL1R2	0.38	6.06	0.32	3.75e-9	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19196182	chr12:99038046	IKBIP;APAF1	0.45	6.51	0.34	2.87e-10	Response to antipsychotic treatment;
CRC	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.45	6.48	0.34	3.44e-10	Life satisfaction;
CRC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg20203395	chr5:56204925	C5orf35	-0.72	-8.49	-0.42	7.3e-16	Type 2 diabetes;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00007981	chr11:93862594	PANX1	0.42	6.04	0.32	4.08e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg10589385	chr1:150898437	SETDB1	0.28	5.98	0.31	5.86e-9	Tonsillectomy;
CRC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg13722127	chr7:150037890	RARRES2	-0.48	-7.46	-0.38	7.65e-13	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg16898833	chr6:26189333	HIST1H4D	0.94	7.65	0.39	2.25e-13	Autism spectrum disorder or schizophrenia;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13804918	chr6:160182841	ACAT2	0.45	6.29	0.33	1.03e-9	Anxiety disorder;
CRC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-16.82	-0.68	3.08e-46	Intelligence (multi-trait analysis);
CRC	cis	rs7254114	0.578	rs12980863	chr19:11309871	C/T	cg02815516	chr19:11306319	KANK2	-0.33	-6.51	-0.34	2.73e-10	Immature fraction of reticulocytes;
CRC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.82	-0.44	6.82e-17	Chronic sinus infection;
CRC	cis	rs1983891	0.954	rs4714481	chr6:41521110	T/C	cg20194872	chr6:41519635	FOXP4	0.42	6.02	0.31	4.74e-9	Prostate cancer;
CRC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg01629716	chr15:45996671	NA	-0.41	-8.47	-0.42	8.19e-16	Waist circumference;Weight;
CRC	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.09	0.52	1.78e-24	Coffee consumption (cups per day);
CRC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.51	7.86	0.4	5.5e-14	Corneal astigmatism;
CRC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.81	-10.52	-0.5	1.6400000000000001e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.49	7.29	0.37	2.32e-12	Corneal astigmatism;
CRC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.03	-0.4	1.71e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.41	-0.42	1.27e-15	Aortic root size;
CRC	trans	rs1901167	1.000	rs7713884	chr5:40964816	C/A	cg07701837	chr2:210516795	MAP2	0.37	6.02	0.31	4.64e-9	Cerebrospinal fluid biomarker levels;
CRC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg03623178	chr6:28175578	NA	0.7	9.33	0.46	1.61e-18	Parkinson's disease;
CRC	cis	rs2160860	0.773	rs7824841	chr8:39799648	A/G	cg11363097	chr8:39792086	IDO2	-0.45	-7.59	-0.39	3.31e-13	Blood metabolite levels;
CRC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.32	-6.83	-0.35	4.22e-11	Reticulocyte count;
CRC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.64	0.34	1.3100000000000001e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.67	-11.01	-0.52	3.18e-24	Motion sickness;
CRC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg05625103	chr10:2543513	NA	-0.39	-6.13	-0.32	2.5e-9	Age-related hearing impairment;
CRC	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg06581033	chr10:766294	NA	-0.53	-5.88	-0.31	1.01e-8	Uric acid levels;
CRC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02725872	chr8:58115012	NA	-0.38	-6.43	-0.33	4.44e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.12	-0.41	9.65e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.3	-0.37	2.13e-12	Height;
CRC	cis	rs2565722	0.622	rs2489946	chr6:161301034	C/T	cg03159191	chr6:161285451	NA	-0.46	-6.28	-0.33	1.07e-9	Blood protein levels;
CRC	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg08773314	chr2:239334832	ASB1	0.35	7.26	0.37	2.77e-12	Multiple system atrophy;
CRC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.42	-7.51	-0.38	5.56e-13	Prostate cancer;
CRC	cis	rs73206853	0.563	rs56386451	chr12:111174516	A/G	cg12870014	chr12:110450643	ANKRD13A	0.65	6.06	0.32	3.78e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.8	-14.18	-0.62	6.24e-36	Lewy body disease;
CRC	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.72	-9.2	-0.45	4.26e-18	Blood pressure (smoking interaction);
CRC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.44	6.9	0.36	2.6e-11	Subjective well-being;Cardiovascular disease risk factors;
CRC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-10.07	-0.49	5.64e-21	Schizophrenia;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03860466	chr19:12912941	PRDX2	0.48	6.88	0.35	3.08e-11	Intelligence (multi-trait analysis);
CRC	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.09	-15.38	-0.65	1.37e-40	Exhaled nitric oxide output;
CRC	cis	rs7632954	0.900	rs10866089	chr3:8514038	C/T	cg03495237	chr3:8533978	NA	0.32	5.62	0.3	4.13e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg03684893	chr10:554711	DIP2C	0.35	5.82	0.31	1.41e-8	Psychosis in Alzheimer's disease;
CRC	cis	rs7725052	0.609	rs10063276	chr5:40476587	T/A	cg09067459	chr5:40385259	NA	0.4	6.57	0.34	1.94e-10	Pediatric autoimmune diseases;
CRC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.85	-0.31	1.16e-8	Life satisfaction;
CRC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.72	-10.34	-0.5	7.18e-22	Platelet distribution width;
CRC	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg13385794	chr1:248469461	NA	0.4	6.83	0.35	4.21e-11	Common traits (Other);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13038030	chr17:73267041	MIF4GD	0.43	5.99	0.31	5.62e-9	Response to antipsychotic treatment;
CRC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg20684491	chr1:25596433	NA	0.43	7.52	0.38	5.13e-13	Erythrocyte sedimentation rate;
CRC	cis	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg02972257	chr16:68554789	NA	0.44	5.61	0.3	4.28e-8	Colorectal cancer;
CRC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.77	-13.35	-0.59	8.43e-33	Body mass index;
CRC	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg21836586	chr14:55907198	TBPL2	0.31	5.62	0.3	4.1e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg12564285	chr5:131593104	PDLIM4	-0.33	-5.88	-0.31	9.97e-9	Blood metabolite levels;
CRC	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-6.92	-0.36	2.41e-11	Coronary artery disease;
CRC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18402987	chr7:1209562	NA	0.47	6.81	0.35	4.76e-11	Longevity;Endometriosis;
CRC	trans	rs2303319	0.504	rs56039028	chr2:162516363	G/A	cg12500891	chr11:57225987	NA	-0.67	-6.03	-0.32	4.51e-9	Cognitive function;
CRC	trans	rs1146361	1.000	rs1146361	chr1:116658817	T/C	cg24991874	chr11:130066626	ST14	-0.54	-6.13	-0.32	2.48e-9	Fear of minor pain;
CRC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.66	0.47	1.32e-19	Lung cancer;
CRC	trans	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg24644049	chr4:85504048	CDS1	0.87	7.15	0.37	5.65e-12	Skin colour saturation;
CRC	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg25174290	chr11:3078921	CARS	0.39	5.72	0.3	2.4e-8	Longevity;
CRC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-5.94	-0.31	7.18e-9	Bipolar disorder and schizophrenia;
CRC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.81	11.85	0.55	3.23e-27	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04202892	chr2:111875749	ACOXL	0.47	7.76	0.39	1.06e-13	Chronic lymphocytic leukemia;
CRC	trans	rs16846053	0.681	rs62187563	chr2:162354653	G/A	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.64	-6.09	-0.32	3.2e-9	Blood osmolality (transformed sodium);
CRC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg00343986	chr7:65444356	GUSB	0.46	6.77	0.35	5.91e-11	Aortic root size;
CRC	cis	rs12760731	0.546	rs6699087	chr1:178433200	G/T	cg00404053	chr1:178313656	RASAL2	0.74	8.77	0.44	9.65e-17	Obesity-related traits;
CRC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg05501817	chr11:14380813	RRAS2	-0.45	-5.88	-0.31	1.03e-8	Sense of smell;
CRC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.46	-7.97	-0.4	2.56e-14	Electroencephalogram traits;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg26761047	chr1:15944228	DDI2	0.48	6.89	0.36	2.89e-11	Response to antipsychotic treatment;
CRC	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	9.21	0.45	3.84e-18	Spherical equivalent (joint analysis main effects and education interaction);
CRC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-7.69	-0.39	1.7e-13	Response to antipsychotic treatment;
CRC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.37	5.85	0.31	1.19e-8	Total body bone mineral density;
CRC	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.81	0.68	3.37e-46	Electrocardiographic conduction measures;
CRC	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.37	6.28	0.33	1.08e-9	Blood metabolite levels;
CRC	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg06583696	chr2:26101536	ASXL2	0.39	6.34	0.33	7.8e-10	Myopia;
CRC	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	7.69	0.39	1.78e-13	Bipolar disorder;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05224705	chr19:18112040	ARRDC2	0.4	6.42	0.33	4.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg22676075	chr6:135203613	NA	0.39	6.03	0.32	4.51e-9	Red blood cell count;
CRC	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-8.85	-0.44	5.43e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.21	-0.37	3.78e-12	Capecitabine sensitivity;
CRC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.32	0.33	8.35e-10	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.6	8.9	0.44	3.88e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.41	-5.9	-0.31	9.15e-9	Menarche (age at onset);
CRC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.58	-0.47	2.49e-19	Heart rate;
CRC	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.56	-9.38	-0.46	1.11e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.39	-0.38	1.22e-12	Bladder cancer;
CRC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.82	12.67	0.57	3.15e-30	Cognitive function;
CRC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg08200582	chr11:442649	ANO9	-0.69	-7.21	-0.37	3.75e-12	Body mass index;
CRC	cis	rs7617773	0.963	rs6771787	chr3:48194242	C/T	cg11946769	chr3:48343235	NME6	-0.51	-6.85	-0.35	3.73e-11	Coronary artery disease;
CRC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.4	5.67	0.3	3.13e-8	Erythrocyte sedimentation rate;
CRC	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-7.81	-0.4	7.55e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01861096	chr22:19279212	CLTCL1	0.43	6.78	0.35	5.72e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.06	0.32	3.81e-9	Height;
CRC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.48	8.79	0.44	8.41e-17	Acylcarnitine levels;
CRC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-10.76	-0.51	2.4e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.28	-0.56	8.67e-29	Alzheimer's disease;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.62	10.21	0.49	1.97e-21	Prudent dietary pattern;
CRC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.9	-0.31	8.84e-9	Life satisfaction;
CRC	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.63	10.16	0.49	2.84e-21	Cancer;
CRC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12172441	chr6:28176163	NA	0.59	7.19	0.37	4.51e-12	Parkinson's disease;
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	5.8	0.3	1.53e-8	Prudent dietary pattern;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.63	9.49	0.46	4.9e-19	Lymphocyte counts;
CRC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.91	-0.36	2.57e-11	Response to antipsychotic treatment;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11797717	chr17:43198278	PLCD3	0.38	6.07	0.32	3.53e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9969804	0.905	rs9886781	chr9:95373251	T/C	cg14631576	chr9:95140430	CENPP	-0.32	-5.91	-0.31	8.49e-9	Height;
CRC	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-6.02	-0.31	4.74e-9	Pulmonary function;
CRC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.57	8.44	0.42	1.01e-15	Aortic root size;
CRC	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg09455208	chr3:40491958	NA	0.32	6.5	0.34	2.97e-10	Renal cell carcinoma;
CRC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.55	8.86	0.44	5.15e-17	Prostate cancer;
CRC	cis	rs939584	0.935	rs13396119	chr2:637508	T/C	cg03610516	chr2:642275	NA	0.43	5.77	0.3	1.82e-8	Body mass index;
CRC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg10298567	chr3:47292165	KIF9	-0.4	-6.29	-0.33	1.04e-9	Colorectal cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19991689	chr14:59104318	DACT1	0.39	6.02	0.31	4.54e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-5.98	-0.31	5.8e-9	Aortic root size;
CRC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	7.91	0.4	4e-14	Schizophrenia;
CRC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.6	-0.43	3.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.55	-6.36	-0.33	6.6e-10	Bipolar disorder;
CRC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg16576597	chr16:28551801	NUPR1	0.48	6.73	0.35	7.37e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg13440265	chr4:20701914	PACRGL	-0.49	-7.2	-0.37	3.99e-12	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg26762873	chr11:5879799	OR52E8	0.46	6.98	0.36	1.66e-11	DNA methylation (variation);
CRC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg04155289	chr7:94953770	PON1	-0.6	-7.43	-0.38	9.3e-13	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg05527609	chr1:210001259	C1orf107	-0.52	-5.88	-0.31	1.02e-8	Red blood cell count;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24441022	chr1:154946677	SHC1;CKS1B	0.41	5.97	0.31	6.02e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg04719120	chr6:96025338	MANEA	0.62	8.14	0.41	8.25e-15	Behavioural disinhibition (generation interaction);
CRC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02421172	chr7:1938701	MAD1L1	0.43	5.77	0.3	1.79e-8	Bipolar disorder;
CRC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.3	3.86e-8	Lung cancer;
CRC	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg23260525	chr10:116636907	FAM160B1	-0.31	-6.79	-0.35	5.26e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	17.36	0.69	2.17e-48	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CRC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-15.01	-0.64	3.85e-39	Schizophrenia;
CRC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg00290607	chr11:67383545	NA	-0.34	-5.94	-0.31	7.18e-9	Mean corpuscular volume;
CRC	cis	rs8005677	0.828	rs34584578	chr14:23411690	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-6.3	-0.33	9.66e-10	Cognitive ability (multi-trait analysis);
CRC	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg11995313	chr8:8860691	ERI1	0.39	6.25	0.33	1.3e-9	Mean corpuscular volume;
CRC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.08	-0.36	9.03e-12	Monocyte percentage of white cells;
CRC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.91	-15.76	-0.66	4.29e-42	Height;
CRC	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg04110750	chr16:69646130	NFAT5	-0.53	-7.11	-0.36	7.4e-12	IgE levels;
CRC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg21285383	chr16:89894308	SPIRE2	0.39	6.8	0.35	4.81e-11	Vitiligo;
CRC	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.44	5.68	0.3	2.98e-8	Platelet distribution width;
CRC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.72	-0.43	1.39e-16	Bipolar disorder;
CRC	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-5.95	-0.31	6.69e-9	Adiponectin levels;
CRC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.36	-0.33	6.72e-10	Bipolar disorder;
CRC	cis	rs7112925	0.738	rs11227673	chr11:66832528	C/T	cg24851651	chr11:66362959	CCS	-0.33	-5.76	-0.3	1.95e-8	Height;
CRC	cis	rs2398893	0.774	rs10993047	chr9:96846500	C/T	cg14459158	chr9:96720562	NA	-0.5	-7.96	-0.4	2.77e-14	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.45	-7.41	-0.38	1.1e-12	Developmental language disorder (linguistic errors);
CRC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg07636037	chr3:49044803	WDR6	-0.83	-6.8	-0.35	4.84e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.55	8.26	0.41	3.58e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.85	-0.4	6.1e-14	Metabolite levels (Pyroglutamine);
CRC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg10729496	chr3:10149963	C3orf24	0.51	6.7	0.35	9.12e-11	Alzheimer's disease;
CRC	cis	rs3996993	0.597	rs10948728	chr6:52723635	C/T	cg20803780	chr6:52668592	GSTA1	0.41	7.03	0.36	1.2e-11	Hemoglobin concentration;
CRC	trans	rs2303319	0.504	rs1023835	chr2:162593973	A/G	cg09481857	chr22:21368659	P2RX6;MGC16703	-0.65	-6.31	-0.33	9.13e-10	Cognitive function;
CRC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13198984	chr17:80129470	CCDC57	0.46	8.18	0.41	6.3e-15	Life satisfaction;
CRC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.33	5.62	0.3	3.97e-8	Major depressive disorder;
CRC	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.37	-5.89	-0.31	9.49e-9	Height;
CRC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.59	-0.47	2.27e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg01152455	chr12:88535851	TMTC3;CEP290	-0.4	-6.01	-0.31	4.84e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	11.18	0.52	7.96e-25	Bone mineral density;
CRC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-5.72	-0.3	2.33e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.6	-6.19	-0.32	1.78e-9	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-11.01	-0.52	3.14e-24	Platelet distribution width;
CRC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-7.5	-0.38	6.13e-13	Developmental language disorder (linguistic errors);
CRC	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg08075719	chr14:103021372	NA	-0.68	-7.93	-0.4	3.47e-14	Platelet count;
CRC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.63	8.97	0.44	2.28e-17	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	0.98	10.51	0.5	1.85e-22	Diabetic retinopathy;
CRC	cis	rs9361491	0.657	rs9352625	chr6:79454754	G/A	cg05283184	chr6:79620031	NA	-0.38	-5.79	-0.3	1.68e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-10.8	-0.51	1.8e-23	Bipolar disorder and schizophrenia;
CRC	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg08071915	chr8:12219732	FAM66A	0.31	5.65	0.3	3.47e-8	Retinal vascular caliber;
CRC	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.54	9.08	0.45	1.04e-17	Dupuytren's disease;
CRC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.19	13.88	0.61	8.17e-35	Uric acid levels;
CRC	cis	rs4356975	0.545	rs35749478	chr4:69949580	A/T	cg25583503	chr4:69962676	UGT2B7	-0.31	-5.68	-0.3	2.92e-8	Obesity-related traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19935506	chr2:242626874	DTYMK	0.47	6.06	0.32	3.75e-9	Thyroid stimulating hormone;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07596482	chr17:42633968	FZD2	0.41	6.06	0.32	3.7e-9	Myopia (pathological);
CRC	cis	rs9903692	0.789	rs12601675	chr17:46190928	T/C	cg21215337	chr17:46176117	CBX1	-0.43	-7.95	-0.4	2.95e-14	Pulse pressure;
CRC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.51	7.06	0.36	9.72e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.84	0.4	6.22e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs11229555	0.645	rs11229435	chr11:58185796	G/C	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg25985355	chr7:65971099	NA	0.32	5.78	0.3	1.75e-8	Aortic root size;
CRC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.43	6.7	0.35	9e-11	Height;
CRC	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg21153622	chr11:89784906	NA	-0.44	-7.1	-0.36	7.5e-12	HDL cholesterol;
CRC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg18827107	chr12:86230957	RASSF9	-0.37	-6.12	-0.32	2.61e-9	Major depressive disorder;
CRC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg04880052	chr2:219191631	PNKD	-0.44	-6.94	-0.36	2.1e-11	Colorectal cancer;
CRC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg10130564	chr11:117069849	TAGLN	0.34	6.11	0.32	2.87e-9	Blood protein levels;
CRC	cis	rs4731207	0.596	rs10239507	chr7:124596785	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.08	-0.32	3.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.88	-0.35	2.99e-11	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg24761882	chr9:96214934	FAM120AOS;FAM120A	0.42	6.04	0.32	4.07e-9	Intelligence (multi-trait analysis);
CRC	cis	rs7113874	0.610	rs12576736	chr11:8512281	A/C	cg17679104	chr11:8615758	STK33	-0.36	-5.92	-0.31	8.19e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.45	6.75	0.35	6.72e-11	Dialysis-related mortality;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg23239078	chr11:2907332	CDKN1C	0.48	6.81	0.35	4.73e-11	Anxiety disorder;
CRC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.67	-0.47	1.2e-19	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-9.74	-0.47	7.43e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.18	-0.32	1.94e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg08288130	chr8:21771540	DOK2	0.28	5.66	0.3	3.33e-8	Mean corpuscular volume;
CRC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.47	7.98	0.4	2.39e-14	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.58	7.32	0.37	1.86e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg25985355	chr7:65971099	NA	-0.32	-5.62	-0.3	3.97e-8	Aortic root size;
CRC	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.67	-7.67	-0.39	1.97e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-10.52	-0.5	1.6400000000000001e-22	Developmental language disorder (linguistic errors);
CRC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.12	10.48	0.5	2.32e-22	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07362569	chr17:61921086	SMARCD2	0.37	5.71	0.3	2.47e-8	Prudent dietary pattern;
CRC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.96	0.66	7.31e-43	Chronic sinus infection;
CRC	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24249390	chr15:90295951	MESP1	-0.58	-9.3	-0.46	1.95e-18	Coronary artery aneurysm in Kawasaki disease;
CRC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.5	-7.67	-0.39	1.94e-13	Coronary artery disease;
CRC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.32	-0.69	3.26e-48	Height;
CRC	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.61	9.62	0.47	1.82e-19	Corneal astigmatism;
CRC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.74	12.69	0.57	2.68e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.54	0.38	4.76e-13	Eye color traits;
CRC	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.71	0.3	2.59e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg06470822	chr6:28175283	NA	0.95	13.58	0.6	1.14e-33	Parkinson's disease;
CRC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg02683197	chr6:28174875	NA	0.63	8.77	0.44	9.62e-17	Parkinson's disease;
CRC	trans	rs3805389	0.504	rs28416150	chr4:56474378	C/T	cg23217153	chr2:242808611	NA	-0.45	-6.05	-0.32	3.83e-9	Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.61	10.08	0.49	5.45e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2257205	0.588	rs77430462	chr17:56804085	C/G	cg25885038	chr17:56607967	SEPT4	-0.52	-5.71	-0.3	2.5e-8	Pancreatic cancer;
CRC	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg14844989	chr11:31128820	NA	0.35	6.18	0.32	1.94e-9	Red blood cell count;
CRC	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06307176	chr5:131281290	NA	-0.39	-5.73	-0.3	2.33e-8	Life satisfaction;
CRC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.73	11.24	0.53	4.86e-25	Corneal astigmatism;
CRC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.45	-6.99	-0.36	1.54e-11	Monocyte count;
CRC	cis	rs55702914	0.712	rs6730590	chr2:198148084	A/G	cg03934865	chr2:198174659	NA	-0.36	-6.22	-0.32	1.5e-9	Major depression and alcohol dependence;
CRC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.4	6.05	0.32	3.99e-9	Hemoglobin concentration;
CRC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg27661571	chr11:113659931	NA	-0.89	-10.36	-0.5	5.8e-22	Hip circumference adjusted for BMI;
CRC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.92	16.97	0.68	7.49e-47	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.79	14.96	0.64	5.82e-39	Prudent dietary pattern;
CRC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg12100956	chr17:78086420	GAA	-0.38	-6.08	-0.32	3.39e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg13390004	chr1:15929781	NA	0.5	7.09	0.36	8.36e-12	Systolic blood pressure;
CRC	cis	rs6743226	0.840	rs10933549	chr2:242240702	A/G	cg10021735	chr2:242295487	FARP2	0.48	6.96	0.36	1.9e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
CRC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg03929089	chr4:120376271	NA	-0.56	-7.15	-0.37	5.78e-12	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg24057373	chr1:100818342	CDC14A	0.4	6.54	0.34	2.39e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.23	14.81	0.63	2.18e-38	Eosinophil percentage of granulocytes;
CRC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg25456477	chr12:86230367	RASSF9	-0.33	-5.63	-0.3	3.81e-8	Major depressive disorder;
CRC	cis	rs4290604	0.748	rs10754942	chr2:238075187	T/C	cg23555395	chr2:238036564	NA	-0.61	-6.18	-0.32	1.86e-9	Asthma;
CRC	cis	rs3812762	0.912	rs4929936	chr11:8792622	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-6.38	-0.33	5.97e-10	Hypospadias;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg19990379	chr1:145611441	POLR3C;RNF115	0.46	6.09	0.32	3.21e-9	Anxiety disorder;
CRC	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg10523679	chr1:76189770	ACADM	-0.4	-5.62	-0.3	4.07e-8	Daytime sleep phenotypes;
CRC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.72	-7.85	-0.4	6e-14	Psoriasis;
CRC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.43	6.31	0.33	8.95e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg15845792	chr6:28175446	NA	0.6	6.37	0.33	6.2e-10	Depression;
CRC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-15.02	-0.64	3.5e-39	Height;
CRC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.64	10.62	0.51	7.3e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg02135003	chr7:105160482	PUS7	-0.9	-12.2	-0.56	1.71e-28	Bipolar disorder (body mass index interaction);
CRC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.59	9.76	0.47	6.07e-20	Prudent dietary pattern;
CRC	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.32	0.33	8.37e-10	Breast cancer;
CRC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-9.1	-0.45	9.16e-18	IgG glycosylation;
CRC	cis	rs35883536	1.000	rs1832121	chr1:101159476	A/G	cg14515779	chr1:101123966	NA	-0.35	-6.3	-0.33	9.5e-10	Monocyte count;
CRC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	15.41	0.65	1.03e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.67	10.56	0.5	1.19e-22	Longevity;Endometriosis;
CRC	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg00495681	chr13:53174319	NA	0.55	8.0	0.4	2.1e-14	Lewy body disease;
CRC	cis	rs6604026	0.656	rs2774954	chr1:93363525	G/A	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg03189282	chr8:37962497	ASH2L	0.38	5.96	0.31	6.5e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	0.61	5.63	0.3	3.8e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CRC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.76	-0.3	1.94e-8	Menopause (age at onset);
CRC	cis	rs6840360	1.000	rs6535821	chr4:152678974	T/C	cg09659197	chr4:152720779	NA	0.53	11.58	0.54	3.16e-26	Intelligence (multi-trait analysis);
CRC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-8.12	-0.41	9.45e-15	Height;
CRC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.6	10.17	0.49	2.58e-21	Prudent dietary pattern;
CRC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.6	-8.23	-0.41	4.37e-15	Height;
CRC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.59	8.07	0.41	1.35e-14	Menopause (age at onset);
CRC	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	10.1	0.49	4.43e-21	Myopia (pathological);
CRC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.79	0.3	1.64e-8	Protein C levels;
CRC	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg21918786	chr6:109611834	NA	-0.33	-5.72	-0.3	2.33e-8	Reticulocyte fraction of red cells;
CRC	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.82	-13.4	-0.59	5.5e-33	Hypospadias;
CRC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg14844989	chr11:31128820	NA	0.36	6.45	0.33	4.06e-10	Red blood cell count;
CRC	cis	rs4750440	0.702	rs7917812	chr10:14030067	G/A	cg00551146	chr10:14014579	FRMD4A	0.37	5.9	0.31	8.89e-9	Adiponectin levels;
CRC	cis	rs6681460	1.000	rs4655648	chr1:67114309	C/T	cg02459107	chr1:67143332	SGIP1	0.46	7.98	0.4	2.44e-14	Presence of antiphospholipid antibodies;
CRC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg05313129	chr8:58192883	C8orf71	-0.43	-6.11	-0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.87	10.66	0.51	5.61e-23	Eosinophil percentage of granulocytes;
CRC	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg04837898	chr3:45731254	SACM1L	-0.35	-5.75	-0.3	2.03e-8	Response to anti-depressant treatment in major depressive disorder;
CRC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	9.77	0.47	5.98e-20	Cognitive test performance;
CRC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg08888203	chr3:10149979	C3orf24	0.71	8.58	0.43	3.91e-16	Alzheimer's disease;
CRC	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.64	8.8	0.44	7.65e-17	Coronary artery disease;
CRC	cis	rs12618769	0.597	rs3769712	chr2:99153443	A/T	cg18455616	chr2:99124870	INPP4A	0.36	5.92	0.31	8.23e-9	Bipolar disorder;
CRC	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg12091567	chr17:66097778	LOC651250	0.68	9.66	0.47	1.32e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg27417294	chr10:81904244	PLAC9	-0.37	-5.83	-0.31	1.29e-8	Sarcoidosis;
CRC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg18478394	chr8:109455254	TTC35	0.37	5.78	0.3	1.75e-8	Dupuytren's disease;
CRC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.7	9.58	0.47	2.5e-19	Alzheimer's disease;
CRC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg02631126	chr6:28058918	ZSCAN12L1	-0.27	-5.69	-0.3	2.87e-8	Parkinson's disease;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06391300	chr11:119600292	PVRL1	0.41	6.02	0.31	4.58e-9	Myopia (pathological);
CRC	cis	rs61996546	0.622	rs34916314	chr15:26833559	A/G	cg15066197	chr15:26874202	GABRB3	-0.41	-6.06	-0.32	3.78e-9	Response to methotrexate in juvenile idiopathic arthritis;
CRC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-8.09	-0.41	1.15e-14	Glomerular filtration rate (creatinine);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23134169	chr19:16682794	SLC35E1	0.49	6.34	0.33	7.71e-10	Thyroid stimulating hormone;
CRC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg08886695	chr4:3369023	RGS12	-0.4	-6.36	-0.33	6.59e-10	Parental longevity (mother's age at death);
CRC	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09915433	chr19:53449742	NA	0.57	8.63	0.43	2.64e-16	Psoriasis;
CRC	cis	rs4523957	0.928	rs216180	chr17:2172416	C/G	cg16513277	chr17:2031491	SMG6	0.54	9.26	0.45	2.67e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.98	0.31	5.7e-9	Hip circumference adjusted for BMI;
CRC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.92	-15.28	-0.64	3.3e-40	Ulcerative colitis;
CRC	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.49	-7.58	-0.39	3.45e-13	Type 2 diabetes;
CRC	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg03037974	chr15:76606532	NA	-0.51	-7.61	-0.39	3.01e-13	Blood metabolite levels;
CRC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg09491104	chr22:46646882	C22orf40	-0.43	-6.6	-0.34	1.67e-10	LDL cholesterol;Cholesterol, total;
CRC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.25	0.33	1.28e-9	Lung cancer;
CRC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.51	9.56	0.47	2.88e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	6.74	0.35	7.01e-11	Rheumatoid arthritis;
CRC	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg11900509	chr10:81946545	ANXA11	0.39	6.39	0.33	5.54e-10	Sarcoidosis;
CRC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	13.5	0.6	2.41e-33	Alzheimer's disease;
CRC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg22638593	chr5:131593259	PDLIM4	0.35	6.37	0.33	6.2e-10	Blood metabolite levels;
CRC	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.84	15.73	0.66	5.61e-42	Hip circumference;
CRC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg20982606	chr12:109535391	UNG	-0.43	-6.04	-0.32	4.14e-9	Select biomarker traits;
CRC	cis	rs3772130	0.583	rs4296627	chr3:121567684	G/A	cg20356878	chr3:121714668	ILDR1	0.37	6.08	0.32	3.24e-9	Cognitive performance;
CRC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg08999081	chr20:33150536	PIGU	0.45	5.84	0.31	1.25e-8	Protein C levels;
CRC	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.78	-10.81	-0.51	1.6e-23	Blood pressure (smoking interaction);
CRC	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.45	-0.38	8.2e-13	Neuroticism;
CRC	cis	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg15845792	chr6:28175446	NA	0.87	5.64	0.3	3.73e-8	Intelligence (multi-trait analysis);
CRC	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg03938978	chr2:103052716	IL18RAP	0.42	6.67	0.35	1.06e-10	Blood protein levels;
CRC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.49	7.95	0.4	3.08e-14	Mean corpuscular hemoglobin concentration;
CRC	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.56	9.54	0.47	3.26e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.47	-8.06	-0.41	1.4e-14	Height;
CRC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg20354231	chr13:53171401	NA	-0.51	-8.23	-0.41	4.57e-15	Lewy body disease;
CRC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Parkinson's disease;
CRC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg07865391	chr16:88106882	BANP	0.46	6.05	0.32	3.86e-9	Menopause (age at onset);
CRC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.46	5.79	0.3	1.64e-8	Aortic root size;
CRC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.39	-5.79	-0.3	1.61e-8	Breast size;
CRC	cis	rs10046574	0.519	rs7781819	chr7:135205700	A/T	cg27474649	chr7:135195673	CNOT4	0.62	5.99	0.31	5.57e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg14352298	chr13:112236639	NA	0.29	6.74	0.35	7.32e-11	Hepatitis;
CRC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	10.69	0.51	4.27e-23	Prudent dietary pattern;
CRC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.61	11.3	0.53	3.09e-25	Glomerular filtration rate (creatinine);
CRC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.93	0.4	3.43e-14	Menopause (age at onset);
CRC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.54	8.74	0.43	1.24e-16	Gout;
CRC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg25174290	chr11:3078921	CARS	-0.4	-5.65	-0.3	3.49e-8	Calcium levels;
CRC	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg08992911	chr2:238395768	MLPH	0.61	6.18	0.32	1.91e-9	Prostate cancer;
CRC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg08807892	chr2:162101083	NA	0.46	6.7	0.35	9.01e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CRC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-8.31	-0.42	2.52e-15	Schizophrenia;
CRC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.75	-0.35	6.85e-11	Total body bone mineral density;
CRC	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg16724585	chr3:197361211	NA	0.47	6.95	0.36	1.92e-11	Pancreatic cancer;
CRC	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg16342193	chr10:102329863	NA	-0.4	-6.43	-0.33	4.55e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg09455208	chr3:40491958	NA	0.31	6.31	0.33	8.76e-10	Renal cell carcinoma;
CRC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg06470822	chr6:28175283	NA	0.63	6.5	0.34	2.93e-10	Depression;
CRC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.47	6.79	0.35	5.17e-11	Aortic root size;
CRC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg15845792	chr6:28175446	NA	0.7	7.72	0.39	1.43e-13	Parkinson's disease;
CRC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg19812747	chr11:111475976	SIK2	0.44	6.43	0.33	4.54e-10	Primary sclerosing cholangitis;
CRC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.47	-7.57	-0.39	3.78e-13	Obesity-related traits;
CRC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.72	-11.02	-0.52	2.9e-24	Blood metabolite levels;
CRC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.18	-0.32	1.87e-9	Axial length;
CRC	cis	rs6479527	0.904	rs10739969	chr9:96866877	C/T	cg14459158	chr9:96720562	NA	-0.4	-6.86	-0.35	3.49e-11	Esophageal adenocarcinoma;
CRC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-10.86	-0.51	1.11e-23	Personality dimensions;
CRC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	7.24	0.37	3.25e-12	Total body bone mineral density;
CRC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.53	0.34	2.46e-10	Cognitive ability;
CRC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.84	19.23	0.73	8.89e-56	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.71	-8.84	-0.44	5.82e-17	Developmental language disorder (linguistic errors);
CRC	cis	rs3219474	0.502	rs41343546	chr1:45908263	A/G	cg06784218	chr1:46089804	CCDC17	0.7	6.94	0.36	2.14e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.32	-0.33	8.29e-10	Aortic root size;
CRC	cis	rs9468186	1	rs9468186	chr6:27626631	A/G	cg02683197	chr6:28174875	NA	0.48	5.75	0.3	2.09e-8	Neuroticism;
CRC	cis	rs12431939	0.671	rs2999384	chr14:51650328	G/T	cg23942311	chr14:51606299	NA	0.51	7.1	0.36	7.85e-12	Cancer;
CRC	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg04586622	chr2:25135609	ADCY3	-0.49	-8.36	-0.42	1.74e-15	Body mass index;
CRC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg23283495	chr1:209979779	IRF6	0.49	6.88	0.35	3.03e-11	Cleft lip with or without cleft palate;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02604819	chr2:70418301	C2orf42	0.46	6.48	0.34	3.37e-10	Response to antipsychotic treatment;
CRC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg13662093	chr20:33865505	NA	0.43	6.03	0.32	4.34e-9	Attention deficit hyperactivity disorder;
CRC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.49	7.46	0.38	7.64e-13	Corneal astigmatism;
CRC	cis	rs7300001	0.667	rs7298716	chr12:110506181	A/T	cg12870014	chr12:110450643	ANKRD13A	0.94	9.82	0.48	3.97e-20	Headache;
CRC	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.57	9.1	0.45	8.64e-18	Vitiligo;
CRC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg11843238	chr5:131593191	PDLIM4	-0.33	-6.23	-0.32	1.46e-9	Blood metabolite levels;
CRC	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	10.39	0.5	4.66e-22	Intelligence (multi-trait analysis);
CRC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg19812747	chr11:111475976	SIK2	0.52	7.5	0.38	6.11e-13	Primary sclerosing cholangitis;
CRC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23161317	chr6:28129485	ZNF389	0.51	6.36	0.33	6.66e-10	Depression;
CRC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.46	6.78	0.35	5.45e-11	Obesity-related traits;
CRC	cis	rs17234274	0.622	rs984613	chr11:23235665	T/C	cg05245346	chr11:23248277	NA	0.34	5.62	0.3	4.17e-8	Cancer;
CRC	cis	rs12369635	1.000	rs12372807	chr12:129561332	C/T	cg01909103	chr12:129572610	TMEM132D	-0.74	-7.05	-0.36	1.04e-11	Schizophrenia (inflammation and infection response interaction);
CRC	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg14664628	chr15:75095509	CSK	0.44	6.13	0.32	2.5e-9	Systemic lupus erythematosus;
CRC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.72	8.67	0.43	1.96e-16	Type 2 diabetes nephropathy;
CRC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	ch.11.42038R	chr11:967971	AP2A2	0.59	10.18	0.49	2.44e-21	Alzheimer's disease (late onset);
CRC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.6	-7.95	-0.4	3.08e-14	Refractive error;
CRC	cis	rs12973672	0.904	rs12974791	chr19:35767218	A/G	cg12095397	chr19:35769544	USF2	0.43	5.67	0.3	3.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg06470822	chr6:28175283	NA	0.67	5.79	0.3	1.66e-8	Breast cancer;
CRC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.09	0.36	8.45e-12	Iron status biomarkers;
CRC	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.44	6.57	0.34	1.94e-10	HDL cholesterol;
CRC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	7.84	0.4	6.18e-14	Platelet count;
CRC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg02683197	chr6:28174875	NA	0.57	7.29	0.37	2.33e-12	Parkinson's disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01579706	chr4:83821883	THAP9	0.37	5.96	0.31	6.46e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.75	12.45	0.57	2e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
CRC	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg23815491	chr16:72088622	HP	0.5	7.32	0.37	1.87e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg07884673	chr3:53033167	SFMBT1	-0.75	-5.86	-0.31	1.14e-8	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.4	5.8	0.3	1.56e-8	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg24562669	chr7:97807699	LMTK2	-0.45	-7.71	-0.39	1.53e-13	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6066835	1.000	rs6066835	chr20:47355009	A/G	cg18078177	chr20:47281410	PREX1	0.55	5.66	0.3	3.24e-8	Multiple myeloma;
CRC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.39	8.51	0.42	6.46e-16	Eye color traits;
CRC	trans	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	5.98	0.31	5.9e-9	Metabolite levels;
CRC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg16342193	chr10:102329863	NA	-0.36	-5.91	-0.31	8.56e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-0.77	-7.62	-0.39	2.73e-13	Schizophrenia;
CRC	cis	rs4733770	0.581	rs12550366	chr8:131136047	A/T	cg26053073	chr8:131455383	NA	-0.35	-5.63	-0.3	3.84e-8	Schizophrenia;
CRC	cis	rs9783347	0.925	rs3825025	chr11:18343822	C/G	cg15585147	chr11:18324498	HPS5	0.45	6.34	0.33	7.44e-10	Pancreatic cancer;
CRC	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.5	6.36	0.33	6.68e-10	Systolic blood pressure;
CRC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.48	6.35	0.33	7.08e-10	Obesity-related traits;
CRC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg10578777	chr12:7781093	NA	0.46	6.14	0.32	2.42e-9	HDL cholesterol levels;
CRC	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg10477989	chr11:68039601	C11orf24	0.51	6.0	0.31	5.15e-9	Kashin-Beck disease;
CRC	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.57	11.17	0.52	8.58e-25	Alcoholic chronic pancreatitis;
CRC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.47	-7.98	-0.4	2.38e-14	Height;
CRC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.21	-0.45	3.84e-18	Coronary artery disease;
CRC	cis	rs4731207	0.596	rs7794959	chr7:124649139	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.24	-0.33	1.35e-9	Cutaneous malignant melanoma;
CRC	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.37	-5.76	-0.3	1.89e-8	Educational attainment (years of education);
CRC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-12.93	-0.58	3.44e-31	Glomerular filtration rate (creatinine);
CRC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg00129232	chr17:37814104	STARD3	0.58	7.22	0.37	3.68e-12	Glomerular filtration rate (creatinine);
CRC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.51	8.9	0.44	3.7e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00857557	chr6:42982050	MEA1;KLHDC3	0.38	6.39	0.33	5.62e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	1.01	17.72	0.7	8.74e-50	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg25985355	chr7:65971099	NA	-0.5	-5.76	-0.3	1.88e-8	Diabetic kidney disease;
CRC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.66	9.72	0.47	8.22e-20	Corneal astigmatism;
CRC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.44	6.57	0.34	2e-10	Bone properties (heel);
CRC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg20673091	chr1:2541236	MMEL1	0.35	5.61	0.3	4.26e-8	Ulcerative colitis;
CRC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.41	-0.33	5e-10	Total cholesterol levels;
CRC	cis	rs7940866	0.817	rs961491	chr11:130866090	G/T	cg12179176	chr11:130786555	SNX19	0.56	8.22	0.41	4.78e-15	Schizophrenia;
CRC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg06522879	chr11:64358276	SLC22A12	-0.53	-8.32	-0.42	2.36e-15	Urate levels in obese individuals;
CRC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.75	-0.3	2.06e-8	Life satisfaction;
CRC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg06204229	chr3:52865917	ITIH4	0.5	5.93	0.31	7.74e-9	Immune reponse to smallpox (secreted IL-2);
CRC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.46	6.97	0.36	1.79e-11	Menopause (age at onset);
CRC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-6.12	-0.32	2.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg02683197	chr6:28174875	NA	0.62	8.5	0.42	6.57e-16	Parkinson's disease;
CRC	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.23	-0.37	3.51e-12	Diisocyanate-induced asthma;
CRC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.51	8.22	0.41	4.86e-15	Uric acid clearance;
CRC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg13010199	chr12:38710504	ALG10B	-0.42	-6.05	-0.32	3.97e-9	Bladder cancer;
CRC	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00938859	chr5:1591904	SDHAP3	0.73	7.76	0.39	1.07e-13	Breast cancer;
CRC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg12590608	chr7:158785262	NA	0.47	8.72	0.43	1.43e-16	Facial morphology (factor 20);
CRC	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	0.78	7.97	0.4	2.72e-14	Severe influenza A (H1N1) infection;
CRC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg19980929	chr12:42632907	YAF2	-0.4	-6.19	-0.32	1.82e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs17767392	0.781	rs34388001	chr14:71883500	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.49	-6.27	-0.33	1.13e-9	Mitral valve prolapse;
CRC	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.57	-8.06	-0.41	1.4e-14	Coronary artery disease;
CRC	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.6	9.72	0.47	8.36e-20	Itch intensity from mosquito bite;
CRC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.67	-7.83	-0.4	6.88e-14	Diabetic retinopathy;
CRC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	17.37	0.69	2.09e-48	Electrocardiographic conduction measures;
CRC	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.34	12.55	0.57	8.9e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2252790	0.899	rs2501052	chr6:116658955	A/G	cg18764771	chr6:116381957	FRK	-0.22	-5.94	-0.31	7.42e-9	Fast beta electroencephalogram;
CRC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.88	0.31	1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06656553	chr16:89960601	TCF25	-0.7	-5.84	-0.31	1.23e-8	Skin colour saturation;
CRC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.37	5.88	0.31	9.83e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4664293	1.000	rs12692554	chr2:160451288	G/A	cg08347373	chr2:160653686	CD302	-0.37	-6.03	-0.32	4.29e-9	Monocyte percentage of white cells;
CRC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16447950	chr5:562315	NA	-0.83	-10.81	-0.51	1.71e-23	Lung disease severity in cystic fibrosis;
CRC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.12	-0.32	2.66e-9	Aortic root size;
CRC	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-6.72	-0.35	8.25e-11	Schizophrenia;
CRC	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg05784532	chr1:230284198	GALNT2	0.47	6.45	0.33	4.09e-10	Coronary artery disease;
CRC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg21770322	chr7:97807741	LMTK2	0.55	9.29	0.46	2.16e-18	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.65	6.81	0.35	4.74e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.78	0.3	1.76e-8	Self-reported allergy;
CRC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.2	0.32	1.67e-9	Diabetic kidney disease;
CRC	cis	rs524281	0.773	rs10791861	chr11:66008470	G/A	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg11212589	chr17:38028394	ZPBP2	-0.44	-8.02	-0.4	1.89e-14	Self-reported allergy;
CRC	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.84	-0.31	1.29e-8	Daytime sleep phenotypes;
CRC	cis	rs11009175	0.556	rs11009173	chr10:33292325	A/G	cg00146027	chr10:33299147	NA	0.24	5.68	0.3	2.96e-8	Depression (quantitative trait);
CRC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg02421172	chr7:1938701	MAD1L1	0.42	5.73	0.3	2.26e-8	Bipolar disorder;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10292851	chr8:101572103	ANKRD46	0.44	6.3	0.33	9.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg10437265	chr15:77819839	NA	0.7	12.76	0.58	1.43e-30	Type 2 diabetes;
CRC	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.32	6.47	0.34	3.62e-10	Schizophrenia;
CRC	cis	rs4132462	0.888	rs62182999	chr2:212605745	T/C	cg15635483	chr2:212618994	ERBB4	-0.4	-5.8	-0.3	1.58e-8	Intelligence (multi-trait analysis);
CRC	trans	rs8035957	1.000	rs4924273	chr15:38846738	C/G	cg01402409	chr4:78978133	FRAS1	-0.51	-6.15	-0.32	2.28e-9	Type 1 diabetes;
CRC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg02549819	chr16:58548995	SETD6	1.2	7.85	0.4	5.77e-14	Schizophrenia;
CRC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg03037974	chr15:76606532	NA	0.68	11.83	0.55	3.67e-27	Blood metabolite levels;
CRC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.72	-9.13	-0.45	7.04e-18	Coronary artery disease;
CRC	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg16358738	chr2:241808595	AGXT	-0.41	-7.21	-0.37	3.8e-12	Urinary metabolites;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21515243	chr18:21033072	RIOK3	0.48	7.13	0.37	6.61e-12	Response to antipsychotic treatment;
CRC	cis	rs526821	0.595	rs499446	chr11:55355722	A/G	cg04317927	chr11:55418816	OR4S2	0.39	6.64	0.34	1.28e-10	Pediatric bone mineral density (spine);
CRC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.65	-0.39	2.2e-13	Bipolar disorder and schizophrenia;
CRC	cis	rs4743820	0.603	rs7045740	chr9:93926650	A/G	cg14446406	chr9:93919335	NA	0.4	6.84	0.35	3.9e-11	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg09264619	chr17:80180166	NA	0.53	7.69	0.39	1.72e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13198984	chr17:80129470	CCDC57	0.46	8.16	0.41	6.94e-15	Life satisfaction;
CRC	cis	rs9491140	0.539	rs10872287	chr6:124694573	T/G	cg19267163	chr6:125004984	NKAIN2	0.54	6.65	0.34	1.22e-10	Neuroticism;
CRC	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.41	-11.64	-0.54	1.88e-26	Psoriasis vulgaris;
CRC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.42	5.75	0.3	2.09e-8	Longevity;Endometriosis;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03133777	chr2:170361364	BBS5	-0.43	-6.65	-0.34	1.19e-10	HDL cholesterol;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00320645	chr10:72163720	EIF4EBP2	0.49	6.44	0.33	4.29e-10	Anxiety disorder;
CRC	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.6	0.43	3.31e-16	Brugada syndrome;
CRC	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg04110750	chr16:69646130	NFAT5	-0.53	-6.98	-0.36	1.63e-11	IgE levels;
CRC	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	1.01	12.23	0.56	1.28e-28	Obesity-related traits;
CRC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.66	-12.27	-0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.34	-0.46	1.55e-18	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg19500275	chr17:80737654	TBCD	-0.4	-6.04	-0.32	4.19e-9	Glycated hemoglobin levels;
CRC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg10589385	chr1:150898437	SETDB1	0.32	6.83	0.35	4.05e-11	Melanoma;
CRC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.51	8.09	0.41	1.19e-14	Psychosis in Alzheimer's disease;
CRC	cis	rs9391253	0.571	rs314281	chr6:105400605	T/C	cg02098413	chr6:105308735	HACE1	0.31	5.62	0.3	4.03e-8	Height;Age at voice drop;Puberty onset (breast development);
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-5.99	-0.31	5.52e-9	Total body bone mineral density;
CRC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-7.22	-0.37	3.73e-12	Schizophrenia;
CRC	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.49	9.7	0.47	1.01e-19	Schizophrenia;
CRC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.45	5.7	0.3	2.72e-8	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg27534772	chr1:16042836	PLEKHM2	0.54	10.46	0.5	2.7e-22	Systolic blood pressure;
CRC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg11189052	chr15:85197271	WDR73	0.61	8.88	0.44	4.41e-17	Schizophrenia;
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.77	14.5	0.62	3.45e-37	Prudent dietary pattern;
CRC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg01721255	chr8:58191610	C8orf71	0.49	6.17	0.32	2e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg11645453	chr3:52864694	ITIH4	0.35	6.65	0.34	1.26e-10	Electroencephalogram traits;
CRC	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.53	8.45	0.42	9.68e-16	Corneal astigmatism;
CRC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg24562669	chr7:97807699	LMTK2	0.45	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.42	-20.29	-0.75	6.11e-60	Hip circumference adjusted for BMI;
CRC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.34	7.04	0.36	1.12e-11	Lung cancer;
CRC	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.47	7.25	0.37	2.95e-12	HDL cholesterol;
CRC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.69	10.92	0.52	6.64e-24	Corneal astigmatism;
CRC	cis	rs7605827	0.930	rs3805102	chr2:15518312	G/A	cg19274914	chr2:15703543	NA	0.38	5.66	0.3	3.29e-8	Educational attainment (years of education);
CRC	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg14003231	chr6:33640908	ITPR3	0.55	8.73	0.43	1.3e-16	Plateletcrit;
CRC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.76	-7.47	-0.38	7.06e-13	Coronary artery disease;
CRC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.28	0.42	3.22e-15	Menopause (age at onset);
CRC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.59	-8.78	-0.44	8.99e-17	Aortic root size;
CRC	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.57	7.74	0.39	1.25e-13	Optic cup area;Vertical cup-disc ratio;
CRC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-12.73	-0.57	1.93e-30	Hemoglobin concentration;
CRC	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.36	5.94	0.31	7.44e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg02927042	chr1:21476669	EIF4G3	-0.51	-8.07	-0.41	1.37e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg00166722	chr3:10149974	C3orf24	0.43	6.37	0.33	6.36e-10	Alzheimer's disease;
CRC	trans	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg17903999	chr18:56338584	MALT1	-0.41	-6.57	-0.34	1.95e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs939584	1.000	rs6719883	chr2:651482	T/G	cg03610516	chr2:642275	NA	-0.43	-5.94	-0.31	7.19e-9	Body mass index;
CRC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.62	-0.43	2.82e-16	Aortic root size;
CRC	cis	rs73206853	0.764	rs60027620	chr12:111103669	T/G	cg12870014	chr12:110450643	ANKRD13A	0.87	10.08	0.49	5.28e-21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	cis	rs1552172	1.000	rs1552172	chr1:145704759	T/A	cg11743829	chr1:145714124	CD160	-0.41	-6.09	-0.32	3.13e-9	Breast cancer;
CRC	cis	rs698833	0.852	rs698768	chr2:44576549	C/T	cg04920474	chr2:44395004	PPM1B	0.41	6.13	0.32	2.54e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CRC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.2	0.45	4.14e-18	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12273811	chr6:28175739	NA	0.73	9.16	0.45	5.8e-18	Parkinson's disease;
CRC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.92	-0.31	8.26e-9	Lung cancer;
CRC	trans	rs2303319	0.582	rs16845851	chr2:162295623	A/C	cg19471553	chr17:41393123	NA	-0.72	-6.22	-0.32	1.53e-9	Cognitive function;
CRC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.51	8.55	0.43	4.75e-16	Coronary artery disease;
CRC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.36	0.38	1.47e-12	Electroencephalogram traits;
CRC	cis	rs1572438	0.868	rs1577625	chr6:860044	C/A	cg21062780	chr6:887772	NA	-0.35	-5.72	-0.3	2.39e-8	Aging;
CRC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	11.5	0.54	5.74e-26	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg19610905	chr11:61596333	FADS2	-0.65	-8.13	-0.41	8.86e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg10784414	chr3:48647031	UQCRC1	0.37	6.09	0.32	3.13e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03934478	chr11:495069	RNH1	0.71	7.89	0.4	4.58e-14	Body mass index;
CRC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.36	-0.38	1.46e-12	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.63	0.3	3.85e-8	Autism spectrum disorder or schizophrenia;
CRC	cis	rs524281	0.773	rs2236652	chr11:66002681	G/A	cg16950941	chr11:66035639	RAB1B	-0.7	-8.04	-0.41	1.67e-14	Electroencephalogram traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17199681	chr17:3540328	CTNS;SHPK	0.4	6.58	0.34	1.89e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.71	-10.39	-0.5	4.75e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.46	-7.36	-0.38	1.46e-12	Breast cancer;
CRC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg26646896	chr5:158686746	NA	-0.55	-6.12	-0.32	2.65e-9	Plasma thyroid-stimulating hormone levels;
CRC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg05535760	chr7:792225	HEATR2	-0.44	-5.63	-0.3	3.89e-8	Perceived unattractiveness to mosquitoes;
CRC	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg05639522	chr1:247681581	NA	0.56	6.07	0.32	3.48e-9	Acute lymphoblastic leukemia (childhood);
CRC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.62	9.7	0.47	1.03e-19	Educational attainment (years of education);
CRC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.54	-8.23	-0.41	4.52e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CRC	cis	rs17592366	0.517	rs7147621	chr14:35275704	G/A	cg09327582	chr14:35236912	BAZ1A	0.45	6.08	0.32	3.37e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
CRC	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-8.65	-0.43	2.38e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.32	-0.33	8.42e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg05623727	chr3:50126028	RBM5	0.4	6.3	0.33	9.8e-10	Intelligence (multi-trait analysis);
CRC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg06207120	chr15:45996521	NA	0.32	7.81	0.4	7.61e-14	Waist circumference;Weight;
CRC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.49	7.62	0.39	2.75e-13	Corneal astigmatism;
CRC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.37	-6.05	-0.32	4e-9	Iron status biomarkers;
CRC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg03030879	chr14:75389066	RPS6KL1	0.41	6.27	0.33	1.15e-9	Height;
CRC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg25164649	chr6:28176230	NA	0.47	6.89	0.36	2.78e-11	Cardiac Troponin-T levels;
CRC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.47	-6.43	-0.33	4.55e-10	Gut microbiome composition (summer);
CRC	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.92	-11.45	-0.53	8.97e-26	Exhaled nitric oxide output;
CRC	cis	rs243505	0.660	rs3807451	chr7:148538622	T/C	cg09806900	chr7:148480153	CUL1	0.52	6.61	0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.41	-0.33	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02359409	chr6:42947317	PEX6	-0.67	-11.15	-0.52	1.02e-24	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.51	7.61	0.39	2.89e-13	Night sleep phenotypes;
CRC	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.71	6.12	0.32	2.6e-9	Major depressive disorder;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg02987130	chr19:45927004	ERCC1	0.41	6.06	0.32	3.8e-9	Schizophrenia;
CRC	cis	rs6988985	0.703	rs7833723	chr8:143925666	A/G	cg10324643	chr8:143916377	GML	0.35	5.73	0.3	2.25e-8	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CRC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.71	6.52	0.34	2.65e-10	Diabetic kidney disease;
CRC	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.72	11.28	0.53	3.48e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg16892393	chr17:41919603	NA	0.57	8.01	0.4	1.97e-14	Triglycerides;
CRC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.52	8.09	0.41	1.15e-14	Lung cancer;
CRC	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg14593290	chr7:50529359	DDC	0.59	7.85	0.4	5.95e-14	Malaria;
CRC	cis	rs10751667	0.601	rs10902272	chr11:1040821	A/C	ch.11.42038R	chr11:967971	AP2A2	0.52	6.69	0.35	9.86e-11	Alzheimer's disease (late onset);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg10488476	chr17:48133676	ITGA3	0.48	6.28	0.33	1.05e-9	Anxiety disorder;
CRC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.45	6.11	0.32	2.74e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-14.84	-0.63	1.71e-38	Height;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg03623178	chr6:28175578	NA	0.95	12.17	0.56	2.13e-28	Parkinson's disease;
CRC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	10.75	0.51	2.73e-23	Menarche (age at onset);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03425219	chr11:18548609	TSG101	0.47	6.94	0.36	2.12e-11	Intelligence (multi-trait analysis);
CRC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg01483505	chr11:975446	AP2A2	0.46	7.66	0.39	2.11e-13	Alzheimer's disease (late onset);
CRC	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.63	-7.95	-0.4	3.08e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-0.63	-11.39	-0.53	1.41e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.4	5.91	0.31	8.59e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.37	6.23	0.32	1.41e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.96	-0.36	1.86e-11	Bipolar disorder;
CRC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.28	0.42	3.21e-15	Rheumatoid arthritis;
CRC	cis	rs867529	0.695	rs62157805	chr2:89014728	T/C	cg26627705	chr2:89060884	NA	-0.57	-7.48	-0.38	6.63e-13	Height;
CRC	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.6	-7.02	-0.36	1.28e-11	Coronary artery disease;
CRC	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.14	-0.37	5.85e-12	Menarche (age at onset);
CRC	cis	rs10924970	0.934	rs12402243	chr1:235431792	A/C	cg26050004	chr1:235667680	B3GALNT2	0.39	5.8	0.3	1.56e-8	Asthma;
CRC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg04121214	chr22:50244548	NA	0.41	5.81	0.3	1.49e-8	Schizophrenia;
CRC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.02	-0.32	4.64e-9	Diabetic kidney disease;
CRC	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.48	6.86	0.35	3.34e-11	Eye color traits;
CRC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.74	0.54	7.8e-27	Alzheimer's disease;
CRC	cis	rs2070997	0.702	rs11793797	chr9:133755282	T/G	cg01000188	chr9:133769184	QRFP	0.56	5.75	0.3	2e-8	Response to amphetamines;
CRC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.59	-12.03	-0.55	7.03e-28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs1223397	0.938	rs17700321	chr6:13280666	G/T	cg20827128	chr6:13274284	PHACTR1	0.54	6.54	0.34	2.32e-10	Blood pressure;
CRC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.51	7.06	0.36	1.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-5.95	-0.31	7.05e-9	Lung cancer;
CRC	cis	rs9311676	0.632	rs11130642	chr3:58420042	C/T	cg06643156	chr3:58380774	PXK	0.42	6.43	0.33	4.39e-10	Systemic lupus erythematosus;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg03623178	chr6:28175578	NA	0.97	12.38	0.56	3.55e-29	Depression;
CRC	trans	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.7	-0.35	8.99e-11	Depression;
CRC	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg27534772	chr1:16042836	PLEKHM2	0.42	7.07	0.36	9.23e-12	Systolic blood pressure;
CRC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.9	-16.52	-0.67	4.76e-45	Intelligence (multi-trait analysis);
CRC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.84	-18.54	-0.71	4.83e-53	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg19812747	chr11:111475976	SIK2	0.42	6.23	0.32	1.44e-9	Primary sclerosing cholangitis;
CRC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.08	-0.32	3.3e-9	Parkinson's disease;
CRC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.08	0.36	8.73e-12	Hemoglobin concentration;
CRC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.39	6.86	0.35	3.32e-11	Longevity;
CRC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.7	-10.5	-0.5	1.96e-22	Huntington's disease progression;
CRC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.64	-11.51	-0.54	5.4e-26	Aortic root size;
CRC	trans	rs295140	0.647	rs295132	chr2:201233502	A/G	cg05062854	chr22:32435553	NA	0.39	6.03	0.32	4.48e-9	QT interval;
CRC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg19812747	chr11:111475976	SIK2	0.48	7.57	0.39	3.87e-13	Primary sclerosing cholangitis;
CRC	cis	rs11212617	0.870	rs227063	chr11:108207304	T/G	cg12106634	chr11:108092400	ATM;NPAT	0.43	6.45	0.33	4.03e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.48	-5.71	-0.3	2.59e-8	Coronary artery disease;
CRC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-7.4	-0.38	1.18e-12	Bladder cancer;
CRC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg00343986	chr7:65444356	GUSB	0.43	6.3	0.33	9.66e-10	Aortic root size;
CRC	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg17470449	chr10:769945	NA	0.64	8.39	0.42	1.42e-15	Uric acid levels;
CRC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.36	-0.42	1.75e-15	Personality dimensions;
CRC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.82	9.97	0.48	1.25e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.45	0.46	6.55e-19	Colonoscopy-negative controls vs population controls;
CRC	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	6.76	0.35	6.41e-11	Mean corpuscular volume;
CRC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14895029	chr7:2775587	GNA12	-0.46	-6.8	-0.35	4.87e-11	Height;
CRC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19904058	chr10:135279010	LOC619207	-0.35	-6.78	-0.35	5.56e-11	Systemic lupus erythematosus;
CRC	cis	rs2979489	0.945	rs13250272	chr8:30294942	A/G	cg26383811	chr8:30366931	RBPMS	0.7	9.62	0.47	1.89e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CRC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg20908204	chr19:46285434	DMPK	0.33	7.44	0.38	9.07e-13	Coronary artery disease;
CRC	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-17.41	-0.69	1.42e-48	Coffee consumption;Coffee consumption (cups per day);
CRC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg03233332	chr7:66118400	NA	-0.45	-6.45	-0.33	4.03e-10	Aortic root size;
CRC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.83	-0.4	6.57e-14	Putamen volume;
CRC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg27535305	chr1:53392650	SCP2	0.38	7.28	0.37	2.55e-12	Monocyte count;
CRC	trans	rs9460578	0.561	rs6913323	chr6:20891190	A/T	cg14519598	chr9:36906608	PAX5	-0.47	-6.2	-0.32	1.74e-9	Breast cancer;
CRC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-6.98	-0.36	1.64e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg12855166	chr17:30846586	MYO1D	-0.37	-6.01	-0.31	4.94e-9	Schizophrenia;
CRC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.48	7.03	0.36	1.2e-11	Corneal astigmatism;
CRC	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg11519256	chr10:5708881	ASB13	0.5	7.36	0.38	1.53e-12	Menopause (age at onset);
CRC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.63	-9.39	-0.46	9.92e-19	Hip circumference adjusted for BMI;
CRC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.53	-7.23	-0.37	3.49e-12	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs10979	0.631	rs12530338	chr6:143872563	C/T	cg25407410	chr6:143891975	LOC285740	-0.51	-7.14	-0.37	6.03e-12	Hypospadias;
CRC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.53	-7.35	-0.38	1.59e-12	Intelligence (multi-trait analysis);
CRC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-8.23	-0.41	4.37e-15	Bipolar disorder;
CRC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	7.72	0.39	1.45e-13	Motion sickness;
CRC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.81	-13.6	-0.6	9.63e-34	Cystic fibrosis severity;
CRC	cis	rs3823572	0.504	rs2346268	chr7:133642742	G/A	cg03336402	chr7:133662267	EXOC4	-0.67	-10.39	-0.5	4.59e-22	Intelligence (multi-trait analysis);
CRC	cis	rs4731207	0.596	rs2402763	chr7:124709732	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.08	-0.32	3.3e-9	Cutaneous malignant melanoma;
CRC	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.46	8.08	0.41	1.26e-14	Schizophrenia;
CRC	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg23815491	chr16:72088622	HP	0.44	6.45	0.34	3.92e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CRC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg01304814	chr3:48885189	PRKAR2A	0.75	5.91	0.31	8.55e-9	Cognitive function;
CRC	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-6.37	-0.33	6.39e-10	Breast cancer;
CRC	cis	rs6840360	0.642	rs7677131	chr4:152353015	T/C	cg09659197	chr4:152720779	NA	0.34	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
CRC	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.39	6.4	0.33	5.2e-10	Sitting height ratio;
CRC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.44	0.42	1.02e-15	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs3996993	0.724	rs2749014	chr6:52627322	G/A	cg20803780	chr6:52668592	GSTA1	-0.32	-5.64	-0.3	3.71e-8	Hemoglobin concentration;
CRC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg21251018	chr6:28226885	NKAPL	0.49	7.8	0.4	8.17e-14	Autism spectrum disorder or schizophrenia;
CRC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg12317470	chr15:67143691	NA	0.73	6.4	0.33	5.37e-10	Lung cancer (smoking interaction);
CRC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Depression;
CRC	cis	rs6968419	0.747	rs9969224	chr7:115861660	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.31	-0.33	9.04e-10	Intraocular pressure;
CRC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg25834613	chr7:1915315	MAD1L1	0.42	6.1	0.32	3.04e-9	Bipolar disorder;
CRC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.54	8.22	0.41	4.87e-15	Lymphocyte counts;
CRC	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.51	9.11	0.45	8.4e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg25456477	chr12:86230367	RASSF9	0.4	6.71	0.35	8.75e-11	Major depressive disorder;
CRC	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg02276845	chr11:3876248	STIM1	-0.56	-6.61	-0.34	1.59e-10	Diisocyanate-induced asthma;
CRC	cis	rs7209700	0.778	rs3851807	chr17:45351519	C/G	cg17185639	chr17:45330862	ITGB3	0.35	5.96	0.31	6.4e-9	IgG glycosylation;
CRC	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg01304814	chr3:48885189	PRKAR2A	0.92	6.64	0.34	1.29e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CRC	cis	rs3736485	0.966	rs4775944	chr15:51775610	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-6.43	-0.33	4.41e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.57	9.12	0.45	7.76e-18	Tonsillectomy;
CRC	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.67	-0.35	1.07e-10	Response to antipsychotic treatment;
CRC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg12100956	chr17:78086420	GAA	-0.38	-6.08	-0.32	3.39e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
CRC	cis	rs10242455	0.571	rs80045298	chr7:99307453	T/A	cg18809830	chr7:99032528	PTCD1	-1.05	-7.59	-0.39	3.23e-13	Blood metabolite levels;
CRC	cis	rs7192750	0.583	rs2550043	chr16:72067491	T/C	cg14768367	chr16:72042858	DHODH	0.83	6.41	0.33	5.11e-10	LDL cholesterol levels;Total cholesterol levels;
CRC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg08755490	chr11:65554678	OVOL1	0.43	6.39	0.33	5.53e-10	Acne (severe);
CRC	trans	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg26043149	chr18:55253948	FECH	-0.5	-7.62	-0.39	2.81e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg05313129	chr8:58192883	C8orf71	-0.43	-6.07	-0.32	3.55e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-1.21	-11.42	-0.53	1.14e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	trans	rs55637147	0.671	rs4939140	chr11:57130473	G/T	cg22097425	chr11:125774311	DDX25;PUS3	-0.32	-5.96	-0.31	6.45e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.6	8.81	0.44	7.53e-17	Systolic blood pressure;
CRC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-7.46	-0.38	7.55e-13	Colorectal cancer;
CRC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.51	7.54	0.38	4.75e-13	Response to temozolomide;
CRC	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg06606381	chr12:133084897	FBRSL1	-1.44	-10.94	-0.52	5.61e-24	Depression;
CRC	cis	rs6546324	0.580	rs4410279	chr2:67850620	A/C	cg15745817	chr2:67799979	NA	-0.55	-9.5	-0.46	4.36e-19	Endometriosis;
CRC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.68	7.38	0.38	1.34e-12	Diabetic retinopathy;
CRC	cis	rs10924970	0.781	rs10802590	chr1:235444051	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.01	0.31	4.84e-9	Asthma;
CRC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.76	-8.95	-0.44	2.67e-17	Hemostatic factors and hematological phenotypes;
CRC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-6.73	-0.35	7.37e-11	Schizophrenia;
CRC	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.71	-11.01	-0.52	3.16e-24	Response to temozolomide;
CRC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-10.47	-0.5	2.49e-22	Colorectal cancer;
CRC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.38	-0.56	3.72e-29	Type 2 diabetes;
CRC	cis	rs6901250	0.568	rs4946198	chr6:117176599	C/T	cg12892004	chr6:117198278	RFX6	-0.42	-6.18	-0.32	1.88e-9	C-reactive protein levels;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23260255	chr3:187871479	LPP	0.49	6.43	0.33	4.55e-10	Thyroid stimulating hormone;
CRC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.77	-13.64	-0.6	6.85e-34	Extrinsic epigenetic age acceleration;
CRC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg02135003	chr7:105160482	PUS7	-0.67	-10.05	-0.48	6.81e-21	Bipolar disorder (body mass index interaction);
CRC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.25	15.65	0.65	1.15e-41	Lung disease severity in cystic fibrosis;
CRC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.75	-11.86	-0.55	2.85e-27	Bipolar disorder and schizophrenia;
CRC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg26260408	chr4:53727979	RASL11B	0.41	5.86	0.31	1.12e-8	Optic nerve measurement (cup area);
CRC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.49	-8.88	-0.44	4.45e-17	Vitiligo;
CRC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	8.83	0.44	6.17e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.43	6.76	0.35	6.17e-11	Monocyte count;
CRC	cis	rs10991814	0.920	rs16907297	chr9:94008934	T/C	cg14446406	chr9:93919335	NA	0.5	5.61	0.3	4.33e-8	Neutrophil percentage of granulocytes;
CRC	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.84	10.31	0.49	8.57e-22	Obesity-related traits;
CRC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-6.84	-0.35	3.87e-11	Bipolar disorder;
CRC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg11645453	chr3:52864694	ITIH4	0.35	6.58	0.34	1.89e-10	Electroencephalogram traits;
CRC	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.46	-7.29	-0.37	2.37e-12	Schizophrenia;
CRC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17467752	chr17:38218738	THRA	0.41	6.14	0.32	2.42e-9	Asthma;
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00556514	chr3:38066524	PLCD1	0.5	6.45	0.34	4.09e-10	Hip circumference;
CRC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.68	-0.47	1.13e-19	Colorectal cancer;
CRC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.49	9.16	0.45	5.55e-18	Smoking initiation;
CRC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg24562669	chr7:97807699	LMTK2	0.46	7.82	0.4	7.01e-14	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs96067	0.805	rs12033824	chr1:36600307	C/T	cg25304816	chr1:36627734	MAP7D1	0.42	6.03	0.32	4.36e-9	Corneal structure;
CRC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.65	-8.83	-0.44	6.57e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.38	5.88	0.31	1e-8	Lung cancer;
CRC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg08260959	chr6:26240920	HIST1H4F	-0.35	-5.6	-0.3	4.44e-8	Gout;Renal underexcretion gout;
CRC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.38	-5.67	-0.3	3.1e-8	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.57	-9.69	-0.47	1.06e-19	Prostate cancer (SNP x SNP interaction);
CRC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-6.55	-0.34	2.2e-10	Menarche (age at onset);
CRC	cis	rs17092148	0.887	rs2144956	chr20:33145868	G/A	cg08999081	chr20:33150536	PIGU	0.5	6.44	0.33	4.27e-10	Neuroticism;
CRC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg11211951	chr8:145729740	GPT	-0.37	-6.45	-0.34	3.98e-10	Age at first birth;
CRC	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	14.62	0.63	1.22e-37	Hypertriglyceridemia;
CRC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.47	7.49	0.38	6.2800000000000005e-13	Crohn's disease;
CRC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02421172	chr7:1938701	MAD1L1	0.45	6.09	0.32	3.07e-9	Bipolar disorder;
CRC	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg09218773	chr11:619014	MUPCDH	-0.41	-5.63	-0.3	3.78e-8	Systemic lupus erythematosus and Systemic sclerosis;
CRC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.49	-8.39	-0.42	1.48e-15	Facial morphology (factor 20);
CRC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.42	-9.25	-0.45	2.86e-18	Glomerular filtration rate (creatinine);
CRC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg26587870	chr6:27730563	NA	-0.55	-6.52	-0.34	2.67e-10	Lung cancer in ever smokers;
CRC	trans	rs75828804	1.000	rs77561412	chr16:77607089	A/G	cg19423196	chr10:82049429	MAT1A	0.58	6.21	0.32	1.56e-9	Intraocular pressure;
CRC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.75	-0.39	1.12e-13	Blood metabolite levels;
CRC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg23259851	chr6:27775964	HIST1H2AI;HIST1H2BL	0.67	5.69	0.3	2.85e-8	Breast cancer;
CRC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-9.47	-0.46	5.52e-19	Monocyte count;
CRC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-15.88	-0.66	1.52e-42	Body mass index;
CRC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg26666090	chr16:58549219	SETD6	0.92	6.25	0.33	1.26e-9	Schizophrenia;
CRC	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.08	22.0	0.77	1.28e-66	Triglycerides;
CRC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-18.37	-0.71	2.21e-52	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.57	8.57	0.43	4.13e-16	Colonoscopy-negative controls vs population controls;
CRC	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg21452805	chr1:244014465	NA	0.5	6.76	0.35	6.47e-11	RR interval (heart rate);
CRC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg20512303	chr5:131592959	PDLIM4	-0.38	-6.6	-0.34	1.6e-10	Blood metabolite levels;
CRC	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.52	7.68	0.39	1.89e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CRC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-6.61	-0.34	1.54e-10	Menopause (age at onset);
CRC	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.13	-0.37	6.51e-12	Inflammatory bowel disease;
CRC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.81	-0.31	1.45e-8	Monocyte percentage of white cells;
CRC	cis	rs11166629	1.000	rs935119	chr8:135638353	C/T	cg27224718	chr8:135614730	ZFAT	-0.47	-7.46	-0.38	7.76e-13	Smoking quantity;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg25164649	chr6:28176230	NA	-0.66	-7.43	-0.38	9.46e-13	Parkinson's disease;
CRC	cis	rs7605827	0.930	rs2160691	chr2:15598197	G/A	cg19274914	chr2:15703543	NA	0.4	6.06	0.32	3.81e-9	Educational attainment (years of education);
CRC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.61	-0.3	4.37e-8	Extrinsic epigenetic age acceleration;
CRC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-14.47	-0.62	4.47e-37	Ulcerative colitis;
CRC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.48	6.1	0.32	3.01e-9	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg22723502	chr6:26240528	HIST1H4F	-0.37	-6.09	-0.32	3.11e-9	Gout;Renal underexcretion gout;
CRC	trans	rs950037	0.681	rs7518750	chr1:89148503	A/C	cg26267483	chr5:156143683	SGCD	0.4	5.96	0.31	6.43e-9	Coronary artery disease;
CRC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.38	-5.93	-0.31	7.62e-9	Testicular germ cell tumor;
CRC	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg24140574	chr1:16342155	HSPB7	0.47	6.74	0.35	7.16e-11	Dilated cardiomyopathy;
CRC	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.45	6.41	0.33	5.04e-10	Height;
CRC	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg19025524	chr12:109796872	NA	-0.46	-6.5	-0.34	2.98e-10	Neuroticism;
CRC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg06494592	chr3:125709126	NA	-0.57	-6.79	-0.35	5.14e-11	Blood pressure (smoking interaction);
CRC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-11.34	-0.53	2.27e-25	Developmental language disorder (linguistic errors);
CRC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.54	-9.67	-0.47	1.26e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg25834613	chr7:1915315	MAD1L1	-0.42	-5.93	-0.31	7.82e-9	Bipolar disorder;
CRC	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.17	-10.05	-0.48	6.71e-21	Mitochondrial DNA levels;
CRC	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-0.79	-7.7	-0.39	1.59e-13	Blood protein levels;
CRC	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26714650	chr12:56694279	CS	-1.44	-11.18	-0.52	8.02e-25	Psoriasis vulgaris;
CRC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.93	-16.86	-0.68	2e-46	Height;
CRC	cis	rs1179624	0.679	rs4731232	chr7:75264765	G/A	cg05145297	chr7:75264568	HIP1	0.6	8.2	0.41	5.44e-15	Age-related nuclear cataracts;
CRC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.51	8.68	0.43	1.9e-16	Coronary artery disease;
CRC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.36	-6.32	-0.33	8.52e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.74	-11.74	-0.54	8.38e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg00105475	chr2:10696890	NA	0.46	7.47	0.38	7.36e-13	Prostate cancer;
CRC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00802000	chr16:706648	WDR90	-0.42	-6.03	-0.32	4.47e-9	Height;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04172079	chr20:35974269	SRC	0.42	6.04	0.32	4.1e-9	Intelligence (multi-trait analysis);
CRC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02359409	chr6:42947317	PEX6	-0.69	-11.52	-0.54	5e-26	Alzheimer's disease in APOE e4+ carriers;
CRC	trans	rs800082	0.934	rs1007566	chr3:144311752	G/A	cg24215973	chr2:240111563	HDAC4	-0.52	-7.28	-0.37	2.53e-12	Smoking behavior;
CRC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.47	5.79	0.3	1.63e-8	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.57	7.72	0.39	1.4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12843489	chr17:35061545	NA	0.29	6.77	0.35	6.02e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg18478394	chr8:109455254	TTC35	0.42	6.24	0.33	1.36e-9	Dupuytren's disease;
CRC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.68	11.63	0.54	1.97e-26	Mean corpuscular volume;
CRC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.3	15.02	0.64	3.32e-39	Uric acid levels;
CRC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-0.98	-14.32	-0.62	1.7e-36	Hip circumference adjusted for BMI;
CRC	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg25856811	chr1:152973957	SPRR3	-0.21	-5.69	-0.3	2.74e-8	Inflammatory skin disease;
CRC	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg20291162	chr17:40259547	DHX58	-0.55	-7.97	-0.4	2.57e-14	Fibrinogen levels;
CRC	cis	rs2882667	0.728	rs10068786	chr5:138276944	C/T	cg09476006	chr5:138032270	NA	0.56	9.15	0.45	6.17e-18	Age-related hearing impairment (SNP x SNP interaction);
CRC	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	6.68	0.35	1.01e-10	Body mass index;
CRC	cis	rs4728302	0.869	rs6955279	chr7:133612113	C/T	cg03336402	chr7:133662267	EXOC4	-0.47	-6.86	-0.35	3.49e-11	Intelligence;Intelligence (multi-trait analysis);
CRC	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg20356878	chr3:121714668	ILDR1	0.53	8.2	0.41	5.58e-15	Cognitive performance;
CRC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.41	6.76	0.35	6.13e-11	Colonoscopy-negative controls vs population controls;
CRC	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg00867472	chr1:156714808	HDGF	-0.45	-6.39	-0.33	5.75e-10	Lymphocyte counts;
CRC	cis	rs4964805	0.672	rs4964823	chr12:104181420	A/T	cg02344784	chr12:104178138	NT5DC3	0.53	7.68	0.39	1.88e-13	Attention deficit hyperactivity disorder;
CRC	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg09127314	chr1:152161683	NA	0.46	5.92	0.31	8.22e-9	Atopic dermatitis;
CRC	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.2	-0.37	4.11e-12	Total cholesterol levels;
CRC	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.47	-6.14	-0.32	2.33e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CRC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.9	-16.85	-0.68	2.39e-46	Intelligence (multi-trait analysis);
CRC	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg27053337	chr8:124217698	FAM83A	0.45	6.84	0.35	3.77e-11	Urinary uromodulin levels;
CRC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.03e-11	Lung cancer;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19442480	chr19:14530103	DDX39	0.39	6.02	0.31	4.54e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg25452165	chr22:42524984	CYP2D6	0.41	5.82	0.31	1.39e-8	Cognitive function;
CRC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.38	6.53	0.34	2.56e-10	Coronary artery disease;
CRC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.58	9.34	0.46	1.46e-18	Vitiligo;
CRC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.63	8.39	0.42	1.41e-15	Smoking initiation;
CRC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25517755	chr10:38738941	LOC399744	-0.44	-6.42	-0.33	4.69e-10	Extrinsic epigenetic age acceleration;
CRC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.68	12.16	0.56	2.33e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.43	7.82	0.4	7.39e-14	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs12470590	chr2:162493102	A/G	cg04269497	chr6:167369491	RNASET2	-0.74	-6.06	-0.32	3.72e-9	Cognitive function;
CRC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg17321639	chr7:2759063	NA	-0.54	-7.2	-0.37	4.04e-12	Height;
CRC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.67	-9.7	-0.47	9.74e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.56	7.27	0.37	2.61e-12	Coronary artery disease;
CRC	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma (childhood onset);
CRC	trans	rs57506017	0.517	rs16877363	chr7:12272026	A/G	cg26461140	chr11:72811902	FCHSD2	0.58	6.53	0.34	2.54e-10	Neuroticism;
CRC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17554472	chr22:41940697	POLR3H	-0.57	-5.74	-0.3	2.21e-8	Vitiligo;
CRC	cis	rs4073416	0.518	rs10150412	chr14:65916791	C/T	cg03016385	chr14:66212404	NA	-0.42	-5.74	-0.3	2.18e-8	N-glycan levels;
CRC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg23758597	chr6:163146217	PARK2	-0.67	-6.71	-0.35	8.57e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs7527798	0.592	rs7539772	chr1:207833301	G/A	cg21110645	chr1:207815933	NA	-0.38	-5.79	-0.3	1.68e-8	Erythrocyte sedimentation rate;
CRC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.72	-7.86	-0.4	5.63e-14	Lung disease severity in cystic fibrosis;
CRC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.5	6.23	0.32	1.46e-9	Recombination rate (females);
CRC	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg03339077	chr11:47165057	C11orf49	-0.44	-6.31	-0.33	9e-10	Bone mineral density (hip);Bone mineral density;
CRC	trans	rs2383876	0.550	rs13278169	chr8:74067495	C/T	cg23880589	chr17:7826623	KCNAB3	-0.36	-6.12	-0.32	2.67e-9	Corneal curvature;
CRC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-6.25	-0.33	1.29e-9	Total body bone mineral density;
CRC	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	15.86	0.66	1.84e-42	Fuchs's corneal dystrophy;
CRC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg25164649	chr6:28176230	NA	0.55	5.75	0.3	2e-8	Depression;
CRC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.84	15.15	0.64	1.04e-39	Menopause (age at onset);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg19161053	chr7:99036702	CPSF4;PTCD1	-0.5	-6.16	-0.32	2.06e-9	Diisocyanate-induced asthma;
CRC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.64	0.34	1.3100000000000001e-10	Drug-induced liver injury (flucloxacillin);
CRC	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.12	-0.52	1.33e-24	Colorectal cancer;
CRC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.22	-16.66	-0.68	1.26e-45	Breast cancer;
CRC	cis	rs12137294	0.866	rs1078362	chr1:205209530	A/G	cg24159697	chr1:205181237	DSTYK	-0.34	-6.25	-0.33	1.31e-9	Red cell distribution width;
CRC	cis	rs1050846	0.507	rs62053114	chr16:87423600	C/G	cg27585878	chr16:87386489	FBXO31	-0.43	-6.87	-0.35	3.25e-11	Neuroticism;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg12078486	chr1:155108334	RAG1AP1	0.41	6.04	0.32	4.26e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.76	-0.39	1.05e-13	Self-reported allergy;
CRC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.57	7.6	0.39	3.08e-13	Intelligence (multi-trait analysis);
CRC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg24503407	chr1:205819492	PM20D1	0.45	6.18	0.32	1.91e-9	Parkinson's disease;
CRC	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.49	8.44	0.42	1.05e-15	Testicular germ cell tumor;
CRC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-12.57	-0.57	7.4e-30	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.38	5.76	0.3	1.97e-8	Menarche (age at onset);
CRC	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.44	-8.54	-0.43	5.19e-16	Alcohol dependence;
CRC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.65	11.94	0.55	1.56e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg10667969	chr3:149181941	NA	-0.51	-7.08	-0.36	9e-12	Lung cancer;
CRC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg18132624	chr14:105716052	BTBD6;BRF1	-0.47	-7.45	-0.38	8.54e-13	Mean platelet volume;Platelet distribution width;
CRC	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.34	16.61	0.68	2.05e-45	Uric acid levels;
CRC	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg00246817	chr9:123691163	NA	-0.47	-6.0	-0.31	5.15e-9	Rheumatoid arthritis;
CRC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-13.41	-0.59	5.34e-33	Chronic sinus infection;
CRC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18912574	chr7:65842487	NCRNA00174	0.36	6.18	0.32	1.88e-9	Aortic root size;
CRC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.93	-0.31	7.58e-9	Total body bone mineral density;
CRC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.85	0.63	1.61e-38	Intelligence (multi-trait analysis);
CRC	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.33	-0.37	1.8e-12	QT interval;
CRC	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.29	6.07	0.32	3.56e-9	Height;
CRC	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg19875535	chr5:140030758	IK	0.4	6.17	0.32	1.96e-9	Depressive symptoms (multi-trait analysis);
CRC	cis	rs2289328	0.882	rs7164606	chr15:40645133	G/A	cg13931752	chr15:40660718	DISP2	0.52	6.23	0.33	1.39e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CRC	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg07299736	chr8:135490787	ZFAT	-0.37	-6.2	-0.32	1.73e-9	Hypertension (SNP x SNP interaction);
CRC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.6	5.93	0.31	7.46e-9	Breast cancer;
CRC	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg14515779	chr1:101123966	NA	-0.45	-8.57	-0.43	3.95e-16	Monocyte count;
CRC	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg06076350	chr7:157294107	NA	0.33	6.17	0.32	1.96e-9	Inattentive symptoms;
CRC	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.84	-13.81	-0.61	1.53e-34	Plateletcrit;Platelet count;
CRC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.63	-6.58	-0.34	1.86e-10	Axial length;
CRC	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.64	6.56	0.34	2.1e-10	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01712016	chr3:13521531	HDAC11	0.41	6.12	0.32	2.62e-9	Intelligence (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.97	0.31	6.04e-9	Prudent dietary pattern;
CRC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.57	0.54	3.2e-26	Bone mineral density;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08990198	chr1:202318195	PPP1R12B	0.44	6.03	0.32	4.47e-9	Response to antipsychotic treatment;
CRC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.55	8.9	0.44	3.76e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg13410877	chr18:55712976	NEDD4L	0.49	6.67	0.35	1.06e-10	Thyroid stimulating hormone;
CRC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.65	6.84	0.35	3.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs9659323	1.000	rs10923714	chr1:119512913	C/T	cg26570165	chr1:119541833	NA	-0.38	-6.41	-0.33	5.12e-10	Body mass index;
CRC	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.42	-5.9	-0.31	9.16e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CRC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.45	-6.09	-0.32	3.2e-9	Response to angiotensin II receptor blocker therapy;
CRC	cis	rs10779751	0.762	rs3010222	chr1:11326922	T/C	cg08854313	chr1:11322531	MTOR	-0.42	-5.75	-0.3	2e-8	Body mass index;
CRC	cis	rs6679356	0.624	rs7535591	chr1:67817147	T/C	cg24364144	chr1:67875067	SERBP1	0.43	5.71	0.3	2.48e-8	Primary biliary cholangitis;
CRC	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.84	-11.06	-0.52	2.15e-24	Hair shape;
CRC	cis	rs11212617	1.000	rs680113	chr11:108165406	G/A	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.97	0.31	6.04e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.96	-0.31	6.55e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CRC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg08798685	chr6:27730294	NA	-0.49	-6.39	-0.33	5.62e-10	Breast cancer;
CRC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.57	11.38	0.53	1.59e-25	Asthma (sex interaction);
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09379601	chr19:12992224	DNASE2	0.46	6.51	0.34	2.73e-10	Response to antipsychotic treatment;
CRC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg04731861	chr2:219085781	ARPC2	0.33	6.57	0.34	1.94e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09597638	chr17:3907349	NA	-0.66	-11.73	-0.54	9.08e-27	Type 2 diabetes;
CRC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg24209194	chr3:40518798	ZNF619	0.42	6.42	0.33	4.76e-10	Renal cell carcinoma;
CRC	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg09659197	chr4:152720779	NA	0.42	8.72	0.43	1.44e-16	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg25985355	chr7:65971099	NA	0.52	6.01	0.31	4.92e-9	Diabetic kidney disease;
CRC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.54	8.26	0.41	3.49e-15	Aortic root size;
CRC	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg18165381	chr3:44552316	NA	-0.4	-5.9	-0.31	9.09e-9	Depressive symptoms;
CRC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.66	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
CRC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg11843238	chr5:131593191	PDLIM4	-0.43	-7.35	-0.38	1.56e-12	Breast cancer;
CRC	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.37	-0.33	6.27e-10	Autism spectrum disorder or schizophrenia;
CRC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20456258	chr4:962124	DGKQ	0.28	5.76	0.3	1.95e-8	Sjögren's syndrome;
CRC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.58	8.73	0.43	1.35e-16	Liver enzyme levels (gamma-glutamyl transferase);
CRC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg24289452	chr6:170231220	NA	-0.58	-6.58	-0.34	1.81e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CRC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.41	-0.38	1.07e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.44	5.78	0.3	1.72e-8	Daytime sleep phenotypes;
CRC	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg14036092	chr11:66035641	RAB1B	-0.47	-5.71	-0.3	2.54e-8	Electroencephalogram traits;
CRC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.94	-17.92	-0.7	1.32e-50	Height;
CRC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.22	-0.32	1.55e-9	Menopause (age at onset);
CRC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-9.28	-0.46	2.26e-18	Body mass index (adult);
CRC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.05	0.52	2.31e-24	Prudent dietary pattern;
CRC	trans	rs67981189	0.593	rs221917	chr14:71590003	C/T	cg00881440	chr7:2595255	C7orf27	-0.41	-5.96	-0.31	6.49e-9	Schizophrenia;
CRC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.63	-11.78	-0.54	5.88e-27	Educational attainment;
CRC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.66	9.16	0.45	5.75e-18	Mean platelet volume;
CRC	cis	rs4716602	0.596	rs10244786	chr7:156157989	C/T	cg16983916	chr7:156159713	NA	-0.38	-6.79	-0.35	5.35e-11	Anti-saccade response;
CRC	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.42	6.78	0.35	5.73e-11	Sitting height ratio;
CRC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.33	-6.81	-0.35	4.6e-11	Electroencephalogram traits;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg26035463	chr12:117627651	FBXO21	0.5	6.72	0.35	7.82e-11	Thyroid stimulating hormone;
CRC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.49	7.53	0.38	4.82e-13	Methadone dose in opioid dependence;
CRC	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.53	-8.99	-0.44	1.99e-17	Dupuytren's disease;
CRC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.36	5.84	0.31	1.26e-8	Ulcerative colitis;
CRC	cis	rs1223397	1.000	rs1223397	chr6:13270945	C/G	cg20827128	chr6:13274284	PHACTR1	0.48	6.15	0.32	2.27e-9	Blood pressure;
CRC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg08888203	chr3:10149979	C3orf24	0.71	9.54	0.47	3.42e-19	Alzheimer's disease;
CRC	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	5.65	0.3	3.57e-8	Lung function (FEV1/FVC);
CRC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.45	6.6	0.34	1.65e-10	Menopause (age at onset);
CRC	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.84	-13.72	-0.6	3.53e-34	Hypospadias;
CRC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg20615401	chr6:28092323	ZSCAN16	0.44	5.8	0.3	1.52e-8	Parkinson's disease;
CRC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.94	-19.3	-0.73	4.91e-56	Menopause (age at onset);
CRC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.57	-8.04	-0.41	1.69e-14	Urate levels in lean individuals;
CRC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg27532560	chr4:187881888	NA	-0.53	-9.66	-0.47	1.29e-19	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.49	-6.12	-0.32	2.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg21786873	chr4:4250096	TMEM128	0.4	6.02	0.31	4.61e-9	Intelligence (multi-trait analysis);
CRC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg25985355	chr7:65971099	NA	-0.5	-5.69	-0.3	2.86e-8	Diabetic kidney disease;
CRC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-6.1	-0.32	2.92e-9	Axial length;
CRC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg19980929	chr12:42632907	YAF2	-0.4	-6.18	-0.32	1.86e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CRC	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg23254163	chr1:152506842	NA	0.43	8.46	0.42	8.8e-16	Hair morphology;
CRC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.53	-0.38	5.06e-13	Bipolar disorder;
CRC	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg18755752	chr8:142205143	DENND3	-0.45	-6.44	-0.33	4.14e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CRC	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg20307385	chr11:47447363	PSMC3	0.48	5.98	0.31	5.86e-9	Migraine - clinic-based;
CRC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	10.26	0.49	1.26e-21	Intelligence (multi-trait analysis);
CRC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg19622623	chr12:86230825	RASSF9	-0.4	-6.34	-0.33	7.41e-10	Major depressive disorder;
CRC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg23262073	chr20:60523788	NA	-0.41	-7.1	-0.36	7.97e-12	Body mass index;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07531158	chr16:29818226	MAZ	0.45	6.26	0.33	1.19e-9	Response to antipsychotic treatment;
CRC	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.34	-0.33	7.6e-10	Superior frontal gyrus grey matter volume;
CRC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.94	-11.71	-0.54	1.06e-26	Diabetic kidney disease;
CRC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.45	7.61	0.39	2.98e-13	Alzheimer's disease (late onset);
CRC	trans	rs587242	0.866	rs12037267	chr1:96904093	C/T	cg10631902	chr5:14652156	NA	0.44	6.84	0.35	3.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
CRC	cis	rs11031096	0.542	rs2412338	chr11:3977521	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-6.85	-0.35	3.61e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CRC	trans	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg25214090	chr10:38739885	LOC399744	-0.42	-6.53	-0.34	2.57e-10	Diastolic blood pressure;
CRC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.44	-0.33	4.13e-10	Total body bone mineral density;
CRC	trans	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg16141378	chr3:129829833	LOC729375	0.42	6.28	0.33	1.08e-9	Mood instability;
CRC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.15	-0.41	7.61e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	15.53	0.65	3.62e-41	Gut microbiome composition (summer);
CRC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-10.72	-0.51	3.39e-23	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02290350	chr8:58132656	NA	-0.53	-7.83	-0.4	6.55e-14	Developmental language disorder (linguistic errors);
CRC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg06470822	chr6:28175283	NA	1.03	13.59	0.6	1.04e-33	Depression;
CRC	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg11941060	chr3:133502564	NA	0.38	6.1	0.32	3e-9	Iron status biomarkers;
CRC	trans	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg04077850	chr5:125800366	GRAMD3	0.37	6.27	0.33	1.15e-9	Developmental language disorder (linguistic errors);
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg17524854	chr12:67663046	CAND1	-0.52	-6.45	-0.34	4e-10	Diisocyanate-induced asthma;
CRC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.5	-7.28	-0.37	2.52e-12	Pyoderma gangrenosum in inflammatory bowel disease;
CRC	cis	rs11212617	0.967	rs183460	chr11:108090710	A/C	cg01991180	chr11:108092276	ATM;NPAT	0.46	6.61	0.34	1.6e-10	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg07506560	chr2:240697449	NA	0.52	6.81	0.35	4.54e-11	Obesity-related traits;
CRC	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.56	6.67	0.35	1.07e-10	Neuroticism;
CRC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.52	-9.21	-0.45	3.84e-18	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg04110750	chr16:69646130	NFAT5	-0.51	-7.17	-0.37	4.89e-12	IgE levels;
CRC	cis	rs10971721	0.822	rs72727332	chr9:33929477	A/G	cg13495928	chr9:33750294	PRSS3	0.56	5.99	0.31	5.44e-9	Body mass index;
CRC	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.33	5.76	0.3	1.91e-8	Mean corpuscular hemoglobin concentration;
CRC	trans	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg07393940	chr7:158741817	NA	-0.52	-7.41	-0.38	1.07e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg18200150	chr17:30822561	MYO1D	0.45	8.7	0.43	1.62e-16	Schizophrenia;
CRC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.38	6.27	0.33	1.16e-9	Glomerular filtration rate (creatinine);
CRC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.46	6.74	0.35	6.91e-11	Tonsillectomy;
CRC	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg10263370	chr3:44754102	ZNF502	-0.38	-6.41	-0.33	5.14e-10	Depressive symptoms;
CRC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.84	0.31	1.26e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg15845792	chr6:28175446	NA	0.83	6.55	0.34	2.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.78	-0.35	5.53e-11	Response to antipsychotic treatment;
CRC	cis	rs4865169	0.811	rs6841086	chr4:57903268	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-6.06	-0.32	3.67e-9	Breast cancer;
CRC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg01262667	chr19:19385393	TM6SF2	-0.37	-6.22	-0.32	1.51e-9	Tonsillectomy;
CRC	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg26816564	chr1:7831052	VAMP3	-0.49	-5.93	-0.31	7.71e-9	Inflammatory bowel disease;
CRC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg16060761	chr17:80687452	NA	0.4	6.2	0.32	1.69e-9	Breast cancer;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04212884	chr16:67876131	CENPT;THAP11	0.46	6.67	0.35	1.09e-10	Intelligence (multi-trait analysis);
CRC	cis	rs3751196	0.901	rs74524744	chr12:104191696	A/G	cg02344784	chr12:104178138	NT5DC3	0.69	7.05	0.36	1.06e-11	Sense of smell;
CRC	cis	rs9341808	0.667	rs742833	chr6:80921446	C/T	cg08355045	chr6:80787529	NA	0.33	5.72	0.3	2.44e-8	Sitting height ratio;
CRC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg10723962	chr6:26240782	HIST1H4F	-0.38	-6.07	-0.32	3.47e-9	Gout;Renal underexcretion gout;
CRC	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.79	0.3	1.67e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.55	7.35	0.38	1.61e-12	Posterior cortical atrophy and Alzheimer's disease;
CRC	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.35	0.38	1.61e-12	Diisocyanate-induced asthma;
CRC	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	8.3	0.42	2.66e-15	Glomerular filtration rate in chronic kidney disease;
CRC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg09835421	chr16:68378352	PRMT7	-0.56	-5.65	-0.3	3.39e-8	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	11.28	0.53	3.52e-25	Prudent dietary pattern;
CRC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg10729496	chr3:10149963	C3orf24	0.5	6.63	0.34	1.37e-10	Alzheimer's disease;
CRC	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.99	-0.31	5.37e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.55	6.11	0.32	2.76e-9	Vitiligo;
CRC	cis	rs6968419	0.585	rs9692117	chr7:115927959	G/T	cg19719915	chr7:115928094	NA	0.42	6.78	0.35	5.68e-11	Intraocular pressure;
CRC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.69	-11.85	-0.55	3.36e-27	Dental caries;
CRC	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.26	-0.33	1.18e-9	Triglycerides;
CRC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.82	-0.55	4.04e-27	Type 2 diabetes;
CRC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.35	0.46	1.4e-18	Colonoscopy-negative controls vs population controls;
CRC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.69	8.89	0.44	4.24e-17	Blood metabolite levels;Acylcarnitine levels;
CRC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg06494592	chr3:125709126	NA	-0.54	-6.49	-0.34	3.14e-10	Blood pressure (smoking interaction);
CRC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg14979609	chr8:8086686	FLJ10661	0.38	6.46	0.34	3.79e-10	Mood instability;
CRC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.3	17.02	0.68	5.1e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg22676075	chr6:135203613	NA	0.49	7.55	0.38	4.45e-13	Red blood cell count;
CRC	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.54	-10.17	-0.49	2.58e-21	Schizophrenia;
CRC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04562611	chr16:615315	C16orf11	0.35	5.87	0.31	1.07e-8	Height;
CRC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg13607699	chr17:42295918	UBTF	-0.47	-6.2	-0.32	1.67e-9	Total body bone mineral density;
CRC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg18065981	chr2:242570529	THAP4	-0.41	-6.41	-0.33	5.16e-10	HDL cholesterol;
CRC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17507749	chr15:85114479	UBE2QP1	0.6	8.59	0.43	3.61e-16	Schizophrenia;
CRC	cis	rs6604026	0.656	rs9440134	chr1:93370813	C/T	cg17283838	chr1:93427260	FAM69A	-0.43	-5.79	-0.3	1.61e-8	Multiple sclerosis;
CRC	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.27	5.84	0.31	1.22e-8	Educational attainment (years of education);
CRC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	11.15	0.52	1.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.35	0.33	6.99e-10	Body mass index;
CRC	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg09040174	chr2:113837401	NA	0.65	10.31	0.49	9.07e-22	Protein quantitative trait loci;
CRC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.54	8.82	0.44	6.96e-17	Platelet count;
CRC	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg21153622	chr11:89784906	NA	-0.46	-7.3	-0.37	2.22e-12	Height;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg12719510	chr1:155024394	ADAM15	-0.41	-6.1	-0.32	3e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg19676328	chr12:49525230	TUBA1B	-0.48	-6.09	-0.32	3.21e-9	Total cholesterol levels;
CRC	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg03689076	chr20:33865952	NA	0.49	6.94	0.36	2.14e-11	Attention deficit hyperactivity disorder;
CRC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.54	0.47	3.27e-19	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg09592903	chr2:55203963	RTN4	0.71	11.29	0.53	3.25e-25	Mean platelet volume;
CRC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.0	-10.22	-0.49	1.75e-21	Diabetic retinopathy;
CRC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.65	8.52	0.43	5.72e-16	IgE levels in asthmatics (D.p. specific);
CRC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg02776659	chr21:47717406	C21orf57	-0.34	-5.62	-0.3	4.13e-8	Testicular germ cell tumor;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg05969063	chr14:70193782	NA	0.45	6.58	0.34	1.81e-10	Intelligence (multi-trait analysis);
CRC	cis	rs6908034	0.607	rs79406203	chr6:19816221	T/G	cg02682789	chr6:19804855	NA	0.81	6.48	0.34	3.35e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12463550	chr7:65579703	CRCP	0.75	6.82	0.35	4.5e-11	Diabetic kidney disease;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05021743	chr1:151810893	C2CD4D;LOC100132111	0.25	7.18	0.37	4.8e-12	Liver disease severity in Alagille syndrome;
CRC	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.51	7.48	0.38	6.68e-13	Testicular germ cell tumor;
CRC	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21659725	chr3:3221576	CRBN	-0.42	-6.35	-0.33	7.2e-10	Menarche (age at onset);
CRC	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.34	16.68	0.68	1.08e-45	Uric acid levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01587390	chr19:10221818	PPAN-P2RY11;P2RY11;PPAN	-0.4	-6.5	-0.34	2.97e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs7539624	0.588	rs28370014	chr1:223903167	A/G	cg10100437	chr1:223903862	CAPN2	0.44	6.27	0.33	1.15e-9	Schizophrenia;
CRC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.46	-7.33	-0.37	1.81e-12	Menopause (age at onset);
CRC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg18132624	chr14:105716052	BTBD6;BRF1	-0.43	-7.14	-0.37	6.11e-12	Mean platelet volume;Platelet distribution width;
CRC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.5	7.43	0.38	9.39e-13	Platelet distribution width;
CRC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg19223190	chr17:80058835	NA	0.39	6.23	0.32	1.43e-9	Life satisfaction;
CRC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.49	-8.55	-0.43	4.64e-16	Primary biliary cholangitis;
CRC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	10.06	0.48	6.32e-21	Prudent dietary pattern;
CRC	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.53	8.85	0.44	5.48e-17	Dupuytren's disease;
CRC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg21251018	chr6:28226885	NKAPL	0.64	12.1	0.55	4.06e-28	Pubertal anthropometrics;
CRC	cis	rs59104589	0.521	rs886809	chr2:242397460	A/G	cg19488206	chr2:242435732	STK25	0.49	7.77	0.39	1.03e-13	Fibrinogen levels;
CRC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg26695010	chr11:65641043	EFEMP2	-0.41	-5.99	-0.31	5.44e-9	Eosinophil percentage of white cells;
CRC	cis	rs13144136	0.687	rs6850317	chr4:10664294	T/C	cg10242279	chr4:10666415	CLNK	-0.38	-6.48	-0.34	3.41e-10	Resistance to antihypertensive treatment in hypertension;
CRC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.6	0.34	1.6e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CRC	cis	rs6585424	1.000	rs34100029	chr10:81923598	C/G	cg11900509	chr10:81946545	ANXA11	-0.72	-8.81	-0.44	7.22e-17	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.45	6.44	0.33	4.12e-10	HIV-1 control;
CRC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.58	5.78	0.3	1.72e-8	Fat distribution (HIV);
CRC	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg20647610	chr2:228736258	WDR69	-0.5	-6.78	-0.35	5.7e-11	Blood pressure;
CRC	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg04586622	chr2:25135609	ADCY3	-0.54	-9.94	-0.48	1.55e-20	Body mass index;
CRC	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg17330251	chr7:94953956	PON1	0.48	7.08	0.36	8.93e-12	Yu-Zhi constitution type in type 2 diabetes;
CRC	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg02033258	chr5:131593261	PDLIM4	0.32	5.86	0.31	1.15e-8	Blood metabolite levels;
CRC	cis	rs1656402	0.906	rs883803	chr2:233458453	C/T	cg03852847	chr2:233439513	NA	0.36	6.17	0.32	2e-9	Non-small cell lung cancer (survival);
CRC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.2	-0.45	4.31e-18	Bipolar disorder and schizophrenia;
CRC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.52	6.85	0.35	3.62e-11	Morning vs. evening chronotype;
CRC	trans	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg17712092	chr4:129076599	LARP1B	0.42	6.15	0.32	2.31e-9	Acne (severe);
CRC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	8.11	0.41	1.04e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CRC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-6.2	-0.32	1.73e-9	Body mass index;
CRC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.45	-5.68	-0.3	2.93e-8	Coronary artery disease;
CRC	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.6	8.69	0.43	1.69e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CRC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.52	9.04	0.45	1.37e-17	Aortic root size;
CRC	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.53	-6.68	-0.35	1.04e-10	Colonoscopy-negative controls vs population controls;
CRC	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	9.3	0.46	1.98e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg00086871	chr4:6988644	TBC1D14	0.88	6.52	0.34	2.66e-10	Granulocyte percentage of myeloid white cells;
CRC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.62	-10.32	-0.49	8.39e-22	Prostate cancer;
CRC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.76	-12.27	-0.56	9.7e-29	Obesity-related traits;
CRC	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-7.61	-0.39	2.99e-13	Total bilirubin levels in HIV-1 infection;
CRC	cis	rs4700695	0.841	rs251305	chr5:65249859	C/T	cg21114390	chr5:65439923	SFRS12	0.5	6.21	0.32	1.57e-9	Facial morphology (factor 19);
CRC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-5.91	-0.31	8.54e-9	Schizophrenia;
CRC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-6.82	-0.35	4.41e-11	Renal function-related traits (BUN);
CRC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.37	-7.03	-0.36	1.2e-11	Schizophrenia;
CRC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.77	11.97	0.55	1.2100000000000001e-27	Schizophrenia;
CRC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16447950	chr5:562315	NA	-0.73	-9.65	-0.47	1.41e-19	Obesity-related traits;
CRC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg23161317	chr6:28129485	ZNF389	0.47	6.64	0.34	1.28e-10	Parkinson's disease;
CRC	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-7.11	-0.37	7.16e-12	QT interval;
CRC	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02837488	chr7:73868870	GTF2IRD1	0.54	6.23	0.32	1.47e-9	Interleukin-4 levels;
CRC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.17	0.41	6.83e-15	Waist circumference;Hip circumference;
CRC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27220968	chr7:100493724	ACHE	-0.41	-5.99	-0.31	5.48e-9	Asthma;
CRC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.46	-0.34	3.85e-10	Aortic root size;
CRC	trans	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg04077850	chr5:125800366	GRAMD3	0.38	6.39	0.33	5.59e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.8	14.04	0.61	1.97e-35	Breast cancer;
CRC	cis	rs1552172	0.887	rs1471629	chr1:145707240	C/A	cg11743829	chr1:145714124	CD160	-0.41	-6.09	-0.32	3.19e-9	Breast cancer;
CRC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.69	12.25	0.56	1.1e-28	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.77	13.72	0.6	3.44e-34	Lewy body disease;
CRC	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.44	6.64	0.34	1.34e-10	Red blood cell count;
CRC	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.44	-8.5	-0.42	6.71e-16	Alcohol dependence;
CRC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.45	7.75	0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg20354231	chr13:53171401	NA	-0.52	-8.17	-0.41	6.74e-15	Lewy body disease;
CRC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.84	12.24	0.56	1.22e-28	Gut microbiome composition (summer);
CRC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.59	10.03	0.48	7.61e-21	Prudent dietary pattern;
CRC	cis	rs73206853	0.841	rs56887341	chr12:110947185	T/C	cg12870014	chr12:110450643	ANKRD13A	0.81	9.5	0.46	4.54e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CRC	trans	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg17939434	chr2:96931590	CIAO1;TMEM127	0.44	6.19	0.32	1.83e-9	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
CRC	cis	rs62432291	0.681	rs388001	chr6:159658459	C/T	cg14500486	chr6:159655392	FNDC1	-0.77	-10.43	-0.5	3.48e-22	Joint mobility (Beighton score);
CRC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.48	7.74	0.39	1.21e-13	Uric acid clearance;
CRC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-9.45	-0.46	6.59e-19	Developmental language disorder (linguistic errors);
CRC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.57	7.95	0.4	2.99e-14	Celiac disease or Rheumatoid arthritis;
CRC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12273811	chr6:28175739	NA	0.73	9.18	0.45	4.85e-18	Depression;
CRC	cis	rs1572438	1.000	rs9379167	chr6:866372	C/T	cg13447295	chr6:887704	NA	-0.5	-6.92	-0.36	2.3e-11	Aging;
CRC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.49	-6.8	-0.35	4.93e-11	Obesity-related traits;
CRC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.36	-5.88	-0.31	9.87e-9	Glycated hemoglobin levels;
CRC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.6	7.07	0.36	9.23e-12	LDL cholesterol;Cholesterol, total;
CRC	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	6.98	0.36	1.6e-11	Mean corpuscular volume;
CRC	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg24848437	chr7:2645542	IQCE	0.59	6.12	0.32	2.66e-9	Urate levels in lean individuals;
CRC	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.51	-0.34	2.82e-10	Crohn's disease;Inflammatory bowel disease;
CRC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.36	-5.79	-0.3	1.63e-8	Lymphocyte counts;
CRC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg19318889	chr4:1322082	MAEA	0.41	6.3	0.33	9.63e-10	Obesity-related traits;
CRC	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg09695851	chr17:3907499	NA	0.65	11.44	0.53	1e-25	Type 2 diabetes;
CRC	trans	rs559356	0.561	rs511922	chr3:34834934	C/T	cg19071035	chr6:20404090	E2F3	0.46	6.0	0.31	5.29e-9	Cognitive function;
CRC	trans	rs16846053	0.786	rs72873607	chr2:162471174	G/A	cg18122310	chr12:50236657	BCDIN3D	-0.73	-6.17	-0.32	2.02e-9	Blood osmolality (transformed sodium);
CRC	trans	rs2303319	0.504	rs72877343	chr2:162607487	A/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg02007433	chr3:129722099	NA	-0.61	-9.23	-0.45	3.33e-18	Blood pressure (smoking interaction);
CRC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12463550	chr7:65579703	CRCP	0.63	5.72	0.3	2.34e-8	Diabetic kidney disease;
CRC	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	9.0	0.44	1.79e-17	Iron status biomarkers;
CRC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg11168104	chr5:1857477	NA	-0.38	-6.59	-0.34	1.79e-10	Cardiovascular disease risk factors;
CRC	cis	rs35883536	0.708	rs34689792	chr1:101097753	A/G	cg14515779	chr1:101123966	NA	-0.43	-8.22	-0.41	4.84e-15	Monocyte count;
CRC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	8.6	0.43	3.22e-16	IgG glycosylation;
CRC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg19913688	chr11:428466	ANO9	-0.56	-6.11	-0.32	2.88e-9	Body mass index;
CRC	cis	rs58365266	1.000	rs58365266	chr3:195813757	C/T	cg01181863	chr3:195395398	SDHAP2	-0.59	-6.2	-0.32	1.67e-9	Red cell distribution width;
CRC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.81	12.33	0.56	5.83e-29	Cognitive function;
CRC	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.54	-6.46	-0.34	3.68e-10	Coronary artery calcification;
CRC	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-8.44	-0.42	1e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.86	-0.31	1.13e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CRC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.86	-0.44	5.21e-17	Alcohol dependence;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg12568633	chr10:73533407	CDH23;C10orf54	0.42	7.04	0.36	1.09e-11	Obesity-related traits;
CRC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg08222913	chr3:52553049	STAB1	-0.34	-6.21	-0.32	1.64e-9	Bipolar disorder;
CRC	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	6.36	0.33	6.76e-10	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.55	8.1	0.41	1.05e-14	Resting heart rate;
CRC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	1.3	14.37	0.62	1.07e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.52	6.3	0.33	9.68e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg10556349	chr10:835070	NA	-0.35	-6.73	-0.35	7.63e-11	Survival in rectal cancer;
CRC	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.17	-0.32	1.97e-9	Mean corpuscular hemoglobin concentration;
CRC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.67	13.96	0.61	4.12e-35	Schizophrenia;
CRC	cis	rs17713451	0.593	rs112258991	chr7:151270296	T/C	cg18404559	chr7:151322523	PRKAG2	-0.57	-6.41	-0.33	5.12e-10	Interleukin-4 levels;
CRC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.37	-6.06	-0.32	3.77e-9	Red cell distribution width;
CRC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg06470822	chr6:28175283	NA	0.51	7.53	0.38	4.92e-13	Pubertal anthropometrics;
CRC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.26	-0.45	2.81e-18	Migraine;Coronary artery disease;
CRC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg02527881	chr3:46936655	PTH1R	-0.34	-5.92	-0.31	7.94e-9	Colorectal cancer;
CRC	cis	rs1760803	0.754	rs2879788	chr1:154204310	A/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.35	-0.33	7.04e-10	Nicotine dependence;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19268579	chr10:43904406	HNRNPF	0.37	6.2	0.32	1.65e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-0.91	-15.67	-0.65	9.55e-42	Body mass index;
CRC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.38	5.75	0.3	2.02e-8	Menarche (age at onset);
CRC	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.33	12.72	0.57	2.04e-30	Granulocyte percentage of myeloid white cells;
CRC	cis	rs7635838	0.963	rs7627171	chr3:11413429	G/C	cg00170343	chr3:11313890	ATG7	0.42	6.37	0.33	6.28e-10	HDL cholesterol;
CRC	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.78	8.68	0.43	1.91e-16	Systolic blood pressure;
CRC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.49	7.1	0.36	7.64e-12	High light scatter reticulocyte count;
CRC	cis	rs77861329	1.000	rs9809254	chr3:52111474	T/C	cg08692210	chr3:52188851	WDR51A	0.85	8.08	0.41	1.21e-14	Macrophage inflammatory protein 1b levels;
CRC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-6.79	-0.35	5.1e-11	Total body bone mineral density;
CRC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.97	-0.36	1.7e-11	Total cholesterol levels;
CRC	cis	rs4743820	0.590	rs73650935	chr9:93917658	T/C	cg14446406	chr9:93919335	NA	0.77	13.61	0.6	9.16e-34	Ulcerative colitis;Inflammatory bowel disease;
CRC	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-0.67	-9.56	-0.47	2.93e-19	Type 2 diabetes;
CRC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg23565292	chr14:50234668	KLHDC2	-0.4	-5.62	-0.3	4.06e-8	Carotid intima media thickness;
CRC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg21399703	chr1:247681439	NA	0.46	7.61	0.39	2.97e-13	Acute lymphoblastic leukemia (childhood);
CRC	trans	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg25214090	chr10:38739885	LOC399744	-0.43	-6.7	-0.35	9.26e-11	Diastolic blood pressure;
CRC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.56	0.47	2.87e-19	Colonoscopy-negative controls vs population controls;
CRC	cis	rs775227	0.574	rs2018912	chr3:113060140	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-6.71	-0.35	8.75e-11	Dental caries;
CRC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.45	-6.87	-0.35	3.14e-11	Cardiovascular disease risk factors;
CRC	cis	rs6743376	0.556	rs1374285	chr2:113818738	G/A	cg09040174	chr2:113837401	NA	0.44	6.44	0.33	4.3e-10	Inflammatory biomarkers;
CRC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	8.34	0.42	2e-15	Colorectal cancer;
CRC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.52	-7.43	-0.38	9.59e-13	Menarche (age at onset);
CRC	trans	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.36	-0.38	1.5e-12	Endometrial cancer;
CRC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.8	-11.46	-0.53	8.11e-26	Coronary artery disease;
CRC	cis	rs7605827	0.930	rs2111451	chr2:15654483	T/C	cg19274914	chr2:15703543	NA	0.38	5.78	0.3	1.71e-8	Educational attainment (years of education);
CRC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.44	6.24	0.33	1.35e-9	Lymphocyte counts;
CRC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.57	7.07	0.36	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.79	-12.8	-0.58	1.0500000000000001e-30	Glaucoma (primary open-angle);
CRC	cis	rs8040855	0.597	rs994989	chr15:85660716	G/C	cg10818794	chr15:86012489	AKAP13	-0.44	-5.68	-0.3	2.93e-8	Bulimia nervosa;
CRC	cis	rs6679356	0.789	rs10889681	chr1:67799170	T/C	cg24364144	chr1:67875067	SERBP1	0.4	5.63	0.3	3.94e-8	Primary biliary cholangitis;
CRC	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.44	-5.92	-0.31	7.98e-9	Metabolite levels;
CRC	trans	rs72991	0.556	rs297489	chr11:121256366	C/T	cg27192990	chr6:129479024	LAMA2	-0.37	-6.08	-0.32	3.28e-9	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-7.02	-0.36	1.29e-11	Psychosis in Alzheimer's disease;
CRC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.7	-7.83	-0.4	6.55e-14	Psoriasis;
CRC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.61	8.4	0.42	1.37e-15	Arsenic metabolism;
CRC	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg04165759	chr1:150448943	RPRD2	0.36	5.86	0.31	1.15e-8	Migraine;
CRC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.46	7.26	0.37	2.86e-12	Testicular germ cell tumor;
CRC	cis	rs7408868	0.572	rs2074616	chr19:15294991	C/T	cg14696996	chr19:15285081	NOTCH3	0.6	6.83	0.35	4.2e-11	Pulse pressure;
CRC	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.57	-6.31	-0.33	8.9e-10	Coronary artery disease;
CRC	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.32	-0.42	2.33e-15	Biliary atresia;
CRC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.63	-0.34	1.36e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.25	-5.65	-0.3	3.47e-8	Depressive symptoms (multi-trait analysis);
CRC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg06470822	chr6:28175283	NA	0.51	7.43	0.38	9.25e-13	Pubertal anthropometrics;
CRC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg04969067	chr8:143858791	LYNX1	0.44	7.53	0.38	5.09e-13	Urinary tract infection frequency;
CRC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.62	9.67	0.47	1.25e-19	Educational attainment;
CRC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.62	10.6	0.5	9.06e-23	Mean corpuscular volume;
CRC	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg18200150	chr17:30822561	MYO1D	0.46	8.97	0.44	2.26e-17	Schizophrenia;
CRC	trans	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg18187862	chr3:45730750	SACM1L	0.43	6.14	0.32	2.38e-9	Primary sclerosing cholangitis;
CRC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg15845792	chr6:28175446	NA	1.04	13.81	0.61	1.6e-34	Depression;
CRC	trans	rs2055729	0.736	rs11249965	chr8:9740863	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.45	-0.34	3.88e-10	Multiple myeloma (hyperdiploidy);
CRC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.52	7.3	0.37	2.16e-12	Melanoma;
CRC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.8	-11.53	-0.54	4.47e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg04969067	chr8:143858791	LYNX1	-0.42	-6.66	-0.34	1.17e-10	Urinary tract infection frequency;
CRC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12172441	chr6:28176163	NA	0.62	7.27	0.37	2.56e-12	Parkinson's disease;
CRC	cis	rs1681630	1.000	rs1681630	chr11:47969152	A/G	cg05585544	chr11:47624801	NA	-0.42	-6.99	-0.36	1.58e-11	Height;
CRC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.91	0.48	1.95e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.26	-0.53	4.41e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs965469	0.947	rs4611719	chr20:3228423	G/A	cg25506879	chr20:3388711	C20orf194	-0.4	-5.7	-0.3	2.61e-8	IFN-related cytopenia;
CRC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg01420254	chr6:26195488	NA	0.83	8.87	0.44	4.86e-17	Gout;Renal underexcretion gout;
CRC	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.47	6.76	0.35	6.29e-11	Coronary artery disease;
CRC	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06307176	chr5:131281290	NA	0.42	6.14	0.32	2.42e-9	Life satisfaction;
CRC	cis	rs6761276	0.866	rs12469822	chr2:113830563	C/T	cg09040174	chr2:113837401	NA	0.52	7.74	0.39	1.22e-13	Protein quantitative trait loci;
CRC	cis	rs7215564	1.000	rs7215564	chr17:78737287	A/G	cg09596252	chr17:78655493	RPTOR	0.56	5.97	0.31	6.07e-9	Myopia (pathological);
CRC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-10.04	-0.48	7.52e-21	Breast cancer;
CRC	cis	rs12476592	0.602	rs6546018	chr2:63817422	G/T	cg10828910	chr2:63850056	LOC388955	0.49	6.06	0.32	3.75e-9	Childhood ear infection;
CRC	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.93	18.89	0.72	1.97e-54	Metabolite levels;
CRC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.63	-0.54	2.08e-26	Mean platelet volume;Platelet distribution width;
CRC	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg05805236	chr11:65401703	PCNXL3	-0.42	-6.64	-0.34	1.29e-10	Acne (severe);
CRC	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg08645402	chr16:4508243	NA	0.49	6.49	0.34	3.2e-10	Schizophrenia;
CRC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg03623178	chr6:28175578	NA	0.92	13.02	0.58	1.52e-31	Parkinson's disease;
CRC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg11292332	chr7:45801988	SEPT13	-0.35	-6.22	-0.32	1.51e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg11204139	chr17:3907470	NA	-0.75	-13.53	-0.6	1.83e-33	Type 2 diabetes;
CRC	cis	rs755249	0.567	rs16826069	chr1:39797055	A/G	cg18385671	chr1:39797026	MACF1	-0.4	-5.68	-0.3	2.98e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg01732804	chr2:220118692	TUBA4A;TUBA4B	0.44	6.06	0.32	3.79e-9	Anxiety disorder;
CRC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.54	7.76	0.39	1.09e-13	Obesity-related traits;
CRC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.13	0.59	6.13e-32	Alzheimer's disease;
CRC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.55	6.01	0.31	4.84e-9	Schizophrenia;
CRC	cis	rs10221833	0.599	rs355834	chr2:165618056	G/A	cg03182029	chr2:165697222	COBLL1	0.5	5.87	0.31	1.07e-8	Response to statin therapy;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.16	0.49	2.96e-21	Heart rate;
CRC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14863265	chr7:2801509	GNA12	-0.42	-5.78	-0.3	1.69e-8	Height;
CRC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.68	-0.35	1.02e-10	HDL cholesterol;
CRC	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.58	-6.28	-0.33	1.08e-9	Coronary artery disease;
CRC	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.75	-11.86	-0.55	3e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CRC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg21784768	chr11:537496	LRRC56	-0.66	-5.94	-0.31	7.19e-9	Body mass index;
CRC	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.61	-0.63	1.27e-37	Exhaled nitric oxide output;
CRC	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.3	-0.37	2.15e-12	Eosinophil percentage of granulocytes;
CRC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	11.2	0.53	7.15e-25	Hip circumference adjusted for BMI;
CRC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.61	-7.76	-0.39	1.09e-13	Gut microbiome composition (summer);
CRC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg04204079	chr8:58130323	NA	-0.45	-5.84	-0.31	1.27e-8	Developmental language disorder (linguistic errors);
CRC	trans	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg26043149	chr18:55253948	FECH	0.5	7.46	0.38	7.54e-13	Cleft plate (environmental tobacco smoke interaction);
CRC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg11503833	chr11:492997	NA	0.53	5.75	0.3	2.02e-8	Body mass index;
CRC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.67	-6.73	-0.35	7.75e-11	Diabetic retinopathy;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06363041	chr3:131100598	NUDT16	0.41	6.35	0.33	7.11e-10	Schizophrenia;
CRC	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg02158880	chr13:53174818	NA	0.47	6.95	0.36	1.94e-11	Lewy body disease;
CRC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg21770322	chr7:97807741	LMTK2	0.53	8.73	0.43	1.33e-16	Prostate cancer (SNP x SNP interaction);
CRC	trans	rs6693295	0.729	rs2185073	chr1:246213341	G/A	cg03680032	chr11:94965610	SESN3	0.53	6.57	0.34	2e-10	Migraine - clinic-based;Migraine with aura;
CRC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.48	0.46	5.06e-19	Age-related macular degeneration (geographic atrophy);
CRC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	0.91	12.55	0.57	8.93e-30	Red blood cell traits;
CRC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.52	7.21	0.37	3.97e-12	Longevity;Endometriosis;
CRC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	13.42	0.59	4.67e-33	Platelet count;
CRC	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03864326	chr16:67927170	PSKH1	-0.37	-6.02	-0.31	4.66e-9	Obesity-related traits;
CRC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg24375607	chr4:120327624	NA	0.47	7.68	0.39	1.83e-13	Corneal astigmatism;
CRC	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.69	-9.17	-0.45	5.12e-18	Hair shape;
CRC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg25456477	chr12:86230367	RASSF9	0.37	6.38	0.33	5.95e-10	Major depressive disorder;
CRC	cis	rs2033908	0.620	rs1440271	chr11:12852068	A/G	cg25843174	chr11:12811716	TEAD1	-0.42	-7.56	-0.38	3.93e-13	Sitting height ratio;
CRC	trans	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg13565492	chr6:43139072	SRF	-0.72	-7.46	-0.38	7.77e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	trans	rs1979967	0.524	rs35014239	chr15:79658557	G/A	cg14802097	chr12:42970349	PRICKLE1	0.52	6.06	0.32	3.64e-9	Interleukin-18 levels;
CRC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.29	5.91	0.31	8.38e-9	Parkinson's disease;
CRC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg06238570	chr21:40685208	BRWD1	0.78	10.7	0.51	3.88e-23	Cognitive function;
CRC	cis	rs2730260	0.537	rs73169246	chr7:158890593	C/T	cg02254261	chr7:158964346	NA	-0.54	-6.19	-0.32	1.8e-9	Myopia (pathological);
CRC	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.57	9.31	0.46	1.91e-18	Corneal structure;
CRC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.57	-9.51	-0.46	4.21e-19	Personality dimensions;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01772115	chr1:90460555	ZNF326;LOC492303	0.41	6.39	0.33	5.57e-10	Interleukin-6 levels;
CRC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.6	-10.23	-0.49	1.64e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg08779649	chr13:50194554	NA	0.33	6.25	0.33	1.28e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.57	-7.92	-0.4	3.74e-14	Intelligence (multi-trait analysis);
CRC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.67	10.39	0.5	4.82e-22	Blood protein levels;
CRC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg10729496	chr3:10149963	C3orf24	0.59	6.99	0.36	1.53e-11	Alzheimer's disease;
CRC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.48	7.31	0.37	2.07e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.67	10.02	0.48	8.25e-21	Corneal astigmatism;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02273166	chr14:105487914	CDCA4	0.49	6.78	0.35	5.73e-11	Response to antipsychotic treatment;
CRC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.53	-7.26	-0.37	2.82e-12	DNA methylation (variation);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02743050	chr15:57999273	GRINL1A;GCOM1	0.5	6.42	0.33	4.85e-10	Thyroid stimulating hormone;
CRC	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.47	-6.05	-0.32	3.87e-9	Alopecia areata;
CRC	trans	rs2303319	0.504	rs62189042	chr2:162602320	G/T	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg17145862	chr1:211918768	LPGAT1	0.49	6.4	0.33	5.47e-10	Crohn's disease;
CRC	cis	rs17767392	0.509	rs72726677	chr14:71695208	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.51	-6.46	-0.34	3.84e-10	Mitral valve prolapse;
CRC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.41	6.2	0.32	1.69e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04221910	chr5:616842	CEP72	-0.42	-6.93	-0.36	2.28e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CRC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.33	6.96e-10	Diabetic kidney disease;
CRC	cis	rs755249	0.567	rs72661961	chr1:39831768	A/G	cg18385671	chr1:39797026	MACF1	-0.4	-5.78	-0.3	1.74e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-12.04	-0.55	6.39e-28	Glomerular filtration rate (creatinine);
CRC	cis	rs10512697	0.655	rs35093298	chr5:3460454	T/C	cg19473799	chr5:3511975	NA	-0.83	-6.34	-0.33	7.66e-10	Immune response to smallpox vaccine (IL-6);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26671687	chr1:54872113	SSBP3	0.39	6.39	0.33	5.76e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.67	-11.66	-0.54	1.59e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg04289385	chr6:36355825	ETV7	0.38	5.61	0.3	4.25e-8	Platelet distribution width;
CRC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.4	-6.35	-0.33	7.22e-10	High light scatter reticulocyte count;
CRC	cis	rs4664293	0.867	rs1834761	chr2:160601789	A/C	cg08347373	chr2:160653686	CD302	-0.47	-7.43	-0.38	9.32e-13	Monocyte percentage of white cells;
CRC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.78	0.3	1.74e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CRC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg22110888	chr17:80059540	CCDC57	0.4	6.38	0.33	5.96e-10	Life satisfaction;
CRC	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg00852783	chr1:26633632	UBXN11	-0.49	-5.66	-0.3	3.34e-8	Obesity-related traits;
CRC	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg04165759	chr1:150448943	RPRD2	0.35	5.76	0.3	1.91e-8	Migraine;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg06227326	chr17:4269555	UBE2G1	0.46	6.37	0.33	6.25e-10	Response to antipsychotic treatment;
CRC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-10.37	-0.5	5.56e-22	Breast cancer;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11700415	chr19:49140818	SEC1;DBP	0.44	6.97	0.36	1.72e-11	Schizophrenia;
CRC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.37	6.48	0.34	3.29e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.9	-0.48	2.17e-20	Total cholesterol levels;
CRC	cis	rs7264396	0.887	rs2236164	chr20:34097353	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-6.13	-0.32	2.58e-9	Total cholesterol levels;
CRC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg15845792	chr6:28175446	NA	0.84	7.96	0.4	2.84e-14	Depression;
CRC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.56	0.38	3.94e-13	Menopause (age at onset);
CRC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.98	17.96	0.7	9.57e-51	Diastolic blood pressure;Systolic blood pressure;
CRC	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.44	-6.85	-0.35	3.69e-11	Asthma;
CRC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg06470822	chr6:28175283	NA	0.98	13.34	0.59	9.69e-33	Parkinson's disease;
CRC	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg02927042	chr1:21476669	EIF4G3	-0.5	-7.83	-0.4	6.85e-14	Superior frontal gyrus grey matter volume;
CRC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.62	-9.12	-0.45	7.76e-18	Systolic blood pressure;
CRC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	9.33	0.46	1.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg22800191	chr3:148847598	HPS3	0.42	5.96	0.31	6.35e-9	Response to antipsychotic treatment;
CRC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg23018236	chr17:30244563	NA	-0.66	-7.86	-0.4	5.69e-14	Hip circumference adjusted for BMI;
CRC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg20243544	chr17:37824526	PNMT	0.56	9.05	0.45	1.3e-17	Asthma;
CRC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.52	7.55	0.38	4.37e-13	Monocyte percentage of white cells;
CRC	cis	rs11229555	0.574	rs12272096	chr11:58186118	A/G	cg15696309	chr11:58395628	NA	-0.81	-10.31	-0.49	8.83e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CRC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-6.49	-0.34	3.17e-10	Blood protein levels;Circulating chemerin levels;
CRC	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg23100626	chr2:96804247	ASTL	0.27	7.11	0.36	7.33e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.39	8.62	0.43	2.89e-16	Eye color traits;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02631680	chr6:44094852	TMEM63B;MRPL14	0.4	6.45	0.34	4.05e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs713587	0.571	rs546217	chr2:25311537	A/C	cg22495460	chr2:25135724	ADCY3	0.39	5.86	0.31	1.15e-8	Body mass index in non-asthmatics;
CRC	cis	rs1800978	1.000	rs1800978	chr9:107665978	C/G	cg14313833	chr9:107666037	ABCA1	-0.56	-5.77	-0.3	1.81e-8	Coronary artery disease;
CRC	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-8.4	-0.42	1.39e-15	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg14074117	chr16:1909714	C16orf73	-0.33	-5.83	-0.31	1.36e-8	Insulin-like growth factors;
CRC	cis	rs6969780	1.000	rs73071548	chr7:27147430	A/G	cg26364809	chr7:27145159	NA	-0.73	-6.73	-0.35	7.69e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
CRC	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg02421172	chr7:1938701	MAD1L1	-0.43	-6.05	-0.32	3.84e-9	Bipolar disorder;
CRC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14828511	chr1:107599125	PRMT6	0.57	8.0	0.4	2.11e-14	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.42	7.64	0.39	2.34e-13	Huntington's disease progression;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19407570	chr11:61735476	FTH1	0.4	6.32	0.33	8.65e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg20354231	chr13:53171401	NA	0.42	6.95	0.36	1.92e-11	Lewy body disease;
CRC	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg01867433	chr22:38966164	DMC1	0.39	6.27	0.33	1.13e-9	Interleukin-6 levels;
CRC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.6	9.79	0.47	5.14e-20	Depressive symptoms (multi-trait analysis);
CRC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.52	-9.56	-0.47	2.84e-19	Longevity;
CRC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg16797656	chr11:68205561	LRP5	0.36	5.75	0.3	2.08e-8	Total body bone mineral density;
CRC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg08477640	chr19:41863820	B9D2	0.48	7.43	0.38	9.36e-13	Migraine;Coronary artery disease;
CRC	cis	rs6456156	0.904	rs2023305	chr6:167524898	A/G	cg05540913	chr6:167530185	CCR6	0.33	5.72	0.3	2.44e-8	Primary biliary cholangitis;
CRC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg12273811	chr6:28175739	NA	0.45	6.81	0.35	4.63e-11	Cardiac Troponin-T levels;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03341697	chr11:94277138	FUT4	0.44	6.05	0.32	3.88e-9	Response to antipsychotic treatment;
CRC	cis	rs1838105	0.780	rs1623402	chr17:44994280	C/T	cg16759221	chr17:45003025	GOSR2	-0.65	-10.49	-0.5	2.07e-22	Nonsyndromic cleft lip with cleft palate;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25266327	chr19:16435660	KLF2	0.56	9.77	0.47	5.59e-20	Liver disease severity in Alagille syndrome;
CRC	trans	rs11661542	0.967	rs11082043	chr18:20222985	C/G	cg15543045	chr4:3487334	DOK7	-0.38	-5.97	-0.31	6.01e-9	Intracranial aneurysm;
CRC	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.58	-7.15	-0.37	5.78e-12	Ulcerative colitis;
CRC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg07274523	chr3:49395745	GPX1	0.47	6.41	0.33	5.12e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs375066	0.623	rs1549955	chr19:44349861	T/C	cg19542119	chr19:44331823	ZNF283	0.4	5.61	0.3	4.24e-8	Breast cancer;
CRC	cis	rs11191205	0.686	rs10883676	chr10:103445325	A/C	cg15320455	chr10:103880129	LDB1	-0.57	-6.48	-0.34	3.32e-10	Intelligence (multi-trait analysis);
CRC	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.53	-0.34	2.49e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CRC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.43	8.93	0.44	3.05e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CRC	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg21466736	chr12:48725269	NA	-0.48	-7.48	-0.38	6.81e-13	Glycated hemoglobin levels;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01172338	chr17:7297763	PLSCR3	0.45	6.9	0.36	2.73e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.44	-5.62	-0.3	4.06e-8	Response to diuretic therapy;
CRC	trans	rs10805346	0.505	rs35995899	chr4:10112862	T/C	cg26043149	chr18:55253948	FECH	0.43	6.26	0.33	1.17e-9	Urate levels in overweight individuals;Urate levels in obese individuals;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg20918730	chr15:34629953	SLC12A6	0.44	6.09	0.32	3.23e-9	Anxiety disorder;
CRC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00166722	chr3:10149974	C3orf24	0.65	7.7	0.39	1.56e-13	Alzheimer's disease;
CRC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.35	5.68	0.3	2.93e-8	Huntington's disease progression;
CRC	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.4	-6.72	-0.35	8.22e-11	Mean arterial pressure;
CRC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.53	0.47	3.56e-19	Intelligence (multi-trait analysis);
CRC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	0.91	8.4	0.42	1.36e-15	Plateletcrit;
CRC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.58	8.66	0.43	2.14e-16	Longevity;Endometriosis;
CRC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg27661571	chr11:113659931	NA	-0.61	-8.01	-0.4	1.97e-14	Hip circumference adjusted for BMI;
CRC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.53	-9.05	-0.45	1.28e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-7.05	-0.36	1.05e-11	Caudate activity during reward;
CRC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.38	6.01	0.31	5.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs41005	0.967	rs17433703	chr2:8115300	A/G	cg03155496	chr2:8117019	LOC339788	0.4	6.98	0.36	1.6e-11	Response to anti-TNF therapy in rheumatoid arthritis;
CRC	trans	rs6066835	0.867	rs11696900	chr20:47336967	C/A	cg21109867	chr19:55897418	RPL28	-0.77	-6.37	-0.33	6.47e-10	Multiple myeloma;
CRC	trans	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg25722142	chr6:139695762	CITED2	-0.53	-6.62	-0.34	1.42e-10	Diisocyanate-induced asthma;
CRC	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg13491945	chr12:107078410	RFX4	0.36	6.19	0.32	1.8e-9	Heart rate;
CRC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.52	-8.35	-0.42	1.95e-15	Type 2 diabetes;
CRC	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.85	15.8	0.66	3.01e-42	Hip circumference;
CRC	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.51	8.09	0.41	1.18e-14	Red blood cell count;Amyotrophic lateral sclerosis;
CRC	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg19683494	chr5:74908142	NA	-0.49	-6.15	-0.32	2.26e-9	Age-related disease endophenotypes;
CRC	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.69	7.14	0.37	6.03e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
CRC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	10.35	0.5	6.3e-22	Bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13824859	chr6:109804376	ZBTB24	0.38	6.25	0.33	1.27e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.72	-10.32	-0.49	8.19e-22	Platelet distribution width;
CRC	cis	rs6908034	0.607	rs112824001	chr6:19804691	C/T	cg02682789	chr6:19804855	NA	0.81	6.89	0.35	2.9100000000000002e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
CRC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg18721089	chr20:30220636	NA	-0.35	-5.7	-0.3	2.68e-8	Mean corpuscular hemoglobin;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg08222913	chr3:52553049	STAB1	-0.42	-8.56	-0.43	4.49e-16	Electroencephalogram traits;
CRC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.61	-9.0	-0.44	1.82e-17	Lung cancer;
CRC	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.6	9.21	0.45	3.86e-18	Corneal astigmatism;
CRC	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.52	-7.16	-0.37	5.41e-12	Tuberculosis;
CRC	cis	rs2415984	0.579	rs2123129	chr14:46960920	G/T	cg14871534	chr14:47121158	RPL10L	-0.4	-6.08	-0.32	3.32e-9	Number of children ever born;
CRC	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.47	8.31	0.42	2.53e-15	Testicular germ cell tumor;
CRC	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	6.08	0.32	3.3e-9	Blood protein levels;
CRC	cis	rs8177179	0.503	rs9985395	chr3:133413119	A/G	cg16262614	chr3:133464971	TF	-0.32	-5.79	-0.3	1.64e-8	Iron status biomarkers (transferrin levels);
CRC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-7.53	-0.38	4.82e-13	Major depressive disorder;
CRC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.57	-8.19	-0.41	5.65e-15	Obesity-related traits;
CRC	cis	rs9341808	0.622	rs682482	chr6:80961139	A/G	cg08355045	chr6:80787529	NA	-0.36	-6.01	-0.31	4.93e-9	Sitting height ratio;
CRC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.66	-8.3	-0.42	2.75e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CRC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.43	6.84	0.35	3.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12172441	chr6:28176163	NA	0.69	9.14	0.45	6.56e-18	Depression;
CRC	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.55	7.49	0.38	6.6e-13	Coronary artery disease;
CRC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.48	6.84	0.35	3.87e-11	Aortic root size;
CRC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg03030879	chr14:75389066	RPS6KL1	0.37	5.72	0.3	2.45e-8	Neuroticism;
CRC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.53	7.15	0.37	5.67e-12	Alzheimer's disease;
CRC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08905662	chr7:102789948	NAPEPLD	0.42	6.35	0.33	7.27e-10	Myopia (pathological);
CRC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-8.41	-0.42	1.3e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.64	-10.33	-0.49	7.45e-22	Hepatocellular carcinoma;
CRC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg25985355	chr7:65971099	NA	-0.52	-5.92	-0.31	7.91e-9	Gout;
CRC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.43	6.01	0.31	5.01e-9	Breast cancer;
CRC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	8.36	0.42	1.75e-15	Hemoglobin concentration;
CRC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.44	6.2	0.32	1.72e-9	Aortic root size;
CRC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	1.04	12.48	0.57	1.53e-29	Eosinophil percentage of granulocytes;
CRC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.34	2.61e-10	Diabetic kidney disease;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg27466237	chr4:184319924	NA	0.39	6.05	0.32	3.89e-9	Obesity-related traits;
CRC	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg09380636	chr19:4791861	FEM1A	-0.54	-6.48	-0.34	3.33e-10	Optic disc area;
CRC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.55	-8.16	-0.41	7.35e-15	Immature fraction of reticulocytes;Schizophrenia;
CRC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.99	0.44	2.01e-17	Mean platelet volume;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg21864845	chr1:1208426	UBE2J2	0.45	5.97	0.31	6.23e-9	Thyroid stimulating hormone;
CRC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg19223190	chr17:80058835	NA	0.39	6.26	0.33	1.21e-9	Life satisfaction;
CRC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.6	7.91	0.4	4.01e-14	Methadone dose in opioid dependence;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg17895626	chr17:1588142	PRPF8	0.43	5.98	0.31	5.95e-9	Anxiety disorder;
CRC	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.36	-5.89	-0.31	9.65e-9	Mean corpuscular volume;
CRC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg14008862	chr17:28927542	LRRC37B2	0.55	5.74	0.3	2.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CRC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.95	13.63	0.6	7.53e-34	Breast cancer;
CRC	cis	rs938554	0.784	rs13145758	chr4:9981997	G/A	cg00071950	chr4:10020882	SLC2A9	0.48	6.73	0.35	7.5e-11	Blood metabolite levels;
CRC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.57	9.62	0.47	1.82e-19	Total body bone mineral density;
CRC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.59	8.39	0.42	1.42e-15	Psychosis in Alzheimer's disease;
CRC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg27266060	chr8:22091797	NA	0.35	5.77	0.3	1.81e-8	Hypertriglyceridemia;
CRC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.76	16.63	0.68	1.76e-45	Sjögren's syndrome;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg07577668	chr15:29432172	FAM189A1	0.4	6.33	0.33	8.23e-10	Intelligence (multi-trait analysis);
CRC	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg14003231	chr6:33640908	ITPR3	0.49	7.85	0.4	5.97e-14	Plateletcrit;
CRC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.78	-12.61	-0.57	5.16e-30	Paraoxonase activity;
CRC	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.57	9.4	0.46	9.64e-19	Metabolite levels;
CRC	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg10820045	chr2:198174542	NA	0.41	6.89	0.36	2.88e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.41	6.61	0.34	1.56e-10	Blood metabolite levels;
CRC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg07074390	chr21:40555500	PSMG1	-0.45	-6.01	-0.31	5.02e-9	Cognitive function;
CRC	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.5	-7.03	-0.36	1.2e-11	Metabolite levels;
CRC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.15	0.41	7.66e-15	Menopause (age at onset);
CRC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.49	6.77	0.35	5.94e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.67	12.67	0.57	3.14e-30	Bone mineral density;
CRC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg21251018	chr6:28226885	NKAPL	0.48	6.22	0.32	1.48e-9	Parkinson's disease;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01994328	chr10:30723347	MAP3K8	0.41	6.37	0.33	6.2e-10	Intelligence (multi-trait analysis);
CRC	trans	rs2303319	0.504	rs60495163	chr2:162408807	C/T	cg18122310	chr12:50236657	BCDIN3D	-0.72	-6.07	-0.32	3.58e-9	Cognitive function;
CRC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg18827107	chr12:86230957	RASSF9	-0.37	-6.1	-0.32	2.98e-9	Major depressive disorder;
CRC	cis	rs11958404	0.789	rs78112793	chr5:157428226	A/G	cg05962755	chr5:157440814	NA	0.87	11.03	0.52	2.87e-24	IgG glycosylation;
CRC	cis	rs9462846	0.853	rs7757363	chr6:42876386	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-5.84	-0.31	1.23e-8	Blood protein levels;
CRC	cis	rs55675132	0.510	rs72691963	chr1:115297986	T/C	cg12756093	chr1:115239321	AMPD1	0.52	6.24	0.33	1.34e-9	Schizophrenia;
CRC	cis	rs6840360	0.573	rs6810430	chr4:152259759	C/T	cg09659197	chr4:152720779	NA	0.31	6.05	0.32	3.97e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg22723502	chr6:26240528	HIST1H4F	-0.36	-5.92	-0.31	8.02e-9	Gout;Renal underexcretion gout;
CRC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.3	0.33	9.6e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.53	-0.38	4.79e-13	Colorectal cancer;
CRC	trans	rs2303319	0.504	rs62189055	chr2:162625749	C/A	cg03757145	chr4:76555832	CDKL2	-0.65	-6.0	-0.31	5.07e-9	Cognitive function;
CRC	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.54	9.11	0.45	8.15e-18	Dupuytren's disease;
CRC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg20885578	chr2:198174922	NA	-0.38	-6.73	-0.35	7.61e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.98	0.48	1.15e-20	Drug-induced liver injury (flucloxacillin);
CRC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg18230493	chr5:56204884	C5orf35	0.6	8.91	0.44	3.62e-17	Initial pursuit acceleration;
CRC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg03030879	chr14:75389066	RPS6KL1	-0.47	-7.22	-0.37	3.69e-12	Height;
CRC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg26816564	chr1:7831052	VAMP3	0.55	6.05	0.32	3.92e-9	Inflammatory bowel disease;
CRC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-5.96	-0.31	6.54e-9	Extrinsic epigenetic age acceleration;
CRC	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg01420254	chr6:26195488	NA	0.66	5.87	0.31	1.04e-8	Iron status biomarkers (total iron binding capacity);
CRC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-13.29	-0.59	1.51e-32	Glomerular filtration rate (creatinine);
CRC	cis	rs12900463	0.813	rs186266	chr15:85402795	A/G	cg17507749	chr15:85114479	UBE2QP1	0.43	5.77	0.3	1.87e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
CRC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.62	9.46	0.46	5.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg12108527	chr1:43233151	LEPRE1;C1orf50	0.5	6.39	0.33	5.81e-10	Thyroid stimulating hormone;
CRC	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.57	8.89	0.44	4.02e-17	Breast cancer;
CRC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg15786705	chr6:28176104	NA	-0.57	-6.33	-0.33	7.86e-10	Parkinson's disease;
CRC	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.58	7.78	0.39	9.32e-14	Adiposity;
CRC	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg12458913	chr13:53173898	NA	0.8	15.02	0.64	3.28e-39	Lewy body disease;
CRC	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.75	10.01	0.48	9.2e-21	Prostate cancer;
CRC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-8.34	-0.42	2e-15	Gut microbiome composition (summer);
CRC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.87	15.26	0.64	3.78e-40	Coronary artery disease;
CRC	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg04969067	chr8:143858791	LYNX1	-0.34	-5.81	-0.31	1.45e-8	Urinary tract infection frequency;
CRC	cis	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg18809830	chr7:99032528	PTCD1	-1.08	-8.01	-0.4	2.03e-14	Blood metabolite levels;
CRC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.49	5.95	0.31	6.98e-9	Bronchopulmonary dysplasia;
CRC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.46	9.08	0.45	1.01e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
CRC	cis	rs9462027	0.561	rs2262245	chr6:34567694	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.01	-0.31	4.79e-9	Systemic lupus erythematosus;
CRC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg20607287	chr7:12443886	VWDE	-0.62	-6.58	-0.34	1.84e-10	Coronary artery disease;
CRC	cis	rs9398803	0.835	rs59698523	chr6:126733094	T/C	cg19875578	chr6:126661172	C6orf173	0.4	5.74	0.3	2.12e-8	Male-pattern baldness;
CRC	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.47	6.76	0.35	6.35e-11	Coronary heart disease;
CRC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.8	-8.56	-0.43	4.32e-16	Developmental language disorder (linguistic errors);
CRC	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-6.39	-0.33	5.62e-10	Autism spectrum disorder or schizophrenia;
CRC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04844971	chr15:50979486	TRPM7	0.42	6.15	0.32	2.24e-9	Response to antipsychotic treatment;
CRC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.72	0.51	3.39e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.62	9.74	0.47	7.35e-20	Corneal astigmatism;
CRC	cis	rs12024301	0.557	rs56758429	chr1:183637537	A/C	cg11505048	chr1:183622726	RGL1;APOBEC4	0.81	7.0	0.36	1.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.27	-0.37	2.59e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CRC	cis	rs1712517	0.740	rs4293062	chr10:105052624	G/A	cg05636881	chr10:105038444	INA	0.47	8.08	0.41	1.23e-14	Migraine;
CRC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.33	-5.85	-0.31	1.19e-8	Iron status biomarkers;
CRC	cis	rs6499255	0.951	rs10163235	chr16:69739867	G/T	cg04110750	chr16:69646130	NFAT5	-0.56	-7.78	-0.39	9.55e-14	IgE levels;
CRC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.03	-0.4	1.79e-14	Aortic root size;
CRC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.45	3.06e-18	Lymphocyte counts;
CRC	trans	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg11704114	chr12:21509398	SLCO1A2	-0.33	-6.22	-0.32	1.52e-9	Tuberculosis;
CRC	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	1.02	17.35	0.69	2.36e-48	Gout;Urate levels;Serum uric acid levels;
CRC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.42	-6.91	-0.36	2.46e-11	Coronary artery disease;
CRC	trans	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg13565492	chr6:43139072	SRF	-0.72	-7.5	-0.38	6.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.6	9.64	0.47	1.6e-19	Hemostatic factors and hematological phenotypes;
CRC	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.59	10.12	0.49	3.77e-21	Asthma;
CRC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02290350	chr8:58132656	NA	-0.58	-8.16	-0.41	7.29e-15	Developmental language disorder (linguistic errors);
CRC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.65	-0.39	2.26e-13	Hemoglobin concentration;
CRC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg25164649	chr6:28176230	NA	0.67	9.1	0.45	8.98e-18	Parkinson's disease;
CRC	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-7.69	-0.39	1.71e-13	Granulocyte percentage of myeloid white cells;
CRC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-10.87	-0.51	1.03e-23	Motion sickness;
CRC	cis	rs117623576	0.941	rs72784857	chr10:32441029	C/T	cg03047570	chr10:32398778	NA	-0.68	-6.56	-0.34	2.09e-10	Anti-saccade response;
CRC	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.52	9.4	0.46	9.66e-19	Blood metabolite ratios;
CRC	trans	rs11105468	1.000	rs7975788	chr12:90273927	T/G	cg23572944	chr11:60720130	SLC15A3	-0.44	-6.08	-0.32	3.26e-9	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
CRC	cis	rs4400599	0.618	rs1194580	chr1:154219485	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.71	-0.3	2.49e-8	Platelet distribution width;
CRC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.73	-10.92	-0.52	6.61e-24	Blood trace element (Zn levels);
CRC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	10.71	0.51	3.6e-23	Motion sickness;
CRC	cis	rs1552172	0.887	rs2318299	chr1:145662666	C/T	cg11743829	chr1:145714124	CD160	0.41	6.16	0.32	2.15e-9	Breast cancer;
CRC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.68	-0.35	1.01e-10	Bipolar disorder and schizophrenia;
CRC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.66	-8.06	-0.41	1.42e-14	Menarche (age at onset);
CRC	cis	rs6123683	0.738	rs6025465	chr20:55824147	A/G	cg13236649	chr20:55835020	BMP7	0.49	7.51	0.38	5.63e-13	Facial morphology (factor 5, width of mouth relative to central midface);
CRC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.54	8.51	0.42	6.04e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CRC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-5.82	-0.31	1.4e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CRC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg04166393	chr7:2884313	GNA12	0.4	6.09	0.32	3.18e-9	Height;
CRC	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg19875535	chr5:140030758	IK	0.39	6.02	0.31	4.67e-9	Depressive symptoms (multi-trait analysis);
CRC	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg03929089	chr4:120376271	NA	0.64	6.1	0.32	2.95e-9	Axial length;
CRC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.68	-0.35	1.04e-10	Menopause (age at onset);
CRC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg21251018	chr6:28226885	NKAPL	0.54	8.56	0.43	4.32e-16	Depression;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg00040446	chr1:40367965	MYCL1	0.42	6.76	0.35	6.42e-11	Obesity-related traits;
CRC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.52	8.38	0.42	1.6e-15	Aortic root size;
CRC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.28	0.46	2.29e-18	Lymphocyte counts;
CRC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg03609598	chr5:56110824	MAP3K1	0.59	7.99	0.4	2.34e-14	Initial pursuit acceleration;
CRC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	0.71	6.48	0.34	3.37e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	8.05	0.41	1.48e-14	Coronary artery disease;
CRC	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg04586622	chr2:25135609	ADCY3	-0.43	-7.56	-0.38	3.96e-13	Body mass index in non-asthmatics;
CRC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.52	-7.18	-0.37	4.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	11.6	0.54	2.64e-26	Prudent dietary pattern;
CRC	cis	rs8010715	0.816	rs2332224	chr14:24598544	C/G	cg23112188	chr14:24563095	PCK2	-0.36	-6.97	-0.36	1.73e-11	IgG glycosylation;
CRC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.69	-11.7	-0.54	1.14e-26	Breast cancer;
CRC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.48	-7.33	-0.37	1.84e-12	Multiple myeloma (IgH translocation);
CRC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.67	10.14	0.49	3.45e-21	Menopause (age at onset);
CRC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.31	-5.67	-0.3	3.21e-8	Sudden cardiac arrest;
CRC	cis	rs4731207	0.698	rs6415362	chr7:124530650	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.09	-0.32	3.13e-9	Cutaneous malignant melanoma;
CRC	cis	rs7605827	0.930	rs6708288	chr2:15535477	A/G	cg19274914	chr2:15703543	NA	0.39	5.88	0.31	9.87e-9	Educational attainment (years of education);
CRC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.75	0.35	6.62e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs728616	0.764	rs56122289	chr10:81746027	G/A	cg05935833	chr10:81318306	SFTPA2	-0.74	-8.01	-0.4	1.94e-14	Chronic obstructive pulmonary disease-related biomarkers;
CRC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.75	0.3	2.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CRC	cis	rs2857891	0.817	rs2239733	chr11:6976666	T/C	cg04053776	chr11:6947353	ZNF215	0.39	5.69	0.3	2.78e-8	Response to cytadine analogues (cytosine arabinoside);
CRC	cis	rs9039	1.000	rs11075212	chr16:9203899	G/A	cg08831531	chr16:9218945	NA	-0.57	-6.8	-0.35	4.8e-11	Menopause (age at onset);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01026373	chr5:141071769	NA	0.42	6.41	0.33	4.99e-10	Liver disease severity in Alagille syndrome;
CRC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.38	0.33	5.85e-10	Lung cancer;
CRC	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	1.0	12.81	0.58	9.7e-31	IgG glycosylation;
CRC	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.42	7.64	0.39	2.35e-13	Blood metabolite ratios;
CRC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	1.04	18.15	0.71	1.62e-51	Parkinson's disease;
CRC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.63	9.79	0.47	5.05e-20	Corneal astigmatism;
CRC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg26695010	chr11:65641043	EFEMP2	-0.4	-6.09	-0.32	3.17e-9	Eosinophil percentage of white cells;
CRC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-10.04	-0.48	7.09e-21	Height;
CRC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.4	-6.52	-0.34	2.64e-10	Blood metabolite levels;
CRC	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.32	7.51	0.38	5.73e-13	Corneal astigmatism;
CRC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.5	7.2	0.37	4.16e-12	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.73	9.83	0.48	3.72e-20	Platelet count;
CRC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.91	-15.56	-0.65	2.66e-41	Height;
CRC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.41	-6.21	-0.32	1.59e-9	Menopause (age at onset);
CRC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-0.85	-9.99	-0.48	1.06e-20	Breast cancer;
CRC	cis	rs2336384	1.000	rs4846085	chr1:12050634	T/C	cg13216073	chr1:12042593	MFN2	0.48	7.06	0.36	1.03e-11	Platelet count;
CRC	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	7.51	0.38	5.61e-13	Coronary artery disease;
CRC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.44	7.39	0.38	1.19e-12	Colonoscopy-negative controls vs population controls;
CRC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02290350	chr8:58132656	NA	-0.42	-5.96	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
CRC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	ch.11.42038R	chr11:967971	AP2A2	0.57	9.75	0.47	6.98e-20	Alzheimer's disease (late onset);
CRC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.53	-0.47	3.63e-19	Platelet count;
CRC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.91	-0.44	3.55e-17	Electroencephalogram traits;
CRC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.82	-14.28	-0.62	2.44e-36	Height;
CRC	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.34	-5.93	-0.31	7.82e-9	Pneumonia;
CRC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.55	10.09	0.49	4.85e-21	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	18.38	0.71	2.03e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CRC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.68	12.13	0.56	3.13e-28	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs6545883	0.524	rs2463101	chr2:61574422	G/C	cg10580144	chr2:61372316	C2orf74	-0.35	-7.78	-0.39	9.7e-14	Tuberculosis;
CRC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06656553	chr16:89960601	TCF25	-0.69	-5.74	-0.3	2.15e-8	Skin colour saturation;
CRC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg06713675	chr4:122721982	EXOSC9	-0.37	-6.01	-0.31	4.96e-9	Type 2 diabetes;
CRC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.64	7.32	0.37	1.94e-12	Vitiligo;
CRC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg19635926	chr16:89946313	TCF25	0.68	6.39	0.33	5.65e-10	Skin colour saturation;
CRC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg24910161	chr17:38119198	GSDMA	-0.43	-7.65	-0.39	2.24e-13	Asthma;
CRC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.64	10.63	0.51	7.18e-23	Systemic lupus erythematosus;
CRC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.54	10.66	0.51	5.66e-23	Lipoprotein (a) levels;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg15114836	chr19:925199	ARID3A	0.43	6.03	0.32	4.46e-9	Intelligence (multi-trait analysis);
CRC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-14.46	-0.62	4.91e-37	Height;
CRC	trans	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg09872104	chr7:134855509	C7orf49	-0.81	-7.1	-0.36	7.61e-12	Amyotrophic lateral sclerosis (sporadic);
CRC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg08798685	chr6:27730294	NA	-0.62	-5.95	-0.31	7.04e-9	Breast cancer;
CRC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.41	6.24	0.33	1.32e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24308560	chr3:49941425	MST1R	0.46	7.11	0.36	7.33e-12	Intelligence (multi-trait analysis);
CRC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg10729496	chr3:10149963	C3orf24	0.52	6.33	0.33	8.22e-10	Alzheimer's disease;
CRC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.58	-9.21	-0.45	3.86e-18	Tonsillectomy;
CRC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.54	-0.34	2.39e-10	Total body bone mineral density;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg12683173	chr7:69063404	AUTS2	0.3	6.13	0.32	2.49e-9	Liver disease severity in Alagille syndrome;
CRC	trans	rs11581859	0.950	rs17392625	chr1:99381704	T/C	cg12183875	chr3:169587454	LRRC31	0.27	6.2	0.32	1.74e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CRC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.94	11.56	0.54	3.59e-26	Eosinophil percentage of granulocytes;
CRC	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.72	-0.35	8.04e-11	Myopia (pathological);
CRC	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg13385794	chr1:248469461	NA	0.39	6.74	0.35	7.22e-11	Common traits (Other);
CRC	cis	rs8105895	0.935	rs62111034	chr19:22284720	A/C	cg02912127	chr19:22235281	ZNF257	-0.41	-5.7	-0.3	2.62e-8	Body mass index (change over time);
CRC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg23815491	chr16:72088622	HP	0.51	7.78	0.39	9.45e-14	Fibrinogen levels;
CRC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg08314208	chr16:67682810	RLTPR	-0.55	-6.14	-0.32	2.34e-9	HDL cholesterol;Metabolic syndrome;
CRC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.1	-19.24	-0.73	8.63e-56	Dilated cardiomyopathy;
CRC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.68	10.08	0.49	5.22e-21	Corneal astigmatism;
CRC	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	9.26	0.45	2.64e-18	Lupus nephritis in systemic lupus erythematosus;
CRC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	11.06	0.52	2.19e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CRC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.49	6.81	0.35	4.75e-11	Developmental language disorder (linguistic errors);
CRC	cis	rs2276314	0.512	rs1789515	chr18:33635893	G/A	cg19628046	chr18:33552617	C18orf21	-0.39	-6.0	-0.31	5.21e-9	Endometriosis;Drug-induced torsades de pointes;
CRC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.3	-0.37	2.19e-12	Bipolar disorder;
CRC	cis	rs6460942	0.908	rs77034890	chr7:12244506	A/T	cg06484146	chr7:12443880	VWDE	-0.65	-6.36	-0.33	6.91e-10	Coronary artery disease;
CRC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.53	6.58	0.34	1.85e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.08	26.29	0.82	7.78e-83	Testicular germ cell tumor;
CRC	cis	rs4731207	0.698	rs7781148	chr7:124458044	G/A	cg23710748	chr7:124431027	NA	0.38	6.08	0.32	3.42e-9	Cutaneous malignant melanoma;
CRC	cis	rs12760731	0.623	rs61520802	chr1:178428494	G/A	cg00404053	chr1:178313656	RASAL2	0.7	8.74	0.43	1.21e-16	Obesity-related traits;
CRC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-0.64	-11.55	-0.54	3.85e-26	Developmental language disorder (linguistic errors);
CRC	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg11130432	chr3:121712080	ILDR1	-0.51	-6.68	-0.35	9.97e-11	Multiple sclerosis;
CRC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.55	8.26	0.41	3.58e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05655935	chr10:93683722	BTAF1	0.36	6.02	0.31	4.78e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.71	10.88	0.51	9.53e-24	Corneal astigmatism;
CRC	trans	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg21302420	chr1:112162376	RAP1A	0.72	6.01	0.31	5.05e-9	Skin colour saturation;
CRC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.97	-18.7	-0.72	1.09e-53	Height;
CRC	cis	rs501120	1.000	rs573141	chr10:44758587	G/A	cg09554077	chr10:44749378	NA	0.78	12.0	0.55	9.18e-28	Coronary artery disease;Coronary heart disease;
CRC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.7	9.17	0.45	5.21e-18	Alzheimer's disease;
CRC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.99	-0.31	5.63e-9	Monocyte percentage of white cells;
CRC	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg06223162	chr1:101003688	GPR88	-0.35	-6.37	-0.33	6.44e-10	Monocyte count;
CRC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg08992911	chr2:238395768	MLPH	0.52	5.66	0.3	3.21e-8	Prostate cancer;
CRC	trans	rs10242455	1.000	rs2301889	chr7:98931105	A/G	cg09045935	chr12:6379348	NA	0.77	7.22	0.37	3.56e-12	Blood metabolite levels;
CRC	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.56	-8.19	-0.41	5.84e-15	Multiple sclerosis;
CRC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	0.73	6.76	0.35	6.48e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	0.97	10.14	0.49	3.4e-21	Gut microbiota (bacterial taxa);
CRC	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg00825309	chr19:58991885	ZNF446	-0.39	-5.78	-0.3	1.73e-8	Uric acid clearance;
CRC	cis	rs6772849	0.930	rs4857916	chr3:128376014	C/G	cg08795948	chr3:128337044	NA	0.36	6.28	0.33	1.06e-9	Monocyte percentage of white cells;Monocyte count;
CRC	cis	rs9549328	0.700	rs4907568	chr13:113617574	A/T	cg24588162	chr13:113633484	MCF2L	-0.36	-6.69	-0.35	9.8e-11	Systolic blood pressure;
CRC	cis	rs10450586	0.863	rs7481109	chr11:27298062	A/G	cg10370305	chr11:27303972	NA	0.38	6.23	0.32	1.42e-9	Total body bone mineral density;
CRC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.64	8.62	0.43	2.84e-16	Smoking initiation;
CRC	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.46	-7.45	-0.38	8.11e-13	Refractive error;
CRC	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg26816564	chr1:7831052	VAMP3	0.54	6.01	0.31	5e-9	Inflammatory bowel disease;
CRC	cis	rs394563	0.601	rs382720	chr6:149795261	C/T	cg07828024	chr6:149772892	ZC3H12D	0.36	6.12	0.32	2.68e-9	Dupuytren's disease;
CRC	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.65	-10.42	-0.5	3.66e-22	Hepatocellular carcinoma;
CRC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.41	-6.76	-0.35	6.16e-11	Breast cancer;
CRC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.62	-0.43	2.88e-16	Intelligence (multi-trait analysis);
CRC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.04	23.84	0.8	1.16e-73	Multiple system atrophy;
CRC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.65	-7.89	-0.4	4.56e-14	Menarche (age at onset);
CRC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.88	16.19	0.67	9.31e-44	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg24375607	chr4:120327624	NA	0.47	7.6	0.39	3.06e-13	Corneal astigmatism;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg22753607	chr9:37120306	ZCCHC7	0.48	6.26	0.33	1.23e-9	Thyroid stimulating hormone;
CRC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.57	-0.43	4.19e-16	Monocyte percentage of white cells;
CRC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.49	7.2	0.37	4.09e-12	Headache;
CRC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg01262667	chr19:19385393	TM6SF2	-0.4	-6.59	-0.34	1.72e-10	Tonsillectomy;
CRC	cis	rs12760731	0.565	rs12037429	chr1:178224741	C/T	cg00404053	chr1:178313656	RASAL2	1.03	10.81	0.51	1.61e-23	Obesity-related traits;
CRC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.91	-0.4	3.92e-14	Monocyte percentage of white cells;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19304507	chr22:30278992	MTMR3	0.4	6.12	0.32	2.68e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.01	19.81	0.74	4.7e-58	Schizophrenia;
CRC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg27534772	chr1:16042836	PLEKHM2	0.55	11.0	0.52	3.66e-24	Systolic blood pressure;
CRC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg17496447	chr4:144435124	SMARCA5	-0.38	-6.18	-0.32	1.89e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CRC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.52	0.34	2.64e-10	Diastolic blood pressure;
CRC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.43	-6.15	-0.32	2.28e-9	Aortic root size;
CRC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.16	-0.32	2.07e-9	Aortic root size;
CRC	cis	rs73195822	0.527	rs55728229	chr12:111169374	T/A	cg12870014	chr12:110450643	ANKRD13A	0.74	7.96	0.4	2.88e-14	Itch intensity from mosquito bite;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg05572020	chr16:3989254	NA	0.48	6.44	0.33	4.25e-10	Anxiety disorder;
CRC	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg05562828	chr17:3906858	NA	0.42	5.92	0.31	8.29e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
CRC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02725872	chr8:58115012	NA	-0.44	-7.86	-0.4	5.64e-14	Developmental language disorder (linguistic errors);
CRC	trans	rs948562	1.000	rs79475579	chr11:58295900	G/A	cg26660744	chr1:1573181	CDK11B	0.53	6.2	0.32	1.69e-9	Lymphoma;
CRC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg02461776	chr11:598696	PHRF1	0.41	5.61	0.3	4.33e-8	Systemic lupus erythematosus;
CRC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg00129232	chr17:37814104	STARD3	0.54	7.34	0.38	1.68e-12	Glomerular filtration rate (creatinine);
CRC	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09019002	chr7:102715232	ARMC10;FBXL13	0.48	6.26	0.33	1.23e-9	Hip circumference;
CRC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.46	-0.42	8.97e-16	Chronic sinus infection;
CRC	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.63	0.47	1.63e-19	Ileal carcinoids;
CRC	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg09654669	chr8:57350985	NA	-0.44	-5.95	-0.31	6.89e-9	Obesity-related traits;
CRC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.4	-0.42	1.37e-15	Monocyte percentage of white cells;
CRC	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.42	-5.98	-0.31	5.81e-9	Height;
CRC	cis	rs4664293	0.867	rs3771718	chr2:160636908	A/G	cg08347373	chr2:160653686	CD302	-0.47	-7.47	-0.38	7.5e-13	Monocyte percentage of white cells;
CRC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg03790207	chr6:42947109	PEX6	-0.46	-6.73	-0.35	7.65e-11	Alzheimer's disease in APOE e4+ carriers;
CRC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.55	9.21	0.45	3.92e-18	Schizophrenia;
CRC	cis	rs17270561	0.636	rs9379779	chr6:25695441	G/T	cg16482183	chr6:26056742	HIST1H1C	0.71	8.65	0.43	2.38e-16	Iron status biomarkers;
CRC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.68	11.86	0.55	2.95e-27	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.62	-0.3	4.09e-8	Morning vs. evening chronotype;
CRC	cis	rs2415984	0.622	rs1955262	chr14:46940639	A/G	cg14871534	chr14:47121158	RPL10L	-0.44	-6.21	-0.32	1.6e-9	Number of children ever born;
CRC	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.49	6.06	0.32	3.75e-9	Recombination rate (females);
CRC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.3	4.08e-8	Morning vs. evening chronotype;
CRC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg17298326	chr8:142245477	NA	0.4	5.97	0.31	6.28e-9	Immature fraction of reticulocytes;
CRC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg08200770	chr17:80723486	TBCD	-0.5	-7.83	-0.4	6.79e-14	Glycated hemoglobin levels;
CRC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.4	-0.56	3.15e-29	Bipolar disorder and schizophrenia;
CRC	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.58	8.56	0.43	4.48e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg23781003	chr4:120988207	MAD2L1	0.48	6.33	0.33	8.14e-10	Thyroid stimulating hormone;
CRC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	10.22	0.49	1.74e-21	Alzheimer's disease (late onset);
CRC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.37	6.14	0.32	2.37e-9	Blood metabolite levels;
CRC	trans	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg21302420	chr1:112162376	RAP1A	0.72	5.96	0.31	6.38e-9	Skin colour saturation;
CRC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.29	0.42	2.87e-15	Height;
CRC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	10.13	0.49	3.5e-21	Cognitive test performance;
CRC	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg04165759	chr1:150448943	RPRD2	0.36	5.87	0.31	1.05e-8	Migraine;
CRC	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	1.04	8.44	0.42	1.01e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CRC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.17	0.41	6.8e-15	Parkinson's disease;
CRC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.39	6.19	0.32	1.78e-9	Cognitive ability (multi-trait analysis);
CRC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	5.95	0.31	6.97e-9	Prudent dietary pattern;
CRC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.62	-9.1	-0.45	8.95e-18	Facial morphology (factor 21, depth of nasal alae);
CRC	cis	rs11212617	1.000	rs11212610	chr11:108274593	T/C	cg01991180	chr11:108092276	ATM;NPAT	0.41	5.99	0.31	5.52e-9	Response to metformin in type 2 diabetes (glycemic);
CRC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg16576597	chr16:28551801	NUPR1	0.49	7.07	0.36	9.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
CRC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.46	-6.74	-0.35	7.09e-11	Subjective well-being;
CRC	cis	rs4731207	0.623	rs12706629	chr7:124574045	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.19	-0.32	1.8e-9	Cutaneous malignant melanoma;
CRC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg21153622	chr11:89784906	NA	0.42	6.93	0.36	2.26e-11	Coronary artery disease;
CRC	cis	rs12476592	0.543	rs12713494	chr2:63698162	G/T	cg10828910	chr2:63850056	LOC388955	0.47	5.69	0.3	2.8e-8	Childhood ear infection;
CRC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg10298567	chr3:47292165	KIF9	0.44	7.24	0.37	3.21e-12	Colorectal cancer;
CRC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.38	6.8	0.35	4.95e-11	Primary biliary cholangitis;
CRC	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg21836586	chr14:55907198	TBPL2	0.3	5.6	0.3	4.51e-8	Pediatric bone mineral content (femoral neck);
CRC	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-7.68	-0.39	1.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CRC	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.59	-8.39	-0.42	1.44e-15	Body mass index;
CRC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.46	-6.1	-0.32	2.94e-9	Longevity;
CRC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-6.13	-0.32	2.56e-9	Menarche (age at onset);
CRC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.47	7.0	0.36	1.45e-11	Menopause (age at onset);
CRC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg10589385	chr1:150898437	SETDB1	0.31	6.38	0.33	6.04e-10	Melanoma;
CRC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg21665744	chr7:39171113	POU6F2	0.45	5.96	0.31	6.67e-9	IgG glycosylation;
CRC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg02007433	chr3:129722099	NA	-0.46	-5.98	-0.31	5.71e-9	Blood pressure (smoking interaction);
CRC	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.6	-6.2	-0.32	1.72e-9	Age-related hearing impairment (SNP x SNP interaction);
CRC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.46	-6.58	-0.34	1.83e-10	HDL cholesterol;
CRC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.84	12.79	0.58	1.09e-30	Body mass index;
CRC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.47	7.47	0.38	7.28e-13	Colonoscopy-negative controls vs population controls;
CRC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	0.33	6.33	0.33	8.2e-10	Colorectal cancer;
CRC	cis	rs972578	1.000	rs2284097	chr22:43400006	C/G	cg01576275	chr22:43409880	NA	-0.43	-6.76	-0.35	6.22e-11	Mean platelet volume;
CRC	cis	rs939584	1.000	rs10190052	chr2:646674	T/C	cg03610516	chr2:642275	NA	0.42	5.88	0.31	9.94e-9	Body mass index;
CRC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18912574	chr7:65842487	NCRNA00174	-0.37	-6.2	-0.32	1.69e-9	Aortic root size;
CRC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg16342193	chr10:102329863	NA	-0.35	-5.9	-0.31	8.84e-9	Palmitoleic acid (16:1n-7) levels;
CRC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg13390004	chr1:15929781	NA	0.5	7.11	0.37	7.21e-12	Systolic blood pressure;
CRC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.5	-6.93	-0.36	2.26e-11	Coronary artery disease;
CRC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg02683197	chr6:28174875	NA	0.87	10.73	0.51	3.25e-23	Depression;
CRC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg27661571	chr11:113659931	NA	-0.96	-11.24	-0.53	5.07e-25	Hip circumference adjusted for BMI;
CRC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg05347473	chr6:146136440	FBXO30	0.37	5.91	0.31	8.46e-9	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.42	8.26	0.41	3.55e-15	Mean corpuscular volume;
CRC	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg20608306	chr11:116969690	SIK3	-0.31	-5.66	-0.3	3.23e-8	Subjective well-being;
CRC	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg26248373	chr2:1572462	NA	-0.62	-6.5	-0.34	2.96e-10	Placebo response in major depressive disorder (% change in symptom score);
CRC	cis	rs9469578	0.892	rs73743334	chr6:33714094	G/C	cg18708504	chr6:33715942	IP6K3	0.66	7.56	0.38	4e-13	Phosphorus levels;
CRC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.54	0.38	4.63e-13	Mean platelet volume;
CRC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.5	6.17	0.32	1.99e-9	Vitiligo;
CRC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	11.15	0.52	1.04e-24	Motion sickness;
CRC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg02560186	chr11:3602584	NA	-0.63	-9.53	-0.47	3.69e-19	Blood pressure (smoking interaction);
CRC	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.79	-9.51	-0.46	4.25e-19	Multiple sclerosis;
CRC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg08222913	chr3:52553049	STAB1	-0.33	-6.1	-0.32	2.98e-9	Electroencephalogram traits;
CRC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.85	15.9	0.66	1.23e-42	Dental caries;
CRC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11645453	chr3:52864694	ITIH4	0.34	6.4	0.33	5.31e-10	Electroencephalogram traits;
CRC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	9.48	0.46	5.15e-19	Mean corpuscular hemoglobin;
CRC	cis	rs7259376	0.902	rs10409947	chr19:22512518	G/A	cg02657401	chr19:22469223	NA	-0.37	-8.16	-0.41	7.14e-15	Menopause (age at onset);
CRC	cis	rs990171	0.865	rs6717915	chr2:103079619	A/C	cg03938978	chr2:103052716	IL18RAP	0.46	5.88	0.31	1e-8	Lymphocyte counts;
CRC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.55	8.13	0.41	8.77e-15	Schizophrenia;
CRC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.66	12.27	0.56	9.04e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CRC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.47	6.07	0.32	3.49e-9	Lymphocyte counts;
CRC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg18827107	chr12:86230957	RASSF9	-0.37	-6.11	-0.32	2.84e-9	Major depressive disorder;
CRC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.1	13.52	0.6	2e-33	Vitiligo;
CRC	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.27	5.84	0.31	1.26e-8	Migraine;
CRC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.55	-7.58	-0.39	3.46e-13	Colorectal cancer;
CRC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg15147215	chr3:52552868	STAB1	-0.63	-10.4	-0.5	4.44e-22	Bipolar disorder;
CRC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.43	5.77e-16	Colorectal cancer;
CRC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg18683604	chr14:51561293	TRIM9	-0.32	-6.22	-0.32	1.47e-9	Cancer;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg00949670	chr12:120967105	COQ5	0.45	5.96	0.31	6.45e-9	Thyroid stimulating hormone;
CRC	cis	rs6679356	0.789	rs10889683	chr1:67809317	A/T	cg24364144	chr1:67875067	SERBP1	0.42	6.35	0.33	6.96e-10	Primary biliary cholangitis;
CRC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg09658497	chr7:2847517	GNA12	-0.37	-6.15	-0.32	2.3e-9	Height;
CRC	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-6.02	-0.32	4.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CRC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.53	-8.81	-0.44	7.15e-17	Brugada syndrome;
CRC	trans	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg07393940	chr7:158741817	NA	-0.55	-7.89	-0.4	4.55e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.06	-0.36	9.75e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg27661571	chr11:113659931	NA	-0.8	-9.48	-0.46	5.16e-19	Hip circumference adjusted for BMI;
CRC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.97	-16.94	-0.68	9.95e-47	Height;
CRC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.84	-14.41	-0.62	7.84e-37	Intelligence (multi-trait analysis);
CRC	cis	rs17152411	0.947	rs7079199	chr10:126590820	A/C	cg07906193	chr10:126599966	NA	0.59	5.78	0.3	1.71e-8	Height;
CRC	cis	rs2013441	1.000	rs3850783	chr17:20184501	C/T	cg13482628	chr17:19912719	NA	0.39	5.85	0.31	1.17e-8	Obesity-related traits;
CRC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.62	-7.44	-0.38	8.57e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CRC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg25985355	chr7:65971099	NA	0.51	5.72	0.3	2.46e-8	Diabetic kidney disease;
CRC	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.56	0.47	2.93e-19	Blood protein levels;
CRC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.36	5.83	0.31	1.34e-8	Inflammatory bowel disease;Ulcerative colitis;
CRC	cis	rs2108622	0.727	rs12611242	chr19:15978564	G/A	cg13772218	chr19:15982569	NA	0.48	6.72	0.35	8.16e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CRC	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg10820045	chr2:198174542	NA	0.43	7.46	0.38	7.97e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CRC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18301423	chr5:131593218	PDLIM4	0.45	7.78	0.39	9.31e-14	Acylcarnitine levels;
CRC	cis	rs4664293	0.967	rs13032135	chr2:160532099	T/C	cg08347373	chr2:160653686	CD302	-0.37	-6.08	-0.32	3.32e-9	Monocyte percentage of white cells;
CRC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-7.69	-0.39	1.7e-13	Aortic root size;
CRC	trans	rs773506	0.965	rs298718	chr9:94081674	A/G	cg01894875	chr1:2121521	C1orf86;LOC100128003	0.39	6.01	0.31	5.03e-9	Type 2 diabetes nephropathy;
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21123913	chr4:89513664	HERC3	0.41	6.96	0.36	1.85e-11	Liver disease severity in Alagille syndrome;
CRC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-20.15	-0.74	2.29e-59	Primary sclerosing cholangitis;
CRC	trans	rs10411161	0.702	rs8110531	chr19:52383510	C/T	cg22319618	chr22:45562946	NUP50	-0.68	-7.53	-0.38	4.85e-13	Breast cancer;
CRC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.37	-6.31	-0.33	8.76e-10	Glomerular filtration rate (creatinine);
CRC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	0.99	14.76	0.63	3.48e-38	Breast cancer;
CRC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.7	-0.39	1.5700000000000001e-13	Bipolar disorder and schizophrenia;
CRC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-17.66	-0.7	1.48e-49	Height;
CRC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg14844989	chr11:31128820	NA	-0.34	-6.05	-0.32	3.85e-9	Red blood cell count;
CRC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.8	12.82	0.58	8.77e-31	Height;
CRC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.76	11.09	0.52	1.74e-24	Longevity;
CRC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01932091	chr1:29213675	EPB41	0.39	6.02	0.31	4.54e-9	Schizophrenia;
CRC	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg05756136	chr1:119680316	WARS2	-0.52	-7.14	-0.37	6e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CRC	cis	rs6011002	0.564	rs2260045	chr20:62343013	T/C	cg01176363	chr20:62369445	LIME1	-0.72	-5.67	-0.3	3.14e-8	Dental caries;
CRC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-5.87	-0.31	1.09e-8	Developmental language disorder (linguistic errors);
CRC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.55	-6.86	-0.35	3.34e-11	Body mass index;
CRC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22029157	chr1:209979665	IRF6	0.61	6.77	0.35	5.84e-11	Cleft lip with or without cleft palate;
CRC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.9	-15.34	-0.65	1.98e-40	Body mass index;
CRC	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg27398640	chr15:77910606	LINGO1	-0.4	-6.91	-0.36	2.56e-11	Type 2 diabetes;
CRC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-9.16	-0.45	5.88e-18	Bipolar disorder;
CRC	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.84	0.31	1.24e-8	Educational attainment;
CRC	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	0.79	8.25	0.41	3.9e-15	Pediatric areal bone mineral density (radius);
CRC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.75	-9.27	-0.45	2.61e-18	Initial pursuit acceleration;
CRC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.51	-7.86	-0.4	5.61e-14	Intelligence (multi-trait analysis);
CRC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg02766259	chr12:125626809	AACS	0.4	6.74	0.35	6.9e-11	Post bronchodilator FEV1/FVC ratio;
CRC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.49	7.5	0.38	6.06e-13	Corneal astigmatism;
CRC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.39	7.42	0.38	1.01e-12	Ulcerative colitis;
CRC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.51	-6.24	-0.33	1.35e-9	Body mass index;
CRC	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg26875233	chr11:93583750	C11orf90	0.29	5.74	0.3	2.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CRC	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.68	-8.0	-0.4	2.08e-14	Systolic blood pressure;
CRC	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.56	-7.45	-0.38	8.31e-13	Hypertension (SNP x SNP interaction);
CRC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg16892393	chr17:41919603	NA	0.47	7.24	0.37	3.23e-12	Triglycerides;
CRC	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.82	10.34	0.5	6.81e-22	Prostate cancer;
CRC	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg23815491	chr16:72088622	HP	0.62	8.05	0.41	1.55e-14	Blood protein levels;
CRC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg06470822	chr6:28175283	NA	0.98	12.98	0.58	2.22e-31	Depression;
CRC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.53	-6.39	-0.33	5.55e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.41	6.98	0.36	1.68e-11	Arsenic metabolism;
CRC	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg01692110	chr13:113365389	ATP11A	-0.51	-6.34	-0.33	7.55e-10	Glycated hemoglobin levels;
CRC	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.34	6.35	0.33	7.02e-10	Ulcerative colitis;
CRC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.76	9.97	0.48	1.21e-20	Platelet count;
CRC	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg08501292	chr6:25962987	TRIM38	0.94	8.44	0.42	1.05e-15	Autism spectrum disorder or schizophrenia;
CRC	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg03690763	chr11:133734501	NA	-0.36	-5.99	-0.31	5.46e-9	Childhood ear infection;
CRC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-8.02	-0.4	1.89e-14	Colorectal cancer;
CRC	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.73	11.31	0.53	2.87e-25	QRS interval (sulfonylurea treatment interaction);
CRC	cis	rs4766646	0.619	rs7966820	chr12:110302270	A/G	cg01252219	chr12:110302105	GLTP	-0.38	-6.0	-0.31	5.2e-9	Metabolite levels (MHPG);
CRC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.6	9.3	0.46	1.95e-18	Corneal astigmatism;
CRC	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.52	7.8	0.4	8.29e-14	Alzheimer's disease (cognitive decline);
CRC	cis	rs7538876	0.903	rs6688886	chr1:17753639	G/A	cg07965774	chr1:17746286	RCC2	0.33	6.07	0.32	3.59e-9	Basal cell carcinoma;
CRC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.63	0.6	7.31e-34	Platelet count;
CRC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.48	-9.49	-0.46	4.89e-19	Subjective well-being;
CRC	trans	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg21774064	chr8:1626419	DLGAP2	-0.58	-6.47	-0.34	3.45e-10	Liver enzyme levels (alkaline phosphatase);
CRC	cis	rs2486012	1.000	rs2485991	chr1:44391722	C/T	cg12908607	chr1:44402522	ARTN	-0.42	-5.82	-0.31	1.43e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12463550	chr7:65579703	CRCP	0.64	5.79	0.3	1.66e-8	Gout;
CRC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg24375607	chr4:120327624	NA	0.45	7.12	0.37	6.85e-12	Corneal astigmatism;
CRC	trans	rs7428796	0.507	rs11127935	chr3:86364123	C/T	cg02184338	chr7:101331866	NA	-0.44	-6.53	-0.34	2.47e-10	Myopia (pathological);
CRC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.56	9.87	0.48	2.67e-20	Huntington's disease progression;
CRC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.6	9.31	0.46	1.84e-18	Longevity;Endometriosis;
CRC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg27480539	chr19:16770792	TMEM38A;C19orf42	0.43	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
CRC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.71	11.02	0.52	2.99e-24	Corneal astigmatism;
CRC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.73	0.3	2.28e-8	Intelligence (multi-trait analysis);
CRC	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg06632207	chr12:54070931	ATP5G2	0.49	8.66	0.43	2.2e-16	Height;
CRC	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg26741380	chr15:41871084	TYRO3	-0.48	-7.11	-0.36	7.14e-12	Response to tocilizumab in rheumatoid arthritis;
CRC	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg16898833	chr6:26189333	HIST1H4D	0.87	7.3	0.37	2.2e-12	Autism spectrum disorder or schizophrenia;
CRC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.54	-0.34	2.35e-10	Height;
CRC	trans	rs2303319	0.504	rs56026147	chr2:162614089	T/C	cg22902534	chr3:183892754	AP2M1	-0.7	-6.1	-0.32	2.96e-9	Cognitive function;
CRC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-10.34	-0.5	7.21e-22	Coronary artery disease;
CRC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.57	8.56	0.43	4.52e-16	Total body bone mineral density;
CRC	cis	rs2077654	0.822	rs12280242	chr11:17433737	C/T	cg25308976	chr11:17434268	ABCC8	0.81	8.39	0.42	1.48e-15	Gout;
CRC	cis	rs9826463	0.757	rs2229032	chr3:142178144	A/G	cg20824294	chr3:142316082	PLS1	-0.38	-6.49	-0.34	3.14e-10	QRS duration in Tripanosoma cruzi seropositivity;
CRC	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.48	0.42	7.86e-16	Corneal astigmatism;
CRC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	8.28	0.42	3.06e-15	Menopause (age at onset);
CRC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-6.04	-0.32	4.23e-9	Alzheimer's disease (late onset);
CRC	cis	rs4663866	1.000	rs71426510	chr2:239178909	T/G	cg16914508	chr2:239161102	PER2	0.77	7.86	0.4	5.51e-14	Irritable bowel syndrome;
CRC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.6	-11.25	-0.53	4.69e-25	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg20512303	chr5:131592959	PDLIM4	-0.35	-5.65	-0.3	3.47e-8	Lymphocyte counts;Fibrinogen;
CRC	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.47	6.78	0.35	5.68e-11	Primary sclerosing cholangitis;
CRC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	7.31	0.37	2.03e-12	Reticulocyte count;
CRC	cis	rs12745968	0.619	rs10874738	chr1:93224219	T/A	cg17283838	chr1:93427260	FAM69A	-0.43	-5.78	-0.3	1.77e-8	Bipolar disorder and schizophrenia;
CRC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg27094323	chr7:1216898	NA	-0.4	-6.39	-0.33	5.6e-10	Longevity;Endometriosis;
CRC	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14764050	chr21:46221651	UBE2G2	0.44	6.12	0.32	2.71e-9	Anxiety disorder;
CRC	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg15038512	chr6:170123185	PHF10	-0.39	-6.05	-0.32	3.86e-9	Obesity-related traits;
CRC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.61	9.07	0.45	1.07e-17	Subjective well-being;
CRC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg18944383	chr4:111397179	ENPEP	0.46	6.06	0.32	3.75e-9	Coronary artery disease;
CRC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg05994458	chr11:13484274	BTBD10	0.49	6.23	0.32	1.4e-9	Thyroid stimulating hormone;
CRC	cis	rs12024301	0.557	rs6699011	chr1:183622379	A/G	cg11505048	chr1:183622726	RGL1;APOBEC4	0.78	6.97	0.36	1.78e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CRC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg13073564	chr4:8508604	NA	0.4	6.06	0.32	3.66e-9	Response to antineoplastic agents;
CRC	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.81	0.44	7.18e-17	Coffee consumption (cups per day);
CRC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.75	9.2	0.45	4.15e-18	Breast cancer;
CRC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	11.34	0.53	2.25e-25	Motion sickness;
CRC	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.37	0.53	1.8e-25	Coffee consumption (cups per day);
CRC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg08200582	chr11:442649	ANO9	-0.71	-7.44	-0.38	8.72e-13	Body mass index;
CRC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	-0.67	-7.57	-0.38	3.9e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CRC	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.18	-0.37	4.67e-12	Bipolar disorder and schizophrenia;
CRC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg07507251	chr3:52567010	NT5DC2	0.48	7.49	0.38	6.54e-13	Bipolar disorder;
CRC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.8	11.82	0.55	4.06e-27	Cognitive function;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	0.42	6.8	0.35	5.06e-11	Obesity-related traits;
CRC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.42	-5.91	-0.31	8.47e-9	Intelligence (multi-trait analysis);
CRC	cis	rs9925964	0.933	rs12448321	chr16:31048280	C/T	cg03418659	chr16:31128414	MYST1	0.47	6.78	0.35	5.52e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CRC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.51	-9.64	-0.47	1.59e-19	Iron status biomarkers (transferrin levels);
CRC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.41	6.47	0.34	3.46e-10	Lobe attachment (rater-scored or self-reported);
CRC	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.43	6.76	0.35	6.47e-11	Red blood cell count;
CRC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	17.49	0.69	6.57e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CRC	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.39	5.9	0.31	8.87e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CRC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg06219103	chr11:63990595	FERMT3	0.45	7.27	0.37	2.63e-12	Platelet count;
CRC	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg17554553	chr10:31321002	ZNF438	0.36	6.21	0.32	1.59e-9	Obesity-related traits;
CRC	cis	rs1847505	0.663	rs8002365	chr13:61589772	A/G	cg14094164	chr13:61491000	NA	-0.3	-5.82	-0.31	1.41e-8	Polychlorinated biphenyl levels;
CRC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg18653534	chr16:772142	FAM173A	-0.36	-5.8	-0.3	1.54e-8	Height;
CRC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-11.24	-0.53	4.89e-25	Schizophrenia;
CRC	cis	rs447	1.000	rs7804563	chr7:83777694	G/A	cg22846510	chr7:83753280	SEMA3A	-0.55	-6.79	-0.35	5.24e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CRC	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02709840	chr16:67062875	CBFB	0.39	6.24	0.33	1.36e-9	Liver disease severity in Alagille syndrome;
CRC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08219700	chr8:58056026	NA	0.56	6.4	0.33	5.3e-10	Developmental language disorder (linguistic errors);
CRC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.48	7.64	0.39	2.33e-13	Osteoporosis;
CRC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.5	7.23	0.37	3.41e-12	Lobe attachment (rater-scored or self-reported);
CRC	trans	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	6.15	0.32	2.25e-9	Menarche (age at onset);
CRC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.68	8.14	0.41	8.52e-15	Lung cancer (smoking interaction);
CRC	cis	rs2692947	0.702	rs4907291	chr2:96654605	T/G	cg23100626	chr2:96804247	ASTL	0.24	6.76	0.35	6.17e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CRC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-15.15	-0.64	1.08e-39	Dental caries;
CRC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-10.76	-0.51	2.55e-23	Ileal carcinoids;
CRC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.83	8.23	0.41	4.37e-15	Diabetic retinopathy;
CRC	trans	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg06206626	chr22:26825900	ASPHD2	0.43	6.23	0.32	1.42e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
CRC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.54	8.76	0.43	1.05e-16	Coronary artery disease;
CRC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.66	10.52	0.5	1.6400000000000001e-22	Sudden cardiac arrest;
CRC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg23262073	chr20:60523788	NA	-0.47	-7.23	-0.37	3.36e-12	Body mass index;